
PMID- 23755305
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Suppression of Gluconeogenic Gene Expression by LSD1-Mediated Histone
      Demethylation.
PG  - e66294
LID - 10.1371/journal.pone.0066294 [doi]
AB  - Aberrant gluconeogenic gene expression is associated with diabetes, glycogen
      storage disease, and liver cancer. However, little is known how these genes are
      regulated at the chromatin level. In this study, we investigated in HepG2 cells
      whether histone demethylation is a potential mechanism. We found that knockdown
      or pharmacological inhibition of histone demethylase LSD1 causes remarkable
      transcription activation of two gluconeogenic genes, FBP1 and G6Pase, and
      consequently leads to increased de novo glucose synthesis and decreased
      intracellular glycogen content. Mechanistically, LSD1 occupies the promoters of
      FBP1 and G6Pase, and modulates their H3K4 dimethylation levels. Thus, our work
      identifies an epigenetic pathway directly governing gluconeogenic gene
      expression, which might have important implications in metabolic physiology and
      diseases.
AD  - Program in Gene Function and Expression and Program in Molecular Medicine,
      University of Massachusetts Medical School, Worcester, Massachusetts, United
      States of America.
FAU - Pan, Dongning
AU  - Pan D
FAU - Mao, Chunxiao
AU  - Mao C
FAU - Wang, Yong-Xu
AU  - Wang YX
LA  - eng
PT  - Journal Article
DEP - 20130605
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/08 [received]
PHST- 2013/05/07 [accepted]
PHST- 2013/06/05 [epublish]
AID - 10.1371/journal.pone.0066294 [doi]
AID - PONE-D-12-35565 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 5;8(6):e66294. doi: 10.1371/journal.pone.0066294. Print 2013.

PMID- 23755289
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Cooperative anti-diabetic effects of deoxynojirimycin-polysaccharide by
      inhibiting glucose absorption and modulating glucose metabolism in
      streptozotocin-induced diabetic mice.
PG  - e65892
LID - 10.1371/journal.pone.0065892 [doi]
AB  - We had previously shown that deoxynojirimycin-polysaccharide mixture (DPM) not
      only decreased blood glucose but also reversed the damage to pancreatic
      beta-cells in diabetic mice, and that the anti-hyperglycemic efficacy of this
      combination was better than that of 1-deoxynojirimycin (DNJ) or polysachharide
      alone. However, the mechanisms behind these effects were not fully understood.
      The present study aimed to evaluate the therapeutic effects of DPM on
      streptozotocin (STZ)-induced diabetic symptoms and their potential mechanisms.
      Diabetic mice were treated with DPM (150 mg/kg body weight) for 90 days and
      continued to be fed without DPM for an additional 30 days. Strikingly, decrease
      of blood glucose levels was observed in all DPM treated diabetic mice, which
      persisted 30 days after cessation of DPM administration. Significant decrease of 
      glycosylated hemoglobin and hepatic pyruvate concentrations, along with marked
      increase of serum insulin and hepatic glycogen levels were detected in DPM
      treated diabetic mice. Results of a labeled (13)C6-glucose uptake assay indicated
      that DPM can restrain glucose absorption. Additionally, DPM down-regulated the
      mRNA and protein expression of jejunal Na(+)/glucose cotransporter,
      Na(+)/K(+)-ATPase and glucose transporter 2, and enhanced the activities as well 
      as mRNA and protein levels of hepatic glycolysis enzymes (glucokinase,
      phosphofructokinase, private kinase and pyruvate decarboxylas E1). Activity and
      expression of hepatic gluconeogenesis enzymes (phosphoenolpyruvate carboxykinase 
      and glucose-6-phosphatase) were also found to be attenuated in diabetic mice
      treated with DPM. Purified enzyme activity assays verified that the increased
      activities of glucose glycolysis enzymes resulted not from their direct
      activation, but from the relative increase in protein expression. Importantly,
      our histopathological observations support the results of our biochemical
      analyses and validate the protective effects of DPM on STZ-induced damage to the 
      pancreas. Thus, DPM has significant potential as a therapeutic agent against
      diabetes.
AD  - Sericultural Research Institute, Zhejiang Academy of Agricultural Science,
      Hangzhou, China.
FAU - Li, You-Gui
AU  - Li YG
FAU - Ji, Dong-Feng
AU  - Ji DF
FAU - Zhong, Shi
AU  - Zhong S
FAU - Lv, Zhi-Qiang
AU  - Lv ZQ
FAU - Lin, Tian-Bao
AU  - Lin TB
LA  - eng
PT  - Journal Article
DEP - 20130606
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/13 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/06/06 [epublish]
AID - 10.1371/journal.pone.0065892 [doi]
AID - PONE-D-12-35972 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 6;8(6):e65892. doi: 10.1371/journal.pone.0065892. Print 2013.

PMID- 23755276
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Multi-targeted mechanisms underlying the endothelial protective effects of the
      diabetic-safe sweetener erythritol.
PG  - e65741
LID - 10.1371/journal.pone.0065741 [doi]
AB  - Diabetes is characterized by hyperglycemia and development of vascular pathology.
      Endothelial cell dysfunction is a starting point for pathogenesis of vascular
      complications in diabetes. We previously showed the polyol erythritol to be a
      hydroxyl radical scavenger preventing endothelial cell dysfunction onset in
      diabetic rats. To unravel mechanisms, other than scavenging of radicals, by which
      erythritol mediates this protective effect, we evaluated effects of erythritol in
      endothelial cells exposed to normal (7 mM) and high glucose (30 mM) or diabetic
      stressors (e.g. SIN-1) using targeted and transcriptomic approaches. This study
      demonstrates that erythritol (i.e. under non-diabetic conditions) has minimal
      effects on endothelial cells. However, under hyperglycemic conditions erythritol 
      protected endothelial cells against cell death induced by diabetic stressors
      (i.e. high glucose and peroxynitrite). Also a number of harmful effects caused by
      high glucose, e.g. increased nitric oxide release, are reversed. Additionally,
      total transcriptome analysis indicated that biological processes which are
      differentially regulated due to high glucose are corrected by erythritol. We
      conclude that erythritol protects endothelial cells during high glucose
      conditions via effects on multiple targets. Overall, these data indicate a
      therapeutically important endothelial protective effect of erythritol under
      hyperglycemic conditions.
AD  - Department of Toxicology, Maastricht University, Maastricht, The Netherlands.
FAU - Boesten, Danielle M P H J
AU  - Boesten DM
FAU - Berger, Alvin
AU  - Berger A
FAU - de Cock, Peter
AU  - de Cock P
FAU - Dong, Hua
AU  - Dong H
FAU - Hammock, Bruce D
AU  - Hammock BD
FAU - den Hartog, Gertjan J M
AU  - den Hartog GJ
FAU - Bast, Aalt
AU  - Bast A
LA  - eng
PT  - Journal Article
DEP - 20130605
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/20 [received]
PHST- 2013/04/26 [accepted]
PHST- 2013/06/05 [epublish]
AID - 10.1371/journal.pone.0065741 [doi]
AID - PONE-D-12-40064 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 5;8(6):e65741. doi: 10.1371/journal.pone.0065741. Print 2013.

PMID- 23755253
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Exploring the Influence of Carbon Nanoparticles on the Formation of
      beta-Sheet-Rich Oligomers of IAPP22-28 Peptide by Molecular Dynamics Simulation.
PG  - e65579
LID - 10.1371/journal.pone.0065579 [doi]
AB  - Recent advances in nanotechnologies have led to wide use of nanomaterials in
      biomedical field. However, nanoparticles are found to interfere with protein
      misfolding and aggregation associated with many human diseases. It is still a
      controversial issue whether nanoparticles inhibit or promote protein aggregation.
      In this study, we used molecular dynamics simulations to explore the effects of
      three kinds of carbon nanomaterials including graphene, carbon nanotube and C60
      on the aggregation behavior of islet amyloid polypeptide fragment 22-28
      (IAPP22-28). The diverse behaviors of IAPP22-28 peptides on the surfaces of
      carbon nanomaterials were studied. The results suggest these nanomaterials can
      prevent beta-sheet formation in differing degrees and further affect the
      aggregation of IAPP22-28. The pi-pi stacking and hydrophobic interactions are
      different in the interactions between peptides and different nanoparticles. The
      subtle differences in the interaction are due to the difference in surface
      curvature and area. The results demonstrate the adsorption interaction has
      competitive advantages over the interactions between peptides. Therefore, the
      fibrillation of IAPP22-28 may be inhibited at its early stage by graphene or
      SWCNT. Our study can not only enhance the understanding about potential effects
      of nanomaterials to amyloid formation, but also provide valuable information to
      develop potential beta-sheet formation inhibitors against type II diabetes.
AD  - School of Pharmacy, Lanzhou University, Lanzhou, China ; State Key Laboratory of 
      Applied Organic Chemistry and Department of Chemistry, Lanzhou University,
      Lanzhou, China.
FAU - Guo, Jingjing
AU  - Guo J
FAU - Li, Jiazhong
AU  - Li J
FAU - Zhang, Yan
AU  - Zhang Y
FAU - Jin, Xiaojie
AU  - Jin X
FAU - Liu, Huanxiang
AU  - Liu H
FAU - Yao, Xiaojun
AU  - Yao X
LA  - eng
PT  - Journal Article
DEP - 20130605
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/25 [received]
PHST- 2013/04/26 [accepted]
PHST- 2013/06/05 [epublish]
AID - 10.1371/journal.pone.0065579 [doi]
AID - PONE-D-13-04559 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 5;8(6):e65579. doi: 10.1371/journal.pone.0065579. Print 2013.

PMID- 23755222
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Antioxidant and Anti-Inflammatory Effects in RAW264.7 Macrophages of Malvidin, a 
      Major Red Wine Polyphenol.
PG  - e65355
LID - 10.1371/journal.pone.0065355 [doi]
AB  - BACKGROUND: Red wine polyphenols can prevent cardiovascular and inflammatory
      diseases. Resveratrol, the most extensively studied constituent, is unlikely to
      solely account for these beneficial effects because of its rather low abundance
      and bioavailability. Malvidin is far the most abundant polyphenol in red wine;
      however, very limited data are available about its effect on inflammatory
      processes and kinase signaling pathways. METHODS FINDINGS: The present study was 
      carried out by using RAW 264.7 macrophages stimulated by bacterial
      lipopolysaccharide in the presence and absence of malvidin. From the cells,
      activation of nuclear factor-kappaB, mitogen-activated protein kinase, protein
      kinase B/Akt and poly ADP-ribose polymerase, reactive oxygen species production, 
      mitogen-activated protein kinase phosphatase-1 expression and mitochondrial
      depolarization were determined. We found that malvidin attenuated
      lipopolysaccharide-induced nuclear factor-kappaB, poly ADP-ribose polymerase and 
      mitogen-activated protein kinase activation, reactive oxygen species production
      and mitochondrial depolarization, while upregulated the compensatory processes;
      mitogen-activated protein kinase phosphatase-1 expression and Akt activation.
      CONCLUSIONS: These effects of malvidin may explain the previous findings and at
      least partially account for the positive effects of moderate red wine consumption
      on inflammation-mediated chronic maladies such as obesity, diabetes, hypertension
      and cardiovascular disease.
AD  - Departments of Biochemistry and Medical Chemistry, University of Pecs Medical
      School, Pecs, Hungary ; Nuclear-Mitochondrial Interactions Research Group,
      Hungarian Academy of Sciences, Budapest, Hungary.
FAU - Bognar, Eszter
AU  - Bognar E
FAU - Sarszegi, Zsolt
AU  - Sarszegi Z
FAU - Szabo, Aliz
AU  - Szabo A
FAU - Debreceni, Balazs
AU  - Debreceni B
FAU - Kalman, Nikoletta
AU  - Kalman N
FAU - Tucsek, Zsuzsanna
AU  - Tucsek Z
FAU - Sumegi, Balazs
AU  - Sumegi B
FAU - Gallyas, Ferenc Jr
AU  - Gallyas F Jr
LA  - eng
PT  - Journal Article
DEP - 20130605
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2012/09/21 [received]
PHST- 2013/04/26 [accepted]
PHST- 2013/06/05 [epublish]
AID - 10.1371/journal.pone.0065355 [doi]
AID - PONE-D-12-28742 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 5;8(6):e65355. doi: 10.1371/journal.pone.0065355. Print 2013.

PMID- 23755203
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Lower Cerebrospinal Fluid/Plasma Fibroblast Growth Factor 21 (FGF21) Ratios and
      Placental FGF21 Production in Gestational Diabetes.
PG  - e65254
LID - 10.1371/journal.pone.0065254 [doi]
AB  - OBJECTIVES: Circulating Fibroblast Growth Factor 21 (FGF21) levels are increased 
      in insulin resistant states such as obesity, type 2 diabetes mellitus and
      gestational diabetes mellitus (GDM). In addition, GDM is associated with serious 
      maternal and fetal complications. We sought to study human cerebrospinal fluid
      (CSF) and corresponding circulating FGF21 levels in women with gestational
      diabetes mellitus (GDM) and in age and BMI matched control subjects. We also
      assessed FGF21 secretion from GDM and control human placental explants. DESIGN:
      CSF and corresponding plasma FGF21 levels of 24 women were measured by ELISA [12 
      GDM (age: 26-47 years, BMI: 24.3-36.3 kg/m(2)) and 12 controls (age: 22-40 years,
      BMI: 30.1-37.0 kg/m(2))]. FGF21 levels in conditioned media were secretion from
      GDM and control human placental explants were also measured by ELISA. RESULTS:
      Glucose, HOMA-IR and circulating NEFA levels were significantly higher in women
      with GDM compared to control subjects. Plasma FGF21 levels were significantly
      higher in women with GDM compared to control subjects [234.3 (150.2-352.7) vs.
      115.5 (60.5-188.7) pg/ml; P<0.05]. However, there was no significant difference
      in CSF FGF21 levels in women with GDM compared to control subjects.
      Interestingly, CSF/Plasma FGF21 ratio was significantly lower in women with GDM
      compared to control subjects [0.4 (0.3-0.6) vs. 0.8 (0.5-1.6); P<0.05]. FGF21
      secretion into conditioned media was significantly lower in human placental
      explants from women with GDM compared to control subjects (P<0.05). CONCLUSIONS: 
      The central actions of FGF21 in GDM subjects maybe pivotal in the pathogenesis of
      insulin resistance in GDM subjects. The significance of FGF21 produced by the
      placenta remains uncharted and maybe crucial in our understanding of the
      patho-physiology of GDM and its associated maternal and fetal complications.
      Future research should seek to elucidate these points.
AD  - Divisions of Metabolic & Vascular Health and Reproduction, Warwick Medical
      School, University of Warwick, Coventry, United Kingdom.
FAU - Tan, Bee K
AU  - Tan BK
FAU - Sivakumar, Kavitha
AU  - Sivakumar K
FAU - Bari, Muhammad F
AU  - Bari MF
FAU - Vatish, Manu
AU  - Vatish M
FAU - Randeva, Harpal S
AU  - Randeva HS
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/23 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/06/03 [epublish]
AID - 10.1371/journal.pone.0065254 [doi]
AID - PONE-D-13-03626 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 3;8(6):e65254. doi: 10.1371/journal.pone.0065254. Print 2013.

PMID- 23755196
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - An Ethanolic Extract of Lindera obtusiloba Stems, YJP-14, Improves Endothelial
      Dysfunction, Metabolic Parameters and Physical Performance in Diabetic db/db
      Mice.
PG  - e65227
LID - 10.1371/journal.pone.0065227 [doi]
AB  - Lindera obtusiloba is a medicinal herb traditionally used in Asia for improvement
      of blood circulation, treatment of inflammation, and prevention of liver damage. 
      A previous study has shown that an ethanolic extract of Lindera obtusiloba stems 
      (LOE) has vasoprotective and antihypertensive effects. The possibility that
      Lindera obtusiloba improves endothelial function and metabolic parameters in type
      2 diabetes mellitus (T2DM) remains to be examined. Therefore, the aim of the
      present study was to determine the potential of LOE to prevent the development of
      an endothelial dysfunction, and improve metabolic parameters including
      hyperglycemia, albuminuria and physical exercise capacity in db/db mice, an
      experimental model of T2DM. The effect of LOE (100 mg/kg/day by gavage for 8
      weeks) on these parameters was compared to that of an oral antidiabetic drug,
      pioglitazone (30 mg/kg/day by gavage). Reduced blood glucose level, body weight
      and albumin-creatinine ratio were observed in the group receiving LOE compared to
      the control db/db group. The LOE treatment improved endothelium-dependent
      relaxations, abolished endothelium-dependent contractions to acetylcholine in the
      aorta, and normalized the increased vascular oxidative stress and expression of
      NADPH oxidase, cyclooxygenases, angiotensin II, angiotensin type 1 receptors and 
      peroxynitrite and the decreased expression of endothelial NO synthase in db/db
      mice. The angiotensin-converting enzyme (ACE) activity was reduced in the LOE
      group compared to that in the control db/db group. LOE also inhibited the
      activity of purified ACE, COX-1 and COX-2 in a dose-dependent manner. In
      addition, LOE improved physical exercise capacity. Thus, the present findings
      indicate that LOE has a beneficial effect on the vascular system in db/db mice by
      improving endothelium-dependent relaxations and vascular oxidative stress most
      likely by normalizing the angiotensin system, and also on metabolic parameters,
      and these effects are associated with an enhanced physical exercise capacity.
AD  - UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculte de
      Pharmacie, Universite de Strasbourg, Illkirch, France ; Research and Development 
      Center, Hanwha Pharma. Co., Ltd., Chuncheon, Republic of Korea.
FAU - Lee, Jung-Ok
AU  - Lee JO
FAU - Auger, Cyril
AU  - Auger C
FAU - Park, Dong Hyun
AU  - Park DH
FAU - Kang, Moonkyu
AU  - Kang M
FAU - Oak, Min-Ho
AU  - Oak MH
FAU - Kim, Kyoung Rak
AU  - Kim KR
FAU - Schini-Kerth, Valerie B
AU  - Schini-Kerth VB
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/29 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/06/03 [epublish]
AID - 10.1371/journal.pone.0065227 [doi]
AID - PONE-D-12-33944 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 3;8(6):e65227. doi: 10.1371/journal.pone.0065227. Print 2013.

PMID- 23755169
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Inhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated
      atherosclerosis in diabetic mice.
PG  - e65020
LID - 10.1371/journal.pone.0065020 [doi]
AB  - OBJECTIVE OF THE STUDY: Diabetic patients have a much more widespread and
      aggressive form of atherosclerosis and therefore, higher risk for myocardial
      infarction, peripheral vascular disease and stroke, but the molecular mechanisms 
      leading to accelerated damage are still unclear. Recently, we showed that
      hyperglycemia activates the transcription factor NFAT in the arterial wall,
      inducing the expression of the pro-atherosclerotic protein osteopontin. Here we
      investigate whether NFAT activation may be a link between diabetes and
      atherogenesis. METHODOLOGY AND PRINCIPAL FINDINGS: Streptozotocin (STZ)-induced
      diabetes in apolipoprotein E(-/-) mice resulted in 2.2 fold increased aortic
      atherosclerosis and enhanced pro-inflammatory burden, as evidenced by elevated
      blood monocytes, endothelial activation- and inflammatory markers in aorta, and
      pro-inflammatory cytokines in plasma. In vivo treatment with the NFAT blocker
      A-285222 for 4 weeks completely inhibited the diabetes-induced aggravation of
      atherosclerosis, having no effect in non-diabetic mice. STZ-treated mice
      exhibited hyperglycemia and higher plasma cholesterol and triglycerides, but
      these were unaffected by A-285222. NFAT-dependent transcriptional activity was
      examined in aorta, spleen, thymus, brain, heart, liver and kidney, but only
      augmented in the aorta of diabetic mice. A-285222 completely blocked this
      diabetes-driven NFAT activation, but had no impact on the other organs or on
      splenocyte proliferation or cytokine secretion, ruling out systemic
      immunosuppression as the mechanism behind reduced atherosclerosis. Instead, NFAT 
      inhibition effectively reduced IL-6, osteopontin, monocyte chemotactic protein 1,
      intercellular adhesion molecule 1, CD68 and tissue factor expression in the
      arterial wall and lowered plasma IL-6 in diabetic mice. CONCLUSIONS: Targeting
      NFAT signaling may be a novel and attractive approach for the treatment of
      diabetic macrovascular complications.
AD  - Department of Clinical Sciences in Malmo, Lund University, Malmo, Sweden.
FAU - Zetterqvist, Anna V
AU  - Zetterqvist AV
FAU - Berglund, Lisa M
AU  - Berglund LM
FAU - Blanco, Fabiana
AU  - Blanco F
FAU - Garcia-Vaz, Eliana
AU  - Garcia-Vaz E
FAU - Wigren, Maria
AU  - Wigren M
FAU - Duner, Pontus
AU  - Duner P
FAU - Andersson, Anna-Maria Dutius
AU  - Andersson AM
FAU - To, Fong
AU  - To F
FAU - Spegel, Peter
AU  - Spegel P
FAU - Nilsson, Jan
AU  - Nilsson J
FAU - Bengtsson, Eva
AU  - Bengtsson E
FAU - Gomez, Maria F
AU  - Gomez MF
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/20 [received]
PHST- 2013/04/21 [accepted]
PHST- 2013/06/03 [epublish]
AID - 10.1371/journal.pone.0065020 [doi]
AID - PONE-D-12-36579 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 3;8(6):e65020. doi: 10.1371/journal.pone.0065020. Print 2013.

PMID- 23755138
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Serum resistin, cardiovascular disease and all-cause mortality in patients with
      type 2 diabetes.
PG  - e64729
LID - 10.1371/journal.pone.0064729 [doi]
AB  - BACKGROUND: High serum resistin has been associated with increased risk of
      cardiovascular disease in the general population, Only sparse and conflicting
      results, limited to Asian individuals, have been reported, so far, in type 2
      diabetes. We studied the role of serum resistin on coronary artery disease, major
      cardiovascular events and all-cause mortality in type 2 diabetes. METHODS: We
      tested the association of circulating resistin concentrations with coronary
      artery disease, major cardiovascular events (cardiovascular death, non-fatal
      myocardial infarction and non-fatal stroke) and all-cause mortality in 2,313
      diabetic patients of European ancestry from two cross-sectional and two
      prospective studies. In addition, the expression of resistin gene (RETN) was
      measured in blood cells of 68 diabetic patients and correlated with their serum
      resistin levels. RESULTS: In a model comprising age, sex, smoking habits, BMI,
      HbA1c, and insulin, antihypertensive and antidyslipidemic therapies, serum
      resistin was associated with coronary artery disease in both cross-sectional
      studies: OR (95%CI) per SD increment = 1.35 (1.10-1.64) and 1.99 (1.55-2.55).
      Additionally, serum resistin predicted incident major cardiovascular events (HR
      per SD increment = 1.31; 1.10-1.56) and all-cause mortality (HR per SD increment 
      = 1.16; 1.06-1.26). Adjusting also for fibrinogen levels affected the association
      with coronary artery disease and incident cardiovascular events, but not that
      with all cause-mortality. Finally, serum resistin was positively correlated with 
      RETN mRNA expression (rho = 0.343). CONCLUSIONS: This is the first study showing 
      that high serum resistin (a likely consequence, at least partly, of increased
      RETN expression) is a risk factor for cardiovascular disease and all-cause
      mortality in diabetic patients of European ancestry.
AD  - Research Unit of Diabetes and Endocrine Diseases, IRCCS Casa Sollievo della
      Sofferenza, San Giovanni Rotondo, Italy.
FAU - Menzaghi, Claudia
AU  - Menzaghi C
FAU - Bacci, Simonetta
AU  - Bacci S
FAU - Salvemini, Lucia
AU  - Salvemini L
FAU - Mendonca, Christine
AU  - Mendonca C
FAU - Palladino, Giuseppe
AU  - Palladino G
FAU - Fontana, Andrea
AU  - Fontana A
FAU - De Bonis, Concetta
AU  - De Bonis C
FAU - Marucci, Antonella
AU  - Marucci A
FAU - Goheen, Elizabeth
AU  - Goheen E
FAU - Prudente, Sabrina
AU  - Prudente S
FAU - Morini, Eleonora
AU  - Morini E
FAU - Rizza, Stefano
AU  - Rizza S
FAU - Kanagaki, Alyssa
AU  - Kanagaki A
FAU - Fini, Grazia
AU  - Fini G
FAU - Mangiacotti, Davide
AU  - Mangiacotti D
FAU - Federici, Massimo
AU  - Federici M
FAU - De Cosmo, Salvatore
AU  - De Cosmo S
FAU - Pellegrini, Fabio
AU  - Pellegrini F
FAU - Doria, Alessandro
AU  - Doria A
FAU - Trischitta, Vincenzo
AU  - Trischitta V
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/16 [received]
PHST- 2013/04/18 [accepted]
PHST- 2013/06/03 [epublish]
AID - 10.1371/journal.pone.0064729 [doi]
AID - PONE-D-13-02553 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 3;8(6):e64729. doi: 10.1371/journal.pone.0064729. Print 2013.

PMID- 23755131
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Complex Multi-Block Analysis Identifies New Immunologic and Genetic Disease
      Progression Patterns Associated with the Residual beta-Cell Function 1 Year after
      Diagnosis of Type 1 Diabetes.
PG  - e64632
LID - 10.1371/journal.pone.0064632 [doi]
AB  - The purpose of the present study is to explore the progression of type 1 diabetes
      (T1D) in Danish children 12 months after diagnosis using Latent Factor Modelling.
      We include three data blocks of dynamic paraclinical biomarkers, baseline
      clinical characteristics and genetic profiles of diabetes related SNPs in the
      analyses. This method identified a model explaining 21.6% of the total variation 
      in the data set. The model consists of two components: (1) A pattern of declining
      residual beta-cell function positively associated with young age, presence of
      diabetic ketoacidosis and long duration of disease symptoms (P = 0.0004), and
      with risk alleles of WFS1, CDKN2A/2B and RNLS (P = 0.006). (2) A second pattern
      of high ZnT8 autoantibody levels and low postprandial glucagon levels associated 
      with risk alleles of IFIH1, TCF2, TAF5L, IL2RA and PTPN2 and protective alleles
      of ERBB3 gene (P = 0.0005). These results demonstrate that Latent Factor
      Modelling can identify associating patterns in clinical prospective data - future
      functional studies will be needed to clarify the relevance of these patterns.
AD  - Department of Pediatrics, Herlev Hospital, Faculty of Health Science, University 
      of Copenhagen, Copenhagen, Denmark.
FAU - Andersen, Marie Louise Max
AU  - Andersen ML
FAU - Rasmussen, Morten Arendt
AU  - Rasmussen MA
FAU - Porksen, Sven
AU  - Porksen S
FAU - Svensson, Jannet
AU  - Svensson J
FAU - Vikre-Jorgensen, Jennifer
AU  - Vikre-Jorgensen J
FAU - Thomsen, Jane
AU  - Thomsen J
FAU - Hertel, Niels Thomas
AU  - Hertel NT
FAU - Johannesen, Jesper
AU  - Johannesen J
FAU - Pociot, Flemming
AU  - Pociot F
FAU - Petersen, Jacob Sten
AU  - Petersen JS
FAU - Hansen, Lars
AU  - Hansen L
FAU - Mortensen, Henrik Bindesbol
AU  - Mortensen HB
FAU - Nielsen, Lotte Brondum
AU  - Nielsen LB
LA  - eng
PT  - Journal Article
DEP - 20130605
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/14 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/06/05 [epublish]
AID - 10.1371/journal.pone.0064632 [doi]
AID - PONE-D-12-35400 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 5;8(6):e64632. doi: 10.1371/journal.pone.0064632. Print 2013.

PMID- 23755114
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Mastication and risk for diabetes in a Japanese population: a cross-sectional
      study.
PG  - e64113
LID - 10.1371/journal.pone.0064113 [doi]
AB  - BACKGROUND: Associations between mastication and insufficient nutrient intake,
      obesity, and glucose metabolism have been shown in previous studies. However, the
      association between mastication and diabetes has not been clarified. Our
      objective was to examine the association between mastication, namely masticatory 
      performance or rate of eating, and diabetes in a population-based cohort.
      METHODS: We conducted a cross-sectional study of the association between
      mastication and diabetes in the Nagahama Prospective Cohort Study, an ongoing
      study which recruits citizens of Nagahama City in Shiga Prefecture, central
      Japan. 2,283 male and 4,544 female residents aged 40-74 years were enrolled from 
      July 2009 to November 2010. Masticatory performance was evaluated by
      spectrophotometric measurement of color changes after masticating
      color-changeable chewing gum. Categorical rate of eating (fast, intermediate or
      slow) was self-assessed using a questionnaire. RESULTS: 177 males (7.7%) and 112 
      (2.4%) females were diagnosed with diabetes. We divided participants into four
      groups by quartile of masticatory performance, namely Q1 (lowest), 2, and 3 and 4
      (highest). Compared to the lowest performance group, the multivariable adjusted
      odds ratio (OR) of diabetes was 0.91 (95% confidence interval (CI), 0.58-1.4) in 
      Q2, 0.77 (95% CI, 0.48-1.2) in Q3, and 0.53 (95% CI, 0.31-0.90) in the highest
      group in males, and 1.2 (95% CI, 0.73-2.0), 0.95 (95% CI, 0.54-1.6) and 0.56 (95%
      CI, 0.30-1.0) in females. We also estimated ORs of diabetes by rate of eating.
      Compared to the fast eating group, ORs in males were 0.87 (95% CI, 0.61-1.2) in
      the intermediate group and 0.38 (95% CI, 0.16-0.91) in the slow group, and ORs in
      females were 0.92 (95% CI, 0.59-1.4) and 1.5 (95% CI, 0.73-3.0). CONCLUSIONS:
      These findings support the hypothesis that higher masticatory performance and
      slow eating prevent the occurrence of diabetes.
AD  - Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto 
      University, Kyoto, Japan.
FAU - Yamazaki, Toru
AU  - Yamazaki T
FAU - Yamori, Masashi
AU  - Yamori M
FAU - Asai, Keita
AU  - Asai K
FAU - Nakano-Araki, Ikuko
AU  - Nakano-Araki I
FAU - Yamaguchi, Akihiko
AU  - Yamaguchi A
FAU - Takahashi, Katsu
AU  - Takahashi K
FAU - Sekine, Akihiro
AU  - Sekine A
FAU - Matsuda, Fumihiko
AU  - Matsuda F
FAU - Kosugi, Shinji
AU  - Kosugi S
FAU - Nakayama, Takeo
AU  - Nakayama T
FAU - Inagaki, Nobuya
AU  - Inagaki N
FAU - Bessho, Kazuhisa
AU  - Bessho K
CN  - Nagahama Study Collaboration Group
LA  - eng
PT  - Journal Article
DEP - 20130605
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/14 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/06/05 [epublish]
AID - 10.1371/journal.pone.0064113 [doi]
AID - PONE-D-13-02709 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 5;8(6):e64113. doi: 10.1371/journal.pone.0064113. Print 2013.

PMID- 23755088
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1861-8863 (Electronic)
IS  - 1861-8863 (Linking)
VI  - 9
DP  - 2013
TI  - Medical specialist attendance in nursing homes.
PG  - Doc02
LID - 10.3205/hta000108 [doi]
AB  - The care in nursing homes was examined based on scientific studies. The analysis 
      focuses on dementia and type II diabetes. There is evidence for deficits in the
      supply of medical specialist attendance to nursing home residents with these
      diseases in Germany. Compared with corresponding guidelines the medical care for 
      nursing home residents may be too low or inadequate.
AD  - Nursing research group, Institute for Social Medicine and Epidemiology,
      University of Lubeck, Lubeck, Germany.
FAU - Balzer, Katrin
AU  - Balzer K
FAU - Butz, Stefanie
AU  - Butz S
FAU - Bentzel, Jenny
AU  - Bentzel J
FAU - Boulkhemair, Dalila
AU  - Boulkhemair D
FAU - Luhmann, Dagmar
AU  - Luhmann D
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Germany
TA  - GMS Health Technol Assess
JT  - GMS health technology assessment
JID - 101276045
OAB - Publisher: Abstract available from the publisher.
OTO - NOTNLM
OT  - Germany
OT  - aged
OT  - delivery of health care, integrated
OT  - nursing homes
OT  - primary health care
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/23 [epublish]
AID - 10.3205/hta000108 [doi]
AID - hta000108 [pii]
PST - epublish
SO  - GMS Health Technol Assess. 2013 Apr 23;9:Doc02. doi: 10.3205/hta000108. Print
      2013.

PMID- 23755078
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1738-5520 (Print)
IS  - 1738-5520 (Linking)
VI  - 43
IP  - 5
DP  - 2013 May
TI  - Comparison of cardiovascular risk factors for peripheral artery disease and
      coronary artery disease in the korean population.
PG  - 316-28
LID - 10.4070/kcj.2013.43.5.316 [doi]
AB  - BACKGROUND AND OBJECTIVES: The objective of this study was to analyze and compare
      risk factors for peripheral artery disease (PAD) and coronary artery disease
      (CAD). SUBJECTS AND METHODS: The sample included 7936 Korean patients aged >/=20 
      years who were hospitalized from 1994 to 2004. Of the 7936 subjects, PAD (n=415),
      CAD (n=3686), and normal controls (Control) (n=3835) were examined at the Health 
      Promotion Center, Samsung Medical Center. RESULTS: The mean age (years) of PAD
      subjects was 64.4 (+/-9.3), while CAD subjects was 61.2 (+/-9.9), and Control
      subjects was 59.9 (+/-9.1) (p<0.01). The proportion of males was 90.6% for PAD,
      71.4% for CAD, and 75.5% for Control subjects (p<0.01). The adjusted odds ratios 
      (ORs) for hypertension, diabetes mellitus, hypercholesterolemia, smoking,
      metabolic syndrome and chronic kidney disease were significantly higher in
      subjects with PAD or CAD compared to those in Control. However, the ORs for high 
      density lipoprotein, being overweight, and being obese were significantly lower
      in PAD subjects compared to those in Control. CONCLUSION: We found that
      cardiovascular risk factors were in fact risk factors for both PAD and CAD.
AD  - Division of Cardiology, Department of Medicine, Cardiovascular Imaging Center,
      Cardiac and Vascular Center, Samsung Medical Center, Sungkyunkwan University
      School of Medicine, Seoul, Korea. ; Graduate School of Public Health, Seoul
      National University, Seoul, Korea.
FAU - Jang, Shin Yi
AU  - Jang SY
FAU - Ju, Eun Young
AU  - Ju EY
FAU - Cho, Sung-Il
AU  - Cho SI
FAU - Lee, Seung Wook
AU  - Lee SW
FAU - Kim, Duk-Kyung
AU  - Kim DK
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - Korea (South)
TA  - Korean Circ J
JT  - Korean circulation journal
JID - 101247141
OTO - NOTNLM
OT  - Coronary artery disease
OT  - Peripheral artery disease
OT  - Risk factors
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/01/11 [received]
PHST- 2013/03/04 [revised]
PHST- 2013/03/18 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.4070/kcj.2013.43.5.316 [doi]
PST - ppublish
SO  - Korean Circ J. 2013 May;43(5):316-28. doi: 10.4070/kcj.2013.43.5.316. Epub 2013
      May 31.

PMID- 23755065
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 3
DP  - 2012
TI  - Mapping Novel Pathways in Cardiovascular Disease Using eQTL Data: The Past,
      Present, and Future of Gene Expression Analysis.
PG  - 232
LID - 10.3389/fgene.2012.00232 [doi]
AB  - Genome-wide association studies (GWAS) have identified genetic variants
      associated with numerous cardiovascular and metabolic diseases. Newly identified 
      polymorphisms associated with myocardial infarction, dyslipidemia, hypertension, 
      diabetes, and insulin resistance suggest novel mechanistic pathways that underlie
      these and other complex diseases. Working out the connections between the
      polymorphisms identified in GWAS and their biological mechanisms has been
      especially challenging given the number of non-coding variants identified thus
      far. In this review, we discuss the utility of expression quantitative trait
      locus (eQTL) databases in the study of non-coding variants with respect to
      cardiovascular and metabolic phenotypes. Recent successes in using eQTL data to
      link variants with functional candidate genes will be reviewed, and the
      shortcomings of this approach will be outlined. Finally, we discuss the emerging 
      next generation of eQTL studies that take advantage of the ability to generate
      induced pluripotent stem cell lines from population cohorts.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University Cambridge,
      MA, USA ; Division of Cardiovascular Medicine, Brigham and Women's Hospital
      Boston, MA, USA.
FAU - Gupta, Rajat M
AU  - Gupta RM
FAU - Musunuru, Kiran
AU  - Musunuru K
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
OTO - NOTNLM
OT  - GWAS
OT  - RNA-seq
OT  - cardiovascular disease
OT  - eQTL
OT  - induced pluripotent stem cells
EDAT- 2012/01/01 00:00
MHDA- 2012/01/01 00:00
CRDT- 2013/06/12 06:00
PHST- 2012 [ppublish]
PHST- 2012/05/10 [received]
PHST- 2012/10/15 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.3389/fgene.2012.00232 [doi]
PST - epublish
SO  - Front Genet. 2013 May 31;3:232. doi: 10.3389/fgene.2012.00232. Print 2012.

PMID- 23755040
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 4
DP  - 2013
TI  - Diabetes and change in bone mineral density at the hip, calcaneus, spine, and
      radius in older women.
PG  - 62
LID - 10.3389/fendo.2013.00062 [doi]
AB  - Older women with type 2 diabetes mellitus (DM) have higher bone mineral density
      (BMD) but also have higher rates of fracture compared to those without DM.
      Limited evidence suggests that DM may also be associated with more rapid bone
      loss. To determine if bone loss rates differ by DM status in older women, we
      analyzed BMD data in the Study of Osteoporotic Fractures (SOF) between 1986 and
      1998. SOF participants were women >/=65 years at baseline who were recruited from
      four regions in the U.S. DM was ascertained by self-report. BMD was measured with
      dual-energy x-ray absorptiometry (DXA) at baseline and at least one follow-up
      visit at the hip (N = 6624) and calcaneus (N = 6700) and, on a subset of women,
      at the spine (N = 396) and distal radius (N = 306). Annualized percent change in 
      BMD was compared by DM status, using random effects models. Of 6,867 women with
      at least one follow-up DXA scan, 409 had DM at baseline. Mean age was 70.8 (SD
      4.7) years. Baseline BMD was higher in women with DM at all measured sites. In
      models adjusted for age and clinic, women with prevalent DM lost bone more
      rapidly than those without DM at the femoral neck (-0.96 vs. -0.59%/year, p <
      0.001), total hip (-0.98 vs. -0.70%/year, p < 0.001), calcaneus (-1.64 vs.
      -1.40%/year, p = 0.005), and spine (-0.33 vs. +0.33%/year, p = 0.033), but not at
      the distal radius (-0.97 vs. -0.90%/year, p = 0.91). These findings suggest that 
      despite higher baseline BMD, older women with DM experience more rapid bone loss 
      than those without DM at the hip, spine, and calcaneus, but not the radius.
      Higher rates of bone loss may partially explain higher fracture rates in older
      women with DM.
AD  - Department of Epidemiology and Biostatistics, University of California San
      Francisco , San Francisco, CA , USA.
FAU - Schwartz, Ann V
AU  - Schwartz AV
FAU - Ewing, Susan K
AU  - Ewing SK
FAU - Porzig, Anne M
AU  - Porzig AM
FAU - McCulloch, Charles E
AU  - McCulloch CE
FAU - Resnick, Helaine E
AU  - Resnick HE
FAU - Hillier, Teresa A
AU  - Hillier TA
FAU - Ensrud, Kristine E
AU  - Ensrud KE
FAU - Black, Dennis M
AU  - Black DM
FAU - Nevitt, Michael C
AU  - Nevitt MC
FAU - Cummings, Steven R
AU  - Cummings SR
FAU - Sellmeyer, Deborah E
AU  - Sellmeyer DE
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
OTO - NOTNLM
OT  - bone mineral density
OT  - longitudinal studies
OT  - older adults
OT  - type 2 diabetes mellitus
OT  - women
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/15 [received]
PHST- 2013/05/16 [accepted]
PHST- 2013/05/30 [epublish]
AID - 10.3389/fendo.2013.00062 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2013 May 30;4:62. doi: 10.3389/fendo.2013.00062.
      Print 2013.

PMID- 23754948
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1553-7404 (Electronic)
IS  - 1553-7390 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - Sex-stratified Genome-wide Association Studies Including 270,000 Individuals Show
      Sexual Dimorphism in Genetic Loci for Anthropometric Traits.
PG  - e1003500
LID - 10.1371/journal.pgen.1003500 [doi]
AB  - Given the anthropometric differences between men and women and previous evidence 
      of sex-difference in genetic effects, we conducted a genome-wide search for
      sexually dimorphic associations with height, weight, body mass index, waist
      circumference, hip circumference, and waist-to-hip-ratio (133,723 individuals)
      and took forward 348 SNPs into follow-up (additional 137,052 individuals) in a
      total of 94 studies. Seven loci displayed significant sex-difference (FDR<5%),
      including four previously established (near GRB14/COBLL1, LYPLAL1/SLC30A10,
      VEGFA, ADAMTS9) and three novel anthropometric trait loci (near MAP3K1, HSD17B4, 
      PPARG), all of which were genome-wide significant in women (P<5x10(-8)), but not 
      in men. Sex-differences were apparent only for waist phenotypes, not for height, 
      weight, BMI, or hip circumference. Moreover, we found no evidence for genetic
      effects with opposite directions in men versus women. The PPARG locus is of
      specific interest due to its role in diabetes genetics and therapy. Our results
      demonstrate the value of sex-specific GWAS to unravel the sexually dimorphic
      genetic underpinning of complex traits.
AD  - Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom ; Wellcome
      Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
FAU - Randall, Joshua C
AU  - Randall JC
FAU - Winkler, Thomas W
AU  - Winkler TW
FAU - Kutalik, Zoltan
AU  - Kutalik Z
FAU - Berndt, Sonja I
AU  - Berndt SI
FAU - Jackson, Anne U
AU  - Jackson AU
FAU - Monda, Keri L
AU  - Monda KL
FAU - Kilpelainen, Tuomas O
AU  - Kilpelainen TO
FAU - Esko, Tonu
AU  - Esko T
FAU - Magi, Reedik
AU  - Magi R
FAU - Li, Shengxu
AU  - Li S
FAU - Workalemahu, Tsegaselassie
AU  - Workalemahu T
FAU - Feitosa, Mary F
AU  - Feitosa MF
FAU - Croteau-Chonka, Damien C
AU  - Croteau-Chonka DC
FAU - Day, Felix R
AU  - Day FR
FAU - Fall, Tove
AU  - Fall T
FAU - Ferreira, Teresa
AU  - Ferreira T
FAU - Gustafsson, Stefan
AU  - Gustafsson S
FAU - Locke, Adam E
AU  - Locke AE
FAU - Mathieson, Iain
AU  - Mathieson I
FAU - Scherag, Andre
AU  - Scherag A
FAU - Vedantam, Sailaja
AU  - Vedantam S
FAU - Wood, Andrew R
AU  - Wood AR
FAU - Liang, Liming
AU  - Liang L
FAU - Steinthorsdottir, Valgerdur
AU  - Steinthorsdottir V
FAU - Thorleifsson, Gudmar
AU  - Thorleifsson G
FAU - Dermitzakis, Emmanouil T
AU  - Dermitzakis ET
FAU - Dimas, Antigone S
AU  - Dimas AS
FAU - Karpe, Fredrik
AU  - Karpe F
FAU - Min, Josine L
AU  - Min JL
FAU - Nicholson, George
AU  - Nicholson G
FAU - Clegg, Deborah J
AU  - Clegg DJ
FAU - Person, Thomas
AU  - Person T
FAU - Krohn, Jon P
AU  - Krohn JP
FAU - Bauer, Sabrina
AU  - Bauer S
FAU - Buechler, Christa
AU  - Buechler C
FAU - Eisinger, Kristina
AU  - Eisinger K
CN  - DIAGRAM Consortium
FAU - Bonnefond, Amelie
AU  - Bonnefond A
FAU - Froguel, Philippe
AU  - Froguel P
CN  - MAGIC Investigators
FAU - Hottenga, Jouke-Jan
AU  - Hottenga JJ
FAU - Prokopenko, Inga
AU  - Prokopenko I
FAU - Waite, Lindsay L
AU  - Waite LL
FAU - Harris, Tamara B
AU  - Harris TB
FAU - Smith, Albert Vernon
AU  - Smith AV
FAU - Shuldiner, Alan R
AU  - Shuldiner AR
FAU - McArdle, Wendy L
AU  - McArdle WL
FAU - Caulfield, Mark J
AU  - Caulfield MJ
FAU - Munroe, Patricia B
AU  - Munroe PB
FAU - Gronberg, Henrik
AU  - Gronberg H
FAU - Chen, Yii-Der Ida
AU  - Chen YD
FAU - Li, Guo
AU  - Li G
FAU - Beckmann, Jacques S
AU  - Beckmann JS
FAU - Johnson, Toby
AU  - Johnson T
FAU - Thorsteinsdottir, Unnur
AU  - Thorsteinsdottir U
FAU - Teder-Laving, Maris
AU  - Teder-Laving M
FAU - Khaw, Kay-Tee
AU  - Khaw KT
FAU - Wareham, Nicholas J
AU  - Wareham NJ
FAU - Zhao, Jing Hua
AU  - Zhao JH
FAU - Amin, Najaf
AU  - Amin N
FAU - Oostra, Ben A
AU  - Oostra BA
FAU - Kraja, Aldi T
AU  - Kraja AT
FAU - Province, Michael A
AU  - Province MA
FAU - Cupples, L Adrienne
AU  - Cupples LA
FAU - Heard-Costa, Nancy L
AU  - Heard-Costa NL
FAU - Kaprio, Jaakko
AU  - Kaprio J
FAU - Ripatti, Samuli
AU  - Ripatti S
FAU - Surakka, Ida
AU  - Surakka I
FAU - Collins, Francis S
AU  - Collins FS
FAU - Saramies, Jouko
AU  - Saramies J
FAU - Tuomilehto, Jaakko
AU  - Tuomilehto J
FAU - Jula, Antti
AU  - Jula A
FAU - Salomaa, Veikko
AU  - Salomaa V
FAU - Erdmann, Jeanette
AU  - Erdmann J
FAU - Hengstenberg, Christian
AU  - Hengstenberg C
FAU - Loley, Christina
AU  - Loley C
FAU - Schunkert, Heribert
AU  - Schunkert H
FAU - Lamina, Claudia
AU  - Lamina C
FAU - Wichmann, H Erich
AU  - Wichmann HE
FAU - Albrecht, Eva
AU  - Albrecht E
FAU - Gieger, Christian
AU  - Gieger C
FAU - Hicks, Andrew A
AU  - Hicks AA
FAU - Johansson, Asa
AU  - Johansson A
FAU - Pramstaller, Peter P
AU  - Pramstaller PP
FAU - Kathiresan, Sekar
AU  - Kathiresan S
FAU - Speliotes, Elizabeth K
AU  - Speliotes EK
FAU - Penninx, Brenda
AU  - Penninx B
FAU - Hartikainen, Anna-Liisa
AU  - Hartikainen AL
FAU - Jarvelin, Marjo-Riitta
AU  - Jarvelin MR
FAU - Gyllensten, Ulf
AU  - Gyllensten U
FAU - Boomsma, Dorret I
AU  - Boomsma DI
FAU - Campbell, Harry
AU  - Campbell H
FAU - Wilson, James F
AU  - Wilson JF
FAU - Chanock, Stephen J
AU  - Chanock SJ
FAU - Farrall, Martin
AU  - Farrall M
FAU - Goel, Anuj
AU  - Goel A
FAU - Medina-Gomez, Carolina
AU  - Medina-Gomez C
FAU - Rivadeneira, Fernando
AU  - Rivadeneira F
FAU - Estrada, Karol
AU  - Estrada K
FAU - Uitterlinden, Andre G
AU  - Uitterlinden AG
FAU - Hofman, Albert
AU  - Hofman A
FAU - Zillikens, M Carola
AU  - Zillikens MC
FAU - den Heijer, Martin
AU  - den Heijer M
FAU - Kiemeney, Lambertus A
AU  - Kiemeney LA
FAU - Maschio, Andrea
AU  - Maschio A
FAU - Hall, Per
AU  - Hall P
FAU - Tyrer, Jonathan
AU  - Tyrer J
FAU - Teumer, Alexander
AU  - Teumer A
FAU - Volzke, Henry
AU  - Volzke H
FAU - Kovacs, Peter
AU  - Kovacs P
FAU - Tonjes, Anke
AU  - Tonjes A
FAU - Mangino, Massimo
AU  - Mangino M
FAU - Spector, Tim D
AU  - Spector TD
FAU - Hayward, Caroline
AU  - Hayward C
FAU - Rudan, Igor
AU  - Rudan I
FAU - Hall, Alistair S
AU  - Hall AS
FAU - Samani, Nilesh J
AU  - Samani NJ
FAU - Attwood, Antony Paul
AU  - Attwood AP
FAU - Sambrook, Jennifer G
AU  - Sambrook JG
FAU - Hung, Joseph
AU  - Hung J
FAU - Palmer, Lyle J
AU  - Palmer LJ
FAU - Lokki, Marja-Liisa
AU  - Lokki ML
FAU - Sinisalo, Juha
AU  - Sinisalo J
FAU - Boucher, Gabrielle
AU  - Boucher G
FAU - Huikuri, Heikki
AU  - Huikuri H
FAU - Lorentzon, Mattias
AU  - Lorentzon M
FAU - Ohlsson, Claes
AU  - Ohlsson C
FAU - Eklund, Niina
AU  - Eklund N
FAU - Eriksson, Johan G
AU  - Eriksson JG
FAU - Barlassina, Cristina
AU  - Barlassina C
FAU - Rivolta, Carlo
AU  - Rivolta C
FAU - Nolte, Ilja M
AU  - Nolte IM
FAU - Snieder, Harold
AU  - Snieder H
FAU - Van der Klauw, Melanie M
AU  - Van der Klauw MM
FAU - Van Vliet-Ostaptchouk, Jana V
AU  - Van Vliet-Ostaptchouk JV
FAU - Gejman, Pablo V
AU  - Gejman PV
FAU - Shi, Jianxin
AU  - Shi J
FAU - Jacobs, Kevin B
AU  - Jacobs KB
FAU - Wang, Zhaoming
AU  - Wang Z
FAU - Bakker, Stephan J L
AU  - Bakker SJ
FAU - Mateo Leach, Irene
AU  - Mateo Leach I
FAU - Navis, Gerjan
AU  - Navis G
FAU - van der Harst, Pim
AU  - van der Harst P
FAU - Martin, Nicholas G
AU  - Martin NG
FAU - Medland, Sarah E
AU  - Medland SE
FAU - Montgomery, Grant W
AU  - Montgomery GW
FAU - Yang, Jian
AU  - Yang J
FAU - Chasman, Daniel I
AU  - Chasman DI
FAU - Ridker, Paul M
AU  - Ridker PM
FAU - Rose, Lynda M
AU  - Rose LM
FAU - Lehtimaki, Terho
AU  - Lehtimaki T
FAU - Raitakari, Olli
AU  - Raitakari O
FAU - Absher, Devin
AU  - Absher D
FAU - Iribarren, Carlos
AU  - Iribarren C
FAU - Basart, Hanneke
AU  - Basart H
FAU - Hovingh, Kees G
AU  - Hovingh KG
FAU - Hypponen, Elina
AU  - Hypponen E
FAU - Power, Chris
AU  - Power C
FAU - Anderson, Denise
AU  - Anderson D
FAU - Beilby, John P
AU  - Beilby JP
FAU - Hui, Jennie
AU  - Hui J
FAU - Jolley, Jennifer
AU  - Jolley J
FAU - Sager, Hendrik
AU  - Sager H
FAU - Bornstein, Stefan R
AU  - Bornstein SR
FAU - Schwarz, Peter E H
AU  - Schwarz PE
FAU - Kristiansson, Kati
AU  - Kristiansson K
FAU - Perola, Markus
AU  - Perola M
FAU - Lindstrom, Jaana
AU  - Lindstrom J
FAU - Swift, Amy J
AU  - Swift AJ
FAU - Uusitupa, Matti
AU  - Uusitupa M
FAU - Atalay, Mustafa
AU  - Atalay M
FAU - Lakka, Timo A
AU  - Lakka TA
FAU - Rauramaa, Rainer
AU  - Rauramaa R
FAU - Bolton, Jennifer L
AU  - Bolton JL
FAU - Fowkes, Gerry
AU  - Fowkes G
FAU - Fraser, Ross M
AU  - Fraser RM
FAU - Price, Jackie F
AU  - Price JF
FAU - Fischer, Krista
AU  - Fischer K
FAU - Krjuta Kov, Kaarel
AU  - Krjuta Kov K
FAU - Metspalu, Andres
AU  - Metspalu A
FAU - Mihailov, Evelin
AU  - Mihailov E
FAU - Langenberg, Claudia
AU  - Langenberg C
FAU - Luan, Jian'an
AU  - Luan J
FAU - Ong, Ken K
AU  - Ong KK
FAU - Chines, Peter S
AU  - Chines PS
FAU - Keinanen-Kiukaanniemi, Sirkka M
AU  - Keinanen-Kiukaanniemi SM
FAU - Saaristo, Timo E
AU  - Saaristo TE
FAU - Edkins, Sarah
AU  - Edkins S
FAU - Franks, Paul W
AU  - Franks PW
FAU - Hallmans, Goran
AU  - Hallmans G
FAU - Shungin, Dmitry
AU  - Shungin D
FAU - Morris, Andrew David
AU  - Morris AD
FAU - Palmer, Colin N A
AU  - Palmer CN
FAU - Erbel, Raimund
AU  - Erbel R
FAU - Moebus, Susanne
AU  - Moebus S
FAU - Nothen, Markus M
AU  - Nothen MM
FAU - Pechlivanis, Sonali
AU  - Pechlivanis S
FAU - Hveem, Kristian
AU  - Hveem K
FAU - Narisu, Narisu
AU  - Narisu N
FAU - Hamsten, Anders
AU  - Hamsten A
FAU - Humphries, Steve E
AU  - Humphries SE
FAU - Strawbridge, Rona J
AU  - Strawbridge RJ
FAU - Tremoli, Elena
AU  - Tremoli E
FAU - Grallert, Harald
AU  - Grallert H
FAU - Thorand, Barbara
AU  - Thorand B
FAU - Illig, Thomas
AU  - Illig T
FAU - Koenig, Wolfgang
AU  - Koenig W
FAU - Muller-Nurasyid, Martina
AU  - Muller-Nurasyid M
FAU - Peters, Annette
AU  - Peters A
FAU - Boehm, Bernhard O
AU  - Boehm BO
FAU - Kleber, Marcus E
AU  - Kleber ME
FAU - Marz, Winfried
AU  - Marz W
FAU - Winkelmann, Bernhard R
AU  - Winkelmann BR
FAU - Kuusisto, Johanna
AU  - Kuusisto J
FAU - Laakso, Markku
AU  - Laakso M
FAU - Arveiler, Dominique
AU  - Arveiler D
FAU - Cesana, Giancarlo
AU  - Cesana G
FAU - Kuulasmaa, Kari
AU  - Kuulasmaa K
FAU - Virtamo, Jarmo
AU  - Virtamo J
FAU - Yarnell, John W G
AU  - Yarnell JW
FAU - Kuh, Diana
AU  - Kuh D
FAU - Wong, Andrew
AU  - Wong A
FAU - Lind, Lars
AU  - Lind L
FAU - de Faire, Ulf
AU  - de Faire U
FAU - Gigante, Bruna
AU  - Gigante B
FAU - Magnusson, Patrik K E
AU  - Magnusson PK
FAU - Pedersen, Nancy L
AU  - Pedersen NL
FAU - Dedoussis, George
AU  - Dedoussis G
FAU - Dimitriou, Maria
AU  - Dimitriou M
FAU - Kolovou, Genovefa
AU  - Kolovou G
FAU - Kanoni, Stavroula
AU  - Kanoni S
FAU - Stirrups, Kathleen
AU  - Stirrups K
FAU - Bonnycastle, Lori L
AU  - Bonnycastle LL
FAU - Njolstad, Inger
AU  - Njolstad I
FAU - Wilsgaard, Tom
AU  - Wilsgaard T
FAU - Ganna, Andrea
AU  - Ganna A
FAU - Rehnberg, Emil
AU  - Rehnberg E
FAU - Hingorani, Aroon
AU  - Hingorani A
FAU - Kivimaki, Mika
AU  - Kivimaki M
FAU - Kumari, Meena
AU  - Kumari M
FAU - Assimes, Themistocles L
AU  - Assimes TL
FAU - Barroso, Ines
AU  - Barroso I
FAU - Boehnke, Michael
AU  - Boehnke M
FAU - Borecki, Ingrid B
AU  - Borecki IB
FAU - Deloukas, Panos
AU  - Deloukas P
FAU - Fox, Caroline S
AU  - Fox CS
FAU - Frayling, Timothy
AU  - Frayling T
FAU - Groop, Leif C
AU  - Groop LC
FAU - Haritunians, Talin
AU  - Haritunians T
FAU - Hunter, David
AU  - Hunter D
FAU - Ingelsson, Erik
AU  - Ingelsson E
FAU - Kaplan, Robert
AU  - Kaplan R
FAU - Mohlke, Karen L
AU  - Mohlke KL
FAU - O'Connell, Jeffrey R
AU  - O'Connell JR
FAU - Schlessinger, David
AU  - Schlessinger D
FAU - Strachan, David P
AU  - Strachan DP
FAU - Stefansson, Kari
AU  - Stefansson K
FAU - van Duijn, Cornelia M
AU  - van Duijn CM
FAU - Abecasis, Goncalo R
AU  - Abecasis GR
FAU - McCarthy, Mark I
AU  - McCarthy MI
FAU - Hirschhorn, Joel N
AU  - Hirschhorn JN
FAU - Qi, Lu
AU  - Qi L
FAU - Loos, Ruth J F
AU  - Loos RJ
FAU - Lindgren, Cecilia M
AU  - Lindgren CM
FAU - North, Kari E
AU  - North KE
FAU - Heid, Iris M
AU  - Heid IM
LA  - eng
PT  - Journal Article
DEP - 20130606
PL  - United States
TA  - PLoS Genet
JT  - PLoS genetics
JID - 101239074
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06 [ppublish]
PHST- 2012/05/04 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/06/06 [epublish]
AID - 10.1371/journal.pgen.1003500 [doi]
AID - PGENETICS-D-12-01098 [pii]
PST - ppublish
SO  - PLoS Genet. 2013 Jun;9(6):e1003500. doi: 10.1371/journal.pgen.1003500. Epub 2013 
      Jun 6.

PMID- 23754846
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 Jun 10
TI  - High-glucose levels and elastin degradation products accelerate osteogenesis in
      vascular smooth muscle cells.
AB  - Diabetes mellitus (DM) is a chronic disease in which the body either does not use
      or produce the glucose metabolising hormone insulin efficiently. Calcification of
      elastin in the arteries of diabetics is a major predictor of cardiovascular
      diseases. It has been previously shown that elastin degradation products work
      synergistically with transforming growth factor-beta 1 (TGF-beta1) to induce
      osteogenesis in vascular smooth muscle cells. In this study, we tested the
      hypothesis that high concentration of glucose coupled with elastin degradation
      products and TGF-beta1 (a cytokine commonly associated with diabetes) will cause 
      a greater degree of osteogenesis compared to normal vascular cells. Thus, the
      goal of this study was to analyse the effects of high concentration of glucose,
      elastin peptides and TGF-beta1 on bone-specific markers like alkaline phosphatase
      (ALP), osteocalcin (OCN) and runt-related transcription factor 2 (RUNX2). We
      demonstrated using relative gene expression and specific protein assays that
      elastin degradation products in the presence of high glucose cause the increase
      in expression of the specific elastin-laminin receptor-1 (ELR-1) and activin
      receptor-like kinase-5 (ALK-5) present on the surface of the vascular cells, in
      turn leading to overexpression of typical osteogenic markers like ALP, OCN and
      RUNX2. Conversely, blocking of ELR-1 and ALK-5 strongly suppressed the expression
      of the osteogenic proteins. In conclusion, our results indicate that glucose
      plays an important role in amplifying the osteogenesis induced by elastin
      peptides and TGF-beta1, possibly by activating the ELR-1 and ALK-5 signalling
      pathways.
AD  - Department of Bioengineering, Clemson University, Clemson, SC, USA.
FAU - Sinha, Aditi
AU  - Sinha A
FAU - Vyavahare, Naren R
AU  - Vyavahare NR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
OTO - NOTNLM
OT  - High glucose
OT  - elastin peptides
OT  - transforming growth factor-β1
OT  - vascular calcification
OT  - vascular smooth muscle cells
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 1479164113485101 [pii]
AID - 10.1177/1479164113485101 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 Jun 10.

PMID- 23754845
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 Jun 10
TI  - Serum 25-hydroxyvitamin D level is associated with aortic distensibility and left
      ventricle hypertrophy in newly diagnosed type 2 diabetes mellitus.
AB  - We aimed to evaluate the association between serum vitamin D status and elastic
      properties of aorta in patients with diabetes mellitus (DM). We studied 136
      patients with newly diagnosed DM (mean age: 62.9 +/- 10.6 years). Serum
      25-hydroxyvitamin D was measured using a direct competitive chemiluminescent
      immunoassay. Aortic distensibility was calculated from the echocardiographically 
      derived ascending aorta diameters and haemodynamic pressure measurements. Left
      ventricle mass index (LVMI) was determined according to the Devereux formula.
      Multiple linear regression analysis showed that vitamin D level is independently 
      associated with LVMI (beta = -0.259, p = 0.001), aortic distensibility (beta =
      0.369, p < 0.001), high-sensitive C-reactive protein (hs-CRP) (beta = -0.220, p =
      0.002) and body mass index (beta = -0.167, p = 0.015) in patients with DM. In
      diabetic patients, serum 25-hydroxyvitamin D level is independently associated
      with aortic distensibility. Vitamin D may play a role on pathogenesis of impaired
      elastic properties of aorta in type 2 DM.
AD  - Department of Cardiology, Adana Numune Training and Research Hospital, Adana,
      Turkey.
FAU - Kuloglu, Osman
AU  - Kuloglu O
FAU - Gur, Mustafa
AU  - Gur M
FAU - Seker, Taner
AU  - Seker T
FAU - Kalkan, Gulhan Yuksel
AU  - Kalkan GY
FAU - Kirim, Sinan
AU  - Kirim S
FAU - Sahin, Durmus Y
AU  - Sahin DY
FAU - Harbalioglu, Hazar
AU  - Harbalioglu H
FAU - Turkoglu, Caner
AU  - Turkoglu C
FAU - Acele, Armagan
AU  - Acele A
FAU - Elbasan, Zafer
AU  - Elbasan Z
FAU - Ozaltun, Betul
AU  - Ozaltun B
FAU - Cayli, Murat
AU  - Cayli M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
OTO - NOTNLM
OT  - Diabetes
OT  - aortic distensibility
OT  - hypertrophy
OT  - inflammation
OT  - vitamin D
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 1479164113491125 [pii]
AID - 10.1177/1479164113491125 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 Jun 10.

PMID- 23754777
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
DP  - 2013 Jun 10
TI  - Predicting Readmission or Death After Acute ST-Elevation Myocardial Infarction.
LID - 10.1002/clc.22156 [doi]
AB  - BACKGROUND: Risk factors for emergent readmissions or death after acute
      myocardial infarction (AMI) are important in identifying patients at risk for
      major adverse events. However, there has been limited investigation conducted of 
      prospective clinical registries to determine relevant risk factors. HYPOTHESIS:
      We hypothesize 30-day readmission or death could be predicted using patient,
      procedural, and process factors. METHODS: Patients presenting with ST-elevation
      myocardial infarction (STEMI) from 2006 to 2011 were prospectively enrolled in a 
      STEMI registry (1271 patients). Thirty-day readmission was ascertained by
      administrative claims data. Death was determined by linking to the Social
      Security Death Master File. Univariate and stepwise multivariate logistic
      regression was conducted with Hosmer-Lemeshow goodness-of-fit statistics for
      model calibration and receiver operating characteristic (ROC) curve for model
      discrimination. RESULTS: The combined end point of 30-day readmission or
      postdischarge death included 135 patients (10.6%), including 109 emergent
      readmissions and 26 deaths. Factors associated with an increase risk of 30-day
      readmission or postdischarge death included age >/=80 years, diabetes, chest pain
      or cardiac arrest at presentation, and 3-vessel disease found at initial
      angiography. Factors associated with a decreased risk of 30-day readmission or
      postdischarge death included transfer to the catheterization lab from another
      emergency department, clopidogrel given during the procedure
      hypercholesterolemia, and receiving aspirin, beta-blockers, and
      angiotensin-converting enzyme or angiotensin receptor blocker inhibitors at
      discharge. Index admission outcomes indicative of readmission or death
      postdischarge only included a new diagnosis of congestive heart failure. The
      model discriminated well with an ROC of 0.71 (95% confidence interval:
      0.66-0.76). CONCLUSIONS: Prehospitalization factors are overlooked and are
      important factors to incorporate in routine risk prediction models for
      readmission or death within 30 days following an AMI.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of
      Medicine at Dartmouth,Lebanon, New Hampshire; Section of Cardiology, Department
      of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
FAU - Brown, Jeremiah R
AU  - Brown JR
FAU - Conley, Sheila M
AU  - Conley SM
FAU - Niles, Nathaniel W 2nd
AU  - Niles NW 2nd
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/03/15 [received]
PHST- 2013/05/11 [revised]
AID - 10.1002/clc.22156 [doi]
PST - aheadofprint
SO  - Clin Cardiol. 2013 Jun 10. doi: 10.1002/clc.22156.

PMID- 23754773
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1875-8312 (Electronic)
IS  - 1569-5794 (Linking)
DP  - 2013 Jun 11
TI  - Asymptomatic subjects with zero coronary calcium score: coronary CT angiographic 
      features of plaques in event-prone patients.
AB  - The aims of this study were: (a) to assess clinical predictors and coronary
      computed tomography angiography (CCTA) characteristics of noncalcified coronary
      plaques (NCP) in subjects who had cardiac events despite a zero coronary artery
      calcium score (CACS), and (b) to describe computed tomography (CT) plaque
      characteristics in subjects with cardiac events. A total of 7,961 subjects with
      zero CACS were evaluated; 6,531 subjects underwent CCTA as part of a health
      check-up. Those who had zero CACS were included in our mid-term follow-up study. 
      Cardiac events included cardiac death, acute coronary syndrome or
      revascularization with stable angina. More than one NCP was identified in 441
      subjects with zero CACS, including 48 subjects with obstructive coronary artery
      disease (CAD) caused by NCPs. Age, male gender, hypertension, diabetes and low
      density lipoprotein were independent predictors of obstructive CAD. Among
      subjects with obstructive CAD, young adults were classified into low (79.2 %) or 
      moderate (72.9 %) risk groups by the National Centers for Environmental
      Prediction III guidelines. Approximately 0.2 % of subjects had cardiac events
      during our follow-up period. All patients with cardiac events had NCPs with
      significantly lower mean CT numbers, higher remodeling indexes and worse degree
      of stenosis. In asymptomatic subjects with zero CACS, NCP was associated with
      cardiac events. CCTA might be useful for risk stratification among select
      populations with CAD and zero CACS who have certain plaque characteristics
      associated with cardiac events.
AD  - Division of Cardiovascular Imaging, Department of Radiology, Seoul National
      University Bundang Hospital, 300 Gumi-dong, Bungdang-gu, Seongnam-si,
      Gyeonggi-do, 436-707, Korea.
FAU - Lee, Min Su
AU  - Lee MS
FAU - Chun, Eun Ju
AU  - Chun EJ
FAU - Kim, Kil Joong
AU  - Kim KJ
FAU - Kim, Jeong A
AU  - Kim JA
FAU - Yoo, Jin Young
AU  - Yoo JY
FAU - Choi, Sang Il
AU  - Choi SI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Int J Cardiovasc Imaging
JT  - The international journal of cardiovascular imaging
JID - 100969716
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/05/24 [received]
PHST- 2013/06/05 [accepted]
PHST- 2013/06/11 [aheadofprint]
AID - 10.1007/s10554-013-0257-z [doi]
PST - aheadofprint
SO  - Int J Cardiovasc Imaging. 2013 Jun 11.

PMID- 23754690
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
DP  - 2013 Jun 10
TI  - Presence of Angina Pectoris Is Related to Extensive Coronary Artery Disease in
      Diabetic Patients.
LID - 10.1002/clc.22151 [doi]
AB  - BACKGROUND: Due to sensorial autonomic neuropathy, the type and severity of
      angina pectoris in patients with diabetes mellitus (DM) may be rather different
      from the type and severity of angina pectoris in patients without DM. HYPOTHESIS:
      The aim of the study was to understand if angina pectoris is related to extensive
      coronary artery disease (CAD) in patients with DM. METHODS: The study included
      530 patients with DM who underwent coronary angiography at our center in 2009 and
      2010. Patients were divided into 4 groups according to type of chest pain: group 
      1, noncardiac chest pain or no pain; group 2, angina equivalent; group 3,
      atypical angina; and group 4, typical angina. All angiograms were re-evaluated
      and Gensini scores were calculated. Three-vessel disease was diagnosed in the
      presence of stenosis >50% in all 3 coronary artery systems. RESULTS: There were
      no statistically significant differences between the groups with regard to age,
      sex, systolic or diastolic blood pressures, body mass index, creatinine
      clearance, or lipid profile. Fasting blood glucose was significantly higher in
      group 4 than in group 2. Gensini scores were not statistically different between 
      groups 1 and 2 or between groups 3 and 4; however, the scores for groups 3 and 4 
      were higher than the score for either group 1 or group 2. Prevalence of 3-vessel 
      disease was significantly higher in groups 3 and 4 compared with the other
      groups. CONCLUSIONS: The presence of angina pectoris was related to extensive CAD
      in patients with DM. The extent of CAD was not correlated with the type of angina
      (typical or atypical).
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Faculty of Medicine, Department of Cardiology, Gaziosmanpasa University, Tokat,
      Turkey.
FAU - Celik, Atac
AU  - Celik A
FAU - Karayakali, Metin
AU  - Karayakali M
FAU - Erkorkmaz, Unal
AU  - Erkorkmaz U
FAU - Altunkas, Fatih
AU  - Altunkas F
FAU - Karaman, Kayihan
AU  - Karaman K
FAU - Koc, Fatih
AU  - Koc F
FAU - Ceyhan, Koksal
AU  - Ceyhan K
FAU - Kadi, Hasan
AU  - Kadi H
FAU - Avsar, Alaettin
AU  - Avsar A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/04/05 [received]
PHST- 2013/05/02 [revised]
AID - 10.1002/clc.22151 [doi]
PST - aheadofprint
SO  - Clin Cardiol. 2013 Jun 10. doi: 10.1002/clc.22151.

PMID- 23754673
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 Jun 11
TI  - Independent glucose and weight-reducing effects of Liraglutide in a real-world
      population of type 2 diabetic outpatients.
AB  - The GLP-1 receptor agonist Liraglutide is effective in reducing HbA1c in type 2
      diabetic (T2D) patients. In addition, treatment with Liraglutide is associated
      with significant weight loss. In this study, we analyzed the inter-relationships 
      between glycemic and weight effects of Liraglutide treatment in a population of
      type 2 diabetic outpatients. T2D patients initiating Liraglutide therapy since
      September 2010 to July 2012 at 3 outpatient clinics were enrolled and
      followed-up. We collected baseline information about anthropometric data,
      cardiovascular risk factors, diabetes duration, prevalence of complications and
      history of anti-diabetic medications. We collected HbA1c and body weight at
      baseline and every 4 months. A total of 166 patients were included, who were on
      average 56.6 +/- 8.9 (mean +/- SD) years old and had a baseline HbA1c of 8.7 +/- 
      1.3 % and BMI 36.3 +/- 6.4 kg/m2. Mean follow-up was 9.4 +/- 4.2 months (range
      4-16). Patients lost on average 1.5 +/- 1.3 % HbA1c and 4.0 +/- 5.0 kg body
      weight. Most patients (73.5 %) improved HbA1c and loosed weight. Significant
      independent determinants of HbA1c drop were baseline HbA1c (r = 0.673; p < 0.001)
      and previous insulin therapy (r = -0.251; p < 0.001). The only independent
      determinant of weight loss was baseline BMI (r = 0.429; p < 0.001). Drop in HbA1c
      was unrelated to baseline BMI or weight loss. Weight loss was unrelated to
      baseline HbA1c or drop in HbA1c. Glycemic improvement and weight reduction
      obtained with Liraglutide treatment in T2D patients in a real-world setting are
      independent and possibly mediated by different mechanisms.
AD  - Department of Medicine, University Hospital of Padova, Via Giustiniani, 2, 35100,
      Padua, Italy, gianpaolofadini@hotmail.com.
FAU - Fadini, Gian Paolo
AU  - Fadini GP
FAU - Simioni, Natalino
AU  - Simioni N
FAU - Frison, Vera
AU  - Frison V
FAU - Dal Pos, Michela
AU  - Dal Pos M
FAU - Bettio, Michela
AU  - Bettio M
FAU - Rocchini, Paola
AU  - Rocchini P
FAU - Avogaro, Angelo
AU  - Avogaro A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/05/06 [received]
PHST- 2013/05/28 [accepted]
PHST- 2013/06/11 [aheadofprint]
AID - 10.1007/s00592-013-0489-3 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 Jun 11.

PMID- 23754672
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 Jun 11
TI  - "Normoalbuminuric" diabetic nephropathy: tubular damage and NGAL.
AB  - The aim of this study was to demonstrate that neutrophil gelatinase-associated
      lipocalin (NGAL) increased before the onset of microalbuminuria in patients with 
      type 1 diabetes mellitus (T1DM), representing an important biochemical parameter 
      with high sensitivity and specificity to make a precocious diagnosis of
      "normoalbuminuric" diabetic nephropathy (DN). Serum NGAL (sNGAL) and urinary NGAL
      (uNGAL) levels were evaluated in a cohort of fifty patients affected by T1DM.
      They had no signs of clinical nephropathy. Thirty-five healthy subjects (HS) were
      recruited. sNGAL levels were significantly higher compared with those measured in
      HS [193.7 (103.2-405.4) vs. 46.4 (39.8-56.2) ng/ml; p < 0.0001], as were uNGAL
      levels [25.5 (14.2-40.2) vs. 6.5 (2.9-8.5) ng/ml; p < 0.0001]. sNGAL was found to
      be directly correlated with glycated hemoglobin. uNGAL also positively correlated
      with albuminuria, whereas an inverse correlation was found with uric acid. After 
      multivariate analysis, significance was maintained for the correlation between
      uNGAL and microalbuminuria. In ROC analysis, sNGAL showed a good diagnostic
      profile such as uNGAL. NGAL increases in patients with T1DM, even before
      diagnosis of microalbuminuria representing an early biomarker of
      "normoalbuminuric" DN with a good sensitivity and specificity. NGAL measurement
      could be useful for the evaluation of early renal involvement in the course of
      diabetes.
AD  - Department of Internal Medicine, University of Messina, Messina, Italy,
      ant.lacq@gmail.com.
FAU - Lacquaniti, Antonio
AU  - Lacquaniti A
FAU - Donato, Valentina
AU  - Donato V
FAU - Pintaudi, Basilio
AU  - Pintaudi B
FAU - Di Vieste, Giacoma
AU  - Di Vieste G
FAU - Chirico, Valeria
AU  - Chirico V
FAU - Buemi, Antoine
AU  - Buemi A
FAU - Di Benedetto, Antonino
AU  - Di Benedetto A
FAU - Arena, Adriana
AU  - Arena A
FAU - Buemi, Michele
AU  - Buemi M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/12/08 [received]
PHST- 2013/05/21 [accepted]
PHST- 2013/06/11 [aheadofprint]
AID - 10.1007/s00592-013-0485-7 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 Jun 11.

PMID- 23754667
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1613-4133 (Electronic)
IS  - 1613-4125 (Linking)
DP  - 2013 Jun 10
TI  - Methionine-induced hyperhomocysteinemia impairs the antioxidant ability of
      high-density lipoproteins without reducing in vivo macrophage-specific reverse
      cholesterol transport.
LID - 10.1002/mnfr.201300133 [doi]
AB  - SCOPE: High plasma homocysteine concentrations have been associated with
      increased risk of cardiovascular disease both in humans and experimental animal
      models, whereas plasma HDL-cholesterol concentration is inversely correlated with
      such disorders. This work aimed to study the impact of methionine-induced
      hyperhomocysteinemia (HHcy) on two major antiatherogenic functions of HDL, namely
      their capacity to prevent LDL oxidation and induce in vivo macrophage-specific
      reverse cholesterol transport. METHODS AND RESULTS: Methionine-induced HHcy in
      mice resulted in an approximately 20% decreased concentration of HDL-cholesterol 
      and HDL main protein component, apolipoprotein A-I. The HDL potential to resist
      oxidation as well as to prevent LDL oxidative modification was impaired in
      hyperhomocysteinemic mice. Activities of paraoxonase-1 and platelet activation
      factor acetylhydrolase, two of the main HDL-associated enzymes with antioxidant
      activity, were reduced. The ability of HDL to efflux cholesterol from macrophages
      was decreased in hyperhomocysteinemic mice; however, the in vivo
      macrophage-specific reverse cholesterol transport measured as the output of
      labeled cholesterol into feces did not significantly differ between groups.
      CONCLUSION: Our data indicate that the HDL from methionine-induced
      hyperhomocysteinemic mice was more prone to oxidation and displayed lower
      capacity to protect LDL against oxidative modification than that of control mice,
      highlighting a mechanism by which a diet-induced HHcy may facilitate progression 
      of atherosclerosis.
CI  - (c) 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
AD  - Institut d'Investigacions Biomediques Sant Pau (IIB-Sant Pau), Barcelona, Spain; 
      CIBER de Diabetes y Enfermedades Metabolicas Asociadas, CIBERDEM, Spain.
FAU - Julve, Josep
AU  - Julve J
FAU - Escola-Gil, Joan C
AU  - Escola-Gil JC
FAU - Rodriguez-Millan, Elisabeth
AU  - Rodriguez-Millan E
FAU - Martin-Campos, Jesus M
AU  - Martin-Campos JM
FAU - Jauhiainen, Matti
AU  - Jauhiainen M
FAU - Quesada, Helena
AU  - Quesada H
FAU - Renteria-Obregon, Ivy M
AU  - Renteria-Obregon IM
FAU - Osada, Jesus
AU  - Osada J
FAU - Sanchez-Quesada, Jose L
AU  - Sanchez-Quesada JL
FAU - Blanco-Vaca, Francisco
AU  - Blanco-Vaca F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Mol Nutr Food Res
JT  - Molecular nutrition & food research
JID - 101231818
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/02/20 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/03/31 [accepted]
AID - 10.1002/mnfr.201300133 [doi]
PST - aheadofprint
SO  - Mol Nutr Food Res. 2013 Jun 10. doi: 10.1002/mnfr.201300133.

PMID- 23754632
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1633-8065 (Electronic)
IS  - 1633-8065 (Linking)
DP  - 2013 Jun 11
TI  - Surgical site infection after open reduction and internal fixation of tibial
      plateau fractures.
AB  - OBJECTIVE : The aim of this study was to identify risk factors for surgical site 
      infections and to quantify the contribution of independent risk factors to the
      probability of developing infection after definitive fixation of tibial plateau
      fractures in adult patients. METHODS: A retrospective analysis was performed at a
      level I trauma center between January 2004 and December 2010. Data were collected
      from a review of the patient's electronic medical records. A total of 251
      consecutive patients (256 cases) were divided into two groups, those with
      surgical site infections and those without surgical site infections. Preoperative
      and perioperative variables were compared between these groups, and risk factors 
      were determined by univariate analyses and multivariate logistic regression.
      Variables analyzed included age, gender, smoking history, diabetes, presence of
      an open fracture, presence of compartment syndrome, Schatzker classification,
      polytrauma status, ICU stay, time from injury to surgery, use of temporary
      external fixation, surgical approach, surgical fixation, operative time, and use 
      of a drain. RESULTS: The overall rate of surgical site infection after ORIF of
      tibial plateau fractures during the 7 years of this study was 7.8 % (20 of 256). 
      The most common causative pathogens was Staphylococcus aureus (n = 15, 75 %).
      Independent predictors of surgical site infection identified by multivariate
      analyses were open tibial plateau fracture (odds ratio = 3.9; 95 % CI = 1.3-11.6;
      p = 0.015) and operative time (odds ratio = 2.7; 95 % CI = 1.6-4.4; p < 0.001).
      The presence of compartment syndrome (odds ratio = 3.4; 95 % CI = 0.7-15.9; p =
      0.119), use of temporary external fixation (odds ratio = 0.5; 95 % CI = 0.2-1.7; 
      p = 0.298), and ICU stay (odds ratio = 1.0; 95 % CI = 1.0-1.1; p = 0.074) were
      not determined to be independent predictors of surgical site infection.
      CONCLUSIONS: Both open fracture and operative time are independent risks factors 
      for postoperative infection.
AD  - Department of Orthopaedic Surgery, School of Medicine, Denver Health Medical
      Center, University of Colorado Denver, 777 Bannock Street, MC 0188, Denver, CO,
      80204, USA.
FAU - Lin, Shishui
AU  - Lin S
FAU - Mauffrey, Cyril
AU  - Mauffrey C
FAU - Hammerberg, E Mark
AU  - Hammerberg EM
FAU - Stahel, Philip F
AU  - Stahel PF
FAU - Hak, David J
AU  - Hak DJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Eur J Orthop Surg Traumatol
JT  - European journal of orthopaedic surgery & traumatology : orthopedie traumatologie
JID - 9518037
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/04/22 [received]
PHST- 2013/05/29 [accepted]
PHST- 2013/06/11 [aheadofprint]
AID - 10.1007/s00590-013-1252-8 [doi]
PST - aheadofprint
SO  - Eur J Orthop Surg Traumatol. 2013 Jun 11.

PMID- 23754616
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Linking)
DP  - 2013 Jun 11
TI  - Experimental diabetes treated with trigonelline: effect on key enzymes related to
      diabetes and hypertension, beta-cell and liver function.
AB  - Type 2 diabetes is quite diverse, including the improvement of insulin
      sensitivity by dipeptidylpeptidase-4 (DPP-4) inhibitor, alpha-glucosidase
      inhibitors, and the protection of beta-cells islet. The aim of this study was to 
      search the effect of trigonelline (Trig) on DPP-4, alpha-glucosidase and
      angiotensin converting enzyme (ACE) activities as well as beta-cells
      architecture, and starch and glucose tolerance test. In surviving diabetic rats, 
      the supplement of Trig potentially inhibited DPP-4 and alpha-glucosidase
      activities in both plasma and small intestine. The pancreas islet and less
      beta-cells damage were observed after the administration of trig to diabetic
      rats. The increase of GLP-1 in surviving diabetic rats suppressed the increase of
      blood glucose level and improved results in the oral glucose and starch tolerance
      test. Trig also normalized key enzyme related to hypertension as ACE and improved
      the hemoglobin A1c and lipid profiles (plasma triglyceride, HDL-cholesterol,
      LDL-cholesterol, and total cholesterol), and liver indices toxicity. Therefore,
      these results revealed that Trig was successful in improving glycemic control,
      metabolic parameters, and liver function in diabetic rats. It is therefore
      suggested that Trig may be a potential agent for the treatment of type 2
      diabetes.
AD  - Biotechnology High School of Sfax (ISBS), University of Sfax, Soukra Km 4.5, P.O.
      Box 261, 3038, Sfax, Tunisia, khaled.hamden@yahoo.fr.
FAU - Hamden, Khaled
AU  - Hamden K
FAU - Bengara, Amel
AU  - Bengara A
FAU - Amri, Zahra
AU  - Amri Z
FAU - Elfeki, Abdelfattah
AU  - Elfeki A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/03/09 [received]
PHST- 2013/05/16 [accepted]
PHST- 2013/06/11 [aheadofprint]
AID - 10.1007/s11010-013-1690-y [doi]
PST - aheadofprint
SO  - Mol Cell Biochem. 2013 Jun 11.

PMID- 23754497
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1520-6300 (Electronic)
IS  - 1042-0533 (Linking)
DP  - 2013 Jun 10
TI  - Modeling multisystem biological risk in later life: Allostatic load in the
      lothian birth cohort study 1936.
LID - 10.1002/ajhb.22406 [doi]
AB  - OBJECTIVES: To investigate and replicate a multisystem model of biological risk, 
      or allostatic load, in a sample of generally healthy older adults. METHODS:
      Multigroup confirmatory factor analysis (MG-CFA) was applied to data from the
      Lothian Birth Cohort 1936 (n = 726). Blood samples were taken at a physical
      examination. Three markers of inflammation (fibrinogen, interleukin-6, and
      C-reactive protein), five metabolic markers (high- and low-density lipoprotein,
      body mass index, glycated hemoglobin, and triglyceride), and blood pressure (mean
      sitting systolic and diastolic blood pressure) were used to estimate a
      second-order CFA model of allostatic load. Our sample was split into those taking
      antihypertensive, anti-inflammatory, lipid-lowering, and diabetes medications (n 
      = 470), and those who were not (n = 256), in order to test the stability of the
      CFA model across groups. RESULTS: In the nonmedicated sample, a second-order
      allostatic load model showed good fit to the data. However, the second-order
      model failed to estimate in the medicated group. The factor correlations between 
      blood pressure and inflammation and metabolism were smaller in magnitude in the
      medicated group. Invariance analysis on the first-order measurement model
      suggested significant differences across groups in the associations of
      low-density lipoprotein and HbA1c with metabolism. CONCLUSIONS: Reliable
      measurement of allostatic load is possible in ageing samples free of medications 
      but is complicated in the presence of medications. MG-CFA represents a highly
      versatile method for the analysis of allostatic load. Am. J. Hum. Biol., 2013.
      (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Centre for Cognitive Ageing and Cognitive Epidemiology, Department of Psychology,
      The University of Edinburgh, Edinburgh, EH8 9JZ, United Kingdom; Department of
      Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, United Kingdom.
FAU - Booth, Tom
AU  - Booth T
FAU - Starr, John M
AU  - Starr JM
FAU - Deary, Ian
AU  - Deary I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Am J Hum Biol
JT  - American journal of human biology : the official journal of the Human Biology
      Council
JID - 8915029
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/04/05 [received]
PHST- 2013/04/05 [accepted]
AID - 10.1002/ajhb.22406 [doi]
PST - aheadofprint
SO  - Am J Hum Biol. 2013 Jun 10. doi: 10.1002/ajhb.22406.

PMID- 23754300
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1531-4995 (Electronic)
IS  - 0023-852X (Linking)
DP  - 2013 Jun 11
TI  - Modalities of treatment for laryngotracheal stenosis: The EVMS experience.
LID - 10.1002/lary.24237 [doi]
AB  - Objectives: The aims of the study were to identify trends in surgical management 
      of laryngotracheal stenosis (LTS) based on lesion location, as well as to
      recognize factors associated with recurrence and repeat surgical intervention.
      Design: The study is a retrospective review of all adult patients cared for at a 
      tertiary care Laryngology practice with a diagnosis of laryngotracheal stenosis
      between October 2001 and July 2010, following IRB approval. Methods: This study
      collectively measured demographics, co-morbidities, etiologies, sites of
      stenoses, treatment modalities, and recurrences. Results: Incisions made with the
      CO2 laser were the most common modality of treatment; patients with multi-level
      tracheal stenosis were most likely to have undergone at least one operation in
      which the CO2 laser was used to make incisions (78.7%). Balloon dilation was most
      commonly employed in patients with multi-level tracheal stenosis (66.0%). Lowest 
      rates of decannulation were identified in patients with a pure tracheal stenosis 
      (23.1%). Patients presenting with multi-level tracheal stenosis underwent the
      most procedures (6.7). Supraglottic, glottic, and multi-level laryngeal stenosis 
      recurred at the lowest rates. Patients suffering from diabetes mellitus recurred 
      in an average period of 3.9 months, a shorter time frame than those without
      diabetes, who recurred every 10.5 months. Conclusions: Laser incision and/or
      balloon dilation, are most effective in treatment of pure glottic, subglottic and
      tracheal stenosis. ultilevel tracheal stenosis warrant closer follow up, and are 
      more likely to require multiple procedures. Worsening stenosis despite endoscopic
      management warrants an open procedure. Diabetes is associated with an earlier
      recurrence of stenosis.
CI  - Copyright (c) 2013 The American Laryngological, Rhinological, and Otological
      Society, Inc.
AD  - Department of Otolaryngology, Norfolk, Virginia, USA; Eastern Virginia Medical
      School, Norfolk, Virginia, USA.
FAU - Sinacori, John T
AU  - Sinacori JT
FAU - Taliercio, Sal J
AU  - Taliercio SJ
FAU - Duong, Elizabeth
AU  - Duong E
FAU - Benson, Chris
AU  - Benson C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/10/31 [received]
PHST- 2013/05/03 [revised]
PHST- 2013/05/14 [accepted]
AID - 10.1002/lary.24237 [doi]
PST - aheadofprint
SO  - Laryngoscope. 2013 Jun 11. doi: 10.1002/lary.24237.

PMID- 23754254
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
DP  - 2013 Jun 11
TI  - Second-versus first-generation "Limus"-eluting stents in diabetic patients with
      coronary artery disease: A randomized comparison in setting of ISAR-TEST-4 trial.
LID - 10.1002/ccd.24741 [doi]
AB  - BACKGROUND: Patients with diabetes mellitus remain at higher risk for adverse
      events following percutaneous coronary intervention and the identification of the
      optimum drug eluting stents (DES) in these patients is of high clinical
      relevance. We compared effectiveness of everolimus-eluting stents (EES; Xience)
      versus sirolimus-eluting stents (SES; Cypher) in patients with diabetes mellitus 
      enrolled in the Intracoronary Stenting and Angiographic Results: Test Efficacy of
      3 Limus-Eluting Stents (ISAR-TEST-4) trial. METHODS: In the setting of the
      ISAR-TEST-4 trial, 1304 patients with broad inclusion criteria were randomized to
      treatment with EES or SES. The focus of the present analysis is on a cohort of
      377 patients with diabetes mellitus assigned to receive EES (n = 184) or SES (n =
      193). The primary endpoint was the composite of cardiac death, myocardial
      infarction (MI) related to the target vessel, or target lesion revascularization 
      (TLR) at 3-year follow-up. Secondary endpoints were parameters of angiographic
      and clinical restenosis (in-stent late lumen loss, binary restenosis, and TLR),
      all-cause mortality and definite/probable stent thrombosis. RESULTS: EES was
      comparable to SES concerning the incidence of the primary endpoint (21% vs. 24%, 
      respectively; relative risk = 0.87; 95% CI, 0.57-1.34; P = 0.53). Concerning the 
      secondary endpoint, TLR at 3 years with EES versus SES stents was not
      statistically different (14.7% vs. 16.6%, respectively; relative risk = 0.85; 95%
      CI, 0.51-1.43; P = 0.55). In terms of angiographic outcomes patients treated with
      EES as compared to SES had significantly lower late lumen loss (0.22 +/- 0.46 mm 
      vs. 0.44 +/- 0.66 mm, respectively; P < 0.001) and binary restenosis (8.4% vs.
      17%, respectively; P = 0.02) at 6- to 8-month angiographic follow-up. EES was
      comparable to SES concerning the incidence of all-cause death (10% vs. 16%,
      respectively; relative risk = 0.66; 95% CI, 0.37-1.18; P = 0.16) and stent
      thrombosis (1.1% vs. 3.1%, respectively; P = 0.19). CONCLUSIONS: In patients with
      diabetes mellitus enrolled in a real-world randomized control trial, EES is
      comparable to SES in terms of clinical efficacy and safety out to 3 years;
      angiographic markers of antirestenotic efficacy favored EES. (c) 2013 Wiley
      Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc., a Wiley company.
AD  - Deutsches Herzzentrum, Technische Universitat, Munich, Germany.
FAU - Kufner, Sebastian
AU  - Kufner S
FAU - Byrne, Robert A
AU  - Byrne RA
FAU - Mehilli, Julinda
AU  - Mehilli J
FAU - Massberg, Steffen
AU  - Massberg S
FAU - Birkmeier, Katrin A
AU  - Birkmeier KA
FAU - Schulz, Stefanie
AU  - Schulz S
FAU - Pache, Jurgen
AU  - Pache J
FAU - Schomig, Albert
AU  - Schomig A
FAU - Kastrati, Adnan
AU  - Kastrati A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the
      Society for Cardiac Angiography & Interventions
JID - 100884139
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/08/26 [received]
PHST- 2012/11/03 [accepted]
AID - 10.1002/ccd.24741 [doi]
PST - aheadofprint
SO  - Catheter Cardiovasc Interv. 2013 Jun 11. doi: 10.1002/ccd.24741.

PMID- 23753849
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 127
IP  - 23
DP  - 2013 Jun 11
TI  - Letter by koh regarding article, "statins and risk of new-onset diabetes
      mellitus".
PG  - e837
LID - 10.1161/CIRCULATIONAHA.112.000524 [doi]
FAU - Koh, Kwang Kon
AU  - Koh KK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 127/23/e837 [pii]
AID - 10.1161/CIRCULATIONAHA.112.000524 [doi]
PST - ppublish
SO  - Circulation. 2013 Jun 11;127(23):e837. doi: 10.1161/CIRCULATIONAHA.112.000524.

PMID- 23753259
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Linking)
DP  - 2013 Jun 10
TI  - Glucose Control in Older Adults With Diabetes Mellitus-More Harm Than Good?:
      Comment on "The Association Between Hypoglycemia and Dementia in a Biracial
      Cohort of Older Adults With Diabetes Mellitus"
PG  - 1-2
LID - 10.1001/jamainternmed.2013.6189 [doi]
FAU - Lipska, Kasia J
AU  - Lipska KJ
FAU - Montori, Victor M
AU  - Montori VM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 1696174 [pii]
AID - 10.1001/jamainternmed.2013.6189 [doi]
PST - aheadofprint
SO  - JAMA Intern Med. 2013 Jun 10:1-2. doi: 10.1001/jamainternmed.2013.6189.

PMID- 23753199
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Linking)
DP  - 2013 Jun 10
TI  - Association Between Hypoglycemia and Dementia in a Biracial Cohort of Older
      Adults With Diabetes Mellitus.
PG  - 1-6
LID - 10.1001/jamainternmed.2013.6176 [doi]
AB  - IMPORTANCE Hypoglycemia commonly occurs in patients with diabetes mellitus (DM)
      and may negatively influence cognitive performance. Cognitive impairment in turn 
      can compromise DM management and lead to hypoglycemia. OBJECTIVE To prospectively
      evaluate the association between hypoglycemia and dementia in a biracial cohort
      of older adults with DM. DESIGN AND SETTING Prospective population-based study.
      PARTICIPANTS We studied 783 older adults with DM (mean age, 74.0 years; 47.0% of 
      black race/ethnicity; and 47.6% female) who were participating in the prospective
      population-based Health, Aging, and Body Composition Study beginning in 1997 and 
      who had baseline Modified Mini-Mental State Examination scores of 80 or higher.
      MAIN OUTCOME MEASURES Dementia diagnosis was determined during the follow-up
      period from hospital records indicating an admission associated with dementia or 
      the use of prescribed dementia medications. Hypoglycemic events were determined
      during the follow-up period by hospital records. RESULTS During the 12-year
      follow-up period, 61 participants (7.8%) had a reported hypoglycemic event, and
      148 (18.9%) developed dementia. Those who experienced a hypoglycemic event had a 
      2-fold increased risk for developing dementia compared with those who did not
      have a hypoglycemic event (34.4% vs 17.6%, P &lt; .001; multivariate-adjusted
      hazard ratio, 2.1; 95% CI, 1.0-4.4). Similarly, older adults with DM who
      developed dementia had a greater risk for having a subsequent hypoglycemic event 
      compared with participants who did not develop dementia (14.2% vs 6.3%, P &lt;
      .001; multivariate-adjusted hazard ratio, 3.1; 95% CI, 1.5-6.6). Further
      adjustment for stroke, hypertension, myocardial infarction, and cognitive change 
      scores produced similar results. CONCLUSION AND RELEVANCE Among older adults with
      DM, there seems to be a bidirectional association between hypoglycemia and
      dementia.
FAU - Yaffe, Kristine
AU  - Yaffe K
FAU - Falvey, Cherie M
AU  - Falvey CM
FAU - Hamilton, Nathan
AU  - Hamilton N
FAU - Harris, Tamara B
AU  - Harris TB
FAU - Simonsick, Eleanor M
AU  - Simonsick EM
FAU - Strotmeyer, Elsa S
AU  - Strotmeyer ES
FAU - Shorr, Ronald I
AU  - Shorr RI
FAU - Metti, Andrea
AU  - Metti A
FAU - Schwartz, Ann V
AU  - Schwartz AV
CN  - for the Health ABC Study
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 1696172 [pii]
AID - 10.1001/jamainternmed.2013.6176 [doi]
PST - aheadofprint
SO  - JAMA Intern Med. 2013 Jun 10:1-6. doi: 10.1001/jamainternmed.2013.6176.

PMID- 23753092
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1098-4275 (Electronic)
IS  - 0031-4005 (Linking)
DP  - 2013 Jun 10
TI  - Acute Ovarian Torsion and Primary Hypothyroidism.
AB  - A 12-year-old girl presented with acute abdominal pain due to an acute ovarian
      torsion. She required an oophorectomy. Clinical and laboratory assessment
      confirmed severe primary hypothyroidism. In this report, we review this rare
      complication of untreated primary hypothyroidism and the physiologic mechanisms
      proposed to explain this phenomenon.
AD  - Seattle Children's Hospital, Division of Endocrinology and Diabetes, Department
      of Pediatrics, University of Washington, Seattle, Washington.
FAU - Nandi-Munshi, Debika
AU  - Nandi-Munshi D
FAU - Tridgell, Angela
AU  - Tridgell A
FAU - Taplin, Craig E
AU  - Taplin CE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Pediatrics
JT  - Pediatrics
JID - 0376422
OTO - NOTNLM
OT  - abdominal pain/diagnosis
OT  - child
OT  - female
OT  - humans
OT  - hypothyroidism/diagnosis
OT  - hypothyroidism/drug therapy
OT  - ovarian cysts/drug therapy
OT  - precocious/diagnosis
OT  - precocious/drug therapy
OT  - precocious/metabolism
OT  - puberty
OT  - thyroxine/therapeutic use
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - peds.2012-3574 [pii]
AID - 10.1542/peds.2012-3574 [doi]
PST - aheadofprint
SO  - Pediatrics. 2013 Jun 10.

PMID- 23753040
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
DP  - 2013 Jun 10
TI  - A cohort study of metformin exposure and survival in patients with stage I-III
      colorectal cancer.
AB  - Background: Preclinical evidence suggests a beneficial effect of metformin in
      colorectal cancer. This study aimed to investigate associations between metformin
      exposure and colorectal cancer-specific survival using population-level data.
      Methods: Adult stage I-III colorectal cancer patients diagnosed 2001-2006 were
      identified from the National Cancer Registry Ireland. Use of metformin and other 
      anti-diabetic medications was determined from a linked national prescription
      claims database. Multivariate Cox regression was used to estimate hazard ratios
      (HR) with 95% confidence intervals (CI) for associations between pre-diagnostic
      metformin exposure (versus non-metformin anti-diabetic drugs) and colorectal
      cancer-specific mortality. Models were stratified by anti-diabetic drug
      co-prescription and intensity of metformin exposure. Results: The cohort included
      207 diabetics who received metformin, 108 diabetics not exposed to metformin, and
      3501 non-diabetic patients. In multivariate analyses a non-significant reduction 
      in colorectal cancer-specific mortality was observed for metformin exposed
      patients relative to other treated diabetics (HR 0.61, 95% CI 0.37-1.01). In
      stratified analyses no significant association was observed for patients
      receiving low intensity metformin or metformin in combination with other
      anti-diabetic drugs. High intensity exclusive metformin use was associated with a
      significant reduction in colorectal cancer-specific mortality (HR 0.44, 95% CI
      0.20-0.95). Conclusions: Significant associations between metformin exposure and 
      colorectal cancer-specific mortality were observed only for high intensity
      exclusive metformin use in the diabetic cohort. Impact: This study provides
      moderate evidence of an association between metformin exposure and improved
      colorectal cancer survival in a diabetic population. Additional studies in larger
      cohorts, with detailed information on diabetes severity, are required to confirm 
      these results.
AD  - Department of Pharmacology & Therapeutics Trinity College, University of Dublin.
FAU - Spillane, Susan C
AU  - Spillane SC
FAU - Bennett, Kathleen
AU  - Bennett K
FAU - Sharp, Linda
AU  - Sharp L
FAU - Barron, Thomas I
AU  - Barron TI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American
      Association for Cancer Research, cosponsored by the American Society of
      Preventive Oncology
JID - 9200608
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 1055-9965.EPI-13-0347 [pii]
AID - 10.1158/1055-9965.EPI-13-0347 [doi]
PST - aheadofprint
SO  - Cancer Epidemiol Biomarkers Prev. 2013 Jun 10.

PMID- 23752878
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Linking)
DP  - 2013 Jun 11
TI  - Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in
      the United States.
LID - 10.1038/ajg.2013.160 [doi]
AB  - OBJECTIVES:Risk factors for hepatocellular carcinoma (HCC) include hepatitis B
      and C viruses (HBV, HCV), excessive alcohol consumption, rare genetic disorders
      and diabetes/obesity. The population attributable fractions (PAF) of these
      factors, however, have not been investigated in population-based studies in the
      United States.METHODS:Persons >/=68 years diagnosed with HCC (n=6,991) between
      1994 and 2007 were identified in the SEER-Medicare database. A 5% random sample
      (n=255,702) of persons residing in SEER locations were selected for comparison.
      For each risk factor, odds ratios (ORs), 95% confidence intervals (95% CI) and
      PAFs were calculated.RESULTS:As anticipated, the risk of HCC was increased in
      relationship to each factor: HCV (OR 39.89, 95% CI: 36.29-43.84), HBV (OR 11.17, 
      95% CI: 9.18-13.59), alcohol-related disorders (OR 4.06, 95% CI: 3.82-4.32), rare
      metabolic disorders (OR 3.45, 95% CI: 2.97-4.02), and diabetes and/or obesity (OR
      2.47, 95% CI: 2.34-2.61). The PAF of all factors combined was 64.5% (males 65.6%;
      females 62.2%). The PAF was highest among Asians (70.1%) and lowest among black
      persons (52.4%). Among individual factors, diabetes/obesity had the greatest PAF 
      (36.6%), followed by alcohol-related disorders (23.5%), HCV (22.4%), HBV (6.3%)
      and rare genetic disorders (3.2%). While diabetes/obesity had the greatest PAF
      among both males (36.4%) and females (36.7%), alcohol-related disorders had the
      second greatest PAF among males (27.8%) and HCV the second greatest among females
      (28.1%). Diabetes/obesity had the greatest PAF among whites (38.9%) and Hispanics
      (38.1%), while HCV had the greatest PAF among Asians (35.4%) and blacks (34.9%). 
      The second greatest PAF was alcohol-related disorders in whites (25.6%),
      Hispanics (30.1%) and blacks (and 18.5%) and HBV in Asians
      (28.5%).CONCLUSIONS:The dominant risk factors for HCC in the United States among 
      persons >/=68 years differ by sex and race/ethnicity. Overall, eliminating
      diabetes/obesity could reduce the incidence of HCC more than the elimination of
      any other factor.Am J Gastroenterol advance online publication, 11 June 2013;
      doi:10.1038/ajg.2013.160.
AD  - Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany.
FAU - Welzel, Tania M
AU  - Welzel TM
FAU - Graubard, Barry I
AU  - Graubard BI
FAU - Quraishi, Sabah
AU  - Quraishi S
FAU - Zeuzem, Stefan
AU  - Zeuzem S
FAU - Davila, Jessica A
AU  - Davila JA
FAU - El-Serag, Hashem B
AU  - El-Serag HB
FAU - McGlynn, Katherine A
AU  - McGlynn KA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/11 [aheadofprint]
AID - ajg2013160 [pii]
AID - 10.1038/ajg.2013.160 [doi]
PST - aheadofprint
SO  - Am J Gastroenterol. 2013 Jun 11. doi: 10.1038/ajg.2013.160.

PMID- 23752802
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 2038-2502 (Electronic)
IS  - 0035-6484 (Linking)
VI  - 48
IP  - 3
DP  - 2013 May-Jun
TI  - [Tardive dyskinesia: diagnosis, assessment and treatment].
PG  - 187-96
LID - 10.1708/1292.14287 [doi]
AB  - Tardive dyskinesia is a potentially fatal side effect of antipsychotics. In the
      classic form is characterized by involuntary hyperkinetic movements, especially
      those affecting the mimic and mastication muscles. The main hypothesis considers 
      that the pathophysiological basis of the disorder is an overexpression of D2
      receptors in the striatum, in response to dopamine block neuroleptics-mediated,
      especially the older ones. Because fortunately not all patients undergo this
      severe adverse effects, many efforts have been conducted in trying to delineate
      the risk factors so as to try to prevent tardive dyskinesia by administering
      lower doses of neuroleptics in vulnerable groups. Advanced age, female sex,
      smoking habits, diabetes mellitus, alcohol abuse are known as risk factors. The
      instead the role of the type of psychiatric disorder, instead, is still debated. 
      Since there was a direct relationship between cumulative dose of antipsychotic
      and treatment duration, recent studies are aimed at identifying factors that
      contribute to increased plasma concentrations of the drug, such as genetic
      polymorphisms of metabolizer enzymes that encode for enzymatic variants with
      decreased activity.
FAU - Frascarelli, Marianna
AU  - Frascarelli M
FAU - Paolemili, Marco
AU  - Paolemili M
FAU - Gallo, Mariana
AU  - Gallo M
FAU - Parente, Fabrizio
AU  - Parente F
FAU - Biondi, Massimo
AU  - Biondi M
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Discinesia tardiva: diagnosi, valutazione e terapia.
PL  - Italy
TA  - Riv Psichiatr
JT  - Rivista di psichiatria
JID - 0425672
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1708/1292.14287 [doi]
PST - ppublish
SO  - Riv Psichiatr. 2013 May-Jun;48(3):187-96. doi: 10.1708/1292.14287.

PMID- 23752780
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Linking)
DP  - 2013 Jun 10
TI  - Device-Guided Breathing as Treatment for Hypertension in Type 2 Diabetes
      Mellitus: A Randomized, Double-blind, Sham-Controlled Trial.
PG  - 1-5
LID - 10.1001/jamainternmed.2013.6883 [doi]
AB  - IMPORTANCE Biofeedback with device-guided lowering of breathing frequency could
      be an alternate nonpharmacologic treatment option for hypertension. Evidence from
      trials with high methodologic quality is lacking. OBJECTIVE To evaluate the
      effects of device-guided lowering of breathing frequency on blood pressure in
      patients with type 2 diabetes mellitus and hypertension. DESIGN Single-center,
      double-blind, sham-controlled trial. SETTING A large nonacademic teaching
      hospital in the Netherlands. PARTICIPANTS Patients with type 2 diabetes mellitus 
      and hypertension. INTERVENTION Fifteen-minute sessions with either the device
      that guides breathing through musical tones to a lower breathing frequency
      (aiming at &lt;10 breaths/min) or a sham device (music without aiming at lowering
      of breathing frequency) for an 8-week study period. MAIN OUTCOMES AND MEASURES
      Systolic and diastolic blood pressure measured in the physician's office. RESULTS
      Forty-eight patients were randomized; 21 patients (88%) in the intervention group
      and 24 patients (100%) in the control group completed the study. There were no
      significant changes in systolic and diastolic blood pressure, with a difference
      in systolic blood pressure of 2.35 mm Hg (95% CI, -6.50 to 11.20) in favor of the
      control group and a difference in diastolic blood pressure of 2.25 mm Hg (95% CI,
      -2.16 to 6.67) in favor of the intervention group. Three patients in the
      intervention group experienced adverse events. CONCLUSIONS AND RELEVANCE This
      high methodologic quality study shows no significant effect of device-guided
      lowering of breathing frequency on office-measured blood pressure in patients
      with type 2 diabetes. On the basis of this study, together with results from all 
      but one previous trial, device-guided lowering of breathing frequency does not
      appear to be a viable nonpharmacologic option for hypertension treatment.
FAU - Landman, Gijs W D
AU  - Landman GW
FAU - Drion, Iefke
AU  - Drion I
FAU - van Hateren, Kornelis J J
AU  - van Hateren KJ
FAU - van Dijk, Peter R
AU  - van Dijk PR
FAU - Logtenberg, Susan J J
AU  - Logtenberg SJ
FAU - Lambert, Jan
AU  - Lambert J
FAU - Groenier, Klaas H
AU  - Groenier KH
FAU - Bilo, Henk J G
AU  - Bilo HJ
FAU - Kleefstra, Nanne
AU  - Kleefstra N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 1696186 [pii]
AID - 10.1001/jamainternmed.2013.6883 [doi]
PST - aheadofprint
SO  - JAMA Intern Med. 2013 Jun 10:1-5. doi: 10.1001/jamainternmed.2013.6883.

PMID- 23752778
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Jun 11
TI  - Diabetes: Have the gut(s) to test the risk of developing type 2 diabetes
      mellitus.
LID - 10.1038/nrendo.2013.115 [doi]
FAU - Kugelberg, Elisabeth
AU  - Kugelberg E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/11 [aheadofprint]
AID - nrendo.2013.115 [pii]
AID - 10.1038/nrendo.2013.115 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Jun 11. doi: 10.1038/nrendo.2013.115.

PMID- 23752776
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Jun 11
TI  - Diabetes: Sleep apnoea in patients with type 2 diabetes mellitus.
LID - 10.1038/nrendo.2013.119 [doi]
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/11 [aheadofprint]
AID - nrendo.2013.119 [pii]
AID - 10.1038/nrendo.2013.119 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Jun 11. doi: 10.1038/nrendo.2013.119.

PMID- 23752773
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Jun 11
TI  - Diabetes: Individualized HbA targets in elderly patients with T2DM.
LID - 10.1038/nrendo.2013.114 [doi]
FAU - Koch, Linda
AU  - Koch L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/11 [aheadofprint]
AID - nrendo.2013.114 [pii]
AID - 10.1038/nrendo.2013.114 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Jun 11. doi: 10.1038/nrendo.2013.114.

PMID- 23752772
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Jun 11
TI  - New pharmacological approaches for obesity management.
LID - 10.1038/nrendo.2013.113 [doi]
AB  - Obesity, which results from an imbalance between calorie intake and expenditure, 
      now affects over 500 million individuals worldwide. Lifestyle and behavioural
      interventions aimed at reducing calorie intake and/or increasing energy
      expenditure have limited long-term effectiveness due to complex and persistent
      hormonal, metabolic and neurochemical adaptations that defend against weight loss
      and promote weight regain. Surgical treatments for obesity, although highly
      effective, are unavailable or unsuitable for the majority of individuals with
      excess adiposity. Accordingly, few effective treatment options are available to
      most individuals with obesity. In the past, the use of antiobesity drugs,
      seemingly the logical choice to fill this therapeutic gap, has been limited
      because of a lack of efficacy, poor long-term adherence rates and serious adverse
      effects. In 2012, the FDA approved two new medications-lorcaserin and
      phentermine-topiramate controlled release-and is currently reviewing the
      resubmission of naltrexone sustained release-bupropion sustained release. This
      Review presents the available data on the efficacy and safety of these three
      medications and discusses future perspectives and challenges related to
      pharmacological weight management.
AD  - Obesity Research & Management, Alberta Diabetes Institute, Department of
      Medicine, Faculty of Medicine & Dentistry, University of Alberta, Li Ka Shing
      Building, 87th Avenue and 112th Street, Edmonton, AB T6G 2E1, Canada.
FAU - Rueda-Clausen, Christian F
AU  - Rueda-Clausen CF
FAU - Padwal, Raj S
AU  - Padwal RS
FAU - Sharma, Arya M
AU  - Sharma AM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/11 [aheadofprint]
AID - nrendo.2013.113 [pii]
AID - 10.1038/nrendo.2013.113 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Jun 11. doi: 10.1038/nrendo.2013.113.

PMID- 23752741
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 2040-3372 (Electronic)
IS  - 2040-3364 (Linking)
DP  - 2013 Jun 10
TI  - Highly stable and degradable multifunctional microgel for self-regulated insulin 
      delivery under physiological conditions.
AB  - The response to glucose, pH and temperature, high drug loading capacity,
      self-regulated drug delivery and degradation in vivo are simultaneously probable 
      by applying a multifunctional microgel under a rational design in a colloid
      chemistry method. Such multifunctional microgels are fabricated with
      N-isopropylacrylamide (NIPAAm), (2-dimethylamino)ethyl methacrylate (DMAEMA) and 
      3-acrylamidephenylboronic acid (AAPBA) through a precipitation emulsion method
      and cross-linked by reductive degradable N,N'-bis(arcyloyl)cystamine (BAC). This 
      novel kind of microgel with a narrow size distribution ( approximately 250 nm) is
      suitable for diabetes because it can adapt to the surrounding medium of different
      glucose concentrations over a clinically relevant range (0-20 mM), control the
      release of preloaded insulin and is highly stable under physiological conditions 
      (pH 7.4, 0.15 M NaCl, 37 degrees C). When synthesized multifunctional microgels
      regulate drug delivery, they gradually degrade as time passes and, as a result,
      show enhanced biocompatibility. This exhibits a new proof-of-concept for diabetes
      treatment that takes advantage of the properties of each building block from a
      multifunctional micro-object. These highly stable and versatile multifunctional
      microgels have the potential to be used for self-regulated therapy and monitoring
      of the response to treatment, or even simultaneous diagnosis as nanobiosensors.
AD  - State Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous
      Metal Chemistry and Resources Utilization of Gansu Province and Department of
      Chemistry, Lanzhou University, Lanzhou 730000, P.R. China. mzliu@lzu.edu.cn.
FAU - Zhang, Xinjie
AU  - Zhang X
FAU - Lu, Shaoyu
AU  - Lu S
FAU - Gao, Chunmei
AU  - Gao C
FAU - Chen, Chen
AU  - Chen C
FAU - Zhang, Xuan
AU  - Zhang X
FAU - Liu, Mingzhu
AU  - Liu M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Nanoscale
JT  - Nanoscale
JID - 101525249
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1039/c3nr00835e [doi]
PST - aheadofprint
SO  - Nanoscale. 2013 Jun 10.

PMID- 23752710
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 2
IP  - 3
DP  - 2013
TI  - Antihypertensive drug class interactions and risk for incident diabetes: a nested
      case-control study.
PG  - e000125
LID - 10.1161/JAHA.113.000125 [doi]
AB  - BACKGROUND: We aimed to determine how single and combination antihypertensive
      therapy alters risk for diabetes mellitus (DM).Thiazide diuretics (TD), beta
      blockers (BB), and renin-angiotensin system blockers (RASB) impact DM risk while 
      calcium channel blockers (CCB) are neutral. DM risk associated with combinations 
      is unclear. METHODS AND RESULTS: We enrolled nondiabetic patients from Kaiser
      Permanente Northwest with a fasting plasma glucose (FPG) <126 mg/dL between 1997 
      and 2010. DM cases were defined by a FPG >/=126 mg/dL, random plasma glucose
      >/=200 mg/dL, HbA1c >/=7.0%, or new DM prescription (index date). We used
      incidence density sampling to match 10 controls per case on the date of follow-up
      glucose test (to reduce detection bias), in addition to age and date of cohort
      entry. Exposure to antihypertensive class was assessed during the 30 days prior
      to index date. Our cohort contained 134 967 patients and had 412 604 glucose
      tests eligible for matching. A total of 9097 DM cases were matched to 90 495
      controls (median age 51 years). Exposure to TD (OR 1.54, 95% CI 1.41 to 1.68) or 
      BB (OR 1.19, 95% CI 1.11 to 1.28) was associated with an increased DM risk, while
      CCB and RASB exposure was not. TD+BB combination resulted in the fully combined
      diabetogenic risk of both agents (OR 1.99, 95% CI 1.80 to 2.20; interaction OR
      1.09, 95% CI 0.97 to 1.22). In contrast, combination of RASB with either TD or BB
      showed significant negative interactions, resulting in a smaller DM risk than TD 
      or BB monotherapy. CONCLUSIONS: Diabetogenic potential of combination therapy
      should be considered when prescribing antihypertensive therapy.
AD  - Department of Pharmacotherapy and Translational Research, College of Pharmacy,
      University of Florida, Gainesville, FL.
FAU - Cooper-Dehoff, Rhonda M
AU  - Cooper-Dehoff RM
FAU - Bird, Steven T
AU  - Bird ST
FAU - Nichols, Gregory A
AU  - Nichols GA
FAU - Delaney, Joseph A
AU  - Delaney JA
FAU - Winterstein, Almut G
AU  - Winterstein AG
LA  - eng
PT  - Journal Article
DEP - 20130610
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
SB  - IM
OTO - NOTNLM
OT  - RAS blockers
OT  - diabetes
OT  - diabetogenic
OT  - drug interactions
OT  - hypertension
OT  - thiazide diuretics
OT  - β blockers
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 2/3/e000125 [pii]
AID - 10.1161/JAHA.113.000125 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2013 Jun 10;2(3):e000125. doi: 10.1161/JAHA.113.000125.

PMID- 23752663
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
DP  - 2013 Jun 11
TI  - Brand-Name Prescription Drug Use Among Veterans Affairs and Medicare Part D
      Patients With Diabetes: A National Cohort Comparison.
LID - 10.7326/0003-4819-159-2-201307160-00664 [doi]
AB  - BACKGROUND: Medicare Part D and the U.S. Department of Veterans Affairs (VA) use 
      different approaches to manage prescription drug benefits, with implications for 
      spending. Medicare relies on private plans with distinct formularies, whereas the
      VA administers its own benefit using a national formulary. OBJECTIVE: To compare 
      overall and regional rates of brand-name drug use among older adults with
      diabetes in Medicare and the VA. DESIGN: Retrospective cohort. SETTING: Medicare 
      and the VA, 2008. PATIENTS: 1 061 095 Medicare Part D beneficiaries and 510 485
      veterans aged 65 years or older with diabetes. MEASUREMENTS: Percentage of
      patients taking oral hypoglycemics, statins, and angiotensin-converting enzyme
      (ACE) inhibitors or angiotensin-receptor blockers (ARBs) who filled brand-name
      drug prescriptions and percentage of patients taking long-acting insulins who
      filled analogue prescriptions. Sociodemographic- and health status-adjusted
      hospital referral region (HRR) brand-name drug use was compared, and changes in
      spending were calculated if brand-name drug use in 1 system mirrored the other.
      RESULTS: Brand-name drug use in Medicare was 2 to 3 times that in the VA: 35.3%
      versus 12.7% for oral hypoglycemics, 50.7% versus 18.2% for statins, 42.5% versus
      20.8% for ACE inhibitors or ARBs, and 75.1% versus 27.0% for insulin analogues.
      Adjusted HRR-level brand-name statin use ranged (from the 5th to 95th
      percentiles) from 41.0% to 58.3% in Medicare and 6.2% to 38.2% in the VA. For
      each drug group, the 95th-percentile HRR in the VA had lower brand-name drug use 
      than the 5th-percentile HRR in Medicare. Medicare spending in this population
      would have been $1.4 billion less if brand-name drug use matched that of the VA. 
      LIMITATION: This analysis cannot fully describe the factors underlying
      differences in brand-name drug use. CONCLUSION: Medicare beneficiaries with
      diabetes use 2 to 3 times more brand-name drugs than a comparable group within
      the VA, at substantial excess cost. PRIMARY FUNDING SOURCE: U.S. Department of
      Veterans Affairs, National Institutes of Health, and Robert Wood Johnson
      Foundation.
FAU - Gellad, Walid F
AU  - Gellad WF
FAU - Donohue, Julie M
AU  - Donohue JM
FAU - Zhao, Xinhua
AU  - Zhao X
FAU - Mor, Maria K
AU  - Mor MK
FAU - Thorpe, Carolyn T
AU  - Thorpe CT
FAU - Smith, Jeremy
AU  - Smith J
FAU - Good, Chester B
AU  - Good CB
FAU - Fine, Michael J
AU  - Fine MJ
FAU - Morden, Nancy E
AU  - Morden NE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 1696030 [pii]
AID - 10.7326/0003-4819-159-2-201307160-00664 [doi]
PST - aheadofprint
SO  - Ann Intern Med. 2013 Jun 11. doi: 10.7326/0003-4819-159-2-201307160-00664.

PMID- 23752631
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 0966-0461 (Print)
IS  - 0966-0461 (Linking)
VI  - 22
IP  - 9
DP  - 2013 May 8
TI  - The need for additional training for nutritional management of diabetes.
PG  - 1234-8
AB  - The purpose of this study was to investigate nurses' and nursing students'
      knowledge and perceived role in assisting patients with the nutritional
      management of diabetes.
FAU - Carney, Trish
AU  - Carney T
FAU - Stein, Susan E
AU  - Stein SE
FAU - Quinlan, Jennifer J
AU  - Quinlan JJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Nurs
JT  - British journal of nursing (Mark Allen Publishing)
JID - 9212059
SB  - N
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PST - ppublish
SO  - Br J Nurs. 2013 May 8;22(9):1234-8.

PMID- 23752610
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
DP  - 2013 Jun 10
TI  - Different Modulation of Ptpn22 in Effector and Regulatory T Cells Leads to
      Attenuation of Autoimmune Diabetes in Transgenic Nonobese Diabetic Mice.
AB  - Ptpn22 encodes PEST domain-enriched tyrosine phosphatase (Pep), which negatively 
      regulates TCR proximal signaling and is strongly associated with a variety of
      autoimmune diseases in humans. The net effect of Pep on the balance of immunity
      and tolerance is uncertain because of the simultaneous inhibition of TCR-mediated
      signaling of effector and regulatory T cells (Tregs). In this study, we generated
      transgenic NOD mice that overexpressed Pep in T cells. The transgenic mice had a 
      significantly lower incidence of spontaneous autoimmune diabetes, which was
      accompanied by fewer IFN-gamma-producing T cells, and an increased ratio of
      CD4+Foxp3+ Tregs to CD4+IFN-gamma+ or to CD8+IFN-gamma+ T cells, respectively, in
      pancreatic islets. Transgenic T cells showed markedly decreased TCR-mediated
      effector cell responses such as proliferation and Th1 differentiation. By
      contrast, the inhibitory effect of transgenic Pep on TCR signaling did not affect
      the differentiation of Tregs or their suppressive activity. Adoptive transfer
      experiments showed that transgenic splenocytes exhibited attenuated diabetogenic 
      ability. To examine further the pathogenic features of transgenic T cells, we
      generated Ptpn22/BDC2.5 doubly transgenic mice and found reduced proliferation
      and Th1 differentiation in CD4+ T lymphocytes with additional Pep in pancreatic
      lymph nodes but not in inguinal lymph nodes of NOD/SCID recipients. This finding 
      indicates that transgenic Pep attenuates T cell functions in an islet Ag-driven
      manner. Taken together, our results demonstrate that Pep overexpression in T
      cells attenuates autoimmune diabetes in NOD mice by preferentially modulating TCR
      signaling-mediated functions in diabetogenic T cells but not in Tregs.
AD  - Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei
      114, Taiwan;
FAU - Yeh, Li-Tzu
AU  - Yeh LT
FAU - Miaw, Shi-Chuen
AU  - Miaw SC
FAU - Lin, Ming-Hong
AU  - Lin MH
FAU - Chou, Feng-Cheng
AU  - Chou FC
FAU - Shieh, Shing-Jia
AU  - Shieh SJ
FAU - Chuang, Yi-Ping
AU  - Chuang YP
FAU - Lin, Shih-Hua
AU  - Lin SH
FAU - Chang, Deh-Ming
AU  - Chang DM
FAU - Sytwu, Huey-Kang
AU  - Sytwu HK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - jimmunol.1203380 [pii]
AID - 10.4049/jimmunol.1203380 [doi]
PST - aheadofprint
SO  - J Immunol. 2013 Jun 10.

PMID- 23752597
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1732-2693 (Electronic)
IS  - 0032-5449 (Linking)
VI  - 67
IP  - 0
DP  - 2013
TI  - The importance of glycemic load of the diet in the development of cancer .
PG  - 449-62
LID - 10.5604/17322693.1050032 [doi]
AB  - Treatment of cancer involves not only appropriate pharmacological or
      psychological therapy and rehabilitation, but also diet aimed at prevention of
      the process of cachexia. Postprandial hyperglycemia exerts a significant effect
      on the growth and proliferation of tumor cells. It promotes formation of a number
      of metabolic changes in every tissue of the organism. Chronic postprandial
      hyperglycemia, occurring in type 2 diabetes, enhances all these changes. Although
      the results of epidemiological studies on the relationship between the overall
      risk of cancer development, or tumors in different parts of the organism, are
      heterogeneous, most of them indicate that the risk increases with an increase in 
      glycemic load of the examined population's diets. Researchers also suggest a
      beneficial effect of limiting the amount of easily assimilable carbohydrate in
      the diet to stabilize the disease and for better tolerance of chemoor radiation
      therapy. However, further studies are required.
FAU - Dudziak, Katarzyna
AU  - Dudziak K
FAU - Regulska-Ilow, Bozena
AU  - Regulska-Ilow B
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - Poland
TA  - Postepy Hig Med Dosw (Online)
JT  - Postepy higieny i medycyny doswiadczalnej (Online)
JID - 101206517
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 1050032 [pii]
AID - 10.5604/17322693.1050032 [doi]
PST - epublish
SO  - Postepy Hig Med Dosw (Online). 2013 May 21;67(0):449-62. doi:
      10.5604/17322693.1050032.

PMID- 23752542
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1678-4561 (Electronic)
IS  - 1413-8123 (Linking)
VI  - 18
IP  - 6
DP  - 2013 Jun
TI  - [Adherence to pharmacological and non pharmacological treatment for arterial
      hypertension and associated factors in primary care].
PG  - 1763-72
LID - S1413-81232013000600027 [pii]
AB  - A cross-sectional study was conducted with 385 hypertensive patients between 20
      and 79 years of age in a family health unit in Londrina, State of Parana, Brazil,
      to determine the adherence to pharmacological and non pharmacological treatment
      for arterial hypertension in primary healthcare and identify associated factors. 
      The adherence to pharmacological treatment was 59%. Regular physical activity was
      reported by 68 (17.7%) hypertensive patients and 266 (69.1%) mentioned dietary
      changes. In the multiple regression analysis, adherence to drug treatment was
      associated with: increased age (50 to 79), consulting with a physician at least
      once a year, no regular alcohol consumption and previous myocardial infarction.
      Hypertensive males, with education up to 4th grade and above, who had at least
      one consultation per year, with diabetes or no history of high cholesterol, were 
      more adherent to physical activity. Dietary changes were associated with
      education below the 4th grade and consulting with a physician at least once a
      year. These results show variable levels of adherence to treatment and
      demonstrate the importance of comprehensive actions in the care for hypertensive 
      patients.
FAU - Girotto, Edmarlon
AU  - Girotto E
FAU - Andrade, Selma Maffei de
AU  - Andrade SM
FAU - Cabrera, Marcos Aparecido Sarria
AU  - Cabrera MA
FAU - Matsuo, Tiemi
AU  - Matsuo T
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Adesao ao tratamento farmacologico e nao farmacologico e fatores associados na
      atencao primaria da hipertensao arterial.
PL  - Brazil
TA  - Cien Saude Colet
JT  - Ciencia & saude coletiva
JID - 9713483
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2011/08/15 [received]
PHST- 2011/11/28 [accepted]
AID - S1413-81232013000600027 [pii]
PST - ppublish
SO  - Cien Saude Colet. 2013 Jun;18(6):1763-72.

PMID- 23752410
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1546-1696 (Electronic)
IS  - 1087-0156 (Linking)
VI  - 31
IP  - 6
DP  - 2013 Jun
TI  - SGLT2 inhibitors enter crowded diabetes space.
PG  - 469-70
LID - 10.1038/nbt0613-469 [doi]
FAU - Bouchie, Aaron
AU  - Bouchie A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nat Biotechnol
JT  - Nature biotechnology
JID - 9604648
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - nbt0613-469 [pii]
AID - 10.1038/nbt0613-469 [doi]
PST - ppublish
SO  - Nat Biotechnol. 2013 Jun;31(6):469-70. doi: 10.1038/nbt0613-469.

PMID- 23752340
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Linking)
DP  - 2013 Jun 11
TI  - Comparison of diagnostic criteria for acute kidney injury in cardiac surgery.
LID - S0066-782X2013005000042 [pii]
AB  - BACKGROUND: There is considerable controversy regarding the diagnosis of Acute
      Kidney Injury (AKI), and there are over 30 different definitions. OBJECTIVE: To
      evaluate the incidence and risk factors for the development of AKI following
      cardiac surgery according to the RIFLE, AKIN and KDIGO criteria, and compare the 
      prognostic power of these criteria. METHODS: Cross-sectional study that included 
      321 consecutively patients (median age 62 [53-71] years; 140 men) undergoing
      cardiac surgery between June 2011 and January 2012. The patients were followed
      for up to 30 days, for a composite outcome (mortality, need for dialysis and
      extended hospitalization). RESULTS: The incidence of AKI ranged from 15% - 51%,
      accordingly to the diagnostic criterion adopted. While age was associated with
      risk of AKI in the three criteria, there were variations in the remaining risk
      factors. During follow-up, 89 patients developed the outcome and all criteria
      were associated with increased risk in the univariate Cox analysis and after
      adjustment for age, gender, diabetes, and type of surgery. However, after further
      adjustment for extracorporeal circulation and the presence of low cardiac output,
      only AKI diagnosed by the KDIGO criterion maintained this significant association
      (HR= 1.89 [95% CI: 1.18 - 3.06]). CONCLUSION: The incidence and risk factors for 
      AKI after cardiac surgery vary significantly according to the diagnostic criteria
      used. In our analysis, AKI the KDIGO criterion was superior to AKIN and RIFLE
      with regard its prognostic power.
FAU - Sampaio, Marcio Campos
AU  - Sampaio MC
FAU - Maximo, Carlos Alberto Goncalves
AU  - Maximo CA
FAU - Montenegro, Carolina Moreira
AU  - Montenegro CM
FAU - Mota, Diandro Marinho
AU  - Mota DM
FAU - Fernandes, Tatiana Rocha
AU  - Fernandes TR
FAU - Bianco, Antonio Carlos Mugayar
AU  - Bianco AC
FAU - Amodeo, Celso
AU  - Amodeo C
FAU - Cordeiro, Antonio Carlos
AU  - Cordeiro AC
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
TT  - Comparacao de criterios diagnosticos de insuficiencia renal aguda em cirurgia
      cardiaca.
DEP - 20130611
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/11/21 [received]
PHST- 2013/02/21 [accepted]
AID - S0066-782X2013005000042 [pii]
PST - aheadofprint
SO  - Arq Bras Cardiol. 2013 Jun 11. pii: S0066-782X2013005000042.

PMID- 23752339
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Linking)
DP  - 2013 Jun 11
TI  - Correlation between plaque composition as assessed by virtual histology and
      C-reactive protein.
LID - S0066-782X2013005000041 [pii]
AB  - BACKGROUND: Previous studies have shown that coronary plaque composition plays a 
      pivotal role in plaque instability, and imaging modalities and serum biomarkers
      have been investigated to identify vulnerable plaque. Virtual histology IVUS
      (VH-IVUS) characterizes plaque components as calcified, fibrotic, fibrofatty, or 
      necrotic core. C-reactive protein (hsCRP) is an independent risk factor and a
      powerful predictor of future coronary events. However, a relationship between
      inflammatory response indicated by CRP and plaque characteristics in ACS patients
      remains not well established. OBJECTIVE: To determine, by using VH-IVUS, the
      relation between coronary plaque components and plasma high-sensitivity CRP
      levels in patients with acute coronary syndromes (ACS). METHODS: 52 patients with
      ACS were enrolled in this prospective study. Electrocardiographically-gated
      VH-IVUS were performed in the culprit lesion before PCI. Blood sample was drawn
      from all patients before the procedure and after 24 hours, and hs-CRP levels were
      determined. RESULTS: Mean age was 55.3+/-4.9 years, 76.9% were men and 30.9% had 
      diabetes. Mean MLA was 3.9+/-1.3 mm(2), and plaque burden was 69+/-11.3%, as
      assessed by IVUS. VH-IVUS analysis at the minimum luminal site identified plaque 
      components: fibrotic (59.6+/-15.8%), fibrofatty (7.6+/-8.2%), dense calcium
      (12.1+/-9.2%) and necrotic core (20.7+/-12.7%). Plasma hs-CRP (mean 16.02+/-18.07
      mg/L) did not correlate with necrotic core (r=-0.089, p = 0.53) and other plaque 
      components. CONCLUSIONS: In this prospective study with patients with ACS, the
      predominant components of the culprit plaque were fibrotic and necrotic core.
      Serum hs C-reactive protein levels did not correlate with plaque composition.
FAU - Siqueira, Dimytri Alexandre de Alvim
AU  - Siqueira DA
FAU - Sousa, Amanda Guerra Moraes R
AU  - Sousa AG
FAU - Costa Junior, Jose de Ribamar
AU  - Costa Junior JD
FAU - Costa, Ricardo Alves da
AU  - Costa RA
FAU - Staico, Rodolfo
AU  - Staico R
FAU - Tanajura, Luis Fernando Leite
AU  - Tanajura LF
FAU - Centemero, Marinella Patrizia
AU  - Centemero MP
FAU - Feres, Fausto
AU  - Feres F
FAU - Abizaid, Alexandre Antonio Cunha
AU  - Abizaid AA
FAU - Sousa, J Eduardo Moraes R
AU  - Sousa JE
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
TT  - Correlacao da composicao de placas a histologia virtual com proteina C-reativa.
DEP - 20130611
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/11/19 [received]
PHST- 2013/02/14 [accepted]
AID - S0066-782X2013005000041 [pii]
PST - aheadofprint
SO  - Arq Bras Cardiol. 2013 Jun 11. pii: S0066-782X2013005000041.

PMID- 23752193
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1476-5594 (Electronic)
IS  - 0950-9232 (Linking)
DP  - 2013 Jun 10
TI  - A novel Ku70 function in colorectal homeostasis separate from nonhomologous end
      joining.
LID - 10.1038/onc.2013.234 [doi]
AB  - Ku70, a known nonhomologous end-joining (NHEJ) factor, also functions in tumor
      suppression, although this molecular mechanism remains uncharacterized.
      Previously, we showed that mice deficient for DNA ligase IV (Lig4), another key
      NHEJ factor, succumbed to aggressive lymphoma in the absence of tumor suppressor 
      p53. However, the tumor phenotype is abrogated by the introduction of a
      hypomorphic mutant p53R172P, which impaired p53-mediated apoptosis but not
      cell-cycle arrest. However, Lig4-/-p53R172P mice succumbed to severe diabetes. To
      further elucidate the role of NHEJ and p53-mediated apoptosis in vivo, we bred
      Ku70-/- p53R172P mice. Unexpectedly, these mice were free of diabetes, although
      80% of the mutant mice had abnormally enlarged colons with pronounced
      inflammation. Remarkably, most of these mutant mice progressed to dysplasia,
      adenoma and adenocarcinoma; this is in contrast to the Lig4-/-p53R172P phenotype,
      strongly suggesting an NHEJ-independent function of Ku70. Significantly, our
      analyses of Ku70-/-p53R172P colonic epithelial cells show nuclear stabilization
      of beta-catenin accompanied by higher expression of cyclin D1 and c-Myc in
      affected colon sections than in control samples. This is not due to the p53
      mutation, as Ku70-/- mice share this phenotype. Our results not only unravel a
      novel function of Ku70 essential for colon homeostasis, but also establish an
      excellent in vivo model in which to study how chronic inflammation and abnormal
      cellular proliferation underlie tumorigenesis and tumor progression in the
      colon.Oncogene advance online publication, 10 June 2013;
      doi:10.1038/onc.2013.234.
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center,
      Houston, TX, USA.
FAU - Puebla-Osorio, N
AU  - Puebla-Osorio N
FAU - Kim, J
AU  - Kim J
FAU - Ojeda, S
AU  - Ojeda S
FAU - Zhang, H
AU  - Zhang H
FAU - Tavana, O
AU  - Tavana O
FAU - Li, S
AU  - Li S
FAU - Wang, Y
AU  - Wang Y
FAU - Ma, Q
AU  - Ma Q
FAU - Schluns, K S
AU  - Schluns KS
FAU - Zhu, C
AU  - Zhu C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Oncogene
JT  - Oncogene
JID - 8711562
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/10 [aheadofprint]
AID - onc2013234 [pii]
AID - 10.1038/onc.2013.234 [doi]
PST - aheadofprint
SO  - Oncogene. 2013 Jun 10. doi: 10.1038/onc.2013.234.

PMID- 23752171
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1544-0591 (Electronic)
IS  - 0022-0345 (Linking)
DP  - 2013 Jun 10
TI  - Patient Stratification for Preventive Care in Dentistry.
AB  - Prevention reduces tooth loss, but little evidence supports biannual preventive
      care for all adults. We used risk-based approaches to test tooth loss association
      with 1 vs. 2 annual preventive visits in high-risk (HiR) and low-risk (LoR)
      patients. Insurance claims for 16 years for 5,117 adults were evaluated
      retrospectively for tooth extraction events. Patients were classified as HiR for 
      progressive periodontitis if they had >/= 1 of the risk factors (RFs) smoking,
      diabetes, interleukin-1 genotype; or as LoR if no RFs. LoR event rates were 13.8%
      and 16.4% for 2 or 1 annual preventive visits (absolute risk reduction, 2.6%;
      95%CI, 0.5% to 5.8%; p = .092). HiR event rates were 16.9% and 22.1% for 2 and 1 
      preventive visits (absolute risk reduction, 5.2%; 95%CI, 1.8% to 8.4%; p = .002).
      Increasing RFs increased events (p < .001). Oral health care costs were not
      increased by any single RF, regardless of prevention frequency (p > .41), but
      multiple RFs increased costs vs. no (p < .001) or 1 RF (p = .001). For LoR
      individuals, the association between preventive dental visits and tooth loss was 
      not significantly different whether the frequency was once or twice annually. A
      personalized medicine approach combining gene biomarkers with conventional risk
      factors to stratify populations may be useful in resource allocation for
      preventive dentistry (ClinicalTrials.gov, NCT01584479).
AD  - Michigan Center for Oral Health Research, University of Michigan School of
      Dentistry, Ann Arbor, MI, USA.
FAU - Giannobile, W V
AU  - Giannobile WV
FAU - Braun, T M
AU  - Braun TM
FAU - Caplis, A K
AU  - Caplis AK
FAU - Doucette-Stamm, L
AU  - Doucette-Stamm L
FAU - Duff, G W
AU  - Duff GW
FAU - Kornman, K S
AU  - Kornman KS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - J Dent Res
JT  - Journal of dental research
JID - 0354343
OTO - NOTNLM
OT  - comparative effectiveness research
OT  - health care delivery
OT  - interleukin polymorphisms
OT  - oral health
OT  - periodontal disease
OT  - personalized medicine
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 0022034513492336 [pii]
AID - 10.1177/0022034513492336 [doi]
PST - aheadofprint
SO  - J Dent Res. 2013 Jun 10.

PMID- 23752138
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1660-2110 (Electronic)
IS  - 1660-2110 (Linking)
VI  - 123
IP  - 1-2
DP  - 2013 Jun 6
TI  - Chronic Kidney Disease and the Foot in Diabetes - Is Inflammation the Missing
      Link?
PG  - 36-40
AB  - Diabetes is commonly complicated by the development of chronic kidney disease
      (CKD). Equally prevalent is the development of diabetic foot disease and it is
      now recognised that there is a higher risk of the development of foot disease and
      major amputation in those patients with CKD. This is particularly marked in those
      patients with end-stage kidney disease receiving renal replacement therapy for
      which there are many possible mechanisms, including the effect of dialysis on
      tissue hypoxia. What has been recognised recently is that the risk of the
      development of foot disease appears to start prior to the onset of renal
      replacement therapy. Whilst this may be due to the fact that the emphasis of care
      shifts towards the requirements of the patients' renal disease, here we discuss
      the possibility that the presence of a foot ulcer itself may contribute to the
      development or progression of CKD through repeated episodes of sepsis or chronic 
      inflammation, or both.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Diabetes, Derby Hospitals NHS Trust, Derby, UK.
FAU - Game, F L
AU  - Game FL
FAU - Selby, N M
AU  - Selby NM
FAU - McIntyre, C W
AU  - McIntyre CW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Nephron Clin Pract
JT  - Nephron. Clinical practice
JID - 101159763
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/04/18 [received]
PHST- 2013/05/01 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 000351813 [pii]
AID - 10.1159/000351813 [doi]
PST - aheadofprint
SO  - Nephron Clin Pract. 2013 Jun 6;123(1-2):36-40.

PMID- 23752133
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - Insulin stimulation regulates AS160 and TBC1D1 phosphorylation sites in human
      skeletal muscle.
PG  - e74
LID - 10.1038/nutd.2013.13 [doi]
AB  - INTRODUCTION: Individuals with obesity and type 2 diabetes (T2D) are typically
      insulin resistant, exhibiting impaired skeletal muscle glucose uptake. Animal and
      cell culture experiments have shown that site-specific phosphorylation of the
      Rab-GTPase-activating proteins AS160 and TBC1D1 is critical for GLUT4
      translocation facilitating glucose uptake, but their regulation in human skeletal
      muscle is not well understood. METHODS: Here, lean, obese and T2D subjects
      underwent a euglycemic-hyperinsulinemic clamp, and vastus lateralis muscle
      biopsies were obtained before, and at 30 and 180 min post insulin infusion.
      RESULTS: Obese and T2D subjects had higher body mass indexes and fasting insulin 
      concentrations, and T2D subjects showed insulin resistance. Consistent with the
      clamp findings, T2D subjects had impaired insulin-stimulated phosphorylation of
      AS160 Thr(642), a site previously shown to be important in glucose uptake in
      rodents. Interestingly, insulin-stimulated phosphorylation of TBC1D1 Thr(590), a 
      site shown to be regulated by insulin in rodents, was only increased in T2D
      subjects, although the functional significance of this difference is unknown.
      CONCLUSION: These data show that insulin differentially regulates AS160 and
      TBC1D1 phosphorylation in human skeletal muscle. Impaired insulin-stimulated
      glucose uptake in T2D subjects is accompanied by dysregulation of AS160 and
      TBC1D1 phosphorylation in skeletal muscle, suggesting that these proteins may
      regulate glucose uptake in humans.
AD  - Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Boston,
      MA, USA.
FAU - Middelbeek, R J W
AU  - Middelbeek RJ
FAU - Chambers, M A
AU  - Chambers MA
FAU - Tantiwong, P
AU  - Tantiwong P
FAU - Treebak, J T
AU  - Treebak JT
FAU - An, D
AU  - An D
FAU - Hirshman, M F
AU  - Hirshman MF
FAU - Musi, N
AU  - Musi N
FAU - Goodyear, L J
AU  - Goodyear LJ
LA  - eng
PT  - Journal Article
DEP - 20130610
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - nutd201313 [pii]
AID - 10.1038/nutd.2013.13 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 Jun 10;3:e74. doi: 10.1038/nutd.2013.13.

PMID- 23752132
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - The relationship between family and child weight status by household structure in
      South Korea: 2007-2010.
PG  - e73
LID - 10.1038/nutd.2013.16 [doi]
AB  - Objective:Parental obesity has been identified as a predominant risk factor for
      childhood overweight and obesity. We investigated the relationship between parent
      and child obesity in South Korea, particularly linked with varying family
      structures.Subjects and methods:Data for households with children aged 2-18 years
      were taken from the pooled data of the Korea National Health and Nutrition
      Examination Survey (KNHANES) 2007-2010 conducted by the Korea Centers for Disease
      Control and Prevention (KCDC). The sample consisted of 17 453 individuals (7879
      children and 9574 adults) from 5048 households with children for this study.
      Children's overweight and obesity prevalence was compared using both
      International Obesity Taskforce (IOTF) and KCDC cutoff points according to
      parental weight status and household structure. Logistic regression analysis was 
      used.Results:Significantly greater odds of overweight and obesity existed among
      children living with both parents (odds ratio (OR)=3.5, 95% confidence interval
      (CI): 2.71, 4.65) or one parent (mother: OR=1.6, 95% CI: 1.22, 2.12; father:
      OR=1.7, 95% CI: 1.37, 1.99). The adjusted ORs for overweight and obesity among
      children living with overweight mother only or overweight grandparent only were
      approximately double that of children living with normal-weight mother (OR=2.2,
      95% CI: 1.22-3.82) or normal-weight grandparent (OR=2.1, 95% CI:
      1.06-4.05).Conclusion:Children living with overweight parent(s) or grandparent(s)
      were positively correlated with the risk for childhood overweight and obesity.
      Socioeconomic status did not affect the observed relationships in this
      population, whereas the role of genetic, dietary and activity patterns requires
      further exploration.
AD  - Department of Health Industry and Policy, Korea Health Industry Development
      Institute, Gangoe-Myeon, Republic of Korea.
FAU - Lee, H-S
AU  - Lee HS
FAU - Duffey, K J
AU  - Duffey KJ
FAU - Kim, C-I
AU  - Kim CI
FAU - Popkin, B M
AU  - Popkin BM
LA  - eng
PT  - Journal Article
DEP - 20130610
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - nutd201316 [pii]
AID - 10.1038/nutd.2013.16 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 Jun 10;3:e73. doi: 10.1038/nutd.2013.16.

PMID- 23752097
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1750-8460 (Print)
IS  - 1750-8460 (Linking)
VI  - 74
IP  - 4
DP  - 2013 Apr 9
TI  - Treating people with type 2 diabetes.
PG  - 182-Unknown
AB  - As the symposium of articles in this issue shows, there are now many options for 
      managing type 2 diabetes. Potent new oral or injectable hypoglycaemic medications
      can be added to older drugs or used alone. In addition to metformin, the British 
      National Formulary (Joint Formulary Committee, 2013) lists five sulfonylureas,
      two meglitinides, four dipeptidyl peptidase-4 inhibitors, two glucagon-like
      peptide-1 agonists, an inhibitor of intestinal alpha glucosidases, a
      sodium-glucose co-transporter 2 inhibitor, and a thiazolidinedione. Their various
      formulations form a list of 30 drugs in MIMS (www.mims.co.uk/).
FAU - Hillson, Rowan
AU  - Hillson R
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - Br J Hosp Med (Lond)
JT  - British journal of hospital medicine (London, England : 2005)
JID - 101257109
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PST - ppublish
SO  - Br J Hosp Med (Lond). 2013 Apr 9;74(4):182-Unknown.

PMID- 23751972
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1423-0267 (Electronic)
IS  - 0030-3755 (Linking)
DP  - 2013 Jun 6
TI  - Is Smoking a Risk Factor for Proliferative Diabetic Retinopathy in Type 1
      Diabetes?
PG  - 50-54
AB  - Aim: The aim was to evaluate if smoking was a risk factor for proliferative
      retinopathy (PDR) in a 25-year follow-up study. Methods: 201 persons from a
      population-based cohort of Danish type 1 diabetic patients were examined at
      baseline and again 25 years later. At both examinations the patients were asked
      about their smoking habits. The level of retinopathy was evaluated by
      ophthalmoscopy at baseline and by nine 45-degree colour field fundus photos at
      the follow-up. Results: In multivariate analyses there was a trend that current
      smokers at baseline were more likely to develop PDR at the follow-up (odds ratio 
      1.90, 95% confidence interval 0.88-4.11, p = 0.10). Neither smoking status at the
      follow-up nor pack-years of smoking were associated with PDR. Conclusions: We
      found neither a beneficial nor a harmful effect of smoking on long-term
      incidence. Selective mortality among smokers and patients with PDR at baseline
      might provide at least part of the explanation for this.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
FAU - Gaedt Thorlund, Mie
AU  - Gaedt Thorlund M
FAU - Borg Madsen, Mette
AU  - Borg Madsen M
FAU - Green, Anders
AU  - Green A
FAU - Sjolie, Anne Katrin
AU  - Sjolie AK
FAU - Grauslund, Jakob
AU  - Grauslund J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Ophthalmologica
JT  - Ophthalmologica. Journal international d'ophtalmologie. International journal of 
      ophthalmology. Zeitschrift fur Augenheilkunde
JID - 0054655
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/08/08 [received]
PHST- 2013/03/19 [accepted]
PHST- 2013/06/07 [aheadofprint]
AID - 000350813 [pii]
AID - 10.1159/000350813 [doi]
PST - aheadofprint
SO  - Ophthalmologica. 2013 Jun 6:50-54.

PMID- 23751970
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 Jun 7
TI  - Reproducibility of peripheral arterial tonometry for the assessment of
      endothelial function in adults.
AB  - OBJECTIVES:: Endothelial dysfunction is associated to cardiovascular risk factors
      and predicts cardiovascular events. Peripheral arterial tonometry (PAT) is a
      novel noninvasive method to assess endothelial function. However, there is a
      paucity of data about its reproducibility. The aim of this study was to assess
      the feasibility and reproducibility of PAT in adults. METHODS:: PAT exams were
      performed twice in the same day in 123 participants of a cohort about the
      determinants of diabetes and cardiovascular diseases (Brazilian Longitudinal
      Study of Adult Health - ELSA-Brasil). The interval between the exams was 2-6 h
      (mean = 4 h). Endothelial function in PAT method is measured by reactive
      hyperemia index (RHI), which evaluates arterial pulsatile volume changes in
      response to hyperemia. Agreement of RHI values was compared by Bland-Altman
      method, coefficient of variation and coefficient of repeatability. Reliability
      was assessed by intraclass correlation coefficient (ICC). RESULTS:: Mean values
      of RHI did not differ significantly between the exams of each participant (1.92
      +/- 0.56 vs. 1.96 +/- 0.58, P = 0.48). There were no systematic errors between
      the exams (mean of differences = -0.03 +/- 0.5). Measurement error was 0.35,
      coefficient of variation was 18.0% and ICC was 0.61. Sex, age or the presence of 
      obesity did not have a considerable influence on the reproducibility of PAT.
      CONCLUSION:: PAT exam is feasible and has acceptable reproducibility in adults
      when compared with other noninvasive methods for endothelial function assessment.
      This performance makes PAT a promising method for future clinical and
      epidemiological studies.
AD  - aBrazilian Longitudinal Study of Adult Health, ELSA-Brasil bHospital das Clinicas
      and School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte,
      Minas Gerais, Brazil.
FAU - Brant, Luisa C C
AU  - Brant LC
FAU - Barreto, Sandhi M
AU  - Barreto SM
FAU - Passos, Valeria M A
AU  - Passos VM
FAU - Ribeiro, Antonio L P
AU  - Ribeiro AL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1097/HJH.0b013e328362d913 [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 Jun 7.

PMID- 23751917
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 80
IP  - 24
DP  - 2013 Jun 11
TI  - Meeting the challenges of stroke in india.
PG  - 2246-7
LID - 10.1212/WNL.0b013e318296e7c3 [doi]
AB  - Worldwide, cerebrovascular diseases are responsible for 6.15 million deaths
      (10.8% of all deaths)(1) and are the second most common cause of mortality; 87%
      of stroke deaths occur in low or middle income countries.(2) With the world's
      second largest population, India is witnessing several adverse trends for the
      cardiovascular health of its population, including a rapid rise in the proportion
      of patients with diabetes and dyslipidemia, and the relative lack of exercise
      among the general population. India has the world's largest population of
      patients with diabetes, with over 62 million people with diabetes in 2011.(3) At 
      the current time, the population in India is projected to have over 1 million
      strokes per year. This figure will surely rise in the coming decades due to
      longer life expectancy and the downstream influence of risk factors such as
      diabetes.
AD  - From the Department of Neurology (M.M.M.), GB Pant Hospital, New Delhi, India;
      Department of Neurology (A.B.S.), Massachusetts General Hospital; Boston;
      Department of Neurology (S.C.), Wayne State University, Detroit, MI; Senior
      Consultant Neurologist (M.R.S.), Chennai, India; and Department of Neurology
      (M.M.), University of Massachusetts, Worcester.
FAU - Mehndiratta, Man Mohan
AU  - Mehndiratta MM
FAU - Singhal, Aneesh B
AU  - Singhal AB
FAU - Chaturvedi, Seemant
AU  - Chaturvedi S
FAU - Sivakumar, M R
AU  - Sivakumar MR
FAU - Moonis, Majaz
AU  - Moonis M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 80/24/2246 [pii]
AID - 10.1212/WNL.0b013e318296e7c3 [doi]
PST - ppublish
SO  - Neurology. 2013 Jun 11;80(24):2246-7. doi: 10.1212/WNL.0b013e318296e7c3.

PMID- 23751906
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Helping patients make sense of the risks of taking GLP-1 agonists.
PG  - f3692
LID - 10.1136/bmj.f3692 [doi]
LID - bmj.f3692 [pii]
AD  - Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic,
      Rochester, MN 55902, USA.
FAU - Montori, Victor M
AU  - Montori VM
LA  - eng
PT  - Journal Article
DEP - 20130610
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PST - epublish
SO  - BMJ. 2013 Jun 10;346:f3692. doi: 10.1136/bmj.f3692.

PMID- 23751905
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Incretin therapy: should adverse consequences have been anticipated?
PG  - f3617
LID - 10.1136/bmj.f3617 [doi]
LID - bmj.f3617 [pii]
AD  - Department of Diabetes and Metabolism, Southmead Hospital, Bristol BS10 5NB, UK.
FAU - Gale, Edwin
AU  - Gale E
LA  - eng
PT  - Journal Article
DEP - 20130610
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PST - epublish
SO  - BMJ. 2013 Jun 10;346:f3617. doi: 10.1136/bmj.f3617.

PMID- 23751904
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Diabetic ketoacidosis: not always due to type 1 diabetes.
PG  - f3501
LID - 10.1136/bmj.f3501 [doi]
LID - bmj.f3501 [pii]
AD  - Department of Metabolic Medicine and Clinical Biochemistry, Imperial Healthcare
      NHS Trust, Charing Cross Hospital, London W6 8RF, UK.
FAU - Misra, S
AU  - Misra S
FAU - Oliver, Ns
AU  - Oliver N
FAU - Dornhorst, A
AU  - Dornhorst A
LA  - eng
PT  - Journal Article
DEP - 20130610
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PST - epublish
SO  - BMJ. 2013 Jun 10;346:f3501. doi: 10.1136/bmj.f3501.

PMID- 23751893
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1938-2022 (Electronic)
VI  - 5
IP  - 2
DP  - 2013 Mar 1
TI  - Murine animal models for preclinical islet transplantation: No model fits all
      (research purposes).
AB  - Advances in islet transplantation research have led to remarkable improvements in
      the outcome in humans with type 1 diabetes. However, pitfalls, mainly linked both
      to early liver-specific inflammatory events and to pre-existing and
      transplant-induced auto- and allo-specific adaptive immune responses, still
      remain. In this scenario research into pancreatic islet transplantation,
      essential to investigate new strategies to overcome open issues, needs very
      well-designed preclinical studies to obtain consistent and reliable results and
      select only promising strategies that may be translated into the clinical
      practice. This review discusses the main shortcomings of the mouse models
      currently used in islet transplantation research, outlining the main factors and 
      variables to take into account for the design of new preclinical studies. Since
      several parameters concerning both the graft (i.e., islets) and the recipient
      (i.e., diabetic mice) may influence transplant outcome, we recommend considering 
      several critical points in designing future bench-to-bedside islet
      transplantation research.
AD  - San Raffaele Diabetes Research Institute (OSR-DRI); San Raffaele Scientific
      Institute; Milan, Italy.
FAU - Cantarelli, Elisa
AU  - Cantarelli E
FAU - Citro, Antonio
AU  - Citro A
FAU - Marzorati, Simona
AU  - Marzorati S
FAU - Melzi, Raffaella
AU  - Melzi R
FAU - Scavini, Marina
AU  - Scavini M
FAU - Piemonti, Lorenzo
AU  - Piemonti L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130301
TA  - Islets
JT  - Islets
JID - 101495366
OTO - NOTNLM
OT  - equivalent islet
OT  - hyperglycemia
OT  - intra-hepatic islet infusion
OT  - islet transplantation
OT  - preclinical model
OT  - type 1 diabetes
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 24698 [pii]
PST - aheadofprint
SO  - Islets. 2013 Mar 1;5(2).

PMID- 23751877
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1532-5520 (Electronic)
IS  - 0009-9201 (Linking)
DP  - 2013 Jun 6
TI  - Developmental Programming of Offspring Obesity, Adipogenesis, and Appetite.
AB  - A newly recognized primary cause of the obesity epidemic is the developmental
      programming effects of infants born to mothers with obesity or gestational
      diabetes, intrauterine growth-restricted newborns, and offspring exposed to
      environmental toxins including bisphenol A. The mechanisms which result in
      offspring obesity include the programming of the hypothalamic appetite pathway
      and adipogenic signals regulating lipogenesis. Processes include nutrient
      sensors, epigenetic modifications, and alterations in stem cell precursors of
      both appetite/satiety neurons and adipocytes which are modulated to potentiate
      offspring obesity. Future strategies for the prevention and therapy of obesity
      must address programming effects of the early life environment.
AD  - *Perinatal Research Laboratories, Department of Obstetrics and Gynecology, David 
      Geffen School of Medicine, University of California, Los Angeles daggerDepartment
      of Ob/Gyn, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center,
      Torrance, California.
FAU - Ross, Michael G
AU  - Ross MG
FAU - Desai, Mina
AU  - Desai M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Clin Obstet Gynecol
JT  - Clinical obstetrics and gynecology
JID - 0070014
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1097/GRF.0b013e318299c39d [doi]
PST - aheadofprint
SO  - Clin Obstet Gynecol. 2013 Jun 6.

PMID- 23751875
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 Jun 10
TI  - Teasaponin reduces inflammation and central leptin resistance in diet-induced
      obese male mice.
AB  - Chronic inflammation is involved in the pathogenesis of obesity and type 2
      diabetes. Recently, teasaponin, an extract from tea, has been shown to have
      anti-inflammatory effects. We examined the effect of teasaponin on obesity,
      inflammation, glucose metabolism and central leptin sensitivity, in obese mice
      fed a high-fat (HF) diet for 16 weeks. Intraperitoneal injections of teasaponin
      (10mg/kg, daily) for 21 days significantly decreased the food intake and body
      weight of HF diet-induced obese mice. Teasaponin treatment also reduced the
      protein levels of pro-inflammatory cytokines (TNF-alpha, IL-6 and/or IL-1beta)
      and NF-kappaB signaling (p-IKK and p-IkappaBalpha) in adipose tissue and the
      liver. The anti-inflammatory effects of teasaponin were associated with improved 
      glycemic status in the treated animals, evidenced by improved glucose tolerance, 
      homeostasis model assessment (HOMA) and fasting plasma insulin. In the
      hypothalamus teasaponin decreased both pro-inflammatory cytokines and
      inflammatory signaling in the mediobasal hypothalamus. Teasaponin treatment also 
      enhanced the anorexigenic effect of central leptin administration, restored
      leptin p-STAT3 signaling in the Arc, and increased hypothalamic expression of the
      anorexigenic peptide proopiomelanocortin (POMC). These results identify a
      potential novel application for teasaponin as an anti-obesity and
      anti-inflammatory agent.
AD  - 1Illawarra Health and Medical Research Institute, School of Health Sciences,
      University of Wollongong, Wollongong, NSW, 2522, Australia.
FAU - Yu, Yinghua
AU  - Yu Y
FAU - Wu, Yizhen
AU  - Wu Y
FAU - Szabo, Alexander
AU  - Szabo A
FAU - Wu, Zhixiang
AU  - Wu Z
FAU - Wang, Hongqin
AU  - Wang H
FAU - Li, Duo
AU  - Li D
FAU - Huang, Xu-Feng
AU  - Huang XF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - en.2013-1218 [pii]
AID - 10.1210/en.2013-1218 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 Jun 10.

PMID- 23751871
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 Jun 10
TI  - FTO deficiency induces UCP-1 expression and mitochondrial uncoupling in
      adipocytes.
AB  - Variants in the fat mass and obesity associated (FTO) gene are associated with
      obesity and body fat mass in genome wide association studies (GWAS). However, the
      mechanism by which FTO predisposes individuals to obesity is not clear so far.
      First mechanistic evidence was shown in Fto negative mice. These mice are
      resistant to obesity due to enhanced energy expenditure while the mass of brown
      adipose tissue (BAT) remains unchanged. We hypothesize that FTO is involved in
      the induction of white adipose tissue browning which leads to mitochondrial
      uncoupling and increases energy expenditure.Uncoupling protein 1 (Ucp-1) was
      significantly higher expressed in both gonadal and inguinal adipose depots of
      Fto-/- compared to Fto+/+ littermates accompanied by appearance of multivacuolar,
      Ucp-1 positive adipocytes in these tissues. By using lentiviral shRNA constructs,
      we established FTO-deficient human preadipocytes and adipocytes and analyzed key 
      metabolic processes. FTO deficient adipocytes showed an adipogenic
      differentiation rate comparable to control cells, but exhibited a reduced de novo
      lipogenesis despite unchanged glucose uptake. In agreement with the mouse data,
      FTO deficient adipocytes exhibited 4-fold higher expression of UCP-1 in
      mitochondria compared to control cells. The up-regulation of UCP-1 in FTO
      deficient adipocytes resulted in enhanced mitochondrial uncoupling.We conclude
      that FTO deficiency leads to the induction of a brown adipocyte phenotype,
      thereby enhancing energy expenditure. Further understanding of the signaling
      pathway connecting FTO with UCP-1 expression might lead to new options for
      obesity and overweight treatment.
AD  - 1Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and
      Adolescent Medicine, University Medical Center Ulm, Eythstr. 24, 89075 Ulm,
      Germany.
FAU - Tews, D
AU  - Tews D
FAU - Fischer-Posovszky, P
AU  - Fischer-Posovszky P
FAU - Fromme, T
AU  - Fromme T
FAU - Klingenspor, M
AU  - Klingenspor M
FAU - Fischer, J
AU  - Fischer J
FAU - Ruther, U
AU  - Ruther U
FAU - Marienfeld, R
AU  - Marienfeld R
FAU - Barth, Tf
AU  - Barth T
FAU - Moller, P
AU  - Moller P
FAU - Debatin, Km
AU  - Debatin K
FAU - Wabitsch, M
AU  - Wabitsch M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - en.2012-1873 [pii]
AID - 10.1210/en.2012-1873 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 Jun 10.

PMID- 23751612
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1942-0870 (Electronic)
IS  - 1942-0862 (Linking)
VI  - 5
IP  - 4
DP  - 2013 Apr 18
TI  - Characterization of a surrogate murine antibody to model anti-human CD3
      therapies.
AB  - Fc-modified anti-human CD3epsilon monoclonal antibodies (mAbs) are in clinical
      development for the treatment of autoimmune diseases. These next generation mAbs 
      have completed clinical trials in patients with type-1 diabetes and inflammatory 
      bowel disease demonstrating a narrow therapeutic window. Lowered doses are
      ineffective, yet higher pharmacologically-active doses cause an undesirable level
      of adverse events. Thus, there is a critical need for a return to bench research 
      to explore ways of improving clinical outcomes. Indeed, we recently reported that
      a short course of treatment affords synergy, providing long-term disease
      amelioration when combining anti-mouse CD3 and anti-mouse tumor necrosis factor
      mAbs in experimental arthritis. Such strategies may widen the window between risk
      and benefit; however, to more accurately assess experimentally the biology and
      pharmacology, reagents that mimic the current development candidates were
      required. Consequently, we engineered an Fc-modified anti-mouse CD3epsilon mAb,
      2C11-Novi. Here, we report the functional characterization of 2C11-Novi
      demonstrating that it does not bind FcgammaR in vitro and elicits little cytokine
      release in vivo, while maintaining classical pharmacodynamic effects (CD3-TCR
      downregulation and T cell killing). Furthermore, we observed that oral
      administration of 2C11-Novi ameliorated progression of remitting-relapsing
      experimental autoimmune encephalitis in mice, significantly reducing the primary 
      acute and subsequent relapse phase of the disease. With innovative approaches
      validated in two experimental models of human disease, 2C11-Novi represents a
      meaningful tool to conduct further mechanistic studies aiming at exploiting the
      immunoregulatory properties of Fc-modified anti-CD3 therapies via combination
      therapy using parenteral or oral routes of administration.
AD  - NovImmune SA; Plan-Les-Ouates, Switzerland.
FAU - Depis, Fabien
AU  - Depis F
FAU - Hatterer, Eric
AU  - Hatterer E
FAU - Ballet, Romain
AU  - Ballet R
FAU - Daubeuf, Bruno
AU  - Daubeuf B
FAU - Cons, Laura
AU  - Cons L
FAU - Glatt, Sophie
AU  - Glatt S
FAU - Reith, Walter
AU  - Reith W
FAU - Kosco-Vilbois, Marie
AU  - Kosco-Vilbois M
FAU - Dean, Yann
AU  - Dean Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - MAbs
JT  - mAbs
JID - 101479829
OTO - NOTNLM
OT  - EAE
OT  - Monoclonal antibody
OT  - T cell activation
OT  - anti-CD3
OT  - oral antibody
OT  - pharmacodynamics
OT  - pharmacokinetics
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 24736 [pii]
PST - aheadofprint
SO  - MAbs. 2013 Apr 18;5(4).

PMID- 23751528
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1002-0098 (Print)
IS  - 1002-0098 (Linking)
VI  - 48
IP  - 3
DP  - 2013 Mar
TI  - [Detection of periodontal pathogens from saliva of type 2 diabetic patients in
      urban area of Beijing].
PG  - 144-9
AB  - OBJECTIVE: To investigate the prevalence of periodontal pathogens from saliva of 
      patients with type 2 diabetes mellitus (T2DM), and to characterize the
      association between the glucose status and periodontal pathogens in oral cavity. 
      METHODS: All the subjects were hypertension patients under regular care at
      Beijing hypertension prevention and management institute. Whole unstimulated
      saliva samples were collected from 45 non-diabetic subjects (non-DM group), 80
      well-controlled diabetic patients (DM-well group) and 100 poor-controlled
      diabetic patients (DM-poor group). DNA was extracted from the salivary
      deposition, Porphyromonas gingivalis (Pg), Tannerella forsythia (Tf) and
      Treponema denticola (Td) were detected by polymerase chain reaction (PCR) method 
      based on 16SrRNA. Prevalence and quantity of the pathogens under different
      glucose states were compared and logistic regression model was set to analyze the
      factors related to each bacterium. RESULTS: The prevalence of Tf in DM-well group
      and DM-poor group was significantly lower than that of non-DM group [81% (65/80),
      80% (80/100) vs 91% (41/45), P = 0.048], meanwhile the quantity of Tf was also
      lower than that of non-DM group [1.9(2.6), 2.1(5.3) vs 3.4(6.4)] (P > 0.05). With
      the worsening of glucose control, the quantity of Tf was declining (P = 0.032).
      However, the prevalence and the quantity of Pg, Td in 3 groups had no statistical
      differences (P > 0.05). After adjusting age, gender, number of missing teeth and 
      other periodontal parameters, OR of having Tf in saliva from DM-well group and
      DM-poor group was 0.58 and 0.53, respectively. CONCLUSIONS: Abnormal blood
      glucose state may affect the colonization of Tf in oral cavity.
AD  - Department of Periodotology, Peking University School and Hospital of
      Stomatology, Beijing 100081, China. Email: helubj@tom.com.
FAU - Liao, Yan-Ting
AU  - Liao YT
FAU - He, Lu
AU  - He L
FAU - Meng, Huan-Xin
AU  - Meng HX
FAU - Li, Peng
AU  - Li P
FAU - Sha, Yue-Qin
AU  - Sha YQ
FAU - Wang, Xing-Yu
AU  - Wang XY
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Kou Qiang Yi Xue Za Zhi
JT  - Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese
      journal of stomatology
JID - 8711066
SB  - D
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PST - ppublish
SO  - Zhonghua Kou Qiang Yi Xue Za Zhi. 2013 Mar;48(3):144-9.

PMID- 23751526
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1002-0098 (Print)
IS  - 1002-0098 (Linking)
VI  - 48
IP  - 3
DP  - 2013 Mar
TI  - [Progress of investigations on the effects of chronic periodontitis on diabetes].
PG  - 138-41
FAU - Zhang, Jin-Cai
AU  - Zhang JC
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Kou Qiang Yi Xue Za Zhi
JT  - Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese
      journal of stomatology
JID - 8711066
SB  - D
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PST - ppublish
SO  - Zhonghua Kou Qiang Yi Xue Za Zhi. 2013 Mar;48(3):138-41.

PMID- 23751485
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1421-9670 (Electronic)
IS  - 0250-8095 (Linking)
VI  - 37
IP  - 5
DP  - 2013
TI  - Metabolic Syndrome, Vitamin D Deficiency and Hypoadiponectinemia among
      Nondiabetic Patients Early after Kidney Transplantation.
PG  - 399-404
LID - 10.1159/000349930 [doi]
AB  - Background and Aims: Metabolic syndrome (MetS) is common among kidney transplant 
      patients. We studied the relationship between MetS, vitamin D
      deficiency/insufficiency and hypoadiponectinemia early posttransplantation and
      their impact on clinical outcomes. Methods: Seventy-four previously nondiabetic
      kidney transplant patients were enrolled in a prospective cohort study between
      February and November 2008. Participants underwent a 2-hour oral glucose
      tolerance test and had their plasma levels of 25-hydroxyvitamin D (25[OH]D),
      adiponectin, insulin, intact parathyroid hormone and lipids measured at 11 weeks 
      posttransplantation. Clinical events including cardiovascular events, new-onset
      diabetes after transplantation, acute rejection, graft loss and death were
      recorded during the follow-up to December 2012. Results: Thirty-four study
      patients (45.9%) had MetS. Patients with MetS had lower plasma concentrations of 
      25[OH]D (20.5 +/- 7.2 vs. 24.8 +/- 11.1 ng/ml, p = 0.049) and adiponectin (8.2
      +/- 4.5 vs. 14.6 +/- 8.0 mug/ml, p < 0.0001) early on, and higher composite
      clinical event rate (61.8 vs. 27.5%, p = 0.003) during the follow-up.
      Multivariate analysis showed that the presence of MetS early after
      transplantation was independently associated with 25[OH]D
      deficiency/insufficiency (OR: 14.0, 95% CI: 1.8, 107.5; p = 0.011), depressed
      plasma adiponectin levels (beta -6.39, r(2) 0.195, p < 0.0001) and increased risk
      for clinical events (OR: 5.6, 95% CI: 1.9, 16.5; p = 0.002). Conclusion: Kidney
      transplant patients with MetS early after transplantation had lower levels of
      25[OH]D and adiponectin, and unfavorable clinical outcomes.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Division of Nephrology, Department of Internal Medicine, University of Michigan, 
      Ann Arbor, Mich., USA.
FAU - Kulshrestha, Satyarth
AU  - Kulshrestha S
FAU - Ojo, Akinlolu O
AU  - Ojo AO
FAU - Luan, Fu L
AU  - Luan FL
LA  - eng
PT  - Journal Article
DEP - 20130403
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/09/26 [received]
PHST- 2013/02/17 [accepted]
PHST- 2013/04/03 [aheadofprint]
AID - 000349930 [pii]
AID - 10.1159/000349930 [doi]
PST - ppublish
SO  - Am J Nephrol. 2013;37(5):399-404. doi: 10.1159/000349930. Epub 2013 Apr 3.

PMID- 23751483
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
DP  - 2013 Jun 7
TI  - Association of urinary sodium/creatinine ratio and urinary sodium/specific
      gravity units ratio with blood pressure and hypertension: KNHANES 2009-2010.
LID - S0009-8981(13)00241-6 [pii]
LID - 10.1016/j.cca.2013.05.027 [doi]
AB  - BACKGROUND: We investigated the association between urinary sodium/creatinine
      ratio (U[Na+]/Cr) or urinary sodium/specific gravity units ratio (U[Na+]/SGU),
      estimated from spot urine, and blood pressure (BP) and hypertension. METHODS: The
      study population consisted of a total of 9674 adults (4478 men, 5196 women) who
      participated in the Korea National Health and Nutrition Examination Surveys
      conducted in 2009 and 2010. Urine levels of sodium and creatinine, urine specific
      gravity (SG), and BP were measured along with other risk factors of hypertension.
      SGU is the calculated parameter of (SG - 1) x 100. RESULTS: There were
      significant trends of increasing mean systolic and diastolic BP and prevalence of
      hypertension with increasing quartile of U[Na+]/Cr and U[Na+]/SGU. After
      adjusting for age, total cholesterol, alcohol drinking, obesity, current smoking,
      mild renal dysfunction, and diabetes mellitus, the odds ratios (ORs) for
      hypertension in the top quartile of U[Na+]/Cr compared with the bottom quartile
      were 1.40 in man and 2.68 in women. Similarly, the ORs for hypertension in the
      top quartile of U[Na+]/SGU were 1.29 in men and 3.02 in women after adjustment.
      CONCLUSIONS: U[Na+]/Cr and U[Na+]/SGU are associated with BP and hypertension,
      supporting the possible clinical value of U[Na+]/Cr and U[Na+]/SGU in general
      medical facilities.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Lee, Sang-Guk
AU  - Lee SG
FAU - Lee, Woonhyoung
AU  - Lee W
FAU - Kwon, Oh Hun
AU  - Kwon OH
FAU - Kim, Jeong-Ho
AU  - Kim JH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/02/14 [received]
PHST- 2013/05/28 [revised]
PHST- 2013/05/28 [accepted]
AID - S0009-8981(13)00241-6 [pii]
AID - 10.1016/j.cca.2013.05.027 [doi]
PST - aheadofprint
SO  - Clin Chim Acta. 2013 Jun 7. pii: S0009-8981(13)00241-6. doi:
      10.1016/j.cca.2013.05.027.

PMID- 23751451
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
DP  - 2013 Jun 7
TI  - Extending Indications for Islet Autotransplantation in Pancreatic Surgery.
AB  - OBJECTIVE:: To assess metabolic and oncologic outcomes of islet
      autotransplantation (IAT) in patients undergoing pancreatic surgery for either
      benign or malignant disease. BACKGROUND:: IAT is performed to improve glycemic
      control after extended pancreatectomy, almost exclusively in patients with
      chronic pancreatitis. Limited experience is available for other indications or in
      patients with pancreatic malignancy. METHODS:: In addition to chronic
      pancreatitis, indications for IAT were grade C pancreatic fistula (treated with
      completion or left pancreatectomy, as indicated); total pancreatectomy as an
      alternative to high-risk anastomosis during pancreaticoduodenectomy; and distal
      pancreatectomy for benign/borderline neoplasm of pancreatic body-neck. Malignancy
      was not an exclusion criterion. Metabolic and oncologic follow-up is presented.
      RESULTS:: From November 2008 to June 2012, 41 patients were candidates to IAT
      (accounting for 7.5% of all pancreatic resections). Seven of 41 did not receive
      transplantation for inadequate islet mass (4 pts), patient instability (2 pts),
      or contamination of islet culture (1 pt). IAT-related complications occurred in 8
      pts (23.5%): 4 bleeding, 3 portal thromboses (1 complete, 2 partial), and 1
      sepsis. Median follow-up was 546 days. Fifteen of 34 patients (44%) reached
      insulin independence, 16 patients (47%) had partial graft function, 2 patients
      (6%) had primary graft nonfunction, and 1 patient (3%) had early graft loss.
      Seventeen IAT recipients had malignancy (pancreatic or periampullary
      adenocarcinoma in 14). Two of them had already liver metastases at surgery, 13
      were disease-free at last follow-up, and none of 2 patients with tumor recurrence
      developed metastases in the transplantation site. CONCLUSIONS:: Although larger
      data are needed to definitely exclude the risk of disease dissemination, the
      present study suggests that IAT indications can be extended to selected patients 
      with neoplasm.
AD  - *Department of Surgery, San Raffaele Scientific Institute daggerIslet
      Transplantation Unit, Diabetes Research Institute (HSR-DRI); Division of
      Immunology, Transplantation and Infectious Diseases; San Raffaele Scientific
      Institute double daggerBeta Cell Biology Unit, Diabetes Research Institute
      (HSR-DRI); Division of Immunology, Transplantation and Infectious Diseases; San
      Raffaele Scientific Institute section signPancreatic Surgery Section, Department 
      of General Surgery, University of Milan, Istituto Clinico Humanitas IRCCS
      paragraph signDepartment of Radiology, San Raffaele Scientific Institute
      ||Epidemiology & Data Management Unit, Diabetes Research Institute (HSR-DRI);
      Division of Immunology, Transplantation and Infectious Diseases; San Raffaele
      Scientific Institute **Clinical Transplant Unit, Division of Immunology,
      Transplantation and Infectious Diseases; San Raffaele Scientific Institute
      daggerdaggerVita-Salute San Raffaele University, Milan, Italy.
FAU - Balzano, Gianpaolo
AU  - Balzano G
FAU - Maffi, Paola
AU  - Maffi P
FAU - Nano, Rita
AU  - Nano R
FAU - Zerbi, Alessandro
AU  - Zerbi A
FAU - Venturini, Massimo
AU  - Venturini M
FAU - Melzi, Raffaella
AU  - Melzi R
FAU - Mercalli, Alessia
AU  - Mercalli A
FAU - Magistretti, Paola
AU  - Magistretti P
FAU - Scavini, Marina
AU  - Scavini M
FAU - Castoldi, Renato
AU  - Castoldi R
FAU - Carvello, Michele
AU  - Carvello M
FAU - Braga, Marco
AU  - Braga M
FAU - Del Maschio, Alessandro
AU  - Del Maschio A
FAU - Secchi, Antonio
AU  - Secchi A
FAU - Staudacher, Carlo
AU  - Staudacher C
FAU - Piemonti, Lorenzo
AU  - Piemonti L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1097/SLA.0b013e31829c790d [doi]
PST - aheadofprint
SO  - Ann Surg. 2013 Jun 7.

PMID- 23751444
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 Jun 7
TI  - Forensic aspects of insulin.
LID - S0168-8227(13)00186-1 [pii]
LID - 10.1016/j.diabres.2013.05.002 [doi]
AB  - Insulin or, more appropriately, hypoglycaemia gives rise to a wide variety of
      interactions with the law. In most cases its role is not seriously open to
      question occasionally however, it is. This is especially true of situations in
      which insulin is suspected of having been used inappropriately or maliciously.
      The major differences between investigation of hypoglycaemia in clinical and
      forensic situation are that in the latter the history is often unreliable,
      appropriate samples for analysis were not collected, preserved or labelled
      correctly and analytical results are likely to be challenged on grounds of
      specificity, accuracy and interpretation. Immunoassay remains the mainstay of
      clinical investigation of hypoglycaemia but likely to become displaced by
      mass-spectrometry in the forensic situation especially now that human insulin is 
      being replaced by synthetic insulin analogues for the treatment of diabetes.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Post Graduate Medical School, University of Surrey, Guildford, UK. Electronic
      address: vincentmarks@btinternet.com.
FAU - Marks, Vincent
AU  - Marks V
FAU - Wark, Gwen
AU  - Wark G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/04/17 [received]
PHST- 2013/05/10 [accepted]
AID - S0168-8227(13)00186-1 [pii]
AID - 10.1016/j.diabres.2013.05.002 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 Jun 7. pii: S0168-8227(13)00186-1. doi:
      10.1016/j.diabres.2013.05.002.

PMID- 23751425
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1872-8278 (Electronic)
IS  - 1567-7249 (Linking)
DP  - 2013 Jun 7
TI  - Mitochondrial response to oxidative and nitrosative stress in early stages of
      diabetes.
LID - S1567-7249(13)00096-2 [pii]
LID - 10.1016/j.mito.2013.05.012 [doi]
AB  - Diabetes mellitus (DM) is associated with increased production of reactive oxygen
      and nitrogen species; consequently, an increase in lipid peroxidation and a
      decrease in antioxidants resulting in mitochondrial dysfunction. Using a rat
      model of DM induced by streptozotocin, we show the opposite: an increase in NO
      levels, S-nitrosylation, aconitase activity, and total glutathione and a decrease
      in lipid peroxidation at early stages of diabetes. These data imply that the
      decrease in lipid peroxidation is a vital early response to hyperglycemia to
      prevent escalation of ROS generation in mitochondria. These results also suggest 
      a need for novel therapeutic targets to prevent the neurological consequences of 
      diabetes.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Instituto de Investigaciones Quimico-Biologicas, Universidad Michoacana de San
      Nicolas de Hidalgo. Morelia, Mich. Mexico.
FAU - Noriega-Cisneros, Ruth
AU  - Noriega-Cisneros R
FAU - Cortes-Rojo, Christian
AU  - Cortes-Rojo C
FAU - Manzo-Avalos, Salvador
AU  - Manzo-Avalos S
FAU - Clemente-Guerrero, Monica
AU  - Clemente-Guerrero M
FAU - Calderon-Cortes, Elizabeth
AU  - Calderon-Cortes E
FAU - Salgado-Garciglia, Rafael
AU  - Salgado-Garciglia R
FAU - Montoya-Perez, Rocio
AU  - Montoya-Perez R
FAU - Boldogh, Istvan
AU  - Boldogh I
FAU - Saavedra-Molina, Alfredo
AU  - Saavedra-Molina A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Mitochondrion
JT  - Mitochondrion
JID - 100968751
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/07/13 [received]
PHST- 2013/05/04 [revised]
PHST- 2013/05/30 [accepted]
AID - S1567-7249(13)00096-2 [pii]
AID - 10.1016/j.mito.2013.05.012 [doi]
PST - aheadofprint
SO  - Mitochondrion. 2013 Jun 7. pii: S1567-7249(13)00096-2. doi:
      10.1016/j.mito.2013.05.012.

PMID- 23751386
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 Jun 8
TI  - Frequency and severity of ketoacidosis at onset of autoimmune type 1 diabetes
      over the past decade in children referred to a tertiary paediatric care centre:
      potential impact of a national programme highlighted.
PG  - 1-7
LID - 10.1515/jpem-2013-0060 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0060/jpem-2013-0060.xml [pii]
AB  - Abstract Aims: To assess the frequency and severity of diabetic ketoacidosis
      (DKA) at disease onset in children newly diagnosed with autoimmune type 1
      diabetes (T1D) in Istanbul in the last decade. Also, to evaluate the potential
      contribution of the national diabetes awareness programme (NDAP) initiated in
      2010. Methods: Four hundred and one consecutive children (mean+/-standard
      deviation, age 8.1+/-4.1 years) with a diagnosis of autoimmune T1D were evaluated
      retrospectively with respect to demographic, clinical, and laboratory data in
      relation to DKA at disease onset. The possible impact of NDAP on the rate of DKA 
      at disease onset in the last 2 years was also evaluated by comparing the data
      related to the time intervals before and after the onset of the programme. The
      results were evaluated at 95% confidence interval and significance was granted
      for p</=0.05. Results: The overall frequency of DKA at disease onset was 44.2%,
      with a significant trend for decline in rate of DKA at disease onset in the last 
      decade (p=0.0001). There were no significant differences in proportions of newly 
      diagnosed T1D patients with severe or moderate DKA over time. Mean body mass
      index standard deviation score tended to increase in the last decade, but not
      significantly (p=0.09). When the time intervals before and after the onset of
      NDAP were evaluated, there was a more than two-fold decrease in rate of DKA (from
      49.3% to 23.9%) (p<0.0001). Conclusions: The frequency of a DKA event at onset of
      T1D is still high in Istanbul children despite a decreasing trend in the last
      decade. NDAP may significantly contribute to the reduction in rate of DKA.
FAU - Ucar, Ahmet
AU  - Ucar A
FAU - Saka, Nurcin
AU  - Saka N
FAU - Bas, Firdevs
AU  - Bas F
FAU - Sukur, Mine
AU  - Sukur M
FAU - Poyrazoglu, Sukran
AU  - Poyrazoglu S
FAU - Darendeliler, Feyza
AU  - Darendeliler F
FAU - Bundak, Ruveyde
AU  - Bundak R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/02/12 [received]
PHST- 2013/05/14 [accepted]
AID - 10.1515/jpem-2013-0060 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0060/jpem-2013-0060.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 Jun 8:1-7. doi: 10.1515/jpem-2013-0060.

PMID- 23751385
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 Jun 8
TI  - Prevalence of metabolic syndrome among urban Indian adolescents and its relation 
      with insulin resistance (HOMA-IR).
PG  - 1-8
LID - 10.1515/jpem-2013-0020 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0020/jpem-2013-0020.xml [pii]
AB  - Abstract Aim: To assess prevalence of metabolic syndrome (MS) in urban Indian
      adolescents. MS in adolescents is a forerunner of diabetes mellitus and
      cardiovascular disease in adults, therefore, its identification provides an
      opportunity to intervene with lifestyle changes to prevent disease progression
      into adulthood. We randomly selected 900 adolescents (300 for each group) to
      participate in the study from a total of 15,101 adolescents (10-18 years) who
      were grouped as normal, overweight, and obese (total population). Methods: From
      the 900 adolescents, 695 consented to participate in the study and underwent a
      detailed anthropometric and biochemical evaluation, therefore, these adolescents 
      constituted the study population. MS was defined by criteria proposed by the
      International Diabetes Federation (MS-IDF) and the Adult Treatment Panel
      (MS-ATP). The prevalence of MS in the study population was used to calculate the 
      prevalence of MS in the total population based on the distribution of the
      different BMI categories in this larger sample (n=15,101). Results: Calculated
      prevalence of MS in urban Indian adolescents was 4.3% and 3.0% in the total
      population using MS-ATP and MS-IDF criteria, respectively. Among the study
      population, MS was higher in girls than boys (MS-ATP, G: 22.3% vs. B: 16.6%,
      p=0.03; MS-IDF, G: 20.5% vs. B: 13.5%, p=0.006). The most common component of MS-
      ATP and MS-IDF was central obesity (89.8% vs. 100.0%, p<0.00001), followed by
      hypertriglyceridemia (83.0% vs. 82.2%, p=0.35), low high density
      lipoprotein-cholesterol (71.1% vs. 71.2%, p=0.48), hypertension (44.4% vs. 44.9%,
      p=0.025), and dysglycemia (40.0% vs. 34.7%, p=0.94). The mean serum insulin
      levels and HOMA-IR progressively increased with the increasing number of
      components present in an individual. Conclusions: Metabolic syndrome is common in
      urban Indian overweight and obese adolescents.
FAU - Tandon, Nikhil
AU  - Tandon N
FAU - Garg, M K
AU  - Garg MK
FAU - Singh, Yashpal
AU  - Singh Y
FAU - Marwaha, Raman K
AU  - Marwaha RK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/01/16 [received]
PHST- 2013/05/14 [accepted]
AID - 10.1515/jpem-2013-0020 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0020/jpem-2013-0020.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 Jun 8:1-8. doi: 10.1515/jpem-2013-0020.

PMID- 23751384
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 Jun 8
TI  - Clinical characteristics and management of cranial diabetes insipidus in infants.
PG  - 1-6
LID - 10.1515/jpem-2013-0026 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0026/jpem-2013-0026.xml [pii]
AB  - Abstract Aim: Cranial diabetes insipidus (CDI) is rare in infants with no
      guidelines on its management. We describe the first case series, characterizing
      the clinical features and treatment challenges. Method: Retrospective case note
      review of infants diagnosed with CDI between April 1992 and February 2011.
      Results: Nineteen infants (52% male) were identified. Eight were born preterm.
      Median (range) age at diagnosis was 24 days (5-300); preterm babies were younger 
      at diagnosis (21 vs. 46 days). In 58% (11/19) of infants, hypernatraemia was
      discovered incidentally. In 37% of cases there was associated midline anomalies, 
      however, only four patients (21%) had absent posterior pituitary signal on a
      magnetic resonance imaging brain scan. The most frequent (5/19) underlying
      diagnosis was septo-optic dysplasia. Eight patients had isolated CDI and 11 had
      multiple pituitary hormone deficiencies. Isolated CDI tended to be more common in
      preterm, compared to term babies (p=0.11). Des-amino arginine vasopressin (DDAVP)
      was administered intranasally in eight and orally in 11 infants. Plasma sodium
      nadir following DDAVP administration was lower following intranasal compared to
      an oral route of administration (median: 128 vs. 133 mmol/L, p=0.022). No cases
      resolved on follow-up. Conclusions: CDI in infants is often diagnosed
      incidentally. Aetiology, clinical, and imaging features are very variable, with
      some differences between preterm and term infants. Oral DDAVP appears to be
      superior to intranasal with less pronounced serum sodium fluctuations.
FAU - Karthikeyan, Ambika
AU  - Karthikeyan A
FAU - Abid, Noina
AU  - Abid N
FAU - Sundaram, Prem C B
AU  - Sundaram PC
FAU - Shaw, Nicholas J
AU  - Shaw NJ
FAU - Barrett, Tim G
AU  - Barrett TG
FAU - Hogler, Wolfgang
AU  - Hogler W
FAU - Kirk, Jeremy M W
AU  - Kirk JM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/01/19 [received]
PHST- 2013/05/14 [accepted]
AID - 10.1515/jpem-2013-0026 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0026/jpem-2013-0026.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 Jun 8:1-6. doi: 10.1515/jpem-2013-0026.

PMID- 23751369
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1546-4156 (Electronic)
IS  - 0893-0341 (Linking)
DP  - 2013 Jun 6
TI  - The Red Cell Distribution Width and Anemia in Association With Prevalent
      Dementia.
AB  - The red cell distribution width (RDW), a measure of anisocytosis, independently
      predicts cardiovascular disease outcomes and chronic disease mortality. Little is
      known about the RDW, or the interplay between RDW and anemia, in relation to
      dementia risk. We evaluated the association between the RDW and prevalent
      dementia, overall and by anemia status, among 2556 community-dwelling older
      adults participating in the Chicago Health and Aging Project. RDW measurements
      came from complete blood counts, and participants underwent diagnosis for
      dementia according to standard clinical criteria. Five hundred twenty-five
      participants were diagnosed with dementia. Elevated RDW was associated with
      increased odds of having dementia: after adjusting for age, sex, race, and
      education, the odds of prevalent dementia increased progressively over increasing
      quartile of RDW (Ptrend=0.02), and persons in the highest RDW quartile (>/=14.8%)
      had 42% greater odds of having dementia than those in the lowest quartile [odds
      ratio (OR), 1.42; 95% confidence interval (CI), 1.05-1.92)]. Per unit (%)
      increment in RDW, the odds of dementia were higher by 6% (OR, 1.06; 95% CI,
      1.00-1.13). Findings were similar upon further adjustment for health behaviors
      and diabetes. In analyses adjusted for hemoglobin concentration, the RDW-dementia
      association was attenuated, whereas the inverse association between hemoglobin
      and dementia remained significant. However, RDW was associated with dementia more
      strongly among participants without anemia (OR, 1.09; 95% CI, 1.00-1.43) than
      among those with anemia (OR, 0.99; 95% CI, 0.86-1.18), although this difference
      was not statistically significant. The RDW, a readily available and inexpensive
      hematologic measure, may offer novel information about dementia risk,
      particularly among persons without anemia. Future studies should establish the
      RDW's ability to predict risk prospectively.
AD  - *Rush Institute for Healthy Aging section signRush Alzheimer's Disease Center,
      Rush University Medical Center, Chicago, IL daggerDepartment of Environmental
      Health, Harvard School of Public Health, Boston, MA double daggerDepartment of
      Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI.
FAU - Weuve, Jennifer
AU  - Weuve J
FAU - Mendes de Leon, Carlos F
AU  - Mendes de Leon CF
FAU - Bennett, David A
AU  - Bennett DA
FAU - Dong, Xinqi
AU  - Dong X
FAU - Evans, Denis A
AU  - Evans DA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Alzheimer Dis Assoc Disord
JT  - Alzheimer disease and associated disorders
JID - 8704771
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1097/WAD.0b013e318299673c [doi]
PST - aheadofprint
SO  - Alzheimer Dis Assoc Disord. 2013 Jun 6.

PMID- 23751314
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
DP  - 2013 Jun 7
TI  - Early manifestations of pancreatic cancer: The effect of cancer-nerve
      interaction.
LID - S0306-9877(13)00239-9 [pii]
LID - 10.1016/j.mehy.2013.05.010 [doi]
AB  - Clinical manifestation is important for the diagnosis of pancreatic cancer
      (PanCa). No typical symptoms have been identified that clearly indicate the early
      stage of PanCa, although most patients with PanCa have symptoms before the cancer
      is diagnosed. These symptoms are often regarded as common gastrointestinal
      symptoms and are ignored. The pancreas is richly supplied with nerves, and
      neuro-cancer interactions begin prior to PanCa cell migration. We hypothesise
      that the cancer-nerve interaction does generate typical symptoms such as
      pseudomorphous satiety and mild pain in early PanCa. Constant satiety leads to
      weight loss. This biological behaviour allows the cancer to progress without
      attention from the cancer-bearing host. Cancer cells also target the endocrine
      pancreas, generating a hyperglycaemic state that results in increased energy for 
      cancer cells. The combination of the so-called common gastrointestinal symptoms
      and diabetes may represent early typical symptoms of PanCa that can be used to
      improve early diagnosis.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of General Surgery, Second Affiliated Hospital, School of Medicine,
      Xi'an Jiaotong University, Xi'an, People's Republic of China. Electronic address:
      ljh991049@yahoo.com.cn.
FAU - Li, Junhui
AU  - Li J
FAU - Li, Yiming
AU  - Li Y
FAU - Cao, Gang
AU  - Cao G
FAU - Guo, Kun
AU  - Guo K
FAU - Zhang, Li
AU  - Zhang L
FAU - Ma, Qingyong
AU  - Ma Q
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/01/31 [received]
PHST- 2013/05/09 [revised]
PHST- 2013/05/15 [accepted]
AID - S0306-9877(13)00239-9 [pii]
AID - 10.1016/j.mehy.2013.05.010 [doi]
PST - aheadofprint
SO  - Med Hypotheses. 2013 Jun 7. pii: S0306-9877(13)00239-9. doi:
      10.1016/j.mehy.2013.05.010.

PMID- 23751310
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
DP  - 2013 Jun 7
TI  - Adverse effect of metformin therapy on serum vitamin B12 and folate: Short-term
      treatment causes disadvantages?
LID - S0306-9877(13)00254-5 [pii]
LID - 10.1016/j.mehy.2013.05.025 [doi]
AB  - Diabetes is a global public health challenge that imposes heavy burdens on
      communities and individuals. Metformin, the first-line medication for diabetes,
      has the superiority of reducing risk of macrovascular diseases, all-cause
      mortality and even possibly cancers. Recent observational studies, however, have 
      demonstrated that long-term metformin therapy increases the probability of
      vitamin B12 and folate deficiency, and might contribute to the progression of
      diabetic peripheral neuropathy. Despite metformin is widely used and extensively 
      studied, randomized controlled trials performed to explore the effects of
      metformin on vitamin B12 and folate are limited. Besides, whether short-term
      treatment causes vitamin deficiency is a pending issue. We postulate that even a 
      few-month treatment with metformin results in the decrease of vitamin B12 and
      folate. However, supplementation of vitamin B12 rather than the combination of
      vitamin B12 and folate might be profitable based on the mechanism of metformin on
      vitamins in patients with type 2 diabetes. This viewpoint differs from those of
      majority that a combined supplementation of vitamin B12 and folate is inclined to
      be advised.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen
      University, 58th of Zhongshan Er Road, Guangzhou 510080, China.
FAU - Xu, Lijuan
AU  - Xu L
FAU - Huang, Zhimin
AU  - Huang Z
FAU - He, Xiaoying
AU  - He X
FAU - Wan, Xuesi
AU  - Wan X
FAU - Fang, Donghong
AU  - Fang D
FAU - Li, Yanbing
AU  - Li Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/10/15 [received]
PHST- 2013/05/19 [accepted]
AID - S0306-9877(13)00254-5 [pii]
AID - 10.1016/j.mehy.2013.05.025 [doi]
PST - aheadofprint
SO  - Med Hypotheses. 2013 Jun 7. pii: S0306-9877(13)00254-5. doi:
      10.1016/j.mehy.2013.05.025.

PMID- 23751157
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1743-6109 (Electronic)
IS  - 1743-6095 (Linking)
DP  - 2013 Jun 10
TI  - Nitric Oxide-Releasing Polymeric Microspheres Improve Diabetes-Related Erectile
      Dysfunction.
LID - 10.1111/jsm.12216 [doi]
AB  - INTRODUCTION: We have used a long-acting nitric oxide (NO)-releasing polymer to
      develop injectable biodegradable microspheres capable of localized NO release
      over prolonged periods of time. AIM: The aim of this study was to evaluate the
      therapeutic potential of these microspheres for diabetes-related erectile
      dysfunction (ED) in the rat model. METHODS: NO-releasing microspheres were
      incubated in physiologic buffer, and in vitro NO release was measured using a
      Griess assay. To ensure no migration, microspheres were fluorescently tagged and 
      injected into the corpus cavernosum of adult rats, and fluorescent imaging was
      performed weekly for 4 weeks, at which point rats were sacrificed. To assess
      physiologic efficacy, diabetes was induced in 40 rats using streptozotocin (STZ),
      whereas 10 rats were kept as age-matched controls. Diabetic rats were divided
      into four groups: no treatment, sildenafil, NO-releasing microspheres, and
      combination therapy. For each rat, the cavernosal nerve (CN) was stimulated at
      various voltages, and intracavernosal pressure (ICP) and mean arterial pressure
      (MAP) were measured via corpus cavernosum and carotid artery catheterization,
      respectively. Long-term efficacy was determined by injecting diabetic rats with
      microspheres and measuring erectile response at predetermined intervals for up to
      5 weeks. MAIN OUTCOME MEASURES: Erectile response was determined via calculation 
      of mean peak ICP/MAP and area under curve (AUC) for each experimental group.
      RESULTS: Under physiologic conditions in vitro, microspheres continued NO release
      for up to 4 weeks. Fluorescent imaging revealed no detectable signal in tissues
      besides cavernosal tissue at 4 weeks postinjection. Upon CN stimulation, peak
      ICP/MAP ratio and AUC of diabetic rats improved significantly (P < 0.05) in
      microsphere and combination therapy groups compared with no treatment and
      sildenafil groups. In long-term efficacy studies, microspheres augmented the
      effect of sildenafil for 3 weeks following injection (P < 0.05). CONCLUSIONS:
      NO-releasing microspheres significantly improved erectile response in diabetic
      rats for 3 weeks and hence offer a promising approach to ED therapy, either as
      monotherapy or combination therapy. Soni SD, Song W, West JL, and Khera M. Nitric
      oxide-releasing polymeric microspheres improve diabetes-related erectile
      dysfunction. J Sex Med **;**:**-**.
CI  - (c) 2013 International Society for Sexual Medicine.
AD  - Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
FAU - Soni, Samit D
AU  - Soni SD
FAU - Song, Weitao
AU  - Song W
FAU - West, Jennifer L
AU  - West JL
FAU - Khera, Mohit
AU  - Khera M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1111/jsm.12216 [doi]
PST - aheadofprint
SO  - J Sex Med. 2013 Jun 10. doi: 10.1111/jsm.12216.

PMID- 23751144
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 35
IP  - 6
DP  - 2013 Jul
TI  - Effect of hemoglobin variability on mortality and some cardiovascular parameters 
      in hemodialysis patients.
PG  - 819-24
LID - 10.3109/0886022X.2013.801270 [doi]
AB  - Abstract Background and objectives: Most hemodialysis patients show hemoglobin
      fluctuations between low-normal and high levels. This hemoglobin variability may 
      cause left ventricle hypertrophy and may increase mortality as well. Recently,
      many studies were designed to evaluate the effect of hemoglobin variability on
      mortality but results were conflicting. We aimed to investigate the effect of
      hemoglobin variability on mortality and some cardiovascular parameters in
      hemodialysis population. Design, setting, participants and measurements: Hundred 
      and seventy-five prevalent hemodialysis patients classified into three hemoglobin
      variability groups according to their hemoglobin levels throughout 24 month
      observation period: Low-Normal, Low-High, Normal-High. Groups were compared in
      terms of laboratory, demographical data and mortality rates, initial and the end 
      of 24 month echocardiographic data. Initial and last echocardiographic data were 
      compared within groups in terms of left ventricle mass index increase. Results:
      Mortality rates and cardiovascular risk factors such as coronary heart disease,
      diabetes mellitus and hypertension that may affect mortality were same between
      three groups. There was no significant difference between three groups in terms
      of echocardiographic and laboratory parameters. Only Low-High group showed
      significant increase on left ventricle mass index when initial and last
      echocardiographic parameters were compared. Conclusions: Consistent with previous
      studies, we found that most of the patients exhibited hemoglobin variability and 
      our study is consistent with some of the studies that did not find any
      relationship between hemoglobin variability and mortality. Firstly, in this study
      based on objective data, it was shown that hemoglobin variability has adverse
      effect on left ventricle geometry independent from anemia.
AD  - Department of Nephrolory .
FAU - Altunoren, Orcun
AU  - Altunoren O
FAU - Dogan, Ekrem
AU  - Dogan E
FAU - Sayarlioglu, Hayriye
AU  - Sayarlioglu H
FAU - Acar, Gurkan
AU  - Acar G
FAU - Yavuz, Yasemin Coskun
AU  - Yavuz YC
FAU - Aydin, Naci
AU  - Aydin N
FAU - Sahin, Murat
AU  - Sahin M
FAU - Akkoyun, Murat
AU  - Akkoyun M
FAU - Isik, Ismet Onder
AU  - Isik IO
FAU - Altunoren, Ozlem
AU  - Altunoren O
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.3109/0886022X.2013.801270 [doi]
PST - ppublish
SO  - Ren Fail. 2013 Jul;35(6):819-24. doi: 10.3109/0886022X.2013.801270.

PMID- 23751087
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
DP  - 2013 Jun 11
TI  - Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal 
      and pancreatic function in db/db mice.
LID - 10.1111/bph.12269 [doi]
AB  - BACKGROUND AND PURPOSE: Although recent clinical studies have shown that
      inhibition of renal sodium-glucose co-transporter 2 (SGLT2) has a stable
      glucose-lowering effect in patients with type 2 diabetes (T2D), the effect of
      renal SGLT2 inhibition on renal dysfunction in T2D remains to be determined. To
      evaluate the renoprotective effect of SGLT2 inhibition more precisely, we
      compared the effects of tofogliflozin (a specific SGLT2 inhibitor) with those of 
      losartan (an angiotensin II receptor blocker) on renal function and beta-cell
      function in db/db mice. EXPERIMENTAL APPROACH: The effects of 8-week
      tofogliflozin or losartan treatment on renal and beta-cell function were
      investigated in db/db mice by quantitative image analysis of glomerular size,
      mesangial matrix expansion, and islet beta-cell mass. KEY RESULTS: Tofogliflozin 
      suppressed plasma glucose and glycated hemoglobin and preserved pancreatic
      beta-cell mass and plasma insulin levels. No improvement of glycemic condition or
      insulin level was observed with losartan treatment. Although the urine
      albumin/creatinine ratio (ACR) of untreated db/db mice gradually increased from
      baseline, tofogliflozin and losartan treatment each significantly prevented the
      increase of ACR (by 50-70%). Tofogliflozin attenuated glomerular hypertrophy,
      whereas losartan had no effect on glomerular size. Neither tofogliflozin nor
      losartan significantly alter matrix expansion. CONCLUSIONS AND IMPLICATIONS: Our 
      findings provide evidence that the long-term inhibition of renal SGLT2 by
      tofogliflozin may not only preserve pancreatic beta-cell function but also
      prevent kidney dysfunction in a T2D mice model. These findings suggest the
      therapeutic utility of long-term use of tofogliflozin in T2D patients to prevent 
      the progression of diabetic nephropathy.
CI  - This article is protected by copyright. All rights reserved.
AD  - Research Division, Chugai Pharmaceutical Co., Ltd., Inc. Gotemba, Shizuoka,
      Japan.
FAU - Nagata, T
AU  - Nagata T
FAU - Fukuzawa, T
AU  - Fukuzawa T
FAU - Takeda, M
AU  - Takeda M
FAU - Fukazawa, M
AU  - Fukazawa M
FAU - Mori, T
AU  - Mori T
FAU - Nihei, T
AU  - Nihei T
FAU - Honda, K
AU  - Honda K
FAU - Suzuki, Y
AU  - Suzuki Y
FAU - Kawabe, Y
AU  - Kawabe Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/04 [accepted]
AID - 10.1111/bph.12269 [doi]
PST - aheadofprint
SO  - Br J Pharmacol. 2013 Jun 11. doi: 10.1111/bph.12269.

PMID- 23751050
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1365-2796 (Electronic)
IS  - 0954-6820 (Linking)
DP  - 2013 Jun 10
TI  - The required beta cell research for improving treatment of type 2 diabetes.
LID - 10.1111/joim.12096 [doi]
AB  - In healthy individuals, insulin resistance is associated with physiological
      conditions such as pregnancy or body weight gain and triggers an increase in beta
      cell number and insulin secretion capacity to preserve normoglycaemia. Failure of
      this beta cell compensation capacity is a fundamental cause of diabetic
      hyperglycaemia. Incomplete understanding of the molecular mechanisms controlling 
      the plasticity of adult beta cell mechanisms and how these cells fail during the 
      pathogenesis of diabetes strongly limits the ability to develop new beta
      cell-specific therapies. Here, current knowledge of the signalling pathways
      controlling beta cell plasticity is reviewed and possible directions for future
      research are discussed. This article is protected by copyright. All rights
      reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.
FAU - Thorens, Bernard
AU  - Thorens B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/04/23 [accepted]
AID - 10.1111/joim.12096 [doi]
PST - aheadofprint
SO  - J Intern Med. 2013 Jun 10. doi: 10.1111/joim.12096.

PMID- 23750979
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1486-3847 (Print)
IS  - 1486-3847 (Linking)
VI  - 74
IP  - 2
DP  - 2013 Summer
TI  - Role of the Nutrition Professional In High-risk Obstetrics Inpatient Teams.
PG  - 75-9
AB  - Beyond the management of gestational diabetes and weight control, limited
      literature exists on nutritional management in high-risk pregnancies. This study 
      is a starting point for understanding the role of the registered dietitian (RD)
      in high-risk obstetrics (HRO) inpatient teams. Demographic information was
      gathered on Ontario HRO inpatient units and patient characteristics, and the RD's
      role in this setting was explored. Representatives from all six HRO units in
      Ontario completed a questionnaire. Five of the HRO units had an RD on the team.
      The RDs stated that their primary role in the unit involved providing nutrition
      education and support, screening patients for nutritional risk, and writing
      vitamin and mineral orders. This was the first study in which RDs' role in HRO
      inpatient units was examined. Existing literature supports the role of good
      nutrition in preventing and treating the conditions seen in HRO units; however,
      RDs' specific role remains unclear. Future studies are needed to analyze the
      effect of nutrition on these HRO conditions, and to support the development of
      best practice guidelines.
AD  - Sunnybrook Health Sciences Centre.
FAU - Gurau, Julia
AU  - Gurau J
FAU - Cronk, Aleris
AU  - Cronk A
FAU - Pelliccia, Maria
AU  - Pelliccia M
FAU - Vandenbussche, Katherine
AU  - Vandenbussche K
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Diet Pract Res
JT  - Canadian journal of dietetic practice and research : a publication of Dietitians 
      of Canada = Revue canadienne de la pratique et de la recherche en dietetique :
      une publication des Dietetistes du Canada
JID - 9811151
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PST - ppublish
SO  - Can J Diet Pract Res. 2013 Summer;74(2):75-9.

PMID- 23750823
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1447-0594 (Electronic)
IS  - 1447-0594 (Linking)
DP  - 2013 Jun 10
TI  - Evaluation of an intra-institutional diabetes disease management program for the 
      glycemic control of elderly long-term care diabetic patients.
LID - 10.1111/ggi.12104 [doi]
AB  - AIM: Increasing numbers of nursing home elderly patients suffer from diabetes
      requiring individually optimized glycemic control. This is a complicated
      challenge because of their high comorbidity level, and heterogeneous and changing
      eating status varying from independent to dysphagia and enteral feeding. In order
      to cope with these complex needs, we developed and implemented a diabetes disease
      management program. The purpose of the present study was to evaluate this
      program. METHODS: We used the point prevalence approach by checking for fasting
      blood glucose, glycated hemoglobin and other routine biochemical tests. Eating
      status was evaluated by the Functional Outcome Swallowing Scale. Details about
      the diabetes disease management program are given in the text. RESULTS: A total
      of 86 (36%) of the 234 patients on the study day were diabetics. Of these, 80
      were eligible for the study. Their mean fasting blood glucose was 143.1 +/- 60.6 
      mg/dL. The mean glycated hemoglobin level was 7.23 +/- 1.39%. CONCLUSION: No case
      of hypoglycemia was detected on the examination day, or during the preceding 3
      weeks. No significant difference was found among the different Functional Outcome
      Swallowing Scale categories. These results are within satisfactory range for this
      category of patients suggesting that our diabetes disease management program
      contributes to a better glycemic control. Geriatr Gerontol Int 2013; : -.
CI  - (c) 2013 Japan Geriatrics Society.
AD  - Geriatric Department, Shmuel Harofeh Medical Center, Beer Yaakov, Israel.
FAU - Lubart, Emily
AU  - Lubart E
FAU - Segal, Refael
AU  - Segal R
FAU - Wainstein, Julio
AU  - Wainstein J
FAU - Marinov, Galina
AU  - Marinov G
FAU - Yarovoy, Alexandra
AU  - Yarovoy A
FAU - Leibovitz, Arthur
AU  - Leibovitz A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Geriatr Gerontol Int
JT  - Geriatrics & gerontology international
JID - 101135738
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/05/01 [accepted]
AID - 10.1111/ggi.12104 [doi]
PST - aheadofprint
SO  - Geriatr Gerontol Int. 2013 Jun 10. doi: 10.1111/ggi.12104.

PMID- 23750800
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
DP  - 2013 Jun 10
TI  - Delayed Anti-CD3 Therapy Results in Depletion of Alloreactive T Cells and the
      Dominance of Foxp3 CD4 Graft Infiltrating Cells.
LID - 10.1111/ajt.12272 [doi]
AB  - The engineered Fc-nonbinding (crystallizable fragment-nonbinding) CD3 antibody
      has lower mitogenicity and a precise therapeutic window for disease remission in 
      patients with type 1 diabetes. Before anti-CD3 can be considered for use in
      transplantation, the most effective timing of treatment relative to
      transplantation needs to be elucidated. In this study anti-CD3F(ab')2 fragments
      or saline were administered intravenously for 5 consecutive days (early: d1-3 or 
      delayed: d3-7) to mice transplanted with a cardiac allograft (H2b -to-H2k ; d0). 
      Survival of allografts was prolonged in mice treated with the early protocol (MST
      = 48 days), but most were rejected by d100. In contrast, in mice treated with the
      delayed protocol allografts continued to survive long term. The delayed protocol 
      significantly inhibited donor alloreactivity at d30 as compared to the early
      protocol. A marked increase in Foxp3+ T cells (50.3 +/- 1.6%) infiltrating the
      allografts in mice treated with the delayed protocol was observed (p < 0.0001 vs.
      early (24.9 +/- 2.1%)) at d10; a finding that was maintained in the accepted
      cardiac allografts at d100. We conclude that the timing of treatment with
      anti-CD3 therapy is critical for inducing long-term graft survival. Delaying
      administration effectively inhibits the alloreactivity and promotes the dominance
      of intragraft Foxp3+ T cells allowing long-term graft acceptance.
CI  - (c) 2013 The Authors. American Journal of Transplantation Published by Wellcome
      Trust.
AD  - Transplantation Research Immunology Group, Nuffield Department of Surgical
      Sciences, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
FAU - Goto, R
AU  - Goto R
FAU - You, S
AU  - You S
FAU - Zaitsu, M
AU  - Zaitsu M
FAU - Chatenoud, L
AU  - Chatenoud L
FAU - Wood, K J
AU  - Wood KJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2012/08/14 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/31 [accepted]
AID - 10.1111/ajt.12272 [doi]
PST - aheadofprint
SO  - Am J Transplant. 2013 Jun 10. doi: 10.1111/ajt.12272.

PMID- 23750710
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Linking)
DP  - 2013 Jun 10
TI  - Essential role of Pin1 via STAT3 signalling and mitochondria-dependent pathways
      in restenosis in type 2 diabetes.
LID - 10.1111/jcmm.12082 [doi]
AB  - Type 2 diabetes (T2D) is associated with accelerated restenosis rates after
      angioplasty. We have previously proved that Pin1 played an important role in
      vascular smooth muscle cell (VSMC) cycle and apoptosis. But neither the role of
      Pin1 in restenosis by T2D, nor the molecular mechanism of Pin1 in these processes
      has been elucidated. A mouse model of T2D was generated by the combination of
      high-fat diet (HFD) and streptozotocin (STZ) injections. Both
      Immunohistochemistry and Western blot revealed that Pin1 expression was
      up-regulated in the arterial wall in T2D mice and in VSMCs in culture conditions 
      mimicking T2D. Next, increased activity of Pin1 was observed in neointimal
      hyperplasia after arterial injury in T2D mice. Further analysis confirmed that
      10% serum of T2D mice and Pin1-forced expression stimulated proliferation,
      inhibited apoptosis, enhanced cell cycle progression and migration of VSMCs,
      whereas Pin1 knockdown resulted in the converse effects. We demonstrated that
      STAT3 signalling and mitochondria-dependent pathways played critical roles in the
      involvement of Pin1 in cell cycle regulation and apoptosis of VSMCs in T2D. In
      addition, VEGF expression was stimulated by Pin1, which unveiled part of the
      mechanism of Pin1 in regulating VSMC migration in T2D. Finally, the
      administration of juglone via pluronic gel onto injured common femoral artery
      resulted in a significant inhibition of the neointima/media ratio. Our findings
      demonstrated the vital effect of Pin1 on the VSMC proliferation, cell cycle
      progression, apoptosis and migration that underlie neointima formation in T2D and
      implicated Pin1 as a potential therapeutic target to prevent restenosis in T2D.
CI  - (c) 2013 The Authors. Published by Foundation for Cellular and Molecular
      Medicine/Blackwell Publishing Ltd.
AD  - Department of Vascular Surgery, Renji Hospital, Shanghai Jiaotong University,
      College of Medicine, Shanghai, China.
FAU - Lv, Lei
AU  - Lv L
FAU - Zhang, Jiwei
AU  - Zhang J
FAU - Zhang, Lan
AU  - Zhang L
FAU - Xue, Guanhua
AU  - Xue G
FAU - Wang, Peng
AU  - Wang P
FAU - Meng, Qiurong
AU  - Meng Q
FAU - Liang, Wei
AU  - Liang W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/01/14 [received]
PHST- 2013/04/17 [accepted]
AID - 10.1111/jcmm.12082 [doi]
PST - aheadofprint
SO  - J Cell Mol Med. 2013 Jun 10. doi: 10.1111/jcmm.12082.

PMID- 23750704
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1447-0594 (Electronic)
IS  - 1447-0594 (Linking)
DP  - 2013 Jun 10
TI  - High normotension is associated with higher metabolic syndrome risk in
      postmenopausal women.
LID - 10.1111/ggi.12097 [doi]
AB  - AIM: Cardiovascular disease and diabetes are important causes for mortality in
      older people. Both hypertension and prehypertension are correlated with them.
      Recently, health promotion and disease prevention in postmenopausal women have
      become an essential issue of public health policy. The present study aimed to
      evaluate whether the harmful effects of blood pressure (BP) could still be found 
      in normotensive postmenopausal women (below 120/80 mmHg). METHODS: A total of
      4539 normotensive postmenopausal women aged 51 years or older, undergoing routine
      health examinations, were enrolled in the cross-sectional analyses. To mitigate
      the effect of age on BP, participants within the same age were divided into
      tertiles according to their systolic BP (SBP). Then, participants in the low-SBP 
      tertile of each age stratum were pooled together to form a larger group
      (low-normal SBP group [LNSBP]). Similarly, the middle- and high-normal SBP were
      grouped accordingly (MNSBP and HNSBP). Metabolic syndrome (MetS) was considered
      to be a surrogate for future cardiovascular disease and diabetes. RESULTS: The
      study showed that HNSBP bore a higher likelihood of having abnormal MetS
      components, elevated low-density lipoprotein cholesterol levels and a higher odds
      ratio (1.46; 95% confidence interval 1.17-1.81) for having MetS than LNSBP. In
      contrast, age, body mass index, fasting plasma glucose and low-density
      lipoprotein cholesterol were significantly related to SBP in multiple regression 
      analysis. CONCLUSIONS: The risk of having MetS was significantly associated with 
      higher SBP even within normotension. Primary prevention, such as lifestyle
      modification, and more strict control of BP should be stressed in postmenopausal 
      women. Geriatr Gerontol Int 2013; : -.
CI  - (c) 2013 Japan Geriatrics Society.
AD  - Department of Family Medicine, Cardinal Tien Hospital, School of Medicine, Fu Jen
      Catholic University, Taipei, Taiwan.
FAU - Hsu, Chun-Hsien
AU  - Hsu CH
FAU - Lin, Jiunn-Diann
AU  - Lin JD
FAU - Wu, Chung-Ze
AU  - Wu CZ
FAU - Lau, Shu Chuen
AU  - Lau SC
FAU - Chen, Yen-Lin
AU  - Chen YL
FAU - Tang, Sai-Hung
AU  - Tang SH
FAU - Yu, Shu-Man
AU  - Yu SM
FAU - Pei, Dee
AU  - Pei D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Geriatr Gerontol Int
JT  - Geriatrics & gerontology international
JID - 101135738
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/04/16 [accepted]
AID - 10.1111/ggi.12097 [doi]
PST - aheadofprint
SO  - Geriatr Gerontol Int. 2013 Jun 10. doi: 10.1111/ggi.12097.

PMID- 23750681
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 11
IP  - 6
DP  - 2013 Jun
TI  - Assessment and management of left ventricular hypertrophy in Type 2 diabetes
      patients with high blood pressure.
PG  - 719-28
LID - 10.1586/erc.13.36 [doi]
AB  - Diabetes is associated with left ventricular hypertrophy (LVH). This article
      reviews the assessment and management of LVH in Type 2 diabetic patients and the 
      available evidence on blood-pressure management in these patients in order to
      reduce LVH. The best treatment of LVH starts with early identification and rapid 
      implementation of adequate treatment, especially in populations at higher risk.
      Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors 
      should be the first-line therapy, because they are proven to be the most
      effective in reducing LVH in Type 2 diabetic patients. In patients where
      angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors 
      are contraindicated or not tolerated, calcium-channel blockers should be the
      second option.
AD  - Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione
      IRCCS Policlinico S. Matteo, P.le Golgi, 2-27100, Pavia, Italy.
FAU - Derosa, Giuseppe
AU  - Derosa G
FAU - Maffioli, Pamela
AU  - Maffioli P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1586/erc.13.36 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2013 Jun;11(6):719-28. doi: 10.1586/erc.13.36.

PMID- 23750676
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 11
IP  - 6
DP  - 2013 Jun
TI  - An update on telmisartan/hydrochlorothiazide combinations for the management of
      hypertensive patients with additional cardiovascular risk factors.
PG  - 673-82
LID - 10.1586/erc.13.63 [doi]
AB  - International hypertension guidelines endorse the use of combination therapy to
      achieve blood pressure control in the majority of patients. Angiotensin AT1
      receptor blockers, in combination with diuretics, are among the preferred
      combinations, with telmisartan plus hydrochlorothiazide (HCTZ) being an effective
      and well-tolerated combination. This article provides an up-to-date review of the
      existing data on telmisartan/HCTZ combination for the management of hypertension 
      in patients with additional cardiovascular risk factors, including reports
      emerging from a number of recent clinical trials and secondary analyses of older 
      trials. The accumulated evidence from clinical trials demonstrates that
      telmisartan/HCTZ combinations are effective and well tolerated in patients with
      mild-to-severe hypertension, including subgroups of patients with cardiovascular 
      risk factors such as advanced age, obesity, chronic kidney disease, diabetes
      mellitus and treatment-resistant hypertension.
AD  - Department of Cardiology, Ulleval Hospital, N-0407 Oslo, Norway.
      uxsvkj@ous-hf.no.
FAU - Kjeldsen, Sverre
AU  - Kjeldsen S
FAU - Mancia, Giuseppe
AU  - Mancia G
FAU - Schmieder, Roland
AU  - Schmieder R
FAU - Mattheus, Michaela
AU  - Mattheus M
FAU - Unger, Thomas
AU  - Unger T
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1586/erc.13.63 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2013 Jun;11(6):673-82. doi: 10.1586/erc.13.63.

PMID- 23750675
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 11
IP  - 6
DP  - 2013 Jun
TI  - The next 10 years in antihypertensive treatment.
PG  - 669-71
LID - 10.1586/erc.13.57 [doi]
AB  - Interview by Tanya Stezhka Dr Cooper-DeHoff is an Associate Professor in the
      Department of Pharmacotherapy and Translational Research, and the Department of
      Pharmaceutics in the College of Pharmacy, and in the Division of Cardiovascular
      Medicine, at the University of Florida (FL, USA). Her principle research focuses 
      on hypertension, diabetes and the metabolic syndrome. She was a principle
      investigator of the INVEST study, which evaluated hypertension treatments in
      older coronary artery disease patients, and is currently a coinvestigator on two 
      NIH grants evaluating pharmacogenetic hypertension associations. She is a member 
      of the American Heart Association, American Society of Hypertension, American
      College of Cardiology and Florida Society of Hospital Pharmacists.
AD  - Department of Pharmacotherapy & Translational Research, College of Pharmacy,
      University of Florida, PO Box 100486, Gainesville, FL 32610-0486, USA.
      dehoff@cop.ufl.edu.
FAU - Cooper-Dehoff, Rhonda M
AU  - Cooper-Dehoff RM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.1586/erc.13.57 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2013 Jun;11(6):669-71. doi: 10.1586/erc.13.57.

PMID- 23750647
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1750-192X (Electronic)
IS  - 1750-192X (Linking)
VI  - 5
IP  - 3
DP  - 2013 Jun
TI  - Genes, assisted reproductive technology and trans-illumination.
PG  - 331-40
LID - 10.2217/epi.13.28 [doi]
AB  - Genomic imprinting is a parent-of-origin allele-specific epigenetic process that 
      is critical for normal development and health. The establishment and maintenance 
      of normal imprinting is dependent on both cis-acting imprinting control centers, 
      which are marked by differentially (parental allele specific) methylated marks,
      and trans mechanisms, which regulate the establishment and/or maintenance of the 
      correct methylation epigenotype at the imprinting control centers. Studies of
      rare human imprinting disorders such as familial hydatidiform mole,
      Beckwith-Wiedemann syndrome and familial transient neonatal diabetes mellitus
      have enabled the identification of genetic (e.g., mutations in KHDC3L [C6ORF221],
      NLRP2 [NALP2], NLRP7 [NALP7] and ZFP57) and environmental (assisted reproductive 
      technologies) factors that can disturb the normal trans mechanisms for imprinting
      establishment and/or maintenance. Here we review the clinical and molecular
      aspects of these imprinting disorders in order to demonstrate how the study of
      rare inherited disorders can illuminate the molecular characteristics of
      fundamental epigenetic processes, such as genomic imprinting.
AD  - Centre for Rare Diseases & Personalised Medicine, School of Clinical &
      Experimental Medicine, College of Medical & Dental Sciences, University of
      Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
FAU - Dias, Renuka P
AU  - Dias RP
FAU - Maher, Eamonn R
AU  - Maher ER
LA  - eng
PT  - Journal Article
PL  - England
TA  - Epigenomics
JT  - Epigenomics
JID - 101519720
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
AID - 10.2217/epi.13.28 [doi]
PST - ppublish
SO  - Epigenomics. 2013 Jun;5(3):331-40. doi: 10.2217/epi.13.28.

PMID- 23750586
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
DP  - 2013 Jun 11
TI  - Chronic activation of the low affinity site of beta -adrenoceptors stimulates
      haemodynamics but exacerbated pressure-overload cardiac remodelling.
LID - 10.1111/bph.12272 [doi]
AB  - BACKGROUND AND PURPOSE: The beta1 -adrenoceptor has at least two binding sites,
      high and low affinity sites (beta1H and beta1L , respectively), which mediate
      cardiostimulation. While beta1H - adrenoceptor can be blocked by all clinically
      used beta-blockers, beta1L -adrenoceptor is relatively resistant to blockade.
      Thus, chronic beta1L -adrenoceptor activation may mediate persistent
      cardiostimulation, despite the concurrent blockade of beta1H -adrenoceptors. It
      is important to determine the potential significance of beta1L -adrenoceptors in 
      vivo, particularly in the setting of disease. EXPERIMENTAL APPROACH: C57Bl/6 male
      mice were used. Chronic (4 or 8 weeks) beta1L -adrenoceptor activation was
      achieved by treatment, via osmotic minipumps, with (-)-CGP12177 (10 mg kg-1 day-1
      ). Cardiac function was assessed by echocardiography and micromanometry. KEY
      RESULTS: (-)-CGP12177 treatment in healthy mice increased heart rate and left
      ventricular (LV) contractility. In mice subjected to transverse aorta
      constriction (TAC), (-)-CGP12177 treatment during 4-8 or 4-12 weeks,
      respectively, after TAC led to a positive inotropic effect and exacerbated
      fibrogenic signalling while cardiac hypertrophy tended to be more severe.
      (-)-CGP12177 treatment to mice with TAC exacerbated myocardial expression of
      hypertrophic, fibrogenic and inflammatory genes (all P<0.05 vs. non-treated mice 
      with aorta banding). Washout of (-)-CGP12177 revealed a more pronounced cardiac
      dysfunction after 12 weeks TAC. CONCLUSIONS AND IMPLICATIONS: beta1L
      -adrenoceptor activation provides functional support to the heart, in both normal
      and diseased (pressure overload) settings. Sustained beta1L -adrenoceptor
      activation in the diseased heart exacerbates LV remodelling and therefore may
      promote disease progression from compensatory hypertrophy to heart failure.
CI  - This article is protected by copyright. All rights reserved.
AD  - Experimental Cardiology Laboratory, Baker IDI Heart and Diabetes Institute,
      Melbourne, Australia.
FAU - Kiriazis, Helen
AU  - Kiriazis H
FAU - Tugiono, Niquita
AU  - Tugiono N
FAU - Xu, Qi
AU  - Xu Q
FAU - Gao, Xiao-Ming
AU  - Gao XM
FAU - Jennings, Nicole L
AU  - Jennings NL
FAU - Ming, Ziqui
AU  - Ming Z
FAU - Su, Yidan
AU  - Su Y
FAU - Klenowski, Paul
AU  - Klenowski P
FAU - Summers, Roger J
AU  - Summers RJ
FAU - Kaumann, Alberto
AU  - Kaumann A
FAU - Molenaar, Peter
AU  - Molenaar P
FAU - Du, Xiao-Jun
AU  - Du XJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/06/07 [accepted]
AID - 10.1111/bph.12272 [doi]
PST - aheadofprint
SO  - Br J Pharmacol. 2013 Jun 11. doi: 10.1111/bph.12272.

PMID- 23750554
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
DP  - 2013 Jun 10
TI  - Impact of diabetes mellitus on clinical parameters and treatment outcomes of
      newly diagnosed pulmonary tuberculosis patients in Thailand.
LID - 10.1111/ijcp.12215 [doi]
AB  - BACKGROUND: To assess the clinical and laboratory parameters, response to therapy
      and development of antituberculosis (TB) drug resistance in pulmonary TB (PTB)
      patients with diabetes mellitus (DM) and without DM. METHODS: Using a prospective
      design, 227 of 310 new cases of culture-positive PTB diagnosed at the Queen
      Savang Vadhana Memorial Hospital and the Chonburi Hospital between April 2010 and
      July 2012 that met the study criteria were selected. Data regarding clinical and 
      laboratory parameters, drug susceptibility and treatment outcomes were compared
      between PTB patients with DM and those without DM. To control for age, the
      patients were stratified into two age groups (< 50 and >/= 50 years) and their
      data were analysed. RESULTS: Of the 227 patients, 37 (16.3%) had DM, of which 26 
      (70.3%) had been diagnosed with DM prior to PTB diagnosis and 11 (29.7%) had
      developed DM at PTB diagnosis. After controlling for age, no significant
      differences were found between the two groups regarding mycobacterium burden,
      sputum-culture conversion rate, evidence of multidrug-resistant tuberculosis,
      frequency of adverse drug events from anti-TB medications, treatment outcomes and
      relapse rate. The presenting symptoms of anorexia (p = 0.050) and haemoptysis (p 
      = 0.036) were observed significantly more frequently in PTB patients with DM,
      while the presenting symptom of cough was observed significantly more frequently 
      in PTB patients without DM (p = 0.047). CONCLUSIONS: Plasma glucose levels should
      be monitored in all newly diagnosed PTB patients and a similar treatment regimen 
      should be prescribed to PTB patients with DM and those without DM in high
      TB-burden countries.
CI  - (c) 2013 The Authors. International Journal of Clinical Practice published by
      John Wiley & Sons Ltd.
AD  - Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol
      University, Bangkok, Thailand.
FAU - Duangrithi, D
AU  - Duangrithi D
FAU - Thanachartwet, V
AU  - Thanachartwet V
FAU - Desakorn, V
AU  - Desakorn V
FAU - Jitruckthai, P
AU  - Jitruckthai P
FAU - Phojanamongkolkij, K
AU  - Phojanamongkolkij K
FAU - Rienthong, S
AU  - Rienthong S
FAU - Chuchottaworn, C
AU  - Chuchottaworn C
FAU - Pitisuttithum, P
AU  - Pitisuttithum P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/01/31 [received]
PHST- 2013/05/19 [accepted]
AID - 10.1111/ijcp.12215 [doi]
PST - aheadofprint
SO  - Int J Clin Pract. 2013 Jun 10. doi: 10.1111/ijcp.12215.

PMID- 23750335
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 2211-8160 (Print)
VI  - 8
IP  - 1
DP  - 2013 Mar
TI  - Cardiovascular Disease Risk Assessment: Insights from Framingham.
PG  - 11-23
AB  - Cardiovascular disease (CVD) is among the leading causes of death and disability 
      worldwide. Since its beginning, the Framingham study has been a leader in
      identifying CVD risk factors. Clinical trials have demonstrated that when the
      modifiable risk factors are treated and corrected, the chances of CVD occurring
      can be reduced. The Framingham study also recognized that CVD risk factors are
      multifactorial and interact over time to produce CVD. In response, Framingham
      investigators developed the Framingham Risk Functions (also called Framingham
      Risk Scores) to evaluate the chance or likelihood of developing CVD in
      individuals. These functions are multivariate functions (algorithms) that combine
      the information in CVD risk factors such as sex, age, systolic blood pressure,
      total cholesterol, high-density lipoprotein cholesterol, smoking behavior, and
      diabetes status to produce an estimate (or risk) of developing CVD or a component
      of CVD (such as coronary heart disease, stroke, peripheral vascular disease, or
      heart failure) over a fixed time, for example, the next 10 years. These estimates
      of CVD risk are often major inputs in recommending drug treatments such as
      cholesterol-lowering drugs.
AD  - Mathematics and Statistics Department, Boston University, Boston, MA, USA ;
      Framingham Study, Framingham, MA, USA ; Biostatistics Department, Boston
      University, Boston, MA, USA.
FAU - D'Agostino, Ralph B Sr
AU  - D'Agostino RB Sr
FAU - Pencina, Michael J
AU  - Pencina MJ
FAU - Massaro, Joseph M
AU  - Massaro JM
FAU - Coady, Sean
AU  - Coady S
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - Glob Heart
JT  - Global heart
JID - 101584391
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1016/j.gheart.2013.01.001 [doi]
PST - ppublish
SO  - Glob Heart. 2013 Mar;8(1):11-23.

PMID- 23750281
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - A binding-site barrier affects imaging efficiency of high affinity
      amyloid-reactive Peptide radiotracers in vivo.
PG  - e66181
LID - 10.1371/journal.pone.0066181 [doi]
AB  - Amyloid is a complex pathology associated with a growing number of diseases
      including Alzheimer's disease, type 2 diabetes, rheumatoid arthritis, and
      myeloma. The distribution and extent of amyloid deposition in body organs
      establishes the prognosis and can define treatment options; therefore,
      determining the amyloid load by using non-invasive molecular imaging is
      clinically important. We have identified a heparin-binding peptide designated p5 
      that, when radioiodinated, was capable of selectively imaging systemic visceral
      AA amyloidosis in a murine model of the disease. The p5 peptide was posited to
      bind effectively to amyloid deposits, relative to similarly charged polybasic
      heparin-reactive peptides, because it adopted a polar alpha helix secondary
      structure. We have now synthesized a variant, p5R, in which the 8 lysine amino
      acids of p5 have been replaced with arginine residues predisposing the peptide
      toward the alpha helical conformation in an effort to enhance the reactivity of
      the peptide with the amyloid substrate. The p5R peptide had higher affinity for
      amyloid and visualized AA amyloid in mice by using SPECT/CT imaging; however, the
      microdistribution, as evidenced in micro-autoradiographs, was dramatically
      altered relative to the p5 peptide due to its increased affinity and a resultant 
      "binding site barrier" effect. These data suggest that radioiodinated peptide p5R
      may be optimal for the in vivo detection of discreet, perivascular amyloid, as
      found in the brain and pancreatic vasculature, by using molecular imaging
      techniques; however, peptide p5, due to its increased penetration, may yield more
      quantitative imaging of expansive tissue amyloid deposits.
AD  - Department of Medicine, University of Tennessee Graduate School of Medicine,
      Knoxville, Tennessee, United States of America ; Department of Radiology,
      University of Tennessee Graduate School of Medicine, Knoxville, Tennessee, United
      States of America.
FAU - Wall, Jonathan S
AU  - Wall JS
FAU - Williams, Angela
AU  - Williams A
FAU - Richey, Tina
AU  - Richey T
FAU - Stuckey, Alan
AU  - Stuckey A
FAU - Huang, Ying
AU  - Huang Y
FAU - Wooliver, Craig
AU  - Wooliver C
FAU - Macy, Sallie
AU  - Macy S
FAU - Heidel, Eric
AU  - Heidel E
FAU - Gupta, Neil
AU  - Gupta N
FAU - Lee, Angela
AU  - Lee A
FAU - Rader, Brianna
AU  - Rader B
FAU - Martin, Emily B
AU  - Martin EB
FAU - Kennel, Stephen J
AU  - Kennel SJ
LA  - eng
PT  - Journal Article
DEP - 20130604
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/21 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/06/04 [epublish]
AID - 10.1371/journal.pone.0066181 [doi]
AID - PONE-D-13-11586 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 4;8(6):e66181. doi: 10.1371/journal.pone.0066181. Print 2013.

PMID- 23750273
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Elevated Protein Carbonylation, and Misfolding in Sciatic Nerve from db/db and
      Sod1(-/-) Mice: Plausible Link between Oxidative Stress and Demyelination.
PG  - e65725
LID - 10.1371/journal.pone.0065725 [doi]
AB  - Diabetic peripheral polyneuropathy is associated with decrements in motor/sensory
      neuron myelination, nerve conduction and muscle function; however, the mechanisms
      of reduced myelination in diabetes are poorly understood. Chronic elevation of
      oxidative stress may be one of the potential determinants for demyelination as
      lipids and proteins are important structural constituents of myelin and highly
      susceptible to oxidation. The goal of the current study was to determine whether 
      there is a link between protein oxidation/misfolding and demyelination. We chose 
      two distinct models to test our hypothesis: 1) the leptin receptor deficient
      mouse (dbdb) model of diabetic polyneuropathy and 2) superoxide dismutase 1
      knockout (Sod1(-/-) ) mouse model of in vivo oxidative stress. Both experimental 
      models displayed a significant decrement in nerve conduction, increase in tail
      distal motor latency as well as reduced myelin thickness and fiber/axon diameter.
      Further biochemical studies demonstrated that oxidative stress is likely to be a 
      potential key player in the demyelination process as both models exhibited
      significant elevation in protein carbonylation and alterations in protein
      conformation. Since peripheral myelin protein 22 (PMP22) is a key component of
      myelin sheath and has been found mutated and aggregated in several peripheral
      neuropathies, we predicted that an increase in carbonylation and aggregation of
      PMP22 may be associated with demyelination in dbdb mice. Indeed, PMP22 was found 
      to be carbonylated and aggregated in sciatic nerves of dbdb mice. Sequence-driven
      hydropathy plot analysis and in vitro oxidation-induced aggregation of purified
      PMP22 protein supported the premise for oxidation-dependent aggregation of PMP22 
      in dbdb mice. Collectively, these data strongly suggest for the first time that
      oxidation-mediated protein misfolding and aggregation of key myelin proteins may 
      be linked to demyelination and reduced nerve conduction in peripheral
      neuropathies.
AD  - Department of Cellular and Structural Biology, University of Texas Health Science
      Center, San Antonio, Texas, United States of America ; Sam and Ann Barshop
      Institute for Longevity and Aging Studies, San Antonio, Texas, United States of
      America.
FAU - Hamilton, Ryan T
AU  - Hamilton RT
FAU - Bhattacharya, Arunabh
AU  - Bhattacharya A
FAU - Walsh, Michael E
AU  - Walsh ME
FAU - Shi, Yun
AU  - Shi Y
FAU - Wei, Rochelle
AU  - Wei R
FAU - Zhang, Yiqiang
AU  - Zhang Y
FAU - Rodriguez, Karl A
AU  - Rodriguez KA
FAU - Buffenstein, Rochelle
AU  - Buffenstein R
FAU - Chaudhuri, Asish R
AU  - Chaudhuri AR
FAU - Van Remmen, Holly
AU  - Van Remmen H
LA  - eng
PT  - Journal Article
DEP - 20130604
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/17 [received]
PHST- 2013/04/27 [accepted]
PHST- 2013/06/04 [epublish]
AID - 10.1371/journal.pone.0065725 [doi]
AID - PONE-D-13-02753 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 4;8(6):e65725. doi: 10.1371/journal.pone.0065725. Print 2013.

PMID- 23750268
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 6
DP  - 2013
TI  - Skin autofluorescence based decision tree in detection of impaired glucose
      tolerance and diabetes.
PG  - e65592
LID - 10.1371/journal.pone.0065592 [doi]
AB  - AIM: Diabetes (DM) and impaired glucose tolerance (IGT) detection are
      conventionally based on glycemic criteria. Skin autofluorescence (SAF) is a
      noninvasive proxy of tissue accumulation of advanced glycation endproducts (AGE) 
      which are considered to be a carrier of glycometabolic memory. We compared SAF
      and a SAF-based decision tree (SAF-DM) with fasting plasma glucose (FPG) and
      HbA1c, and additionally with the Finnish Diabetes Risk Score (FINDRISC)
      questionnaire+/-FPG for detection of oral glucose tolerance test (OGTT)- or
      HbA1c-defined IGT and diabetes in intermediate risk persons. METHODS:
      Participants had >/=1 metabolic syndrome criteria. They underwent an OGTT, HbA1c,
      SAF and FINDRISC, in adition to SAF-DM which includes SAF, age, BMI, and
      conditional questions on DM family history, antihypertensives, renal or
      cardiovascular disease events (CVE). RESULTS: 218 persons, age 56 yr, 128M/90F,
      97 with previous CVE, participated. With OGTT 28 had DM, 46 IGT, 41 impaired
      fasting glucose, 103 normal glucose tolerance. SAF alone revealed 23 false
      positives (FP), 34 false negatives (FN) (sensitivity (S) 68%; specificity (SP)
      86%). With SAF-DM, FP were reduced to 18, FN to 16 (5 with DM) (S 82%; SP 89%).
      HbA1c scored 48 FP, 18 FN (S 80%; SP 75%). Using HbA1c-defined DM-IGT/suspicion
      >/=6%/42 mmol/mol, SAF-DM scored 33 FP, 24 FN (4 DM) (S76%; SP72%), FPG 29 FP, 41
      FN (S71%; SP80%). FINDRISC>/=10 points as detection of HbA1c-based
      diabetes/suspicion scored 79 FP, 23 FN (S 69%; SP 45%). CONCLUSION: SAF-DM is
      superior to FPG and non-inferior to HbA1c to detect diabetes/IGT in
      intermediate-risk persons. SAF-DM's value for diabetes/IGT screening is further
      supported by its established performance in predicting diabetic complications.
AD  - Department of Medicine, University Medical Center Groningen, and University of
      Groningen, Groningen, The Netherlands.
FAU - Smit, Andries J
AU  - Smit AJ
FAU - Smit, Jitske M
AU  - Smit JM
FAU - Botterblom, Gijs J
AU  - Botterblom GJ
FAU - Mulder, Douwe J
AU  - Mulder DJ
LA  - eng
PT  - Journal Article
DEP - 20130604
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/15 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/06/04 [epublish]
AID - 10.1371/journal.pone.0065592 [doi]
AID - PONE-D-13-07464 [pii]
PST - epublish
SO  - PLoS One. 2013 Jun 4;8(6):e65592. doi: 10.1371/journal.pone.0065592. Print 2013.

PMID- 23750089
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130610
DCOM- 20130611
IS  - 0973-2063 (Electronic)
IS  - 0973-2063 (Linking)
VI  - 9
IP  - 8
DP  - 2013
TI  - Molecular signaling cascade of miRNAs in causing Diabetes Nephropathy.
PG  - 401-8
LID - 10.6026/97320630009401 [doi]
AB  - Diabetic nephropathy (DN) is one of the major microvascular diseases and most
      common in diabetic patient, finally results in kidney failure. The main features 
      of DN are basement membrane thickening, microalbuminuria, proteinuria,
      glomerular, mesangial hypertrophy and ECM protein accumulation. Recent
      discoveries have been shown that numerous pathways are activated during the
      development of DN in Diabetes mellitus. The small non-coding miRNA plays an
      important role in regulating the pathway which is involved in DN. In our study we
      consolidate different pathways which regulated by miRNAs in molecular signaling
      which results in causing DN. We embedded entire pathway in the form of regulatory
      network and we could able to understand that some of the miRNAs like miR-29
      family, miR-377 and miR-25 would be able to control DN.
AD  - Department of Biochemistry, Central College Campus, Bangalore University,
      Bangalore 560 001.
FAU - Padmashree, Dyave Gowda
AU  - Padmashree DG
FAU - Swamy, Narayanaswamy Ramachandra
AU  - Swamy NR
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Singapore
TA  - Bioinformation
JT  - Bioinformation
JID - 101258255
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:01
CRDT- 2013/06/11 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/15 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.6026/97320630009401 [doi]
AID - 97320630009401 [pii]
PST - epublish
SO  - Bioinformation. 2013 Apr 30;9(8):401-8. doi: 10.6026/97320630009401. Print 2013.

PMID- 23750084
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130610
DCOM- 20130611
IS  - 0973-2063 (Electronic)
IS  - 0973-2063 (Linking)
VI  - 9
IP  - 7
DP  - 2013
TI  - InDiaMed: A Comprehensive Database of Indian Medicinal plants for Diabetes.
PG  - 378-80
LID - 10.6026/97320630009378 [doi]
AB  - According to International Diabetes Federation (IDF), India has 62.4 million
      people with diabetes and by 2030 it is predicted that the number will rise to 100
      million. Studies claim that there are around 410 experimentally proven Indian
      medicinal plants which have anti-diabetic activity, of which the mechanism of
      action of 109 plants has been elucidated or reported. So, the need of the hour is
      to explore the claims of Indian medicinal flora and open up the facets of many
      Indian plants which are being examined for their beneficial role in diabetes. So,
      we created a database (InDiaMed) of Indian medicinal plants that captures their
      role in anti-diabetic activity. InDiaMed's features include chemical,
      pharmacological, biochemical and geographical information of the medicinal plant,
      scientifically relevant information of the plant, and the coherent research done 
      on it in the field of diabetes. The database also includes the list of
      poly-herbal formulations which are used for treatment of diabetes in India.
      AVAILABILITY: http://www.indiamed.info.
AD  - National Institute of Pharmaceutical Education and Research, Department of
      Pharmacology, Hyderabad, Andhra Pradesh, India - 500037 ; Authors Equally
      Contributed.
FAU - Tota, Kumudini
AU  - Tota K
FAU - Rayabarapu, Nihar
AU  - Rayabarapu N
FAU - Moosa, Sowmya
AU  - Moosa S
FAU - Talla, Venu
AU  - Talla V
FAU - Bhyravbhatla, Balaji
AU  - Bhyravbhatla B
FAU - Rao, Srinivasa
AU  - Rao S
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - Singapore
TA  - Bioinformation
JT  - Bioinformation
JID - 101258255
OTO - NOTNLM
OT  - Database
OT  - Diabetes
OT  - Medicinal Plants
OT  - Poly-herbal formulations
OT  - active constituents
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:01
CRDT- 2013/06/11 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/19 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/13 [epublish]
AID - 10.6026/97320630009378 [doi]
AID - 97320630009378 [pii]
PST - epublish
SO  - Bioinformation. 2013 Apr 13;9(7):378-80. doi: 10.6026/97320630009378. Print 2013.

PMID- 23750083
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130610
DCOM- 20130611
IS  - 0973-2063 (Electronic)
IS  - 0973-2063 (Linking)
VI  - 9
IP  - 7
DP  - 2013
TI  - Phyto diab care: Phytoremedial database for antidiabetics.
PG  - 375-7
LID - 10.6026/97320630009375 [doi]
AB  - Diabetes, a chronic disease debilitating to normal healthy lifestyle, onsets due 
      to insufficient amount of insulin production or ineffective utilization of the
      amount produced. Although, pharmaceutical research has brought up remedial drugs 
      and numerous candidates in various phases of clinical trials, off-target effects 
      and unwanted physiological actions are a constant source of concern and contra
      indicatory in case of diabetic patients. Here we present a phytoremedial
      database, Phyto Diab Care, broadly applicable to any known anti-diabetic
      medicinal plant and phytochemicals sourced from them. Utilization of the
      traditional medicine knowledge for combating diabetes without creating unwanted
      physiological actions is our major emphasis. Data collected from peer-reviewed
      publications and phytochemicals were added to the customizable database by means 
      of an extended relational design. The strength of this resource is in providing
      rapid retrieval of data from large volumes of text at a high degree of accuracy. 
      Enhanced web interface allows multi-criteria based information filtering.
      Furthermore, the availability of 2D and 3D structures from molecular docking
      studies with any efficacy on the insulin signaling pathway makes the resource
      searchable and comparable in an intuitive manner. Phyto Diab Care compendium is
      publicly available and can be found in online. AVAILABILITY:
      http://www.gbpuat-cbsh.ac.in/departments/bi/database/phytodiabcare/HOME%20PAGE/Ho
      me%20page.html.
AD  - Department of Molecular Biology & Genetic Engineering College of Basic Sciences &
      Humanities G.B. Pant University of Agriculture & Technology, Pantnagar-263 145
      India.
FAU - Luhach, Shruti
AU  - Luhach S
FAU - Goel, Anshita
AU  - Goel A
FAU - Taj, Gohar
AU  - Taj G
FAU - Goyal, Peyush
AU  - Goyal P
FAU - Kumar, Anil
AU  - Kumar A
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - Singapore
TA  - Bioinformation
JT  - Bioinformation
JID - 101258255
OTO - NOTNLM
OT  - Diabetes
OT  - Insulin signaling pathway
OT  - Phyto Diab Care
OT  - Phytochemicals
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:01
CRDT- 2013/06/11 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/22 [received]
PHST- 2012/12/01 [revised]
PHST- 2012/12/03 [accepted]
PHST- 2013/04/13 [epublish]
AID - 10.6026/97320630009375 [doi]
AID - 97320630009375 [pii]
PST - epublish
SO  - Bioinformation. 2013 Apr 13;9(7):375-7. doi: 10.6026/97320630009375. Print 2013.

PMID- 23750032
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Jun 7
TI  - Severe hyperemesis gravidarum is associated with reduced insulin sensitivity in
      the offspring in childhood.
AB  - Background:Hyperemesis gravidarum alters maternal (and possibly fetal) nutrition 
      throughout pregnancy, but there are no data on long-term effects on offspring
      metabolism. Thus, we aimed to assess whether severe hyperemesis gravidarum
      affects glucose homeostasis and body composition in the offspring in
      childhood.Methods:Healthy pre-pubertal children (aged 4-11 years) born at term
      were studied: offspring of mothers who were admitted to hospital with severe
      hyperemesis gravidarum (SHG; n=36) and offspring of mothers from control
      pregnancies (Control; n=42). Primary outcome was insulin sensitivity measured
      using intravenous glucose tolerance tests and Bergman's minimal model. Other
      assessments included lipid and hormonal profiles, and body composition using
      whole-body dual-energy X-ray absorptiometry.Results:Insulin sensitivity in SHG
      children was 20% lower than in controls (8.49 vs 10.60 x10-4.min-1.(mU/l);
      p=0.014). SHG children also had higher fasting insulin (6.88 vs 5.04 mIU/l;
      p=0.024) and lower IGFBP-1 (11.8 vs 19.0 ng/ml; p=0.004) concentrations than
      controls. Baseline cortisol concentrations were 22% higher in SHG offspring (256 
      vs 210 nmol/l; p=0.021). Children in both groups were anthropometrically
      similar.Conclusion:Children born to mothers who experienced severe hyperemesis
      gravidarum have lower insulin sensitivity, which may increase their long-term
      risk of developing diabetes mellitus. Follow up of SHG offspring is essential to 
      determine later risk of metabolic disease.
AD  - 1 Liggins Institute, University of Auckland, Auckland, New Zealand.
FAU - Ayyavoo, Ahila
AU  - Ayyavoo A
FAU - Derraik, Jose G B
AU  - Derraik JG
FAU - Hofman, Paul L
AU  - Hofman PL
FAU - Biggs, Janene
AU  - Biggs J
FAU - Bloomfield, Frank H
AU  - Bloomfield FH
FAU - Cormack, Barbara E
AU  - Cormack BE
FAU - Stone, Peter
AU  - Stone P
FAU - Cutfield, Wayne S
AU  - Cutfield WS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - jc.2013-2043 [pii]
AID - 10.1210/jc.2013-2043 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Jun 7.

PMID- 23750005
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1477-9137 (Electronic)
IS  - 0021-9533 (Linking)
DP  - 2013 Jun 7
TI  - Reprogrammed pancreatic progenitor-like intermediate state of hepatic cells is
      more susceptible to pancreatic beta cell differentiation.
AB  - Induced pluripotent stem cells (iPSCs) hold great promise for cell therapy.
      However, their low efficiency of lineage-specific differentiation and
      tumorigenesis severely hinder clinical translation. We hypothesized that
      reprogramming of somatic cells into lineage-specific progenitor cells might allow
      for large-scale expansion, avoiding the tumorigenesis inherent with iPSCs and
      simultaneously facilitating lineage-specific differentiation. Here we aimed at
      reprogramming rat hepatic WB cells, using four Yamanaka factors, into pancreatic 
      progenitor cells (PPCs) or intermediate (IM) cells that have characteristics of
      PPCs. IM clones were selected based on their specific morphology and alkaline
      phosphatase activity and stably passaged under defined culture conditions. IM
      cells did not have iPSC properties, can be stably expanded in large quantity, and
      expressed all 14 genes that are used to define the PPC developmental stage.
      Directed differentiation of IM and WB cells by Pdx1-Ngn3-MafA (PNM) into
      pancreatic beta-like cells revealed that the IM cells are more susceptible to
      directed beta cell differentiation due to open chromatin configuration, as
      demonstrated by expression of key pancreatic beta cell genes, secretion of
      insulin in response to glucose stimulation, and easy access to exogenous PNM
      proteins at the rat insulin 1 and Pdx1 promoters. This notion of IM cells
      superior to their parental cells is further supported by the epigenetic
      demonstration of accessibility of Pdx1 and insulin 1 promoters. In conclusion, we
      have developed a strategy to derive and expand IM cells from hepatic WB cells via
      conventional cell reprogramming. This proof-of-principal study may offer a novel,
      safe, and effective way to generate autologous pancreatic beta cells for cell
      therapy of diabetes.
FAU - Wang, Qiwei
AU  - Wang Q
FAU - Wang, Hai
AU  - Wang H
FAU - Sun, Yu
AU  - Sun Y
FAU - Li, Shi-Wu
AU  - Li SW
FAU - Donelan, William
AU  - Donelan W
FAU - Chang, Lung-Ji
AU  - Chang LJ
FAU - Jin, Shouguang
AU  - Jin S
FAU - Terada, Naohiro
AU  - Terada N
FAU - Cheng, Henrique
AU  - Cheng H
FAU - Reeves, Westley
AU  - Reeves W
FAU - Yang, Li-Jun
AU  - Yang LJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Cell Sci
JT  - Journal of cell science
JID - 0052457
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - jcs.124925 [pii]
AID - 10.1242/jcs.124925 [doi]
PST - aheadofprint
SO  - J Cell Sci. 2013 Jun 7.

PMID- 23749791
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
DP  - 2013 Jun 8
TI  - An association between gestational diabetes mellitus and long-term maternal
      cardiovascular morbidity.
AB  - OBJECTIVE: To investigate whether a diagnosis of gestational diabetes mellitus
      (GDM) is a risk factor for subsequent long-term cardiovascular morbidity. DESIGN:
      A population-based study. SETTING: Soroka University Medical Center, a tertiary
      centre in the southern region of Israel. PATIENTS: A cohort of women with and
      without a diagnosis of GDM who delivered during the years 1988-1999 with a
      follow-up period until 2010. INTERVENTIONS: A comparison of the incidence of
      cardiovascular morbidity. RESULTS: Of 47 909 deliveries that met the inclusion
      criteria, 4928 (10.3%) occurred in patients who were diagnosed with GDM. During a
      follow-up period of more than 10 years, compared with women who gave birth at the
      same time period, after adjustment for age and ethnicity, patients with GDM had
      higher rates of cardiovascular morbidity including non-invasive cardiac
      diagnostic procedures (OR=1.8; 95% CI 1.4 to 2.2), simple cardiovascular events
      (OR=2.7; 95% CI 2.4 to 3.1) and total cardiovascular hospitalisations (OR=2.3;
      95% CI 2.0 to 2.5). In a Cox proportional hazards model, adjusted for
      comorbidities such as pre-eclampsia and obesity, GDM was independently associated
      with cardiovascular hospitalisations (adjusted HR 2.6, 95% CI 2.3 to 3).
      CONCLUSIONS: GDM is an independent risk factor for long-term cardiovascular
      morbidity in a follow-up period of more than a decade.
AD  - Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion
      University of the Negev, , Beer-Sheva, Israel.
FAU - Kessous, Roy
AU  - Kessous R
FAU - Shoham-Vardi, Ilana
AU  - Shoham-Vardi I
FAU - Pariente, Gali
AU  - Pariente G
FAU - Sherf, Michael
AU  - Sherf M
FAU - Sheiner, Eyal
AU  - Sheiner E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - heartjnl-2013-303945 [pii]
AID - 10.1136/heartjnl-2013-303945 [doi]
PST - aheadofprint
SO  - Heart. 2013 Jun 8.

PMID- 23749774
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 Jun 7
TI  - Evaluation of a Community Health Worker Pilot Intervention to Improve Diabetes
      Management in Bangladeshi Immigrants With Type 2 Diabetes in New York City.
AB  - PurposeThe purpose of this study is to explore the impact and feasibility of a
      pilot Community Health Worker (CHW) intervention to improve diabetes management
      among Bangladeshi-American individuals with type 2 diabetes living in New York
      City.MethodsParticipants were recruited at clinic- and community-based venues.
      The intervention consisted of 6 monthly, CHW-facilitated group sessions on topics
      related to management of diabetes. Surveys were collected at baseline and
      follow-up time points. Study outcomes included clinical, behavioral, and
      satisfaction measures for participants, as well as qualitative measures from
      CHWs.ResultsImprovements were seen in diabetes knowledge, exercise and diet to
      control diabetes, frequency of checking feet, medication compliance, and
      self-efficacy of health and physical activity from baseline to 12 months.
      Additionally, there were decreases in A1C, weight, and body mass index. Program
      evaluation revealed a high acceptability of the intervention, and qualitative
      findings indicated that CHWs helped overcome barriers and facilitated program
      outcomes through communal concordance, trust, and leadership.ConclusionsThe
      intervention demonstrated high acceptability and suggested efficacy in improving 
      diabetes management outcomes among Bangladeshi immigrants in an urban setting.
      The US Bangladeshi population will continue to increase, and given the high rates
      of diabetes, as well as linguistic and economic barriers faced by this community,
      effective and culturally tailored health interventions are needed to overcome
      barriers and provide support for diabetes management.
AD  - Center for the Study of Asian American Health, NYU School of Medicine, New York, 
      New York (Dr Islam, Ms Wyatt, Ms Patel, Dr Shapiro, Dr Rey, Dr Trinh-Shevrin).
FAU - Islam, Nadia S
AU  - Islam NS
FAU - Wyatt, Laura C
AU  - Wyatt LC
FAU - Patel, Shilpa D
AU  - Patel SD
FAU - Shapiro, Ephraim
AU  - Shapiro E
FAU - Tandon, S Darius
AU  - Tandon SD
FAU - Mukherji, B Runi
AU  - Mukherji BR
FAU - Tanner, Michael
AU  - Tanner M
FAU - Rey, Mariano J
AU  - Rey MJ
FAU - Trinh-Shevrin, Chau
AU  - Trinh-Shevrin C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 0145721713491438 [pii]
AID - 10.1177/0145721713491438 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 Jun 7.

PMID- 23749773
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 Jun 7
TI  - Using the Common Sense Model of Self-Regulation to Review the Effects of
      Self-Monitoring of Blood Glucose on Glycemic Control for Non-Insulin-Treated
      Adults With Type 2 Diabetes.
AB  - PurposeThis systematic review examined the relationship between self-monitoring
      of blood glucose (SMBG) and glycemic control in patients with type 2 diabetes.
      The Common Sense Model of Self-Regulation (CSM) served as a theoretical framework
      for examining how, when (mediators), and for whom (moderators) SMBG improved
      glycemic control.Data SourcesFive databases were searched: Medline, PsychInfo,
      Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled 
      Trials, and Cumulative Index to Nursing & Allied Health Literature.Study
      SelectionIncluded studies had cross-sectional, longitudinal, or randomized
      controlled trial designs; were published between 2007 and 2011; and included
      patients with type 2 diabetes at least some of whom were not taking insulin; 1318
      studies were screened, 119 were reviewed in detail, and 26 were included.Data
      ExtractionData were collected on the relationship between SMBG and glycemic
      control, study design, mediators, moderators, participant characteristics, the
      CSM, and limitations.Data SynthesisTwenty-six studies met criteria for inclusion:
      11 cross-sectional, 4 longitudinal, and 11 randomized controlled trials. The
      results of the cross-sectional studies were inconclusive. Results from the
      longitudinal studies and randomized control trials suggested that SMBG may
      improve glycemic control. The few studies investigating mediators or moderators
      reported mixed results. Few studies effectively measured the CSM.ConclusionData
      suggested that SMBG may help improve glycemic control. Future trials must be
      designed to test hypotheses and improve our understanding of when, how, and for
      whom SMBG can enhance glycemic control. Rigorously controlled repetitions of
      current 2-arm trials will yield little new knowledge of theoretical or practical 
      value.
AD  - Department of Psychology and the Institute for Health, Healthcare Policy & Aging 
      Research, Rutgers, the State University of New Jersey, New Brunswick, New Jersey 
      (Ms Breland, Dr H. Leventhal).
FAU - Breland, Jessica Y
AU  - Breland JY
FAU - McAndrew, Lisa M
AU  - McAndrew LM
FAU - Burns, Edith
AU  - Burns E
FAU - Leventhal, Elaine A
AU  - Leventhal EA
FAU - Leventhal, Howard
AU  - Leventhal H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 0145721713490079 [pii]
AID - 10.1177/0145721713490079 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 Jun 7.

PMID- 23749750
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
DP  - 2013 Jun 8
TI  - Long-Term Effects of Beraprost Sodium on Arteriosclerosis Obliterans: a
      Single-Center Retrospective Study of Japanese Patients.
AB  - INTRODUCTION: Arteriosclerosis obliterans (ASO) causes ischemic symptoms of the
      lower limbs, reducing quality of life (QOL), and has a poor prognosis. Early
      diagnosis and treatment are necessary. In this study, the effects of long-term
      administration of beraprost sodium (beraprost) to treat ASO were investigated.
      METHODS: One hundred and eighty eight patients treated with beraprost for >/=1
      year were retrospectively identified. Outcomes were lower limb ischemic symptoms,
      carotid intima/media thickness (IMT), and cardiovascular events. Patients
      reported visual analog scale scores for major symptoms at baseline and after 3,
      6, and 12 months of treatment. RESULTS: Overall, 188 patients (mean age 70.8 +/- 
      10.15 years, Fontaine classification: grade I 14.4%, grade II 85.6%) treated with
      beraprost for 2.4-10.7 years (mean 6.5 years) were included in this study.
      Administration of beraprost significantly reduced patient-reported severity of
      lower limb ischemic symptoms in all patients at 12 months, including those with
      diabetes, hypertension, or dyslipidemia. IMT decreased from 1.09 +/- 0.09 mm at
      baseline to 1.04 +/- 0.11 mm at 12 months (P < 0.001). Decreases in IMT were
      similar in patients with diabetes, hypertension, or dyslipidemia. Overall, 26
      (13.8%) events occurred during a mean follow-up of 6.5 years, including 23
      cardiovascular events (unstable angina in three patients, myocardial infarction
      in six patients, cerebral infarction in eight patients, and transient cerebral
      ischemic attack in six patients) and non-cardiovascular death in three patients. 
      Beraprost at 120 mug/day significantly reduced the risk of ischemic symptoms
      compared with <120 mug/day (adjusted hazard ratio: 0.17; 95% confidence interval:
      0.06, 0.45; P < 0.001). No severe adverse events or adverse events requiring dose
      reductions/discontinuation occurred during long-term administration of beraprost.
      CONCLUSION: Beraprost reduced lower limb ischemic symptoms, IMT, and the
      incidence of cardiovascular events in patients with ASO.
AD  - Arai Clinic, Yamagata, Gifu, Japan, ta34718arai@cg7.so-net.ne.jp.
FAU - Arai, Tadashi
AU  - Arai T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/10/24 [received]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s12325-013-0030-7 [doi]
PST - aheadofprint
SO  - Adv Ther. 2013 Jun 8.

PMID- 23749611
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
DP  - 2013 Jun 8
TI  - Treating spondyloarthritis, including ankylosing spondylitis and psoriatic
      arthritis, to target: recommendations of an international task force.
AB  - BACKGROUND: Therapeutic targets have been defined for diseases like diabetes,
      hypertension or rheumatoid arthritis and adhering to them has improved outcomes. 
      Such targets are just emerging for spondyloarthritis (SpA). OBJECTIVE: To define 
      the treatment target for SpA including ankylosing spondylitis and psoriatic
      arthritis (PsA) and develop recommendations for achieving the target, including a
      treat-to-target management strategy. METHODS: Based on results of a systematic
      literature review and expert opinion, a task force of expert physicians and
      patients developed recommendations which were broadly discussed and voted upon in
      a Delphi-like process. Level of evidence, grade and strength of the
      recommendations were derived by respective means. The commonalities between axial
      SpA, peripheral SpA and PsA were discussed in detail. RESULTS: Although the
      literature review did not reveal trials comparing a treat-to-target approach with
      another or no strategy, it provided indirect evidence regarding an optimised
      approach to therapy that facilitated the development of recommendations. The
      group agreed on 5 overarching principles and 11 recommendations; 9 of these
      recommendations related commonly to the whole spectrum of SpA and PsA, and only 2
      were designed separately for axial SpA, peripheral SpA and PsA. The main
      treatment target, which should be based on a shared decision with the patient,
      was defined as remission, with the alternative target of low disease activity.
      Follow-up examinations at regular intervals that depend on the patient's status
      should safeguard the evolution of disease activity towards the targeted goal.
      Additional recommendations relate to extra-articular and extramusculoskeletal
      aspects and other important factors, such as comorbidity. While the level of
      evidence was generally quite low, the mean strength of recommendation was 9-10
      (10: maximum agreement) for all recommendations. A research agenda was
      formulated. CONCLUSIONS: The task force defined the treatment target as remission
      or, alternatively, low disease activity, being aware that the evidence base is
      not strong and needs to be expanded by future research. These recommendations can
      inform the various stakeholders about expert opinion that aims for reaching
      optimal outcomes of SpA.
AD  - Division of Rheumatology, Department of Medicine 3, Medical University of Vienna,
      Vienna, Austria.
FAU - Smolen, Josef S
AU  - Smolen JS
FAU - Braun, Jurgen
AU  - Braun J
FAU - Dougados, Maxime
AU  - Dougados M
FAU - Emery, Paul
AU  - Emery P
FAU - Fitzgerald, Oliver
AU  - Fitzgerald O
FAU - Helliwell, Philip
AU  - Helliwell P
FAU - Kavanaugh, Arthur
AU  - Kavanaugh A
FAU - Kvien, Tore K
AU  - Kvien TK
FAU - Landewe, Robert
AU  - Landewe R
FAU - Luger, Thomas
AU  - Luger T
FAU - Mease, Philip
AU  - Mease P
FAU - Olivieri, Ignazio
AU  - Olivieri I
FAU - Reveille, John
AU  - Reveille J
FAU - Ritchlin, Christopher
AU  - Ritchlin C
FAU - Rudwaleit, Martin
AU  - Rudwaleit M
FAU - Schoels, Monika
AU  - Schoels M
FAU - Sieper, Joachim
AU  - Sieper J
FAU - Wit, Martinus de
AU  - Wit MD
FAU - Baraliakos, Xenofon
AU  - Baraliakos X
FAU - Betteridge, Neil
AU  - Betteridge N
FAU - Burgos-Vargas, Ruben
AU  - Burgos-Vargas R
FAU - Collantes-Estevez, Eduardo
AU  - Collantes-Estevez E
FAU - Deodhar, Atul
AU  - Deodhar A
FAU - Elewaut, Dirk
AU  - Elewaut D
FAU - Gossec, Laure
AU  - Gossec L
FAU - Jongkees, Merryn
AU  - Jongkees M
FAU - Maccarone, Mara
AU  - Maccarone M
FAU - Redlich, Kurt
AU  - Redlich K
FAU - van den Bosch, Filip
AU  - van den Bosch F
FAU - Wei, James Cheng-Chung
AU  - Wei JC
FAU - Winthrop, Kevin
AU  - Winthrop K
FAU - van der Heijde, Desiree
AU  - van der Heijde D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
OTO - NOTNLM
OT  - Treat-to-target
OT  - ankylosing spondylitis
OT  - psoriatic arthritis
OT  - spondyloarthritis
OT  - therapy
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - annrheumdis-2013-203419 [pii]
AID - 10.1136/annrheumdis-2013-203419 [doi]
PST - aheadofprint
SO  - Ann Rheum Dis. 2013 Jun 8.

PMID- 23749585
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2013 Jun 8
TI  - Concomitant myasthenia gravis and macroprolactinoma: the immunomodulatory role of
      prolactin and its potential therapeutic use.
AB  - Considerable evidence attests to the role of the hypothalamic-pituitary endocrine
      axis (HPA) in the maintenance of normal immunocompetence. The immune and
      neuroendocrine systems are integrally linked and coordinated with bidirectional
      communication maintaining immune balance. Any disturbance of the normal function 
      of the HPA may significantly alter native immunocompetence and therefore be
      associated with the development of disorders which have a clearly established
      autoimmune basis. Molecular and functional evidence shows prolactin, produced by 
      the anterior pituitary, to be a cytokine, exerting its effect via both paracrine 
      and endocrine mechanisms [1]. Its involvement in the activation of multiple
      immune responses may adversely upregulate certain autoimmune diseases. Myasthenia
      gravis (MG) has long been recognized as an autoimmune disorder. In this mini
      review, we present the coterminous presentation of MG and prolactin-secreting
      macroadenoma. We review published cases in the world literature, discuss
      pathological mechanism, and consider future targeted therapies.
AD  - Departments of Endocrinology, Neurology and Radiology, Medway Maritime Hospital, 
      c/o Diabetes Centre, Residence 9, Gillingham, ME7 5NY, UK,
      sophieharris88@gmail.com.
FAU - Harris, S M
AU  - Harris SM
FAU - Leong, H M C
AU  - Leong HM
FAU - Chowdhury, R
AU  - Chowdhury R
FAU - Ellis, C
AU  - Ellis C
FAU - Brennan, John
AU  - Brennan J
FAU - Scobie, I N
AU  - Scobie IN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Endocrine
JT  - Endocrine
JID - 9434444
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/10 [received]
PHST- 2013/05/22 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s12020-013-9991-1 [doi]
PST - aheadofprint
SO  - Endocrine. 2013 Jun 8.

PMID- 23749557
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1099-1263 (Electronic)
IS  - 0260-437X (Linking)
DP  - 2013 Jun 10
TI  - In utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
      modulates dysregulation of the lipid metabolism in mouse offspring fed a
      high-calorie diet.
LID - 10.1002/jat.2881 [doi]
AB  - Exposure to environmental chemicals, including dioxins, is a risk factor for type
      2 diabetes mellitus in humans. This study explored the hypothesis that in utero
      and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the most 
      toxic congener among dioxins, aggravates this disease state later in adulthood.
      Pregnant C57Bl/6 J mice were administered either a single oral dose of TCDD (3.0 
      microg kg-1 body weight) or corn oil on gestational day 12.5. The male pups born 
      to these two groups of dams were given either a regular diet or a high-calorie
      diet, after postnatal day (PND) 28. The four groups of investigated offspring
      were thus termed T-R (TCDD regular diet), T-H (TCDD high-calorie diet), V-R
      (vehicle regular diet), and V-H (vehicle high-calorie diet). The mice were
      regularly monitored for body weight, blood pressure and glucose, until they
      reached 26 weeks of age. Mice in the V-H group were significantly obese at weeks 
      15 and 26, but they exhibited no diabetes-associated signs of insulin resistance 
      or hypertension. However, metabolic syndrome-related alterations with marginal
      signs of liver damage were found at week 26. Pronounced signs of dysregulated
      lipid metabolism with altered gene expression and liver inflammation were already
      present at week 15, whereas such alterations were suppressed in the T-H group.
      Although the mechanism is unclear, this study showed that in utero and
      lactational exposure to low-dose TCDD does not aggravate obesity-induced disease 
      states, such as adult-onset diabetes, but instead attenuates the dysregulation of
      lipid metabolism brought on by a high-calorie diet. Copyright (c) 2013 John Wiley
      & Sons, Ltd.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
AD  - Laboratory of Environmental Health Sciences, Center for Disease Biology and
      Integrative Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1
      Bunkyo-ku, Tokyo, 113-0033, Japan.
FAU - Sugai, Etsuko
AU  - Sugai E
FAU - Yoshioka, Wataru
AU  - Yoshioka W
FAU - Kakeyama, Masaki
AU  - Kakeyama M
FAU - Ohsako, Seiichiroh
AU  - Ohsako S
FAU - Tohyama, Chiharu
AU  - Tohyama C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - J Appl Toxicol
JT  - Journal of applied toxicology : JAT
JID - 8109495
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/10/01 [received]
PHST- 2013/03/04 [revised]
PHST- 2013/03/04 [accepted]
AID - 10.1002/jat.2881 [doi]
PST - aheadofprint
SO  - J Appl Toxicol. 2013 Jun 10. doi: 10.1002/jat.2881.

PMID- 23749405
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
DP  - 2013 Jun 8
TI  - A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 
      100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec.
AB  - BACKGROUND AND OBJECTIVE: Insulin degludec (IDeg) is a new-generation basal
      insulin that forms soluble multi-hexamers upon subcutaneous injection, resulting 
      in a depot from which IDeg monomers are slowly and continuously absorbed to
      provide an ultra-long action profile. This double-blind, crossover, randomized
      study compared the pharmacokinetic and pharmacodynamic properties between IDeg
      100 U/mL (U100) and IDeg 200 U/mL (U200) under steady-state (SS) conditions in
      subjects with type 1 diabetes mellitus. METHODS: Participants (n = 33 adults)
      underwent 8-day treatment periods with 0.4 U/kg IDeg U100 and IDeg U200 given
      once daily with insulin aspart at mealtimes. On day 8, a 26-h euglycaemic glucose
      clamp (5.5 mmol/L) was performed. RESULTS: The concentration-time profiles of
      IDeg U100 and IDeg U200 were similar, and a post-hoc analysis showed
      bioequivalence between these formulations, as the 90 % confidence intervals (CIs)
      of the U200/U100 ratios for area under the steady-state serum IDeg
      concentration-time curve during a dosing interval (tau; 0-24 h) (AUCtau,SS,IDeg) 
      (0.99 [0.91-1.07]) and maximum steady-state IDeg concentration during a dosing
      interval (tau) (C max,SS,IDeg) (0.93 [0.84-1.02]) were within the interval
      0.80-1.25. Comparable glucose infusion rates (GIR) were observed for IDeg U100
      and IDeg U200 (AUCtau,SS,GIR [mg/kg]: 2,255 vs. 2,123) and the mean ratio (95 %
      CI) of IDeg U200/U100 for the primary endpoint (AUCtau,SS,GIR) was 0.94
      [0.86-1.03]. For both formulations, the glucose-lowering effect of IDeg was
      evenly distributed between the first and second 12 h post-dosing (U100:
      AUC12,SS,GIR/AUC24,SS,GIR = 48 %; U200: AUC12,SS,GIR/AUC24,SS,GIR = 46 %). Both
      formulations were well tolerated, and no safety events of significance were
      identified. CONCLUSION: IDeg U100 and U200 formulations are bioequivalent and
      have similar pharmacodynamic profiles at SS, implying that they can be used
      interchangeably in clinical practice.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      Medical University Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
FAU - Korsatko, Stefan
AU  - Korsatko S
FAU - Deller, Sigrid
AU  - Deller S
FAU - Koehler, Gerd
AU  - Koehler G
FAU - Mader, Julia K
AU  - Mader JK
FAU - Neubauer, Katharina
AU  - Neubauer K
FAU - Adrian, Charlotte L
AU  - Adrian CL
FAU - Thomsen, Henrik
AU  - Thomsen H
FAU - Haahr, Hanne
AU  - Haahr H
FAU - Pieber, Thomas R
AU  - Pieber TR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1007/s40261-013-0096-7 [doi]
PST - aheadofprint
SO  - Clin Drug Investig. 2013 Jun 8.

PMID- 23749387
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1534-6285 (Electronic)
IS  - 1527-2737 (Linking)
DP  - 2013 Jun 11
TI  - Update on the Evaluation of Repeated Stone Formers.
AB  - Office management of stone disease is an important component of a urologist's
      practice. Evaluation should include analysis of stone composition, 24-hour urine 
      studies, identification of modifiable risk factors, and targeted dietary,
      lifestyle, and/or medical therapy. A sizeable portion of investigated etiologies 
      and risk factors for stone disease have centered on the complex interplay between
      obesity, diabetes, and other disease states that comprise the metabolic syndrome.
      Alternatives to traditional preventive therapy, such as probiotics and various
      fruit juices, are still being studied but may prove useful adjuncts to
      traditional preventive therapy, where the mainstays remain increased fluid
      intake, dietary modification, and pharmacologic therapy. Future studies on
      preventive therapy of urolithiasis are likely to focus on strategies to increase 
      compliance, cost-effectiveness, and systems-based implementation.
AD  - Department of Urology, Loyola University Medical Center, 2160 S. First Ave, Bldg 
      54, Maywood, IL, 60153, USA, akadlec@lumc.edu.
FAU - Kadlec, Adam O
AU  - Kadlec AO
FAU - Turk, Thomas M
AU  - Turk TM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130611
TA  - Curr Urol Rep
JT  - Current urology reports
JID - 100900943
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1007/s11934-013-0347-4 [doi]
PST - aheadofprint
SO  - Curr Urol Rep. 2013 Jun 11.

PMID- 23749254
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1741-2889 (Electronic)
IS  - 1367-4935 (Linking)
DP  - 2013 Jun 6
TI  - Factors influencing the diabetes-specific health-related quality of life in
      children and adolescents with type 1 diabetes mellitus.
AB  - This study aimed to investigate the association of the anthropometric, clinical
      variables and maximal oxygen uptake (V<sc>o</sc>2max) with diabetes-specific
      health-related quality of life (HRQoL) in youths with type 1 diabetes mellitus
      (T1DM) and to find the predictors of HRQoL and blood glucose control. A total of 
      239 youths with diabetes (124 boys and 115 girls) were recruited from
      diabetes-based summer camps. HRQoL assessment was carried out with the Pediatric 
      Quality of Life Inventory 3.0 Diabetes Module (Information Resources Centre, Mapi
      Research Trust, France); V<sc>o</sc>2max was evaluated by conducting the 20-m
      shuttle run test. Higher V<sc>o</sc>2max and the insulin pump therapy were
      significant predictors of the HRQoL in the multiple regression analysis; other
      clinical and anthropometric variables had no effect. The better blood glucose
      control was explained only by the higher V<sc>o</sc>2max. The good
      cardiorespiratory fitness (expressed by V<sc>o</sc>2max) has clinical and QoL
      benefits for paediatric patients with T1DM.
AD  - Department of Theoretical Health Science, Faculty of Health Care, University of
      Miskolc, Hungary.
FAU - Lukacs, Andrea
AU  - Lukacs A
FAU - Varga, Beatrix
AU  - Varga B
FAU - Kiss-Toth, Emoke
AU  - Kiss-Toth E
FAU - Soos, Andrea
AU  - Soos A
FAU - Barkai, Laszlo
AU  - Barkai L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Child Health Care
JT  - Journal of child health care : for professionals working with children in the
      hospital and community
JID - 9806360
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 1367493513486964 [pii]
AID - 10.1177/1367493513486964 [doi]
PST - aheadofprint
SO  - J Child Health Care. 2013 Jun 6.

PMID- 23749218
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1436-2023 (Electronic)
IS  - 0949-2658 (Linking)
DP  - 2013 Jun 8
TI  - More radial shortening after low-energy Colles' fractures is associated with type
      2 diabetes mellitus among postmenopausal women, irrespective of bone mineral
      density.
AB  - BACKGROUND: Recent meta-analysis data reveal that patients with type 2 diabetes
      mellitus (DM) have a higher risk of fracture, despite higher bone mineral density
      (BMD), than patients without type 2 DM. The purpose of this study was to compare 
      BMD and distal radial shortening after low-energy Colles' fractures among
      Japanese postmenopausal women aged >/=50 years with type 2 DM with those in women
      without it (non-DM). METHODS: One-hundred and ten postmenopausal women aged >/=50
      years with distal radius fractures resulting from a fall were enrolled in this
      study. Twelve patients had DM. BMD, type I collagen cross-linked N-telopeptide
      (NTX), undercarboxylated osteocalcin (ucOC), estimated glomerular filtration rate
      (eGFR), grip strength of the unfractured hand, unipedal standing time, and the
      degree of radial shortening were measured. RESULTS: There were no significant
      differences in age and body height between the two groups. The DM group had
      significantly greater body weight and body mass index than the non-DM group. BMDs
      of the lumbar spine and proximal hip were significantly higher in the DM group
      than in the non-DM group. NTX, ucOC, grip strength, and the percentage of women
      with unipedal standing time <15 s did not differ between the two groups. Stepwise
      regression analysis identified DM and shorter unipedal standing time as
      significant factors associated with more radial shortening, and identified more
      radial shortening and lower eGFR as significant factors associated with DM.
      CONCLUSIONS: More radial shortening after low-energy Colles' fractures was
      significantly associated with type 2 DM among postmenopausal women aged >/=50
      years, irrespective of BMD.
AD  - Department of Orthopaedic Surgery, School of Medicine, University of Occupational
      and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555,
      Japan, a-sakai@med.uoeh-u.ac.jp.
FAU - Sakai, Akinori
AU  - Sakai A
FAU - Menuki, Kunitaka
AU  - Menuki K
FAU - Zenke, Yukichi
AU  - Zenke Y
FAU - Yamanaka, Yoshiaki
AU  - Yamanaka Y
FAU - Furukawa, Kayoko
AU  - Furukawa K
FAU - Fuse, Yoshifumi
AU  - Fuse Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - J Orthop Sci
JT  - Journal of orthopaedic science : official journal of the Japanese Orthopaedic
      Association
JID - 9604934
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/14 [received]
PHST- 2013/05/16 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s00776-013-0419-9 [doi]
PST - aheadofprint
SO  - J Orthop Sci. 2013 Jun 8.

PMID- 23749200
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1432-0878 (Electronic)
IS  - 0302-766X (Linking)
DP  - 2013 Jun 8
TI  - Are cultured human myotubes far from home?
AB  - Satellite cells can be isolated from skeletal muscle biopsies, activated to
      proliferating myoblasts and differentiated into multinuclear myotubes in culture.
      These cell cultures represent a model system for intact human skeletal muscle and
      can be modulated ex vivo. The advantages of this system are that the most
      relevant genetic background is available for the investigation of human disease
      (as opposed to rodent cell cultures), the extracellular environment can be
      precisely controlled and the cells are not immortalized, thereby offering the
      possibility of studying innate characteristics of the donor. Limitations in
      differentiation status (fiber type) of the cells and energy metabolism can be
      improved by proper treatment, such as electrical pulse stimulation to mimic
      exercise. This review focuses on the way that human myotubes can be employed as a
      tool for studying metabolism in skeletal muscles, with special attention to
      changes in muscle energy metabolism in obesity and type 2 diabetes.
AD  - Institute of Pharmacy and Biomedical Laboratory Science, Faculty of Health
      Sciences, Oslo and Akershus University College of Applied Sciences, Oslo, Norway,
      vigdis.aas@hioa.no.
FAU - Aas, Vigdis
AU  - Aas V
FAU - Bakke, Siril S
AU  - Bakke SS
FAU - Feng, Yuan Z
AU  - Feng YZ
FAU - Kase, Eili Tranheim
AU  - Kase ET
FAU - Jensen, Jorgen
AU  - Jensen J
FAU - Bajpeyi, Sudip
AU  - Bajpeyi S
FAU - Thoresen, G Hege
AU  - Thoresen GH
FAU - Rustan, Arild C
AU  - Rustan AC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Cell Tissue Res
JT  - Cell and tissue research
JID - 0417625
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/05 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s00441-013-1655-1 [doi]
PST - aheadofprint
SO  - Cell Tissue Res. 2013 Jun 8.

PMID- 23749168
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Linking)
DP  - 2013 Jun 8
TI  - PIP3 but not PIP2 increases GLUT4 surface expression and glucose metabolism
      mediated by AKT/PKCzeta/lambda phosphorylation in 3T3L1 adipocytes.
AB  - Phosphatidylinositol-3,4,5-triphosphate (PIP3) and
      phosphatidylinositol-4,5-biphosphate (PIP2) are two well-known membrane bound
      polyphosphoinositides. Diabetes is associated with impaired glucose metabolism.
      Using a 3T3L1 adipocyte cell model, this study investigated the role of PIP3 and 
      PIP2 on insulin stimulated glucose metabolism in high glucose (HG) treated cells.
      Exogenous PIP3 supplementation (1, 5, or 10 nM) increased the phosphorylation of 
      AKT and PKCzeta/lambda, which in turn upregulated GLUT4 total protein expression 
      as well as its surface expression, glucose uptake, and glucose utilization in
      cells exposed to HG (25 mM); however, PIP2 had no effect. Comparative signal
      silencing studies with antisense AKT2 and antisense PKCzeta revealed that
      phosphorylation of PKCzeta/lambda is more effective in PIP3 mediated GLUT4
      activation and glucose utilization than in AKT phosphorylation. Supplementation
      with PIP3 in combination with insulin enhanced glucose uptake and glucose
      utilization compared to PIP2 with insulin, or insulin alone, in HG-treated
      adipocytes. This suggests that a decrease in cellular PIP3 levels may cause
      impaired insulin sensitivity in diabetes. PIP3 supplementation also prevented
      HG-induced MCP-1 and resistin secretion and lowered adiponectin levels. This
      study for the first time demonstrates that PIP3 but not PIP2 plays an important
      role in GLUT4 upregulation and glucose metabolism mediated by AKT/PKCzeta/lambda 
      phosphorylation. Whether PIP3 levels in blood can be used as a biomarker of
      insulin resistance in diabetes needs further investigation.
AD  - Department of Pediatrics, Louisiana State University Health Sciences Center, 1501
      Kings Highway, Shreveport, LA, 71130, USA.
FAU - Manna, Prasenjit
AU  - Manna P
FAU - Jain, Sushil K
AU  - Jain SK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/12/19 [received]
PHST- 2013/05/29 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s11010-013-1714-7 [doi]
PST - aheadofprint
SO  - Mol Cell Biochem. 2013 Jun 8.

PMID- 23749021
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0300-5283 (Print)
IS  - 0300-5283 (Linking)
VI  - 68
IP  - 3
DP  - 2013 Jun
TI  - Ochrobactrum anthropi catheter-related bloodstream infection: the first case
      report in malaysia.
PG  - 267-8
AB  - A 60-year old Malay man presented with an intermittent lowgrade fever for 3 days 
      and worsening of right ankle ulcers. He was known to have ischaemic heart
      disease, diabetes mellitus type 2, hypertension and end stage renal failure and
      was on regular haemodialysis. The organisms isolated from the peripheral and
      central blood specimens were identified as Ochrobactrum anthropi, a rarely
      encountered gramnegative bacillus with a unique antibiotic susceptibility
      profile. His condition improved after removal of the catheters and administration
      of antibiotic therapy. This case report highlights the importance of being wary
      of such rare, opportunistic pathogens and good communication between the
      microbiologists and the clinicians.
AD  - UKMMC, Medical Microbiology & Immunology, Jalan Yaacob Latif, Bandar Tun Razak,
      Cheras, Kuala Lumpur 56000, Malaysia. tzar@ppukm.ukm.edu.my.
FAU - Siti Rohani, A H
AU  - Siti Rohani AH
FAU - Tzar, M N
AU  - Tzar MN
LA  - eng
PT  - Journal Article
PL  - Malaysia
TA  - Med J Malaysia
JT  - The Medical journal of Malaysia
JID - 0361547
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - ppublish
SO  - Med J Malaysia. 2013 Jun;68(3):267-8.

PMID- 23748991
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1538-9782 (Electronic)
IS  - 0887-6274 (Linking)
VI  - 27
IP  - 4
DP  - 2013 Jul-Aug
TI  - Perceived Knowledge and Self-confidence of Pediatric Nurses as Patient Educators.
PG  - 188-93
LID - 10.1097/NUR.0b013e3182955703 [doi]
AB  - Patient education is an integral component of nursing care. Patient education has
      been associated with favorable patient outcomes but may be difficult if resources
      are unavailable, "teachable moments" are unrecognized, or if self-confidence of
      the nurses providing the education is low. Using the theoretical model developed 
      by the authors and focusing on the delivery of patient/family education, we
      examined pediatric nurses' perceptions about patient/family education in the
      hospital setting. A 20-item questionnaire that explored factors affecting
      teaching behaviors of 54 pediatric nurses in an acute care hospital setting was
      completed. Results from this study suggest that pediatric nurses' confidence was 
      disorder-specific. Nurses were confident providing education about common
      disorders (asthma, pneumonia, and bronchiolitis) and less confident providing
      education about less common disorders (oncology, cardiac). The barrier to
      providing education identified most often was lack of written materials. Findings
      from this study can be used to develop teaching resources for nurses and to plan 
      educational programs specific to less common pediatric problems.
AD  - Author Affiliations: Pediatric Clinical Nurse Specialist (Ms Lahl), Diabetes
      Clinical Nurse Specialist (Ms Modic), and Senior Nurse Researcher (Dr Siedlecki),
      Cleveland Clinic, Ohio.
FAU - Lahl, Meredith
AU  - Lahl M
FAU - Modic, Mary Beth
AU  - Modic MB
FAU - Siedlecki, Sandra
AU  - Siedlecki S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Nurse Spec
JT  - Clinical nurse specialist CNS
JID - 8709115
SB  - N
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1097/NUR.0b013e3182955703 [doi]
AID - 00002800-201307000-00006 [pii]
PST - ppublish
SO  - Clin Nurse Spec. 2013 Jul-Aug;27(4):188-93. doi: 10.1097/NUR.0b013e3182955703.

PMID- 23748978
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
DP  - 2013 Jun 6
TI  - Is There an Association Between Inflammatory Bowel Diseases and Carotid
      Intima-media Thickness? Preliminary Data.
AB  - Inflammation is a predictor of cardiovascular disease (CVD). Thus, inflammatory
      bowel diseases (IBD) may be associated with CVD. We assessed carotid intima-media
      thickness (cIMT; an indicator of CVD risk) in 42 patients with IBD, free of CVD
      or diabetes; 26 with Crohn's disease (CD) and 16 with ulcerative colitis (UC).
      The cIMT was significantly greater in patients with IBD compared to 42 healthy
      controls (0.62 +/- 0.08 vs 0.52 +/- 0.06 mm; P < .0005). The cIMT did not differ 
      between patients with CD and UC or between the different disease activity and
      treatment groups. Factors associated with cIMT were age, body mass index, and
      IBD, with the latter making a greater contribution. The IBD is a predictor of
      cIMT, even when other CVD risk factors are considered. These findings suggest an 
      association between early arterial wall alterations and IBD. Such an association 
      should be proven in larger studies that should assess the incidence of CVD in
      patients with IBD.
AD  - 12nd Propaedeutic Department of Internal Medicine, Hippokration General Hospital 
      of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Theocharidou, Eleni
AU  - Theocharidou E
FAU - Gossios, Thomas D
AU  - Gossios TD
FAU - Griva, Theodora
AU  - Griva T
FAU - Giouleme, Olga
AU  - Giouleme O
FAU - Douma, Stella
AU  - Douma S
FAU - Athyros, Vasilios G
AU  - Athyros VG
FAU - Karagiannis, Asterios
AU  - Karagiannis A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Angiology
JT  - Angiology
JID - 0203706
OTO - NOTNLM
OT  - C-reactive protein
OT  - atherosclerosis
OT  - cardiovascular disease
OT  - carotid intima-media thickness
OT  - inflammatory bowel disease
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 0003319713489876 [pii]
AID - 10.1177/0003319713489876 [doi]
PST - aheadofprint
SO  - Angiology. 2013 Jun 6.

PMID- 23748976
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1347-7439 (Electronic)
IS  - 0916-7250 (Linking)
DP  - 2013 Jun 7
TI  - Insulin-Ameliorated Peripheral Motor Neuropathy in Spontaneously Diabetic WBN/Kob
      Rats.
AB  - Rodent models of diabetes develop a slowing of nerve conduction velocity and mild
      axonal atrophy, but generally lack overt degenerative neuropathy. Spontaneously
      diabetic Wistar Bonn Kobori (WBN/Kob) rats develop severe diabetic peripheral
      motor neuropathy with a slowing of nerve conduction velocity. We examined the
      effect of glycemic control, using insulin implant, on neuropathic changes in
      these rats. Animals were divided into 2 groups: WBN group (spontaneously
      occurring diabetes rats) and WBN + insulin group (spontaneously occurring
      diabetes rats treated with insulin implants until 90 weeks of age). Conduction
      velocity was measured in sciatic-tibial motor nerves. These nerves also underwent
      qualitative and quantitative histomorphologic analysis. Mild to severe
      hyperglycemia (>200 mg/dl) and glycosuria (>100 mg/dl) were observed in the WBN
      group. In contrast, the blood glucose level of the WBN + insulin group fluctuated
      between normoglycemia (<200 mg/dl) and hyperglycemia. Conduction velocity
      significantly decreased in WBN group compared with WBN + insulin group.
      Morphologic analysis of the sciatic and tibial nerves of WBN group showed severe 
      changes, including axonal degeneration, myelin distention, endoneurial fibrosis
      and microangiopathy. Insulin treatment corrected these changes without
      microangiopathy. These results suggest that insulin could decrease axonal atrophy
      and myelin distension of peripheral nerve in diabetic WBN/Kob rats. Observation
      of WBN/Kob rats revealed changes of axon, myelin and capillary caused by
      diabetes, thus indicating that this animal is a suitable model for investigating 
      diabetic peripheral neuropathy.
AD  - Department of Pathology, Setsunan University.
FAU - Ozaki, Kiyokazu
AU  - Ozaki K
FAU - Yamano, Shotaro
AU  - Yamano S
FAU - Matsuura, Tetsuro
AU  - Matsuura T
FAU - Narama, Isao
AU  - Narama I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Vet Med Sci
JT  - The Journal of veterinary medical science / the Japanese Society of Veterinary
      Science
JID - 9105360
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - DN/JST.JSTAGE/jvms/13-0184 [pii]
PST - aheadofprint
SO  - J Vet Med Sci. 2013 Jun 7.

PMID- 23748861
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Jun 8
TI  - Do current incretin mimetics exploit the full therapeutic potential inherent in
      GLP-1 receptor stimulation?
AB  - Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are incretin-derived
      glucose-lowering agents that have been used for the treatment of type 2 diabetes 
      since 2007. Agents such as exenatide (short-acting and once weekly preparations),
      liraglutide, taspoglutide, albiglutide and lixisenatide lower fasting glucose and
      HbA1c upon subcutaneous injection, leading to glycaemic control that is
      equivalent to, or better than, that observed with other oral glucose-lowering
      agents or bedtime insulin. However, varying proportions of patients report nausea
      and vomiting, adverse events that typically narrow the therapeutic dose range.
      Furthermore, GLP-1 RAs reduce fasting glucose to a clinically meaningful extent, 
      but not into the normal range. In contrast, where GLP-1 is administered as a
      short-term intravenous infusion, a full normalisation of glucose concentrations
      (approximately 5 mmol/l) has been observed without any risk of gastrointestinal
      side effects. Subcutaneous infusions or injections of GLP-1 are much less
      effective. The present analysis relates the proportion of patients who report
      nausea following treatment with GLP-1 and GLP-1 RAs to the clinical effectiveness
      of the treatment (represented by the fasting glucose concentration achieved with 
      treatment). The results suggest that GLP-1 RAs injected into the subcutaneous
      compartment do not exploit the full potential inherent in GLP-1 receptor
      activation. Reasons for this may include modifications of the peptide molecules
      in the subcutaneous environment or high local concentrations triggering side
      effects through GLP-1 receptors on autonomic nerves in subcutaneous adipose
      tissue. Elucidation of the mechanisms underlying differential responses to
      GLP-1/GLP-1 RAs administered intravenously vs subcutaneously may help to develop 
      improved agents or modes of administration that are more effective and have fewer
      side effects.
AD  - Diabeteszentrum Bad Lauterberg, Kirchberg 21, 37431, Bad Lauterberg im Harz,
      Germany, nauck@diabeteszentrum.de.
FAU - Nauck, M A
AU  - Nauck MA
FAU - Baranov, O
AU  - Baranov O
FAU - Ritzel, R A
AU  - Ritzel RA
FAU - Meier, J J
AU  - Meier JJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/05 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s00125-013-2953-6 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Jun 8.

PMID- 23748860
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Jun 8
TI  - Hepatic DNA methylation modifications in early development of rats resulting from
      perinatal BPA exposure contribute to insulin resistance in adulthood.
AB  - AIMS/HYPOTHESIS: Perinatal exposure to bisphenol A (BPA), a widely distributed
      environmental endocrine disruptor, is associated with insulin resistance and
      diabetes in offspring. The underlying molecular mechanisms could involve
      epigenetics, as adverse effects induced by environmental exposure in early life
      are suggested through DNA methylation. In this study we sought to elucidate the
      relationship between perinatal BPA exposure and alteration of hepatic DNA
      methylation. METHODS: Pregnant Wistar rats were administered BPA (50 mug/kg/day) 
      or corn oil by oral gavage throughout gestation and lactation. Variables
      associated with insulin resistance and hepatic DNA methylation were examined at
      postnatal week 3 and week 21 in male offspring. RESULTS: In BPA-treated
      offspring, serum insulin and HOMA-insulin resistance were increased, and the
      insulin sensitivity index and hepatic glycogen storage were decreased compared
      with controls at week 21. At week 3, none of these variables were significantly
      changed. However, hepatic global DNA methylation was decreased, accompanied by
      overexpression of DNA methyltransferase 3B mRNA at week 3. Meanwhile, perinatal
      exposure to BPA induced promoter hypermethylation and a reduction in gene
      expression of hepatic glucokinase. Moreover, increased promoter hypermethylation 
      of Gck became more pronounced in BPA-treated offspring at week 21.
      CONCLUSIONS/INTERPRETATION: Abnormal DNA methylation in hepatic tissue precedes
      development of insulin resistance induced by perinatal BPA exposure. These
      findings support the potential role of epigenetics in fetal reprogramming by
      BPA-induced metabolic disorders.
AD  - Key Laboratory of Environment and Health, Ministry of Education & Ministry of
      Environmental Protection, School of Public Health, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, 430030, People's Republic
      of China.
FAU - Ma, Y
AU  - Ma Y
FAU - Xia, W
AU  - Xia W
FAU - Wang, D Q
AU  - Wang DQ
FAU - Wan, Y J
AU  - Wan YJ
FAU - Xu, B
AU  - Xu B
FAU - Chen, X
AU  - Chen X
FAU - Li, Y Y
AU  - Li YY
FAU - Xu, S Q
AU  - Xu SQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/26 [received]
PHST- 2013/05/07 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s00125-013-2944-7 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Jun 8.

PMID- 23748859
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Jun 8
TI  - Casein hydrolysate diet controls intestinal T cell activation, free radical
      production and microbial colonisation in NOD mice.
AB  - AIMS/HYPOTHESIS: Dietary and microbial factors and the gut immune system are
      important in autoimmune diabetes. We evaluated inflammatory activity in the whole
      gut in prediabetic NOD mice using ex vivo imaging of reactive oxygen and nitrogen
      species (RONS), and correlated this with the above-mentioned factors. METHODS:
      NOD mice were fed a normal diet or an anti-diabetogenic casein hydrolysate (CH)
      diet. RONS activity was detected by chemiluminescence imaging of the whole gut.
      Proinflammatory and T cell cytokines were studied in the gut and islets, and
      dietary effects on gut microbiota and short-chain fatty acids were determined.
      RESULTS: Prediabetic NOD mice displayed high RONS activity in the epithelial
      cells of the distal small intestine, in conjunction with a proinflammatory
      cytokine profile. RONS production was effectively reduced by the CH diet, which
      also controlled (1) the expression of proinflammatory cytokines and
      colonisation-dependent RegIIIgamma (also known as Reg3g) in ileum; (2) intestinal
      T cell activation; and (3) islet cytokines. The CH diet diminished microbial
      colonisation, increased the Bacteroidetes:Firmicutes ratio, and reduced lactic
      acid and butyric acid production in the gut. CONCLUSIONS/INTERPRETATION:
      Epithelial RONS production and proinflammatory T cell activation appears in the
      ileum of NOD mice after weaning to normal laboratory chow, but not after weaning 
      to an anti-diabetogenic CH diet. Our data suggest a link between dietary factors,
      microbial colonisation and mucosal immune activation in NOD mice.
AD  - Department of Medical Microbiology and Immunology, Kiinamyllynkatu 13, FIN-20520,
      Turku, Finland.
FAU - Emani, R
AU  - Emani R
FAU - Asghar, M N
AU  - Asghar MN
FAU - Toivonen, R
AU  - Toivonen R
FAU - Lauren, L
AU  - Lauren L
FAU - Soderstrom, M
AU  - Soderstrom M
FAU - Toivola, D M
AU  - Toivola DM
FAU - van Tol, E A F
AU  - van Tol EA
FAU - Hanninen, A
AU  - Hanninen A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/08 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s00125-013-2941-x [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Jun 8.

PMID- 23748855
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1555-824X (Electronic)
IS  - 1062-8606 (Linking)
DP  - 2013 Jun 7
TI  - Evaluation of Quality Improvement Performance in the Community Diabetes Education
      (CoDE) Program for Uninsured Mexican Americans: Results of a Randomized
      Controlled Trial.
AB  - The objective of this article is to quantify quality improvement using data from 
      a randomized controlled trial that tested the effectiveness of a community health
      worker in the primary role of diabetes educator in a clinic serving uninsured
      Mexican Americans. The intervention group received 7 hours of diabetes
      education/case management in excess of usual medical care. Of 16 process and
      outcome measures evaluated, the intervention group was significantly more likely 
      to have received a dilated retinal examination, and 53% achieved a hemoglobin A1c
      below 7% compared with 38% of the control group participants. Composite quality
      measures were similar in magnitude with published practice-based benchmarks at
      study conclusion. This suggests that the overall diabetes care delivered in this 
      clinic serving uninsured patients was comparable to the levels of excellence
      achieved in other primary care settings. Quantitative measurements of quality
      improvement can inform health policy regarding the relative effectiveness of
      diabetes interventions.
AD  - 1University of Texas School of Public Health, Dallas, TX.
FAU - Prezio, Elizabeth A
AU  - Prezio EA
FAU - Balasubramanian, Bijal A
AU  - Balasubramanian BA
FAU - Shuval, Kerem
AU  - Shuval K
FAU - Cheng, Dunlei
AU  - Cheng D
FAU - Kendzor, Darla E
AU  - Kendzor DE
FAU - Culica, Dan
AU  - Culica D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Am J Med Qual
JT  - American journal of medical quality : the official journal of the American
      College of Medical Quality
JID - 9300756
OTO - NOTNLM
OT  - community health worker
OT  - diabetes education
OT  - quality improvement
OT  - randomized controlled trial
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 1062860613489165 [pii]
AID - 10.1177/1062860613489165 [doi]
PST - aheadofprint
SO  - Am J Med Qual. 2013 Jun 7.

PMID- 23748846
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1538-9235 (Electronic)
IS  - 1040-5488 (Linking)
DP  - 2013 Jun 6
TI  - Demodex.
AB  - PURPOSE: Demodex folliculorum and Demodex brevis are ectoparasites with an
      astounding prevalence of 100% in patients aged 70 years and older. Every person
      in this age group is estimated to carry a colony of 1000 to 2000 mites. With such
      a high prevalence, little attention has been paid to the mite among eye care
      practitioners. We demonstrate a clinical sequence in a set of case reports to
      identify the mite. The clinical sequence includes a clinical history of
      blepharitis, dry eyes, and/or ocular allergy; slit lamp examination of
      cylindrical dandruff; and confirmation using light microscope evaluation of
      epilated lashes. CASE REPORTS: Patient 1 was a 68-year-old woman who demonstrates
      associations with dry eyes and diabetes. Patient 2 was a 44-year-old man with
      uncommonly seen D. brevis present. Patient 3 was a 40-year-old woman with dry
      eyes and allergy, showing mite tails protruding from base of lashes. Patient 4
      was a 60-year-old woman who demonstrates the association with rosacea. Patient 5 
      was a 53-year-old woman intermittently taking topical steroid and antibiotic
      combination medications, with an actual mite photographed on the surface.
      CONCLUSIONS: Following a clinical sequence helps identify Demodex, the
      underdiagnosed, undertreated, and underappreciated ocular surface disease.
AD  - *OD, FAAO daggerMS, OD, FAAO double daggerOD Private Practice, Azusa, California 
      (MMH); Omni Eye Surgery, New York, New York (KMM); Southern California College of
      Optometry, Fullerton, California (SES); and Private Practice, Pismo Beach,
      California (SES).
FAU - Hom, Milton M
AU  - Hom MM
FAU - Mastrota, Katherine M
AU  - Mastrota KM
FAU - Schachter, Scott E
AU  - Schachter SE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Optom Vis Sci
JT  - Optometry and vision science : official publication of the American Academy of
      Optometry
JID - 8904931
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1097/OPX.0b013e3182968c77 [doi]
PST - aheadofprint
SO  - Optom Vis Sci. 2013 Jun 6.

PMID- 23748787
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1347-6947 (Electronic)
IS  - 0916-8451 (Linking)
DP  - 2013 Jun 7
TI  - Stilbene Analogs of Resveratrol Improve Insulin Resistance through Activation of 
      AMPK.
AB  - Resveratrol (RSV), 3,5,4'-trihydroxy-trans-stilbene, is known to have many
      beneficial physiological activities. We have synthesized several stilbene
      anlogues and have reported that the hydroxyl group in the 4' position of RSV
      exhibited strong radical scavenging action. Using stilbene analogs, we
      investigated the structure of RSV to explain its protective effect against
      obesity and type 2 diabetes. All six analogs used in this study inhibited the
      differentiation of 3T3-L1 adipocytes. 3-Hydroxy-trans stilbene (3(OH)ST), and
      3,4'-dihydroxy-trans stilbene (3,4'(OH)2ST) increased glucose uptake and induced 
      adenosine monophosphate kinase (AMPK) phosphorylation independently of insulin in
      C2C12 myotubes. An in vivo study using mice fed high-fat diets indicated that
      3(OH)ST was more effective than RSV in improving insulin resistance. In
      conclusion, RSV and its derivatives, particularly 3(OH)ST, inhibited adipocyte
      differentiation and enhanced glucose uptake in the myotubes, resulting in a
      reduction of obesity and an improvement in glucose tolerance in vivo.
AD  - Department of Food and Nutritional Sciences, Graduate School of Humanities and
      Sciences, Ochanomizu University.
FAU - Ito-Nagahata, Tomomi
AU  - Ito-Nagahata T
FAU - Kurihara, Chiaki
AU  - Kurihara C
FAU - Hasebe, Miki
AU  - Hasebe M
FAU - Ishii, Akiko
AU  - Ishii A
FAU - Yamashita, Kaori
AU  - Yamashita K
FAU - Iwabuchi, Mari
AU  - Iwabuchi M
FAU - Sonoda, Mariko
AU  - Sonoda M
FAU - Fukuhara, Kiyoshi
AU  - Fukuhara K
FAU - Sawada, Rumi
AU  - Sawada R
FAU - Matsuoka, Atsuko
AU  - Matsuoka A
FAU - Fujiwara, Yoko
AU  - Fujiwara Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Biosci Biotechnol Biochem
JT  - Bioscience, biotechnology, and biochemistry
JID - 9205717
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - DN/JST.JSTAGE/bbb/121000 [pii]
PST - aheadofprint
SO  - Biosci Biotechnol Biochem. 2013 Jun 7.

PMID- 23748764
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1347-6947 (Electronic)
IS  - 0916-8451 (Linking)
DP  - 2013 Jun 7
TI  - Orally and Topically Administered Sparassis crispa (Hanabiratake) Improved
      Healing of Skin Wounds in Mice with Streptozotocin-Induced Diabetes.
AB  - Sparassis crispa (SC) contains significant concentrations of beta-glucan, which
      can accelerate wound healing, but the dose dependence for oral administration and
      the effects of topical administration are unknown. In streptozotocin-induced
      diabetic mice, dietary SC promoted dose-dependent effective wound healing.
      Similar wound-healing activity was observed when purified SC beta-glucan was
      topically applied to wounds of diabetic mice.
AD  - Research and Development Center, Unitika Ltd.
FAU - Yamamoto, Kyosuke
AU  - Yamamoto K
FAU - Kimura, Takashi
AU  - Kimura T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Biosci Biotechnol Biochem
JT  - Bioscience, biotechnology, and biochemistry
JID - 9205717
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - DN/JST.JSTAGE/bbb/121016 [pii]
PST - aheadofprint
SO  - Biosci Biotechnol Biochem. 2013 Jun 7.

PMID- 23748522
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Review of insulin-dependent and insulin-independent agents for treating patients 
      with type 2 diabetes mellitus and potential role for sodium-glucose
      co-transporter 2 inhibitors.
PG  - 214-26
LID - 10.3810/pgm.2013.05.2672 [doi]
AB  - Diabetes, especially type 2 diabetes mellitus (T2DM), continues to be a global
      health care problem. Although the beneficial effects of glycemic control are well
      established, in the United States, > 40% of adults with diabetes fail to achieve 
      target glycated hemoglobin levels. Antidiabetic drug classes vary with respect to
      their mechanisms of action, glucose-lowering potential, and safety and
      tolerability profiles. Antidiabetic drug classes include some agents that depend 
      on the presence or action of insulin for their therapeutic effect. As the disease
      state of T2DM progresses, patient pancreatic beta-cell function declines, and
      therapies that stimulate insulin secretion or improve insulin sensitivity become 
      less effective for this population. Therefore, the development of additional
      antidiabetic agents with novel mechanisms of action that can be used alone or in 
      combination with currently approved medications may help patients achieve
      glycemic control. Agents that have comparable glucose-lowering capabilities but
      different mechanisms of action may fill treatment gaps or meet the needs of
      patient subpopulations. For example, inhibitors of sodium-glucose co-transporter 
      2 (SGLT2) represent an emerging class of glucose-lowering agents. The SGLT2
      inhibitors reduce glucose reabsorption by the kidney, leading to increased
      urinary glucose excretion and caloric loss. In clinical trials, these agents have
      been shown to improve glycemic control and to reduce body weight in patients with
      T2DM. Additionally, SGLT2 inhibitors pose a low risk for hypoglycemia and are
      generally well tolerated; however, their use has been associated with an increase
      in the frequency of genital infections and, in some studies, urinary tract
      infections. Sodium-glucose co-transporter 2 inhibitors may provide an alternative
      or an addition to existing therapies for the treatment of patients with T2DM.
AD  - Division of Endocrinology, Philadelphia College of Osteopathic Medicine,
      Philadelphia, PA. jeffreyfreemando@aol.com.
FAU - Freeman, Jeffrey S
AU  - Freeman JS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2672 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):214-26. doi: 10.3810/pgm.2013.05.2672.

PMID- 23748521
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Clinical and economic outcomes among patients with diabetes mellitus initiating
      insulin glargine pen versus vial.
PG  - 204-13
LID - 10.3810/pgm.2013.05.2656 [doi]
AB  - Background: Insulin pens may help patients reach glycated hemoglobin (HbA1c)
      target levels, but a substantial proportion of patients continue to use insulin
      vials/syringes. The objective of the current study was to evaluate real-world
      clinical and economic outcomes of patients with type 2 diabetes mellitus (T2DM)
      initiating insulin glargine via pen delivery (pen) or vial/syringe (vial) within 
      a large managed-care population in the United States. Methods: This retrospective
      administrative claims study used data on adult, insulin-naive patients with T2DM 
      treated with >/= 1 oral antidiabetic or glucagon-like peptide-1 receptor agonist 
      at baseline. The index date was the earliest pen or vial prescription date.
      Propensity score matching (1:1) of patients in the pen and vial cohorts was used 
      when comparing 1-year outcomes, including treatment persistence and adherence,
      HbA1c levels, hypoglycemia rates, and all-cause and diabetes-related health care 
      costs (computed as paid amounts on claims). Results: Patients in the matched
      cohorts (n = 733 per cohort) were well balanced with regard to demographics (mean
      age 52 years; 43% women), clinical measures (mean HbA1c level, 9.4%; mean
      Quan-Modified Charlson Comorbidity Index score, 0.9), and health care utilization
      at baseline. Following initiation of insulin glargine, pen patients were more
      persistent (60.6% vs 50.1%; P < 0.001) and adherent (medication possession ratio,
      0.73 vs 0.57; P < 0.001), with lower HbA1c levels during follow-up (mean adjusted
      change, -1.05 vs -0.73; P < 0.001), compared with vial patients. Hypoglycemic
      events occurred at similar rates across pen and vial cohorts (3.8% vs 5.2%,
      respectively; P = 0.21). Study drug costs were higher among pen users ($1164 vs
      $762, respectively; P < 0.001), but this did not translate into higher total
      all-cause or diabetes-related costs. Conclusion: For patients with diabetes newly
      initiating insulin glargine, using an insulin pen device was associated with
      increased therapy persistence and adherence, and lower HbA1c levels relative to
      vial/syringe, without increasing total all-cause or diabetes-related costs.
AD  - HealthCore, Inc., Wilmington, DE. mgrabner@healthcore.com.
FAU - Grabner, Michael
AU  - Grabner M
FAU - Chu, James
AU  - Chu J
FAU - Raparla, Swetha
AU  - Raparla S
FAU - Quimbo, Ralph
AU  - Quimbo R
FAU - Zhou, Steve
AU  - Zhou S
FAU - Conoshenti, Joseph
AU  - Conoshenti J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2656 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):204-13. doi: 10.3810/pgm.2013.05.2656.

PMID- 23748520
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Value and utility of self-monitoring of blood glucose in non-insulin-treated
      patients with type 2 diabetes mellitus.
PG  - 191-204
LID - 10.3810/pgm.2013.05.2668 [doi]
AB  - Self-monitoring of blood glucose (SMBG) levels provides important information
      regarding glycemic control for patients with diabetes, and is recommended by
      European and American diabetes organizations as an essential adjunct to periodic 
      glycated hemoglobin (HbA1c) level monitoring. The benefits of SMBG in improving
      glycemic control in patients with type 1 diabetes and those with type 2 diabetes 
      (T2DM) who are being treated with insulin are well recognized. In contrast, the
      potential role of SMBG in patients with T2DM not treated with insulin remains
      controversial, which may lead to underutilization of SMBG in this population.
      Structured SMBG, introduced as part of a treatment intervention, has been
      associated with modest but significant improvements in HbA1c levels in patients
      with T2DM who are not taking insulin as part of their management plan.
      Patient-obtained readings provide valuable real-time feedback on glucose
      responses to meals and exercise, and provide the patient with guidance on the
      day-to-day management of their diabetes. Studies have shown that when patients
      perform self-monitoring as part of their treatment interventions, support through
      appropriate educational initiatives is critical to ensure that patients
      understand the rationale for SMBG. Patients should be trained in correct testing 
      technique and data recording for SMBG, as well as target blood glucose and goal
      HbA1c levels so that they will know when their SMBG readings are out of range.
      Technology has a potential role in facilitating SMBG-based interventions by
      improving patient-physician communication and optimizing glycemic control through
      the use of remote data uploading, data analysis tools, and, perhaps, even text
      messaging. This review outlines the benefits of SMBG in the management of
      patients with T2DM not treated with insulin, and highlights strategies for
      improving the effectiveness of SMBG-based treatment interventions in this
      population.
AD  - Texas Diabetes and Endocrinology, Austin, TX. tblevins@texasdiabetes.com.
FAU - Blevins, Thomas
AU  - Blevins T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2668 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):191-204. doi: 10.3810/pgm.2013.05.2668.

PMID- 23748519
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Effects of dapagliflozin on cardiovascular risk factors.
PG  - 181-9
LID - 10.3810/pgm.2013.05.2667 [doi]
AB  - People with diabetes are more likely to develop a cardiovascular (CV) disease
      compared with those without diabetes. Although effective glycemic control has
      been the focus of the management of type 2 diabetes mellitus (T2DM), it is also
      important to control other CV risk factors to improve outcomes in these patients.
      Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, lowers glucose levels
      in patients with T2DM by increasing urinary glucose excretion. Dapagliflozin
      therapy has been shown to impact a number of CV risk factors. Dapagliflozin
      improved glycemia with a low intrinsic propensity to cause hypoglycemia. Caloric 
      loss associated with dapagliflozin-induced glucosuria also led to body weight
      reduction. Small changes from baseline in mean lipid parameters and reductions in
      serum uric acid levels were observed in patients taking dapagliflozin. Blood
      pressure reductions were also noted, consistent with modest drug-induced diuresis
      and weight loss.Furthermore, a lower rate of cardiac events was seen in patients 
      taking dapagliflozin compared with those taking comparators in a meta-analysis of
      clinical trials on dapagliflozin. Overall, dapagliflozin has shown beneficial
      effects on CV risk factors in patients with T2DM. Further studies are underway to
      evaluate the effect of dapagliflozin on CV outcomes.
AD  - Group Director, Global Clinical Development, Metabolics, Bristol-Myers Squibb,
      Princeton, NJ.
FAU - Ptaszynska, Agata
AU  - Ptaszynska A
FAU - Hardy, Elise
AU  - Hardy E
FAU - Johnsson, Eva
AU  - Johnsson E
FAU - Parikh, Shamik
AU  - Parikh S
FAU - List, James
AU  - List J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2667 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):181-9. doi: 10.3810/pgm.2013.05.2667.

PMID- 23748518
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - A practice-based research network focused on comparative effectiveness research
      in type 2 diabetes management.
PG  - 172-80
LID - 10.3810/pgm.2013.05.2658 [doi]
AB  - Purpose: To establish a real-world research platform focused on comparative
      effectiveness research and health care decision making in diabetes care in order 
      to obtain a detailed understanding of individualized patient management in
      primary care. Methods: Diabetes FORWARD (Foundation of Real-World Assessment and 
      Research in Diabetes) is a North American research platform being organized to
      conduct longitudinal, noninterventional investigations of an anticipated 10 000
      patients with type 2 diabetes mellitus (T2DM). Recruitment will be stratified to 
      reflect typical (primarily primary care) clinical T2DM populations. Streamlined
      data collection relying on electronic medical records (retrospective) and
      periodic surveys (prospective) will reduce the burden of study participation and,
      therefore, enhance enrollment by busy primary care and endocrinology practices.
      Physician data will include baseline demographic and practice information.
      Patient data will include demographics, T2DM characteristics and treatment,
      resource utilization information, and patient-reported outcomes. Responses can be
      tracked within the observation window in near-real time, allowing immediate,
      noninterventional reaction at the point of nonresponse. Expected Outcomes:
      Diabetes FORWARD is expected to provide important real-world data describing how 
      actual clinical T2DM management differs across sites, settings, and clinicians,
      and its impact on glycemic control, treatment adherence and persistence, and
      clinical outcomes. These data will also help to identify the effect of diabetes
      management on the onset and progression of retinopathy, neuropathy, nephropathy, 
      and cardiovascular disease at 6-month intervals. Conclusion: To our knowledge,
      Diabetes FORWARD is the first diabetes-focused, practice-based research network
      in the United States and Canada. The current study will provide robust data that 
      should reflect typical management of T2DM in clinical practice in North America.
AD  - The Frist Clinic, Nashville, TN. john.anderson1@hcahealthcare.com.
FAU - Anderson, John E
AU  - Anderson JE
FAU - Rhinehart, Andrew S
AU  - Rhinehart AS
FAU - Reid, Timothy S
AU  - Reid TS
FAU - Cuddihy, Robert M
AU  - Cuddihy RM
FAU - Vlajnic, Aleksandra
AU  - Vlajnic A
FAU - Dalal, Mehul R
AU  - Dalal MR
FAU - Gemmen, Eric
AU  - Gemmen E
FAU - Johnstone, Bryan
AU  - Johnstone B
FAU - Abbaszadeh, Babak
AU  - Abbaszadeh B
FAU - Reed, Josh
AU  - Reed J
FAU - Sheller, Jennifer
AU  - Sheller J
FAU - Stewart, John
AU  - Stewart J
FAU - Mozaffari, Essy
AU  - Mozaffari E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2658 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):172-80. doi: 10.3810/pgm.2013.05.2658.

PMID- 23748515
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and
      cardiovascular disease history or cardiovascular risk factors: Results of a
      pooled analysis of phase 3 clinical trials.
PG  - 145-54
LID - 10.3810/pgm.2013.05.2657 [doi]
AB  - Objective: This post hoc analysis sought to assess the efficacy, safety, and
      tolerability of saxagliptin in patients with type 2 diabetes mellitus and
      cardiovascular (CV) risk factors or disease (CVD). Methods: Data from 5
      randomized controlled trials were pooled to compare saxagliptin 5 mg with
      placebo: 2 studies of saxagliptin as monotherapy in drug-naive patients and 1
      each of saxagliptin as add-on therapy to metformin, glyburide, or a
      thiazolidinedione. Analysis was performed according to the following
      baseline/trial entry criteria: 1) history/no history of CVD; 2) >/= 2 versus 0 to
      1 CV risk factors; 3) statin use versus no statin use; and 4) hypertension versus
      no hypertension. Change from baseline glycated hemoglobin (HbA1c), fasting plasma
      glucose, and postprandial glucose levels; and the proportion of patients
      achieving an HbA1c level < 7% were analyzed (week 24). Safety was assessed by
      adverse events, hypoglycemia, and body weight. Results: In total, 882 patients
      received saxagliptin 5 mg and 799 received placebo. Differences in adjusted mean 
      change from baseline HbA1c (95% CI) were greater with saxagliptin compared with
      placebo in patients with a history of CVD (-0.64% [-0.90 to -0.38]) and no
      history of CVD (-0.68% [-0.78 to -0.58]); with >/= 2 CV risk factors (-0.73%
      [-0.85 to -0.60]) and 0 to 1 CV risk factor (-0.62% [-0.75 to -0.48]); with
      statin use (-0.70% [-0.89 to -0.52]) and no statin use (-0.66% [-0.77 to -0.56]);
      and with hypertension (-0.69% [-0.82 to -0.57]) and no hypertension (-0.66%
      [-0.80 to -0.52]). Saxagliptin was well tolerated, with similar adverse event
      rates and types compared with placebo. There was a < 1% rate of confirmed
      hypoglycemia in all groups except in patients with CV history who received
      placebo (2.1%). Conclusion: Saxagliptin improved glycemic measures, resulted in
      low rates of confirmed hypoglycemia, and was well tolerated in patients with or
      without CVD and CV risk factors.
AD  - Medical Affairs, AstraZeneca, Wilmington, DE. william.cook@astrazeneca.com.
FAU - Cook, William
AU  - Cook W
FAU - Bryzinski, Brian
AU  - Bryzinski B
FAU - Slater, Jill
AU  - Slater J
FAU - Frederich, Robert
AU  - Frederich R
FAU - Allen, Elsie
AU  - Allen E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2657 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):145-54. doi: 10.3810/pgm.2013.05.2657.

PMID- 23748514
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Pramlintide improved measures of glycemic control and body weight in patients
      With type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion
      therapy.
PG  - 136-44
LID - 10.3810/pgm.2013.05.2635 [doi]
AB  - Objective: To assess the safety and efficacy of the addition of pramlintide to
      continuous subcutaneous insulin infusion (CSII) therapy in patients with type 1
      diabetes mellitus (T1DM). Research Design and Methods: We conducted a post hoc
      analysis of 2 studies: a 29-week, multicenter, randomized, double-blind,
      placebo-controlled trial (referred to as RCT) (pramlintide, n = 82; placebo, n = 
      73) and an open-ended, multicenter, open-label, single-arm, observational study
      (referred to as clinical practice trial) (n = 150), which assessed the addition
      of pramlintide to CSII therapy in patients with T1DM. Pramlintide was initiated
      at 15 mug and titrated to 30 or 60 mug with major meals. The mealtime insulin
      dose was reduced by 30% to 50% at initiation, and then adjusted to optimize
      glycemic control. Endpoints at 29 weeks (RCT) and 6 months (clinical practice
      trial) included change in glycated hemoglobin (HbA1c) level, insulin dose, body
      weight, pre- and postprandial blood glucose level, and tolerability and safety.
      Results: In both studies, mean baseline age was approximately 42 years, duration 
      of diabetes was 20 to 24 years, and HbA1c level was approximately 8%. Pramlintide
      reduced blood glucose excursions and improved the percentage of recorded
      postprandial blood glucose levels < 180 mg/dL. Mean (+/- standard deviation)
      reduction in HbA1c level in the clinical practice trial was -0.3% +/- 0.1% (P <
      0.0001), and in the RCT was similar between pramlintide- and placebo-treated
      patients (-0.4% +/- 0.1% and -0.3% +/- 0.1%, respectively). Glycemic improvements
      were accomplished, with reductions in mealtime insulin doses (RCT: pramlintide,
      -23.8% +/- 5.2%; placebo, -3.2% +/- 4.1%; P < 0.0005; clinical practice trial:
      -27.5% +/- 2.9%; P < 0.0001) and body weight (RCT: pramlintide, -2.2 kg +/- 0.5
      kg; placebo, +1.4 kg +/- 0.3 kg; P < 0.0001; clinical practice trial: -3.2 kg +/-
      0.4 kg; P < 0.0001). Short-lived nausea, primarily mild to moderate in intensity,
      was the most common adverse event associated with pramlintide therapy. Severe
      hypoglycemic events occurred at a rate of 0.56 and 0.34 events per patient-year
      in pramlintide- and placebo-treated patients, respectively, in the RCT, and at a 
      rate of 0.12 events per patient-year in the clinical practice trial. Conclusion: 
      Addition of pramlintide to CSII therapy was safe and effective in patients with
      T1DM. Pramlintide should be considered for patients who are not able to optimize 
      glycemic control with CSII therapy alone, particularly those with difficulty
      controlling postprandial blood glucose levels and/or body weight. Trial
      registration: www.ClinicalTrials.gov identifiers: NCT00042458, NCT00108004.
AD  - Amylin Pharmaceuticals, LLC, San Diego, CA. kathrin.herrmann@bms.com.
FAU - Herrmann, Kathrin
AU  - Herrmann K
FAU - Frias, Juan P
AU  - Frias JP
FAU - Edelman, Steven V
AU  - Edelman SV
FAU - Lutz, Karen
AU  - Lutz K
FAU - Shan, Kevin
AU  - Shan K
FAU - Chen, Steven
AU  - Chen S
FAU - Maggs, David
AU  - Maggs D
FAU - Kolterman, Orville G
AU  - Kolterman OG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2635 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):136-44. doi: 10.3810/pgm.2013.05.2635.

PMID- 23748512
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Physiologic and weight-focused treatment strategies for managing type 2 diabetes 
      mellitus: The metformin, glucagon-like peptide-1 receptor agonist, and insulin
      (MGI) approach.
PG  - 112-26
LID - 10.3810/pgm.2013.05.2666 [doi]
AB  - The prevalence of type 2 diabetes mellitus (T2DM) is rising in association with
      an increase in obesity rates. Current treatment options for patients with T2DM
      include lifestyle modifications and numerous antidiabetic medications. Despite
      the availability of effective and well-tolerated treatments, many patients do not
      achieve recommended glycemic targets. Lack of efficacy is complicated by the wide
      range of available agents and little specificity in treatment guidelines, thus
      challenging clinicians to understand the relative benefits and risks of
      individual options for each patient. In this article, lifestyle intervention
      strategies and current antidiabetic agents are evaluated for their efficacy,
      safety, and weight-loss potential. Because of the heterogeneous and progressive
      nature of T2DM, physicians should advocate approaches that emphasize weight
      management, limit the risk of hypoglycemia and adverse events, and focus on the
      core pathophysiologic defects in patients with T2DM. A healthy, plant-based diet 
      that is low in saturated fat and refined carbohydrates but high in whole grains, 
      vegetables, legumes, and fruits, coupled with resistance and aerobic exercise
      regimens, are recommended for patients with T2DM. When necessary, drug
      intervention, described in this article as the MGI (metformin, glucagon-like
      peptide-1 receptor agonist, and insulin) approach, should begin with metformin
      and progress to the early addition of glucagon-like peptide-1 receptor agonists
      because of their weight loss potential and ability to target multiple
      pathophysiologic defects in patients with T2DM. For most patients, treatments
      that induce weight gain and hypoglycemia should be avoided. Long-acting insulin
      should be initiated if glycemic control is not achieved with metformin and
      glucagon-like peptide-1 receptor agonist combination therapy, focusing on
      long-acting insulin analogs that induce the least weight gain and have the lowest
      hypoglycemic risk. Ultimately, a patient-centered treatment approach that
      addresses the core pathologies of T2DM and obesity will not only increase overall
      efficacy and the likelihood that a patient adheres to treatment, but may also
      improve a patient's mental well-being and quality of life.
AD  - Diabetes and Endocrine Associates, York Hospital, York, ME. dnadeaumd@gmail.com.
FAU - Nadeau, Daniel A
AU  - Nadeau DA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2666 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):112-26. doi: 10.3810/pgm.2013.05.2666.

PMID- 23748510
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Accuracy and clinical utility of a point-of-care HbA1c testing device.
PG  - 91-8
LID - 10.3810/pgm.2013.05.2664 [doi]
AB  - Background: Point-of-care testing (POCT) is widely used to measure blood glucose 
      levels in people with diabetes, although its use in measuring glycated hemoglobin
      (HbA1c) levels is less common, perhaps due to perceived performance issues and
      access to the technology. Methods: Forty blood samples were analyzed in duplicate
      using Bayer's A1CNow + (R) Multi-Test A1C system (A1CNow + ) with 3 different
      reagent lots; HbA1c levels of the samples spanned the clinically relevant range
      of 4% to 10%. Corresponding samples were sent to a National Glycohemoglobin
      Standardization Program (NGSP) secondary reference laboratory (University of
      Missouri Secondary Reference Laboratory #9), which analyzed the samples with a
      Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 (Tosoh G8; Tosoh Bioscience,
      Inc). Results: Glycated hemoglobin levels measured with the A1CNow + aligned with
      measurements obtained using the laboratory method, with correlation coefficients 
      of 0.985, 0.987, and 0.989 for the 3 lots, respectively. The 95% CIs for the
      differences between the A1CNow + levels and the mean HbA1c levels were within
      -0.55% to +0.50% for the 3 reagent lots, which is well within the currently
      acceptable limits of +/-0.75% HbA1c required by the NGSP. Results were further
      analyzed per the new tighter NGSP performance criteria effective September 1,
      2012, requiring that 37 of 40 results be within +/-7% (relative bias) of the NGSP
      reference laboratory measures. All 3 lots met the tighter NGSP criteria.
      Conclusion: The A1CNow + provides accuracy and precision when performing POCT of 
      HbA1c as an aid in diabetes management. Ongoing improvements in this and other
      HbA1c POCT devices may lead to a greater global acceptance of the role of POCT of
      HbA1c in diabetes management.
AD  - Scientific Affairs Liaison, Diabetes Care, Bayer HealthCare LLC, Sunnyvale, CA.
      jennifer.knaebel@bayer.com.
FAU - Knaebel, Jennifer
AU  - Knaebel J
FAU - Irvin, Benjamin R
AU  - Irvin BR
FAU - Xie, Charles Z
AU  - Xie CZ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2664 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):91-8. doi: 10.3810/pgm.2013.05.2664.

PMID- 23748509
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
PG  - 79-90
LID - 10.3810/pgm.2013.05.2663 [doi]
AB  - Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as new
      options in the management of type 2 diabetes mellitus, demonstrating meaningful
      antihyperglycemic effects and good tolerability profiles. Glycemic control is
      improved by preventing the DPP-4-mediated degradation of incretin hormones, with 
      a resulting increase in insulin secretion and inhibition of glucagon secretion.
      Purpose: This article provides a discussion of the clinical utility of
      linagliptin. Results and Conclusion: Linagliptin is a xanthine-based, oral DPP-4 
      inhibitor that has been approved in the United States and Europe. It has been
      evaluated extensively in clinical trials, and results in improved glycemic
      control when used as monotherapy, initial combination therapy with metformin or
      pioglitazone, add-on therapy to metformin and/or a sulfonylurea, or add-on
      therapy to basal insulin (with or without oral antidiabetic drugs). Consistent
      with other members of its class, the benefits of linagliptin also include a low
      risk of hypoglycemia and weight gain. However, linagliptin is the first DPP-4
      inhibitor to be approved as a once-daily, 5-mg dose and, due to its primarily
      non-renal route of excretion, no dosage adjustment is required for patients with 
      renal or hepatic impairment. The pharmacokinetics and pharmacodynamics of
      linagliptin are not affected to a clinically meaningful degree by race or
      ethnicity and linagliptin has very low potential for drug-drug interactions.
AD  - Grunberger Diabetes Institute, Bloomfield Hills, MI. grunberger@gdi-pc.com.
FAU - Grunberger, George
AU  - Grunberger G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2663 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):79-90. doi: 10.3810/pgm.2013.05.2663.

PMID- 23748508
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Exenatide once weekly: Opportunities in the primary care setting.
PG  - 68-78
LID - 10.3810/pgm.2013.05.2662 [doi]
AB  - Type 2 diabetes mellitus is a pandemic, with millions of new diagnoses made each 
      year. In the United States, > 90% of patients with type 2 diabetes mellitus are
      cared for by primary care physicians who bear the primary responsibility of
      diagnosing and treating this disease. Building an optimal treatment regimen for a
      patient from the many choices available depends on many factors, including the
      ability of a given therapy to safely and effectively lower blood glucose levels, 
      and potential benefits on body weight, cardiovascular risk factors, and
      hypoglycemia risk. With these considerations at the forefront, this article
      provides an overview of exenatide once weekly (EQW), a recently available
      antidiabetes therapy in the glucagon-like peptide-1 receptor agonist class
      designed to provide continuous glycemic control with once-weekly dosing. We
      discuss the clinical trials that have demonstrated the ability of EQW to
      effectively lower blood glucose levels and body weight with a minimal risk of
      hypoglycemia. In addition, we examine other issues likely to be relevant in a
      primary care setting, including safety and tolerability profiles, pharmacology
      and dosing, ease of use, recommended place in treatment, and patient perceptions 
      of EQW.
AD  - Department of Medicine, Division of Endocrinology, Touchstone Diabetes Center,
      University of Texas Southwestern Medical Center, Dallas, TX.
      jaime.davidson@utsouthwestern.edu.
FAU - Davidson, Jaime A
AU  - Davidson JA
FAU - Nikkel, Carla
AU  - Nikkel C
FAU - Grimm, Michael
AU  - Grimm M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2662 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):68-78. doi: 10.3810/pgm.2013.05.2662.

PMID- 23748507
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients
      with type 2 diabetes mellitus: A retrospective analysis of pooled clinical trial 
      data.
PG  - 58-67
LID - 10.3810/pgm.2013.05.2661 [doi]
AB  - Aim: Therapies for type 2 diabetes mellitus that leverage the glucagon-like
      peptide-1 (GLP-1) receptor signaling pathway have been shown to reduce rates of
      hyperglycemia and have beneficial effects on body weight. This post hoc analysis 
      compared the effects of 2 GLP-1 receptor- based therapies, exenatide once weekly 
      (EQW), a GLP-1 receptor agonist, and sitagliptin (sita), a dipeptidyl peptidase-4
      inhibitor, on glucose control across the range of baseline glycated hemoglobin
      (HbA1c) levels specified in the American Association of Clinical Endocrinologists
      and American College of Endocrinology treatment algorithm. Materials and Methods:
      Data from patients treated with either EQW or sita for 26 weeks in 2 randomized, 
      double-blind, comparator-controlled clinical trials were pooled and analyzed.
      Glycemic endpoints and cardiovascular risk factors were evaluated in subgroups
      and the overall population. Results: Analysis included 737 patients on background
      therapies of diet and exercise and/or metformin. While both agents reduced HbA1c 
      and fasting blood glucose (FBG) levels from baseline, significantly greater
      reductions in HbA1c and FBG levels occurred with EQW compared with sita across
      all baseline HbA1c level strata, and significantly more patients in the EQW group
      achieved goal HbA1c levels compared with the sita group. Patients treated with
      EQW also experienced significantly greater reductions in body weight and
      cholesterol levels compared with patients treated with sita. The incidences of
      the most common adverse events of nausea and diarrhea were higher in the EQW
      group compared with the sita group, and incidences of these adverse events
      decreased over time. Both groups experienced a low incidence of minor
      hypoglycemic events.Conclusion:Significantly greater improvements in HbA1c and
      FBG levels were observed in EQW- compared with sita-treated patients across all
      baseline HbA1c level strata. Additionally, greater reductions in body weight and 
      some cardiovascular risk factors were observed with EQW treatment compared with
      sita treatment. Both EQW and sita were generally well tolerated; sita-treated
      patients experienced fewer adverse events than EQW-treated patients. Trial
      registration: www.ClinicalTrials.gov identifiers: NCT00637273, NCT00676338.
AD  - Amylin Pharmaceuticals, LLC, San Diego, CA. jaret.malloy@amylin.com.
FAU - Malloy, Jaret
AU  - Malloy J
FAU - Meloni, Alison
AU  - Meloni A
FAU - Han, Jenny
AU  - Han J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2661 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):58-67. doi: 10.3810/pgm.2013.05.2661.

PMID- 23748506
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Efficacy, safety, and tolerability of exenatide once weekly in patients with type
      2 diabetes mellitus: An integrated analysis of the DURATION trials.
PG  - 47-57
LID - 10.3810/pgm.2013.05.2660 [doi]
AB  - Background and Aim: Exenatide is a glucagon-like peptide-1 receptor agonist
      demonstrated to improve glycemic control with low hypoglycemia risk in patients
      with type 2 diabetes mellitus. The Diabetes Therapy Utilization: Researching
      Changes in A1C, Weight, and Other Factors Through Intervention With Exenatide
      Once Weekly (DURATION) program comprised 6 randomized, comparator-controlled, 24-
      to 30-week trials of exenatide once weekly (EQW), an extended-release
      formulation. This post hoc analysis pooled data from patients taking EQW across 6
      trials to assess efficacy and safety in a large, varied patient population.
      Materials and Methods: The intent-to-treat (ITT) population contained 1379
      patients (baseline mean +/- standard deviation glycated hemoglobin [HbA1c] levels
      of 8.4% +/- 1.1%) who were treated with EQW over the course of 24 to 30 weeks.
      Changes from baseline in efficacy parameters for the ITT population and a
      completer population (1195 patients with >/= 22 weeks of exposure) were
      evaluated. Results: The ITT population experienced significant reductions from
      baseline (least-squares mean [95% CI]) in HbA1c levels (-1.4% [-1.5% to -1.4%]), 
      fasting blood glucose levels (-36 mg/dL [-38.4 mg/dL to -33.8 mg/dL]), and body
      weight (-2.5 kg [-2.8 kg to -2.3 kg]) after 24 to 30 weeks of EQW treatment.
      Reductions in HbA1c and fasting blood glucose levels were observed across
      baseline HbA1c level strata; patients with higher baseline HbA1c levels
      experienced greater reductions. Treatment with EQW was associated with modest,
      significant reductions in blood pressure (systolic blood pressure, -2.8 mm Hg
      [-3.5 mm Hg to -2.1 mm Hg]; diastolic blood pressure, -0.8 mm Hg [-1.2 mm Hg to
      -0.4 mm Hg]), and fasting lipid levels (total cholesterol, -6.5 mg/dL [-8.2 mg/dL
      to -4.7 mg/dL]; low-density lipoprotein cholesterol, -3.9 mg/dL [5.3 mg/dL to
      -2.5 mg/dL]; and triglyceride [geometric least-squares mean percent change (95%
      CI)], -6% [-8% to -4%] levels). Similar reductions were observed in the completer
      population. Exenatide once weekly was generally well tolerated. Transient,
      mild-to-moderate gastrointestinal treatment-emergent adverse events and
      injection-site treatment-emergent adverse events were reported most frequently,
      but were seldom treatment limiting. No major hypoglycemic events were observed;
      minor hypoglycemic events occurred infrequently in patients not using a
      sulfonylurea. Conclusion: This post hoc analysis of > 1300 patients demonstrated 
      that EQW was associated with significant reductions in HbA1c levels, body weight,
      blood pressure, and fasting lipid levels, with minimal hypoglycemia risk.
      Consistent with established safety profiles, EQW therapy was generally well
      tolerated. Trial registration: www.ClinicalTrials.gov identifiers: NCT00308139,
      NCT00637273, NCT00641056, NCT00676338, NCT00877890, NCT01029886.
AD  - Amylin Pharmaceuticals, LLC, San Diego, CA.
FAU - Grimm, Michael
AU  - Grimm M
FAU - Han, Jenny
AU  - Han J
FAU - Weaver, Carole
AU  - Weaver C
FAU - Griffin, Pete
AU  - Griffin P
FAU - Schulteis, Christine T
AU  - Schulteis CT
FAU - Dong, Haiying
AU  - Dong H
FAU - Malloy, Jaret
AU  - Malloy J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2660 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):47-57. doi: 10.3810/pgm.2013.05.2660.

PMID- 23748505
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Genital mycotic infections in patients with diabetes.
PG  - 33-46
LID - 10.3810/pgm.2013.05.2650 [doi]
AB  - Patients with diabetes, especially those with poorly controlled glycemia, are
      prone to developing genital mycotic infections-vulvovaginal candidiasis in women 
      and Candida balanitis in men-the latter almost exclusively in uncircumcised men. 
      Candida albicans is the most common pathogen causing balanitis and is also the
      dominant cause of vulvovaginal candidiasis in women with diabetes, although
      Candida glabrata is a prominent pathogen in women with type 2 diabetes mellitus. 
      Candida glabrata is less virulent but also less susceptible to conventional
      antifungal treatment. High blood glucose levels promote yeast attachment and
      growth, and also interfere with immune responses in the host. In uncircumcised
      men, the moist, warm space underneath the foreskin is thought to promote yeast
      growth, especially when hygiene is poor. Several other risk factors have been
      identified that predispose to genital mycotic infections, including antibiotic
      use, corticosteroid use, immunosuppression, atopy, and, in women only, genetics, 
      pregnancy, estrogen/oral contraceptive use, and select sexual behaviors (eg,
      orogenital sex). In patients with hyperglycemia, risk is increased for not only
      incident infection but also for recurrence, underscoring the key role of
      establishing and maintaining euglycemia in the management of genital mycotic
      infections in patients with diabetes. In addition to blood glucose control,
      first-line treatment involves either an antifungal cream/ointment (or suppository
      for women only) that is applied intravaginally by women and directly to the
      affected area(s) by men, or oral treatment, which infrequently causes systemic
      side effects. Antifungal treatment should also be offered to sexual partners of
      patients with diabetes with a genital mycotic infection if the partner is
      similarly infected. Given high efficacy rates, follow-up test-of-cure after the
      completion of treatment is generally unnecessary.
AD  - Drexel University College of Medicine, Philadelphia, PA.
      paul.nyirjesy@drexelmed.edu.
FAU - Nyirjesy, Paul
AU  - Nyirjesy P
FAU - Sobel, Jack D
AU  - Sobel JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2650 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):33-46. doi: 10.3810/pgm.2013.05.2650.

PMID- 23748504
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular
      risk reduction in patients with type 2 diabetes mellitus.
PG  - 21-32
LID - 10.3810/pgm.2013.05.2654 [doi]
AB  - Background: Clinical development programs of investigational antidiabetic agents 
      now include evaluation of cardiovascular (CV) risk as a major research focus.
      Recently, several compounds in a new class of antihyperglycemic therapy have
      reached the final stages of development. Treatment with inhibitors of
      sodium-glucose co-transporters 2 (SGLT2) leads to urinary excretion of glucose in
      patients with type 2 diabetes mellitus (T2DM), and is associated with clinically 
      significant reductions in blood glucose levels. The glucosuria-based mechanism of
      this class has the potential to induce weight loss through reduced caloric
      availability, and, in addition, may affect blood pressure (BP) via osmotic
      diuresis or other as yet incompletely characterized mechanisms. Methods: Searches
      of the PubMed database were conducted for published studies evaluating the use of
      SGLT2 inhibitors that reported data on CV risk factors (eg, weight, BP, lipid
      levels) or CV events. Searches for presentations at recent major diabetes
      congresses were performed using the Online Submission and Invitation System.
      Results: Treatment with SGLT2 inhibitors has consistently been associated with
      reduction in body weight and BP. Qualitative graphical assessment of 21 studies
      shows unadjusted reductions in systolic BP and body weight typically ranging
      between 3 to 5 mm Hg and 2 to 3 kg, respectively. A few reports have suggested
      the potential for improvement in lipid parameters, such as high-density
      lipoprotein cholesterol levels; however, not all studies have demonstrated
      significant changes, and some have noted small increases in low-density
      lipoprotein cholesterol levels. Conclusion: Inhibition of SGLT2 in patients with 
      T2DM may be associated with significant weight loss and BP reduction that are
      sustainable over the average time span of an investigational clinical study (ie, 
      3-6 months). When considered in terms of the potential for combination therapy,
      these features may offer a means of further reducing metabolic and CV risk in
      patients with T2DM.
AD  - Professor Emeritus of Emergency Medicine, The Ohio State University, Dublin, OH. 
      robertguthriemd@gmail.com.
FAU - Guthrie, Robert M
AU  - Guthrie RM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2654 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):21-32. doi: 10.3810/pgm.2013.05.2654.

PMID- 23748503
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 125
IP  - 3
DP  - 2013 May
TI  - Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: From risk factors to
      clinical outcomes.
PG  - 7-20
LID - 10.3810/pgm.2013.05.2659 [doi]
AB  - Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are oral incretin-based
      glucose-lowering agents with proven efficacy and safety in the management of type
      2 diabetes mellitus (T2DM). In addition, preclinical data and mechanistic studies
      suggest a possible additional non-glycemic beneficial action on blood vessels and
      the heart, via both glucagon-like peptide-1-dependent and glucagon-like
      peptide-1-independent effects. As a matter of fact, DPP-4 inhibitors improve
      several cardiovascular risk factors: they improve glucose control (mainly by
      reducing the risk of postprandial hyperglycemia) and are weight neutral; may
      lower blood pressure somewhat; improve postprandial (and even fasting) lipemia;
      reduce inflammatory markers; diminish oxidative stress; improve endothelial
      function; and reduce platelet aggregation in patients with T2DM. In addition,
      positive effects on the myocardium have been described in patients with ischemic 
      heart disease. Results of post hoc analyses of phase 2/3 controlled trials
      suggest a possible cardioprotective effect with a trend (sometimes significant)
      toward lower incidence of major cardiovascular events with sitagliptin,
      vildagliptin, saxagliptin, linagliptin, or alogliptin compared with placebo or
      other active glucose-lowering agents. However, the definite relationship between 
      DPP-4 inhibition and better cardiovascular outcomes remains to be proven. Major
      prospective clinical trials involving various DPP-4 inhibitors with predefined
      cardiovascular outcomes are under way in patients with T2DM and a high-risk
      cardiovascular profile: the Sitagliptin Cardiovascular Outcome Study (TECOS) on
      sitagliptin, the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients
      With Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53
      trial on saxagliptin, the Cardiovascular Outcomes Study of Alogliptin in Subjects
      With Type 2 Diabetes and Acute Coronary Syndrome (EXAMINE) trial on alogliptin,
      and the Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in
      Patients With Type 2 Diabetes (CAROLINA) on linagliptin. If these trials confirm 
      that a DPP-4 inhibitor can reduce the cardiovascular burden of T2DM, it would be 
      major progress that would dramatically influence the management of the disease.
AD  - Division of Diabetes, Nutrition and Metabolic Disorders; Division of Clinical
      Pharmacology, Department of Medicine, CHU Sart Tilman, University of Liege,
      Liege, Belgium. andre.scheen@chu.ulg.ac.be.
FAU - Scheen, Andre J
AU  - Scheen AJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.3810/pgm.2013.05.2659 [doi]
PST - ppublish
SO  - Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659.

PMID- 23748486
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
DP  - 2013 Jun 8
TI  - Incidence and predictors of febrile neutropenia during chemotherapy in patients
      with head and neck cancer.
AB  - PURPOSE: Febrile neutropenia (FN) is an oncologic emergency, and its management
      is critical during chemotherapy. However, little is known about FN in patients
      with head and neck cancer. The purpose of this study was to investigate the
      incidence and predictors of FN in patients with head and neck cancer. METHODS: We
      performed a retrospective study in a university hospital in Japan between January
      2008 and December 2012. Head and neck cancer patients treated with a
      platinum-based regimen were included in the analysis. RESULTS: FN occurred in 47 
      out of 138 cycles, and the incidence of FN was highest during the first cycle.
      Severe sepsis or more serious events were observed in 46 % of FN episodes.
      Patients treated with TPF (docetaxel, cisplatin, and fluorouracil) were more
      susceptible to FN than those treated with DC (docetaxel, cisplatin). The
      patient-specific risk factors revealed using univariate analysis were tube
      feeding, the presence of diabetes mellitus, and gastrointestinal adverse effects.
      Of these, logistic regression analysis demonstrated tube feeding and diabetes
      mellitus as independent predictors of FN. CONCLUSIONS: The incidence of FN in
      head and neck cancer patients in the community setting is higher than previously 
      reported. Patients receiving enteral nutrition and those with diabetes are at
      high risk for FN.
AD  - Department of Otolaryngology-Head and Neck Surgery, Osaka University Graduate
      School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan,
      ytakenaka@ent.med.osaka-u.ac.jp.
FAU - Takenaka, Yukinori
AU  - Takenaka Y
FAU - Cho, Hironori
AU  - Cho H
FAU - Yamamoto, Masashi
AU  - Yamamoto M
FAU - Nakahara, Susumu
AU  - Nakahara S
FAU - Yamamoto, Yoshifumi
AU  - Yamamoto Y
FAU - Inohara, Hidenori
AU  - Inohara H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/05 [received]
PHST- 2013/05/29 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s00520-013-1873-9 [doi]
PST - aheadofprint
SO  - Support Care Cancer. 2013 Jun 8.

PMID- 23748438
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1553-0779 (Electronic)
IS  - 1553-0779 (Linking)
VI  - 29
IP  - 1
DP  - 2013
TI  - NIH Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus.
PG  - 1-31
AB  - OBJECTIVE: To provide healthcare providers, patients, and the general public with
      a responsible assessment of currently available data on diagnosing gestational
      diabetes mellitus (GDM). PARTICIPANTS: A non-U.S. Department of Health and Human 
      Services, nonadvocate 15-member panel representing the fields of obstetrics and
      gynecology, maternal-fetal medicine, pediatrics, diabetic research,
      biostatistics, women's health issues, health services research, decision
      analysis, health management and policy, health economics, epidemiology, and
      community engagement. In addition, 16 experts from pertinent fields presented
      data to the panel and conference audience. EVIDENCE: Presentations by experts and
      a systematic review of the literature prepared by the University of Alberta
      Evidence-based Practice Centre, through the Agency for Healthcare Research and
      Quality (AHRQ). Scientific evidence was given precedence over anecdotal
      experience. CONFERENCE PROCESS: The panel drafted its statement based on
      scientific evidence presented in open forum and on published scientific
      literature. The draft statement was posted at http://prevention.nih.gov/ for
      public comment and the panel released a final statement approximately 10 weeks
      later. The final statement is an independent report of the panel and is not a
      policy statement of the NIH or the Federal Government. CONCLUSIONS: At present,
      GDM is commonly diagnosed in the United States using a 1-hour screening test with
      a 50-gram glucose load followed by a 3-hour 100-gram glucose tolerance test (a
      two-step approach) for those found to be abnormal on the screen. This approach
      identifies approximately 5% to 6% of the population as having GDM. In contrast,
      newly proposed diagnostic strategies rely on the administration of a 2-hour
      glucose tolerance test (a one-step approach) with a fasting component and a
      75-gram glucose load. These strategies differ on whether a 1-hour sample is
      included, whether two abnormal values are required, and the diagnostic cutoffs
      that are used. The International Association of Diabetes and Pregnancy Study
      Groups (IADPSG) has proposed diagnostic thresholds based on demonstrated
      associations between glycemic levels and an increased risk of obstetric and
      perinatal morbidities. The panel considered whether a one-step approach to the
      diagnosis of GDM should be adopted in place of the two-step approach. The
      one-step approach offers certain operational advantages. The current two-step
      approach is used only during pregnancy and is largely restricted to the United
      States. There would be value in a consistent, international diagnostic standard
      across one's lifespan. This unification would allow better standardization of
      best practices in patient care and comparability of research outcomes. The
      one-step approach also holds potential advantages for women and their health care
      providers, as it would allow a diagnosis to be achieved within the context of one
      visit as opposed to two. However, the one-step approach, as proposed by the
      IADPSG, is anticipated to increase the frequency of the diagnosis of GDM by
      twofold to threefold, to a prevalence of approximately 15% to 20%. There are
      several concerns regarding the diagnosis of GDM in these additional women. It is 
      not well understood whether the additional women identified by this approach will
      benefit from treatment, and if so, to what extent. Moreover, the care of these
      women will generate additional direct and indirect health care costs. There is
      also evidence that the labeling of these women may have unintended consequences, 
      such as an increase in cesarean delivery and more intensive newborn assessments. 
      In addition, increased patient costs, life disruptions, and psychosocial burdens 
      have been identified. Available studies do not provide clear evidence that a
      one-step approach is cost-effective in comparison with the current two-step
      approach. After much deliberation, the panel believes that there are clear
      benefits to international standardization with regard to the one-step approach.
      Nevertheless, at present, the panel believes that there is not sufficient
      evidence to adopt a one-step approach. The panel is particularly concerned about 
      the adoption of new criteria that would increase the prevalence of GDM, and the
      corresponding costs and interventions, without clear demonstration of
      improvements in the most clinically important health and patient-centered
      outcomes. Thus, the panel recommends that the two-step approach be continued.
      However, given the potential benefits of a one-step approach, resolution of the
      uncertainties associated with its use would warrant revision of this conclusion.
FAU - Vandorsten, James P
AU  - Vandorsten JP
FAU - Dodson, William C
AU  - Dodson WC
FAU - Espeland, Mark A
AU  - Espeland MA
FAU - Grobman, William A
AU  - Grobman WA
FAU - Guise, Jeanne Marie
AU  - Guise JM
FAU - Mercer, Brian M
AU  - Mercer BM
FAU - Minkoff, Howard L
AU  - Minkoff HL
FAU - Poindexter, Brenda
AU  - Poindexter B
FAU - Prosser, Lisa A
AU  - Prosser LA
FAU - Sawaya, George F
AU  - Sawaya GF
FAU - Scott, James R
AU  - Scott JR
FAU - Silver, Robert M
AU  - Silver RM
FAU - Smith, Lisa
AU  - Smith L
FAU - Thomas, Alyce
AU  - Thomas A
FAU - Tita, Alan T N
AU  - Tita AT
LA  - eng
PT  - Journal Article
DEP - 20130306
PL  - United States
TA  - NIH Consens State Sci Statements
JT  - NIH consensus and state-of-the-science statements
JID - 101160100
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 2013-00124-STMT [pii]
PST - epublish
SO  - NIH Consens State Sci Statements. 2013 Mar 6;29(1):1-31.

PMID- 23748430
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1524-4571 (Electronic)
IS  - 0009-7330 (Linking)
DP  - 2013 Jun 7
TI  - A Novel Mouse Model of Atherosclerotic Plaque Instability for Drug Testing and
      Mechanistic/Therapeutic Discoveries Using Gene and microRNA Expression Profiling.
AB  - Rationale: The high morbidity/mortality of atherosclerosis is typically
      precipitated by plaque rupture and consequent thrombosis. However, research on
      underlying mechanisms and therapeutic approaches is limited by the lack of animal
      models that reproduce plaque instability observed in humans. Objective:
      Development and utilization of a mouse model of plaque rupture that reflects the 
      end stage of human atherosclerosis. Methods and Results: Based on flow
      measurements and computational fluid dynamics, we applied a tandem stenosis to
      the carotid artery of ApoE-/- mice on high fat diet. At 7 weeks postoperatively, 
      we observed intraplaque hemorrhage in ~50% of mice, as well as disruption of
      fibrous caps, intra notluminal thrombosis, neovascularization and further
      characteristics typically seen in human unstable plaques. Administration of
      atorvastatin was associated with plaque stabilization and down regulation of
      MCP-1 and ubiquitin. Microarray profiling of mRNA and microRNA and in particular 
      its combined analysis demon notstrated major differences in the hierarchical
      clustering of genes and microRNAs between non-atherosclerotic arteries, stable
      and unstable plaques and allows the identification of distinct genes/microRNAs,
      potentially representing novel therapeutic targets for plaque stabilization. The 
      feasibility of the described animal model as a discovery tool was established in 
      a pilot approach, identifying ADAMTS4 and miR-322 as potential pathogenic factors
      of plaque instability in mice and validated in human plaques. Conclusions: The
      newly described mouse model reflects human atherosclerotic plaque instability and
      represents a discovery tool towards the development and testing of therapeutic
      strategies aimed at preventing plaque rupture. Distinctly expressed genes and
      microRNAs can be linked to plaque instability.
AD  - Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road Central,
      Melbourne, N/A, x, AUSTRALIA.
FAU - Peter, Karlheinz
AU  - Peter K
FAU - Chen, Yung-Chih
AU  - Chen YC
FAU - Bui, Anh Viet
AU  - Bui AV
FAU - Diesch, Jeannine
AU  - Diesch J
FAU - Manasseh, Richard
AU  - Manasseh R
FAU - Hausding, Christian
AU  - Hausding C
FAU - Rivera, Jennifer
AU  - Rivera J
FAU - Haviv, Izhak
AU  - Haviv I
FAU - Agrotis, Alex
AU  - Agrotis A
FAU - Htun, Nay Min
AU  - Htun NM
FAU - Jowett, Jeremy
AU  - Jowett J
FAU - Hagemeyer, Christoph Eugen
AU  - Hagemeyer CE
FAU - Hannan, Ross D
AU  - Hannan RD
FAU - Bobik, Alex
AU  - Bobik A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Circ Res
JT  - Circulation research
JID - 0047103
OTO - NOTNLM
OT  - animal model cardiovascular disease
OT  - atherosclerosis
OT  - gene expression profiling
OT  - inflammation
OT  - microRNA profiling
OT  - mouse model
OT  - plaque instability
OT  - plaque rupture
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - CIRCRESAHA.113.301562 [pii]
AID - 10.1161/CIRCRESAHA.113.301562 [doi]
PST - aheadofprint
SO  - Circ Res. 2013 Jun 7.

PMID- 23748392
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1172-6156 (Electronic)
IS  - 1172-6156 (Linking)
VI  - 5
IP  - 2
DP  - 2013
TI  - Understanding barriers to glycaemic control from the patient's perspective.
PG  - 114-22
AB  - INTRODUCTION: To better understand barriers to glycaemic control from the
      patient's perspective. METHODS: An interpretative phenomenological approach was
      used to study the experiences of 15 adults with Type 2 diabetes. Participants
      each gave a semi-structured interview of their experiences of living with
      diabetes. Interviews were transcribed, and themes extracted and organised using a
      patientcentred framework. FINDINGS: Participants' stories confirmed many of the
      barriers in the literature, particularly those related to context, such as
      family, finances, work. Barriers also related to negative emotional reactions to 
      diabetes: fear of new events (diagnosis, starting pills/insulin); guilt about
      getting diabetes and not controlling it; and shame about having diabetes.
      Barriers also related to unscientific beliefs and personal beliefs. There were
      additional barriers related to poor clinician-patient relationships. Overall,
      participants had a poor understanding of diabetes, and complained that their
      clinician simply 'told them what to do'. CONCLUSION: Using a patient-centred
      approach, this study identified many barriers to glycaemic control. We suggest
      that a key barrier is clinician ignorance of their patients' fears, beliefs,
      expectations, context; of what constitutes a positive therapeutic relationship;
      and of the limitations of a biomedical approach to patient non-adherence. Faced
      with both a worsening diabetes epidemic and increasing health care workforce
      shortages, clinicians urgently need to understand that it is they, not their
      patients, who must change their approach if diabetes care is to be improved.
AD  - Wairoa Medical Centre, 24 Kitchener St, PO Box 341, Wairoa, New Zealand.
      ronjanes@xtra.co.nz.
FAU - Janes, Ron
AU  - Janes R
FAU - Titchener, Janet
AU  - Titchener J
FAU - Pere, Joseph
AU  - Pere J
FAU - Pere, Rose
AU  - Pere R
FAU - Senior, Joy
AU  - Senior J
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - New Zealand
TA  - J Prim Health Care
JT  - Journal of primary health care
JID - 101524060
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - epublish
SO  - J Prim Health Care. 2013 Jun 1;5(2):114-22.

PMID- 23748390
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1172-6156 (Electronic)
IS  - 1172-6156 (Linking)
VI  - 5
IP  - 2
DP  - 2013
TI  - The impact of patient and practice characteristics on retention in the diabetes
      annual review programme.
PG  - 99-104
AB  - INTRODUCTION: Despite more than 10 years of the diabetes annual review (DAR)
      programme, ensuring the annual return of diabetic patients for review remains a
      challenge for primary care. Regardless of future arrangements for diabetes review
      programmes, regular review of patients remains clinically important. AIM: To
      investigate the effect of patient and practice characteristics on the retention
      of patients continuously enrolled with the same practice in the DAR programme.
      METHODS: We undertook a retrospective, observational study of a cohort of
      enrolled diabetic patients who had a DAR in the July 2006 - June 2007 reporting
      year and remained enrolled with the same practice for the following three years. 
      Controlling for death and migration, retention rates were calculated for age,
      gender, ethnicity, rurality, practice funding type and practice nurse (PN) to
      general practitioner (GP) ratio. RESULTS: The study included data from 78
      practices and 6610 patients with Type 2 diabetes. Non-Maori and those aged 60
      years and over were more likely to be retained in the programme. For practice
      factors, those with a higher PN to GP ratio had a significant retention
      advantage. Rurality and funding type was not shown to have a significant role in 
      retention. DISCUSSION: Results support the view that both patient and practice
      factors influence a patient's retention within the DAR programme. The PN to GP
      ratio may be an important factor in the retention of patients in a DAR programme 
      and warrants further research and consideration when planning future primary care
      models.
AD  - Midlands Health Network, PO Box 983, Hamilton 3240, New Zealand.
      rawiri.keenan@midlandshn.health.nz.
FAU - Keenan, Rawiri
AU  - Keenan R
FAU - Amey, Janet
AU  - Amey J
FAU - Lawrenson, Ross
AU  - Lawrenson R
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - New Zealand
TA  - J Prim Health Care
JT  - Journal of primary health care
JID - 101524060
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - epublish
SO  - J Prim Health Care. 2013 Jun 1;5(2):99-104.

PMID- 23748285
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 104
IP  - 3
DP  - 2013 Jun
TI  - Association between fetal overgrowth and metabolic parameters in cord blood of
      newborns of women with GDM.
PG  - 317-24
AB  - Aim: There is evidence that arthrosclerosis may originate at birth, so assessment
      of serum lipid levels in cord blood might be important. The aim of this study was
      to investigate the association between fetal overgrowth and metabolic parameters 
      in cord blood of newborns of women with gestational diabetes mellitus (GDM) and
      to compare these parameters with those in newborns of non-diabetic. Methods: The 
      study group included 112 women (singleton pregnancy, and GDM diagnosed following 
      WHO criteria), and as controlled subjects, 159 matched healthy pregnant women and
      their newborn babies were selected. A sample of cord blood was obtained at
      delivery. The cord blood's insulin, glucose, and lipids (total cholesterol,
      high-density cholesterol, low- density cholesterol, and triglyceride) were
      determined. The relationships between these metabolic parameters and large for
      gestational age (LGA) were also assessed. Results: There were no significant
      differences between total cholesterol (TC), HDL cholesterol (HDL -C),
      triglyceride (TG) and glucose levels between two groups but the LDL-C level,
      LDL/HDL ratio and insulin level were significantly higher in newborns of mother
      with GDM. LGA newborns of diabetic mothers, show the HDL-C level were
      significantly lower and LDL-C level were significantly higher than AGA
      (Appropriate for Gestational Age). Conclusion: These results show that GDM
      altered neonatal plasma lipids metabolism and so newborns of diabetic mothers may
      be predisposed early in life to LDL hypercholesterolemia and thus may be at a
      greater risk of developing coronary heart disease later in life.
AD  - Perinatology Division, Obstetrics and Gynecology Department, University of
      Medical Sciences, Tehran, Iran - dr_akbari_s@yahoo.com.
FAU - Eslamian, L
AU  - Eslamian L
FAU - Akbari, S
AU  - Akbari S
FAU - Marsoosi, V
AU  - Marsoosi V
FAU - Jamal, A
AU  - Jamal A
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - R10Y2013N03A0317 [pii]
PST - ppublish
SO  - Minerva Med. 2013 Jun;104(3):317-24.

PMID- 23748283
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 104
IP  - 3
DP  - 2013 Jun
TI  - Evidences of dual role of vitamin D through cellular energy homeostasis and
      inflammation pathway in risk of cancer in obese subjects.
PG  - 295-307
AB  - Aim: The underlying molecular mechanisms of the role obesity plays in increasing 
      the risk of cancer are not well illuminated. Several mechanisms are proposed for 
      vitamin D as an anti-cancer agent in various malignancies which may be attributed
      to both its both its anti-inflammatory characteristics as well as its mediatory
      role in cellular energy homeostasis. This study evaluates the expression of
      PBMCs' genes which are involved in cellular energy homeostasis such as VDR,
      PPARgamma, PGC1a and UCP2. Moreover, considering the possible role of vitamin D
      in the inflammation mechanisms, we also aimed at measurement of some inflammatory
      mediators such as TNF-alpha, IL-1beta, IL4, IL-6, IL10, IL13 and IL17 in
      inflammatory state in samples obtained from obese persons with and without
      positive family history of cancer. Moreover, to expand the study to a clinical
      context, we assessed the correlation of the resting metabolic rate with the
      evaluated gene. Methods: A total of 274 obese women were included in the current 
      cross-sectional study. All of participants were class I obese. By constructing a 
      pedigree that includes 3 generations, twenty-one subjects were at increased risk 
      because of a positive family history of colorectal cancer. Accordingly, current
      study's analysis was based on positive and negative family history of colorectal 
      cancer. Results: The concentration of Insulin and PTH were significantly high in 
      group with positive history of cancer. 25 (OH) vitamin D, REE/kg and REE/FFM
      statuses in two groups; the level of mentioned terms were lower in group with
      positive history of cancer compared to group with negative history of cancer. We 
      found significantly lower REE/kg in deficiency of vitamin D and higher REE/kg in 
      sufficiency status. Our results demonstrated significant higher concentrations of
      IL1beta, IL17, TNFalpha and IL6 in group with positive history of cancer compared
      to group with negative history of cancer. The concentrations of IL13, IL10 and
      IL4 were significantly lower in group with positive history of cancer compared to
      group with negative history of cancer. The relative expression of VDR,
      PGC1alphaand PPARgamma gene was significantly lower in group with positive
      history of cancer. The relative expression of UCP2 was almost significantly
      lesser in group with positive history of cancer also. Conclusion: The observed
      mutual alteration in the levels of inflammatory markers and relative expression
      of important gene in energy homeostasis may be caused by vitamin D deficiency
      among the obese subjects with positive history of colorectal cancer.
AD  - Section of Endocrinology, Nutrition, and Diabetes, Vitamin D, Skin and Bone
      Research Laboratory, Tehran University of Medical Sciences, Tehran, Iran -
      arashh@bu.edu.
FAU - Hossein-Nezhad, A
AU  - Hossein-Nezhad A
FAU - Mirzaei, K
AU  - Mirzaei K
FAU - Keshavarz, S A
AU  - Keshavarz SA
FAU - Ansar, H
AU  - Ansar H
FAU - Saboori, S
AU  - Saboori S
FAU - Tootee, A
AU  - Tootee A
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - R10Y2013N03A0295 [pii]
PST - ppublish
SO  - Minerva Med. 2013 Jun;104(3):295-307.

PMID- 23748282
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0026-4806 (Print)
IS  - 0026-4806 (Linking)
VI  - 104
IP  - 3
DP  - 2013 Jun
TI  - Effects of omega-3 polyunsaturated fatty acid supplementation on serum fetuin-A
      levels in type 2 diabetic patients.
PG  - 287-93
AB  - Fetuin-A is an endogenous inhibitor of the insulin-stimulated insulin receptor
      tyrosine kinase recently shown that high levels of circulating fetuin-A are
      associated with insulin resistance in humans suggesting that fetuin-A may
      represent a novel mechanism involved in the pathophysiology of type 2 diabetes
      (T2DM). Dietary omega-3 polyunsaturated fatty acids (n-3 PUFAs) are known to
      reduce triglyceride levels, but their impact on glycemic control are not well
      known. The aim of this study to determine the effects of omega-3 PUFA
      supplementation on fetuin-A and glycemic control in patients with type 2 diabetes
      mellitus. 40 T2DM patients (17 males/23 females; aged 39-65 years) were included 
      in the study. Serum fetuin-A levels and metabolic and biochemical profiles were
      measured before (baseline) and two months after n-3 PUFA supplementations (1.2
      g/day). Serum fetuin-A levels were measured by enzyme-linked immunosorbent assay.
      Our results indicated that serum fetuin-A, fasting glucose, HbA1c and
      triglyceride levels were significantly decreased after supplementation (P<0.02,
      P<0.001, P<0.02 and P<0.01, respectively). At baseline, serum fetuin-A levels
      were correlated with HbA1c (r:-0.391, P<0.04). A significant positive correlation
      between fetuin-A and both triglycerides (r: 0.343, P<0.05) and total cholesterol 
      (r: 0.330, P<0.05) and negative correlation between fetuin-A and fasting glucose 
      (r: -0.405, P<0.01) were found after the supplementations. When performed
      multiply regression analysis, we found that serum fetuin-a levels were related
      with triglyceride levels (r: 0.351, P<0.01) at baseline and HbA1c levels (r:
      0.344, P<0.04) after the supplementation. Based on the results, it thought that
      omega-3 PUFA intake decreases serum fetuin-A levels and serum fetuin-A is
      associated with plasma lipids and glycemic controls in type 2 diabetic patients. 
      Further studies are required to resolve the question.
AD  - Department of Pharmacology and Clinical Pharmacology, Cerrahpasa Faculty of
      Medicine, Istanbul University, Istanbul, Turkey - ozyazgans@yahoo.com.
FAU - Ozyazgan, S
AU  - Ozyazgan S
FAU - Karaoglu, K
AU  - Karaoglu K
FAU - Kurt, A
AU  - Kurt A
FAU - Altinok, A
AU  - Altinok A
FAU - Konukoglu, D
AU  - Konukoglu D
FAU - Osar Siva, Z
AU  - Osar Siva Z
FAU - Andican, G
AU  - Andican G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - R10Y2013N03A0287 [pii]
PST - ppublish
SO  - Minerva Med. 2013 Jun;104(3):287-93.

PMID- 23748249
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1349-9092 (Electronic)
IS  - 0917-5040 (Linking)
DP  - 2013 Jun 8
TI  - Nutritional Epidemiology of Type 2 Diabetes and Depressive Symptoms.
AB  - In Japan, the prevalences of type 2 diabetes and depression are increasing, but
      evidence linking these diseases to diet is limited. The present study reviewed
      the association of type 2 diabetes with intakes of rice, fish/seafood, and soy
      product and isoflavone, and the association of depressive symptoms with folate,
      vitamin D, and dietary pattern, in the Japanese population. The analysis of type 
      2 diabetes comprised around 55 000 men and women aged 45 to 75 years who
      completed a questionnaire for the Japan Public Health Center-based Prospective
      Study and were free of type 2 diabetes at baseline. The odds ratio of
      self-reported physician-diagnosed type 2 diabetes during the subsequent 5 years
      increased with rice intake among women and among physically inactive men but
      decreased with total fish/seafood intake among men. In addition, risk tended to
      decrease with soy product and isoflavone intake among overweight and
      postmenopausal women. Depressive symptoms were assessed using the Center for
      Epidemiologic Studies Depression Scale. The participants were approximately 530
      workers aged 21 to 67 years who participated in a health survey at the time of a 
      periodic health check. A cross-sectional and prospective inverse association
      between serum folate and depressive symptoms was observed. Serum
      25-hydroxyvitamin D level was suggestively associated with decreased prevalence
      of depressive symptoms in late autumn. In addition, a healthy Japanese
      pattern-characterized by high intakes of vegetables, fruit, mushrooms, and soy
      products-was inversely associated with depressive symptoms. The findings suggest 
      that diet has a role in the development of type 2 diabetes and depression in
      Japanese.
AD  - Department of Epidemiology and Prevention, Clinical Research Center, National
      Center for Global Health and Medicine.
FAU - Nanri, Akiko
AU  - Nanri A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - J Epidemiol
JT  - Journal of epidemiology / Japan Epidemiological Association
JID - 9607688
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - DN/JST.JSTAGE/jea/JE20130018 [pii]
PST - aheadofprint
SO  - J Epidemiol. 2013 Jun 8.

PMID- 23748164
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1945-4589 (Electronic)
IS  - 1945-4589 (Linking)
DP  - 2013 May 25
TI  - FOXO1 regulates expression of a microRNA cluster on X chromosome.
AB  - Phosphoinositol-3-kinase (PI3K) pathway is a crucial modulator of many
      physiological and pathophysiological phenomena, including aging, diabetes and
      cancer. Protein kinase Akt, a downstream effector of PI3K, controls a plethora of
      cellular functions, including gene transcription. A key mechanism connecting Akt 
      activity to changes in gene expression is inhibitory phosphorylation of FOXO
      family of transcription factors. Accordingly, altered expression of FOXO targets 
      may account for many biological consequences of PI3K/Akt signaling. While the
      previous efforts focused on FOXO-dependent regulation of protein-coding genes,
      non-coding RNA genes have emerged as equally important targets of many
      transcription factors. Therefore, we utilized a regulated form of FOXO1 to
      profile FOXO1-dependent changes in miRNA expression in human cells. Both
      microarray hybridization and next-generation sequencing revealed changes in the
      products of a miRNA cluster on X chromosome. Rapid induction of these miRNAs
      occurred independently of de novo protein synthesis. Furthermore, inhibition of
      PI3K in cancer cell lines caused derepression of these miRNAs, as would be
      expected for FOXO-regulated genes. Members of the major oncogenic cascades are
      significantly overrepresented among the predicted targets of the miRNAs,
      consistent with tumor-suppressive role of FOXO1. The discovered miRNAs represent 
      new candidate mediators of FOXO1 functions and possible biomarkers of its
      activity.
AD  - Department of Cell Stress Biology, Roswell Park Cancer Institute, BLSC L3-318,
      Buffalo, NY 14263, USA.
FAU - Singhal, Ruchi
AU  - Singhal R
FAU - Bard, Jonathan E
AU  - Bard JE
FAU - Nowak, Norma J
AU  - Nowak NJ
FAU - Buck, Michael J
AU  - Buck MJ
FAU - Kandel, Eugene S
AU  - Kandel ES
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Aging (Albany NY)
JT  - Aging
JID - 101508617
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 100558 [pii]
PST - aheadofprint
SO  - Aging (Albany NY). 2013 May 25.

PMID- 23748147
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1438-8871 (Electronic)
IS  - 1438-8871 (Linking)
VI  - 15
IP  - 6
DP  - 2013
TI  - The conceptual and practical ethical dilemmas of using health discussion board
      posts as research data.
PG  - e112
LID - 10.2196/jmir.2435 [doi]
AB  - BACKGROUND: Increasing numbers of people living with a long-term health condition
      are putting personal health information online, including on discussion boards.
      Many discussion boards contain material of potential use to researchers; however,
      it is unclear how this information can and should be used by researchers. To date
      there has been no evaluation of the views of those individuals sharing health
      information online regarding the use of their shared information for research
      purposes. OBJECTIVE: To explore the views of contributors to online diabetes
      discussion boards with regards to if (and how) they feel their contributions to
      boards should be used by health researchers. METHODS: A qualitative approach was 
      employed using online semistructured asynchronous (email) interviews.
      Interpretative description methodology was used to assess the interview
      transcripts, and quotations were extracted and anonymized to support each theme. 
      RESULTS: 26 interviews were carried out. Participants agreed that forum posts are
      in the public domain and that aggregated information could be freely used by
      researchers. This was agreed to be a good way of ensuring that the view of people
      living with diabetes is being heard in research. There was no consensus on the
      need for permission to use individual information, such as quotations, with some 
      people happy for this to be freely used and others feeling that permission is
      necessary. CONCLUSIONS: Participants acknowledged the dichotomy of having placed 
      information into the public domain in an unrestricted way, with some interviewees
      also wanting to retain control of its use. The Internet is a new research
      location, and rather than trying to apply traditional ethical norms to this new
      genre, a new modus operandi is required. The authors propose introducing new
      norms for presenting research carried out with online discussion boards.
AD  - School of Health and Social Care, Bournemouth University, Bournemouth, United
      Kingdom. cbond@bournemouth.ac.uk.
FAU - Bond, Carol S
AU  - Bond CS
FAU - Ahmed, Osman Hassan
AU  - Ahmed OH
FAU - Hind, Martin
AU  - Hind M
FAU - Thomas, Bronwen
AU  - Thomas B
FAU - Hewitt-Taylor, Jaqui
AU  - Hewitt-Taylor J
LA  - eng
PT  - Journal Article
DEP - 20130607
PL  - Canada
TA  - J Med Internet Res
JT  - Journal of medical Internet research
JID - 100959882
SB  - IM
OTO - NOTNLM
OT  - health
OT  - research design
OT  - research ethics
OT  - social media
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/13 [received]
PHST- 2013/03/28 [accepted]
PHST- 2013/02/25 [revised]
AID - v15i6e112 [pii]
AID - 10.2196/jmir.2435 [doi]
PST - epublish
SO  - J Med Internet Res. 2013 Jun 7;15(6):e112. doi: 10.2196/jmir.2435.

PMID- 23748128
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?
PG  - f3680
LID - 10.1136/bmj.f3680 [doi]
LID - bmj.f3680 [pii]
AD  - BMJ, London WC1H 9JR, UK.
FAU - Cohen, Deborah
AU  - Cohen D
LA  - eng
PT  - Journal Article
DEP - 20130607
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - epublish
SO  - BMJ. 2013 Jun 7;346:f3680. doi: 10.1136/bmj.f3680.

PMID- 23748127
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 28
IP  - 6
DP  - 2013 Jun
TI  - Improving student knowledge in medication management through an advanced pharmacy
      practice experience.
PG  - 390-5
LID - 10.4140/TCP.n.2013.390 [doi]
AB  - Objectives: To assess the impact of an advanced pharmacy practice rotation on
      student therapeutic knowledge, confidence in performing medication therapy
      management (MTM), and ability to use MTM documentation platforms.Design:
      Pretest/post-test quasi-experiment.Setting: This study was conducted at the
      InterNational Center for Advanced Pharmacy Services (INCAPS), a licensed pharmacy
      that provides MTM services to geriatric patients in Louisville,
      Kentucky.Patients, Participants: This research evaluated 37 advanced pharmacy
      practice students who participated in the five-week learning rotation at INCAPS
      between October 1, 2011, and June 30, 2012.Interventions: Thirty-seven students
      were tested before (pretest) beginning the rotation. During the rotation,
      students performed daily MTM consultations and participated in weekly topic
      discussions pertaining to relevant areas of chronic disease management and
      geriatric pharmacotherapy. Following the five-week rotation, a post-test was
      administered to these 37 students to analyze the changes in their knowledge.Main 
      Outcome Measures: The primary outcome measure was the test score for the
      assessment of chronic disease management and geriatric pharmacotherapy.Results:
      Compared with baseline, post-test scores showed a statistically significant
      improvement in the areas that were assessed-osteoporosis, hypertension, diabetes,
      asthma/chronic obstructive pulmonary disease, and inappropriate medication use in
      the elderly. A post-rotation survey also reflected positive improvements in
      student confidence when performing MTM consults for geriatric
      patients.Conclusions: The five-week MTM-focused rotation at INCAPS with weekly
      topic discussions and daily MTM consults showed a positive impact on students'
      ability to manage medication therapy for chronically ill and geriatric patients.
AD  - The InterNational Center for Advanced Pharmacy Services (INCAPS), Sullivan
      University College of Health Sciences, Louisville, Kentucky.
FAU - Childress, Bc
AU  - Childress B
FAU - Bosler, Julie N
AU  - Bosler JN
FAU - Beck, Morgan
AU  - Beck M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant
      Pharmacists
JID - 9013983
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - Q871H56474522480 [pii]
AID - 10.4140/TCP.n.2013.390 [doi]
PST - ppublish
SO  - Consult Pharm. 2013 Jun;28(6):390-5. doi: 10.4140/TCP.n.2013.390.

PMID- 23748125
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 28
IP  - 6
DP  - 2013 Jun
TI  - Demographic and clinical profile of nursing facility residents with gout.
PG  - 370-82
LID - 10.4140/TCP.n.2013.370 [doi]
AB  - Objective: To develop a demographic and clinical profile of nursing facility
      residents with a diagnosis of gout.Design: Descriptive, retrospective database
      analysis.Setting: U.S. nursing facilities.Patients, Participants: Nursing
      facility residents with a diagnosis of gout.Interventions: Minimum Data Set and
      prescription claims records of residents served by Omnicare, Inc., with an
      International Classification of Diseases Ninth Revision, Clinical Modification
      (ICD-9-CM) diagnosis of gout, for the time period of October 1, 2009, to
      September 30, 2010, were linked and de-identified. Acute gouty attacks were
      defined by a proxy measure of a ? 14-day course of oral nonsteroidal
      anti-inflammatory drugs (NSAIDs), oral or injectable steroids, or oral
      colchicine.Results: In the 138,724 residents (36.8% male: 76.8% white, 11.6%
      black) evaluated, the incidence of gout was 1.8% (n = 2,487). Of those with gout,
      males and females were represented relatively equally. There were 1,420 (57.2%)
      residents 80 years of age or older. Two-thirds of residents with gout required at
      least extensive assistance with most activities of daily living. Comorbid
      conditions-hypertension (82.2%), diabetes mellitus (46.6%), arthritis (43.7%),
      and renal failure (22.4%)-were common. Pain was reported in 68.7% of residents.
      Allopurinol (60.2%), colchicine (18.6%), febuxostat (2.3%), probenecid (1.1%),
      and probenecid/colchicine (< 1%) were prescribed in treated residents. While
      treatment may or may not have been indicated, 375/2,152 (17.4%) received no
      treatment. Diuretic therapy was received by 75.8% of residents. Acute gouty
      attacks were noted in 38% of residents; 53%, 25.2%, and 21.8% received
      short-course treatment with oral or injectable steroids, oral colchicines, or
      oral NSAIDs, respectively.Conclusions: Despite the limitations of a retrospective
      database analysis, this study reveals that nursing facility residents with a
      diagnosis of gout have significant disease burden. Clinicians should be aware of 
      the potential impact of this disease on physical functioning, pain, and falls in 
      this often-frail population.
AD  - Clinical Services, Omnicare, Inc., Livonia, Michigan College of Pharmacy and
      Health Sciences, Wayne State University, Detroit, Michigan.
FAU - Zarowitz, Barbara J
AU  - Zarowitz BJ
FAU - O'Shea, Terrence E
AU  - O'Shea TE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant
      Pharmacists
JID - 9013983
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - H8577J4J322U111X [pii]
AID - 10.4140/TCP.n.2013.370 [doi]
PST - ppublish
SO  - Consult Pharm. 2013 Jun;28(6):370-82. doi: 10.4140/TCP.n.2013.370.

PMID- 23748122
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 28
IP  - 6
DP  - 2013 Jun
TI  - Wound care basics for the pharmacist.
PG  - 344-52
LID - 10.4140/TCP.n.2013.344 [doi]
AB  - Elderly skin is prone to wounds as a result of age-related changes and
      comorbidities such as diabetes and vascular disease. Wound healing is a complex
      process that can become compromised, leading to the development of chronic,
      nonhealing wounds in a frail elderly patient. Pharmacists and other practitioners
      who care for the elderly should be attuned to the wound-healing process and to
      the types of medications and wound care products available to aid healing.
AD  - Greensboro, North Carolina.
FAU - Martin, Caren McHenry
AU  - Martin CM
FAU - Hawkins, Lauren
AU  - Hawkins L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant
      Pharmacists
JID - 9013983
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 93Q586075147P0J7 [pii]
AID - 10.4140/TCP.n.2013.344 [doi]
PST - ppublish
SO  - Consult Pharm. 2013 Jun;28(6):344-52. doi: 10.4140/TCP.n.2013.344.

PMID- 23748113
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1872-6623 (Electronic)
IS  - 0304-3959 (Linking)
DP  - 2013 Jun 5
TI  - Objective evidence that small-fiber polyneuropathy underlies some illnesses
      currently labeled as fibromyalgia.
LID - S0304-3959(13)00294-7 [pii]
LID - 10.1016/j.pain.2013.06.001 [doi]
AB  - Fibromyalgia is a common, disabling, syndrome that includes chronic widespread
      pain plus other diverse symptoms. No specific objective abnormalities have been
      identified, precluding definitive testing, disease-modifying treatments, and
      identification of causes. In contrast, small-fiber polyneuropathy (SFPN), despite
      causing similar symptoms, is definitionally a disease caused by dysfunction and
      degeneration of peripheral small-fiber neurons. SFPN has established etiologies, 
      some diagnosable and definitively treatable, e.g., diabetes. To evaluate the
      hypothesis that some patients labeled with "fibromyalgia" have unrecognized SFPN 
      causing their illness symptoms, we analyzed SFPN-associated symptoms, signs, and 
      pathological and physiological markers in 27 fibromyalgia patients and 30 matched
      normal controls. Fibromyalgia subjects had to satisfy American College of
      Rheumatology criteria plus document actual fibromyalgia diagnoses. Study
      instruments comprised the Michigan Neuropathy Screening Instrument (MNSI), the
      Utah Early Neuropathy Scale (UENS), distal-leg neurodiagnostic skin biopsies,
      plus autonomic-function testing (AFT). 41% of skin biopsies from fibromyalgia
      subjects vs. 3% of biopsies from control subjects were diagnostic for SFPN, and
      MNSI and UENS scores were higher among fibromyalgia than control subjects (all P 
      0.001). Abnormal AFTs were equally prevalent suggesting that
      fibromyalgia-associated SFPN is primarily somatic. Blood tests from all 13
      fibromyalgia subjects with SFPN-diagnostic skin biopsies provided insights into
      etiologies. All glucose tolerance tests were normal, but eight subjects had
      dysimmune markers, 2 had hepatitis C serologies, and one family had apparent
      genetic causality. These findings suggest that some pain patients labeled with
      "fibromyalgia" have unrecognized small-fiber polyneuropathy, a distinct disease
      that can be objectively tested for and sometimes definitively treated.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts, 02114; Department of Pathology (Neuropathology),
      Massachusetts General Hospital, Boston, Massachusetts, 02114. Electronic address:
      aoaklander@partners.org.
FAU - Oaklander, Anne Louise
AU  - Oaklander AL
FAU - Herzog, Zeva Daniela
AU  - Herzog ZD
FAU - Downs, Heather
AU  - Downs H
FAU - Klein, Max M
AU  - Klein MM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Pain
JT  - Pain
JID - 7508686
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/07 [received]
PHST- 2013/05/10 [revised]
PHST- 2013/06/03 [accepted]
AID - S0304-3959(13)00294-7 [pii]
AID - 10.1016/j.pain.2013.06.001 [doi]
PST - aheadofprint
SO  - Pain. 2013 Jun 5. pii: S0304-3959(13)00294-7. doi: 10.1016/j.pain.2013.06.001.

PMID- 23748069
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1308-5735 (Electronic)
VI  - 5
IP  - 2
DP  - 2013 Jun 6
TI  - Diabetic ketoacidosis presenting with pseudonormoglycemia in a 15-year-old girl
      with type 1 diabetes mellitus.
PG  - 133-5
LID - 10.4274/Jcrpe.905 [doi]
AB  - Pseudonormoglycemic diabetic ketoacidosis (DKA) is a rare condition and has been 
      reported only in a few adult patients. We present a 15-year-old girl with a
      9-year history of type 1 diabetes who presented with euglycemic and extreme
      hypertriglyceridemia. The acidosis and hypertriglyceridemia resolved with
      intravenous insulin therapy and rehydration. Hyperlipidemia was the apparent
      cause of pseudonormoglycemia in this patient. The findings in the present case
      demonstrate that also in children, DKA can rarely occur without abnormal blood
      glucose levels. Assessment of the acid-base status, urinary glucose, and ketone
      readings is therefore important in all diabetic patients who are unwell at
      admission and have normal glucose levels. In such patients, hyperlipidemia may
      cause pseudonormoglycemia. An awareness of this rare treatable life-threatening
      condition is important.
AD  - Izmir Katip Celebi University Faculty of Medicine, Department of Pediatric
      Endocrinology, Izmir, Turkey. bumindundar@gmail.com.
FAU - Akbay, Sinem
AU  - Akbay S
FAU - Yel, Arda
AU  - Yel A
FAU - Yildirimer, Ulku
AU  - Yildirimer U
FAU - Can, Sule
AU  - Can S
FAU - Dundar, Bumin
AU  - Dundar B
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - J Clin Res Pediatr Endocrinol
JT  - Journal of clinical research in pediatric endocrinology
JID - 101519456
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.4274/Jcrpe.905 [doi]
PST - ppublish
SO  - J Clin Res Pediatr Endocrinol. 2013 Jun 6;5(2):133-5. doi: 10.4274/Jcrpe.905.

PMID- 23748067
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1308-5735 (Electronic)
VI  - 5
IP  - 2
DP  - 2013 Jun 6
TI  - Transient Neonatal Diabetes Mellitus in a Turkish Patient with Three Novel
      Homozygous Variants in the ZFP57 Gene.
PG  - 125-8
LID - 10.4274/Jcrpe.928 [doi]
AB  - Neonatal diabetes mellitus (NDM) is a rare form of diabetes that presents within 
      the first six months of life. Nearly 70% of these cases have loss of methylation 
      at the differentially methylated region on chromosome 6q24. To describe the
      findings in a Turkish male patient with NDM caused by a loss of methylation at
      chromosome 6q24 and three novel homozygous mutations in the ZFP57 gene,
      methylation-specific PCR was carried out at 6q24 and mutation analysis of ZFP57
      gene was maintained by direct sequencing. Sequencing of ZFP57 gene revealed the
      hypomethylation of chromosome 6q24 and three novel mutations (chr6:29.641.413
      A>T, 29.641.073 C>T, and 29.640.855 G>C), respectively. The latter mutation seems
      to display the patient's condition due to a highly conservative amino acid
      substitution in the protein. We suggest the ZFP57 gene as a causative factor for 
      NDM and it should be considered in genetic testing. Further studies including
      functional analysis of the detected mutations will provide precise information
      regarding the effect of the mutations.
AD  - Uskudar University, Faculty of Engineering and Natural Sciences, Department of
      Molecular Biology and Genetics, Istanbul, Turkey. korkutulucan@hotmail.com.
FAU - Boyraz, Mehmet
AU  - Boyraz M
FAU - Ulucan, Korkut
AU  - Ulucan K
FAU - Taskin, Necati
AU  - Taskin N
FAU - Akcay, Teoman
AU  - Akcay T
FAU - Flanagan, Sarah E
AU  - Flanagan SE
FAU - Mackay, Deborah J G
AU  - Mackay DJ
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - J Clin Res Pediatr Endocrinol
JT  - Journal of clinical research in pediatric endocrinology
JID - 101519456
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.4274/Jcrpe.928 [doi]
PST - ppublish
SO  - J Clin Res Pediatr Endocrinol. 2013 Jun 6;5(2):125-8. doi: 10.4274/Jcrpe.928.

PMID- 23748062
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1308-5735 (Electronic)
VI  - 5
IP  - 2
DP  - 2013 Jun 6
TI  - Incidence of type 1 diabetes mellitus in Turkish children from the southeastern
      region of the country: a regional report.
PG  - 98-103
LID - 10.4274/Jcrpe.954 [doi]
AB  - Objective: Variability in the incidence of type 1 diabetes mellitus (T1DM)
      related to geographical region, ethnic background, gender, and age indicates a
      need for further epidemiological studies. To date, there are no reported studies 
      on the incidence of T1DM in the pediatric age group from the Southeastern region 
      of Turkey. To define the incidence, demographic and clinical characteristics of
      T1DM in children 0-14 years of age in Diyarbakir, one of the largest cities in
      the Southeast region of Turkey.Methods: Hospital files of patients with the
      diagnosis of T1DM were reviewed. Data of all patients diagnosed between 1 June
      2010 and 31 May 2011 were evaluated. Population data on the 0-14 age group were
      obtained from the Turkish Statistical Institute (TSI) reports.Results: From a
      total of 41 T1DM patients, 24 (58.5%) were female (male: 41.5%) with a
      male/female ratio of 1.4. The overall annual incidence of T1DM was 7.2/105, being
      8.7/105 in females and 5.7/105 in males. The peak incidence was found to occur at
      age 5-9 years in the girls and 10-14 years in the boys. Mean age at diagnosis was
      8.1+/-3.8 years. Rate of presentation with diabetic ketoacidosis was 65.9%.
      Patients applied most frequently in spring and winter months.Conclusions: In this
      first T1DM incidence study on the pediatric age group in Diyarbakir, Turkey, T1DM
      incidence was found to be similar to that in countries with low-middle incidence.
AD  - Diyarbakir Children State Hospital, Division of Pediatric Endocrinology,
      Diyarbakir, Turkey. dr_huseyin@hotmail.com.
FAU - Demirbilek, Huseyin
AU  - Demirbilek H
FAU - Ozbek, Mehmet Nuri
AU  - Ozbek MN
FAU - Baran, Riza Taner
AU  - Baran RT
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - J Clin Res Pediatr Endocrinol
JT  - Journal of clinical research in pediatric endocrinology
JID - 101519456
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.4274/Jcrpe.954 [doi]
PST - ppublish
SO  - J Clin Res Pediatr Endocrinol. 2013 Jun 6;5(2):98-103. doi: 10.4274/Jcrpe.954.

PMID- 23748058
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1308-5735 (Electronic)
VI  - 5
IP  - 2
DP  - 2013 Jun 6
TI  - Can HbA1c and One-Hour Glucose Concentration in Standard OGTT Be Used for
      Evaluation of Glucose Homeostasis in Childhood?
PG  - 80-4
LID - 10.4274/Jcrpe.889 [doi]
AB  - Objective: To investigate whether glycosylated hemoglobin (HbA1c) and 1-hour
      glucose level in oral glucose tolerance test (OGTT) are useful parameters for
      evaluation of glucose homeostasis in childhood. Methods: The medical records of
      106 obese/overweight children aged from 7 to 18 years who underwent OGTT were
      evaluated retrospectively. The subjects were divided into 2 groups according to
      their one-hour glucose concentration. Group 1 consisted of subjects whose
      one-hour glucose level was <155 mg/dL, and Group 2 consisted of subjects whose
      one-hour glucose level was >/=155 mg/dL. The fasting and 2-hour glucose
      concentrations of the groups were compared. The sensitivity and specificity
      levels were determined using the ROC curve to assess the predictive value of
      HbA1c for impaired glucose tolerance (IGT). Results: The mean 2-hour glucose
      concentration of the subjects in Group 2 was significantly higher than that of
      the subjects in Group 1 (137.8+/-35.5 mg/dL versus 113.1+/-21.2 mg/dL, p<0.05).
      If a 5.5% cut-off value for HbA1c was accepted as predictor of IGT, the
      sensitivity was 63% and specificity was 70%. 31% of the subjects with HbA1c
      levels at or above 5.5% had IGT. This rate was significantly lower in subjects
      who had HbA1c levels below 5.5% (p<0.05). Conclusions: Obese/overweight children 
      and adolescents whose 1-hour glucose level is >/=155 mg/dL in the standard OGTT
      carry a high risk for IGT. Obese/overweight children and adolescents whose HbA1c 
      level is at or above 5.5% may have IGT even though their fasting glucose level is
      normal, thus, OGTT is necessary to evaluate the glucose tolerance.
AD  - Kocaeli University Medical Faculty, Department of Pediatrics, Division of
      Pediatric Endocrinology and Diabetes, Kocaeli, Turkey. sukruhatun@gmail.com.
FAU - Mutlu, Gul Yesiltepe
AU  - Mutlu GY
FAU - Ozsu, Elif
AU  - Ozsu E
FAU - Cizmecioglu, Filiz Mine
AU  - Cizmecioglu FM
FAU - Hatun, Sukru
AU  - Hatun S
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - J Clin Res Pediatr Endocrinol
JT  - Journal of clinical research in pediatric endocrinology
JID - 101519456
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.4274/Jcrpe.889 [doi]
PST - ppublish
SO  - J Clin Res Pediatr Endocrinol. 2013 Jun 6;5(2):80-4. doi: 10.4274/Jcrpe.889.

PMID- 23748031
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1878-1810 (Electronic)
IS  - 1878-1810 (Linking)
DP  - 2013 Jun 6
TI  - Telomeres and cardiovascular disease risk: an update 2013.
LID - S1931-5244(13)00147-3 [pii]
LID - 10.1016/j.trsl.2013.05.004 [doi]
AB  - Leukocyte telomere length (LTL) has been regarded as a potential marker of
      biologic aging because it usually shortens in a predictable way with age.
      Recently, a growing interest in cardiovascular aging has led to a number of new
      epidemiologic studies investigating LTL in various disease conditions. Some
      methodological problems exist because there are different methods available to
      determine LTL, and standardization is much needed. For example, in the majority
      of studies, patients with early-onset coronary heart disease have been shown to
      have shorter LTL. In addition, patients with diabetes mellitus complications tend
      to have shorter LTL than control subjects. On the other hand, increased left
      ventricular hypertrophy or mass is associated with longer LTL, and studies
      investigating hypertension have reported both shorter and longer LTL than found
      in normotensive control subjects. There is, therefore, a need for longitudinal
      studies to elucidate these complicated relationships further, to provide
      estimations of telomere attrition rates, and to overcome analytical problems when
      only cross-sectional studies are used. The understanding of cardiovascular aging 
      and telomere biology may open up new avenues for interventions, such as stem cell
      therapy or agents that could retard this aging process over and beyond
      conventional risk factor control.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - From the Department of Clinical Sciences, Lund University, Skane University
      Hospital, Malmo, Sweden. Electronic address: Peter.Nilsson@med.lu.se.
FAU - Nilsson, Peter M
AU  - Nilsson PM
FAU - Tufvesson, Hanna
AU  - Tufvesson H
FAU - Leosdottir, Margret
AU  - Leosdottir M
FAU - Melander, Olle
AU  - Melander O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Transl Res
JT  - Translational research : the journal of laboratory and clinical medicine
JID - 101280339
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/27 [received]
PHST- 2013/05/12 [revised]
PHST- 2013/05/14 [accepted]
AID - S1931-5244(13)00147-3 [pii]
AID - 10.1016/j.trsl.2013.05.004 [doi]
PST - aheadofprint
SO  - Transl Res. 2013 Jun 6. pii: S1931-5244(13)00147-3. doi:
      10.1016/j.trsl.2013.05.004.

PMID- 23747959
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
DP  - 2013 Jun 5
TI  - Comparison between IDMS-traceable Jaffe and enzymatic creatinine assays FOR
      estimation of glomerular filtration rate by the CKD-EPI equation in healthy and
      diabetic subjects.
LID - S0009-9120(13)00272-5 [pii]
LID - 10.1016/j.clinbiochem.2013.05.067 [doi]
AB  - OBJECTIVES: The aim of this paper was to compare the agreement between creatinine
      measured by Jaffe and enzymatic methods and their putative influence on eGFR as
      calculated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
      equation in healthy and diabetic individuals. METHODS: Cross-sectional study
      conducted in 123 adult Southern Brazilians with GFR > 60 mL/min/1.73 m2 (53 with 
      type 2 diabetes, 70 healthy volunteers). Mean age was 49+/-16 years (range
      19-86). Most were female (55%) and white (83%). Creatinine was measured by a
      traceable Jaffe method (Modular P, Roche Diagnostic) and by an enzymatic method
      (CREA plus, Roche/Hitachi 917). GFR was measured by the 51Cr-EDTA
      single-injection method. RESULTS: Serum creatinine measured by the Jaffe and
      enzymatic methods was similar in healthy subjects (0.79+/-0.15 vs. 0.79+/-0.15
      mg/dL, respectively, P=0.76), and diabetic patients (0.96+/-0.22 vs. 0.92+/-0.29 
      mg/dL, respectively, P=0.17). However, the correlation between the two methods
      was higher in the healthy group (r=0.90 vs. 0.76, P<0.001). The difference
      between Jaffe creatinine and enzymatic creatinine was <10% in 63% of cases in the
      healthy group and 40% of cases in the diabetes group (P=0.018). In the subset of 
      patients with diabetes, eGFR based on enzymatic assay results showed better
      agreement with measured GFR than did eGFR based on Jaffe results. CONCLUSION:
      Jaffe and enzymatic creatinine methods show adequate agreement in healthy
      subjects, but in the presence of diabetes, the enzymatic method performed
      slightly better.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Graduate Program in Medical Science: Endocrinology, Universidade Federal do Rio
      Grande do Sul (UFRGS), Brazil.
FAU - Cheuiche, Amanda Veiga
AU  - Cheuiche AV
FAU - Soares, Ariana Aguiar
AU  - Soares AA
FAU - Camargo, Eduardo Guimaraes
AU  - Camargo EG
FAU - Weinert, Leticia Schwerz
AU  - Weinert LS
FAU - Camargo, Joiza Lins
AU  - Camargo JL
FAU - Silveiro, Sandra Pinho
AU  - Silveiro SP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/27 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/05/25 [accepted]
AID - S0009-9120(13)00272-5 [pii]
AID - 10.1016/j.clinbiochem.2013.05.067 [doi]
PST - aheadofprint
SO  - Clin Biochem. 2013 Jun 5. pii: S0009-9120(13)00272-5. doi:
      10.1016/j.clinbiochem.2013.05.067.

PMID- 23747931
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-4596 (Electronic)
IS  - 0891-5849 (Linking)
DP  - 2013 Jun 5
TI  - N-Acetylcysteine And Allopurinol Up-regulated the Jak/STAT3 and PI3K/Akt pathway 
      via Adiponectin and Attenuated Myocardial Post-Ischemic Injury In Diabetes.
LID - S0891-5849(13)00271-2 [pii]
LID - 10.1016/j.freeradbiomed.2013.05.043 [doi]
AB  - N-acetylcysteine (NAC) and allopurinol (ALP) synergistically reduce myocardial
      ischemia reperfusion (MI/R) injury in diabetes. However, the mechanism is
      unclear. We postulated that NAC and ALP attenuated diabetic MI/R injury by
      up-regulating phosphatidylinositol 3-kinase/Akt (PI3K/Akt) and Janus kinase
      2/signal transducer and activator of transcription-3 (JAK2/STAT3) pathways
      subsequent to adiponectin (APN) activation. Control (C) or streptozotocin-induced
      diabetic rats (D) were untreated or treated with NAC and ALP followed by MI/R. D 
      rats displayed larger infarct size accompanied by decreased phosphorylation of
      Akt, STAT3 and decreased cardiac nitric oxide (NO) and APN levels. NAC and ALP
      decreased MI/R injury in D rats, enhanced phosphorylation of Akt and STAT3 and
      increased NO and APN. High glucose and hypoxia/reoxygenation exposure induced
      cell death and Akt and STAT3 inactivation in cultured cardiomyocytes, which was
      prevented by NAC and ALP. PI3K inhibitor wortmannin and Jak2 inhibitor AG490,
      abolished the protection of NAC and ALP. Similarly, APN restored post-hypoxic Akt
      and STAT3 activation and decreased cell death in cardiomyocytes. Gene silencing
      with AdipoR2 siRNA or STAT3 siRNA but not AdipoR1 siRNA abolished the protection 
      of NAC and ALP. In conclusion, NAC and ALP prevented diabetic MI/R injury through
      PI3K/Akt and Jak2/STAT3 and that cardiac APN may serve as a mediator via AdipoR2 
      in this process.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Anesthesiology, The University of Hong Kong, Hong Kong SAR, China; 
      Department of Anesthesiology and Critical Care, Union Hospital, Tongji Medical
      College, Huazhong University of Science and Technology, Wuhan, China.
FAU - Wang, Tingting
AU  - Wang T
FAU - Mao, Xiaowen
AU  - Mao X
FAU - Li, Haobo
AU  - Li H
FAU - Qiao, Shigang
AU  - Qiao S
FAU - Xu, Aimin
AU  - Xu A
FAU - Wang, Junwen
AU  - Wang J
FAU - Lei, Shaoqing
AU  - Lei S
FAU - Liu, Zipeng
AU  - Liu Z
FAU - Ng, Kwok F J
AU  - Ng KF
FAU - Wong, Gordon T
AU  - Wong GT
FAU - Vanhoutte, Paul M
AU  - Vanhoutte PM
FAU - Irwin, Michael G
AU  - Irwin MG
FAU - Xia, Zhengyuan
AU  - Xia Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/12/17 [received]
PHST- 2013/05/07 [revised]
PHST- 2013/05/29 [accepted]
AID - S0891-5849(13)00271-2 [pii]
AID - 10.1016/j.freeradbiomed.2013.05.043 [doi]
PST - aheadofprint
SO  - Free Radic Biol Med. 2013 Jun 5. pii: S0891-5849(13)00271-2. doi:
      10.1016/j.freeradbiomed.2013.05.043.

PMID- 23747866
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1093-4715 (Electronic)
IS  - 1093-4715 (Linking)
VI  - 18
DP  - 2013
TI  - Octamer-binding transcription factors: genomics and functions.
PG  - 1051-71
AB  - The Octamer-binding proteins (Oct) are a group of highly conserved transcription 
      factors that specifically bind to the octamer motif (ATGCAAAT) and closely
      related sequences in promoters and enhancers of a wide variety of genes. Oct
      factors belong to the larger family of POU domain factors that are characterized 
      by the presence of an amino-terminal specific subdomain (POUS) and a
      carboxyl-terminal homeo-subdomain (POUH). Eleven Oct proteins have been named
      (Oct1-11), and currently, eight genes encoding Oct proteins (Oct1, Oct2, Oct3/4, 
      Oct6, Oct7, Oct8, Oct9, and Oct11) have been cloned. Oct1 and Oct2 are widely
      expressed in adult tissues, while other Oct proteins are much more restricted in 
      their expression patterns. Oct proteins are implicated in crucial and versatile
      biological events, such as embryogenesis, neurogenesis, immunity, and body
      glucose and amino acid metabolism. The aberrant expression and null function of
      Oct proteins have also been linked to various diseases, including deafness,
      diabetes and cancer. In this review, I will report both the genomic structure and
      major functions of individual Oct proteins in physiological and pathological
      processes.
AD  - Department of Animal Science, University of Vermont.
FAU - Zhao, Feng-Qi
AU  - Zhao FQ
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - United States
TA  - Front Biosci
JT  - Frontiers in bioscience : a journal and virtual library
JID - 9709506
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 4162 [pii]
PST - epublish
SO  - Front Biosci. 2013 Jun 1;18:1051-71.

PMID- 23747808
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 65C
DP  - 2013 May 18
TI  - Discovery and structure-activity relationships of ent-Kaurene diterpenoids as
      potent and selective 11beta-HSD1 inhibitors: Potential impact in diabetes.
PG  - 403-414
LID - S0223-5234(13)00310-3 [pii]
LID - 10.1016/j.ejmech.2013.05.010 [doi]
AB  - The biological screening of a collection of nature occurring diterpenoids against
      11beta-HSD1 resulted in the discovery of the lead compound 1b, which pointed to
      the therapeutic potential for type 2 diabetes. Subsequently, an optimization
      project was initiated. Starting from compound 1b and its counterpart 2, the
      hemi-synthesis was performed on kaurenic acid scaffolds yielding 36 derivatives. 
      Further evaluations on both human and mouse 11beta-HSD revealed that seven urea
      derivatives exhibited significant improved potency and selectivity. Especially,
      the urea 19a has an IC50 (human 11beta-HSD1) = 9.4 nM and selectivity index
      (human 11beta-HSD) > 10,649. The 2D and 3D binding models of the complex
      19a/11beta-HSD1 were generated using docking simulations. Based on the results,
      the structural-activity relationships (SARs) of compounds 1b and 2 were also
      discussed.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming
      Institute of Botany, Chinese Academy of Sciences, Kunming 650204, China.
FAU - Deng, Xu
AU  - Deng X
FAU - Shen, Yu
AU  - Shen Y
FAU - Yang, Jing
AU  - Yang J
FAU - He, Juan
AU  - He J
FAU - Zhao, Yu
AU  - Zhao Y
FAU - Peng, Li-Yan
AU  - Peng LY
FAU - Leng, Ying
AU  - Leng Y
FAU - Zhao, Qin-Shi
AU  - Zhao QS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/12/26 [received]
PHST- 2013/05/08 [revised]
PHST- 2013/05/09 [accepted]
AID - S0223-5234(13)00310-3 [pii]
AID - 10.1016/j.ejmech.2013.05.010 [doi]
PST - aheadofprint
SO  - Eur J Med Chem. 2013 May 18;65C:403-414. doi: 10.1016/j.ejmech.2013.05.010.

PMID- 23747732
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
DP  - 2013 Jun 4
TI  - Oral Delivery of an Anti-diabetic Peptide Drug via Conjugation and Complexation
      with Low Molecular Weight Chitosan.
LID - S0168-3659(13)00321-0 [pii]
LID - 10.1016/j.jconrel.2013.05.031 [doi]
AB  - Despite the therapeutic potential of exendin-4 as a glucagon-like peptide-1
      (GLP-1) mimetic for the treatment of type 2 diabetes, its utility has so far been
      limited because of the low level of patient compliance due to the requirement for
      frequent injections. In this study, an orally available exendin-4 was produced by
      conjugating it to low molecular weight chitosan (LMWC). Conjugation between the
      LMWC and cysteinylated exendin-4 was carried out using a cleavable linker system 
      in order to maximize the availability of the active peptide. The LMWC-exendin-4
      conjugate formed a nanoparticle structure with a mean particle size of 101 +/- 41
      nm through complexation between the positively charged LMWC backbone and the
      negatively charged exendin-4 of individual conjugate molecules. The biological
      activity of the LMWC-exendin-4 conjugate was evaluated in an INS-1 cell line. The
      LMWC-exendin-4 conjugate stimulated insulin secretion in a dose dependent manner 
      as similar as that of native exendin-4. From the pharmacokinetic study after oral
      administration of the conjugate, a Cmax value of 344 pg/mL and a Tmax of 6 h were
      observed, and the bioavailability, relative to the subcutaneous counterpart, was 
      found to be 6.4 %. Furthermore, the absorbed exendin-4 demonstrated a
      significantly enhanced hypoglycemic effect. These results suggest that the
      LMWC-exendin-4 conjugate could be used as a potential oral anti-diabetic agent
      for the treatment of type 2 diabetes.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - KAIST Institute for the BioCentury, Department of Biological Sciences, Korea
      Advanced Institute of Science and Technology, Daejeon 305-701, Republic of Korea.
FAU - Ahn, Sukyung
AU  - Ahn S
FAU - Lee, In-Hyun
AU  - Lee IH
FAU - Lee, Eunhye
AU  - Lee E
FAU - Kim, Hyungjun
AU  - Kim H
FAU - Kim, Yong-Chul
AU  - Kim YC
FAU - Jon, Sangyong
AU  - Jon S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release
      Society
JID - 8607908
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/22 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/05/28 [accepted]
AID - S0168-3659(13)00321-0 [pii]
AID - 10.1016/j.jconrel.2013.05.031 [doi]
PST - aheadofprint
SO  - J Control Release. 2013 Jun 4. pii: S0168-3659(13)00321-0. doi:
      10.1016/j.jconrel.2013.05.031.

PMID- 23747725
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
DP  - 2013 Jun 5
TI  - Generation of mouse models for type 1 diabetes by selective depletion of
      pancreatic beta cells using toxin receptor-mediated cell knockout.
LID - S0006-291X(13)00932-7 [pii]
LID - 10.1016/j.bbrc.2013.05.114 [doi]
AB  - By using the toxin receptor-mediated cell knockout (TRECK) method, we have
      generated two transgenic (Tg) murine lines that model type 1 (insulin-dependent) 
      diabetes. The first strain, C.B-17/Icr-Prkdcscid/Prkdcscid-INS-TRECK-Tg, carries 
      the diphtheria toxin receptor (hDTR) driven by the human insulin gene promoter,
      while the other strain, C57BL/6-ins2(BAC)-TRECK-Tg, expresses hDTR cDNA under the
      control of the mouse insulin II gene promoter. With regard to the
      C.B-17/Icr-Prkdcscid/Prkdcscid-INS-TRECK-Tg strain, only one of three Tg strains 
      exhibited proper expression of hDTR in pancreatic beta cells. By contrast, hDTR
      was expressed in the pancreatic beta cells of all four of the generated
      C57BL/6-ins2(BAC)-TRECK-Tg strains. Hyperglycemia, severe ablation of pancreatic 
      beta cells and depletion of serum insulin were observed within 3 days after the
      administration of diphtheria toxin (DT) in these Tg mice. Subcutaneous injection 
      of a suitable dosage of insulin was sufficient for recovery from hyperglycemia in
      all of the examined strains. Using the
      C.B-17/Icr-Prkdcscid/Prkdcscid-INS-TRECK-Tg model, we tried to perform
      regenerative therapeutic approaches: allogeneic transplantation of pancreatic
      islet cells from C57BL/6 and xenogeneic transplantation of CD34+ human umbilical 
      cord blood cells. Both approaches successfully rescued
      C.B-17/Icr-Prkdcscid/Prkdcscid-INS-TRECK-Tg mice from hyperglycemia caused by DT 
      administration. The high specificity with which DT causes depletion in pancreatic
      beta cells of these Tg mice is highly useful for diabetogenic research.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Mammalian Genetics Project, Department of Genome Medicine, Tokyo Metropolitan
      Institute of Medical Science, 2-1-6, Kamikitazawa, Setagaya-ku, Tokyo 156-8506,
      Japan; Bio-oriented Technology Research Advancement Institution (BRAIN), 1-40-2, 
      Nisshin, Kita-ku, Saitama 331-8537, Japan. Electronic address:
      matsuoka-kn@igakuken.or.jp.
FAU - Matsuoka, Kunie
AU  - Matsuoka K
FAU - Saito, Michiko
AU  - Saito M
FAU - Shibata, Kosuke
AU  - Shibata K
FAU - Sekine, Michiko
AU  - Sekine M
FAU - Shitara, Hiroshi
AU  - Shitara H
FAU - Taya, Choji
AU  - Taya C
FAU - Zhang, Xiaohong
AU  - Zhang X
FAU - Takahashi, Tsuneo A
AU  - Takahashi TA
FAU - Kohno, Kenji
AU  - Kohno K
FAU - Kikkawa, Yoshiaki
AU  - Kikkawa Y
FAU - Yonekawa, Hiromichi
AU  - Yonekawa H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/05/21 [received]
PHST- 2013/05/28 [accepted]
AID - S0006-291X(13)00932-7 [pii]
AID - 10.1016/j.bbrc.2013.05.114 [doi]
PST - aheadofprint
SO  - Biochem Biophys Res Commun. 2013 Jun 5. pii: S0006-291X(13)00932-7. doi:
      10.1016/j.bbrc.2013.05.114.

PMID- 23747606
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-5169 (Electronic)
IS  - 0196-9781 (Linking)
DP  - 2013 Jun 5
TI  - The apelinergic system: Sexual dimorphism and tissue-specific modulations by
      obesity and insulin resistance in female mice.
LID - S0196-9781(13)00204-0 [pii]
LID - 10.1016/j.peptides.2013.05.013 [doi]
AB  - It has been proposed that the apelinergic system (apelin and its receptor APJ)
      may be a promising therapeutic target in obesity-associated insulin resistance
      syndrome. However, due to the extended tissue-distribution of this system, the
      therapeutic use of specific ligands for APJ may target numerous tissues resulting
      putatively to collateral deleterious effects. To unravel specific tissular
      dysfunctions of this system under obesity and insulin-resistance conditions, we
      measured the apelinemia and gene-expression level of both apelin (APL) and APJ in
      12-selected tissues of insulin-resistant obese female mice fed with a high fat
      (HF) diet. In a preliminary study, we compared between adult male and female
      mice, the circadian plasma apelin variation and the effect of fasting on
      apelinemia. No significant differences were found for these parameters suggesting
      that the apelinemia is not affected by the sex. Moreover, plasma apelin level was
      not modulated during the four days of the estrous cycle in females. In obese and 
      insulin-resistant HF female mice, plasma apelin concentration after fasting was
      not modified but, the gene-expression level of the APL/APJ system was augmented
      in the white adipose tissue (WAT) and reduced in the brown adipose tissue (BAT), 
      the liver and in kidneys. BAT apelin content was reduced in HF female mice. Our
      data suggest that the apelinergic system may be implicated into specific
      dysfunctions of these tissues under obesity and diabetes and that, pharmacologic 
      modulations of this system may be of interest particularly in the treatment of
      adipose, liver and renal dysfunctions that occur during these pathologies.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Universite Lille Nord de France, Unite Environnement Perinatal et Croissance, EA 
      4489, Faculte de Medecine, Pole Recherche, IFR 114, 59045 Lille, France.
FAU - Butruille, Laura
AU  - Butruille L
FAU - Drougard, Anne
AU  - Drougard A
FAU - Knauf, Claude
AU  - Knauf C
FAU - Moitrot, Emmanuelle
AU  - Moitrot E
FAU - Valet, Philippe
AU  - Valet P
FAU - Storme, Laurent
AU  - Storme L
FAU - Deruelle, Philippe
AU  - Deruelle P
FAU - Lesage, Jean
AU  - Lesage J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Peptides
JT  - Peptides
JID - 8008690
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/12 [received]
PHST- 2013/05/28 [revised]
PHST- 2013/05/28 [accepted]
AID - S0196-9781(13)00204-0 [pii]
AID - 10.1016/j.peptides.2013.05.013 [doi]
PST - aheadofprint
SO  - Peptides. 2013 Jun 5. pii: S0196-9781(13)00204-0. doi:
      10.1016/j.peptides.2013.05.013.

PMID- 23747576
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1095-8304 (Electronic)
IS  - 0195-6663 (Linking)
DP  - 2013 Jun 5
TI  - Stress Eating and Health: Findings from MIDUS, a National Study of U.S. Adults.
LID - S0195-6663(13)00211-0 [pii]
LID - 10.1016/j.appet.2013.05.020 [doi]
AB  - The epidemic of obesity and its related chronic diseases has provoked interest in
      the predictors of eating behavior. Eating in response to stress has been
      extensively examined, but currently unclear is whether stress eating is
      associated with obesity and morbidity. We tested whether self-reported stress
      eating was associated with worse glucose metabolism among nondiabetic adults as
      well as with increased odds of prediabetes and diabetes. Further, we investigated
      whether these relationships were mediated by central fat distribution.
      Participants were 1138 adults (937 without diabetes) in the Midlife in the U.S.
      study (MIDUS II). Glucose metabolism was characterized by fasting glucose,
      insulin, insulin resistance (HOMAIR), glycosylated hemoglobin (HbA1c),
      prediabetes, and diabetes status. Multivariate-adjusted analyses showed that
      stress eating was associated with significantly higher nondiabetic levels of
      glucose, insulin, insulin resistance, and HbA1c as well as higher odds of
      prediabetes or diabetes. Relationships between stress eating and all outcomes
      were no longer statistically significant once waist circumference was added to
      the models, suggesting that it mediates such relationships. Findings add to the
      growing literature on the relationships among psychosocial factors, obesity, and 
      chronic disease by documenting associations between stress eating and objectively
      measured health outcomes in a national sample of adults. The findings have
      important implications for interventive targets related to obesity and chronic
      disease, namely, strategies to modify the tendency to use food as a coping
      response to stress.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Institute on Aging University of Wisconsin-Madison 1300 University Ave 2245 MSC
      Madison, WI 53706. Electronic address: tsenkova@wisc.edu.
FAU - Tsenkova, Vera
AU  - Tsenkova V
FAU - Boylan, Jenifer Morozink
AU  - Boylan JM
FAU - Ryff, Carol
AU  - Ryff C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Appetite
JT  - Appetite
JID - 8006808
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/19 [received]
PHST- 2013/05/29 [revised]
PHST- 2013/05/30 [accepted]
AID - S0195-6663(13)00211-0 [pii]
AID - 10.1016/j.appet.2013.05.020 [doi]
PST - aheadofprint
SO  - Appetite. 2013 Jun 5. pii: S0195-6663(13)00211-0. doi:
      10.1016/j.appet.2013.05.020.

PMID- 23747564
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 Jun 6
TI  - Uptake of advanced glycation end products by proximal tubule epithelial cells via
      macropinocytosis.
LID - S0167-4889(13)00214-0 [pii]
LID - 10.1016/j.bbamcr.2013.05.024 [doi]
AB  - Chronic hyperglycaemia during diabetes leads to non-enzymatic glycation of
      proteins to form advanced glycation end products (AGEs) that contribute to
      nephropathy. We describe AGE uptake in LLC-PK1 and HK2 proximal tubule cell lines
      by macropinocytosis, a non-specific, endocytic mechanism. AGE-BSA induced dorsal 
      circular actin ruffles and amiloride-sensitive dextran-TRITC uptake,
      significantly increased AGE-BSA-FITC uptake (167 +/- 18% vs BSA control, p<0.01) 
      and was ezrin-dependent. AGE-BSA-FITC uptake was significantly inhibited by
      amiloride and inhibitors of Arf6, Rac1, racGEF Tiam1, PAK1 and actin
      polymerisation. AGE-BSA-FITC, Arf6 and PIP2 co-localised within dorsal circular
      actin ruffles. AGE-BSA increased PAK1 kinase activity (212 +/- 41% vs control,
      p<0.05) and protein levels of Tiam1, a Rac1 activator. AGE-BSA significantly
      increased TGF-beta1 protein levels (160 +/- 6%, p<0.001 vs BSA), which were
      significantly inhibited by inhibitors of Arf6 (82 +/- 19%, p<0.001 vs AGE) and
      actin polymerisation (107 +/- 11%, p<0.001 vs AGE), suggesting AGEs partially
      exert their profibrotic effects via macropinocytosis. PAK1 and PIP5Kgamma siRNA
      significantly decreased AGE-BSA-FITC uptake (81 +/- 6% and 64 +/- 7%,
      respectively, p<0.05 vs control for both), and AGE-stimulated TGF-beta1 protein
      release (99 +/- 15% and 49 +/- 8% of control, p<0.05 and p<0.001, respectively). 
      Inhibition of AGE uptake by macropinocytosis inhibitors and a neutralising
      TGF-beta1 antibody, reversed the AGE-induced decrease in surface Na+K+ATPase,
      suggesting AGE uptake by macropinocytosis may contribute to diabetic kidney
      fibrosis and/or EMT by modulating this pump. Understanding methods of cellular
      uptake and signalling by AGEs may lead to novel therapies for diabetic
      nephropathy.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Monash University, Department of Medicine, Alfred Hospital, Commercial Rd.,
      Prahran, Victoria, 3004.
FAU - Gallicchio, Marisa A
AU  - Gallicchio MA
FAU - Bach, Leon A
AU  - Bach LA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/29 [received]
PHST- 2013/05/15 [revised]
PHST- 2013/05/28 [accepted]
AID - S0167-4889(13)00214-0 [pii]
AID - 10.1016/j.bbamcr.2013.05.024 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 Jun 6. pii: S0167-4889(13)00214-0. doi:
      10.1016/j.bbamcr.2013.05.024.

PMID- 23747551
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1879-1026 (Electronic)
IS  - 0048-9697 (Linking)
VI  - 461-462C
DP  - 2013 Jun 4
TI  - Studying the effects of polycyclic aromatic hydrocarbons on peripheral arterial
      disease in the United States.
PG  - 341-347
LID - S0048-9697(13)00523-8 [pii]
LID - 10.1016/j.scitotenv.2013.04.089 [doi]
AB  - PURPOSE: Polycyclic aromatic hydrocarbons are a group of prevalent pollutants
      which are produced by incomplete combustion of organic materials such as coal,
      fuel, tobacco smoking and food cooking. The associations between exposures to
      polycyclic aromatic hydrocarbons (PAHs) and peripheral arterial disease (PAD)
      have not been well studied. METHODS: We used the 2001-2004 National Health and
      Nutrition Examination Survey (NHANES) to investigate the associations between
      eight monohydroxy urinary metabolites of four PAHs and PAD. RESULTS: In a
      logistic regression model, subjects within the middle and highest tertiles of
      fluorene metabolites, 2-hydroxyfluorene (2-FLUO) and 3-hydroxyfluorene (3-FLUO), 
      and phenanthrene metabolites, 1-hydroxyphenanthrene (1-PHEN) and
      2-hydroxyphenanthrene (2-PHEN), had significantly higher prevalence of PAD as
      compared to subjects within the lowest tertile after adjusting for cigarette
      smoking, diabetes mellitus and other covariates (For 2-FLUO, the 3rd tertile:
      OR=2.22, 95% CI=1.13-4.37, p for trend=0.02; For 3-FLUO, the 3rd tertile:
      OR=2.36, 95% CI: 1.16-4.77, p for trend=0.02; For 1-PHEN, the 3rd tertile:
      OR=1.84, 95% CI: 1.01-3.37, p for trend=0.04; For 2-PHEN, the 3rd tertile:
      OR=1.76, 95% CI: 1.07-2.88, p for trend=0.03). CONCLUSIONS: Our findings suggest 
      that exposure to PAHs may increase the risk of PAD. Further studies are necessary
      to explore the associations between PAHs and PAD.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Epidemiology, College of Public Health and Health Professions,
      College of Medicine, University of Florida, Gainesville, FL, United States.
      Electronic address: xhxu@phhp.ufl.edu.
FAU - Xu, Xiaohui
AU  - Xu X
FAU - Hu, Hui
AU  - Hu H
FAU - Kearney, Gregory D
AU  - Kearney GD
FAU - Kan, Haidong
AU  - Kan H
FAU - Sheps, David S
AU  - Sheps DS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Sci Total Environ
JT  - The Science of the total environment
JID - 0330500
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/09 [received]
PHST- 2013/04/15 [revised]
PHST- 2013/04/26 [accepted]
AID - S0048-9697(13)00523-8 [pii]
AID - 10.1016/j.scitotenv.2013.04.089 [doi]
PST - aheadofprint
SO  - Sci Total Environ. 2013 Jun 4;461-462C:341-347. doi:
      10.1016/j.scitotenv.2013.04.089.

PMID- 23747418
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
DP  - 2013 Jun 4
TI  - Activation of type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation
      through the SIRT1/PGC-1alpha pathway.
LID - S0006-291X(13)00915-7 [pii]
LID - 10.1016/j.bbrc.2013.05.108 [doi]
AB  - Abnormal fatty acid oxidation has been associated with obesity and type 2
      diabetes. At the transcriptional level, peroxisome proliferator-activated
      receptor-gamma coactivator 1alpha (PGC-1alpha) has been reported to strongly
      increase the ability of hormone nuclear receptors PPARalpha and ERRalpha to drive
      transcription of fatty acid oxidation enzymes. In this study, we report that a
      specific agonist of the type 2 cannabinoid receptor (CB2R) can lead to fatty acid
      oxidation through the PGC-1alpha pathway. We have found that CB2R is expressed in
      differentiated C2C12 myotubes, and that use of the specific agonist
      trans-caryophyllene (TC) stimulates sirtuin 1 (SIRT1) deacetylase activity by
      increasing the phosphorylation of cAMP response element-binding protein (CREB),
      thus leading to increased levels of PGC-1alpha deacetylation. This use of TC
      treatment increases the expression of genes linked to the fatty acid oxidation
      pathway in a SIRT1/PGC-1alpha-dependent mechanism and also drastically
      accelerates the rate of complete fatty acid oxidation in C2C12 myotubes, neither 
      of which occur when CB2R mRNA is knocked down using siRNA. These results reveal
      that activation of CB2R by a selective agonist promotes lipid oxidation through a
      signaling/transcriptional pathway. Our findings imply that pharmacological
      manipulation of CB2R may provide therapeutic possibilities to treat metabolic
      diseases associated with lipid dysregulation.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Endocrinology, First Affiliated Hospital Nanjing Medical
      University, Nanjing, Jiangsu Province, 210029, China.
FAU - Zheng, Xuqin
AU  - Zheng X
FAU - Sun, Tao
AU  - Sun T
FAU - Wang, Xiaodong
AU  - Wang X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/05/24 [received]
PHST- 2013/05/25 [accepted]
AID - S0006-291X(13)00915-7 [pii]
AID - 10.1016/j.bbrc.2013.05.108 [doi]
PST - aheadofprint
SO  - Biochem Biophys Res Commun. 2013 Jun 4. pii: S0006-291X(13)00915-7. doi:
      10.1016/j.bbrc.2013.05.108.

PMID- 23747356
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Linking)
DP  - 2013 Jun 6
TI  - Global Confluence of Infectious and Non-communicable Diseases - The Case of Type 
      2 Diabetes.
LID - S0091-7435(13)00190-4 [pii]
LID - 10.1016/j.ypmed.2013.05.027 [doi]
AD  - Department of Global Health, Rollins School of Public Health, Emory University,
      Atlanta, 1518 Clifton Road, Atlanta, GA 30322, USA; Department of Epidemiology,
      Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA
      30322, USA. Electronic address: MJMAGEE@emory.edu.
FAU - Magee, M J
AU  - Magee MJ
FAU - Narayan, K M Venkat
AU  - Narayan KM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/29 [received]
PHST- 2013/05/27 [revised]
PHST- 2013/05/29 [accepted]
AID - S0091-7435(13)00190-4 [pii]
AID - 10.1016/j.ypmed.2013.05.027 [doi]
PST - aheadofprint
SO  - Prev Med. 2013 Jun 6. pii: S0091-7435(13)00190-4. doi:
      10.1016/j.ypmed.2013.05.027.

PMID- 23747347
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
DP  - 2013 Jun 6
TI  - AMP-activated Protein Kinase: a target for old drugs against diabetes and cancer.
LID - S0006-2952(13)00349-3 [pii]
LID - 10.1016/j.bcp.2013.05.023 [doi]
AB  - The AMP-activated protein kinase (AMPK) is considered a key checkpoint to ensure 
      energy balance in both cells and organisms. AMPK is an alphabetagamma
      heterotrimer controlled by allosteric regulation by AMP, ADP and ATP,
      auto-inhibitory features and phosphorylation, with the threonine-172
      phosphorylation on the catalytic alpha-subunit by LKB1, CaMKKbeta or Tak1 being
      essential for its fully activation. AMPK acts as a protective response to energy 
      stress in numerous systems, but it is also a key player in diabetes and related
      metabolic diseases and cancer. Pharmacological activation of AMPK by metformin or
      other compounds holds a considerable potential to reverse the metabolic
      abnormalities associated with type 2 diabetes. In cancer, correction of the
      dysregulated metabolic pathway LKB1/AMPK/mTORC1 can lower the Warburg effect,
      suggesting AMPK as a potential target for cancer prevention and/or treatment. In 
      this commentary, we review recent findings that support the role and function of 
      AMPK in normal and pathological conditions. We also discuss how the activation of
      AMPK by naturally occurring compounds could help to prevent the development of
      numerous chronic diseases contributing in such a way to the well-being of aging
      population.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Institute of Food Sciences, National Research Council, 83100, Avellino, Italy.
      Electronic address: glrusso@isa.cnr.it.
FAU - Russo, Gian Luigi
AU  - Russo GL
FAU - Russo, Maria
AU  - Russo M
FAU - Ungaro, Paola
AU  - Ungaro P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/08 [received]
PHST- 2013/05/17 [revised]
PHST- 2013/05/17 [accepted]
AID - S0006-2952(13)00349-3 [pii]
AID - 10.1016/j.bcp.2013.05.023 [doi]
PST - aheadofprint
SO  - Biochem Pharmacol. 2013 Jun 6. pii: S0006-2952(13)00349-3. doi:
      10.1016/j.bcp.2013.05.023.

PMID- 23747312
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1878-7533 (Electronic)
IS  - 1550-7289 (Linking)
DP  - 2013 Apr 17
TI  - Metabolic syndrome, hypertension, and diabetes mellitus after gastric banding:
      The role of aging and of duration of obesity.
LID - S1550-7289(13)00106-8 [pii]
LID - 10.1016/j.soard.2013.04.001 [doi]
AB  - BACKGROUND: Bariatric surgery leads to resolution of arterial hypertension and
      diabetes mellitus; isolated reports indicate that response to bariatric surgery
      is lower in aged patients. The aim of this study was to evaluate the role of age 
      and of duration of obesity on the frequency of co-morbidities in morbid obesity, 
      as well as on improvement of co-morbidities. METHODS: A total of 837 consecutive 
      patients with known duration of obesity, undergoing gastric banding, were
      considered for this study; they were divided into quartiles of age and of
      duration of obesity. Presence of co-morbidities (diabetes mellitus, arterial
      hypertension, metabolic syndrome), metabolic variables (cholesterol and HDL-C,
      triglycerides, blood glucose), anthropometric variables, and loss of weight
      during 24 months were considered. RESULTS: Older patients had a higher frequency 
      of co-morbidities; duration of obesity only affected frequency of co-morbidities,
      but not response to surgery. At logistic regression, duration of obesity had a
      moderate independent effect on the frequency of diabetes. Older patients lost
      less weight than younger patients, but diabetes mellitus and arterial
      hypertension improved to the same extent in patients of different ages, and
      metabolic syndrome disappeared more in older patients, associated with a greater 
      decrease of blood glucose. Frequency of removal of gastric banding and loss to
      follow-up were not different in different quartiles of age or in different
      quartiles of duration of obesity. CONCLUSIONS: Older patients, despite lower
      weight loss, have a response to bariatric surgery that is similar to that of
      younger patients; age and duration of obesity should not be considered as limits 
      to indications to bariatric surgery.
CI  - Copyright (c) 2013 American Society for Bariatric Surgery. Published by Elsevier 
      Inc. All rights reserved.
AD  - Dipartimento di Scienze della Salute, Universita degli studi di Milano, Milano,
      Italy. Electronic address: antonio.pontiroli@unimi.it.
FAU - Pontiroli, Antonio E
AU  - Pontiroli AE
FAU - Alberto, Morabito
AU  - Alberto M
FAU - Paganelli, Michele
AU  - Paganelli M
FAU - Saibene, Alessandro
AU  - Saibene A
FAU - Busetto, Luca
AU  - Busetto L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Surg Obes Relat Dis
JT  - Surgery for obesity and related diseases : official journal of the American
      Society for Bariatric Surgery
JID - 101233161
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/07/21 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/20 [accepted]
AID - S1550-7289(13)00106-8 [pii]
AID - 10.1016/j.soard.2013.04.001 [doi]
PST - aheadofprint
SO  - Surg Obes Relat Dis. 2013 Apr 17. pii: S1550-7289(13)00106-8. doi:
      10.1016/j.soard.2013.04.001.

PMID- 23747284
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
DP  - 2013 May 30
TI  - Quality of Diabetes and Hyperlipidemia Screening Before a First Myocardial
      Infarction.
LID - S0828-282X(13)00155-4 [pii]
LID - 10.1016/j.cjca.2013.03.015 [doi]
AB  - BACKGROUND: There has been significant attention to the quality of care for acute
      myocardial infarction (MI). However, little is known about the quality of
      preventive care before a patient's first MI. METHODS: We conducted a
      retrospective, cohort analysis of 5688 patients admitted with their first MI to
      96 acute care hospitals in Ontario, Canada, from April 2004 to March 2005 using
      the Enhanced Feedback For Effective Cardiac Treatment clinical study database. We
      calculated rates of screening for diabetes and hyperlipidemia according to
      guidelines using linkages to the Ontario Health Insurance Plan database.
      Screening rates were stratified by age, sex, socioeconomic status, and number of 
      primary care visits in the past 5 years. RESULTS: Among the 5688 eligible
      patients, 27.1% did not receive serum cholesterol screening in the 5 years
      preceding their MI and 27.5% of patients did not receive a fasting blood glucose 
      or glucose tolerance test in the 3 years before their MI. Women were more likely 
      to be screened than men. Screening rates generally increased with age and were
      similar across socioeconomic categories. There was a positive association between
      the number of primary care visits and the likelihood of being screened.
      CONCLUSIONS: A significant number of patients admitted with their first MI were
      not screened for important modifiable risk factors. Opportunities for the
      prevention of coronary disease are being missed. More emphasis is needed on
      identifying risk factors before the development of acute coronary disease.
CI  - Copyright (c) 2013 Canadian Cardiovascular Society. Published by Elsevier Inc.
      All rights reserved.
AD  - University of Toronto, Toronto, Ontario, Canada.
FAU - Lugomirski, Peter
AU  - Lugomirski P
FAU - Guo, Helen
AU  - Guo H
FAU - Boom, Nicole K
AU  - Boom NK
FAU - Donovan, Linda R
AU  - Donovan LR
FAU - Ko, Dennis T
AU  - Ko DT
FAU - Tu, Jack V
AU  - Tu JV
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/13 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/15 [accepted]
AID - S0828-282X(13)00155-4 [pii]
AID - 10.1016/j.cjca.2013.03.015 [doi]
PST - aheadofprint
SO  - Can J Cardiol. 2013 May 30. pii: S0828-282X(13)00155-4. doi:
      10.1016/j.cjca.2013.03.015.

PMID- 23747250
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun 4
TI  - The Cancer-Associated FGFR4-G388R Polymorphism Enhances Pancreatic Insulin
      Secretion and Modifies the Risk of Diabetes.
PG  - 929-40
LID - 10.1016/j.cmet.2013.05.002 [doi]
LID - S1550-4131(13)00191-5 [pii]
AB  - The fibroblast growth factor receptor 4 (FGFR4)-R388 single-nucleotide
      polymorphism has been associated with cancer risk and prognosis. Here we show
      that the FGFR4-R388 allele yields a receptor variant that preferentially promotes
      STAT3/5 signaling. This STAT activation transcriptionally induces Grb14 in
      pancreatic endocrine cells to promote insulin secretion. Knockin mice with the
      FGFR4 variant allele develop pancreatic islets that secrete more insulin, a
      feature that is reversed through Grb14 deletion and enhanced with FGF19
      administration. We also show in humans that the FGFR4-R388 allele enhances islet 
      function and may protect against type 2 diabetes. These data support a common
      genetic link underlying cancer and hyperinsulinemia.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Ontario Cancer Institute, University Health Network, Toronto, ON M5G 2M9, Canada.
      Electronic address: shereen.ezzat@utoronto.ca.
FAU - Ezzat, Shereen
AU  - Ezzat S
FAU - Zheng, Lei
AU  - Zheng L
FAU - Florez, Jose C
AU  - Florez JC
FAU - Stefan, Norbert
AU  - Stefan N
FAU - Mayr, Thomas
AU  - Mayr T
FAU - Hliang, Maw Maw
AU  - Hliang MM
FAU - Jablonski, Kathleen
AU  - Jablonski K
FAU - Harden, Maegan
AU  - Harden M
FAU - Stancakova, Alena
AU  - Stancakova A
FAU - Laakso, Markku
AU  - Laakso M
FAU - Haring, Hans-Ulrich
AU  - Haring HU
FAU - Ullrich, Axel
AU  - Ullrich A
FAU - Asa, Sylvia L
AU  - Asa SL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/08/23 [received]
PHST- 2013/01/18 [revised]
PHST- 2013/04/05 [accepted]
AID - S1550-4131(13)00191-5 [pii]
AID - 10.1016/j.cmet.2013.05.002 [doi]
PST - ppublish
SO  - Cell Metab. 2013 Jun 4;17(6):929-40. doi: 10.1016/j.cmet.2013.05.002.

PMID- 23747246
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun 4
TI  - Innate immune receptors: key regulators of metabolic disease progression.
PG  - 873-82
LID - 10.1016/j.cmet.2013.05.011 [doi]
LID - S1550-4131(13)00201-5 [pii]
AB  - The study of the intersection of immunology and metabolism is a growing field
      fueled by the increased prevalence of obesity-associated pathologies.
      Importantly, the capacity of the innate immune system to sense metabolic stress
      induced by nutritional surplus has been linked with the progression of obesity,
      insulin resistance, type 2 diabetes mellitus, nonalcoholic fatty liver disease,
      and atherosclerosis. Moreover, it is clear that the innate immune system
      regulates the composition of the intestinal microbiota, which impacts multiple
      host metabolic processes. Here we review recent studies in this emerging field
      with an emphasis on how innate immune receptors determine metabolic disease
      progression.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Immunobiology, Yale University School of Medicine, New Haven, CT
      06520, USA.
FAU - Jin, Chengcheng
AU  - Jin C
FAU - Henao-Mejia, Jorge
AU  - Henao-Mejia J
FAU - Flavell, Richard A
AU  - Flavell RA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/02 [received]
PHST- 2013/05/15 [revised]
PHST- 2013/05/16 [accepted]
AID - S1550-4131(13)00201-5 [pii]
AID - 10.1016/j.cmet.2013.05.011 [doi]
PST - ppublish
SO  - Cell Metab. 2013 Jun 4;17(6):873-82. doi: 10.1016/j.cmet.2013.05.011.

PMID- 23747245
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun 4
TI  - Inflammation in obesity and diabetes: islet dysfunction and therapeutic
      opportunity.
PG  - 860-72
LID - 10.1016/j.cmet.2013.05.001 [doi]
LID - S1550-4131(13)00189-7 [pii]
AB  - The role of the immune system is to restore functionality in response to stress. 
      Increasing evidence shows that this function is not limited to insults by
      infection or injury and plays a role in response to overnutrition. Initially,
      this metabolic activation of the immune system is a physiological response, but
      it may become deleterious with time. Therefore, therapeutic interventions should 
      aim at modulating the immune system rather than simply damping it. In this
      article, we describe the physiology and pathology of the immune system during
      obesity and diabetes with a focus on islet inflammation, the IL-1beta pathway,
      and clinical translation.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Endocrinology, Diabetes, and Metabolism and Department of Biomedicine, University
      Hospital Basel, 4031 Basel, Switzerland. Electronic address: marc.donath@usb.ch.
FAU - Donath, Marc Y
AU  - Donath MY
FAU - Dalmas, Elise
AU  - Dalmas E
FAU - Sauter, Nadine S
AU  - Sauter NS
FAU - Boni-Schnetzler, Marianne
AU  - Boni-Schnetzler M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/11 [received]
PHST- 2013/04/15 [revised]
PHST- 2013/05/01 [accepted]
AID - S1550-4131(13)00189-7 [pii]
AID - 10.1016/j.cmet.2013.05.001 [doi]
PST - ppublish
SO  - Cell Metab. 2013 Jun 4;17(6):860-72. doi: 10.1016/j.cmet.2013.05.001.

PMID- 23747244
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun 4
TI  - Immunological Goings-on in Visceral Adipose Tissue.
PG  - 851-9
LID - 10.1016/j.cmet.2013.05.008 [doi]
LID - S1550-4131(13)00198-8 [pii]
AB  - Chronic, low-grade inflammation of visceral adipose tissue, and systemically, is 
      a critical link between recent strikingly parallel rises in the incidence of
      obesity and type 2 diabetes. Macrophages have been recognized for some time to be
      critical participants in obesity-induced inflammation of adipose tissue. Of late,
      a score of other cell types of the innate and adaptive arms of the immune system 
      have been suggested to play a positive or negative role in adipose tissue
      infiltrates. This piece reviews the existing data on these new participants;
      discusses experimental uncertainties, inconsistencies, and complexities; and puts
      forward a minimalist synthetic scheme.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Immunology, Department of Microbiology and Immunobiology, Harvard
      Medical School, Boston, MA 02115, USA. Electronic address: cbdm@hms.harvard.edu.
FAU - Mathis, Diane
AU  - Mathis D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - S1550-4131(13)00198-8 [pii]
AID - 10.1016/j.cmet.2013.05.008 [doi]
PST - ppublish
SO  - Cell Metab. 2013 Jun 4;17(6):851-9. doi: 10.1016/j.cmet.2013.05.008.

PMID- 23747239
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun 4
TI  - Metformin, microbes, and aging.
PG  - 809-11
LID - 10.1016/j.cmet.2013.05.014 [doi]
LID - S1550-4131(13)00204-0 [pii]
AB  - The mechanisms underlying the biological activity of metformin, a widely
      prescribed drug to treat type 2 diabetes, remain elusive. In a recent issue of
      Cell, Cabreiro et al. report that in C. elegans, metformin indirectly impacts
      lifespan by altering the methionine metabolism of its microbial partner E. coli
      (Cabreiro et al., 2013).
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Institut de Genomique Fonctionnelle de Lyon (IGFL), Ecole Normale Superieure de
      Lyon, CNRS UMR 5242, Universite Claude Bernard Lyon-1, 46 Allee d'Italie, 69364
      Lyon Cedex 07, France.
FAU - Storelli, Gilles
AU  - Storelli G
FAU - Tefit, Melisandre
AU  - Tefit M
FAU - Leulier, Francois
AU  - Leulier F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - S1550-4131(13)00204-0 [pii]
AID - 10.1016/j.cmet.2013.05.014 [doi]
PST - ppublish
SO  - Cell Metab. 2013 Jun 4;17(6):809-11. doi: 10.1016/j.cmet.2013.05.014.

PMID- 23747238
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun 4
TI  - Does a Single Nucleotide Polymorphism in the FGFR Explain the Connection between 
      Diabetes and Cancer?
PG  - 808-9
LID - 10.1016/j.cmet.2013.05.006 [doi]
LID - S1550-4131(13)00196-4 [pii]
AB  - A polymorphism in the fibroblast growth factor receptor 4 gene has been
      associated with cancer progression and treatment resistance and is now reported
      to increase insulin secretion, providing a possible genetic link between
      hyperinsulinemia and cancer (Ezzat et al., 2013).
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Endocrinology, Diabetes & Bone Disease and the Diabetes, Obesity,
      Metabolism Institute, Icahn School of Medicine at Sinai, 1 Gustave L. Levy Place,
      Atran 4(th) floor-36, Box 1055, New York, NY 10029-6574, USA.
FAU - Gallagher, Emily J
AU  - Gallagher EJ
FAU - Leroith, Derek
AU  - Leroith D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - S1550-4131(13)00196-4 [pii]
AID - 10.1016/j.cmet.2013.05.006 [doi]
PST - ppublish
SO  - Cell Metab. 2013 Jun 4;17(6):808-9. doi: 10.1016/j.cmet.2013.05.006.

PMID- 23747192
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-4162 (Electronic)
IS  - 1344-6223 (Linking)
DP  - 2013 Jun 7
TI  - Accidental death of elderly persons under the influence of chlorpheniramine.
LID - S1344-6223(13)00046-1 [pii]
LID - 10.1016/j.legalmed.2013.04.002 [doi]
AB  - Older individuals are susceptible to accident, such as falls, some of which are
      fatal. In such cases, autopsies and toxicological analysis may be deemed
      unnecessary, especially if the critical injuries and manner of death can be
      determined conclusively based on information at the scene and an external
      investigation. Here, we report the results of two autopsies performed on elderly 
      individuals who died accidentally under the influence of chlorpheniramine. These 
      autopsies revealed valuable additional information. Case 1: A woman in her 70s,
      who was living alone, was found dead under the stairs in her house. She had no
      history of a condition that could have led to sudden death. The autopsy revealed 
      a neck fracture, multiple rib fractures, and a coccyx fracture. The
      histopathological findings showed fat embolisms in numerous small vessels of the 
      interalveolar septum. Toxicological analysis of blood samples revealed the
      presence of chlorpheniramine (0.41mug/ml). Case 2: A woman in her 70s, who was
      living alone, was found dead in the bathtub in her house. There was no past
      medical history other than diabetes mellitus and vertigo. The autopsy revealed
      hyper-inflated lungs and brown-red fluids in the trachea, but there was no
      evidence of a pathology or injury that could have induced a loss of
      consciousness. Toxicological analysis of the fluids in the right thoracic cavity 
      revealed the presence of chlorpheniramine (0.57mug/ml). In both cases,
      re-examination of the scene after the autopsy revealed the presence of common
      cold medicine containing chlorpheniramine. The victim may have accidentally
      overdosed on common cold medicine. This overdose would have been compounded by
      anti-histamine-induced drowsiness. The present cases suggest that forensic
      pathologists should always notify physicians/pharmacists of findings pertaining
      to unexpected drug side effects. Such intervention would prevent many accidental 
      deaths. In addition, each autopsy must be performed in conjunction with a
      detailed postmortem investigation. Such efforts would also increase the accuracy 
      of the public health record's mortality statistics.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Tokyo Medical Examiner's Office, Tokyo Metropolitan Government, Japan. Electronic
      address: hideto-@qk9.so-net.ne.jp.
FAU - Suzuki, Hideto
AU  - Suzuki H
FAU - Shigeta, Akio
AU  - Shigeta A
FAU - Fukunaga, Tatsushige
AU  - Fukunaga T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Leg Med (Tokyo)
JT  - Legal medicine (Tokyo, Japan)
JID - 100889186
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/07 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/04/17 [accepted]
AID - S1344-6223(13)00046-1 [pii]
AID - 10.1016/j.legalmed.2013.04.002 [doi]
PST - aheadofprint
SO  - Leg Med (Tokyo). 2013 Jun 7. pii: S1344-6223(13)00046-1. doi:
      10.1016/j.legalmed.2013.04.002.

PMID- 23747181
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
DP  - 2013 Jun 6
TI  - Kidney Transplantation in Type 2 Diabetic Patients: A Matched Survival Analysis.
LID - S0041-1345(12)01333-4 [pii]
LID - 10.1016/j.transproceed.2012.11.013 [doi]
AB  - BACKGROUND: Diabetes mellitus (DM) is the most prevalent cause of kidney failure.
      Some concerns have been raised about the kidney transplantation (KT) results in
      diabetic patients. Therefore, we compared outcomes between diabetic and
      non-diabetic KT patients. METHODS: We included all KT performed in type 2
      diabetic patients in our center from July 1983 to December 2009 with graft
      survivals beyond 3 months. Nondiabetic controls were individually matched with
      diabetic patients with respect to gender, age, year of transplantation, number of
      donor HLA mismatches, and dialysis vintage. The two groups were compared
      concerning patient and graft survivals, delayed graft function (DGF), and
      prevalence of acute rejection episodes (ARE). RESULTS: The 62 diabetic and 62
      nondiabetic patients had a mean follow-up after KT of 102 +/- 64 months. Diabetic
      patients and controls were similar for the matched variables. Death censored
      graft survivals of diabetics versus nondiabetics were 70% and 83% at 5 years and 
      54% and 71% at 10 years, respectively (P = .13). Patient survivals at 5 and 10
      years were 69% and 50% for diabetic versus 96% and 84% for nondiabetic patients, 
      respectively (P < .001). The prevalence of ARE and DGF did not differ
      (chi-squared test, P = .12). Multivariate Cox's proportional hazards analysis
      revealed DM (hazard ratio [HR] 7.72; P = .001) and viral hepatitis (HR = 4.18; P 
      = .02) to correlate with reduced patient survival. CONCLUSION: Survival of
      diabetic patients after KT was reduced but death-censored graft outcomes were
      similar compared with matched nondiabetic patients. Concerns about graft survival
      should not prevent KT for diabetic patients with kidney failure.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Nephrology, Centro Hospitalar do Porto, Porto, Portugal. Electronic
      address: acrisbraga@gmail.com.
FAU - Rocha, A
AU  - Rocha A
FAU - Malheiro, J
AU  - Malheiro J
FAU - Martins, L S
AU  - Martins LS
FAU - Fonseca, I
AU  - Fonseca I
FAU - Dias, L
AU  - Dias L
FAU - Pedroso, S
AU  - Pedroso S
FAU - Almeida, M
AU  - Almeida M
FAU - Henriques, A C
AU  - Henriques AC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/07/23 [received]
PHST- 2012/09/23 [revised]
PHST- 2012/11/08 [accepted]
AID - S0041-1345(12)01333-4 [pii]
AID - 10.1016/j.transproceed.2012.11.013 [doi]
PST - aheadofprint
SO  - Transplant Proc. 2013 Jun 6. pii: S0041-1345(12)01333-4. doi:
      10.1016/j.transproceed.2012.11.013.

PMID- 23747168
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1531-6564 (Electronic)
IS  - 0363-5023 (Linking)
DP  - 2013 Jun 5
TI  - Histopathological Characteristics of Stenosing Flexor Tenosynovitis in Diabetic
      Patients and Possible Associations With Diabetes-Related Variables.
LID - S0363-5023(13)00438-3 [pii]
LID - 10.1016/j.jhsa.2013.03.049 [doi]
AB  - PURPOSE: To compare the histopathological findings of stenosing flexor
      tenosynovitis (SFTS) in diabetic patients with those in nondiabetic patients and 
      to analyze the predominant characteristics of SFTS in diabetic patients by
      statistical methods. METHODS: We included 63 patients (63 specimens) who
      underwent excision of A1 pulleys for SFTS. A total of 38 patients (38 digits)
      were diabetic and 25 (25 digits) were nondiabetic. We obtained specimens from the
      proximal one-third of each A1 pulley and analyzed them by histological and
      immunohistochemical methods. After we identified the predominant
      histopathological characteristics of SFTS in patients with diabetes, we performed
      multiple logistic regression analysis to examine the possible associations
      between the histopathological characteristics and diabetes-related variables.
      RESULTS: We divided histopathological findings into 3 types in both diabetic and 
      nondiabetic groups. Types 1 and 2 showed fibrocartilage metaplasia including
      fibrocartilage-like cells surrounded by basophilic extracellular substances. Type
      2 was characterized by the presence of granulation tissue in the middle layer,
      which was not recognized in type 1. The granulation tissue contained newly formed
      microvessels, stromal cells, a small number of inflammatory cells, and
      extracellular matrix that showed myxomatous degeneration. Type 3 showed a
      decrease in fibrocartilage-like cells with surrounding extracellular eosinophilic
      substances, which was similar to hyaline degeneration. The histopathological
      features of type 2 were found in 68% of the diabetic group and in 28% of the
      nondiabetic group. This difference was statistically significant. The findings of
      type 2 were significantly associated with the severity of diabetic retinopathy
      and hemoglobin A1c values in the diabetic group. CONCLUSIONS: Type 2 findings
      were more frequent in the diabetic group than in the nondiabetic group. A
      pathomechanism to accelerate neovascularization and hypercellularity in the
      granulation tissue in the middle layer of A1 pulley may exist, especially in
      diabetic patients with severe retinopathy and poorly controlled hyperglycemia.
      TYPE OF STUDY/LEVEL OF EVIDENCE: Diagnostic III.
CI  - Copyright (c) 2013 American Society for Surgery of the Hand. Published by
      Elsevier Inc. All rights reserved.
AD  - Departments of Orthopaedic Surgery, Dermatology, Diagnostic Pathology and the
      Clinical Research Center in Diabetes Mellitus, Saiseikai Central Hospital, Tokyo,
      Japan. Electronic address: BZA00713@nifty.com.
FAU - Kameyama, Makoto
AU  - Kameyama M
FAU - Chen, Ko-Ron
AU  - Chen KR
FAU - Mukai, Kiyoshi
AU  - Mukai K
FAU - Shimada, Akira
AU  - Shimada A
FAU - Atsumi, Yoshihito
AU  - Atsumi Y
FAU - Yanagimoto, Shigeru
AU  - Yanagimoto S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Hand Surg Am
JT  - The Journal of hand surgery
JID - 7609631
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/10/03 [received]
PHST- 2013/03/23 [revised]
PHST- 2013/03/25 [accepted]
AID - S0363-5023(13)00438-3 [pii]
AID - 10.1016/j.jhsa.2013.03.049 [doi]
PST - aheadofprint
SO  - J Hand Surg Am. 2013 Jun 5. pii: S0363-5023(13)00438-3. doi:
      10.1016/j.jhsa.2013.03.049.

PMID- 23747163
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1549-4713 (Electronic)
IS  - 0161-6420 (Linking)
DP  - 2013 Jun 6
TI  - Isolated Third, Fourth, and Sixth Cranial Nerve Palsies from Presumed
      Microvascular versus Other Causes: A Prospective Study.
LID - S0161-6420(13)00340-0 [pii]
LID - 10.1016/j.ophtha.2013.04.009 [doi]
AB  - PURPOSE: To estimate the proportion of patients presenting with isolated third,
      fourth, or sixth cranial nerve palsy of presumed microvascular origin versus
      other causes. DESIGN: Prospective, multicenter, observational case series.
      PARTICIPANTS: A total of 109 patients aged 50 years or older with acute isolated 
      ocular motor nerve palsy. TESTING: Magnetic resonance imaging (MRI) of the brain.
      MAIN OUTCOME MEASURES: Causes of acute isolated ocular motor nerve palsy
      (presumed microvascular or other) as determined with early MRI and clinical
      assessment. RESULTS: Among 109 patients enrolled in the study, 22 had cranial
      nerve III palsy, 25 had cranial nerve IV palsy, and 62 had cranial nerve VI
      palsy. A cause other than presumed microvascular ischemia was identified in 18
      patients (16.5%; 95% confidence interval, 10.7-24.6). The presence of 1 or more
      vasculopathic risk factors (diabetes, hypertension, hypercholesterolemia,
      coronary artery disease, myocardial infarction, stroke, and smoking) was
      significantly associated with a presumed microvascular cause (P = 0.003, Fisher
      exact test). Vasculopathic risk factors were also present in 61% of patients
      (11/18) with other causes. In the group of patients who had vasculopathic risk
      factors only, with no other significant medical condition, 10% of patients (8/80)
      were found to have other causes, including midbrain infarction, neoplasms,
      inflammation, pituitary apoplexy, and giant cell arteritis (GCA). By excluding
      patients with third cranial nerve palsies and those with GCA, the incidence of
      other causes for isolated fourth and sixth cranial nerve palsies was 4.7% (3/64).
      CONCLUSIONS: In our series of patients with acute isolated ocular motor nerve
      palsies, a substantial proportion of patients had other causes, including
      neoplasm, GCA, and brain stem infarction. Brain MRI and laboratory workup have a 
      role in the initial evaluation of older patients with isolated acute ocular motor
      nerve palsies regardless of whether vascular risk factors are present. FINANCIAL 
      DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any
      materials discussed in this article.
CI  - Copyright (c) 2013 American Academy of Ophthalmology. Published by Elsevier Inc. 
      All rights reserved.
AD  - Departments of Ophthalmology and Neurology, University of Pennsylvania,
      Philadelphia, Pennsylvania. Electronic address: madhura.tamhankar@uphs.upenn.edu.
FAU - Tamhankar, Madhura A
AU  - Tamhankar MA
FAU - Biousse, Valerie
AU  - Biousse V
FAU - Ying, Gui-Shuang
AU  - Ying GS
FAU - Prasad, Sashank
AU  - Prasad S
FAU - Subramanian, Prem S
AU  - Subramanian PS
FAU - Lee, Michael S
AU  - Lee MS
FAU - Eggenberger, Eric
AU  - Eggenberger E
FAU - Moss, Heather E
AU  - Moss HE
FAU - Pineles, Stacy
AU  - Pineles S
FAU - Bennett, Jeffrey
AU  - Bennett J
FAU - Osborne, Benjamin
AU  - Osborne B
FAU - Volpe, Nicholas J
AU  - Volpe NJ
FAU - Liu, Grant T
AU  - Liu GT
FAU - Bruce, Beau B
AU  - Bruce BB
FAU - Newman, Nancy J
AU  - Newman NJ
FAU - Galetta, Steven L
AU  - Galetta SL
FAU - Balcer, Laura J
AU  - Balcer LJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/19 [received]
PHST- 2013/03/31 [revised]
PHST- 2013/04/09 [accepted]
AID - S0161-6420(13)00340-0 [pii]
AID - 10.1016/j.ophtha.2013.04.009 [doi]
PST - aheadofprint
SO  - Ophthalmology. 2013 Jun 6. pii: S0161-6420(13)00340-0. doi:
      10.1016/j.ophtha.2013.04.009.

PMID- 23747137
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 0003-4266 (Electronic)
IS  - 0003-4266 (Linking)
DP  - 2013 Jun 5
TI  - Do published ADA studies support the ADA-EASD position statement for the
      management of hyperglycaemia in type 2 diabetics?
LID - S0003-4266(13)00070-X [pii]
LID - 10.1016/j.ando.2013.04.001 [doi]
AB  - The American Diabetes Association (ADA) and the European Association for the
      Study of Diabetes (EASD) published a position statement in 2012 on the management
      of hyperglycaemia in patients with type 2 diabetes. The Societe Francophone du
      Diabete (SFD) adopted it while awaiting future French recommendations. This new
      care approach individualises the therapeutic choices and objectives for each
      patient based on their characteristics, through emphasis on the need for mutual
      cooperation with the patient in decision-making. Glycaemic management should
      naturally be considered in the context of overall cardiovascular risk reduction, 
      which should remain the primary objective of treatment. The cornerstone of this
      treatment is based on lifestyle modifications, with the addition of metformin
      monotherapy if the desired glycaemic control is not attained. There are multiple 
      second- and third-line treatment possibilities, and insulin therapy is an option 
      that can be considered early in the bitherapy stage. On the whole, large
      published studies at the ADA conference in Philadelphia in June 2012, which are
      the subject of this article, support this patient-centred position statement.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Service de diabetologie, maladies metaboliques et nutrition, pole
      cardiovasculaire et metabolique, CHU Rangueil, Toulouse, France. Electronic
      address: rimareix.f@chu-toulouse.fr.
FAU - Rimareix, Frederique
AU  - Rimareix F
FAU - Bauduceau, Bernard
AU  - Bauduceau B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Ann Endocrinol (Paris)
JT  - Annales d'endocrinologie
JID - 0116744
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - S0003-4266(13)00070-X [pii]
AID - 10.1016/j.ando.2013.04.001 [doi]
PST - aheadofprint
SO  - Ann Endocrinol (Paris). 2013 Jun 5. pii: S0003-4266(13)00070-X. doi:
      10.1016/j.ando.2013.04.001.

PMID- 23747089
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-5134 (Electronic)
IS  - 0738-3991 (Linking)
DP  - 2013 Jun 6
TI  - Evaluation of a treatment and teaching refresher programme for the optimization
      of intensified insulin therapy in type 1 diabetes.
LID - S0738-3991(13)00208-5 [pii]
LID - 10.1016/j.pec.2013.05.008 [doi]
AB  - OBJECTIVE: Evaluation of an ambulatory diabetes teaching and treatment refresher 
      programme (DTTP) for the optimization of intensified insulin therapy in patients 
      with type 1 diabetes (refresher course). METHODS: 85 outpatients took part in
      this prospective multicentre trial. Metabolic and psychosocial data were analyzed
      at baseline (V1), 6 weeks (V2) and 12 months after DTTP (V3). RESULTS: In
      patients with baseline HbA1c>7% (88%), HbA1c decreased by 0.36% (p=0.004). The
      percentage of patients with HbA1c</=7% increased from 21.3 to 34.9% and with
      HbA1c above 10% decreased from 6.6 to 1.6% at V3. The incidence of hypoglycaemia 
      decreased significantly: non severe hypoglycaemia from 3.31 to
      1.39episodes/pat/week (p=0.001) and severe hypoglycaemia from 0.16 to
      0.03episodes/pat/year (p=0.02). The treatment satisfaction increased by +10 of
      maximal +/-18 points. The negative influence of diabetes on quality of life
      decreased from -1.93 to -1.69 points (p=0.031). CONCLUSION: In a group of
      patients with moderately controlled diabetes type 1 who were already treated with
      intensified insulin therapy, metabolic control, treatment satisfaction and
      quality of life were improved after participation in an ambulatory DTTP without
      increasing insulin dosage, number of injections or insulin species. PRACTICE
      IMPLICATIONS: This DTTP is effective for the optimization of intensified insulin 
      therapy.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Internal Medicine III, University Hospital, Jena, Germany.
      Electronic address: nicolle.mueller@med.uni-jena.de.
FAU - Muller, Nicolle
AU  - Muller N
FAU - Kloos, Christof
AU  - Kloos C
FAU - Samann, Alexander
AU  - Samann A
FAU - Wolf, Gunter
AU  - Wolf G
FAU - Muller, Ulrich Alfons
AU  - Muller UA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Patient Educ Couns
JT  - Patient education and counseling
JID - 8406280
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/29 [received]
PHST- 2013/04/11 [revised]
PHST- 2013/05/13 [accepted]
AID - S0738-3991(13)00208-5 [pii]
AID - 10.1016/j.pec.2013.05.008 [doi]
PST - aheadofprint
SO  - Patient Educ Couns. 2013 Jun 6. pii: S0738-3991(13)00208-5. doi:
      10.1016/j.pec.2013.05.008.

PMID- 23747070
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1879-0410 (Electronic)
IS  - 0955-0674 (Linking)
DP  - 2013 Jun 7
TI  - Assembling a primary cilium.
LID - S0955-0674(13)00074-4 [pii]
LID - 10.1016/j.ceb.2013.04.011 [doi]
AB  - Cilia are evolutionarily conserved, membrane-bound, microtubular projections
      emanating from the cell surface. They are assembled on virtually all cell types
      in the human body, with very few exceptions, and several recent reviews have
      covered the topic in great detail [1-3]. The cilium is assembled from mature
      (mother) centrioles or basal bodies, which serve to nucleate growth of axonemes
      that give rise to two structurally distinct variants, motile and nonmotile cilia.
      Whereas motile cilia are typically found in large bundles and beat synchronously 
      to generate fluid flow, primary cilia (with the exception of those found at the
      embryonic node) are generally immotile and are found as solitary organelles
      [3,4]. Remarkably, until recently, the primary cilium was considered a vestigial 
      organelle without apparent biological function. However, research over the past
      decade has established that the primary cilium is capable of transducing
      essential signaling information from the extracellular milieu [1,5]. Defects in
      the cilium, and the structure from which it arises, the basal body, have been
      shown to cause a spectrum of diseases, ranging from developmental defects to
      obesity, diabetes, and cancer [6]. Many of these diseases, or ciliopathies, are
      manifested as genetic syndromes, such as Joubert syndrome, Bardet-Biedel (BBS),
      Meckel-Gruber (MKS), and Nephronophthisis (NPHP) [6], illustrating the importance
      of understanding cilium structure and function and the mechanisms required for
      its assembly. This review focuses primarily on recent advances in our
      understanding of the regulatory controls governing the assembly and maintenance
      of the primary cilium.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Pathology and Cancer Institute, Smilow Research Center, New York
      University School of Medicine, New York, NY 10016, USA.
FAU - Kim, Sehyun
AU  - Kim S
FAU - Dynlacht, Brian David
AU  - Dynlacht BD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Curr Opin Cell Biol
JT  - Current opinion in cell biology
JID - 8913428
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/08 [received]
PHST- 2013/04/24 [accepted]
AID - S0955-0674(13)00074-4 [pii]
AID - 10.1016/j.ceb.2013.04.011 [doi]
PST - aheadofprint
SO  - Curr Opin Cell Biol. 2013 Jun 7. pii: S0955-0674(13)00074-4. doi:
      10.1016/j.ceb.2013.04.011.

PMID- 23747044
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Jun 5
TI  - Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With
      Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary
      Intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity]
      Study).
LID - S0002-9149(13)01122-3 [pii]
LID - 10.1016/j.amjcard.2013.05.010 [doi]
AB  - High residual platelet reactivity (RPR) on clopidogrel treatment has been
      associated with increased risk for ischemic events during follow-up in patients
      with acute coronary syndromes. The aim of this study was to assess the incidence,
      predictors, and clinical consequences of high RPR in a large population of
      patients with non-ST-segment elevation acute coronary syndromes who underwent
      percutaneous coronary intervention and stenting. Overall, 833 patients received
      point-of-care testing of platelet inhibition 30 days after percutaneous coronary 
      intervention. High RPR was diagnosed on the basis of P2Y12 reaction units >230.
      The incidence and predictors of death, myocardial infarction, stroke, and serious
      bleeding events were assessed up to 1 year from the day of testing. P2Y12
      reaction units were normally distributed, and 264 patients were classified as
      poor responders (31.7%). Independent predictors of response to clopidogrel were
      male gender (odds ratio [OR] 1.51), age (OR 0.96), diabetes mellitus (OR 0.51),
      and use of proton pump inhibitors (OR 0.59). At 1 year, poor responders showed
      higher rates of death (4.6% vs 1.9%, p = 0.032) and serious bleeding events (4.9%
      vs 1.8%, p = 0.009) compared with good responders. After adjustment for
      confounders, high RPR did not emerge as an independent predictor of mortality (OR
      0.57, 95% confidence interval [CI] 0.23 to 1.42, p = 0.23) or serious bleeding
      events (OR 0.61, 95% CI 0.25 to 1.52, p = 0.29). The results did not change using
      the a cut-off value for P2Y12 reaction units of 208. In conclusion, 1/3 of
      patients with acute coronary syndromes who underwent percutaneous coronary
      intervention and stenting showed high on-treatment RPR on bedside monitoring.
      They had a worse prognosis, but the level of platelet inhibition was not
      independently associated with the incidence of ischemic or bleeding events.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Institute of Cardiology, University of Bologna, Policlinico S. Orsola-Malpighi,
      Bologna, Italy. Electronic address: francesco.saia@unibo.it.
FAU - Saia, Francesco
AU  - Saia F
FAU - Marino, Massimiliano
AU  - Marino M
FAU - Campo, Gianluca
AU  - Campo G
FAU - Valgimigli, Marco
AU  - Valgimigli M
FAU - Guastaroba, Paolo
AU  - Guastaroba P
FAU - Taglieri, Nevio
AU  - Taglieri N
FAU - Tondi, Stefano
AU  - Tondi S
FAU - Manari, Antonio
AU  - Manari A
FAU - Guiducci, Vincenzo
AU  - Guiducci V
FAU - Sangiorgio, Pietro
AU  - Sangiorgio P
FAU - Varani, Elisabetta
AU  - Varani E
FAU - Magnavacchi, Paolo
AU  - Magnavacchi P
FAU - De Palma, Rossana
AU  - De Palma R
FAU - Marzocchi, Antonio
AU  - Marzocchi A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/02 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/02 [accepted]
AID - S0002-9149(13)01122-3 [pii]
AID - 10.1016/j.amjcard.2013.05.010 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Jun 5. pii: S0002-9149(13)01122-3. doi:
      10.1016/j.amjcard.2013.05.010.

PMID- 23746960
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
DP  - 2013 May 28
TI  - Effect of sleeve gastrectomy on body weight, food intake, glucose tolerance, and 
      metabolic hormone level in two different rat models: Goto-Kakizaki and
      diet-induced obese rat.
LID - S0022-4804(13)00471-X [pii]
LID - 10.1016/j.jss.2013.05.019 [doi]
AB  - BACKGROUND: It is still an important question whether sleeve gastrectomy (SG) is 
      appropriate only in the context of obesity-the condition for which it was
      originally developed-or whether lean people with insulin-deficient diabetes might
      also benefit. The aim of this study is to evaluate the effects of SG in
      Goto-Kakizaki (GK) and diet-induced obese (DIO) rats that have distinct
      characteristics in beta-cell function and fat mass. MATERIALS AND METHODS: SG was
      performed in GK and DIO rats. Body weight, food intake, and fasting blood glucose
      were monitored after surgery. Des-acyl ghrelin in fasting condition and blood
      glucose, insulin, and glucagon-like peptide-1 levels during meal test were
      measured. Homeostatic model assessment and insulinogenic index were examined.
      RESULTS: In both GK and DIO rats, SG improved glucose tolerance with increased
      glucagon-like peptide-1 and insulin secretion during meal test, and reduced
      fasting des-acyl ghrelin levels. Insulin sensitivity was enhanced after SG in DIO
      rats. The improvement in glucose tolerance after SG was shown earlier in DIO rats
      than in GK rats and weight regain after SG occurred faster and was more prominent
      in GK rats than in DIO rats. CONCLUSIONS: In both DIO and GK rats, SG could
      improve glucose tolerance with increased insulin secretion and/or action. The
      improvement in glucose tolerance was shown earlier in DIO rats than in GK rats.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowa-cho,
      Otsu, Shiga, Japan.
FAU - Trung, Vo Nguyen
AU  - Trung VN
FAU - Yamamoto, Hiroshi
AU  - Yamamoto H
FAU - Yamaguchi, Tsuyoshi
AU  - Yamaguchi T
FAU - Murata, Satoshi
AU  - Murata S
FAU - Akabori, Hiroya
AU  - Akabori H
FAU - Ugi, Satoshi
AU  - Ugi S
FAU - Maegawa, Hiroshi
AU  - Maegawa H
FAU - Tani, Tohru
AU  - Tani T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/22 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/05/03 [accepted]
AID - S0022-4804(13)00471-X [pii]
AID - 10.1016/j.jss.2013.05.019 [doi]
PST - aheadofprint
SO  - J Surg Res. 2013 May 28. pii: S0022-4804(13)00471-X. doi:
      10.1016/j.jss.2013.05.019.

PMID- 23746867
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1097-6833 (Electronic)
IS  - 0022-3476 (Linking)
DP  - 2013 Jun 6
TI  - Metabolic Safety of Growth Hormone in Type 1 Diabetes and Idiopathic Growth
      Hormone Deficiency.
LID - S0022-3476(13)00510-6 [pii]
LID - 10.1016/j.jpeds.2013.04.045 [doi]
AB  - OBJECTIVE: To evaluate metabolic consequences of growth hormone (GH) treatment in
      children with type 1 diabetes. STUDY DESIGN: This study is an analysis of
      metabolic changes in 37 patients with childhood-onset GH deficiency and type 1
      diabetes, documented in the Diabetes Patienten Verlaufsdocumentationsystem
      database. Main outcome measures were changes in hemoglobin A1c and daily insulin 
      requirements during GH therapy in children with GH deficiency and type 1 diabetes
      compared with a large cohort of adolescents with type 1 diabetes. RESULTS:
      Thirty-seven patients with type 1 diabetes and a diagnosis of idiopathic GH
      deficiency after onset of diabetes were compared with 48 856 patients with type 1
      diabetes. After adjustment for age, sex, duration of diabetes, and migration
      background, a significant difference in mean daily insulin requirement was seen
      between the 2 groups (1.0 IU/kg/day in subjects with GH deficiency and type 1
      diabetes vs 0.85 IU/kg/day in controls; P < .01) and height-SDS (-2.0 in subjects
      with GH deficiency and diabetes vs +0.03 in controls; P < .0001). There was no
      significant between-group difference in hemoglobin concentration, however (8.1%
      +/- 1.4% in patients with GH deficiency and type 1 diabetes vs 8.2% +/- 1.7% in
      those with type 1 diabetes only; P > .05). CONCLUSION: An increased daily insulin
      requirement should be considered in patients with type 1 diabetes treated with
      GH. With adequate adaptation of insulin dosage, metabolic control is not impaired
      during GH treatment.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Technical
      University Munchen, Munich, Germany. Electronic address:
      Walter.Bonfig@lrz.tum.de.
FAU - Bonfig, Walter
AU  - Bonfig W
FAU - Molz, Katharina
AU  - Molz K
FAU - Woelfle, Joachim
AU  - Woelfle J
FAU - Hofer, Sabine E
AU  - Hofer SE
FAU - Hauffa, Berthold P
AU  - Hauffa BP
FAU - Schoenau, Eckhard
AU  - Schoenau E
FAU - Golembowski, Sven
AU  - Golembowski S
FAU - Wudy, Stefan A
AU  - Wudy SA
FAU - Holl, Reinhard W
AU  - Holl RW
CN  - Diabetes Patienten Verlaufsdocumentationsystem Initiative of the German Working
      Group for Pediatric Diabetology and the German Bundesministerium fur Bildung und 
      Forschung Competence Net for Diabetes Mellitus
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/08 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/04/23 [accepted]
AID - S0022-3476(13)00510-6 [pii]
AID - 10.1016/j.jpeds.2013.04.045 [doi]
PST - aheadofprint
SO  - J Pediatr. 2013 Jun 6. pii: S0022-3476(13)00510-6. doi:
      10.1016/j.jpeds.2013.04.045.

PMID- 23746852
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 Jun 6
TI  - Intensity of peri-operative glycemic control and postoperative outcomes in
      patients with diabetes: a meta-analysis.
LID - S0168-8227(13)00187-3 [pii]
LID - 10.1016/j.diabres.2013.05.003 [doi]
AB  - AIMS: Peri-operative hyperglycemia is a risk factor for postoperative morbidity
      and mortality. However, the role of specific glycemic targets in reducing this
      risk has not been defined, particularly among patients with diabetes. Thus, our
      objective was to conduct a meta-analysis relating distinct peri-operative
      glycemic targets and postoperative outcomes in patients with diabetes. METHODS: A
      systematic review was performed by two authors utilizing pre-specified terms:
      "diabetes mellitus" and "perioperative" and "mortality" and "blood glucose" or
      "strict glucose control" or "intensive insulin therapy" in PUBMED, CENTRAL and
      EMBASE. Glycemic control was considered strict when perioperative targets ranged 
      between 100 and 150mg/dL (5.6-8.3mmol/l), moderate when the targets ranged
      between 150 and 200mg/dL 8.3-11.1mmol/l), and liberal when the target was
      >200mg/dL (11.1mmol/l). The data were combined utilizing the Dersimoan-Laird
      random-effects method. The primary endpoint was postoperative mortality with
      secondary endpoints of postoperative atrial fibrillation, wound infection, and
      stroke. RESULTS: The literature search yielded 760 studies, of which only 6 met
      inclusion criteria. When compared with a liberal target, pooled data showed that 
      a moderate glycemic target was associated with reduced postoperative mortality
      (OR=0.48, 95% CI 0.24-0.76) and stroke (OR=0.61, 95% CI 0.38-0.98), but no
      differences in atrial fibrillation or wound infection were found. There were no
      significant differences in postoperative outcomes between moderate versus strict 
      perioperative glycemic target. CONCLUSIONS: Pooled results suggest that in
      patients with diabetes, a moderate peri-operative glycemic target (150-200mg/dl
      [5.6-8.3mmol/l]) is associated with reduction in postoperative mortality and
      stroke compared with a liberal target (>200mg/dl [11.1mmol/l]), whereas no
      significant additional benefit was found with more strict glycemic control
      (<150mg/dl [5.6mmol/l]).
CI  - Published by Elsevier Ireland Ltd.
AD  - Department of Medicine, Brown University and Hospitalist, Rhode Island Hospital, 
      United States.
FAU - Sathya, Bharath
AU  - Sathya B
FAU - Davis, Rebecca
AU  - Davis R
FAU - Taveira, Tracey
AU  - Taveira T
FAU - Whitlatch, Hilary
AU  - Whitlatch H
FAU - Wu, Wen-Chih
AU  - Wu WC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/25 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/05/13 [accepted]
AID - S0168-8227(13)00187-3 [pii]
AID - 10.1016/j.diabres.2013.05.003 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 Jun 6. pii: S0168-8227(13)00187-3. doi:
      10.1016/j.diabres.2013.05.003.

PMID- 23746838
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 153
IP  - 6
DP  - 2013 Jun 6
TI  - The hallmarks of aging.
PG  - 1194-217
LID - 10.1016/j.cell.2013.05.039 [doi]
LID - S0092-8674(13)00645-4 [pii]
AB  - Aging is characterized by a progressive loss of physiological integrity, leading 
      to impaired function and increased vulnerability to death. This deterioration is 
      the primary risk factor for major human pathologies, including cancer, diabetes, 
      cardiovascular disorders, and neurodegenerative diseases. Aging research has
      experienced an unprecedented advance over recent years, particularly with the
      discovery that the rate of aging is controlled, at least to some extent, by
      genetic pathways and biochemical processes conserved in evolution. This Review
      enumerates nine tentative hallmarks that represent common denominators of aging
      in different organisms, with special emphasis on mammalian aging. These hallmarks
      are: genomic instability, telomere attrition, epigenetic alterations, loss of
      proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular
      senescence, stem cell exhaustion, and altered intercellular communication. A
      major challenge is to dissect the interconnectedness between the candidate
      hallmarks and their relative contributions to aging, with the final goal of
      identifying pharmaceutical targets to improve human health during aging, with
      minimal side effects.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Departamento de Bioquimica y Biologia Molecular, Instituto Universitario de
      Oncologia (IUOPA), Universidad de Oviedo, Oviedo, Spain.
FAU - Lopez-Otin, Carlos
AU  - Lopez-Otin C
FAU - Blasco, Maria A
AU  - Blasco MA
FAU - Partridge, Linda
AU  - Partridge L
FAU - Serrano, Manuel
AU  - Serrano M
FAU - Kroemer, Guido
AU  - Kroemer G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/08/12 [received]
AID - S0092-8674(13)00645-4 [pii]
AID - 10.1016/j.cell.2013.05.039 [doi]
PST - ppublish
SO  - Cell. 2013 Jun 6;153(6):1194-217. doi: 10.1016/j.cell.2013.05.039.

PMID- 23746795
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
DP  - 2013 Jun 5
TI  - Association of ALOX5AP1 SG13S114T/A variant with ischemic stroke, stroke subtypes
      and aspirin resistance.
LID - S0022-510X(13)00247-5 [pii]
LID - 10.1016/j.jns.2013.05.024 [doi]
AB  - The important role of genetic variants in the etiology and pathophysiology of
      stroke is being increasingly recognized. Simultaneously, the influence of genetic
      factors in the clinical outcome of drug therapy cannot be ignored. 5-lipoxygenase
      activating (ALOX5AP) gene involved in the synthesis of leukotrienes, has been
      recognized as an important gene contributing towards susceptibility of stroke
      risk. Leukotrienes are involved in the physiological mechanism of atherosclerotic
      events and inflammation. The present study was designed to identify the
      association of SG13S114T/A polymorphism in ALOX5AP1 gene with risk of stroke, its
      subtypes and aspirin resistance. We studied six hundred and ten patients with
      ischemic stroke and six hundred and ten age and sex matched healthy controls. The
      ischemic stroke was classified according to Trial of Org 10172 in Acute stroke
      Treatment. ALOX5AP1 SG13S114T/A polymorphism was determined using PCR RFLP
      methods. Follow-up was done for all the patients for a period of 3months, 6months
      and 12months. The patients were classified into two groups responders and
      non-responders. The non-responders were identified to have a poor clinical
      outcome defined as a score of more than 2 on modified Rankin Scale Score and less
      than 5 on extended Glassgow Outcome Scale from stroke onset. We found
      statistically significant difference in the genotypic distribution between
      patients and controls (for AA vs TT, chi2=9.894; p=0.001, odds ratio=1.68 (95%
      confidence interval (CI); 1.215, 2.326). Significant difference was observed in
      the frequency of A and T alleles in patients and controls (A vs T chi2=10.23;
      p=0.001, odds ratio=1.301 (95% CI; 1.107, 1.528). Multiple logistic regression
      analysis revealed, the most predictive risk factor for stroke was AA genotype
      [adjusted odds ratio=1.660 (95% CI; 1.167-2.361) and p=0.005], hypertension,
      smoking and diabetes (p<0.001 in each case). We also found a significant
      association of AA genotype with intracranial large artery atherosclerosis
      (p=0.002, odds ratio=2.04, (95%CI; 1.279-3.275) and cardioembolism (p<0.001, odds
      ratio=4.73 (95% CI; 2.661-8.439). The risk of aspirin resistance was
      significantly higher among patients with AA genotype in comparison to carriers of
      homozygous TT genotype (AA vs TT, chi2=22.25, odds ratio=2.983, 95% CI; 1.884-
      4.723, p<0.001). The frequency of recurrence and death events was more in
      non-responders. We didn't find a significant association of the aspirin dose with
      outcome. Our results indicate that the individuals bearing AA genotype of
      ALOX5AP1 SG13S114T/A polymorphism are more prone to stroke and bad outcome as
      well as with aspirin resistance than TA and TT genotypes.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Institute of Genetics and Hospital for Genetic Diseases, Osmania University,
      Begumpet, Hyderabad-500016, India; Dr. NTR University of Health Sciences,
      Vijayawada, Andhra Pradesh, India.
FAU - Sharma, Vandana
AU  - Sharma V
FAU - Dadheech, Sneha
AU  - Dadheech S
FAU - Kaul, Subhash
AU  - Kaul S
FAU - Jyothy, A
AU  - Jyothy A
FAU - Munshi, Anjana
AU  - Munshi A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/09 [received]
PHST- 2013/05/17 [revised]
PHST- 2013/05/17 [accepted]
AID - S0022-510X(13)00247-5 [pii]
AID - 10.1016/j.jns.2013.05.024 [doi]
PST - aheadofprint
SO  - J Neurol Sci. 2013 Jun 5. pii: S0022-510X(13)00247-5. doi:
      10.1016/j.jns.2013.05.024.

PMID- 23746772
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
DP  - 2013 Jun 5
TI  - Maternal and child undernutrition and overweight in low-income and middle-income 
      countries.
LID - S0140-6736(13)60937-X [pii]
LID - 10.1016/S0140-6736(13)60937-X [doi]
AB  - Maternal and child malnutrition in low-income and middle-income countries
      encompasses both undernutrition and a growing problem with overweight and
      obesity. Low body-mass index, indicative of maternal undernutrition, has declined
      somewhat in the past two decades but continues to be prevalent in Asia and
      Africa. Prevalence of maternal overweight has had a steady increase since 1980
      and exceeds that of underweight in all regions. Prevalence of stunting of linear 
      growth of children younger than 5 years has decreased during the past two
      decades, but is higher in south Asia and sub-Saharan Africa than elsewhere and
      globally affected at least 165 million children in 2011; wasting affected at
      least 52 million children. Deficiencies of vitamin A and zinc result in deaths;
      deficiencies of iodine and iron, together with stunting, can contribute to
      children not reaching their developmental potential. Maternal undernutrition
      contributes to fetal growth restriction, which increases the risk of neonatal
      deaths and, for survivors, of stunting by 2 years of age. Suboptimum
      breastfeeding results in an increased risk for mortality in the first 2 years of 
      life. We estimate that undernutrition in the aggregate-including fetal growth
      restriction, stunting, wasting, and deficiencies of vitamin A and zinc along with
      suboptimum breastfeeding-is a cause of 3.1 million child deaths annually or 45%
      of all child deaths in 2011. Maternal overweight and obesity result in increased 
      maternal morbidity and infant mortality. Childhood overweight is becoming an
      increasingly important contributor to adult obesity, diabetes, and
      non-communicable diseases. The high present and future disease burden caused by
      malnutrition in women of reproductive age, pregnancy, and children in the first 2
      years of life should lead to interventions focused on these groups.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA. 
      Electronic address: rblack@jhsph.edu.
FAU - Black, Robert E
AU  - Black RE
FAU - Victora, Cesar G
AU  - Victora CG
FAU - Walker, Susan P
AU  - Walker SP
FAU - Bhutta, Zulfiqar A
AU  - Bhutta ZA
FAU - Christian, Parul
AU  - Christian P
FAU - de Onis, Mercedes
AU  - de Onis M
FAU - Ezzati, Majid
AU  - Ezzati M
FAU - Grantham-McGregor, Sally
AU  - Grantham-McGregor S
FAU - Katz, Joanne
AU  - Katz J
FAU - Martorell, Reynaldo
AU  - Martorell R
FAU - Uauy, Ricardo
AU  - Uauy R
CN  - the Maternal and Child Nutrition Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Lancet
JT  - Lancet
JID - 2985213R
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - S0140-6736(13)60937-X [pii]
AID - 10.1016/S0140-6736(13)60937-X [doi]
PST - aheadofprint
SO  - Lancet. 2013 Jun 5. pii: S0140-6736(13)60937-X. doi:
      10.1016/S0140-6736(13)60937-X.

PMID- 23746697
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1471-499X (Electronic)
IS  - 1471-4914 (Linking)
DP  - 2013 Jun 5
TI  - Chronic adipose tissue inflammation: all immune cells on the stage.
LID - S1471-4914(13)00076-2 [pii]
LID - 10.1016/j.molmed.2013.05.001 [doi]
AB  - Inflammation is indispensable for host homeostasis against invading pathogens and
      efficient wound healing upon tissue malfunction and has to be tightly controlled 
      by various mechanisms to limit excess responses harmful to host tissues. A myriad
      of disease conditions ranging from type 2 diabetes (T2D) to neurodegenerative and
      cardiovascular disorders are now shown to progress due to persistent, unresolved 
      inflammation in metabolic tissues such as adipose, liver, pancreas, muscle, and
      brain. However, their underlying mechanisms are incompletely understood. The
      actions of innate and adaptive immune cells in these ailments are increasingly
      appreciated so much so that a new research area called 'immunometabolism' has
      emerged. In this review, we will highlight the fundamental roles of various
      immune cells in adipose tissue during the initiation and progression of
      obesity-induced inflammation and discuss potential anti-inflammatory therapies
      from different mechanistic points of view.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Laboratory of NF-kappaB Signaling, Institute of Molecular and Cell Biology
      (IMCB), 61 Biopolis Drive, Proteos, Singapore 138673, Singapore; Department of
      Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore
      (NUS), Singapore 117597, Singapore.
FAU - Cildir, Gokhan
AU  - Cildir G
FAU - Akincilar, Semih Can
AU  - Akincilar SC
FAU - Tergaonkar, Vinay
AU  - Tergaonkar V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Trends Mol Med
JT  - Trends in molecular medicine
JID - 100966035
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/20 [received]
PHST- 2013/05/03 [revised]
PHST- 2013/05/06 [accepted]
AID - S1471-4914(13)00076-2 [pii]
AID - 10.1016/j.molmed.2013.05.001 [doi]
PST - aheadofprint
SO  - Trends Mol Med. 2013 Jun 5. pii: S1471-4914(13)00076-2. doi:
      10.1016/j.molmed.2013.05.001.

PMID- 23746556
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 Jun 6
TI  - Impact of diabetes on costs before and after major lower extremity amputations in
      Germany.
LID - S1056-8727(13)00109-8 [pii]
LID - 10.1016/j.jdiacomp.2013.05.001 [doi]
AB  - AIMS: To compare direct medical costs 1year before up to 3years after first major
      lower extremity amputation (LEA) between patients with and without diabetes.
      METHODS: We used health insurance claims data and included patients with a first 
      major LEA between 2005 and 2009. Costs for hospitalization, rehabilitation,
      outpatient care, outpatient drug prescriptions, non-physician services, durable
      medical equipment and long-term care were assessed. We estimated cost ratios (CR)
      for diabetes status using generalized linear models adjusted for age, sex,
      amputation level, care dependency as well as observation time and mortality
      within the corresponding period and costs before LEA. RESULTS: We included 444
      patients with first major LEA (58.3% had diabetes), 71.8% were male and the
      average age was 69.1years. Total mean costs for 1year before LEA were higher in
      patients with diabetes (24,504 vs. 18,961 Euros), which was also confirmed by the
      multivariate analysis (CR: 1.27; 95% CI: 1.06-1.52). Costs up to 24weeks after
      LEA were virtually the same in both groups (36,686 vs. 35,858 Euros), but
      thereafter differences increase again with higher costs for diabetics. Costs for 
      3years after LEA were 115,676 vs. 92,862 Euros, respectively (CR: 1.26; 95% CI:
      1.12-1.42). Hospitalizations accounted for more than 50% of total costs
      irrespective of diabetes status and period. CONCLUSIONS: Costs up to 24weeks
      after first major LEA are mainly driven by the amputation itself irrespective of 
      diabetes. Thereafter, costs for diabetic patients were higher again, which
      underlines the importance of studying long-term costs.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - University of Bremen, Centre for Social Policy Research, Division Health
      Economics, Health Policy and Outcomes Research, Postfach 33 04 40, D-28334,
      Bremen, Germany. Electronic address: hoffmann@zes.uni-bremen.de.
FAU - Hoffmann, Falk
AU  - Hoffmann F
FAU - Claessen, Heiner
AU  - Claessen H
FAU - Morbach, Stephan
AU  - Morbach S
FAU - Waldeyer, Regina
AU  - Waldeyer R
FAU - Glaeske, Gerd
AU  - Glaeske G
FAU - Icks, Andrea
AU  - Icks A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/12/23 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/03 [accepted]
AID - S1056-8727(13)00109-8 [pii]
AID - 10.1016/j.jdiacomp.2013.05.001 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 Jun 6. pii: S1056-8727(13)00109-8. doi:
      10.1016/j.jdiacomp.2013.05.001.

PMID- 23746555
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 Jun 6
TI  - One-year sustained glycemic control and weight reduction in type 2 diabetes after
      addition of liraglutide to metformin followed by insulin detemir according to HbA
      target.
LID - S1056-8727(13)00103-7 [pii]
LID - 10.1016/j.jdiacomp.2013.04.008 [doi]
AB  - AIM: To investigate durability of efficacy and safety over 1year of the sequence 
      of liraglutide added to metformin followed by add-on insulin detemir if glycated 
      hemoglobin (HbA1c) remains >/=7.0%. METHODS: Patients previously uncontrolled on 
      metformin+/-sulfonylurea with HbA1c >/=7.0% after 12weeks of adding liraglutide
      1.8mg to metformin (run-in; sulfonylurea discontinued) were randomized 1:1 to
      52weeks' open-label add-on detemir (randomized treatment [RT] group; n=162) or
      continuation without detemir (randomized control [RC] group; n=161). Patients
      with HbA1c <7.0% continued 52weeks' unchanged treatment (observational group;
      n=498). RESULTS: Run-in HbA1c improvement from 8.3% to 7.6% (-0.6%) was further
      enhanced in the RT group (-0.50%) and maintained in the RC group (+0.01%) over
      52weeks; estimated treatment difference (ETD)[95%CI]: -0.51 [-0.70;-0.31];
      P<0.0001. More RT (52%) than RC patients (22%) achieved HbA1c <7.0% at 52weeks
      (P<0.0001). Run-in weight loss (-3.5kg) was maintained in the RT (-0.05kg) and
      enhanced in the RC group (-1.02kg) after 52weeks; ETD [95%CI]: 0.97 [0.04;1.91]; 
      P=0.04. No major hypoglycemia occurred; minor hypoglycemia rates were low across 
      groups (0.034-0.228 events/patient-year). CONCLUSIONS: Supplementing
      metformin+liraglutide with detemir for 52weeks improved glycemic control with
      sustained weight loss and low hypoglycemia rate.
CI  - Copyright (c) 2013 the authors. Published by Elsevier Inc. All rights reserved.
AD  - Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA.
FAU - Rosenstock, Julio
AU  - Rosenstock J
FAU - Rodbard, Helena W
AU  - Rodbard HW
FAU - Bain, Stephen C
AU  - Bain SC
FAU - D'Alessio, David
AU  - D'Alessio D
FAU - Seufert, Jochen
AU  - Seufert J
FAU - Thomsen, Anne B
AU  - Thomsen AB
FAU - Svendsen, Claus Bo
AU  - Svendsen CB
FAU - Devries, J Hans
AU  - Devries JH
CN  - on behalf of the Liraglutide-Detemir Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/12/18 [received]
PHST- 2013/04/11 [revised]
PHST- 2013/04/11 [accepted]
AID - S1056-8727(13)00103-7 [pii]
AID - 10.1016/j.jdiacomp.2013.04.008 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 Jun 6. pii: S1056-8727(13)00103-7. doi:
      10.1016/j.jdiacomp.2013.04.008.

PMID- 23746545
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-2364 (Electronic)
IS  - 0960-8966 (Linking)
DP  - 2013 Jun 6
TI  - Multisystem disorder and limb girdle muscular dystrophy caused by LMNA p.R28W
      mutation.
LID - S0960-8966(13)00141-7 [pii]
LID - 10.1016/j.nmd.2013.04.008 [doi]
AB  - Primary laminopathies caused by mutations in the LMNA gene typically display an
      extremely pleiotropic clinical presentation including cardiac, muscular and
      metabolic phenotypes. Additionally, many atypical laminopathies have been
      described combining features of two or more of the distinctive disorders or
      syndromes associated with LMNA mutations. We report on a 46-year-old female
      patient with a heterozygous p.R28W LMNA mutation, who presented with a novel
      clinical phenotype comprising severe limb-girdle muscular dystrophy, pronounced
      partial lipodystrophy, cardiac conduction defect, polycystic ovary disease and a 
      metabolic syndrome with insulin-resistant diabetes mellitus and
      hypertriglyceridemia. On examination, her 23-year old daughter solely showed
      early signs of a LGMD phenotype.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Neurology, University of Erlangen, Schwabachanlage 6, 91054
      Erlangen, Germany.
FAU - Turk, Matthias
AU  - Turk M
FAU - Wehnert, Manfred
AU  - Wehnert M
FAU - Schroder, Rolf
AU  - Schroder R
FAU - Chevessier, Frederic
AU  - Chevessier F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Neuromuscul Disord
JT  - Neuromuscular disorders : NMD
JID - 9111470
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/09 [received]
PHST- 2013/04/12 [revised]
PHST- 2013/04/30 [accepted]
AID - S0960-8966(13)00141-7 [pii]
AID - 10.1016/j.nmd.2013.04.008 [doi]
PST - aheadofprint
SO  - Neuromuscul Disord. 2013 Jun 6. pii: S0960-8966(13)00141-7. doi:
      10.1016/j.nmd.2013.04.008.

PMID- 23746413
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
DP  - 2013 Jun 5
TI  - Social connectedness and predictors of successful ageing.
LID - S0378-5122(13)00150-3 [pii]
LID - 10.1016/j.maturitas.2013.05.002 [doi]
AB  - OBJECTIVES: As populations age it is important to minimize the time people live
      in a less than successful state of ageing. Our aim was to identify predictors of 
      successful ageing. STUDY DESIGN: At baseline (1990-1994), demographic,
      anthropometric, health, social connectedness and behavioural data were collected 
      for 41,514 men and women participating in the Melbourne Collaborative Cohort
      Study. Only those born in Australia, New Zealand and UK were included in this
      analysis. At follow-up in 2003-2007 data on health conditions, physical
      disability and psychological stress were collected and used to define successful 
      ageing. A total of 5512 eligible participants with full data who were aged 70 and
      over, were included in this longitudinal analysis. OUTCOME MEASURES: Successful
      ageing at follow-up was defined as aged 70 years or over and absence of diabetes,
      heart attack, coronary artery bypass graft surgery, angioplasty, stroke, cancer; 
      impairment, perceived major difficulty with physical functioning; and low risk of
      psychological distress. RESULTS: A body mass index in the healthy range, low
      waist/hip ratio, not smoking, being physically active, and not having arthritis, 
      asthma, hypertension, or gallstones were associated prospectively with successful
      ageing. There was no evidence for an association of social connectedness with
      successful ageing. CONCLUSIONS: A healthy lifestyle and maintenance of healthy
      weight, but not social connectedness, may improve the chances of ageing
      successfully by our definition. Social connectedness may be related to a
      perception of ageing well, but it does not appear to help avoid the usual
      conditions associated with ageing.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Cancer Epidemiology Centre, The Cancer Council of Victoria, 100 Drummond Street, 
      Carlton, Victoria 3053, Australia. Electronic address:
      allison.hodge@cancervic.org.au.
FAU - Hodge, Allison M
AU  - Hodge AM
FAU - English, Dallas R
AU  - English DR
FAU - Giles, Graham G
AU  - Giles GG
FAU - Flicker, Leon
AU  - Flicker L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Maturitas
JT  - Maturitas
JID - 7807333
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/17 [received]
PHST- 2013/04/30 [revised]
PHST- 2013/05/02 [accepted]
AID - S0378-5122(13)00150-3 [pii]
AID - 10.1016/j.maturitas.2013.05.002 [doi]
PST - aheadofprint
SO  - Maturitas. 2013 Jun 5. pii: S0378-5122(13)00150-3. doi:
      10.1016/j.maturitas.2013.05.002.

PMID- 23746396
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 0870-2551 (Print)
IS  - 0870-2551 (Linking)
DP  - 2013 Jun 6
TI  - Diagnostic yield of current referral strategies for elective coronary angiography
      in suspected coronary artery disease-An analysis of the ACROSS registry.
LID - S0870-2551(13)00100-5 [pii]
LID - 10.1016/j.repc.2012.11.008 [doi]
AB  - INTRODUCTION AND OBJECTIVES: The purpose of this study was to assess the
      diagnostic yield of current referral strategies for elective invasive coronary
      angiography (ICA). METHODS: We performed a cross-sectional observational study of
      consecutive patients without known coronary artery disease (CAD) undergoing
      elective ICA due to chest pain symptoms. The proportion of patients with
      obstructive CAD (defined as the presence of at least one >/=50% stenosis on ICA) 
      was determined according to the use of noninvasive testing. RESULTS: The study
      population consisted of 1892 individuals (60% male, mean age 64+/-11 years), of
      whom 1548 (82%) had a positive noninvasive test: exercise stress test (41%),
      stress myocardial perfusion imaging (36%), stress echocardiogram (3%) or coronary
      computed tomography angiography (3%). Referral without testing occurred in 18% of
      patients. The overall prevalence of obstructive CAD was 57%, higher among those
      with previous testing (58% vs. 51% without previous testing, p=0.026) and when
      anatomic rather than functional tests were used (81.3% vs. 57.1%, p=0.001). A
      positive test and conventional risk factors were all independent predictors of
      obstructive CAD, with adjusted odds ratios (95% confidence interval) of 1.34
      (1.03-1.74) for noninvasive testing, 1.05 (1.04-1.06) for age, 3.48 (2.81-4.29)
      for male gender, 1.86 (1.32-2.62) for current smoking, 1.74 (1.38-2.20) for
      diabetes, 1.30 (1.04-1.62) for hypercholesterolemia, and 1.39 (1.08-1.80) for
      hypertension. CONCLUSIONS: More than 40% of patients without known CAD undergoing
      elective ICA did not have obstructive lesions, even though four out of five had a
      positive noninvasive test. These exams were relatively weak gatekeepers;
      functional tests were more often used but appeared to be outperformed by the
      anatomic test.
CI  - Copyright (c) 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier
      Espana. All rights reserved.
AD  - Departamento de Cardiologia, Hospital de Santa Cruz, Lisboa, Portugal. Electronic
      address: c.miguel.santos@gmail.com.
FAU - Borges Santos, Miguel
AU  - Borges Santos M
FAU - Antonio Miguel, Ferreira
AU  - Antonio Miguel F
FAU - Pedro, de Araujo Goncalves
AU  - Pedro DA
FAU - Raposo, Luis
AU  - Raposo L
FAU - Campante Teles, Rui
AU  - Campante Teles R
FAU - Almeida, Manuel
AU  - Almeida M
FAU - Mendes, Miguel
AU  - Mendes M
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Rev Port Cardiol
JT  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de
      Cardiologia = Portuguese journal of cardiology : an official journal of the
      Portuguese Society of Cardiology
JID - 8710716
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/09/05 [received]
PHST- 2012/11/01 [accepted]
AID - S0870-2551(13)00100-5 [pii]
AID - 10.1016/j.repc.2012.11.008 [doi]
PST - aheadofprint
SO  - Rev Port Cardiol. 2013 Jun 6. pii: S0870-2551(13)00100-5. doi:
      10.1016/j.repc.2012.11.008.

PMID- 23746394
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1748-1716 (Electronic)
IS  - 1748-1708 (Linking)
DP  - 2013 Jun 10
TI  - Sleep, its regulation and possible mechanisms of sleep disturbances.
LID - 10.1111/apha.12134 [doi]
AB  - Disturbances of sleep are among the most common causes to seek medical
      counseling. The feeling of unrefreshing sleep, difficulty to fall asleep and
      early morning awakenings are typical complains. Common experience, as well as
      experimental studies evidence severely compromised cognitive and social
      performance after a prolonged period of wakefulness and/or unrefreshing sleep.
      Recent epidemiological research has identified associations between many common
      diseases and short/long sleep; among them cardiovascular diseases and type II
      diabetes. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Institute of Biomedicine, University of Helsinki.
FAU - Porkka-Heiskanen, Tarja
AU  - Porkka-Heiskanen T
FAU - Zitting, Kirsi-Marja
AU  - Zitting KM
FAU - Wigren, Henna-Kaisa
AU  - Wigren HK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Acta Physiol (Oxf)
JT  - Acta physiologica (Oxford, England)
JID - 101262545
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/12 [received]
PHST- 2013/06/03 [revised]
PHST- 2013/06/04 [accepted]
AID - 10.1111/apha.12134 [doi]
PST - aheadofprint
SO  - Acta Physiol (Oxf). 2013 Jun 10. doi: 10.1111/apha.12134.

PMID- 23746381
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-1244 (Electronic)
IS  - 0899-9007 (Linking)
DP  - 2013 Jun 6
TI  - Effect of glycemic index and glycemic load on energy intake in children.
LID - S0899-9007(13)00096-8 [pii]
LID - 10.1016/j.nut.2013.02.004 [doi]
AB  - OBJECTIVE: Several studies assessed the effect of glycemic index (GI) and
      glycemic load (GL) on energy intake in children but findings are not consistent
      in this regard. The aim of this study is to summarize and assess the evidence for
      the effect of GI and GL on energy intake by conducting a meta-analysis on
      published randomized clinical trials. METHOD: Our search process was conducted in
      PUBMED, Web of Science, and Google Scholar databases. The following keywords were
      searched in any part of published articles: "glycemic index" OR "glycaemic index"
      OR "glycemic load" OR "glycaemic load" OR "energy intake" AND "child" OR
      "children" OR "adolescent" OR "youth." RESULTS: We gathered 5099 articles.
      Non-clinical trial studies that did not intervene by GI or GL or those not
      assessing energy intake as a dependent variable and those that were conducted on 
      patients over age 18 y were excluded. Each included study was evaluated three
      times and the exclusion criteria was checked. Eventually, six studies from 1999
      to 2012 met the criteria (213 participants ages 4-17.5 y). There is heterogeneity
      in the study's participants in the present paper. Children with type 2 diabetes, 
      obesity, or normal-weight children were recruited in different studies. Overall
      effect of consuming low GI (LGI) and low GL (LGL) meals on energy intake was not 
      significant. Subgroup analysis showed that LGI (not LGL) meals decreased
      subsequent energy intake, whereas heterogeneity was significant in the LGI group 
      of studies. Although a slight asymmetry was shown by Begg's funnel plot, the
      Egger's asymmetry was not significant. We did not find any evidence of
      publication bias for studies assessing the effect of low GI or GL meals on energy
      intake. CONCLUSION: Consuming LGI diet (not LGL) has favorable effect on reducing
      energy intake and obesity, subsequently.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Food Security Research Center, Isfahan University of Medical Sciences, Isfahan,
      Iran; Department of Community Nutrition, School of Nutrition and Food Science,
      Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Rouhani, Mohammad Hossein
AU  - Rouhani MH
FAU - Salehi-Abargouei, Amin
AU  - Salehi-Abargouei A
FAU - Azadbakht, Leila
AU  - Azadbakht L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Nutrition
JT  - Nutrition (Burbank, Los Angeles County, Calif.)
JID - 8802712
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/10/30 [received]
PHST- 2012/12/28 [revised]
PHST- 2013/02/01 [accepted]
AID - S0899-9007(13)00096-8 [pii]
AID - 10.1016/j.nut.2013.02.004 [doi]
PST - aheadofprint
SO  - Nutrition. 2013 Jun 6. pii: S0899-9007(13)00096-8. doi:
      10.1016/j.nut.2013.02.004.

PMID- 23746376
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
DP  - 2013 Jun 5
TI  - Association Between Estimated GFR, Health-Related Quality of Life, and Depression
      Among Older Adults With Diabetes: The Diabetes and Aging Study.
LID - S0272-6386(13)00787-7 [pii]
LID - 10.1053/j.ajkd.2013.03.039 [doi]
AB  - BACKGROUND: Although chronic kidney disease (CKD) is a highly prevalent condition
      among older adults with diabetes, the associations between health-related quality
      of life (HRQoL) and severity of CKD in this population are not well understood.
      The objective of this study was to assess HRQoL and depressive symptoms across
      estimated glomerular filtration rate (eGFR) stages. STUDY DESIGN:
      Cross-sectional. SETTING & PARTICIPANTS: 5,805 members of Kaiser Permanente
      Northern California, 60 years or older with diabetes, from the 2005-2006 Diabetes
      Study of Northern California (DISTANCE) survey. PREDICTOR: eGFR categories were
      defined as >/=90 (referent category), 75-89, 60-74, 45-59, 30-44, or </=29
      mL/min/1.73 m2. OUTCOMES: HRQoL was measured using the modified Short Form-8
      Physical Component Summary (PCS) and Mental Component Summary (MCS) scores.
      Depressive symptoms were measured using the Patient Health Questionnaire-8.
      RESULTS: In unadjusted linear regression analyses, physical (PCS) and mental
      (MCS) HRQoL scores were significantly lower with worsening eGFR level. However,
      after adjustment for sociodemographics, diabetes duration, obesity, and
      cardiovascular comorbid conditions and taking into account interactions with
      proteinuria, none of the eGFR categories was significantly or substantively
      associated with PCS or MCS score. In both unadjusted and adjusted analyses,
      higher risk of depressive symptoms was observed in respondents with eGFR </=29
      mL/min/1.73 m2 (relative risk, 2.02; 95% CI, 1.10-3.71; P < 0.05) compared with
      the referent group. However, this eGFR-depression relationship was no longer
      significant after adjusting for hemoglobin level. LIMITATIONS: Participants are
      part of a single health care delivery system. CONCLUSIONS: Our findings suggest
      the need for greater attention to and potential interventions for depression in
      patients with reduced eGFR.
CI  - Copyright (c) 2013 National Kidney Foundation, Inc. All rights reserved.
AD  - Department of Medicine, University of Chicago, Chicago, IL. Electronic address:
      kcampbel@medicine.bsd.uchicago.edu.
FAU - Campbell, Kellie Hunter
AU  - Campbell KH
FAU - Huang, Elbert S
AU  - Huang ES
FAU - Dale, William
AU  - Dale W
FAU - Parker, Melissa M
AU  - Parker MM
FAU - John, Priya M
AU  - John PM
FAU - Young, Bessie A
AU  - Young BA
FAU - Moffet, Howard H
AU  - Moffet HH
FAU - Laiteerapong, Neda
AU  - Laiteerapong N
FAU - Karter, Andrew J
AU  - Karter AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/09/10 [received]
PHST- 2013/03/21 [accepted]
AID - S0272-6386(13)00787-7 [pii]
AID - 10.1053/j.ajkd.2013.03.039 [doi]
PST - aheadofprint
SO  - Am J Kidney Dis. 2013 Jun 5. pii: S0272-6386(13)00787-7. doi:
      10.1053/j.ajkd.2013.03.039.

PMID- 23746309
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 Jun 7
TI  - The Heritability of Circulating Testosterone, Estradiol, Estrone, and SHBG
      Concentrations in Men: The Framingham Heart Study.
LID - 10.1111/cen.12260 [doi]
AB  - OBJECTIVE: Circulating testosterone, estradiol, and estrone concentrations vary
      considerably between men. Though a substantial proportion of this variation may
      be attributed to morbidity and behavioral factors, these cannot account for its
      entirety, suggesting genetic inheritance as a potential additional determinant.
      The analysis described here was intended to estimate the heritability of male
      circulating total testosterone (TT), calculated free testosterone (cFT), estrone 
      (E1), estradiol (E2), and sex hormone-binding globulin (SHBG), along with the
      genetic correlation between these factors. DESIGN: Cross-sectional, observational
      analysis of data from male members of the Offspring and Generation Three cohorts 
      of the Framingham Heart Study. Data were collected in the years 1998-2005.
      PARTICIPANTS: A total of 3,367 community-dwelling men contributed to the
      analysis, including 1,066 father/son and 1,284 brother pairs among other family
      relationships. MEASUREMENTS: Serum sex steroids (TT, E1 and E2) by liquid
      chromatography-tandem mass spectrometry, SHBG by immunofluorometric assay, cFT by
      mass action equation. Heritability was obtained using variance components
      analysis with adjustment for covariates including age, diabetes mellitus, body
      mass index, and smoking status. RESULTS: Age-adjusted heritability estimates were
      0.19, 0.40, 0.40, 0.30, and 0.41 for cFT, TT, E1, E2, and SHBG, respectively.
      Adjustment for covariates did not substantially attenuate these estimates;
      SHBG-adjusted TT results were similar to those obtained for cFT. Genetic
      correlation coefficients (rhoG) indicated substantial genetic association between
      TT and cFT (rhoG=0.68), between TT and SHBG (pG = 0.87), between E1 and E2 (rhoG 
      = 0.46), and between TT and E2 (rhoG = 0.48). CONCLUSION: Circulating
      testosterone, estradiol, and estrone concentrations exhibit substantial
      heritability in adult men. Significant genetic association between testosterone
      and estrogen levels suggests shared genetic pathways. This article is protected
      by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Sections of Endocrinology, Diabetes, and Nutrition; Department of Medicine,
      Boston University School of Medicine, and Department of Biostatistics, Boston
      University School of Public Health, Boston, Massachusetts, 02118.
FAU - Travison, Tg
AU  - Travison T
FAU - Zhuang, Wv
AU  - Zhuang W
FAU - Lunetta, Kl
AU  - Lunetta K
FAU - Karasik, D
AU  - Karasik D
FAU - Bhasin, S
AU  - Bhasin S
FAU - Kiel, Dp
AU  - Kiel D
FAU - Coviello, Ad
AU  - Coviello A
FAU - Murabito, Jm
AU  - Murabito J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/04 [received]
PHST- 2013/01/29 [revised]
PHST- 2013/05/23 [revised]
PHST- 2013/06/02 [accepted]
AID - 10.1111/cen.12260 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 Jun 7. doi: 10.1111/cen.12260.

PMID- 23746308
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
DP  - 2013 Jun 7
TI  - Pretreatment of Donor Islets With the Na /Ca Exchanger Inhibitor Improves the
      Efficiency of Islet Transplantation.
LID - 10.1111/ajt.12306 [doi]
AB  - Pancreatic islet transplantation is an attractive therapy for the treatment of
      insulin-dependent diabetes mellitus. However, the low efficiency of this
      procedure necessitating sequential transplantations of islets with the use of 2-3
      donors for a single recipient, mainly due to the early loss of transplanted
      islets, hampers its clinical application. Previously, we have shown in mice that 
      a large amount of HMGB1 is released from islets soon after their transplantation 
      and that this triggers innate immune rejection with activation of DC, NKT cells
      and neutrophils to produce IFN-gamma, ultimately leading to the early loss of
      transplanted islets. Thus, HMGB1 release plays an initial pivotal role in this
      process; however, its mechanism remains unclear. Here we demonstrate that release
      of HMGB1 from transplanted islets is due to hypoxic damage resulting from Ca2+
      influx into beta cells through the Na+ /Ca2+ exchanger (NCX). Moreover, the
      hypoxia-induced beta cell damage was prevented by pretreatment with an
      NCX-specific inhibitor prior to transplantation, resulting in protection and
      long-term survival of transplanted mouse and human islets when grafted into mice.
      These findings suggest a novel strategy with potentially great impact to improve 
      the efficiency of islet transplantation in clinical settings by targeting donor
      islets rather than recipients.
CI  - (c) Copyright 2013 The American Society of Transplantation and the American
      Society of Transplant Surgeons.
AD  - Central Research Institute for Islet Biology, Fukuoka University, Fukuoka, Japan;
      Department of Regenerative Medicine & Transplantation, Faculty of Medicine,
      Fukuoka University, Fukuoka, Japan.
FAU - Mera, T
AU  - Mera T
FAU - Itoh, T
AU  - Itoh T
FAU - Kita, S
AU  - Kita S
FAU - Kodama, S
AU  - Kodama S
FAU - Kojima, D
AU  - Kojima D
FAU - Nishinakamura, H
AU  - Nishinakamura H
FAU - Okamoto, K
AU  - Okamoto K
FAU - Ohkura, M
AU  - Ohkura M
FAU - Nakai, J
AU  - Nakai J
FAU - Iyoda, T
AU  - Iyoda T
FAU - Iwamoto, T
AU  - Iwamoto T
FAU - Matsuda, T
AU  - Matsuda T
FAU - Baba, A
AU  - Baba A
FAU - Omori, K
AU  - Omori K
FAU - Ono, J
AU  - Ono J
FAU - Watarai, H
AU  - Watarai H
FAU - Taniguchi, M
AU  - Taniguchi M
FAU - Yasunami, Y
AU  - Yasunami Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/12 [received]
PHST- 2013/04/15 [revised]
PHST- 2013/04/16 [accepted]
AID - 10.1111/ajt.12306 [doi]
PST - aheadofprint
SO  - Am J Transplant. 2013 Jun 7. doi: 10.1111/ajt.12306.

PMID- 23746304
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 91
IP  - 6
DP  - 2013 Jun
TI  - The effect of 25-hydroxyvitamin D on insulin sensitivity in obesity: is it
      mediated via adiponectin?
PG  - 496-501
LID - 10.1139/cjpp-2012-0436 [doi]
AB  - There has been substantial recent interest in using vitamin D to improve insulin 
      sensitivity and preventing/delaying diabetes in those at risk. There is little
      consensus on the physiological mechanisms and whether the association is direct
      or indirect through enhanced production of insulin-sensitising chemicals,
      including adiponectin. We examined cross-sectional associations between serum
      25-hydroxyvitamin D (25(OH)D) and insulin sensitivity (Matsuda index),
      parathyroid hormone (PTH), waist circumference, body mass index (BMI),
      triglycerides (TG), total and high molecular weight (HMW) adiponectin, HMW :
      total adiponectin ratio (HMW : total adiponectin), and total cholesterol : HDL
      cholesterol ratio (TC:HDL cholesterol) in 137 Caucasian adults of mean age 43.3
      +/- 8.3 years and BMI 38.8 +/- 6.9 kg/m(2). Total adiponectin (standardised beta 
      = 0.446; p < 0.001), waist circumference (standardised beta = -0.216; p < 0.05), 
      BMI (standardised beta = -0.212; p < 0.05), and age (standardised beta = -0.298; 
      p < 0.001) were independently associated with insulin sensitivity. Serum 25(OH)D 
      (standardised beta = 0.114; p = 0.164) was not associated with insulin
      sensitivity, total or HMW adiponectin, HMW : total adiponectin, or lipids. Our
      results provide the novel finding that 25(OH)D is not associated with HMW
      adiponectin or HMW : total adiponectin in nondiabetic, obese adults and support
      the lack of association between 25(OH)D and lipids noted by others in similar
      groups of patients.
AD  - a Centre for Dietetics Research (C-DIET-R), School of Human Movement Studies,
      Connell Building, The University of Queensland, Brisbane, Queensland, Australia; 
      Mater Medical Research Institute, Brisbane, Queensland, Australia; Translational 
      Research Institute, Brisbane, Queensland, Australia.
FAU - Wright, Olivia R L
AU  - Wright OR
FAU - Hickman, Ingrid J
AU  - Hickman IJ
FAU - Petchey, William G
AU  - Petchey WG
FAU - Sullivan, Clair M
AU  - Sullivan CM
FAU - Ong, Cynthia
AU  - Ong C
FAU - Rose, Felicity J
AU  - Rose FJ
FAU - Ng, Choaping
AU  - Ng C
FAU - Prins, Johannes B
AU  - Prins JB
FAU - Whitehead, Jonathan P
AU  - Whitehead JP
FAU - O'Moore-Sullivan, Trisha M
AU  - O'Moore-Sullivan TM
LA  - eng
PT  - Journal Article
DEP - 20130311
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/11 [aheadofprint]
AID - 10.1139/cjpp-2012-0436 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2013 Jun;91(6):496-501. doi: 10.1139/cjpp-2012-0436.
      Epub 2013 Mar 11.

PMID- 23746214
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 Jun 7
TI  - A comparison of cardiovascular risk indices in patients with polycystic ovary
      syndrome with and without co-existing non-alcoholic fatty liver disease.
LID - 10.1111/cen.12258 [doi]
AB  - BACKGROUND: Women with polycystic ovary syndrome (PCOS) have an adverse
      cardiovascular risk profile and an increased prevalence of non-alcoholic fatty
      liver disease (NAFLD) which is also associated with an adverse cardiovascular
      risk profile. OBJECTIVE: To compare the cardiovascular risk profile of women with
      PCOS alone and women with PCOS and NAFLD. DESIGN, SETTING AND PARTICIPANTS:
      Twenty-five oligoanovulatory women with PCOS were screened for NAFLD (including
      liver biopsy if appropriate) and had their cardiovascular risk factors measured
      which included the inflammatory marker (CRP), endothelial function (measured
      using endoPAT 2000 and serum markers (ICAM-1, VCAM-1, E-selectin and P-selectin))
      and clot structure and function (maximum absorbance (MA), and lysis potential
      (LT)). RESULTS: 12 patients had confirmed PCOS without evidence of NAFLD and 13
      patients had confirmed PCOS with evidence of NAFLD. The PCOS and NAFLD group were
      heavier (BMI 43.9+/-2.2 kg/m2 ) compared to the PCOS alone group (BMI 37.6+/-1.4 
      kg/m2 p=0.03). There was no difference in CRP (7.57+/-0.95 vs 6.59+/-1.87 mmol/L 
      p=0.62) or endothelial function (RH-PAT 1.96+/-0.1 vs 1.74+/-0.16 p=0.25, ICAM-1 
      (221+/-48 vs 250+/-60 ng/ml p=0.19), VCAM-1 (2124+/-78 vs 2314+/-91 ng/ml
      p=0.13), E-selectin (33.9+/-3.3 vs 39.5+/-15.5 ng/ml p=0.31) and P-selectin
      (101.0+/-6.6 vs 95.9+/-10.2 ng/ml p=0.69)). There was no difference in clot
      formation or lysis. CONCLUSION: The patients with PCOS and NAFLD were heavier
      compared to patients with PCOS alone. Despite this we were unable to demonstrate 
      differences in inflammatory markers, endothelial function or clot structure and
      function, suggesting that severity of steatosis is not the most important
      determinant of cardiovascular risk in PCOS. This article is protected by
      copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Diabetes and Endocrinology, University of Hull, Hull, UK.
FAU - Dawson, Alison J
AU  - Dawson AJ
FAU - Sathypalan, Thozhukat
AU  - Sathypalan T
FAU - Smithson, Jacqueline A J
AU  - Smithson JA
FAU - Vince, Rebecca V
AU  - Vince RV
FAU - Coady, Anne-Marie
AU  - Coady AM
FAU - Ajjan, Ramzi
AU  - Ajjan R
FAU - Kilpatrick, Eric S
AU  - Kilpatrick ES
FAU - Atkin, Stephen L
AU  - Atkin SL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/09/04 [received]
PHST- 2012/10/03 [revised]
PHST- 2013/04/29 [revised]
PHST- 2013/06/03 [accepted]
AID - 10.1111/cen.12258 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 Jun 7. doi: 10.1111/cen.12258.

PMID- 23746200
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
VI  - 14
DP  - 2013 Jun 1
TI  - The Emerging Potential of Byproducts as Platforms for Drug Delivery Systems.
AB  - Natural resources are widely used as raw materials by industries. In most cases, 
      abundant byproducts with low economic interest are also generated from
      agro-industrial supply chains. There are several examples for the rational use of
      agro-industrial byproducts in nanobiotechnology field aiming for the development 
      of novel products and processes with high value-added. Examples of these raw
      materials include carapaces, pelages, blood, bagasses, straws, and other
      byproducts. Molecules from such materials (e.g. chitosan, cellulose, and albumin)
      are used as scaffolds of unprecedented novel nanostructures. Research efforts
      comprising a combination of sustainability, nanobiotechnology, and nanomedicine
      have emerged. One major area of nanobiotechnological research of agro-industrial 
      byproducts is the field of drug delivery systems (DDS). Among the main advantages
      of agro-industrial byproducts used as drug carriers are their abundance; low
      price; high biocompatibility; good biodegradability; moderate bioresorbability,
      associated with reduced systemic toxicity or even no toxicity; and often
      bioactivity. The goal of these efforts include not only the possibility to
      characterize and manipulate matter on nanoscale, but also to develop sustainable 
      products and processes, including the development of platforms for drug carriers 
      aiming for the treatment of pathologies such as cancer and diabetes. Indeed,
      there is great hope that the use of agro-industrial byproducts on
      nanobiotechnology will increase not only agricultural and livestock productivity,
      but will also contribute to other areas such as the development of DDS with new
      properties and low production costs; and sustainable environmental management due
      to the reuse of industrial discharged byproducts. This review will compile
      current findings on this perspective in drug delivery describing the challenges
      and applications of byproducts as building blocks for modern drug carrier
      systems.
AD  - Laboratorio de Espectrometria de Massa, Embrapa Recursos Geneticos e
      Biotecnologia, Brasilia, 70770-917, DF, Brazil.
FAU - Joanitti, Graziella A
AU  - Joanitti GA
FAU - Silva, Luciano P
AU  - Silva LP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/04/17 [received]
PHST- 2013/01/29 [revised]
PHST- 2013/02/13 [accepted]
AID - 52757 [pii]
PST - aheadofprint
SO  - Curr Drug Targets. 2013 Jun 1;14.

PMID- 23746128
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1469-4409 (Electronic)
IS  - 0950-2688 (Linking)
DP  - 2013 Jun 7
TI  - Differences in the epidemiology between paediatric and adult invasive
      Streptococcus pyogenes infections.
PG  - 1-8
AB  - SUMMARY In order to investigate for possible differences between paediatric and
      adult invasive Streptococcus pyogenes (iGAS) infections, a total of 142 cases
      were identified in 17 Greek hospitals during 2003-2007, of which 96 were children
      and 46 adults. Bacteraemia, soft tissue infections, streptococcal toxic shock
      syndrome (STSS), and necrotizing fasciitis were the main clinical presentations
      (67.6%, 45.1%, 13.4%, and 12.0% of cases, respectively). Bacteraemia and
      lymphadenitis were significantly more frequent in children (P = 0.019 and 0.021, 
      respectively), whereas STSS was more frequent in adults (P = 0.017). The main
      predisposing factors in children were varicella and streptococcal
      pharyngotonsillitis (25% and 19.8%, respectively), as opposed to malignancy,
      intravenous drug abuse and diabetes mellitus in adults (19.6%, 15.2% and 10.9%,
      respectively). Of the two dominant emm-types, 1 and 12 (28.2% and 8.5%,
      respectively), the proportion of emm-type 12 remained stable during the study
      period, whereas emm-type 1 rates fluctuated considerably. Strains of emm-type 1
      from children were associated with erythromycin susceptibility, STSS and
      intensive-care-unit admission, whereas emm-type 12 isolates from adults were
      associated with erythromycin and clindamycin resistance. Finally, specific
      emm-types were detected exclusively in adults or in children. In conclusion,
      several clinical and epidemiological differences were detected, that could prove 
      useful in designing age-focused strategies for prevention and treatment of iGAS
      infections.
AD  - Department of Microbiology, Aghia Sophia Children's Hospital, Athens, Greece.
FAU - Zachariadou, L
AU  - Zachariadou L
FAU - Stathi, A
AU  - Stathi A
FAU - Tassios, P T
AU  - Tassios PT
FAU - Pangalis, A
AU  - Pangalis A
FAU - Legakis, N J
AU  - Legakis NJ
CN  - the Hellenic Strep-Euro Study Group
FAU - Papaparaskevas, J
AU  - Papaparaskevas J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Epidemiol Infect
JT  - Epidemiology and infection
JID - 8703737
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - S0950268813001386 [pii]
AID - 10.1017/S0950268813001386 [doi]
PST - aheadofprint
SO  - Epidemiol Infect. 2013 Jun 7:1-8.

PMID- 23746107
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 91
IP  - 6
DP  - 2013 Jun
TI  - Garlic and cardioprotection: insights into the molecular mechanisms.
PG  - 448-58
LID - 10.1139/cjpp-2012-0315 [doi]
AB  - Garlic is widely recognized for its immense therapeutic potential. Garlic has
      been shown to exert its beneficial effects against a wide spectrum of diseases,
      including cancer, diabetes, and microbial infections, as well as immunological
      and cardiovascular disorders. Most of the research on garlic has indicated that
      garlic and its active compounds are effective in reducing cardiovascular and
      metabolic risk by normalizing abnormal plasma lipids, oxidized low density
      lipoproteins, abnormal platelet aggregation, high blood pressure, and cardiac
      injury. Some of the beneficial effects of dietary garlic against cardiovascular
      disorders are mediated via the generation of hydrogen sulfide and nitric oxide in
      cardiomyocytes and endothelial cells. Garlic has the potential to protect the
      heart against myocardial infarction, doxorubicin-induced cardiotoxicity,
      arrhythmia, hypertrophy, and ischemia-reperfusion injury. The induction of
      cardiac endogenous antioxidants and the reduction of lipid peroxidation by garlic
      has been reported by several different groups. Other mechanisms, such as
      regulating ion channels, modulating Akt signaling pathways, histone deacetylase
      inhibition, and cytochrome P450 inhibition, could be responsible for the
      cardioprotective effect of garlic. Although several mechanisms have been
      identified for the cardioprotective effect of garlic, there is a need for further
      research to identify the specific molecular mechanism of cardioprotection in
      different cardiac diseases.
AD  - Division of Medicinal Chemistry and Pharmacology, Indian Institute of Chemical
      Technology (IICT), Hyderabad, India.
FAU - Khatua, Tarak Nath
AU  - Khatua TN
FAU - Adela, Ramu
AU  - Adela R
FAU - Banerjee, Sanjay K
AU  - Banerjee SK
LA  - eng
PT  - Journal Article
DEP - 20130306
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/06 [aheadofprint]
AID - 10.1139/cjpp-2012-0315 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2013 Jun;91(6):448-58. doi: 10.1139/cjpp-2012-0315. Epub
      2013 Mar 6.

PMID- 23746081
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
VI  - 9
DP  - 2013 Jun 7
TI  - Targeting Peroxisome Proliferator-Activated Receptor Gamma for Generation of
      Antidiabetic Drug.
AB  - The incidence of Diabetes Mellitus (DM) has increased to alarming levels not only
      in developed countries but also in developing and underdeveloped countries.
      Scientific data have made it clear by now that patients with DM are predisposed
      to many other diseases. One of the worst associations of DM is with obesity and
      the number of DM patients with obesity is increasing at a very fast pace due to
      dramatic change in life style around the world in last few decades. This
      necessitates the discovery of new drugs to treat increasing numbers of people
      with both DM and obesity. Peroxisome Proliferator activated receptor gamma
      (PPARgamma) is a well known target for DM and thiazolidiniones (TZDs; a common
      class of antidiabetic drug) which includes rosiglitazone and pioglitazone act
      through PPARgamma. Recent studies have demonstrated that PPARgamma apart from
      being important in glucose utilization also plays a critical role in lipid
      metabolism and energy homeostasis affecting long-term metabolic status. The
      possibility of selective modulation of PPARgamma has opened up a whole new avenue
      of research and has the potential of producing some drug which can simultaneously
      fight both DM and obesity, without the side-effects of the currently available
      PPARgamma modulators. Here, we discuss various aspects of selective modulation of
      PPARgamma action.
AD  - Department of Applied Chemistry, Birla Institute of Technology, Mesra, Jharkhand,
      India.asharon@bitmesra.ac.in.
FAU - Karak, Milandip
AU  - Karak M
FAU - Bal, Naresh Chandra
AU  - Bal NC
FAU - Bal, Chandralata
AU  - Bal C
FAU - Sharon, Ashoke
AU  - Sharon A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/12/23 [received]
PHST- 2013/05/06 [revised]
PHST- 2013/05/10 [accepted]
AID - 52683 [pii]
PST - aheadofprint
SO  - Curr Diabetes Rev. 2013 Jun 7;9.

PMID- 23746073
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
DP  - 2013 Jun 7
TI  - Prevalence and risk factors of asymptomatic intracranial arterial stenosis in a
      community-based population of Chinese adults.
LID - 10.1111/ene.12210 [doi]
AB  - BACKGROUND AND PURPOSE: Intracranial arterial stenosis (ICAS) is one of the most 
      common causes of ischaemic stroke in Asia. Knowledge of the prevalence and risk
      factors of asymptomatic ICAS is limited. The prevalence of ICASwas therefore
      investigated and its risk factors in a Chinese community-based population were
      explored. METHODS: From 2010 to 2011, a stratified (by sex and age) random sample
      of 5440 participants aged 40 years or older were enrolled in the study. ICAS was 
      assessed using transcranial Doppler. Logistic regression was used to evaluate
      potential risk factors associated with ICAS in participants. RESULTS: In total,
      13.2% (95% CI 12.3-14.1) of the subjects had ICAS, and women were more likely
      than men to have ICAS in the 40-49 year age group. Hypertension [odds ratio (OR) 
      = 2.23, 95%CI 1.87-2.66], diabetes (OR = 1.99, 95%CI 1.62-2.45), left ventricular
      hypertrophy (OR = 1.66, 95%CI 1.18-2.34) and elevated high-sensitivity C-reactive
      protein (OR = 1.55, 95%CI 1.19-2.02) were independently associated with higher
      prevalence of ICAS after adjusting for age, gender, body mass index, smoking
      status and other covariates. Of the 716 ICAS individuals, 90.6% had one or more
      of these risk factors. Amongst the subjects who had at least one risk factor,
      15.2% had ICAS. CONCLUSIONS: Intracranial artery stenosis is common in the
      Chinese population. Individuals who had one or more risk factors were more likely
      to have ICAS, suggesting more aggressive risk factor management.
CI  - (c) 2013 The Author(s) European Journal of Neurology (c) 2013 EFNS.
AD  - Department of Neurology, BeijingTianTan Hospital, Capital Medical University,
      Beijing, China; Department of Neurology, The General Hospital of Chinese People's
      Armed Police Forces, Beijing, China.
FAU - Zhang, S
AU  - Zhang S
FAU - Zhou, Y
AU  - Zhou Y
FAU - Zhang, Y
AU  - Zhang Y
FAU - Gao, X
AU  - Gao X
FAU - Zhang, Q
AU  - Zhang Q
FAU - Wang, A
AU  - Wang A
FAU - Jia, Z
AU  - Jia Z
FAU - Wu, S
AU  - Wu S
FAU - Zhao, X
AU  - Zhao X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Eur J Neurol
JT  - European journal of neurology : the official journal of the European Federation
      of Neurological Societies
JID - 9506311
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/08/20 [received]
PHST- 2013/04/30 [accepted]
AID - 10.1111/ene.12210 [doi]
PST - aheadofprint
SO  - Eur J Neurol. 2013 Jun 7. doi: 10.1111/ene.12210.

PMID- 23746063
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1535-3907 (Electronic)
IS  - 1535-3893 (Linking)
DP  - 2013 Jun 7
TI  - Peptidomic Profiling of Secreted Products from Pancreatic Islet Culture Results
      in a Higher Yield of Full-Length Peptide Hormones than Found Using Cell Lysis
      Procedures.
AB  - Peptide Hormone Acquisition through Smart Sampling Technique-Mass Spectrometry
      (PHASST-MS) is a peptidomics platform that employs high resolution liquid
      chromatography/mass spectrometry (LC/MS) techniques to identify peptide hormones 
      secreted from in vitro or ex vivo cultures enriched in endocrine cells.
      Application of the methodology to the study of murine pancreatic islets has
      permitted evaluation of the strengths and weaknesses of the approach, as well as 
      comparison of our results with a published islet study that employed traditional 
      cellular lysis procedures. We found that, while our PHASST-MS approach identified
      fewer peptides in total, we had greater representation of intact peptide
      hormones. The technique was further refined to improve coverage of hydrophilic as
      well as hydrophobic peptides, and subsequently applied to human pancreatic islet 
      cultures derived from normal donors or donors with type 2 diabetes.
      Interestingly, in addition to the expected islet hormones, we identified
      alpha-cell-derived bioactive GLP-1, consistent with recent reports of paracrine
      effects of this hormone on beta-cell function. We also identified many novel
      peptides derived from neurohormonal precursors and proteins related to the cell
      secretory system. Taken together, these results suggest the PHASST-MS strategy of
      focusing on cellular secreted products rather than the total tissue peptidome may
      improve the probability of discovering novel bioactive peptides, and also has the
      potential to offer important new insights into the secretion and function of
      known hormones.
FAU - Taylor, Steven W
AU  - Taylor SW
FAU - Nikoulina, Svetlana E
AU  - Nikoulina SE
FAU - Andon, Nancy L
AU  - Andon NL
FAU - Lowe, Carolyn
AU  - Lowe C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Proteome Res
JT  - Journal of proteome research
JID - 101128775
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1021/pr400115q [doi]
PST - aheadofprint
SO  - J Proteome Res. 2013 Jun 7.

PMID- 23746040
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 91
IP  - 6
DP  - 2013 Jun
TI  - Germinated grains: a superior whole grain functional food?
PG  - 429-41
LID - 10.1139/cjpp-2012-0351 [doi]
AB  - Grains are global dietary staples that when consumed in whole grain form, offer
      considerable health benefits compared with milled grain foods, including reduced 
      body weight gain and reduced cardiovascular and diabetes risks. Dietary patterns,
      functional foods, and other lifestyle factors play a fundamental role in the
      development and management of epidemic lifestyle diseases that share risks of
      developing adverse metabolic outcomes, including hyperglycaemia, hypertension,
      dyslipidaemia, oxidative stress, and inflammation. Whole grains provide energy,
      nutrients, fibres, and bioactive compounds that may synergistically contribute to
      their protective effects. Despite their benefits, the intake of grains appears to
      be lower than recommended in many countries. Of emerging interest is the
      application of germination processes, which may significantly enhance the
      nutritional and bioactive content of grains, as well as improve palatability.
      Enhancing grain foods in a natural way using germination techniques may therefore
      offer a practical, natural, dietary intervention to increase the health benefits 
      and acceptability of whole grains, with potentially widespread effects across
      populations in attenuating adverse lifestyle disease outcomes. Continuing to
      build on the growing body of in-vitro studies requires substantiation with
      extended in-vivo trials so that we may further develop our understanding of the
      potential of germinated grains as a functional food.
AD  - College of Health and Biomedicine, Victoria University, Melbourne, VIC 8001,
      Australia.
FAU - Nelson, Kristina
AU  - Nelson K
FAU - Stojanovska, Lily
AU  - Stojanovska L
FAU - Vasiljevic, Todor
AU  - Vasiljevic T
FAU - Mathai, Michael
AU  - Mathai M
LA  - eng
PT  - Journal Article
DEP - 20130326
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/26 [aheadofprint]
AID - 10.1139/cjpp-2012-0351 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2013 Jun;91(6):429-41. doi: 10.1139/cjpp-2012-0351. Epub
      2013 Mar 26.

PMID- 23745995
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 43
IP  - 6
DP  - 2013 Jun
TI  - Relationship between glycaemia and length of hospital stay during an acute
      exacerbation of chronic obstructive pulmonary disease.
PG  - 721-4
LID - 10.1111/imj.12157 [doi]
AB  - We have assessed whether glucose concentration and patient outcome are related in
      hospitalised patients when glycaemia is quantified in detail. Continuous glucose 
      monitoring was performed on 47 consecutive subjects with an acute exacerbation of
      chronic obstructive pulmonary disease. Length of hospital stay increased by 10%
      for each mmol/L increase in mean glucose (P = 0.01). In a multivariable analysis,
      mean glucose was independently associated with length of hospital stay (P =
      0.02). These data add weight to evidence that hyperglycaemia may adversely affect
      patient outcomes in hospitalised patients.
CI  - (c) 2013 The Authors; Internal Medicine Journal (c) 2013 Royal Australasian
      College of Physicians.
AD  - Southern Adelaide Diabetes and Endocrine Services, Repatriation General Hospital,
      Australia; Faculty of Health Science, Flinders University, Adelaide, South
      Australia, Australia.
FAU - Burt, M G
AU  - Burt MG
FAU - Roberts, G W
AU  - Roberts GW
FAU - Aguilar-Loza, N R
AU  - Aguilar-Loza NR
FAU - Quinn, S J
AU  - Quinn SJ
FAU - Frith, P A
AU  - Frith PA
FAU - Stranks, S N
AU  - Stranks SN
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/07/17 [received]
PHST- 2012/11/13 [accepted]
AID - 10.1111/imj.12157 [doi]
PST - ppublish
SO  - Intern Med J. 2013 Jun;43(6):721-4. doi: 10.1111/imj.12157.

PMID- 23745945
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 91
IP  - 6
DP  - 2013 Jun
TI  - Phytochemicals targeting genes relevant for type 2 diabetes.
PG  - 397-411
LID - 10.1139/cjpp-2012-0350 [doi]
AB  - Nutrigenomic approaches based on ethnopharmacology and phytotherapy concepts have
      revealed that type 2 diabetes mellitus (T2DM) may be susceptible to dietary
      intervention. Interaction between bioactive food components and the genome may
      influence cell processes and modulate the onset and progression of the disease.
      T2DM, characterized by insulin resistance and beta cell dysfunction, is one of
      the leading causes of death and disability. Despite the great advances that have 
      been made in the understanding and management of this complex, multifactorial
      disease, T2DM has become a worldwide epidemic in the 21st century. Population and
      family studies have revealed a strong genetic component of T2DM, and a number of 
      candidate genes have been identified in humans. Variations in the gene sequences 
      such as single nucleotide polymorphisms, explain the individual differences in
      traits like disease susceptibility and response to treatment. A clear
      understanding of how nutrients affect the expression of genes should facilitate
      the development of individualized intervention and, eventually, treatment
      strategies for T2DM. Review of the literature identified many
      phytochemicals/extracts from traditional medicinal plants that can target
      diabetogenic genes. This review focuses on the genetic aspects of T2DM, nutrient 
      modification of genes relevant for diabetes, and future prospects of nutritional 
      therapy of T2DM.
AD  - Department of Biochemistry and Biotechnology, Annamalai University, Annamalai
      Nagar - 608 002, Tamil Nadu, India.
FAU - Anuradha, Carani Venkatraman
AU  - Anuradha CV
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/05/30 [aheadofprint]
AID - 10.1139/cjpp-2012-0350 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2013 Jun;91(6):397-411. doi: 10.1139/cjpp-2012-0350.
      Epub 2013 May 30.

PMID- 23745830
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 91
IP  - 6
DP  - 2013 Jun
TI  - Functional foods and nutraceuticals as therapeutic tools for the treatment of
      diet-related diseases.
PG  - 387-96
LID - 10.1139/cjpp-2012-0307 [doi]
AB  - In Western societies, the incidence of diet-related diseases is progressively
      increasing due to greater availability of hypercaloric food and a sedentary
      lifestyle. Obesity, diabetes, atherosclerosis, and neurodegeneration are major
      diet-related pathologies that share a common pathogenic denominator of low-grade 
      inflammation. Functional foods and nutraceuticals may represent a novel
      therapeutic approach to prevent or attenuate diet-related disease in view of
      their ability to exert anti-inflammatory responses. In particular, activation of 
      intestinal T regulatory cells and homeostatic regulation of the gut microbiota
      have the potential to reduce low-grade inflammation in diet-related diseases. In 
      this review, clinical applications of polyphenol-rich functional foods and
      nutraceuticals in postprandial inflammation, obesity, and ageing will be
      discussed. We have placed special emphasis on polyphenols since they are broadly 
      distributed in plants.
AD  - a Department of Basic Medical Sciences, Neuroscience and Sensory Organs,
      University of Bari, Policlinico, Piazza G. Cesare 11-70124 Bari, Italy.
FAU - Magrone, Thea
AU  - Magrone T
FAU - Perez de Heredia, Fatima
AU  - Perez de Heredia F
FAU - Jirillo, Emilio
AU  - Jirillo E
FAU - Morabito, Giuseppa
AU  - Morabito G
FAU - Marcos, Ascension
AU  - Marcos A
FAU - Serafini, Mauro
AU  - Serafini M
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/12 [aheadofprint]
AID - 10.1139/cjpp-2012-0307 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2013 Jun;91(6):387-96. doi: 10.1139/cjpp-2012-0307. Epub
      2013 Apr 12.

PMID- 23745825
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
DP  - 2013 Jun 8
TI  - Endothelial Caveolar Subcellular Domain Regulation of Endothelial Nitric Oxide
      Synthase.
LID - 10.1111/1440-1681.12136 [doi]
AB  - Complex regulatory processes alter the activity of endothelial nitric oxide
      synthase (eNOS) leading to nitric oxide (NO) production by endothelial cells
      under various physiological states. These complex processes require specific
      sub-cellular eNOS partitioning between plasma membrane caveolar domains and
      non-caveolar compartments. eNOS translocation from the plasma membrane to
      intracellular compartments is important for eNOS activation and subsequent NO
      biosynthesis. We present data reviewing and interpreting information: 1) the
      coupling of endothelial plasma membrane receptor systems in the caveolar
      structure relative to eNOS trafficking; 2) how eNOS trafficking relates to
      specific protein-protein interaction for inactivation and activation of eNOS; and
      3) how these complex mechanisms confer specific subcellular location relative to 
      eNOS multi-site phosphorylation and signaling. Dysfunction in regulation of eNOS 
      activation may contribute to several disease states; in particular gestational
      endothelial abnormalities (preeclampsia, gestational diabetes, etc) that have
      life-long deleterious health consequences that predispose the offspring to
      develop hypertensive disease, type II diabetes and adiposity.1 This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Obstetrics and Gynecology, University of Texas Medical Branch,
      Galveston, Texas, USA.
FAU - Ramadoss, Jayanth
AU  - Ramadoss J
FAU - Pastore, Mayra B
AU  - Pastore MB
FAU - Magness, Ronald R
AU  - Magness RR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/17 [received]
PHST- 2013/05/29 [revised]
PHST- 2013/05/31 [accepted]
AID - 10.1111/1440-1681.12136 [doi]
PST - aheadofprint
SO  - Clin Exp Pharmacol Physiol. 2013 Jun 8. doi: 10.1111/1440-1681.12136.

PMID- 23745812
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
DP  - 2013 May 31
TI  - Micrornas In Cardiovascular Therapeutics.
AB  - Recent research reveals the crucial role microRNAs (miRNAs) in the pathogenesis
      and progression of many pathological conditions, including cardiovascular
      diseases. It is widely documented that miRNAs represent critical regulators of
      cardiovascular function and participate in almost all aspects of cardiovascular
      biology. In particular, they are involved in several pathophysiological pathways 
      of various manifestations of cardiovascular disease, such as coronary artery
      disease, heart failure, stroke, diabetes mellitus, arterial hypertension and
      cardiac arrhythmias. In the present article we review the available literature
      regarding to the role of miRNAs in certain cardiovascular conditions. Moreover,
      we discuss the therapeutic potential of miRNAs for treating cardiovascular
      diseases and we attempt to highlight future directions.
AD  - 75 Mikras Asias Str, 115 27, Athens, Greece. gsiasos@med.uoa.gr.
FAU - Siasos, Gerasimos
AU  - Siasos G
FAU - Tousoulis, Dimitris
AU  - Tousoulis D
FAU - Tourikis, Panagiotis
AU  - Tourikis P
FAU - Mazaris, Savas
AU  - Mazaris S
FAU - Zakynthinos, Giorgos
AU  - Zakynthinos G
FAU - Oikonomou, Evangelos
AU  - Oikonomou E
FAU - Kokkou, Eleni
AU  - Kokkou E
FAU - Kollia, Christina
AU  - Kollia C
FAU - Stefanadis, Christodoulos
AU  - Stefanadis C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/14 [received]
PHST- 2013/04/29 [accepted]
AID - CTMC-EPUB-20130531-13 [pii]
PST - aheadofprint
SO  - Curr Top Med Chem. 2013 May 31.

PMID- 23745809
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
DP  - 2013 May 31
TI  - The emerging role of microRNA in stroke.
AB  - MicroRNAs (miRNAs) are small non-coding RNAs approximately 22 nucleotides in
      length that play a pivotal role in post-transcriptional gene regulation by
      binding to complementary sites in the 3'-untranslated region of messenger RNAs.
      In the past decade, their role in several human diseases, from cancer to
      cardiovascular disease, has been established by a wealth of evidence. Stroke is
      responsible for 10% of deaths worldwide and is one of the leading causes of
      disability. MiRNAs are involved in stroke risk factors including hypertension,
      atherosclerosis, atrial fibrillation, diabetes and dyslipidemia. The role of
      miRNAs in the pathophysiology of stroke has been the subject of more recent
      investigations. Animal studies, which dominate the field, have demonstrated the
      differential expression of miRNAs in brain and blood following ischemic or
      hemorrhagic insult and the potential use of miRNA antagonists to reduce focal
      cerebral damage. In particular, antagomirs to miR-145, -497, -181a, -1 and let-7f
      have been found to be neuroprotective in vivo. The discovery of circulating
      miRNAs in peripheral blood, which are unexpectedly stable, has allowed the recent
      completion of several studies in human stroke patients that have confirmed the
      differential expression of specific miRNAs following stroke and have addressed
      their potential use as diagnostic and prognostic markers. With miRNA research in 
      stroke still in its infancy, it is anticipated that in the next few years
      significant discoveries that may have important therapeutic implications will
      emerge.
AD  - 1st Department of Neurology, University of Athens Medical School, Eginition
      Hospital, 74 Vas. Sophias Ave., Athens 11528, Greece. kspengos@otenet.gr.
FAU - Koutsis, Georgios
AU  - Koutsis G
FAU - Siasos, Gerasimos
AU  - Siasos G
FAU - Spengos, Konstantinos
AU  - Spengos K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/26 [received]
PHST- 2013/04/29 [accepted]
AID - CTMC-EPUB-20130531-10 [pii]
PST - aheadofprint
SO  - Curr Top Med Chem. 2013 May 31.

PMID- 23745805
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
DP  - 2013 May 31
TI  - Micrornas: Biomarkers For Cardiovascular Disease In Patients With Diabetes
      Mellitus.
AB  - Diabetes mellitus (DM) is a complex metabolic disorder characterized by low
      insulin production/secretion by pancreatic beta cells and/or low responsiveness
      by insulin target tissues MicroRNAs have been associated with DM, but it is not
      clear whether this is a cause or an effect of metabolic abnormalities related to 
      DM. In the hyperglycemic environment miRNAs are in involved in multiple stages of
      cardiovascular disease development and progression. In diabetic patients with
      cardiovascular disease miRNAs could potentially serve as early biomarkers for
      diagnosis and as therapeutic agents. The current review focuses on the
      involvement of miRNAs in molecular mechanisms underlying the pathogenesis of DM
      and its cardiovascular complications.
AD  - University of Chicago Medical Center, Department of Medicine 5841 S. Maryland Ave
      Chicago, IL 60637. alexbriasoulis@uchicago.edu.
FAU - Briasoulis, Alexandros
AU  - Briasoulis A
FAU - Tousoulis, Dimitris
AU  - Tousoulis D
FAU - Vogiatzi, Georgia
AU  - Vogiatzi G
FAU - Siasos, Gerasimos
AU  - Siasos G
FAU - Papageorgiou, Nikos
AU  - Papageorgiou N
FAU - Oikonomou, Evangelos
AU  - Oikonomou E
FAU - Genimata, Vasiliki
AU  - Genimata V
FAU - Konsola, Theodosia
AU  - Konsola T
FAU - Stefanadis, Christodoulos
AU  - Stefanadis C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/26 [received]
PHST- 2013/04/29 [accepted]
AID - CTMC-EPUB-20130531-6 [pii]
PST - aheadofprint
SO  - Curr Top Med Chem. 2013 May 31.

PMID- 23745744
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-5550 (Electronic)
IS  - 1389-2037 (Linking)
DP  - 2013 Jun 4
TI  - Insulin Resistance-Induced Hypertension and a Role of Perivascular Cgrpergic
      Nerves.
AB  - Insulin resistance is defined as a preliminary step of type 2 diabetes mellitus
      with decreased insulin action evoked by continuous postprandial hyperglycemia,
      which is provoked by high fat and calories dieting, a lack of physical activity
      and obesity. In the early phase of type 2 diabetes mellitus, patients have a
      hyperinsulinemia to compensate deficient insulin action by increased secretion
      from the pancreas to maintain euglycemia. Then, pancreatic beta cells
      progressively decrease secretion function, resulting in the development of
      diabetes mellitus with decreased serum insulin levels. Accumulating evidences
      show that insulin resistance is associated with hypertension. However, the
      mechanisms underlying hypertension associated with type 2 diabetes mellitus have 
      still unknown. Therefore, to elucidate the mechanisms of insulin
      resistance-induced hypertension, we investigated that the effects of
      hyperinsulinemia or hyperglycemia on vascular responses mediated by perivascular 
      nerves including sympathetic adrenergic nerves and calcitonin gene-related
      peptide (CGRP)-containing nerves (CGRPergic nerves). In this article, we show
      evidence that insulin resistance-induced hypertension could be resulted from
      increased density and function of sympathetic nerve, and decreased density and
      function of CGRPergic nerves. Furthermore, our findings provide a new insight
      into the research of therapeutic drugs for insulin resistance-induced
      hypertension.
AD  - Department of Clinical Pharmaceutical Science, Graduate School of Medicine,
      Dentistry and Pharmaceutical Sciences, Okayama University, Kita-ku, Okayama,
      Japan.
FAU - Takatori, Shingo
AU  - Takatori S
FAU - Zamami, Yoshito
AU  - Zamami Y
FAU - Hashikawa-Hobara, Narumi
AU  - Hashikawa-Hobara N
FAU - Kawasaki, Hiromu
AU  - Kawasaki H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Curr Protein Pept Sci
JT  - Current protein & peptide science
JID - 100960529
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/08/23 [received]
PHST- 2012/09/18 [revised]
PHST- 2012/09/18 [accepted]
AID - CPPS-EPUB-20130604-4 [pii]
PST - aheadofprint
SO  - Curr Protein Pept Sci. 2013 Jun 4.

PMID- 23745697
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-5550 (Electronic)
IS  - 1389-2037 (Linking)
DP  - 2013 Jun 4
TI  - Islet Amyloid Polypeptide and Diabetes.
AB  - Islet amyloid polypeptide (IAPP, amylin) is a 37 amino acid residue hormone
      expressed mainly by pancreatic islet beta cells and to less extent by some
      gastrointestinal endocrine cells and by certain regions in central nervous
      system. In experimental systems a number of different effects have been ascribed 
      to IAPP but the in vivo importance of many of them is still unknown. At least
      effects on the central nervous system and on endocrine pancreatic cells are
      likely to be physiologically relevant. In these tissues calcitonin receptors and 
      receptor activity-modifying proteins (RAMPs) 1 and 3, creating high affinity IAPP
      receptors have been identified. How expression of the components of these
      complexes are regulated and how further signaling is conducted are more or less
      unknown. IAPP is most well-known for its ability to aggregate into amyloid
      fibrils in islets of Langerhans in association with type 2 diabetes leading to
      loss of beta cells. In addition, amyloid is deposited between endocrine cells and
      between such cells and capillaries and most likely disturbs important
      interactions between the cells. How IAPP receptor complexes are affected by the
      amyloid formation process or by amyloid itself, or vice versa, are completely
      unknown.
AD  - Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, SE-751 85
      Uppsala, Sweden.
FAU - Westermark, Gunilla T
AU  - Westermark GT
FAU - Westermark, Per
AU  - Westermark P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Curr Protein Pept Sci
JT  - Current protein & peptide science
JID - 100960529
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/10/17 [received]
PHST- 2013/01/05 [revised]
PHST- 2013/01/05 [accepted]
AID - CPPS-EPUB-20130604-7 [pii]
PST - aheadofprint
SO  - Curr Protein Pept Sci. 2013 Jun 4.

PMID- 23745680
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1557-7430 (Electronic)
IS  - 1044-5498 (Linking)
DP  - 2013 Jun 8
TI  - Association of Angiotensin-Converting Enzyme and Angiotensin II Type I Receptor
      Gene Polymorphisms with Extreme Obesity in Polish Individuals.
AB  - There is strong evidence for the presence of a functional renin-angiotensin
      system in human adipose tissue. The aim of our study was to investigate the
      association of polymorphic variants of angiotensin-converting enzyme gene (ACE
      I/D) and angiotensin II type I receptor gene (AGTR1 A1166C) with extreme obesity 
      and obesity-associated type 2 diabetes mellitus (T2DM) and to examine their
      combined effect on extremely obese patients. Overall, no significant associations
      were detected between ACE and AGTR1 gene polymorphisms and extreme obesity.
      However, extremely obese patients with T2DM showed an increased frequency of ACE 
      II genotype compared with controls (p<0.05) and with non-diabetic extremely obese
      patients (p<0.01). The results suggest that II genotype of ACE was a significant 
      contributor to extreme obesity in AA homozygotes of AGTR1 gene, regardless of the
      presence of T2DM. Moreover, the analysis of genetic polymorphisms demonstrated
      that ACE II and AGTR1 AC genotypes were most frequently observed in patients with
      extreme obesity and T2DM. On the basis of our results, we suggest that ACE II
      homozygosity may be a significant predictor of extreme obesity and T2DM and that 
      the interaction between ACE and AGTR1 genes may be considered a predisposing
      factor for extreme obesity and extreme obesity-associated T2DM development.
AD  - 1 Department of Biology and Medical Genetics, Medical University of Lodz , Lodz, 
      Poland .
FAU - Pacholczyk, Marta
AU  - Pacholczyk M
FAU - Ferenc, Tomasz
AU  - Ferenc T
FAU - Kowalski, Jan
AU  - Kowalski J
FAU - Adamczyk, Przemyslaw
AU  - Adamczyk P
FAU - Chojnowski, Jacek
AU  - Chojnowski J
FAU - Ponikowska, Irena
AU  - Ponikowska I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - DNA Cell Biol
JT  - DNA and cell biology
JID - 9004522
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1089/dna.2013.2014 [doi]
PST - aheadofprint
SO  - DNA Cell Biol. 2013 Jun 8.

PMID- 23745648
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 22
IP  - 13-14
DP  - 2013 Jul
TI  - Dealing with the devil: weight loss concerns in young adult women with type 1
      diabetes.
PG  - 2030-8
LID - 10.1111/jocn.12231 [doi]
AB  - AIMS AND OBJECTIVES: To examine the weight loss concerns of young adults with
      type 1 diabetes. BACKGROUND: Eating disorders are prevalent in young women with
      type 1 diabetes. DESIGN: Qualitative. METHODS: Interviews with 35 young adults
      (23-30 years of age) with type 1 diabetes and 13 healthcare professionals.
      RESULTS: Most female interviewees were concerned about the difficulties of losing
      weight when having diabetes. Six female interviewees developed severe eating
      disturbances when they were younger. These women initially regarded their
      disturbed eating behaviour positively and engaged in weight loss activities
      intermittently. However, over time, they lost control of their behaviour, and it 
      came to dominate their lives. Family conflict often intensified disordered eating
      behaviours. Eventually all of these women managed to transition away from their
      behaviour, although this process took, for some of them, several years. Several
      of them (now in their early to late twenties), however, continued to struggle
      with weight loss impulses. Healthcare professionals felt that eating- and
      weight-related issues often went undiagnosed and undocumented in young adult
      women with type 1 diabetes. CONCLUSION: Many young women with type 1 diabetes are
      worried about their weight, but will not engage in risky weight loss activities
      because of concerns about their health. A minority of young adult women will
      develop more severe eating-related disturbances. These eating disturbances may
      last a significant amount of time before clinicians become aware of them. These
      women may also experience disordered weight loss impulses for sometime after
      clinical interventions. RELEVANCE TO CLINICAL PRACTICE: Clinicians should screen 
      young adult women with type 1 diabetes for eating disorders and monitor young
      adult women who have developed eating disorders over the longer term. There may
      be a need to provide asymptomatic young women with diabetes with information
      about the potential risks of insulin omission.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Epidemiology and Public Health Medicine, Royal College of Surgeons 
      in Ireland, Dublin, Ireland.
FAU - Balfe, Myles
AU  - Balfe M
FAU - Doyle, Frank
AU  - Doyle F
FAU - Smith, Diarmuid
AU  - Smith D
FAU - Sreenan, Seamus
AU  - Sreenan S
FAU - Conroy, Ronan
AU  - Conroy R
FAU - Brugha, Ruairi
AU  - Brugha R
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
SB  - N
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/12/09 [accepted]
AID - 10.1111/jocn.12231 [doi]
PST - ppublish
SO  - J Clin Nurs. 2013 Jul;22(13-14):2030-8. doi: 10.1111/jocn.12231.

PMID- 23745643
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 22
IP  - 13-14
DP  - 2013 Jul
TI  - Exploring staff diabetes medication knowledge and practices in regional
      residential care: triangulation study.
PG  - 1933-40
LID - 10.1111/jocn.12043 [doi]
AB  - AIMS AND OBJECTIVES: This study is drawn from a larger project that aimed to
      identify the staffing and organisational factors influencing the quality of
      diabetes care for older people living in residential care in regional Victoria,
      Australia. The focus of the current study is on medication management for
      residents with diabetes. BACKGROUND: With a continuous rise in diabetes in the
      population, there is an associated increase in the prevalence of diabetes in aged
      care residential settings. However, there is little specific guidance on how to
      manage diabetes in older people living in institutional settings who experience
      multiple concurrent chronic conditions. DESIGN: A triangulation strategy
      consisting of three phases. METHODS: A one-shot cross-sectional survey (n = 68)
      focus group interviews and a case file audit (n = 20). Data were collected
      between May 2009-January 2010. FINDINGS: Staff knowledge of diabetes and its
      contemporary medication management was found to be suboptimal. Challenges to
      managing residents with diabetes included limited time, resident characteristics 
      and communication systems. Additionally, the variability in medical support
      available to residents and a high level of polypharmacy added to the complexity
      of medication management of resident. CONCLUSIONS: The current study suggests
      administering medicine to residents in aged care settings is difficult and has
      potentially serious medical, professional and economic consequences. Limitations 
      to staff knowledge of contemporary diabetes care and medications potentially
      place residents with diabetes at risk of receiving less than optimal diabetes
      care. RELEVANCE TO CLINICAL PRACTICE: Providing evidence-based guidelines about
      diabetes care in residential care settings is essential to achieve acceptable
      outcomes and increase the quality of life for residents in public aged care.
      Continuing education programs in diabetes care specifically related to medication
      must be provided to all health professionals and encompass scope of practice.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - School of Health Sciences, University of Ballarat, Ballarat, Victoria, Vic.,
      Australia.
FAU - Wellard, Sally Jane
AU  - Wellard SJ
FAU - Rasmussen, Bodil
AU  - Rasmussen B
FAU - Savage, Sally
AU  - Savage S
FAU - Dunning, Trisha
AU  - Dunning T
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
SB  - N
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/08/21 [accepted]
AID - 10.1111/jocn.12043 [doi]
PST - ppublish
SO  - J Clin Nurs. 2013 Jul;22(13-14):1933-40. doi: 10.1111/jocn.12043.

PMID- 23745642
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 22
IP  - 13-14
DP  - 2013 Jul
TI  - Religion and self-management of Thai Buddhist and Muslim women with type 2
      diabetes.
PG  - 1907-16
LID - 10.1111/jocn.12130 [doi]
AB  - AIMS AND OBJECTIVES: To report of a qualitative study of how religion affects the
      self-management of Thai Buddhist and Muslim women with type 2 diabetes.
      BACKGROUND: The importance of diabetes self-management is well recognised.
      However, research on such self-management in Thailand is scarce, in particular on
      the influence of religion on the self-management of Thai Buddhist and Muslim
      women with type 2 diabetes. DESIGN: A descriptive qualitative study was
      conducted. METHODS: Purposive convenience sampling was used, and 48 women, 19
      Buddhist and 29 Muslim, aged from 28-80 years, participated. Data were collected 
      in 2008-09 and analysed by use of manifest and latent content analysis. RESULTS: 
      Four themes of the influence of religion on the self-management among Thai women 
      with type 2 diabetes emerged: religion - a way of coping with diabetes, spiritual
      practice - a help for disease control, spiritual practice - an effort to struggle
      with everyday life, and support from family - a cultural practice. CONCLUSIONS:
      The Buddhist and Muslim women had self-management capabilities that were often
      related to their religions. However, many of them had poor control of their blood
      sugar levels and needed assistance. RELEVANCE TO CLINICAL PRACTICE: Reference to 
      religion and spiritual practice can be an effective means of helping diabetes
      patients better manage their disease and change their lifestyles. Furthermore,
      family and economic and social environments should be taken into account both in 
      care and in interventions aimed at helping patients cope and empowering them to
      control their disease.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Public Health and Caring Sciences, Uppsala University, Uppsala,
      Sweden.
FAU - Lundberg, Pranee C
AU  - Lundberg PC
FAU - Thrakul, Supunnee
AU  - Thrakul S
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
SB  - N
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/10/03 [accepted]
AID - 10.1111/jocn.12130 [doi]
PST - ppublish
SO  - J Clin Nurs. 2013 Jul;22(13-14):1907-16. doi: 10.1111/jocn.12130.

PMID- 23745620
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1557-8518 (Electronic)
IS  - 1540-4196 (Linking)
DP  - 2013 Jun 7
TI  - Postprandial Adiponectin Levels Are Associated with Improvements in Postprandial 
      Triglycerides After Roux-en-Y Gastric Bypass in Type 2 Diabetic Patients.
AB  - Abstract Background: Postprandial hypertrygliceridemia is a known factor for
      cardiovascular disease and is often observed in patients with type 2 diabetes
      mellitus (T2DM) and visceral adiposity. Adiponectin is a hormone with
      antiatherogenic and anti-inflammatory effects, which decreases in obesity and
      T2DM subjects. The weight loss induced by diet or bariatric surgery could be
      restoring adiponectin levels. Objective: The aim of the study was to evaluate the
      impact of weight loss induced by bariatric surgery, which could restore
      adiponectin and triglycerides (TG) levels in obese and diabetic patients.
      Methods: Ten patients with T2DM (BMI 39.3+2.44) were evaluated before and at 7
      and 90 days after Roux-en-Y gastric bypass (RYGB). A meal test was performed and 
      plasma insulin, glucagon-like peptide-1 (GLP-1), glucose, TG, and adiponectin
      levels were measured at fasting and at 30, 60, 90, and 120 min postprandial.
      Results: Seven days after surgery, significant reductions in the insulin
      resistance were observed, while TG and adiponectin levels remained unchanged
      during the meal test. Ninety days after surgery, TG and glucose levels decreased 
      significantly at fasting, and postprandial, adiponectin, GLP-1, and insulin
      curves increased significantly after meal ingestion. Both changes in the area
      under the curve (AUC) of adiponectin correlated with changes in the AUC of TG
      (R=-0.64, P=0.003) and changes in AUC of adiponectin correlated with changes in
      total fat mass. No correlation was found between changes in insulin, GLP-1, and
      TG levels. Conclusions: The adiponectin levels may be involved in the mechanism
      responsible for high TG levels in obese and diabetic patients. These
      abnormalities can be reversed by RYGB.
AD  - 1 Department of Medicine, Division of Endocrinology, Universidade Federal de Sao 
      Paulo , Sao Paulo, Brazil .
FAU - Umeda, Luciana M
AU  - Umeda LM
FAU - Pereira, Andrea Z
AU  - Pereira AZ
FAU - Carneiro, Glaucia
AU  - Carneiro G
FAU - Arasaki, Carlos H
AU  - Arasaki CH
FAU - Zanella, Maria Teresa
AU  - Zanella MT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Metab Syndr Relat Disord
JT  - Metabolic syndrome and related disorders
JID - 101150318
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1089/met.2012.0042 [doi]
PST - aheadofprint
SO  - Metab Syndr Relat Disord. 2013 Jun 7.

PMID- 23745619
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1557-8518 (Electronic)
IS  - 1540-4196 (Linking)
DP  - 2013 Jun 7
TI  - Nonalcoholic Fatty Liver Disease and Reduced Serum Vitamin D levels.
AB  - Abstract Nonalcoholic fatty liver disease (NAFLD) and vitamin D3 deficiency are
      two highly prevalent pathologic conditions worldwide that share several
      cardiometabolic risk factors. In addition to its traditional calcium-related
      effects on the skeleton, vitamin D3 deficiency has now been recognized to exert
      nonskeletal adverse effects on several other organ systems. Accumulating
      epidemiological evidence suggests that low levels of serum 25-hydroxyvitamin D3
      are associated with the presence and severity of NAFLD, independently of several 
      potential confounders, including features of the metabolic syndrome. The
      molecular mechanisms of this association remain incompletely understood. A
      variety of biologically plausible mechanisms may mediate a hepato-protective role
      for the active metabolite of vitamin D3. 1alpha,25-dihydroxyvitamin D3 modulates 
      the insulin signaling pathway/insulin resistance, suppresses fibroblast
      proliferation and collagen production, exerts anticoagulant and profibrinolytic
      effects, and modulates macrophage activity and inflammatory cytokine generation. 
      Overall, the high prevalence of vitamin D3 deficiency and the plausible
      biological mechanisms linking this to NAFLD suggest that treatment of vitamin D3 
      deficiency to prevent and/or treat NAFLD is a promising field to explore. Large
      placebo-controlled randomized clinical trials are urgently needed to determine
      whether vitamin D3 supplementation could have any potential benefit in reducing
      the development and progression of NAFLD.
AD  - 1 Division of Endocrinology, Diabetes and Metabolism, University and Azienda
      Ospedaliera Universitaria Integrata of Verona , Verona, Italy .
FAU - Targher, Giovanni
AU  - Targher G
FAU - Scorletti, Eleonora
AU  - Scorletti E
FAU - Mantovani, Alessandro
AU  - Mantovani A
FAU - Byrne, Christopher D
AU  - Byrne CD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Metab Syndr Relat Disord
JT  - Metabolic syndrome and related disorders
JID - 101150318
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1089/met.2013.0044 [doi]
PST - aheadofprint
SO  - Metab Syndr Relat Disord. 2013 Jun 7.

PMID- 23745583
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-5666 (Electronic)
IS  - 1566-5240 (Linking)
DP  - 2013 Jun 4
TI  - Triamcinolone Acetonide Inhibits p38MAPK Activation and Neuronal Apoptosis in
      Early Diabetic Retinopathy.
AB  - Objective: Intravitreal glucocorticoids and anti-vascular endothelial growth
      factor (VEGF) therapies are novel strategies for the treatment of advanced
      diabetic retinopathy, a condition with inflammatory and neuropathic elements. In 
      contrast with anti-VEGF therapy, glucocorticoids may also exert neuroprotective
      effects. How glucocorticoids protect retinal neurons is unknown. The aims of the 
      study are to investigate the anti-apoptotic actions of glucocorticoids on
      diabetic retinal neurons, and characterize the signalling pathways involved.
      Research Design and Methods: The regulation of gene expression of the four p38
      mitogen-activated protein kinase (MAPK) isoforms (alpha, beta, delta and gamma)
      and the glucocorticoid receptor (GR) in the retinas was evaluated using
      quantitative RT-PCR, Western blot and immunohistochemistry. Phosphorylation of
      all isoforms p38MAPK (Thr180/Tyr182) and GR (S-211) was further evaluated.
      Apoptosis was confirmed by immunolocalization of active CASPASE-3 and the
      subsequent cleavage of poly (ADP-ribose) polymerase (PARP) following intravitreal
      injection of triamcinolone acetonide (IVTA), in an early diabetic rat model (26
      days after induction of diabetes). Results: IVTA significantly down-regulated
      mRNA expression of Caspase 3. Activation of CASPASE-3, the subsequent cleavage of
      PARP-1 and phosphorylation of p38MAPK induced by diabetes were attenuated by IVTA
      treatment, concomitantly with activation by phosphorylation of the glucocorticoid
      receptor (GR S-211). Conclusions: IVTA activates the GR and exerts neural
      protective effects on retinal neurons. Inhibition of the p38MAPK pathway and
      activation of GR play a critical anti-apoptotic role in retinal neurons of
      diabetes following IVTA treatment. Both the anti-inflammatory and anti-apoptotic 
      effects of glucocorticoids may be mediated through inhibition of the p38MAPK
      pathway in diabetic retinopathy.
AD  - Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren
      Hospital, Capital Medical University; Beijing Ophthalmology & Visual Sciences Key
      Lab 100730 P.R. China. mmzxy@yahoo.com , zhangxy1@trhos.com.
FAU - Zhang, Xinyuan
AU  - Zhang X
FAU - Lai, Donna
AU  - Lai D
FAU - Bao, Shisan
AU  - Bao S
FAU - Hambly, Brett D
AU  - Hambly BD
FAU - Gillies, Mark C
AU  - Gillies MC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Curr Mol Med
JT  - Current molecular medicine
JID - 101093076
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/06 [received]
PHST- 2013/04/28 [revised]
PHST- 2013/05/30 [accepted]
AID - CMM-EPUB-20130604-3 [pii]
PST - aheadofprint
SO  - Curr Mol Med. 2013 Jun 4.

PMID- 23745582
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-5666 (Electronic)
IS  - 1566-5240 (Linking)
DP  - 2013 Jun 4
TI  - Mitochondria-Targeted Antioxidant Peptide SS31 Protects the Retinas of Diabetic
      Rats.
AB  - Oxidative stress is one of the main contributors in the pathogenesis of diabetic 
      retinopathy. The aim of this study is to investigate the effects of SS31 which is
      a mitochondria-targeted antioxidant peptide on the retinas of streptozotocin
      (STZ)-induced diabetic rats. Two weeks after induction of diabetes, SS31 (3
      mg/kg) or the same volume of normal saline (N.S.) was injected subcutaneously
      into the back of diabetic rats every day. Four months later, the integrity of
      inner blood retinal barrier (iBRB) was measured by Evans blue perfusion. The
      expression and distribution of claudin-5, occludin, acrolein, 8-OHdG and
      nitrotyrosine in the rat retinas were detected by immunofluorescent staining.
      Retinal ultrastructures were observed by transmission electron microscopy. The
      protein level of VEGFR2, Trx-2, Bcl-2, Bax, caspase-3, p53, and NF-kappaB in the 
      rat retinas were assayed by western blot. Four months after subcutaneous
      injection, the diabetic rats treated with SS31 had better structures of retinal
      ganglion cells, thinner capillary basement membrane, less iBRB leakage, more
      uniform staining of claudin-5 and occludin in the retinal vessels, lower levels
      of acrolein, 8-OHdG, nitrotyrosine, Bax, caspase-3, p53, and NF-kappaB, and
      higher levels of Trx-2 and Bcl-2 in the retinas than those treated with N.S. In
      conclusion, SS31 could protect the retinal structures and inhibit the breakdown
      of iBRB by reducing oxidative damage, increasing Trx-2 and Bcl-2 expression, and 
      decreasing p53, NF-kappaB, Bax, caspase-3, and VEGFR2 expression in the retinas
      of diabetic rats. SS31 could be a potential new treatment for diabetic
      retinopathy and other oxidative stress-related diseases.
AD  - State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen
      University, Guangzhou, 510060, P.R. China. luoyan2@mail.sysu.edu.cn.
FAU - Huang, Juan
AU  - Huang J
FAU - Li, Xianghong
AU  - Li X
FAU - Li, Mei
AU  - Li M
FAU - Li, Jianqiao
AU  - Li J
FAU - Xiao, Wei
AU  - Xiao W
FAU - Ma, Wei
AU  - Ma W
FAU - Chen, Xiaoyun
AU  - Chen X
FAU - Liang, Xiaoling
AU  - Liang X
FAU - Tang, Shibo
AU  - Tang S
FAU - Luo, Yan
AU  - Luo Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Curr Mol Med
JT  - Current molecular medicine
JID - 101093076
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/02/22 [received]
PHST- 2013/04/28 [revised]
PHST- 2013/05/29 [accepted]
AID - CMM-EPUB-20130604-2 [pii]
PST - aheadofprint
SO  - Curr Mol Med. 2013 Jun 4.

PMID- 23745581
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-5666 (Electronic)
IS  - 1566-5240 (Linking)
DP  - 2013 Jun 4
TI  - Common Variant in VEGFA and Response to Anti-VEGF Therapy for Neovascular
      Age-Related Macular Degeneration.
AB  - Age-related macular degeneration (AMD) is a leading cause of visual impairment in
      aging populations in industrialized countries. Here we investigated whether the
      genotype of vascular endothelial growth factor A (VEGFA) gene is associated with 
      response to anti-VEGF therapy. 223 eyes with neovascular AMD were treated with
      intravitreal anti-VEGF therapy. Responders were defined as patients who had an
      improvement in best corrected visual acuity (BCVA) of at least 5 letters or one
      line on the EDTRS visual acuity chart along with resolution of intraretinal or
      subretinal fluid over 12 months. Patients who did not meet the definition of
      responders were classified as poor-responders. The vision of responders (n = 148)
      improved while the vision of poor-responders (n = 75) worsened (P <0.001).
      Responders on average had a decrease in central foveal thickness (CFT), while
      poor-responders had an increase in CFT (P <0.001). Compared with the responder
      group, the poor-responder group had a higher frequency of the risk (T) allele
      (Allelic P = 0.019) and TT genotype (P = 0.002 under a recessive model) for the
      VEGFA-rs943080 polymorphism. VEGFA expression was 1.8-fold higher in cells with
      the VEGFA rs943080 TT genotype than in cells with the VEGFA rs943080CC genotype
      (P = 0.012). Age, gender, smoking, diabetes mellitus, and hypertension did not
      play a significant role in treatment response, but BMI was found to be
      significantly different between responders and poor-responders (P = 0.033). In
      conclusion, we demonstrated a potential pharmacogenetic relationship between the 
      VEGFA gene and treatment response to anti-VEGF therapy. The studies are
      registered at ClinicalTrials.gov under the identifiers NCT00474695.
AD  - Department of Ophthalmology at Shiley Eye Center and Institute for Genomic
      Medicine, University of California, San Diego, 9415 Campus Point Drive #0946, La 
      Jolla, CA 92093-0838, USA. kang.zhang@gmail.com.
FAU - Zhao, Ling
AU  - Zhao L
FAU - Grob, Seanna
AU  - Grob S
FAU - Avery, Robert
AU  - Avery R
FAU - Kimura, Alan
AU  - Kimura A
FAU - Pieramici, Dante
AU  - Pieramici D
FAU - Lee, Janet
AU  - Lee J
FAU - Rabena, Melvin
AU  - Rabena M
FAU - Ortiz, Sara
AU  - Ortiz S
FAU - Quach, John
AU  - Quach J
FAU - Cao, Guiqun
AU  - Cao G
FAU - Luo, Hongrong
AU  - Luo H
FAU - Zhang, Ming
AU  - Zhang M
FAU - Tornambe, Paul
AU  - Tornambe P
FAU - Goldbaum, Michael
AU  - Goldbaum M
FAU - Ferreyra, Henry
AU  - Ferreyra H
FAU - Kozak, Igor
AU  - Kozak I
FAU - Zhang, Kang
AU  - Zhang K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Curr Mol Med
JT  - Current molecular medicine
JID - 101093076
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/12 [received]
PHST- 2013/04/28 [revised]
PHST- 2013/05/28 [accepted]
AID - CMM-EPUB-20130604-1 [pii]
PST - aheadofprint
SO  - Curr Mol Med. 2013 Jun 4.

PMID- 23745571
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 82
IP  - 1
DP  - 2013 Jul
TI  - Transmission disequilibrium analysis of 31 type 1 diabetes susceptibility loci in
      Finnish families.
PG  - 35-42
LID - 10.1111/tan.12143 [doi]
AB  - Currently more than 50 type 1 diabetes (T1D) loci outside the human leukocyte
      antigen (HLA)-region have been established in large European and/or North
      American populations. Our aim was to attempt to replicate these findings in the
      less heterogenic Finnish population and to explore evidence for genetic
      heterogeneity. We analyzed 1761 Finnish T1D trio families for association in 31
      T1D loci (25 confirmed and 6 have inconsistent prior evidence). Families were
      categorized into nine different subgroups according to potential features that
      reflect underlying genetic heterogeneity in patients (age at diagnosis, sex and
      HLA genotypes). Seventeen confirmed loci and one nonconfirmed locus (1p31.1)
      presented significant evidence for association in the full data set. Magnitude
      and direction of effect was consistent with prior evidence. The strongest effects
      were seen at the insulin gene, PTPN22 and IL2RA regions. Tentative evidence of
      odds ratio (OR) heterogeneity within subgroups was seen in eight loci. Our
      findings were well in line with those reported in the latest meta-analyses using 
      large admixed Caucasian populations, which concurs with the notion that the
      currently confirmed T1D loci, that have been discovered and replicated mostly in 
      diverse populations, are common to all European populations. The observed effect 
      modifications by subgrouping require validation in later studies with more
      statistical power.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Immunogenetics Laboratory, University of Turku, Turku, Finland.
FAU - Laine, A P
AU  - Laine AP
FAU - Knip, M
AU  - Knip M
FAU - Ilonen, J
AU  - Ilonen J
CN  - Finnish Pediatric Diabetes Register
LA  - eng
PT  - Journal Article
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/03/04 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/05/17 [accepted]
AID - 10.1111/tan.12143 [doi]
PST - ppublish
SO  - Tissue Antigens. 2013 Jul;82(1):35-42. doi: 10.1111/tan.12143.

PMID- 23745559
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 May 27
TI  - HOT TOPIC: New Insights in the Pathogenesis and Treatment of Diabetic
      Retinopathy.
AD  - Diabetes nd Metabolism Reseach Unit, Vall d'Hebron Institute of Research (VHIR), 
      Universitat Autonoma de Barcelona, Pg Vall d'Hebron 119-129. Barcelona, Spain.
      rafael.simo@vhir.org.
FAU - Simo, Rafael
AU  - Simo R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/04/08 [received]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130527-16 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 May 27.

PMID- 23745551
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 May 27
TI  - Mitochondria Damage in the Pathogenesis of Diabetic Retinopathy and in the
      Metabolic Memory Associated with its Continued Progression.
AB  - Diabetic retinopathy is the leading cause of blindness in young adults, and with 
      the incidence of diabetes increasing at a frightening rate, retinopathy is
      estimated to threaten vision for almost 51 million patients worldwide. In
      diabetes, mitochondria structure, function and DNA (mtDNA) are damaged in the
      retina and its vasculature, and the mtDNA repair machinery and biogenesis are
      compromised. Proteins encoded by mtDNA become subnormal contributing to
      dysfunctional electron transport system, and the transport of proteins that are
      important in mtDNA biogenesis and function, but are encoded by nuclear DNA, is
      impaired. These diabetes-induced abnormalities in mitochondria continue even when
      hyperglycemic insult is terminated, and are implicated in the metabolic memory
      phenomenon associated with the continued progression of diabetic retinopathy.
      Diabetes also facilitates epigenetic modifications-the changes in histones and
      DNA methylation in response to cells changing environmental stimuli, which the
      cell can memorize and pass to the next generation. Epigenetic modifications
      contribute to the mitochondria damage, and are postulated in the development of
      diabetic retinopathy, and also to the metabolic memory phenomenon. Thus,
      strategies targeting mitochondria homeostasis and/or enzymes important for
      histone and DNA methylation could serve as potential therapies to halt the
      development and progression of diabetic retinopathy.
AD  - Wayne State University, 4717 St. Antoine, Detroit, MI 48201, USA.
      rkowluru@med.wayne.edu.
FAU - Kowluru, Renu A
AU  - Kowluru RA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/25 [received]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130527-8 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 May 27.

PMID- 23745550
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 May 27
TI  - Mimicking Microvascular Alterations of Human Diabetic Retinopathy: a Challenge
      for the Mouse Models.
AB  - Although it is becoming accepted that neuroretinal cells are also affected in
      diabetes, vascular lesions continue to be considered as the hallmarks of diabetic
      retinopathy. Animal models are essential for the understanding and treatment of
      human diabetic retinopathy, and the mouse is intensively used as a model because 
      of its similarity to human and the possibility to be genetically modified.
      However, until today not all retinal vascular lesions developed in diabetic
      patients have been reproduced in diabetic mice, and the reasons for this are not 
      completely understood. In this review, we will summarize retinal vascular lesions
      found in diabetic and diabetic-like mouse models and its comparison to human
      lesions. The goal is to provide insights to better understand human and mice
      differences and thus, to facilitate the development of new mouse models that
      mimic better human diabetic retinopathy.
AD  - Center for Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autonoma
      de Barcelona, E-08193-Bellaterra, Spain. jesus.ruberte@uab.es.
FAU - Ramos, D
AU  - Ramos D
FAU - Carretero, A
AU  - Carretero A
FAU - Navarro, M
AU  - Navarro M
FAU - Mendes-Jorge, L
AU  - Mendes-Jorge L
FAU - Nacher, V
AU  - Nacher V
FAU - Rodriguez-Baeza, A
AU  - Rodriguez-Baeza A
FAU - Ruberte, J
AU  - Ruberte J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2012/11/01 [received]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130527-7 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 May 27.

PMID- 23745549
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 May 27
TI  - Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular
      Mechanisms and Therapeutic Implications.
AB  - Diabetic retinopathy (DR), commonly classified as a microvascular complication of
      diabetes, is now recognized as a neurovascular complication or sensory neuropathy
      resulting from disruption of the neurovascular unit. Current therapies for DR
      target the vascular complications of the disease process, including
      neovascularization and diabetic macular edema. Since neurodegeneration is an
      early event in the pathogenesis of DR, it will be important to unravel the
      mechanisms that contribute to neural apoptosis in order to develop novel
      treatments for the early stages of DR. In this review we comment on how
      inflammation, the metabolic derangements associated with diabetes, loss of
      neuroprotective factors, and dysregulated glutamate metabolism might contribute
      to retinal neurodegeneration during diabetes. Promising potential therapies based
      on these specific aspects of DR pathophysiology are also discussed. Finally, we
      stress the importance of developing and validating new markers of visual function
      that can be used to shorten the duration of clinical trials and accelerate the
      delivery of novel treatments for DR to the public.
AD  - University of Michigan, W. K. Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI
      48105, USA. tomwgard@umich.edu.
FAU - Stem, Maxwell S
AU  - Stem MS
FAU - Gardner, Thomas W
AU  - Gardner TW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/14 [received]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130527-6 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 May 27.

PMID- 23745548
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 May 27
TI  - Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and
      Future Perspectives.
AB  - Despite improving standards of care, people with diabetes remain at risk of
      development and progression of diabetic retinopathy (DR) and visual impairment.
      Identifying novel therapeutic approaches, preferably targeting more than one
      pathogenic pathway in DR, and at an earlier stage of disease, is attractive.
      There is now consistent evidence from two major trials, the Fenofibrate
      Intervention and Event Lowering in Diabetes (FIELD) study and the Action to
      Control Cardiovascular Risk in Diabetes Eye (ACCORD-Eye) study, totalling 11,388 
      people with type 2 diabetes (5,701 treated with fenofibrate) that fenofibrate
      reduces the risk of development and progression of DR. Therefore, fenofibrate may
      be considered a preventive strategy for patients without DR or early intervention
      strategy for those with mild DR. A number of putative therapeutic mechanisms for 
      fenofibrate, both dependent and independent of lipids, have been proposed. A
      deeper understanding of the mode of action of fenofibrate will further help to
      define how best to use fenofibrate clinically as an adjunct to current management
      of DR.
AD  - Diabetes nd Metabolism Reseach Unit, Vall d'Hebron Institute of Research (VHIR), 
      Universitat Autonoma de Barcelona, Pg Vall d'Hebron 119-129. Barcelona, Spain.
      rafael.simo@vhir.org.
FAU - Simo, Rafael
AU  - Simo R
FAU - Roy, Sayon
AU  - Roy S
FAU - Behar-Cohen, Francine
AU  - Behar-Cohen F
FAU - Keech, Anthony
AU  - Keech A
FAU - Mitchell, Paul
AU  - Mitchell P
FAU - Wong, Tien Yin
AU  - Wong TY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/04 [received]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130527-5 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 May 27.

PMID- 23745547
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 May 27
TI  - Advanced Glycation End Products and Diabetic Retinopathy.
AB  - Diabetic retinopathy (DR) has a complex pathogenesis which is impacted by a raft 
      of systemic abnormalities and tissue-specific alterations occurring in response
      to the diabetes milieu. Many pathogenic processes play key roles in retinal
      damage in diabetic patients. One such pathway is the formation and accumulation
      of advanced glycation endproducts (AGEs) and advanced lipoxidation end products
      (ALEs) which are relevant modifications with roles in the initiation and
      progression of pathoology. In this review, AGE/ALE formation in the diabetic
      retina are discussed alongside their impact on retinal cell function. In
      addition, various inhibitors of the AGE-RAGE system and their therapeutic utility
      for DR will also be evaluated.
AD  - Centre for Vision & Vascular Science, Queen's University Belfast, Royal Victoria 
      Hospital , Grosvenor Road, Belfast BT12 6BA, Northern Ireland, UK.
      a.stitt@qub.ac.uk.
FAU - Chen, Mei
AU  - Chen M
FAU - Curtis, Timothy M
AU  - Curtis TM
FAU - Stitt, Alan W
AU  - Stitt AW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/04 [received]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130527-4 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 May 27.

PMID- 23745546
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 May 27
TI  - Somatostatin replacement: a new strategy for treating diabetic retinopathy.
AB  - Diabetic retinopathy (DR) has been classically considered to be a
      microcirculatory disease of the retina. However, there is growing evidence to
      suggest that retinal neurodegeneration is an early event in the pathogenesis of
      DR which participates in the microcirculatory abnormalities that occur in DR.
      Among the neuroprotective factors synthesized by the retina, somatostatin (SST)
      is one of the most relevant. In DR there is a downregulation of retinal
      expression of SST that is associated with retinal neurodegeneration. There is
      growing evidence suggesting that SST could play a key role in the main pathogenic
      mechanisms involved in the development of DR (neurodegeneration,
      neovascularization and vascular leackage). Recently, first evidence that the
      topical administration of SST prevents retinal neurodegeneration in
      streptozotozin-induced diabetic rats has been reported. Indeed, SST eye drops
      prevented b-wave abnormalities in the ERG which are considered sensitive
      indicators of DR. In addition, SST eye drops prevented, glial activation,
      apoptosis and the misbalance between proapoptotic and survival signalling caused 
      by diabetes. Furthermore, SST eye drops reduces glutamate-induced excitotoxicity.
      Therefore, topical administration of SST could be contemplated as an appropriate 
      therapeutic approach for DR. However, clinical trials will be needed to establish
      its exact position in the treatment of this devastating complication of diabetes.
AD  - Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca, Pg.
      Vall d'Hebron 119-129, 08035 Barcelona, Spain. cristina.hernandez@vhir.org.
FAU - Hernandez, Cristina
AU  - Hernandez C
FAU - Simo, Rafael
AU  - Simo R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/10 [received]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130527-3 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 May 27.

PMID- 23745545
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 May 27
TI  - Traditional and Novel Risk Factors of Diabetic Retinopathy and Research
      Challenges.
AB  - Diabetic retinopathy affects a third of persons with diabetes and is the most
      frequent case of blindness in working aged adults. Although diabetic retinopathy 
      blindness appear to have fallen in the developed world, the rapidly increasing
      number of persons with diabetes worldwide has lead to a continuing increase in
      the global burden of this disease. The major risk factors for diabetic
      retinopathy include duration of diabetes, hyperglycemia, and hypertension, but
      these account for only a small amount of the variation in the risk of diabetic
      retinopathy. Research into new markers for retinopathy including genetics, blood 
      biomarkers and retinal imaging will further our understanding of the risk factors
      and pathogenesis of diabetic retinopathy.
AD  - Singapore Eye Research Institute 11 Third Hospital Ave #05-00 SNEC Bldg Singapore
      168751. tien_yin_wong@nuhs.edu.sg.
FAU - Tan, Gavin S
AU  - Tan GS
FAU - Ikram, M Kamran
AU  - Ikram MK
FAU - Wong, Tien Y
AU  - Wong TY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PHST- 2013/01/04 [received]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130527-2 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 May 27.

PMID- 23745519
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
DP  - 2013 Jun 10
TI  - Variations in blood pressure and lipid goal attainment in primary care.
AB  - Abstract Background: Hypertension and dyslipidemia are the most prevalent
      cardiovascular risk factors. Blood pressure (BP) and lipid levels are modifiable 
      and yet, most patients fail to achieve their recommended target goals. The
      objective of this review was to examine the variations in achievement of optimal 
      BP and lipid levels in individuals with cardiovascular risk factors or
      cardiovascular disease at a primary care level. Scope: A comprehensive literature
      review and evaluation was conducted from January 2000 to June 2012 using
      electronic databases. The search was limited to studies reported in English
      language, published between January 2000 to June 2012 and those conducted in the 
      US adult population (>/=18 years). The inclusion of articles was limited to
      populations with cardiovascular risk factors or any cardiovascular disease.
      Findings: The review identified a total of 32 studies that assessed variations in
      attainment of BP or lipid goals. The demographic factors (age, sex, and race) and
      clinical factors (obesity, presence of diabetes, and history of cardiovascular
      conditions) were most commonly evaluated by the studies. However, modifiable
      factors such as diet, physical exercise, adherence to medication, or smoking
      habit were least commonly evaluated by the studies documented in this review.
      Conclusion: The studies conducted in a range of settings, reflect disparities in 
      attainment of recommended BP or lipid goals. Given such disparities, future
      research is required to better understand the complexity of different factors
      underlying the failure of patients to achieve BP and lipid goals. This can help
      identify appropriate treatment strategies or interventions that can address
      patient-specific needs at a primary care level.
AD  - Department of Pharmacy Administration, Duquesne University, Mylan School of
      Pharmacy, 600 Forbes Avenue, Pittsburgh PA 15282.
FAU - Chopra, Ishveen
AU  - Chopra I
FAU - Kamal, Khalid M
AU  - Kamal KM
FAU - Candrilli, Sean D
AU  - Candrilli SD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130610
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
AID - 10.1185/03007995.2013.813842 [doi]
PST - aheadofprint
SO  - Curr Med Res Opin. 2013 Jun 10.

PMID- 23745492
OWN - NLM
STAT- In-Process
DA  - 20130610
IS  - 0210-5020 (Print)
IS  - 0210-5020 (Linking)
VI  - 36
IP  - 4
DP  - 2013 Apr
TI  - [Continuous monitoring systems of glucose].
PG  - 43-6
AB  - The possibility of obtaining a continuous reading of glucose may represent a
      breakthrough and a useful tool for the management of diabetes. Technological
      advances can improve the quality of life and people with diabetes metabolic
      control, even if this means having to learn and incorporate new technical
      concepts, new algorithms for pattern modification and new challenges in
      Therapeutic Education.
AD  - Servei d'Endocrinologia i Nutricio, Unitat de Diabetis, Hospital Clinic,
      Barcelona. mvidal@clinic.ub.esi
FAU - Vidal, Merce
AU  - Vidal M
FAU - Jansa, Margarida
AU  - Jansa M
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Sistemas de monitorizacion continua de la glucosa.
PL  - Spain
TA  - Rev Enferm
JT  - Revista de enfermeria (Barcelona, Spain)
JID - 8309920
SB  - N
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - ppublish
SO  - Rev Enferm. 2013 Apr;36(4):43-6.

PMID- 23745350
OWN - NLM
STAT- In-Process
DA  - 20130610
IS  - 0370-8179 (Print)
IS  - 0370-8179 (Linking)
VI  - 141
IP  - 3-4
DP  - 2013 Mar-Apr
TI  - Small bowel adenocarcinoma mimicking a large adrenal tumor.
PG  - 232-6
AB  - INTRODUCTION: Adenocarcinoma of the small bowel is a rare gastrointestinal
      neoplasm usually affecting the distal duodenum and proximal jejunum. Because of
      their rarity and poorly defined abdominal symptoms, a correct diagnosis is often 
      delayed. CASE OUTLINE: We present a 43-year-old woman admitted at the Clinic for 
      Endocrinology due to a large tumor (over 7 cm) of the left adrenal gland.The
      tumor was detected by ultrasound and confirmed by CT scan.The patient complained 
      of abdominal pain in the left upper quadrant, fatigue and septic fever. Normal
      urinary catecholamines excluded pheochromocytoma. The endocrine evaluations
      revealed laboratory signs of subclinical hypercorticism: midnight cortisol 235
      nmol/L, post 1 mg - overnight Dexamethasone suppression test for cortisol 95.5
      nmol/L and basal ACTH 4.2 pg/mL. Plasma rennin activity and aldosterone were
      within the normal range. Surgery was performed. Intraoperative findings showed
      signs of acute peritonitis and a small ulceration of the jejunum below at 70 cm
      on the anal side from the Treitz's ligament. Adrenal glands were not enlarged.
      Patohistology and immunochemistry identified adenocarcinoma of the jejunum
      without infiltration of the lymphatic nodules. The extensive jejunal resection
      and lavage of the peritoneum were performed. Due to complications of massive
      peritonitis, the patient died seven days after surgery. CONCLUSION: Poorly
      defined symptoms and a low incidence make the diagnosis of small bowel carcinoma,
      particularly of the jejunal region, very difficult in spite of the new endoscopic
      techniques.
AD  - Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of
      Serbia, 11000 Belgrade, Serbia. imiomira@yahoo.com
FAU - Ivovic, Miomira
AU  - Ivovic M
FAU - Zivaljevic, Vladan
AU  - Zivaljevic V
FAU - Vujovic, Svetlana
AU  - Vujovic S
FAU - Marina, Ljiljana
AU  - Marina L
FAU - Gajic, Milina Tancic
AU  - Gajic MT
FAU - Dundjerovic, Dusan
AU  - Dundjerovic D
FAU - Barac, Marija
AU  - Barac M
FAU - Micic, Dragan
AU  - Micic D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Serbia
TA  - Srp Arh Celok Lek
JT  - Srpski arhiv za celokupno lekarstvo
JID - 0027440
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - ppublish
SO  - Srp Arh Celok Lek. 2013 Mar-Apr;141(3-4):232-6.

PMID- 23745334
OWN - NLM
STAT- In-Process
DA  - 20130610
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 34
IP  - 202
DP  - 2013 Apr
TI  - [Glycoxidative modification of albumin in medical research].
PG  - 239-42
AB  - Human albumin is a major, multi-functional serum protein. As the other protein is
      subjected to many modifications, including glycation and oxidation, which occurs 
      physiologically in low intensity, however, are significantly increased in various
      pathological conditions. They often co-occur with each other, reinforcing its
      negative effects, and therefore are referred to common name - glycoxidative
      processes. Glycation, increased especially in diabetes, causes structural and
      functional changes of many proteins, both short-and long-lived, and it may result
      in increased oxidative stress and protein oxidation, which secondarily may
      increase their susceptibility to glycation. Studies in vivo and in vitro
      processes of oxidation and glycation of albumin and other proteins allowed us to 
      identify biochemical markers that are routinely used in the diagnosis and
      monitoring of diseases (ischemia modified albumin, fructosamine) and those
      commonly used in research (e.g. AGE, CML, SH and CO groups, AOPP), which in
      perspective could be used in clinical trials (especially AGEs and AOPP). The
      study presents current state of knowledge on the mechanisms, the importance and
      the possibility of using glycoxidative modified albumin in medical science.
AD  - Uniwersytet Medyczny im. Piastow Slaskich we Wroclawiu. ewa.grzebyk@gmail.com
FAU - Grzebyk, Ewa
AU  - Grzebyk E
FAU - Piwowar, Agnieszka
AU  - Piwowar A
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Modyfikacje glikooksydacyjne albuminy w badaniach medycznych.
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - ppublish
SO  - Pol Merkur Lekarski. 2013 Apr;34(202):239-42.

PMID- 23745331
OWN - NLM
STAT- In-Process
DA  - 20130610
IS  - 1426-9686 (Print)
IS  - 1426-9686 (Linking)
VI  - 34
IP  - 202
DP  - 2013 Apr
TI  - [Chronic inflammation and metabolic syndrome in comparison with other signs
      belonging to the image of polycystic ovary syndrome].
PG  - 228-31
AB  - Polycystic ovary syndrome (PCOS) is a disorder which concern even 5-10% of women 
      in reproductive age. PCOS is a cause of hyperandrogenism and menstrual disorders 
      with chronic anovulation. The most common clinical symptoms observed in PCOS are 
      hirsutism, acne and obesity. Patients with PCOS often suffer from metabolic
      disorders like insulin resistance, hyperinsulinemia, dyslipidemia,
      arteriosclerosis and other abnormalities of the metabolic syndrome. 35 to 60% of 
      women with PCOS are obese and about 50% of them have insulin resistance and
      hyperinsulinemia. The pathogenesis of atherosclerosis emphasizes the role of
      inflammatory processes. There are a number of markers of the inflammation
      process. They are also observed in PCOS and may indicate an increased risk of
      cardiovascular disease in women. More than 46% of women with PCOS can be
      diagnosed with metabolic syndrome. Because of the fact that patients with PCOS
      are at higher risk group of the earlier development of complications such as
      diabetes t 2, atherosclerosis, hypertension and cardiovascular system diseases,
      it is important to carry out metabolic disorders diagnosis in every patient with 
      PCOS. It will help to estimate the risk of complications and allow for the
      implementation of prevention or treatment of metabolic diseases belonging to the 
      image of PCOS.
AD  - Pomorski Uniwersytet Medyczny w Szczecinie, Klinika Ginekologii i Uroginekologii.
      o.marciniak@wp.pl
FAU - Marciniak, Aleksandra
AU  - Marciniak A
FAU - Nawrocka-Rutkowska, Jolanta
AU  - Nawrocka-Rutkowska J
FAU - Wisniewska, Berenika
AU  - Wisniewska B
FAU - Brodowska, Agnieszka
AU  - Brodowska A
FAU - Starczewski, Andrzej
AU  - Starczewski A
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Przewlekly stan zapalny oraz zespo1 metaboliczny na tie innych objawow nalezacych
      do obrazu zespolu policystycznych jajnikow.
PL  - Poland
TA  - Pol Merkur Lekarski
JT  - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
JID - 9705469
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - ppublish
SO  - Pol Merkur Lekarski. 2013 Apr;34(202):228-31.

PMID- 23745307
OWN - NLM
STAT- In-Process
DA  - 20130610
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 96
IP  - 5
DP  - 2013 May
TI  - High on-clopidogrel treatment platelet reactivity in Thai patients with chronic
      stable angina scheduled for percutaneous coronary intervention.
PG  - 538-43
AB  - OBJECTIVE: To determine the prevalence, clinical profile, and risk factors of
      high on-clopidogrel treatment platelet reactivity in Thai patients with chronic
      stable angina scheduled for percutaneous coronary intervention. MATERIAL AND
      METHOD: The patients were prospectively recruited from the consecutive patients
      undergoing coronary angiography and planned for elective percutaneous coronary
      intervention (PCI). Ten ml of blood samples were cautiously drawn from the
      antecubital vein of the patients to determine the hemoglobin and platelet count. 
      Platelet aggregation test was performed by light transmittance aggregometry using
      platelet-rich plasma. Platelets were stimulated with 5 microM adenosine
      diphosphate (ADP). Platelet aggregation was expressed as the maximal percent
      change in light transmittance from baseline. High on-clopidogrel treatment
      platelet reactivity was defined as post treatment maximal platelet aggregation > 
      46% with 5 micromol/l ADP used as agonist. RESULTS: The present study
      consecutively enrolled two hundred four patients diagnosed with chronic stable
      angina planned for PCI. Seventy-nine patients demonstrated the high
      on-clopidogrel treatment platelet reactivity (38.7%). Among these patients, 48%
      were men with a mean age of 66 years. Diabetes mellitus and chronic kidney
      disease were detected in 34.2%. Original clopidogrel (Plavix) was prescribed in
      72% of the patients and 28% received generic clopidogrel (Apolets). The
      prevalence of high on-clopidogrel treatment platelet reactivity increased in the 
      older patients, patients with CKD and patients receiving angiotensin receptor
      blockers (ARB). However from multivariate analysis, none of the risk factors,
      including age, BMl, diabetes mellitus, smoking, CKD, ARB use, and type of
      clopidogrel (Plavix versus Apolets) had a statistically significant association
      with the high on-clopidogrel treatment platelet reactivity. CONCLUSION: The
      prevalence of high on-clopidogrel treatment platelet reactivity in the present
      study was 38.7%. No significant association was demonstrated between age, BMI,
      diabetes mellitus, smoking, CKD, ARB use, type of clopidogrel, and high
      on-clopidogrel treatment platelet reactivity.
AD  - Division of Cardiology, Department of Medicine Siriraj Hospital, Mahidol
      University, Bangkok, Thailand. rewat.pha@mahidol.ac.th
FAU - Phankingthongkum, Rewat
AU  - Phankingthongkum R
FAU - Panchavinnin, Pradit
AU  - Panchavinnin P
FAU - Chinthammitr, Yingyong
AU  - Chinthammitr Y
FAU - Tresukosol, Damras
AU  - Tresukosol D
FAU - Chotinaiwattarakul, Chunhakasem
AU  - Chotinaiwattarakul C
FAU - Tungsubutra, Wiwun
AU  - Tungsubutra W
FAU - Wongpraparut, Nattawut
AU  - Wongpraparut N
FAU - Kitrattana, Bussakorn
AU  - Kitrattana B
FAU - Leewanun, Piyachat
AU  - Leewanun P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - ppublish
SO  - J Med Assoc Thai. 2013 May;96(5):538-43.

PMID- 23745217
OWN - NLM
STAT- In-Process
DA  - 20130607
IS  - 1080-6059 (Electronic)
IS  - 1080-6040 (Linking)
VI  - 19
IP  - 3
DP  - 2013 Mar
TI  - Clinical and therapeutic features of pulmonary nontuberculous mycobacterial
      disease, Brazil, 1993-2011.
PG  - 393-9
LID - http://dx.doi.org/10.3201/eid/1903.120735 [doi]
AB  - To identify clinical and therapeutic features of pulmonary nontuberculous
      mycobacterial (PNTM) disease, we conducted a retrospective analysis of patients
      referred to the Brazilian reference center, Oswaldo Cruz Foundation, Rio de
      Janeiro, Brazil, who received a diagnosis of PNTM during 1993-2011 with at least 
      1 respiratory culture positive for NTM. Associated conditions included
      bronchiectasis (21.8%), chronic obstructive pulmonary disease (20.7%),
      cardiovascular disease (15.5%), AIDS (9.8%), diabetes (9.8%), and hepatitis C
      (4.6%).Two patients had Hansen disease; 1 had Marfan syndrome. Four mycobacterial
      species comprised 85.6% of NTM infections: Mycobacterium kansasii, 59 cases
      (33.9%); M. avium complex, 53 (30.4%); M. abscessus, 23 (13.2%); and M.
      fortuitum, 14 (8.0%). A total of 42 (24.1%) cases were associated with rapidly
      growing mycobacteria. In countries with a high prevalence of tuberculosis, PNTM
      is likely misdiagnosed as tuberculosis, thus showing the need for improved
      capacity to diagnose mycobacterial disease as well as greater awareness of PNTM
      disease prevalence.
AD  - National School of Public Heath, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
FAU - de Mello, Karla Gripp Couto
AU  - de Mello KG
FAU - Mello, Fernanda C Queiroz
AU  - Mello FC
FAU - Borga, Liamar
AU  - Borga L
FAU - Rolla, Valeria
AU  - Rolla V
FAU - Duarte, Rafael S
AU  - Duarte RS
FAU - Sampaio, Elizabeth P
AU  - Sampaio EP
FAU - Holland, Steven M
AU  - Holland SM
FAU - Prevots, D Rebecca
AU  - Prevots DR
FAU - Dalcolmo, Margareth P
AU  - Dalcolmo MP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Emerg Infect Dis
JT  - Emerging infectious diseases
JID - 9508155
SB  - IM
EDAT- 2013/06/12 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/06/11 06:00
PST - ppublish
SO  - Emerg Infect Dis. 2013 Mar;19(3):393-9. doi:
      http://dx.doi.org/10.3201/eid/1903.120735.

PMID- 23745049
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Current and future initiatives for vascular health management in clinical
      practice.
PG  - 255-64
LID - 10.2147/VHRM.S42947 [doi]
AB  - Central arterial structure and function comprise a primary determinant of
      vascular health, and are integral to the important concept of ventriculo-vascular
      coupling or interaction. Central aortic stiffening is a major influence on
      central blood pressure, and directly relates to coronary perfusion. The joint
      session of the International Society of Vascular Health (Eastern Region) and the 
      Ukrainian Congress of Cardiology was held in Kiev, Ukraine, on September 23,
      2011; it provided an expert forum to discuss arterial evaluations, clinical
      applications, and progress toward translating arterial protection into
      cardiovascular benefits. The conclusions of the expert panel were: Aortic
      stiffness is not presently a treatment target but may be useful for
      substratifying cardiovascular risk in individuals in order to better target the
      intensity of conventional therapy, and it may be useful in assessing response to 
      treatment.Crosstalk between macro- and microcirculation in hypertension has
      important implications for pharmacological treatment. An antihypertensive regimen
      should abolish the vicious cycle between the increased resistance in the
      microcirculation and the increased stiffness of the larger arteries. Such
      treatment should be based on drugs with multiple actions on the vascular tree, or
      on drug combinations that target the various segments of the arterial
      system.Several blood pressure-independent mechanisms of large artery stiffness
      exist. Future considerations for clinical understanding of large artery stiffness
      should involve new drugs and new evaluation methods - with a focus on vascular
      health, for the initiation of cardiovascular prevention, for newly designed
      studies for treatment evaluation, and for new studies of drug
      combinations.Arterial stiffening is a sign of cardiovascular aging and is a major
      factor affecting the biomechanics of large arteries. Arterial stiffness is an
      attractive therapeutic target in terms of vascular aging. Healthy lifestyle,
      physical exercise, and smoking cessation are the most effective ways of
      preventing and treating early vascular aging. Long-term effects of cardiovascular
      drugs on arterial stiffness need to be further investigated.The emerging clinical
      data on the cardio ankle vascular index (CAVI) technique of arterial health
      assessment is presented, showing that the CAVI is elevated in aging, coronary
      artery diseases, chronic kidney disease, hypertension, diabetes mellitus,
      smoking, and stress. The CAVI decreased with the administration of statins,
      angiotensin II receptor blocking agents, and calcium channel blockers. The CAVI
      is suggested as an important predictor of cardiovascular diseases. Future
      development of a clinical understanding of large artery stiffness is important
      and should include consideration of new drugs and new evaluation methods, with a 
      focus on vascular health aimed at cardiovascular prevention.
AD  - Monash Cardiovascular Research Centre, Clayton, Melbourne, Victoria, Australia.
FAU - Cameron, James D
AU  - Cameron JD
FAU - Asmar, Roland
AU  - Asmar R
FAU - Struijker-Boudier, Harry
AU  - Struijker-Boudier H
FAU - Shirai, Kohji
AU  - Shirai K
FAU - Sirenko, Yuriy
AU  - Sirenko Y
FAU - Kotovskaya, Yulia
AU  - Kotovskaya Y
FAU - Topouchian, Jirar
AU  - Topouchian J
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
SB  - IM
PMC - PMC3671794
OID - NLM: PMC3671794
OTO - NOTNLM
OT  - arterial hemodynamic evaluation
OT  - arterial stiffness
OT  - cardiovascular protection
OT  - hypertension
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/28 [epublish]
AID - 10.2147/VHRM.S42947 [doi]
AID - vhrm-9-255 [pii]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:255-64. doi: 10.2147/VHRM.S42947. Epub 2013 May
      28.

PMID- 23745035
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 21
DP  - 2013 Jun 7
TI  - Effect of endogenous insulin-like growth factor and stem cell factor on diabetic 
      colonic dysmotility.
PG  - 3324-31
LID - 10.3748/wjg.v19.i21.3324 [doi]
AB  - AIM: To investigate whether the reduction of stem cell factor (SCF) is mediated
      by decreased endogenous insulin-like growth factor (IGF)-1 in diabetic rat colon 
      smooth muscle. METHODS: Sixteen Sprague-Dawley rats were randomly divided into
      two groups: control group and streptozotocin-induced diabetic group. After 8 wk
      of streptozotocin administration, colonic motility function and contractility of 
      circular muscle strips were measured. The expression of endogenous IGF-1 and SCF 
      was tested in colonic tissues. Colonic smooth muscle cells were cultured from
      normal adult rats. IGF-1 siRNA transfection was used to investigate whether SCF
      expression was affected by endogenous IGF-1 expression in smooth muscle cells,
      and IGF-1 induced SCF expression effects were studied. The effect of high glucose
      on the expression of endogenous IGF-1 and SCF was also investigated. RESULTS:
      Diabetic rats showed prolonged colonic transit time (252 +/- 16 min vs 168 +/- 9 
      min, P < 0.01) and weakness of circular muscle contraction (0.81 +/- 0.09 g vs
      2.48 +/- 0.23 g, P < 0.01) compared with the control group. Endogenous IGF-1 and 
      SCF protein expression was significantly reduced in the diabetic colonic muscle
      tissues. IGF-1 and SCF mRNA expression also showed a paralleled reduction in
      diabetic rats. In the IGF-1 siRNA transfected smooth muscle cells, SCF mRNA and
      protein expression was significantly decreased. IGF-1 could induce SCF expression
      in a concentration and time-dependent manner, mainly through the
      extracellular-signal-regulated kinase 1/2 signal pathway. High glucose inhibited 
      endogenous IGF-1 and SCF expression and the addition of IGF-1 to the medium
      reversed the SCF expression. CONCLUSION: Myopathy may resolve in colonic motility
      dysfunction in diabetic rats. Deficiency of endogenous IGF-1 in colonic smooth
      muscle cells leads to reduction of SCF expression.
AD  - Yun Wang, Xin-Yu Xu, Yu-Rong Tang, Wei-Wei Yang, Yu-Feng Yuan, Yue-Ji Ning,
      Yin-Juan Yu, Lin Lin, Department of Gastroenterology, First Affiliated Hospital
      of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
FAU - Wang, Yun
AU  - Wang Y
FAU - Xu, Xin-Yu
AU  - Xu XY
FAU - Tang, Yu-Rong
AU  - Tang YR
FAU - Yang, Wei-Wei
AU  - Yang WW
FAU - Yuan, Yu-Feng
AU  - Yuan YF
FAU - Ning, Yue-Ji
AU  - Ning YJ
FAU - Yu, Yin-Juan
AU  - Yu YJ
FAU - Lin, Lin
AU  - Lin L
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Gastroenterol
JT  - World journal of gastroenterology : WJG
JID - 100883448
SB  - IM
PMC - PMC3671085
OID - NLM: PMC3671085
OTO - NOTNLM
OT  - Diabetes
OT  - Gastrointestinal motility function
OT  - Insulin-like growth factor-1
OT  - Smooth muscle cell
OT  - Stem cell factor
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/01/30 [received]
PHST- 2013/03/23 [revised]
PHST- 2013/04/18 [accepted]
AID - 10.3748/wjg.v19.i21.3324 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 Jun 7;19(21):3324-31. doi: 10.3748/wjg.v19.i21.3324.

PMID- 23745006
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
DP  - 2013 Jun 6
TI  - Hierarchical cluster analysis identifies three different phenotypes of mild NPDR 
      in patients with diabetes type 2, with different risks for development of CSME.
LID - iovs.13-11895v1 [pii]
LID - 10.1167/iovs.13-11895 [doi]
AB  - PURPOSE: To identify different phenotypes of non-proliferative diabetic
      retinopathy (NPDR) and their progression to clinically significant macular edema 
      (CSME). METHODS: A prospective observational study was designed to follow
      eyes/patients with diabetes type 2 and NPDR with no prior laser treatment for
      two-years or until development of CSME. 410 patients, one eye per patient,
      fulfilled the inclusion/exclusion criteria and were included in the study.
      Ophthalmological examinations including BCVA, fundus photography with Retmarker
      analysis, and optical coherence tomography (OCT) were performed at baseline,
      month-6 and month-24 or before laser treatment. Hierarchical cluster analysis was
      used to identify homogeneous sub-groups and clinically significant thresholds of 
      the data collected. RESULTS: 376 eyes/patients performed the 6-month visit and
      were considered for cluster analysis. This mathematical method identified 3
      different phenotypes based on statistically significant differences for the
      microaneurysm (MA) turnover and for the central retinal thickness (RT): phenotype
      A (low MA turnover and normal RT, 48.1%); phenotype B (low MA turnover and
      increased central RT, 23.2%); and phenotype C (high MA turnover, 28.7%). From the
      348 eyes/patients that reached the study end-point or completed the 24-month
      visit, 26 developed CSME, 3 from phenotype A (1.8%), 7 from phenotype B (8.5%)
      and 16 from phenotype C (16.2%). Eyes/patients from phenotype C showed a higher
      risk for CSME development (OR = 3.536; P<0.001). CONCLUSIONS: Hierarchical
      cluster analysis identifies three different phenotypes of NPDR based on MA
      turnover and central macular thickness. Eyes/patients from phenotype C show a
      higher risk for the development of CSME.
AD  - Association for Innovation and Biomedical Research on Light and Image (AIBILI),
      Coimbra, Portugal.
FAU - Nunes, Sandrina Goncalves
AU  - Nunes SG
FAU - Ribeiro, Maria Luisa Ferreira Soares E Silva Reis
AU  - Ribeiro ML
FAU - Lobo da Fonseca, Maria Conceicao Lopes
AU  - Lobo da Fonseca MC
FAU - da Cunha-Vaz, Jose Guilherme Fernandes
AU  - da Cunha-Vaz JG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - iovs.13-11895 [pii]
AID - 10.1167/iovs.13-11895 [doi]
PST - aheadofprint
SO  - Invest Ophthalmol Vis Sci. 2013 Jun 6. pii: iovs.13-11895v1. doi:
      10.1167/iovs.13-11895.

PMID- 23744994
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1464-3685 (Electronic)
IS  - 0300-5771 (Linking)
DP  - 2013 Jun 5
TI  - The contributions of risk factor trends to cardiometabolic mortality decline in
      26 industrialized countries.
AB  - BACKGROUND: Cardiovascular disease mortality has declined and diabetes mortality 
      has increased in high-income countries. We estimated the potential role of trends
      in population body mass index, systolic blood pressure, serum total cholesterol
      and smoking in cardiometabolic mortality decline in 26 industrialized countries. 
      METHODS: Mortality data were from national vital statistics. Body mass index,
      systolic blood pressure and serum total cholesterol were from a systematic
      analysis of population-based data. We estimated the associations between change
      in cardiometabolic mortality and changes in risk factors, adjusted for change in 
      per-capita gross domestic product. We calculated the potential contribution of
      risk factor trends to mortality decline. RESULTS: Between 1980 and 2009,
      age-standardized cardiometabolic mortality declined in all 26 countries, with the
      annual decline between <1% in Mexico to approximately 5% in Australia. Across the
      26 countries together, risk factor trends may have accounted for approximately
      48% (men) and approximately 40% (women) of cardiometabolic mortality decline.
      Risk factor trends may have accounted for >60% of decline among men and women in 
      Finland and Switzerland, men in New Zealand and France, and women in Italy; their
      benefits were smallest in Mexican, Portuguese, and Japanese men and Mexican
      women. Risk factor trends may have slowed down mortality decline in Chilean men
      and women and had virtually no effect in Argentinean women. The contributions of 
      risk factors to mortality decline seemed substantially larger among men than
      among women in the USA, Canada and The Netherlands. CONCLUSIONS: Industrialized
      countries have varied widely in the extent of risk factor prevention, and its
      likely benefits for cardiometabolic mortality.
AD  - MRC-HPA Centre for Environment and Health, Department of Epidemiology and
      Biostatistics, Imperial College London, London, UK, Department of Health
      Statistics and Information Systems, World Health Organization, Geneva,
      Switzerland and Department of Global Health and Population, Harvard School of
      Public Health, Boston, MA, USA.
FAU - Di Cesare, Mariachiara
AU  - Di Cesare M
FAU - Bennett, James E
AU  - Bennett JE
FAU - Best, Nicky
AU  - Best N
FAU - Stevens, Gretchen A
AU  - Stevens GA
FAU - Danaei, Goodarz
AU  - Danaei G
FAU - Ezzati, Majid
AU  - Ezzati M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Int J Epidemiol
JT  - International journal of epidemiology
JID - 7802871
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - blood pressure
OT  - cholesterol
OT  - diabetes
OT  - obesity
OT  - smoking
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - dyt063 [pii]
AID - 10.1093/ije/dyt063 [doi]
PST - aheadofprint
SO  - Int J Epidemiol. 2013 Jun 5.

PMID- 23744795
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1520-6777 (Electronic)
IS  - 0733-2467 (Linking)
DP  - 2013 Jun 6
TI  - Effect of amitriptyline in treatment interstitial cystitis or bladder pain
      syndrome according to two criteria: Does ESSIC criteria change the response rate?
LID - 10.1002/nau.22407 [doi]
AB  - AIMS: The European Society for the Study of Interstitial Cystitis (ESSIC)
      recommended that interstitial cystitis (IC) should be replaced by bladder pain
      syndrome (BPS), which focused more attention on the painful or discomfort feeling
      related to bladder and weakened the importance of cystoscopy in diagnosis
      process. Our study aimed to explore whether this alteration changed the treatment
      outcomes of amitriptyline and whether cystoscopy was meaningful for the treatment
      of this disease. METHODS: We conducted a retrospective study including 25 IC
      patients fulfilled the National Institute of Diabetes and Digestive and Kidney
      Disease (NIDDK) criteria and 42 BPS patients diagnosed according to ESSIC
      criteria. All the patients received amitriptyline with a self-uptitration
      protocol. We compared the response rates of two groups by a patient reported
      global response assessment after 3 months and reclassified all the 67 patients
      according to ESSIC criteria, the response rates of different BPS types were also 
      assessed. RESULTS: There was no significant difference of response rate between
      IC patients (12/25, 48%) and BPS patients (19/42, 45.2%) according to different
      criteria (P = 0.337). The response rate of BPS type 1 (13/30, 43.3%) was similar 
      to that of type 2 or 3 (18/37, 48.6%) (P = 0.664). CONCLUSIONS: ESSIC criteria
      did not decrease the response rate of amitriptyline treatment for BPS patients
      compared to IC patients with complaint of bladder pain or discomfort. Cystoscopy 
      showed no predictive effect for the treatment outcome of amitriptyline.
      Neurourol. Urodynam. 9999:XX-XX, 2013. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Sun, Yaofei
AU  - Sun Y
FAU - Fang, Zujun
AU  - Fang Z
FAU - Ding, Qiang
AU  - Ding Q
FAU - Zheng, Jie
AU  - Zheng J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Neurourol Urodyn
JT  - Neurourology and urodynamics
JID - 8303326
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/12/10 [received]
PHST- 2013/03/06 [accepted]
AID - 10.1002/nau.22407 [doi]
PST - aheadofprint
SO  - Neurourol Urodyn. 2013 Jun 6. doi: 10.1002/nau.22407.

PMID- 23744749
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
DP  - 2013 Jun 6
TI  - The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in 
      Adults with Type 2 Diabetes Mellitus.
LID - 10.1002/phar.1303 [doi]
AB  - The use of currently available antihyperglycemic agents can be limited by
      contraindications; cost; renal and hepatic dosage adjustments; dosing schedules; 
      and adverse effects such as gastrointestinal upset, weight gain, and
      hypoglycemia. These limitations have led the pharmaceutical industry to identify 
      and pursue alternative therapies. Sodium glucose cotransporter-2 (SGLT-2)
      inhibitors belong to a new class of diabetes drugs and have a novel mechanism of 
      action. These agents are unique in that they increase glucose excretion,
      independent of insulin secretion, by inhibiting the renal reabsorption of
      glucose, inducing glycosuria. To summarize the current evidence for SGLT-2
      inhibitor therapy, we reviewed abstracts and published data from human trials
      evaluating the efficacy and safety of dapagliflozin, canagliflozin, and
      empagliflozin through February 2013. Data from these trials suggest that SGLT-2
      inhibitors are able to lower hemoglobin A1c and fasting blood glucose when used
      as either monotherapy or combination therapy. Cardiometabolic benefits included a
      reduction in systolic blood pressure, reduction in triglycerides, and weight loss
      of up to 3 kg. Common and serious adverse effects including infections, cancer,
      and pollakiuria were identified and reviewed. Although these agents have
      generally demonstrated efficacy, the adverse effects associated with
      dapagliflozin have caused a delay in its regulatory approval. Continued research 
      in this area will determine the risk:benefit ratio of SGLT-2 inhibitor therapy.
CI  - (c) 2013 Pharmacotherapy Publications, Inc.
AD  - Wingate University School of Pharmacy, Hendersonville Campus, Hendersonville,
      North Carolina.
FAU - Riser Taylor, Shawn
AU  - Riser Taylor S
FAU - Harris, Kira B
AU  - Harris KB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1002/phar.1303 [doi]
PST - aheadofprint
SO  - Pharmacotherapy. 2013 Jun 6. doi: 10.1002/phar.1303.

PMID- 23744726
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
DP  - 2013 Jun 6
TI  - Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of
      Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized
      Placebo-Controlled Trial.
LID - 10.1002/phar.1301 [doi]
AB  - STUDY OBJECTIVE: To evaluate the effects of exenatide on some inflammatory
      markers and to quantify the effect of exenatide on beta-cell function. DESIGN: A 
      randomized, double-blind, placebo-controlled trial. SETTING: Seven hospitals in
      Italy. PATIENTS: A total of 174 white treatment-naive adults with type 2 diabetes
      and a glycated hemoglobin (HbA1c ) level higher than 7.5%. INTERVENTION: After an
      open-label run-in period of 8 +/- 2 months with metformin, patients were
      randomized to take exenatide (5 mug twice/day for the first 4 weeks, 10 mug
      twice/day thereafter) or a placebo volume equivalent for 12 months. MEASUREMENTS 
      AND MAIN RESULTS: Body mass index, HbA1c , fasting plasma glucose, postprandial
      plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment
      insulin resistance index, homeostasis model assessment beta-cell function index
      (HOMA-beta), fasting plasma proinsulin (FPPr), proinsulin-to-fasting plasma
      insulin ratio (Pr:FPI ratio), C-peptide, glucagon, vaspin, chemerin, and resistin
      were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months.
      Patients also underwent a combined euglycemic, hyperinsulinemic, and
      hyperglycemic clamp with subsequent arginine stimulation to assess insulin
      sensitivity and insulin secretion. HbA1c was significantly improved with
      exenatide plus metformin compared with placebo plus metformin. Exenatide plus
      metformin was also significantly more effective than placebo plus metformin in
      increasing HOMA-beta C-peptide, and all measures of beta-cell function after the 
      euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide
      plus metformin also reduced resistin compared with placebo plus metformin. No
      variations in vaspin and chemerin were noted in group-to-group comparisons. We
      observed a significant correlation between M value increase, an index of insulin 
      sensitivity, and a decrease in inflammatory parameters in the exenatide plus
      metformin group. CONCLUSIONS: The combination of exenatide plus metformin was
      more effective than metformin alone in improving glycemic control, beta-cell
      function, and inflammatory parameters.
CI  - (c) 2013 Pharmacotherapy Publications, Inc.
AD  - Department of Internal Medicine and Therapeutics, University of Pavia, Pavia,
      Italy; Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical
      Research, University of Pavia, Pavia, Italy.
FAU - Derosa, Giuseppe
AU  - Derosa G
FAU - Franzetti, Ivano G
AU  - Franzetti IG
FAU - Querci, Fabrizio
AU  - Querci F
FAU - Carbone, Anna
AU  - Carbone A
FAU - Ciccarelli, Leonardina
AU  - Ciccarelli L
FAU - Piccinni, Mario N
AU  - Piccinni MN
FAU - Fogari, Elena
AU  - Fogari E
FAU - Maffioli, Pamela
AU  - Maffioli P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1002/phar.1301 [doi]
PST - aheadofprint
SO  - Pharmacotherapy. 2013 Jun 6. doi: 10.1002/phar.1301.

PMID- 23744716
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1461-7277 (Electronic)
IS  - 1359-1053 (Linking)
DP  - 2013 Jun 6
TI  - 'Healthy' individuals' perceptions of type 1 and type 2 diabetes cause and
      management: A 'think-aloud,' mixed-methods study using video-based vignettes.
AB  - This study investigated 'healthy' participants' perceptions of types 1 and 2
      diabetes using mixed methods. A total of 38 participants were asked about their
      perceptions of both types of diabetes using video-based vignettes of four cases. 
      Participants answered standardised questionnaires while thinking aloud and could 
      expand during semi-structured interview sections. Four themes were identified:
      knowledge of diabetes, power to influence diabetes, limitations of responsibility
      or blame for diabetes and feelings about individuals with diabetes. Perceived
      controllability of causes and perceptions of illness management informs
      understanding of stigma and risk and emphasises the importance of comparing
      perceptions of both types of diabetes.
AD  - University of Otago, New Zealand.
FAU - Anderson-Lister, Gina
AU  - Anderson-Lister G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Health Psychol
JT  - Journal of health psychology
JID - 9703616
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 1359105313490315 [pii]
AID - 10.1177/1359105313490315 [doi]
PST - aheadofprint
SO  - J Health Psychol. 2013 Jun 6.

PMID- 23744621
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
DP  - 2013 Jun 6
TI  - Stachydrine ameliorates high-glucose induced endothelial cell senescence and
      SIRT1 downregulation.
LID - 10.1002/jcb.24598 [doi]
AB  - Hyperglycaemia, a characteristic feature of diabetes mellitus, induces
      endothelial dysfunction and vascular complications by accelerating endothelial
      cell (EC) senescence and limiting the proliferative potential of these cells.
      Here we aimed to investigate the effect of stachydrine, a proline betaine present
      in considerable quantities in juices from fruits of the Citrus genus, on EC under
      high-glucose stimulation, and its underlying mechanism. The senescence model of
      EC was set up by treating cells with high-glucose (30 mM) for different times.
      Dose-dependent (0.001-1mM) evaluation of cell viability revealed that stachydrine
      does not affect cell proliferation with a similar trend up to 72 h. Noticeable,
      stachydrine (0.1 mM) significantly attenuated the high-glucose induced EC growth 
      arrest and senescence. Indeed, co-treatment with high-glucose and stachydrine for
      48 h kept the percentage of EC in the G0 /G1 cell cycle phase near to control
      values and significantly reduced cell senescence. Western blot analysis and
      confocal-laser scanning microscopy revealed that stachydrine also blocked the
      high-glucose induced upregulation of p16INK4A and downregulation of SIRT1
      expression and enzyme activity. Taken together, results here presented are the
      first evidence that stachydrine, a naturally occurring compound abundant in
      citrus fruit juices, inhibits the deleterious effect of high-glucose on EC and
      acts through the modulation of SIRT1 pathway. These results may open new
      prospective in the identification of stachydrine as an important component of
      healthier eating patterns in prevention of cardiovascular diseases. J. Cell.
      Biochem. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Biochemistry, Biophysics and General Pathology, Second University
      of Naples, Naples, Italy.
FAU - Servillo, Luigi
AU  - Servillo L
FAU - D'Onofrio, Nunzia
AU  - D'Onofrio N
FAU - Longobardi, Lara
AU  - Longobardi L
FAU - Sirangelo, Ivana
AU  - Sirangelo I
FAU - Giovane, Alfonso
AU  - Giovane A
FAU - Cautela, Domenico
AU  - Cautela D
FAU - Castaldo, Domenico
AU  - Castaldo D
FAU - Giordano, Antonio
AU  - Giordano A
FAU - Balestrieri, Maria Luisa
AU  - Balestrieri ML
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/05/10 [received]
PHST- 2013/05/14 [accepted]
AID - 10.1002/jcb.24598 [doi]
PST - aheadofprint
SO  - J Cell Biochem. 2013 Jun 6. doi: 10.1002/jcb.24598.

PMID- 23744618
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1473-5830 (Electronic)
IS  - 0954-6928 (Linking)
DP  - 2013 Jun 5
TI  - Typical angina without significant coronary stenosis: comparison of clinical
      profile, circadian presentation, and long-term follow-up between patients with
      and patients without vasospastic angina.
AB  - OBJECTIVES: The spectrum of patients with 'angina and normal coronary arteries'
      ranges from severe vasospasm to atypical chest pain. Among those with typical
      angina, however, little is known about similarities in the clinical profile and
      circadian presentation between typical nonvasospastic angina and normal coronary 
      arteries (tANCA) and vasospastic angina (VA). MATERIALS AND METHODS: Clinical,
      ECG, and angiographic features as well as the circadian characteristics of angina
      were compared between 384 tANCA and 273 VA patients. Follow-up events were also
      analyzed. RESULTS: tANCA patients had greater female predominance (61 vs. 18%),
      higher incidence of dyspnea to moderate exertion (49 vs. 12%), lower incidence of
      tobacco smoking (25 vs. 67%), but a similar low rate of diabetes (8.9 vs. 4.4%). 
      In both groups, however, dyspnea and smoking were associated with female and male
      sex, respectively. tANCA patients showed lower but non-negligible frequency of
      early morning (25 vs. 67%) and evening angina (37 vs. 54%), similar rate of
      nocturnal angina (47 vs. 50%), and higher rate of emotional angina (49 vs. 31%). 
      Moreover, a high proportion of patients gained pain relief with nitroglycerin
      (97% in VA, 246/253, and 76% in tANCA, 231/306). At 140 months, frequent angina
      (>10 episodes/year) was rare (VA: 7.1% vs. tANCA: 6.3%) as was the rate of
      cardiac death/myocardial infarction (7.3 vs. 6.0%, P=0.524). CONCLUSION: Despite 
      differences in the clinical profile between VA and tANCA patients, there is
      notable sharing of circadian presentation of rest angina, response to
      nitroglycerin, and long-term presence and frequency of angina that suggests more 
      similarities in underlying mechanisms than heretofore suspected.
AD  - Coronary Care Unit, Cardiology Service, Hospital General Universitari Vall
      d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
FAU - Figueras, Jaume
AU  - Figueras J
FAU - Domingo, Enric
AU  - Domingo E
FAU - Ferreira, Ignacio
AU  - Ferreira I
FAU - Lidon, Rosa M
AU  - Lidon RM
FAU - Bellera, Neus
AU  - Bellera N
FAU - Garcia-Dorado, David
AU  - Garcia-Dorado D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Coron Artery Dis
JT  - Coronary artery disease
JID - 9011445
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/MCA.0b013e328362230e [doi]
PST - aheadofprint
SO  - Coron Artery Dis. 2013 Jun 5.

PMID- 23744560
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 6
DP  - 2013 Jun 6
TI  - Hormone replacement therapy for women with type 1 diabetes mellitus.
PG  - CD008613
AB  - BACKGROUND: There is conflicting information about the impact of the menopause on
      glycaemic control amongst women with type 1 diabetes. Some menopausal women with 
      type 1 diabetes are treated with hormone replacement therapy (HRT) but the
      effects of this treatment have, to date, not been established. OBJECTIVES: To
      assess the effects of HRT for women with type 1 diabetes mellitus. SEARCH
      METHODS: We searched The Cochrane Library, MEDLINE, EMBASE, CINAHL and PsycINFO
      from their inception to June 2012. The last search was run for all databases on
      18 June 2012. SELECTION CRITERIA: We selected randomised controlled trials or
      controlled clinical trials that involved peri- or postmenopausal women with type 
      1 diabetes undergoing HRT as an intervention. DATA COLLECTION AND ANALYSIS: Two
      researchers independently applied the inclusion criteria to the identified
      studies and assessed risk of bias. Disagreements were resolved by discussion or
      by intervention by a third party. Descriptive analysis was conducted for the
      review. MAIN RESULTS: Ninety-two publications were screened. No studies met the
      inclusion criteria exclusively but one study that included both type 1 and type 2
      diabetes participants was considered. This randomised clinical trial (RCT)
      compared HRT (N = 27) with placebo (N = 29) over 12 months. The outcome measures 
      were cardiovascular risk factors, including lipid profile, glycaemic control,
      blood pressure and body weight. No significant differences between placebo and
      HTR were detected. Patient-important outcomes like all-cause mortality,
      cardiovascular disease, diabetic complications or health-related quality of life 
      were not investigated. AUTHORS' CONCLUSIONS: There is a lack of evidence around
      the use of HRT in women with type 1 diabetes. The one study that has been
      undertaken in this area is underpowered. More RCTs are required in the area to
      examine the impact of HRT on glycaemic control and cardiovascular outcomes.
AD  - Metabolic Unit, Western General Hospital Edinburgh, Crewe Road, Edinburgh,
      Lothian, UK, EH4 2XU.
FAU - Mackay, Liz
AU  - Mackay L
FAU - Kilbride, Lynn
AU  - Kilbride L
FAU - Adamson, Karen A
AU  - Adamson KA
FAU - Chisholm, John
AU  - Chisholm J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1002/14651858.CD008613.pub2 [doi]
PST - aheadofprint
SO  - Cochrane Database Syst Rev. 2013 Jun 6;6:CD008613.

PMID- 23744539
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 6
DP  - 2013 Jun 6
TI  - Chinese herbal medicines for hypertriglyceridaemia.
PG  - CD009560
AB  - BACKGROUND: Hypertriglyceridaemia is associated with many diseases including
      atherosclerosis, diabetes, hypertension and chylomicronaemia. Chinese herbal
      medicines have been used for a long time as lipid-lowering agents. OBJECTIVES: To
      assess the effects and safety of Chinese herbal medicines for
      hypertriglyceridaemia. SEARCH METHODS: We searched a number of databases
      including The Cochrane Library, MEDLINE, EMBASE and several Chinese databases
      (all until May 2012). SELECTION CRITERIA: Randomised controlled trials in
      participants with hypertriglyceridaemia comparing Chinese herbal medicines with
      placebo, no treatment, and pharmacological or non-pharmacological interventions. 
      DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and
      assessed the risk of bias. Any disagreement was resolved by discussion and a
      decision was achieved based on consensus. We assessed trials for risk of bias
      against key criteria: random sequence generation, allocation concealment,
      blinding of participants, incomplete outcome data, selective outcome reporting
      and other sources of bias. MAIN RESULTS: We included three randomised trials with
      170 participants. Ninety participants were randomised to the Chinese herbal
      medicines groups and 80 to the comparator groups with numbers ranging from 50 to 
      60 participants per trial. The duration of treatment varied from four to six
      weeks. All the included trials were conducted in China and published in Chinese. 
      Overall, the risk of bias of included trials was unclear. There were no outcome
      data in any of the trials on death from any cause, cardiovascular or
      cerebrovascular events, health-related quality of life, or costs.Three different 
      herbal medicines, including Zhusuan Huoxue decoction, Huoxue Huayu Tongluo
      decoction, and Chushi Huayu decoction were evaluated. All three trials
      investigating Chinese herbal medicines treatment alone (two studies) or in
      combination with gemfibrozil (one study) reported results on serum triglyceride
      (TG) in favour of the herbal treatment. We did not perform a meta-analysis due to
      significant clinical heterogeneity between the studies.No relevant differences in
      adverse effects occurred and no serious adverse events were noted. AUTHORS'
      CONCLUSIONS: The present systematic review suggests that Chinese herbal medicines
      may have positive effects on hypertriglyceridaemia. The trials did not report
      serious adverse effects following Chinese herbal medicines treatment. However,
      based on an unclear risk of bias in included studies and lack of
      patient-important long-term outcomes, no definite conclusion could be reached.
AD  - Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese
      Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, China, 100029.
FAU - Liu, Zhao Lan
AU  - Liu ZL
FAU - Li, George Q
AU  - Li GQ
FAU - Bensoussan, Alan
AU  - Bensoussan A
FAU - Kiat, Hosen
AU  - Kiat H
FAU - Chan, Kelvin
AU  - Chan K
FAU - Liu, Jian Ping
AU  - Liu JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1002/14651858.CD009560.pub2 [doi]
PST - aheadofprint
SO  - Cochrane Database Syst Rev. 2013 Jun 6;6:CD009560.

PMID- 23744409
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Jun 6
TI  - Thyroid Diseases and Adverse Pregnancy Outcomes in a Contemporary US Cohort.
AB  - Context:Thyroid diseases are inconsistently reported to increase risk for
      pregnancy complications.Objective:The objective of this study was to study
      pregnancy complications associated with common and uncommon thyroid
      diseases.Design, Setting, and Participants:We analyzed singleton pregnancies (N =
      223 512) from a retrospective US cohort, the Consortium on Safe Labor
      (2002-2008). Thyroid diseases and outcomes were derived from electronic medical
      records. Multivariable logistic regression with generalized estimating equations 
      estimated adjusted odds ratios (ORs) with 99% confidence intervals (99% CI).Main 
      Outcome Measures:Hypertensive diseases, diabetes, preterm birth, cesarean
      sections, inductions, and intensive care unit (ICU) admissions were
      analyzed.Results:Primary hypothyroidism was associated with increased odds of
      preeclampsia (OR = 1.47, 99% CI = 1.20-1.81), superimposed preeclampsia (OR =
      2.25, 99% CI = 1.53-3.29), gestational diabetes (OR = 1.57, 99% CI = 1.33-1.86), 
      preterm birth (OR = 1.34, 99% CI = 1.17-1.53), induction (OR = 1.15, 99% CI =
      1.04-1.28), cesarean section (prelabor, OR = 1.31, 99% CI = 1.11-1.54; after
      spontaneous labor OR = 1.38, 99% CI = 1.14-1.66), and ICU admission (OR = 2.08,
      99% CI = 1.04-4.15). Iatrogenic hypothyroidism was associated with increased odds
      of placental abruption (OR = 2.89, 99% CI = 1.14-7.36), breech presentation (OR =
      2.09, 99% CI = 1.07-4.07), and cesarean section after spontaneous labor (OR =
      2.05, 99% CI = 1.01-4.16). Hyperthyroidism was associated with increased odds of 
      preeclampsia (OR = 1.78, 99% CI = 1.08-2.94), superimposed preeclampsia (OR =
      3.64, 99% CI = 1.82-7.29), preterm birth (OR = 1.81, 99% CI = 1.32-2.49),
      induction (OR = 1.40, 99% CI = 1.06-1.86), and ICU admission (OR = 3.70, 99% CI =
      1.16-11.80).Conclusions:Thyroid diseases were associated with obstetrical, labor,
      and delivery complications. Although we lacked information on treatment during
      pregnancy, these nationwide data suggest either that there is a need for better
      thyroid disease management during pregnancy or that there may be an intrinsic
      aspect of thyroid disease that causes poor pregnancy outcomes.
AD  - Epidemiology Branch (T.M., P.M., J.G., S.K.L.) and Biostatistics and
      Bioinformatics Branch (Y.X., Z.C.), Division of Epidemiology, Statistics and
      Prevention Research, Eunice Kennedy Shriver National Institute for Child Health
      and Human Development, National Institutes of Health, Rockville, Maryland 20852.
FAU - Mannisto, Tuija
AU  - Mannisto T
FAU - Mendola, Pauline
AU  - Mendola P
FAU - Grewal, Jagteshwar
AU  - Grewal J
FAU - Xie, Yunlong
AU  - Xie Y
FAU - Chen, Zhen
AU  - Chen Z
FAU - Laughon, S Katherine
AU  - Laughon SK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - jc.2012-4233 [pii]
AID - 10.1210/jc.2012-4233 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Jun 6.

PMID- 23744407
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Jun 6
TI  - Decreased concentrations of the lipoprotein lipase inhibitor angiopoietin-like
      protein 4 and increased serum triacylglycerol are associated with increased
      neonatal fat mass in pregnant women with gestational diabetes mellitus.
AB  - CONTEXT:Angiopoietin-like protein 4 (ANGPTL4) is an extracellular inhibitor of
      lipoprotein lipase (LPL) activity. No studies have been done in pregnancy where
      hypertriglyceridemia and tissue specific changes in LPL activity are
      present.OBJECTIVE:To determine the relationship between neonatal fat mass (FM)
      and concentrations of ANGPTL4, and triacylglycerols (TAG) in maternal and cord
      serum of pregnant women with gestational diabetes mellitus (GDM) compared to
      controls.DESIGN:Maternal blood samples (n=90 control and n= 80 GDM) and umbilical
      cord blood were drawn before and after vaginal delivery respectively. Control and
      GDM subjects were grouped separately into three subgroups, according to neonatal 
      FM: 0-25th percentiles, 25th-75th percentiles and 75th-100th percentiles.OUTCOME 
      MEASURES:Glucose, insulin, TAG, non-esterified fatty acids (NEFA) and ANGPTL4
      were determined in maternal and neonatal serum.RESULTS:Age and pre-gestational
      BMI did not differ between GDM and control women in any subgroups. Maternal serum
      of GDM pregnant women who delivered the newborn with the highest FM, showed the
      highest concentrations of TAG and NEFA and lowest concentration of ANGPTL4,
      despite glucose and insulin concentrations being independent of changes in
      neonatal FM. However, cord serum of neonates of GDM patients with the highest FM,
      showed higher concentrations of insulin and lower concentrations of TAG than
      those with lower neonatal FM, but no significant differences in NEFA or ANGPTL4
      concentrations.CONCLUSIONS:In well-controlled GDM pregnancies, decreased maternal
      ANGPTL4 concentrations and a gradient of TAG towards the fetus are related with
      higher neonatal FM. However, in GDM fetuses with the highest FM, the potential
      effect of ANGPTL4 inhibiting adipose tissue LPL activity could be overcome by
      their hyperinsulinemia.
AD  - 1Faculties of Pharmacy and Medicine, University CEU San Pablo, Madrid, Spain;
FAU - Ortega-Senovilla, Henar
AU  - Ortega-Senovilla H
FAU - Schaefer-Graf, Ute
AU  - Schaefer-Graf U
FAU - Meitzner, Katrin
AU  - Meitzner K
FAU - Abou-Dakn, Michael
AU  - Abou-Dakn M
FAU - Herrera, Emilio
AU  - Herrera E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - jc.2013-1614 [pii]
AID - 10.1210/jc.2013-1614 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Jun 6.

PMID- 23744406
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Jun 6
TI  - Presence of brown adipocytes in retroperitoneal fat from patients with benign
      adrenal tumors: Relationship with outdoor temperature.
AB  - Context:Brown adipose tissue (BAT) is a metabolically highly active organ with
      increased thermogenic activity in rodents exposed to cold temperature. Recently
      its presence in the cervical adipose tissue of human adults and its association
      with a favorable metabolic phenotype has been reported.Objective:The objective of
      the study was to determine the prevalence of retroperitoneal BAT in human
      adults.Design:This was an observational cohort study.Setting:The study was
      conducted at a tertiary referral hospital.Patients:57 patients who underwent
      surgery for benign adrenal tumors were included in this study.Main outcome
      measures:Prevalence of retroperitoneal BAT adjacent to the removed adrenal tumor 
      as determined by UCP1 protein and mRNA expression.Results:Using protein and mRNA 
      expression analysis, we detected UCP1 protein in 26 out of 57 patients (45.6%) as
      well as high mRNA expression of genes characteristic for brown adipocytes,
      independent of the adrenal tumor type. The presence of brown adipocytes within
      the retroperitoneal fat was associated with a significantly lower outdoor
      temperature during the month prior to surgery. Importantly, UCP1 expression both 
      on mRNA and on protein level was inversely correlated to outdoor temperature,
      while BMI, sex, age, and diabetes status were not.Conclusions:These findings
      suggest that human retroperitoneal adipose tissue can acquire a BAT phenotype,
      thereby adapting to environmental challenges. These adaptive processes might
      provide a valuable therapeutic target in the treatment of obesity and insulin
      resistance.
AD  - 1Department of Medical and Clinical Genetics, Institute of Biomedicine, The
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
FAU - Betz, Matthias J
AU  - Betz MJ
FAU - Slawik, Marc
AU  - Slawik M
FAU - Lidell, Martin E
AU  - Lidell ME
FAU - Osswald, Andrea
AU  - Osswald A
FAU - Heglind, Mikael
AU  - Heglind M
FAU - Nilsson, Daniel
AU  - Nilsson D
FAU - Lichtenauer, Urs D
AU  - Lichtenauer UD
FAU - Mauracher, Brigitte
AU  - Mauracher B
FAU - Mussack, Thomas
AU  - Mussack T
FAU - Beuschlein, Felix
AU  - Beuschlein F
FAU - Enerback, Sven
AU  - Enerback S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - jc.2012-3535 [pii]
AID - 10.1210/jc.2012-3535 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Jun 6.

PMID- 23744306
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Jun 7
TI  - The use of intermediate endpoints in the design of type 1 diabetes prevention
      trials.
AB  - AIMS/HYPOTHESIS: This paper presents a rationale for the selection of
      intermediate endpoints to be used in the design of type 1 diabetes prevention
      clinical trials. METHODS: Relatives of individuals diagnosed with type 1 diabetes
      were enrolled on the TrialNet Natural History Study and screened for
      diabetes-related autoantibodies. Those with two or more such autoantibodies were 
      analysed with respect to increased HbA1c, decreased C-peptide following an OGTT, 
      or abnormal OGTT values as intermediate markers of disease progression. RESULTS: 
      Over 2 years, a 10% increase in HbA1c, and a 20% or 30% decrease in C-peptide
      from baseline, or progression to abnormal OGTT, occurred with a frequency between
      20% and 41%. The 3- to 5-year risk of type 1 diabetes following each intermediate
      endpoint was high, namely 47% to 84%. The lower the incidence of the endpoint
      being reached, the higher the risk of diabetes. A diabetes prevention trial using
      these intermediate endpoints would require a 30% to 50% smaller sample size than 
      one using type 1 diabetes as the endpoint. CONCLUSIONS/INTERPRETATION: The use of
      an intermediate endpoint in diabetes prevention is based on the generally held
      view of disease progression from initial occurrence of autoantibodies through
      successive immunological and metabolic changes to manifest type 1 diabetes. Thus,
      these markers are suitable for randomised phase 2 trials, which can more rapidly 
      screen promising new therapies, allowing them to be subsequently confirmed in
      definitive phase 3 trials.
AD  - Division of Informatics and Biostatistics, Department of Pediatrics, University
      of South Florida, Tampa, FL, 33612, USA, jpkrischer@epi.usf.edu.
FAU - Krischer, Jeffrey P
AU  - Krischer JP
CN  - the Type 1 Diabetes TrialNet Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/01/08 [received]
PHST- 2013/05/16 [accepted]
PHST- 2013/06/07 [aheadofprint]
AID - 10.1007/s00125-013-2960-7 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Jun 7.

PMID- 23744129
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 Jun 7
TI  - Factors associated with abnormal T-wave axis and increased QRS-T angle in type 2 
      diabetes.
AB  - Frontal plane T-wave axis and QRS-T angle are novel electrocardiographic
      ventricular repolarization parameters that have been scarcely evaluated in type 2
      diabetes. The aim was to investigate the factors associated with these parameters
      of abnormal ventricular repolarization in a cross-sectional analysis of 594
      patients with type 2 diabetes. Clinical, laboratory, 2D-echocardiographic,
      ambulatory blood pressure (BP) monitoring, aortic pulse wave velocity (PWV) and
      carotid ultrasonographic data were obtained. Digital 12-lead ECG was recorded,
      and frontal plane T-wave axis and QRS-T angle were automatically measured. T-wave
      axis was considered abnormal if >75 degrees or <15 degrees and QRS-T angle if
      >/=73 degrees in men and >/=67 degrees in woman. Associations were assessed by
      bivariate tests and multivariate logistic regressions. One hundred and four (20.9
      %) patients had abnormal T-wave axis, and 84 (14 %) had increased QRS-T angle.
      Patients with abnormal ventricular repolarization were older and had greater
      prevalence of micro- and macrovascular diabetic complications than patients with 
      normal repolarization. They had higher office and ambulatory BPs, greater
      prevalence of the non-dipping pattern, and greater left ventricular mass, aortic 
      PWV and carotid intima-media thickness. On multivariate analysis, abnormal
      ventricular repolarization parameters were independently associated with left
      ventricular hypertrophy, non-dipping pattern, higher ambulatory systolic BPs,
      glycated hemoglobin and common carotid intima-media thickness, and with the
      presence of coronary artery disease. In conclusion, abnormal frontal plane T-wave
      axis and QRS-T angle are independently associated with several markers of
      pre-clinical atherosclerotic disease; whether these associations represent
      additional cardiovascular risk in type 2 diabetes shall be confirmed in
      prospective studies.
AD  - Department of Internal Medicine, University Hospital Clementino Fraga Filho,
      Medical School, Universidade Federal do Rio de Janeiro, Rua Croton, 72, Rio de
      Janeiro, RJ, CEP: 22750-240, Brazil.
FAU - Cardoso, Claudia R L
AU  - Cardoso CR
FAU - Leite, Nathalie C
AU  - Leite NC
FAU - Salles, Gil F
AU  - Salles GF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/12/16 [received]
PHST- 2013/05/20 [accepted]
PHST- 2013/06/07 [aheadofprint]
AID - 10.1007/s00592-013-0483-9 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 Jun 7.

PMID- 23744070
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 Jun 6
TI  - A Mixed Mirror-image DNA/RNA Aptamer Inhibits Glucagon and Acutely Improves
      Glucose Tolerance in Models of Type 1 and Type 2 Diabetes.
AB  - Excessive secretion of glucagon - a functional insulin antagonist - significantly
      contributes to hyperglycemia in type 1 and type 2 diabetes. Accordingly,
      immunoneutralization of glucagon or genetic deletion of the glucagon receptor
      improved glucose homeostasis in animal models of diabetes. Despite this strong
      evidence, agents that selectively interfere with endogenous glucagon have not
      been implemented in clinical practice yet. We report the discovery of
      mirror-image DNA-aptamers (Spiegelmers) that bind and inhibit glucagon. The
      affinity of the best-binding DNA oligonucleotide was remarkably increased
      (>25-fold) by the introduction of oxygen atoms at selected 2'-positions through
      deoxyribo- to ribonucleotide exchanges resulting in a mixed DNA/RNA-Spiegelmer
      (NOX-G15) that binds glucagon with a Kd of 3 nM. NOX-G15 shows no
      cross-reactivity with related peptides such as glucagon-like peptide 1 (GLP-1),
      GLP-2, gastric-inhibitory peptide, and prepro-vasoactive intestinal peptide
      (prepro-VIP). In vitro, NOX-G15 inhibits glucagon-stimulated cAMP-production in
      CHO-cells overexpressing the human glucagon receptor with an IC50 of 3.4 nM. A
      single injection of NOX-G15 ameliorated glucose excursions in intraperitoneal
      glucose tolerance tests (ipGTT) in mice with streptozotocin-induced (type 1)
      diabetes and in a non-genetic mouse model of type 2 diabetes. In conclusion, the 
      data suggest NOX-G15 as a therapeutic candidate with the potential to acutely
      attenuate hyperglycemia in type 1 and type 2 diabetes.
AD  - NOXXON Pharma AG, Germany;
FAU - Vater, Axel
AU  - Vater A
FAU - Sell, Simone
AU  - Sell S
FAU - Kaczmarek, Przemyslaw
AU  - Kaczmarek P
FAU - Maasch, Christian
AU  - Maasch C
FAU - Buchner, Klaus
AU  - Buchner K
FAU - Pruszynska-Oszmalek, Ewa
AU  - Pruszynska-Oszmalek E
FAU - Kolodziejski, Pawel
AU  - Kolodziejski P
FAU - Purschke, Werner G
AU  - Purschke WG
FAU - Nowak, Krzysztof W
AU  - Nowak KW
FAU - Strowski, Mathias Z
AU  - Strowski MZ
FAU - Klussmann, Sven
AU  - Klussmann S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Aptamers
OT  - DNA
OT  - Diabetes
OT  - Drug design
OT  - Drug discovery
OT  - Spiegelmer
OT  - glucagon inhibitor
OT  - mirror-image aptamer
OT  - type 1 diabetes
OT  - type 2 diabetes
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - M112.444414 [pii]
AID - 10.1074/jbc.M112.444414 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 Jun 6.

PMID- 23744065
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 Jun 6
TI  - Enhanced Fasting Glucose Turnover in Mice with Disrupted Action of TUG Protein in
      Skeletal Muscle.
AB  - Insulin stimulates glucose uptake in 3T3-L1 adipocytes in part by causing
      endoproteolytic cleavage of TUG proteins. Cleavage liberates intracellularly
      sequestered GLUT4 glucose transporters for translocation to the cell surface. To 
      test the role of this regulation in muscle, we used mice with muscle-specific
      transgenic expression of a truncated TUG fragment, UBX-Cter. This fragment causes
      GLUT4 translocation in unstimulated 3T3-L1 adipocytes. We predicted that
      transgenic mice would have GLUT4 translocation in muscle during fasting. UBX-Cter
      expression caused depletion of PIST proteins, which transmit an insulin signal to
      TUG. Whereas insulin stimulated TUG proteolysis in control muscles, proteolysis
      was constitutive in transgenic muscles. Fasting transgenic mice had decreased
      plasma glucose and insulin concentrations, compared to controls. Whole-body
      glucose turnover was increased during fasting, but not during hyperinsulinemic
      clamp studies. In muscles with greatest UBX-Cter expression, 2-deoxyglucose
      uptake during fasting was similar to that in control muscles during
      hyperinsulinemic clamps. Fasting transgenic mice had increased muscle glycogen,
      and GLUT4 targeting to T-tubule fractions was increased 5.7-fold. Whole-body VO2,
      VCO2, and energy expenditure were increased by 12-13%. After 3 weeks on a
      high-fat diet, the decreased fasting plasma glucose in transgenic mice, compared 
      to controls, was more marked, and increased glucose turnover was not observed;
      the transgenic mice continued to have an increased metabolic rate. We conclude
      that insulin stimulates TUG proteolysis to translocate GLUT4 in muscle, that this
      pathway impacts systemic glucose homeostasis and energy metabolism, and that
      effects of activating this pathway are maintained during high fat diet-induced
      insulin resistance in mice.
AD  - Yale University, United States;
FAU - Loffler, Michael G
AU  - Loffler MG
FAU - Birkenfeld, Andreas L
AU  - Birkenfeld AL
FAU - Philbrick, Katerina M
AU  - Philbrick KM
FAU - Belman, Jonathan P
AU  - Belman JP
FAU - Habtemichael, Estifanos N
AU  - Habtemichael EN
FAU - Booth, Carmen J
AU  - Booth CJ
FAU - Castorena, Carlos M
AU  - Castorena CM
FAU - Choi, Cheol Soo
AU  - Choi CS
FAU - Jornayvaz, Francois R
AU  - Jornayvaz FR
FAU - Gassaway, Brandon M
AU  - Gassaway BM
FAU - Lee, Hui-Young
AU  - Lee HY
FAU - Cartee, Gregory D
AU  - Cartee GD
FAU - Philbrick, William
AU  - Philbrick W
FAU - Shulman, Gerald I
AU  - Shulman GI
FAU - Samuel, Varman T
AU  - Samuel VT
FAU - Bogan, Jonathan S
AU  - Bogan JS
LA  - ENG
GR  - R01 DK092661/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Diabetes
OT  - Energy metabolism
OT  - Glucose metabolism
OT  - Glucose transport
OT  - Glut4
OT  - Insulin
OT  - Insulin resistance
OT  - Membrane trafficking
OT  - Nutrition
OT  - Transgenic mice
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - M113.458075 [pii]
AID - 10.1074/jbc.M113.458075 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 Jun 6.

PMID- 23744028
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 4
DP  - 2013 Jun 7
TI  - The orphan receptor Gpr83 regulates systemic energy metabolism via
      ghrelin-dependent and ghrelin-independent mechanisms.
PG  - 1968
LID - 10.1038/ncomms2968 [doi]
AB  - The G protein-coupled receptor 83 (Gpr83) is widely expressed in brain regions
      regulating energy metabolism. Here we report that hypothalamic expression of
      Gpr83 is regulated in response to nutrient availability and is decreased in obese
      mice compared with lean mice. In the arcuate nucleus, Gpr83 colocalizes with the 
      ghrelin receptor (Ghsr1a) and the agouti-related protein. In vitro analyses show 
      heterodimerization of Gpr83 with Ghsr1a diminishes activation of Ghsr1a by
      acyl-ghrelin. The orexigenic and adipogenic effect of ghrelin is accordingly
      potentiated in Gpr83-deficient mice. Interestingly, Gpr83 knock-out mice have
      normal body weight and glucose tolerance when fed a regular chow diet, but are
      protected from obesity and glucose intolerance when challenged with a high-fat
      diet, despite hyperphagia and increased hypothalamic expression of agouti-related
      protein, Npy, Hcrt and Ghsr1a. Together, our data suggest that Gpr83 modulates
      ghrelin action but also indicate that Gpr83 regulates systemic metabolism through
      other ghrelin-independent pathways.
AD  - 1] Institute for Diabetes and Obesity, Helmholtz Center Munich and Division of
      Metabolic Diseases, Department of Medicine, Technical University Munich, Germany 
      [2].
FAU - Muller, Timo D
AU  - Muller TD
FAU - Muller, Anne
AU  - Muller A
FAU - Yi, Chun-Xia
AU  - Yi CX
FAU - M Habegger, Kirk
AU  - M Habegger K
FAU - Meyer, Carola W
AU  - Meyer CW
FAU - Gaylinn, Bruce D
AU  - Gaylinn BD
FAU - Finan, Brian
AU  - Finan B
FAU - Heppner, Kristy
AU  - Heppner K
FAU - Trivedi, Chitrang
AU  - Trivedi C
FAU - Bielohuby, Maximilian
AU  - Bielohuby M
FAU - Abplanalp, William
AU  - Abplanalp W
FAU - Meyer, Franziska
AU  - Meyer F
FAU - Piechowski, Carolin L
AU  - Piechowski CL
FAU - Pratzka, Juliane
AU  - Pratzka J
FAU - Stemmer, Kerstin
AU  - Stemmer K
FAU - Holland, Jenna
AU  - Holland J
FAU - Hembree, Jazzmin
AU  - Hembree J
FAU - Bhardwaj, Nakul
AU  - Bhardwaj N
FAU - Raver, Christine
AU  - Raver C
FAU - Ottaway, Nickki
AU  - Ottaway N
FAU - Krishna, Radha
AU  - Krishna R
FAU - Sah, Renu
AU  - Sah R
FAU - Sallee, Floyd R
AU  - Sallee FR
FAU - Woods, Stephen C
AU  - Woods SC
FAU - Perez-Tilve, Diego
AU  - Perez-Tilve D
FAU - Bidlingmaier, Martin
AU  - Bidlingmaier M
FAU - Thorner, Michael O
AU  - Thorner MO
FAU - Krude, Heiko
AU  - Krude H
FAU - Smiley, David
AU  - Smiley D
FAU - Dimarchi, Richard
AU  - Dimarchi R
FAU - Hofmann, Susanna
AU  - Hofmann S
FAU - Pfluger, Paul T
AU  - Pfluger PT
FAU - Kleinau, Gunnar
AU  - Kleinau G
FAU - Biebermann, Heike
AU  - Biebermann H
FAU - Tschop, Matthias H
AU  - Tschop MH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
SB  - IM
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/10/30 [received]
PHST- 2013/05/02 [accepted]
AID - ncomms2968 [pii]
AID - 10.1038/ncomms2968 [doi]
PST - ppublish
SO  - Nat Commun. 2013 Jun 7;4:1968. doi: 10.1038/ncomms2968.

PMID- 23743942
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1938-3800 (Electronic)
IS  - 0742-3225 (Linking)
VI  - 45
IP  - 6
DP  - 2013 Jun
TI  - Clinical utility of a brief screen for health literacy and numeracy among adults 
      with diabetes mellitus.
PG  - 417-23
AB  - BACKGROUND AND OBJECTIVES: Our objectives were to (1) compare Newest Vital Sign
      (NVS) scores and administration characteristics with the short (S) version of the
      Test of Functional Health Literacy in Adults (S-TOFHLA) and Spoken Knowledge in
      Low-Literacy Diabetes (SKILLD) tool and (2) gather information from research
      assistants (RAs) regarding their perceptions of patient understanding of NVS
      items. METHODS: Adults, age ? 18 years, with diabetes mellitus visiting a primary
      care clinic were recruited to participate. An RA orally administered a
      sociodemographic questionnaire. Patients completed, in random order, the NVS,
      S-TOFHLA, and SKILLD. Completion time for each tool was electronically recorded, 
      while patients assessed tool difficulty using a 5-point Likert-type scale. RAs'
      comments regarding patients' understanding of individual NVS items were tallied. 
      RESULTS: A total of 226 patients (mean age=53.8 years, 31% male, 45.1% African
      American, 28.8% high school graduate) participated. African Americans were
      significantly less likely to score ?4 on the NVS (adjusted OR=0.23, 95% CI=0.13, 
      0.42) as compared to Caucasians. NVS scores were highly correlated with S-TOFHLA 
      scores, rho=0.62, and moderately correlated with SKILLD scores, rho=0.39. NVS
      scores were inversely correlated with completion time, rho=-0.25 and difficulty
      rating, rho=-0.37. CONCLUSIONS: Related to the care of patients with diabetes,
      the most important feature of the NVS is that it can quickly provide a clinician 
      with valuable insight regarding their patients' ability to complete a practical
      skill (ie, interpreting a food label) needed to achieve tight blood glucose
      control.
AD  - Department of Family Medicine, Ohio State University.
FAU - Miser, William F
AU  - Miser WF
FAU - Jeppesen, Kelly M
AU  - Jeppesen KM
FAU - Wallace, Lorraine S
AU  - Wallace LS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Fam Med
JT  - Family medicine
JID - 8306464
SB  - IM
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PST - ppublish
SO  - Fam Med. 2013 Jun;45(6):417-23.

PMID- 23743940
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1938-3800 (Electronic)
IS  - 0742-3225 (Linking)
VI  - 45
IP  - 6
DP  - 2013 Jun
TI  - Assessing culturally competent diabetes care with unannounced standardized
      patients.
PG  - 400-8
AB  - BACKGROUND AND OBJECTIVES: More effective diabetes care is desperately needed,
      especially for ethnic minority populations. Provider cultural competence promises
      to be an important means for reducing disparities in outcomes for patients with
      diabetes. The objectives of this study were to understand the role of cultural
      competence in the diabetes office visit. METHODS: Unannounced standardized
      patients (SPs) were sent to the offices of 29 family and internal medicine
      residents and practicing physicians. The SPs portrayed a Mexican American woman
      newly diagnosed with type 2 diabetes. Using a checklist developed with the input 
      of experts in Hispanic/Latino health care and cultural competence, the SPs
      evaluated physicians' cultural competence, diabetes care, and general
      communications skills. RESULTS: The average total SP Checklist score was
      70.7-11.0%, with a range of 43.9% to 90.2%. Physicians scored highly on items
      that measured general communication skills (95.9%) but were less likely to ask
      about social history (ie, family and community support issues, 51.9% and 48.1%,
      respectively). Sixty-seven percent of physicians ordered a hemoglobin A1c, 44%
      referred to ophthalmology, and 15% performed a monofilament exam. Physicians'
      inquiry into SPs explanatory model of disease (ie, asking about the SPs' views
      regarding their disease and its treatment) correlated with the performance of
      several diabetes treatment-related behaviors, Spearman's rho=.466. CONCLUSIONS:
      The findings provide support for a relationship between inquiry into patients'
      explanatory models of disease and effective diabetes care. Social history and
      explanatory model elicitation skills are vital parts of cultural competence
      training programs and potentially valuable tools for mitigating health
      disparities.
AD  - Department of Family and Community Medicine, University of Arizona.
FAU - Kutob, Randa M
AU  - Kutob RM
FAU - Bormanis, John
AU  - Bormanis J
FAU - Crago, Marjorie
AU  - Crago M
FAU - Senf, Janet
AU  - Senf J
FAU - Gordon, Paul
AU  - Gordon P
FAU - Shisslak, Catherine M
AU  - Shisslak CM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Fam Med
JT  - Family medicine
JID - 8306464
SB  - IM
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PST - ppublish
SO  - Fam Med. 2013 Jun;45(6):400-8.

PMID- 23743909
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 0080-6234 (Print)
IS  - 0080-6234 (Linking)
VI  - 47
IP  - 2
DP  - 2013 Apr
TI  - Assessment of self-care competence of elderly people with diabetes.
PG  - 415-420
LID - S0080-62342013000200020 [pii]
AB  - This descriptive, cross-sectional and correlational study aimed to assess the
      self-care competencies of senior citizens with diabetes using the Scale to
      Identify Diabetes Mellitus Patients' Competence for Self-Care and personal
      factors associated with it. The study population consisted of seniors registered 
      in primary healthcare units in Fortaleza, CE, Brazil. Only 6% of the patients
      were considered to have diabetes self-care competence. Low educational level and 
      decreased visual acuity were identified as factors that influenced these low
      scores. The results, which showed that a small number of seniors were considered 
      competent to practice self-care, indicated the importance of developing health
      promotion activities targeted to this population, assessing skills and
      encouraging self-care practices to facilitate the planning of health
      interventions.
FAU - Marques, Marilia Braga
AU  - Marques MB
FAU - Silva, Maria Josefina da
AU  - Silva MJ
FAU - Coutinho, Janaina Fonseca Victor
AU  - Coutinho JF
FAU - Lopes, Marcos Venicios de Oliveira
AU  - Lopes MV
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
TT  - Avaliacao da competencia de idosos diabeticos para o autocuidado.
TA  - Rev Esc Enferm USP
JT  - Revista da Escola de Enfermagem da U S P
JID - 0242726
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/02/18 [received]
PHST- 2012/08/17 [accepted]
AID - S0080-62342013000200020 [pii]
PST - ppublish
SO  - Rev Esc Enferm USP. 2013 Apr;47(2):415-420.

PMID- 23743906
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 0080-6234 (Print)
IS  - 0080-6234 (Linking)
VI  - 47
IP  - 2
DP  - 2013 Apr
TI  - Morbidity and quality of life of elderly individuals with diabetes mellitus
      living in urban and rural areas.
PG  - 393-400
LID - S0080-62342013000200017 [pii]
AB  - This study aimed to describe the socio-demographic variables and to compare the
      morbidities and the quality of life (QoL) of elderly individuals with diabetes
      mellitus (DM) residing in urban and rural areas. The sample consisted of 271
      elderly individuals from urban areas and 104 from rural areas with self-reported 
      DM. A descriptive analysis was used, and in the location comparison, an age
      adjustment was employed through linear and logistic multiple regression models
      (p<0.05). The elderly individuals from the rural area were younger, more
      educated, earned a higher income and were more often married in relation to the
      urban residents. Furthermore, the rural residents presented a higher QoL score in
      the physical and social relationships domains and in the autonomy, past, present 
      and future activities, and intimacy facets compared to the urban residents. The
      elderly individuals residing in the urban area displayed a larger number of
      verified comorbidities. The elderly DM patients residing in the rural area
      generally presented better health conditions than those who lived in the urban
      area.
FAU - Santos, Erica Aparecida Dos
AU  - Santos EA
FAU - Tavares, Darlene Mara Dos Santos
AU  - Tavares DM
FAU - Rodrigues, Leiner Resende
AU  - Rodrigues LR
FAU - Dias, Flavia Aparecida
AU  - Dias FA
FAU - Ferreira, Pollyana Cristina Dos Santos
AU  - Ferreira PC
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
TT  - Morbidades e qualidade de vida de idosos com diabetes mellitus residentes nas
      zonas rural e urbana.
TA  - Rev Esc Enferm USP
JT  - Revista da Escola de Enfermagem da U S P
JID - 0242726
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2011/07/26 [received]
PHST- 2012/09/20 [accepted]
AID - S0080-62342013000200017 [pii]
PST - ppublish
SO  - Rev Esc Enferm USP. 2013 Apr;47(2):393-400.

PMID- 23743900
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 0080-6234 (Print)
IS  - 0080-6234 (Linking)
VI  - 47
IP  - 2
DP  - 2013 Apr
TI  - Quality of life in patients with diabetes mellitus before and after their
      participation in an educational program.
PG  - 348-354
LID - S0080-62342013000200011 [pii]
AB  - This quasi-experimental study aimed to evaluate the health-related quality of
      life in individuals with diabetes mellitus before and after their participation
      in a five-month educational program in a primary care service in Brazil in 2008. 
      The sample consisted of 51 individuals, 56.9% female and 43.1% male, who had a
      mean age of 57.65 +/- 11.44 years. Data were collected using the Portuguese
      version of the SF-36 questionnaire. The instrument had adequate reliability
      estimates for the study sample. Cronbach's alpha for the two components of the
      instrument, physical and mental, were 0.83 and 0.89, respectively. The findings
      suggested improvements in all the domain components; however, only the general
      health domain, before (63.96 +/- 19.03) and after (70.59 +/- 17.82) the
      educational program, presented statistically significant mean differences, t(50) 
      = 2.16, p<0.05. Participation in the educational program also contributed to
      improvements in the perceptions of the individuals regarding their general health
      status.
FAU - Faria, Heloisa Turcatto Gimenes
AU  - Faria HT
FAU - Veras, Vivian Saraiva
AU  - Veras VS
FAU - Xavier, Antonia Tayana da Franca
AU  - Xavier AT
FAU - Teixeira, Carla Regina de Souza
AU  - Teixeira CR
FAU - Zanetti, Maria Lucia
AU  - Zanetti ML
FAU - Santos, Manoel Antonio Dos
AU  - Santos MA
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
TT  - Qualidade de vida de pacientes com diabetes mellitus antes e apos participacao em
      programa educativo.
TA  - Rev Esc Enferm USP
JT  - Revista da Escola de Enfermagem da U S P
JID - 0242726
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2011/07/14 [received]
PHST- 2012/07/24 [accepted]
AID - S0080-62342013000200011 [pii]
PST - ppublish
SO  - Rev Esc Enferm USP. 2013 Apr;47(2):348-354.

PMID- 23743897
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 0080-6234 (Print)
IS  - 0080-6234 (Linking)
VI  - 47
IP  - 2
DP  - 2013 Apr
TI  - Risk factors and cardiovascular events in adult Latin American immigrants in the 
      Macarena District, Seville, Spain: a pilot study.
PG  - 328-334
LID - S0080-62342013000200008 [pii]
AB  - In order to estimate the prevalence of self-reported risk factors and
      cardiovascular events in an adult immigrant Latin American population of District
      2 (Macarena) in Seville, we conducted a pilot study using cross-sectional
      descriptive research. We used an anonymous questionnaire with self-reported risk 
      factors and cardiovascular events. 34 people participated (18% of the sample);
      mean age: 31.8 years, mean residence: 6.5 years, women: 52.9%. Prevalence of risk
      factors: diabetes 8.8%, high cholesterol 14.7% and high blood pressure 23.5%.
      Prevalence of coronary events was 8.8%; angina pectoris, myocardial infarction
      and stroke, 2.9% each. The conclusion is that self-reported prevalence of
      cardiovascular events was higher than in the literature, this issue deserving the
      attention of health agencies. This knowledge should be considered by nurses to
      develop culturally appropriate care plans of the context of immigrants.
FAU - Gonzalez-Lopez, Jose Rafael
AU  - Gonzalez-Lopez JR
FAU - Lomas-Campos, Maria de Las Mercedes
AU  - Lomas-Campos MD
FAU - Rodriguez-Gazquez, Maria de Los Angeles
AU  - Rodriguez-Gazquez MD
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Factores de riesgo y eventos cardiovasculares en inmigrantes latinoamericanos
      adultos en el Distrito Macarena, Sevilla, Espana: estudio piloto.
TA  - Rev Esc Enferm USP
JT  - Revista da Escola de Enfermagem da U S P
JID - 0242726
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2011/05/08 [received]
PHST- 2012/07/16 [accepted]
AID - S0080-62342013000200008 [pii]
PST - ppublish
SO  - Rev Esc Enferm USP. 2013 Apr;47(2):328-334.

PMID- 23743889
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1573-2606 (Electronic)
IS  - 1389-9155 (Linking)
DP  - 2013 Jun 7
TI  - HIV and thyroid dysfunction.
AB  - Human Immunodeficiency virus (HIV) infection and Acquired Immunodeficiency
      Syndrome (AIDS) are associated with dysfunction of many endocrine organs and
      their axis. HIV infectivity leads to altered metabolism, poor oral intake and
      increased prevalence of weight loss and wasting which may have a role in thyroid 
      dysfunction. Overt thyroid dysfunction occurs at similar rates as the general
      population while subclinical disease such as nonthyroidal illness (sick euthyroid
      syndrome), subclinical hypothyroidism and isolated low T4 levels are more
      frequent. Moreover, HAART therapy can complicate thyroid function further through
      drug interactions and the immune reconstitution inflammatory syndrome (IRIS). In 
      this review we report the common thyroid dysfunctions associated with HIV before 
      and after HAART therapy. We discuss presentation, diagnostic work up, treatment
      and follow up in each condition.
AD  - Endocrinology, Diabetes & Metabolism, Cedars-Sinai Medical Center, Los Angeles,
      CA, USA.
FAU - Parsa, Alan A
AU  - Parsa AA
FAU - Bhangoo, Amrit
AU  - Bhangoo A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Rev Endocr Metab Disord
JT  - Reviews in endocrine & metabolic disorders
JID - 100940588
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1007/s11154-013-9248-6 [doi]
PST - aheadofprint
SO  - Rev Endocr Metab Disord. 2013 Jun 7.

PMID- 23743882
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1435-1269 (Electronic)
IS  - 0948-6704 (Linking)
DP  - 2013 Jun 8
TI  - [Gender aspects in cardiovascular diseases.]
AB  - Cardiovascular diseases are the main cause of death in women and men worldwide,
      and, especially as far as coronary heart disorders are concerned, this is true of
      an increasing number of older and elderly persons. For decades, Gender Medicine
      research has shown gender differences in cardiology to the detriment of women,
      for example it takes longer for them to receive and they are less likely to have 
      access to high-tech medicine, such as the ICU, heart catheters, bypass surgery,
      and they have a poorer outcome. Meanwhile, numerous scientific studies and
      awareness campaigns have been conducted. However, the more recent publications
      still show the same trends, albeit at a decreasing rate. Thanks to the emphasis
      placed on prevention and, thus, also the attention called to the leading heart
      risk factors such as smoking, high blood pressure, blood lipids, diabetes
      mellitus and overweight, namely for women and men, heart death is no longer
      exclusively male. In order to promote equal opportunity, Gender Medicine must be 
      further implemented in medical training and post-graduate training, and-above
      all-the scientific findings concerning Gender Medicine must be incorporated into 
      the guidelines of our professional societies.
AD  - Frauengesundheitszentrum, Universitatskliniken Innsbruck, Innrain 66, 6020,
      Innsbruck, Osterreich, margarethe.hochleitner@i-med.ac.at.
FAU - Hochleitner, M
AU  - Hochleitner M
LA  - GER
PT  - JOURNAL ARTICLE
TT  - Genderaspekte bei kardiovaskularen Krankheiten.
DEP - 20130608
TA  - Z Gerontol Geriatr
JT  - Zeitschrift fur Gerontologie und Geriatrie
JID - 9506215
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1007/s00391-013-0506-8 [doi]
PST - aheadofprint
SO  - Z Gerontol Geriatr. 2013 Jun 8.

PMID- 23743842
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 0034-7167 (Print)
IS  - 0034-7167 (Linking)
VI  - 66
IP  - 2
DP  - 2013 Apr
TI  - [Gestational diabetes from the perspective of hospitalized pregnant women].
PG  - 222-7
LID - S0034-71672013000200011 [pii]
AB  - This phenomenological qualitative study aimed to understand the meaning of the
      experiences lived by women with gestational diabetes mellitus. The sample
      consisted of 12 patients hospitalized at a maternity hospital in the city of
      Fortaleza, state of Ceara, Brazil, which expressed their feelings and perceptions
      through open interviews and drawings. The empirical material was fully
      transcribed and then organized and analyzed by the phenomenological method. The
      results revealed two themes: (1) Living experiences that bring happiness and
      well-being, and (2) Living experiences that cause suffering. This
      phenomenological study showed the experience of women with gestational diabetes
      mellitus, thus enabling to plan and to implement intervention programs based on a
      participatory model of health in order to prioritize the subjective aspects
      involved in high-risk pregnancy.
FAU - Araujo, Marcio Flavio Moura
AU  - Araujo MF
FAU - Pessoa, Sarah Maria Fraxe
AU  - Pessoa SM
FAU - Damasceno, Marta Maria Coelho
AU  - Damasceno MM
FAU - Zanetti, Maria Lucia
AU  - Zanetti ML
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Diabetes gestacional na perspectiva de mulheres gravidas hospitalizadas.
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
SB  - N
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2011/07/06 [received]
PHST- 2013/04/10 [accepted]
AID - S0034-71672013000200011 [pii]
PST - ppublish
SO  - Rev Bras Enferm. 2013 Apr;66(2):222-7.

PMID- 23743841
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 0034-7167 (Print)
IS  - 0034-7167 (Linking)
VI  - 66
IP  - 2
DP  - 2013 Apr
TI  - [Perceptions of people with diabetes about the disease: nursing contributions].
PG  - 215-21
LID - S0034-71672013000200010 [pii]
AB  - This study aimed to identify the perceptions of patients concerning diabetes.
      This is a descriptive exploratory study with a qualitative approach, which was
      conducted with 32 subjects, in a hospital in the city of Belem-PA, Brazil. The
      thematic content analysis was used, from which four categories emerged: Diabetes 
      control: nursing in the self-monitoring of blood glucose; The diabetic individual
      and nursing: an interaction with self-care; Nursing consultations provided to
      diabetic individuals: an intervention in the health-disease continuum; Diabetes
      and its complications: fear of loosing functioning. It was observed that patients
      start self-care driven by the fear of losing their health, that is, fear forces
      the patient to practice self-care. Nurses are directly linked to diabetes control
      as they start providing care and guidance for patients who self-monitor their
      disease.
FAU - Chaves, Miriam de Oliveira
AU  - Chaves Mde O
FAU - Teixeira, Mirian Rose Franco
AU  - Teixeira MR
FAU - Silva, Silvio Eder Dias da
AU  - Silva SE
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Percepcoes de portadores de diabetes sobre a doenca: contribuicoes da Enfermagem.
PL  - Brazil
TA  - Rev Bras Enferm
JT  - Revista brasileira de enfermagem
JID - 7910105
SB  - N
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2011/04/07 [received]
PHST- 2013/03/21 [accepted]
AID - S0034-71672013000200010 [pii]
PST - ppublish
SO  - Rev Bras Enferm. 2013 Apr;66(2):215-21.

PMID- 23743808
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 Jun 5
TI  - Persistent organic pollutants and abnormal geometry of the left ventricle in the 
      elderly.
AB  - BACKGROUND:: Established risk factors for left ventricular hypertrophy (LVH) are 
      hypertension, diabetes, and obesity. However, as these risk factors explain only 
      part of the variation in left ventricular mass, we investigated whether
      persistent organic pollutants (POPs) might also play a role in LVH, because
      exposure to polychlorinated biphenyl 126 induced cardiac growth in rats.
      METHODS:: In the Prospective Investigation of the Vasculature in Uppsala Seniors 
      (PIVUS), left ventricular mass index (LVMI), relative wall thickness (RWT), and
      geometric groups of LVH, were determined by echocardiography and 21 POPs were
      measured by high-resolution chromatography coupled to high-resolution mass
      spectrometry (HRGC/HRMS) in 1016 individuals aged 70 years. All individuals with 
      a history of myocardial infarction were excluded from analysis (n = 72).
      RESULTS:: Several of the POPs were related to abnormal left ventricular geometry 
      before adjustment for established risk factors, but lost in significance
      following adjustment. However, the pesticide hexachlorobenzene (HCB) levels were 
      significantly related to RWT, and concentric left ventricular remodeling, also
      following adjustment for sex, blood pressure, antihypertensive treatment,
      diabetes, and BMI (P <0.0001). CONCLUSION:: In this cross-sectional study,
      circulating levels of HCB were related to increased wall thickness of the left
      ventricle and concentric left ventricular remodeling, independently of LVH risk
      factors, suggesting a role of this environmental contaminant in abnormal growth
      of the left ventricle.
AD  - aDepartment of Emergency Medicine, Linkoping University Hospital, Linkoping
      bDepartment of Medicine, Uppsala University, Uppsala cMTM Research Center, School
      of Science and Technology, Orebro University, Orebro dOccupational and
      Environmental Medicine, Uppsala University, Uppsala, Sweden.
FAU - Sjoberg Lind, Ylva
AU  - Sjoberg Lind Y
FAU - Lind, Lars
AU  - Lind L
FAU - Salihovic, Samira
AU  - Salihovic S
FAU - van Bavel, Bert
AU  - van Bavel B
FAU - Lind, P Monica
AU  - Lind PM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/HJH.0b013e32836221b3 [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 Jun 5.

PMID- 23743807
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 Jun 5
TI  - Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary 
      albumin?
AB  - OBJECTIVE:: Urinary levels of renin-angiotensin-aldosterone system (RAAS)
      components may reflect renal RAAS activity and/or the renal efficacy of RAAS
      inhibition. Our aim was to determine whether urinary angiotensinogen and renin
      are circulating RAAS-independent markers during RAAS blockade. METHODS:: Urinary 
      and plasma levels of angiotensinogen, renin, and albumin were measured in 22
      patients with type 2 diabetes, hypertension, and albuminuria, during 2-month
      treatment periods with placebo, aliskiren, irbesartan, or their combination in
      random order in a crossover study. RESULTS:: Aliskiren and irbesartan both
      increased plasma renin 3-4-fold, and above 10-fold when combined. Irbesartan
      decreased plasma angiotensinogen by approximately 25%, and no changes in plasma
      angiotensinogen were observed during the combination. Urine contained aliskiren
      at micromolar levels, blocking urinary renin by above 90%. Both blockers reduced 
      urinary angiotensinogen, significant for irbesartan only. Combination blockade
      reduced urinary angiotensinogen even further. Reductions in urinary
      angiotensinogen paralleled albuminuria changes, and the urine/plasma
      concentration ratio of angiotensinogen was identical to that of albumin under all
      conditions. In contrast, urinary renin did not follow albumin, and remained
      unaltered after all treatments. Yet, the urine/plasma concentration ratio of
      renin was more than 100-fold higher than that of angiotensinogen and albumin, and
      approximately 4-fold reduced by single RAAS blockade, and more than 10-fold by
      dual RAAS blockade. CONCLUSIONS:: Aliskiren filters into urine and influences
      urinary renin measurements. The urine/plasma renin ratio, but not urinary renin
      alone, may reflect the renal efficacy of RAAS blockade. Urinary angiotensinogen
      is a marker of filtration barrier damage rather than intrarenal RAAS activity.
AD  - aSteno Diabetes Center, Gentofte, Denmark bDivision of Pharmacology and Vascular 
      Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
      cFaculty of Health Science, University of Aarhus dNNF Center for Basic Metabolic 
      Research eDepartment of Medical Endocrinology, University of Copenhagen, Denmark 
      *Both authors contributed equally.
FAU - Persson, Frederik
AU  - Persson F
FAU - Lu, Xifeng
AU  - Lu X
FAU - Rossing, Peter
AU  - Rossing P
FAU - Garrelds, Ingrid M
AU  - Garrelds IM
FAU - Danser, A H Jan
AU  - Danser AH
FAU - Parving, Hans-Henrik
AU  - Parving HH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/HJH.0b013e328362217c [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 Jun 5.

PMID- 23743798
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1432-136X (Electronic)
IS  - 0174-1578 (Linking)
DP  - 2013 Jun 7
TI  - Liver glucose-6-phosphatase proteins in suckling and weaned grey seal pups:
      structural similarities to other mammals and relationship to nutrition, insulin
      signalling and metabolite levels.
AB  - Phocid seals have been proposed as models for diabetes because they exhibit
      limited insulin response to glucose, high blood glucose and increasing insulin
      resistance when fasting. Liver glucose-6-phosphatase (G6Pase) catalyses the final
      step in glucose production and is central to glucose regulation in other animals.
      G6Pase comprises a translocase (SLC37A4) and a catalytic subunit (G6PC). G6PC and
      SLC37A4 expression and activity are normally regulated by nutritional state and
      glucostatic hormones, particularly insulin, and are elevated in diabetes. We
      tested the hypotheses that (1) grey seal G6PC and SLC37A4 cDNA and predicted
      protein sequences differ from other species' at functional sites, (2) relative
      G6Pase protein abundances are lower during feeding than fasting and (3) relative 
      G6Pase protein abundances are related to insulin, insulin receptor
      phosphorylation and key metabolite levels. We show that G6PC and partial SLC37A4 
      cDNA sequences encode proteins sharing 82-95 % identity with other mammals. Seal 
      G6PC contained no differences in sites responsible for activity, stability or
      subcellular location. Several substitutions in seal SLC37A4 were predicted to be 
      tolerated with low probability, which could affect glucose production. Suckling
      pups had higher relative abundance of both subunits than healthy, postweaned
      fasting pups. Furthermore, relative G6PC abundance was negatively related to
      glucose levels. These findings contrast markedly with the response of relative
      hepatic G6Pase abundance to feeding, fasting, insulin, insulin sensitivity and
      key metabolites in other animals, and highlight the need to understand the
      regulation of enzymes involved in glucose control in phocids if these animals are
      to be informative models of diabetes.
AD  - Marine Biology and Ecology Research Centre, School of Marine Science and
      Engineering, Plymouth University, Portland Square, Drake Circus, Plymouth, Devon,
      PL4 8AA, UK, kimberley.bennett@plymouth.ac.uk.
FAU - Bennett, K A
AU  - Bennett KA
FAU - Hammill, M
AU  - Hammill M
FAU - Currie, S
AU  - Currie S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Comp Physiol B
JT  - Journal of comparative physiology. B, Biochemical, systemic, and environmental
      physiology
JID - 8413200
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/02/10 [received]
PHST- 2013/05/21 [accepted]
PHST- 2013/05/10 [revised]
PHST- 2013/06/07 [aheadofprint]
AID - 10.1007/s00360-013-0768-x [doi]
PST - aheadofprint
SO  - J Comp Physiol B. 2013 Jun 7.

PMID- 23743705
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 0019-1639 (Print)
IS  - 0019-1639 (Linking)
VI  - 69
IP  - 2
DP  - 2013 Mar-Apr
TI  - [Immunotherapeutic approach for the prevention and treatment of chronic
      diseases].
PG  - 261-71
AB  - Alzheimer disease, diabetes and cardiovascular diseases are among the leading
      causes of morbidity and mortality worldwide. Different immunotherapeutic
      approaches for prevention and treatment of these diseases are currently object of
      several researches. In this paper, recent trials describing active and passive
      immunotherapy for the management of these pathologies are discussed. The recent
      immunotherapeutic and preventive approaches for the treatment of Alzheimer's
      disease are based on the use of ss-amyloid peptides and to tau-based immunization
      strategies but new possibility are explored. Immunotherapeutic vaccine against
      angiotensin II showed promising results for the management of hypertension. Heath
      shock proteins and ss2-glycoprotein I have been tested to reduce atherosclerosis.
      Insulin agonists were used for preventing type 1 diabetes in mouse; IL-1ss was
      effective in experimental type 2 diabetes. Research in the field of immunological
      approach to treatment and prevention of chronic diseases is promising even if the
      present results have been obtained mainly in animal models.
AD  - Dipartimento di Biomedicina e Prevenzione, Universita Tor Vergata, Roma.
FAU - Bagnato, Barbara
AU  - Bagnato B
FAU - Marino, Maria Giulia
AU  - Marino MG
FAU - Franco, Elisabetta
AU  - Franco E
LA  - ita
PT  - English Abstract
PT  - Journal Article
TT  - Approccio immunoterapeutico per la prevenzione e la terapia delle malattie
      cronico-degenerative.
PL  - Italy
TA  - Ig Sanita Pubbl
JT  - Igiene e sanita pubblica
JID - 0373022
SB  - IM
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PST - ppublish
SO  - Ig Sanita Pubbl. 2013 Mar-Apr;69(2):261-71.

PMID- 23743666
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1559-0720 (Electronic)
IS  - 0163-4984 (Linking)
DP  - 2013 Jun 8
TI  - The Relationship Between Maternal Serum Iron and Zinc Levels and Their
      Nutritional Intakes in Early Pregnancy with Gestational Diabetes.
AB  - The aim of this study was to investigate the association between maternal
      iron/zinc serum levels and their nutritional intake in early pregnancy with
      gestational diabetes. The maternal serum zinc/iron levels were measured in 1,033 
      healthy singleton pregnant women aged 20-35 between 14 and 20 weeks of gestation,
      within two groups: namely, normal and gestational diabetes, and participants were
      followed up to 24-28 weeks of gestation. Food frequency questionnaire was used to
      assess nutritional intakes of iron/zinc. The main outcome was gestational
      diabetes screened with the 50-g glucose challenge test and diagnosed with oral
      glucose tolerance test at 24-28 weeks of gestation. Gestational diabetes occurred
      in 72 (6.96 %) of 1,033 women in study. There was a statistical relationship
      between early pregnancy maternal serum iron and gestational diabetes, mean (SD), 
      143.8 (48.7) vs. 112.5 (83.5) mug/dl, P value of <0.0001. There was no
      statistical significant difference in zinc levels and iron/zinc nutritional
      intake between groups. The results remained unchanged after using regression
      model for adjustment of potential risk factors with an adjusted OR of 1.006 (95 %
      CI 1.002 to 1.009; P = 0.001) for early pregnancy maternal serum iron to cause
      gestational diabetes. The receiver-operator characteristic curve identified that 
      a maternal serum iron above 100 mug/dl in early pregnancy is the optimum cutoff
      value for predicting gestational diabetes, which showed a sensitivity and
      specificity of 80.6 and 50.7 %, respectively. In conclusion, high maternal serum 
      iron in early pregnancy could increase the risk of gestational diabetes. Also, it
      could be used as a sensitive and specific predictor for gestational diabetes.
AD  - Department of Midwifery and Reproductive Health, Faculty of Medical Sciences,
      Tarbiat Modares University, Al-e-Ahmad Highway, Tehran, Islamic Republic of Iran,
      s.behboudi@modares.ac.ir.
FAU - Behboudi-Gandevani, Samira
AU  - Behboudi-Gandevani S
FAU - Safary, Kolsum
AU  - Safary K
FAU - Moghaddam-Banaem, Lida
AU  - Moghaddam-Banaem L
FAU - Lamyian, Minoor
AU  - Lamyian M
FAU - Goshtasbi, Azita
AU  - Goshtasbi A
FAU - Alian-Moghaddam, Narges
AU  - Alian-Moghaddam N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130608
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/03/16 [received]
PHST- 2013/05/13 [accepted]
PHST- 2013/06/08 [aheadofprint]
AID - 10.1007/s12011-013-9703-y [doi]
PST - aheadofprint
SO  - Biol Trace Elem Res. 2013 Jun 8.

PMID- 23743646
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1752-2978 (Electronic)
IS  - 1752-296X (Linking)
DP  - 2013 Jun 5
TI  - The case for virus-induced type 1 diabetes.
AB  - PURPOSE OF REVIEW: Type 1 diabetes (T1D) results from the immune-mediated
      destruction of pancreatic insulin-producing cells because of the interaction
      among genetic susceptibility, the immune system and environmental factor(s). A
      possible role of viral infections in T1D pathogenesis has been hypothesized for
      some time; however, only in the most recent years, studies performed at the
      molecular and cellular level are starting to shed light on this issue. RECENT
      FINDINGS: Studies in animal models and in man have shown that viruses can indeed 
      infect pancreatic beta-cells, inducing islet inflammation and functional damage. 
      In addition, recent in-situ investigations performed on pancreatic tissue samples
      have provided evidence that in addition to adaptive immune response, innate
      immunity is involved in T1D pathogenesis and the whole pancreas (not only its
      endocrine portion) is infiltrated by immune-mediated phenomena. SUMMARY: The
      established role of inflammation in the insulitic process and the increasing
      evidence in support of the contribution of viral infections to a proinflammatory 
      islet scenario are strongly suggestive that viruses may indeed contribute to
      beta-cell damage and dysfunction, thus setting the stage for the design of
      antiviral strategies (e.g. vaccines and antiviral drugs) aimed at protecting the 
      beta-cells.
AD  - aDiabetes Unit, Department of Medicine, Surgery and Neuroscience, University of
      Siena bFondazione Umberto Di Mario ONLUS, c/o Toscana Life Science Park, Siena,
      Italy.
FAU - Spagnuolo, Isabella
AU  - Spagnuolo I
FAU - Patti, Aurora
AU  - Patti A
FAU - Sebastiani, Guido
AU  - Sebastiani G
FAU - Nigi, Laura
AU  - Nigi L
FAU - Dotta, Francesco
AU  - Dotta F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Curr Opin Endocrinol Diabetes Obes
JT  - Current opinion in endocrinology, diabetes, and obesity
JID - 101308636
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/MED.0b013e328362a7d7 [doi]
PST - aheadofprint
SO  - Curr Opin Endocrinol Diabetes Obes. 2013 Jun 5.

PMID- 23743645
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1752-2978 (Electronic)
IS  - 1752-296X (Linking)
DP  - 2013 Jun 5
TI  - Persistent C-peptide: what does it mean?
AB  - PURPOSE OF REVIEW: The assumption that patients with an extended duration of type
      1 diabetes mellitus (T1D) do not retain residual functional beta cells and
      endogenous insulin production has recently been challenged. The purpose to this
      review is to highlight some of the key emerging evidence supporting residual
      insulin and C-peptide secretion in long-standing T1D. RECENT FINDINGS: Recent
      investigations conducted in a group of type 1 diabetics of long-term duration,
      characterized clinically and histologically, provided solid evidence to suggest
      that pancreatic beta cells are still present even after 50 years in a majority of
      these individuals. These residual beta cells can secrete insulin in a
      physiologically regulated manner. Several published reports showed promising
      effects of glucagon-like peptide 1 (GLP-1) agonists on the glycemic control and
      residual C-peptide production in long-term T1D, although prospective studies are 
      needed to rule out the potential long-term adverse effects of these drugs.
      SUMMARY: C-peptide is no longer considered an irrelevant by-product of insulin
      biosynthesis. In-depth basic and translational investigations aimed at
      understanding the molecular immunology and the pathophysiology are needed to
      elucidate the mechanisms underlying the residual insulin and C-peptide production
      in long-term T1D. This may shed light on to the regenerative capacity of beta
      cells, the genetic susceptibility of the mechanisms of resistance to beta-cell
      destruction, and possibly identifying new therapeutic strategies for T1D. Studies
      evaluating the long-term effects of insulin secretogogue agents along with immune
      intervention hold promise for their use in future clinical trials for long-term
      T1D.
AD  - Division of Metabolism, Endocrinology & Diabetes, Department of Internal
      Medicine, The Brehm Center for Diabetes Research, University of Michigan Medical 
      School, Ann Arbor, Michigan, USA.
FAU - Pietropaolo, Massimo
AU  - Pietropaolo M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Curr Opin Endocrinol Diabetes Obes
JT  - Current opinion in endocrinology, diabetes, and obesity
JID - 101308636
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/MED.0b013e3283628610 [doi]
PST - aheadofprint
SO  - Curr Opin Endocrinol Diabetes Obes. 2013 Jun 5.

PMID- 23743644
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1752-2978 (Electronic)
IS  - 1752-296X (Linking)
DP  - 2013 Jun 5
TI  - The interplay between the gut microbiota and the immune system in the mechanism
      of type 1 diabetes.
AB  - PURPOSE OF REVIEW: Discuss recent data linking the intestinal microbiome with
      mechanisms of inflammation and islet destruction. RECENT FINDINGS: Type 1
      diabetes (T1D) is a proinflammatory disease that results in the loss of
      insulin-producing beta cells. How T1D is triggered is unclear; however, both
      genetic and environmental factors were implicated in disease mechanisms. Emerging
      evidence supports the notion that there is a complex interaction between the
      intestinal microbiome and the immune system and this cross-talk is involved in
      maintaining normal immune homeostasis in the gut and periphery. Under some
      circumstances the gut microbiota could lead to pathogenic immune responses
      resulting in inflammation in the intestine as well as other organs. Indeed,
      recent data from genetically susceptible individuals suggested that alterations
      in gut bacterial communities may be involved in the mechanism of islet
      destruction. Studies performed in animal models of T1D indicated that
      manipulating the gut microbiome can protect from islet destruction via mechanisms
      that may involve down-regulating both the adaptive and innate immune systems.
      SUMMARY: Further work is required to identify specific bacterial communities and 
      mechanisms involved in triggering T1D. A better knowledge of the role of the gut 
      microbiome in islet destruction could lead to new clinical interventions to
      restore healthy homeostasis and prevent disease development.
AD  - Barbara Davis Center for Childhood Diabetes, University of Colorado Denver,
      Aurora, Colorado, USA.
FAU - Zipris, Danny
AU  - Zipris D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Curr Opin Endocrinol Diabetes Obes
JT  - Current opinion in endocrinology, diabetes, and obesity
JID - 101308636
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/MED.0b013e3283628569 [doi]
PST - aheadofprint
SO  - Curr Opin Endocrinol Diabetes Obes. 2013 Jun 5.

PMID- 23743593
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 Jun 7
TI  - Adipocyte differentiation is affected by media height above the cell layer.
LID - 10.1038/ijo.2013.96 [doi]
AB  - Background3T3-L1 cells have been widely used as a model for adipogenesis.
      However, despite its popularity, differentiation of this cell line has been
      reported to be inconsistent with low efficiency.ObjectiveTo investigate the
      effect of media height during adipocyte differentiation on lipid accumulation and
      adipokine secretion in mature adipocytes.MethodsThree cell lines (3T3-L1, OP9,
      and ChubS7) were used to test the influence of media volume on adipogenesis.
      Total lipid content and lipid droplet size and number were quantified. Adipocyte 
      related gene expressions were quantified during the course of differentiation.
      Secretion of leptin and adiponectin from mature adipocytes were measured using
      Enzyme-Linked Immunosorbent Assays. The influence of oxygen partial pressure on
      adipogenesis was investigated using three oxygen percentages: 5, 21, and 30%.
      Insulin sensitivity was measured by insulin inhibition of isoproterenol-induced
      lipolysis and phosphorylation of Insulin Receptor Substrate-1 (IRS-1).ResultsA
      lower media height during adipogenesis increased total lipid accumulation, NEFA
      release and leptin and adiponectin secretion in mature adipocytes. Insulin
      sensitivity was not affected by media height during
      differentiation.ConclusionMedia height during adipogenesis was inversely
      correlated with lipid content in mature adipocytes. To achieve a high lipid
      content and greater adipokine secretion, it is best to use a low media volume
      during differentiation.International Journal of Obesity accepted article preview 
      online, 7 June 2013; doi:10.1038/ijo.2013.96.
AD  - Divisions of Endocrinology, Diabetes & Metabolism.
FAU - Sheng, X
AU  - Sheng X
FAU - Tucci, J
AU  - Tucci J
FAU - Malvar, J
AU  - Malvar J
FAU - Mittelman, S D
AU  - Mittelman SD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/06/07 [aheadofprint]
AID - ijo201396 [pii]
AID - 10.1038/ijo.2013.96 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 Jun 7. doi: 10.1038/ijo.2013.96.

PMID- 23743561
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
DP  - 2013 Jun 5
TI  - Men with celiac disease are shorter than their peers in the general population.
AB  - OBJECTIVE: Late diagnosis of celiac disease (CD) is increasingly common, the
      implications of which are largely unknown. Although short stature is a common
      sign of childhood CD, the data on the height of adult CD patients is conflicting.
      This study investigates the final height of men and women diagnosed with CD in
      adulthood and attempts to identify influencing factors. PATIENTS AND METHODS: We 
      performed a cross-sectional study of 585 adults at the Celiac Disease Center at
      Columbia University, comparing their height with the control population (NHANES).
      Patients were included if they were older than 18 years of age at diagnosis and
      if baseline height and weight were available. In addition, we examined for
      differences in demographic and physical features, mode of presentation, and
      concomitant illnesses in shorter versus taller celiac patients. RESULTS: Men
      (n=162) with CD diagnosed in adulthood were shorter than men in the general
      population (CD: 169.3+/-10.5 vs. 177.3+/-7.0 cm, P<0.01) whereas women (n=423)
      were not (CD: 166.3+/-9.4 vs. 163.2+/-6.7 cm). There were no statistically
      significant differences in age at diagnosis, BMI, concomitant autoimmune
      illnesses (hypothyroidism, type I diabetes, dermatitis herpetiformis), or mode of
      presentation in shorter versus taller CD patients of either sex. Hemoglobin was
      associated with short stature in CD men (short: 13.9 g/dl, tall: 14.6 g/dl;
      P=0.01), but not women (short: 12.9 g/dl, tall: 13.0 g/dl, P=0.41). CONCLUSION:
      Short stature is a well described phenomenon in pediatric CD with the potential
      for 'catch-up growth' on a gluten-free diet. However, among adults with CD who
      had attained final height before diagnosis, we found that men, not women, are
      shorter relative to the general population.
AD  - Department of Medicine, Celiac Disease Center, Columbia University Medical
      Center, New York, New York, USA.
FAU - Sonti, Rajiv
AU  - Sonti R
FAU - Lebwohl, Benjamin
AU  - Lebwohl B
FAU - Lewis, Suzanne K
AU  - Lewis SK
FAU - Abu Daya, Hussein
AU  - Abu Daya H
FAU - Klavan, Heather
AU  - Klavan H
FAU - Aguilar, Kathleen
AU  - Aguilar K
FAU - Green, Peter H R
AU  - Green PH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/MEG.0b013e328362e461 [doi]
PST - aheadofprint
SO  - Eur J Gastroenterol Hepatol. 2013 Jun 5.

PMID- 23743557
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1473-6500 (Electronic)
IS  - 0952-7907 (Linking)
DP  - 2013 Jun 5
TI  - Perioperative glycemic control: what is worth the effort?
AB  - PURPOSE OF REVIEW: Diabetes mellitus and its related comorbidities present a
      growing challenge in perioperative medicine. And also largely independent from a 
      history of diabetes, dysregulations of glucose homeostasis occur as part of the
      body's stress response. Dysregulations of glucose homeostasis, acute or chronic, 
      are closely correlated with impaired prognosis in perioperative medicine.
      Treatment strategies remain somewhat controversial, as both the affliction and
      its correction have a blind side. RECENT FINDINGS: Anesthesia requires vigilant
      attention to diabetes-related comorbidities such as neuropathy, angiopathy,
      cardiopathy and immune dysfunction. Dysregulations of glycemia of any kind, in
      other words, hypoglycemia and hyperglycemia and fluctuations of blood glucose,
      should be avoided. Target glycemia remains a matter of discussion: moderate,
      achievable glycemic target below 180 or 150 mg/dl appears to be reasonable.
      Modern technical developments like continuous glucose measurement devices and
      computer-assisted control algorithms are under development, and will hopefully
      facilitate perioperative glycemic control in the future. SUMMARY: Literature
      clearly shows that leaving glycemic control out of focus is dangerous for the
      patient; efforts to control glycemia to a moderate target improve the patient's
      outcome.
AD  - aDepartment of Cardiothoracic Surgery bDepartment of Anesthesiology, Intensive
      Care Medicine and Pain Therapy, University Hospital Muenster, Munster, Germany.
FAU - Dell'aquila, Angelo M
AU  - Dell'aquila AM
FAU - Ellger, Bjorn
AU  - Ellger B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Curr Opin Anaesthesiol
JT  - Current opinion in anaesthesiology
JID - 8813436
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/ACO.0b013e328362d16a [doi]
PST - aheadofprint
SO  - Curr Opin Anaesthesiol. 2013 Jun 5.

PMID- 23743467
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
DP  - 2013 Jun 5
TI  - Perioperative Oxygen Supplementation and Surgical Site Infection After Cesarean
      Delivery: A Randomized Trial.
AB  - OBJECTIVE:: To evaluate whether supplemental perioperative oxygen decreases
      surgical site wound infections or endometritis. STUDY DESIGN:: This was a
      prospective, randomized trial. Patients who were to undergo cesarean delivery
      were recruited and randomly allocated to either 30% or 80% oxygen during the
      cesarean delivery and for 1 hour after surgery. The obstetricians and patients
      were blinded to the concentration of oxygen used. Patients were evaluated for
      wound infection or endometritis during their hospital stay and by 6 weeks
      postpartum. The primary end point was a composite of either surgical site
      infection or endometritis. RESULTS:: Eight hundred thirty-one patients were
      recruited. Of these, 415 participants received 30% oxygen perioperatively and 416
      received 80% oxygen. The groups were well matched for age, race, parity,
      diabetes, number of previous cesarean deliveries, and scheduled compared with
      unscheduled cesarean deliveries. An intention-to-treat analysis was used. There
      was no difference in the primary composite outcome (8.2% in women who received
      30% oxygen compared with 8.2% in women who received 80% oxygen, P=.89), no
      difference in surgical site infection in the two groups (5.5% compared with 5.8%,
      P=.98), and no significant difference in endometritis in the two groups (2.7%
      compared with 2.4%, P=.66), respectively. CONCLUSION:: Women who received 80%
      supplemental oxygen perioperatively did not have a lower rate of a surgical site 
      infection or endometritis as compared with women who received 30% supplemental
      oxygen concentration. CLINICAL TRIAL REGISTRATION:: ClinicalTrials.gov,
      www.clincaltrials.gov, NCT00876005. LEVEL OF EVIDENCE:: I.
AD  - Departments of Obstetrics and Gynecology, Santa Clara Valley Medical Center, San 
      Jose, California, and Oregon Health and Science University, Portland, Oregon.
FAU - Duggal, Neena
AU  - Duggal N
FAU - Poddatorri, Vineela
AU  - Poddatorri V
FAU - Noroozkhani, Sara
AU  - Noroozkhani S
FAU - Siddik-Ahmad, R Iram
AU  - Siddik-Ahmad RI
FAU - Caughey, Aaron B
AU  - Caughey AB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/AOG.0b013e318297ec6c [doi]
PST - aheadofprint
SO  - Obstet Gynecol. 2013 Jun 5.

PMID- 23743465
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
DP  - 2013 Jun 5
TI  - Cost Analysis of Maternal Disease Associated With Suboptimal Breastfeeding.
AB  - OBJECTIVE:: To estimate the U.S. maternal health burden from current
      breastfeeding rates both in terms of premature death as well as economic costs.
      METHODS:: Using literature on associations between lactation and maternal health,
      we modeled the health outcomes and costs expected for a U.S. cohort of
      15-year-old females followed to age 70 years. In 2002, this cohort included 1.88 
      million individuals. Using Monte Carlo simulations, we compared the outcomes
      expected if 90% of mothers were able to breastfeed for at least 1 year after each
      birth with outcomes under the current 1-year breastfeeding rate of 23%. We
      modeled cases of breast cancer, premenopausal ovarian cancer, hypertension, type 
      2 diabetes mellitus, and myocardial infarction considering direct costs, indirect
      costs, and cost of premature death (before age 70 years) expressed in 2011
      dollars. RESULTS:: If observed associations between breastfeeding duration and
      maternal health are causal, we estimate that current breastfeeding rates result
      in 4,981 excess cases of breast cancer, 53,847 cases of hypertension, and 13,946 
      cases of myocardial infarction compared with a cohort of 1.88 million U.S. women 
      who optimally breastfed. Using a 3% discount rate, suboptimal breastfeeding
      incurs a total of $17.4 billion in cost to society resulting from premature death
      (95% confidence interval [CI] $4.38-24.68 billion), $733.7 million in direct
      costs (95% CI $612.9-859.7 million), and $126.1 million indirect morbidity costs 
      (95% CI $99.00-153.22 million). We found a nonsignificant difference in number of
      deaths before age 70 years under current breastfeeding rates (4,396 additional
      premature deaths, 95% CI -810-7,918). CONCLUSIONS:: Suboptimal breastfeeding may 
      increase U.S. maternal morbidity and health care costs. Thus, investigating
      whether the observed associations between suboptimal breastfeeding and adverse
      maternal health outcomes are causal should be a research priority.
AD  - Department of Medicine, Cambridge Health Alliance and Harvard Medical School,
      Cambridge, Massachusetts; the Department of Obstetrics and Gynecology, Division
      of Maternal-Fetal Medicine, University of North Carolina School of Medicine, and 
      the Department of Statistics and Operations Research, University of North
      Carolina, Chapel Hill, North Carolina; the Departments of Medicine, Obstetrics,
      Gynecology and Reproductive Sciences, and Epidemiology, University of Pittsburgh,
      Pittsburgh, Pennsylvania; the Alliance for the Prudent Use of Antibiotics,
      Boston, Massachusetts; and the Department of Health Care Organization and Policy,
      School of Public Health, University of Alabama, Birmingham, Alabama.
FAU - Bartick, Melissa C
AU  - Bartick MC
FAU - Stuebe, Alison M
AU  - Stuebe AM
FAU - Schwarz, Eleanor Bimla
AU  - Schwarz EB
FAU - Luongo, Christine
AU  - Luongo C
FAU - Reinhold, Arnold G
AU  - Reinhold AG
FAU - Foster, E Michael
AU  - Foster EM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/AOG.0b013e318297a047 [doi]
PST - aheadofprint
SO  - Obstet Gynecol. 2013 Jun 5.

PMID- 23743464
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
DP  - 2013 Jun 5
TI  - Treatment of Severe Insulin Resistance in Pregnancy With 500 Units per Milliliter
      of Concentrated Insulin.
AB  - OBJECTIVE:: To evaluate glycemic control and pregnancy outcomes among pregnant
      women with severe insulin resistance treated with 500 units/mL concentrated
      insulin. METHODS:: Retrospective analysis of gravid women with severe insulin
      resistance (need for greater than 100 units of insulin per injection or greater
      than 200 units/d) treated with either 500 units/mL concentrated insulin or
      conventional insulin therapy. We performed a two-part analysis: 1) between gravid
      women treated with and without 500 units/mL concentrated insulin; and 2) among
      gravid women treated with 500 units/mL concentrated insulin, comparing glycemic
      control before and after its initiation. RESULTS:: Seventy-three pregnant women
      with severe insulin resistance were treated with 500 units/mL concentrated
      insulin and 78 with conventional insulin regimens. Patients treated with 500
      units/mL concentrated insulin were older and more likely to have type 2 diabetes 
      mellitus. Average body mass index was comparable between both groups (38.6
      compared with 40.4, P=.11) as were obstetric and perinatal outcomes and glycemic 
      control during the last week of gestation. Within the 500 units/mL concentrated
      insulin cohort, after initiation of this medication, fasting and postprandial
      blood glucose concentrations improved. However, the rates of blood glucose values
      less than 60 mg/dL and less than 50 mg/dL were higher in the 500 units/mL
      concentrated insulin group after initiation than before, 4.8% compared with 2.0% 
      (P<.01) and 2.0% compared with 0.7% (P<.01), respectively. CONCLUSION:: The use
      of 500 units/mL concentrated insulin in severely obese insulin-resistant pregnant
      women confers similar glycemic control compared with traditional insulin regimens
      but may increase the risk of hypoglycemia. LEVEL OF EVIDENCE:: II.
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology,
      Women and Infants' Hospital, Warren Alpert Medical School of Brown University,
      Providence, Rhode Island.
FAU - Mendez-Figueroa, Hector
AU  - Mendez-Figueroa H
FAU - Maggio, Lindsay
AU  - Maggio L
FAU - Dahlke, Joshua D
AU  - Dahlke JD
FAU - Daley, Julie
AU  - Daley J
FAU - Lopes, Vrishali V
AU  - Lopes VV
FAU - Coustan, Donald R
AU  - Coustan DR
FAU - Rouse, Dwight J
AU  - Rouse DJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/AOG.0b013e3182978a11 [doi]
PST - aheadofprint
SO  - Obstet Gynecol. 2013 Jun 5.

PMID- 23743461
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
DP  - 2013 Jun 5
TI  - Relationship of the Length of the First Stage of Labor to the Length of the
      Second Stage.
AB  - OBJECTIVE:: To evaluate the relationship between the lengths of the first and
      second stages of labor. METHODS:: In this observational study of women delivering
      at our hospital, the onset of the first stage of labor was defined as admission
      at 3-cm to 4-cm dilatation in the presence of uterine contractions with or
      without rupture of membranes. This study was limited to nulliparous women with a 
      singleton, cephalic live birth at 37 0/7 weeks of gestation or more. Women
      presenting with more advanced cervical dilatation (greater than 4 cm), prior
      cesarean delivery, diabetes, hypertension, and placental accidents were excluded.
      Each woman was analyzed based on her specific lengths of first and second stages 
      of labor, that is, paired observations for each woman. RESULTS:: Between January 
      1, 2001, and June 30, 2012, a total of 172,522 women were delivered and 12,523
      (7.3%) met the inclusion criteria. The 95 percentile was 15.6 and 2.9 hours for
      the first and second stages, respectively. Women with first stages greater than
      the 95 percentile had a 16.3% rate of a second-stage length greater than the 95
      percentile compared with 4.5% (P<.001) in women with first stages less than the
      95 percentile. This relationship persisted when analyzed for variables
      influencing labor to include neonate birth weight, epidural analgesia, or
      maternal size. CONCLUSION:: Overall, the length of the second stage significantly
      increased concomitantly with increasing length of the first stage (P<.001). LEVEL
      OF EVIDENCE:: II.
AD  - Department of Obstetrics and Gynecology, University of Texas Southwestern Medical
      Center, Dallas, Texas.
FAU - Nelson, David B
AU  - Nelson DB
FAU - McIntire, Donald D
AU  - McIntire DD
FAU - Leveno, Kenneth J
AU  - Leveno KJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1097/AOG.0b013e3182972907 [doi]
PST - aheadofprint
SO  - Obstet Gynecol. 2013 Jun 5.

PMID- 23743288
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
DP  - 2013 May 16
TI  - Recent progress and future options in the development of GLP-1 receptor agonists 
      for the treatment of diabesity.
LID - S0960-894X(13)00608-2 [pii]
LID - 10.1016/j.bmcl.2013.05.022 [doi]
AB  - The dramatic rise of the twin epidemics, type 2 diabetes and obesity is
      associated with increased mortality and morbidity worldwide. Based on this global
      development there is clinical need for anti-diabetic therapies with accompanied
      weight reduction. From the approved therapies, the injectable glucagon-like
      peptide-1 receptor agonists (GLP-1 RAs) are the only class of agents which are
      associated with a modest weight reduction. Physiological effects of the
      gastro-intestinal hormone GLP-1 are improvement of glycemic control as well as a 
      reduction in appetite and food intake. Different approaches are currently under
      clinical evaluation to optimize the therapeutic potential of GLP-1 RAs directed
      to once-weekly up to once-monthly administration. The next generation of peptidic
      co-agonists comprises the activity of GLP-1 plus additional gastro-intestinal
      hormones with the potential for increased therapeutic benefits compared to GLP-1 
      RAs.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Diabetes Division/Res. & Transl. Med, Sanofi-Aventis Deutschland GmbH,
      Industriepark Hochst, 65926 Frankfurt am Main, Germany. Electronic address:
      Martin.Lorenz@sanofi.com.
FAU - Lorenz, Martin
AU  - Lorenz M
FAU - Evers, Andreas
AU  - Evers A
FAU - Wagner, Michael
AU  - Wagner M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/03/16 [received]
PHST- 2013/05/06 [revised]
PHST- 2013/05/07 [accepted]
AID - S0960-894X(13)00608-2 [pii]
AID - 10.1016/j.bmcl.2013.05.022 [doi]
PST - aheadofprint
SO  - Bioorg Med Chem Lett. 2013 May 16. pii: S0960-894X(13)00608-2. doi:
      10.1016/j.bmcl.2013.05.022.

PMID- 23743192
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
DP  - 2013 Jun 3
TI  - Orally active hypoglycemic protein from Costus igneus N. E. Br.: An in vitro and 
      in vivo study.
LID - S0006-291X(13)00900-5 [pii]
LID - 10.1016/j.bbrc.2013.05.093 [doi]
AB  - Plants have been used for the treatment of Diabetes since time immemorial. In the
      present study, insulin-like protein (ILP) is purified from Costus igneus
      belonging to family Costaceae from Western ghats of India. The ILP showed cross
      reactivity with murine anti-insulin antibodies hence was purified by affinity
      chromatography using anti-insulin antibodies. The characterization of ILP showed 
      that it is structurally different from Insulin but functionally similar. The ILP 
      showed a hypoglycemic activity in an in vitro assay with insulin responsive cell 
      line RIN 5f. Interestingly ILP showed significant decrease in blood glucose level
      when administered orally in oral glucose tolerance test. This was compared to
      insulin a positive control given intraperitoneally in streptozotocine induced
      diabetic mice. There was no toxic effect seen on animals after administrating the
      ILP. Therefore we conclude that the ILP purified in the present study from C.
      igneus is a novel protein having hypoglycemic activity.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Biometry and Nutrition Group, Agharkar Research Institute, Pune 411 004.
      Electronic address: bimbajoshi@aripune.org.
FAU - Joshi, Bimba N
AU  - Joshi BN
FAU - Munot, Hitendra
AU  - Munot H
FAU - Hardikar, Manasi
AU  - Hardikar M
FAU - Kulkarni, Anjali A
AU  - Kulkarni AA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/05/17 [received]
PHST- 2013/05/23 [accepted]
AID - S0006-291X(13)00900-5 [pii]
AID - 10.1016/j.bbrc.2013.05.093 [doi]
PST - aheadofprint
SO  - Biochem Biophys Res Commun. 2013 Jun 3. pii: S0006-291X(13)00900-5. doi:
      10.1016/j.bbrc.2013.05.093.

PMID- 23743154
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
DP  - 2013 Jun 7
TI  - Oxidative stress and other risk factors for white matter lesions in chronic
      hemodialysis patients.
AB  - Background: Chronic kidney disease (CKD) is a risk factor for cardiovascular
      disease and promotes oxidative tress (OS), which has been implicated in the
      pathogenesis of white matter lesions (WML), a form of small-vessel
      cerebrovascular disease. The relationship between OS and WML in chronic
      hemodialysis (HD) patients has not yet been studied. Methods: We studied 67
      chronic HD patients, aged 40 - 65 years (average 54 years) without known
      cerebrovascular disease. All patients underwent brain magnetic resonance imaging 
      and subcortical and periventricular WML were evaluated using semiquantitative
      measures. Patients were classified into two groups depending on the presence or
      absence of WML (Fazekas classification), and the WML were scored. Carotid
      ultrasonography was also performed to evaluate the presence of carotid artery
      plaques and/or stenosis. Markers of protein and lipid oxidation (protein carbonyl
      and oxLDL antibodies), the glutathione system, enzymatic antioxidants (superoxide
      dismutase, glutathione peroxidase, glutathione reductase and catalase) and total 
      antioxidant capacity (ORAC) were measured. OS markers were compared to those of a
      group of 36 healthy subjects. Results: WML were present in 54% of the total
      population. Patients who had WML were older and had lower predialysis diastolic
      blood pressure than patients without WML. Other potential cardiovascular risk
      factors for WML, including obesity, hyperlipidemia, diabetes mellitus, presence
      of carotid artery plaques or stenosis, and duration and adequacy of HD were not
      related to the presence of WML. Compared to controls, HD patients had increased
      OS and decreased antioxidant capacity. However, OS did not differ between
      patients with WML and those without, and we found no association between OS
      markers and mean WML scores. After adjusting for several factors, only age and
      low predialysis diastolic blood pressure independently predicted an increased
      risk of WML. Conclusions: Our results confirm that chronic HD patients have
      increased OS, but this is not related to the presence or severity of WML.
FAU - Munoz-Cortes, Monica
AU  - Munoz-Cortes M
FAU - Cabre, Carme
AU  - Cabre C
FAU - Villa, Diasol
AU  - Villa D
FAU - Vives, Joan Pere
AU  - Vives JP
FAU - Arruche, Mercedes
AU  - Arruche M
FAU - Soler, Jordi
AU  - Soler J
FAU - Compte, Maria Teresa
AU  - Compte MT
FAU - Aguilera, Josep
AU  - Aguilera J
FAU - Jariod, Manel
AU  - Jariod M
FAU - Romeu, Marta
AU  - Romeu M
FAU - Giralt, Montserrat
AU  - Giralt M
FAU - Martinez-Vea, Alberto
AU  - Martinez-Vea A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/06/07 [accepted]
AID - 10.5414/CN107943 [doi]
AID - 10689 [pii]
PST - aheadofprint
SO  - Clin Nephrol. 2013 Jun 7.

PMID- 23743139
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 Jun 3
TI  - Gender and ethnic differences in the prevalence of type 2 diabetes among Asian
      subgroups in California.
LID - S1056-8727(13)00003-2 [pii]
LID - 10.1016/j.jdiacomp.2013.01.002 [doi]
AB  - AIMS: To investigate gender and ethnic type 2 diabetes (DM) prevalences among
      California Asian subgroups versus other ethnic groups and if risk factors explain
      these differences. METHODS: We identified the prevalence of DM and associated
      risk factors, stratified by gender, among Chinese, Filipino, South Asian,
      Japanese, Korean, Vietnamese, Mexican, Other Hispanic, African-American,
      Caucasian, and Native American adults in a large survey conducted in 2009
      (n=46,091, projected n=26.6 million). RESULTS: The highest age-adjusted DM
      prevalence was seen in Native Americans (32.4%), Filipinos (15.8%), and Japanese 
      (11.8%) among men and in Native Americans (16.0%) and African-Americans (13.3%)
      among women. Caucasian and Mexican men had higher DM prevalences than women. Age 
      and risk factor-adjusted logistic regression showed DM more likely (relative to
      Caucasians) among women in Koreans (OR=4.6, p<0.01), Native Americans (OR=3.0,
      p<0.01), and Other Hispanics (OR 2.9, p<0.01) and among men in Filipinos (OR=7.0,
      p<0.01), South Asians (OR=4.7, p<0.01), and Native Americans (OR=4.7, p<0.01). No
      specific risk factors accounted for the gender differences. CONCLUSIONS: Ethnic
      and gender differences in DM prevalence persist, even after adjusting for
      lifestyle and other risk factors; prevalence is high among certain Asian American
      subgroups. Different diabetes prevention approaches may be needed across
      ethnic/gender groups.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Program in Nursing Science, College of Health Sciences, University of California,
      Irvine, CA, USA. Electronic address: sechoi@uci.edu.
FAU - Choi, Sarah E
AU  - Choi SE
FAU - Liu, Michael
AU  - Liu M
FAU - Palaniappan, Latha P
AU  - Palaniappan LP
FAU - Wang, Elsie J
AU  - Wang EJ
FAU - Wong, Nathan D
AU  - Wong ND
LA  - ENG
GR  - KL2 TR000147/TR/NCATS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/09/19 [received]
PHST- 2012/12/12 [revised]
PHST- 2013/01/13 [accepted]
AID - S1056-8727(13)00003-2 [pii]
AID - 10.1016/j.jdiacomp.2013.01.002 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 Jun 3. pii: S1056-8727(13)00003-2. doi:
      10.1016/j.jdiacomp.2013.01.002.

PMID- 23743120
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1873-6351 (Electronic)
IS  - 0278-6915 (Linking)
DP  - 2013 Jun 3
TI  - Effects of Korean red ginseng extract on acute renal failure induced by
      gentamicin and pharmacokinetic changes by metformin in rats.
LID - S0278-6915(13)00331-1 [pii]
LID - 10.1016/j.fct.2013.05.025 [doi]
AB  - AIM OF THE STUDY: Korean red ginseng is one of the best selling dietary
      supplements and its individual constituents enhance renal function. Acute renal
      failure (ARF) is a predisposing complication of diabetes mellitus as a result of 
      combination drug therapy. The combination of antibiotic-antidiabetic drugs can
      entail toxicities and drug interactions because of the antibiotic resistance in
      patients with severe bacterial infection. Currently, gentamicin-metformin
      combination therapy is commonly prescribed for treating bacterial infections and 
      diabetes, even though both drugs are mainly excreted via the kidney. Thus, this
      study was designed to investigate whether a Korean red ginseng extract (KRG)
      prevents renal impairment and pharmacokinetic changes by metformin in rats with
      renal failure induced by gentamicin. MATERIALS AND METHODS: The in vivo
      pharmacokinetics and in vitro hepatic/intestinal metabolism of metformin were
      assessed using control (CON), control with Korean red ginseng extract (KRG-CON), 
      acute renal failure induced by gentamicin (ARF), and ARF with Korean red ginseng 
      (KRG-ARF) rats. RESULTS AND CONCLUSIONS: Pharmacokinetic changes of metformin did
      not occur in KRG-ARF rats because KRG reduce the renal accumulation of gentamicin
      compared to ARF rats. Thus, KRG seemed to prevent acute renal failure induced by 
      gentamicin treatment.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - College of Pharmacy, Dongguk University-Seoul, Dongguk-lo 32, Ilsandong-gu,
      Goyang, Gyeonggi-do 410-820, South Korea.
FAU - Lee, Yu Kyung
AU  - Lee YK
FAU - Chin, Young-Won
AU  - Chin YW
FAU - Choi, Young Hee
AU  - Choi YH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Food Chem Toxicol
JT  - Food and chemical toxicology : an international journal published for the British
      Industrial Biological Research Association
JID - 8207483
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/12/24 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/07 [accepted]
AID - S0278-6915(13)00331-1 [pii]
AID - 10.1016/j.fct.2013.05.025 [doi]
PST - aheadofprint
SO  - Food Chem Toxicol. 2013 Jun 3. pii: S0278-6915(13)00331-1. doi:
      10.1016/j.fct.2013.05.025.

PMID- 23742948
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
DP  - 2013 Jun 6
TI  - Predictors of Anticoagulant Treatment in Patients With Nonvalvular Atrial
      Fibrillation: Results From Atrial Fibrillation in Turkey: Epidemiologic Registry.
AB  - The aim of the study was to assess the factors associated with the
      anticoagulation treatment in patients with atrial fibrillation (AF). A total of
      2242 consecutive patients who had been admitted with AF on their
      electrocardiogram were included in the study. After excluding valvular AF, 1745
      patients with nonvalvular AF were analyzed. Mean CHA2DS2-VASc score [cardiac
      failure, hypertension, age >/= 75 (doubled), diabetes, stroke (doubled), vascular
      disease, age 65 -74 and sex category (female)], frequency of persistent/permanent
      AF, hypertension, diabetes mellitus (DM), stroke history, body mass index, and
      left atrial diameter were significantly higher in patients receiving
      anticoagulant therapy. Stroke history, persistent/permanent AF, hypertension, DM,
      age, heart failure, and left atrial diameter were independent predictors of
      warfarin prescription. Labile international normalized ratio was the only
      independent negative predictor of effective treatment with warfarin. In this
      study, we demonstrated that stroke history, persistent/permanent AF,
      hypertension, DM, and left atrial diameter were positive predictors, whereas
      advanced age and heart failure were negative predictors of oral anticoagulant use
      in patients with nonvalvular AF.
FAU - Kaya, Hasan
AU  - Kaya H
FAU - Ertas, Faruk
AU  - Ertas F
FAU - Koroglu, Bayram
AU  - Koroglu B
FAU - Vatan, Bulent
AU  - Vatan B
FAU - Cagliyan, Caglar Emre
AU  - Cagliyan CE
FAU - Gedik, Selcuk
AU  - Gedik S
FAU - Yeter, Ekrem
AU  - Yeter E
FAU - Aydin, Mesut
AU  - Aydin M
FAU - Akil, Mehmet Ata
AU  - Akil MA
FAU - Soydinc, Mehmet Serdar
AU  - Soydinc MS
FAU - Ozhan, Hakan
AU  - Ozhan H
FAU - Ulgen, Mehmet Siddik
AU  - Ulgen MS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 1076029613491459 [pii]
AID - 10.1177/1076029613491459 [doi]
PST - aheadofprint
SO  - Clin Appl Thromb Hemost. 2013 Jun 6.

PMID- 23742940
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1545-1151 (Electronic)
VI  - 10
DP  - 2013
TI  - A church-based diet and physical activity intervention for rural, lower
      Mississippi delta african american adults: delta body and soul effectiveness
      study, 2010-2011.
PG  - E92
LID - 10.5888/pcd10.120286 [doi]
AB  - INTRODUCTION: Obesity, diabetes, and hypertension have reached epidemic levels in
      the largely rural Lower Mississippi Delta (LMD) region. We assessed the
      effectiveness of a 6-month, church-based diet and physical activity intervention,
      conducted during 2010 through 2011, for improving diet quality (measured by the
      Healthy Eating Index-2005) and increasing physical activity of African American
      adults in the LMD region. METHODS: We used a quasi-experimental design in which 8
      self-selected eligible churches were assigned to intervention or control.
      Assessments included dietary, physical activity, anthropometric, and clinical
      measures. Statistical tests for group comparisons included chi(2), Fisher's
      exact, and McNemar's tests for categorical variables, and mixed-model regression 
      analysis for continuous variables and modeling intervention effects. RESULTS:
      Retention rates were 85% (176 of 208) for control and 84% (163 of 195) for
      intervention churches. Diet quality components, including total fruit, total
      vegetables, and total quality improved significantly in both control (mean
      [standard deviation], 0.3 [1.8], 0.2 [1.1], and 3.4 [9.6], respectively) and
      intervention (0.6 [1.7], 0.3 [1.2], and 3.2 [9.7], respectively) groups, while
      significant increases in aerobic (22%) and strength/flexibility (24%) physical
      activity indicators were apparent in the intervention group only. Regression
      analysis indicated that intervention participation level and vehicle ownership
      were significant positive predictors of change for several diet quality
      components. CONCLUSION: This church-based diet and physical activity intervention
      may be effective in improving diet quality and increasing physical activity of
      LMD African American adults. Components key to the success of such programs are
      participant engagement in educational sessions and vehicle access.
AD  - University of Illinois at Chicago, 1747 W. Roosevelt Rd, Chicago, IL 60618.
      E-mail: ltussing@uic.edu. At the time the study was completed, Dr
      Tussing-Humphreys was affiliated with the US Department of Agriculture,
      Agricultural Research Service, Baton Rouge, Louisiana.
FAU - Tussing-Humphreys, Lisa
AU  - Tussing-Humphreys L
FAU - Thomson, Jessica L
AU  - Thomson JL
FAU - Mayo, Tanyatta
AU  - Mayo T
FAU - Edmond, Emanuel
AU  - Edmond E
LA  - eng
PT  - Journal Article
DEP - 20130606
PL  - United States
TA  - Prev Chronic Dis
JT  - Preventing chronic disease
JID - 101205018
SB  - IM
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.5888/pcd10.120286 [doi]
AID - E92 [pii]
PST - epublish
SO  - Prev Chronic Dis. 2013 Jun 6;10:E92. doi: 10.5888/pcd10.120286.

PMID- 23742927
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 Jun 3
TI  - The adequacy of myocardial revascularization in patients with multivessel
      coronary artery disease.
LID - S0167-5273(13)00913-3 [pii]
LID - 10.1016/j.ijcard.2013.05.004 [doi]
AB  - In patients with multi-vessel coronary artery disease (MVCAD) myocardial
      revascularization may be accomplished either on all diseased lesions - complete
      myocardial revascularization - or on selectively targeted coronary segments by
      percutaneous coronary intervention (PCI) or coronary artery bypass grafting
      (CABG). Complete revascularization has a potential long-term prognostic benefit, 
      but is more complex and may increase in-hospital events when compared with
      incomplete revascularization. No conclusive agreement has been yet reached on the
      "optimal" extent of revascularization, and guidelines have only recently
      mentioned the adequacy of revascularization in the decision whether to submit a
      patient to CABG or PCI. In the absence of any trial specifically designed to
      assess the relative benefit of either strategy, the present review explores
      current concepts about the completeness of revascularization, the growing
      evidence on the relevance of lesion and myocardial functional evaluation, and
      analyzes currently available data in relation to different clinical settings,
      including acute coronary syndromes, diabetes, chronic kidney disease and impaired
      left ventricular function. Considerations on the adequacy of revascularization
      should guide the choice among PCI and CABG in patients with MVCAD during the
      decision-making process, taking into account the clinical presentation, the
      extent and relevance of ischemia and the presence of other comorbidities.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Institute of Cardiology and Center of Excellence on Aging "G. d'Annunzio"
      University of Chieti, Italy. Electronic address: m.zimarino@unich.it.
FAU - Zimarino, Marco
AU  - Zimarino M
FAU - Curzen, Nick
AU  - Curzen N
FAU - Cicchitti, Vincenzo
AU  - Cicchitti V
FAU - De Caterina, Raffaele
AU  - De Caterina R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/06/28 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/05/03 [accepted]
AID - S0167-5273(13)00913-3 [pii]
AID - 10.1016/j.ijcard.2013.05.004 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 Jun 3. pii: S0167-5273(13)00913-3. doi:
      10.1016/j.ijcard.2013.05.004.

PMID- 23742849
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 Jun 3
TI  - Microbial profile of diabetic foot infections in Trinidad and Tobago.
LID - S1751-9918(13)00055-7 [pii]
LID - 10.1016/j.pcd.2013.05.001 [doi]
AB  - AIMS: To examine the microbiologic profile of diabetic foot infections in order
      to guide empiric antibiotic choices. METHODS: All patients with moderate-severe
      diabetic foot infections at a tertiary care facility were identified from July
      2011 to June 2012. Culture samples were routinely collected before empiric
      antibiotics were commenced. Retrospective chart review was performed to extract
      the following data: demographics, clinical details, empiric antibiotic choice and
      microbiologic data. Descriptive analyses were performed using SPSS 12.0. RESULTS:
      There were 139 patients at a mean age of 56.9+/-12.4years. Mixed poly-microbial
      infections were present in 56.8% of cases. Of 221 organisms isolated, 64.7% were 
      gram-negative aerobes, 32.1% were gram-positive aerobes and 3.2% were obligate
      anaerobes. Multidrug resistant organisms were encountered in 25.9% of cases and
      included ESBL producers (11.3%), MRSA (4.5%) and VRE (1.4%). Both ciprofloxacin
      and ceftazidime had good overall anti-microbial activity against gram-negative
      (68% and 62%, respectively) and gram-positive pathogens (69% and 48%,
      respectively). Obligate anaerobes were uncommonly isolated due to institutional
      constraints. CONCLUSION: In this environment, both ciprofloxacin and ceftazidime 
      provide good broad-spectrum anti-microbial activity against the commonly isolated
      pathogens. Either agent can be used as single agent empiric therapy in patients
      with moderate/severe diabetic infections in our setting. Although institutional
      limitations precluded isolation of anaerobes in most cases, there is sufficient
      evidence for anti-anaerobic agents to be recommended as a part of empiric
      therapy.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Department of Surgery, San Fernando General Hospital, Trinidad and Tobago.
FAU - Islam, Shariful
AU  - Islam S
FAU - Cawich, Shamir O
AU  - Cawich SO
FAU - Budhooram, Steve
AU  - Budhooram S
FAU - Harnarayan, Patrick
AU  - Harnarayan P
FAU - Mahabir, Vijai
AU  - Mahabir V
FAU - Ramsewak, Shivaa
AU  - Ramsewak S
FAU - Naraynsingh, Vijay
AU  - Naraynsingh V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/02/26 [received]
PHST- 2013/05/06 [revised]
PHST- 2013/05/09 [accepted]
AID - S1751-9918(13)00055-7 [pii]
AID - 10.1016/j.pcd.2013.05.001 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 Jun 3. pii: S1751-9918(13)00055-7. doi:
      10.1016/j.pcd.2013.05.001.

PMID- 23742811
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1138-3593 (Print)
IS  - 1138-3593 (Linking)
DP  - 2013 Jun 3
TI  - [Links between obesity and diabetes mellitus.]
LID - S1138-3593(13)00056-7 [pii]
LID - 10.1016/j.semerg.2013.01.018 [doi]
AD  - Facultad de Ciencias Medicas <<Mariana Grajales Coello>>, Universidad de Ciencias
      Medicas, Holguin, Cuba. Electronic address: soca@ucm.hlg.sld.cu.
FAU - Miguel-Soca, P E
AU  - Miguel-Soca PE
LA  - SPA
PT  - LETTER
TT  - Vinculos entre la obesidad y la diabetes mellitus.
DEP - 20130603
TA  - Semergen
JT  - Semergen / Sociedad Espanola de Medicina Rural y Generalista
JID - 9610769
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/01/14 [received]
PHST- 2013/01/31 [accepted]
AID - S1138-3593(13)00056-7 [pii]
AID - 10.1016/j.semerg.2013.01.018 [doi]
PST - aheadofprint
SO  - Semergen. 2013 Jun 3. pii: S1138-3593(13)00056-7. doi:
      10.1016/j.semerg.2013.01.018.

PMID- 23742753
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Jun 6
TI  - A risk score for identifying methicillin-resistant Staphylococcus aureus in
      patients presenting to the hospital with pneumonia.
PG  - 268
AB  - BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) represents an
      important pathogen in healthcare-associated pneumonia (HCAP). The concept of
      HCAP, though, may not perform well as a screening test for MRSA and can lead to
      overuse of antibiotics. We developed a risk score to identify patients presenting
      to the hospital with pneumonia unlikely to have MRSA. METHODS: We identified
      patients admitted with pneumonia (Apr 2005 -- Mar 2009) at 62 hospitals in the
      US. We only included patients with lab evidence of bacterial infection (e.g.,
      positive respiratory secretions, blood, or pleural cultures or urinary antigen
      testing). We determined variables independently associated with the presence of
      MRSA based on logistic regression (two-thirds of cohort) and developed a risk
      prediction model based on these factors. We validated the model in the remaining 
      population. RESULTS: The cohort included 5975 patients and MRSA was identified in
      14%. The final risk score consisted of eight variables and a potential total
      score of 10. Points were assigned as follows: two for recent hospitalization or
      ICU admission; one each for age < 30 or >79 years, prior IV antibiotic exposure, 
      dementia, cerebrovascular disease, female with diabetes, or recent exposure to a 
      nursing home/long term acute care facility/skilled nursing facility. This study
      shows how the prevalence of MRSA rose with increasing score after stratifying the
      scores into Low (0 to 1 points), Medium (2 to 5 points) and High (6 or more
      points) risk. When the score was 0 or 1, the prevalence of MRSA was < 10% while
      the prevalence of MRSA climbed to >30% when the score was 6 or greater.
      CONCLUSIONS: MRSA represents a cause of pneumonia presenting to the hospital.
      This simple risk score identifies patients at low risk for MRSA and in whom
      anti-MRSA therapy might be withheld.
FAU - Shorr, Andrew F
AU  - Shorr AF
FAU - Myers, Daniela E
AU  - Myers DE
FAU - Huang, David B
AU  - Huang DB
FAU - Nathanson, Brian H
AU  - Nathanson BH
FAU - Emons, Matthew F
AU  - Emons MF
FAU - Kollef, Marin H
AU  - Kollef MH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/08/14 [received]
PHST- 2013/06/06 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 1471-2334-13-268 [pii]
AID - 10.1186/1471-2334-13-268 [doi]
PST - aheadofprint
SO  - BMC Infect Dis. 2013 Jun 6;13(1):268.

PMID- 23742704
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Linking)
DP  - 2013 Jun 7
TI  - Associations between serum hepcidin, ferritin and Hb concentrations and type 2
      diabetes risks in a Han Chinese population.
PG  - 1-6
AB  - Systemic Fe overload can contribute to abnormal glucose metabolism and the onset 
      of type 2 diabetes (T2D). Although hepcidin is the master regulator of systemic
      Fe homeostasis, few studies have systematically evaluated the associations of
      serum hepcidin concentrations with Fe metabolism parameters and risks for the
      development of T2D. In this regard, whether hepcidin concentrations are
      associated with T2D remains controversial. We measured serum hepcidin and
      ferritin concentrations in a case-control study of 1259 Han Chinese participants 
      to evaluate the possible associations of serum hepcidin concentrations with Fe
      metabolism parameters and risks of T2D. Individuals with diabetes (n 555) and
      control participants (n 704) were recruited and serum hepcidin and ferritin
      concentrations were quantified. Additionally, selected biochemical and
      anthropometric variables were determined. A logistic regression analysis was
      performed to evaluate the association of serum hepcidin and ferritin
      concentrations with T2D. A linear regression analysis was used to test for
      associations between serum hepcidin and ferritin concentrations and a number of
      clinical, demographic and diabetes-associated variables. We found that serum
      hepcidin concentrations correlated with Hb and serum ferritin concentrations. No 
      differences in hepcidin concentrations were found between the group with diabetes
      and the control group. Hepcidin concentrations were not significantly correlated 
      with T2D risk factors. We also found that serum ferritin concentrations were
      elevated in individuals with diabetes and were positively correlated with both Hb
      concentrations and T2D risk factors. The present findings suggest that serum
      ferritin concentrations correlate with T2D risk factors, while serum hepcidin
      concentrations are positively associated with Hb and serum ferritin
      concentrations, but do not correlate with T2D.
AD  - Department of Nutrition, School of Public Health, Institute of Nutrition and Food
      Safety, Collaborative Innovation Center for Diagnosis and Treatment of Infectious
      Diseases, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, People's
      Republic of China.
FAU - Guo, Xin
AU  - Guo X
FAU - Zhou, Daizhan
AU  - Zhou D
FAU - An, Peng
AU  - An P
FAU - Wu, Qian
AU  - Wu Q
FAU - Wang, Hao
AU  - Wang H
FAU - Wu, Aimin
AU  - Wu A
FAU - Mu, Mingdao
AU  - Mu M
FAU - Zhang, Di
AU  - Zhang D
FAU - Zhang, Zhou
AU  - Zhang Z
FAU - Wang, Hui
AU  - Wang H
FAU - He, Lin
AU  - He L
FAU - Liu, Yun
AU  - Liu Y
FAU - Wang, Fudi
AU  - Wang F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - S0007114513001827 [pii]
AID - 10.1017/S0007114513001827 [doi]
PST - aheadofprint
SO  - Br J Nutr. 2013 Jun 7:1-6.

PMID- 23742658
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1540-8175 (Electronic)
IS  - 0742-2822 (Linking)
DP  - 2013 Jun 6
TI  - Coronary Flow Reserve and Myocardial Performance Index in Newly Diagnosed
      Diabetic Patients.
LID - 10.1111/echo.12275 [doi]
AB  - BACKGROUND: Patients with diabetes mellitus (DM) are at high risk of left
      ventricular (LV) dysfunction. A reduction of coronary flow reserve (CFR) has been
      demonstrated in diabetic patients without coronary artery stenosis. In this
      study, we investigated the association between LV myocardial diastolic and
      systolic functions and the CFR in newly diagnosed diabetic patients in the
      absence of coronary artery disease. METHOD: We studied 88 patients (mean age 49
      +/- 10 years) with newly diagnosed DM and 40 healthy control subjects (mean age
      50 +/- 9 years). All subjects underwent transthoracic echocardiography. The
      myocardial performance index (MPI) was determined by using pulsed-wave Doppler.
      The CFR was calculated as the hyperemic to resting coronary diastolic peak
      velocities ratio. RESULTS: Patients with diabetes had significantly longer mitral
      E-wave deceleration time and higher MPI value than control group (P = 0.023 and P
      < 0.001, respectively). The mean CFR was lower in diabetic patients compared with
      controls (P = 0.001). The MPI was significantly correlated with CFR (r = -0.371, 
      P < 0.001), LV ejection fraction (r = -0.274, P = 0.018) E/A ratio (r = -0.244, P
      = 0.024), and glycosylated hemoglobin (HbA1c) (r = 0.476, P < 0.001).
      Multivariate regression analysis showed that MPI was independently associated
      with CFR (beta = -0.292, P < 0.0001) and HbA1c level (beta = 0.372, P < 0.0001). 
      CONCLUSIONS: The MPI was independently associated with CFR in newly diagnosed
      diabetic patients. The decrease in CFR may cause LV systolic and diastolic
      dysfunction in asymptomatic diabetic patients.
CI  - (c) 2013, Wiley Periodicals, Inc.
AD  - Department of Cardiology, Adana Numune Training and Research Hospital, Adana,
      Turkey.
FAU - Kalkan, Gulhan Yuksel
AU  - Kalkan GY
FAU - Gur, Mustafa
AU  - Gur M
FAU - Sahin, Durmus Yildiray
AU  - Sahin DY
FAU - Baykan, Ahmet Oytun
AU  - Baykan AO
FAU - Elbasan, Zafer
AU  - Elbasan Z
FAU - Kuloglu, Osman
AU  - Kuloglu O
FAU - Kivrak, Ali
AU  - Kivrak A
FAU - Turkoglu, Caner
AU  - Turkoglu C
FAU - Arik, Osman Ziya
AU  - Arik OZ
FAU - Cayli, Murat
AU  - Cayli M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Echocardiography
JT  - Echocardiography (Mount Kisco, N.Y.)
JID - 8511187
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1111/echo.12275 [doi]
PST - aheadofprint
SO  - Echocardiography. 2013 Jun 6. doi: 10.1111/echo.12275.

PMID- 23742649
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 6
IP  - 1
DP  - 2013 Jun 6
TI  - Early aggressive macrovascular disease and type 1 diabetes mellitus without
      chronic complications: a case report.
PG  - 222
AB  - BACKGROUND: Type 1 diabetes (T1DM) is considered to be one of the most
      significant risk factors for the development of coronary artery disease (CAD).
      However, the specific risk predictor models for T1DM are subject to many
      limitations. CASE PRESENTATION: We report the case of a 42-year-old Caucasian
      woman presenting with T1DM for 26 years. During her chronic hyperglycemic
      evolution (mean of HbA1c > 3 percentage points above the superior limit) without 
      microvascular complications, this patient presented with early and aggressive
      coronary artery disease, despite the lack of classical risk factors for CAD
      CONCLUSIONS: The rapidly progressive macrovascular disease observed in this case 
      demonstrates the different degrees of aggressiveness and unpredictable clinical
      evolution observed in some cases. It also confirms the need for a
      multi-factorial, early and optimized clinical management regime.
FAU - Saldanha de Mattos Matheus, Alessandra
AU  - Saldanha de Mattos Matheus A
FAU - Brito Gomes, Marilia
AU  - Brito Gomes M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2012/07/16 [received]
PHST- 2013/06/06 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 1756-0500-6-222 [pii]
AID - 10.1186/1756-0500-6-222 [doi]
PST - aheadofprint
SO  - BMC Res Notes. 2013 Jun 6;6(1):222.

PMID- 23742315
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1755-3768 (Electronic)
IS  - 1755-375X (Linking)
DP  - 2013 Jun 7
TI  - Impaired retinal vasodilator responses in prediabetes and type 2 diabetes.
LID - 10.1111/aos.12129 [doi]
AB  - Purpose: In diabetes, endothelial dysfunction and subsequent structural damage to
      blood vessels can lead to heart attacks, retinopathy and strokes. However, it is 
      unclear whether prediabetic subjects exhibit microvascular dysfunction indicating
      early stages of arteriosclerosis and vascular risk. The purpose of this study was
      to examine whether retinal reactivity may be impaired early in the hyperglycaemic
      continuum and may be associated with markers of inflammation. Methods:
      Individuals with prediabetes (n = 22), type 2 diabetes (n = 25) and healthy age
      and body composition matched controls (n = 19) were studied. We used the Dynamic 
      Vessel Analyzer to assess retinal vasoreactivity (percentage change in vessel
      diameter) during a flickering light stimulation. Fasting highly sensitive
      c-reactive protein (hs-CRP), a marker of inflammation, was measured in blood
      plasma. Results: Prediabetic and diabetic individuals had attenuated peak
      vasodilator and relative amplitude changes in retinal vein diameters to the
      flickering light stimulus compared with healthy controls (peak dilation:
      prediabetic subjects 3.3 +/- 1.8%, diabetic subjects 3.3 +/- 2.1% and controls
      5.6 +/- 2.6%, p = 0.001; relative amplitude: prediabetic subjects 4.3 +/- 2.2%,
      diabetic subjects 5.0 +/- 2.6% and control subjects 7.2 +/- 3.2%, p = 0.003).
      Similar findings were observed in retinal arteries. Levels of hs-CRP were not
      associated with either retinal vessel response parameters. Conclusion: Retinal
      reactivity was impaired in prediabetic and type 2 diabetic individuals in
      parallel with reduced insulin sensitivity but not associated with levels of
      hs-CRP. Retinal vasoreactivity measurements may be a sensitive tool to assess
      early vascular risk.
CI  - (c) 2013 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & 
      Sons Ltd.
AD  - Heart and Vascular Institute, Penn State Hershey Medical Center, Hershey,
      Pennsylvania, USA Department of Neurology, Penn State Hershey Medical Center,
      Hershey, Pennsylvania, USA Department of Ophthalmology, Penn State Hershey
      Medical Center, Hershey, Pennsylvania, USA Division of Endocrinology, Diabetes
      and Metabolism, Penn State Hershey Diabetes and Obesity Institute, Penn State
      College of Medicine, Hershey, Pennsylvania, USA Kellogg Eye Center, University of
      Michigan, Ann Arbor, Michigan, USA.
FAU - Lott, Mary E J
AU  - Lott ME
FAU - Slocomb, Julia E
AU  - Slocomb JE
FAU - Shivkumar, Vikram
AU  - Shivkumar V
FAU - Smith, Bruce
AU  - Smith B
FAU - Quillen, David
AU  - Quillen D
FAU - Gabbay, Robert A
AU  - Gabbay RA
FAU - Gardner, Thomas W
AU  - Gardner TW
FAU - Bettermann, Kerstin
AU  - Bettermann K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Acta Ophthalmol
JT  - Acta ophthalmologica
JID - 101468102
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1111/aos.12129 [doi]
PST - aheadofprint
SO  - Acta Ophthalmol. 2013 Jun 7. doi: 10.1111/aos.12129.

PMID- 23742222
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1365-2788 (Electronic)
IS  - 0964-2633 (Linking)
DP  - 2013 Jun 7
TI  - Aerobic training improved low-grade inflammation in obese women with intellectual
      disability.
LID - 10.1111/jir.12056 [doi]
AB  - BACKGROUND: Obesity is a major health problem in people with intellectual
      disabilities. It is also widely accepted that low-grade systemic inflammation
      associated to obesity plays a key role in the pathogenic mechanism of several
      disorders. Fortunately, physical activity has shown to improve inflammation in
      people with metabolic syndrome and type 2 diabetes. Accordingly, we assessed the 
      influence of aerobic training on pro-inflammatory cytokines and acute phase
      proteins in women with Down syndrome. METHODS: To achieve this outcome, 20
      premenopausal obese young women with Down syndrome volunteered for this study.
      Eleven were randomly assigned to the intervention group and performed a 10-week
      aerobic training programme, three sessions per week, consisting of a warm-up then
      a 30- to 40-min treadmill exercise at a work intensity of 55-65% of peak heart
      rate followed by a cooling-down period. The control group included nine age-,
      sex- and body mass index-matched women with Down syndrome. Fat mass percentage
      and fat distribution were measured. Plasmatic levels of tumour necrosis factor
      (TNF)-alpha, interleukin (IL)-6 and fibrinogen were assessed by commercial
      enzyme-linked immunosorbent assay kits. C-reactive protein (CRP) was assessed by 
      nephelometry. RESULTS: Plasmatic levels of TNF-alpha (11.7 +/- 1.6 vs. 9.2 +/-
      1.3 pg/ml; P = 0.022), IL-6 (8.2 +/- 1.1 vs. 6.1 +/- 0.9 pg/ml; P = 0.014) and
      high sensitive CRP (0.62 +/- 0.11 vs. 0.53 +/- 0.09 mg/dl; P = 0.009) were
      significantly reduced in the intervention group. Further, significant
      correlations between plasmatic and anthropometric parameters were found.
      CONCLUSION: A 10-week training programme reduced pro-inflammatory cytokines and
      acute phase proteins in obese young women with Down syndrome. Long-term,
      well-conducted studies are still required to determine whether correction of this
      low-grade inflammation improves clinical outcomes of women with trisomy 21.
CI  - (c) 2013 John Wiley & Sons Ltd, MENCAP & IASSID.
AD  - School of Sports Medicine, University of Cadiz, Cadiz, Spain.
FAU - Ordonez, F J
AU  - Ordonez FJ
FAU - Rosety, M A
AU  - Rosety MA
FAU - Camacho, A
AU  - Camacho A
FAU - Rosety, I
AU  - Rosety I
FAU - Diaz, A J
AU  - Diaz AJ
FAU - Fornieles, G
AU  - Fornieles G
FAU - Garcia, N
AU  - Garcia N
FAU - Rosety-Rodriguez, M
AU  - Rosety-Rodriguez M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Intellect Disabil Res
JT  - Journal of intellectual disability research : JIDR
JID - 9206090
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/05/02 [accepted]
AID - 10.1111/jir.12056 [doi]
PST - aheadofprint
SO  - J Intellect Disabil Res. 2013 Jun 7. doi: 10.1111/jir.12056.

PMID- 23742221
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1743-6109 (Electronic)
IS  - 1743-6095 (Linking)
DP  - 2013 Jun 6
TI  - Influence of Vascular Comorbidities and Race on Erectile Dysfunction after
      Prostate Cancer Radiotherapy.
LID - 10.1111/jsm.12215 [doi]
AB  - INTRODUCTION: Vascular comorbidities (VC) (hypertension, diabetes, and
      hyperlipidemia) are known factors related to erectile dysfunction (ED) in men.
      However, no data are yet available for the effects of VC on ED incidence after
      prostate cancer radiotherapy (XRT). AIM: To investigate the influence of VC on
      post-XRT ED incidence and to further characterize ED incidence by racial groups. 
      MAIN OUTCOME MEASURES: ED incidence. METHODS: We reviewed 732 charts of patients 
      (267 Caucasian and 465 African American [AA]) who received prostate XRT (external
      beam radiotherapy and/or brachytherapy) with or without hormone therapy between
      1999 and 2010. The number of pre-XRT VC (0, 1, 2, or 3) was determined by medical
      history and medication list. ED (defined by use of erectile aids or by
      documentation of moderate or high sexual dysfunction on patient history) was
      determined pre-XRT as well as 1, 2, and 4 years post-XRT. RESULTS: ED incidence
      progressively increased from 22% pre-XRT to 58% 4 years post-XRT (P < 0.01).
      Additionally, ED incidence significantly increased with number of VC-4-year
      incidence between patients with 1 vs. 0 (P = 0.02), 2 vs. 0 (P < 0.01), 3 vs. 0
      (P < 0.01), 3 vs. 1 (P < 0.01), and 3 vs. 2 (P = 0.04) VC (2 vs. 1 VC was
      nonsignificant). Compared with the Caucasian patients, ED incidences were
      slightly higher for the AA group with 0, 1, 2, and 3 comorbidities at 4 years
      follow-up (but statistically nonsignificant). CONCLUSIONS: The number of VCs have
      a significant effect on development of post-XRT ED. Pre- and post-XRT ED appear
      to be independent of race when number of VCs are considered. Our results can be
      used to guide physicians in counseling patients on the incidence of ED by number 
      of VC and as preliminary data for prospective efforts aimed at reducing post-XRT 
      ED. Wang Y, Liu T, Rossi PJ, Watkins-Bruner D, Hsiao W, Cooper S, Yang X, and
      Jani AB. Influence of vascular comorbidities and race on erectile dysfunction
      after prostate cancer radiotherapy. J Sex Med **;**:**-**.
CI  - (c) 2013 International Society for Sexual Medicine.
AD  - Department of Radiation Oncology, Emory University, Atlanta, GA, USA.
FAU - Wang, Yuefeng
AU  - Wang Y
FAU - Liu, Tian
AU  - Liu T
FAU - Rossi, Peter J
AU  - Rossi PJ
FAU - Watkins-Bruner, Deborah
AU  - Watkins-Bruner D
FAU - Hsiao, Wayland
AU  - Hsiao W
FAU - Cooper, Sherrie
AU  - Cooper S
FAU - Yang, Xiaofeng
AU  - Yang X
FAU - Jani, Ashesh B
AU  - Jani AB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
AID - 10.1111/jsm.12215 [doi]
PST - aheadofprint
SO  - J Sex Med. 2013 Jun 6. doi: 10.1111/jsm.12215.

PMID- 23742173
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
DP  - 2013 Jun 6
TI  - Relaxin Improves Multiple Markers of Wound Healing and Ameliorates the Disturbed 
      Healing Pattern of the Genetically Diabetic Mice.
AB  - Diabetic mice are characterized by a disrupted expression pattern of
      vascular-endothelial-growth-factor (VEGF), and impaired vasculogenesis during
      healing. Experimental evidence suggest that relaxin (RLX) can improve several
      parameters associated with wound healing. Therefore, we investigated the effects 
      of porcine derived relaxin in diabetes-related wound healing defects in
      genetically diabetic mice. An incisional wound model was produced on the back of 
      female diabetic C57BL/KsJ-m+/+Leptdb (db+/db+) mice and their normal littermates 
      (db+/+m). Animals were treated daily with porcine RLX (25microg mouse/day/s.c.)
      or its vehicle. Mice were killed on 3, 6 and 12 days after skin injury for
      measurements of VEGF mRNA and protein synthesis, stromal cell-derived
      factor-1alpha (SDF-1alpha) mRNA and endothelial nitric oxide synthase (eNOS)
      expression. Furthermore, we evaluated wound-breaking strength, histological
      changes, angiogenesis and vasculogenesis at day 12. Diabetic animals showed a
      reduced expression of VEGF, eNOS and SDF-1alpha compared to nondiabetic animals. 
      At day 6, RLX administration resulted in an increase in VEGF mRNA expression and 
      protein wound content, in eNOS expression and in SDF-1alpha mRNA. Furthermore the
      histological evaluation indicated that RLX improved the impaired wound healing,
      enhanced the staining of matrix metalloproteinase-11 (MMP-11) and increased wound
      breaking strength at day 12 in diabetic mice. Immunohistochemistry showed that
      RLX in diabetic animals augmented new vessel formation by stimulating both
      angiogenesis and vasculogenesis. RLX significantly reduced the time to complete
      skin normalization and this effect was abrogated by a concomitant treatment with 
      antibodies against VEGF and CXCR4, the SDF-1alpha receptor. These data strongly
      suggest that RLX may have a potential application in diabetes-related wound
      disorders.
FAU - Bitto, Alessandra
AU  - Bitto A
FAU - Irrera, Natasha
AU  - Irrera N
FAU - Minutoli, Letteria
AU  - Minutoli L
FAU - Calo, Margherita
AU  - Calo M
FAU - Lo Cascio, Patrizia
AU  - Lo Cascio P
FAU - Caccia, Paolo
AU  - Caccia P
FAU - Pizzino, Gabriele
AU  - Pizzino G
FAU - Pallio, Giovanni
AU  - Pallio G
FAU - Micali, Antonio
AU  - Micali A
FAU - Vaccaro, Mario
AU  - Vaccaro M
FAU - Saitta, Antonino
AU  - Saitta A
FAU - Squadrito, Francesco
AU  - Squadrito F
FAU - Altavilla, Domenica
AU  - Altavilla D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/02/28 [received]
PHST- 2013/05/28 [revised]
PHST- 2013/06/06 [accepted]
AID - CS20130105 [pii]
AID - 10.1042/CS20130105 [doi]
PST - aheadofprint
SO  - Clin Sci (Lond). 2013 Jun 6.

PMID- 23742157
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
DP  - 2013 Jun 7
TI  - Dietary supplementation and engaging in physical activity as predictors of
      coronary artery disease among middle-aged women.
LID - 10.1111/jocn.12263 [doi]
AB  - AIM AND OBJECTIVES: To explore risk factors for coronary artery disease (CAD)
      among middle-aged women in Taiwan. BACKGROUND: Coronary artery disease is a
      leading cause of death among females. Risk factors for CAD vary due to
      differences in ethnicity, gender and age. However, few studies have documented
      risk factors among middle-aged women. DESIGN: We employed a cross-sectional,
      comparative study design. METHODS: Sixty-five middle-aged women who were
      suspected of having CAD and who received cardiac catheterisation were purposively
      sampled and divided into a CAD group (with at least one coronary artery with >
      50% stenosis) and a control group, according to the results of catheterisation.
      Individual questionnaires regarding their medical history, blood test results,
      sociodemographic characteristics, metabolism, biomarkers and lifestyle risk
      factors were administered and quantified. RESULTS: The mean age of the 65 women
      (31 CAD and 34 controls) was 56.2 years. Within the CAD group, there was a
      greater incidence of women with a history of diabetes mellitus (DM), increased
      fasting blood glucose and increased diastolic blood pressure. Comparatively fewer
      women within the CAD category used dietary supplements or had a lower level of
      physical activity. After adjusting for other confounders, it was discovered that 
      women who used dietary supplements (OR = 0.28; p = 0.04) and engaged in physical 
      activities (OR = 0.16; p = 0.02) were less likely to develop CAD. CONCLUSIONS:
      Use of dietary supplements and engaging in physical activities can significantly 
      predict the incidence of CAD among middle-aged women in Taiwan. RELEVANCE TO
      CLINICAL PRACTICE: Middle-aged women should be encouraged to take appropriate
      dietary supplements and engage in physical activity in order to prevent CAD.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Graduate Institute of Nursing, College of Nursing, Taipei Medical University,
      Taipei, Taiwan; Department of Nursing, Chang Gung University of Science and
      Technology, Tao Yuan, Taiwan.
FAU - Tsai, Ching-Ching
AU  - Tsai CC
FAU - Hsieh, Ming-Hsiung
AU  - Hsieh MH
FAU - Li, Ai-Hsien
AU  - Li AH
FAU - Chen, Ping-Ling
AU  - Chen PL
FAU - Jeng, Chii
AU  - Jeng C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/01/04 [accepted]
AID - 10.1111/jocn.12263 [doi]
PST - aheadofprint
SO  - J Clin Nurs. 2013 Jun 7. doi: 10.1111/jocn.12263.

PMID- 23742066
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 35
IP  - 6
DP  - 2013 Jul
TI  - Suicide commitment with metformin: our experience with five cases.
PG  - 863-5
LID - 10.3109/0886022X.2013.801299 [doi]
AB  - Abstract Biguanides can function as oral antihyperglycemic drugs. They were used 
      for diabetes mellitus or prediabetes treatment over the last nine decades, but
      they lost their popularity in 1970s because of phenformin and regained with
      metformin. For metformin, the most common side effects are diarrhea and
      dyspepsia, occurring in up to 30% of patients. The most important and serious
      side effect is lactic acidosis. Phenformin was removed from the markets before
      1970, because it caused lactic acidosis in 40-65 patients in 100,000
      patient-years. Metformin causes lactate accumulation only in patients who have
      hepatic failure, renal failure or in patients who attempt suicide with high
      dosage of drugs. In this report, we present five patients who used high doses of 
      metformin for suicide attempt.
AD  - Department of Internal Medicine, Kayseri Research and Training Hospital , Kayseri
      , Turkey and.
FAU - Avci, Deniz
AU  - Avci D
FAU - Cetinkaya, Ali
AU  - Cetinkaya A
FAU - Karahan, Samet
AU  - Karahan S
FAU - Oguzhan, Nilufer
AU  - Oguzhan N
FAU - Karagoz, Hatice
AU  - Karagoz H
FAU - Basak, Mustafa
AU  - Basak M
FAU - Erden, Abdulsamet
AU  - Erden A
LA  - eng
PT  - Journal Article
DEP - 20130606
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
SB  - IM
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PHST- 2013/06/06 [aheadofprint]
AID - 10.3109/0886022X.2013.801299 [doi]
PST - ppublish
SO  - Ren Fail. 2013 Jul;35(6):863-5. doi: 10.3109/0886022X.2013.801299. Epub 2013 Jun 
      6.

PMID- 23741881
OWN - NLM
STAT- In-Process
DA  - 20130607
IS  - 0305-7518 (Print)
IS  - 0305-7518 (Linking)
VI  - 84
IP  - 1
DP  - 2013 Mar
TI  - Pure neuritic leprosy in patients from a high endemic region of Colombia.
PG  - 41-50
AB  - Agua de Dios was a leprosarium for leprosy patients' obligatory isolation
      (1872-1961). Its leprosy incidence is the highest in Colombia (1.5-7/10000).
      Relapses are common. Government grant of US$ 200 per month subsidy is available
      to patients with disabilities. Spontaneous consultation with neural symptoms is
      frequent and simulation to get the subsidy has to be considered. We studied 36
      subjects (2007-2009), with ages from 29-78, 19 of them men, with neural symptoms 
      of 6 months to 20 years evolution. All had clinical examination, bacteriological 
      examination, skin and nerve biopsies, electromyography (EMG), PCR for M. leprae, 
      IgM anti-PGL1, and lepromin A. All but two are household contacts of leprosy
      patients. Symptoms were hypoesthesia of the hands and feet, and difficulty using 
      hands with loss of muscular strength. None had skin lesions. Three had thickening
      of ulnar nerve. Lepromin was positive in all; bacteriology and biopsies were
      negative in all. The speed and amplitude of neural conduction were altered in 34 
      patients; two women had normal EMG and were considered to be feigning the
      disease; 21 were diagnosed as PNL by clinical, epidemiological and EMG findings; 
      five of them had a positive PCR and one, high titers for IgM anti PGL1. Nine
      other subjects had diabetes and six carpal tunnel syndrome (CTS). Slow
      progression of disease, the lack of neural enlargement and the neural biopsies
      without inflammation suggest that most of these patients could have spontaneously
      cured PNL, as happens with other cases of paucibacillary leprosy. Diabetes and
      CTS are important differential diagnoses of PNL. Patients were treated with MDT
      and received the state subsidy.
AD  - Molecular Microbiology Group, School of Medicine, Universidad de La Sabana, Chia,
      Cundinamarca, Colombia.
FAU - Rodriguez, Gerzain
AU  - Rodriguez G
FAU - Pinto, Rafael
AU  - Pinto R
FAU - Gomez, Yenny
AU  - Gomez Y
FAU - Rengifo, Maria Leonor
AU  - Rengifo ML
FAU - Estrada, Olga Lucia
AU  - Estrada OL
FAU - Sarmiento, Marta
AU  - Sarmiento M
FAU - Lopez, Fernando
AU  - Lopez F
FAU - Beltran-Alzate, Juan Camilo
AU  - Beltran-Alzate JC
FAU - Cardona-Castro, Nora
AU  - Cardona-Castro N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Lepr Rev
JT  - Leprosy review
JID - 0243711
SB  - IM
EDAT- 2013/06/08 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/06/08 06:00
PST - ppublish
SO  - Lepr Rev. 2013 Mar;84(1):41-50.

PMID- 23741662
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 2229-5178 (Print)
IS  - 2229-5178 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr
TI  - Smokers' hair: Does smoking cause premature hair graying?
PG  - 90-2
LID - 10.4103/2229-5178.110586 [doi]
AB  - AIMS: To determine if there is a significant association between premature hair
      graying and cigarette smoking. MATERIALS AND METHODS: A cross-sectional
      observational study was conducted in a nonclinical setting on 207 participants on
      August 24 until 25, 2010. Participants were classified into two groups [premature
      hair graying (PHG) and normal hair graying]. PHG was defined as the first
      appearance of gray hair before the age of 30. Data were collected using an
      interview questionnaire and measurements of body mass index, waist circumference,
      fasting blood glucose and blood pressure. Collected data were statistically
      analyzed using SPSS 16, Chicago, IL. RESULTS: Of the 207 subjects, 104 (50.2%)
      had first appearance of gray hair before the age of 30 (PHG group) while the
      other 103 (49.8%) were considered normal hair graying group. The prevalence of
      smokers in the "PHG" group was higher (40.2% vs. 24.7%, P = 0.031). Smokers had
      earlier onset of hair graying (smokers: 31 (7.4) vs. nonsmokers: 34 (8.6), P =
      0.034). Using multiple logistic regression with conditional likelihood, smokers
      were two and half times (95% CI: 1.5-4.6) more prone to develop PHG. CONCLUSION: 
      This study suggests that there is a significant relation (with adjusted odds
      ratio of two and half) between onset of gray hair before the age of 30 and
      cigarette smoking.
AD  - Department of Internal Medicine, Division of Endocrinology, Diabetes and
      Metabolism, Faculty of Medicine, Jordan University Hospital, The University of
      Jordan, Amman, Jordan.
FAU - Zayed, Ayman A
AU  - Zayed AA
FAU - Shahait, Awni D
AU  - Shahait AD
FAU - Ayoub, Musa N
AU  - Ayoub MN
FAU - Yousef, Al-Motassem
AU  - Yousef AM
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian Dermatol Online J
JT  - Indian dermatology online journal
JID - 101586880
PMC - PMC3673399
OID - NLM: PMC3673399
OTO - NOTNLM
OT  - Jordan
OT  - premature hair graying
OT  - smoking
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.4103/2229-5178.110586 [doi]
AID - IDOJ-4-90 [pii]
PST - ppublish
SO  - Indian Dermatol Online J. 2013 Apr;4(2):90-2. doi: 10.4103/2229-5178.110586.

PMID- 23741625
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 2084-6835 (Print)
VI  - 1
DP  - 2013 Mar
TI  - Exposure to Maternal Diabetes in Utero and DNA Methylation Patterns in the
      Offspring.
PG  - 1-9
AB  - Perturbations in early life environments, including intrauterine exposure to
      maternal gestational diabetes (GDM), are hypothesized to lead to metabolic
      imprinting resulting in increased risk of cardiometabolic outcomes later in life.
      We aimed to 1) identify candidate genes and biological pathways associated with
      differentially methylated regions (DMRs) in relation to exposure to GDM in utero 
      and, 2) using mediation analysis, more definitively investigate the potential for
      mediation of the effect of exposure to maternal diabetes in utero on
      cardiometabolic traits in childhood risk through our identified DMRs. Genome-wide
      methylation analysis of peripheral blood mononuclear cell's DNA was conducted in 
      21 healthy children, ages 8-12 years. P-values from multiple linear regression
      analyses for >27,000 CpG sites were ranked to identify DMRs between the exposure 
      groups. Among the top 10 ranked DMRs, we identified several genes, including
      NPR1, PANK1, SCAND1, and GJA4, which are known to be associated with
      cardiometabolic traits. Gene enrichment analysis of the top 84 genes, each with
      p<=0.005, identified the ubiquitin proteasome system (UPS) as the most enriched
      biological pathway (p = 0.07). The UPS pathway reflects biological processes
      known to be associated with endothelial function, inflammation, lipid metabolism,
      insulin resistance and beta-cell apoptosis, whose derangements are central to the
      pathogenesis of cardiometabolic diseases. Increased methylation of PYGO1 and CLN8
      had the greatest relative mediation effect (RME = 87%, p=0.005 and RME=50%,
      p=0.01) on the impact of exposure to maternal diabetes in utero on VCAM-1 levels 
      in the offspring. Multiple candidate genes and the UPS were identified for future
      study as possible links between exposure to maternal gestational diabetes in
      utero and adverse cardiometabolic traits in the offspring. In particular,
      increased methylation of PYGO1 and CLN8 may be biological links between
      intrauterine exposure to maternal diabetes and significantly increased VCAM-1
      levels in the offspring.
AD  - Department of Epidemiology, University of Colorado Anschutz Medical Campus,
      Aurora, Colorado, USA.
FAU - West, Nancy A
AU  - West NA
FAU - Kechris, Katerina
AU  - Kechris K
FAU - Dabelea, Dana
AU  - Dabelea D
LA  - ENG
GR  - R01 DK068001/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
TA  - Immunometabolism
JT  - Immunometabolism
JID - 101607751
PMC - PMC3670583
MID - NIHMS463796
OTO - NOTNLM
OT  - Cardiometabolic
OT  - DNA methylation
OT  - Epigenetics
OT  - Gestational diabetes
OT  - Intrauterine
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.2478/immun-2013-0001 [doi]
PST - ppublish
SO  - Immunometabolism. 2013 Mar;1:1-9.

PMID- 23741528
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - DGCR8-Mediated Production of Canonical Micrornas Is Critical for Regulatory T
      Cell Function and Stability.
PG  - e66282
LID - 10.1371/journal.pone.0066282 [doi]
AB  - Regulatory T cells (Treg) are integral for immune homeostasis. Here we
      demonstrate that canonical microRNAs (miRNAs) are required for Treg function
      because mice with DGCR8-deficient Treg cells spontaneously develop a scurfy-like 
      disease. Using genetic lineage marking we show that absence of miRNAs leads to
      reduced FoxP3 expression in Treg cells in vivo. In vitro culture of purified
      DGCR8-deficient Treg leads to a loss of FoxP3 expression. We conclude that
      canonical miRNAs are essential to maintain stable FoxP3 expression and Treg
      function. Thus, signals interfering with miRNA homeostasis might contribute to
      autoimmune diseases.
AD  - Diabetes Center and the Department of Medicine, University of California San
      Francisco, San Francisco, California, United States of America ; Department of
      Pathology, University of California San Francisco, San Francisco, California,
      United States of America.
FAU - Jeker, Lukas T
AU  - Jeker LT
FAU - Zhou, Xuyu
AU  - Zhou X
FAU - Blelloch, Robert
AU  - Blelloch R
FAU - Bluestone, Jeffrey A
AU  - Bluestone JA
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669207
OID - NLM: PMC3669207
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2012/08/10 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0066282 [doi]
AID - PONE-D-12-24088 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e66282. doi: 10.1371/journal.pone.0066282. Print 2013.

PMID- 23741513
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Association of Cardiovascular Burden with Mobility Limitation among Elderly
      People: A Population-Based Study.
PG  - e65815
LID - 10.1371/journal.pone.0065815 [doi]
AB  - BACKGROUND: Cardiovascular risk factors (CRFs) such as smoking and diabetes have 
      been associated with mobility limitations among older adults. We seek to examine 
      to what extent individual and aggregated CRFs and cardiovascular diseases (CVDs) 
      are associated with mobility limitation. METHODS: The study sample included 2725 
      participants (age >/=60 years, mean age 72.7 years, 62% women) in the Swedish
      National Study on Aging and Care in the Kungsholmen district of central
      Stockholm, Sweden, who were living either at their own home or in institutions.
      Data on demographic features, CRFs, and CVDs were collected through interview,
      clinical examination, self-reported history, laboratory tests, and inpatient
      register. Mobility limitation was defined as walking speed <0.8 m/s. Data were
      analyzed using multiple logistic models controlling for potential confounders.
      RESULTS: Of the 2725 participants, 581 (21.3%) had mobility limitation. The
      likelihood of mobility limitation increased linearly with the increasing number
      of CRFs (i.e., hypertension, high C-reactive protein, obesity, diabetes and
      smoking) (p for linear trend<0.010) and of CVDs (i.e., ischemic heart disease,
      atrial fibrillation, heart failure and stroke) (p for linear trend<0.001). There 
      were statistical interactions of aggregated CRFs with age and APOE epsilon4
      allele on mobility limitation (p interaction<0.05), such that the association of 
      mobility limitation with aggregated CRFs was statistically evident only among
      people aged <80 years and among carriers of the APOE epsilon4 allele. CONCLUSION:
      Aggregations of multiple CRFs and CVDs are associated with an increased
      likelihood of mobility limitation among older adults; however the associations of
      CRFs with mobility limitation vary by age and genetic susceptibility.
AD  - Aging Research Center (ARC), Department of Neurobiology, Care Sciences and
      Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden ;
      Karolinska University Hospital, Stockholm, Sweden.
FAU - Welmer, Anna-Karin
AU  - Welmer AK
FAU - Angleman, Sara
AU  - Angleman S
FAU - Rydwik, Elisabeth
AU  - Rydwik E
FAU - Fratiglioni, Laura
AU  - Fratiglioni L
FAU - Qiu, Chengxuan
AU  - Qiu C
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669202
OID - NLM: PMC3669202
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/11 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0065815 [doi]
AID - PONE-D-13-02877 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e65815. doi: 10.1371/journal.pone.0065815. Print 2013.

PMID- 23741493
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Apolipoprotein A-I glycation by Glucose and Reactive Aldehydes Alters
      Phospholipid Affinity but Not Cholesterol Export from Lipid-Laden Macrophages.
PG  - e65430
LID - 10.1371/journal.pone.0065430 [doi]
AB  - Increased protein glycation in people with diabetes may promote atherosclerosis. 
      This study examined the effects of non-enzymatic glycation on the association of 
      lipid-free apolipoproteinA-I (apoA-I) with phospholipid, and cholesterol efflux
      from lipid-loaded macrophages to lipid-free and lipid-associated apoA-I.
      Glycation of lipid-free apoA-I by methylglyoxal and glycolaldehyde resulted in
      Arg, Lys and Trp loss, advanced glycation end-product formation and protein
      cross-linking. The association of apoA-I glycated by glucose, methylglyoxal or
      glycolaldehyde with phospholipid multilamellar vesicles was impaired in a
      glycating agent dose-dependent manner, with exposure of apoA-I to both 30 mM
      glucose (42% decrease in kslow) and 3 mM glycolaldehyde (50% decrease in kfast,
      60% decrease in kslow) resulting is significantly reduced affinity. Cholesterol
      efflux to control or glycated lipid-free apoA-I, or discoidal reconstituted HDL
      containing glycated apoA-I (drHDL), was examined using cholesterol-loaded murine 
      (J774A.1) macrophages treated to increase expression of ATP binding cassette
      transporters A1 (ABCA1) or G1 (ABCG1). Cholesterol efflux from J774A.1
      macrophages to glycated lipid-free apoA-I via ABCA1 or glycated drHDL via an
      ABCG1-dependent mechanism was unaltered, as was efflux to minimally modified
      apoA-I from people with Type 1 diabetes, or controls. Changes to protein
      structure and function were prevented by the reactive carbonyl scavenger
      aminoguanidine. Overall these studies demonstrate that glycation of lipid-free
      apoA-I, particularly late glycation, modifies its structure, its capacity to bind
      phospholipids and but not ABCA1- or ABCG1-dependent cholesterol efflux from
      macrophages.
AD  - The Heart Research Institute, Sydney, New South Wales, Australia ; Faculty of
      Medicine, University of Sydney, Sydney, New South Wales, Australia.
FAU - Brown, Bronwyn E
AU  - Brown BE
FAU - Nobecourt, Estelle
AU  - Nobecourt E
FAU - Zeng, Jingmin
AU  - Zeng J
FAU - Jenkins, Alicia J
AU  - Jenkins AJ
FAU - Rye, Kerry-Anne
AU  - Rye KA
FAU - Davies, Michael J
AU  - Davies MJ
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669297
OID - NLM: PMC3669297
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/28 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0065430 [doi]
AID - PONE-D-12-33293 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e65430. doi: 10.1371/journal.pone.0065430. Print 2013.

PMID- 23741490
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Natural history of skeletal muscle mass changes in chronic kidney disease stage 4
      and 5 patients: an observational study.
PG  - e65372
LID - 10.1371/journal.pone.0065372 [doi]
AB  - Cross-sectional studies in dialysis demonstrate muscle wasting associated with
      loss of function, increased morbidity and mortality. The relative drivers are
      poorly understood. There is a paucity of data regarding interval change in muscle
      in pre-dialysis and dialysis-dependant patients. This study aimed to examine
      muscle and fat mass change and elucidate associations with muscle wasting in
      advanced CKD. 134 patients were studied (60 HD, 28 PD, 46 CKD 4-5) and followed
      up for two years. Groups were similar in age, sex and diabetes prevalence. Soft
      tissue cross-sectional area (CSA) was measured annually on 3 occasions by a
      standardised multi-slice CT thigh. Potential determinants of muscle and fat CSA
      were assessed. Functional ability was assessed by sit-to-stand testing. 88
      patients completed follow-up (40 HD, 16 PD, 32 CKD). There was a significant
      difference in percentage change in muscle CSA (MCSA) over year 1, dependant on
      treatment modality (chi(2) = 6.46; p = 0.039). Muscle loss was most pronounced in
      pre-dialysis patients. Muscle loss during year 1 was partially reversed in year 2
      in 39%. Incident dialysis patients significantly lost MCSA during the year which 
      they commenced dialysis, but not the subsequent year. Baseline MCSA, change in
      MCSA during year 1 and dialysis modality predicted year 2 change in MCSA
      (adjusted R(2) = 0.77, p<0.001). There was no correlation between muscle or fat
      CSA change and any other factors. MCSA correlated with functional testing,
      although MCSA change correlated poorly with change in functional ability. These
      data demonstrate marked variability in MCSA over 2 years. Loss of MCSA in both
      pre-dialysis and established dialysis patients is reversible. Factors previously 
      cross-sectionally shown to correlate with MCSA did not correlate with wasting
      progression. The higher rate of muscle loss in undialysed CKD patients, and its
      reversal after dialysis commencement, suggests that conventional indicators may
      not result in optimal timing of dialysis initiation.
AD  - Department of Renal Medicine, Royal Derby Hospital, Derby, United Kingdom.
FAU - John, Stephen G
AU  - John SG
FAU - Sigrist, Mhairi K
AU  - Sigrist MK
FAU - Taal, Maarten W
AU  - Taal MW
FAU - McIntyre, Christopher W
AU  - McIntyre CW
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669290
OID - NLM: PMC3669290
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/09 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0065372 [doi]
AID - PONE-D-12-31246 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e65372. doi: 10.1371/journal.pone.0065372. Print 2013.

PMID- 23741411
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Dietary Glycemic Index during Pregnancy Is Associated with Biomarkers of the
      Metabolic Syndrome in Offspring at Age 20 Years.
PG  - e64887
LID - 10.1371/journal.pone.0064887 [doi]
AB  - OBJECTIVE: Growing evidence indicates that metabolic syndrome is rooted in fetal 
      life with a potential key role of nutrition during pregnancy. The objective of
      the study was to assess the possible associations between the dietary glycemic
      index (GI) and glycemic load (GL) during pregnancy and biomarkers of the
      metabolic syndrome in young adult offspring. METHODS: Dietary GI and GL were
      assessed by questionnaires and interviews in gestation week 30 and offspring were
      clinically examined at the age of 20 years. Analyses based on 428
      mother-offspring dyads were adjusted for maternal smoking during pregnancy,
      height, pre-pregnancy body mass index (BMI), education, energy intake, and the
      offspring's ambient level of physical activity. In addition, possible confounding
      by gestational diabetes mellitus was taken into account. OUTCOME MEASURES: Waist 
      circumference, blood pressure, HOMA insulin resistance (HOMA-IR) and plasma
      levels of fasting glucose, triglycerides, HDL cholesterol, LDL cholesterol, total
      cholesterol, insulin, and leptin were measured in the offspring. RESULTS:
      Significant associations were found between dietary GI in pregnancy and HOMA-IR
      (the relative increase in HOMA-IR per 10 units' GI increase was 1.09 [95% CI:
      1.01, 1.16], p = 0.02), insulin (1.09 [95% CI: 1.02, 1.16], p = 0.01) and leptin 
      (1.21 [95% CI: 1.06, 1.38], p = 0.01) in the offspring; whereas no associations
      were detected for GL. CONCLUSIONS: Our data suggests that high dietary GI in
      pregnancy may affect levels of markers for the metabolic syndrome in young adult 
      offspring in a potentially harmful direction.
AD  - Centre for Fetal Programming, Department of Epidemiology Research, Statens Serum 
      Institute, Copenhagen, Denmark.
FAU - Danielsen, Inge
AU  - Danielsen I
FAU - Granstrom, Charlotta
AU  - Granstrom C
FAU - Haldorsson, Thorhallur
AU  - Haldorsson T
FAU - Rytter, Dorte
AU  - Rytter D
FAU - Hammer Bech, Bodil
AU  - Hammer Bech B
FAU - Henriksen, Tine Brink
AU  - Henriksen TB
FAU - Vaag, Allan Arthur
AU  - Vaag AA
FAU - Olsen, Sjurdur Frodi
AU  - Olsen SF
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669023
OID - NLM: PMC3669023
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/24 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0064887 [doi]
AID - PONE-D-13-03758 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e64887. doi: 10.1371/journal.pone.0064887. Print 2013.

PMID- 23741386
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Plant oils were associated with low prevalence of impaired glucose metabolism in 
      Japanese workers.
PG  - e64758
LID - 10.1371/journal.pone.0064758 [doi]
AB  - Fatty acid has been suggested to be involved in development of diabetes. However,
      its association is unclear among Japanese populations, which consume large
      amounts of fish rich in n-3 polyunsaturated fatty acids. The present
      cross-sectional study examined the association of individual dietary fatty acids 
      and dietary fatty acid patterns with abnormal glucose metabolism among 1065
      Japanese employees, aged 18-69 years. Impaired glucose metabolism is defined if a
      person has a history of diabetes, current use of anti-diabetic drug, fasting
      plasma glucose of 110 mg/dl (>/=6.1 mmol/L) or greater, or hemoglobin A1C of 6.0%
      (>/=42 mmol/mol) or greater. Dietary intake was assessed with a self-administered
      diet history questionnaire. Dietary fatty acid patterns were extracted by
      principal component analysis. Odds ratios of impaired glucose metabolism
      according to tertile categories of each fatty acids and dietary fatty acid
      patterns were estimated using logistic regression with adjustment for potential
      confounding variables. A higher intake of polyunsaturated fatty acid, n-6 fatty
      acid, linoleic acid, and oleic acid were significantly associated with a
      decreased prevalence of impaired glucose metabolism (P for trend = 0.03, 0.01,
      0.02, and 0.04, respectively). Alpha-linolenic acid was marginally significantly 
      associated with a decreased prevalence of impaired glucose metabolism (P for
      trend = 0.12). Of three fatty acid patterns identified, a higher plant oil
      pattern score, which characterized by high intake of alpha-linolenic acid,
      linoleic acid, and oleic acid, was associated with a decreased prevalence of
      impaired glucose metabolism (P for trend = 0.03). No association was observed for
      other patterns. In conclusion, plant source fatty acids might be protectively
      associated with development of diabetes in Japanese adults.
AD  - Department of Epidemiology and Prevention, Clinical Research Center, National
      Center for Global Health and Medicine, Tokyo, Japan.
FAU - Kurotani, Kayo
AU  - Kurotani K
FAU - Kochi, Takeshi
AU  - Kochi T
FAU - Nanri, Akiko
AU  - Nanri A
FAU - Tsuruoka, Hiroko
AU  - Tsuruoka H
FAU - Kuwahara, Keisuke
AU  - Kuwahara K
FAU - Pham, Ngoc Minh
AU  - Pham NM
FAU - Kabe, Isamu
AU  - Kabe I
FAU - Mizoue, Tetsuya
AU  - Mizoue T
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669390
OID - NLM: PMC3669390
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/07 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0064758 [doi]
AID - PONE-D-13-09818 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e64758. doi: 10.1371/journal.pone.0064758. Print 2013.

PMID- 23741327
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Branched Motifs Enable Long-Range Interactions in Signaling Networks through
      Retrograde Propagation.
PG  - e64409
LID - 10.1371/journal.pone.0064409 [doi]
AB  - Branched structures arise in the intra-cellular signaling network when a molecule
      is involved in multiple enzyme-substrate reaction cascades. Such branched motifs 
      are involved in key biological processes, e.g., immune response activated by
      T-cell and B-cell receptors. In this paper, we demonstrate long-range
      communication through retrograde propagation between branches of signaling
      pathways whose molecules do not directly interact. Our numerical simulations and 
      experiments on a system comprising branches with JNK and p38MAPK as terminal
      molecules respectively that share a common MAP3K enzyme MEKK3/4 show that
      perturbing an enzyme in one branch can result in a series of changes in the
      activity levels of molecules "upstream" to the enzyme that eventually reaches the
      branch-point and affects other branches. In the absence of any evidence for
      explicit feedback regulation between the functionally distinct JNK and p38MAPK
      pathways, the experimentally observed modulation of phosphorylation amplitudes in
      the two pathways when a terminal kinase is inhibited implies the existence of
      long-range coordination through retrograde information propagation previously
      demonstrated in single linear reaction pathways. An important aspect of
      retrograde propagation in branched pathways that is distinct from previous work
      on retroactivity focusing exclusively on single chains is that varying the type
      of perturbation, e.g., between pharmaceutical agent mediated inhibition of
      phosphorylation or suppression of protein expression, can result in opposing
      responses in the other branches. This can have potential significance in
      designing drugs targeting key molecules which regulate multiple pathways
      implicated in systems-level diseases such as cancer and diabetes.
AD  - The Institute of Mathematical Sciences, Chennai, India ; Health Physics Division,
      Bhabha Atomic Research Centre, Kalpakkam, India.
FAU - Jesan, Tharmaraj
AU  - Jesan T
FAU - Sarma, Uddipan
AU  - Sarma U
FAU - Halder, Subhadra
AU  - Halder S
FAU - Saha, Bhaskar
AU  - Saha B
FAU - Sinha, Sitabhra
AU  - Sinha S
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669326
OID - NLM: PMC3669326
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/31 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0064409 [doi]
AID - PONE-D-13-00848 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e64409. doi: 10.1371/journal.pone.0064409. Print 2013.

PMID- 23741322
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Obestatin Enhances In Vitro Generation of Pancreatic Islets through Regulation of
      Developmental Pathways.
PG  - e64374
LID - 10.1371/journal.pone.0064374 [doi]
AB  - Availability of large amounts of in vitro generated beta-cells may support
      replacement therapy in diabetes. However, methods to obtain beta-cells from
      stem/progenitor cells are limited by inefficient endocrine differentiation. We
      have recently shown that the ghrelin gene product obestatin displays beneficial
      effects on pancreatic beta-cell survival and function. Obestatin prevents
      beta-cell apoptosis, preserves beta-cell mass and stimulates insulin secretion in
      vitro and in vivo, in both normal and diabetic conditions. In the present study, 
      we investigated whether obestatin may promote in vitro beta-cell generation from 
      mouse pancreatic islet-derived precursor cells. Treatment of cultured islets of
      Langerhans with obestatin (i) enriched cells expressing the mesenchymal/neuronal 
      marker nestin, which is associated with pancreatic precursors; (ii) increased
      cell survival and reduced apoptosis during precursor selection; (iii) promoted
      the generation of islet-like cell clusters (ICCs) with increased insulin gene
      expression and C-peptide secretion. Furthermore, obestatin modulated the
      expression of fibroblast growth factor receptors (FGFRs), Notch receptors and
      neurogenin 3 (Ngn3) during islet-derived precursor cell selection and endocrine
      differentiation. These results indicate that obestatin improves the generation of
      functional beta-cells/ICCs in vitro, suggesting implications for cell-based
      replacement therapy in diabetes. Moreover, obestatin may play a role in
      regulating pathways involved in pancreas development and regeneration.
AD  - Division of Endocrinology, Diabetology and Metabolism, Department of Medical
      Sciences, University of Torino, Torino, Italy.
FAU - Baragli, Lessandra
AU  - Baragli L
FAU - Grande, Cristina
AU  - Grande C
FAU - Gesmundo, Iacopo
AU  - Gesmundo I
FAU - Settanni, Fabio
AU  - Settanni F
FAU - Taliano, Marina
AU  - Taliano M
FAU - Gallo, Davide
AU  - Gallo D
FAU - Gargantini, Eleonora
AU  - Gargantini E
FAU - Ghigo, Ezio
AU  - Ghigo E
FAU - Granata, Riccarda
AU  - Granata R
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669302
OID - NLM: PMC3669302
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/08 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0064374 [doi]
AID - PONE-D-13-05759 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e64374. doi: 10.1371/journal.pone.0064374. Print 2013.

PMID- 23741311
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Increased Levels of Plasma Soluble Sema4D in Patients with Heart Failure.
PG  - e64265
LID - 10.1371/journal.pone.0064265 [doi]
AB  - Semaphorin 4D (Sema4D/CD100) is a 150-kDa transmembrane glycoprotein expressed by
      platelets and T-cells. When these cells are activated, Sema4D is cleaved
      proteolytically, generating a biologically active 120-kDa fragment (soluble
      Sema4D) capable of targeting receptors on platelets, B-cells, endothelial cells
      and tumor cells. However, its plasma levels and significance in heart failure
      (HF) have not been reported. In this study, we established an ELISA and detected 
      soluble Sema4D in human plasma. In healthy controls, plasma Sema4D levels were
      higher in men than women (5.15+/-3.30 ng/mL, n = 63, vs. 4.19+/-2.39 ng/mL, n =
      63, P<0.05). In HF patients, plasma Sema4D levels were significantly higher than 
      those in healthy controls (8.94+/-5.89 ng/mL, n = 157 vs. 4.67+/-2.99 ng/mL, n = 
      126, P<0.0001) with the highest levels being in HF patients with diabetes
      mellitus (DM) (10.45+/-5.76 ng/mL, n = 40). We also found that there was a higher
      percentage of Sema4D(high) CD3(+) (P<0.01), CD4(+) (P<0.001), and CD8(+) (P<0.01)
      T-cells in samples from HF patients, but no changes in Sema4D expression levels
      in B cells and platelets. Therefore, our investigation shows that plasma Sema4D
      levels are increased in HF patients, especially in those who also have diabetes. 
      There was an accompanying increase in the Sema4D(high) population of T-cells,
      suggesting a potential role of these T-cells in heart failure.
AD  - Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu, China.
FAU - Lu, Qiongyu
AU  - Lu Q
FAU - Dong, Ningzheng
AU  - Dong N
FAU - Wang, Qi
AU  - Wang Q
FAU - Yi, Wenxiu
AU  - Yi W
FAU - Wang, Yuxin
AU  - Wang Y
FAU - Zhang, Shengjie
AU  - Zhang S
FAU - Gu, Haibo
AU  - Gu H
FAU - Zhao, Xin
AU  - Zhao X
FAU - Tang, Xiaorong
AU  - Tang X
FAU - Jin, Boquan
AU  - Jin B
FAU - Wu, Qingyu
AU  - Wu Q
FAU - Brass, Lawrence F
AU  - Brass LF
FAU - Zhu, Li
AU  - Zhu L
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669357
OID - NLM: PMC3669357
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/08 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0064265 [doi]
AID - PONE-D-13-06222 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e64265. doi: 10.1371/journal.pone.0064265. Print 2013.

PMID- 23741292
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Insulin receptor substrate 2 is required for testicular development.
PG  - e62103
LID - 10.1371/journal.pone.0062103 [doi]
AB  - Insulin receptor substrate (IRS) proteins are key mediators of insulin and
      insulin-like growth factor (IGF) signalling. In mice, deletion of Irs1 is
      associated with profound growth retardation and increased longevity whereas
      Irs2-deficiency causes diabetes and female infertility. Clinical studies suggest 
      that diabetes and obesity diminish male fertility. However, the role of IRS
      proteins in male reproduction is unknown. We observed that testis weight is
      reduced by 45% in Irs2-deficient mice as compared with control males. The weight 
      of these organs in Irs1 (-/-) males was similar to controls; however, since
      Irs1-deficient mice are 50% smaller, testis weight:body weight was increased in
      this model. Neonatal Irs2 (-/-) mice also exhibited reduced testicular size,
      suggesting that impairments in this model occur during development. Histological 
      examination of testicular cross sections from Irs2 (-/-) mice revealed normal
      cellular associations without obvious abnormalities in the seminiferous
      epithelium. Reduced testicular weight was associated with fewer Sertoli cells,
      spermatogonia, spermatocytes, elongated spermatids, and epididymal spermatozoa.
      However, Leydig cell number and the concentration of serum testosterone were
      equivalent between Irs2-deficient and control males. Testicular weight was
      reduced similarly in non-diabetic and diabetic Irs2 (-/-) mice, indicating that
      hyperglycemia does not compound the effects of Irs2 deletion on impaired testis
      development. Expression of Irs1, Irs3, and Irs4 was comparable between
      experimental groups. Collectively, our results demonstrate that IRS2 plays a
      critical role in testicular development, potentially by mediating IGF1 signalling
      during embryonic and early postnatal development.
AD  - Centro de Investigacion Principe Felipe, Valencia, Spain.
FAU - Griffeth, Richard J
AU  - Griffeth RJ
FAU - Carretero, Jose
AU  - Carretero J
FAU - Burks, Deborah J
AU  - Burks DJ
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3669358
OID - NLM: PMC3669358
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/29 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/05/31 [epublish]
AID - 10.1371/journal.pone.0062103 [doi]
AID - PONE-D-12-37841 [pii]
PST - epublish
SO  - PLoS One. 2013 May 31;8(5):e62103. doi: 10.1371/journal.pone.0062103. Print 2013.

PMID- 23741228
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130606
DCOM- 20130607
LR  - 20130610
IS  - 1664-5464 (Electronic)
IS  - 1664-5464 (Linking)
VI  - 3
IP  - 1
DP  - 2013 Jan
TI  - Lack of Genetic Associations of PPAR-gamma and PGC-1alpha with Alzheimer's
      Disease and Parkinson's Disease with Dementia.
PG  - 161-7
LID - 10.1159/000351419 [doi]
AB  - BACKGROUND AND AIMS: Similar clinical and pathological features have been
      observed in Alzheimer's disease (AD) and Parkinson's disease with dementia (PDD).
      Both the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and
      the peroxisome proliferator-activated receptor-gamma coactivator-1alpha
      (PGC-1alpha) gene are candidates modifying the risk for both diseases. The aim of
      this study was to clarify whether common single nucleotide polymorphisms (SNPs)
      of the PPAR-gamma gene and the PGC-1alpha gene affect the onset of AD and PDD
      genetically. METHODS: Four exonic SNPs of both genes (rs1801282 and rs3856806 of 
      the PPAR-gamma gene, rs3736265 and rs8192678 of the PGC-1alpha gene) were
      genotyped in 171 AD patients, 136 age-matched controls and 53 PDD patients.
      Haplotype analysis and logistic regression analysis with apolipoprotein E (APO E)
      status were performed for AD. RESULTS: There was no statistical difference
      between AD cases and controls for the 4 SNPs, nor was there any statistical
      difference between PDD cases and controls for the 4 SNPs. We could not find any
      synergetic associations between these SNPs, APO E4 and AD. CONCLUSIONS: The 4
      SNPs studied here did not influence the risk for AD in a Japanese population. As 
      the number of PDD cases was small, comprehensive genetic studies considering
      diabetes would be needed.
AD  - Departments of Psychiatry, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Shibata, Nobuto
AU  - Shibata N
FAU - Motoi, Yumiko
AU  - Motoi Y
FAU - Tomiyama, Hiroyuki
AU  - Tomiyama H
FAU - Ohnuma, Tohru
AU  - Ohnuma T
FAU - Kuerban, Bolati
AU  - Kuerban B
FAU - Tomson, Katrin
AU  - Tomson K
FAU - Komatsu, Miwa
AU  - Komatsu M
FAU - Shimazaki, Hiromi
AU  - Shimazaki H
FAU - Hattori, Nobutaka
AU  - Hattori N
FAU - Arai, Heii
AU  - Arai H
LA  - eng
PT  - Journal Article
DEP - 20130518
PL  - Switzerland
TA  - Dement Geriatr Cogn Dis Extra
JT  - Dementia and geriatric cognitive disorders extra
JID - 101564825
PMC - PMC3670632
OID - NLM: PMC3670632
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Apolipoprotein E
OT  - Dementia
OT  - PGC-1α
OT  - PPAR-γ
OT  - Parkinson's disease
OT  - Polymorphism
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:01
CRDT- 2013/06/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/18 [epublish]
AID - 10.1159/000351419 [doi]
AID - dee-0003-0161 [pii]
PST - epublish
SO  - Dement Geriatr Cogn Dis Extra. 2013 May 18;3(1):161-7. doi: 10.1159/000351419.
      Print 2013 Jan.

PMID- 23741090
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130606
DCOM- 20130607
LR  - 20130610
IS  - 0970-2113 (Print)
IS  - 0970-2113 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Apr
TI  - Pulmonary function tests in type 2 diabetes mellitus and their association with
      glycemic control and duration of the disease.
PG  - 108-12
LID - 10.4103/0970-2113.110417 [doi]
AB  - BACKGROUND: Pulmonary complications of diabetes mellitus (DM) have been poorly
      characterized. Some authors have reported normal pulmonary functions and even
      concluded that spirometry is not at all necessary in diabetic patients. Some
      studies have shown abnormal respiratory parameters in patients of DM. Moreover,
      the duration of DM and glycemic control have varied impact on the pulmonary
      functions. AIMS AND OBJECTIVES: The study was undertaken to analyze the pulmonary
      function parameters in diabetic patients and compare them with age and gender
      matched healthy subjects. We correlated forced vital capacity (FVC) and forced
      expiratory volume in 1 second (FEV1) in diabetic patients with duration of the
      disease and glycosylated hemoglobin (HbA1c). MATERIALS AND METHODS: Pulmonary
      function tests (PFTs) were recorded in 60 type 2 diabetic male patients and 60
      normal healthy male controls aged 40-60 years by using Helios 702 spirometer. The
      PFTs recorded were - FVC, FEV1, FEV1/FVC, FEF25, FEF50, FEF75, FEF25-75,
      FEF0.2-1.2, and peak expiratory flow rate (PEFR). HbA1c of all the patients was
      estimated by ion exchange resin method, which is a very standard method of
      estimation. PFTs of diabetic patients and controls were compared by applying
      Student's unpaired t test. Associations between FVC and FEV1 and HbA1c and
      duration of illness in diabetic patients were analyzed by applying Pearson's
      coefficient. RESULTS: The PFTs were significantly decreased in diabetic patients 
      compared with the healthy controls except FEV1/FVC. There was no correlation
      found between FVC and FEV1 and duration of illness as well as HbA1c. CONCLUSION: 
      DM being a systemic disease, which also affects lungs causing restrictive type of
      ventilatory changes probably because of glycosylation of connective tissues,
      reduced pulmonary elastic recoil and inflammatory changes in lungs. We found
      glycemic levels and duration of disease are probably not the major determinants
      of lung pathology, which requires further research.
AD  - Department of Physiology, B. J. Medical College and Sassoon General Hospitals,
      Pune, Maharashtra, India.
FAU - Shah, Swati H
AU  - Shah SH
FAU - Sonawane, Pranali
AU  - Sonawane P
FAU - Nahar, Pradeep
AU  - Nahar P
FAU - Vaidya, Savita
AU  - Vaidya S
FAU - Salvi, Sundeep
AU  - Salvi S
LA  - eng
PT  - Journal Article
PL  - India
TA  - Lung India
JT  - Lung India : official organ of Indian Chest Society
JID - 8405380
PMC - PMC3669549
OID - NLM: PMC3669549
OTO - NOTNLM
OT  - Diabetes
OT  - glycemic control
OT  - pulmonary function
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:01
CRDT- 2013/06/07 06:00
AID - 10.4103/0970-2113.110417 [doi]
AID - LI-30-108 [pii]
PST - ppublish
SO  - Lung India. 2013 Apr;30(2):108-12. doi: 10.4103/0970-2113.110417.

PMID- 23740968
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0022-2275 (Electronic)
IS  - 0022-2275 (Linking)
DP  - 2013 Jun 5
TI  - Distinct populations of adipogenic and myogenic Myf5-lineage progenitors in white
      adipose tissues.
AB  - Brown adipose tissues (BAT) are derived from a Myf5-expressing cell lineage and
      white adipose tissues (WAT) predominantly arise from non-Myf5 lineages, though a 
      subpopulation of adipocytes in some WAT depots can be derived from the
      Myf5-lineage. However, the functional implication of the Myf5 and non-Myf5
      lineage cells in WAT is unclear. We found that the Myf5-lineage constitution in
      subcutaneous WAT depots is negatively correlated to the expression of classical
      BAT and newly defined beige/brite adipocyte-specific genes. Consistently,
      FACS-purified Myf5-lineage adipo-progenitors give rise to adipocytes expressing
      lower levels of BAT-specific Ucp1, Prdm16, Cidea and Ppargc1a genes and beige
      adipocyte-specific CD137, Tmem26 and Tbx1 genes compared to the non-Myf5-lineage 
      adipocytes from the same depots. Ablation of the Myf5-lineage progenitors in WAT 
      stromal vascular cell cultures leads to increased expression of BAT and beige
      cell signature genes. Strikingly, the Myf5-lineage cells in WAT are heterogeneous
      and contain distinct adipogenic (Sca1+) and myogenic (Sca1-) progenitors. The
      latter differentiate robustly into myofibers in vitro and in vivo, and restore
      dystrophin expression after transplantation into mdx mouse, a model for Duchenne 
      muscular dystrophy. These results demonstrate the heterogeneity and functional
      differences of the Myf5- and non-Myf5-lineage cells in the white adipose tissue.
AD  - Purdue University, United States.
FAU - Shan, Tizhong
AU  - Shan T
FAU - Liang, Xinrong
AU  - Liang X
FAU - Bi, Pengpeng
AU  - Bi P
FAU - Zhang, Pengpeng
AU  - Zhang P
FAU - Liu, Weiyi
AU  - Liu W
FAU - Kuang, Shihuan
AU  - Kuang S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Lipid Res
JT  - Journal of lipid research
JID - 0376606
OTO - NOTNLM
OT  - Adipocytes
OT  - Adipose tissue
OT  - Diabetes
OT  - Fluorescence microscopy
OT  - Lineage
OT  - Muscle
OT  - Myf5
OT  - Progenitor
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - jlr.M038711 [pii]
AID - 10.1194/jlr.M038711 [doi]
PST - aheadofprint
SO  - J Lipid Res. 2013 Jun 5.

PMID- 23740954
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
DP  - 2013 Jun 5
TI  - Intrinsic Molecular Factors Cause Aberrant Expansion of the Splenic Marginal Zone
      B Cell Population in Nonobese Diabetic Mice.
AB  - Marginal zone (MZ) B cells are an innate-like population that oscillates between 
      MZ and follicular areas of the splenic white pulp. Differentiation of B cells
      into the MZ subset is governed by BCR signal strength and specificity, NF-kappaB 
      activation through the B cell-activating factor belonging to the TNF family
      (BAFF) receptor, Notch2 signaling, and migration signals mediated by chemokine,
      integrin, and sphingosine-1-phosphate receptors. An imbalance in splenic B cell
      development resulting in expansion of the MZ subset has been associated with
      autoimmune pathogenesis in various murine models. One example is the NOD inbred
      mouse strain, in which MZ B cell expansion has been linked to development of type
      1 diabetes and Sjogren's syndrome. However, the cause of MZ B cell expansion in
      this strain remains poorly understood. We have determined that increased MZ B
      cell development in NOD mice is independent of T cell autoimmunity, BCR
      specificity, BCR signal strength, and increased exposure to BAFF. Rather, mixed
      bone marrow chimeras showed that the factor(s) responsible for expansion of the
      NOD MZ subset is B cell intrinsic. Analysis of microarray expression data
      indicated that NOD MZ and precursor transitional 2-MZ subsets were particularly
      dysregulated for genes controlling cellular trafficking, including Apoe, Ccbp2,
      Cxcr7, Lgals1, Pla2g7, Rgs13, S1pr3, Spn, Bid, Cd55, Prf1, and Tlr3. Furthermore,
      these B cell subsets exhibited an increased steady state dwell time within
      splenic MZ areas. Our data therefore reveal that precursors of mature B cells in 
      NOD mice exhibit an altered migration set point, allowing increased occupation of
      the MZ, a niche favoring MZ B cell differentiation.
AD  - Garvan Institute of Medical Research, Immunology Program, Darlinghurst, New South
      Wales 2010, Australia.
FAU - Stolp, Jessica
AU  - Stolp J
FAU - Marino, Eliana
AU  - Marino E
FAU - Batten, Marcel
AU  - Batten M
FAU - Sierro, Frederic
AU  - Sierro F
FAU - Cox, Selwyn L
AU  - Cox SL
FAU - Grey, Shane T
AU  - Grey ST
FAU - Silveira, Pablo A
AU  - Silveira PA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - jimmunol.1203252 [pii]
AID - 10.4049/jimmunol.1203252 [doi]
PST - aheadofprint
SO  - J Immunol. 2013 Jun 5.

PMID- 23740952
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
DP  - 2013 Jun 5
TI  - Synergistic Expression of the CXCL10 Gene in Response to IL-1beta and IFN-gamma
      Involves NF-kappaB, Phosphorylation of STAT1 at Tyr701, and Acetylation of
      Histones H3 and H4.
AB  - The CXCL10 gene encodes a peptide that chemoattracts a variety of leukocytes
      associated with type 1 and type 2 diabetes. The present study was undertaken to
      determine the molecular mechanisms required for expression of the CXCL10 gene in 
      response to IL-1beta and IFN-gamma using rat islets and beta cell lines. IL-1beta
      induced the expression of the CXCL10 gene and promoter activity, whereas the
      combination of IL-1beta plus IFN-gamma was synergistic. Small interfering
      RNA-mediated suppression of NF-kappaB p65 markedly inhibited the ability of
      cytokines to induce the expression of the CXCL10 gene, whereas targeting STAT1
      only diminished the synergy provided by IFN-gamma. Furthermore, we found that a
      JAK1 inhibitor dose dependently reduced IFN-gamma-controlled CXCL10 gene
      expression and promoter activity, concomitant with a decrease in STAT1
      phosphorylation at Tyr701. We further discovered that, although the Tyr701
      phosphorylation site is inducible (within 15 min of IFN-gamma exposure), the
      Ser727 site within STAT1 is constitutively phosphorylated. Thus, we generated
      single-mutant STAT1 Y701F and double-mutant STAT1 Y701F/S727A adenoviruses. Using
      these recombinant adenoviruses, we determined that overexpression of either the
      single- or double-mutant STAT1 decreased the IFN-gamma-mediated potentiation of
      CXCL10 gene expression, promoter activity, and secretion of protein. Moreover,
      the Ser727 phosphorylation was neither contingent on a functional Y701 site in
      beta cells nor was it required for cytokine-mediated expression of the CXCL10
      gene. We conclude that the synergism of IL-1beta and IFN-gamma to induce
      expression of the CXCL10 gene requires NF-kappaB, STAT1 phosphorylated at Tyr701,
      recruitment of coactivators, and acetylation of histones H3 and H4.
AD  - Department of Nutrition, University of Tennessee, Knoxville, TN 37996;
FAU - Burke, Susan J
AU  - Burke SJ
FAU - Goff, Matthew R
AU  - Goff MR
FAU - Lu, Danhong
AU  - Lu D
FAU - Proud, David
AU  - Proud D
FAU - Karlstad, Michael D
AU  - Karlstad MD
FAU - Collier, J Jason
AU  - Collier JJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - jimmunol.1300344 [pii]
AID - 10.4049/jimmunol.1300344 [doi]
PST - aheadofprint
SO  - J Immunol. 2013 Jun 5.

PMID- 23740949
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
DP  - 2013 Jun 5
TI  - Dendritic Cell-Dependent In Vivo Generation of Autoregulatory T Cells by
      Antidiabetogenic MHC Class II.
AB  - Several mechanisms have been proposed to explain how certain MHC class II
      molecules afford dominant resistance to autoimmune diseases like type 1 diabetes 
      (T1D). However, it remains unclear how protective MHC types can blunt
      autoreactive T cell responses directed against a diverse repertoire of
      autoantigenic epitopes presented by disease-promoting MHCs. In this study, we
      show that expression of I-E on dendritic cells (DCs) of NOD mice promotes the
      differentiation of MHC promiscuous autoreactive CD4+ clonotypes into
      antidiabetogenic autoregulatory T cells. We expressed an I-EalphakloxP transgene 
      in NOD mice and used cell type-specific I-E ablation to show that I-E-expressing 
      DCs, but not B cells, promote the generation of autoreactive CD4+Foxp3+
      regulatory T cells (Tregs) and their accumulation in the pancreas-draining lymph 
      nodes. There, these Tregs suppress the presentation of beta cell Ags to naive
      autoreactive CD4+ and CD8+ T cells restricted by diabetogenic MHC molecules in an
      I-E-independent manner. Whereas selective removal of I-E on DCs abrogated
      autoregulatory Treg formation and T1D protection, selective removal of I-E on B
      cells was inconsequential. These results explain how certain MHC class II
      molecules can completely suppress antigenically complex autoimmune responses in
      an Ag-nonspecific manner.
AD  - Department of Microbiology, Immunology and Infectious Diseases and Julia
      McFarlane Diabetes Research Centre, Snyder Institute for Chronic Diseases,
      Faculty of Medicine, University of Calgary, Calgary, Alberta T2N 4N1, Canada;
FAU - Tsai, Sue
AU  - Tsai S
FAU - Serra, Pau
AU  - Serra P
FAU - Clemente-Casares, Xavier
AU  - Clemente-Casares X
FAU - Slattery, Robyn M
AU  - Slattery RM
FAU - Santamaria, Pere
AU  - Santamaria P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - jimmunol.1300168 [pii]
AID - 10.4049/jimmunol.1300168 [doi]
PST - aheadofprint
SO  - J Immunol. 2013 Jun 5.

PMID- 23740857
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
DP  - 2013 Jun 6
TI  - Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?
LID - 10.1002/jcph.113 [doi]
AB  - Iron plays a crucial role in a number of metabolic pathways including oxygen
      transport, DNA synthesis, and ATP generation. Although insufficient systemic iron
      can result in physical impairment, excess iron has also been implicated in a
      number of diseases including ischemic heart disease, diabetes, and cancer. Iron
      chelators are agents which bind iron and facilitate its excretion. Experimental
      iron chelators have demonstrated potent anti-neoplastic properties in a number of
      cancers in vitro. These agents have yet to be translated into clinical practice, 
      however, largely due to the significant side effects encountered in pre-clinical 
      models. A number of licenced chelators, however, are currently in clinical use
      for the treatment of iron overload associated with certain non-neoplastic
      diseases. Deferasirox is one such agent and the drug has shown significant
      anti-tumor effects in a number of in vitro and in vivo studies. Deferasirox is
      orally administered and has demonstrated a good side effect profile in clinical
      practice to date. It represents an attractive agent to take forward into clinical
      trials of iron chelators as anti-cancer agents.
CI  - (c) The Author(s) 2013.
AD  - School of Cancer Studies, Department of Medical and Dental Sciences, University
      of Birmingham, Birmingham, United Kingdom.
FAU - Bedford, Matthew R
AU  - Bedford MR
FAU - Ford, Samuel J
AU  - Ford SJ
FAU - Horniblow, Richard D
AU  - Horniblow RD
FAU - Iqbal, Tariq H
AU  - Iqbal TH
FAU - Tselepis, Chris
AU  - Tselepis C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/02/06 [received]
PHST- 2013/05/08 [accepted]
AID - 10.1002/jcph.113 [doi]
PST - aheadofprint
SO  - J Clin Pharmacol. 2013 Jun 6. doi: 10.1002/jcph.113.

PMID- 23740806
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1097-0223 (Electronic)
IS  - 0197-3851 (Linking)
DP  - 2013 Jun 5
TI  - Placental three-dimensional power Doppler indices in mid and late pregnancy
      complicated by gestational diabetes mellitus.
LID - 10.1002/pd.4172 [doi]
AB  - OBJECTIVES: The aim of our study was to evaluate placental three-dimensional
      power Doppler indices in diabetic pregnancies in the second and third trimester
      and to compare them with those of the normal controls. METHODS: Placental
      vascularisation of pregnant women were determined by three-dimensional power
      Doppler ultrasound technique. The calculated indices included vascularisation
      index, flow index and vascularisation flow index. Uncomplicated pregnancies (n = 
      113) were compared to pregnancies complicated by gestational diabetes mellitus (n
      = 56) and diabetes mellitus (n = 43). RESULTS: The three-dimensional power
      Doppler indices were not significantly different between the two diabetic
      subgroups. All the indices in diabetic patients were significantly reduced
      compared to those in non-diabetic individuals (p < 0.001). Placental
      three-dimensional power Doppler indices are slightly diminished throughout
      diabetic pregnancy (regression coefficients: -0.23 (FI), -0,06 (VI) and -0.04
      (VFI) and normal pregnancy (regression coefficients: -0.13 (FI), -0,20 (VI) and
      -0.11 (VFI). The uteroplacental circulation (umbilical and uterine artery) was
      not correlated significantly to the three-dimensional power Doppler indices. If
      all placental indices are low during late pregnancy, then the odds of the
      diabetes is significantly high (adjusted odds ratio: 1.10). CONCLUSIONS: A
      decreased placental vascularisation could be an adjunct sonographic marker in the
      diagnosis of diabetic pregnancy in mid and late gestation This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Obstetrics and Gynecology, University of Szeged, Szeged, Hungary.
FAU - Suranyi, A
AU  - Suranyi A
FAU - Kozinszky, Z
AU  - Kozinszky Z
FAU - Molnar, A
AU  - Molnar A
FAU - Nyari, T
AU  - Nyari T
FAU - Bito, T
AU  - Bito T
FAU - Pal, A
AU  - Pal A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Prenat Diagn
JT  - Prenatal diagnosis
JID - 8106540
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/03/25 [received]
PHST- 2013/05/23 [revised]
PHST- 2013/05/31 [accepted]
AID - 10.1002/pd.4172 [doi]
PST - aheadofprint
SO  - Prenat Diagn. 2013 Jun 5. doi: 10.1002/pd.4172.

PMID- 23740766
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 6
DP  - 2013 Jun 6
TI  - Foam dressings for healing diabetic foot ulcers.
PG  - CD009111
AB  - BACKGROUND: Foot ulcers in people with diabetes are a prevalent and serious
      global health issue. Dressings form a key part of ulcer treatment, with
      clinicians and patients having many different types to choose from. A clear and
      current overview of current evidence is required to facilitate decision-making
      regarding dressing use. OBJECTIVES: The review aimed to evaluate the effects of
      foam wound dressings on the healing of foot ulcers in people with diabetes.
      SEARCH METHODS: For this first update we searched the following databases the
      Cochrane Wounds Group Specialised Register; The Cochrane Central Register of
      Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE
      (In-Process & Other Non-Indexed Citations); Ovid EMBASE; and EBSCO CINAHL in
      April 2013. There were no restrictions based on language or date of publication. 
      SELECTION CRITERIA: Published or unpublished randomised controlled trials (RCTs) 
      that evaluated the effects on ulcer healing of one or more foam wound dressings
      in the treatment of foot ulcers in people with diabetes. DATA COLLECTION AND
      ANALYSIS: Two review authors independently performed study selection, risk of
      bias assessment and data extraction. MAIN RESULTS: We included six studies (157
      participants) in this review. Meta analysis of two studies indicated that foam
      dressings do not promote the healing of diabetic foot ulcers compared with basic 
      wound contact dressings (RR 2.03, 95%CI 0.91 to 4.55). Pooled data from two
      studies comparing foam and alginate dressing found no statistically significant
      difference in ulcer healing (RR 1.50, 95% CI 0.92 to 2.44). There was no
      statistically significant difference in the number of diabetic foot ulcers healed
      when foam dressings were compared with hydrocolloid (matrix) dressings. All
      included studies were small and/or had limited follow-up times. AUTHORS'
      CONCLUSIONS: Currently there is no research evidence to suggest that foam wound
      dressings are more effective in healing foot ulcers in people with diabetes than 
      other types of dressing however all trials in this field are very small. Decision
      makers may wish to consider aspects such as dressing cost and the wound
      management properties offered by each dressing type e.g. exudate management.
AD  - Department of Nursing, Midwifery and Social Work, University of Manchester,
      Manchester, UK, M13 9PL.
FAU - Dumville, Jo C
AU  - Dumville JC
FAU - Deshpande, Sohan
AU  - Deshpande S
FAU - O'Meara, Susan
AU  - O'Meara S
FAU - Speak, Katharine
AU  - Speak K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.1002/14651858.CD009111.pub3 [doi]
PST - aheadofprint
SO  - Cochrane Database Syst Rev. 2013 Jun 6;6:CD009111.

PMID- 23740755
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1552-4957 (Electronic)
IS  - 1552-4949 (Linking)
DP  - 2013 Jun 5
TI  - Personalized cytomic assessment of vascular health: Evaluation of the vascular
      health profile in diabetes mellitus.
PG  - 0
LID - 10.1002/cyto.b.21095 [doi]
AB  - BACKGROUND: An inexpensive and accurate blood test does not currently exist that 
      can evaluate the cardiovascular health of a patient. This study evaluated a novel
      high dimensional flow cytometry approach in combination with cytometric
      fingerprinting (CF), to comprehensively enumerate differentially expressed
      subsets of pro-angiogenic circulating progenitor cells (CPCs), involved in the
      repair of vasculature, and microparticles (MPs), frequently involved in
      inflammation and thrombosis. CF enabled discovery of a unique pattern, involving 
      both MPs and CPCs and generated a personalized signature of vascular health, the 
      vascular health profile (VHP). METHODS: Levels of CPCs and MPs were measured with
      a broad panel of cell surface markers in a population with atherosclerosis and
      type 2 diabetes mellitus (DM) and age-similar Healthy controls (HC) using an
      unbiased computational approach, termed CF. RESULTS: Circulating hematopoietic
      stem and progenitor cell (CHSPCAng ) levels were detected at significantly lower 
      concentrations in DM (P < 0.001), whereas levels of seven phenotypically distinct
      MPs were present at significantly higher concentrations in DM patients and one MP
      subset was present at significantly lower concentration in DM patients.
      Collectively, the combination of CHSPCAng and MP levels was more informative than
      any one measure alone. CONCLUSIONS: This work provides the basis for a
      personalized cytomic vascular health profile that may be useful for a variety of 
      applications including drug development, clinical risk assessment and companion
      diagnostics. (c) 2013 International Clinical Cytometry Society.
CI  - Copyright (c) 2013 International Clinical Cytometry Society.
AD  - Department of Pathology, Perelman School of Medicine at the University of
      Pennsylvania, Philadelphia, Pennsylvania.
FAU - Kurtzman, Nicholas
AU  - Kurtzman N
FAU - Zhang, Lifeng
AU  - Zhang L
FAU - French, Benjamin
AU  - French B
FAU - Jonas, Rebecca
AU  - Jonas R
FAU - Bantly, Andrew
AU  - Bantly A
FAU - Rogers, Wade T
AU  - Rogers WT
FAU - Moore, Jonni S
AU  - Moore JS
FAU - Rickels, Michael R
AU  - Rickels MR
FAU - Mohler, Emile R 3rd
AU  - Mohler ER 3rd
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Cytometry B Clin Cytom
JT  - Cytometry. Part B, Clinical cytometry
JID - 101235690
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/10/18 [received]
PHST- 2013/01/29 [revised]
PHST- 2013/03/26 [accepted]
AID - 10.1002/cyto.b.21095 [doi]
PST - aheadofprint
SO  - Cytometry B Clin Cytom. 2013 Jun 5:0. doi: 10.1002/cyto.b.21095.

PMID- 23740684
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0792-6855 (Print)
IS  - 0792-6855 (Linking)
DP  - 2013 May 30
TI  - Inhibition of key enzymes linked to type 2 diabetes and sodium
      nitroprusside-induced lipid peroxidation in rat pancreas by water-extractable
      phytochemicals from unripe pawpaw fruit (Carica papaya).
PG  - 1-14
LID - 10.1515/jbcpp-2013-0002 [doi]
LID - /j/jbcpp.ahead-of-print/jbcpp-2013-0002/jbcpp-2013-0002.xml [pii]
AB  - Abstract Background: Various parts of unripe pawpaw (Carica papaya Linn) fruit
      have been reportedly used for the management or treatment of diabetes mellitus in
      folklore medicine. Therefore, the present study sought to investigate the
      inhibitory effects of the aqueous extract of different parts of unripe pawpaw
      fruit on key enzymes linked to type 2 diabetes (alpha-amylase and
      alpha-glucosidase) and sodium nitroprusside (SNP)-induced lipid peroxidation in
      rat pancreas in vitro. Methods: The aqueous extracts of the unripe pawpaw (C.
      papaya) fruit parts were prepared (1:20 w/v) and the ability of the extracts to
      inhibit alpha-amylase, alpha-glucosidase and SNP-induced lipid peroxidation in
      rat pancreas in vitro was investigated. Results: The results revealed that all
      the extracts inhibited alpha-amylase (IC50=0.87-1.11 mg/mL), alpha-glucosidase
      (IC50=1.76-2.64 mg/mL) and SNP-induced lipid peroxidation (IC50=1.99-2.42 mg/mL) 
      in a dose-dependent manner. However, combination of the flesh, seed and peel in
      equal amounts had the highest inhibitory effect on alpha-amylase and
      alpha-glucosidase activities. Conclusions: Strong inhibitory activities of the
      unripe pawpaw fruit against key enzymes linked to type 2 diabetes and SNP-induced
      lipid peroxidation in rat pancreas could be part of the mechanism by which unripe
      pawpaw is used in the management/prevention of diabetes mellitus in folk
      medicine. However, combining the unripe pawpaw fruit parts in equal amounts
      exhibited synergistic properties on alpha-amylase and alpha-glucosidase
      inhibitory activities.
FAU - Oboh, Ganiyu
AU  - Oboh G
FAU - Olabiyi, Ayodeji A
AU  - Olabiyi AA
FAU - Akinyemi, Ayodele J
AU  - Akinyemi AJ
FAU - Ademiluyi, Adedayo O
AU  - Ademiluyi AO
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Basic Clin Physiol Pharmacol
JT  - Journal of basic and clinical physiology and pharmacology
JID - 9101750
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/01/08 [received]
PHST- 2013/04/12 [accepted]
AID - 10.1515/jbcpp-2013-0002 [doi]
AID - /j/jbcpp.ahead-of-print/jbcpp-2013-0002/jbcpp-2013-0002.xml [pii]
PST - aheadofprint
SO  - J Basic Clin Physiol Pharmacol. 2013 May 30:1-14. doi: 10.1515/jbcpp-2013-0002.

PMID- 23740676
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 30
TI  - Observational study of diabetes management in type 1 diabetic school-age children
      during holiday versus school days.
PG  - 1-4
LID - 10.1515/jpem-2013-0045 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0045/jpem-2013-0045.xml [pii]
AB  - Abstract Background: Type 1 diabetes (T1D) management requires year-round
      adherence to treatment regimen. Holidays may present a challenge towards
      achieving good metabolic control. Objectives: Our aim was to investigate the
      effect of holidays on diabetes management of schoolchildren with T1D. Methods:
      Observational, case-crossover study of 45 schoolchildren, age range 7-19 years,
      mean 13.2+/-3.4 years, followed in a pediatric diabetes clinic. Subjects were
      stratified by age [<12 years (n=21), >12 years (n=24)] and treatment modality
      [insulin pump (n=29) or multiple daily injections (n=16)]. Data were downloaded
      from glucometers and insulin pumps during five non-weekend holidays and five
      subsequent school days. Results: The mean number of blood glucose (BG) readings
      was significantly lower (4.4+/-1.9 vs. 4.8+/-1.9, p<0.01) and mean BG marginally 
      higher (11.4+/-2.7 vs. 10.7+/-3.1 mmol/L, p=0.1) during holidays than during
      school days in the entire cohort. Children were significantly more adherent to
      diabetes management than adolescents as expressed by lower mean glycated
      hemoglobin level (7.7+/-0.8% vs. 8.6+/-1.4%, p<0.05), more BG readings per day
      (p<0.001) and lower mean BG on holidays (p<0.05) and on schooldays (p<0.01). In
      pump users, no difference in the mean number of boluses per day and mean insulin 
      units per kilogram per day was observed between holidays and school days.
      Conclusions: The management of school-aged children with T1D during holidays was 
      worse than during school days; these finding were more pronounced in adolescents.
      The diabetes team should be aware of suboptimal therapy during holidays and
      should consider intervention programs in attempts to educate patients
      accordingly.
FAU - Landau, Zohar
AU  - Landau Z
FAU - Lebenthal, Yael
AU  - Lebenthal Y
FAU - Boaz, Mona
AU  - Boaz M
FAU - Pinhas-Hamiel, Orit
AU  - Pinhas-Hamiel O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/02/02 [received]
PHST- 2013/05/06 [accepted]
AID - 10.1515/jpem-2013-0045 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0045/jpem-2013-0045.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 30:1-4. doi: 10.1515/jpem-2013-0045.

PMID- 23740619
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
DP  - 2013 Jun 6
TI  - Short-term weight loss patterns, baseline predictors, and longer-term follow-up
      within a randomized controlled trial.
LID - 10.1002/oby.20510 [doi]
AB  - OBJECTIVE: To examine weight loss patterns and predictors among participants in a
      primary care-based translation study of the Diabetes Prevention Program lifestyle
      intervention. DESIGN AND METHODS: Cluster analysis identified short-term
      (12-week) weight loss patterns among 72 intervention participants. Analysis of
      variance assessed cluster differences in weight loss maintenance at 15-month
      follow-up. Discriminant analysis identified baseline characteristics that best
      differentiated between clusters. RESULTS: Participants had baseline mean (SD) age
      of 55.0 (10.8) years and BMI of 31.9 (5.2) kg/m2 . Cluster analysis identified
      three short-term weight loss patterns: modest (n=15; 21%), moderate-and-steady
      (n=43; 60%), and substantial-and-early (n=14; 19%). Only participants with the
      latter two patterns achieved clinically significant (>/= 5%) short-term weight
      loss and maintained it at 15 months. On discriminant analysis, the modest cluster
      was most differentiated from other clusters by high friend encouragement for
      dietary change, high obesity-related problems, and low physical well-being. The
      moderate-and-steady cluster was differentiated by lower physical activity, family
      encouragement, and depression symptoms. CONCLUSION: Results provide insight into 
      the heterogeneity of response to an effective lifestyle intervention by
      identifying short-term weight loss patterns and their baseline predictors and
      relationship to 15-month success. If replicated, results may help tailor
      strategies for participant subgroups in weight loss programs.
CI  - Copyright (c) 2013 The Obesity Society.
AD  - Department of Medicine, Stanford University School of Medicine; Department of
      Health Services Research, Palo Alto Medical Foundation Research Institute.
FAU - Yank, Veronica
AU  - Yank V
FAU - Xiao, Lan
AU  - Xiao L
FAU - Wilson, Sandra R
AU  - Wilson SR
FAU - Stafford, Randall S
AU  - Stafford RS
FAU - Rosas, Lisa Goldman
AU  - Rosas LG
FAU - Ma, Jun
AU  - Ma J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/05/06 [accepted]
AID - 10.1002/oby.20510 [doi]
PST - aheadofprint
SO  - Obesity (Silver Spring). 2013 Jun 6. doi: 10.1002/oby.20510.

PMID- 23740603
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Linking)
DP  - 2013 Jun 5
TI  - Endothelin-1 induced endoplasmic reticulum stress in disease.
AB  - The accumulation of unfolded proteins in the endoplasmic reticulum (ER)
      represents a cellular stress induced by multiple stimuli and pathological
      conditions. Recent evidence implicates Endothelin (ET)-1 in the induction of
      placental ER stress in pregnancy disorders. ER stress has previously also been
      implicated in various other disease states, including neurodegenerative
      disorders, diabetes and cardiovascular diseases, as has ET-1 in the
      pathophysiology of these conditions. However, till date, there has been no
      investigation on the link between ET-1 and the induction of ER stress in these
      disease states. Based on recent evidence and mechanistic insight on the role of
      ET-1 in the induction of placental ER stress, the following review attempts to
      outline the broader implications of ET-1 induced ER stress, as well as strategies
      for therapeutic intervention based around ET-1.
AD  - TransCure Institute, Switzerland.
FAU - Jain, Arjun
AU  - Jain A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
OTO - NOTNLM
OT  - cardiovascular disease
OT  - diabetes
OT  - endoplasmic reticulum
OT  - endothelins
OT  - neurodegeneration
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - jpet.113.205567 [pii]
AID - 10.1124/jpet.113.205567 [doi]
PST - aheadofprint
SO  - J Pharmacol Exp Ther. 2013 Jun 5.

PMID- 23740599
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1720-8319 (Electronic)
IS  - 1594-0667 (Linking)
DP  - 2013 Jun 4
TI  - Prevalence of cardiovascular disorders and risk factors in two 75-year-old birth 
      cohorts examined in 1976-1977 and 2005-2006.
AB  - BACKGROUND AND AIMS: The number of older people are increasing worldwide, and
      cardiovascular diseases are the major causes of death in western societies. This 
      study examines birth cohort differences in cardiovascular disorders and risk
      factors in Swedish elderly. METHODS: Representative samples of 75-year-olds
      living in Gothenburg, Sweden, examined in 1976-1977 and in 2005-2006. Blood
      pressure, s-cholesterol, s-triglycerides, height, body weight, body mass index,
      history of myocardial infarction, angina pectoris and stroke/TIA, and diabetes
      mellitus were measured. RESULTS: The prevalence of total cardiovascular
      disorders, hypertension and hypercholesterolemia decreased, and the prevalence of
      stroke increased in both genders. The prevalence of cardiovascular disorders was 
      higher in women than in men in 1976-1977, and higher in men than in women in
      2005-2006. The decrease in blood pressure occurred independently of
      antihypertensive treatment. The prevalence of current smokers decreased in men
      and increased in women. The prevalence of life-time smokers and diabetes mellitus
      increased only in women. The proportion on antihypertensive treatment and
      overweight and obesity increased only in men. Hypertension, overweight and
      obesity were more common in women in 1976-1977. These sex differences were not
      observed in 2005-2006. CONCLUSIONS: The overall prevalence of cardiovascular
      disorders decreased, and sex differences reversed between the 1970s and 2000s
      among Swedish septuagenarians. Our findings emphasize the importance of
      environmental factors, not only for the prevalence of cardiovascular disorders,
      but also as explanations for sex differences. Reasons for changes could be
      increased survival in those with disorders and risk factors, changes in lifestyle
      and diet, and better preventive strategies, such as treatment of
      hypercholesterolemia and hypertension.
AD  - Neuropsychiatric Epidemiology Unit, Neuropsykiatri SU/Molndal, Department of
      Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology,
      Sahlgrenska Academy at the University of Gothenburg, Wallinsgatan 6, Molndal, 431
      41, Gothenburg, Sweden, zhixinyue@tijmu.edu.cn.
FAU - Zhi, Xinyue
AU  - Zhi X
FAU - Joas, Erik
AU  - Joas E
FAU - Waern, Margda
AU  - Waern M
FAU - Ostling, Svante
AU  - Ostling S
FAU - Borjesson-Hanson, Anne
AU  - Borjesson-Hanson A
FAU - Skoog, Ingmar
AU  - Skoog I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Aging Clin Exp Res
JT  - Aging clinical and experimental research
JID - 101132995
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/10/27 [received]
PHST- 2013/03/05 [accepted]
PHST- 2013/06/04 [aheadofprint]
AID - 10.1007/s40520-013-0058-1 [doi]
PST - aheadofprint
SO  - Aging Clin Exp Res. 2013 Jun 4.

PMID- 23740526
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 143
DP  - 2013
TI  - Impact of diabetes on platelet activation in different manifestations of
      atherosclerosis.
PG  - 0
LID - 10.4414/smw.2013.13800 [doi]
LID - Swiss Med Wkly. 2013;143:w13800 [pii]
AB  - BACKGROUND: Atherosclerosis affects many patients with type 2 diabetes. Both are 
      associated with platelet activation, but it remains unclear how diabetes
      contributes to, or even enhances, platelet activation in patients with
      atherosclerosis. We therefore investigated the impact of diabetes on platelet
      activation and protease activated receptor-1 (PAR-1) mediated platelet response
      in patients with symptomatic coronary artery disease (CAD), as compared with
      other manifestations of atherosclerosis. METHODS: Baseline P-selectin expression,
      thrombin receptor activating peptide-6 (TRAP-6) inducible P-selectin, and
      relative increase of platelet P-selectin after activation with TRAP-6 were
      measured using flow cytometry in platelets from 317 patients after angioplasty
      and stenting for symptomatic atherosclerotic disease, and from 50 healthy
      controls. RESULTS: Patients with symptomatic atherosclerosis exhibited
      significantly higher levels of baseline P-selectin expression, TRAP-6-inducible
      P-selectin and relative increase of platelet P-selectin after stimulation with
      TRAP-6 than healthy controls. Patients with symptomatic peripheral artery disease
      or cerebrovascular disease (PAD/CVD) had higher levels of platelet activation and
      PAR-1-mediated platelet reactivity than patients with symptomatic CAD. Of
      interest, CAD patients with diabetes responded more strongly to TRAP-6 than those
      without diabetes, and their platelet activation and PAR-1-mediated platelet
      reactivity resembled those from PAD/CVD patients. CONCLUSION: Compared with
      healthy controls, platelets from patients with symptomatic atherosclerotic
      disease are activated and susceptible to PAR-1-mediated activation. Diabetes
      affects platelet reactivity only in patients with symptomatic CAD, while other
      manifestations of atherosclerosis may have an overwhelming effect on platelet
      reactivity that is not further enhanced by diabetes.
AD  - Department of Internal Medicine II Medical University of Vienna, AUSTRIA;
      thomas.gremmel@meduniwien.ac.at.
FAU - Gremmel, T
AU  - Gremmel T
FAU - Kopp, C W
AU  - Kopp CW
FAU - Seidinger, D
AU  - Seidinger D
FAU - Koppensteiner, R
AU  - Koppensteiner R
FAU - Steiner, S
AU  - Steiner S
FAU - Panzer, S
AU  - Panzer S
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.4414/smw.2013.13800 [doi]
AID - smw-13800 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2013 May 28;143:0. doi: 10.4414/smw.2013.13800.

PMID- 23740459
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 10
DP  - 2013 May
TI  - Vernal keratoconjunctivitis: atopy and autoimmunity.
PG  - 1419-23
LID - 4296 [pii]
AB  - BACKGROUND: Vernal Keratoconjunctivitis (VKC) is a rare chronic ocular
      inflammatory disease and it mainly affects boys in the first decade of life.
      Although it is a self-limiting disease, patients may present many phases
      characterized by an exacerbation of inflammatory symptoms with a consequent
      decline of the quality of life. PURPOSE: define the clinical and immunological
      profile of patients affected by VKC and investigate their familiar history of
      autoimmune disorders and their autoimmunity pattern. PATIENTS AND METHODS: 28
      children were enrolled (20 males, 71%) aged between 4 and 14 years of life
      affected by VKC. Family history of allergic and immunological diseases was
      collected for each patient. In particular, it was asked whether some components
      of their families were affected by Hashimoto's thyroiditis, type I diabetes,
      psoriasis or rheumatoid arthritis and Systemic Lupus Erythematosus (SLE). All VKC
      children underwent a serological evaluation of anti-nuclear antibodies (ANA).
      RESULTS: A family history of immunological disorders was found in 46% of
      patients, 28% of Hashimoto's thyroiditis, 14% of type I diabetes, 14% of
      psoriasis, and 1 of Systemic Lupus Erythematosus. Furthermore, 35% of patients
      was ANA positive and they corresponded to patients with a higher ocular score and
      with the most important clinical symptoms. CONCLUSIONS: the detection of ANA
      positivity and of a familiar history of autoimmune disorders in a high percentage
      of children with VKC may help us to better understand the association of this
      ocular inflammatory disease with systemic autoimmune disorders and atopic
      condition.
AD  - Department of Pediatrics, and Department of Sense Organs, Sapienza University of 
      Rome, Rome, Italy. marcella.nebbioso@uniroma1.it.
FAU - Zicari, A M
AU  - Zicari AM
FAU - Nebbioso, M
AU  - Nebbioso M
FAU - Lollobrigida, V
AU  - Lollobrigida V
FAU - Bardanzellu, F
AU  - Bardanzellu F
FAU - Celani, C
AU  - Celani C
FAU - Occasi, F
AU  - Occasi F
FAU - Cesoni Marcelli, A
AU  - Cesoni Marcelli A
FAU - Duse, M
AU  - Duse M
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 May;17(10):1419-23.

PMID- 23740412
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0012-6667 (Electronic)
IS  - 0012-6667 (Linking)
DP  - 2013 Jun 6
TI  - Metreleptin: First Global Approval.
AB  - Metreleptin is an analogue of the human hormone leptin being developed by Amylin 
      Pharmaceuticals (a subsidiary of Bristol-Myers Squibb) for the subcutaneous
      treatment of metabolic disorders including lipodystrophy. The compound is
      expected to improve insulin sensitivity, hypertriglyceridaemia and hyperglycaemia
      in patients with lipodystrophy who are unresponsive to conventional treatment.
      Metreleptin has been approved in Japan as a leptin therapy for the treatment of
      lipodystrophy. Amylin has also completed a submission for regulatory approval to 
      the US FDA for metreleptin in the treatment of diabetes mellitus and/or
      hypertriglyceridaemia in patients with rare forms of lipodystrophy. Clinical
      development of the drug is also underway in the USA for the treatment of type 1
      diabetes. Amgen was previously assessing the use of metreleptin as a treatment
      for amenorrhoea; however, it appears that development in this indication has been
      discontinued. This article summarizes the milestones in the development of
      metreleptin leading to this first approval for lipodystrophy.
AD  - Adis R & D Insight, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North
      Shore, 0754, Auckland, New Zealand, dru@adis.com.
FAU - Chou, Ken
AU  - Chou K
FAU - Perry, Caroline M
AU  - Perry CM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Drugs
JT  - Drugs
JID - 7600076
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.1007/s40265-013-0074-7 [doi]
PST - aheadofprint
SO  - Drugs. 2013 Jun 6.

PMID- 23740405
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 143
DP  - 2013
TI  - Erratum regarding article "The diagnostic value of measuring pressure pain
      perception in patients with diabetes mellitus", Swiss Med Wkly. 2012;142:w13682.
PG  - 0
LID - 10.4414/smw.2013.13798 [doi]
LID - Swiss Med Wkly. 2013;143:w13798 [pii]
AD  - Diabetic foot clinic, Heinrich Heine University of DA(1/4)sseldorf, Germany;
      tobi.w@gmx.de.
FAU - Wienemann, T
AU  - Wienemann T
FAU - Chantelau, E
AU  - Chantelau E
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.4414/smw.2013.13798 [doi]
AID - smw-13798 [pii]
PST - epublish
SO  - Swiss Med Wkly. 2013 Apr 18;143:0. doi: 10.4414/smw.2013.13798.

PMID- 23740366
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1433-3023 (Electronic)
IS  - 0937-3462 (Linking)
DP  - 2013 Jun 6
TI  - Assessment of urinary incontinence in the women in Eastern Turkey.
AB  - INTRODUCTION AND HYPOTHESIS: The aims of the present study were to determine the 
      types of UI among women visiting the urology department, to identify the
      potential risk factors associated with each type of UI, and to identify
      healthcare-seeking behaviors of affected women in our region. METHODS: The data
      of 617 community-dwelling women, who were at least 18 years of age or older and
      who presented with a complaint of UI ongoing over a year, and those without UI,
      who were admitted for any other reason, from June 2010 to April 2012, were
      evaluated. RESULTS: Mean age was 51.29 years (range 18-110 years); median parity 
      was 3.54 (range 0-11) and 88.2 % of the women were married. Mean BMI was 28.01
      kg/m2. Very few women (18.5 %) accepted UI as a disease and searched for medical 
      help by themselves; however, the remaining women (81.5 %) were brought or
      directed for evaluation by someone else. Stress UI was reported by 43 women (10.5
      %), urge UI and mixed UI were noted by 153 (37.5 %) and 212 (52 %) women
      respectively. CONCLUSIONS: The most frequent type of UI was mixed UI in our
      region. Age, BMI, multiparity, and hypertension were identified to have a
      different importance for each type of UI, but diabetes mellitus, birth trauma,
      gynecological surgery, lumbar disc hernia (LDH), and multiple sclerosis (MS) were
      the other important related factors. However, a small number of patients accepted
      UI as a disease and searched for therapy. This reveals that the public should be 
      informed in detail about female UI in developing countries.
AD  - Department of Urology, Medical Faculty, Inonu University, 44280, Malatya, Turkey,
      ramazan.altintas@inonu.edu.tr.
FAU - Altintas, Ramazan
AU  - Altintas R
FAU - Beytur, Ali
AU  - Beytur A
FAU - Oguz, Fatih
AU  - Oguz F
FAU - Tasdemir, Cemal
AU  - Tasdemir C
FAU - Kati, Bulent
AU  - Kati B
FAU - Cimen, Serhan
AU  - Cimen S
FAU - Colak, Cemil
AU  - Colak C
FAU - Gunes, Ali
AU  - Gunes A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Int Urogynecol J
JT  - International urogynecology journal
JID - 101567041
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/02/13 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 10.1007/s00192-013-2137-4 [doi]
PST - aheadofprint
SO  - Int Urogynecol J. 2013 Jun 6.

PMID- 23740329
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 15
IP  - 7
DP  - 2013 Jul
TI  - C-Peptide and its career from innocent bystander to active player in diabetic
      atherogenesis.
PG  - 339
LID - 10.1007/s11883-013-0339-3 [doi]
AB  - The incidence and prevalence of diabetes are increasing worldwide. According to
      the International Diabetes Federation, more than 55 million people in the
      European region have diabetes, and this number is expected to rise to 64 million 
      in 2030, with most of the cases being due to type 2 diabetes. Diabetes is
      associated with potentially serious microvascular and macrovascular complications
      such as nephropathy, neuropathy, and retinopathy as well as coronary artery
      disease. The pathophysiological mechanism behind this phenomenon is complex. In
      recent years the impact of proinsulin C-peptide in the development of vascular
      disease has been highlighted, but it displays differential function in type 1 and
      type 2 diabetes. In type 1 diabetes, which is characterized by a lack of insulin 
      and C-peptide, supplementation of C-peptide has been shown to improve
      microvascular complications. In type 2 diabetes, however, C-peptide levels are
      increased above normal levels and correlate with the occurrence of macrovascular 
      complications and cardiovascular deaths. This review focuses on the impact of
      C-peptide in the atherogenic process.
AD  - Department of Internal Medicine I, University Hospital Aachen, Pauwelsstrasse 30,
      52074, Aachen, Germany.
FAU - Lebherz, Corinna
AU  - Lebherz C
FAU - Marx, Nikolaus
AU  - Marx N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.1007/s11883-013-0339-3 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2013 Jul;15(7):339. doi: 10.1007/s11883-013-0339-3.

PMID- 23740195
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Jun 6
TI  - Setting the record straight on TIDE: a lost opportunity for patients with
      diabetes.
AB  - Much has been written regarding the recently discontinued Thiazolidinedione
      Intervention with Vitamin D Evaluation (TIDE) trial (ClinicalTrials.gov
      NCT00879970; Diabetologia 55: 36-45) and a variety of opinions have been advanced
      regarding its purpose, context and design (N Engl J Med 397: 959-964). As such,
      we deemed it appropriate to clarify TIDE's objectives, research questions and
      design and the clinical equipoise regarding its research questions.
AD  - Population Health Research Institute, McMaster University, 1280 Main Street West,
      HSC 3V51, Hamilton, ON, Canada, L8S 4K1, zubin.punthakee@mcmaster.ca.
FAU - Punthakee, Zubin
AU  - Punthakee Z
FAU - Bosch, Jackie
AU  - Bosch J
FAU - Gerstein, Hertzel C
AU  - Gerstein HC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/04/10 [received]
PHST- 2013/05/16 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 10.1007/s00125-013-2959-0 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Jun 6.

PMID- 23740194
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Jun 6
TI  - Effects of triple antioxidant therapy on measures of cardiovascular autonomic
      neuropathy and on myocardial blood flow in type 1 diabetes: a randomised
      controlled trial.
AB  - AIMS/HYPOTHESIS: We evaluated the effects of a combination triple antioxidant
      therapy on measures of cardiovascular autonomic neuropathy (CAN) and myocardial
      blood flow (MBF) in patients with type 1 diabetes. METHODS: This was a
      randomised, parallel, placebo-controlled trial. Participants were allocated to
      interventions by sequentially numbered, opaque, sealed envelopes provided to the 
      research pharmacist. All participants and examiners were masked to treatment
      allocation. Participants were evaluated by cardiovascular autonomic reflex
      testing, positron emission tomography with [11C]meta-hydroxyephedrine ([11C]HED) 
      and [13N]ammonia, and adenosine stress testing. Markers of oxidative stress
      included 24 h urinary F2-isoprostanes. Diabetic peripheral neuropathy (DPN) was
      evaluated by symptoms, signs, electrophysiology and intra-epidermal nerve fibre
      density. Randomised participants included 44 eligible adults with type 1 diabetes
      and mild-to-moderate CAN, who were aged 46 +/- 11 years and had HbA1c 58 +/- 5
      mmol/mol (7.5 +/- 1.0%), with no evidence of ischaemic heart disease.
      Participants underwent a 24-month intervention, consisting of antioxidant
      treatment with allopurinol, alpha-lipoic acid and nicotinamide, or placebo. The
      main outcome was change in the global [11C]HED retention index (RI) at 24 months 
      in participants on the active drug compared with those on placebo. RESULTS: We
      analysed data from 44 participants (22 per group). After adjusting for age, sex
      and in-trial HbA1c, the antioxidant regimen was associated with a slight, but
      significant worsening of the global [11C]HED left ventricle RI (-0.010 [95% CI
      -0.020, -0.001] p = 0.045) compared with placebo. There were no significant
      differences at follow-up between antioxidant treatment and placebo in the global 
      MBF, coronary flow reserve, or in measures of DPN and markers of oxidative
      stress. The majority of adverse events were of mild-to-moderate severity and did 
      not differ between groups CONCLUSIONS/INTERPRETATION: In this cohort of type 1
      diabetes patients with mild-to-moderate CAN, a combination antioxidant treatment 
      regimen did not prevent progression of CAN, had no beneficial effects on
      myocardial perfusion or DPN, and may have been detrimental. However, a larger
      study is necessary to assess the underlying causes of these findings. TRIAL
      REGISTRATION: ClinicalTrials.gov NCT00116207 FUNDING: The study was funded by the
      JDRF Centre for the Study of Complications in Diabetes; and by grants P60DK020572
      and P30DK092926 to the Michigan Diabetes Research and Training Centre (MDRTC) and
      the Michigan Center for Diabetes Translational Research (MCDTR) from the National
      Institute of Diabetes and Digestive and Kidney Diseases.
AD  - Department of Internal Medicine, Division of Metabolism, Endocrinology and
      Diabetes, University of Michigan, 5329 Brehm Tower, 1000 Wall Street, Ann Arbor, 
      MI, 48109, USA, rpbusui@umich.edu.
FAU - Pop-Busui, R
AU  - Pop-Busui R
FAU - Stevens, M J
AU  - Stevens MJ
FAU - Raffel, D M
AU  - Raffel DM
FAU - White, E A
AU  - White EA
FAU - Mehta, M
AU  - Mehta M
FAU - Plunkett, C D
AU  - Plunkett CD
FAU - Brown, M B
AU  - Brown MB
FAU - Feldman, E L
AU  - Feldman EL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/03/13 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 10.1007/s00125-013-2942-9 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Jun 6.

PMID- 23740164
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 Jun 6
TI  - Preliminary evidence that obese patients with obstructive sleep apnea/hypopnea
      syndrome are refractory to the acute beneficial metabolic effects of a very low
      calorie diet.
AB  - Since obesity seems to play a causal role in both obstructive sleep
      apnea/hypopnea syndrome (OSAHS) and type 2 diabetes, the question arises whether 
      diet-induced weight loss is equally efficacious in type 2 diabetic patients with 
      and without OSAHS. The present study was aimed to investigate the effect of 1
      week very low calorie diet (VLCD) on oxygen desaturation index (ODI) and on
      glucose regulation in OSAHS versus non-OSAHS patients. Fourteen patients with
      type 2 diabetes mellitus and morbid obesity were enrolled. According to ODI,
      patients were divided into 2 groups (with and without OSAHS) and evaluated by a
      hyperglycemic clamp study, before and after a 7 day-VLCD. After a VLCD, a
      significant reduction of anthropometric parameters, in the overall group and in
      subgroups, was observed. M-value and acute insulin response increased
      significantly only in patients without obstructive sleep apnea (990.10 +/- 170.19
      vs. 1,205.22 +/- 145.73 mumol min-1 m-2, p = 0.046; -1.05 +/- 8.40 vs. 48.26 +/- 
      11. 90 pmol/L, p = 0.028, respectively). The average 24-h heart rate (24-h HR)
      fell significantly (p = 0.05), primarily because of a decrease during daytime (p 
      = 0.041), in the whole group. In conclusion, we observed that morbidly obese
      patients with type 2 diabetes and OSAHS are specifically resistant to the acute
      beneficial effects of VLCD on metabolic parameters. Our preliminary observation
      deserves further investigation to clarify the pathogenetic mechanisms involved.
AD  - Department of Medicina dei Sistemi, University of Rome Tor Vergata, Rome, Italy.
FAU - Giordani, Ilaria
AU  - Giordani I
FAU - Malandrucco, Ilaria
AU  - Malandrucco I
FAU - Picconi, Fabiana
AU  - Picconi F
FAU - Longo, Susanna
AU  - Longo S
FAU - Di Flaviani, Alessandra
AU  - Di Flaviani A
FAU - Chioma, Laura
AU  - Chioma L
FAU - Moscatelli, Barbara
AU  - Moscatelli B
FAU - Donno, Silvia
AU  - Donno S
FAU - Frontoni, Simona
AU  - Frontoni S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/04/22 [received]
PHST- 2013/05/27 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 10.1007/s00592-013-0487-5 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 Jun 6.

PMID- 23740153
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 Jun 7
TI  - Obstructive Sleep Apnea Is Associated with Fatty Liver and Abnormal Liver
      Enzymes: a Meta-analysis.
AB  - BACKGROUND: Obstructive sleep apnea (OSA) is associated with the cluster of
      clinical conditions that comprise the metabolic syndrome, including nonalcoholic 
      fatty liver disease (NAFLD). Our primary purpose was to estimate the effect of
      OSA on serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
      Our secondary purpose was to investigate the potential influence of OSA on
      histological severity of NAFLD to explore whether chronic intermittent hypoxia is
      associated with inflammation and fibrosis. METHODS: Our literature search
      identified 11 studies, from which we extracted information about numbers of
      control subjects and OSA patients, and ALT, AST, and NAFLD. RESULTS: From a total
      of 668 OSA patients and 404 controls, we found that the standardized difference
      in mean values of ALT and AST levels in patients with OSA was significantly
      different from that in the controls. Meta-regression showed that the association 
      was independent of body mass index and type 2 diabetes. Fatty liver was
      associated with OSA in five studies with 400 subjects. OSA was significantly
      associated with liver fibrosis in 208 subjects, but not with lobular
      inflammation. CONCLUSIONS: Routine assessment of liver enzymes and liver damage
      should be implemented in OSA patients because they have an increase of 13.3 % of 
      ALT and 4.4 % of AST levels, and a 2.6-fold higher risk of liver fibrosis when
      they have NAFLD, which is 2.6 times more frequent in OSA patients.
AD  - Department of Clinical and Molecular Hepatology, Institute of Medical Research A 
      Lanari-IDIM, University of Buenos Aires-National Council of Scientific and
      Technological Research (CONICET), Ciudad Autonoma de Buenos Aires, Argentina,
      sookoian.silvia@lanari.fmed.uba.ar.
FAU - Sookoian, Silvia
AU  - Sookoian S
FAU - Pirola, Carlos J
AU  - Pirola CJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.1007/s11695-013-0981-4 [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 Jun 7.

PMID- 23739939
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1678-9741 (Electronic)
IS  - 0102-7638 (Linking)
VI  - 28
IP  - 1
DP  - 2013 Mar
TI  - Religion, spirituality and cardiovascular disease: research, clinical
      implications, and opportunities in Brazil.
PG  - 103-28
LID - 10.5935/1678-9741.20130015 [doi]
LID - S0102-76382013000100015 [pii]
AB  - In this paper we comprehensively review published quantitative research on the
      relationship between religion, spirituality (R/S), and cardiovascular (CV)
      disease, discuss mechanisms that help explain the associations reported, examine 
      the clinical implications of those findings, and explore future research needed
      in Brazil on this topic. First, we define the terms religion, spirituality, and
      secular humanism. Next, we review research examining the relationships between
      R/S and CV risk factors (smoking, alcohol/drug use, physical inactivity, poor
      diet, cholesterol, obesity, diabetes, blood pressure, and psychosocial stress).
      We then review research on R/S, cardiovascular functions (CV reactivity, heart
      rate variability, etc.), and inflammatory markers (IL-6, IFN-gamma, CRP,
      fibrinogen, IL-4, IL-10). Next we examine research on R/S and coronary artery
      disease, hypertension, stroke, dementia, cardiac surgery outcomes, and mortality 
      (CV mortality in particular). We then discuss mechanisms that help explain these 
      relationships (focusing on psychological, social, and behavioral pathways) and
      present a theoretical causal model based on a Western religious perspective. Next
      we discuss the clinical applications of the research, and make practical
      suggestions on how cardiologists and cardiac surgeons can sensitively and
      sensibly address spiritual issues in clinical practice. Finally, we explore
      opportunities for future research. No research on R/S and cardiovascular disease 
      has yet been published from Brazil, despite the tremendous interest and
      involvement of the population in R/S, making this an area of almost unlimited
      possibilities for researchers in Brazil.
FAU - Lucchese, Fernando A
AU  - Lucchese FA
FAU - Koenig, Harold G
AU  - Koenig HG
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Rev Bras Cir Cardiovasc
JT  - Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade
      Brasileira de Cirurgia Cardiovascular
JID - 9104279
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/12/05 [received]
PHST- 2013/02/12 [accepted]
AID - S0102-76382013000100015 [pii]
AID - 10.5935/1678-9741.20130015 [doi]
PST - ppublish
SO  - Rev Bras Cir Cardiovasc. 2013 Mar;28(1):103-28. doi: 10.5935/1678-9741.20130015.

PMID- 23739911
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1720-8319 (Electronic)
IS  - 1594-0667 (Linking)
VI  - 25
IP  - 2
DP  - 2013 May
TI  - Percutaneous transluminal angioplasty for critical limb ischemia in very elderly 
      diabetic patients.
PG  - 225-8
LID - 10.1007/s40520-013-0033-x [doi]
AB  - In diabetic subjects, new less invasive therapies for critical limb ischemia
      (CLI) are available to obtain limb salvage. One of these is the percutaneous
      transluminal angioplasty (PTA), a minor surgical intervention which allows
      obtaining an effective revascularization, avoiding the traditional major surgery 
      and its post-operative complications. Our case report regards a 94-year-old woman
      with CLI due to critical obstruction (stage IV according to Leriche's
      classification) of superficial femoral and popliteal arteries and infrapopliteal 
      arteries that should have been treated by the left limb amputation considering
      her age, severe co-morbidities, and poor compliance. Instead of this quite common
      approach, our team treated the patient with PTA. This led to very good outcomes, 
      above all in terms of pain control. PTA is able to avoid major surgery, lower
      intra and post-operative risks, reduce length of hospital stay, and preserve
      functional autonomy. Therefore, this procedure should be taken into account also 
      for frail very elderly diabetic patients with peripheral artery disease (PAD).
AD  - Internal medicine, diabetes, endocrine-metabolic diseases and cardiovascular
      prevention Unit and the Centre for Applied Clinical Research (Ce.R.C.A.),
      Clinical Institute "Beato Matteo", Corso Pavia 84, 27029, Vigevano, Italy,
      c.gazzaruso@gmail.com.
FAU - Gazzaruso, Carmine
AU  - Gazzaruso C
FAU - Coppola, Adriana
AU  - Coppola A
FAU - Collaviti, Silvia
AU  - Collaviti S
FAU - Saluzzo, Cesare Massa
AU  - Saluzzo CM
FAU - Furlani, Federica
AU  - Furlani F
FAU - Gallotti, Pietro
AU  - Gallotti P
FAU - Clerissi, Jacques
AU  - Clerissi J
FAU - Solerte, Bruno Sebastiano
AU  - Solerte BS
FAU - Giustina, Andrea
AU  - Giustina A
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Italy
TA  - Aging Clin Exp Res
JT  - Aging clinical and experimental research
JID - 101132995
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/03/06 [received]
PHST- 2012/08/21 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s40520-013-0033-x [doi]
PST - ppublish
SO  - Aging Clin Exp Res. 2013 May;25(2):225-8. doi: 10.1007/s40520-013-0033-x. Epub
      2013 Apr 18.

PMID- 23739800
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1573-0832 (Electronic)
IS  - 0301-486X (Linking)
DP  - 2013 Jun 6
TI  - Characterization of Edenia gomezpompae Isolated from a Patient with Keratitis.
AB  - Edenia gomezpompae, isolated from a patient suffering from keratitis, who was an 
      agricultural worker with a 4-year history of diabetes mellitus, is described.
      Fungal hyphae were detected in corneal scrapings after microscopic examination
      and repeated culture. Isolates were identified by morphology and by sequencing
      the internal transcribed spacer region of ribosomal DNA. Chlamydospore
      characteristics of E. gomezpompae are described for the first time. The in vitro 
      antifungal susceptibilities of the isolate were tested using five antifungal
      agents. With the exception of fluconazole, the other drugs (natamycin,
      amphotericin B, itraconazole, and voriconazole) assayed were highly effective
      against this fungus. The keratitis was cured after debridement of the corneal
      ulcer and treatment with 5 % natamycin. After 3 months, when the patient was
      reexamined, the corneal ulcer showed signs of healing, with no recurrence. To our
      knowledge, this is the first reported case of keratitis caused by E. gomezpompae,
      as well as being the first known case of disease in humans caused by this
      species.
AD  - Department of Pathogenobiology, Jilin University Mycology Research Center, Norman
      Bethune College of Medicine, Jilin University, Changchun, 130021, China.
FAU - Cui, Yan
AU  - Cui Y
FAU - Jia, Hui
AU  - Jia H
FAU - He, Dan
AU  - He D
FAU - Yu, Huimei
AU  - Yu H
FAU - Gao, Song
AU  - Gao S
FAU - Yokoyama, Koji
AU  - Yokoyama K
FAU - Li, Jing
AU  - Li J
FAU - Wang, Li
AU  - Wang L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Mycopathologia
JT  - Mycopathologia
JID - 7505689
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/02/22 [received]
PHST- 2013/05/27 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 10.1007/s11046-013-9667-7 [doi]
PST - aheadofprint
SO  - Mycopathologia. 2013 Jun 6.

PMID- 23739758
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1945-1997 (Electronic)
IS  - 0098-6151 (Linking)
VI  - 113
IP  - 6
DP  - 2013 Jun
TI  - Osteopathic Manual Treatment in Patients With Diabetes Mellitus and Comorbid
      Chronic Low Back Pain: Subgroup Results From the OSTEOPATHIC Trial.
PG  - 468-78
AB  - CONTEXT: Chronic pain is often present in patients with diabetes mellitus.
      OBJECTIVE: To assess the effects of osteopathic manual treatment (OMT) in
      patients with diabetes mellitus and comorbid chronic low back pain (LBP). Design:
      Randomized, double-blind, sham-controlled, 2x2 factorial trial, including OMT and
      ultrasound therapy (UST) interventions. SETTING: University-based study in
      Dallas-Fort Worth, Texas. PATIENTS: A subgroup of 34 patients (7%) with diabetes 
      mellitus within 455 adult patients with nonspecific chronic LBP enrolled in the
      OSTEOPAThic Health outcomes In Chronic low back pain (OSTEOPATHIC) Trial. Main
      Study Measures: The Outpatient Osteopathic SOAP Note Form was used to measure
      somatic dysfunction at baseline. A 100-mm visual analog scale was used to measure
      LBP severity over 12 weeks from randomization to study exit. Paired serum
      concentrations of tumor-necrosis factor (TNF)-alpha obtained at baseline and
      study exit were available for 6 subgroup patients. RESULTS: Key osteopathic
      lesions were observed in 27 patients (79%) with diabetes mellitus vs 243 patients
      (58%) without diabetes mellitus (P=.01). The reduction in LBP severity over 12
      weeks was significantly greater in 19 patients with diabetes mellitus who
      received OMT than in 15 patients with diabetes mellitus who received sham OMT
      (mean between-group difference in changes in the visual analog scale pain score, 
      -17 mm; 95% confidence interval [CI], -32 mm to -1 mm; P=.04). This difference
      was clinically relevant (Cohen d=0.7). A corresponding significantly greater
      reduction in TNF-alpha serum concentration was noted in patients with diabetes
      mellitus who received OMT, compared with those who received sham OMT (mean
      between-group difference, -6.6 pg/mL; 95% CI, -12.4 to -0.8 pg/mL; P=.03). This
      reduction was also clinically relevant (Cohen d=2.7). No significant changes in
      LBP severity or TNF-alpha serum concentration were associated with UST during the
      12-week period. CONCLUSION: Severe somatic dysfunction was present significantly 
      more often in patients with diabetes mellitus than in patients without diabetes
      mellitus. Patients with diabetes mellitus who received OMT had significant
      reductions in LBP severity during the 12-week period. Decreased circulating
      levels of TNF-alpha may represent a possible mechanism for OMT effects in
      patients with diabetes mellitus. A larger clinical trial of patients with
      diabetes mellitus and comorbid chronic LBP is warranted to more definitively
      assess the efficacy and mechanisms of action of OMT in this population.
AD  - The Osteopathic Research Center, University of North Texas Health Science Center 
      Texas College of Osteopathic Medicine, 3500 Camp Bowie Blvd, Fort Worth, TX
      76107-2644. john.licciardone@unthsc.edu.
FAU - Licciardone, John C
AU  - Licciardone JC
FAU - Kearns, Cathleen M
AU  - Kearns CM
FAU - Hodge, Lisa M
AU  - Hodge LM
FAU - Minotti, Dennis E
AU  - Minotti DE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 113/6/468 [pii]
PST - ppublish
SO  - J Am Osteopath Assoc. 2013 Jun;113(6):468-78.

PMID- 23739717
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1806-4841 (Electronic)
IS  - 0365-0596 (Linking)
VI  - 88
IP  - 2
DP  - 2013 Apr
TI  - OralCandida sppcarriers: its prevalence in patients with type 2Diabetes Mellitus.
LID - 10.1590/S0365-05962013000200006 [doi]
LID - S0365-05962013000200222 [pii]
AB  - BACKGROUND: Prevalence of oral candidiasis in diabetic patients is 13.7-64%.
      Candida albicans was the most frequently isolated species (75-86.5%). OBJECTIVE: 
      To obtain the prevalence of Candida carriers among patients with type 2 diabetes 
      mellitus to identify the species of the yeast. Study design: It is an open,
      observational, descriptive, cross-sectional, and prospective study. METHODS: We
      included voluntary patients from the National Diabetes Marathon and performed a
      blood glucose measurement, sialometry test, Gram-stained exfoliative cytology,
      and culture on Sabouraud dextrose agar and CHROMagar Candida TM. Results were
      analyzed using descriptive statistics. RESULTS: We examined 141 patients (mean
      age 57 years): 103 women (73%) and 38 men (26.9%). Exfoliative cytology was
      positive in 32 cases (23 with oral lesions); 78 had oral lesions but no Candida
      (93.9%). Candida was isolated in 58 patients (41.1%), 21 (45.6 %) had blood
      glucose greater than 126 mg/dl, and 37 (38.9%) had less than 126 mg/dl. The most 
      frequent species was C. albicans (82.7%). Forty-two Candida carriers had salivary
      flow greater than 20 mm (72.4%), and 16 (27.5%) had hyposalivation. Candida was
      isolated in 25 of 79 patients with dental prosthesis (31.6%), 9 of 15 were
      smokers (60%), and 22 of 71 had symptoms (30.9%). CONCLUSIONS: Prevalence of oral
      Candida carriers in patients with type 2 diabetes mellitus in Mexico was similar 
      to that found in other countries; exfoliative cytology was effective in finding
      Candida; salivary flow rate, use of prosthesis, and presence of oral lesions and 
      symptoms were similar in oral Candida carriers and negative patients. Most
      smokers were Candida carriers.
AD  - Mycology Section, Hospital General Dr. Manuel Gea Gonzalez, Delegacion Tlalpan,, 
      Mexico.
FAU - Martinez, Ramon Felipe Fernandez
AU  - Martinez RF
FAU - Jaimes-Aveldanez, Alejandra
AU  - Jaimes-Aveldanez A
FAU - Hernandez-Perez, Francisco
AU  - Hernandez-Perez F
FAU - Arenas, Roberto
AU  - Arenas R
FAU - Miguel, Guadalupe Fabian-San
AU  - Miguel GF
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - An Bras Dermatol
JT  - Anais brasileiros de dermatologia
JID - 0067662
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/05/31 [received]
PHST- 2012/07/23 [accepted]
AID - S0365-05962013000200222 [pii]
AID - 10.1590/S0365-05962013000200006 [doi]
PST - ppublish
SO  - An Bras Dermatol. 2013 Apr;88(2). pii: S0365-05962013000200222. doi:
      10.1590/S0365-05962013000200006.

PMID- 23739668
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1488-2353 (Electronic)
IS  - 0147-958X (Linking)
VI  - 36
IP  - 3
DP  - 2013
TI  - Association of pericardial adipose tissue volume with presence and severity of
      coronary atherosclerosis.
PG  - E143
AB  - Purpose: This study was to investigate whether high pericardial adipose tissue
      (PAT) volume is related to the presence and severity of coronary artery disease
      (CAD). Methods: Consecutive patients (310 patients) who underwent both
      dual-source 64-slice CT and percutaneous coronary angiography were recruited into
      this study. Waist circumference (WC), body mass index (BMI), blood biochemical
      variables, coronary artery calcium (CAC) score and Gensini score were measured.
      Pericardial adipose tissue (PAT) volume was determined by dual-source CT.
      Results: PAT volume was positively correlated with BMI, WC, gender (male),
      hypertension, diabetes, age, total cholesterol and low-density
      lipoprotein-cholesterol. PAT volume in CAD patients was significantly higher than
      that in patients without CAD (238.36 +/- 81.21 cm3 vs. 200.13+/-72.34 cm3). PAT
      volumes in patients with multi-vessel lesions were significantly higher than
      those with one-vessel lesions (P < 0.001). A significant correlation between PAT 
      volume and CAC score (r=0.305, P < 0.001) was found. PAT volume was an
      independent factor affecting Gensini score. Conclusion: PAT volume was
      significantly correlated with traditional cardiovascular risk factors, the
      severity of coronary atherosclerosis and the number of stenotic coronary vessels.
      Thus, PAT volume may be a reliable marker to evaluate the presence and severity
      of CAD.
AD  - . wang455342@sina.com.
FAU - Wang, Jing
AU  - Wang J
FAU - Wang, Li-Jun
AU  - Wang LJ
FAU - Peng, Yong-Ping
AU  - Peng YP
FAU - Zhang, Long-Jiang
AU  - Zhang LJ
FAU - Jiang, Shi-Sen
AU  - Jiang SS
FAU - Gong, Jian-Bin
AU  - Gong JB
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - Canada
TA  - Clin Invest Med
JT  - Clinical and investigative medicine. Medecine clinique et experimentale
JID - 7804071
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/06/05 [received]
PST - epublish
SO  - Clin Invest Med. 2013 Jun 1;36(3):E143.

PMID- 23739629
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1473-6519 (Electronic)
IS  - 1363-1950 (Linking)
VI  - 16
IP  - 4
DP  - 2013 Jul
TI  - Monitoring states of altered carbohydrate metabolism via breath analysis: are
      times ripe for transition from potential to reality?
PG  - 466-72
LID - 10.1097/MCO.0b013e328361f91f [doi]
AB  - PURPOSE OF REVIEW: To introduce the potential of breath analysis as a diagnostic 
      or monitoring tool in diabetes. RECENT FINDINGS: Blood testing for plasma glucose
      and other metabolic variables is the base for the diagnosis and management of
      diabetes, whose two main types (type 1 and type 2, T1DM, T2DM) are projected to
      affect 450 million by 2030. As blood testing is often uncomfortable, painful,
      costly, and in some situations unreliable, the quest for alternative, noninvasive
      methods has been ongoing for decades. Breath analysis has emerged as an ideal
      alternative as sample collection is easy, painless, flexible, noninvasive,
      practical, and inexpensive. No single exhaled gas can reflect systemic glucose
      concentrations. Multiple gases, however, have been linked to various aspects of
      glucose metabolism, and integrated analysis of their simultaneous profiles during
      prolonged glycemic fluctuations has yielded accurate predictions of plasma
      values, building expectation that a clinically usable breath-based glucometer may
      be developed within a few years. SUMMARY: While prototypes of hand-held breath
      testing glucometers may still be several years away, current research shows the
      imminent promise of this methodology and the widening support for its
      development.
AD  - Institute for Clinical and Translational Science, University of California,
      Irvine, California, USA *Both the authors contributed equally to the manuscript.
FAU - Dowlaty, Newsha
AU  - Dowlaty N
FAU - Yoon, Amanda
AU  - Yoon A
FAU - Galassetti, Pietro
AU  - Galassetti P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Clin Nutr Metab Care
JT  - Current opinion in clinical nutrition and metabolic care
JID - 9804399
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.1097/MCO.0b013e328361f91f [doi]
AID - 00075197-201307000-00016 [pii]
PST - ppublish
SO  - Curr Opin Clin Nutr Metab Care. 2013 Jul;16(4):466-72. doi:
      10.1097/MCO.0b013e328361f91f.

PMID- 23739628
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1473-6519 (Electronic)
IS  - 1363-1950 (Linking)
VI  - 16
IP  - 4
DP  - 2013 Jul
TI  - Fatty acids regulation of inflammatory and metabolic genes.
PG  - 418-24
LID - 10.1097/MCO.0b013e32836236df [doi]
AB  - PURPOSE OF REVIEW: Fatty acids influence human health and diseases in various
      ways. In recent years, much work has been carried out to elucidate the mechanisms
      by which dietary fatty acids control short-term and long-term cellular functions.
      We have reviewed herein the most recent studies on modulation of gene expression 
      by fatty acids. A number of genes respond to transcription factors and present a 
      transcription factor response element in their promoter regions. Fatty acids may 
      exert their effects on metabolism by regulating gene transcription via
      transcription factors. Understanding how fatty acids control expression of
      metabolic genes is a promising strategy to be investigated by aiming to treat
      metabolic diseases such as insulin resistance, obesity, and type 2 diabetes
      mellitus. RECENT FINDINGS: Fatty acids exert many of their biological effects
      through the modulation of the activity of transcription factors, such as sterol
      regulatory element-binding proteins, peroxisome proliferator-activated receptors,
      and liver X receptors. SUMMARY: Fatty acid action through transcription factors
      controls the expression of several inflammatory and metabolic genes.
AD  - aDepartment of Physiology and Biophysics bDepartment of Pharmacology, Institute
      of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
FAU - Masi, Laureane N
AU  - Masi LN
FAU - Rodrigues, Alice C
AU  - Rodrigues AC
FAU - Curi, Rui
AU  - Curi R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Clin Nutr Metab Care
JT  - Current opinion in clinical nutrition and metabolic care
JID - 9804399
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.1097/MCO.0b013e32836236df [doi]
AID - 00075197-201307000-00009 [pii]
PST - ppublish
SO  - Curr Opin Clin Nutr Metab Care. 2013 Jul;16(4):418-24. doi:
      10.1097/MCO.0b013e32836236df.

PMID- 23739610
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1476-5470 (Electronic)
IS  - 1466-4879 (Linking)
DP  - 2013 Jun 6
TI  - Temporal induction of immunoregulatory processes coincides with age-dependent
      resistance to viral-induced type 1 diabetes.
LID - 10.1038/gene.2013.31 [doi]
AB  - The dilute plasma cytokine milieu associated with type 1 diabetes (T1D), while
      difficult to measure directly, is sufficient to drive transcription in a bioassay
      that uses healthy leukocytes as reporters. Previously, we reported
      disease-associated, partially IL-1 dependent, transcriptional signatures in both 
      T1D patients and the BioBreeding (BB) rat model. Here, we examine temporal
      signatures in congenic BBDR.lyp/lyp rats that develop spontaneous T1D, and BBDR
      rats where T1D progresses only after immunological perturbation in young animals.
      After weaning, the BBDR temporal signature showed early coincident induction of
      transcription related to innate inflammation as well as IL-10- and
      TGF-beta-mediated regulation. BBDR plasma cytokine levels mirrored the signatures
      showing early inflammation, followed by induction of a regulated state that
      correlated with failure of virus to induce T1D in older rats. In contrast, the
      BBDR.lyp/lyp temporal signature exhibited asynchronous dynamics, with delayed
      induction of inflammatory transcription and later, weaker induction of regulatory
      transcription, consistent with their deficiency in regulatory T cells. Through
      longitudinal analyses of plasma-induced signatures in BB rats and a human T1D
      progressor, we have identified changes in immunoregulatory processes that
      attenuate a preexisting innate inflammatory state in BBDR rats, suggesting a
      mechanism underlying the decline in T1D susceptibility with age.Genes and
      Immunity advance online publication, 6 June 2013; doi:10.1038/gene.2013.31.
AD  - 1] The Max McGee National Research Center for Juvenile Diabetes, Children's
      Research Institute of the Children's Hospital of Wisconsin, Milwaukee, WI, USA
      [2] Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
FAU - Chen, Y-G
AU  - Chen YG
FAU - Mordes, J P
AU  - Mordes JP
FAU - Blankenhorn, E P
AU  - Blankenhorn EP
FAU - Kashmiri, H
AU  - Kashmiri H
FAU - Kaldunski, M L
AU  - Kaldunski ML
FAU - Jia, S
AU  - Jia S
FAU - Geoffrey, R
AU  - Geoffrey R
FAU - Wang, X
AU  - Wang X
FAU - Hessner, M J
AU  - Hessner MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Genes Immun
JT  - Genes and immunity
JID - 100953417
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/06/06 [aheadofprint]
AID - gene201331 [pii]
AID - 10.1038/gene.2013.31 [doi]
PST - aheadofprint
SO  - Genes Immun. 2013 Jun 6. doi: 10.1038/gene.2013.31.

PMID- 23739524
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1477-1128 (Electronic)
IS  - 1463-4236 (Linking)
VI  - 14
IP  - 3
DP  - 2013 Jul
TI  - Diet and physical activity in the self-management of type 2 diabetes: barriers
      and facilitators identified by patients and health professionals.
PG  - 293-306
LID - 10.1017/S1463423612000412 [doi]
AB  - Aim To explore the views of individuals recently diagnosed with type 2 diabetes
      in relation to self-management of dietary intake and physical activity, and to
      compare these with the views of health professionals (HPs). BACKGROUND: Diabetes 
      education has become a priority area in primary and secondary care, and many
      education programmes are now embedded within a patient's care package. There are 
      few contemporaneous explorations of patients' views about lifestyle
      self-management. Such research is vital in order to identify areas that require
      further support, refinement or enhancement in terms of patient education.
      METHODS: Focus groups were held with patients recently diagnosed with type 2
      diabetes (n = 16, 38% female, aged 45-73 years). In-depth semi-structured
      interviews were conducted with HPs (n = 7). Discussions focussed on
      self-management specifically in relation to making dietary and physical activity 
      changes. All discussions were tape recorded, transcribed and analysed by emergent
      themes analysis using NVivo to manage the coded data. Findings Barriers were
      divided into six main categories: difficulty changing well-established habits,
      negative perception of the 'new' or recommended regimen, barriers relating to
      social circumstances, lack of knowledge and understanding, lack of motivation and
      barriers relating to the practicalities of making lifestyle changes. HPs
      generally echoed the views of patients. In conclusion, even against a background 
      of diabetes education, recently diagnosed patients with type 2 diabetes discussed
      a wide range of barriers to self-management of diet and physical activity. The
      findings could help to provide HPs with a deeper understanding of the needs of
      recently diagnosed patients and may help refine current diabetes education
      activities and inform the development of educational resources.
AD  - 1Lecturer, Institute of Clinical Science, Nutrition and Metabolism Research
      Group, School of Medicine, Dentistry and Biomedical Science, Queen's University
      Belfast, Belfast, UK.
FAU - Booth, Alison O
AU  - Booth AO
FAU - Lowis, Carole
AU  - Lowis C
FAU - Dean, Moira
AU  - Dean M
FAU - Hunter, Steven J
AU  - Hunter SJ
FAU - McKinley, Michelle C
AU  - McKinley MC
LA  - eng
PT  - Journal Article
PL  - England
TA  - Prim Health Care Res Dev
JT  - Primary health care research & development
JID - 100897390
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - S1463423612000412 [pii]
AID - 10.1017/S1463423612000412 [doi]
PST - ppublish
SO  - Prim Health Care Res Dev. 2013 Jul;14(3):293-306. doi: 10.1017/S1463423612000412.

PMID- 23739218
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1460-2350 (Electronic)
IS  - 0268-1161 (Linking)
DP  - 2013 Jun 5
TI  - Fasting glucose measurement as a potential first step screening for glucose
      metabolism abnormalities in women with anovulatory polycystic ovary syndrome.
AB  - STUDY QUESTION: Is routine screening by oral glucose tolerance test (OGTT) needed
      for all women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Screening
      for glucose metabolism abnormalities of PCOS patients by an OGTT could
      potentially be limited to patients who present with a fasting glucose
      concentration between 6.1 and 7.0 mmol/l only. WHAT IS KNOWN ALREADY: Women with 
      PCOS are at increased risk of developing diabetes. This study proposes a stepwise
      screening strategy for (pre)diabetes for PCOS patients based on risk
      stratification by fasting plasma glucose. STUDY DESIGN, SIZE, DURATION: A
      cross-sectional study of 226 women diagnosed with anovulatory PCOS. PARTICIPANTS 
      AND SETTING: A consecutive series of 226 patients, diagnosed with PCOS at the
      University Medical Centre Utrecht, the Netherlands, were screened for glucose
      metabolism abnormalities by OGTT (75 g glucose load). MAIN RESULTS AND ROLE OF
      CHANCE: The majority of the 226 women (mean age: 29.6 +/- 4.3 years; BMI: 27.3
      +/- 6.7 kg/m2; 81% Caucasian) presented with a normal OGTT (169 women (75%)). Of 
      the 57 (25%) women presenting with mild to moderate glucose abnormalities, 53
      (93%) could be identified by fasting glucose concentrations only. Diabetes was
      diagnosed in a total of eight women (3.5%). In six women, the diagnosis was based
      on fasting glucose >7.0 mmol/l. The other two cases of diabetes initially
      presented with fasting glucose between 6.1 and 7.0 mmol/l and were diagnosed by
      OGTT assessment. No women diagnosed with diabetes presented with fasting glucose 
      levels below 6.1 mmol/l. We therefore conclude that all diabetes patients could
      potentially be found by initial fasting glucose assessment followed by OGTT only 
      in patients with fasting glucose between 6.1 and 7.0 mmol/l. LIMITATIONS, REASONS
      FOR CAUTION: Before general implementation can be advised, this screening
      algorithm should be validated in a prospective study of a similar or greater
      number of PCOS women. WIDER IMPLICATIONS OF THE FINDINGS: Our study comprised of 
      a mostly Caucasian (81%) population, therefore generalization to other ethnic
      populations should be done with caution. STUDY FUNDING/COMPETING INTEREST(S): No 
      external finance was involved in this study. B.C.J.M.F. has received fees and
      grant support from the following companies (in alphabetic order); Andromed,
      Ardana, Ferring, Genovum, Merck Serono, MSD, Organon, Pantharei Bioscience,
      PregLem, Schering, Schering Plough, Serono and Wyeth. A.J.G. has received fees
      from Abbott, Bayer Schering and IBSA. T.W.H. has received fees from Merck, Sharpe
      & Dohme, GlaxoSmithKline, NovoNordisk and Eli Lilly. The authors declare complete
      independence from funders. CLINICAL TRIAL REGISTRATION NUMBER: NCT00821379.
AD  - Department of Reproductive Medicine and Gynaecology, University Medical Centre
      Utrecht, P.O. Box 85500, Utrecht 3508 GA, The Netherlands.
FAU - Veltman-Verhulst, Susanne M
AU  - Veltman-Verhulst SM
FAU - Goverde, Angelique J
AU  - Goverde AJ
FAU - van Haeften, Timon W
AU  - van Haeften TW
FAU - Fauser, Bart C J M
AU  - Fauser BC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Hum Reprod
JT  - Human reproduction (Oxford, England)
JID - 8701199
OTO - NOTNLM
OT  - OGTT
OT  - diabetes
OT  - fasting
OT  - glucose
OT  - polycystic ovary syndrome
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - det226 [pii]
AID - 10.1093/humrep/det226 [doi]
PST - aheadofprint
SO  - Hum Reprod. 2013 Jun 5.

PMID- 23739212
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1897-9483 (Electronic)
IS  - 0032-3772 (Linking)
DP  - 2013 Jun 5
TI  - Analysis of the influence of nutrition and the aterogenicity index of diet on the
      occurrence and intensity of insulin resistance.
LID - AOP_13_031 [pii]
AB  - INTRODUCTION Diet is one of the factors that can stimulate genetic conditions and
      in consequence lead to insulin resistance. Proper supply of nutrients,
      appropriate energy-rich diet and increased physical activity are the most
      effective methods to prevent metabolic disorders. OBJECTIVES The objective of
      this study was to determine whether there is a relationship between nutrition and
      the occurrence of insulin resistance. PATIENTS AND METHODS The studies have been 
      conducted in the group of 143 people. Each person's concentration of fasting
      insulin and fasting glucose has been measured, followed by individually
      calculated HOMA - IR. Patients without diabetes mellitus were divided into two
      groups - the study group and the control group. The following assessment were
      performed: anthropometric measurements (body mass, height and waist
      circumference), biochemical analyzes (fasting glucose and fasting insulin) and
      dietary interview. RESULTS A negative correlation has been observed between the
      percentage content of saccharose in the diet and HOMA - IR value, and a positive 
      one between the percentage of protein intake and HOMA - IR value. CONCLUSIONS
      There was a significantly higher intake of lactose in men without insulin
      resistance in comparison to men with insulin resistance . Results of this study
      encourage to take further steps and a more detailed analysis on a larger group of
      people in order to obtain a broader look at the problem of association between
      diet content and insulin resistance.
FAU - Ostrowska, Lucyna
AU  - Ostrowska L
FAU - Witczak, Katarzyna
AU  - Witczak K
FAU - Adamska, Edyta
AU  - Adamska E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/06/05 [aheadofprint]
AID - AOP_13_031 [pii]
PST - aheadofprint
SO  - Pol Arch Med Wewn. 2013 Jun 5. pii: AOP_13_031.

PMID- 23739127
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Linking)
DP  - 2013 Jun 6
TI  - Regional DNA methylation differences between humans and chimpanzees are
      associated with genetic changes, transcriptional divergence and disease genes.
LID - 10.1038/jhg.2013.55 [doi]
AB  - Changes in gene expression have been proposed to have an important role in the
      evolutionary changes in phenotypes. Interspecific changes in gene expression can 
      result not only from genetic changes in regulatory regions but also from
      epigenetic changes in such regions. Here we report the identification of genomic 
      regions showing differences in DNA methylation between humans and chimpanzees
      (termed S-DMRs for species-specific differentially methylated regions) on
      chromosomes 21 and 22. These regional methylation differences are frequently
      associated with genes, including those relevant to a disease, such as Alzheimer's
      disease, diabetes mellitus or cancer. Methylation differences are often
      correlated with changes in promoter activity or alternative splicing. Comparative
      studies including other great ape species provide evidence for the contribution
      of genetic changes to some of these S-DMRs. Genetic changes responsible for the
      S-DMRs include gain or loss of CTCF-binding site and changes in CpG density in
      microsatellite repeats. Our results suggest that DNA methylation changes, often
      caused by small sequence changes, contribute to transcriptional and phenotypic
      diversification in hominid evolution.Journal of Human Genetics advance online
      publication, 6 June 2013; doi:10.1038/jhg.2013.55.
AD  - Division of Epigenomics and Development, Medical Institute of Bioregulation, and 
      Epigenome Network Research Center, Kyushu University, Fukuoka, Japan.
FAU - Fukuda, Kei
AU  - Fukuda K
FAU - Ichiyanagi, Kenji
AU  - Ichiyanagi K
FAU - Yamada, Yoichi
AU  - Yamada Y
FAU - Go, Yasuhiro
AU  - Go Y
FAU - Udono, Toshifumi
AU  - Udono T
FAU - Wada, Seitaro
AU  - Wada S
FAU - Maeda, Toshiyuki
AU  - Maeda T
FAU - Soejima, Hidenobu
AU  - Soejima H
FAU - Saitou, Naruya
AU  - Saitou N
FAU - Ito, Takashi
AU  - Ito T
FAU - Sasaki, Hiroyuki
AU  - Sasaki H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/06/06 [aheadofprint]
AID - jhg201355 [pii]
AID - 10.1038/jhg.2013.55 [doi]
PST - aheadofprint
SO  - J Hum Genet. 2013 Jun 6. doi: 10.1038/jhg.2013.55.

PMID- 23739024
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1938-4114 (Electronic)
IS  - 1937-1888 (Linking)
VI  - 74
IP  - 4
DP  - 2013 Jul
TI  - Integration and sustainability of alcohol screening, brief intervention, and
      pharmacotherapy in primary care settings.
PG  - 598-604
AB  - ABSTRACT. Objective: At-risk drinking and alcohol use disorders are common in
      primary care and may adversely affect the treatment of patients with diabetes
      and/or hypertension. The purpose of this article is to report the impact of
      dissemination of a practice-based quality improvement approach (Practice Partner 
      Research Network-Translating Research into Practice [PPRNet-TRIP]) on alcohol
      screening, brief intervention for at-risk drinking and alcohol use disorders, and
      medications for alcohol use disorders in primary care practices. Method: Nineteen
      primary care practices from 15 states representing 26,005 patients with diabetes 
      and/or hypertension participated in a group-randomized trial (early intervention 
      vs. delayed intervention). The 12-month intervention consisted of practice site
      visits for academic detailing and participatory planning and network meetings for
      "best practice" dissemination. Results: At the end of Phase 1, eligible patients 
      in early-intervention practices were significantly more likely than patients in
      delayed-intervention practices to have been screened (odds ratio [OR] = 3.30, 95%
      CI [1.15, 9.50]) and more likely to have been provided a brief intervention (OR =
      6.58, 95% CI [1.69, 25.7]. At the end of Phase 2, patients in
      delayed-intervention practices were more likely than at the end of Phase 1 to
      have been screened (OR = 5.18, 95% CI [4.65, 5.76]) and provided a brief
      intervention (OR = 1.80, 95% CI [1.31, 2.47]). Early-intervention practices
      maintained their screening and brief intervention performance during Phase 2.
      Medication for alcohol use disorders was prescribed infrequently. Conclusions:
      PPRNet-TRIP is effective in improving and maintaining improvement in alcohol
      screening and brief intervention for patients with diabetes and/or hypertension
      in primary care settings. (J. Stud. Alcohol Drugs, 74, 598-604, 2013).
AD  - Department of Family Medicine, Medical University of South Carolina, Charleston, 
      South Carolina.
FAU - Ornstein, Steven M
AU  - Ornstein SM
FAU - Miller, Peter M
AU  - Miller PM
FAU - Wessell, Andrea M
AU  - Wessell AM
FAU - Jenkins, Ruth G
AU  - Jenkins RG
FAU - Nemeth, Lynne S
AU  - Nemeth LS
FAU - Nietert, Paul J
AU  - Nietert PJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Stud Alcohol Drugs
JT  - Journal of studies on alcohol and drugs
JID - 101295847
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PST - ppublish
SO  - J Stud Alcohol Drugs. 2013 Jul;74(4):598-604.

PMID- 23738910
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
DP  - 2013 Jun 5
TI  - Assessment of Insulin Initiation on Resource Utilisation and Direct Costs of
      Treatment over 12 Months in Patients with Type 2 Diabetes in Europe: Results from
      INSTIGATE and TREAT Observational Studies.
AB  - Abstract Objectives: To describe the changes in resource utilisation in 7
      European countries (Germany, Greece, Portugal, Romania, Sweden, Spain, and
      Turkey) and direct costs in 4 European countries (Germany, Spain, Sweden, and
      Greece) over the first 12 months of insulin treatment in patients with type 2
      diabetes mellitus (T2DM). Methods: INSTIGATE and TREAT (2005-2010) were
      non-interventional, prospective, observational studies in patients with T2DM and 
      initiating insulin for the first time. A 6-month retrospective data capture was
      conducted at baseline (insulin initiation) followed by prospective data
      collections at approximately 3, 6, and 12 months. Statistical analyses were
      descriptive; estimated costs are presented as nominal values. Results: We present
      data for 1450 patients. Overall, in the first 6 months after insulin initiation, 
      the use and cost of blood glucose monitoring and insulin increased; while, the
      cost of oral diabetic medication decreased. Contributors to total direct costs
      differed between countries. Ranges of total mean direct costs over the 6-month
      period before insulin initiation were euro489.1-euro658.5 (Greece-Spain); 0-6
      months after insulin initiation, euro573.4-euro1084.7 (Greece-Spain); and 6-12
      months, euro495.8-euro859.3 (Greece-Germany). Thus, the mean cost of treatment
      increased in all countries in the first 6 months after insulin initiation and
      then returned to baseline except in Germany. Limitations: Overall, 15% of
      patients were lost to follow-up over 12 months. Costs were not prorated to
      account for variation of visits. Participating centres may not have been fully
      representative of all levels of care. Conclusions: Contributors to total cost
      differed between countries, potentially reflecting local clinical practice
      patterns and insulin regimens. In each country, mean direct total costs of T2DM
      care increased during the first 6 months after insulin initiation and decreased
      thereafter.
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet; Department
      of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital,
      Stockholm, Sweden.
FAU - Brismar, Kerstin
AU  - Brismar K
FAU - Benroubi, Marianna
AU  - Benroubi M
FAU - Nicolay, Claudia
AU  - Nicolay C
FAU - Schmitt, Henry
AU  - Schmitt H
FAU - Giaconia, Joseph
AU  - Giaconia J
FAU - Reaney, Matthew
AU  - Reaney M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.3111/13696998.2013.812040 [doi]
PST - aheadofprint
SO  - J Med Econ. 2013 Jun 5.

PMID- 23738904
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1525-6073 (Electronic)
IS  - 0742-0528 (Linking)
DP  - 2013 Jun 5
TI  - Circadian-clock system in mouse liver affected by insulin resistance.
AB  - Circadian rhythms are exhibited in the physiological and behavioral processes of 
      all mammals; they are generated by intracellular levels of circadian oscillators,
      which are named as a set of circadian-clock genes. These genes compose the
      transcriptional/translational feedback loops to regulate not only circadian
      rhythmicity, but also energy metabolism. Previous studies have shown that obesity
      and diabetes cause the dysregulation of the circadian-clock system, and vice
      versa. However, some diabetes subjects are lean with insulin resistance and the
      mechanisms of insulin resistance without obesity are much less well known.
      Therefore, whether insulin resistance alone is enough to influence the expression
      of circadian-clock genes is uncertain. This study employs a neonatal
      streptozotocin (STZ)-treated paradigm in mice to model the molecular and
      physiological progress of nonobese insulin resistance. A single injection of STZ 
      into 2-d-old male C57BL/6 mice induces nonobese, hyperglycemic and
      hyperinsulinemic conditions, and the levels of gene expression in the liver by a 
      real-time quantitative polymerase chain reaction are then measured. Although the 
      levels of Bmal1 (brain and muscle Arnt-like protein-1), Per2 (period 2), and Cry1
      (cryptochrome 1) mRNA expression in the liver change during the progress of
      insulin resistance conditions, the gene expression patterns still show circadian 
      rhythmicity. This study suggests that changes in the hepatic circadian-clock gene
      expression mark an early event in the metabolic disruption associated with
      insulin resistance. Furthermore, 2 wks of treatment with the thiazolidinedione,
      pioglitazone, fully resolve the dysfunction in metabolic parameters and the
      changes in circadian-clock gene expression from early insulin resistance
      conditions. These results indicate that the circadian-clock system is sensitive
      to insulin resistance, and that treatment with thiazolidinediones can resolve
      changes in the circadian-clock system in a timely manner. Thus, strengthening the
      peripheral circadian-clock system may counteract the adverse physiological
      consequences in the metabolic syndrome.
AD  - General Education Center, Tzu Chi College of Technology , Hualien , Taiwan .
FAU - Yang, Shu-Chuan
AU  - Yang SC
FAU - Tseng, Huey-Lin
AU  - Tseng HL
FAU - Shieh, Kun-Ruey
AU  - Shieh KR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.3109/07420528.2013.766204 [doi]
PST - aheadofprint
SO  - Chronobiol Int. 2013 Jun 5.

PMID- 23738826
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013 Jun 6
TI  - Glycogen Storage Disease type 1a -- a secondary cause for hyperlipidemia: report 
      of five cases.
PG  - 25
AB  - Background and aims: Glycogen storage disease type Ia (GSD Ia) is a rare
      metabolic disorder, caused by deficient activity of glucose-6-phosphatase-alpha. 
      It produces fasting induced hypoglycemia and hepatomegaly, usually manifested in 
      the first semester of life. Besides, it is also associated with growth delay,
      anemia, platelet dysfunction, osteopenia and sometimes osteoporosis.
      Hyperlipidemia and hyperuricemia are almost always present and hepatocellular
      adenomas and renal dysfunction frequent late complications. METHODS: The authors 
      present a report of five adult patients with GSD Ia followed in internal medicine
      appointments and subspecialties. RESULTS: Four out of five patients were
      diagnosed in the first 6 months of life, while the other one was diagnosed in
      adult life after the discovery of hepatocellular adenomas. In two cases genetic
      tests were performed, being identified the missense mutation R83C in one, and the
      mutation IVS4-3C > G in the intron 4 of glucose-6-phosphatase gene, not
      previously described, in the other. Growth retardation was present in 3 patients,
      and all of them had anemia, increased bleeding tendency and hepatocellular
      adenomas; osteopenia/osteoporosis was present in three cases. All but one patient
      had marked hyperlipidemia and hyperuricemia, with evidence of endothelial
      dysfunction in one case and of brain damage with refractory epilepsy in another
      case. Proteinuria was present in two cases and end-stage renal disease in another
      case. There was a great variability in the dietary measures; in one case, liver
      transplantation was performed, with correction of the metabolic derangements.
      CONCLUSIONS: Hyperlipidemia is almost always present and only partially responds 
      to dietary and drug therapy; liver transplantation is the only definitive
      solution. Although its association with premature atherosclerosis is rare, there 
      have been reports of endothelial dysfunction, raising the possibility for
      increased cardiovascular risk in this group of patients. Being a rare disease, no
      single metabolic center has experience with large numbers of patients and the
      recommendations are based on clinical experience more than large scale studies.
FAU - Carvalho, Patricia Margarida
AU  - Carvalho PM
FAU - Silva, Nuno Jose
AU  - Silva NJ
FAU - Dias, Patricia Gloria
AU  - Dias PG
FAU - Porto, Joao Filipe
AU  - Porto JF
FAU - Santos, Lelita Conceicao
AU  - Santos LC
FAU - Costa, Jose Manuel
AU  - Costa JM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/07/29 [received]
PHST- 2013/06/06 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 2251-6581-12-25 [pii]
AID - 10.1186/2251-6581-12-25 [doi]
PST - aheadofprint
SO  - J Diabetes Metab Disord. 2013 Jun 6;12(1):25.

PMID- 23738819
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
DP  - 2013 Jun 5
TI  - Mean platelet volume is decreased in HIV-infected women.
LID - 10.1111/hiv.12048 [doi]
AB  - OBJECTIVES: HIV infection is associated with higher than expected cardiovascular 
      event rates and lowered platelet counts. These conditions are associated with an 
      elevation of mean platelet volume (MPV). The present study compared MPV in
      HIV-infected and uninfected women and identified factors influencing MPV values
      in HIV-infected women. METHODS: A total of 234 HIV-infected and 134
      HIV-uninfected participants from the Women's Interagency HIV Study (WIHS) had MPV
      values obtained. HIV-infected women were older, were more likely to have diabetes
      and had higher triglyceride levels than HIV-uninfected women. RESULTS: The mean
      platelet count was lower in HIV-infected vs. uninfected women [249 cells/muL (95%
      confidence interval (CI) 238, 259 cells/muL) vs. 276 cells/muL (95% CI 265, 287
      cells/muL), respectively; P < 0.01]. Adjusted mean MPV values were lower in the
      HIV-infected than in the uninfected group [8.66 fL (95% CI 8.52, 8.79 fL) vs.
      9.05 fL (95% CI 8.87, 9.24 fL), respectively]. In multiple regression analysis,
      after adjusting for other covariates, MPV was positively associated with platelet
      count, and negatively with HIV infection (model R2 = 0.20; P < 0.01). In multiple
      regression analysis confined to HIV-infected women, a lower MPV was independently
      associated with a history of AIDS-defining illness (R2 = 0.28; P = 0.03), but not
      with nadir CD4 count or highly active antiretroviral therapy (HAART) use.
      CONCLUSIONS: HIV-infected women had lower MPV values than uninfected women,
      suggesting impaired production rather than increased destruction. Higher than
      expected cardiovascular event rates cannot be attributed to greater platelet
      reactivity as measured by MPV.
CI  - (c) 2013 British HIV Association.
AD  - Division of Cardiovascular Medicine, State University of New York, Downstate
      Medical Center, Brooklyn, NY, USA.
FAU - Qadri, S
AU  - Qadri S
FAU - Holman, S
AU  - Holman S
FAU - Dehovitz, J
AU  - Dehovitz J
FAU - Crystal, H
AU  - Crystal H
FAU - Minkoff, H
AU  - Minkoff H
FAU - Lazar, Jm
AU  - Lazar J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/04/16 [accepted]
AID - 10.1111/hiv.12048 [doi]
PST - aheadofprint
SO  - HIV Med. 2013 Jun 5. doi: 10.1111/hiv.12048.

PMID- 23738766
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1752-4458 (Print)
IS  - 1752-4458 (Linking)
VI  - 7
IP  - 1
DP  - 2013 Jun 6
TI  - Do competing demands of physical illness in type 2 diabetes influence depression 
      screening, documentation and management in primary care: a cross-sectional
      analytic study in aboriginal and torres strait islander primary health care
      settings.
PG  - 16
AB  - BACKGROUND: Relatively little is known about how depression amongst people with
      chronic illness is identified and managed in diverse primary health care
      settings. We evaluated the role of complex physical needs in influencing current 
      practice of depression screening, documentation and antidepressant prescriptions 
      during a 12-month period, among adults with Type 2 diabetes attending Aboriginal 
      and Torres Strait Islander primary care health centres in Australia. METHODS: We 
      analysed clinical audit data from 44 health centres participating in a continuous
      quality improvement initiative, using previously reported standard sampling and
      data extraction protocols. Eligible patients were those with Type 2 diabetes with
      health centre attendance within the past 12 months. We compared current practice 
      in depression screening, documentation and antidepressant prescription between
      patients with different disease severity and co-morbidity. We used random effects
      multiple logistic regression models to adjust for potential confounders and for
      clustering by health centre. RESULTS: Among the 1174 patients with diabetes
      included, median time since diagnosis was 7 years, 19% of patients had a
      co-existing diagnosis of Ischaemic Heart Disease and 1/3 had renal disease. Some 
      70% of patients had HbAc1>7.0%; 65% had cholesterol >4.0mmol1-1 and 64% had blood
      pressure>130/80mmHg. Documentation of screening for depression and of diagnosed
      depression were low overall (5% and 6% respectively) and lower for patients with 
      renal disease (Adjusted odds ratio [AOR] 0.21; 95% confidence interval [CI] 0.14 
      to 0.31 and AOR 0.34; 95% CI 0.15 to 0.75), and for those with poorly controlled 
      disease (HbA1c>7.00 (AOR 0.40; 95% CI 0.23 to 0.68 and AOR 0.51; 95% CI 0.30 to
      84)). Screening for depression was lower for those on pharmaceutical treatment
      for glycaemic control compared to those not on such treatment. Antidepressant
      prescription was not associated with level of diabetes control or disease
      severity. CONCLUSIONS: Background levels of depression screening and
      documentation were low overall and significantly lower for patients with greater 
      disease severity. Strategies to improve depression care for vulnerable
      populations are urgently required. An important first step in the Australian
      Indigenous primary care context is to identify and address barriers to the use of
      current clinical guidelines for depression screening and care.
FAU - Schierhout, Gill
AU  - Schierhout G
FAU - Nagel, Tricia
AU  - Nagel T
FAU - Si, Damin
AU  - Si D
FAU - Connors, Christine
AU  - Connors C
FAU - Brown, Alex
AU  - Brown A
FAU - Bailie, Ross
AU  - Bailie R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Int J Ment Health Syst
JT  - International journal of mental health systems
JID - 101294224
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/03/19 [received]
PHST- 2013/06/06 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 1752-4458-7-16 [pii]
AID - 10.1186/1752-4458-7-16 [doi]
PST - aheadofprint
SO  - Int J Ment Health Syst. 2013 Jun 6;7(1):16.

PMID- 23738733
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 65
IP  - 7
DP  - 2013 Jul
TI  - Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis
      and glycosaminoglycan hyperelongation in human vascular smooth muscle cells.
PG  - 1055-63
LID - 10.1111/jphp.12064 [doi]
AB  - OBJECTIVES: Suramin is a polysulfonated naphthylurea with antiparasitic and
      potential antineoplastic activity. Suramin's pharmacological actions, which have 
      not yet been fully elucidated, include antagonism of the action of
      platelet-derived growth factor (PDGF) at its receptor. We investigated the
      effects of suramin on PDGF-stimulated proteoglycan synthesis. METHODS: Human
      vascular smooth muscle cells (VSMCs) were incubated in the presence and absence
      of PDGF and suramin with [(3) H]thymidine or (35) SO4 as radiolabels. Mitogenic
      response was determined by [(3) H]thymidine incorporation. PDGFbeta receptor
      phosphorylation was assessed by western blotting. Proteoglycan size and
      glycosaminoglycan chain synthesis and size were determined by sodium dodecyl
      sulfate-polyacrylamide gel electrophoresis. The Alphascreen phosphotyrosine assay
      kit was used to investigate PDGFbeta receptor tyrosine kinase inhibition by
      suramin. KEY FINDINGS: Suramin decreased PDGF-stimulated proliferation,
      proteoglycan synthesis and GAG chain hyperelongation. Suramin also directly
      inhibited PDGFbeta receptor kinase activity as well as PDGFbeta receptor
      phosphorylation in intact VSMCs. CONCLUSIONS: These data show that inhibition of 
      PDGFbeta receptor phosphorylation in intact cells is necessary to define a fully 
      active PDGF antagonist. They also confirm that PDGFbeta receptor kinase activity 
      is necessary for PDGF-mediated atherogenic changes in proteoglycan synthesis and 
      support efforts to develop PDGFbeta receptor antagonists as potential
      anti-atherosclerotic agents.
CI  - (c) 2013 Royal Pharmaceutical Society.
AD  - Discipline of Pharmacy, School of Medical Sciences, Diabetes Complications Group,
      Health Innovations Research Institute, Melbourne, VIC, Australia; Departments of 
      Medicine and Immunology, Central and Eastern Clinical School, Alfred Health,
      Monash University, Melbourne, VIC, Australia.
FAU - Little, Peter J
AU  - Little PJ
FAU - Rostam, Muhamad Ashraf
AU  - Rostam MA
FAU - Piva, Terrence J
AU  - Piva TJ
FAU - Getachew, Robel
AU  - Getachew R
FAU - Kamato, Danielle
AU  - Kamato D
FAU - Guidone, Daniel
AU  - Guidone D
FAU - Ballinger, Mandy L
AU  - Ballinger ML
FAU - Zheng, Wenhua
AU  - Zheng W
FAU - Osman, Narin
AU  - Osman N
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/11/08 [received]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1111/jphp.12064 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2013 Jul;65(7):1055-63. doi: 10.1111/jphp.12064. Epub 2013 Apr
      24.

PMID- 23738730
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 65
IP  - 7
DP  - 2013 Jul
TI  - (S)-[6]-Gingerol inhibits TGF-beta-stimulated biglycan synthesis but not
      glycosaminoglycan hyperelongation in human vascular smooth muscle cells.
PG  - 1026-36
LID - 10.1111/jphp.12060 [doi]
AB  - OBJECTIVES: (S)-[6]-Gingerol is under investigation for a variety of therapeutic 
      uses. Transforming growth factor (TGF)-beta stimulates proteoglycan synthesis,
      leading to increased binding of low-density lipoproteins, which is the initiating
      step in atherosclerosis. We evaluated the effects of (S)-[6]-gingerol on these
      TGF-beta-mediated proteoglycan changes to explore its potential as an
      anti-atherosclerotic agent. METHODS: Purified (S)-[6]-gingerol was assessed for
      its effects on proteoglycan synthesis by [(35) S]-sulfate incorporation into
      glycosaminoglycan chains and [(35) S]-Met/Cys incorporation into proteoglycans
      and total proteins in human vascular smooth muscle cells. Biglycan level was
      assessed by real-time quantitative polymerase chain reactions and the effects of 
      (S)-[6]-gingerol on TGF-beta signalling by assessment of the phosphorylation of
      Smads and Akt by western blotting. KEY FINDINGS: (S)-[6]-Gingerol
      concentration-dependently inhibited TGF-beta-stimulated proteoglycan core protein
      synthesis, and this was not secondary to inhibition of total protein synthesis.
      (S)-[6]-Gingerol inhibited biglycan mRNA expression. (S)-[6]-Gingerol did not
      inhibit TGF-beta-stimulated glycosaminoglycan hyperelongation or phosphorylation 
      of Smad 2, in either the carboxy terminal or linker region, or Akt
      phosphorylation. CONCLUSIONS: The activity of (S)-[6]-gingerol to inhibit
      TGF-beta-stimulated biglycan synthesis suggests a potential role for ginger in
      the prevention of atherosclerosis or other lipid-binding diseases. The signalling
      studies indicate a novel site of action of (S)-[6]-gingerol in inhibiting
      TGF-beta responses.
CI  - (c) 2013 Royal Pharmaceutical Society.
AD  - Discipline of Pharmacy, School of Medical Sciences and Diabetes Complications
      Group, Health Innovations Research Institute, RMIT University, Bundoora.
FAU - Kamato, Danielle
AU  - Kamato D
FAU - Babaahmadi Rezaei, Hossein
AU  - Babaahmadi Rezaei H
FAU - Getachew, Robel
AU  - Getachew R
FAU - Thach, Lyna
AU  - Thach L
FAU - Guidone, Daniel
AU  - Guidone D
FAU - Osman, Narin
AU  - Osman N
FAU - Roufogalis, Basil
AU  - Roufogalis B
FAU - Duke, Colin C
AU  - Duke CC
FAU - Tran, Van Hoan
AU  - Tran VH
FAU - Zheng, Wenhua
AU  - Zheng W
FAU - Little, Peter J
AU  - Little PJ
LA  - eng
PT  - Journal Article
DEP - 20130327
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/09/27 [received]
PHST- 2013/02/26 [accepted]
PHST- 2013/03/27 [aheadofprint]
AID - 10.1111/jphp.12060 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2013 Jul;65(7):1026-36. doi: 10.1111/jphp.12060. Epub 2013 Mar
      27.

PMID- 23738648
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1651-2227 (Electronic)
IS  - 0803-5253 (Linking)
DP  - 2013 Jun 5
TI  - Health Related Quality of Life among Norwegian children and adolescents with
      Type1 diabetes on Intensive Insulin Treatment. A population based study.
LID - 10.1111/apa.12312 [doi]
AB  - AIM: To examine Health Related Quality of Life (HRQOL) in children and
      adolescents with Type 1 diabetes on intensive insulin treatment. METHODS: All
      children and adolescents with Type 1 diabetes above 8 years of age scheduled for 
      follow-up at 21 paediatric departments in Norway and one of their parents were
      invited to describe HRQOL by completing DISABKIDS questionnaires. HRQOL was
      related to sociodemographic factors (i.e. parental economy, education, marital
      status and to level of physical activity and disease characteristics, obtained
      from the Norwegian Childhood Diabetes Registry. RESULTS: 937 (48%) and one of
      their parents responded. Mean duration of diabetes was 4.9 years (SD 3.3), 51%
      were girls, 56% used insulin pumps and 44% used multiple insulin injections,
      predominantly of long acting and rapid insulin analogues. Mean HbA1c was 8.5% (SD
      1.3). Lower HRQOL scores were significantly associated with higher HbA1c, being a
      girl and experience of diabetes ketoacidosis. Mothers scored lower than fathers
      on total score and most subscales. No significant differences in scores were
      found between users of an insulin pump and multi-injection treatment.
      CONCLUSIONS: HRQOL was related to metabolic control and gender, but not to mode
      of intensified insulin treatment. This article is protected by copyright. All
      rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Research Center for Child and Youth Competence Development, Lillehammer
      University College; Department of Paediatrics, Innlandet Hospital Trust,
      Lillehammer.
FAU - Froisland, Dag Helge
AU  - Froisland DH
FAU - Graue, Marit
AU  - Graue M
FAU - Markestad, Trond
AU  - Markestad T
FAU - Skrivarhaug, Torild
AU  - Skrivarhaug T
FAU - Wentzel-Larsen, Tore
AU  - Wentzel-Larsen T
FAU - Dahl-Jorgensen, Knut
AU  - Dahl-Jorgensen K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Acta Paediatr
JT  - Acta paediatrica (Oslo, Norway : 1992)
JID - 9205968
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/03/18 [received]
PHST- 2013/05/06 [revised]
PHST- 2013/06/04 [accepted]
AID - 10.1111/apa.12312 [doi]
PST - aheadofprint
SO  - Acta Paediatr. 2013 Jun 5. doi: 10.1111/apa.12312.

PMID- 23738623
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1748-295X (Electronic)
IS  - 1748-2941 (Linking)
VI  - 15
IP  - 2
DP  - 2013 Jun
TI  - Stress hyperglycemia in acute ST-segment elevation myocardial infarction is a
      marker of left ventricular remodeling.
PG  - 38-43
LID - 10.3109/17482941.2013.781190 [doi]
AB  - Abstract Introduction: Stress hyperglycemia (SH) in STEMI is associated with high
      risk of in-hospital mortality. It is still controversial if SH is marker of high 
      post-hospital risk. Objectives: The aim was to analyze in-hospital and one-year
      risk associated with SH in STEMI and to study if SH is marker of LV remodeling.
      Methods: We enrolled 275 patients who were admitted with first STEMI and
      reperfused. Patients were divided according to admission glycemia in three
      groups: (1) with diabetes mellitus (DM); (2) with SH, without DM and; (3) without
      both DM and SH. SH was defined as admission blood glucose level >/= 8 mmol/l.
      Results: In-hospital mortality was higher in patients with known DM (5%) and
      highest in patients with SH without previous DM (9.3%), and only 1.6% in the
      third group, P < 0.05. In patients without known DM, SH was associated with
      6.378-fold higher in-hospital mortality. Total mortality was double in group with
      SH without DM compared to the third group (13.9% versus 6.3%). EDV changed in
      patients with SH without DM from 126 +/- 37 to 145 +/- 30 ml after one year, P < 
      0.05. Conclusion: SH is associated with high in-hospital mortality risk and it
      could be marker of LV remodeling (significant increase of EDV during one year).
AD  - Clinic for cardiovascular diseases, Clinical Center Nis , Serbia.
FAU - Djordjevic-Radojkovic, Danijela
AU  - Djordjevic-Radojkovic D
FAU - Koracevic, Goran
AU  - Koracevic G
FAU - Stanojevic, Dragana
AU  - Stanojevic D
FAU - Damjanovic, Miodrag
AU  - Damjanovic M
FAU - Apostolovic, Svetlana
AU  - Apostolovic S
FAU - Pavlovic, Milan
AU  - Pavlovic M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acute Card Care
JT  - Acute cardiac care
JID - 101276603
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.3109/17482941.2013.781190 [doi]
PST - ppublish
SO  - Acute Card Care. 2013 Jun;15(2):38-43. doi: 10.3109/17482941.2013.781190.

PMID- 23738609
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Jun 5
TI  - Prevalence of obesity and associated cardiovascular risk: the DARIOS study.
PG  - 542
AB  - BACKGROUND: To estimate the prevalence of overweight and obesity in the Spanish
      population as measured with body mass index (BMI), waist circumference (WC) and
      waist to height ratio (WHtR) and to determine the associated cardiovascular risk 
      factors. METHODS: Pooled analysis with individual data from 11 studies conducted 
      in the first decade of the 21st century. Participants aged 35--74 years were
      asked about the history of cardiovascular diseases, hypertension, diabetes and
      hypercholesterolemia. Height, weight, WC, blood pressure, glycaemia, total
      cholesterol, low-density and high-density lipoprotein cholesterol and coronary
      risk were measured. The prevalence of overweight (BMI 25--29.9 kg/m2), general
      obesity (BMI >=30 kg/m2), suboptimal WC (>= 80 cm and < 88 in women, >= 94 and < 
      102 in men), abdominal obesity (WC >=88 cm >=102 cm in women and men,
      respectively) and WHtR >=0.5 was estimated, standardized for the European
      population. RESULTS: We included 28,743 individuals. The prevalence of overweight
      and suboptimal WC was 51% and 30% in men and 36% and 22% in women, respectively; 
      general obesity was 28% in both sexes and abdominal obesity 36% in men and 55% in
      women. The prevalence of WHtR >=0.5 was 89% and 77% in men and women,
      respectively. All cardiovascular risk factors were significantly associated with 
      abnormal increased values of BMI, WC and WHtR. Hypertension showed the strongest 
      association with overweight [OR = 1.99 (95% confidence interval 1.81-2.21) and OR
      = 2.10 (1.91-2.31)]; suboptimal WC [OR = 1.78 (1.60-1.97) and OR = 1.45
      (1.26-1.66)], with general obesity [OR = 4.50 (4.02-5.04), and OR = 5.20
      (4.70-5.75)] and with WHtR >=0.5 [OR = 2.94 (2.52-3.43), and OR = 3.02
      (2.66-3.42)] in men and women respectively, besides abdominal obesity in men only
      [OR = 3.51 (3.18-3.88)]. Diabetes showed the strongest association with abdominal
      obesity in women [OR = 3,86 (3,09-4,89). CONCLUSIONS: The prevalence of obesity
      in Spain was high. Overweight, suboptimal WC, general, abdominal obesity and WHtR
      >=0.5 was significantly associated with diabetes, hypertension,
      hypercholesterolemia and coronary risk. The use of lower cut-off points for both 
      BMI and particularly WC and could help to better identify the population at risk 
      and therefore achieve more effective preventive measures.
FAU - Felix-Redondo, Francisco Javier
AU  - Felix-Redondo FJ
FAU - Grau, Maria
AU  - Grau M
FAU - Baena-Diez, Jose Miguel
AU  - Baena-Diez JM
FAU - Degano, Irene R
AU  - Degano IR
FAU - de Leon, Antonio Cabrera
AU  - de Leon AC
FAU - Guembe, Maria Jesus
AU  - Guembe MJ
FAU - Alzamora, Maria Teresa
AU  - Alzamora MT
FAU - Vega-Alonso, Tomas
AU  - Vega-Alonso T
FAU - Robles, Nicolas R
AU  - Robles NR
FAU - Ortiz, Honorato
AU  - Ortiz H
FAU - Rigo, Fernando
AU  - Rigo F
FAU - Mayoral-Sanchez, Eduardo
AU  - Mayoral-Sanchez E
FAU - Tormo, Maria Jose
AU  - Tormo MJ
FAU - Segura-Fragoso, Antonio
AU  - Segura-Fragoso A
FAU - Fernandez-Berges, Daniel
AU  - Fernandez-Berges D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2012/11/21 [received]
PHST- 2013/06/05 [accepted]
PHST- 2013/06/05 [aheadofprint]
AID - 1471-2458-13-542 [pii]
AID - 10.1186/1471-2458-13-542 [doi]
PST - aheadofprint
SO  - BMC Public Health. 2013 Jun 5;13(1):542.

PMID- 23738600
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 15
IP  - 7
DP  - 2013 Jul
TI  - Issue information.
PG  - i
LID - 10.1111/dom.1685 [doi]
LA  - eng
PT  - Journal Article
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
SB  - IM
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.1111/dom.1685 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2013 Jul;15(7):i. doi: 10.1111/dom.1685.

PMID- 23738538
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
IP  - 1
DP  - 2013 Jun 6
TI  - Diabetes severity and the role of leisure time physical exercise on
      cardiovascular mortality: the Nord-Tr[latin small letter o with stroke]ndelag
      Health study (HUNT), Norway.
PG  - 83
AB  - BACKGROUND: Physical activity has been associated with lower cardiovascular
      mortality in people with diabetes, but how diabetes severity influence this
      association has not been extensively studied. METHODS: We prospectively examined 
      the joint association of diabetes severity, measured as medical treatment status 
      and disease duration, and physical exercise with cardiovascular mortality. A
      total of 56,170 people were followed up for 24 years through the Norwegian Cause 
      of Death Registry. Cox proportional adjusted hazard ratios (HRs) with 95%
      confidence intervals (CI) were estimated. RESULTS: Overall, 7,723 people died
      from cardiovascular disease during the follow-up. Compared to the reference group
      of inactive people without diabetes, people with diabetes who reported no medical
      treatment had a hazard ratio (HR) of 1.65 (95% CI: 1.34, 2.03) if they were
      inactive and a HR of 0.99 (95% CI: 0.68, 1.45) if they reported >=2.0 hours
      physical exercise per week. Among people who received oral hypoglycemic drugs or 
      insulin, the corresponding comparison gave HRs of 2.46 (95% CI: 2.08-2.92) and
      1.58 (95% CI: 1.21, 2.05), respectively. CONCLUSIONS: The data suggest a more
      favourable effect of exercise in people with diabetes who used medication than in
      those who did not, suggesting that physical exercise should be encouraged as a
      therapeutic measure additional to medical treatment.
FAU - Moe, Borge
AU  - Moe B
FAU - Augestad, Liv Berit
AU  - Augestad LB
FAU - Nilsen, Tom Il
AU  - Nilsen TI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/02/26 [received]
PHST- 2013/06/06 [accepted]
PHST- 2013/06/06 [aheadofprint]
AID - 1475-2840-12-83 [pii]
AID - 10.1186/1475-2840-12-83 [doi]
PST - aheadofprint
SO  - Cardiovasc Diabetol. 2013 Jun 6;12(1):83.

PMID- 23738509
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
DP  - 2013 Jun 5
TI  - Central Precocious Puberty Caused by Mutations in the Imprinted Gene MKRN3.
AB  - Background The onset of puberty is first detected as an increase in pulsatile
      secretion of gonadotropin-releasing hormone (GnRH). Early activation of the
      hypothalamic-pituitary-gonadal axis results in central precocious puberty. The
      timing of pubertal development is driven in part by genetic factors, but only a
      few, rare molecular defects associated with central precocious puberty have been 
      identified. Methods We performed whole-exome sequencing in 40 members of 15
      families with central precocious puberty. Candidate variants were confirmed with 
      Sanger sequencing. We also performed quantitative real-time
      polymerase-chain-reaction assays to determine levels of messenger RNA (mRNA) in
      the hypothalami of mice at different ages. Results We identified four novel
      heterozygous mutations in MKRN3, the gene encoding makorin RING-finger protein 3,
      in 5 of the 15 families; both sexes were affected. The mutations included three
      frameshift mutations, predicted to encode truncated proteins, and one missense
      mutation, predicted to disrupt protein function. MKRN3 is a paternally expressed,
      imprinted gene located in the Prader-Willi syndrome critical region (chromosome
      15q11-q13). All affected persons inherited the mutations from their fathers, a
      finding that indicates perfect segregation with the mode of inheritance expected 
      for an imprinted gene. Levels of Mkrn3 mRNA were high in the arcuate nucleus of
      prepubertal mice, decreased immediately before puberty, and remained low after
      puberty. Conclusions Deficiency of MKRN3 causes central precocious puberty in
      humans. (Funded by the National Institutes of Health and others.).
AD  - From the Division of Endocrinology, Diabetes, and Hypertension, Brigham and
      Women's Hospital and Harvard Medical School (A.P.A., S.D.N., J.C.G., I.R.T.,
      V.M.N., R.S.C., U.B.K.), and the Divisions of Endocrinology (A.D., J.N.H.) and
      Genetics (J.N.H.), Boston Children's Hospital, Boston; the Program in Medical and
      Population Genetics, Broad Institute, Cambridge, MA (A.D., J.N.H.); Unidade de
      Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular,
      LIM42, Hospital das Clinicas, Disciplina de Endocrinologia, Faculdade de Medicina
      da Universidade de Sao Paulo (A.P.A., D.B.M., V.N.B., P.C., L.R.M., B.B.M.,
      A.C.L.), Departamento de Pediatria, Faculdade de Ciencias Medicas da Santa Casa
      de Sao Paulo (C.K., C.A.L.), Sao Paulo, and the Division of Pediatric
      Endocrinology, Hospital das Clinicas da Universidade Federal de Minas Gerais,
      Belo Horizonte (T.R.) - all in Brazil; the Division of Endocrinology, Diabetes,
      and Metabolism, Nemours Children's Clinic, Jacksonville, FL (P.C.G.); and the
      Department of Pediatrics, University Hospital Gasthuisberg, University of Leuven,
      Leuven, Belgium (D.B., F.Z.).
FAU - Abreu, Ana Paula
AU  - Abreu AP
FAU - Dauber, Andrew
AU  - Dauber A
FAU - Macedo, Delanie B
AU  - Macedo DB
FAU - Noel, Sekoni D
AU  - Noel SD
FAU - Brito, Vinicius N
AU  - Brito VN
FAU - Gill, John C
AU  - Gill JC
FAU - Cukier, Priscilla
AU  - Cukier P
FAU - Thompson, Iain R
AU  - Thompson IR
FAU - Navarro, Victor M
AU  - Navarro VM
FAU - Gagliardi, Priscila C
AU  - Gagliardi PC
FAU - Rodrigues, Tania
AU  - Rodrigues T
FAU - Kochi, Cristiane
AU  - Kochi C
FAU - Longui, Carlos Alberto
AU  - Longui CA
FAU - Beckers, Dominique
AU  - Beckers D
FAU - de Zegher, Francis
AU  - de Zegher F
FAU - Montenegro, Luciana R
AU  - Montenegro LR
FAU - Mendonca, Berenice B
AU  - Mendonca BB
FAU - Carroll, Rona S
AU  - Carroll RS
FAU - Hirschhorn, Joel N
AU  - Hirschhorn JN
FAU - Latronico, Ana Claudia
AU  - Latronico AC
FAU - Kaiser, Ursula B
AU  - Kaiser UB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
AID - 10.1056/NEJMoa1302160 [doi]
PST - aheadofprint
SO  - N Engl J Med. 2013 Jun 5.

PMID- 23738508
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 14
IP  - 1
DP  - 2013 Jun 5
TI  - The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic
      nephropathy: study protocol for a randomized, double-blind and placebo-controlled
      clinical trial.
PG  - 165
AB  - BACKGROUND: Diabetic nephropathy (DN) is a major microvascular complication with 
      diabetes. In China, an estimated 34.7 percent of people diagnosed with diabetes
      have renal complications and a further 50 percent die of renal failure. Hence,
      identification of alternative treatments for these patients should be given
      priority. The Shenyan Kangfu tablet (SYKFT) is a new formulation of an existing
      and widely acclaimed Chinese herbal tea for treating qi-yin deficiency syndrome. 
      Because a considerable portion of DN patients presenting with symptoms of
      swelling, fatigue and weak limbs would be diagnosed with qi-yin deficiency
      syndrome according to the traditional Chinese medicine (TCM) diagnostic criteria,
      we hypothesize that SYKFT may represent a complementary drug for DN patients with
      the corresponding syndrome. In view of this, we have designed a trial to assess
      the efficacy and safety of SYKFT for patients with diabetic nephropathy
      exhibiting signs of qi and yin deficiency. METHODS: This is a multicenter,
      double-blind, randomized controlled trial (RCT). The total target sample size is 
      planned at 80 participants, with a balanced (1:1) treatment allocation. The
      experimental intervention will be SYKFY plus irbesartan (SI regimen) and the
      control intervention will be a placebo plus irbesartan (PI regimen). Participants
      will receive two courses of medication treatment each lasting 8 weeks. The
      primary outcome will be the composite of the quantitative 24-hour urinary protein
      level and urinary albumin excretion rate (UAER). Changes in urine
      albumin-to-creatinine ratio (UACR) and DN staging, and TCM symptom improvement
      will be the secondary outcome measures. Adverse events (AEs) will be monitored
      throughout the trial DISCUSSION: This study will be the first placebo-controlled 
      RCT to assess whether SYKFT plus irbesartan will have beneficial effects on
      enhancing overall response rate (ORR), changing DN staging, improving clinical
      symptoms, and reducing the frequency of AEs for DN patients with qi-yin
      deficiency syndrome. The results of this trial will help to provide
      evidence-based recommendations for clinicians.Trial registration: Chinese
      Clinical Trials Register, Identifier: ChiCTR-TRC-12002182.
FAU - Wang, Hui
AU  - Wang H
FAU - Mu, Wei
AU  - Mu W
FAU - Zhai, Jingbo
AU  - Zhai J
FAU - Xing, Dongmei
AU  - Xing D
FAU - Miao, Shujie
AU  - Miao S
FAU - Wang, Jia
AU  - Wang J
FAU - Deng, Yueyi
AU  - Deng Y
FAU - Wang, Niansong
AU  - Wang N
FAU - Chen, Hongyu
AU  - Chen H
FAU - Yang, Hongtao
AU  - Yang H
FAU - He, Xuehong
AU  - He X
FAU - Shang, Hongcai
AU  - Shang H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Trials
JT  - Trials
JID - 101263253
EDAT- 2013/06/07 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/07 06:00
PHST- 2013/02/22 [received]
PHST- 2013/06/05 [accepted]
PHST- 2013/06/05 [aheadofprint]
AID - 1745-6215-14-165 [pii]
AID - 10.1186/1745-6215-14-165 [doi]
PST - aheadofprint
SO  - Trials. 2013 Jun 5;14(1):165.

PMID- 23738337
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 2314-6753 (Electronic)
VI  - 2013
DP  - 2013
TI  - Impact of High Glucose and Proteasome Inhibitor MG132 on Histone H2A and H2B
      Ubiquitination in Rat Glomerular Mesangial Cells.
PG  - 589474
LID - 10.1155/2013/589474 [doi]
AB  - Background. Hyperglycemia plays a pivotal role in the development of diabetic
      nephropathy (DN) and may be related to epigenetic metabolic memory. One of the
      most crucial epigenetic mechanisms is histone modification, which is associated
      with the expression of a fibrosis factor in vascular injury. Aim .In this study, 
      we investigated the ubiquitination of histones H2A and H2B to explore the
      epigenetic mechanisms of DN. Materials and Methods. The GMCs were cultured as
      follows: normal group, high glucose group, mannitol group, and intervention
      group. After 12 hr, 24 hr, and 48 hr, histones ubiquitination, transforming
      growth factor-beta (TGF-beta), and fibronectin (FN) were measured using WB,
      RT-PCR, and IF. Result. High glucose can induce the upregulation of FN. H2A
      ubiquitination in GMCs increased in high glucose group (P < 0.01), whereas it
      decreased significantly in intervention group (P < 0.05). In contrast, H2B
      ubiquitination decreased with an increasing concentration of glucose, but it was 
      recovered in the intervention group (P < 0.05). Expression of TGF-beta changed in
      response to abnormal histone ubiquitination. Conclusions. The high glucose may
      induce H2A ubiquitination and reduce H2B ubiquitination in GMCs. The changes of
      histone ubiquitination may be due in part to DN by activating TGF-beta signaling 
      pathway.
AD  - Department of Endocrinology, Affiliated Hospital of Luzhou Medical College,
      Luzhou 646000, China.
FAU - Gao, Chenlin
AU  - Gao C
FAU - Chen, Guo
AU  - Chen G
FAU - Liu, Li
AU  - Liu L
FAU - Li, Xia
AU  - Li X
FAU - He, Jianhua
AU  - He J
FAU - Jiang, Lan
AU  - Jiang L
FAU - Zhu, Jianhua
AU  - Zhu J
FAU - Xu, Yong
AU  - Xu Y
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
SB  - IM
PMC - PMC3657404
OID - NLM: PMC3657404
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/10/28 [received]
PHST- 2013/01/12 [revised]
PHST- 2013/02/17 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.1155/2013/589474 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:589474. doi: 10.1155/2013/589474. Epub 2013 Apr 30.

PMID- 23738032
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1942-0994 (Electronic)
VI  - 2013
DP  - 2013
TI  - Red orange: experimental models and epidemiological evidence of its benefits on
      human health.
PG  - 157240
LID - 10.1155/2013/157240 [doi]
AB  - In recent years, there has been increasing public interest in plant antioxidants,
      thanks to the potential anticarcinogenic and cardioprotective actions mediated by
      their biochemical properties. The red (or blood) orange (Citrus sinensis (L.)
      Osbeck) is a pigmented sweet orange variety typical of eastern Sicily (southern
      Italy), California, and Spain. In this paper, we discuss the main health-related 
      properties of the red orange that include anticancer, anti-inflammatory, and
      cardiovascular protection activities. Moreover, the effects on health of its main
      constituents (namely, flavonoids, carotenoids, ascorbic acid, hydroxycinnamic
      acids, and anthocyanins) are described. The red orange juice demonstrates an
      important antioxidant activity by modulating many antioxidant enzyme systems that
      efficiently counteract the oxidative damage which may play an important role in
      the etiology of numerous diseases, such as atherosclerosis, diabetes, and cancer.
      The beneficial effects of this fruit may be mediated by the synergic effects of
      its compounds. Thus, the supply of natural antioxidant compounds through a
      balanced diet rich in red oranges might provide protection against oxidative
      damage under differing conditions and could be more effective than, the
      supplementation of an individual antioxidant.
AD  - Section of Hygiene and Public Health, Department of G.F. Ingrassia, University of
      Catania, Via S. Sofia No. 85-95123, Catania, Italy ; Section of Biochemistry,
      Department of Drug Sciences, University of Catania, Catania, Italy.
FAU - Grosso, Giuseppe
AU  - Grosso G
FAU - Galvano, Fabio
AU  - Galvano F
FAU - Mistretta, Antonio
AU  - Mistretta A
FAU - Marventano, Stefano
AU  - Marventano S
FAU - Nolfo, Francesca
AU  - Nolfo F
FAU - Calabrese, Giorgio
AU  - Calabrese G
FAU - Buscemi, Silvio
AU  - Buscemi S
FAU - Drago, Filippo
AU  - Drago F
FAU - Veronesi, Umberto
AU  - Veronesi U
FAU - Scuderi, Alessandro
AU  - Scuderi A
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
SB  - IM
PMC - PMC3659473
OID - NLM: PMC3659473
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/02/27 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/02 [epublish]
AID - 10.1155/2013/157240 [doi]
PST - ppublish
SO  - Oxid Med Cell Longev. 2013;2013:157240. doi: 10.1155/2013/157240. Epub 2013 May
      2.

PMID- 23737999
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Microwell scaffolds for the extrahepatic transplantation of islets of langerhans.
PG  - e64772
LID - 10.1371/journal.pone.0064772 [doi]
AB  - Allogeneic islet transplantation into the liver has the potential to restore
      normoglycemia in patients with type 1 diabetes. However, the suboptimal
      microenvironment for islets in the liver is likely to be involved in the
      progressive islet dysfunction that is often observed post-transplantation. This
      study validates a novel microwell scaffold platform to be used for the
      extrahepatic transplantation of islet of Langerhans. Scaffolds were fabricated
      from either a thin polymer film or an electrospun mesh of poly(ethylene oxide
      terephthalate)-poly(butylene terephthalate) (PEOT/PBT) block copolymer
      (composition: 4000PEOT30PBT70) and were imprinted with microwells, approximately 
      400 microm in diameter and approximately 350 microm in depth. The water contact
      angle and water uptake were 39+/-2 degrees and 52.1+/-4.0 wt%, respectively. The 
      glucose flux through electrospun scaffolds was three times higher than for thin
      film scaffolds, indicating enhanced nutrient diffusion. Human islets cultured in 
      microwell scaffolds for seven days showed insulin release and insulin content
      comparable to those of free-floating control islets. Islet morphology and insulin
      and glucagon expression were maintained during culture in the microwell
      scaffolds. Our results indicate that the microwell scaffold platform prevents
      islet aggregation by confinement of individual islets in separate microwells,
      preserves the islet's native rounded morphology, and provides a protective
      environment without impairing islet functionality, making it a promising platform
      for use in extrahepatic islet transplantation.
AD  - Department of Developmental BioEngineering, MIRA Institute for Biomedical
      Technology and Technical Medicine, University of Twente, Enschede, The
      Netherlands.
FAU - Buitinga, Mijke
AU  - Buitinga M
FAU - Truckenmuller, Roman
AU  - Truckenmuller R
FAU - Engelse, Marten A
AU  - Engelse MA
FAU - Moroni, Lorenzo
AU  - Moroni L
FAU - Ten Hoopen, Hetty W M
AU  - Ten Hoopen HW
FAU - van Blitterswijk, Clemens A
AU  - van Blitterswijk CA
FAU - de Koning, Eelco Jp
AU  - de Koning EJ
FAU - van Apeldoorn, Aart A
AU  - van Apeldoorn AA
FAU - Karperien, Marcel
AU  - Karperien M
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3667808
OID - NLM: PMC3667808
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/13 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/05/30 [epublish]
AID - 10.1371/journal.pone.0064772 [doi]
AID - PONE-D-13-02468 [pii]
PST - epublish
SO  - PLoS One. 2013 May 30;8(5):e64772. doi: 10.1371/journal.pone.0064772. Print 2013.

PMID- 23737983
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Eukaryotic translation initiation factor 3 subunit e controls intracellular
      calcium homeostasis by regulation of cav1.2 surface expression.
PG  - e64462
LID - 10.1371/journal.pone.0064462 [doi]
AB  - Inappropriate surface expression of voltage-gated Ca(2+)channels (CaV) in
      pancreatic ss-cells may contribute to the development of type 2 diabetes. First, 
      failure to increase intracellular Ca(2+) concentrations at the sites of
      exocytosis impedes insulin release. Furthermore, excessive Ca(2+) influx may
      trigger cytotoxic effects. The regulation of surface expression of CaV channels
      in the pancreatic beta-cells remains unknown. Here, we used real-time 3D confocal
      and TIRFM imaging, immunocytochemistry, cellular fractionation,
      immunoprecipitation and electrophysiology to study trafficking of L-type CaV1.2
      channels upon beta-cell stimulation. We found decreased surface expression of
      CaV1.2 and a corresponding reduction in L-type whole-cell Ca(2+) currents in
      insulin-secreting INS-1 832/13 cells upon protracted (15-30 min) stimulation.
      This internalization occurs by clathrin-dependent endocytosis and could be
      prevented by microtubule or dynamin inhibitors. eIF3e (Eukaryotic translation
      initiation factor 3 subunit E) is part of the protein translation initiation
      complex, but its effect on translation are modest and effects in ion channel
      trafficking have been suggested. The factor interacted with CaV1.2 and regulated 
      CaV1.2 traffic bidirectionally. eIF3e silencing impaired CaV1.2 internalization, 
      which resulted in an increased intracellular Ca(2+) load upon stimulation. These 
      findings provide a mechanism for regulation of L-type CaV channel surface
      expression with consequences for beta-cell calcium homeostasis, which will affect
      pancreatic beta-cell function and insulin production.
AD  - Lund University Diabetes Center, Malmo, Sweden.
FAU - Buda, Pawel
AU  - Buda P
FAU - Reinbothe, Thomas
AU  - Reinbothe T
FAU - Nagaraj, Vini
AU  - Nagaraj V
FAU - Mahdi, Taman
AU  - Mahdi T
FAU - Luan, Cheng
AU  - Luan C
FAU - Tang, Yunzhao
AU  - Tang Y
FAU - Axelsson, Annika S
AU  - Axelsson AS
FAU - Li, Daiqing
AU  - Li D
FAU - Rosengren, Anders H
AU  - Rosengren AH
FAU - Renstrom, Erik
AU  - Renstrom E
FAU - Zhang, Enming
AU  - Zhang E
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3667822
OID - NLM: PMC3667822
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/11 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/05/30 [epublish]
AID - 10.1371/journal.pone.0064462 [doi]
AID - PONE-D-12-35341 [pii]
PST - epublish
SO  - PLoS One. 2013 May 30;8(5):e64462. doi: 10.1371/journal.pone.0064462. Print 2013.

PMID- 23737927
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130605
DCOM- 20130606
LR  - 20130607
IS  - 1925-8348 (Electronic)
IS  - 1925-8348 (Linking)
VI  - 16
IP  - 2
DP  - 2013
TI  - Do Antidepressants Lower the Prevalence of Lithium-associated Hypernatremia in
      the Elderly? A Retrospective Study.
PG  - 38-42
LID - 10.5770/cgj.16.50 [doi]
AB  - BACKGROUND: Clinically important measures of lithium-induced nephrogenic diabetes
      insipidus (NDI) such as hypernatremia have not been well-studied. This is
      especially relevant for the elderly who, in comparison to younger adults, may
      become symptomatic and require hospitalization with relatively small elevations
      in sodium levels. We hypothesized that antidepressant use, which has been
      associated with the syndrome of inappropriate antidiuretic hormone secretion, has
      a protective effect against lithium-associated hypernatremia in the elderly.
      METHODS: Retrospective cohort study of 55 geriatric psychiatry outpatients
      followed at tertiary-care hospitals. Patients using lithium and antidepressants
      were compared with those using lithium alone for prevalence rates of
      hypernatremia during a 15-year observational period. RESULTS: The prevalence of
      hypernatremia was less in patients who had concurrent use of lithium and
      antidepressants, as compared to lithium alone 3/35 (8.6%) vs. 8/20 (40%), OR
      0.14, p = .011. CONCLUSIONS: Our results suggest that elderly lithium patients
      are less likely to develop hypernatremia if they are taking antidepressants
      concurrently. Whether antidepressants may be useful in the prevention of
      lithium-associated hypernatremia should be assessed in future prospective
      observational or treatment studies.
AD  - Department of Psychiatry, McGill University, Montreal;
FAU - Rej, Soham
AU  - Rej S
FAU - Looper, Karl
AU  - Looper K
FAU - Segal, Marilyn
AU  - Segal M
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - Canada
TA  - Can Geriatr J
JT  - Canadian geriatrics journal : CGJ
JID - 101579189
PMC - PMC3671010
OID - NLM: PMC3671010
OTO - NOTNLM
OT  - diabetes insipidus
OT  - geriatric
OT  - lithium
OT  - psychopharmacology
OT  - renal effects
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:01
CRDT- 2013/06/06 06:00
PHST- 2013 [ppublish]
PHST- 2013/06/03 [epublish]
AID - 10.5770/cgj.16.50 [doi]
AID - cgj-16-38 [pii]
PST - epublish
SO  - Can Geriatr J. 2013 Jun 3;16(2):38-42. doi: 10.5770/cgj.16.50. Print 2013.

PMID- 23737909
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 5
IP  - 5
DP  - 2013 May
TI  - Ileal interposition surgery-induced improvement of hyperglycemia and insulin
      resistance in Goto-Kakizaki rats by upregulation of TCF7L2 expression.
PG  - 1511-1515
AB  - The aim of this study was to investigate the effects of ileal interposition (IT) 
      on glucose and insulin resistance (IR) in type 2 diabetic mellitus (T2DM), and
      the role of T-cell factor 7-like 2 (TCF7L2), formerly known as TCF4, in the
      downregulation of hyperglycemia following IT. Goto-Kakizaki (GK) rats subjected
      to IT surgery (GK-IT group), GK rats subjected to sham surgery (GK-Sham group)
      and Wistar (WS) rats subjected to sham surgery (WS-Sham group) were investigated 
      in this study. Fasting plasma glucose, body weight, food intake per 1 kg body
      weight, insulin and a homeostasis model assessment of insulin resistance
      (HOMA-IR) were measured pre- and post-surgery. The rats were euthanized 28 days
      post-surgery and the pancreas of each rat was dissected. The expression levels of
      TCF7L2 mRNA and protein were analyzed by quantitative RT-PCR and western
      blotting, respectively. Our results revealed that IT improved both fasting plasma
      glucose levels and IR in GK rats by upregulating the expression of the TCF7L2
      protein. IT provides a valuable therapeutic option for patients with T2DM.
      Upregulation of TCF7L2 protein expression may be a possible mechanism underlying 
      the improvement of T2DM following IT.
AD  - Department of General Surgery, Beijing Tiantan Hospital, Capital Medical
      University, Beijing 100050, P.R. China ;
FAU - Sun, Xu
AU  - Sun X
FAU - Song, Maomin
AU  - Song M
FAU - Bai, Rixing
AU  - Bai R
FAU - Cheng, Shi
AU  - Cheng S
FAU - Xing, Ying
AU  - Xing Y
FAU - Yuan, Huisheng
AU  - Yuan H
FAU - Wang, Pilin
AU  - Wang P
FAU - Zhou, Lisa
AU  - Zhou L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130312
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3671895
OTO - NOTNLM
OT  - T-cell factor 7-like 2
OT  - hyperglycemia
OT  - ileal interposition
OT  - type 2 diabetes mellitus
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/12/25 [received]
PHST- 2013/03/05 [accepted]
PHST- 2013/03/12 [epublish]
AID - 10.3892/etm.2013.998 [doi]
AID - etm-05-05-1511 [pii]
PST - ppublish
SO  - Exp Ther Med. 2013 May;5(5):1511-1515. Epub 2013 Mar 12.

PMID- 23737904
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 5
IP  - 5
DP  - 2013 May
TI  - Predictors of diffuse-type in-stent restenosis following drug-eluting stent
      implantation.
PG  - 1486-1490
AB  - Diffuse-type in-stent restenosis (ISR) is known to be associated with a higher
      rate of restenosis than focal-type ISR. Therefore, it is clinically important to 
      identify the determinants of diffuse-type ISR following drug-eluting stent (DES) 
      implantation. We investigated the clinical, procedural and angiographic variables
      for predicting diffuse-type ISR following DES implantation. A total of 173 ISR
      lesions in 159 patients (diffuse-type: 61 lesions, focal-type: 112 lesions)
      following DES implantation from February 2003 to May 2008 were included in this
      study. Clinical, procedural and quantitative coronary angiographic variables were
      analyzed to determine predictors of diffuse-type ISR following DES implantation. 
      Univariate analysis showed that the absence of hypertension [odds ratio (OR),
      0.493; 95% confidence interval (CI), 1.025-4.103, P=0.042], use of a
      paclitaxel-eluting stent (PES) (OR, 3.318; 95% CI, 1.730-6.365, P<0.001) and
      smaller post-stenting minimal luminal diameter (MLD; OR, 0.368, 95% CI,
      0.168-0.808, P=0.013) were significantly associated with diffuse-type ISR.
      However, use of a PES (OR, 3.957; 95% CI, 1.977-7.922, P<0.001) and smaller
      post-stenting MLD (OR, 0.320; CI, 0.140-0.731, P=0.007) were only independent
      predictors of diffuse-type ISR by multivariate analysis. Diabetes was not a
      predictor of diffuse-type ISR. The use of a PES and the post-stenting MLD were
      related to diffuse-type ISR following DES implantation.
AD  - Department of Internal Medicine, Graduate School of Medicine, Kyung Hee
      University at Gangdong, Kyung Hee University, Seoul, Republic of Korea.
FAU - Park, Chang-Bum
AU  - Park CB
FAU - Park, Hoon-Ki
AU  - Park HK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3671824
OTO - NOTNLM
OT  - predictor
OT  - restenosis
OT  - stent
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/12/10 [received]
PHST- 2013/02/13 [accepted]
PHST- 2013/03/21 [epublish]
AID - 10.3892/etm.2013.1024 [doi]
AID - etm-05-05-1486 [pii]
PST - ppublish
SO  - Exp Ther Med. 2013 May;5(5):1486-1490. Epub 2013 Mar 21.

PMID- 23737887
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 5
IP  - 5
DP  - 2013 May
TI  - Prevalence and incidence of retinopathy in elderly diabetic patients receiving
      early diagnosis and treatment.
PG  - 1393-1396
AB  - Diabetic retinopathy (DR) is one of the most common and specific complications of
      diabetes. Thus, intervention is required to lower the incidence and prevalence of
      sight-threatening retinopathy. The aim of this study was to investigate the
      prevalence and incidence of diabetic retinopathy in elderly diabetic patients
      receiving early diagnosis and proper treatment and to explore risk factors for
      DR. From May 2005 to May 2011, fundus examination was performed for elderly
      diabetic patients during routine medical examinations. The presence of a
      microaneurysm or more severe presentations was used to diagnose DR, which was
      followed by fundus fluorescein angiography. Logistic regression analysis was
      employed to analyze the risk factors for DR development within 5 years. A total
      of 2,194 diabetic patients were recruited and followed-up for a mean of 5.8
      years. The prevalence of DR was 15.38-16.20% and the incidence of DR was
      8.38/1,000 person-years. Logistic multiple stepwise regression revealed that
      fasting plasma glucose (FPG), mean arterial pressure (MAP), duration of diabetes,
      body mass index (BMI) and microalbuminuria (MAU) were significantly associated
      with the occurrence of DR (all P<0.05). In the present study, the prevalence and 
      incidence of DM were higher compared with those reported in the general
      population; however, the prevalence and incidence of DR were lower compared with 
      those reported in similar studies. This suggests that favorable control of blood 
      glucose, blood pressure and blood lipids effectively prevents the occurrence of
      DR in diabetic patients.
AD  - Departments of Internal Medicine, Chinese PLA General Hospital, Beijing 100853,
      P.R. China.
FAU - Li, Xin
AU  - Li X
FAU - Wang, Zhaoyan
AU  - Wang Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130320
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3671843
OTO - NOTNLM
OT  - diabetes
OT  - diabetic retinopathy
OT  - elderly
OT  - incidence
OT  - prevalence
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/01/04 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/03/20 [epublish]
AID - 10.3892/etm.2013.1021 [doi]
AID - etm-05-05-1393 [pii]
PST - ppublish
SO  - Exp Ther Med. 2013 May;5(5):1393-1396. Epub 2013 Mar 20.

PMID- 23737829
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Assessing the metabolic effects of aromatherapy in human volunteers.
PG  - 356381
LID - 10.1155/2013/356381 [doi]
AB  - Aromatherapy, a form of complementary and alternative medicine (CAM) that uses
      essential oils through inhalation, is believed to enhance physical and spiritual 
      conditions. Although clinical studies suggest that the use of essential oils may 
      have therapeutic potential, evidence for the efficacy of aromatherapy in treating
      medical conditions remains poor, with a particular lack of studies employing
      rigorous analytical methods that capture its identifiable impact on human
      biology. Here, we report a comprehensive metabolomics study that reveals
      metabolic changes in people after exposed to aroma inhalation for 10 continuous
      days. In this study, the metabolic alterations in urine of 31 females with mild
      anxiety symptoms exposed to aerial diffusion of aromas were measured by GC-TOF-MS
      and UPLC-Q-TOF-MS analyses. A significant alteration of metabolic profile in
      subjects responsive to essential oil was found, which is characterized by the
      increased levels of arginine, homocysteine, and betaine, as well as decreased
      levels of alcohols, carbohydrates, and organic acids in urine. Notably, the
      metabolites from tricarboxylic acid (TCA) cycle and gut microbial metabolism were
      significantly altered. This study demonstrates that the metabolomics approach can
      capture the subtle metabolic changes resulting from exposure to essential oils,
      which may lead to an improved mechanistic understanding of aromatherapy.
AD  - Center for Translational Medicine and Shanghai Key Laboratory of Diabetes
      Mellitus, Department of Endocrinology and Metabolism, Shanghai Jiao Tong
      University Affiliated Sixth People's Hospital, Shanghai 200233, China.
FAU - Zhang, Yinan
AU  - Zhang Y
FAU - Wu, Yani
AU  - Wu Y
FAU - Chen, Tianlu
AU  - Chen T
FAU - Yao, Lei
AU  - Yao L
FAU - Liu, Jiajian
AU  - Liu J
FAU - Pan, Xiaolan
AU  - Pan X
FAU - Hu, Yixue
AU  - Hu Y
FAU - Zhao, Aihua
AU  - Zhao A
FAU - Xie, Guoxiang
AU  - Xie G
FAU - Jia, Wei
AU  - Jia W
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3659644
OID - NLM: PMC3659644
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/01/04 [received]
PHST- 2013/04/12 [revised]
PHST- 2013/04/14 [accepted]
PHST- 2013/05/02 [epublish]
AID - 10.1155/2013/356381 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:356381. doi: 10.1155/2013/356381.
      Epub 2013 May 2.

PMID- 23737828
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Treating type 2 diabetes mellitus with traditional chinese and Indian medicinal
      herbs.
PG  - 343594
LID - 10.1155/2013/343594 [doi]
AB  - Type II diabetes mellitus (T2DM) is a fast-growing epidemic affecting people
      globally. Furthermore, multiple complications and comorbidities are associated
      with T2DM. Lifestyle modifications along with pharmacotherapy and patient
      education are the mainstay of therapy for patients afflicted with T2DM. Western
      medications are frequently associated with severe adverse drug reactions and high
      costs of treatment. Herbal medications have long been used in the treatment and
      prevention of T2DM in both traditional Chinese medicine (TCM) and traditional
      Indian medicine (TIM). This review examines in vivo, in vitro, and clinical
      evidence supporting the use of various herbs used in TCM and TIM. The problems,
      challenges, and opportunities for the incorporation of herbal frequently used in 
      TCM and TIM into Western therapy are presented and discussed.
AD  - Center for Advancement of Drug Research and Evaluation, College of Pharmacy,
      Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766,
      USA.
FAU - Wang, Zhijun
AU  - Wang Z
FAU - Wang, Jeffrey
AU  - Wang J
FAU - Chan, Patrick
AU  - Chan P
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3662109
OID - NLM: PMC3662109
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/02/01 [received]
PHST- 2013/04/01 [accepted]
PHST- 2013/05/07 [epublish]
AID - 10.1155/2013/343594 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:343594. doi: 10.1155/2013/343594.
      Epub 2013 May 7.

PMID- 23737827
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - The rs1142345 in TPMT Affects the Therapeutic Effect of Traditional Hypoglycemic 
      Herbs in Prediabetes.
PG  - 327629
LID - 10.1155/2013/327629 [doi]
AB  - Therapeutic interventions in prediabetes are important in the primary prevention 
      of type 2 diabetes (T2D) and its chronic complications. However, little is known 
      about the pharmacogenetic effect of traditional herbs on prediabetes treatment. A
      total of 194 impaired glucose tolerance (IGT) subjects were treated with
      traditional hypoglycemic herbs (Tianqi Jiangtang) for 12 months in this study.
      DNA samples were genotyped for 184 mutations in 34 genes involved in drug
      metabolism or transportation. Multinomial logistic regression analysis indicated 
      that rs1142345 (A > G) in the thiopurine S-methyltransferase (TPMT) gene was
      significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR
      P = 0.043). The "G" allele frequencies of rs1142345 in the healthy (subjects
      reverted from IGT to normal glucose tolerance), maintenance (subjects still had
      IGT), and deterioration (subjects progressed from IGT to T2D) groups were 0.094, 
      0.214, and 0.542, respectively. Binary logistic regression analysis indicated
      that rs1142345 was also significantly associated with the hypoglycemic effect of 
      the drug between the healthy and maintenance groups (P = 0.027, OR = 4.828) and
      between the healthy and deterioration groups (P = 0.001, OR = 7.811). Therefore, 
      rs1142345 was associated with the clinical effect of traditional hypoglycemic
      herbs. Results also suggested that TPMT was probably involved in the
      pharmacological mechanisms of T2D.
AD  - Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central 
      South University, Changsha, Hunan 410078, China.
FAU - Li, Xi
AU  - Li X
FAU - Lian, Feng-Mei
AU  - Lian FM
FAU - Guo, Dong
AU  - Guo D
FAU - Fan, Lan
AU  - Fan L
FAU - Tang, Jie
AU  - Tang J
FAU - Peng, Jing-Bo
AU  - Peng JB
FAU - Deng, Hong-Wen
AU  - Deng HW
FAU - Liu, Zhao-Qian
AU  - Liu ZQ
FAU - Xiao, Xin-Hua
AU  - Xiao XH
FAU - Wang, Yan-Rong
AU  - Wang YR
FAU - Qu, Ke-Yi
AU  - Qu KY
FAU - Deng, Sheng
AU  - Deng S
FAU - Zhong, Qi
AU  - Zhong Q
FAU - Sha, Yi-Ling
AU  - Sha YL
FAU - Zhu, Yan
AU  - Zhu Y
FAU - Bai, Yu-Jing
AU  - Bai YJ
FAU - Chen, Xin-Yan
AU  - Chen XY
FAU - Zhou, Qiang
AU  - Zhou Q
FAU - Zhou, Hong-Hao
AU  - Zhou HH
FAU - Tong, Xiao-Lin
AU  - Tong XL
FAU - Zhang, Wei
AU  - Zhang W
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3657408
OID - NLM: PMC3657408
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/01/06 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/29 [epublish]
AID - 10.1155/2013/327629 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:327629. doi: 10.1155/2013/327629.
      Epub 2013 Apr 29.

PMID- 23737780
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130605
DCOM- 20130606
LR  - 20130607
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Intrahepatic Lipid Content and Insulin Resistance Are More Strongly Associated
      with Impaired NEFA Suppression after Oral Glucose Loading Than with Fasting NEFA 
      Levels in Healthy Older Individuals.
PG  - 870487
LID - 10.1155/2013/870487 [doi]
AB  - Introduction. The mechanisms underlying the association between insulin
      resistance and intrahepatic lipid (IHL) accumulation are not completely
      understood. We sought to determine whether this association was explained by
      differences in fasting non-esterified fatty acid (NEFA) levels and/or NEFA
      suppression after oral glucose loading. Materials and Methods. We performed a
      cross-sectional analysis of 70 healthy participants in the Hertfordshire Physical
      Activity Trial (39 males, age 71.3 +/- 2.4 years) who underwent oral glucose
      tolerance testing with glucose, insulin, and NEFA levels measured over two hours.
      IHL was quantified with magnetic resonance spectroscopy. Insulin sensitivity was 
      measured with the oral glucose insulin sensitivity (OGIS) model, the leptin:
      adiponectin ratio (LAR), and the homeostasis model assessment (HOMA). Results.
      Measures of insulin sensitivity were not associated with fasting NEFA levels, but
      OGIS was strongly associated with NEFA suppression at 30 minutes and strongly
      inversely associated with IHL. Moreover, LAR was strongly inversely associated
      with NEFA suppression and strongly associated with IHL. This latter association
      (beta = 1.11 [1.01, 1.21], P = 0.026) was explained by reduced NEFA suppression
      (P = 0.24 after adjustment). Conclusions. Impaired postprandial NEFA suppression,
      but not fasting NEFA, contributes to the strong and well-established association 
      between whole body insulin resistance and liver fat accumulation.
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital,
      P.O. Box 285 Hills Road, Cambridge CB20QQ, UK ; Galway Diabetes Research Centre, 
      School of Medicine, Clinical Science Institute, NUI Galway, Galway, Ireland.
FAU - Finucane, Francis M
AU  - Finucane FM
FAU - Sharp, Stephen J
AU  - Sharp SJ
FAU - Hatunic, Mensud
AU  - Hatunic M
FAU - Sleigh, Alison
AU  - Sleigh A
FAU - De Lucia Rolfe, Ema
AU  - De Lucia Rolfe E
FAU - Sayer, Avan Aihie
AU  - Sayer AA
FAU - Cooper, Cyrus
AU  - Cooper C
FAU - Griffin, Simon J
AU  - Griffin SJ
FAU - Savage, David B
AU  - Savage DB
FAU - Wareham, Nicholas J
AU  - Wareham NJ
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3659510
OID - NLM: PMC3659510
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:01
CRDT- 2013/06/06 06:00
PHST- 2013/01/08 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/04/11 [accepted]
PHST- 2013/05/02 [epublish]
AID - 10.1155/2013/870487 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:870487. doi: 10.1155/2013/870487. Epub 2013 May 2.

PMID- 23737779
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130605
DCOM- 20130606
LR  - 20130607
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Endocrine actions of osteocalcin.
PG  - 846480
LID - 10.1155/2013/846480 [doi]
AB  - Osteocalcin is the most abundant noncollagenous protein of bone matrix. Once
      transcribed, this protein undergoes posttranslational modifications within
      osteoblastic cells before its secretion, including the carboxylation of three
      glutamic residues in glutamic acid, which is essential for hydroxyapatite binding
      and deposition in the extracellular matrix of bone. Recent provocative data from 
      experimental observations in mice showed that the circulating undercarboxylated
      fraction of osteocalcin increases insulin secretion and sensitivity, lowers blood
      glucose, and decreases visceral fat in both genders, while it enhances
      testosterone production by the testes in males. Moreover, both total and
      undercarboxylated osteocalcins increase following physical activity with
      potential positive effects on glucose tolerance. Despite that these evidences
      have been only in part confirmed in humans, further prospective investigations
      are needed to definitively establish the endocrine role of osteocalcin both in
      the general population and cohorts of patients with diabetes or other metabolic
      disorders.
AD  - Department of Clinical, Surgical and Neurological Sciences, University of Siena, 
      53100 Siena, Italy.
FAU - Patti, Aurora
AU  - Patti A
FAU - Gennari, Luigi
AU  - Gennari L
FAU - Merlotti, Daniela
AU  - Merlotti D
FAU - Dotta, Francesco
AU  - Dotta F
FAU - Nuti, Ranuccio
AU  - Nuti R
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3657394
OID - NLM: PMC3657394
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:01
CRDT- 2013/06/06 06:00
PHST- 2012/12/28 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/02 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.1155/2013/846480 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:846480. doi: 10.1155/2013/846480. Epub 2013 Apr 30.

PMID- 23737776
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130605
DCOM- 20130606
LR  - 20130607
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Comparison of a multiple daily insulin injection regimen (glargine or detemir
      once daily plus prandial insulin aspart) and continuous subcutaneous insulin
      infusion (aspart) in short-term intensive insulin therapy for poorly controlled
      type 2 diabetes patients.
PG  - 614242
LID - 10.1155/2013/614242 [doi]
AB  - Aims. To examine the potential differences between multiple daily injection (MDI)
      regimens based on new long-acting insulin analogues (glargine or detemir) plus
      prandial insulin aspart and continuous subcutaneous insulin aspart infusion
      (CSII) in patients with poorly controlled type 2 diabetes. Methods. Patients (n =
      119) with poorly controlled type 2 diabetes of a duration exceeding five years
      were randomly assigned into three groups: Group A treated with CSII using insulin
      aspart; Group B treated with glargine-based MDI and Group C treated with
      detemir-based MDI. Results. Good glycemic control was achieved by patients in
      Group A in a significantly shorter duration than patients in Groups B and C.
      Total daily insulin, basal insulin dose and dose per kg body weight in Group A
      were significantly less than those in Groups B and C. Daily blood glucose
      fluctuation in Group A was significantly less than that in Groups B and C. There 
      were no differences between Groups B and C. Conclusions. Aspart-based CSII may
      achieve good blood glucose control with less insulin doses over a shorter period 
      compared with glargine or detemir-based MDI. No differences between glargine- and
      detemir-based MDI were detected in poorly controlled subjects with type 2
      diabetes.
AD  - The Department of Internal Medicine, The Affiliated Hospital of Medical College, 
      Qingdao University, Qingdao 266100, China.
FAU - Lv, Wen-Shan
AU  - Lv WS
FAU - Li, Li
AU  - Li L
FAU - Wen, Jun-Ping
AU  - Wen JP
FAU - Pan, Rong-Fang
AU  - Pan RF
FAU - Sun, Rui-Xia
AU  - Sun RX
FAU - Wang, Jing
AU  - Wang J
FAU - Xian, Yu-Xin
AU  - Xian YX
FAU - Cao, Cai-Xia
AU  - Cao CX
FAU - Gao, Yan-Yan
AU  - Gao YY
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3662171
OID - NLM: PMC3662171
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:01
CRDT- 2013/06/06 06:00
PHST- 2012/05/16 [received]
PHST- 2013/03/27 [revised]
PHST- 2013/04/13 [accepted]
PHST- 2013/05/08 [epublish]
AID - 10.1155/2013/614242 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:614242. doi: 10.1155/2013/614242. Epub 2013 May 8.

PMID- 23737771
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130605
DCOM- 20130606
LR  - 20130607
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Significant independent predictors of vitamin d deficiency in inpatients and
      outpatients of a nephrology unit.
PG  - 237869
LID - 10.1155/2013/237869 [doi]
AB  - Aims. Kidney disease was found to be a major risk factor for vitamin D deficiency
      in a population study of patients hospitalized. The aims of the study were to
      describe the prevalence of vitamin D deficiency inpatients and outpatients in a
      nephrology department during fall and to evaluate effect of assessing serum
      25-hydroxyvitamin D (25(OH)D) levels and previous supplementation of
      cholecalciferol on vitamin D status. Methods. We studied 280 subjects in total,
      between October and January. The subjects were recruited from the following two
      groups: (a) inpatients and (b) outpatients in nephrology unit. We examined
      previous documentary evidence of vitamin D supplementation of the patients.
      Results. The prevalence of vitamin D deficiency among these 280 patients was
      62,1% (174 patients). Fifty-three patients (18.9%) had severe vitamin D
      deficiency, 121 patients (43.2%) moderate vitamin D deficiency, and 66 patients
      (23.6%) vitamin D insufficiency. In logistic regression analysis female gender,
      not having vitamin D supplementation history, low serum albumin, and low blood
      urea nitrogen levels were significant independent predictors of vitamin D
      deficiency while no association of vitamin D deficiency with diabetes mellitus,
      serum creatinine, eGFR, and being hospitalized was found. Conclusion. Vitamin D
      deficiency, seems to be an important problem in both inpatients and outpatients
      of nephrology. Monitoring serum 25(OH)D concentrations regularly and replacement 
      of vitamin D are important. Women in Turkey are at more risk of deficiency and
      may therefore need to consume higher doses of vitamin D.
AD  - Internal Medicine Department, Medical Faculty, Inonu University, Malatya, Turkey.
FAU - Bentli, Recep
AU  - Bentli R
FAU - Taskapan, Hulya
AU  - Taskapan H
FAU - Toktas, Halil
AU  - Toktas H
FAU - Ulutas, Ozkan
AU  - Ulutas O
FAU - Ozkahraman, Adnan
AU  - Ozkahraman A
FAU - Comert, Melda
AU  - Comert M
LA  - eng
PT  - Journal Article
DEP - 20130512
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3662121
OID - NLM: PMC3662121
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:01
CRDT- 2013/06/06 06:00
PHST- 2013/02/26 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/15 [accepted]
PHST- 2013/05/12 [epublish]
AID - 10.1155/2013/237869 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:237869. doi: 10.1155/2013/237869. Epub 2013 May 12.

PMID- 23737756
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1553-7404 (Electronic)
IS  - 1553-7390 (Linking)
VI  - 9
IP  - 5
DP  - 2013 May
TI  - GLIS3, a Susceptibility Gene for Type 1 and Type 2 Diabetes, Modulates Pancreatic
      Beta Cell Apoptosis via Regulation of a Splice Variant of the BH3-Only Protein
      Bim.
PG  - e1003532
LID - 10.1371/journal.pgen.1003532 [doi]
AB  - Mutations in human Gli-similar (GLIS) 3 protein cause neonatal diabetes. The
      GLIS3 gene region has also been identified as a susceptibility risk locus for
      both type 1 and type 2 diabetes. GLIS3 plays a role in the generation of
      pancreatic beta cells and in insulin gene expression, but there is no information
      on the role of this gene on beta cell viability and/or susceptibility to immune- 
      and metabolic-induced stress. GLIS3 knockdown (KD) in INS-1E cells, primary
      FACS-purified rat beta cells, and human islet cells decreased expression of MafA,
      Ins2, and Glut2 and inhibited glucose oxidation and insulin secretion, confirming
      the role of this transcription factor for the beta cell differentiated phenotype.
      GLIS3 KD increased beta cell apoptosis basally and sensitized the cells to death 
      induced by pro-inflammatory cytokines (interleukin 1beta + interferon-gamma) or
      palmitate, agents that may contribute to beta cell loss in respectively type 1
      and 2 diabetes. The increased cell death was due to activation of the intrinsic
      (mitochondrial) pathway of apoptosis, as indicated by cytochrome c release to the
      cytosol, Bax translocation to the mitochondria and activation of caspases 9 and
      3. Analysis of the pathways implicated in beta cell apoptosis following GLIS3 KD 
      indicated modulation of alternative splicing of the pro-apoptotic BH3-only
      protein Bim, favouring expression of the pro-death variant BimS via inhibition of
      the splicing factor SRp55. KD of Bim abrogated the pro-apoptotic effect of GLIS3 
      loss of function alone or in combination with cytokines or palmitate. The present
      data suggest that altered expression of the candidate gene GLIS3 may contribute
      to both type 1 and 2 type diabetes by favouring beta cell apoptosis. This is
      mediated by alternative splicing of the pro-apoptotic protein Bim and exacerbated
      formation of the most pro-apoptotic variant BimS.
AD  - Laboratory of Experimental Medicine, Medical Faculty, Universite Libre de
      Bruxelles, Brussels, Belgium.
FAU - Nogueira, Tatiane C
AU  - Nogueira TC
FAU - Paula, Flavia M
AU  - Paula FM
FAU - Villate, Olatz
AU  - Villate O
FAU - Colli, Maikel L
AU  - Colli ML
FAU - Moura, Rodrigo F
AU  - Moura RF
FAU - Cunha, Daniel A
AU  - Cunha DA
FAU - Marselli, Lorella
AU  - Marselli L
FAU - Marchetti, Piero
AU  - Marchetti P
FAU - Cnop, Miriam
AU  - Cnop M
FAU - Julier, Cecile
AU  - Julier C
FAU - Eizirik, Decio L
AU  - Eizirik DL
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - United States
TA  - PLoS Genet
JT  - PLoS genetics
JID - 101239074
SB  - IM
PMC - PMC3667755
OID - NLM: PMC3667755
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05 [ppublish]
PHST- 2012/10/29 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/30 [epublish]
AID - 10.1371/journal.pgen.1003532 [doi]
AID - PGENETICS-D-12-02709 [pii]
PST - ppublish
SO  - PLoS Genet. 2013 May;9(5):e1003532. doi: 10.1371/journal.pgen.1003532. Epub 2013 
      May 30.

PMID- 23737732
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1537-744X (Electronic)
IS  - 1537-744X (Linking)
VI  - 2013
DP  - 2013
TI  - Pathogenesis and novel treatment from the mouse model of type 2 diabetic
      nephropathy.
PG  - 928197
LID - 10.1155/2013/928197 [doi]
AB  - Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease
      worldwide. However, current treatments remain suboptimal. Many factors, such as
      genetic and nongenetic promoters, hypertension, hyperglycemia, the accumulation
      of advanced glycation end products (AGEs), dyslipidemia, and
      albuminuria/proteinuria itself, influence the progression of this disease. It is 
      important to determine the molecular mechanisms and treatment of this disease.
      The development of diabetes results in the formation of AGEs, oxidative stress,
      and the activation of the renin-angiotensin-aldosterone system (RAAS) within the 
      kidney, which promotes progressive inflammation and fibrosis, leading to DN and
      declining renal function. A number of novel therapies have also been tested in
      the experimental diabetic model, including exercise, inhibitors of the RAAS
      (angiotensin type 1 receptor blockers (ARB), angiotensin-converting enzyme (ACE) 
      inhibitors), inhibitors of AGE (pyridoxamine), peroxisome proliferator-activated 
      receptor (PPAR) gamma agonists (pioglitazone), inhibitors of lipid accumulation
      (statins and eicosapentaenoic acid (EPA)), and the vitamin D analogues. This
      review summarizes the advances in knowledge gained from our studies and
      therapeutic interventions that may prevent this disease.
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University
      Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
FAU - Furukawa, Masako
AU  - Furukawa M
FAU - Gohda, Tomohito
AU  - Gohda T
FAU - Tanimoto, Mitsuo
AU  - Tanimoto M
FAU - Tomino, Yasuhiko
AU  - Tomino Y
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - England
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
SB  - IM
PMC - PMC3655660
OID - NLM: PMC3655660
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/28 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/04/24 [epublish]
AID - 10.1155/2013/928197 [doi]
PST - epublish
SO  - ScientificWorldJournal. 2013 Apr 24;2013:928197. doi: 10.1155/2013/928197. Print 
      2013.

PMID- 23737658
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130605
DCOM- 20130606
LR  - 20130607
IS  - 1177-5467 (Print)
IS  - 1177-5467 (Linking)
VI  - 7
DP  - 2013
TI  - Ultra-widefield fluorescein angiography of white without pressure.
PG  - 959-64
LID - 10.2147/OPTH.S43450 [doi]
AB  - PURPOSE: To describe ultra-widefield fluorescein angiography (UWFA) findings in
      eyes with white without pressure (WWOP) and in eyes without any obvious
      peripheral chorioretinal disease, and to determine if a difference exists between
      these two groups. METHODS: A retrospective review of 379 eyes undergoing
      diagnostic UWFA using the Optos 200Tx imaging system. Eyes were excluded if the
      quality of the color photograph or UWFA prevented reliable evaluation. Eyes were 
      also excluded if there was any evidence of peripheral retinal or choroidal
      disease, which was thought to have an effect on UWFA (eg, peripheral background
      diabetic or hypertensive retinopathy, vein occlusion, or any other peripheral
      vascular disorder). Eyes were determined to have WWOP, based on a dilated fundus 
      examination and color fundus photography that contained areas of peripheral
      retinal whitening consistent with the diagnosis. UWFA was evaluated by trained
      masked graders, and determined to have or not have peripheral vascular leakage
      and/or staining. RESULTS: Of the 379 eyes evaluated, 45 eyes were included in the
      study. Twelve eyes were determined to have peripheral WWOP; 33 eyes did not have 
      WWOP on examination or color fundus photography. Three common UWFA peripheral
      patterns were visualized. Eyes with and without WWOP were grouped into one of
      three patterns. The majority of eyes without WWOP demonstrated UWFA pattern one
      (69.7%), while those in the WWOP group demonstrated pattern three (50%). The
      distribution of UWFA patterns is statistically different between those with and
      without WWOP (P = 0.002). In eyes without WWOP, in patients with no documented
      systemic microvascular disease (diabetes, hypertension), 71.4% of eyes had UWFA
      pattern one while 14.3% had both patterns two and three. CONCLUSION: This study
      is one of the first to specifically evaluate peripheral vascular leakage/staining
      in eyes with WWOP as well as in eyes without any obvious peripheral chorioretinal
      disease. We demonstrate that a significant portion of WWOP eyes exhibit
      peripheral findings on UWFA (pattern one) compared to eyes without WWOP.
      Importantly, even in eyes that are apparently unremarkable in the periphery on
      exam and color photography, UWFA can still show peripheral vascular
      abnormalities. These results warrant further investigation.
AD  - Department of Ophthalmology, Weill Cornell Medical College, New York, NY, USA.
FAU - Orlin, Anton
AU  - Orlin A
FAU - Fatoo, Aalya
AU  - Fatoo A
FAU - Ehrlich, Joshua
AU  - Ehrlich J
FAU - D'Amico, Donald J
AU  - D'Amico DJ
FAU - Chan, Rv Paul
AU  - Chan RP
FAU - Kiss, Szilard
AU  - Kiss S
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC3667996
OID - NLM: PMC3667996
OTO - NOTNLM
OT  - ocular imaging
OT  - ptos imaging
OT  - retina periphery
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:01
CRDT- 2013/06/06 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/24 [epublish]
AID - 10.2147/OPTH.S43450 [doi]
AID - opth-7-959 [pii]
PST - ppublish
SO  - Clin Ophthalmol. 2013;7:959-64. doi: 10.2147/OPTH.S43450. Epub 2013 May 24.

PMID- 23737653
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Linking)
VI  - 2013
DP  - 2013
TI  - Update on the protective molecular pathways improving pancreatic Beta-cell
      dysfunction.
PG  - 750540
LID - 10.1155/2013/750540 [doi]
AB  - The primary function of pancreatic beta-cells is to produce and release insulin
      in response to increment in extracellular glucose concentrations, thus
      maintaining glucose homeostasis. Deficient beta-cell function can have profound
      metabolic consequences, leading to the development of hyperglycemia and,
      ultimately, diabetes mellitus. Therefore, strategies targeting the maintenance of
      the normal function and protecting pancreatic beta-cells from injury or death
      might be crucial in the treatment of diabetes. This narrative review will update 
      evidence from the recently identified molecular regulators preserving beta-cell
      mass and function recovery in order to suggest potential therapeutic targets
      against diabetes. This review will also highlight the relevance for novel
      molecular pathways potentially improving beta-cell dysfunction.
AD  - Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132
      Genova, Italy.
FAU - Puddu, Alessandra
AU  - Puddu A
FAU - Sanguineti, Roberta
AU  - Sanguineti R
FAU - Mach, Francois
AU  - Mach F
FAU - Dallegri, Franco
AU  - Dallegri F
FAU - Viviani, Giorgio Luciano
AU  - Viviani GL
FAU - Montecucco, Fabrizio
AU  - Montecucco F
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
SB  - IM
PMC - PMC3659509
OID - NLM: PMC3659509
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/02/05 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/02 [epublish]
AID - 10.1155/2013/750540 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2013;2013:750540. doi: 10.1155/2013/750540. Epub 2013 May 2.

PMID- 23737652
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Linking)
VI  - 2013
DP  - 2013
TI  - Paradoxical Glucose-Sensitizing yet Proinflammatory Effects of Acute ASP
      Administration in Mice.
PG  - 713284
LID - 10.1155/2013/713284 [doi]
AB  - Acylation stimulating protein (ASP) is an adipokine derived from the immune
      complement system, which stimulates fat storage and is typically increased in
      obesity, type 2 diabetes, and cardiovascular disease. Using a diet-induced
      obesity (DIO) mouse model, the acute effects of ASP on energy metabolism and
      inflammatory processes in vivo were evaluated. We hypothesized that ASP would
      specifically exert proinflammatory effects. C57Bl/6 wild-type mice were put on a 
      high-fat-high-sucrose diet for 12 weeks. Mice were then subjected to both glucose
      and insulin tolerance tests, each manipulation being preceded by recombinant ASP 
      or vehicle (control) bolus injection. ASP supplementation increased whole-body
      glucose excursion, and this was accomplished with reduced concomitant insulin
      levels. However, ASP did not directly alter insulin sensitivity. ASP
      supplementation induced a proinflammatory phenotype, with higher levels of
      cytokines including IL-6 and TNF-alpha in plasma and in adipose tissue, liver,
      and skeletal muscle mRNA. Additionally, ASP increased M1 macrophage content of
      these tissues. ASP exerted a direct concentration-dependent role in the migration
      and M1 activation of cultured macrophages. Altogether, the in vivo and in vitro
      experiments demonstrate that ASP plays a role in both energy metabolism and
      inflammation, with paradoxical whole-body glucose-sensitizing yet proinflammatory
      effects.
AD  - Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie 
      de Quebec, Universite Laval, Y4332, 2725 Chemin Ste-Foy, Quebec, QC, Canada G1V
      4G5.
FAU - Fisette, Alexandre
AU  - Fisette A
FAU - Poursharifi, Pegah
AU  - Poursharifi P
FAU - Oikonomopoulou, Katerina
AU  - Oikonomopoulou K
FAU - Munkonda, Mercedes N
AU  - Munkonda MN
FAU - Lapointe, Marc
AU  - Lapointe M
FAU - Cianflone, Katherine
AU  - Cianflone K
LA  - eng
PT  - Journal Article
DEP - 20130512
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
SB  - IM
PMC - PMC3666230
OID - NLM: PMC3666230
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/03/07 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/19 [accepted]
PHST- 2013/05/12 [epublish]
AID - 10.1155/2013/713284 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2013;2013:713284. doi: 10.1155/2013/713284. Epub 2013 May 12.

PMID- 23737649
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Linking)
VI  - 2013
DP  - 2013
TI  - Protective effect of short-term genistein supplementation on the early stage in
      diabetes-induced renal damage.
PG  - 510212
LID - 10.1155/2013/510212 [doi]
AB  - Hyperglycemia-induced oxidative stress has been concerned in the development of
      diabetic nephropathy (DN), which may cause kidney damage associated with
      inflammation and fibrosis. This study has been conducted to investigate the role 
      of genistein supplementation in an acute DN state. Mice with FBG levels more than
      250 mg/dL after alloxan injection (single i.p., 150 mg/kg) were considered as
      diabetic. Diabetic mice (DM) were further subdivided according to their FBG
      levels, medium-high FBG (DMMH < 450 mg/dL) and high FBG (DMH; 450 mg/dL) and were
      administrated by an AIG-93G diet supplemented with different doses of genistein
      (0, 0.025 or 0.1%). After 2 weeks' treatment, the levels of kidney
      malondialdehyde (MDA), blood urea nitrogen (BUN), and plasma creatinine and lipid
      profiles, as well as oxidative stress and inflammation-related markers, were
      measured (P < 0.05). Genistein supplementation improved levels of FBG in the DMMH
      groups, but not in the DMH group, regardless of the treatment dose. Moreover, the
      supplementation attenuated kidney oxidative stress indicated by MDA, BUN, and
      plasma creatinine. In addition, genistein treatment decreased inflammatory
      markers such as nuclear factor kappa B (p65), phosphorylated inhibitory kappa B
      alpha, C-reactive protein, monocyte chemotactic protein-1, cyclooxygenase-2, and 
      tumor necrosis factor-alpha and improved oxidative stress markers
      (nuclear-related factor E2, heme oxygenase-1, glutathione peroxidase, and
      superoxide dismutase isoforms) in treatment groups, regardless of the genistein
      treatment dose. Furthermore, genistein supplementation inhibited the
      fibrosis-related markers (protein kinase C, protein kinase C-beta II, and
      transforming growth factor-beta I) in the DN state. However, 0.1% genistein
      supplementation in diabetes with high FBG levels selectively showed a preventive 
      effect on kidney damage. These results suggest that genistein might be a good
      protective substance for DN through regulation of oxidative stress and
      inflammation. In particular, genistein is more efficient in diabetes patients
      with medium-high blood glucose levels. Finally, it is required to establish the
      beneficial dosage of genistein according to blood glucose levels.
AD  - Department of Food and Nutrition, Kyung Hee University, Seoul 130-701, Republic
      of Korea.
FAU - Kim, Min Ju
AU  - Kim MJ
FAU - Lim, Yunsook
AU  - Lim Y
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
SB  - IM
PMC - PMC3657423
OID - NLM: PMC3657423
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/01/14 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/29 [epublish]
AID - 10.1155/2013/510212 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2013;2013:510212. doi: 10.1155/2013/510212. Epub 2013 Apr 29.

PMID- 23737644
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Linking)
VI  - 2013
DP  - 2013
TI  - Glucagon-like Peptide-1 triggers protective pathways in pancreatic Beta-cells
      exposed to glycated serum.
PG  - 317120
LID - 10.1155/2013/317120 [doi]
AB  - Advanced glycation end products (AGEs) might play a pathophysiological role in
      the development of diabetes and its complications. AGEs negatively affect
      pancreatic beta-cell function and the expression of transcriptional factors
      regulating insulin gene. Glucagon-like peptide-1 (GLP-1), an incretin hormone
      that regulates glucose homeostasis, might counteract the harmful effects of AGEs 
      on the beta cells in culture. The aim of this study was to identify the
      intracellular mechanisms underlying GLP-1-mediated protection from AGE-induced
      detrimental activities in pancreatic beta cells. HIT-T15 cells were cultured for 
      5 days with glycated serum (GS, consisting in a pool of AGEs), in the presence or
      absence of 10 nmol/L GLP-1. After evaluation of oxidative stress, we determined
      the expression and subcellular localization of proteins involved in maintaining
      redox balance and insulin gene expression, such as nuclear factor
      erythroid-derived 2 (Nrf2), glutathione reductase, PDX-1, and MafA. Then, we
      investigated proinsulin production. The results showed that GS increased
      oxidative stress, reduced protein expression of all investigated factors through 
      proteasome activation, and decreased proinsulin content. Furthermore, GS reduced 
      ability of PDX-1 and MafA to bind DNA. Coincubation with GLP-1 reversed these
      GS-mediated detrimental effects. In conclusion, GLP-1, protecting cells against
      oxidants, triggers protective intercellular pathways in HIT-T15 cells exposed to 
      GS.
AD  - Department of Internal Medicine and Medical Specialties, University of Genova, 6 
      Viale Benedetto XV, 16132 Genova, Italy.
FAU - Puddu, Alessandra
AU  - Puddu A
FAU - Sanguineti, Roberta
AU  - Sanguineti R
FAU - Durante, Arianna
AU  - Durante A
FAU - Nencioni, Alessio
AU  - Nencioni A
FAU - Mach, Francois
AU  - Mach F
FAU - Montecucco, Fabrizio
AU  - Montecucco F
FAU - Viviani, Giorgio L
AU  - Viviani GL
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
SB  - IM
PMC - PMC3657444
OID - NLM: PMC3657444
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/01/21 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/04 [accepted]
PHST- 2013/04/29 [epublish]
AID - 10.1155/2013/317120 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2013;2013:317120. doi: 10.1155/2013/317120. Epub 2013 Apr 29.

PMID- 23737639
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1071-1007 (Print)
IS  - 1071-1007 (Linking)
DP  - 2013 Jun 4
TI  - Navicular Subluxation as a Radiographic Finding in Charcot Neuroarthropathy.
AB  - BACKGROUND: Treatment of patients with Charcot midfoot destruction is a difficult
      and increasingly common clinical problem. The pathoanatomical features of Charcot
      neuropathy have been evaluated in only a few studies. This study evaluated
      whether medial navicular subluxation (adduction of the navicular on the talus) is
      a radiographic finding present in patients with Charcot neuroarthropathy.
      METHODS: A retrospective review of 143 consecutive patients diagnosed with
      Charcot arthropathy of the foot from January 2004 to May 2011 was performed.
      Patients were identified based on a clinical diagnosis code 713.5 during an
      outpatient clinic visit with 2 surgeons at a single institution. After exclusion 
      criteria were applied, a series of radiographs of 50 feet in 40 patients were
      compared with radiographs from an age-matched control group. Radiographic data
      including talonavicular coverage angle and talonavicular uncoverage percentage
      were collected. RESULTS: The mean talonavicular coverage angle of the Charcot
      arthropathy group was 1.5 degrees and of the control group 12.1 degrees (P <
      .05). The talonavicular uncoverage value for the Charcot arthropathy group was
      12.2% and for the control group 22.0% (P < .001). CONCLUSIONS: Medial navicular
      subluxation was a radiographic finding that was more commonly present in patients
      with Charcot arthropathy than in a matched control group. It is theorized that
      this finding is attributable to an unopposed pull of the posterior tibial tendon 
      on the destabilized navicular.
AD  - Department of Orthopedic Surgery, University of Southern California, Los Angeles,
      CA, USA.
FAU - Estess, Allyson
AU  - Estess A
FAU - Marquand, Nicole
AU  - Marquand N
FAU - Charlton, Timothy P
AU  - Charlton TP
FAU - Thordarson, David B
AU  - Thordarson DB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Foot Ankle Int
JT  - Foot & ankle international. / American Orthopaedic Foot and Ankle Society [and]
      Swiss Foot and Ankle Society
JID - 9433869
OTO - NOTNLM
OT  - Charcot
OT  - arthropathy
OT  - coverage
OT  - diabetes
OT  - talonavicular
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 1071100713491729 [pii]
AID - 10.1177/1071100713491729 [doi]
PST - aheadofprint
SO  - Foot Ankle Int. 2013 Jun 4.

PMID- 23737573
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Prenatal diagnosis of caudal dysplasia sequence associated with undiagnosed type 
      I diabetes.
LID - 10.1136/bcr-2013-009043 [doi]
LID - bcr2013009043 [pii]
AB  - Caudal regression or caudal dysplasia sequence (CDS) is a rare congenital
      malformation, which includes a wide spectrum of musculoskeletal abnormalities
      involving the lumbosacral spine, pelvis and lower limbs. It can be associated to 
      visceral defects in various degrees. Maternal diabetes, genetic predisposition
      and vascular hypoperfusion have been suggested as possible causative factors.
      Women with diabetes who are dependent on insulin are 200-400 times more likely to
      have a child with caudal regression, making CDS the most characteristic fetal
      abnormality of diabetic embryopathy. Prenatal diagnosis is possible by
      ultrasonographic examination. The sonographic findings include abrupt
      interruption of the lumbar spine and 'Buddha or frog position' of the lower
      limbs. MRI has demonstrated the level of the vertebral anomalies as well as the
      associated abnormalities and this is crucial because the prognosis of this
      condition depends on the severity of the lesion and the presence of associated
      disorders.
AD  - Department of Obstetrics and Gynaecology, University General Hospital of
      Alicante, Alicante, Spain.
FAU - Palacios-Marques, Ana
AU  - Palacios-Marques A
FAU - Oliver, Cecilia
AU  - Oliver C
FAU - Martin-Bayon, Tina
AU  - Martin-Bayon T
FAU - Martinez-Escoriza, Juan Carlos
AU  - Martinez-Escoriza JC
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - bcr-2013-009043 [pii]
AID - 10.1136/bcr-2013-009043 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Jun 3;2013. pii: bcr2013009043. doi: 10.1136/bcr-2013-009043.

PMID- 23737568
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Successfully treated bilateral renal artery stenosis in a patient with coronary
      artery disease.
LID - 10.1136/bcr-2012-008464 [doi]
LID - bcr2012008464 [pii]
AB  - Renal artery stenosis (RAS) is the most common cause of secondary hypertension
      and accounts for approximately 1-3% of all causes of hypertension. Over 90% of
      RASs are caused by atherosclerosis; atherosclerotic RAS is increasingly common in
      aging populations, particularly elderly people with diabetes, hyperlipidaemia,
      aortoiliac occlusive disease, coronary artery disease or hypertension. Three
      therapeutic options are currently available for patients with renovascular
      hypertension: medical antihypertensive therapy, surgical revascularisation and
      transluminal angioplasty including stent implantation. We present in this report 
      a male patient with bilateral severe ostial stenosis and coronary artery disease,
      and who was successfully treated with renal stent implantation in one session.
AD  - Department of Radiology, Sakarya University Medical Faculty, Sakarya, Turkey.
FAU - Gunduz, Yasemin
AU  - Gunduz Y
FAU - Akdemir, Ramazan
AU  - Akdemir R
FAU - Sahinkus, Salih
AU  - Sahinkus S
FAU - Vatan, Mehmet Bulent
AU  - Vatan MB
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - bcr-2012-008464 [pii]
AID - 10.1136/bcr-2012-008464 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Jun 3;2013. pii: bcr2012008464. doi: 10.1136/bcr-2012-008464.

PMID- 23737551
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1937-9145 (Electronic)
VI  - 6
IP  - 278
DP  - 2013
TI  - TGF-beta Induces Acetylation of Chromatin and of Ets-1 to Alleviate Repression of
      miR-192 in Diabetic Nephropathy.
PG  - ra43
LID - 10.1126/scisignal.2003389 [doi]
AB  - MicroRNAs (miRNAs), such as miR-192, mediate the actions of transforming growth
      factor-beta1 (TGF-beta) related to the pathogenesis of diabetic kidney diseases. 
      We found that the biphasic induction of miR-192 expression by TGF-beta in mouse
      renal glomerular mesangial cells initially involved the Smad transcription
      factors, followed by sustained expression that was promoted by acetylation of the
      transcription factor Ets-1 and of histone H3 by the acetyltransferase p300, which
      was activated by the serine and threonine kinase Akt. In mesangial cells from
      Ets-1-deficient mice or in cells in which Ets-1 was knocked down, basal amounts
      of miR-192 were higher than those in control cells, but sustained induction of
      miR-192 by TGF-beta was attenuated. Furthermore, inhibition of Akt or ectopic
      expression of dominant-negative histone acetyltransferases decreased
      p300-mediated acetylation and Ets-1 dissociation from the miR-192 promoter and
      prevented miR-192 expression in response to TGF-beta. Activation of Akt and p300 
      and acetylation of Ets-1 and histone H3 were increased in glomeruli from diabetic
      db/db mice compared to nondiabetic db/+ mice, suggesting that this pathway may
      contribute to diabetic nephropathy. These findings provide insight into the
      regulation of miRNAs through signaling-mediated changes in transcription factor
      activity and in epigenetic histone acetylation under normal and disease states.
AD  - 1Department of Diabetes and Division of Molecular Diabetes Research, Beckman
      Research Institute of the City of Hope, Duarte, CA 91010, USA.
FAU - Kato, Mitsuo
AU  - Kato M
FAU - Dang, Varun
AU  - Dang V
FAU - Wang, Mei
AU  - Wang M
FAU - Park, Jung Tak
AU  - Park JT
FAU - Deshpande, Supriya
AU  - Deshpande S
FAU - Kadam, Swati
AU  - Kadam S
FAU - Mardiros, Armen
AU  - Mardiros A
FAU - Zhan, Yumei
AU  - Zhan Y
FAU - Oettgen, Peter
AU  - Oettgen P
FAU - Putta, Sumanth
AU  - Putta S
FAU - Yuan, Hang
AU  - Yuan H
FAU - Lanting, Linda
AU  - Lanting L
FAU - Natarajan, Rama
AU  - Natarajan R
LA  - eng
PT  - Journal Article
DEP - 20130604
PL  - United States
TA  - Sci Signal
JT  - Science signaling
JID - 101465400
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 6/278/ra43 [pii]
AID - 10.1126/scisignal.2003389 [doi]
PST - epublish
SO  - Sci Signal. 2013 Jun 4;6(278):ra43. doi: 10.1126/scisignal.2003389.

PMID- 23737541
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Jun 4
TI  - FullA Standardized Assessment of Thyroid Nodules in Children Confirms Higher
      Cancer Prevalence than in Adults.
AB  - CONTEXT:Thyroid cancer is the most common endocrine malignancy but, due to its
      rare occurrence in the pediatric population, the cancer risk of childhood thyroid
      nodules is incompletely defined and optimal management of children with suspected
      nodules is debated.OBJECTIVE:To study the presenting features and cancer risk of 
      sporadic childhood thyroid nodules, using a standardized clinical assessment and 
      management plan.DESIGN AND SETTING:Boston Children's Hospital and Brigham and
      Women's Hospital collaborated to create a multidisciplinary pediatric thyroid
      nodule clinic and implement a standardized assessment plan. Upon referral for a
      suspected nodule, serum TSH was measured and hypothyrotropinemic patients
      underwent 123I scintigraphy. All others underwent thyroid ultrasonography and, if
      this confirmed nodule(s) >/=1 cm, ultrasound-guided fine-needle aspiration was
      performed. Medical records were retrospectively reviewed and compared to a
      control population of 2582 adults evaluated by identical methods.PATIENTS AND
      RESULTS:Of 300 consecutive children referred for the initial evaluation of
      suspected thyroid nodules from 1997 to 2011, 17 were diagnosed with autonomous
      nodules by scintigraphy. Neck ultrasonography performed in the remainder revealed
      that biopsy was unnecessary in over half, either by documenting only
      subcentimeter nodules or showing that no nodule was present. One-hundred and
      twenty five children met criteria for thyroid biopsy, which was performed without
      complication. Their rate of cancer was 22%, significantly higher than the adult
      rate of 14% (p =0.02).CONCLUSIONS:Neck ultrasonography and biopsy were key to the
      evaluation of children with suspected thyroid nodules. While the relative cancer 
      prevalence of sonographically-confirmed nodules >/=1 cm is higher in pediatric
      patients than adults, most children referred for suspected nodules have benign
      conditions and efforts to avoid unnecessary surgery in this majority are
      warranted.
AD  - Institutions: From the Thyroid Program of the Division of Endocrinology (A.G.,
      S.L., L.A.C., H.A.F., A.J.W., J.R.S., S.W., S.A.H.), Clinical Research Center
      (H.A.F.), the Department of Radiology (H.J.P.), the Department of Pathology
      (H.K.), and the Department of Surgery (B.P.M., R.C.S) of Boston Children's
      Hospital, Boston, MA 02115; the Thyroid Section of the Division of Endocrinology,
      Diabetes, and Hypertension (A.J.W., J.R.S., E.K.A., E.M., P.R.L., S.A.H.), the
      Department of Radiology (M.C.F., C.B.B., P.M.D. H.E.P), the Department of
      Pathology (J.B., E.S.C.), and the Department of Surgery (F.D.M. Jr.) of the
      Brigham and Women's Hospital, Boston, MA 02115; and the Dana Farber Cancer
      Institute (E.M., E.K.A., P.R.L., S.A.H.).
FAU - Gupta, Anjuli
AU  - Gupta A
FAU - Ly, Samantha
AU  - Ly S
FAU - Castroneves, Luciana A
AU  - Castroneves LA
FAU - Frates, Mary C
AU  - Frates MC
FAU - Benson, Carol B
AU  - Benson CB
FAU - Feldman, Henry A
AU  - Feldman HA
FAU - Wassner, Ari J
AU  - Wassner AJ
FAU - Smith, Jessica R
AU  - Smith JR
FAU - Marqusee, Ellen
AU  - Marqusee E
FAU - Alexander, Erik K
AU  - Alexander EK
FAU - Barletta, Justine
AU  - Barletta J
FAU - Doubilet, Peter M
AU  - Doubilet PM
FAU - Peters, Hope E
AU  - Peters HE
FAU - Webb, Susan
AU  - Webb S
FAU - Modi, Biren P
AU  - Modi BP
FAU - Paltiel, Harriet J
AU  - Paltiel HJ
FAU - Kozakewich, Harry
AU  - Kozakewich H
FAU - Cibas, Edmund S
AU  - Cibas ES
FAU - Moore, Francis D Jr
AU  - Moore FD Jr
FAU - Shamberger, Robert C
AU  - Shamberger RC
FAU - Larsen, P Reed
AU  - Larsen PR
FAU - Huang, Stephen A
AU  - Huang SA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - jc.2013-1796 [pii]
AID - 10.1210/jc.2013-1796 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Jun 4.

PMID- 23737522
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 Jun 4
TI  - Divergent sequence tunes ligand sensitivity in phospholipid-regulated hormone
      receptors.
AB  - The NR5A subfamily family of nuclear receptors (NRs) are important regulators of 
      pluripotency, lipid and glucose homeostasis, and steroidogenesis. Liver receptor 
      homologue 1 (LRH-1; NR5A2) and steroidogenic factor 1 (SF-1; NR5A1), have
      therapeutic potential for the treatment of metabolic and neoplastic disease;
      however, a poor understanding of their ligand regulation has hampered the pursuit
      of these proteins as pharmaceutical targets. In this study, we dissect how
      sequence variation among LRH-1 orthologs affects phospholipid (PL) binding and
      regulation. Both human and mouse LRH-1 (mLRH-1) respond to newly discovered
      medium chain PL agonists to modulate lipid and glucose homeostasis. These PLs
      activate human LRH-1 (hLRH-1) by altering receptor dynamics in a newly identified
      alternate activation function region. Mouse and Drosophila orthologs contain
      divergent sequence in this region potentially altering PL-driven activation.
      Structural evidence suggests that these sequence differences in mouse LRH-1
      (mLRH-1) and Drosophila FTZ-f1 (dmFTZ-f1), confer at least partial ligand
      independence, making them poor models for hLRH-1 studies; however, the mechanisms
      of ligand independence remain untested. We show using structural and biochemical 
      methods that the recent evolutionary divergence of the mLRH-1 stabilizes the
      active conformation in the absence of ligand, yet does not abrogate PL-dependent 
      activation. We also show by mass spectrometry and biochemical assays that FTZ-f1 
      is incapable of PL binding. This work provides a structural mechanism for the
      differential tuning of PL-sensitivity in NR5A orthologs and supports the use of
      mice as viable therapeutic models for LRH-1-dependent diseases.
AD  - Emory University, United States;
FAU - Musille, Paul M
AU  - Musille PM
FAU - Pathak, Manish
AU  - Pathak M
FAU - Lauer, Jenelle L
AU  - Lauer JL
FAU - Griffin, Patrick R
AU  - Griffin PR
FAU - Ortlund, Eric A
AU  - Ortlund EA
LA  - ENG
GR  - R01 DK095750/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Diabetes
OT  - Glucose metabolism
OT  - Hormone receptors
OT  - Mouse
OT  - Phosphatidylcholine
OT  - Phospholipid
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - M113.472837 [pii]
AID - 10.1074/jbc.M113.472837 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 Jun 4.

PMID- 23737516
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
DP  - 2013 Jun 4
TI  - Intravenous Sodium Bicarbonate Therapy in Severely Acidotic Diabetic Ketoacidosis
      (July/August).
AB  - BACKGROUND:The use of intravenous bicarbonate in diabetic ketoacidosis (DKA) may 
      be considered for patients with a pH less than 6.9 according to the American
      Diabetes Association. The impact of this therapy on resolution of acidosis in
      patients with DKA is unclear.OBJECTIVE:To determine whether the use of
      intravenous bicarbonate therapy was associated with improved outcomes in patients
      with severe DKA who were seen in the emergency department.METHODS:This review was
      conducted from 2007 to 2011 in the emergency department of a tertiary teaching
      hospital. Adults diagnosed with DKA with an initial pH less than 7.0 were
      included. Patients were stratified into 2 groups based on receipt of intravenous 
      bicarbonate. The primary study outcome was time to resolution of acidosis,
      defined as return to pH greater than 7.2. Secondary outcomes included length of
      stay; continuous infusion insulin use; and intravenous fluid, potassium, and
      insulin requirements within the first 24 hours of hospital admission, beginning
      upon admittance to the emergency department. We also conducted a subgroup
      analysis of patients with an initial pH less than 6.9.RESULTS:There was no
      significant difference in time to resolution of acidosis (8 hours vs 8 hours; p =
      0.7) or time to hospital discharge (68 hours vs 61 hours; p = 0.3) between
      patients who received intravenous bicarbonate (n = 44) compared with those who
      did not (n = 42). The median dose of intravenous bicarbonate was 100 mEq
      (100-150) for patients who received intravenous bicarbonate. Insulin and fluid
      requirements in the first 24 hours were significantly higher in patients who
      received intravenous bicarbonate compared with those who did not (100 units vs 86
      units; p = 0.04 and 7.6 L vs 7.2 L; p = 0.01, respectively). There was no
      significant difference in hours of continuous insulin infusion (27 hours vs 26
      hours; p = 0.09) or potassium requirements in the first 24 hours of hospital stay
      (135 mEq vs 120 mEq; p = 0.84).CONCLUSIONS:Intravenous bicarbonate therapy did
      not decrease time to resolution of acidosis or time to hospital discharge for
      patients with DKA with an initial pH less than 7.0.
AD  - < University Hospital, University Health System, San Antonio, TX; Pharmacotherapy
      Division, College of Pharmacy, The University of Texas at Austin; Pharmacotherapy
      Education and Research Center, School of Medicine, The University of Texas Health
      Science Center at San Antonio; Feik School of Pharmacy, University of the
      Incarnate Word, San Antonio.
FAU - Duhon, Bryson
AU  - Duhon B
FAU - Attridge, Rebecca L
AU  - Attridge RL
FAU - Franco-Martinez, A Crystal
AU  - Franco-Martinez AC
FAU - Maxwell, Pamela R
AU  - Maxwell PR
FAU - Hughes, Darrel W
AU  - Hughes DW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - aph.1S014 [pii]
AID - 10.1345/aph.1S014 [doi]
PST - aheadofprint
SO  - Ann Pharmacother. 2013 Jun 4.

PMID- 23737484
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1460-2385 (Electronic)
IS  - 0931-0509 (Linking)
DP  - 2013 Jun 4
TI  - Obesity and nephrology: results of a knowledge and practice pattern survey.
AB  - BACKGROUND: Obesity, the largest epidemic of modern time, carries a markedly
      increased risk of type-2 diabetes, cancer, fatty liver, sleep apnea,
      hypertension, dyslipidemia and atherosclerotic cardiovascular disease. In
      addition, obesity increases the risk of chronic kidney disease (CKD) and its
      progression to end-stage renal disease (ESRD). There are limited data regarding
      the basic knowledge of nephrologists on how to assess and manage obesity in the
      setting of CKD. METHODS: To learn more about practice patterns among
      nephrologists, a survey on obesity was published online in NDT-Educational
      between 8 November 2012 and 31 January 2013. Three-hundred and ninety-nine
      responses were received mostly from nephrologists in Europe (57%), South and
      Central America (12%) and the Middle East (10%). The majority practiced in
      clinical nephrology (64%) and outpatient dialysis clinics (23%). Whereas 54% of
      the participants worked in hospitals, 31% worked in academic centers. RESULTS:
      Most participants stated that the number of obese patients has increased both
      among their CKD stage 2-5 patients and in their dialysis clinics during the last 
      10 years. For routine estimation of body fat content in the dialysis clinic, the 
      majority of nephrologists (43%) still rely on the body mass index (BMI). A
      majority (72%) does not think that weight gain should be promoted in dialysis
      patients with a BMI of <35 kg/m2. The survey also showed that 30% of the
      responders did not have any predetermined cut-off level for BMI. However, 29%
      used a cut-off level of 35 kg/m2 and 27% used a cut-off level of 30 kg/m2 for
      approval for kidney transplantation in their clinics. CONCLUSIONS: The level of
      understanding of the intricacies of obesity in the setting of CKD needs
      improvement among nephrologists. Similarly, there is no consensus regarding
      weight management strategies in CKD patients with obesity. Studies are needed in 
      this orphan area of renal research.
AD  - Division of Renal Medicine, Department of Clinical Science, Intervention and
      Technology, Karolinska Institute, Stockholm, Sweden.
FAU - Stenvinkel, Peter
AU  - Stenvinkel P
FAU - Ikizler, T Alp
AU  - Ikizler TA
FAU - Mallamaci, Francesca
AU  - Mallamaci F
FAU - Zoccali, Carmine
AU  - Zoccali C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
OTO - NOTNLM
OT  - BMI
OT  - bariatric surgery
OT  - obesity
OT  - survey
OT  - transplantation
OT  - waist–hip ratio
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - gft193 [pii]
AID - 10.1093/ndt/gft193 [doi]
PST - aheadofprint
SO  - Nephrol Dial Transplant. 2013 Jun 4.

PMID- 23737475
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
DP  - 2013 Jun 4
TI  - Adiponectin-Induced Dilation of Isolated Porcine Retinal Arterioles via
      Production of Nitric Oxide from Endothelial Cells.
LID - iovs.13-11756v1 [pii]
LID - 10.1167/iovs.13-11756 [doi]
AB  - PURPOSE: Adiponectin, an important adipocytokine secreted by adipocytes, has
      anti-inflammatory and atheroprotective effects on vascular tissue via the
      adiponectin receptor (adipoR). However, the action of adiponectin in the retinal 
      microcirculation is unknown. We examined the direct effect and underlying
      mechanism of the vasomotor action of adiponectin in porcine retinal arterioles.
      METHODS: Porcine retinal arterioles (internal diameter, 60-90 microm) were
      isolated, cannulated, and pressurized (55 cmH2O) without flow in this in vitro
      study. Videomicroscopic techniques were used to record changes in diameter in
      response to adiponectin. RESULTS: The retinal arterioles dilated in a
      dose-dependent (0.125-7.5 microg/ml) manner in response to adiponectin. The
      vasodilation decreased significantly after removal of the endothelium.
      NG-nitro-L-arginine methyl ester (a nitric oxide [NO] synthase inhibitor),
      1H-1,2,4-oxadia-zolo[4,3-a]quinoxalin-1-one (a soluble guanylyl cyclase
      inhibitor) but not wortmannin (a phosphatidylinositol 3-kinase inhibitor)
      inhibited the effect of adiponectin-induced vasodilation comparable to that of
      denudation. Pretreatment with compound C, an activated protein kinase (AMPK)
      inhibitor, partially but significantly reduced vasodilation. Incubation with
      GW6471, a peroxisome proliferator-activated receptor blocker, did not
      significantly inhibit vasodilation by adiponectin. AdipoR1 and adipoR2
      immunoreactions were observed in the endothelium of retinal arterioles.
      CONCLUSION: Adiponectin elicits mainly endothelium-dependent dilation of the
      retinal arterioles. Endothelium-dependent vasodilation likely induced by
      adiponectin results from NO via activation of guanylyl cyclase that is partially 
      dependent on AMPK activity. Understanding the activity of adiponectin on the
      retinal vasculature may help improve potential therapies for retinal vascular
      disorders, especially diabetic retinopathy in patients with type 2 diabetes
      mellitus.
AD  - Department of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan.
FAU - Omae, Tsuneaki
AU  - Omae T
FAU - Nagaoka, Taiji
AU  - Nagaoka T
FAU - Tanano, Ichiro
AU  - Tanano I
FAU - Yoshida, Akitoshi
AU  - Yoshida A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - iovs.13-11756 [pii]
AID - 10.1167/iovs.13-11756 [doi]
PST - aheadofprint
SO  - Invest Ophthalmol Vis Sci. 2013 Jun 4. pii: iovs.13-11756v1. doi:
      10.1167/iovs.13-11756.

PMID- 23737390
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
DP  - 2013 Jun 4
TI  - Long term efficacy and safety of zotarolimus eluting stent in patients with
      diabetes mellitus: Pooled 5-year results from the ENDEAVOR III and IV trials.
LID - 10.1002/ccd.25045 [doi]
AB  - OBJECTIVE: To assess long-term outcomes of Endeavor-Zotarolimus eluting stent
      (E-ZES) implantation in patients with diabetes mellitus (DM). BACKGROUND:
      Patients with DM and coronary artery disease have lower restenosis with drug
      eluting stent (DES) compared with bare-metal stents. Recent data suggest that the
      E-ZES is inferior to other DES in this population. METHODS: Patient-level data
      for 601 patients with DM from the ENDEAVOR III and ENDEAVOR IV trials were
      pooled, of which 337 were treated with E-ZES and 264 were treated with other DES.
      The primary outcome was target vessel failure (TVF) in the course of 5 years.
      Outcomes are reported as rates using Kaplan-Meier (KM) survival method and
      differences between E-ZES and other stent types (sirolimus-eluting stent or
      paclitaxel-eluting stent) were compared using the log rank statistic. The
      independent effect of stent type on TVF was assessed using Cox proportional
      hazards regression. RESULTS: Baseline characteristics were similar between the
      groups. Five-year TVF KM rate estimate was numerically lower for E-ZES, but the
      difference did not reach statistical significance (20.2% vs. 26.9%, p=0.065). The
      5-year KM rate estimates of major adverse cardiac events (17.7% vs. 26.6%,
      p=0.012), death (7.6% vs. 15.0%, p=0.004) and myocardial infarction (1.3% vs.
      5.1%, p=0.011) were also lower for E-ZES versus other DES. CONCLUSIONS: Patients 
      with DM implanted with E-ZES have favorable long term outcomes compared to
      first-generation DES. Long term performance of DES should be assessed routinely, 
      and may differ from initial performance. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc., a Wiley company.
AD  - Harvard Clinical Research Institute, Boston, MA; Beth Israel Deaconess Medical
      Center, Boston, MA.
FAU - Vardi, Moshe
AU  - Vardi M
FAU - Burke, David A
AU  - Burke DA
FAU - Bangalore, Sripal
AU  - Bangalore S
FAU - Pencina, Michael J
AU  - Pencina MJ
FAU - Mauri, Laura
AU  - Mauri L
FAU - Kandzari, David E
AU  - Kandzari DE
FAU - Leon, Martin B
AU  - Leon MB
FAU - Cutlip, Donald E
AU  - Cutlip DE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the
      Society for Cardiac Angiography & Interventions
JID - 100884139
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/16 [received]
PHST- 2013/05/22 [accepted]
AID - 10.1002/ccd.25045 [doi]
PST - aheadofprint
SO  - Catheter Cardiovasc Interv. 2013 Jun 4. doi: 10.1002/ccd.25045.

PMID- 23737371
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 6
DP  - 2013 Jun 4
TI  - Increased consumption of fruit and vegetables for the primary prevention of
      cardiovascular diseases.
PG  - CD009874
AB  - BACKGROUND: There is increasing evidence that high consumption of fruit and
      vegetables is beneficial for cardiovascular disease (CVD) prevention. OBJECTIVES:
      The primary objective is to determine the effectiveness of i) advice to increase 
      fruit and vegetable consumption ii) the provision of fruit and vegetables to
      increase consumption, for the primary prevention of CVD. SEARCH METHODS: We
      searched the following electronic databases: The Cochrane Library (2012, issue
      9-CENTRAL, HTA, DARE, NEED), MEDLINE (1946 to week 3 September 2012); EMBASE
      (1980 to 2012 week 39) and the Conference Proceedings Citation Index - Science on
      ISI Web of Science (5 October 2012). We searched trial registers, screened
      reference lists and contacted authors for additional information where necessary.
      No language restrictions were applied. SELECTION CRITERIA: Randomised controlled 
      trials with at least three months follow-up (follow-up was considered to be the
      time elapsed since the start of the intervention) involving healthy adults or
      those at high risk of CVD. Trials investigated either advice to increase fruit
      and vegetable intake (via any source or modality) or the provision of fruit and
      vegetables to increase intake. The comparison group was no intervention or
      minimal intervention. Outcomes of interest were CVD clinical events (mortality
      (CVD and all-cause), myocardial infarction (MI), coronary artery bypass grafting 
      (CABG) or percutaneous transluminal coronary angioplasty (PTCA),
      angiographically-defined angina pectoris, stroke, carotid endarterectomy,
      peripheral arterial disease (PAD)) and major CVD risk factors (blood pressure,
      blood lipids, type 2 diabetes). Trials involving multifactorial lifestyle
      interventions (including different dietary patterns, exercise) or where the focus
      was weight loss were excluded to avoid confounding. DATA COLLECTION AND ANALYSIS:
      Two review authors independently selected trials for inclusion, extracted data
      and assessed the risk of bias. Trials of provision of fruit and vegetables were
      analysed separately from trials of dietary advice. MAIN RESULTS: We identified 10
      trials with a total of 1730 participants randomised, and one ongoing trial. Six
      trials investigated the provision of fruit and vegetables, and four trials
      examined advice to increase fruit and vegetable consumption.The ongoing trial is 
      examining the provision of an avocado-rich diet.The number and type of
      intervention components for provision, and the dietary advice provided differed
      between trials.None of the trials reported clinical events as they were all
      relatively short term. There was no strong evidence for effects of individual
      trials of provision of fruit and vegetables on cardiovascular risk factors, but
      trials were heterogeneous and short term. Furthermore, five of the six trials
      only provided one fruit or vegetable. Dietary advice showed some favourable
      effects on blood pressure (systolic blood pressure (SBP): mean difference (MD)
      -3.0 mmHg (95% confidence interval (CI) -4.92 to -1.09), diastolic blood pressure
      (DBP): MD -0.90 mmHg (95% CI -2.03 to 0.24)) and low-density lipoprotein (LDL)
      cholesterol but analyses were based on only two trials. Three of the 10 included 
      trials examined adverse effects, which included increased bowel movements, bad
      breath and body odour. AUTHORS' CONCLUSIONS: There are very few studies to date
      examining provision of, or advice to increase the consumption of, fruit and
      vegetables in the absence of additional dietary interventions or other lifestyle 
      interventions for the primary prevention of CVD. The limited evidence suggests
      advice to increase fruit and vegetables as a single intervention has favourable
      effects on CVD risk factors but more trials are needed to confirm this.
AD  - Division of Health Sciences, Warwick Medical School, University of Warwick,
      Coventry, Warwickshire, UK, CV4 7AL.
FAU - Hartley, Louise
AU  - Hartley L
FAU - Igbinedion, Ewemade
AU  - Igbinedion E
FAU - Holmes, Jennifer
AU  - Holmes J
FAU - Flowers, Nadine
AU  - Flowers N
FAU - Thorogood, Margaret
AU  - Thorogood M
FAU - Clarke, Aileen
AU  - Clarke A
FAU - Stranges, Saverio
AU  - Stranges S
FAU - Hooper, Lee
AU  - Hooper L
FAU - Rees, Karen
AU  - Rees K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1002/14651858.CD009874 [doi]
PST - aheadofprint
SO  - Cochrane Database Syst Rev. 2013 Jun 4;6:CD009874.

PMID- 23737320
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 51
IP  - 5
DP  - 2013
TI  - An unusual combination of parathyroid adenoma, medullary and papillary thyroid
      carcinoma.
PG  - 337-40
AB  - The coexistence of medullary thyroid carcinoma (MTC), papillary thyroid carcinoma
      (PTC) and parathyroid adenoma is an uncommon clinical entity. Here, we report a
      case of MTC, PTC, and parathyroid adenoma diagnosed incidentally on a routine
      physical examination of the neck for the work-up of diabetes. The patient had
      neither symptoms of hypercalcemia nor those related to MTC and PTC.
AD  - Department of Pathology, Shariati Hospital, Tehran University of Medical
      Sciences, Tehran, Iran. tavangar@ams.ac.ir.
FAU - Sabetkish, Nastaran
AU  - Sabetkish N
FAU - Tavangar, Seyyed Mohammad
AU  - Tavangar SM
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/30 [received]
PHST- 2013/05/30 [accepted]
PST - epublish
SO  - Acta Med Iran. 2013 May 30;51(5):337-40.

PMID- 23737314
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 51
IP  - 5
DP  - 2013
TI  - Predictive value of having positive family history of cardiovascular disorders,
      diabetes mellitus, dyslipidemia, and hypertension in non-alcoholic Fatty liver
      disease patients.
PG  - 307-13
AB  - In the present study, we examined the relationship between family history of
      cardiovascular diseases (CVD), dyslipidemia, hypertension, and diabetes with
      laboratorial abnormalities and syndromes in Iranian patients with non-alcoholic
      fatty liver disease (NAFLD). A total of 332 NAFLD patients from our outpatient
      clinic were consecutively entered into analysis. Exclusion criteria were having
      diabetes mellitus and fasting blood glucose over 126, active hepatitis B virus
      infection, having HCV positive serology, and to be under corticosteroid therapy. 
      Family history of CVD, diabetes, dyslipidemia, and hypertension were taken from
      patients and related to the study variables. Family history of cardiovascular
      diseases (CVD) was associated with low HDL levels (P=0.05). Patients with
      positive family history of diabetes mellitus were significantly more likely to
      have AST/ALT levels proportion of higher than one (P=0.044). Family history of
      dyslipidemia was a predictor for hypertriglyceridemia (P=0.02), higher
      prothrombin time levels (P=0.013), lower albumin (P=0.024) and T4 (P=0.043)
      levels. Family history of hypertension was associated with dysglycemia/diabetes
      (P=0.038), high ALT (P=0.008), and low TIBC (P=0.007) and albumin levels
      (P=0.001). Family history for CVD, diabetes, dyslipidemia, and hypertension were 
      of clinical importance in the Iranian patients with NAFLD. We therefore recommend
      that physicians should precisely get family history of main disorders in all
      NAFLD patients; and to pay more attention to those having the mentioned family
      histories. Further studies with larger patient population and prospective
      approach are needed for confirming our findings.
AD  - Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah
      University of Medical Sciences, Tehran, Iran. dr.mohsen.amini@gmail.com.
FAU - Ghamar-Chehreh, Mohammad Ebrahim
AU  - Ghamar-Chehreh ME
FAU - Khedmat, Hossein
AU  - Khedmat H
FAU - Amini, Mohsen
AU  - Amini M
FAU - Taheri, Saeed
AU  - Taheri S
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/30 [received]
PHST- 2013/05/30 [accepted]
PST - epublish
SO  - Acta Med Iran. 2013 May 30;51(5):307-13.

PMID- 23737277
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Where is the evidence based on hard endpoints for the safety and effectiveness of
      sitagliptin in type 2 diabetes?
PG  - f3568
LID - 10.1136/bmj.f3568 [doi]
LID - bmj.f3568 [pii]
AD  - Universidade Federal Fluminense, Rio de Janeiro, RJ 22230-001, Brazil.
FAU - de Oliveira, Jose Mario Franco
AU  - de Oliveira JM
LA  - eng
PT  - Journal Article
DEP - 20130604
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PST - epublish
SO  - BMJ. 2013 Jun 4;346:f3568. doi: 10.1136/bmj.f3568.

PMID- 23737217
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Linking)
DP  - 2013 Jun 5
TI  - Primary Hypertension in Children and Adolescents is an Immuno-Metabolic Disease
      with Hemodynamic Consequences.
AB  - With the rise in obesity epidemic primary hypertension (PH) is now one of the
      most common chronic diseases in adolescence. In contrast to hypertensive adults, 
      hypertensive children usually are not exposed to other comorbidities such as
      diabetes, chronic kidney disease and atherosclerosis. Thus, PH in children and
      adolescents can be treated as the early stage of development of cardiovascular
      disease. There is increasing amount of data indicating that PH is not only
      hemodynamic phenomenon but a complex syndrome involving disturbed activity of
      sympathetic nervous system, metabolic abnormalities and activation of innate and 
      adaptive immune system. We discuss results of the studies on clinical, metabolic 
      and immunological phenotype of hypertensive children, associations between
      metabolic and immunological abnormalities with target organ damage and results of
      antihypertensive treatment.
AD  - Department of Nephrology and Arterial Hypertension, The Children's Memorial
      Health Institute, Warsaw, Poland, m.litwin@czd.pl.
FAU - Litwin, Mieczyslaw
AU  - Litwin M
FAU - Michalkiewicz, Jacek
AU  - Michalkiewicz J
FAU - Gackowska, Lidia
AU  - Gackowska L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1007/s11906-013-0360-5 [doi]
PST - aheadofprint
SO  - Curr Hypertens Rep. 2013 Jun 5.

PMID- 23737113
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 24
DP  - 2013 Jun
TI  - [Diagnostic accuracy of a standardized carbohydrate-rich breakfast compared to an
      oral glucose tolerance test in occupational medicine].
PG  - 1297-303
LID - 10.1055/s-0033-1343196 [doi]
AB  - Background: Increasing prevalence of type 2 diabetes mellitus is not only a
      problem for the health care system but also impairs working environment. In order
      to reduce costs by illness and early retirement and the development of diabetic
      complications occupational medicine is important for early diabetes detection.
      However, the diagnostic gold standard, oral glucose tolerance test (oGTT), is
      rarely accepted. Aim of our investigation was to evaluate diagnostic accuracy of 
      a standardizable and cost-effective test-breakfast in comparison to oGTT which
      might be accepted in workplace.Methods: During a workplace health promotion
      program diagnostic accuracy (sensitivity and specificity) of a test-breakfast
      (index test) was analyzed in a random-cross-over-design with healthy volunteers
      in comparison to an oGTT (reference test).Results: 278 subjects participated and 
      rated the health promotion program to be useful (99 %). 74 % stated that they
      preferred the test-breakfast in contrast to the oGTT. Both screening methods
      showed comparable plasma glucose and insulin curves. The plasma glucose levels
      measured capillary and venously during test-breakfast and oGTT were very
      consistent. Differences were only seen for the 2 h plasma glucose values in the
      fully adjusted model. The test-breakfast demonstrated high sensitivity and
      specificity for diabetes diagnosis compared to the reference test with highly
      comparable results, i. e. 8 persons (2,9 %) newly diagnosed with diabetes by the 
      test-breakfast vs. 7 (2,5 %) by oGTT.Conclusion: A test-breakfast seems to be a
      useful first screening instrument to increase the compliance of occupational
      health promotions and might improve early diabetes diagnosis.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Westdeutsches Diabetes- und Gesundheitszentrum, Verbund Katholischer Kliniken
      Dusseldorf, Dusseldorf.
FAU - Kempf, K
AU  - Kempf K
FAU - Martin, S
AU  - Martin S
FAU - Haastert, B
AU  - Haastert B
FAU - Schneider, M
AU  - Schneider M
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Diagnostische Genauigkeit eines standardisierten kohlenhydrathaltigen Fruhstucks 
      im Vergleich zum oralen Glukosetoleranztest in der betriebsmedizinischen Praxis.
DEP - 20130604
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/06/04 [epublish]
AID - 10.1055/s-0033-1343196 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 Jun;138(24):1297-303. doi: 10.1055/s-0033-1343196.
      Epub 2013 Jun 4.

PMID- 23737070
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1432-1327 (Electronic)
IS  - 0949-8257 (Linking)
DP  - 2013 Jun 5
TI  - Vanadyl acetylacetonate upregulates PPARgamma and adiponectin expression in
      differentiated rat adipocytes.
AB  - Vanadium compounds are promising agents in the therapeutic treatment of diabetes 
      mellitus, but their mechanism of action has not been fully elucidated. The
      current work investigated the effects of vanadyl acetylacetonate, VO(acac)2, on
      peroxisome-proliferator-activated receptor gamma (PPARgamma) and adiponectin,
      which are important targets of antidiabetic drugs. The experimental results
      revealed that vanadyl complexes increased the expression and multimerization of
      adiponectin in differentiated rat adipocytes. VO(acac)2 caused activation of p38 
      mitogen-activated protein kinase (MAPK) and AMP-activated protein kinase (AMPK)
      and elevation of PPARgamma levels. The specific inhibitors SB203580 (p38 MAPK
      inhibitor) and T0070907 (PPARgamma inhibitor) decreased the expression of
      adiponectin; however, compound C (AMPK inhibitor) did not significantly reduce
      the expression of adiponectin. In addition, vanadyl complexes induced
      protein-protein interaction between PPARgamma and a vanadium-binding chaperone,
      heat shock protein 60 kDa. Overall, our results suggest that vanadyl complexes
      may upregulate PPARgamma by suppressing PPARgamma degradation, and thus stimulate
      adiponectin expression and multimerization. The present work has provided new
      insights into the mechanism of the antidiabetic actions of vanadium compounds.
AD  - State Key Laboratories of Natural and Biomimetic Drugs and Department of Chemical
      Biology, School of Pharmaceutical Sciences, Peking University Health Science
      Center, Beijing, 100191, People's Republic of China.
FAU - Wu, Yaling
AU  - Wu Y
FAU - Huang, Meiling
AU  - Huang M
FAU - Zhao, Pan
AU  - Zhao P
FAU - Yang, Xiaoda
AU  - Yang X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Biol Inorg Chem
JT  - Journal of biological inorganic chemistry : JBIC : a publication of the Society
      of Biological Inorganic Chemistry
JID - 9616326
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/01/30 [received]
PHST- 2013/05/10 [accepted]
PHST- 2013/06/05 [aheadofprint]
AID - 10.1007/s00775-013-1007-3 [doi]
PST - aheadofprint
SO  - J Biol Inorg Chem. 2013 Jun 5.

PMID- 23737027
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1573-7225 (Electronic)
IS  - 0957-5243 (Linking)
DP  - 2013 Jun 5
TI  - Pregnancy-related characteristics and breast cancer risk.
AB  - Breast tissues undergo extensive physiologic changes during pregnancy, which may 
      affect breast carcinogenesis. Gestational hypertension, preeclampsia/eclampsia,
      gestational diabetes, pregnancy weight gain, and nausea and vomiting (N&V) during
      pregnancy may be indicative of altered hormonal and metabolic profiles and could 
      impact breast cancer risk. Here, we examined associations between these
      characteristics of a woman's pregnancy and her subsequent breast cancer risk.
      Participants were parous women that were recruited to a population-based
      case-control study (Western New York Exposures and Breast Cancer Study). Cases (n
      = 960), aged 35-79 years, had incident, primary, histologically confirmed breast 
      cancer. Controls (n = 1,852) were randomly selected from motor vehicle records
      (<65 years) or Medicare rolls (>/=65 years). Women were queried on their lifetime
      pregnancy experiences. Multivariable-adjusted logistic regression was used to
      estimate odds ratios (ORs) and 95 % confidence intervals (CIs). N&V during
      pregnancy was inversely associated with breast cancer risk. Relative to those who
      never experienced N&V, ever experiencing N&V was associated with decreased risk
      (OR 0.69, 95 % CI 0.56-0.84) as were increased N&V severity (p trend < 0.001),
      longer duration (p trend < 0.01), and larger proportion of affected pregnancies
      (p trend < 0.0001) among women with >/=3 pregnancies. Associations were stronger 
      for more recent pregnancies (<5 years). Findings did not differ by menopausal
      status or breast cancer subtype including estrogen receptor and HER2 expression
      status. Other pregnancy characteristics examined were not associated with risk.
      We observed strong inverse associations between pregnancy N&V and breast cancer
      risk. Replication of these findings and exploration of underlying mechanisms
      could provide important insight into breast cancer etiology and prevention.
AD  - Division of Cancer Prevention and Control, The Ohio State University College of
      Medicine, Columbus, OH, USA, Theodore.Brasky@osumc.edu.
FAU - Brasky, Theodore M
AU  - Brasky TM
FAU - Li, Yanli
AU  - Li Y
FAU - Jaworowicz, David J Jr
AU  - Jaworowicz DJ Jr
FAU - Potischman, Nancy
AU  - Potischman N
FAU - Ambrosone, Christine B
AU  - Ambrosone CB
FAU - Hutson, Alan D
AU  - Hutson AD
FAU - Nie, Jing
AU  - Nie J
FAU - Shields, Peter G
AU  - Shields PG
FAU - Trevisan, Maurizio
AU  - Trevisan M
FAU - Rudra, Carole B
AU  - Rudra CB
FAU - Edge, Stephen B
AU  - Edge SB
FAU - Freudenheim, Jo L
AU  - Freudenheim JL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Cancer Causes Control
JT  - Cancer causes & control : CCC
JID - 9100846
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/02/20 [received]
PHST- 2013/05/25 [accepted]
PHST- 2013/06/05 [aheadofprint]
AID - 10.1007/s10552-013-0242-9 [doi]
PST - aheadofprint
SO  - Cancer Causes Control. 2013 Jun 5.

PMID- 23736989
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 6
DP  - 2013 Jun 5
TI  - Interconception care for women with a history of gestational diabetes for
      improving maternal and infant outcomes.
PG  - CD010211
AB  - BACKGROUND: Gestational diabetes mellitus (GDM) is associated with adverse health
      outcomes for both mother and infant both perinatally and long-term. Women with a 
      history of GDM are at risk of recurrence in subsequent pregnancies and may
      benefit from intervention in the interconception period to improve maternal and
      infant health outcomes. OBJECTIVES: To investigate the effects of interconception
      care for women with a history of GDM on maternal and infant health outcomes.
      SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials 
      Register (31 January 2013). SELECTION CRITERIA: Randomised controlled trials,
      including quasi-randomised controlled trials and cluster-randomised trials
      evaluating any protocol of interconception care with standard care or other forms
      of interconception care for women with a history of GDM in a previous pregnancy
      on maternal and infant health outcomes. DATA COLLECTION AND ANALYSIS: Two review 
      authors independently assessed study eligibility. In future updates of this
      review, at least two review authors will extract data and assess the risk of bias
      of included studies. MAIN RESULTS: One ongoing trial was identified. No eligible 
      completed trials were identified. AUTHORS' CONCLUSIONS: The role of
      interconception care for women with a history of gestational diabetes remains
      unclear. Randomised controlled trials are required evaluating different forms and
      protocols of interconception care for these women on perinatal and long-term
      maternal and infant health outcomes, acceptability of such interventions and
      cost-effectiveness.
AD  - ARCH: Australian Research Centre for Health of Women and Babies, The Robinson
      Institute, Discipline of Obstetrics and Gynaecology, The University of Adelaide, 
      Women's and Children's Hospital, 1st floor, Queen Victoria Building, 72 King
      William Road, Adelaide, South Australia, Australia, 5006.
FAU - Tieu, Joanna
AU  - Tieu J
FAU - Bain, Emily
AU  - Bain E
FAU - Middleton, Philippa
AU  - Middleton P
FAU - Crowther, Caroline A
AU  - Crowther CA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1002/14651858.CD010211.pub2 [doi]
PST - aheadofprint
SO  - Cochrane Database Syst Rev. 2013 Jun 5;6:CD010211.

PMID- 23736950
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 6
DP  - 2013 Jun 4
TI  - Increased consumption of fruit and vegetables for the primary prevention of
      cardiovascular diseases.
PG  - CD009874
AB  - BACKGROUND: There is increasing evidence that high consumption of fruit and
      vegetables is beneficial for cardiovascular disease (CVD) prevention. OBJECTIVES:
      The primary objective is to determine the effectiveness of i) advice to increase 
      fruit and vegetable consumption ii) the provision of fruit and vegetables to
      increase consumption, for the primary prevention of CVD. SEARCH METHODS: We
      searched the following electronic databases: The Cochrane Library (2012, issue
      9-CENTRAL, HTA, DARE, NEED), MEDLINE (1946 to week 3 September 2012); EMBASE
      (1980 to 2012 week 39) and the Conference Proceedings Citation Index - Science on
      ISI Web of Science (5 October 2012). We searched trial registers, screened
      reference lists and contacted authors for additional information where necessary.
      No language restrictions were applied. SELECTION CRITERIA: Randomised controlled 
      trials with at least three months follow-up (follow-up was considered to be the
      time elapsed since the start of the intervention) involving healthy adults or
      those at high risk of CVD. Trials investigated either advice to increase fruit
      and vegetable intake (via any source or modality) or the provision of fruit and
      vegetables to increase intake. The comparison group was no intervention or
      minimal intervention. Outcomes of interest were CVD clinical events (mortality
      (CVD and all-cause), myocardial infarction (MI), coronary artery bypass grafting 
      (CABG) or percutaneous transluminal coronary angioplasty (PTCA),
      angiographically-defined angina pectoris, stroke, carotid endarterectomy,
      peripheral arterial disease (PAD)) and major CVD risk factors (blood pressure,
      blood lipids, type 2 diabetes). Trials involving multifactorial lifestyle
      interventions (including different dietary patterns, exercise) or where the focus
      was weight loss were excluded to avoid confounding. DATA COLLECTION AND ANALYSIS:
      Two review authors independently selected trials for inclusion, extracted data
      and assessed the risk of bias. Trials of provision of fruit and vegetables were
      analysed separately from trials of dietary advice. MAIN RESULTS: We identified 10
      trials with a total of 1730 participants randomised, and one ongoing trial. Six
      trials investigated the provision of fruit and vegetables, and four trials
      examined advice to increase fruit and vegetable consumption.The ongoing trial is 
      examining the provision of an avocado-rich diet.The number and type of
      intervention components for provision, and the dietary advice provided differed
      between trials.None of the trials reported clinical events as they were all
      relatively short term. There was no strong evidence for effects of individual
      trials of provision of fruit and vegetables on cardiovascular risk factors, but
      trials were heterogeneous and short term. Furthermore, five of the six trials
      only provided one fruit or vegetable. Dietary advice showed some favourable
      effects on blood pressure (systolic blood pressure (SBP): mean difference (MD)
      -3.0 mmHg (95% confidence interval (CI) -4.92 to -1.09), diastolic blood pressure
      (DBP): MD -0.90 mmHg (95% CI -2.03 to 0.24)) and low-density lipoprotein (LDL)
      cholesterol but analyses were based on only two trials. Three of the 10 included 
      trials examined adverse effects, which included increased bowel movements, bad
      breath and body odour. AUTHORS' CONCLUSIONS: There are very few studies to date
      examining provision of, or advice to increase the consumption of, fruit and
      vegetables in the absence of additional dietary interventions or other lifestyle 
      interventions for the primary prevention of CVD. The limited evidence suggests
      advice to increase fruit and vegetables as a single intervention has favourable
      effects on CVD risk factors but more trials are needed to confirm this.
AD  - Division of Health Sciences, Warwick Medical School, University of Warwick,
      Coventry, Warwickshire, UK, CV4 7AL.
FAU - Hartley, Louise
AU  - Hartley L
FAU - Igbinedion, Ewemade
AU  - Igbinedion E
FAU - Holmes, Jennifer
AU  - Holmes J
FAU - Flowers, Nadine
AU  - Flowers N
FAU - Thorogood, Margaret
AU  - Thorogood M
FAU - Clarke, Aileen
AU  - Clarke A
FAU - Stranges, Saverio
AU  - Stranges S
FAU - Hooper, Lee
AU  - Hooper L
FAU - Rees, Karen
AU  - Rees K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1002/14651858.CD009874.pub2 [doi]
PST - aheadofprint
SO  - Cochrane Database Syst Rev. 2013 Jun 4;6:CD009874.

PMID- 23736850
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1424-8220 (Electronic)
IS  - 1424-8220 (Linking)
VI  - 13
IP  - 6
DP  - 2013
TI  - Non-invasive continuous glucose monitoring with multi-sensor systems: a monte
      carlo-based methodology for assessing calibration robustness.
PG  - 7279-95
LID - 10.3390/s130607279 [doi]
AB  - In diabetes research, non-invasive continuous glucose monitoring (NI-CGM) devices
      represent a new and appealing frontier. In the last years, some multi-sensor
      devices for NI-CGM have been proposed, which exploit several sensors measuring
      phenomena of different nature, not only for measuring glucose related signals,
      but also signals reflecting some possible perturbing processes (temperature,
      blood perfusion). Estimation of glucose levels is then obtained combining these
      signals through a mathematical model which requires an initial calibration step
      exploiting one reference blood glucose (RBG) sample. Even if promising results
      have been obtained, especially in hospitalized volunteers, at present the
      temporal accuracy of NI-CGM sensors may suffer because of environmental and
      physiological interferences. The aim of this work is to develop a general
      methodology, based on Monte Carlo (MC) simulation, to assess the robustness of
      the calibration step used by NI-CGM devices against these disturbances. The
      proposed methodology is illustrated considering two examples: the first concerns 
      the possible detrimental influence of sweat events, while the second deals with
      calibration scheduling. For implementing both examples, 45 datasets collected by 
      the Solianis Multisensor system are considered. In the first example, the MC
      methodology suggests that no further calibration adjustments are needed after the
      occurrence of sweat events, because the "Multisensor+model" system is able to
      deal with the disturbance. The second case study shows how to identify the best
      time interval to update the model's calibration for improving the accuracy of the
      estimated glucose. The methodology proposed in this work is of general
      applicability and can be helpful in making those incremental steps in NI-CGM
      devices development needed to further improve their performance.
AD  - Department of Information Engineering, University of Padova, via Gradenigo 6B,
      Padova 35131, Italy. cobelli@dei.unipd.it.
FAU - Zanon, Mattia
AU  - Zanon M
FAU - Sparacino, Giovanni
AU  - Sparacino G
FAU - Facchinetti, Andrea
AU  - Facchinetti A
FAU - Talary, Mark S
AU  - Talary MS
FAU - Mueller, Martin
AU  - Mueller M
FAU - Caduff, Andreas
AU  - Caduff A
FAU - Cobelli, Claudio
AU  - Cobelli C
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - Switzerland
TA  - Sensors (Basel)
JT  - Sensors (Basel, Switzerland)
JID - 101204366
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/04/02 [received]
PHST- 2013/04/25 [revised]
PHST- 2013/05/22 [accepted]
AID - s130607279 [pii]
AID - 10.3390/s130607279 [doi]
PST - epublish
SO  - Sensors (Basel). 2013 Jun 3;13(6):7279-95. doi: 10.3390/s130607279.

PMID- 23736840
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1473-6543 (Electronic)
IS  - 1062-4821 (Linking)
VI  - 22
IP  - 4
DP  - 2013 Jul
TI  - Nephrolithiasis and loss of kidney function.
PG  - 390-6
LID - 10.1097/MNH.0b013e32836214b9 [doi]
AB  - PURPOSE OF REVIEW: The prevalence of nephrolithiasis has been on the rise over
      recent decades. There have also been extensive efforts to identify risk factors
      for chronic kidney disease (CKD). The purpose of this review is to highlight
      recent evidence on the association of nephrolithiasis with the development of CKD
      and end-stage renal disease (ESRD). RECENT FINDINGS: Several epidemiologic
      studies over the past decade assessed the relationship between history of
      nephrolithiasis and CKD. Across several studies, patients with nephrolithiasis
      had about a two-fold higher risk for decreased renal function or need for renal
      replacement therapy. This risk appears to be independent of risk factors for CKD 
      that are common in stone formers such as hypertension and diabetes mellitus.
      Specific risk factors for CKD in stone formers include recurrent urinary tract
      infections, struvite and possibly uric acid stone composition, symptomatic
      stones, solitary kidney, ileal conduit, neurogenic bladder, and hydronephrosis.
      SUMMARY: Recent evidence has shown a consistent relationship between
      nephrolithiasis history and an increased risk of CKD and ESRD. Understanding the 
      characteristics that predispose to CKD may better inform how to optimally manage 
      patients with nephrolithiasis and prevent this complication.
AD  - Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic,
      Rochester, Minnesota, USA.
FAU - Keddis, Mira T
AU  - Keddis MT
FAU - Rule, Andrew D
AU  - Rule AD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Nephrol Hypertens
JT  - Current opinion in nephrology and hypertension
JID - 9303753
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1097/MNH.0b013e32836214b9 [doi]
AID - 00041552-201307000-00006 [pii]
PST - ppublish
SO  - Curr Opin Nephrol Hypertens. 2013 Jul;22(4):390-6. doi:
      10.1097/MNH.0b013e32836214b9.

PMID- 23736818
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 28
IP  - 4
DP  - 2013 Jul
TI  - What should be the blood pressure target for patients with chronic kidney
      disease?
PG  - 439-45
LID - 10.1097/HCO.0b013e32836208c2 [doi]
AB  - PURPOSE OF REVIEW: Persons with chronic kidney disease (CKD) exhibit a
      disproportionate burden of elevated blood pressure (BP) with a high prevalence of
      premature end-stage renal disease and cardiovascular events. RECENT FINDINGS:
      Results of recent randomized controlled clinical trials suggest that most
      patients with reduced estimated glomerular filtration rate (eGFR) and
      hypertension experience optimal clinical outcomes when SBP is less than 140 mmHg 
      and DBP is less than 90 mmHg. The benefit of additional lowering of SBP to less
      than 130 mmHg and DBP to less than 80 mmHg remains controversial, and appears to 
      be of most benefit to the subset of CKD patients with proteinuria (>300 mg/day). 
      The combination of a diuretic and an angiotensin receptor blocker (ARB) or
      angiotensin-converting enzyme inhibitor (ACEI) has demonstrated particular
      promise in patients with reduced eGFR and proteinuria. SUMMARY: A practical
      approach in clinical practice for the treatment of elevated BP in persons with
      CKD is to achieve a BP less than 140/90 mmHg with a combination of diuretic and
      an ARB or ACEI. Consideration for a lower BP goal and other therapeutic and
      nontherapeutic interventions can be made based on the cause of CKD, presence of
      proteinuria, or other coexisting medical conditions.
AD  - aDivision of Nephrology bDivision of Endocrinology, Diabetes and Hypertension
      cDepartment of Medicine, David Geffen School of Medicine, University of
      California dCharles R. Drew University of Medicine and Science, Los Angeles,
      California eDivision of Nephrology and Hypertension, Departments of Medicine,
      Physiology and Biophysics, University of California, Irvine, Irvine, California, 
      USA.
FAU - Nicholas, Susanne B
AU  - Nicholas SB
FAU - Vaziri, Nosratola D
AU  - Vaziri ND
FAU - Norris, Keith C
AU  - Norris KC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1097/HCO.0b013e32836208c2 [doi]
AID - 00001573-201307000-00010 [pii]
PST - ppublish
SO  - Curr Opin Cardiol. 2013 Jul;28(4):439-45. doi: 10.1097/HCO.0b013e32836208c2.

PMID- 23736807
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1532-2092 (Electronic)
IS  - 1099-5129 (Linking)
DP  - 2013 Jun 4
TI  - Cardiac resynchronization therapy in pacemaker-dependent patients with left
      ventricular dysfunction.
AB  - AIMS: Heart failure and left ventricular (LV) systolic dysfunction (LVSD) are
      common in patients with permanent pacemakers. The aim was to determine if cardiac
      resynchronization therapy (CRT) at the time of pulse generator replacement (PGR) 
      is of benefit in patients with unavoidable RV pacing and LVSD.METHODS AND
      RESULTS: Fifty patients with unavoidable RV pacing, LVSD, and mild or no symptoms
      of heart failure, listed for PGR were randomized 1 : 1 to either standard RV-PGR 
      (comparator) or CRT. The primary endpoint was the difference in change in LV
      ejection fraction (LVEF) between RV-PGR and CRT groups from baseline to 6 months.
      Secondary endpoints included peak oxygen consumption, quality of life, and
      N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. At 6 months there
      was a difference in change in median (interquartile range) LVEF [9 (6-12) vs.
      -1.5 (-4.5 to -0.8)%; P < 0.0001] between the CRT and RV-PGR arms. There were
      also improvements in exercise capacity (P = 0.007), quality of life (P = 0.03),
      and NT-proBNP (P = 0.007) in those randomized to CRT. After 809 (729-880) days,
      17 patients had died or been hospitalized (6 in CRT group and 11 in the
      comparator RV-PGR group) and two patients in the RV-PGR arm had required CRT for 
      deteriorating heart failure. Patients with standard RV-PGR had more days in
      hospital during follow-up than those in the CRT group [4 (2-7) vs. 11 (6-16)
      days; P = 0.047].CONCLUSION: Performing CRT in pacemaker patients with
      unavoidable RV pacing and LVSD but without severe symptoms of heart failure, at
      the time of PGR, improves cardiac function, exercise capacity, quality of life,
      and NT-pro-BNP levels.
AD  - Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics,
      Health and Therapeutics, Multidisciplinary Cardiovascular Research Centre,
      University of Leeds, Clarendon Way, Leeds LS2 9JT, UK.
FAU - Gierula, John
AU  - Gierula J
FAU - Cubbon, Richard M
AU  - Cubbon RM
FAU - Jamil, Haqeel A
AU  - Jamil HA
FAU - Byrom, Rowenna
AU  - Byrom R
FAU - Baxter, Paul D
AU  - Baxter PD
FAU - Pavitt, Sue
AU  - Pavitt S
FAU - Gilthorpe, Mark S
AU  - Gilthorpe MS
FAU - Hewison, Jenny
AU  - Hewison J
FAU - Kearney, Mark T
AU  - Kearney MT
FAU - Witte, Klaus K A
AU  - Witte KK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Europace
JT  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal 
      of the working groups on cardiac pacing, arrhythmias, and cardiac cellular
      electrophysiology of the European Society of Cardiology
JID - 100883649
OTO - NOTNLM
OT  - Heart failure
OT  - Left ventricular dysfunction
OT  - Pacemaker
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - eut148 [pii]
AID - 10.1093/europace/eut148 [doi]
PST - aheadofprint
SO  - Europace. 2013 Jun 4.

PMID- 23736779
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1423-0143 (Electronic)
IS  - 1420-4096 (Linking)
VI  - 37
IP  - 2-3
DP  - 2013
TI  - Proteinuria as a risk factor for decline in residual renal function in
      non-diabetic peritoneal dialysis patients.
PG  - 199-210
LID - 10.1159/000350145 [doi]
AB  - Background: Preservation of residual renal function (RRF) is a major issue for
      patients on peritoneal dialysis (PD). Whether proteinuria is associated with a
      decline in RRF in patients on PD remains unclear. Patients and Methods: We
      reviewed the medical records at the Yeungnam University Hospital in Korea and
      identified patients who started PD between June 1995 and August 2011. A total of 
      147 non-diabetic patients were enrolled in the study. The patients were divided
      into 3 groups with respect to the tertile of initial proteinuria level: Low (n = 
      49; <320 mg/day), Middle (n = 49; 320-822 mg/day), and High groups (n = 49; >822 
      mg/day). Results: The mean patient age was 50.2 +/- 15.0 years in the Low
      tertile, 50.2 +/- 15.4 years in the Middle tertile, and 49.0 +/- 15.1 years in
      the High tertile. Decline in RRF during follow-up period was greater in the High 
      tertile than that in the other tertiles (P = 0.001). The proportion of patients
      with RRF >50% of baseline at 24 months after the initiation of PD was 83% in the 
      Low tertile, 66% in the Middle tertile, and 40% in the High tertile (P < 0.001). 
      The multivariate analysis after adjusting for initial RRF, age, gender,
      underlying disease of end-stage renal disease except diabetes mellitus, PD
      modality, use of icodextrin, PD-associated peritonitis, and tertile of the
      initial proteinuria level revealed that High tertile of the initial proteinuria
      level was associated with a decline in RRF (hazard ratios: 2.442 for the Middle
      tertile, P = 0.007 ; 3.713 for the Low tertile, P < 0.001). Conclusion: The
      present study demonstrates that proteinuria may be is associated with a rapid
      decline in RRF in non-diabetic patients on PD, although the potential role of
      additional factors should be further investigated in prospective studies.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Division of Nephrology, Department of Internal Medicine, Yeungnam University
      Hospital, Daegu, Korea.
FAU - Kang, Seok Hui
AU  - Kang SH
FAU - Cho, Kyu Hyang
AU  - Cho KH
FAU - Park, Jong Won
AU  - Park JW
FAU - Yoon, Kyung Woo
AU  - Yoon KW
FAU - Do, Jun Young
AU  - Do JY
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - Switzerland
TA  - Kidney Blood Press Res
JT  - Kidney & blood pressure research
JID - 9610505
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/04/22 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 000350145 [pii]
AID - 10.1159/000350145 [doi]
PST - ppublish
SO  - Kidney Blood Press Res. 2013;37(2-3):199-210. doi: 10.1159/000350145. Epub 2013
      May 30.

PMID- 23736777
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1423-0143 (Electronic)
IS  - 1420-4096 (Linking)
VI  - 37
IP  - 2-3
DP  - 2013
TI  - Uric Acid levels and all-cause mortality in peritoneal dialysis patients.
PG  - 181-9
LID - 10.1159/000350143 [doi]
AB  - Background: Epidemiological studies have shown that hyperuricemia is associated
      with all-cause and cardiovascular mortality in chronic kidney disease (CKD) and
      hemodialysis patients. Our study investigated the influence of serum uric acid
      (UA) levels on survival in peritoneal dialysis (PD) patients. Methods: This was a
      retrospective study involving 156 subjects who had undergone PD. The patient
      demographics, etiology of ESRD, comorbid conditions and other laboratory
      parameters were collected. The subjects were divided into three groups according 
      to their serum UA concentrations (group 1, the lowest quartile; group 2, the
      middle quartiles; group 3, the highest quartile). The risk of death was
      calculated using a multivariate Cox regression model. Results: There were 41
      deaths during a follow-up period of 31.3+/-17.5 months. Compared with group 2,
      which had a mortality rate of 5.7 per 1000 person-months, the mortality rates
      were higher in group 1 (14.3 per 1000 person-months, p<0.05) and group 3 (13.3
      per 1000 person-months, p<0.05). A multivariable Cox regression model revealed
      that age, serum albumin, diabetes mellitus (DM), hypertensive nephropathy,
      residual renal function and UA group were factors associated with mortality in
      the PD patients. Using group 2 as a reference, the hazard ratio (HR) of mortality
      was found to be 1.15 (95% confidence interval [CI] 0.20-2.57, p>0.05) for group 1
      and 2.96 (95% CI 1.29-6.80, p=0.01) for group 3. Conclusions: In PD patients, a
      higher serum UA level is related to increased mortality and is an independent
      risk factor for all-cause mortality. Uric acid levels and all-cause mortality in 
      peritoneal dialysis patients.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Nephrology, Second Affiliated Hospital of Soochow University,
      Suzhou, China.
FAU - Feng, Sheng
AU  - Feng S
FAU - Jiang, Linseng
AU  - Jiang L
FAU - Shi, Yongbing
AU  - Shi Y
FAU - Shen, Huaying
AU  - Shen H
FAU - Shi, Xiaosong
AU  - Shi X
FAU - Jin, Donghua
AU  - Jin D
FAU - Zeng, Ying
AU  - Zeng Y
FAU - Wang, Zhi
AU  - Wang Z
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - Switzerland
TA  - Kidney Blood Press Res
JT  - Kidney & blood pressure research
JID - 9610505
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/04/12 [accepted]
PHST- 2013/05/21 [aheadofprint]
AID - 000350143 [pii]
AID - 10.1159/000350143 [doi]
PST - ppublish
SO  - Kidney Blood Press Res. 2013;37(2-3):181-9. doi: 10.1159/000350143. Epub 2013 May
      21.

PMID- 23736775
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130605
DCOM- 20130606
IS  - 2162-2531 (Electronic)
VI  - 2
DP  - 2013
TI  - A Short-activating RNA Oligonucleotide Targeting the Islet beta-cell
      Transcriptional Factor MafA in CD34(+) Cells.
PG  - e97
LID - 10.1038/mtna.2013.23 [doi]
AB  - Upon functional loss of insulin producing islet beta-cells, some patients with
      diabetes become dependent on life-long insulin supplementation therapy.
      Bioengineering surrogate insulin producing cells is an alternative replacement
      strategy. We have developed a novel approach using short-activating RNA
      oligonucleotides to differentiate adult human CD34(+) cells into
      insulin-secreting cells. By transfecting RNA to increase transcript levels of the
      master regulator of insulin biosynthesis, v-maf musculoaponeurotic fibrosarcoma
      oncogene homolog A (MafA), several pancreatic endodermal genes were upregulated
      during the differentiation procedure. These included Pancreatic and duodenal
      homeobox gene-1 (PDX1), Neurogenin 3, NeuroD, and NK6 homeobox 1 (NKx6-1).
      Differentiated CD34(+) cells also expressed glucokinase, glucagon-like peptide 1 
      receptor (GLP1R), sulfonylurea receptor-1 (SUR1) and phogrin-all essential for
      glucose sensitivity and insulin secretion. The differentiated cells appropriately
      processed C-peptide and insulin in response to increasing glucose stimulation as 
      shown by enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell
      sorting analysis, western blotting, and immunofluorescence staining. We provide a
      new approach using short-activating RNA in developing insulin producing surrogate
      cells for treating diabetes.Molecular Therapy - Nucleic Acids (2013) 2, e97;
      doi:10.1038/mtna.2013.23; advance online publication 4 June 2013.
AD  - Department of Surgery and Cancer, Imperial College London, London, UK.
FAU - Reebye, Vikash
AU  - Reebye V
FAU - Saetrom, Pal
AU  - Saetrom P
FAU - Mintz, Paul J
AU  - Mintz PJ
FAU - Rossi, John J
AU  - Rossi JJ
FAU - Kasahara, Noriyuki
AU  - Kasahara N
FAU - Nteliopoulos, Georgios
AU  - Nteliopoulos G
FAU - Nicholls, Joanna
AU  - Nicholls J
FAU - Haoudi, Abdelali
AU  - Haoudi A
FAU - Gordon, Myrtle
AU  - Gordon M
FAU - Habib, Nagy A
AU  - Habib NA
LA  - eng
PT  - Journal Article
DEP - 20130604
PL  - United States
TA  - Mol Ther Nucleic Acids
JT  - Molecular therapy. Nucleic acids
JID - 101581621
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:01
CRDT- 2013/06/06 06:00
AID - mtna201323 [pii]
AID - 10.1038/mtna.2013.23 [doi]
PST - epublish
SO  - Mol Ther Nucleic Acids. 2013 Jun 4;2:e97. doi: 10.1038/mtna.2013.23.

PMID- 23736769
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1530-0447 (Electronic)
IS  - 0031-3998 (Linking)
DP  - 2013 Jun 4
TI  - Vitamin D status and cardiometabolic assessment in infancy.
LID - 10.1038/pr.2013.91 [doi]
AB  - Background:Infants are at risk of vitamin D insufficiency, owing to their limited
      exposure to direct sunlight and the low levels of vitamin D in breastmilk. While 
      vitamin D insufficiency has been associated with cardio-metabolic risk factors in
      children, these associations have not been studied in infants, despite their
      unique risks. Thus, we sought to determine whether vitamin D status was
      associated with cardio-metabolic measures in infants.Methods:Ninety-nine
      full-term infants were evaluated at age 1-year, with measurement of 25-hydroxy
      vitamin D (25-OH-D) and an array of traditional (fasting glucose, insulin,
      low-density-lipoprotein cholesterol, high-density-lipoprotein cholesterol,
      triglycerides) and emerging (C-reactive protein, adiponectin, leptin)
      cardio-metabolic risk factors. Based on 25-OH-D level, infants were classified as
      vitamin D-sufficient (n=59), vitamin D-insufficient (n=29), or vitamin
      D-deficient (n=11).Results:Duration of exclusive breastfeeding and prevalence of 
      non-white ethnicity were highest in the vitamin D-deficient group (p=0.05 and
      0.03, respectively). Current use of vitamin D supplementation was highest in the 
      sufficient group (p=0.02). Importantly, however, there were no significant
      differences between the 3 groups in any of the cardio-metabolic risk factors, on 
      both unadjusted and covariate-adjusted analyses.Conclusions:Vitamin D
      insufficiency/deficiency is not associated with an adverse cardiometabolic risk
      factor profile in one-year-old infants.Pediatric Research (2013);
      doi:10.1038/pr.2013.91.
AD  - Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario,
      Canada.
FAU - Kew, Simone
AU  - Kew S
FAU - Hamilton, Jill K
AU  - Hamilton JK
FAU - Ye, Chang
AU  - Ye C
FAU - Hanley, Anthony J
AU  - Hanley AJ
FAU - Zinman, Bernard
AU  - Zinman B
FAU - Retnakaran, Ravi
AU  - Retnakaran R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Pediatr Res
JT  - Pediatric research
JID - 0100714
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/06/04 [aheadofprint]
AID - pr201391 [pii]
AID - 10.1038/pr.2013.91 [doi]
PST - aheadofprint
SO  - Pediatr Res. 2013 Jun 4. doi: 10.1038/pr.2013.91.

PMID- 23736737
OWN - NLM
STAT- MEDLINE
DA  - 20130605
DCOM- 20130606
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 309
IP  - 21
DP  - 2013 Jun 5
TI  - Treating diabetes with surgery.
PG  - 2274-5
LID - 10.1001/jama.2013.4772 [doi]
FAU - Wolfe, Bruce M
AU  - Wolfe BM
FAU - Purnell, Jonathan Q
AU  - Purnell JQ
FAU - Belle, Steven H
AU  - Belle SH
LA  - eng
PT  - Comment
PT  - Editorial
PL  - United States
TA  - JAMA
JT  - JAMA : the journal of the American Medical Association
JID - 7501160
SB  - AIM
SB  - IM
CON - JAMA. 2013 Jun 5;309(21):2240-9. PMID: 23736733
CON - JAMA. 2013 Jun 5;309(21):2250-61. PMID: 23736734
MH  - *Bariatric Surgery
MH  - Diabetes Mellitus/*surgery
MH  - Diabetes Mellitus, Type 2/*drug therapy/*surgery
MH  - Female
MH  - *Gastric Bypass
MH  - Humans
MH  - Hyperlipidemias/*drug therapy/*surgery
MH  - Hypertension/*drug therapy/*surgery
MH  - Male
MH  - Obesity/*surgery
MH  - *Weight Loss
EDAT- 2013/06/06 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/06 06:00
AID - 1693867 [pii]
AID - 10.1001/jama.2013.4772 [doi]
PST - ppublish
SO  - JAMA. 2013 Jun 5;309(21):2274-5. doi: 10.1001/jama.2013.4772.

PMID- 23736734
OWN - NLM
STAT- MEDLINE
DA  - 20130605
DCOM- 20130606
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 309
IP  - 21
DP  - 2013 Jun 5
TI  - Bariatric surgery for weight loss and glycemic control in nonmorbidly obese
      adults with diabetes: a systematic review.
PG  - 2250-61
LID - 10.1001/jama.2013.4851 [doi]
AB  - IMPORTANCE: Bariatric surgery is beneficial in persons with a body mass index
      (BMI) of 35 or greater with obesity-related comorbidities. There is interest in
      using these procedures in persons with lower BMI and diabetes. OBJECTIVE: To
      assess the association between bariatric surgery vs nonsurgical treatments and
      weight loss and glycemic control among patients with diabetes or impaired glucose
      tolerance and BMI of 30 to 35. EVIDENCE REVIEW: PubMed, EMBASE, and Cochrane
      Library databases were searched from January 1985 through September 2012. Of 1291
      screened articles, we included 32 surgical studies, 11 systematic reviews on
      nonsurgical treatments, and 11 large nonsurgical studies published after those
      reviews. Weight loss, metabolic outcomes, and adverse events were abstracted by 2
      independent reviewers. FINDINGS: Three randomized clinical trials (RCTs) (N =
      290; including 1 trial of 150 patients with type 2 diabetes and mean BMI of 37, 1
      trial of 80 patients without diabetes [38% with metabolic syndrome] and BMI of 30
      to 35, and 1 trial of 60 patients with diabetes and BMI of 30 to 40 [13 patients 
      with BMI <35]) found that surgery was associated with greater weight loss (range,
      14.4-24 kg) and glycemic control (range, 0.9-1.43 point improvements in
      hemoglobin A1c levels) during 1 to 2 years of follow-up than nonsurgical
      treatment. Indirect comparisons of evidence from observational studies of
      bariatric procedures (n approximately 600 patients) and meta-analyses of
      nonsurgical therapies (containing more than 300 RCTs) support this finding at 1
      or 2 years of follow-up. However, there are no robust surgical data beyond 5
      years of follow-up on outcomes of diabetes, glucose control, or macrovascular and
      microvascular outcomes. In contrast, some RCT data of nonsurgical therapies show 
      benefits at 10 years of follow-up or more. Surgeon-reported adverse events were
      low (eg, hospital deaths of 0.3%-1.0%), but data were from select centers and
      surgeons. Long-term adverse events are unknown. CONCLUSIONS AND RELEVANCE:
      Current evidence suggests that, when compared with nonsurgical treatments,
      bariatric surgical procedures in patients with a BMI of 30 to 35 and diabetes are
      associated with greater short-term weight loss and better intermediate glucose
      outcomes. Evidence is insufficient to reach conclusions about the appropriate use
      of bariatric surgery in this population until more data are available about
      long-term outcomes and complications of surgery.
AD  - Rand Health, Santa Monica, California, USA. mmaggard@mednet.ucla.edu
FAU - Maggard-Gibbons, Melinda
AU  - Maggard-Gibbons M
FAU - Maglione, Margaret
AU  - Maglione M
FAU - Livhits, Masha
AU  - Livhits M
FAU - Ewing, Brett
AU  - Ewing B
FAU - Maher, Alicia Ruelaz
AU  - Maher AR
FAU - Hu, Jianhui
AU  - Hu J
FAU - Li, Zhaoping
AU  - Li Z
FAU - Shekelle, Paul G
AU  - Shekelle PG
LA  - eng
GR  - 290-2007-10062I/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - JAMA
JT  - JAMA : the journal of the American Medical Association
JID - 7501160
RN  - 0 (Blood Glucose)
SB  - AIM
SB  - IM
CIN - JAMA. 2013 Jun 5;309(21):2274-5. PMID: 23736737
MH  - *Bariatric Surgery/adverse effects/methods
MH  - Blood Glucose
MH  - Body Mass Index
MH  - Diabetes Complications
MH  - Diabetes Mellitus/*surgery
MH  - Glucose Intolerance
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Obesity/complications/*surgery
MH  - Randomized Controlled Trials as Topic
MH  - *Weight Loss
EDAT- 2013/06/06 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/06 06:00
AID - 1693893 [pii]
AID - 10.1001/jama.2013.4851 [doi]
PST - ppublish
SO  - JAMA. 2013 Jun 5;309(21):2250-61. doi: 10.1001/jama.2013.4851.

PMID- 23736733
OWN - NLM
STAT- MEDLINE
DA  - 20130605
DCOM- 20130606
IS  - 1538-3598 (Electronic)
IS  - 0098-7484 (Linking)
VI  - 309
IP  - 21
DP  - 2013 Jun 5
TI  - Roux-en-Y gastric bypass vs intensive medical management for the control of type 
      2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study
      randomized clinical trial.
PG  - 2240-9
LID - 10.1001/jama.2013.5835 [doi]
AB  - IMPORTANCE: Controlling glycemia, blood pressure, and cholesterol is important
      for patients with diabetes. How best to achieve this goal is unknown. OBJECTIVE: 
      To compare Roux-en-Y gastric bypass with lifestyle and intensive medical
      management to achieve control of comorbid risk factors. DESIGN, SETTING, AND
      PARTICIPANTS: A 12-month, 2-group unblinded randomized trial at 4 teaching
      hospitals in the United States and Taiwan involving 120 participants who had a
      hemoglobin A1c (HbA1c) level of 8.0% or higher, body mass index (BMI) between
      30.0 and 39.9, C peptide level of more than 1.0 ng/mL, and type 2 diabetes for at
      least 6 months. The study began in April 2008. INTERVENTIONS: Lifestyle-intensive
      medical management intervention and Roux-en-Y gastric bypass surgery. Medications
      for hyperglycemia, hypertension, and dyslipidemia were prescribed according to
      protocol and surgical techniques that were standardized. MAIN OUTCOMES AND
      MEASURES: Composite goal of HbA1c less than 7.0%, low-density lipoprotein
      cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg.
      RESULTS: All 120 patients received the intensive lifestyle-medical management
      protocol and 60 were randomly assigned to undergo Roux-en-Y gastric bypass. After
      12-months, 28 participants (49%; 95% CI, 36%-63%) in the gastric bypass group and
      11 (19%; 95% CI, 10%-32%) in the lifestyle-medical management group achieved the 
      primary end points (odds ratio [OR], 4.8; 95% CI, 1.9-11.7). Participants in the 
      gastric bypass group required 3.0 fewer medications (mean, 1.7 vs 4.8; 95% CI for
      the difference, 2.3-3.6) and lost 26.1% vs 7.9% of their initial body weigh
      compared with the lifestyle-medical management group (difference, 17.5%; 95% CI, 
      14.2%-20.7%). Regression analyses indicated that achieving the composite end
      point was primarily attributable to weight loss. There were 22 serious adverse
      events in the gastric bypass group, including 1 cardiovascular event, and 15 in
      the lifestyle-medical management group. There were 4 perioperative complications 
      and 6 late postoperative complications. The gastric bypass group experienced more
      nutritional deficiency than the lifestyle-medical management group. CONCLUSIONS
      AND RELEVANCE: In mild to moderately obese patients with type 2 diabetes, adding 
      gastric bypass surgery to lifestyle and medical management was associated with a 
      greater likelihood of achieving the composite goal. Potential benefits of adding 
      gastric bypass surgery to the best lifestyle and medical management strategies of
      diabetes must be weighed against the risk of serious adverse events. TRIAL
      REGISTRATION: clinicaltrials.gov Identifier: NCT00641251.
AD  - Department of Surgery, School of Public Health, University of Minnesota,
      Minneapolis, MN 55455, USA. ikram001@umn.edu
FAU - Ikramuddin, Sayeed
AU  - Ikramuddin S
FAU - Korner, Judith
AU  - Korner J
FAU - Lee, Wei-Jei
AU  - Lee WJ
FAU - Connett, John E
AU  - Connett JE
FAU - Inabnet, William B
AU  - Inabnet WB
FAU - Billington, Charles J
AU  - Billington CJ
FAU - Thomas, Avis J
AU  - Thomas AJ
FAU - Leslie, Daniel B
AU  - Leslie DB
FAU - Chong, Keong
AU  - Chong K
FAU - Jeffery, Robert W
AU  - Jeffery RW
FAU - Ahmed, Leaque
AU  - Ahmed L
FAU - Vella, Adrian
AU  - Vella A
FAU - Chuang, Lee-Ming
AU  - Chuang LM
FAU - Bessler, Marc
AU  - Bessler M
FAU - Sarr, Michael G
AU  - Sarr MG
FAU - Swain, James M
AU  - Swain JM
FAU - Laqua, Patricia
AU  - Laqua P
FAU - Jensen, Michael D
AU  - Jensen MD
FAU - Bantle, John P
AU  - Bantle JP
LA  - eng
SI  - ClinicalTrials.gov/NCT00641251
GR  - UL1 RR024156/RR/NCRR NIH HHS/United States
GR  - UL1 TR000040/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JAMA
JT  - JAMA : the journal of the American Medical Association
JID - 7501160
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Hypolipidemic Agents)
SB  - AIM
SB  - IM
CIN - JAMA. 2013 Jun 5;309(21):2274-5. PMID: 23736737
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/therapeutic use
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/*surgery
MH  - Female
MH  - *Gastric Bypass/adverse effects
MH  - Hospitals, Teaching
MH  - Humans
MH  - Hyperlipidemias/complications/*drug therapy/*surgery
MH  - Hypertension/complications/*drug therapy/*surgery
MH  - Hypoglycemic Agents/therapeutic use
MH  - Hypolipidemic Agents/therapeutic use
MH  - Life Style
MH  - Male
MH  - Middle Aged
MH  - Obesity/complications
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Weight Loss
EDAT- 2013/06/06 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/06/06 06:00
AID - 1693889 [pii]
AID - 10.1001/jama.2013.5835 [doi]
PST - ppublish
SO  - JAMA. 2013 Jun 5;309(21):2240-9. doi: 10.1001/jama.2013.5835.

PMID- 23736674
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1432-198X (Electronic)
IS  - 0931-041X (Linking)
DP  - 2013 Jun 6
TI  - Urinary concentration: different ways to open and close the tap.
AB  - Nephrogenic diabetes insipidus (NDI) provides an excellent model for the benefits
      and insights that can be gained from studying rare diseases. The discovery of
      underlying genes identified key molecules involved in urinary concentration,
      including the type 2 vasopressin receptor AVPR2 and the water channel AQP2, which
      constitute obvious pharmacologic targets. Subsequently developed drugs targeting 
      AVPR2 not only provide potential benefit to some patients with NDI, but are now
      used for much more common clinical applications as diverse as nocturnal enuresis 
      and heart failure. Yet, the story is still evolving: clinical observations and
      animal experiments continue to discover new ways to affect urinary concentration.
      These novel pathways can potentially be exploited for therapeutic gain. Here we
      review the (patho)physiology of water homoeostasis, the current status of
      clinical management, and potential new treatments.
AD  - UCL Institute of Child Health, Nephro-Urology and Great Ormond Street Hospital
      for Children NHS Foundation Trust, 30 Guildford Street, London, WC1N 3EH, UK,
      d.bockenhauer@ucl.ac.uk.
FAU - Bockenhauer, Detlef
AU  - Bockenhauer D
FAU - Bichet, Daniel G
AU  - Bichet DG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Pediatr Nephrol
JT  - Pediatric nephrology (Berlin, Germany)
JID - 8708728
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/04/04 [received]
PHST- 2013/05/20 [accepted]
PHST- 2013/05/15 [revised]
PHST- 2013/06/06 [aheadofprint]
AID - 10.1007/s00467-013-2526-4 [doi]
PST - aheadofprint
SO  - Pediatr Nephrol. 2013 Jun 6.

PMID- 23736545
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Jun 4
TI  - Adipose tissue inflammation contributes to short-term HFD-induced hepatic insulin
      resistance.
AB  - High fat feeding for three to four days impairs glucose tolerance and hepatic
      insulin sensitivity. However, it remains unclear whether the evolving hepatic
      insulin resistance is due to acute lipid overload or is the result of induced
      adipose tissue inflammation and consequent dys-functional adipose tissue-liver
      crosstalk. In the present study, feeding C57Bl6/J mice a fat-enriched diet (high 
      fat diet; HFD) for four days induced glucose intolerance, hepatic insulin
      resistance (as assessed by hyperinsulinemic-euglycemic clamp studies), hepatic
      steatosis as well as adipose tissue inflammation (i.e. TNFalpha expression) when 
      compared to standard chow-fed mice. Adipocyte-specific depletion of the
      anti-apoptotic/anti-inflammatory factor Fas (CD95) attenuated adipose tissue
      inflammation and improved glucose tolerance as well as hepatic insulin
      sensitivity without altering the level of hepatic steatosis-induced by HFD. In
      summary, our results identify adipose tissue inflammation and resulting
      dys-functional adipose tissue-liver crosstalk as an early event in the
      development of HFD-induced hepatic insulin resistance.
AD  - 1University Children's Hospital.
FAU - Wiedemann, Michael S F
AU  - Wiedemann MS
FAU - Wueest, Stephan
AU  - Wueest S
FAU - Item, Flurin
AU  - Item F
FAU - Schoenle, Eugen J
AU  - Schoenle EJ
FAU - Konrad, Daniel
AU  - Konrad D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - adipose tissue-liver crosstalk
OT  - diabetes mellitus
OT  - lipotoxicity
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - ajpendo.00179.2013 [pii]
AID - 10.1152/ajpendo.00179.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Jun 4.

PMID- 23736544
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Jun 4
TI  - One year of sitagliptin treatment protects against islet amyloid-associated
      beta-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
AB  - The DPP-4 inhibitor sitagliptin is an attractive therapy for diabetes as it
      increases insulin release and may preserve beta-cell mass. However, sitagliptin
      also increases beta-cell release of human islet amyloid polypeptide (hIAPP), the 
      peptide component of islet amyloid, which is co-secreted with insulin. Thus,
      sitagliptin treatment may promote islet amyloid formation and its associated
      beta-cell toxicity. Conversely, metformin treatment decreases islet amyloid
      formation by decreasing beta-cell secretory demand, and could therefore offset
      sitagliptin's potential pro-amyloidogenic effects. Sitagliptin treatment has also
      been reported to be detrimental to the exocrine pancreas. We investigated whether
      long-term sitagliptin treatment, alone or with metformin, increased islet amyloid
      deposition and beta-cell toxicity, and induced pancreatic ductal proliferation,
      pancreatitis and/or pancreatic metaplasia/neoplasia. hIAPP transgenic and
      non-transgenic littermates were followed for one year on no treatment,
      sitagliptin, metformin, or the combination. Islet amyloid deposition, beta-cell
      mass, insulin release and measures of exocrine pancreas pathology were
      determined. Relative to untreated mice, sitagliptin treatment did not increase
      amyloid deposition, despite increasing hIAPP release, and prevented
      amyloid-induced beta-cell loss. Metformin treatment alone or with sitagliptin
      decreased islet amyloid deposition to a similar extent vs untreated mice. Ductal 
      proliferation was not altered among treatment groups and no evidence of
      pancreatitis, ductal metaplasia or neoplasia, were observed. Therefore, long-term
      sitagliptin treatment stimulates beta-cell secretion without increasing amyloid
      formation and protects against amyloid-induced beta-cell loss. This suggests a
      novel effect of sitagliptin to protect the beta cell in type 2 diabetes which
      appears to occur without adverse effects on the exocrine pancreas.
AD  - 1VA Puget Sound Health Care Sytem and University of Washington.
FAU - Aston-Mourney, Kathryn
AU  - Aston-Mourney K
FAU - Subramanian, Shoba L
AU  - Subramanian SL
FAU - Zraika, Sakeneh
AU  - Zraika S
FAU - Samarasekera, Thanya
AU  - Samarasekera T
FAU - Meier, Daniel T
AU  - Meier DT
FAU - Goldstein, Lynn C
AU  - Goldstein LC
FAU - Hull, Rebecca L
AU  - Hull RL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - DPP-4 inhibitor
OT  - IAPP
OT  - amyloid
OT  - beta-cell mass
OT  - exocrine pancreas pathology
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - ajpendo.00025.2013 [pii]
AID - 10.1152/ajpendo.00025.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Jun 4.

PMID- 23736542
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Jun 4
TI  - Na+/H+-exchanger-1 inhibition reverses manifestation of peripheral diabetic
      neuropathy in type 1 diabetic rats.
AB  - Evidence for an important role for Na+/H+-exchangers in diabetic complications is
      emerging. The aim of this study was to evaluate if Na+/H+-exchanger-1 inhibition 
      reverses experimental peripheral diabetic neuropathy. Control and
      streptozotocin-diabetic rats were treated with the specific Na+/H+-exchanger-1
      inhibitor cariporide for 4 weeks after 12 weeks without treatment. Neuropathy
      endpoints included sciatic motor and sensory nerve conduction velocities,
      endoneurial nutritive blood flow, vascular reactivity of epineurial arterioles,
      thermal nociception, tactile allodynia and intraepidermal nerve fiber density.
      Advanced glycation endproduct and markers of oxidative stress including nitrated 
      protein levels in sciatic nerve were evaluated by Western blot. Rats with 12-week
      duration of diabetes developed motor and sensory nerve conduction deficits,
      thermal hypoalgesia, tactile allodynia, and intraepidermal nerve fiber loss. All 
      these changes including impairment of nerve blood flow and vascular reactivity of
      epineurial arterioles were partially reversed by 4-weeks of cariporide treatment.
      Na+/H+-exchanger-1 inhibition was also associated with reduction of
      diabetes-induced accumulation of advanced glycation endproduct, oxidative stress 
      and nitrated proteins in sciatic nerve. In conclusion, these findings support an 
      important role for Na+/H+-exchanger-1 in functional, structural, and biochemical 
      manifestations of peripheral diabetic neuropathy, and provide rationale for
      development of Na+/H+-exchanger-1 inhibitors for treatment of diabetic vascular
      and neural complications.
AD  - 1University of Iowa.
FAU - Lupachyk, Sergey
AU  - Lupachyk S
FAU - Watcho, Pierre
AU  - Watcho P
FAU - Shevalye, Hanna
AU  - Shevalye H
FAU - Vareniuk, Igor
AU  - Vareniuk I
FAU - Obrosov, Alexander
AU  - Obrosov A
FAU - Obrosova, Irina G
AU  - Obrosova IG
FAU - Yorek, Mark A
AU  - Yorek MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - Na+/H+ exchanger
OT  - advanced glycation endproduct
OT  - diabetic peripheral neuropathy
OT  - nerve conduction velocity
OT  - vascular reactivity
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - ajpendo.00186.2013 [pii]
AID - 10.1152/ajpendo.00186.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Jun 4.

PMID- 23736541
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Jun 4
TI  - Effects of Transaldolase Exchange on Estimates of Gluconeogenesis in Type 2
      Diabetes.
AB  - Transaldolase exchange (TA) overestimates gluconeogenesis measured with
      deuterated water (2H2O). However, it is unknown if TA differs in people with type
      2 diabetes (T2DM). 2H2O was ingested and [1-13C]acetate and [3-3H]glucose infused
      in T2DM (n=10) and healthy nondiabetic (ND, n=8) subjects. TA was assessed from
      the ratio of 13C3 to 13C4 glucose enrichment (13C3/13C4) measured by 13C NMR.
      Glucose turnover was measured before (~16hr fast) and during hyperglycemic
      (~10mM) moderate dose insulin (~0.35 mU/kg/min) clamp. 13C3/13C4 in T2DM vs. ND
      were <1.0 and not different at baseline and clamp indicating equivalent TA. To
      determine if incomplete triose-phosphate isomerase exchange (TPI) contributed to 
      asymmetric 13C3/13C4, [U-13C]glycerol was infused in lieu of [1-13C]acetate at a 
      separate visit in a subset of ND (n=7) subjects. Ratio of 13C3/13C4 obtained
      following either tracer were < 1.0 at baseline and during clamp indicating that
      TPI exchange was essentially complete and did not contribute to asymmetric
      glucose enrichment. Uncorrected and corrected rates of gluconeogenesis were no
      different (p=ns) in T2DM vs. ND both at baseline and during clamp. TA correction 
      resulted in equivalent estimates of corrected gluconeogenesis in T2DM and ND that
      were ~25-35% lower than uncorrected gluconeogenesis both at baseline and during
      the clamp. The asymmetric enrichment of glucose from 13C-gluconeogenic tracers is
      attributable to TA exchange and can be utilized to correct for TA exchange. In
      conclusion, TA exchange does not differ between T2DM and ND under fasting and
      hyperglycemic clamp conditions and the 2H2O method continues to provide an
      accurate estimation of gluconeogenesis.
AD  - 1Mayo Clinic.
FAU - Rajpal, Aman
AU  - Rajpal A
FAU - Dube, Simmi
AU  - Dube S
FAU - Carvalho, Filipa
AU  - Carvalho F
FAU - Simoes, Ana Rita
AU  - Simoes AR
FAU - Figueiredo, Angelo
AU  - Figueiredo A
FAU - Basu, Ananda
AU  - Basu A
FAU - Jones, John G
AU  - Jones JG
FAU - Basu, Rita
AU  - Basu R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - deuterated water
OT  - gluconeogenesis
OT  - transaldolase
OT  - triose phosphate isomerase
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - ajpendo.00245.2013 [pii]
AID - 10.1152/ajpendo.00245.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Jun 4.

PMID- 23736539
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Jun 4
TI  - Interactions between p-Akt and Smad3 in injured muscles initiate myogenesis or
      fibrogenesis.
AB  - In catabolic conditions such as aging and diabetes, IGF signaling is impaired and
      fibrosis develops in skeletal muscles. To examine if impaired IGF signaling
      initiates muscle fibrosis, we generated IGF-1R+/- heterozygous mice by crossing
      LoxP floxed IGF-1R (exon 3) mice with MyoD-cre mice. IGF-1R+/- mice were studied 
      because we were unable to obtain homozygous IGF-1R KO mice. In IGF-1R+/- mice,
      both growth and expression of myogenic genes (MyoD and myogenin, markers of
      satellite cell proliferation and differentiation respectively) were depressed.
      Likewise, in injured muscles of IGF-1R+/- mice, there was impaired regeneration, 
      depressed expression of MyoD and myogenin and increased expression of TGF-beta1, 
      alpha-SMA, collagen-1 and fibrosis. To uncover mechanisms stimulating fibrosis,
      we isolated satellite cells from muscles of IGF-1R+/- mice and found reduced
      proliferation and differentiation plus increased TGF-beta1 production. In C2C12
      myoblasts (a model of satellite cells), IGF-1 treatment inhibited
      TGF-beta1-stimulated Smad3 phosphorylation, its nuclear translocation and
      expression of fibronectin. Using immunoprecipitation assay, we found an
      interaction between p-Akt or Akt with Smad3 in wild type mouse muscles and in
      C2C12 myoblasts; importantly IGF-1 increased p-Akt and Smad3 interaction while
      TGF-beta1 decreased it. Therefore, in muscles of IGF-1R+/- mice, the reduction in
      IGF-1R reduces p-Akt allowing for dissociation and nuclear translocation of Smad3
      to enhance TGF-beta1 signaling pathway, leading to fibrosis. Thus, strategies to 
      improve IGF signaling could prevent fibrosis in catabolic conditions with
      impaired IGF signaling.
AD  - 1Baylor College of Medicine.
FAU - Dong, Yanjun
AU  - Dong Y
FAU - Lakhia, Ronak
AU  - Lakhia R
FAU - Thomas, Sandhya
AU  - Thomas S
FAU - Dong, Yanlan
AU  - Dong Y
FAU - Wang, Xiaonan H
AU  - Wang XH
FAU - Silva, Kleiton Augusto Santos
AU  - Silva KA
FAU - Zhang, Liping
AU  - Zhang L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - Fibrogenesis
OT  - IGF-1
OT  - Myogenesis
OT  - Satellite cells
OT  - TGF-b1
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - ajpendo.00644.2012 [pii]
AID - 10.1152/ajpendo.00644.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Jun 4.

PMID- 23736519
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5010 (Electronic)
IS  - 1759-5002 (Linking)
DP  - 2013 Jun 4
TI  - Statins in the primary prevention of cardiovascular disease.
LID - 10.1038/nrcardio.2013.80 [doi]
AB  - Statins are widely used in the evidence-based lowering of cardiovascular disease 
      (CVD) risk. The use of these drugs for secondary prevention of CVD is well
      founded, but their expanding use in primary prevention-in individuals without
      documented CVD-has raised some concerns. Firstly, evidence suggests that, in
      primary prevention, statins substantially decrease CVD morbidity, but only
      moderately reduce CVD mortality. Secondly, long-term statin use might cause
      adverse effects, such as incident diabetes mellitus. Thirdly, the
      cost-effectiveness of such a strategy is unclear, and has to be balanced against 
      the risk of 'overmedicating' the general population. Data clearly support the use
      of statins for primary prevention in high-risk individuals, in whom the strategy 
      is cost-effective and the benefits exceed the risks. Whether primary prevention
      is beneficial in individuals at low or moderate risk is not certain. Therefore,
      the prescription of statins for primary prevention should be individualized on
      the basis of clinical judgment, particularly for low-risk individuals. In
      appropriately selected individuals, statins should also be used for primary
      prevention of ischaemic stroke and transient ischaemic attack.
AD  - Department of Internal Medicine, University Hospital Centre Zagreb, School of
      Medicine, University of Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
      zreiner@kbc-zagreb.hr.
FAU - Reiner, Zeljko
AU  - Reiner Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Nat Rev Cardiol
JT  - Nature reviews. Cardiology
JID - 101500075
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/06/04 [aheadofprint]
AID - nrcardio.2013.80 [pii]
AID - 10.1038/nrcardio.2013.80 [doi]
PST - aheadofprint
SO  - Nat Rev Cardiol. 2013 Jun 4. doi: 10.1038/nrcardio.2013.80.

PMID- 23736373
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 May 21
TI  - Functional thermogenic beige adipogenesis is inducible in human neck fat.
LID - 10.1038/ijo.2013.82 [doi]
AB  - Background:Recent studies suggest human neck brown adipose tissue (BAT) to
      consist of 'brown adipocyte-like' or beige adipocytes. However, little is known
      about their thermogenic function. Within the beige adipocyte transcriptome,
      fibroblast growth factor-21 (FGF21) is a gene whose protein product acts as an
      adipokine, regulating cold-induced thermogenesis (CIT) in animals. Here, we
      explored (i) the adipogenic potential, thermogenic function and FGF21 secretory
      capacity of beige adipocytes derived from human neck fat and (ii) the role of
      FGF21 in modulating adipose bioenergetics.Methods:Progenitors isolated from human
      cervical fat were differentiated into adipocytes with either a brown
      adipocyte-like (BA) or white adipocyte (WA) phenotype. FGF21 secretion was
      measured by enzyme-linked immuosorbent assay. Real-time PCR/western blotting were
      used to determine cellular mRNA/protein levels. Extra-cellular flux bioanalyzer
      was used to quantify adipocyte oxygen consumption and fatty acid oxidation.
      Adipocyte heat production was measured by infrared thermography
      (IRT).Results:Under hormonal manipulation, primary human neck pre-adipocytes
      differentiated into adipocytes with either BA or WA phenotypes, on gene/protein
      and functional levels. BA expressed beige but not classic brown adipocyte
      markers. During BA differentiation, FGF21 gene expression and secretion were
      increased, and were augmented following norepinephrine exposure (a cold mimic in 
      vitro). Differentiated WA expressed beta-Klotho, a critical co-factor mediating
      FGF21 action. Treatment of WA with FGF21 induced UCP1 expression and increased
      oxygen consumption, respiratory uncoupling, norepinephrine-mediated
      thermogenesis, fatty acid oxidation and heat production, thus recapitulating the 
      association between cold-induced FGF21 secretion and CIT in vivo.Conclusion:Beige
      adipocytes are thermogenic in humans. FGF21 is a beige adipokine capable of
      promoting a brown fat-like thermogenic program in white
      adipocytes.Significance:This study provides first evidence of inducible
      functional thermogenic beige adipogenesis in human neck fat. FGF21 holds promise 
      as a cold-induced beige adipokine with metabolic benefits of therapeutic
      relevance through browning of white adipose tissue.International Journal of
      Obesity accepted article preview online, 21 May 2013; doi:10.1038/ijo.2013.82.
AD  - Diabetes, Endocrinology, Obesity Branch, National Institute of Diabetes and
      Digestive and Kidney Diseases, Bethesda, USA.
FAU - Lee, P
AU  - Lee P
FAU - Werner, C D
AU  - Werner CD
FAU - Kebebew, E
AU  - Kebebew E
FAU - Celi, F S
AU  - Celi FS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/21 [aheadofprint]
AID - ijo201382 [pii]
AID - 10.1038/ijo.2013.82 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 May 21. doi: 10.1038/ijo.2013.82.

PMID- 23736372
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 May 27
TI  - Improvements in Hippocampal-Dependent memory and Microglial-Infiltration with
      calorie restriction and gastric bypass surgery but not with vertical sleeve
      gastrectomy.
LID - 10.1038/ijo.2013.100 [doi]
AB  - Background:Much recent evidence suggests that obesity and related comorbidities
      contribute to cognitive decline, including the development of non age-related
      dementia and Alzheimer's disease. Obesity is a serious threat to public health,
      and few treatments offer proven long-term weight-loss. In fact, bariatric surgery
      remains the most effective long-term therapy to reduce weight and alleviate other
      aspects of the Metabolic Syndrome. Unlike the demonstrated benefits of caloric
      restriction to prevent weight gain, few if any studies have compared various
      means of weight-loss on CNS function and hippocampal-dependent cognitive
      processes.Design and Results:Our studies comprise the first direct comparisons of
      caloric restriction to two bariatric surgeries (RYGB and VSG) on cognitive
      function. Weight-loss following caloric restriction, RYGB and VSG was associated 
      with generalized improvements in metabolic health and hippocampal-dependent
      learning as measured in the radial arm maze and spontaneous alternation tests.
      However, VSG-treated rats exhibited deficits on spatial learning tasks in the
      Morris water maze. In addition, while VSG animals had elevated hippocampal
      inflammation, comparable to that of OBESE controls, RYGB and calorie-restricted
      (pair-fed, PF) controls exhibited an amelioration of inflammation, as measured by
      the microglial protein IBA1. We also assessed whether ghrelin-replacement would
      attenuate hippocampal inflammation in VSG, since post-surgical ghrelin levels are
      significantly reduced in VSG relative to RYGB and PF rats. However, ghrelin
      treatment did not attenuate the hippocampal inflammation.Conclusion:Whereas VSG
      was comparably effective at reducing body weight and improving glucose regulation
      as RYGB, VSG did not appear to confer an equal benefit on cognitive function and 
      markers of inflammation.International Journal of Obesity accepted article preview
      online, 27 May 2013; doi:10.1038/ijo.2013.100.
AD  - The University of CincinnatiCollege of Medicine, Department of Internal Medicine,
      Division of Endocrinology, Diabetes and Metabolism.
FAU - Grayson, B E
AU  - Grayson BE
FAU - Fitzgerald, M F
AU  - Fitzgerald MF
FAU - Hakala-Finch, A P
AU  - Hakala-Finch AP
FAU - Ferris, V M
AU  - Ferris VM
FAU - Begg, D P
AU  - Begg DP
FAU - Tong, J
AU  - Tong J
FAU - Woods, S C
AU  - Woods SC
FAU - Seeley, R J
AU  - Seeley RJ
FAU - Davidson, T L
AU  - Davidson TL
FAU - Benoit, S C
AU  - Benoit SC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/27 [aheadofprint]
AID - ijo2013100 [pii]
AID - 10.1038/ijo.2013.100 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 May 27. doi: 10.1038/ijo.2013.100.

PMID- 23736368
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 May 23
TI  - Body Composition and Energy Expenditure Predict Ad-Libitum Food and Macronutrient
      Intake in Humans.
LID - 10.1038/ijo.2013.85 [doi]
AB  - Background:Obesity is the result of chronic positive energy balance. The
      mechanisms underlying the regulation of energy homeostasis and food intake are
      not understood. Despite large increases in fat mass (FM), recent evidence
      indicates that fat-free mass (FFM) rather than FM is positively associated with
      intake in humans.Methods:In 184 humans (73 F/111 M; age 34.5+/-8.8y; % body fat
      [PFAT] 31.6+/-8.1%) we investigated the relationship of FFM index (FFMI kg*m2),
      FM index (FMI kg*m2;), and 24-h energy expenditure (EE, n=127) with ad-libitum
      food intake using a 3d vending machine paradigm. Mean daily calories (CAL), and
      macronutrient intake (PRO, CHO, FAT) were determined and used to calculate the
      relative caloric contribution of each (%PRO, %CHO, %FAT) and percent of caloric
      intake over weight maintaining energy needs (%WMEN).Results:FFMI was positively
      associated with CAL (P<0.0001), PRO (P=0.0001), CHO (P=0.0075), and FAT
      (P<0.0001). This remained significant after adjusting for FMI. Total EE predicted
      CAL and macronutrient intake (all P<0.0001). FMI was positively associated with
      CAL (P=0.019), PRO (P=0.025) and FAT (P=0.0008). In models with both FFMI and
      FMI, FMI was negatively associated with CAL (P=0.019) and PRO (P=0.033). Both
      FFMI and FMI were negatively associated with %CHO and positively associated with 
      %FAT (all P<0.001). EE and FFMI (adjusted for FMI) were positively (EE P=0.0085; 
      FFMI P=0.0018) and FMI negatively (P=0.0018; adjusted for FFMI) associated with
      %WMEN.Conclusion:Food and macronutrient intake is predicted by FFMI and to a
      lesser degree by FMI. FFM and FM may have opposing effects on energy
      homeostasis.International Journal of Obesity accepted article preview online, 23 
      May 2013; doi:10.1038/ijo.2013.85.
AD  - Obesity and Diabetes Clinical Research Section, NIDDK-NIH, DHHS, Phoenix, AZ,
      USA.
FAU - Weise, C M
AU  - Weise CM
FAU - Hohenadel, M G
AU  - Hohenadel MG
FAU - Krakoff, J
AU  - Krakoff J
FAU - Votruba, S B
AU  - Votruba SB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/23 [aheadofprint]
AID - ijo201385 [pii]
AID - 10.1038/ijo.2013.85 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 May 23. doi: 10.1038/ijo.2013.85.

PMID- 23736364
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 May 27
TI  - DNA hypomethylation of inflammation associated genes in adipose tissue of female 
      mice after multigenerational high fat diet feeding.
LID - 10.1038/ijo.2013.98 [doi]
AB  - Objective:Maternal obesity significantly increases the susceptibility of
      offspring to develop obesity and chronic diseases in adulthood. The offspring of 
      obese mothers are shown to prefer high fat diet (HFD) due to their altered neural
      circuitry, creating a 'feed forward cycle' across generations. We hypothesized
      that the 'feed forward cycle' caused by multigenerational HFD feeding would have 
      exacerbated effects in adipose tissue of the offspring.Methods:Three generations 
      (F0, F1 and F2) of HFD (60% Kcal fat)-fed and corresponding normal chow (NC)-fed 
      C57BL/6 mice were generated. Body weight (BW) and food intake were monitored
      weekly. Parametrial adipose tissue (pAT) weight and endocrine parameters were
      measured in nine-month old female offspring. Gene expression microarray,
      quantitative RT-PCR, and bisulfite sequencing were performed using pAT.Results:BW
      and pAT weight increased in female mice across generations under continuous HFD
      stress, with the most severe phenotype found in the F2 generation. Genes involved
      in inflammatory response showed increased expression across generations in the
      pAT, accompanied by increased macrophage infiltration. The promoters of toll-like
      receptor 1 (Tlr1), toll-like receptor 2 (Tlr2) and linker for activation of T
      cells (Lat) were hypomethylated in the HF groups compared to the NC group, with
      additional hypomethylation on some specific CpG sites in the F2
      generation.Conclusions:A feed-forward cycle exists in female mice after
      continuous HFD stress as demonstrated by increased adiposity and progressive
      inflammation in adipose tissue across generations. DNA hypomethylation over
      generations lead to epigenetically altered expression of Tlr1, Tlr2 and Lat,
      which may contribute to the inflammation in adipose tissue. Our study provides a 
      potential mechanism for enhanced inflammation in adipose tissue under
      multigenerational HFD-fed stress.International Journal of Obesity accepted
      article preview online, 27 May 2013; doi:10.1038/ijo.2013.98.
AD  - 1] College of Life Sciences, Wuhan University, Wuhan, PR China [2] Diabetes
      Center, Wuhan University, Wuhan, P.R. China.
FAU - Ding, Y
AU  - Ding Y
FAU - Li, J
AU  - Li J
FAU - Liu, S
AU  - Liu S
FAU - Zhang, L
AU  - Zhang L
FAU - Xiao, H
AU  - Xiao H
FAU - Li, J
AU  - Li J
FAU - Chen, H
AU  - Chen H
FAU - Petersen, R B
AU  - Petersen RB
FAU - Huang, K
AU  - Huang K
FAU - Zheng, L
AU  - Zheng L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/27 [aheadofprint]
AID - ijo201398 [pii]
AID - 10.1038/ijo.2013.98 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 May 27. doi: 10.1038/ijo.2013.98.

PMID- 23736354
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 May 21
TI  - Increased Fibroblast Growth Factor 21 expression in high-fat diet sensitive
      non-human primates (Macaca mulatta).
LID - 10.1038/ijo.2013.79 [doi]
AB  - Objective:Fibroblast growth Factor 21 (FGF21) is a metabolic regulator of glucose
      and lipid metabolism. The physiological role of FGF21 is not yet fully elucidated
      however administration of FGF21 lowers blood glucose in diabetic animals.
      Moreover, increased levels of FGF21 are found in obese and diabetic rodents and
      humans compared to lean/non-diabetic controls.Methods:Adult male rhesus macaque
      monkeys were chronically maintained on a high-fat diet (HFD) or a standard diet
      (CTR). Plasma levels of FGF21, triglycerides, and cholesterol were measured and
      body weight was record. Glucose stimulated insulin secretion (GSIS) and glucose
      clearance was determined during an i.v. glucose tolerance test. Furthermore,
      expression of FGF21 and its receptors were determined in liver, pancreas, three
      white adipose tissues (WATs) and two skeletal muscles.Results:A cohort of the
      high-fat fed monkeys responded to the HFD with increasing body weight, plasma
      lipids, total cholesterol, GSIS, and decreased glucose tolerance. These monkeys
      were termed HFD-sensitive. Another cohort of monkeys did not become obese and
      maintained normal insulin sensitivity. These animals were defined as
      HFD-resistant. Plasma FGF21 levels were significantly increased in all HFD fed
      monkeys compared to the CTR group. The HFD-sensitive monkeys showed a significant
      increase in FGF21 mRNA expression in all examined tissues compared to CTR, while 
      FGF21 expression in the HFD-resistant group was only increased in the liver,
      pancreas and the retroperitoneal WAT. In the WAT, the co-receptor beta-klotho was
      down-regulated in the HFD-sensitive monkeys compared to the HDF-resistant
      group.Conclusion:The current study demonstrates that HFD changes FGF21 and FGF21 
      receptor expression in a tissue-specific manner in rhesus monkeys; differential
      regulation is moreover observed between HFD-sensitive and resistant monkeys.
      Monkeys which maintain normal levels of the FGF21 co-receptor beta-klotho in the 
      WAT upon HFD were protected towards development of dyslipidemia and
      hyperglycemia.International Journal of Obesity accepted article preview online,
      21 May 2013; doi:10.1038/ijo.2013.79.
AD  - 1] Department of Drug Design and Pharmacology, University of Copenhagen,
      Copenhagen, Denmark [2] Department of Diabetes NBEs & Obesity Biology, Malov,
      Denmark.
FAU - Nygaard, E B
AU  - Nygaard EB
FAU - Moller, C L
AU  - Moller CL
FAU - Kievit, P
AU  - Kievit P
FAU - Grove, K L
AU  - Grove KL
FAU - Andersen, B
AU  - Andersen B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/21 [aheadofprint]
AID - ijo201379 [pii]
AID - 10.1038/ijo.2013.79 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 May 21. doi: 10.1038/ijo.2013.79.

PMID- 23736306
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1432-1203 (Electronic)
IS  - 0340-6717 (Linking)
DP  - 2013 Jun 5
TI  - Genetic epidemiology of cardiometabolic risk factors and their clustering
      patterns in Mexican American children and adolescents: the SAFARI Study.
AB  - Pediatric metabolic syndrome (MS) and its cardiometabolic components (MSCs) have 
      become increasingly prevalent, yet little is known about the genetics underlying 
      MS risk in children. We examined the prevalence and genetics of MS-related traits
      among 670 non-diabetic Mexican American (MA) children and adolescents, aged 6-17 
      years (49 % female), who were participants in the San Antonio Family Assessment
      of Metabolic Risk Indicators in Youth study. These children are offspring or
      biological relatives of adult participants from three well-established Mexican
      American family studies in San Antonio, TX, at increased risk of type 2 diabetes.
      MS was defined as >/=3 abnormalities among 6 MSC measures: waist circumference,
      systolic and/or diastolic blood pressure, fasting insulin, triglycerides,
      HDL-cholesterol, and fasting and/or 2-h OGTT glucose. Genetic analyses of MS,
      number of MSCs (MSC-N), MS factors, and bivariate MS traits were performed.
      Overweight/obesity (53 %), pre-diabetes (13 %), acanthosis nigricans (33 %), and 
      MS (19 %) were strikingly prevalent, as were MS components, including abdominal
      adiposity (32 %) and low HDL-cholesterol (32 %). Factor analysis of MS traits
      yielded three constructs: adipo-insulin-lipid, blood pressure, and glucose
      factors, and their factor scores were highly heritable. MS itself exhibited 68 % 
      heritability. MSC-N showed strong positive genetic correlations with obesity,
      insulin resistance, inflammation, and acanthosis nigricans, and negative genetic 
      correlation with physical fitness. MS trait pairs exhibited strong genetic and/or
      environmental correlations. These findings highlight the complex genetic
      architecture of MS/MSCs in MA children, and underscore the need for early
      screening and intervention to prevent chronic sequelae in this vulnerable
      pediatric population.
AD  - University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, 
      TX, USA.
FAU - Fowler, Sharon P
AU  - Fowler SP
FAU - Puppala, Sobha
AU  - Puppala S
FAU - Arya, Rector
AU  - Arya R
FAU - Chittoor, Geetha
AU  - Chittoor G
FAU - Farook, Vidya S
AU  - Farook VS
FAU - Schneider, Jennifer
AU  - Schneider J
FAU - Resendez, Roy G
AU  - Resendez RG
FAU - Upadhayay, Ram Prasad
AU  - Upadhayay RP
FAU - Vandeberg, Jane
AU  - Vandeberg J
FAU - Hunt, Kelly J
AU  - Hunt KJ
FAU - Bradshaw, Benjamin
AU  - Bradshaw B
FAU - Cersosimo, Eugenio
AU  - Cersosimo E
FAU - Vandeberg, John L
AU  - Vandeberg JL
FAU - Almasy, Laura
AU  - Almasy L
FAU - Curran, Joanne E
AU  - Curran JE
FAU - Comuzzie, Anthony G
AU  - Comuzzie AG
FAU - Lehman, Donna M
AU  - Lehman DM
FAU - Jenkinson, Christopher P
AU  - Jenkinson CP
FAU - Lynch, Jane L
AU  - Lynch JL
FAU - Defronzo, Ralph A
AU  - Defronzo RA
FAU - Blangero, John
AU  - Blangero J
FAU - Hale, Daniel E
AU  - Hale DE
FAU - Duggirala, Ravindranath
AU  - Duggirala R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Hum Genet
JT  - Human genetics
JID - 7613873
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/03/14 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/06/05 [aheadofprint]
AID - 10.1007/s00439-013-1315-2 [doi]
PST - aheadofprint
SO  - Hum Genet. 2013 Jun 5.

PMID- 23736294
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 Jun 4
TI  - Cocaine- and amphetamine-regulated transcript is a potent stimulator of GnRH and 
      Kisspeptin cells and may contribute to negative energy balance-induced
      reproductive inhibition in females.
AB  - Cocaine- and amphetamine-regulated transcript (CART) is a hypothalamic
      neuropeptide implicated in both metabolic and reproductive regulation, raising
      the possibility that CART plays a role in reproductive inhibition during negative
      metabolic conditions. The current study characterized CART's regulatory influence
      on GnRH and kisspeptin (Kiss1) cells and determined the sensitivity of different 
      CART populations to negative energy balance. CART fibers made close appositions
      to 60% of GnRH cells, with the majority of the fibers (<80%) originating from the
      arcuate nucleus (ARH) CART/POMC population. Electrophysiological recordings in
      GnRH-GFP rats demonstrated that CART postsynaptically depolarizes GnRH cells.
      CART fibers from the ARH were also observed in close contact with Kiss1 cells in 
      the ARH and anteroventral periventricular nucleus (AVPV). Recordings in Kiss1-GFP
      mice demonstrated CART also postsynaptically depolarizes ARH Kiss1 cells,
      suggesting CART may act directly and indirectly, via Kiss1 populations, to
      stimulate GnRH neurons. CART protein and mRNA levels were analyzed in two models 
      of negative energy balance: caloric restriction (CR) and lactation. Both CART
      mRNA levels and the number of CART-ir cells was suppressed in the ARH during CR
      but not during lactation. AVPV CART mRNA was suppressed during CR, but not during
      lactation when there was a dramatic increase in CART-ir cells. These data suggest
      differing regulatory signals of CART between the models. In conclusion, both
      morphological and electrophysiological methods identify CART as a novel and
      potent stimulator of Kiss1 and GnRH neurons and suppression of CART expression
      during negative metabolic conditions could contribute to inhibition of the
      reproductive axis.
AD  - Divisions of Diabetes, Obesity & Metabolism and Neuroscience, OR National Primate
      Research Center, OR Health & Science University, Beaverton, OR 97006.
FAU - True, Cadence
AU  - True C
FAU - Verma, Saurabh
AU  - Verma S
FAU - Grove, Kevin L
AU  - Grove KL
FAU - Smith, M Susan
AU  - Smith MS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - en.2013-1156 [pii]
AID - 10.1210/en.2013-1156 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 Jun 4.

PMID- 23736176
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 106
IP  - 6
DP  - 2013 Jun
TI  - Surgical treatment of lung cancer in octogenarians.
PG  - 356-61
LID - 10.1097/SMJ.0b013e318296d8e2 [doi]
AB  - BACKGROUND: As the population ages, octogenarians are becoming the fastest
      growing patient demographic for non-small-cell lung cancer. We examined
      lobectomies and 30-day outcomes in this group compared with younger patients to
      gain insight into the optimal treatment for this challenging group. METHODS: We
      analyzed data from the American College of Surgeons National Quality Improvement 
      Program for patients with lung cancer undergoing lobectomy during calendar years 
      2005-2010. We compared clinical risk factors, intraoperative factors, and 30-day 
      operative mortality and major morbidity in octogenarians versus younger patients 
      undergoing either open traditional thoracotomy (OPEN) or video-assisted (VATS)
      pulmonary lobar resection. RESULTS: Of 2171 patients who had lobar resections for
      lung cancer, 245 (11%) were octogenarians. Six hundred eight lobectomies (28.0%) 
      were VATS procedures and 1563 (72.0%) were OPEN procedures. The VATS rate
      increased as patient age increased (34% VATS for octogenarians vs 27% for
      patients younger than 80 years; P = 0.01). Thoracic surgeons performed VATS with 
      greater frequency compared with general surgeons, especially in octogenarians
      (41% VATS for thoracic surgeons vs 29% for general surgeons; P < 0.001).
      Univariate analysis suggests significantly increased major morbidity (pulmonary, 
      renal, and sepsis), but not operative mortality in octogenarians; however,
      multivariate predictors of major morbidity include OPEN procedures, preoperative 
      decreased functional status, history of chronic obstructive pulmonary disease,
      preoperative sepsis, prior radiation, diabetes, and dyspnea on exertion (all P < 
      0.05), but they do not include advanced age. CONCLUSIONS: Comorbidities predict
      most increased morbidity in octogenarians, and advanced age per se is not an
      important multivariate predictor of postoperative morbidity or mortality. The
      frequency of VATS lobectomy increased with increasing patient age, and VATS
      predisposes to decreased morbidity in octogenarians.
AD  - From the Department of Surgery, University of Kentucky College of Medicine,;
      Lexington.
FAU - Saha, Sibu P
AU  - Saha SP
FAU - Bender, Matthew
AU  - Bender M
FAU - Ferraris, Victor A
AU  - Ferraris VA
FAU - Davenport, Daniel L
AU  - Davenport DL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
SB  - AIM
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1097/SMJ.0b013e318296d8e2 [doi]
AID - 00007611-201306000-00005 [pii]
PST - ppublish
SO  - South Med J. 2013 Jun;106(6):356-61. doi: 10.1097/SMJ.0b013e318296d8e2.

PMID- 23736174
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 106
IP  - 6
DP  - 2013 Jun
TI  - Clinical outcomes of a veterans affairs outpatient antimicrobial treatment
      program.
PG  - 345-9
LID - 10.1097/SMJ.0b013e3182967e8f [doi]
AB  - OBJECTIVES: The outpatient parenteral antibiotic therapy (OPAT) program of the
      Portland Veterans Affairs Medical Center (PVAMC), which has a self-administration
      model, is staffed by visiting nurses from a specialist infusion company. This
      study evaluates the clinical outcomes of these patients. METHODS: This study was 
      a retrospective chart review of 262 patients at PVAMC who had received OPAT
      between 2007 and 2009. Patients were included only if they received ongoing care 
      at PVAMC. The data collected included conditions and organisms being treated and 
      types and durations of antibiotics used. Clinical cure was defined as documented 
      cure at the end of treatment and 90 days post-OPAT. RESULTS: One hundred ninety
      patients of 262 were analyzed. The mean age was 63.2 years. Diabetes was the main
      comorbid factor (17%). The most common indications for OPAT were osteomyelitis
      (38%), urinary tract infection (23%), and skin and soft tissue infection (12.6%).
      Mixed bacterial culture (26%) and Staphylococcus aureus (31%) were the most
      common organisms treated. Vancomycin was the most frequently used antibiotic
      (26%) followed by ceftriaxone (12%). The median duration of OPAT was 30 days. The
      rate of clinical cure at end of treatment observed for all infections treated was
      78%, which then decreased to 58% at 90 days post-OPAT (P < 0.001). Patients with 
      diabetes and osteomyelitis had an increased risk of relapse at 90 days post-OPAT 
      on multivariate analysis (P = 0.025). CONCLUSIONS: An OPAT program using a
      self-administration model treating patients who were military veterans had
      successful outcomes. Patients with diabetes and osteomyelitis had worse clinical 
      outcomes 90 days after the completion of OPAT therapy.
AD  - From the Division of Infectious Diseases and the Department of Pharmacy, Portland
      Veterans Affairs Medical Center, Portland, Oregon.
FAU - Mohammadi, Shahrzad
AU  - Mohammadi S
FAU - Mackay, Kimberly
AU  - Mackay K
FAU - Ward, Thomas T
AU  - Ward TT
FAU - Forrest, Graeme N
AU  - Forrest GN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
SB  - AIM
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1097/SMJ.0b013e3182967e8f [doi]
AID - 00007611-201306000-00003 [pii]
PST - ppublish
SO  - South Med J. 2013 Jun;106(6):345-9. doi: 10.1097/SMJ.0b013e3182967e8f.

PMID- 23736110
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1941-7225 (Electronic)
IS  - 0895-7061 (Linking)
DP  - 2013 Jun 4
TI  - Insulin Resistance and the Metabolic Syndrome Are Associated With Arterial
      Stiffness in Patients With Chronic Kidney Disease.
AB  - BACKGROUND: Insulin resistance (IR) and the metabolic syndrome (MetS) may
      contribute to cardiovascular risk in chronic kidney disease (CKD). We examine the
      association between IR and vascular function in CKD. Furthermore, we define the
      prevalence of MetS and examine the association between defining MetS and vascular
      function. METHODS: This cross-sectional study of 71 stage 3-4 CKD subjects
      assessed arterial stiffness (pulse wave velocity (PWV) and endothelial
      dysfunction (ED). IR was assessed using Homeostasis Model Assessment-IR
      (HOMA-IR). MetS was defined by the unified International Diabetes Federation and 
      American Heart Association/National Heart Lung and Blood Institute criteria.
      RESULTS: CKD subjects with HOMA-IR score above the median had significantly
      higher body mass index and waist circumference. They also had higher PWV, higher 
      triglycerides with lower high-density lipoprotein concentration (P < 0.05). Age, 
      systolic blood pressure, and HOMA-IR were independently associated with PWV, even
      after exclusion of diabetic subjects (n = 16) (P </= 0.05). MetS was more
      prevalent in CKD (78.9%) than controls (2.5%). MetS in CKD was associated with
      increased PWV (MetS(+) geometric mean = 9.5 m/s, 95% confidence interval (95% CI)
      = 8.9-10.2 m/s; vs. MetS(-) 8.1 m/s, 95% CI = 7.1-9.3 m/s; P = 0.03) but not ED. 
      In a multiple logistic regression analysis, PWV higher than the median was
      independently associated with dysglycemia. CONCLUSIONS: IR is independently
      associated with arterial stiffness, even in nondiabetic CKD. MetS is common and
      identified a subgroup of CKD patients with increased arterial stiffness, which is
      associated with dysglycemia.
AD  - School Of Medicine and Pharmacology, Royal Perth Hospital Unit, University of
      Western Australia, Western Australia, Australia;
FAU - Chan, Doris T
AU  - Chan DT
FAU - Watts, Gerald F
AU  - Watts GF
FAU - Irish, Ashley B
AU  - Irish AB
FAU - Ooi, Esther M M
AU  - Ooi EM
FAU - Dogra, Gursharan K
AU  - Dogra GK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Am J Hypertens
JT  - American journal of hypertension
JID - 8803676
OTO - NOTNLM
OT  - blood pressure
OT  - chronic kidney disease
OT  - hypertension
OT  - insulin resistance
OT  - metabolic syndrome
OT  - vascular function.
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - hpt077 [pii]
AID - 10.1093/ajh/hpt077 [doi]
PST - aheadofprint
SO  - Am J Hypertens. 2013 Jun 4.

PMID- 23736094
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1365-2346 (Electronic)
IS  - 0265-0215 (Linking)
DP  - 2013 Jun 1
TI  - Impact of haemoglobin concentration on cardiovascular outcome after vascular
      surgery: A retrospective observational cohort study.
AB  - CONTEXT: Although low preoperative haemoglobin (Hb) concentration is a well known
      risk factor for adverse outcome, little is known about decreases in Hb and
      postoperative Hb concentrations. OBJECTIVES: The aim of this study was to
      evaluate the prognostic impact of both pre- and postoperative Hb concentrations
      (divided into low, intermediate and high tertiles) as well as Hb decrease,
      defined as preoperative minus postoperative Hb (g dl), on postoperative
      cardiovascular events in vascular surgery patients. DESIGN: An observational
      cohort study. SETTING: Erasmus University Medical Centre, Rotterdam, the
      Netherlands, from 1 January 2002 to 31 December 2011. PATIENTS: One thousand four
      hundred and eighty-four patients underwent elective open or endovascular
      abdominal aortic repair (aneurysm or stenosis), lower extremity arterial repair
      or carotid surgery. Patients for whom pre or postoperative Hb concentrations were
      not available were excluded. MAIN OUTCOME MEASURES: The study endpoint was 30-day
      postoperative cardiovascular events, including myocardial infarction, heart
      failure, arrhythmias, stroke, asymptomatic troponin-T release and cardiovascular 
      death. RESULTS: In 1041 patients, both pre and postoperative Hb concentrations
      were available. Thirty-day cardiovascular events occurred in 221 (21%) patients. 
      Multivariable logistic regression analyses, adjusting for age, sex, Revised
      Cardiac Risk Index (high-risk surgery, coronary heart disease, heart failure,
      cerebrovascular disease, diabetes mellitus, renal insufficiency), hypertension
      and hypercholesterolaemia, demonstrated that low preoperative Hb (8.7 to 12.9 g
      dl) was associated with 30-day events [odds ratio (OR) 1.7; 95% confidence
      interval (CI) 1.1 to 2.5]. Intermediate (10.6 to 12.1 g dl) and low (7.4 to 10.5 
      g dl) postoperative Hb and Hb decrease were also associated with an independently
      increased risk of 30-day events (intermediate Hb: OR 1.7; 95% CI 1.1 to 2.7; low 
      Hb: OR 3.1; 95% CI 2.0 to 4.8; and Hb decrease: OR 1.2; 95% CI 1.1 to 1.3,
      respectively). Sensitivity analyses excluding patients with transfusions (n =
      314) demonstrated that only postoperative Hb concentrations remained associated
      with a high risk of 30-day cardiovascular events (intermediate Hb: OR 1.8; 95% CI
      1.0 to 3.3 and low Hb: OR 2.0; 95% CI 1.0 to 4.0). CONCLUSION: Pre and
      postoperative Hb concentrations and Hb decrease are all related to 30-day
      cardiovascular events in elective vascular surgery patients. Postoperative Hb
      concentrations are the strongest predictor of 30-day cardiovascular events.
AD  - From the Department of Anaesthesiology (TMV, SEH, KAM, EJB, RJS, FvL), and
      Department of Vascular Surgery, Erasmus University Medical Centre, Rotterdam, the
      Netherlands (TMV, KMvdL, HJV).
FAU - Valentijn, Tabita M
AU  - Valentijn TM
FAU - Hoeks, Sanne E
AU  - Hoeks SE
FAU - Martienus, Kelsey A
AU  - Martienus KA
FAU - Bakker, Erik Jan
AU  - Bakker EJ
FAU - van de Luijtgaarden, Koen M
AU  - van de Luijtgaarden KM
FAU - Verhagen, Hence J
AU  - Verhagen HJ
FAU - Stolker, Robert J
AU  - Stolker RJ
FAU - van Lier, Felix
AU  - van Lier F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Eur J Anaesthesiol
JT  - European journal of anaesthesiology
JID - 8411711
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1097/EJA.0b013e328362a5fd [doi]
PST - aheadofprint
SO  - Eur J Anaesthesiol. 2013 Jun 1.

PMID- 23736000
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 35
IP  - 5
DP  - 2013 May 31
TI  - Asymptomatic Cerebral Microbleeds in Adult Patients with Moyamoya Disease: A
      Prospective Cohort Study with 2 Years of Follow-Up.
PG  - 469-475
AB  - Objective: Risk factors for cerebral microbleeds (CMBs) in moyamoya disease (MMD)
      remain unknown, and whether the presence or distribution of CMBs is related to
      the subsequent hemorrhagic events needs to be confirmed. This study aimed to
      investigate the relationship between intracranial vascular morphology and the
      incidence/distribution patterns of CMBs as well as to determine the outcome in
      adult patients with MMD. Methods: Eighty-five consecutive adult patients with MMD
      were prospectively evaluated by 3.0-tesla high-intensity susceptibility-weighted 
      magnetic resonance imaging and catheter-based digital subtraction angiography
      from June 2009 to January 2012. The differences in intracranial angiography
      (Suzuki stages, posterior cerebral artery stages, and angiographic features of
      the anterior choroidal and posterior communicating arteries) and clinical
      parameters (age, gender, hemorrhagic onset, antiplatelet treatment,
      systolic/diastolic blood pressure, diabetes, and plasma fibrinogen) among various
      CMB distribution patterns were analyzed with multinomial logistic regression.
      Moreover, after a median follow-up of 23 months, the relationship between CMB
      distribution patterns and subsequent intraventricular hemorrhage was also
      analyzed with Kaplan-Meier survival analysis and a Cox proportional hazards
      model. Results: Forty-five female and 40 male patients were finally enrolled in
      the study with an average age of 41.4 +/- 12.7 years. Thirty-one CMB foci were
      detected in 24 (28.2%) patients. Most of the lesions (n = 22, 71.0%) were located
      in the region of deep and periventricular white matter (DPWM). Dilation and
      extension of anterior choroidal and posterior communicating arteries (AChA-PComA)
      was found to be an independent risk factor associated with the CMBs located in
      DPWM (p = 0.045; odds ratio 3.39, 95% CI 1.03-11.19). Patients with DPWM CMBs
      showed a statistically higher likelihood of subsequent intraventricular
      hemorrhage compared to patients without CMB foci and with CMBs in other regions
      (p = 0.014) during the follow-up period. Multivariable analysis suggested that
      DPWM CMBs were independent predictors of subsequent intraventricular hemorrhage
      (p = 0.028; hazard ratio 5.53, 95% CI 1.20-25.41). Conclusions: Dilation and
      extension of AChA-PComA is a determinant of CMBs involved in DPWM. CMBs in DPWM
      are probably predictors of subsequent intraventricular hemorrhage.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Neurology, Jinling Hospital, Southern Medical University, Nanjing, 
      PR China.
FAU - Sun, Wen
AU  - Sun W
FAU - Yuan, Cuiping
AU  - Yuan C
FAU - Liu, Wenhua
AU  - Liu W
FAU - Li, Yongkun
AU  - Li Y
FAU - Huang, Zhixin
AU  - Huang Z
FAU - Zhu, Wusheng
AU  - Zhu W
FAU - Li, Min
AU  - Li M
FAU - Xu, Gelin
AU  - Xu G
FAU - Liu, Xinfeng
AU  - Liu X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/11/05 [received]
PHST- 2013/02/20 [accepted]
PHST- 2013/05/31 [aheadofprint]
AID - 000350203 [pii]
AID - 10.1159/000350203 [doi]
PST - aheadofprint
SO  - Cerebrovasc Dis. 2013 May 31;35(5):469-475.

PMID- 23735965
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1932-8095 (Electronic)
IS  - 1932-8087 (Linking)
VI  - 18
IP  - 4
DP  - 2013 July/August
TI  - Applications of Comparative Effectiveness Research to Case Management.
PG  - 168-179
AB  - PURPOSE/OBJECTIVES:: This article is intended to update case managers on recent
      advances in comparative effectiveness research (CER) led by the Agency for
      Healthcare Research and Quality. The article explores potential implications and 
      applications of CER findings to case management practice. PRIMARY PRACTICE
      SETTINGS:: All case management settings. FINDINGS/CONCLUSIONS:: An ongoing
      national movement to advance CER is intended to provide health care professionals
      with answers to questions about which diagnostic methods, therapies, devices, and
      services, among the available alternatives for a given disease or condition, may 
      be most effective and safe for individual patients. IMPLICATIONS FOR CASE
      MANAGEMENT:: Knowledge and application of CER findings may benefit case managers 
      in their roles of improving resource utilization, controlling costs, providing
      stewardship, coordinating care, educating patients, and promoting treatment
      adherence and self-sufficiency. The findings from a 2013 study on the comparative
      effectiveness of outpatient case management programs have implications for
      improving case management models, reinforcing standards in the profession, and
      advancing research in the field. Continuing education on CER is important for
      promoting positive values and appropriate applications of its findings to case
      management practice.
AD  - Kathleen Moreo, RN-BC, BSN, BHSA, CCM, Cm, CDMS, is President of PRIME Education,
      Inc., a national continuing education health care company holding contracts with 
      AHRQ to provide educational programs in comparative effectiveness research. She
      is a past president of CMSA and has authored peer-reviewed journal articles and
      books in case management. Laurence Greene, PhD, is Director of Scientific
      Education and Outcomes at PRIME Education, Inc. His position involves outcomes
      assessment of continuing education programs for health care professionals. He is 
      the coauthor of several educational programs and peer-reviewed journal articles
      on comparative effectiveness research. Tamar Sapir, PhD, is Director of
      Scientific Affairs at PRIME Education, Inc. She is responsible for the scientific
      integrity of the content and educational designs developed by PRIME. She has
      authored peer-reviewed journal articles and educational programs in various
      disease areas including diabetes, oncology, neurology, rheumatology, and
      cardiology. Davecia R. Cameron, MS, is a senior medical writer at PRIME
      Education, Inc. She is responsible for developing content for CME programs for
      health care professionals on various clinical and disease-specific topics. She
      has coauthored several peer-reviewed journal articles and authored physician,
      nurse, and pharmacist newsletters and medical pocket guides for health care
      professionals and patients on topics such as rheumatology, oncology, and
      cardiology.
FAU - Moreo, Kathleen
AU  - Moreo K
FAU - Greene, Laurence
AU  - Greene L
FAU - Sapir, Tamar
AU  - Sapir T
FAU - Cameron, Davecia R
AU  - Cameron DR
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - Prof Case Manag
JT  - Professional case management
JID - 101291585
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1097/NCM.0b013e3182901e57 [doi]
AID - 01269241-201307000-00003 [pii]
PST - ppublish
SO  - Prof Case Manag. 2013 July/August;18(4):168-179.

PMID- 23735822
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1421-9778 (Electronic)
IS  - 1015-8987 (Linking)
VI  - 31
IP  - 6
DP  - 2013 May 31
TI  - Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies.
PG  - 761-777
AB  - Depression is a multicausal disorder and has been associated with the risk to
      develop cancer, dementia, diabetes, epilepsy and stroke. As a metabolic disorder 
      depression has been associated with obesity, diabetes, insulin sensitivity,
      neuropeptide Y, glucose regulation, poor glycemic control, glucagone-like
      peptide-1, cholezystokinin, ghrelin, leptin, the endocannabinoid system,
      insulin-like growth factor and gastrin-releasing peptide. As a cardiovascular
      disease a close relationship exists between depression and blood pressure, heart 
      rate, norepinephrine, sympathetic tone, vascular resistance, blood viscosity,
      plasma volume, intima thickness and atherosclerosis. Additionally blood
      coagulation, fibrinolysis, D-dimers, plasminogen activator inhibitor-1 protein,
      platelet activation, VEGF, plasma nitric oxide and its synthase are changed in
      depressed patients. As an endocrinological and stress disorder depression has
      been connected with the concentration of free T4, TSH, CRH, arginine vasopressin,
      corticotrophin, corticosteroid release and ACTH. Depression as an inflammatory
      disorder is mediated by pro-inflammatory cytokines, interleukin-1, interleukin-6,
      TNF-alpha, soluble interleukin-2 receptors, interferon-alpha, interleukin 8,
      interleukin-10, hs-CRP, acute phase proteins, haptoglobin, toll like receptor 4, 
      interleukin-1beta, mammalian target of rapamycin pathway, substance P,
      cyclooxygenase-2, prostaglandin-E2, lipid peroxidation levels and acid
      sphingomyelinase. Nutritional factors might influence depression risk, i.e. the
      consumption of folate, omega-3 fatty acids, monounsaturated fatty acids, olive
      oil, fish, fruits, vegetables, nuts, legumes, vitamin B6 and vitamin B12. The
      neurodegenerative hypothesis of depression explains decreased hippocampal volumes
      in depressed patients and changes of neurotrophic support by BDNF,
      erythropoietin, GDNF, FGF-2, NT3, NGF and growth hormone. In this context, a fast
      neuroprotective and antidepressant effect has also been observed by ketamine,
      which acts via the glutamatergic system. Hence, GABA, AMPA, EAAT, NMDA- and
      metabotropic glutamate receptors (mGluR1 to mGluR8) have gained interest in
      depression recently. Alternative, causative or also easy available treatment
      strategies beyond serotonin and noradrenaline reuptake inhibition might be a
      major topic of future psychiatric care. In this review, an attempt is made to
      overview concepts of the disease and search for perspectives on antidepressant
      treatment strategies beyond approved medications.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - University Hospital of Basel, Department of Psychiatry and Psychotherapy, Basel.
FAU - Lang, Undine E
AU  - Lang UE
FAU - Borgwardt, Stefan
AU  - Borgwardt S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Cell Physiol Biochem
JT  - Cellular physiology and biochemistry : international journal of experimental
      cellular physiology, biochemistry, and pharmacology
JID - 9113221
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/21 [accepted]
PHST- 2013/05/31 [aheadofprint]
AID - 000350094 [pii]
AID - 10.1159/000350094 [doi]
PST - aheadofprint
SO  - Cell Physiol Biochem. 2013 May 31;31(6):761-777.

PMID- 23735728
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Jun 4
TI  - Inflammation and Cognitive Dysfunction in Type 2 Diabetic Carotid Endarterectomy 
      Patients.
AB  - OBJECTIVEType 2 diabetic patients have a high incidence of cerebrovascular
      disease, elevated inflammation, and high risk of developing cognitive dysfunction
      following carotid endarterectomy (CEA). To elucidate the relationship between
      inflammation and the risk of cognitive dysfunction in type 2 diabetic patients,
      we aim to determine whether elevated levels of systemic inflammatory markers are 
      associated with cognitive dysfunction 1 day after CEA.RESEARCH DESIGN AND
      METHODSOne hundred fifteen type 2 diabetic CEA patients and 156 reference
      surgical patients were recruited with written informed consent in this
      single-center cohort study. All patients were evaluated with an extensive battery
      of neuropsychometric tests. Preoperative monocyte counts, HbA1c, C-reactive
      protein (CRP), intercellular adhesion molecule 1, and matrix metalloproteinase 9 
      activity levels were obtained.RESULTSIn a multivariate logistic regression model 
      constructed to identify predictors of cognitive dysfunction in type 2 diabetic
      CEA patients, each unit of monocyte counts (odds ratio [OR] 1.76 [95% CI
      1.17-2.93]; P = 0.005) and CRP (OR 1.17 [1.10-1.29]; P < 0.001) was significantly
      associated with higher odds of developing cognitive dysfunction 1 day after CEA
      in type 2 diabetic patients.CONCLUSIONSType 2 diabetic patients with elevated
      levels of preoperative systemic inflammatory markers exhibit more cognitive
      dysfunction 1 day after CEA. These observations have implications for the
      preoperative medical management of this high-risk group of surgical patients
      undergoing carotid revascularization with CEA.
AD  - Department of Anesthesiology, Columbia University, New York, New York.
FAU - Heyer, Eric J
AU  - Heyer EJ
FAU - Mergeche, Joanna L
AU  - Mergeche JL
FAU - Bruce, Samuel S
AU  - Bruce SS
FAU - Connolly, E Sander
AU  - Connolly ES
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - dc12-2507 [pii]
AID - 10.2337/dc12-2507 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Jun 4.

PMID- 23735727
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Jun 4
TI  - Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in
      Healthy Subjects and Subjects With Type 2 Diabetes.
AB  - OBJECTIVETo examine the effect of dapagliflozin, a sodium-glucose cotransporter 2
      (SGLT2) inhibitor, on the major components of renal glucose reabsorption
      (decreased TmG, increased splay, and reduced threshold), using the
      pancreatic/stepped hyperglycemic clamp (SHC) technique.RESEARCH DESIGN AND
      METHODSSubjects with type 2 diabetes (n = 12) and matched healthy subjects (n =
      12) underwent pancreatic/SHC (plasma glucose range 5.5-30.5 mmol/L) at baseline
      and after 7 days of dapagliflozin treatment. A pharmacodynamic model was
      developed to describe the major components of renal glucose reabsorption for both
      groups and then used to estimate these parameters from individual glucose
      titration curves.RESULTSAt baseline, type 2 diabetic subjects had elevated
      maximum renal glucose reabsorptive capacity (TmG), splay, and threshold compared 
      with controls. Dapagliflozin treatment reduced the TmG and splay in both groups. 
      However, the most significant effect of dapagliflozin was a reduction of the
      renal threshold for glucose excretion in type 2 diabetic and control
      subjects.CONCLUSIONThe SGLT2 inhibitor dapagliflozin improves glycemic control in
      diabetic patients by reducing the TmG and threshold at which glucose is excreted 
      in the urine.
AD  - Diabetes Division, Department of Medicine, University of Texas Health Science
      Center, San Antonio, Texas.
FAU - Defronzo, Ralph A
AU  - Defronzo RA
FAU - Hompesch, Marcus
AU  - Hompesch M
FAU - Kasichayanula, Sreeneeranj
AU  - Kasichayanula S
FAU - Liu, Xiaoni
AU  - Liu X
FAU - Hong, Ying
AU  - Hong Y
FAU - Pfister, Marc
AU  - Pfister M
FAU - Morrow, Linda A
AU  - Morrow LA
FAU - Leslie, Bruce R
AU  - Leslie BR
FAU - Boulton, David W
AU  - Boulton DW
FAU - Ching, Agatha
AU  - Ching A
FAU - Lacreta, Frank P
AU  - Lacreta FP
FAU - Griffen, Steven C
AU  - Griffen SC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - dc13-0387 [pii]
AID - 10.2337/dc13-0387 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Jun 4.

PMID- 23735726
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Jun 4
TI  - REDEEM: A pragmatic trial to reduce diabetes distress.
AB  - OBJECTIVETo compare three interventions to reduce diabetes distress (DD) and
      improve self-management among non-clinically depressed adults with type 2
      diabetes mellitus (T2DM).RESEARCH DESIGN AND METHODSIn REDEEM, 392 adults with
      T2DM and DD were randomized to computer-assisted self-management (CASM); CASM
      plus DD-specific problem solving (CAPS), or a computer-administered minimal
      supportive intervention. Primary outcomes were Diabetes Distress Scale (DDS)
      total, the Emotional Burden (EB) and Regimen Distress (RD) DDS subscales, and
      diet, exercise, and medication adherence.RESULTSSignificant and clinically
      meaningful reductions in DD (DDS, EB, and RD) and self-management behaviors
      occurred in all three conditions (P < 0.001), with no significant between-group
      differences. There was, however, a significant group x baseline distress
      interaction (P < 0.02), in which patients with high baseline RD in the CAPS
      condition displayed significantly larger RD reductions than those in the other
      two conditions. RD generated the most distress and displayed the greatest
      distress reduction as a result of intervention. The pace of DD reduction varied
      by patient age: older patients demonstrated significant reductions in DD early in
      the intervention, whereas younger adults displayed similar reductions later.
      Reductions in DD were accompanied by significant improvements in healthy eating, 
      physical activity, and medication adherence, although not by change in
      HbA1c.CONCLUSIONSDD is malleable and highly responsive to intervention.
      Interventions that enhance self-management also reduce DD significantly, but
      DD-specific interventions may be necessary for patients with high initial levels 
      of DD. Future research should identify the minimal, most cost-effective
      interventions to reduce DD and improve self-management.
AD  - University of California, San Francisco, San Francisco, California.
FAU - Fisher, Lawrence
AU  - Fisher L
FAU - Hessler, Danielle
AU  - Hessler D
FAU - Glasgow, Russell E
AU  - Glasgow RE
FAU - Arean, Patricia A
AU  - Arean PA
FAU - Masharani, Umesh
AU  - Masharani U
FAU - Naranjo, Diana
AU  - Naranjo D
FAU - Strycker, Lisa A
AU  - Strycker LA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - dc12-2493 [pii]
AID - 10.2337/dc12-2493 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Jun 4.

PMID- 23735725
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Jun 4
TI  - Comorbid Diabetes and COPD: Impact of corticosteroid use on diabetes
      complications.
AB  - OBJECTIVETo identify if there is a dose-dependent risk of diabetes complications 
      in patients treated with corticosteroids that have both diabetes and chronic
      obstructive pulmonary disorder (COPD).RESEARCH DESIGN AND METHODSA retrospective 
      study of administrative claims data from the Australian Government Department of 
      Veterans' Affairs, from 1 July 2001 to 30 June 2008, of diabetes patients newly
      initiated on metformin or sulfonylurea. COPD was identified by dispensings of
      tiotropium or ipratropium in the 6 months preceding study entry. Total
      corticosteroid use (inhaled and systemic) in the 12 months after study entry was 
      determined. The outcome was time to hospitalization for a diabetes-related
      complication. Competing risks and Cox proportional hazard regression analyses
      were conducted with adjustment for a number of covariates.RESULTSA total of
      18,226 subjects with diabetes were identified, of which 5.9% had COPD. Of those
      with COPD, 67.2% were dispensed corticosteroids in the 12 months from study
      entry. Stratification by dose of corticosteroids demonstrated a 94% increased
      likelihood of hospitalization for a diabetes complication for those who received 
      a total defined daily dose (DDD) of corticosteroids >/=0.83/day (subhazard ratio 
      1.94 [95% CI 1.14-3.28], P = 0.014), by comparison with those who did not receive
      a corticosteroid. Lower doses of corticosteroid (<0.83 DDD/day) were not
      associated with an increased risk of diabetes-related
      hospitalization.CONCLUSIONSIn patients with diabetes and COPD, an increased risk 
      of diabetes-related hospitalizations was only evident with use of high doses of
      corticosteroids. This highlights the need for constant revision of corticosteroid
      dose in those with diabetes and COPD, to ensure that the minimally effective dose
      is used, together with review of appropriate response to therapy.
AD  - Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and
      Medical Sciences, University of South Australia, Adelaide, South Australia,
      Australia.
FAU - Caughey, Gillian E
AU  - Caughey GE
FAU - Preiss, Adrian K
AU  - Preiss AK
FAU - Vitry, Agnes I
AU  - Vitry AI
FAU - Gilbert, Andrew L
AU  - Gilbert AL
FAU - Roughead, Elizabeth E
AU  - Roughead EE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - dc12-2197 [pii]
AID - 10.2337/dc12-2197 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Jun 4.

PMID- 23735724
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Jun 4
TI  - Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in
      Noninsulin-Treated Type 2 Diabetes: The PRISMA Randomized Trial.
AB  - OBJECTIVEWe aimed to evaluate the added value of intensive self-monitoring of
      blood glucose (SMBG), structured in timing and frequency, in noninsulin-treated
      patients with type 2 diabetes.RESEARCH DESIGN AND METHODSThe 12-month,
      randomized, clinical trial enrolled 1,024 patients with noninsulin-treated type 2
      diabetes (median baseline HbA1c, 7.3% [IQR, 6.9-7.8%]) at 39 diabetes clinics in 
      Italy. After standardized education, 501 patients were randomized to intensive
      structured monitoring (ISM) with 4-point glycemic profiles (fasting, preprandial,
      2-h postprandial, and postabsorptive measurements) performed 3 days/week; 523
      patients were randomized to active control (AC) with 4-point glycemic profiles
      performed at baseline and at 6 and 12 months. Two primary end points were tested 
      in hierarchical order: HbA1c change at 12 months and percentage of patients on
      target for being at risk for low and high blood glucose
      index.RESULTSIntent-to-treat analysis showed greater HbA1c reductions over 12
      months in ISM (-0.39%) than in AC patients (-0.27%), with a between-group
      difference of -0.12% (95% CI, -0.210 to -0.024; P = 0.013). In the per-protocol
      analysis, the between-group difference was -0.21% (-0.331 to -0.089; P = 0.0007).
      More ISM than AC patients achieved clinically meaningful reductions in HbA1c
      (>0.3, >0.4, or >0.5%) at study end (P < 0.025). The proportion of patients
      reaching/maintaining the risk target at month 12 were similar in ISM (74.6%) and 
      AC (70.1%) patients (P = 0.131). At visits 2, 3, and 4, diabetes medications were
      changed more often in ISM than in AC patients (P < 0.001).CONCLUSIONSUse of
      structured SMBG improves glycemic control and provides guidance in prescribing
      diabetes medications in patients with relatively well-controlled
      noninsulin-treated type 2 diabetes.
AD  - Diabetes Research Institute, San Raffaele Hospital and Scientific Institute,
      Milan, Italy.
FAU - Bosi, Emanuele
AU  - Bosi E
FAU - Scavini, Marina
AU  - Scavini M
FAU - Ceriello, Antonio
AU  - Ceriello A
FAU - Cucinotta, Domenico
AU  - Cucinotta D
FAU - Tiengo, Antonio
AU  - Tiengo A
FAU - Marino, Raffaele
AU  - Marino R
FAU - Bonizzoni, Erminio
AU  - Bonizzoni E
FAU - Giorgino, Francesco
AU  - Giorgino F
CN  - on behalf of the PRISMA Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - dc13-0092 [pii]
AID - 10.2337/dc13-0092 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Jun 4.

PMID- 23735723
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Jun 4
TI  - Favorable Effects of Insulin Sensitizers Pertinent to Peripheral Arterial Disease
      in Type 2 Diabetes: Results from the Bypass Angioplasty Revascularization
      Investigation 2 Diabetes (BARI 2D) trial.
AB  - OBJECTIVEThe aim of this manuscript was to report the risk of incident peripheral
      arterial disease (PAD) in a large randomized clinical trial that enrolled
      participants with stable coronary artery disease and type 2 diabetes and compare 
      the risk between assigned treatment arms.RESEARCH DESIGN AND METHODSThe Bypass
      Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial randomly
      assigned participants to insulin sensitization (IS) therapy versus
      insulin-providing (IP) therapy for glycemic control. Results showed similar
      5-year mortality in the two glycemic treatment arms. In secondary analyses
      reported here, we examine the effects of treatment assignment on the incidence of
      PAD. A total of 1,479 BARI 2D participants with normal ankle-brachial index (ABI)
      (0.91-1.30) were eligible for analysis. The following PAD-related outcomes are
      evaluated in this article: new low ABI </=0.9, a lower-extremity
      revascularization, lower-extremity amputation, and a composite of the three
      outcomes.RESULTSDuring an average 4.6 years of follow-up, 303 participants
      experienced one or more of the outcomes listed above. Incidence of the composite 
      outcome was significantly lower among participants assigned to IS therapy than
      those assigned to IP therapy (16.9 vs. 24.1%; P < 0.001). The difference was
      significant in time-to-event analysis (hazard ratio 0.66 [95% CI 0.51-0.83], P < 
      0.001) and remained significant after adjustment for in-trial HbA1c (0.76
      [0.59-0.96], P = 0.02).CONCLUSIONSIn participants with type 2 diabetes who are
      free from PAD, a glycemic control strategy of insulin sensitization may be the
      preferred therapeutic strategy to reduce the incidence of PAD and subsequent
      outcomes.
AD  - Department of Epidemiology, Graduate School of Public Health, University of
      Pittsburgh, Pittsburgh, Pennsylvania.
FAU - Althouse, Andrew D
AU  - Althouse AD
FAU - Abbott, J Dawn
AU  - Abbott JD
FAU - Sutton-Tyrrell, Kim
AU  - Sutton-Tyrrell K
FAU - Forker, Alan D
AU  - Forker AD
FAU - Lombardero, Manuel S
AU  - Lombardero MS
FAU - Buitron, L Virginia
AU  - Buitron LV
FAU - Pena-Sing, Ivan
AU  - Pena-Sing I
FAU - Tardif, Jean-Claude
AU  - Tardif JC
FAU - Mori Brooks, Maria
AU  - Mori Brooks M
CN  - for the BARI 2D Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - dc12-2265 [pii]
AID - 10.2337/dc12-2265 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Jun 4.

PMID- 23735722
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Jun 4
TI  - Insulin Resistance, Incident Cardiovascular Diseases, and Decreased Kidney
      Function Among Nondiabetic American Indians: The Strong Heart Study.
AB  - OBJECTIVEPrevalence of insulin resistance is high in the American Indian
      population, likely as a result of the high prevalence of obesity. This condition 
      may be influential for clinical outcomes such as cardiovascular disease (CVD) and
      decreased kidney function.RESEARCH DESIGN AND METHODSNormal glucose tolerant
      (NGT) participants free of hypertension and CVD at the baseline examination
      (1989-1992) (N = 964) of the Strong Heart Study were selected to explore the
      cross-sectional association between insulin resistance quantified by homeostasis 
      model assessment (HOMA-IR) and demographic, behavioral, and cardiometabolic
      variables. The longitudinal association between baseline HOMA-IR and the
      development of CVD was also explored. The longitudinal association between
      baseline HOMA-IR and the development of high urinary albumin-to-creatinine ratio 
      was explored among nondiabetic participants (N = 1,401).RESULTSCross-sectionally,
      HOMA-IR was associated with sex, residence location, smoking, and high-risk
      cardiometabolic profile. Prospectively, insulin resistance is associated with the
      development of CVD and decreased kidney function in this
      population.CONCLUSIONSInsulin resistance may have an important role in the
      pathogenesis of CVD and chronic kidney disease. Since obesity contributes to the 
      development of insulin resistance, intervention focusing on modifiable factors
      such as physical activity and weight control may reduce the development of these 
      diseases.
AD  - Department of Biostatistics and Epidemiology, College of Public Health,
      University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
FAU - Zhang, Ying
AU  - Zhang Y
FAU - Lee, Elisa T
AU  - Lee ET
FAU - Howard, Barbara V
AU  - Howard BV
FAU - Best, Lyle G
AU  - Best LG
FAU - Umans, Jason G
AU  - Umans JG
FAU - Yeh, Jeunliang
AU  - Yeh J
FAU - Wang, Wenyu
AU  - Wang W
FAU - Yeh, Fawn
AU  - Yeh F
FAU - Ali, Tauqeer
AU  - Ali T
FAU - Devereux, Richard B
AU  - Devereux RB
FAU - de Simone, Giovanni
AU  - de Simone G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - dc12-2368 [pii]
AID - 10.2337/dc12-2368 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Jun 4.

PMID- 23735664
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
DP  - 2013 Jun 2
TI  - Zinc supplementation inhibits the increase in osteoclastogenesis and decrease in 
      osteoblastogenesis in streptozotocin-induced diabetic rats.
LID - S0014-2999(13)00405-6 [pii]
LID - 10.1016/j.ejphar.2013.05.020 [doi]
AB  - Zinc (Zn) has been shown to stimulate bone formation and inhibit osteoclastic
      bone resorption and osteoclastogenesis. However, the effects of Zn on bone
      metabolism in diabetic animals remain to be clarified in vivo. Here, the effects 
      of Zn supplementation on bone metabolism, including osteoclastogenesis and
      osteoblastogenesis, were investigated using streptozotocine (STZ)-induced
      diabetic rats. Zn-supplemented water (7.5mg/L) was given for 1 week to diabetic
      rats injected with STZ (30mg/kg body weight) 1 week earlier. The Zn supplement
      prevented a decrease in the activity and mRNA of alkaline phosphatase (ALP),
      osteocalcin mRNA, and hydroxyproline and calcium levels, and an increase in the
      activity and mRNA of tartrate-resistant acid phosphatase and cathepsin K in the
      proximal tibia of diabetic rats. Histological analysis revealed that the Zn
      supplement inhibited the diabetes-induced increase and decrease in the number of 
      osteoclasts and osteoblasts, respectively, in the metaphysis of the proximal
      tibia. The increase in mRNA levels of receptor for activation of NF-kappaB
      (RANK), c-fos, c-jun, TRAP, and cathepsin K and decrease in the expression of
      Runx2, Dlx5, osterix, ALP, osteocalcin, and collagen were prevented by the
      supplement. The decrease in beta-catenin, phosphorylated GSK3beta, phosphorylated
      Akt, insulin-like growth factor 1 (IGF-1), and IGF-1 receptor (IGF-1R) protein
      levels in diabetic rats was also inhibited, although Zn did not affect the
      diabetes-increased gene and protein expression of Sost and Dkk1. These results
      suggested that Zn prevented the diabetes-induced increase in osteoclastogenesis
      and decrease in osteoblastogenesis by inhibiting RANK expression and stimulating 
      IGF-1/IGF-1R/Akt/GSK3beta/beta-catenin signaling, respectively.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Food Science and Nutrition, Nara Women's University, Nara 630,
      Japan.
FAU - Iitsuka, Natsumi
AU  - Iitsuka N
FAU - Hie, Mamiko
AU  - Hie M
FAU - Tsukamoto, Ikuyo
AU  - Tsukamoto I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/02/12 [received]
PHST- 2013/05/03 [revised]
PHST- 2013/05/20 [accepted]
AID - S0014-2999(13)00405-6 [pii]
AID - 10.1016/j.ejphar.2013.05.020 [doi]
PST - aheadofprint
SO  - Eur J Pharmacol. 2013 Jun 2. pii: S0014-2999(13)00405-6. doi:
      10.1016/j.ejphar.2013.05.020.

PMID- 23735647
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Jun 1
TI  - Plasma Vitamin D-Binding Protein and Risk of Heart Failure in Male Physicians.
LID - S0002-9149(13)01126-0 [pii]
LID - 10.1016/j.amjcard.2013.05.014 [doi]
AB  - Previous studies have suggested that vitamin D deficiency might contribute to the
      pathogenesis of heart failure (HF); however, limited data are available on the
      association of vitamin D-binding protein (VDBP)-a major transport protein for
      vitamin D-and the development of HF. Thus, we investigated whether plasma VDBP is
      inversely associated with HF risk. Using a prospective nested case-control
      design, we selected 464 cases and 464 matched controls from the Physicians'
      Health Study for the present analyses. VDBP was determined using an enzyme-linked
      immunoassay. Self-reported HF was obtained through annual follow-up
      questionnaires and validated in a subsample by a review of the medical records.
      We used conditional logistic regression analyses to compute the adjusted odds
      ratios. The mean age was 58.6 years, and the median VDBP was 307.8 mug/ml
      (interquartile range 265.2 to 354.6). Plasma VDBP was not associated with HF in
      our study. Across the consecutive quintiles of VDBP, the odds ratio was 1.0 (95% 
      confidence interval [CI] reference), 1.05 (95% CI 0.66 to 1.65), 1.28 (95% CI
      0.80 to 2.06), 1.07 (95% CI 0.65 to 1.75), and 1.28 (95% CI 0.76 to 2.15); p for 
      linear trend = 0.41, after adjustment for matching factors, body mass index,
      diabetes, atrial fibrillation, hypertension, and high-sensitivity C-reactive
      protein. In conclusion, our data have shown no significant association between
      the plasma levels of VDBP and HF risk in apparently healthy male physicians.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Aging, Department of Medicine, Brigham and Women's Hospital, Boston, 
      Massachusetts.
FAU - Petrone, Andrew B
AU  - Petrone AB
FAU - Weir, Natalie L
AU  - Weir NL
FAU - Steffen, Brian T
AU  - Steffen BT
FAU - Tsai, Michael Y
AU  - Tsai MY
FAU - Gaziano, John Michael
AU  - Gaziano JM
FAU - Djousse, Luc
AU  - Djousse L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/04/02 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/02 [accepted]
AID - S0002-9149(13)01126-0 [pii]
AID - 10.1016/j.amjcard.2013.05.014 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Jun 1. pii: S0002-9149(13)01126-0. doi:
      10.1016/j.amjcard.2013.05.014.

PMID- 23735590
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
DP  - 2013 May 3
TI  - Epstein-Barr virus-positive nodal peripheral T cell lymphomas: Clinicopathologic 
      and gene expression profiling study.
LID - S0344-0338(13)00098-8 [pii]
LID - 10.1016/j.prp.2013.04.013 [doi]
AB  - Epstein-Barr virus-positive peripheral T cell lymphoma, not otherwise specified
      (EBV+ PTCL-NOS), in which virtually all neoplastic T cells harbor EBV, is a very 
      rare disease with poor prognosis. To analyze the clinicopathologic
      characteristics and gene expression profile, we retrospectively collected six
      cases of EBV+ PTCL-NOS with no known primary immunodeficiency. The patients were 
      5 men and 1 woman, their age ranging from 48 years to 88 years (median 61.5
      years). Lymphadenopathy was the most common presentation. Four patients had
      underlying disease, including HBV carrier, HCV infection, diabetes mellitus, and 
      prostate cancer. All patients showed fatal clinical course in spite of
      chemotherapy. Histopathologically, monotonous infiltration of atypical
      lymphocytes of small to medium size was shown in four patients and medium to
      large tumor cells in two patients. Five patients showed CD4-/CD8+/bF-1+ phenotype
      with TIA-1 expression. In gene expression analysis using mRNA microarray, genes
      differentially expressed in EBV+ PTCL-NOS compared to normal reactive lymph nodes
      included 1515 genes (Mann-Whitney U-test p<0.05, folder change >/=4 times).
      Enriched functional annotation terms by DAVID were mostly related to immune
      response, defense response, cell-to-cell signaling, and membrane signaling.
      Especially, the genes involved in B cell differentiation or activation were
      mostly down-regulated, and T cell activation was mostly suppressed by
      down-regulation of activation genes and up-regulation of regulatory genes. Genes 
      associated with cytotoxic activity were mostly up-regulated. Based on its
      peculiar clinical, histopathologic, and gene expression findings in EBV+
      PTCL-NOS, we suggest EBV+ PTCL-NOS as a distinct disease entity from PTCL-NOS. In
      this study, the finding that most significantly enriched the functional term was 
      immune response, suggesting a specific relation between EBV infection and
      alteration of immune response in the patients with EBV+ PTCL-NOS.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
AD  - Department of Pathology, Samsung Medical Center, Sungkyunkwan University School
      of Medicine, Seoul, Republic of Korea.
FAU - Ha, Sang Yun
AU  - Ha SY
FAU - Sung, Jiyeon
AU  - Sung J
FAU - Ju, Hyunjung
AU  - Ju H
FAU - Karube, Kennosuke
AU  - Karube K
FAU - Kim, Soek Jin
AU  - Kim SJ
FAU - Kim, Won Seog
AU  - Kim WS
FAU - Seto, Masao
AU  - Seto M
FAU - Ko, Young-Hyeh
AU  - Ko YH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/03/13 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/04/20 [accepted]
AID - S0344-0338(13)00098-8 [pii]
AID - 10.1016/j.prp.2013.04.013 [doi]
PST - aheadofprint
SO  - Pathol Res Pract. 2013 May 3. pii: S0344-0338(13)00098-8. doi:
      10.1016/j.prp.2013.04.013.

PMID- 23735589
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
DP  - 2013 Jun 1
TI  - Postpartum wound and bleeding complications in women who received peripartum
      anticoagulation.
LID - S0049-3848(13)00191-6 [pii]
LID - 10.1016/j.thromres.2013.04.034 [doi]
AB  - INTRODUCTION: The objective of this study was to compare wound and bleeding
      complications between women who received anticoagulation after cesarean delivery 
      due to history of prior venous thromboembolic disease, arterial disease, or being
      a thrombophilia carrier with adverse pregnancy outcome, to women not receiving
      anticoagulation. METHODS: Women in the Duke Thrombosis Center Registry who
      underwent cesarean delivery during 2003-2011 and received postpartum
      anticoagulation (anticoagulation group, n=77), were compared with a subset of
      women who delivered during the same time period, but did not receive
      anticoagulation (no anticoagulation group, n=77). The no anticoagulation group
      comprised women who were matched to the anticoagulation group by age, body mass
      index, type of cesarean (no labor vs. labor), and date of delivery. Bleeding and 
      wound complications were compared between the two groups. A multivariable
      logistic regression model was constructed to determine if anticoagulation was an 
      independent predictor of wound complication. RESULTS: Women who received
      anticoagulation during pregnancy had a greater incidence of wound complications
      compared to those who did not (30% vs. 8%, p<0.001). Using multivariable logistic
      regression, while controlling for race, diabetes, chorioamnionitis, and aspirin
      use, anticoagulation predicted the development of any wound complication (OR 5.8,
      95% CI 2.2, 17.6), but there were no differences in the mean estimated blood loss
      at delivery (782 vs. 778ml, p=0.91), change in postpartum hematocrit (5.4 vs.
      5.2%, p=0.772), or percent of women receiving blood products (6.5 vs. 1.3%,
      p=0.209) between the two groups. CONCLUSIONS: Anticoagulation following cesarean 
      delivery is associated with an increased risk of post-cesarean wound
      complications, but not other postpartum bleeding complications.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA.
FAU - Limmer, Jane S
AU  - Limmer JS
FAU - Grotegut, Chad A
AU  - Grotegut CA
FAU - Thames, Elizabeth
AU  - Thames E
FAU - Dotters-Katz, Sarah K
AU  - Dotters-Katz SK
FAU - Brancazio, Leo R
AU  - Brancazio LR
FAU - James, Andra H
AU  - James AH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/03/10 [received]
PHST- 2013/04/20 [revised]
PHST- 2013/04/30 [accepted]
AID - S0049-3848(13)00191-6 [pii]
AID - 10.1016/j.thromres.2013.04.034 [doi]
PST - aheadofprint
SO  - Thromb Res. 2013 Jun 1. pii: S0049-3848(13)00191-6. doi:
      10.1016/j.thromres.2013.04.034.

PMID- 23735571
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
DP  - 2013 Jun 1
TI  - Pivotal role of oxidative stress in tumor metastasis under diabetic conditions in
      mice.
LID - S0168-3659(13)00318-0 [pii]
LID - 10.1016/j.jconrel.2013.05.028 [doi]
AB  - Diabetic patients are reported to have a high incidence and mortality of cancer, 
      but little is known about the linkage. In this study, we investigated whether
      high oxidative stress is involved in the acceleration of tumor metastasis in
      diabetic mice. Murine melanoma B16-BL6 cells stably labeled with firefly
      luciferase (B16-BL6/Luc) were inoculated into the tail vein of streptozotocin
      (STZ)-treated or untreated mice. A luciferase assay demonstrated that tumor cells
      were present largely in the lung of untreated mice, whereas large numbers of
      tumor cells were detected in both the lung and liver of STZ-treated mice.
      Repeated injections of polyethylene glycol-conjugated catalase (PEG-catalase), a 
      long-circulating derivative, reduced the elevated fasting blood glucose levels
      and plasma lipoperoxide levels of STZ-treated mice, but had no significant
      effects on these parameters in untreated mice. In addition, the injections
      significantly reduced the number of tumor cells in the lung and liver in both
      untreated and STZ-treated mice. Culture of B16-BL6/Luc cells in medium containing
      over 45 mg/dl glucose hardly affected the proliferation of the cells, whereas the
      addition of plasma of STZ-treated mice to the medium significantly increased the 
      number of cells. Plasma samples of STZ-treated mice receiving PEG-catalase
      exhibited no such effect on proliferation. These findings indicate that a
      hyperglycemia-induced increase in oxidative stress is involved in the
      acceleration of tumor metastasis, and removal of systemic hydrogen peroxide by
      PEG-catalase can inhibit the progression of diabetic conditions and tumor
      metastasis in diabetes.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Drug Delivery Research, Kyoto University, Sakyo-ku, Kyoto, Japan.
FAU - Ikemura, Mai
AU  - Ikemura M
FAU - Nishikawa, Makiya
AU  - Nishikawa M
FAU - Kusamori, Kousuke
AU  - Kusamori K
FAU - Fukuoka, Miho
AU  - Fukuoka M
FAU - Yamashita, Fumiyoshi
AU  - Yamashita F
FAU - Hashida, Mitsuru
AU  - Hashida M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release
      Society
JID - 8607908
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/11/08 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/05/27 [accepted]
AID - S0168-3659(13)00318-0 [pii]
AID - 10.1016/j.jconrel.2013.05.028 [doi]
PST - aheadofprint
SO  - J Control Release. 2013 Jun 1. pii: S0168-3659(13)00318-0. doi:
      10.1016/j.jconrel.2013.05.028.

PMID- 23735522
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1873-2860 (Electronic)
IS  - 0933-3657 (Linking)
DP  - 2013 Jun 1
TI  - Safety and usability evaluation of a web-based insulin self-titration system for 
      patients with type 2 diabetes mellitus.
LID - S0933-3657(13)00072-9 [pii]
LID - 10.1016/j.artmed.2013.04.009 [doi]
AB  - OBJECTIVE: The rising incidence of type 2 diabetes mellitus (T2DM) induces severe
      challenges for the health care system. Our research group developed a web-based
      system named PANDIT that provides T2DM patients with insulin dosing advice using 
      state of the art clinical decision support technology. The PANDIT interface
      resembles a glucose diary and provides advice through pop-up messages. Diabetes
      nurses (DNs) also have access to the system, allowing them to intervene when
      needed. The objective of this study was to establish whether T2DM patients can
      safely use PANDIT at home. To this end, we assessed whether patients experience
      usability problems with a high risk of compromising patient safety when
      interacting with the system, and whether PANDIT's insulin dosing advice are
      clinically safe. RESEARCH DESIGN AND METHODS: The study population consisted of
      patients with T2DM (aged 18-80) who used a once daily basal insulin as well as
      DNs from a university hospital. The usability evaluation consisted of think-aloud
      sessions with four patients and three DNs. Video data, audio data and verbal
      utterances were analyzed for usability problems encountered during PANDIT
      interactions. Usability problems were rated by a physician and a usability expert
      according to their potential impact on patient safety. The usability evaluation
      was followed by an implementation with a duration of four weeks. This
      implementation took place at the patients' homes with ten patients to evaluate
      clinical safety of PANDIT advice. PANDIT advice were systematically compared with
      DN advice. Deviating advice were evaluated with respect to patient safety by a
      panel of experienced physicians, which specialized in diabetes care. RESULTS: We 
      detected seventeen unique usability problems, none of which was judged to have a 
      high risk of compromising patient safety. Most usability problems concerned the
      lay-out of the diary, which did not clearly indicate which data entry fields had 
      to be entered in order to obtain an advice. 27 out of 74 (36.5%) PANDIT advice
      differed from those provided by DNs. However, only one of these (1.4%) was
      considered unsafe by the panel. CONCLUSION: T2DM patients with no prior
      experience with the web-based self-management system were capable of consulting
      the system without encountering significant usability problems. Furthermore, the 
      large majority of PANDIT advice were considered clinically safe according to the 
      expert panel. One advice was considered unsafe. This could however easily be
      corrected by implementing a small modification to the system's knowledge base.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Medical Informatics, Academic Medical Center, Meibergdreef 9, 1105 
      AZ Amsterdam, The Netherlands; Department of Internal Medicine, Academic Medical 
      Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address:
      a.c.simon@amc.uva.nl.
FAU - Simon, Airin C R
AU  - Simon AC
FAU - Holleman, Frits
AU  - Holleman F
FAU - Gude, Wouter T
AU  - Gude WT
FAU - Hoekstra, Joost B L
AU  - Hoekstra JB
FAU - Peute, Linda W
AU  - Peute LW
FAU - Jaspers, Monique W M
AU  - Jaspers MW
FAU - Peek, Niels
AU  - Peek N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Artif Intell Med
JT  - Artificial intelligence in medicine
JID - 8915031
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/06/30 [received]
PHST- 2013/04/08 [revised]
PHST- 2013/04/24 [accepted]
AID - S0933-3657(13)00072-9 [pii]
AID - 10.1016/j.artmed.2013.04.009 [doi]
PST - aheadofprint
SO  - Artif Intell Med. 2013 Jun 1. pii: S0933-3657(13)00072-9. doi:
      10.1016/j.artmed.2013.04.009.

PMID- 23735478
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1553-3840 (Electronic)
IS  - 1553-3840 (Linking)
VI  - 10
IP  - 1
DP  - 2013
TI  - Structure elucidation and inhibitory effects on human platelet aggregation of
      chlorogenic acid from Wrightia tinctoria.
PG  - 1-8
LID - 10.1515/jcim-2012-0048 [doi]
LID - /j/jcim.2013.10.issue-1/jcim-2012-0048/jcim-2012-0048.xml [pii]
AB  - Abstract Background: Interest in natural compounds as sources of potentially new 
      treatment options is growing rapidly. Preliminary screening of many different
      plant extracts showed that Wrightia tinctoria acts as a potent human platelet
      aggregation inhibitor. The aim of the present study was to isolate and
      characterize the active compound responsible for potent inhibition of human
      platelet aggregation in vitro.Methods: A 70% ethanolic extract derived from W.
      tinctoria seeds was fractionated with chloroform followed by ethyl acetate. The
      ethyl acetate fraction was further fractionated and purified through a series of 
      three successive column chromatographic separations using silica gel, Sephadex
      LH-20, and C-18 columns. Liquid chromatography coupled to negative electrospray
      ionization tandem mass spectrometry (LC-MS/MS) and nuclear magnetic resonance
      (NMR) studies were performed in the structure determination of the active
      phenolic compound present in the ethyl acetate fraction of W. tinctoria
      seeds.Results: A phenolic compound has been isolated and identified as
      chlorogenic acid by LC-MS/MS and NMR studies. Chlorogenic acid showed
      concentration-dependent inhibitory effect on collagen-induced platelet
      aggregation in vitro with an IC50 of 0.2363 mug/mul.Conclusion: The present data 
      suggest that chlorogenic acid can be developed as potential antiplatelet agent in
      the treatment of cardiovascular diseases in diabetes mellitus.
FAU - Amin, Ripal P
AU  - Amin RP
FAU - Kunaparaju, Naveen
AU  - Kunaparaju N
FAU - Kumar, Sunil
AU  - Kumar S
FAU - Taldone, Tony
AU  - Taldone T
FAU - Barletta, Michael A
AU  - Barletta MA
FAU - Zito, S William
AU  - Zito SW
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - Germany
TA  - J Complement Integr Med
JT  - Journal of complementary & integrative medicine
JID - 101313855
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/04/29 [accepted]
AID - 10.1515/jcim-2012-0048 [doi]
AID - /j/jcim.2013.10.issue-1/jcim-2012-0048/jcim-2012-0048.xml [pii]
PST - epublish
SO  - J Complement Integr Med. 2013 May 24;10(1):1-8. doi: 10.1515/jcim-2012-0048.

PMID- 23735465
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1552-9924 (Electronic)
IS  - 0091-6765 (Linking)
DP  - 2013 Jun 4
TI  - Ulcerative Colitis and Perfluorooctanoic Acid (PFOA) in a Highly Exposed
      Population of Community Residents and Workers in the Mid-Ohio Valley.
AB  - BACKGROUND: Little is known about environmental determinants of autoimmune
      diseases. OBJECTIVES: To study autoimmune disease in relation to
      perfluorooctanoic acid (PFOA), which was introduced in the late 1940s and is now 
      ubiquitous in the serum of residents of industrialized countries. METHODS: In
      2008-2011 we interviewed 32,254 U.S. adults with high serum PFOA serum levels
      (median 28 ng/ml) from drinking contaminated water near a chemical plant. Disease
      history was assessed retrospectively from 1952 or birth (if later than 1952)
      until interview. Self-reported history of autoimmune disease was validated via
      medical records. Cumulative exposure to PFOA was derived from estimates of annual
      mean serum PFOA levels during follow up, which were based on plant emissions,
      residential/work history, and a fate-transport model. Cox regression models were 
      used to estimate associations between quartiles of cumulative PFOA serum levels
      and the incidence of autoimmune diseases with 50 or more validated cases,
      including ulcerative colitis (n=151), Crohn's disease (n=96), rheumatoid
      arthritis (n=346), insulin-dependent-diabetes (presumed to be Type 1) (n=160),
      lupus (n=75), and multiple sclerosis (n=98). RESULTS: The incidence of ulcerative
      colitis (UC) was significantly increased in association with PFOA exposure, with 
      adjusted rate ratios by quartile of exposure of 1.00, 1.76 (95%CI: 1.04, 2.99),
      2.63 (95% CI: 1.56, 4.43), and 2.86 (95% CI: 1.65, 4.96) (trend p-value <
      0.0001). A prospective analysis of ulcerative colitis diagnosed after the
      baseline 2005-2006 survey (n = 29 cases) suggested a positive but non-monotonic
      trend (test for trend, p=0.21). DISCUSSION: To our knowledge, this is the first
      study of associations between this common environmental exposure and autoimmune
      diseases in humans. We found evidence that PFOA is associated with ulcerative
      colitis.
AD  - Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
FAU - Steenland, Kyle
AU  - Steenland K
FAU - Zhao, Liping
AU  - Zhao L
FAU - Winquist, Andrea
AU  - Winquist A
FAU - Parks, Christine
AU  - Parks C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Environ Health Perspect
JT  - Environmental health perspectives
JID - 0330411
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/12/19 [received]
PHST- 2013/02/09 [revised]
PHST- 2013/05/30 [accepted]
AID - 10.1289/ehp.1206449 [doi]
PST - aheadofprint
SO  - Environ Health Perspect. 2013 Jun 4.

PMID- 23735410
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1478-5242 (Electronic)
IS  - 0960-1643 (Linking)
VI  - 63
IP  - 611
DP  - 2013 Jun
TI  - Development and evaluation of a brief self-completed family history screening
      tool for common chronic disease prevention in primary care.
PG  - 393-400
LID - 10.3399/bjgp13X668186 [doi]
AB  - Background Family history is an important risk factor for many common chronic
      diseases, but it remains underutilised for diagnostic assessment and disease
      prevention in routine primary care. Aim To develop and validate a brief
      self-completed family history questionnaire (FHQ) for systematic primary care
      assessment for family history of diabetes, ischaemic heart disease, breast
      cancer, and colorectal cancer. Design and setting Two-stage diagnostic validation
      study in 10 general practices in eastern England. Method Participants aged 18-50 
      years were identified via random sampling from electronic searches of general
      practice records. Participants completed a FHQ then had a three-generational
      'gold standard' pedigree taken, to determine disease risk category. In stage 1,
      the FHQ comprised 12 items; in stage 2 the shorter 6-item FHQ was validated
      against the same 'gold standard'. Results There were 1147 participants (stage 1: 
      618; stage 2: 529). Overall, 32% were at increased risk of one or more marker
      conditions (diabetes 18.9%, ischaemic heart disease 13.3%, breast cancer 6.2%,
      colorectal cancer 2.2%). The shorter 6-item FHQ performed very well for all four 
      conditions: pooled data from both stages show diabetes, sensitivity = 98%,
      specificity = 94%; ischaemic heart disease, sensitivity = 93%, specificity = 81%;
      breast cancer, sensitivity = 81%, specificity = 83%; colorectal cancer,
      sensitivity = 96%, specificity = 88%, with an area under the receiver operating
      characteristic curve of 0.90 for males and 0.89 for females. Conclusion This
      brief self-completed FHQ shows good diagnostic accuracy for identifying people at
      higher risk of four common chronic diseases. It could be used in routine primary 
      care to identify patients who would be most likely to benefit from a more
      detailed pedigree and risk assessment, and consequent management strategies.
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge.
FAU - Walter, Fiona M
AU  - Walter FM
FAU - Prevost, A Toby
AU  - Prevost AT
FAU - Birt, Linda
AU  - Birt L
FAU - Grehan, Nicola
AU  - Grehan N
FAU - Restarick, Kathy
AU  - Restarick K
FAU - Morris, Helen C
AU  - Morris HC
FAU - Sutton, Stephen
AU  - Sutton S
FAU - Rose, Peter
AU  - Rose P
FAU - Downing, Sarah
AU  - Downing S
FAU - Emery, Jon D
AU  - Emery JD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of
      General Practitioners
JID - 9005323
SB  - IM
PMC - PMC3662456
OID - NLM: PMC3662456 [Available on 06/01/14]
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PMCR- 2014/06/01 00:00
AID - 10.3399/bjgp13X668186 [doi]
PST - ppublish
SO  - Br J Gen Pract. 2013 Jun;63(611):393-400. doi: 10.3399/bjgp13X668186.

PMID- 23735381
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1478-5242 (Electronic)
IS  - 0960-1643 (Linking)
VI  - 63
IP  - 611
DP  - 2013 Jun
TI  - The challenge of communication in interpreted consultations in diabetes care.
PG  - 290-1
LID - 10.3399/bjgp13X668069 [doi]
AD  - Emeritus Professor of Primary Care Medicine, University of Hull. <email></email>,
      Email: P.D.Campion@hull.ac.uk.
FAU - Campion, Peter
AU  - Campion P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of
      General Practitioners
JID - 9005323
SB  - IM
PMC - PMC3662427
OID - NLM: PMC3662427 [Available on 06/01/14]
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PMCR- 2014/06/01 00:00
AID - 10.3399/bjgp13X668069 [doi]
PST - ppublish
SO  - Br J Gen Pract. 2013 Jun;63(611):290-1. doi: 10.3399/bjgp13X668069.

PMID- 23735372
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
DP  - 2013 Jun 1
TI  - C-reactive Protein and Homocysteine Predict Long-term Mortality in Young Ischemic
      Stroke Patients.
LID - S1052-3057(13)00159-6 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2013.04.031 [doi]
AB  - BACKGROUND: We investigated the relationship between C-reactive protein (CRP) and
      homocysteine on follow-up and subsequent mortality in young ischemic stroke
      patients in a population-based study. METHODS: Young ischemic stroke patients
      were followed-up on average 6 years after the index stroke. CRP and homocysteine 
      levels were measured and risk factors were recorded, including myocardial
      infarction, diabetes mellitus, hypertension, smoking, alcoholism, and cancer.
      Stroke outcome was measured using the modified Rankin Scale score. Subsequent
      survival was obtained by examining the official population registry. Cox
      regression analyses were performed. RESULTS: In total, 198 patients were included
      in this study (82 [41%] women and 116 [59%] men). The mean age on follow-up was
      47.8 years. In total, 36 (18.2%) patients died during the subsequent mean
      follow-up of 12.4 years. Cox regression analysis revealed that mortality was
      associated with CRP (hazard ratio [HR] 1.05; P = .001) and homocysteine levels
      (HR 1.04; P = .02) in patients without dissection. Kaplan-Meier curves grouped by
      dichotomized CRP (CRP </=1 v >1 mg/L) showed increasing separation between the
      survival curves, and likewise for dichotomized homocysteine (</=9 v >9 mug/L).
      CONCLUSIONS: There is an independent association between CRP and homocysteine
      levels obtained several years after ischemic stroke in young adults and
      subsequent mortality, even when adjusting for traditional risk factors. This
      association seems to continue for at least 12 years after the measurements.
CI  - Copyright (c) 2013 National Stroke Association. Published by Elsevier Inc. All
      rights reserved.
AD  - Department of Neurology, Haukeland University Hospital, Bergen, Norway.
      Electronic address: haln@haukeland.no.
FAU - Naess, Halvor
AU  - Naess H
FAU - Nyland, Harald
AU  - Nyland H
FAU - Idicula, Titto
AU  - Idicula T
FAU - Waje-Andreassen, Ulrike
AU  - Waje-Andreassen U
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National
      Stroke Association
JID - 9111633
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/02/26 [received]
PHST- 2013/04/21 [revised]
PHST- 2013/04/26 [accepted]
AID - S1052-3057(13)00159-6 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2013.04.031 [doi]
PST - aheadofprint
SO  - J Stroke Cerebrovasc Dis. 2013 Jun 1. pii: S1052-3057(13)00159-6. doi:
      10.1016/j.jstrokecerebrovasdis.2013.04.031.

PMID- 23735361
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1557-2501 (Electronic)
IS  - 1042-3931 (Linking)
VI  - 25
IP  - 6
DP  - 2013 Jun
TI  - The link between vasculogenic erectile dysfunction, coronary artery disease, and 
      peripheral artery disease: role of metabolic factors and endovascular therapy.
PG  - 313-9
AB  - Erectile dysfunction (ED) is estimated to affect 150 million people worldwide and
      may indicate diffuse systemic macrovascular disease. Endothelial dysfunction
      represents the probable pathophysiological link between vasculogenic ED, coronary
      artery disease (CAD), and peripheral artery disease (PAD), and the artery size
      hypothesis along with evidence-based research support ED as the incident clinical
      event. Given that many common risk factors for atherosclerosis, including
      smoking, diabetes mellitus, hyperlipidemia, and obesity are prevalent and
      causative in patients with ED, it is likely that metabolic factors play a crucial
      role in the link between the two disorders. The interplay of these factors
      provides a unifying physiological, endocrinological, and behavioral model for the
      association between ED, CAD, and PAD. Current therapy is unlikely to reverse the 
      natural history of ED. Percutaneous revascularization may improve ED symptoms,
      and thereby quality of life, in a select group of patients. Large prospective
      studies are needed to define male pelvic arterial anatomy and thus enhance the
      utilization of internal pudendal angiography and revascularization. In this
      review, we provide an overview of normal erectile anatomy and physiology, the
      pathophysiology of ED, currently accepted diagnostic imaging modalities and
      treatments for ED, and recently investigated endovascular therapies for ED.
AD  - Yale University School of Medicine, Department of Internal Medicine, Section of
      Cardiovascular Medicine, 333 Cedar Street, DANA3 Cardiology, New Haven, CT 06510 
      USA. carlos.mena-hurtado@yale.edu.
FAU - Meller, Stephanie M
AU  - Meller SM
FAU - Stilp, Erik
AU  - Stilp E
FAU - Walker, Charles N
AU  - Walker CN
FAU - Mena-Hurtado, Carlos
AU  - Mena-Hurtado C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
SB  - IM
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PST - ppublish
SO  - J Invasive Cardiol. 2013 Jun;25(6):313-9.

PMID- 23735333
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1421-9735 (Electronic)
IS  - 0253-5068 (Linking)
VI  - 36
IP  - 1
DP  - 2013 May 25
TI  - Coronary Artery Calcification and Outcomes in Diabetic Patients with and without 
      Chronic Kidney Disease.
PG  - 17-20
AB  - Background/Aims: Presence and progression of coronary artery calcification (CAC) 
      indicate severe atherosclerosis and predict cardiovascular events (CVE) in
      dialysis (ESRD patients) and nondialysis patients (CKD patients). This study
      aimed at evaluating the prevalence and progression of CAC and CVE in CKD patients
      with diabetes in whom atherosclerosis of coronary arteries is the leading cause
      of CVE. Methods: This was a retrospective study conducted in both out- and
      in-patients with chronic kidney disease, stage 2-5. CAC were assessed by the
      total calcium (TC) score. CT scans were performed at the entry and at the end of 
      the study. Results: Patients (n = 341) were divided into nondiabetic (n = 281)
      and diabetic patients (n = 60). CAC prevalence and TC score were higher in
      diabetics and associated with age, diabetes mellitus and pulse pressure.
      Diabetics with CKD presented a higher percentage of CAC progression and CVE.
      Conclusion: Prevalence, extent, progression of CAC and CVE are higher in
      diabetics with concomitant CKD. These findings may promote a more aggressive
      protocol of screening and care in type 2 diabetics with concomitant CKD.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Nephrology, University Federico II of Naples, Naples, Italy.
FAU - Russo, D
AU  - Russo D
FAU - Morrone, L F P
AU  - Morrone LF
FAU - Imbriaco, M
AU  - Imbriaco M
FAU - Pota, A
AU  - Pota A
FAU - Russo, L
AU  - Russo L
FAU - Scognamiglio, B
AU  - Scognamiglio B
FAU - Sorrentino, R
AU  - Sorrentino R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Blood Purif
JT  - Blood purification
JID - 8402040
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/05/25 [aheadofprint]
AID - 000350580 [pii]
AID - 10.1159/000350580 [doi]
PST - aheadofprint
SO  - Blood Purif. 2013 May 25;36(1):17-20.

PMID- 23735317
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1873-1244 (Electronic)
IS  - 0899-9007 (Linking)
DP  - 2013 Jun 1
TI  - Metabolic effects of aloe vera gel complex in obese prediabetes and early
      non-treated diabetic patients: Randomized controlled trial.
LID - S0899-9007(13)00107-X [pii]
LID - 10.1016/j.nut.2013.02.015 [doi]
AB  - OBJECTIVE: The metabolic effects of an aloe vera gel complex (Aloe QDM complex)
      on people with prediabetes or early diabetes mellitus (DM) are unknown. The goal 
      of this study was to determine the effects of Aloe QDM complex on body weight,
      body fat mass (BFM), fasting blood glucose (FBG), fasting serum insulin, and
      Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) in obese
      individuals with prediabetes or early DM who were not on diabetes medications.
      METHODS: Participants (n = 136) were randomly assigned to an intervention or a
      control group and evaluated at baseline and at 4 and 8 wk. RESULTS: The study
      lost six participants in the control group and eight in the intervention group.
      At 8 wk, body weight (P = 0.02) and BFM (P = 0.03) were significantly lower in
      the intervention group. At 4 wk, serum insulin level (P = 0.04) and HOMA-IR (P = 
      0.047) were lower in the intervention group; they also were lower at 8 wk but
      with borderline significance (P = 0.09; P = 0.08, respectively). At 8 wk, FBG
      tended to decrease in the intervention group (P = 0.02), but the between-group
      difference was not significant (P = 0.16). CONCLUSION: In obese individuals with 
      prediabetes or early untreated DM, Aloe QDM complex reduced body weight, BFM, and
      insulin resistance.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Family Medicine, Seoul National University Hospital, Seoul, South
      Korea.
FAU - Choi, Ho-Chun
AU  - Choi HC
FAU - Kim, Seok-Joong
AU  - Kim SJ
FAU - Son, Ki-Young
AU  - Son KY
FAU - Oh, Bum-Jo
AU  - Oh BJ
FAU - Cho, Be-Long
AU  - Cho BL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Nutrition
JT  - Nutrition (Burbank, Los Angeles County, Calif.)
JID - 8802712
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/10/26 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/02/18 [accepted]
AID - S0899-9007(13)00107-X [pii]
AID - 10.1016/j.nut.2013.02.015 [doi]
PST - aheadofprint
SO  - Nutrition. 2013 Jun 1. pii: S0899-9007(13)00107-X. doi:
      10.1016/j.nut.2013.02.015.

PMID- 23735219
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1477-1128 (Electronic)
IS  - 1463-4236 (Linking)
DP  - 2013 Jun 5
TI  - Weight loss surgery for non-morbidly obese populations with type 2 diabetes: is
      this an acceptable option for patients?
PG  - 1-10
AB  - Aim To explore the views of non-morbidly obese people (BMI 30-40 kg/m2) with type
      2 diabetes regarding: (a) the acceptability of bariatric surgery (BS) as a
      treatment for type 2 diabetes, and (b) willingness to participate in randomised
      controlled trials comparing BS versus non-surgical intervention. BACKGROUND:
      Despite weight management being a key therapeutic goal in type 2 diabetes,
      achieving and sustaining weight loss is problematic. BS is an effective treatment
      for people with morbid obesity and type 2 diabetes; it is less certain whether
      non-morbidly obese patients (BMI 30-39.9 kg/m2) with type 2 diabetes benefit from
      this treatment and whether this approach would be cost-effective. Before
      evaluating this issue by randomised trials, it is important to understand whether
      BS and such research are acceptable to this population. METHODS: Non-morbidly
      obese people with type 2 diabetes were purposively sampled from primary care and 
      invited to participate in semi-structured interviews. Interviews explored
      participants' thoughts surrounding their diabetes and weight, the acceptability
      of BS and the willingness to participate in BS research. Data were analysed using
      Framework Analysis.
AD  - 1Health Services Research Fellow, Primary Care and Population Sciences, Faculty
      of Medicine, University of Southampton, Southampton, UK.
FAU - Summers, Rachael H
AU  - Summers RH
FAU - Elsey, Helen
AU  - Elsey H
FAU - Moore, Michael
AU  - Moore M
FAU - Byrne, Christopher
AU  - Byrne C
FAU - Byrne, James
AU  - Byrne J
FAU - Welbourn, Richard
AU  - Welbourn R
FAU - Roderick, Paul
AU  - Roderick P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Prim Health Care Res Dev
JT  - Primary health care research & development
JID - 100897390
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - S146342361300025X [pii]
AID - 10.1017/S146342361300025X [doi]
PST - aheadofprint
SO  - Prim Health Care Res Dev. 2013 Jun 5:1-10.

PMID- 23735216
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 Jun 2
TI  - Deconstructing the roles of glucocorticoids in adipose tissue biology and the
      development of central obesity.
LID - S0925-4439(13)00191-9 [pii]
LID - 10.1016/j.bbadis.2013.05.029 [doi]
AB  - Central obesity is associated with insulin resistance and dyslipidemia. Thus, the
      mechanisms that control fat distribution and its impact on systemic metabolism
      have importance for understanding the risk for diabetes and cardiovascular
      disease. Hypercortisolemia at the systemic (Cushing's syndrome) or local levels
      (due to adipose-specific overproduction via 11beta-hydroxysteroid dehydrogenase
      1) results in the preferential expansion of central, especially visceral fat
      depots. At the same time, peripheral subcutaneous depots can become depleted. The
      biochemical and molecular mechanisms underlying the depot-specific actions of
      glucocorticoids (GCs) on adipose tissue function remain poorly understood. GCs
      exert pleiotropic effects on adipocyte metabolic, endocrine and immune functions,
      and dampen adipose tissue inflammation. GCs also regulate multiple steps in the
      process of adipogenesis. Acting synergistically with insulin, GCs increase the
      expression of numerous genes involved in fat deposition. Variable effects of GC
      on lipolysis are reported, and GC can improve or impair insulin action depending 
      on the experimental conditions. Thus, the net effect of GC on fat storage appears
      to depend on the physiologic context. The preferential effects of GC on visceral 
      adipose tissue have been linked to higher cortisol production and glucocorticoid 
      receptor expression, but the molecular details of the depot-dependent actions of 
      GCs are only beginning to be understood. In addition, increasing evidence
      underlines the importance of circadian variations in GCs in relationship to the
      timing of meals for determining their anabolic actions on the adipocyte. In
      summary, although the molecular mechanisms remain to be fully elucidated, there
      is increasing evidence that GCs have multiple, depot-dependent effects on
      adipocyte gene expression and metabolism that promote central fat deposition.
      This article is part of a Special Issue entitled: Modulation of Adipose Tissue in
      Health and Disease.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston 
      University School of Medicine, Boston, MA, USA.
FAU - Lee, Mi-Jeong
AU  - Lee MJ
FAU - Pramyothin, Pornpoj
AU  - Pramyothin P
FAU - Karastergiou, Kalypso
AU  - Karastergiou K
FAU - Fried, Susan K
AU  - Fried SK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/01/26 [received]
PHST- 2013/05/18 [revised]
PHST- 2013/05/24 [accepted]
AID - S0925-4439(13)00191-9 [pii]
AID - 10.1016/j.bbadis.2013.05.029 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 Jun 2. pii: S0925-4439(13)00191-9. doi:
      10.1016/j.bbadis.2013.05.029.

PMID- 23735215
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 Jun 2
TI  - Understanding the variegation of fat: Novel regulators of adipocyte
      differentiation and fat tissue biology.
LID - S0925-4439(13)00193-2 [pii]
LID - 10.1016/j.bbadis.2013.05.031 [doi]
AB  - The differentiation of uncommitted cells into specialized adipocytes occurs
      through a cascade of transcriptional events culminating in the induction and
      activation of the nuclear receptor PPARgamma, the central coordinator of fat cell
      function. Since the discovery of PPARgamma, two decades ago, our views of how
      this molecule is activated have been significantly refined. Beyond the cell, we
      also now know that diverse signals and regulators control PPARgamma function in a
      fat-depot specific manner. The goal of this article is to review the latest in
      our understanding of the early and late transcriptional events that regulate
      adipocyte development and their potential impact on energy storage and
      expenditure in different fat depots. This article is part of a Special Issue
      entitled: Modulation of Adipose Tissue in Health and Disease.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
AD  - Genetics of Development and Disease Branch, National Institute of Diabetes and
      Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892,
      USA. Electronic address: elisabettam@niddk.nih.gov.
FAU - Mueller, Elisabetta
AU  - Mueller E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/03/02 [received]
PHST- 2013/05/21 [revised]
PHST- 2013/05/22 [accepted]
AID - S0925-4439(13)00193-2 [pii]
AID - 10.1016/j.bbadis.2013.05.031 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 Jun 2. pii: S0925-4439(13)00193-2. doi:
      10.1016/j.bbadis.2013.05.031.

PMID- 23735214
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 Jun 2
TI  - Adipocytes under assault: Environmental disruption of adipose physiology.
LID - S0925-4439(13)00190-7 [pii]
LID - 10.1016/j.bbadis.2013.05.028 [doi]
AB  - The burgeoning obesity epidemic has placed enormous strains on individual and
      societal health mandating a careful search for pathogenic factors, including the 
      contributions made by endocrine disrupting chemicals (EDCs). In addition to
      evidence that some exogenous chemicals have the capacity to modulate classical
      hormonal signaling axes, there is mounting evidence that several EDCs can also
      disrupt metabolic pathways and alter energy homeostasis. Adipose tissue appears
      to be a particularly important target of these metabolic disruptions. A diverse
      array of compounds has been shown to alter adipocyte differentiation, and several
      EDCs have been shown to modulate adipocyte physiology, including adipocytic
      insulin action and adipokine secretion. This rapidly emerging evidence
      demonstrating that environmental contaminants alter adipocyte function emphasizes
      the potential role that disruption of adipose physiology by EDCs may play in the 
      global epidemic of metabolic disease. Further work is required to better
      characterize the molecular targets responsible for mediating the effects of EDCs 
      on adipose tissue. Improved understanding of the precise signaling pathways
      altered by exposure to environmental contaminants will enhance our understanding 
      of which chemicals pose a threat to metabolic health and how those compounds
      synergize with lifestyle factors to promote obesity and its associated
      complications. This knowledge may also improve our capacity to predict which
      synthetic compounds may alter energy homeostasis before they are released into
      the environment while also providing critical evidentiary support for efforts to 
      restrict the production and use of chemicals that pose the greatest threat to
      human metabolic health. This article is part of a Special Issue entitled:
      Modulation of Adipose Tissue in Health and Disease.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Committee on Molecular Metabolism and Nutrition, Diabetes and Metabolism,
      University of Chicago, Chicago, IL, USA.
FAU - Regnier, Shane M
AU  - Regnier SM
FAU - Sargis, Robert M
AU  - Sargis RM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/01/31 [received]
PHST- 2013/04/29 [revised]
PHST- 2013/05/24 [accepted]
AID - S0925-4439(13)00190-7 [pii]
AID - 10.1016/j.bbadis.2013.05.028 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 Jun 2. pii: S0925-4439(13)00190-7. doi:
      10.1016/j.bbadis.2013.05.028.

PMID- 23735164
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1520-6882 (Electronic)
IS  - 0003-2700 (Linking)
DP  - 2013 Jun 5
TI  - Miniature biofuel cell as a potential power source for glucose-sensing contact
      lenses.
AB  - A microscale membrane-less biofuel cell, capable of generating electrical energy 
      from human lachrymal liquid, was developed by utilizing the ascorbate and oxygen 
      naturally present in tears as fuel and oxidant. The biodevice is based on
      three-dimensional nanostructured gold electrodes covered with abiotic (conductive
      organic complex) and biological (redox enzyme) materials functioning as efficient
      anodic and cathodic catalysts, respectively. Three-dimensional nanostructured
      electrodes were fabricated by modifying 100 microm gold wires with 17 nm gold
      nanoparticles, which were further modified with
      tetrathiafulvalene-tetracyanoquinodimethane conducting complex to create the
      anode and with Myrothecium verrucaria bilirubin oxidase to create the biocathode.
      When operated in human tears, the biodevice exhibited the following
      characteristics: an open circuit voltage of 0.54 V, a maximal power density of
      3.1 microW cm-2 at 0.25 V and 0.72 microW cm-2 at 0.4 V, with a stable current
      density output of over 0.55 microA cm-2 at 0.4 V for 6 h of continuous operation.
      These findings support our proposition that an ascorbate/oxygen biofuel cell
      could be a suitable power source for glucose-sensing contact lenses to be used
      for continuous health monitoring by diabetes patients.
FAU - Falk, Magnus
AU  - Falk M
FAU - Andoralov, Viktor
AU  - Andoralov V
FAU - Silow, Maria
AU  - Silow M
FAU - Toscano, Miguel Duarte
AU  - Toscano MD
FAU - Shleev, Sergey
AU  - Shleev S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1021/ac4006793 [doi]
PST - aheadofprint
SO  - Anal Chem. 2013 Jun 5.

PMID- 23735119
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Linking)
DP  - 2013 Jun 4
TI  - An in vitro model for spontaneous angiogenesis using rat mesenteric endothelial
      cells: Possible therapeutic perspective for obesity and related disorders.
AB  - Abstract Context: Abnormal obesity and the related diseases, such as diabetes and
      cardiovascular disease, are the main causes of mortality, around the world. A key
      feature of the adipogenesis and obesity is angiogenesis-dependent tissue growth
      accompanied with extracellular remodeling. In this way, suppression of
      angiogenesis may be a key point for preventing the adipogenesis. Objective: In
      the present study, to provide a deeper insight to understand obesity and
      screening for more effective therapeutics, we have developed a three-dimensional 
      in vitro model of microvessel formation under collagen matrix culture using
      endothelial cells, extracted from a suitable tissue. Materials and methods: In a 
      successful approach for developing an angiogenesis model, the rat mesenteric
      microvascular endothelial cells (RMMECs) were isolated, coated on dextran beads
      and then suspended in collagen gel. Additionally, the proliferation as well as
      migration of endothelial cells were analyzed and compared with human umbilical
      vein endothelial cells (HUVECs). Results: RMMECs showed remarkable migration
      ability and had higher growth during the logarithmic growth phase, when compared 
      with HUVECs. Also, no significance differences in morphogenesis were observed
      between HUVECs and RMMECs. Discussion and conclusion: The model may be useful in 
      providing insights to develop potential intervention strategies in vivo against
      obesity-related disorders. Targeting endothelial cells is an interesting and
      exciting possibility that may be raised in further investigations.
AD  - Molecular Medicine Department, School of Advanced Medical Technologies, Tehran
      University of Medical Sciences , Tehran , Iran .
FAU - Mansouri, Kamran
AU  - Mansouri K
FAU - Khodarahmi, Reza
AU  - Khodarahmi R
FAU - Ghadami, Seyyed Abolghasem
AU  - Ghadami SA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.3109/13880209.2013.773452 [doi]
PST - aheadofprint
SO  - Pharm Biol. 2013 Jun 4.

PMID- 23735096
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1742-7924 (Electronic)
IS  - 1742-7924 (Linking)
VI  - 10
IP  - 1
DP  - 2013 Jun
TI  - Barriers to diabetes control from Syrian women's perspectives.
PG  - 121-9
LID - 10.1111/j.1742-7924.2012.00218.x [doi]
AB  - Aim: Diabetes constitutes a major public health problem and is a leading cause of
      morbidity and mortality. The purpose of this study was to explore the barriers to
      diabetes control of middle-aged Syrian women with type 2 diabetes. Methods: A
      qualitative approach was adopted using conventional content analysis of
      semi-structured interviews carried out with 12 women with type 2 diabetes in the 
      diabetic center in Lattakia (Syria) between March 2010 and December 2010. The
      participants were recruited by the purposeful sampling method. Results: Three
      main themes emerged from the data analysis: (i) a poor patient-healthcare
      provider relationship; (ii) inadequate education; (iii) and psychosocial
      problems. The first theme had two subthemes: (i) relationship with doctors; and
      (ii) relationship with nurses. The second theme was without subthemes. The third 
      theme consisted of six subthemes: (i) work and family responsibilities; (ii)
      motherhood role; (iii) lack of social support; (iv) anxiety; (v) depression; and 
      (vi) low self-efficacy. Conclusion: The findings support that effective
      relationships can be enhanced through active listening and by opening a free
      channel for the flow of ideas and information between patients and healthcare
      providers. Additionally, providers have an important role to play in learning to 
      identify and manage the psychosocial problems that arise in living with diabetes,
      so that their patients can be supported in overcoming barriers to managing their 
      diabetes more effectively.
CI  - (c) 2012 The Authors. Japan Journal of Nursing Science (c) 2012 Japan Academy of 
      Nursing Science.
AD  - Department of Nursing, Faculty of Medical Sciences, Tarbiat Modares University,
      Tehran, Iran.
FAU - Zamzam, Suzan
AU  - Zamzam S
FAU - Anoosheh, Monireh
AU  - Anoosheh M
FAU - Ahmadi, Fazlollah
AU  - Ahmadi F
LA  - eng
PT  - Journal Article
DEP - 20120619
PL  - Japan
TA  - Jpn J Nurs Sci
JT  - Japan journal of nursing science : JJNS
JID - 101227890
SB  - IM
SB  - N
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/06/19 [aheadofprint]
AID - 10.1111/j.1742-7924.2012.00218.x [doi]
PST - ppublish
SO  - Jpn J Nurs Sci. 2013 Jun;10(1):121-9. doi: 10.1111/j.1742-7924.2012.00218.x. Epub
      2012 Jun 19.

PMID- 23735047
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
DP  - 2013 Jun 5
TI  - Diabetes in young people in the Top End of the Northern Territory.
LID - 10.1111/jpc.12265 [doi]
AB  - AIM: There is an increasing prevalence and burden of diabetes in young people,
      particularly Indigenous Australians. There have been no previous reports of the
      prevalence or burden of diabetes in young people in the Top End of the Northern
      Territory, a region of many risk factors for diabetes. METHODS: This is a
      retrospective study of cases of diabetes in children and adults aged less than 25
      years who were seen at Royal Darwin Hospital as inpatients or outpatients between
      2007 and 2011. RESULTS: From a population base of approximately 75 000 young
      people living north of Tenant Creek, there were 70 young people with type 1
      diabetes (12 Aboriginal and/or Torres Strait Islander Australians) and 37 young
      people with type 2 diabetes (31 Aboriginal or Torres Strait Islander
      Australians). The median body mass index of those with type 2 diabetes was 28
      kg/m2 , and only 29% had a body mass index >30 kg/m2 . Overall, glycaemic control
      was poor. CONCLUSIONS: Rates of diabetes in young people in the Top End appear
      high. Case ascertainment and data collection were difficult for this study,
      highlighting the need for better database and systems for diabetes management.
CI  - (c) 2013 The Authors. Journal of Paediatrics and Child Health (c) 2013
      Paediatrics and Child Health Division (Royal Australasian College of Physicians).
AD  - Department of Paediatrics, Royal Darwin Hospital, Darwin, Northern Territory,
      Australia.
FAU - Stone, Monique
AU  - Stone M
FAU - Baker, Alice
AU  - Baker A
FAU - Maple Brown, Louise
AU  - Maple Brown L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/02/27 [accepted]
AID - 10.1111/jpc.12265 [doi]
PST - aheadofprint
SO  - J Paediatr Child Health. 2013 Jun 5. doi: 10.1111/jpc.12265.

PMID- 23734998
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1557-7600 (Electronic)
IS  - 1096-620X (Linking)
DP  - 2013 Jun 4
TI  - Antidiabetic Effect of the Chrysobalanus icaco L. Aqueous Extract in Rats.
AB  - Abstract Chrysobalanus icaco L. is a medicinal plant popularly known in Brazil as
      "Grageru" or "Abageru." It is used in African and American continents as
      medicinal food in the treatment of several diseases, including diabetes. This
      study used phytochemical screening to determine the antioxidant and alpha-amylase
      inhibitor activities of the aqueous extract (AECI) of C. icaco, and evaluated its
      antidiabetic potential in rodents. Phytochemical screening was performed using
      colorimetric tests with specific reagents. The in vitro antioxidant activity was 
      evaluated by the scavenging activity of 2,2-diphenyl-1-picril-hydrazyl. The
      lethality test and behavioral screening was performed using an oral
      administration of 5 g/kg of AECI. The AECI antidiabetic potential was evaluated
      through the oral glucose tolerance test (OGTT) and chronic hypoglycemic test at
      the doses of 100, 200, and 400 mg/kg (orally). Metformin was used as a reference 
      drug in all tests. Diabetes was induced by injection of alloxan (40 mg/kg;
      intravenously). Phytochemical screening showed the presence of various compounds,
      including tannins, flavones, triterpenoids, steroids, saponins, and alkaloids.
      The in vitro antioxidant test demonstrated that AECI presented potent antioxidant
      activity. The lethality test and behavioral screening did not show lethality
      signs. In the OGTT test, AECI administration was not able to inhibit the
      elevation of glycemia. However, chronically administrated, it was able to cause a
      significant (P<.05) reduction of glycemia from 335+/-27 up to 197+/-15 mg/dL.
      These results demonstrate that the AECI presents a potential beneficial effect
      for diabetes.
AD  - 1 Department of Physiology, Federal University of Sergipe , Sao Cristovao,
      Sergipe, Brazil.
FAU - Barbosa, Ana Paula de Oliveira
AU  - Barbosa AP
FAU - Silveira, Gabriela de Oliveira
AU  - Silveira GD
FAU - de Menezes, Igor Alexandre Cortes
AU  - de Menezes IA
FAU - Rezende Neto, Jose Melquiades
AU  - Rezende Neto JM
FAU - Bitencurt, Jose Leal C
AU  - Bitencurt JL
FAU - Estavam, Charles Dos Santos
AU  - Estavam CD
FAU - de Lima, Amanda do Carmo Bion
AU  - de Lima AD
FAU - Thomazzi, Sara Maria
AU  - Thomazzi SM
FAU - Guimaraes, Adriana Gibara
AU  - Guimaraes AG
FAU - Quintans-Junior, Lucindo Jose
AU  - Quintans-Junior LJ
FAU - Dos Santos, Marcio Roberto Viana
AU  - Dos Santos MR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - J Med Food
JT  - Journal of medicinal food
JID - 9812512
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1089/jmf.2012.0084 [doi]
PST - aheadofprint
SO  - J Med Food. 2013 Jun 4.

PMID- 23734996
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1557-7600 (Electronic)
IS  - 1096-620X (Linking)
DP  - 2013 Jun 4
TI  - Berberine Ameliorates Cold and Mechanical Allodynia in a Rat Model of Diabetic
      Neuropathy.
AB  - Abstract This study evaluated the antiallodynic properties of berberine on cold
      and mechanical allodynia after streptozotocin (STZ)-induced diabetes using a rat 
      model. Diabetic neuropathy was induced in rats by intraperitoneal injection of
      STZ. To measure cold and mechanical allodynia, a 4 degrees C plate and von Frey
      filament were used, respectively. Cold and mechanical allodynia induced by
      diabetes were significantly decreased by single and repeated intraperitoneal
      treatment of amitriptyline at 10 mg/kg, and berberine at 10 and 20 mg/kg. The
      hepatic malondialdehyde, superoxide dismutase, catalase, and glutathione
      peroxidase activities were significantly increased in diabetic rats as compared
      with those in intact rats; however, in amitriptyline- and berberine-treated rats,
      they were significantly decreased as compared to the STZ control. The overall
      effects of berberine 20 mg/kg on cold and mechanical allodynia were quite similar
      to those of amitriptyline 10 mg/kg, and berberine exhibited similar antioxidant
      effects as the same dosage of amitriptyline. In conclusion, berberine (10 and 20 
      mg/kg) was observed to have antiallodynic effects against diabetes, which are
      presumed to be associated with antioxidative effects. It can be considered that
      the anti-inflammatory or antidepressant capacity of berberine could contribute to
      the antiallonynic effects shown in this study.
AD  - 1 Department of Anesthesiology and Pain Medicine, Kyungpook National University
      School of Medicine , Daegu, Korea.
FAU - Kim, Si Oh
AU  - Kim SO
FAU - Kim, Hyun Jee
AU  - Kim HJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - J Med Food
JT  - Journal of medicinal food
JID - 9812512
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1089/jmf.2012.2648 [doi]
PST - aheadofprint
SO  - J Med Food. 2013 Jun 4.

PMID- 23734906
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
DP  - 2013 Jun 4
TI  - Real-World Comparative Outcomes of US Type 2 Diabetes Patients Initiating Analog 
      Basal Insulin Therapy.
AB  - Abstract Objective To evaluate outcomes in insulin-naive patients with type 2
      diabetes mellitus (T2DM) who initiated insulin glargine or insulin detemir.
      Methods Retrospective data were analyzed from the US General Electric Centricity 
      electronic medical records (EMR) database from patients (>/= 18 years old) with
      T2DM initiating insulin glargine or detemir between January 1, 2006, and December
      31, 2010. Included patients had EMR data for >/= 6 months prior to (baseline) and
      >/= 12 months after (follow-up) the index date (date of first insulin
      prescription), and at least one OAD and/or GLP-1 receptor agonist prescription
      order during baseline, but no previous insulin prescription. Patients were
      matched on baseline characteristics 5:1, insulin glargine to detemir, to
      ameliorate selection bias. Outcomes assessed were persistence with insulin
      therapy, glycemic control, hypoglycemia, body weight, and body mass index over
      follow-up. Results Insulin glargine and detemir groups were similar in terms of
      gender (51.0% and 51.5% female, P = 0.7356), age (57.8 and 57.4 years, P =
      0.3368), A1C (9.4% and 9.4%, P = 0.6642), and body weight (101.9 kg and 102.4 kg,
      P = 0.4920) at baseline. During follow-up, patients initiating insulin glargine
      were more persistent (80.1% vs 67.8%, P < 0.0001) and had a greater change in A1C
      (-1.11% vs -0.96%, P = 0.0479). Percentage change in weight (0.91% and 0.65%, P =
      0.2734) and hypoglycemia prevalence (3.6% vs 4.1%, P = 0 .4338) were similar
      between groups. Conclusions Results from this real-world EMR analysis suggest
      that among T2DM patients, initiating insulin treatment with insulin glargine may 
      be associated with better treatment persistence and glycemic control, with
      similar prevalence of hypoglycemia and weight change, compared with initiating
      with insulin detemir. This study is limited by the retrospective nature of the
      data collection using EMRs and inability to confirm accuracy and completeness of 
      data by secondary chart review.
AD  - RTI Health Solutions, Research Triangle Park, NC, USA.
FAU - Davis, Keith L
AU  - Davis KL
FAU - Tangirala, Muralikrishna
AU  - Tangirala M
FAU - Meyers, Juliana L
AU  - Meyers JL
FAU - Wei, Wenhui
AU  - Wei W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1185/03007995.2013.811403 [doi]
PST - aheadofprint
SO  - Curr Med Res Opin. 2013 Jun 4.

PMID- 23734852
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1472-6823 (Print)
IS  - 1472-6823 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Jun 4
TI  - A case report of syndrome of inappropriate antidiuretic hormone secretion with
      Castleman's disease and lymphoma.
PG  - 19
AB  - BACKGROUND: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a
      common cause of hyponatremia in hospitalized patients and is often described in
      patients with small-cell carcinoma of the lung. In this report, we described both
      Castleman's disease and lymphoma coexisting in one patient with SIADH. CASE
      PRESENTATION: A 70-year-old Chinese woman with a history of diabetes mellitus and
      insulin therapy had severe hyponatremia and gastrointestinal symptoms. Through a 
      series of examinations, common causes such as pulmonary carcinoma were excluded. 
      An abdominal mass was detected by computed tomography. Although the peripheral
      lymph node biopsy showed the pathological result as Castleman's disease, the
      pathology of the abdominal lymph node revealed diffuse large B-cell lymphoma.
      After chemotherapy, the hyponatremia was treated during a period of follow-up.
      CONCLUSION: This patient presented with the rare clinical condition of
      inappropriate antidiuretic hormone secretion alongside Castleman's disease and
      lymphoma. Asymptomatic hyponatremia may persist for some time suggesting that
      clinical physicians should pay attention to the mild cases of hyponatremia. We
      also hypothesized that Castleman's disease is a condition of pre-lymphoma with
      both having the ability to cause SIADH. The possibility of lymphoma as well as
      Castleman's disease triggering the development of SIADH should also be taken into
      consideration for conducting recurrent biopsies.
FAU - Zhu, Chong-Gui
AU  - Zhu CG
FAU - Zhang, Qiu-Zi
AU  - Zhang QZ
FAU - Zhu, Mei
AU  - Zhu M
FAU - Zhai, Qiong-Li
AU  - Zhai QL
FAU - Liang, Xiao-Yu
AU  - Liang XY
FAU - Shao, Zong-Hong
AU  - Shao ZH
FAU - Hoeve, Emily C Ver
AU  - Hoeve EC
FAU - Qu, Hui-Qi
AU  - Qu HQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/10/04 [received]
PHST- 2013/06/04 [accepted]
PHST- 2013/06/04 [aheadofprint]
AID - 1472-6823-13-19 [pii]
AID - 10.1186/1472-6823-13-19 [doi]
PST - aheadofprint
SO  - BMC Endocr Disord. 2013 Jun 4;13(1):19.

PMID- 23734839
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 12
IP  - 1
DP  - 2013 Jun 5
TI  - Total cholesterol and lipoprotein composition are associated with dry eye disease
      in Korean women.
PG  - 84
AB  - BACKGROUND: This study aimed to determine the relationship between dyslipidemia
      and dry eye disease (DED) in a Korean population. METHODS: This population-based 
      study enrolled 5,627 adults (aged >19 years) who were participating in the first 
      year of the fifth annual Korea National Health and Nutrition Examination Survey
      from 2010 to 2011. Clinically diagnosed DED and its symptoms were surveyed, and
      biochemical blood analysis data were collected. Dyslipidemia was defined as any
      of the following: hypercholesterolemia (total cholesterol > 200 mg/dL),
      hypertriglyceridemia (triglyceride > 150 mg/dL), low levels of high-density
      lipoprotein (<40 mg/dL), or high levels of low-density lipoprotein (>100 mg/dL). 
      RESULTS: After adjusting for demographics (age and body mass index), lifestyle
      (smoking, drinking, exercise, and residential district), and medical factors
      (diabetes, hypertension, previous ophthalmic surgery, menopause, and
      rheumatologic disease), elevated serum cholesterol level was found to be
      associated with increased likelihood of DED (odds ratio, 1.77; 95% confidence
      interval, 1.127--2.78) in women. CONCLUSIONS: DED in a Korean population was
      found to be associated with high serum cholesterol levelsThe results of this
      study highlight the significance of eye examinations and independent lipid
      profile monitoring in patients with dyslipidemia because of its possible
      correlation with DED progression.
FAU - Chun, Yoon Hong
AU  - Chun YH
FAU - Kim, Hye Rang
AU  - Kim HR
FAU - Han, Kyungdo
AU  - Han K
FAU - Park, Yong-Gyu
AU  - Park YG
FAU - Song, Ho Jin
AU  - Song HJ
FAU - Na, Kyung-Sun
AU  - Na KS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/04/15 [received]
PHST- 2013/06/05 [accepted]
PHST- 2013/06/05 [aheadofprint]
AID - 1476-511X-12-84 [pii]
AID - 10.1186/1476-511X-12-84 [doi]
PST - aheadofprint
SO  - Lipids Health Dis. 2013 Jun 5;12(1):84.

PMID- 23734826
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1525-6006 (Electronic)
IS  - 1064-1963 (Linking)
DP  - 2013 Jun 4
TI  - The relationship between exercise capacity and masked hypertension in sedentary
      patients with diabetes mellitus.
AB  - Abstract Aim: Although exaggerated blood pressure responses (EBPR) to exercise
      have been related to future hypertension and masked hypertension (MHT), the
      relationship between exercise capacity and MHT remains unclear. A sedentary life 
      style has been related to increased cardiovascular mortality, diabetes mellitus
      (DM), and hypertension. In this study, we aimed to examine the relationship
      between exercise capacity and MHT in sedentary patients with DM. Methods: This
      study included 85 sedentary and normotensive patients with DM. Each patient's
      daily physical activity level was assessed according to the INTERHEART study. All
      patients underwent an exercise treadmill test, and exercise duration and capacity
      were recorded. Blood pressure (BP) was recorded during all exercise stages and BP
      values >/=200/110 mmHg were accepted as EBPR. MHT was diagnosed in patients
      having an office BP <140/90 mmHg and a daytime ambulatory BP >135/85 mmHg.
      Patients were divided into two groups according to their ambulatory BP monitoring
      (MHT and normotensive group). Results: The prevalence of MHT was 28.2%. Exercise 
      duration and capacity were lower in the MHT group than in the normotensive group 
      (p < 0.05) and were negatively correlated with age, HbA1c, mean daytime BP, and
      mean 24 hour BP. Peak exercise systolic BP and the frequency of EBPR were both
      increased in the MHT group (25.0% and 8.1%, respectively, p = 0.03). According to
      a multivariate regression, exercise capacity (OR: 0.61, CI95%: 0.39-0.95, p =
      0.03), EBPR (OR: 9.45, CI95%: 1.72-16.90, p = 0.01), and the duration of DM (OR: 
      0.84, CI95%: 0.71-0.96, p = 0.03) were predictors of MHT. Conclusion: Exercise
      capacity, EBPR, and the duration of DM were predictors of MHT in sedentary
      subjects with DM.
AD  - Department of Cardiology, Necmettin Erbakan University, Meram Faculty of Medicine
      , Konya , Turkey and.
FAU - Akilli, Hakan
AU  - Akilli H
FAU - Kayrak, Mehmet
AU  - Kayrak M
FAU - Aribas, Alpay
AU  - Aribas A
FAU - Tekinalp, Mehmet
AU  - Tekinalp M
FAU - Ayhan, Selim Suzi
AU  - Ayhan SS
FAU - Gunduz, Mehmet
AU  - Gunduz M
FAU - Alibasic, Hajrudin
AU  - Alibasic H
FAU - Altunbas, Gokhan
AU  - Altunbas G
FAU - Yazici, Mehmet
AU  - Yazici M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Clin Exp Hypertens
JT  - Clinical and experimental hypertension (New York, N.Y. : 1993)
JID - 9305929
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.3109/10641963.2013.783047 [doi]
PST - aheadofprint
SO  - Clin Exp Hypertens. 2013 Jun 4.

PMID- 23734776
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1607-842X (Electronic)
IS  - 0891-6934 (Linking)
DP  - 2013 Jun 4
TI  - Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune
      diseases: A meta-analysis.
AB  - Abstract Published data on the association between the IFIH1 rs1990760
      polymorphism and multiple autoimmune diseases are controversial and inconclusive.
      To more precisely estimate the association between the IFIH1 rs1990760
      polymorphism and susceptibility to autoimmune diseases, a meta-analysis was
      conducted. Studies examining the association of the IFIH1 rs1990760 polymorphism 
      with autoimmune diseases were exhaustively searched using PubMed, Web of Science 
      and a review of the references. A total of 19 studies with 26 comparisons
      including 8 type 1 diabetes (T1D), 5 systemic lupus erythematosus (SLE), 5
      Graves' disease (GD), 2 multiple scleorosis (MS), 2 rheumatoid arthritis (RA), 2 
      Hashimoto's thyroiditis (HT), 2 autoimmune Addison's disease (AAD) were available
      for this meta-analysis. Meta-analysis was performed for genotype T/T + T/C
      (dominant model), genotype T/T (recessive model) and T-allele in fixed or
      random-effects models. The overall odds ratios (ORs) and 95% confidence intervals
      (CIs) for T-allele were T1D (OR = 1.184, 95% CI = 1.142-1.229), SLE (OR = 1.143, 
      95% CI = 1.073-1.217), MS (OR = 1.181, 95% CI = 1.062-1.313) and RA (OR = 1.115, 
      95% CI = 1.004-1.239), respectively. For T1D and SLE, significant association was
      observed in the population of European ancestry, but not in the Asian population.
      This meta-analysis demonstrates that the IFIH1 rs1990760 T-allele confers
      susceptibility to T1D, SLE, MS and RA and suggests that the IFIH1 rs1990760
      polymorphism might have no effect on GD and AAD. Our result provides further
      evidence for the notion of common gene underlying multiple autoimmune diseases.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui
      Medical University , 81 Meishan Road, Hefei, Anhui , PR China .
FAU - Cen, Han
AU  - Cen H
FAU - Wang, Wei
AU  - Wang W
FAU - Leng, Rui-Xue
AU  - Leng RX
FAU - Wang, Ting-Yu
AU  - Wang TY
FAU - Pan, Hai-Feng
AU  - Pan HF
FAU - Fan, Yin-Guang
AU  - Fan YG
FAU - Wang, Bin
AU  - Wang B
FAU - Ye, Dong-Qing
AU  - Ye DQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Autoimmunity
JT  - Autoimmunity
JID - 8900070
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.3109/08916934.2013.796937 [doi]
PST - aheadofprint
SO  - Autoimmunity. 2013 Jun 4.

PMID- 23734759
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1557-8518 (Electronic)
IS  - 1540-4196 (Linking)
DP  - 2013 Jun 4
TI  - Metabolic Syndrome, Adiponectin, and Cardiovascular Risk in Spain (The Segovia
      Study): Impact of Consensus Societies Criteria.
AB  - Abstract Background: We aimed to investigate the prevalence of metabolic syndrome
      in rural and urban areas in the province of Segovia, Spain, and its relationship 
      to lifestyle habits, cardiovascular risk, and serum adiponectin concentrations.
      Methods: The study had a cross-sectional design and included 888 individual
      residents in the province of Segovia, Autonomous Community of Castilla-Leon.
      Results: The age/sex standardized prevalence of the metabolic syndrome was by:
      (1) American Heart Association/National Heart Lung and Blood Institute criteria
      (AHA/NHLBI), 17%; (2) International Diabetes Federation (IDF), 24.3%; and (3)
      Consensus Societies/Joint Interim Statement (CS), 27.8%. A high correlation was
      found between the different criteria. No formal education [odds ratio (OR) 6.9
      (2.4-20.2)] and primary education [6.7 (2.8-15.9)] were independently associated 
      with metabolic syndrome. An inverse association with metabolic syndrome was found
      for subjects doing a high level of exercise during work [0.4 (0.2-0.7)] as well
      as those who were mild drinkers [alcohol intake of less than 15 grams/daily, 0.4 
      (0.3-0.8)]. Among subjects with low estimated cardiovascular risk, adiponectin
      levels are higher in those who do not meet criteria of metabolic syndrome. A
      total of 29.7% of subjects meeting CS criteria had >20% 10-year predicted risk of
      cardiovascular disease (CVD) by the Framingham risk score criteria [4.5
      (2.4-8.5)]. Conclusions: Our results show: (1) A higher estimated prevalence of
      metabolic syndrome according to IDF and CS criteria. (2) Low educational level
      was independently associated with metabolic syndrome. A high level of physical
      activity and a daily alcohol intake of less than 15 grams/day were inversely
      associated with metabolic syndrome. (3) Metabolic syndrome increases the
      predicted CVD risk. (4) Adiponectin levels are not inversely related to insulin
      resistance in subjects with high cardiovascular risk and metabolic syndrome.
AD  - 1 Spanish Biomedical Research Centre in Diabetes and Associated Metabolic
      Disorders (CIBERDEM) and Hospital Clinico San Carlos , Madrid, Spain .
FAU - Corbaton-Anchuelo, Arturo
AU  - Corbaton-Anchuelo A
FAU - Martinez-Larrad, Maria Teresa
AU  - Martinez-Larrad MT
FAU - Fernandez-Perez, Cristina
AU  - Fernandez-Perez C
FAU - Vega-Quiroga, Saturio
AU  - Vega-Quiroga S
FAU - Ibarra-Rueda, Jose Maria
AU  - Ibarra-Rueda JM
FAU - Serrano-Rios For The Segovia Insulin Resistance Study Group, Manuel
AU  - Serrano-Rios For The Segovia Insulin Resistance Study Group M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Metab Syndr Relat Disord
JT  - Metabolic syndrome and related disorders
JID - 101150318
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1089/met.2012.0115 [doi]
PST - aheadofprint
SO  - Metab Syndr Relat Disord. 2013 Jun 4.

PMID- 23734746
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 2251-6581 (Print)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013 Jun 4
TI  - The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial
      lipid profile in the patients with type 2 Diabetes mellitus.
PG  - 24
AB  - BACKGROUND: Postprandial hypertriglyceridemia in diabetes mellitus can be
      followed by endothelial dysfunction, impaired vascular compliance and increased
      cardiovascular complications. So focus on better control of postprandial
      hypertriglyceridemia is as important as controlling fasting triglyceride levele
      in type 2 DM. OBJECTIVE: We evaluated the effect of ezetimibe adding to fibrate
      or statin on postprandial hypertriglyceridemia. METHODS: In a randomized
      controlled clinical trial, 47 subjects with type 2 diabetes and
      hypertiglyceridemia were enrolled and divided in three treatment groups including
      Gemfibrozil 1200mg/d + placebo(group A), Ezetimibe10mg/d + Gemfibrozile
      1200mg/d(group B) or Ezetimibe10mg/d + Atorvastatin10mg/d (group C)for a 6- week 
      period. Oral fat loading test were performed in the initiation and also at the
      end of the study and lipid profile and APOB were measured. RESULTS: Fasting and
      postprandial serum triglyceride (TG) decreased significantly with all the three
      treatment groups with no difference between them in the percent of TG reduction. 
      Although serum total cholesterol decreased significantly in all the three groups 
      of treatment its reduction was more prominent in group C(-38.1% +/- 11.2%in group
      C vs. -16.5% +/- 19.6% and -7.2% +/- 10.7% in group B & A respectively, p <
      0.0001 ). Fasting serum HDL increased significantly only by Gemfibrozil (23.4%
      +/- 28.4% vs. 6.4% +/- 18.9% and 1.8% +/- 17.7%, p < 0.05 ). Fasting serum APOB
      was reduced only in ezetimibe containing groups(B &C). CONCLUSION: Adding
      ezetimibe to gemfibrozil has no additional effect on reducing postprandial TG but
      ezetimibe can potentiate the effect of low-dose atorvastatin on lowering TG and
      LDL-c.
FAU - Sharifi, Faranak
AU  - Sharifi F
FAU - Hojeghani, Nima
AU  - Hojeghani N
FAU - Mazloomzadeh, Saeideh
AU  - Mazloomzadeh S
FAU - Shajari, Zahra
AU  - Shajari Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PHST- 2012/10/20 [received]
PHST- 2013/06/04 [accepted]
PHST- 2013/06/04 [aheadofprint]
AID - 2251-6581-12-24 [pii]
AID - 10.1186/2251-6581-12-24 [doi]
PST - aheadofprint
SO  - J Diabetes Metab Disord. 2013 Jun 4;12(1):24.

PMID- 23734571
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1557-9077 (Electronic)
IS  - 1050-7256 (Linking)
DP  - 2013 Jun 4
TI  - SEX RATIO AT BIRTH IS ASSOCIATED WITH FIRST TRIMESTER MATERNAL TSH IN WOMEN
      RECEIVING LEVOTHYROXINE.
AB  - Background: Sex ratio at birth (male out of total alive newborns) is historically
      established at 0.515 and is influenced by numerous factors. It is not known,
      however, whether it is different in maternal thyroid conditions. Our aim was to
      analyze its association with maternal thyroid autoimmunity and first trimester
      TSH. Methods: We performed a retrospective cohort study at a tertiary care
      centre. We studied 167 women receiving pregestational treatment with
      levothyroxine for hypothyroidism or differentiated thyroid carcinoma that gave
      birth to live infants. Women with secondary/tertiary hypothyroidism,
      pregestational diabetes mellitus or multiple pregnancies were excluded.
      Autoimmunity was defined as present/absent and mean first trimester TSH was
      tested both as a quantitative variable and using five predefined categories. The 
      outcome measure was sex ratio at birth. Results: Sex ratio at birth was 0.485,
      not significantly different from expected. Maternal characteristics were similar 
      in mothers of female and male newborns with the exception of mean first trimester
      TSH that was higher in pregnancies of female fetuses (3.27 vs. 2.52 mUI/l, p
      <0.025). Newborn sex differed across predefined TSH categories (p<0.021, with a
      sex ratio of 0.200 (CI95 0.00-0.402) for TSH >=10 mUI/l. A multiple logistic
      regression analysis to predict newborn male sex confirmed maternal mean first
      trimester TSH as the single predictor (OR 0.900, CI95 0.823, 0.984, p <0.020).
      Conclusions: In women under pregestational treatment with levothyroxine, mean
      maternal first trimester TSH is negatively associated with sex ratio at birth.
      This association has not been previously described.
AD  - Hospital de la Santa Creu i Sant Pau, Endocrinology, Sant Antoni Maria Claret
      167, Barcelona, Spain, 08025, 0034935565661 ; iminambres@santpau.cat.
FAU - Minambres, Inka
AU  - Minambres I
FAU - Ovejero, Diana
AU  - Ovejero D
FAU - Garcia-Paterson, Apolonia
AU  - Garcia-Paterson A
FAU - Adelantado, Juan Maria
AU  - Adelantado JM
FAU - Corcoy, Rosa
AU  - Corcoy R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Thyroid
JT  - Thyroid : official journal of the American Thyroid Association
JID - 9104317
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
AID - 10.1089/thy.2012.0530 [doi]
PST - aheadofprint
SO  - Thyroid. 2013 Jun 4.

PMID- 23734470
OWN - NLM
STAT- In-Process
DA  - 20130605
IS  - 1046-7041 (Print)
IS  - 1046-7041 (Linking)
VI  - 24
IP  - 2
DP  - 2013 Spring
TI  - Increasing awareness in African American BSN students of the health risks of
      obesity.
PG  - 40-1
AB  - This paper reports on the perceived effectiveness of a program to increase
      awareness of the health risks of obesity among African-American students. Thirty 
      (n = 30) senior level Bachelor of Science in Nursing students attending a
      Historically Black College and University (HBCU) took a knowledge test, then
      participated in an hour-long educational session on obesity. Following the
      session, the students completed a 10-item post-test to evaluate the effectiveness
      of the program in increasing awareness of obesity as a risk for heart disease and
      diabetes. The findings suggested a need to further educate African-American
      students on the consequences of obesity as well as recommendations to advance the
      science of personal and family risk awareness in nursing students.
AD  - School of Nursing, North Carolina A&T University, Greensboro, NC, USA.
FAU - Williamson, Wanda
AU  - Williamson W
FAU - Kautz, Donald D
AU  - Kautz DD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - ABNF J
JT  - The ABNF journal : official journal of the Association of Black Nursing Faculty
      in Higher Education, Inc
JID - 9112807
SB  - N
EDAT- 2013/06/06 06:00
MHDA- 2013/06/06 06:00
CRDT- 2013/06/06 06:00
PST - ppublish
SO  - ABNF J. 2013 Spring;24(2):40-1.

PMID- 23734358
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 2042-8189 (Electronic)
IS  - 1478-2715 (Linking)
VI  - 43
IP  - 2
DP  - 2013 Jun
TI  - Cystic fibrosis.
PG  - 144-50
LID - 10.4997/JRCPE.2013.212 [doi]
AB  - There are now more adult than paediatric cystic fibrosis (CF) patients and their 
      life expectancy continues to improve. This means that CF patients will be more
      commonly encountered in a variety of hospital settings including fertility
      services, gastrointestinal (GI) clinics, diabetes clinics, surgical wards, and
      acute admissions. Cystic fibrosis units welcome early contact when patients are
      admitted to other units and it is important to have a structured approach to
      their assessment and management.
AD  - HC Rodgers, Adult Scottish CF Service, Respiratory Unit, Western General
      Hospital, Edinburgh, UK. helen.rodgers@luht.scot.nhs.uk.
FAU - Leitch, A E
AU  - Leitch AE
FAU - Rodgers, H C
AU  - Rodgers HC
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - J R Coll Physicians Edinb
JT  - The journal of the Royal College of Physicians of Edinburgh
JID - 101144324
SB  - IM
OTO - NOTNLM
OT  - CF services
OT  - Cystic fibrosis
OT  - bronchiectasis
OT  - lung transplantation
OT  - management
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.4997/JRCPE.2013.212 [doi]
PST - ppublish
SO  - J R Coll Physicians Edinb. 2013 Jun;43(2):144-50. doi: 10.4997/JRCPE.2013.212.

PMID- 23734349
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 2042-8189 (Electronic)
IS  - 1478-2715 (Linking)
VI  - 43
IP  - 2
DP  - 2013 Jun
TI  - Hospital-acquired Clostridium difficile infection among patients with type 2
      diabetes mellitus in acute medical wards.
PG  - 103-7
LID - 10.4997/JRCPE.2013.203 [doi]
AB  - Background: Clostridum difficile (C. difficile) infection is increasingly seen
      among hospitalised patients with type 2 diabetes mellitus but its rate and
      associated risk factors are not known. We aimed to determine the rate and
      characteristics of hospital-acquired C. difficile infection in subjects with type
      2 diabetes mellitus admitted into acute medical wards. Methods: Our prospective
      cross-sectional study involved 159 patients with established type 2 diabetes
      mellitus admitted into acute medical wards who developed a hospital-acquired C.
      difficile infection. Stools were tested for C. difficile toxins using a toxin A/B
      kit and a toxin A kit. Clinical features, laboratory findings, types of
      antibiotics, and use of a proton pump inhibitor were examined for their
      association with the infection. Results: Thirteen subjects were positive for
      toxin A and one for toxin B. Using univariable analysis, we found that patients
      with type 2 diabetes mellitus and hospitalacquired C. difficile infection were
      younger (mean 53.8 years, p=0.02), had diarrhoea and abdominal pain (p=0.001) but
      no fever. Sepsis (p=0.02) and use of a proton pump inhibitor (p=0.01) were more
      commonly implicated as the cause of the infection. Of the various types of
      antibiotics prescribed, carbapenem (28.6% vs 4.1%, p=0.01) and metronidazole
      (42.9% vs 19.3%, p=0.04) were significantly associated with hospitalacquired C.
      difficile infection. Conclusions: Patients with type 2 diabetes mellitus admitted
      into acute medical wards and who developed hospital-acquired C. difficile
      infection have distinct characteristics.
AD  - Yeong Yeh Lee, Department of Medicine, School of Medical Sciences, Universiti
      Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia. justnleeyy@gmail.com.
FAU - Hassan, S A
AU  - Hassan SA
FAU - Rahman, R A
AU  - Rahman RA
FAU - Huda, N
AU  - Huda N
FAU - Wan Bebakar, W M
AU  - Wan Bebakar WM
FAU - Lee, Y Y
AU  - Lee YY
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - J R Coll Physicians Edinb
JT  - The journal of the Royal College of Physicians of Edinburgh
JID - 101144324
SB  - IM
OTO - NOTNLM
OT  - Clostridium difficile
OT  - acute medical wards
OT  - antibiotics
OT  - nosocomial
OT  - type 2 diabetes mellitus
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.4997/JRCPE.2013.203 [doi]
PST - ppublish
SO  - J R Coll Physicians Edinb. 2013 Jun;43(2):103-7. doi: 10.4997/JRCPE.2013.203.

PMID- 23734260
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Women Versus Men with Chronic Atrial Fibrillation: Insights from the Standard
      Versus Atrial Fibrillation spEcific managemenT studY (SAFETY).
PG  - e65795
LID - 10.1371/journal.pone.0065795 [doi]
AB  - BACKGROUND: Gender-based clinical differences are increasingly being identified
      as having significant influence on the outcomes of patients with cardiovascular
      disease (CVD), including atrial fibrillation (AF). OBJECTIVE: To perform detailed
      clinical phenotyping on a cohort of hospitalised patients with chronic forms of
      AF to understand if gender-based differences exist in the clinical presentation, 
      thrombo-embolic risk and therapeutic management of high risk patients
      hospitalised with chronic AF. METHODS: We are undertaking the Standard versus
      Atrial Fibrillation spEcific managemenT studY (SAFETY) - a multi-centre,
      randomised controlled trial of an AF-specific management intervention versus
      usual care. Extensive baseline profiling of recruited patients was undertaken to 
      identify gender-specific differences for risk delineation. RESULTS: We screened
      2,438 patients with AF and recruited 335 into SAFETY. Of these, 48.1% were women 
      who were, on average, 5 years older than their male counterparts. Women and men
      displayed divergent antecedent profiles, with women having a higher
      thrombo-embolic risk but being prescribed similar treatment regimens. More women 
      than men presented to hospital with co-morbid thyroid dysfunction, depression,
      renal impairment and obesity. In contrast, more men presented with coronary
      artery disease (CAD) and/or chronic obstructive pulmonary disease (COPD). Even
      when data was age-adjusted, women were more likely to live alone (odds ratio [OR]
      2.33; 95% confidence interval [CI] 1.47 to 3.69), have non-tertiary education (OR
      2.69; 95% CI 1.61 to 4.48) and be symptomatic (OR 1.93; 95% CI 1.06 to 3.52).
      CONCLUSION: Health care providers should be cognisant of gender-specific
      differences in an attempt to individualise and, hence, optimise the management of
      patients with chronic AF and reduce potential morbidity and mortality.
AD  - Centre of Research Excellence to Reduce Inequality in Heart Disease, Preventative
      Health, Baker IDI Heart and Diabetes Institute, Melbourne, Australia ; Department
      of Epidemiology and Preventative Medicine, Monash University, Melbourne,
      Australia.
FAU - Ball, Jocasta
AU  - Ball J
FAU - Carrington, Melinda J
AU  - Carrington MJ
FAU - Wood, Kathryn A
AU  - Wood KA
FAU - Stewart, Simon
AU  - Stewart S
CN  - SAFETY Investigators
LA  - eng
PT  - Journal Article
DEP - 20130529
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3667075
OID - NLM: PMC3667075
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/14 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/05/29 [epublish]
AID - 10.1371/journal.pone.0065795 [doi]
AID - PONE-D-13-11032 [pii]
PST - epublish
SO  - PLoS One. 2013 May 29;8(5):e65795. doi: 10.1371/journal.pone.0065795. Print 2013.

PMID- 23734259
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Regulation of SIRT1 in Vascular Smooth Muscle Cells from Streptozotocin-Diabetic 
      Rats.
PG  - e65666
LID - 10.1371/journal.pone.0065666 [doi]
AB  - Sirtuins enzymes are a conserved family of nicotinamide adenine dinucleotide
      (NAD)-dependent deacetylases and ADP-ribosyltransferases that mediate responses
      to oxidative stress, fasting and dietary restriction in mammals. Vascular smooth 
      muscle cells (VSMCs) are involved in many mechanisms that regulate vascular
      biology in vivo but the role of SIRT1 has not been explored in much detail.
      Therefore, we investigated the regulation of SIRT1 in cultured VSMCs under
      various stress conditions including diabetes. Sprague-Dawley rats were made
      diabetic by injecting a single dose of streptozotocin (65 mg/Kg), and aortic
      VSMCs were isolated after 4 weeks. Immunocytochemistry showed that SIRT1 was
      localized predominantly in the nucleus, with lower staining in VSMCs from
      STZ-diabetic as compared with normoglycemic rats. Previous diabetes induction in 
      vivo and high glucose concentrations in vitro significantly downregulated SIRT1
      amounts as detected in Western blot assays, whereas TNF-alpha (30 ng/ml)
      stimulation failed to induce significant changes. Because estrogen signaling
      affects several pathways of oxidative stress control, we also investigated SIRT1 
      modulation by 17beta-estradiol. Treatment with the hormone (10 nM) or a selective
      estrogen receptor-alpha agonist decreased SIRT1 levels in VSMCs from
      normoglycemic but not in those from STZ-diabetic animals. 17beta-estradiol
      treatment also enhanced activation of AMP-dependent kinase, which partners with
      SIRT1 in a signaling axis. SIRT1 downregulation by 17beta-estradiol could be
      observed as well in human peripheral blood mononuclear cells, a cell type in
      which SIRT1 downregulation is associated with insulin resistance and subclinical 
      atherosclerosis. These data suggest that SIRT1 protein levels are regulated by
      diverse cellular stressors to a variable extent in VSMCs from diabetic and
      normoglycemic rats, warranting further investigation on SIRT1 as a modulator of
      VSMC activity in settings of vascular inflammation.
AD  - Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 
      Padova, Italy.
FAU - Toniolo, Alice
AU  - Toniolo A
FAU - Warden, Erica Alessia
AU  - Warden EA
FAU - Nassi, Alberto
AU  - Nassi A
FAU - Cignarella, Andrea
AU  - Cignarella A
FAU - Bolego, Chiara
AU  - Bolego C
LA  - eng
PT  - Journal Article
DEP - 20130529
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3667130
OID - NLM: PMC3667130
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
PHST- 2012/08/31 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/05/29 [epublish]
AID - 10.1371/journal.pone.0065666 [doi]
AID - PONE-D-12-27087 [pii]
PST - epublish
SO  - PLoS One. 2013 May 29;8(5):e65666. doi: 10.1371/journal.pone.0065666. Print 2013.

PMID- 23734252
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Obstructive sleep apnea is a predictor of abnormal glucose metabolism in
      chronically sleep deprived obese adults.
PG  - e65400
LID - 10.1371/journal.pone.0065400 [doi]
AB  - CONTEXT: Sleep abnormalities, including obstructive sleep apnea (OSA), have been 
      associated with insulin resistance. OBJECTIVE: To determine the relationship
      between sleep, including OSA, and glucose parameters in a prospectively assembled
      cohort of chronically sleep-deprived obese subjects. DESIGN: Cross-sectional
      evaluation of a prospective cohort study. SETTING: Tertiary Referral Research
      Clinical Center. MAIN OUTCOME MEASURES: Sleep duration and quality assessed by
      actigraphy, sleep diaries and questionnaires, OSA determined by a portable
      device; glucose metabolism assessed by oral glucose tolerance test (oGTT), and
      HbA1c concentrations in 96 obese individuals reporting sleeping less than 6.5 h
      on a regular basis. RESULTS: Sixty % of subjects had an abnormal respiratory
      disturbance index (RDI>/=5) and 44% of these subjects had abnormal oGTT results. 
      Severity of OSA as assessed by RDI score was associated with fasting glucose (R =
      0.325, p = 0.001) and fasting insulin levels (rho = 0.217, p = 0.033). Subjects
      with moderate to severe OSA (RDI>15) had higher glucose concentrations at 120 min
      than those without OSA (RDI<5) (p = 0.017). Subjects with OSA also had
      significantly higher concentrations of plasma ACTH (p = 0.009). Several
      pro-inflammatory cytokines were higher in subjects with OSA (p<0.050). CRP levels
      were elevated in this sample, suggesting increased cardiovascular risk.
      CONCLUSIONS: OSA is associated with impaired glucose metabolism in obese, sleep
      deprived individuals. Since sleep apnea is common and frequently undiagnosed,
      health care providers should be aware of its occurrence and associated risks.
      TRIAL REGISTRATION: This study was conducted under the NIDDK protocol 06-DK-0036 
      and is listed in ClinicalTrials.gov NCT00261898.
AD  - Section on Neuroendocrinology of Obesity, National Institute of Diabetes,
      Digestive, and Kidney Disease, Bethesda, Maryland, United States of America.
FAU - Cizza, Giovanni
AU  - Cizza G
FAU - Piaggi, Paolo
AU  - Piaggi P
FAU - Lucassen, Eliane A
AU  - Lucassen EA
FAU - de Jonge, Lilian
AU  - de Jonge L
FAU - Walter, Mary
AU  - Walter M
FAU - Mattingly, Megan S
AU  - Mattingly MS
FAU - Kalish, Heather
AU  - Kalish H
FAU - Csako, Gyorgy
AU  - Csako G
FAU - Rother, Kristina I
AU  - Rother KI
CN  - Sleep Extension Study Group
LA  - eng
PT  - Journal Article
DEP - 20130529
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3667085
OID - NLM: PMC3667085
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/25 [received]
PHST- 2013/05/01 [accepted]
PHST- 2013/05/29 [epublish]
AID - 10.1371/journal.pone.0065400 [doi]
AID - PONE-D-12-33097 [pii]
PST - epublish
SO  - PLoS One. 2013 May 29;8(5):e65400. doi: 10.1371/journal.pone.0065400. Print 2013.

PMID- 23734095
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 7
DP  - 2013
TI  - Ion channels in the central regulation of energy and glucose homeostasis.
PG  - 85
LID - 10.3389/fnins.2013.00085 [doi]
AB  - Ion channels are critical regulators of neuronal excitability and synaptic
      function in the brain. Recent evidence suggests that ion channels expressed by
      neurons within the brain are responsible for regulating energy and glucose
      homeostasis. In addition, the central effects of neurotransmitters and hormones
      are at least in part achieved by modifications of ion channel activity. This
      review focuses on ion channels and their neuronal functions followed by a
      discussion of the identified roles for specific ion channels in the central
      pathways regulating food intake, energy expenditure, and glucose balance.
AD  - Division of Hypothalamic Research, Department of Internal Medicine, The
      University of Texas Southwestern Medical Center Dallas, TX, USA.
FAU - Sohn, Jong-Woo
AU  - Sohn JW
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC3661948
OID - NLM: PMC3661948
OTO - NOTNLM
OT  - GABAA receptors
OT  - K+ channels
OT  - TRPC channels
OT  - diabetes mellitus
OT  - ionotropic glutamate receptors (iGluRs)
OT  - obesity
OT  - patch clamp electrophysiology
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/29 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/23 [epublish]
AID - 10.3389/fnins.2013.00085 [doi]
PST - epublish
SO  - Front Neurosci. 2013 May 23;7:85. doi: 10.3389/fnins.2013.00085. Print 2013.

PMID- 23734081
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1090-0535 (Electronic)
IS  - 1090-0535 (Linking)
VI  - 19
DP  - 2013
TI  - Age-dependent alteration of intraocular soluble heparan sulfate levels and its
      implications for proliferative diabetic retinopathy.
PG  - 1125-31
AB  - PURPOSE: To assess the relationship between intraocular soluble heparan sulfate
      (HS) concentration and age in subjects with and without diabetic retinopathy.
      METHODS: Vitreous from subjects with idiopathic maculopathies (n=17), i.e.,
      macula hole or epiretinal membrane, or nonproliferative diabetic retinopathy
      (non-PDR; n=5) and aqueous humor from subjects with PDR (n=16), non-PDR (n=7), or
      cataracts (n=15) was collected. The levels of HS and vascular endothelial growth 
      factor (VEGF) were measured using enzyme-linked immunosorbent assay.
      Concentrations of sulfated glycosaminoglycan were determined through
      dimethylmethylene blue-based assay. The effect of the vitreal HS level on the
      binding of exogenous VEGF to surface-bound heparin was determined in vitro.
      RESULTS: The level of HS in vitreous samples from subjects with idiopathic
      maculopathies increased concomitantly with age (p=0.020, R (2)=0.327). Meanwhile,
      HS levels in aqueous humor were lower in PDR subjects than in non-PDR (p=0.003)
      and cataract subjects (p=0.007). However, the PDR subjects were significantly
      younger than the non-PDR subjects (p<0.001) or cataract subjects (p<0.001). When 
      the three groups were controlled for age, the levels of HS glycosaminoglycans
      were no longer different between the three (p=0.247). The increasing level of HS 
      or sulfated glycosaminoglycan in the vitreous was associated with its increased
      inhibitory effect on interaction between VEGF and surface heparin in vitro
      (p=0.014, R (2)=0.377). CONCLUSIONS: The HS level of the intraocular fluid
      increased with age. The possible link between low HS in intraocular fluid and
      increased localization of VEGF at the retinal surface may provide one explanation
      for the higher susceptibility of younger subjects with diabetes mellitus to
      developing PDR.
AD  - Nagoya University School of Medicine, Department of Ophthalmology, Showa-ku,
      Nagoya, Japan.
FAU - Nishiguchi, Koji M
AU  - Nishiguchi KM
FAU - Ushida, Hiroaki
AU  - Ushida H
FAU - Tomida, Daisuke
AU  - Tomida D
FAU - Kachi, Shu
AU  - Kachi S
FAU - Kondo, Mineo
AU  - Kondo M
FAU - Terasaki, Hiroko
AU  - Terasaki H
LA  - eng
PT  - Journal Article
DEP - 20130529
PL  - United States
TA  - Mol Vis
JT  - Molecular vision
JID - 9605351
SB  - IM
PMC - PMC3669540
OID - NLM: PMC3669540
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/30 [received]
PHST- 2013/05/27 [accepted]
PHST- 2013/05/29 [epublish]
PST - epublish
SO  - Mol Vis. 2013 May 29;19:1125-31. Print 2013.

PMID- 23734074
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1090-0535 (Electronic)
IS  - 1090-0535 (Linking)
VI  - 19
DP  - 2013
TI  - Retinal O-linked N-acetylglucosamine protein modifications: implications for
      postnatal retinal vascularization and the pathogenesis of diabetic retinopathy.
PG  - 1047-59
AB  - PURPOSE: Hyperglycemia activates several metabolic pathways, including the
      hexosamine biosynthetic pathway. Uridine diphosphate N-acetylglucosamine (GlcNAc)
      is the product of the hexosamine biosynthetic pathway and the substrate for
      O-linked GlcNAc (O-GlcNAc) modification. This modification affects a wide range
      of proteins by altering their activity, cellular localization, and/or protein
      interactions. However, the role O-GlcNAcylation may play in normal postnatal
      retinal vascular development and in the ocular complications of diabetes,
      including diabetic retinopathy, requires further investigation. METHODS: The
      total levels of O-GlcNAc-modified proteins were evaluated by western blot
      analysis of lysates prepared from retinas obtained at different days during
      postnatal retinal vascularization and oxygen-induced ischemic retinopathy.
      Similar experiments were performed with retinal lysate prepared from diabetic
      Ins2(Akita/+) mice with different durations of diabetes and retinal vascular
      cells cultured under various glucose conditions. The localization of
      O-GlcNAc-modified proteins in the retinal vasculature was confirmed by
      immunofluorescence staining. The impact of altered O-GlcNAcylation on the
      migration of retinal vascular cells was determined using scratch wound and
      transwell migration assays. RESULTS: We detected an increase in protein
      O-GlcNAcylation during mouse postnatal retinal vascularization and aging, in part
      through the regulation of the enzymes that control this modification. The study
      of the diabetic Ins2(Akita/+) mouse retina showed an increase in the O-GlcNAc
      modification of retinal proteins. We also observed an increase in retinal
      O-GlcNAcylated protein levels during the neovascularization phase of
      oxygen-induced ischemic retinopathy. Our fluorescence microscopy data confirmed
      that the alterations in retinal O-GlcNAcylation are similarly represented in the 
      retinal vasculature and in retinal pericytes and endothelial cells. Particularly,
      the migration of retinal pericytes, but not retinal endothelial cells, was
      attenuated by increased O-GlcNAc modification. CONCLUSIONS: The O-GlcNAc
      modification pattern changes during postnatal retinal vascular development and
      neovascularization, and its dysregulation under hyperglycemia and/or ischemia may
      contribute to the pathogenesis of the diabetic retinopathy and retinal
      neovascularization.
AD  - Department of Ophthalmology and Visual Sciences, University of Wisconsin School
      of Medicine and Public Health, Madison,WI.
FAU - Gurel, Zafer
AU  - Gurel Z
FAU - Sieg, Kelsey M
AU  - Sieg KM
FAU - Shallow, Keegan D
AU  - Shallow KD
FAU - Sorenson, Christine M
AU  - Sorenson CM
FAU - Sheibani, Nader
AU  - Sheibani N
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - United States
TA  - Mol Vis
JT  - Molecular vision
JID - 9605351
SB  - IM
PMC - PMC3668662
OID - NLM: PMC3668662
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/15 [received]
PHST- 2013/05/18 [accepted]
PHST- 2013/05/21 [epublish]
PST - epublish
SO  - Mol Vis. 2013 May 21;19:1047-59. Print 2013.

PMID- 23734033
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1488-2329 (Electronic)
IS  - 0820-3946 (Linking)
DP  - 2013 Jun 3
TI  - Risks and benefits of intensive blood pressure lowering in patients with type 2
      diabetes.
FAU - Rabi, Doreen M
AU  - Rabi DM
FAU - Padwal, Raj
AU  - Padwal R
FAU - Tobe, Sheldon W
AU  - Tobe SW
FAU - Gilbert, Richard E
AU  - Gilbert RE
FAU - Leiter, Lawrence A
AU  - Leiter LA
FAU - Quinn, Robert R
AU  - Quinn RR
FAU - Khan, Nadia
AU  - Khan N
CN  - Canadian Hypertensive Education Program and Canadian Diabetes Association
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - CMAJ
JT  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale
      canadienne
JID - 9711805
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - cmaj.120112 [pii]
AID - 10.1503/cmaj.120112 [doi]
PST - aheadofprint
SO  - CMAJ. 2013 Jun 3.

PMID- 23734031
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1488-2329 (Electronic)
IS  - 0820-3946 (Linking)
DP  - 2013 Jun 3
TI  - US approves "new class" of diabetes drug, under review in Canada.
FAU - Lange-Chenier, Hanna
AU  - Lange-Chenier H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - CMAJ
JT  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale
      canadienne
JID - 9711805
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - cmaj.109-4483 [pii]
AID - 10.1503/cmaj.109-4483 [doi]
PST - aheadofprint
SO  - CMAJ. 2013 Jun 3.

PMID- 23733961
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
DP  - 2013 Jun 3
TI  - Molecular basis for the role of glucokinase regulatory protein as the allosteric 
      switch for glucokinase.
AB  - Glucokinase (GK) is a monomeric allosteric enzyme and plays a pivotal role in
      blood glucose homeostasis. GK is regulated by GK regulatory protein (GKRP), and
      indirectly by allosteric effectors of GKRP. Despite the critical roles of GK and 
      GKRP, the molecular basis for the allosteric regulation mechanism of GK by GKRP
      remains unclear. We determined the crystal structure of Xenopus GK and GKRP
      complex in the presence of fructose-6-phosphate at 2.9 A. GKRP binds to a
      super-open conformation of GK mainly through hydrophobic interaction, inhibiting 
      the GK activity by locking a small domain of GK. We demonstrate the molecular
      mechanism for the modulation of GK activity by allosteric effectors of GKRP.
      Importantly, GKRP releases GK in a sigmoidal manner in response to glucose
      concentration by restricting a structural rearrangement of the GK small domain
      via a single ion pair. We find that GKRP acts as an allosteric switch for GK in
      blood glucose control by the liver.
AD  - Department of Biological Sciences and Graduate School of Nanoscience and
      Technology, Korea Advanced Institute of Science and Technology, Daejeon 305-701, 
      Korea.
FAU - Choi, Jung Min
AU  - Choi JM
FAU - Seo, Moon-Hyeong
AU  - Seo MH
FAU - Kyeong, Hyun-Ho
AU  - Kyeong HH
FAU - Kim, Eunkyung
AU  - Kim E
FAU - Kim, Hak-Sung
AU  - Kim HS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
OTO - NOTNLM
OT  - hexokinase
OT  - sigmoidicity I conformational restriction
OT  - type 2 diabetes
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 1300457110 [pii]
AID - 10.1073/pnas.1300457110 [doi]
PST - aheadofprint
SO  - Proc Natl Acad Sci U S A. 2013 Jun 3.

PMID- 23733915
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1941-3297 (Electronic)
IS  - 1941-3289 (Linking)
DP  - 2013 Jun 3
TI  - The Failing Heart of Patients with Type 2 Diabetes Can Adapt to Extreme
      Short-Term Increases in Circulating Lipids and Does Not Display Features of Acute
      Myocardial Lipotoxicity.
AB  - BACKGROUND: -Circulating lipid levels and myocardial lipid content (MyLC) is
      increased in type 2 diabetes (T2D). This may cause a state of lipotoxicity that
      compromises left ventricular function and aggravate heart failure. We
      investigated the relationship between circulating lipid levels, MyLC, and cardiac
      function together with the acute cardiac effects of high as opposed to low
      circulating free fatty acid (FFA) and triglyceride (TG) levels in patients with
      T2D and heart failure. METHODS AND RESULTS: -Eighteen patients underwent 8-hour
      intralipid/heparin-infusion (high-FFA) and hyperinsulinemic-euglycemic clamping
      (low-FFA) in a randomized cross-over-designed study. We applied
      MR-proton-spectroscopy to measure MyLC. Cardiac function was assessed by advanced
      echocardiography, cardiopulmonary exercise, and MR imaging. MyLC correlated
      positively with circulating TG (r=0.47, r2=0.22, p=0.003) and FFA (r=0.45,
      r2=0.20, p=0.001) levels and inversely with left ventricular ejection fraction
      (LVEF) (r=-0.54, r2=0.29, p=0.004). Circulating FFA concentrations differed
      between study arms (0.05+/-0.04mmol/L (low-FFA) vs 1.04+/-0.27mmol/L (high-FFA), 
      p<0.001) and MyLC increased from 0.78+/-0.59% (low-FFA) to 1.16+/-0.73%
      (high-FFA) (p<0.01). Resting LVEF and global strain did not differ between high- 
      and low-FFA, whereas resting systolic mitral plane velocity (S'max) was highest
      during high-FFA (3.6+/-0.8cm/s (low-FFA) vs. 3.8+/-0.7cm/s (high-FFA), p=0.02).
      Peak exercise capacity and oxygen consumption did not differ between the study
      arms, and neither did post exercise measurements of LVEF, global strain, and
      S'max. CONCLUSIONS: -Our findings indicate that the failing heart of patients
      with T2D can adapt to short-term extreme changes in circulating substrates and
      does not display features of acute myocardial lipotoxicity. Clinical Trial
      Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01192373.
AD  - 1Aarhus University Hospital, Aarhus, Denmark.
FAU - Nielsen, Roni
AU  - Nielsen R
FAU - Norrelund, Helene
AU  - Norrelund H
FAU - Kampmann, Ulla
AU  - Kampmann U
FAU - Kim, Won Yong
AU  - Kim WY
FAU - Ringgaard, Steffen
AU  - Ringgaard S
FAU - Schar, Michael
AU  - Schar M
FAU - Moller, Niels
AU  - Moller N
FAU - Botker, Hans Erik
AU  - Botker HE
FAU - Wiggers, Henrik
AU  - Wiggers H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Circ Heart Fail
JT  - Circulation. Heart failure
JID - 101479941
OTO - NOTNLM
OT  - contrast echocardiography
OT  - heart failure
OT  - left ventricular function
OT  - magnetic resonance spectroscopy
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - CIRCHEARTFAILURE.113.000187 [pii]
AID - 10.1161/CIRCHEARTFAILURE.113.000187 [doi]
PST - aheadofprint
SO  - Circ Heart Fail. 2013 Jun 3.

PMID- 23733895
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1479-6813 (Electronic)
IS  - 0952-5041 (Linking)
DP  - 2013 Jun 3
TI  - Why is Type 1 Diabetes Increasing?
AB  - A series of studies have reported a constant global rise in the incidence of type
      1 diabetes. Epidemiological and immunological studies have demonstrated that
      environmental factors may influence the pathogenesis, leading to a cell-mediated 
      pancreatic beta cell destruction associated with humoral immunity. The search for
      the triggering factor(s) has been going on for the past century and yet it is
      still unknown. This review provides an overview of some of the most well-known
      theories found in the literature: hygiene, viral, vitamin D deficiency, breast
      milk, and cow's milk hypotheses. Although the hygiene hypothesis appears to be
      the most promising, positive evidence from animal, human and epidemiological
      studies precludes us from completely discarding any of the other hypotheses.
      Moreover, due to contrasting evidence in the literature, a single factor is
      unlikely to cause an increase in diabetes all over the world; which suggests that
      a multifactorial process might be involved. Although the immunological mechanisms
      are still unclear, there seems to be some overlap between the various hypotheses.
      It is thought that the emphasis should be shifted from a single to a
      multifactorial process, and perhaps consider the 'balance shift' model as a
      possible explanation for the rise in incidence in type 1 diabetes.
AD  - F Egro, Department of Cellular and Molecular Medicine, University of Bristol,
      Bristol, United Kingdom.
FAU - Egro, Francesco Maria
AU  - Egro FM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - J Mol Endocrinol
JT  - Journal of molecular endocrinology
JID - 8902617
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - JME-13-0067 [pii]
AID - 10.1530/JME-13-0067 [doi]
PST - aheadofprint
SO  - J Mol Endocrinol. 2013 Jun 3.

PMID- 23733851
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1943-2631 (Electronic)
IS  - 0016-6731 (Linking)
VI  - 194
IP  - 2
DP  - 2013 Jun
TI  - Autophagic processes in yeast: mechanism, machinery and regulation.
PG  - 341-61
LID - 10.1534/genetics.112.149013 [doi]
AB  - Autophagy refers to a group of processes that involve degradation of cytoplasmic 
      components including cytosol, macromolecular complexes, and organelles, within
      the vacuole or the lysosome of higher eukaryotes. The various types of autophagy 
      have attracted increasing attention for at least two reasons. First, autophagy
      provides a compelling example of dynamic rearrangements of subcellular membranes 
      involving issues of protein trafficking and organelle identity, and thus it is
      fascinating for researchers interested in questions pertinent to basic cell
      biology. Second, autophagy plays a central role in normal development and cell
      homeostasis, and, as a result, autophagic dysfunctions are associated with a
      range of illnesses including cancer, diabetes, myopathies, some types of
      neurodegeneration, and liver and heart diseases. That said, this review focuses
      on autophagy in yeast. Many aspects of autophagy are conserved from yeast to
      human; in particular, this applies to the gene products mediating these pathways 
      as well as some of the signaling cascades regulating it, so that the information 
      we relate is relevant to higher eukaryotes. Indeed, as with many cellular
      pathways, the initial molecular insights were made possible due to genetic
      studies in Saccharomyces cerevisiae and other fungi.
AD  - Department of Cell Biology, University Medical Center Utrecht, 3584 CX Utrecht,
      The Netherlands.
FAU - Reggiori, Fulvio
AU  - Reggiori F
FAU - Klionsky, Daniel J
AU  - Klionsky DJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Genetics
JT  - Genetics
JID - 0374636
SB  - IM
PMC - PMC3664846
OID - NLM: PMC3664846 [Available on 06/01/14]
OTO - NOTNLM
OT  - autophagy
OT  - macroautophagy
OT  - membrane
OT  - organelle
OT  - protein degradation
OT  - protein trafficking
OT  - stress
OT  - vacuole
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PMCR- 2014/06/01 00:00
AID - 194/2/341 [pii]
AID - 10.1534/genetics.112.149013 [doi]
PST - ppublish
SO  - Genetics. 2013 Jun;194(2):341-61. doi: 10.1534/genetics.112.149013.

PMID- 23733741
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 2047-4881 (Electronic)
IS  - 2047-4873 (Linking)
DP  - 2013 Jun 3
TI  - Red flags for persistent or worsening anxiety and depression after an acute
      cardiac event: a 6-month longitudinal study in regional and rural Australia.
AB  - BACKGROUND: While early symptoms of anxiety and depression resolve for many
      patients soon after an acute cardiac event, the persistence or worsening of
      symptoms indicates increased mortality risk. It is therefore important to
      identify the predictors, or red flags, of persistent or worsening anxiety and
      depression symptoms. Most previous research has focussed on metropolitan
      patients, hence the need for studies of regional and rural dwellers. METHOD: In
      this study, 160 cardiac patients consecutively admitted to two hospitals in
      regional Victoria, Australia, were interviewed in hospital and 2 and 6 months
      after discharge. Anxiety and depression were assessed using the Hospital Anxiety 
      and Depression Scale. Growth mixture modelling was used to identify the
      trajectories of anxiety and depression over the 6 months after the acute event,
      and post-hoc tests identified predictors of persistent or worsening symptoms.
      RESULTS: For both anxiety and depression, three common symptom trajectories were 
      identified. Inhospital anxiety symptoms tended to persist over time, whereas
      inhospital depression symptoms resolved for some patients and worsened for
      others. A mental health history, younger age, smoking, financial stress, poor
      self-rated health, and social isolation were red flags for persistent anxiety and
      worsening depression. Additionally, diabetes, and other comorbidities were red
      flags for persistent anxiety. CONCLUSIONS: The results highlight several
      potential red flags for increased risk of persistent anxiety or worsening
      depressive symptoms after a cardiac event, including demographic, psychosocial,
      and behavioural indicators. These red flags could assist with identification of
      at-risk patients on admission to or discharge from hospital, thereby enabling
      targeting of interventions.
AD  - Heart Research Centre, Melbourne, VIC, Australia.
FAU - Murphy, Barbara
AU  - Murphy B
FAU - Ludeman, Deborah
AU  - Ludeman D
FAU - Elliott, Peter
AU  - Elliott P
FAU - Judd, Fiona
AU  - Judd F
FAU - Humphreys, John
AU  - Humphreys J
FAU - Edington, John
AU  - Edington J
FAU - Jackson, Anthony
AU  - Jackson A
FAU - Worcester, Marian
AU  - Worcester M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Eur J Prev Cardiol
JT  - European journal of preventive cardiology
JID - 101564430
OTO - NOTNLM
OT  - Anxiety
OT  - coronary heart disease
OT  - depression
OT  - risk factors
OT  - screening
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 2047487313493058 [pii]
AID - 10.1177/2047487313493058 [doi]
PST - aheadofprint
SO  - Eur J Prev Cardiol. 2013 Jun 3.

PMID- 23733671
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1559-0283 (Electronic)
IS  - 1085-9195 (Linking)
DP  - 2013 Jun 4
TI  - Profiling Deleterious Non-synonymous SNPs of Smoker's Gene CYP1A1.
AB  - CYP1A1 gene belongs to the cytochrome P450 family and is known better as smokers'
      gene due to its hyperactivation as a consequence of long term smoking. The
      expression of CYP1A1 induces polycyclic aromatic hydrocarbon production in the
      lungs, which when over expressed, is known to cause smoking related diseases,
      such as cardiovascular pathologies, cancer, and diabetes. Single nucleotide
      polymorphisms (SNPs) are the simplest form of genetic variations that occur at a 
      higher frequency, and are denoted as synonymous and non-synonymous SNPs on the
      basis of their effects on the amino acids. This study adopts a systematic in
      silico approach to predict the deleterious SNPs that are associated with disease 
      conditions. It is inferred that four SNPs are highly deleterious, among which the
      SNP with rs17861094 is commonly predicted to be harmful by all tools. Hydrophobic
      (isoleucine) to hydrophilic (serine) amino acid variation was observed in the
      candidate gene. Hence, this investigation aims to characterize a candidate gene
      from 159 SNPs of CYP1A1.
AD  - School of Biosciences and Technology, VIT University, Vellore, 632 014, Tamil
      Nadu, India.
FAU - Sai Ramesh, A
AU  - Sai Ramesh A
FAU - Khan, Imran
AU  - Khan I
FAU - Farhan, Md
AU  - Farhan M
FAU - Thiagarajan, Padma
AU  - Thiagarajan P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Cell Biochem Biophys
JT  - Cell biochemistry and biophysics
JID - 9701934
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1007/s12013-013-9671-z [doi]
PST - aheadofprint
SO  - Cell Biochem Biophys. 2013 Jun 4.

PMID- 23733658
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1718-4304 (Electronic)
IS  - 0896-8608 (Linking)
DP  - 2013 Jun 3
TI  - SEVENTEEN YEARS' EXPERIENCE OF PERITONEAL DIALYSIS IN IRAN: FIRST OFFICIAL REPORT
      OF THE IRANIAN PERITONEAL DIALYSIS REGISTRY.
AB  - BACKGROUND: To facilitate planning, national renal registries provide reliable
      and up-to-date information on numbers of patients with end-stage renal disease
      (ESRD), developing trends, treatment modalities, and outcomes. To that end, the
      present publication represents the first official report from Iranian Peritoneal 
      Dialysis Registry. METHODS: The prevalence, demographics, and clinical
      characteristics of patients on peritoneal dialysis (PD) were collected from all
      PD centers throughout the country. RESULTS: By the end of 2009, the prevalence of
      ESRD was 507 per million population in Iran. The most common renal replacement
      modality was hemodialysis (51.2%), followed by kidney transplantation (44.7%),
      and then PD (4.1%). The mean age of PD patients was 46 years, and the most common
      causes of ESRD were diabetes (33.5%), hypertension (24.4%), and
      glomerulonephritis (8.2%). Overall patient mortality was 25%, with cardiac events
      (46%), cerebral stroke (10%), and infection (8%) being the main causes of death. 
      The 1-, 3-, and 5-year survivals were 89%, 64%, and 49% respectively. The most
      common cause of dropout was peritonitis (17.6%). Staphylococcus
      (coagulase-negative and S. aureus) was the most prevalent causative organism in
      peritonitis episodes; however, in more than 50% of episodes, a sterile culture
      was reported. Mean baseline serum hemoglobin and albumin were 10.7 g/dL and 3.6
      g/dL respectively. CONCLUSIONS: Our registry results, representing the second
      largest report of PD in the Middle East, is almost comparable to available
      regional data. We hope that, in future, we can improve our shortcomings and
      lessen the gap with developed countries.
AD  - Division of Nephrology, Shariati Hospital, and Nephrology Research Center, Tehran
      University of Medical Sciences, Tehran, Iran, Islamic Republic of.
FAU - Najafi, Iraj
AU  - Najafi I
FAU - Alatab, Sudabeh
AU  - Alatab S
FAU - Atabak, Shahnaz
AU  - Atabak S
FAU - Nouri Majelan, Nader
AU  - Nouri Majelan N
FAU - Sanadgol, Hoshang
AU  - Sanadgol H
FAU - Makhdoomi, Khadijeh
AU  - Makhdoomi K
FAU - Ardalan, Mohammad Reza
AU  - Ardalan MR
FAU - Azmandian, Jalal
AU  - Azmandian J
FAU - Shojaee, Abbas
AU  - Shojaee A
FAU - Keshvari, Amir
AU  - Keshvari A
FAU - Hosseini, Mostafa
AU  - Hosseini M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Perit Dial Int
JT  - Peritoneal dialysis international : journal of the International Society for
      Peritoneal Dialysis
JID - 8904033
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - pdi.2012.00054 [pii]
AID - 10.3747/pdi.2012.00054 [doi]
PST - aheadofprint
SO  - Perit Dial Int. 2013 Jun 3.

PMID- 23733596
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
DP  - 2013 Jun 4
TI  - L-cysteine and hydrogen sulfide increase PIP3 and AMPK/PPARgamma expression and
      decrease ROS and vascular inflammation markers in high glucose treated human U937
      monocytes.
LID - 10.1002/jcb.24578 [doi]
AB  - Diabetic patients have lower blood levels of L-cysteine (LC) and hydrogen sulfide
      (H2 S) and a higher incidence of vascular inflammation. This study examined
      whether impaired LC or H2 S levels affect vascular inflammation markers in
      diabetes. Human U937 monocytic cells were treated with high-glucose (HG, 25 mM,
      20 h) in the presence or absence of LC (100, 500, or 1000 microM, an endogenous
      precursor of H2 S) or Na2 S (5 or 25 microM, an exogenous source of H2 S). Both
      LC and Na2 S supplementation decreased intracellular ROS production and increased
      cellular PIP3 (phosphatidylinositol-3,4,5-trisphosphate) in HG-exposed cells. The
      effect of LC on PIP3 was prevented by propargylglycine, an inhibitor of
      cystathionine-gamma-lyase (CSE) that catalyzes H2 S formation from LC. Signal
      silencing studies with CSE siRNA also showed the inhibition of H2 S formation and
      PIP3 upregulation in LC-supplemented CSE knockdown cells exposed to HG. This
      demonstrates that H2 S plays a role in mediating the effect of LC on increased
      PIP3. Using the PI3K specific inhibitor LY294002, this study demonstrated that
      PI3K activation mediates the effect of LC and Na2 S on PIP3 upregulation. Results
      showed that supplementation with LC and Na2 S reduced NF-kappaB phosphorylation
      and the secretion of TNF-alpha, MCP-1, IL-8, IL-1beta, and IP-10. Treatment with 
      LC (500 microM), Na2 S (25 microM), and PIP3 (5 nM) increased the AMPK
      phosphorylation and PPARgamma expression in cells exposed to HG. This study
      reports for the first time a novel molecular mechanism by which Na2 S or LC
      supplementation can lower oxidative stress and various markers of vascular
      inflammation in diabetes. J. Cell. Biochem. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Pediatrics, Louisiana State University Health Sciences Center,
      Shreveport, LA, 71103.
FAU - Manna, Prasenjit
AU  - Manna P
FAU - Jain, Sushil K
AU  - Jain SK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/03/15 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/04/18 [accepted]
AID - 10.1002/jcb.24578 [doi]
PST - aheadofprint
SO  - J Cell Biochem. 2013 Jun 4. doi: 10.1002/jcb.24578.

PMID- 23733546
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1099-0461 (Electronic)
IS  - 1095-6670 (Linking)
DP  - 2013 Jun 3
TI  - Angiotensin-Converting Enzyme Inhibition and Angiotensin AT1 Receptor Blockade
      Downregulate Angiotensin-Converting Enzyme Expression and Attenuate Renal Injury 
      in Streptozotocin-Induced Diabetic Rats.
LID - 10.1002/jbt.21500 [doi]
AB  - Angiotensin-converting enzyme (ACE) is upregulated in the diabetic kidney and
      contributes to renal injury. This study investigates the possible beneficial
      effects of the ACE inhibitor (ACEI), enalapril and the AT1 receptor blocker
      (ARB), valsartan, on renal ACE expression, renal structure, and function in
      streptozotocin (STZ)-induced diabetic rats. Male Wistar rats were allocated into 
      four groups: control, STZ-diabetic rats, and STZ-diabetic rats treated with
      either enalapril (10 mg/kg/day) or valsartan (50 mg/kg/day) for 8 weeks.
      Enalapril and valsartan reduced renal ACE mRNA and protein expression, Na+ /K+
      -ATPase activity, oxidative stress, and serum transforming growth factor-beta1
      levels compared to the diabetic group. Both treatments normalized renal
      nitrate/nitrite levels and ameliorated the observed histopathological changes. In
      conclusion, ACE downregulation by ACEI and ARB indicates that angiotensin II
      upregulates ACE through AT1 receptor. Prevention of diabetes-induced changes in
      ACE expression and Na+ /K+ -ATPase activity could be a new explanation of the
      renoprotective effects of ACEIs and ARBs.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
FAU - Motawi, Tarek K
AU  - Motawi TK
FAU - El-Maraghy, Shohda A
AU  - El-Maraghy SA
FAU - Senousy, Mahmoud A
AU  - Senousy MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - J Biochem Mol Toxicol
JT  - Journal of biochemical and molecular toxicology
JID - 9717231
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/02/28 [received]
PHST- 2013/04/28 [revised]
PHST- 2013/05/03 [accepted]
AID - 10.1002/jbt.21500 [doi]
PST - aheadofprint
SO  - J Biochem Mol Toxicol. 2013 Jun 3. doi: 10.1002/jbt.21500.

PMID- 23733525
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 Jun 5
TI  - Imaging of the Parafoveal Capillary Network in Diabetes.
AB  - The retinal vasculature is an extremely complex system that is adapted to support
      the metabolic demands of the retinal structures, but on the other hand maintain
      the optimal optical qualities of this tissue. Through histological studies and
      clinical studies using fluorescein angiography we have learned a lot about the
      retinal vasculature in its physiological state and in different diseases, but
      both of these study methods have serious limitations that limit their extensive
      application in healthy subjects or in patients with early disease. In this
      current review we will present early observations about the retinal vasculature
      from several novel noninvasive imaging modalities like adaptive optics SLO,
      retinal functional imager, adaptive optics OCT and Doppler OCT. Some of these
      instruments allow a more detailed in vivo examination of the retinal vasculature 
      than fluorescein angiography without its potentially serious side effects, thus
      better allowing us to further study retinal vascular homeostasis in healthy
      subjects and to identify preclinical changes in early disease stages.
AD  - Department of Ophthalmology, Medical University of Vienna, 1090, Vienna, Austria.
FAU - Deak, Gabor Gyorgy
AU  - Deak GG
FAU - Schmidt-Erfurth, Ursula
AU  - Schmidt-Erfurth U
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1007/s11892-013-0389-5 [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 Jun 5.

PMID- 23733389
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1179-1918 (Electronic)
IS  - 1173-2563 (Linking)
DP  - 2013 Jun 4
TI  - The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of
      Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor.
AB  - BACKGROUND: Ipragliflozin (ASP1941), a potent selective sodium glucose
      co-transporter 2 inhibitor, is in development for the treatment of type 2
      diabetes mellitus. Ipragliflozin is primarily eliminated via conjugation by the
      liver as five pharmacologically inactive metabolites (M1, M2, M3, M4 and M6).
      This study evaluated the effect of moderate hepatic impairment on the
      pharmacokinetics of ipragliflozin and its metabolites. METHODS: In an open-label,
      single-dose, parallel-group study, 16 subjects (eight with moderate hepatic
      impairment [Child-Pugh score 7-9] and eight healthy, matched controls) received a
      single oral dose of 100-mg ipragliflozin. Plasma concentrations of ipragliflozin 
      and its metabolites were determined. Adverse events (AEs) and other clinical
      laboratory parameters were monitored. RESULTS: All subjects completed the study. 
      Least-squares geometric mean ratios (GMRs) (90 % confidence interval [CI]) for
      maximum plasma concentration (C max) and area under the plasma concentration-time
      curve from time zero to infinity (AUCinfinity) of ipragliflozin were 127 %
      (93-173 %) and 125 % (94-166 %), respectively, in moderate hepatic impairment
      versus controls. No changes in elimination half-life and protein binding of
      ipragliflozin were observed in moderate hepatic impairment subjects.
      Least-squares GMRs for C max and AUCinfinity of M2, the major metabolite, were
      respectively 95 % (68-133 %) and 100 % (77-130 %) in moderate hepatic impairment 
      versus controls. No deaths, other serious AEs or AEs leading to discontinuation
      occurred. CONCLUSIONS: Moderate hepatic impairment had no clinically relevant
      effects on the single-dose pharmacokinetics of ipragliflozin and its major
      metabolite, M2. A single oral dose of ipragliflozin, 100 mg, was well tolerated
      in both healthy subjects and those with moderate hepatic impairment.
AD  - Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, 
      USA, Wenhui.Zhang@astellas.com.
FAU - Zhang, Wenhui
AU  - Zhang W
FAU - Krauwinkel, Walter J J
AU  - Krauwinkel WJ
FAU - Keirns, James
AU  - Keirns J
FAU - Townsend, Robert W
AU  - Townsend RW
FAU - Lasseter, Kenneth C
AU  - Lasseter KC
FAU - Plumb, Lisa
AU  - Plumb L
FAU - Kadokura, Takeshi
AU  - Kadokura T
FAU - Ushigome, Fumihiko
AU  - Ushigome F
FAU - Smulders, Ronald
AU  - Smulders R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1007/s40261-013-0089-6 [doi]
PST - aheadofprint
SO  - Clin Drug Investig. 2013 Jun 4.

PMID- 23733288
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1970-7096 (Electronic)
IS  - 1827-1987 (Linking)
VI  - 7
IP  - 2
DP  - 2013 May
TI  - Increased cancer mortality in Taiwanese inter-island migrants.
PG  - 251-63
AB  - Higher mortality due to various forms of cancer was observed in emigrants, who
      had moved from the isolated and impoverished Taiwanese island of Matsu to the
      more affluent main island. A total of 13,691 ethnic Matsunese aged 30 years and
      above were enrolled in a study comparing cumulative and standardised mortality
      rates between emigrants to the main island of Taiwan and those who stayed behind.
      Poisson regression modelling was used to analyse the effects of migration. For
      all causes of mortality, the adjusted relative risk was 1.24 with a confidence
      interval (CI) at the 95% level of 1.08-1.42 for emigrants compared to Matsunese
      non-emigrants. Deaths from cancer and diabetes in emigrants showed similar
      results, i.e. an adjusted relative risk of 1.25 (95% CI, 1.00-1.57) and 1.93 (95%
      CI, 1.20-3.11), respectively. Higher cumulative incidence rates for all cancers
      and the three leading cancer forms (hepatocellular carcinoma, gastric cancer and 
      lung cancer) in emigrants were also observed. However, no significant difference 
      in the survival time of most of the cancer forms was noted between the two
      groups. The finding that moving to a more affluent area paradoxically leads to
      incidence of cancer and higher mortality might be explained by adoption of
      various forms of unhealthy behaviour, psycho-social factors and the general risks
      related to life in urbanized environments.
AD  - Department of Family Medicine, National Taiwan University Hsin-Chu Branch,
      Taipei, Taiwan.
FAU - Chen, Meng-Kan
AU  - Chen MK
FAU - Chen, Hsiu-Hsi
AU  - Chen HH
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Geospat Health
JT  - Geospatial health
JID - 101302943
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PST - ppublish
SO  - Geospat Health. 2013 May;7(2):251-63.

PMID- 23733238
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1875-8312 (Electronic)
IS  - 1569-5794 (Linking)
DP  - 2013 Jun 4
TI  - Prognosis of normal stress-only gated-SPECT myocardial perfusion imaging: a
      single center study.
AB  - It has been advocated that using the stress followed by rest protocol, if the
      stress images were normal there is no need of rest images, reducing radiation
      exposure and costs. Our purpose was to assess the prognosis of a group of
      patients with normal stress-only gated-SPECT myocardial perfusion imaging. This
      was retrospective study that includes 790 patients with normal myocardial
      stressonly perfusion gated SPECT images. Images were considered as normal if a
      homogeneous myocardial distribution of the tracer was associated with a normal
      ejection fraction. The mean follow-up was of 42.8 +/- 13.3 months. The considered
      events were death of all causes, myocardial infarction and myocardial
      revascularization. During this period there were 85 events (10.8 %), including 57
      deaths of all causes (67.1 %), 9 myocardial infarctions (10.6 %), 19
      revascularizations (2.4 %). In the first year of follow-up there were 32 events
      (4.0 %) and excluding non cardiac deaths there were 8 events (1.0 %). Using Cox
      survival analysis, diabetes (HR = 2.2; CI = 1.4-3.4; p </= 0.0005), the history
      of coronary artery disease (CAD) (HR = 2.1; CI = 1.3-3.2; p </= 0.001), age (HR =
      1.0; CI = 1.0-1.0; p </= 0.05) and type of stress protocol were related with
      events (exercise test vs. adenosine) (Exercise test: HR = 0.5; CI = 0.3-0.8; p
      </= 0.01). In a multivariate analysis the independent predictors were diabetes,
      CAD and the type of stress protocol. Based on these results, normal stress-only
      images are associated with an excellent prognosis even in patients at higher
      risk, diabetics and patients with known CAD.
AD  - Department of Cardiology, Faculty of Medicine of Coimbra University and Coimbra
      Hospital and University Center, Coimbra, Portugal, mjvidigal@netc.pt.
FAU - Ferreira, Maria Joao Vidigal
AU  - Ferreira MJ
FAU - Cunha, Maria Joao
AU  - Cunha MJ
FAU - Albuquerque, Anabela
AU  - Albuquerque A
FAU - Moreira, Ana Paula
AU  - Moreira AP
FAU - Ramos, Domingos
AU  - Ramos D
FAU - Costa, Gracinda
AU  - Costa G
FAU - Lima, Joao
AU  - Lima J
FAU - Pego, Mariano
AU  - Pego M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Int J Cardiovasc Imaging
JT  - The international journal of cardiovascular imaging
JID - 100969716
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/03/02 [received]
PHST- 2013/05/24 [accepted]
PHST- 2013/06/04 [aheadofprint]
AID - 10.1007/s10554-013-0245-3 [doi]
PST - aheadofprint
SO  - Int J Cardiovasc Imaging. 2013 Jun 4.

PMID- 23733201
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Jun 3
TI  - Mitochondrial Substrate Availability and its Role in Lipid-Induced Insulin
      Resistance and Proinflammatory Signalling in Skeletal Muscle.
AB  - The relationship between glucose and lipid metabolism has been of significant
      interest in understanding the pathogenesis of obesity-induced insulin resistance.
      To gain insight into this metabolic paradigm, we explored the potential interplay
      between cellular glucose flux and lipid-induced metabolic dysfunction within
      skeletal muscle. Here we show that palmitate-induced insulin resistance and
      pro-inflammation in muscle cells, which is associated with reduced mitochondrial 
      integrity and oxidative capacity, can be attenuated under conditions of
      glucose-withdrawal or glycolytic inhibition using 2-deoxyglucose (2DG).
      Importantly, these glucopenic-driven improvements coincide with the preservation 
      of mitochondrial function, and are dependent on palmitate oxidation which becomes
      markedly enhanced in the absence of glucose. Intriguingly, despite its ability to
      upregulate mitochondrial palmitate oxidation, glucose withdrawal did not
      attenuate palmitate-induced increases in total intramyocellular diacylglycerol
      and ceramide. Furthermore, consistent with our findings in cultured muscle cells,
      we also report enhanced insulin sensitivity and reduced pro-inflammatory tone in 
      soleus muscle from obese Zucker rats fed a 2DG-supplemented diet. Notably, this
      improved metabolic status following 2DG dietary intervention is associated with
      markedly reduced plasma free fatty acids. Collectively, our data highlights the
      key role that mitochondrial substrate availability plays in lipid-induced
      metabolic dysregulation both in vitro and in vivo.
AD  - Division of Cell Signalling and Immunology, Sir James Black Centre, College of
      Life Sciences, University of Dundee, Dundee, DD1 5EH, UK.
FAU - Lipina, Christopher
AU  - Lipina C
FAU - Macrae, Katherine
AU  - Macrae K
FAU - Suhm, Tamara
AU  - Suhm T
FAU - Weigert, Cora
AU  - Weigert C
FAU - Blachnio-Zabielska, Agnieszka
AU  - Blachnio-Zabielska A
FAU - Baranowksi, Marcin
AU  - Baranowksi M
FAU - Gorski, Jan
AU  - Gorski J
FAU - Burgess, Karl
AU  - Burgess K
FAU - Hundal, Harinder S
AU  - Hundal HS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - db13-0264 [pii]
AID - 10.2337/db13-0264 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Jun 3.

PMID- 23733200
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Jun 3
TI  - Effects of a Single Bout of Interval Hypoxia on Cardio-Respiratory Control in
      Patients with Type 1 Diabetes Mellitus.
AB  - Hypoxemia is common in diabetes, and reflex responses to hypoxia are blunted.
      These abnormalities could lead to cardiovascular/renal complications. Interval
      hypoxia (5-6 short periods of hypoxia each day over 1-3 weeks, IH), was
      successfully used to improve the adaptation to hypoxia in COPD. We tested whether
      IH over one day could initiate a long-lasting response potentially leading to
      better adaptation to hypoxia.In 15 patients with type 1 diabetes we measured
      hypoxic and hypercapnic ventilatory responses, ventilatory recruitment threshold,
      (VRT-CO2), baroreflex sensitivity (BRS), blood pressure and blood lactate before,
      after 0, 3 and 6 hours of 1-hour single bout of IH. All measurements were
      repeated on a placebo day (single-blind protocol, randomized sequence).After IH
      (immediately and after 3 hours), hypoxic and hypercapnic ventilatory responses
      increased, whereas the VRT-CO2 dropped. No such changes were observed on the
      placebo day. Systolic and diastolic blood pressure increased whereas blood
      lactate decreased after IH. Despite exposure to hypoxia, BRS remained
      unchanged.Repeated exposures to hypoxia over one day induced an initial
      adaptation to hypoxia, with improvement in respiratory reflexes. Prolonging the
      exposure to IH (>2 weeks) in type 1 diabetes patients will be matter of further
      studies.
AD  - Department of Sport Science, Medical Section, University of Innsbruck, Austria.
FAU - Duennwald, Tobias
AU  - Duennwald T
FAU - Bernardi, Luciano
AU  - Bernardi L
FAU - Gordin, Daniel
AU  - Gordin D
FAU - Sandelin, Anna
AU  - Sandelin A
FAU - Syreeni, Anna
AU  - Syreeni A
FAU - Fogarty, Christopher
AU  - Fogarty C
FAU - Kyto, Janne P
AU  - Kyto JP
FAU - Gatterer, Hannes
AU  - Gatterer H
FAU - Lehto, Markku
AU  - Lehto M
FAU - Horkko, Sohvi
AU  - Horkko S
FAU - Forsblom, Carol
AU  - Forsblom C
FAU - Burtscher, Martin
AU  - Burtscher M
FAU - Groop, Per-Henrik
AU  - Groop PH
CN  - on behalf of the FinnDiane Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - db13-0167 [pii]
AID - 10.2337/db13-0167 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Jun 3.

PMID- 23733199
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Jun 3
TI  - N-terminal pro-Brain Natriuretic Peptide and Risk of Diabetes.
AB  - Brain natriuretic peptide (BNP) has an established role in cardiovascular
      disease. However, recent animal studies suggest direct metabolic effects of BNP. 
      To determine the association of BNP with the risk of diabetes, we conducted a
      prospective analysis of participants from the Atherosclerosis Risk in Communities
      (ARIC) Study. We included 7,822 men and women without history of diabetes,
      cardiovascular disease or reduced kidney function at baseline. At baseline,
      N-terminal (NT)-proBNP, a cleavage product of BNP, was inversely associated with 
      adiposity, fasting glucose, insulin, and cholesterol, but positively associated
      with blood pressure and C-reactive protein levels. During a median follow-up of
      12 years, 1740 participants reported a new diagnosis of diabetes or medication
      use for diabetes. Baseline quartiles of NT-proBNP were inversely associated with 
      diabetes risk, even after multivariable adjustment including fasting glucose. The
      adjusted HRs for diabetes were 1.0 (reference), 0.84 (95%CI 0.74- 0.96), 0.79
      (95%CI 0.68- 0.90) and 0.75 (95%CI 0.64-0.87) for the 1st, 2nd, 3rd and 4th
      quartiles of baseline NT-proBNP, respectively (p-for-trend<0.001). This inverse
      association was robust across sex, race and obesity subgroups. Our results extend
      animal studies and support a direct and important metabolic role of BNP in
      humans.
AD  - Department of Medicine, Division of General Internal Medicine, Johns Hopkins
      School of Medicine, Johns Hopkins University, Baltimore, Maryland.
FAU - Lazo, Mariana
AU  - Lazo M
FAU - Young, J Hunter
AU  - Young JH
FAU - Brancati, Frederick L
AU  - Brancati FL
FAU - Coresh, Josef
AU  - Coresh J
FAU - Whelton, Seamus
AU  - Whelton S
FAU - Ndumele, Chiadi E
AU  - Ndumele CE
FAU - Hoogeveen, Ron
AU  - Hoogeveen R
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
FAU - Selvin, Elizabeth
AU  - Selvin E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - db13-0478 [pii]
AID - 10.2337/db13-0478 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Jun 3.

PMID- 23733198
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Jun 3
TI  - ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetics and
      Response to Therapy.
AB  - In diabetics, impaired ADAMTS13 proteolysis of highly-thrombogenic VWF multimers 
      may accelerate renal and cardiovascular complications. Restoring physiological
      VWF handling might contribute to ACE inhibitors (ACEi) reno- and cardioprotective
      effects.To assess how Pro618Ala ADAMTS13 variants and related proteolytic
      activity interact with ACEi therapy in predicting renal and cardiovascular
      complications, we genotyped 1163 normoalbuminuric type 2 diabetics from the
      BENEDICT trial. Interaction between Pro618Ala and ACEi was significant in
      predicting both renal and combined renal and cardiovascular events. The risk
      [HR(95%CI)] for renal or combined events vs reference Ala carriers on ACEi
      progressively increased from Pro/Pro homozygotes on ACEi [2.80(0.849-9.216) and
      1.58(0.737-3.379), respectively], to Pro/Pro homozygotes on non-ACEi
      [4.77(1.484-15.357) and 1.99(0.944-4.187)], to Ala carriers on non-ACEi
      [8.50(2.416-29.962) and 4.00(1.739-9.207)]. In a sub-study, serum ADAMTS13
      activity was significantly lower in Ala carriers than in Pro/Pro homozygotes and 
      in cases with renal, cardiovascular or combined events than in uneventful
      diabetic controls. ADAMTS13 activity significantly and negatively correlated with
      all outcomes.In diabetics, ADAMTS13 618Ala variant associated with less
      proteolytic activity, higher risk of chronic complications and better response to
      ACEi therapy. Screening for Pro618Ala polymorphism may help identifying diabetics
      at highest risk who may benefit the most from early reno- and cardioprotective
      therapy.
AD  - "Mario Negri" Institute for Pharmacological Research, IRCCS, Bergamo, Italy.
FAU - Rurali, Erica
AU  - Rurali E
FAU - Noris, Marina
AU  - Noris M
FAU - Chianca, Antonietta
AU  - Chianca A
FAU - Donadelli, Roberta
AU  - Donadelli R
FAU - Banterla, Federica
AU  - Banterla F
FAU - Galbusera, Miriam
AU  - Galbusera M
FAU - Gherardi, Giulia
AU  - Gherardi G
FAU - Gastoldi, Sara
AU  - Gastoldi S
FAU - Ilieva, Aneliya Parvanova
AU  - Ilieva AP
FAU - Iliev, Ilian Petrov
AU  - Iliev IP
FAU - Bossi, Antonio
AU  - Bossi A
FAU - Haefliger, Carolina
AU  - Haefliger C
FAU - Trevisan, Roberto
AU  - Trevisan R
FAU - Remuzzi, Giuseppe
AU  - Remuzzi G
FAU - Ruggenenti, Piero
AU  - Ruggenenti P
CN  - for the BENEDICT Study Group (See Online Supplemental Material)
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - db13-0530 [pii]
AID - 10.2337/db13-0530 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Jun 3.

PMID- 23733197
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Jun 3
TI  - Weight Cycling Increases T Cell Accumulation in Adipose Tissue and Impairs
      Systemic Glucose Tolerance.
AB  - Obesity is one of the leading causes of morbidity in the United States.
      Accumulation of pro-inflammatory immune cells in adipose tissue (AT) contributes 
      to the development of obesity-associated disorders. Weight loss is the ideal
      method to counteract the negative consequences of obesity; however, losses are
      rarely maintained, leading to bouts of weight cycling. Fluctuations in weight
      have been associated with worsened metabolic and cardiovascular outcomes; yet,
      the mechanisms explaining this potential correlation are not known. To determine 
      if weight cycling modulates AT immune cell populations, inflammation, and insulin
      resistance, mice were subjected to a diet-switch protocol designed to induce
      weight cycling. Weight-cycled mice displayed decreased systemic glucose tolerance
      and impaired AT insulin sensitivity when compared to mice that gained weight but 
      did not cycle. AT macrophage number and polarization were not modulated by weight
      cycling. However, weight cycling did increase the number of CD4+ and CD8+ T cells
      in AT. Expression of multiple TH1-associated cytokines was also elevated
      subsequent to weight cycling. Additionally, CD8+ effector memory T cells were
      present in AT of both obese and weight-cycled mice. These studies indicate that
      an exaggerated adaptive immune response in AT may contribute to metabolic
      dysfunction during weight cycling.
AD  - Department of Molecular Physiology and Biophysics, Vanderbilt University School
      of Medicine, Nashville, TN 37232.
FAU - Anderson, Emily K
AU  - Anderson EK
FAU - Gutierrez, Dario A
AU  - Gutierrez DA
FAU - Kennedy, Arion
AU  - Kennedy A
FAU - Hasty, Alyssa H
AU  - Hasty AH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Diabetes
JT  - Diabetes
JID - 0372763
OTO - NOTNLM
OT  - Obesity
OT  - T cells
OT  - adipose tissue
OT  - weight cycling
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - db12-1076 [pii]
AID - 10.2337/db12-1076 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Jun 3.

PMID- 23733196
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Jun 3
TI  - Autologous Pancreatic Islet Transplantation in Human Bone Marrow.
AB  - The liver is the current site of choice for pancreatic islet transplantation,
      even though it is far from being ideal. In mice we have recently shown that the
      bone marrow (BM) may be a valid alternative to the liver and here we report a
      pilot study to test feasibility and safety of BM as a site for islet
      transplantation in humans. Four patients who developed diabetes after total
      pancreatectomy were candidates for the autologous transplantation of pancreatic
      islet. Since the patients had contraindications for intraportal infusion, islets 
      were infused in the BM. In all recipients islets engrafted successfully, as shown
      by measurable post-transplantation C-peptide levels and histopathological
      evidence of insulin producing cells and/or molecular markers of endocrine tissue 
      on BM biopsies performed during follow-up. Thus far we have recorded no adverse
      events related to the infusion procedure or the presence of islets in the BM.
      Islet function was sustained up to the maximum follow-up of 944 days. The
      encouraging results of this pilot study open new perspectives in identifying
      alternative sites for islet infusion in patients with type 1 diabetes. Moreover, 
      this is the first unequivocal example of successful engraftment of an endocrine
      tissue in the BM in humans.
AD  - Islet Transplantation Unit, Diabetes Research Institute (OSR-DRI); Division of
      Immunology, Transplantation and Infectious Diseases; San Raffaele Scientific
      Institute, Milan, Italy.
FAU - Maffi, Paola
AU  - Maffi P
FAU - Balzano, Gianpaolo
AU  - Balzano G
FAU - Ponzoni, Maurilio
AU  - Ponzoni M
FAU - Nano, Rita
AU  - Nano R
FAU - Sordi, Valeria
AU  - Sordi V
FAU - Melzi, Raffaella
AU  - Melzi R
FAU - Mercalli, Alessia
AU  - Mercalli A
FAU - Scavini, Marina
AU  - Scavini M
FAU - Esposito, Antonio
AU  - Esposito A
FAU - Peccatori, Jacopo
AU  - Peccatori J
FAU - Cantarelli, Elisa
AU  - Cantarelli E
FAU - Messina, Carlo
AU  - Messina C
FAU - Bernardi, Massimo
AU  - Bernardi M
FAU - Del Maschio, Alessandro
AU  - Del Maschio A
FAU - Staudacher, Carlo
AU  - Staudacher C
FAU - Doglioni, Claudio
AU  - Doglioni C
FAU - Ciceri, Fabio
AU  - Ciceri F
FAU - Secchi, Antonio
AU  - Secchi A
FAU - Piemonti, Lorenzo
AU  - Piemonti L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - db13-0465 [pii]
AID - 10.2337/db13-0465 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Jun 3.

PMID- 23733179
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 2168-6211 (Electronic)
IS  - 2168-6203 (Linking)
DP  - 2013 Jun 3
TI  - Reducing Racial/Ethnic Disparities in Childhood Obesity: The Role of Early Life
      Risk Factors.
PG  - 1-7
LID - 10.1001/jamapediatrics.2013.85 [doi]
AB  - IMPORTANCE Many early life risk factors for childhood obesity are more prevalent 
      among blacks and Hispanics than among whites and may explain the higher
      prevalence of obesity among racial/ethnic minority children. OBJECTIVE To examine
      the extent to which racial/ethnic disparities in adiposity and overweight are
      explained by differences in risk factors during pregnancy (gestational diabetes
      and depression), infancy (rapid infant weight gain, feeding other than exclusive 
      breastfeeding, and early introduction of solid foods), and early childhood
      (sleeping &lt;12 h/d, presence of a television set in the room where the child
      sleeps, and any intake of sugar-sweetened beverages or fast food). DESIGN
      Prospective prebirth cohort study. SETTING Multisite group practice in
      Massachusetts. PARTICIPANTS Participants included 1116 mother-child pairs (63%
      white, 17% black, and 4% Hispanic) EXPOSURE Mother's report of child's
      race/ethnicity. MAIN OUTCOMES AND MEASURES Age- and sex-specific body mass index 
      (BMI) z score, total fat mass index from dual-energy x-ray absorptiometry, and
      overweight or obesity, defined as a BMI in the 85th percentile or higher at age 7
      years. RESULTS Black (0.48 U [95% CI, 0.31 to 0.64]) and Hispanic (0.43 [0.12 to 
      0.74]) children had higher BMI z scores, as well as higher total fat mass index
      and overweight/obesity prevalence, than white children. After adjustment for
      socioeconomic confounders and parental BMI, differences in BMI z score were
      attenuated for black and Hispanic children (0.22 U [0.05 to 0.40] and 0.22 U
      [-0.08 to 0.52], respectively). Adjustment for pregnancy risk factors did not
      substantially change these estimates. However, after further adjustment for
      infancy and childhood risk factors, we observed only minimal differences in BMI z
      scores between whites, blacks (0.07 U [-0.11 to 0.26]), and Hispanics (0.04 U
      [-0.27 to 0.35]). We observed similar attenuation of racial/ethnic differences in
      adiposity and prevalence of overweight or obesity. CONCLUSIONS AND RELEVANCE
      Racial/ethnic disparities in childhood adiposity and obesity are determined by
      factors operating in infancy and early childhood. Efforts to reduce obesity
      disparities should focus on preventing early life risk factors.
FAU - Taveras, Elsie M
AU  - Taveras EM
FAU - Gillman, Matthew W
AU  - Gillman MW
FAU - Kleinman, Ken P
AU  - Kleinman KP
FAU - Rich-Edwards, Janet W
AU  - Rich-Edwards JW
FAU - Rifas-Shiman, Sheryl L
AU  - Rifas-Shiman SL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - JAMA Pediatr
JT  - JAMA pediatrics
JID - 101589544
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 1692336 [pii]
AID - 10.1001/jamapediatrics.2013.85 [doi]
PST - aheadofprint
SO  - JAMA Pediatr. 2013 Jun 3:1-7. doi: 10.1001/jamapediatrics.2013.85.

PMID- 23733079
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1879-3134 (Electronic)
IS  - 0025-5564 (Linking)
DP  - 2013 Jun 1
TI  - Mathematical modeling of the glucose-insulin system: A review.
LID - S0025-5564(13)00130-2 [pii]
LID - 10.1016/j.mbs.2013.05.006 [doi]
AB  - Mathematical modeling of the glucose-insulin feedback system is necessary to the 
      understanding of the homeostatic control, to analyze experimental data, to
      identify and quantify relevant biophysical parameters, to design clinical trials 
      and to evaluate diabetes prevention or disease modification therapies. Much work 
      has been made over the last 30years, and the time now seems ripe to provide a
      comprehensive review. The one here proposed is focused on the most important
      clinical/experimental tests performed to understand the mechanism of glucose
      homeostasis. The review proceeds from models of pancreatic insulin production,
      with a coarser/finer level of detail ranging over cellular and subcellular
      scales, to short-term organ/tissue models accounting for the intra-venous and the
      oral glucose tolerance tests as well as for the euglycemic hyperinsulinemic
      clamp, to total-body, long-term diabetes models aiming to represent disease
      progression in terms of beta-cell population dynamics over a long period of
      years.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - BioMatLab, IASI "A. Ruberti", National Council of Researches, UCSC Largo A.
      Gemelli 8, 00168 Rome, Italy.
FAU - Palumbo, Pasquale
AU  - Palumbo P
FAU - Ditlevsen, Susanne
AU  - Ditlevsen S
FAU - Bertuzzi, Alessandro
AU  - Bertuzzi A
FAU - De Gaetano, Andrea
AU  - De Gaetano A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Math Biosci
JT  - Mathematical biosciences
JID - 0103146
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/03 [received]
PHST- 2013/05/10 [revised]
PHST- 2013/05/16 [accepted]
AID - S0025-5564(13)00130-2 [pii]
AID - 10.1016/j.mbs.2013.05.006 [doi]
PST - aheadofprint
SO  - Math Biosci. 2013 Jun 1. pii: S0025-5564(13)00130-2. doi:
      10.1016/j.mbs.2013.05.006.

PMID- 23732970
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1535-7228 (Electronic)
IS  - 0002-953X (Linking)
VI  - 170
IP  - 6
DP  - 2013 Jun 1
TI  - Sustained weight loss after treatment with a glucagon-like Peptide-1 receptor
      agonist in an obese patient with schizophrenia and type 2 diabetes.
PG  - 681-2
LID - 10.1176/appi.ajp.2013.12101344 [doi]
FAU - Ishoy, Pelle L
AU  - Ishoy PL
FAU - Knop, Filip K
AU  - Knop FK
FAU - Vilsboll, Tina
AU  - Vilsboll T
FAU - Glenthoj, Birte Y
AU  - Glenthoj BY
FAU - Ebdrup, Bjorn H
AU  - Ebdrup BH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Psychiatry
JT  - The American journal of psychiatry
JID - 0370512
SB  - AIM
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 1694230 [pii]
AID - 10.1176/appi.ajp.2013.12101344 [doi]
PST - ppublish
SO  - Am J Psychiatry. 2013 Jun 1;170(6):681-2. doi: 10.1176/appi.ajp.2013.12101344.

PMID- 23732816
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 Jun 4
TI  - The impact of ethnicity on glucose homeostasis after gestational diabetes
      mellitus.
AB  - The objective of this study was to examine measures of insulin resistance and
      beta cell function in relation to ethnicity and the development of diabetes after
      gestational diabetes mellitus (GDM). Glucose homeostasis was assessed during a 75
      g oral glucose tolerance test 1-2 years after delivery in 456 women with previous
      GDM (362 European, 94 non-European; including 41 Arab and 43 Asian women) and 133
      control women. Insulin resistance was estimated using homeostasis model
      assessment of insulin resistance (HOMA-IR). The insulinogenic index (I/G30) and
      the disposition index [(I/G30)/HOMA-IR] were used to quantify insulin secretion. 
      Women developing diabetes after GDM were characterized by increased HOMA-IR [p = 
      0.010, adjusted for body mass index (BMI)], whereas the disposition index was
      decreased in all women with previous GDM irrespective of glucose tolerance, most 
      pronounced in the presence of diabetes (BMI-adjusted p = 1 x 10-5). Non-European 
      origin was associated with increased HOMA-IR (p = 0.001 vs. European),
      strengthened by adjustment for BMI in Asian women (p = 0.046 vs. p = 0.016), but 
      eradicated among Arab women (p = 0.004 vs. p = 0.65). Non-European women
      exhibited an increased frequency of diabetes after GDM (17 % vs. European 4 %, p 
      = 2 x 10-5). In addition to BMI, non-European and Asian origin was associated
      with the development of diabetes after GDM in a multivariate logistic regression 
      analysis, whereas Arab origin was not. Our results highlight the importance of
      preventive measures to ensure a healthy lifestyle in women with GDM, particularly
      in high-risk ethnic groups.
AD  - Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden,
      Claes.Ignell@med.lu.se.
FAU - Ignell, Claes
AU  - Ignell C
FAU - Shaat, Nael
AU  - Shaat N
FAU - Ekelund, Magnus
AU  - Ekelund M
FAU - Berntorp, Kerstin
AU  - Berntorp K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/03/05 [received]
PHST- 2013/05/20 [accepted]
PHST- 2013/06/04 [aheadofprint]
AID - 10.1007/s00592-013-0484-8 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 Jun 4.

PMID- 23732679
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - A simple scoring method using cardiometabolic risk measurements in pregnancy to
      determine 10-year risk of type 2 diabetes in women with gestational diabetes.
PG  - e72
LID - 10.1038/nutd.2013.15 [doi]
AB  - Objective:To examine if clustering of cardiometabolic risk factors in pregnancy
      predicts type 2 diabetes and cardiovascular disease (CVD) risk at 10 years in
      women with gestational diabetes mellitus (GDM).Study design and subjects:A
      prospective case-control study in 150 GDM and 72 overweight women with normal
      glucose tolerance (NGT) measured cardiometabolic risk factors (body mass index
      (BMI), systolic blood pressure (SBP), fasting glucose, insulin, and triglycerides
      and high-density lipoprotein (HDL) cholesterol) at 28 weeks gestation and 6
      months and 10 years after pregnancy. Cluster analysis of cardiometabolic risk
      factors in pregnancy was used to stratify GDM as 'high' and 'low risk' for
      diabetes and CVD risk at 10 years. The data in pregnancy were used to determine a
      simple method for assessing risk of future diabetes.Results:BMI in the 150 GDM at
      study entry was similar to NGT, but 35% of GDM fell into a 'high-risk cluster'
      with elevated BMI, SBP, glucose, insulin and triglycerides and lower HDL levels. 
      At 10 years, type 2 diabetes was sixfold higher in 'high-risk' GDM (odds ratio
      (OR)=6.75, confidence interval (CI)=2.0, 22.7, P=0.002) compared with 'low-risk' 
      GDM and was not reported in NGT. The 'high-risk' cluster predicted type 2
      diabetes better than BMI>30 (OR=2.13, CI=0.71, 6.4, P=0.179) or fasting glucose
      >5.5 mmol l(-1), (OR=4.56, CI=1.50, 13.85, P=0.007). We determined that GDM with 
      any four of the cardiometabolic risk factors (BMI>30 kg m(-2), fasting
      glucose>5.0 mmol l(-1), insulin>7.8 mU l(-1), triglycerides >2.4 mmol l(-1),
      HDL<1.6 mmol l(-1) or SBP>105 mm Hg) in pregnancy would be in a 'high-risk'
      cluster.Conclusions:A metabolic syndrome-like cluster in pregnant GDM identifies 
      risk for type 2 diabetes providing an opportunity to focus on rigorous lifestyle 
      interventions after delivery to reduce the burden of disease attributed to this
      condition.
AD  - School of Medicine and Pharmacology, University of Western Australia, Perth,
      Western Australia, Australia.
FAU - Barden, A
AU  - Barden A
FAU - Singh, R
AU  - Singh R
FAU - Walters, B
AU  - Walters B
FAU - Phillips, M
AU  - Phillips M
FAU - Beilin, L J
AU  - Beilin LJ
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
AID - nutd201315 [pii]
AID - 10.1038/nutd.2013.15 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 Jun 3;3:e72. doi: 10.1038/nutd.2013.15.

PMID- 23732667
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 0253-9772 (Print)
IS  - 0253-9772 (Linking)
VI  - 35
IP  - 5
DP  - 2013 May
TI  - [Sterol regulatory element binding protein 1 and its target gene networks].
PG  - 607-15
AB  - Sterol regulatory element binding protein 1 (SREBP-1) is one of the important
      nuclear transcription factors. SREBP-1 can maintain lipids dynamic equilibrium by
      regulating the expression of enzymes required for synthesis of endogenous
      cholesterol, fatty acids, triglycerides and phospholipids. Anomalies of SREBP-1
      and its target genes can cause a series of metabolic diseases such as insulin
      resistance, type diabetes, heart dysfunction, vascular complications and hepatic 
      steatosis. In these years, the development of high-throughput technologies has
      greatly expanded our knowledge about SREBP-1 target genes and the pattern of
      transcriptional regulation. Here we reviewed recent research progress of SREBP-1,
      with a focus on the protein structure, activation process, DNA binding sites and 
      target genes. Most importantly, we showed the transcriptional regulatory networks
      based on omics datasets, which will contribute to a better understanding of the
      role of SREBP-1 in lipid metabolism and provide new clues for the treatment of
      lipid metabolism disorders.
AD  - 1. Department of Physiology, Medical College of Nanchang University, Nanchang
      330001, China; 2. Department of Biochemistry, Medical College of Nanchang
      University, Nanchang 330001, China E-mail: xltangmail@163.com.
FAU - Tang, Xiao-Li
AU  - Tang XL
FAU - Deng, Li-Bin
AU  - Deng LB
FAU - Lin, Jia-Ri
AU  - Lin JR
FAU - Zhang, Wei-Long
AU  - Zhang WL
FAU - Liu, Shuang-Mei
AU  - Liu SM
FAU - Wei, Yi
AU  - Wei Y
FAU - Mei, Pu-Ming
AU  - Mei PM
FAU - Wang, Yan
AU  - Wang Y
FAU - Liang, Shang-Dong
AU  - Liang SD
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Yi Chuan
JT  - Yi chuan = Hereditas / Zhongguo yi chuan xue hui bian ji
JID - 9436478
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 0253-9772(2013)5-607-09 [pii]
PST - ppublish
SO  - Yi Chuan. 2013 May;35(5):607-15.

PMID- 23732656
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 May 14
TI  - Clinical and laboratory characteristics of 1179 Czech adolescents evaluated for
      antibodies to human adenovirus 36.
LID - 10.1038/ijo.2013.72 [doi]
AB  - Background:Human adenovirus 36 (Adv36) is associated with obesity in children.
      Most prior studies have been small and the association of Adv36 status with
      markers of metabolic risks has been inconsistent.Objectives:To determine the
      prevalence of Adv36 antibodies in different weight categories of adolescents and 
      to evaluate the association of Adv36 infection with anthropometric parameters and
      cardiometabolic health risks.Subjects and methods:In 1179 Czech adolescents (85
      underweight, 506 normal weight, 160 overweight and 428 obese), the following
      variables were evaluated: anthropometric (body weight, height, body mass index,
      circumferences, fat mass), blood pressure, biochemical and hormonal (lipid
      profile, glucose, insulin, liver enzymes, adiponectin) and Adv36 antibodies
      (enzyme-linked immunosorbent assay).Results:Of the total cohort, 26.5% were
      positive for Adv36 antibodies (underweight: 22.3%; normal weight: 21.5%;
      overweight: 40.0% and obese: 28.0%). The odds ratio for Adv36 antibody positivity
      evaluated vs normal weight was 2.61 for overweight (95% confidence interval (CI):
      1.77-3.86, P<0.001) and 1.46 for obesity (95% CI: 1.07-1.99, P=0.016). A
      significantly higher prevalence of Adv36 infection was observed in female
      subjects (32.5%) in comparison to male subjects (19.7%; P<0.001). Adv36
      positivity of the whole cohort was significantly related to body weight
      (P=0.042), body mass index (P=0.015), hip circumference (P=0.004), body height
      z-score (P=0.029), and total body fat (P=0.000) and trunk fat (P=0.000). Adv36
      antibody-positive girls demonstrated significantly higher body height (167.8 vs
      165.0 cm, P=0.01) and waist circumference (77.0 vs 72.0 cm, P=0.01). Infected
      adolescents exhibited significantly higher levels of total cholesterol (TC) and
      low-density lipoprotein cholesterol (LDL-C), but lower levels of blood glucose.
      Liver enzymes were significantly increased only in Adv36-positive
      boys.Conclusion:These results demonstrated an association of Adv36 antibodies
      with obesity and an even greater association with overweight. Adv36 positivity
      was related to increased fat mass, levels of TC and LDL-C, but to decreased level
      of blood glucose. No relation to adiponectin levels was revealed.International
      Journal of Obesity advance online publication, 4 June 2013;
      doi:10.1038/ijo.2013.72.
AD  - 1] Obesity Management Center, Institute of Endocrinology, Prague, Czech Republic 
      [2] Department of Pediatrics and Center for Research of Diabetes, Metabolism and 
      Nutrition, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
FAU - Aldhoon-Hainerova, I
AU  - Aldhoon-Hainerova I
FAU - Zamrazilova, H
AU  - Zamrazilova H
FAU - Atkinson, R L
AU  - Atkinson RL
FAU - Dusatkova, L
AU  - Dusatkova L
FAU - Sedlackova, B
AU  - Sedlackova B
FAU - Hlavaty, P
AU  - Hlavaty P
FAU - Lee, Z P
AU  - Lee ZP
FAU - Kunesova, M
AU  - Kunesova M
FAU - Hainer, V
AU  - Hainer V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/05/14 [aheadofprint]
PHST- 2013/06/04 [aheadofprint]
AID - ijo201372 [pii]
AID - 10.1038/ijo.2013.72 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 May 14. doi: 10.1038/ijo.2013.72.

PMID- 23732613
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 143
IP  - 6
DP  - 2013 Jun 1
TI  - An 87-year-old woman with diabetes, hypertension, and liver cirrhosis in
      respiratory distress.
PG  - e1-4
LID - 10.1378/chest.13-0824 [doi]
FAU - Patel, Purvesh
AU  - Patel P
FAU - Narasimhan, Mangala
AU  - Narasimhan M
FAU - Koenig, Seth
AU  - Koenig S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
SB  - AIM
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 1690797 [pii]
AID - 10.1378/chest.13-0824 [doi]
PST - ppublish
SO  - Chest. 2013 Jun 1;143(6):e1-4. doi: 10.1378/chest.13-0824.

PMID- 23732370
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 0391-1977 (Print)
IS  - 0391-1977 (Linking)
VI  - 38
IP  - 2
DP  - 2013 Jun
TI  - New technologies for treating obesity.
PG  - 165-72
AB  - Obesity has become a national epidemic and a disease of global magnitude. The
      numbers of patients with obesity have grown exponentially in the last 10 years to
      the degree that the Centers for Disease Control and Prevention reports that one
      third of the US population is obese. The prevalence of diabetes has grown by more
      than 50% in that same time period. Unfortunately, the traditional therapies of
      diets, exercise, behavioral modification and medications have had little effect, 
      especially in the severely obese. The introduction of bariatric surgery has
      changed the natural history of the super obese. Operative approaches now provide 
      the most effective treatment of obesity but carry with them possible risks. Only 
      1% of patients who are estimated to benefit from bariatric surgery have undergone
      a procedure. The burgeoning field of endoluminal therapy has now allowed us to
      consider even more minimally invasive procedures to reach a larger patient
      population. This article will review the most recent advances in innovative
      technologies to treat the growing numbers of obese patients.
AD  - East Carolina University, Greenville, NC, USA - Pories@aol.com.
FAU - Bermudez, D M
AU  - Bermudez DM
FAU - Pories, W J
AU  - Pories WJ
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Endocrinol
JT  - Minerva endocrinologica
JID - 8406505
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - R07Y2013N02A0165 [pii]
PST - ppublish
SO  - Minerva Endocrinol. 2013 Jun;38(2):165-72.

PMID- 23732369
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 0391-1977 (Print)
IS  - 0391-1977 (Linking)
VI  - 38
IP  - 2
DP  - 2013 Jun
TI  - Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal
      control.
PG  - 145-63
AB  - Type 1 diabetes is a disorder where slow destruction of pancreatic beta-cells
      occurs through autoimmune mechanisms. The result is a progressive and ultimately 
      complete lack of endogenous insulin. Due to beta-cell lack, secondary
      abnormalities in glucagon and likely in incretins occur. These multiple hormonal 
      abnormalities cause metabolic instability and extreme glycemic variability, which
      is the primary phenotype. As the disease progresses patients often develop
      hypoglycemia unawareness and defects in their counterregulatory defenses.
      Intensive insulin therapy may thus lead to 3-fold excess of severe hypoglycemia
      and severely hinder the effective and safe control of hyperglycemia. The main
      goal of the therapy for type 1 diabetes has long been physiological mimicry of
      normal insulin secretion based on monitoring which requires considerable effort
      and understanding of the underlying physiology. Attainment of this goal is
      challenged by the nature of the disease and our current lack of means to fully
      repair the abnormal endocrine pancreas interactive functions. As a result,
      various insulin preparations have been developed to partially compensate for the 
      inability to deliver timely exogenous insulin directly to the
      portal/intrapancreatic circulation. It remains an ongoing task to identify the
      ideal routes and regimens of their delivery and potentially that of other
      hormones to restore the deficient and disordered hormonal environment of the
      pancreas to achieve a near normal metabolic state. Several recent technological
      advances help addressing these goals, including the rapid progress in insulin
      pumps, continuous glucose sensors, and ultimately the artificial pancreas
      closed-loop technology and the recent start of dual-hormone therapies.
AD  - Department of Medicine and Center for Diabetes Technology, University of
      Virginia, Charlottesville, VA, USA - alm3j@virginia.edu.
FAU - McCall, A L
AU  - McCall AL
FAU - Farhy, L S
AU  - Farhy LS
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Endocrinol
JT  - Minerva endocrinologica
JID - 8406505
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - R07Y2013N02A0145 [pii]
PST - ppublish
SO  - Minerva Endocrinol. 2013 Jun;38(2):145-63.

PMID- 23732368
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 0391-1977 (Print)
IS  - 0391-1977 (Linking)
VI  - 38
IP  - 2
DP  - 2013 Jun
TI  - Clinical update on insulin pump therapy in combination with continuous glucose
      monitoring.
PG  - 133-43
AB  - In recent years, the treatment of type 1 diabetes has changed significantly. An
      important diagnostic and therapeutic support tool is the continuous glucose
      monitoring (CGM) showing its best performance when used in combination with an
      insulin pump therapy. Before the availability of CGM the consideration of glucose
      regulation and therapeutic success was based solely on selectively measured blood
      glucose levels and HbA1c. In contrast to the blood glucose measurements CGM
      measures in the interstitial fluid and opens a new dimension of diabetes therapy,
      we call it "glucose dynamics". The knowledge of the continuous glucose course and
      its trends has proved to be a highly relevant additional parameter which in
      practical terms has a particularly stabilizing influence on blood glucose
      profiles. CGM therefore offers the option of a fine-tuning of metabolic control
      by experienced heath care professionals and the patient, making blood glucose
      control in general and unplanned activities and problems in everyday life better 
      controllable. However, despite the tremendous potential of CGM in combination
      with a pump therapy the basic settings of an effective pump therapy are crucial. 
      Particularly the right basal insulin coverage as the first step is the key issue 
      for success. With support of CGM there is an enormous potential to facilitate the
      adjustment and optimization of insulin pump therapy.
AD  - Department for Endocrinology, Diabetes and Vascular Medicine, Academic Teaching
      Hospital Munich Bogenhausen, Munich, Germany - thorsten_siegmund@gmx.de.
FAU - Siegmund, T
AU  - Siegmund T
FAU - Kolassa, R
AU  - Kolassa R
FAU - Thomas, A
AU  - Thomas A
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Endocrinol
JT  - Minerva endocrinologica
JID - 8406505
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - R07Y2013N02A0133 [pii]
PST - ppublish
SO  - Minerva Endocrinol. 2013 Jun;38(2):133-43.

PMID- 23732367
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 0391-1977 (Print)
IS  - 0391-1977 (Linking)
VI  - 38
IP  - 2
DP  - 2013 Jun
TI  - Managing type 1 diabetes A journey from starvation to insulin pump.
PG  - 123-31
AB  - With the discovery of insulin in 1921, hopes were high that type 1 diabetes
      mellitus would soon be cured. However, this goal has remained elusive.
      Nevertheless, technological advances have improved the management of diabetes and
      the quality of life of patients with diabetes. One of these advances has been the
      development of the insulin pump. This article reviews the development of insulin 
      pumps and outlines the advantages and disadvantages of insulin pumps currently
      available.
AD  - Stony Brook Children's Hospital, Stony Brook, NY, USA -
      thomas.a.wilson@sunysb.edu.
FAU - Ejaz, S
AU  - Ejaz S
FAU - Wilson, T
AU  - Wilson T
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Endocrinol
JT  - Minerva endocrinologica
JID - 8406505
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - R07Y2013N02A0123 [pii]
PST - ppublish
SO  - Minerva Endocrinol. 2013 Jun;38(2):123-31.

PMID- 23732281
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Jun 4
TI  - Diabetes: Hypertension during pregnancy and future diabetes mellitus.
LID - 10.1038/nrendo.2013.110 [doi]
AD  - Magee-Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213, USA.
FAU - Feghali, Maisa
AU  - Feghali M
FAU - Miodovnik, Menachem
AU  - Miodovnik M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/06/04 [aheadofprint]
AID - nrendo.2013.110 [pii]
AID - 10.1038/nrendo.2013.110 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Jun 4. doi: 10.1038/nrendo.2013.110.

PMID- 23732280
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Jun 4
TI  - Therapy: Immunotherapy for T1DM-targeting innate immunity.
LID - 10.1038/nrendo.2013.103 [doi]
AD  - Diabetes Research Group, Institute of Molecular and Experimental Medicine,
      Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, UK.
FAU - Wong, F Susan
AU  - Wong FS
FAU - Wen, Li
AU  - Wen L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/06/04 [aheadofprint]
AID - nrendo.2013.103 [pii]
AID - 10.1038/nrendo.2013.103 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Jun 4. doi: 10.1038/nrendo.2013.103.

PMID- 23732262
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
DP  - 2013 May 31
TI  - Effects of Roux-en-Y Gastric Bypass or Diabetes Support and Education on Insulin 
      Sensitivity and Insulin Secretion in Morbidly Obese Patients With Type 2
      Diabetes.
AB  - OBJECTIVE:: The long-term changes in insulin sensitivity and beta-cell function
      in morbidly obese patients with type 2 diabetes mellitus who undergo Roux-en-Y
      gastric bypass (RYGB) surgery or standard medical care remain unclear. We
      prospectively studied longitudinal changes of glucostatic parameters in morbidly 
      obese patients with type 2 diabetes mellitus undergoing RYGB surgery or diabetes 
      support and education (DSE). RESEARCH METHODS AND DESIGN:: Sixty-one morbidly
      obese subjects (41.7 +/- 0.6 kg/m) with type 2 diabetes mellitus were assigned to
      RYGB surgery (n = 30) or DSE (n = 31). They were matched for sex, age, and body
      weight. Insulin sensitivity index (Si) and acute insulin response (AIR) were
      derived from frequently sampled intravenous glucose tolerance test. Body
      composition was measured using dual-energy x-ray absorptiometry. General linear
      model with repeated measures was used to examine the longitudinal changes
      (baseline, 6 months, 12 months) in these parameters. RESULTS:: At 12-month
      follow-up, significant improvement in obesity measures, body composition, glucose
      homeostasis, Si, and AIR was observed after RYGB surgery and weight loss. These
      outcomes were not influenced by preoperative insulin use. Although there were no 
      significant changes in the body composition among DSE subjects, they experienced 
      a decline in the Si and AIR, along with an increase in fasting glucose and HbA1c.
      The between-group differences in Si and AIR at 12-month follow-up were completely
      attenuated with adjustment to changes in body weight. CONCLUSIONS:: The long-term
      effects of RYGB surgery on glucostatic parameters are partly dependent on weight 
      loss. In morbidly obese patients with diabetes who were offered DSE, a
      progressive decline in the glucose homeostasis and glucostatic parameters is
      observed despite absence of weight gain. (NCT00787670).
AD  - *Sarah W. Stedman Nutrition & Metabolism Center, Duke University Medical Center, 
      Durham, NC daggerDepartment of Medicine, National University Health System,
      Singapore double daggerDepartment of General Surgery, Duke University Medical
      Center, Durham, NC.
FAU - Khoo, Chin Meng
AU  - Khoo CM
FAU - Chen, Jiegen
AU  - Chen J
FAU - Pamuklar, Zehra
AU  - Pamuklar Z
FAU - Torquati, Alfonso
AU  - Torquati A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1097/SLA.0b013e318294d19c [doi]
PST - aheadofprint
SO  - Ann Surg. 2013 May 31.

PMID- 23732245
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Linking)
DP  - 2013 May 31
TI  - Initiating and maintaining recreational walking: A longitudinal study on the
      influence of neighborhood green space.
LID - S0091-7435(13)00178-3 [pii]
LID - 10.1016/j.ypmed.2013.05.015 [doi]
AB  - OBJECTIVE: This study examined prospective relationships of green space
      attributes with adults initiating or maintaining recreational walking. METHODS:
      Postal surveys were completed by 1036 adults living in Adelaide, Australia, at
      baseline (two time points in 2003-04) and follow-up (2007-08). Initiating or
      maintaining recreational walking was determined using self-reported walking
      frequency. Green space attributes examined were perceived presence, quality,
      proximity, and the objectively measured area (total and largest) and number of
      green spaces within a 1.6km buffer drawn from the centre of each study
      neighborhood. Multilevel regression analyses examined the odds of initiating or
      maintaining walking separately for each green space attribute. RESULTS: At
      baseline, participants were categorized into non-regular (n=395), regular
      (n=286), and irregular walkers (n=313). Among non-regular walkers, 30% had
      initiated walking, while 70% of regular walkers had maintained walking at
      follow-up. No green space attributes were associated with initiating walking.
      However, positive perceptions of the presence of and proximity to green spaces
      and the total and largest areas of green space were significantly associated with
      a higher likelihood of walking maintenance over four years. CONCLUSION:
      Neighborhood green spaces may not assist adults to initiate walking, but their
      presence and proximity may facilitate them to maintain recreational walking over 
      time.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Behavioural Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne,
      Australia. Electronic address: takemi.sugiyama@bakeridi.edu.au.
FAU - Sugiyama, Takemi
AU  - Sugiyama T
FAU - Giles-Corti, Billie
AU  - Giles-Corti B
FAU - Summers, Jacqui
AU  - Summers J
FAU - du Toit, Lorinne
AU  - du Toit L
FAU - Leslie, Eva
AU  - Leslie E
FAU - Owen, Neville
AU  - Owen N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/01/21 [received]
PHST- 2013/05/14 [revised]
PHST- 2013/05/26 [accepted]
AID - S0091-7435(13)00178-3 [pii]
AID - 10.1016/j.ypmed.2013.05.015 [doi]
PST - aheadofprint
SO  - Prev Med. 2013 May 31. pii: S0091-7435(13)00178-3. doi:
      10.1016/j.ypmed.2013.05.015.

PMID- 23732116
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
DP  - 2013 May 31
TI  - Hepatic ERK activity plays a role in energy metabolism.
LID - S0303-7207(13)00225-6 [pii]
LID - 10.1016/j.mce.2013.05.021 [doi]
AB  - Mitogen activated protein kinases (MAPKs), such as c-Jun N-terminal kinase (JNK) 
      and P38, have been reported to play important roles in energy homeostasis. In
      this study, we show that the activity of extracellular signal-regulated kinase
      (ERK) is increased in the livers of diet induced and genetically obese mice.
      Activation of ERK in the livers of lean mice by over-expressing the
      constitutively active MAPK kinase 1 (MEK CA) results in decreased energy
      expenditure, lowered expression of genes involved in fatty acid oxidation,
      increases fasting hyperglycemia and causes systemic insulin resistance.
      Interestingly, hepatic glycogen content is markedly increased and expression of
      G6Pase gene is decreased in mice over-expressing MEK CA compared to control mice 
      expressing green fluorescent protein (GFP), therefore hepatic glucose output is
      not likely the major contributor of hyperglycemia. One potential mechanism of
      decreased expression of G6Pase gene by MEK CA is likely due to ERK mediated
      phosphorylation and cytosolic retention of FOXO1. Adipocytes isolated from MEK CA
      mice display increased lipolysis. Circulating levels of free fatty acids (FFAs)
      in these mice are also increased, which possibly contribute to systemic insulin
      resistance and subsequent hyperglycemia. Consistent with these results, knocking 
      down ERK expression in the liver of diet induced obese (DIO) mice improves
      systemic insulin and glucose tolerance. These results indicate that increased
      hepatic ERK activity in DIO mice may contribute to increased liver glycogen
      content and decreased energy expenditure in obesity.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - Hallett Center for Diabetes and Endocrinology, Rhode Island Hospital, Warren
      Alpert Medical School of Brown University, Providence, RI 02903, USA; School of
      Pharmaceutical Sciences, Jilin University, Changchun, Jilin Province, China.
FAU - Jiao, Ping
AU  - Jiao P
FAU - Feng, Bin
AU  - Feng B
FAU - Li, Yujie
AU  - Li Y
FAU - He, Qin
AU  - He Q
FAU - Xu, Haiyan
AU  - Xu H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/01/15 [received]
PHST- 2013/05/01 [revised]
PHST- 2013/05/22 [accepted]
AID - S0303-7207(13)00225-6 [pii]
AID - 10.1016/j.mce.2013.05.021 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 May 31. pii: S0303-7207(13)00225-6. doi:
      10.1016/j.mce.2013.05.021.

PMID- 23732088
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 0767-0974 (Print)
IS  - 0767-0974 (Linking)
VI  - 29
IP  - 5
DP  - 2013 May
TI  - [Role of the nucleus of the solitary tract in the detection and integration of
      multiple metabolic signals].
PG  - 449-52
LID - 10.1051/medsci/2013295002 [doi]
AD  - Albert Einstein College of Medicine, Diabetes Research Center, 1300 Morris Park
      avenue, Golding 501, Bronx, 10461, New York, Etats-Unis.
FAU - Blouet, Clemence
AU  - Blouet C
LA  - fre
PT  - Journal Article
TT  - Le role du noyau du tractus solitaire dans la detection et l'integration de
      multiples signaux metaboliques.
DEP - 20130528
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/05/28 [epublish]
AID - 10.1051/medsci/2013295002 [doi]
AID - medsci2013295p449 [pii]
PST - ppublish
SO  - Med Sci (Paris). 2013 May;29(5):449-52. doi: 10.1051/medsci/2013295002. Epub 2013
      May 28.

PMID- 23731967
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1741-203X (Electronic)
IS  - 1041-6102 (Linking)
DP  - 2013 Jun 4
TI  - Medication adherence survey of drugs useful in prevention of dementia of
      Alzheimer's type among Indian patients.
PG  - 1-5
AB  - ABSTRACT Background: Good medication adherence is the cornerstone of therapeutic 
      success. Alzheimer's disease (AD) is the most common type of dementia and most
      patients are old and on multiple drugs, and good compliance therefore is even
      more important in this population. Dementia of Alzheimer's type (DAT) at present 
      is yet to find a cure. Anticholinesterases and N-methyl-D-aspartate blockers are 
      specific anti-AD therapies available. Hypertension, diabetes, and dyslipidemia
      can contribute to cognitive worsening. Keeping hypertension, diabetes, and
      dyslipidemia in control can therefore possibly prevent further cognitive decline.
      Methods: Patients with subjective memory complaints (n = 75) were chosen
      randomly. Upon thorough neurological diagnostic work up for dementia, those with 
      mild cognitive impairment/questionable dementia (Clinical Dementia Rating = 0.5) 
      or those with AD were recruited in this study (n = 67). Those with hypertension, 
      diabetes, and deranged lipid profile were further interviewed if they were able
      to take medicines regularly or not. An attempt was made to know causes of
      non-compliance. Results: Forty-one percent of patients were not taking the drugs 
      that have potential to prevent cardiovascular complications or ability to slow
      down cognitive decline in AD on regular basis. The lack of awareness, ignorance, 
      medicines being "too expensive," and the pressure of taking medicines regularly
      were cited as the reasons for non-compliance. Being illiterate and having low
      education contributed majorly to poor compliance in this study. Conclusion:
      Compliance to drugs that have potential or real ability to slow down cognitive
      decline is low in elderly people with DAT.
AD  - Department of Neurology, Dr RML Hospital and Postgraduate Institute of Medical
      Education and Research (PGIMER), GGS-IP University, Baba Kharak Singh Marg, New
      Delhi 110001, India.
FAU - Dhikav, Vikas
AU  - Dhikav V
FAU - Singh, Pritika
AU  - Singh P
FAU - Anand, Kuljeet Singh
AU  - Anand KS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Int Psychogeriatr
JT  - International psychogeriatrics / IPA
JID - 9007918
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - S1041610213000744 [pii]
AID - 10.1017/S1041610213000744 [doi]
PST - aheadofprint
SO  - Int Psychogeriatr. 2013 Jun 4:1-5.

PMID- 23731923
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
DP  - 2013 May 31
TI  - Clinical characteristics and long-term clinical outcomes of Japanese heart
      failure patients with preserved versus reduced left ventricular ejection
      fraction: A prospective cohort of Shinken Database 2004-2011.
LID - S0914-5087(13)00123-8 [pii]
LID - 10.1016/j.jjcc.2013.03.013 [doi]
AB  - BACKGROUND: Clinical data on the mortality and morbidity of unselected Japanese
      patients with heart failure (HF) are limited. In this study, we aimed to
      determine the clinical characteristics, long-term outcomes, and prognostic
      factors of Japanese HF patients with preserved or reduced left ventricular
      ejection fraction (LVEF). METHODS AND RESULTS: We used a single hospital-based
      cohort from the Shinken Database 2004-2011 that comprised all new patients
      (n=17,517) visiting the Cardiovascular Institute Hospital. A total of 1525
      patients diagnosed with symptomatic HF at the initial visit were included in the 
      analysis. Of these, 1121 patients (74%) exhibited a preserved LVEF (>50%) and 404
      patients (26%) had a reduced LVEF (</=50%). HF patients with preserved LVEF
      (HFpEF) were older and more often female than patients with reduced LVEF (HFrEF).
      Kaplan-Meier curves and log-rank test results showed that HFpEF patients had a
      better prognosis than HFrEF patients. However, there were no significant
      differences in clinical outcomes between HFpEF and HFrEF patients when the
      analysis was limited to inpatients. Cox regression analysis showed that HFpEF
      patients had a significantly lower risk of all-cause death (p=0.027; hazard
      ratio, 0.547, 95% confidence interval, 0.321-0.933). Multivariate analyses
      performed separately showed that the independent predictors of all-cause death in
      HFrEF were advanced age, lower body mass index, diabetes mellitus, and the
      absence of statin treatment, whereas those for HFpEF were advanced age, absence
      of dyslipidemia, anemia, and left ventricular hypertrophy. CONCLUSIONS: This
      prospective cohort study identified the clinical characteristics, long-term
      outcomes, and prognostic factors of Japanese HF patients with reduced and
      preserved ejection fractions in a real-world clinical setting.
CI  - Copyright (c) 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All
      rights reserved.
AD  - The Cardiovascular Institute, Tokyo, Japan. Electronic address:
      h-kaneko@cvi.or.jp.
FAU - Kaneko, Hidehiro
AU  - Kaneko H
FAU - Suzuki, Shinya
AU  - Suzuki S
FAU - Yajima, Junji
AU  - Yajima J
FAU - Oikawa, Yuji
AU  - Oikawa Y
FAU - Sagara, Koichi
AU  - Sagara K
FAU - Otsuka, Takayuki
AU  - Otsuka T
FAU - Matsuno, Shunsuke
AU  - Matsuno S
FAU - Kano, Hiroto
AU  - Kano H
FAU - Uejima, Tokuhisa
AU  - Uejima T
FAU - Koike, Akira
AU  - Koike A
FAU - Nagashima, Kazuyuki
AU  - Nagashima K
FAU - Kirigaya, Hajime
AU  - Kirigaya H
FAU - Sawada, Hitoshi
AU  - Sawada H
FAU - Aizawa, Tadanori
AU  - Aizawa T
FAU - Yamashita, Takeshi
AU  - Yamashita T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/01/20 [received]
PHST- 2013/03/07 [revised]
PHST- 2013/03/11 [accepted]
AID - S0914-5087(13)00123-8 [pii]
AID - 10.1016/j.jjcc.2013.03.013 [doi]
PST - aheadofprint
SO  - J Cardiol. 2013 May 31. pii: S0914-5087(13)00123-8. doi:
      10.1016/j.jjcc.2013.03.013.

PMID- 23731902
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 Jun 4
TI  - Diabetes Mellitus and Decompensated Cirrhosis: Risk of Hepatic Encephalopathy in 
      Different Age Groups.
LID - 10.1111/1753-0407.12067 [doi]
AB  - OBJECTIVE: To examine the association of diabetes mellitus with prevalence and
      severity of hepatic encephalopathy in patients with decompensated cirrhosis and
      determine the impact of age and gender on this relationship. METHODS: We
      prospectively evaluated 352 consecutive patients of decompensated cirrhosis for
      the presence of HE using West Haven criteria. Detailed clinicobiochemical
      profiling of patients was carried out. Modified Child Pugh and Model for End
      Stage Liver Disease scores (MELD) were calculated. Chi-square test for
      independence was used for categorical data while chi-squares test for trend was
      employed for ordered categorical variables. T-test and Mann-Whitney U test were
      used for continuous normal and continuous non-parametric data respectively.
      RESULTS: Hepatic encephalopathy (HE) was present in 50.3% of patients at time of 
      admission. A total of 118 patients had DM (33.5%). Among diabetics, prevalence
      (58.5% vs. 42.6%, p=0.03) and severity of HE (P (trend) = 0.01) was significantly
      higher as compared to patients without DM. The two groups, however, did not
      differ in Child Pugh class, MELD scores, presence of ascites and esophageal
      varices. Patients with DM had higher platelet levels than those without DM (P
      (trend) = 0.003). Trend for increasing serum creatinine was significant for
      diabetics (p=0.04) while trend for increasing AST levels (p=0.03) and serum
      bilirubin (p=0.04) was significant for non-diabetics. In the age and gender
      subgroup analysis, older patients with DM had significantly higher evidence of HE
      (p=0.02) as do males with DM (p=0.03). Multivariate analysis showed that DM
      (p=0.03) and older age (p=0.0.006) were independently related to HE while gender 
      remained insignificant. CONCLUSION: DM and older age are independently associated
      with HE in patients with cirrhosis. THE SIGNIFICANT FINDING (S) OF THE STUDY:
      Cirrhotic patients with diabetes are more likely to present with hepatic
      encephalopathy than cirrhotic patients without diabetes. Moreover, diabetes and
      age independently increase prevalence of hepatic encephalopathy in decompensated 
      cirrhosis. THIS STUDY ADDS: Diabetes and advancing age interact with each other
      in increasing prevalence of hepatic encephalopathy and both are also
      independently associated with hepatic encephalopathy.
CI  - This article is protected by copyright. All rights reserved.
AD  - King Edward Medical University/Mayo Hospital, Lahore, Pakistan; Center for
      Biomedical Research, Lahore, Pakistan.
FAU - Butt, Zeeshan
AU  - Butt Z
FAU - Jadoon, Nauman A
AU  - Jadoon NA
FAU - Salaria, Osman N
AU  - Salaria ON
FAU - Mushtaq, Kamran
AU  - Mushtaq K
FAU - Riaz, Irbaz B
AU  - Riaz IB
FAU - Shahzad, Ahmed
AU  - Shahzad A
FAU - Hashmi, Ali M
AU  - Hashmi AM
FAU - Sarwar, Shahid
AU  - Sarwar S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/26 [accepted]
AID - 10.1111/1753-0407.12067 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 Jun 4. doi: 10.1111/1753-0407.12067.

PMID- 23731887
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1878-1594 (Electronic)
IS  - 1521-690X (Linking)
VI  - 27
IP  - 2
DP  - 2013 Apr
TI  - Diagnostic imaging in obesity.
PG  - 261-77
LID - 10.1016/j.beem.2013.02.003 [doi]
LID - S1521-690X(13)00021-3 [pii]
AB  - Magnetic resonance of the body offers different techniques for mapping fat
      deposits (MR Imaging) and analysis of organs with small amounts of lipids (MR
      Spectroscopy). Possible approaches for whole-body assessment of adipose tissue
      are presented and discussed and spectroscopic examinations in different organs
      are depicted. With magnetic resonance imaging (MRI) it has been shown that
      obesity per se is not a marker for metabolic failure, but depends on regional
      variations of body composition and ectopic lipid accumulation. In addition MRI of
      the brain is a powerful research tool to understand the brain's role in the
      development and maintenance of obesity and the overconsumption of foods in obese 
      individuals. Sonography has a low accuracy in estimating hepatic steatosis until 
      now. New sonographic methods have been evaluated to detect hepatic steatosis by
      physical properties of fatty tissue as tissue stiffness, sound absorption or
      sound speed. Nuclear medicine and in particular Positron Emission Tomography
      (PET) methods are used to explore central pathophysiology, brown adipose tissue
      activity and alterations in homeostatic feedback and gut-brain communication.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz
      Center Munich at the University of Tubingen (Paul Langerhans Institute Tubingen),
      Tubingen, Germany; Section on Experimental Radiology, Department of Diagnostic
      and Interventional Radiology, University Hospital Tubingen, Tubingen, Germany.
      Electronic address: juergen.machann@med.uni-tuebingen.de.
FAU - Machann, Jurgen
AU  - Machann J
FAU - Horstmann, Annette
AU  - Horstmann A
FAU - Born, Mark
AU  - Born M
FAU - Hesse, Swen
AU  - Hesse S
FAU - Hirsch, Franz Wolfgang
AU  - Hirsch FW
LA  - eng
PT  - Journal Article
DEP - 20130305
PL  - Netherlands
TA  - Best Pract Res Clin Endocrinol Metab
JT  - Best practice & research. Clinical endocrinology & metabolism
JID - 101120682
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/03/05 [aheadofprint]
AID - S1521-690X(13)00021-3 [pii]
AID - 10.1016/j.beem.2013.02.003 [doi]
PST - ppublish
SO  - Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):261-77. doi:
      10.1016/j.beem.2013.02.003. Epub 2013 Mar 5.

PMID- 23731885
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1878-1594 (Electronic)
IS  - 1521-690X (Linking)
VI  - 27
IP  - 2
DP  - 2013 Apr
TI  - Surgical interventions for obesity and metabolic disease.
PG  - 239-46
LID - 10.1016/j.beem.2012.12.001 [doi]
LID - S1521-690X(12)00117-0 [pii]
AB  - Obesity continues to be a growing problem in both the developed and the
      developing world. Its strong link with co-morbid conditions such as type 2
      diabetes, hypertension, obstructive sleep apnea, and depression presents an
      increasing strain on health care systems around the world. Diet and exercise
      alone has been shown to be largely ineffective at managing obesity. Surgery is
      the only evidence-based method of allowing morbidly obese patients to lose weight
      and to maintain this weight loss. Weight-reduction in obese individuals from
      bariatric surgery has also been found to markedly improve obesity-related
      co-morbid conditions, particularly, type 2-diabetes. Diabetic remission from
      bariatric surgery has resulted in the inclusion of bariatric surgery, by the
      International Diabetes Taskforce, as a treatment modality for type-2 diabetes.
      This consensus statement named four surgical options that have been found to be
      effective in both weight-loss and in inducing diabetes remission. These four
      surgical procedures lead to weight-loss through restrictive and malabsorptive
      mechanisms. Each specific operation has a different level of efficacy in inducing
      weight-loss and diabetic remission, as well as distinct types and rates of
      complications. This article reviews the best evidence that exists for the
      effectiveness and complications of these four operations.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
AD  - Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
FAU - Vu, Lan
AU  - Vu L
FAU - Switzer, Noah J
AU  - Switzer NJ
FAU - De Gara, Christopher
AU  - De Gara C
FAU - Karmali, Shahzeer
AU  - Karmali S
LA  - eng
PT  - Journal Article
DEP - 20130109
PL  - Netherlands
TA  - Best Pract Res Clin Endocrinol Metab
JT  - Best practice & research. Clinical endocrinology & metabolism
JID - 101120682
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/01/09 [aheadofprint]
AID - S1521-690X(12)00117-0 [pii]
AID - 10.1016/j.beem.2012.12.001 [doi]
PST - ppublish
SO  - Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):239-46. doi:
      10.1016/j.beem.2012.12.001. Epub 2013 Jan 9.

PMID- 23731882
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1878-1594 (Electronic)
IS  - 1521-690X (Linking)
VI  - 27
IP  - 2
DP  - 2013 Apr
TI  - Urogenital complications of obesity.
PG  - 209-18
LID - 10.1016/j.beem.2013.04.002 [doi]
LID - S1521-690X(13)00034-1 [pii]
AB  - We performed a critical review focused on the main non-oncologic disorders that
      have a strong, direct association with obesity: chronic kidney disease, kidney
      stones and female and male lower urinary tract symptoms/disorders. We discuss the
      epidemiology, pathogenesis and therapeutic aspects regarding the association
      between obesity and non-diabetic and non-hypertensive forms of chronic kidney
      disease directly caused or worsened by weight excess, with particular attention
      on obesity-related glomerulopathy (ORG), which is typical of severe obesity, and 
      the consequences of intentional weight loss on proteinuria and glomerular
      filtration rate. The associations of obesity with kidney stones and lower urinary
      tract conditions are also discussed from the epidemiological, physiopathological 
      and therapeutical points of view, with emphasis on the principal concerns raised 
      by the heterogeneity of study designs and outcome definitions typical of research
      in these fields. We also call attention to important clinical and scientific
      questions that should be addressed by future research.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Complex Operative Unit of Pediatric Diabetes, Clinical Nutrition and Obesity,
      Department of Life and Reproduction Sciences, University of Verona, Via Bengasi, 
      4, 37134 Verona, Italy.
FAU - Morandi, Anita
AU  - Morandi A
FAU - Maffeis, Claudio
AU  - Maffeis C
LA  - eng
PT  - Journal Article
DEP - 20130504
PL  - Netherlands
TA  - Best Pract Res Clin Endocrinol Metab
JT  - Best practice & research. Clinical endocrinology & metabolism
JID - 101120682
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/05/04 [aheadofprint]
AID - S1521-690X(13)00034-1 [pii]
AID - 10.1016/j.beem.2013.04.002 [doi]
PST - ppublish
SO  - Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):209-18. doi:
      10.1016/j.beem.2013.04.002. Epub 2013 May 4.

PMID- 23731880
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1878-1594 (Electronic)
IS  - 1521-690X (Linking)
VI  - 27
IP  - 2
DP  - 2013 Apr
TI  - Metabolic complications of obesity.
PG  - 179-93
LID - 10.1016/j.beem.2013.02.004 [doi]
LID - S1521-690X(13)00022-5 [pii]
AB  - Obesity is a risk factor for several metabolic complications, with insulin
      resistance being the common denominator in these conditions. Impaired blood
      glucose regulation is one of the most important of these complications, and
      includes type 2 diabetes mellitus (T2DM), prediabetes, and gestational diabetes. 
      Metabolic syndrome describes a constellation of features including insulin
      resistance, hypertension, dyslipidemia, and abdominal obesity. Polycystic ovary
      syndrome is a condition characterized by ovulatory dysfunction and clinical
      evidence of hyperandrogenism. As many of these complications can go unnoticed for
      years without overt clinical complications, awareness of both patients and health
      care professionals is essential such that appropriate screening and diagnostic
      strategies can be undertaken. Aggressive management strategies of diabetic and
      prediabetic states are essential for prevention of complications over time.
      Strategies for identification of vascular risk factors must be implemented such
      that appropriate risk reduction strategies can be undertaken to minimize the risk
      of development of cardiovascular complications.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - C-ENDO Endocrinology Centre Calgary, Suite 240, 1016 - 68th Avenue SW, Calgary,
      AB T2V 4J2, Canada. Electronic address: drsuepedersen@gmail.com.
FAU - Pedersen, Sue D
AU  - Pedersen SD
LA  - eng
PT  - Journal Article
DEP - 20130306
PL  - Netherlands
TA  - Best Pract Res Clin Endocrinol Metab
JT  - Best practice & research. Clinical endocrinology & metabolism
JID - 101120682
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/03/06 [aheadofprint]
AID - S1521-690X(13)00022-5 [pii]
AID - 10.1016/j.beem.2013.02.004 [doi]
PST - ppublish
SO  - Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):179-93. doi:
      10.1016/j.beem.2013.02.004. Epub 2013 Mar 6.

PMID- 23731879
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1878-1594 (Electronic)
IS  - 1521-690X (Linking)
VI  - 27
IP  - 2
DP  - 2013 Apr
TI  - Adipose tissue dysfunction contributes to obesity related metabolic diseases.
PG  - 163-77
LID - 10.1016/j.beem.2013.02.005 [doi]
LID - S1521-690X(13)00023-7 [pii]
AB  - Obesity significantly increases the risk of developing type 2 diabetes,
      hypertension, coronary heart disease, stroke, fatty liver disease, dementia,
      obstructive sleep apnea and several types of cancer. Adipocyte and adipose tissue
      dysfunction represent primary defects in obesity and may link obesity to
      metabolic and cardiovascular diseases. Adipose tissue (AT) dysfunction manifests 
      by a proinflammatory adipokine secretion pattern that mediate auto/paracrine and 
      endocrine communication and by inflammatory cell infiltration, particularly in
      intra-abdominal fat. Impaired AT function is caused by the interaction of
      genetic, behavioral and environmental factors which lead to adipocyte
      hypertrophy, ectopic fat accumulation, hypoxia, AT stresses, impaired AT
      mitochondrial function and inflammatory processes within adipose tissue.
      Recently, increased autophagy has been linked to obesity and AT dysfunction and
      may represent a mechanism to compensate for AT stresses. A better understanding
      of mechanisms causing or maintaining AT dysfunction may provide new therapeutic
      strategies in the treatment of obesity-induced metabolic diseases.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Medicine, University of Leipzig, Liebigstr. 20, 04103 Leipzig,
      Germany. Electronic address: bluma@medizin.uni-leipzig.de.
FAU - Bluher, Matthias
AU  - Bluher M
LA  - eng
PT  - Journal Article
DEP - 20130306
PL  - Netherlands
TA  - Best Pract Res Clin Endocrinol Metab
JT  - Best practice & research. Clinical endocrinology & metabolism
JID - 101120682
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/03/06 [aheadofprint]
AID - S1521-690X(13)00023-7 [pii]
AID - 10.1016/j.beem.2013.02.005 [doi]
PST - ppublish
SO  - Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):163-77. doi:
      10.1016/j.beem.2013.02.005. Epub 2013 Mar 6.

PMID- 23731827
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 31
TI  - Obesity and hyperlipidemia are risk factors for early diabetic neuropathy.
LID - S1056-8727(13)00071-8 [pii]
LID - 10.1016/j.jdiacomp.2013.04.003 [doi]
AB  - The Utah Diabetic Neuropathy Study (UDNS) examined 218 type 2 diabetic subjects
      without neuropathy symptoms, or with symptoms of<5years, in order to evaluate
      risk factors for neuropathy development. Each subject completed symptom
      questionnaires, the Utah Early Neuropathy Scale (UENS), nerve conduction studies 
      (NCS), quantitative sensory testing (QST) for vibration and cold detection,
      quantitative sudomotor axon reflex testing (QSART), and skin biopsy with
      measurement of intraepidermal nerve fiber density (IENFD). Those with
      abnormalities of>/=3 were classified as having probable, and those with 1-2 as
      possible neuropathy. The relationship between glycemic control, lipid parameters 
      (high density lipoprotein and triglyceride levels), blood pressure, and obesity, 
      and neuropathy risk was examined. There was a significant relationship between
      the number of abnormalities among these features and neuropathy status (p<0.01). 
      Hypertriglyceridemia, obesity and 3 or more abnormalities increased neuropathy
      risk (risk ratios 2.1 p<0.03, 2.9 p>0.02 and 3.0 p<0.004 respectively).
      Multivariate analysis found obesity and triglycerides were related to loss of
      small unmyelinated axons based on IENFD whereas elevated hemoglobin A1c was
      related to large myelinated fiber loss (motor conduction velocity). These
      findings indicate obesity and hypertriglyceridemia significantly increase risk
      for peripheral neuropathy, independent of glucose control.
      Obesity/hypertriglyceridemia and hyperglycemia may have differential effects on
      small versus large fibers.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Neurology, University of Utah, Salt Lake City, UT, USA. Electronic 
      address: Gordon.smith@hsc.utah.edu.
FAU - Smith, A Gordon
AU  - Smith AG
FAU - Singleton, J Robinson
AU  - Singleton JR
LA  - ENG
GR  - R01 DK064814/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/10/01 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/04/05 [accepted]
AID - S1056-8727(13)00071-8 [pii]
AID - 10.1016/j.jdiacomp.2013.04.003 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 31. pii: S1056-8727(13)00071-8. doi:
      10.1016/j.jdiacomp.2013.04.003.

PMID- 23731805
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1579-2021 (Electronic)
IS  - 1575-0922 (Linking)
DP  - 2013 May 31
TI  - Estimated glucose disposal rate in patients under 18 years of age with type 1
      diabetes mellitus and overweight or obesity.
LID - S1575-0922(13)00119-8 [pii]
LID - 10.1016/j.endonu.2013.02.005 [doi]
AB  - OBJECTIVE: To assess the estimated glucose disposal rate (eGDR), insulin dose,
      and lipoprotein profile in children with type 1 diabetes mellitus (T1DM) and
      overweight or obesity as compared to children with T1DM and normal weight.
      METHODS: A total of 115 patients (aged 5-16 years) with T1DM on intensive insulin
      therapy were recruited. The following parameters were measured: weight, height,
      body mass index, waist and hip circumference, insulin dose, eGDR, glycosylated
      hemoglobin, blood pressure, and lipoprotein profile. Results were stratified by
      sex and age. RESULTS: No significant differences were found in eGDR between
      children with normal weight, overweight, and obesity. However, obese children
      older than 11 years had lower eGDR values (9.3+/-1.3 vs 10.1+/-0.8mg kg-1min-1;
      p<0.01). Insulin dose was higher in overweight and obese children, especially in 
      IU/m2/day (37.7 vs 36.1 vs 29.4 respectively; p<0.01). Obese children had higher 
      low-density lipoprotein cholesterol levels than children with overweight and
      normal weight (106.5 vs 91.7 vs 91.5mg/dL respectively; p<0.01). No correlation
      was found between waist circumference and the different markers of insulin
      resistance. CONCLUSIONS: Values of eGDR values were lower in obese children with 
      T1DM older than 11 years, and this may therefore be considered a marker of
      insulin resistance. Insulin dose was higher in diabetic patients with overweight 
      or obesity, specially in IU/m2/day. Obese children with T1DM had a lipoprotein
      profile of cardiovascular risk.
CI  - Copyright (c) 2012 SEEN. Published by Elsevier Espana. All rights reserved.
AD  - Unidad de Endocrinologia Pediatrica, Hospital General Universitario de Ciudad
      Real, Ciudad Real, Espana. Electronic address: palomo.enrique@gmail.com.
FAU - Palomo Atance, Enrique
AU  - Palomo Atance E
FAU - Ballester Herrera, M Jose
AU  - Ballester Herrera MJ
FAU - Giralt Muina, Patricio
AU  - Giralt Muina P
FAU - Ruiz Cano, Rafael
AU  - Ruiz Cano R
FAU - Leon Martin, Alberto
AU  - Leon Martin A
FAU - Giralt Muina, Juan
AU  - Giralt Muina J
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Tasa estimada de disposicion de glucosa en pacientes menores de 18 anos con
      diabetes mellitus tipo 1 y sobrepeso-obesidad.
DEP - 20130531
TA  - Endocrinol Nutr
JT  - Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y
      Nutricion
JID - 100886482
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/10/17 [received]
PHST- 2013/01/24 [revised]
PHST- 2013/02/04 [accepted]
AID - S1575-0922(13)00119-8 [pii]
AID - 10.1016/j.endonu.2013.02.005 [doi]
PST - aheadofprint
SO  - Endocrinol Nutr. 2013 May 31. pii: S1575-0922(13)00119-8. doi:
      10.1016/j.endonu.2013.02.005.

PMID- 23731804
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1579-2021 (Electronic)
IS  - 1575-0922 (Linking)
DP  - 2013 May 31
TI  - DiabeTIC website: a pilot study of satisfaction and impact on metabolic control.
LID - S1575-0922(13)00118-6 [pii]
LID - 10.1016/j.endonu.2013.01.017 [doi]
AB  - OBJECTIVES: To evaluate satisfaction and short-term impact on metabolic control
      of diabetes monitoring through the DiabeTIC website. PATIENTS AND METHODS: A
      prospective, uncontrolled intervention study was conducted in 32 patients aged
      29.7+/-9.7 years (65% female) incorporated to the telemedicine platform DiabeTIC 
      between March and September 2012. All patients completed a satisfaction
      questionnaire in the first month, and impact on metabolic control was evaluated
      at three and six months. RESULTS: In the satisfaction survey conducted in the
      first month of follow-up, the following mean scores (0-10) were obtained: overall
      impression with the platform: 8.6+/-1.8; ease of use: 8.1+/-1.5; intuitive
      navigation: 6.7+/-3.0; value of measurements: 9.1+/-1.1; importance of the
      platform in diabetes management: 9.5+/-0.9; sense of security: 9.5+/-0.8; value
      of the library: 9.4+/-1.1; value of messages: 9.1+/-1.4, and recommendation to
      use the platform: 9.4+/-0.9. Glycosilated hemoglobin concentrations significantly
      improved at six months as compared to study start (7.0+/-0.8 versus 8.1+/-1.9;
      p=0.007). Nine patients were discharged from DiabeTIC before completing six
      months of follow-up. CONCLUSIONS: Patients with diabetes monitored through the
      DiabeTIC website report a high degree of satisfaction, showing improved metabolic
      control at short-term follow-up.
CI  - Copyright (c) 2012 SEEN. Published by Elsevier Espana. All rights reserved.
AD  - Unidad de Gestion Clinica (UGC) de Endocrinologia y Nutricion, Hospital
      Universitario Puerto Real, Cadiz, Espana. Electronic address:
      florencarral@hotmail.com.
FAU - Carral San Laureano, Florentino
AU  - Carral San Laureano F
FAU - Ayala Ortega, Maria Del Carmen
AU  - Ayala Ortega MD
FAU - Jimenez Millan, Ana Isabel
AU  - Jimenez Millan AI
FAU - Pinero Zaldivar, Antonia
AU  - Pinero Zaldivar A
FAU - Garcia Calzado, Concepcion
AU  - Garcia Calzado C
FAU - Prieto Ferron, Matilde
AU  - Prieto Ferron M
FAU - Jose Silva Rodriguez, Juan
AU  - Jose Silva Rodriguez J
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Pagina web DiabeTIC: estudio piloto de la satisfaccion e impacto sobre el control
      metabolico.
DEP - 20130531
TA  - Endocrinol Nutr
JT  - Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y
      Nutricion
JID - 100886482
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/05 [received]
PHST- 2013/01/21 [revised]
PHST- 2013/01/29 [accepted]
AID - S1575-0922(13)00118-6 [pii]
AID - 10.1016/j.endonu.2013.01.017 [doi]
PST - aheadofprint
SO  - Endocrinol Nutr. 2013 May 31. pii: S1575-0922(13)00118-6. doi:
      10.1016/j.endonu.2013.01.017.

PMID- 23731777
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1477-7525 (Electronic)
IS  - 1477-7525 (Linking)
VI  - 11
DP  - 2013
TI  - Health-related quality of life associated with daytime and nocturnal
      hypoglycaemic events: a time trade-off survey in five countries.
PG  - 90
LID - 10.1186/1477-7525-11-90 [doi]
AB  - BACKGROUND: Hypoglycaemic events, particularly nocturnal, affect health-related
      quality of life (HRQoL) via acute symptoms, altered behaviour and fear of future 
      events. We examined the respective disutility associated with a single event of
      daytime, nocturnal, severe and non-severe hypoglycaemia. METHODS: Representative 
      samples were taken from Canada, Germany, Sweden, the United States and the United
      Kingdom. Individuals completed an internet-based questionnaire designed to
      quantify the HRQoL associated with different diabetes- and/or
      hypoglycaemia-related health states. HRQoL was measured on a utility scale: 1
      (perfect health) to 0 (death) using the time trade-off method. Three populations 
      were studied: 8286 respondents from the general population; 551 people with type 
      1 diabetes; and 1603 with type 2 diabetes. Respondents traded life expectancy for
      improved health states and evaluated the health states of well-controlled
      diabetes and diabetes with non-severe/severe and daytime/nocturnal hypoglycaemic 
      events. RESULTS: In the general population, non-severe nocturnal hypoglycaemic
      events were associated with a 0.007 disutility compared with 0.004 for non-severe
      daytime episodes, equivalent to a significant 63% increase in negative impact.
      Severe daytime and nocturnal events were associated with a 0.057 and a 0.062
      disutility, respectively, which were not significantly different. CONCLUSIONS:
      This study applies an established health economic methodology to derive
      disutilities associated with hypoglycaemia stratified by onset time and severity 
      using a large multinational population. It reveals substantial individual and
      cumulative detrimental effects of hypoglycaemic events - particularly nocturnal -
      on HRQoL, reinforcing the clinical imperative of avoiding hypoglycaemia.
AD  - Department of Diabetes, University Hospital Llandough, Llandough Hospital, Penlan
      Road, Cardiff, Penarth, CF64 2XX, UK. marc.evans2@ntlworld.com.
FAU - Evans, Marc
AU  - Evans M
FAU - Khunti, Kamlesh
AU  - Khunti K
FAU - Mamdani, Muhammad
AU  - Mamdani M
FAU - Galbo-Jorgensen, Claus B
AU  - Galbo-Jorgensen CB
FAU - Gundgaard, Jens
AU  - Gundgaard J
FAU - Bogelund, Mette
AU  - Bogelund M
FAU - Harris, Stewart
AU  - Harris S
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - England
TA  - Health Qual Life Outcomes
JT  - Health and quality of life outcomes
JID - 101153626
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/03/07 [received]
PHST- 2013/05/22 [accepted]
PHST- 2013/06/03 [aheadofprint]
AID - 1477-7525-11-90 [pii]
AID - 10.1186/1477-7525-11-90 [doi]
PST - epublish
SO  - Health Qual Life Outcomes. 2013 Jun 3;11:90. doi: 10.1186/1477-7525-11-90.

PMID- 23731773
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 0873-2159 (Electronic)
IS  - 0873-2159 (Linking)
DP  - 2013 May 31
TI  - Patients with a high risk for obstructive sleep apnea syndrome: Postoperative
      respiratory complications.
LID - S0873-2159(13)00023-8 [pii]
LID - 10.1016/j.rppneu.2013.01.003 [doi]
AB  - BACKGROUND: STOP-BANG score (snore; tired; observed apnea; arterial pressure;
      body mass index; age; neck circumference and gender) can predict the risk of a
      patient having Obstructive Syndrome Apnea (OSA). The aim of this study was to
      evaluate the incidence STOP-BANG score>/=3, in surgical patients admitted to the 
      Post-Anesthesia Care Unit (PACU). METHODS: Observational, prospective study
      conducted in a post-anesthesia care unit (PACU) during three weeks (2011). The
      study population consisted of adult patients after noncardiac and
      non-neurological surgery. Patients were classified as high risk of OSA (HR-OSA)
      if STOP-BANG score>/=3 and Low-risk of OSA (LR-OSA) if STOP-BANG score<3
      (LR-OSA). Patient demographics, intraoperative and postoperative data were
      collected. Patient characteristics were compared using Mann-Whitney U-test,
      t-test for independent groups, and chi-square or Fisher's exact test. RESULTS: A 
      total of 357 patients were admitted to PACU; 340 met the inclusion criteria. 179 
      (52%) were considered HR-OSA. These patients were older, more likely to be
      masculine, had higher BMI, higher ASA physical status, higher incidence of
      ischemic heart disease, heart failure, hypertension, dyslipidemia and underwent
      more frequently insulin treatment for diabetes. These patients had more
      frequently mild/moderated hypoxia in the PACU (9% vs. 3%, p=0.012) and had a
      higher incidence of residual neuromuscular blockade (NMB) (20% vs. 16%, p=0.035).
      Patients with HR-OSA had a longer hospital stay. CONCLUSIONS: Patients with
      HR-OSA had an important incidence among patients scheduled for surgery in our
      hospital. These patients had more co-morbidities and were more prone to
      post-operative complications.
CI  - Copyright (c) 2012 Sociedade Portuguesa de Pneumologia. Published by Elsevier
      Espana. All rights reserved.
AD  - Department of Anesthesiology, Centro Hospitalar de Sao Joao, Porto, Portugal.
FAU - Pereira, H
AU  - Pereira H
FAU - Xara, D
AU  - Xara D
FAU - Mendonca, J
AU  - Mendonca J
FAU - Santos, A
AU  - Santos A
FAU - Abelha, F J
AU  - Abelha FJ
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Rev Port Pneumol
JT  - Revista portuguesa de pneumologia
JID - 9813736
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/10/03 [received]
PHST- 2013/01/29 [revised]
PHST- 2013/01/30 [accepted]
AID - S0873-2159(13)00023-8 [pii]
AID - 10.1016/j.rppneu.2013.01.003 [doi]
PST - aheadofprint
SO  - Rev Port Pneumol. 2013 May 31. pii: S0873-2159(13)00023-8. doi:
      10.1016/j.rppneu.2013.01.003.

PMID- 23731765
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 15
IP  - 7
DP  - 2013 Jul
TI  - Smooth muscle cell transplantation improves bladder contractile function in
      streptozocin-induced diabetic rats.
PG  - 869-78
LID - 10.1016/j.jcyt.2013.02.015 [doi]
LID - S1465-3249(13)00490-8 [pii]
AB  - BACKGROUND AIMS: Damage to smooth muscle has been the primary cause of
      dysfunction in diabetic bladders. Major changes in the filling phase of the
      bladder result in the loss of compliance and incomplete emptying in patients.
      METHODS: Cell-based therapies in the lower urinary tract have shown promising
      results. We argue that because diabetic bladder dysfunction is primarily a
      problem arising out of altered smooth muscle cells (SMCs), it would be an
      interesting approach to introduce healthy SMCs into the bladder wall. RESULTS:
      Furthering this hypothesis, in this experiment, we were successful in introducing
      syngeneic, healthy SMCs into diabetic bladders. We attempted a method wherein
      bladder function can be improved in streptozocin-induced diabetes mellitus. Ex
      vivo-cultured healthy SMCs were introduced into the diabetic bladders of
      syngeneic Sprague-Dawley rats during the hypercontractile phase after induction
      of diabetes. Cystometry, metabolic cage evaluation, organ bath studies and
      histological analyses were performed on the healthy control, the diabetic and the
      diabetic group transplanted with SMCs. CONCLUSIONS: During the 2-week follow-up
      period after transplantation, we noticed an increase in contractile response of
      the bladder correlating to a decrease in residual urine. Cell survival studies
      revealed a cell survival rate close to 1.5%.
CI  - Copyright (c) 2013 International Society for Cellular Therapy. Published by
      Elsevier Inc. All rights reserved.
AD  - Department of Urology, University of Antwerp, Antwerp, Belgium.
FAU - Gopinath, Chaitanya
AU  - Gopinath C
FAU - Ponsaerts, Peter
AU  - Ponsaerts P
FAU - Fransen, Erik
AU  - Fransen E
FAU - Boeykens, Nele
AU  - Boeykens N
FAU - Pauwels, Patrick
AU  - Pauwels P
FAU - Wyndaele, Jean-Jacques
AU  - Wyndaele JJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/10/12 [received]
PHST- 2013/01/18 [revised]
PHST- 2013/02/23 [accepted]
AID - S1465-3249(13)00490-8 [pii]
AID - 10.1016/j.jcyt.2013.02.015 [doi]
PST - ppublish
SO  - Cytotherapy. 2013 Jul;15(7):869-78. doi: 10.1016/j.jcyt.2013.02.015.

PMID- 23731602
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1138-3593 (Print)
IS  - 1138-3593 (Linking)
DP  - 2013 May 31
TI  - [Links between obesity and diabetes mellitus. Reply from the authors.]
LID - S1138-3593(13)00054-3 [pii]
LID - 10.1016/j.semerg.2013.02.004 [doi]
AD  - Medicina de Familia y Comunitaria, Equipo de Atencion Primaria
      Montornes-Montmelo, Direccion de Atencion Primaria Metropolitana Norte,
      Barcelona, Espana. Electronic address: josepguil@hotmail.com.
FAU - Guil Sanchez, J
AU  - Guil Sanchez J
FAU - Rodriguez-Martin, M
AU  - Rodriguez-Martin M
LA  - SPA
PT  - LETTER
TT  - Vinculos entre la obesidad y la diabetes mellitus. Respuesta de los autores.
DEP - 20130531
TA  - Semergen
JT  - Semergen / Sociedad Espanola de Medicina Rural y Generalista
JID - 9610769
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/02/11 [received]
PHST- 2013/02/11 [accepted]
AID - S1138-3593(13)00054-3 [pii]
AID - 10.1016/j.semerg.2013.02.004 [doi]
PST - aheadofprint
SO  - Semergen. 2013 May 31. pii: S1138-3593(13)00054-3. doi:
      10.1016/j.semerg.2013.02.004.

PMID- 23731592
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Diabetes and the millennium development goals.
PG  - 409-10
LID - 10.1016/j.diabres.2013.05.001 [doi]
LID - S0168-8227(13)00169-1 [pii]
CN  - International Diabetes Federation
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - S0168-8227(13)00169-1 [pii]
AID - 10.1016/j.diabres.2013.05.001 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):409-10. doi:
      10.1016/j.diabres.2013.05.001.

PMID- 23731579
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1879-1271 (Electronic)
IS  - 0268-0033 (Linking)
DP  - 2013 Jun 1
TI  - Effect of rocker shoe design features on forefoot plantar pressures in people
      with and without diabetes.
LID - S0268-0033(13)00114-9 [pii]
LID - 10.1016/j.clinbiomech.2013.05.005 [doi]
AB  - BACKGROUND: There is no consensus on the precise rocker shoe outsole design that 
      will optimally reduce plantar pressure in people with diabetes. This study aimed 
      to understand how peak plantar pressure is influenced by systematically varying
      three design features which characterise a curved rocker shoe: apex angle, apex
      position and rocker angle. METHODS: A total of 12 different rocker shoe designs, 
      spanning a range of each of the three design features, were tested in 24 people
      with diabetes and 24 healthy participants. Each subject also wore a flexible
      control shoe. Peak plantar pressure, in four anatomical regions, was recorded for
      each of the 13 shoes during walking at a controlled speed. FINDINGS: There were a
      number of significant main effects for each of the three design features,
      however, the precise effect of each feature varied between the different regions.
      The results demonstrated maximum pressure reduction in the 2nd-4th metatarsal
      regions (39%) but that lower rocker angles (<20 degrees ) and anterior apex
      positions (>60% shoe length) should be avoided for this region. The effect of
      apex angle was most pronounced in the 1st metatarsophalangeal region with a clear
      decrease in pressure as the apex angle was increased to 100 degrees .
      INTERPRETATION: We suggest that an outsole design with a 95 degrees apex angle,
      apex position at 60% of shoe length and 20 degrees rocker angle may achieve an
      optimal balance for offloading different regions of the forefoot. However, future
      studies incorporating additional design feature combinations, on high risk
      patients, are required to make definitive recommendations.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - University of Salford, UK. Electronic address: j.d.chapman@edu.salford.ac.uk.
FAU - Chapman, J D
AU  - Chapman JD
FAU - Preece, S
AU  - Preece S
FAU - Braunstein, B
AU  - Braunstein B
FAU - Hohne, A
AU  - Hohne A
FAU - Nester, C J
AU  - Nester CJ
FAU - Brueggemann, P
AU  - Brueggemann P
FAU - Hutchins, S
AU  - Hutchins S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Clin Biomech (Bristol, Avon)
JT  - Clinical biomechanics (Bristol, Avon)
JID - 8611877
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/03/06 [received]
PHST- 2013/05/10 [revised]
PHST- 2013/05/13 [accepted]
AID - S0268-0033(13)00114-9 [pii]
AID - 10.1016/j.clinbiomech.2013.05.005 [doi]
PST - aheadofprint
SO  - Clin Biomech (Bristol, Avon). 2013 Jun 1. pii: S0268-0033(13)00114-9. doi:
      10.1016/j.clinbiomech.2013.05.005.

PMID- 23731530
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1532-866X (Electronic)
IS  - 0049-0172 (Linking)
DP  - 2013 May 31
TI  - Primary preventive services in patients with systemic lupus erythematosus: Study 
      from a population-based sample in Southeast U.S.
LID - S0049-0172(13)00058-9 [pii]
LID - 10.1016/j.semarthrit.2013.04.003 [doi]
AB  - OBJECTIVES: Systemic lupus erythematosus (SLE) patients are at risk for
      complications that can be mitigated by appropriate preventive care. We examined
      the receipt of immunizations, cancer screening, and cardiovascular risk
      preventive services in a predominantly Black cohort of SLE patients from the
      Southeast U.S. To identify gaps in primary preventive services (PPS) that might
      be specific to SLE as opposed to local health system factors, we used as
      reference a population-based sample from the same area. METHODS: A
      cross-sectional design was used to characterize the percentage of PPS received by
      751 SLE patients from Atlanta, GA, and 9040 subjects from the same community, of 
      whom 938 had diabetes. Factors associated with the receipt of PPS were examined
      with multivariable analysis of variance. RESULTS: Approximately 65% of
      recommended PPS were provided to the SLE, overall community (OC), and diabetes
      samples. However, only 22.5%, 45.7%, and 27.6% of SLE, OC, and diabetes subjects,
      respectively, received all recommended services. Factors associated with a higher
      percentage of PPS received by SLE patients included older age (63.6% if age >/=65
      years, 45.8% if age between 18 and 35 years), having medical insurance (61.1% for
      insured, 49.7% for uninsured), having a primary care physician (PCP) (59.0% if
      patient had PCP, 51.8% if patient did not have PCP), and being a non-smoker
      (61.9% for non-smokers, 49.9% for smokers). CONCLUSIONS: Less than one-quarter of
      SLE patients from a southeast U.S. community received all the recommended
      services that were studied. Further research is warranted to unravel the barriers
      that prevent SLE patients from reaching appropriate standards of preventive care.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Medicine, Emory University School of Medicine, Atlanta, GA.
      Electronic address: cdrenka@emory.edu.
FAU - Drenkard, Cristina
AU  - Drenkard C
FAU - Rask, Kimberly J
AU  - Rask KJ
FAU - Easley, Kirk A
AU  - Easley KA
FAU - Bao, Gaobin
AU  - Bao G
FAU - Lim, S Sam
AU  - Lim SS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Semin Arthritis Rheum
JT  - Seminars in arthritis and rheumatism
JID - 1306053
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/01/07 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/11 [accepted]
AID - S0049-0172(13)00058-9 [pii]
AID - 10.1016/j.semarthrit.2013.04.003 [doi]
PST - aheadofprint
SO  - Semin Arthritis Rheum. 2013 May 31. pii: S0049-0172(13)00058-9. doi:
      10.1016/j.semarthrit.2013.04.003.

PMID- 23731528
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1755-5949 (Electronic)
IS  - 1755-5930 (Linking)
DP  - 2013 Jun 3
TI  - Resveratrol Protects Vascular Endothelial Cells from High Glucose-Induced
      Apoptosis through Inhibition of NADPH Oxidase Activation-Driven Oxidative Stress.
LID - 10.1111/cns.12131 [doi]
AB  - INTRODUCTION: Hyperglycemia-induced oxidative stress has been implicated in
      diabetic vascular complications in which NADPH oxidase is a major source of
      reactive oxygen species (ROS) generation. Resveratrol is a naturally occurring
      polyphenol, which has vasoprotective effects in diabetic animal models and
      inhibits high glucose (HG)-induced oxidative stress in endothelial cells. AIMS:
      We aimed to examine whether HG-induced NADPH oxidase activation and ROS
      production contribute to glucotoxicity to endothelial cells and the effect of
      resveratrol on glucotoxicity. RESULTS: Using a murine brain microvascular
      endothelial cell line bEnd3, we found that NADPH oxidase inhibitor (apocynin) and
      resveratrol both inhibited HG-induced endothelial cell apoptosis. HG-induced
      elevation of NADPH oxidase activity and production of ROS were inhibited by
      apocynin, suggesting that HG induces endothelial cell apoptosis through NADPH
      oxidase-mediated ROS production. Mechanistic studies revealed that HG upregulated
      NADPH oxidase subunit Nox1 but not Nox2, Nox4, and p22phox expression through
      NF-kappaB activation, which resulted in elevation of NADPH oxidase activity and
      consequent ROS production. Resveratrol prevented HG-induced endothelial cell
      apoptosis through inhibiting HG-induced NF-kappaB activation, NADPH oxidase
      activity elevation, and ROS production. CONCLUSIONS: HG induces endothelial cell 
      apoptosis through NF-kappaB/NADPH oxidase/ROS pathway, which was inhibited by
      resveratrol. Our findings provide new potential therapeutic targets against brain
      vascular complications of diabetes.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Key Laboratory of Food Safety Research, Institute for Nutritional Sciences,
      Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
      Shanghai, China; Department of Neurology, Changzheng Hospital, Second Military
      Medical University, Shanghai, China; Key Laboratory of Food Safety Risk
      Assessment, Ministry of Health, Beijing, China.
FAU - Chen, Feng
AU  - Chen F
FAU - Qian, Li-Hua
AU  - Qian LH
FAU - Deng, Bo
AU  - Deng B
FAU - Liu, Zhi-Min
AU  - Liu ZM
FAU - Zhao, Ying
AU  - Zhao Y
FAU - Le, Ying-Ying
AU  - Le YY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - CNS Neurosci Ther
JT  - CNS neuroscience & therapeutics
JID - 101473265
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/02 [received]
PHST- 2013/04/26 [revised]
PHST- 2013/04/27 [accepted]
AID - 10.1111/cns.12131 [doi]
PST - aheadofprint
SO  - CNS Neurosci Ther. 2013 Jun 3. doi: 10.1111/cns.12131.

PMID- 23731527
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 Jun 1
TI  - The role of C-reactive protein genetic variability in the onset of carotid artery
      disease and renal function impairment in patients with diabetes mellitus type 2.
LID - S0167-5273(13)01015-2 [pii]
LID - 10.1016/j.ijcard.2013.05.087 [doi]
AD  - 1st Cardiology Department, Athens University Medical School, Greece.
FAU - Papaoikonomou, Stavroula
AU  - Papaoikonomou S
FAU - Tousoulis, Dimitris
AU  - Tousoulis D
FAU - Tentolouris, Nikolaos
AU  - Tentolouris N
FAU - Papadogiannis, Dimitris
AU  - Papadogiannis D
FAU - Miliou, Antigoni
AU  - Miliou A
FAU - Hatzis, George
AU  - Hatzis G
FAU - Papageorgiou, Nikolaos
AU  - Papageorgiou N
FAU - Antoniades, Charalambos
AU  - Antoniades C
FAU - Stefanadis, Christodoulos
AU  - Stefanadis C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/08 [received]
PHST- 2013/05/04 [accepted]
AID - S0167-5273(13)01015-2 [pii]
AID - 10.1016/j.ijcard.2013.05.087 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 Jun 1. pii: S0167-5273(13)01015-2. doi:
      10.1016/j.ijcard.2013.05.087.

PMID- 23731526
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 May 31
TI  - Prediabetes is not an independent risk factor for incident heart failure, other
      cardiovascular events or mortality in older adults: Findings from a
      population-based cohort study.
LID - S0167-5273(13)00947-9 [pii]
LID - 10.1016/j.ijcard.2013.05.038 [doi]
AB  - BACKGROUND: Whether prediabetes is an independent risk factor for incident heart 
      failure (HF) in non-diabetic older adults remains unclear. METHODS: Of the 4602
      Cardiovascular Health Study participants, age>/=65years, without baseline HF and 
      diabetes, 2157 had prediabetes, defined as fasting plasma glucose (FPG)
      100-125mg/dL. Propensity scores for prediabetes, estimated for each of the 4602
      participants, were used to assemble a cohort of 1421 pairs of individuals with
      and without prediabetes, balanced on 44 baseline characteristics. RESULTS:
      Participants had a mean age of 73years, 57% were women, and 13% African American.
      Incident HF occurred in 18% and 20% of matched participants with and without
      prediabetes, respectively (hazard ratio {HR} associated with prediabetes, 0.90;
      95% confidence interval {CI}, 0.76-1.07; p=0.239). Unadjusted and
      multivariable-adjusted HRs (95% CIs) for incident HF associated with prediabetes 
      among 4602 pre-match participants were 1.22 (95% CI, 1.07-1.40; p=0.003) and 0.98
      (95% CI, 0.85-1.14; p=0.826), respectively. Among matched individuals,
      prediabetes had no independent association with incident acute myocardial
      infarction (HR, 1.02; 95% CI, 0.81-1.28; p=0.875), angina pectoris (HR, 0.93; 95%
      CI, 0.77-1.12; p=0.451), stroke (HR, 0.86; 95% CI, 0.70-1.06; p=0.151) or
      all-cause mortality (HR, 0.99; 95% CI, 0.88-1.11; p=0.840). CONCLUSIONS: We found
      no evidence that prediabetes is an independent risk factor for incident HF, other
      cardiovascular events or mortality in community-dwelling older adults. These
      findings question the wisdom of routine screening for prediabetes in older adults
      and targeted interventions to prevent adverse outcomes in older adults with
      prediabetes.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - University of California, San Francisco, CA, USA.
FAU - Deedwania, Prakash
AU  - Deedwania P
FAU - Patel, Kanan
AU  - Patel K
FAU - Fonarow, Gregg C
AU  - Fonarow GC
FAU - Desai, Ravi V
AU  - Desai RV
FAU - Zhang, Yan
AU  - Zhang Y
FAU - Feller, Margaret A
AU  - Feller MA
FAU - Ovalle, Fernando
AU  - Ovalle F
FAU - Love, Thomas E
AU  - Love TE
FAU - Aban, Inmaculada B
AU  - Aban IB
FAU - Mujib, Marjan
AU  - Mujib M
FAU - Ahmed, Mustafa I
AU  - Ahmed MI
FAU - Anker, Stefan D
AU  - Anker SD
FAU - Ahmed, Ali
AU  - Ahmed A
LA  - ENG
GR  - R01 HL085561/HL/NHLBI NIH HHS/United States
GR  - R01 HL097047/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2011/09/04 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/05/04 [accepted]
AID - S0167-5273(13)00947-9 [pii]
AID - 10.1016/j.ijcard.2013.05.038 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 May 31. pii: S0167-5273(13)00947-9. doi:
      10.1016/j.ijcard.2013.05.038.

PMID- 23731488
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1755-5949 (Electronic)
IS  - 1755-5930 (Linking)
DP  - 2013 Jun 3
TI  - The Involvement of Autophagy Pathway in Exaggerated Ischemic Brain Damage in
      Diabetic Mice.
LID - 10.1111/cns.12123 [doi]
AB  - BACKGROUND: Patients with Diabetes are at greater risk for ischemic stroke and
      usually suffer more severe ischemic brain damage than nondiabetic patients.
      However, the underlying mechanism of the exaggerated injury is not well defined. 
      AIMS: Macroautophagy (hereafter called autophagy in this report) plays a key role
      in cellular homeostasis and may contribute to cell death as well. Our aim was to 
      determine whether autophagy was involved in the enhanced susceptibility of
      diabetic brain cells to ischemic injury and explore it as a possible target for
      the treatment of stroke in a diabetic condition. RESULTS: A type II diabetic
      mouse model generated by combined administration of streptozotocin and
      nicotinamide showed enlarged infarct volume, increased cell death and excessive
      blood-brain barrier (BBB) disruption compared with nondiabetic stroke mice. After
      ischemic stroke, both diabetic and nondiabetic mice showed enhanced autophagosome
      formation and autophagic flux as demonstrated by increased expression of
      autophagy signals Beclin 1, microtubule-associated protein light-chain II
      (LC3-II), and decreased autophagy-specific substrate p62. The increased
      autophagic activity was significantly higher in diabetic stroke mice than that in
      nondiabetic stroke mice. The autophagy inhibitor 3-methyladenine (3-MA)
      attenuated the exaggerated brain injury and improved functional recovery.
      CONCLUSIONS: These data suggest that autophagy contributes to exacerbated brain
      injury in diabetic condition, and autophagy-mediated cell death may be a
      therapeutic target in diabetic stroke.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Neurology, Nanjing University School of Medicine, Jinling Hospital,
      Nanjing, China; Department of Anesthesiology, Emory University School of
      Medicine, Atlanta, GA, USA.
FAU - Wei, Ning
AU  - Wei N
FAU - Yu, Shan-Ping
AU  - Yu SP
FAU - Gu, Xiao-Huan
AU  - Gu XH
FAU - Chen, Dong-Dong
AU  - Chen DD
FAU - Whalin, Matthew K
AU  - Whalin MK
FAU - Xu, Ge-Lin
AU  - Xu GL
FAU - Liu, Xin-Feng
AU  - Liu XF
FAU - Wei, Ling
AU  - Wei L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - CNS Neurosci Ther
JT  - CNS neuroscience & therapeutics
JID - 101473265
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/01/11 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/07 [accepted]
AID - 10.1111/cns.12123 [doi]
PST - aheadofprint
SO  - CNS Neurosci Ther. 2013 Jun 3. doi: 10.1111/cns.12123.

PMID- 23731451
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1742-481X (Electronic)
IS  - 1742-4801 (Linking)
DP  - 2013 Jun 3
TI  - Preliminary investigation of topical nitroglycerin formulations containing
      natural wound healing agent in diabetes-induced foot ulcer.
LID - 10.1111/iwj.12084 [doi]
AB  - Nitroglycerin (NTG) is an organic nitrate rapidly denitrated by enzymes to
      release free radical nitric oxide and shows improved wound healing and tissue
      protection from oxidative damage. The purpose of this study was to evaluate
      whether topical application of NTG in the form of gel/ointment along with a
      natural wound healing agent, aloe vera, would bring about wound healing by using 
      diabetes-induced foot ulcer model and rat excision wound model. All these
      formulations were evaluated for pH, viscosity, drug content and ex vivo diffusion
      studies using rat skin. Based on ex vivo permeation studies, the formulation
      consisting of carbopol 974p as a gelling agent and aloe vera was found to be
      suitable. The in vivo study used streptozotocin-induced diabetic foot ulcer and
      rat excision wound models to analyse wound healing activity. The wound size in
      animals of all treated groups was significantly reduced compared with that of the
      diabetic control and marketed treated animals. This study showed that the gel
      formed with carbopol 974p (1%) and aloe vera promotes significant wound healing
      and closure in diabetic rats compared with the commercial product and provides a 
      promising product to be used in diabetes-induced foot ulcer.
CI  - (c) 2013 The Authors. International Wound Journal (c) 2013 John Wiley & Sons Ltd 
      and Medicalhelplines.com Inc.
AD  - Department of Pharmaceutics, Sinhgad College of Pharmacy, Vadgaon (Bk), India.
FAU - Hotkar, Mukesh S
AU  - Hotkar MS
FAU - Avachat, Amelia M
AU  - Avachat AM
FAU - Bhosale, Sagar S
AU  - Bhosale SS
FAU - Oswal, Yogesh M
AU  - Oswal YM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Int Wound J
JT  - International wound journal
JID - 101230907
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1111/iwj.12084 [doi]
PST - aheadofprint
SO  - Int Wound J. 2013 Jun 3. doi: 10.1111/iwj.12084.

PMID- 23731449
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1753-4887 (Electronic)
IS  - 0029-6643 (Linking)
VI  - 71
IP  - 6
DP  - 2013 Jun
TI  - Dietary sodium, potassium, and alcohol: key players in the pathophysiology,
      prevention, and treatment of human hypertension.
PG  - 402-11
LID - 10.1111/nure.12036 [doi]
AB  - Western industrialized societies are currently experiencing an epidemic expansion
      of hypertension (HTN), which extends alarmingly even to children and adolescents.
      HTN constitutes an independent risk factor for cardiorenal disease and represents
      an extremely common comorbidity of diabetes and obesity. Numerous randomized
      clinical trials and meta-analyses have provided robust scientific evidence that
      reduced dietary salt intake, increased dietary potassium intake, moderation of
      alcohol consumption, optimal weight maintenance, and the adoption of
      "heart-friendly" dietary patterns such as the Dietary Approaches to Stop
      Hypertension or the Mediterranean diet can effectively lower blood pressure.
      Interestingly, the susceptibility of blood pressure to nutritional interventions 
      is greatly variable among individuals, depending on age, race, genetic
      background, and comorbidities. The purpose of this review is to provide a
      comprehensive overview of currently available scientific evidence in the
      constantly evolving field of diet and HTN, placing particular emphasis on the key
      role of dietary sodium, dietary potassium, and alcohol intake in the
      pathophysiology, prevention, and treatment of human hypertension.
CI  - (c) 2013 International Life Sciences Institute.
AD  - Eugenideion Hospital, Athens University Medical School, Athens, Greece.
FAU - Koliaki, Chrysi
AU  - Koliaki C
FAU - Katsilambros, Nicholas
AU  - Katsilambros N
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - United States
TA  - Nutr Rev
JT  - Nutrition reviews
JID - 0376405
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/11 [aheadofprint]
AID - 10.1111/nure.12036 [doi]
PST - ppublish
SO  - Nutr Rev. 2013 Jun;71(6):402-11. doi: 10.1111/nure.12036. Epub 2013 Apr 11.

PMID- 23731442
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Increased glycemic variability at the onset and during progression of type 2
      diabetes-commentary.
PG  - 445-7
LID - 10.1089/dia.2013.0146 [doi]
AD  - Biomedical Informatics Consultants LLC , Potomac, Maryland.
FAU - Rodbard, David
AU  - Rodbard D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1089/dia.2013.0146 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 Jun;15(6):445-7. doi: 10.1089/dia.2013.0146.

PMID- 23731386
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 Jun 3
TI  - Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy
      to improve glucose metabolism in obese rats co-morbid with insulin resistant
      type-2 diabetes.
LID - 10.1111/dom.12130 [doi]
AB  - BACKGROUND: Visceral adiposity and impaired glucose metabolism are common
      patho-physiological features in patients co-morbid with obesity and type-2
      diabetes. We investigated the effects of the heme-oxygenase (HO) inducer, hemin
      and the HO-blocker, stannous-mesoporphyrin (SnMP) on glucose metabolism,
      adipocyte hypertrophy, pro-inflammatory cytokines/mediators in
      Zucker-diabetic-fatty rats (ZDF), a model characterized by obesity and type-2
      diabetes. METHODS: Histological, morphological/morphometrical, Western
      immunoblotting, enzyme immunoassay, ELISA and spectrophotometric analysis were
      used. RESULTS: Treatment with hemin enhanced HO-1, HO-activity, cGMP, but
      suppressed retroperitoneal adiposity and abated the elevated levels of
      macrophage-chemoattractant-protein-1 (MCP-1), ICAM-1, TNF-alpha, IL-6, IL-1beta, 
      NF-kappaB, c-Jun-NH2-terminal-kinase (JNK) and activating-protein (AP-1), with
      parallel reduction of adipocyte hypertrophy. Correspondingly, important proteins 
      of lipid metabolism and insulin-signaling such as lipoprotein lipase (LPL),
      insulin-receptor substrate-1 (IRS-1), GLUT4, PKB/Akt, adiponectin, the
      insulin-sensitizing and anti-inflammatory protein, and
      adenosine-monophosphate-activated protein-kinase (AMPK) were significantly
      enhanced in hemin-treated ZDF. CONCLUSION: Elevated retroperitoneal adiposity and
      the high levels of MCP-1, ICAM-1, TNF-alpha, IL-6, IL-1beta, NF-kappaB, JNK and
      AP-1 in untreated ZDF are patho-physiological factors that exacerbate
      inflammatory insults, aggravate adipocyte hypertrophy, with corresponding
      reduction of adiponectin and deregulation of insulin-signaling and lipid
      metabolism. Therefore, the suppression of MCP-1, ICAM-1, TNF-alpha, IL-6,
      IL-1beta, NF-kappaB, JNK, AP-1 and adipocyte hypertrophy, with the associated
      enhancement of LPL, adiponectin, AMPK, IRS-1, GLUT4, PKB/Akt and cGMP in
      hemin-treated ZDF are among the multifaceted mechanisms by which the HO-system
      combat inflammation to potentiate insulin-signaling and improve glucose and lipid
      metabolism. Thus, HO-inducers may be explored in the search of novel remedies
      against the co-morbidities of obesity, dysfunctional lipid metabolism and
      impaired glucose metabolism.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Physiology, College of Medicine, University of Saskatchewan, 107
      Wiggins Road, Saskatoon, SK, Canada, S7N 5E5.
FAU - Ndisang, Joseph Fomusi
AU  - Ndisang JF
FAU - Jadhav, Ashok
AU  - Jadhav A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/18 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/05/08 [accepted]
AID - 10.1111/dom.12130 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 Jun 3. doi: 10.1111/dom.12130.

PMID- 23731337
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1365-2214 (Electronic)
IS  - 0305-1862 (Linking)
DP  - 2013 Jun 4
TI  - Associations of family meal frequency with family meal habits and meal
      preparation characteristics among families of youth with type 1 diabetes.
LID - 10.1111/cch.12078 [doi]
AB  - BACKGROUND: While benefits of family mealtimes, such as improved dietary quality 
      and increased family communication, have been well-documented in the general
      population, less is known about family meal habits that contribute to more
      frequent family meals in youth with type 1 diabetes. METHODS: This
      cross-sectional study surveyed 282 youth ages 8-18 years with type 1 diabetes and
      their parents on measures regarding diabetes-related and dietary behaviours.
      T-tests determined significant differences in youth's diet quality, adherence to 
      diabetes management and glycaemic control between those with and without regular 
      family meals (defined as >/=5 meals per week). Logistic regression analyses
      determined unadjusted and adjusted associations of age, socio-demographics,
      family meal habits, and family meal preparation characteristics with regular
      family meals. RESULTS: 57% of parents reported having regular family meals.
      Families with regular family meals had significantly better diet quality as
      measured by the Healthy Eating Index (P < 0.05) and the NRF9.3 (P < 0.01), and
      adherence to diabetes management (P < 0.001); the difference in glycaemic control
      approached statistical significance (P = 0.06). Priority placed on, pleasant
      atmosphere and greater structure around family meals were each associated with
      regular family meals (P < 0.05). Meals prepared at home were positively
      associated with regular family meals, while convenience and fast foods were
      negatively associated (P < 0.05). Families in which at least one parent worked
      part-time or stayed at home were significantly more likely to have regular family
      meals than families in which both parents worked full-time (P < 0.05). In the
      multivariate logistic regression model, greater parental priority given to family
      mealtimes (P < 0.001) and more home-prepared meals (P < 0.001) predicted
      occurrence of regular family meals; adjusting for parent work status and other
      family meal habits. CONCLUSIONS: Strategies for promoting families meals should
      not only highlight the benefits of family meals, but also facilitate parents'
      skills for and barriers to home-prepared meals.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
FAU - Kornides, M L
AU  - Kornides ML
FAU - Nansel, T R
AU  - Nansel TR
FAU - Quick, V
AU  - Quick V
FAU - Haynie, D L
AU  - Haynie DL
FAU - Lipsky, L M
AU  - Lipsky LM
FAU - Laffel, L M B
AU  - Laffel LM
FAU - Mehta, S N
AU  - Mehta SN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Child Care Health Dev
JT  - Child: care, health and development
JID - 7602632
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/14 [accepted]
AID - 10.1111/cch.12078 [doi]
PST - aheadofprint
SO  - Child Care Health Dev. 2013 Jun 4. doi: 10.1111/cch.12078.

PMID- 23731324
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
DP  - 2013 Jun 3
TI  - The First Simultaneous Kidney-Adrenal Gland-Pancreas Transplantation: Outcome at 
      1 Year.
LID - 10.1111/ajt.12296 [doi]
AB  - Adrenal insufficiency is a rare but life-threatening disease. Replacement therapy
      sometimes fails to prevent an acute adrenal crisis and most often does not lead
      to restoration of well-being. We report here the 1-year outcome of the first
      simultaneous kidney-adrenal gland-pancreas transplantation in a 33-year-old
      patient with type 1 diabetes and concomitant autoimmune adrenal insufficiency. En
      bloc left adrenal gland and kidney grafts were anastomosed on the left iliac
      vessels in normal vascular conditions and the pancreas graft was anastomosed on
      the right iliac vessels. The immunosuppressive regimen was not modified by the
      addition of the adrenal gland. We observed no additional morbidity due to the
      adrenal gland transplantation, as there were no surgical complications. One-year 
      kidney and pancreas graft functions were satisfactory (estimated glomerular
      filtration rate: 55 mL/min/1.73 m2 and HbA1c: 4.8%). The adrenal graft functioned
      well at 12 months with a normalization of cortisol and aldosterone baseline
      levels. Functional imaging at 3 months showed good uptake of [123
      I]-metaiodobenzylguanidine by the adrenal graft. Transplantation of the adrenal
      gland en bloc with the left kidney appears to be a good therapeutic option in
      patients with adrenal insufficiency awaiting kidney or kidney-pancreas
      transplantation.
CI  - (c) Copyright 2013 The American Society of Transplantation and the American
      Society of Transplant Surgeons.
AD  - Department of Endocrinology, Diabetes and Nutrition, Hospices Civils de Lyon,
      Centre Hospitalier Lyon-Sud, Pierre Benite, France.
FAU - Vouillarmet, J
AU  - Vouillarmet J
FAU - Buron, F
AU  - Buron F
FAU - Houzard, C
AU  - Houzard C
FAU - Carlier, M C
AU  - Carlier MC
FAU - Chauvet, C
AU  - Chauvet C
FAU - Brunet, M
AU  - Brunet M
FAU - Thivolet, C
AU  - Thivolet C
FAU - Morelon, E
AU  - Morelon E
FAU - Badet, L
AU  - Badet L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/02/14 [received]
PHST- 2013/03/30 [revised]
PHST- 2013/04/01 [accepted]
AID - 10.1111/ajt.12296 [doi]
PST - aheadofprint
SO  - Am J Transplant. 2013 Jun 3. doi: 10.1111/ajt.12296.

PMID- 23731267
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
DP  - 2013 Jun 3
TI  - Glucose impairs B-1 cell function in diabetes.
LID - 10.1111/cei.12148 [doi]
AB  - B-1 lymphocytes produce natural IgM among which a large proportion is directed
      against apoptotic cells and altered self-antigens, such as modified LDL. Thereby,
      natural IgM maintains homeostasis in the body and they are also protective
      against atherosclerosis. Diabetic patients have an increased risk of developing
      certain infections as well as atherosclerosis compared with healthy subjects but 
      the underlying reason is not known. The aim of this study was to investigate
      whether diabetes and insulin resistance affects B-1 lymphocytes and their
      production of natural IgM. We found that diabetic db/db mice had lower levels of 
      peritoneal B-1a cells in the steady state-condition compared to controls. Also,
      activation of B-1 cells with the TLR4 agonist Kdo2-Lipid A or immunization
      against S. pneumoniae led to a blunted IgM response in the diabetic db/db mice.
      In vitro experiments with isolated B-1 cells showed that high concentrations of
      glucose, but not insulin or leptin, caused a reduced secretion of total IgM and
      CuOx-LDL- and MDA-LDL specific IgM from B-1 cells in addition to a decreased
      differentiation into antibody-producing cells, proliferation arrest and increased
      apoptosis. These results suggest that metabolic regulation of B-1 cells is of
      importance for the understanding of the role of this cell type in
      life-style-related conditions.
CI  - This article is protected by copyright. All rights reserved.
AD  - Wallenberg Laboratory for Cardiovascular Research, Department of Molecular and
      Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at University of
      Gothenburg, Gothenburg, Sweden.
FAU - Jennbacken, K
AU  - Jennbacken K
FAU - Stahlman, S
AU  - Stahlman S
FAU - Grahnemo, L
AU  - Grahnemo L
FAU - Wiklund, O
AU  - Wiklund O
FAU - Fogelstrand, L
AU  - Fogelstrand L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/05/23 [accepted]
AID - 10.1111/cei.12148 [doi]
PST - aheadofprint
SO  - Clin Exp Immunol. 2013 Jun 3. doi: 10.1111/cei.12148.

PMID- 23731019
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1651-1999 (Electronic)
IS  - 0803-7051 (Linking)
DP  - 2013 Jun 3
TI  - Metabolic effects of telmisartan in subjects with abdominal obesity: A
      prospective randomized controlled trial.
AB  - Background. Abdominal obesity, characterized by ectopic fat deposition in
      skeletal muscle and liver tissue, has been associated with insulin resistance and
      increased risk for type 2 diabetes mellitus. The aim of this study was to
      evaluate whether treatment with the angiotensin II type 1 (AT-1) receptor blocker
      telmisartan can reduce intramyocellular lipid (IMCL) and hepatic fat storage,
      thereby improving insulin sensitivity among individuals with abdominal obesity.
      Methods. Ninety-five adults with abdominal obesity (body mass index >/= 30 kg/m2 
      and waist circumference > 102 cm in men and > 88 cm in women) were randomized to 
      double-blind treatment with telmisartan or placebo for 24 weeks. Following 4
      weeks of 80 mg telmisartan per day, the dose was increased to 160 mg telmisartan 
      for the duration of the study. Soleus muscle IMCL and liver fat content were
      assessed by 1H-magnetic resonance imaging (1H-MRI) spectroscopy. Secondary
      outcomes included changes in body composition, plasma lipids, glucose profiles,
      insulin sensitivity, beta-cell function and total adiponectin levels. Results.
      There was no significant effect of telmisartan in abdominally obese individuals
      consuming either a low or high glycemic diet, on IMCL content (5.73 +/- 1.11 vs
      6.11 +/- 1.11; p = 0.13) or liver fat (0.08 +/- 0.05 vs 0.09 +/- 0.05; p = 0.60).
      Body composition, lipid and glucose profiles, insulin sensitivity and adiponectin
      were likewise unaffected. Beta-cell function, as determined by the insulinogenic 
      index (IGI), improved significantly (19.3 +/- 13.7 vs 22.5 +/- 17.6; p = 0.03;
      16.5% increase from baseline in the telmisartan group). Conclusions. Telmisartan 
      increased beta-cell function but did not decrease IMCL or liver fat content or
      other metabolic parameters among individuals with abdominal obesity.
AD  - McMaster University , Hamilton, Ontario , Canada.
FAU - Chetty, V Tony
AU  - Chetty VT
FAU - Damjanovic, Suzana
AU  - Damjanovic S
FAU - Gerstein, Hertzel
AU  - Gerstein H
FAU - Singh, Nina
AU  - Singh N
FAU - Yusuf, Salim
AU  - Yusuf S
FAU - Anand, Sonia S
AU  - Anand SS
FAU - Sharma, Arya M
AU  - Sharma AM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Blood Press
JT  - Blood pressure
JID - 9301454
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.3109/08037051.2013.791411 [doi]
PST - aheadofprint
SO  - Blood Press. 2013 Jun 3.

PMID- 23730996
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 Jun 3
TI  - A randomized trial comparing the rate of hypoglycemia-assessed using continuous
      glucose monitoring-in 125 preschool children with type 1 diabetes treated with
      insulin glargine or NPH insulin (the PRESCHOOL study).
LID - 10.1111/pedi.12051 [doi]
AB  - BACKGROUND: Avoidance of hypoglycemia is a key consideration in treating young
      children with type 1 diabetes (T1DM). KEY OBJECTIVE: To evaluate hypoglycemia
      with insulin glargine vs. neutral protamine Hagedorn (NPH) insulin in young
      children, using continuous glucose monitoring (CGM). SUBJECTS: Children of 1 to
      <6 yr treated with once-daily glargine vs. once- or twice-daily NPH, with bolus
      insulin lispro/regular human insulin provided to all. METHODS: Twenty-four week, 
      multicenter, randomized, open-label study. Primary endpoint was event rate of
      composite hypoglycemia [symptomatic hypoglycemia, low CGM excursions (<3.9
      mmol/L) or low fingerstick blood glucose (FSBG; <3.9 mmol/L)]. Noninferiority of 
      glargine vs. NPH was assessed for the primary endpoint. RESULTS: One hundred and 
      twenty-five patients (mean age, 4.2 yr) were randomized to treatment (glargine, n
      = 61; NPH, n = 64). At baseline, mean HbA1c was 8.0 and 8.2% with glargine and
      NPH, respectively. Composite hypoglycemia episodes/100 patient-yr was 1.93 for
      glargine and 1.69 for NPH; glargine noninferiority was not met. Events/100
      patient-yr of symptomatic hypoglycemia were 0.26 for glargine vs. 0.33 for NPH;
      low CGM excursions 0.75 vs. 0.72; and low FSBG 1.93 vs.1.68. There was a slight
      difference in between-group severe/nocturnal/severe nocturnal hypoglycemia and
      glycemic control. All glargine-treated patients received once-daily injections;
      on most study days NPH-treated patients received twice-daily injections.
      CONCLUSIONS: While glargine noninferiority was not achieved, in young children
      with T1DM, there was a slight difference in hypoglycemia outcomes and glycemic
      control between glargine and NPH. Once-daily glargine may therefore be a feasible
      alternative basal insulin in young populations, in whom administering injections 
      can be problematic.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Kinder- und Jugendkrankenhaus "AUF DER BULT", Hannover, Germany.
FAU - Danne, Thomas
AU  - Danne T
FAU - Philotheou, Areti
AU  - Philotheou A
FAU - Goldman, David
AU  - Goldman D
FAU - Guo, Xiang
AU  - Guo X
FAU - Ping, Lin
AU  - Ping L
FAU - Cali, Anna
AU  - Cali A
FAU - Johnston, Peter
AU  - Johnston P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/01/25 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/04/18 [accepted]
AID - 10.1111/pedi.12051 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 Jun 3. doi: 10.1111/pedi.12051.

PMID- 23730992
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Pheochromocytoma/Paraganglioma: review of perioperative management of blood
      pressure and update on genetic mutations associated with pheochromocytoma.
PG  - 428-34
LID - 10.1111/jch.12084 [doi]
AB  - Pheochromocytomas and paragangliomas are rare tumors with high morbidity rates
      caused by excessive catecholamine secretion, even though the majority of tumors
      are benign. The use of perioperative blockade regimens, together with improved
      surgical techniques, has greatly impacted the perioperative morbidity associated 
      with these tumors. The old dogma of the "tumor of tens" no longer holds true. For
      example, at least one third of all pheochromocytomas and paragangliomas are
      hereditary, with mutations in 1 of 10 well-characterized susceptibility genes,
      and one quarter of all tumors are malignant. This review focuses on the
      perioperative management of pheochromocytoma and paragangliomas and the clinical 
      implications of the associated genetic mutations.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Medicine, University of Pennsylvania Perelman School of Medicine,
      Philadelphia, PA; Division of Endocrinology, Diabetes and Metabolism, University 
      of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
FAU - Fishbein, Lauren
AU  - Fishbein L
FAU - Orlowski, Robert
AU  - Orlowski R
FAU - Cohen, Debbie
AU  - Cohen D
LA  - eng
PT  - Journal Article
DEP - 20130315
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/04 [received]
PHST- 2013/01/28 [revised]
PHST- 2013/01/29 [accepted]
PHST- 2013/03/15 [aheadofprint]
AID - 10.1111/jch.12084 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2013 Jun;15(6):428-34. doi: 10.1111/jch.12084. Epub
      2013 Mar 15.

PMID- 23730989
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Similar blood pressure values across racial and economic groups: baseline data
      from a group randomized clinical trial.
PG  - 404-12
LID - 10.1111/jch.12091 [doi]
AB  - This paper examines baseline characteristics from a prospective,
      cluster-randomized trial in 32 primary care offices. Offices were first
      stratified by percentage of minorities and level of clinical pharmacy services
      and then randomized into 1 of 3 study groups. The only differences between
      randomized arms were for marital status (P=.03) and type of insurance coverage
      (P<.001). Blood pressures (BPs) were similar in Caucasians and minority patients,
      primarily blacks, who were hypertensive at baseline. On multivariate analyses,
      patients who were 65 years and older had higher systolic BP (152.4+/-14.3 mm Hg),
      but lower diastolic BP (77.3+/-11.8 mm Hg) compared with those younger than 65
      years (147.4+/-15.0/88.6+/-10.6 mm Hg, P<.001 for both systolic and diastolic
      BP). Other factors significantly associated with higher systolic BP were a longer
      duration of hypertension (P=.04) and lower basal metabolic index (P=.011).
      Patients with diabetes or chronic kidney disease had a lower systolic BP than
      those without these conditions (P<.0001). BP was similar across racial and
      socioeconomic groups for patients with uncontrolled hypertension in primary care,
      suggesting that patients with uncontrolled hypertension and an established
      primary care relationship likely have different reasons for poor BP control than 
      other patient populations.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Pharmacy Practice and Science, College of Pharmacy, Iowa City, IA; 
      Department of Family Medicine, Roy J. and Lucille A. Carver College of Medicine, 
      University of Iowa, Iowa City, IA; The Iowa City Veterans Administration, Iowa
      City, IA.
FAU - Carter, Barry L
AU  - Carter BL
FAU - Coffey, Christopher S
AU  - Coffey CS
FAU - Uribe, Liz
AU  - Uribe L
FAU - James, Paul A
AU  - James PA
FAU - Egan, Brent M
AU  - Egan BM
FAU - Ardery, Gail
AU  - Ardery G
FAU - Chrischilles, Elizabeth A
AU  - Chrischilles EA
FAU - Ecklund, Dixie
AU  - Ecklund D
FAU - Vander Weg, Mark
AU  - Vander Weg M
FAU - Vaughn, Thomas
AU  - Vaughn T
CN  - Collaboration Among Pharmacists and Physicians to Improve Outcomes Now (CAPTION) 
      trial investigators
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/30 [received]
PHST- 2013/02/07 [revised]
PHST- 2013/02/10 [accepted]
PHST- 2013/04/01 [aheadofprint]
AID - 10.1111/jch.12091 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2013 Jun;15(6):404-12. doi: 10.1111/jch.12091. Epub
      2013 Apr 1.

PMID- 23730987
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Health behaviors for hypertension management in people with and without
      coexisting diabetes.
PG  - 389-96
LID - 10.1111/jch.12093 [doi]
AB  - Since blood pressure (BP) control is less often achieved by individuals with
      diabetes, the authors sought to determine whether receipt of and adherence to
      health behavior advice for hypertension control differs between people with and
      without diabetes, using data from the 2009 Survey on Living With Chronic Diseases
      in Canada. Individuals with coexisting diabetes were more likely to report
      receiving advice to control/lose weight (81% vs 66%), be physically active (79%
      vs 68%), limit alcohol consumption (78% vs 55%), and modify diet (70% vs 61%) but
      not limit dietary salt (65% vs 64%) compared with individuals with hypertension
      alone (n=4.965). People with and without diabetes were equally likely to report
      following the advice they received, with receipt of advice positively associated 
      with engagement in healthy behaviors. Since receipt of advice appears to
      influence behavior, health professionals should be encouraged to further promote 
      BP self-management strategies.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Community Health and Epidemiology, Queen's University, Kingston,
      ON, Canada; Centre for Chronic Disease Prevention, Public Health Agency of
      Canada, Ottawa, ON, Canada.
FAU - Gee, Marianne E
AU  - Gee ME
FAU - Pickett, William
AU  - Pickett W
FAU - Janssen, Ian
AU  - Janssen I
FAU - Johnson, Jeffrey A
AU  - Johnson JA
FAU - Campbell, Norman R C
AU  - Campbell NR
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/20 [received]
PHST- 2013/02/09 [revised]
PHST- 2013/02/21 [accepted]
PHST- 2013/04/01 [aheadofprint]
AID - 10.1111/jch.12093 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2013 Jun;15(6):389-96. doi: 10.1111/jch.12093. Epub
      2013 Apr 1.

PMID- 23730984
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Treatment of hypertension among african americans: the jackson heart study.
PG  - 367-74
LID - 10.1111/jch.12088 [doi]
AB  - Hypertension treatment regimens used by African American adults in the Jackson
      Heart Study were evaluated at the first two clinical examinations (2415 treated
      hypertensive persons at examination I [exam I], 2000-2004; 2577 at examination II
      [exam II], 2005-2008). Blood pressure (BP) was below 140/90 mm Hg for 66% and 70%
      of treated participants at exam I and exam II, respectively. The Seventh Report
      of the Joint National Committee on Prevention, Detection, Evaluation, and
      Treatment of High Blood Pressure treatment targets were met for 56% and 61% at
      exam I and exam II, respectively. Persons with diabetes or chronic kidney disease
      were less likely to have BP at target, as were men compared with women. Thiazide 
      diuretics were the most commonly used antihypertensive medication, and persons
      taking a thiazide were more likely to have their BP controlled than persons not
      taking them; thiazides were used significantly less among men than women.
      Although calcium channel blockers are often considered to be effective
      monotherapy for African Americans, persons using calcium channel blocker
      monotherapy were significantly less likely to be at target BP than persons using 
      thiazide monotherapy.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute,
      Bethesda, MD.
FAU - Harman, Jane
AU  - Harman J
FAU - Walker, Evelyn R
AU  - Walker ER
FAU - Charbonneau, Vicki
AU  - Charbonneau V
FAU - Akylbekova, Ermeg L
AU  - Akylbekova EL
FAU - Nelson, Cheryl
AU  - Nelson C
FAU - Wyatt, Sharon B
AU  - Wyatt SB
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/11/19 [received]
PHST- 2013/01/24 [revised]
PHST- 2013/01/29 [accepted]
PHST- 2013/04/01 [aheadofprint]
AID - 10.1111/jch.12088 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2013 Jun;15(6):367-74. doi: 10.1111/jch.12088. Epub
      2013 Apr 1.

PMID- 23730977
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1520-5118 (Electronic)
IS  - 0021-8561 (Linking)
DP  - 2013 Jun 3
TI  - Dietary Chinese quince polyphenols suppress generation of alpha-dicarbonyl
      compounds in diabetic KK-Ay mice.
AB  - Many dietary polyphenols can provide health benefits, such as antioxidant and
      antidiabetic effects, and can downregulate the progression of glycation (one
      cause of diabetic complications). Chinese quince (CQ) is rich in polyphenols,
      especially procyanidins. A few studies have indicated that CQ has an effect on
      diabetes. In this study, a procyanidin-rich extract was prepared from Chinese
      quince fruit (CQE) and its effects were investigated and compared with green tea 
      extract (GTE) in type 2 diabetes model KK-Ay mice. Mice were provided one of two 
      high fat (HF) diets for four weeks: a HF diet containing 0.5% CQE or a HF diet
      containing 0.5% GTE. Blood glucose was suppressed in mice fed CQE and GTE during 
      the experimental period (p < 0.05), although the effect of CQE was weaker than
      that of GTE. Intake of CQE had no effect on the blood insulin level, while GTE
      decreased the insulin level. Body weight gain was suppressed in mice fed CQE
      similarly to mice fed GTE (p < 0.05). Hepatic lipid content and alpha-dicarbonyl 
      compounds in the kidney were reduced in mice fed CQE and GTE (p < 0.05). These
      results suggest that intake of CQE could moderate type 2 diabetes and diabetic
      complications.
FAU - Nagahora, Nozomi
AU  - Nagahora N
FAU - Ito, Yoshiaki
AU  - Ito Y
FAU - Nagasawa, Takashi
AU  - Nagasawa T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - J Agric Food Chem
JT  - Journal of agricultural and food chemistry
JID - 0374755
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1021/jf401231j [doi]
PST - aheadofprint
SO  - J Agric Food Chem. 2013 Jun 3.

PMID- 23730973
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1943-3670 (Electronic)
IS  - 0022-3492 (Linking)
DP  - 2013 Jun 3
TI  - Altered Gene Expression in Gingival Tissues and Enhanced Bone Loss in Diabetic
      Rats With Experimental Periodontitis.
AB  - Background: Systemic hyperglycemia is clearly related to severity of
      periodontitis, meaning that periodontitis can be exacerbated by diabetes.
      However, the biological mechanisms responsible for this relationship remain
      unclear. Thus, we profiled global gene expression in gingival tissue with
      periodontitis in diabetic Zucker Diabetic Fatty (ZDF) rats compared with their
      normoglycemic littermates (Lean). Methods: At age 8 weeks, ZDF and Lean rats
      received ligature placement around the second right maxillary molar. At 0, 14,
      28, 42, and 56 days after ligature placement, the maxilla around the molar was
      analyzed using a micro-computed tomography. Two and 7 days after ligature
      placement, total RNA in the gingival tissue was isolated and gene expression
      analysis was conducted using an Agilent Rat Oligo array. To validate the
      microarray findings, we further analyzed the selected genes using real-time
      quantitative PCR assays. Results: There was a significant difference regarding
      the average amount of bone resorption between ZDF and Lean rats from day 14 to
      56. On day 2, we found that 113 genes were regulated (20 up-regulated, 93
      down-regulated) in the presence of diabetes. Lipopolysaccharide binding protein
      (LBP) mRNA expression was significantly higher in gingival tissue with
      periodontitis from ZDF rats compared with that from Lean rats. On day 7,
      interleukin (IL)-10 and IL-24 mRNA levels were significantly lower, while IL-2
      level was significantly elevated. Conclusion: The results of this study indicate 
      that the role of diabetes in modulating bone destruction related to periodontitis
      may involve an increased level of LBP and reduced levels of Th2 cytokines.
AD  - Departments of Periodontology and.
FAU - Soboku, Kyoko
AU  - Soboku K
FAU - Kikuchi, Takeshi
AU  - Kikuchi T
FAU - Fujita, Sachiko
AU  - Fujita S
FAU - Takeda, Hiroaki
AU  - Takeda H
FAU - Naruse, Keiko
AU  - Naruse K
FAU - Matsubara, Tatsuaki
AU  - Matsubara T
FAU - Noguchi, Toshihide
AU  - Noguchi T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1902/jop.2013.120705 [doi]
PST - aheadofprint
SO  - J Periodontol. 2013 Jun 3.

PMID- 23730887
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - Improving patient tolerability in immunoglobulin treatment: focus on stabilizer
      effects.
PG  - 577-87
LID - 10.1586/eci.13.39 [doi]
AB  - Various types of excipients are added to immunoglobulin preparations to stabilize
      the product and prevent aggregation and dimer formation. These excipients, which 
      are also called stabilizers or additives, are not inert chemicals and may have
      clinical implications. This is one reason why immunoglobulin products are not
      interchangeable. Herein, immunoglobulin preparation, excipient types and the
      differences among sugar stabilizers and the amino acids, glycine and proline as
      excipients, are presented. Preclinical studies that unravel the complexities of
      dimer reduction are summarized. Details of patient considerations with respect to
      excipient content are outlined focusing on patients with renal insufficiency,
      diabetes, corn allergy, hereditary fructose intolerance, inborn errors of proline
      metabolism, DiGeorge Syndrome and neuropsychiatric disorders associated with
      hyperprolinemia. Excipients are essential components of immunoglobulin
      preparations and their presence should be a consideration when matching patient
      needs to product characteristics.
AD  - Baxter Biosciences, 4501 Colorado Blvd, Los Angeles, CA 90039, USA.
FAU - Sun, Adam
AU  - Sun A
FAU - Teschner, Wolfgang
AU  - Teschner W
FAU - Yel, Leman
AU  - Yel L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 10.1586/eci.13.39 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2013 Jun;9(6):577-87. doi: 10.1586/eci.13.39.

PMID- 23730845
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1365-2893 (Electronic)
IS  - 1352-0504 (Linking)
VI  - 20
IP  - 7
DP  - 2013 Jul
TI  - Incidence of diabetes mellitus in a population-based cohort of persons with
      chronic hepatitis B virus infection.
PG  - 510-3
LID - 10.1111/jvh.12071 [doi]
AB  - To investigate the effect of hepatitis B virus (HBV) infection on the development
      of diabetes mellitus (DM), we compared DM incidence and characteristics of Alaska
      Native persons with and without HBV infection. From 1990 to 2010, there were 52
      incident DM cases among 1309 persons with infection vs 4557 DM cases among 85 698
      persons without infection (log-rank test, P = 0.20). Compared to infected persons
      without DM, those with DM were significantly older (57.0 vs 47.4 years, P <
      0.001) and had higher body mass index (34.5 vs 28.4 kg/m(2) , P < 0.001).
      Genotype, immune active disease and the presence of cirrhosis were not associated
      with DM. In this population-based cohort with over 20 years of follow-up, there
      was no effect of HBV infection on DM development.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD
      and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, GA,
      USA.
FAU - Spradling, P R
AU  - Spradling PR
FAU - Simons, B
AU  - Simons B
FAU - Narayanan, M
AU  - Narayanan M
FAU - Xing, J
AU  - Xing J
FAU - Homan, C
AU  - Homan C
FAU - Bulkow, L
AU  - Bulkow L
FAU - Cagle, H
AU  - Cagle H
FAU - Schraer, C D
AU  - Schraer CD
FAU - McMahon, B J
AU  - McMahon BJ
LA  - eng
PT  - Journal Article
DEP - 20130325
PL  - England
TA  - J Viral Hepat
JT  - Journal of viral hepatitis
JID - 9435672
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/11/13 [received]
PHST- 2012/12/18 [accepted]
PHST- 2013/03/25 [aheadofprint]
AID - 10.1111/jvh.12071 [doi]
PST - ppublish
SO  - J Viral Hepat. 2013 Jul;20(7):510-3. doi: 10.1111/jvh.12071. Epub 2013 Mar 25.

PMID- 23730671
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2249-782X (Print)
IS  - 0973-709X (Linking)
VI  - 7
IP  - 4
DP  - 2013 Apr
TI  - The relationship between periodontitis and systemic diseases - hype or hope?
PG  - 758-62
LID - 10.7860/JCDR/2013/4500.2906 [doi]
AB  - Investigations have definitely acknowledged a clinically relevant two-way
      relationship between periodontitis and certain systemic diseases and conditions, 
      which are significant for the dentist in the daily practice and for a physician
      as well. This review article yields the most up-to-date information on the role
      of periodontal diseases in systemic diseases, that include cardiovascular
      diseases and atherosclerosis, diabetes mellitus, respiratory diseases and
      unfavourable pregnancy outcomes. It debates the role of diabetes and smoking in
      the periodontal tissues.
AD  - Reader, Department of Periodontology, Pravara Institute of Medical Sciences ,
      Rural Dental College, Loni, India .
FAU - Ameet M, Mani
AU  - Ameet M M
FAU - Avneesh H, Tejnani
AU  - Avneesh H T
FAU - Babita R, Pawar
AU  - Babita R P
FAU - Pramod P, Marawar
AU  - Pramod P M
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC3644469
OID - NLM: PMC3644469
OTO - NOTNLM
OT  - Periodontitis
OT  - Systemic conditions
OT  - Systemic diseases
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2012/05/19 [received]
PHST- 2012/12/10 [accepted]
PHST- 2013/04/01 [epublish]
AID - 10.7860/JCDR/2013/4500.2906 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2013 Apr;7(4):758-62. doi: 10.7860/JCDR/2013/4500.2906. Epub
      2013 Apr 1.

PMID- 23730642
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2249-782X (Print)
IS  - 0973-709X (Linking)
VI  - 7
IP  - 4
DP  - 2013 Apr
TI  - A study on the drug utilization trends in the cardiovascular emergencies in a
      tertiary care hospital.
PG  - 666-70
LID - 10.7860/JCDR/2013/5277.2877 [doi]
AB  - Objectives: To observe the cardiovascular emergencies which were most frequently 
      treated and to quantify the drug utilization trends in the cardiovascular
      emergencies, in terms of the Defined Daily Doses [DDD] and the prescribing
      prevalence in the cardiovascular emergencies. Methods: This prescription based
      study was undertaken in the Medicine ICU of the government medical hospital. The 
      age, sex, diagnosis (only cardiovascular) and the drugs which were prescribed,
      were recorded for each patient. Also, the brand names and the generic names of
      the prescribed drugs were noted. The collected data was analyzed to study the
      drug utilization trends. Results: It was observed that the most commonly treated 
      cardiovascular disease was IHD. The IHD was more in males than in females who
      were below 50 years of age and it was nearly equal in the age groups which were
      above 50 years. The use of Angiotensin Converting Enzyme (ACE) inhibitors was
      higher than that of the beta blockers and the calcium channel blockers. The
      patients with cardiovascular emergencies also had preceding associated diseases
      like diabetes mellitus and hypertension. Conclusions: The protocol of the
      management which was followed by the college in the treatment of cardiovascular
      emergencies was competent enough, as the clinical outcomes of the patients were
      favourable. But there was a guideline incongruent prescribing behaviour which was
      statistically significant, for which there is a need to undertake large scale
      studies.
AD  - Tutor, Department of Pharmacology, Bharati Vidyapeeth University, Medical College
      and Hospital , sangli, Maharashtra, India .
FAU - Pendhari, Shabbir Rafiq
AU  - Pendhari SR
FAU - Chaudhari, Devendra Ramesh
AU  - Chaudhari DR
FAU - Burute, Shreyas Ramchandra
AU  - Burute SR
FAU - Bite, Bapurao Motiram
AU  - Bite BM
LA  - eng
PT  - Journal Article
DEP - 20130220
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC3644440
OID - NLM: PMC3644440
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Defined Daily Dose (DDD)
OT  - Prescribing prevalence
OT  - and Drugs utilization in ICU
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2012/11/06 [received]
PHST- 2013/01/20 [accepted]
PHST- 2013/02/20 [epublish]
AID - 10.7860/JCDR/2013/5277.2877 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2013 Apr;7(4):666-70. doi: 10.7860/JCDR/2013/5277.2877. Epub
      2013 Feb 20.

PMID- 23730641
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2249-782X (Print)
IS  - 0973-709X (Linking)
VI  - 7
IP  - 4
DP  - 2013 Apr
TI  - Compliance to anti-diabetic drugs: observations from the diabetic clinic of a
      medical college in kolkata, India.
PG  - 661-5
LID - 10.7860/JCDR/2013/5352.2876 [doi]
AB  - Background: The poor glycaemic control among the patients with type 2 diabetes
      constitutes a major public health problem and a major risk factor for the
      development of diabetes complications. Aim of the Study: To study the compliance 
      rate of the patients with type 2 diabetes to the prescribed medications, to find 
      out its correlation with different socio-demographic factors and other patient
      characteristics and to find out the reasons behind the non-compliance, if any.
      Settings and Design: This cross sectional study was conducted on the patients
      with type 2 diabetes, who Attended the Diabetic Clinic of a Medical College in
      Kolkata, India. Methods and Material: The patients of type 2 diabetes who
      attended the diabetes clinic between April to August 2012 were recruited in the
      study by systematic random sampling and they were interviewed by using the help
      of a structured interview schedule. The patients who reported taking less than
      80% of their prescribed anti-diabetes medicines in the preceding week and had
      HbA1C of < 7% were considered to be non-compliant. Statistical Analysis Used: The
      data was analyzed by using the SPSS software. The Chi-square test was used to
      assess the association of the compliance with the different study variables. A
      binary logistic regression analysis helped in identifying the factors which
      contributed to the non-compliance. Results: The compliance rate to the
      anti-diabetic drugs was found to be 57.7%. A univariate analysis showed that it
      decreased significantly with increasing age and that it was also significantly
      lower among males, illiterates, those with a poor per capita monthly income and
      those who had a longer duration of diabetes. It varied significantly with the
      type of drugs, being lowest with an oral drug and insulin combination (43.4%). No
      knowledge on the complications of diabetes was significantly associated with a
      lower compliance. The binary logistic regression also helped in identifying these
      as the significant contributory factors. The common reasons behind the
      non-compliance were forgetfulness (44.7%) and financial constraints (32.7%).
      Conclusion: It can be concluded that the compliance to anti-diabetic drugs was
      quite poor among the participants. Increasing age, the male sex, illiteracy, a
      low monthly income and a longer duration of diabetes were significantly
      associated with the non compliance. A more concerning fact was the significant
      association of the non-compliance with the types of drug regimens and a lack of
      knowledge on the complications of diabetes, which emphasized the role of a
      repeated patient education regarding the basic aspects of diabetes.
AD  - Assistant Professor, Department of Community Medicine, Calcutta National Medical 
      College & Hospital , Kolkata, West Bengal, India .
FAU - Mukherjee, Shuvankar
AU  - Mukherjee S
FAU - Sharmasarkar, Biswanath
AU  - Sharmasarkar B
FAU - Das, Kaushik Kumar
AU  - Das KK
FAU - Bhattacharyya, Agnihotri
AU  - Bhattacharyya A
FAU - Deb, Animesh
AU  - Deb A
LA  - eng
PT  - Journal Article
DEP - 20130215
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC3644439
OID - NLM: PMC3644439
OTO - NOTNLM
OT  - Anti-Diabetic drugs
OT  - Compliance
OT  - Type 2 diabetes
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2012/11/23 [received]
PHST- 2013/01/21 [accepted]
PHST- 2013/02/15 [epublish]
AID - 10.7860/JCDR/2013/5352.2876 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2013 Apr;7(4):661-5. doi: 10.7860/JCDR/2013/5352.2876. Epub
      2013 Feb 15.

PMID- 23730634
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2249-782X (Print)
IS  - 0973-709X (Linking)
VI  - 7
IP  - 4
DP  - 2013 Apr
TI  - Association Between Waist Circumference and Serum Triacylglcerol Status in Type 2
      Diabetes Mellitus (T2DM): A Study Performed on a Rural Population in Puducherry.
PG  - 631-4
LID - 10.7860/JCDR/2013/5198.2869 [doi]
AB  - Introduction: India is on the verge of being the diabetic capital of the world,
      owing to the increasing prevalence of diabetes in India. The aim of this study
      was to find the association between anthropometry and dyslipidaemia, with a
      particular reference to the triacylglycerol levels, besides suggesting a better
      anthropometric variable. Method: A group of eighty diabetic patients took part in
      the study. The Waist Circumference (WC), the waist to hip ratio, the serum
      triacylglycerol (TAG) levels and the glycated haemoglobin (HbA1c) levels were
      measured and studied. Results: We found out that there was a significant
      association between the WC and the TAG levels (p-value = 0.030), between high TAG
      levels and high HbA1c values (p-value = 0.038) with greater accuracy, in favour
      of the waist circumference. Conclusion: This depicted the fact that a simple
      measuring tape which is used in measuring the WC, could prove to be a useful and 
      a cost-effective diagnostic approach for monitoring the metabolic complications
      of type 2 DM.
AD  - Third Year MBBS Student Mahatma Gandhi Medical College and Research Institute ,
      Puducherry, India .
FAU - Srinivasan, Arunkumar
AU  - Srinivasan A
FAU - Joshi, Prabal
AU  - Joshi P
FAU - A Raghavan, Srinivasan
AU  - A Raghavan S
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC3644432
OID - NLM: PMC3644432
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Dyslipidaemia
OT  - HbA1c
OT  - Triacylglycerol
OT  - Waist circumference
OT  - Waist to hip ratio
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2012/10/19 [received]
PHST- 2013/01/29 [accepted]
PHST- 2013/04/01 [epublish]
AID - 10.7860/JCDR/2013/5198.2869 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2013 Apr;7(4):631-4. doi: 10.7860/JCDR/2013/5198.2869. Epub
      2013 Apr 1.

PMID- 23730633
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2249-782X (Print)
IS  - 0973-709X (Linking)
VI  - 7
IP  - 4
DP  - 2013 Apr
TI  - A comparative study on the fasting and the postprandial dyslipidaemia in type 2
      diabetes mellitus.
PG  - 627-30
LID - 10.7860/JCDR/2013/4845.2868 [doi]
AB  - Background and Objectives: Type 2 Diabetes Mellitus (Type 2 DM), which is
      characterized by a relative insulin deficiency or insulin resistance is
      associated with a cluster of metabolic abnormalities, which includes glucose
      intolerance, hypertension, a unique dyslipidaemia, a procoagulant state, and an
      increase in macrovascular diseases. The present study was conducted to assess the
      significance of postprandial dyslipidaemia with respect to fasting dyslipidaemia,
      in the pathogenesis of atherosclerotic changes and possible cardiovascular
      diseases (CVD) and complications. Methods and Statistical Analysis: Fifty
      diagnosed cases of type 2 DM which were in the age group of 35-65 years, which
      had a duration of diabetes of more than five years, were included in the study
      and 50 age and sex matched healthy subjects were taken as the controls. In both
      the study groups, we measured the serum levels of fasting as well as the
      postprandial lipid profile, which was comprised of the total Cholesterol (TC),
      triglycerides (TGs), high density lipoprotein cholesterol (HDL-C), low density
      lipoprotein cholesterol (LDL-C) and the waist-hip ratio (WHI) as the
      cardiovascular risk factors. The statistical analysis was done by using the
      Students unpaired 't'-test. Results: The results of this study showed
      significantly increased levels of serum total cholesterol, TGs, LDL-C and VLDL-C 
      in the postprandial state as compared to those in the fasting state (p<0.001) and
      as compared to those in the fasting and the postprandial states of the controls
      (p<0.001). The serum HDL-C level was significantly lower in the postprandial
      state as compared to that in the fasting state (p<0.001). Also, the postprandial 
      and the fasting HDL-C levels were significantly lower as compared to the levels
      in their respective control groups (p<0.001). Conclusion: The findings of the
      present study indicated that the lipid profile, as a cardiovascular risk factor, 
      was significantly elevated in the postprandial state as compared to that in the
      fasting state and that it was significantly elevated in the postprandial and the 
      fasting states in the Type 2 DM patients as compared to the levels in their
      respective control groups. This signified a routine estimation of the
      postprandial lipid profile, rather than the fasting lipid parameters, in the
      cardiovascular risk assessment in Type 2 DM.
AD  - Assistant Professor, Department of Biochemistry, Seth G.S. Medical College and
      K.E.M. Hospital Mumbai, India .
FAU - Suryabhan L, Lokhande
AU  - Suryabhan L L
FAU - Chandrashekhar M, Iyer
AU  - Chandrashekhar M I
FAU - Ratnendra R, Shinde
AU  - Ratnendra R S
FAU - Prerna D, Nandedkar
AU  - Prerna D N
LA  - eng
PT  - Journal Article
DEP - 20130309
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC3644431
OID - NLM: PMC3644431
OTO - NOTNLM
OT  - Cardiovascular disease (CVD)
OT  - Postprandial blood glucose (PBG)
OT  - Waist-hip ratio (WHR)
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2012/12/22 [received]
PHST- 2013/01/18 [accepted]
PHST- 2013/03/09 [epublish]
AID - 10.7860/JCDR/2013/4845.2868 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2013 Apr;7(4):627-30. doi: 10.7860/JCDR/2013/4845.2868. Epub
      2013 Mar 9.

PMID- 23730632
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2249-782X (Print)
IS  - 0973-709X (Linking)
VI  - 7
IP  - 4
DP  - 2013 Apr
TI  - Comparison of urinary protein: creatinine index and dipsticks for detection of
      microproteinuria in diabetes mellitus patients.
PG  - 622-6
LID - 10.7860/JCDR/2013/4745.2867 [doi]
AB  - Background: Proteinuria has been recognized as one of the earliest signs of renal
      function deterioration in Diabetes mellitus. Proteinuria occurs due to
      alterations in the glomerular permeability and later, due to a failure in the
      reabsorption of filtered protein by the tubular cells. Normally, most of the
      healthy adults excrete 20-150 mg of protein in urine over 24 hours. Objectives:
      To find out the normal urinary Protein Creatinine Index (PCI) in healthy
      subjects, to compare the urinary PCI of diabetic patients with that of healthy
      subjects and to compare the urinary PCI with dipsticks for the detection of
      microproteinuria. Material and Methods: This study was conducted on 28 type 2
      Diabetes mellitus patients and 40 age and sex matched healthy controls. Freshly
      collected urine samples were tested qualitatively for the presence of proteinuria
      by Heller's test, the sulfosalicylic acid test, heat-coagulation tests and urine 
      dipsticks. Later on, the results were compared by performing a quantitative
      analysis of the protein in the spot urine samples by the sulfosalicylic acid
      method. A quantitative analysis of creatinine was done by the modified Jaffe's
      test. The PCI was calculated for each of the participant in the study. The Mean
      and Standard Deviation (SD) of the PCI was calculated and it was compared between
      the two groups. Results: The normal range of the PCI which was established in
      this study was 60 to 220. Significantly higher amount of proteins were found to
      be excreted in urine in diabetic patients (25.37 +/- 12.51 mg/dl) as compared to 
      those in normal subjects (8.93 +/- 3.54 mg/dl). On comparison of the PCI between 
      the controls and the diabetic subjects, it was found to be significantly elevated
      in the Diabetes mellitus patients (controls = 114.65 +/-47.97 and in the diabetic
      patients =373.04 +/- 98.53) (p < 0.001). Conclusion: The PCI of a random urine
      sample can provide a very useful, simple and convenient method for the
      quantitative assessment of proteinuria, to judge the extent of kidney damage and 
      for avoiding the drawbacks of the 24 - hr urine collections.
AD  - MSc. Medical Biochemistry, Demonstrator, Department of Biochemistry, Rama Medical
      College , Ghaziabad (U.P.), India .
FAU - Kumar, Anoop
AU  - Kumar A
FAU - Kapoor, Sangeeta
AU  - Kapoor S
FAU - Gupta, R C
AU  - Gupta RC
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC3644430
OID - NLM: PMC3644430
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Protein-creatinine index
OT  - Proteinuria
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2012/06/23 [received]
PHST- 2013/02/24 [accepted]
PHST- 2013/04/01 [epublish]
AID - 10.7860/JCDR/2013/4745.2867 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2013 Apr;7(4):622-6. doi: 10.7860/JCDR/2013/4745.2867. Epub
      2013 Apr 1.

PMID- 23730597
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2234-6163 (Print)
IS  - 2234-6163 (Linking)
VI  - 40
IP  - 3
DP  - 2013 May
TI  - Versatility of the distally-based sural artery fasciocutaneous flap on the lower 
      leg and foot in patients with chronic disease.
PG  - 220-5
LID - 10.5999/aps.2013.40.3.220 [doi]
AB  - BACKGROUND: A recent advancement in microsurgery, the free flap is widely used in
      the reconstruction of the lower leg and foot. The simple and effective methods of
      local flaps, including transposition and advancement flaps, have been considered 
      for patients with chronic debilitation who are unable to endure long surgical
      procedures or general anesthesia. However, the location and size of the wound may
      restrict the clinical application of a local flap. Under these circumstances, a
      sural flap can be an excellent alternative, rendering satisfying clinical
      outcomes in chronically debilitated patients. METHODS: Between 2008 and 2012, 39 
      patients underwent soft tissue defect treatment by sural artery flap as a final
      method. All of the patients had at least one chronic disease or more (diabetes,
      hypertension, vascular disease, etc.). Also, all of the patients had a history of
      chronic lower extremity ulceration, which revealed no response to several months 
      of conservative treatment. RESULTS: The results of the 39 cases had a success
      rate of 100% with 39 complete recoveries. Nine cases suffered complications:
      partial necrosis (n=4), wound dehiscence without necrosis (n=3), hematoma (n=1), 
      and infection (n=1). CONCLUSIONS: The sural artery flap is not only useful for
      the lower leg but also for the heel, and other various parts. Furthermore, it is 
      a relatively simple surgical technique for reconstructing the defect area for
      patients with various chronic conditions with a high surgical risk or
      contraindications to surgery.
AD  - Department of Plastic and Reconstructive Surgery, Chonbuk National University
      School of Medicine, Jeonju, Korea.
FAU - Park, Jin-Su
AU  - Park JS
FAU - Roh, Si-Gyun
AU  - Roh SG
FAU - Lee, Nae-Ho
AU  - Lee NH
FAU - Yang, Kyoung-Moo
AU  - Yang KM
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - Korea (South)
TA  - Arch Plast Surg
JT  - Archives of plastic surgery
JID - 101577999
PMC - PMC3665865
OID - NLM: PMC3665865
OTO - NOTNLM
OT  - Soft tissue injuries
OT  - Sural
OT  - Surgical flap
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2013/02/20 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/21 [accepted]
PHST- 2013/05/16 [epublish]
AID - 10.5999/aps.2013.40.3.220 [doi]
PST - ppublish
SO  - Arch Plast Surg. 2013 May;40(3):220-5. doi: 10.5999/aps.2013.40.3.220. Epub 2013 
      May 16.

PMID- 23730508
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2078-6891 (Print)
IS  - 2078-6891 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Jun
TI  - Hepatosplenic alpha/beta T-cell lymphoma masquerading as cirrhosis.
PG  - 131-6
LID - 10.3978/j.issn.2078-6891.2013.017 [doi]
AB  - A 59-year-old man with diabetes mellitus, prior hepatitis B infection and
      recently diagnosed cirrhosis with prior Babesiosis presented to our institution
      from an outside hospital with six months of worsening abdominal pain, myalgias
      and fevers. On admission, physical examination revealed jaundice,
      hepatosplenomegaly and diffuse lymphadenopathy. Laboratory investigations
      demonstrated mild anemia, thrombocytopenia, hyperbilirubinemia and elevated
      lactate dehydrogenase. Tests for human immunodeficiency virus, and active Babesia
      microti infection were negative, however Epstein-Barr virus DNA by quantitative
      PCR was markedly elevated. CT scan revealed features suggestive of a cirrhotic
      liver without focal mass lesions as well as massive splenomegaly with axillary,
      retroperitoneal and inguinal lymphadenopathy. Bone marrow and lymph node biopsies
      were obtained which ultimately revealed hepatosplenic T-cell lymphoma. The
      patient's initial liver biopsy from five months prior to presentation was
      re-evaluated by our institution's pathologists. Histologic analysis showed
      hepatic sinusoidal and portal infiltration of atypical lymphocytes
      morphologically identical to those present on the more recently excised lymph
      node tissue. The hepatic sinusoidal lymphoid cells were strongly positive for
      CD2, CD3 and CD5 whereas CD4, CD8 stained only minor subsets of the T cells.
      Subsequent flow cytometric immunophenotypying of peripheral blood identified
      T-cell receptor alpha/beta positive cells that lacked CD4 and CD8 (double
      negative alpha/beta T cells). Given the established bone marrow involvement, he
      was diagnosed with stage IV disease and treated with chemotherapy. His clinical
      course involved multiple hospitalizations complicated by hyponatremia,
      neutropenic fevers and pulmonary emboli. Following his fourth cycle of
      chemotherapy, he developed worsening liver failure and expired approximately
      three months after initial diagnosis of lymphoma. Hepatosplenic lymphoma of
      alpha/beta T cells is a rare malignancy with largely unclear risk factors and
      varied clinical presentations. Notably, diffuse infiltration of liver parenchyma 
      is a prominent feature and the disease can mimic cirrhosis clinically as well as 
      radiographically. Early recognition of this aggressive lymphoma is important and 
      should be considered in the evaluation of patients in whom the etiology of
      cirrhosis remains in question.
AD  - Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess
      Medical Center and Harvard Medical School, Boston, Massachusetts, USA;
FAU - Cohen, Jonah
AU  - Cohen J
FAU - Hariton, Eduardo
AU  - Hariton E
FAU - Kothari, Darshan
AU  - Kothari D
FAU - Pihan, German A
AU  - Pihan GA
FAU - Robson, Simon C
AU  - Robson SC
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC3635184
OID - NLM: PMC3635184
OTO - NOTNLM
OT  - Babesia microti
OT  - Liver cirrhosis
OT  - T-cell lymphoma
OT  - autoimmune hepatitis
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2013/02/14 [received]
PHST- 2013/03/12 [accepted]
AID - 10.3978/j.issn.2078-6891.2013.017 [doi]
AID - jgo-04-02-131 [pii]
PST - ppublish
SO  - J Gastrointest Oncol. 2013 Jun;4(2):131-6. doi:
      10.3978/j.issn.2078-6891.2013.017.

PMID- 23730503
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2042-0188 (Print)
IS  - 2042-0188 (Linking)
VI  - 4
IP  - 3
DP  - 2013 Jun
TI  - Safety and efficacy of linagliptin in type 2 diabetes patients with common renal 
      and cardiovascular risk factors.
PG  - 95-105
LID - 10.1177/2042018813486165 [doi]
AB  - Dipeptidyl-peptidase-IV (DPP-4) inhibitors have become an important orally active
      drug class for the treatment of type 2 diabetes as second-line therapy after
      metformin failure or as monotherapy or combination therapy with other drugs when 
      metformin is not tolerated or contraindicated. DPP-4 inhibitors act mainly by
      increasing endogenous incretin hormone concentrations. They stimulate insulin
      secretion and inhibit glucagon secretion in a glucose-dependent manner with a
      significantly lower risk for hypoglycaemia than sulfonylureas. Furthermore, DPP-4
      inhibitors are weight neutral. Linagliptin is a DPP-4 inhibitor that is
      eliminated by a hepatobiliary route, whereas the other DPP-4 inhibitors available
      today show a renal elimination. Therefore, it can be used in normal kidney
      function as well as in all stages of chronic kidney disease to stage 5
      (glomerular filtration rate <15 ml/min/1.73 m(2)) without dose adjustments.
      Linagliptin was noninferior to metformin and sulfonylureas in clinical studies.
      In recent studies, it showed a superior safety profile over sulfonylurea
      treatment regarding hypoglycaemia and weight gain. More patients reached an HbA1c
      <7% without hypoglycaemia and weight gain with linagliptin compared with
      glimepiride. The safety profile with respect to a composite cardiovascular
      endpoint and stroke was also favourable for linagliptin, most likely due to a
      higher incidence of hypoglycaemia associated with glimepiride therapy and
      titration. This review gives an overview on the efficacy and safety of
      linagliptin in comparison with other antidiabetic drugs in type 2 diabetes
      patients with renal and cardiovascular risk factors as well as an outlook on the 
      perspective for linagliptin in this patient population in the future.
AD  - Department of Medicine IV, Eberhard-Karls-University Tubingen, Otfried-Muller
      Strasse 10, 72076 Tubingen, Germany.
FAU - Gallwitz, Baptist
AU  - Gallwitz B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ther Adv Endocrinol Metab
JT  - Therapeutic advances in endocrinology and metabolism
JID - 101532143
PMC - PMC3666443
OID - NLM: PMC3666443
OTO - NOTNLM
OT  - DPPP-4 inhibitors
OT  - cardiovascular risk
OT  - incretin-based therapies
OT  - linagliptin
OT  - oral antidiabetic drugs
OT  - renal impairment
OT  - type 2 diabetes
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
AID - 10.1177/2042018813486165 [doi]
AID - 10.1177_2042018813486165 [pii]
PST - ppublish
SO  - Ther Adv Endocrinol Metab. 2013 Jun;4(3):95-105. doi: 10.1177/2042018813486165.

PMID- 23730502
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2042-0188 (Print)
IS  - 2042-0188 (Linking)
VI  - 4
IP  - 3
DP  - 2013 Jun
TI  - Improving major amputation rates in the multicomplex diabetic foot patient: focus
      on the severity of peripheral arterial disease.
PG  - 83-94
LID - 10.1177/2042018813489719 [doi]
AB  - OBJECTIVE: Peripheral arterial disease (PAD), as well as diabetic neuropathy, is 
      a risk factor for the development of diabetic foot ulcers. The aim of this study 
      was to evaluate differences and predictors of outcome parameters in patients with
      diabetic foot by stratifying these subjects according to the severity of PAD.
      RESEARCH DESIGN AND METHODS: In a prospective study, patients with new diabetic
      foot ulcers have been treated and investigated by structured healthcare. Subjects
      were recruited between 1 January 2000 and 31 December 2007. All study
      participants underwent a 2-year follow-up observation period. The patients
      underwent a standardized examination and classification of their foot ulcers
      according to a modification of the University of Texas Wound Classification
      System. The severity of PAD was estimated by measurement of the ankle brachial
      index (ABI) and the continuous wave Doppler flow curve into undisturbed perfusion
      (0.9 < ABI < 1.3), compensated perfusion (0.5 < ABI < 0.9), decompensated
      perfusion (ABI < 0.5) and medial arterial calcification. RESULTS: A total of 678 
      patients with diabetic foot were consecutively included into the study (69% male,
      mean age 66.3 +/- 11.0 years, mean diabetes duration 15.8 +/- 10.2 years). Major 
      amputations (above the ankle) were performed in 4.7% of the patients. 22.1% of
      these subjects had decompensated PAD. These subjects had delayed ulcer healing,
      higher risk for major amputation [odds ratio (OR) 7.7, 95% confidence interval
      (CI) 2.8-21.2, p < 0.001] and mortality (OR 4.9, 95 % CI 1.1-22.1, p < 0.05).
      CONCLUSION: This prospective study shows that the severity of PAD significantly
      influences the outcome of diabetic foot ulcers regarding to wound healing, major 
      amputation and mortality.
AD  - Department of Diabetes, Interdisciplinary Diabetic Foot Unit,
      Weisseritztal-Kliniken Freital-Dippoldiswalde, Freital, Germany.
FAU - Brechow, Andrej
AU  - Brechow A
FAU - Slesaczeck, Torsten
AU  - Slesaczeck T
FAU - Munch, Dirk
AU  - Munch D
FAU - Nanning, Thomas
AU  - Nanning T
FAU - Paetzold, Hartmut
AU  - Paetzold H
FAU - Schwanebeck, Uta
AU  - Schwanebeck U
FAU - Bornstein, Stefan
AU  - Bornstein S
FAU - Weck, Matthias
AU  - Weck M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ther Adv Endocrinol Metab
JT  - Therapeutic advances in endocrinology and metabolism
JID - 101532143
PMC - PMC3666444
OID - NLM: PMC3666444
OTO - NOTNLM
OT  - diabetic foot
OT  - major amputation
OT  - medial arterial calcification
OT  - peripheral arterial disease
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
AID - 10.1177/2042018813489719 [doi]
AID - 10.1177_2042018813489719 [pii]
PST - ppublish
SO  - Ther Adv Endocrinol Metab. 2013 Jun;4(3):83-94. doi: 10.1177/2042018813489719.

PMID- 23730489
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2005-6443 (Print)
IS  - 2005-6443 (Linking)
VI  - 34
IP  - 3
DP  - 2013 May
TI  - Association of abdominal aortic calcification with lifestyle and risk factors of 
      cardiovascular disease.
PG  - 213-20
LID - 10.4082/kjfm.2013.34.3.213 [doi]
AB  - BACKGROUND: Abdominal aortic calcification (AAC) is a marker of subclinical
      atherosclerotic disease and an independent predictor of subsequent vascular
      morbidity and mortality. This study was conducted to investigate the association 
      of AAC with lifestyle and risk factors of cardiovascular disease. METHODS: The
      results of the abdominal computed tomography of 380 patients who visited Chungnam
      National University Hospital for a health checkup from January 1, 2008 to
      December 31, 2009 were reviewed. A six-point scale was used in grading the
      overall severity of the calcification in three areas of the abdominal aorta,
      including the area superior to the renal artery, the upper-half area inferior to 
      the renal artery, and the lower-half area inferior to the renal artery, in
      addition to the common iliac artery. The association of the AAC severity with the
      age, lifestyle factors, and risk factors of cardiovascular disease was analyzed
      via multiple linear regression analysis. RESULTS: In the male subjects, the age, 
      presence of dyslipidemia and smoking were positively related to AAC, but
      exercising was negatively related to AAC (total R(2) = 0.563). In the female
      subjects, the age and presence of diabetes mellitus, hypertension, and
      dyslipidemia were positively related to AAC, but exercising was negatively
      related to AAC (total R(2) = 0.547). CONCLUSION: AAC was related to both the male
      and female subjects' age, presence of dyslipidemia, and exercising, to smoking in
      the male subjects and to the presence of diabetes mellitus and hypertension in
      the female subjects.
AD  - Department of Family Medicine, Research Institute for Medical Sciences, Chungnam 
      National University School of Medicine, Daejeon, Korea.
FAU - Kim, Eung-Du
AU  - Kim ED
FAU - Kim, Jong Sung
AU  - Kim JS
FAU - Kim, Sung-Soo
AU  - Kim SS
FAU - Jung, Jin-Gyu
AU  - Jung JG
FAU - Yun, Seok-Jun
AU  - Yun SJ
FAU - Kim, Ji-Young
AU  - Kim JY
FAU - Ryu, Jung-Sun
AU  - Ryu JS
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - Korea (South)
TA  - Korean J Fam Med
JT  - Korean journal of family medicine
JID - 101502902
PMC - PMC3667229
OID - NLM: PMC3667229
OTO - NOTNLM
OT  - Aorta
OT  - Atherosclerosis
OT  - Calcification
OT  - Life Style
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2011/08/31 [received]
PHST- 2013/02/28 [accepted]
PHST- 2013/05/24 [epublish]
AID - 10.4082/kjfm.2013.34.3.213 [doi]
PST - ppublish
SO  - Korean J Fam Med. 2013 May;34(3):213-20. doi: 10.4082/kjfm.2013.34.3.213. Epub
      2013 May 24.

PMID- 23730487
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2005-6443 (Print)
IS  - 2005-6443 (Linking)
VI  - 34
IP  - 3
DP  - 2013 May
TI  - Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50
      Years or Older.
PG  - 199-205
LID - 10.4082/kjfm.2013.34.3.199 [doi]
AB  - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease 
      (CKD) share common pathogenic mechanisms and many risk factors, and both are
      linked to an increased risk of cardiovascular diseases. The aim of this study was
      to assess the association between NAFLD and CKD according to the presence of
      hypertension and diabetes mellitus in Koreans aged 50 years or older. METHODS: A 
      cross-sectional study of 1,706 subjects who received their routine health
      examination was conducted between May 2008 and April 2010 at Konkuk University
      medical center. Biochemical tests for liver and abdominal ultrasonography were
      performed. CKD was defined as either proteinuria or glomerular filtration rate
      </=60 mL/min per 1.73 m(2). RESULTS: Among the 1,706 subjects, There were 545
      (31.9%) with non-alcoholic fatty liver disease and 424 (24.9%) with chronic
      kidney disease. In univariate logistic regression analysis, NAFLD was
      significantly associated with CKD (odds ratio [OR], 1.69; 95% confidence interval
      [CI], 1.34 to 2.12). In multivariate logistic regression analysis adjusted for
      age, sex, current smoking, abdominal obesity, aspartate aminotransferases,
      alanine aminotransferases, gamma-glutamyltransferase, hypertension, diabetes
      mellitus, hypertriglyceridemia, and low high-density lipoprotein cholesterol,
      NAFLD was associated with CKD (adjusted OR, 1.68; 95% CI, 1.27 to 2.24). This
      relationship remained significant after classification according to the presence 
      of hypertension or diabetes mellitus. CONCLUSION: NAFLD diagnosed by
      ultrasonography was significantly associated with CKD in Koreans aged 50 years or
      older.
AD  - Department of Family Medicine, Konkuk University School of Medicine, Seoul,
      Korea.
FAU - Ahn, Ah-Leum
AU  - Ahn AL
FAU - Choi, Jae-Kyung
AU  - Choi JK
FAU - Kim, Mi-Na
AU  - Kim MN
FAU - Kim, Seun-Ah
AU  - Kim SA
FAU - Oh, Eun-Jung
AU  - Oh EJ
FAU - Kweon, Hyuk-Jung
AU  - Kweon HJ
FAU - Cho, Dong-Yung
AU  - Cho DY
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - Korea (South)
TA  - Korean J Fam Med
JT  - Korean journal of family medicine
JID - 101502902
PMC - PMC3667227
OID - NLM: PMC3667227
OTO - NOTNLM
OT  - Chronic Renal Insufficiency
OT  - Glomerular Filtration Rate
OT  - Non-alcoholic Fatty Liver Disease
OT  - Proteinuria
OT  - Ultrasonography
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2011/08/26 [received]
PHST- 2013/05/07 [accepted]
PHST- 2013/05/24 [epublish]
AID - 10.4082/kjfm.2013.34.3.199 [doi]
PST - ppublish
SO  - Korean J Fam Med. 2013 May;34(3):199-205. doi: 10.4082/kjfm.2013.34.3.199. Epub
      2013 May 24.

PMID- 23730483
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 2005-6443 (Print)
IS  - 2005-6443 (Linking)
VI  - 34
IP  - 3
DP  - 2013 May
TI  - Factors associated with persistent smoking after the diagnosis of cardiovascular 
      disease.
PG  - 160-8
LID - 10.4082/kjfm.2013.34.3.160 [doi]
AB  - BACKGROUND: Although cigarette smoking is a major modifiable risk factor for the 
      occurrence of primary and secondary cardiovascular disease (CVD), not all
      survivors from CVD attacks can successfully stop smoking. However, little is
      known about the factors associated with the change in smoking behavior after CVD 
      attack. METHODS: Study subjects included 16,807 participants (>/=19 years) in the
      fourth Korean National Health and Nutrition Examination Surveys. From them, we
      selected 180 persons who had previous CVD diagnosis (angina pectoris, myocardial 
      infarction, or stroke) and were smoking at the time of CVD diagnosis. Then, we
      categorized the 180 persons into two groups according to change in smoking status
      after the CVD: quitter and non-quitter. Logistic regression analysis was done to 
      evaluate multivariable-adjusted association. RESULTS: Even after CVD diagnosis,
      63.60% continued to smoke. Fully-adjusted analysis revealed that regular drinking
      (odds ratio [OR], 4.44) and presence of smokers among family members (OR, 5.86)
      were significantly (P < 0.05) associated with greater risk of persistent smoking,
      whereas lower education level (OR, 0.20), larger amount of smoking (OR, 0.95),
      longer time since diagnosis (OR, 0.88), and diabetes (OR, 0.36) were
      significantly (P < 0.05) associated with decreased risk of persistent smoking
      after CVD. CONCLUSION: A great proportion of CVD patients tended to continue
      smoking in the Korean population. In order to reduce smoking rates among CVD
      patients further, more aggressive efforts towards smoking cessation should be
      continuously made with consideration of individual socioeconomic, behavioral, and
      clinical characteristics of CVD patients.
AD  - Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University
      School of Medicine, Seoul, Korea.
FAU - Kim, Hyo-Eun
AU  - Kim HE
FAU - Song, Yun-Mi
AU  - Song YM
FAU - Kim, Bo-Kyoung
AU  - Kim BK
FAU - Park, Yong-Soon
AU  - Park YS
FAU - Kim, Mi-Hyun
AU  - Kim MH
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - Korea (South)
TA  - Korean J Fam Med
JT  - Korean journal of family medicine
JID - 101502902
PMC - PMC3667223
OID - NLM: PMC3667223
OTO - NOTNLM
OT  - Cardiovascular Diseases
OT  - Health Surveys
OT  - Korean
OT  - Risk Factors
OT  - Smoking Cessation
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2012/08/28 [received]
PHST- 2013/05/07 [accepted]
PHST- 2013/05/24 [epublish]
AID - 10.4082/kjfm.2013.34.3.160 [doi]
PST - ppublish
SO  - Korean J Fam Med. 2013 May;34(3):160-8. doi: 10.4082/kjfm.2013.34.3.160. Epub
      2013 May 24.

PMID- 23730480
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 2005-4408 (Electronic)
IS  - 2005-291X (Linking)
VI  - 5
IP  - 2
DP  - 2013 Jun
TI  - Effects of beraprost sodium on subjective symptoms in diabetic patients with
      peripheral arterial disease.
PG  - 145-51
LID - 10.4055/cios.2013.5.2.145 [doi]
AB  - BACKGROUND: This study evaluated the effects of Beraprost sodium (Berasil) on
      subjective leg symptoms in patients with peripheral arterial disease caused by
      diabetes mellitus. METHODS: Ninety-four diabetic patients with peripheral
      arterial disease were treated with Beraprost in a fixed-dose, prospective,
      multicenter, cohort study. Beraprost (40 microg) was administered orally 3 times 
      daily (120 microg/day) for 12 weeks. We developed a new disease-specific symptom 
      questionnaire, which evaluated the effect of peripheral arterial disease on leg
      discomfort in daily life and assessed therapeutic responses to treatment.
      Patients were asked for their subjective assessment of symptoms on a written
      questionnaire before treatment and after 12 weeks of therapy. RESULTS: There was 
      significant improvement in all estimated subjective symptoms (burning, coldness, 
      edema, exertional pain, stabbing, and paresthesias) in the lower extremities at
      12 weeks (p < 0.001). There were 18 patients with neuropathy in whom significant 
      improvement was noted for 6 subjective symptoms at 12 weeks (p < 0.05). Adverse
      events considered to be drug-related were observed in 4 patients (4.3%), all of
      which were mild and resolved with discontinuation of the medication. CONCLUSIONS:
      Beraprost is effective as a treatment for improving various subjective symptoms
      in the lower extremities, such as burning, coldness, edema, exertional pain,
      stabbing, and paresthesias, in diabetic patients with peripheral arterial
      disease.
AD  - Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Yoon, Hang Seob
AU  - Yoon HS
FAU - Choi, Woo Jin
AU  - Choi WJ
FAU - Sung, Il Hoon
AU  - Sung IH
FAU - Lee, Ho Seong
AU  - Lee HS
FAU - Chung, Hyung Jin
AU  - Chung HJ
FAU - Lee, Jin Woo
AU  - Lee JW
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - Korea (South)
TA  - Clin Orthop Surg
JT  - Clinics in orthopedic surgery
JID - 101505087
SB  - IM
PMC - PMC3664675
OID - NLM: PMC3664675
OTO - NOTNLM
OT  - Beraprost sodium
OT  - Diabetes mellitus
OT  - Intermittent claudication
OT  - Peripheral arterial disease
OT  - Prostaglandin I2
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/09/18 [received]
PHST- 2012/12/07 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.4055/cios.2013.5.2.145 [doi]
PST - ppublish
SO  - Clin Orthop Surg. 2013 Jun;5(2):145-51. doi: 10.4055/cios.2013.5.2.145. Epub 2013
      May 15.

PMID- 23730478
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 2005-4408 (Electronic)
IS  - 2005-291X (Linking)
VI  - 5
IP  - 2
DP  - 2013 Jun
TI  - Postoperative urinary retention following anterior cervical spine surgery for
      degenerative cervical disc diseases.
PG  - 134-7
LID - 10.4055/cios.2013.5.2.134 [doi]
AB  - BACKGROUND: Postoperative urinary retention (POUR) may cause bladder dysfunction,
      urinary tract infection, and catheter-related complications. It is important to
      be aware and to be able to identify patients at risk of developing POUR. However,
      there has been no study that has investigated the incidence and risk factors for 
      the development of POUR following anterior cervical spine surgery for
      degenerative cervical disc disease. METHODS: We included 325 patients (164 male
      and 161 female), who underwent anterior cervical spine surgery for cervical
      radiculopathy or myelopathy due to primary cervical disc herniation and/or
      spondylosis, in the study. We did not perform en bloc catheterization in our
      patients before the operation. RESULTS: There were 36 patients (27 male and 9
      female) that developed POUR with an overall incidence of 11.1%. The mean numbers 
      of postoperative in-and-out catheterizations was 1.6 times and mean urine output 
      was 717.7 mL. Thirteen out of 36 POUR patients (36%) underwent indwelling
      catheterization for a mean 4.3 days after catheterization for in-and-out surgery,
      because of persisting POUR. Seven out of 36 POUR patients (19%) were treated for 
      voiding difficulty, urinary tract irritation, or infection. Chi-square test
      showed that patients who were male, had diabetes mellitus, benign prostate
      hypertrophy or myelopathy, or used Demerol were at higher risk of developing
      POUR. The mean age of POUR patients was higher than non-POUR patients (68.5 years
      vs. 50.8 years, p < 0.01). CONCLUSIONS: To avoid POUR and related complications
      as a result of anterior cervical spine surgery for degenerative cervical disc
      disease, we recommend that a catheter be placed selectively before the operation 
      in at-risk patients, the elderly in particular, male gender, diabetes mellitus,
      benign prostate hypertrophy, and myelopathy. We recommend that Demerol not be
      used for postoperative pain control.
AD  - Department of Anesthesiology and Pain Medicine, Uijeongbu St. Mary's Hospital,
      The Catholic University of Korea College of Medicine, Uijeongbu, Korea.
FAU - Jung, Hyun Ju
AU  - Jung HJ
FAU - Park, Jong-Beom
AU  - Park JB
FAU - Kong, Chae-Gwan
AU  - Kong CG
FAU - Kim, Young-Yul
AU  - Kim YY
FAU - Park, Jangsu
AU  - Park J
FAU - Kim, Jong Bun
AU  - Kim JB
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - Korea (South)
TA  - Clin Orthop Surg
JT  - Clinics in orthopedic surgery
JID - 101505087
SB  - IM
PMC - PMC3664673
OID - NLM: PMC3664673
OTO - NOTNLM
OT  - Anterior cervical spine surgery
OT  - Degenerative cervical disc diseases
OT  - Postoperative urinary retention
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/10/22 [received]
PHST- 2012/10/31 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.4055/cios.2013.5.2.134 [doi]
PST - ppublish
SO  - Clin Orthop Surg. 2013 Jun;5(2):134-7. doi: 10.4055/cios.2013.5.2.134. Epub 2013 
      May 15.

PMID- 23730475
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 2005-4408 (Electronic)
IS  - 2005-291X (Linking)
VI  - 5
IP  - 2
DP  - 2013 Jun
TI  - Relations between Long-term Glycemic Control and Postoperative Wound and
      Infectious Complications after Total Knee Arthroplasty in Type 2 Diabetics.
PG  - 118-23
LID - 10.4055/cios.2013.5.2.118 [doi]
AB  - BACKGROUND: The authors examined whether poor preoperative glucose control, as
      indicated by the hemoglobin A1c (HbA1c) level of more than 8%, is associated with
      postoperative wound and infectious complications in diabetic patients that have
      undergone total knee arthroplasty (TKA). METHODS: One hundred and sixty-seven
      TKAs performed in 115 patients with type 2 diabetes mellitus, from January 2001
      through March 2007, were retrospectively reviewed. Logistic regression was used
      to identify the variables that had a significant effect on the risk of wound
      complications or early deep infection. The variables considered were age, gender,
      body mass index, comorbidities, operation time, antibiotic-impregnated cement
      use, amount of blood transfusion, close suction drain use, duration of diabetes, 
      method of diabetes treatment, diabetes complications, and preoperative HbA1c
      level. RESULTS: The overall incidence of wound complications was 6.6% (n = 11)
      and there were seven cases (4.2%) of early postoperative deep infection. Logistic
      regression revealed that the independent risk factors of wound complications were
      preoperative HbA1C >/= 8% (odds ratio [OR], 6.07; 95% confidence interval [CI],
      1.12 to 33.0) and operation time (OR, 1.01; 95% CI, 1.00 to 1.03). No variable
      examined was found to be significantly associated with the risk of early
      postoperative deep infection. CONCLUSIONS: Poorly controlled hyperglycemia before
      surgery may increase the incidence of wound complications among diabetic patients
      after TKA.
AD  - Department of Orthopedic Surgery, Seoul Metropolitan Government Seoul National
      University Boramae Medical Center, Seoul, Korea.
FAU - Han, Hyuk-Soo
AU  - Han HS
FAU - Kang, Seung-Baik
AU  - Kang SB
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - Korea (South)
TA  - Clin Orthop Surg
JT  - Clinics in orthopedic surgery
JID - 101505087
SB  - IM
PMC - PMC3664670
OID - NLM: PMC3664670
OTO - NOTNLM
OT  - Early deep infection
OT  - Total knee replacements
OT  - Type 2 diabetes mellitus
OT  - Wound complication
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/05/29 [received]
PHST- 2012/08/26 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.4055/cios.2013.5.2.118 [doi]
PST - ppublish
SO  - Clin Orthop Surg. 2013 Jun;5(2):118-23. doi: 10.4055/cios.2013.5.2.118. Epub 2013
      May 15.

PMID- 23730305
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 1664-8021 (Electronic)
IS  - 1664-8021 (Linking)
VI  - 4
DP  - 2013
TI  - The systems genetics resource: a web application to mine global data for complex 
      disease traits.
PG  - 84
LID - 10.3389/fgene.2013.00084 [doi]
AB  - The Systems Genetics Resource (SGR) (http://systems.genetics.ucla.edu) is a new
      open-access web application and database that contains genotypes and clinical and
      intermediate phenotypes from both human and mouse studies. The mouse data include
      studies using crosses between specific inbred strains and studies using the
      Hybrid Mouse Diversity Panel. SGR is designed to assist researchers studying
      genes and pathways contributing to complex disease traits, including obesity,
      diabetes, atherosclerosis, heart failure, osteoporosis, and lipoprotein
      metabolism. Over the next few years, we hope to add data relevant to deafness,
      addiction, hepatic steatosis, toxin responses, and vascular injury. The
      intermediate phenotypes include expression array data for a variety of tissues
      and cultured cells, metabolite levels, and protein levels. Pre-computed tables of
      genetic loci controlling intermediate and clinical phenotypes, as well as
      phenotype correlations, are accessed via a user-friendly web interface. The web
      site includes detailed protocols for all of the studies. Data from published
      studies are freely available; unpublished studies have restricted access during
      their embargo period.
AD  - Department of Human Genetics, University of California Los Angeles, Los Angeles, 
      CA, USA.
FAU - van Nas, Atila
AU  - van Nas A
FAU - Pan, Calvin
AU  - Pan C
FAU - Ingram-Drake, Leslie A
AU  - Ingram-Drake LA
FAU - Ghazalpour, Anatole
AU  - Ghazalpour A
FAU - Drake, Thomas A
AU  - Drake TA
FAU - Sobel, Eric M
AU  - Sobel EM
FAU - Papp, Jeanette C
AU  - Papp JC
FAU - Lusis, Aldons J
AU  - Lusis AJ
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - Switzerland
TA  - Front Genet
JT  - Frontiers in genetics
JID - 101560621
PMC - PMC3657633
OID - NLM: PMC3657633
OTO - NOTNLM
OT  - data analysis
OT  - data integration
OT  - database
OT  - genomics
OT  - systems biology
OT  - web services
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/04 [received]
PHST- 2013/04/25 [accepted]
PHST- 2013/05/20 [epublish]
AID - 10.3389/fgene.2013.00084 [doi]
PST - epublish
SO  - Front Genet. 2013 May 20;4:84. doi: 10.3389/fgene.2013.00084. Print 2013.

PMID- 23730303
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130606
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 4
DP  - 2013
TI  - Arginase promotes skeletal muscle arteriolar endothelial dysfunction in diabetic 
      rats.
PG  - 119
LID - 10.3389/fimmu.2013.00119 [doi]
AB  - Endothelial dysfunction is a characteristic feature in diabetes that contributes 
      to the development of vascular disease. Recently, arginase has been implicated in
      triggering endothelial dysfunction in diabetic patients and animals by competing 
      with endothelial nitric oxide synthase for substrate l-arginine. While most
      studies have focused on the coronary circulation and large conduit blood vessels,
      the role of arginase in mediating diabetic endothelial dysfunction in other
      vascular beds has not been fully investigated. In the present study, we
      determined whether arginase contributes to endothelial dysfunction in skeletal
      muscle arterioles of diabetic rats. Diabetes was induced in male Sprague Dawley
      rats by streptozotocin injection. Four weeks after streptozotocin administration,
      blood glucose, glycated hemoglobin, and vascular arginase activity were
      significantly increased. In addition, a significant increase in arginase I and II
      mRNA expression was detected in gracilis muscle arterioles of diabetic rats
      compared to age-matched, vehicle control animals. To examine endothelial
      function, first-order gracilis muscle arterioles were isolated, cannulated in a
      pressure myograph system, exposed to graded levels of luminal flow, and internal 
      vessel diameter measured. Increases in luminal flow (0-50 muL/min) caused
      progressive vasodilation in arterioles isolated from control, normoglycemic
      animals. However, flow-induced vasodilation was absent in arterioles obtained
      from streptozotocin-treated rats. Acute in vitro pretreatment of blood vessels
      with the arginase inhibitors N (omega)-hydroxy-nor-l-arginine or
      S-(2-boronoethyl)-l-cysteine restored flow-induced responses in arterioles from
      diabetic rats and abolished differences between diabetic and control animals.
      Similarly, acute in vitro pretreatment with l-arginine returned flow-mediated
      vasodilation in vessels from diabetic animals to that of control rats. In
      contrast, d-arginine failed to restore flow-induced dilation in arterioles
      isolated from diabetic animals. Administration of sodium nitroprusside resulted
      in a similar degree of dilation in arterioles isolated from control or diabetic
      rats. In conclusion, the present study identifies arginase as an essential
      mediator of skeletal muscle arteriolar endothelial dysfunction in diabetes. The
      ability of arginase to induce endothelial dysfunction in skeletal muscle
      arterioles may further compromise glucose utilization and facilitate the
      development of hypertension in diabetes.
AD  - Department of Physiology and Pharmacology, Lincoln Memorial University Harrogate,
      TN, USA.
FAU - Johnson, Fruzsina K
AU  - Johnson FK
FAU - Johnson, Robert A
AU  - Johnson RA
FAU - Peyton, Kelly J
AU  - Peyton KJ
FAU - Shebib, Ahmad R
AU  - Shebib AR
FAU - Durante, William
AU  - Durante W
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC3657690
OID - NLM: PMC3657690
OTO - NOTNLM
OT  - arginase
OT  - arginine
OT  - diabetes
OT  - endothelial dysfunction
OT  - flow-mediated vasodilation
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/20 [received]
PHST- 2013/05/04 [accepted]
PHST- 2013/05/20 [epublish]
AID - 10.3389/fimmu.2013.00119 [doi]
PST - epublish
SO  - Front Immunol. 2013 May 20;4:119. doi: 10.3389/fimmu.2013.00119. Print 2013.

PMID- 23729940
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1550-9109 (Electronic)
IS  - 0161-8105 (Linking)
VI  - 36
IP  - 6
DP  - 2013
TI  - Differences in insulin secretion and sensitivity in short-sleep insomnia.
PG  - 955-7
LID - 10.5665/sleep.2734 [doi]
AB  - OBJECTIVE: Short-sleep insomnia is associated with increased risk of diabetes.
      The role of altered insulin secretion and action in this association is poorly
      understood. DESIGN: Observational study. SETTING: Academic clinical research
      center. PARTICIPANTS: Nondiabetic individuals with insomnia (mean [standard
      deviation] age 48 [9] y, body mass index 25.6 [3.9] kg/m(2)) with </= 6 h (short 
      sleep, n = 14) and > 6 h of sleep (n = 14) during overnight laboratory
      polysomnography. MEASUREMENTS AND RESULTS: Standard oral glucose testing was used
      to assess glucose tolerance, beta-cell function (homeostasis model assessment
      [HOMA-B]; second-phase insulin secretion) and insulin resistance (HOMA-IR;
      insulin sensitivity index). There was no significant difference in hemoglobin A1C
      and fasting or 2-h blood glucose concentrations between sleep groups. Short-sleep
      insomnia sufferers had lower fasting and postchallenge serum insulin
      concentrations associated with lower estimates of fasting and glucose-stimulated 
      insulin secretion, and increased insulin sensitivity. CONCLUSIONS: Individuals
      with short-sleep insomnia appear to have higher indices of systemic insulin
      sensitivity and secrete less insulin without changes in overall glucose
      tolerance. CITATION: Vasisht KP; Kessler LE; Booth JN; Imperial JG; Penev PD.
      Differences in insulin secretion and sensitivity in short-sleep insomnia. SLEEP
      2013;36(6):955-957.
AD  - Department of Medicine.
FAU - Vasisht, Kaveeta P
AU  - Vasisht KP
FAU - Kessler, Lynn E
AU  - Kessler LE
FAU - Booth, John N 3rd
AU  - Booth JN 3rd
FAU - Imperial, Jacqueline G
AU  - Imperial JG
FAU - Penev, Plamen D
AU  - Penev PD
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
SB  - IM
PMC - PMC3649837
OID - NLM: PMC3649837 [Available on 12/01/13]
OTO - NOTNLM
OT  - Decreased quantity and quality of sleep
OT  - oral glucose tolerance
OT  - pancreatic beta-cell function
OT  - systemic insulin resistance
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PMCR- 2013/12/01 00:00
AID - 10.5665/sleep.2734 [doi]
PST - epublish
SO  - Sleep. 2013 Jun 1;36(6):955-7. doi: 10.5665/sleep.2734.

PMID- 23729926
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1550-9109 (Electronic)
IS  - 0161-8105 (Linking)
VI  - 36
IP  - 6
DP  - 2013
TI  - Comorbidity and mortality of narcolepsy: a controlled retro- and prospective
      national study.
PG  - 835-40
LID - 10.5665/sleep.2706 [doi]
AB  - STUDY OBJECTIVES: To identify the factual morbidity and mortality of narcolepsy
      in a controlled design. SETTING: National Patient Registry. PATIENTS: All
      national diagnosed patients (757) with health information at least 3 years prior 
      to and after diagnose of narcolepsy. CONTROLS: Randomly selected four citizens
      (3,013) matched for age, sex, and socioeconomic status from the Danish Civil
      Registration System Statistics. RESULTS: Increased morbidity prior to narcolepsy 
      diagnosis included (odds ratio, 95% confidence interval):- diseases of the
      endocrine, nutritional, and metabolic systems (2.10, 1.32-3.33); nervous system
      (5.27, 3.65-7.60); musculoskeletal system (1.59, 1.23-2.05); and other abnormal
      symptoms and laboratory findings (1.66, 1.25-2.22). After the diagnosis,
      narcolepsy patients experienced diseases of the endocrine, nutritional, and
      metabolic (2.31, 1.51-3.54), nervous (9.19, 6.80-12.41), musculoskeletal (1.70,
      1.28-2.26), eye (1.67, 1.03-2.71), and respiratory systems (1.84, 1.21-2.81).
      Specific diagnoses were diabetes (2.4, 1,2-4.7, P < 0.01), obesity (13.4,
      3.1-57.6, P < 0.001), sleep apnea (19.2, 7.7-48.3, P < 0.001), other sleep
      disorders (78.5, 11.8-523.3, P < 0.001), chronic obstructive pulmonary disease
      (2.8, 1.4-5.8, P < 0.01), lower back pain (2.5, 1.4-4.2, P < 0.001),
      arthrosis/arthritis (2.5, 1.3-4.8, P < 0.01), observation of neurological
      diseases (3.5, 1.9-6.5, P < 0.001), observation of other diseases (1.7, 1.2-2.5, 
      P < 0.01), and rehabilitation (5.0, 1.5-16.5, P < 0.005). There was a trend
      towards greater mortality in narcolepsy (P = 0.07). CONCLUSIONS: Patients with
      narcolepsy present higher morbidity several years prior to diagnose and even
      higher thereafter. The mortality rate due to narcolepsy was slightly but not
      significantly higher. CITATION: Jennum P; Ibsen R; Knudsen S; Kjellberg J.
      Comorbidity and mortality of narcolepsy: a controlled retro- and prospective
      national study. SLEEP 2013;36(6):835-840.
AD  - Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Center 
      for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Glostrup
      Hospital, Copenhagen, Denmark.
FAU - Jennum, Poul
AU  - Jennum P
FAU - Ibsen, Rikke
AU  - Ibsen R
FAU - Knudsen, Stine
AU  - Knudsen S
FAU - Kjellberg, Jakob
AU  - Kjellberg J
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
SB  - IM
PMC - PMC3649826
OID - NLM: PMC3649826 [Available on 12/01/13]
OTO - NOTNLM
OT  - Narcolepsy
OT  - morbidity
OT  - mortality
OT  - sleep apnea
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PMCR- 2013/12/01 00:00
AID - 10.5665/sleep.2706 [doi]
PST - epublish
SO  - Sleep. 2013 Jun 1;36(6):835-40. doi: 10.5665/sleep.2706.

PMID- 23729920
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1550-9109 (Electronic)
IS  - 0161-8105 (Linking)
VI  - 36
IP  - 6
DP  - 2013
TI  - Sleep restriction in adolescents: forging the path towards obesity and diabetes?
PG  - 813-4
LID - 10.5665/sleep.2694 [doi]
AD  - New York Obesity Nutrition Research Center, St. Luke's/Roosevelt Hospital Center,
      and Institute of Human Nutrition, College of Physicians and Surgeons, Columbia
      University, New York, NY.
FAU - St-Onge, Marie-Pierre
AU  - St-Onge MP
FAU - Shechter, Ari
AU  - Shechter A
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
SB  - IM
PMC - PMC3649820
OID - NLM: PMC3649820 [Available on 12/01/13]
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PMCR- 2013/12/01 00:00
AID - 10.5665/sleep.2694 [doi]
PST - epublish
SO  - Sleep. 2013 Jun 1;36(6):813-4. doi: 10.5665/sleep.2694.

PMID- 23729813
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
DP  - 2013 May 31
TI  - Selective Kv1.3 channel blocker as therapeutic for obesity and insulin
      resistance.
AB  - Obesity is an epidemic, calling for innovative and reliable pharmacological
      strategies. Here, we show that ShK-186, a selective and potent blocker of the
      voltage-gated Kv1.3 channel, counteracts the negative effects of increased
      caloric intake in mice fed a diet rich in fat and fructose. ShK-186 reduced
      weight gain, adiposity, and fatty liver; decreased blood levels of cholesterol,
      sugar, HbA1c, insulin, and leptin; and enhanced peripheral insulin sensitivity.
      These changes mimic the effects of Kv1.3 gene deletion. ShK-186 did not alter
      weight gain in mice on a chow diet, suggesting that the obesity-inducing diet
      enhances sensitivity to Kv1.3 blockade. Several mechanisms may contribute to the 
      therapeutic benefits of ShK-186. ShK-186 therapy activated brown adipose tissue
      as evidenced by a doubling of glucose uptake, and increased beta-oxidation of
      fatty acids, glycolysis, fatty acid synthesis, and uncoupling protein 1
      expression. Activation of brown adipose tissue manifested as augmented oxygen
      consumption and energy expenditure, with no change in caloric intake, locomotor
      activity, or thyroid hormone levels. The obesity diet induced Kv1.3 expression in
      the liver, and ShK-186 caused profound alterations in energy and lipid metabolism
      in the liver. This action on the liver may underlie the differential
      effectiveness of ShK-186 in mice fed a chow vs. an obesity diet. Our results
      highlight the potential use of Kv1.3 blockers for the treatment of obesity and
      insulin resistance.
AD  - Departments of Physiology and Biophysics, Biochemistry and Center for Epigenetics
      and Metabolism, Radiological Sciences, Microbiology and Molecular Genetics, and
      Medicine, School of Medicine, University of California, Irvine, CA 92697.
FAU - Upadhyay, Sanjeev Kumar
AU  - Upadhyay SK
FAU - Eckel-Mahan, Kristin L
AU  - Eckel-Mahan KL
FAU - Mirbolooki, M Reza
AU  - Mirbolooki MR
FAU - Tjong, Indra
AU  - Tjong I
FAU - Griffey, Stephen M
AU  - Griffey SM
FAU - Schmunk, Galina
AU  - Schmunk G
FAU - Koehne, Amanda
AU  - Koehne A
FAU - Halbout, Briac
AU  - Halbout B
FAU - Iadonato, Shawn
AU  - Iadonato S
FAU - Pedersen, Brian
AU  - Pedersen B
FAU - Borrelli, Emiliana
AU  - Borrelli E
FAU - Wang, Ping H
AU  - Wang PH
FAU - Mukherjee, Jogeshwar
AU  - Mukherjee J
FAU - Sassone-Corsi, Paolo
AU  - Sassone-Corsi P
FAU - Chandy, K George
AU  - Chandy KG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
OTO - NOTNLM
OT  - brown fat
OT  - diabetes mellitus
OT  - inflammation
OT  - metabolic syndrome
OT  - potassium channel
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 1221206110 [pii]
AID - 10.1073/pnas.1221206110 [doi]
PST - aheadofprint
SO  - Proc Natl Acad Sci U S A. 2013 May 31.

PMID- 23729782
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1525-3163 (Electronic)
IS  - 0021-8812 (Linking)
VI  - 91
IP  - 5
DP  - 2013 May
TI  - DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Intestinal bile acid sensing is linked
      to key endocrine and metabolic signaling pathways.
PG  - 1991-2000
LID - 10.2527/jas.2013-6331 [doi]
AB  - Bile acids have historically been considered to mainly function in cholesterol
      homeostasis and facilitate fat digestion in the gastrointestinal tract. Recent
      discoveries show that bile acids also function as signaling molecules that exert 
      diverse endocrine and metabolic actions by activating G protein-coupled bile acid
      receptor 1 (GPBAR1/G-protein-coupled bile acid receptor 1 or TGR5), a membrane G 
      protein-coupled receptor, and farnesoid X receptor (FXR), a member of the nuclear
      hormone receptor superfamily. These bile acid sensing receptors are expressed in 
      intestinal epithelial cells, TGR5 in enteroendocrine cells and FXR in
      enterocytes, which line the mucosa of gut lumen. A dominant effect of intestinal 
      FXR activation by bile acids is secretion of fibroblast growth factor (FGF) 19, a
      novel enterokine that functions as a central enterohepatic signal to maintain
      bile acid homeostasis in the liver. Activation of TGR5 on enteroendocrine cells
      stimulates secretion of glucagon-like peptides (GLP)-1 and -2, which function,
      respectively, as the major incretin hormone involved in glucose homeostasis and
      key trophic hormone in intestinal adaptation and growth in response to food
      ingestion. The biological actions induced by bile acid activation of intestinal
      FXR and TGR5 have important therapeutic implications for the pathogenesis and
      treatment of several metabolic diseases, such as cholestasis and diabetes. This
      review highlights these new developments in the biology of intestinal bile acid
      sensing and metabolic function and discusses the potential implications for the
      health and agricultural production of domestic swine.
AD  - USDA Children's Nutrition Research Center, Section of Gastroenterology,
      Hepatology, and Nutrition, Department of Pediatrics.
FAU - Burrin, D
AU  - Burrin D
FAU - Stoll, B
AU  - Stoll B
FAU - Moore, D
AU  - Moore D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Anim Sci
JT  - Journal of animal science
JID - 8003002
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 91/5/1991 [pii]
AID - 10.2527/jas.2013-6331 [doi]
PST - ppublish
SO  - J Anim Sci. 2013 May;91(5):1991-2000. doi: 10.2527/jas.2013-6331.

PMID- 23729712
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Idiopathic bilateral adrenal haemorrhage related to acute adrenal insufficiency.
LID - 10.1136/bcr-2013-009626 [doi]
LID - bcr2013009626 [pii]
AB  - A 54-year-old woman presented with sudden epigastralgia and left back pain. She
      had no significant history. Laboratory data showed mild inflammation and no liver
      or renal dysfunction. Abdominal CT showed left adrenal enlargement and
      haemorrhage. Hydrocortisone therapy was started to prevent adrenal insufficiency 
      before laboratory findings for ACTH (adrenocorticotropic hormone) and cortisol
      levels. On the second hospital day, abdominal CT showed additional right adrenal 
      enlargement and haemorrhage. The serum cortisol level suggested adrenal
      insufficiency. No specific findings were detected by bilateral adrenal
      angiography. 6 to 12 months later, abdominal CT showed decreased bilateral
      adrenal haemorrhage. This case illustrates the importance of prompt diagnosis and
      treatment of acute adrenal insufficiency, and shows sequential changes in the
      size of bilateral adrenal haemorrhage. Rapid corticosteroid replacement is
      important if acute adrenal insufficiency is suspected. In a case with unilateral 
      adrenal haemorrhage, the possibility of additional adrenal haemorrhage on the
      opposite side should also be considered.
AD  - Department of Diabetes, Endocrine and Metabolic Diseases, Tokyo Women's Medical
      University Yachiyo Medical Center, Chiba, Japan.
FAU - Ogino, Jun
AU  - Ogino J
FAU - Toda, Joe
AU  - Toda J
FAU - Onitsuka, Shiro
AU  - Onitsuka S
FAU - Hashimoto, Naotake
AU  - Hashimoto N
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - bcr-2013-009626 [pii]
AID - 10.1136/bcr-2013-009626 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 31;2013. pii: bcr2013009626. doi: 10.1136/bcr-2013-009626.

PMID- 23729682
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Linking)
DP  - 2013 May 31
TI  - Liver Aminotransferases and Risk of Incident Type 2 Diabetes: A Systematic Review
      and Meta-Analysis.
AB  - We evaluated the associations of liver aminotransferases with risk of type 2
      diabetes (T2D) in general populations by conducting a systematic review and
      meta-analysis of published prospective studies. Studies were identified in a
      literature search of PubMed, EMBASE, and Web of Science from 1950 through October
      2012. Of the 2,729 studies reviewed, 17 studies involving 60,359 participants and
      3,890 incident T2D events were included. All of the studies assessed associations
      between alanine aminotransferase (ALT) level and T2D, with heterogeneous findings
      (I2 = 88%, 95% confidence interval (CI): 82, 92; P < 0.001). The pooled fully
      adjusted relative risk of T2D was 1.26 (95% CI: 1.14, 1.41) per
      1-standard-deviation change in log baseline ALT level. This association became
      nonsignificant after trim-and-fill correction for publication bias. Nine studies 
      evaluated associations between aspartate aminotransferase (AST) levels and T2D
      risk, with a corresponding relative risk of 1.02 (95% CI: 0.99, 1.04). The
      relative risk of T2D per 5-IU/L increase in ALT level was 1.16 (95% CI: 1.08,
      1.25). Available data indicate moderate associations of ALT with risk of T2D
      events, which may be attributable to publication bias. There was no evidence for 
      an increased risk of T2D with AST. Large prospective studies may still be needed 
      to establish the magnitude and nature of these associations.
FAU - Kunutsor, Setor K
AU  - Kunutsor SK
FAU - Apekey, Tanefa A
AU  - Apekey TA
FAU - Walley, John
AU  - Walley J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
OTO - NOTNLM
OT  - aminotransferases
OT  - liver enzymes
OT  - meta-analysis
OT  - risk
OT  - type 2 diabetes
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - kws469 [pii]
AID - 10.1093/aje/kws469 [doi]
PST - aheadofprint
SO  - Am J Epidemiol. 2013 May 31.

PMID- 23729657
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1758-0463 (Electronic)
VI  - 2013
IP  - 0
DP  - 2013
TI  - The non-obese diabetic mouse sequence, annotation and variation resource: an aid 
      for investigating type 1 diabetes.
PG  - bat032
LID - 10.1093/database/bat032 [doi]
AB  - Model organisms are becoming increasingly important for the study of complex
      diseases such as type 1 diabetes (T1D). The non-obese diabetic (NOD) mouse is an 
      experimental model for T1D having been bred to develop the disease spontaneously 
      in a process that is similar to humans. Genetic analysis of the NOD mouse has
      identified around 50 disease loci, which have the nomenclature Idd for
      insulin-dependent diabetes, distributed across at least 11 different chromosomes.
      In total, 21 Idd regions across 6 chromosomes, that are major contributors to T1D
      susceptibility or resistance, were selected for finished sequencing and
      annotation at the Wellcome Trust Sanger Institute. Here we describe the
      generation of 40.4 mega base-pairs of finished sequence from 289 bacterial
      artificial chromosomes for the NOD mouse. Manual annotation has identified 738
      genes in the diabetes sensitive NOD mouse and 765 genes in homologous regions of 
      the diabetes resistant C57BL/6J reference mouse across 19 candidate Idd regions. 
      This has allowed us to call variation consequences between homologous exonic
      sequences for all annotated regions in the two mouse strains. We demonstrate the 
      importance of this resource further by illustrating the technical difficulties
      that regions of inter-strain structural variation between the NOD mouse and the
      C57BL/6J reference mouse can cause for current next generation sequencing and
      assembly techniques. Furthermore, we have established that the variation rate in 
      the Idd regions is 2.3 times higher than the mean found for the whole genome
      assembly for the NOD/ShiLtJ genome, which we suggest reflects the fact that
      positive selection for functional variation in immune genes is beneficial in
      regard to host defence. In summary, we provide an important resource, which aids 
      the analysis of potential causative genes involved in T1D susceptibility.
      Database URLs: http://www.sanger.ac.uk/resources/mouse/nod/;
      http://vega-previous.sanger.ac.uk/info/data/mouse_regions.html.
AD  - The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.
FAU - Steward, Charles A
AU  - Steward CA
FAU - Gonzalez, Jose M
AU  - Gonzalez JM
FAU - Trevanion, Steve
AU  - Trevanion S
FAU - Sheppard, Dan
AU  - Sheppard D
FAU - Kerry, Giselle
AU  - Kerry G
FAU - Gilbert, James G R
AU  - Gilbert JG
FAU - Wicker, Linda S
AU  - Wicker LS
FAU - Rogers, Jane
AU  - Rogers J
FAU - Harrow, Jennifer L
AU  - Harrow JL
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - England
TA  - Database (Oxford)
JT  - Database : the journal of biological databases and curation
JID - 101517697
SB  - IM
PMC - PMC3668384
OID - NLM: PMC3668384
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013 [ppublish]
AID - bat032 [pii]
AID - 10.1093/database/bat032 [doi]
PST - epublish
SO  - Database (Oxford). 2013 May 31;2013(0):bat032. doi: 10.1093/database/bat032.
      Print 2013.

PMID- 23729615
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 25
TI  - Pituitary gigantism presenting with depressive mood disorder and diabetic
      ketoacidosis in an Asian adolescent.
PG  - 1-4
LID - 10.1515/jpem-2013-0136 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0136/jpem-2013-0136.xml [pii]
AB  - Abstract Hyperglycemia is seldom described in young patients with pituitary
      gigantism. Here, we describe the case of a 17-year-old Taiwanese boy who
      developed depressive mood disorder and diabetic ketoacidosis (DKA) at the
      presentation of pituitary gigantism. The boy complained of lethargy and dysphoric
      mood in June 2008. He presented at the emergency department with epigastralgia
      and dyspnea in January 2009. Results of laboratory tests suggested type 1
      diabetes mellitus with DKA. However, serum C-peptide level was normal on
      follow-up. Although he had no obvious features of acral enlargement, a high level
      of insulin-like growth factor 1 was detected, and a 75 g oral glucose suppression
      test showed no suppression of serum growth hormone levels. A pituitary
      macroadenoma was found on subsequent magnetic resonance imaging. The pituitary
      adenoma was surgically removed, followed by gamma-knife radiosurgery, and
      Sandostatin long-acting release treatment. He was then administered metformin,
      500 mg twice daily, and to date, his serum glycohemoglobin has been <7%.
FAU - Kuo, Sheng-Fong
AU  - Kuo SF
FAU - Chuang, Wen-Yu
AU  - Chuang WY
FAU - Ng, Sohching
AU  - Ng S
FAU - Chen, Chih-Hung
AU  - Chen CH
FAU - Chang, Chen-Nen
AU  - Chang CN
FAU - Chou, Chi-Hsiang
AU  - Chou CH
FAU - Weng, Wei-Chieh
AU  - Weng WC
FAU - Yeh, Chih-Hua
AU  - Yeh CH
FAU - Lin, Jen-Der
AU  - Lin JD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/06 [received]
PHST- 2013/04/18 [accepted]
AID - 10.1515/jpem-2013-0136 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0136/jpem-2013-0136.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 25:1-4. doi: 10.1515/jpem-2013-0136.

PMID- 23729614
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 25
TI  - Type II vitamin D-dependent rickets with diabetic ketoacidosis.
PG  - 1-3
LID - 10.1515/jpem-2013-0137 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0137/jpem-2013-0137.xml [pii]
AB  - Abstract The high prevalence of vitamin D deficiency in relation to diabetes
      mellitus is well reported in the literature. However, type I diabetes mellitus
      (T1DM) in association with resistant rickets is extremely rare and reported in
      only one previous case. The authors describe here a case of type II vitamin
      D-dependent rickets (VDDR type II) in a 10-year-old Indian girl who presented
      with diabetic ketoacidosis (DKA). DKA as a presenting manifestation of T1DM in a 
      patient with VDDR type II has never been reported before in worldwide literature.
FAU - Sarkar, Sumantra
AU  - Sarkar S
FAU - Mondal, Rakesh
AU  - Mondal R
FAU - Banerjee, Indira
AU  - Banerjee I
FAU - Sabui, Tapas
AU  - Sabui T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/07 [received]
PHST- 2013/04/22 [accepted]
AID - 10.1515/jpem-2013-0137 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0137/jpem-2013-0137.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 25:1-3. doi: 10.1515/jpem-2013-0137.

PMID- 23729613
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 25
TI  - A rare case of granuloma annulare in a 6-year-old child with type 1 diabetes.
PG  - 1-2
LID - 10.1515/jpem-2013-0143 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0143/jpem-2013-0143.xml [pii]
FAU - Akyurek, Nesibe
AU  - Akyurek N
FAU - Atabek, Mehmet Emre
AU  - Atabek ME
FAU - Eklioglu, Beray Selver
AU  - Eklioglu BS
FAU - Tol, Huseyin
AU  - Tol H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/22 [received]
PHST- 2013/05/06 [accepted]
AID - 10.1515/jpem-2013-0143 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0143/jpem-2013-0143.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 25:1-2. doi: 10.1515/jpem-2013-0143.

PMID- 23729611
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 24
TI  - The influence of carbohydrate quality on cardiovascular disease, the metabolic
      syndrome, type 2 diabetes, and obesity - an overview.
PG  - 1-13
LID - 10.1515/jpem-2012-0419 [doi]
LID - /j/jpem.ahead-of-print/jpem-2012-0419/jpem-2012-0419.xml [pii]
AB  - Abstract There is compelling evidence that carbohydrate quality has important
      influences on cardiovascular disease, the metabolic syndrome, type 2 diabetes,
      and obesity. Cohort and interventional studies indicate that dietary fiber is an 
      important determinant of satiation, satiety, and weight gain, and also protects
      against cardiovascular disease. Cohort studies have shown that vegetables and
      fruits protect against coronary heart disease, whereas whole grains provide
      protection against cardiovascular disease, type 2 diabetes, and weight gain.
      Dietary glycemia within the range eaten by most of the population seems not to
      have a significant influence on body weight, although it may influence waist
      circumference. There is strong evidence from interventional trials that dietary
      glycemia does influence insulin resistance and diabetes control. Moreover,
      replacing saturated fat with high-glycemic carbohydrate may increase
      cardiovascular risk. Soft drink consumption is a proven cause of weight gain,
      which may relate to the lack of satiation provided by these drinks. In large
      amounts, dietary fructose leads to greater adverse metabolic changes than
      equivalent amounts of glucose, although the extent to which fructose per se is
      contributing to many of the metabolic changes found in the obese, as distinct
      from the calories it provides, is still a matter of debate.
FAU - Slyper, Arnold H
AU  - Slyper AH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/26 [received]
PHST- 2013/04/22 [accepted]
AID - 10.1515/jpem-2012-0419 [doi]
AID - /j/jpem.ahead-of-print/jpem-2012-0419/jpem-2012-0419.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 24:1-13. doi: 10.1515/jpem-2012-0419.

PMID- 23729594
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
DP  - 2013 May 31
TI  - Increased expression of STK25 leads to impaired glucose utilization and insulin
      sensitivity in mice challenged with a high-fat diet.
AB  - Partial depletion of serine/threonine protein kinase 25 (STK25), a member of the 
      Ste20 superfamily of kinases, increases lipid oxidation and glucose uptake in
      rodent myoblasts. Here we show that transgenic mice overexpressing STK25, when
      challenged with a high-fat diet, develop reduced glucose tolerance and insulin
      sensitivity compared to wild-type siblings, as evidenced by impairment in glucose
      and insulin tolerance tests as well as in euglycemic-hyperinsulinemic clamp
      studies. The fasting plasma insulin concentration was elevated in Stk25
      transgenic mice compared to wild-type littermates (4.9+/-0.8 vs. 2.6+/-0.4 ng/ml 
      after 17 wk on high-fat diet, P<0.05). Overexpression of STK25 decreased energy
      expenditure during the dark phase of observation (P<0.05), despite increased
      spontaneous activity. The oxidative capacity of skeletal muscle of transgenic
      carriers was reduced, as evidenced by altered expression of Cpt1, Acox1, and ACC.
      Hepatic triglycerides and glycogen were elevated (1.6- and 1.4-fold,
      respectively; P<0.05) and expression of key enzymes regulating lipogenesis
      (Fasn), glycogen synthesis (Gck), and gluconeogenesis (G6pc, Fbp1) was increased 
      in the liver of the transgenic mice. Our findings suggest that overexpression of 
      STK25 in conditions of excess dietary fuels associates with a shift in the
      metabolic balance in peripheral tissues from lipid oxidation to storage, leading 
      to a systemic insulin resistance.-Cansby, E., Amrutkar, M., Manneras Holm, L.,
      Nerstedt, A., Reyahi, A., Stenfeldt, E., Boren, J., Carlsson, P., Smith, U.,
      Zierath, J.R., Mahlapuu, M. Increased expression of STK25 leads to impaired
      glucose utilization and insulin sensitivity in mice challenged with a high-fat
      diet.
AD  - *Lundberg Laboratory for Diabetes Research and daggerWallenberg Laboratory,
      Department of Molecular and Clinical Medicine, and double daggerDepartment of
      Cell and Molecular Biology, University of Gothenburg, Gothenburg, Sweden; and.
FAU - Cansby, Emmelie
AU  - Cansby E
FAU - Amrutkar, Manoj
AU  - Amrutkar M
FAU - Manneras Holm, Louise
AU  - Manneras Holm L
FAU - Nerstedt, Annika
AU  - Nerstedt A
FAU - Reyahi, Azadeh
AU  - Reyahi A
FAU - Stenfeldt, Elin
AU  - Stenfeldt E
FAU - Boren, Jan
AU  - Boren J
FAU - Carlsson, Peter
AU  - Carlsson P
FAU - Smith, Ulf
AU  - Smith U
FAU - Zierath, Juleen R
AU  - Zierath JR
FAU - Mahlapuu, Margit
AU  - Mahlapuu M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
OTO - NOTNLM
OT  - metabolic balance
OT  - serine/threonine protein kinase 25
OT  - type 2 diabetes
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - fj.13-228494 [pii]
AID - 10.1096/fj.13-228494 [doi]
PST - aheadofprint
SO  - FASEB J. 2013 May 31.

PMID- 23729590
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
DP  - 2013 May 31
TI  - Differential effects of maternal obesity and weight loss in the periconceptional 
      period on the epigenetic regulation of hepatic insulin-signaling pathways in the 
      offspring.
AB  - Our aim was to determine the effect of exposure to maternal obesity or to
      maternal weight loss around conception on the programming of hepatic insulin
      signaling in the offspring. We used an embryo transfer model in sheep to
      investigate the effects of exposure to either maternal obesity or to weight loss 
      in normal and obese mothers preceding and for 1 wk after conception on the
      expression of hepatic insulin-signaling and gluconeogenic factors and key miRNAs 
      involved in insulin signaling in the offspring. We found that exposure to
      maternal obesity resulted in increased hepatic miR-29b (P<0.05), miR-103
      (P<0.01), and miR-107 (P<0.05) expression, a decrease in IR (P<0.05), phopsho-Akt
      (P<0.01), and phospho-FoxO1 (P<0.01) abundance, and a paradoxical decrease in
      11betaHSD1 (P<0.05), PEPCK-C (P<0.01), and PEPCK-M (P<0.05) expression in lambs. 
      These changes were ablated by a period of moderate dietary restriction imposed
      during the periconceptional period. Maternal dietary restriction alone also
      resulted in decreased abundance of a separate subset of hepatic insulin-signaling
      molecules, namely, IRS1 (P<0.05), PDK1 (P<0.01), phospho-PDK1 (P<0.05), and
      aPKCzeta (P<0.05) and in decreased PEPCK-C (P<0.01) and G6Pase (P<0.01)
      expression in the lamb. Our findings highlight the sensitivity of the epigenome
      to maternal nutrition around conception and the need for dietary interventions
      that maximize metabolic benefits and minimize metabolic costs for the next
      generation.-Nicholas, L. M., Rattanatray, L., MacLaughlin, S. M., Ozanne, S. E., 
      Kleemann, D. O., Walker, S. K., Morrison, J. L., Zhang, S., Muhlhausler, B. S.,
      Martin-Gronert, M. S., McMillen, I. C. Differential effects of maternal obesity
      and weight loss in the periconceptional period on the epigenetic regulation of
      hepatic insulin-signaling pathways in the offspring.
AD  - *Sansom Institute for Health Research, School of Pharmacy and Medical Sciences,
      University of South Australia, Adelaide, South Australia, Australia;
FAU - Nicholas, Lisa M
AU  - Nicholas LM
FAU - Rattanatray, Leewen
AU  - Rattanatray L
FAU - Maclaughlin, Severence M
AU  - Maclaughlin SM
FAU - Ozanne, Susan E
AU  - Ozanne SE
FAU - Kleemann, Dave O
AU  - Kleemann DO
FAU - Walker, Simon K
AU  - Walker SK
FAU - Morrison, Janna L
AU  - Morrison JL
FAU - Zhang, Song
AU  - Zhang S
FAU - Muhlhausler, Beverley S
AU  - Muhlhausler BS
FAU - Martin-Gronert, Malgorzata S
AU  - Martin-Gronert MS
FAU - McMillen, Isabella C
AU  - McMillen IC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
OTO - NOTNLM
OT  - diabetes
OT  - embryo
OT  - fetus
OT  - microRNAs
OT  - pregnancy
OT  - programming
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - fj.13-227918 [pii]
AID - 10.1096/fj.13-227918 [doi]
PST - aheadofprint
SO  - FASEB J. 2013 May 31.

PMID- 23729573
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1434-6621 (Electronic)
IS  - 1434-6621 (Linking)
DP  - 2013 May 13
TI  - Standardization and analytical goals for glycated hemoglobin measurement.
PG  - 1-8
LID - 10.1515/cclm-2013-0060 [doi]
LID - /j/cclm.ahead-of-print/cclm-2013-0060/cclm-2013-0060.xml [pii]
AB  - Abstract Glycated hemoglobin (HbA1c) plays a key role in diagnosing diabetes and 
      monitoring the glycemic state. To guarantee the reliability of its measurement at
      the global level, the IFCC has defined a reference measurement system, based on
      the definition of the measurand as hemoglobin molecules having a special
      hexapeptide in common, which is the stable adduct of glucose to the N-terminal
      valine of the hemoglobin beta-chain. In addition to the traceability of HbA1c
      results to the reference system, the establishment of analytical goals to make
      HbA1c measurements clinically reliable becomes crucial. However, allowable goals 
      will depend on the assay specificity (i.e., selectivity) and, consequently, on
      units in which HbA1c results are expressed [mmol/mol for IFCC-aligned systems or 
      % for National Glycohemoglobin Standardization Program (NGSP) converted numbers].
      In this regard, analytical goals derived from biological variability studies in
      which the determination of HbA1c has been carried out by an assay providing the
      same selectivity for the measurand as defined by the IFCC are recommended. Only
      these targets should be used for evaluating the performance of commercial assays 
      traceable to the IFCC system and of clinical laboratories using them through
      appropriately structured quality assessment schemes. Analytical systems following
      different calibration hierarchies (e.g., the NGSP-aligned assays) will require
      different analytical goals, possibly derived from clinical outcome data.
FAU - Braga, Federica
AU  - Braga F
FAU - Panteghini, Mauro
AU  - Panteghini M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine : CCLM / FESCC
JID - 9806306
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/01/30 [received]
PHST- 2013/04/18 [accepted]
AID - 10.1515/cclm-2013-0060 [doi]
AID - /j/cclm.ahead-of-print/cclm-2013-0060/cclm-2013-0060.xml [pii]
PST - aheadofprint
SO  - Clin Chem Lab Med. 2013 May 13:1-8. doi: 10.1515/cclm-2013-0060.

PMID- 23729563
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0792-6855 (Print)
IS  - 0792-6855 (Linking)
DP  - 2013 May 17
TI  - Testosterone promotes glucose intolerance, lipid disorder and oxidative stress in
      type 1 diabetic rats.
PG  - 1-8
LID - 10.1515/jbcpp-2012-0072 [doi]
LID - /j/jbcpp.ahead-of-print/jbcpp-2012-0072/jbcpp-2012-0072.xml [pii]
AB  - Abstract Background: A bidirectional relationship has been established between
      testosterone deficiency (TD) and type 2 diabetes mellitus (T2DM). Low
      testosterone level has been reported to be a predisposing factor to T2DM, whereas
      recent clinical studies have shown a high prevalence of low testosterone in
      diabetic individuals. However, it is not known if any relationship exists between
      type 1 diabetes mellitus (T1DM) and testosterone level. This study was designed
      to investigate the effects of TD on T1DM. Twenty-four Sprague-Dawley rats were
      randomly divided into four groups designated as control, diabetic, orchiectomized
      and orchiectomized-diabetic. Methods: Diabetes was induced with an intravenous
      injection of alloxan, and orchiectomy was done under sterile conditions. Fasting 
      blood glucose (FBG), insulin level, lipid and oxidative parameters were
      determined in all experimental rats. Results: The area under the curve during
      oral glucose tolerance test showed that the orchiectomized-diabetic group
      expressed an enhanced ability to metabolize glucose than the diabetic group. The 
      malondialdehyde level in the diabetic group was significantly higher compared
      with that in the control and orchiectomized groups. Moreover, there was a
      significant decrease in glutathione (GSH) activity and an increase in superoxide 
      dismutase activity in the diabetic group compared with control. Meanwhile, the
      activities of GSH and catalase were significantly reduced in the orchiectomized
      as well as the orchiectomized-diabetic group when compared with both control and 
      diabetic groups. Conclusions: These data indicate that TD attenuates glucose
      intolerance under diabetic conditions and is equally associated with a
      considerable reduction in oxidative stress, which implies that testosterone may
      be a pro-oxidant.
FAU - Morakinyo, Ayodele Olufemi
AU  - Morakinyo AO
FAU - Adekunbi, Daniel Abiodun
AU  - Adekunbi DA
FAU - Dada, Kayode Akanni
AU  - Dada KA
FAU - Adegoke, Olufeyi Adefunke
AU  - Adegoke OA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Basic Clin Physiol Pharmacol
JT  - Journal of basic and clinical physiology and pharmacology
JID - 9101750
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/11/24 [received]
PHST- 2013/04/02 [accepted]
AID - 10.1515/jbcpp-2012-0072 [doi]
AID - /j/jbcpp.ahead-of-print/jbcpp-2012-0072/jbcpp-2012-0072.xml [pii]
PST - aheadofprint
SO  - J Basic Clin Physiol Pharmacol. 2013 May 17:1-8. doi: 10.1515/jbcpp-2012-0072.

PMID- 23729552
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 17
TI  - Diabetes mellitus with Laron syndrome: case report.
PG  - 1-4
LID - 10.1515/jpem-2012-0411 [doi]
LID - /j/jpem.ahead-of-print/jpem-2012-0411/jpem-2012-0411.xml [pii]
AB  - Abstract There are different opinions concerning changes in glucose metabolism in
      patients with Laron syndrome. In this paper we discuss the treatment results of
      our patient with Laron syndrome who developed diabetes during late adolescence. A
      19-year-old boy with Laron syndrome was referred to our clinic for follow-up. He 
      had been diagnosed with Laron syndrome (LS) at 4 years old and rIGF-1 therapy was
      initiated. After 4 months the treatment was discontinued. At the age of 17,
      rIGF-1 therapy was restarted. A height gain of 8.8 cm. was observed during the
      2-year treatment period. He was admitted to our hospital at the age of 19 years
      following discontinuation of the therapy. At that time, his height was 142 cm,
      and weight for height was 136%. His blood glucose was 85 mg/dL (4.72 mmol/L),
      insulin was 26.39 pmol/L, and HbA1c was 5.4%. At the age of 20, when he has not
      been receiving IGF-1 therapy for 1 year, his weight for height was 143 cm.
      Laboratory evaluation revealed that fasting blood glucose was 176 mg/dL (9.77
      mmol/L), fasting insulin was 29.86 pmol/L, and HbA1c was 7.5%. Primary insulin
      therapy was then initiated. His parents both had a diagnosis of type 2 diabetes. 
      Insulin therapy was switched to oral antidiabetic (OAD) therapy at the end of the
      second year because of a normal C-peptide level of 0.8 nmol/L under insulin
      therapy. After 6 months of OAD, HbA1c was 5.7%. The treatment was then switched
      to IGF-1 therapy, but his blood glucose profile was impaired and OAD therapy was 
      restarted. In conclusion, we observed that genetic susceptibility and abdominal
      obesity caused type 2 diabetes in this patient. We believe that oral antidiabetic
      agents and life-style changes may be the appropriate approach when diabetes is
      developed in LS patients.
FAU - Agladioglu, Sebahat Yilmaz
AU  - Agladioglu SY
FAU - Cetinkaya, Semra
AU  - Cetinkaya S
FAU - Erdeve, Senay Savas
AU  - Erdeve SS
FAU - Onder, Asan
AU  - Onder A
FAU - Kendirci, Havva Nur Peltek
AU  - Kendirci HN
FAU - Bas, Veysel Nijat
AU  - Bas VN
FAU - Aycan, Zehra
AU  - Aycan Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/18 [received]
PHST- 2013/03/24 [accepted]
AID - 10.1515/jpem-2012-0411 [doi]
AID - /j/jpem.ahead-of-print/jpem-2012-0411/jpem-2012-0411.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 17:1-4. doi: 10.1515/jpem-2012-0411.

PMID- 23729551
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 17
TI  - Effect of insulin therapy on IGF-1 level in children with new-onset type 1
      diabetes mellitus: a comparison between DKA and non-DKA.
PG  - 1-4
LID - 10.1515/jpem-2013-0057 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0057/jpem-2013-0057.xml [pii]
AB  - Abstract Background and objective: The issue of insulin-like growth factor 1
      (IGF-1) and diabetes in adults and type 2 diabetes has been well investigated. A 
      few studies have investigated the serum IGF-1 level at the onset of type 1
      diabetes mellitus (T1DM) in children. In the present study, we investigated the
      IGF-1 level of T1DM children before and after insulin therapy. Subjects and
      methods: Between August 2011 and October 2012, 62 children with newly diagnosed
      T1DM were recruited. Serum IGF-1 levels were compared before and 1 month after
      insulin therapy between diabetic ketoacidosis (DKA) and non-DKA patients.
      Results: Thirty-one patients without DKA (18 girls and 13 boys, mean age
      8.8+/-3.01 years) and 31 patients with DKA (18 girls and 13 boys, mean age
      8.3+/-3.7 years) were studied. The mean IGF-1 in the DKA group was lower than
      that in the non-DKA group; however, this difference was not statistically
      significant (p=0.10). Serum IGF-1 levels increased significantly 1 month after
      insulin therapy in both the DKA (p<0.001) and non-DKA (p<0.001) groups.
      Conclusion: Serum IGF-1 level is reduced in new-onset T1DM children. A
      significant increase in serum IGF-1 level can occur with insulin therapy in both 
      DKA and non-DKA children.
FAU - Shiva, Siamak
AU  - Shiva S
FAU - Behbod, Haleh
AU  - Behbod H
FAU - Ghergherechi, Robabeh
AU  - Ghergherechi R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/02/10 [received]
PHST- 2013/04/22 [accepted]
AID - 10.1515/jpem-2013-0057 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0057/jpem-2013-0057.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 17:1-4. doi: 10.1515/jpem-2013-0057.

PMID- 23729549
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 17
TI  - Parental dyadic coping in families of children and adolescents with type 1
      diabetes.
PG  - 1-9
LID - 10.1515/jpem-2012-0410 [doi]
LID - /j/jpem.ahead-of-print/jpem-2012-0410/jpem-2012-0410.xml [pii]
AB  - Abstract Background: The strains of type 1 diabetes mellitus in children and
      adolescents pose a challenge to the minor and his/her parents. Objective: The
      objective of this study was to identify parental dyadic coping patterns and
      explore their relation to psychosocial and disease variables. Subjects: Parents
      (n=44 dyads) of children/adolescents with type 1 diabetes. Methods: Cluster
      analysis employing Ward's method was conducted as a multivariate classification
      procedure without predetermined cluster centers. Results: Three parental coping
      clusters were identified and labeled: avoiders, negotiators, and doers. Although 
      not reaching statistical significance, the HbA1c levels of children/adolescents
      with parental dyads exhibiting the negotiator coping pattern were consistently
      lower than the levels of children with parents classified as avoiders or doers.
      Conclusions: Parental dyads were distinguishable based on their dyadic coping
      patterns with a substantial proportion employing avoidant coping and suboptimal
      communication strategies. These parental dyads may benefit from minimal
      psychosocial intervention.
FAU - Korner, Annett
AU  - Korner A
FAU - Wurz, Julia
AU  - Wurz J
FAU - Brosseau, Danielle C
AU  - Brosseau DC
FAU - Brahler, Elmar
AU  - Brahler E
FAU - Kapellen, Thomas
AU  - Kapellen T
FAU - Kiess, Wieland
AU  - Kiess W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/12/18 [received]
PHST- 2013/04/18 [accepted]
AID - 10.1515/jpem-2012-0410 [doi]
AID - /j/jpem.ahead-of-print/jpem-2012-0410/jpem-2012-0410.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 17:1-9. doi: 10.1515/jpem-2012-0410.

PMID- 23729545
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 17
TI  - Characteristics of infants at risk of hypoglycaemia secondary to being 'infant of
      a diabetic mother'
PG  - 1-5
LID - 10.1515/jpem-2013-0012 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0012/jpem-2013-0012.xml [pii]
AB  - Abstract Background: Infants of diabetic mothers (IDMs) are at risk of
      hypoglycaemia in the neonatal period. The prediction of which of these infants
      are at higher risk of developing hypoglycaemia is complex. Aims: To determine the
      characteristics of infants of diabetic mothers who are more likely to need an
      admission to the neonatal intensive care unit to manage their hypoglycaemia.
      Methods: Retrospective chart review of maternal and infant characteristics of
      'at-risk' infants. Electronic patient records and neonatal and obstetric database
      accessed to obtain data. Results: A total of 326 infants were identified in a
      study period accessible to electronic patient records. Macrosomia was present in 
      15% of the infants. Hypoglycaemic episodes occurred in 109 (33.4%) infants.
      Maternal diabetes type, HbA1c, prematurity, macrosomia, and temperature
      instability were identified as risk factors most commonly associated in infants
      who actually went on to develop hypoglycaemia. Conclusions: A weighted risk score
      to predict hypoglycaemia in this at-risk population may serve to rationalise
      admission to the neonatal unit and management of IDMs.
FAU - Vanhaltren, Karen
AU  - Vanhaltren K
FAU - Malhotra, Atul
AU  - Malhotra A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2012/10/04 [received]
PHST- 2013/04/15 [accepted]
AID - 10.1515/jpem-2013-0012 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0012/jpem-2013-0012.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 17:1-5. doi: 10.1515/jpem-2013-0012.

PMID- 23729543
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 17
TI  - Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus 
      (PHID) syndrome is associated with severe chronic inflammation and
      cardiomyopathy, and represents a new monogenic autoinflammatory syndrome.
PG  - 1-6
LID - 10.1515/jpem-2013-0062 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0062/jpem-2013-0062.xml [pii]
AB  - Abstract Mutations in SLC29A3 lead to pigmentary hypertrichosis and
      non-autoimmune insulin-dependent diabetes mellitus (PHID) and H syndromes,
      familial Rosai-Dorfman disease, and histiocytosis-lymphadenopathy plus syndrome. 
      We report a new association of PHID syndrome with severe systemic inflammation,
      scleroderma-like changes, and cardiomyopathy. A 12-year-old girl with PHID
      syndrome presented with shortness of breath, hepatosplenomegaly, and raised
      erythrocyte sedimentation rate and C-reactive protein. An echocardiogram showed
      biventricular myocardial hypertrophy, and cardiac magnetic resonance imaging
      showed circumferential late gadolinium enhancement of the myocardium. No systemic
      amyloid deposits were observed on a whole-body serum amyloid P scintigraphy scan.
      Abdominal ultrasound revealed intra-abdominal fat surrounding the solid organs,
      suggesting a possibility of evolving lipodystrophy with visceral adiposity. PHID 
      syndrome is a novel monogenic autoinflammatory syndrome (AIS) associated with
      severe elevation of serum amyloid. Lipodystrophy, cutaneous sclerodermatous
      changes, and cardiomyopathy were also present in this case. In contrast to other 
      AIS, blockade of interleukin-1 and tumor necrosis-alpha was ineffective.
FAU - Senniappan, Senthil
AU  - Senniappan S
FAU - Hughes, Marina
AU  - Hughes M
FAU - Shah, Pratik
AU  - Shah P
FAU - Shah, Vanita
AU  - Shah V
FAU - Kaski, Juan Pablo
AU  - Kaski JP
FAU - Brogan, Paul
AU  - Brogan P
FAU - Hussain, Khalid
AU  - Hussain K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/02/13 [received]
PHST- 2013/04/22 [accepted]
AID - 10.1515/jpem-2013-0062 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0062/jpem-2013-0062.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 17:1-6. doi: 10.1515/jpem-2013-0062.

PMID- 23729541
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 17
TI  - Type 1 diabetes in women with endometriosis: what is the risk of occurrence?
PG  - 1-2
LID - 10.1515/jpem-2013-0134 [doi]
LID - /j/jpem.ahead-of-print/jpem-2013-0134/jpem-2013-0134.xml [pii]
FAU - Mormile, Raffaella
AU  - Mormile R
FAU - Vittori, Giorgio
AU  - Vittori G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/04/04 [received]
PHST- 2013/04/18 [accepted]
AID - 10.1515/jpem-2013-0134 [doi]
AID - /j/jpem.ahead-of-print/jpem-2013-0134/jpem-2013-0134.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 17:1-2. doi: 10.1515/jpem-2013-0134.

PMID- 23729495
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1465-3621 (Electronic)
IS  - 0368-2811 (Linking)
DP  - 2013 May 31
TI  - Diabetes Mellitus with Obesity is a Predictor of Recurrence in Patients with
      Non-metastatic Renal Cell Carcinoma.
AB  - OBJECTIVE: To investigate the associations of diabetes mellitus with recurrence
      and prognosis after surgery for non-metastatic renal cell carcinoma and the
      effect modification of obesity on the above relationships. METHODS: We
      retrospectively evaluated 543 patients with non-metastatic renal cell carcinoma
      (pT1-4N0M0) who underwent radical or partial nephrectomy. The association of
      diabetes mellitus with recurrence was analyzed using the Kaplan-Meier method and 
      the Cox regression model. We also examined whether the above relationships were
      modified by obesity using subgroup analysis and tests of interaction. For
      subgroup analysis, the body mass index was categorized as non-obese (<25 kg/m2)
      and obese (>/=25 kg/m2). RESULTS: Eighty-two patients (15.1%) had a history of
      diabetes mellitus. During the mean follow-up of 66.7 months, 68 patients (12.5%) 
      developed recurrence. Although the body mass index was not associated with
      recurrence, diabetes mellitus was an independent predictor of recurrence in
      multivariate analysis (hazard ratio 2.43, P = 0.003), along with tumor diameter, 
      grade and pathological T stage. In further subgroup analysis, the same
      relationship between diabetes mellitus and recurrence was clearly shown in the
      obese group (hazard ratio 4.07, P = 0.010), but not in the non-obese group
      (hazard ratio 1.95, P = 0.125). At the same time, obesity modified the effect of 
      diabetes mellitus on recurrence with a trend (P-interaction = 0.086). In the
      obese group, 5-year recurrence-free survival rates were 75.3 and 91.9% for
      diabetes mellitus and non-diabetes mellitus patients, respectively (P < 0.001).
      Restricting analyses to patients with clear cell type histology did not
      materially change these results. CONCLUSIONS: Diabetes mellitus is a predictor of
      recurrence following surgery for non-metastatic renal cell carcinoma, especially 
      in obese patients.
AD  - Department of Urology, Tokyo Medical and Dental University Graduate School,
      Tokyo, Japan.
FAU - Fukushima, Hiroshi
AU  - Fukushima H
FAU - Masuda, Hitoshi
AU  - Masuda H
FAU - Yokoyama, Minato
AU  - Yokoyama M
FAU - Tatokoro, Manabu
AU  - Tatokoro M
FAU - Yoshida, Soichiro
AU  - Yoshida S
FAU - Ishioka, Junichiro
AU  - Ishioka J
FAU - Matsuoka, Yoh
AU  - Matsuoka Y
FAU - Numao, Noboru
AU  - Numao N
FAU - Koga, Fumitaka
AU  - Koga F
FAU - Saito, Kazutaka
AU  - Saito K
FAU - Fujii, Yasuhisa
AU  - Fujii Y
FAU - Kihara, Kazunori
AU  - Kihara K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Jpn J Clin Oncol
JT  - Japanese journal of clinical oncology
JID - 0313225
OTO - NOTNLM
OT  - diabetes mellitus
OT  - obesity
OT  - recurrence
OT  - renal cell carcinoma
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - hyt070 [pii]
AID - 10.1093/jjco/hyt070 [doi]
PST - aheadofprint
SO  - Jpn J Clin Oncol. 2013 May 31.

PMID- 23729488
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1460-2229 (Electronic)
IS  - 0263-2136 (Linking)
DP  - 2013 Jun 1
TI  - Insulin therapy attitudes and beliefs of physicians in Middle Eastern Arab
      countries.
AB  - BACKGROUND: Studies assessing attitudes and beliefs of physicians regarding
      insulin therapy in Arab countries are scant despite the high prevalence of type 2
      diabetes mellitus (T2DM). OBJECTIVE: This study examines family physicians'
      attitudes and beliefs towards insulin therapy in T2DM patients in the East
      Mediterranean Region of the World Organization of National Colleges, Academies
      and Academic Associations of General Practitioners/Family Physicians. METHODS:
      This is a cross-sectional study conducted on 348 family physicians invited via
      email to fill an anonymous online questionnaire about their attitudes, beliefs
      and perceived barriers regarding insulin initiation in T2DM patients. RESULTS:
      One hundred and twenty-two physicians completed the questionnaire. Of the 122
      physicians, 73.6% preferred to delay insulin initiation until it is absolutely
      essential and 59.0% initiated it themselves. The majority agreed that T2DM
      patients benefit from insulin prior to the development of complications (85.7%)
      and that patient education is important (99.1%) and uncomplicated (74.7%).
      Sixty-three per cent expressed reluctance to start insulin mostly because of
      perceived patients' reluctance. Referral to endocrinologists to initiate insulin 
      therapy was associated with inadequate experience and concern about risks,
      particularly in elderly patients (backward logistic regression, P < 0.05).
      Physicians' reluctance to initiate insulin therapy was associated with patients' 
      perception of insulin initiation as a personal failure and threat to the quality 
      of life (backward logistic regression, P < 0.05). CONCLUSIONS: Although family
      physicians in the Arab world believe in the benefits of insulin therapy, many are
      reluctant to initiate it themselves. Further studies are needed per country, as
      well as multiple measures to minimize the physicians' barriers to insulin
      prescription.
AD  - Department of Family Medicine, American University of Beirut Medical Center
      (AUBMC), Beirut, Lebanon.
FAU - Lakkis, Najla A
AU  - Lakkis NA
FAU - Maalouf, Grace J
AU  - Maalouf GJ
FAU - Mahmassani, Dina M
AU  - Mahmassani DM
FAU - Hamadeh, Ghassan N
AU  - Hamadeh GN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Fam Pract
JT  - Family practice
JID - 8500875
OTO - NOTNLM
OT  - Attitude
OT  - behaviour
OT  - belief
OT  - clinical inertia
OT  - diabetes mellitus
OT  - insulin barriers
OT  - perception
OT  - psychological insulin resistance.
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - cmt022 [pii]
AID - 10.1093/fampra/cmt022 [doi]
PST - aheadofprint
SO  - Fam Pract. 2013 Jun 1.

PMID- 23729470
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Linking)
DP  - 2013 May 31
TI  - PlantLoc: an accurate web server for predicting plant protein subcellular
      localization by substantiality motif.
AB  - Knowledge of subcellular localizations (SCLs) of plant proteins relates to their 
      functions and aids in understanding the regulation of biological processes at the
      cellular level. We present PlantLoc, a highly accurate and fast webserver for
      predicting the multi-label SCLs of plant proteins. The PlantLoc server has two
      innovative characters: building localization motif libraries by a recursive
      method without alignment and Gene Ontology information; and establishing simple
      architecture for rapidly and accurately identifying plant protein SCLs without a 
      machine learning algorithm. PlantLoc provides predicted SCLs results, confidence 
      estimates and which is the substantiality motif and where it is located on the
      sequence. PlantLoc achieved the highest accuracy (overall accuracy of 80.8%) of
      identification of plant protein SCLs as benchmarked by using a new test dataset
      compared other plant SCL prediction webservers. The ability of PlantLoc to
      predict multiple sites was also significantly higher than for any other
      webserver. The predicted substantiality motifs of queries also have great
      potential for analysis of relationships with protein functional regions. The
      PlantLoc server is available at http://cal.tongji.edu.cn/PlantLoc/.
AD  - Department of Chemistry, Tongji University, Shanghai 200092, China, Department of
      Biology and Molecular Biology, Montclair State University, Montclair, NJ 07043,
      USA and Units of Molecular Metabolism, Lund University Diabetes Centre, SE-205 02
      Malmo, Sweden.
FAU - Tang, Shengnan
AU  - Tang S
FAU - Li, Tonghua
AU  - Li T
FAU - Cong, Peisheng
AU  - Cong P
FAU - Xiong, Wenwei
AU  - Xiong W
FAU - Wang, Zhiheng
AU  - Wang Z
FAU - Sun, Jiangming
AU  - Sun J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - gkt428 [pii]
AID - 10.1093/nar/gkt428 [doi]
PST - aheadofprint
SO  - Nucleic Acids Res. 2013 May 31.

PMID- 23729468
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Linking)
DP  - 2013 May 31
TI  - Comparison of pyogenic liver abscesses caused by hypermucoviscous Klebsiella
      pneumoniae and non-Klebsiella pneumoniae pathogens in Beijing: A retrospective
      analysis.
AB  - OBJECTIVE: To perform a retrospective comparison of the clinical and radiological
      features of Klebsiella pneumoniae (KP)-associated and non-KP-associated pyogenic 
      liver abscesses (PLA) in Chinese patients. METHODS: Patients with confirmed
      diagnoses of bacterial liver abscess at three Beijing hospitals were enrolled.
      Clinical isolates from liver abscesses were used to determine serology and
      expression of hypermucoviscosity genes. Basic clinical, ultrasonographic (US) and
      computed tomography (CT) data were recorded and compared between patients with
      KP- and non-KP-associated PLA. RESULTS: A total of 101 (77.10%) and 30 (22.90%)
      cases were due to KP and non-KP pathogens, respectively. Compared with the non-KP
      cohort, the KP cohort demonstrated a significantly higher incidence of underlying
      diabetes mellitus, and more gas-forming abscesses, as demonstrated by US and CT
      examinations. Prior abdominal surgery or chemoradiation therapy was significantly
      associated with non-KP cases. The non-KP group had a higher chance of a clear
      edge, compared with the KP group, on pre-contrast CT images. CONCLUSION: KP and
      non-KP-associated PLA have distinctive risk factors and unique US and CT
      features, in Chinese patients.
AD  - Department of Microbiology, Chinese PLA General Hospital, Beijing, China.
FAU - Wang, Jing
AU  - Wang J
FAU - Yan, Yan
AU  - Yan Y
FAU - Xue, Xinying
AU  - Xue X
FAU - Wang, Kaifei
AU  - Wang K
FAU - Shen, Dingxia
AU  - Shen D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
OTO - NOTNLM
OT  - Klebsiella pneumoniae
OT  - Liver abscess
OT  - aerobactin
OT  - hypermucoviscosity
OT  - magA
OT  - rmpA
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - 0300060513487645 [pii]
AID - 10.1177/0300060513487645 [doi]
PST - aheadofprint
SO  - J Int Med Res. 2013 May 31.

PMID- 23729385
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
DP  - 2013 Jun 1
TI  - Prognostic impact of atrial fibrillation occurrence in patients with
      non-ST-elevation acute coronary syndromes: is dysrhythmia duration a parameter to
      focus on?
AB  - Several studies have evaluated the prognostic impact of atrial fibrillation (AF) 
      in ST-elevation myocardial infarction (STEMI) patients, but scarce data are
      available on the role of AF in non-ST-elevation acute coronary syndromes
      (NSTE-ACS). The aim of this study was to investigate long-term outcome of
      NSTE-ACS patients experiencing an episode of AF during in-hospital course. Of
      1,147 NSTE-ACS patients, 54.4 % for non-STEMI (NSTEMI) and 45.6 % for unstable
      angina, 65 (5.7 %) had an episode of AF. Long-term survival was compared with
      that of 1,082 NSTE-ACS patients who did not develop AF. Patients who developed
      AF, with respect to those who did not, were older and more frequently with NSTEMI
      at admission (69.2 vs. 53.5 %, p = 0.013), diabetes, dyslipidemia and history of 
      heart failure. Moreover, patients who developed AF had a significantly higher New
      York Heart Association class and lower values of glomerular filtration rate.
      During a median follow-up of 40.7 months, we observed a significantly higher
      mortality in NSTE-ACS patients who developed AF versus those who did not (42.2
      vs. 19.8 %, p < 0.001). AF occurrence in NSTE-ACS was a significant predictor of 
      mortality at Cox regression (adjusted HR: 1.85; p = 0.03). After propensity score
      analysis, only patients with AF duration >6 h showed a significantly higher
      mortality at Cox regression (p = 0.021). Our results suggest that NSTE-ACS
      patients who develop AF are characterized by a higher clinical complexity. The
      occurrence of AF, when longer than 6 h, represents an important negative
      prognostic factor for long-term survival.
AD  - Department of Heart and Vessels, Azienda Ospedaliero-Universitaria Careggi, Viale
      Morgagni, 85, 50134, Florence, Italy, cristinagiglioli@yahoo.it.
FAU - Giglioli, Cristina
AU  - Giglioli C
FAU - Minelli, Martina
AU  - Minelli M
FAU - Chiostri, Marco
AU  - Chiostri M
FAU - Landi, Daniele
AU  - Landi D
FAU - Romano, Salvatore Mario
AU  - Romano SM
FAU - Balzi, Daniela
AU  - Balzi D
FAU - Valente, Serafina
AU  - Valente S
FAU - Padeletti, Luigi
AU  - Padeletti L
FAU - Gensini, Gian Franco
AU  - Gensini GF
FAU - Cecchi, Emanuele
AU  - Cecchi E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
PHST- 2013/02/28 [received]
PHST- 2013/05/13 [accepted]
PHST- 2013/06/01 [aheadofprint]
AID - 10.1007/s11739-013-0959-1 [doi]
PST - aheadofprint
SO  - Intern Emerg Med. 2013 Jun 1.

PMID- 23729209
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1522-1539 (Electronic)
IS  - 0363-6135 (Linking)
DP  - 2013 May 31
TI  - HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal
      rat cardiomyocytes: potential therapeutic advantages of HNO over NO*
AB  - Nitroxyl (HNO) is a redox congener of NO*. We now directly compare the
      antihypertrophic efficacy of HNO and NO* donors in neonatal rat cardiomyocytes,
      and compare their contributing mechanisms of actions in this setting.
      Isopropylamine-NONOate (IPA-NO) elicited concentration-dependent inhibition of
      endothelin-1 (ET1)-induced increases in cardiomyocyte size, with similar
      suppression of hypertrophic genes. Antihypertrophic IPA-NO actions were
      significantly attenuated by L-cysteine (HNO scavenger), Rp-8-pCTP-cGMPS
      (cGMP-dependent protein kinase inhibitor), and ODQ (to target soluble guanylyl
      cyclase, sGC), but were unaffected by carboxy-PTIO (NO* scavenger) or CGRP8-37
      (calcitonin gene-related peptide antagonist). Furthermore, IPA-NO significantly
      increased cardiomyocyte cGMP 3.5-fold (an L-cysteine-sensitive effect), and
      stimulated sGC activity 3-fold, without detectable NO* release. IPA-NO also
      suppressed ET1-induced cardiomyocyte superoxide generation. The pure NO* donor,
      DEA-NO, reproduced these IPA-NO actions, but were sensitive to carboxy-PTIO
      rather than L-cysteine. Although IPA-NO stimulation of purified sGC was preserved
      under pyrogallol oxidant stress (in direct contrast to DEA-NO), cardiomyocyte sGC
      activity after either donor were attenuated by this stress. Excitingly IPA-NO
      also exhibited acute antihypertrophic actions in response to pressure-overload in
      the intact heart. Together these data strongly suggest that IPA-NO protection
      against cardiomyocyte hypertrophy is independent of both NO* and CGRP, but rather
      utilizes novel HNO activation of cGMP signaling. Thus HNO acutely limits
      hypertrophy independently of NO*, even under conditions of elevated superoxide.
      Development of longer-acting HNO donors may thus represent an attractive new
      strategy for the treatment of cardiac hypertrophy, as stand-alone and/or add-on
      therapy to standard care.
AD  - 1Baker IDI Heart & Diabetes Research Institute.
FAU - Irvine, Jennifer C
AU  - Irvine JC
FAU - Cao, Nga
AU  - Cao N
FAU - Gossain, Swati
AU  - Gossain S
FAU - Alexander, Amy E
AU  - Alexander AE
FAU - Love, Jane E
AU  - Love JE
FAU - Qin, Chengxue
AU  - Qin C
FAU - Horowitz, John David
AU  - Horowitz JD
FAU - Kemp-Harper, Barbara Kathryn
AU  - Kemp-Harper BK
FAU - Ritchie, Rebecca H
AU  - Ritchie RH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
OTO - NOTNLM
OT  - cGMP-dependent protein kinase
OT  - cardiac hypertrophy
OT  - nitric oxide
OT  - nitroxyl
OT  - superoxide
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - ajpheart.00495.2012 [pii]
AID - 10.1152/ajpheart.00495.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Heart Circ Physiol. 2013 May 31.

PMID- 23729199
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1941-3297 (Electronic)
IS  - 1941-3289 (Linking)
DP  - 2013 May 31
TI  - Plasma Vitamin C But Not Vitamin E Is Associated with Reduced Risk of Heart
      Failure in Older Men.
AB  - BACKGROUND: -Oxidative stress has been implicated in the pathogenesis of heart
      failure (HF). However, data on the association between antioxidant intakes and
      circulating levels and risk of incident HF in the older general population are
      limited. We have examined prospectively the associations between plasma vitamin C
      and E, dietary intakes of vitamin C and E and incident HF. METHODS AND RESULTS:
      -Prospective study of 3919 men aged 60-79 years with no prevalent HF followed up 
      for a mean period of 11 years, in whom there were 263 incident HF cases. Higher
      plasma vitamin C level was associated with significantly lower risk of incident
      HF in both men with and without previous myocardial infarction (MI) after
      adjustment for lifestyle characteristics, diabetes, blood lipids, blood pressure 
      and heart rate [hazards ratio (HR) (95%CI) 0.81 (0.70,0.93) and 0.75 (0.59,0.97) 
      for a 1SD increase in log vitamin C respectively]. Plasma vitamin E and dietary
      vitamin C intake showed no association with HF. High levels of dietary vitamin E 
      intake (which correlated weakly with plasma vitamin E) were associated with
      increased risk of HF in men with no previous MI even after adjustment [adjusted
      HR (95%CI) 1.23 (1.06,1.42) for a 1SD increase]. CONCLUSIONS: -Higher plasma
      Vitamin C is associated with a reduced risk of HF in older men with and without
      MI. High intake of dietary vitamin E may be associated with increased HF risk.
      Primary intervention trials assessing the effect of vitamin C supplements on HF
      risk in the elderly are needed.
AD  - 1University College London, London, United Kingdom.
FAU - Wannamethee, Sasiwarang Goya
AU  - Wannamethee SG
FAU - Bruckdorfer, Karl Richard
AU  - Bruckdorfer KR
FAU - Shaper, Andrew Gerald
AU  - Shaper AG
FAU - Papacosta, Olia
AU  - Papacosta O
FAU - Lennon, Lucy
AU  - Lennon L
FAU - Whincup, Peter H
AU  - Whincup PH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Circ Heart Fail
JT  - Circulation. Heart failure
JID - 101479941
OTO - NOTNLM
OT  - heart failure
OT  - vitamin C
OT  - vitamin E
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/05 06:00
AID - CIRCHEARTFAILURE.112.000281 [pii]
AID - 10.1161/CIRCHEARTFAILURE.112.000281 [doi]
PST - aheadofprint
SO  - Circ Heart Fail. 2013 May 31.

PMID- 23725245
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 19
IP  - 2 Spec No.
DP  - 2013 Mar-Apr
TI  - Reexamining the roles of diabetes educators.
PG  - SP
FAU - Farina, Kim
AU  - Farina K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
SB  - H
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/04 06:00
AID - 84876 [pii]
PST - ppublish
SO  - Am J Manag Care. 2013 Mar-Apr;19(2 Spec No.):SP.

PMID- 23725242
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 19
IP  - 2 Spec No.
DP  - 2013 Mar-Apr
TI  - Targeting insulin resistance: the ongoing paradigm shift in diabetes prevention.
PG  - SP
AD  - Director of Clinical Trials, Health Diagnostic Laboratory, Inc, 737 N 5th St, Ste
      103, Richmond, VA 23219. Email: svarvel@hdlabinc.com.
FAU - Dall, Tara
AU  - Dall T
FAU - Thiselton, Dawn
AU  - Thiselton D
FAU - Varvel, Stephen
AU  - Varvel S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
SB  - H
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/04 06:00
AID - 84867 [pii]
PST - ppublish
SO  - Am J Manag Care. 2013 Mar-Apr;19(2 Spec No.):SP.

PMID- 23725240
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 19
IP  - 2 Spec No.
DP  - 2013 Mar-Apr
TI  - Is there a business case for diabetes disease management?
PG  - SP
FAU - Mehr, Stanton R
AU  - Mehr SR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
SB  - H
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/04 06:00
AID - 84862 [pii]
PST - ppublish
SO  - Am J Manag Care. 2013 Mar-Apr;19(2 Spec No.):SP.

PMID- 23725239
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 19
IP  - 2 Spec No.
DP  - 2013 Mar-Apr
TI  - Examining models of care and reimbursement, including patient management fees,
      ACOs, and PCMHs: a panel discussion.
PG  - SP
AB  - A panel discussion on healthcare reimbursement and payment fees at Diabetes
      Innovation 2012 that included leaders from diverse backgrounds in the healthcare 
      industry was moderated by Susan Dentzer, editor-in-chief of Health Affairs and
      publisher of Project HOPE. Panelists included James (Larry) Holly, MD, chief
      executive officer of Southeast Texas Medical Associates (SETMA), LLP; Keith
      Shealy, MD, president of Mackey Family Practice; Laura Long, MD, MPH, vice
      president of clinical innovation for BlueCross BlueShield of South Carolina; and 
      Sam Ho, MD, chief medical officer and executive vice president at
      UnitedHealthcare.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
SB  - H
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/04 06:00
AID - 84859 [pii]
PST - ppublish
SO  - Am J Manag Care. 2013 Mar-Apr;19(2 Spec No.):SP.

PMID- 23725238
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 19
IP  - 2 Spec No.
DP  - 2013 Mar-Apr
TI  - Managing benefits for diabetes: changing payer strategies for changing times.
PG  - SP
AD  - National Medical Director, HumanaOne and KMG, Clinical Leadership and Policy
      Development, Humana, N19 W24133 Riverwood Dr, Ste 300, Waukesha, WI 53188.
      E-mail: atzeelmd@humana.com.
FAU - Tzeel, Albert
AU  - Tzeel A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
SB  - H
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/04 06:00
AID - 84856 [pii]
PST - ppublish
SO  - Am J Manag Care. 2013 Mar-Apr;19(2 Spec No.):SP.

PMID- 23725237
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 19
IP  - 2 Spec No.
DP  - 2013 Mar-Apr
TI  - Measuring the value of better diabetes management.
PG  - SP
AD  - Schaeffer Center for Health Policy and Economics, University of Southern
      California, 3335 S Figueroa St, Unit A, Los Angeles, CA 90089. E-mail:
      dlakdawa@healthpolicy.usc.edu.
FAU - Lakdawala, Darius
AU  - Lakdawala D
FAU - Eber, Michael R
AU  - Eber MR
FAU - Forma, Felicia M
AU  - Forma FM
FAU - Sullivan, Jeffrey
AU  - Sullivan J
FAU - Eber, Michael R
AU  - Eber MR
FAU - Michaud, Pierre-Carl
AU  - Michaud PC
FAU - Bradley, Lily A
AU  - Bradley LA
FAU - Goldman, Dana P
AU  - Goldman DP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
SB  - H
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/04 06:00
AID - 84897 [pii]
PST - ppublish
SO  - Am J Manag Care. 2013 Mar-Apr;19(2 Spec No.):SP.

PMID- 23725236
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 19
IP  - 2 Spec No.
DP  - 2013 Mar-Apr
TI  - Diabetes and the patient-centered medical home.
PG  - SP
AD  - Halleland Habicht Consulting, LLC, 33 South Sixth Street, Minneapolis, MN 55402. 
      E-mail: tpearson9@comcast.net.
FAU - Pearson, Teresa L
AU  - Pearson TL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
SB  - H
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/06/04 06:00
AID - 84887 [pii]
PST - ppublish
SO  - Am J Manag Care. 2013 Mar-Apr;19(2 Spec No.):SP.

PMID- 23718989
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1545-8636 (Electronic)
IS  - 0892-3787 (Linking)
VI  - 62 Suppl
DP  - 2013 May 31
TI  - Surveillance for certain health behaviors among States and selected local areas -
      United States, 2010.
PG  - 1-247
AB  - Problem: Chronic diseases (e.g., heart disease, stroke, cancer, and diabetes) are
      the leading causes of morbidity and mortality in the United States. Engaging in
      healthy behaviors (e.g., quitting smoking and tobacco use, being more physically 
      active, and eating a nutritious diet) and accessing preventive health-care
      services (e.g., routine physical checkups, screening for cancer, checking blood
      pressure, testing blood cholesterol, and receiving recommended vaccinations) can 
      reduce morbidity and mortality from chronic and infectious disease and lower
      medical costs. Monitoring and evaluating health-risk behaviors and the use of
      health services is essential to developing intervention programs, promotion
      strategies, and health policies that address public health at multiple levels,
      including state, territory, metropolitan and micropolitan statistical area
      (MMSA), and county. Reporting Period: January-December 2010. Description of the
      System: The Behavioral Risk Factor Surveillance System (BRFSS) is an ongoing,
      state-based, random-digit-dialed telephone survey of noninstitutionalized adults 
      aged >/=18 years residing in the United States. BRFSS collects data on
      health-risk behaviors, chronic diseases and conditions, access to health care,
      and use of preventive health services and practices related to the leading causes
      of death and disabilities in the United States. This report presents results for 
      2010 for all 50 states, the District of Columbia, the Commonwealth of Puerto
      Rico, Guam, the U.S. Virgin Islands, 192 MMSAs, and 302 counties. Results: In
      2010, the estimated prevalence of high-risk health behaviors, chronic diseases
      and conditions, access to health care, and use of preventive health services
      varied substantially by state and territory, MMSA, and county. In the following
      summary of results, each set of proportions refers to the range of estimated
      prevalence for the disease, condition, or behaviors, as reported by survey
      respondents. Adults reporting good or better health: 67.9%-89.3% for states and
      territories, 72.2%-92.1% for MMSAs, and 72.8%-95.8% for counties. Adults with
      health-care coverage: 69.4%-95.7% for states and territories, 45.7%-97.0% for
      MMSAs, and 45.7%-97.2% for counties. Adults who had a dental visit in the past
      year: 57.2%-81.7% for states and territories, 47.1%-83.5% for MMSAs, and
      47.1%-88.2% for counties. Adults aged >/=65 years having had all their natural
      teeth extracted (edentulism): 7.4%-36.0% for states and territories, 4.8%-34.8%
      for MMSAs, and 2.4%-39.3% for counties. A routine physical checkup during the
      preceding 12 months: 53.8%-80.0% for states and territories, 49.5%-82.6% for
      MMSAs, and 49.5%-85.3% for counties. Influenza vaccination received during the
      preceding 12 months among adults aged >/=65 years: 26.9%-73.4% for states and
      territories, 51.7%-77.1% for MMSAs, and 49.3%-87.8% for counties. Pneumococcal
      vaccination ever received among adults aged >/=65 years: 24.7%-74.0% for states
      and territories, 48.6%-79.9% for MMSAs, and 47.6%-83.1% for counties.
      Sigmoidoscopy or colonoscopy ever received among adults aged >/=50 years:
      37.8%-75.7% for states and territories, 37.3%-79.9% for MMSAs, and 37.3%-82.5%
      for counties. Blood stool test received during the preceding 2 years among adults
      aged >/=50 years: 8.5%-27.0% for states and territories, 6.7%-51.3% for MMSAs,
      and 6.8%-57.2% for counties. Women who reported having had a Papanicolaou test
      during the preceding 3 years: 67.8%-88.9% for states and territories, 63.3%-91.2%
      for MMSAs, and 63.2%-95.7% for counties. Women aged >/=40 years who had a
      mammogram during the preceding 2 years: 63.8%-83.6% for states and territories,
      60.3%-86.2% for MMSAs, and 59.3%-89.7% for counties. Current cigarette smokers:
      5.8%-26.8% for states and territories, 5.8%-28.5% for MMSAs, and 5.9%-29.8% for
      counties. Binge drinking during the preceding month: 6.6%-21.6% for states and
      territories, 3.6%-23.0% for MMSAs, and 3.8%-24.0% for counties. Heavy drinking
      during the preceding month: 2.0%-7.2% for states and territories, 1.0%-10.0% for 
      MMSAs, and 1.0%-14.2% for counties. Adults reporting no leisure-time physical
      activity: 17.5%-42.3% for states and territories, 13.1%-37.6% for MMSAs, and
      8.5%-39.0% for counties. Adults who were overweight: 32.6%-40.7% for states and
      territories, 28.5%-42.5% for MMSAs, and 27.2%-46.4% for counties. Adults aged
      >/=20 years who were obese: 22.1%-35.0% for states and territories, 17.1%-42.1%
      for MMSAs, and 13.3%-42.1% for counties. Adults with current asthma: 5.2%-11.1%
      for states and territories, 3.4%-14.5% for MMSAs, and 3.3%-14.6% for counties.
      Adults with diagnosed diabetes: 5.3%-13.2% for states and territories, 4.6%-15.4%
      for MMSAs, and 2.6%-18.8% for counties. Adults with limited activities because of
      physical, mental or emotional problems: 10.8%-28.2% for states and territories,
      13.5%-38.3% for MMSAs, and 11.7%-32.0% for counties. Adults using special
      equipment because of any health problem: 2.8%-10.6% for states and territories,
      4.5%-15.5% for MMSAs, and 1.3%-15.5% for counties. Adults aged >/=45 years who
      have had coronary heart disease: 5.3%-16.7% for states and territories,
      6.5%-19.6% for MMSAs, and 4.9%-19.6% for counties. Adults aged >/=45 years who
      have had a stroke: 2.4%-7.1% for states and territories, 2.3%-8.8% for MSMAs, and
      1.7%-8.8% for counties. Interpretation: The findings in this report indicate
      substantial variations in the health-risk behaviors, chronic diseases and
      conditions, access to health-care services, and the use of the preventive health 
      services among U.S. adults at the state and territory, MMSA, and county levels.
      Healthy People 2010 (HP 2010) objectives were established to monitor health
      behaviors, conditions, and the use of preventive health services for the first
      decade of the 2000s. The findings in this report indicate that many of the HP
      2010 objectives were not achieved by 2010. The findings underscore the continued 
      need for surveillance of health-risk behaviors, chronic diseases, and conditions 
      and of the use of preventive health-care services. Public Health Action: Local
      and state health departments and federal agencies use BRFSS data to identify
      populations at high risk for certain health-risk behaviors, chronic diseases, and
      conditions and to evaluate the use of preventive health-care services. BRFSS data
      also are used to direct, implement, monitor, and evaluate public health programs 
      and policies that can lead to a reduction in morbidity and mortality from chronic
      conditions and corresponding health-risk behaviors.
FAU - Xu, Fang
AU  - Xu F
FAU - Town, Machell
AU  - Town M
FAU - Balluz, Lina S
AU  - Balluz LS
FAU - Bartoli, William P
AU  - Bartoli WP
FAU - Murphy, Wilmon
AU  - Murphy W
FAU - Chowdhury, Pranesh P
AU  - Chowdhury PP
FAU - Garvin, William S
AU  - Garvin WS
FAU - Pierannunzi, Carol
AU  - Pierannunzi C
FAU - Zhong, Yuna
AU  - Zhong Y
FAU - Salandy, Simone W
AU  - Salandy SW
FAU - Jones, Candace K
AU  - Jones CK
FAU - Crawford, Carol A
AU  - Crawford CA
CN  - Division of Behavioral Surveillance, Office of Surveillance, Epidemiology, and
      Laboratory Services, CDC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - MMWR Surveill Summ
JT  - Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. :
      2002)
JID - 101142015
SB  - IM
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/05/31 06:00
AID - ss6201a1 [pii]
PST - ppublish
SO  - MMWR Surveill Summ. 2013 May 31;62 Suppl:1-247.

PMID- 23729046
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - Snack attack.
PG  - 60, 62, 64
FAU - Neithercott, Tracey
AU  - Neithercott T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):60, 62, 64.

PMID- 23729045
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - Nice nibbles.
PG  - 56-9
FAU - Webb, Robyn
AU  - Webb R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):56-9.

PMID- 23729044
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - Officers & gentlemen.
PG  - 52-4
FAU - Neithercott, Tracey
AU  - Neithercott T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):52-4.

PMID- 23729043
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - So you want to be a scientist.
PG  - 36-40
FAU - Gebel, Erika
AU  - Gebel E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):36-40.

PMID- 23729042
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - Arthritis answers.
PG  - 34-5
FAU - Gebel, Erika
AU  - Gebel E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):34-5.

PMID- 23729041
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - Stand up for health.
PG  - 22-4
FAU - Gebel, Erika
AU  - Gebel E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):22-4.

PMID- 23729007
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1942-3268 (Electronic)
IS  - 1942-3268 (Linking)
DP  - 2013 May 31
TI  - Two Chromosome 9p21 Haplotype Blocks Distinguish Between Coronary Artery Disease 
      and Myocardial Infarction Risk.
AB  - BACKGROUND: -Variants at the 9p21 locus associate with the risk of coronary
      artery disease (CAD) or myocardial infarction (MI). However, atherosclerotic
      plaque deposition is distinct from MI (plaque rupture and thrombosis) and recent 
      studies showed no association between these variants and MI in patients with
      preexisting CAD. We performed haplotype analysis at the 9p21 locus to test
      whether haplotypes at distinct linkage disequilibrium (LD) blocks predict these
      phenotypes. METHODS AND RESULTS: -Using 24 single-nucleotide polymorphisms
      genotyped in Caucasians without diabetes, we reconstructed haplotypes at the 9p21
      locus. Angiographic CAD/MI patients had at least 1 epicardial stenosis > 50%
      (n=2352) whereas controls were asymptomatic and over age 60 (n=2116). For CAD
      patients, regression models examined association of haplotypes with initial age
      of symptomatic CAD, number of diseased vessels, and history of MI. In the
      case-control study, only haplotypes at one block tagged by rs1333049 associated
      with CAD more so than MI. These haplotypes also associated with early onset of
      CAD (beta=-0.13 p=1.37*10-4) and disease severity (beta=0.1823, p=0.006), but not
      with prevalent MI among CAD patients. In contrast, haplotypes at another block
      tagged by rs518394 associated with prevalent MI (beta=0.239, p= 2.05*10-4), but
      remarkably these are inversely associated with disease severity (beta=-0.196,
      p=0.003). This MI association was replicated in the Cleveland Clinic GeneBank
      premature CAD cohort (n=1385, beta=0.207, p= 0.019). CONCLUSIONS:
      -Variants/haplotypes at two blocks are distinguished at 9p21, those at one block 
      predispose to atherosclerosis whereas those at the other predispose to MI among
      individuals with preexisting CAD.
AD  - 1The John and Jennifer Ruddy Canadian Cardiovascular Genetics Centre, University 
      of Ottawa Heart Institute, Ottawa, Canada.
FAU - Fan, Meng
AU  - Fan M
FAU - Dandona, Sonny
AU  - Dandona S
FAU - McPherson, Ruth
AU  - McPherson R
FAU - Allayee, Hooman
AU  - Allayee H
FAU - Hazen, Stanley L
AU  - Hazen SL
FAU - Wells, George A
AU  - Wells GA
FAU - Roberts, Robert
AU  - Roberts R
FAU - Stewart, Alexandre F R
AU  - Stewart AF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Circ Cardiovasc Genet
JT  - Circulation. Cardiovascular genetics
JID - 101489144
OTO - NOTNLM
OT  - atherosclerosis
OT  - chromosome 9p21
OT  - coronary angiography
OT  - haplotype
OT  - myocardial infarction
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - CIRCGENETICS.113.000104 [pii]
AID - 10.1161/CIRCGENETICS.113.000104 [doi]
PST - aheadofprint
SO  - Circ Cardiovasc Genet. 2013 May 31.

PMID- 23729000
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 0012-6667 (Electronic)
IS  - 0012-6667 (Linking)
DP  - 2013 Jun 1
TI  - Canagliflozin: First Global Approval.
AB  - Canagliflozin (Invokana), an oral selective sodium-glucose co-transporter 2
      (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and 
      Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment
      of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of
      the kidney and are involved in the reabsorption of filtered glucose from the
      glomeruli into the body. Inhibition of SGLT2 lowers blood glucose in an insulin
      independent manner as a consequence of blocking reabsorption of filtered glucose 
      in the glomeruli, thereby increasing urinary excretion of glucose and, in turn,
      potentially reducing bodyweight. Canagliflozin is the first SGLT2 inhibitor to be
      approved in the USA and is under regulatory review in the EU. This article
      summarizes the milestones in the development of canagliflozin, leading to its
      first approval for use in adults with type 2 diabetes.
AD  - Adis R&D Insight, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North
      Shore 0754, Auckland, New Zealand, dru@adis.com.
FAU - Elkinson, Shelley
AU  - Elkinson S
FAU - Scott, Lesley J
AU  - Scott LJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Drugs
JT  - Drugs
JID - 7600076
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1007/s40265-013-0064-9 [doi]
PST - aheadofprint
SO  - Drugs. 2013 Jun 1.

PMID- 23728881
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1552-485X (Electronic)
IS  - 1552-4841 (Linking)
DP  - 2013 May 31
TI  - Convergent functional genomics of psychiatric disorders.
LID - 10.1002/ajmg.b.32163 [doi]
AB  - Human studies and animal model studies of psychiatric and other medical disorders
      are becoming increasingly integrated. Particularly for genomics, the convergence 
      and integration of data across species, experimental modalities and technical
      platforms is providing a fit-to-disease way of extracting reproducible and
      biologically important signal, in contrast to the fit-to-cohort effect and
      limited reproducibility of human genetic analyses alone. With the advent of
      whole-genome sequencing and the realization that a major portion of the
      non-coding genome may contain regulatory variants, convergent functional genomics
      approaches are going to be essential to identify disease-relevant signal from the
      tremendous polymorphic variation present in the general population. Such work in 
      psychiatry can provide an example of how to address other genetically complex
      disorders, and in turn will benefit by incorporating concepts from other areas,
      such as cancer, cardiovascular diseases, and diabetes. (c) 2013 Wiley
      Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Psychiatry, Indiana University School of Medicine and Indianapolis 
      VA Medical Center, Indianapolis, Indiana.
FAU - Niculescu, Alexander B
AU  - Niculescu AB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Am J Med Genet B Neuropsychiatr Genet
JT  - American journal of medical genetics. Part B, Neuropsychiatric genetics : the
      official publication of the International Society of Psychiatric Genetics
JID - 101235742
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/03/06 [received]
PHST- 2013/03/19 [accepted]
AID - 10.1002/ajmg.b.32163 [doi]
PST - aheadofprint
SO  - Am J Med Genet B Neuropsychiatr Genet. 2013 May 31. doi: 10.1002/ajmg.b.32163.

PMID- 23728879
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1573-3645 (Electronic)
IS  - 1041-3545 (Linking)
DP  - 2013 Jun 2
TI  - Experimenting with Styles of Living: Bernard, Canguilhem and Type 2 Diabetes
      Education.
AB  - The paper links a debate in the history of medical science between statistics and
      the experimental method with contemporary diabetes educational practices. An
      empirical example of a tension between neglect and concern in diabetes
      self-regulation frames the subsequent theoretical discussion between first,
      Claude Bernard and statistics and afterwards, Georges Canguilhem as a correlative
      to Bernard. Through these philosophers of medical science a connection between
      the experimental method and education is demonstrated. Finally, a case
      description of an experimental approach to alcohol and experimentation frames and
      highlights the educational aspect of the methodological discussion.
AD  - Department of Education, Aarhus University, Campus Emdrup, Tuborgvej 164,
      Building B, room 216, Copenhagen, 2400, NV, Denmark, ankl@dpu.dk.
FAU - Ljungdalh, Anders Kruse
AU  - Ljungdalh AK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - J Med Humanit
JT  - The Journal of medical humanities
JID - 8917478
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1007/s10912-013-9231-y [doi]
PST - aheadofprint
SO  - J Med Humanit. 2013 Jun 2.

PMID- 23728830
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
DP  - 2013 Jun 1
TI  - Effects of Ezetimibe/Simvastatin 10/20 mg vs. Atorvastatin 20 mg on
      Apolipoprotein B/Apolipoprotein A1 in Korean Patients with Type 2 Diabetes
      Mellitus: Results of a Randomized Controlled Trial.
AB  - BACKGROUND: Although the efficacy of ezetimibe/simvastatin and atorvastatin on
      traditional lipid parameters has been studied extensively, the apolipoprotein
      B/apolipoprotein A1 (ApoB/ApoA1) ratio, which has a better predictive value for
      cardiovascular events, has not previously been used as a primary endpoint in
      these two treatment groups. OBJECTIVE: Our objective was to compare the efficacy 
      and safety of ezetimibe/simvastatin 10/20 mg versus atorvastatin 20 mg once daily
      in Korean patients with type 2 diabetes mellitus. STUDY DESIGN: This study was an
      open-label, randomized, controlled study. Type 2 diabetes patients with high
      levels of low-density lipoprotein (LDL) cholesterol (>100 mg/dL) were randomized 
      to receive ezetimibe/simvastatin or atorvastatin. MAIN OUTCOME MEASURE: The
      primary endpoint was the difference in the percent change of ApoB/ApoA1 at 12
      weeks, and secondary endpoints were changes in lipid profiles, glycosylated
      hemoglobin (HbA1c), homeostatic model assessment (HOMA) index, and C-reactive
      protein. RESULTS: In total, 132 patients (66 for each group) were enrolled and
      randomized. After 12 weeks of treatment, the ApoB/ApoA1 ratio was significantly
      reduced in both groups; however, the difference of changes between the two groups
      was not statistically significant (ezetimibe/simvastatin -38.6 +/- 18.0 % vs.
      atorvastatin -34.4 +/- 15.5 %; p = 0.059). There were no significant differences 
      in changes to total cholesterol, LDL cholesterol, high-density lipoprotein
      cholesterol, triglycerides, ApoB, and ApoB48 between the two groups. However, the
      increments of ApoA1 were significantly greater in the ezetimibe/simvastatin group
      than in the atorvastatin group (2.8 +/- 10.0 vs. -1.8 +/- 9.8 %; p = 0.002). In
      the per-protocol analysis, improvement in ApoB/ApoA1 was significantly greater in
      the ezetimibe/simvastatin group (-42.8 +/- 11.8 vs. -36.7 +/- 13.2 %; p = 0.019).
      The changes in HbA1c, HOMA index, and C-reactive protein were comparable between 
      the two groups. The adverse reaction rate was similar between the two groups
      (24.2 vs. 34.9 %; p = 0.180). CONCLUSION: Ezetimibe/simvastatin 10/20 mg is
      comparable to atorvastatin 20 mg for the management of dyslipidemia, and may have
      more favorable effects on apolipoprotein profiles than atorvastatin 20 mg in
      Korean patients with type 2 diabetes mellitus.
AD  - Division of Cardiology, Department of Internal Medicine, Seoul National
      University Hospital, College of Medicine, Seoul National University, 101
      Deahakro, Chongno-gu, Seoul, 110-744, South Korea.
FAU - Lee, Ju-Hee
AU  - Lee JH
FAU - Kang, Hyun-Jae
AU  - Kang HJ
FAU - Kim, Hyo-Soo
AU  - Kim HS
FAU - Sohn, Dae-Won
AU  - Sohn DW
FAU - Oh, Byung-Hee
AU  - Oh BH
FAU - Park, Young-Bae
AU  - Park YB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other
      interventions
JID - 100967755
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1007/s40256-013-0031-6 [doi]
PST - aheadofprint
SO  - Am J Cardiovasc Drugs. 2013 Jun 1.

PMID- 23728750
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 0036-9330 (Print)
IS  - 0036-9330 (Linking)
VI  - 58
IP  - 2
DP  - 2013 May
TI  - Monitoring and adverse events in relation to ACE inhibitor/angiotensin receptor
      blocker initiation in people with diabetes in general practice: a population
      database study.
PG  - 69-76
LID - 10.1177/0036933013482634 [doi]
AB  - BACKGROUND AND AIM: To determine whether angiotensin-converting enzyme
      inhibitor/angiotensin receptor blocker (ACEI/ARB) initiation in people with
      diabetes is monitored as recommended by recent guidelines and the incidence of
      associated adverse renal events. DESIGN: Retrospective population database
      analysis of 4056 people in Tayside, Scotland with type 2 diabetes prescribed an
      ACEI/ARB between 1 January 2005 and 31 December 2009. METHOD: Measurement of urea
      and electrolytes (U&Es) before and after ACEI/ARB initiation and renal adverse
      events; defined as a >/=30% rise in serum creatinine and post-initiation
      potassium of >/=5.6 mmol/L. Associations of adverse events with patient
      demographics or co-prescription of drugs with known renal effects were examined. 
      RESULTS: Overall, 89% of initiations were with an ACE inhibitor. A total of
      18.84% (CI 95% 18.82-18.86) of patients initiating ACE inhibitor or ARB had U&Es 
      measured in the 90 days before initiation and within 5-14 days after initiation. 
      Only 1.7% of patients had an adverse renal event. Patients prescribed with an ARB
      were less likely to be monitored than those prescribed with an ACE inhibitor, but
      no less likely to suffer harm. CONCLUSIONS: Current clinical practice of
      biochemical monitoring of ACE inhibitor/ARB is poor, but adverse events are rare.
      Further studies with serial U&Es are needed to establish the critical time window
      for adverse renal events and evaluate whether intensive biochemical monitoring
      recommended is required in low-risk groups.
AD  - Foundation Year 2 Doctor, NHS Tayside, UK.
FAU - Mathieson, L
AU  - Mathieson L
FAU - Severn, A
AU  - Severn A
FAU - Guthrie, B
AU  - Guthrie B
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Scott Med J
JT  - Scottish medical journal
JID - 2983335R
SB  - IM
OTO - NOTNLM
OT  - Type 2 diabetes
OT  - adverse effects
OT  - angiotensin-converting enzyme inhibitors
OT  - drug monitoring
OT  - family practice
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 58/2/69 [pii]
AID - 10.1177/0036933013482634 [doi]
PST - ppublish
SO  - Scott Med J. 2013 May;58(2):69-76. doi: 10.1177/0036933013482634.

PMID- 23728725
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1347-4715 (Electronic)
IS  - 1342-078X (Linking)
DP  - 2013 Jun 2
TI  - Distribution of and factors contributing to chronic kidney disease in a
      middle-aged working population.
AB  - OBJECTIVES: To clarify the distribution of chronic kidney disease (CKD) and the
      factors contributing to its development and progression in middle-aged Japanese
      workers/employees. METHODS: This was a retrospective study involving 3,964 men
      and 2,698 women aged 35-64 years in 2009 who had been followed-up until 2003.
      Data on proteinuria determined with a dipstick and glomerular filtration rate
      estimated from serum creatinine concentration (eGFR) were collected in the annual
      health check-ups. RESULTS: Proteinuria was detected in 2.9 and 1.1 % of the men
      and women, respectively, and total CKD was detected in 16.0 and 16.1 % of the men
      and women respectively. Moderate or severe CKD associated a high risk of
      cardiovascular diseases and end-stage kidney disease was found mostly in the male
      subjects [2.0 (men) vs. 0.6 % (women)]. High-risk CKD was found in 3.3 % of the
      men aged 55-64 years. A body mass index (BMI) of >/=30, hypertension, diabetes
      mellitus (DM), current smoking and some job types were independently related to
      the development of proteinuria, while age, BMI, hypertriglyceridemia, and job
      types were related to total CKD. The development of high-risk CKD was related to 
      preceding mild CKD signs of reduced eGFR and proteinuria as well as to
      hypertension, DM, smoking, and job type. CONCLUSIONS: Chronic kidney disease was 
      found in 16 % of middle-aged workers with an equal prevalence in both sexes,
      while high-risk CKD was found mostly in men, of whom 3.3 % were aged 55-64 years.
      Obesity, hypertension, DM, smoking and some job types were related to the
      development and progression of CKD.
AD  - Department of Social and Environmental Medicine, Kanazawa Medical University
      School of Medicine, 1-1 Daigaku, Uchinada, Ishikawa, 920-0293, Japan,
      hygiene@kanazawa-med.ac.jp.
FAU - Noborisaka, Yuka
AU  - Noborisaka Y
FAU - Ishizaki, Masao
AU  - Ishizaki M
FAU - Yamada, Yuichi
AU  - Yamada Y
FAU - Honda, Ryumon
AU  - Honda R
FAU - Yokoyama, Hitoshi
AU  - Yokoyama H
FAU - Miyao, Masaru
AU  - Miyao M
FAU - Tabata, Masaji
AU  - Tabata M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - Environ Health Prev Med
JT  - Environmental health and preventive medicine
JID - 9609642
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/05 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/06/02 [aheadofprint]
AID - 10.1007/s12199-013-0343-9 [doi]
PST - aheadofprint
SO  - Environ Health Prev Med. 2013 Jun 2.

PMID- 23728721
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 Jun 1
TI  - Magnetic Resonance Imaging of the Central Nervous System in Diabetic Neuropathy.
AB  - Diabetic 'peripheral' neuropathy (DPN) is one of the common sequelae to the
      development of both type-1 and type-2 diabetes mellitus. Neuropathy has a major
      negative impact on quality of life. Abnormalities in both peripheral vasculature 
      and nerve function are well documented and, in addition, evidence is emerging
      regarding changes within the central nervous system (CNS) that are concomitant
      with the presence of DPN. The often-resistant nature of DPN to medical treatment 
      highlights the need to understand the role of the CNS in neuropathic
      symptomatology and progression, as this may modulate therapeutic approaches.
      Advanced neuroimaging techniques, especially those that can provide quantitative 
      measures of structure and function, can provide objective markers of CNS status. 
      With that comes great potential for not only furthering our understanding of
      involvement of the CNS in neuropathic etiology but also most importantly aiding
      the development of new and more effective, targeted, analgesic interventions.
AD  - Academic Radiology, University of Sheffield, C-Floor, Royal Hallamshire Hospital,
      Glossop Road, Sheffield, S10 2JF, UK, i.d.wilkinson@sheffield.ac.uk.
FAU - Wilkinson, Iain D
AU  - Wilkinson ID
FAU - Selvarajah, Dinesh
AU  - Selvarajah D
FAU - Greig, Marni
AU  - Greig M
FAU - Shillo, Pallai
AU  - Shillo P
FAU - Boland, Elaine
AU  - Boland E
FAU - Gandhi, Rajiv
AU  - Gandhi R
FAU - Tesfaye, Solomon
AU  - Tesfaye S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130601
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1007/s11892-013-0394-8 [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 Jun 1.

PMID- 23728720
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1573-2606 (Electronic)
IS  - 1389-9155 (Linking)
DP  - 2013 Jun 2
TI  - Human immune deficiency virus (HIV) infection and the hypothalamic pituitary
      adrenal axis.
AB  - The hypothalamic pituitary adrenal (HPA) axis is the most common of the endocrine
      lines/axis' to be affected by HIV infection. There are multiple factors that
      contribute to this HPA axis dysregulation. Direct invasion of the various organs 
      in the axis can be either by opportunistic infections or infiltrative diseases.
      The soluble factors or cytokines released during viral infection and the chronic 
      inflammatory state that follows, also contribute to these alterations. The
      actions of these cytokines released by the immune response can both activate the 
      HPA axis and cause a glucocorticoid resistant state. Further, many of the
      anti-retroviral and other medications used to treat HIV infection can contribute 
      to HPA axis dysfunction. While the diagnosis and treatment of endocrine
      dysfunction is the same as in any other patient, management pathways may be quite
      different. While some may be adaptive responses, life threatening adrenal
      insufficiency can also be present. It is important the latter be picked up
      expeditiously and treated promptly to avoid mortality.
AD  - Department of Pediatrics, Section of Pediatric Endocrinology and Diabetes, The
      University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
FAU - George, Minu M
AU  - George MM
FAU - Bhangoo, Amrit
AU  - Bhangoo A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - Rev Endocr Metab Disord
JT  - Reviews in endocrine & metabolic disorders
JID - 100940588
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1007/s11154-013-9244-x [doi]
PST - aheadofprint
SO  - Rev Endocr Metab Disord. 2013 Jun 2.

PMID- 23728681
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 5
DP  - 2013
TI  - Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant
      recipients.
PG  - CD008817
LID - 10.1002/14651858.CD008817.pub2 [doi]
AB  - BACKGROUND: Lung transplantation is a well-accepted treatment for people with
      most end-stage lung diseases. Although both tacrolimus and cyclosporin are used
      as primary immunosuppressive agents in lung transplant recipients, it is unclear 
      which of these drugs is better in reducing rejection and death without causing
      adverse effects. OBJECTIVES: To assess the benefits and harms of tacrolimus
      versus cyclosporin for primary immunosuppression in lung transplant recipients.
      SEARCH METHODS: We searched the Cochrane Renal Group's Specialised Register to 10
      April 2013 through contact with the Trials Search Co-ordinator using search terms
      relevant to this review. We also searched Science Citation Index Expanded and the
      Transplant Library to 20 April 2013. SELECTION CRITERIA: We included all
      randomised controlled trials (RCT) that compared any dose and duration of
      administration of tacrolimus versus cyclosporin as primary immunosuppressive
      treatment in lung transplant recipients. Our selection criteria required that all
      included patients received the same additional immunosuppressive therapy within
      each study. DATA COLLECTION AND ANALYSIS: Three authors extracted data. For
      dichotomous data we used risk ratio (RR) and used mean difference (MD) for
      continuous data, each with 95% confidence intervals (CI). Methodological
      components of the included studies were used to assess risk of systematic errors 
      (bias). Trial sequential analysis was used to assess risk of random errors (play 
      of chance). MAIN RESULTS: We included three studies that enrolled a total of 413 
      adult patients that compared tacrolimus with microemulsion or oral solution
      cyclosporin. All studies were found to be at high risk of bias. Tacrolimus seemed
      to be significantly superior to cyclosporin regarding the incidence of
      bronchiolitis obliterans syndrome (RR 0.46, 95% CI 0.29 to 0.74), lymphocytic
      bronchitis score (MD -0.60, 95% CI -1.04 to -0.16), treatment withdrawal (RR
      0.27, 95% CI 0.16 to 0.46), and arterial hypertension (RR 0.67, 95% CI 0.50 to
      0.89). However, the finding for arterial hypertension was not confirmed when
      analysed using a random-effects model (RR 0.54, 95% CI 0.17 to 1.73).
      Furthermore, trial sequential analysis found that none of the meta-analyses
      reached the required information sizes and cumulative Z-curves did not cross
      trial sequential monitoring boundaries. Diabetes mellitus occurred more
      frequently among people in the tacrolimus group compared with the cyclosporin
      group when the fixed-effect model was applied (RR 4.24, 95% CI 1.58 to 11.40),
      but no difference was found when the random-effects model was used for analysis
      (RR 4.43, 95% CI 0.75 to 26.05). Again, trial sequential analysis found that the 
      required information threshold was not reached and cumulative Z-curve did not
      cross the trial sequential monitoring boundary. No significant difference between
      treatment groups was observed regarding mortality (RR 1.06, 95% CI 0.75 to 1.49),
      incidence of acute rejection (RR 0.89, 95% CI 0.77 to 1.03), numbers of
      infections/100 patient-days (MD -0.15, 95% CI -0.30 to 0.00), cancer (RR 0.21,
      95% CI 0.04 to 1.16), kidney dysfunction (RR 1.41, 95% CI 0.93 to 2.14), kidney
      failure (RR 1.57, 95% CI 0.28 to 8.94), neurotoxicity (RR 7.06, 95% CI 0.37 to
      135.19), and hyperlipidaemia (RR 0.60, 95% CI 0.30 to 1.20). Trial sequential
      analysis showed the required information thresholds were not reached for any of
      these outcome measures. AUTHORS' CONCLUSIONS: Tacrolimus may be superior to
      cyclosporin regarding bronchiolitis obliterans syndrome, lymphocytic bronchitis, 
      treatment withdrawal, and arterial hypertension, but may be inferior regarding
      development of diabetes. No difference in mortality and acute rejection was
      observed between patients treated with tacrolimus and cyclosporin. There were few
      studies comparing tacrolimus and cyclosporin after lung transplantation, and the 
      numbers of patients and events in the included studies were limited. Furthermore,
      the included studies were deemed to be at high risk of bias. Hence, more RCTs are
      needed to assess the results of the present review. Such studies ought to be
      conducted with low risks of systematic errors (bias) and of random errors (play
      of chance).
AD  - Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department
      7812, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, 
      Denmark, DK-2100.
FAU - Penninga, Luit
AU  - Penninga L
FAU - Penninga, Elisabeth I
AU  - Penninga EI
FAU - Moller, Christian H
AU  - Moller CH
FAU - Iversen, Martin
AU  - Iversen M
FAU - Steinbruchel, Daniel A
AU  - Steinbruchel DA
FAU - Gluud, Christian
AU  - Gluud C
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - England
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1002/14651858.CD008817.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2013 May 31;5:CD008817. doi:
      10.1002/14651858.CD008817.pub2.

PMID- 23728669
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 5
DP  - 2013
TI  - Beta-blockers for preventing stroke recurrence.
PG  - CD007890
LID - 10.1002/14651858.CD007890.pub2 [doi]
AB  - BACKGROUND: Stroke affects 15 million people per year worldwide. Despite recent
      developments in acute stroke treatment, prevention remains very important. Stroke
      has a high rate of recurrence; therefore secondary prevention is also important. 
      Many clinical approaches to control risk factors have been proposed. One of these
      approaches is the prescription of beta-blockers that have effects beyond the
      reduction of blood pressure, which can reduce the recurrence of stroke.
      OBJECTIVES: To evaluate the efficacy of beta-blockers for preventing stroke
      recurrence and for reducing death and major vascular events in people with a
      previous stroke or transient ischaemic attack (TIA), and to determine their
      safety, particularly with regard to the development of diabetes mellitus. SEARCH 
      METHODS: We searched the Cochrane Stroke Group Trials Register (December 2011),
      the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane
      Database of Systematic Reviews (CDSR) (The Cochrane Library 2011, Issue 12), the 
      Database of Abstracts of Reviews of Effects (DARE) (December 2011), MEDLINE (1966
      to December 2011), EMBASE (1980 to December 2011), and Latin American and
      Caribbean Health Sciences Literature (LILACS) (1982 to December 2011). We also
      searched ongoing trials registers and reference lists. SELECTION CRITERIA:
      Randomised controlled trials (RCTs) that included participants with previous
      stroke or TIA due to arterial thrombosis or embolism.The intervention was any
      beta-blocker versus control, or beta-blocker plus other treatment versus other
      treatment. DATA COLLECTION AND ANALYSIS: Two review authors independently
      screened the trials identified, appraised quality, and extracted data. MAIN
      RESULTS: We included two RCTs involving 2193 participants in the review. Both
      studies randomised participants to either beta-blocker (atenolol 5 mg) or
      placebo. No statistical differences were noted among the groups in risks of fatal
      and non-fatal stroke (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.75 to 
      1.17). For all other outcomes analysed (death from all causes, cardiac death,
      non-fatal myocardial infarction, major vascular events), we observed no
      significant differences between the groups. AUTHORS' CONCLUSIONS: To date, no
      available evidence supports the routine use of beta-blockers for secondary
      prevention after stroke or TIA. More studies with larger samples are needed.
AD  - Brazilian Cochrane Centre, Universidade Federal de Sao Paulo, Rua Pedro de Toledo
      598, Sao Paulo, Sao Paulo, Brazil, 04039-001.
FAU - De Lima, Luiz Gustavo
AU  - De Lima LG
FAU - Soares, Bernardo Go
AU  - Soares BG
FAU - Saconato, Humberto
AU  - Saconato H
FAU - Atallah, Alvaro N
AU  - Atallah AN
FAU - da Silva, Edina Mk
AU  - da Silva EM
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - England
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1002/14651858.CD007890.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2013 May 31;5:CD007890. doi:
      10.1002/14651858.CD007890.pub2.

PMID- 23728631
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 5
DP  - 2013
TI  - Physician advice for smoking cessation.
PG  - CD000165
LID - 10.1002/14651858.CD000165.pub4 [doi]
AB  - BACKGROUND: Healthcare professionals frequently advise people to improve their
      health by stopping smoking. Such advice may be brief, or part of more intensive
      interventions. OBJECTIVES: The aims of this review were to assess the
      effectiveness of advice from physicians in promoting smoking cessation; to
      compare minimal interventions by physicians with more intensive interventions; to
      assess the effectiveness of various aids to advice in promoting smoking
      cessation, and to determine the effect of anti-smoking advice on disease-specific
      and all-cause mortality. SEARCH METHODS: We searched the Cochrane Tobacco
      Addiction Group trials register in January 2013 for trials of interventions
      involving physicians. We also searched Latin American databases through BVS
      (Virtual Library in Health) in February 2013. SELECTION CRITERIA: Randomised
      trials of smoking cessation advice from a medical practitioner in which
      abstinence was assessed at least six months after advice was first provided. DATA
      COLLECTION AND ANALYSIS: We extracted data in duplicate on the setting in which
      advice was given, type of advice given (minimal or intensive), and whether aids
      to advice were used, the outcome measures, method of randomisation and
      completeness of follow-up.The main outcome measure was abstinence from smoking
      after at least six months follow-up. We also considered the effect of advice on
      mortality where long-term follow-up data were available. We used the most
      rigorous definition of abstinence in each trial, and biochemically validated
      rates where available. People lost to follow-up were counted as smokers. Effects 
      were expressed as relative risks. Where possible, we performed meta-analysis
      using a Mantel-Haenszel fixed-effect model. MAIN RESULTS: We identified 42
      trials, conducted between 1972 and 2012, including over 31,000 smokers. In some
      trials, participants were at risk of specified diseases (chest disease, diabetes,
      ischaemic heart disease), but most were from unselected populations. The most
      common setting for delivery of advice was primary care. Other settings included
      hospital wards and outpatient clinics, and industrial clinics.Pooled data from 17
      trials of brief advice versus no advice (or usual care) detected a significant
      increase in the rate of quitting (relative risk (RR) 1.66, 95% confidence
      interval (CI) 1.42 to 1.94). Amongst 11 trials where the intervention was judged 
      to be more intensive the estimated effect was higher (RR 1.84, 95% CI 1.60 to
      2.13) but there was no statistical difference between the intensive and minimal
      subgroups. Direct comparison of intensive versus minimal advice showed a small
      advantage of intensive advice (RR 1.37, 95% CI 1.20 to 1.56). Direct comparison
      also suggested a small benefit of follow-up visits. Only one study determined the
      effect of smoking advice on mortality. This study found no statistically
      significant differences in death rates at 20 years follow-up. AUTHORS'
      CONCLUSIONS: Simple advice has a small effect on cessation rates. Assuming an
      unassisted quit rate of 2 to 3%, a brief advice intervention can increase
      quitting by a further 1 to 3%. Additional components appear to have only a small 
      effect, though there is a small additional benefit of more intensive
      interventions compared to very brief interventions.
AD  - Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
      2Research Division, Fundacion Universitaria deCiencias de la Salud, University,
      Bogota, Colombia. UK. lindsay.stead@phc.ox.ac.uk.
FAU - Stead, Lindsay F
AU  - Stead LF
FAU - Buitrago, Diana
AU  - Buitrago D
FAU - Preciado, Nataly
AU  - Preciado N
FAU - Sanchez, Guillermo
AU  - Sanchez G
FAU - Hartmann-Boyce, Jamie
AU  - Hartmann-Boyce J
FAU - Lancaster, Tim
AU  - Lancaster T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130531
PL  - England
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
SB  - IM
UOF - Cochrane Database Syst Rev. 2008;(2):CD000165. PMID: 18425860
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1002/14651858.CD000165.pub4 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2013 May 31;5:CD000165. doi:
      10.1002/14651858.CD000165.pub4.

PMID- 23728592
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1573-5001 (Electronic)
IS  - 0925-2738 (Linking)
DP  - 2013 Jun 2
TI  - Protein backbone and sidechain torsion angles predicted from NMR chemical shifts 
      using artificial neural networks.
AB  - A new program, TALOS-N, is introduced for predicting protein backbone torsion
      angles from NMR chemical shifts. The program relies far more extensively on the
      use of trained artificial neural networks than its predecessor, TALOS+.
      Validation on an independent set of proteins indicates that backbone torsion
      angles can be predicted for a larger, >/=90 % fraction of the residues, with an
      error rate smaller than ca 3.5 %, using an acceptance criterion that is nearly
      two-fold tighter than that used previously, and a root mean square difference
      between predicted and crystallographically observed (varphi, psi) torsion angles 
      of ca 12 masculine. TALOS-N also reports sidechain chi1 rotameric states for
      about 50 % of the residues, and a consistency with reference structures of 89 %. 
      The program includes a neural network trained to identify secondary structure
      from residue sequence and chemical shifts.
AD  - Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and 
      Kidney Diseases, National Institutes of Health, Building 5, Room 126 NIH,
      Bethesda, MD, 20892-0520, USA.
FAU - Shen, Yang
AU  - Shen Y
FAU - Bax, Ad
AU  - Bax A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - J Biomol NMR
JT  - Journal of biomolecular NMR
JID - 9110829
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/04/05 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/06/02 [aheadofprint]
AID - 10.1007/s10858-013-9741-y [doi]
PST - aheadofprint
SO  - J Biomol NMR. 2013 Jun 2.

PMID- 23728591
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1745-7262 (Electronic)
IS  - 1008-682X (Linking)
DP  - 2013 Jun 3
TI  - The effect of diet-induced insulin resistance on DNA methylation of the androgen 
      receptor promoter in the penile cavernosal smooth muscle of mice.
LID - 10.1038/aja.2013.26 [doi]
AB  - Population studies have suggested an association between diabetes and the
      symptoms of testosterone deficiency. Recently, the expression of the androgen
      receptor (AR) has been shown to be decreased in diabetic patients. Furthermore,
      diabetes has been shown to induce global methylation. In this study, we used an
      animal model to investigate whether diabetes results in increased methylation of 
      the AR promoter and whether these changes are associated with the decreased
      expression of AR in penile cavernosal smooth muscle tissue. Twenty C57BL/6J mice 
      were divided into two groups, receiving either high- (mature diabetic) or low-
      (mature control) caloric meals for 14 weeks. Another 10 mice were killed at 1
      week (young control). Animals in the mature diabetic group showed decreased
      testosterone levels, although this was not statistically significant. In both
      control groups, no significant methylation was observed in the AR promoter region
      CpG island (-85 to +339). In the mature diabetic group, significant methylation
      was observed at +185 and +200 of the AR promoter. These changes were associated
      with increased homeostatic model assessment for insulin resistance (HOMA-IR) and 
      decreased corpus cavernosal tissue mass and expression of AR mRNA and protein. We
      conclude that in these animals, insulin resistance increased the methylation of
      the GC-rich regions of the AR promoter, leading to decreased AR expression.Asian 
      Journal of Andrology advance online publication, 3 June 2013;
      doi:10.1038/aja.2013.26.
AD  - Department of Urology, Korea University Medical Center Guro Hospital, Seoul
      152-703, Korea.
FAU - Kim, Jin-Wook
AU  - Kim JW
FAU - Oh, Mi-Mi
AU  - Oh MM
FAU - Yoon, Cheol-Yong
AU  - Yoon CY
FAU - Bae, Jae-Hyun
AU  - Bae JH
FAU - Kim, Je-Jong
AU  - Kim JJ
FAU - Moon, Du-Geon
AU  - Moon DG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Asian J Androl
JT  - Asian journal of andrology
JID - 100942132
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/06/03 [aheadofprint]
AID - aja201326 [pii]
AID - 10.1038/aja.2013.26 [doi]
PST - aheadofprint
SO  - Asian J Androl. 2013 Jun 3. doi: 10.1038/aja.2013.26.

PMID- 23728520
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1473-5628 (Electronic)
IS  - 0143-3636 (Linking)
DP  - 2013 May 30
TI  - 18F-FDG PET/CT findings of radiotherapy-related myocardial changes in patients
      with thoracic malignancies.
AB  - OBJECTIVE: The purpose of this study was to investigate myocardial findings of
      F-fluorodeoxyglucose PET/computed tomography (F-FDG PET/CT) after thoracic
      radiotherapy. METHODS: F-Fluorodeoxyglucose PET/CT examination was performed in
      38 patients at least 4 months after radiotherapy. Patients with known cardiac
      diseases, high cardiovascular risk factors, or diabetes mellitus were excluded.
      RESULTS: On visual analysis, 28 patients were seen to have regional myocardial
      F-FDG uptake (74%), five patients were seen to have diffuse myocardial F-FDG
      uptake (13%), and five patients were seen to have no significant myocardial F-FDG
      uptake (13%). Regions of interest were drawn on irradiated and nonirradiated
      segments of the myocardium. The standardized uptake value measurements of the 28 
      patients with regional myocardial F-FDG uptake revealed significantly higher
      values in the irradiated segments in comparison with nonirradiated segments
      (P<0.001). CONCLUSION: Annular or focal increased F-FDG uptake in irradiated
      myocardial segments may be observed after thoracic radiotherapy. These myocardial
      uptake regions were not consistent with the vascular territory of coronary
      arteries, and the patients had no prior myocardial infarction or coronary artery 
      disease. The patients with a history of thoracic radiotherapy, who showed
      increased F-FDG uptake on PET/CT, especially in the basal myocardium, should be
      followed up cautiously for the early diagnosis of cardiac events.
AD  - aDepartment of Nuclear Medicine, Izmir University, Izmir Departments of bNuclear 
      Medicine cRadiation Oncology, Gazi University, Ankara, Turkey.
FAU - Unal, Kemal
AU  - Unal K
FAU - Mustafa, Unlu
AU  - Mustafa U
FAU - Akdemir, Ozgur
AU  - Akdemir O
FAU - Akmansu, Muge
AU  - Akmansu M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Nucl Med Commun
JT  - Nuclear medicine communications
JID - 8201017
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1097/MNM.0b013e328362f824 [doi]
PST - aheadofprint
SO  - Nucl Med Commun. 2013 May 30.

PMID- 23728449
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
DP  - 2013 May 30
TI  - Risk Factors, Incidence, and Effect of Cardiac Failure and Myocardial Infarction 
      in Aneurysmal Subarachnoid Hemorrhage Patients.
AB  - BACKGROUND:: Cardiac dysfunction is a well-known complication of aneurysmal
      subarachnoid hemorrhage (aSAH). However, the clinical significance of cardiac
      complications is largely unknown. OBJECTIVE:: To determine whether cardiac
      complications are independently related to outcomes, and to identify potential
      predictors associated with these complications. METHODS:: We extracted all
      hospitalizations for aSAH from the National Inpatient Sample database, years
      2002-2009. We used generalized estimating equations (GEE) to determine whether
      cardiac complications were associated with the patient outcomes, and to evaluate 
      potential predictors of cardiac complications. RESULTS:: Among 53,713 cases of
      aSAH, there were 3,609 (6.72%) and 151 (0.28%) incidences of cardiac failure (CF)
      and myocardial infarction (MI), respectively. The overall in-hospital mortality
      rate was 24.8%, while mortality for patients with CF was 34.4% and mortality for 
      patients with MI was 29.8%. Patients who suffered CF were significantly more
      likely than other patients to die in the hospital (OR=1.6, 95% CI=[1.47, 1.68],
      p<.001). The difference in mortality rates between MI patients and other
      patients, however, was not statistically significant. The GEE model identified
      seven factors that were predictive of CF: age, gender, race, primary payer,
      diabetes, smoker and cardiac disease. For MI, the model identified age, race and 
      primary payer as significant predictors of MI. CONCLUSION:: Our results suggest
      that an important association exists between cardiac complications and
      mortality/morbidity in aSAH patients. aSAH patients with CF appear to have a
      higher mortality rate, longer LOS, and higher hospitalization costs compared to
      those without CF.
AD  - 1Department of Neurosurgery, Bucheon St. Mary's Hospital, College of Medicine,
      The Catholic University of Korea, Bucheon, Republic of Korea 2Department of
      Neurosurgery, University of Florida, Gainesville, Florida, USA.
FAU - Kim, Young Woo
AU  - Kim YW
FAU - Neal, Dan
AU  - Neal D
FAU - Hoh, Brian L
AU  - Hoh BL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1227/NEU.0000000000000001 [doi]
PST - aheadofprint
SO  - Neurosurgery. 2013 May 30.

PMID- 23728366
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1615-2573 (Electronic)
IS  - 0910-8327 (Linking)
DP  - 2013 Jun 2
TI  - Non-invasively estimated end-systolic elastance in patients with resistant
      hypertension and type 2 diabetes mellitus.
AB  - Ventriculo-arterial coupling (VAC) has been shown to be impaired in patients with
      type 2 diabetes mellitus (type 2 DM) and hypertension, and to improve with
      antihypertensive treatment. We examined if VAC in patients with type 2 DM and
      hypertension improved after a period of intensified antihypertensive treatment.
      VAC was estimated as the ratio of effective arterial elastance (E A) to
      end-systolic elastance (E ES) using pressure and flow curves obtained
      non-invasively (applanation tonometry and echocardiography). Left ventricular
      (LV) systolic and diastolic functions were evaluated using LV volumes, ejection
      fraction (EF), mitral inflow pattern, and Doppler tissue mitral annulus
      velocities. In total, 180 patients were included and for 100 patients the data
      met the quality criteria. Patients were categorized as having controlled (CH, n =
      34), uncontrolled (UH, n = 32) or resistant (RH, n = 34) hypertension. In
      patients with RH, EF at follow-up was reduced from 48 to 42 % (p = 0.005) and E
      ES from 2.18 mmHg/ml to 1.47 mmHg/ml (p = 0.003). EES, however, was also reduced 
      in patients with CH and UH (CH 2.41-2.26, p = 0.05, UH 2.51-2.04, p = 0.05). In
      the present study, intensified antihypertensive treatment did not improve VAC or 
      LV function in patients with hypertension and type 2 DM despite better control of
      BP. We speculate whether this is due to a reduction in myocardial perfusion
      pressure or to a gradual progression of diabetic cardiomyopathy.
AD  - Heymans Institute of Pharmacology, Ghent University, De Pintelaan 185, 9000,
      Ghent, Belgium, trine@tom-trine.dk.
FAU - Soender, Trine K
AU  - Soender TK
FAU - De Backer, Tine
AU  - De Backer T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - Heart Vessels
JT  - Heart and vessels
JID - 8511258
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/11/17 [received]
PHST- 2013/05/17 [accepted]
PHST- 2013/06/02 [aheadofprint]
AID - 10.1007/s00380-013-0371-9 [doi]
PST - aheadofprint
SO  - Heart Vessels. 2013 Jun 2.

PMID- 23728300
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
DP  - 2013 Jun 2
TI  - BACH2 represses effector programs to stabilize T-mediated immune homeostasis.
LID - 10.1038/nature12199 [doi]
AB  - Through their functional diversification, distinct lineages of CD4+ T cells can
      act to either drive or constrain immune-mediated pathology. Transcription factors
      are critical in the generation of cellular diversity, and negative regulators
      antagonistic to alternate fates often act in conjunction with positive regulators
      to stabilize lineage commitment. Genetic polymorphisms within a single locus
      encoding the transcription factor BACH2 are associated with numerous autoimmune
      and allergic diseases including asthma, Crohn's disease, coeliac disease,
      vitiligo, multiple sclerosis and type 1 diabetes. Although these associations
      point to a shared mechanism underlying susceptibility to diverse immune-mediated 
      diseases, a function for BACH2 in the maintenance of immune homeostasis has not
      been established. Here, by studying mice in which the Bach2 gene is disrupted, we
      define BACH2 as a broad regulator of immune activation that stabilizes
      immunoregulatory capacity while repressing the differentiation programs of
      multiple effector lineages in CD4+ T cells. BACH2 was required for efficient
      formation of regulatory (Treg) cells and consequently for suppression of lethal
      inflammation in a manner that was Treg-cell-dependent. Assessment of the
      genome-wide function of BACH2, however, revealed that it represses genes
      associated with effector cell differentiation. Consequently, its absence during
      Treg polarization resulted in inappropriate diversion to effector lineages. In
      addition, BACH2 constrained full effector differentiation within TH1, TH2 and
      TH17 cell lineages. These findings identify BACH2 as a key regulator of CD4+
      T-cell differentiation that prevents inflammatory disease by controlling the
      balance between tolerance and immunity.
AD  - 1] Center for Cancer Research, National Cancer Institute, National Institutes of 
      Health (NIH), Bethesda, Maryland 20892, USA [2].
FAU - Roychoudhuri, Rahul
AU  - Roychoudhuri R
FAU - Hirahara, Kiyoshi
AU  - Hirahara K
FAU - Mousavi, Kambiz
AU  - Mousavi K
FAU - Clever, David
AU  - Clever D
FAU - Klebanoff, Christopher A
AU  - Klebanoff CA
FAU - Bonelli, Michael
AU  - Bonelli M
FAU - Sciume, Giuseppe
AU  - Sciume G
FAU - Zare, Hossein
AU  - Zare H
FAU - Vahedi, Golnaz
AU  - Vahedi G
FAU - Dema, Barbara
AU  - Dema B
FAU - Yu, Zhiya
AU  - Yu Z
FAU - Liu, Hui
AU  - Liu H
FAU - Takahashi, Hayato
AU  - Takahashi H
FAU - Rao, Mahadev
AU  - Rao M
FAU - Muranski, Pawel
AU  - Muranski P
FAU - Crompton, Joseph G
AU  - Crompton JG
FAU - Punkosdy, George
AU  - Punkosdy G
FAU - Bedognetti, Davide
AU  - Bedognetti D
FAU - Wang, Ena
AU  - Wang E
FAU - Hoffmann, Victoria
AU  - Hoffmann V
FAU - Rivera, Juan
AU  - Rivera J
FAU - Marincola, Francesco M
AU  - Marincola FM
FAU - Nakamura, Atsushi
AU  - Nakamura A
FAU - Sartorelli, Vittorio
AU  - Sartorelli V
FAU - Kanno, Yuka
AU  - Kanno Y
FAU - Gattinoni, Luca
AU  - Gattinoni L
FAU - Muto, Akihiko
AU  - Muto A
FAU - Igarashi, Kazuhiko
AU  - Igarashi K
FAU - O'Shea, John J
AU  - O'Shea JJ
FAU - Restifo, Nicholas P
AU  - Restifo NP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - Nature
JT  - Nature
JID - 0410462
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/11/22 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/06/02 [aheadofprint]
AID - nature12199 [pii]
AID - 10.1038/nature12199 [doi]
PST - aheadofprint
SO  - Nature. 2013 Jun 2. doi: 10.1038/nature12199.

PMID- 23728225
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
DP  - 2013 May 27
TI  - Increased YKL-40 levels in patients with isolated coronary artery ectasia: an
      observational study.
LID - 10.5152/akd.2013.145 [doi]
AB  - Objective: YKL-40, a new biomarker of localized inflammation, is secreted by
      macrophages within the atherosclerotic plaques. Coronary artery ectasia (CAE) is 
      a clinical entity with unclear etiopathogenesis. Some studies have revealed that 
      CAE may be a form of atherosclerosis that has more localized and intense
      inflammatory properties than atherosclerosis. The goal of this study was to
      investigate YKL-40 and C-reactive protein (CRP) levels in patients with isolated 
      CAE compared to patients with normal coronary arteries (NCA) and coronary artery 
      disease (CAD). Methods: Our study has an observational and cross-sectional
      design. Forty-nine patients with isolated CAE (mean age: 60+/-10 years), 30
      age-and gender-matched control participants with NCA (30 patients, mean age:
      58+/-12 years) and 30 patients with CAD (mean age: 61+/-10 years), were included 
      in the study. The relationship between YKL-40, CRP levels and the presence of CAE
      was investigated. Univariate and multiple logistic regression analysis were used 
      for analysis of independent variables to predict CAE. Results: Serum YKL-40
      levels were significantly different among study groups (NCA: 110+/-53 mug/L, CAE:
      144+/-68 and CAD: 180+/-117, p=0.005). CAD group and CAE group had significantly 
      higher YKL-40 levels than NCA group (p=0.004 and p=0.015, respectively). CRP was 
      not significantly different between three groups. In addition, there were no any 
      statistically significant differences, with respect to age, gender, the presence 
      of hypertension or diabetes mellitus, and the smoking status (p>0.05). Logistic
      regression analysis revealed only YKL-40 level as the determinant of CAE (OR:
      1.010, 95% CI: 1.001-1.019, p=0.027). Conclusion: YKL-40 levels in patients with 
      isolated CAE compared to patients with NCA were found significantly high and only
      YKL-40 level was established as the determinant of CAE. We believe that further
      studies are needed to clarify the possible causative roles of YKL-40 in patients 
      with isolated CAE.
AD  - Departments of Cardiology, of Medicine, Rize University, Rize-Turkey.
      sinanaltan@gmail.com.
FAU - Erdogan, Turan
AU  - Erdogan T
FAU - Kocaman, Sinan Altan
AU  - Kocaman SA
FAU - Cetin, Mustafa
AU  - Cetin M
FAU - Durakoglugil, Murtaza Emre
AU  - Durakoglugil ME
FAU - Kirbas, Aynur
AU  - Kirbas A
FAU - Canga, Aytun
AU  - Canga A
FAU - Yilmaz, Adnan
AU  - Yilmaz A
FAU - Dogan, Sitki
AU  - Dogan S
FAU - Cicek, Yuksel
AU  - Cicek Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
OAB - Publisher: Abstract available from the publisher.
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.5152/akd.2013.145 [doi]
PST - aheadofprint
SO  - Anadolu Kardiyol Derg. 2013 May 27. doi: 10.5152/akd.2013.145.

PMID- 23728174
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
DP  - 2013 May 20
TI  - Exenatide and the treatment of patients with Parkinson's disease.
LID - 68295 [pii]
LID - 10.1172/JCI68295 [doi]
AB  - Background. There is increasing interest in methods to more rapidly and
      cost-efficiently investigate drugs that are approved for clinical use in the
      treatment of another condition. Exenatide is a type 2 diabetes treatment that has
      been shown to have neuroprotective/neurorestorative properties in preclinical
      models of neurodegeneration. Methods. As a proof of concept, using a single-blind
      trial design, we evaluated the progress of 45 patients with moderate Parkinson's 
      disease (PD), randomly assigned to receive subcutaneous exenatide injection for
      12 months or to act as controls. Their PD was compared after overnight withdrawal
      of conventional PD medication using blinded video assessment of the Movement
      Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), together 
      with several nonmotor tests, at baseline, 6 months, and 12 months and after a
      further 2-month washout period (14 months). Results. Exenatide was well
      tolerated, although weight loss was common and l-dopa dose failures occurred in a
      single patient. Single-blinded rating of the exenatide group suggested clinically
      relevant improvements in PD across motor and cognitive measures compared with the
      control group. Exenatide-treated patients had a mean improvement at 12 months on 
      the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control 
      patients (P = 0.037). Conclusion. These results demonstrate a potential
      cost-efficient approach through which preliminary clinical data of possible
      biological effects are obtainable, prior to undertaking the major investment
      required for double-blind trials of a potential disease-modifying drug in PD.
      Trial registration. Clinicaltrials.gov NCT01174810. Funding. Cure Parkinson's
      Trust.
FAU - Aviles-Olmos, Iciar
AU  - Aviles-Olmos I
FAU - Dickson, John
AU  - Dickson J
FAU - Kefalopoulou, Zinovia
AU  - Kefalopoulou Z
FAU - Djamshidian, Atbin
AU  - Djamshidian A
FAU - Ell, Peter
AU  - Ell P
FAU - Soderlund, Therese
AU  - Soderlund T
FAU - Whitton, Peter
AU  - Whitton P
FAU - Wyse, Richard
AU  - Wyse R
FAU - Isaacs, Tom
AU  - Isaacs T
FAU - Lees, Andrew
AU  - Lees A
FAU - Limousin, Patricia
AU  - Limousin P
FAU - Foltynie, Thomas
AU  - Foltynie T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
PMC - PMC3668846
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/07 [received]
PHST- 2013/03/21 [accepted]
AID - 68295 [pii]
AID - 10.1172/JCI68295 [doi]
PST - aheadofprint
SO  - J Clin Invest. 2013 May 20. pii: 68295. doi: 10.1172/JCI68295.

PMID- 23728166
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
DP  - 2013 May 20
TI  - A new approach to disease-modifying drug trials in Parkinson's disease.
PG  - 1-2
LID - 69690 [pii]
LID - 10.1172/JCI69690 [doi]
AB  - Translating new findings in the laboratory into therapies for patients is a slow 
      and expensive process. The development of therapies for neurodegenerative
      diseases is further complicated by the difficulty in determining whether the drug
      truly retards the slow degenerative process or provides only symptomatic benefit.
      In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD)
      patient study using a drug previously approved for diabetes treatment. In
      addition to suggesting that the drug may indeed be disease modifying in PD, their
      innovative approach suggests there may be more rapid and inexpensive avenues for 
      testing novel therapies in PD.
FAU - Barker, Roger A
AU  - Barker RA
FAU - Stacy, Mark
AU  - Stacy M
FAU - Brundin, Patrik
AU  - Brundin P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
PMC - PMC3668828
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PMCR- 2014/01/01 00:00
AID - 69690 [pii]
AID - 10.1172/JCI69690 [doi]
PST - aheadofprint
SO  - J Clin Invest. 2013 May 20:1-2. doi: 10.1172/JCI69690.

PMID- 23728009
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
VI  - 83
IP  - 6
DP  - 2013 Jun
TI  - The authors reply.
PG  - 1203
LID - 10.1038/ki.2013.40 [doi]
AD  - National Institute of Diabetes and Digestive and Kidney Diseases, National
      Institutes of Health, Phoenix, Arizona, USA.
FAU - Jennifer Weil, E
AU  - Jennifer Weil E
FAU - Lemley, Kevin V
AU  - Lemley KV
FAU - Myers, Bryan D
AU  - Myers BD
FAU - Nelson, Robert G
AU  - Nelson RG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - ki201340 [pii]
AID - 10.1038/ki.2013.40 [doi]
PST - ppublish
SO  - Kidney Int. 2013 Jun;83(6):1203. doi: 10.1038/ki.2013.40.

PMID- 23727938
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130603
DCOM- 20130604
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 14
IP  - 6
DP  - 2013
TI  - Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases.
PG  - 11742-66
LID - 10.3390/ijms140611742 [doi]
AB  - Melatonin is the major secretory product of the pineal gland during the night and
      has multiple activities including the regulation of circadian and seasonal
      rhythms, and antioxidant and anti-inflammatory effects. It also possesses the
      ability to modulate immune responses by regulation of the T helper 1/2 balance
      and cytokine production. Autoimmune diseases, which result from the activation of
      immune cells by autoantigens released from normal tissues, affect around 5% of
      the population. Activation of autoantigen-specific immune cells leads to
      subsequent damage of target tissues by these activated cells. Melatonin therapy
      has been investigated in several animal models of autoimmune disease, where it
      has a beneficial effect in a number of models excepting rheumatoid arthritis, and
      has been evaluated in clinical autoimmune diseases including rheumatoid arthritis
      and ulcerative colitis. This review summarizes and highlights the role and the
      modulatory effects of melatonin in several inflammatory autoimmune diseases
      including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis,
      type 1 diabetes mellitus, and inflammatory bowel disease.
AD  - Department of Biology and Anatomy, National Defense Medical Center, No. 161,
      Section 6, MinChuan East Road, Neihu, Taipei City 114, Taiwan.
      sytwu@ndmctsgh.edu.tw.
FAU - Lin, Gu-Jiun
AU  - Lin GJ
FAU - Huang, Shing-Hwa
AU  - Huang SH
FAU - Chen, Shyi-Jou
AU  - Chen SJ
FAU - Wang, Chih-Hung
AU  - Wang CH
FAU - Chang, Deh-Ming
AU  - Chang DM
FAU - Sytwu, Huey-Kang
AU  - Sytwu HK
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:01
CRDT- 2013/06/04 06:00
PHST- 2013/02/28 [received]
PHST- 2013/05/15 [revised]
PHST- 2013/05/16 [accepted]
AID - ijms140611742 [pii]
AID - 10.3390/ijms140611742 [doi]
PST - epublish
SO  - Int J Mol Sci. 2013 May 31;14(6):11742-66. doi: 10.3390/ijms140611742.

PMID- 23727699
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 2
IP  - 3
DP  - 2013
TI  - Impact of prenatal risk factors on congenital heart disease in the current era.
PG  - e000064
LID - 10.1161/JAHA.113.000064 [doi]
AB  - BACKGROUND: The healthcare burden related to congenital heart disease (CHD) is
      increasing with improving survival. We assessed changing trends in prenatal risk 
      factors for CHD in the current era in a Canadian cohort. METHODS AND RESULTS: CHD
      patients <18 years old (n=2339) and controls without structural heart disease
      (n=199) were prospectively enrolled in an Ontario province-wide biobank registry 
      from 2008-2011. Family history, frequency of extra-cardiac anomalies (ECAs), and 
      antenatal risk factors were assessed. Temporal trends were analyzed and
      associations with CHD were measured using linear and logistic regression. Family 
      history of CHD and frequency of major ECAs was higher in cases versus controls
      (P<0.001). Despite an increase in genetic testing in the recent era, only 9.5% of
      cases with CHD had a confirmed genetic diagnosis. Yield of genetic testing (ie,
      frequency of abnormal results) was higher in familial and syndromic cases. There 
      was an increase in parental age at conception, maternal prepregnancy body mass
      index, maternal urinary tract infections, type 1 diabetes, and exposure to
      nonfertility medications during pregnancy from 1990-2011. Later year of birth,
      family history of CHD, presence of major ECAs, maternal smoking during pregnancy,
      and maternal medication exposure were associated with increased odds of CHD
      (P<0.05 for all). Advanced parental age was associated with increased odds of CHD
      caused by genetic abnormalities. CONCLUSIONS: The increase in prenatal risk
      factors for CHD highlights the need for more rigorous ascertainment of genetic
      and environmental factors including gene-environment interactions that contribute
      to CHD.
AD  - Division of Cardiology, Department of Pediatrics, Hospital for Sick Children,
      University of Toronto, Toronto, Ontario, Canada.
FAU - Fung, Alan
AU  - Fung A
FAU - Manlhiot, Cedric
AU  - Manlhiot C
FAU - Naik, Sapna
AU  - Naik S
FAU - Rosenberg, Herschel
AU  - Rosenberg H
FAU - Smythe, John
AU  - Smythe J
FAU - Lougheed, Jane
AU  - Lougheed J
FAU - Mondal, Tapas
AU  - Mondal T
FAU - Chitayat, David
AU  - Chitayat D
FAU - McCrindle, Brian W
AU  - McCrindle BW
FAU - Mital, Seema
AU  - Mital S
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
SB  - IM
OTO - NOTNLM
OT  - congenital heart disease
OT  - environment
OT  - fetal cardiovascular abnormality
OT  - genetic testing
OT  - prenatal diagnosis
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 2/3/e000064 [pii]
AID - 10.1161/JAHA.113.000064 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2013 May 31;2(3):e000064. doi: 10.1161/JAHA.113.000064.

PMID- 23727660
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
DP  - 2013 May 30
TI  - Urinary liver type fatty acid binding protein in diabetic nephropathy.
LID - S0009-8981(13)00224-6 [pii]
LID - 10.1016/j.cca.2013.05.020 [doi]
AB  - Deterioration of diabetic nephropathy (DN) is largely determined by the degree of
      tubulointerstitial changes rather than the extent of histological changes in the 
      glomeruli. Therefore, a tubular marker that accurately reflects
      tubulointerstitial damage may be an excellent biomarker for early detection or
      prediction of DN. Liver-type fatty-acid binding protein (L-FABP) is a 14kDa small
      molecule that is expressed in the cytoplasm of human proximal tubules. In vivo
      experimental studies revealed that renal L-FABP gene expression was up-regulated 
      by various stresses that cause tubulointerstitial damage, such as massive
      proteinuria, hyperglycemia, hypertension, ischemia and toxins, and that urinary
      excretion of L-FABP was increased. Recent clinical studies of patients with type 
      1 or type 2 diabetes demonstrated that urinary excretion of L-FABP derived from
      proximal tubules is a suitable biomarker for predicting and monitoring
      deterioration of renal function in DN. Moreover, therapeutic interventions with
      renoprotective effects reduced urinary L-FABP concentrations. Therefore, urinary 
      L-FABP measured using the Human L-FABP ELISA Kit developed by CMIC Co., Ltd.
      (Tokyo, Japan) was confirmed as a newly established tubular biomarker by the
      Ministry of Health, Labour and Welfare in Japan in 2010. This review article
      summarizes the clinical significance of urinary L-FABP in DN.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
AD  - Department of Nephrology and Hypertension, Internal Medicine, St. Marianna
      University School of Medicine, Kanagawa, Japan; Department of Anatomy, St.
      Marianna University School of Medicine, Kanagawa, Japan.
FAU - Kamijo-Ikemori, Atsuko
AU  - Kamijo-Ikemori A
FAU - Sugaya, Takeshi
AU  - Sugaya T
FAU - Ichikawa, Daisuke
AU  - Ichikawa D
FAU - Hoshino, Seiko
AU  - Hoshino S
FAU - Matsui, Katsuomi
AU  - Matsui K
FAU - Yokoyama, Takeshi
AU  - Yokoyama T
FAU - Yasuda, Takashi
AU  - Yasuda T
FAU - Hirata, Kazuaki
AU  - Hirata K
FAU - Kimura, Kenjiro
AU  - Kimura K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/05/01 [received]
PHST- 2013/05/21 [revised]
PHST- 2013/05/23 [accepted]
AID - S0009-8981(13)00224-6 [pii]
AID - 10.1016/j.cca.2013.05.020 [doi]
PST - aheadofprint
SO  - Clin Chim Acta. 2013 May 30. pii: S0009-8981(13)00224-6. doi:
      10.1016/j.cca.2013.05.020.

PMID- 23727386
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1872-8278 (Electronic)
IS  - 1567-7249 (Linking)
DP  - 2013 May 30
TI  - Mitochondria in biology and medicine - 2012.
LID - S1567-7249(13)00091-3 [pii]
LID - 10.1016/j.mito.2013.05.010 [doi]
AB  - As the understanding of mitochondria and their importance for the cell and
      organism is developing, increasing evidence is demonstrating the organelle to be 
      intricately involved in an extensive range of pathologies. This range of
      pathologies include general signs of premature aging, neuro-muscular
      dysfunctions, cancer, diabetes, various heart diseases, inflammation and other
      conditions not previously known to be related to mitochondrial function. A better
      understanding of mitochondria therefore allows a better understanding of related 
      pathologies. It enables the usage of mitochondrial function as biomarkers for the
      diseases and most important, it opens the possibility of a treatment or a cure
      for a disease. "Mitochondria in Biology and Medicine" was the title of the second
      annual conference of Society of Mitochondrial Research and Medicine - India. The 
      conference was organized by Rana P. Singh, Keshav Singh and Kumarasamy Thangaraj,
      and was held at the newly opened School of Life Sciences, Central University of
      Gujarat (CUG), Gandhinagar, India, during 2-3 November 2012. The conference
      featured talks from internationally renowned scientists within the field of
      mitochondrial research and offered both students and fellow researchers a
      comprehensive update to the newest research within the field. This paper
      summarizes key outcomes of the presentations.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Center for Healthy Aging, Department of Cellular and Molecular Medicine,
      University of Copenhagen, DK-2200 Copenhagen, Denmark.
FAU - Desler, Claus
AU  - Desler C
FAU - Rasmussen, Lene Juel
AU  - Rasmussen LJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Mitochondrion
JT  - Mitochondrion
JID - 100968751
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/04/05 [received]
PHST- 2013/05/21 [accepted]
AID - S1567-7249(13)00091-3 [pii]
AID - 10.1016/j.mito.2013.05.010 [doi]
PST - aheadofprint
SO  - Mitochondrion. 2013 May 30. pii: S1567-7249(13)00091-3. doi:
      10.1016/j.mito.2013.05.010.

PMID- 23727264
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1528-0012 (Electronic)
IS  - 0016-5085 (Linking)
DP  - 2013 May 30
TI  - Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in
      Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
LID - S0016-5085(13)00840-8 [pii]
LID - 10.1053/j.gastro.2013.05.042 [doi]
AB  - BACKGROUND & AIMS: Obeticholic acid (OCA, INT-747, 6alpha-ethyl-chenodeoxycholic 
      acid) is a semi-synthetic derivative of the primary human bile acid
      chenodeoxycholic acid, the natural agonist of the farnesoid X receptor (FXR)-a
      nuclear hormone receptor that regulates glucose and lipid metabolism. In animal
      models, OCA decreases insulin resistance and hepatic steatosis. METHODS: We
      performed a double-blind, placebo-controlled, proof-of-concept study to evaluate 
      the effects of OCA on insulin sensitivity in patients with nonalcoholic fatty
      liver disease (NAFLD) and type 2 diabetes. Patients were randomly assigned to
      groups given placebo (n=17), 25 mg OCA (n=15), or 50 mg OCA (n=13) once daily for
      6 weeks. A 2-stage hyperinsulinemic euglycemic insulin clamp was used to measure 
      insulin sensitivity before and after the 6-week treatment period. We also
      measured levels of liver enzymes, lipid analytes, fibroblast growth factor 19
      (FGF19), 7alpha-hydroxy-4-cholesten-3-one (C4, a BA precursor), endogenous BAs,
      and markers of liver fibrosis. RESULTS: When patients were given a low-dose
      insulin infusion, insulin sensitivity increased by 28.0% from baseline in the
      group given 25 mg OCA (P=.019) and 20.1% from baseline in the group given 50 mg
      OCA (P=.060). In combined OCA groups, insulin sensitivity increased by 24.5%
      (P=.011), whereas it decreased by 5.5% in the placebo group. A similar pattern
      was observed in patients given a high-dose insulin infusion. The OCA groups had
      significant reductions in levels of gamma-glutamyltransferase and alanine
      aminotransferase and dose-related weight loss. They also had increased serum
      levels of LDL cholesterol and FGF19, associated with decreased levels of C4 and
      endogenous BA, indicating activation of FXR. Markers of liver fibrosis decreased 
      significantly in the 25 mg OCA group. Adverse experiences were similar among
      groups. CONCLUSIONS: In this phase 2 trial, administration of 25 or 50 mg OCA for
      6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of
      liver inflammation and fibrosis in patients with type 2 diabetes an NAFLD.
      Longer, larger studies are warranted. ClinicalTrials.gov: NCT00501592.
CI  - Copyright (c) 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
AD  - Center for Metabolic Research, VA San Diego Healthcare System & University of
      California, San Diego, CA, USA. Electronic address: smudaliar@vapop.ucsd.edu.
FAU - Mudaliar, Sunder
AU  - Mudaliar S
FAU - Henry, Robert R
AU  - Henry RR
FAU - Sanyal, Arun J
AU  - Sanyal AJ
FAU - Morrow, Linda
AU  - Morrow L
FAU - Marschall, Hanns-Ulrich
AU  - Marschall HU
FAU - Kipnes, Mark
AU  - Kipnes M
FAU - Adorini, Luciano
AU  - Adorini L
FAU - Sciacca, Cathi I
AU  - Sciacca CI
FAU - Clopton, Paul
AU  - Clopton P
FAU - Castelloe, Erin
AU  - Castelloe E
FAU - Dillon, Paul
AU  - Dillon P
FAU - Pruzanski, Mark
AU  - Pruzanski M
FAU - Shapiro, David
AU  - Shapiro D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/12 [received]
PHST- 2013/04/30 [revised]
PHST- 2013/05/22 [accepted]
AID - S0016-5085(13)00840-8 [pii]
AID - 10.1053/j.gastro.2013.05.042 [doi]
PST - aheadofprint
SO  - Gastroenterology. 2013 May 30. pii: S0016-5085(13)00840-8. doi:
      10.1053/j.gastro.2013.05.042.

PMID- 23727212
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 May 29
TI  - Chronic Kidney Disease: The "Perfect Storm" of Cardiometabolic Risk Illuminates
      Genetic Diathesis in Cardiovascular Disease.
LID - S0735-1097(13)02074-3 [pii]
LID - 10.1016/j.jacc.2013.04.063 [doi]
AD  - Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute 
      at Lake Nona, Translational Research Institute at Florida Hospital, Orlando, FL. 
      Electronic address: dtowler@sanfordburnham.org.
FAU - Towler, Dwight A
AU  - Towler DA
LA  - ENG
PT  - EDITORIAL
DEP - 20130529
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/04/15 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/04/29 [accepted]
AID - S0735-1097(13)02074-3 [pii]
AID - 10.1016/j.jacc.2013.04.063 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 May 29. pii: S0735-1097(13)02074-3. doi:
      10.1016/j.jacc.2013.04.063.

PMID- 23727187
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1527-3792 (Electronic)
IS  - 0022-5347 (Linking)
DP  - 2013 May 28
TI  - Interactions between Lower Urinary Tract Symptoms and Cardiovascular Risk factors
      determine distinct patterns of Erectile Dysfunction: a Latent Class Analysis.
LID - S0022-5347(13)04413-3 [pii]
LID - 10.1016/j.juro.2013.05.048 [doi]
AB  - INTRODUCTION: An epidemiological association between Lower Urinary Tract Symptoms
      (LUTS) and Erectile Dysfunction (ED) is well established. However, interactions
      between multiple risk factors and the role of each one in pathological mechanisms
      are not fully elucidated METHODS: We enrolled 898 men undergoing prostate cancer 
      screening for evaluation with the IPSS and IIEF-5 questionnaires. Age, race,
      hypertension, diabetes, dyslipidemia, metabolic syndrome, cardiovascular disease,
      serum hormones and anthropometric parameters were also evaluated. Risk factors
      for ED were identified on logistic regression. Men with at least mild-to-moderate
      ED (IIEF</=16; n=333) were included in a Latent Class Model to identify
      relationships between risk factors for ED RESULTS: Age, hypertension, diabetes,
      LUTS and cardiovascular event were independent predictors of ED(p<0.05). Three
      latent classes (LC) of patients with ED were identified(Entropy=0.82). LC1 had
      younger subjects, with low cardiovascular risk and moderate/high prevalence of
      LUTS. LC2 had the oldest patients, with moderate cardiovascular risk and elevated
      prevalence of LUTS. LC3 included subjects with intermediate age and the highest
      prevalence of cardiovascular risk factors and LUTS. LUTS and ED severity
      increased from LC1 to LC3. CONCLUSION: Risk factor interactions determined
      different severities of LUTS and ED. The effect of LUTS and cardiovascular risk
      outweighed that of age. While for youngest patients LUTS acted as a lone risk
      factor for ED, the contribution of vascular disease resulted in significantly
      more severe dysfunction. The application of a risk factor interaction model to
      prospective trials could reveal distinct classes of response to drugs and help
      define optimal treatment strategies for specific groups.
CI  - Copyright (c) 2013 American Urological Association Education and Research, Inc.
      Published by Elsevier Inc. All rights reserved.
AD  - University of Sao Paulo Medical School, Division of Urology. Electronic address: 
      jbrunhara@gmail.com.
FAU - Barbosa, Joao A B A
AU  - Barbosa JA
FAU - Muracca, Eduardo
AU  - Muracca E
FAU - Nakano, Elcio
AU  - Nakano E
FAU - Assalin, Adriana R
AU  - Assalin AR
FAU - Cordeiro, Paulo
AU  - Cordeiro P
FAU - Paranhos, Mario
AU  - Paranhos M
FAU - Cury, Jose
AU  - Cury J
FAU - Srougi, Miguel
AU  - Srougi M
FAU - Antunes, Alberto A
AU  - Antunes AA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/05/20 [accepted]
AID - S0022-5347(13)04413-3 [pii]
AID - 10.1016/j.juro.2013.05.048 [doi]
PST - aheadofprint
SO  - J Urol. 2013 May 28. pii: S0022-5347(13)04413-3. doi: 10.1016/j.juro.2013.05.048.

PMID- 23727169
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
DP  - 2013 May 30
TI  - Chronic kidney disease: global dimension and perspectives.
LID - S0140-6736(13)60687-X [pii]
LID - 10.1016/S0140-6736(13)60687-X [doi]
AB  - Chronic kidney disease is defined as a reduced glomerular filtration rate,
      increased urinary albumin excretion, or both, and is an increasing public health 
      issue. Prevalence is estimated to be 8-16% worldwide. Complications include
      increased all-cause and cardiovascular mortality, kidney-disease progression,
      acute kidney injury, cognitive decline, anaemia, mineral and bone disorders, and 
      fractures. Worldwide, diabetes mellitus is the most common cause of chronic
      kidney disease, but in some regions other causes, such as herbal and
      environmental toxins, are more common. The poorest populations are at the highest
      risk. Screening and intervention can prevent chronic kidney disease, and where
      management strategies have been implemented the incidence of end-stage kidney
      disease has been reduced. Awareness of the disorder, however, remains low in many
      communities and among many physicians. Strategies to reduce burden and costs
      related to chronic kidney disease need to be included in national programmes for 
      non-communicable diseases.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Postgraduate Institute of Medical Education and Research, Chandigarh, India;
      George Institute of Global Health, New Delhi, India. Electronic address:
      vjha@pginephro.org.
FAU - Jha, Vivekanand
AU  - Jha V
FAU - Garcia-Garcia, Guillermo
AU  - Garcia-Garcia G
FAU - Iseki, Kunitoshi
AU  - Iseki K
FAU - Li, Zuo
AU  - Li Z
FAU - Naicker, Saraladevi
AU  - Naicker S
FAU - Plattner, Brett
AU  - Plattner B
FAU - Saran, Rajiv
AU  - Saran R
FAU - Wang, Angela Yee-Moon
AU  - Wang AY
FAU - Yang, Chih-Wei
AU  - Yang CW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Lancet
JT  - Lancet
JID - 2985213R
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - S0140-6736(13)60687-X [pii]
AID - 10.1016/S0140-6736(13)60687-X [doi]
PST - aheadofprint
SO  - Lancet. 2013 May 30. pii: S0140-6736(13)60687-X. doi:
      10.1016/S0140-6736(13)60687-X.

PMID- 23727147
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
DP  - 2013 May 30
TI  - Cardiology for gynecologists-A minireview.
LID - S0378-5122(13)00129-1 [pii]
LID - 10.1016/j.maturitas.2013.04.018 [doi]
AB  - Despite cardiovascular disease (CVD) being by far the most common cause of death 
      in women worldwide, awareness is low. Myocardial infarction occurs 10 years later
      in women than in men. Symptoms may be atypical: dyspnea rather than chest pain.
      Also more women than men have myocardial infarction with normal coronary
      angiography, probably due to microvascular disease or coronary spasm. The
      prognosis of non-obstructive disease is now recognized to be the same than for
      obstructive disease. The conventional risk factors for CVD are the same for both 
      genders but have a different impact for women. One example is psychosocial stress
      and angina pectoris can more often be induced by mental stress in women than in
      men. Also there are risk factors specific to women such as a history of
      pre-eclampsia, gestational hypertension or diabetes and polycystic ovary syndrome
      (PCOS). Furthermore atrial fibrillation increases the risk of stroke more in
      women than in men. However, 6 out of 10 deaths from CVD can be prevented by a
      healthy life style and dealing with preexisting risk factors. Hence it is
      important that gynecologists who start seeing women at an earlier age than
      cardiologists should be aware of cardiovascular disease.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Medicine, Cardiac Unit and Centre for Gender Medicine, Karolinska
      Institutet, Solna, Sweden; Centre for Gender Medicine, Karolinska University
      Hospital, N3: 06, Thorax, S 17176 Stockholm, Sweden. Electronic address:
      karin.schenck-gustafsson@ki.se.
FAU - Schenck-Gustafsson, Karin
AU  - Schenck-Gustafsson K
FAU - Rees, Margaret
AU  - Rees M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Maturitas
JT  - Maturitas
JID - 7807333
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/04/18 [received]
PHST- 2013/04/25 [accepted]
AID - S0378-5122(13)00129-1 [pii]
AID - 10.1016/j.maturitas.2013.04.018 [doi]
PST - aheadofprint
SO  - Maturitas. 2013 May 30. pii: S0378-5122(13)00129-1. doi:
      10.1016/j.maturitas.2013.04.018.

PMID- 23727105
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 May 30
TI  - Prehospital ECG signs of acute coronary occlusion are associated with reduced
      one-year mortality.
LID - S0167-5273(13)00992-3 [pii]
LID - 10.1016/j.ijcard.2013.05.064 [doi]
AB  - BACKGROUND: We wanted to evaluate predictors of direct admittance to a coronary
      care unit (CCU) and predictors of death in patients with suspected acute coronary
      syndromes (ACS). METHODS: During 2004-2007, all consecutive prehospitally triaged
      patients with suspected ACS were prospectively included. Prehospital and
      emergency data were collected at point of care. Data from medical records, ECG-, 
      echocardiography- and laboratory databases was collected retrospectively.
      RESULTS: In all, 2757 patients were included. Out of these 858 were directly
      admitted to the CCU or cath/lab. Predictors for direct admittance to the CCU were
      ST-segment elevation on the initial ECG; odds ratio (OR) 46.11, left bundle
      branch block; OR 3.30, ongoing symptoms; OR 2.90, current smoking; OR 2.18 and
      ST-segment depression; OR 2.05. Independent predictors for 1-year mortality were 
      cardiogenic shock; OR 14.40, increasing age OR (per year) 1.08, diabetes; OR 2.09
      and chronic heart failure; OR 1.67. ST-segment elevation was associated with a
      lower 1-year mortality rate; OR 0.52. CONCLUSIONS: Among patients with a
      suspected ACS, prehospital ECG-signs indicating an acute coronary occlusion were 
      not only a predictor for direct admission to acute coronary care but also a
      predictor for increased survival. To improve future outcome in acute ischemic
      heart diseases we must find and treat not only the STEMI's but also the high-risk
      NSTEMIs that otherwise would have a poor prognosis.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Institution of Medicine, Department of Molecular and Clinical Medicine,
      Sahlgrenska University Hospital, Goteborg, Sweden. Electronic address:
      annica.ravn-fischer@vgregion.se.
FAU - Ravn-Fischer, Annica
AU  - Ravn-Fischer A
FAU - Karlsson, Thomas
AU  - Karlsson T
FAU - Johanson, Per
AU  - Johanson P
FAU - Herlitz, Johan
AU  - Herlitz J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/10/26 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/05/04 [accepted]
AID - S0167-5273(13)00992-3 [pii]
AID - 10.1016/j.ijcard.2013.05.064 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 May 30. pii: S0167-5273(13)00992-3. doi:
      10.1016/j.ijcard.2013.05.064.

PMID- 23727064
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
DP  - 2013 May 29
TI  - Association of POL1, MALT1, MC4R, PHLPP and DSEL single nucleotide polymorphisms 
      in chromosome 18q region with type 2 diabetes in Tunisians.
LID - S0378-1119(13)00651-3 [pii]
LID - 10.1016/j.gene.2013.05.015 [doi]
AB  - Previous studies and replication analyses have linked chromosome 18q21.1-23 with 
      type 2 diabetes (T2DM) and its complications, including diabetic nephropathy
      (DN). Here we investigated the association of POL1-nearby variant rs488846,
      MALT1-nearby variant rs2874116, MC4R-nearby variant rs1942872, PHLPP rs9958800
      and DSEL-nearby variant rs9966483 single nucleotide polymorphisms (SNPs) in the
      18q region, previously linked with DN in African-Americans, with T2DM in (North
      African) Tunisian subjects, followed by their association with DN, which was
      performed subsequent to the analysis of the association with T2DM. Study subjects
      comprised 900 T2DM cases and 748 normoglycemic control, and genotyping was
      carried out by PCR-RFLP analysis. Of the 5 SNPs analyzed, POL1-nearby variant
      rs488846 [P=0.044], and MC4R-nearby variant rs1942872 [P=0.012] were associated
      with moderate risk of T2DM. However, there was a lack of consistency in the
      association of the 5 tested SNPs with DN. As such, it appears that the three
      chromosome 18q region variants appear to play a role in T2DM pathogenesis, but
      not with DN in North African Tunisian Arabs.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Research Unit of Biology and Genetics of Cancer and Haematological and Autoimmune
      Diseases, Faculty of Pharmacy of Monastir, Tunisia.
FAU - Turki, Amira
AU  - Turki A
FAU - Mahjoub, Touhami
AU  - Mahjoub T
FAU - Mtiraoui, Nabil
AU  - Mtiraoui N
FAU - Abdelhedi, Miled
AU  - Abdelhedi M
FAU - Frih, Ameur
AU  - Frih A
FAU - Almawi, Wassim Y
AU  - Almawi WY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Gene
JT  - Gene
JID - 7706761
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/09/02 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/05/06 [accepted]
AID - S0378-1119(13)00651-3 [pii]
AID - 10.1016/j.gene.2013.05.015 [doi]
PST - aheadofprint
SO  - Gene. 2013 May 29. pii: S0378-1119(13)00651-3. doi: 10.1016/j.gene.2013.05.015.

PMID- 23727030
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
DP  - 2013 May 30
TI  - Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451)
      and non-alcoholic fatty liver.
LID - S0009-8981(13)00225-8 [pii]
LID - 10.1016/j.cca.2013.05.021 [doi]
AB  - BACKGROUND: In many industrialized countries, non-alcoholic fatty liver disease
      (NAFLD) is recognized as an important disease that increases the risk of
      cardiovascular disease, type-2 diabetes, and metabolic syndrome. Most people with
      NAFLD are asymptomatic, and the disease is discovered incidentally during
      clinical laboratory tests. Present screening methods for NAFLD use ultrasound,
      and CT scans that are time-consuming, and a simple screening method for NAFLD is 
      needed. In this study, we investigated whether serum miRNAs are associated with
      NAFLD and assessed the potential of serum miRNAs as a biomarker for NAFLD.
      METHODS: We assessed intrahepatic fat by ultrasound scan, and the serum levels of
      five miRNAs (miR-21, miR-34a, miR-122, miR-145, and miR-451), which help regulate
      cholesterol and fatty acid homeostasis in liver tissue, by real-time PCR in a
      cross-sectional sample of 403 participants who attended health examinations.
      RESULTS: Serum levels of miRNAs, miR-21, miR-34a, miR-122, and miR-451 were
      higher in participants with NAFLD. The serum level of miR-122 was correlated with
      the severity of liver steatosis. CONCLUSION: Serum levels of miRNAs, particularly
      miR-122, may be a useful biomarker for NAFLD.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Hygiene, Fujita Health University School of Medicine, Toyoake,
      Japan. Electronic address: hyamada@fujita-hu.ac.jp.
FAU - Yamada, Hiroya
AU  - Yamada H
FAU - Suzuki, Koji
AU  - Suzuki K
FAU - Ichino, Naohiro
AU  - Ichino N
FAU - Ando, Yoshitaka
AU  - Ando Y
FAU - Sawada, Akira
AU  - Sawada A
FAU - Osakabe, Keisuke
AU  - Osakabe K
FAU - Sugimoto, Keiko
AU  - Sugimoto K
FAU - Ohashi, Koji
AU  - Ohashi K
FAU - Teradaira, Ryouji
AU  - Teradaira R
FAU - Inoue, Takashi
AU  - Inoue T
FAU - Hamajima, Nobuyuki
AU  - Hamajima N
FAU - Hashimoto, Shuji
AU  - Hashimoto S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/04/18 [received]
PHST- 2013/05/23 [revised]
PHST- 2013/05/23 [accepted]
AID - S0009-8981(13)00225-8 [pii]
AID - 10.1016/j.cca.2013.05.021 [doi]
PST - aheadofprint
SO  - Clin Chim Acta. 2013 May 30. pii: S0009-8981(13)00225-8. doi:
      10.1016/j.cca.2013.05.021.

PMID- 23726993
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 29
TI  - Allosteric modulation of zinc speciation by fatty acids.
LID - S0304-4165(13)00224-9 [pii]
LID - 10.1016/j.bbagen.2013.05.028 [doi]
AB  - BACKGROUND: Serum albumin is the major protein component of blood plasma and is
      responsible for the circulatory transport of a range of small molecules that
      include fatty acids, hormones, metal ions and drugs. Studies examining the
      ligand-binding properties of albumin make up a large proportion of the
      literature. However, many of these studies do not address the fact that albumin
      carries multiple ligands (including metal ions) simultaneously in vivo. Thus the 
      binding of a particular ligand may influence both the affinity and dynamics of
      albumin interactions with another. SCOPE OF REVIEW: Here we review the Zn2+ and
      fatty acid transport properties of albumin and highlight an important interplay
      that exists between them. Also the impact of this dynamic interaction upon the
      distribution of plasma Zn2+, its effect upon cellular Zn2+ uptake and its
      importance in the diagnosis of myocardial ischemia are considered. MAJOR
      CONCLUSIONS: We previously identified the major binding site for Zn2+ on albumin.
      Furthermore, we revealed that Zn2+-binding at this site and fatty acid-binding at
      the FA2 site are interdependent. This suggests that the binding of fatty acids to
      albumin may serve as an allosteric switch to modulate Zn2+-binding to albumin in 
      blood plasma. GENERAL SIGNIFICANCE: Fatty acid levels in the blood are dynamic
      and chronic elevation of plasma fatty acid levels is associated with some
      metabolic disorders such as cardiovascular disease and diabetes. Since the
      binding of Zn2+ to albumin is important for the control of circulatory/cellular
      Zn2+ dynamics, this relationship is likely to have important physiological and
      pathological implications. This article is part of a Special Issue entitled Serum
      Albumin.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
AD  - Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK.
FAU - Barnett, James P
AU  - Barnett JP
FAU - Blindauer, Claudia A
AU  - Blindauer CA
FAU - Kassaar, Omar
AU  - Kassaar O
FAU - Khazaipoul, Siavash
AU  - Khazaipoul S
FAU - Martin, Esther M
AU  - Martin EM
FAU - Sadler, Peter J
AU  - Sadler PJ
FAU - Stewart, Alan J
AU  - Stewart AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/28 [received]
PHST- 2013/05/09 [revised]
PHST- 2013/05/20 [accepted]
AID - S0304-4165(13)00224-9 [pii]
AID - 10.1016/j.bbagen.2013.05.028 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 29. pii: S0304-4165(13)00224-9. doi:
      10.1016/j.bbagen.2013.05.028.

PMID- 23726972
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1878-5875 (Electronic)
IS  - 1357-2725 (Linking)
DP  - 2013 May 31
TI  - Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells 
      via integrin alphabeta and RhoA/ROCK-mediated mechanisms.
LID - S1357-2725(13)00165-9 [pii]
LID - 10.1016/j.biocel.2013.05.021 [doi]
AB  - Lipoprotein(a) (Lp(a)) is an independent risk factor for the development of
      cardiovascular disease. Vascular smooth muscle cell (SMC) motility and
      plasticity, functions that are influenced by environmental cues, are vital to
      adaptation and remodelling in vascular physiology and pathophysiology. Lp(a) is
      reportedly damaging to SMC function via unknown molecular mechanisms.
      Apolipoprotein(a) (apo(a)), a unique glycoprotein moiety of Lp(a), has been
      demonstrated as its active component. The aims of this study were to determine
      functional effects of recombinant apo(a) on human vascular SMC motility and
      explore the underlying mechanism(s). Exposure of SMC to apo(a) in migration
      assays induced a potent, concentration-dependent chemorepulsion that was RhoA and
      integrin alphaVbeta3-dependent, but transforming growth factor beta-independent. 
      SMC manipulation through RhoA gene silencing, Rho kinase inhibition, statin
      pre-treatment, alphaVbeta3 neutralising antibody and tyrosine kinase inhibition
      all markedly inhibited apo(a)-mediated SMC migration. Our data reveal unique and 
      potent activities of apo(a) that may negatively influence SMC remodelling in
      cardiovascular disease. Circulating levels of Lp(a) are resistant to
      lipid-lowering strategies and hence a greater understanding of the mechanisms
      underlying its functional effects on SMC may provide alternative therapeutic
      targets.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics,
      Health and Therapeutics (LIGHT), University of Leeds, Leeds, UK;
      Multidisciplinary Cardiovascular Research Centre (MCRC), University of Leeds,
      Leeds, UK.
FAU - Riches, Kirsten
AU  - Riches K
FAU - Franklin, Larissa
AU  - Franklin L
FAU - Maqbool, Azhar
AU  - Maqbool A
FAU - Peckham, Michelle
AU  - Peckham M
FAU - Adams, Matthew
AU  - Adams M
FAU - Bond, Jacquelyn
AU  - Bond J
FAU - Warburton, Philip
AU  - Warburton P
FAU - Feric, Nicole T
AU  - Feric NT
FAU - Koschinsky, Marlys L
AU  - Koschinsky ML
FAU - O'Regan, David J
AU  - O'Regan DJ
FAU - Ball, Stephen G
AU  - Ball SG
FAU - Turner, Neil A
AU  - Turner NA
FAU - Porter, Karen E
AU  - Porter KE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Int J Biochem Cell Biol
JT  - The international journal of biochemistry & cell biology
JID - 9508482
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/01/03 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/05/21 [accepted]
AID - S1357-2725(13)00165-9 [pii]
AID - 10.1016/j.biocel.2013.05.021 [doi]
PST - aheadofprint
SO  - Int J Biochem Cell Biol. 2013 May 31. pii: S1357-2725(13)00165-9. doi:
      10.1016/j.biocel.2013.05.021.

PMID- 23726789
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
DP  - 2013 May 28
TI  - Quantitative evaluation of therapeutic effect of Liriope platyphylla on phthalic 
      anhydride-induced atopic dermatitis in IL-4/Luc/CNS-1 Tg mice.
LID - S0378-8741(13)00372-3 [pii]
LID - 10.1016/j.jep.2013.05.036 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: A variety of previous pharmacological studies
      have suggested that Liriope platyphylla may exert beneficial biological effects
      on inflammation, diabetes, neurodegenerative disorder, obesity, and atopic
      dermatitis (AD). AIM OF THE STUDY: The therapeutic effect of aqueous extract of
      Liriope platyphylla (AEtLP) on AD was quantified using the luciferase report
      system in IL-4/Luc/CNS-1 transgenic (Tg) mice. MATERIALS AND METHODS: Alteration 
      of the luciferase signal was quantified in IL-4/Luc/CNS-1 Tg mice co-treated with
      phthalic anhydride (PA) and AEtLP for 2 weeks using the IVIS imaging system.
      Phenotypes of AD were assessed by ear thickness analysis, measurement of
      immune-related organ weights, ELISA, and histological and pathological analysis
      in Tg mice. RESULTS: A strong luciferase signal was detected in the abdominal
      region of IL-4/Luc/CNS-1 Tg mice treated with only PA. However, this signal was
      significantly reduced in IL-4/Luc/CNS-1 Tg mice co-treated with PA+AEtLP in an
      AEtLP concentration-dependent manner. Especially, three organs, the thymus,
      pancreas, and submandibular lymph node (SL), showed a high signal response to PA 
      treatment. Furthermore, to verify whether or not alteration of the luciferase
      signal is associated with AD, these disease response phenotypes were measured in 
      the same group of mice. Common allergenic responses including increases in ear
      thickness, lymph node weight, IgE concentration, and infiltrated mast cells were 
      detected in IL-4/Luc/CNS-1 Tg mice treated with PA. However, these responses were
      dramatically decreased by AEtLP treatment for 2 weeks. CONCLUSION: These results 
      indicate that the luciferase signal may successfully reflect the therapeutic
      effects of AEtLP in IL-4/Luc/CNS-1 Tg mice. Further, we suggest additional
      evidence that Liriope platyphylla may be considered as an effective therapeutic
      drug for the treatment of AD.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights
      reserved.
AD  - Department of Biomaterials Science, College of Natural Resources & Life Science, 
      Pusan National University, Miryang 627-706, Republic of Korea.
FAU - Kwak, Moon Hwa
AU  - Kwak MH
FAU - Kim, Ji Eun
AU  - Kim JE
FAU - Hwang, In Sik
AU  - Hwang IS
FAU - Lee, Young Ju
AU  - Lee YJ
FAU - An, Bum Su
AU  - An BS
FAU - Hong, Jin Tae
AU  - Hong JT
FAU - Lee, Sang Hak
AU  - Lee SH
FAU - Hwang, Dae Youn
AU  - Hwang DY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/01/16 [received]
PHST- 2013/04/28 [revised]
PHST- 2013/05/09 [accepted]
AID - S0378-8741(13)00372-3 [pii]
AID - 10.1016/j.jep.2013.05.036 [doi]
PST - aheadofprint
SO  - J Ethnopharmacol. 2013 May 28. pii: S0378-8741(13)00372-3. doi:
      10.1016/j.jep.2013.05.036.

PMID- 23726741
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 30
TI  - Dry eye and its correlation to diabetes microvascular complications in people
      with type 2 diabetes mellitus.
LID - S1056-8727(13)00074-3 [pii]
LID - 10.1016/j.jdiacomp.2013.04.006 [doi]
AB  - AIMS: This study was performed to investigate the correlation between dry eye
      disease and diabetes microvascular complications. METHODS: In this study 243
      people with type 2 diabetes were enrolled. Tear osmolarity was measured using
      tear lab osmolarity system. All of the participants were evaluated for diabetes
      microvascular complications. The Michigan neuropathy screening instrument was
      used for detection of peripheral neuropathy, and the albumin/creatinine ratio in 
      a spot urine sample was considered to diagnose diabetic nephropathy. RESULTS: The
      prevalence of dry eye disease was 27.7%. The mean value for tear osmolarity was
      301.97+/-13.52 mOsm/L. We found a significant correlation between dry eye disease
      and diabetic retinopathy (P=0.01). However no significant correlation was found
      between dry eye disease, diabetic neuropathy, and diabetic nephropathy. Dry eye
      disease was more prevalent in people with proliferative diabetic retinopathy
      and/or clinically significant macular edema (0.006). In a binary logistic
      regression analysis model, there was a significant correlation between dry eye
      disease and retinopathy (OR=2.29, CI=1.16-4.52, P=0.016). In addition, both dry
      eye and retinopathy had significant correlation with HbA1C. CONCLUSIONS: Dry eye 
      disease is common in people with type 2 diabetes, especially in those with
      diabetic retinopathy. In addition, it is more prevalent in people who suffer from
      advanced stages of diabetic retinopathy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Endocrine Research Center (Firouzgar), Institute of Endocrinology and Metabolism,
      Tehran University of Medical Sciences (TUMS), Tehran, Iran.
FAU - Najafi, Laily
AU  - Najafi L
FAU - Malek, Mojtaba
AU  - Malek M
FAU - Valojerdi, Ameneh Ebrahim
AU  - Valojerdi AE
FAU - Aghili, Rokhsareh
AU  - Aghili R
FAU - Khamseh, Mohammad E
AU  - Khamseh ME
FAU - Fallah, Afshin Eshghi
AU  - Fallah AE
FAU - Tokhmehchi, Mohammad Reza Famil
AU  - Tokhmehchi MR
FAU - Behrouz, Mahmoud Jabarvand
AU  - Behrouz MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/11 [received]
PHST- 2013/04/09 [revised]
PHST- 2013/04/09 [accepted]
AID - S1056-8727(13)00074-3 [pii]
AID - 10.1016/j.jdiacomp.2013.04.006 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 30. pii: S1056-8727(13)00074-3. doi:
      10.1016/j.jdiacomp.2013.04.006.

PMID- 23726736
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1138-3593 (Print)
IS  - 1138-3593 (Linking)
VI  - 39
IP  - 4
DP  - 2013 May-Jun
TI  - [Pharmacological iatrogenesis in a cardiac-renal patient: Presentation of a
      case].
PG  - 226-30
LID - 10.1016/j.semerg.2012.02.009 [doi]
LID - S1138-3593(12)00041-X [pii]
AB  - A case is presented of a 75 year-old patient with chronic kidney failure, atrial 
      fibrillation, diabetes mellitus, and hypertension. She had regularly been
      admitted to hospital due to episodes of rapid atrial fibrillation that were not
      well tolerated in relation to the concomitant hypotension and dyspnea. An adverse
      drug reaction was deduced from the clinical course, and the relative importance
      of this in daily medical practice is emphasized.
CI  - Copyright (c) 2011 Sociedad Espanola de Medicos de Atencion Primaria (SEMERGEN). 
      Publicado por Elsevier Espana. All rights reserved.
AD  - Medicina de Familia y Comunitaria, Centro de Atencion Primaria La Gavarra,
      Barcelona, Espana. Electronic address: jverdu@ambitcp.catsalut.net.
FAU - Verdu Solans, J
AU  - Verdu Solans J
FAU - Ojeda Cuchillero, I
AU  - Ojeda Cuchillero I
FAU - Soler Costa, M
AU  - Soler Costa M
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Iatrogenia farmacologica en el paciente cardiorrenal. A proposito de un caso.
DEP - 20120903
PL  - Spain
TA  - Semergen
JT  - Semergen / Sociedad Espanola de Medicina Rural y Generalista
JID - 9610769
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2011/09/18 [received]
PHST- 2012/02/04 [revised]
PHST- 2012/02/13 [accepted]
PHST- 2012/09/03 [aheadofprint]
AID - S1138-3593(12)00041-X [pii]
AID - 10.1016/j.semerg.2012.02.009 [doi]
PST - ppublish
SO  - Semergen. 2013 May-Jun;39(4):226-30. doi: 10.1016/j.semerg.2012.02.009. Epub 2012
      Sep 3.

PMID- 23726644
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Laparoscopic fenestration versus percutaneous catheter drainage for lymphocele
      treatment after kidney transplantation.
PG  - 1667-70
LID - 10.1016/j.transproceed.2012.11.019 [doi]
LID - S0041-1345(12)01388-7 [pii]
AB  - BACKGROUND: Laparoscopic fenestration (LF) and percutaneous catheter drainage
      (PCD) are widely accepted treatments for symptomatic lymphoceles. The aim of this
      study was to review the results and compare the outcomes of LF with those of PCD.
      PATIENTS AND METHODS: Among 1363 patients who underwent kidney transplantation at
      our institute between 1999 and 2011, 35 (2.5%) developed symptomatic lymphoceles.
      Among them, 7 were treated by LF after PCD; 10, LF only, and 18 PCD only. The
      patients were divided into 2 groups based upon the treatment method: LF (n = 17) 
      and PCD-only groups (n = 18). RESULTS: No intergroup differences in age, gender, 
      diabetes prevalence, retransplant rate, delayed graft function, or serum
      creatinine was observed at 7 days after the treatment. However, acute rejection
      episodes and sirolimus use were more frequent among the LF group (P = .028).
      Furthermore, median drainage on the first day was significantly greater in the LF
      versus PCD group. After catheter insertion, the PCD group showed a significant
      decrease in drainage on the following day, but no decrease was observed in the LF
      group. CONCLUSIONS: LF is a safe treatment for symptomatic lymphocele. LF should 
      be held in reserve for treatment failures after PCD. LF seems to be a more
      reasonable first-line treatment for symptomatic lymphoceles in patients at high
      risk for graft dysfunction.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
FAU - Lee, H S
AU  - Lee HS
FAU - Joo, D J
AU  - Joo DJ
FAU - Huh, K H
AU  - Huh KH
FAU - Kim, M S
AU  - Kim MS
FAU - Kim, S I
AU  - Kim SI
FAU - Kim, Y S
AU  - Kim YS
FAU - Lee, W J
AU  - Lee WJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/10/13 [received]
PHST- 2012/11/20 [accepted]
AID - S0041-1345(12)01388-7 [pii]
AID - 10.1016/j.transproceed.2012.11.019 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1667-70. doi: 10.1016/j.transproceed.2012.11.019.

PMID- 23726625
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Risk factors for recurrent urinary tract infection in kidney transplant
      recipients.
PG  - 1584-9
LID - 10.1016/j.transproceed.2012.12.011 [doi]
LID - S0041-1345(12)01374-7 [pii]
AB  - BACKGROUND: Urinary tract infections (UTIs) are the most common infectious
      complication in kidney transplant recipients (KTRs). The aim of this study to
      investigate the risk factors for and causative organisms of UTI as well as to
      evaluate the impact these diseases on allograft function in KTRs. METHODS: We
      analyzed patients who underwent kidney transplantation (KT) between January 2000 
      and December 2010. Among a total of 344 KTRs, 50 (14.5%) patients experienced 106
      UTI episodes during a mean follow-up of 35.9 +/- 26.0 months. Twenty three
      patients experiencing recurrent UTI were compared with 27 nonrecurrent UTI
      patients and with 50 non-UTI patients matched for age, gender, and
      transplantation date. RESULTS: The number of patients with renal calculi,
      diabetes, or prior dialysis was significantly greater among the UTI group
      compared with control subjects. In addition, the number of patients with renal
      calculi was significantly higher among the recurrent compared with the
      nonrecurrent cohort (43.5 vs 7.4%; P = .003). The most common causative organism 
      was Escherichia coli (64.1%), followed by Enterococcus species (20.5%). Higher
      rates of antibiotic resistance, especially Extended Spectrum Beta-Lactamasc
      (ESBL) production, were observed among the recurrent compared with the
      nonrecurrent group (53.1 vs 0%; P = .013). The rate of decline of estimated
      glomerular filtration rate was significantly faster in the UTI than the non-UTI
      group, whereas it did not differ between the recurrent and nonrecurrent group.
      CONCLUSIONS: Adequate treatment of an initial UTI to prevent as recurrent
      infection and prolong graft longevity is especially reasonable for KTRs with
      renal calculi or in cases of antibiotic-resistant microorganisms.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Internal Medicine, Kyungpook National University School of
      Medicine, Daegu, Korea.
FAU - Lim, J-H
AU  - Lim JH
FAU - Cho, J-H
AU  - Cho JH
FAU - Lee, J-H
AU  - Lee JH
FAU - Park, Y-J
AU  - Park YJ
FAU - Jin, S
AU  - Jin S
FAU - Park, G-Y
AU  - Park GY
FAU - Kim, J-S
AU  - Kim JS
FAU - Kang, Y-J
AU  - Kang YJ
FAU - Kwon, O
AU  - Kwon O
FAU - Choi, J-Y
AU  - Choi JY
FAU - Kim, C-D
AU  - Kim CD
FAU - Kim, Y-L
AU  - Kim YL
FAU - Kim, H-K
AU  - Kim HK
FAU - Huh, S
AU  - Huh S
FAU - Park, S-H
AU  - Park SH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/11/19 [received]
PHST- 2012/12/04 [accepted]
AID - S0041-1345(12)01374-7 [pii]
AID - 10.1016/j.transproceed.2012.12.011 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1584-9. doi: 10.1016/j.transproceed.2012.12.011.

PMID- 23726624
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Infectious complications in the first year post renal transplantation.
PG  - 1579-83
LID - 10.1016/j.transproceed.2012.10.047 [doi]
LID - S0041-1345(12)01385-1 [pii]
AB  - BACKGROUND: The aim of this study was a prospective assessment and determination 
      of risk factors for infections among renal transplant recipients (Rtr) during the
      1st year after renal transplantation (Rtx). METHODS: From June 2004 to October
      2005, we performed 133 Rtx in 88 men and 45 women of overall mean age of 46 +/-
      14 years (range; 13-75). RESULTS: During the first year post-Rtx, 88 (58 men and 
      30 women) infectious episodes were observed in 60 patients (45%). Thirty-nine
      (65%) required >/=1 hospitalization. Most common was urinary tract infections
      (UTI; 54 episodes; 61%). The causative organism was identified in 61 of the 88
      (69%) episodes: In 51 it was bacterial, in 8 cytomegalovirus (CMV), and in 2
      fungi. Forty-three episodes (49%) were observed during the first 3 months; 22
      (25%) between 3 and 6 months and 23 (26%) between 6 and 12 months post-Rtx. There
      were no significant differences between patients with versus without
      hospitalization owing to infections with regard to recipient gender and age,
      duration of dialysis pre-Rtx, donor kidney source, acute rejection episodes,
      donor age, or arterial hypertension. Diabetes was a significant risk factor for
      infections (odds ratio [OR], 1.154; 95% confidence interval [CI], 1.045-1.274; P 
      = .001], as well as an immunosuppressive regimen that included tacrolimus,
      mammalian target of rapamycin inhibitor, corticosteroids, and anti-interleukin-2 
      monoclonal antibody as initial treatment (OR, 3.053; 95% CI, 1.007-9.349; P =
      .043). There was an increased prevalence of CMV infections after the
      chemoprophylaxis period (OR, 0.456; 95% CI, 0.358-0.580; P = .002). Mean duration
      of hospitalization was 11.5 days (range, 2-109). In 3 of 133 (5%) Rtr, the
      outcome was fatal. CONCLUSION: The frequency of infections during the 1 st year
      post-Rtx is influenced by the primary disease of the Rtr as well by the choice of
      immunosuppressive regimen. UTI remains the commonest infection, accounting for
      half of all infections in the first 3 months post-Rtx. There was an increased
      risk for CMV infection after the chemoprophylaxis period.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Renal Transplant Unit, Laiko Hospital, Athens, Greece. Electronic address:
      George.kosmadakis@gmail.com.
FAU - Kosmadakis, G
AU  - Kosmadakis G
FAU - Daikos, G L
AU  - Daikos GL
FAU - Pavlopoulou, I D
AU  - Pavlopoulou ID
FAU - Gobou, A
AU  - Gobou A
FAU - Kostakis, A
AU  - Kostakis A
FAU - Tzanatou-Exarchou, H
AU  - Tzanatou-Exarchou H
FAU - Boletis, J N
AU  - Boletis JN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/10/09 [received]
PHST- 2012/10/30 [accepted]
AID - S0041-1345(12)01385-1 [pii]
AID - 10.1016/j.transproceed.2012.10.047 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1579-83. doi: 10.1016/j.transproceed.2012.10.047.

PMID- 23726622
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Effect of Reduced Sympathetic Hyperactivity on Cardiovascular Risk Factors in
      Kidney Transplantation Patients.
PG  - 1571-1574
LID - S0041-1345(12)01401-7 [pii]
LID - 10.1016/j.transproceed.2012.10.051 [doi]
AB  - BACKGROUND: Hyperactivity of the sympathetic nervous system caused by chronic
      kidney disease has detrimental effects on hypertension and cardiovascular
      morbidity. Kidney transplantation does not ameliorate sympathetic nerve
      overactivity; however, bilateral nephrectomy eliminates it. The aim of the study 
      was to evaluate the effect of bilateral nephrectomy on risk factors for
      cardiovascular morbidity and mortality in long-term follow-up. MATERIAL AND
      METHODS: We studied 24 kidney recipients aged 44 +/- 13 years who had undergone
      native bilateral nephrectomy. The control group included 17 recipients with
      preserved native kidneys who were matched for age, gender, cause of end-stage
      renal disease, immunosuppressive treatment, and time after transplantation. The
      mean follow-up after transplantation was 103 months. We evaluated arterial blood 
      pressure, pulse pressure, metabolic markers, allograft function,
      echocardiography, and cardiac morbidity in all patients throughout follow-up.
      RESULTS: Systolic and diastolic blood pressures, number of antihypertensive
      drugs, and pulse pressure (a marker of arterial stiffness), were significantly
      lower among the study versus the control group (P < .05). The left ventricular
      mass, left ventricular mass index, left ventricular posterior wall thickness, and
      interventricular septum thickness were also lower in the study than in the
      control group (P < .05). Cardiac morbidity, including ischemic heart disease,
      atrial fibrillation, heart failure and stroke, occurred in 4 (16%) study group
      and 6 (35%) control subjects. Metabolic disorders, namely, new onset diabetes
      after transplantation, hyperuricemia, and dyslipidemia, occurred with similar
      frequencies in both groups. Serum levels of creatinine and estimated glomerular
      filtration rates were comparable in both groups, remaining stable throughout the 
      observation time. CONCLUSIONS: Reduction of sympathetic hyperactivity by
      nephrectomy improved blood pressure control as well as decreased arterial
      stiffness and left ventricular hypertrophy over long-term follow-up. These
      results support native renal denervation to prevent the harmful effects of
      sympathetic hyperactivity on the cardiovascular system of renal transplant
      recipients.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Nephrology and Transplantation Medicine, Medical University,
      Wroclaw, Poland. Electronic address: maria.boratynska@op.pl.
FAU - Boratynska, M
AU  - Boratynska M
FAU - Zon, A M
AU  - Zon AM
FAU - Obremska, M
AU  - Obremska M
FAU - Poczatek, K
AU  - Poczatek K
FAU - Protasiewicz, M
AU  - Protasiewicz M
FAU - Magott, M
AU  - Magott M
FAU - Klinger, M
AU  - Klinger M
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/10/06 [received]
PHST- 2012/10/30 [accepted]
AID - S0041-1345(12)01401-7 [pii]
AID - 10.1016/j.transproceed.2012.10.051 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1571-1574. doi:
      10.1016/j.transproceed.2012.10.051.

PMID- 23726616
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Body fat percentage as a marker of new-onset diabetes mellitus after kidney
      transplantation.
PG  - 1544-7
LID - 10.1016/j.transproceed.2012.12.009 [doi]
LID - S0041-1345(12)01368-1 [pii]
AB  - BACKGROUND: New-onset diabetes after transplantation (NODAT) is a serious
      metabolic complication that can follow kidney transplantation. Several risk
      factors, including obesity, have been related to NODAT development. Obesity is
      defined as an excessive accumulation of body fat, and body fat percentage (BF%)
      has been commonly measured by different techniques, including bioelectrical
      impedance analysis. However, the correlation between an increase in BF% and the
      development of NODAT during outpatient follow-up has not yet been explored. We
      aimed to elucidate the association between BF% changes and the development of
      NODAT. METHODS: We performed a retrospective study involving 45 patients without 
      diabetes who underwent kidney transplantation in our hospital between March 2008 
      and December 2010. We compared the BF% and demographic variables of patients who 
      did and did not develop NODAT during follow-up. RESULTS: Four patients (8.9%)
      developed NODAT during a mean follow-up period of 30.3 months. The
      post-transplantation increase in BF% was much higher in NODAT+ patients than the 
      NODAT- patients. Univariate analysis indicated that the rate of increase in BF%
      was a risk factor for NODAT (hazard ratio [HR], 1.08 [1.02-1.18]; P < .005).
      CONCLUSIONS: A large increase in BF% may be a risk factor for NODAT. These
      findings underline the importance of routine BF% measurements in medical
      practice.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, Sendai Shakaihoken Hospital, Sendai, Japan. Electronic
      address: tsu7ka5so8mi@yahoo.co.jp.
FAU - Tokodai, K
AU  - Tokodai K
FAU - Amada, N
AU  - Amada N
FAU - Kikuchi, H
AU  - Kikuchi H
FAU - Haga, I
AU  - Haga I
FAU - Takayama, T
AU  - Takayama T
FAU - Nakamura, A
AU  - Nakamura A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/11/24 [received]
PHST- 2012/12/04 [accepted]
AID - S0041-1345(12)01368-1 [pii]
AID - 10.1016/j.transproceed.2012.12.009 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1544-7. doi: 10.1016/j.transproceed.2012.12.009.

PMID- 23726615
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Insulin resistance and insulin secretion in renal transplant recipients with
      hepatitis C.
PG  - 1540-3
LID - 10.1016/j.transproceed.2013.01.053 [doi]
LID - S0041-1345(13)00088-2 [pii]
AB  - BACKGROUND: Several reports have suggested an association between hepatitis C
      virus (HCV) infection and new-onset diabetes after transplantation (NODAT). NODAT
      is a common complication after renal transplantation, and it has been associated 
      with increased long-term morbidity and mortality. HCV-positive recipients may
      have abnormal glucose metabolism, even though NODAT has never been previously
      diagnosed. The aim of this study was to analyze the pathogenic factors
      responsible for glucose metabolism in a series of HCV-positive renal transplant
      recipients. METHODS: The study population comprised 16 renal transplant patients 
      who received their grafts from deceased or living donors with anti-HCV
      antibodies. HCV-negative transplant recipients were individually matched with
      these HCV-positive recipients by year of transplantation, sex, age, serum
      creatinine levels, and type of calcineurin inhibitors. None of the patients had
      been diagnosed with diabetes. Insulin secretion and insulin resistance were
      determined by a 75-g oral glucose tolerance test (OGTT) and compared between the 
      2 groups. Categories of glucose tolerance were defined according to World Health 
      Organization criteria. RESULTS: Glucose intolerance (impaired fasting glucose,
      impaired glucose tolerance, diabetes mellitus) as assessed by OGTT was detected
      in 7 of the HCV-positive recipients (43.8%) and 3 of the HCV-negative recipients.
      The homeostasis model assessment of insulin resistance was greater in the
      HCV-positive recipients than in the HCV-negative recipients. The homeostasis
      model assessment of beta-cell function was higher in the HCV-positive recipients 
      than in the HCV-negative recipients. CONCLUSIONS: The frequency of glucose
      intolerance tended to be higher in HCV-positive recipients. Furthermore, insulin 
      resistance was greater and insulin secretion higher in HCV-positive recipients,
      which indicated that the increase in insulin secretion compensated for insulin
      resistance observed in these patients. However, HCV-positive renal transplant
      recipients may ultimately develop NODAT as this compensation diminishes with
      time.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Urology, Osaka City University Graduate School of Medicine, Osaka, 
      Japan. Electronic address: m9492120@msic.med.osaka-cu.ac.jp.
FAU - Uchida, J
AU  - Uchida J
FAU - Iwai, T
AU  - Iwai T
FAU - Machida, Y
AU  - Machida Y
FAU - Kuwabara, N
AU  - Kuwabara N
FAU - Kabei, K
AU  - Kabei K
FAU - Kumada, N
AU  - Kumada N
FAU - Nakatani, T
AU  - Nakatani T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/12/11 [received]
PHST- 2013/01/03 [accepted]
AID - S0041-1345(13)00088-2 [pii]
AID - 10.1016/j.transproceed.2013.01.053 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1540-3. doi: 10.1016/j.transproceed.2013.01.053.

PMID- 23726614
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Glucose intolerance is associated with increased intimal-medial thickness of the 
      carotid artery and increased pulse-wave velocity in renal transplant recipients.
PG  - 1535-9
LID - 10.1016/j.transproceed.2013.01.052 [doi]
LID - S0041-1345(13)00087-0 [pii]
AB  - BACKGROUND: Although new-onset diabetes after transplantation has been
      demonstrated to have a significant negative impact on allograft and patient
      survival, the role of glucose intolerance (impaired fasting glucose [IFG] and/or 
      impaired glucose tolerance [IGT], as asymptomatic hyperglycemia and borderline
      diabetes, has not been identified in renal transplant recipients. METHODS: We
      enrolled 32 renal transplant recipients (at least 1year after transplantation)
      without prior evidence of diabetes at our institution in this study. Transplant
      recipients were divided into 2 groups (normal glucose tolerance group and glucose
      intolerance group) according to the results of their oral glucose tolerance test 
      with 75 g of glucose. Glucose intolerance included IFG, IGT, and IFG/IGT. Normal 
      glucose tolerance was detected in 19 patients, and glucose intolerance in 13: had
      6 IGT, 2 IFG, and 5 IGT/IFG. Bilateral brachial-ankle pulse-wave velocity (baPWV)
      and intimal-media thickness (IMT) measured as markers of atherosclerosis were
      compared between the 2 groups. Insulin resistance was estimated with the
      homeostasis model assessment of insulin resistance (HOMA-R), and pancreatic
      beta-cell function evaluated by the homeostasis model assessment of beta-cell
      function and insulinogenic index. RESULTS: The patients in the glucose
      intolerance group showed significantly greater baPWV and IMT than those in the
      normal glucose tolerance group. HOMA-R in the glucose intolerance patients was
      significantly higher than in the normal glucose tolerance patients. Linear
      regression analysis showed the increased IMT in the renal transplant recipients
      to be significantly correlated with HOMA-R. CONCLUSIONS: Renal transplant
      recipients with glucose intolerance had increased IMT and baPWV, suggesting that 
      glucose intolerance in renal transplant recipients may induce atherosclerosis and
      that the rise in insulin resistance may contribute to the increased IMT in renal 
      transplant recipients.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Urology, Osaka City University Graduate School of Medicine, Osaka, 
      Japan. Electronic address: m9492120@msic.med.osaka-cu.ac.jp.
FAU - Uchida, J
AU  - Uchida J
FAU - Machida, Y
AU  - Machida Y
FAU - Iwai, T
AU  - Iwai T
FAU - Kuwabara, N
AU  - Kuwabara N
FAU - Kabei, K
AU  - Kabei K
FAU - Naganuma, T
AU  - Naganuma T
FAU - Kumada, N
AU  - Kumada N
FAU - Nakatani, T
AU  - Nakatani T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/12/11 [received]
PHST- 2013/01/03 [accepted]
AID - S0041-1345(13)00087-0 [pii]
AID - 10.1016/j.transproceed.2013.01.052 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1535-9. doi: 10.1016/j.transproceed.2013.01.052.

PMID- 23726613
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Antithymocyte antibody-induced coagulopathy in renal transplant recipients.
PG  - 1531-4
LID - 10.1016/j.transproceed.2012.10.057 [doi]
LID - S0041-1345(12)01407-8 [pii]
AB  - BACKGROUND: Antithymocyte antibody (ATA) remains the most commonly used induction
      immunosuppressive agent in renal transplantation (RT). To date, few case reports 
      of ATA-induced coagulopathy exist. METHODS: We performed a single-center,
      retrospective analysis of renal transplant recipients (RTRs) who underwent RT
      followed by ATA therapy between 2007 and 2011. The protocol used for deceased
      donor and unrelated living donor recipient immunosuppression was Thymoglobulin
      (TMG), methylprednisolone, Cellcept, Prograf, and Rapamune. In related living
      donor recipients, Simulect (SIM) was substituted for TMG. The international
      normalized ratio (INR) was routinely checked on days 0 and 2, and thereafter at
      the discretion of the surgeon. RTRs were transfused packed red blood cells
      (PRBCs) or fresh frozen plasma (FFP) at the discretion of the surgeon. RESULTS:
      During the study period, 257 RTs were performed at our institution. The following
      18 RTR were excluded: simultaneous kidney and pancreas transplant recipients (4),
      RTRs on warfarin at the time of admission (2), RTRs who received OKT3 (2), and
      RTRs with INR >/= 1.2 at the time of admission (10). Of the remaining 239 RTR,
      208 (87%) underwent TMG induction therapy; 31 RTR (13%) underwent SIM induction
      therapy. The mean INR peaked in both groups on day 4 but was higher in TMG
      recipients (TMG 1.35, SIM 1.20). FFP was transfused in 65 TMG (31%) and 3 SIM
      (10%) recipients (P = .01); PRBCs were transfused in 88 TMG (44%) and 6 SIM (19%)
      recipients (P = .02). No patients returned to the operating room for bleeding
      complications within 7 days of RT. Patient age, gender, ethnicity, and diabetes
      status were not statistically significant factors in the development of
      coagulopathy. CONCLUSION: TMG administration is associated with coagulopathy.
      Using an INR screening protocol and an aggressive transfusion protocol, bleeding 
      complications associated with coagulopathy can be avoided in this higher-risk
      group.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Section of Transplantation, Department of Surgery, Albany Medical College,
      Albany, NY. Electronic address: siparsn@mail.amc.edu.
FAU - Siparsky, N F
AU  - Siparsky NF
FAU - Klein, R
AU  - Klein R
FAU - Kushnir, L F
AU  - Kushnir LF
FAU - Gallichio, M H
AU  - Gallichio MH
FAU - Conti, D J
AU  - Conti DJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/10/02 [received]
PHST- 2012/10/10 [revised]
PHST- 2012/10/30 [accepted]
AID - S0041-1345(12)01407-8 [pii]
AID - 10.1016/j.transproceed.2012.10.057 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1531-4. doi: 10.1016/j.transproceed.2012.10.057.

PMID- 23726605
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Early steroid withdrawal compared with steroid avoidance correlates with graft
      failure among kidney transplant recipients with an history of diabetes.
PG  - 1497-502
LID - 10.1016/j.transproceed.2012.10.055 [doi]
LID - S0041-1345(12)01405-4 [pii]
AB  - BACKGROUND: Steroid minimization strategies attempt to reduce morbidity in kidney
      transplantation. Concern still exists regarding long-term outcomes using either
      steroid withdrawal or steroid avoidance regimens. METHODS: During a 10-year
      period, 572 primary kidney transplant recipients were treated with basiliximab,
      calcineurin inhibitors, and mycophenolate mofetil: 417 (72.9%) underwent a
      steroid-taper regimen over 2-3 months (steroid withdrawal) and 155 (27.1%),
      complete steroid avoidance (steroid avoidance). RESULTS: Despite no significant
      difference during the first 3 months (hazard ratio [HR], 1.23; P = .5349),
      steroid withdrawal recipients showed an increased risk of late acute rejection
      episodes (HR, 4.06; P = .0585), independent of recipient age >55 years (HR, 1.84;
      P = .0272). The risk of any adverse event was not different among steroid regimen
      groups (HR, 0.98; P = .8458), independent of recipient age >55 years (HR, 1.69; P
      = .0002), delayed graft function (DGF) (HR, 1.54; P = .0001), and positive donor 
      Epstein-Barr virus serology (HR, 0.68; P = .0471). Intention-to-treat analyses
      revealed a significantly greater risk of graft failure only in diabetic
      recipients in the steroid withdrawal group (HR, 8.18; P = .0065), independent of 
      confounding risk factors such as recipient age >55 years (HR, 1.99; P = .0244),
      >4 human leukocyte antigen-A, -B, and -DR incompatibilities (HR, 1.64; P =
      .0475), and DGF occurrence (HR, 2.63; P < .0001). CONCLUSION: Although both
      steroid minimization strategies were comparable regarding long-term safety and
      efficacy, an increased rate of graft failure was observed among diabetics who
      underwent steroid withdrawal compared with steroid avoidance.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Institut de Transplantation-Urologie-Nephrologie (ITUN) and Inserm UMR 1064,
      Nantes University Hospital, Nantes, France. Electronic address:
      diego.cantarovich@chu-nantes.fr.
FAU - Cantarovich, D
AU  - Cantarovich D
FAU - Hodemon-Corne, B
AU  - Hodemon-Corne B
FAU - Trebern-Launay, K
AU  - Trebern-Launay K
FAU - Giral, M
AU  - Giral M
FAU - Foucher, Y
AU  - Foucher Y
FAU - Dantan, E
AU  - Dantan E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/09/21 [received]
PHST- 2012/10/30 [accepted]
AID - S0041-1345(12)01405-4 [pii]
AID - 10.1016/j.transproceed.2012.10.055 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1497-502. doi:
      10.1016/j.transproceed.2012.10.055.

PMID- 23726583
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Survival of renal transplantation patients older than 60 years: a single-center
      experience.
PG  - 1402-9
LID - 10.1016/j.transproceed.2012.10.053 [doi]
LID - S0041-1345(12)01403-0 [pii]
AB  - BACKGROUND: Elderly patients are the fastest growing population requiring renal
      replacement therapy. It has been stated that renal transplantation may be the
      best treatment option for these patients. However, it has been observed that
      older patients have a higher mortality rate than those who are younger. Yet the
      factors that determine post-transplantation outcomes in this population remain
      poorly defined. The aims of this study were to evaluate the graft and patient
      survival in kidney transplant recipients who are older than 60 years of age to
      identify relevant predictive factors. METHODS: In this population-based
      retrospective cohort study of 201 kidney transplantations performed in elderly
      patients from January 2002 throughout June 2009, we estimated the 1-,3-,and
      5-year patients and graft survival rates. We also evaluated the complications and
      the predictors of poor outcomes. Survival times were analyzed using the
      Kaplan-Meier method and survival differences assessed with Mantel-Cox log
      rank-test. We performed a Cox proportional hazards regression models to evaluate 
      the impact of baseline and treatment characteristics on patient and graft
      survival. RESULTS: Graft and patient survival rates at 1, 3, and 5 years were
      76.4%, 71.3%, and 54.3%, and 78.2%, 73.8%, and 56.4%, respectively. Graft
      survival rates censored for patient death with a functioning graft were 93.1,
      92.1, and 89%. Patient survival rates differed between diabetic and nondiabetic
      subjects at 1, 3 and 5 years (69.5% versus 83.6%; 59.8% versus 72.3%; 43.6%
      versus 65.7%; P = .008). On multivariate analysis, the factors associated with
      patients survival were diabetes mellitus (hazard ratio [HR] 2.058, 95% confidence
      interval [CI] 1.173-3.611, P = .012) and the 1-month serum creatinine value was >
      1.6 mg/dL (HR 2.108 for each point increase, 95% CI 1.521-2.921, P = .000).
      Furthermore, there was an insignificant trend forward an association between
      active or past smoker and lower patient survival (HR 1.689, 95% CI 0.937-3.043, P
      = .08). The main causes of graft loss were patient death (79.5%). acute rejection
      (6.8%), and chronic allograft nephropathy (5.5%). CONCLUSION: Renal
      transplantation can be performed safely and with acceptable outcomes in elderly
      patients after appropriate clinical evaluation. The grafts show excellent
      survival albeit that deaths with a functional graft continue to be an important
      issue.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Transplant Group, Nephrology Division, Universidad de Antioquia and Hospital
      Pablo Tobon Uribe, Medellin, Colombia. Electronic address: jrodelo@une.net.co.
FAU - Rodelo, J R
AU  - Rodelo JR
FAU - Nieto-Rios, J F
AU  - Nieto-Rios JF
FAU - Serna-Higuita, L M
AU  - Serna-Higuita LM
FAU - Henao, J E
AU  - Henao JE
FAU - Garcia, A
AU  - Garcia A
FAU - Reino, A C
AU  - Reino AC
FAU - Tobon, J C
AU  - Tobon JC
FAU - Arbelaez, M
AU  - Arbelaez M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/10/10 [received]
PHST- 2012/10/30 [accepted]
AID - S0041-1345(12)01403-0 [pii]
AID - 10.1016/j.transproceed.2012.10.053 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1402-9. doi: 10.1016/j.transproceed.2012.10.053.

PMID- 23726575
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 4
DP  - 2013 May
TI  - Should we do cardiac stress tests in asymptomatic renal transplant candidates?
PG  - 1371-3
LID - 10.1016/j.transproceed.2013.01.063 [doi]
LID - S0041-1345(13)00110-3 [pii]
AB  - BACKGROUND: There is controversy regarding the best method and benefit of cardiac
      evaluation of asymptomatic renal transplant candidates. The positive predictive
      value of ischemia on a noninvasive stress test was approximately 5%-10% in Kidney
      Disease Outcomes Quality Initative (KDOQI), American Society of Transplantation
      (AST), and Lisbon guidelines. We compared prediction of cardiac events with the
      use of simple transthoracic echocardiography versus a noninvasive stress test in 
      asymptomatic candidates. METHODS: We selected asymptomatic patients with good
      functional capacity who would be recommended a cardiac stress test by both KDOQI 
      and AST guidelines, we excluding those with a history of cardiovascular disease. 
      Group A (n = 124) underwent only echocardiography, and group B (n = 41) underwent
      echocardiography and noninvasive stress test. We measured the incidences of
      cardiac events and cardiac death within 3 years after transplantation. RESULTS:
      The mean age of group A was 39 +/- 7 and group B 40 +/- 5 years. Diabetic
      patients among groups A and B were 8.8% (11/124) and 9.7% (4/41), respectively.
      The mean duration of dialysis was 2.9 +/- 5 years. Only 4 group B patients showed
      a positive result on the noninvasive stress test, but they had no obstructive
      disease on coronary angiograms. The incidences of ischemic heart disease after
      transplantation of groups A and B were 4% (5/124) and 4.8% (2/41), respectively
      (P = .88). There was no death due to cardiac events in either group. CONCLUSIONS:
      In this study, simple echocardiography showed an ability similar to stress test
      to predict ischemic heart disease in asymptomatic renal transplant candidates
      with good functional capacity, relatively younger age, lower prevalence of
      diabetes, and shorter duration of dialysis.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, Gachon University of Medicine and Science, Incheon, Korea.
FAU - Park, Y H
AU  - Park YH
FAU - Kim, Y S
AU  - Kim YS
FAU - Chang, J H
AU  - Chang JH
FAU - Jung, J Y
AU  - Jung JY
FAU - Ro, H
AU  - Ro H
FAU - Chung, W K
AU  - Chung WK
FAU - Lee, H H
AU  - Lee HH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/12/04 [received]
PHST- 2013/01/24 [accepted]
AID - S0041-1345(13)00110-3 [pii]
AID - 10.1016/j.transproceed.2013.01.063 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 May;45(4):1371-3. doi: 10.1016/j.transproceed.2013.01.063.

PMID- 23726468
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1579-2021 (Electronic)
IS  - 1575-0922 (Linking)
DP  - 2013 May 29
TI  - Costs of temporary disability in Spain related to diabetes mellitus and its
      complications.
LID - S1575-0922(13)00117-4 [pii]
LID - 10.1016/j.endonu.2013.02.004 [doi]
AB  - INTRODUCTION AND OBJECTIVES: To ascertain the socioeconomic impact of diabetes,
      it is essential to estimate overall costs, including both direct and indirect
      costs (premature retirements, working hours lost, or sick leaves). This study
      analyzed indirect costs for temporary disability (TD) due to diabetes and its
      complications in Spain in 2011 by assessing the related ICD-9 MC codes. MATERIAL 
      AND METHOD: For this purpose, the number of TD processes and their mean duration 
      were recorded. The indirect costs associated to loss of working days were also
      estimated. RESULTS: In 2011, diabetes and its complications were related to 2.567
      TD processes, which resulted in the loss of 154.214 days. In terms of costs, this
      disease represented for Spanish public health administrations an expense of
      3,297.095.3 euro, with an estimated cost per patient and year of 141 euro.
      CONCLUSIONS: These data suggest an urgent need to devise plans for prevention and
      early diagnosis of diabetes and its complications, as well as programs to
      optimize the available health care resources by creating multidisciplinary teams 
      where occupational medical services assume an important role. A decrease in
      absenteeism would result in benefits for diabetic patients, society overall, and 
      companies or public institutions.
CI  - Copyright (c) 2012 SEEN. Published by Elsevier Espana. All rights reserved.
AD  - Grupo Correos-Valencia, Espana; Grupo Investigacion Medicina del Trabajo.
      Electronic address: grupo.gimt@gmail.com.
FAU - Vicente-Herrero, M Teofila
AU  - Vicente-Herrero MT
FAU - Terradillos Garcia, M Jesus
AU  - Terradillos Garcia MJ
FAU - Capdevila Garcia, Luisa M
AU  - Capdevila Garcia LM
FAU - Ramirez Iniguez de la Torre, M Victoria
AU  - Ramirez Iniguez de la Torre MV
FAU - Lopez-Gonzalez, Angel Arturo
AU  - Lopez-Gonzalez AA
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Costes por incapacidad temporal en Espana derivados de la diabetes mellitus y sus
      complicaciones.
DEP - 20130529
TA  - Endocrinol Nutr
JT  - Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y
      Nutricion
JID - 100886482
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/12/20 [received]
PHST- 2013/02/05 [revised]
PHST- 2013/02/13 [accepted]
AID - S1575-0922(13)00117-4 [pii]
AID - 10.1016/j.endonu.2013.02.004 [doi]
PST - aheadofprint
SO  - Endocrinol Nutr. 2013 May 29. pii: S1575-0922(13)00117-4. doi:
      10.1016/j.endonu.2013.02.004.

PMID- 23726417
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 2
DP  - 2013 May
TI  - Prediabetes and impaired lung function in asymptomatic adults.
PG  - e51-4
LID - 10.1016/j.diabres.2013.01.021 [doi]
LID - S0168-8227(13)00022-3 [pii]
AB  - Diabetes and metabolic syndrome are associated with impaired lung function.
      However, it is unknown whether this is also true in prediabetes. In a
      cross-sectional study of 1237 asymptomatic adults, we found that diabetes and
      prediabetes were both significantly associated with low vital capacity, even
      after adjustment for relevant confounding factors.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Division of Clinical Nutrition, Department of Medical Dietetics, Faculty of
      Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama
      350-0295, Japan.
FAU - Li, Yulan
AU  - Li Y
FAU - Saito, Masafumi
AU  - Saito M
FAU - Tobimatsu, Satoshi
AU  - Tobimatsu S
FAU - Oshida, Haruki
AU  - Oshida H
FAU - Hori, Yumiko
AU  - Hori Y
FAU - Fuchigami, Hiroshi
AU  - Fuchigami H
FAU - Munakata, Hiromi
AU  - Munakata H
FAU - Nakajima, Kei
AU  - Nakajima K
LA  - eng
PT  - Journal Article
DEP - 20130208
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/07/18 [received]
PHST- 2013/01/10 [revised]
PHST- 2013/01/21 [accepted]
PHST- 2013/02/08 [aheadofprint]
AID - S0168-8227(13)00022-3 [pii]
AID - 10.1016/j.diabres.2013.01.021 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 May;100(2):e51-4. doi:
      10.1016/j.diabres.2013.01.021. Epub 2013 Feb 8.

PMID- 23726416
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 2
DP  - 2013 May
TI  - From targets to action-Implementing the global monitoring framework for diabetes.
PG  - 287-8
LID - 10.1016/j.diabres.2013.04.001 [doi]
LID - S0168-8227(13)00153-8 [pii]
CN  - International Diabetes Federation
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - S0168-8227(13)00153-8 [pii]
AID - 10.1016/j.diabres.2013.04.001 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 May;100(2):287-8. doi:
      10.1016/j.diabres.2013.04.001.

PMID- 23726399
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 88
IP  - 6
DP  - 2013 Jun
TI  - Scientific decision making, policy decisions, and the obesity pandemic.
PG  - 593-604
LID - 10.1016/j.mayocp.2013.04.005 [doi]
LID - S0025-6196(13)00265-6 [pii]
AB  - Rising and epidemic rates of obesity in many parts of the world are leading to
      increased suffering and economic stress from diverting health care resources to
      treating a variety of serious, but preventable, chronic diseases etiologically
      linked to obesity, particularly type 2 diabetes mellitus and cardiovascular
      diseases. Despite decades of research into the causes of the obesity pandemic, we
      seem to be no nearer to a solution now than when the rise in body weights was
      first chronicled decades ago. The case is made that impediments to a clear
      understanding of the nature of the problem occur at many levels. These obstacles 
      begin with defining obesity and include lax application of scientific standards
      of review, tenuous assumption making, flawed measurement and other methods,
      constrained discourse limiting examination of alternative explanations of cause, 
      and policies that determine funding priorities. These issues constrain creativity
      and stifle expansive thinking that could otherwise advance the field in
      preventing and treating obesity and its complications. Suggestions are made to
      create a climate of open exchange of ideas and redirection of policies that can
      remove the barriers that prevent us from making material progress in solving a
      pressing major public health problem of the early 21st century.
CI  - Copyright (c) 2013 Mayo Foundation for Medical Education and Research. Published 
      by Elsevier Inc. All rights reserved.
AD  - South Carolina Statewide Cancer Prevention and Control Program, University of
      South Carolina, Columbia; Departments of Epidemiology and Biostatistics,
      University of South Carolina, Columbia. Electronic address: jhebert@sc.edu.
FAU - Hebert, James R
AU  - Hebert JR
FAU - Allison, David B
AU  - Allison DB
FAU - Archer, Edward
AU  - Archer E
FAU - Lavie, Carl J
AU  - Lavie CJ
FAU - Blair, Steven N
AU  - Blair SN
LA  - eng
PT  - Journal Article
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings. Mayo Clinic
JID - 0405543
SB  - AIM
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/26 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/04/01 [accepted]
AID - S0025-6196(13)00265-6 [pii]
AID - 10.1016/j.mayocp.2013.04.005 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2013 Jun;88(6):593-604. doi: 10.1016/j.mayocp.2013.04.005.

PMID- 23726398
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1942-5546 (Electronic)
IS  - 0025-6196 (Linking)
VI  - 88
IP  - 6
DP  - 2013 Jun
TI  - Family history of chronic disease and meeting public health guidelines for
      physical activity: the cooper center longitudinal study.
PG  - 588-92
LID - 10.1016/j.mayocp.2013.04.006 [doi]
LID - S0025-6196(13)00266-8 [pii]
AB  - We aimed to assess whether a family history of coronary heart disease, diabetes, 
      or cancer is linked to meeting public health guidelines for health-promoting
      physical activity. To achieve this objective, we analyzed data on 29,513 adults
      who came to the Cooper Clinic (Dallas, Texas) between January 1, 1990, and
      December 31, 2010, for a preventive medicine visit. Patients completed a
      comprehensive medical survey including information on family medical history,
      physical activity, and other lifestyle behaviors. Bivariate and multivariate
      logistic regression were used to examine the relationship between having a family
      history of chronic disease and meeting physical activity guidelines. The results 
      indicated that individuals with a family history of disease had reduced odds for 
      meeting or exceeding physical activity guidelines. For example, participants with
      a family history of 3 diseases were 36% less likely to meet or exceed physical
      activity guidelines than their counterparts without a family history of disease
      (odds ratio, 0.64; 95% CI, 0.58-0.72), while controlling for covariates. Among
      this large sample of adults, those with a family history of chronic disease were 
      less inclined to regularly engage in physical activity. Thus, targeted programs
      encouraging adoption and maintenance of health-promoting physical activity might 
      be warranted, specifically targeting individuals with familial history of
      disease.
CI  - Copyright (c) 2013 Mayo Foundation for Medical Education and Research. Published 
      by Elsevier Inc. All rights reserved.
AD  - University of Texas Health Science Center at Houston, School of Public Health,
      Dallas, TX; Harold C. Simmons Comprehensive Cancer Center, University of Texas
      Southwestern Medical Center, Dallas, TX. Electronic address:
      kerem.shuval@UTSouthwestern.edu.
FAU - Shuval, Kerem
AU  - Shuval K
FAU - Chiu, Chung-Yi
AU  - Chiu CY
FAU - Barlow, Carolyn E
AU  - Barlow CE
FAU - Gabriel, Kelley Pettee
AU  - Gabriel KP
FAU - Kendzor, Darla E
AU  - Kendzor DE
FAU - Businelle, Michael S
AU  - Businelle MS
FAU - Skinner, Celette Sugg
AU  - Skinner CS
FAU - Balasubramanian, Bijal A
AU  - Balasubramanian BA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Mayo Clin Proc
JT  - Mayo Clinic proceedings. Mayo Clinic
JID - 0405543
SB  - AIM
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/01/29 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/04/02 [accepted]
AID - S0025-6196(13)00266-8 [pii]
AID - 10.1016/j.mayocp.2013.04.006 [doi]
PST - ppublish
SO  - Mayo Clin Proc. 2013 Jun;88(6):588-92. doi: 10.1016/j.mayocp.2013.04.006.

PMID- 23726314
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 May 28
TI  - High prevalence of diabetes mellitus and hospital-related hyperglycaemia in
      French general wards.
LID - S1262-3636(13)00081-5 [pii]
LID - 10.1016/j.diabet.2013.04.002 [doi]
AB  - AIM: The study evaluated the in-hospital prevalence of diabetes and
      hospital-related hyperglycaemia in a variety of French general wards. METHODS:
      The multicentre cross-sectional study involving nine French hospitals measured
      venous fasting plasma glucose (FPG) on a single day in patients hospitalized in
      adult medical and surgical short-term wards. Diabetes status and length of stay
      were recorded. RESULTS: Of the 2141 inpatients included in the study, 355 (16.5%)
      had known diabetes, 156 (7.3%) had screened diabetes (FPG>/=7mmol/L with no
      diabetes history), 515 (24.1%) had impaired fasting glucose (IFG; FPG
      5.5-6.9mmol/L) and 1115 (52.1%) had normal glucose values (FPG<5.5mmol/L).
      Diabetes prevalence varied from 11% in hospitals in the west of France to 21% in 
      hospitals in northern and eastern regions. The highest known diabetes prevalence 
      was observed in units for cardiovascular surgery (33%), infectious diseases (27%)
      and kidney disorders (26%). In cancer units, one-fifth of patients had screened
      diabetes and one-sixth had known diabetes. Among the known diabetes patients, 127
      (36%) were already being treated with insulin, while an additional 41 (12%)
      started insulin therapy during their hospital stay. Patients with known and
      screened diabetes were older (70.8+/-12.2 and 71.1+/-15.6 years, respectively)
      than the normal-glucose patients (65.6+/-18.9 years; P<0.001). Average length of 
      stay was no different between known diabetes and normal-glucose patients after
      adjusting for age (11.3+/-7.7 vs 10.0+/-7.4 days; NS). CONCLUSION: Overall,
      metabolic glucose disorders (known or screened diabetes and IFG) were found in
      48% of inpatients in various French hospital general wards.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - CHNO des Quinze-Vingts, Department of Internal Medicine, 75012 Paris, France.
      Electronic address: s.feldman@quinze-vingts.fr.
FAU - Feldman-Billard, S
AU  - Feldman-Billard S
FAU - Joubert, M
AU  - Joubert M
FAU - Morello, R
AU  - Morello R
FAU - Dorey, F
AU  - Dorey F
FAU - Seret-Begue, D
AU  - Seret-Begue D
FAU - Getin-Bouyer, F
AU  - Getin-Bouyer F
FAU - Jan, P
AU  - Jan P
FAU - Colobert, A
AU  - Colobert A
FAU - Verlet, E
AU  - Verlet E
FAU - Roques, M
AU  - Roques M
FAU - Reznik, Y
AU  - Reznik Y
CN  - for the HOPTIDIAB Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/06 [received]
PHST- 2013/04/12 [revised]
PHST- 2013/04/15 [accepted]
AID - S1262-3636(13)00081-5 [pii]
AID - 10.1016/j.diabet.2013.04.002 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 May 28. pii: S1262-3636(13)00081-5. doi:
      10.1016/j.diabet.2013.04.002.

PMID- 23726303
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 29
TI  - Frequency of blood glucose testing in well educated patients with diabetes
      mellitus type 1: How often is enough?
LID - S0168-8227(12)00522-0 [pii]
LID - 10.1016/j.diabres.2012.12.024 [doi]
AB  - AIMS: Self-monitored blood glucose (SMBG) and knowledge of insulin requirements
      are pivotal for good metabolic control in patients with diabetes mellitus type 1.
      However, the SMBG-frequency needed for optimal glycaemic control especially in
      well educated patients is unclear. METHODS: In patients with type 1 diabetes
      treated with flexible intensified insulin therapy, we evaluated HbA1c values and 
      the directly preceding computerised SMBG-frequencies over a 12 months period. To 
      estimate the association between HbA1c and SMBG-frequency, we fitted a piecewise 
      linear spline model with a change in slope at 4 SMBGs per day which is the
      recommended minimal SMBG-frequency at our institution. RESULTS: A total of 150
      patients were available for analysis, with a median baseline HbA1c of 7.1%
      (interquartile range 6.6, 7.8). In the multivariable analysis (adjusted for
      gender and psychological problems), each additional SMBG measurement was
      associated with an estimated difference in HbA1c of -0.19% (95% confidence
      interval (CI) -0.42, 0.05) for </=4 SMBGs per day and of -0.02% (95% CI -0.10,
      0.06) for >4 SMBGs per day. CONCLUSIONS: Good diabetes control can be achieved in
      routine diabetes care with flexible intensified insulin therapy based on
      continuing patients' education and with a minimum of 4 SMBGs per day.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Division of Endocrinology Diabetes and Metabolism, University Hospital Basel,
      Petersgraben 4, 4031 Basel, Switzerland.
FAU - Minder, Anna Elisabeth
AU  - Minder AE
FAU - Albrecht, Dominique
AU  - Albrecht D
FAU - Schafer, Juliane
AU  - Schafer J
FAU - Zulewski, Henryk
AU  - Zulewski H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2011/12/19 [received]
PHST- 2012/11/01 [revised]
PHST- 2012/12/17 [accepted]
AID - S0168-8227(12)00522-0 [pii]
AID - 10.1016/j.diabres.2012.12.024 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 29. pii: S0168-8227(12)00522-0. doi:
      10.1016/j.diabres.2012.12.024.

PMID- 23726275
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 28
TI  - Deferoxamine enhances neovascularization and accelerates wound healing in
      diabetic rats via the accumulation of hypoxia-inducible factor-1alpha
LID - S0168-8227(13)00168-X [pii]
LID - 10.1016/j.diabres.2013.04.012 [doi]
AB  - AIMS: Hypoxia-inducible factor (HIF)-1alpha plays a pivotal role during the
      process of wound healing. Previous studies reported that deferoxamine (DFO) could
      increase HIF-1alpha stability. This study aimed to investigate the effects of DFO
      on wound healing in diabetic rats and explore the underlying mechanism both in
      vivo and in vitro. METHODS: An excisional diabetic wound model was established
      and the wound healing among vehicle control, DFO and vascular endothelial growth 
      factor (VEGF) treatment groups was evaluated by macroscopy, histology and Western
      blot analysis. Human umbilical vein endothelial cells (HUVECs) were treated with 
      DFO or HIF-1alpha siRNA, and then endothelial tube formation, cell proliferation 
      and migration were examined. RESULTS: DFO-treated wounds exhibited accelerated
      wound healing with enhanced granulation formation and increased
      re-epithelialization. Compared to the vehicle or VEGF treatment, DFO
      significantly increased neovascularization through up-regulation of HIF-1alpha
      and target genes including VEGF and stromal cell-derived factor-1alpha
      (SDF-1alpha). DFO failed to stimulate the expression of VEGF and SDF-1alpha in
      HUVECs depleted of HIF-1alpha. In addition, DFO promoted the
      angiogenic-associated processes of endothelial tube formation, cell proliferation
      and migration in HIF-1alpha dependent manner. CONCLUSIONS: DFO enhances
      neovascularization and accelerates diabetic wound healing through the
      accumulation of HIF-1alpha and the regulation of endothelial cell function.
CI  - Crown Copyright (c) 2013. Published by Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Emergency Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Hou, Zhanjiang
AU  - Hou Z
FAU - Nie, Chunlei
AU  - Nie C
FAU - Si, Zhenxing
AU  - Si Z
FAU - Ma, Yongsheng
AU  - Ma Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/26 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/04/25 [accepted]
AID - S0168-8227(13)00168-X [pii]
AID - 10.1016/j.diabres.2013.04.012 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 28. pii: S0168-8227(13)00168-X. doi:
      10.1016/j.diabres.2013.04.012.

PMID- 23726250
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1872-7654 (Electronic)
IS  - 0301-2115 (Linking)
DP  - 2013 May 28
TI  - Ambulatory arterial stiffness index in type 1 diabetes mellitus: any different
      during pregnancy?
LID - S0301-2115(13)00191-7 [pii]
LID - 10.1016/j.ejogrb.2013.04.010 [doi]
AB  - OBJECTIVE: To analyze the ambulatory arterial stiffness index (AASI) and pulse
      pressure (PP) during pregnancy and 3 months after delivery in type 1 diabetes
      mellitus (T1DM) and compare it to healthy pregnant controls. STUDY DESIGN:
      Prospective, descriptive study of 59 women with T1DM and 42 non-diabetic women.
      Blood pressure was measured using a portable oscillometry monitor and AASI was
      calculated as 1 minus the regression slope of diastolic on systolic blood
      pressure obtained from 24-h monitoring. Main outcome measures were comparisons of
      the AASI and PP between T1DM women and controls examined during pregnancy, and of
      the AASI and PP during and after pregnancy in T1DM women. RESULTS: PP and AASI
      were higher at all times during pregnancy in T1DM compared to postpartum
      (p<0.01). AASI and PP were significantly associated with albumin excretion rate
      when adjusting for retinopathy, preeclampsia, duration of diabetes, HbA1c, age,
      and BMI. The AASI was positively correlated with night-day ratio in the 1st and
      3rd trimesters during pregnancy. No difference was found in AASI compared with
      non-diabetic controls during pregnancy. CONCLUSIONS: AASI and PP increased during
      diabetic pregnancy and were associated with the women's albuminuria grade.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Obstetrics/Gynaecology, Herning Hospital, Denmark; Department of
      Obstetrics/Gynaecology, Skejby Hospital, Denmark. Electronic address:
      finlau@rm.dk.
FAU - Lauszus, Finn F
AU  - Lauszus FF
FAU - Fuglsang, Jens
AU  - Fuglsang J
FAU - Rosgaard, Anni
AU  - Rosgaard A
FAU - Lousen, Thea
AU  - Lousen T
FAU - Klebe, Joachim G
AU  - Klebe JG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Eur J Obstet Gynecol Reprod Biol
JT  - European journal of obstetrics, gynecology, and reproductive biology
JID - 0375672
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/12/18 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/04/29 [accepted]
AID - S0301-2115(13)00191-7 [pii]
AID - 10.1016/j.ejogrb.2013.04.010 [doi]
PST - aheadofprint
SO  - Eur J Obstet Gynecol Reprod Biol. 2013 May 28. pii: S0301-2115(13)00191-7. doi:
      10.1016/j.ejogrb.2013.04.010.

PMID- 23726157
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1872-7484 (Electronic)
IS  - 1566-0702 (Linking)
DP  - 2013 May 28
TI  - High-fat diet and age-dependent effects on enteric glial cell populations of
      mouse small intestine.
LID - S1566-0702(13)00125-2 [pii]
LID - 10.1016/j.autneu.2013.04.014 [doi]
AB  - Diabetes and obesity are increasing in prevalence at an alarming rate throughout 
      the world. Autonomic diabetic neuropathy is evident in individuals that
      experience a long-standing diabetic disease state, and gastrointestinal (GI)
      dysmotility is thought to be the outcome of neuropathies within the enteric
      nervous system (ENS) of these patients. To date, an analysis of enteric glial
      cell population changes during diabetic symptoms has not been performed, and may 
      bring insight into disease pathology and neuropathy, given glial cell
      implications in gastrointestinal and neuronal homeostasis. Diabetes and obesity
      were monitored in C57Bl/6J mice fed a 72% high-fat diet, and duodenal glial
      expression patterns were evaluated by immunohistochemistry and RT-PCR for
      S100beta, Sox10 and GFAP proteins and transcripts, as well as transmission
      electron microscopy (TEM). The high-fat diet caused obesity, hyperglycemia and
      insulin resistance after 4weeks. These changes were associated with a significant
      decline in the area density indices of mucosa-associated glial cell networks,
      evidenced by S100beta staining at 8 and 20weeks. All three markers and TEM showed
      that myenteric glial cells were unaffected by early and late disease periods.
      However, analysis of Sox10 transcript expression and immunoreactivity showed a
      diet independent, age-associated decline in glial cell populations. This is the
      first study showing that mucosal glia cell damage occurs during diabetic
      symptoms, suggesting that mucosal enteric glia injury may have a
      pathophysiological significance during this disease. Our results also provide
      support for age-associated changes in longitudinal studies of enteric glial
      cells.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - University of Idaho, 875 Perimeter Drive, LSS 252, Moscow ID 83844, USA.
FAU - Stenkamp-Strahm, Chloe
AU  - Stenkamp-Strahm C
FAU - Patterson, Savannah
AU  - Patterson S
FAU - Boren, Jennifer
AU  - Boren J
FAU - Gericke, Martin
AU  - Gericke M
FAU - Balemba, Onesmo
AU  - Balemba O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Auton Neurosci
JT  - Autonomic neuroscience : basic & clinical
JID - 100909359
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/03/12 [received]
PHST- 2013/04/26 [revised]
PHST- 2013/04/29 [accepted]
AID - S1566-0702(13)00125-2 [pii]
AID - 10.1016/j.autneu.2013.04.014 [doi]
PST - aheadofprint
SO  - Auton Neurosci. 2013 May 28. pii: S1566-0702(13)00125-2. doi:
      10.1016/j.autneu.2013.04.014.

PMID- 23726135
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-4332 (Electronic)
IS  - 1083-3188 (Linking)
DP  - 2013 May 28
TI  - Differences in the Management of Adolescents with Polycystic Ovary Syndrome
      across Pediatric Specialties.
LID - S1083-3188(13)00114-9 [pii]
LID - 10.1016/j.jpag.2013.03.007 [doi]
AB  - STUDY OBJECTIVE: Evaluate for differences in the management of adolescents with
      polycystic ovarian syndrome (PCOS) across 3 pediatric specialties. DESIGN:
      Retrospective review of medical records. SETTING: Academic children's hospital.
      PARTICIPANTS: 181 adolescents seen between July 2008 and June 2010 by providers
      in Pediatric Endocrinology (PEndo), Adolescent Medicine (AMed), or Pediatric and 
      Adolescent Gynecology (PGyn) identified via billing data (ICD-9 code for PCOS,
      256.4). INTERVENTIONS: None. MAIN OUTCOME MEASURES: (1) Percentage of adolescents
      with a billing diagnosis of PCOS who met diagnostic criteria; (2) Percentage of
      individuals screened for comorbidities and differences across specialties; (3)
      Differences in treatment recommendations across specialties; (4) Factors
      associated with recommendation for metformin and hormonal contraceptives.
      RESULTS: Thirteen percent of PEndo patients did not meet diagnostic criteria for 
      PCOS; 20% of AMed and PGyn patients did not meet criteria. There were significant
      differences in rates of screening for obesity, insulin resistance, and Type 2
      diabetes. There were significant differences in treatment recommendations for
      lifestyle changes, metformin, and anti-androgen therapy across specialties.
      Specialty and obesity were significant predictors of metformin recommendation;
      specifically PEndo predicted metformin recommendation. PGyn and AMed specialties 
      predicted hormonal contraceptive recommendation. CONCLUSIONS: The variability
      observed among specialties may be due to differences in training, accounting for 
      a range of comfort with aspects of PCOS. Formulation of consensus guidelines for 
      diagnosis and management of PCOS are needed, along with broad educational
      efforts. By correctly diagnosing, screening for comorbidities, and managing PCOS 
      appropriately during adolescence, providers may reduce the risk for long-term
      consequences.
CI  - Copyright (c) 2013 North American Society for Pediatric and Adolescent
      Gynecology. Published by Elsevier Inc. All rights reserved.
AD  - Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical
      Center and the University of Cincinnati College of Medicine, Cincinnati, OH.
FAU - Auble, Bethany
AU  - Auble B
FAU - Elder, Deborah
AU  - Elder D
FAU - Gross, Andrea
AU  - Gross A
FAU - Hillman, Jennifer B
AU  - Hillman JB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Pediatr Adolesc Gynecol
JT  - Journal of pediatric and adolescent gynecology
JID - 9610774
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/09/14 [received]
PHST- 2013/01/28 [revised]
PHST- 2013/03/15 [accepted]
AID - S1083-3188(13)00114-9 [pii]
AID - 10.1016/j.jpag.2013.03.007 [doi]
PST - aheadofprint
SO  - J Pediatr Adolesc Gynecol. 2013 May 28. pii: S1083-3188(13)00114-9. doi:
      10.1016/j.jpag.2013.03.007.

PMID- 23726120
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1879-0267 (Electronic)
IS  - 0020-1383 (Linking)
DP  - 2013 May 29
TI  - Early hospital readmission in the trauma population: Are the risk factors
      different?
LID - S0020-1383(13)00223-4 [pii]
LID - 10.1016/j.injury.2013.04.029 [doi]
AB  - INTRODUCTION: Hospital readmission rates will soon impact Medicare
      reimbursements. While risk factors for readmission have been described for
      medical and elective surgical patients, little is known about their predictive
      value specifically in trauma patients. PATIENTS AND METHODS: We retrospectively
      identified all admissions after trauma resuscitation to our urban level 1 trauma 
      centre from 1/1/2004 to 8/31/2010. All patients discharged alive were included.
      Data collected included demographics, Injury Severity Score (ISS), and length of 
      stay (LOS). We analyzed these index admissions for the development of
      complications that have previously been shown to be associated with readmission. 
      Readmissions that occurred within 30 days of index admission were identified.
      Univariable and multivariable analyses were performed. p<0.05 was considered
      significant. RESULTS: We identified 10,306 index admissions, with 447 (4.3%)
      early (within 30 days) readmissions. Mean ISS was 11.1 (SD 10.4). On
      multivariable analysis, African-American race (OR 1.3, p=0.009), pre-existing
      chronic obstructive pulmonary disease (COPD) (OR 1.5, p=0.02), and diabetes
      mellitus (OR 1.8, p<0.001) were associated with readmission, along with higher
      ISS (OR 1.01, p<0.001), ICU admission (OR 2.1, p<0.001), and increased LOS (OR
      1.01, p<0.001). Among many in-hospital complications examined, only the
      development of surgical site infection (SSI) (OR 1.9, p=0.02) was associated with
      increased risk of readmission. CONCLUSIONS: Trauma patients have a low risk of
      readmission. In contrast to elective surgical patients, the only modifiable risk 
      factor for readmission in our trauma population was SSI. Other risk factors may
      present clinicians with opportunities for targeted interventions, such as
      proactive follow up or early phone contact. With future changes to health care
      policy, clinicians may have even greater motivation to prevent readmission.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Division of Traumatology, Surgical Critical Care, and Emergency Surgery,
      Department of Surgery, Hospital of the University of Pennsylvania, 3400 Spruce
      Street, Philadelphia, PA 19104, United States. Electronic address:
      morris.david@mayo.edu.
FAU - Morris, David S
AU  - Morris DS
FAU - Rohrbach, Jeff
AU  - Rohrbach J
FAU - Sundaram, Latha Mary Thanka
AU  - Sundaram LM
FAU - Sonnad, Seema
AU  - Sonnad S
FAU - Sarani, Babak
AU  - Sarani B
FAU - Pascual, Jose
AU  - Pascual J
FAU - Reilly, Patrick
AU  - Reilly P
FAU - Schwab, C William
AU  - Schwab CW
FAU - Sims, Carrie
AU  - Sims C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Injury
JT  - Injury
JID - 0226040
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/10/12 [received]
PHST- 2013/04/08 [revised]
PHST- 2013/04/27 [accepted]
AID - S0020-1383(13)00223-4 [pii]
AID - 10.1016/j.injury.2013.04.029 [doi]
PST - aheadofprint
SO  - Injury. 2013 May 29. pii: S0020-1383(13)00223-4. doi:
      10.1016/j.injury.2013.04.029.

PMID- 23726071
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 28
TI  - New options for the treatment of obesity and type 2 diabetes mellitus (narrative 
      review).
LID - S1056-8727(13)00106-2 [pii]
LID - 10.1016/j.jdiacomp.2013.04.011 [doi]
AB  - Moderate weight loss (>5%), which has been associated with improvements in
      glycemic parameters in patients with dysglycemia, also reduces the presence of
      other comorbidities, including dyslipidemia and hypertension, culminating in a
      reduced risk of cardiovascular disease. Lifestyle changes are the recommended
      preliminary approach to weight loss, with an initial weight-loss goal of 10% of
      body weight achieved over 6 months at a rate of 1-2 pounds per week selected as
      an appropriate target to decrease the severity of obesity-related risk factors.
      Implementing and maintaining the lifestyle changes associated with weight loss
      can, however, be challenging for many patients. Therefore, additional
      interventions sometimes may be necessary. Bariatric surgery can also be a highly 
      effective option for weight loss and comorbidity reduction, but surgery carries
      considerable risks and is still applicable only to selected patients with type 2 
      diabetes. Thus, attention is turning to the use of weight-loss medications,
      including 2 recently approved compounds: twice-daily lorcaserin and a once-daily 
      combination of phentermine and topiramate extended-release, both shown to be safe
      and effective therapies in the management of obesity in patients with type 2
      diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Center for Metabolic Research, VA San Diego Healthcare System and University of
      California San Diego, San Diego, CA, USA. Electronic address:
      rrhenry@vapop.ucsd.edu.
FAU - Henry, Robert R
AU  - Henry RR
FAU - Chilton, Robert
AU  - Chilton R
FAU - Garvey, W Timothy
AU  - Garvey WT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/01/28 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/04/22 [accepted]
AID - S1056-8727(13)00106-2 [pii]
AID - 10.1016/j.jdiacomp.2013.04.011 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 28. pii: S1056-8727(13)00106-2. doi:
      10.1016/j.jdiacomp.2013.04.011.

PMID- 23726024
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
DP  - 2013 May 11
TI  - Anti-CD3 clinical trials in type 1 diabetes mellitus.
LID - S1521-6616(13)00120-4 [pii]
LID - 10.1016/j.clim.2013.05.001 [doi]
AB  - Two humanized, anti-CD3 mAbs with reduced FcR binding, teplizumab and
      otelixizumab, have been evaluated in over 1500 subjects, ages 7-45, with new and 
      recently diagnosed T1D with a range of intravenous doses (3-48mg) and regimens
      (6-14days, single or repeat courses). In general, studies that used adequate
      dosing demonstrated improvement in stimulated C-peptide responses and reduced
      need for exogenous insulin for two years and even longer after diagnosis. Drug
      treatment causes a transient reduction in circulating T cells, but the available 
      data suggest that the mechanism of action may involve induction of regulatory
      mechanisms. The adverse effects of anti-CD3 treatment are infusion-related and
      transient. The studies have identified significant differences in efficacy among 
      patient groups suggesting that a key aspect for development of this immune
      therapy is identification of the demographic, metabolic, and immunologic features
      that distinguish subjects who are most likely to show beneficial clinical
      responses.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - MacroGenics, Inc. 9640 Medical Center Drive, Rockville, MD 20850, USA. Electronic
      address: daifotisa@macrogenics.com.
FAU - Daifotis, Anastasia G
AU  - Daifotis AG
FAU - Koenig, Scott
AU  - Koenig S
FAU - Chatenoud, Lucienne
AU  - Chatenoud L
FAU - Herold, Kevan C
AU  - Herold KC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130511
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/14 [received]
PHST- 2013/04/29 [revised]
PHST- 2013/05/01 [accepted]
AID - S1521-6616(13)00120-4 [pii]
AID - 10.1016/j.clim.2013.05.001 [doi]
PST - aheadofprint
SO  - Clin Immunol. 2013 May 11. pii: S1521-6616(13)00120-4. doi:
      10.1016/j.clim.2013.05.001.

PMID- 23725919
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1933-2874 (Print)
IS  - 1876-4789 (Linking)
VI  - 7
IP  - 3
DP  - 2013 May-Jun
TI  - Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese
      subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3
      fatty acids randomized double-blind (ORD) study.
PG  - 199-207
LID - 10.1016/j.jacl.2013.01.006 [doi]
LID - S1933-2874(13)00050-0 [pii]
AB  - BACKGROUND: Hypertriglyceridemia is a risk factor for cardiovascular disease, and
      clinical practice guidelines advocate treatment to reduce triglyceride (TG)
      levels. In Japan, an EPA-E (eicosapentaenoic acid-ethyl ester) product has been
      used clinically for treating dyslipidemia. OBJECTIVE: We investigated the
      TG-lowering effects of TAK-085 (EPA-E + docosahexaenoic acid-ethyl ester) in
      comparison with EPA-E in Japanese patients with hypertriglyceridemia (TG >/=150
      mg/dL and <750 mg/dL). METHODS: In this multicenter, 12-week, double-blind study,
      subjects were stratified for coadministration of a
      3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor then randomized to TAK-085 2 
      g once daily (n = 205), TAK-085 2 g twice daily (n = 210), or EPA-E 0.6 g three
      times daily (n = 195). Each one gram of fatty acid in TAK-085 contains
      approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl
      esters. Guidance on lifestyle modifications was provided throughout. RESULTS: The
      primary end point was the percent change in TG levels (baseline from end of
      treatment), which was -10.8 +/- 22.6, -22.9 +/- 23.1, and -11.2 +/- 25.7 in the
      TAK-085 2 g/day, TAK-085 4 g/day, and EPA-E 1.8 g/day groups, respectively.
      TAK-085 4 g/day produced a significantly greater reduction in TG than EPA-E 1.8
      g/day (P < .0001), whereas TAK-085 2 g/day was not inferior to EPA-E 1.8 g/day.
      Changes in other lipid parameters were relatively modest. There were no notable
      safety or tolerability differences between the groups. CONCLUSIONS: In Japanese
      patients with modest hypertriglyceridemia who also underwent lifestyle
      intervention, TAK-085 4 g/day reduced TG more than EPA-E 1.8 g/day. TAK-085 2
      g/day had similar effects on TG as EPA-E 1.8 g/day. TAK-085 was well-tolerated.
CI  - Copyright (c) 2013 National Lipid Association. Published by Elsevier Inc. All
      rights reserved.
AD  - Center for Diabetes, Metabolism and Endocrinology, Toho University Sakura Medical
      Center, Chiba 285-8741, Japan. Electronic address:
      ichiro.tatsuno@med.toho-u.ac.jp.
FAU - Tatsuno, Ichiro
AU  - Tatsuno I
FAU - Saito, Yasushi
AU  - Saito Y
FAU - Kudou, Kentarou
AU  - Kudou K
FAU - Ootake, Jun
AU  - Ootake J
LA  - eng
PT  - Journal Article
DEP - 20130204
PL  - United States
TA  - J Clin Lipidol
JT  - Journal of clinical lipidology
JID - 101300157
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/06/18 [received]
PHST- 2013/01/18 [revised]
PHST- 2013/01/27 [accepted]
PHST- 2013/02/04 [aheadofprint]
AID - S1933-2874(13)00050-0 [pii]
AID - 10.1016/j.jacl.2013.01.006 [doi]
PST - ppublish
SO  - J Clin Lipidol. 2013 May-Jun;7(3):199-207. doi: 10.1016/j.jacl.2013.01.006. Epub 
      2013 Feb 4.

PMID- 23725918
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1933-2874 (Print)
IS  - 1876-4789 (Linking)
VI  - 7
IP  - 3
DP  - 2013 May-Jun
TI  - Low prevalence of type 2 diabetes mellitus among patients with high levels of
      high-density lipoprotein cholesterol.
PG  - 194-8
LID - 10.1016/j.jacl.2013.02.003 [doi]
LID - S1933-2874(13)00060-3 [pii]
AB  - BACKGROUND: Diabetes mellitus and low levels of high-density lipoprotein
      cholesterol (HDL-C) are among several known risk factors for coronary artery
      disease. Recent research has shown potential mechanistic links between these two 
      diseases. OBJECTIVES: The aim of our study was to characterize, by examining
      particular coronary artery disease risk factors, patients with extremely high and
      low levels of HDL-C who were referred to a prevention clinic. METHODS: We
      compared the phenotypes of 113 patients with HDL-C levels greater than the 90th
      percentile with 212 patients with levels less than the 10th percentile by using a
      retrospective chart review. RESULTS: The cohort with high HDL-C had a remarkable 
      difference in the incidence of type 2 diabetes (1.8% vs 21.7%). The high HDL-C
      cohort also had a greater age (52.1 years vs 46.7 years), more light or moderate 
      alcohol consumption (70.8% vs 49.4%), more healthy diet (30.1% vs 22.4%), more
      light or moderate exercise (90.8% vs 52.2%), and a lower body mass index (25.2
      kg/m(2) vs 28.1 kg/m(2)). CONCLUSIONS: Compared with the low HDL-C group-and also
      the general population-the high HDL-C cohort had a remarkably low prevalence of
      diabetes mellitus.
CI  - Copyright (c) 2013 National Lipid Association. Published by Elsevier Inc. All
      rights reserved.
AD  - Healthy Heart Program Prevention Clinic, James Hogg iCAPTURE Centre for
      Cardiovascular and Pulmonary Research, St. Paul's Hospital, Vancouver, British
      Columbia, Canada. Electronic address: andrew.juren@stjohn.org.
FAU - Juren, Andrew J
AU  - Juren AJ
FAU - Sarwal, Gautamn
AU  - Sarwal G
FAU - Al-Sarraf, Ahmad
AU  - Al-Sarraf A
FAU - Vrablik, Michal
AU  - Vrablik M
FAU - Chan, Darren
AU  - Chan D
FAU - Humphries, Karin H
AU  - Humphries KH
FAU - Frohlich, Jiri J
AU  - Frohlich JJ
LA  - eng
PT  - Journal Article
DEP - 20130226
PL  - United States
TA  - J Clin Lipidol
JT  - Journal of clinical lipidology
JID - 101300157
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/05/31 [received]
PHST- 2013/02/05 [revised]
PHST- 2013/02/18 [accepted]
PHST- 2013/02/26 [aheadofprint]
AID - S1933-2874(13)00060-3 [pii]
AID - 10.1016/j.jacl.2013.02.003 [doi]
PST - ppublish
SO  - J Clin Lipidol. 2013 May-Jun;7(3):194-8. doi: 10.1016/j.jacl.2013.02.003. Epub
      2013 Feb 26.

PMID- 23725845
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1875-5364 (Electronic)
IS  - 1672-3651 (Linking)
VI  - 11
IP  - 3
DP  - 2013 May
TI  - Synthesis and hypoglycemic activity of esterified-derivatives of mangiferin.
PG  - 296-301
LID - 10.1016/S1875-5364(13)60032-1 [doi]
LID - S1875-5364(13)60032-1 [pii]
AB  - AIM: To synthesize three novel esterified-derivatives of mangiferin and evaluate 
      their hypoglycemic activities. METHODS: Acetic, propionic, and butyric anhydride 
      were reacted with mangiferin, respectively. The hypoglycemic activity of the
      derivatives was evaluated using a hyperglycemic mouse model induced by
      streptozotocin (STZ), and the islet cells were checked by biopsy inspection.
      RESULTS: 7, 2', 3', 4', 6'-penta-acetyl-mangiferin (PAM), 3, 6, 7, 2', 3', 4',
      6'-hepta-propionyl-mangiferin (HPM) and 3, 6, 7, 2', 3',
      4'-hexa-butyryl-mangiferin (HBM) were synthesized and their structures were
      identified by MS,(1)H, (13)C NMR, and 2D NMR. These three compounds were reported
      for the first time. PAM group (0.5, 0.25 mmol.kg(-1)), HPM group (0.5, 0.25
      mmol.kg(-1)), and HBM group (0.5, 0.25, 0.125 mmol.kg(-1)) mice showed strong
      hypoglycemic activity (P < 0.01); mangiferin group (1, 0.5 mmol.kg(-1)), PAM
      group (0.125 mmol.kg(-1)) and HPM group (0.125 mmol.kg(-1)) showed marginal
      hypoglycemic activity (P < 0.05); mangiferin group (0.25 mmol.kg(-1)) had the
      potential for a hypoglycemic effect, although it did not demonstrate that
      statistically. In histological examination, the islet cells of the PAM, HPM, and 
      HBM groups could recover from the STZ damage; islet cells of the mangiferin group
      could recover also, but less than the esterified-derivative groups. CONCLUSION:
      Derivatives could repair the damaged islet cells, and had higher lipid-solubility
      and stronger hypoglycemic activity than mangiferin itself. There existed a
      structure activity effect, and a solubility effect relationship: the larger
      esterification moieties, or the higher lipid-solubility, the stronger the
      hypoglycemic activity (no ester --> acetyl --> propionyl --> butyryl). Esterified
      derivatives of mangiferin are potential compounds for new anti-diabetes drugs.
CI  - Copyright (c) 2013 China Pharmaceutical University. Published by Elsevier B.V.
      All rights reserved.
AD  - School of Pharmaceutical Sciences, Guangxi Medical University, Nanning 530021,
      China; Drugs R&D Centre, Guangxi Traditional Chinese Medical University, Nanning 
      530023, China.
FAU - Li, Xue-Jian
AU  - Li XJ
FAU - DU, Zheng-Cai
AU  - DU ZC
FAU - Huang, Yan
AU  - Huang Y
FAU - Liu, Bu-Ming
AU  - Liu BM
FAU - Hu, Wen-Ji
AU  - Hu WJ
FAU - Lu, Wen-Jie
AU  - Lu WJ
FAU - Deng, Jia-Gang
AU  - Deng JG
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Nat Med
JT  - Chinese journal of natural medicines
JID - 101504416
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/05/12 [received]
AID - S1875-5364(13)60032-1 [pii]
AID - 10.1016/S1875-5364(13)60032-1 [doi]
PST - ppublish
SO  - Chin J Nat Med. 2013 May;11(3):296-301. doi: 10.1016/S1875-5364(13)60032-1.

PMID- 23725770
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
DP  - 2013 May 28
TI  - The limited clinical value of a specific diabetic cardiomyopathy.
LID - S0939-4753(13)00087-2 [pii]
LID - 10.1016/j.numecd.2013.03.008 [doi]
AB  - AIMS: Diabetic patients show a higher likelihood of developing heart failure
      (HF), independently of the atherosclerotic process, than their nondiabetic
      counterparts. This suggests the presence of an intrinsic vulnerability of the
      heart in patients with diabetes mellitus. DATA SYNTHESIS: A cardiomyopathy
      specific to the diabetic patient was first hypothesized by Rubler and co-workers,
      in 1972 and recognized as a nosologic entity by the World Health Organization
      (WHO) in 1995. All patients falling under Rubler's definition had ascertained
      diabetic glomerusclerosis, but were unaffected by major coronary artery disease
      (CAD). Notably, the mean plasma glucose in those patients was 417 +/- 209 mg/dl. 
      Since then, several studies conducted in both animals and in humans have focused 
      on pathogenetic mechanisms, clinical manifestations, diagnostic as well as
      therapeutic approaches utilized for the treatment of diabetic cardiomyopathy
      (DCM). Despite the large body of literature available, the clinical entity and
      significance of this diabetic complication continue to be elusive. CONCLUSIONS:
      In the present report, recent pathophysiological findings and diagnostic
      strategies to treat DCM are reviewed. Particular attention is dedicated to the
      clinical manifestation of DCM, that is to heart failure (HF), and to the
      implications of co-morbidities and metabolic control on its evolution.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128
      Padova, Italy. Electronic address: saula.dekreutzenberg@unipd.it.
FAU - Vigili de Kreutzenberg, S
AU  - Vigili de Kreutzenberg S
FAU - Avogaro, A
AU  - Avogaro A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/07/20 [received]
PHST- 2013/01/29 [revised]
PHST- 2013/03/30 [accepted]
AID - S0939-4753(13)00087-2 [pii]
AID - 10.1016/j.numecd.2013.03.008 [doi]
PST - aheadofprint
SO  - Nutr Metab Cardiovasc Dis. 2013 May 28. pii: S0939-4753(13)00087-2. doi:
      10.1016/j.numecd.2013.03.008.

PMID- 23725732
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 381
IP  - 9881
DP  - 2013 Jun 1
TI  - Is type 2 diabetes a category error?
PG  - 1956-7
LID - 10.1016/S0140-6736(12)62207-7 [doi]
LID - S0140-6736(12)62207-7 [pii]
AD  - University of Bristol, Bristol, UK. edwin.gale@bristol.ac.uk
FAU - Gale, Edwin A M
AU  - Gale EA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet
JID - 2985213R
SB  - AIM
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - S0140-6736(12)62207-7 [pii]
AID - 10.1016/S0140-6736(12)62207-7 [doi]
PST - ppublish
SO  - Lancet. 2013 Jun 1;381(9881):1956-7. doi: 10.1016/S0140-6736(12)62207-7.

PMID- 23725712
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1878-108X (Electronic)
IS  - 0166-2236 (Linking)
DP  - 2013 May 28
TI  - Novel pathogenic pathways in diabetic neuropathy.
LID - S0166-2236(13)00082-9 [pii]
LID - 10.1016/j.tins.2013.04.008 [doi]
AB  - Diabetic peripheral neuropathy (DPN) is a common complication affecting more than
      one third of diabetes mellitus (DM) patients. Although all cellular components
      participating in peripheral nerve function are exposed to and affected by the
      metabolic consequences of DM, nodal regions, areas of intense interactions
      between Schwann cells and axons, may be particularly sensitive to DM-induced
      alterations. Nodes are enriched in insulin receptors, glucose transporters, Na+
      and K+ channels, and mitochondria, all implicated in the development and
      progression of DPN. Latest results particularly reinforce the idea that changes
      in ion-channel function and energy metabolism, both of which depend on axon-glia 
      crosstalk, are among the important contributors to DPN. These insights provide a 
      basis for new therapeutic approaches aimed at delaying or reversing DPN.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Medical Genetics, University of Lausanne, 1005 Lausanne,
      Switzerland.
FAU - Zenker, Jennifer
AU  - Zenker J
FAU - Ziegler, Dan
AU  - Ziegler D
FAU - Chrast, Roman
AU  - Chrast R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Trends Neurosci
JT  - Trends in neurosciences
JID - 7808616
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/12/09 [received]
PHST- 2013/04/20 [revised]
PHST- 2013/04/24 [accepted]
AID - S0166-2236(13)00082-9 [pii]
AID - 10.1016/j.tins.2013.04.008 [doi]
PST - aheadofprint
SO  - Trends Neurosci. 2013 May 28. pii: S0166-2236(13)00082-9. doi:
      10.1016/j.tins.2013.04.008.

PMID- 23725569
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1744-7623 (Electronic)
IS  - 1472-8214 (Linking)
VI  - 18
IP  - 2
DP  - 2013 Jun
TI  - Emerging gliptins for type 2 diabetes.
PG  - 245-58
LID - 10.1517/14728214.2013.807796 [doi]
AB  - Introduction: The dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are novel 
      oral hypoglycemic drugs which have been in clinical use for the past 7 years. The
      drugs are safe, weight neutral and widely prescribed. There are currently eight
      gliptins registered worldwide with several more in advanced stages of
      development. Areas covered: The place of the gliptins in the treatment algorithm 
      of type 2 diabetes is discussed as well as unique features of the individual
      drugs. The gliptins may possess cardiovascular protective effects and their
      administration may promote beta-cell survival; claims currently being evaluated
      in clinical and preclinical studies. The global market revenues and future
      prospects of the gliptins are discussed and the gliptins in Phases II and III of 
      development are reviewed. Expert opinion: The gliptins are an optional
      second-line therapy after metformin; they are generally well tolerated with low
      risk of hypoglycemia. The various compounds differ with respect to their
      pharmacokinetic and pharmacodynamic properties; however, their clinical efficacy 
      appears to be similar. The clinical differences between the various compounds
      stem from effects other than hypoglycemic effects, their safety and side effects 
      profile. The currently registered compounds appear to have maximized the clinical
      potential of DPP-4 inhibition, and the new compounds in the companies' pipelines 
      seem to be as effective as the ones presently in use. There are two gliptins in
      advanced stages of development which will be registered for once-weekly dosing,
      possibly increasing patient adherence to therapy. Several individual gliptins are
      being evaluated for treatment in diabetes subpopulations such as type 1 patients 
      or adolescents.
AD  - Hadassah Hebrew University Medical Center, The Diabetes Research Center ,
      Jerusalem , Israel.
FAU - Cahn, Avivit
AU  - Cahn A
FAU - Raz, Itamar
AU  - Raz I
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Opin Emerg Drugs
JT  - Expert opinion on emerging drugs
JID - 101135662
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1517/14728214.2013.807796 [doi]
PST - ppublish
SO  - Expert Opin Emerg Drugs. 2013 Jun;18(2):245-58. doi:
      10.1517/14728214.2013.807796.

PMID- 23725524
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1939-022X (Electronic)
IS  - 1939-0211 (Linking)
VI  - 10
IP  - 2
DP  - 2013 Jun
TI  - The effect of green tea and sour tea on blood pressure of patients with type 2
      diabetes: a randomized clinical trial.
PG  - 105-15
LID - 10.3109/19390211.2013.790333 [doi]
AB  - ABSTRACT Introduction: The use of herbal medicines including different types of
      tea is among the different strategies for preventing and controlling the
      side-effects of diabetes. The aim of the present study was to compare the effect 
      of sour tea and green tea on mildly hypertensive patients with diabetes. Methods:
      The present study was a randomized clinical trial in which 100 mildly
      hypertensive patients with diabetes were randomly assigned into sour tea group
      (ST) and green tea group (GT). They were instructed to drink sour tea and green
      tea infusion, respectively, three times a day 2 hr after each meal for 4 weeks.
      The participants' blood pressure was measured at days 1, 15, and at the end of
      study. Results: The systolic pressure of both groups statistically decreased at
      the end of the study; it decreased from 123.1 +/- 15.5 to 116.8 +/- 16.3 mmHg in 
      the ST and from 119.4 +/- 15.1 to 114.8 +/- 15.9 mmHg in the GT. The diastolic
      pressure of both groups statistically decreased by the end of the study; it
      decreased from 79.4 +/- 11.1 to 74.5 +/- 9.3 mmHg in the ST and from 78.9 +/- 8.3
      to 75.3 +/- 7.7 mmHg in the GT. The therapeutic effectiveness of tea drinking by 
      the end of intervention was 43.5% in the ST and 39.6% in the GT compared to the
      beginning. Conclusions: The present study revealed that mildly hypertensive type 
      2 diabetic individuals who drink three glasses of green or sour tea daily for 4
      weeks show significant decreased systolic and diastolic blood pressures.
AD  - 1Department of Nutrition, Faculty of Health, Shahid Sadoughi University of
      Medical Sciences , Yazd , Iran.
FAU - Mozaffari-Khosravi, Hassan
AU  - Mozaffari-Khosravi H
FAU - Ahadi, Zeinab
AU  - Ahadi Z
FAU - Barzegar, Kazem
AU  - Barzegar K
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Diet Suppl
JT  - Journal of dietary supplements
JID - 101249830
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.3109/19390211.2013.790333 [doi]
PST - ppublish
SO  - J Diet Suppl. 2013 Jun;10(2):105-15. doi: 10.3109/19390211.2013.790333.

PMID- 23725523
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1939-022X (Electronic)
IS  - 1939-0211 (Linking)
VI  - 10
IP  - 2
DP  - 2013 Jun
TI  - A short-term evaluation of the relationship between plasma ascorbic Acid levels
      and periodontal disease in systemically healthy and type 2 diabetes mellitus
      subjects.
PG  - 93-104
LID - 10.3109/19390211.2013.790332 [doi]
AB  - ABSTRACT Background: Deficient ascorbic acid levels (AALs) and Type 2 diabetes
      mellitus (T2DM) are associated with periodontal disease. This study evaluated the
      relationship between plasma AAL and periodontitis in systemically healthy and
      T2DM subjects, which to the best of our knowledge is being reported for the first
      time. Methods: One hundred twenty subjects were categorized into four groups of
      30 each as group 1: without periodontal disease; group 2: chronic gingivitis;
      group 3: chronic periodontitis, and group 4: chronic periodontitis and freshly
      diagnosed T2DM. Plaque index (PlI), sulcus bleeding index (SBI), and probing
      pocket depths (PPDs) were evaluated. Venous blood was evaluated for plasma AAL
      spectrophotometrically. Randomized subjects were subgrouped within groups 2-4, to
      receive either scaling and root planing (SRP) with dietary supplementation (450
      mg) of ascorbic acid (AA) for two weeks or only SRP. After two weeks, the
      clinical parameters were reassessed. Tukey's multiple post hoc procedures and
      paired t test were used with the level of statistical significance adjusted to p 
      </= .05. Results: AAL plasma levels were significantly greater in group 1 than in
      group 2 (p = .0007) and in group 4 (p = .0003). A significant reduction in the
      SBI was seen in the subgroups that received dietary supplementation of vitamin C 
      within group 2 (p = .0012) and group 4 (p = .036). Conclusions: Plasma AAL is
      below the normal range in systemically healthy subjects with gingivitis and
      diabetics with periodontitis. Dietary AA supplementation with SRP improves the
      SBI in subjects with gingivitis and diabetics with periodontitis.
AD  - 1Department of Periodontics, Sri Dharmasthala Manjunatheshwara College of Dental 
      Sciences & Hospital , Sattur, Dharwad, Karnataka , India.
FAU - Gokhale, Neeraja H
AU  - Gokhale NH
FAU - Acharya, Anirudh B
AU  - Acharya AB
FAU - Patil, Vidya S
AU  - Patil VS
FAU - Trivedi, Dheeraj J
AU  - Trivedi DJ
FAU - Thakur, Srinath L
AU  - Thakur SL
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Diet Suppl
JT  - Journal of dietary supplements
JID - 101249830
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.3109/19390211.2013.790332 [doi]
PST - ppublish
SO  - J Diet Suppl. 2013 Jun;10(2):93-104. doi: 10.3109/19390211.2013.790332.

PMID- 23725521
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 31
TI  - Factors influencing participation in a vascular disease prevention lifestyle
      program among participants in a cluster randomized trial.
PG  - 201
AB  - BACKGROUND: Previous research suggests that lifestyle intervention for the
      prevention of diabetes and cardiovascular disease (CVD) are effective, however
      little is known about factors affecting participation in such programs. This
      study aims to explore factors influencing levels of participation in a lifestyle 
      modification program conducted as part of a cluster randomized controlled trial
      of CVD prevention in primary care. METHODS: This concurrent mixed methods study
      used data from the intervention arm of a cluster RCT which recruited 30 practices
      through two rural and three urban primary care organizations. Practices were
      randomly allocated to intervention (n = 16) and control (n = 14) groups. In each 
      practice up to 160 eligible patients aged between 40 and 64 years old, were
      invited to participate. Intervention practice staff were trained in lifestyle
      assessment and counseling and referred high risk patients to a lifestyle
      modification program (LMP) consisting of two individual and six group sessions
      over a nine month period. Data included a patient survey, clinical audit,
      practice survey on capacity for preventive care, referral and attendance records 
      at the LMP and qualitative interviews with Intervention Officers facilitating the
      LMP. Multi-level logistic regression modelling was used to examine independent
      predictors of attendance at the LMP, supplemented with qualitative data from
      interviews with Intervention Officers facilitating the program. RESULTS: A total 
      of 197 individuals were referred to the LMP (63% of those eligible). Over a third
      of patients (36.5%) referred to the LMP did not attend any sessions, with 59.4%
      attending at least half of the planned sessions. The only independent predictors 
      of attendance at the program were employment status - not working (OR: 2.39 95%
      CI 1.15-4.94) and having high psychological distress (OR: 2.17 95% CI:
      1.10-4.30). Qualitative data revealed that physical access to the program was a
      barrier, while GP/practice endorsement of the program and flexibility in program 
      delivery facilitated attendance. CONCLUSION: Barriers to attendance at a LMP for 
      CVD prevention related mainly to external factors including work commitments and 
      poor physical access to the programs rather than an individuals' health risk
      profile or readiness to change. Improving physical access and offering
      flexibility in program delivery may enhance future attendance. Finally,
      associations between psychological distress and attendance rates warrant further 
      investigation.Trial registration: ACTRN12607000423415.
FAU - Laws, Rachel A
AU  - Laws RA
FAU - Fanaian, Mahnaz
AU  - Fanaian M
FAU - Jayasinghe, Upali W
AU  - Jayasinghe UW
FAU - McKenzie, Suzanne
AU  - McKenzie S
FAU - Passey, Megan
AU  - Passey M
FAU - Davies, Gawaine Powell
AU  - Davies GP
FAU - Lyle, David
AU  - Lyle D
FAU - Harris, Mark F
AU  - Harris MF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/08/22 [received]
PHST- 2013/05/31 [accepted]
PHST- 2013/05/31 [aheadofprint]
AID - 1472-6963-13-201 [pii]
AID - 10.1186/1472-6963-13-201 [doi]
PST - aheadofprint
SO  - BMC Health Serv Res. 2013 May 31;13(1):201.

PMID- 23725518
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 11
IP  - 1
DP  - 2013 May 31
TI  - Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a
      prospective, randomized, controlled clinical trial.
PG  - 134
AB  - BACKGROUND: Diabetic nephropathy (DN) is the most common cause of end-stage renal
      failure. Although angiotensin II receptor blockers (ARBs) can be used to
      attenuate proteinuria in DN patients, their efficacy remains limited. This
      clinical trial aimed to evaluate the efficacy of Tripterygium wilfordii Hook F
      (TwHF) extract in the treatment of type 2 diabetes mellitus (DM)-induced
      nephropathy. METHODS: A total of 65 DN patients with proteinuria levels >= 2.5
      g/24 h and serum creatinine levels < 3 mg/dl were enrolled in this six-month,
      prospective, randomized, controlled study. The patients were randomized into
      treatment groups that received either 120 mg of TwHF extract per day for three
      months, followed by 60 mg per day for three more months, or 160 mg of valsartan
      daily for six months. The urinary protein and estimated glomerular filtration
      (eGFR) level were measured at one, three, and six months after the commencement
      of treatment. The primary measure of treatment efficacy was a reduction in the
      24-h urine protein level between baseline and the end of the study, and the
      secondary measure of treatment efficacy was a reduction in the eGFR value.
      RESULTS: At the end of the treatment period, the mean urine protein level in the 
      TwHF group was dramatically decreased (4.99 +/- 2.25 g/24 h vs 2.99 +/- 1.81 g/24
      h, p < 0.01), with decreases at one, three, and six months of 32.9%, 38.8%, and
      34.3%, respectively. In contrast, the proteinuria in the valsartan group was not 
      significantly attenuated, and the decreases in urine protein levels at treatment 
      months one, three, and six were 1.05%, 10.1%, and -11.7%, respectively. The mean 
      decrease in eGFR in the valsartan group was greater than that in the TwHF group
      (26.4% vs. 13.7%, respectively; p =0.067). CONCLUSIONS: TwHF extract can reduce
      the urine protein level of DN patients and represents a novel, potentially
      effective, and safe drug for the treatment of DN patients with proteinuria.Trial 
      registrationClinicalTrials.gov: NCT00518362.
FAU - Ge, Yongchun
AU  - Ge Y
FAU - Xie, Honglang
AU  - Xie H
FAU - Li, Shijun
AU  - Li S
FAU - Jin, Bo
AU  - Jin B
FAU - Hou, Jinhua
AU  - Hou J
FAU - Zhang, Haitao
AU  - Zhang H
FAU - Shi, Mingjun
AU  - Shi M
FAU - Liu, Zhihong
AU  - Liu Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
PMC - PMC3670993
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/27 [received]
PHST- 2013/05/31 [accepted]
PHST- 2013/05/31 [aheadofprint]
AID - 1479-5876-11-134 [pii]
AID - 10.1186/1479-5876-11-134 [doi]
PST - aheadofprint
SO  - J Transl Med. 2013 May 31;11(1):134.

PMID- 23725496
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 14
IP  - 1
DP  - 2013 Jun 2
TI  - Metabolic syndrome, C-reactive protein and microalbuminuria in a rural Chinese
      population: a cross-sectional study.
PG  - 118
AB  - BACKGROUND: Microalbuminuria is an early marker of chronic kidney disease (CKD). 
      Previous studies have shown that either metabolic syndrome (MetS) or chronic
      inflammation is related to renal impairment. The aim of this study was to
      investigate the association between MetS, C-reactive protein (CRP) and
      microalbuminuria in a rural Chinese population. METHODS: This was a
      cross-sectional study using data from the Handan Eye Study. MetS was defined
      according to the Chinese Diabetes Society (CDS) criteria. CRP levels >= 3 mg/L
      were classified as high CRP. Microalbuminuria was defined as a urinary
      albumin/creatinine ratio (ACR) of 30--300 mg/g. RESULTS: We included 4191
      subjects aged >= 30 years in this analysis. The prevalence of MetS and
      microalbuminuria in the group was 25.7% and 15.6%, respectively. The odds ratio
      (OR) of microalbuminuria in subjects with MetS was 1.25 (95% confidence interval 
      (CI): 1.03 - 1.51) compared with those without microalbuminuria. In multivariate 
      logistic regression analysis, high blood pressure (OR 1.36, 95% CI: 1.10 - 1.67) 
      and high fasting blood glucose (OR 1.44, 95% CI: 1.17 - 1.76) were independently 
      associated with microalbuminuria. Subjects with high CRP and MetS had a 1.46-fold
      greater risk of having microalbuminuria compared with those with low CRP without 
      MetS (95% CI: 1.06 - 2.01). CONCLUSIONS: In this rural Chinese population aged
      >=30 years, MetS and microalbuminuria were independently related and the
      combination of high CRP and MetS was associated with an increased risk of
      microalbuminuria.
FAU - Jiang, Liping
AU  - Jiang L
FAU - Huang, Wen
AU  - Huang W
FAU - Liang, Yuanbo
AU  - Liang Y
FAU - Wang, Fenghua
AU  - Wang F
FAU - Duan, Xinrong
AU  - Duan X
FAU - Yang, Xiaohui
AU  - Yang X
FAU - Wen, Jiangping
AU  - Wen J
FAU - Wang, Ningli
AU  - Wang N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130602
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
PMC - PMC3674949
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/10/21 [received]
PHST- 2013/06/02 [accepted]
PHST- 2013/06/02 [aheadofprint]
AID - 1471-2369-14-118 [pii]
AID - 10.1186/1471-2369-14-118 [doi]
PST - aheadofprint
SO  - BMC Nephrol. 2013 Jun 2;14(1):118.

PMID- 23725484
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130606
DCOM- 20130607
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Medical risk factors of diabetes mellitus among professional drivers.
PG  - 23
LID - 10.1186/2251-6581-12-23 [doi]
AB  - BACKGROUND: Road transport drivers are one of the professional groups whose
      activities have a strong impact of public safety. In view of the natural
      professional activity, the drivers are at a higher risk of obesity, hypertension 
      and hyperlipidemia, and carbohydrate metabolism disorders such as diabetes
      mellitus. MATERIALS AND METHODS: Medical documentation was the source of data for
      the reported study. It derived from medical examinations of 1903 drivers applying
      for driving license. RESULTS: Hyperglycemia was found in 52.1% of the drivers,
      9.1% of them were in diabetic stage, and with HbA1C criteria 77.6% of these
      drivers were in this stage. Excessive body weight was recorded in 65.6% of the
      study population, 44.8% were diagnosed with overweight and 20.8% with obesity.
      High blood pressure was recorded in 16.4% of drivers. CONCLUSION: High prevalence
      of excessive body weight and high blood pressure and hyperlipidemia are risk
      factors for diabetes mellitus in professional drivers that indicates a need to
      undertake multidimensional actions target on this particular profession and
      involving various health care sectors. Prophylactic and detailed pre-placement
      examinations should be considered, depending on the rate and the intensity of
      disorders. These should be coupled with an introduction of primary and secondary 
      prophylactic activities and monitoring of relevant treatment.
AD  - Center for Research on Occupational Diseases, Tehran University of Medical
      Sciences, Tehran, Iran. saraie_m@yahoo.com.
FAU - Izadi, Nazanin
AU  - Izadi N
FAU - Malek, Maryam
AU  - Malek M
FAU - Aminian, Omid
AU  - Aminian O
FAU - Saraei, Maryam
AU  - Saraei M
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3674897
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:01
CRDT- 2013/06/04 06:00
PHST- 2013/04/19 [received]
PHST- 2013/05/21 [accepted]
PHST- 2013/06/01 [aheadofprint]
AID - 2251-6581-12-23 [pii]
AID - 10.1186/2251-6581-12-23 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 Jun 1;12(1):23. doi: 10.1186/2251-6581-12-23.

PMID- 23725474
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 May 31
TI  - Performance Comparison of the Medtronic Sof-Sensor and Enlite Glucose Sensors in 
      Inpatient Studies of Individuals with Type 1 Diabetes.
AB  - Abstract Objective: Knowledge of the accuracy of continuous glucose monitoring
      (CGM) devices is important for its use as a management tool for individuals with 
      diabetes and for its use to assess outcomes in clinical studies. Using data from 
      several inpatient studies, we compared the accuracy of two sensors, the Medtronic
      Enlite using MiniMed Paradigm(R) Veo calibration and the Sof-Sensor(R) glucose
      sensor using Guardian(R) REAL-Time CGM calibration (all from Medtronic Diabetes, 
      Northridge, CA). Subjects and Methods: Nocturnal data were analyzed from eight
      inpatient studies in which both CGM and reference glucose measurements were
      available. The analyses included 1,666 CGM-reference paired glucose values for
      the Enlite in 54 participants over 69 nights and 3,627 paired values for the
      Sof-Sensor in 66 participants over 91 nights. Results: The Enlite sensor tended
      to report glucose levels lower than the reference over the entire range of
      glucose values, whereas the Sof-Sensor values tended to be higher than reference 
      values in the hypoglycemic range and lower than reference values in the
      hyperglycemic range. The overall median sensor-reference difference was -15 mg/dL
      for the Enlite and -1 mg/dL for the Sof-Sensor (P<0.001). The median relative
      absolute difference was 15% for the Enlite versus 12% for the Sof-Sensor
      (P=0.06); 66% of Enlite values and 73% of Sof-Sensor values met International
      Organization for Standardization criteria. Conclusions: We found that the Enlite 
      tended to be biased low over the entire glucose range, whereas the Sof-Sensor
      showed the more typical sensor pattern of being biased high in the hypoglycemic
      range and biased low in the hyperglycemic range.
AD  - Jaeb Center for Health Research , Tampa, Florida.
FAU - Calhoun, Peter
AU  - Calhoun P
FAU - Lum, John
AU  - Lum J
FAU - Beck, Roy W
AU  - Beck RW
FAU - Kollman, Craig
AU  - Kollman C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1089/dia.2013.0042 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 May 31.

PMID- 23725454
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1554-8937 (Electronic)
IS  - 1554-8929 (Linking)
DP  - 2013 May 31
TI  - Development of a highly visual, simple and rapid test for the discovery of novel 
      insulin mimetics in living vertebrates.
AB  - Diabetes mellitus is a global epidemic with major impacts on human health and
      society. Drug discovery for diabetes can be facilitated by the development of a
      rapid, vertebrate-based screen for identifying new insulin mimetic compounds. Our
      study describes the first development of a zebrafish-based system validated for
      identifying novel anti-diabetic drugs. Our system utilizes a fluorescent-tagged
      glucose probe in an experimentally convenient 96-well plate format. To validate
      our new system, we identified compounds that can induce glucose uptake via
      activity guided fractionation of the inner shell from the Japanese Chestnut
      (Castanea crenata). The best performing compound, fraxidin, was validated as
      novel insulin mimetic using a mammalian adipocyte system. Moreover, our
      zebrafish-based system allows concomitant toxicological analysis of anti-diabetic
      drug candidates. Thus, we have developed a rapid and inexpensive vertebrate model
      that can enhance diabetes drug discovery by pre-selecting hits from chemical
      library screens, before testing in relatively expensive rodent assays.
FAU - Lee, Jinho
AU  - Lee J
FAU - Jung, Da-Woon
AU  - Jung DW
FAU - Kim, Woong-Hee
AU  - Kim WH
FAU - Jung-In, Um
AU  - Jung-In U
FAU - Yim, Soon-Ho
AU  - Yim SH
FAU - Oh, Won Keun
AU  - Oh WK
FAU - Williams, Darren R
AU  - Williams DR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - ACS Chem Biol
JT  - ACS chemical biology
JID - 101282906
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.1021/cb4000162 [doi]
PST - aheadofprint
SO  - ACS Chem Biol. 2013 May 31.

PMID- 23725447
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130607
DCOM- 20130610
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Effects of sprint interval and continuous endurance training on serum levels of
      inflammatory biomarkers.
PG  - 22
LID - 10.1186/2251-6581-12-22 [doi]
AB  - Chronic and inflammatory diseases are major causes of mortality. Although the
      anti-inflammatory effects of exercise have been confirmed, but the effect of
      different types of exercise on inflammatory markers is different. The aim of this
      study is comparing the effects of two types of sprint interval (SIT) and
      continuous endurance (CET) training on inflammatory markers. Sixteen students who
      had recreational activities participated in this study and were randomly assigned
      to one of the two protocols. The SIT protocol consisted of four to six 30-s
      "all-out" Wingate tests separated by 4 minutes of recovery and The CET protocol
      included 90-120 minutes of cycling at 65% Vo2max. The two protocols were
      performed 3 days per week and for two weeks. In each group, two blood samples
      were collected before and 2 days (24 and 48 hrs) after the training. Results
      showed that there was no significant difference between the two training
      protocols on all measured parameters (p>0.05). The results of present study
      showed that the SIT and CET have identical effects on inflammatory markers.
AD  - Faculty of Physical Education and Sport Sciences, Shahid Beheshti University,
      Tehran, 1983963113, Iran. Tarlanrad@Gmail.Com.
FAU - Hovanloo, Fariborz
AU  - Hovanloo F
FAU - Arefirad, Tahereh
AU  - Arefirad T
FAU - Ahmadizad, Sajad
AU  - Ahmadizad S
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3674904
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:01
CRDT- 2013/06/04 06:00
PHST- 2013/02/12 [received]
PHST- 2013/05/19 [accepted]
PHST- 2013/05/31 [aheadofprint]
AID - 2251-6581-12-22 [pii]
AID - 10.1186/2251-6581-12-22 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 May 31;12(1):22. doi: 10.1186/2251-6581-12-22.

PMID- 23725345
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1474-9726 (Electronic)
IS  - 1474-9718 (Linking)
DP  - 2013 Jun 3
TI  - Aging aggravates ischemic stroke-induced brain damage in mice with chronic
      peripheral infection.
LID - 10.1111/acel.12106 [doi]
AB  - Ischemic stroke is confounded by conditions such as atherosclerosis, diabetes and
      infection, all of which alter peripheral inflammatory processes with concomitant 
      impact on stroke outcome. The majority of the stroke patients are elderly, but
      the impact of interactions between aging and inflammation on stroke remains
      unknown. We thus investigated the influence of age on the outcome of stroke in
      animals predisposed to systemic chronic infection. Th1-polarized chronic systemic
      infection was induced in 18-22 month and 4-month-old C57BL/6j mice by
      administration of T. muris (gut parasite). One month after infection, mice
      underwent permanent middle cerebral artery occlusion and infarct size, brain
      gliosis and brain and plasma cytokine profiles were analyzed. Chronic infection
      increased the infarct size in aged but not in young mice at 24 hours. Aged,
      ischemic mice showed altered plasma and brain cytokine responses while the lesion
      size correlated with plasma pre-stroke levels of RANTES. Moreover, the old,
      infected mice exhibited significantly increased neutrophil recruitment and
      up-regulation of both plasma interleukin-17alpha and tumor necrosis factor alpha 
      levels. Neither age nor infection status alone or in combination altered the
      ischemia-induced brain microgliosis. Our results show that chronic peripheral
      infection in aged animals renders the brain more vulnerable to ischemic insults, 
      possibly by increasing the invasion of neutrophils and altering the inflammation 
      status in the blood and brain. Understanding the interactions between age and
      infections is crucial for developing a better therapeutic regimen for ischemic
      stroke and when modeling it as a disease of the elderly. This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Neurobiology, A. I. Virtanen Institute for Molecular Sciences,
      Biocenter Kuopio, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio,
      Finland.
FAU - Dhungana, Hiramani
AU  - Dhungana H
FAU - Malm, Tarja
AU  - Malm T
FAU - Denes, Adam
AU  - Denes A
FAU - Valonen, Piia
AU  - Valonen P
FAU - Wojciechowski, Sara
AU  - Wojciechowski S
FAU - Magga, Johanna
AU  - Magga J
FAU - Savchenko, Ekaterina
AU  - Savchenko E
FAU - Humphreys, Neil
AU  - Humphreys N
FAU - Grencis, Richard
AU  - Grencis R
FAU - Rothwell, Nancy
AU  - Rothwell N
FAU - Koistinaho, Jari
AU  - Koistinaho J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Aging Cell
JT  - Aging cell
JID - 101130839
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/05/05 [accepted]
AID - 10.1111/acel.12106 [doi]
PST - aheadofprint
SO  - Aging Cell. 2013 Jun 3. doi: 10.1111/acel.12106.

PMID- 23725283
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 5
IP  - 6
DP  - 2013 Jun
TI  - The potential role of dendritic cells in the therapy of Type 1 diabetes.
PG  - 591-606
LID - 10.2217/imt.13.48 [doi]
AB  - Type 1 diabetes (T1D) is the result of T-cell mediated autoimmune destruction of 
      pancreatic islet beta-cells. The two current treatments for T1D are based on
      insulin or islet-cell replacement rather than the pathogenesis of T1D and remain 
      problematic. Islet/pancreas transplantation does not cater for the majority of
      sufferers due to the lack of supply of organs and the need for continuous
      immunosuppression regimens. The mainstay treatment is insulin replacement, but
      this is disruptive to lifestyle and does not protect against severe long-term
      complications. An early vaccination and long-term restoration of immune tolerance
      to self-antigens in T1D patients (reversing the immunopathogenesis of the
      disease) would be preferable. Dendritic cells (DCs) are potent APCs and play an
      important role in inducing and maintaining immune tolerance. Targeting DCs
      through different DC surface molecules shows effective modulation of immune
      responses. Their feasibility for immunotherapy to prolong transplant survival and
      cancer immunotherapy has been demonstrated. Therefore, DCs could potentially be
      used in the treatment of autoimmune diseases. This review summarizes new insights
      into DCs as a potential therapeutic target for the treatment of T1D.
AD  - Molecular Immunology Division, The Walter & Eliza Hall Institute of Medical
      Research, 1G Royal Parade, Parkville, VIC 3052, Australia.
FAU - Lee, Chin-Nien
AU  - Lee CN
FAU - Lew, Andrew M
AU  - Lew AM
FAU - Wu, Li
AU  - Wu L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.2217/imt.13.48 [doi]
PST - ppublish
SO  - Immunotherapy. 2013 Jun;5(6):591-606. doi: 10.2217/imt.13.48.

PMID- 23725280
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1750-7448 (Electronic)
IS  - 1750-743X (Linking)
VI  - 5
IP  - 6
DP  - 2013 Jun
TI  - Tolerogenic dendritic cells for Type 1 diabetes.
PG  - 569-71
LID - 10.2217/imt.13.50 [doi]
AB  - Evaluation of: Pujol-Autonell I, Ampudia RM, Monge P et al. Immunotherapy with
      tolerogenic dendritic cells alone or in combination with rapamycin does not
      reverse diabetes in NOD mice. ISRN Endocrinol. doi:10.1155/2013/346987 (2013)
      (Epub ahead of print). Many reports confirm that dendritic cells (DCs) can
      prevent autoimmune diseases in mice and rats including Type 1 diabetes mellitus. 
      Reversal of new-onset Type 1 diabetes mellitus using DCs has not yet been
      reported in the literature. The findings of Pujol-Autonell and colleagues suggest
      that reversal using DCs may not be possible, at least in the NOD/LtJ mouse
      strain. At first sight, these data suggest that DC-based therapies may not be
      effective in treating new-onset disease in humans. This evaluation provides a
      potential explanation for why the approach of Pujol-Autonell was not successful
      and offer alternatives that may result in a successful outcome. Based on this
      analysis, the importance of quality control testing DCs to ensure that their
      tolerogenic character is stable in vitro and in vivo is highlighted.
AD  - Department of Pathology, University of Pittsburgh School of Medicine, Children's 
      Hospital of Pittsburgh, Rangos Research Center 6123, 4401 Penn Avenue,
      Pittsburgh, PA 15224, USA. ngiann1@pitt.edu.
FAU - Giannoukakis, Nick
AU  - Giannoukakis N
LA  - eng
PT  - Journal Article
PL  - England
TA  - Immunotherapy
JT  - Immunotherapy
JID - 101485158
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.2217/imt.13.50 [doi]
PST - ppublish
SO  - Immunotherapy. 2013 Jun;5(6):569-71. doi: 10.2217/imt.13.50.

PMID- 23725216
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1460-2202 (Electronic)
IS  - 0271-3683 (Linking)
VI  - 38
IP  - 7
DP  - 2013 Jul
TI  - The effect of a systemic Angiotensin receptor blocker on vascular endothelial
      growth factor in the vitreous of patients with proliferative diabetic
      retinopathy.
PG  - 774-80
LID - 10.3109/02713683.2013.772206 [doi]
AB  - Abstract Purpose: Renin-angiotensin system (RAS) is reportedly associated with
      the vitreous level of vascular endothelial growth factor (VEGF) in proliferative 
      diabetic retinopathy (PDR). This study was conducted to investigate the effect of
      systemic angiotensin receptor blocker (ARB) on vitreous VEGF in PDR. Method:
      Patients who underwent a vitrectomy due to PDR were divided into two groups:
      patients who were taking ARB to control hypertension (Group A) and normotensive
      patients (Group B). Patients having epiretinal membrane or macular hole without
      diabetes or hypertension were included in the control group (Group C). We
      assessed the best-corrected visual acuity (BCVA) and VEGF levels of the vitreous 
      fluid and the serum using enzyme-linked immunosorbent assay. Results: Nineteen
      eyes were in Group A, 27 eyes in Group B, and 30 eyes in Group C. The mean levels
      of vitreous VEGF were 487.5 pg/ml in Group A and 553.0 pg/ml in Group B. In Group
      C, the vitreous VEGF was below the detection limit in 29 of the 30 eyes. The mean
      serum VEGF levels were 384.8 pg/ml, 384.6 pg/ml, and 388.1 pg/ml, respectively.
      The ratio of vitreous VEGF to serum was 4.0 in Group A and 2.97 in Group B. There
      were no differences in vitreous and serum VEGF levels between two groups. The
      median BCVA of Groups A and B significantly improved from 1.55 and 1.10 at
      baseline to 0.55 and 0.30 respectively at 6 months (logarithm of minimal angle
      resolution, p < 0.005). No differences were found in visual acuity. Conclusion:
      Systemic ARB did not show beneficial effects with respect to the vitreous level
      of VEGF or functional outcomes after vitrectomy in patients with PDR.
AD  - Department of Ophthalmology, Pusan National University Hospital , Busan , Korea .
FAU - Byon, Ik Soo
AU  - Byon IS
FAU - Jeon, Hye Shin
AU  - Jeon HS
FAU - Kim, Hyun Woong
AU  - Kim HW
FAU - Lee, Sang Joon
AU  - Lee SJ
FAU - Lee, Ji Eun
AU  - Lee JE
FAU - Oum, Boo Sup
AU  - Oum BS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Eye Res
JT  - Current eye research
JID - 8104312
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.3109/02713683.2013.772206 [doi]
PST - ppublish
SO  - Curr Eye Res. 2013 Jul;38(7):774-80. doi: 10.3109/02713683.2013.772206.

PMID- 23725211
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1470-8744 (Electronic)
IS  - 0885-4513 (Linking)
DP  - 2013 May 31
TI  - Human Umblical Cord Derived Mesenchymal Stem Cells Can Secret Insulin In Vitro
      and In Vivo.
LID - 10.1002/bab.1127 [doi]
AB  - Diabetes mellitus is characterized by autoimmune destruction of pancreatic beta
      cells, leading to decrease insulin production. Differentiation of mesenchymal
      stem cells (MSCs) into insulin producing cells offers novel ways to diabetes
      treatment. MSCs can be isolated from the human umbilical cord tissue and
      differentiate into insulin-secreting cells. Human umbilical cord derived stem
      cells (hUDSCs) were obtained after birth, selected by plastic adhesion, and
      characterized by flow cytometric analysis. Human UDSCs transduced with
      Non-integrated lentivirus harboring PDX1 (Non-integrated LV-PDX1) and cultured in
      differentiation medium in 21 days. Pancreatic duodenum homeobox protein-1 (PDX1) 
      is a transcription factor in pancreatic development. Significant expressions of
      PDX1, neurogenin3 (Ngn3), glucagon, glucose transporter2 (Glut2), somatostatin
      were detected by quantitative RT-PCR (P < 0.05). PDX1 and insulin proteins were
      shown by immunocytochemistry analysis. The insulin secretion of hUDSCs PDX1+ in
      the high-glucose medium was 1.8 muU/ml. They were used for treatment of diabetic 
      rats and could decrease the blood glucose level from 400 mg/dL to the normal
      level in 4 days. In conclusion, our results demonstrated that hUDSCs are able to 
      differentiate into insulin producing cells by transduction with non-integrated
      LV-PDX1. This hUDSCs PDX1+ have the potential to be used as a viable resource in 
      cell-based gene therapy of type 1 diabetes. This article is protected by
      copyright. All rights reserved.
CI  - Copyright (c) 2013 International Union of Biochemistry and Molecular Biology,
      Inc.
AD  - National Institute of Genetic Engineering and Biotechnology, P. O. Box14155-6343,
      Tehran, Iran.
FAU - Boroujeni, Zahra
AU  - Boroujeni Z
FAU - Aleyasin, Ahmad
AU  - Aleyasin A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Biotechnol Appl Biochem
JT  - Biotechnology and applied biochemistry
JID - 8609465
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/24 [received]
PHST- 2013/04/22 [accepted]
AID - 10.1002/bab.1127 [doi]
PST - aheadofprint
SO  - Biotechnol Appl Biochem. 2013 May 31. doi: 10.1002/bab.1127.

PMID- 23725198
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130606
DCOM- 20130607
LR  - 20130607
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 13
DP  - 2013
TI  - Younger adult type 2 diabetic patients have poorer glycaemic control: a
      cross-sectional study in a primary care setting in Singapore.
PG  - 18
LID - 10.1186/1472-6823-13-18 [doi]
AB  - BACKGROUND: The aim was to study the glycaemic control of type 2 diabetic
      patients, and to identify factors associated with unacceptable glycaemic control 
      (defined as HbA1c >8.0%). METHODS: Analysis of data collected in a
      cross-sectional survey of type 2 diabetic patients in eight SingHealth
      Polyclinics in January 2009. HbA1c value was measured on the day of the survey,
      while information on patient and diabetic characteristics was obtained through a 
      questionnaire. Odds ratio of having unacceptable glycaemic control was estimated 
      for selected variables using multiple logistic regression models. RESULTS: A
      total of 688 patients were included in the analysis. The mean (+/- standard
      deviation) and median (range) HbA1c levels were 7.6% (+/- 1.35) and 7.3% (5.0% to
      14.0%), respectively. 25.4% of the patients had an unacceptable HbA1c level of
      >8.0% and the odds of this were higher (p < 0.05) in patients with the following 
      characteristics: younger age, longer diabetes duration, presence of insulin
      treatment, and poorer compliance to medication. CONCLUSION: Younger adult
      patients were found to have poorer glycaemic control, and hence targeted
      educational and behaviour modification programmes would be required to
      effectively manage this group of patients.
AD  - SingHealth Polyclinics- Outram Polyclinic, 3 Second Hospital Avenue, Health
      Promotion Board building Level 2, Singapore 168937, Singapore.
      joanne.quah.h.m@singhealth.com.sg.
FAU - Quah, Joanne Hui Min
AU  - Quah JH
FAU - Liu, Yan Ping
AU  - Liu YP
FAU - Luo, Nan
AU  - Luo N
FAU - How, Choon How
AU  - How CH
FAU - Tay, Ee Guan
AU  - Tay EG
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
PMC - PMC3674913
OID - NLM: PMC3674913
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:01
CRDT- 2013/06/04 06:00
PHST- 2012/10/11 [received]
PHST- 2013/05/29 [accepted]
PHST- 2013/06/03 [aheadofprint]
AID - 1472-6823-13-18 [pii]
AID - 10.1186/1472-6823-13-18 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2013 Jun 3;13:18. doi: 10.1186/1472-6823-13-18.

PMID- 23725092
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 13
DP  - 2013
TI  - Comparing the effectiveness of two cardiovascular prevention programmes for
      highly educated professionals in general practice: a randomised clinical trial.
PG  - 38
LID - 10.1186/1471-2261-13-38 [doi]
AB  - BACKGROUND: Cardiovascular disease is a major cause of mortality and morbidity
      and its prevalence is set to increase. While the benefits of medical and
      lifestyle interventions are established, the effectiveness of interventions which
      seek to improve the way preventive care is delivered in general practice is less 
      so. The aim was to study and to compare the effectiveness of 2 intervention
      programmes for reducing cardiovascular risk factors within general practice.
      METHODS: A randomised controlled trial was conducted in Belgium between 2007-2010
      with 314 highly educated and mainly healthy professionals allocated to a medical 
      (MP) or a medical + lifestyle (MLP) programme. The MP consisted of medical
      assessments (screening and follow-up) and the MLP added a tailored lifestyle
      change programme (web-based and individual coaching) to the MP. Primary outcomes 
      were total cholesterol, blood pressure, and body mass index (BMI). The secondary 
      outcomes were smoking status, fitness-score, and total cardiovascular risk.
      RESULTS: The mean age was 41 years, 95 (32%) participants were female, 7 had a
      personal cardiovascular event in their medical history and 3 had diabetes. There 
      were no significant differences found between MP and MLP in primary or secondary 
      outcomes. In both study conditions decreases of cholesterol, systolic blood
      pressure, and diastolic blood pressure were found. Unfavourable increases were
      found for BMI (p < .05). A significant decrease of the overall cardiovascular
      risk was reported (p < .001). CONCLUSIONS: Both interventions are effective in
      reducing cardiovascular risk. In our population the combined medical and
      lifestyle programme was not superior to the medical programme. TRIAL
      REGISTRATION: ISRCTN23940498.
AD  - Faculty of Medicine, Hasselt University, Agoralaan Building D, Diepenbeek, 3590, 
      Belgium. neree.claes@uhasselt.be.
FAU - Claes, Neree
AU  - Claes N
FAU - Jacobs, Nele
AU  - Jacobs N
FAU - Clays, Els
AU  - Clays E
FAU - Schrooten, Ward
AU  - Schrooten W
FAU - De Bourdeaudhuij, Ilse
AU  - De Bourdeaudhuij I
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
SB  - IM
PMC - PMC3674968
OID - NLM: PMC3674968
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2012/11/29 [received]
PHST- 2013/05/20 [accepted]
PHST- 2013/06/01 [aheadofprint]
AID - 1471-2261-13-38 [pii]
AID - 10.1186/1471-2261-13-38 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2013 Jun 1;13:38. doi: 10.1186/1471-2261-13-38.

PMID- 23725084
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1525-6065 (Electronic)
IS  - 1064-1955 (Linking)
VI  - 32
IP  - 2
DP  - 2013 May
TI  - Clinical characterization and outcomes of preeclampsia with normal angiogenic
      profile.
PG  - 189-201
LID - 10.3109/10641955.2013.784788 [doi]
AB  - Objective: To compare the clinical characteristics and outcomes of preeclamptic
      women presenting with a normal plasma angiogenic profile with those subjects who 
      are characterized by an abnormal angiogenic profile. Methods: This was a
      secondary analysis of a prospective cohort study in women presenting to
      obstetrical triage at <37 weeks of gestation and diagnosed with preeclampsia
      within 2 weeks of enrollment and in whom angiogenic factors (sFlt1 and PlGF)
      measurements were available. Patients were divided into two groups based on their
      circulating levels of these factors described as a ratio; the sFlt1/PlGF ratio,
      non-angiogenic preeclampsia (sFlt1/PlGF ratio <85) and angiogenic preeclampsia
      (sFlt1/PlGF ratio >/=85). The data are presented by sFlt1/PlGF category using
      median and quartile 1-quartile 3 for continuous variables and by frequency and
      sample sizes for categorical variables. Results: In our cohort, the patients with
      non-angiogenic preeclampsia (N = 46) were more obese [BMI: 35.2 (31.6, 38.7)
      versus 31.1 (28.0, 39.0), p = 0.04], more likely to have preexisting diabetes
      (21.7% versus 2.0%, p = 0.002) and presented at a later gestational age [35 (32, 
      37) versus 32 (29, 34) weeks, p < 0.0001] as compared with women with angiogenic 
      preeclampsia (N = 51). Women with non-angiogenic preeclampsia had no serious
      adverse outcomes (elevated liver function tests/low platelets: 0% versus 23.5%,
      abruption: 0% versus 9.8%, pulmonary edema: 0% versus 3.9%, eclampsia: 0% versus 
      2.0 %, small for gestational age: 0% versus 17.7% and fetal/neonatal death: 0%
      versus 5.9%) as compared with women with angiogenic preeclampsia. The rate of
      preterm delivery <34 weeks was 8.7% in non-angiogenic preeclampsia compared with 
      64.7% in angiogenic preeclampsia (p < 0.0001). Interestingly, delivery between 34
      and 37 weeks and resource utilization (hospital admission days) were similar in
      the two groups. Conclusion: In contrast to the angiogenic form, the
      non-angiogenic form of preeclampsia is characterized by little to no risk of
      preeclampsia-related adverse outcomes, other than iatrogenic prematurity.
      Incorporation of angiogenic biomarkers in the evaluation of preeclampsia may
      allow accurate and early identification of severe disease.
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology,
      Beth Israel Deaconess Medical Center and Harvard Medical School , Boston, MA ,
      USA.
FAU - Rana, Sarosh
AU  - Rana S
FAU - Schnettler, William T
AU  - Schnettler WT
FAU - Powe, Camille
AU  - Powe C
FAU - Wenger, Julia
AU  - Wenger J
FAU - Salahuddin, Saira
AU  - Salahuddin S
FAU - Cerdeira, Ana Sofia
AU  - Cerdeira AS
FAU - Verlohren, Stefan
AU  - Verlohren S
FAU - Perschel, Frank H
AU  - Perschel FH
FAU - Arany, Zoltan
AU  - Arany Z
FAU - Lim, Kee-Hak
AU  - Lim KH
FAU - Thadhani, Ravi
AU  - Thadhani R
FAU - Karumanchi, S Ananth
AU  - Karumanchi SA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hypertens Pregnancy
JT  - Hypertension in pregnancy : official journal of the International Society for the
      Study of Hypertension in Pregnancy
JID - 9421297
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.3109/10641955.2013.784788 [doi]
PST - ppublish
SO  - Hypertens Pregnancy. 2013 May;32(2):189-201. doi: 10.3109/10641955.2013.784788.

PMID- 23724977
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1651-2006 (Electronic)
IS  - 1401-7431 (Linking)
DP  - 2013 May 31
TI  - Does high sensitive CRP improve cardiovascular risk prediction in metabolic
      syndrome among the aged?
AB  - Objectives. To analyze whether an elevated level of high hsCRP has an additive
      effect on metabolic syndrome (MetS) in predicting future cardiovascular events
      (CVEs) as well as on all-cause mortality among the aged subjects. Design. A
      prospective, population-based study with a 9-year follow-up. The study population
      consisted of persons aged 64 and above in 1998-99 without vascular disease and
      CRP less than 10 mg/l at baseline (n = 733). Adjusted hazard ratios (HRs) and
      their 95% confidence intervals (CIs) for CVEs and all-cause mortality predicted
      by baseline MetS (defined by both International Diabetes Federation (IDF) and
      World Health Organization (WHO)) and hsCRP-level were estimated. Results. During 
      the 9-year follow-up, a total of 142 CVEs and 206 deaths occurred. After
      multivariable adjustment, no significant interactions were found between hsCRP
      and MetS in CVEs (IDF: p = 0.828; WHO: p = 0.572) or in all-cause mortality (IDF:
      p = 0.113; WHO: p = 0.374). HsCRP was not associated with the occurrence of CVEs 
      (IDF: HR = 1.10, 95% CI = 0.92-1.32, p = 0.281; WHO: HR = 1.10, 95% CI =
      0.93-1.32, p = 0.247) or with all-cause mortality (IDF: HR = 1.12, 95% CI =
      0.97-1.29, p = 0.134; WHO: HR = 1.11, 95% CI = 0.96-1.28, p = 0.146).
      Conclusions. It seems that hsCRP does not give any extra value in evaluation of
      CVE risk or all-cause mortality of older subjects with MetS.
AD  - Institute of Clinical Medicine, Family Medicine, University of Turku , Turku ,
      Finland.
FAU - Salminen, Marika
AU  - Salminen M
FAU - Kuoppamaki, Marikka
AU  - Kuoppamaki M
FAU - Vahlberg, Tero
AU  - Vahlberg T
FAU - Raiha, Ismo
AU  - Raiha I
FAU - Irjala, Kerttu
AU  - Irjala K
FAU - Kivela, Sirkka-Liisa
AU  - Kivela SL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Scand Cardiovasc J
JT  - Scandinavian cardiovascular journal : SCJ
JID - 9708377
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.3109/14017431.2013.798427 [doi]
PST - aheadofprint
SO  - Scand Cardiovasc J. 2013 May 31.

PMID- 23724973
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
DP  - 2013 Jun 3
TI  - Diagnostic advantage of S1 foramen-evoked H-reflex for S1 radiculopathy in
      patients with diabetes mellitus.
AB  - Abstract Hoffmann reflex to tibial nerve stimulation at the popliteal fossa
      (tibial H-reflex) is routinely used to evaluate S1 radiculopathy. However, it
      lacks sensitivity because other lesions along this reflex circuit affect the
      H-reflex bilaterally. This study was undertaken to determine whether the H-reflex
      evoked by stimulating proximally at the S1 foramen (S1 foramen H-reflex) could
      improve S1 root lesion evaluation sensitivity in patients with diabetes mellitus.
      A randomized paired study was designed to evaluate tibial and S1 foramen
      H-reflexes; bilateral H-M interval (HMI) and H-reflex latency were compared in 22
      diabetic patients with unilateral S1 radiculopathy. Other electrophysiological
      evaluations included standard tibial conduction studies, sural conduction
      studies, and needle electromyography (EMG). The S1 foramen H-reflex had a
      significantly higher sensitivity (91.0% 20 of 22) in evaluating S1 radiculopathy 
      than the conventional tibial H-reflex (63.6%, 14 of 22, P < 0.05). Bilateral
      tibial compound muscle action potential (CMAP) amplitudes were reduced in three
      patients, and sural sensory nerve action potential (SNAP) amplitudes decreased in
      seven patients. Needle EMG revealed denervation restricted to the paraspinal
      muscle and myotomes supplied by the S1 nerve root on the ipsilateral side in 18
      patients, and multiple lumbosacral nerve roots were involved bilaterally in the
      other 4 patients. Our results demonstrate that the S1 foramen H-reflex is a more 
      sensitive assessment of S1 compressive radiculopathy in patients with diabetes
      mellitus.
AD  - 1Department of Orthopedics, Huashan Hospital, Fudan University , Shanghai 200040 
      , China.
FAU - Zheng, Chaojun
AU  - Zheng C
FAU - Zhu, Yu
AU  - Zhu Y
FAU - Lu, Feizhou
AU  - Lu F
FAU - Xia, Xinlei
AU  - Xia X
FAU - Jin, Xiang
AU  - Jin X
FAU - Weber, Robert
AU  - Weber R
FAU - Jiang, Jianyuan
AU  - Jiang J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.3109/00207454.2013.801843 [doi]
PST - aheadofprint
SO  - Int J Neurosci. 2013 Jun 3.

PMID- 23724947
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1744-4160 (Electronic)
IS  - 1381-3455 (Linking)
DP  - 2013 May 31
TI  - Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis.
AB  - Abstract The close link between type 2 diabetes and excess body weight highlights
      the need to consider the effects on weight of different treatments used for
      correction of hyperglycaemia. Indeed, specific currently available diabetes
      therapies can cause weight gain, including insulin and its analogues,
      sulphonylureas, and thiazolidinediones, while others, such as metformin and the
      GLP-1 receptor agonists, can promote weight loss. Excess body weight in patients 
      with diabetes is largely due to expansion of adipose tissue, and these drugs
      could interfere with the mechanisms underlying the expansion and differentiation 
      of adipocyte precursors. Almost all anti-diabetes drugs could also potentially
      affect adipocyte metabolism directly, by modulating lipogenesis, lipolysis, and
      fat oxidation. This review will examine the available evidence for specific
      effects of various anti-diabetes drugs on adipose tissue development and function
      with the ultimate goal of increasing our understanding of how pharmacological
      agents can modulate energy balance and body fat.
AD  - Department of Emergency and Organ Transplantation, Section of Internal Medicine, 
      Endocrinology, Andrology, and Metabolic Diseases, University of Bari "Aldo Moro" 
      , Bari , Italy and.
FAU - Cignarelli, A
AU  - Cignarelli A
FAU - Giorgino, F
AU  - Giorgino F
FAU - Vettor, R
AU  - Vettor R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Arch Physiol Biochem
JT  - Archives of physiology and biochemistry
JID - 9510153
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
AID - 10.3109/13813455.2013.796996 [doi]
PST - aheadofprint
SO  - Arch Physiol Biochem. 2013 May 31.

PMID- 23724887
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1715-5312 (Print)
VI  - 38
IP  - 6
DP  - 2013 Jun
TI  - Consumption of sucrose and high-fructose corn syrup does not increase liver fat
      or ectopic fat deposition in muscles.
PG  - 681-8
LID - 10.1139/apnm-2012-0322 [doi]
AB  - It has been postulated that fructose-induced triglyceride synthesis is augmented 
      when accompanied by glucose. Chronic elevations could lead to excess fat
      accumulation in the liver and ectopic fat deposition in muscles, which in turn
      could contribute to the induction of abnormalities in glucose homeostasis,
      insulin resistance, and the subsequent development of type 2 diabetes. Our
      objective was to evaluate the effect of the addition of commonly consumed
      fructose- and (or) glucose-containing sugars in the usual diet on liver fat
      content and intramuscular adipose tissue. For 10 weeks, 64 individuals (mean age,
      42.16 +/- 11.66 years) consumed low-fat milk sweetened with either high-fructose 
      corn syrup (HFCS) or sucrose; the added sugar matched consumption levels of
      fructose in the 25th, 50th, and 90th percentiles of the population. The fat
      content of the liver was measured with unenhanced computed tomography imaging,
      and the fat content of muscle was assessed with magnetic resonance imaging. When 
      the 6 HFCS and sucrose groups were averaged, there was no change over the course 
      of 10 weeks in the fat content of the liver (13.32% +/- 10.49% vs. 13.21% +/-
      10.75%; p > 0.05), vastus lateralis muscle (3.07 +/- 0.74 g per 100 mL vs. 3.15
      +/- 0.84 g per 100 mL; p > 0.05), or gluteus maximus muscle (4.08 +/- 1.50 g per 
      100 mL vs. 4.24 +/- 1.42 g per 100 mL; p > 0.05). Group assignment did not affect
      the result (interaction > 0.05). These data suggest that when fructose is
      consumed as part of a typical diet in normally consumed sweeteners, such as
      sucrose or HFCS, ectopic fat storage in the liver or muscles is not promoted.
AD  - a School of Medicine, University of Central Florida, Orlando, FL 32819, USA.
FAU - Bravo, Stephen
AU  - Bravo S
FAU - Lowndes, Joshua
AU  - Lowndes J
FAU - Sinnett, Stephanie
AU  - Sinnett S
FAU - Yu, Zhiping
AU  - Yu Z
FAU - Rippe, James
AU  - Rippe J
LA  - eng
PT  - Journal Article
DEP - 20130212
PL  - Canada
TA  - Appl Physiol Nutr Metab
JT  - Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition 
      et metabolisme
JID - 101264333
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PHST- 2013/02/12 [aheadofprint]
AID - 10.1139/apnm-2012-0322 [doi]
PST - ppublish
SO  - Appl Physiol Nutr Metab. 2013 Jun;38(6):681-8. doi: 10.1139/apnm-2012-0322. Epub 
      2013 Feb 12.

PMID- 23724567
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - Where's the fat?
PG  - 72-3
FAU - Curry, Andrew
AU  - Curry A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):72-3.

PMID- 23724566
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - Leading lady.
PG  - 48-50
FAU - Wahowiak, Lindsey
AU  - Wahowiak L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):48-50.

PMID- 23724565
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - The diabetes belt.
PG  - 42-7
FAU - Wahowiak, Lindsey
AU  - Wahowiak L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):42-7.

PMID- 23724564
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - Packing for camp.
PG  - 26-9
FAU - Wahowiak, Lindsey
AU  - Wahowiak L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 May;66(5):26-9.

PMID- 23724439
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 1565-4753 (Print)
IS  - 1565-4753 (Linking)
VI  - 10
IP  - 3
DP  - 2013 Mar-Apr
TI  - Bone health in children and adolescents: risk factors for low bone density.
PG  - 318-35
AB  - Osteoporosis is a common disease that is characterized by low bone mineral
      density (BMD). Decreased BMD is associated with increased fracture risk. In
      adults, normal BMD results from the balance between accrual of peak bone mass
      (PBM) at the end of adolescence, and subsequent bone loss with age. Although
      environmental factors play a role, hereditary factors are the major contributors 
      (up to 80%) to the variability in PBM. This review examines the effects of
      genetics, physical activity and immobilization, smoking, chronic diseases and
      medications, vitamin D, calcium, and various other dietary factors on bone
      integrity in children, adolescents, and adults.
AD  - Center for Endocrinology, Diabetes, and Metabolism, Children's Hospital Los
      Angeles, Keck School of Medicine of USC, Los Angeles, CA 90027 USA.
      dpisit@chla.usc.edu
FAU - Pitukcheewanont, Pisit
AU  - Pitukcheewanont P
FAU - Austin, Juliana
AU  - Austin J
FAU - Chen, Paul
AU  - Chen P
FAU - Punyasavatsut, Natavut
AU  - Punyasavatsut N
LA  - eng
PT  - Journal Article
PL  - Israel
TA  - Pediatr Endocrinol Rev
JT  - Pediatric endocrinology reviews : PER
JID - 101202124
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Pediatr Endocrinol Rev. 2013 Mar-Apr;10(3):318-35.

PMID- 23724434
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 1565-4753 (Print)
IS  - 1565-4753 (Linking)
VI  - 10
IP  - 3
DP  - 2013 Mar-Apr
TI  - If one daily injection of IGF-I has the same growth-promoting effect as 2
      injections per day, why continue to give two injections?
PG  - 277-9
AB  - Comparison of the growth velocity of 1 vs. 2 IGF-I injections per day in patients
      with Laron Syndrome (primary GH insensitivity) revealed similar effects.
AD  - Endocrinology and Diabetes Research Unit, WHO Collaborating Center for the Study 
      of Diabetes in Youth, Schneider Children's Medical Center of Israel (SCMCI) Rabin
      Campus, Sackler School of Medicine, Tel Aviv University, Israel.
      laronz@clalit.org.il
FAU - Laron, Zvi
AU  - Laron Z
LA  - eng
PT  - Journal Article
PL  - Israel
TA  - Pediatr Endocrinol Rev
JT  - Pediatric endocrinology reviews : PER
JID - 101202124
SB  - IM
EDAT- 2013/06/04 06:00
MHDA- 2013/06/04 06:00
CRDT- 2013/06/04 06:00
PST - ppublish
SO  - Pediatr Endocrinol Rev. 2013 Mar-Apr;10(3):277-9.

PMID- 23724409
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 49
IP  - 5
DP  - 2013 May
TI  - Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
PG  - 289-301
LID - 10.1358/dot.2013.49.5.1964714 [doi]
AB  - Dapagliflozin is a selective, competitive inhibitor of sodium/glucose
      cotransporter 2 (SGLT2) acting to block reabsorption of filtered glucose in the
      kidney. Independent of pancreatic beta cell function or the modulation of insulin
      sensitivity, this novel treatment strategy promotes glucosuria and direct
      lowering of plasma glucose concentrations. Dapagliflozin has been approved for
      the treatment of type 2 diabetes in the European Union; however, the United
      States Food and Drug Administration rejected the approval of dapagliflozin based 
      on lack of clinical data to effectively assess the benefit-to-risk profile. This 
      manuscript will highlight the physiology of renal glucose regulation and
      reabsorption, briefly outline the pharmacology of dapagliflozin and discuss the
      results of completed clinical trials as well as the current status of the drug.
CI  - Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.
AD  - Washington State University, Spokane, Washington, USA. kdemaris@wsu.edu.
FAU - Demaris, K M
AU  - Demaris KM
FAU - White, J R
AU  - White JR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
SB  - IM
OTO - NOTNLM
OT  - BMS-512148
OT  - Dapagliflozin
OT  - SGLT2 inhibitor
OT  - Sodium/glucose cotransporter
OT  - Type 2 diabetes
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 1964714 [pii]
AID - 10.1358/dot.2013.49.5.1964714 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2013 May;49(5):289-301. doi: 10.1358/dot.2013.49.5.1964714.

PMID- 23724189
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130604
IS  - 2008-2142 (Print)
IS  - 2008-2142 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Apr
TI  - GCK Mutation in a Child with Maturity Onset Diabetes of the Young, Type 2.
PG  - 226-8
AB  - BACKGROUND: Maturity onset diabetes of the young type 2 (MODY) is an inherited
      disorder due to mutations in glucokinase (GCK) gene, which lead to mild fasting
      hyperglycemia. CASE PRESENTATION: Herein an otherwise healthy 9-year old boy with
      hyperglycemia is presented in whom the diagnosis of MODY2 was suspected. Genetic 
      studies showed heterozygous inactivating GCK gene mutation in exon 8 (c.1010delA)
      in this patient. The same mutation was found in his father as well. The patient
      received some dietary advices without any medication. CONCLUSION: The
      identification of GCK mutation and diagnosis of MODY2 helps the clinicians to
      predict the disease course, prognosis and to exclude other types of diabetes.
AD  - Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Noorian, Shahab
AU  - Noorian S
FAU - Sayarifard, Fatemeh
AU  - Sayarifard F
FAU - Farhadi, Elham
AU  - Farhadi E
FAU - Barbetti, Fabrizio
AU  - Barbetti F
FAU - Rezaei, Nima
AU  - Rezaei N
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Pediatr
JT  - Iranian journal of pediatrics
JID - 101274724
PMC - PMC3663319
OID - NLM: PMC3663319
OTO - NOTNLM
OT  - Diabetes
OT  - Fasting Hyperglycemia
OT  - GCK
OT  - Maturity-onset Diabetes
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
PHST- 2012/04/11 [received]
PHST- 2012/12/29 [accepted]
PST - ppublish
SO  - Iran J Pediatr. 2013 Apr;23(2):226-8.

PMID- 23724167
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130604
IS  - 1943-8141 (Electronic)
VI  - 5
IP  - 4
DP  - 2013
TI  - Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl
      sulfate polyacrylamide gel electrophoresis.
PG  - 441-9
AB  - Sodium/glucose co-transporter 1 (SGLT1), which actively and energy-dependently
      uptakes glucose, plays critical roles in the development of various diseases
      including diabetes mellitus and cancer, and has been viewed as a promising
      therapeutic target for these diseases. Protein-protein interaction with EGFR has 
      been shown to regulate the expression and activity of SGLT1. Exogenous expression
      of SGLT1 is one of the essential approaches to characterize its functions;
      however, exogenously expressed SGLT1 is not firmly detectable by Western blot at 
      its calculated molecular weight, which creates a hurdle for further understanding
      the molecular events by which SGLT1 is regulated. In this study, we demonstrated 
      that exogenous SGLT1 functions in glucose-uptake normally but is consistently
      detected near the interface between stacking gel and running gel rather than at
      the calculated molecular weight in Western blot analysis, suggesting that the
      overexpressed SGLT1 forms SDS-resistant aggregates, which cannot be denatured and
      effectively separated on SDS-PAGE. Co-expression of EGFR enhances both the
      glucose-uptake activity and protein level of the SGLT1. However, fusion with Flag
      or HA tag at its carboxy- but not its amino-terminus abolished the glucose-uptake
      activity of exogenous SGLT1 without affecting its protein level. Furthermore, the
      solubility of SGLT1 aggregates was not affected by other detergents but was
      partially improved by inhibition of o-link glycosylation. These findings
      suggested exogenous overexpression of SGLT1 can function normally but may not be 
      consistently detectable at its formula weight due to its gel-shift behavior by
      forming the SDS-resistant aggregates.
AD  - Center for Molecular Medicine, China Medical University Hospital Taichung 404,
      Taiwan ; Graduate Institute of Cancer Biology, China Medical University Taichung 
      404, Taiwan ; the Ph.D. program for Cancer Biology and Drug Discovery, China
      Medical University Taichung 404, Taiwan ; Department of Biotechnology, Asia
      University Taichung 413, Taiwan.
FAU - Huang, Wei-Chien
AU  - Huang WC
FAU - Hsu, Sheng-Chie
AU  - Hsu SC
FAU - Huang, Shyh-Jer
AU  - Huang SJ
FAU - Chen, Yun-Ju
AU  - Chen YJ
FAU - Hsiao, Yu-Chun
AU  - Hsiao YC
FAU - Zhang, Weihua
AU  - Zhang W
FAU - Fidler, Isaiah J
AU  - Fidler IJ
FAU - Hung, Mien-Chie
AU  - Hung MC
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC3665917
OID - NLM: PMC3665917
OTO - NOTNLM
OT  - Sodium/glucose cotranspoter 1
OT  - epidermal growth factor receptor
OT  - glucose uptake
OT  - o-link glycosylation
OT  - protein aggregation
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/01 [received]
PHST- 2013/05/15 [accepted]
PHST- 2013/05/24 [epublish]
PST - epublish
SO  - Am J Transl Res. 2013 May 24;5(4):441-9. Print 2013.

PMID- 23724162
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130604
IS  - 1943-8141 (Electronic)
VI  - 5
IP  - 4
DP  - 2013
TI  - Novel autoantigens in type 1 diabetes.
PG  - 379-92
AB  - Type 1 diabetes mellitus (T1DM) is characterized by recognition of beta cell
      proteins as self-antigens, called autoantigens (AAgs), by patients' own CD4+ and 
      CD8+ T cells and/or the products of self-reactive B cells, called autoantibodies.
      These AAgs are divided into two categories on the basis of beta-cell-specificity.
      The list of the targets associated with beta cell-specific AAgs is continuously
      growing. Many T1DM-associated AAgs are well characterized and have important
      clinical applications for disease prediction, diagnosis, and antigen-specific
      tolerance immunotherapy. Identification of T1DM-associated AAgs provides insight 
      into the pathogenesis of T1DM and to understanding the clinical aspects of the
      disease. Since many excellent reviews have covered the previously identified
      T1DM-associated AAgs exhaustedly, here we only focus on several recently
      discovered T1DM-AAgs (PDX1, ZnT8, CHGA, and IAAP).
AD  - Department of Medicine, University of Florida College of Medicine Gainesville,
      Florida 32610, USA.
FAU - Han, Shuhong
AU  - Han S
FAU - Donelan, William
AU  - Donelan W
FAU - Wang, Hai
AU  - Wang H
FAU - Reeves, Westley
AU  - Reeves W
FAU - Yang, Li-Jun
AU  - Yang LJ
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC3665912
OID - NLM: PMC3665912
OTO - NOTNLM
OT  - CHGA
OT  - IAPP
OT  - Pdx1
OT  - Type 1 diabetes
OT  - ZnT8
OT  - autoantibodies
OT  - autoantigen
OT  - immune tolerance
OT  - immunotherapy
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/05 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/05/24 [epublish]
PST - epublish
SO  - Am J Transl Res. 2013 May 24;5(4):379-92. Print 2013.

PMID- 23724160
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130604
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 6
IP  - 5
DP  - 2013
TI  - Perioperative management of a patient with Rett syndrome.
PG  - 393-403
AB  - Rett syndrome is a neurodevelopmental disorder that results from mutations in the
      genes encoding methyl-cytosine-guanosine binding protein 2 located on the X
      chromosome. Clinical features of central nervous system involvement include
      regression of developmental milestones in the late infant and early toddler
      stages, mental retardation, seizures and other electroencephalographic
      abnormalities. Given the invariable association of this degenerative disorder
      with orthopedic deformities including scoliosis, patients with Rett syndrome may 
      present for anesthetic care during various surgical procedures. The complexity of
      the end-organ involvement, specifically the progressive nature of respiratory and
      cardiac involvement, makes the anesthetic care of such patients challenging.
      Specific perioperative concerns include potential difficulties with airway
      management, an underlying seizure disorder, an increased sensitivity to
      anesthetic agents, prolonged QT syndrome, and diabetes mellitus. We present an
      11-year-old girl with Rett syndrome who required anesthetic care for posterior
      spinal fusion. Previous reports of anesthetic care for these patients are
      reviewed, the end-organ involvement discussed, and options for anesthetic care
      presented.
AD  - Departments of Anesthesiology & Pain Medicine, Nationwide Children's Hospital
      Columbus, Ohio.
FAU - Kako, Hiromi
AU  - Kako H
FAU - Martin, David P
AU  - Martin DP
FAU - Cartabuke, Richard
AU  - Cartabuke R
FAU - Beebe, Allan
AU  - Beebe A
FAU - Klamar, Jan
AU  - Klamar J
FAU - Tobias, Joseph D
AU  - Tobias JD
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC3664008
OID - NLM: PMC3664008
OTO - NOTNLM
OT  - Rett syndrome
OT  - diabetes mellitus
OT  - long QT syndrome
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/26 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/22 [epublish]
PST - epublish
SO  - Int J Clin Exp Med. 2013 May 22;6(5):393-403. Print 2013.

PMID- 23724078
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - The Evolutionary Portrait of Metazoan NAD Salvage.
PG  - e64674
LID - 10.1371/journal.pone.0064674 [doi]
AB  - Nicotinamide Adenine Dinucleotide (NAD) levels are essential for cellular
      homeostasis and survival. Main sources of intracellular NAD are the salvage
      pathways from nicotinamide, where Nicotinamide phosphoribosyltransferases
      (NAMPTs) and Nicotinamidases (PNCs) have a key role. NAMPTs and PNCs are
      important in aging, infection and disease conditions such as diabetes and cancer.
      These enzymes have been considered redundant since either one or the other exists
      in each individual genome. The co-occurrence of NAMPT and PNC was only recently
      detected in invertebrates though no structural or functional characterization
      exists for them. Here, using expression and evolutionary analysis combined with
      homology modeling and protein-ligand docking, we show that both genes are
      expressed simultaneously in key species of major invertebrate branches and
      emphasize sequence and structural conservation patterns in metazoan NAMPT and PNC
      homologues. The results anticipate that NAMPTs and PNCs are simultaneously
      active, raising the possibility that NAD salvage pathways are not redundant as
      both are maintained to fulfill the requirement for NAD production in some
      species.
AD  - IPATIMUP-Institute of Molecular Pathology and Immunology of the University of
      Porto, Porto, Portugal ; Faculty of Sciences, University of Porto, Porto,
      Portugal.
FAU - Carneiro, Joao
AU  - Carneiro J
FAU - Duarte-Pereira, Sara
AU  - Duarte-Pereira S
FAU - Azevedo, Luisa
AU  - Azevedo L
FAU - Castro, L Filipe C
AU  - Castro LF
FAU - Aguiar, Paulo
AU  - Aguiar P
FAU - Moreira, Irina S
AU  - Moreira IS
FAU - Amorim, Antonio
AU  - Amorim A
FAU - Silva, Raquel M
AU  - Silva RM
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3665594
OID - NLM: PMC3665594
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/03 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/05/28 [epublish]
AID - 10.1371/journal.pone.0064674 [doi]
AID - PONE-D-13-05957 [pii]
PST - epublish
SO  - PLoS One. 2013 May 28;8(5):e64674. doi: 10.1371/journal.pone.0064674. Print 2013.

PMID- 23724063
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Metformin vs Insulin in the Management of Gestational Diabetes: A Meta-Analysis.
PG  - e64585
LID - 10.1371/journal.pone.0064585 [doi]
AB  - BACKGROUND: Nowadays, there have been increasing studies comparing metformin with
      insulin. But the use of metformin in pregnant women is still controversial,
      therefore, we aim to examine the efficiency and safety of metformin by conducting
      a meta-analysis of randomized controlled trials (RCTs) comparing the effects of
      metformin with insulin on glycemic control, maternal and neonatal outcomes in
      gestational diabetes mellitus (GDM). METHODS: We used the key words "gestational 
      diabetes" in combination with "metformin" and searched the databases including
      Pubmed, the Cochrane Library, Web of knowledge, and Clinical Trial Registries. A 
      random-effects model was used to compute the summary risk estimates. RESULTS:
      Meta-analysis of 5 RCTs involving 1270 participants detected that average weight 
      gains after enrollment were much lower in the metformin group (n = 1006, P =
      0.003, SMD = -0.47, 95%CI [-0.77 to -0.16]); average gestational ages at delivery
      were significantly lower in the metformin group (n = 1270, P = 0.02, SMD = -0.14,
      95%CI [-0.25 to -0.03]); incidence of preterm birth was significantly more in
      metformin group (n = 1110, P = 0.01, OR = 1.74, 95%CI [1.13 to 2.68]); the
      incidence of pregnancy induced hypertension was significantly less in the
      metformin group (n = 1110, P = 0.02, OR = 0.52, 95%CI [0.30 to 0.90]). The
      fasting blood sugar levels of OGTT were significantly lower in the metformin only
      group than in the supplemental insulin group (n = 478, P = 0.0006, SMD = -0.83,
      95%CI [-1.31 to -0.36]). CONCLUSIONS: Metformin is comparable with insulin in
      glycemic control and neonatal outcomes. It might be more suitable for women with 
      mild GDM. This meta-analysis also provides some significant benefits and risks of
      the use of metformin in GDM and help to inform further development of management 
      guidelines.
AD  - Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College,
      Huazhong University of Science and Technology, Wuhan, Hubei, China.
FAU - Gui, Juan
AU  - Gui J
FAU - Liu, Qing
AU  - Liu Q
FAU - Feng, Ling
AU  - Feng L
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3664585
OID - NLM: PMC3664585
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/28 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/05/27 [epublish]
AID - 10.1371/journal.pone.0064585 [doi]
AID - PONE-D-13-00617 [pii]
PST - epublish
SO  - PLoS One. 2013 May 27;8(5):e64585. doi: 10.1371/journal.pone.0064585. Print 2013.

PMID- 23724055
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Electrofusion of mesenchymal stem cells and islet cells for diabetes therapy: a
      rat model.
PG  - e64499
LID - 10.1371/journal.pone.0064499 [doi]
AB  - Islet transplantation is a minimally invasive treatment for severe diabetes.
      However, it often requires multiple donors to accomplish insulin-independence and
      the long-term results are not yet satisfying. Therefore, novel ways to overcome
      these problems have been explored. Isolated islets are fragile and susceptible to
      pro-apoptotic factors and poorly proliferative. In contrast, mesenchymal stem
      cells (MSCs) are highly proliferative, anti-apoptotic and pluripotent to
      differentiate toward various cell types, promote angiogenesis and modulate
      inflammation, thereby studied as an enhancer of islet function and engraftment.
      Electrofusion is an efficient method of cell fusion and nuclear reprogramming
      occurs in hybrid cells between different cell types. Therefore, we hypothesized
      that electrofusion between MSC and islet cells may yield robust islet cells for
      diabetes therapy. We establish a method of electrofusion between dispersed islet 
      cells and MSCs in rats. The fusion cells maintained glucose-responsive insulin
      release for 20 days in vitro. Renal subcapsular transplantation of fusion cells
      prepared from suboptimal islet mass (1,000 islets) that did not correct
      hyperglycemia even if co-transplanted with MSCs, caused slow but consistent
      lowering of blood glucose with significant weight gain within the observation
      period in streptozotocin-induced diabetic rats. In the fusion cells between rat
      islet cells and mouse MSCs, RT-PCR showed new expression of both rat MSC-related 
      genes and mouse beta-cell-related genes, indicating bidirectional reprogramming
      of both beta-cell and MSCs nuclei. Moreover, decreased caspase3 expression and
      new expression of Ki-67 in the islet cell nuclei suggested alleviated apoptosis
      and gain of proliferative capability, respectively. These results show that
      electrofusion between MSCs and islet cells yield special cells with beta-cell
      function and robustness of MSCs and seems feasible for novel therapeutic strategy
      for diabetes mellitus.
AD  - Department of Organ Reconstruction, Institute for Frontier Medical Sciences,
      Kyoto University, Kyoto, Japan.
FAU - Yanai, Goichi
AU  - Yanai G
FAU - Hayashi, Takashi
AU  - Hayashi T
FAU - Zhi, Qi
AU  - Zhi Q
FAU - Yang, Kai-Chiang
AU  - Yang KC
FAU - Shirouzu, Yasumasa
AU  - Shirouzu Y
FAU - Shimabukuro, Takashi
AU  - Shimabukuro T
FAU - Hiura, Akihito
AU  - Hiura A
FAU - Inoue, Kazutomo
AU  - Inoue K
FAU - Sumi, Shoichiro
AU  - Sumi S
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3665804
OID - NLM: PMC3665804
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/16 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/05/28 [epublish]
AID - 10.1371/journal.pone.0064499 [doi]
AID - PONE-D-12-31829 [pii]
PST - epublish
SO  - PLoS One. 2013 May 28;8(5):e64499. doi: 10.1371/journal.pone.0064499. Print 2013.

PMID- 23723955
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130604
IS  - 1874-3579 (Electronic)
VI  - 7
DP  - 2013
TI  - Tropism Analysis of Two Coxsackie B5 Strains Reveals Virus Growth in Human
      Primary Pancreatic Islets but not in Exocrine Cell Clusters In Vitro.
PG  - 49-56
LID - 10.2174/1874357901307010049 [doi]
AB  - Human Enteroviruses (HEVs) have been implicated in human pancreatic diseases such
      as pancreatitis and type 1 diabetes (T1D). Human studies are sparse or
      inconclusive and our aim was to investigate the tropism of two strains of
      Coxsackie B virus 5 (CBV-5) in vitro to primary human pancreatic cells. Virus
      replication was measured with TCID50 titrations of aliquots of the culture medium
      at different time points post inoculation. The presence of virus particles or
      virus proteins within the pancreatic cells was studied with immunohistochemistry 
      (IHC) and electron microscopy (EM). None of the strains replicated in the human
      exocrine cell clusters, in contrast, both strains replicated in the endocrine
      islets of Langerhans. Virus particles were found exclusively in the endocrine
      cells, often in close association with insulin granules. In conclusion, CBV-5 can
      replicate in human endocrine cells but not in human exocrine cells, thus they
      might not be the cause of pancreatitis in humans. The association of virus with
      insulin granules might reflect the use of these as replication scaffolds.
AD  - Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala
      University, Uppsala, Sweden.
FAU - Hodik, M
AU  - Hodik M
FAU - Lukinius, A
AU  - Lukinius A
FAU - Korsgren, O
AU  - Korsgren O
FAU - Frisk, G
AU  - Frisk G
LA  - eng
PT  - Journal Article
DEP - 20130405
PL  - Netherlands
TA  - Open Virol J
JT  - The open virology journal
JID - 101480213
PMC - PMC3657700
OID - NLM: PMC3657700
OTO - NOTNLM
OT  - Coxsackie B virus
OT  - human enterovirus
OT  - human enterovirus capsid protein 1
OT  - human islets of langerhans
OT  - pancreas
OT  - pancreatitis
OT  - type 1 diabetes.
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
PHST- 2013 [ppublish]
PHST- 2012/07/08 [received]
PHST- 2012/12/14 [revised]
PHST- 2012/12/17 [accepted]
PHST- 2013/04/05 [epublish]
AID - 10.2174/1874357901307010049 [doi]
AID - TOVJ-7-49 [pii]
PST - epublish
SO  - Open Virol J. 2013 Apr 5;7:49-56. doi: 10.2174/1874357901307010049. Print 2013.

PMID- 23723691
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130604
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 7
DP  - 2013
TI  - Health locus of control and the sense of self-efficacy in patients with systolic 
      heart failure: a pilot study.
PG  - 337-43
LID - 10.2147/PPA.S41863 [doi]
AB  - BACKGROUND: Treatment of heart failure (HF) requires the lifelong adherence to
      medical self-care regimes. The objective of this study was to examine
      health-control beliefs and the sense of self-efficacy (psychological features
      particularly important for efficient compliance among patients suffering from
      chronic diseases) in patients with systolic HF in relation to clinical status and
      depressive symptoms. SUBJECTS AND METHODS: Sixty-six consecutive patients with
      chronic systolic HF, hospitalized in the Centre for Heart Diseases, Military
      Hospital (94% men, age: 61 +/- 11 years, ischemic etiology: 63%, left ventricular
      ejection fraction: 32% +/- 12%), filled in (during their hospital stay): (1) the 
      Multidimensional Health Locus of Control Scale measuring three possible
      localizations of health control: "internality" (ie, the belief that health status
      depends only on personal decisions and behaviors); "powerful others externality" 
      ([PHLC subscale] ie, the conviction that health depends on "powerful people" such
      as doctors, family members, close friends), and "chance externality" (ie, belief 
      that health status is determined by chance, fate, or luck), and (2) the
      Generalized Self-Efficacy Scale. The results obtained by HF patients were
      compared to those reported by patients with other chronic diseases and healthy
      subjects. RESULTS: In patients with HF, internality was similar to values
      obtained by patients with diabetes, men after myocardial infarction, and women
      after mastectomy; and was lower than in healthy subjects. Powerful others
      externality was more pronounced in patients with HF as compared to other groups
      of patients and healthy people. Only women after mastectomy had higher scores of 
      PHLC. In patients with HF, chance externality was similar to values reported in
      patients with renal failure, men after myocardial infarction, and women after
      mastectomy; and was less pronounced than in healthy subjects. The majority (77%) 
      of patients with HF were characterized by a high sense of self-efficacy (>the 7th
      sten score), having the highest sense of self-efficacy among patients with other 
      chronic diseases and healthy controls. Higher internality was accompanied by
      higher sense of self-efficacy (P < 0.05) in patients with HF. Subjects with high 
      plasma N-terminal pro-B type natriuretic peptide (reflecting the disease
      severity) had the least pronounced internality (P < 0.05), whereas those with
      more advance depressive symptoms had the lower sense of self-efficacy (P = <
      0.05). CONCLUSION: Patients with systolic HF demonstrate a conviction that other 
      people, including physicians, have a large influence on their health status, and 
      at the same time are aware of the efficacy of their own activities in coping with
      the disease. Such a configuration of psychological features seems to be
      beneficial in the context of the developing modern strategies, which due to the
      improved cooperation between the physicians and the patients could enhance the
      compliance in patients with HF.
AD  - Centre for Heart Diseases, Department of Cardiology, Military Hospital, Wroclaw, 
      Poland ; Department of Heart Diseases, Wroclaw Medical University, Wroclaw
      Poland.
FAU - Rydlewska, Agnieszka
AU  - Rydlewska A
FAU - Krzysztofik, Justyna
AU  - Krzysztofik J
FAU - Libergal, Julia
AU  - Libergal J
FAU - Rybak, Agata
AU  - Rybak A
FAU - Banasiak, Waldemar
AU  - Banasiak W
FAU - Ponikowski, Piotr
AU  - Ponikowski P
FAU - Jankowska, Ewa A
AU  - Jankowska EA
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC3666548
OID - NLM: PMC3666548
OTO - NOTNLM
OT  - compliance
OT  - depressive symptoms
OT  - health locus of control
OT  - heart failure
OT  - self-efficacy
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/19 [epublish]
AID - 10.2147/PPA.S41863 [doi]
AID - ppa-7-337 [pii]
PST - epublish
SO  - Patient Prefer Adherence. 2013 Apr 19;7:337-43. doi: 10.2147/PPA.S41863. Print
      2013.

PMID- 23723615
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130604
IS  - 0974-2700 (Print)
IS  - 0974-2700 (Linking)
VI  - 6
IP  - 2
DP  - 2013 Apr
TI  - Significance of urinary incontinence, age, and consciousness level on arrival
      among patients with stroke.
PG  - 83-6
LID - 10.4103/0974-2700.110750 [doi]
AB  - PURPOSE: We retrospectively investigated prognostic factors including urinary
      incontinence on arrival among the patients with stroke. MATERIALS AND METHODS: A 
      medical chart review was retrospectively performed for patients with stoke
      admitted between January 2010 and December 2010 in Ken-o Tokorozawa Hospital
      which had stroke care unit. The subjects were divided into a control group
      (functional outcome with modified Rankin scale (mRS) 0-3 at 3 months) and a poor 
      group (severe disability or death, mRS 4-6). RESULTS: There were 160 cases that
      had favorable outcome (the Control group) and 77 cases that had poor outcome (the
      Poor group). There were no significant differences between the two groups
      concerning the sex ratio, systolic blood pressure, heart rate, temperature, ratio
      of diabetes mellitus. However, the average age, ratio of hemorrhagic stroke,
      ratio of patients with a previous stroke, ratio of urinary incontinence upon
      admission, and duration of hospitalization in the Poor group was significantly
      higher than in the Control group. The Glasgow Coma Scale upon admission and ratio
      of hypertension in the Poor group were significantly lower than that in the
      Control group. Using a multiple logistic regression analysis, urinary
      incontinence (odds ratio, 3.17; 95% confidence interval, 1.45-6.93; P = 0.002),
      age (odds ratio, 1.04; 95% confidence interval, 1.01-1.07; P = 0.003) and Glasgow
      Coma Scale (odds ratio, 0.87; 95% confidence interval, 0.78-0.97; P = 0.01) were 
      found to be factors independently associated with a poor outcome. CONCLUSION:
      Among the patients with strokes, the presence of urinary incontinence on arrival,
      the old age, and the level of consciousness are important prognostic factors.
      Physicians should therefore check for these factors when evaluating a patient who
      has experienced a stroke or suspected stroke.
AD  - Department of Emergency and Disaster Medicine, Juntendo University, Tokyo, Japan.
FAU - Yanagawa, Youichi
AU  - Yanagawa Y
FAU - Yoshihara, Tomoyuki
AU  - Yoshihara T
FAU - Kato, Hiroshi
AU  - Kato H
FAU - Iba, Toshiaki
AU  - Iba T
FAU - Tanaka, Hiroshi
AU  - Tanaka H
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Emerg Trauma Shock
JT  - Journal of emergencies, trauma, and shock
JID - 101493921
PMC - PMC3665076
OID - NLM: PMC3665076
OTO - NOTNLM
OT  - Outcome
OT  - stroke
OT  - urinary incontinence
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
PHST- 2012/04/09 [received]
PHST- 2012/07/05 [accepted]
AID - 10.4103/0974-2700.110750 [doi]
AID - JETS-6-83 [pii]
PST - ppublish
SO  - J Emerg Trauma Shock. 2013 Apr;6(2):83-6. doi: 10.4103/0974-2700.110750.

PMID- 23723485
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130604
IS  - 1998-3611 (Electronic)
IS  - 0019-5154 (Linking)
VI  - 58
IP  - 3
DP  - 2013 May
TI  - Skin tags: a link between lesional mast cell count/tryptase expression and
      obesity and dyslipidemia.
PG  - 240
LID - 10.4103/0019-5154.110843 [doi]
AB  - BACKGROUND: The etiology of skin tags (STs) is not fully understood. A relation
      to diabetes mellitus and obesity was suggested. Few studies of possible mast
      cells (MCs) involvement were reported. Tyrptase is a mast cell mediator and a
      potent fibroblast growth factor. It may provide a molecular link between mast
      cell activation and fibrosis. AIMS: The aim was to assess clinical and laboratory
      findings in patients with STs, and the possible link between obesity,
      dyslipidemia, and lesional MC count/tryptase expression. MATERIALS AND METHODS: A
      total of 20 patients with STs were subjected to clinical examination, estimation 
      of body mass index (BMI), fasting blood glucose (FBG), postprandial blood glucose
      (PPBG), serum cholesterol and triglycerides, abdominal ultrasound for fatty liver
      assessment, in addition to study of MCs through staining for MC tryptase in two
      skin biopsies; lesional and nonlesional (control). RESULTS: All patients showed
      abnormally high BMI and hypertriglyceridemia, with abnormal sonographic pattern
      in 15 patients (75%). STs number positively correlated with the age of patients. 
      STs showed significantly higher MC counts and tryptase expression, compared with 
      control skin (P < 0.001), with no correlation of the STs number or MC count with 
      BMI, FBG, PPBG or serum cholesterol. Obese patients showed a significantly higher
      MC count than overweight and there was a positive correlation between MC count
      and serum triglycerides. Axilla and under breast STs showed a higher MC count
      compared with other sites. CONCLUSIONS: STs seem to be related to obesity and
      hypertriglyceridemia. MCs with their tryptase are possibly involved in
      pathogenesis of STs. MC count is related to the associated factors; obesity and
      serum triglycerides. MC tryptase expression is a reliable method for accurate
      tissue MC counting.
AD  - Department of Dermatology, Venereology and Andrology, Cairo, Egypt.
FAU - Salem, Samar Abdallah M
AU  - Salem SA
FAU - Attia, Enas As
AU  - Attia EA
FAU - Osman, Wesam M
AU  - Osman WM
FAU - El Gendy, Marwa A
AU  - El Gendy MA
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Dermatol
JT  - Indian journal of dermatology
JID - 0370750
PMC - PMC3667297
OID - NLM: PMC3667297
OTO - NOTNLM
OT  - Dyslipidemia
OT  - mast cell
OT  - obesity
OT  - skin tag
OT  - tryptase
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
AID - 10.4103/0019-5154.110843 [doi]
AID - IJD-58-240a [pii]
PST - ppublish
SO  - Indian J Dermatol. 2013 May;58(3):240. doi: 10.4103/0019-5154.110843.

PMID- 23723366
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
DP  - 2013 May 30
TI  - Oxidative Stress-Mediated Thrombospondin-2 Upregulation Impairs Bone
      Marrow-Derived Angiogenic Cell Function in Diabetes Mellitus.
AB  - OBJECTIVE: Circulating angiogenic cells play an essential role in angiogenesis
      but are dysfunctional in diabetes mellitus characterized by excessive oxidative
      stress. We hypothesize that oxidative stress-mediated upregulation of
      thrombospondin-2 (TSP-2), a potent antiangiogenic protein, contributes to
      diabetic bone marrow-derived angiogenic cell (BMAC) dysfunction. APPROACH AND
      RESULTS: BMACs were isolated from adult male type 2 diabetic db/db mice and
      control db/+ (C57BLKS/J) mice. In Matrigel tube formation assay, angiogenic
      function was impaired in diabetic BMACs, accompanied by increased oxidative
      stress and nicotinamide adenine dinucleotide phosphate oxidase activity. BMAC
      angiogenic function was restored by overexpression of dominant negative Rac1 or
      by overexpression of manganese superoxide dismutase. TSP-2 mRNA and protein were 
      both significantly upregulated in diabetic BMACs, mediated by increased oxidative
      stress as shown by a decrease in TSP-2 level after overexpression of dominant
      negative Rac1 or manganese superoxide dismutase. Silencing TSP-2 by its small
      interfering RNA in diabetic BMACs improved BMAC function in tube formation,
      adhesion, and migration assays. Notably, the upregulation of TSP-2 was also found
      in BMACs from streptozotocin-induced type 1 diabetic mice, and normal BMACs with 
      high glucose treatment. let-7f, a microRNA which has been related to endothelial 
      angiogenic function, is found to play key role in TSP-2 increase, but let-7f did 
      not directly interact with TSP-2 mRNA. CONCLUSIONS: The upregulation of TSP-2
      mediated by increased oxidative stress contributes to angiogenesis dysfunction in
      diabetic BMACs.
AD  - From the Department of Cardiology, Center of Clinical Pharmacology, Third Xiangya
      Hospital, Central South University, Changsha, Hunan, China (J.-M.W., Q.W., H.Y., 
      A.F.C.); Department of Surgery, University of Pittsburgh School of Medicine,
      Pittsburgh, PA (J.-M.W., Q.W., A.F.C.); Vascular Surgery Research, Veterans
      Affairs Pittsburgh Healthcare System, Pittsburgh, PA (J.-M.W., Q.W., A.F.C.);
      Department of Pharmacology and Toxicology, Michigan State University, East
      Lansing, MI (O.-N.B., S.-H.B.); College of Pharmacy, Hanyang University, Ansan,
      Gyeonggido, Korea (O.-N.B.); and College of Pharmacy, Ajou University, Suwon,
      Gyeonggido, Korea (S.-H.B.).
FAU - Bae, Ok-Nam
AU  - Bae ON
FAU - Wang, Jie-Mei
AU  - Wang JM
FAU - Baek, Seung-Hoon
AU  - Baek SH
FAU - Wang, Qingde
AU  - Wang Q
FAU - Yuan, Hong
AU  - Yuan H
FAU - Chen, Alex F
AU  - Chen AF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
OTO - NOTNLM
OT  - angiogenesis
OT  - diabetes mellitus
OT  - oxidative stress
OT  - thrombospondin-2
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - ATVBAHA.113.301609 [pii]
AID - 10.1161/ATVBAHA.113.301609 [doi]
PST - aheadofprint
SO  - Arterioscler Thromb Vasc Biol. 2013 May 30.

PMID- 23723356
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 30
TI  - Rapid Increase in Diabetes Incidence Among Chinese Canadians Between 1996 and
      2005.
AB  - OBJECTIVETo examine trends in diabetes incidence among Ontario residents with
      Chinese and European origins.RESEARCH DESIGN AND METHODSRespondents to
      population-based health surveys in 1996, 2001, 2003, and 2005 who were aged >/=30
      years, who did not have diabetes, and who self-identified as having European (n =
      76,285) or Chinese (n = 1,041) origins were followed for diabetes incidence
      through a validated administrative data-derived diabetes registry.RESULTSAge- and
      sex-standardized diabetes incidence increased from 1.3 to 19.6 per 1,000
      person-years in the Chinese population and from 7.8 to 10.0 in the European
      population. Relative to the 1996 European population, the adjusted hazard ratio
      for diabetes was 4.50 (95% CI 1.89-7.49) for the 2005 Chinese population and 1.22
      (1.05-1.39) for the 2005 European population.CONCLUSIONSDiabetes incidence
      increased much more rapidly between 1996 and 2005 in the Chinese population than 
      in the European population, independent of age, obesity, and other risk factors.
AD  - Department of Family Medicine, McMaster University, Hamilton, Ontario.
FAU - Alangh, Avreet
AU  - Alangh A
FAU - Chiu, Maria
AU  - Chiu M
FAU - Shah, Baiju R
AU  - Shah BR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - dc13-0052 [pii]
AID - 10.2337/dc13-0052 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 30.

PMID- 23723355
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 30
TI  - Epidemiology and Mortality of New-Onset Diabetes Mellitus After Dialysis: Taiwan 
      national cohort study.
AB  - OBJECTIVEWe examined the predictors and risks associated with pre-existing versus
      new-onset diabetes mellitus (DM) after initiation of chronic dialysis therapy in 
      end-stage renal disease (ESRD) patients.RESEARCH DESIGN AND METHODSIn the Taiwan 
      National Health Insurance Research Database, we examined records of ESRD patients
      who initiated dialysis between 1999 and 2005. Patients were followed until death,
      transplant, dialysis withdrawal, or 31 December 2008. Predictors of new-onset DM 
      and mortality were calculated using Cox models.RESULTSA total 51,487 incident
      dialysis patients were examined in this study, including 25,321 patients with
      pre-existing DM, 3,346 with new-onset DM, and 22,820 without DM at any time.
      Patients' age (mean +/- SD) was 61.8 +/- 11.5, 61.6 +/- 13.7, and 56.5 +/- 16.6
      years in pre-existing, new-onset DM, and without DM groups, respectively. The
      cumulative incidence rate of new-onset DM was 4% at 1 year and 21% at 9 years.
      Dialysis modality was not a risk factor for new-onset DM (peritoneal dialysis to 
      hemodialysis hazard ratio [HR] of new onset DM, 0.94 [95% CI 0.83-1.06]).
      Pre-existing DM was associated with 80% higher death risk (HR 1.81 [95% CI
      1.75-1.87]), whereas the new-onset DM was associated with 10% increased death
      risk (HR 1.10 [95% CI 1.03-1.17]).CONCLUSIONSWhereas dialysis modality does not
      appear to associate with new-onset DM, both pre-existing and new-onset DM are
      related to higher long-term mortality in maintenance dialysis patients.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      Chi-Mei Medical Center, Tainan, Taiwan.
FAU - Tien, Kai-Jen
AU  - Tien KJ
FAU - Lin, Zhe-Zhong
AU  - Lin ZZ
FAU - Chio, Chung-Ching
AU  - Chio CC
FAU - Wang, Jhi-Joung
AU  - Wang JJ
FAU - Chu, Chin-Chen
AU  - Chu CC
FAU - Sun, Yih-Min
AU  - Sun YM
FAU - Kan, Wei-Chih
AU  - Kan WC
FAU - Chien, Chih-Chiang
AU  - Chien CC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - dc12-2148 [pii]
AID - 10.2337/dc12-2148 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 30.

PMID- 23723354
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 30
TI  - Early Electrophysiological Abnormalities and Clinical Neuropathy: A prospective
      study in patients with type 1 diabetes.
AB  - OBJECTIVEThe aim of this study was to elucidate whether subclinical nerve
      dysfunction as reflected by neurophysiological testing predicts the development
      of clinical neuropathy in patients with type 1 diabetes.RESEARCH DESIGN AND
      METHODSFifty-nine patients were studied twice with neurophysiological
      measurements at baseline and at follow-up. At baseline, patients were 15.5 +/-
      3.22 years (range 7-22 years) of age, and duration of diabetes was 6.8 +/- 3.3
      years. At follow-up, patients were 20-35 years of age, and disease duration was
      20 +/- 5.3 years (range 10-31 years).RESULTSAt baseline, patients showed modestly
      reduced nerve conduction velocities and amplitudes compared with healthy
      subjects, but all were free of clinical neuropathy. At follow-up, clinical
      neuropathy was present in nine (15%) patients. These patients had a more
      pronounced reduction in peroneal motor nerve conduction velocity (MCV), median
      MCV, and sural sensory nerve action potential at baseline (P < 0.010-0.003). In
      simple logistic regression analyses, the predictor with the strongest association
      with clinical neuropathy was baseline HbA1c (R2 = 48%, odds ratio 7.9, P < 0.002)
      followed by peroneal MCV at baseline (R2 = 38%, odds ratio 0.6, P < 0.006). With 
      the use of a stepwise forward analysis that included all predictors, first
      baseline HbA1c and then only peroneal MCV at baseline entered significantly (R2 =
      61%). Neuropathy impairment assessment showed a stronger correlation with
      baseline HbA1c (rho = 0.40, P < 0.002) than with follow-up HbA1c (rho = 0.034, P 
      < 0.007).CONCLUSIONSEarly defects in nerve conduction velocity predict the
      development of diabetic neuropathy. However, the strongest predictor was HbA1c
      during the first years of the disease.
AD  - Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet,
      Karolinska Hospital, Stockholm, Sweden.
FAU - Hyllienmark, Lars
AU  - Hyllienmark L
FAU - Alstrand, Nils
AU  - Alstrand N
FAU - Jonsson, Bjorn
AU  - Jonsson B
FAU - Ludvigsson, Johnny
AU  - Ludvigsson J
FAU - Cooray, Gerald
AU  - Cooray G
FAU - Wahlberg-Topp, Jeanette
AU  - Wahlberg-Topp J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - dc12-2226 [pii]
AID - 10.2337/dc12-2226 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 30.

PMID- 23723353
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 30
TI  - No Racial Differences in the Association of Glycated Hemoglobin With Kidney
      Disease and Cardiovascular Outcomes.
AB  - OBJECTIVEThere is debate regarding the clinical significance of well-established 
      racial differences in HbA1c. We compared the associations of diabetes diagnostic 
      categories for HbA1c and fasting glucose with clinical outcomes in black and
      white persons in the community.RESEARCH DESIGN AND METHODSWe conducted a
      prospective cohort analysis of participants without diabetes or cardiovascular
      disease from the Atherosclerosis Risk in Communities study. We examined the
      associations of clinical categories of HbA1c (<5.7%, 5.7-6.4%, >/=6.5%) and
      fasting glucose (<100, 100-125, >/=126 mg/dL) with outcomes separately among
      2,484 black and 8,593 white participants and tested for race
      interactions.RESULTSBaseline characteristics differed significantly in blacks
      compared with whites, including HbA1c (5.8 vs. 5.4%; P < 0.001). During 18 years 
      of follow-up, there were trends of increased risk of kidney disease, fatal and
      nonfatal coronary heart disease, and stroke across categories of HbA1c in both
      blacks and whites. The adjusted hazard ratios for each outcome across categories 
      of HbA1c were similar in blacks and whites (P for interaction >0.05) except for
      all-cause mortality. Patterns of association were similar, but weaker, for
      fasting glucose. HbA1c and fasting glucose both were more strongly associated
      with all-cause mortality in whites compared with blacks, largely explained by
      racial differences in the rate of cardiovascular deaths.CONCLUSIONSHbA1c is a
      risk factor for vascular outcomes and mortality in both black and white adults.
      Patterns of association for HbA1c were similar to or stronger than those for
      fasting glucose. With respect to long-term outcomes, our findings support a
      similar interpretation of HbA1c in blacks and whites for diagnosis and treatment 
      of diabetes mellitus.
AD  - Department of Epidemiology and the Welch Center for Prevention, Epidemiology, and
      Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore,
      Maryland.
FAU - Selvin, Elizabeth
AU  - Selvin E
FAU - Rawlings, Andreea M
AU  - Rawlings AM
FAU - Bergenstal, Richard M
AU  - Bergenstal RM
FAU - Coresh, Josef
AU  - Coresh J
FAU - Brancati, Frederick L
AU  - Brancati FL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - dc12-2715 [pii]
AID - 10.2337/dc12-2715 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 30.

PMID- 23723352
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
DP  - 2013 May 30
TI  - Viral underpinning to the Austrian record of type 2 diabetes?
AD  - School of Public Health, University of California, Berkeley, CA 94720.
FAU - Klitz, William
AU  - Klitz W
FAU - Niklasson, Bo
AU  - Niklasson B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 1305074110 [pii]
AID - 10.1073/pnas.1305074110 [doi]
PST - aheadofprint
SO  - Proc Natl Acad Sci U S A. 2013 May 30.

PMID- 23723340
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Linking)
DP  - 2013 May 30
TI  - Preeclampsia and Prevalence of Microalbuminuria 10 Years Later.
AB  - BACKGROUND AND OBJECTIVES: A recent meta-analysis found that about 30% of women
      with a previous preeclamptic pregnancy had persistent microalbuminuria at
      follow-up. The analysis was, however, based on small studies, and more data are
      needed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using data from the
      Medical Birth Registry in Norway, this study identified women with or without
      preeclampsia in their first pregnancy 9-11 years previously (1998-2000). Women
      with diabetes, rheumatic disease, essential hypertension, or renal disease before
      first pregnancy and/or preeclampsia in later pregnancies were excluded.
      Eighty-nine women with and 69 women without preeclampsia participated in the
      study. Urinary albumin-to-creatinine ratio (ACR) was measured in three morning
      urine samples. Estimated GFR (eGFR) was calculated using the CKD-Epidemiology
      Collaboration formula. RESULTS: Median urinary ACR in follow-up urine samples was
      0.53 mg/mmol for women with and 0.50 mg/mmol for women without preeclampsia
      (P=0.54). Only one woman (1%) with previous preeclampsia had urinary ACR >2.5
      mg/mmol in two of three urine samples. Preeclampsia was not associated with
      urinary ACR above the 75th percentile. Women with preeclampsia did not have
      significantly higher eGFR than women without preeclampsia (107.9 versus 104.9
      ml/min per 1.73 m2; P=0.12), but preterm preeclampsia was significantly
      associated with eGFR above the 75th percentile (P=0.03). CONCLUSIONS: In this
      population-based study of otherwise healthy women, preeclampsia 10 years earlier 
      was not associated with increased risk of persisting microalbuminuria. Estimated 
      GFR was not significantly different between women with and those without
      preeclampsia, but preterm preeclampsia was associated with high normal eGFR.
AD  - Renal Research Group, Institute of Medicine, University of Bergen, Bergen,
      Norway, daggerDepartment of Medicine, St. Olav University Hospital, Trondheim,
      Norway, double daggerDepartment of Cancer Research and Molecular Biology, Faculty
      of Medicine, Norwegian University of Science and Technology, Trondheim, Norway,
      section signDepartment of Medicine, Haukeland University Hospital, Bergen,
      Norway, ||Department of Medicine, Haugesund Hospital, Haugesund, Norway.
FAU - Sandvik, Miriam Kristine
AU  - Sandvik MK
FAU - Hallan, Stein
AU  - Hallan S
FAU - Svarstad, Einar
AU  - Svarstad E
FAU - Vikse, Bjorn Egil
AU  - Vikse BE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - CJN.10641012 [pii]
AID - 10.2215/CJN.10641012 [doi]
PST - aheadofprint
SO  - Clin J Am Soc Nephrol. 2013 May 30.

PMID- 23723338
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Linking)
DP  - 2013 May 30
TI  - Association between Genotype and Phenotype in Uromodulin-Associated Kidney
      Disease.
AB  - BACKGROUND AND OBJECTIVES: Uromodulin-associated kidney disease (UAKD) is an
      autosomal dominant disease caused by uromodulin (UMOD) gene mutations. This study
      explored genotype-phenotype correlations by examining the relationship between
      the type of UMOD mutation and the age at onset of ESRD. DESIGN, SETTING,
      PARTICIPANTS & MEASUREMENTS: Extensive bibliographic research was used to
      ascertain patient-level data of all patients with UAKD published up to October
      2011. Data included sex; ages at onset of hyperuricemia, gout, and ESRD; and UMOD
      genotype. Kaplan-Meier analysis and Cox proportional hazards models fitted with
      shared gamma frailty terms to adjust for within-family correlations were used to 
      model time to event. RESULTS: Thirty-one peer-reviewed publications reporting on 
      202 patients from 74 families with 59 different UMOD mutations were included.
      Median ages at onset of hyperuricemia, gout, and ESRD were 24, 40, and 56 years, 
      respectively. Men developed gout and ESRD significantly earlier than did women
      (age at ESRD was 50 years for men and 60 for women; P=0.04, shared frailty
      model). Median ages at ESRD development were lowest with Cys77Tyr (37.5 years)
      and highest with Gln316Pro (65.5 years) UMOD mutations. Onset of ESRD was
      significantly earlier with UMOD mutations located within the epidermal growth
      factor domains 2 and 3 (range, 45-52 years; P<0.01 and 0.04, respectively)
      compared with the cysteine-rich domains (range, 60-65 years; by shared frailty
      model). CONCLUSIONS: The UMOD genotype is related to the clinical phenotype of
      UAKD. This finding may assist in counseling of patients.
AD  - Renal Research Institute, New York, New York, daggerAcademic Endocrine Unit,
      Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and
      Metabolism, Churchill Hospital, University of Oxford, Oxford, United Kingdom,
      double daggerDepartment of Nephrology and Dialysis and, section signVorarlberg
      Institute for Vascular Investigation and Treatment, Academic Teaching Hospital
      Feldkirch, Feldkirch, Austria, ||Division of Medical Genetics, McGill University 
      Health Centre, Montreal, Quebec, Canada.
FAU - Moskowitz, Jonathan L
AU  - Moskowitz JL
FAU - Piret, Sian E
AU  - Piret SE
FAU - Lhotta, Karl
AU  - Lhotta K
FAU - Kitzler, Thomas M
AU  - Kitzler TM
FAU - Tashman, Adam P
AU  - Tashman AP
FAU - Velez, Erin
AU  - Velez E
FAU - Thakker, Rajesh V
AU  - Thakker RV
FAU - Kotanko, Peter
AU  - Kotanko P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - CJN.11151012 [pii]
AID - 10.2215/CJN.11151012 [doi]
PST - aheadofprint
SO  - Clin J Am Soc Nephrol. 2013 May 30.

PMID- 23723111
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1872-9061 (Electronic)
IS  - 0300-2977 (Linking)
VI  - 71
IP  - 4
DP  - 2013 May
TI  - Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and
      consequences.
PG  - 174-87
AB  - The epidemic of overweight and obesity is a major problem because of the plethora
      of health and economic issues that it induces. Key among these is the sharply
      increasing prevalence of type 2 diabetes (T2D) and cardiovascular disease. The
      development of T2D is characterised by two processes: 1) insulin resistance,
      resulting from impaired insulin signalling and leading to an increased demand for
      insulin, which must be met by increased insulin production by pancreatic b-cells 
      (compensatory b-cell function); and 2) b-cell dysfunction, with T2D developing
      when the amount of insulin that is produced is insufficient to meet the demand.
      Overweight and obesity, especially in case of abdominal fat accumulation, are
      associated with systemic low-grade inf lammation. This low-grade inf lammation is
      characterised by, among other things, higher levels of circulating
      proinflammatory cytokines and fatty acids. These can interfere with normal
      insulin function and thereby induce insulin resistance, and have also been
      implicated in b-cell dysfunction. This review focuses on the known and emerging
      relations between inflammation and T2D. We first discuss current views on the
      effects of fat distribution on adipose tissue inflammation and adipose tissue
      dysfunction. Next we focus on the detrimental roles of proinflammatory cytokines 
      and fatty acids on insulin signalling and b-cell function. In the last part of
      this review we provide some insight into novel players in (the initiation of)
      inflammation in overweight and obesity, and their effects on T2D and vascular
      dysfunction.
AD  - Department of Internal Medicine & Laboratory for Metabolism and Vascular
      Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands.
FAU - van Greevenbroek, M M J
AU  - van Greevenbroek MM
FAU - Schalkwijk, C G
AU  - Schalkwijk CG
FAU - Stehouwer, C D A
AU  - Stehouwer CD
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Neth J Med
JT  - The Netherlands journal of medicine
JID - 0356133
SB  - IM
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PST - ppublish
SO  - Neth J Med. 2013 May;71(4):174-87.

PMID- 23723106
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Refractory changes in hyperosmolar diabetic decompensation: when hyperglycaemia
      improves vision.
LID - 10.1136/bcr-2013-009760 [doi]
LID - bcr2013009760 [pii]
AB  - Type 2 diabetes is a frequent condition in humans with about 350 million affected
      people. One of the complications is blindness caused by damage of the blood
      vessels in retina, cataract or glaucoma. But in an acute developing
      hyperglycaemia, changes in sugar level in blood modify the refraction in the eye.
      Thus people complain of blurred vision. We present a case of a patient with
      hypermetropia who reported quick amelioration of his vision as hyperglycaemia
      developed, because of myopisation.
AD  - Department of Internal Medicine, Hopital Riviera Site Samaritain, Vevey,
      Switzerland.
FAU - Golay, Michel
AU  - Golay M
FAU - Ferrini, Walter
AU  - Ferrini W
FAU - Tagan, Damien
AU  - Tagan D
LA  - eng
PT  - Journal Article
DEP - 20130529
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - bcr-2013-009760 [pii]
AID - 10.1136/bcr-2013-009760 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 29;2013. pii: bcr2013009760. doi: 10.1136/bcr-2013-009760.

PMID- 23723078
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 May 30
TI  - Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy from the pediatric
      perspective.
AB  - Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare
      autosomal recessive disease caused by mutations of the autoimmune regulator gene.
      The clinical spectrum of the disease encompasses several autoimmune endocrine and
      non endocrine manifestations, which may lead to acute metabolic alterations and
      eventually life-threatening events. The clinical diagnosis is defined by the
      presence of at least two components of the classic triad including chronic
      mucocoutaneous candidiasis (CMC), chronic hypoparathyroidism (CH), Addison's
      disease (AD). Other common features of the disease are hypergonadotropic
      hypogonadism, alopecia, vitiligo, autoimmune hepatitis, type 1 diabetes,
      gastrointestinal dysfunction. APECED usually begins in childhood. CMC is the
      first manifestation to appear, usually before the age of 5 years, followed by CH 
      and then by AD. The clinical phenotype may evolve over several years and many
      components of the disease may not appear until the 4th or 5th decade of life. The
      phenotypical expression of the syndrome shows a wide variability even between
      siblings with the same genotype. In view of this heterogeneity, an early
      diagnosis of APECED can be very challenging often leading to a considerable
      diagnostic delay. Therefore, clinicians should be aware that the presence of even
      a minor component of APECED in children should prompt a careful investigation for
      other signs and symptoms of the disease, thus allowing an early diagnosis and
      prevention of severe and life-threatening events. Aim of this review is to focus 
      on clinical presentation, diagnosis and management of the major components of
      APECED in children particularly focusing on endocrine features of the disease.
AD  - Pediatric Endocrinology Unit, Department of Translational Medical Sciences,
      University "Federico II" of Naples, Naples, Italy.
FAU - Capalbo, D
AU  - Capalbo D
FAU - Improda, N
AU  - Improda N
FAU - Esposito, A
AU  - Esposito A
FAU - De Martino, L
AU  - De Martino L
FAU - Barbieri, F
AU  - Barbieri F
FAU - Betterle, C
AU  - Betterle C
FAU - Pignata, C
AU  - Pignata C
FAU - Salerno, M
AU  - Salerno M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 8999 [pii]
AID - 10.3275/8999 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 May 30.

PMID- 23723063
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1755-3245 (Electronic)
IS  - 0008-6363 (Linking)
DP  - 2013 May 30
TI  - Cardioprotection in the aging, diabetic heart: the loss of protective Akt
      signaling.
AB  - AIMS: Old age and diabetes are risk factors which often coexist increasing the
      vulnerability of the heart to the lethal effects of ischemia-reperfusion injury
      (IRI). However, to our knowledge, no investigations have examined IRI and
      cardioprotective signalling in animal models bearing these comorbidies
      concomitantly. The ability of the heart to recover following IRI is greatly
      dependent on its innate cardioprotective potential, in which a central role is
      played by Akt. We aimed to investigate in an aging diabetic rat model, the
      susceptibility of the heart to IRI, the achievability of ischemic preconditioning
      (IPC) against this lethal event and the changes in Akt signalling, as the main
      prosurvival intracellular pathway.Methods and ResultsOur data showed that the
      isolated hearts of aged, diabetic Goto-Kakizaki rats were more susceptible to sub
      lethal injury and not amenable to cardioprotection via IPC, compared to younger
      diabetic rat hearts. Western blot analysis of the heart tissue suggested a
      chronic up regulation of Akt phosphorylation, and reduced expression of the
      mitochondrial regulator PGC-1alpha and of the antioxidant enzyme catalase,
      potentially due to the Akt up regulation. Moreover, no further activation of Akt 
      could be achieved following IPC. CONCLUSIONS: An increased susceptibility to IRI 
      in the aged, diabetic heart could be a consequence of impaired Akt signalling due
      to chronic Akt phosphorylation. Additional Akt phosphorylation required for IPC
      protection may therefore not be possible in the aged diabetic rat heart and may
      explain why this cardioprotective maneuver cannot be achieved in these hearts.
AD  - The Hatter Cardiovascular Institute, University College London, London, UK.
FAU - Whittington, Hannah J
AU  - Whittington HJ
FAU - Harding, Idris
AU  - Harding I
FAU - Stephenson, Clemency I M
AU  - Stephenson CI
FAU - Bell, Robert
AU  - Bell R
FAU - Hausenloy, Derek J
AU  - Hausenloy DJ
FAU - Mocanu, Mihaela M
AU  - Mocanu MM
FAU - Yellon, Derek M
AU  - Yellon DM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - cvt140 [pii]
AID - 10.1093/cvr/cvt140 [doi]
PST - aheadofprint
SO  - Cardiovasc Res. 2013 May 30.

PMID- 23723009
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1559-0283 (Electronic)
IS  - 1085-9195 (Linking)
DP  - 2013 May 31
TI  - Advanced Type 1 Diabetes is Associated with ASIC Alterations in Mouse Lower
      Thoracic Dorsal Root Ganglia Neurons.
AB  - Acid-sensing ion channels (ASICs) from dorsal root ganglia (DRG) neurons are
      proton sensors during ischemia and inflammation. Little is known about their role
      in type 1 diabetes (T1D). Our study was focused on ASICs alterations determined
      by advanced T1D status. Primary neuronal cultures were obtained from lower
      (T9-T12) thoracic DRG neurons from Balb/c and TCR-HA+/-/Ins-HA+/- diabetic male
      mice (16 weeks of age). Patch-clamp recordings indicate a change in the number of
      small DRG neurons presenting different ASIC-type currents. Multiple molecular
      sites of ASICs are distinctly affected in T1D, probably due to particular steric 
      constraints for glycans accessibility to the active site: (i) ASIC1 current
      inactivates faster, while ASIC2 is slower; (ii) PcTx1 partly reverts diabetes
      effects against ASIC1- and ASIC2-inactivations; (iii) APETx2 maintains unaltered 
      potency against ASIC3 current amplitude, but slows ASIC3 inactivation.
      Immunofluorescence indicates opposite regulation of different ASIC transcripts
      while qRT-PCR shows that ASIC mRNA ranking (ASIC2 > ASIC1 > ASIC3) remains
      unaltered. In conclusion, our study has identified biochemical and biophysical
      ASIC changes in lower thoracic DRG neurons due to advanced T1D. As hypoalgesia is
      present in advanced T1D, ASICs alterations might be the cause or the consequence 
      of diabetic insensate neuropathy.
AD  - Section of Anatomy and Histology, Department of Neurological, Neuropsychological,
      Morphological and Movement Sciences, University of Verona, Strada Le Grazie 8,
      37134, Verona, Italy.
FAU - Radu, Beatrice Mihaela
AU  - Radu BM
FAU - Dumitrescu, Diana Ionela
AU  - Dumitrescu DI
FAU - Marin, Adela
AU  - Marin A
FAU - Banciu, Daniel Dumitru
AU  - Banciu DD
FAU - Iancu, Adina Daniela
AU  - Iancu AD
FAU - Selescu, Tudor
AU  - Selescu T
FAU - Radu, Mihai
AU  - Radu M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Cell Biochem Biophys
JT  - Cell biochemistry and biophysics
JID - 9701934
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 10.1007/s12013-013-9678-5 [doi]
PST - aheadofprint
SO  - Cell Biochem Biophys. 2013 May 31.

PMID- 23723006
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1559-0283 (Electronic)
IS  - 1085-9195 (Linking)
DP  - 2013 May 31
TI  - Relationship Between Downregulation of miRNAs and Increase of Oxidative Stress in
      the Development of Diabetic Cardiac Dysfunction: Junctin as a Target Protein of
      miR-1.
AB  - Oxidative stress is involved in the etiology of diabetes-induced cardiac
      dysfunction while microRNAs (miRNAs) are known as regulators for genes involved
      in cardiac remodeling. However, a functional link between miRNAs and
      diabetes-induced cardiac dysfunction remains to be investigated. Here, we aimed
      to identify whether the expression levels of miRNAs are associated with oxidative
      stress/diabetic heart and if proteins responsible from contractile activity
      during diabetes might be directly modulated by miRNAs. Diabetic cardiomyopathy
      developed with streptozotocin, is characterized with marked changes in sarcomere 
      and mitochondria, depressed left ventricular developed pressure, and a massive
      oxidative stress that is particularly evident in the heart. miRNA profiling was
      performed in freshly isolated left ventricular cells from diabetic rats. Using
      microarray analysis, we identified marked changes in the expression of 43 miRNAs 
      (37 of them were downregulated while 6 miRNAs were upregulated) out of examined
      total of 351 miRNAs. Among them, 6 miRNAs were further validated by real-time
      PCR. The expression levels of miR-1, miR-499, miR-133a, and miR-133b were
      markedly depressed in the diabetic cardiomyocytes while miR-21 level increased
      and miR-16 level was unchanged. Notably, normalization of cardiac function and
      oxidant/antioxidant level after N-acetylcysteine (NAC)-treatment of diabetic rats
      resulted with a significant restoration in the expression levels of miR-499,
      miR-1, miR-133a, and miR-133b in the myocardium. Since changes in the level of
      muscle-specific miR-1 has been implicated in cardiac diseases and its specific
      molecular targets involved in its action, in part, associated with oxidative
      stress are limited, we first examined the protein levels of some SR-associated
      proteins such as junctin and triadin. Junctin but not triadin is markedly
      overexpressed in diabetic cardiomyocytes while its level was normalized in
      NAC-treated diabetics. Luciferase reporter assay showed that junctin is targetted
      by miR-1. Taken together, our data demonstrates that intervention with an
      antioxidant treatment for 4-week leads to significant cardioprotection against
      diabetes-induced injury, controlling oxidant/antioxidant level, which may
      directly control the levels of some miRNAs including miR-1 and its target protein
      junctin, which is involved in the development of diabetic cardiomyopathy.
AD  - Department of Biophysics, Faculty of Medicine, Ankara University, Ankara, Turkey.
FAU - Yildirim, Samet Serdar
AU  - Yildirim SS
FAU - Akman, Duygu
AU  - Akman D
FAU - Catalucci, Daniele
AU  - Catalucci D
FAU - Turan, Belma
AU  - Turan B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Cell Biochem Biophys
JT  - Cell biochemistry and biophysics
JID - 9701934
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 10.1007/s12013-013-9672-y [doi]
PST - aheadofprint
SO  - Cell Biochem Biophys. 2013 May 31.

PMID- 23722999
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1559-0283 (Electronic)
IS  - 1085-9195 (Linking)
DP  - 2013 May 31
TI  - Diabetic Peripheral Neuropathy: Role of Reactive Oxygen and Nitrogen Species.
AB  - The prevalence of diabetes has reached epidemic proportions. There are two forms 
      of diabetes: type 1 diabetes mellitus is due to auto-immune-mediated destruction 
      of pancreatic beta-cells resulting in absolute insulin deficiency and type 2
      diabetes mellitus is due to reduced insulin secretion and or insulin resistance. 
      Both forms of diabetes are characterized by chronic hyperglycemia, leading to the
      development of diabetic peripheral neuropathy (DPN) and microvascular pathology. 
      DPN is characterized by enhanced or reduced thermal, chemical, and mechanical
      pain sensitivities. In the long-term, DPN results in peripheral nerve damage and 
      accounts for a substantial number of non-traumatic lower-limb amputations. This
      review will address the mechanisms, especially the role of reactive oxygen and
      nitrogen species in the development and progression of DPN.
AD  - Department of Pharmacology, Southern Illinois University School of Medicine,
      Springfield, IL, 62702, USA, lpremkumar@siumed.edu.
FAU - Premkumar, Louis S
AU  - Premkumar LS
FAU - Pabbidi, Reddy M
AU  - Pabbidi RM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Cell Biochem Biophys
JT  - Cell biochemistry and biophysics
JID - 9701934
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 10.1007/s12013-013-9609-5 [doi]
PST - aheadofprint
SO  - Cell Biochem Biophys. 2013 May 31.

PMID- 23722991
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1528-8951 (Electronic)
IS  - 0148-0731 (Linking)
DP  - 2013 May 1
TI  - The effect of prior compression tests on the plantar soft tissue compressive and 
      shear properties.
LID - 10.1115/1.4024572 [doi]
AB  - Changes in the shear plantar soft tissue properties with diabetes are believed to
      play a role in plantar ulceration, yet little is known about these properties.
      Our group recently conducted shear tests on specimens previously tested in
      compression to fully characterize the tissue under both these loading modes.
      However, previously tested specimens may not necessarily provide representative
      mechanical properties as prior testing may have altered the tissue to an unknown 
      extent. Thus, the purpose of this study was to test the effect of prior
      compression testing on both the plantar soft tissue shear and compressive
      properties using paired specimens. First, one specimen from each pair was subject
      to compression using our standard protocol with modifications to compare
      compressive properties before and after the protocol while the other specimen
      from each pair was left untested. Then, both specimens (i.e., one previously
      compression tested and one previously untested) were subject to shear testing.
      The results indicate that prior compression testing may affect the tissue
      compressive properties by reducing peak stress and modulus, although additional
      testing is needed since these results were likely confounded by stress softening 
      effects. In contrast, neither the elastic nor the viscoelastic plantar soft
      tissue shear properties were affected by prior testing in compression, indicating
      that previously compression tested specimens should be viable for use in future
      shear tests. However, these results are limited given the small sample size of
      the study and the fact that only non-diabetic specimens were examined.
FAU - Ledoux, William R
AU  - Ledoux WR
FAU - Pai, Shruti
AU  - Pai S
FAU - Vawter, Paul
AU  - Vawter P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Biomech Eng
JT  - Journal of biomechanical engineering
JID - 7909584
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/08/03 [received]
AID - 1693302 [pii]
AID - 10.1115/1.4024572 [doi]
PST - aheadofprint
SO  - J Biomech Eng. 2013 May 1. doi: 10.1115/1.4024572.

PMID- 23722904
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
DP  - 2013 Jun 3
TI  - Dominant protein interactions that influence the pathogenesis of conformational
      diseases.
LID - 67260 [pii]
LID - 10.1172/JCI67260 [doi]
AB  - Misfolding of exportable proteins can trigger endocrinopathies. For example,
      misfolding of insulin can result in autosomal dominant mutant INS gene-induced
      diabetes of youth, and misfolding of thyroglobulin can result in autosomal
      recessive congenital hypothyroidism with deficient thyroglobulin. Both proinsulin
      and thyroglobulin normally form homodimers; the mutant versions of both proteins 
      misfold in the ER, triggering ER stress, and, in both cases, heterozygosity
      creates potential for cross-dimerization between mutant and WT gene products.
      Here, we investigated these two ER-retained mutant secretory proteins and the
      selectivity of their interactions with their respective WT counterparts. In both 
      cases and in animal models of these diseases, we found that conditions favoring
      an increased stoichiometry of mutant gene product dominantly inhibited export of 
      the WT partner, while increased relative level of the WT gene product helped to
      rescue secretion of the mutant partner. Surprisingly, the bidirectional
      consequences of secretory blockade and rescue occur simultaneously in the same
      cells. Thus, in the context of heterozygosity, expression level and stability of 
      WT subunits may be a critical factor influencing the effect of protein misfolding
      on clinical phenotype. These results offer new insight into dominant as well as
      recessive inheritance of conformational diseases and offer opportunities for the 
      development of new therapies.
FAU - Wright, Jordan
AU  - Wright J
FAU - Wang, Xiaofan
AU  - Wang X
FAU - Haataja, Leena
AU  - Haataja L
FAU - Kellogg, Aaron P
AU  - Kellogg AP
FAU - Lee, Jaemin
AU  - Lee J
FAU - Liu, Ming
AU  - Liu M
FAU - Arvan, Peter
AU  - Arvan P
LA  - ENG
GR  - F30 DK095504/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/10/08 [received]
PHST- 2013/03/28 [accepted]
AID - 67260 [pii]
AID - 10.1172/JCI67260 [doi]
PST - aheadofprint
SO  - J Clin Invest. 2013 Jun 3. pii: 67260. doi: 10.1172/JCI67260.

PMID- 23722623
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 31
TI  - Cancer detection rates following enrolment in a disease management programme for 
      type 2 diabetes.
AB  - AIMS/HYPOTHESIS: Recent prospective studies found an elevated cancer risk shortly
      after diabetes diagnosis, and this was probably due to increased ascertainment.
      This study investigated whether site-specific cancer risks are also raised
      following enrolment in a disease management programme for type 2 diabetes
      mellitus (DMP-DM2). METHODS: We linked records from a DMP-DM2 to population
      cancer registry data. The study period was from June 2003 to December 2009.
      Standardised incidence ratios (SIRs) were calculated for time intervals following
      DMP enrolment using the cancer incidence rates of the general source population. 
      Additionally, Poisson regression with natural splines was used to assess
      time-dependent cancer incidence by diabetes duration. RESULTS: There were 2,034
      first invasive cancer cases identified over 163,738 person-years of follow-up.
      Pancreatic cancer risk was significantly increased mainly in the first year after
      enrolment (SIR 1.62); the increment was only seen for patients in whom diabetes
      had been diagnosed less than 1 year before DMP-DM2 enrolment. Risk of endometrial
      cancer was similarly raised in the first year after DMP-DM2 enrolment among
      individuals newly diagnosed with diabetes but decreased rapidly thereafter. There
      was no time dependence in the incidence of cancers of the liver, lung, colon,
      breast and prostate. CONCLUSIONS/INTERPRETATION: Enrolment in a DMP-DM2 did not
      appear to induce ascertainment bias for most cancers. Cancer risks were initially
      increased, especially for pancreatic cancer, potentially as a result of reverse
      causality. Ascertainment bias and time-dependent incidence of cancer appear to be
      less of a problem in settings using DMP-like structures for the study of the
      association between diabetes duration, glucose-lowering medication and cancer
      incidence.
AD  - Institute of Epidemiology and Social Medicine, Westfalische Wilhelms-Universitat 
      Munster, Albert-Schweitzer-Campus 1 D3, 48149, Munster, Germany,
      ageier@uni-muenster.de.
FAU - Geier, A S
AU  - Geier AS
FAU - Wellmann, J
AU  - Wellmann J
FAU - Wellmann, I
AU  - Wellmann I
FAU - Kajuter, H
AU  - Kajuter H
FAU - Heidinger, O
AU  - Heidinger O
FAU - Hempel, G
AU  - Hempel G
FAU - Hense, H W
AU  - Hense HW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/11/13 [received]
PHST- 2013/04/26 [accepted]
PHST- 2013/05/31 [aheadofprint]
AID - 10.1007/s00125-013-2947-4 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 31.

PMID- 23722617
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1399-3003 (Electronic)
IS  - 0903-1936 (Linking)
DP  - 2013 May 30
TI  - The impact of COPD on health status: findings from the BOLD study.
AB  - The aim of this study was to describe the impact of COPD on health status in the 
      Burden of Obstructive Lung Disease (BOLD) populations.We conducted a
      cross-sectional, general population-based survey in 11,985 subjects from 17
      countries. We measured spirometric lung function and assessed health status using
      the short form 12 questionnaire (SF 12). The physical (PCS) and mental health
      (MCS) component scores were calculated.Subjects with COPD (post-bronchodilator
      FEV1/FVC<0.70, n=2269) had lower PCS (44+/-10 vs. 48+/-10 units, p<0.0001) and
      MCS (51+/-10 vs. 52+/-10 units, p=0.005) than subjects without COPD. The effect
      of reported heart disease, hypertension, and diabetes on PCS (-3 to -4 units) was
      considerably less than the effect of COPD GOLD grade 3 (-8 units) or 4 (-11
      units). Dyspnoea was the most important determinant of a low PCS and MCS. In
      addition, lower FEV1, chronic cough, chronic phlegm and the presence of
      comorbidities were all associated with a lower PCS.COPD is associated with poorer
      health status but the effect is stronger on the physical than the mental aspects 
      of health status. Severe COPD has a greater negative impact on health status than
      self-reported cardiovascular disease and diabetes.
AD  - Uppsala University, Uppsala, Sweden.
FAU - Janson, Christer
AU  - Janson C
FAU - Marks, Guy
AU  - Marks G
FAU - Buist, Sonia
AU  - Buist S
FAU - Gnatiuc, Louisa
AU  - Gnatiuc L
FAU - Gislason, Thorarinn
AU  - Gislason T
FAU - McBurnie, Mary Ann
AU  - McBurnie MA
FAU - Nielsen, Rune
AU  - Nielsen R
FAU - Studnicka, Michael
AU  - Studnicka M
FAU - Toelle, Brett
AU  - Toelle B
FAU - Benediktsdottir, Bryndis
AU  - Benediktsdottir B
FAU - Burney, Peter
AU  - Burney P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
OTO - NOTNLM
OT  - COPD
OT  - Comorbidities
OT  - dyspnoea
OT  - epidemiology
OT  - health status
OT  - quality of life
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 09031936.00153712 [pii]
AID - 10.1183/09031936.00153712 [doi]
PST - aheadofprint
SO  - Eur Respir J. 2013 May 30.

PMID- 23722579
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1536-3708 (Electronic)
IS  - 0148-7043 (Linking)
DP  - 2013 May 30
TI  - Retrospective Analysis of Never Events in Panniculectomy and Abdominoplasty
      Patients and Their Financial Implications.
AB  - In 2008, the Centers for Medicare and Medicaid Service adapted a list from the
      National Quality Forum consisting of 10 hospital-acquired conditions, also known 
      as never events. Deeming such events as preventable in a safe-hospital setting,
      reimbursement is no longer provided for treatments arising secondary to these
      events. A retrospective chart review identified 90 panniculectomy and
      abdominoplasty patients. The hospital-acquired conditions examined include
      surgical-site infections (SSI), vascular-catheter associated infections, deep
      venous thrombosis/pulmonary embolism, retained foreign body, catheter-related
      urinary tract infection, manifestations of poor glycemic control, falls and
      trauma, air embolism, pressure ulcers (stages III and IV), and blood
      incompatibility. Information regarding age, American Society of Anesthesiologists
      (ASA) classification, body mass index, smoking, and chemotherapy were collected. 
      Patients were divided into 2 groups, namely, those who developed never events and
      those with no events. Of the 90 patients, 14 (15.5%) developed never events
      because of SSI. No events occurred in the remaining 9 categories. Statistically
      significant risk factors included American Society of Anesthesiologists
      classification, age, and diabetes mellitus. The most common never event was SSI. 
      In light of the obvious prevalence of the risk factors in patients who develop
      these events, the question of whether never events are truly unavoidable arises. 
      Despite this, awareness of the impact on patient care, health care and hospital
      reimbursement is vital to understanding the new paradigm of the "one size fits
      all."
AD  - From the Department of Plastic Surgery, Loma Linda University Medical Center,
      Loma Linda, CA.
FAU - Champaneria, Manish C
AU  - Champaneria MC
FAU - Workman, Adrienne D
AU  - Workman AD
FAU - Pham, Anh Tuan
AU  - Pham AT
FAU - Adetayo, Oluwaseun A
AU  - Adetayo OA
FAU - Gupta, Subhas C
AU  - Gupta SC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Ann Plast Surg
JT  - Annals of plastic surgery
JID - 7805336
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 10.1097/SAP.0b013e31827fb36b [doi]
PST - aheadofprint
SO  - Ann Plast Surg. 2013 May 30.

PMID- 23722292
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1432-2161 (Electronic)
IS  - 0364-2348 (Linking)
DP  - 2013 May 31
TI  - Metastatic paraganglioma presenting as a primary shoulder mass.
AB  - Paragangliomas uncommonly metastasize, including to the bones, wherein these
      tumors are designated as malignant paragangliomas. A 56-year-old man presented
      with pain and immobility in his right arm for 1 year. He had a history of
      controlled hypertension and diabetes mellitus for 2 years. He had also been
      taking anti-anxiety medications for 25 years. His shoulder imaging revealed an
      expansile, lytic, destructive lesion in the glenoid cavity, measuring 4.6 x 3.9 x
      3.2 cm, involving the adjacent bones and soft tissues. A whole-body PET-CT scan
      revealed a hypermetabolic destructive mass in the right glenoid cavity and
      another lesion in his abdomen in the aortocaval region. Initial biopsy and
      subsequent scapular resection microscopically revealed a multinodular tumor with 
      polygonal cells arranged in a nesting and diffuse pattern, in a vascularized and 
      sclerotic stroma. Tumor cells displayed moderate to abundant, eosinophilic to
      clear cytoplasm, fine nuclear chromatin, focal intranuclear inclusions, and
      scattered mitotic figures. Immunohistochemically, tumor cells were positive for
      vimentin, synaptophysin, chromogranin, and CD56 and negative for AE1/AE3, CK,
      EMA, CD10, SMA, Melan A, HMB-45, desmin, and S100-P. Biopsy of the abdominal mass
      revealed foci of tumor cells resembling the scapular tumor. Diagnosis of a
      malignant paraganglioma was finally offered. The patient's post-operative blood
      pressure is controlled. Currently, his urinary vanillylmandelic acid and
      metanephrine levels are normal. He is asymptomatic 11 months post-surgery and is 
      on follow-up. This unusual case is presented to increase a diagnostic index of
      suspicion for a malignant paraganglioma, including at unconventional
      musculoskeletal sites. The diagnostic challenge and therapeutic implications are 
      discussed herewith.
AD  - Department of Pathology, Tata Memorial Hospital, Dr E.B. Road, Parel, Mumbai,
      India, 400012, rekhi.bharat@gmail.com.
FAU - Rekhi, Bharat
AU  - Rekhi B
FAU - Verma, Anuj
AU  - Verma A
FAU - Gulia, Ashish
AU  - Gulia A
FAU - Kumar, Rajiv
AU  - Kumar R
FAU - Dhanda, Sunita
AU  - Dhanda S
FAU - Jambhekar, Nirmala A
AU  - Jambhekar NA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Skeletal Radiol
JT  - Skeletal radiology
JID - 7701953
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/02/04 [received]
PHST- 2013/05/12 [accepted]
PHST- 2013/05/09 [revised]
PHST- 2013/05/31 [aheadofprint]
AID - 10.1007/s00256-013-1651-2 [doi]
PST - aheadofprint
SO  - Skeletal Radiol. 2013 May 31.

PMID- 23722055
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 2044-5423 (Electronic)
IS  - 2044-5415 (Linking)
DP  - 2013 May 30
TI  - Restructuring of the Diabetes Day Centre: a pilot lean project in a tertiary
      referral centre in the West of Ireland.
AB  - INTRODUCTION: Diabetes is a chronic disease amenable to management in the
      community and outpatient setting. The increasing incidence of diabetes places
      outpatient endocrinology services under pressure to provide a quality service in 
      a timely manner. Our aim was to apply lean thinking to the diabetes clinic in a
      tertiary referral centre in the West of Ireland to improve flow, as reflected in 
      reduced patient journey times. METHODS: The project lasted 6 months, from January
      to June 2011. An introductory seminar on lean thinking was arranged to inform and
      motivate the Diabetes Day Centre staff. Two 'rapid improvement events' took
      place. Value stream mapping (VSM) was the predominant lean tool employed. Patient
      journeys were mapped and quantified (minutes) using timesheets allocated to each 
      step in the process at baseline, and following intervention. Data were analysed
      using Minitab V.16.0. RESULTS: VSM allowed the value-adding and problem-causing
      steps in the patient journey through the diabetes clinic process to be identified
      and addressed. Total patient journey time through the clinic was significantly
      reduced from 118 (+/-38.02) min to 58 (+/-18.30) min (p<0.001). CONCLUSIONS: This
      project reflects the successful application of VSM as a lean tool in a pilot
      study at our institution as evidenced by improved patient flow and a significant 
      reduction in patient journey time through the clinic. Through the incorporation
      of Lean into the ethos of the hospital, we have the potential to deliver
      excellent care in a safe environment and in an efficient manner, while benefiting
      the patient, employees and tax-payer.
AD  - Discipline , of Surgery, National University of Ireland, , Galway, Ireland.
FAU - McDermott, A M
AU  - McDermott AM
FAU - Kidd, P
AU  - Kidd P
FAU - Gately, M
AU  - Gately M
FAU - Casey, R
AU  - Casey R
FAU - Burke, H
AU  - Burke H
FAU - O'Donnell, P
AU  - O'Donnell P
FAU - Kirrane, F
AU  - Kirrane F
FAU - Dinneen, S F
AU  - Dinneen SF
FAU - O'Brien, T
AU  - O'Brien T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - BMJ Qual Saf
JT  - BMJ quality & safety
JID - 101546984
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Lean management
OT  - Patient-centred care
OT  - Process mapping
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - bmjqs-2012-001676 [pii]
AID - 10.1136/bmjqs-2012-001676 [doi]
PST - aheadofprint
SO  - BMJ Qual Saf. 2013 May 30.

PMID- 23722016
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
DP  - 2013 May 3
TI  - Correlation between number of renal cysts and aortic circumferences measured
      using autopsy material.
LID - S0344-0338(13)00097-6 [pii]
LID - 10.1016/j.prp.2013.04.012 [doi]
AB  - Although the presence of renal cysts has been reported to be associated with
      aortic aneurysm or dissection by imaging studies, an autopsy study has not been
      performed. Therefore, in our institute, recent consecutive adult autopsy cases
      (n=108, 64 males and 44 females) were reviewed. The circumferences and
      atherosclerosis ratios of both thoracic and abdominal aorta were individually
      measured and graded. The number of renal cysts was scored and graded. Age of
      subjects along with histories of smoking, hypertension, and diabetes mellitus
      were confirmed. Multiple linear regression analyses demonstrated that severity of
      atherosclerosis and the number of renal cysts were correlated with thoracic
      aortic circumference, while only the number of renal cysts was correlated with
      abdominal aortic circumference (p<0.05), which was more predominant in female
      subjects (p<0.05). Microscopically, significantly more dilated renal tubules (by 
      Student's t-test, p<0.05) along with decreased stainability of basement membrane 
      by Periodic acid-Schiff staining and immunostaining of type IV collagen were
      noted in background renal tissues in cases with numerous renal cysts than in age-
      and sex-matched controls without renal cysts (n=10 vs. 10). The present study
      suggests that a syndrome that affects both aorta and renal tubules may exist.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
AD  - Department of Molecular Pathology, Tokyo Medical University, Japan. Electronic
      address: akurata@ks.kyorin-u.ac.jp.
FAU - Kurata, Atsushi
AU  - Kurata A
FAU - Inoue, Shigeru
AU  - Inoue S
FAU - Ohno, Shin-Ichiro
AU  - Ohno SI
FAU - Nakatsubo, Ryosuke
AU  - Nakatsubo R
FAU - Takahashi, Kengo
AU  - Takahashi K
FAU - Ito, Tatsuya
AU  - Ito T
FAU - Kawasaki, Kenta
AU  - Kawasaki K
FAU - Kokubo, Reiji
AU  - Kokubo R
FAU - Sakai, Takashi
AU  - Sakai T
FAU - Ubukata, Jun
AU  - Ubukata J
FAU - Matsubara, Shuya
AU  - Matsubara S
FAU - Muraoka, Ryu
AU  - Muraoka R
FAU - Yamazaki, Jun
AU  - Yamazaki J
FAU - Hirose, Takao
AU  - Hirose T
FAU - Hojo, Mayuko
AU  - Hojo M
FAU - Watanabe, Eri
AU  - Watanabe E
FAU - Kuroda, Masahiko
AU  - Kuroda M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/10/17 [received]
PHST- 2013/04/22 [revised]
PHST- 2013/04/23 [accepted]
AID - S0344-0338(13)00097-6 [pii]
AID - 10.1016/j.prp.2013.04.012 [doi]
PST - aheadofprint
SO  - Pathol Res Pract. 2013 May 3. pii: S0344-0338(13)00097-6. doi:
      10.1016/j.prp.2013.04.012.

PMID- 23721995
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1773-0449 (Electronic)
IS  - 1156-5233 (Linking)
DP  - 2013 May 27
TI  - Rhinocerebral mucormycosis due to Rhizopus oryzae in a diabetic patient: A case
      report.
LID - S1156-5233(13)00026-7 [pii]
LID - 10.1016/j.mycmed.2013.04.002 [doi]
AB  - Mucormycosis is an opportunistic fulminant fungal infection, which affects nose
      and paranasal sinuses by direct invasion or through the blood vessels mainly in
      diabetic and immunocompromised patients. In the present study, a
      rhino-orbito-cerebral mucormycosis in a 24-year-old female with diabetes mellitus
      as underlying disease was reported. Computed tomography (CT scan) demonstrated an
      increase in the soft tissue densities in the left nasal cavity, maxillary and
      ethmoid sinuses and destruction of the antral wall with soft tissue densities in 
      the pterygopalatine fossa and retromaxillary fissure. In histopathology, wide
      ribbon-shape non-septate hyphae were seen in tissue sections stained with
      hematoxylin-eosin (H&E). The etiologic fungus isolated from tissue biopsy on
      mycological media was identified by the amplification and sequencing of the 5.8S 
      RNA gene and of the adjacent internal transcriber spacer domains, ITS1/ITS4, as
      Rhizopous oryzae. Recognition of the unique patterns of this high mortality
      rhinocerebral fungal infection in patients with diabetes is a key to early
      diagnosis and successful treatment.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Infectious Division, Kashan Shahidbeheshti Hospital, Kashan, Iran.
FAU - Erami, M
AU  - Erami M
FAU - Shams-Ghahfarokhi, M
AU  - Shams-Ghahfarokhi M
FAU - Jahanshiri, Z
AU  - Jahanshiri Z
FAU - Sharif, A
AU  - Sharif A
FAU - Razzaghi-Abyaneh, M
AU  - Razzaghi-Abyaneh M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - J Mycol Med
JT  - Journal de mycologie medicale
JID - 9425651
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/01/07 [received]
PHST- 2013/03/10 [revised]
PHST- 2013/04/09 [accepted]
AID - S1156-5233(13)00026-7 [pii]
AID - 10.1016/j.mycmed.2013.04.002 [doi]
PST - aheadofprint
SO  - J Mycol Med. 2013 May 27. pii: S1156-5233(13)00026-7. doi:
      10.1016/j.mycmed.2013.04.002.

PMID- 23721961
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1879-3061 (Electronic)
IS  - 1043-2760 (Linking)
DP  - 2013 May 27
TI  - The regulation of ApoB metabolism by insulin.
LID - S1043-2760(13)00064-7 [pii]
LID - 10.1016/j.tem.2013.04.001 [doi]
AB  - The leading cause of death in diabetic patients is cardiovascular disease.
      Apolipoprotein B (ApoB)-containing lipoprotein particles, which are secreted and 
      cleared by the liver, are essential for the development of atherosclerosis.
      Insulin plays a key role in the regulation of ApoB. Insulin decreases ApoB
      secretion by promoting ApoB degradation in the hepatocyte. In parallel, insulin
      promotes clearance of circulating ApoB particles by the liver via the low-density
      lipoprotein receptor (LDLR), LDLR-related protein 1 (LRP1), and heparan sulfate
      proteoglycans (HSPGs). Consequently, the insulin-resistant state of type 2
      diabetes (T2D) is associated with increased secretion and decreased clearance of 
      ApoB. Here, we review the mechanisms by which insulin controls the secretion and 
      uptake of ApoB in normal and diabetic livers.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Division of Endocrinology, Boston Children's Hospital, Harvard Medical School,
      Boston, MA 02115, USA.
FAU - Haas, Mary E
AU  - Haas ME
FAU - Attie, Alan D
AU  - Attie AD
FAU - Biddinger, Sudha B
AU  - Biddinger SB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Trends Endocrinol Metab
JT  - Trends in endocrinology and metabolism: TEM
JID - 9001516
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/02/19 [received]
PHST- 2013/04/10 [revised]
PHST- 2013/04/12 [accepted]
AID - S1043-2760(13)00064-7 [pii]
AID - 10.1016/j.tem.2013.04.001 [doi]
PST - aheadofprint
SO  - Trends Endocrinol Metab. 2013 May 27. pii: S1043-2760(13)00064-7. doi:
      10.1016/j.tem.2013.04.001.

PMID- 23721938
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1579-2242 (Electronic)
IS  - 0300-8932 (Linking)
DP  - 2013 May 27
TI  - Survival in Mediterranean Ambulatory Patients With Chronic Heart Failure. A
      Population-based Study.
LID - S0300-8932(13)00176-0 [pii]
LID - 10.1016/j.recesp.2013.04.002 [doi]
AB  - INTRODUCTION AND OBJECTIVES: Scarce research has been performed in ambulatory
      patients with chronic heart failure in the Mediterranean area. Our aim was to
      describe survival trends in our target population and the impact of prognostic
      factors. METHODS: We carried out a population-based retrospective cohort study in
      Catalonia (north-east Spain) of 5659 ambulatory patients (60% women; mean age 77 
      [10] years) with incident chronic heart failure. Eligible patients were selected 
      from the electronic patient records of primary care practices from 2005 and were 
      followed-up until 2007. RESULTS: During the follow-up period deaths occurred in
      950 patients (16.8%). Survival after the onset of chronic heart failure at 1, 2, 
      and 3 years was 90%, 80%, 69%, respectively. No significant differences in
      survival were found between men and women (P=.13). Cox proportional hazard
      modelling confirmed an increased risk of death with older age (hazard ratio=1.06;
      95% confidence interval, 1.06-1.07), diabetes mellitus (hazard ratio=1.53; 95%
      confidence interval, 1.33-1.76), chronic kidney disease (hazard ratio=1.73; 95%
      confidence interval, 1.45-2.05), and ischemic heart disease (hazard ratio=1.18;
      95% confidence interval, 1.02-1.36). Hypertension (hazard ratio=0,73; 95%
      confidence interval, 0,64-0,84) had a protective effect. CONCLUSIONS: Service
      planning and prevention programs should take into consideration the relatively
      high survival rates found in our area and the effect of prognostic factors that
      can help to identify high risk patients. Full English text available
      from:www.revespcardiol.org/en.
CI  - Copyright (c) 2013 Sociedad Espanola de Cardiologia. Publicado por Elsevier
      Espana. All rights reserved.
AD  - Radboud University Nijmegen, Medical Centre, Scientific Institute for Quality of 
      Healthcare, Nijmegen, Paises Bajos; Instituto Universitario Avedis Donabedian,
      Universitat Autonoma de Barcelona, Barcelona, Espana; Red de Investigacion en
      Servicios de Salud en Enfermedades Cronicas (REDISSEC), Espana; Translab Research
      Group, Departament de Ciencies Mediques, Universitat de Girona, Girona, Espana.
      Electronic address: eva.frigola@gmail.com.
FAU - Frigola-Capell, Eva
AU  - Frigola-Capell E
FAU - Comin-Colet, Josep
AU  - Comin-Colet J
FAU - Davins-Miralles, Josep
AU  - Davins-Miralles J
FAU - Gich-Saladich, Ignasi J
AU  - Gich-Saladich IJ
FAU - Wensing, Michel
AU  - Wensing M
FAU - Verdu-Rotellar, Jose M
AU  - Verdu-Rotellar JM
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Supervivencia de pacientes ambulatorios con insuficiencia cardiaca cronica del
      area mediterranea. Un estudio de base poblacional.
DEP - 20130527
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/04/17 [received]
PHST- 2013/03/13 [accepted]
AID - S0300-8932(13)00176-0 [pii]
AID - 10.1016/j.recesp.2013.04.002 [doi]
PST - aheadofprint
SO  - Rev Esp Cardiol. 2013 May 27. pii: S0300-8932(13)00176-0. doi:
      10.1016/j.recesp.2013.04.002.

PMID- 23721931
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
DP  - 2013 May 14
TI  - Diabetes mellitus is not associated with major morbidity following open abdominal
      aortic aneurysm repair.
LID - S0022-4804(13)00403-4 [pii]
LID - 10.1016/j.jss.2013.04.025 [doi]
AB  - BACKGROUND: It has been suggested that there is an increased morbidity and
      mortality risk for diabetics undergoing elective aortic surgery. This, however,
      is not universally accepted. In this study, we utilize a national database to
      determine if diabetes is associated with adverse outcomes following open,
      elective, infrarenal abdominal aortic aneurysm (AAA) repair. METHODS: The
      American College of Surgeons' National Surgical Quality Improvement Program
      database was queried to identify all patients who underwent an open, elective,
      nonruptured AAA repair from January 1, 2005 to December 31, 2007. Patient
      demographics, comorbidities, and outcomes were compared by diabetes status.
      Multivariate analysis was performed adjusting for demographics and comorbidities.
      RESULTS: There were 2110 American College of Surgeons' National Surgical Quality 
      Improvement Program patients who underwent an open, elective, nonruptured AAA
      repair during this time period. Of these patients, 245 (11.6%) had diabetes
      mellitus. The overall mortality rate was 3.7% (5.3% for diabetics and 3.5% for
      nondiabetics, P = 0.171). On bivariate analysis, diabetics were more likely to
      present preoperatively with cardiovascular and renal comorbidities.
      Postoperatively, there was no significant difference in mortality or in cardiac, 
      pulmonary, or renal complications. Diabetics were more likely to develop
      superficial surgical site infections (SSIs) (4.5% versus 1.6%, P = 0.002). On
      multivariate regression, there was no difference in mortality or major
      complications between diabetics and nondiabetics (OR 1.4, 95% CI 0.68-2.71).
      Diabetics, however, were almost three times more likely to develop superficial
      SSIs (OR 2.8, 95% CI 1.29-6.00). CONCLUSIONS: Diabetes mellitus is not associated
      with significantly worse major outcomes following open, elective, infrarenal AAA 
      repair. Diabetics, however, are more likely to develop superficial SSIs.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, Howard University College of Medicine, Washington,
      District of Columbia. Electronic address: kakrahughes@gmail.com.
FAU - Hughes, Kakra
AU  - Hughes K
FAU - Jackson, Jade D
AU  - Jackson JD
FAU - Prendergast, Tahira I
AU  - Prendergast TI
FAU - Rose, David A
AU  - Rose DA
FAU - Bolorunduro, Oluwaseyi
AU  - Bolorunduro O
FAU - Obirieze, Augustine
AU  - Obirieze A
FAU - Cornwell, Edward E 3rd
AU  - Cornwell EE 3rd
FAU - Greene, Wendy R
AU  - Greene WR
FAU - Obisesan, Thomas
AU  - Obisesan T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2011/01/04 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/04/10 [accepted]
AID - S0022-4804(13)00403-4 [pii]
AID - 10.1016/j.jss.2013.04.025 [doi]
PST - aheadofprint
SO  - J Surg Res. 2013 May 14. pii: S0022-4804(13)00403-4. doi:
      10.1016/j.jss.2013.04.025.

PMID- 23721922
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
DP  - 2013 May 27
TI  - Recurrent depression, cardiovascular disease, and diabetes among middle-aged and 
      older adult women.
LID - S0165-0327(13)00366-2 [pii]
LID - 10.1016/j.jad.2013.05.008 [doi]
AB  - BACKGROUND: The goal of this study was to investigate the concurrent and
      prospective relationships between a history of single and recurrent major
      depression disorder (MDD) and the medical conditions of cardiovascular disease
      (CVD) and diabetes using a community sample of middle- and older-aged women.
      METHODS: Data from women (n=557 at baseline; mean age=55.7 years) participating
      in a two-wave longitudinal study (5-year interval) were used to examine
      associations between single and recurrent MDD, assessed with a structured
      clinical interview, and three self-report indicators of CVD (heart attack or
      myocardial infarction, stroke, angina), major CVD risk markers (hypertension,
      high cholesterol), and diabetes. Analyses were conducted to evaluate hypotheses
      which proposed that recurrent depression would be significantly associated with
      the three medical outcomes, but not single episode MDD. RESULTS: After
      controlling for a range of important covariates (e.g., BMI, smoking, alcohol
      use), cross-sectional analyses indicated that recurrent MDD, but not single
      episode MDD, significantly predicted CVD risk and diabetes. Prospective analyses 
      indicated that recurrent MDD, but not single episode MDD, increased the risk for 
      CVD and diabetes. LIMITATIONS: The sample was a predominantly white, middle-class
      sample so generalizability of findings may be limited for minorities and men.
      Reliance on self-report data may have biased the findings. CONCLUSIONS: These
      findings suggest the benefits of measuring single versus recurrent MDD when
      investigating the risk of depression on chronic diseases. Findings also suggest
      the importance of identifying individuals suffering from recurrent MDD early in
      their lifespan with the goal of preventing future depressive episodes.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Behavioral Sciences and Health Education, Emory University, United 
      States. Electronic address: mwindle@emory.edu.
FAU - Windle, Michael
AU  - Windle M
FAU - Windle, Rebecca C
AU  - Windle RC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/03/25 [received]
PHST- 2013/05/03 [accepted]
AID - S0165-0327(13)00366-2 [pii]
AID - 10.1016/j.jad.2013.05.008 [doi]
PST - aheadofprint
SO  - J Affect Disord. 2013 May 27. pii: S0165-0327(13)00366-2. doi:
      10.1016/j.jad.2013.05.008.

PMID- 23721890
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1096-7206 (Electronic)
IS  - 1096-7192 (Linking)
DP  - 2013 May 10
TI  - Characterization of two deletions of the CTRC locus.
LID - S1096-7192(13)00152-2 [pii]
LID - 10.1016/j.ymgme.2013.04.022 [doi]
AB  - Novel variants associated with chronic pancreatitis are being increasingly
      reported. However, most studies have so far only analyzed point mutations and
      small insertions or deletions. Here we report the characterization of two
      distinct deletions of the CTRC locus. Variants in four chronic pancreatitis
      genes, PRSS1, SPINK1, CTRC and CFTR, were systematically analyzed in the studied 
      cases. Copy number change of the CTRC gene was analyzed by quantitative
      fluorescent multiplex PCR (QFM-PCR). Walking QFM-PCR followed by long-range PCR
      and direct sequencing were employed to identify the deletion breakpoints at the
      nucleotide level. A heterozygous CTRC-deleting complex rearrangement, which was
      co-inherited with different trans variants in SPINK1, CFTR or PRSS1, is
      associated with variable phenotypes (chronic pancreatitis; pancreatic cancer and 
      chronic pancreatitis; and type 1 diabetes). Moreover, a different homozygous
      deletion of the CTRC locus was found in an unrelated patient with asymptomatic
      chronic pancreatitis. Our findings revealed a hitherto unrecognized level of
      complexity of genotype-phenotype correlation in chronic pancreatitis. The
      CTRC-deleting complex rearrangement probably resulted from LINE-1-mediated Alu
      insertion, which represents a novel mutational mechanism causing chronic
      pancreatitis.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM), U1078, Brest,
      France; Laboratoire de Genetique Moleculaire et d'Histocompatibilite, Centre
      Hospitalier Universitaire (CHU) Brest, Hopital Morvan, Brest, France.
FAU - Masson, Emmanuelle
AU  - Masson E
FAU - Hammel, Pascal
AU  - Hammel P
FAU - Garceau, Cecile
AU  - Garceau C
FAU - Benech, Caroline
AU  - Benech C
FAU - Quemener-Redon, Sylvia
AU  - Quemener-Redon S
FAU - Chen, Jian-Min
AU  - Chen JM
FAU - Ferec, Claude
AU  - Ferec C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Mol Genet Metab
JT  - Molecular genetics and metabolism
JID - 9805456
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/03/26 [received]
PHST- 2013/04/30 [revised]
PHST- 2013/04/30 [accepted]
AID - S1096-7192(13)00152-2 [pii]
AID - 10.1016/j.ymgme.2013.04.022 [doi]
PST - aheadofprint
SO  - Mol Genet Metab. 2013 May 10. pii: S1096-7192(13)00152-2. doi:
      10.1016/j.ymgme.2013.04.022.

PMID- 23721855
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
DP  - 2013 May 27
TI  - Association of RAGE gene polymorphism with circulating AGE level and paraoxonase 
      activity in relation to macro-vascular complications in Indian type 2 diabetes
      mellitus patients.
LID - S0378-1119(13)00649-5 [pii]
LID - 10.1016/j.gene.2013.05.013 [doi]
AB  - BACKGROUND AND AIMS: Sustained interaction of advanced glycation end products
      (AGEs) with their receptor RAGE and subsequent signaling plays an important role 
      in the development of diabetic complications. Genetic variation of RAGE gene may 
      be associated with the development of vascular complications in type 2 diabetes
      mellitus (T2DM). OBJECTIVES: The present study aimed to explore the possible
      association of RAGE gene polymorphisms namely -374T/A, -429T/C and G82S with
      serum level of AGEs, paraoxonase (PON1) activity and macro-vascular complications
      (MVC) in Indian type 2 diabetes mellitus patients (T2DM). METHODS: A total of 265
      diabetic patients, including DM without any complications (n=135), DM-MVC (n=130)
      and 171 healthy individuals were enrolled. Genotyping of RAGE variants were
      assessed by polymerase chain reaction-restriction fragment length polymorphism.
      Serum AGEs were estimated by ELISA and fluorometrically. and PON1 activity was
      assessed spectrophotometrically. RESULTS: Of the three examined SNPs, association
      of -429T/C polymorphism with MVC in T2DM was observed (OR=3.001, p=0.001) in the 
      dominant model. Allele 'A' of -374T/A polymorphism seems to confer better cardiac
      outcome in T2DM. Patients carrying C allele (-429T/C) and S allele (G82S) had
      significantly higher AGE levels. -429T/C polymorphism was also found to be
      associated with low PON1 activity. Interaction analysis revealed that the risk of
      development of MVC was higher in T2DM patients carrying both a CC genotype of
      -429T/C polymorphism and a higher level of AGEs (OR=1.343, p=0.040). CONCLUSION: 
      RAGE gene polymorphism has a significant effect on AGE level and PON1 activity in
      diabetic subjects compared to healthy individuals. Diabetic patients with a CC
      genotype of -429T/C are prone to develop MVC, more so if AGE levels are high and 
      PON1 activity is low.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Biochemistry and Immunology Laboratory, Department of Biochemistry, University
      College of Medical Sciences (University of Delhi) and G.T.B. Hospital, Dilshad
      Garden, Delhi 110095, India. Electronic address: bansalsavita_1916@yahoo.com.
FAU - Bansal, Savita
AU  - Bansal S
FAU - Chawla, Diwesh
AU  - Chawla D
FAU - Banerjee, Basu Dev
AU  - Banerjee BD
FAU - Madhu, Sri Venkata
AU  - Madhu SV
FAU - Tripathi, Ashok Kumar
AU  - Tripathi AK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Gene
JT  - Gene
JID - 7706761
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/01/31 [received]
PHST- 2013/05/01 [revised]
PHST- 2013/05/06 [accepted]
AID - S0378-1119(13)00649-5 [pii]
AID - 10.1016/j.gene.2013.05.013 [doi]
PST - aheadofprint
SO  - Gene. 2013 May 27. pii: S0378-1119(13)00649-5. doi: 10.1016/j.gene.2013.05.013.

PMID- 23721739
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1471-4973 (Electronic)
IS  - 1471-4892 (Linking)
DP  - 2013 May 27
TI  - Diabetic kidney disease and immune modulation.
LID - S1471-4892(13)00062-3 [pii]
LID - 10.1016/j.coph.2013.05.002 [doi]
AB  - Immune modulation is now known to contribute to the development of
      glomerulosclerosis, tubulointerstitial fibrosis and end-stage renal disease in a 
      large number of kidney diseases. Similarly, diabetic nephropathy is increasingly 
      considered an inflammatory disease, with immune modulation being involved in both
      the development and progression of the disease. Infiltration of immune cells
      including macrophages, T cells, B cells and mast cells into the kidney has been
      reported. A number of pro-inflammatory cytokines and chemokines also play a major
      role in pathogenesis of diabetic nephropathy. Consequently, a variety of
      therapeutic strategies involving modulation of the immune response are currently 
      being investigated in diabetic kidney disease.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - UCD Diabetes Complications Research Centre, UCD Conway Institute, University
      College Dublin, Belfield, Dublin 4, Ireland; School of Medicine and Medical
      Sciences, University College Dublin, Belfield, Dublin 4, Ireland.
FAU - Hickey, Fionnuala B
AU  - Hickey FB
FAU - Martin, Finian
AU  - Martin F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/03/14 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/05/03 [accepted]
AID - S1471-4892(13)00062-3 [pii]
AID - 10.1016/j.coph.2013.05.002 [doi]
PST - aheadofprint
SO  - Curr Opin Pharmacol. 2013 May 27. pii: S1471-4892(13)00062-3. doi:
      10.1016/j.coph.2013.05.002.

PMID- 23721738
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1471-4973 (Electronic)
IS  - 1471-4892 (Linking)
DP  - 2013 May 28
TI  - Mechanisms and therapy of atherosclerosis and its clinical complications.
LID - S1471-4892(13)00061-1 [pii]
LID - 10.1016/j.coph.2013.05.001 [doi]
AB  - In 1913, exactly 100 years ago, Nikolai Nikolaevich Anichkov (1885-1964) and
      Semen Sergeevich Chalatov (1884-1951) discovered in St. Petersburg, Russia, that 
      atherosclerosis of large arteries is critically dependent on cholesterol. The
      inflammatory nature of atherosclerosis was first observed and suggested by Rudolf
      Virchow in 1856. Today, we have orally active drugs at our disposition that not
      only lower cholesterol levels but also interfere with vascular inflammation and
      atherogenesis. The disease process is multifactorial and its development is
      accelerated by modifiable and given risk factors such as cigarette smoking,
      dyslipidemia, arterial hypertension, diabetes, obesity, physical inactivity,
      estrogen deficiency, chronic renal disease, genetic predisposition, and the
      physiological aging process, among others. The present issue of Current Opinion
      in Pharmacology features a series of articles by clinicians and scientists-many
      of whom are world authorities in their field-on mechanisms, preventive measures, 
      clinical complications, and treatment of coronary artery disease. This monograph 
      provides a '2013 update' on the pathogenesis, prevention, and therapy of
      atherosclerosis.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Molecular Internal Medicine, University of Zurich, 8057 Zurich, Switzerland.
      Electronic address: barton@access.uzh.ch.
FAU - Barton, Matthias
AU  - Barton M
LA  - ENG
PT  - EDITORIAL
DEP - 20130528
TA  - Curr Opin Pharmacol
JT  - Current opinion in pharmacology
JID - 100966133
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - S1471-4892(13)00061-1 [pii]
AID - 10.1016/j.coph.2013.05.001 [doi]
PST - aheadofprint
SO  - Curr Opin Pharmacol. 2013 May 28. pii: S1471-4892(13)00061-1. doi:
      10.1016/j.coph.2013.05.001.

PMID- 23721703
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 23
IP  - 7
DP  - 2013 Jun
TI  - [Laparoscopic nephrectomy with vaginal extraction in obese or overweight
      patients: The end of wound complications?].
PG  - 444-9
LID - 10.1016/j.purol.2013.03.001 [doi]
LID - S1166-7087(13)00101-2 [pii]
AB  - PURPOSE: To study the feasibility and to present results of laparoscopic
      nephrectomy with vaginal extraction in overweight or obese patients. PATIENTS AND
      METHODS: Three patients having BMI>28kg/m(2) underwent surgery. Median age was
      56years, median BMI was 44.4. Medical history included for the three patients
      type 2 diabetes mellitus and arterial hypertension. Two of the three patients
      were multiparous, one was nulliparous. Patients underwent standard laparoscopic
      nephrectomy with vaginal extraction of the specimen through a short incision of
      the posterior vaginal fornix. Feeding was normal on the first operating day. No
      morphine was prescribed during hospitalization stay. RESULTS: No intraoperative
      complication occurred. Mean procedure time was 224min. Mean blood loss was 140mL.
      Postoperative period was uneventful and walking was normal on the first operating
      day. Hospitalization stays were 2, 3 and 5days. One month follow up found no
      complication including normal sexual activity. CONCLUSION: Laparoscopic
      nephrectomy with vaginal extraction is a feasible technique in obese or
      overweight patients. Wound morbidity (infection, hernia) is reduced due to the
      small abdominal incisions.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Service de chirurgie urologique, centre hospitalier Lyon Sud, 165, chemin du
      Grand-Revoyet, 69495 Pierre-Benite, France.
FAU - Adam, E
AU  - Adam E
FAU - Golfier, F
AU  - Golfier F
FAU - Lunel Potencier, A
AU  - Lunel Potencier A
FAU - Ruffion, A
AU  - Ruffion A
FAU - Paparel, P
AU  - Paparel P
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Nephrectomies laparoscopiques avec extraction vaginale chez la patiente obese ou 
      en surcharge ponderale : la fin des complications parietales ?
DEP - 20130408
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la
      Societe francaise d'urologie
JID - 9307844
SB  - IM
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/02/11 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/03/04 [accepted]
PHST- 2013/04/08 [aheadofprint]
AID - S1166-7087(13)00101-2 [pii]
AID - 10.1016/j.purol.2013.03.001 [doi]
PST - ppublish
SO  - Prog Urol. 2013 Jun;23(7):444-9. doi: 10.1016/j.purol.2013.03.001. Epub 2013 Apr 
      8.

PMID- 23721622
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
DP  - 2013 May 27
TI  - Prevalence and Risk Factors for Stroke in an Adult Population in a Rural
      Community in the Niger Delta, South-South Nigeria.
LID - S1052-3057(13)00127-4 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2013.04.010 [doi]
AB  - Sub-Saharan Africa is experiencing an epidemiologic transition with stroke
      contributing to the disease burden. However, community-based stroke prevalence
      studies are sparse. This study aimed to determine the prevalence of stroke in a
      rural population in the Niger Delta region in south-south Nigeria and to describe
      known risk factors for stroke among them. A door-to-door stroke prevalence study 
      was conducted in 2008 among randomly selected adults of 18 years or older in
      rural Kegbara-Dere community in Rivers State, south-south Nigeria. We
      administered a modified screening tool by the World Health Organization, a
      stroke-specific questionnaire, and conducted a physical/neurological examination 
      (on persons screening positive) in 3 stages of assessments. The crude prevalence 
      of stroke was 8.51/1000 (95% confidence interval [CI] = 3.9-16.1) representing 9 
      of 1057 participants. The age-adjusted prevalence was 12.3/1000 using the US
      Population 2000. Men had higher unadjusted prevalence than women (12.9/1000
      versus 5.1/1000) but were not at more risk (unadjusted relative risk = .99; 95%
      CI = .98-1.00). Stroke prevalence increased with age (Mantel-Haenszel chi2P =
      .00). Hypertension (blood pressure >/=140/90 mm Hg) was present in all stroke
      cases and diabetes mellitus (fasting blood sugar >126 mg/dL) in 1 person, but
      none had hypercholesterolemia, obesity (body mass index >30 kg/m2), or a history 
      of alcohol intake or smoking. Stroke prevalence was found to be high, commoner
      among men and the elderly population, and likely to be predisposed by
      hypertension, in rural south-south Nigeria. The need to conduct follow-up studies
      on the burden and outcomes of stroke among this study population is acknowledged.
CI  - Copyright (c) 2013 National Stroke Association. Published by Elsevier Inc. All
      rights reserved.
AD  - Department of Internal Medicine, University of Port Harcourt Teaching Hospital,
      Port Harcourt, Nigeria. Electronic address: ac_onwuchekwa@yahoo.com.
FAU - Onwuchekwa, Arthur C
AU  - Onwuchekwa AC
FAU - Tobin-West, Charles
AU  - Tobin-West C
FAU - Babatunde, Seye
AU  - Babatunde S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National
      Stroke Association
JID - 9111633
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/02/04 [received]
PHST- 2013/04/10 [accepted]
AID - S1052-3057(13)00127-4 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2013.04.010 [doi]
PST - aheadofprint
SO  - J Stroke Cerebrovasc Dis. 2013 May 27. pii: S1052-3057(13)00127-4. doi:
      10.1016/j.jstrokecerebrovasdis.2013.04.010.

PMID- 23721616
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
DP  - 2013 May 27
TI  - Outcome of 312 Japanese Patients with Carotid Endarterectomy and Factors
      Associated with Cardiovascular Events-a Single-Center Study in Japan.
LID - S1052-3057(13)00158-4 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2013.04.030 [doi]
AB  - BACKGROUND: There have only been a few reports regarding the outcomes and risk
      factors after CEA. To clarify the factors associated with outcome in patients
      with carotid stenosis who underwent carotid endarterectomy (CEA), we investigated
      cardiovascular events and mortality in the Kyushu Medical Center in Japan.
      METHODS: We consecutively registered patients with significant carotid stenosis
      who had CEA performed over 10 years and compared the incidences of stroke,
      myocardial infarction, and death. On admission, we evaluated medical records for 
      stroke risk factors, including hypertension, diabetes mellitus,
      hypercholesterolemia, atrial fibrillation, and current smoking habits. When
      performing CEA, blood pressure, heart rate, blood gases, and Doppler flow
      parameters in the carotid artery, and an electroencephalogram, were continuously 
      monitored during the procedure. A shunt tube was inserted into both ends of the
      carotid artery, and a microscope was used. Although it was recommended that
      patients be evaluated by magnetic resonance imaging and ultrasound after the
      operation, we attempted to obtain information from the patient or a family member
      through a questionnaire or telephone survey if a patient did not come for
      assessment. We determined the factors associated with stroke, myocardial
      infarction, and death using Kaplan-Meier analyses. RESULTS: Of 312 CEA patients, 
      302 (96.8%) with confirmed outcomes were analyzed. We found that a factor
      associated with stroke was a history of ischemic stroke (P = .028). A history of 
      myocardial infarction (P = .009) and the presence of peripheral arterial disease 
      (PAD) (P = .001) were factors related to the future occurrence of myocardial
      infarction. Perioperative complications occurred in 6 patients (1.99%) including 
      1 death because of sepsis and 1 major ipsilateral stroke. Of the 302 patients who
      underwent CEA, 43 patients died in the follow-up period, and the 5-year survival 
      rate was 83.9%. The number of patients who died because of myocardial infarction 
      and cancer was 9 for each, and they were the leading causes of their death. Only 
      1 patient died because of stroke (2.3%). Patients with PAD had a significantly
      high mortality (P < .001). CONCLUSIONS: In patients who underwent CEA, a risk
      factor of future stroke was a history of stroke. A history of myocardial
      infarction or PAD was strongly associated with future occurrence of myocardial
      infarction or high mortality.
CI  - Copyright (c) 2013 National Stroke Association. Published by Elsevier Inc. All
      rights reserved.
AD  - Department of Neurosurgery, Faculty of Medicine, Fukuoka University, National
      Hospital Organization Kyushu Medical Center, Fukuoka, Japan. Electronic address: 
      toshi.ogata1@gmail.com.
FAU - Ogata, Toshiyasu
AU  - Ogata T
FAU - Inoue, Tooru
AU  - Inoue T
FAU - Okada, Yasushi
AU  - Okada Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National
      Stroke Association
JID - 9111633
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/02/19 [received]
PHST- 2013/04/13 [revised]
PHST- 2013/04/26 [accepted]
AID - S1052-3057(13)00158-4 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2013.04.030 [doi]
PST - aheadofprint
SO  - J Stroke Cerebrovasc Dis. 2013 May 27. pii: S1052-3057(13)00158-4. doi:
      10.1016/j.jstrokecerebrovasdis.2013.04.030.

PMID- 23721587
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 May 31
TI  - Evidence of early beta-cell deficiency among children who show impaired fasting
      glucose: 10-yr cohort study (EarlyBird 56).
LID - 10.1111/pedi.12049 [doi]
AB  - OBJECTIVE: Impaired fasting glucose (IFG) is a predictor of future diabetes and
      is increasingly common in children, but the extent to which it results from
      excess insulin demand or failure of supply is unclear. Our aim was to compare the
      behaviour of insulin sensitivity and beta-cell function in children who developed
      IFG with those whose glucose levels remained within the normal range. METHODS: We
      examined trends in fasting glucose, insulin sensitivity (HOMA-S) and beta-cell
      function (HOMA-B) in 327 healthy children annually from 5 to 15 yr, and the
      parents at baseline. RESULTS: Fifty-five children showed IFG, mostly after age 11
      yr. Fasting glucose rose progressively and was higher throughout in those who
      developed IFG compared with those who did not (p < 0.001). Beta-cell function was
      lower from the age of 5 yr in those who developed IFG (p = 0.006), but there was 
      no difference in BMI (p = 0.71). A difference in insulin sensitivity was revealed
      on adjustment for covariates (p = 0.03). Glucose was higher (p < 0.001),
      beta-cell function lower (p = 0.01), and insulin sensitivity the same (p = 0.86) 
      in the mothers of children who showed IFG, compared with those who did not.
      CONCLUSIONS: IFG is common in contemporary children, and appears to be related to
      a defect in beta-cell function already present at 5 yr. Similar findings in the
      mothers of IFG children suggest that the beta-cell defect may be transmissible.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - University Medicine, Level 07 Derriford Hospital, Plymouth University Peninsula
      Schools of Medicine and Dentistry, Plymouth, UK.
FAU - Hosking, Joanne
AU  - Hosking J
FAU - Metcalf, Brad S
AU  - Metcalf BS
FAU - Jeffery, Alison N
AU  - Jeffery AN
FAU - Streeter, Adam J
AU  - Streeter AJ
FAU - Voss, Linda D
AU  - Voss LD
FAU - Wilkin, Terence J
AU  - Wilkin TJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/11/20 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/04/09 [accepted]
AID - 10.1111/pedi.12049 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 May 31. doi: 10.1111/pedi.12049.

PMID- 23721572
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1651-1999 (Electronic)
IS  - 0803-7051 (Linking)
DP  - 2013 May 31
TI  - Masked hypertension in renal transplant recipients.
AB  - Purpose: Arterial hypertension is a risk factor affecting graft function in renal
      transplant recipients (RTRs). In pediatric RTRs, high prevalence of masked and
      nocturnal hypertension was reported. Most of the RTRs had a history of
      hypertension and some of them were normotensive at outpatient visits whereas home
      blood pressure (BP) levels were higher. Masked hypertension (MHT) is defined as a
      normal office BP but an elevated ambulatory BP. Previous reports have
      demonstrated the detrimental role of MHT in clinical outcomes in hypertensive
      patients. However, the true prevalence of MHT in RTRs is yet to be defined.
      Methods: A total of 113 RTRs (mean age 44 +/- 16 years, 72 males, 41 females)
      with normal office BP (< 140/90 mmHg) were enrolled to the study from the
      outpatient renal transplantation clinic. Ambulatory BP monitoring (ABPM) was
      performed in all participants for a 24-h period. Average daytime BP values above 
      135 mmHg systolic and 85 mmHg diastolic were defined as MHT. Results: The
      prevalence of MHT in our cohort was 39% (n = 45). Fasting glucose and C-reactive 
      protein levels were higher in patients with MHT compared with normal BP group (p 
      = 0.02 and p = 0.04, respectively). RTRs with deceased donor type had higher
      prevalence of MHT than RTRs with living donor (40% vs 19%, p = 0.003). In
      multivariate analysis, deceased donor type could predict the MHT independent of
      age, gender, office systolic BP level, diabetes mellitus, serum creatinine,
      C-reactive protein, and glucose levels (OR = 3.62, 95% CI 1.16-11.31, p = 0.03). 
      Conclusion: We demonstrated an increased prevalence of MHT in a typical renal
      transplant cohort. In addition, transplantation from a deceased donor may be a
      predictor of MHT. The prevalence of MHT may help to explain high rate of
      cardiovascular events in RTRs. Therefore, routine application of ABPM in RTRs may
      be plausible, particularly in RTRs with deceased donor type.
AD  - Department of Cardiology, Meram School of Medicine, Necmettin Erbakan University 
      , Konya , Turkey.
FAU - Kayrak, Mehmet
AU  - Kayrak M
FAU - Gul, Enes Elvin
AU  - Gul EE
FAU - Kaya, Coskun
AU  - Kaya C
FAU - Solak, Yalcin
AU  - Solak Y
FAU - Turkmen, Kultigin
AU  - Turkmen K
FAU - Yazici, Raziye
AU  - Yazici R
FAU - Guney, Ibrahim
AU  - Guney I
FAU - Altintepe, Lutfullah
AU  - Altintepe L
FAU - Turk, Suleyman
AU  - Turk S
FAU - Ozdemir, Kurtulus
AU  - Ozdemir K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Blood Press
JT  - Blood pressure
JID - 9301454
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 10.3109/08037051.2013.796688 [doi]
PST - aheadofprint
SO  - Blood Press. 2013 May 31.

PMID- 23721563
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 May 31
TI  - Associations of polymorphisms in non-HLA loci with autoantibodies at the
      diagnosis of type 1 diabetes: INS and IKZF4 associate with insulin
      autoantibodies.
LID - 10.1111/pedi.12046 [doi]
AB  - OBJECTIVE: More than 50 loci outside the human leukocyte antigen (HLA) region
      have been confirmed to affect type 1 diabetes (T1D) risk but their effect on
      beta-cell autoimmunity is poorly defined. We analyzed the association of 35
      single nucleotide polymorphism (SNP) markers previously associated with T1D with 
      the presence of disease-predictive autoantibodies at the time of T1D diagnosis.
      SUBJECTS AND METHODS: The study cohort comprised 1554 children diagnosed with T1D
      before the age of 15 yr. The associations between various genotypes and
      positivity for antibodies against islet cells [islet cell antibodies (ICA)],
      insulin [insulin autoantibodies (IAA)], glutamic acid decarboxylase (GADA), islet
      antigen 2 (IA2A), and zinc transporter 8 (ZnT8A) were analyzed. RESULTS: INS gene
      polymorphism rs689 and IKZF4 polymorphism (rs1701704) were strongly associated
      with IAA positivity at the time of T1D diagnosis (p = 0.000004 and 0.00044,
      respectively). The presence of the T1D-risk conferring INS AA genotype was
      associated with IAA. In contrast, the presence of the susceptible C allele of the
      IKZF4 marker was inversely associated with IAA. The INS and IKZF4 polymorphisms
      were not significantly associated with ICA, GADA, IA2A, or ZnT8A positivity.
      CONCLUSIONS: Both INS and IKZF4 polymorphisms modified the probability of IAA
      positivity at time of T1D onset but the inverse association of IKZF4 risk allele 
      with IAA suggests that the IKZF4 polymorphism is involved in a pathway of
      beta-cell autoimmunity alternate to the route characterized by IAA and
      development of T1D in early childhood. The IKZF4 gene encodes Eos, which is
      implicated to play an important role in Treg programming where this gene might
      exert its influence on T1D risk.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Immunogenetics Laboratory, University of Turku, Turku, Finland; Department of
      Pediatrics, Turku University Hospital, University of Turku, Turku, Finland.
FAU - Lempainen, J
AU  - Lempainen J
FAU - Harkonen, T
AU  - Harkonen T
FAU - Laine, Ap
AU  - Laine A
FAU - Knip, M
AU  - Knip M
FAU - Ilonen, J
AU  - Ilonen J
CN  - The Finnish Pediatric Diabetes Register
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/02/04 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/04/04 [accepted]
AID - 10.1111/pedi.12046 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 May 31. doi: 10.1111/pedi.12046.

PMID- 23721527
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130606
DCOM- 20130607
IS  - 1758-5996 (Electronic)
VI  - 5
IP  - 1
DP  - 2013
TI  - Prevalence rate of Metabolic Syndrome in a group of light and heavy smokers.
PG  - 28
LID - 10.1186/1758-5996-5-28 [doi]
AB  - BACKGROUND: Smoking is an important cause of morbidity and mortality worldwide.
      It is widely accepted as a major risk factor for metabolic and cardiovascular
      disease. Smoking reduces insulin sensitivity or induces insulin resistance and
      enhances cardiovascular risk factors such as elevated plasma triglycerides,
      decreases high-density lipoprotein cholesterol and causes hyperglycemia. Several 
      studies show that smoking is associated with metabolic abnormalities and
      increases the risk of Metabolic Syndrome. The aim of this study was to estimate
      the prevalence of the metabolic syndrome in a group of light and heavy smokers,
      wishing to give up smoking. METHODS: In this cross-sectional study all the
      enrolled subjects voluntary joined the smoking cessation program held by the
      Respiratory Pathophysiology Unit of San Matteo Hospital, Pavia, Northern
      Italy.All the subjects enrolled were former smokers from at least 10 years and
      had no cancer or psychiatric disorders, nor history of diabetes or CVD or
      coronary artery disease and were not on any medication. RESULTS: The subjects
      smoke 32.3 +/- 16.5 mean Pack Years. The prevalence of the metabolic syndrome is 
      52.1%: 57.3% and 44.9% for males and females respectively. Analysing the smoking 
      habit influence on the IDF criteria for the metabolic syndrome diagnosis we found
      that all the variables show an increasing trend from light to heavy smokers,
      except for HDL cholesterol. A statistical significant correlation among Pack
      Years and waist circumference (R = 0.48, p < 0.0001), Systolic Blood Pressure (R 
      = 0.18, p < 0.05), fasting plasma glucose (R = 0.19, p < 0.005) and HDL
      cholesterol (R = -0.26, p = 0.0005) has been observed. CONCLUSIONS: Currently
      smoking subjects are at high risk of developing the metabolic
      syndrome.Therapeutic lifestyle changes, including smoking cessation are a
      desirable Public health goal and should successfully be implemented in clinical
      practice at any age.
AD  - Department of Public Health, Experimental and Forensic Medicine, Section of Human
      Nutrition, University of Pavia, Via Bassi 21, 27100, Pavia, Italy.
      hcena@unipv.it.
FAU - Cena, Hellas
AU  - Cena H
FAU - Tesone, Antonella
AU  - Tesone A
FAU - Niniano, Rosanna
AU  - Niniano R
FAU - Cerveri, Isa
AU  - Cerveri I
FAU - Roggi, Carla
AU  - Roggi C
FAU - Turconi, Giovanna
AU  - Turconi G
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC3673853
OID - NLM: PMC3673853
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:01
CRDT- 2013/06/01 06:00
PHST- 2013/01/30 [received]
PHST- 2013/05/11 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 1758-5996-5-28 [pii]
AID - 10.1186/1758-5996-5-28 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2013 May 30;5(1):28. doi: 10.1186/1758-5996-5-28.

PMID- 23721491
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 30
TI  - Prevalence, incidence and remission of urinary incontinence in women:
      longitudinal data from the Norwegian HUNT study (EPINCONT).
PG  - 27
AB  - BACKGROUND: To determine incidence and remission of UI as well as changes in UI
      prevalence in the Norwegian EPINCONT surveys. METHODS: The EPINCONT surveys were 
      conducted in the county of Nord-Tr[latin small letter o with stroke]ndelag,
      Norway, as part of two large cross-sectional health surveys (HUNT2 and HUNT3) in 
      1995 -- 1997 (EPINCONT1 (E1)), and 2006 -- 2008 (EPINCONT2 (E2)). EPINCONT
      collected information about prevalence of UI, as well as information about type
      and severity of UI. RESULTS: A 16% relative increase in UI prevalence was found
      in 11 years. The women who answered E2 were significantly older, had a higher BMI
      and higher prevalence of diseases such as asthma, diabetes and angina compared
      with the women who answered E1.The incidence of UI was 18.7%. Increase in BMI (OR
      1.03, 95% CI: 1.02 -- 1.04), weight increase (OR 1.29 (95% CI: 1.14 -- 1.45) for 
      gaining 3 -- 10 kilos and OR 1.71 (95% CI: 1.47 -- 1.99) for gaining 10 kilos or 
      more) and parity (OR 1.37 (95% CI: 1.04 -- 1.79) for 1 childbirth, OR 1.28 (95%
      CI: 1.03 -- 1.61) for 2 childbirths, and OR 1.56 (95% CI: 1.26 -- 1.95) for 3 or 
      more childbirths when participating in E2) were all found to be associated with
      increased odds of incident UI in adjusted regression analyses. Increasing age
      reduced the odds of incident UI. The 11 year remission of UI was 34.1%.
      Increasing age (OR 0.98, 95% CI: 0.98 -- 0.99), increasing BMI (OR 0.96, 95% CI: 
      0.95 -- 0.98) and large weight gains of 10 kilos or more (OR 0.69, 95% CI: 0.54
      -- 0.88) were all associated with reduced remission of UI. CONCLUSION: Crude UI
      prevalence increased between the studies. Changes in known risk factors for UI
      such as age, BMI, weight and parity could explain some of the relative increase
      in prevalence, and were also found to be associated with either incidence of UI, 
      remission of UI or both.
FAU - Ebbesen, Marit Helen
AU  - Ebbesen MH
FAU - Hunskaar, Steinar
AU  - Hunskaar S
FAU - Rortveit, Guri
AU  - Rortveit G
FAU - Hannestad, Yngvild Skaatun
AU  - Hannestad YS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
PMC - PMC3674916
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/08/05 [received]
PHST- 2013/05/30 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 1471-2490-13-27 [pii]
AID - 10.1186/1471-2490-13-27 [doi]
PST - aheadofprint
SO  - BMC Urol. 2013 May 30;13(1):27.

PMID- 23721430
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1477-7525 (Electronic)
IS  - 1477-7525 (Linking)
VI  - 11
IP  - 1
DP  - 2013 May 30
TI  - Factors associated with health-related quality of life in renal transplant
      recipients: results of a national survey in France.
PG  - 88
AB  - BACKGROUND: This study aims to identify factors associated with health related
      quality of life (HRQOL) through a comprehensive analysis of sociodemographic and 
      clinical variables among a representative sample size of renal transplant
      recipients (RTR) in France. METHODS: A cross-sectional multicenter study was
      carried out in 2008. All RTR over 18 years old with a functioning graft for at
      least one year were included. Data included socio-demographic, health status, and
      treatment characteristics. To evaluate HRQOL, the Short Form-36 Health Survey
      (SF-36) and a HRQOL instrument for RTR (ReTransQol) were administered.
      Multivariate linear regression models were performed. RESULTS: A total of 1061
      RTR were included, with a return rate of 72.5%. The variance explained in
      regression models of SF-36 ranges from 20% to 40% and from 9% to 33% for
      ReTransQol.The variables which decreased scores of both HRQOL questionnaires
      were: females, unemployment, lower education, living alone, high BMI, diabetes,
      recent critical illness and hospitalization, non-compliance, a long duration of
      dialysis and treatment side effects.Specific variables which decreased ReTransQol
      scores were dismissal and a recent surgery on the graft. These which decreased
      SF36 scores were being old and a recent infectious disease.The variables the most
      predictors of worse HRQOL were: side effects, infectious disease, recent
      hospitalization and female gender. CONCLUSIONS: The originality of our study's
      findings was that novel variables, particularly treatment side effects and
      unemployment, have a negative effect on quality of life of RTR. The French
      Biomedicine Agency and the National Health Institute for Public Health
      Surveillance conduct specific actions for professional reintegration and
      therapeutic education programs in the national plan to improve the HRQOL of
      people living with chronic diseases.
FAU - Gentile, Stephanie
AU  - Gentile S
FAU - Beauger, Davy
AU  - Beauger D
FAU - Speyer, Elodie
AU  - Speyer E
FAU - Jouve, Elisabeth
AU  - Jouve E
FAU - Dussol, Bertrand
AU  - Dussol B
FAU - Jacquelinet, Christian
AU  - Jacquelinet C
FAU - Briancon, Serge
AU  - Briancon S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Health Qual Life Outcomes
JT  - Health and quality of life outcomes
JID - 101153626
PMC - PMC3673846
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/11/02 [received]
PHST- 2013/05/30 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 1477-7525-11-88 [pii]
AID - 10.1186/1477-7525-11-88 [doi]
PST - aheadofprint
SO  - Health Qual Life Outcomes. 2013 May 30;11(1):88.

PMID- 23721405
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1607-842X (Electronic)
IS  - 0891-6934 (Linking)
DP  - 2013 May 30
TI  - Vitamin D receptor (VDR) gene polymorphisms and age onset in type 1 diabetes
      mellitus.
AB  - Abstract Vitamin D receptor is a mediator of immune responses through the action 
      of vitamin D, which is capable of regulate the insulin secretion by the pancreas.
      Since polymorphisms in the vitamin D receptor (VDR) gene might modulate vitamin D
      function, and thus immunologic response, VDR is possibly able to influence the
      predisposition to type 1 diabetes mellitus (T1DM). The aim of this work was to
      perform an association study among VDR polymorphisms and T1DM susceptibility, as 
      well as the correlation with the disease onset. Two hundred and four T1DM
      patients and 217 controls, from Northeast Brazil, were genotyped for five
      tagSNPs, covering the whole VDR gene. Our results indicated an association
      between rs1540339 and rs4760648 SNPs (p = 0.02 and p = 0.03, respectively) and
      T1DM. No association was found with T1DM onset and age at diagnose. To our
      knowledge, this is the first association study in T1DM where the whole VDR gene
      was analyzed, and our results indicate that VDR polymorphisms could be important 
      for T1DM susceptibility, but do not seem to be associated to age at disease
      onset.
AD  - Department of Genetics, Federal University of Pernambuco , Recife, Pernambuco ,
      Brazil .
FAU - De Azevedo Silva, Jaqueline
AU  - De Azevedo Silva J
FAU - Guimaraes, Rafael Lima
AU  - Guimaraes RL
FAU - Brandao, Lucas Andre Cavalcanti
AU  - Brandao LA
FAU - Araujo, Jacqueline
AU  - Araujo J
FAU - Segat, Ludovica
AU  - Segat L
FAU - Crovella, Sergio
AU  - Crovella S
FAU - Sandrin-Garcia, Paula
AU  - Sandrin-Garcia P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Autoimmunity
JT  - Autoimmunity
JID - 8900070
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
AID - 10.3109/08916934.2013.795952 [doi]
PST - aheadofprint
SO  - Autoimmunity. 2013 May 30.

PMID- 23721377
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 30
TI  - Incidence, microbiology, and patient characteristics of skin and soft-tissue
      infections in a U.S. Population: a retrospective population-based study.
PG  - 252
AB  - BACKGROUND: Skin and soft tissue infections (SSTIs) are commonly occurring
      infections with wide-ranging clinical manifestations, from mild to
      life-threatening. There are few population-based studies of SSTIs in the period
      after the rapid increase in community-acquired methicillin-resistant Staphyloccus
      aureus (MRSA). METHODS: We used electronic databases to describe the incidence,
      microbiology, and patient characteristics of clinically-diagnosed skin and soft
      tissue infections (SSTIs) among members of a Northern California integrated
      health plan. We identified demographic risk factors associated with SSTIs and
      MRSA infection. RESULTS: During the three-year study period from 2009 to 2011,
      376,262 individuals experienced 471,550 SSTI episodes, of which 23% were
      cultured. Among cultured episodes, 54% were pathogen-positive. Staphylococcus
      aureus (S. aureus) was isolated in 81% of pathogen-positive specimens, of which
      nearly half (46%) were MRSA. The rate of clinically-diagnosed SSTIs in this
      population was 496 per 10,000 person-years. After adjusting for age group,
      gender, race/ethnicity and diabetes, Asians and Hispanics were at reduced risk of
      SSTIs compared to whites, while diabetics were at substantially higher risk
      compared to non-diabetics. There were strong age group by race/ethnicity
      interactions, with African Americans aged 18 to <50 years being
      disproportionately at risk for SSTIs compared to persons in that age group
      belonging to other race/ethnicity groups. Compared to Whites, S. aureus isolates 
      of African-Americans and Hispanics were more likely to be MRSA (Odds Ratio (OR): 
      1.79, Confidence Interval (CI): 1.67 to 1.92, and, OR: 1.24, CI: 1.18 to 1.31,
      respectively), while isolates from Asians were less likely to be MRSA (OR: 0.73, 
      CI: 0.68 to 0.78). CONCLUSIONS: SSTIs represent a significant burden to the
      health care system. The majority of culture-positive SSTIs were caused by S.
      aureus, and almost half of the S. aureus SSTIs were methicillin-resistant. The
      reasons for African-Americans having a higher likelihood, and Asians a lower
      likelihood, for their S. aureus isolates to be methicillin-resistant, should be
      further investigated.
FAU - Ray, Gary Thomas
AU  - Ray GT
FAU - Suaya, Jose Antonio
AU  - Suaya JA
FAU - Baxter, Roger
AU  - Baxter R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/01/11 [received]
PHST- 2013/05/30 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 1471-2334-13-252 [pii]
AID - 10.1186/1471-2334-13-252 [doi]
PST - aheadofprint
SO  - BMC Infect Dis. 2013 May 30;13(1):252.

PMID- 23721312
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1875-5550 (Electronic)
IS  - 1389-2037 (Linking)
DP  - 2013 May 28
TI  - Marine Peptides For Preventing Metabolic Syndrome.
AB  - Recently, there has been a growing in alternative prevents and therapies of
      marine organisms for metabolic syndrome. Marine-derived bioactive peptides
      attracted extensive interest due to its numerous health beneficial effects
      including antioxidant, antihypertensive, anti-diabetes, anti-obesity. The
      bioactive peptides may provide novel therapeutic applications for the prevention 
      of metabolic syndrome. The facts summarized here may provide improvement of
      metabolic syndrome by peptide from marine organisms. However, further insightful 
      researches on the prevention of metabolic syndrome by marine peptides in in vivo 
      and clinical studies are needed to firmly establish their therapeutic potency.
AD  - Department of Marine Life Science, Jeju National University, Jeju 690-756,
      Republic of Korea.
FAU - Ko, Seok-Chun
AU  - Ko SC
FAU - Jeon, You-Jin
AU  - Jeon YJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Curr Protein Pept Sci
JT  - Current protein & peptide science
JID - 100960529
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/04/01 [received]
PHST- 2012/08/25 [revised]
PHST- 2012/09/20 [accepted]
AID - CPPS-EPUB-20130528-5 [pii]
PST - aheadofprint
SO  - Curr Protein Pept Sci. 2013 May 28.

PMID- 23721292
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 30
TI  - Determinants of self-monitoring of blood glucose in patients with Type1 diabetes:
      a multi-centre study in Brazil.
LID - 10.1111/dme.12236 [doi]
AB  - AIM: The aim of this study was to determine the relationship between the daily
      frequency of self-monitoring of blood glucose and glycaemic control, demographic 
      and socio-economic status in patients with Type 1 diabetes under routine clinical
      care in Brazil. METHODS: This was a cross-sectional, multi-centre study conducted
      between December 2008 and December 2010 in 28 public clinics in 20 Brazilian
      cities. The data were obtained from 3176 patients, aged 22 +/- 11.8 years, of
      whom 56.3% were female and 57.4% were Caucasian. The mean time since diabetes
      diagnosis was 11.7 +/- 8.1 years. RESULTS: The prevalence of self-monitoring of
      blood glucose was 88.5%. There was a significant increase in self-monitoring
      frequency associated with female gender, lower ages, more intensive diabetes
      management and higher socio-economic status. A correlation between HbA1c levels
      and the daily frequency of self-monitoring was observed (rs = -0.13; P = 0.001). 
      The mean HbA1c levels were related to the daily frequency of self-monitoring (P <
      0.001) without additional benefit to patients who performed self-monitoring more 
      than four times daily (9.2, 11.2, 10.2,15.2 and 15% for one, two, three, four,
      five or more self-monitoring tests daily, respectively; P < 0.0001). CONCLUSIONS:
      The majority of our patients (88.5%) performed three or more self-monitoring
      tests daily, with more frequent testing reported by females, younger patients,
      those on intensive insulin regimens and of higher socio-economic status. No
      additional benefit was found in patients who performed self-monitoring more than 
      four times daily. The diabetes care team must improve patients' education
      regarding self-monitoring of blood glucose and its benefits. This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Internal Medicine, Diabetes Unit, State University Hospital of Rio 
      de Janeiro.
FAU - Gomes, M B
AU  - Gomes MB
FAU - Tannus, L R M
AU  - Tannus LR
FAU - Cobas, R A
AU  - Cobas RA
FAU - Matheus, A S M
AU  - Matheus AS
FAU - Dualib, P
AU  - Dualib P
FAU - Zucatti, A T
AU  - Zucatti AT
FAU - Cani, C
AU  - Cani C
FAU - Guedes, A D
AU  - Guedes AD
FAU - Santos, F M
AU  - Santos FM
FAU - Sepulveda, J
AU  - Sepulveda J
FAU - Tolentino, M
AU  - Tolentino M
FAU - Facanha, M C
AU  - Facanha MC
FAU - Faria, A C R A
AU  - Faria AC
FAU - Lavigne, S
AU  - Lavigne S
FAU - Montenegro, A P
AU  - Montenegro AP
FAU - Rodacki, M
AU  - Rodacki M
FAU - Guedes, M F
AU  - Guedes MF
FAU - Szundy, R
AU  - Szundy R
FAU - Cordeiro, M M
AU  - Cordeiro MM
FAU - Santos, P T S
AU  - Santos PT
FAU - Negrato, C A
AU  - Negrato CA
CN  - The Brazilian Type 1 Diabetes Study Group (BrazDiab1SG)
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/12/17 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/05/15 [accepted]
AID - 10.1111/dme.12236 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 30. doi: 10.1111/dme.12236.

PMID- 23721205
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1875-5631 (Electronic)
IS  - 1566-5232 (Linking)
VI  - 13
DP  - 2013 May 27
TI  - Insulin secreted from genetically engineered intestinal cells reduces blood
      glucose levels in diabetic mice.
AB  - Poorly controlled diabetes mellitus can result in serious complications. Gene
      therapy is increasingly being considered as an alternative approach to treat
      diabetes, because of its ability to induce physiological insulin secretion and it
      allows patients to escape insulin injections. The properties of gut K and
      L-cells, including glucose sensitivity, the ability to process insulin and a
      regulated secretion pathway support their use as surrogate beta-cells. Previous
      in vitro studies have provided sufficient evidence supporting the use of these
      cells for gene therapy studies. Therefore, we examined the ability of K and
      L-cells to produce insulin in diabetic mice. Chitosan nanoparticles were used to 
      transfer the insulin gene into intestinal cells via oral administration. The
      efficiency of chitosan as a gene vehicle was investigated through the use of
      reporter gene. Insulin mRNA and protein expression levels were measured by RT-PCR
      and ELISA, respectively. Blood glucose testing revealed that this treatment
      reduced glucose levels in diabetic mice. The decrease in blood glucose level in
      the first week of treatment was greater in mice with K-cell specific insulin
      expression compared with mice with L-cell-specific insulin expression. These
      results indicate that inducing insulin secretion in K-cells conferred a quicker
      response to gene therapy.
AD  - Pathology Department, Faculty of Medicine and Health Sciences, Universiti Putra
      Malaysia, UPM, Serdang, 43400, Selangor, Malaysia.
      zalinah@medic.upm.edu.my;zalinahmedic@gmail.com.
FAU - Rasouli, Mina
AU  - Rasouli M
FAU - Allaudin, Zeenathul N
AU  - Allaudin ZN
FAU - Omar, Abdul Rahman
AU  - Omar AR
FAU - Ahmad, Zalinah
AU  - Ahmad Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Curr Gene Ther
JT  - Current gene therapy
JID - 101125446
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/12/24 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/05/22 [accepted]
AID - CGT-EPUB-52364 [pii]
PST - aheadofprint
SO  - Curr Gene Ther. 2013 May 27;13.

PMID- 23721199
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
IP  - 1
DP  - 2013 May 31
TI  - Selective peroxisome proliferator-activated receptoralpha modulators
      (SPPARMalpha): The next generation of peroxisome proliferator-activated receptor 
      alpha-agonists.
PG  - 82
AB  - Dyslipidemia is a major risk factor for cardiovascular (CV) disease -- the
      primary cause of death, worldwide. Although reducing levels of low-density
      lipoprotein-cholesterol can significantly reduce CV risk, a high level of
      residual risk persists, especially in people with obesity-related conditions,
      such as metabolic syndrome and type 2 diabetes mellitus. Peroxisome
      proliferator-activated receptor alpha- (PPARalpha-) agonists (e.g. fibrates),
      play a central role in the reduction of macro- and microvascular risk in these
      patients. However, the currently available fibrates are weak (PPARalpha-agonists)
      with limited efficacy due to dose-related adverse effects. To address this
      problem, a new generation of highly potent and selective PPARalpha-modulators
      (SPPARMalpha) is being developed that separate the benefits of the
      PPARalpha-agonists from their unwanted side effects. Among these, aleglitazar (a 
      dual PPARalpha/gamma agonist) and GFT505 (a dual PPAR alpha/delta agonist) have
      recently entered late-phase development. Although both compounds are more potent 
      PPARalpha-activators than fenofibrate in vitro, only aleglitezar is more
      effective in lowering triglycerides and raising high-density
      lipoprotein-cholesterol (HDL-C) in humans. However, it is also associated with a 
      potential risk of adverse effects. More recently, a highly potent, specific
      PPARalpha-agonist (K-877) has emerged with SPPARMalpha characteristics. Compared 
      to fenofibrate, K-877 has more potent PPARalpha-activating efficacy in vitro,
      greater effects on triglycerides- and HDL-C levels in humans, and a reduced risk 
      of adverse effects. If successful, K-877 has the potential to supersede the
      fibrates as the treatment of choice for patients with residual CV risk associated
      with metabolic syndrome and type 2 diabetes.
FAU - Fruchart, Jean-Charles
AU  - Fruchart JC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/04/18 [received]
PHST- 2013/05/31 [accepted]
PHST- 2013/05/31 [aheadofprint]
AID - 1475-2840-12-82 [pii]
AID - 10.1186/1475-2840-12-82 [doi]
PST - aheadofprint
SO  - Cardiovasc Diabetol. 2013 May 31;12(1):82.

PMID- 23721170
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - Management of hyperglycemia in type 2 diabetes: evidence and uncertainty.
PG  - 81
LID - 10.1186/1475-2840-12-81 [doi]
AB  - The panoply of treatment algorithms, periodically released to improve guidance,
      is one mean to face therapeutic uncertainty in pharmacological management of
      hyperglycemia in type 2 diabetes, especially after metformin failure. Failure of 
      recent guidelines to give advice on the use of specific antidiabetic drugs in
      patients with co-morbidity may generate further uncertainty, given the frequent
      association of type 2 diabetes with common comorbidity, including, although not
      limited to obesity, cardiovascular disease, impaired renal function, and frailty.
      The Italian Association of Diabetologists (Associazione Medici Diabetologi, AMD) 
      recognized the need to develop personalized treatment plans for people with type 
      2 diabetes, taking into account the patients' individual profile (phenotype),
      with the objective of the safest possible glycemic control. As not every subject 
      with type 2 diabetes benefits from intensive glycemic control, flexible regimens 
      of treatment with diabetes drugs (including insulin) are needed for reaching
      individualized glycemic goals. Whether personalized diabetology will improve the 
      quality healthcare practice of diabetes management is unknown, but specific
      research has been launched.
AD  - Department of Clinical and Experimental Medicine, Second University of Naples,
      Naples, Italy. katherine.esposito@unina2.it.
FAU - Esposito, Katherine
AU  - Esposito K
FAU - Gentile, Sandro
AU  - Gentile S
FAU - Candido, Riccardo
AU  - Candido R
FAU - De Micheli, Alberto
AU  - De Micheli A
FAU - Gallo, Marco
AU  - Gallo M
FAU - Medea, Gerardo
AU  - Medea G
FAU - Ceriello, Antonio
AU  - Ceriello A
CN  - Associazione Medici Diabetologi (AMD)
LA  - eng
PT  - Editorial
DEP - 20130530
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3669612
OID - NLM: PMC3669612
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/05/06 [received]
PHST- 2013/05/19 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 1475-2840-12-81 [pii]
AID - 10.1186/1475-2840-12-81 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 May 30;12:81. doi: 10.1186/1475-2840-12-81.

PMID- 23721159
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
DP  - 2013 May 31
TI  - Time Trends and Gender Differences in Incidence and Prevalence of Type 1 Diabetes
      In Sweden.
AB  - There are different opinions on a possible sex bias in diabetes. In Sweden we
      have access to data since the 1930s, making it an ideal model. We aimed to study 
      gender differences and time trends in the incidence and prevalence of type 1
      diabetes in Sweden. We found 30 articles on incidence and 8 on prevalence (6
      overlapping). Times series on incidence were found regarding&nbsp; children
      0&ndash;15 years of age (with the Swedish Childhood Diabetes Registry, SCDR,
      since 1977), with up to 14,721 children with diabetes and with a high degree of
      ascertainment. Incidence time series were also found for subjects aged
      15&ndash;34 (Diabetes Incidence Study in Sweden, DISS, since 1983), with up to
      7,369 subjects and with a lower degree of ascertainment compared to SCDR.
      Regarding age from 40 years and above fewer studies were found, and with a much
      lower number of subjects with type 1 diabetes. Diabetes incidence in children has
      had a relative increase of approximately 2% per year since 1938. Incidence rates 
      in children 0&ndash;14 years of age show no gender differences, but in subjects
      aged 15&ndash;39 years a male preponderance up to twofold is found. Figures for
      subjects 40 years or older are more uncertain, but show a fairly equal incidence 
      among men and women. The male preponderance in type 1 diabetes from age 15 up to 
      40&ndash;50 could be due to hormonal influence, with higher peripheral insulin
      resistance among men in young adults and younger middle age.
AD  - Per Wandell, MD PhD, Centre for Family Medicine, Karolinska Institutet, Alfred
      Nobels alle 12, S-141 83 Huddinge, Sweden. per.wandell@ki.se.
FAU - Wandell, Per E
AU  - Wandell PE
FAU - Carlsson, Axel C
AU  - Carlsson AC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2012/07/19 [received]
PHST- 2013/05/24 [revised]
PHST- 2013/05/24 [accepted]
AID - CDR-EPUB-20130531-2 [pii]
PST - aheadofprint
SO  - Curr Diabetes Rev. 2013 May 31.

PMID- 23721158
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
DP  - 2013 May 31
TI  - Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus: An Update on Recent
      Developments.
AB  - Type 1 diabetes mellitus is an autoimmune disease that is characterized by the
      destruction of the islets of Langerhans cells which produce insulin. The current 
      gold standard treatment is exogenous insulin injection, but this is onerous for
      the patients, and can lead to severe complications. Another approach involves
      transplanting pancreatic islet cells in order to restore endogenous insulin
      production under physiologic regulation. Although there has been some success
      with this treatment plan, there have been several hurdles. The largest hurdle is 
      improving the 5 year survival of the graft, which is currently at 10%. In order
      to do so, there has been research into better locations for the graft, better
      isolation techniques, alternate immune suppression regimens, and novel
      transplantation methodologies utilizing encapsulated grafts. Another hurdle for
      pancreatic islet transplantation is that current methodologies require islets
      from several pancreata in order to create one successful graft, which leads to
      difficulties since there is a limited supply. However, there has been research
      looking into single donor transplants and porcine xenografts to increase the
      supply and address this problem. In this article, we review the current state of 
      research regarding pancreatic islet transplantation.
AD  - Department of Surgery, University of Virginia School of Medicine, P.O. Box
      800709, Charlottesville, VA 22908-0709. klb9r@hscmail.mcc.virginia.edu.
FAU - Ramesh, Arjun
AU  - Ramesh A
FAU - Chhabra, Preeti
AU  - Chhabra P
FAU - Brayman, Kenneth L
AU  - Brayman KL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/04/01 [received]
PHST- 2013/05/16 [revised]
PHST- 2013/05/16 [accepted]
AID - CDR-EPUB-20130531-1 [pii]
PST - aheadofprint
SO  - Curr Diabetes Rev. 2013 May 31.

PMID- 23721100
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1750-2659 (Electronic)
IS  - 1750-2640 (Linking)
DP  - 2013 May 30
TI  - Severe acute respiratory infections caused by 2009 pandemic influenza A (H1N1)
      among American Indians-southwestern United States, May 1-July 21, 2009.
LID - 10.1111/irv.12123 [doi]
AB  - BACKGROUND: During April-July 2009, U.S. hospitalization rates for 2009 pandemic 
      influenza A (H1N1) virus (H1N1pdm09) infection were estimated at 4.5/100 000
      persons. We describe rates and risk factors for H1N1pdm09 infection among
      American Indians (AIs) in four isolated southwestern U.S. communities served by
      the Indian Health Service (IHS). METHODS: We reviewed clinical and demographic
      information from medical records of AIs hospitalized during May 1-July 21, 2009
      with severe acute respiratory infection (SARI). Hospitalization rates were
      determined using denominator data provided by IHS. H1N1pdm09 infection was
      confirmed with polymerase chain reaction, rapid tests, or convalescent serology. 
      Risk factors for more severe (SARI) versus milder [influenza-like illness (ILI)] 
      illness were determined by comparing confirmed SARI patients with outpatients
      with ILI. RESULTS: Among 168 SARI-hospitalized patients, 52% had confirmed
      H1N1pdm09 infection and 93% had >1 high-risk condition for influenza
      complications. The H1N1pdm09 SARI hospitalization rate was 131/100 000 persons
      [95% confidence interval (CI), 102-160] and was highest among ages 0-4 years
      (353/100 000; 95% CI, 215-492). Among children, asthma (adjusted odds ratio [aOR]
      3.2; 95% CI, 1.2-8.4) and age <2 years (aOR 3.8; 95% CI, 1.4-10.0) were
      associated with H1N1pdm09 SARI-associated hospitalization, compared with
      outpatient ILI. Among adults, diabetes (aOR 3.1; 95% CI, 1.5-6.4) was associated 
      with hospitalization after controlling for obesity. CONCLUSIONS: H1N1pdm09
      hospitalization rates among this isolated AI population were higher than reported
      for other U.S. populations. Almost all case patients had high-risk health
      conditions. Prevention strategies for future pandemics should prioritize AIs,
      particularly in isolated rural areas.
CI  - Published 2013. This article is U.S. Government work and in the public domain in 
      the USA.
AD  - Epidemic Intelligence Service, Scientific Education and Professional Development 
      Program Office, Centers for Disease Control and Prevention, Atlanta, GA, USA;
      Division of Epidemiology and Disease Prevention, Indian Health Service,
      Albuquerque, NM, USA.
FAU - Suryaprasad, Anil
AU  - Suryaprasad A
FAU - Redd, John T
AU  - Redd JT
FAU - Hancock, Kathy
AU  - Hancock K
FAU - Branch, Alicia
AU  - Branch A
FAU - Steward-Clark, Evelene
AU  - Steward-Clark E
FAU - Katz, Jacqueline M
AU  - Katz JM
CN  - For the Influenza Serology Working Group
FAU - Fry, Alicia M
AU  - Fry AM
FAU - Cheek, James E
AU  - Cheek JE
CN  - For the American Indian and Alaska Native Pandemic Influenza A (H1N1)
      Investigation Team
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Influenza Other Respi Viruses
JT  - Influenza and other respiratory viruses
JID - 101304007
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/04/18 [accepted]
AID - 10.1111/irv.12123 [doi]
PST - aheadofprint
SO  - Influenza Other Respi Viruses. 2013 May 30. doi: 10.1111/irv.12123.

PMID- 23720930
OWN - NLM
STAT- In-Process
DA  - 20130531
IS  - 0300-9041 (Print)
IS  - 0300-9041 (Linking)
VI  - 81
IP  - 4
DP  - 2013 Apr
TI  - [Metabolic disorders in women during climacterium].
PG  - 186-9
AB  - BACKGROUND: As part of preventive medicine climacteric and menopause clinics
      should identify the chronic-degenerative diseases that accompany this stage of
      women and which are increasing as the age increases. OBJECTIVE: To dentify
      following chronic degenerative diseases that occur during climacteric: diabetes, 
      hypertension, obesity and dyslipidemia. MATERIAL AND METHODS: A descriptive and
      transversal study was performed with 688 patients in the clinic of the
      climacteric and menopause, 98 were removed for failing to comply with all the
      requirements that included: determining serum glucose and lipids, weight, height,
      diameter of waist and hip. Controls were done every three to four months forming 
      two groups: menopause and perimenopause. RESULTS: The average age of menopause
      was 47.5 years, in which predominated the chronic degenerative diseases,
      highlighting the overweight and obesity (66%), dyslipidemia (59%), hypertension
      (22%) and diabetes (19%). CONCLUSION: The gynecologist must be attentive to
      identify early risk factors for chronic degenerative diseases from the
      reproductive stage.
AD  - Servico de Ginecologia y Obstetricia, Hospital General del ISSSTE,
      Aquascalientes, Ags. chicho420314@yahoo.com.mx
FAU - Munoz Enciso, Jose Manuel
AU  - Munoz Enciso JM
FAU - Rosales Aujang, Enrique
AU  - Rosales Aujang E
FAU - Arias Ulloa, Raul
AU  - Arias Ulloa R
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Trastornos metabolicos de mujeres en el climaterio.
PL  - Mexico
TA  - Ginecol Obstet Mex
JT  - Ginecologia y obstetricia de Mexico
JID - 0376552
SB  - IM
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PST - ppublish
SO  - Ginecol Obstet Mex. 2013 Apr;81(4):186-9.

PMID- 23720882
OWN - NLM
STAT- In-Process
DA  - 20130531
IS  - 0301-1208 (Print)
IS  - 0301-1208 (Linking)
VI  - 50
IP  - 2
DP  - 2013 Apr
TI  - Association of family history of type 2 diabetes mellitus with markers of
      endothelial dysfunction in South Indian population.
PG  - 93-8
AB  - Studies indicate that risk for type 2 diabetes mellitus (T2D) or cardiovascular
      disease is detectable in childhood, though these disorders may not emerge until
      adulthood. This study was aimed to assess the markers of endothelial dysfunction 
      in patients with the family history of T2D from South Indian population. A total 
      of 450 subjects were included in the study comprising Group I (n = 200) of T2D,
      Group II (n = 200) of age- and sex-matched healthy controls, Group III (n = 25)
      of children of T2D patients and Group IV (n = 25) of children of healthy
      controls. Results showed that intimal medial thickening (IMT) was significantly
      higher in T2D patients, compared with control subjects with no family history of 
      diabetes. The fasting plasma glucose, glycated hemoglobin, serum total
      cholesterol, triglyceride, LDL-cholesterol, apolipoprotein B (ApoB) and
      high-sensitive C-reactive protein (hsCRP) levels were significantly increased,
      whereas HDL-cholesterol and serum nitrite levels were significantly decreased in 
      T2D patients. However, children of T2D patients who were not diabetic did not
      show significant increase in the IMT, as compared to those of healthy controls.
      In conclusion, the present study demonstrate that IMT was significantly higher in
      the T2D patients and increased with age and family history. The increased levels 
      of lipids, hsCRP, IMT and decreased nitrite levels might contribute to the risk
      of endothelial dysfunction in patients with T2D. However, further studies are
      warranted with other biomarkers of endothelial dysfunction in T2D patients with
      increased sample size.
AD  - Dept of Biochemistry, ACS Medical College & Hospital, Chennai, India.
      arjunbio@gmail.com
FAU - Dhananjayan, R
AU  - Dhananjayan R
FAU - Malati, T
AU  - Malati T
FAU - Brindha, G
AU  - Brindha G
FAU - Kutala, Vijay Kumar
AU  - Kutala VK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Indian J Biochem Biophys
JT  - Indian journal of biochemistry & biophysics
JID - 0310774
SB  - IM
EDAT- 2013/06/01 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/06/01 06:00
PST - ppublish
SO  - Indian J Biochem Biophys. 2013 Apr;50(2):93-8.

PMID- 23720787
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 6
DP  - 2013 Jun
TI  - Prediction of gestational diabetes mellitus by soluble (pro)renin receptor during
      the first trimester.
PG  - 2528-35
LID - 10.1210/jc.2012-4139 [doi]
AB  - Context: There are currently no factors that have been shown to predict
      gestational diabetes mellitus (GDM) during early pregnancy. The soluble
      (pro)renin receptor [s(P)RR] may contribute to the development of GDM. Objective:
      The objective of the study was to determine whether plasma s(P)RR concentrations 
      during early pregnancy are associated with the development of GDM later in
      pregnancy. Design, Setting, and Participants: This prospective cohort study was
      conducted at a referral birth center. Pregnant women who first visited our
      hospital during the first trimester (<14 weeks of gestation) between 2010 and
      2011 were enrolled. Inclusion criteria included singleton pregnancy and the
      absence of preexisting diabetes mellitus. A total of 716 women participated in
      this study. Main Outcome Measure: The association of plasma s(P)RR concentrations
      with the onset of GDM later in pregnancy was measured. Results: Among 716
      participants, 44 (6.1%) had GDM and 672 (93.9%) did not. There were 176
      participants in the first plasma s(P)RR concentration quartile (Q1: < 25.8
      ng/mL), 179 in the second (Q2: 25.8-30.2 ng/mL), 181 in the third (Q3: 30.2-34.2 
      ng/mL), and 180 in the fourth (Q4: > 34.2 ng/mL). GDM distribution was 7 (4.0%)
      in Q1, 5 (2.8%) in Q2, 13 (7.2%) in Q3, and 19 (10.6%) in Q4. A multivariate
      model adjusted for baseline characteristics, medical complications, and
      gestational characteristics revealed that the risk of developing GDM among women 
      in Q4 compared with Q1 was 2.90 (95% confidence interval 1.11-7.49). Conclusion: 
      Increased s(P)RR concentrations during the first trimester may predict the
      development of GDM later in pregnancy.
AD  - MD, PhD, Department of Endocrinology and Hypertension, Tokyo Women's Medical
      University, 8-1 Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan.
      atzichi@endm.twmu.ac.jp.
FAU - Watanabe, Noriyoshi
AU  - Watanabe N
FAU - Morimoto, Satoshi
AU  - Morimoto S
FAU - Fujiwara, Takeo
AU  - Fujiwara T
FAU - Suzuki, Tomo
AU  - Suzuki T
FAU - Taniguchi, Kosuke
AU  - Taniguchi K
FAU - Mori, Fumiko
AU  - Mori F
FAU - Ando, Takashi
AU  - Ando T
FAU - Watanabe, Daisuke
AU  - Watanabe D
FAU - Kimura, Tadashi
AU  - Kimura T
FAU - Sago, Haruhiko
AU  - Sago H
FAU - Ichihara, Atsuhiro
AU  - Ichihara A
LA  - eng
PT  - Journal Article
DEP - 20130529
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/05/29 [aheadofprint]
AID - jc.2012-4139 [pii]
AID - 10.1210/jc.2012-4139 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Jun;98(6):2528-35. doi: 10.1210/jc.2012-4139. Epub 
      2013 May 29.

PMID- 23720784
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 29
TI  - Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote
      invasion and progression of thyroid cancer.
AB  - Context:The functional relationships between intronic miRNAs and their host genes
      in thyroid cancer remain unclear. MiR-218, a miRNA down-regulated in several
      kinds of cancers and associated with multiple cancer phenotypes, is transcribed
      from two loci located on chromosomes 4p15.31 (miR-218-1) and 5q35.1 (miR-218-2)
      within the introns of SLIT2 and SLIT3, respectively.Objective:The aim of our work
      was to investigate the expression and the roles of miR-218-1 and miR-218-2, as
      well as their host genes SLIT2 and SLIT3 in thyroid carcinogenesis.Design:The
      expression of miR-218-1 and miR-218-2, as well as their host genes SLIT2 and
      SLIT3 in a panel of normal and neoplastic human thyroid tissues was assessed by
      quantitative RT-PCR. We restored the expression of miR-218-2 and SLIT3 in thyroid
      cancer cells and evaluated their effects on cell invasion, migration, and
      proliferation.Results:We found that miR-218-2 and its host gene SLIT3 were
      down-regulated concomitantly in thyroid cancer. Synergistic inhibitory effects of
      miR-218-2 with SLIT3 on thyroid cancer cell invasion, migration, and
      proliferation were observed. Moreover, the effects of miR-218-2 on thyroid cancer
      cells were due to, at least partially, targeting PDGFRA and
      PLCG1.Conclusions:These results implicate the involvement of miR-218-2 and its
      host genes SLIT3 in thyroid cancer cell invasion, migration, and proliferation.
      Our findings highlight the functional associations of intronic miRNAs and their
      host genes in thyroid carcinogenesis.
AD  - Department of Endocrinology and Diabetes Center (H.G., G. W., D. F., Z. L., H.
      X., Y. L.), The First Affiliated Hospital of Sun Yat-sen University; Key
      Laboratory of Tropical Disease Control (Sun Yat-sen University) (J. W., M. L.),
      Ministry of Education, Guangzhou, Guangdong 510080, China.
FAU - Guan, Hongyu
AU  - Guan H
FAU - Wei, Gouhong
AU  - Wei G
FAU - Wu, Jueheng
AU  - Wu J
FAU - Fang, Donghong
AU  - Fang D
FAU - Liao, Zhihong
AU  - Liao Z
FAU - Xiao, Haipeng
AU  - Xiao H
FAU - Li, Mengfeng
AU  - Li M
FAU - Li, Yanbing
AU  - Li Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - jc.2013-1053 [pii]
AID - 10.1210/jc.2013-1053 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 29.

PMID- 23720772
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 May 29
TI  - Metformin Increases Mitochondrial Energy Formation in L6 Muscle Cell Cultures.
AB  - A popular hypothesis for the action of metformin, the widely used anti-diabetes
      drug, is the inhibition of mitochondrial respiration, specifically at complex I. 
      This is consistent with metformin stimulation of glucose uptake by muscle and
      inhibition of gluconeogenesis by liver. Yet, mitochondrial inhibition is
      inconsistent with metformin stimulation of fatty acid oxidation in both tissues. 
      In the present study we measured mitochondrial energy production in intact cells 
      adapting an in vivo technique of phosphocreatine (PCr) formation following energy
      interruption (PCr recovery) to cell cultures. Metformin increased PCr recovery
      from either dinitrophenol (DNP) or azide in L6 cells. We found that metformin
      alone had no effect on cell viability as measured by total ATP concentration,
      trypan blue exclusion, or MTT reduction. However, treatments with low
      concentrations of DNP or azide reversibly decreased ATP concentration. Metformin 
      increased MTT reduction during recovery from either agent. Viability measured by 
      trypan blue exclusion indicated that cells were intact under these conditions. We
      also found that metformin increased free AMP, and to a smaller extent, free ADP
      concentrations in cells, an action that was duplicated by a structurally
      unrelated AMP deaminase inhibitor. We conclude that, in intact cells, metformin
      can lead to a stimulation of energy formation, rather than an inhibition.
AD  - St. John's University, United States.
FAU - Vytla, Veeravenkata S
AU  - Vytla VS
FAU - Ochs, Raymond S
AU  - Ochs RS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - AMP
OT  - AMP kinase
OT  - AMP-activated kinase (AMPK)
OT  - ATP
OT  - Cell metabolism
OT  - Metabolic regulation
OT  - Mitochondrial metabolism
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - M113.482646 [pii]
AID - 10.1074/jbc.M113.482646 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 May 29.

PMID- 23720760
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1535-9484 (Electronic)
IS  - 1535-9476 (Linking)
DP  - 2013 May 29
TI  - Mass isotopomer analysis of metabolically labeled nucleotide sugars and N- and
      O-glycans for tracing nucleotide sugar metabolisms.
AB  - Nucleotide sugars are the donor substrates of various glycosyltransferases, and
      an important building block in N- and O-glycan biosynthesis. Their intercellular 
      concentrations are regulated by cellular metabolic states including diseases such
      as cancer and diabetes. In order to investigate the fate of UDP-GlcNAc, we
      developed a tracing method for UDP-GlcNAc synthesis and utilization, and GlcNAc
      utilization using 13C6-glucose and 13C2-glucosamine, respectively, followed by
      the analysis of mass isotopomers using liquid chromatography-mass spectrometry.
      Metabolic labeling of cultured cells with 13C6-glucose and the analysis of
      isotopomers of UDP-HexNAc (UDP-GlcNAc plus UDP-GalNAc) and CMP-NeuAc revealed the
      relative contributions of metabolic pathways leading to UDP-GlcNAc synthesis and 
      utilization. In pancreatic insulinoma cells, the labeling efficiency of a
      13C6-glucose motif in CMP-NeuAc was lower compared with that in hepatoma cells.
      Using 13C2-glucosamine, the diversity of the labeling efficiency was observed in 
      each sugar residue of N- and O-glycans on the basis of isotopomer analysis. In
      the insulinoma cells, the low labeling efficiencies were found for sialic acids
      as well as tri- and tetra-sialo N-glycans, whereas asialo N-glycans were found to
      be abundant. Essentially no significant difference in secreted hyaluronic acids
      was found among hepatoma and insulinoma cell lines. This indicates that metabolic
      flows are responsible for the low sialylation in the insulinoma cells. Our
      strategy would be useful for systematically tracing each stage of cellular GlcNAc
      metabolism.
AD  - RIKEN Global Research Cluster, Japan;
FAU - Nakajima, Kazuki
AU  - Nakajima K
FAU - Ito, Emi
AU  - Ito E
FAU - Ohtsubo, Kazuaki
AU  - Ohtsubo K
FAU - Shirato, Ken
AU  - Shirato K
FAU - Takamiya, Rina
AU  - Takamiya R
FAU - Kitazume, Shinobu
AU  - Kitazume S
FAU - Angata, Takashi
AU  - Angata T
FAU - Taniguchi, Naoyuki
AU  - Taniguchi N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Mol Cell Proteomics
JT  - Molecular & cellular proteomics : MCP
JID - 101125647
OTO - NOTNLM
OT  - Glycoprotein Pathways*
OT  - Glycoproteins*
OT  - Mass Spectrometry
OT  - Metabolomics
OT  - Separation Technologies
OT  - glycomics
OT  - nucleotide sugar
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - M112.027151 [pii]
AID - 10.1074/mcp.M112.027151 [doi]
PST - aheadofprint
SO  - Mol Cell Proteomics. 2013 May 29.

PMID- 23720653
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130530
DCOM- 20130531
LR  - 20130603
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 4
DP  - 2013
TI  - Anti-neurotrophic effects from autoantibodies in adult diabetes having primary
      open angle glaucoma or dementia.
PG  - 58
LID - 10.3389/fendo.2013.00058 [doi]
AB  - Aim: To test for anti-endothelial and anti-neurotrophic effects from
      autoantibodies in subsets of diabetes having open-angle glaucoma, dementia, or
      control subjects. Methods: Protein-A eluates from plasma of 20 diabetic subjects 
      having glaucoma or suspects and 34 age-matched controls were tested for effects
      on neurite outgrowth in rat pheochromocytoma PC12 cells or endothelial cell
      survival. The mechanism of the diabetic glaucoma autoantibodies'
      neurite-inhibitory effect was investigated in co-incubations with the selective
      Rho kinase inhibitor Y27632 or the sulfated proteoglycan synthesis inhibitor
      sodium chlorate. Stored protein-A eluates from certain diabetic glaucoma or
      dementia subjects which contained long-lasting, highly stable cell inhibitory
      substances were characterized using mass spectrometry and amino acid sequencing. 
      Results: Diabetic primary open angle glaucoma (POAG) or suspects (n = 20) or
      diabetic dementia (n = 3) autoantibodies caused significantly greater mean
      inhibition of neurite outgrowth in PC12 cells (p < 0.0001) compared to
      autoantibodies in control diabetic (n = 24) or non-diabetic (n = 10) subjects
      without glaucoma (p < 0.01). Neurite inhibition by the diabetic glaucoma
      autoantibodies was completely abolished by 10 muM concentrations of Y27632 (n =
      4). It was substantially reduced by 30 mM concentrations of sodium chlorate (n = 
      4). Peak, long-lasting activity survived storage x5 years at 0-4 degrees C and
      was associated with a restricted subtype of Ig kappa light chain. Diabetic
      glaucoma or dementia autoantibodies (n = 5) caused contraction and process
      retraction in quiescent cerebral cortical astrocytes effects which were blocked
      by 5 muM concentrations of Y27632. Conclusion: These data suggest that
      autoantibodies in subsets of adult diabetes having POAG (glaucoma suspects)
      and/or dementia inhibit neurite outgrowth and promote a reactive astrocyte
      morphology by a mechanism which may involve activation of the RhoA/p160 ROCK
      signaling pathway.
AD  - Medical Service, New Jersey Health Care System, Department of Veterans Affairs
      Lyons, NJ, USA ; Robert Wood Johnson Medical School, University of Medicine and
      Dentistry of New Jersey New Brunswick, NJ, USA.
FAU - Zimering, Mark B
AU  - Zimering MB
FAU - Moritz, Thomas E
AU  - Moritz TE
FAU - Donnelly, Robert J
AU  - Donnelly RJ
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC3654220
OID - NLM: PMC3654220
OTO - NOTNLM
OT  - autoantibodies
OT  - dementia
OT  - diabetes mellitus
OT  - neurite outgrowth
OT  - open angle glaucoma
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:01
CRDT- 2013/05/31 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/25 [received]
PHST- 2013/05/01 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.3389/fendo.2013.00058 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2013 May 15;4:58. doi: 10.3389/fendo.2013.00058.
      Print 2013.

PMID- 23720608
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130530
DCOM- 20130531
LR  - 20130603
IS  - 0044-5991 (Print)
IS  - 0044-5991 (Linking)
VI  - 46
IP  - 2
DP  - 2013 Apr 30
TI  - Altered dynamics in the renal lymphatic circulation of type 1 and type 2 diabetic
      mice.
PG  - 97-104
LID - 10.1267/ahc.13006 [doi]
AB  - The dynamics of the renal lymphatic circulation in diabetic nephropathy is not
      fully elucidated. The present study evaluated the effect of diabetic nephropathy 
      on the renal lymphatic circulation in streptozotocin (STZ)-induced type 1
      diabetic mice (ICR-STZ) and in type 2 diabetic KK/Ta mice which were fed a high
      fat diet (KK/Ta-HF). The diabetic mouse kidneys developed edema because of the
      nephropathy. In control mice renal lymphatic vessels distributed in the cortex
      but rarely in the medulla while in ICR-STZ and KK/Ta-HF mice, there were many
      lymphatic vessels with small lumen in both cortex and medulla. Total numbers and 
      areas of renal blood vessels in the diabetic mice were similar to those in the
      controls while the total numbers and areas of renal lymphatic vessels were larger
      in diabetic mice than in the controls. There were statistically significant
      differences in the numbers of lymphatic vessels with diameters of 50-100 microm
      between the ICR-STZ and the control ICR mice, and in the numbers of lymphatic
      capillaries with diameters smaller than 50 microm between the KK/Ta-HF and the
      control KK/Ta mice. The diabetic nephropathy may induce the lymphangiogenesis or 
      result in at least the renal lymphatic vessel expansion.
AD  - Department of Oral Growth & Development, Fukuoka Dental College 2-15-1 Tamura,
      Sawara-ku, Fukuoka 814-0193, Japan.
FAU - Uchiyama, Takanobu
AU  - Uchiyama T
FAU - Takata, Shunsuke
AU  - Takata S
FAU - Ishikawa, Hiroyuki
AU  - Ishikawa H
FAU - Sawa, Yoshihiko
AU  - Sawa Y
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - Japan
TA  - Acta Histochem Cytochem
JT  - Acta histochemica et cytochemica
JID - 0147110
PMC - PMC3661779
OID - NLM: PMC3661779
OTO - NOTNLM
OT  - diabetes
OT  - kidney
OT  - lymphangiogenesis
OT  - lymphatics
OT  - nephropathy
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:01
CRDT- 2013/05/31 06:00
PHST- 2013/02/06 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/12 [epublish]
AID - 10.1267/ahc.13006 [doi]
AID - AHC13006 [pii]
PST - ppublish
SO  - Acta Histochem Cytochem. 2013 Apr 30;46(2):97-104. doi: 10.1267/ahc.13006. Epub
      2013 Apr 12.

PMID- 23720603
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130530
DCOM- 20130531
LR  - 20130603
IS  - 0044-5991 (Print)
IS  - 0044-5991 (Linking)
VI  - 46
IP  - 2
DP  - 2013 Apr 30
TI  - TGF-beta Signaling Regulates Pancreatic beta-Cell Proliferation through Control
      of Cell Cycle Regulator p27 Expression.
PG  - 51-8
LID - 10.1267/ahc.12035 [doi]
AB  - Proliferation of pancreatic beta-cells is an important mechanism underlying
      beta-cell mass adaptation to metabolic demands. Increasing beta-cell mass by
      regeneration may ameliorate or correct both type 1 and type 2 diabetes, which
      both result from inadequate production of insulin by beta-cells of the pancreatic
      islet. Transforming growth factor beta (TGF-beta) signaling is essential for
      fetal development and growth of pancreatic islets. In this study, we exposed
      HIT-T15, a clonal pancreatic beta-cell line, to TGF-beta signaling. We found that
      inhibition of TGF-beta signaling promotes proliferation of the cells
      significantly, while TGF-beta signaling stimulation inhibits proliferation of the
      cells remarkably. We confirmed that this proliferative regulation by TGF-beta
      signaling is due to the changed expression of the cell cycle regulator p27.
      Furthermore, we demonstrated that there is no observed effect on transcriptional 
      activity of p27 by TGF-beta signaling. Our data show that TGF-beta signaling
      mediates the cell-cycle progression of pancreatic beta-cells by regulating the
      nuclear localization of CDK inhibitor, p27. Inhibition of TGF-beta signaling
      reduces the nuclear accumulation of p27, and as a result this inhibition promotes
      proliferation of beta-cells.
AD  - Department of Pathology and Cell Regulation, Kyoto Prefectural University of
      Medicine ; Department of Transplantation and Regenerative Surgery, Kyoto
      Prefectural University of Medicine.
FAU - Suzuki, Tomoyuki
AU  - Suzuki T
FAU - Dai, Ping
AU  - Dai P
FAU - Hatakeyama, Tomoya
AU  - Hatakeyama T
FAU - Harada, Yoshinori
AU  - Harada Y
FAU - Tanaka, Hideo
AU  - Tanaka H
FAU - Yoshimura, Norio
AU  - Yoshimura N
FAU - Takamatsu, Tetsuro
AU  - Takamatsu T
LA  - eng
PT  - Journal Article
DEP - 20130305
PL  - Japan
TA  - Acta Histochem Cytochem
JT  - Acta histochemica et cytochemica
JID - 0147110
PMC - PMC3661777
OID - NLM: PMC3661777
OTO - NOTNLM
OT  - HIT-T15 cells
OT  - TGF-β signaling
OT  - inhibition
OT  - p27
OT  - pancreatic β-cell proliferation
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:01
CRDT- 2013/05/31 06:00
PHST- 2012/10/01 [received]
PHST- 2013/01/31 [accepted]
PHST- 2013/03/05 [epublish]
AID - 10.1267/ahc.12035 [doi]
AID - AHC12035 [pii]
PST - ppublish
SO  - Acta Histochem Cytochem. 2013 Apr 30;46(2):51-8. doi: 10.1267/ahc.12035. Epub
      2013 Mar 5.

PMID- 23720487
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
DP  - 2013 May 29
TI  - Ethnicity and stroke risk in patients with atrial fibrillation.
AB  - OBJECTIVE: To examine the prevalence of atrial fibrillation (AF) and stroke risk 
      by ethnic group in south and east London; to compare classification with
      CHA2DS2VASc and CHADS2; to examine the appropriateness of anticoagulant treatment
      and historic trends in prescribing by gender, age, and ethnicity. DESIGN:
      Cross-sectional study. SETTING: Routine general practice records from south and
      east London. PATIENTS: Patients aged 18 years or over with AF. MAIN OUTCOME
      MEASURES: Risk of stroke by CHA2DS2VASc and CHADS2 score, and prescription of
      anticoagulant. RESULTS: In 2011, we identified 6292 patients with AF, with an age
      adjusted prevalence of 0.63% (1.2% white, 0.4% black African/Caribbean and 0.2%
      South Asian). 93% of the AF population were at high risk of stroke with a
      CHA2DS2VASc score >/=1, of whom 54% were on warfarin. South Asian patients were
      at higher stroke risk than white patients (OR 1.67, 95% CI 1.02 to 2.73).
      Warfarin under-prescribing in people over 80 years of age persisted without
      improvement throughout 2008-2011. There were no clear differences in warfarin use
      by ethnic group. CONCLUSIONS: Despite a reduced prevalence of AF among South
      Asian patients, their risk of stroke is higher than for white patients or black
      African/Caribbean patients in association with diabetes, cardiovascular disease, 
      and hypertension. Under-prescription of anticoagulation persists in all ethnic
      groups, a deficit most pronounced in the elderly. Use of the CHA2DS2VASc score
      would enhance optimal management in primary care.
AD  - Queen Mary University of London, , London, UK.
FAU - Mathur, Rohini
AU  - Mathur R
FAU - Pollara, Elizabeth
AU  - Pollara E
FAU - Hull, Sally
AU  - Hull S
FAU - Schofield, Peter
AU  - Schofield P
FAU - Ashworth, Mark
AU  - Ashworth M
FAU - Robson, John
AU  - Robson J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - heartjnl-2013-303767 [pii]
AID - 10.1136/heartjnl-2013-303767 [doi]
PST - aheadofprint
SO  - Heart. 2013 May 29.

PMID- 23720454
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
DP  - 2013 May 29
TI  - Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary
      tract cancer and hepatocellular carcinoma in a European cohort.
AB  - BACKGROUND: Evidence on associations between self-reported diabetes mellitus,
      diabetes duration, age at diabetes diagnosis, insulin treatment, and risk of
      biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), independent of
      general and abdominal obesity is scarce. PATIENTS AND METHODS: We conducted a
      prospective analysis in the EPIC-cohort study among 363 426 participants with
      self-reported diabetes data. Multivariable adjusted relative risks and 95%
      confidence intervals were estimated from Cox regression models. In a nested
      case-control subset, analyses were carried out in HCV/HBV-negative individuals.
      RESULTS: During 8.5 years of follow-up, 204 BTC cases [including 75 gallbladder
      cancer (GBC) cases], and 176 HCC cases were identified. Independent of body mass 
      index and waist-to-height ratio diabetes status was associated with higher risk
      of BTC and HCC [1.77 (1.00-3.13) and 2.17 (1.36-3.47)]. For BTC, the risk seemed 
      to be higher in participants with shorter diabetes duration and those not treated
      with insulin. Regarding cancer subsites, diabetes was only associated with GBC
      [2.72 (1.17-6.31)]. The risk for HCC was particularly higher in participants
      treated with insulin. The results were not appreciably different in
      HCV/HBV-negative individuals. CONCLUSION(S): This study supports the hypothesis
      that diabetes is a risk factor for BTC (particularly GBC) and HCC. Further
      research is required to establish whether diabetes treatment or duration is
      associated with these cancers.
AD  - Institute of Epidemiology, Christian-Albrechts University of Kiel, Kiel.
FAU - Schlesinger, S
AU  - Schlesinger S
FAU - Aleksandrova, K
AU  - Aleksandrova K
FAU - Pischon, T
AU  - Pischon T
FAU - Jenab, M
AU  - Jenab M
FAU - Fedirko, V
AU  - Fedirko V
FAU - Trepo, E
AU  - Trepo E
FAU - Overvad, K
AU  - Overvad K
FAU - Roswall, N
AU  - Roswall N
FAU - Tjonneland, A
AU  - Tjonneland A
FAU - Boutron-Ruault, M C
AU  - Boutron-Ruault MC
FAU - Fagherazzi, G
AU  - Fagherazzi G
FAU - Racine, A
AU  - Racine A
FAU - Kaaks, R
AU  - Kaaks R
FAU - Grote, V A
AU  - Grote VA
FAU - Boeing, H
AU  - Boeing H
FAU - Trichopoulou, A
AU  - Trichopoulou A
FAU - Pantzalis, M
AU  - Pantzalis M
FAU - Kritikou, M
AU  - Kritikou M
FAU - Mattiello, A
AU  - Mattiello A
FAU - Sieri, S
AU  - Sieri S
FAU - Sacerdote, C
AU  - Sacerdote C
FAU - Palli, D
AU  - Palli D
FAU - Tumino, R
AU  - Tumino R
FAU - Peeters, P H
AU  - Peeters PH
FAU - Bueno-de-Mesquita, H B
AU  - Bueno-de-Mesquita HB
FAU - Weiderpass, E
AU  - Weiderpass E
FAU - Quiros, J R
AU  - Quiros JR
FAU - Zamora-Ros, R
AU  - Zamora-Ros R
FAU - Sanchez, M J
AU  - Sanchez MJ
FAU - Arriola, L
AU  - Arriola L
FAU - Ardanaz, E
AU  - Ardanaz E
FAU - Tormo, M J
AU  - Tormo MJ
FAU - Nilsson, P
AU  - Nilsson P
FAU - Lindkvist, B
AU  - Lindkvist B
FAU - Sund, M
AU  - Sund M
FAU - Rolandsson, O
AU  - Rolandsson O
FAU - Khaw, K T
AU  - Khaw KT
FAU - Wareham, N
AU  - Wareham N
FAU - Travis, R C
AU  - Travis RC
FAU - Riboli, E
AU  - Riboli E
FAU - Nothlings, U
AU  - Nothlings U
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical
      Oncology / ESMO
JID - 9007735
OTO - NOTNLM
OT  - biliary tract neoplasms
OT  - diabetes duration
OT  - diabetes mellitus
OT  - gallbladder neoplasms
OT  - hepatocellular carcinoma
OT  - insulin treatment
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - mdt204 [pii]
AID - 10.1093/annonc/mdt204 [doi]
PST - aheadofprint
SO  - Ann Oncol. 2013 May 29.

PMID- 23720331
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 2040-4603 (Electronic)
IS  - 2040-4603 (Linking)
VI  - 3
IP  - 2
DP  - 2013 Apr 1
TI  - Renal vascular structure and rarefaction.
PG  - 817-31
LID - 10.1002/cphy.c120012 [doi]
AB  - An intact microcirculation is vital for diffusion of oxygen and nutrients and for
      removal of toxins of every organ and system in the human body. The functional
      and/or anatomical loss of microvessels is known as rarefaction, which can
      compromise the normal organ function and have been suggested as a possible
      starting point of several diseases. The purpose of this overview is to discuss
      the potential underlying mechanisms leading to renal microvascular rarefaction,
      and the potential consequences on renal function and on the progression of renal 
      damage. Although the kidney is a special organ that receives much more blood than
      its metabolic needs, experimental and clinical evidence indicates that renal
      microvascular rarefaction is associated to prevalent cardiovascular diseases such
      as diabetes, hypertension, and atherosclerosis, either as cause or consequence.
      On the other hand, emerging experimental evidence using progenitor cells or
      angiogenic cytokines supports the feasibility of therapeutic interventions
      capable of modifying the progressive nature of microvascular rarefaction in the
      kidney. This overview will also attempt to discuss the potential renoprotective
      mechanisms of the therapeutic targeting of the renal microcirculation. (c) 2013
      American Physiological Society. Compr Physiol 3:817-831, 2013.
AD  - The Department of Physiology and Biophysics, Center for Excellence in
      Cardiovascular-Renal Research, and the Department of Medicine, University of
      Mississippi Medical Center, Jackson, Mississippi.
FAU - Chade, Alejandro R
AU  - Chade AR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Compr Physiol
JT  - Comprehensive Physiology
JID - 101574442
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1002/cphy.c120012 [doi]
PST - ppublish
SO  - Compr Physiol. 2013 Apr 1;3(2):817-31. doi: 10.1002/cphy.c120012.

PMID- 23720325
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 2040-4603 (Electronic)
IS  - 2040-4603 (Linking)
VI  - 3
IP  - 2
DP  - 2013 Apr 1
TI  - Hepatic nervous system and neurobiology of the liver.
PG  - 655-65
LID - 10.1002/cphy.c120018 [doi]
AB  - The liver has a nervous system containing both afferent and efferent neurons that
      are involved in a number of processes. The afferent arm includes the sensation of
      lipids, glucose, and metabolites (after eating and drinking) and triggers the
      nervous system to make appropriate physiological changes. The efferent arm is
      essential for metabolic regulation, modulation of fibrosis and biliary function
      and the control of a number of other processes. Experimental models have helped
      us to establish how: (i) the liver is innervated by the autonomic nervous system;
      and (ii) the cell types that are involved in these processes. Thus, the liver
      acts as both a sensor and effector that is influenced by neurological signals and
      ablation. Understanding these processes hold significant implications in disease 
      processes such as diabetes and obesity, which are influenced by appetite and
      hormonal signals. (c) 2013 American Physiological Society. Compr Physiol
      3:655-6665, 2013.
AD  - Department of Medicine, Division of Gastroenterology, and Texas A&M Health
      Science Center, College of Medicine, Temple, Texas.
FAU - Jensen, Kendal Jay
AU  - Jensen KJ
FAU - Alpini, Gianfranco
AU  - Alpini G
FAU - Glaser, Shannon
AU  - Glaser S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Compr Physiol
JT  - Comprehensive Physiology
JID - 101574442
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1002/cphy.c120018 [doi]
PST - ppublish
SO  - Compr Physiol. 2013 Apr 1;3(2):655-65. doi: 10.1002/cphy.c120018.

PMID- 23720247
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
DP  - 2013 May 29
TI  - Mortality Implications of Angina and Blood Pressure in Hypertensive Patients With
      Coronary Artery Disease: New Data From Extended Follow-up of the International
      Verapamil/Trandolapril Study (INVEST).
LID - 10.1002/clc.22145 [doi]
AB  - BACKGROUND: Angina and hypertension are common in patients with coronary artery
      disease (CAD); however, the effect on mortality is unclear. We conducted this
      prespecified analysis of the International Verapamil/Trandolapril Study (INVEST) 
      to assess relationships between angina, blood pressure (BP), and mortality among 
      elderly, hypertensive CAD patients. HYPOTHESIS: Angina and elevated BP will be
      associated with higher mortality. METHODS: Extended follow-up was performed using
      the National Death Index for INVEST patients in the United States (n = 16 951).
      Based on angina history at enrollment and during follow-up visits, patients were 
      divided into groups: persistent angina (n = 7184), new-onset angina (n = 899),
      resolved angina (n = 4070), and never angina (n = 4798). Blood pressure was
      evaluated at baseline, during drug titration, and during follow-up on-treatment. 
      On-treatment systolic BP was classified as tightly controlled (<130 mm Hg),
      controlled (130-139 mm Hg), or uncontrolled (>/=140 mm Hg). A Cox proportional
      hazards model was created adjusting for age, heart failure, diabetes, renal
      impairment, myocardial infarction, stroke, and smoking. The angina groups and BP 
      control groups were compared using the never-angina group as the reference.
      RESULTS: Only in the persistent-angina group was a significant association with
      mortality observed, with an apparent protective effect (hazard ratio: 0.82, 95%
      confidence interval: 0.75-0.89, P < 0.0001). Uncontrolled BP was associated with 
      increased mortality risk (hazard ratio: 1.29, 95% confidence interval: 1.20-1.40,
      P < 0.0001), as were several other known cardiovascular risk factors.
      CONCLUSIONS: In hypertensive CAD patients, persistent angina was associated with 
      lower mortality. The observed effect was small compared with other cardiovascular
      risk factors, such as BP, which were associated with increased mortality.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Division of Cardiovascular Medicine, College of Medicine, University of Florida, 
      Gainesville, Florida.
FAU - Winchester, David E
AU  - Winchester DE
FAU - Cooper-Dehoff, Rhonda M
AU  - Cooper-Dehoff RM
FAU - Gong, Yan
AU  - Gong Y
FAU - Handberg, Eileen M
AU  - Handberg EM
FAU - Pepine, Carl J
AU  - Pepine CJ
CN  - for the INVEST Investigators
LA  - ENG
GR  - K23 HL086558/HL/NHLBI NIH HHS/United States
GR  - UL1 TR000064/TR/NCATS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/03/07 [received]
PHST- 2013/04/18 [revised]
AID - 10.1002/clc.22145 [doi]
PST - aheadofprint
SO  - Clin Cardiol. 2013 May 29. doi: 10.1002/clc.22145.

PMID- 23720171
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 23
DP  - 2013 Jun
TI  - [Diabetes and the liver].
PG  - 1204-6
LID - 10.1055/s-0033-1343180 [doi]
AD  - Molekulare Stoffwechselkontrolle (A170), Deutsches Krebsforschungszentrum (DKFZ).
FAU - Herzig, S
AU  - Herzig S
FAU - Roden, M
AU  - Roden M
LA  - ger
PT  - Journal Article
TT  - Diabetes und Leber.
DEP - 20130529
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/05/29 [epublish]
AID - 10.1055/s-0033-1343180 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 Jun;138(23):1204-6. doi: 10.1055/s-0033-1343180. Epub 
      2013 May 29.

PMID- 23720123
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1432-2323 (Electronic)
IS  - 0364-2313 (Linking)
DP  - 2013 May 30
TI  - Effect of Diabetes on Outcomes in Patients Undergoing Emergency Cholecystectomy
      for Acute Cholecystitis.
AD  - Department of Visceral Surgery and Medicine, Bern University Hospital, University
      of Bern, Bern, Switzerland.
FAU - Schettle, Markus
AU  - Schettle M
FAU - Beldi, Guido
AU  - Beldi G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - World J Surg
JT  - World journal of surgery
JID - 7704052
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1007/s00268-013-2113-7 [doi]
PST - aheadofprint
SO  - World J Surg. 2013 May 30.

PMID- 23720058
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
DP  - 2013 May 29
TI  - Which Patient is Most Likely to Benefit From Dronedarone? Analysis From the
      Magdeburg Dronedarone Registry (MADRE Study).
LID - 10.1002/jcph.103 [doi]
AB  - Based on an analysis of the Magdeburg Dronedarone Registry data we sought to
      determine which patients could benefit from dronedarone therapy regarding rhythm 
      control. The study included 191 patients (85 women) aged 63 +/- 10 years with a
      history of paroxysmal or persistent AF and a follow-up of 14 +/- 5 months. The
      total AF recurrence rate was 67% and lone AF was significantly more often
      associated with AF recurrences than non-lone AF (84% vs. 62%, P = .01). Arterial 
      hypertension, treated coronary artery disease, and diabetes mellitus were not
      significantly related to AF recurrences (64%, 67%, 58% resp. P = .3). Response
      rate to dronedarone in patients with slightly increased left atrial size was
      significantly greater than in patients with normal or markedly increased left
      atrial size (47%, 16%, 27% resp., P = .001). The rate of adverse effects was 32% 
      in the study sample, and was significantly lower in patients with lone AF as
      compared to those with non-lone AF (11% vs. 37%, P = .002). The body mass index
      was a predictor neither of response rate nor adverse effects. The results suggest
      that dronedarone is more effective in patients with non-lone AF and slightly
      increased left atrial size.
CI  - (c) The Author(s) 2013.
AD  - Division of Cardiology, Otto-von-Guericke University, University Hospital
      Magdeburg, Centre of Internal Medicine, Magdeburg, Germany.
FAU - Said, Samir M
AU  - Said SM
FAU - Esperer, Hans D
AU  - Esperer HD
FAU - Kluba, Kathrin
AU  - Kluba K
FAU - Genz, Conrad
AU  - Genz C
FAU - Rauwolf, Thomas
AU  - Rauwolf T
FAU - Schmeisser, Alexander
AU  - Schmeisser A
FAU - Braun-Dullaeus, Ruediger C
AU  - Braun-Dullaeus RC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/02/20 [received]
PHST- 2012/04/14 [accepted]
AID - 10.1002/jcph.103 [doi]
PST - aheadofprint
SO  - J Clin Pharmacol. 2013 May 29. doi: 10.1002/jcph.103.

PMID- 23720049
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1477-9129 (Electronic)
IS  - 0950-1991 (Linking)
DP  - 2013 May 29
TI  - Specification of hepatopancreas progenitors in zebrafish by hnf1ba and wnt2bb.
AB  - Although the liver and ventral pancreas are thought to arise from a common
      multipotent progenitor pool, it is unclear whether these progenitors of the
      hepatopancreas system are specified by a common genetic mechanism. Efforts to
      determine the role of Hnf1b and Wnt signaling in this crucial process have been
      confounded by a combination of factors, including a narrow time frame for
      hepatopancreas specification, functional redundancy among Wnt ligands, and
      pleiotropic defects caused by either severe loss of Wnt signaling or Hnf1b
      function. Using a novel hypomorphic hnf1ba zebrafish mutant that exhibits
      pancreas hypoplasia, as observed in HNF1B monogenic diabetes, we show that hnf1ba
      plays essential roles in regulating beta-cell number and pancreas specification, 
      distinct from its function in regulating pancreas size and liver specification,
      respectively. By combining Hnf1ba partial loss of function with conditional loss 
      of Wnt signaling, we uncover a crucial developmental window when these pathways
      synergize to specify the entire ventrally derived hepatopancreas progenitor
      population. Furthermore, our in vivo genetic studies demonstrate that hnf1ba
      generates a permissive domain for Wnt signaling activity in the foregut endoderm.
      Collectively, our findings provide a new model for HNF1B function, yield insight 
      into pancreas and beta-cell development, and suggest a new mechanism for
      hepatopancreatic specification.
FAU - Lancman, Joseph J
AU  - Lancman JJ
FAU - Zvenigorodsky, Natasha
AU  - Zvenigorodsky N
FAU - Gates, Keith P
AU  - Gates KP
FAU - Zhang, Danhua
AU  - Zhang D
FAU - Solomon, Keely
AU  - Solomon K
FAU - Humphrey, Rohan K
AU  - Humphrey RK
FAU - Kuo, Taiyi
AU  - Kuo T
FAU - Setiawan, Linda
AU  - Setiawan L
FAU - Verkade, Heather
AU  - Verkade H
FAU - Chi, Young-In
AU  - Chi YI
FAU - Jhala, Ulupi S
AU  - Jhala US
FAU - Wright, Christopher V E
AU  - Wright CV
FAU - Stainier, Didier Y R
AU  - Stainier DY
FAU - Dong, P Duc Si
AU  - Dong PD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Development
JT  - Development (Cambridge, England)
JID - 8701744
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - dev.090993 [pii]
AID - 10.1242/dev.090993 [doi]
PST - aheadofprint
SO  - Development. 2013 May 29.

PMID- 23720025
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2013 May 30
TI  - The prevalence of thyroid nodules and its relationship with metabolic parameters 
      in a Chinese community-based population aged over 40 years.
AB  - To investigate the prevalence of thyroid nodules (TN) among a community
      population aged >40 years and to explore the association between TN and its
      metabolic risk factors. Data from 9,533 adults aged over 40 years who
      participated in the epidemiological investigation of thyroid nodules in a Chinese
      community-based population from June to December 2011 were included in the
      analyses. We compared the levels of metabolic indices between the TN group and
      healthy controls. The prevalence of TN was 46.6 % (39.7 %, men; 50.3 %, women)
      and it increased significantly with increasing age (P < 0.001). It was
      significantly higher in the group with hypertension than in that with
      normotension (P < 0.001) and was 43.0 % in the normal blood glucose group, 49.4 %
      in the prediabetes group, and 50.9 % in the diabetes group (P < 0.001). Logistic 
      regression analysis indicated that hypertension [odds ratio (OR) = 1.121
      (1.025-1.225)] as well as prediabetes and diabetes [OR = 1.130 (1.036-1.233)]
      were all independent risk factors for TN after adjustment for sex, age, body mass
      index, blood lipid levels, smoking status, and alcohol consumption. The elderly
      population had a high prevalence of TN. Hypertension as well as prediabetes and
      diabetes might be independent risk factors for TN.
AD  - Department of Endocrinology, First Affiliated Hospital of Nanjing Medical
      University, 300 Guangzhou Rd, Nanjing, 210029, China.
FAU - Guo, Hongwei
AU  - Guo H
FAU - Sun, Min
AU  - Sun M
FAU - He, Wei
AU  - He W
FAU - Chen, Huanhuan
AU  - Chen H
FAU - Li, Wen
AU  - Li W
FAU - Tang, Jinmei
AU  - Tang J
FAU - Tang, Wei
AU  - Tang W
FAU - Lu, Jieli
AU  - Lu J
FAU - Bi, Yufang
AU  - Bi Y
FAU - Ning, Guang
AU  - Ning G
FAU - Yang, Tao
AU  - Yang T
FAU - Duan, Yu
AU  - Duan Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Endocrine
JT  - Endocrine
JID - 9434444
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2012/11/25 [received]
PHST- 2013/04/20 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 10.1007/s12020-013-9968-0 [doi]
PST - aheadofprint
SO  - Endocrine. 2013 May 30.

PMID- 23719966
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1742-2051 (Electronic)
IS  - 1742-2051 (Linking)
DP  - 2013 May 30
TI  - Biomarkers for early diagnosis of type 2 diabetic nephropathy: a study based on
      an integrated biomarker system.
AB  - Diabetic nephropathy is a devastating disease that affects a growing number of
      diabetic patients. A complete cure is very hard to achieve once the disease has
      been diagnosed, therefore the diagnosis of early stages in diabetic nephropathy
      has become a hot area. Numbers of molecules have been proposed to be potential
      biomarkers for this purpose. However, some problems still remain, such as
      discovering effective biomarkers to diagnose the disease before obvious clinical 
      evidence appears. Thus, the main purpose of this study was to find plasma
      biomarkers for early diagnosis of type 2 diabetic nephropathy stage 1 and stage
      2, as well as separating them from diabetes. 182 subjects (Chinese) were
      recruited for this study, including 50 healthy controls, 33 type 2 diabetic
      patients and 99 type 2 diabetic nephropathy patients (33 of these were stage 3). 
      Important clinical indicators including proteinuria, serum creatinine, and urea
      nitrogen were measured and the glomerular filtration rate was estimated to assess
      kidney function; fasting blood glucose, postprandial blood glucose and glycated
      hemoglobin were measured to assess the blood glucose control. Key metabolites and
      genes in plasma samples were identified and determined using -omic and
      quantitative techniques. The potential biomarkers were then combined and
      carefully screened to determine the most informative ones for early diagnosis of 
      type 2 diabetic nephropathy. An integrated biomarker system (IBS) incorporating 6
      clinical indicators, 40 metabolites and 5 genes was established. Correlation
      analysis results revealed that most of the potential biomarkers significantly
      correlated with the 6 clinical indicators. Discriminant analysis results showed
      that the developed IBS gave the highest total predictive accuracy (98.9%).
      Significant test and receiver operating characteristic analysis results indicated
      that inosine had the highest sensitivity (0.889), specificity (1.000), positive
      predictive rate (1.000) and negative predictive rate (0.900) amongst the 48
      potential biomarkers when separating patients with diabetes from patients with
      diabetic nephropathy stage 3. Finally, inosine with a cutoff of 0.086 mg L-1 was 
      combined with estimated GFR to differentiate between diabetic nephropathy stages 
      1 and 2 from diabetes. The results demonstrate that IBS combined with a proper
      statistical analysis technique is a powerful tool for biomarker screening.
AD  - Department of Chemistry, Tsinghua University, Beijing 100084, PR China.
      luoga@mail.tsinghua.edu.cn liangql@mail.tsinghua.edu.cn.
FAU - Huang, Min
AU  - Huang M
FAU - Liang, Qionglin
AU  - Liang Q
FAU - Li, Ping
AU  - Li P
FAU - Xia, Jianfei
AU  - Xia J
FAU - Wang, Yong
AU  - Wang Y
FAU - Hu, Ping
AU  - Hu P
FAU - Jiang, Zhiting
AU  - Jiang Z
FAU - He, Yongxin
AU  - He Y
FAU - Pang, Liqiong
AU  - Pang L
FAU - Han, Lida
AU  - Han L
FAU - Wang, Yiming
AU  - Wang Y
FAU - Luo, Guoan
AU  - Luo G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Mol Biosyst
JT  - Molecular bioSystems
JID - 101251620
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1039/c3mb25543c [doi]
PST - aheadofprint
SO  - Mol Biosyst. 2013 May 30.

PMID- 23719877
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 70
IP  - 12
DP  - 2013 Jun 15
TI  - Hypertension and diabetes mellitus medication management in sleeve gastrectomy
      patients.
PG  - 1018-20
LID - 10.2146/ajhp120607 [doi]
AD  - Dwight D. Eisenhower Army Medical CenterHospital Road Building 300Fort Gordon, GA
      30905chris.bland@us.army.milAdjunct Assistant ProfessorCollege of
      PharmacyUniversity of GeorgiaAthens, GA.
FAU - Bland, Christopher M
AU  - Bland CM
FAU - Tritsch, Adam M
AU  - Tritsch AM
FAU - Bookstaver, David A
AU  - Bookstaver DA
FAU - Sweeney, Lori B
AU  - Sweeney LB
FAU - Wiley, Dan
AU  - Wiley D
FAU - Choi, Yong U
AU  - Choi YU
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the
      American Society of Health-System Pharmacists
JID - 9503023
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 70/12/1018 [pii]
AID - 10.2146/ajhp120607 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2013 Jun 15;70(12):1018-20. doi: 10.2146/ajhp120607.

PMID- 23719847
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
DP  - 2013 May 30
TI  - Prevalence and clinical characteristics of primary aldosteronism in Japanese
      patients with type 2 diabetes mellitus and hypertension.
AB  - The prevalence of primary aldosteronism (PA) is around 3-15% in patients with
      hypertension. Hypertension is a frequent complication of type 2 diabetes mellitus
      (DM) because of the close etiological relationship between these two diseases.
      However, the possibility of PA in patients with DM and hypertension is often
      overlooked and the prevalence of PA in patients with DM and hypertension in Japan
      is unknown. We enrolled 124 hospitalized patients with both DM and hypertension. 
      PA was diagnosed according to the modified criteria for Japanese patients. We
      examined the prevalence of PA and compared clinical characteristics between
      patients with and without PA. In another analysis of 43 patients with a confirmed
      diagnosis of PA, we compared the characteristics of patients with and without DM.
      Overall, 14/124 patients with DM and hypertension (11.3%) were diagnosed with PA.
      Multivariate logistic regression showed that the duration of DM was significantly
      shorter in the PA group. Fisher's direct probability test revealed that history
      of hypertension before the diagnosis of DM was a significant factor in patients
      with PA. Treatment with an angiotensin II receptor blocker (ARB) did not affect
      the diagnosis of PA in these patients. Among 43 patients with PA, those with DM
      were significantly older and the delay to the diagnosis of PA was significantly
      longer compared with patients without DM. In conclusion, almost 10% of patients
      with DM and hypertension actually have PA. More extensive screening for PA is
      recommended in patients with DM and hypertension, regardless of the use of ARBs.
AD  - Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka
      University, Fukuoka 814-0180, Japan.
FAU - Murase, Kunitaka
AU  - Murase K
FAU - Nagaishi, Ryoko
AU  - Nagaishi R
FAU - Takenoshita, Hiromasa
AU  - Takenoshita H
FAU - Nomiyama, Takashi
AU  - Nomiyama T
FAU - Akehi, Yuko
AU  - Akehi Y
FAU - Yanase, Toshihiko
AU  - Yanase T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - DN/JST.JSTAGE/endocrj/EJ13-0060 [pii]
PST - aheadofprint
SO  - Endocr J. 2013 May 30.

PMID- 23719783
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
DP  - 2013 May 29
TI  - Cell transplantation therapy for diabetes mellitus: endocrine pancreas and
      adipocyte [Review].
AB  - Experimental transplantation of endocrine tissues has led to significant advances
      in our understanding of endocrinology and metabolism. Endocrine cell
      transplantation therapy is expected to be applied to the treatment of metabolic
      endocriopathies. Restoration of functional pancreatic beta-cell mass or of
      functional adipose mass are reasonable treatment approaches for patients with
      diabetes or lipodystrophy, respectively. Human induced pluripotent stem (iPS)
      cell research is having a great impact on life sciences. Doctors Takahashi and
      Yamanaka discovered that the forced expression of a set of genes can convert
      mouse and human somatic cells into a pluripotent state [1, 2]. These iPS cells
      can differentiate into a variety of cell types. Therefore, iPS cells from
      patients may be a potential cell source for autologous cell replacement therapy. 
      This review briefly summarizes the current knowledge about transplantation
      therapy for diabetes mellitus, the development of the endocrine pancreas and
      adipocytes, and endocrine-metabolic disease-specific iPS cells.
AD  - Division of Endocrinology and Metabolism, Kyoto University Hospital, Kyoto
      606-8507, Japan.
FAU - Fujikura, Junji
AU  - Fujikura J
FAU - Hosoda, Kiminori
AU  - Hosoda K
FAU - Nakao, Kazuwa
AU  - Nakao K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - DN/JST.JSTAGE/endocrj/EJ13-0162 [pii]
PST - aheadofprint
SO  - Endocr J. 2013 May 29.

PMID- 23719722
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1172-7047 (Electronic)
IS  - 1172-7047 (Linking)
DP  - 2013 May 30
TI  - Intranasal Insulin as a Treatment for Alzheimer's Disease: A Review of Basic
      Research and Clinical Evidence.
AB  - Research in animals and humans has associated Alzheimer's disease (AD) with
      decreased cerebrospinal fluid levels of insulin in combination with decreased
      insulin sensitivity (insulin resistance) in the brain. This phenomenon is
      accompanied by attenuated receptor expression of insulin and insulin-like growth 
      factor, enhanced serine phosphorylation of insulin receptor substrate-1, and
      impaired transport of insulin across the blood-brain barrier. Moreover, clinical 
      trials have demonstrated that intranasal insulin improves both memory performance
      and metabolic integrity of the brain in patients suffering from AD or its
      prodrome, mild cognitive impairment. These results, in conjunction with the
      finding that insulin mitigates hippocampal synapse vulnerability to beta amyloid,
      a peptide thought to be causative in the development of AD, provide a strong
      rationale for hypothesizing that pharmacological strategies bolstering brain
      insulin signaling, such as intranasal administration of insulin, could have
      significant potential in the treatment and prevention of AD. With this view in
      mind, the review at hand will present molecular mechanisms potentially underlying
      the memory-enhancing and neuroprotective effects of intranasal insulin. Then, we 
      will discuss the results of intranasal insulin studies that have demonstrated
      that enhancing brain insulin signaling improves memory and learning processes in 
      both cognitively healthy and impaired humans. Finally, we will provide an
      overview of neuroimaging studies indicating that disturbances in insulin
      metabolism-such as insulin resistance in obesity, type 2 diabetes and AD-and
      altered brain responses to insulin are linked to decreased cerebral volume and
      especially to hippocampal atrophy.
AD  - Department of Diagnostic and Interventional Neuroradiology, RWTH Aachen
      University, Pauwelsstr. 30, 52074, Aachen, Germany, jfreiherr@ukaachen.de.
FAU - Freiherr, Jessica
AU  - Freiherr J
FAU - Hallschmid, Manfred
AU  - Hallschmid M
FAU - Frey, William H 2nd
AU  - Frey WH 2nd
FAU - Brunner, Yvonne F
AU  - Brunner YF
FAU - Chapman, Colin D
AU  - Chapman CD
FAU - Holscher, Christian
AU  - Holscher C
FAU - Craft, Suzanne
AU  - Craft S
FAU - De Felice, Fernanda G
AU  - De Felice FG
FAU - Benedict, Christian
AU  - Benedict C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - CNS Drugs
JT  - CNS drugs
JID - 9431220
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1007/s40263-013-0076-8 [doi]
PST - aheadofprint
SO  - CNS Drugs. 2013 May 30.

PMID- 23719693
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1347-7439 (Electronic)
IS  - 0916-7250 (Linking)
DP  - 2013 May 28
TI  - Molecular Characterization and Tissue Distribution of Feline Retinol-Binding
      Protein 4.
AB  - Retinol-binding protein 4 (RBP4) is a specific transporter of retinol and was
      recently identified as an adipokine potentially involved in type 2 diabetes in
      humans and rodents. However, the function and structure of feline RBP4 have not
      been reported. In this study, we describe the molecular cloning and expression
      analysis of feline RBP4. The complete feline RBP4 cDNA encodes a precursor
      protein comprising an 18 amino acid signal peptide and a 183 amino acid mature
      protein. Feline RBP4 was mapped to chromosome D2. Mature feline RBP4 is 83-94%
      homologous to the RBPs of humans, cows and rodents. RT-PCR analysis revealed
      feline RBP4 expression in liver and adipose tissues.
AD  - Laboratory of Veterinary Biochemistry, School of Veterinary Medicine, Nippon
      Veterinary and Life Science University.
FAU - Sasaki, Noriyasu
AU  - Sasaki N
FAU - Ishibashi, Miwa
AU  - Ishibashi M
FAU - Soeta, Satoshi
AU  - Soeta S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Vet Med Sci
JT  - The Journal of veterinary medical science / the Japanese Society of Veterinary
      Science
JID - 9105360
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - DN/JST.JSTAGE/jvms/13-0131 [pii]
PST - aheadofprint
SO  - J Vet Med Sci. 2013 May 28.

PMID- 23719679
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 0312-5963 (Electronic)
IS  - 0312-5963 (Linking)
DP  - 2013 May 30
TI  - The Role of Pharmacogenetics in Drug Disposition and Response of Oral
      Glucose-Lowering Drugs.
AB  - The primary goal of type 2 diabetes mellitus (T2DM) disease management is
      improvement of quality of life and prevention of complications. One way to
      achieve these goals is improving glycemic control by using different types of
      oral glucose-lowering medications. Currently seven different pharmacological oral
      glucose-lowering drug classes are available, each with its own mechanism of
      action and characteristics regarding absorption, distribution, metabolism, and
      elimination. Unfortunately, the response to the different types of
      glucose-lowering medication is highly variable between individuals resulting in
      unnecessary treatment failure. Genetic factors are thought to contribute to the
      variability in response and may present an opportunity to improve treatment
      outcome. In recent years, many efforts were taken to identify genetic variants
      that influence the pharmacokinetics, pharmacodynamics, and ultimately the
      therapeutic response of the different oral glucose-lowering drugs. Indeed several
      genetic variants are associated with the response to oral glucose-lowering drugs.
      This review comprises current knowledge on genetic variants affecting both
      pharmacokinetics and pharmacodynamics of oral glucose-lowering drugs. Included
      variants are located in genes coding for drug transporters, i.e., the organic
      anion-transporting family and the organic cation transporter family; genes
      involved in metabolism, i.e., cytochrome P450 superfamily; genes coding for drug 
      receptors; T2DM-associated genes; and genes identified by genome-wide association
      studies (GWASs). Furthermore, this review provides insight into current status
      and future directions for personalized medicine in T2DM.
AD  - Department of Molecular Cell Biology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - van Leeuwen, N
AU  - van Leeuwen N
FAU - Swen, J J
AU  - Swen JJ
FAU - Guchelaar, H-J
AU  - Guchelaar HJ
FAU - 't Hart, L M
AU  - 't Hart LM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Clin Pharmacokinet
JT  - Clinical pharmacokinetics
JID - 7606849
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1007/s40262-013-0076-3 [doi]
PST - aheadofprint
SO  - Clin Pharmacokinet. 2013 May 30.

PMID- 23719610
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1424-3911 (Electronic)
IS  - 1424-3903 (Linking)
VI  - 13
IP  - 3
DP  - 2013 May-Jun
TI  - Pancreatic glucagonoma with pancreatic calcification.
PG  - 327-9
LID - 10.1016/j.pan.2012.11.308 [doi]
LID - S1424-3903(12)00526-1 [pii]
AB  - BACKGROUND: Glucagonoma is an uncommon type of pancreatic neuroendocrine tumor
      [NET] which is characterized by diabetes mellitus, necrolytic migratory erythema,
      depression and deep vein thrombosis. The typical rash is often misdiagnosed and
      the diagnosis is delayed by 7-8 years. Pancreatic NETs and other pancreatic
      tumors are known to show calcifications within the tumor but calcification of the
      remaining normal pancreas is very uncommon. It occurs when there is ductal
      obstruction leading to acute or chronic pancreatitis. CASE REPORT: We present a
      case of glucagonoma with coexistent pancreatic calcification. CONCLUSION:
      Glucagonoma should be suspected in a diabetic patient with migratory rash.
      Pancreatic tumor should be suspected in patient with idiopathic focal
      pancreatitis.
CI  - Copyright (c) 2012 IAP and EPC. Published by Elsevier B.V. All rights reserved.
AD  - Department of Surgical Gastroenterology, Jaslok Hospital and Research Centre,
      Mumbai, Maharashtra, India.
FAU - Gupta, Rahul Amreesh
AU  - Gupta RA
FAU - Udwadia, F E
AU  - Udwadia FE
FAU - Agrawal, Pravin
AU  - Agrawal P
FAU - Doctor, Nilesh
AU  - Doctor N
LA  - eng
PT  - Journal Article
DEP - 20121123
PL  - Switzerland
TA  - Pancreatology
JT  - Pancreatology : official journal of the International Association of
      Pancreatology (IAP) ... [et al.]
JID - 100966936
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2012/11/04 [received]
PHST- 2012/11/12 [revised]
PHST- 2012/11/12 [accepted]
PHST- 2012/11/23 [aheadofprint]
AID - S1424-3903(12)00526-1 [pii]
AID - 10.1016/j.pan.2012.11.308 [doi]
PST - ppublish
SO  - Pancreatology. 2013 May-Jun;13(3):327-9. doi: 10.1016/j.pan.2012.11.308. Epub
      2012 Nov 23.

PMID- 23719602
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1424-3911 (Electronic)
IS  - 1424-3903 (Linking)
VI  - 13
IP  - 3
DP  - 2013 May-Jun
TI  - Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic
      cancer.
PG  - 285-9
LID - 10.1016/j.pan.2013.03.013 [doi]
LID - S1424-3903(13)00077-X [pii]
AB  - BACKGROUND/OBJECTIVES: Diabetes mellitus (DM) is recognized as a risk factor for 
      pancreatic cancer (PaC) and expected to be a clue for early diagnosis. However,
      it is still obscure whether a diagnostic strategy using DM as a clue can improve 
      the prognosis or not. METHODS: We retrospectively reviewed 540 patients with PaC,
      and investigated the prognosis with regard to the reasons for diagnosis. We
      compared patients diagnosed by imaging studies performed when DM was newly
      diagnosed or deteriorated, and patients diagnosed by symptoms. RESULTS: The
      prevalence of DM in PaC patients was 45% (256/540) and did not differ between
      disease stages. More than half of DM in PaC patients (150/256) were new-onset (<2
      years in duration). One hundred sixty one patients (30%) were asymptomatic at PaC
      diagnosis. There were 38 patients diagnosed in association with DM (by new-onset 
      DM, 16; by aggravation of long-standing DM, 22). Asymptomatic patients had
      smaller primary tumor and were diagnosed at an earlier stage. The prognosis of
      PaC patients complicated with DM did not differ from that of patients without DM;
      however, patients had better prognosis if they were diagnosed in association with
      DM alone (median survival time, 20.2 months), compared with patients diagnosed by
      symptoms (10.2 months, P < 0.01). CONCLUSIONS: Our analysis revealed that
      patients diagnosed in association with DM had better survival than symptomatic
      patients. Given the high prevalence of DM in PaC patients, DM can be a useful
      diagnostic clue for screening and lead to improvement of prognosis in PaC
      patients.
CI  - Copyright (c) 2013 IAP and EPC. Published by Elsevier B.V. All rights reserved.
AD  - Department of Gastroenterology, Graduate School of Medicine, The University of
      Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
FAU - Mizuno, Suguru
AU  - Mizuno S
FAU - Nakai, Yousuke
AU  - Nakai Y
FAU - Isayama, Hiroyuki
AU  - Isayama H
FAU - Takahara, Naminatsu
AU  - Takahara N
FAU - Miyabayashi, Koji
AU  - Miyabayashi K
FAU - Yamamoto, Keisuke
AU  - Yamamoto K
FAU - Kawakubo, Kazumichi
AU  - Kawakubo K
FAU - Mohri, Dai
AU  - Mohri D
FAU - Kogure, Hirofumi
AU  - Kogure H
FAU - Sasaki, Takashi
AU  - Sasaki T
FAU - Yamamoto, Natsuyo
AU  - Yamamoto N
FAU - Sasahira, Naoki
AU  - Sasahira N
FAU - Hirano, Kenji
AU  - Hirano K
FAU - Tsujino, Takeshi
AU  - Tsujino T
FAU - Ijichi, Hideaki
AU  - Ijichi H
FAU - Tateishi, Keisuke
AU  - Tateishi K
FAU - Tada, Minoru
AU  - Tada M
FAU - Koike, Kazuhiko
AU  - Koike K
LA  - eng
PT  - Journal Article
DEP - 20130402
PL  - Switzerland
TA  - Pancreatology
JT  - Pancreatology : official journal of the International Association of
      Pancreatology (IAP) ... [et al.]
JID - 100966936
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/01/23 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/02 [aheadofprint]
AID - S1424-3903(13)00077-X [pii]
AID - 10.1016/j.pan.2013.03.013 [doi]
PST - ppublish
SO  - Pancreatology. 2013 May-Jun;13(3):285-9. doi: 10.1016/j.pan.2013.03.013. Epub
      2013 Apr 2.

PMID- 23719562
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1348-4400 (Electronic)
IS  - 0916-8818 (Linking)
DP  - 2013 May 30
TI  - Insulin-like Growth Factor 1 (IGF1) mRNA Expression in the Uterus of
      Streptozotocin (STZ)-treated Diabetic Mice.
AB  - Reproductive functions decline with the onset of diabetes in female mice.
      Diabetic mice have smaller uteri with an underdeveloped endometrium, suggesting
      diminished estrogen-induced growth. We aimed to clarify the changes in the
      estrous cycle and in insulin-like growth factor 1 (IGF1) expression in the uteri 
      of streptozotocin (STZ)-treated diabetic mice, because IGF1 is one of the main
      growth factors involved in estrogen-induced uterine growth. ICR female mice were 
      intraperitoneally administered STZ (10 mg/100 g BW), and blood glucose levels
      were determined. Mice with blood glucose levels > 200 mg/dl were classified as
      diabetic mice. The onset of diabetes was associated with acyclic estrous cycles. 
      Diabetes was also induced with STZ in ovariectomized mice. Uterine Igf1 mRNA
      levels were reduced in ovariectomized STZ-treated diabetic mice. Estrogen is
      known to stimulate Igf1 mRNA expression in the uterus, but estrogen action was
      abolished in the uteri of STZ-treated diabetic mice. mRNA expressions of estrogen
      receptor alpha (ERalpha) and steroid hormone receptor coactivators (SRC-1/Ncoa1, 
      SRC-2/Ncoa2, SRC-3/Ncoa3 and CBP/p300/Crebbp) were reduced in the uteri of
      ovariectomized STZ-treated diabetic mice. The present study demonstrates that
      diabetes induces a decline in female reproductive functions in mice. Igf1
      expression in ovariectomized diabetic female mice was decreased, and decreased
      responsiveness to estrogen in the uteri of diabetic mice is probably associated
      with a reduction in ERalpha and steroid receptor coactivator mRNA expression.
AD  - The Graduate School of Natural Science and Technology, Okayama University,
      Okayama 700-8530, Japan.
FAU - Manabe, Yoshie
AU  - Manabe Y
FAU - Tochigi, Makoto
AU  - Tochigi M
FAU - Moriwaki, Akiyoshi
AU  - Moriwaki A
FAU - Takeuchi, Sakae
AU  - Takeuchi S
FAU - Takahashi, Sumio
AU  - Takahashi S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Reprod Dev
JT  - The Journal of reproduction and development
JID - 9438792
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - DN/JST.JSTAGE/jrd/2012-169 [pii]
PST - aheadofprint
SO  - J Reprod Dev. 2013 May 30.

PMID- 23719550
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1938-3207 (Electronic)
IS  - 0002-9165 (Linking)
DP  - 2013 May 29
TI  - Weight-loss diets in people with type 2 diabetes and renal disease: a randomized 
      controlled trial of the effect of different dietary protein amounts.
AB  - BACKGROUND: Higher-protein weight-loss diets (defined as >25% of energy as
      protein) are not recommended for individuals with type 2 diabetes because of
      their potential adverse effect on renal function. OBJECTIVE: We aimed to examine 
      the effect of such diets on renal function over 12 mo in people with type 2
      diabetes and early renal disease. DESIGN: Overweight and obese people with type 2
      diabetes were screened to identify those with an albumin:creatinine ratio from 3 
      to 30 mg/mmol. Seventy-six subjects were randomly assigned to either a
      moderate-protein weight-loss diet or a standard-protein weight-loss diet for 12
      mo. The primary endpoint was the change in renal function as assessed by the
      isotope glomerular filtration rate (GFR), estimated GFR, and cystatin C.
      Forty-five subjects (moderate protein: n = 21; standard protein: n = 24)
      completed the study. RESULTS: The mean (+/-SE) weight loss was not different
      between diets at 9.7 +/- 13.4 kg for the moderate-protein diet and 6.6 +/- 7.1 kg
      for the standard-protein diet. There were no changes in renal function or
      albuminuria or blood pressure, although glycated hemoglobin was lowered with both
      diets. Changes in renal function were related to the baseline estimated GFR.
      Patients with stage 1-3 renal disease (<120 mL . min-1 . 1.73 m-2; n = 33) had an
      improvement in renal function, whereas patients with hyperfiltration (>120 mL .
      min-1 . 1.73 m-2; n = 12) had a decrease in the GFR. After adjustment for weight 
      loss, the baseline GFR remained a significant predictor of outcomes with no
      effect of dietary treatment. An average difference in protein intake between
      diets of 19 +/- 6 g/d was achieved. CONCLUSION: Weight loss improved renal
      function, but differences in dietary protein had no effect. This trial was
      registered at the Australian and New Zealand Clinical Trial Register as
      ACTRN12608000045314.
AD  - Commonwealth Scientific and Industrial Research Organisation Animal Food and
      Health Science, Adelaide University, Centre for Clinical Research Excellence in
      Nutrition and University of South Australia, Adelaide, Australia.
FAU - Jesudason, David R
AU  - Jesudason DR
FAU - Pedersen, Eva
AU  - Pedersen E
FAU - Clifton, Peter M
AU  - Clifton PM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - ajcn.113.060889 [pii]
AID - 10.3945/ajcn.113.060889 [doi]
PST - aheadofprint
SO  - Am J Clin Nutr. 2013 May 29.

PMID- 23719521
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 38
IP  - 5
DP  - 2013 May
TI  - [Effect of Cordyceps sinensis on expressions of HIF-1alpha and VEGF in the kidney
      of rats with diabetic nephropathy].
PG  - 448-57
LID - 10.3969/j.issn.1672-7347.2013.05.003 [doi]
AB  - Objective: To examine the expressions of hypoxia inducible factor-1alpha
      (HIF-1alpha) and vascular endothelial growth factor (VEGF) in the kidney of rats 
      with diabetic nephropathy before and after the treatment of Cordyceps sinensis,
      and to explore the mechanism of Cordyceps sinensis against hypoxia. Methods: The 
      diabetes model was produced by intraperitoneal injection of 60 mg/kg
      streptozotocin, then the rats whose 24 h urine protein level was above 30 mg/d
      were thought to have suffered diabetic nephropathy. Thirty rats were randomly
      divided into a diabetic nephropathy group (DN group, n=15) and a Cordyceps
      sinensis group (CS group, n=15), and another 15 normal rats served as a normal
      control group (NC group, n=15). The CS group were intragastrically administered
      Cordyceps sinensis extract liquid [5.0 g/(kg.d)], the other groups were
      intragastrically administered drinking water of equal volume. Five rats in each
      group were killed after 2, 4, and 6 weeks. The 24 h urine protein excretion,
      urine beta-N-acetyl glucosaminidase (NAGase) and serum creatinine were measured; 
      the renal pathological changes were evaluated by HE and Masson staining; the mRNA
      and protein expressions of HIF-1alpha and VEGF were dectected by reverse
      transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry.
      Results: Compared with the normal control group, the renal tubular vacuolar
      degeneration was obvious, and the glomerular mesangial matrix increased in the DN
      group. The 24 h urinary protein excretion, urine NAGase and serum creatinine also
      increased significantly (all P<0.05); the expressions of HIF-1alpha and VEGF in
      the renal tissue gradually increased with time, and the expression of HIF-1alpha 
      was correlated with that of VEGF in the 2 groups (r=0.850, r=0.887, both P<0.05) 
      . Compared with the DN group, the pathological changes were relieved, the 24 h
      urinary protein excretion, urine NAGase and serum creatinine level were
      decreased, and the expressions of HIF-1alpha and VEGF decreased in the CS group
      (all P<0.05), but they were still higher than those in the normal contral group
      (P<0.05). There was no significant difference in the mRNA and protein expression 
      of HIF-1alpha between the 4th week and the 6th week after the treatment of CS
      (P>0.05). Conclusion: The expressions of HIF-1alpha and VEGF increase in the
      kidney of rats with diabetic nephropathy, and the positive correlation suggests
      that there is chronic hypoxia in the renal tissue of diabetic nephropathy.
      Cordyceps sinensis may protect against chronic hypoxia injury in diabetic
      nephropathy by lowering the expressions of HIF-1alpha and VEGF.
AD  - Department of Nephrology , Xiangya Hospital, Central South University, Changsha
      410008, China.
FAU - Yuan, Mingxia
AU  - Yuan M
FAU - Tang, Rong
AU  - Tang R
FAU - Zhou, Qiaoling
AU  - Zhou Q
FAU - Liu, Kanghan
AU  - Liu K
FAU - Xiao, Zhou
AU  - Xiao Z
FAU - Pouranan, Veeraragoo
AU  - Pouranan V
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University.
      Medical sciences
JID - 101230586
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.3969/j.issn.1672-7347.2013.05.003 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 May;38(5):448-57. doi:
      10.3969/j.issn.1672-7347.2013.05.003.

PMID- 23719501
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 0917-5857 (Print)
IS  - 0917-5857 (Linking)
VI  - 23
IP  - 6
DP  - 2013 Jun
TI  - [Wnt signal and Bone. Serum sclerostin levels and metabolic bone diseases].
PG  - 877-83
LID - CliCa1306877883 [doi]
AB  - Serum sclerostin levels are being investigated in various metabolic bone
      diseases. Since serum sclerostin levels are decreased in primary
      hyperparathyroidism and elevated in hypoparathyroidism, parathyroid hormone (PTH)
      is thought to be a regulatory factor for sclerostin. Serum sclerostin levels
      exhibit a significant positive correlation with bone mineral density. On the
      other hand, a couple of studies on postmenopausal women have shown that high
      serum sclerostin levels are a risk factor for fracture. Although glucocorticoid
      induced osteoporosis and diabetes are both diseases that reduce bone formation,
      serum sclerostin levels have been reported to be decreased in the former and
      elevated in the latter, suggesting differences in the effects of sclerostin in
      the two diseases. Serum sclerostin levels are correlated with renal function, and
      increase with reduction in renal function. Serum sclerostin level may be a new
      index of bone assessment that differs from bone mineral density and bone
      metabolic markers.
AD  - Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
FAU - Yamauchi, Mika
AU  - Yamauchi M
FAU - Sugimoto, Toshitsugu
AU  - Sugimoto T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Clin Calcium
JT  - Clinical calcium
JID - 9433326
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 1306877883 [pii]
AID - CliCa1306877883 [doi]
PST - ppublish
SO  - Clin Calcium. 2013 Jun;23(6):877-83. doi: CliCa1306877883.

PMID- 23719477
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1878-5506 (Electronic)
IS  - 1389-9457 (Linking)
DP  - 2013 May 26
TI  - The prevalence of impaired glucose regulation in psychiatric patients with sleep 
      disorders and its relationship with altered hypothalamopituitary-adrenal and
      hypothalamopituitary-thyroid axis activity.
LID - S1389-9457(13)00135-4 [pii]
LID - 10.1016/j.sleep.2013.04.004 [doi]
AB  - BACKGROUND: Sleep restriction, an important symptom of psychiatric diseases, is
      associated with adverse effects on glucose regulation, but few studies have
      examined its association with impaired glucose regulation and altered
      hypothalamic activity. Our study was designed to evaluate the sleep duration,
      fasting glucose, tolerance glucose, and concentration of plasma insulin; to
      assess the function of both the hypothalamopituitary-thyroid (HPT) and
      hypothalamopituitary-adrenal (HPA) axis; and to investigate the relationship of
      altered hypothalamic function with glucose metabolism in psychiatric patients
      with a sleep disorders. METHODS: From January 2010 to December 2011, 324 women
      (64.7%) and 177 men (35.32%) with a diagnosis of a sleep disorder participated in
      our cross-sectional study in the psychiatric outpatient department of the West
      China Hospital of Sichuan University. Results from 75-g glucose tolerance tests, 
      insulin-releasing tests, morning (8:00am) serum cortisol, and thyroid-stimulating
      hormone (TSH) (TT3, TT4, FT3, FT4) were collected, as well as body mass index and
      waist-hip ratio to assess the prevalence of impaired glucose regulation and
      function of the HPA and HPT axis. Sleep quality was assessed through
      self-reported questionnaires. RESULTS: There were 301 patients previously
      diagnosed with an anxiety disorder (78%), and 200 patients previously diagnosed
      with depression and other psychiatric diseases (22%). Crude prevalence rates were
      15.0% for diabetes mellitus (DM), 11.6% for impaired glucose tolerance, 15.8% for
      impaired fasting glucose, and 11.6% for impaired glucose regulation (impaired
      glucose tolerance [IGT]+impaired fasting glucose [IFG]). Total prevalence of
      impaired glucose regulation in patients with a sleep disorder was 48.8%. Mean
      cortisol level was 463.5+/-178.8nmol/L, and the cortisol concentration at 8:00am 
      was significantly associated with a higher prevalence of impaired glucose
      regulation and insulin resistance. TSH values above 2.5mU/L accounted for over
      58% and were significantly associated with insulin resistance. CONCLUSIONS: These
      results partially confirm that a high level of cortisol and an increased activity
      of the HPT axis are associated with impaired glucose regulation. Therefore, as a 
      pathophysiologic event abnormal activity of the hypothalamic function of
      psychiatric patients with sleep disorders could be viewed as a potential risk
      factor for increasing incidence of DM.
CI  - Crown Copyright (c) 2013. Published by Elsevier B.V. All rights reserved.
AD  - Department of Endocrinology and Metabolism, West China Hospital, Sichuan
      University, Chengdu, China.
FAU - Li, Jiaqi
AU  - Li J
FAU - Sun, Xueli
AU  - Sun X
FAU - Yu, Yerong
AU  - Yu Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Sleep Med
JT  - Sleep medicine
JID - 100898759
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2012/11/13 [received]
PHST- 2013/02/03 [revised]
PHST- 2013/04/03 [accepted]
AID - S1389-9457(13)00135-4 [pii]
AID - 10.1016/j.sleep.2013.04.004 [doi]
PST - aheadofprint
SO  - Sleep Med. 2013 May 26. pii: S1389-9457(13)00135-4. doi:
      10.1016/j.sleep.2013.04.004.

PMID- 23719380
OWN - NLM
STAT- In-Process
DA  - 20130606
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 498
IP  - 7452
DP  - 2013 Jun 6
TI  - Gut metagenome in European women with normal, impaired and diabetic glucose
      control.
PG  - 99-103
LID - 10.1038/nature12198 [doi]
AB  - Type 2 diabetes (T2D) is a result of complex gene-environment interactions, and
      several risk factors have been identified, including age, family history, diet,
      sedentary lifestyle and obesity. Statistical models that combine known risk
      factors for T2D can partly identify individuals at high risk of developing the
      disease. However, these studies have so far indicated that human genetics
      contributes little to the models, whereas socio-demographic and environmental
      factors have greater influence. Recent evidence suggests the importance of the
      gut microbiota as an environmental factor, and an altered gut microbiota has been
      linked to metabolic diseases including obesity, diabetes and cardiovascular
      disease. Here we use shotgun sequencing to characterize the faecal metagenome of 
      145 European women with normal, impaired or diabetic glucose control. We observe 
      compositional and functional alterations in the metagenomes of women with T2D,
      and develop a mathematical model based on metagenomic profiles that identified
      T2D with high accuracy. We applied this model to women with impaired glucose
      tolerance, and show that it can identify women who have a diabetes-like
      metabolism. Furthermore, glucose control and medication were unlikely to have
      major confounding effects. We also applied our model to a recently described
      Chinese cohort and show that the discriminant metagenomic markers for T2D differ 
      between the European and Chinese cohorts. Therefore, metagenomic predictive tools
      for T2D should be specific for the age and geographical location of the
      populations studied.
AD  - Department of Chemical and Biological Engineering, Chalmers University of
      Technology, SE-412 96 Gothenburg, Sweden.
FAU - Karlsson, Fredrik H
AU  - Karlsson FH
FAU - Tremaroli, Valentina
AU  - Tremaroli V
FAU - Nookaew, Intawat
AU  - Nookaew I
FAU - Bergstrom, Goran
AU  - Bergstrom G
FAU - Behre, Carl Johan
AU  - Behre CJ
FAU - Fagerberg, Bjorn
AU  - Fagerberg B
FAU - Nielsen, Jens
AU  - Nielsen J
FAU - Backhed, Fredrik
AU  - Backhed F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130529
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
SB  - IM
CIN - Nature. 2013 Jun 6;498(7452):48-9. PMID: 23719383
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2012/12/13 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - nature12198 [pii]
AID - 10.1038/nature12198 [doi]
PST - ppublish
SO  - Nature. 2013 Jun 6;498(7452):99-103. doi: 10.1038/nature12198. Epub 2013 May 29.

PMID- 23719289
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1536-5166 (Electronic)
IS  - 1070-8022 (Linking)
DP  - 2013 May 29
TI  - Nonarteritic Anterior Ischemic Optic Neuropathy and Obstructive Sleep Apnea.
AB  - BACKGROUND:: To evaluate the obstructive sleep apnea syndrome (OSAS) in patients 
      with nonarteritic anterior ischemic optic neuropathy (NAION). METHODS:: We
      recruited 27 patients with NAION and 27 age-matched and sex-matched controls who 
      also were similar for systemic risk factors such as diabetes mellitus,
      hypertension, and hypercholesterolemia. All patients and controls underwent
      overnight polysomnography for the diagnosis of OSAS and calculation of
      apnea-hypopnea index (AHI). RESULTS:: Patients and controls were statistically
      similar in terms of age, sex, gender, smoking, systemic risk factors, neck
      circumference, and body mass index. The subjects with AHI >/= 20 were accepted as
      OSAS. Fifteen of 27 patients (55.6%) with NAION and 6 of 27 controls (22.2%) had 
      OSAS (P < 0.05). CONCLUSION:: The prevalence of OSAS was higher in patients with 
      NAION, and the difference between patient and control groups was statistically
      significant (P < 0.05). This result supports prior series suggesting the
      association between NAION and OSAS.
AD  - Jules Stein Eye Institute (GB, ACA), Neuro-Ophthalmology Division, University of 
      California, Los Angeles, Los Angeles, California; and Ophthalmology Division
      (YK), Bayburt State Hospital, Bayburt, Turkey.
FAU - Bilgin, Gorkem
AU  - Bilgin G
FAU - Koban, Yaran
AU  - Koban Y
FAU - Arnold, Anthony C
AU  - Arnold AC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - J Neuroophthalmol
JT  - Journal of neuro-ophthalmology : the official journal of the North American
      Neuro-Ophthalmology Society
JID - 9431308
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1097/WNO.0b013e31828eecbd [doi]
PST - aheadofprint
SO  - J Neuroophthalmol. 2013 May 29.

PMID- 23719151
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1473-5628 (Electronic)
IS  - 0143-3636 (Linking)
DP  - 2013 May 27
TI  - The prognostic efficacy of myocardial perfusion imaging in optimally treated
      diabetic patients with no manifestations of coronary artery disease.
AB  - OBJECTIVE: This study investigates the efficacy of radionuclide myocardial
      perfusion imaging (MPI) in the evaluation of cardiac outcome in optimally treated
      diabetic patients without manifestations of coronary artery disease (CAD) in
      relation to the inherent clinical risk. METHODS: Follow-up data were collected
      from 86 diabetic patients who had undergone adenosine stressing MPI. These
      patients either had no symptoms or had noncardiac chest discomfort, had a normal 
      resting electrocardiogram, had no known CAD or prior positive stress test
      results, and were receiving currently recommended therapy. Endpoints were cardiac
      death, myocardial infarction, new-onset heart failure, and CAD diagnosed by
      angiography at least 2 months from the MPI, irrespective of subsequent
      revascularization. RESULTS: Twenty-six (30%) diabetic patients had abnormal
      perfusion and the remaining had a normal scan. Over a median follow-up period of 
      32.5 months 14 cardiac events occurred. In patients with normal MPI, the annual
      cardiac event rate was 4.0% compared with 12.2% in those with abnormal MPI
      (P=0.008). In multivariate analysis, myocardial ischemia (hazard ratio 5.3;
      P=0.006), obesity (hazard ratio 6.8; P=0.005), the ALFEDIAM/SFC risk (hazard
      ratio 6.8; P=0.002), and type 2 diabetes (hazard ratio 5.3; P=0.035) were found
      to be independent predictors of cardiac events. The former two variables remained
      independent determinants of the outcome, together with peripheral arterial
      disease, when a different clinical risk classification system was applied. MPI
      provided incremental prognostic information over both clinical models formed.
      CONCLUSION: Adenosine MPI can effectively risk-stratify optimally treated
      diabetic patients without manifestations of CAD. In this subset, clinical
      variables can also determine the outcome independently, but MPI adds incremental 
      predictability over them.
AD  - aPropedeutic Department of Internal Medicine bDepartment of Nuclear Medicine,
      AHEPA Hospital, Aristotle University Medical School, Thessaloniki, Greece.
FAU - Kakaletsis, Nikolaos
AU  - Kakaletsis N
FAU - Moralidis, Efstratios
AU  - Moralidis E
FAU - Iliadis, Fotios
AU  - Iliadis F
FAU - Hilidis, Ilias
AU  - Hilidis I
FAU - Gotzamani-Psarrakou, Anna
AU  - Gotzamani-Psarrakou A
FAU - Didangelos, Triantafyllos
AU  - Didangelos T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Nucl Med Commun
JT  - Nuclear medicine communications
JID - 8201017
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1097/MNM.0b013e328362cc81 [doi]
PST - aheadofprint
SO  - Nucl Med Commun. 2013 May 27.

PMID- 23719143
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1473-6519 (Electronic)
IS  - 1363-1950 (Linking)
VI  - 16
IP  - 4
DP  - 2013 Jul
TI  - Carbohydrates and the human gut microbiota.
PG  - 453-60
LID - 10.1097/MCO.0b013e3283619e63 [doi]
AB  - PURPOSE OF REVIEW: Due to its scale and its important role in maintaining health,
      the gut microbiota can be considered as a 'new organ' inside the human body. Many
      complex carbohydrates are degraded and fermented by the human gut microbiota in
      the large intestine to both yield basic energy salvage and impact gut health
      through produced metabolites. RECENT FINDINGS: This review will focus on the gut 
      microbes and microbial mechanisms responsible for polysaccharides degradation and
      fermentation in the large intestine. Gut microbes and bacterial metabolites
      impact the host at many levels, including modulation of inflammation, and glucose
      and lipid metabolisms. SUMMARY: A complex relationship occurs in the intestine
      between the human gut microbiota, diet and the host. Research on carbohydrates
      and gut microbiota composition and functionality is fast developing and will open
      opportunities for prevention and treatment of obesity, diabetes and other related
      metabolic disorders through manipulation of the gut ecosystem.
AD  - Laboratory of Food Biotechnology, Institute of Food, Nutrition and Health, ETH
      Zurich, Zurich, Switzerland.
FAU - Chassard, Christophe
AU  - Chassard C
FAU - Lacroix, Christophe
AU  - Lacroix C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Clin Nutr Metab Care
JT  - Current opinion in clinical nutrition and metabolic care
JID - 9804399
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1097/MCO.0b013e3283619e63 [doi]
PST - ppublish
SO  - Curr Opin Clin Nutr Metab Care. 2013 Jul;16(4):453-60. doi:
      10.1097/MCO.0b013e3283619e63.

PMID- 23719031
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1476-5470 (Electronic)
IS  - 1466-4879 (Linking)
DP  - 2013 May 30
TI  - Genetic control of murine invariant natural killer T cells maps to multiple type 
      1 diabetes regions.
LID - 10.1038/gene.2013.32 [doi]
AB  - Reduced frequency of invariant natural killer T (iNKT) cells has been indicated
      as a contributing factor to type 1 diabetes (T1D) development in NOD mice. To
      further understand the genetic basis of the defect, we generated (NOD x ICR)F2
      mice to map genes that control iNKT-cell development. We determined frequencies
      of thymic and splenic iNKT cells, as well as the ratio of CD4-positive and
      -negative subsets in the spleens of 209 F2 males. Quantitative trait loci (QTL)
      analysis revealed five loci that exceed the significant threshold for the
      frequency of thymic and/or splenic iNKT cells on Chromosomes (Chr) 1, 5, 6, 12
      and 17. Three significant loci on Chr 1, 4 and 5 were found for the ratio of
      CD4-positive and -negative splenic iNKT cells. Comparisons with previously known 
      mouse T1D susceptibility (Idd) loci revealed two significant QTL peak locations, 
      respectively, mapped to Idd regions on Chr 4 and 6. The peak marker location of
      the significant Chr 12 iNKT QTL maps to within 0.5 Mb of a syntenic human T1D
      locus. Collectively, our results reveal several novel loci controlling iNKT-cell 
      development and provide additional information for future T1D genetic
      studies.Genes and Immunity advance online publication, 30 May 2013;
      doi:10.1038/gene.2013.32.
AD  - Medical College of Wisconsin, Human and Molecular Genetics Center, Milwaukee, WI,
      USA.
FAU - Tsaih, S-W
AU  - Tsaih SW
FAU - Khaja, S
AU  - Khaja S
FAU - Ciecko, A E
AU  - Ciecko AE
FAU - Mackinney, E
AU  - Mackinney E
FAU - Chen, Y-G
AU  - Chen YG
LA  - ENG
GR  - R00 DK077443/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Genes Immun
JT  - Genes and immunity
JID - 100953417
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/05/30 [aheadofprint]
AID - gene201332 [pii]
AID - 10.1038/gene.2013.32 [doi]
PST - aheadofprint
SO  - Genes Immun. 2013 May 30. doi: 10.1038/gene.2013.32.

PMID- 23718981
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
DP  - 2013 May 26
TI  - Brown adipose tissue in humans: Therapeutic potential to combat obesity.
LID - S0163-7258(13)00124-1 [pii]
LID - 10.1016/j.pharmthera.2013.05.009 [doi]
AB  - Harnessing the considerable capacity of brown adipose tissue (BAT) to consume
      energy was first proposed as a potential target to control obesity nearly 40years
      ago. The plausibility of this approach was, however, questioned due to the
      prevailing view that BAT was either not present or not functional in adult
      humans. Recent definitive identification of functional BAT in adult humans as
      well as a number of important advances in the understanding of BAT biology has
      reignited interest in BAT as an anti-obesity target. Proof-of-concept evidence
      demonstrating drug-induced BAT activation provides an important foundation for
      development of targeted pharmacological approaches with clinical application.
      This review considers evidence from both human and relevant animal studies to
      determine whether harnessing BAT for the treatment of obesity via pharmacological
      intervention is a realistic goal.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Metabolic and Vascular Physiology Laboratory, Baker IDI Heart and Diabetes
      Institute, Melbourne, Victoria, Australia. Electronic address:
      andrew.carey@bakeridi.edu.au.
FAU - Carey, Andrew L
AU  - Carey AL
FAU - Kingwell, Bronwyn A
AU  - Kingwell BA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/05/08 [received]
PHST- 2013/05/09 [accepted]
AID - S0163-7258(13)00124-1 [pii]
AID - 10.1016/j.pharmthera.2013.05.009 [doi]
PST - aheadofprint
SO  - Pharmacol Ther. 2013 May 26. pii: S0163-7258(13)00124-1. doi:
      10.1016/j.pharmthera.2013.05.009.

PMID- 23718978
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1527-330X (Electronic)
IS  - 1090-820X (Linking)
DP  - 2013 May 29
TI  - Acute Adipocyte Viability After Third-Generation Ultrasound-Assisted Liposuction.
AB  - Background:Although clinical evidence of successful autologous fat transfer (AFT)
      using third-generation ultrasound-assisted liposuction (UAL) is readily
      available, no study has quantified adipocyte viability using standardized
      methods.Objectives:The authors assess acute adipocyte viability following fat
      aspiration as a first step in determining the overall efficacy of using
      third-generation UAL for AFT.Methods:Lipoaspirate samples were collected from
      patients who underwent elective liposuction procedures at multiple surgery
      centers. Patients with a history of bleeding disorders, diabetes, human
      immunodeficiency virus, or lipoatrophy disorders were excluded. The UAL system
      (VASER; Sound Surgical Technologies, Inc, Louisville, Colorado) was set at 60%
      amplitude in pulsed mode with vacuum aspiration of 15 in Hg or less. Laboratory
      analysis included free lipid volume, viability via lipolysis and propidium iodide
      staining, and cytological analysis, including cell surface protein examination
      and hematoxylin and eosin staining.Results:The lipolysis assay revealed
      metabolically active adipocytes with a mean (SD) correlative viability of 85.1%
      (11%). Direct measures of acute viability via propidium iodide staining resulted 
      in a mean (SD) viability measure of 88.7% (3.5%). Both mean values are within the
      historical range reported from syringe and vacuum-assisted lipoaspiration.
      Aqueous and lipid contents were favorably reduced after washing and filtering
      (Puregraft system; Cytori Therapeutics, Inc, San Diego, California). Cellular
      phenotypes identified were primarily white blood cells or vascular endothelial
      and vascular associated cells.Conclusions:Adipose tissue acquired via
      third-generation UAL is viable at harvest and is potentially a suitable source
      for autologous fat grafts. These results confirm reported clinical successes
      utilizing third-generation ultrasound lipoaspirate for AFT.
AD  - Dr Schafer is the Chief Technology Officer at Sound Surgical Technologies, LLC,
      Louisville, Colorado.
FAU - Schafer, Mark E
AU  - Schafer ME
FAU - Hicok, Kevin C
AU  - Hicok KC
FAU - Mills, Daniel C
AU  - Mills DC
FAU - Cohen, Steve R
AU  - Cohen SR
FAU - Chao, James J
AU  - Chao JJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Aesthet Surg J
JT  - Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery
JID - 9707469
OTO - NOTNLM
OT  - AFT
OT  - UAL
OT  - adipocyte viability
OT  - autologous fat transfer
OT  - body contouring
OT  - lipoaspirate
OT  - liposuction
OT  - third-generation ultrasound
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 1090820X13485239 [pii]
AID - 10.1177/1090820X13485239 [doi]
PST - aheadofprint
SO  - Aesthet Surg J. 2013 May 29.

PMID- 23718959
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1550-5057 (Electronic)
IS  - 0160-6379 (Linking)
VI  - 36
IP  - 3
DP  - 2013 Jul-Sep
TI  - Predictors of change in fruit and vegetable consumption in a faith-based
      intervention with african american adults.
PG  - 236-47
LID - 10.1097/FCH.0b013e318293159b [doi]
AB  - A majority of African American adults do not eat the recommended daily amount of 
      fruit and vegetables. This study examined baseline demographic, health-related,
      and psychosocial variables as predictors of change in fruit and vegetable
      consumption from baseline to postprogram in a sample of church members taking
      part in a 15-month intervention. Participants who had a greater waist
      circumference, greater baseline fruit and vegetable consumption, greater leisure 
      time physical activity, higher levels of social support, greater attendance at
      worship service, were obese, and did not have diabetes at baseline showed higher 
      posttest fruit and vegetable consumption.
AD  - Department of Food, Nutrition, and Packaging Sciences, 216 Poole Agricultural
      Center, Clemson University, Clemson, South Carolina (Dr Condrasky and Mr Carter);
      and Department of Exercise Science (Drs Baruth and Wilcox) and Prevention
      Research Center (Dr Wilcox), Arnold School of Public Health, University of South 
      Carolina, Columbia, South Carolina.
FAU - Condrasky, Margaret D
AU  - Condrasky MD
FAU - Baruth, Meghan
AU  - Baruth M
FAU - Wilcox, Sara
AU  - Wilcox S
FAU - Carter, Chad
AU  - Carter C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Fam Community Health
JT  - Family & community health
JID - 7809641
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.1097/FCH.0b013e318293159b [doi]
AID - 00003727-201307000-00007 [pii]
PST - ppublish
SO  - Fam Community Health. 2013 Jul-Sep;36(3):236-47. doi:
      10.1097/FCH.0b013e318293159b.

PMID- 23718927
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1479-5868 (Electronic)
IS  - 1479-5868 (Linking)
VI  - 10
IP  - 1
DP  - 2013 May 30
TI  - Television screen time, but not computer use and reading time, is associated with
      cardio-metabolic biomarkers in a multiethnic Asian population: a cross-sectional 
      study.
PG  - 70
AB  - BACKGROUND: Recent evidence shows that sedentary behaviour may be an independent 
      risk factor for cardiovascular diseases, diabetes, cancers and all-cause
      mortality. However, results are not consistent and different types of sedentary
      behaviour might have different effects on health. Thus the aim of this study was 
      to evaluate the association between television screen time, computer/reading time
      and cardio-metabolic biomarkers in a multiethnic urban Asian population. We also 
      sought to understand the potential mediators of this association. METHODS: The
      Singapore Prospective Study Program (2004--2007), was a cross-sectional
      population-based study in a multiethnic population in Singapore. We studied 3305 
      Singaporean adults of Chinese, Malay and Indian ethnicity who did not have
      pre-existing diseases and conditions that could affect their physical activity.
      Multiple linear regression analysis was used to assess the association of
      television screen time and computer/reading time with cardio-metabolic biomarkers
      [blood pressure, lipids, glucose, adiponectin, C reactive protein and homeostasis
      model assessment of insulin resistance (HOMA-IR)]. Path analysis was used to
      examine the role of mediators of the observed association. RESULTS: Longer
      television screen time was significantly associated with higher systolic blood
      pressure, total cholesterol, triglycerides, C reactive protein, HOMA-IR, and
      lower adiponectin after adjustment for potential socio-demographic and lifestyle 
      confounders. Dietary factors and body mass index, but not physical activity, were
      potential mediators that explained most of these associations between television 
      screen time and cardio-metabolic biomarkers. The associations of television
      screen time with triglycerides and HOMA-IR were only partly explained by dietary 
      factors and body mass index. No association was observed between computer/
      reading time and worse levels of cardio-metabolic biomarkers. CONCLUSIONS: In
      this urban Asian population, television screen time was associated with worse
      levels of various cardio-metabolic risk factors. This may reflect detrimental
      effects of television screen time on dietary habits rather than replacement of
      physical activity.
FAU - Nang, Ei Ei
AU  - Nang EE
FAU - Salim, Agus
AU  - Salim A
FAU - Wu, Yi
AU  - Wu Y
FAU - Tai, E Shyong
AU  - Tai ES
FAU - Lee, Jeannette
AU  - Lee J
FAU - Van Dam, Rob M
AU  - Van Dam RM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Int J Behav Nutr Phys Act
JT  - The international journal of behavioral nutrition and physical activity
JID - 101217089
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2012/10/23 [received]
PHST- 2013/05/30 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 1479-5868-10-70 [pii]
AID - 10.1186/1479-5868-10-70 [doi]
PST - aheadofprint
SO  - Int J Behav Nutr Phys Act. 2013 May 30;10(1):70.

PMID- 23718775
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 0379-8577 (Print)
IS  - 0379-8577 (Linking)
VI  - 36
IP  - 1
DP  - 2013
TI  - Perceptions of diabetes in rural areas of Eastern Uganda.
PG  - E1-7
LID - 10.4102/curationis.v36i1.121 [doi]
AB  - Background: People diagnosed with diabetes mellitus are increasing in sub-Saharan
      Africa and prompt care seeking depends on perceptions of the illness. Objective: 
      The objective was to explore perceptions of diabetes in rural areas. Method: We
      conducted a qualitative, explorative and descriptive study in rural eastern
      Uganda. Eight focus group discussions with community members were conducted.
      Community members were presented with a story about a person with diabetes
      symptoms and their perceptions of the diagnosis and treatment elicited. Four
      focus group discussions with people with diabetes and seven key informant
      interviews with health workers were conducted. Respondents were asked how the
      community interpreted symptoms of diabetes, its causes and whether it was
      curable. Manifest content analysis was used. Results: Some respondents thought
      people with diabetes symptoms had HIV or were bewitched. Causes of diabetes
      mentioned included consuming too much fatty food. Some respondents thought
      diabetes is transmitted through air, sharing utensils with or sitting close to
      people with diabetes. Some respondents thought that diabetes could heal fast
      whilst others thought it was incurable. Conclusion: Misdiagnosis may cause delay 
      in seeking proper care. Preventive programmes could build on people's thinking
      that too much fatty food causes diabetes to promote diets with less fat. The
      perception of diabetes as a contagious disease leads to stigmatisation and
      affects treatment seeking. Seeing diabetes as curable could create patient
      expectations that may not be fulfilled in the management of diabetes. Rural
      communities would benefit from campaigns creating awareness of prevention,
      symptoms, diagnosis and management of diabetes.
AD  - Department of Health Policy, Planning and Management, Makerere University School 
      of Public Health. ellie@musph.ac.ug.
FAU - Rutebemberwa, Elizeus
AU  - Rutebemberwa E
FAU - Katureebe, Sheila K
AU  - Katureebe SK
FAU - Gitta, Sheba N
AU  - Gitta SN
FAU - Mwaka, Amos D
AU  - Mwaka AD
FAU - Atuyambe, Lynn
AU  - Atuyambe L
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - South Africa
TA  - Curationis
JT  - Curationis
JID - 7901092
SB  - N
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2012/06/12 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/03/01 [revised]
PST - epublish
SO  - Curationis. 2013 May 23;36(1):E1-7. doi: 10.4102/curationis.v36i1.121.

PMID- 23718748
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 39
IP  - 6
DP  - 2013 Jun
TI  - Glyburide as treatment option for gestational diabetes mellitus.
PG  - 1147-52
LID - 10.1111/jog.12042 [doi]
AB  - AIM: The aim of this study was to assess the efficacy of glyburide in the
      treatment of gestational diabetes mellitus and to compare the maternal and fetal 
      outcome between two groups treated either with insulin or glyburide. MATERIAL AND
      METHODS: Women with gestational diabetes not responding to diet control were
      randomized into two groups: (i) the control group receiving insulin (n = 32); and
      (ii) the study group receiving glyburide (n = 32). Primary outcome was assessed
      in terms of achievement of glycemic control and secondary outcome was assessed by
      the incidence of maternal and fetal complications in the insulin and glyburide
      treated groups. RESULTS: The achievement of glycemic control between the insulin 
      and the glyburide treated groups showed no significant difference (97.1%, 93.8%).
      The occurrence of maternal complications (P = 0.87) and fetal complications (P = 
      0.32) were comparable between the insulin and glyburide treated groups.
      CONCLUSION: Glyburide was found to be as efficacious as insulin in achieving
      euglycemia in the treatment of gestational diabetic women who require treatment
      beyond diet control.
CI  - (c) 2013 The Authors. Journal of Obstetrics and Gynaecology Research (c) 2013
      Japan Society of Obstetrics and Gynecology.
AD  - Obstetrics and Gynaecology Department, Maulana Azad Medical College and Lok Nayak
      Hospital, New Delhi, India.
FAU - Tempe, Anjali
AU  - Tempe A
FAU - Mayanglambam, Ronita Devi
AU  - Mayanglambam RD
LA  - eng
PT  - Journal Article
DEP - 20130530
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
SB  - IM
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2012/08/11 [received]
PHST- 2012/11/30 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 10.1111/jog.12042 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2013 Jun;39(6):1147-52. doi: 10.1111/jog.12042. Epub 2013 
      May 30.

PMID- 23718724
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1365-2613 (Electronic)
IS  - 0959-9673 (Linking)
DP  - 2013 May 30
TI  - Neuronal regulation of tendon homoeostasis.
LID - 10.1111/iep.12028 [doi]
AB  - The regulation of tendon homoeostasis, including adaptation to loading, is still 
      not fully understood. Accumulating data, however, demonstrates that in addition
      to afferent (sensory) functions, the nervous system, via efferent pathways which 
      are associated with through specific neuronal mediators plays an active role in
      regulating pain, inflammation and tendon homeostasis. This neuronal regulation of
      intact-, healing- and tendinopathic tendons has been shown to be mediated by
      three major groups of molecules including opioid, autonomic and excitatory
      glutamatergic neuroregulators. In intact healthy tendons the neuromediators are
      found in the surrounding structures: paratenon, endotenon and epitenon, whereas
      the proper tendon itself is practically devoid of neurovascular supply. This
      neuroanatomy reflects that normal tendon homoeostasis is regulated from the
      tendon surroundings. After injury and during tendon repair, however, there is
      extensive nerve ingrowth into the tendon proper, followed by a time-dependent
      emergence of sensory, autonomic and glutamatergic mediators, which amplify and
      fine-tune inflammation and regulate tendon regeneration. In tendinopathic
      condition, excessive and protracted presence of sensory and glutamatergic
      neuromediators has been identified, suggesting involvement in inflammatory,
      nociceptive and hypertrophic (degenerative) tissue responses. Under experimental 
      and clinical conditions of impaired (e.g. diabetes) as well as excessive (e.g.
      tendinopathy) neuromediator release, dysfunctional tendon homoeostasis develops
      resulting in chronic pain and gradual degeneration. Thus there is a prospect that
      in the future pharmacotherapy and tissue engineering approaches targeting
      neuronal mediators and their receptors may prove to be effective therapies for
      painful, degenerative and traumatic tendon disorders.
CI  - (c) 2013 The Authors. International Journal of Experimental Pathology (c) 2013
      International Journal of Experimental Pathology.
AD  - Karolinska Institutet, Department of Molecular Medicine and Surgery, Karolinska
      University Hospital, Stockholm, Sweden.
FAU - Ackermann, Paul W
AU  - Ackermann PW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Int J Exp Pathol
JT  - International journal of experimental pathology
JID - 9014042
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2012/12/28 [received]
PHST- 2013/04/16 [accepted]
AID - 10.1111/iep.12028 [doi]
PST - aheadofprint
SO  - Int J Exp Pathol. 2013 May 30. doi: 10.1111/iep.12028.

PMID- 23718682
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
DP  - 2013 May 29
TI  - Validation of Economic and Health outcomes Simulation Model of Type 2 Diabetes
      Mellitus (ECHO-T2DM).
AB  - Abstract Objective We constructed the Economic and Health Outcomes Model for type
      2 diabetes mellitus (ECHO-T2DM), a long-term stochastic microsimulation model, to
      predict the costs and health outcomes in patients with T2DM. Naturally, the
      usefulness of the model depends upon its predictive accuracy. The objective of
      this work is to present results of a formal validation exercise of ECHO-T2DM.
      Methods We assessed the validity of ECHO-T2DM using criteria recommended by the
      International Society for Pharmacoeconomics and Outcomes Research/Society for
      Medical Decision Making (ISPOR/SMDM). Specifically, we predicted the results of a
      number of clinical trials and compared them with observed study endpoints using a
      scatterplot and regression approach. An F test of the best-fitting regression was
      added to assess whether it differs statistically from the identity (45 degrees ) 
      line defining perfect predictions. In addition to testing the full model using
      all of the validation study data, we also performed tests of microvascular,
      macrovascular, and survival outcomes separately. We also performed the validation
      tests separately by type of data (used vs. not used to construct the model,
      economic simulations, and treatment effects). Results The intercept and slope
      coefficients of the best-fitting regression line between the predicted outcomes
      and corresponding trial endpoints in the main analysis were -0.0011 and 1.067,
      respectively, and the R2 was 0.95. A formal F test of no difference between the
      fitted line and the identity line could not be rejected (p=0.16). The high R2
      confirms that the data points are closely (and linearly) associated with the
      fitted regression line. Additional analyses identified that disagreement was
      highest for macrovascular endpoints, for which the intercept and slope
      coefficients were 0.0095 and 1.225, respectively. The R2 was 0.95 and the
      estimated intercept and slope coefficients were 0.017 and 1.048, respectively,
      for mortality, and the F test was narrowly rejected (p=0.04). The subset of
      microvascular endpoints showed some tendency to over-predict (the slope
      coefficient was 1.095), though concordance between predictions and observed
      values could not be rejected (p=0.16). Limitations Important study limitations
      include: (1) Data availability limited us to tests based on end-of-study outcomes
      rather than time-varying outcomes during the studies analyzed; (2) complex
      inclusion and exclusion criteria in two studies were difficult to replicate; (3) 
      some of the studies were older and reflect outdated treatment patterns; and (4)
      we were unable to identify published data on resource use and costs of T2DM
      suitable for testing the validity of the economic calculations. Conclusions Using
      conventional methods, ECHO-T2DM simulated the treatment, progression, and patient
      outcomes observed in important clinical trials with an accuracy consistent with
      other well-accepted models. Macrovascular outcomes were over-predicted, which is 
      common in health-economic models of diabetes (and may be related to a general
      over-prediction of event rates in the United Kingdom Prospective Diabetes Study
      [UKPDS] Outcomes Model). Work is underway in ECHO-T2DM to incorporate new risk
      equations to improve model prediction.
AD  - The Swedish Institute for Health Economics, 220 02 Lund, Sweden.
FAU - Willis, Michael
AU  - Willis M
FAU - Asseburg, Christian
AU  - Asseburg C
FAU - He, Jianming
AU  - He J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
AID - 10.3111/13696998.2013.809352 [doi]
PST - aheadofprint
SO  - J Med Econ. 2013 May 29.

PMID- 23718573
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
DP  - 2013 May 29
TI  - Vitamin E and changes in serum alanine aminotransferase levels in patients with
      non-alcoholic steatohepatitis.
LID - 10.1111/apt.12352 [doi]
AB  - BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a common cause of serum
      alanine aminotransferase (ALT) elevations and chronic liver disease, but it is
      unclear how well ALT elevations reflect the liver injury. AIM: To assess how well
      changes in ALT elevations reflect improvements in liver histology in response to 
      vitamin E therapy. METHODS: The vitamin E and placebo arms of the Pioglitazone
      vs. Vitamin E vs. Placebo in Non-alcoholic Steatohepatitis (PIVENS) trial were
      reassessed for associations among changes in ALT levels, body weight and liver
      histology. An ALT response was defined as a decrease to </=40 U/L and by >/=30%
      of baseline. Liver biopsies taken before and after treatment were scored for
      non-alcoholic fatty liver disease activity (NAS) and fibrosis. RESULTS: ALT
      responses were more frequent among vitamin E (48%) than placebo (16%) recipients 
      (P < 0.001). Among vitamin E recipients, ALT responses were associated with
      decreases in NAS (P < 0.001), but not fibrosis scores (P = 0.34), whereas among
      placebo recipients, ALT responses were associated with significant decreases in
      both (P < 0.05). Weight loss (>/=2 kg) was also associated with ALT response (P <
      0.001), improvements in NAS (P < 0.001) and fibrosis (P < 0.02), but vitamin E
      had an added effect both with and without weight loss. Weight gain (>/=2 kg) was 
      associated with lack of ALT response and worsening NAS and fibrosis scores in
      patients not on vitamin E. CONCLUSIONS: Decrease of ALT levels to normal in
      patients with NASH is usually associated with improved histological activity.
      Management should stress the value of weight loss and strongly discourage weight 
      gain. Vitamin E can improve both ALT levels and histology with and without weight
      loss. Clinical Trial Number: NCT00063622.
CI  - Published 2013. This article is a US Government work and is in the public domain 
      in the USA.
AD  - Liver Disease Research Branch, Division of Digestive Diseases and Nutrition,
      National Institute of Diabetes and Digestive and Kidney Diseases, National
      Institutes of Health, Bethesda, MD, USA.
FAU - Hoofnagle, J H
AU  - Hoofnagle JH
FAU - Van Natta, M L
AU  - Van Natta ML
FAU - Kleiner, D E
AU  - Kleiner DE
FAU - Clark, J M
AU  - Clark JM
FAU - Kowdley, K V
AU  - Kowdley KV
FAU - Loomba, R
AU  - Loomba R
FAU - Neuschwander-Tetri, B A
AU  - Neuschwander-Tetri BA
FAU - Sanyal, A J
AU  - Sanyal AJ
FAU - Tonascia, J
AU  - Tonascia J
CN  - the Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN)
LA  - ENG
GR  - K23 DK090303/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/03/05 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/04/26 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/apt.12352 [doi]
PST - aheadofprint
SO  - Aliment Pharmacol Ther. 2013 May 29. doi: 10.1111/apt.12352.

PMID- 23718315
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 13
DP  - 2013
TI  - Antidiabetic and antioxidant properties of Ficus deltoidea fruit extracts and
      fractions.
PG  - 118
LID - 10.1186/1472-6882-13-118 [doi]
AB  - BACKGROUND: Diabetes is a serious metabolic disorder affecting the metabolism of 
      carbohydrate, protein and fat. A number of studies have shown that diabetes
      mellitus is associated with oxidative stress, leading to an increased production 
      of reactive oxygen species. Ficus deltoidea is traditionally used in Malaysia for
      regulating blood sugar, blood pressure and cholesterol levels. The use of F.
      deltoidea as an alternative medicinal herb is increasingly gaining popularity
      with the sale of F. deltoidea tea bags and capsules in the local market. The
      present study was undertaken to investigate the antidiabetic and antioxidant
      activities of the fruits from different varieties of F. deltoidea, employing in
      vitro methods. METHOD: Two fruit varieties of F. deltoidea (var. angustifolia
      (SF) and var. kunstleri (BF)) were extracted separately using double-distilled
      water. The resulting aqueous extracts were partitioned using ethyl acetate to
      obtain the ethyl acetate and water fractions. The crude aqueous extracts and the 
      corresponding fractions were evaluated for their phenolic, flavonoid, sugar and
      protein contents. Protein profiling of the extracts and fractions were also
      carried out by means of SDS-PAGE and SELDI-TOF MS. Antidiabetic activities were
      assessed based on the ability of the samples to inhibit yeast and mammalian
      alpha-glucosidase as well as alpha-amylase. Antioxidant capacities were examined 
      by measuring the ability of the samples to reduce ferric ions and to scavenge
      DPPH, superoxide anion, ABTS and nitric oxide radicals. RESULTS: The crude
      extracts and fractions of SF and BF inhibited both yeast and rat intestinal
      alpha-glucosidases in a dose-dependent manner, but did not inhibit porcine
      pancreatic alpha-amylase. The water fraction of BF showed the highest percentage 
      of alpha-glucosidase inhibition while having the highest amount of protein (73.33
      +/- 4.99 mug/mg fraction). All the extracts and fractions exhibited antioxidant
      activities, with SF crude extract showing the highest antioxidant activity and
      phenolic content (121.62 +/- 4.86 mg/g extract). Fractionation of the crude
      extracts resulted in loss of antioxidant activities. There was no positive
      correlation between phenolic and flavonoid content with alpha-glucosidase
      inhibitory activities. However, phenolic content correlated well with antioxidant
      activities of the crude extracts but not with the fractions. CONCLUSIONS: The
      antioxidant activities of the fruits of F. deltoidea might be asserted by the
      phenolic content but other polar plant components were possibly involved in the
      antidiabetic properties. The study of these compounds having both
      antihyperglycemic and antioxidant activities may provide a new approach in the
      treatment of diabetes mellitus.
AD  - Institute of Biological Sciences, Faculty of Science, University of Malaya,
      50603, Kuala Lumpur, Malaysia. hanizaaminudin@um.edu.my.
FAU - Misbah, Hasni
AU  - Misbah H
FAU - Aziz, Azlina Abdul
AU  - Aziz AA
FAU - Aminudin, Norhaniza
AU  - Aminudin N
LA  - eng
PT  - Journal Article
DEP - 20130529
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
SB  - IM
PMC - PMC3668304
OID - NLM: PMC3668304
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/02/08 [received]
PHST- 2013/05/23 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 1472-6882-13-118 [pii]
AID - 10.1186/1472-6882-13-118 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2013 May 29;13:118. doi: 10.1186/1472-6882-13-118.

PMID- 23718253
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1471-0528 (Electronic)
IS  - 1470-0328 (Linking)
DP  - 2013 May 30
TI  - Haptoglobin phenotype, pre-eclampsia, and response to supplementation with
      vitamins C and E in pregnant women with type-1 diabetes.
LID - 10.1111/1471-0528.12288 [doi]
AB  - OBJECTIVE: The phenotype of the antioxidant and pro-angiogenic protein
      haptoglobin (Hp) predicts cardiovascular disease risk and treatment response to
      antioxidant vitamins in individuals with diabetes. Our objective was to determine
      whether Hp phenotype influences pre-eclampsia risk, or the efficacy of vitamins C
      and E in preventing pre-eclampsia, in women with type-1 diabetes. DESIGN: This is
      a secondary analysis of a randomised controlled trial in which women with
      diabetes received daily vitamins C and E, or placebo, from 8 to 22 weeks of
      gestation until delivery. SETTING: Twenty-five antenatal metabolic clinics across
      the UK (in north-west England, Scotland, and Northern Ireland). POPULATION:
      Pregnant women with type-1 diabetes. METHODS: Hp phenotype was determined in
      white women who completed the study and had plasma samples available (n = 685).
      MAIN OUTCOME MEASURE: Pre-eclampsia. RESULTS: Compared with Hp 2-1, Hp 1-1 (OR
      0.59, 95% CI 0.30-1.16) and Hp 2-2 (OR 0.93, 95% CI 0.60-1.45) were not
      associated with significantly decreased pre-eclampsia risk after adjusting for
      treatment group and HbA1c at randomisation. Our study was not powered to detect
      an interaction between Hp phenotype and treatment response; however, our
      preliminary analysis suggests that vitamins C and E did not prevent pre-eclampsia
      in women of any Hp phenotype (Hp 1-1, OR 0.77, 95% CI 0.22-2.71; Hp 2-1, OR 0.81,
      95% CI 0.46-1.43; Hp 2-2, 0.67, 95% CI 0.34-1.33), after adjusting for HbA1c at
      randomisation. CONCLUSIONS: The Hp phenotype did not significantly affect
      pre-eclampsia risk in women with type-1 diabetes.
CI  - (c) 2013 RCOG.
AD  - Magee-Womens Research Institute and the Department of Obstetrics, Gynaecology and
      Reproductive Science, University of Pittsburgh, Pittsburgh, PA, USA.
FAU - Weissgerber, Tl
AU  - Weissgerber T
FAU - Gandley, Re
AU  - Gandley R
FAU - Roberts, Jm
AU  - Roberts J
FAU - Patterson, Cc
AU  - Patterson C
FAU - Holmes, Va
AU  - Holmes V
FAU - Young, Is
AU  - Young I
FAU - McCance, Dr
AU  - McCance D
CN  - the Diabetes and Pre-eclampsia Intervention Trial Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - BJOG
JT  - BJOG : an international journal of obstetrics and gynaecology
JID - 100935741
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/03/30 [accepted]
AID - 10.1111/1471-0528.12288 [doi]
PST - aheadofprint
SO  - BJOG. 2013 May 30. doi: 10.1111/1471-0528.12288.

PMID- 23718222
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 29
TI  - Impact of a self-care education programme on patients with type 2 diabetes in
      primary care in the Basque Country.
PG  - 521
AB  - BACKGROUND: Type 2 diabetes mellitus (DM2) is a disease with high prevalence and 
      significant impact in terms of mortality and morbidity. The increased prevalence 
      of the disease requires the implementation of new strategies to promote patient
      self-management. The Spanish Diabetes Self-Management Program (SDSMP) has proven 
      to be effective in other settings. The objective of this study is to assess its
      effectiveness in terms of care for DM2 patients in primary care settings within
      the Basque Health Service -- Osakidetza (Spain).Method/Design: This is a
      randomised clinical trial in which patients diagnosed with DM2, 18--79 years of
      age, from four health regions within the Basque Health Service will be randomised
      into two groups: an intervention group, who will follow the SDSMP, and a control 
      group, who will receive usual care in accordance with the clinical guidelines for
      DM2 and existing regulations in our region. The intervention consists of 2,5
      hour-group sessions once a week for six weeks. The sessions cover target setting 
      and problem solving techniques, promotion of physical exercise, basic knowledge
      of nutrition, proper use of medication, effective communication with relatives
      and health professionals, and basic knowledge about DM2 and its complications.
      This content is complemented by educational material: books, leaflets and CDs.
      The primary outcome measure will be the change in glycated haemoglobin (HbA1c),
      and secondary outcome measures will include changes in levels of physical
      activity and intake of fruit and vegetables, cardiovascular risk, quality of
      life, self-efficacy, number of consultations and drug prescriptions. The results 
      will be analysed 6, 12 and 24 months after the intervention. DISCUSSION: If the
      intervention were to be effective, the programme should be extended/spread to the
      entire diabetic population in the Basque Country and it could also be applied for
      other diseases.Trial registration: ClinicalTrials.gov identifier NCT01642394.
FAU - Gamboa Moreno, Estibaliz
AU  - Gamboa Moreno E
FAU - Sanchez Perez, Alvaro
AU  - Sanchez Perez A
FAU - Vrotsou, Kalliopi
AU  - Vrotsou K
FAU - Arbonies Ortiz, Juan Carlos
AU  - Arbonies Ortiz JC
FAU - Del Campo Pena, Emma
AU  - Del Campo Pena E
FAU - Ochoa de Retana Garcia, Lourdes
AU  - Ochoa de Retana Garcia L
FAU - Angeles Rua Portu, Ma
AU  - Angeles Rua Portu M
FAU - Pinera Elorriaga, Koldo
AU  - Pinera Elorriaga K
FAU - Zenarutzabeitia Pikatza, Amaya
AU  - Zenarutzabeitia Pikatza A
FAU - Urquiza Bengoa, Miren Nekane
AU  - Urquiza Bengoa MN
FAU - Sanz Echave, Rosario
AU  - Sanz Echave R
FAU - Mendez Sanpedro, Tomas
AU  - Mendez Sanpedro T
FAU - Oses Portu, Ana
AU  - Oses Portu A
FAU - Gorostidi Fano, Lourdes
AU  - Gorostidi Fano L
FAU - Aguirre Sorondo, Miren Bakarne
AU  - Aguirre Sorondo MB
FAU - Rotaeche Del Campo, Rafael
AU  - Rotaeche Del Campo R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/04/15 [received]
PHST- 2013/05/29 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 1471-2458-13-521 [pii]
AID - 10.1186/1471-2458-13-521 [doi]
PST - aheadofprint
SO  - BMC Public Health. 2013 May 29;13(1):521.

PMID- 23718140
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1746-4269 (Electronic)
IS  - 1746-4269 (Linking)
VI  - 9
IP  - 1
DP  - 2013 May 30
TI  - Peril in the market-classification and dosage of species used as anti-diabetics
      in Lima, Peru.
PG  - 37
AB  - BACKGROUND: Peru is what Peruvian anthropologist Lupe Camino calls the "health
      axis" of the old Central Andean culture area stretching from Ecuador to Bolivia. 
      In particular in the North of the country the traditional use of medicinal dates 
      back as far as the first millennium B.C. Both healers, and the wider population, 
      often buy their medicinal plants in local markets, but there is very little
      comparative information available about which plants are sold under which
      vernacular name at any given time, for which indication, and which dosage
      information and information about side effects is given by vendors. For this
      study we used two traditionally used species groups "Hercampuri" Gentianella
      spec. (Gentianaceae) and "Pasuchaca" Geranium spec. (Geraniaceae.), found in the 
      Mercado Aviacion in Lima, as small, clearly circumscribed plant group frequently 
      used to treat symptoms of diabetes as a test case to study the taxonomy,
      indications, dosage, indicated side effects, and additional species used as
      admixtures and hypothesized that: 1. A wide variety of different species is sold 
      under the same common name, and often several common names exist for one species.
      2. There is no consistency in the dosage, or a relationship between dosage and
      species marketed under one name. 3. However, there is consistency in the
      knowledge about usage and side effects. METHODS: Surveys focusing on medicinal
      plants sold and their properties were conducted at the Mercado Aviacion in Lima
      in December 2012. Vouchers of all specimens were deposited at the National
      Herbarium of Peru.Results and conclusions: Our surveys in Mercado Aviacion in
      Lima yielded four species of Gentianella, two of Geranium, and three additional
      species from three genera used as common additives that were sold as
      anti-diabetic. These results indicate that even in case of only a few plant
      species, used for a very clearly circumscribed application, patients run a
      considerable risk when purchasing their remedies in the market. The possible side
      effects in this case are the more serious because diabetes has to be treated long
      term, and as such the patients are ingesting possible toxic remedies over a long 
      period of time. Much more control, and a much more stringent identification of
      the material sold in public markets, and entering the global supply chain via
      internet sales, would be needed.
FAU - Bussmann, Rainer W
AU  - Bussmann RW
FAU - Zambrana, Narel Paniagua
AU  - Zambrana NP
FAU - Chamorro, Marinoli Rivas
AU  - Chamorro MR
FAU - Moreira, Natalia Molina
AU  - Moreira NM
FAU - Del Rosario Cuadros Negri, Maria Luisa
AU  - Del Rosario Cuadros Negri ML
FAU - Olivera, Jose
AU  - Olivera J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Ethnobiol Ethnomed
JT  - Journal of ethnobiology and ethnomedicine
JID - 101245794
EDAT- 2013/05/31 06:00
MHDA- 2013/05/31 06:00
CRDT- 2013/05/31 06:00
PHST- 2013/04/03 [received]
PHST- 2013/05/30 [accepted]
PHST- 2013/05/30 [aheadofprint]
AID - 1746-4269-9-37 [pii]
AID - 10.1186/1746-4269-9-37 [doi]
PST - aheadofprint
SO  - J Ethnobiol Ethnomed. 2013 May 30;9(1):37.

PMID- 23717842
OWN - NLM
STAT- In-Process
DA  - 20130528
IS  - 1931-843X (Electronic)
IS  - 1540-9996 (Linking)
VI  - 22
IP  - 4
DP  - 2013 Apr
TI  - The lipid accumulation product for the early prediction of gestational insulin
      resistance and glucose dysregulation.
PG  - 362-7
AB  - BACKGROUND: Recent insights linking insulin resistance and lipid overaccumulation
      suggest a novel approach for the early identification of women who may soon
      experience glucose dysregulation. Among women without a history of gestational
      diabetes, we tested the association between the lipid accumulation product (LAP) 
      obtained in early pregnancy and glucose dysregulation or insulin resistance in
      the second trimester. METHODS: A total of 180 white pregnant women of
      French-Canadian origin were included in this study. At 11-14 weeks' gestation,
      fasting insulin, glucose, C-peptide concentrations, and estimated insulin
      resistance (HOMA-IR) were obtained. The waist circumference (WC) and fasting
      triglycerides (TG) were measured to calculate LAP as(WC[cm] - 58) . TG[mmol/L].
      At 24-28 weeks' gestation, glucose was measured 2 hours after a 75-g oral glucose
      challenge and other fasting variables were repeated. RESULTS: Among the
      nulliparous women tested at the end of the second trimester, fasting insulin,
      C-peptide, insulin resistance (HOMA-IR index), fasting glucose, and 2-hour
      glucose progressively increased ( p pound 0.002)according to their
      first-trimester LAP tertiles. Similar results were observed in parous women
      except for the glucose variables. The first-trimester LAP tended to show a
      stronger correlation to the second-trimester HOMAIR index (r = 0.56) than fasting
      triglyceride levels alone (r = 0.40) or waist circumference alone (r = 0.44)
      among nulliparous women. Similar associations were observed for parous women.
      Adjustment for body mass index weakened these associations, especially among
      parous women. CONCLUSIONS: An increased value of LAP at the beginning of a
      pregnancy could be associated with an increased risk of insulin resistance or
      hyperglycemia later in gestation.
AD  - Department of Medicine, Universite de Montre al, ECOGENE-21 and Lipid Clinic,
      Chicoutimi Hospital, Saguenay, Quebec, Canada. diane.brisson@ecogene21.org
FAU - Brisson, Diane
AU  - Brisson D
FAU - Perron, Patrice
AU  - Perron P
FAU - Kahn, Henry S
AU  - Kahn HS
FAU - Gaudet, Daniel
AU  - Gaudet D
FAU - Bouchard, Luigi
AU  - Bouchard L
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Womens Health (Larchmt)
JT  - Journal of women's health (2002)
JID - 101159262
SB  - IM
PMC - PMC3627434
OID - NLM: PMC3627434 [Available on 04/01/14]
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PMCR- 2014/04/01 00:00
PST - ppublish
SO  - J Womens Health (Larchmt). 2013 Apr;22(4):362-7.

PMID- 23717776
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 2008-7802 (Print)
IS  - 2008-7802 (Linking)
VI  - 4
IP  - Suppl 1
DP  - 2013 Apr
TI  - Effect of resistance training on plasma nitric oxide and asymmetric
      dimethylarginine concentrations in type I diabetic rats.
PG  - S78-84
AB  - BACKGROUND: Asymmetric dimethylarginine (ADMA) has a predominant role in
      progression of some cardiovascular diseases, including diabetes. It interferes
      with L-arginine in production of nitric oxide (NO) by inhibition of NO synthase. 
      The purpose of this study was to evaluate the effect of resistance training on
      plasma NO and ADMA concentrations in type 1 diabetic male rats. METHODS:
      Thirty-six male wistar rats were randomly divided into four groups: (1) control; 
      (2) diabetic; (3) diabetic trained, and (4) control trained (n = 9 each). In the 
      trained groups, the animals undertook one training session per day, 3 days/week, 
      for 4 weeks. At the end of experiment, blood samples were taken and the
      concentrations of plasma glucose, insulin, lipid profile, NO and ADMA
      concentrations were determined. RESULTS: plasma ADMA concentration showed a
      significant increase in diabetic rats compare to control group (0.73 +/- 0.07 vs.
      0.62 +/- 0.04 mumol/l; P < 0.05). The plasma ADMA level in the trained diabetic
      and control were lower than the sedentary groups, although it was not
      statistically significant. Plasma NO concentration in diabetic group was lower
      than control (P < 0.05). Resistance training significantly increased plasma NO
      concentration in diabetic animals (P < 0.05). CONCLUSION: Elevated ADMA level in 
      diabetic animals can normalize during resistance exercise. Reduced ADMA level and
      increased NO level following resistance training might improve cardiovascular
      risk in diabetic subjects.
AD  - Department of Physical Education and Sports, Tarbiat Modarres University, Tehran,
      Iran ; School Management and Medical Informatics, Isfahan University of Medical
      Sciences, Isfahan, Iran.
FAU - Esfahani, Parivash Shekarchizadeh
AU  - Esfahani PS
FAU - Gharakhanlou, Reza
AU  - Gharakhanlou R
FAU - Karimian, Jahangir
AU  - Karimian J
FAU - Khazaei, Majid
AU  - Khazaei M
FAU - Feizi, Awat
AU  - Feizi A
FAU - Safarzade, Alireza
AU  - Safarzade A
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Int J Prev Med
JT  - International journal of preventive medicine
JID - 101535380
PMC - PMC3665032
OID - NLM: PMC3665032
OTO - NOTNLM
OT  - Asymmetric dimethylarginine
OT  - diabetes
OT  - nitric oxide
OT  - resistance training
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
PHST- 2012/03/02 [received]
PHST- 2012/06/10 [accepted]
PST - ppublish
SO  - Int J Prev Med. 2013 Apr;4(Suppl 1):S78-84.

PMID- 23717773
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 2008-7802 (Print)
IS  - 2008-7802 (Linking)
VI  - 4
IP  - Suppl 1
DP  - 2013 Apr
TI  - The Relationship Between Vegetables and Fruits Intake and Glycosylated Hemoglobin
      Values, Lipids Profiles and Nitrogen Status in Type II Inactive Diabetic
      Patients.
PG  - S63-7
AB  - BACKGROUND: The prevalence of obesity and associated chronic disease such as
      diabetes is rapidly increasing in all part of the world. The World Health
      Organization has predicted that between 1997 and 2025 the number of diabetic
      patients will increase from 143 million to about 300 million. In diabetic
      patients, oxidative stress leads to non-enzymatic glycosylation of proteins such 
      as hemoglobin and albumin, these proteins can play a significant role in
      pathogenesis of diabetes and development of chronic disorders in diabetic
      patients. Antioxidant nutrients can reduce the chronic disorders and
      complications of diabetes by inhibiting the oxidative reactions. Some important
      antioxidant such as vitamin A, vitamin C, vitamin E and selenium occur in
      vegetables and fruits. Our objective of this study was investigation of the
      relationship between vegetables and fruits intake ssand glycosylated hemoglobin
      (HbA1C) values in diabetic patients. METHODS: One hundred and five diabetic
      patients participated in this cross-sectional study. The patients were referred
      to health center in Khomeini shahr. Glycosylated hemoglobin (HbA1C) values were
      measured by chromatography method. Data on dietary intake and vegetables and
      fruits consumption were obtained from validated food frequency questionnaires.
      RESULTS: The unadjusted mean glycosylated hemoglobin (HbA1C) is significantly
      associated with the amount of vegetables and fruits intake (P = 0.014), but the
      relationship between consumption of fruits and HbA1C is not significant and the
      relationship between consumption of vegetables and HbA1C was roughly significant 
      (P = 0.049). There were no significant relationship between vegetables and fruits
      intake and lipids profiles, BUN/creatinine and 24 h urinary protein (P > 0.05).
      CONCLUSIONS: Intake of vegetables and fruits may reduce the glycosylated
      hemoglobin, therefore choosing the appropriate diet with high fruits and
      vegetables may help to develop antioxidant defense and reduce the HbA1C in
      diabetic patients but it did not have any impact on lipids profiles,
      BUN/creatinine and urine protein 24 h.
AD  - Child Growth and Development Research Center, Isfahan University of Medical
      Sciences, Isfahan, Iran.
FAU - Tabesh, Marjan
AU  - Tabesh M
FAU - Hariri, Mitra
AU  - Hariri M
FAU - Askari, Gholamreza
AU  - Askari G
FAU - Ghiasvand, Reza
AU  - Ghiasvand R
FAU - Tabesh, Maryam
AU  - Tabesh M
FAU - Heydari, Asieh
AU  - Heydari A
FAU - Darvishi, Leila
AU  - Darvishi L
FAU - Khorvash, Fariba
AU  - Khorvash F
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Int J Prev Med
JT  - International journal of preventive medicine
JID - 101535380
PMC - PMC3665029
OID - NLM: PMC3665029
OTO - NOTNLM
OT  - 24 h urinary protein
OT  - BUN/creatinine
OT  - glycosylated hemoglobin (HbA1C)
OT  - lipids profiles
OT  - vegetables and fruits intake
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
PHST- 2012/03/02 [received]
PHST- 2012/06/10 [accepted]
PST - ppublish
SO  - Int J Prev Med. 2013 Apr;4(Suppl 1):S63-7.

PMID- 23717759
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 2008-7802 (Print)
IS  - 2008-7802 (Linking)
VI  - 4
IP  - Suppl 1
DP  - 2013 Apr
TI  - Influence of ginger and cinnamon intake on inflammation and muscle soreness
      endued by exercise in Iranian female athletes.
PG  - S11-5
AB  - BACKGROUND: Ginger rhizomes (rich in gingerols, shogaols, paradols and zingerone)
      have been used in Asia for the treatment of asthma, diabetes, and pain, and have 
      shown potent anti-inflammatory attributes. Common spices such as Cinnamon
      (including cinnamic aldehyde and cinnamyl aldehydeis) are used in food and many
      studies have focused on its anti-inflammatory components. Intense exercise can
      result in an inflammatory response to cell damage and also muscle soreness. The
      efficacy of dietary ginger and cinnamon as anti-inflammatory agents and their
      effectiveness in reducing muscle soreness has been investigated in limited
      studies on humans. Therefore, we have studied the effects of dietary ginger and
      cinnamon on inflammation and muscle soreness in Iranian female taekwondo players.
      METHODS: Sixty healthy, trained women, aged 13-25 years, were enrolled in the
      six-week investigation and randomly categorized into three groups (cinnamon,
      ginger or placebo) and received 3 g of ginger, cinnamon or placebo powder each
      day, depending on the group they belonged to. The IL-6 level and Likert Scale of 
      Muscle Soreness were evaluated at the beginning and the end of the study and
      compared among the groups. RESULTS: Forty-nine of the participants completed the 
      six-week intervention. There were no significant changes in the IL-6 cinnamon and
      ginger group when compared with the placebo group, whereas, there was a
      significant fall in muscle soreness in the cinnamon group and placebo (P < 0.1)
      and ginger group and placebo (P < 0.01). CONCLUSIONS: Administration of ginger
      and cinnamon in athlete women for six weeks did not show any significant change
      in the IL-6 level, but showed a decrease in muscle soreness in the cinnamon and
      ginger groups.
AD  - Food Security Research Center, Isfahan University of Medical Sciences, Isfahan,
      Isfahan, Iran ; Department of Community Nutrition, School of Nutrition and Food
      Science, Isfahan University of Medical Sciences, Isfahan, Iran.
FAU - Mashhadi, Nafiseh Shokri
AU  - Mashhadi NS
FAU - Ghiasvand, Reza
AU  - Ghiasvand R
FAU - Askari, Gholamreza
AU  - Askari G
FAU - Feizi, Awat
AU  - Feizi A
FAU - Hariri, Mitra
AU  - Hariri M
FAU - Darvishi, Leila
AU  - Darvishi L
FAU - Barani, Azam
AU  - Barani A
FAU - Taghiyar, Maryam
AU  - Taghiyar M
FAU - Shiranian, Afshin
AU  - Shiranian A
FAU - Hajishafiee, Maryam
AU  - Hajishafiee M
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Int J Prev Med
JT  - International journal of preventive medicine
JID - 101535380
PMC - PMC3665015
OID - NLM: PMC3665015
OTO - NOTNLM
OT  - Athletes
OT  - cinnamon
OT  - ginger
OT  - inflammation
OT  - muscle soreness
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
PHST- 2012/08/21 [received]
PHST- 2013/11/09 [accepted]
PST - ppublish
SO  - Int J Prev Med. 2013 Apr;4(Suppl 1):S11-5.

PMID- 23717739
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 1948-5182 (Electronic)
VI  - 5
IP  - 5
DP  - 2013 May 27
TI  - Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of
      Bangladesh.
PG  - 281-7
LID - 10.4254/wjh.v5.i5.281 [doi]
AB  - AIM: To explore the prevalence and risk factors for nonalcoholic steatohepatitis 
      (NASH) in nonalcoholic fatty liver disease (NAFLD) patients. METHODS: We have
      included 493 patients with sonographic evidence of a fatty change, and 177 of
      these individuals were evaluated and confirmed after liver biopsy. The exclusion 
      criteria consisted of significant alcohol abuse (< 20 g daily), evidence of
      hepatitis B and C, evidence of drug-induced fatty liver disease and other
      specific liver diseases such as hemochromatosis, Wilson's disease or autoimmune
      liver disease. The patients were assessed for metabolic syndrome, and
      biochemical, anthropometric and histopathological evaluations were carried out.
      The degree of disease activity in the NAFLD patients was evaluated using the
      NAFLD Activity Score. The data were analyzed by SPSS, version 16.0. RESULTS:
      Females predominated among the study participants (250, 57.0%), and the mean age 
      was 40.8 +/- 10.2 years. The numbers of overweight, obese I and obese II patients
      were 58 (13.2%), 237 (53.9%) and 93 (21.2%), respectively. However, there were
      422 (96.2%) centrally obese patients. NASH was absent in 10 (5.6%) cases,
      borderline in 92 (52.6%) cases and present in 75 (42.4%) cases. The presence of
      diabetes could significantly (P = 0.001) differentiate NASH from simple
      steatosis. The following parameters did not influence the development of NASH:
      age, sex, basal metabolic index, waist circumference, serum high-density
      lipoprotein, triglyceride, insulin resistance index, hypertension and metabolic
      syndrome. The serum gamma-glutamyl transpeptidase (GGT) level was significantly
      higher (P = 0.05, 51.7 +/- 32.8 and 40.4 +/- 22.6 U/L) in the NASH patients, with
      a sensitivity of 45% and a specificity of only 68%. The serum alanine
      aminotransferase and aspartate aminotransferase levels were not able to predict
      NASH. CONCLUSION: Females were the predominant sufferers of NAFLD in Bangladesh. 
      The prevalence of NASH was high. Diabetes was found to be the main culprit in
      developing NASH. GGT was the only biochemical marker of NASH. We recommend liver 
      biopsy in NAFLD patients who have diabetes and elevated GGT.
AD  - Shahinul Alam, Sheikh Mohammad Noor-E-Alam, Ziaur Rahman Chowdhury, Mahabubul
      Alam, Jahangir Kabir, Department of Hepatology, Bangabandhu Sheikh Mujib Medical 
      University, Shahbag, Dhaka 1000, Bangladesh.
FAU - Alam, Shahinul
AU  - Alam S
FAU - Noor-E-Alam, Sheikh Mohammad
AU  - Noor-E-Alam SM
FAU - Chowdhury, Ziaur Rahman
AU  - Chowdhury ZR
FAU - Alam, Mahabubul
AU  - Alam M
FAU - Kabir, Jahangir
AU  - Kabir J
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Hepatol
JT  - World journal of hepatology
JID - 101532469
PMC - PMC3664286
OID - NLM: PMC3664286
OTO - NOTNLM
OT  - Alanine aminotransferase
OT  - Basal metabolic index
OT  - Fatty liver
OT  - Gamma-glutamyl transpeptidase
OT  - Nonalcoholic fatty liver disease
OT  - Nonalcoholic steatohepatitis
OT  - Obesity
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
PHST- 2013/02/17 [received]
PHST- 2013/04/30 [revised]
PHST- 2013/05/08 [accepted]
AID - 10.4254/wjh.v5.i5.281 [doi]
PST - ppublish
SO  - World J Hepatol. 2013 May 27;5(5):281-7. doi: 10.4254/wjh.v5.i5.281.

PMID- 23717738
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 1948-5182 (Electronic)
VI  - 5
IP  - 5
DP  - 2013 May 27
TI  - Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with
      psoriasis.
PG  - 275-80
LID - 10.4254/wjh.v5.i5.275 [doi]
AB  - AIM: To establish the prevalence of liver fibrosis and to evaluate the possible
      risk factors for fibrosis and progression in Asian with psoriasis treated with
      methotrexate (MTX) based on liver histology. METHODS: Patients with psoriasis
      treated with MTX referred to the Department of Gastroenterology, Tan Tock Seng
      Hospital for liver biopsy were identified and retrospectively studied. Patient
      case notes and electronic records were retrieved from the hospital database and
      relevant data collated. Histological changes of liver biopsies were staged
      according to Roengik score. The factors assessed were age, gender, ethnicity,
      cumulative dose of MTX, presence of comorbid conditions such as diabetes,
      hypertension, hyperlipidemia, and ethanol use. We also assessed the histological 
      change in those with multiple liver biopsies. Statistical analysis was performed 
      using Stata V.9.2. RESULTS: There were altogether 59 patients (median age 50
      years old, range 22-81 years old, male, 88%) with 98 biopsies liver biopsies; 6
      normal [median cumulative dose (MCD), 2285 mg]; 62 grade I (MCD 2885 mg), 23
      grade II (MCD 1800 mg) and 7 grade III (MCD 1500 mg). There was no grade IV or
      cirrhosis. The prevalence of liver fibrosis (grade III) was 12%. Of the factors
      assessed, diabetes (P = 0.001) and hypertension (P = 0.003) were significant for 
      fibrosis on univariate analysis but not on multivariate analysis. Of the 26
      patients who had more than one biopsy (median 2, range 2-6), 57.7% (n = 15) were 
      stable, 34.6% (n = 9) had progression and 7.7% (n = 2) had regression of
      histological grades. On univariate analysis, non-Chinese ethnicity (P = 0.031),
      diabetes (P = 0.018), and hyperlipidemia (P = 0.011) were predictive of
      progression of grades, but these were not significant on multivariate analysis.
      CONCLUSION: Liver fibrosis in Asian psoriatic population on MTX is comparable to 
      the West. Cumulative dose was not associated with liver fibrosis. Metabolic
      syndrome is important factors.
AD  - Chong Meng Yeo, Wei Lyn Yang, Department of Gastroenterology, Tan Tock Seng
      Hospital, Singapore 308433, Singapore.
FAU - Yeo, Chong Meng
AU  - Yeo CM
FAU - Chong, Vui Heng
AU  - Chong VH
FAU - Earnest, Arul
AU  - Earnest A
FAU - Yang, Wei Lyn
AU  - Yang WL
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Hepatol
JT  - World journal of hepatology
JID - 101532469
PMC - PMC3664285
OID - NLM: PMC3664285
OTO - NOTNLM
OT  - Cirrhosis
OT  - Hepatotoxicity
OT  - Liver fibrosis
OT  - Methotrexate
OT  - Risk factors
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
PHST- 2013/02/06 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.4254/wjh.v5.i5.275 [doi]
PST - ppublish
SO  - World J Hepatol. 2013 May 27;5(5):275-80. doi: 10.4254/wjh.v5.i5.275.

PMID- 23717715
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1937-8688 (Electronic)
VI  - 14
DP  - 2013
TI  - [Characteristics of the association type 2 diabetes and hypertension in the
      elderly aged 65 and over].
PG  - 100
LID - 10.11604/pamj.2013.14.100.1880 [doi]
AD  - Service d'endocrinologie, diabetologie et maladies metaboliques, Laboratoire de
      recherche de pneumo-cardio-immunopathologie et metabolisme PCIM, Faculte de
      Medecine et de Pharmacie de Marrakech, Universite cadi Ayyad. CHU Mohamed VI. Rue
      el mostachfa, Gueliz, 40 000, Marrakech, Maroc.
FAU - Diyane, Khadija
AU  - Diyane K
FAU - El Ansari, Nawal
AU  - El Ansari N
FAU - El Mghari, Ghizlane
AU  - El Mghari G
FAU - Anzid, Karim
AU  - Anzid K
FAU - Cherkaoui, Mohamed
AU  - Cherkaoui M
LA  - fre
PT  - Journal Article
TT  - Caracteristiques de l'association diabete type 2 et hypertension arterielle chez 
      le sujet age de 65 ans et plus.
DEP - 20130312
PL  - Uganda
TA  - Pan Afr Med J
JT  - The Pan African medical journal
JID - 101517926
SB  - IM
PMC - PMC3664871
OID - NLM: PMC3664871
OTO - NOTNLM
OT  - Type 2 diabetes
OT  - degenerative complications
OT  - dyslipidemia
OT  - elderly
OT  - hypertension
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/07/11 [received]
PHST- 2012/11/01 [accepted]
PHST- 2013/03/12 [epublish]
AID - 10.11604/pamj.2013.14.100.1880 [doi]
AID - PAMJ-14-100 [pii]
PST - epublish
SO  - Pan Afr Med J. 2013 Mar 12;14:100. doi: 10.11604/pamj.2013.14.100.1880. Print
      2013.

PMID- 23717693
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Impact of GLO1 Knock Down on GLUT4 Trafficking and Glucose Uptake in L6
      Myoblasts.
PG  - e65195
LID - 10.1371/journal.pone.0065195 [doi]
AB  - Methylglyoxal (MG), a highly reactive alpha-dicarbonyl metabolite of glucose
      degradation pathways, protein and fatty acid metabolism, plays an important role 
      in the pathogenesis of diabetic complications. Hyperglycemia triggers enhanced
      production of MG and increased generation of advanced glycation endproducts
      (AGEs). In non-enzymatic reactions, MG reacts with arginine residues of proteins 
      to form the AGEs argpyrimidine and hydroimidazolone. Glyoxalase 1 (GLO1), in
      combination with glyoxalase 2 and the co-factor glutathione constitute the
      glyoxalase system, which is responsible for the detoxification of MG. A GLO1
      specific knock down results in accumulation of MG in targeted cells. The aim of
      this study was to investigate the effect of intracellularly accumulated MG on
      insulin signaling and on the translocation of the glucose transporter 4 (GLUT4). 
      Therefore, L6 cells stably expressing a myc-tagged GLUT4 were examined. For the
      intracellular accumulation of MG, GLO1, the first enzyme of the glyoxalase
      pathway, was down regulated by siRNA knock down and cells were cultivated under
      hyperglycemic conditions (25 mM glucose) for 48 h. Here we show that GLO1 knock
      down augmented GLUT4 level on the cell surface of L6 myoblasts at least in part
      through reduction of GLUT4 internalization, resulting in increased glucose
      uptake. However, intracellular accumulation of MG had no effect on GLUT4
      concentration or modification. The antioxidant and MG scavenger NAC prevented the
      MG-induced GLUT4 translocation. Tiron, which is also a well-known antioxidant,
      had no impact on MG-induced GLUT4 translocation.
AD  - Ruhr-University Bochum, Diabetes Center, Heart and Diabetes Center NRW, Bad
      Oeynhausen, Germany.
FAU - Engelbrecht, Britta
AU  - Engelbrecht B
FAU - Stratmann, Bernd
AU  - Stratmann B
FAU - Hess, Cornelius
AU  - Hess C
FAU - Tschoepe, Diethelm
AU  - Tschoepe D
FAU - Gawlowski, Thomas
AU  - Gawlowski T
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3662699
OID - NLM: PMC3662699
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/02/23 [received]
PHST- 2013/04/26 [accepted]
PHST- 2013/05/23 [epublish]
AID - 10.1371/journal.pone.0065195 [doi]
AID - PONE-D-12-05979 [pii]
PST - epublish
SO  - PLoS One. 2013 May 23;8(5):e65195. doi: 10.1371/journal.pone.0065195. Print 2013.

PMID- 23717692
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Crucial role of calcium-sensing receptor activation in cardiac injury of diabetic
      rats.
PG  - e65147
LID - 10.1371/journal.pone.0065147 [doi]
AB  - Cardiac injury is a common pathological change frequently accompanied by diabetes
      mellitus. Recently, some evidence indicated that calcium-sensing receptor (CaSR) 
      expressed in the cardiac tissue. However, the functional role of CaSR in diabetic
      cardiac injury remains unclear. The present study was designed to investigate the
      relationship between CaSR activation and diabetes-induced cardiac injury.
      Diabetic model was successfully established by administration of streptozotocin
      (STZ) in vivo, and cardiomyocyte injury was simulated by 25.5 mM glucose in
      vitro. Apoptotic rate, intracellular calcium concentration ([Ca(2+)]i) and the
      expression of Bcl-2, Bax, extracellular signal-regulated protein kinase (ERK),
      c-Jun NH2-terminal protein kinase (JNK), and p38 were examined. We demonstrated a
      significant increase in left ventricular end-diastolic pressure (LVEDP) as well
      as decrease in maximum rate of left ventricular pressure rise and fall
      (+/-dp/dtmax), and left ventricular systolic pressure (LVSP), apoptosis of
      cardiomyocytes was also observed by TUNEL staining. In vitro, 25.5 mM
      glucose-induced apoptosis was detected by flow cytometry in neonatal rat
      cardiomyocytes. Further results showed that 25.5 mM glucose significantly
      increased [Ca(2+)]i, up-regulated the expression of Bax, P-ERK and P-JNK, and
      suppressed Bcl-2 expression. However, the above deleterious changes were further 
      confirmed when co-treatment with CaSR agonist GdCl3 (300 microM). But the effects
      of GdCl3 were attenuated by 10 microM NPS-2390, a specific CaSR inhibitor. When
      CaSR was silence by siRNA transfection, the effects of high glucose were
      inhibited. These results suggest that CaSR activation could lead to the apoptosis
      of cardiomyocytes in diabetic cardiac injury through the induction of calcium
      overload, the activation of the mitochondrial, and mitogen-activated protein
      kinase pathway.
AD  - Department of Pharmacology, Harbin Medical University-Daqing, Daqing,
      Heilongjiang, China.
FAU - Qi, Hanping
AU  - Qi H
FAU - Cao, Yonggang
AU  - Cao Y
FAU - Huang, Wei
AU  - Huang W
FAU - Liu, Yang
AU  - Liu Y
FAU - Wang, Ye
AU  - Wang Y
FAU - Li, Lei
AU  - Li L
FAU - Liu, Lijuan
AU  - Liu L
FAU - Ji, Zhong
AU  - Ji Z
FAU - Sun, Hongli
AU  - Sun H
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3661517
OID - NLM: PMC3661517
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/15 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/22 [epublish]
AID - 10.1371/journal.pone.0065147 [doi]
AID - PONE-D-12-32865 [pii]
PST - epublish
SO  - PLoS One. 2013 May 22;8(5):e65147. doi: 10.1371/journal.pone.0065147. Print 2013.

PMID- 23717600
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Role of SMC1 in Overcoming Drug Resistance in Triple Negative Breast Cancer.
PG  - e64338
LID - 10.1371/journal.pone.0064338 [doi]
AB  - Triple-negative breast cancer (TNBC) is one of the hardest subtypes of breast
      cancer to treat due to the heterogeneity of the disease and absence of
      well-defined molecular targets. Emerging evidence has shown the role of cohesin
      in the formation and progression of various cancers including colon and lung
      cancer but the role of cohesin in breast cancer remains elusive. Our data showed 
      that structural maintenance of chromosome 1 (SMC1), a subunit of the cohesin
      protein complex, is differentially overexpressed both at RNA and protein level in
      a panel of TNBC cell lines as compared to normal epithelial or luminal breast
      cancer cells, suggesting that the amplified product of this normal gene may play 
      role in tumorigenesis in TNBC. In addition, our results show that induced
      overexpression of SMC1 through transient transfection enhanced cell migration and
      anchorage independent growth while its suppression with targeted small
      interfering RNA (siRNA) reduced the migration ability of TNBC cells. Increased
      expression of SMC1 also lead to increase in the mesenchymal marker vimentin and
      decrease in the normal epithelial marker, E-cadherin. Immunocytochemical studies 
      along with flow cytometry and cell fractionation showed the localization of SMC1 
      in the nucleus, cytoplasm and also in the plasma membrane. The knockdown of SMC1 
      by siRNA sensitized the TNBC cells towards a PARP inhibitor (ABT-888) and IC50
      was approximately three fold less than ABT-888 alone. The cytotoxic effect of
      combination of SMC1 suppression and ABT-888 was also confirmed by the colony
      propagation assay. Taken together, these studies report for the first time that
      SMC1 is overexpressed in TNBC cells where it plays a role in cell migration and
      drug sensitivity, and thus provides a potential therapeutic target for this
      highly invasive breast cancer subtype.
AD  - Department of Diabetes, Endocrinology and Metabolic Diseases, City of Hope
      Comprehensive Cancer Center, Duarte, California, United States of America.
FAU - Yadav, Sushma
AU  - Yadav S
FAU - Sehrawat, Archana
AU  - Sehrawat A
FAU - Eroglu, Zeynep
AU  - Eroglu Z
FAU - Somlo, George
AU  - Somlo G
FAU - Hickey, Robert
AU  - Hickey R
FAU - Yadav, Sailee
AU  - Yadav S
FAU - Liu, Xueli
AU  - Liu X
FAU - Awasthi, Yogesh C
AU  - Awasthi YC
FAU - Awasthi, Sanjay
AU  - Awasthi S
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3661439
OID - NLM: PMC3661439
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/08 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/22 [epublish]
AID - 10.1371/journal.pone.0064338 [doi]
AID - PONE-D-13-06887 [pii]
PST - epublish
SO  - PLoS One. 2013 May 22;8(5):e64338. doi: 10.1371/journal.pone.0064338. Print 2013.

PMID- 23717591
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - A Variable CD3(+) T-Cell Frequency in Peripheral Blood Lymphocytes Associated
      with Type 1 Diabetes Mellitus Development in the LEW.1AR1-iddm Rat.
PG  - e64305
LID - 10.1371/journal.pone.0064305 [doi]
AB  - PURPOSE: The LEW.1AR1-iddm rat is an animal model of human type 1 diabetes
      mellitus (T1DM), which arose through a spontaneous mutation within the
      MHC-congenic inbred strain LEW.1AR1 (RT1(r2) ). In contrast to the
      diabetes-resistant LEW.1AR1 background strain in LEW.1AR1-iddm rats a highly
      variable T-cell frequency could be observed in peripheral blood lymphocytes
      (PBLs). METHODS: In this study we therefore characterised the T-cell repertoire
      within the PBLs of the two strains by flow cytometry analysis and identified the 
      CD3(+) T-cell phenotype and its possible linkage to diabetes susceptibility. To
      map loci conferring susceptibility to variable CD3(+) T-cell frequency, backcross
      strains (N2) were generated with the genetically divergent BN and PAR rats for
      microsatellite analysis. RESULTS: The LEW.1AR1-iddm rat strain was characterised 
      by a higher variability of CD3(+) T-cells in PBLs along with a slightly decreased
      mean value compared to the LEW.1AR1 background strain. The reason for this
      reduction was a decrease in the CD4(+) T-cell count while the CD8(+) T-cell
      proportion remained unchanged. However, both T-cell subpopulations showed a high 
      variability. This resulted in a lower CD4(+)/CD8(+) T-cell ratio than in LEW.1AR1
      rats. Like LEW.1AR1-iddm rats all animals of the backcross populations, N2 BN and
      N2 PAR rats, also showed large variations of the CD3(+) T-cell frequency. The
      phenotype of variable CD3(+) T-cell frequency mapped to the telomeric region of
      chromosome 1 (RNO1), which is identical with the already known Iddm8 diabetes
      susceptibility region. The data indicate that a variable CD3(+) T-cell frequency 
      in PBLs is genetically linked to diabetes susceptibility in the LEW.1AR1-iddm
      rat. CONCLUSION: The T-cell variability in PBLs could be related to the
      previously reported imbalance between regulatory and effector T-cell populations 
      which results in beta-cell autoimmunity. Since similar T-cell phenotypes have
      also been described in human T1DM the identification of the functional role of
      the observed variable CD3(+) T-cell frequency may help to understand the
      mechanisms of autoimmunity in T1DM.
AD  - Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany ; 
      Institute for Laboratory Animal Science, Hannover Medical School, Hannover,
      Germany.
FAU - Arndt, Tanja
AU  - Arndt T
FAU - Jorns, Anne
AU  - Jorns A
FAU - Weiss, Heike
AU  - Weiss H
FAU - Tiedge, Markus
AU  - Tiedge M
FAU - Hedrich, Hans-Jurgen
AU  - Hedrich HJ
FAU - Lenzen, Sigurd
AU  - Lenzen S
FAU - Wedekind, Dirk
AU  - Wedekind D
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3661438
OID - NLM: PMC3661438
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/21 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/05/22 [epublish]
AID - 10.1371/journal.pone.0064305 [doi]
AID - PONE-D-13-03369 [pii]
PST - epublish
SO  - PLoS One. 2013 May 22;8(5):e64305. doi: 10.1371/journal.pone.0064305. Print 2013.

PMID- 23717501
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Short and Long Term Mortality after Coronary Artery Bypass Grafting (CABG) Is
      Influenced by Socioeconomic Position but Not by Migration Status in Sweden,
      1995-2007.
PG  - e63877
LID - 10.1371/journal.pone.0063877 [doi]
AB  - BACKGROUND: There are no nationwide studies on mortality after coronary artery
      bypass grafting (CABG) among foreign-born populations that include detailed
      information about country of birth and information about socioeconomic position. 
      The objective was to investigate the risk of mortality after CABG considering
      socioeconomic position, sex and country of birth. MATERIAL AND METHODS: We
      included all 72 333 patients undergoing a first isolated CABG in Sweden, during
      1995 - 2007 of whom 12.7% were foreign-born. The patients were classified
      according to educational level, sex, and country of birth and were followed up to
      December 2007. We estimated the risk of short and long term mortality after CABG 
      in a multivariable model adjusted for age, calendar year of surgery, diabetes,
      educational level, and waiting time for surgery. Hazard ratios (HR) with 95%
      confidence intervals (CI) were calculated based on the Cox proportional hazard
      model. FINDINGS: There were 15,284 deaths during the follow-up, 10.4% of whom
      were foreign-born. The foreign-born patients were 3 to 4 years younger than
      Sweden-born patients at the time of CABG surgery. There were no significant
      differences in overall early or late mortality between foreign-born and
      Sweden-born men and women after CABG. All-cause mortality differed in between
      regions and was highest in foreign-born men from Eastern Africa (HR 3.80, 95% CI 
      1.58-9.17), China (HR 3.61, 95% CI 1.50-8.69), and in Chile (HR 2.12, 95% CI
      1.01-4.47). Patients with low level of education had worse survival compared to
      those with longer than 12 years of education irrespective of sex and country of
      birth. This difference was more pronounced among foreign-born women (HR 1.50, 95%
      CI 1.00-2.33). CONCLUSION: This national study showed higher CABG mortality in
      patients from lower socioeconomic position. Early and late mortality did not
      differ after isolated CABG in foreign-born and Sweden-born patients.
AD  - Institute of Environmental Medicine, Division of Epidemiology, Karolinska
      Institutet, Stockholm, Sweden.
FAU - Dzayee, Dashti Ali M
AU  - Dzayee DA
FAU - Ivert, Torbjorn
AU  - Ivert T
FAU - Beiki, Omid
AU  - Beiki O
FAU - Alfredsson, Lars
AU  - Alfredsson L
FAU - Ljung, Rickard
AU  - Ljung R
FAU - Moradi, Tahereh
AU  - Moradi T
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3661557
OID - NLM: PMC3661557
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/06 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/22 [epublish]
AID - 10.1371/journal.pone.0063877 [doi]
AID - PONE-D-13-05275 [pii]
PST - epublish
SO  - PLoS One. 2013 May 22;8(5):e63877. doi: 10.1371/journal.pone.0063877. Print 2013.

PMID- 23717483
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Quercetin Protects against Diabetes-Induced Exaggerated Vasoconstriction in Rats:
      Effect on Low Grade Inflammation.
PG  - e63784
LID - 10.1371/journal.pone.0063784 [doi]
AB  - Vascular complications are the leading cause of morbidity and mortality in
      patients with diabetes. Quercetin is an important flavonoid with antioxidant and 
      anti-inflammatory activity. Here, the effect of quercetin on diabetes-induced
      exaggerated vasoconstriction in insulin deficient and insulin resistant rat
      models was investigated. Insulin deficiency was induced by streptozotocin while, 
      insulin resistance by fructose. Rats were left 8 weeks or 12 weeks after STZ or
      fructose administration respectively. Quercetin was daily administered in the
      last 6 weeks. Then, tail blood pressure (BP) was recorded in conscious animals;
      concentration-response curves for phenylephrine (PE) and KCl were studied in
      thoracic aorta rings. Non-fasting blood glucose level, serum insulin level,
      insulin resistance index, serum tumour necrosis factor-alpha (TNF-alpha) and
      serum C-reactive protein (CRP) were determined. Nuclear transcription
      factor-kappaB (NF-kappaB) was assessed by immunofluorescence technique.
      Histopathological examination was also performed. The results showed that
      quercetin protected against diabetes-induced exaggerated vasoconstriction and
      reduced the elevated blood pressure. In addition, quercetin inhibited diabetes
      associated adventitial leukocyte infiltration, endothelial pyknosis and increased
      collagen deposition. These effects were accompanied with reduction in serum level
      of both TNF-alpha and CRP and inhibition of aortic NF-kappaB by quercetin in both
      models of diabetes. On the other hand, quercetin did not affect glucose level in 
      any of the used diabetic models. This suggests that the protective effect of
      quercetin is mediated by its anti-inflammatory effect rather than its metabolic
      effects. In summary, quercetin is potential candidate to prevent diabetic
      vascular complications in both insulin deficiency and resistance via its
      inhibitory effect on inflammatory pathways especially NF-kappaB signaling.
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig
      University, Zagazig, Egypt.
FAU - Mahmoud, Mona F
AU  - Mahmoud MF
FAU - Hassan, Noura A
AU  - Hassan NA
FAU - El Bassossy, Hany M
AU  - El Bassossy HM
FAU - Fahmy, Ahmed
AU  - Fahmy A
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3661670
OID - NLM: PMC3661670
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/17 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/22 [epublish]
AID - 10.1371/journal.pone.0063784 [doi]
AID - PONE-D-12-40120 [pii]
PST - epublish
SO  - PLoS One. 2013 May 22;8(5):e63784. doi: 10.1371/journal.pone.0063784. Print 2013.

PMID- 23717464
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Temporal trend in hospitalizations for acute diabetic complications: a nationwide
      study, Italy, 2001-2010.
PG  - e63675
LID - 10.1371/journal.pone.0063675 [doi]
AB  - BACKGROUND: We investigated temporal trends and geographic variations in both
      hospitalizations and in-hospital mortality rates for acute diabetic complications
      (ADC) in the Italian universal health care system. METHODS AND FINDINGS: A
      retrospective review of the medical records of patients with either primary or
      secondary discharge diagnosis of hyperglycaemic acute complications (ICD-9-CM
      codes 250.1, 250.2, 250.3) or hypoglycemic coma (ICD-9-CM code 251.0) was
      performed in period 2001-2010. Standardized rates by age and gender on 2001
      Italian population and by diabetic population were calculated. We identified
      7,601.883 diabetes-related hospital discharges. Out of them, 266,374 (3.5%) were 
      due to ADC, either ketoacidosis/hyperosmolarity (94.4%) or hypoglycemic coma
      (5.6%). The rate of discharge for ADC decreased by 51.1% from 2001 to 2010 (14.4 
      vs. 7.1 discharge rate/1,000 diabetic people; 5.7% decrease per year, test for
      trend, p<0.001) with a similar trend for both hyperglycemic and hypoglycemic
      complications. Diabetic people in the younger age groups (</=19 and 20-44 years
      old) had a significantly greater rate of discharge for ADC than people aged 65
      years and over (</=19 10-fold increase; 20-44: 2-fold increase). In-hospital
      mortality rate was 7.6%, with 211 preventable deaths in younger diabetic people
      (</=44 years old). There was a large variability among Italian Regions and the
      ratio between the highest and the lowest regional discharge rate reached 300% in 
      2010. CONCLUSIONS: Decreasing temporal trend in hospitalizations for preventable 
      ADC suggests improving outpatient care. In younger diabetic patients, however,
      both hospitalization rates and in-hospital mortality are still a matter of
      concern.
AD  - National Institute of Health, Rome, Italy.
FAU - Lombardo, Flavia
AU  - Lombardo F
FAU - Maggini, Marina
AU  - Maggini M
FAU - Gruden, Gabriella
AU  - Gruden G
FAU - Bruno, Graziella
AU  - Bruno G
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3662780
OID - NLM: PMC3662780
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/17 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/23 [epublish]
AID - 10.1371/journal.pone.0063675 [doi]
AID - PONE-D-13-03126 [pii]
PST - epublish
SO  - PLoS One. 2013 May 23;8(5):e63675. doi: 10.1371/journal.pone.0063675. Print 2013.

PMID- 23717456
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Pancreatic Islet Xenograft Survival in Mice Is Extended by a Combination of
      Alpha-1-Antitrypsin and Single-Dose Anti-CD4/CD8 Therapy.
PG  - e63625
LID - 10.1371/journal.pone.0063625 [doi]
AB  - Clinical pancreatic islet transplantation is under evaluation for the treatment
      of autoimmune diabetes, yet several limitations preclude widespread use. For
      example, there is a critical shortage of human pancreas donors.
      Xenotransplantation may solve this problem, yet it evokes a rigorous immune
      response which can lead to graft rejection. Alpha-1-antitrypsin (AAT), a
      clinically available and safe circulating anti-inflammatory and tissue protective
      glycoprotein, facilitates islet alloimmune-tolerance and protects from
      inflammation in several models. Here, we examine whether human AAT (hAAT), alone 
      or in combination with clinically relevant approaches, achieves long-term islet
      xenograft survival. Rat-to-mouse islet transplantation was examined in the
      following groups: untreated (n = 6), hAAT (n = 6, 60-240 mg/kg every 3 days from 
      day -10), low-dose co-stimulation blockade (anti-CD154/LFA-1) and single-dose
      anti-CD4/CD8 (n = 5-7), either as mono- or combination therapies. Islet grafting 
      was accompanied by blood glucose follow-up. In addition, skin xenografting was
      performed in order to depict responses that occur in draining lymph nodes.
      According to our results hAAT monotherapy and hAAT/anti-CD154/LFA-1 combined
      therapy, did not delay rejection day (11-24 days untreated vs. 10-22 day
      treated). However, host and donor intragraft inflammatory gene expression was
      diminished by hAAT therapy in both setups. Single dose T-cell depletion using
      anti-CD4/CD8 depleting antibodies, which provided 14-15 days of reduced
      circulating T-cells, significantly delayed rejection day (28-52 days) but did not
      achieve graft acceptance. In contrast, in combination with hAAT, the group
      displayed significantly extended rejection days and a high rate of graft
      acceptance (59, 61, >90, >90, >90). In examination of graft explants, marginal
      mononuclear-cell infiltration containing regulatory T-cells predominated
      surviving xenografts. We suggest that temporal T-cell depletion, as in the
      clinically practiced anti-thymocyte-globulin therapy, combined with hAAT, may
      promote islet xenograft acceptance. Further studies are required to elucidate the
      mechanism behind the observed synergy, as well as the applicability of the
      approach for pig-to-human islet xenotransplantation.
AD  - Ben-Gurion University of the Negev, Faculty of Health Sciences, Department of
      Clinical Biochemistry and Pharmacology, Be'er Sheva, Israel.
FAU - Ashkenazi, Efrat
AU  - Ashkenazi E
FAU - Baranovski, Boris M
AU  - Baranovski BM
FAU - Shahaf, Galit
AU  - Shahaf G
FAU - Lewis, Eli C
AU  - Lewis EC
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3661573
OID - NLM: PMC3661573
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/27 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/05/22 [epublish]
AID - 10.1371/journal.pone.0063625 [doi]
AID - PONE-D-12-36719 [pii]
PST - epublish
SO  - PLoS One. 2013 May 22;8(5):e63625. doi: 10.1371/journal.pone.0063625. Print 2013.

PMID- 23717413
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Glucose homeostasis in mice is transglutaminase 2 independent.
PG  - e63346
LID - 10.1371/journal.pone.0063346 [doi]
AB  - Transglutaminase type 2 (TG2) has been reported to be a candidate gene for
      maturity onset diabetes of the young (MODY) because three different mutations
      that impair TG2 transamidase activity have been found in 3 families with MODY.
      TG2 null (TG2(-/-)) mice have been reported to be glucose intolerant and have
      impaired glucose-stimulated insulin secretion (GSIS). Here we rigorously
      evaluated the role of TG2 in glucose metabolism using independently generated
      murine models of genetic TG2 disruption, which show no compensatory enhanced
      expression of other TGs in pancreatic islets or other tissues. First, we
      subjected chow- or fat-fed congenic SV129 or C57BL/6 wild type (WT) and TG2(-/-) 
      littermates, to oral glucose gavage. Blood glucose and serum insulin levels were 
      similar for both genotypes. Pancreatic islets isolated from these animals and
      analysed in vitro for GSIS and cholinergic potentiation of GSIS, showed no
      significant difference between genotypes. Results from intraperitoneal glucose
      tolerance tests (GTTs) and insulin tolerance tests (ITTs) were similar for both
      genotypes. Second, we directly investigated the role of TG2 transamidase activity
      in insulin secretion using a coisogenic model that expresses a mutant form of TG2
      (TG2(R579A)), which is constitutively active for transamidase activity.
      Intraperitoneal GTTs and ITTs revealed no significant differences between WT and 
      TG2(R579A/R579A) mice. Given that neither deletion nor constitutive activation of
      TG2 transamidase activity altered basal responses, or responses to a glucose or
      insulin challenge, our data indicate that glucose homeostasis in mice is TG2
      independent, and question a link between TG2 and diabetes.
AD  - Molecular Cardiology and Biophysics Division, Victor Chang Cardiac Research
      Institute, Sydney, New South Wales, Australia ; University of New South Wales,
      Sydney, New South Wales, Australia.
FAU - Iismaa, Siiri E
AU  - Iismaa SE
FAU - Aplin, Mark
AU  - Aplin M
FAU - Holman, Sara
AU  - Holman S
FAU - Yiu, Ting W
AU  - Yiu TW
FAU - Jackson, Kristy
AU  - Jackson K
FAU - Burchfield, James G
AU  - Burchfield JG
FAU - Mitchell, Christopher J
AU  - Mitchell CJ
FAU - O'Reilly, Liam
AU  - O'Reilly L
FAU - Davenport, Aimee
AU  - Davenport A
FAU - Cantley, James
AU  - Cantley J
FAU - Schmitz-Peiffer, Carsten
AU  - Schmitz-Peiffer C
FAU - Biden, Trevor J
AU  - Biden TJ
FAU - Cooney, Gregory J
AU  - Cooney GJ
FAU - Graham, Robert M
AU  - Graham RM
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3661676
OID - NLM: PMC3661676
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/16 [received]
PHST- 2013/03/29 [accepted]
PHST- 2013/05/22 [epublish]
AID - 10.1371/journal.pone.0063346 [doi]
AID - PONE-D-13-02423 [pii]
PST - epublish
SO  - PLoS One. 2013 May 22;8(5):e63346. doi: 10.1371/journal.pone.0063346. Print 2013.

PMID- 23717386
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Nutrient-Deprivation Autophagy Factor-1 (NAF-1): Biochemical Properties of a
      Novel Cellular Target for Anti-Diabetic Drugs.
PG  - e61202
LID - 10.1371/journal.pone.0061202 [doi]
AB  - Nutrient-deprivation autophagy factor-1 (NAF-1) (synonyms: Cisd2, Eris, Miner1,
      and Noxp70) is a [2Fe-2S] cluster protein immune-detected both in endoplasmic
      reticulum (ER) and mitochondrial outer membrane. It was implicated in human
      pathology (Wolfram Syndrome 2) and in BCL-2 mediated antagonization of Beclin
      1-dependent autophagy and depression of ER calcium stores. To gain insights about
      NAF-1 functions, we investigated the biochemical properties of its 2Fe-2S cluster
      and sensitivity of those properties to small molecules. The structure of the
      soluble domain of NAF-1 shows that it forms a homodimer with each protomer
      containing a [2Fe-2S] cluster bound by 3 Cys and one His. NAF-1 has shown the
      unusual abilities to transfer its 2Fe-2S cluster to an apo-acceptor protein
      (followed in vitro by spectrophotometry and by native PAGE electrophoresis) and
      to transfer iron to intact mitochondria in cell models (monitored by fluorescence
      imaging with iron fluorescent sensors targeted to mitochondria). Importantly, the
      drug pioglitazone abrogates NAF-1's ability to transfer the cluster to acceptor
      proteins and iron to mitochondria. Similar effects were found for the
      anti-diabetes and longevity-promoting antioxidant resveratrol. These results
      reveal NAF-1 as a previously unidentified cell target of anti-diabetes
      thiazolidinedione drugs like pioglitazone and of the natural product resveratrol,
      both of which interact with the protein and stabilize its labile [2Fe-2S]
      cluster.
AD  - The Alexander Silberman Institute of Life Science, Hebrew University of
      Jerusalem, Edmond J. Safra Campus at Givat Ram, Jerusalem, Israel.
FAU - Tamir, Sagi
AU  - Tamir S
FAU - Zuris, John A
AU  - Zuris JA
FAU - Agranat, Lily
AU  - Agranat L
FAU - Lipper, Colin H
AU  - Lipper CH
FAU - Conlan, Andrea R
AU  - Conlan AR
FAU - Michaeli, Dorit
AU  - Michaeli D
FAU - Harir, Yael
AU  - Harir Y
FAU - Paddock, Mark L
AU  - Paddock ML
FAU - Mittler, Ron
AU  - Mittler R
FAU - Cabantchik, Zvi Ioav
AU  - Cabantchik ZI
FAU - Jennings, Patricia A
AU  - Jennings PA
FAU - Nechushtai, Rachel
AU  - Nechushtai R
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3661554
OID - NLM: PMC3661554
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/11 [received]
PHST- 2013/03/07 [accepted]
PHST- 2013/05/22 [epublish]
AID - 10.1371/journal.pone.0061202 [doi]
AID - PONE-D-12-39222 [pii]
PST - epublish
SO  - PLoS One. 2013 May 22;8(5):e61202. doi: 10.1371/journal.pone.0061202. Print 2013.

PMID- 23717343
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1759-8885 (Print)
VI  - 4
IP  - 2
DP  - 2013 Jun
TI  - Factors Affecting Sustained Medication Adherence and Its Impact on Health Care
      Utilization in Patients with Diabetes.
PG  - 89-94
AB  - To identify factors associated with years of medication adherence and to examine 
      the relationship between years of adherence and health care utilization. This
      retrospective analysis used administrative data from adult patients with diabetes
      enrolled in health plan in Hawaii for four years (n= 23,450 patients). Ordered
      logistic regression was used to examine factors related to years of medication
      adherence for three types of medications (anti-diabetic, antihypertensive,
      lipid-lowering). Multivariable logistic regression and negative binomial
      regression were used to examine relationship between years of adherence and
      health care utilization (hospitalizations and emergency department visits).
      Adherence to any of the medications for all four years was significantly
      associated with lower odds of a hospitalization or emergency department visit in 
      the third year. The magnitude of reduction in utilization was greater for
      adherence to anti-diabetic and lipid-lowering medications, at 31% compared to 22%
      for antihypertensives. The 9% of patients who were adherent to all three types of
      medications for all four years showed a reduction of 53%. Improvement is needed
      in medication adherence across all three types of medication. Interventions may
      need to target younger adults, women, patients with congestive heart failure,
      Filipinos and Native Hawaiians.
AD  - University of Hawaii at Hilo, College of Pharmacy.
FAU - Juarez, Deborah Taira
AU  - Juarez DT
FAU - Tan, Candace
AU  - Tan C
FAU - Davis, James
AU  - Davis J
FAU - Mau, Marjorie
AU  - Mau M
LA  - ENG
GR  - G12 MD007601/MD/NIMHD NIH HHS/United States
GR  - P20 MD000173/MD/NIMHD NIH HHS/United States
GR  - U54 MD007584/MD/NIMHD NIH HHS/United States
PT  - JOURNAL ARTICLE
TA  - J Pharm Health Serv Res
JT  - Journal of pharmaceutical health services research: an official journal of the
      Royal Pharmaceutical Society of Great Britain
JID - 101522005
PMC - PMC3664067
MID - NIHMS457133
OTO - NOTNLM
OT  - Medication adherence
OT  - health care utilization
OT  - health disparities
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PMCR- 2014/06/01 00:00
AID - 10.1111/jphs.12016 [doi]
PST - ppublish
SO  - J Pharm Health Serv Res. 2013 Jun;4(2):89-94.

PMID- 23717318
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 1664-462X (Electronic)
IS  - 1664-462X (Linking)
VI  - 4
DP  - 2013
TI  - Vitamin D in plants: a review of occurrence, analysis, and biosynthesis.
PG  - 136
LID - 10.3389/fpls.2013.00136 [doi]
AB  - The major function of vitamin D in vertebrates is maintenance of calcium
      homeostasis, but vitamin D insufficiency has also been linked to an increased
      risk of hypertension, autoimmune diseases, diabetes, and cancer. Therefore, there
      is a growing awareness about vitamin D as a requirement for optimal health.
      Vitamin D3 is synthesized in the skin by a photochemical conversion of provitamin
      D3, but the necessary rays are only emitted all year round in places that lie
      below a 35 degrees latitude. Unfortunately, very few food sources naturally
      contain vitamin D and the general population as a results fail to meet the
      requirements. Fish have the highest natural content of vitamin D expected to
      derive from an accumulation in the food chain originating from microalgae.
      Microalgae contain both vitamin D3 and provitamin D3, which suggests that vitamin
      D3 exist in the plant kingdom and vitamin D3 has also been identified in several 
      plant species as a surprise to many. The term vitamin D also includes vitamin D2 
      that is produced in fungi and yeasts by UVB-exposure of provitamin D2. Small
      amounts can be found in plants contaminated with fungi and traditionally only
      vitamin D2 has been considered present in plants. This review summarizes the
      current knowledge on sterol biosynthesis leading to provitamin D. It also
      addresses the occurrence of vitamin D and its hydroxylated metabolites in higher 
      plants and in algae and discusses limitations and advantages of analytical
      methods used in studies of vitamin D and related compounds including recent
      advances in analytical technologies. Finally, perspectives for a future
      production of vitamin D biofortified fruits, vegetables, and fish will be
      presented.
AD  - Division of Food Chemistry, National Food Institute, Technical University of
      Denmark Soborg, Denmark.
FAU - Japelt, Rie B
AU  - Japelt RB
FAU - Jakobsen, Jette
AU  - Jakobsen J
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - Switzerland
TA  - Front Plant Sci
JT  - Frontiers in plant science
JID - 101568200
PMC - PMC3651966
OID - NLM: PMC3651966
OTO - NOTNLM
OT  - 1
OT  - 25-dihydroxy vitamin D
OT  - 25-hydroxy vitamin D
OT  - algae
OT  - biosynthesis
OT  - detection
OT  - plants
OT  - sterols
OT  - vitamin D
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/15 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/13 [epublish]
AID - 10.3389/fpls.2013.00136 [doi]
PST - epublish
SO  - Front Plant Sci. 2013 May 13;4:136. doi: 10.3389/fpls.2013.00136. Print 2013.

PMID- 23717210
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1553-7404 (Electronic)
IS  - 1553-7390 (Linking)
VI  - 9
IP  - 5
DP  - 2013 May
TI  - Analysis of the genetic basis of disease in the context of worldwide human
      relationships and migration.
PG  - e1003447
LID - 10.1371/journal.pgen.1003447 [doi]
AB  - Genetic diversity across different human populations can enhance understanding of
      the genetic basis of disease. We calculated the genetic risk of 102 diseases in
      1,043 unrelated individuals across 51 populations of the Human Genome Diversity
      Panel. We found that genetic risk for type 2 diabetes and pancreatic cancer
      decreased as humans migrated toward East Asia. In addition, biliary liver
      cirrhosis, alopecia areata, bladder cancer, inflammatory bowel disease,
      membranous nephropathy, systemic lupus erythematosus, systemic sclerosis,
      ulcerative colitis, and vitiligo have undergone genetic risk differentiation.
      This analysis represents a large-scale attempt to characterize genetic risk
      differentiation in the context of migration. We anticipate that our findings will
      enable detailed analysis pertaining to the driving forces behind genetic risk
      differentiation.
AD  - Division of Systems Medicine, Department of Pediatrics, Stanford University
      School of Medicine, Stanford, California, United States of America ; Program in
      Biomedical Informatics, Stanford University School of Medicine, Stanford,
      California, United States of America ; Lucile Packard Children's Hospital, Palo
      Alto, California, United States of America.
FAU - Corona, Erik
AU  - Corona E
FAU - Chen, Rong
AU  - Chen R
FAU - Sikora, Martin
AU  - Sikora M
FAU - Morgan, Alexander A
AU  - Morgan AA
FAU - Patel, Chirag J
AU  - Patel CJ
FAU - Ramesh, Aditya
AU  - Ramesh A
FAU - Bustamante, Carlos D
AU  - Bustamante CD
FAU - Butte, Atul J
AU  - Butte AJ
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - United States
TA  - PLoS Genet
JT  - PLoS genetics
JID - 101239074
SB  - IM
PMC - PMC3662561
OID - NLM: PMC3662561
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/05 [ppublish]
PHST- 2012/04/24 [received]
PHST- 2013/02/28 [accepted]
PHST- 2013/05/23 [epublish]
AID - 10.1371/journal.pgen.1003447 [doi]
AID - PGENETICS-D-12-00991 [pii]
PST - ppublish
SO  - PLoS Genet. 2013 May;9(5):e1003447. doi: 10.1371/journal.pgen.1003447. Epub 2013 
      May 23.

PMID- 23717171
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 1226-8453 (Print)
IS  - 1226-8453 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Korean red ginseng extract alleviates advanced glycation end product-mediated
      renal injury.
PG  - 187-93
LID - 10.5142/jgr.2013.37.187 [doi]
AB  - The effect of Korean red ginseng (KRG) on diabetic renal damage was investigated 
      using streptozotocin (STZ)-induced diabetic rats. The diabetic rats showed loss
      of body weight gain, and increases in kidney weight and urine volume, whereas the
      oral administration of KRG at a dose of 100 or 250 mg/kg of body weight per day
      for 28 d prevented these diabetes-induced physiological abnormalities. Among the 
      kidney function parameters, elevated plasma levels of urea nitrogen and
      creatinine in diabetic control rats tended to be lowered in KRG-treated rats. In 
      addition, administration of KRG at a dose of 100 mg/kg body weight in the
      diabetic rats showed significant decreases in serum glucose and tumor necrosis
      factor-alpha (TNF-alpha), implying that KRG might prevent the pathogenesis of
      diabetic complications caused by impaired glucose metabolism and oxidative
      stress. KRG also significantly reduced advanced glycation end product (AGE)
      formation and secretion from kidney of diabetic rats. Furthermore, KRG decreased 
      the levels of N-(carboxymethyl) lysine and expression of AGE receptor. KRG also
      reduced the overexpression of cyclooxygenase-2 and inducible nitric oxide
      synthase in the kidney via deactivation of nuclear factor-kappa B. We also found 
      that KRG prevented STZ-induced destruction of glomerular structure and
      significantly suppressed high glucose-induced fibronectin production. Taken
      together, KRG ameliorates abnormalities associated with diabetic nephropathy
      through suppression of inflammatory pathways activated by TNF-alpha and AGEs.
      These findings indicate that KRG has a beneficial effect on pathological
      conditions associated with diabetic nephropathy.
AD  - Department of Pharmacology and Clinical Pharmacy, College of Pharmacy, Kyung Hee 
      University, Seoul 130-701, Korea.
FAU - Quan, Hai Yan
AU  - Quan HY
FAU - Kim, Do Yeon
AU  - Kim do Y
FAU - Chung, Sung Hyun
AU  - Chung SH
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Ginseng Res
JT  - Journal of ginseng research
JID - 100890690
PMC - PMC3659634
OID - NLM: PMC3659634
OTO - NOTNLM
OT  - Advanced glycation end products
OT  - Nuclear factor-kappa B
OT  - Panax ginseng
OT  - Streptozotocin
OT  - Tumor necrosis factor-α
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
PHST- 2012/08/03 [received]
PHST- 2012/10/31 [revised]
PHST- 2012/11/07 [accepted]
AID - 10.5142/jgr.2013.37.187 [doi]
AID - grosbr-37-187 [pii]
PST - ppublish
SO  - J Ginseng Res. 2013 Apr;37(2):187-93. doi: 10.5142/jgr.2013.37.187.

PMID- 23717157
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 1226-8453 (Print)
IS  - 1226-8453 (Linking)
VI  - 37
IP  - 1
DP  - 2013 Mar
TI  - Ginsenoside Rd inhibits the expressions of iNOS and COX-2 by suppressing
      NF-kappaB in LPS-stimulated RAW264.7 cells and mouse liver.
PG  - 54-63
LID - 10.5142/jgr.2013.37.54 [doi]
AB  - Ginsenoside Rd is a primary constituent of the ginseng rhizome and has been shown
      to participate in the regulation of diabetes and in tumor formation. Reports also
      show that ginsenoside Rd exerts anti-oxidative effects by activating anti-oxidant
      enzymes. Treatment with ginsenoside Rd decreased nitric oxide and prostaglandin
      E2 (PGE2) in lipopolysaccharides (LPS)-challenged RAW264.7 cells and in ICR mouse
      livers (5 mg/kg LPS; LPS + ginsenoside Rd [2, 10, and 50 mg/kg]). Furthermore,
      these decreases were associated with the down-regulations of inducible nitric
      oxide synthase (iNOS) and cyclooxygenase (COX)-2 and of nuclear factor
      (NF)-kappaB activity in vitro and in vivo. Our results indicate that ginsenoside 
      Rd treatment decreases; 1) nitric oxide production (40% inhibition); 2) PGE2
      synthesis (69% to 93% inhibition); 3) NF-kappaB activity; and 4) the
      NF-kappaB-regulated expressions of iNOS and COX-2. Taken together, our results
      suggest that the anti-inflammatory effects of ginsenoside Rd are due to the
      down-regulation of NF-kappaB and the consequent expressional suppressions of iNOS
      and COX-2.
AD  - Molecular Inflammation Research Center for Aging Intervention (MRCA), College of 
      Pharmacy, Pusan National University, Busan 609-735, Korea.
FAU - Kim, Dae Hyun
AU  - Kim DH
FAU - Chung, Jae Heun
AU  - Chung JH
FAU - Yoon, Ji Sung
AU  - Yoon JS
FAU - Ha, Young Mi
AU  - Ha YM
FAU - Bae, Sungjin
AU  - Bae S
FAU - Lee, Eun Kyeong
AU  - Lee EK
FAU - Jung, Kyung Jin
AU  - Jung KJ
FAU - Kim, Min Sun
AU  - Kim MS
FAU - Kim, You Jung
AU  - Kim YJ
FAU - Kim, Mi Kyung
AU  - Kim MK
FAU - Chung, Hae Young
AU  - Chung HY
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Ginseng Res
JT  - Journal of ginseng research
JID - 100890690
PMC - PMC3659628
OID - NLM: PMC3659628
OTO - NOTNLM
OT  - Cyclooxygenase-2
OT  - Ginsenoside Rd
OT  - Inducible nitric oxide synthase
OT  - Panax ginseng
OT  - Prostaglandin E2
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
PHST- 2012/04/25 [received]
PHST- 2012/10/05 [revised]
PHST- 2012/10/06 [accepted]
AID - 10.5142/jgr.2013.37.54 [doi]
AID - grosbr-37-54 [pii]
PST - ppublish
SO  - J Ginseng Res. 2013 Mar;37(1):54-63. doi: 10.5142/jgr.2013.37.54.

PMID- 23716995
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 20
DP  - 2013 May 28
TI  - Nonalcoholic fatty liver disease and microvascular complications in type 2
      diabetes.
PG  - 3134-42
LID - 10.3748/wjg.v19.i20.3134 [doi]
AB  - AIM: To evaluate the correlation between nonalcoholic fatty liver disease (NAFLD)
      and microvascular complications in type 2 diabetes mellitus (T2DM). METHODS: Data
      were obtained from 1217 inpatients with T2DM (757 females, 460 males; aged 63.39 
      +/- 12.28 years). NAFLD was diagnosed by hepatic ultrasonography. Diabetic
      nephropathy (DN), diabetic peripheral neuropathy (DPN), and diabetic retinopathy 
      (DR) were diagnosed according to their respective criteria. The prevalence of
      NAFLD and the independent correlations of clinical characteristics with NAFLD
      were determined by cross-tabulation and logistic regression, respectively.
      RESULTS: Approximately 61% of inpatients with T2DM in Qingdao, China had NAFLD,
      which decreased significantly with increase in age and prolonged course of
      diabetes. The prevalence of NAFLD in patients presenting with DN, DPN and DR was 
      49.4%, 57.2% and 54.9%, respectively. These rates were significantly lower than
      those of patients without DN, DPN and DR (65.9%, 65.6% and 66.1%, respectively, P
      < 0.05). Participants with NAFLD had greater body weight, waist circumference
      (WC), body mass index (BMI), fasting blood glucose (FBG), hemoglobin A1c, alanine
      aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, blood
      pressure, as well as triglyceride (TG) levels and lower high-density lipoprotein 
      (HDL) concentration than those without NAFLD (P < 0.05). NAFLD was positively
      correlated with BMI, WC, TG, FBG, diastolic blood pressure, and systolic blood
      pressure but negatively correlated with the duration of diabetes, DR, DPN, DN,
      and HDL. CONCLUSION: Despite the benign nature of NAFLD, efforts should be
      directed toward early diagnosis, intensive blood glucose and blood pressure
      control, and effective dyslipidemia correction.
AD  - Wen-Shan Lv, Rui-Xia Sun, Yan-Yan Gao, Rong-Fang Pan, Li Li, Jing Wang, Yu-Xin
      Xian, Cai-Xia Cao, the Department of Internal Medicine, the Affiliated Hospital
      of Medical College, Qingdao University, Qingdao 266100, Shandong Province, China.
FAU - Lv, Wen-Shan
AU  - Lv WS
FAU - Sun, Rui-Xia
AU  - Sun RX
FAU - Gao, Yan-Yan
AU  - Gao YY
FAU - Wen, Jun-Ping
AU  - Wen JP
FAU - Pan, Rong-Fang
AU  - Pan RF
FAU - Li, Li
AU  - Li L
FAU - Wang, Jing
AU  - Wang J
FAU - Xian, Yu-Xin
AU  - Xian YX
FAU - Cao, Cai-Xia
AU  - Cao CX
FAU - Zheng, Ming
AU  - Zheng M
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Gastroenterol
JT  - World journal of gastroenterology : WJG
JID - 100883448
SB  - IM
PMC - PMC3662955
OID - NLM: PMC3662955
OTO - NOTNLM
OT  - Diabetic nephropathy
OT  - Diabetic neuropathy
OT  - Diabetic retinopathy
OT  - Nonalcoholic fatty liver disease
OT  - Type 2 diabetes mellitus
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/11/28 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/23 [accepted]
AID - 10.3748/wjg.v19.i20.3134 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 May 28;19(20):3134-42. doi: 10.3748/wjg.v19.i20.3134.

PMID- 23716918
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 0971-4065 (Print)
IS  - 0971-4065 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Mar
TI  - Emphysematous pyelonephritis: A single center study.
PG  - 119-24
LID - 10.4103/0971-4065.109418 [doi]
AB  - We present our experience of 22 cases of emphysematous pyelonephritis (EPN)
      treated from 1996 to 2012. Medical records were analyzed retrospectively for
      demographic profile, presence and duration of diabetes mellitus, and mode of
      clinical presentation. EPN was diagnosed based on demonstration of intra-renal
      gas by plain X-ray, ultrasound, and/or computed tomography (CT) scan. Details of 
      medical treatment, reason for surgical intervention, and final outcome were
      recorded. Univariate analysis was performed to identify risk factors for
      mortality and P value of less than 0.05 was taken as significant. Twenty-two
      cases (6 males, 16 females) of EPN were diagnosed. Seven cases presented with
      acute pyelonephritis, seven cases with urosepsis, and the remaining eight
      patients with multi-organ dysfunction. CT grading of EPN was class IV in three,
      class III in four, class II in 14, and class I in one. All were initially managed
      medically with parenteral antibiotics. Ten patients needed additional surgical
      intervention. The overall survival rate was 86.3% (19/22). Among the risk factors
      analyzed higher CT grade, altered sensorium and thrombocytopenia were
      significantly associated with mortality. We conclude that a more conservative
      approach in managing EPN has become the standard of care. Patients having high CT
      grade of lesions (III and IV) with altered sensorium and thrombocytopenia at
      presentation are more likely to die due to the disease and may be better managed 
      by an aggressive surgical plan.
AD  - Department of Nephrology, Medwin Hospital, Hyderabad, India.
FAU - Fatima, R
AU  - Fatima R
FAU - Jha, R
AU  - Jha R
FAU - Muthukrishnan, J
AU  - Muthukrishnan J
FAU - Gude, D
AU  - Gude D
FAU - Nath, V
AU  - Nath V
FAU - Shekhar, S
AU  - Shekhar S
FAU - Narayan, G
AU  - Narayan G
FAU - Sinha, S
AU  - Sinha S
FAU - Mandal, S N
AU  - Mandal SN
FAU - Rao, B Srinivas
AU  - Rao BS
FAU - Ramsubbarayudu, B
AU  - Ramsubbarayudu B
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Nephrol
JT  - Indian journal of nephrology
JID - 8914356
PMC - PMC3658289
OID - NLM: PMC3658289
OTO - NOTNLM
OT  - Diabetes
OT  - emphysematous pyelonephritis
OT  - outcome
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
AID - 10.4103/0971-4065.109418 [doi]
AID - IJN-23-119 [pii]
PST - ppublish
SO  - Indian J Nephrol. 2013 Mar;23(2):119-24. doi: 10.4103/0971-4065.109418.

PMID- 23716916
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 0971-4065 (Print)
IS  - 0971-4065 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Mar
TI  - Weight loss for reduction of proteinuria in diabetic nephropathy: Comparison with
      angiotensin-converting enzyme inhibitor therapy.
PG  - 108-13
LID - 10.4103/0971-4065.109412 [doi]
AB  - Reduction of weight in obese type 2 diabetes mellitus (T2DM) individuals is
      emerging as a significant strategy in the reduction of proteinuria in diabetic
      nephropathy along with control of hyperglycemia, hypertension, and dyslipidemia. 
      The objective was to evaluate the reduction in 24-h proteinuria in T2DM patients 
      with nephropathy by weight loss, with conventional therapy
      (angiotensin-converting enzyme [ACE] inhibitors) as the control arm. A
      prospective, randomized controlled trial was conducted between June 2010 and May 
      2011. T2DM patients with confirmed nephropathy by 24-h urinary protein estimation
      with a body mass index (BMI) of >25 kg/m(2) were studied. Patients who had
      nondiabetic nephropathy, uncontrolled hypertension (>125/75 mmHg) irrespective of
      antihypertensive drugs, excess weight due to edema or obesity due to other
      specific diseases, alcoholics, smokers, and patients who were on hemodialysis
      were excluded from the study. The patients were divided into three groups,
      namely, group A, patients on ACE inhibitor therapy; group B, patients on
      lifestyle modifications for weight loss; and group C, patients on an antiobesity 
      drug (orlistat) and lifestyle modifications. At the end of 6 months, all the
      three groups were compared. Data were analyzed using software SPSS version 15.0. 
      This study encompassed a total of 88 patients; 12 patients were dropped during
      the study period and 76 (group A: 22, group B: 23, and group C: 31) patients
      remained. The mean age of the patients was 58.36 +/- 10.87 years (range: 30-70
      years). At baseline, age, gender, mean BMI, waist-to-hip ratio (WHR), and 24-h
      proteinuria did not vary significantly among the three groups. At 6 months, the
      mean BMI significantly decreased in group C (P < 0.001) compared to that in the
      other two groups. Among the parameters BMI and WHR, the proportional form of BMI 
      correlated well with the degree of reduction in proteinuria (r = 0.397, P =
      0.01). Reduction in weight using lifestyle modifications and antiobesity drugs
      might improve renal function and proteinuria safely as observed in obese patients
      with diabetic nephropathy.
AD  - Department of Internal Medicine, C.S.M. Medical University, Lucknow, India.
FAU - Patil, M R
AU  - Patil MR
FAU - Mishra, A
AU  - Mishra A
FAU - Jain, N
AU  - Jain N
FAU - Gutch, M
AU  - Gutch M
FAU - Tewari, R
AU  - Tewari R
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Nephrol
JT  - Indian journal of nephrology
JID - 8914356
PMC - PMC3658287
OID - NLM: PMC3658287
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - diabetic nephropathy
OT  - obesity
OT  - proteinuria
OT  - weight loss
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
AID - 10.4103/0971-4065.109412 [doi]
AID - IJN-23-108 [pii]
PST - ppublish
SO  - Indian J Nephrol. 2013 Mar;23(2):108-13. doi: 10.4103/0971-4065.109412.

PMID- 23716797
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130529
DCOM- 20130530
LR  - 20130531
IS  - 1998-3611 (Electronic)
IS  - 0019-5154 (Linking)
VI  - 58
IP  - 2
DP  - 2013 Mar
TI  - The Role of EGFR/ERK/ELK-1 MAP Kinase Pathway in the Underlying Damage to
      Diabetic Rat Skin.
PG  - 101-6
LID - 10.4103/0019-5154.108035 [doi]
AB  - BACKGROUND: Diabetes mellitus (DM) is a highly prevalent disease. Atrophy and
      spontaneous ulcers are the most common cutaneous manifestation of diabetic
      dermopathy (DD). Before spontaneous ulcers, we believe there is an underlying
      damage stage although the mechanism is unknown. AIMS: To explore the expression
      of extracellular signal-regulated kinase1/2 (ERK1/2), its correlated upstream
      protein epidermal growth factor receptor (EGFR) and its downstream transcription 
      factor E twenty-six (ETS)-like 1(ELK-1)in the damage of the diabetic rat skin,
      and to explore the role of ERK1/2 on the recessive damage to diabetic rat skin.
      MATERIALS AND METHODS: Eighty Sprague-Dawley (SD) rats weighing 260-300 g were
      randomly divided into control and streptozotocin (STZ)-induced diabetes groups.
      After 0.5, 2, 4, and 8 weeks, the shaved skin specimens from the back of rats in 
      both groups were collected to observe the histological characteristics of the
      skin, to measure the thickness of the epidermis and the dermis, and to observe
      the ultrastructure. Immunohistochemistry (IHC) and Western blot techniques were
      used to detect the expression and activation of ERK1/2, EGFR, ELK-1 in the skin
      of the rats. RESULTS: There are ultrastructural changes in the DM skin. With the 
      continuance of the diabetes course, the thicknesses of the epidermis and dermis
      decreased, and the expression of phospho-ERK1/2 (P-ERK1/2), EGFR, and ELK-1 was
      decreased gradually in the back skin of the diabetes rats. It was significantly
      lower in 4 and 8 week DM than that of the normal control (P < 0.05). The
      expression of P-EGFR and P-ERK1/2 in the back skin of the diabetes rats was
      positively correlated (r = 0.572 P < 0.05), and the positive correlation was also
      obtained between P-ERK1/2 and P-ELK-1 (r = 0.715, P < 0.05). CONCLUSION: THE
      PHENOMENON OF RECESSIVE DAMAGE EXISTS IN THE SKIN OF DIABETES RATS, WHICH
      PROBABLY MAY RELATE TO THE WEAKNESS OF THE SIGNAL TRANSDUCTION: P-EGFR --> ERK1/2
      --> ELK-1.
AD  - Department of Dermatological, General Hospital of Ningxia Medical University,
      Yinchuan, Ningxia Hui Autonomous Region, China.
FAU - Ge, Xinhong
AU  - Ge X
FAU - Shi, Zhiyun
AU  - Shi Z
FAU - Yu, Nan
AU  - Yu N
FAU - Jiao, Yaning
AU  - Jiao Y
FAU - Jin, Li
AU  - Jin L
FAU - Zhang, Jianzhong
AU  - Zhang J
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Dermatol
JT  - Indian journal of dermatology
JID - 0370750
PMC - PMC3657207
OID - NLM: PMC3657207
OTO - NOTNLM
OT  - Activating transcription factors
OT  - diabetes
OT  - epidermal growth factor receptors
OT  - extracellular signal-regulated mitogen-activated protein kinases
OT  - skin
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:01
CRDT- 2013/05/30 06:00
AID - 10.4103/0019-5154.108035 [doi]
AID - IJD-58-101 [pii]
PST - ppublish
SO  - Indian J Dermatol. 2013 Mar;58(2):101-6. doi: 10.4103/0019-5154.108035.

PMID- 23716694
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
DP  - 2013 May 28
TI  - Structure-based design and mechanisms of allosteric inhibitors for mitochondrial 
      branched-chain alpha-ketoacid dehydrogenase kinase.
AB  - The branched-chain amino acids (BCAAs) leucine, isoleucine, and valine are
      elevated in maple syrup urine disease, heart failure, obesity, and type 2
      diabetes. BCAA homeostasis is controlled by the mitochondrial branched-chain
      alpha-ketoacid dehydrogenase complex (BCKDC), which is negatively regulated by
      the specific BCKD kinase (BDK). Here, we used structure-based design to develop a
      BDK inhibitor, (S)-alpha-chloro-phenylpropionic acid [(S)-CPP]. Crystal
      structures of the BDK-(S)-CPP complex show that (S)-CPP binds to a unique
      allosteric site in the N-terminal domain, triggering helix movements in BDK.
      These conformational changes are communicated to the lipoyl-binding pocket, which
      nullifies BDK activity by blocking its binding to the BCKDC core. Administration 
      of (S)-CPP to mice leads to the full activation and dephosphorylation of BCKDC
      with significant reduction in plasma BCAA concentrations. The results buttress
      the concept of targeting mitochondrial BDK as a pharmacological approach to
      mitigate BCAA accumulation in metabolic diseases and heart failure.
AD  - Departments of Biochemistry and Internal Medicine, University of Texas
      Southwestern Medical Center, Dallas, TX 75390.
FAU - Tso, Shih-Chia
AU  - Tso SC
FAU - Qi, Xiangbing
AU  - Qi X
FAU - Gui, Wen-Jun
AU  - Gui WJ
FAU - Chuang, Jacinta L
AU  - Chuang JL
FAU - Morlock, Lorraine K
AU  - Morlock LK
FAU - Wallace, Amy L
AU  - Wallace AL
FAU - Ahmed, Kamran
AU  - Ahmed K
FAU - Laxman, Sunil
AU  - Laxman S
FAU - Campeau, Philippe M
AU  - Campeau PM
FAU - Lee, Brendan H
AU  - Lee BH
FAU - Hutson, Susan M
AU  - Hutson SM
FAU - Tu, Benjamin P
AU  - Tu BP
FAU - Williams, Noelle S
AU  - Williams NS
FAU - Tambar, Uttam K
AU  - Tambar UK
FAU - Wynn, R Max
AU  - Wynn RM
FAU - Chuang, David T
AU  - Chuang DT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
OTO - NOTNLM
OT  - allosteric mechanisms
OT  - branched-chain α-ketoacid dehydrogenase kinase inhibitor
OT  - in vivo kinase inhibitor studies
OT  - kinase-inhibitor complex structures
OT  - structure-based inhibitor design
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 1303220110 [pii]
AID - 10.1073/pnas.1303220110 [doi]
PST - aheadofprint
SO  - Proc Natl Acad Sci U S A. 2013 May 28.

PMID- 23716674
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
DP  - 2013 May 28
TI  - Innate pro-B-cell progenitors protect against type 1 diabetes by regulating
      autoimmune effector T cells.
AB  - Diverse hematopoietic progenitors, including myeloid populations arising in
      inflammatory and tumoral conditions and multipotent cells, mobilized by
      hematopoietic growth factors or emerging during parasitic infections, display
      tolerogenic properties. Innate immune stimuli confer regulatory functions to
      various mature B-cell subsets but immature B-cell progenitors endowed with
      suppressive properties per se or after differentiating into more mature
      regulatory B cells remain to be characterized. Herein we provide evidence for
      innate pro-B cells (CpG-proBs) that emerged within the bone marrow both in vitro 
      and in vivo upon Toll-like receptor-9 activation and whose adoptive transfer
      protected nonobese diabetic mice against type 1 diabetes (T1D). These cells
      responded to IFN-gamma released by activated effector T cells (Teffs), by
      up-regulating their Fas ligand (FasL) expression, which enabled them to kill
      Teffs through apoptosis. In turn, IFN-gamma derived from CpG-proBs enhanced
      IFN-gamma while dramatically reducing IL-21 production by Teffs. In keeping with 
      the crucial pathogenic role played by IL-21 in T1D, adoptively transferred
      IFN-gamma-deficient CpG-proBs did not prevent T1D development. Additionally,
      CpG-proBs matured in vivo into diverse pancreatic and splenic suppressive
      FasLhigh B-cell subsets. CpG-proBs may become instrumental in cell therapy of
      autoimmune diseases either on their own or as graft complement in autologous stem
      cell transplantation.
AD  - Faculte de Medecine Site Necker, Universite Paris Descartes, Centre National de
      la Recherche Scientifique Unite Mixte de Recherche 8147, 75015 Paris, France.
FAU - Montandon, Ruddy
AU  - Montandon R
FAU - Korniotis, Sarantis
AU  - Korniotis S
FAU - Layseca-Espinosa, Esther
AU  - Layseca-Espinosa E
FAU - Gras, Christophe
AU  - Gras C
FAU - Megret, Jerome
AU  - Megret J
FAU - Ezine, Sophie
AU  - Ezine S
FAU - Dy, Michel
AU  - Dy M
FAU - Zavala, Flora
AU  - Zavala F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
OTO - NOTNLM
OT  - B lymphocytes
OT  - MyD88 signaling
OT  - T lymphocytes
OT  - immune therapy
OT  - peripheral tolerance
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 1222446110 [pii]
AID - 10.1073/pnas.1222446110 [doi]
PST - aheadofprint
SO  - Proc Natl Acad Sci U S A. 2013 May 28.

PMID- 23716672
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
DP  - 2013 May 28
TI  - Differential methylation in glucoregulatory genes of offspring born before vs.
      after maternal gastrointestinal bypass surgery.
AB  - Obesity and overnutrition during pregnancy affect fetal programming of adult
      disease. Children born after maternal bariatric gastrointestinal bypass surgery
      (AMS) are less obese and exhibit improved cardiometabolic risk profiles carried
      into adulthood compared with siblings born before maternal surgery (BMS). This
      study was designed to analyze the impact of maternal weight loss surgery on
      methylation levels of genes involved in cardiometabolic pathways in BMS and AMS
      offspring. Differential methylation analysis between a sibling cohort of 25 BMS
      and 25 AMS (2-25 y-old) offspring from 20 mothers was conducted to identify
      biological functions and pathways potentially involved in the improved
      cardiometabolic profile found in AMS compared with BMS offspring. Links between
      gene methylation and expression levels were assessed by correlating genomic
      findings with plasma markers of insulin resistance (fasting insulin and
      homeostatic model of insulin resistance). A total of 5,698 genes were
      differentially methylated between BMS and AMS siblings, exhibiting a
      preponderance of glucoregulatory, inflammatory, and vascular disease genes.
      Statistically significant correlations between gene methylation levels and gene
      expression and plasma markers of insulin resistance were consistent with
      metabolic improvements in AMS offspring, reflected in genes involved in
      diabetes-related cardiometabolic pathways. This unique clinical study
      demonstrates that effective treatment of a maternal phenotype is durably
      detectable in the methylome and transcriptome of subsequent offspring.
AD  - Institute of Nutrition and Functional Foods and Department of Food Science and
      Nutrition, and Departments of Medicine and Surgery, Laval University, Quebec
      City, QC G1V 0A6, Canada.
FAU - Guenard, Frederic
AU  - Guenard F
FAU - Deshaies, Yves
AU  - Deshaies Y
FAU - Cianflone, Katherine
AU  - Cianflone K
FAU - Kral, John G
AU  - Kral JG
FAU - Marceau, Picard
AU  - Marceau P
FAU - Vohl, Marie-Claude
AU  - Vohl MC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
OTO - NOTNLM
OT  - adiposity
OT  - developmental origins
OT  - epigenetics
OT  - glucose metabolism
OT  - intrauterine environment
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 1216959110 [pii]
AID - 10.1073/pnas.1216959110 [doi]
PST - aheadofprint
SO  - Proc Natl Acad Sci U S A. 2013 May 28.

PMID- 23716623
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
DP  - 2013 May 28
TI  - Effect of Pan-Retinal Photocoagulation on Corneal Sensation and the Corneal
      Sub-Basal Nerve Plexus in Diabetes Mellitus.
LID - iovs.12-10571v1 [pii]
LID - 10.1167/iovs.12-10571 [doi]
AB  - PURPOSE: To assess the effects of pan-retinal photocoagulation (PRP) for diabetic
      retinopathy on the human corneal sub-basal nerve plexus (SBNP) and to investigate
      correlations between corneal sub-basal nerve density, corneal sensitivity and
      diabetic peripheral neuropathy. METHODS: Thirty eight subjects with at least a 10
      year history of diabetes mellitus or diabetic retinopathy were included. Subjects
      were assigned to a PRP group (n=19), having undergone a treatment of retinopathy 
      in at least one eye or a non-PRP group (n=19), with no history of PRP. The
      Michigan Neuropathy Screening Instrument (MNSI) was administered to enable
      quantification of neuropathic symptoms. Laser scanning in vivo confocal
      microscopy was performed to capture images of the corneal SBNP to allow
      determination of SBNP density. Central corneal sensitivity (CST) was evaluated by
      non-contact aesthesiometry and peripheral vibration perception threshold was
      measured with a biothesiometer. RESULTS: Mean SBNP densities were 12.27 +/- 4.28 
      mm/mm2 in the PRP group and 12.75 +/- 3.59mm/mm2 in the non-PRP group. There were
      no significant differences in SBNP density (p=0.71), CST (p=0.84), MNSI score
      (p=0.19), and biothesiometry (p=0.77) between the PRP and non-PRP groups.
      However, when data from both groups (n=38) were combined, corneal sensitivity was
      modestly correlated with SBNP density (r=0.30 p=0.06), and peripheral
      biothesiometry (r=0.26, p=0.11). CONCLUSIONS: In diabetes mellitus correlation of
      corneal sensitivity, SBNP density and peripheral biothesiometry may have a
      potential role in estimating the severity of peripheral neuropathy. Corneal
      sub-basal nerve plexus density and sensitivity appear to be unaffected by PRP
      laser treatment compared to non-PRP diabetic eyes.
AD  - Department of Ophthalmology, University of Auckland, New Zealand National Eye
      Centre, Faculty of Medical and Health Sciences, Auckland, New Zealand.
FAU - Misra, Stuti
AU  - Misra S
FAU - Ahn, Ha Na
AU  - Ahn HN
FAU - Craig, Jennifer P
AU  - Craig JP
FAU - Pradhan, Monika
AU  - Pradhan M
FAU - Patel, Dipika V
AU  - Patel DV
FAU - McGhee, Charles N J
AU  - McGhee CN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - iovs.12-10571 [pii]
AID - 10.1167/iovs.12-10571 [doi]
PST - aheadofprint
SO  - Invest Ophthalmol Vis Sci. 2013 May 28. pii: iovs.12-10571v1. doi:
      10.1167/iovs.12-10571.

PMID- 23716596
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1098-5549 (Electronic)
IS  - 0270-7306 (Linking)
DP  - 2013 May 28
TI  - The Keap1-Nrf2 System Prevents Onset of Diabetes Mellitus.
AB  - Transcription factor Nrf2 (NF-E2-related factor 2) regulates a broad
      cytoprotective response to environmental stresses. Keap1 (Kelch-like
      ECH-associated protein 1) is an adaptor protein for Cullin3-based ubiquitin E3
      ligase, and negatively regulates Nrf2. Whereas the Keap1-Nrf2 system plays
      important roles in oxidative stress response and metabolism, the roles Nrf2 plays
      in the prevention of diabetes mellitus remains elusive. Here we show that genetic
      activation of Nrf2 signaling by Keap1 gene hypomorphic knockdown (Keap1flox/--)
      markedly suppresses the onset of diabetes. When Keap1flox/-- were crossed with
      diabetic db/db mice, blood glucose levels became lower through improvement of
      both insulin secretion and insulin resistance. Keap1flox/-- also prevented
      high-calorie diet-induced diabetes. Oral administration of the Nrf2 inducer
      CDDO-Im also attenuated diabetes in db/db mice. Nrf2 induction altered
      antioxidant-, energy consumption-, and gluconeogenesis-related gene expressions
      in metabolic tissues. Thus, the Keap1-Nrf2 system is a critical target for
      preventing the onset of diabetes mellitus.
AD  - Department of Medical Biochemistry.
FAU - Uruno, Akira
AU  - Uruno A
FAU - Furusawa, Yuki
AU  - Furusawa Y
FAU - Yagishita, Yoko
AU  - Yagishita Y
FAU - Fukutomi, Toshiaki
AU  - Fukutomi T
FAU - Muramatsu, Hiroyuki
AU  - Muramatsu H
FAU - Negishi, Takaaki
AU  - Negishi T
FAU - Sugawara, Akira
AU  - Sugawara A
FAU - Kensler, Thomas W
AU  - Kensler TW
FAU - Yamamoto, Masayuki
AU  - Yamamoto M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Mol Cell Biol
JT  - Molecular and cellular biology
JID - 8109087
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - MCB.00225-13 [pii]
AID - 10.1128/MCB.00225-13 [doi]
PST - aheadofprint
SO  - Mol Cell Biol. 2013 May 28.

PMID- 23716579
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
DP  - 2013 May 28
TI  - Seasonal Changes in Blood Pressure: Possible Interaction Between Sunlight and
      Brain Serotonin.
AD  - Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute,
      Melbourne, Australia.
FAU - Dhar, Arup K
AU  - Dhar AK
FAU - Lambert, Gavin W
AU  - Lambert GW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Hypertension
JT  - Hypertension
JID - 7906255
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - HYPERTENSIONAHA.113.01434 [pii]
AID - 10.1161/HYPERTENSIONAHA.113.01434 [doi]
PST - aheadofprint
SO  - Hypertension. 2013 May 28.

PMID- 23716525
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1550-9613 (Electronic)
IS  - 0278-4297 (Linking)
VI  - 32
IP  - 6
DP  - 2013 Jun
TI  - Renal duplex sonographic evaluation of type 2 diabetic patients.
PG  - 1033-40
LID - 10.7863/ultra.32.6.1033 [doi]
AB  - Objectives- The purpose of this study was to evaluate the renal volume and
      intrarenal hemodynamics with duplex sonography in a group of diabetic patients
      with normal renal function in comparison to nondiabetic controls. Methods- The
      renal volume and resistive index (RI) of segmental arteries were assessed by
      duplex sonography in 88 diabetic patients (44 male and 44 female; median age, 58 
      years [range, 37-69 years]) and 73 nondiabetic control participants (48 male and 
      25 female; median age, 53 years [range, 27-75 years]) without renal artery
      stenosis. Results- Both renal volume and RI values in the diabetic patients were 
      significantly higher compared to the controls (mean volume +/- SD: diabetic
      patients, 197.3 +/- 47.6 mL; controls, 162.5 +/- 35.2 mL; P < .0001; RI: diabetic
      patients, 0.70 +/- 0.05; controls, 0.59 +/- 0.06; P < .0001). Renal hypertrophy
      was present even in diabetic patients without proteinuria (renal volume: patients
      without proteinuria, 198.3 +/- 45.9 mL; controls, 162.5 +/- 35.2 mL; P < .005).
      Patients with higher RI values had significantly greater proteinuria (RI <0.75,
      15.9 mg/g [range, 4.2-1718.9 mg/g]; RI >0.75, 37.9 mg/g [range, 11.34-2087.0
      mg/g]; P < .02). Conclusions- Changes in renal volume and hemodynamics are
      detectable on sonography in diabetic patients. Those changes are also present in 
      patients without proteinuria or signs of renal atherosclerosis and with both
      normal and increased glomerular filtration rates. These results indicate a
      potential role of duplex sonography in the early identification of morphologic
      and hemodynamic renal changes in type 2 diabetic patients.
AD  - Institute of Biostructure and Bioimaging, National Research Council, Federico II 
      University School of Medicine, Via De Amicis 95, 80145 Naples, Italy.
      raffaele.liuzzi@cnr.it.
FAU - Mancini, Marcello
AU  - Mancini M
FAU - Masulli, Maria
AU  - Masulli M
FAU - Liuzzi, Raffaele
AU  - Liuzzi R
FAU - Mainenti, Pier Paolo
AU  - Mainenti PP
FAU - Ragucci, Monica
AU  - Ragucci M
FAU - Maurea, Simone
AU  - Maurea S
FAU - Riccardi, Gabriele
AU  - Riccardi G
FAU - Vaccaro, Olga
AU  - Vaccaro O
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Ultrasound Med
JT  - Journal of ultrasound in medicine : official journal of the American Institute of
      Ultrasound in Medicine
JID - 8211547
SB  - IM
OTO - NOTNLM
OT  - diabetes
OT  - diabetic nephropathy
OT  - proteinuria
OT  - renal hypertrophy
OT  - resistive index
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 32/6/1033 [pii]
AID - 10.7863/ultra.32.6.1033 [doi]
PST - ppublish
SO  - J Ultrasound Med. 2013 Jun;32(6):1033-40. doi: 10.7863/ultra.32.6.1033.

PMID- 23716500
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1549-5469 (Electronic)
IS  - 1088-9051 (Linking)
DP  - 2013 May 28
TI  - Cell-type, allelic and genetic signatures in the human pancreatic beta cell
      transcriptome.
AB  - Elucidating the pathophysiology and molecular attributes of common disorders as
      well as developing targeted and effective treatments hinges on the study of the
      relevant cell type and tissues. Pancreatic beta cells within the islets of
      Langerhans are centrally involved in the pathogenesis of both type 1 and type 2
      diabetes. Describing the differentiated state of the human beta cell has been
      hampered so far by technical (low resolution microarrays) and biological
      limitations (whole islet preparations rather than isolated beta cells). We
      circumvent these by deep RNA sequencing of purified beta cells from 11
      individuals, presenting here the first characterization of the human beta cell
      transcriptome. We perform the first comparison of gene expression profiles
      between beta cells, whole islets and beta cell depleted islet preparations,
      revealing thus beta cell specific expression and splicing signatures. Further, we
      demonstrate that genes with consistent increased expression in beta cells have
      neuronal-like properties, a signal previously hypothesized. Finally, we find
      evidence for extensive allelic imbalance in expression and uncover genetic
      regulatory variants (eQTLs) active in beta cells. This first molecular blueprint 
      of the human beta cell offers biological insight into its differentiated function
      including expression of key genes associated with both major types of diabetes.
AD  - University of Geneva.
FAU - Nica, Alexandra C
AU  - Nica AC
FAU - Ongen, Halit
AU  - Ongen H
FAU - Irminger, Jean-Claude
AU  - Irminger JC
FAU - Bosco, Domenico
AU  - Bosco D
FAU - Berney, Thierry
AU  - Berney T
FAU - Antonarakis, Stylianos E
AU  - Antonarakis SE
FAU - Halban, Philippe A
AU  - Halban PA
FAU - Dermitzakis, Emmanouil T
AU  - Dermitzakis ET
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Genome Res
JT  - Genome research
JID - 9518021
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - gr.150706.112 [pii]
AID - 10.1101/gr.150706.112 [doi]
PST - aheadofprint
SO  - Genome Res. 2013 May 28.

PMID- 23716477
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1542-9741 (Electronic)
IS  - 1542-9733 (Linking)
VI  - 98
IP  - 3
DP  - 2013 Jun
TI  - Activin-a in diabetes-induced cardiac malformations in embryos.
PG  - 260-7
LID - 10.1002/bdrb.21060 [doi]
AB  - BACKGROUND: Heart defects are the most common abnormalities in infants of
      diabetic mothers. Cardiac malformation is associated with altered expression of
      the genes in the transforming growth factor beta system, including inhibin betaA,
      which forms activin-A as a homodimer and functions through its effectors, Smad2
      and Smad3. This study aimed to investigate the role of activin-A in
      diabetes-induced cardiac malformations. METHODS: Diabetes mellitus in female mice
      (C57BL/6J) was induced via intravenous injection of streptozotocin. The
      expression of inhibin betaA protein and phosphorylation of Smad2 and Smad3 in the
      embryonic hearts were examined using immunohistochemical, in situ proximity
      ligation, and immunoblot assays. Embryos and endocardial cushions of nondiabetic 
      mice were cultured in a high concentration of glucose and treated with activin-A.
      Mitosis was examined using BrdU incorporation assay and immunohistochemistry of
      phosphorylated histone H3. Migration of the endocardial cells was assessed using 
      a collagen-based cell migration assay. RESULTS: The levels of inhibin betaA
      expression and Smad2 and Smad3 activation were significantly reduced by maternal 
      diabetes. Treatment with activin-A significantly increased cell proliferation in 
      the myocardium and migration of endocardial cells, compared with those in
      vehicle-treated high glucose group, to the level in the euglycemic control group.
      CONCLUSIONS: Maternal diabetes suppresses the expression of inhibin betaA
      protein, as well as the activation of Smad2 and Smad3. Activin-A rescues cell
      proliferation in the myocardium and migration of the endocardial cells suppressed
      by hyperglycemia. The activin-Smad2/3 signaling system appears to play a role in 
      cardiac malformation in diabetic embryopathy. Birth Defects Res (Part B)
      98:260-267, 2013. (c) 2013 Wiley Periodicals, Inc.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, University of
      Maryland School of Medicine, Baltimore, Maryland.
FAU - Zhao, Zhiyong
AU  - Zhao Z
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - United States
TA  - Birth Defects Res B Dev Reprod Toxicol
JT  - Birth defects research. Part B, Developmental and reproductive toxicology
JID - 101155115
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/01/04 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 10.1002/bdrb.21060 [doi]
PST - ppublish
SO  - Birth Defects Res B Dev Reprod Toxicol. 2013 Jun;98(3):260-7. doi:
      10.1002/bdrb.21060. Epub 2013 May 28.

PMID- 23716464
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Diabetes management is bad medicine in France too.
PG  - f3246
LID - 10.1136/bmj.f3246 [doi]
LID - bmj.f3246 [pii]
AD  - 78200 Mantes-La-Jolie, France.
FAU - Grange, Jean-Claude
AU  - Grange JC
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - epublish
SO  - BMJ. 2013 May 28;346:f3246. doi: 10.1136/bmj.f3246.

PMID- 23716028
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1432-2323 (Electronic)
IS  - 0364-2313 (Linking)
DP  - 2013 May 29
TI  - Prophylactic Mesh Reinforcement Reduces Stomal Site Incisional Hernia after
      Ileostomy Closure.
AB  - BACKGROUND: Stomal site incisional hernia is a common complication following
      ileostomy closure. The effectiveness of prophylactic mesh placement at the time
      of stomal closure is unknown because of fear of mesh infection and subsequent
      wound complications. The present study investigated whether prophylactic mesh
      placement reduces the rate of incisional hernia after ileostomy closure without
      increasing wound complications. The study was based on retrospective review of
      consecutive ileostomy closures undertaken at a tertiary referral center between
      January 2007 and December 2011. Hernias were identified through clinical
      examination and computed tomography. RESULTS: Eighty-three cases of ileostomy
      closure were reviewed; 47 patients received mesh reinforcement, and 36 underwent 
      non-mesh closure (controls). In total, 16 (19.3 %) patients developed incisional 
      hernia, 13 (36.1 %) of which occurred in the control group; 3 (6.4 %), in the
      mesh group [odds ratio (OR): 8.29; 95 % confidence interval (CI) 2.14-32.08; p = 
      0.001]. Incisional hernia repair was performed in 3 (23 %) patients in the
      control group; no hernias in the mesh group required surgery. There was no
      significant difference in wound infection rates between mesh (2 patients, 4.3 %) 
      and control (1 patient, 2.8 %) groups. No mesh infection was found. Multivariate 
      analysis demonstrated that malignancy (OR: 21.93, 95 % CI 1.58-303.95; p = 0.021)
      and diabetes (OR: 20.98, 95 % CI 3.23-136.31; p = 0.001) independently predicted 
      incisional herniation, while mesh reinforcement prevented hernia development (OR:
      0.06, 95 % CI 0.01-0.36; p = 0.002). CONCLUSIONS: Mesh placement significantly
      reduced the incidence of incisional hernia following ileostomy closure, but
      without increasing complication rates. This technique should be strongly
      considered in patients at high risk of hernia development.
AD  - Department of Surgery, Austin Hospital, Level 8, 145 Studley Street, Heidelberg, 
      VIC, 3084, Australia, liu.davidsh@gmail.com.
FAU - Liu, David Shi Hao
AU  - Liu DS
FAU - Banham, Elisabeth
AU  - Banham E
FAU - Yellapu, Srinivasa
AU  - Yellapu S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - World J Surg
JT  - World journal of surgery
JID - 7704052
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1007/s00268-013-2109-3 [doi]
PST - aheadofprint
SO  - World J Surg. 2013 May 29.

PMID- 23715962
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
DP  - 2013 May 28
TI  - Glycosylated Hemoglobin A1 Predicts Risk for Symptomatic Hemorrhage After
      Thrombolysis for Acute Stroke.
AB  - BACKGROUND AND PURPOSE: Symptomatic intracerebral hemorrhage (sICH) is the most
      feared acute complication after intravenous thrombolysis. The aim of this study
      was to determine the predictive value of parameters of glycosylated hemoglobin A1
      (HbA1c) on sICH. METHODS: In a retrospective single center series, 1112
      consecutive patients treated with thrombolysis were studied. Baseline blood
      glucose was obtained at admission. HbA1c was determined within hospital stay. A
      second head computed tomography was obtained after 24 hours or when neurological 
      worsening occurred. Modified Rankin Scale was used to assess outcome at 90 days. 
      RESULTS: A total of 222 patients (19.9%) had any hemorrhage; 43 of those had sICH
      (3.9%) per Safe Implementation of Treatments in Stroke definition and 95 (8.5%)
      per National Institute of Neurological Disorders and Stroke definition; 33.2% of 
      patients had a dependent outcome (modified Rankin Scale score 3-5). In univariate
      analysis history of diabetes mellitus, HbA1c, blood glucose, and National
      Institute of Health Stroke Scale score on admission were associated with any
      hemorrhage and sICH. In multivariate analysis National Institute of Health Stroke
      Scale score, a history of diabetes mellitus, and HbA1c were predictors of sICH
      per National Institute of Neurological Disorders and Stroke, and only HbA1c when 
      Safe Implementation of Treatments in Stroke criteria were used. CONCLUSIONS: In
      our study, HbA1c turns out to be an important predictor of sICH after
      thrombolysis for acute stroke. These results suggest that hemorrhage after
      thrombolysis may be a consequence of long-term vascular injury rather than of
      acute hyperglycemia, and that HbA1c may be a better predictor than acute blood
      glucose or a history of diabetes mellitus.
AD  - From the Department of Neurology, University of Heidelberg, Germany.
FAU - Rocco, A
AU  - Rocco A
FAU - Heuschmann, P U
AU  - Heuschmann PU
FAU - Schellinger, P D
AU  - Schellinger PD
FAU - Kohrmann, M
AU  - Kohrmann M
FAU - Diedler, J
AU  - Diedler J
FAU - Sykora, M
AU  - Sykora M
FAU - Nolte, C H
AU  - Nolte CH
FAU - Ringleb, P
AU  - Ringleb P
FAU - Hacke, W
AU  - Hacke W
FAU - Juttler, E
AU  - Juttler E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Stroke
JT  - Stroke; a journal of cerebral circulation
JID - 0235266
OTO - NOTNLM
OT  - acute stroke
OT  - blood glucose
OT  - glycosylated hemoglobin
OT  - outcome
OT  - symptomatic hemorrhage
OT  - thrombolytic therapy
OT  - tissue plasminogen activator
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - STROKEAHA.111.675918 [pii]
AID - 10.1161/STROKEAHA.111.675918 [doi]
PST - aheadofprint
SO  - Stroke. 2013 May 28.

PMID- 23715958
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
DP  - 2013 May 28
TI  - Microvascular Structure and Network in the Retina of Patients With Ischemic
      Stroke.
AB  - BACKGROUND AND PURPOSE: Microvascular disease has been implicated in the
      pathogenesis of stroke. The retina provides a window to assess microcirculation
      noninvasively. We studied the association between quantitatively measured retinal
      microvascular characteristics and acute ischemic stroke. METHODS: We conducted a 
      case-control study with acute ischemic stroke patients recruited from a tertiary 
      hospital in Singapore and controls from the Singapore Epidemiology of Eye Disease
      program matched by 10-year age strata, sex, and race. Strokes were classified
      using modified Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria.
      Retinal vascular parameters were measured from retinal fundus photographs using a
      computer program. Logistic regression models for stroke were constructed
      adjusting for age, sex, race, and additionally for smoking, hypertension,
      diabetes mellitus, and hypercholesterolemia. RESULTS: We included 557 ischemic
      stroke cases (261 lacunar, 185 large artery, and 54 cardioembolic stroke) and 557
      controls. After adjusting for vascular risk factors, decreased arteriolar fractal
      dimension (odds ratio [OR] per standard deviation [SD] decrease, 2.28; 95%
      confidence interval [CI], 1.80-2.87) and venular fractal dimension (OR per SD
      decrease, 1.80; 95% CI, 1.46-2.23), increased arteriolar tortuosity (OR per SD
      increase, 1.56; 95% CI, 1.25-1.95), and venular tortuosity (OR per SD increase,
      1.49; 95% CI, 1.27-1.76), narrower arteriolar caliber (OR per SD decrease, 2.79; 
      95% CI, 2.21-3.53), and wider venular caliber (OR per SD increase, 1.57; 95% CI, 
      1.27-1.95) were associated with stroke. Stratification by stroke subtypes and
      further adjustment for retinopathy signs revealed similar results. CONCLUSIONS:
      Patients with ischemic stroke have a sparser and more tortuous microvascular
      network in the retina. These findings provide insight into the structure and
      pattern of microcirculation changes in stroke.
AD  - From the Singapore Eye Research Institute, Singapore National Eye Centre,
      Singapore, Singapore.
FAU - Ong, Yi-Ting
AU  - Ong YT
FAU - De Silva, Deidre A
AU  - De Silva DA
FAU - Cheung, Carol Y
AU  - Cheung CY
FAU - Chang, Hui-Meng
AU  - Chang HM
FAU - Chen, Christopher P
AU  - Chen CP
FAU - Wong, Meng Cheong
AU  - Wong MC
FAU - Wong, Tien Yin
AU  - Wong TY
FAU - Ikram, Mohammad Kamran
AU  - Ikram MK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Stroke
JT  - Stroke; a journal of cerebral circulation
JID - 0235266
OTO - NOTNLM
OT  - imaging
OT  - ischemic microvascular dysfunction
OT  - stroke
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - STROKEAHA.113.001741 [pii]
AID - 10.1161/STROKEAHA.113.001741 [doi]
PST - aheadofprint
SO  - Stroke. 2013 May 28.

PMID- 23715937
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 2168-6262 (Electronic)
IS  - 2168-6254 (Linking)
VI  - 148
IP  - 4
DP  - 2013 Apr 1
TI  - Low Rates of Short- and Long-term Graft Loss After Kidney-Pancreas Transplant
      From a Single Center.
PG  - 368-73
LID - 10.1001/2013.jamasurg.261 [doi]
AB  - IMPORTANCE Since the 1980s, pancreas transplant has become the most effective
      treatment strategy to restore euglycemia in patients with type 1 diabetes
      mellitus. However, technical complications and BK virus nephropathy continue to
      be important causes of early and late graft loss. These and other complications
      lead to cited 1- and 3-year graft survival rates of 74% and 67% (pancreas) and
      81% and 73% (kidney). OBJECTIVE To examine our center's outcomes with
      pancreas-kidney transplant and early BK virus screening and treatment. DESIGN
      Prospective study from August 2004 to January 2012. SETTING University medical
      center. PARTICIPANTS Sixty-five patients with type 1 diabetes who underwent
      simultaneous kidney and pancreas, pancreas after kidney, or pancreas transplant
      alone at a single center. INTERVENTION Pancreas transplant. MAIN OUTCOME MEASURES
      Pancreas and kidney survival; patient survival; and kidney loss due to BK virus
      nephropathy. RESULTS Patient survival at 1, 3, and 5 years was 100%, 98.4%, and
      98.4%, respectively. Of 2 early pancreatic allograft losses, 1 was due to
      thrombosis (1.6%). One- and 5-year pancreas graft survival rates were 95.4% and
      92.3%; losses after more than 1 year were due to rejection. Kidney survival rates
      were 100% and 95.2% at 1 and 5 years; losses were due to nephropathy and
      noncompliance, with 1 death with function. BK virus incidence was 29.2%, with no 
      graft losses due to BK infection. CONCLUSIONS AND RELEVANCE While pancreas
      transplant can be complicated by early graft loss, our results suggest that
      excellent outcomes at 5 years can be achieved. Posttransplant BK virus screening 
      and treatment are essential tools to long-term success.
FAU - Tai, Denise S
AU  - Tai DS
FAU - Hong, Johnny
AU  - Hong J
FAU - Busuttil, Ronald W
AU  - Busuttil RW
FAU - Lipshutz, Gerald S
AU  - Lipshutz GS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA Surg
JT  - JAMA surgery
JID - 101589553
SB  - AIM
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 1679647 [pii]
AID - 10.1001/2013.jamasurg.261 [doi]
PST - ppublish
SO  - JAMA Surg. 2013 Apr 1;148(4):368-73. doi: 10.1001/2013.jamasurg.261.

PMID- 23715913
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
DP  - 2013 May 28
TI  - Long term (13 years) prognosis after primary intracerebral haemorrhage: a
      prospective population based study of long term mortality, prognostic factors and
      causes of death.
AB  - INTRODUCTION: Many studies have focused on short term mortality after primary
      intracerebral haemorrhage (ICH) whereas long term prognosis and causes of death
      have been less studied. We therefore examined these issues in a population based 
      cohort of 1 year ICH survivors. METHODS: ICH patients in a defined Swedish
      population (1.14 million inhabitants) were prospectively registered during 1996. 
      Patients surviving 1 year after ICH onset were followed-up regarding survival
      status and cause of death until December 2009 using data from the National Census
      Office and the National Cause of Death Register. Patient prognosis was also
      compared with the general population using official Swedish mortality data.
      Clinical and radiological prognostic factors were evaluated. RESULTS: Of 323
      patients with ICH, 172 (53%) survived after 1 year, 127 (39%) after 5 years and
      57 (18%) after 13 years. Mortality of the 172, 1 year survivors (mean age 67.7
      years at ICH) persistently exceeded expected mortality; 13 years post ictus
      survival was only 34% compared with 61% in the general population. Of 115 deaths 
      among the 172, 1 year survivors, 36% were from cerebrovascular disease and 19%
      from ischaemic heart disease. Independent risk factors for death among 1 year
      survivors were age (HR 1.08 per year; 95% CI 1.06 to 1.10; p<0.001), diabetes
      mellitus at baseline (HR 2.10; 95% CI 1.18 to 3.74; p=0.012) and anticoagulant
      therapy (HR 1.99; 95% CI 1.12 to 3.53; p=0.018) at ICH onset. CONCLUSIONS: One
      year survivors after ICH had a substantial and persisting excess mortality
      compared with the general population. Major causes of death were stroke and
      ischaemic heart disease.
AD  - Department of Clinical Sciences Lund, Neurology, Lund University, , Lund, Sweden.
FAU - Hansen, Bjorn M
AU  - Hansen BM
FAU - Nilsson, Ola G
AU  - Nilsson OG
FAU - Anderson, Harald
AU  - Anderson H
FAU - Norrving, Bo
AU  - Norrving B
FAU - Saveland, Hans
AU  - Saveland H
FAU - Lindgren, Arne
AU  - Lindgren A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
OTO - NOTNLM
OT  - Cerebrovascular Disease
OT  - Clinical Neurology
OT  - Epidemiology
OT  - Stroke
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - jnnp-2013-305200 [pii]
AID - 10.1136/jnnp-2013-305200 [doi]
PST - aheadofprint
SO  - J Neurol Neurosurg Psychiatry. 2013 May 28.

PMID- 23715873
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1436-6215 (Electronic)
IS  - 1436-6207 (Linking)
DP  - 2013 May 29
TI  - High-dose thiamine supplementation improves glucose tolerance in hyperglycemic
      individuals: a randomized, double-blind cross-over trial.
AB  - PURPOSE: To assess the effect of high-dose oral thiamine supplements on glucose
      tolerance in patients with impaired glucose metabolism. METHODS: Twelve
      hyperglycemic subjects (10 cases of impaired glucose tolerance and 2 new cases of
      type 2 diabetes) completed this randomized, double-blind trial, where all
      participants received both placebo and thiamine capsules (3 x 100 mg/day) for 6
      weeks in a cross-over manner. The main endpoint was changes in 2-h plasma
      glucose. Fasting plasma glucose and insulin, 2-h plasma insulin, the hemostatic
      model assessment of insulin resistance (HOMA-IR), renal function measurement and 
      thiamin status were also evaluated at the commencement and completion of each
      treatment period. RESULTS: Thiamine supplementation resulted in significant
      decrease in 2-h plasma glucose relative to baseline (8.78 +/- 2.20 vs. 9.89 +/-
      2.50 mmol/l, p = 0.004), with no significant change in the placebo arm. Fasting
      plasma glucose and insulin, and HOMA-IR increased significantly from baseline
      after 6 weeks in the placebo arm (p = 0.003, p = 0.04 and p = 0.02,
      respectively). These variables did not change with thiamine supplementation.
      There were no significant changes in 2-h plasma insulin or renal function marker,
      within or between arms. CONCLUSION/INTERPRETATION: Supplementation with high-dose
      thiamine may prevent deterioration in fasting glucose and insulin, and improve
      glucose tolerance in patients with hyperglycemia. High-dose thiamine
      supplementation may prevent or slow the progression of hyperglycemia toward
      diabetes mellitus in individuals with impaired glucose regulation.
AD  - School of Public Health, Curtin University, Kent Street, Bentley, Perth, WA,
      6102, Australia, fariba.alaeishahmiri@postgrad.curtin.edu.au.
FAU - Alaei Shahmiri, F
AU  - Alaei Shahmiri F
FAU - Soares, M J
AU  - Soares MJ
FAU - Zhao, Y
AU  - Zhao Y
FAU - Sherriff, J
AU  - Sherriff J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Eur J Nutr
JT  - European journal of nutrition
JID - 100888704
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/04/06 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 10.1007/s00394-013-0534-6 [doi]
PST - aheadofprint
SO  - Eur J Nutr. 2013 May 29.

PMID- 23715867
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 28
TI  - Impact of divergent effects of astaxanthin on Insulin Signaling in L6 cells.
AB  - Since oxidative stress promotes insulin resistance in obesity and type 2
      diabetes, it is crucial to find effective antioxidant for the purpose of
      decreasing this threat. In this study, we explored the effect of astaxanthin, a
      carotenoid antioxidant, on insulin signaling and investigated whether astaxanthin
      improves cytokine- and free fatty acid-induced insulin resistance in vitro. We
      examined the effect of astaxanthin on insulin-stimulated GLUT4 translocation,
      glucose uptake and insulin signaling in cultured rat L6 muscle cells using plasma
      membrane lawn assay, 2-Deoxyglucose uptake and Western blot analysis. Next, we
      examined the effect of astaxanthin on TNFalpha- and palmitate-induced insulin
      resistance. The amount of reactive oxygen species (ROS) generated by TNFalpha or 
      palmitate with or without astaxanthin was evaluated by DCF staining. We also
      compared the effect of astaxanthin on insulin signaling with that of other
      antioxidants, alpha-lipoic acid and alpha-tocopherol. We observed astaxanthin
      enhanced insulin-stimulated GLUT4 translocation and glucose uptake, which was
      associated with an increase in IRS-1 tyrosine and Akt phosphorylation and a
      decrease in JNK and IRS-1 serine 307 phosphorylation. Furthermore, astaxanthin
      restored TNFalpha- and palmitate-induced decreases in insulin-stimulated GLUT4
      translocation or glucose uptake with a concomitant decrease in ROS generation.
      alpha-Lipoic acid enhanced Akt phosphorylation and decreased ERK and JNK
      phosphorylation, whereas alpha-tocopherol enhanced ERK and JNK phosphorylation
      but had little effect on Akt phosphorylation. Collectively, these findings
      indicate astaxanthin is a very effective antioxidant for ameliorating insulin
      resistance by protecting cells from oxidative stress generated by various stimuli
      including TNFalpha and palmitate.
AD  - The First Department of Internal Medicine (M.I., S.F., A.T., I.U., K.T.), Faculty
      of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan;
      Research & Development Division (Y.N., H.I.), AstaReal Co., Ltd., 55 Yokohoonji, 
      Kamiichimachi, Nakanikawagun, Toyama 930-0397, Japan; Department of Clinical
      Pharmacology (T.W., T.S.), University of Toyama, 2630 Sugitani, Toyama 930-0194, 
      Japan; Kamiichi General Hospital (M.U.), 51 Hoonji, Kamiichimachi, Nakanikawagun,
      Toyama 930-0353, Japan.
FAU - Ishiki, Manabu
AU  - Ishiki M
FAU - Nishida, Yasuhiro
AU  - Nishida Y
FAU - Ishibashi, Hiroshi
AU  - Ishibashi H
FAU - Wada, Tsutomu
AU  - Wada T
FAU - Fujisaka, Shiho
AU  - Fujisaka S
FAU - Takikawa, Akiko
AU  - Takikawa A
FAU - Urakaze, Masaharu
AU  - Urakaze M
FAU - Sasaoka, Toshiyasu
AU  - Sasaoka T
FAU - Usui, Isao
AU  - Usui I
FAU - Tobe, Kazuyuki
AU  - Tobe K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - en.2012-2198 [pii]
AID - 10.1210/en.2012-2198 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 28.

PMID- 23715814
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1869-6953 (Print)
DP  - 2013 May 29
TI  - A Retrospective Audit of Type 2 Diabetes Patients Prescribed Liraglutide in
      Real-Life Clinical Practice.
AB  - BACKGROUND: In phase 3 trials, the once-daily human glucagon-like peptide-1
      analog liraglutide provided effective glycemic control with low rates of
      hypoglycemia, weight loss, and reduced systolic blood pressure (SBP) in patients 
      with type 2 diabetes. Through a retrospective clinical audit, the authors aimed
      to assess the clinical effectiveness of liraglutide, from initiation to first
      hospital visit, when prescribed at a center in Northern Ireland. METHODS:
      Patients attending Ulster Hospital who were prescribed liraglutide (June
      2009-September 2010) and assessed both at baseline and first post-initiation
      visit were included in the analysis. The primary endpoint was change in glycated 
      hemoglobin (HbA1c) from baseline. Weight, blood pressure, and frequency of
      hypoglycemic events were also assessed. RESULTS: Data from 193 patients are
      reported (baseline HbA1c 9.0%, mean age 55.8 years, diabetes duration 8.8 years, 
      66.8% male). Average time to first visit after initiation was 13.5 weeks, at
      which point 174 patients (90.2%) were prescribed 1.2 mg liraglutide. Mean change 
      in HbA1c from initiation to first visit was -0.9%, while mean body weight change 
      was -2.4 kg and change in SBP was -2.0 mmHg. Transient gastrointestinal side
      effects were experienced by 11.9% of patients. The number of patients
      experiencing minor hypoglycemic events was low (5.7%) and no major events were
      reported. CONCLUSION: Data from clinical studies translate into clinical
      practice: liraglutide provided improved glycemic control after 13.5 weeks of
      treatment, accompanied by weight loss and low incidence of hypoglycemia.
AD  - Diabetes Department, Ulster Hospital, Dundonald, Belfast, BT16 1RH, Northern
      Ireland, UK, ciara.mulligan@setrust.hscni.net.
FAU - Mulligan, Ciara M
AU  - Mulligan CM
FAU - Harper, Roy
AU  - Harper R
FAU - Harding, Janet
AU  - Harding J
FAU - McIlwaine, Werner
AU  - McIlwaine W
FAU - Petruckevitch, Ann
AU  - Petruckevitch A
FAU - McLaughlin, Darren M
AU  - McLaughlin DM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/03/26 [received]
PHST- 2013/05/29 [aheadofprint]
AID - 10.1007/s13300-013-0025-z [doi]
PST - aheadofprint
SO  - Diabetes Ther. 2013 May 29.

PMID- 23715775
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 0148-6071 (Electronic)
IS  - 0148-6071 (Linking)
DP  - 2013 May 30
TI  - Peripherally Inserted Central Catheter (PICC) Complications During Pregnancy.
AB  - Background: Peripherally inserted central catheters (PICCs) are routinely used in
      women with hyperemesis gravidarum. However, little is known about the
      consequences of PICC insertion in these patients. Our aim was to analyze
      PICC-related complication rates among pregnant women. Materials and Methods:
      Pregnant women with PICC insertion between January 2000 and June 2006 were
      studied retrospectively. Infusate type, comorbid conditions, and PICC duration
      were characterized. Major complications, defined as need for surgical
      intervention, bacteremia requiring intravenous antibiotics, or thromboembolic
      events, were identified. Minor complications, including phlebitis, PICC
      malfunction, early PICC removal, infection requiring oral antibiotics, or
      hospitalization for PICC evaluation, were also studied. Results: Eighty-four
      catheters in 66 women were eligible for study, totaling 2544 PICC days. Catheters
      remained in place for 1-177 days; median duration was 21.0 days. PICCs were used 
      for intravenous fluid (IVF, 59.4%), parenteral nutrition (PN, 34.5%), and
      antibiotics (6%). The overall complication rate was 18.5 per 1000 PICC days
      (55.9% of PICCs); 22.6% were major, with bacteremia being most frequent (20.2%). 
      A diagnosis of diabetes was the only factor that significantly predicted
      complications (hazard ratio, 2.71; 95% confidence interval, 1.13-6.13). PICC
      duration and type of infusate (PN vs IVF alone) were not associated with
      complications. Conclusions: PICC insertion in pregnant women is associated with a
      high complication rate, which appears to be independent of the type of infusate
      and occurs in the majority of women. PICCs should be used judiciously and only
      when clearly necessary during pregnancy. Further studies are needed to determine 
      how to reduce PICC-related complications in this population.
AD  - Mount Kisco Medical Group, Mount Kisco, New York.
FAU - Cape, Alison V
AU  - Cape AV
FAU - Mogensen, Kris M
AU  - Mogensen KM
FAU - Robinson, Malcolm K
AU  - Robinson MK
FAU - Carusi, Daniela A
AU  - Carusi DA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - JPEN J Parenter Enteral Nutr
JT  - JPEN. Journal of parenteral and enteral nutrition
JID - 7804134
OTO - NOTNLM
OT  - complication
OT  - infection
OT  - peripherally inserted central catheter
OT  - pregnancy
OT  - thrombosis
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/05/28 [aheadofprint]
AID - 0148607113489994 [pii]
AID - 10.1177/0148607113489994 [doi]
PST - aheadofprint
SO  - JPEN J Parenter Enteral Nutr. 2013 May 30.

PMID- 23715774
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
DP  - 2013 May 28
TI  - Body Iron Stores and the Risk of Type 2 Diabetes in Middle-Aged Men.
AB  - OBJECTIVE: We investigated the risk of type 2 diabetes mellitus (T2DM) over a
      wide range of body iron stores. METHODS: Prospective cohort of 1613 men in the
      Kuopio Ischemic Heart Disease Risk Factor study, aged 42-60 years, free of T2DM
      and hereditary hemochromatosis at baseline in 1984-1989. Baseline serum ferritin 
      (sF) and serum soluble transferrin receptor (sTfR) concentrations were used to
      predict incident T2DM. T2DM was assessed by questionnaires, blood glucose
      measurements, and by medication reimbursement register. RESULTS: There were 331
      cases of incident T2DM during the mean follow-up of 16.8 years (27,098
      person-years). At baseline, subjects who later developed T2DM had average sF
      concentrations of 191 microg/L (SD 155) vs 151 microg/L (SD 119) among those who 
      remained healthy P<0.001. In a multivariate-adjusted logistic regression, each
      100 microg/L increase in sF corresponded to an average 14% increased (OR=1.14,
      95%CI 1.03-1.26, P=0.009) risk of developing T2DM. In a Cox regression, a
      markedly increased risk of developing T2DM was observed from the fourth sF
      quintile (185 microg/L, the median) upwards, (HR first vs fifth quintile=1.5,
      95%CI 1.0-2.2, P-trend=0.05). In a corresponding Cox model in sTfR, the subjects 
      in the third quintile (1840 microg/L, the median) had the least risk (HR=0.63,
      95%CI 0.42-0.97, P=0.04). CONCLUSIONS: Body iron within the sF reference range is
      not an important determinant of T2DM risk, whereas high normal and above is
      associated with markedly increased risk. Iron depletion towards iron deficiency
      as assessed by sTfR is not protective against T2DM. A rule of thumb safe range
      could be 30-200 microg/L of sF.
AD  - A Aregbesola, Institute of Public Health and Clinical Nutrition, University of
      Eastern Finland, Kuopio, FI 70211, Finland.
FAU - Aregbesola, Alex Olukayode
AU  - Aregbesola AO
FAU - Voutilainen, Sari
AU  - Voutilainen S
FAU - Virtanen, Jyrki K
AU  - Virtanen JK
FAU - Mursu, Jaakko
AU  - Mursu J
FAU - Tuomainen, Tomi-Pekka
AU  - Tuomainen TP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - EJE-13-0145 [pii]
AID - 10.1530/EJE-13-0145 [doi]
PST - aheadofprint
SO  - Eur J Endocrinol. 2013 May 28.

PMID- 23715755
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 28
TI  - Short Sleep Duration Measured by Wrist Actimetry Is Associated With Deteriorated 
      Glycemic Control in Type 1 Diabetes.
AB  - OBJECTIVESleep restriction has been associated with deteriorated insulin
      sensitivity. The effects of short sleep duration have been explored little in
      patients with type 1 diabetes. This study addresses the question of whether sleep
      curtailment affects HbA1c levels in patients with type 1 diabetes.RESEARCH DESIGN
      AND METHODSSeventy-nine adult patients with type 1 diabetes (median age 40 years 
      [IQR 23-49]; 47% men) were recruited to wear a wrist actimetry sensor during 3
      consecutive days to assess mean sleep duration during normal daily life. A
      subsample of 37 patients also performed a 24- h ambulatory blood pressure
      monitoring (ABPM). Medical history, sleep questionnaires, and diabetes-related
      quality of life (DQOL) were assessed.RESULTSPatients having shorter sleep
      duration-less than 6.5 h (n = 21)-had higher levels of HbA1c (P = 0.01) than
      patients with longer sleep duration, above 6.5 h (n = 58). In a multivariable
      regression model including shorter versus longer sleep duration, diabetes
      duration, DQOL score, and daily activity, sleep duration was the only variable
      independently associated with HbA1c (R2 = 10%). In patients who performed 24-h
      ABPM, patients with a nondipping pattern of blood pressure exhibited shorter
      sleep duration than patients with a dipping pattern of blood
      pressure.CONCLUSIONSShorter sleep duration is associated with higher HbA1c levels
      in patients with type 1 diabetes, as well as with a nondipping pattern of blood
      pressure, anticipating a long-term deleterious impact on the risk of
      microvascular complications. Further studies should test whether extending the
      duration of sleep may improve both HbA1c and blood pressure in type 1 diabetes.
AD  - Hypoxia Pathophysiology (HP2) Laboratory, Institut national de la sante et de la 
      recherche medicale (INSERM) U1042, Joseph Fourier University, Grenoble, France.
FAU - Borel, Anne-Laure
AU  - Borel AL
FAU - Pepin, Jean-Louis
AU  - Pepin JL
FAU - Nasse, Laure
AU  - Nasse L
FAU - Baguet, Jean-Philippe
AU  - Baguet JP
FAU - Netter, Sophie
AU  - Netter S
FAU - Benhamou, Pierre-Yves
AU  - Benhamou PY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - dc12-2038 [pii]
AID - 10.2337/dc12-2038 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 28.

PMID- 23715754
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 28
TI  - Dual Peroxisome Proliferator-Activated Receptor alpha/delta Agonist GFT505
      Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese
      Subjects.
AB  - OBJECTIVEThe development of new insulin sensitizers is an unmet need for the
      treatment of type 2 diabetes. We investigated the effect of GFT505, a dual
      peroxisome proliferator-activated receptor (PPAR)-alpha/delta agonist, on
      peripheral and hepatic insulin sensitivity.RESEARCH DESIGN AND METHODSTwenty-two 
      abdominally obese insulin-resistant males (homeostasis model assessment of
      insulin resistance >3) were randomly assigned in a randomized crossover study to 
      subsequent 8-week treatment periods with GFT505 (80 mg/day) or placebo, followed 
      by a two-step hyperinsulinemic-euglycemic insulin clamp with a glucose tracer to 
      calculate endogenous glucose production (EGP). The primary end point was the
      improvement in glucose infusion rate (GIR). Gene expression analysis was
      performed on skeletal muscle biopsy specimens.RESULTSGFT505 improved peripheral
      insulin sensitivity, with a 21% (P = 0.048) increase of the GIR at the second
      insulin infusion period. GFT505 also enhanced hepatic insulin sensitivity, with a
      44% (P = 0.006) increase of insulin suppression of EGP at the first insulin
      infusion period. Insulin-suppressed plasma free fatty acid concentrations were
      significantly reduced on GFT505 treatment (0.21 +/- 0.07 vs. 0.27 +/- 0.11
      mmol/L; P = 0.006). Neither PPARalpha nor PPARdelta target genes were induced in 
      skeletal muscle, suggesting a liver-targeted action of GFT505. GFT505
      significantly reduced fasting plasma triglycerides (-21%; P = 0.003) and LDL
      cholesterol (-13%; P = 0.0006), as well as liver enzyme concentrations
      (gamma-glutamyltranspeptidase: -30.4%, P = 0.003; alanine aminotransferase:
      -20.5%, P = 0.004). There was no safety concern or any indication of PPARgamma
      activation with GFT505.CONCLUSIONSThe dual PPARalpha/delta agonist GFT505 is a
      liver-targeted insulin-sensitizer that is a promising drug candidate for the
      treatment of type 2 diabetes and nonalcoholic fatty liver disease.
AD  - Department of Endocrinology, University Hospital of Nantes, Nantes, France.
FAU - Cariou, Bertrand
AU  - Cariou B
FAU - Hanf, Remy
AU  - Hanf R
FAU - Lambert-Porcheron, Stephanie
AU  - Lambert-Porcheron S
FAU - Zair, Yassine
AU  - Zair Y
FAU - Sauvinet, Valerie
AU  - Sauvinet V
FAU - Noel, Benoit
AU  - Noel B
FAU - Flet, Laurent
AU  - Flet L
FAU - Vidal, Hubert
AU  - Vidal H
FAU - Staels, Bart
AU  - Staels B
FAU - Laville, Martine
AU  - Laville M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - dc12-2012 [pii]
AID - 10.2337/dc12-2012 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 28.

PMID- 23715753
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 28
TI  - Low-Volume Insulin Degludec 200 units/mL Once Daily Improves Glycemic Control
      Similar to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive
      Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, 
      treat-to-target trial: The BEGIN LOW VOLUME trial.
AB  - OBJECTIVEThe 200 units/mL formulation of insulin degludec (IDeg 200 units/mL)
      contains equal units of insulin in half the volume compared with the 100 units/mL
      formulation. We compared the efficacy and safety of IDeg 200 units/mL once daily 
      with 100 units/mL insulin glargine (IGlar) in insulin-naive subjects with type 2 
      diabetes (T2DM) inadequately controlled with oral antidiabetic drugs.RESEARCH
      DESIGN AND METHODSIn this 26-week, open-label, treat-to-target trial, subjects (n
      = 457; mean HbA1c 8.3% [67 mmol/mol], BMI 32.4 kg/m2, and fasting plasma glucose 
      [FPG] 9.6 mmol/L [173.2 mg/dL]) were randomized to IDeg 200 units/mL or IGlar,
      both given once daily in combination with metformin with or without a dipeptidyl 
      peptidase-4 inhibitor. Basal insulin was initiated at 10 units/day and titrated
      weekly to an FPG target of <5 mmol/L (<90 mg/dL) according to mean prebreakfast
      self-measured blood glucose values from the preceding 3 days.RESULTSBy 26 weeks, 
      IDeg reduced HbA1c by 1.30% and was not inferior to IGlar. Mean observed FPG
      reductions were significantly greater with IDeg than IGlar (-3.7 vs. -3.4 mmol/L 
      [-67 vs. -61 mg/dL]; estimated treatment difference: -0.42 [95% CI -0.78 to
      -0.06], P = 0.02). Despite this difference, rates of overall confirmed
      hypoglycemia were not higher with IDeg than with IGlar (1.22 and 1.42
      episodes/patient-year, respectively), as were rates of nocturnal confirmed
      hypoglycemia (0.18 and 0.28 episodes/patient-year, respectively). Mean daily
      basal insulin dose was significantly lower by 11% with IDeg 200 units/mL compared
      with IGlar. IDeg was well-tolerated, and the rate of treatment-emergent adverse
      events was similar across groups.CONCLUSIONSIn this treat-to-target trial in
      insulin-naive patients with T2DM, IDeg 200 units/mL improved glycemic control
      similarly to IGlar with a low risk of hypoglycemia.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism and NIHR Oxford
      Biomedical Research Centre, Oxford, U.K.
FAU - Gough, Stephen C L
AU  - Gough SC
FAU - Bhargava, Anuj
AU  - Bhargava A
FAU - Jain, Rajeev
AU  - Jain R
FAU - Mersebach, Henriette
AU  - Mersebach H
FAU - Rasmussen, Soren
AU  - Rasmussen S
FAU - Bergenstal, Richard M
AU  - Bergenstal RM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - dc12-2329 [pii]
AID - 10.2337/dc12-2329 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 28.

PMID- 23715738
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 1862-3514 (Electronic)
VI  - 8
IP  - 1-2
DP  - 2013 Dec
TI  - Low bone mineral density is associated with metabolic syndrome in South Korean
      men but not in women: The 2008-2010 Korean National Health and Nutrition
      Examination Survey.
PG  - 142
LID - 10.1007/s11657-013-0142-3 [doi]
AB  - We examined the relationships between bone mineral density (BMD) and metabolic
      syndrome in 6,659 men and 7,826 women from South Korean. After adjusting for age,
      body mass index (BMI), tobacco and alcohol use, and regular exercise, low BMD is 
      especially associated with metabolic syndrome in South Korean men. PURPOSE: This 
      study examined the relationships between BMD and metabolic syndrome (MS) in South
      Korean adults. METHODS: A total of 14,485 adults (6,659 men and 7,826 women) in
      the Korea National Health and Nutrition Examination Survey conducted from 2008 to
      2010 were analyzed. We used multivariable regression models to examine the
      relationship between low BMD and MS. We calculated homeostasis model assessment
      and insulin resistance (HOMA-IR). MS was defined according to AHA/NHLBI criteria 
      for Asians. BMD was measured at the lumbar spine (LS), femur neck (FN), total hip
      (TH), trochanter, and intertrochanter. RESULTS: After adjustment for age, BMI,
      tobacco and alcohol use, and regular exercise, the TH and FN BMD were
      significantly lower in men with MS than in men without MS (p < 0.05). However,
      there were no differences in premenopausal and postmenopausal women. In men, BMD 
      was positively correlated with BMI, and high density lipoprotein cholesterol, but
      was negatively correlated with insulin, HOMA-IR, and triglyceride at all three
      sites (p < 0.05). Along with an increase of BMD (0.1 g/cm(2)), the odds ratios
      (ORs) for obesity and abdominal obesity were all greater than 1 at all sites in
      both genders. The ORs for hypertension and MS were 0.937 (0.879-0.998) and 0.899 
      (0.840-0.962), respectively at FN, and the OR for diabetes mellitus was 1.103
      (1.017-1.196) at LS in men. In postmenopausal women, the OR for hypertension was 
      1.133 (1.029-1.246) at LS. CONCLUSIONS: Low BMD was especially associated with MS
      in South Korean men.
AD  - Department of Family Medicine, Korea University College of Medicine, 126-1 5Ka
      Anam-dong, Sungbuk-ku, Seoul 136-705, South Korea.
FAU - Kim, Yang-Hyun
AU  - Kim YH
FAU - Cho, Kyung-Hwan
AU  - Cho KH
FAU - Choi, Youn Seon
AU  - Choi YS
FAU - Kim, Seon-Mee
AU  - Kim SM
FAU - Nam, Ga-Eun
AU  - Nam GE
FAU - Lee, Seung-Hwan
AU  - Lee SH
FAU - Ko, Byung-Joon
AU  - Ko BJ
FAU - Park, Yong-Gyu
AU  - Park YG
FAU - Han, Kyung Do
AU  - Han KD
FAU - Lee, Kyung-Shik
AU  - Lee KS
FAU - Kim, Do-Hoon
AU  - Kim DH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130529
PL  - England
TA  - Arch Osteoporos
JT  - Archives of osteoporosis
JID - 101318988
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/11/28 [received]
PHST- 2013/03/29 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 10.1007/s11657-013-0142-3 [doi]
PST - ppublish
SO  - Arch Osteoporos. 2013 Dec;8(1-2):142. doi: 10.1007/s11657-013-0142-3. Epub 2013
      May 29.

PMID- 23715704
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 17
IP  - 3
DP  - 2013 Jun 1
TI  - Development of the Cancer Survivorship Care Plan: What's Next? Life After Cancer 
      Treatment.
PG  - 280-4
LID - 10.1188/13.CJON.280-284 [doi]
AB  - Long-term information needs are increasingly important as more people are
      diagnosed with cancer and living well beyond initial diagnosis and treatment.
      Consequently, cancer is joining the ranks of chronic conditions (e.g., asthma,
      diabetes) for which ongoing, long-term surveillance and management should be the 
      model of care. However, the post-treatment period is fraught with uncertainty for
      patients and care providers. The "who, what, and when" of follow-up care, in
      particular, can be complex and confusing. Therefore, survivorship care plans
      (SCPs) are recommended. The Minnesota Cancer Alliance, a coalition working to
      improve quality of life for cancer survivors, developed a patient-focused SCP.
      This user-friendly SCP could be considered for use in patient care-particularly
      by nurses, who are well suited and positioned to implement SCPs.
AD  - HealthPartners Institute for Education and Research in Bloomington, Minnesota.
FAU - Jackson, Jody M
AU  - Jackson JM
FAU - Scheid, Kathy
AU  - Scheid K
FAU - Rolnick, Sharon J
AU  - Rolnick SJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
SB  - N
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 2P18110428802253 [pii]
AID - 10.1188/13.CJON.280-284 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2013 Jun 1;17(3):280-4. doi: 10.1188/13.CJON.280-284.

PMID- 23715661
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
DP  - 2013 May 28
TI  - Expansion of Pathogen - Specific Th1 and Th17 cells in Pulmonary Tuberculosis
      with Coincident Type 2 Diabetes Mellitus.
AB  - Background. Type 2 diabetes mellitus (DM) is a major risk factor for the
      development of active pulmonary tuberculosis (TB), although the immunological
      mechanisms underlying this interaction remain unexplored. The influence of poorly
      controlled diabetes on pathogen - specific Th1 and Th17 responses have not been
      examined.Methods. To identify the role of Th1 and Th17 cells in TB with
      coincident DM, we examined mycobacteria-specific immune responses in the whole
      blood of individuals with TB-DM and compared them with those without DM
      (TB-NDM).Results. TB-DM is characterized by elevated frequencies of mono - and
      dual - functional CD4+ Th1 cells following TB - antigen stimulation and elevated 
      frequencies of Th17 subsets at both baseline and following antigen - stimulation.
      This was associated with increased systemic (plasma) levels of both Th1 and Th17 
      cytokines and decreased baseline frequencies of natural regulatory T cells but
      not IL-10 or TGFbeta.Conclusions. Therefore, our data reveal that TB-DM is
      characterized by elevated frequencies of Th1 and Th17 cells, indicating that DM
      is associated with an alteration in the immune response to TB leading to a biased
      induction of Th1- and Th17-mediated cellular responses, likely contributing to
      increased immune pathology in TB infection.
AD  - National Institutes of Health-International Center for Excellence in Research,
      Chennai, India.
FAU - Kumar, N Pavan
AU  - Kumar NP
FAU - Sridhar, R
AU  - Sridhar R
FAU - Banurekha, V V
AU  - Banurekha VV
FAU - Jawahar, M S
AU  - Jawahar MS
FAU - Nutman, Thomas B
AU  - Nutman TB
FAU - Babu, Subash
AU  - Babu S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - jit241 [pii]
AID - 10.1093/infdis/jit241 [doi]
PST - aheadofprint
SO  - J Infect Dis. 2013 May 28.

PMID- 23715652
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1873-4626 (Electronic)
IS  - 1091-255X (Linking)
DP  - 2013 May 29
TI  - Impact of Body Mass Index on Postoperative Outcome of Advanced Gastric Cancer
      After Curative Surgery.
AB  - INTRODUCTION: The impact of body mass index (BMI) on the outcome of advanced
      gastric cancer surgery is controversial. Between December 1987 and December 2006,
      a total of 947 advanced gastric cancer patients receiving curative resection with
      retrieved lymph node number >15 were studied and divided into three groups
      according to BMI (<25, 25-30, and >30 kg/m2). RESULTS AND DISCUSSION: With regard
      to comorbidities present prior to surgery, higher BMI patients were more likely
      to have heart disease, type 2 diabetes, and hypertension than lower BMI patients.
      Compared with BMI <25 kg/m2, higher BMI patients had longer operative time and
      more surgery-related morbidity. Multivariate Cox proportional-hazard analysis
      showed that age, pathological T and N categories, and lymphovascular invasion
      were independent prognostic factors. The initial recurrence patterns, 5-year
      overall survival, and cancer-specific survival were similar among the three
      groups. CONCLUSION: Only in stage III gastric cancer with BMI less than 25 kg/m2 
      patients receiving total gastrectomy had a more advanced pathological N category 
      and a worse prognosis compared to those receiving subtotal gastrectomy. Higher
      BMI was associated with longer operative time and more surgery-related morbidity 
      than lower BMI. BMI alone is not an independent prognostic factor.
AD  - Division of General Surgery, Department of Surgery, Taipei Veterans General
      Hospital, 201 Section 2 Shih-Pai Road, Taipei, 11217, Taiwan.
FAU - Lin, Yen-Shu
AU  - Lin YS
FAU - Huang, Kuo-Hung
AU  - Huang KH
FAU - Lan, Yuan-Tzu
AU  - Lan YT
FAU - Fang, Wen-Liang
AU  - Fang WL
FAU - Chen, Jen-Hao
AU  - Chen JH
FAU - Lo, Su-Shun
AU  - Lo SS
FAU - Hsieh, Mao-Chih
AU  - Hsieh MC
FAU - Li, Anna Fen-Yau
AU  - Li AF
FAU - Chiou, Shih-Hwa
AU  - Chiou SH
FAU - Wu, Chew-Wun
AU  - Wu CW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - J Gastrointest Surg
JT  - Journal of gastrointestinal surgery : official journal of the Society for Surgery
      of the Alimentary Tract
JID - 9706084
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/12/30 [received]
PHST- 2013/05/13 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 10.1007/s11605-013-2238-x [doi]
PST - aheadofprint
SO  - J Gastrointest Surg. 2013 May 29.

PMID- 23715643
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 0975-0711 (Electronic)
IS  - 0254-8860 (Linking)
DP  - 2013 May 29
TI  - Pediatric and adult celiac disease: similarities and differences.
AB  - Differences between children and adults in celiac disease (CD) presentation and
      epidemiology are reviewed here. Clinical manifestations, histological changes,
      serology, and response to gluten-free diet are similar. Differences exist in
      epidemiology, type of clinical presentations, coexisting diseases, complications,
      and association with obesity. CD is two to five times more common in children
      than in adults. Classical CD with gastrointestinal symptoms is more common in
      children whereas nonclassical CD dominates in adults. A gene dose phenomenon
      (double-dose HLA-DQB1*02 allele) is postulated to be responsible for this
      difference. Coexisting autoimmune diseases like diabetes mellitus type 1,
      Sjogren's syndrome, and dermatitis herpetiformis are more common in adults than
      in children (42 % vs. 5 %). The association of overweight/obesity and CD is
      stronger in adults than in children (22.5 % vs. 14 %). Besides poor compliance,
      pancreatic insufficiency, bacterial overgrowth, lactose intolerance, irritable
      bowel syndrome, lymphocytic colitis, and microscopic colitis are considered
      responsible for nonresponsive CD in adults but not in children. Complications
      like refractory sprue and small intestinal neoplasms are seen exclusively in
      adults. Existing diagnostic criteria (modified ESPGHAN) are not suitable for
      diagnosing CD in adults as the majority of cases are either nonclassical or
      subclinical CD.
AD  - Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of
      Medical Sciences, Raebareli Road, Lucknow, 226 014, India,
      ujjalpoddar@hotmail.com.
FAU - Poddar, Ujjal
AU  - Poddar U
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Indian J Gastroenterol
JT  - Indian journal of gastroenterology : official journal of the Indian Society of
      Gastroenterology
JID - 8409436
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/06/20 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 10.1007/s12664-013-0339-9 [doi]
PST - aheadofprint
SO  - Indian J Gastroenterol. 2013 May 29.

PMID- 23715623
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 28
TI  - Protection of islet grafts through TGF beta induced tolerogenic DC.
AB  - In Type 1 Diabetes, the insulin producing beta cells are destroyed by the immune 
      system. One way of restoring glucose control is to transplant beta cells from a
      donor. While this procedure may restore endogenous insulin production,
      immunosuppressive treatment is needed to prevent the recipient from rejecting the
      donor-derived islets. We investigated the possibilities of transient expression
      of the immunosuppressive cytokine Transforming Growth Factor (TGF) beta within
      islets to achieve long term graft tolerance. We found that brief expression of
      TGF beta prevented rejection of syngeneic islets, that there was reduction of
      dendritic cell activation in the graft and reduced reactivation of T cells in the
      graft draining lymph nodes. In vitro exposure of bone marrow derived DC to TGF
      beta reduced expression of costimulatory molecules CD80 and CD86 as well as
      production of proinflammatory cytokines such as IL-12 p70 in DC, but did not
      alter levels of MHC class I and II. Furthermore, the capacity of TGF beta-treated
      bone marrow derived DC to activate both CD4+ and CD8+ T cells was reduced. Adding
      TGF beta conditioned tolerogenic DC to the grafted islets led to long term
      survival of the graft, demonstrating that TGF beta-induced tolerogenic DC can
      provide an effective means to restore immune tolerance in an already established 
      autoimmune disease.
AD  - Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge, UK.
FAU - David C Thomas, T
AU  - David C Thomas T
FAU - Wong, F Susan
AU  - Wong FS
FAU - Zaccone, Paola
AU  - Zaccone P
FAU - Green, E Allison
AU  - Green EA
FAU - Wallberg, Maja
AU  - Wallberg M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - db12-1740 [pii]
AID - 10.2337/db12-1740 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 28.

PMID- 23715622
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 28
TI  - Increased Brain Lactate Concentrations without Increased Lactate Oxidation during
      Hypoglycemia in Type 1 Diabetic Individuals.
AB  - Previous studies have reported that brain metabolism of acetate is increased more
      than two-fold during hypoglycemia in type 1 diabetic (T1D) subjects with
      hypoglycemia unawareness. These data support the hypothesis that upregulation of 
      blood-brain barrier monocarboxylic acid (MAC) transport may contribute to the
      maintenance of brain energetics during hypoglycemia in subjects with hypoglycemia
      unawareness. Plasma lactate concentrations are approximately ten-fold higher than
      acetate concentrations, making lactate the most likely alternative MAC as brain
      fuel. We therefore examined transport of [3-13C]-lactate across the blood-brain
      barrier and its metabolism in brain of T1D patients and non-diabetic control
      subjects during a hypoglycemic clamp using 13C magnetic resonance spectroscopy.
      Brain lactate concentrations were more than fivefold higher (P<0.05) during
      hypoglycemia in the T1D subjects compared to the control subjects. Surprisingly, 
      we observed no increase in the oxidation of blood-borne lactate in the T1D
      subjects, as reflected by similar 13C fractional enrichments in brain glutamate
      and glutamine. Taken together these data suggest that in addition to increased
      MCA transport at the blood-brain barrier there may be additional metabolic
      adaptations that contribute to hypoglycemia unawareness in patients with type 1
      diabetes.
AD  - Departments of Diagnostic Radiology.
FAU - De Feyter, Henk M
AU  - De Feyter HM
FAU - Mason, Graeme F
AU  - Mason GF
FAU - Shulman, Gerald I
AU  - Shulman GI
FAU - Rothman, Douglas L
AU  - Rothman DL
FAU - Petersen, Kitt Falk
AU  - Petersen KF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - db13-0313 [pii]
AID - 10.2337/db13-0313 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 28.

PMID- 23715621
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 28
TI  - Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss
      in female mice.
AB  - In diabetic patients, the risk of fracture is high because of impaired bone
      formation. However, the details of the mechanisms in the development of diabetic 
      osteoporosis remain unclear. In the present study, we investigated the role of
      plasminogen activator inhibitor-1 (PAI-1) in the pathogenesis of type 1 diabetic 
      osteoporosis by using PAI-1-deficient mice. Quantitative computed tomography
      analysis showed that PAI-1 deficiency protected against streptozotocin-induced
      bone loss in female mice, but not in male mice. PAI-1-deficiency blunted the
      changes in the levels of Runx2, Osterix, and alkaline phosphatase (ALP) in tibia 
      as well as serum osteocalcin levels suppressed by diabetic state in female mice
      only. Furthermore, the osteoclast levels in tibia, suppressed in diabetes, were
      also blunted by PAI-1 deficiency in female mice. Streptozotocin markedly elevated
      the levels of PAI-1 mRNA in liver, in female mice only. In vitro study
      demonstrated that treatment with active PAI-1 suppressed the levels of osteogenic
      genes and mineralization in primary osteoblasts from female mouse calvaria. In
      conclusion, the present study indicates that PAI-1 is involved in the
      pathogenesis of type 1 diabetic osteoporosis in females. The expression of PAI-1 
      in the liver and the sensitivity of bone cells to PAI-1 may be an underlying
      mechanism. (200 words).
AD  - Department of Physiology and Regenerative Medicine, Kinki University Faculty of
      Medicine, 377-2 Ohnohigashi, Osakasayama, Osaka, 589-8511, Japan.
FAU - Tamura, Yukinori
AU  - Tamura Y
FAU - Kawao, Naoyuki
AU  - Kawao N
FAU - Okada, Kiyotaka
AU  - Okada K
FAU - Yano, Masato
AU  - Yano M
FAU - Okumoto, Katsumi
AU  - Okumoto K
FAU - Matsuo, Osamu
AU  - Matsuo O
FAU - Kaji, Hiroshi
AU  - Kaji H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes
JT  - Diabetes
JID - 0372763
OTO - NOTNLM
OT  - Insulin Deficient Type 1 Diabetes
OT  - Osteoporosis
OT  - PAI
OT  - Streptozotocin
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - db12-1552 [pii]
AID - 10.2337/db12-1552 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 28.

PMID- 23715620
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 28
TI  - Recovery from Overt Type 1 Diabetes Ensues When Immune Tolerance and beta Cell
      Formation Are Coupled with Regeneration of Endothelial Cells in the Pancreatic
      Islets.
AB  - Immune modulation of pancreatic inflammation induces recovery from type 1
      diabetes (T1D) but remission was not durable perhaps due to an inability to
      sustain the formation and function of new pancreatic beta-cells. We have
      previously shown that Ig-GAD2, carrying glutamic acid decarboxylase (GAD) 206-220
      peptide, induced in hyperglycemic mice immune modulation that was able to control
      pancreatic inflammation, stimulate beta-cell regeneration and prevent T1D
      progression. Herein, we show that the same Ig-GAD2 regimen given to mice with
      overt T1D is unable to reverse the course of disease despite eradication of Th1
      and Th17 cells from the pancreas. However, the regimen is able to sustain
      recovery from T1D when Ig-GAD2 was accompanied with transfer of bone marrow (BM) 
      cells from healthy donors. Interestingly, alongside immune modulation there was
      concomitant formation of new beta and endothelial cells in the pancreas. The new 
      beta-cells were of host origin while the donor BM cells gave rise to the
      endothelial cells. Moreover, transfer of purified BM endothelial progenitors
      instead of whole BM cells sustained both beta and endothelial cell formation and 
      reversal of diabetes. Thus, overcoming T1D requires both immune modulation and
      repair of the islet vascular niche to preserve newly formed beta-cells.
AD  - Department of Molecular Microbiology and Immunology, University of Missouri
      School of Medicine, Columbia, MO, USA.
FAU - Wan, Xiaoxiao
AU  - Wan X
FAU - Guloglu, F Betul
AU  - Guloglu FB
FAU - Vanmorlan, Amie M
AU  - Vanmorlan AM
FAU - Rowland, Linda M
AU  - Rowland LM
FAU - Zaghouani, Sarah
AU  - Zaghouani S
FAU - Cascio, Jason A
AU  - Cascio JA
FAU - Dhakal, Mermagya
AU  - Dhakal M
FAU - Hoeman, Christine M
AU  - Hoeman CM
FAU - Zaghouani, Habib
AU  - Zaghouani H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - db12-1281 [pii]
AID - 10.2337/db12-1281 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 28.

PMID- 23715558
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1755-3245 (Electronic)
IS  - 0008-6363 (Linking)
DP  - 2013 May 27
TI  - Defective Nrf2-dependent redox signaling contributes to microvascular dysfunction
      in type 2 diabetes.
AB  - AIMS: In type-2 diabetes, antioxidant depletion contributes to increased
      oxidative stress in the microvasculature. The current study was designed to
      assess how oxidative stress contributes to functional changes in the
      microvasculature, and determine the importance, and the effects of
      pharmacologically targeting, the transcription factor Nrf2.Methods and
      ResultsPressure myography was used to measure myogenic constriction in mesenteric
      arterioles from diabetic (db/db) and nondiabetic (db/m) mice. Compared with db/m,
      myogenic constriction was larger in db/db, independent of the endothelial cell
      layer, and directly correlated with elevated basal and pressure-induced reactive 
      oxygen species (ROS) production. Nrf2 was depleted in db/db vessels and
      associated with downregulation of Nrf2-regulated genes. Notably, expression of
      GCLC and GCLM, enzymes important for glutathione (GSH) synthesis, were
      dramatically reduced, as was total cellular GSH. Normal myogenic function was
      restored to db/db arterioles by incubation with cell-permeant GSH. Similarly, the
      db/db myogenic phenotype was recapitulated in the db/m vessels by pharmacological
      GSH depletion. Treatment with the Nrf2-activator sulforaphane increased Nrf2 and 
      promoted its nuclear localization and increased GCLC and GCLM expression in both 
      db/m and db/db. Sulforaphane dramatically lowered ROS signaling in db/db and
      reduced myogenic tone to levels similar to that seen in db/m vessels.
      CONCLUSIONS: Depleted Nrf2 and expression of its dependent genes compromises
      antioxidant capacity resulting in dysfunctional myogenic tone in diabetes that is
      reversed by the Nrf2 activator sulforaphane.
AD  - Department of Physiology & Biophysics, Rosalind Franklin University of Medicine
      and Science, North Chicago, IL 60064.
FAU - Velmurugan, Gopal V
AU  - Velmurugan GV
FAU - Sundaresan, Nagalingam R
AU  - Sundaresan NR
FAU - Gupta, Mahesh P
AU  - Gupta MP
FAU - White, Carl
AU  - White C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - cvt125 [pii]
AID - 10.1093/cvr/cvt125 [doi]
PST - aheadofprint
SO  - Cardiovasc Res. 2013 May 27.

PMID- 23715541
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1477-9129 (Electronic)
IS  - 0950-1991 (Linking)
VI  - 140
IP  - 12
DP  - 2013 Jun
TI  - How to make a functional beta-cell.
PG  - 2472-83
LID - 10.1242/dev.093187 [doi]
AB  - Insulin-secreting pancreatic beta-cells are essential regulators of mammalian
      metabolism. The absence of functional beta-cells leads to hyperglycemia and
      diabetes, making patients dependent on exogenously supplied insulin. Recent
      insights into beta-cell development, combined with the discovery of pluripotent
      stem cells, have led to an unprecedented opportunity to generate new beta-cells
      for transplantation therapy and drug screening. Progress has also been made in
      converting terminally differentiated cell types into beta-cells using
      transcriptional regulators identified as key players in normal development, and
      in identifying conditions that induce beta-cell replication in vivo and in vitro.
      Here, we summarize what is currently known about how these strategies could be
      utilized to generate new beta-cells and highlight how further study into the
      mechanisms governing later stages of differentiation and the acquisition of
      functional capabilities could inform this effort.
AD  - Department of Stem Cell and Regenerative Biology, Harvard University, 7 Divinity 
      Avenue, Cambridge, MA 02138, USA.
FAU - Pagliuca, Felicia W
AU  - Pagliuca FW
FAU - Melton, Douglas A
AU  - Melton DA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Development
JT  - Development (Cambridge, England)
JID - 8701744
SB  - IM
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Mammalian metabolism
OT  - β cell
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 140/12/2472 [pii]
AID - 10.1242/dev.093187 [doi]
PST - ppublish
SO  - Development. 2013 Jun;140(12):2472-83. doi: 10.1242/dev.093187.

PMID- 23715526
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1477-9234 (Electronic)
IS  - 1477-9226 (Linking)
DP  - 2013 May 29
TI  - New modulated design and synthesis of quercetin-Cu/Zn-Sn scaffold as anticancer
      agents: in vitro DNA binding profile, DNA cleavage pathway and Topo-I activity.
AB  - New molecular topologies quercetin-CuII-Sn2IV and ZnII-Sn2IV and were designed
      and synthesized to act as potential cancer chemotherapeutic agents. Their
      interaction with CT DNA by UV-vis and fluorescence spectroscopy was evaluated
      revealing an electrostatic mode of binding. Quercetin complexes are capable of
      promoting DNA cleavage involving both single and double strand breaks. Complex
      cleaved pBR322 DNA via an oxidative mechanism while followed a hydrolytic
      pathway, accessible to the minor groove of the DNA double helix in accordance
      with molecular docking studies with the DNA duplex of sequence d(CGCGAATTCGCG)2
      dodecamer demonstrating that the complex was stabilized by additional
      electrostatic and hydrogen bonding interactions with the DNA. ROS such as OH ,
      H2O2 and O2 - are the major metabolites responsible for chronic diseases such as 
      cancer, respiratory disorders, HIV, and diabetes etc., therefore eliminating ROS 
      by molecular scaffolds involving SOD enzymatic activity has emerged as a
      potential way to develop a novel class of drugs. Therefore, in vitro superoxide
      dismutase activity of redox active complex was evaluated by using a
      xanthine/xanthine oxidase-NBT assay which showed an IC50 value of 2.26 muM.
      Moreover, the cytotoxicity of both the complexes were screened on a panel of
      human carcinoma cell lines (GI50 values <8.7 muM) which revealed that has a
      better prospect of acting as a cancer chemotherapeutic agent, and to elucidate
      the mechanism of tumor inhibition, Topo-I enzymatic activity was carried out.
      Furthermore, molecular modeling studies were carried out to understand molecular 
      features important for drug-enzyme interactions which offer new insights into the
      experimental model observations.
AD  - Department of Chemistry, Aligarh Muslim University, Aligarh, UP-202002, India.
      tsartaj62@yahoo.com.
FAU - Tabassum, Sartaj
AU  - Tabassum S
FAU - Zaki, Mehvash
AU  - Zaki M
FAU - Afzal, Mohd
AU  - Afzal M
FAU - Arjmand, Farukh
AU  - Arjmand F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Dalton Trans
JT  - Dalton transactions (Cambridge, England : 2003)
JID - 101176026
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1039/c3dt50646k [doi]
PST - aheadofprint
SO  - Dalton Trans. 2013 May 29.

PMID- 23715373
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1022-4742 (Print)
IS  - 1022-4742 (Linking)
VI  - 22
IP  - 2
DP  - 2013 Apr
TI  - Melioidosis in an adult male.
PG  - 413-6
AB  - Infection with Burkholderia pseudomallei has been described, albeit rarely,
      patients in Bangladesh. Infection usually follows percutaneous inoculation or
      inhalation of the causative bacterium, which is present in soil and surface water
      in the endemic region. A 35-year-young male farmer presented with prolonged fever
      and significant weight loss. Patient gradually deteriorated despite getting
      different antibiotics including intravenous ceftriaxone and metronidazole. Panels
      of investigations were done which revealed no diagnostic confirmation except
      uncontrolled diabetes and multiple abscesses in different organs. Melioidosis was
      suspected and serum samples were positive for Burkholderia pseudomallei antibody.
      The case illustrates the importance of non-specific nature of the clinical
      presentation and high index of suspicion of uncommon diseases like melioidosis
      where the disease has not been considered as an endemic.
AD  - Dr Mohammed Ishaque Majumder, Assistant Professor, Department of Medicine, Sir
      Salimullah Medical College (SSMC), Mitford Hospital, Dhaka, Bangladesh.
FAU - Majumder, M I
AU  - Majumder MI
FAU - Haque, M M
AU  - Haque MM
FAU - Ahmed, M W
AU  - Ahmed MW
FAU - Alam, M N
AU  - Alam MN
FAU - Rahman, M W
AU  - Rahman MW
FAU - Akter, F
AU  - Akter F
FAU - Basher, A
AU  - Basher A
FAU - Maude, R J
AU  - Maude RJ
FAU - Faiz, M A
AU  - Faiz MA
LA  - eng
PT  - Journal Article
PL  - Bangladesh
TA  - Mymensingh Med J
JT  - Mymensingh medical journal : MMJ
JID - 9601799
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Mymensingh Med J. 2013 Apr;22(2):413-6.

PMID- 23715361
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1022-4742 (Print)
IS  - 1022-4742 (Linking)
VI  - 22
IP  - 2
DP  - 2013 Apr
TI  - Correlation between Microalbuminuria with Complexity of Coronary Artery Disease
      in Diabetic Patients.
PG  - 353-7
AB  - The present studies found that microalbuminuria is predictive, independent of
      classical risk factor of cardiovascular diseases and all causes of mortality in
      diabetes or hypertension patient groups and in the general population. Coronary
      angiograms for extent of severe CAD (luminal narrowing 50%) in patients with
      Diabetes Mellitus (DM) and general population were examined. The study comprised 
      150 patients undergoing coronary angiography at United Hospital Limited, Dhaka,
      Bangladesh, (M/F 80/70, mean age 57+/-11 years). Urine albumin excretion was
      measured in 24 hours urine samples employing immune precipitation technique.
      Age-gender distribution of coronary risk factors and microalbuminuria were
      compared between patient with and without coronary artery disease. As many as
      70.5% (106) of patient had coronary artery disease and 29.4%(44) had no coronary 
      lesion. Microalbuminuria was detected at 62.9% in patients with CAD and 8.8% in
      those without coronary artery lesion (p<0.001). The presence of 1 or 2 vessel CAD
      showed a linear increase between the groups without microalbuminuria. Patients
      with microalbuminuria have more severe angiographically detected coronary artery 
      disease than those without microalbuminuria, thus a link can be established
      independent of other risk factors.
AD  - Dr Kaisar Nasrullah Khan, Consultant, Department of Cardiology, United Hospital
      Limited, Dhaka, Bangladesh.
FAU - Khan, K N
AU  - Khan KN
FAU - Khan, M H
AU  - Khan MH
FAU - Haque, M Z
AU  - Haque MZ
LA  - eng
PT  - Journal Article
PL  - Bangladesh
TA  - Mymensingh Med J
JT  - Mymensingh medical journal : MMJ
JID - 9601799
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Mymensingh Med J. 2013 Apr;22(2):353-7.

PMID- 23715357
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1022-4742 (Print)
IS  - 1022-4742 (Linking)
VI  - 22
IP  - 2
DP  - 2013 Apr
TI  - Cataract in children and adolescents with fibrocalculous pancreatic diabetes.
PG  - 331-5
AB  - Cataracts have been infrequently reported in Fibrocalculous pancreatic diabetes
      (FCPD) which is a form of diabetes secondary to chronic, non-alcoholic
      pancreatitis in tropical countries. A retrospective study was carried out to find
      out frequency of cataracts in children and adolescents with FCPD admitted in the 
      Paediatric Unit at Bangladesh Institute of Research and Rehabilitation on
      Diabetes, Endocrine and Metabolic disorders (BIRDEM). A total of 83 patients with
      FCPD were admitted during the study period of 2000 to 2007. Among them twenty
      patients (24%) had bilateral cataracts who were enrolled in the study. Mean age
      at the onset of diabetes was 13.9+/-1.7 years. There was female preponderance.
      Ninety percent patients were girls. There was longer duration of symptoms in all 
      patients. Mean duration of symptoms before diagnosis was 15.0+/-10.2 months. All 
      patients had hyperglycaemia, mean HbA1c value was 18.4+/-5.1. Most of the
      patients had snowflake type cortical deposits and posterior subcapsular cataract.
AD  - Dr Bedowra Zabeen, Paediatric Diabetologist & Coordinator, Changing Diabetes in
      Children (CDIC) & Life for a Child Programme - BADAS, BIRDEM, Shahbagh, Dhaka,
      Bangladesh.
FAU - Zabeen, B
AU  - Zabeen B
FAU - Khaled, Z
AU  - Khaled Z
FAU - Nahar, J
AU  - Nahar J
FAU - Nabi, N
AU  - Nabi N
FAU - Mohsin, F
AU  - Mohsin F
FAU - Akhter, S
AU  - Akhter S
FAU - Azad, K
AU  - Azad K
FAU - Nahar, N
AU  - Nahar N
LA  - eng
PT  - Journal Article
PL  - Bangladesh
TA  - Mymensingh Med J
JT  - Mymensingh medical journal : MMJ
JID - 9601799
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Mymensingh Med J. 2013 Apr;22(2):331-5.

PMID- 23715332
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1546-1718 (Electronic)
IS  - 1061-4036 (Linking)
VI  - 45
IP  - 6
DP  - 2013 May 29
TI  - Genome-wide meta-analyses of multiancestry cohorts identify multiple new
      susceptibility loci for refractive error and myopia.
PG  - 712
LID - 10.1038/ng0613-712b [doi]
FAU - Verhoeven, Virginie J M
AU  - Verhoeven VJ
FAU - Hysi, Pirro G
AU  - Hysi PG
FAU - Wojciechowski, Robert
AU  - Wojciechowski R
FAU - Fan, Qiao
AU  - Fan Q
FAU - Guggenheim, Jeremy A
AU  - Guggenheim JA
FAU - Hohn, Rene
AU  - Hohn R
FAU - Macgregor, Stuart
AU  - Macgregor S
FAU - Hewitt, Alex W
AU  - Hewitt AW
FAU - Nag, Abhishek
AU  - Nag A
FAU - Cheng, Ching-Yu
AU  - Cheng CY
FAU - Yonova-Doing, Ekaterina
AU  - Yonova-Doing E
FAU - Zhou, Xin
AU  - Zhou X
FAU - Ikram, M Kamran
AU  - Ikram MK
FAU - Buitendijk, Gabrielle H S
AU  - Buitendijk GH
FAU - McMahon, George
AU  - McMahon G
FAU - Kemp, John P
AU  - Kemp JP
FAU - Pourcain, Beate St
AU  - Pourcain BS
FAU - Simpson, Claire L
AU  - Simpson CL
FAU - Makela, Kari-Matti
AU  - Makela KM
FAU - Lehtimaki, Terho
AU  - Lehtimaki T
FAU - Kahonen, Mika
AU  - Kahonen M
FAU - Paterson, Andrew D
AU  - Paterson AD
FAU - Hosseini, S Mohsen
AU  - Hosseini SM
FAU - Wong, Hoi Suen
AU  - Wong HS
FAU - Xu, Liang
AU  - Xu L
FAU - Jonas, Jost B
AU  - Jonas JB
FAU - Parssinen, Olavi
AU  - Parssinen O
FAU - Wedenoja, Juho
AU  - Wedenoja J
FAU - Yip, Shea Ping
AU  - Yip SP
FAU - Ho, Daniel W H
AU  - Ho DW
FAU - Pang, Chi Pui
AU  - Pang CP
FAU - Chen, Li Jia
AU  - Chen LJ
FAU - Burdon, Kathryn P
AU  - Burdon KP
FAU - Craig, Jamie E
AU  - Craig JE
FAU - Klein, Barbara E K
AU  - Klein BE
FAU - Klein, Ronald
AU  - Klein R
FAU - Haller, Toomas
AU  - Haller T
FAU - Metspalu, Andres
AU  - Metspalu A
FAU - Khor, Chiea-Chuen
AU  - Khor CC
FAU - Tai, E-Shyong
AU  - Tai ES
FAU - Aung, Tin
AU  - Aung T
FAU - Vithana, Eranga
AU  - Vithana E
FAU - Tay, Wan-Ting
AU  - Tay WT
FAU - Barathi, Veluchamy A
AU  - Barathi VA
CN  - Consortium for Refractive Error and Myopia (CREAM)
FAU - Chen, Peng
AU  - Chen P
FAU - Li, Ruoying
AU  - Li R
FAU - Liao, Jiemin
AU  - Liao J
FAU - Zheng, Yingfeng
AU  - Zheng Y
FAU - Ong, Rick T
AU  - Ong RT
FAU - Doring, Angela
AU  - Doring A
CN  - Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions
      and Complications (DCCT/EDIC) Research Group
FAU - Evans, David M
AU  - Evans DM
FAU - Timpson, Nicholas J
AU  - Timpson NJ
FAU - Verkerk, Annemieke J M H
AU  - Verkerk AJ
FAU - Meitinger, Thomas
AU  - Meitinger T
FAU - Raitakari, Olli
AU  - Raitakari O
FAU - Hawthorne, Felicia
AU  - Hawthorne F
FAU - Spector, Tim D
AU  - Spector TD
FAU - Karssen, Lennart C
AU  - Karssen LC
FAU - Pirastu, Mario
AU  - Pirastu M
FAU - Murgia, Federico
AU  - Murgia F
FAU - Ang, Wei
AU  - Ang W
CN  - Wellcome Trust Case Control Consortium 2 (WTCCC2)
FAU - Mishra, Aniket
AU  - Mishra A
FAU - Montgomery, Grant W
AU  - Montgomery GW
FAU - Pennell, Craig E
AU  - Pennell CE
FAU - Cumberland, Phillippa M
AU  - Cumberland PM
FAU - Cotlarciuc, Ioana
AU  - Cotlarciuc I
FAU - Mitchell, Paul
AU  - Mitchell P
FAU - Wang, Jie Jin
AU  - Wang JJ
FAU - Schache, Maria
AU  - Schache M
FAU - Janmahasatian, Sarayut
AU  - Janmahasatian S
FAU - Jr, Robert P Igo
AU  - Jr RP
FAU - Lass, Jonathan H
AU  - Lass JH
FAU - Chew, Emily
AU  - Chew E
FAU - Iyengar, Sudha K
AU  - Iyengar SK
CN  - Fuchs' Genetics Multi-Center Study Group
FAU - Gorgels, Theo G M F
AU  - Gorgels TG
FAU - Rudan, Igor
AU  - Rudan I
FAU - Hayward, Caroline
AU  - Hayward C
FAU - Wright, Alan F
AU  - Wright AF
FAU - Polasek, Ozren
AU  - Polasek O
FAU - Vatavuk, Zoran
AU  - Vatavuk Z
FAU - Wilson, James F
AU  - Wilson JF
FAU - Fleck, Brian
AU  - Fleck B
FAU - Zeller, Tanja
AU  - Zeller T
FAU - Mirshahi, Alireza
AU  - Mirshahi A
FAU - Muller, Christian
AU  - Muller C
FAU - Uitterlinden, Andre G
AU  - Uitterlinden AG
FAU - Rivadeneira, Fernando
AU  - Rivadeneira F
FAU - Vingerling, Johannes R
AU  - Vingerling JR
FAU - Hofman, Albert
AU  - Hofman A
FAU - Oostra, Ben A
AU  - Oostra BA
FAU - Amin, Najaf
AU  - Amin N
FAU - Bergen, Arthur A B
AU  - Bergen AA
FAU - Teo, Yik-Ying
AU  - Teo YY
FAU - Rahi, Jugnoo S
AU  - Rahi JS
FAU - Vitart, Veronique
AU  - Vitart V
FAU - Williams, Cathy
AU  - Williams C
FAU - Baird, Paul N
AU  - Baird PN
FAU - Wong, Tien-Yin
AU  - Wong TY
FAU - Oexle, Konrad
AU  - Oexle K
FAU - Pfeiffer, Norbert
AU  - Pfeiffer N
FAU - Mackey, David A
AU  - Mackey DA
FAU - Young, Terri L
AU  - Young TL
FAU - van Duijn, Cornelia M
AU  - van Duijn CM
FAU - Saw, Seang-Mei
AU  - Saw SM
FAU - Bailey-Wilson, Joan E
AU  - Bailey-Wilson JE
FAU - Stambolian, Dwight
AU  - Stambolian D
FAU - Klaver, Caroline C
AU  - Klaver CC
FAU - Hammond, Christopher J
AU  - Hammond CJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nat Genet
JT  - Nature genetics
JID - 9216904
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - ng0613-712b [pii]
AID - 10.1038/ng0613-712b [doi]
PST - ppublish
SO  - Nat Genet. 2013 May 29;45(6):712. doi: 10.1038/ng0613-712b.

PMID- 23715298
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 2158-3188 (Electronic)
IS  - 2158-3188 (Linking)
VI  - 3
DP  - 2013
TI  - Diabetic db/db mice exhibit central nervous system and peripheral molecular
      alterations as seen in neurological disorders.
PG  - e263
LID - 10.1038/tp.2013.42 [doi]
AB  - The db/db mouse is a widely used preclinical model in diabetes research. Recent
      studies have shown that these mice also display aspects of psychosis and
      depression-like behaviors as seen in some psychiatric disorders. Here, we have
      performed multiplex immunoassay and liquid chromatography mass spectrometry
      profiling of the plasma and brain samples from db/db and control mice to identify
      altered pathways, which could be related to these behavioral abnormalities. This 
      is the first study to carry out profiling of the brain proteome in this model.
      Plasma from the db/db mice had increased levels of leptin and insulin, decreased 
      levels of peptide YY, glucagon and prolactin and alterations in
      inflammation-related proteins, compared with control mice. Frontal cortex tissue 
      from the db/db mice showed changes in proteins involved in energy metabolism,
      cellular structure and neural functioning, and the hippocampus had changes in
      proteins involved in the same pathways, with additional effects on cellular
      signalling proteins. The overlap of these findings with effects seen in type 2
      diabetes, schizophrenia, major depressive disorder and Alzheimer's disease might 
      contribute to a common endophenotype seen in metabolic and neurological
      disorders.
AD  - Department of Chemical Engineering and Biotechnology, University of Cambridge,
      Cambridge, UK.
FAU - Ernst, A
AU  - Ernst A
FAU - Sharma, A N
AU  - Sharma AN
FAU - Elased, K M
AU  - Elased KM
FAU - Guest, P C
AU  - Guest PC
FAU - Rahmoune, H
AU  - Rahmoune H
FAU - Bahn, S
AU  - Bahn S
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - United States
TA  - Transl Psychiatry
JT  - Translational psychiatry
JID - 101562664
SB  - IM
PMC - PMC3669927
OID - NLM: PMC3669927
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - tp201342 [pii]
AID - 10.1038/tp.2013.42 [doi]
PST - epublish
SO  - Transl Psychiatry. 2013 May 28;3:e263. doi: 10.1038/tp.2013.42.

PMID- 23715259
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 0022-4707 (Print)
IS  - 0022-4707 (Linking)
VI  - 53
IP  - 3
DP  - 2013 Jun
TI  - Effect of Nordic walking in type 2 diabetes mellitus: some considerations.
PG  - 336-7
AD  - Department of Medicine, General Hospital of Urbino, Urbino, Italy -
      paolosossai@libero.it.
FAU - Sossai, P
AU  - Sossai P
FAU - Sudano, M
AU  - Sudano M
FAU - Caniglia, C
AU  - Caniglia C
FAU - Amenta, F
AU  - Amenta F
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - J Sports Med Phys Fitness
JT  - The Journal of sports medicine and physical fitness
JID - 0376337
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - R40Y2013N03A0336 [pii]
PST - ppublish
SO  - J Sports Med Phys Fitness. 2013 Jun;53(3):336-7.

PMID- 23715196
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1931-3543 (Electronic)
IS  - 0012-3692 (Linking)
VI  - 143
IP  - 5
DP  - 2013 May 1
TI  - Identification of Stage I Non-small Cell Lung Cancer Patients at High Risk for
      Local Recurrence Following Sublobar Resection.
PG  - 1365-77
LID - 10.1378/chest.12-0710 [doi]
AB  - OBJECTIVE: An increasing proportion of patients with stage I non-small cell lung 
      cancer (NSCLC) is undergoing sublobar resection (L-). However, there is little
      information about the risks and correlates of local recurrence (LR) after such
      surgery, especially compared with patients undergoing lobectomy (L+). METHODS:
      Ninety-three and 318 consecutive patients with stage I NSCLC underwent L- and L+,
      respectively, from 2000 to 2006. Median follow-up was 34 months. RESULTS: In the 
      L- group, the LR rates at 2, 3, and 5 years were 13%, 24%, and 40%, respectively.
      The risk of LR was significantly associated with tumor grade, tumor size, and T
      stage. The crude risk of LR was 33.8% (21 of 62) for patients whose tumors were
      grade >/= 2. In the L+ group, the LR rates at 2, 3, and 5 years were 14%, 19%,
      and 24%, respectively. The risk of LR significantly increased with increasing
      tumor size, length of hospital stay, and the presence of diabetes. The L- group
      experienced a significant increase in failure in the bronchial stump/staple line 
      compared with the L+ group (10% vs 3%; P = .04) and nonsignificant trends toward 
      increased ipsilateral hilar and subcarinal failure rates. CONCLUSIONS: Patients
      with stage I NSCLC who undergo L- have an increased risk of LR compared with
      patients undergoing L+, particularly when they have tumors grade >/= 2 or tumor
      size &gt; 2 cm. If L- is considered, additional local therapy should be
      considered to reduce this risk of LR, especially with tumors grade >/= 2 or size 
      &gt; 2 cm.
FAU - Varlotto, John M
AU  - Varlotto JM
FAU - Medford-Davis, Laura N
AU  - Medford-Davis LN
FAU - Recht, Abram
AU  - Recht A
FAU - Flickinger, John
AU  - Flickinger J
FAU - Yao, Nengliang
AU  - Yao N
FAU - Hess, Clayton
AU  - Hess C
FAU - Reed, Michael F
AU  - Reed MF
FAU - Toth, Jennifer
AU  - Toth J
FAU - Zander, Dani S
AU  - Zander DS
FAU - Decamp, Malcolm M
AU  - Decamp MM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
SB  - AIM
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 1461071 [pii]
AID - 10.1378/chest.12-0710 [doi]
PST - ppublish
SO  - Chest. 2013 May 1;143(5):1365-77. doi: 10.1378/chest.12-0710.

PMID- 23715170
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 19
DP  - 2013
TI  - Effect of common single-nucleotide polymorphisms in acetylsalicylic acid
      metabolic pathway genes on platelet reactivity in patients with diabetes.
PG  - 394-408
LID - 10.12659/MSM.883922 [doi]
AB  - Background Platelet reactivity in patients on acetylsalicylic acid (ASA) therapy 
      can be influenced by physiological or pathological conditions affecting ASA
      pharmacokinetics or pharmacodynamics. The mechanism of such variability in the
      therapeutic response to ASA, particularly in diabetic patients, is poorly
      understood. The rate of elimination of ASA and its metabolite, salicylic acid
      (SA), is likely a major factor determining drug efficacy. The objective of this
      study was to investigate the effect of genetic polymorphisms in the selected
      candidate genes within the ASA metabolic pathway on the platelet reactivity and
      concentration of ASA and thromboxane A2 (TxA2) metabolites in a population of
      patients with type 2 diabetes mellitus (T2DM). Material and Methods The study
      cohort consisted of 287 Caucasians with T2DM who had been taking ASA tablets at
      the dose of 75 mg per day for at least 3 months. Platelet reactivity analyses
      were performed using VerifyNow Aspirin and PFA-100 assays. The measured ASA
      metabolite included salicylic acid (ASA), and TxA2 metabolites included serum
      TxB2 and urinary 11-dh-TxB2. Genotyping for the selected 18 single-nucleotide
      polymorphisms (SNPs) within 5 genes of the ASA metabolic pathway was performed
      using a Sequenom iPLEX platform. Results No statistically significant association
      was observed between the investigated SNPs genotypes, platelet reactivity, and
      measured metabolites in the investigated cohort of patients. Conclusions The
      results of our study failed to confirm that the selected variants in the genes
      within the ASA metabolic pathway might contribute to platelet reactivity in a
      diabetic population treated with ASA.
AD  - Department of Cardiology, Medical University of Warsaw, Warsaw, Poland and
      Department of Experimental and Clinical Pharmacology, Medical University of
      Warsaw, Warsaw, Poland and Department of Noninvasive Cardiology and Hypertension,
      Central Clinical Hospital, Ministry of the Interior, Warsaw, Poland.
FAU - Postula, Marek
AU  - Postula M
FAU - Janicki, Piotr K
AU  - Janicki PK
FAU - Rosiak, Marek
AU  - Rosiak M
FAU - Kaplon-Cieslicka, Agnieszka
AU  - Kaplon-Cieslicka A
FAU - Kondracka, Agnieszka
AU  - Kondracka A
FAU - Trzepla, Ewa
AU  - Trzepla E
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
FAU - Kosior, Dariusz A
AU  - Kosior DA
FAU - Czlonkowski, Andrzej
AU  - Czlonkowski A
FAU - Opolski, Grzegorz
AU  - Opolski G
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and
      clinical research
JID - 9609063
SB  - IM
PMC - PMC3670858
OID - NLM: PMC3670858
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 883922 [pii]
AID - 10.12659/MSM.883922 [doi]
PST - epublish
SO  - Med Sci Monit. 2013 May 27;19:394-408. doi: 10.12659/MSM.883922.

PMID- 23715128
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1523-2859 (Electronic)
IS  - 0025-732X (Linking)
VI  - 55
IP  - 1416
DP  - 2013 May 27
TI  - Alogliptin (nesina) for type 2 diabetes.
PG  - 41-3
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Lett Drugs Ther
JT  - The Medical letter on drugs and therapeutics
JID - 2985240R
SB  - AIM
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Med Lett Drugs Ther. 2013 May 27;55(1416):41-3.

PMID- 23714909
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1536-3732 (Electronic)
IS  - 1049-2275 (Linking)
VI  - 24
IP  - 3
DP  - 2013 May
TI  - Comparison of facial trauma in late middle age (55-64 years) and old age (older
      than 65 years).
PG  - 909-13
LID - 10.1097/SCS.0b013e318287d0b9 [doi]
AB  - In this study, we attempted to compare facial trauma of late-middle-age patients 
      (55-64 years, LM group) and old-age patients (>65 years old, OL group). The goal 
      of this study was to evaluate the natural history of facial trauma in geriatric
      patients.The medical record of patients older than 55 years seeking treatment for
      facial trauma between March 2006 and February 2009 were reviewed, and parameters 
      were collected. Seven hundred seventy-two patients (553 male, 219 female) were
      analyzed. There were 438 patients of the LM group (55-64 years old) and 334
      patients of the OL group (>65 years old).In men (n = 553), the number of patients
      within the LM group (n = 336, 60.8%) was greater than the number in the OL group 
      (n = 217, 39.2%). Of the 219 women, the number within the OL group (n = 117,
      53.4%) was greater than that within the LM group (n = 102, 46.6%) (P = 0.000,
      chi). Facial lacerations comprised a significantly higher proportion in the OL
      group (79.3%) than that in the ML group (70.1%), whereas facial bone fractures
      were more frequent in the ML group (29.9%) than in the OL group (20.7%), which
      was significant (P = 0.004, chi). Assault and automobile accidents were
      significantly more frequent in the ML group (n = 65 [15.1%] and n = 31 [7.2%],
      respectively) than the OL group (n = 20 [6.0%] and n = 11 [3.3%]), whereas falls 
      and pedestrian accidents were more significantly frequent in the OL group (n = 30
      [9.0%] and n = 23 [6.9%], respectively) than in the LM group (n = 30 [7.0%] and n
      = 19 [4.4%]) (P = 0.000, chi). During the hours of the day, between 4 to 6 PM and
      6 to 8 PM, injuries occurred more frequently in the OL group (14.5% and 12.4%,
      respectively) than in the LM group (10.5% and 11.0%, respectively). At the times 
      of 8 to 10 PM and 10 PM to midnight, however, injuries occurred more frequently
      in the LM group (17.1%, 12.1%, respectively) than in the OL group (12.1% and
      8.2%, respectively) (P = 0.03, chi). Frequency of injuries at home within the OL 
      group (n = 68, 22.2%) was significantly higher than within the LM group (n = 55, 
      14.4%) (P = 0.001, chi), whereas frequency of injuries at the workplace of the LM
      group (n = 47, 12.3%) was significantly higher than that of the OL group (n = 16,
      5.2%) (P = 0.001, chi). Alcohol ingestion at the time of injury was significantly
      more frequent in the LM group (n = 146, 34.1%) than in the OL group (n = 57,
      17.3%) (P = 0.000, chi). In regard to diabetes, the OL group (35.6%) showed a
      higher prevalence than that of the LM group (25.4%; odds ratio, 2.65).Prevention 
      of injury is important for elderly patients. It is worthy of notice that more
      than one fourth (26.8%) were in a drunken state at the time of injury. There were
      no significant differences in the days of hospitalization or in the interval from
      injury to operation. However, there were significant differences in the place of 
      the injuries, causes of injuries, and time of injuries, which is important in the
      prevention of injuries. Attention should be paid to assault and automobile
      accidents in the LM group and to falls and pedestrian injuries in the OL group.
      Thus, injury prevention should be prepared for differently for both LM and OL
      groups.
AD  - From the *Department of Plastic Surgery and daggerCenter for Advanced Medical
      Education by BK21 Project, Inha University School of Medicine, Incheon, Korea.
FAU - Hwang, Kun
AU  - Hwang K
FAU - Huan, Fan
AU  - Huan F
FAU - Hwang, Pil Joong
AU  - Hwang PJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Craniofac Surg
JT  - The Journal of craniofacial surgery
JID - 9010410
SB  - D
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1097/SCS.0b013e318287d0b9 [doi]
AID - 00001665-201305000-00051 [pii]
PST - ppublish
SO  - J Craniofac Surg. 2013 May;24(3):909-13. doi: 10.1097/SCS.0b013e318287d0b9.

PMID- 23714774
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
DP  - 2013 May 23
TI  - Heart Failure with Preserved Ejection Fraction: Emerging Drug Strategies.
AB  - Approximately half of heart failure patients have a normal ejection fraction, a
      condition designated as heart failure with preserved ejection fraction (HFpEF).
      This heart failure subtype disproportionately affects women and the elderly and
      is commonly associated with other cardiovascular comorbidities, such as
      hypertension and diabetes. HFpEF is increasing at a steady rate and is predicted 
      to become the leading cause of heart failure within a decade. HFpEF is
      characterized by impaired diastolic function, thought to be due to concentric
      remodeling of the heart along with increased stiffness of both the extracellular 
      matrix and myofilaments. In addition, oxidative stress and inflammation are
      thought to have a role in HFpEF progression, along with endothelial dysfunction
      and impaired nitric oxide-cyclic guanosine monophosphate (cGMP)-protein kinase G 
      (PKG) signaling. Surprisingly a number of clinical studies have failed to
      demonstrate any benefit of drugs effective in heart failure with systolic
      dysfunction in HFpEF patients. Thus, HFpEF is one of the largest unmet needs in
      cardiovascular medicine and there is a substantial need for new therapeutic
      approaches and strategies that target mechanisms specific for HFpEF. This
      conclusion is underscored by the recently reported disappointing results of the
      RELAX trial, which assessed the use of phosphodiesterase-5 inhibitor sildenafil
      for treating HFpEF. In animal models, endothelial nitric oxide synthase (eNOS)
      activators and If current inhibitors have shown benefit in improving diastolic
      function and there is a rationale for assessing matrix metalloproteinase-9
      (MMP-9) inhibitors and nitroxyl donors. LCZ696, a combination drug of angiotensin
      II receptor blocker and neprilysin inhibitor, and the aldosterone receptor
      antagonist spironolactone are currently in clinical trial for treating HFpEF.
      Here we present an overview of the etiology and diagnosis of HFpEF that segues
      into a discussion of new therapeutic approaches emerging from basic research, as 
      well as drugs currently in clinical trial, that primarily target diastolic
      dysfunction or imbalanced ventricular-arterial coupling.
AD  - 1Department of Pharmacology and Toxicology and 2Department of Physiology and
      Biophysics, School of Medicine, The University of Mississippi Medical Center and 
      Jackson Center for Heart Research, Jackson, Mississippi, USA 3San Antonio
      Cardiovascular Proteomics Center, San Antonio, Texas 4Institute of Medical
      Education and Research, Belo Horizonte, Minas Gerais, Brazil 5Research Service,
      G.V. (Sonny) Montgomery Veterans Affairs Medical Center, Jackson, Mississippi,
      USA 6Department of Chemistry and Biochemistry, Faculty of Sciences, Lebanese
      University, Rafic Hariri Educational Campus, Hadath, Lebanon.
FAU - Zouein, Fouad A
AU  - Zouein FA
FAU - de Castro Bras, Lisandra E
AU  - de Castro Bras LE
FAU - da Costa, Danielle V
AU  - da Costa DV
FAU - Lindsey, Merry L
AU  - Lindsey ML
FAU - Kurdi, Mazen
AU  - Kurdi M
FAU - Booz, George W
AU  - Booz GW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1097/FJC.0b013e31829a4e61 [doi]
PST - aheadofprint
SO  - J Cardiovasc Pharmacol. 2013 May 23.

PMID- 23714680
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 28
TI  - Blood Pressure and Stroke Risk among Diabetic Patients.
AB  - Context:Blood pressure (BP) control can reduce the risk of stroke among diabetic 
      patents, however, it is not known if the lowest risk of stroke is among diabetic 
      patients with the lowest BP level.Objective:To investigate the race-specific
      association of different levels of BP with stroke risk among diabetic patients in
      the Louisiana State University Hospital-based Longitudinal study.Design, setting,
      and participants:We prospectively investigated the race-specific association of
      different levels of blood pressure at baseline and during an average of 6.7 years
      of follow-up with incident stroke risk among 17,536 African American and 12,618
      White diabetic patients within the Louisiana State University (LSU) Hospital
      System.Main Outcome Measure:Incident stroke until May 31, 2012.Results:During
      follow up, 2,949 incident cases of stroke were identified. The
      multivariable-adjusted hazard ratios (HRs) of stroke associated with different
      levels of systolic/diastolic blood pressure at baseline (<110/65, 110-119/65-69, 
      120-129/70-80 [reference group], 130-139/80-90, 140-159/90-100, and >/=160/100
      mmHg) were 1.88 (95% confidence interval [CI] 1.38-2.56), 1.05 (0.80-1.42), 1.00,
      1.05 (0.86-1.27), 1.12 (0.94-1.34), and 1.47 (1.24-1.75) for African American
      diabetic patients, and 1.42 (1.06-1.91), 1.22 (0.95-1.57), 1.00, 0.88
      (0.72-1.06), 1.02 (0.86-1.21), and 1.28 (1.07-1.54) for white diabetic patients, 
      respectively. A U-shaped association of isolated systolic or diastolic blood
      pressure at baseline and during follow-up with stroke risk was observed among
      both African American and white diabetic patients. The U-shaped association was
      confirmed in both patients who were and were not taking antihypertensive
      drugs.Conclusions:The current study suggests a U-shaped association between blood
      pressure and the risk of stroke. Aggressive BP control (<110/65 mmHg) and high
      blood pressure (>/=160/100 mmHg) are associated with an increased risk of stroke 
      among both African American and white patients with type 2 diabetes.
AD  - Pennington Biomedical Research Center, Baton Rouge, LA; School of Human Ecology, 
      Baton Rouge, LA; Health Care Service Division, and Earl K Long Medical Center, LA
      State University Health Science Center, Baton Rouge, LA.
FAU - Zhao, Wenhui
AU  - Zhao W
FAU - Katzmarzyk, Peter T
AU  - Katzmarzyk PT
FAU - Horswell, Ronald
AU  - Horswell R
FAU - Wang, Yujie
AU  - Wang Y
FAU - Johnson, Jolene
AU  - Johnson J
FAU - Cefalu, William T
AU  - Cefalu WT
FAU - Ryan, Donna H
AU  - Ryan DH
FAU - Hu, Gang
AU  - Hu G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - jc.2013-1757 [pii]
AID - 10.1210/jc.2013-1757 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 28.

PMID- 23714421
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
DP  - 2013 May 25
TI  - CHADS score predicts functional outcome of stroke in patients with a history of
      coronary artery disease.
LID - S0022-510X(13)00211-6 [pii]
LID - 10.1016/j.jns.2013.05.004 [doi]
AB  - BACKGROUND: The aim of this study was to evaluate the efficacy of the CHADS2
      scoring system as a prognostic tool for stroke patients with a prior history of
      coronary artery disease (CAD). METHODS: We enrolled 148 acute ischemic stroke
      patients (mean age, 74.2years; males, 77.0%) with a history of CAD. Pre-admission
      CHADS2 scores were calculated by assigning a single point for the presence of
      congestive heart failure, hypertension, age >/=75years, and diabetes; and
      assigning 2 points for a prior history of stroke or transient ischemic attack.
      Comparisons were made between patients with poor and good 3-month functional
      outcomes. A multivariate logistic regression analysis was performed to assess the
      predictive value of CHADS2 scores for poor outcome. RESULTS: The patients with
      poor and good outcomes displayed significant differences in CHADS2 scores
      (median, 3 vs. 2, P=0.014), carotid artery stenosis (41.0% vs. 24.6%, P=0.037),
      intracranial artery stenosis (32.5% vs. 15.4%, P=0.017), atrial fibrillation
      (31.3% vs. 16.9%, P=0.045), and admission NIHSS score (median, 11 vs. 5,
      P<0.001). The CHADS2 score was an independent determinant of poor functional
      outcome on a multivariate analysis (per 1 point increase: OR 1.47, 95% CI
      1.05-2.11, P=0.025; CHADS2 score >/=3: OR 1.58, 95% CI 1.01-2.54, P=0.050).
      CONCLUSIONS: The CHADS2 score is a potential useful tool for predicting
      functional outcome in stroke patients with a history of CAD.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Neurology, Tokyo Women's Medical University, 8-1 Kawada-cho,
      Shinjuku-ku, Tokyo 162-8666, Japan. Electronic address: thoshino@nij.twmu.ac.jp.
FAU - Hoshino, Takao
AU  - Hoshino T
FAU - Ishizuka, Kentaro
AU  - Ishizuka K
FAU - Shimizu, Satoru
AU  - Shimizu S
FAU - Uchiyama, Shinichiro
AU  - Uchiyama S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/12/31 [received]
PHST- 2013/05/01 [revised]
PHST- 2013/05/01 [accepted]
AID - S0022-510X(13)00211-6 [pii]
AID - 10.1016/j.jns.2013.05.004 [doi]
PST - aheadofprint
SO  - J Neurol Sci. 2013 May 25. pii: S0022-510X(13)00211-6. doi:
      10.1016/j.jns.2013.05.004.

PMID- 23714362
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 14
IP  - 1
DP  - 2013 May 29
TI  - SMART MOVE - a smartphone-based intervention to promote physical activity in
      primary care: study protocol for a randomized controlled trial.
PG  - 157
AB  - BACKGROUND: Sedentary lifestyles are now becoming a major concern for governments
      of developed and developing countries with physical inactivity related to
      increased all-cause mortality, lower quality of life, and increased risk of
      obesity, diabetes, hypertension and many other chronic diseases. The powerful
      onboard computing capacity of smartphones, along with the unique relationship
      individuals have with their mobile phones, suggests that mobile devices have the 
      potential to influence behavior. However, no previous trials have been conducted 
      using smartphone technology to promote physical activity. This project has the
      potential to provide robust evidence in this area of innovation. The aim of this 
      study is to evaluate the effectiveness of a smartphone application as an
      intervention to promote physical activity in primary care.Methods/design: A
      two-group, parallel randomized controlled trial (RCT) with a main outcome measure
      of mean difference in daily step count between baseline and follow up over eight 
      weeks. A minimum of 80 active android smartphone users over 16 years of age who
      are able to undertake moderate physical activity are randomly assigned to the
      intervention group (n = 40) or to a control group (n = 40) for an eight week
      period. After randomization, all participants will complete a baseline period of 
      one week during which a baseline mean daily step count will be established. The
      intervention group will be instructed in the usability features of the smartphone
      application, will be encouraged to try to achieve 10,000 steps per day as an
      exercise goal and will be given an exercise promotion leaflet. The control group 
      will be encouraged to try to walk an additional 30 minutes per day along with
      their normal activity (the equivalent of 10,000 steps) as an exercise goal and
      will be given an exercise promotion leaflet. The primary outcome is mean
      difference in daily step count between baseline and follow-up. Secondary outcomes
      are systolic and diastolic blood pressure, resting heart rate, mental health
      score using HADS and quality of life score using Euroqol. Randomization and
      allocation to the intervention and groups will be carried out by an independent
      researcher, ensuring the allocation sequence is concealed from the study
      researchers until the interventions are assigned. The primary analysis is based
      on mean daily step count, comparing the mean difference in daily step count
      between the baseline and the trial periods in the intervention and control groups
      at follow up.Trial registration: Current Controlled Trials ISRCTN99944116.
FAU - Glynn, Liam G
AU  - Glynn LG
FAU - Hayes, Patrick S
AU  - Hayes PS
FAU - Casey, Monica
AU  - Casey M
FAU - Glynn, Fergus
AU  - Glynn F
FAU - Alvarez-Iglesias, Alberto
AU  - Alvarez-Iglesias A
FAU - Newell, John
AU  - Newell J
FAU - Olaighin, Gearoid
AU  - Olaighin G
FAU - Heaney, David
AU  - Heaney D
FAU - Murphy, Andrew W
AU  - Murphy AW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Trials
JT  - Trials
JID - 101263253
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/02/20 [received]
PHST- 2013/05/29 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 1745-6215-14-157 [pii]
AID - 10.1186/1745-6215-14-157 [doi]
PST - aheadofprint
SO  - Trials. 2013 May 29;14(1):157.

PMID- 23714352
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - The influence of early exposure to vitamin D for development of diseases later in
      life.
PG  - 515
LID - 10.1186/1471-2458-13-515 [doi]
AB  - BACKGROUND: Vitamin D deficiency is common among otherwise healthy pregnant women
      and may have consequences for them as well as the early development and long-term
      health of their children. However, the importance of maternal vitamin D status on
      offspring health later in life has not been widely studied. The present study
      includes an in-depth examination of the influence of exposure to vitamin D early 
      in life for development of fractures of the wrist, arm and clavicle; obesity, and
      type 1 diabetes (T1D) during child- and adulthood. METHODS/DESIGN: The study is
      based on the fact that in 1961 fortifying margarine with vitamin D became
      mandatory in Denmark and in 1972 low fat milk fortification was allowed. Apart
      from determining the influences of exposure prior to conception and during
      prenatal life, we will examine the importance of vitamin D exposure during
      specific seasons and trimesters, by comparing disease incidence among individuals
      born before and after fortification. The Danish National databases assure that
      there are a sufficient number of individuals to verify any vitamin D effects
      during different gestation phases. Additionally, a validated method will be used 
      to determine neonatal vitamin D status using stored dried blood spots (DBS) from 
      individuals who developed the aforementioned disease entities as adults and their
      time and gender-matched controls. DISCUSSION: The results of the study will
      contribute to our current understanding of the significance of supplementation
      with vitamin D. More specifically, they will enable new research in related
      fields, including interventional research designed to assess supplementation
      needs for different subgroups of pregnant women. Also, other health outcomes can 
      subsequently be studied to generate multiple health research opportunities
      involving vitamin D. Finally, the results of the study will justify the debate of
      Danish health authorities whether to resume vitamin D supplementation policies.
AD  - Institute of Preventive Medicine, Bispebjerg and Frederiksberg Hospitals - a part
      of Copenhagen University Hospital, Nordre Fasanvej 57, DK-2000 Frederiksberg,
      Denmark. berit.lilienthal.heitmann@regionh.dk.
FAU - Jacobsen, Ramune
AU  - Jacobsen R
FAU - Abrahamsen, Bo
AU  - Abrahamsen B
FAU - Bauerek, Marta
AU  - Bauerek M
FAU - Holst, Claus
AU  - Holst C
FAU - Jensen, Camilla B
AU  - Jensen CB
FAU - Knop, Joachim
AU  - Knop J
FAU - Raymond, Kyle
AU  - Raymond K
FAU - Rasmussen, Lone B
AU  - Rasmussen LB
FAU - Stougaard, Maria
AU  - Stougaard M
FAU - Sorensen, Thorkild Ia
AU  - Sorensen TIa
FAU - Vaag, Allan A
AU  - Vaag AA
FAU - Heitmann, Berit L
AU  - Heitmann BL
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3672018
OID - NLM: PMC3672018
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/01/11 [received]
PHST- 2013/05/21 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 1471-2458-13-515 [pii]
AID - 10.1186/1471-2458-13-515 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 28;13:515. doi: 10.1186/1471-2458-13-515.

PMID- 23714278
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1560-8115 (Print)
IS  - 1560-8115 (Linking)
VI  - 21
IP  - 1
DP  - 2013 May 29
TI  - Comparative amino acid decomposition analysis of potent type I p38alpha
      inhibitors.
PG  - 41
AB  - : Background and purpose of the studyp38alpha is a member of mitogen-activated
      protein kinases (MAPK) considered as a prominent target in development of
      anti-inflammatory agents. Any abnormality in the phosphorylation process leads to
      the different human diseases such as cancer, diabetes and inflammatory diseases. 
      Several small molecule p38alpha inhibitors have been developed up to now. In this
      regard, structural elucidation of p38 inhibitors needs to be done enabling us in 
      rational lead development strategies. METHODS: Various interactions of three
      potent inhibitors with p38alpha active site have been evaluated in terms of
      binding energies and bond lengths via density function theory and MD simulations.
      RESULTS: Our comparative study showed that both ab initio and MD simulation led
      to the relatively similar results in pharmacophore discrimination of p38alpha
      inhibitors. CONCLUSION: The results of the present study may find their
      usefulness in pharmacophore based modification of p38alpha inhibitors.
FAU - Ebadi, Ahmad
AU  - Ebadi A
FAU - Razzaghi-Asl, Nima
AU  - Razzaghi-Asl N
FAU - Khoshneviszadeh, Mehdi
AU  - Khoshneviszadeh M
FAU - Miri, Ramin
AU  - Miri R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/04/14 [received]
PHST- 2013/05/29 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 2008-2231-21-41 [pii]
AID - 10.1186/2008-2231-21-41 [doi]
PST - aheadofprint
SO  - Daru. 2013 May 29;21(1):41.

PMID- 23714238
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 28
TI  - Tardive and spontaneous dyskinesia incidence in the general population.
PG  - 152
AB  - BACKGROUND: To identify the incidence rate of spontaneous dyskinesia (SD) and
      tardive dyskinesia (TD) in a general population and to examine the association
      between dykinesia and potential risk factors (exposure to metoclopramide [MCP],
      antipsychotic drugs, and history of diabetes and psychoses). METHODS: A
      retrospective cohort study was conducted for the years 2001 through 2010, based
      on medical claims data from the Deseret Mutual Benefit Administrators (DMBA).
      RESULTS: Thirty-four cases of TD and 229 cases of SD were identified. The
      incidence rate of TD among persons previously prescribed an antipsychotic or
      metoclopramide (MCP) (per 1,000) was 4.6 (1.6-7.7) for those with antipsychotic
      drug use only, 8.5 (4.8-12.2) for those with MCP use only, and 15.0 (2.0-28.1)
      for those with both antipsychotic and MCP use. In the general population, the
      incidence rate (per 100,000 person-years) of TD was 4.3 and of probable SD was
      28.7. The incidence rates of TD and SD increased with age and were greater for
      females. Those with diabetes or psychoses had almost a 3-fold greater risk of TD 
      than those without either of these diseases. Persons with schizophrenia had 31.2 
      times increased risk of TD than those without the disease. Positive associations 
      also existed between the selected diseases and the incidence rate of probable SD,
      with persons with schizophrenia having 4.4 times greater risk of SD than those
      without the disease. CONCLUSIONS: SD and TD are rare in this general population. 
      Diabetes, psychoses, and especially schizophrenia are positively associated with 
      SD and TD. A higher proportion of those with spontaneous dyskinesia present with 
      spasm of the eyelid muscles (blepharospasm) compared with the tardive dyskinesia 
      cases who present with orofacial muscular problems.
FAU - Merrill, Ray M
AU  - Merrill RM
FAU - Lyon, Joseph L
AU  - Lyon JL
FAU - Matiaco, Paul M
AU  - Matiaco PM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/12/05 [received]
PHST- 2013/05/28 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 1471-244X-13-152 [pii]
AID - 10.1186/1471-244X-13-152 [doi]
PST - aheadofprint
SO  - BMC Psychiatry. 2013 May 28;13(1):152.

PMID- 23714230
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1096-0961 (Electronic)
IS  - 1079-9796 (Linking)
DP  - 2013 May 25
TI  - Diabetes impairs mobilization of mouse bone marrow-derived Lin/VEGF-R2 progenitor
      cells.
LID - S1079-9796(13)00115-0 [pii]
LID - 10.1016/j.bcmd.2013.05.002 [doi]
AB  - Endothelial progenitor cells circulating in the peripheral blood (PB) contribute 
      to vascular repair. This study aimed to evaluate the potential of a 'cocktail'
      consisting of erythropoietin, granulocyte colony-stimulating factor and
      tetrahydrobiopterin to mobilize hematopoietic lineage negative/vascular
      endothelial growth factor receptor 2 positive (Lin-/VEGF-R2+) cells from the bone
      marrow (BM) to PB in non-diabetic and diabetic mice. Diabetes was induced in mice
      by intraperitoneal injection of streptozotocin. Diabetic mice were studied after 
      16weeks of hyperglycemia. Half the mice in each group (non-diabetic and diabetic)
      received daily intraperitoneal injections of the cocktail for 6 consecutive days 
      while the other half received vehicle buffer. Mobilization of Lin-/VEGF-R2+
      cells, which were expanded in MCP301 medium, was evaluated after isolating them
      from BM and PB and their phenotypic and morphological properties were studied. We
      found that 16weeks of diabetes affected neither the total number of BM
      mononucleated cells nor the number of Lin-/VEGF-R2+ cells in BM compared with
      non-diabetic controls. In non-diabetic mice, cocktail treatment resulted in a
      significant decrease in BM Lin-/VEGF-R2+ cells, paralleled by a significant
      increase of these cells in PB. Such changes in the number of Lin-/VEGF-R2+ cells 
      in BM and PB after the cocktail treatment were less marked in diabetic mice. In
      vitro studies of BM Lin-/VEGF-R2+ cells from diabetic and non-diabetic mice did
      not reveal any differences in either phenotypes or colony forming potential.
      These findings indicate that diabetes impairs the mobilization of Lin-/VEGF-R2+
      cells from BM to PB. Impaired mobilization of BM Lin-/VEGF-R2+ cells soon after
      the onset of diabetes may contribute to complications such as diabetic
      retinopathy.
CI  - Crown Copyright (c) 2013. Published by Elsevier Inc. All rights reserved.
AD  - Save Sight Institute, Sydney Hospital and Sydney Eye Hospital, The University of 
      Sydney, Sydney, Australia.
FAU - Barthelmes, D
AU  - Barthelmes D
FAU - Irhimeh, M R
AU  - Irhimeh MR
FAU - Gillies, M C
AU  - Gillies MC
FAU - Karimipour, M
AU  - Karimipour M
FAU - Zhou, M
AU  - Zhou M
FAU - Zhu, L
AU  - Zhu L
FAU - Shen, W Y
AU  - Shen WY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Blood Cells Mol Dis
JT  - Blood cells, molecules & diseases
JID - 9509932
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/05/18 [received]
PHST- 2013/04/29 [revised]
PHST- 2013/04/30 [accepted]
AID - S1079-9796(13)00115-0 [pii]
AID - 10.1016/j.bcmd.2013.05.002 [doi]
PST - aheadofprint
SO  - Blood Cells Mol Dis. 2013 May 25. pii: S1079-9796(13)00115-0. doi:
      10.1016/j.bcmd.2013.05.002.

PMID- 23714220
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1432-2277 (Electronic)
IS  - 0934-0874 (Linking)
VI  - 26
IP  - 7
DP  - 2013 Jul
TI  - Long-term outcome of 'long-term liver transplant survivors'.
PG  - 740-50
LID - 10.1111/tri.12118 [doi]
AB  - There are few studies focusing on long-term complications in liver transplant
      (LT) recipients. The aim of this study was to define the outcome of LT recipients
      having survived at least 10 years from LT. Of 323 adult LT done between 1991 and 
      1997, the 167(52%) alive >10 years post-LT (baseline time) formed the study
      population. Long-term outcome measures included the following: immunosuppression,
      metabolic complications [obesity, arterial hypertension (AH), diabetes,
      dislypidemia], cardiovascular events (CVE), chronic renal dysfunction-CRD, and de
      novo tumors. Median age at LT was 50 years. Most common indication was
      postnecrotic cirrhosis (89%), mostly because of HCV (46%). At study-baseline (10 
      years post-LT), 29% were obese and AH, diabetes, dislypidemia, and CRD were
      present in 75%, 30%, 42%, and 36%, respectively. In most cases, these
      complications were already present 1 year post-LT; less than one quarter
      developed them onward. The 6 year cumulative survival since baseline reached 84% 
      (n = 24 deaths), with most deaths related to recurrent graft diseases (mostly
      HCV) followed by de novo tumors or CVE. 1, 3, 5 and 10 years cumulative rates of 
      CVE and de novo tumors since baseline were 2%, 5%, 10% and 17%, and 1%, 3%, 6%
      and 13%, respectively. Chronic renal impairment was independently associated with
      survival and development of CVE since baseline. The medium-term survival of
      'long-term survivors', i.e. patients alive 10 years after LT is good, but
      metabolic complications and CRD are common and continue to increase afterwards.
      Cardiovascular events and de novo tumors increase gradually over time and
      represent a major cause of late mortality.
CI  - (c) 2013 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
AD  - Liver Transplantation and Hepatology Unit, La Fe Hospital, Valencia, Spain;
      Ciberehd (Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y
      Digestivas), Valencia, Spain.
FAU - Rubin, Angel
AU  - Rubin A
FAU - Sanchez-Montes, Cristina
AU  - Sanchez-Montes C
FAU - Aguilera, Victoria
AU  - Aguilera V
FAU - Juan, Fernando San
AU  - Juan FS
FAU - Ferrer, Isabel
AU  - Ferrer I
FAU - Moya, Angel
AU  - Moya A
FAU - Montalva, Eva
AU  - Montalva E
FAU - Pareja, Eugenia
AU  - Pareja E
FAU - Lopez-Andujar, Rafael
AU  - Lopez-Andujar R
FAU - Prieto, Martin
AU  - Prieto M
FAU - Berenguer, Marina
AU  - Berenguer M
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - England
TA  - Transpl Int
JT  - Transplant international : official journal of the European Society for Organ
      Transplantation
JID - 8908516
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/06/05 [received]
PHST- 2012/07/18 [revised]
PHST- 2013/04/20 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 10.1111/tri.12118 [doi]
PST - ppublish
SO  - Transpl Int. 2013 Jul;26(7):740-50. doi: 10.1111/tri.12118. Epub 2013 May 28.

PMID- 23714218
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 May 29
TI  - SGLT2 inhibition: a new approach to diabetes treatment.
LID - 10.1111/1753-0407.12065 [doi]
AB  - A vexing aspect of the treatment of type 2 diabetes is the potential of both
      insulin and the sulfonylureas to cause hypoglycemia, with increasing recognition 
      of the association of hypoglycemia with adverse outcome.
CI  - This article is protected by copyright. All rights reserved.
AD  - Editor-in-Chief, Mount Sinai School of Medicine, New York, NY, USA.
      zbloom@gmail.com.
FAU - Bloomgarden, Zachary
AU  - Bloomgarden Z
LA  - ENG
PT  - EDITORIAL
DEP - 20130529
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/05/28 [accepted]
AID - 10.1111/1753-0407.12065 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 May 29. doi: 10.1111/1753-0407.12065.

PMID- 23714217
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
DP  - 2013 May 28
TI  - Clinical significance of microscopic hematuria in diabetic nephropathy in type 2 
      diabetes patients with overt proteinuria.
LID - 10.1111/nep.12104 [doi]
AB  - BACKGROUND: Although some patients with diabetic nephropathy with overt
      proteinuria have microscopic hematuria, the pathological characteristics and
      clinical significance related to microscopic hematuria have not yet been
      clarified. PATIENTS AND METHODS: We enrolled 84 type 2 diabetes patients with
      overt proteinuria and biopsy-confirmed diabetic nephropathy. We compared the
      clinical and histological findings between the patients with persistent hematuria
      (group 1, n=25) and those with persistent non-hematuria (group 2, n=23) after
      renal biopsy. We examined the association between persistent hematuria and renal 
      outcome at 5 years. Histological scoring was made according to the original
      system and that of Tervaert et al. RESULTS: Thirty-six patients (43%) had
      microscopic hematuria at the time of renal biopsy. Age was significantly smaller 
      and blood pressure was significantly greater in group 1 than in group 2 (age:
      group 1, 56 +/- 10 years; group 2, 62 +/- 9 years; p=0.03, systolic blood
      pressure: group 1, 152 +/- 16 mmHg; group 2, 140 +/- 16 mmHg; p=0.01). There were
      no significant differences in histological parameters between the two groups. A
      logistic regression model demonstrated that arteriolar hyalinosis was
      significantly associated with persistent hematuria (OR = 2.81; p = 0.04). There
      were no significant differences in changes in reciprocal serum creatinine and
      rates of doubling of serum creatinine after renal biopsy between the two groups. 
      CONCLUSION: Although arteriolar hyalinosis was associated with persistent
      hematuria, the clinical significance of microscopic hematuria was minor in
      diabetic nephropathy in type 2 diabetes patients with overt proteinuria.
CI  - This article is protected by copyright. All rights reserved.
AD  - Departments of Nephrology, Tokyo Medical University, Tokyo, Japan.
FAU - Okada, Tomonari
AU  - Okada T
FAU - Nagao, Toshitaka
AU  - Nagao T
FAU - Matsumoto, Hiroshi
AU  - Matsumoto H
FAU - Nagaoka, Yume
AU  - Nagaoka Y
FAU - Wada, Toshikazu
AU  - Wada T
FAU - Nakao, Toshiyuki
AU  - Nakao T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/05/21 [accepted]
AID - 10.1111/nep.12104 [doi]
PST - aheadofprint
SO  - Nephrology (Carlton). 2013 May 28. doi: 10.1111/nep.12104.

PMID- 23714216
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - How we manage diabetes is like Tantalus in the underworld.
PG  - f3248
LID - 10.1136/bmj.f3248 [doi]
LID - bmj.f3248 [pii]
AD  - Kingstone Surgery, Hereford HR2 9HN, UK.
FAU - Sleath, Jonathan D
AU  - Sleath JD
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - epublish
SO  - BMJ. 2013 May 28;346:f3248. doi: 10.1136/bmj.f3248.

PMID- 23714205
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 May 29
TI  - PCSK9, an enzyme turned escort protein: hepatic and extra hepatic functions.
LID - 10.1111/1753-0407.12064 [doi]
AB  - Proprotein Convertases Subtilisin/Kexin Type 9 (PCSK9) is a serine
      endoproteinase. Biosynthesized as a zymogen, it cleaves itself once, and then
      turns into an escort protein for transmembrane proteins, leading them into
      lysosomes for degradation. It is primarily produced and secreted by the liver. It
      attaches to the low-density lipoprotein receptor (LDLR) at the surface of
      hepatocytes and, after co-endocytosis, directs it into lysosomes where it is
      degraded. By down regulating LDLR, PCSK9 reduces hepatic clearance of
      LDL-cholesterol. Inborn or induced increase of this function causes
      hypercholesterolemia; its decrease causes hypocholesterolemia. This has been
      experimentally demonstrated ex vivo and in vivo, and corroborated by
      epidemiological studies associating PCSK9 genetic variations with plasma
      cholesterol levels. PCSK9 is now a proven target for inactivation in the
      treatment of hypercholesterolemia and associated atherosclerosis. However, it is 
      still uncertain whether its severe or complete inactivation, combined with other 
      predispositions, will be without undesirable side effects. Some experimental data
      suggest that PCSK9 could contribute positively to the physiology of non-hepatic
      cells such as pancreatic islets beta cells, adipocytes and macrophages,
      protecting them from excessive lipid uptake, in an endocrine, autocrine, or
      paracrine manner. Genetic variations that attenuate PCSK9 anti-LDLR activity are 
      common in human populations. Their evolutionary significance still needs to be
      evaluated on the background of environmental pressures, such as infectious
      diseases, cold weather and famine, which have threatened survival and
      reproduction in the course of human prehistory and history.
CI  - This article is protected by copyright. All rights reserved.
AD  - Chronic Disease Program, Ottawa Hospital Research Institute; Departments of
      Medicine, Microbiology and Immunology, Faculty of Medicine, University of Ottawa;
      Departments of Biochemistry, Microbiology and Immunology, Faculty of Medicine,
      University of Ottawa; Division of Endocrinology and Metabolism, The Ottawa
      Hospital, Ottawa, Ontario, Canada.
FAU - Mbikay, Majambu
AU  - Mbikay M
FAU - Mayne, Janice
AU  - Mayne J
FAU - Chretien, Michel
AU  - Chretien M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/05/24 [accepted]
AID - 10.1111/1753-0407.12064 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 May 29. doi: 10.1111/1753-0407.12064.

PMID- 23714175
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1873-5169 (Electronic)
IS  - 0196-9781 (Linking)
DP  - 2013 May 25
TI  - Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition
      of resistin/TLR4/MAPK/NF-kappaB in rats fed with high-fat diet.
LID - S0196-9781(13)00201-5 [pii]
LID - 10.1016/j.peptides.2013.05.010 [doi]
AB  - Obesity is characterized by a pro-inflammatory state commonly associated with
      type 2 diabetes and fat-liver disease. In the last few years, different studies
      pointed out the role of Angiotensin (Ang)-(1-7) in the metabolic regulation. The 
      aim of the present study was to evaluate the effect of oral-administration of
      Ang-(1-7) in metabolism and inflammatory state of high-fat feed rats. Twenty-four
      male Sprague Dawley rats were randomized into three groups: High Fat Diet (HFD); 
      Standard Diet (ST); High Fat Diet+Angiotensin-(1-7) [HFD+Ang-(1-7)]. Glycemic
      profile was evaluated by glucose tolerance and insulin sensitivity tests,
      plasmatic glucose and insulin. Cholesterol, HDL and triglycerides analyses
      presented lipidic profile. RT-PCR evaluated mRNA expression to ACE, ACE2,
      resistin, TLR4, IL-6, TNF-alpha and NF-kappaB genes. The main results showed that
      oral Ang-(1-7) decreased body weight and abdominal fat-mass. In addition,
      HFD+Ang-(1-7) treated rats presented enhanced glucose tolerance,
      insulin-sensitivity and decreased plasma-insulin levels, as well as a significant
      decrease in circulating lipid levels. These alterations were accompanied by a
      marked decreased expression of resistin, TLR4, ACE and increased ACE2 expression 
      in liver. Furthermore, Ang-(1-7) decreases phosphorylation of MAPK and increases 
      NF-kappaB expression. These alterations diminished expression of interleukin-6
      and TNF-alpha, ameliorate inflammatory state in liver. In summary, the present
      study showed that oral-treatment with Ang-(1-7) in high-fat feed rats improved
      metabolism down-regulating resistin/TLR4/NF-kappaB-pathway.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Laboratory of Health Science, Postgraduate Program in Health Sciences,
      Universidade Estadual de Montes Claros (UNIMONTES), Montes Claros, MG, Brazil;
      Pharmacology Department, Biological Sciences Institute (ICB), UFMG, Belo
      Horizonte, MG, Brazil. Electronic address: sergiosousas@hotmail.com.
FAU - Santos, Sergio Henrique Sousa
AU  - Santos SH
FAU - Andrade, Joao Marcus Oliveira
AU  - Andrade JM
FAU - Fernandes, Luciana Rodrigues
AU  - Fernandes LR
FAU - Sinisterra, Ruben D M
AU  - Sinisterra RD
FAU - Sousa, Frederico B
AU  - Sousa FB
FAU - Feltenberger, John David
AU  - Feltenberger JD
FAU - Alvarez-Leite, Jaqueline Izaura
AU  - Alvarez-Leite JI
FAU - Santos, Robson Augusto Souza
AU  - Santos RA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Peptides
JT  - Peptides
JID - 8008690
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/03/19 [received]
PHST- 2013/05/16 [revised]
PHST- 2013/05/18 [accepted]
AID - S0196-9781(13)00201-5 [pii]
AID - 10.1016/j.peptides.2013.05.010 [doi]
PST - aheadofprint
SO  - Peptides. 2013 May 25. pii: S0196-9781(13)00201-5. doi:
      10.1016/j.peptides.2013.05.010.

PMID- 23714172
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
DP  - 2013 May 25
TI  - Early-Life Overweight Trajectory and CKD in the 1946 British Birth Cohort Study.
LID - S0272-6386(13)00777-4 [pii]
LID - 10.1053/j.ajkd.2013.03.032 [doi]
AB  - BACKGROUND: Few studies have examined the impact of childhood obesity on later
      kidney disease, and consequently, our understanding is very limited. STUDY
      DESIGN: Longitudinal population-based cohort. SETTING & PARTICIPANTS: The Medical
      Research Council National Survey of Health and Development, a socially stratified
      sample of 5,362 singletons born in 1 week in March 1946 in England, Scotland, and
      Wales, of which 4,340 were analyzed. PREDICTOR: Early-life overweight latent
      classes (never, prepubertal only, pubertal onset, or always), derived from
      repeated measurements of body mass index between ages 2 and 20 years. OUTCOMES & 
      MEASUREMENTS: The primary outcome was chronic kidney disease (CKD), defined as
      creatinine- or cystatin C-based estimated glomerular filtration rate (eGFRcr and 
      eGFRcys, respectively) <60 mL/min/1.73 m2 or urine albumin-creatinine ratio
      (UACR) >/=3.5 mg/mmol measured at age 60-64 years. Associations were explored
      through regression analysis, with adjustment for socioeconomic position, smoking,
      physical activity level, diabetes, hypertension, and overweight at ages 36 and 53
      years. RESULTS: 2.3% of study participants had eGFRcr <60 mL/min/1.73 m2, 1.7%
      had eGFRcys <60 mL/min/1.73 m2, and 2.9% had UACR >/=3.5 mg/mmol. Relative to
      being in the never-overweight latent class, being in the pubertal-onset- or
      always-overweight latent classes was associated with eGFRcys-defined CKD (OR,
      2.04; 95% CI, 1.09-3.82). Associations with CKD defined by eGFRcr (OR, 1.27; 95% 
      CI, 0.71-2.29) and UACR (OR, 1.33; 95% CI, 0.70-2.54) were less marked, but in
      the same direction. Adjustment for lifestyle and health factors had little impact
      on effect estimates. LIMITATIONS: A low prevalence of CKD resulted in low
      statistical power. No documentation of chronicity for outcomes. All-white study
      population restricts generalizability. CONCLUSIONS: Being overweight in early
      life was found to be associated with eGFRcys-defined CKD in later life. The
      associations with CKD defined by eGFRcr and UACR were less marked, but in the
      same direction. Reducing or preventing overweight in the early years of life may 
      significantly reduce the burden of CKD in the population.
CI  - Copyright (c) 2013 National Kidney Foundation, Inc. Published by Elsevier Inc.
      All rights reserved.
AD  - Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and 
      Population Health, London School of Hygiene and Tropical Medicine, University of 
      London, London. Electronic address: richard.silverwood@lshtm.ac.uk.
FAU - Silverwood, Richard J
AU  - Silverwood RJ
FAU - Pierce, Mary
AU  - Pierce M
FAU - Hardy, Rebecca
AU  - Hardy R
FAU - Thomas, Claudia
AU  - Thomas C
FAU - Ferro, Charles
AU  - Ferro C
FAU - Savage, Caroline
AU  - Savage C
FAU - Sattar, Naveed
AU  - Sattar N
FAU - Kuh, Diana
AU  - Kuh D
FAU - Nitsch, Dorothea
AU  - Nitsch D
CN  - National Survey of Health and Development Scientific and Data Collection Teams
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/10/02 [received]
PHST- 2013/03/07 [accepted]
AID - S0272-6386(13)00777-4 [pii]
AID - 10.1053/j.ajkd.2013.03.032 [doi]
PST - aheadofprint
SO  - Am J Kidney Dis. 2013 May 25. pii: S0272-6386(13)00777-4. doi:
      10.1053/j.ajkd.2013.03.032.

PMID- 23714158
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1600-0641 (Electronic)
IS  - 0168-8278 (Linking)
DP  - 2013 May 25
TI  - The Metabolomic Window into Hepatobiliary Disease.
LID - S0168-8278(13)00362-0 [pii]
LID - 10.1016/j.jhep.2013.05.030 [doi]
AB  - The emergent discipline of metabolomics has attracted considerable research
      effort in hepatology. Here we review the metabolomic data for nonalcoholic fatty 
      liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cirrhosis,
      hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), alcoholic liver disease
      (ALD), hepatitis B and C, cholecystitis, cholestasis, liver transplantation and
      acute hepatotoxicity in animal models. A metabolomic window has permitted a view 
      into the changing biochemistry occurring in the transitional phases between a
      healthy liver and hepatocellular carcinoma or cholangiocarcinoma. Whether
      provoked by obesity and diabetes, alcohol use or oncogenic viruses, the liver
      develops a core metabolomic phenotype (CMP) that involves dysregulation of bile
      acid and phospholipid homeostasis. The CMP commences at the transition between
      the healthy liver (Phase 0) and NAFLD/NASH, ALD or viral hepatitis (Phase 1).
      This CMP is maintained in the presence or absence of cirrhosis (Phase 2) and
      whether or not either HCC or CCA (Phase 3) develop. Inflammatory signalling in
      the liver triggers the appearance of the CMP. Many other metabolomic markers
      distinguish between Phases 0, 1, 2 and 3. A metabolic remodelling in HCC has been
      described but metabolomic data from all four Phases demonstrate that the Warburg 
      shift from mitochondrial respiration to cytosolic glycolysis foreshadows HCC and 
      may occur as early as Phase 1. The metabolic remodelling also involves an
      upregulation of fatty acid beta-oxidation, also beginning in Phase 1. The storage
      of triglycerides in fatty liver provides high energy-yielding substrates for
      Phases 2 and 3 of liver pathology. The metabolomic window into hepatobiliary
      disease sheds new light on the systems pathology of the liver.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Hepatology Research Group Department of Clinical Research University of Bern,
      Bern Switzerland.
FAU - Beyoglu, Diren
AU  - Beyoglu D
FAU - Idle, Jeffrey R
AU  - Idle JR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - J Hepatol
JT  - Journal of hepatology
JID - 8503886
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/04/07 [received]
PHST- 2013/05/14 [revised]
PHST- 2013/05/21 [accepted]
AID - S0168-8278(13)00362-0 [pii]
AID - 10.1016/j.jhep.2013.05.030 [doi]
PST - aheadofprint
SO  - J Hepatol. 2013 May 25. pii: S0168-8278(13)00362-0. doi:
      10.1016/j.jhep.2013.05.030.

PMID- 23714100
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
DP  - 2013 May 29
TI  - The impact of type 2 diabetes mellitus on mortality in hospitalized female cancer
      patients in Taiwan.
LID - 10.1111/ajco.12084 [doi]
AB  - INTRODUCTION: The goal of this study was to determine the relationships among
      type 2 diabetes mellitus (DM), specific cancer histological types and mortality
      in hospitalized women. METHODS: Patients over 19 years of age were included if
      the indication for hospital admission was a diagnosis of type 2 DM or a
      malignancy. In total, 67 660 female patients with a mean age 62.76 +/- 14.48
      years were enrolled. These patients were categorized into the following three
      groups: patients with cancer but without type 2 DM (group A); patients with
      cancer and type 2 DM (group B) and patients with type 2 DM but without cancer
      (group C). Attributable fractions (AF) were calculated as ([hazard ratio -
      1]/hazard ratio) x 100 to evaluate the impact of type 2 DM on mortality for
      specific cancers. RESULTS: Of the study participants, 37 204 (55%) were diagnosed
      with type 2 DM. The patients were categorized as follows: group A, 30 456
      patients; group B, 5992 patients and group C, 31 212 patients. Group B patients
      had high frequencies of pancreatic, liver and renal cancers and low frequencies
      of thyroid, breast and ovarian cancers. Of the 36 448 cancer patients, 2906 (8%) 
      died. The mortality rate in group B (10 %) was significantly higher than that in 
      groups A and C. Type 2 DM was associated with increased mortality and AF for
      thyroid, nasopharyngeal, urinary tract, ovarian, breast and cervical cancers
      (hazard ratio over 1.50). CONCLUSION: The incidence of type 2 DM in patients with
      different histological types of cancer varied widely, ranging from 8-34%. Among
      the cancer patients, type 2 DM had a significantly greater impact on the
      mortality rates of patients with cancers associated with relatively low
      mortality.
CI  - (c) 2013 Wiley Publishing Asia Pty Ltd.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang 
      Gung Memorial Hospital, Chang Gung University, Taoyuan Hsien, Taiwan.
FAU - Chen, Jeng-Yeou
AU  - Chen JY
FAU - Chiou, Wen-Ko
AU  - Chiou WK
FAU - Chou, Wei-Ying
AU  - Chou WY
FAU - Lin, Jen-Der
AU  - Lin JD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/04/14 [accepted]
AID - 10.1111/ajco.12084 [doi]
PST - aheadofprint
SO  - Asia Pac J Clin Oncol. 2013 May 29. doi: 10.1111/ajco.12084.

PMID- 23714083
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1542-474X (Electronic)
IS  - 1082-720X (Linking)
VI  - 18
IP  - 3
DP  - 2013 May
TI  - Quantitative electrocardiographic measures, neuromuscular disorders, and survival
      in left ventricular hypertrabeculation/noncompaction.
PG  - 251-5
LID - 10.1111/anec.12053 [doi]
AB  - BACKGROUND: Left ventricular hypertrabeculation/noncompaction (LVHT) is
      frequently associated with neuromuscular disorders (NMDs) and
      electrocardiographic (ECG) abnormalities. Quantitative ECG-measures (QEMs) are
      risk markers for mortality in cardiomyopathies. We measured QEMs in the ECGs in
      LVHT patients with and without NMDs. METHODS: Included were patients in whom (a) 
      LVHT was diagnosed between 1995 and 2011 and (b) baseline ECG recordings were
      available. All underwent a clinical examination and were invited for a
      neurological investigation. QRS duration, QT, QTc and PR intervals were analyzed.
      Survival status was assessed in June 2011. RESULTS: In 141 patients (mean age 54 
      years, 49 females) QRS duration ranged from 40 to 200 ms, a QRS duration >120 ms 
      was found in 19% and was associated with increased age, heart failure, left
      ventricular dilatation and systolic dysfunction (P < 0.001). QT intervals ranged 
      from 240 to 600 ms. The QTc intervals ranged from 302 to 612 ms, a QTc interval
      >440 ms was found in 38% and was associated with left ventricular dilatation and 
      systolic dysfunction (P < 0.001). PR intervals ranged from 90 to 360 ms, a PR
      interval >200 ms was found in 16% and associated with left ventricular dilatation
      (P < 0.01). No QEM differences were found in 86 patients with and 13 without NMD.
      During 59 months follow-up 45 patients died. QEMs were no mortality predictors,
      whereas multivariate analysis identified heart failure (P < 0.01), atrial
      fibrillation (P < 0.01) and diabetes mellitus (P < 0.05) as mortality predictors.
      CONCLUSIONS: Prolonged QRS complexes, PR and QTc intervals in LVHT are associated
      with heart failure and left ventricular dilatation, but not with NMD. The
      prognostic role of QEMs in LVHT needs further investigations in larger series.
CI  - (c)2013, Wiley Periodicals, Inc.
AD  - Krankenanstalt Rudolfstiftung, Wien, Austria.
FAU - Stollberger, Claudia
AU  - Stollberger C
FAU - Gerger, Daniel
AU  - Gerger D
FAU - Wegner, Christian
AU  - Wegner C
FAU - Finsterer, Josef
AU  - Finsterer J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Noninvasive Electrocardiol
JT  - Annals of noninvasive electrocardiology : the official journal of the
      International Society for Holter and Noninvasive Electrocardiology, Inc
JID - 9607443
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1111/anec.12053 [doi]
PST - ppublish
SO  - Ann Noninvasive Electrocardiol. 2013 May;18(3):251-5. doi: 10.1111/anec.12053.

PMID- 23714080
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1542-474X (Electronic)
IS  - 1082-720X (Linking)
VI  - 18
IP  - 3
DP  - 2013 May
TI  - Electrocardiographic predictors of sudden cardiac death in patients with left
      ventricular hypertrophy.
PG  - 225-9
LID - 10.1111/anec.12003 [doi]
AB  - BACKGROUND: Left ventricular hypertrophy (LVH) has been associated with increased
      risk of sudden cardiac death (SCD), and improvements in risk stratification
      methodology are warranted. METHODS: We evaluated electrocardiographic intervals
      as potential markers of SCD risk in LVH. Corrected QT, QRS, and JT intervals were
      evaluated in consecutive cases with SCD and LVH from the ongoing Oregon Sudden
      Unexpected Death study who underwent a 12-lead electrocardiogram (EKG) and
      echocardiogram prior to and unrelated to the SCD event. Comparisons of age,
      gender, body mass index, LV ejection fraction, and EKG intervals together with
      clinical conditions (hypertension and diabetes) were conducted with
      geographically matched controls that had coronary artery disease but no history
      of ventricular arrhythmias or cardiac arrest. LVH was determined using the
      modified American Society of Echocardiography equation for LV mass. Independent
      samples t-test, Pearson's chi-square test, and multiple logistic regression were 
      used for statistical comparisons. RESULTS: Of the 109 cases and 49 controls who
      met study criteria, age, gender, and comorbidities were similar among cases and
      controls. The mean LV mass index was not significantly different in cases
      compared to controls. However mean QTc (470.6 +/- 53.6 ms vs 440.7 +/- 38.7 ms; P
      < 0.0001) and QRS duration (113.6 +/- 30.0 ms vs 104.9 +/- 18.7 ms; P = 0.03)
      were significantly higher in cases than controls. In logistic regression
      analysis, prolonged QTc was the only EKG interval significantly associated with
      SCD (OR 1.72 [1.23-2.40]). CONCLUSION: Prolonged QTc was independently associated
      with SCD among subjects with LVH and merits further evaluation as a predictor of 
      SCD in LVH.
CI  - (c)2012, Wiley Periodicals, Inc.
AD  - Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
FAU - Panikkath, Ragesh
AU  - Panikkath R
FAU - Reinier, Kyndaron
AU  - Reinier K
FAU - Uy-Evanado, Audrey
AU  - Uy-Evanado A
FAU - Teodorescu, Carmen
AU  - Teodorescu C
FAU - Gunson, Karen
AU  - Gunson K
FAU - Jui, Jonathan
AU  - Jui J
FAU - Chugh, Sumeet S
AU  - Chugh SS
LA  - eng
GR  - R01 HL088416/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20121122
PL  - United States
TA  - Ann Noninvasive Electrocardiol
JT  - Annals of noninvasive electrocardiology : the official journal of the
      International Society for Holter and Noninvasive Electrocardiology, Inc
JID - 9607443
SB  - IM
PMC - PMC3671480
MID - NIHMS407858
OID - NLM: NIHMS407858 [Available on 05/01/14]
OID - NLM: PMC3671480 [Available on 05/01/14]
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PMCR- 2014/05/01 00:00
PHST- 2012/11/22 [aheadofprint]
AID - 10.1111/anec.12003 [doi]
PST - ppublish
SO  - Ann Noninvasive Electrocardiol. 2013 May;18(3):225-9. doi: 10.1111/anec.12003.
      Epub 2012 Nov 22.

PMID- 23714003
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1476-8321 (Electronic)
IS  - 0887-0446 (Linking)
DP  - 2013 May 29
TI  - 'It's not a disease, it's a nuisance': Controlling diabetes and achieving goals
      in the context of men with Type 1 diabetes.
AB  - Despite a steady growth in research into men's health, little is known about how 
      men experience life with a chronic illness like Type 1 diabetes. To address this 
      knowledge gap, we conducted an interview study with 15 men who have Type 1
      diabetes. Following grounded theory analysis of the interview transcripts, we
      generated a number of inter-related themes which were then formulated as a theory
      of adjustment to life with Type 1 diabetes. This theory indicates that men reduce
      the seriousness of diabetes by defining it in ways other than a serious illness. 
      By viewing diabetes in this way, men are then able to prioritise the pursuit of
      their personal goals over adherence to the diabetes regimen. Finally, men
      reassess their relationship with diabetes in light of diabetes-related
      complications. The goal of this process is to find the 'best fit' for diabetes in
      their lives - a place which will allow them to pursue and satisfy their personal 
      goals. As men progress through life, personal goals may change and so too will
      their relationship with diabetes.
AD  - a Division of Psychology , Nottingham Trent University , Nottingham , UK.
FAU - O'Hara, Lesley
AU  - O'Hara L
FAU - Gough, Brendan
AU  - Gough B
FAU - Seymour-Smith, Sarah
AU  - Seymour-Smith S
FAU - Watts, Simon
AU  - Watts S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Psychol Health
JT  - Psychology & health
JID - 8807983
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1080/08870446.2013.800516 [doi]
PST - aheadofprint
SO  - Psychol Health. 2013 May 29.

PMID- 23713896
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1557-9077 (Electronic)
IS  - 1050-7256 (Linking)
DP  - 2013 May 28
TI  - Persistent cAMP Signaling by TSH Receptors Revealed by Phosphodiesterase
      Inhibition.
AB  - Background: It is controversial whether persistent signaling by TSH receptor
      (TSHR) is cell type-specific. We reported persistent TSHR signaling in HEK293
      cells expressing human TSHRs (HEK-TSHRs) whereas another group reported
      persistent signaling in mouse thyroid follicles but not in HEK293 cells. Herein, 
      we test this hypothesis directly. Methods: We used two methods to measure
      persistent signaling in HEK-TSHRs and confirm our previous observations. In
      Method 1, we used a chemiluminescent immunoassay to measure intracellular cAMP
      accumulation over 30 to 60 min by adding a phosphodiesterase inhibitor to the
      incubation medium. In Method 2, we used an intracellular biosensor to record cAMP
      levels continuously. Results: Using Method 1, we show that TSHR signals
      persistently in human thyrocytes and U2OS-TSHR cells. Using Method 1 in
      HEK-TSHRs, we showed that after 5 min the phosphodiesterase inhibitor
      isobutylmethylxanthine (IBMX) increased cAMP to 2.5 pmol/well, TSH increased cAMP
      to 1.6 pmol/well but IBMX added 30 min after TSH withdrawal increased cAMP to 105
      pmol/well. Using Method 2 in HEK-TSHRs, we confirmed that without IBMX, TSH
      caused a transient increase in cAMP and 30 min after TSH withdrawal, IBMX
      increased cAMP in cells pretreated with TSH more rapidly and to a higher level
      than IBMX added to cells not pre-exposed to TSH. Lastly, using Method 2, we
      showed that in HEK-TSHRs phosphodiesterases types 3 and 4 are involved in
      degrading cAMP as the specific inhibitors Rolipram and Milrinone expose
      persistent TSHR signaling. Conclusions: We conclude that persistent TSHR
      activation occurs in human thyrocytes, U2OS-TSHR cells and HEK-TSHRs, is not cell
      type-specific but may be revealed by inhibiting phosphodiesterases.
AD  - National Institutes of Diabetes, Digestive & Kidney,, Laboratory of Endocrinolgy 
      and Receptor Biology, Bethesda, Maryland, United States ;
      Egraaka@intra.niddk.nih.gov.
FAU - Geras-Raaka, Elizabeth
AU  - Geras-Raaka E
FAU - Neumann, Susanne
AU  - Neumann S
FAU - Gershengorn, Marvin C
AU  - Gershengorn MC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Thyroid
JT  - Thyroid : official journal of the American Thyroid Association
JID - 9104317
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1089/thy.2013.0089 [doi]
PST - aheadofprint
SO  - Thyroid. 2013 May 28.

PMID- 23713872
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
DP  - 2013 May 16
TI  - Pharmacologic role of vitamin D natural products.
AB  - Vitamin D is essential for maintaining a healthy mineral and bone metabolism. It 
      stimulates calcium and phosphate absorption by the intestine, regulates bone
      metabolism, and negatively controls PTH secretion through the endocrine action of
      its active metabolite calcitriol. Vitamin D possesses also a variety of effect
      unrelated with mineral and bone metabolism, including the regulation of arterial 
      blood pressure and the prevention of cardiovascular complications, modulation of 
      immunological responses, regulation of insulin production and prevention against 
      diabetes, protection against certain cancers, renoprotection, and other
      beneficial actions. This article provides an update review of the sources and
      pharmacological characteristics of natural vitamin D compounds, their most
      clinical uses, and their most important clinical results.
AD  - Dr. Jean Claude Souberbielle. Service de physiologie et d'explorations
      fonctionnelles renales. Hopital Necker-Enfants Malades. 161, rue de Sevres. 75015
      Paris. France.
FAU - Urena-Torres, Pablo
AU  - Urena-Torres P
FAU - Souberbielle, Jean Claude
AU  - Souberbielle JC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2012/11/17 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/04/26 [accepted]
AID - CVP-EPUB-20130516-4 [pii]
PST - aheadofprint
SO  - Curr Vasc Pharmacol. 2013 May 16.

PMID- 23713866
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1535-3907 (Electronic)
IS  - 1535-3893 (Linking)
DP  - 2013 May 28
TI  - Metabolic Phenotype Modulation by Caloric Restriction in a Life-Long Dog Study.
AB  - Modeling aging and age-related pathologies presents a substantial analytical
      challenge given the complexity of gene-environment influences and interactions
      operating on an individual. A top-down systems approach is used to model the
      effects of life-long caloric restriction, which is known to extend life span in
      several animal models. The metabolic phenotypes of caloric restricted (CR n = 24)
      and pair-housed control fed (CF n = 24) Labrador Retriever dogs were investigated
      using Orthogonal Projection to Latent Structures-Discriminant Analysis (OPLS-DA) 
      to establish both generic and age-specific responses to caloric restriction from 
      the 1H NMR blood serum profiles of young and older dogs. Three aging metabolic
      phenotypes were resolved, the first was an aging metabolic phenotype independent 
      of diet, characterized by high levels of glutamine, creatinine, methylamine,
      dimethylamine, trimethylamine-N-oxide and glycerophosphocholine and decreasing
      levels of glycine, aspartate, creatine and citrate indicative of metabolic
      changes associated largely with muscle mass. A second aging metabolic phenotype
      specific to CR dogs which consisted of relatively lower levels of glucose,
      acetate, choline and tyrosine and relatively higher levels of phosphocholine
      associated with beneficial aging outcomes and preservation of neurological
      function. The third aging metabolic phenotype was specific to CF dogs and
      included lower levels of liproprotein fatty acyl groups, allantoin and relatively
      higher levels of formate, which were indicative of metabolic risk factors
      associated with obesity, diabetes and blood pressure. There was no diet
      metabotype that consistently differentiated the CF and CR fed dogs irrespective
      of age. However, it was observed that creatine and amino acids; valine, leucine, 
      isoleucine, lysine, and phenylalanine were lower in the CR fed dogs (<312 weeks),
      suggestive of differences in energy source utilization. Glucose consistently
      discriminated feeding regime in dogs (>= 312 weeks), being relatively lower in
      the CR group. 1H NMR spectroscopic analysis of longitudinal serum profiles
      enabled an unbiased evaluation of the metabolic markers modulated by life-time of
      caloric restriction. OPLS-DA provided a framework, such that significant
      metabolites relating to life extension could be differentiated and integrated
      with aging processes.
FAU - Richards, Selena Elizabeth
AU  - Richards SE
FAU - Wang, Yulan
AU  - Wang Y
FAU - Claus, Sandrine Paule
AU  - Claus SP
FAU - Lawler, Dennis
AU  - Lawler D
FAU - Kochhar, Sunil
AU  - Kochhar S
FAU - Holmes, Elaine
AU  - Holmes E
FAU - Nicholson, Jeremy Kirk
AU  - Nicholson JK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Proteome Res
JT  - Journal of proteome research
JID - 101128775
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1021/pr301097k [doi]
PST - aheadofprint
SO  - J Proteome Res. 2013 May 28.

PMID- 23713864
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
DP  - 2013 May 13
TI  - The Role of microRNA-126 in Vascular Homeostasis.
AB  - MicroRNAs are negative regulators of gene expression that have been shown to be
      essential elements in the coordination of complex regulatory pathways. One of
      these short non-coding RNAs, microRNA-126, is highly enriched in the vascular
      endothelium and was shown to play distinct roles in angiogenesis, vasculogenesis 
      and endothelial inflammation. Abrogation of this microRNA leads to severe
      complications in the response in vascular development as well as vital repair
      mechanisms carried out by endothelial cells. Interestingly, recent data suggests 
      that the homeostatic role of microRNA-126 may reach far beyond its endothelial
      functions as this microRNA was also found to be present in cells of the
      hematopoietic system and in microvesicles or 'free-form' in the periphery.
      MicroRNA-126 is controlling the fate and/or function of a variety of cells
      differentiating from the hematopoietic lineage, including megakaryocytes and
      erythrocytes. Recent studies identified circulating microRNA-126 as a biomarker
      for myocardial injury and vascular damage in diabetes. Furthermore, reports have 
      suggested a protective role of circulating microRNA-126 in murine models of organ
      ischemia. Here, we review current insights in the role microRNA-126 in vascular
      homeostasis and conclude that this microRNA may serve to integrate and facilitate
      both local as well as systemic functions in vascular maintenance and repair.
AD  - Department of Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 
      ZA Leiden, The Netherlands. a.j.vanzonneveld@lumc.nl.
FAU - Solingen, Coen van
AU  - Solingen CV
FAU - Bijkerk, Roel
AU  - Bijkerk R
FAU - de Boer, Hetty C
AU  - de Boer HC
FAU - Rabelink, Ton J
AU  - Rabelink TJ
FAU - Zonneveld, Anton Jan van
AU  - Zonneveld AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/01/04 [received]
PHST- 2013/02/05 [revised]
PHST- 2013/02/08 [accepted]
AID - CVP-EPUB-20130513-7 [pii]
PST - aheadofprint
SO  - Curr Vasc Pharmacol. 2013 May 13.

PMID- 23713841
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1574-888X (Print)
VI  - 8
IP  - 4
DP  - 2013 Jul 1
TI  - Hematopoietic transplants for disease suppression and cure in type 1 diabetes.
PG  - 333-9
AB  - Recent clinical studies have demonstrated the capacity of immunosuppressive
      therapy to delay progression of inflammatory insulitis in type 1 diabetes (T1D). 
      The procedure includes depletion of pathogenic cells by immunosuppressive therapy
      and support of recovery by reinfusion of autologous hematopoietic progenitors.
      The short-term outcome of these clinical transplants is similar to the
      predictions drawn from NOD mice: debulking of diabetogenic cells is ineffectively
      achieved by immunosuppressive therapy, and resetting of immune homeostasis does
      not restrain autoimmunity. Murine models indicate that allogeneic transplants are
      potentially curative, through restored mechanisms of negative regulation that are
      effective in continuous and indefinite suppression of autoimmunity.
AD  - Frankel Laboratory, Schneider Children's Medical Center of Israel, 14 Kaplan
      Street, Petach Tikva 49202, Israel. anadir@012.net.il.
FAU - Askenasy, Nadir
AU  - Askenasy N
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Stem Cell Res Ther
JT  - Current stem cell research & therapy
JID - 101272517
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/04/01 [received]
PHST- 2013/05/10 [revised]
PHST- 2013/05/10 [accepted]
AID - CSCRT-EPUB-20130524-1 [pii]
PST - ppublish
SO  - Curr Stem Cell Res Ther. 2013 Jul 1;8(4):333-9.

PMID- 23713771
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
DP  - 2013 May 22
TI  - Molecular Characterization of the Hetero-Assembly of beta-Amyloid Peptide with
      Islet Amyloid Polypeptide.
AB  - Increasing amounts of evidence suggest that Alzheimer's disease (AD) and type 2
      diabetes (T2D) are linked to each other. We have recently identified in vitro a
      high affinity interaction between beta-amyloid peptide (Abetaof AD and islet
      amyloid polypeptide (IAPP) of T2D which results in the formation of non-fibrillar
      and non-cytotoxic Abeta-IAPP hetero-oligomers. The Abeta-IAPP interaction delays 
      cytotoxic self-association of both polypeptides albeit it is unable to block it. 
      In this context, IAPP-GI, a soluble conformationally constrained mimic of a
      non-amyloidogenic and non-toxic IAPP conformer, completely blocks Abeta
      amyloidogenesis and cytotoxicity. Here we studied the hetero-association pathways
      of Abeta with IAPP and with IAPP-GI. We found that preformed Abeta or IAPP
      fibrils and cytotoxic assemblies are able to seed amyloidogenesis and
      cytotoxicity in Abeta-IAPP but not in Abeta-IAPP-GI solutions. Initially
      non-fibrillar and non-toxic Abeta-IAPP but not Abeta-IAPP-GI hetero-oligomers
      were found to further aggregate into hetero-fibrils and cytotoxic assemblies in a
      process strongly enhanced under Abeta or IAPP self-assembly promoting conditions.
      Importantly, our studies provided evidence that initially non-fibrillar and
      non-toxic Abeta-IAPP hetero-oligomers are able to misfold into hetero-fibrils and
      indicated a crucial role of the strong amyloidogenic character of IAPP in this
      process. These results uncover a novel molecular property of the Abeta and IAPP
      sequences, i.e. their ability to form hetero-fibrils, and offer mechanistic
      support to a model linking Abeta and IAPP hetero-association to their cytotoxic
      self-association pathways and thus likely to the pathogenesis of AD and T2D.
AD  - Division of Peptide Biochemistry Technische Universitat Munchen
      Emil-Erlenmeyer-Forum 5 D-85354 Freising Germany. akapurniotu@wzw.tum.de.
FAU - Yan, Li-Mei
AU  - Yan LM
FAU - Velkova, Aleksandra
AU  - Velkova A
FAU - Kapurniotu, Aphrodite
AU  - Kapurniotu A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/04/17 [received]
PHST- 2013/05/21 [accepted]
AID - CPD-EPUB-20130522-2 [pii]
PST - aheadofprint
SO  - Curr Pharm Des. 2013 May 22.

PMID- 23713741
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 35
IP  - 6
DP  - 2013 Jul
TI  - Echocardiographic evaluation of epicardial adipose tissue in non-diabetic,
      non-hypertensive hemodialysis patients.
PG  - 891-5
LID - 10.3109/0886022X.2013.794682 [doi]
AB  - Abstract Purpose: It has been found out that the epicardial adipose tissue (EAT) 
      measured by echocardiography is related with various metabolic parameters. Being 
      accepted as the new cardiovascular risk indicator, there have been few studies on
      EAT in relation to the patients with end-stage renal failure. In our study, we
      aim to evaluate EAT and carotid intima media thickness (CIMT) in non-diabetic,
      non-hypertensive hemodialysis (HD) patients. Methods: Our study recruited 47
      non-diabetic, non-hypertensive HD patients (22 males, 25 females, median age 54
      (44.3-60.8) years) and an age-gender matched control group consisting 41 healthy 
      subjects (17 males, 24 females, median age 52 (48-56) years). In all patients,
      EAT was measured by echocardiography and CIMT by ultrasonography; and routine
      laboratory parameters were studied. Results: In our study, we obtained laboratory
      findings matching with the profiles of uremic patients among HD patients and CIMT
      values of HD patients are significantly higher than that of the control group
      [0.79 (0.64-0.93) vs. 0.6 (0.53-0.68) p < 0.001], and EAT values are similar [0.5
      (0.33-0.6) vs. 0.4 (0.4-0.53) p > 0.05]. Conclusions: EAT is not a cardiovascular
      risk indicator in HD patients without diabetes mellitus and hypertension.
      Besides, echocardiographic measurement of EAT is easy, non-invasive, cheap and
      credible method.
AD  - Department of Nephrology, Hitit University Corum Education and Research Hospital 
      , Corum , Turkey .
FAU - Ozkurt, Sultan
AU  - Ozkurt S
FAU - Karavelioglu, Yusuf
AU  - Karavelioglu Y
FAU - Musmul, Ahmet
AU  - Musmul A
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/05/28 [aheadofprint]
AID - 10.3109/0886022X.2013.794682 [doi]
PST - ppublish
SO  - Ren Fail. 2013 Jul;35(6):891-5. doi: 10.3109/0886022X.2013.794682. Epub 2013 May 
      28.

PMID- 23713695
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
DP  - 2013 May 24
TI  - The Need for Physiologically Relevant Peroxisome Proliferator-Activated
      Receptor-gamma (PPAR-gamma) Ligands.
AB  - Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a nuclear
      transcription factor which is involved in the differentiation of fibroblasts to
      adipocytes in vitro. PPAR-gamma also plays a pivotal role in inflammation and
      macrophage activation. Furthermore, type 2 diabetes mellitus (T2DM), a condition 
      in which an individual's ability to respond to insulin is lowered, is treated by 
      drugs called thiazolidinediones (TZDs) that are known to activated PPAR-gamma,
      thus augmenting insulin signaling and glucose uptake by adipose tissue.
      Unfortunately, these otherwise effective drugs are responsible for side effects
      such as obesity and cardiovascular diseases. The ligand-binding ability of
      PPAR-gamma is different from other nuclear receptors since it can bind to a wide 
      variety of ligands. Although a number of compounds have been shown to activate
      PPAR-gamma, knowledge of its endogenous ligands and their physiological functions
      is lacking. The known ligands were either ambiguous or found to produce ill
      effects in vivo. In this review we discuss the structure and functions of
      PPAR-gamma, ligands discovered so far, and focus on the importance of
      identification of physiologically relevant endogenous ligands.
AD  - Department of Zoology, Yogi Vemana University, Kadapa - 516003, AP. India.
      nvrr@yogivemanauniversity.ac.in.
FAU - Subramani, Parasuraman Aiya
AU  - Subramani PA
FAU - Reddy, Madhava C
AU  - Reddy MC
FAU - Narala, Venkata R
AU  - Narala VR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/02/26 [received]
PHST- 2013/04/22 [revised]
PHST- 2013/04/26 [accepted]
AID - CDTIEMD-EPUB-20130524-1 [pii]
PST - aheadofprint
SO  - Endocr Metab Immune Disord Drug Targets. 2013 May 24.

PMID- 23713686
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1651-1999 (Electronic)
IS  - 0803-7051 (Linking)
DP  - 2013 May 29
TI  - Meta-analysis of three observational studies of amlodipine/valsartan in
      hypertensive patients with additional risk factors.
AB  - Objectives. In this study, the effectiveness of amlodipine/valsartan single-pill 
      combination was assessed in hypertensive patients with diabetes, metabolic risk
      or overweight. Methods. Data from 12,265 patients treated with
      amlodipine/valsartan from three studies were analyzed in a meta-analysis. These
      studies focused on (i) non-diabetic hypertensive patients suffering from
      abdominal obesity; (ii) hypertensive patients with at least one metabolic risk
      factor; and (iii) hypertensive patients with type 2 diabetes mellitus. The
      observation periods were 16 weeks for the first two and 24 weeks for the latter
      cohort. Results. At start of observation, the mean blood pressure was 162.3 mmHg 
      (systolic) and 93.5 mmHg (diastolic). A total of 7.4% of patients were aged >/=
      80 years. At end of the observation, a normalized blood pressure was present in
      38.8% of patients. No appreciable differences in blood pressure reduction were
      evident between the study groups. In both age subgroups (< 80 years and >/= 80
      years) blood pressure reduction was comparable. Tolerability was assessed by
      treating physicians as "very good" (69.3%) and "good" (27.3%). Conclusions. In
      daily practice, treatment of hypertensive patients with additional risk factors
      with amlodipine/valsartan single-pill combinations is well tolerated and
      associated with effective reduction of blood pressure.
AD  - Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr 
      University Bochum , Bad Oeynhausen , Germany.
FAU - Eckert, Siegfried
AU  - Eckert S
FAU - Freytag, Siegfried B
AU  - Freytag SB
FAU - Muller, Alfons
AU  - Muller A
FAU - Klebs, Sven H G
AU  - Klebs SH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Blood Press
JT  - Blood pressure
JID - 9301454
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.3109/08037051.2013.793891 [doi]
PST - aheadofprint
SO  - Blood Press. 2013 May 29.

PMID- 23713595
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1541-2563 (Electronic)
IS  - 1541-2563 (Linking)
VI  - 10
IP  - 3
DP  - 2013 Jun
TI  - Impact of co-morbidities on self-rated health in self-reported COPD: An analysis 
      of NHANES 2001-2008.
PG  - 324-32
LID - 10.3109/15412555.2012.744963 [doi]
AB  - Abstract Chronic Obstructive Pulmonary Disease (COPD) coexists with
      co-morbidities. While co-morbidity has been associated with poorer health status,
      it is unclear which conditions have the greatest impact on self-rated health. We 
      sought to determine which, and how much, specific co-morbid conditions impact on 
      self-rated health in current and former smokers with self-reported COPD. Using
      the 2001-2008 National Health and Nutrition Examination Survey we characterized
      the association between thirteen co-morbidities and health status among
      individuals self-reporting COPD. Adjusted odds ratios (ORs) were generated using 
      ordinal logistic regression. Additionally we evaluated the impact of increasing
      number of co-morbidities with self-rated health. Eight illnesses had significant 
      associations with worse self-rated health, however after mutually adjusting for
      these conditions, congestive heart failure (OR 3.07, 95% CI 1.69-5.58), arthritis
      (OR 1.69, 95% CI 1.13-2.52), diabetes (OR 1.63, 95% CI 1.01-2.64), and
      incontinence/prostate disease (OR 1.63, 95% CI 1.01-2.62) remained independent
      predictors of self-rated health. Each increase in co-morbidities was associated
      with a 43% higher chance of worse self-rated health (95% CI 1.27-1.62).
      Individuals with COPD have a substantial burden of co-morbidity, which is
      associated with worse self-rated health. CHF, arthritis, diabetes and
      incontinence/prostate disease have the most impact on self-rated health.
      Targeting these co-morbidities in COPD may result in improved self-rated health.
AD  - 1Johns Hopkins School of Medicine, Department of Medicine, Division of Pulmonary 
      and Critical Care Medicine , Baltimore, Maryland , USA.
FAU - Putcha, Nirupama
AU  - Putcha N
FAU - Puhan, Milo A
AU  - Puhan MA
FAU - Hansel, Nadia N
AU  - Hansel NN
FAU - Drummond, M Brad
AU  - Drummond MB
FAU - Boyd, Cynthia M
AU  - Boyd CM
LA  - eng
PT  - Journal Article
PL  - England
TA  - COPD
JT  - COPD
JID - 101211769
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.3109/15412555.2012.744963 [doi]
PST - ppublish
SO  - COPD. 2013 Jun;10(3):324-32. doi: 10.3109/15412555.2012.744963.

PMID- 23713524
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Linking)
DP  - 2013 May 28
TI  - Collagen IV-Modified Scaffolds Improve Islet Survival and Function and Reduce
      Time to Euglycemia.
AB  - Islet transplantation on extracellular matrix (ECM) protein-modified
      biodegradable microporous poly(lactide-co-glycolide) (PLG) scaffolds is a
      potential curative treatment for type 1 diabetes mellitus (T1DM). Collagen
      IV-modified scaffolds, relative to control scaffolds, significantly decreased the
      time required to restore euglycemia from 17 to 3 days. We investigated the
      processes by which collagen IV-modified scaffolds enhanced islet function and
      mediated early restoration of euglycemia post-transplantation. We characterized
      the effect of collagen IV-modified scaffolds on islet survival, metabolism and
      insulin secretion in vitro and early and intermediate-term islet mass and
      vascular density post-transplantation and correlated these with early restoration
      of euglycemia in a syngeneic mouse model. Control scaffolds maintained native
      islet morphologies and architectures as well as collagen IV-modified scaffolds in
      vivo. Islet size and vascular density increased while beta-cell proliferation
      decreased from day 16 to 113 post-transplantation. Collagen IV-modified scaffolds
      promoted islet cell viability and decreased early-stage apoptosis in islet cells 
      in vitro - phenomena that coincided with enhanced islet metabolic function and
      glucose-stimulated insulin secretion. These findings suggest that collagen
      IV-modified scaffolds promote the early restoration of euglycemia
      post-transplantation by enhancing islet metabolism and glucose-stimulated insulin
      secretion. These studies of ECM proteins, in particular collagen IV, and islet
      function provide key insights for the engineering of a microenvironment that
      would serve as a platform for enhancing islet transplantation as a viable
      clinical therapy for T1DM.
AD  - Northwestern University, Biomedical Engineering, Evanston, Illinois, United
      States ; woonteck@northwestern.edu.
FAU - Yap, Woon Teck
AU  - Yap WT
FAU - Salvay, David M
AU  - Salvay DM
FAU - Silliman, Michael A
AU  - Silliman MA
FAU - Zhang, Xiaomin
AU  - Zhang X
FAU - Bannon, Zachary G
AU  - Bannon ZG
FAU - Kaufman, Dixon B
AU  - Kaufman DB
FAU - Lowe, William
AU  - Lowe W
FAU - Shea, Lonnie D
AU  - Shea LD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
AID - 10.1089/ten.TEA.2013.0033 [doi]
PST - aheadofprint
SO  - Tissue Eng Part A. 2013 May 28.

PMID- 23713195
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Treatment of diabetic macular oedema in a type 1 diabetes patient--mistakes in
      interdisciplinary collaboration].
PG  - 231-3
AB  - Diabetic retinopathy (DR) is a significant microvascular complication of
      diabetes. High quality interdisciplinary collaboration is an important aspect ofa
      successful DR therapy. A case ofa 41-year-old diabetic is presented below, who
      has been in our care for almost four years. His Diabetes ID card only contains
      his current glycaemia values. Although the patient had been regularly given a
      report for his diabetologist with a request for additional information, we have
      only obtained one value of glycated haemoglobin through the course of the
      patient's dispensarisation. For this reason, and the non-stabilisation of DR, we 
      have recommended that the patient starts to see a different diabetologist.
AD  - Oftalmologicka klinika 3. Iekarske fakulty UK a FN Kralovske Vinohrady Praha.
      mveith@email.cz
FAU - Veith, M
AU  - Veith M
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Reseni diabetickeho makularniho edemu u diabetika 1. typu--chyby v mezioborove
      spolupraci.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):231-3.

PMID- 23713194
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Diabetic macular oedema in the third trimester of pregnancy].
PG  - 227-30
AB  - The authors describe a case of a female patient with diabetes mellitus (DM) type 
      1 who faced a progress of diabetic retinopathy (DR) during her pregnancy with a
      development of diabetic macular oedema (DMO) and a deterioration of visual acuity
      (VA) in the right eye. The patient had been under observation for DM for 18
      years, the last six years for the onset of the non-proliferative form of DR.
      During the 28th week of pregnancy, a significant reduction of visual acuity in
      the patient's right eye occurred as a result of a fast developing DMO. The
      patient was generally given corticosteroids for a gynaecological indication to
      accelerate the maturing of the foetus. Betamethasone (Diprophos) in dose 12 mg
      with intramuscular application was administered twice in total, i.e. in the 29th 
      and the 32rd week of pregnancy. After each application, a good effect was
      observed on the improvement of the visual acuity accompanied by a DMO reduction. 
      However, the effect of corticosteroids was only temporary and at the end of their
      application in each case, a fast reduction of VA and a progression of DMO were
      observed, even though retinal laser photocoagulation was initiated. Delivery via 
      Caesarean section was indicated in the 35th week of pregnancy, after a
      consultation with a diabetologist, gynaecologist and ophthalmologist. The
      delivery went without complications; both the child and the mother were in a
      normal condition after the delivery. A gradual improvement in VA was observed
      during the post-delivery period, with a reduction of DMO until a level of VA that
      corresponded to the status before the pregnancy was reached.
AD  - Ocni klinika Lekarske fakulty UP a FN Olomouc. simicak@gmail.com
FAU - Simicak, J
AU  - Simicak J
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Diabeticky makularni edem v poslednim trimestru gravidity.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):227-30.

PMID- 23713191
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Diabetic retinopathy in the Czech National Diabetes Programme 2012-2022].
PG  - 214-7
AB  - Diabetic retinopathy (DR) develops in patients with both type 1 and type 2
      diabetes and is the major cause of vision loss and blindness in people of working
      age. In the Czech Republic, the number of patients with diabetic retinopathy is
      still increasing as well as the number of diabetic patients. It is known, that
      the comprehensive preventive and therapeutic procedures reduce the risk of visual
      loss by more than 90%. These procedures include intervention of modifiable risk
      factors (especially hypertension and hyperglycaemia), active screening of DR and 
      specialized ophthalmologic treatment. The Czech National Diabetes Programme
      2012-2022, which is built on similar initiatives as in 1984 and 2000, has been
      completed in late 2012. Its main goal is to improve the health outcomes for
      people diabetes in the Czech Republic. The programme includes specific procedures
      aimed at improvement of organization and treatment providing to patients with
      diabetic retinopathy.
AD  - Centrum diabetologie IKEM Praha. terezie.pelikanova@ikem.cz
FAU - Pelikanova, T
AU  - Pelikanova T
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Diabeticka retinopatie v narodnim diabetologickem programu 2012-2022.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):214-7.

PMID- 23713190
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Present and future of insulin treatment].
PG  - 209-13
AB  - The main goal of modern insulin treatment is to bring diabetes control to
      physiological regulation as close as possible. We move from human insulin to
      insulin analogues which may due to their properties reduce glucose excursions
      (glucose variability) with hypoglycemic and hyperglycemic episodes. Besides short
      acting insulin analogues diminishing extension of hyperinsulinemia and
      postprandial hypoglycemia observed by human insulin treatment, the long-acting
      analogues are used to create stabilized insulin level and to prevent nocturnal
      hypoglycemia. Individualized insulin treatment is the basement for modern trends 
      in diabetology.
AD  - III Interni klinika 1. lekarske fakulty UK a VFN Praha. jan.skrha@lf1.cuni.cz
FAU - Skrha, J
AU  - Skrha J
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Soucasnost a perspektivy lecby inzulinem.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):209-13.

PMID- 23713189
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Incretin therapy and diabetic retinopathy].
PG  - 204-7
AB  - Therapy based on incretins presents a new group of medicinal substances
      designated for an intervention in patients with type 2 diabetes. It includes a
      therapy that is efficient, safe and effective. Its advantage is a low risk of
      hypoglycaemia and a positive effect on body weight. The analyses that have been
      published so far consistently indicate a positive impact on cardiovascular risk
      factors. The first studies conducted on animal models prove a favourable
      influence ofincretin therapy on the pathophysiology of diabetic retinopathy.
AD  - Interni klinika 2. lekarske fakulty UKa FN Motol Praha. Interna@fnmotol.cz
FAU - Kvapil, M
AU  - Kvapil M
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Inkretinova terapie a diabeticka retinopatie.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):204-7.

PMID- 23713188
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Diabetic nephropathy/diabetic kidney disease].
PG  - 201-3
AB  - Diabetic kidney disease (DKD), which belongs to the triad of diabetic
      microvascular complications, is currently the main cause of end-stage renal
      disease in developed countries. DKD usually simultaneously leads to a
      deteriorated long-term control of glucose metabolism and blood pressure, and to
      the development of diabetic retinopathy, neuropathy and atherosclerotic
      complications, which are the main causes of patients' mortality. Screening of the
      initial stages of DKD is to be based on the detection of increased albumin leak
      into the urine, microalbuminuria, and the reduction of renal function by means of
      estimates of glomerular filtration rate based on the serum creatinine level. The 
      main objective of the prophylactic and treatment measures is to prevent the onset
      of DKD, or at least to stop its transition into an irreversible, progressive
      stage characterised by a permanent, often nephrotic proteinuria. The basic
      procedures in the prevention and treatment of DKD are maintaining the optimal
      metabolic control of diabetes and intensive hypertension treatment based on the
      inhibition of the renin-angiotensin system. Reaching the stage of progressive
      renal insufficiency (serum creatinine level approximately > or = 200 micromol/l) 
      is an indication for further follow-up in the nephrology department, which will
      then take the necessary preparatory measures for dialysis treatment. The optimal 
      method of kidney function replacement for patients with DKD is kidney
      transplantation, or combined kidney-pancreas transplantation in patients with
      type 1 diabetes.
AD  - Centrum diabetologie IKEM Praha. petr.boucek@ikem.cz
FAU - Boucek, P
AU  - Boucek P
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Diabeticka nefropatie/diabeticke onemocneni ledvin.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):201-3.

PMID- 23713187
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Treatment of diabetic macular oedema].
PG  - 194-200
AB  - Diabetic macular oedema (DMO) is currently the main complication associated with 
      diabetes. The percentage of patients with DMO grows alongside the increasing
      number of diabetes occurrences. The DMO treatment has seen major developments in 
      the past few years. A number of new treatment technologies have emerged, which
      enable not only a stabilisation of macular oedema but in the case of an early
      detection also a decrease of retina oedema accompanied by a visual functions
      improvement. Laser coagulation has remained the standard DMO treatment for many
      years; when applying modern diagnostic testing technologies (FAG and OCT), the
      newest trend in DMO treatment is the use of anti-VEGF preparations, depot
      intravitreal corticoids and in some cases also surgical intervention in the form 
      of pars plana vitrectomy (PPV). The DMO treatment algorithm is presented in this 
      paper.
AD  - Ocni klinika 1. lekarske fakulty UK a UVN Praha. ernesjan@uvn.cz
FAU - Ernest, J
AU  - Ernest J
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Lecba diabetickeho makularniho edemu.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):194-200.

PMID- 23713185
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Present state of diagnostic and screening of the diabetic retinopathy and
      diabetic macular oedema].
PG  - 182-6
AB  - Diabetic retinopathy (DR) and its complications are worldwide one ofthe main
      causes ofthe visual impairment and blindness. An incidence of DR is substantially
      raised due to increasing amount of diabetic patients in population. Systematic
      screening of diabetic eye complications makes possible a timely incorporation of 
      patients with diabetes mellitus to a lifelong preventive ophthalmological
      treatment. According to an extent of progress of the DR, these patients are
      treated by retinal laser coagulation or inhibitors of growth factors and/or
      surgical treatment of retinal complications by the pars plana vitrectomy.
      Essential aspects of the effective prevention of the origin and development of
      diabetic eye complications are cooperation of diabetologist and ophthalmologist, 
      education of patients and their active approach to the treatment.
AD  - Ocni klinika 1. lekarske fakulty UKa VFN Praha. kalvodova.bohdana@vfn.cz
FAU - Kalvodova, B
AU  - Kalvodova B
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Soucasny stav diagnostiky a screeningu diabeticke retinopatie a diabetickeho
      makularniho edemu.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):182-6.

PMID- 23713184
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Risk factors for diabetic retinopathy].
PG  - 177-81
AB  - Risk factors for diabetic retinopathy can be divided into modifiable and non
      modifiable. Non modifiable include the type of diabetes, age of the patient at
      the time of onset, duration, and genetic factors. Primarily it can be influenced 
      by glycemic control, as well as systemic factors such as blood pressure, serum
      lipids. Concomitant diseases also affect diabetic retinopathy. The article also
      mentions the risk of rapid compensation and iatrogenic influences.
AD  - Centrum diabetologie IKEM Praha. tomas.sosna@ftn.cz
FAU - Sosna, T
AU  - Sosna T
FAU - Svancarova, R
AU  - Svancarova R
FAU - Netukova, M
AU  - Netukova M
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Rizikove faktory diabeticke retinopatie.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):177-81.

PMID- 23713183
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Patophysiology of diabetic retinopathy].
PG  - 173-6
AB  - Diabetic retinopathy (DR) is the affection of the retina in patients with
      diabetes mellitus (DM). The basic causative factor is prolonged hyperglycaemia.
      DR is microangiopathy, ie impairment of retinal capillaries. Pathophysiology of
      DR is very complex and there are involved in many factors. The first and most
      fundamental factor is the failure blood-retinal barrier (BRB). The major
      mechanism causing malfunction of BRB are advanced glycation end-products (AGE).
      In the failure of the inner BRB are involved losses of endothelial cells in
      capillaries, together with the losses of pericytes. A very important role in the 
      failure of BRB plays too increased adhesivity of leukocytes. Further important
      role play also AGE and their receptor RAGE. They stimulate cascade of
      pathological processes damaging BRB. The second important factors in the
      pathophysiology of DR are vasoactive factors. The most important is vascular
      endothelial growth factor (VEGF), further than protein kinase C (PKC), histamine,
      angiotensin II, matrix metaloproteinases. The third important factor in the
      pathophysiology of DR is the vitreoretinal interface. There plays important role 
      detachment of posterior vitreous, cortical vitreous, internal limiting membrane.
AD  - Ocni klinika Lekarske fakulty MU a FN Brno, pracoviste Bohunice.
      pkolar@med.muni.cz
FAU - Kolar, P
AU  - Kolar P
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Patofyziologie diabeticke retinopatie.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):173-6.

PMID- 23713182
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes 
      mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28
      diabetology departments in the Czech Republic - BIBY-I study (observations
      lasting 3 to 12 months)].
PG  - 165-71
AB  - BIBY STUDY OBJECTIVE: To obtain experience with exenatide treatment (Byetta) in
      patients with diabetes mellitus type 2 in a common clinical practice
      ofdiabetology departments. TYPE OF OBSERVATION: Observational study conducted by 
      a randomly selected group of outpatient medical practitioners from 28 diabetology
      departments in the Czech Republic. OBSERVED AND ASSESSED POPULATION: 465 patients
      underwent at least three months of Byetta treatment; 347 persons (74.6% ofthe
      research population) stayed forthe extended observation of 6-12 months. Apart
      from the basic identification data (year of birth, sex, age when diabetes
      mellitus manifested, height, maximum patient weight before diabetes and when
      diabetes mellitus manifested), the following information was recorded in
      three-month intervals: weight, waistline, glycated haemoglobin (HbA(1c)), and
      diabetes mellitus treatment The population included 50.3% women and 49.7% men,
      and the average age at the time of diabetes manifestation was 48 (20-73 years).
      The period between the diabetes manifestation and the start of exenatide
      treatment was 8.3 years on average. RESULTS: The average maximum BMI value before
      the detection of diabetes was 39.05 (+/- 6.73); at the time of the diabetes
      manifestation 37.88 (+/- 6.40); and at the start of Byetta treatment 39.01 (+/-
      6.22). The BMI after three, six, and 12 months of treatment was as follows: 37.86
      (+/- 6.12), 37.18 (+/- 6.0), and 36.60 (+/- 6.21); it decreased by > or = 0.5 in 
      83.3% patients who were under observation for 12 months. HbA(1c) value decreased 
      in the first three months from 7.39% (+/- 1.57) to 6.41% (+/- 1.34), p < 0.0001. 
      In the period of three-six months, the value decreased to 6.22% (+/- 1.34), and
      after 12 months, HbA(1c) was at 6.04 (+/- 1.20). An improvement in HbA(1c) value 
      of 0.5-2.0% occurred after the first year in 49% of our research population. The 
      waistline was measured on a regular basis in only 267 patients (58.9%). The
      average initial value of 120.7 cm was reduced within three months of the
      treatment to 118.3 cm, and within six and 12 months to 117.3 and 112.6 cm
      respectively. CONCLUSION: Adding Byetta to the currently applied treatment of
      obese patients with diabetes mellitus type 2 led, in 66.8% of the population, to 
      a statistically significant reduction in HbA(1c) levels in the first three-six
      months of the treatment; after 12 months of treatment, 25% of the population was 
      still showing an improvement in HbA(1c) of > 2.0%. Of observed patients, 74.4%
      significantly reduced their BMI (by > 0.5) during the first three months; 39.6%
      of patients reduced their BMI in the period of three-six months.
AD  - Interni klinika 2. Iekarske fakulty UK a FN Motol Praha.
      jindra.perusicova@seznam.cz
FAU - Perusicova, J
AU  - Perusicova J
FAU - Haladova, I
AU  - Haladova I
FAU - Pit'hova, P
AU  - Pit'hova P
FAU - Acsova, D
AU  - Acsova D
FAU - Belobradkova, J
AU  - Belobradkova J
FAU - Belzova, A
AU  - Belzova A
FAU - Berkova, K
AU  - Berkova K
FAU - Dolezalova, B
AU  - Dolezalova B
FAU - Dvorakova, H
AU  - Dvorakova H
FAU - Hejnicova, K
AU  - Hejnicova K
FAU - Hudcova, M
AU  - Hudcova M
FAU - Kallmunzerova, D
AU  - Kallmunzerova D
FAU - Krejsova, Z
AU  - Krejsova Z
FAU - Markofova, G
AU  - Markofova G
FAU - Mullerova, H
AU  - Mullerova H
FAU - Owen, K
AU  - Owen K
FAU - Pelikanova, M
AU  - Pelikanova M
FAU - Raclavska, L
AU  - Raclavska L
FAU - Racicka, E
AU  - Racicka E
FAU - Skarpova, O
AU  - Skarpova O
FAU - Vachova, A
AU  - Vachova A
FAU - Vesela, A
AU  - Vesela A
FAU - Vyoralos, J
AU  - Vyoralos J
FAU - Broz, J
AU  - Broz J
FAU - Edelsberger, T
AU  - Edelsberger T
FAU - Honka, M
AU  - Honka M
FAU - Hrdina, T
AU  - Hrdina T
FAU - Chmura, P
AU  - Chmura P
FAU - Tosovsky, J
AU  - Tosovsky J
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Zmeny hmotnosti a kompenzace diabetu (HbA(1c)) u nemocnych s diabetes mellitus 2.
      tpu po pridani exenatidu (Byetta) ke stavajici lecbe ve 28 diabetologickych
      ambulancich v CR--studie BIBY-I (sledovani 3-12 mesicu).
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):165-71.

PMID- 23713181
OWN - NLM
STAT- In-Process
DA  - 20130529
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 3
DP  - 2013 Mar
TI  - [What has the largest study in the history of diabetology brought us?].
PG  - 160-4
AB  - The main objective of the ORIGIN study was an observation of the effects of
      treatment with insulin analogue, insulin glargine on cardiovascular complications
      in patients with severe atherosclerosis and early stages of well-compensated
      diabetes and prediabetes. The authors expected that a long-term reduction of
      glycaemia on an empty stomach will reduce the number of occurrences of
      cardiovascular complications. The study, which was conducted over a period of
      more than six years, showed neither a positive nor a negative effect of insulin
      treatment on cardiovascular complications. The second main objective of the study
      was the following: to compare the effect of the omega-3 fatty acid treatment
      versus placebo on the development of cardiovascular complications. However, no
      influence of n-3 fatty acids on the development of cardiovascular complications
      was found. The study investigated whether the insulin glargine treatment leads to
      an increased number of cancer occurrences. No correlation between cancer and the 
      insulin glargine treatment was proven in this study. Long-term insulin treatment 
      in the early stages of diabetes led to a minimal increase in weight through the
      course of six years (1.5 kg) and to three times more hypoglycaemia occurrences
      compared to placebo. However, the number of hypoglycaemia occurrences was very
      small. Conclusion: The study has confirmed the safety of the insulin glargine
      treatment combined with metformin in the early stages of diabetes, without an
      increased number of atherosclerosis or cancer occurrences, and with minimal
      weight gain.
AD  - I. Interni klinika Lekarske fakulty UKa FN Plzen. RUSAVY@fnplzen.cz
FAU - Rusavy, Z
AU  - Rusavy Z
FAU - Lacigova, S
AU  - Lacigova S
FAU - Kvapil, M
AU  - Kvapil M
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Co nam prinesla nejvetsi studie v historii diabetologie?
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/30 06:00
MHDA- 2013/05/30 06:00
CRDT- 2013/05/30 06:00
PST - ppublish
SO  - Vnitr Lek. 2013 Mar;59(3):160-4.

PMID- 23712986
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 4
DP  - 2013 Apr
TI  - Association between adiponectin and heart failure risk in the physicians' health 
      study.
PG  - 831-4
LID - 10.1002/oby.20260 [doi]
AB  - OBJECTIVE: To assess the association between adiponectin and incident heart
      failure (HF). DESIGN AND METHODS: In the current ancillary study to the
      Physicians' Health Study (PHS), we used a prospective nested case-control design 
      to examine whether plasma adiponectin concentration was related to the risk of
      HF. We selected 787 incident HF cases and 787 matched controls for the current
      analysis. Each control was selected using a risk set sampling technique at the
      time of the occurrence of the index case and matched on year of birth, age at
      blood collection, and race. Adiponectin was measured using enzyme-linked
      immunosorbent assay. HF occurrence was self-reported in annual follow-up
      questionnaire. Validation of self-reported HF in this cohort has been published. 
      RESULTS: The mean age was 58.7 years. In a conditional logistic regression
      adjusting for age, race, time of blood collection, year of birth, hypertension,
      atrial fibrillation, smoking, alcohol intake, and exercise, estimates of the
      relative risk (95% confidence interval) were 1.0 (reference), 0.74 (0.53-1.04),
      0.67 (0.48-0.94), 0.70 (0.50-0.99), and 0.92 (0.65-1.30) from the lowest to the
      highest quintile of adiponectin, respectively, P for quadratic trend 0.004.
      Additional adjustment for potential mediating factors including diabetes,
      C-reactive protein, and BMI led to the attenuation of the estimate of effect (1.0
      (reference), 0.81 (0.57-1.15), 0.75 (0.53-1.06), 0.83 (0.58-1.18), and 1.26
      (0.87-1.81) across consecutive quintiles of adiponectin). CONCLUSIONS: Our data
      are consistent with a J-shaped association between total adiponectin and the risk
      of HF among US male physicians.
CI  - Copyright (c) 2012 The Obesity Society.
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, Massachusetts, USA; Department of Medicine, Division of Aging, The
      Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC) and
      Geriatric Research, Education, and Clinical Center (GRECC), Boston Veterans
      Affairs Healthcare System, Boston, Massachusetts, USA.
      ldjousse@rics.bwh.harvard.edu.
FAU - Djousse, Luc
AU  - Djousse L
FAU - Wilk, Jemma B
AU  - Wilk JB
FAU - Hanson, Naomi Q
AU  - Hanson NQ
FAU - Glynn, Robert J
AU  - Glynn RJ
FAU - Tsai, Michael Y
AU  - Tsai MY
FAU - Gaziano, J Michael
AU  - Gaziano JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2011/11/02 [received]
PHST- 2012/05/15 [accepted]
AID - 10.1002/oby.20260 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Apr;21(4):831-4. doi: 10.1002/oby.20260.

PMID- 23712978
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 4
DP  - 2013 Apr
TI  - Intestinal Methanobrevibacter smithii but not total bacteria is related to
      diet-induced weight gain in rats.
PG  - 748-54
LID - 10.1002/oby.20277 [doi]
AB  - It is increasingly understood that gastrointestinal (GI) methanogens, including
      Methanobrevibacter smithii, influence host metabolism. OBJECTIVE: Therefore, we
      compared M. smithii colonization and weight gain in a rat model under different
      dietary conditions. DESIGN AND METHODS: Sprague-Dawley rats were inoculated with 
      M. smithii or vehicle (N = 10/group), fed normal chow until day 112
      postinoculation, high-fat chow until day 182, then normal chow until day 253.
      Thereafter, five rats from each group were fed high-fat and normal chow until
      euthanasia. RESULTS: Both groups exhibited M. smithii colonization, which
      increased following inoculation only for the first 9 days. Change to high-fat
      chow correlated with significant increases in weight (P < 0.00001) and stool M.
      smithii (P < 0.01) in all rats, with stool M. smithi decreasing on return to
      normal chow. Rats switched back to high-fat on day 253 further increased weight
      (P < 0.001) and stool M. smithii (P = 0.039). Euthanasia revealed all animals had
      higher M. smithii, but not total bacteria, in the small intestine than in the
      colon. Rats switched back to high-fat chow had higher M. smithii levels in the
      duodenum, ileum, and cecum than those fed normal chow; total bacteria did not
      differ in any bowel segment. Rats which gained more weight had more bowel
      segments colonized, and the lowest weight recorded was in a rat on high-fat chow 
      which had minimal M. smithii colonization. CONCLUSIONS: We conclude that M.
      smithii colonization occurs in the small bowel as well as in the colon, and that 
      the level and extent of M. smithii colonization is predictive of degree of weight
      gain in this animal model.
CI  - Copyright (c) 2012 The Obesity Society.
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine,
      Cedars-Sinai Medical Center, Los Angeles, California, USA.
FAU - Mathur, Ruchi
AU  - Mathur R
FAU - Kim, Gene
AU  - Kim G
FAU - Morales, Walter
AU  - Morales W
FAU - Sung, Jaekyu
AU  - Sung J
FAU - Rooks, Emily
AU  - Rooks E
FAU - Pokkunuri, Venkata
AU  - Pokkunuri V
FAU - Weitsman, Stacy
AU  - Weitsman S
FAU - Barlow, Gillian M
AU  - Barlow GM
FAU - Chang, Christopher
AU  - Chang C
FAU - Pimentel, Mark
AU  - Pimentel M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/02/02 [received]
PHST- 2012/05/08 [accepted]
AID - 10.1002/oby.20277 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Apr;21(4):748-54. doi: 10.1002/oby.20277.

PMID- 23712970
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 4
DP  - 2013 Apr
TI  - Effect of dietary composition of weight loss diets on high-sensitivity c-reactive
      protein: The Randomized POUNDS LOST trial.
PG  - 681-9
LID - 10.1002/oby.20072 [doi]
AB  - OBJECTIVE: Overweight and obesity are associated with increased high-sensitivity 
      C-reactive protein (hsCRP) levels. The purpose of this study was to determine if 
      weight loss diets differing in fat, protein, or carbohydrate composition
      differentially reduce hsCRP. DESIGN AND METHODS: POUNDS (preventing overweight
      using novel dietary strategies) LOST was a 2-year trial of overweight and obese
      adults randomly allocated to one of four weight loss diets with targeted
      percentages of energy derived from fat, protein, and carbohydrates (20, 15, 65%; 
      20, 25, 55%; 40, 15, 45%; 40, 25, 35%, respectively). hsCRP was measured at
      baseline, 6, and 24 months among 710 participants, and adiposity as measured by
      dual X-ray absorptiometry (N = 340) or abdominal computed tomography (N = 126)
      was correlated with hsCRP change. RESULTS: At 6 months, hsCRP was reduced in all 
      trial participants by -24.7% (Interquartile range (IQR) +7%, -50%), weight by
      -6.7% (IQR -3%, -11%), and waist circumference by -6.0% (IQR -3%, -10%) (all P < 
      0.002), with no significant differences according to dietary composition. The
      percent change in hsCRP at 6 and 24 months correlated modestly with change in
      weight, waist circumference, fasting insulin, fasting glucose, HOMA, and most
      lipid levels. Reductions in hsCRP persisted despite approximately 50% regain of
      weight by 24 months. The percent change in hsCRP at 24 months significantly
      correlated with changes in total body fat (r = 0.42), total abdominal adiposity
      (r = 0.52), subcutaneous abdominal adiposity (r = 0.52), visceral adiposity (r = 
      0.47), and hepatic tissue density (r = -0.34) (all P < 0.0006). CONCLUSION:
      Weight loss decreased hsCRP by similar magnitude, irrespective of dietary
      composition. Clinicians concerned about inflammation and cardiovascular risk
      should recommend weight loss diets most likely to succeed for their patients.
CI  - Copyright (c) 2013 The Obesity Society.
AD  - Division of General Medicine and Primary Care, Beth Israel Deaconess Medical
      Center, Harvard Medical School, Brookline, Massachusetts, USA; Division of
      Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston,
      Massachusetts, USA. jnicklas1@partners.org.
FAU - Nicklas, Jacinda M
AU  - Nicklas JM
FAU - Sacks, Frank M
AU  - Sacks FM
FAU - Smith, Steven R
AU  - Smith SR
FAU - Leboff, Meryl S
AU  - Leboff MS
FAU - Rood, Jennifer C
AU  - Rood JC
FAU - Bray, George A
AU  - Bray GA
FAU - Ridker, Paul M
AU  - Ridker PM
LA  - eng
GR  - T32 AT000051/AT/NCCAM NIH HHS/United States
GR  - U01 HL073286/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
PMC - PMC3671388
MID - NIHMS414080
OID - NLM: NIHMS414080 [Available on 10/01/13]
OID - NLM: PMC3671388 [Available on 10/01/13]
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PMCR- 2013/10/01 00:00
PHST- 2012/03/06 [received]
PHST- 2012/08/29 [accepted]
AID - 10.1002/oby.20072 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Apr;21(4):681-9. doi: 10.1002/oby.20072.

PMID- 23712942
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1526-968X (Electronic)
IS  - 1526-954X (Linking)
DP  - 2013 May 25
TI  - The Foxa2-Venus fusion reporter mouse line allows live-cell analysis of
      endoderm-derived organ formation.
LID - 10.1002/dvg.22404 [doi]
AB  - SUMMARY: The Foxa2 winged helix/forkhead box transcription factor (TF) is
      absolutely required for endoderm formation and organogenesis. Foxa2 plays
      essential roles during lung, liver, pancreas and gastro-intestinal tract
      development and regulates cell-type specific programs in the adult organism. To
      specifically address Foxa2 function during organ development and homeostasis, we 
      generated a Foxa2-Venus fusion (FVF) reporter protein by gene targeting in
      embryonic stem (ES) cells. The FVF knock-in reporter is expressed under
      endogenous Foxa2 control and the fluorescent protein fusion does not interfere
      with TF function, as homozygous mice are viable and fertile. Moreover, the FVF
      protein localizes to the nucleus, associates with chromatin during mitosis and
      reflects the endogenous Foxa2 protein distribution pattern in several tissues in 
      heterozygous animals. Importantly, live-cell imaging on single-cell level of the 
      FVF and Sox17-Cherry fusion (SCF) double knock-in reporter ES cell line reveals
      the dynamics of endoderm TF accumulation during ES cell differentiation. The FVF 
      reporter also allowed us to identify the endoderm progenitors during gastrulation
      and to visualize the different branching morphogenesis modes of the lung and
      pancreas epithelium in ex vivo embryo and organ cultures. In summary, the
      generation of the FVF reporter line adds an important new tool to visualize and
      analyse endoderm-derived organ development and homeostasis on the cellular and
      molecular level. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc., a Wiley company.
AD  - Helmholtz Zentrum Munchen, Institute of Diabetes and Regeneration Research,
      Ingolstadter Landstrasse 1, D-85764 Neuherberg, Germany; Institute of Stem Cell
      Research, Ingolstadter Landstrasse 1, D-85764 Neuherberg, Germany.
FAU - Burtscher, Ingo
AU  - Burtscher I
FAU - Barkey, Wenke
AU  - Barkey W
FAU - Lickert, Heiko
AU  - Lickert H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Genesis
JT  - Genesis (New York, N.Y. : 2000)
JID - 100931242
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/28 [received]
PHST- 2013/05/14 [revised]
PHST- 2013/05/18 [accepted]
AID - 10.1002/dvg.22404 [doi]
PST - aheadofprint
SO  - Genesis. 2013 May 25. doi: 10.1002/dvg.22404.

PMID- 23712872
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1559-0283 (Electronic)
IS  - 1085-9195 (Linking)
DP  - 2013 May 28
TI  - The Electrophoretical Determination of Serum Protein Fractions in Lycopene
      Treated Experimental Diabetic Rats.
AB  - This study was planned to determine the effects of lycopene treatment on serum
      protein fractions in experimental diabetic rats. In order to induce diabetes in
      rats in the diabetes (D) and diabetes + lycopene (DL) groups, rats were given 45 
      mg/kg single-dose streptozotocin intraperitoneally. Lycopene (10 mg/kg/day
      dissolved in sunflower oil) was administered to the rats in the lycopene-only (L)
      and DL groups. Blood glucose levels and HbA1c% in DL group and diabetes group
      increased (p < 0.05) compared to control and L group. Total protein, albumin,
      alpha1, alpha2, and beta globulin fractions of diabetic and DL groups were lower 
      than control and L groups (p < 0.05). D group had lowest gamma (gamma) globulin
      levels among other groups (p < 0.05). The gamma globulin levels was slightly
      increased than diabetic groups (D and DL), but it was still lower than control
      and L groups (p < 0.05). The highest value of A/G ratio was observed in diabetic 
      group. Similarly, the % level of A/G ratio of D group was higher than other
      groups. It was noted that the A/G ratio decreased and reached to control group
      levels after lycopene treatment.
AD  - Biochemistry Department, Veterinary Medicine School, Yuzuncu Yil University,
      65080, Van, Turkey.
FAU - Yuksek, Veysel
AU  - Yuksek V
FAU - Dede, Semiha
AU  - Dede S
FAU - Ceylan, Ebubekir
AU  - Ceylan E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Cell Biochem Biophys
JT  - Cell biochemistry and biophysics
JID - 9701934
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.1007/s12013-013-9660-2 [doi]
PST - aheadofprint
SO  - Cell Biochem Biophys. 2013 May 28.

PMID- 23712867
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1559-0283 (Electronic)
IS  - 1085-9195 (Linking)
DP  - 2013 May 28
TI  - Integrin-Linked Kinase Inhibition Attenuates Permeability of the
      Streptozotocin-Induced Diabetic Rat Retina.
AB  - Integrin-linked kinase (ILK), as a multi-functional regulator, has been
      associated with diabetic retinopathy (DR). In this study, we investigated whether
      inhibition of ILK could result in therapeutic effects. Diabetes mellitus's rats
      were induced by streptozotocin (STZ) injection. After 1 weeks induction, rats
      were injected intraperitoneally daily with ILK inhibitor, QLT0267, at 5 mg/kg.
      Then, the rats were examined by 4, 8, and 12 weeks after first STZ injection. We 
      found that QLT0267 treatment could not only lower ILK level in retina at as early
      as 3 weeks after the onset of diabetes but also attenuate retina permeability,
      which was measured by Evan's blue. Maximum effect was found in 11 weeks
      treatment. Meanwhile, QLT0267 did not disturbed blood glucose concentration.
      Furthermore, QLT0267 inhibited Akt (Ser473) activation and reduced expression of 
      HIF1alpha and VEGF which were evaluated by western blot, real time PCR, and
      immunohistochemistry. We conclude that ILK may be a new target for DR.
AD  - Department of Ophthalmology, Tangdu Hospital, The Fourth Military Medical
      University of PLA, Xian, People's Republic of China, fmmuliyjun@gmail.com.
FAU - Li, Yangjun
AU  - Li Y
FAU - Zhang, Jie
AU  - Zhang J
FAU - Yan, Hong
AU  - Yan H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Cell Biochem Biophys
JT  - Cell biochemistry and biophysics
JID - 9701934
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.1007/s12013-013-9647-z [doi]
PST - aheadofprint
SO  - Cell Biochem Biophys. 2013 May 28.

PMID- 23712834
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1559-0720 (Electronic)
IS  - 0163-4984 (Linking)
DP  - 2013 May 29
TI  - Development of New Zinc Dithiosemicarbazone Complex for Use as Oral Antidiabetic 
      Agent.
AB  - The increasing prevalence of diabetes mellitus (DM) worldwide has underscored the
      urgency of developing an efficient therapeutic agent. Recently, Zn complexes have
      been attracting attention due to their antidiabetic activity. In this study, we
      designed and synthesized a new Zn complex, Zn-3,4-heptanedione-bis(N
      4-methylthiosemicarbazonato) (Zn-HTSM), characterized its physicochemical
      properties, and examined its antidiabetic activity in KK-Ay type 2 DM model mice.
      It was demonstrated that Zn-HTSM has adequate lipophilicity for the cellular
      permeability, shows potent hypoglycemic activity, and improves glucose
      intolerance in KK-Ay mice. We also analyzed the levels of serum adipokines after 
      continuous oral administration of Zn-HTSM. The level of serum leptin of KK-Ay
      mice is significantly reduced by the treatment of Zn-HTSM. Nevertheless, the
      levels of serum insulin and adiponectin were not improved. These data suggested
      that the Zn-HTSM acts on the leptin metabolism. Our present studies indicate that
      Zn-HTSM is a candidate oral antidiabetic agent for the treatment of type 2 DM.
AD  - Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama
      University, 1-1-1 Tsushimanaka, Kita-ku, Okayama, 700-8530, Japan.
FAU - Kadowaki, Saori
AU  - Kadowaki S
FAU - Munekane, Masayuki
AU  - Munekane M
FAU - Kitamura, Yoji
AU  - Kitamura Y
FAU - Hiromura, Makoto
AU  - Hiromura M
FAU - Kamino, Shinichiro
AU  - Kamino S
FAU - Yoshikawa, Yutaka
AU  - Yoshikawa Y
FAU - Saji, Hideo
AU  - Saji H
FAU - Enomoto, Shuichi
AU  - Enomoto S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/20 [received]
PHST- 2013/05/13 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 10.1007/s12011-013-9704-x [doi]
PST - aheadofprint
SO  - Biol Trace Elem Res. 2013 May 29.

PMID- 23712652
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 28
TI  - Temporal Profile of Diabetic Nephropathy Pathologic Changes.
AB  - Diabetic nephropathy, by far, is the most common cause of end stage renal disease
      in the US and many other countries. In type 1 diabetes, the natural history of
      diabetic nephropathy is tightly linked to evolution of classic lesions of the
      disease, namely glomerular basement membrane thickening, increased mesangial
      matrix, and reduced glomerular filtration surface density. These lesions progress
      in parallel and correlate with increased albumin excretion rate and reduced
      glomerular filtration rate across a wide range of renal function. In fact, the
      vast majority of the variances of albumin excretion and glomerular filtration
      rates can be explained by these glomerular lesions alone in type 1 diabetic
      patients. Although, classic lesions of diabetic nephropathy, indistinguishable
      from those of type 1 diabetes, also occur in type 2 diabetes, renal lesions are
      more heterogeneous in type 2 diabetic patients with some patients developing more
      advanced vascular or chronic tubulointerstitial lesions than diabetic
      glomerulopathy. More research biopsy longitudinal studies, especially in type 2
      diabetic patients, are needed to better understand various pathways of renal
      injury in diabetic nephropathy.
AD  - Department of Pathology, University of Washington, 1959 NE Pacific St, Seattle,
      WA, Box 356100, 98195, USA.
FAU - Ponchiardi, Cecilia
AU  - Ponchiardi C
FAU - Mauer, Michael
AU  - Mauer M
FAU - Najafian, Behzad
AU  - Najafian B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.1007/s11892-013-0395-7 [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 28.

PMID- 23712594
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1573-3572 (Electronic)
IS  - 1068-9583 (Linking)
DP  - 2013 May 28
TI  - Psychological Treatment Improves Hemoglobin A1c Outcomes in Adolescents with Type
      1 Diabetes Mellitus.
AB  - Adolescents diagnosed with Type 1 Diabetes Mellitus often exhibit reduced
      adherence to their medical regimen and poor glycemic control. A retrospective
      study examined longitudinal hemoglobin A1c (HgbA1c) outcomes for adolescent
      patients referred to the psychology service embedded within an endocrinology
      clinic. Three patient groups were examined: (1) Treatment: 59 adolescents
      referred who engaged in psychotherapy; (2) No Treatment: 40 adolescents referred 
      yet failed to initiate psychotherapy; (3) Control: 58 adolescents not referred
      for treatment and matched on demographics to the two treatment groups. Over 1
      year, the Treatment group had a sustained decrease in HgbA1c while the No
      Treatment and Control groups had an overall increase in HgbA1c. At study end, the
      Treatment group had HgbA1c values that were not significantly different from
      patients who were not considered in need of psychological treatment (Control).
      Adolescents that utilized the pediatric psychology service saw decreased HgbA1c
      values over time.
AD  - Children's Hospital of Richmond, 1101 East Marshall Street, Richmond, VA, 23298, 
      USA, mbitsko@mcvh-vcu.edu.
FAU - Bitsko, Matthew J
AU  - Bitsko MJ
FAU - Bean, Melanie K
AU  - Bean MK
FAU - Bart, Sarah
AU  - Bart S
FAU - Foster, Rebecca H
AU  - Foster RH
FAU - Thacker, Leroy
AU  - Thacker L
FAU - Francis, Gary L
AU  - Francis GL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Clin Psychol Med Settings
JT  - Journal of clinical psychology in medical settings
JID - 9435680
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.1007/s10880-012-9350-z [doi]
PST - aheadofprint
SO  - J Clin Psychol Med Settings. 2013 May 28.

PMID- 23712539
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1437-7799 (Electronic)
IS  - 1342-1751 (Linking)
DP  - 2013 May 28
TI  - Prevalence of renal disease within an urban HIV-infected cohort in northern
      Italy.
AB  - BACKGROUND: Renal disease is an increasingly recognized noninfectious comorbidity
      associated with human immunodeficiency virus (HIV) infection. METHODS: Our
      retrospective, cross-sectional study evaluated prevalence of nephropathy among
      HIV-infected patients followed up in our outpatient clinic during the year 2011. 
      Renal dysfunction and chronic kidney disease (CKD) were defined as estimated
      glomerular filtration rate (eGFR) <90 ml/min per 1.73 m2 and as renal damage or
      eGFR <60 ml/min per 1.73 m2 over a 3-month or greater period, respectively.
      RESULTS: We enrolled 894 HIV-infected patients with a mean age of 44.2 years and 
      a mean current CD4 lymphocyte count of 508 cells/mm3. The prevalence of renal
      dysfunction and CKD was 27.4 and 21.3 %, respectively. Older age, male gender,
      hypertension, diabetes, proteinuria, hypertriglyceridemia, lower nadir CD4 cell
      count, current use of tenofovir or tenofovir plus a ritonavir-boosted protease
      inhibitor were independently associated with renal dysfunction. CONCLUSION: Renal
      dysfunction is a frequent comorbidity among HIV-infected persons and requires a
      careful clinical and laboratory monitoring of renal function.
AD  - Section of Infectious Diseases, Department of Medical and Surgical Sciences,
      "Alma Mater Studiorum" University of Bologna, S.Orsola-Malpighi Hospital, via G. 
      Massarenti 11, 40138, Bologna, Italy, leonardo.calza@unibo.it.
FAU - Calza, Leonardo
AU  - Calza L
FAU - Vanino, Elisa
AU  - Vanino E
FAU - Magistrelli, Eleonora
AU  - Magistrelli E
FAU - Salvadori, Caterina
AU  - Salvadori C
FAU - Cascavilla, Alessandra
AU  - Cascavilla A
FAU - Colangeli, Vincenzo
AU  - Colangeli V
FAU - Di Bari, Maria Assunta
AU  - Di Bari MA
FAU - Manfredi, Roberto
AU  - Manfredi R
FAU - Viale, Pierluigi
AU  - Viale P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Clin Exp Nephrol
JT  - Clinical and experimental nephrology
JID - 9709923
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/01 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 10.1007/s10157-013-0817-5 [doi]
PST - aheadofprint
SO  - Clin Exp Nephrol. 2013 May 28.

PMID- 23712504
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1877-8755 (Electronic)
IS  - 1138-7548 (Linking)
DP  - 2013 May 29
TI  - Exercise-induced changes of MCT1 in cardiac and skeletal muscles of diabetic rats
      induced by high-fat diet and STZ.
AB  - We hypothesized that a part of therapeutic effects of endurance training on
      insulin resistance is mediated by increase in cardiac and skeletal muscle
      mitochondrial lactate transporter, monocarboxylate transporter 1 (MCT1).
      Therefore, we examined the effect of 7 weeks endurance training on the mRNA and
      protein expression of MCT1 and MCT4 and their chaperon, CD147, on both
      sarcolemmal and mitochondrial membrane, separately, in healthy and type 2
      diabetic rats. Diabetes was induced by injection of low dose of streptozotocin
      and feeding with high-fat diet. Insulin resistance was confirmed by homeostasis
      model assessment-estimated insulin resistance index and accuracy of two membranes
      separation was confirmed by negative control markers (glucose transporter 1 and
      cytochrome c oxidase. Real-time PCR and western blotting were used for mRNA and
      protein expression, respectively. Diabetes dramatically reduced MCT1 and MCT4
      mRNA and their expression on sarcolemmal membrane whereas the reduction in MCT1
      expression was less in mitochondrial membrane. Training increased the MCT1 mRNA
      and protein expression in both membranes and decreased insulin resistance as an
      adaptive consequence. In both tissues increase in CD147 mRNA was only parallel to
      MCT1 expression. The response of MCT1 on sarcolemmal and mitochondrial membranes 
      was different between cardiac and skeletal muscles which indicate that
      intracellular lactate kinetic is tissue specific that allows a tissue to
      coordinate whole organism metabolism.
AD  - Department of Exercise Physiology, Faculty of Physical Education and Sport
      Science, Shahid Bahonar University of Kerman, Kerman, Iran.
FAU - Nikooie, Rohollah
AU  - Nikooie R
FAU - Rajabi, Hamid
AU  - Rajabi H
FAU - Gharakhanlu, Reza
AU  - Gharakhanlu R
FAU - Atabi, Fereshteh
AU  - Atabi F
FAU - Omidfar, Kobra
AU  - Omidfar K
FAU - Aveseh, Malihe
AU  - Aveseh M
FAU - Larijani, Bagher
AU  - Larijani B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - J Physiol Biochem
JT  - Journal of physiology and biochemistry
JID - 9812509
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/09/15 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/05/29 [aheadofprint]
AID - 10.1007/s13105-013-0263-6 [doi]
PST - aheadofprint
SO  - J Physiol Biochem. 2013 May 29.

PMID- 23712485
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 28
TI  - In antibody-positive first-degree relatives of patients with type 1 diabetes,
      HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes
      with distinct HLA-DQ interactions.
AB  - AIMS/HYPOTHESIS: Secondary type 1 diabetes prevention trials require selection of
      participants with impending diabetes. HLA-A and -B alleles have been reported to 
      promote disease progression. We investigated whether typing for HLA-B*18 and
      -B*39 may complement screening for HLA-DQ8, -DQ2 and -A*24 and autoantibodies
      (Abs) against islet antigen-2 (IA-2) and zinc transporter 8 (ZnT8) for predicting
      rapid progression to hyperglycaemia. METHODS: A registry-based group of 288
      persistently autoantibody-positive (Ab+) offspring/siblings (aged 0-39 years) of 
      known patients (Ab+ against insulin, GAD, IA-2 and/or ZnT8) were typed for
      HLA-DQ, -A and -B and monitored from the first Ab+ sample for development of
      diabetes within 5 years. RESULTS: Unlike HLA-B*39, HLA-B*18 was associated with
      accelerated disease progression, but only in HLA-DQ2 carriers (p < 0.006). In
      contrast, HLA-A*24 promoted progression preferentially in the presence of HLA-DQ8
      (p < 0.002). In HLA-DQ2- and/or HLA-DQ8-positive relatives (n = 246), HLA-B*18
      predicted impending diabetes (p = 0.015) in addition to HLA-A*24, HLA-DQ2/DQ8 and
      positivity for IA-2A or ZnT8A (p </= 0.004). HLA-B*18 interacted significantly
      with HLA-DQ2/DQ8 and HLA-A*24 in the presence of IA-2 and/or ZnT8 autoantibodies 
      (p </= 0.009). Additional testing for HLA-B*18 and -A*24 significantly improved
      screening sensitivity for rapid progressors, from 38% to 53%, among relatives at 
      high Ab-inferred risk carrying at least one genetic risk factor. Screening for
      HLA-B*18 increased sensitivity for progressors, from 17% to 28%, among
      individuals carrying >/=3 risk markers conferring >85% 5 year risk.
      CONCLUSIONS/INTERPRETATION: These results reinforce the importance of HLA class I
      alleles in disease progression and quantify their added value for preparing
      prevention trials.
AD  - Diabetes Research Center, Brussels Free University-VUB, Laarbeeklaan 103, 1090,
      Brussels, Belgium.
FAU - Mbunwe, E
AU  - Mbunwe E
FAU - Van der Auwera, B J
AU  - Van der Auwera BJ
FAU - Weets, I
AU  - Weets I
FAU - Van Crombrugge, P
AU  - Van Crombrugge P
FAU - Crenier, L
AU  - Crenier L
FAU - Coeckelberghs, M
AU  - Coeckelberghs M
FAU - Seret, N
AU  - Seret N
FAU - Decochez, K
AU  - Decochez K
FAU - Vandemeulebroucke, E
AU  - Vandemeulebroucke E
FAU - Gillard, P
AU  - Gillard P
FAU - Keymeulen, B
AU  - Keymeulen B
FAU - van Schravendijk, C
AU  - van Schravendijk C
FAU - Wenzlau, J M
AU  - Wenzlau JM
FAU - Hutton, J C
AU  - Hutton JC
FAU - Pipeleers, D G
AU  - Pipeleers DG
FAU - Gorus, F K
AU  - Gorus FK
CN  - The Belgian Diabetes Registry
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/20 [received]
PHST- 2013/05/07 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 10.1007/s00125-013-2951-8 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 28.

PMID- 23712484
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Harry keen, 1925-2013.
PG  - 1455-7
LID - 10.1007/s00125-013-2943-8 [doi]
AD  - Diabetes Research Group, King's College London School of Medicine, Guy's
      Hospital, London, SE1 1UL, UK, john.pickup@kcl.ac.uk.
FAU - Pickup, John C
AU  - Pickup JC
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/04/28 [received]
PHST- 2013/05/01 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 10.1007/s00125-013-2943-8 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1455-7. doi: 10.1007/s00125-013-2943-8. Epub 2013
      May 28.

PMID- 23712430
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 210
IP  - 6
DP  - 2013 Jun 3
TI  - MARCH1-mediated MHCII ubiquitination promotes dendritic cell selection of natural
      regulatory T cells.
PG  - 1069-77
LID - 10.1084/jem.20122695 [doi]
AB  - Membrane-associated RING-CH1 (MARCH1) is an E3 ubiquitin ligase that mediates
      ubiquitination of MHCII in dendritic cells (DCs). MARCH1-mediated MHCII
      ubiquitination in DCs is known to regulate MHCII surface expression, thereby
      controlling DC-mediated T cell activation in vitro. However, its role at steady
      state or in vivo is not clearly understood. Here, we show that MARCH1 deficiency 
      resulted in a substantial reduction in the number of thymus-derived regulatory T 
      cells (T reg cells) in mice. A specific ablation of MHCII ubiquitination also
      significantly reduced the number of thymic T reg cells. Indeed, DCs deficient in 
      MARCH1 or MHCII ubiquitination both failed to generate antigen-specific T reg
      cells in vivo and in vitro, although both exhibited an increased capacity for
      antigen presentation in parallel with the increased surface MHCII. Thus,
      MARCH1-mediated MHCII ubiquitination in DCs is required for proper production of 
      naturally occurring T reg cells, suggesting a role in balancing immunogenic and
      regulatory T cell development.
AD  - Department of Microbiology and Immunology, 2 Sandler Asthma Basic Research
      Center, 3 Diabetes Center, University of California, San Francisco, San
      Francisco, CA 94143.
FAU - Oh, Jaehak
AU  - Oh J
FAU - Wu, Nan
AU  - Wu N
FAU - Baravalle, Gunther
AU  - Baravalle G
FAU - Cohn, Benjamin
AU  - Cohn B
FAU - Ma, Jessica
AU  - Ma J
FAU - Lo, Bryan
AU  - Lo B
FAU - Mellman, Ira
AU  - Mellman I
FAU - Ishido, Satoshi
AU  - Ishido S
FAU - Anderson, Mark
AU  - Anderson M
FAU - Shin, Jeoung-Sook
AU  - Shin JS
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
SB  - IM
PMC - PMC3674695
OID - NLM: PMC3674695 [Available on 12/03/13]
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PMCR- 2013/12/03 00:00
PHST- 2013/05/27 [aheadofprint]
AID - jem.20122695 [pii]
AID - 10.1084/jem.20122695 [doi]
PST - ppublish
SO  - J Exp Med. 2013 Jun 3;210(6):1069-77. doi: 10.1084/jem.20122695. Epub 2013 May
      27.

PMID- 23712414
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Linking)
VI  - 173
IP  - 10
DP  - 2013 May 27
TI  - Is it time to eliminate the need for overnight fasting for lipid tests in
      patients with diabetes?-Reply.
PG  - 936-7
LID - 10.1001/jamainternmed.2013.663 [doi]
FAU - Naugler, Christopher
AU  - Naugler C
FAU - Sidhu, Davinder
AU  - Sidhu D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
SB  - AIM
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 1688596 [pii]
AID - 10.1001/jamainternmed.2013.663 [doi]
PST - ppublish
SO  - JAMA Intern Med. 2013 May 27;173(10):936-7. doi: 10.1001/jamainternmed.2013.663.

PMID- 23712413
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Linking)
VI  - 173
IP  - 10
DP  - 2013 May 27
TI  - Is it time to eliminate the need for overnight fasting for lipid tests in
      patients with diabetes?
PG  - 936-7
LID - 10.1001/jamainternmed.2013.398 [doi]
FAU - Aldasouqi, Saleh A
AU  - Aldasouqi SA
FAU - Grunberger, George
AU  - Grunberger G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
SB  - AIM
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 1688595 [pii]
AID - 10.1001/jamainternmed.2013.398 [doi]
PST - ppublish
SO  - JAMA Intern Med. 2013 May 27;173(10):936-7. doi: 10.1001/jamainternmed.2013.398.

PMID- 23712381
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
DP  - 2013 May 28
TI  - Benefits and Harms of Treating Gestational Diabetes Mellitus: A Systematic Review
      and Meta-analysis for the U.S. Preventive Services Task Force and the National
      Institutes of Health Office of Medical Applications of Research.
LID - 10.7326/0003-4819-159-2-201307160-00661 [doi]
AB  - BACKGROUND: Outcomes of treating gestational diabetes mellitus (GDM) are not
      well-established. PURPOSE: To summarize evidence about the maternal and neonatal 
      benefits and harms of treating GDM. DATA SOURCES: 15 electronic databases from
      1995 to May 2012, gray literature, Web sites of relevant organizations, trial
      registries, and reference lists. STUDY SELECTION: English-language randomized,
      controlled trials (n = 5) and cohort studies (n = 6) of women without known
      preexisting diabetes. DATA EXTRACTION: One reviewer extracted data, and a second 
      reviewer verified them. Two reviewers independently assessed methodological
      quality and evaluated strength of evidence for primary outcomes by using a
      Grading of Recommendations Assessment, Development and Evaluation approach. DATA 
      SYNTHESIS: All studies compared diet modification, glucose monitoring, and
      insulin as needed with no treatment. Women who were treated had more prenatal
      visits than those in control groups. Moderate evidence showed fewer cases of
      preeclampsia, shoulder dystocia, and macrosomia in the treated group. Evidence
      was insufficient for maternal weight gain and birth injury. Low evidence showed
      no difference between groups for neonatal hypoglycemia. Evidence was insufficient
      for long-term metabolic outcomes among offspring. No difference was found for
      cesarean delivery (low evidence), induction of labor (insufficient evidence),
      small-for-gestational-age neonates (moderate evidence), or admission to a
      neonatal intensive care unit (low evidence). LIMITATIONS: Evidence is low or
      insufficient for many outcomes of greatest clinical importance. The strongest
      evidence supports reductions in intermediate outcomes; however, other factors
      (for example, maternal weight and gestational weight gain) may impart greater
      risk than GDM, particularly when glucose levels are modestly elevated.
      CONCLUSION: Treating GDM results in less preeclampsia, shoulder dystocia, and
      macrosomia; however, current evidence does not show an effect on neonatal
      hypoglycemia or future poor metabolic outcomes. There is little evidence of
      short-term harm of treating GDM other than an increased demand for services.
      PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
FAU - Hartling, Lisa
AU  - Hartling L
FAU - Dryden, Donna M
AU  - Dryden DM
FAU - Guthrie, Alyssa
AU  - Guthrie A
FAU - Muise, Melanie
AU  - Muise M
FAU - Vandermeer, Ben
AU  - Vandermeer B
FAU - Donovan, Lois
AU  - Donovan L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 1691700 [pii]
AID - 10.7326/0003-4819-159-2-201307160-00661 [doi]
PST - aheadofprint
SO  - Ann Intern Med. 2013 May 28. doi: 10.7326/0003-4819-159-2-201307160-00661.

PMID- 23712377
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1432-1076 (Electronic)
IS  - 0340-6199 (Linking)
DP  - 2013 May 28
TI  - Insulin oedema in a child with newly diagnosed diabetes mellitus.
AB  - Insulin oedema is a rare complication of insulin therapy for diabetes mellitus.
      It has been reported in type 1 diabetes mellitus, in poorly controlled type 2
      diabetes mellitus following either the initiation or intensification of insulin
      therapy and in underweight patients on large doses of insulin. There are only a
      few case reports since it was first described in 1928, showing that it is an
      uncommon and probably an under-reported complication. The majority of those
      reports have been in the adult population. The generalised oedema tends to
      develop shortly after initiation or intensification of insulin therapy and
      resolves spontaneously within few weeks. We present one of the youngest patients 
      reported in the literature, a 9-year-old boy who developed insulin oedema within 
      few days of presenting with diabetic ketoacidosis. The case highlights the
      importance of recognising this generally transient and self-resolving
      complication and differentiating it from other serious causes of oedema.
AD  - Department of Paediatrics, Royal Blackburn Hospital, East Lancashire Hospitals
      NHS Trust, Blackburn, BB2 3HH, UK.
FAU - Aravamudhan, Avinash
AU  - Aravamudhan A
FAU - Gardner, Chris
AU  - Gardner C
FAU - Smith, Claire
AU  - Smith C
FAU - Senniappan, Senthil
AU  - Senniappan S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/25 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 10.1007/s00431-013-2045-0 [doi]
PST - aheadofprint
SO  - Eur J Pediatr. 2013 May 28.

PMID- 23712349
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
DP  - 2013 May 28
TI  - Screening Tests for Gestational Diabetes: A Systematic Review for the U.S.
      Preventive Services Task Force.
LID - 10.7326/0003-4819-159-2-201307160-00657 [doi]
AB  - BACKGROUND: A 50-g oral glucose challenge test (OGCT) is a widely accepted
      screening test for gestational diabetes mellitus (GDM), but other options are
      being considered. PURPOSE: To systematically review the test characteristics of
      various screening methods for GDM across a range of recommended diagnostic
      glucose thresholds. DATA SOURCES: 15 electronic databases from 1995 to May 2012, 
      reference lists, Web sites of relevant organizations, and gray literature. STUDY 
      SELECTION: Two reviewers independently identified English-language prospective
      studies that compared any screening test for GDM with any reference standard.
      DATA EXTRACTION: One reviewer extracted and a second reviewer verified data from 
      51 cohort studies. Two reviewers independently assessed methodological quality.
      DATA SYNTHESIS: The sensitivity, specificity, and positive and negative
      likelihood ratios for the OGCT at a threshold of 7.8 mmol/L (140 mg/dL) were 70% 
      to 88%, 69% to 89%, 2.6 to 6.5, and 0.16 to 0.33, respectively. At a threshold of
      7.2 mmol/L (130 mg/dL), the test characteristics were 88% to 99%, 66% to 77%, 2.7
      to 4.2, and 0.02 to 0.14, respectively. For a fasting plasma glucose threshold of
      4.7 mmol/L (85 mg/dL), they were 87%, 52%, 1.8, and 0.25, respectively. Glycated 
      hemoglobin level had poorer test characteristics than fasting plasma glucose
      level or the OGCT. No studies compared the OGCT with International Association of
      the Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criteria.
      LIMITATIONS: The lack of a gold standard for confirming GDM limits comparisons.
      Few data exist for screening tests before 24 weeks' gestation. CONCLUSION: The
      OGCT and fasting plasma glucose level (at a threshold of 4.7 mmol/L [85 mg/dL])
      by 24 weeks' gestation are good at identifying women who do not have GDM. The
      OGCT is better at identifying women who have GDM. The OGCT has not been validated
      for the IADPSG diagnostic criteria. PRIMARY FUNDING SOURCE: Agency for Healthcare
      Research and Quality.
FAU - Donovan, Lois
AU  - Donovan L
FAU - Hartling, Lisa
AU  - Hartling L
FAU - Muise, Melanie
AU  - Muise M
FAU - Guthrie, Alyssa
AU  - Guthrie A
FAU - Vandermeer, Ben
AU  - Vandermeer B
FAU - Dryden, Donna M
AU  - Dryden DM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 1691699 [pii]
AID - 10.7326/0003-4819-159-2-201307160-00657 [doi]
PST - aheadofprint
SO  - Ann Intern Med. 2013 May 28. doi: 10.7326/0003-4819-159-2-201307160-00657.

PMID- 23712292
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
DP  - 2013 May 28
TI  - Diminishing prognostic role of preexisting diabetes mellitus for patients with
      diffuse large B-cell lymphoma in the rituximab era.
AB  - Rituximab reforms the treatment of diffuse large B-cell lymphoma (DLBCL) and the 
      prognostic significance of baseline patient features should be reevaluated. Few
      population-based studies have investigated the association of diabetes mellitus
      (DM) and outcomes of lymphoma; however, the results remain inconclusive. From
      January 1, 2000 to December 31, 2009, a total of 468 consecutive newly diagnosed 
      DLBCL patients receiving first-line chemotherapy with cyclophosphamide,
      vincristine, doxorubicin, and prednisolone (CHOP) or rituximab plus CHOP (R-CHOP)
      were enrolled. Pre-existing DM was defined according to medical history, use of
      antidiabetic medications, or any record of an abnormal hemoglobin A1c test.
      Progression-free survival (PFS) and overall survival (OS) were estimated and
      compared using the Kaplan-Meier method with a log-rank test. CHOP was
      administered in 194 patients, and 274 patients received R-CHOP. DM was identified
      in 16.2 % (76/468) of patients. Diabetic patients were older and more performance
      restricted, compared to the non-DM patients in both the CHOP and R-CHOP groups.
      In the CHOP group, 5-year PFS and OS were inferior in DM patients (PFS, 32.4 vs. 
      50.0 % (P = 0.039); OS, 38.2 vs. 62.5 % (P = 0.002)). However, outcomes were
      similar for both DM and non-DM patients in the context of R-CHOP treatment (PFS, 
      69.0 vs. 57.3 % (P = 0.179); OS, 76.2 vs. 69.8 % (P = 0.586)). The response rate 
      of chemotherapy in DM patients was also improved to a level similar to non-DM
      patients with rituximab use. In conclusion, the prognostic significance of
      preexisting DM in DLBCL patients is changing in the rituximab era. The
      potentially additional benefit of rituximab in DM patients merits further
      investigation.
AD  - Division of Hematology and Oncology, Department of Medicine, Taipei Veterans
      General Hospital, Taipei, Taiwan.
FAU - Lu, Hsueh-Ju
AU  - Lu HJ
FAU - Huang, Yu-Chung
AU  - Huang YC
FAU - Liu, Chun-Yu
AU  - Liu CY
FAU - Hung, Man-Hsin
AU  - Hung MH
FAU - Hu, Ming-Hung
AU  - Hu MH
FAU - Wu, Chia-Yun
AU  - Wu CY
FAU - Hong, Ying-Chung
AU  - Hong YC
FAU - Hsiao, Liang-Tsai
AU  - Hsiao LT
FAU - Gau, Jyh-Pyng
AU  - Gau JP
FAU - Liu, Jin-Hwang
AU  - Liu JH
FAU - Hsu, Hui-Chi
AU  - Hsu HC
FAU - Chiou, Tzeon-Jye
AU  - Chiou TJ
FAU - Tzeng, Cheng-Hwai
AU  - Tzeng CH
FAU - Yu, Yuan-Bin
AU  - Yu YB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/05 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 10.1007/s00277-013-1789-y [doi]
PST - aheadofprint
SO  - Ann Hematol. 2013 May 28.

PMID- 23712283
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130528
DCOM- 20130529
LR  - 20130605
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - Benefit of a low-fat over high-fat diet on vascular health during alternate day
      fasting.
PG  - e71
LID - 10.1038/nutd.2013.14 [doi]
AB  - Background:Alternate day fasting (ADF) with a low-fat (LF) diet improves brachial
      artery flow-mediated dilation (FMD). Whether these beneficial effects can be
      reproduced with a high-fat (HF) diet remains unclear.Objective:This study
      compared the effects of ADF-HF to ADF-LF regimens on FMD. The role that
      adipokines have in mediating this effect was also investigated.Methods:Thirty-two
      obese subjects were randomized to an ADF-HF (45% fat) or ADF-LF diet (25% fat),
      consisting of two phases: (1) a 2-week baseline weight maintenance period and (2)
      an 8-week ADF weight loss period. Food was provided throughout the
      study.Results:Body weight was reduced (P<0.0001) in the ADF-HF (4.4+/-1.0 kg) and
      ADF-LF group (3.7+/-0.7 kg). FMD decreased (P<0.05) by ADF-HF relative to
      baseline (7+/-1 to 5+/-2%) and increased (P<0.05) by ADF-LF (5+/-1 to 7+/-2%).
      Blood pressure remained unchanged in both groups. Adiponectin increased (P<0.05) 
      in the ADF-HF (43+/-7%) and ADF-LF group (51+/-7%). Leptin and resistin decreased
      (P<0.05) in the ADF-HF (32+/-5%; 23+/-5%) and ADF-LF group (30+/-3%; 27+/-4%).
      Increases in adiponectin were associated with augmented FMD in the ADF-LF group
      only (r=0.34, P=0.03).Conclusion:Thus, improvements in FMD with ADF may only
      occur with LF diets and not with HF diets, and adipokines may not have a
      significant role in mediating this effect.
AD  - Department of Kinesiology and Nutrition, University of Illinois at Chicago,
      Chicago, IL, USA.
FAU - Klempel, M C
AU  - Klempel MC
FAU - Kroeger, C M
AU  - Kroeger CM
FAU - Norkeviciute, E
AU  - Norkeviciute E
FAU - Goslawski, M
AU  - Goslawski M
FAU - Phillips, S A
AU  - Phillips SA
FAU - Varady, K A
AU  - Varady KA
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
PMC - PMC3671747
OID - NLM: PMC3671747
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:01
CRDT- 2013/05/29 06:00
AID - nutd201314 [pii]
AID - 10.1038/nutd.2013.14 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 May 27;3:e71. doi: 10.1038/nutd.2013.14.

PMID- 23712282
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130528
DCOM- 20130529
LR  - 20130605
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - Yacon diet (Smallanthus sonchifolius, Asteraceae) improves hepatic insulin
      resistance via reducing Trb3 expression in Zucker fa/fa rats.
PG  - e70
LID - 10.1038/nutd.2013.11 [doi]
AB  - Objective:Yacon is a perennial plant forming a clump of >20 big, edible
      underground tubers. Yacon, which originates from South America, has become
      increasingly popular in the Japanese diet for tubers have a lower caloric value
      and a high fiber content. Recent studies have suggested that yacon feeding
      ameliorates diabetes as indicated by reduced blood glucose.Methods:We fed male
      Zucker fa/fa rats for 5 weeks with isocaloric normal chow diet containing from
      6.5% control aroid or 6.5% yacon. Insulin sensitivity was evaluated by
      euglycemic-hyperinsulinemic clamp study.Results:Body weight was comparable
      between yacon- and aroid-fed rats. In the basal state, yacon feeding had an
      effect to lower fasting glucose levels from 184.1+/-4.1 to 167.8+/-2.7 mg dl(-1) 
      (P<0.01), as well as basal hepatic glucose output (HGO) from 9.9+/-0.4 to 7.4 +/-
      0.2 mg kg(-1) per min (P<0.01). During the clamp studies, the glucose infusion
      rate required to maintain euglycemia was increased by 12.3% in yacon-fed rat. The
      insulin suppression of HGO was also increased in yacon-fed rats compared with
      control rats (85.3+/-2.4% vs 77.0+/-3.0%; P<0.05), whereas the glucose disposal
      rate was not different between the two groups. Consistent with the clamp data,
      the insulin-stimulated phosphorylation of Akt was significantly enhanced in liver
      but not in skeletal muscle. Furthermore, tribbles 3 (Trb3) expression, which is a
      negative regulator of Akt activity, was markedly reduced in the liver of
      yacon-fed rats compared with control rats.Conclusion:These results indicate that 
      the effect of yacon feeding to reduce blood glucose is likely due to its
      beneficial effects on hepatic insulin sensitivity in the insulin resistant state.
AD  - Department of Nephrology, Hypertension, Diabetology, Endocrinology and
      Metabolism, Fukushima Medical University, Fukushima, Japan.
FAU - Satoh, H
AU  - Satoh H
AUID- ORCID: 0000000203535807
FAU - Audrey Nguyen, M T
AU  - Audrey Nguyen MT
FAU - Kudoh, A
AU  - Kudoh A
FAU - Watanabe, T
AU  - Watanabe T
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
PMC - PMC3671746
OID - NLM: PMC3671746
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:01
CRDT- 2013/05/29 06:00
AID - nutd201311 [pii]
AID - 10.1038/nutd.2013.11 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 May 27;3:e70. doi: 10.1038/nutd.2013.11.

PMID- 23712281
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130528
DCOM- 20130529
LR  - 20130605
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - Measures of body fat in South Asian adults.
PG  - e69
LID - 10.1038/nutd.2013.10 [doi]
AB  - Background:South Asian people who originate from the Indian subcontinent have
      greater percent body fat (%BF) for the same body mass index (BMI) compared with
      white Caucasians. This has been implicated in their increased risk of type 2
      diabetes and cardiovascular disease. There is limited information comparing
      different measures of body fat in this ethnic group.Objectives:The objectives of 
      this study were: (1) to investigate the correlation of %BF measured by a
      foot-to-foot bioelectrical impedance analysis (FF-BIA) against the BOD POD, a
      method of air-displacement plethysmography, and (2) to determine the correlations
      of simple anthropometric measures, (that is, BMI, body adiposity index (BAI),
      waist circumference (WC), hip circumference (HC) and waist-to-hip ratio (WHR))
      against the BOD POD measure of body fat.Methods:Eighty apparently healthy South
      Asian men and women were recruited from the community, and measurements of
      height, weight, WC, HC and body composition using Tanita FF-BIA and BOD POD were 
      taken.Results:The mean+/-s.d. age of participants was 27.78+/-10.49 years, 42.5% 
      were women, and the mean BMI was 22.68+/-3.51 kg m(-2). The mean body fat (%BF)
      calculated by FF-BIA and BOD POD was 21.94+/-7.88% and 26.20+/-8.47%,
      respectively. The %BF calculated by FF-BIA was highly correlated with the BOD POD
      (Pearson's r=0.83, P<0.001), however, FF-BIA underestimated %BF by 4.3%. When
      anthropometric measures were compared with % BF by BOD POD, the BAI showed the
      strongest correlation (r=0.74) and the WHR showed the weakest (r=0.33). BAI
      generally underestimated %BF by 2.6% in comparison with %BF by BOD POD. The
      correlations of BOD POD with other measures of %BF were much stronger in subjects
      with a BMI >21 kg m(-2) than those with a BMI </=21 kg m(-2).Conclusion:The
      FF-BIA and BAI estimates of %BF are highly correlated with that of BOD POD among 
      people of South Asian origin, although both methods somewhat underestimate % BF. 
      Furthermore, their correlations with % BF from BOD POD are significantly weakened
      among men and women with a BMI </=21 kg m(-2).
AD  - 1] Bachelor of Health Sciences, McMaster University, Hamilton, Ontario, Canada
      [2] Chanchlani Research Centre, McMaster University, Hamilton, Ontario, Canada.
FAU - Kalra, S
AU  - Kalra S
FAU - Mercuri, M
AU  - Mercuri M
FAU - Anand, S S
AU  - Anand SS
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
PMC - PMC3671745
OID - NLM: PMC3671745
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:01
CRDT- 2013/05/29 06:00
AID - nutd201310 [pii]
AID - 10.1038/nutd.2013.10 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 May 27;3:e69. doi: 10.1038/nutd.2013.10.

PMID- 23712280
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130528
DCOM- 20130529
LR  - 20130605
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - The cannabinoid Delta(9)-tetrahydrocannabivarin (THCV) ameliorates insulin
      sensitivity in two mouse models of obesity.
PG  - e68
LID - 10.1038/nutd.2013.9 [doi]
AB  - Background:Cannabinoid type-1 (CB1) receptor inverse agonists improve type 2
      diabetes and dyslipidaemia but were discontinued due to adverse psychiatric
      effects. Delta(9)-Tetrahydrocannabivarin (THCV) is a neutral CB1 antagonist
      producing hypophagia and body weight reduction in lean mice. We investigated its 
      effects in dietary-induced (DIO) and genetically (ob/ob) obese mice.Methods:We
      performed two dose-ranging studies in DIO mice; study 1: 0.3, 1, 2.5, 5 and 12.5 
      mg kg(-1), oral twice daily for 30 days and study 2: 0.1, 0.5, 2.5 and 12.5 mg
      kg(-1), oral, once daily for 45 days. One pilot (study 3: 0.3 and 3 mg kg(-1),
      oral, once daily) and one full dose-ranging (study 4: 0.1, 0.5, 2.5 and 12.5 mg
      kg(-1), oral, once daily) studies in ob/ob mice for 30 days. The CB1 inverse
      agonist, AM251, oral, 10 mg kg(-1) once daily or 5 mg kg(-1) twice daily was used
      as the positive control. Cumulative food and water intake, body weight gain,
      energy expenditure, glucose and insulin levels (fasting or during oral glucose
      tolerance tests), plasma high-density lipoprotein and total cholesterol, and
      liver triglycerides were measured. HL-5 hepatocytes or C2C12 myotubes made
      insulin-resistant with chronic insulin or palmitic acid were treated with 0, 1, 3
      and 10 muM THCV or AM251.Results:THCV did not significantly affect food intake or
      body weight gain in any of the studies, but produced an early and transient
      increase in energy expenditure. It dose-dependently reduced glucose intolerance
      in ob/ob mice and improved glucose tolerance and increased insulin sensitivity in
      DIO mice, without consistently affecting plasma lipids. THCV also restored
      insulin signalling in insulin-resistant hepatocytes and myotubes.Conclusions:THCV
      is a new potential treatment against obesity-associated glucose intolerance with 
      pharmacology different from that of CB1 inverse agonists/antagonists.
AD  - Clore Laboratory, University of Buckingham, Buckingham, UK.
FAU - Wargent, E T
AU  - Wargent ET
FAU - Zaibi, M S
AU  - Zaibi MS
FAU - Silvestri, C
AU  - Silvestri C
FAU - Hislop, D C
AU  - Hislop DC
FAU - Stocker, C J
AU  - Stocker CJ
FAU - Stott, C G
AU  - Stott CG
FAU - Guy, G W
AU  - Guy GW
FAU - Duncan, M
AU  - Duncan M
FAU - Di Marzo, V
AU  - Di Marzo V
FAU - Cawthorne, M A
AU  - Cawthorne MA
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
PMC - PMC3671751
OID - NLM: PMC3671751
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:01
CRDT- 2013/05/29 06:00
AID - nutd20139 [pii]
AID - 10.1038/nutd.2013.9 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 May 27;3:e68. doi: 10.1038/nutd.2013.9.

PMID- 23712250
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 May 28
TI  - Diabetes and its comorbidities-where East meets West.
LID - 10.1038/nrendo.2013.102 [doi]
AB  - Fetal programming associated with in utero exposure to maternal stress is thought
      to alter gene expression, resulting in phenotypes that promote survival in a
      pathogen-rich and nutrient-poor environment but substantially increase the risk
      of cardiovascular, metabolic and renal disorders (such as diabetes mellitus) in
      adults with obesity. These (epi)genetic phenomena are modified by environmental
      and socioeconomic factors, resulting in multiple subphenotypes and clinical
      consequences. In individuals from areas undergoing rapid economic development,
      which is associated with a transition from communicable to noncommunicable
      diseases, an efficient innate immune response can exaggerate obesity-associated
      inflammation. By contrast, in individuals with a genetic predisposition to
      autoimmune or monogenic diabetes mellitus, obesity can lead to atypical
      presentation of diabetes mellitus, termed 'double diabetes mellitus'. The
      increasingly young age at diagnosis of diabetes mellitus in developing countries 
      results in prolonged exposure to glucolipotoxicity, low-grade inflammation and
      increased oxidative stress, which put enormous strain on pancreatic beta cells
      and renal function. These conditions create a metabolic milieu conducive to
      cancer growth. This Review discusses how rapid changes in technology and human
      behaviour have brought on the global epidemic of metabolic diseases, and suggests
      that solutions will be based on using system change, technology and behavioural
      strategies to combat this societal-turned-medical problem.
AD  - Department of Medicine and Therapeutics, Hong Kong Institute of Diabetes and
      Obesity, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong
      Kong, Prince of Wales Hospital, Shatin, NT Hong Kong Special Administrative
      Region, China.
FAU - Kong, Alice P S
AU  - Kong AP
FAU - Xu, Gang
AU  - Xu G
FAU - Brown, Nicola
AU  - Brown N
FAU - So, Wing-Yee
AU  - So WY
FAU - Ma, Ronald C W
AU  - Ma RC
FAU - Chan, Juliana C N
AU  - Chan JC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/05/28 [aheadofprint]
AID - nrendo.2013.102 [pii]
AID - 10.1038/nrendo.2013.102 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 May 28. doi: 10.1038/nrendo.2013.102.

PMID- 23712248
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 May 28
TI  - Diabetes: Does lactate sustain brain metabolism during hypoglycaemia?
LID - 10.1038/nrendo.2013.104 [doi]
AD  - Department of Medicine, University of Minnesota, MMC 101, 420 Delaware Street
      South East, Minneapolis, MN 55455, USA.
FAU - Seaquist, Elizabeth R
AU  - Seaquist ER
FAU - Oz, Gulin
AU  - Oz G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/05/28 [aheadofprint]
AID - nrendo.2013.104 [pii]
AID - 10.1038/nrendo.2013.104 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 May 28. doi: 10.1038/nrendo.2013.104.

PMID- 23712196
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - The European perspective of diabetes prevention: The need for individualization
      of diabetes prevention.
PG  - 352-7
AB  - Over the last decade the situation for people with diabetes mellitus in Europe
      has changed significantly. The number of patients increases continuously, the age
      of diagnosis decreases and effective management grows to become a burden for
      European healthcare systems. In this situation numerous stakeholders try to
      develop concepts for innovative chronic care management as well as individualized
      and personalized diabetes management. A major focus is set to activities for
      early screening and prevention of the diabetes and associated diseases. The
      present article will give an overview about current achievements in European
      projects addressing the unmet needs in diabetes management and also to introduce 
      undergoing projects in the field of diabetes prevention and care. Furthermore,
      the SweetSmart concept will be presented, which is the initiation of a strategy
      to individualize interventions for the prevention of diabetes and care
      management. In the current discussion about the management of health care
      resources it is important to have a strategic vision about a realistic future of 
      innovative chronic care management.
AD  - Technical University, Dresden, Germany.
FAU - Muller, G
AU  - Muller G
FAU - Weser, G
AU  - Weser G
FAU - Schwarz, P E H
AU  - Schwarz PE
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 8979 [pii]
PST - ppublish
SO  - J Endocrinol Invest. 2013 May;36(5):352-7.

PMID- 23712034
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-3913 (Electronic)
IS  - 0898-6568 (Linking)
DP  - 2013 May 24
TI  - Proline-rich Akt substrate of 40-kDa contains a nuclear export signal.
LID - S0898-6568(13)00147-2 [pii]
LID - 10.1016/j.cellsig.2013.05.022 [doi]
AB  - The proline-rich Akt substrate of 40-kDa (PRAS40) has been linked to the
      regulation of the activity of the mammalian target of rapamycin complex 1 as well
      as insulin action. Despite these cytosolic functions, PRAS40 was originally
      identified as nuclear phosphoprotein in Hela cells. This study aimed to detail
      mechanisms and consequences of the nucleocytosolic trafficking of PRAS40.
      Sequence analysis identified a potential leucine-rich nuclear export signal (NES)
      within PRAS40. Incubation of A14 fibroblasts overexpressing human PRAS40
      (hPRAS40) resulted in nuclear accumulation of the protein. Furthermore, mutation 
      of the NES mimicked the effects of leptomycin B, a specific inhibitor of nuclear 
      export, on the subcellular localization of hPRAS40. Finally, A14 cells expressing
      the NES-mutant showed impaired activation of components of the Akt-pathway as
      well as of the mTORC1 substrate p70 S6 kinase after insulin stimulation. This
      impaired insulin signaling could be ascribed to reduced protein levels of insulin
      receptor substrate 1 in cells expressing mutant NES. In conclusion, PRAS40
      contains a functional nuclear export signal. Furthermore, enforced nuclear
      accumulation of PRAS40 impairs insulin action, thereby substantiating the
      function of this protein in the regulation of insulin sensitivity.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes
      Center, Duesseldorf, Germany.
FAU - Wiza, Claudia
AU  - Wiza C
FAU - Nascimento, Emmani B M
AU  - Nascimento EB
FAU - Linssen, Margot M L
AU  - Linssen MM
FAU - Carlotti, Francoise
AU  - Carlotti F
FAU - de Wiza, Daniella Herzfeld
AU  - de Wiza DH
FAU - van der Zon, Gerard C M
AU  - van der Zon GC
FAU - Maassen, J Antonie
AU  - Maassen JA
FAU - Diamant, Michaela
AU  - Diamant M
FAU - Guigas, Bruno
AU  - Guigas B
FAU - Ouwens, D Margriet
AU  - Ouwens DM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Cell Signal
JT  - Cellular signalling
JID - 8904683
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/03 [received]
PHST- 2013/05/07 [revised]
PHST- 2013/05/12 [accepted]
AID - S0898-6568(13)00147-2 [pii]
AID - 10.1016/j.cellsig.2013.05.022 [doi]
PST - aheadofprint
SO  - Cell Signal. 2013 May 24. pii: S0898-6568(13)00147-2. doi:
      10.1016/j.cellsig.2013.05.022.

PMID- 23711956
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 24
TI  - The role of phospholipids in the biological activity and structure of the
      endoplasmic reticulum.
LID - S0167-4889(13)00208-5 [pii]
LID - 10.1016/j.bbamcr.2013.05.018 [doi]
AB  - The endoplasmic reticulum (ER) is an interconnected network of tubular and planar
      membranes that supports the synthesis and export of proteins, carbohydrates and
      lipids. Phospholipids, in particular phosphatidylcholine (PC), are synthesized in
      the ER where they have essential functions including provision of membranes
      required for protein synthesis and export, cholesterol homeostasis, and
      triacylglycerol storage and secretion. Coordination of these biological processes
      is essential, as highlighted by findings that link phospholipid metabolism in the
      ER with perturbations in lipid storage/secretion and stress responses, ultimately
      contributing to obesity/diabetes, atherosclerosis and neurological disorders.
      Phospholipid synthesis is not uniformly distributed in the ER but is localized at
      membrane interfaces or contact zones with other organelles, and in dynamic,
      proliferating ER membranes. The topology of phospholipid synthesis is an
      important consideration when establishing the etiology of diseases that arise
      from ER dysfunction. This review will highlight our current understanding of the 
      contribution of phospholipid synthesis to proper ER function, and how alterations
      contribute to aberrant stress responses and disease. This article is part of a
      Special Issue entitled: Functional and structural diversity of endoplasmic
      reticulum.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, Ontario, K1Y 4W7,
      Canada. Electronic address: tlagace@ottawaheart.ca.
FAU - Lagace, Thomas A
AU  - Lagace TA
FAU - Ridgway, Neale D
AU  - Ridgway ND
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/11 [received]
PHST- 2013/05/09 [revised]
PHST- 2013/05/15 [accepted]
AID - S0167-4889(13)00208-5 [pii]
AID - 10.1016/j.bbamcr.2013.05.018 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 24. pii: S0167-4889(13)00208-5. doi:
      10.1016/j.bbamcr.2013.05.018.

PMID- 23711934
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
DP  - 2013 May 24
TI  - Young and elderly patients with type 2 diabetes have optimal B cell responses to 
      the seasonal influenza vaccine.
LID - S0264-410X(13)00559-8 [pii]
LID - 10.1016/j.vaccine.2013.05.003 [doi]
AB  - We evaluated immune response to the seasonal influenza vaccine in young and
      elderly patients with type 2 diabetes (T2D). Immune measures included the in vivo
      serum response to the vaccine by hemagglutination inhibition (HAI) and ELISA in
      22 patients (14 young, 8 elderly) and 65 healthy age-matched controls (37 young, 
      28 elderly). B cell-specific biomarkers of optimal vaccine response were measured
      ex vivo by switched memory B cells and plasmablasts and in vitro by
      activation-induced cytidine deaminase (AID) in stimulated cells. Markers of
      systemic and B cell-intrinsic inflammation were also measured. Results show that 
      in vivo responses, as well as B cell-specific markers identified above, decrease 
      by age in healthy individuals but not in T2D patients. This occurred despite high
      levels of B cell-intrinsic inflammation (TNF-alpha) in T2D patients, which was
      surprising as we had previously demonstrated this negatively impacts B cell
      function. These results altogether suggest that valid protection against
      influenza can be achieved in T2D patients and proposed mechanisms are discussed.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Microbiology and Immunology, University of Miami Miller, School of 
      Medicine, Miami, FL 33101, USA. Electronic address: dfrasca@med.miami.edu.
FAU - Frasca, Daniela
AU  - Frasca D
FAU - Diaz, Alain
AU  - Diaz A
FAU - Romero, Maria
AU  - Romero M
FAU - Mendez, Nicholas V
AU  - Mendez NV
FAU - Landin, Ana Marie
AU  - Landin AM
FAU - Ryan, John G
AU  - Ryan JG
FAU - Blomberg, Bonnie B
AU  - Blomberg BB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Vaccine
JT  - Vaccine
JID - 8406899
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/11/28 [received]
PHST- 2013/02/05 [revised]
PHST- 2013/05/01 [accepted]
AID - S0264-410X(13)00559-8 [pii]
AID - 10.1016/j.vaccine.2013.05.003 [doi]
PST - aheadofprint
SO  - Vaccine. 2013 May 24. pii: S0264-410X(13)00559-8. doi:
      10.1016/j.vaccine.2013.05.003.

PMID- 23711897
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1768-3181 (Electronic)
IS  - 0003-3928 (Linking)
DP  - 2013 Apr 19
TI  - [Prevalence of hypertension in El-Menia oasis, Algeria, and metabolic
      characteristics in population.]
LID - S0003-3928(13)00058-9 [pii]
LID - 10.1016/j.ancard.2013.04.008 [doi]
AB  - INTRODUCTION: El-Menia is an oasis located in the middle of Algerian Sahara. The 
      drinking water in this oasis has low sodium content. The objectives of this study
      were to estimate the prevalence of hypertension, to describe the metabolic
      characteristics of population study and to assess the factors associated with
      blood pressure levels. METHODS: A cross sectional study was conducted in 2010.
      Subjects (n=722) were selected from individuals aged 40 years or older by random 
      cluster sampling. Blood pressure measurements, combined with a clinical
      questionnaire, and standard blood samples for the detection of dyslipidemia and
      diabetes mellitus, were collected. RESULTS: Sixty-seven percent of subjects were 
      females and 18% were black. The mean age was 58.5+/-13.2 years. The prevalence of
      hypertension was 50.2%: 49.7% in females and 51.3% in males. The factors
      associated with presence of hypertension following a logistic multivariate
      regression were age, skin colour, waist circumference, and plasma glucose. The
      treatment and control of hypertension were 41% and 20% respectively. CONCLUSIONS:
      The prevalence oh hypertension was high in this oasis and the rate of treatment
      control was low. Our findings suggest that appropriate healthcare should be given
      to hypertensive subjects, including a better information on hypertension.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Departement de medecine, faculte de medecine, universite Saad Dahlab de Blida,
      9000 Blida, Algerie. Electronic address: hamidafarah@yahoo.fr.
FAU - Hamida, F
AU  - Hamida F
FAU - Atif, M-L
AU  - Atif ML
FAU - Temmar, M
AU  - Temmar M
FAU - Chibane, A
AU  - Chibane A
FAU - Bezzaoucha, A
AU  - Bezzaoucha A
FAU - Bouafia, M-T
AU  - Bouafia MT
LA  - FRE
PT  - JOURNAL ARTICLE
TT  - Prevalence de l'hypertension arterielle dans l'oasis d'El-Menia, Algerie, et
      profil metabolique de la population.
DEP - 20130419
TA  - Ann Cardiol Angeiol (Paris)
JT  - Annales de cardiologie et d'angeiologie
JID - 0142167
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/14 [received]
PHST- 2013/04/01 [accepted]
AID - S0003-3928(13)00058-9 [pii]
AID - 10.1016/j.ancard.2013.04.008 [doi]
PST - aheadofprint
SO  - Ann Cardiol Angeiol (Paris). 2013 Apr 19. pii: S0003-3928(13)00058-9. doi:
      10.1016/j.ancard.2013.04.008.

PMID- 23711880
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1097-6760 (Electronic)
IS  - 0196-0644 (Linking)
DP  - 2013 May 24
TI  - Missed Opportunities for Appropriate Anticoagulation Among Emergency Department
      Patients With Uncomplicated Atrial Fibrillation or Flutter.
LID - S0196-0644(13)00325-9 [pii]
LID - 10.1016/j.annemergmed.2013.04.004 [doi]
AB  - STUDY OBJECTIVE: Emergency department (ED) patients with atrial fibrillation or
      flutter are at risk of stroke, and guidelines recommend anticoagulation for
      patients with increased cardiovascular risk. Emergency physicians have a unique
      opportunity to provide appropriate anticoagulation for such patients, and we
      wished to investigate whether this was accomplished. METHODS: This retrospective 
      cohort study used a database from 2 urban EDs to identify consecutive patients
      with an ED discharge diagnosis of atrial fibrillation or flutter from April 1,
      2006, to March 31, 2010, who were managed solely by the emergency physician.
      Comorbidities, rhythms, and management were obtained by chart review, and
      complicated patients (those with an acute underlying medical condition) were
      excluded by predefined criteria. Patient medications on ED presentations were
      obtained through the provincial Pharmanet database. Patients were stratified into
      CHADS 2 (congestive heart failure, hypertension, age > 75, diabetes,
      stroke/transient ischemic attack) scores, and the primary outcome was the
      proportion of higher-risk (CHADS 2 score >0) patients who were discharged home
      with the incorrect anticoagulation by the emergency physician. The secondary
      outcome was the number of lower-risk (CHADS 2=0) patients who began receiving
      warfarin by the emergency physician orders. The regional ED database was
      interrogated to ascertain the number of patients who had a stroke at 30 days.
      RESULTS: Consecutive patients (1,090) were enrolled and 732 were discharged home 
      with no cardiology consultation (657 fibrillation and 75 flutter). Of 151
      higher-risk (CHADS 2 score >0) patients who should have been anticoagulated, 80
      (53.0%; 95% confidence interval 44.7% to 61.0%) were discharged home from the ED 
      without appropriate anticoagulation. In this group, 1 patient had an ischemic
      stroke at 24 days. Among 300 lower-risk patients (CHADS 2 score=0), 25 (8.3%; 95%
      confidence interval 5.6% to 12.2%) had warfarin initiated. CONCLUSION: In this
      cohort of ED patients with uncomplicated atrial fibrillation or flutter who were 
      discharged without cardiology involvement, many were not appropriately
      anticoagulated before ED arrival, and more than half of such patients did not
      appear to have corrective measures initiated by the emergency physician. This may
      represent a potential opportunity to improve patient care and outcomes.
CI  - Copyright (c) 2013. Published by Mosby, Inc.
AD  - Department of Emergency Medicine, St Paul's Hospital and the University of
      British Columbia, Vancouver, British Columbia, Canada. Electronic address:
      frank.scheuermeyer@gmail.com.
FAU - Scheuermeyer, Frank X
AU  - Scheuermeyer FX
FAU - Innes, Grant
AU  - Innes G
FAU - Pourvali, Reza
AU  - Pourvali R
FAU - Dewitt, Chris
AU  - Dewitt C
FAU - Grafstein, Eric
AU  - Grafstein E
FAU - Heslop, Claire
AU  - Heslop C
FAU - Macphee, Jan
AU  - Macphee J
FAU - Ward, John
AU  - Ward J
FAU - Heilbron, Brett
AU  - Heilbron B
FAU - McGrath, Lorraine
AU  - McGrath L
FAU - Christenson, Jim
AU  - Christenson J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/28 [received]
PHST- 2013/03/16 [revised]
PHST- 2013/04/04 [accepted]
AID - S0196-0644(13)00325-9 [pii]
AID - 10.1016/j.annemergmed.2013.04.004 [doi]
PST - aheadofprint
SO  - Ann Emerg Med. 2013 May 24. pii: S0196-0644(13)00325-9. doi:
      10.1016/j.annemergmed.2013.04.004.

PMID- 23711810
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 May 24
TI  - Usefulness of Intravascular Ultrasound to Predict Outcomes in Short-Length
      Lesions Treated With Drug-Eluting Stents.
LID - S0002-9149(13)01054-0 [pii]
LID - 10.1016/j.amjcard.2013.04.037 [doi]
AB  - Intravascular ultrasound (IVUS) offers tomographic images of the coronary artery,
      helping physicians to refine drug-eluting stent (DES) implantation in
      angiographically complex lesions. However, controversy exists regarding whether
      the routine use of IVUS in short-length lesions leads to improved clinical
      outcomes after DES implantation. Therefore, we evaluated the usefulness of IVUS
      in predicting major adverse cardiac events (MACE), including cardiovascular
      death, myocardial infarction, or target vessel revascularization, at 1 year after
      DES implantation in short-length lesions. The present study was a subanalysis of 
      the REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following
      Endeavor zotarolimus-eluting stent implantation (RESET) study with different
      clinical outcome parameters. The study population consisted of 662 patients with 
      IVUS guidance and 912 patients with angiography guidance who underwent DES
      implantation (stent length </=24 mm). In the IVUS-guided group, adjuvant
      postdilation was more frequently performed (43.0% vs 34.6%, p <0.001), and the
      postintervention minimal lumen diameters were greater (2.88 +/- 0.44 mm vs 2.72
      +/- 0.43 mm, p <0.001). MACE occurred in 15 IVUS-guided (2.3%) and 19
      angiographically guided (2.1%) patients (p = 0.872). In a subset of patients with
      diabetes mellitus (n = 292), the MACE rate was 3.4% (n = 4) and 1.7% (n = 3) in
      the IVUS- and angiographically guided patients, respectively (p = 0.384). The
      MACE rate in the IVUS- and angiographically guided patients with acute coronary
      syndrome (n = 601) was 1.1% (n = 3) and 2.7% (n = 9), respectively (p = 0.194).
      The clinical benefits of IVUS-guided DES implantation compared with
      angiographically guided DES implantation in short-length lesions could not be
      confirmed even in patients with clinically high-risk presentations (acute
      coronary syndrome and diabetes mellitus). In conclusion, routine IVUS guidance
      does not provide clinical benefits when performing short-length DES implantation.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Kangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South
      Korea.
FAU - Yoon, Young-Won
AU  - Yoon YW
FAU - Shin, Sanghoon
AU  - Shin S
FAU - Kim, Byeong-Keuk
AU  - Kim BK
FAU - Kim, Jung-Sun
AU  - Kim JS
FAU - Shin, Dong-Ho
AU  - Shin DH
FAU - Ko, Young-Guk
AU  - Ko YG
FAU - Choi, Donghoon
AU  - Choi D
FAU - Jeon, Dong-Woon
AU  - Jeon DW
FAU - Kwon, Hyuckmoon
AU  - Kwon H
FAU - Jang, Yangsoo
AU  - Jang Y
FAU - Hong, Myeong-Ki
AU  - Hong MK
CN  - RESET Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/24 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/04/19 [accepted]
AID - S0002-9149(13)01054-0 [pii]
AID - 10.1016/j.amjcard.2013.04.037 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 May 24. pii: S0002-9149(13)01054-0. doi:
      10.1016/j.amjcard.2013.04.037.

PMID- 23711799
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1532-8406 (Electronic)
IS  - 0883-5403 (Linking)
DP  - 2013 May 24
TI  - Mortality, Cost, and Downstream Disease of Total Hip Arthroplasty Patients in the
      Medicare Population.
LID - S0883-5403(13)00335-5 [pii]
LID - 10.1016/j.arth.2013.04.031 [doi]
AB  - The purpose of this study is to compare the differences in downstream cost and
      health outcomes between Medicare hip OA patients who undergo total hip
      arthroplasty (THA) and those who do not. All OA patients in the Medicare 5%
      sample (1998-2009) were separated into non-THA and THA groups. Differences in
      costs and risk ratios for mortality and new disease diagnoses were adjusted using
      logistic regression for age, sex, race, socioeconomic status, region, and
      Charlson score. Mortality, heart failure, depression, and diabetes were all
      reduced in the THA group, though there was an increased risk for atherosclerosis 
      in the short term. The potential for selection bias was investigated with two
      separate propensity score analyses. This study demonstrates the potential benefit
      of THA in reducing mortality and improving aspects of overall health in OA
      patients.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Exponent, Inc., Menlo Park, California.
FAU - Lovald, Scott T
AU  - Lovald ST
FAU - Ong, Kevin L
AU  - Ong KL
FAU - Lau, Edmund C
AU  - Lau EC
FAU - Schmier, Jordana K
AU  - Schmier JK
FAU - Bozic, Kevin J
AU  - Bozic KJ
FAU - Kurtz, Steve M
AU  - Kurtz SM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - J Arthroplasty
JT  - The Journal of arthroplasty
JID - 8703515
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/05 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/17 [accepted]
AID - S0883-5403(13)00335-5 [pii]
AID - 10.1016/j.arth.2013.04.031 [doi]
PST - aheadofprint
SO  - J Arthroplasty. 2013 May 24. pii: S0883-5403(13)00335-5. doi:
      10.1016/j.arth.2013.04.031.

PMID- 23711724
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1096-0309 (Electronic)
IS  - 0003-2697 (Linking)
DP  - 2013 May 24
TI  - Improving the Thermal, Radial and Temporal Accuracy of the Analytical
      Ultracentrifuge through External References.
LID - S0003-2697(13)00241-8 [pii]
LID - 10.1016/j.ab.2013.05.011 [doi]
AB  - Sedimentation velocity (SV) is a method based on first-principles that provides a
      precise hydrodynamic characterization of macromolecules in solution. Due to
      recent improvements in data analysis, the accuracy of experimental SV data
      emerges as a limiting factor in its interpretation. Our goal was to unravel the
      sources of experimental error and develop improved calibration procedures. We
      implemented the use of a Thermochron iButton(R) temperature logger to directly
      measure the temperature of a spinning rotor, and detected deviations that can
      translate into an error of as much as 10% in the sedimentation coefficient. We
      further designed a precision mask with equidistant markers to correct for
      instrumental errors in the radial calibration, which were observed to span a
      range of 8.6%. The need for an independent time calibration emerged with use of
      the current data acquisition software (Zhao et al., doi 10.1016/j.ab.2013.02.011)
      and we now show that smaller but significant time errors of up to 2% also occur
      with earlier versions. After application of these calibration corrections, the
      sedimentation coefficients obtained from eleven instruments displayed a
      significantly reduced standard deviation of approximately 0.7%. This study
      demonstrates the need for external calibration procedures and regular control
      experiments with a sedimentation coefficient standard.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and
      Kidney Diseases, NIH, Bethesda, MD.
FAU - Ghirlando, Rodolfo
AU  - Ghirlando R
FAU - Balbo, Andrea
AU  - Balbo A
FAU - Piszczek, Grzegorz
AU  - Piszczek G
FAU - Brown, Patrick H
AU  - Brown PH
FAU - Lewis, Marc S
AU  - Lewis MS
FAU - Brautigam, Chad A
AU  - Brautigam CA
FAU - Schuck, Peter
AU  - Schuck P
FAU - Zhao, Huaying
AU  - Zhao H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Anal Biochem
JT  - Analytical biochemistry
JID - 0370535
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/04/02 [received]
PHST- 2013/05/08 [revised]
PHST- 2013/05/10 [accepted]
AID - S0003-2697(13)00241-8 [pii]
AID - 10.1016/j.ab.2013.05.011 [doi]
PST - aheadofprint
SO  - Anal Biochem. 2013 May 24. pii: S0003-2697(13)00241-8. doi:
      10.1016/j.ab.2013.05.011.

PMID- 23711700
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1995-7645 (Print)
VI  - 6
IP  - 6
DP  - 2013 Jun
TI  - Role of Moringa oleifera in regulation of diabetes-induced oxidative stress.
PG  - 426-32
LID - 10.1016/S1995-7645(13)60068-1 [doi]
LID - S1995-7645(13)60068-1 [pii]
AB  - OBJECTIVE: To evaluate the antioxidant activity of aqueous extract ofMoringa
      oleifera (M. oleifera) young leaves by in vivo as well as in vitro assays.
      METHODS: In vitro study included estimation of total phenolic, total flavonol,
      total flavonoid and total antioxidant power (FRAP assay). In addition, in vivo
      study was done with the identified most effective dose of 200 mg/kg of its
      lyophilized powder on normal and diabetic rats. Its effect on different oxidative
      free radical scavenging enzymes,viz, superoxide dismutase (SOD), catalase (CAT), 
      glutathione-S-transferase (GST), lipid peroxide (LPO) contents were measured.
      RESULTS: Significant increase in activities of SOD, CAT, GST while, a decrease in
      LPO content was observed. Whereas, total phenolic, flavonoid and flavonol
      contents in the extract were found to be 120 mg/g of GAE, 40.5 mg/g of QE and
      12.12 mg/g of QE, respectively. On the other hand, FRAP assay results ofM.
      oleifera leaves was (85.00+/-5.00)muM/g of extract powder. CONCLUSIONS: The
      significant antioxidant activities ofM. oleifera leaves from both in vivo as well
      as in vitro studies suggests that the regular intake of its leaves through diet
      can protect normal as well as diabetic patients against oxidative damage.
CI  - Copyright (c) 2013 Hainan Medical College. Published by Elsevier B.V. All rights 
      reserved.
AD  - Alternative Therapeutics Unit, Drug Development Division, Medicinal Research
      Lab., Department of Chemistry, University of Allahabad, Allahabad-211 002, India.
FAU - Jaiswal, Dolly
AU  - Jaiswal D
FAU - Rai, Prashant Kumar
AU  - Rai PK
FAU - Mehta, Shikha
AU  - Mehta S
FAU - Chatterji, Sanjukta
AU  - Chatterji S
FAU - Shukla, Surekha
AU  - Shukla S
FAU - Rai, Devendra Kumar
AU  - Rai DK
FAU - Sharma, Gaurav
AU  - Sharma G
FAU - Sharma, Bechan
AU  - Sharma B
FAU - Khair, Shahidul
AU  - Khair S
FAU - Watal, Geeta
AU  - Watal G
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Asian Pac J Trop Med
JT  - Asian Pacific journal of tropical medicine
JID - 101533720
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/10 [received]
PHST- 2013/04/15 [revised]
PHST- 2013/05/15 [accepted]
AID - S1995-7645(13)60068-1 [pii]
AID - 10.1016/S1995-7645(13)60068-1 [doi]
PST - ppublish
SO  - Asian Pac J Trop Med. 2013 Jun;6(6):426-32. doi: 10.1016/S1995-7645(13)60068-1.

PMID- 23711668
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
DP  - 2013 May 24
TI  - The impact of folic acid intake on the association between diabetes, obesity, and
      spina bifida.
LID - S0002-9378(13)00536-X [pii]
LID - 10.1016/j.ajog.2013.05.047 [doi]
AB  - OBJECTIVE: To investigate the relationship between spina bifida and two
      established risk factors, pregestational diabetes and obesity, in both the
      presence and absence of the recommended daily folic acid intake in the
      periconceptional period. STUDY DESIGN: Cases of spina bifida (n=1154) and
      controls (n=9439) from the Slone Epidemiology Center Birth Defects Study
      (1976-2011) were included. Information on preexisting diabetes (collected 1976+) 
      and obesity (collected 1993+), defined as BMI >/=30 kg/m2, were collected through
      interviews conducted within six months of delivery. Periconceptional folic acid
      intake was calculated using both dietary and supplement information. Mothers were
      classified as consuming more or less than 400mug/day of folic acid, with food
      folate included at a 30% discount for its lower bioavailability. Logistic
      regression models, adjusted for maternal race, education, and study site, were
      used to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CI)
      for the joint effects of low folic acid intake coupled with diabetes or obesity. 
      RESULTS: Mothers of cases were more likely to have diabetes or be obese (0.7% and
      19.0%, respectively) than control mothers (0.4% and 10.8%, respectively). The
      joint effect of diabetes and lower folic acid intake on spina bifida was larger
      (aOR:3.95; CI: 1.56, 10.00) than that of diabetes and higher folic acid intake
      (aOR:1.31; CI: 0.17, 10.30). Folic acid intake made little difference on the
      association between obesity and spina bifida. CONCLUSION: Our findings suggest
      that folic acid further attenuates, though does not eliminate, the risk of spina 
      bifida associated with diabetes, than that with obesity.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Boston, MA, Slone Epidemiology Center, Boston University; Ms. Electronic address:
      separker@bu.edu.
FAU - Parker, Samantha E
AU  - Parker SE
FAU - Yazdy, Mahsa M
AU  - Yazdy MM
FAU - Tinker, Sarah C
AU  - Tinker SC
FAU - Mitchell, Allen A
AU  - Mitchell AA
FAU - Werler, Martha M
AU  - Werler MM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/04 [received]
PHST- 2013/03/22 [revised]
PHST- 2013/05/22 [accepted]
AID - S0002-9378(13)00536-X [pii]
AID - 10.1016/j.ajog.2013.05.047 [doi]
PST - aheadofprint
SO  - Am J Obstet Gynecol. 2013 May 24. pii: S0002-9378(13)00536-X. doi:
      10.1016/j.ajog.2013.05.047.

PMID- 23711593
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 24
TI  - Concomitant use of miglitol and mitiglinide as initial combination therapy in
      type 2 diabetes mellitus.
LID - S0168-8227(13)00163-0 [pii]
LID - 10.1016/j.diabres.2013.04.007 [doi]
AB  - AIM: To evaluate the efficacy of miglitol and mitiglinide alone or in combination
      on the metabolic profile and incretin secretion in Japanese type 2 diabetes
      patients. METHODS: Patients on diet and exercise with or without metformin, were 
      randomized to receive either miglitol, mitiglinide, or a combination, three times
      daily for 12 weeks. RESULTS: At 12 weeks, HbA1c decreased significantly (p<0.001)
      and 1,5-AG increased significantly (p<0.001) in all three groups, with the
      greatest change seen with combination therapy. Effective improvement of
      postprandial hyperglycemia was demonstrated by a meal-loading test in all three
      interventions but serum insulin concentration was not increased by miglitol. In a
      subset of patients without prior metformin administration, faster and better
      glycemic control was achieved with the initial combination. After meal loading,
      serum total GLP-1 significantly increased only with miglitol monotherapy (p<0.05)
      and serum total GIP significantly decreased (p<0.01) in the arms employing
      miglitol after 12 weeks. CONCLUSION: Miglitol/mitiglinide combination is more
      potent than monotherapy in improving glycemic control through the reduction of
      postprandial glucose excursion and the simultaneous sparing of additional insulin
      secretion. A marked difference in the effects of miglitol and mitiglinide on
      incretin secretion was also demonstrated.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 
      Matsushima, Kurashiki 701-0192, Japan.
FAU - Tatsumi, Fuminori
AU  - Tatsumi F
FAU - Hashiramoto, Mitsuru
AU  - Hashiramoto M
FAU - Hirukawa, Hidenori
AU  - Hirukawa H
FAU - Kimura, Tomohiko
AU  - Kimura T
FAU - Shimoda, Masashi
AU  - Shimoda M
FAU - Tawaramoto, Kazuhito
AU  - Tawaramoto K
FAU - Kanda-Kimura, Yukiko
AU  - Kanda-Kimura Y
FAU - Anno, Taketoshi
AU  - Anno T
FAU - Kawasaki, Fumiko
AU  - Kawasaki F
FAU - Mune, Tomoatsu
AU  - Mune T
FAU - Matsuki, Michihiro
AU  - Matsuki M
FAU - Kaku, Kohei
AU  - Kaku K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/06 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/04/22 [accepted]
AID - S0168-8227(13)00163-0 [pii]
AID - 10.1016/j.diabres.2013.04.007 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 24. pii: S0168-8227(13)00163-0. doi:
      10.1016/j.diabres.2013.04.007.

PMID- 23711582
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 May 27
TI  - Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.
AB  - The Global Partnership for Effective Diabetes Management, established to provide 
      practical guidance to improve patient outcomes in diabetes, has developed and
      modified recommendations to improve glycaemic control in type 2 diabetes. The
      Global Partnership advocates an individualized therapeutic approach and, as part 
      of the process to customize therapy, has previously identified specific type 2
      diabetes patient subgroups that require special consideration. This article
      builds on earlier publications, expanding the scope of practical guidance to
      include newly diagnosed individuals with complications and women with diabetes in
      pregnancy. Good glycaemic control remains the cornerstone of managing type 2
      diabetes, and plays a vital role in preventing or delaying the onset and
      progression of diabetic complications. Individualizing therapeutic goals and
      treatments to meet glycaemic targets safely and without delay remains paramount, 
      in addition to a wider programme of care to reduce cardiovascular risk factors
      and improve patient outcomes.
AD  - Diabetes Research, School of Life & Health Sciences, Aston University,
      Birmingham, UK.
FAU - Bailey, Clifford J
AU  - Bailey CJ
FAU - Aschner, Pablo
AU  - Aschner P
FAU - Del Prato, Stefano
AU  - Del Prato S
FAU - Lasalle, James
AU  - Lasalle J
FAU - Ji, Linong
AU  - Ji L
FAU - Matthaei, Stephan
AU  - Matthaei S
CN  - on behalf of the Global Partnership for Effective Diabetes Management
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
OTO - NOTNLM
OT  - Global Partnership
OT  - Glycaemic targets
OT  - HbA1c
OT  - individualized therapy
OT  - type 2 diabetes
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 1479164113490765 [pii]
AID - 10.1177/1479164113490765 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 May 27.

PMID- 23711556
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1097-6779 (Electronic)
IS  - 0016-5107 (Linking)
DP  - 2013 May 24
TI  - Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical
      sleeve gastrectomy for treatment of obesity.
LID - S0016-5107(13)01865-8 [pii]
LID - 10.1016/j.gie.2013.04.197 [doi]
AB  - BACKGROUND: Obesity and its associated conditions, including type 2 diabetes and 
      cardiovascular disease, have reached epidemic proportions. High-efficacy,
      high-risk surgical approaches are unlikely to meet the increasing burden of
      disease. Emerging endoscopic technologies have opened the door for endoscopic
      approaches to reproduce many of the benefits of GI weight loss surgery and
      thereby contribute to the effective treatment of obesity and its associated
      disorders. OBJECTIVE: To demonstrate the technical feasibility of transoral
      endoscopic gastric volume reduction with an endoscopic suturing device in a
      fashion similar to sleeve gastrectomy for the treatment of obesity. DESIGN:
      Single-center, pilot feasibility study. PATIENTS: Four human subjects with
      obesity. INTERVENTIONS: Transoral sleeve gastroplasty. MAIN OUTCOME MEASUREMENTS:
      Technical feasibility. RESULTS: We successfully used an endoscopic free-hand
      suturing system in 4 subjects, thus demonstrating the technical feasibility of a 
      novel technique to mimic the anatomic manipulations created by surgical sleeve
      gastrectomy endoscopically. LIMITATIONS: Pilot feasibility study with small
      number of subjects. CONCLUSIONS: Endoscopic sleeve gastroplasty for treatment of 
      obesity is feasible.
CI  - Copyright (c) 2013 American Society for Gastrointestinal Endoscopy. Published by 
      Mosby, Inc. All rights reserved.
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota,
      USA.
FAU - Abu Dayyeh, Barham K
AU  - Abu Dayyeh BK
FAU - Rajan, Elizabeth
AU  - Rajan E
FAU - Gostout, Christopher J
AU  - Gostout CJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Gastrointest Endosc
JT  - Gastrointestinal endoscopy
JID - 0010505
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/14 [received]
PHST- 2013/04/30 [accepted]
AID - S0016-5107(13)01865-8 [pii]
AID - 10.1016/j.gie.2013.04.197 [doi]
PST - aheadofprint
SO  - Gastrointest Endosc. 2013 May 24. pii: S0016-5107(13)01865-8. doi:
      10.1016/j.gie.2013.04.197.

PMID- 23711492
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1421-9778 (Electronic)
IS  - 1015-8987 (Linking)
VI  - 31
IP  - 4-5
DP  - 2013
TI  - Klotho Ameliorates Chemically Induced Endoplasmic Reticulum (ER) Stress
      Signaling.
PG  - 659-72
LID - 10.1159/000350085 [doi]
AB  - Background: Both endoplasmic reticulum (ER) stress, a fundamental cell response
      associated with stress-initiated unfolded protein response (UPR), and loss of
      Klotho, an anti-aging hormone linked to NF-kappaB-induced inflammation, occur in 
      chronic metabolic diseases such as obesity and type 2 diabetes. We investigated
      if the loss of Klotho is causally linked to increased ER stress. Methods: We
      treated human renal epithelial HK-2, alveolar epithelial A549, HEK293, and
      SH-SH-SY5Y neuroblastoma cells with ER stress-inducing agents, thapsigargin
      and/or tunicamycin. Effects of overexpression or siRNA-mediated knockdown of
      Klotho on UPR signaling was investigated by immunoblotting and Real-time PCR.
      Results: Elevated Klotho levels in HK-2 cells decreased expression of ER stress
      markers phospho - IRE1, XBP-1s, BiP, CHOP, pJNK, and phospho-p38, all of which
      were elevated in response to tunicamycin and/or thapsigargin. Similar results
      were observed using A549 cells for XBP-1s, BiP, and CHOP in response to
      thapsigargin. Conversely, knockdown of Klotho in HEK 293 cells using siRNA caused
      further thapsigargin-induced increases in pIRE-1, XBP-1s, and BiP. Klotho
      overexpression in A549 cells blocked thapsigargin-induced caspase and PARP
      cleavage and improved cell viability. Conclusion: Our data indicate that Klotho
      has an important role in regulating ER stress and that loss of Klotho is causally
      linked to ER stress-induced apoptosis.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - From Department of Internal Medicine, University of Texas Medical Branch,
      Galveston, TX.
FAU - Banerjee, Srijita
AU  - Banerjee S
FAU - Zhao, Yanhua
AU  - Zhao Y
FAU - Sarkar, Partha S
AU  - Sarkar PS
FAU - Rosenblatt, Kevin P
AU  - Rosenblatt KP
FAU - Tilton, Ronald G
AU  - Tilton RG
FAU - Choudhary, Sanjeev
AU  - Choudhary S
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - Switzerland
TA  - Cell Physiol Biochem
JT  - Cellular physiology and biochemistry : international journal of experimental
      cellular physiology, biochemistry, and pharmacology
JID - 9113221
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/04/16 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 000350085 [pii]
AID - 10.1159/000350085 [doi]
PST - ppublish
SO  - Cell Physiol Biochem. 2013;31(4-5):659-72. doi: 10.1159/000350085. Epub 2013 May 
      8.

PMID- 23711448
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 May 24
TI  - Integration of exercise evaluation into the algorithm for evaluation of patients 
      with suspected heart failure with preserved ejection fraction.
LID - S0167-5273(13)00915-7 [pii]
LID - 10.1016/j.ijcard.2013.05.006 [doi]
AB  - Approximately half of all patients with heart failure (HF) have a preserved left 
      ventricular ejection fraction (HFPEF) and the prevalence of this form of HF is
      increasing. Although dyspnoea on exertion and diminished functional capacity is
      the key symptom of patients with HFPEF, current diagnostic criteria focus on
      resting indices of ventricular function. Specifically, current proposed criteria 
      for the diagnosis of HFPEF, include clinical signs of HF; normal left ventricular
      systolic function; and evidence of abnormal diastolic performance and/or altered 
      natriuretic peptides. By contrast, recent studies demonstrate that the key
      pathophysiologic features of HFPEF may not be evident at rest, and can only be
      detected during exertion. This review addresses the potential role of exercise
      testing using invasive haemodynamic or echocardiographic assessment in patients
      with suspected HFPEF in which current diagnostic criteria are not met.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Baker IDI Heart and Diabetes Institute, Melbourne, Australia; Heart Center,
      Alfred Hospital, Melbourne, Australia. Electronic address:
      Vanessa.VanEmpel@bakeridi.edu.au.
FAU - van Empel, Vanessa P M
AU  - van Empel VP
FAU - Kaye, David M
AU  - Kaye DM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/12/21 [received]
PHST- 2013/04/08 [revised]
PHST- 2013/05/03 [accepted]
AID - S0167-5273(13)00915-7 [pii]
AID - 10.1016/j.ijcard.2013.05.006 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 May 24. pii: S0167-5273(13)00915-7. doi:
      10.1016/j.ijcard.2013.05.006.

PMID- 23711445
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 May 24
TI  - Red cell distribution width is associated with physical inactivity and heart
      failure, independent of established risk factors, inflammation or iron
      metabolism; the EPIC-Norfolk study.
LID - S0167-5273(13)00911-X [pii]
LID - 10.1016/j.ijcard.2013.05.002 [doi]
AB  - AIMS: Red cell distribution width (RDW) is associated with increased risk of
      heart failure (HF). We examined in a healthy population (1) whether this
      association is independent of cardiovascular risk factors and iron metabolism and
      (2) whether RDW associates with physical activity. METHODS AND RESULTS: Hazard
      ratios (HRs, highest quartile versus lowest quartile of RDW) for the risk of HF
      were calculated in 17,533 participants from the European Prospective
      Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort. During a follow-up
      of 11.2+/-2.2years 640 participants developed a HF event. The HR for HF events
      was 1.44 (95%CI 1.15-1.80, p<0.001). There was a non-linear increase in HF risk
      across RDW quartiles. Adjustment for established risk factors (sex, age,
      diabetes, smoking, systolic blood pressure, total and high-density lipoprotein
      cholesterol) attenuated the HR for HF to 1.40 (95%CI 1.11-1.77, p=0.001).
      Adjustment for CRP, iron and ferritin levels did not affect the HR for HF. RDW
      levels are inversely associated with physical activity (per category beta=-0.37, 
      95%CI -0.053 to -0.021, p<0.0001), independent of iron metabolism. However, the
      association between HF and RDW levels was not changed by physical activity.
      CONCLUSIONS: This study confirms that RDW is associated with HF events in an
      apparently healthy middle-aged population. More importantly, we show that the
      underlying pathophysiology linking HF with anisocytosis is not reflected by
      conventional risk factors, nor it is explained by iron metabolism or
      inflammation. Furthermore, RDW levels were associated with physical inactivity,
      but this did not influence the RDW-associated-risk of heart failure.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Cardiology, University Medical Centre, Utrecht, The Netherlands.
      Electronic address: mireille_emans@hotmail.com.
FAU - Emans, Mireille E
AU  - Emans ME
FAU - Gaillard, Carlo A J M
AU  - Gaillard CA
FAU - Pfister, Roman
AU  - Pfister R
FAU - Tanck, Michael W
AU  - Tanck MW
FAU - Boekholdt, S Matthijs
AU  - Boekholdt SM
FAU - Wareham, Nick J
AU  - Wareham NJ
FAU - Khaw, Kay-Tee
AU  - Khaw KT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/06/25 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/05/03 [accepted]
AID - S0167-5273(13)00911-X [pii]
AID - 10.1016/j.ijcard.2013.05.002 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 May 24. pii: S0167-5273(13)00911-X. doi:
      10.1016/j.ijcard.2013.05.002.

PMID- 23711425
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1872-7727 (Electronic)
IS  - 0720-048X (Linking)
DP  - 2013 May 24
TI  - Contrast induced nephropathy in patients undergoing intravenous (IV) contrast
      enhanced computed tomography (CECT) and the relationship with risk factors: A
      meta-analysis.
LID - S0720-048X(13)00226-X [pii]
LID - 10.1016/j.ejrad.2013.04.029 [doi]
AB  - PURPOSE: To summarize the incidence of contrast-induced nephropathy (CIN) and
      associations between CIN incidence and risk factors in patients undergoing
      intravenous contrast-enhanced computed tomography (CECT) with low- or iso-osmolar
      iodinated contrast medium. METHODS: This review is performed in accordance with
      the preferred reporting items in systematic reviews and meta-analysis (PRISMA)
      guidelines. We searched the MEDLINE, EMBASE and Cochrane databases from 2002 till
      November 2012. Two reviewers included papers and extracted data. The pooled data 
      were analysed by either fixed or random-effects approach depending on
      heterogeneity defined as the I2 index. RESULTS: 42 articles with 18,790 patients 
      (mean age 61.5 years (range: 38-83 years)) were included. The mean baseline eGFR 
      was 59.8mL/min and ranged from 4 to 256mL/min. Of all patients 45.0% had an
      estimated glomerular filtration rate (eGFR)<60mL/min, 55.2% had hypertension;
      20.2% had diabetes mellitus (DM) and 6.5% had congestive heart failure (CHF). The
      overall pooled CIN incidence, defined as a SCr increase of >/=25% or >/=0.5mg/dL,
      was 4.96% (95%CI: 3.79-6.47). Data analysis showed associations between CIN and
      the presence of renal insufficiency, DM, malignancy, age>65 years and use of
      non-steroidal anti-inflammatory drugs (NSAID's) with odds ratios of 1.73 (95%CI: 
      1.06-2.82), 1.87 (95%CI: 1.55-2.26), 1.79 (95%CI: 1.03-3.11), 1.95 (95%CI:
      1.02-3.70) and 2.32 (95%CI: 1.04-5.19), respectively while hypertension, anaemia 
      and CFH were not associated (p=0.13, p=0.38, p=0.40). CONCLUSION: The mean
      incidence of CIN after intravenous iodinated CECT was low and associated with
      renal insufficiency, diabetes, presence of malignancy, old age and NSAID's use.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Radiology, Academic Medical Centre, University of Amsterdam,
      Amsterdam, The Netherlands. Electronic address: s.i.moos@amc.uva.nl.
FAU - Moos, Shira I
AU  - Moos SI
FAU - van Vemde, David N H
AU  - van Vemde DN
FAU - Stoker, Jaap
AU  - Stoker J
FAU - Bipat, Shandra
AU  - Bipat S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Eur J Radiol
JT  - European journal of radiology
JID - 8106411
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/07 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/04/24 [accepted]
AID - S0720-048X(13)00226-X [pii]
AID - 10.1016/j.ejrad.2013.04.029 [doi]
PST - aheadofprint
SO  - Eur J Radiol. 2013 May 24. pii: S0720-048X(13)00226-X. doi:
      10.1016/j.ejrad.2013.04.029.

PMID- 23711420
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
DP  - 2013 May 24
TI  - The impossible return to the Garden of Eden: The ORIGIN trial and the original
      sin of early insulin treatment of type 2 diabetes.
LID - S0939-4753(13)00068-9 [pii]
LID - 10.1016/j.numecd.2013.02.008 [doi]
AD  - Diabetes Agency, Careggi teaching Hospital and University of Florence, Italy.
      Electronic address: edoardo.mannucci@unifi.it.
FAU - Mannucci, E
AU  - Mannucci E
FAU - Monami, M
AU  - Monami M
FAU - Dicembrini, I
AU  - Dicembrini I
FAU - Rotella, C
AU  - Rotella C
LA  - ENG
PT  - LETTER
DEP - 20130524
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/28 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/02/23 [accepted]
AID - S0939-4753(13)00068-9 [pii]
AID - 10.1016/j.numecd.2013.02.008 [doi]
PST - aheadofprint
SO  - Nutr Metab Cardiovasc Dis. 2013 May 24. pii: S0939-4753(13)00068-9. doi:
      10.1016/j.numecd.2013.02.008.

PMID- 23711334
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1475-097X (Electronic)
IS  - 1475-0961 (Linking)
DP  - 2013 May 28
TI  - A study of the association with blood pressure difference causing body
      temperature >/=37.5 degrees C and hypertension in department of primary care.
LID - 10.1111/cpf.12050 [doi]
AB  - Previous studies reported the relationship between significant blood pressure
      difference (DeltaBP) and early atherosclerotic markers. Although it is known that
      body temperature is associated with BP and blood flow, as measured on Korotkoff
      sound graph (KSG), as well as heart rate and sympathetic nerve activity, it
      remains unclear whether moderate fever (>/=37.5 degrees C) can be caused by
      significant DeltaBP. DeltaBP was calculated by subtracting the BP of the left arm
      from that of the right arm. The aim of our study was to investigate whether an
      association exists among DeltaBP, body temperature, hypertension and KSG area
      ratio in 1802 new outpatients examined in a seated position in routine clinical
      practice. Our study documented that absolute systolic blood pressure difference
      (|DeltaSBP|) >/= 10 mmHg (observed in 14.6% of the patients) was associated with 
      a significantly higher heart rate, moderate fever, tachycardia and hypertension. 
      In multivariate analysis, the odds ratios (ORs) of |DeltaSBP| >/= 10 mmHg showed 
      significant associated markers of body temperature and hypertension, while the
      ORs of KSG area ratio >/= 170% showed significant associated markers of sex, age,
      body temperature, hypertension, diabetes mellitus, prior vascular event and
      smoking. In conclusion, our study of new outpatients in the department of primary
      care demonstrated that |DeltaSBP| >/= 10 mmHg and KSG area ratio >/= 170% were
      associated with moderate fever and hypertension. Furthermore, our study suggests 
      that the association of moderate fever with |DeltaSBP| >/= 10 mmHg and KSG area
      ratio >/= 170% is physiologic as well as pathologic.
CI  - (c) 2013 Scandinavian Society of Clinical Physiology and Nuclear Medicine.
      Published by John Wiley & Sons Ltd.
AD  - Department of Biostatistics, School of Public Health, The University of Tokyo,
      Tokyo, Japan; Department of General Medicine, Harasanshin Hospital, Fukuoka,
      Japan.
FAU - Shinji, Maeda
AU  - Shinji M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Clin Physiol Funct Imaging
JT  - Clinical physiology and functional imaging
JID - 101137604
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/11 [received]
PHST- 2013/04/16 [accepted]
AID - 10.1111/cpf.12050 [doi]
PST - aheadofprint
SO  - Clin Physiol Funct Imaging. 2013 May 28. doi: 10.1111/cpf.12050.

PMID- 23711328
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 27
TI  - Calorie restriction is a major determinant of the short-term metabolic effects of
      gastric bypass surgery in obese type 2 diabetic patients.
LID - 10.1111/cen.12254 [doi]
AB  - OBJECTIVE: Roux-en-y-gastric bypass (RYGB) and restrictive weight loss
      interventions, such as Gastric banding (GB) and very-low-calorie diets (VLCD)
      directly impact glucose metabolism, possibly by calorie restriction and/or
      altered secretion of gut hormones. We aimed to establish the direct endocrine and
      metabolic effects of RYGB compared to restrictive interventions in obese
      glucose-tolerant (NGT) subjects and subjects with type 2 diabetes (T2DM). DESIGN:
      controlled, non-randomized observational trial. PATIENTS AND MEASUREMENTS: Four
      groups of obese females received a mixed meal at baseline and 3 weeks after
      intervention; NGT-GB (n=11), NGT-RYGB (n=16), T2DM-RYGB (n=15) and T2DM-VLCD
      (n=12). Normal weight controls (n=12) were studied once. RESULTS: At baseline,
      all obese subjects were hyperinsulinemic. T2DM was associated with hyperglycemia 
      and decreased GLP-1 levels. RYGB and VLCD reduced glucose levels to a similar
      extent in T2DM, insulin levels decreased only after VLCD. Comparison of
      restrictive intervention versus RYGB, showed a more pronounced decrease in
      glucose and insulin AUC after restriction. In NGT and T2DM subjects, RYGB
      increased GLP-1 and PYY levels and decreased Ghrelin levels, whereas VLCD and GB 
      only increased GIP levels. CONCLUSIONS: These data indicate that deterioration of
      glucose metabolism in T2DM is associated with a decline of GLP-1 levels. Calorie 
      restriction facilitates glucose metabolism and blunts hyperinsulinemia in obese
      (diabetic) humans. Additional duodenal exclusion through RYGB induces gut hormone
      release and hyperinsulinemia, but does not improve postprandial glucose levels
      any further. Our data thus strongly suggest that calorie restriction underlies
      the short-term metabolic benefits of RYGB in obese T2DM patients. This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Endocrinology and Metabolism, Leiden University Medical Center, The
      Netherlands.
FAU - Lips, Mirjam A
AU  - Lips MA
FAU - de Groot, Gerrit H
AU  - de Groot GH
FAU - van Klinken, Janb
AU  - van Klinken J
FAU - Aarts, Edo
AU  - Aarts E
FAU - Berends, Frits J
AU  - Berends FJ
FAU - Janssen, Ignace M
AU  - Janssen IM
FAU - Van Ramshorst, Bert
AU  - Van Ramshorst B
FAU - Van Wagensveld, Bart A
AU  - Van Wagensveld BA
FAU - Swank, Dingeman J
AU  - Swank DJ
FAU - Van Dielen, Francois
AU  - Van Dielen F
FAU - van Dijk, Ko Willems
AU  - van Dijk KW
FAU - Pijl, Hanno
AU  - Pijl H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/11/22 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/15 [revised]
PHST- 2013/05/23 [accepted]
AID - 10.1111/cen.12254 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 27. doi: 10.1111/cen.12254.

PMID- 23711326
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 35
IP  - 5
DP  - 2013 Jun
TI  - Factors associated with delayed presentation in patients with TIA and minor
      stroke in China: analysis of data from the China National Stroke Registry (CNSR).
PG  - 517-21
LID - 10.1179/1743132813Y.0000000204 [doi]
AB  - OBJECTIVE: We aimed to evaluate the management of patients with transient
      ischemic attack (TIA) and minor stroke in China. METHODS: Data from the China
      National Stroke Registry (CNSR) were used to identify patients who were admitted 
      to 132 urban hospitals across China with TIA or minor stroke. Factors associated 
      with delayed presentation to hospital were evaluated. Univariate and multivariate
      analyses were performed to analyze relationships between patient characteristics 
      and time of presentation. RESULTS: Of the 7467 patients entered into the CNSR
      (1204 with TIA, 6263 with minor stroke), 780 patients (64.78%) with TIA and 3467 
      patients (55.36%) with minor stroke had delayed presentation to hospital (>24
      hours). In both groups, factors associated with early presentation (</=24 hours) 
      included transportation by ambulance and direct presentation to the emergency
      room. In patients with minor stroke, early presentation was associated with older
      age (65-80 years), motor and sensory symptoms, speech impairment, atrial
      fibrillation, previous TIA, and living in central or eastern China; and delayed
      presentation was associated with female sex, cognitive dysfunction, and diabetes.
      In patients with TIA, early presentation was associated with motor symptoms, and 
      delayed presentation was associated with headache or vertigo. DISCUSSION: In
      China, many patients with TIA and minor stroke do not seek medical treatment
      immediately. Further education is needed to teach members of the public about the
      warning signs and symptoms of TIA and minor stroke, and encourage the use of
      ambulance transportation after TIA or stroke.
AD  - The First Affiliated Hospital of Zheng Zhou University, Henan, China.
FAU - Wang, Linyu
AU  - Wang L
FAU - Chao, Yangyun
AU  - Chao Y
FAU - Zhao, Xingquan
AU  - Zhao X
FAU - Liu, Liping
AU  - Liu L
FAU - Wang, Chunxue
AU  - Wang C
FAU - Wang, David Z
AU  - Wang DZ
FAU - Meng, Xia
AU  - Meng X
FAU - Wang, Anxin
AU  - Wang A
FAU - Wang, Yongjun
AU  - Wang Y
FAU - Xu, Yuming
AU  - Xu Y
LA  - eng
PT  - Journal Article
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.1179/1743132813Y.0000000204 [doi]
PST - ppublish
SO  - Neurol Res. 2013 Jun;35(5):517-21. doi: 10.1179/1743132813Y.0000000204.

PMID- 23711224
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130604
DCOM- 20130605
LR  - 20130605
IS  - 1758-5996 (Electronic)
VI  - 5
IP  - 1
DP  - 2013
TI  - Correlations of non-exercise activity thermogenesis to metabolic parameters in
      Japanese patients with type 2 diabetes.
PG  - 26
LID - 10.1186/1758-5996-5-26 [doi]
AB  - BACKGROUND: Non-exercise activity thermogenesis (NEAT) is the energy expenditure 
      due to physical activities besides active sports-like exercise and resistance
      training in daily life. METHODS: We studied 45 subjects (22 women and 23 men)
      with type 2 diabetes who did not take any hypoglycemic, anti-hypertensive, or
      cholesterol-lowering agents and asked them about physical activity concerned with
      NEAT using an original questionnaire modified from a compendium of physical
      activities. We studied the association of the NEAT score to body weight, waist
      circumference, blood pressure, glucose and lipid metabolism, and arterial
      stiffness. RESULTS: The NEAT score was negatively correlated with serum insulin
      levels (r = -0.42, P < 0.05) in all subjects. The NEAT score was also negatively 
      correlated with waist circumference (r = -0.509, P < 0.05) and positively
      correlated with high-density lipoprotein-cholesterol levels (r = 0.494, P < 0.05)
      in women, and negatively associated with serum insulin levels (r = -0.732, p <
      0.005), systolic (r = -0.482, P < 0.05) and diastolic blood pressure (r = -0.538,
      P < 0.05) in patients with abdominal obesity. Furthermore, the NEAT score was
      negatively associated with pulse wave velocity (r = -0.719, P < 0.005) in
      smokers. CONCLUSION: The study demonstrated that NEAT is associated with
      amelioration in insulin sensitivity, waist circumference, high-density
      lipoprotein-cholesterol, blood pressure and the marker for atherosclerosis in
      patients with type 2 diabetes.
AD  - Department of Internal Medicine, National Center for Global Health and Medicine
      Kohnodai Hospital, Chiba, Japan. dyanai@hospk.ncgm.go.jp.
FAU - Hamasaki, Hidetaka
AU  - Hamasaki H
FAU - Yanai, Hidekatsu
AU  - Yanai H
FAU - Mishima, Shuichi
AU  - Mishima S
FAU - Mineyama, Tomoka
AU  - Mineyama T
FAU - Yamamoto-Honda, Ritsuko
AU  - Yamamoto-Honda R
FAU - Kakei, Masafumi
AU  - Kakei M
FAU - Ezaki, Osamu
AU  - Ezaki O
FAU - Noda, Mitsuhiko
AU  - Noda M
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC3671133
OID - NLM: PMC3671133
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:01
CRDT- 2013/05/29 06:00
PHST- 2013/03/27 [received]
PHST- 2013/05/15 [accepted]
PHST- 2013/05/27 [aheadofprint]
AID - 1758-5996-5-26 [pii]
AID - 10.1186/1758-5996-5-26 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2013 May 27;5(1):26. doi: 10.1186/1758-5996-5-26.

PMID- 23711202
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 25
TI  - Blunted Hypothalamic-Pituitary-Adrenal Axis and Insulin Response to Psychosocial 
      Stress in Young Adults Born Preterm at Very Low Birth Weight.
LID - 10.1111/cen.12251 [doi]
AB  - BACKGROUND: Young adults born preterm at very-low-birth-weight (VLBW, </=1500g)
      have higher levels of cardiovascular risk factors, including impaired glucose
      regulation, than their term-born peers. This could be mediated through altered
      hypothalamic-pituitary-adrenal axis (HPAA) response to stress. OBJECTIVE: To
      compare HPAA, glucose and insulin responses provoked by psychosocial stress in
      VLBW subjects versus a comparison group of term-born controls. DESIGN AND
      PARTICIPANTS: We studied 54 unimpaired young adults, aged 19-27 years, born at
      VLBW and a comparison group of 40 adults born at term, group-matched for age, sex
      and birth hospital, from one regional centre in Southern Finland. The
      participants underwent a standardized psychosocial stress test (Trier Social
      Stress Test, TSST). MEASUREMENTS: In conjunction with TSST we measured salivary
      cortisol, plasma ACTH, cortisol, glucose and insulin. Data were analyzed with
      mixed effects model and multiple linear regression analyses. RESULTS: Baseline
      concentrations for cortisol, ACTH, insulin and glucose were similar in VLBW and
      comparison groups. During TSST, analyzed with mixed effects model, overall
      concentrations of plasma cortisol were 17.2% lower (95% CI; 3.5 to 28.9) in the
      VLBW group. The VLBW group also had lower salivary (P=0.04) and plasma cortisol
      (P=0.02) responses to TSST. Insulin and glucose concentrations correlated with
      changes in cortisol concentrations. Accordingly, VLBW subjects had 26.5% lower
      increment of insulin (95% CI; 9.8 to 40.1). Analyses were adjusted for age, sex, 
      BMI, hormonal contraception, menstrual cycle phase, time of day and parental
      education. CONCLUSIONS: VLBW adults have lower HPAA responses to psychosocial
      stress than term-born controls. This is accompanied by a lower insulin response. 
      This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Chronic Disease and Diabetes Prevention, National Institute for
      Health and Welfare, Helsinki, Finland; Children's Hospital, Helsinki University
      Central Hospital and University of Helsinki, Helsinki, Finland.
FAU - Kaseva, Nina
AU  - Kaseva N
FAU - Wehkalampi, Karoliina
AU  - Wehkalampi K
FAU - Pyhala, Riikka
AU  - Pyhala R
FAU - Moltchanova, Elena
AU  - Moltchanova E
FAU - Feldt, Kimmo
AU  - Feldt K
FAU - Pesonen, Anu-Katriina
AU  - Pesonen AK
FAU - Heinonen, Kati
AU  - Heinonen K
FAU - Hovi, Petteri
AU  - Hovi P
FAU - Jarvenpaa, Anna-Liisa
AU  - Jarvenpaa AL
FAU - Andersson, Sture
AU  - Andersson S
FAU - Eriksson, Johan G
AU  - Eriksson JG
FAU - Raikkonen, Katri
AU  - Raikkonen K
FAU - Kajantie, Eero
AU  - Kajantie E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/27 [received]
PHST- 2013/04/17 [revised]
PHST- 2013/05/20 [revised]
PHST- 2013/05/22 [accepted]
AID - 10.1111/cen.12251 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 25. doi: 10.1111/cen.12251.

PMID- 23711193
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 27
TI  - Options for Prandial Glucose Management in Type 2 Diabetes Patients Using Basal
      Insulin: Addition of a Short-acting GLP-1 Analogue versus Progression to
      Basal-Bolus Therapy.
LID - 10.1111/dom.12136 [doi]
AB  - Integrating patient-centered diabetes care and algorithmic medicine poses
      particular challenges when optimized basal insulin fails to maintain glycemic
      control in patients with type 2 diabetes. Multiple entwined physiological,
      psychosocial, and systems barriers to insulin adherence are not easily studied
      and are not adequately considered in most treatment algorithms. Moreover, the
      limited number of alternatives to add-on prandial insulin therapy has hindered
      shared decision-making, a central feature of patient-centered care. This article 
      considers how the addition of a GLP-1 analogue to basal insulin may provide new
      opportunities at this stage of treatment, especially for patients concerned about
      weight gain and risk of hypoglycemia. A flexible framework for patient-clinician 
      discussions is presented to encourage development of decision-support tools
      applicable to both specialty and primary care practice.
CI  - This article is protected by copyright. All rights reserved.
AD  - University of Washington School of Medicine, Seattle, WA.
FAU - Hirsch, Irl B
AU  - Hirsch IB
FAU - Buse, John B
AU  - Buse JB
FAU - Leahy, Jack
AU  - Leahy J
FAU - McGill, Janet B
AU  - McGill JB
FAU - Peters, Anne
AU  - Peters A
FAU - Rodbard, Helena W
AU  - Rodbard HW
FAU - Rubin, Richard R
AU  - Rubin RR
FAU - Skyler, Jay S
AU  - Skyler JS
FAU - Verderese, Carol A
AU  - Verderese CA
FAU - Riddle, Matthew C
AU  - Riddle MC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/04/30 [received]
PHST- 2013/05/16 [revised]
PHST- 2013/05/19 [accepted]
AID - 10.1111/dom.12136 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 27. doi: 10.1111/dom.12136.

PMID- 23711188
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
DP  - 2013 May 27
TI  - Effects of Short-Term Sitagliptin Treatment on Immune Parameters in Healthy
      Individuals, A Randomized Placebo-Controlled Study.
LID - 10.1111/cei.12144 [doi]
AB  - Sitagliptin, a dipeptidyl-peptidase 4 (DPP-4) inhibitor, improves blood glucose
      control in patients with type 2 diabetes by blocking cleavage of glucagon like
      peptide 1 (GLP-1). In type 2 diabetes patients, sitagliptin use is associated
      with an increase in minor infections, and in new-onset type 1 diabetes patients, 
      the ability of sitagliptin to dampen autoimmunity is currently being tested.
      DPP-4, also known as CD26, is expressed on leukocytes and can inactivate many
      chemokines important for leukocyte migration, as well as act as a costimulatory
      molecule on T cells. Therefore, this study was conducted to test whether
      sitagliptin is immunomodulatory. In this randomized, placebo-controlled trial,
      healthy volunteers were given sitagliptin or placebo daily for 28 days, and blood
      was drawn for immune assays. No significant differences were observed in
      percentage of leukocyte subsets within peripheral blood mononuclear cells
      (PBMCs), plasma chemokine/cytokine levels, or cytokines released by stimulation
      of PBMCs with either LPS or anti-CD3. Individuals taking sitagliptin displayed
      increases in the percentage of cells expressing higher levels of CD26 at early
      time points compared to placebo controls, but these differences resolved by day
      28 of treatment. Therefore, in healthy volunteers, treatment with sitagliptin
      daily for 28 days does not overtly alter systemic immune function.
CI  - This article is protected by copyright. All rights reserved.
AD  - Diabetes Endocrinology and Obesity Branch, National Institute of Diabetes and
      Digestive and Kidney Diseases, National Institutes of Health, Bethesda MD 20892.
FAU - Price, Jeffrey D
AU  - Price JD
FAU - Linder, Grace
AU  - Linder G
FAU - Li, Wai Ping
AU  - Li WP
FAU - Zimmermann, Barret
AU  - Zimmermann B
FAU - Rother, Kristina I
AU  - Rother KI
FAU - Malek, Rana
AU  - Malek R
FAU - Alattar, May
AU  - Alattar M
FAU - Tarbell, Kristin V
AU  - Tarbell KV
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/05/21 [accepted]
AID - 10.1111/cei.12144 [doi]
PST - aheadofprint
SO  - Clin Exp Immunol. 2013 May 27. doi: 10.1111/cei.12144.

PMID- 23711060
OWN - NLM
STAT- In-Process
DA  - 20130528
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 4
DP  - 2013 Apr
TI  - [Use of vildagliptin from an internal disease specialists point of view].
PG  - 322-4
AB  - Dipeptidyl peptidase 4 inhibitors (DPP 4) are used as an oral hypoglycaemic agent
      in Type- 2 diabetic patients. From a clinical point of view the most important
      advantages of this preparation are improved diabetes compensation, significant
      reduction of hypoglycaemia risk compared with sulfonylurea derivatives, neutral
      weight profile and good GIT tolerance. Vildagliptin is a molecule from the group 
      of DPP 4 inhibitors which is recently used in internal outpatient care.
AD  - Centrum diabetologie, Klinika diabetologie, Institut Klinicke a experimentalni
      mediciny, Praha.
FAU - Koznarova, R
AU  - Koznarova R
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Vyuziti vildagliptinu z pohledu interniho lekare.
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 40597 [pii]
PST - ppublish
SO  - Vnitr Lek. 2013 Apr;59(4):322-4.

PMID- 23711049
OWN - NLM
STAT- In-Process
DA  - 20130528
IS  - 0042-773X (Print)
IS  - 0042-773X (Linking)
VI  - 59
IP  - 4
DP  - 2013 Apr
TI  - [Changes in weight and diabetes compensation (HbA1c) in patients with diabetes
      mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28
      diabetology departments in the Czech Republic - BIBYII study (observations
      lasting 24 months)].
PG  - 249-55
AB  - BIBYII STUDY OBJECTIVE: To obtain experience with longterm (24 months) exenatide 
      treatment (Byetta) in patients with diabetes mellitus type 2 from a common
      clinical practice of diabetology departments in the Czech Republic. TYPE OF
      OBSERVATION: Observational study conducted by a randomly selected group of
      outpatient medical practitioners from 28 diabetology departments in the Czech
      Republic. OBSERVED AND ASSESSED POPULATION: From the original population of 465
      patients, who underwent a minimum of three months Byetta treatment, 169 patients 
      (36.6%) remained during the second prolonged observation after 18 months, and 76 
      patients completed 24 months of uninterrupted Byetta treatment. The following
      basic information about the patients was collected: year of birth, sex, age when 
      diabetes mellitus (DM) manifested, height, maximum weight before diabetes and
      when DM manifested. The study recorded the following values in three- month
      intervals: weight, waistline, glycated haemoglobin (HbA1c), and DM treatment. The
      population of the prolonged observation comprised 50.3% women and 49.7 % men, and
      the average age at the time of DM2 manifestation was 48.0 (20- 73 years).
      RESULTS: At the beginning of Byetta treatment, the average maximum BMI in the
      subpopulation observed for 24 months was 38.44; after 3, 6, 9, 12 and 24 months
      the following levels were measured, respectively: 36.79, 36.22, 35.91, 35.57 and 
      35.58. The original HbA1c level of 7.44% at the beginning of Byetta treatment
      decreased after 3, 6, 9, 12 and 24 months to 6.33, 5.98, 5.83, 5.86 and 5.93%.
      CONCLUSION: Adding Byetta to the currently applied treatment of obese patients
      with diabetes mellitus type 2 over a period of 24 months has led to an
      improvement in HbA1c level by 1.51%, and BMI level was reduced by 2.37 after two 
      years of Byetta treatment.
AD  - Interni Klinika, Lekarske Fakulty UK a FN Motol, Praha.
      jindra.perusicova@seznam.cz
FAU - Perusicova, J
AU  - Perusicova J
FAU - Pithova, P
AU  - Pithova P
FAU - Haladova, I
AU  - Haladova I
FAU - Diabetologu, A Pracovni Skupina
AU  - Diabetologu AP
FAU - Acsova, D
AU  - Acsova D
FAU - Belobradkova, J
AU  - Belobradkova J
FAU - Belzova, A
AU  - Belzova A
FAU - Berkova, K
AU  - Berkova K
FAU - Dolezalova, B
AU  - Dolezalova B
FAU - Dvorakova, H
AU  - Dvorakova H
FAU - Hejnicova, K
AU  - Hejnicova K
FAU - Hudcova, M
AU  - Hudcova M
FAU - Kallmunzerova, D
AU  - Kallmunzerova D
FAU - Krejsova, Z
AU  - Krejsova Z
FAU - Markofova, G
AU  - Markofova G
FAU - Mullerova, H
AU  - Mullerova H
FAU - Owen, K
AU  - Owen K
FAU - Pelikanova, M
AU  - Pelikanova M
FAU - Raclavska, L
AU  - Raclavska L
FAU - Racicka, E
AU  - Racicka E
FAU - Skarpova, O
AU  - Skarpova O
FAU - Vachova, A
AU  - Vachova A
FAU - Vesela, A
AU  - Vesela A
FAU - Vyoralova, J
AU  - Vyoralova J
FAU - Broz, J
AU  - Broz J
FAU - Edelsberger, T
AU  - Edelsberger T
FAU - Honka, M
AU  - Honka M
FAU - Hrdina, T
AU  - Hrdina T
FAU - Chmura, P
AU  - Chmura P
FAU - Tosovsky, J
AU  - Tosovsky J
LA  - cze
PT  - English Abstract
PT  - Journal Article
TT  - Zmeny hmotnosti a kompenzace diabetu (HbA1c) u nemocnych s diabetes mellitus 2.
      typu po pridani exenatidu (Byetta) ke stavajici lecbe ve 28 diabetologickych
      ambulancich v CR - studie BIBYII (sledovani 24 mesicu).
PL  - Czech Republic
TA  - Vnitr Lek
JT  - Vnitrni lekarstvi
JID - 0413602
SB  - IM
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 40571 [pii]
PST - ppublish
SO  - Vnitr Lek. 2013 Apr;59(4):249-55.

PMID- 23711019
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 27
TI  - WITHDRAWN: Diabetes Attitudes, Wishes and Needs: Second Study
      (DAWN2).Cross-national benchmarking of diabetes-related psychosocial outcomes.
LID - 10.1111/dme.12245 [doi]
AD  - Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy.
FAU - Nicolucci, A
AU  - Nicolucci A
FAU - Kovacs Burns, K
AU  - Kovacs Burns K
FAU - Holt, R I G
AU  - Holt RI
FAU - Comaschi, M
AU  - Comaschi M
FAU - Hermanns, N
AU  - Hermanns N
FAU - Ishii, H
AU  - Ishii H
FAU - Kokoszka, A
AU  - Kokoszka A
FAU - Pouwer, F
AU  - Pouwer F
FAU - Skovlund, S E
AU  - Skovlund SE
FAU - Stuckey, H
AU  - Stuckey H
FAU - Tarkun, I
AU  - Tarkun I
FAU - Vallis, M
AU  - Vallis M
FAU - Wens, J
AU  - Wens J
FAU - Peyrot, M
AU  - Peyrot M
CN  - The DAWN2 Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.1111/dme.12245 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 27. doi: 10.1111/dme.12245.

PMID- 23710993
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1751-553X (Electronic)
IS  - 1751-5521 (Linking)
DP  - 2013 May 28
TI  - Association of 25-hydroxyvitamin D with anemia risk in patients scheduled for
      cardiac surgery.
LID - 10.1111/ijlh.12112 [doi]
AB  - INTRODUCTION: There is emerging data that vitamin D plays a role in
      erythropoiesis. Low 25-hydroxyvitamin D (25OHD) levels may therefore be a risk
      factor for anemia in patients scheduled for cardiac surgery. METHODS: We
      investigated 4428 consecutive cardiac surgical patients to determine an
      association between anemia (hemoglobin concentration <12.5 g/dL, 27.1% of the
      study cohort) and circulating 25OHD. RESULTS: In patients with severe vitamin D
      deficiency (25OHD < 12.5 nm), mean hemoglobin concentrations were 0.80 g/dL lower
      compared with patients with adequate 25OHD levels (50.0-100 nm). Hemoglobin
      levels were not significantly different at 25OHD levels above 100 nm compared
      with 50.0-100 nm. In multivariable-adjusted logistic regression analyses, the
      odds ratios for anemia of the groups with severe and moderate vitamin D
      deficiency (12.5-29.9 nm) were 1.70 (95% CI:1.09-2.63) and 1.41 (95%
      CI:1.02-1.96), respectively, compared with patients who had circulating 25OHD
      levels of 75-100 nm. Prevalence of deficient circulating 25OHD levels was highest
      in anemia of chronic kidney disease. CONCLUSION: This cross-sectional study
      demonstrates an independent association between vitamin D status and anemia risk 
      with optimal 25OHD levels of 75-100 nm. Randomized controlled trials are needed
      to clarify whether this association is causal.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North
      Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany.
FAU - Zittermann, Armin
AU  - Zittermann A
FAU - Kuhn, Joachim
AU  - Kuhn J
FAU - Dreier, Jens
AU  - Dreier J
FAU - Knabbe, Cornelius
AU  - Knabbe C
FAU - Prokop, Sylvana
AU  - Prokop S
FAU - Gummert, Jan F
AU  - Gummert JF
FAU - Borgermann, Jochen
AU  - Borgermann J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/19 [received]
PHST- 2013/04/30 [accepted]
AID - 10.1111/ijlh.12112 [doi]
PST - aheadofprint
SO  - Int J Lab Hematol. 2013 May 28. doi: 10.1111/ijlh.12112.

PMID- 23710971
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 27
TI  - WITHDRAWN: Beyond the data: moving towards a new DAWN in diabetes.
LID - 10.1111/dme.12244 [doi]
AD  - Department of Medical Education, University of Michigan Medical School, Ann
      Arbor, MI, USA.
FAU - Funnell, M
AU  - Funnell M
LA  - ENG
PT  - EDITORIAL
DEP - 20130527
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.1111/dme.12244 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 27. doi: 10.1111/dme.12244.

PMID- 23710907
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 May 27
TI  - Decreased excitability of the distal motor nerve of young patients with type 1
      diabetes mellitus.
LID - 10.1111/pedi.12048 [doi]
AB  - OBJECTIVE: The compound muscle action potential (CMAP) scan is a novel
      neurophysiological technique that appears more sensitive in detecting peripheral 
      motor neuropathy than conventional methods. This study explores the value of the 
      CMAP scan for the detection of subclinical diabetic peripheral motor neuropathy. 
      METHODS: In this cross-sectional pilot study, CMAP scanning of the peroneal nerve
      was performed in (i) 13 well-controlled patients (8-25 yr old) with type 1
      diabetes mellitus (T1DM) duration between 2.5 and 5 yr; (ii) 17 patients (10-25
      yr old) with a duration of T1DM of at least 10 yr, poorly controlled and/or with 
      microvascular complications and (iii) 13 adults with T1DM and established
      clinical diabetic peripheral neuropathy (DPN). Various CMAP scan variables,
      including measures of axonal excitability and axonal loss and reinnervation, were
      compared between patients and healthy controls. RESULTS: Axonal excitability was 
      significantly decreased in the young patient groups as compared to their
      controls. The CMAP scan measures of axonal loss and reinnervation differed only
      between patients with clinical DPN and their controls. CONCLUSIONS: Motor nerve
      axonal excitability seems to be reduced early in T1DM, even in well-controlled
      young patients, and probably before (irreversible) axonal damage occurs. These
      changes can be measured by the CMAP scan, which makes this a promising tool for
      detecting nerve dysfunction in T1DM.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Diabeter, Center for Pediatric and Adolescent Diabetes Care and Research,
      Rotterdam, The Netherlands; Department of Pediatric Endocrinology, Sophia
      Children's Hospital, Erasmus MC, University Medical Centre, Rotterdam, The
      Netherlands.
FAU - van der Heyden, Jc
AU  - van der Heyden J
FAU - van der Meer, P
AU  - van der Meer P
FAU - Birnie, E
AU  - Birnie E
FAU - de Coo, Ifm
AU  - de Coo I
FAU - Castro Cabezas, M
AU  - Castro Cabezas M
FAU - Ozcan, B
AU  - Ozcan B
FAU - Veeze, Hj
AU  - Veeze H
FAU - Visser, Gh
AU  - Visser G
FAU - Aanstoot, Hj
AU  - Aanstoot H
FAU - Blok, Jh
AU  - Blok J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/11/14 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/04/04 [accepted]
AID - 10.1111/pedi.12048 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 May 27. doi: 10.1111/pedi.12048.

PMID- 23710902
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 26
TI  - Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia
      risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart 
      in Type 1 diabetes (BEGIN Basal-Bolus Type 1): 2-year results of a randomized
      clinical trial.
LID - 10.1111/dme.12243 [doi]
AB  - AIMS: The goal of this study was to compare the long-term safety and efficacy of 
      ultra-long-acting basal insulin degludec with insulin glargine (both with insulin
      aspart) in Type 1 diabetes, over a 2-year time period. METHODS: This open-label
      trial comprised a 1-year main trial and a 1-year extension. Patients were
      randomized to once-daily insulin degludec or insulin glargine and titrated to
      pre-breakfast plasma glucose values of 3.9-4.9 mmol/l. RESULTS: The rate of
      nocturnal confirmed hypoglycaemia was 25% lower with insulin degludec than with
      insulin glargine (P = 0.02). Rates of confirmed hypoglycaemia, severe
      hypoglycaemia and adverse events, and reductions in glycated haemoglobin and
      fasting plasma glucose were similar between groups. Despite achieving similar
      glycaemic control, insulin degludec-treated patients used 12% less basal and 9%
      less total daily insulin than did insulin glargine-treated patients (P < 0.01).
      CONCLUSIONS: Long-term basal therapy using insulin degludec in Type 1 diabetes
      required lower doses and was associated with a 25% lower risk for nocturnal
      hypoglycaemia than insulin glargine. (Clinical Trials Registry No; NCT 01198041).
CI  - This article is protected by copyright. All rights reserved.
AD  - Atlanta Diabetes Associates, Atlanta, GA.
FAU - Bode, B W
AU  - Bode BW
FAU - Buse, J B
AU  - Buse JB
FAU - Fisher, M
AU  - Fisher M
FAU - Garg, S K
AU  - Garg SK
FAU - Marre, M
AU  - Marre M
FAU - Merker, L
AU  - Merker L
FAU - Renard, E
AU  - Renard E
FAU - Russell-Jones, D L
AU  - Russell-Jones DL
FAU - Hansen, C T
AU  - Hansen CT
FAU - Rana, A
AU  - Rana A
FAU - Heller, S R
AU  - Heller SR
CN  - The BEGIN(R) Basal-Bolus Type 1 Trial Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/01 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/05/22 [accepted]
AID - 10.1111/dme.12243 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 26. doi: 10.1111/dme.12243.

PMID- 23710892
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1369-7625 (Electronic)
IS  - 1369-6513 (Linking)
DP  - 2013 May 27
TI  - A systematic review of research into black and ethnic minority patients' views on
      self-management of type 2 diabetes.
LID - 10.1111/hex.12080 [doi]
AB  - CONTEXT: Eliciting patients' views of type 2 diabetes self-management provides
      insights on how policy and services might better support the needs of this
      population. OBJECTIVE: To synthesize black and ethnic minority patients' views on
      the barriers and facilitators influencing the self-management of type 2 diabetes.
      SEARCH STRATEGY: A systematic search of international literature published in
      nine electronic databases was undertaken in 2008. Search strategies used both
      MeSH and free-text terms. Two relevant journals were also hand searched.
      INCLUSION CRITERIA: Any primary empirical study published in the English language
      since 1986 that reported black and ethnic minority patients' views on type 2
      diabetes self-management. DATA EXTRACTION AND SYNTHESIS: Data were extracted and 
      study quality was formally assessed. Data were analysed using thematic synthesis.
      MAIN RESULTS: Fifty-seven studies were included, of qualitative (n = 54),
      mixed-method (n = 2) or quantitative (n = 1) design. Studies were from North
      America (n = 41), Europe (n = 14) and Australia (n = 2), including 1735
      participants in total. Three analytical themes emerged: 'Importance of identity';
      'Being understood by others' and 'Making sense of condition', all linked
      conceptually under the overarching theme 'Sense of self'. The quality of the
      studies varied. DISCUSSION AND CONCLUSIONS: The findings provide insight into
      what black and minority ethnic people regard as the barriers to, and facilitators
      of self-management, as opposed to what health professionals, policy makers and
      trial researchers may have assumed. Recognition of the views of people with
      diabetes is essential for the design and delivery of patient-centred care and
      policies.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - School of Healthcare, Baines Wing, University of Leeds, UK.
FAU - Majeed-Ariss, Rabiya
AU  - Majeed-Ariss R
FAU - Jackson, Cath
AU  - Jackson C
FAU - Knapp, Peter
AU  - Knapp P
FAU - Cheater, Francine M
AU  - Cheater FM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Health Expect
JT  - Health expectations : an international journal of public participation in health 
      care and health policy
JID - 9815926
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/04/23 [accepted]
AID - 10.1111/hex.12080 [doi]
PST - aheadofprint
SO  - Health Expect. 2013 May 27. doi: 10.1111/hex.12080.

PMID- 23710887
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 May 27
TI  - Anthropometric predictors of visceral adiposity in normal-weight and obese
      adolescents.
LID - 10.1111/pedi.12042 [doi]
AB  - BACKGROUND: Obesity and fat distribution patterns [subcutaneous vs. visceral
      adipose tissue (VAT)] are important predictors of future cardiometabolic risk. As
      accurate VAT measurement entails imaging, surrogate anthropometric measurements
      that would be cheaper and quicker to obtain would be highly desirable. Sagittal
      abdominal diameter (SAD) may be better than other VAT surrogate measures in
      adults, but the value of SAD to predict magnetic resonance imaging
      (MRI)-determined VAT in adolescents of different races, sexes, and pubertal
      stages has not been determined. AIM: To test the hypothesis that SAD correlates
      more strongly with volumetric VAT than other anthropometric measurements,
      independent of age, sex, race, and Tanner stage. SUBJECTS AND METHODS:
      Twenty-eight normal-weight and 44 obese adolescents underwent Tanner staging,
      anthropometric examinations, and abdominal MRI for volumetric partitioned fat
      calculation. RESULTS: VAT increased exponentially in the body mass index (BMI) > 
      97th percentile range. SAD, waist circumference (WC), BMI, and BMI Z-score
      correlated strongly with VAT (correlation coefficients of 0.85-0.86, all p-values
      < 0.0005); waist-hip ratio was less predictive of VAT (r = 0.68, p < 0.0005). On 
      hierarchical regression, the strongest predictors of VAT in obese subjects were
      BMI Z-score and SAD (R2 = 0.34 vs. 0.31, respectively, p < 0.0005); in
      normal-weight subjects, most anthropometric measures predicted VAT equally (R2 = 
      0.16-0.18, p-values = 0.018-0.026). CONCLUSIONS: Unlike adults, in obese
      adolescents, SAD is not the strongest predictor of visceral adiposity. BMI
      Z-score is equivalently predictive and, together with BMI, provides sufficient
      information to assess visceral adiposity; more specialized anthropometric
      measurements (e.g., SAD and WC) do not add additional predictive value.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Pediatrics-Section of Adult and Pediatric Endocrinology Diabetes, and Metabolism,
      The University of Chicago, Chicago, IL, 60637, USA.
FAU - Koren, Dorit
AU  - Koren D
FAU - Marcus, Carole L
AU  - Marcus CL
FAU - Kim, Christopher
AU  - Kim C
FAU - Gallagher, Paul R
AU  - Gallagher PR
FAU - Schwab, Richard
AU  - Schwab R
FAU - Bradford, Ruth M
AU  - Bradford RM
FAU - Zemel, Babette S
AU  - Zemel BS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/11/21 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/03/26 [accepted]
AID - 10.1111/pedi.12042 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 May 27. doi: 10.1111/pedi.12042.

PMID- 23710839
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 26
TI  - WITHDRAWN: Diabetes Attitudes, Wishes and Needs: Second Study (DAWN2).
      Cross-national comparisons on barriers and resources for optimal care-healthcare 
      professional perspective.
LID - 10.1111/dme.12242 [doi]
AD  - Faculty of Medicine, University of Southampton, Southampton, UK.
FAU - Holt, R I G
AU  - Holt RI
FAU - Nicolucci, A
AU  - Nicolucci A
FAU - Kovacs Burns, K
AU  - Kovacs Burns K
FAU - Escalante, M
AU  - Escalante M
FAU - Forbes, A
AU  - Forbes A
FAU - Hermanns, N
AU  - Hermanns N
FAU - Kalra, S
AU  - Kalra S
FAU - Massi-Benedetti, M
AU  - Massi-Benedetti M
FAU - Mayorov, A
AU  - Mayorov A
FAU - Menendez-Torre, E
AU  - Menendez-Torre E
FAU - Munro, N
AU  - Munro N
FAU - Skovlund, S E
AU  - Skovlund SE
FAU - Tarkun, I
AU  - Tarkun I
FAU - Wens, J
AU  - Wens J
FAU - Peyrot, M
AU  - Peyrot M
CN  - The DAWN2 Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.1111/dme.12242 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 26. doi: 10.1111/dme.12242.

PMID- 23710834
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1365-2567 (Electronic)
IS  - 0019-2805 (Linking)
DP  - 2013 May 25
TI  - Rapamycin unbalances the polarization of human macrophages to M1.
LID - 10.1111/imm.12126 [doi]
AB  - Plasticity is a hallmark of macrophages, and in response to environmental signals
      these cells undergo different forms of polarized activation, the extremes of
      which are called classic (M1) and alternative (M2). Rapamycin (RAPA) is crucial
      for survival and functions of myeloid phagocytes, but its effects on macrophage
      polarization are not yet studied. To address this issue, human macrophages
      obtained from six normal blood donors were polarized to M1 or M2 in vitro by LPS 
      plus IFN-gamma or IL-4, respectively. The presence of RAPA (10 ng/ml) induced
      macrophage apoptosis in M2 but not in M1. Beyond the impact on survival in M2
      RAPA reduced CXCR4, CD206 and CD209 expression and SCGF-beta, CCL18 and CCL13
      release. On the other side, in M1 RAPA increased CD86 and CCR7 expression and
      IL-6, TNF-alpha and IL-1beta1gamma release while it reduced CD206 and CD209
      expression and IL-10, VEGF and CCL18 release. In view of the in vitro data, we
      examined the in vivo effect of RAPA monotherapy (0.1 mg/kg/day) in 12 patients
      who were treated for at least 1 month prior to islet transplant. Cytokine release
      by TLR4-stimulated peripheral blood mononuclear cells showed a clear shift to an 
      M1-like profile. Moreover, macrophage polarization 21 days after treatment showed
      a significant quantitative shift to M1. These results suggest a role of mTOR into
      the molecular mechanisms of macrophage polarization and propose new therapeutic
      strategies for human M2-related diseases through mTOR inhibitor treatment. This
      article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Diabetes Research Institute (HSR-DRI), San Raffaele Scientific Institute, Milan, 
      Italy.
FAU - Mercalli, Alessia
AU  - Mercalli A
FAU - Calavita, Ines
AU  - Calavita I
FAU - Dugnani, Erica
AU  - Dugnani E
FAU - Citro, Antonio
AU  - Citro A
FAU - Cantarelli, Elisa
AU  - Cantarelli E
FAU - Nano, Rita
AU  - Nano R
FAU - Melzi, Raffaella
AU  - Melzi R
FAU - Maffi, Paola
AU  - Maffi P
FAU - Secchi, Antonio
AU  - Secchi A
FAU - Sordi, Valeria
AU  - Sordi V
FAU - Piemonti, Lorenzo
AU  - Piemonti L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Immunology
JT  - Immunology
JID - 0374672
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/26 [received]
PHST- 2013/05/17 [revised]
PHST- 2013/05/21 [accepted]
AID - 10.1111/imm.12126 [doi]
PST - aheadofprint
SO  - Immunology. 2013 May 25. doi: 10.1111/imm.12126.

PMID- 23710767
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 14
IP  - 1
DP  - 2013 May 28
TI  - Restless legs syndrome and quality of sleep in patients with glomerulopathy.
PG  - 113
AB  - BACKGROUND: Despite a confirmed association between restless legs syndrome (RLS) 
      and end-stage renal disease (ESRD), there is no study on patients presenting with
      nephrotic syndrome (NS). To investigate the frequency of RLS and poor quality
      sleep in NS-patients secondary to primary glomerulopathy with nearly normal
      glomerular filtration rate (GFR) and its associated factors. METHODS: Patients
      with NS, defined as 24 h-urine protein greater than 3.5 g/1.73 m2 and
      hypoalbuminemia, (n = 99, 53 women) and a mean age of 36+/-11 years were studied.
      Age and sex-matched controls were used to compare RLS and poor sleep quality
      prevalence. Standardized RLS questionnaire formulated by the International
      Restless Legs Syndrome and Pittsburgh Sleep Quality Index (PSQI) were used.
      RESULTS: RLS was more frequent in NS-patients than in controls (22.8 vs. 4.0%, p 
      = 0.01). Mean time since diagnosis (52.2+/-34.1 vs. 28.6+/-22.5 months, p < 0.01)
      and 24 h-proteinuria (3.7+/-1.3 vs. 2.6+/-0.6 g/1.73 m2, p = 0.001) were greater 
      in NS-patients with RLS those not presenting RLS. Association between RLS with 24
      h-proteinuria [OR = 2.31; p = 0.007; 95% CI 1.87-2.89] and time since diagnosis
      [OR = 1.10; p = 0.003; CI = 1.02-1.39] were identified even after controlling for
      age, GFR and diabetes. Sleep quality was poor in NS-patients than in controls
      (mean PSQI score 7.35+/-3.7 vs. 5.2+/-3.0, p = 0.003). In NS-patients, only RLS
      was associated with poor sleep quality (OR = 1.20; p = 0.004). CONCLUSION: Poor
      quality sleep and RLS are frequent in NS-patients without ESRD. Pathophysiology
      of this association must be further investigated.
FAU - Liborio, Alexandre Braga
AU  - Liborio AB
FAU - Santos, Joao Paulo
AU  - Santos JP
FAU - Minete, Natalia Feitosa
AU  - Minete NF
FAU - de Diogenes, Cecilia Alencar
AU  - de Diogenes CA
FAU - de Farias, Luiza Andrade
AU  - de Farias LA
FAU - de Bruin, Veralice Meireles
AU  - de Bruin VM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/28 [received]
PHST- 2013/05/28 [accepted]
PHST- 2013/05/28 [aheadofprint]
AID - 1471-2369-14-113 [pii]
AID - 10.1186/1471-2369-14-113 [doi]
PST - aheadofprint
SO  - BMC Nephrol. 2013 May 28;14(1):113.

PMID- 23710705
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1748-1716 (Electronic)
IS  - 1748-1708 (Linking)
DP  - 2013 May 25
TI  - Progesterone metabolite influence feeding behaviour.
LID - 10.1111/apha.12122 [doi]
AB  - Obesity is increasing worldwide and is associated with increased risk of
      developing metabolic diseases. One of the factors that have been demonstrated to 
      influence the regulation of appetite and food intake is the different sex
      hormones, one of these being progesterone that in humans increase food intake
      (Hirschberg, 2012). In this issue of Acta Physiologica, Holmberg and colleagues
      present their work where they have investigated the diurnally effect of the
      progesterone metabolite allopregnanolone in male Wistar rats (Holmberg et al.,
      2013). This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Islet cell Exocytosis, Lund University diabetes Centre, Department of Clinical
      sciences, CRC 91-11, Jan Waldenstroms gata 35, 205 02, Malmo, Sweden.
FAU - Wendt, Anna
AU  - Wendt A
FAU - Eliasson, Lena
AU  - Eliasson L
LA  - ENG
PT  - EDITORIAL
DEP - 20130525
TA  - Acta Physiol (Oxf)
JT  - Acta physiologica (Oxford, England)
JID - 101262545
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/05/21 [received]
PHST- 2013/05/22 [accepted]
AID - 10.1111/apha.12122 [doi]
PST - aheadofprint
SO  - Acta Physiol (Oxf). 2013 May 25. doi: 10.1111/apha.12122.

PMID- 23710650
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1029-2470 (Electronic)
IS  - 1029-2470 (Linking)
DP  - 2013 May 28
TI  - Impairment of calcium ATPases by high glucose and potential pharmacological
      protection.
AB  - Abstract The review deals with impairment of Ca2+-ATPases by high glucose or its 
      derivatives in vitro, as well as in human diabetes and experimental animal
      models. Acute increases in glucose level strongly correlate with oxidative
      stress. Dysfunction of Ca2+-ATPases in diabetic and in some cases even in
      nondiabetic conditions may result in nitration of tyrosines-294,295 and in
      irreversible modification of cysteine-674. Nonenyzmatic protein glycation might
      lead to alteration of Ca2+-ATPase structure and function contributing to Ca2+
      imbalance and thus may be involved in development of chronic complications of
      diabetes. The susceptibility to glycation is probably due to the relatively high 
      percentage of lysine and arginine residues at the ATP binding and phosphorylation
      domains. Reversible glycation may develop into irreversible modifications
      (advanced glycation end products, AGEs). Sites of SERCA AGEs are depicted in this
      review. Finally, several mechanisms of prevention of Ca2+-pump glycation, and
      their advantages and disadvantages are discussed.
FAU - Horakova, Lubica
AU  - Horakova L
FAU - Strosova, Miriam K
AU  - Strosova MK
FAU - Spickett, Corinne M
AU  - Spickett CM
FAU - Blaskovic, Dusan
AU  - Blaskovic D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - Free Radic Res
JT  - Free radical research
JID - 9423872
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
AID - 10.3109/10715762.2013.807923 [doi]
PST - aheadofprint
SO  - Free Radic Res. 2013 May 28.

PMID- 23710593
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
DP  - 2013 May 24
TI  - Epidemiology and Outcomes of Deep Surgical Site Infections Following Lung
      Transplantation.
LID - 10.1111/ajt.12292 [doi]
AB  - We conducted a retrospective study of deep surgical site infections (SSIs) among 
      consecutive patients who underwent lung transplantation (LTx) at a single center 
      from 2006 through 2010. Thirty-one patients (5%) developed SSIs at median 25 days
      after LTx. Empyema was most common (42%), followed by surgical wound infections
      (29%), mediastinitis (16%), sternal osteomyelitis (6%), and pericarditis (6%).
      Pathogens included Gram-positive bacteria (41%), Gram-negative bacteria (41%),
      fungi (10%) and Mycobacterium abscessus, Mycoplasma hominis and Lactobacillus sp.
      (one each). Twenty-three percent of SSIs were due to pathogens colonizing
      recipients' native lungs at time of LTx, suggesting surgical seeding as a source.
      Patient-related independent risk factors for SSIs were diabetes and prior
      cardiothoracic surgery; procedure-related independent risk factors were LTx from 
      a female donor, prolonged ischemic time and number of perioperative red blood
      cell transfusions. Mediastinitis and sternal infections were not observed among
      patients undergoing minimally invasive LTx. SSIs were associated with 35%
      mortality at 1 year post-LTx. Lengths of stay and mortality in-hospital and at 6 
      months and 1 year were significantly greater for patients with SSIs other than
      empyema. In conclusion, deep SSIs were uncommon, but important complications in
      LTx recipients because of their diverse microbiology and association with
      increased mortality.
CI  - (c) Copyright 2013 The American Society of Transplantation and the American
      Society of Transplant Surgeons.
AD  - Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
FAU - Shields, R K
AU  - Shields RK
FAU - Clancy, C J
AU  - Clancy CJ
FAU - Minces, L R
AU  - Minces LR
FAU - Shigemura, N
AU  - Shigemura N
FAU - Kwak, E J
AU  - Kwak EJ
FAU - Silveira, F P
AU  - Silveira FP
FAU - Abdel-Massih, R C
AU  - Abdel-Massih RC
FAU - Bhama, J K
AU  - Bhama JK
FAU - Bermudez, C A
AU  - Bermudez CA
FAU - Pilewski, J M
AU  - Pilewski JM
FAU - Crespo, M
AU  - Crespo M
FAU - Toyoda, Y
AU  - Toyoda Y
FAU - Nguyen, M H
AU  - Nguyen MH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/01/25 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/04/04 [accepted]
AID - 10.1111/ajt.12292 [doi]
PST - aheadofprint
SO  - Am J Transplant. 2013 May 24. doi: 10.1111/ajt.12292.

PMID- 23710585
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
DP  - 2013 May 28
TI  - Risk factors associated with PICC-related upper extremity venous thrombosis in
      cancer patients.
LID - 10.1111/jocn.12227 [doi]
AB  - AIMS AND OBJECTIVES: To investigate the incidence and risk factors for
      peripherally inserted central venous catheters-related upper extremity venous
      thrombosis in patients with cancer. BACKGROUND: With the widespread use of
      peripherally inserted central venous catheters, peripherally inserted central
      venous catheters-related upper extremity venous thrombosis in patients with
      cancer leads to increasing morbidity and mortality. It is very important to
      further explore the incidence and risk factors for peripherally inserted central 
      venous catheters-related venous thrombosis. DESIGN AND METHODS: Consecutive
      patients with cancer who were scheduled to receive peripherally inserted central 
      venous catheters, between September 2009 and May 2012, were prospectively studied
      in our centre. They were investigated for venous thrombosis by Doppler sonography
      three times a day within 30 days after catheter insertion. Univariable and
      multivariable logistic regressions' analyses were performed to identify the risk 
      factors for peripherally inserted central venous catheters-related thrombosis.
      RESULTS: A total of 89 patients with cancer were studied in our research. Of
      these, 81 patients were followed up within one month. The mean interval between
      catheter insertion and the onset of thrombosis was 12.45 +/- 6.17 days. The
      multivariable analyses showed that chemotherapy history, less activities and
      diabetes were the key risk factors for thrombosis. CONCLUSIONS: Peripherally
      inserted central venous catheters-related upper extremity venous thrombosis had
      high incidence rate, and most cases had no significant symptoms. The history of
      chemotherapy, less activities and diabetes were found to be the key risk factors.
      It should be routinely scanned in high-risk patients every 3-5 days after
      catheter insertion, which would then find blood clots in time and reduce the
      incidence of pulmonary embolism. RELEVANCE TO CLINICAL PRACTICE: Risk factors
      associated with peripherally inserted central venous catheters-related upper
      extremity venous thrombosis are of critical importance in improving the quality
      of patients' life. It is very important to grasp the indications to reduce the
      incidence rate of peripherally inserted central venous catheters-related upper
      extremity venous thrombosis.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Ultrasound in Medicine, Shanghai Jiao Tong University Affiliated
      Sixth People's Hospital, Shanghai, China.
FAU - Yi, Xiao-Lei
AU  - Yi XL
FAU - Chen, Jie
AU  - Chen J
FAU - Li, Jia
AU  - Li J
FAU - Feng, Liang
AU  - Feng L
FAU - Wang, Yan
AU  - Wang Y
FAU - Zhu, Jia-An
AU  - Zhu JA
FAU - Shen, E
AU  - Shen E
FAU - Hu, Bing
AU  - Hu B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2012/12/09 [accepted]
AID - 10.1111/jocn.12227 [doi]
PST - aheadofprint
SO  - J Clin Nurs. 2013 May 28. doi: 10.1111/jocn.12227.

PMID- 23710584
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1471-2296 (Electronic)
IS  - 1471-2296 (Linking)
VI  - 14
DP  - 2013
TI  - Depression, anxiety and stress symptoms among diabetics in Malaysia: a cross
      sectional study in an urban primary care setting.
PG  - 69
LID - 10.1186/1471-2296-14-69 [doi]
AB  - BACKGROUND: Diabetes mellitus is a highly prevalent condition in Malaysia,
      increasing from 11.6% in 2006 to 15.2% in 2011 among individuals 18 years and
      above. Co-morbid depression in diabetics is associated with hyperglycemia,
      diabetic complications and increased health care costs. The aims of this study
      are to determine the prevalence and predictors of depression, anxiety and stress 
      symptoms in Type II diabetics attending government primary care facilities in the
      urban area of Klang Valley, Malaysia. METHODS: The study was cross sectional in
      design and carried out in 12 randomly selected primary care government clinics in
      the Klang Valley, Malaysia. A total of 2508 eligible consenting respondents
      participated in the study. The Depression, Anxiety and Stress Scale (DASS) 21
      questionnaire was used to measure depression, anxiety and stress symptoms. Data
      was analyzed using the SPSS version 16 software using both descriptive and
      inferential statistics. RESULTS: The prevalence of depression, anxiety and stress
      symptoms among Type II diabetics were 11.5%, 30.5% and 12.5% respectively. Using 
      multiple logistic regression, females, Asian Indians, marital status (never
      married, divorced/widowed/separated), a family history of psychiatric illness,
      less than 2 years duration of diabetes and current alcohol consumption were found
      to be significant predictors of depression. For anxiety, unemployment,
      housewives, HbA1c level of more than 8.5%, a family history of psychiatric
      illness, life events and lack of physical activity were independent risk factors.
      Stress was significantly associated with females, HbA1c level of more than 8.5%, 
      presence of co-morbidity, a family history of psychiatric illness, life events
      and current alcohol consumption. For depression (adjusted OR 2.8, 95% CI 1.1;
      7.0), anxiety (adjusted OR 2.4, 95% CI 1.1;5.5) and stress (adjusted OR 4.2, 95% 
      CI 1.8; 9.8), a family history of psychiatric illness was the strongest
      predictor. CONCLUSION: We found the prevalence of depression, anxiety and stress 
      symptoms to be high among Type II diabetics, with almost a third being classified
      as anxious. Screening of high risk Type II diabetics for depression, anxiety and 
      stress symptoms in the primary care setting is recommended at regular intervals.
AD  - Institute for Public Health, Ministry of Health, Jalan Bangsar, Kuala Lumpur,
      50590, Malaysia. dr.gurpreet@iku.moh.gov.my.
FAU - Kaur, Gurpreet
AU  - Kaur G
FAU - Tee, Guat Hiong
AU  - Tee GH
FAU - Ariaratnam, Suthahar
AU  - Ariaratnam S
FAU - Krishnapillai, Ambigga S
AU  - Krishnapillai AS
FAU - China, Karuthan
AU  - China K
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - England
TA  - BMC Fam Pract
JT  - BMC family practice
JID - 100967792
SB  - IM
PMC - PMC3669622
OID - NLM: PMC3669622
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/02/22 [received]
PHST- 2013/05/22 [accepted]
PHST- 2013/05/27 [aheadofprint]
AID - 1471-2296-14-69 [pii]
AID - 10.1186/1471-2296-14-69 [doi]
PST - epublish
SO  - BMC Fam Pract. 2013 May 27;14:69. doi: 10.1186/1471-2296-14-69.

PMID- 23710571
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
DP  - 2013 May 26
TI  - Lung transplant outcomes in cystic fibrosis patients with pre-operative
      Mycobacterium abscessus respiratory infections.
LID - 10.1111/ctr.12140 [doi]
AB  - BACKGROUND: Mycobacterium abscessus in cystic fibrosis (CF) patients is
      considered a contraindication to lung transplantation. We examine the
      post-transplant outcomes of CF patients with M. abscessus pre-transplant.
      METHODS: CF patients transplanted at the University of North Carolina from 1992
      to 2012 were retrospectively examined. Patients with at least one respiratory
      sample positive for M. abscessus prior to transplantation were included. Data
      collected included age, FEV1 , body mass index (BMI), systemic steroid use,
      diabetes mellitus, ventilatory assistance, co-existent CF pathogens, imaging,
      post-transplant complications, and survival. RESULTS (N = 13): At transplant,
      mean age was 24.6 yr, mean BMI was 18.1 kg/m2 , six had 3+ positive smears for M.
      abscessus, and three were ventilator dependent. All met American Thoracic Society
      microbiological criteria for disease pre-transplant. Three patients developed M. 
      abscessus-related complications, with clearance of the organism following
      treatment. Survival post-transplant shows 77% alive at one yr, 64% at three yr,
      and 50% at five yr; none died of M. abscessus. The survival data showed no
      statistically significant difference (p = 0.8) compared with a contemporaneously 
      transplanted population of CF patients without M. abscessus (n = 154).
      CONCLUSION: Lung transplantation, with favorable survival, is possible in CF
      patients with M. abscessus. Even if M. abscessus recurs, local control and
      clearance is possible.
CI  - (c) 2013 John Wiley & Sons A/S.
AD  - Division of Pulmonary and Critical Care Medicine, University of North Carolina,
      Chapel Hill, NC, USA.
FAU - Lobo, Leonard J
AU  - Lobo LJ
FAU - Chang, Lydia C
AU  - Chang LC
FAU - Esther, Charles R Jr
AU  - Esther CR Jr
FAU - Gilligan, Peter H
AU  - Gilligan PH
FAU - Tulu, Zeynep
AU  - Tulu Z
FAU - Noone, Peadar G
AU  - Noone PG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
EDAT- 2013/05/29 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/29 06:00
PHST- 2013/03/20 [accepted]
AID - 10.1111/ctr.12140 [doi]
PST - aheadofprint
SO  - Clin Transplant. 2013 May 26. doi: 10.1111/ctr.12140.

PMID- 23710470
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 2314-6753 (Electronic)
VI  - 2013
DP  - 2013
TI  - Animal Models of GWAS-Identified Type 2 Diabetes Genes.
PG  - 906590
LID - 10.1155/2013/906590 [doi]
AB  - More than 65 loci, encoding up to 500 different genes, have been implicated by
      genome-wide association studies (GWAS) as conferring an increased risk of
      developing type 2 diabetes (T2D). Whilst mouse models have in the past been
      central to understanding the mechanisms through which more penetrant risk genes
      for T2D, for example, those responsible for neonatal or maturity-onset diabetes
      of the young, only a few of those identified by GWAS, notably TCF7L2 and
      ZnT8/SLC30A8, have to date been examined in mouse models. We discuss here the
      animal models available for the latter genes and provide perspectives for future,
      higher throughput approaches towards efficiently mining the information provided 
      by human genetics.
AD  - Section of Cell Biology, Division of Diabetes, Endocrinology and Metabolism,
      Department of Medicine, Imperial College London, London SW7 2AZ, UK.
FAU - da Silva Xavier, Gabriela
AU  - da Silva Xavier G
FAU - Bellomo, Elisa A
AU  - Bellomo EA
FAU - McGinty, James A
AU  - McGinty JA
FAU - French, Paul M
AU  - French PM
FAU - Rutter, Guy A
AU  - Rutter GA
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
SB  - IM
PMC - PMC3654344
OID - NLM: PMC3654344
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/04 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/11 [epublish]
AID - 10.1155/2013/906590 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:906590. doi: 10.1155/2013/906590. Epub 2013 Apr 11.

PMID- 23710469
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 2314-6753 (Electronic)
VI  - 2013
DP  - 2013
TI  - Application of IgG-Derived Natural Treg Epitopes (IgG Tregitopes) to
      Antigen-Specific Tolerance Induction in a Murine Model of Type 1 Diabetes.
PG  - 621693
LID - 10.1155/2013/621693 [doi]
AB  - HLA class II-restricted regulatory T cell (Treg) epitopes in IgG (also called
      "Tregitopes") have been reported to suppress immune responses to coadministered
      antigens by stimulating the expansion of natural Tregs (nTregs). Here we evaluate
      their impact on human immune responses to islet cell antigens ex vivo and on the 
      modulation of type 1 diabetes (T1D) in a murine model in vivo. Co-administration 
      of Tregitopes and T1D antigens delayed development of hyperglycemia and reduced
      the incidence of diabetes in NOD mice. Suppression of diabetes could be observed 
      even following onset of disease. To measure the impact of Tregitope treatment on 
      T cell responses, we evaluated the effect of Tregitope treatment in DO11.10 mice.
      Upregulation of FoxP3 in KJ1-26-stained OVA-specific CD4(+) T cells was observed 
      following treatment of DO11.10 mice with Tregitopes, along with reductions in
      anti-OVA Ig and T effector responses. In ex vivo studies of human T cells,
      peripheral blood mononuclear cells' (PBMC) responses to GAD65 epitopes in the
      presence and absence of Tregitope were variable. Suppression of immune responses 
      to GAD65 epitopes ex vivo by Tregitope appeared to be more effective in assays
      using PBMC from a newly diagnosed diabetic subject than for other more
      established diabetic subjects, and correlation of the degree of suppression with 
      predicted HLA restriction of the Tregitopes was confirmed. Implementation of
      these defined regulatory T cell epitopes for therapy of T1D and other autoimmune 
      diseases may lead to a paradigm shift in disease management.
AD  - EpiVax, Inc., 146 Clifford Street, Providence, RI 02903, USA.
FAU - Cousens, Leslie P
AU  - Cousens LP
FAU - Su, Yan
AU  - Su Y
FAU - McClaine, Elizabeth
AU  - McClaine E
FAU - Li, Xin
AU  - Li X
FAU - Terry, Frances
AU  - Terry F
FAU - Smith, Robert
AU  - Smith R
FAU - Lee, Jinhee
AU  - Lee J
FAU - Martin, William
AU  - Martin W
FAU - Scott, David W
AU  - Scott DW
FAU - De Groot, Anne S
AU  - De Groot AS
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
SB  - IM
PMC - PMC3655598
OID - NLM: PMC3655598
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/10/09 [received]
PHST- 2013/01/11 [revised]
PHST- 2013/01/19 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.1155/2013/621693 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:621693. doi: 10.1155/2013/621693. Epub 2013 Apr 23.

PMID- 23710468
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 2314-6753 (Electronic)
VI  - 2013
DP  - 2013
TI  - Glomerulopathy in the KK.Cg-A(y) /J Mouse Reflects the Pathology of Diabetic
      Nephropathy.
PG  - 498925
LID - 10.1155/2013/498925 [doi]
AB  - The KK.Cg-A (y) /J (KK-A (y) ) mouse strain is a previously described model of
      type 2 diabetes with renal impairment. In the present study, female KK-A (y) mice
      received an elevated fat content diet (24% of calories), and a cohort was
      uninephrectomized (Unx) to drive renal disease severity. Compared to KK-a/a
      controls, 26-week-old KK-A (y) mice had elevated HbA1c, insulin, leptin,
      triglycerides, and cholesterol, and Unx further elevated these markers of
      metabolic dysregulation. Unx KK-A (y) mice also exhibited elevated serum BUN and 
      reduced glomerular filtration, indicating that reduction in renal mass leads to
      more severe impairment in renal function. Glomerular hypertrophy and
      hypercellularity, mesangial matrix expansion, podocyte effacement, and basement
      membrane thickening were present in both binephric and uninephrectomized cohorts.
      Glomerular size was increased in both groups, but podocyte density was reduced
      only in the Unx animals. Consistent with functional and histological evidence of 
      increased injury, fibrotic (fibronectin 1, MMP9, and TGF beta 1) and inflammatory
      (IL-6, CD68) genes were markedly upregulated in Unx KK-A (y) mice, while podocyte
      markers (nephrin and podocin) were significantly decreased. These data suggest
      podocyte injury developing into glomerulopathy in KK-A (y) mice. The addition of 
      uninephrectomy enhances renal injury in this model, resulting in a disease which 
      more closely resembles human diabetic nephropathy.
AD  - Tissue Protection and Repair, Genzyme, A Sanofi Company, 49 New York Ave.,
      Framingham, MA 01701, USA.
FAU - O'Brien, Stephen P
AU  - O'Brien SP
FAU - Smith, Mandy
AU  - Smith M
FAU - Ling, Hong
AU  - Ling H
FAU - Phillips, Lucy
AU  - Phillips L
FAU - Weber, William
AU  - Weber W
FAU - Lydon, John
AU  - Lydon J
FAU - Maloney, Colleen
AU  - Maloney C
FAU - Ledbetter, Steven
AU  - Ledbetter S
FAU - Arbeeny, Cynthia
AU  - Arbeeny C
FAU - Wawersik, Stefan
AU  - Wawersik S
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
SB  - IM
PMC - PMC3655591
OID - NLM: PMC3655591
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/23 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/24 [epublish]
AID - 10.1155/2013/498925 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:498925. doi: 10.1155/2013/498925. Epub 2013 Apr 24.

PMID- 23710467
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 2314-6753 (Electronic)
VI  - 2013
DP  - 2013
TI  - The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks 
      in type 2 diabetes mellitus.
PG  - 459821
LID - 10.1155/2013/459821 [doi]
AB  - Objective. To review the current literature investigating the effects of
      dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk factors of cardiovascular
      disease (CVD). Methods. We conducted a search of PubMed and MEDLINE database,
      using the term DPP-4 inhibitor in combination with the following terms: metabolic
      syndrome, hypertension, dyslipidemia, insulin resistance, obesity, and CVD. We
      reviewed 100 relevant studies out of 227 articles, excluding single case reports,
      studies using animal models, and reports not written in English. We included 38
      references in this review article. Results. The majority of the recent clinical
      studies have demonstrated that DPP-4 inhibitors have beneficial effects on
      cardiovascular (CV) system. These agents may have the potential to lower blood
      pressure, improve lipid profile and endothelial dysfunction, decrease the
      macrophage-mediated inflammatory response, and prevent myocardial injury.
      Conclusion. DPP-4 inhibitors have some CV protective effects in type 2 diabetes
      mellitus (T2DM) in addition to their antidiabetic actions. Long-term outcome
      clinical trials are under way to investigate the effects of the DPP-4 inhibitors 
      on the elevated CV risks in patients with T2DM. Further investigation in a large 
      cohort is warranted to assess the exact mechanisms of CV protective effects of
      DPP-4 inhibitors.
AD  - Division of Endocrinology, Metabolism and Nutrition, Department of Medicine,
      UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.
FAU - Yousefzadeh, Pegah
AU  - Yousefzadeh P
FAU - Wang, Xiangbing
AU  - Wang X
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
SB  - IM
PMC - PMC3654348
OID - NLM: PMC3654348
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/18 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/28 [accepted]
PHST- 2013/04/22 [epublish]
AID - 10.1155/2013/459821 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:459821. doi: 10.1155/2013/459821. Epub 2013 Apr 22.

PMID- 23710466
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 2314-6753 (Electronic)
VI  - 2013
DP  - 2013
TI  - Variations of Lipoprotein(a) Levels in the Metabolic Syndrome: A Report from the 
      Maracaibo City Metabolic Syndrome Prevalence Study.
PG  - 416451
LID - 10.1155/2013/416451 [doi]
AB  - Background. Lipoprotein(a) [Lp(a)] is a known risk factor for cardiovascular
      disease, yet its influence on metabolic syndrome (MS) is still controversial. The
      purpose of this study was to assess the impact generated by this diagnosis in
      serum Lp(a) concentrations. Materials and Methods. A total of 1807 subjects of
      both genders (55.3% women and 44.7% men) belonging to the Maracaibo City
      Metabolic Syndrome Prevalence Study were evaluated. Results were expressed as
      Mean +/- SD, determining differences through Student's t-test and One-Way ANOVA
      test. Multiple logistic regression models were utilized for analyzing factors
      associated with elevated serum Lp(a) levels and MS. Total cholesterol and LDL-C
      were corrected according to Lp(a)-Cholesterol when necessary. Results. No
      differences were found in Lp(a) values between genders; P = 0,292. The
      association between MS and the classification of Lp(a) was statistically
      significant (chi (2) = 28.33; P < 0,0001), with greater levels in subjects with
      this diagnosis. In the univariate analysis, subjects with each of the separate
      diagnostic criteria showed higher serum Lp(a) concentrations, except for
      hyperglycemia. Conclusions. Lp(a) values exhibit important variations regarding
      MS and each of its components. Impaired fasting glucose appeared as a protecting 
      factor against elevated Lp(a) concentrations, whereas its association with LDL-C 
      and hs-CRP suggests a potential pro-inflammatory role.
AD  - Endocrine-Metabolic Research Center, "Dr. Felix Gomez," Faculty of Medicine,
      University of Zulia, Maracaibo 4004, Venezuela.
FAU - Bermudez, Valmore
AU  - Bermudez V
FAU - Rojas, Joselyn
AU  - Rojas J
FAU - Salazar, Juan
AU  - Salazar J
FAU - Bello, Luis
AU  - Bello L
FAU - Anez, Roberto
AU  - Anez R
FAU - Toledo, Alexandra
AU  - Toledo A
FAU - Chacin, Maricarmen
AU  - Chacin M
FAU - Aguirre, Miguel
AU  - Aguirre M
FAU - Villalobos, Marjorie
AU  - Villalobos M
FAU - Chavez, Mervin
AU  - Chavez M
FAU - Martinez, Maria Sofia
AU  - Martinez MS
FAU - Torres, Wheeler
AU  - Torres W
FAU - Torres, Yaquelin
AU  - Torres Y
FAU - Mejias, Jose
AU  - Mejias J
FAU - Mengual, Edgardo
AU  - Mengual E
FAU - Rojas, Liliana
AU  - Rojas L
FAU - Sanchez de Rosales, Milagro
AU  - Sanchez de Rosales M
FAU - Quevedo, Ana
AU  - Quevedo A
FAU - Cano, Raquel
AU  - Cano R
FAU - Cabrera, Mayela
AU  - Cabrera M
FAU - Paris, Rafael
AU  - Paris R
FAU - Lubo, Adonias
AU  - Lubo A
FAU - Montiel, Maria
AU  - Montiel M
FAU - Cano, Climaco
AU  - Cano C
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
SB  - IM
PMC - PMC3654352
OID - NLM: PMC3654352
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/30 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/03/20 [accepted]
PHST- 2013/04/22 [epublish]
AID - 10.1155/2013/416451 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:416451. doi: 10.1155/2013/416451. Epub 2013 Apr 22.

PMID- 23710464
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 2314-6141 (Electronic)
VI  - 2013
DP  - 2013
TI  - Endoplasmic reticulum stress-mediated hippocampal neuron apoptosis involved in
      diabetic cognitive impairment.
PG  - 924327
LID - 10.1155/2013/924327 [doi]
AB  - Poor management of DM causes cognitive impairment while the mechanism is still
      unconfirmed. The aim of the present study was to investigate the activation of
      C/EBP Homology Protein (CHOP), the prominent mediator of the endoplasmic
      reticulum (ER) stress-induced apoptosis under hyperglycemia. We employed
      streptozotocin- (STZ-) induced diabetic rats to explore the ability of learning
      and memory by the Morris water maze test. The ultrastructure of hippocampus in
      diabetic rats and cultured neurons in high glucose medium were observed by
      transmission electron microscopy and scanning electron microscopy. TUNEL staining
      was also performed to assess apoptotic cells while the expression of CHOP was
      assayed by immunohistochemistry and Western blot assay in these hippocampal
      neurons. Six weeks after diabetes induction, the escape latency increased and the
      average frequency in finding the platform decreased in diabetic rats (P < 0.05). 
      The morphology of neuron and synaptic structure was impaired; the number of
      TUNEL-positive cells and the expression of CHOP in hippocampus of diabetic rats
      and high glucose medium cultured neurons were markedly altered (P < 0.05). The
      present results suggested that the CHOP-dependent endoplasmic reticulum (ER)
      stress-mediated apoptosis may be involved in hyperglycemia-induced hippocampal
      synapses and neurons impairment and promote the diabetic cognitive impairment.
AD  - Department of Anatomy and Cell Biology, School of Medicine, Zhejiang University, 
      866 Yuhangtang Road, Hangzhou 310058, China.
FAU - Zhang, Xiaoming
AU  - Zhang X
FAU - Xu, Linhao
AU  - Xu L
FAU - He, Daqiang
AU  - He D
FAU - Ling, Shucai
AU  - Ling S
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
PMC - PMC3655482
OID - NLM: PMC3655482
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/15 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/02 [accepted]
PHST- 2013/04/24 [epublish]
AID - 10.1155/2013/924327 [doi]
PST - ppublish
SO  - Biomed Res Int. 2013;2013:924327. doi: 10.1155/2013/924327. Epub 2013 Apr 24.

PMID- 23710342
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130527
DCOM- 20130528
LR  - 20130529
IS  - 2090-0384 (Print)
VI  - 2013
DP  - 2013
TI  - Resistant hypertension in nondialysis chronic kidney disease.
PG  - 929183
LID - 10.1155/2013/929183 [doi]
AB  - Resistant hypertension (RH) is defined as blood pressure (BP) that remains above 
      the target of less than 140/90 mmHg in the general population and 130/80 mmHg in 
      people with diabetes mellitus or chronic kidney disease (CKD) in spite of the use
      of at least three full-dose antihypertensive drugs including a diuretic or as BP 
      that reaches the target by means of four or more drugs. In CKD, RH is a common
      condition due to a combination of factors including sodium retention, increased
      activity of the renin-angiotensin system, and enhanced activity of the
      sympathetic nervous system. Before defining the hypertensive patient as resistant
      it is mandatory to exclude the so-called "pseudoresistance." This condition,
      which refers to the apparent failure to reach BP target in spite of an
      appropriate antihypertensive treatment, is mainly caused by white coat
      hypertension that is prevalent (30%) in CKD patients. Recently we have
      demonstrated that "true" RH represents an independent risk factor for renal and
      cardiovascular outcomes in CKD patients.
AD  - Division of Nephrology, Second University of Naples, 80125 Naples, Italy.
FAU - Borrelli, Silvio
AU  - Borrelli S
FAU - De Nicola, Luca
AU  - De Nicola L
FAU - Stanzione, Giovanna
AU  - Stanzione G
FAU - Conte, Giuseppe
AU  - Conte G
FAU - Minutolo, Roberto
AU  - Minutolo R
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - Int J Hypertens
JT  - International journal of hypertension
JID - 101538881
PMC - PMC3654372
OID - NLM: PMC3654372
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:01
CRDT- 2013/05/28 06:00
PHST- 2013/01/24 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/22 [epublish]
AID - 10.1155/2013/929183 [doi]
PST - ppublish
SO  - Int J Hypertens. 2013;2013:929183. doi: 10.1155/2013/929183. Epub 2013 Apr 22.

PMID- 23710339
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130527
DCOM- 20130528
LR  - 20130529
IS  - 2090-0384 (Print)
VI  - 2013
DP  - 2013
TI  - Linking sleep to hypertension: greater risk for blacks.
PG  - 436502
LID - 10.1155/2013/436502 [doi]
AB  - Background. Evidence suggests that insufficient sleep duration is associated with
      an increased likelihood for hypertension. Both short (<6 hours) and long (>8
      hour) sleep durations as well as hypertension are more prevalent among blacks
      than among whites. This study examined associations between sleep duration and
      hypertension, considering differential effects of race and ethnicity among black 
      and white Americans. Methods. Data came from a cross-sectional household
      interview with 25,352 Americans (age range: 18-85 years). Results. Both white and
      black short sleepers had a greater likelihood of reporting hypertension than
      those who reported sleeping 6 to 8 hours. Unadjusted logistic regression analysis
      exploring the race/ethnicity interactions between insufficient sleep and
      hypertension indicated that black short (<6 hours) and long (>8 hours) sleepers
      were more likely to report hypertension than their white counterparts (OR = 1.34 
      and 1.37, resp.; P < 0.01). Significant interactions of insufficient sleep with
      race/ethnicity were observed even after adjusting to effects of age, sex, income,
      education, body mass index, alcohol use, smoking, emotional distress, diabetes,
      coronary heart disease, and stroke. Conclusion. Results suggest that the
      race/ethnicity interaction is a significant mediator in the relationship between 
      insufficient sleep and likelihood of having a diagnosis of hypertension.
AD  - Brooklyn Health Disparities Center, Department of Medicine, SUNY Downstate
      Medical Center, P.O. Box 1199, 450 Clarkson Avenue, Brooklyn, NY 11203-2098, USA.
FAU - Pandey, A
AU  - Pandey A
FAU - Williams, N
AU  - Williams N
FAU - Donat, M
AU  - Donat M
FAU - Ceide, M
AU  - Ceide M
FAU - Brimah, P
AU  - Brimah P
FAU - Ogedegbe, G
AU  - Ogedegbe G
FAU - McFarlane, S I
AU  - McFarlane SI
FAU - Jean-Louis, G
AU  - Jean-Louis G
LA  - eng
PT  - Journal Article
DEP - 20130421
PL  - United States
TA  - Int J Hypertens
JT  - International journal of hypertension
JID - 101538881
PMC - PMC3654341
OID - NLM: PMC3654341
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:01
CRDT- 2013/05/28 06:00
PHST- 2012/10/08 [received]
PHST- 2013/02/06 [accepted]
PHST- 2013/04/21 [epublish]
AID - 10.1155/2013/436502 [doi]
PST - ppublish
SO  - Int J Hypertens. 2013;2013:436502. doi: 10.1155/2013/436502. Epub 2013 Apr 21.

PMID- 23710299
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130527
DCOM- 20130528
LR  - 20130529
IS  - 1949-8462 (Electronic)
VI  - 5
IP  - 5
DP  - 2013 May 26
TI  - Gender differences related to the presence of atrial fibrillation in older
      hypertensive patients.
PG  - 124-31
LID - 10.4330/wjc.v5.i5.124 [doi]
AB  - AIM: To determine whether there are gender differences in the epidemiological
      profile of atrial fibrillation (AF) and to characterise the clinical,
      biochemical, and therapeutic factors associated with AF. METHODS: Each
      investigator (primary care physicians or physicians based in hospital units for
      hypertension treatment) recruited the first 3 patients with an age of >/= 65
      years and a clinical diagnosis of hypertension (ambulatory blood pressure
      monitoring and an electrocardiogram, were performed) on the first working day of 
      the week for 5 wk and identified those individuals with atrial fibrillation. A
      binary logistic regression was performed, including all of the variables that
      were significant in the univariate analysis, to establish the variables that were
      associated with the presence of arrhythmia. RESULTS: A total of 1028 patients
      were included in the study, with a mean age of 72.8 +/- 5.8 years. Of these
      patients, 47.3% were male, 9% were smokers, 27.6% were diabetics, 48.3% had
      dyslipidaemia, 10.9% had angina, and 6.5% had experienced a myocardial
      infarction. Regarding gender differences, the men exhibited a larger waist
      circumference, a lower body mass index, less obesity, and a more extensive
      history of diabetes, smoking, ischaemic heart disease, kidney failure, peripheral
      arterial disease and carotid disease than the women. There were no differences,
      however, in the prevalence of AF between the men and the women (11.5% vs 9.2%,
      respectively; P = no significant). Regarding treatment, the women received
      antiplatelet agents and diuretics less frequently, but there were no other
      differences in the use of antihypertensive and antithrombotic therapies. In the
      multivariate analysis, AF in the total study population was associated with age, 
      alcohol consumption, the presence of heart disease, and decreased glomerular
      filtration. In the women, AF was associated with all of the factors included in
      the overall analysis, as well as the presence of left ventricle hypertrophy. In
      contrast, in the men, the only risk factors associated with AF were age, the
      presence of heart disease and alcohol consumption. CONCLUSION: In patients with
      hypertension over 65 years of age, there are relevant gender differences in the
      factors associated with AF.
AD  - Lorenzo Facila, Servicio de Cardiologia, Consorcio Hospitalario General de
      Valencia, 46014 Valencia, Spain.
FAU - Facila, Lorenzo
AU  - Facila L
FAU - Pallares, Vicente
AU  - Pallares V
FAU - Morillas, Pedro
AU  - Morillas P
FAU - Cordero, Alberto
AU  - Cordero A
FAU - Llisterri, Jose Luis
AU  - Llisterri JL
FAU - Sanchis, Carlos
AU  - Sanchis C
FAU - Gorriz, Jose L
AU  - Gorriz JL
FAU - Castillo, Jesus
AU  - Castillo J
FAU - Gil, Vicente
AU  - Gil V
FAU - Redon, Josep
AU  - Redon J
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Cardiol
JT  - World journal of cardiology
JID - 101537090
PMC - PMC3663126
OID - NLM: PMC3663126
OTO - NOTNLM
OT  - Atrial fibrillation
OT  - Gender differences
OT  - Hypertension
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:01
CRDT- 2013/05/28 06:00
PHST- 2013/01/21 [received]
PHST- 2013/04/20 [revised]
PHST- 2013/04/28 [accepted]
AID - 10.4330/wjc.v5.i5.124 [doi]
PST - ppublish
SO  - World J Cardiol. 2013 May 26;5(5):124-31. doi: 10.4330/wjc.v5.i5.124.

PMID- 23710298
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130527
DCOM- 20130528
LR  - 20130529
IS  - 1949-8462 (Electronic)
VI  - 5
IP  - 5
DP  - 2013 May 26
TI  - Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein
      cholesterol goals in diabetics.
PG  - 119-23
LID - 10.4330/wjc.v5.i5.119 [doi]
AB  - The American Diabetes Association (ADA) 2013 guidelines state that a reasonable
      hemoglobin A1c goal for many nonpregnant adults with diabetes is less than 7.0% a
      hemoglobin A1c level of less than 6.5% may be considered in adults with short
      duration of diabetes, long life expectancy, and no significant cardiovascular
      disease if this can be achieved without significant hypoglycemia or other adverse
      effects of treatment. A hemoglobin A1c level less than 8.0% may be appropriate
      for patients with a history of severe hypoglycemia, limited life expectancy,
      advanced macrovascular and microvascular complications, extensive comorbidities, 
      and long-standing diabetes in whom the hemoglobin A1c goal is difficult to attain
      despite multiple glucose-lowering drugs including insulin. The ADA 2013
      guidelines recommend that the systolic blood pressure in most diabetics with
      hypertension should be reduced to less than 140 mmHg. These guidelines also
      recommend use of an angiotensin-converting enzyme inhibitor or angiotensin
      receptor blocker in the treatment of hypertension in diabetics unless they are
      pregnant. Diabetics at high risk for cardiovascular events should have their
      serum low-density lipoprotein (LDL) cholesterol lowered to less than 70 mg/dL
      with statins. Lower-risk diabetics should have their serum LDL cholesterol
      reduced to less than 100 mg/dL. Combination therapy of a statin with either a
      fibrate or niacin has not been shown to provide additional cardiovascular benefit
      above statin therapy alone and is not recommended. Hypertriglyceridemia should be
      treated with dietary and lifestyle changes. Severe hypertriglyceridemia should be
      treated with drug therapy to reduce the risk of acute pancreatitis.
AD  - Wilbert S Aronow, Division of Cardiology, Department of Medicine, Westchester
      Medical Center/New York Medical College, Valhalla, NY 10595, United States.
FAU - Aronow, Wilbert S
AU  - Aronow WS
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Cardiol
JT  - World journal of cardiology
JID - 101537090
PMC - PMC3663125
OID - NLM: PMC3663125
OTO - NOTNLM
OT  - Blood pressure
OT  - Diabetes mellitus
OT  - Hemoglobin A1c
OT  - Lipid-lowering drugs
OT  - Serum low-density lipoprotein cholesterol
OT  - Statins
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:01
CRDT- 2013/05/28 06:00
PHST- 2013/03/18 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/18 [accepted]
AID - 10.4330/wjc.v5.i5.119 [doi]
PST - ppublish
SO  - World J Cardiol. 2013 May 26;5(5):119-23. doi: 10.4330/wjc.v5.i5.119.

PMID- 23710226
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130527
DCOM- 20130528
LR  - 20130529
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Increased nerve growth factor signaling in sensory neurons of early diabetic rats
      is corrected by electroacupuncture.
PG  - 652735
LID - 10.1155/2013/652735 [doi]
AB  - Diabetic polyneuropathy (DPN), characterized by early hyperalgesia and increased 
      nerve growth factor (NGF), evolves in late irreversible neuropathic symptoms with
      reduced NGF support to sensory neurons. Electroacupuncture (EA) modulates NGF in 
      the peripheral nervous system, being effective for the treatment of DPN symptoms.
      We hypothesize that NGF plays an important pathogenic role in DPN development,
      while EA could be useful in the therapy of DPN by modulating NGF
      expression/activity. Diabetes was induced in rats by streptozotocin (STZ)
      injection. One week after STZ, EA was started and continued for three weeks. NGF 
      system and hyperalgesia-related mediators were analyzed in the dorsal root
      ganglia (DRG) and in their spinal cord and skin innervation territories. Our
      results show that four weeks long diabetes increased NGF and NGF receptors and
      deregulated intracellular signaling mediators of DRG neurons hypersensitization; 
      EA in diabetic rats decreased NGF and NGF receptors, normalized c-Jun N-terminal 
      and p38 kinases activation, decreased transient receptor potential vanilloid-1
      ion channel, and possibly activated the nuclear factor kappa-light-chain-enhancer
      of activated B cells (Nf- kappa B). In conclusion, NGF signaling deregulation
      might play an important role in the development of DPN. EA represents a
      supportive tool to control DPN development by modulating NGF signaling in
      diabetes-targeted neurons.
AD  - Department of Pharmaceutical and Biomedical Sciences (FARMABIOMED) Nanomates,
      University of Salerno, Via Ponte don Melillo, 84084 Fisciano, Italy.
FAU - Nori, Stefania Lucia
AU  - Nori SL
FAU - Rocco, Maria Luisa
AU  - Rocco ML
FAU - Florenzano, Fulvio
AU  - Florenzano F
FAU - Ciotti, Maria Teresa
AU  - Ciotti MT
FAU - Aloe, Luigi
AU  - Aloe L
FAU - Manni, Luigi
AU  - Manni L
LA  - eng
PT  - Journal Article
DEP - 20130421
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3654322
OID - NLM: PMC3654322
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:01
CRDT- 2013/05/28 06:00
PHST- 2012/12/08 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/03/20 [accepted]
PHST- 2013/04/21 [epublish]
AID - 10.1155/2013/652735 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:652735. doi: 10.1155/2013/652735.
      Epub 2013 Apr 21.

PMID- 23710177
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130527
DCOM- 20130528
LR  - 20130529
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Ketosis-onset diabetes and ketosis-prone diabetes: same or not?
PG  - 821403
LID - 10.1155/2013/821403 [doi]
AB  - Objective. To compare clinical characteristics, immunological markers, and beta
      -cell functions of 4 subgroups ("A beta " classification system) of ketosis-onset
      diabetes and ketosis prone diabetes patients without known diabetes, presenting
      with ketosis or diabetic ketoacidosis (DKA) and admitted to our department from
      March 2011 to December 2011 in China, with 50 healthy persons as control group.
      Results. beta -cell functional reserve was preserved in 63.52% of patients. In
      almost each subgroup (except A- beta - subgroup of ketosis prone group), male
      patients were more than female ones. The age of the majority of patients in
      ketosis prone group was older than that of ketosis-onset group, except A- beta - 
      subgroup of ketosis prone group. The durations from the patient first time
      ketosis or DKA onset to admitting to the hospital have significant difference,
      which were much longer for the ketosis prone group except the A+ beta + subgroup.
      BMI has no significant difference among subgroups. FPG of ketosis prone group was
      lower than that of A- beta + subgroup and A+ beta + subgroup in ketosis-onset
      group. A- beta - subgroup and A+ beta + subgroup of ketosis prone group have
      lower HbA1c than ketosis-onset group. Conclusions. Ketosis-onset diabetes and
      ketosis prone diabetes do not absolutely have the same clinical characteristics. 
      Each subgroup shows different specialty.
AD  - Endocrinology and Metabolism Department of the Second Hospital Affiliated to
      Harbin Medical University, Harbin Medical University, Harbin, Heilongjiang
      Province 150086, China.
FAU - Liu, Beiyan
AU  - Liu B
FAU - Yu, Changhua
AU  - Yu C
FAU - Li, Qiang
AU  - Li Q
FAU - Li, Lin
AU  - Li L
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3655588
OID - NLM: PMC3655588
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:01
CRDT- 2013/05/28 06:00
PHST- 2013/03/01 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.1155/2013/821403 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:821403. doi: 10.1155/2013/821403. Epub 2013 Apr 23.

PMID- 23710173
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130527
DCOM- 20130528
LR  - 20130529
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Cigarette Smoking Is Associated with Prolongation of the QTc Interval Duration in
      Patients with Type 2 Diabetes Mellitus.
PG  - 329189
LID - 10.1155/2013/329189 [doi]
AB  - Aims. Aim of the study was to evaluate the effect of smoking on autonomic nervous
      system (ANS) activity and QTc interval duration in patients with Type 2 diabetes 
      mellitus (T2DM). Methods. A total of 70 patients with T2DM (35 chronic smokers,
      35 nonsmokers) treated with oral antidiabetic medications underwent continuous
      ECG Holter monitoring for 24 hours and analysis of time- and frequency-domain
      measures of heart rate variability (HRV). HRV over short time was also assessed
      using the deep breathing test. In addition, baroreflex sensitivity (BRS) was
      evaluated using the spontaneous sequence method. The mean QTc interval was
      measured from the 24-hour ECG recordings. Results. Smokers had lower body mass
      index (BMI) and exhibited higher 24-hour mean heart rate. There was no difference
      regarding all measures of ANS activity between the two groups. Smokers showed
      increased mean QTc duration during the 24 hours (439.25 +/- 26.95 versus 425.05
      +/- 23.03 ms, P = 0.021) as well as in both day (439.14 +/- 24.31 ms, P = 0.042) 
      and night periods (440.91 +/- 32.30 versus 425.51 +/- 24.98 ms, P = 0.033). The
      association between smoking status and mean QTc interval persisted after
      adjusting for BMI. Conclusions. Cigarette smoking is associated with prolongation
      of the QTc interval in patients with T2DM by a mechanism independent of ANS
      dysfunction.
AD  - First Department of Propaedeutic Medicine, Athens University Medical School,
      Laiko General Hospital, 17 Agiou Thoma Street, 11527 Athens, Greece.
FAU - Thomakos, Petros
AU  - Thomakos P
FAU - Liatis, Stavros
AU  - Liatis S
FAU - Kalopita, Stavroula
AU  - Kalopita S
FAU - Vlahodimitris, Ioannis
AU  - Vlahodimitris I
FAU - Stathi, Chryssoula
AU  - Stathi C
FAU - Katsilambros, Nicholas
AU  - Katsilambros N
FAU - Tentolouris, Nicholas
AU  - Tentolouris N
FAU - Makrilakis, Konstantinos
AU  - Makrilakis K
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3655597
OID - NLM: PMC3655597
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:01
CRDT- 2013/05/28 06:00
PHST- 2013/03/20 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/04/24 [epublish]
AID - 10.1155/2013/329189 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:329189. doi: 10.1155/2013/329189. Epub 2013 Apr 24.

PMID- 23709760
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
DP  - 2013 May 24
TI  - Metformin reduces airway glucose permeability and hyperglycaemia-induced
      Staphylococcus aureus load independently of effects on blood glucose.
LID - 10.1136/thoraxjnl-2012-203178 [doi]
AB  - BACKGROUND: Diabetes is a risk factor for respiratory infection, and
      hyperglycaemia is associated with increased glucose in airway surface liquid and 
      risk of Staphylococcus aureus infection. OBJECTIVES: To investigate whether
      elevation of basolateral/blood glucose concentration promotes airway
      Staphylococcus aureus growth and whether pretreatment with the antidiabetic drug 
      metformin affects this relationship. METHODS: Human airway epithelial cells grown
      at air-liquid interface (+/-18 h pre-treatment, 30 muM-1 mM metformin) were
      inoculated with 5x105 colony-forming units (CFU)/cm2 S aureus 8325-4 or JE2 or
      Pseudomonas aeruginosa PA01 on the apical surface and incubated for 7 h.
      Wild-type C57BL/6 or db/db (leptin receptor-deficient) mice, 6-10 weeks old, were
      treated with intraperitoneal phosphate-buffered saline or 40 mg/kg metformin for 
      2 days before intranasal inoculation with 1x107 CFU S aureus. Mice were culled 24
      h after infection and bronchoalveolar lavage fluid collected. RESULTS: Apical S
      aureus growth increased with basolateral glucose concentration in an in vitro
      airway epithelia-bacteria co-culture model. S aureus reduced transepithelial
      electrical resistance (RT) and increased paracellular glucose flux. Metformin
      inhibited the glucose-induced growth of S aureus, increased RT and decreased
      glucose flux. Diabetic (db/db) mice infected with S aureus exhibited a higher
      bacterial load in their airways than control mice after 2 days and metformin
      treatment reversed this effect. Metformin did not decrease blood glucose but
      reduced paracellular flux across ex vivo murine tracheas. CONCLUSIONS:
      Hyperglycaemia promotes respiratory S aureus infection, and metformin modifies
      glucose flux across the airway epithelium to limit hyperglycaemia-induced
      bacterial growth. Metformin might, therefore, be of additional benefit in the
      prevention and treatment of respiratory infection.
AD  - Division of Biomedical Sciences, Centre for Cell Physiology and Pharmacology, St 
      George's, University of London, , London, UK.
FAU - Garnett, James P
AU  - Garnett JP
FAU - Baker, Emma H
AU  - Baker EH
FAU - Naik, Sonam
AU  - Naik S
FAU - Lindsay, Jodi A
AU  - Lindsay JA
FAU - Knight, Gwenan M
AU  - Knight GM
FAU - Gill, Simren
AU  - Gill S
FAU - Tregoning, John S
AU  - Tregoning JS
FAU - Baines, Deborah L
AU  - Baines DL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Thorax
JT  - Thorax
JID - 0417353
OTO - NOTNLM
OT  - Airway Epithelium
OT  - Bacterial Infection
OT  - COPD Exacerbations
OT  - Respiratory Infection
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - thoraxjnl-2012-203178 [pii]
AID - 10.1136/thoraxjnl-2012-203178 [doi]
PST - aheadofprint
SO  - Thorax. 2013 May 24. doi: 10.1136/thoraxjnl-2012-203178.

PMID- 23709681
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
DP  - 2013 May 24
TI  - Thymic Damage, Impaired Negative Selection, and Development of Chronic
      Graft-versus-Host Disease Caused by Donor CD4+ and CD8+ T Cells.
AB  - Prevention of chronic graft-versus-host disease (cGVHD) remains a major challenge
      in allogeneic hematopoietic cell transplantation (HCT) owing to limited
      understanding of cGVHD pathogenesis and lack of appropriate animal models. In
      this study, we report that, in classical acute GVHD models with C57BL/6 donors
      and MHC-mismatched BALB/c recipients and with C3H.SW donors and MHC-matched
      C57BL/6 recipients, GVHD recipients surviving for >60 d after HCT developed cGVHD
      characterized by cutaneous fibrosis, tissue damage in the salivary gland, and the
      presence of serum autoantibodies. Donor CD8+ T cells were more potent than CD4+ T
      cells for inducing cGVHD. The recipient thymus and de novo-generated,
      donor-derived CD4+ T cells were required for induction of cGVHD by donor CD8+ T
      cells but not by donor CD4+ T cells. Donor CD8+ T cells preferentially damaged
      recipient medullary thymic epithelial cells and impaired negative selection,
      resulting in production of autoreactive CD4+ T cells that perpetuated damage to
      the thymus and augmented the development of cGVHD. Short-term anti-CD4 mAb
      treatment early after HCT enabled recovery from thymic damage and prevented
      cGVHD. These results demonstrate that donor CD8+ T cells cause cGVHD solely
      through thymic-dependent mechanisms, whereas CD4+ T cells can cause cGVHD through
      either thymic-dependent or independent mechanisms.
AD  - Department of Diabetes/Endocrinology, Beckman Research Institute, City of Hope,
      Duarte, CA 91010;
FAU - Wu, Tao
AU  - Wu T
FAU - Young, James S
AU  - Young JS
FAU - Johnston, Heather
AU  - Johnston H
FAU - Ni, Xiong
AU  - Ni X
FAU - Deng, Ruishu
AU  - Deng R
FAU - Racine, Jeremy
AU  - Racine J
FAU - Wang, Miao
AU  - Wang M
FAU - Wang, Audrey
AU  - Wang A
FAU - Todorov, Ivan
AU  - Todorov I
FAU - Wang, Jianmin
AU  - Wang J
FAU - Zeng, Defu
AU  - Zeng D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - jimmunol.1300657 [pii]
AID - 10.4049/jimmunol.1300657 [doi]
PST - aheadofprint
SO  - J Immunol. 2013 May 24.

PMID- 23709655
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 24
TI  - Sex hormone binding globulin and sex steroids among premenopausal women in the
      Diabetes Prevention Program.
AB  - ContextIt is unknown whether intensive lifestyle modification (ILS) or metformin 
      change sex steroids among premenopausal women without a history of polycystic
      ovarian syndrome (PCOS).ObjectivesTo examine one-year intervention impact upon
      sex steroids (estradiol, testosterone, dehydroepiandrosterone, and
      androstenedione [A4]) and sex hormone binding globulin (SHBG) and differences by 
      race/ethnicityParticipantsA subgroup of Diabetes Prevention Program (DPP)
      participants who were premenopausal, not using estrogen, without a history of
      PCOS or irregular menses, and who reported non-Hispanic white (NHW), Hispanic, or
      African-American race/ethnicity (n=301).InterventionsRandomization arms were: 1) 
      ILS with the goals of weight reduction of 7% of initial weight and 150 minutes
      per week of moderate intensity exercise, 2) metformin 850 mg twice a day, or 3)
      placebo.ResultsNeither intervention changed sex steroids compared to placebo.
      ILS, but not metformin, increased median SHBG by 3.1 nmol/l ( approximately 11%) 
      compared to decreases of 1.1 nmol/l in the placebo arm (p<0.05). This comparison 
      remained significant after adjustment for changes in covariates including waist
      circumference. However, associations with glucose were not significant. Median
      baseline A4 was lower in Hispanics compared to NHWs (5.7 nmol/l vs. 6.5 nmol/l,
      p<0.05) and increases in A4 were greater in Hispanics compared to NHWs (3.0 nmol/
      vs. 1.2 nmol/l, p<0.05), and these differences did not differ significantly by
      intervention arm. No other racial/ethnic differences were
      significant.ConclusionsAmong premenopausal glucose intolerant women, no
      intervention changed sex steroids. ILS increased SHBG, although associations with
      glucose were not significant. SHBG and sex steroids were similar by
      race/ethnicity, with the possible exception of lower baseline A4 levels in
      Hispanics compared to NHWs.
AD  - Catherine Kim, M.D. M.P.H., University of Michigan; Xavier Pi-Sunyer, M.D.
      M.P.H., Columbia University, NY; Elizabeth Barrett-Connor, University of
      California, San Diego; Frankie B. Stentz, M.S. University of Tennessee, Memphis; 
      Mary Beth Murphy, R.N., M.S., C.D.E., M.B.A., C.C.R.P. University of Tennessee,
      Memphis; Shengchun Kong, M.S., University of Michigan; Bin Nan, Ph.D., University
      of Michigan; Abbas E. Kitabchi, Ph.D. M.D., University of Tennessee, Memphis; And
      the Diabetes Prevention Program Research Group Key terms: premenopause, sex
      steroids, metformin, weight.
FAU - Kim, Catherine
AU  - Kim C
FAU - Pi-Sunyer, Xavier
AU  - Pi-Sunyer X
FAU - Barrett-Connor, Elizabeth
AU  - Barrett-Connor E
FAU - Stentz, Frankie B
AU  - Stentz FB
FAU - Beth Murphy, Mary
AU  - Beth Murphy M
FAU - Kong, Shengchun
AU  - Kong S
FAU - Nan, Bin
AU  - Nan B
FAU - Kitabchi, Abbas E
AU  - Kitabchi AE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - jc.2013-1341 [pii]
AID - 10.1210/jc.2013-1341 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 24.

PMID- 23709654
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 24
TI  - Treatment with Metformin is Associated with Higher Remission Rate in Diabetic
      Patients with Thyroid Cancer.
AB  - Context:Clinical trials demonstrated that metformin increases the efficiency of
      systemic therapy in cancer patients.Objective:We examined whether the efficacy of
      conventional treatment of differentiated thyroid cancer (DTC) is affected by
      therapy with metformin in diabetic patients.Design:We compared the rate of
      complete response (CR) between diabetics treated (Group MF+, n=34), or
      non-treated with metformin (Group MF-, n=21) and control non-diabetic patients
      (Group C, n=185). We also examined the effects of metformin on DTC cells in
      vitro.Results:The groups were comparable in terms of age, sex, BMI, diabetes
      management, frequencies of multifocal tumor growth, extrathyroidal extension,
      loco-regional and distant metastases. Tumor size was significantly smaller in MF+
      compared with MF- and C groups (1.37+/-0.97 cm vs 2.44+/-1.49 cm vs 2.39+/-1.73
      cm, p=0.026). A multivariate model revealed that extrathyroidal extension
      (p=0.018), distant metastases (p<0.0001) and lack of treatment with metformin of 
      diabetics (p<0.0001) decreased the likelihood of CR. A Cox hazards model revealed
      that age (p=0.025), loco-regional metastases (p=0.022), distant metastases
      (p=0.003) and lack of treatment with metformin of patients with diabetes
      (p=0.014) are associated with increased risk for shortened progression free
      survival (PFS).In vitro data revealed that metformin inhibited cancer cells
      growth, activated cAMP-inducible protein kinase (AMPK) and down-regulated
      p70S6K/pS6. Metformin potentiated H2O2-inducible activation of AMPK but
      attenuated pERK and p70S6K. Tumors from MF+ patients demonstrated lower level of 
      phospho-p70S6K compared with MF- group.Conclusions:Tumor size is smaller in
      patients treated with metformin suggesting inhibition of tumor growth by the
      drug. Among diabetics, absence of metformin therapy is an independent factor for 
      decreased likelihood of CR and increased risk of shorter PFS. In vitro data
      suggest that p70S6K/pS6 is likely a molecular target of metformin in DTC cells.
AD  - 1Department of Pediatrics, Uniformed Services University of the Health Sciences, 
      4301 Jones Bridge Rd, Bethesda, MD, 20814-4712 USA;
FAU - Klubo-Gwiezdzinska, Joanna
AU  - Klubo-Gwiezdzinska J
FAU - Costello, J Jr
AU  - Costello J Jr
FAU - Patel, Aneeta
AU  - Patel A
FAU - Bauer, Andrew
AU  - Bauer A
FAU - Jensen, Kirk
AU  - Jensen K
FAU - Mete, Mihriye
AU  - Mete M
FAU - Burman, Kenneth D
AU  - Burman KD
FAU - Wartofsky, Leonard
AU  - Wartofsky L
FAU - Vasko, Vasyl
AU  - Vasko V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - jc.2012-3799 [pii]
AID - 10.1210/jc.2012-3799 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 24.

PMID- 23709646
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1464-3553 (Electronic)
IS  - 0379-864X (Linking)
DP  - 2013 May 24
TI  - Presence of Neuropathic Pain May Explain Poor Performances on Olfactory Testing
      in Diabetes Mellitus Patients.
AB  - Olfactory dysfunction in neurodegenerative conditions such as Parkinson's
      syndrome and Alzheimer's disease can hallmark disease onset. We hypothesized that
      patients with diabetes mellitus, a condition featuring peripheral and central
      neurodegeneration, would have decreased olfaction abilities. We examined
      participants with diabetic peripheral neuropathy, participants with diabetes
      without diabetic peripheral neuropathy, and control participants in blinded
      fashion using standardized Sniffin' Sticks. Diabetic peripheral neuropathy
      severity was quantified using the Utah Early Neuropathy Scale. Further
      subcategorization of diabetic peripheral neuropathy based on presence of
      neuropathic pain was performed with Douleur Neuropathique 4 Questionnaires.
      Participants with diabetes had decreased olfactory sensitivity, impaired
      olfactory discrimination abilities, and reduced odor identification skills when
      compared with controls. However, loss of olfaction ability was, at least
      partially, attributed to presence of neuropathic pain on subcategory assessment, 
      although pain severity was not associated with dysfunction. Those participants
      with diabetes without diabetic peripheral neuropathy and those with diabetic
      peripheral neuropathy without neuropathic pain had similar olfactory function as 
      controls in general. The presence of neuropathic pain, associated with limited
      attention and concentration, may explain at least a portion of the olfactory
      dysfunction witnessed in the diabetic patient population.
AD  - Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of
      Calgary, Calgary, AB, Canada.
FAU - Brady, Shauna
AU  - Brady S
FAU - Lalli, Paul
AU  - Lalli P
FAU - Midha, Nisha
AU  - Midha N
FAU - Chan, Ayechen
AU  - Chan A
FAU - Garven, Alexandra
AU  - Garven A
FAU - Chan, Cynthia
AU  - Chan C
FAU - Toth, Cory
AU  - Toth C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Chem Senses
JT  - Chemical senses
JID - 8217190
OTO - NOTNLM
OT  - diabetic neuropathic pain
OT  - diabetic neuropathy
OT  - olfaction
OT  - type 2 diabetes mellitus
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - bjt013 [pii]
AID - 10.1093/chemse/bjt013 [doi]
PST - aheadofprint
SO  - Chem Senses. 2013 May 24.

PMID- 23709617
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
DP  - 2013 May 24
TI  - Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline.
AB  - Hospitalization for major surgery or critical illness often associates with
      cognitive decline. Inflammation and dysregulation of the innate immune system can
      exert broad effects in the periphery and central nervous system (CNS), yet the
      mechanisms underlying memory impairment after surgery remain poorly understood
      and without effective therapy. Endogenous regulation of acute inflammation is
      providing novel approaches to treat several disease states including sepsis,
      pain, obesity and diabetes. Resolvins are potent endogenous lipid mediators
      biosynthesized during the resolution phase of acute inflammation that display
      immunoresolvent actions. Here, using a mouse model of surgery-induced cognitive
      decline we report that orthopedic surgery affects hippocampal neuronal-glial
      function, including synaptic transmission and plasticity. Systemic prophylaxis
      with aspirin-triggered resolvin D1 (AT-RvD1:
      7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid, as little as 100
      ng dose per mouse) improved memory decline following surgery and abolished signs 
      of synaptic dysfunction. Moreover, delayed administration 24 h after surgery also
      attenuated signs of neuronal dysfunction postoperatively. AT-RvD1 also limited
      peripheral damage by modulating the release of systemic interleukin (IL)-6 and
      improved other clinical markers of tissue injury. Collectively, these results
      demonstrate a novel role of AT-RvD1 in modulating the proinflammatory milieu
      after aseptic injury and protecting the brain from neuroinflammation, synaptic
      dysfunction and cognitive decline. These findings provide novel and safer
      approaches to treat postoperative cognitive decline and potentially other forms
      of memory dysfunctions.-Terrando, N., Gomez-Galan, M., Yang, T., Carlstrom, M.,
      Gustavsson, D., Harding, R. E., Lindskog, M., Eriksson, L. I. Aspirin-triggered
      resolvin D1 prevents surgery-induced cognitive decline.
AD  - *Department of Physiology and Pharmacology and daggerDepartment of Neuroscience, 
      Karolinska Institutet, Stockholm, Sweden;
FAU - Terrando, Niccolo
AU  - Terrando N
FAU - Gomez-Galan, Marta
AU  - Gomez-Galan M
FAU - Yang, Ting
AU  - Yang T
FAU - Carlstrom, Mattias
AU  - Carlstrom M
FAU - Gustavsson, Daniel
AU  - Gustavsson D
FAU - Harding, Ralph E
AU  - Harding RE
FAU - Lindskog, Maria
AU  - Lindskog M
FAU - Eriksson, Lars I
AU  - Eriksson LI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
OTO - NOTNLM
OT  - astrocytes
OT  - dementia
OT  - inflammation
OT  - long-term potentiation
OT  - resolution
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - fj.13-230276 [pii]
AID - 10.1096/fj.13-230276 [doi]
PST - aheadofprint
SO  - FASEB J. 2013 May 24.

PMID- 23709595
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1522-1539 (Electronic)
IS  - 0363-6135 (Linking)
DP  - 2013 May 24
TI  - Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via
      normalizing cardiac steatosis and oxidative stress in type 2 diabetes.
AB  - [RATIONALE] Glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex-4) is
      a remedy for type 2 diabetes mellitus (T2DM). Ex-4 ameliorates cardiac
      dysfunction induced by myocardial infarction in preclinical and clinical
      settings. However, it remains unclear whether Ex-4 may modulate diabetic
      cardiomyopathy. [METHODS AND RESULTS] We tested the impact of Ex-4 on 2 types of 
      diabetic cardiomyopathy models; genetic (KK) and acquired T2DM induced by high
      fat diet (DIO) to clarify whether Ex-4 may combat independently of etiology. Each
      type of mice was divided into Ex-4 (24 nmole/kg/day for 40 days; KK-ex4 and
      DIO-ex4) and vehicle groups (KK-v and DIO-v). Ex-4 ameliorated systemic and
      cardiac insulin resistance and dyslipidemia in both T2DM models. T2DM mice
      exhibited systolic (DIO-v) and diastolic (DIO-v and KK-v) left-ventricular (LV)
      dysfunctions, which were restored by Ex-4 with reduction in LV hypertropy. DIO-v 
      and KK-v exhibited increased myocardial fibrosis and steatosis (lipid
      accumulation), in which observed cardiac mitochondrial remodeling and enhanced
      mitochondrial oxidative damage. Ex-4 treatment reversed these cardiac remodeling 
      and oxidative stress. Cytokine array revealed that Ex-4-sensitive inflammatory
      cytokines were ICAM-1 and M-CSF. Ex-4 ameliorated myocardial oxidative stress via
      suppression of Nox4 with concomitant elevation of antioxidants (SOD-1 and GPx).
      [CONCLUSIONS] GLP-1R agonism reverses cardiac remodeling and dysfunction observed
      in T2DM via normalizing imbalance of lipid metabolism and related
      inflammation/oxidative stress.
AD  - 1Nagoya University.
FAU - Monji, Akio
AU  - Monji A
FAU - Mitsui, Toko
AU  - Mitsui T
FAU - Bando, Yasuko K
AU  - Bando YK
FAU - Aoyama, Morihiko
AU  - Aoyama M
FAU - Shigeta, Toshimasa
AU  - Shigeta T
FAU - Murohara, Toyoaki
AU  - Murohara T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
OTO - NOTNLM
OT  - diabetes mellitus
OT  - glucagon-like peptide-1
OT  - insulin resistance
OT  - mitochondria
OT  - oxidative stress
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - ajpheart.00990.2012 [pii]
AID - 10.1152/ajpheart.00990.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Heart Circ Physiol. 2013 May 24.

PMID- 23709585
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1469-445X (Electronic)
IS  - 0958-0670 (Linking)
DP  - 2013 May 24
TI  - Impaired Pancreatic Beta Cell Function by Chronic Intermittent Hypoxia.
AB  - Breathing disorders with recurrent apnea produce periodic decreases in arterial
      blood O2 or chronic intermittent hypoxia (CIH). Recurrent apnea patients and CIH 
      exposed rodents exhibit several co-morbidities including diabetes. However, the
      effects of CIH on pancreatic beta cell function are not known. In the present
      study, we investigated pancreatic beta cell function in C57BL6 mice exposed to 30
      days of CIH. CIH-exposed mice exhibited elevated levels of fasting plasma
      insulin, but comparable glucose levels, and higher homeostasis model assessment
      (HOMA), indicating insulin resistance. Pancreatic beta cell morphology was
      unaltered in CIH exposed mice. Insulin content was decreased in CIH exposed beta 
      cells, and this effect was associated with increased pro-insulin levels. mRNA and
      protein levels of the enzyme pro-hormone convertase 1 (PC1) which converts
      pro-insulin to insulin were down regulated in CIH-treated islets. More
      importantly, glucose-stimulated insulin secretion (GSIS) was impaired in CIH
      exposed mice and in isolated islets. Mitochondrial reactive oxygen species (ROS) 
      levels were elevated in CIH exposed pancreatic islets. Treatment of mice with
      mito-tempol, a scavenger of mitochondrial ROS during CIH exposure, prevented the 
      augmented insulin secretion and restored the pro-insulin as well as HOMA values
      to control levels. These results demonstrate that CIH leads to pancreatic beta
      cell dysfunction manifested by augmented basal insulin secretion, insulin
      resistance, defective pro-insulin processing, impaired GSIS and mitochondrial ROS
      mediates the effects of CIH on pancreatic beta cell function.
AD  - University of Chicago.
FAU - Wang, Ning
AU  - Wang N
FAU - Khan, Shakil A
AU  - Khan SA
FAU - Prabhakar, Nanduri R
AU  - Prabhakar NR
FAU - Nanduri, Jayasri
AU  - Nanduri J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Exp Physiol
JT  - Experimental physiology
JID - 9002940
OTO - NOTNLM
OT  - Diabetes
OT  - Hypoxia
OT  - Intermittent hypoxia
OT  - Islet of Langerhans
OT  - beta cells
OT  - reactive oxygen species
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - expphysiol.2013.072454 [pii]
AID - 10.1113/expphysiol.2013.072454 [doi]
PST - aheadofprint
SO  - Exp Physiol. 2013 May 24.

PMID- 23709567
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Statins and the risk of developing diabetes.
PG  - f3156
LID - 10.1136/bmj.f3156 [doi]
LID - bmj.f3156 [pii]
AD  - Department of Pharmacology, Drug Development and Therapeutics, University of
      Turku, 20520 Turku, Finland.
FAU - Huupponen, Risto
AU  - Huupponen R
FAU - Viikari, Jorma
AU  - Viikari J
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PST - epublish
SO  - BMJ. 2013 May 23;346:f3156. doi: 10.1136/bmj.f3156.

PMID- 23709565
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 2
IP  - 3
DP  - 2013
TI  - Risk-treatment paradox in the selection of transradial access for percutaneous
      coronary intervention.
PG  - e000174
LID - 10.1161/JAHA.113.000174 [doi]
AB  - BACKGROUND: Access site complications contribute to morbidity and mortality
      during percutaneous coronary intervention (PCI). Transradial arterial access
      significantly lowers the risk of access site complications compared to
      transfemoral arteriotomy. We sought to develop a prediction model for access site
      complications in patients undergoing PCI with femoral arteriotomy, and assess
      whether transradial access was selectively used in patients at high risk for
      complications. METHODS AND RESULTS: We analyzed 17 509 patients who underwent PCI
      without circulatory support from 2008 to 2011 at 5 institutions. Transradial
      arterial access was used in 17.8% of patients. In those who underwent
      transfemoral access, 177 (1.2%) patients had access site complications. Using
      preprocedural clinical and demographic data, a prediction model for femoral
      arteriotomy complications was generated. The variables retained in the model
      included: elevated age (P<0.001), female gender (P<0.001), elevated troponin
      (P<0.001), decreased renal function or dialysis (P=0.002), emergent PCI (P=0.01),
      prior PCI (P=0.005), diabetes (P=0.008), and peripheral artery disease (P=0.003).
      The model showed moderate discrimination (optimism-adjusted c-statistic=0.72) and
      was internally validated via bootstrap resampling. Patients with higher predicted
      risk of complications via transfemoral access were less likely to receive
      transradial access (P<0.001). Similar results were seen in patients presenting
      with and without ST-segment myocardial infarction and when adjusting for
      individual physician operator. CONCLUSIONS: We generated and validated a model
      for transfemoral access site complications during PCI. Paradoxically, patients
      most likely to develop access site complications from transfemoral access, and
      therefore benefit from transradial access, were the least likely to receive
      transradial access.
AD  - Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard
      Medical School, Boston, MA.
FAU - Wimmer, Neil J
AU  - Wimmer NJ
FAU - Resnic, Frederic S
AU  - Resnic FS
FAU - Mauri, Laura
AU  - Mauri L
FAU - Matheny, Michael E
AU  - Matheny ME
FAU - Piemonte, Thomas C
AU  - Piemonte TC
FAU - Pomerantsev, Eugene
AU  - Pomerantsev E
FAU - Ho, Kalon K L
AU  - Ho KK
FAU - Robbins, Susan L
AU  - Robbins SL
FAU - Waldman, Howard M
AU  - Waldman HM
FAU - Yeh, Robert W
AU  - Yeh RW
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
SB  - IM
OTO - NOTNLM
OT  - catheterization
OT  - complications
OT  - coronary disease
OT  - stents
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - 2/3/e000174 [pii]
AID - 10.1161/JAHA.113.000174 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2013 May 24;2(3):e000174. doi: 10.1161/JAHA.113.000174.

PMID- 23709491
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1941-2479 (Electronic)
IS  - 1010-5395 (Linking)
DP  - 2013 May 23
TI  - Risk Factors of Breast Cancer: A Systematic Review and Meta-Analysis.
AB  - The etiology of breast cancer might be explained by 2 mechanisms, namely,
      differentiation and proliferation of breast epithelial cells mediated by hormonal
      factors. We performed a systematic review and meta-analysis to update effects of 
      risk factors for both mechanisms. MEDLINE and EMBASE were searched up to January 
      2011. Studies that assessed association between oral contraceptives (OC),
      hormonal replacement therapy (HRT), diabetes mellitus (DM), or breastfeeding and 
      breast cancer were eligible. Relative risks with their confidence intervals (CIs)
      were extracted. A random-effects method was applied for pooling the effect size. 
      The pooled odds ratios of OC, HRT, and DM were 1.10 (95% CI = 1.03-1.18), 1.23
      (95% CI = 1.21-1.25), and 1.14 (95% CI = 1.09-1.19), respectively, whereas the
      pooled odds ratio of ever-breastfeeding was 0.72 (95% CI = 0.58-0.89). Our study 
      suggests that OC, HRT, and DM might increase risks, whereas breastfeeding might
      lower risks of breast cancer.
AD  - 1Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
FAU - Anothaisintawee, Thunyarat
AU  - Anothaisintawee T
FAU - Wiratkapun, Cholatip
AU  - Wiratkapun C
FAU - Lerdsitthichai, Panuwat
AU  - Lerdsitthichai P
FAU - Kasamesup, Vijj
AU  - Kasamesup V
FAU - Wongwaisayawan, Sansanee
AU  - Wongwaisayawan S
FAU - Srinakarin, Jiraporn
AU  - Srinakarin J
FAU - Hirunpat, Siriporn
AU  - Hirunpat S
FAU - Woodtichartpreecha, Piyanoot
AU  - Woodtichartpreecha P
FAU - Boonlikit, Sarawan
AU  - Boonlikit S
FAU - Teerawattananon, Yot
AU  - Teerawattananon Y
FAU - Thakkinstian, Ammarin
AU  - Thakkinstian A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Asia Pac J Public Health
JT  - Asia-Pacific journal of public health / Asia-Pacific Academic Consortium for
      Public Health
JID - 8708538
OTO - NOTNLM
OT  - breast cancer
OT  - meta-analysis
OT  - risk factor
OT  - systematic review
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - 1010539513488795 [pii]
AID - 10.1177/1010539513488795 [doi]
PST - aheadofprint
SO  - Asia Pac J Public Health. 2013 May 23.

PMID- 23709472
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1555-824X (Electronic)
IS  - 1062-8606 (Linking)
DP  - 2013 Jun 7
TI  - Inpatient Glycemic Control: Best Practice Advice From the Clinical Guidelines
      Committee of the American College of Physicians.
AB  - Hyperglycemia is associated with poor outcomes in hospitalized medical and
      surgical patients. Although some early evidence showed benefits of intensive
      insulin therapy (IIT), recent evidence does not show a consistent benefit and
      even shows harm associated with the use of IIT. The overuse of some therapeutic
      interventions and the resulting harms to a patient are an important component of 
      unnecessary health care costs. The goal of this article is to address the
      management of hyperglycemia and evaluate the benefits and harms associated with
      the use of IIT to achieve tight glycemic control in hospitalized patients with or
      without diabetes mellitus. This article is based on the evidence review and the
      guideline developed by the American College of Physicians on this topic.Best
      Practice Advice 1: Clinicians should target a blood glucose level of 7.8 to 11.1 
      mmol/L (140 to 200 mg/dL) if insulin therapy is used in SICU/MICU patients. Best 
      Practice Advice 2: Clinicians should avoid targets less than 7.8 mmol/L
      (<140mg/dL) because harms are likely to increase with lower blood glucose
      targets.
AD  - 1American College of Physicians, Philadelphia, PA.
FAU - Qaseem, Amir
AU  - Qaseem A
FAU - Chou, Roger
AU  - Chou R
FAU - Humphrey, Linda L
AU  - Humphrey LL
FAU - Shekelle, Paul
AU  - Shekelle P
CN  - for the Clinical Guidelines Committee of the American College of Physicians
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - Am J Med Qual
JT  - American journal of medical quality : the official journal of the American
      College of Medical Quality
JID - 9300756
OTO - NOTNLM
OT  - blood glucose level
OT  - high-value care
OT  - inpatient glycemic control
OT  - intensive insulin therapy
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/05/23 [aheadofprint]
PHST- 2013/05/24 [aheadofprint]
AID - 1062860613489339 [pii]
AID - 10.1177/1062860613489339 [doi]
PST - aheadofprint
SO  - Am J Med Qual. 2013 Jun 7.

PMID- 23709458
OWN - NLM
STAT- In-Process
DA  - 20130527
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 19
IP  - 3
DP  - 2013 May-Jun
TI  - Narrative review of yoga intervention clinical trials including weight-related
      outcomes.
PG  - 32-46
AB  - CONTEXT: Medical authorities have identified obesity as a causal factor in the
      development of diabetes, hypertension, and cardiovascular disease (CVD), and more
      broadly, of metabolic syndrome/insulin resistance syndrome. To provide solutions 
      that can modify this risk factor, researchers need to identify methods of
      effective risk reduction and primary prevention of obesity. Research on the
      effectiveness of yoga as a treatment for obesity is limited, and studies vary in 
      overall quality and methodological rigor. OBJECTIVE: This narrative review
      assessed the quantity and quality of clinical trials of yoga as an intervention
      for weight loss or as a means of risk reduction or treatment for obesity and
      diseases in which obesity is a causal factor. This review summarized the studies'
      research designs and evaluated the efficacy of yoga for weight loss via the
      current evidence base. DESIGN: The research team evaluated published studies to
      determine the appropriateness of research designs, comparability of programs'
      intervention elements, and standardization of outcome measures. The research
      team's literature search used the key terms yoga and obesity or yoga and weight
      loss in three primary medical-literature databases (PubMed, PsychInfo, and Web of
      Science). The study excluded clinical trials with no quantitative obesity related
      measure. Extracted data included each study's (1) design; (2) setting and
      population; (3) nature, duration, and frequency of interventions; (4) comparison 
      groups; (5) recruitment strategies; (6) outcome measures; (7) data analysis and
      presentation; and (8) results and conclusions. The research team developed an
      overall evaluation parameter to compare disparate trials. OUTCOME MEASURES: The
      research team reviewed each study to determine its key features, each worth a
      specified number of points, with a maximum total of 20 points. The features
      included a study's (1) duration, (2) frequency of yoga practice, (3) intensity of
      (length of) each practice, (4) number of yogic elements, (5) inclusion of dietary
      modification, (6) inclusion of a residential component, (7) the number of
      weight-related outcome measures, and (8) a discussion of the details of the yogic
      elements. RESULTS: Overall, therapeutic yoga programs are frequently effective in
      promoting weight loss and/or improvements in body composition. The effectiveness 
      of yoga for weight loss is related to the following key features: (1) an
      increased frequency of practice; (2) a longer intervention duration (3) a yogic
      dietary component; (4) a residential component; (5) the comprehensive inclusion
      of yogic components; (5) and a home-practice component. CONCLUSIONS: Yoga appears
      to be an appropriate and potentially successful intervention for weight
      maintenance, prevention of obesity, and risk reduction for diseases in which
      obesity plays a significant causal role.
AD  - Department of Family and Community Medicine, University of Arizona, AZ, USA.
      rioux@email.arizona.edu
FAU - Rioux, Jennifer Grace
AU  - Rioux JG
FAU - Ritenbaugh, Cheryl
AU  - Ritenbaugh C
LA  - eng
GR  - T32-AT001287/AT/NCCAM NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PST - ppublish
SO  - Altern Ther Health Med. 2013 May-Jun;19(3):32-46.

PMID- 23709153
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Co-infusion of adipose tissue derived mesenchymal stem cell-differentiated
      insulin-making cells and haematopoietic cells with renal transplantation: a novel
      therapy for type 1 diabetes mellitus with end-stage renal disease.
LID - 10.1136/bcr-2013-009901 [doi]
LID - bcr2013009901 [pii]
AB  - Type 1 diabetes mellitus (T1DM) is a common cause of end-stage renal disease
      (ESRD). Various factors contribute to wide fluctuations in blood glucose levels
      and exogenous insulin requirement in such patients even after renal
      transplantation (RT). Simultaneous pancreas-kidney transplantation is one of the 
      therapies for these patients. Stem cell (SC) therapy for T1DM and for
      minimisation of immunosuppression after RT has shown encouraging results. We
      report a 30-year-old-man with T1DM since 15 years and ESRD since 2 years, who
      underwent living donor RT and co-infusion of in vitro generated insulin-making
      cells differentiated from donor adipose tissue derived mesenchymal stem cells and
      bone marrow -derived haematopoietic SC into subcutaneous tissue, portal and
      thymic circulation under non-myeloablative conditioning. Over follow-up of 13
      months he has stable graft function with serum creatinine, 1.2 mg/dl, zero
      rejection and glycosylated haemoglobin level of 6.1% on calcineurin-inhibitor
      based therapy.
AD  - Department of Pathology, Laboratory Medicine, Transfusion Services and
      Immunohematology, G. R. Doshi and K. M. Mehta Institute of Kidney Diseases &
      Research Centre (IKDRC)-Dr. H.L. Trivedi Institute of Transplantation Sciences
      (ITS), Ahmedabad, Gujarat, India.
FAU - Dave, Shruti D
AU  - Dave SD
FAU - Vanikar, Aruna V
AU  - Vanikar AV
FAU - Trivedi, Hargovind L
AU  - Trivedi HL
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - bcr-2013-009901 [pii]
AID - 10.1136/bcr-2013-009901 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 23;2013. pii: bcr2013009901. doi: 10.1136/bcr-2013-009901.

PMID- 23709097
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1573-2649 (Electronic)
IS  - 0962-9343 (Linking)
DP  - 2013 May 26
TI  - Impact of diagnosis of diabetes on health-related quality of life among high risk
      individuals: the Diabetes Prevention Program outcomes study.
AB  - PURPOSE: The purpose of this study is to assess if diagnosis of type 2 diabetes
      affected health-related quality of life (HRQoL) among participants in the
      Diabetes Prevention Program/Diabetes Prevention Program Outcome Study and changes
      with treatment or diabetes duration. METHODS: 3,210 participants with
      pre-diabetes were randomized to metformin (MET), intensive lifestyle intervention
      (ILS), or placebo (PLB). HRQoL was assessed using the SF-36 including: (1) 8
      SF-36 subscales; (2) the physical component (PCS) and mental component summary
      (MCS) scores; and (3) the SF-6D. The sample was categorized by diabetes free
      versus diagnosed. For diagnosed subgroup, mean scores in the diabetes-free
      period, at 6 months, 2, 4 and 6 years post-diagnosis, were compared. RESULTS: PCS
      and SF-6D scores declined in all participants in all treatment arms (P < .001).
      MCS scores did not change significantly in any treatment arm regardless of
      diagnosis. ILS participants reported a greater decrease in PCS scores at 6 months
      post-diagnosis (P < .001) and a more rapid decline immediately post-diagnosis in 
      SF-6D scores (P = .003) than the MET or PLB arms. ILS participants reported a
      significant decrease in the social functioning subscale at 6 months (P < .001)
      and two years (P < .001) post-diagnosis. CONCLUSIONS: Participants reported a
      decline in measures of overall health state (SF-6D) and overall physical HRQoL,
      whether or not they were diagnosed with diabetes during the study. There was no
      change in overall mental HRQoL. Participants in the ILS arm with diabetes
      reported a more significant decline in some HRQoL measures than those in the MET 
      and PLB arms that developed diabetes.
AD  - Indiana University School of Medicine, Indianapolis, IN, USA,
      dppmail@bsc.gwu.edu.
FAU - Marrero, D
AU  - Marrero D
FAU - Pan, Q
AU  - Pan Q
FAU - Barrett-Connor, E
AU  - Barrett-Connor E
FAU - de Groot, M
AU  - de Groot M
FAU - Zhang, P
AU  - Zhang P
FAU - Percy, C
AU  - Percy C
FAU - Florez, H
AU  - Florez H
FAU - Ackermann, R
AU  - Ackermann R
FAU - Montez, M
AU  - Montez M
FAU - Rubin, R R
AU  - Rubin RR
CN  - the DPPOS Research Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Qual Life Res
JT  - Quality of life research : an international journal of quality of life aspects of
      treatment, care and rehabilitation
JID - 9210257
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/05/14 [accepted]
PHST- 2013/05/26 [aheadofprint]
AID - 10.1007/s11136-013-0436-3 [doi]
PST - aheadofprint
SO  - Qual Life Res. 2013 May 26.

PMID- 23709089
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 24
TI  - High fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and
      mitochondrial function despite peripheral insulin resistance.
AB  - In obesity, reduced cardiac glucose uptake and mitochondrial abnormalities are
      putative causes of cardiac dysfunction. However, high fat diet (HFD) does not
      consistently induce cardiac insulin resistance and mitochondrial damage, and
      recent studies suggest HFD may be cardioprotective. To determine cardiac
      responses to HFD, we investigated cardiac function, glucose uptake and
      mitochondrial respiration in young (3-month-old) and middle-aged (MA;
      12-month-old) male Ldlr-/- mice fed chow or 3 months HFD to induce obesity,
      systemic insulin resistance and hyperinsulinemia. In MA Ldlr-/- mice, HFD induced
      accelerated atherosclerosis and nonalcoholic steatohepatitis, common
      complications of human obesity. Surprisingly, HFD-fed mice demonstrated increased
      cardiac glucose uptake, which was most prominent in MA mice, in the absence of
      cardiac contractile dysfunction or hypertrophy. Moreover, hearts of HFD-fed mice 
      had enhanced mitochondrial oxidation of palmitoyl carnitine, glutamate, and
      succinate, and greater basal insulin signaling compared to those of chow-fed
      mice, suggesting cardiac insulin sensitivity was maintained, despite systemic
      insulin resistance. Streptozotocin (STZ)-induced ablation of insulin production
      markedly reduced cardiac glucose uptake and mitochondrial dysfunction in HFD-fed,
      but not in chow-fed mice. Insulin injection reversed these effects, suggesting
      that insulin may protect cardiac mitochondria during HFD. These results have
      implications for cardiac metabolism and preservation of mitochondrial function in
      obesity.
AD  - 1Methodist Diabetes and Metabolism Institute, The Methodist Hospital Research
      Institute, Weill Cornell Medical College, Houston, TX 77030, USA;
FAU - Gupte, Anisha A
AU  - Gupte AA
FAU - Minze, Laurie J
AU  - Minze LJ
FAU - Reyes, Maricela
AU  - Reyes M
FAU - Ren, Yuelan
AU  - Ren Y
FAU - Wang, Xukui
AU  - Wang X
FAU - Brunner, Gerd
AU  - Brunner G
FAU - Ghosn, Mohamad
AU  - Ghosn M
FAU - Cordero-Reyes, Andrea M
AU  - Cordero-Reyes AM
FAU - Ding, Karen
AU  - Ding K
FAU - Pratico, Domenico
AU  - Pratico D
FAU - Morrisett, Joel
AU  - Morrisett J
FAU - Shi, Zheng-Zheng
AU  - Shi ZZ
FAU - Hamilton, Dale J
AU  - Hamilton DJ
FAU - Lyon, Christopher J
AU  - Lyon CJ
FAU - Hsueh, Willa A
AU  - Hsueh WA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - en.2012-2272 [pii]
AID - 10.1210/en.2012-2272 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 24.

PMID- 23709000
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1479-6805 (Electronic)
IS  - 0022-0795 (Linking)
DP  - 2013 May 24
TI  - 2D-DIGE to identify proteins associated with gestational diabetes in omental
      adipose tissue.
AB  - Gestational diabetes mellitus (GDM) is a significant risk factor for the type 2
      diabetes epidemic in many populations. Maternal adipose tissue plays a central
      role in the pathophysiology of GDM. Thus, the aim of this study was to determine 
      the effect of GDM on the proteome of adipose tissue. Omental adipose tissue was
      obtained at the time of term Caesarean section from women with normal glucose
      tolerance (NGT) or GDM. 2D-difference gel electrophoresis (DIGE), followed by
      mass spectrometry (MS), was used to identify protein spots (n=6 patients per
      group). Western blotting was used for confirmation of 6 of the spot differences
      (n= 6 patients per group). We found 14 proteins that were differentially
      expressed between NGT and GDM adipose tissue (>/=1.4-fold, P<0.05). GDM was
      associated with an up-regulation of 4 proteins; collagen alpha-2(VI) chain
      (CO6A2), fibrinogen beta chain (FIBB), lumican (LUM) and S100A9. On the other
      hand, a total of 10 proteins were found to be down-regulated in adipose tissue
      from GDM women. These were alpha-1-antitrypsin (AIAT), annexin A5 (ANXA5), fatty 
      acid-binding protein, adipocyte (FABP4), glutathione S-transferase P (GSTP), heat
      shock protein beta-1 (HSP27), lactate dehydrogenase B chain (LDHB), perilipin-1
      (PLIN1), peroxiredoxin-6 (PRX6), selenium-binding protein 1 (SBP1), and vinculin 
      (VINC). In conclusion, proteomic analysis of omental fat reveals differential
      expression of several proteins in GDM patients and NGT pregnant women. This study
      revealed differences in expression of proteins that are involved in inflammation,
      lipid and glucose metabolism and oxidative stress, and adds further evidence to
      support the role of visceral adiposity in the pathogenesis of GDM.
AD  - K Oliva, UQCCR, University of Queensland, Brisbane, Australia.
FAU - Oliva, Karen
AU  - Oliva K
FAU - Barker, Gillian
AU  - Barker G
FAU - Rice, Gregory
AU  - Rice G
FAU - Bailey, Mark John
AU  - Bailey MJ
FAU - Lappas, Martha
AU  - Lappas M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - JOE-13-0010 [pii]
AID - 10.1530/JOE-13-0010 [doi]
PST - aheadofprint
SO  - J Endocrinol. 2013 May 24.

PMID- 23708985
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 154
IP  - 22
DP  - 2013 Jun 1
TI  - [Role of simultaneous pancreas-kidney transplantation in the treatment of
      diabetes mellitus].
PG  - 850-6
LID - 10.1556/OH.2013.29637 [doi]
AB  - The life expectancy of patients with type 1 diabetes mellitus is inferior to that
      of patients with some malignancies. Simultaneous pancreas-kidney transplantation 
      is the procedure providing the best survival results among all options of renal
      replacement therapy. The operative techniques and immunosuppresion have been
      standardized in the last decade. Although the number of transplantable organs
      falls behind the need, simultaneous pancreas-kidney transplantation is the method
      of choice for the eligible patients. The results of the two Hungarian
      simultaneous pancreas-kidney transplantation programs are in accordance with data
      published in the international literature. Orv. Hetil., 2013, 154, 850-856.
AD  - Pecsi Tudomanyegyetem, Altalanos Orvostudomanyi Kar Klinikai Kozpont, Sebeszeti
      Klinika Pecs Rakoczi ut 2. 7622.
FAU - Kalmar Nagy, Karoly
AU  - Kalmar Nagy K
FAU - Horvath, Szabolcs
AU  - Horvath S
FAU - Szakaly, Peter
AU  - Szakaly P
FAU - Piros, Laszlo
AU  - Piros L
FAU - Langer, Robert
AU  - Langer R
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - Szimultan hasnyalmirigy-vese transzplantacio helye a diabetes mellitus
      kezeleseben.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
SB  - IM
OAB - Publisher: Abstract available from the publisher.
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - 3P5K081770051719 [pii]
AID - 10.1556/OH.2013.29637 [doi]
PST - ppublish
SO  - Orv Hetil. 2013 Jun 1;154(22):850-6. doi: 10.1556/OH.2013.29637.

PMID- 23708729
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 0219-1032 (Electronic)
IS  - 1016-8478 (Linking)
DP  - 2013 May 24
TI  - Autophagy: A critical regulator of cellular metabolism and homeostasis.
AB  - Autophagy is a dynamic process by which cytosolic material, including organelles,
      proteins, and pathogens, are sequestered into membrane vesicles called
      autophagosomes, and then delivered to the lysosome for degradation. By recycling 
      cellular components, this process provides a mechanism for adaptation to
      starvation. The regulation of autophagy by nutrient signals involves a complex
      network of proteins that include mammalian target of rapamycin, the class III
      phosphatidylinositol-3 kinase/Beclin 1 complex, and two ubiquitin-like
      conjugation systems. Additionally, autophagy, which can be induced by multiple
      forms of chemical and physical stress, including endoplasmic reticulum stress,
      and hypoxia, plays an integral role in the mammalian stress response. Recent
      studies indicate that, in addition to bulk assimilation of cytosol, autophagy may
      proceed through selective pathways that target distinct cargoes to
      autophagosomes. The principle homeostatic functions of autophagy include the
      selective clearance of aggregated protein to preserve proteostasis, and the
      selective removal of dysfunctional mitochondria (mitophagy). Additionally,
      autophagy plays a central role in innate and adaptive immunity, with diverse
      functions such as regulation of inflammatory responses, antigen presentation, and
      pathogen clearance. Autophagy can preserve cellular function in a wide variety of
      tissue injury and disease states, however, maladaptive or pro-pathogenic outcomes
      have also been described. Among the many diseases where autophagy may play a role
      include proteopathies which involve aberrant accumulation of proteins (e.g.,
      neurodegenerative disorders), infectious diseases, and metabolic disorders such
      as diabetes and metabolic syndrome. Targeting the autophagy pathway and its
      regulatory components may eventually lead to the development of therapeutics.
AD  - Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard
      Medical School, Boston, MA, 02115, USA, sryter@partners.org.
FAU - Ryter, Stefan W
AU  - Ryter SW
FAU - Cloonan, Suzanne M
AU  - Cloonan SM
FAU - Choi, Augustine M K
AU  - Choi AM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Mol Cells
JT  - Molecules and cells
JID - 9610936
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/05/03 [received]
PHST- 2013/05/06 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 10.1007/s10059-013-0140-8 [doi]
PST - aheadofprint
SO  - Mol Cells. 2013 May 24.

PMID- 23708564
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
DP  - 2013 May 27
TI  - Inhibitory effect of soluble RAGE in disturbed flow-induced atherogenesis.
LID - 10.3892/ijmm.2013.1393 [doi]
AB  - Soluble receptor for advanced glycation end products RAGE (sRAGE), a secretory
      form of RAGE, plays an important role in suppressing RAGE signals that induce
      pro-inflammatory gene activation in a range of inflammatory diseases, such as
      Alzheimer's disease, complications of diabetes mellitus and atherosclerosis.
      Recent studies have suggested that fluid shear stress generated by laminar blood 
      flow protects blood vessels from atherosclerosis, whereas low and oscillatory
      shear stress (OSS) generated by disturbed blood flow causes atherosclerosis.
      Although RAGE levels are increased in atherosclerotic plaque, the regulatory
      mechanisms of sRAGE in the occurrence of atherosclerotic plaque induced by
      disturbed blood flow remain largely unknown. This study aimed to determine the
      effects of sRAGE as a competitive inhibitor of RAGE in atherogenesis induced by
      disturbed blood flow. To determine the role of sRAGE in atherosclerosis induced
      by disturbed blood flow, we used a mouse model of partial carotid artery ligation
      using ApoE-/- and C57BL/6 mice. Our results revealed that the expression of RAGE 
      was significantly increased in the region of atherosclerotic plaque and that
      treatment with sRAGE attenuated the development of plaque formation. We found
      that the expression levels of RAGE and high mobility group box 1 (HMGB1), the
      agonistic ligand of RAGE, were significantly increased in human umbilical vein
      endothelial cells (HUVECs) under shear stress conditions induced by disturbed
      blood flow and suppressed following treatment with sRAGE. We further observed
      that treatment with sRAGE decreased the expression of vascular cell adhesion
      molecule1 (VCAM-1) and markedly attenuated monocyte-endothelial cell adhesion.
      Taken together, our results reveal that sRAGE exerts anti-atherogenic effects by 
      blocking the activation of the RAGE signaling pathway induced by disturbed blood 
      flow and may thus be a potential therapeutic target for the prevention of
      atherosclerosis.
AD  - Medical Research Institute, Ewha Womans University, Yangcheon-gu, Seoul 158-710, 
      Republic of Korea.
FAU - Ha, Chang Hoon
AU  - Ha CH
FAU - Kim, Sunghyen
AU  - Kim S
FAU - Chung, Jihwa
AU  - Chung J
FAU - An, Shung Hyen
AU  - An SH
FAU - Park, Sungha
AU  - Park S
FAU - Choi, Donghoon
AU  - Choi D
FAU - Kwon, Kihwan
AU  - Kwon K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/04/02 [received]
PHST- 2013/05/15 [accepted]
AID - 10.3892/ijmm.2013.1393 [doi]
PST - aheadofprint
SO  - Int J Mol Med. 2013 May 27. doi: 10.3892/ijmm.2013.1393.

PMID- 23708532
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 112
DP  - 2013 Aug 15
TI  - Portable method of measuring gaseous acetone concentrations.
PG  - 26-30
LID - 10.1016/j.talanta.2013.03.052 [doi]
LID - S0039-9140(13)00201-4 [pii]
AB  - Measurement of acetone in human breath samples has been previously shown to
      provide significant non-invasive diagnostic insight into the control of a
      patient's diabetic condition. In patients with diabetes mellitus, the body
      produces excess amounts of ketones such as acetone, which are then exhaled during
      respiration. Using various breath analysis methods has allowed for the accurate
      determination of acetone concentrations in exhaled breath. However, many of these
      methods require instrumentation and pre-concentration steps not suitable for
      point-of-care use. We have found that by immobilizing resorcinol reagent into a
      perfluorosulfonic acid polymer membrane, a controlled organic synthesis reaction 
      occurs with acetone in a dry carrier gas. The immobilized, highly selective
      product of this reaction (a flavan) is found to produce a visible spectrum color 
      change which could measure acetone concentrations to less than ppm. We here
      demonstrate how this approach can be used to produce a portable optical sensing
      device for real-time, non-invasive acetone analysis.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Chemical Engineering Program, University of Cincinnati, Cincinnati, OH 45221,
      USA.
FAU - Worrall, Adam D
AU  - Worrall AD
FAU - Bernstein, Jonathan A
AU  - Bernstein JA
FAU - Angelopoulos, Anastasios P
AU  - Angelopoulos AP
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/12/31 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/21 [accepted]
PHST- 2013/03/31 [aheadofprint]
AID - S0039-9140(13)00201-4 [pii]
AID - 10.1016/j.talanta.2013.03.052 [doi]
PST - ppublish
SO  - Talanta. 2013 Aug 15;112:26-30. doi: 10.1016/j.talanta.2013.03.052. Epub 2013 Mar
      31.

PMID- 23708319
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 0009-479X (Electronic)
IS  - 0009-479X (Linking)
VI  - 78
DP  - 2013
TI  - Czy zespol kanalu nadgarstka jest choroba zawodowa? Przeglad pismiennictwa.
PG  - 121-6
AB  - In many countries, including Poland, carpal tunnel syndrome is considered to be a
      disease of possible occupational etiology. This review presents information about
      work-related risk-factors which comprise the use of handheld vibrating machinery,
      forceful gripping of objects with hands, repetitive and frequent manual tasks and
      forced postures of the wrist (flexion/extension). However, the character of the
      job is only one of possible several factors leading to the development of the
      disease, as its etiology is multifactorial. Conditions to be taken into
      consideration when recognizing a case as occupational carpal tunnel syndrome were
      shown to include: coexistence of predisposing diseases (diabetes), constitutional
      factors (obesity), character, level and duration of the exposure to harmful
      stimuli during the workday as well as total duration of work upon exposure.
      Consideration of these circumstances provides adequate ground for recognizing a
      particular case as occupational. Nonetheless, even accepting the disease as
      occupational should be temporary, as surgical carpal tunnel release is an
      effective method of treatment and should allow the patient to return to
      previously performed work.
AD  - Clinic of General Surgery and Hand Surgery, Pomeranian Medical University,
      Szczecin, Poland.
FAU - Zyluk, Andrzej
AU  - Zyluk A
LA  - eng
PT  - Journal Article
DEP - 20130527
PL  - United States
TA  - Pol Orthop Traumatol
JT  - Polish orthopedics & traumatology
JID - 101593867
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - 883923 [pii]
PST - epublish
SO  - Pol Orthop Traumatol. 2013 May 27;78:121-6.

PMID- 23708292
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 19
IP  - 6
DP  - 2013 Jun
TI  - Hepatitis C virus infection activates an innate pathway involving IKK-alpha in
      lipogenesis and viral assembly.
PG  - 722-9
LID - 10.1038/nm.3190 [doi]
AB  - Hepatitis C virus (HCV) interacts extensively with host factors to not only
      establish productive infection but also trigger unique pathological processes.
      Our recent genome-wide siRNA screen demonstrated that IkappaB kinase-alpha
      (IKK-alpha) is a crucial host factor for HCV. Here we describe a new nuclear
      factor kappaB (NF-kappaB)-independent and kinase-mediated nuclear function of
      IKK-alpha in HCV assembly. HCV, through its 3' untranslated region, interacts
      with DEAD box polypeptide 3, X-linked (DDX3X) to activate IKK-alpha, which
      translocates to the nucleus and induces a CBP/p300-mediated transcriptional
      program involving sterol regulatory element-binding proteins (SREBPs). This
      innate pathway induces lipogenic genes and enhances core-associated lipid droplet
      formation to facilitate viral assembly. Chemical inhibitors of IKK-alpha suppress
      HCV infection and IKK-alpha-induced lipogenesis, offering a proof-of-concept
      approach for new HCV therapeutic development. Our results show that HCV uses a
      novel mechanism to exploit intrinsic innate responses and hijack lipid
      metabolism, which may contribute to high chronicity rates and the pathological
      hallmark of steatosis in HCV infection.
AD  - Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney
      Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
FAU - Li, Qisheng
AU  - Li Q
FAU - Pene, Veronique
AU  - Pene V
FAU - Krishnamurthy, Siddharth
AU  - Krishnamurthy S
FAU - Cha, Helen
AU  - Cha H
FAU - Liang, T Jake
AU  - Liang TJ
LA  - eng
PT  - Journal Article
DEP - 20130526
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
SB  - IM
PMC - PMC3676727
MID - NIHMS466266
OID - NLM: NIHMS466266 [Available on 12/01/13]
OID - NLM: PMC3676727 [Available on 12/01/13]
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PMCR- 2013/12/01 00:00
PHST- 2012/08/29 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/05/26 [aheadofprint]
AID - nm.3190 [pii]
AID - 10.1038/nm.3190 [doi]
PST - ppublish
SO  - Nat Med. 2013 Jun;19(6):722-9. doi: 10.1038/nm.3190. Epub 2013 May 26.

PMID- 23708182
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
DP  - 2013 Apr 3
TI  - Study on the mechanism causing elevation of serum CA19-9 levels in diabetic
      patients.
AB  - Serum CA19-9 levels are often elevated in diabetic patients. To elucidate this
      mechanism, we investigated the metabolism of CA19-9 in diabetic patients without 
      obvious cancer. Study 1 included 119 patients in whom HbA1c, glycated albumin
      (GA) and CA19-9 were measured at the time of hospital admission. Study 2 examined
      6 patients with markedly elevated CA19-9 levels (>/=100 U/ml). Their half-lives
      for HbA1c, GA, and serum CA19-9 were calculated using the data before and after
      diabetes treatment. Three diabetic patients with pancreatic cancer were also
      examined as controls. In Study 1, serum CA19-9 (logarithmically transformed
      value) was significantly correlated with fasting plasma glucose (FPG), HbA1c and 
      GA. On multivariate analysis, GA and FPG, but not HbA1c, were significant
      explanatory variables for serum CA19-9. In Study 2, serum CA19-9 decreased
      together with HbA1c and GA after diabetes treatment. The calculated half-lives
      for HbA1c, GA, and serum CA19-9 were 33.8 days, 16.1 days, and 10.9 days,
      respectively. The half-life of serum CA19-9 was longer in the study patients than
      that reported in patients with malignant tumors. By contrast, in the diabetic
      patients with pancreatic cancer serum CA19-9 showed a marginal decrease after
      diabetes treatment. Taken all together, prolonged half-life of serum CA19-9 may
      contribute to the increase in serum CA19-9 levels in diabetic patients without
      obvious cancer.
AD  - Department of Internal Medicine, Kinki Central Hospital, Itami 664-8533, Japan.
FAU - Murai, Jun
AU  - Murai J
FAU - Soga, Sumiko
AU  - Soga S
FAU - Saito, Hiroshi
AU  - Saito H
FAU - Otsuki, Michio
AU  - Otsuki M
FAU - Kitada, Takatoshi
AU  - Kitada T
FAU - Saisho, Yoshifumi
AU  - Saisho Y
FAU - Nakamura, Hideji
AU  - Nakamura H
FAU - Kasayama, Soji
AU  - Kasayama S
FAU - Koga, Masafumi
AU  - Koga M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130403
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - DN/JST.JSTAGE/endocrj/EJ12-0364 [pii]
PST - aheadofprint
SO  - Endocr J. 2013 Apr 3.

PMID- 23708174
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 165
IP  - 6
DP  - 2013 Jun
TI  - Lack of association between SLCO1B1 polymorphisms and clinical myalgia following 
      rosuvastatin therapy.
PG  - 1008-14
LID - 10.1016/j.ahj.2013.01.025 [doi]
LID - S0002-8703(13)00085-9 [pii]
AB  - BACKGROUND: Carriers of the rs4363657C and rs4149056C alleles in SLCO1B1 have
      increased myopathic complaints when taking simvastatin. Whether rosuvastatin has 
      a similar effect is uncertain. This study assesses whether SLCO1B1 polymorphisms 
      relate to clinical myalgia after rosuvastatin therapy. METHODS: In the JUPITER
      trial, participants without prior cardiovascular disease or diabetes who had
      low-density lipoprotein cholesterol <130 mg/dL and C-reactive protein >/=2 mg/L
      were randomly allocated to rosuvastatin 20 mg or placebo and followed for the
      first cardiovascular disease events and adverse effects. We evaluated the effect 
      of rs4363657 and rs4149056 in SLCO1B1, which encodes organic anion-transporting
      polypeptide OATP1B1, a regulator of hepatic statin uptake, on clinically reported
      myalgia. RESULTS: Among 4,404 participants allocated to rosuvastatin, clinical
      myalgia occurred with a rate of 4.1 events per 100 person-years as compared with 
      3.7 events per 100 person-years among 4,378 participants allocated to placebo
      (hazard ratio [HR] 1.13, 95% CI 0.98-1.30). Among those on rosuvastatin, there
      were no differences in the rate of myalgia among those with the rs4363657C (HR
      0.95, 95% CI 0.79-1.14 per allele) or the rs4149056C allele (HR 0.95, 95% CI
      0.79-1.15 per allele) compared with those without the C allele. Similar null data
      were observed when the myalgia definition was broadened to include muscle
      weakness, stiffness, or pain. None of the 3 participants on rosuvastatin or the 3
      participants on placebo with frank myopathy had the minor allele at either
      polymorphism. CONCLUSION: There appears to be no increased risk of myalgia among 
      users of rosuvastatin who carry the rs4363657C or the rs4149056C allele in
      SLCO1B1.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA. Electronic address: jdanik@partners.org.
FAU - Danik, Jacqueline S
AU  - Danik JS
FAU - Chasman, Daniel I
AU  - Chasman DI
FAU - Macfadyen, Jean G
AU  - Macfadyen JG
FAU - Nyberg, Fredrik
AU  - Nyberg F
FAU - Barratt, Bryan J
AU  - Barratt BJ
FAU - Ridker, Paul M
AU  - Ridker PM
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
SB  - AIM
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/09/26 [received]
PHST- 2013/01/17 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0002-8703(13)00085-9 [pii]
AID - 10.1016/j.ahj.2013.01.025 [doi]
PST - ppublish
SO  - Am Heart J. 2013 Jun;165(6):1008-14. doi: 10.1016/j.ahj.2013.01.025. Epub 2013
      Apr 10.

PMID- 23708162
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 165
IP  - 6
DP  - 2013 Jun
TI  - Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes
      among patients with high-risk non-ST-segment elevation acute coronary syndrome.
PG  - 918-925.e2
LID - 10.1016/j.ahj.2013.01.005 [doi]
LID - S0002-8703(13)00051-3 [pii]
AB  - BACKGROUND: We examined the prevalence of undiagnosed diabetes or prediabetes and
      associations with ischemic outcomes among non-ST-segment elevation acute coronary
      syndrome (ACS) patients. METHODS: We categorized 8795 EARLY ACS trial patients
      into one of the following groups: "known diabetes" (n = 2860 [32.5%]; reported on
      the case report form), "undiagnosed diabetes" (n = 1069 [12.2%]; no diabetes
      history and fasting glucose >/=126 mg/dL or hemoglobin A1c >/=6.5%),
      "prediabetes" (n = 947 [10.8%]; fasting glucose >/=110 to <126 mg/dL, or "normal"
      (n = 3919 [44.5%]). Adjusted associations of known diabetes, undiagnosed
      diabetes, and prediabetes (versus normal) with 30-day and 1-year outcomes were
      determined. RESULTS: Undiagnosed diabetes was associated with greater 30-day
      death or myocardial infarction (MI) (ORadj 1.28, 95% CI 1.05-1.57), driven
      primarily by greater 30-day mortality (ORadj 1.65, 95% CI 1.09-2.48). Known
      diabetic patients had 30-day death or MI outcomes similar to those of normal
      patients, but 30-day mortality was higher (ORadj 1.40, 95% CI 1.01-1.93).
      Prediabetic patients had 30-day death or MI outcomes similar to those of normal
      patients. One-year mortality was greater among known diabetic patients (HRadj
      1.38, 95% CI 1.13-1.67) but not among those with undiagnosed diabetes or
      prediabetes. CONCLUSIONS: Undiagnosed diabetes and prediabetes were common among 
      high-risk non-ST-segment elevation ACS patients. Routine screening for
      undiagnosed diabetes may be useful since these patients seem to have worse
      short-term outcomes and deserve consideration of alternative management
      strategies.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Instituto do Coracao-Hospital das Clinicas da Faculdade de Medicina da
      Universidade de Sao Paulo and the Brazilian Clinical Research Institute, Sao
      Paulo, Brazil.
FAU - Giraldez, Roberto R
AU  - Giraldez RR
FAU - Clare, Robert M
AU  - Clare RM
FAU - Lopes, Renato D
AU  - Lopes RD
FAU - Dalby, Anthony J
AU  - Dalby AJ
FAU - Prabhakaran, Dorairaj
AU  - Prabhakaran D
FAU - Brogan, Gerard X Jr
AU  - Brogan GX Jr
FAU - Giugliano, Robert P
AU  - Giugliano RP
FAU - James, Stefan K
AU  - James SK
FAU - Tanguay, Jean-Francois
AU  - Tanguay JF
FAU - Pollack, Charles V Jr
AU  - Pollack CV Jr
FAU - Harrington, Robert A
AU  - Harrington RA
FAU - Braunwald, Eugene
AU  - Braunwald E
FAU - Newby, L Kristin
AU  - Newby LK
LA  - eng
PT  - Journal Article
DEP - 20130213
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
SB  - AIM
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/12/06 [received]
PHST- 2013/01/11 [accepted]
PHST- 2013/02/13 [aheadofprint]
AID - S0002-8703(13)00051-3 [pii]
AID - 10.1016/j.ahj.2013.01.005 [doi]
PST - ppublish
SO  - Am Heart J. 2013 Jun;165(6):918-925.e2. doi: 10.1016/j.ahj.2013.01.005. Epub 2013
      Feb 13.

PMID- 23708151
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1436-6215 (Electronic)
IS  - 1436-6207 (Linking)
DP  - 2013 May 26
TI  - Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the 
      expression of the vitamin C transporters SVCT1 and SVCT2.
AB  - PURPOSE: Owing to its ability to inactivate harmful radicals, vitamin C plays a
      key role in antioxidant defense. The bioavailability of this vitamin depends upon
      the nutritional intake and its uptake by cells, mainly through the
      sodium-dependent transporters SVCT1/Svct1 and SVCT2/Svct2 (human/rat). Here, we
      investigated the effect of liver metabolic/oxidative stress on the expression of 
      these transporters in extrahepatic tissues. METHODS AND RESULTS: In Zucker rats, 
      used here as a model of liver steatosis, Svct1-2 mRNA levels were similar in
      obese and lean animals, except for lung tissue, where Svct2 was up-regulated.
      Diabetes mellitus, developed by streptozotocin administration, was accompanied by
      a down-regulation of Svct1 in liver and kidney, together with a down-regulation
      of Svct2 in kidney and brain. Complete obstructive cholestasis due to bile duct
      ligation for 1 week induced a significant down-regulation of both Svct1 and Svct2
      in ileum, whereas Svct2 was up-regulated in liver, and no significant changes in 
      the expression of either transporter were found in kidney, brain or lung. In rat 
      hepatoma Can-10 cells, bile acids, but not the FXR agonist GW4064, induced an
      up-regulation of Svct1 and Svct2. In human hepatoma Alexander cells transfected
      with FXR/RXRalpha/OATP1B1, neither GW4064 nor unconjugated or
      glycine-/taurine-conjugated major bile acids were able to up-regulate either
      SVCT1 or SVCT2. CONCLUSIONS: Pathological circumstances characterized by the
      presence of metabolic/oxidative stress in the liver induce different responses in
      the expression of ascorbic acid transporters in intrahepatic and extrahepatic
      tissues, which may affect the overall bioavailability and cellular uptake of this
      vitamin.
AD  - Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM), Department
      of Physiology and Pharmacology, University of Salamanca, IBSAL, Campus Miguel de 
      Unamuno E.I.D. B-17, 37007, Salamanca, Spain.
FAU - Hierro, Carlos
AU  - Hierro C
FAU - Monte, Maria J
AU  - Monte MJ
FAU - Lozano, Elisa
AU  - Lozano E
FAU - Gonzalez-Sanchez, Ester
AU  - Gonzalez-Sanchez E
FAU - Marin, Jose J G
AU  - Marin JJ
FAU - Macias, Rocio I R
AU  - Macias RI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Eur J Nutr
JT  - European journal of nutrition
JID - 100888704
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/22 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/05/26 [aheadofprint]
AID - 10.1007/s00394-013-0536-4 [doi]
PST - aheadofprint
SO  - Eur J Nutr. 2013 May 26.

PMID- 23707958
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Linking)
VI  - 177
IP  - 12
DP  - 2013 Jun 15
TI  - Risk Factors for Type 2 Diabetes Mellitus Preceded by beta-Cell Dysfunction,
      Insulin Resistance, or Both in Older Adults: The Cardiovascular Health Study.
PG  - 1418-29
LID - 10.1093/aje/kws440 [doi]
AB  - Insulin resistance (IR) and pancreatic beta-cell dysfunction lead to type 2
      diabetes mellitus (DM). We tested whether risk factors would differ for DM that
      was preceded predominantly by IR, beta-cell dysfunction, or both among 4,384
      older adults (mean age, 72.7 (standard deviation, 5.6) years) in the
      Cardiovascular Health Study, which was conducted in North Carolina, California,
      Maryland, and Pennsylvania (1989-2007). When evaluating established risk factors,
      we found older age, greater adiposity, higher systolic blood pressure, a lower
      high-density lipoprotein cholesterol level, a higher triglyceride level, and a
      lower alcohol intake to be independently associated with greater IR but,
      conversely, with better beta-cell function (P < 0.001). The prospective
      associations between some risk factors and incident DM varied significantly
      depending on whether DM was preceded predominantly by IR, beta-cell dysfunction, 
      or both. For example, obesity and lower high-density lipoprotein cholesterol
      levels were positively associated with DM preceded predominantly by IR (hazard
      ratio (HR) = 5.02, 95% confidence interval (CI): 2.81, 9.00; and HR = 1.97, 95%
      CI: 1.32, 2.93, respectively), with a significant association with and an
      insignificant trend toward a lower risk of DM preceded predominantly by beta-cell
      dysfunction (HR = 0.33, 95% CI: 0.14, 0.80; and HR = 0.78, 95% CI: 0.43, 1.39,
      respectively). In conclusion, among older adults, DM risk factors were
      differentially associated with DM preceded predominantly by IR or beta-cell
      dysfunction. Biologic and clinical implications of putative subtypes of DM
      require further investigation.
FAU - Imamura, Fumiaki
AU  - Imamura F
FAU - Mukamal, Kenneth J
AU  - Mukamal KJ
FAU - Meigs, James B
AU  - Meigs JB
FAU - Luchsinger, Jose A
AU  - Luchsinger JA
FAU - Ix, Joachim H
AU  - Ix JH
FAU - Siscovick, David S
AU  - Siscovick DS
FAU - Mozaffarian, Dariush
AU  - Mozaffarian D
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - United States
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
SB  - IM
OTO - NOTNLM
OT  - aging
OT  - diabetes mellitus
OT  - incidence
OT  - insulin resistance
OT  - insulin-secreting cells
OT  - risk factors
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/05/24 [aheadofprint]
AID - kws440 [pii]
AID - 10.1093/aje/kws440 [doi]
PST - ppublish
SO  - Am J Epidemiol. 2013 Jun 15;177(12):1418-29. doi: 10.1093/aje/kws440. Epub 2013
      May 24.

PMID- 23707930
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-6815 (Electronic)
IS  - 0531-5565 (Linking)
DP  - 2013 May 23
TI  - Role of mineralocorticoid receptors in arterial stiffness in human aging.
LID - S0531-5565(13)00192-7 [pii]
LID - 10.1016/j.exger.2013.05.058 [doi]
AB  - Arterial stiffness, an independent predictor of cardiovascular disease, is
      increased in aging, but the underlying mechanisms are not completely understood. 
      Mineralocorticoid receptors (MR) may contribute to oxidative stress and arterial 
      stiffness in healthy older adults. To test the hypothesis that short-term MR
      blockade may reduce oxidative stress and improve arterial stiffness, we conducted
      a randomized, double blind, crossover study using the selective MR blocker
      Eplerenone or placebo in 23 older adults (age, 64+/-1years; mean+/-SE) free from 
      over cardiovascular and other clinical disease (e.g, diabetes, renal and liver
      disease). In response to MR blockade, brachial and carotid blood pressure
      decreased (P</=0.01). However, MR blockade had no effect on oxidative stress
      (oxidized LDL, 61.2+/-6.8 vs. 62.4+/-7.4U/L, P=0.9; placebo vs. Eplerenone) and
      arterial stiffness (aortic pulse wave velocity (PWV), 9.17+/-1.19 vs.
      8.92+/-1.19m/s, P=0.5; leg PWV, 13.45+/-0.45 vs. 12.81+/-0.47m/s, P=0.3; arm PWV,
      11.43+/-0.62 vs. 11.73+/-0.68m/s, P=0.7; carotid artery compliance, 0.150+/-0.013
      vs. 0.149+/-0.014mm2/mmHg, P=0.8; distensibility, 23.1+/-1.8 vs. 23.3+/-1.7
      10-3/kPa, P=0.8; beta stiffness index, 3.5+/-0.3 vs. 3.6+/-0.3, P=0.6; and
      augmentation index, 16.0+/-2.2 vs. 15.6+/-2.8%, P=0.8). These results provide the
      first evidence that MR do not appear to contribute to oxidative stress in human
      aging and that short-term MR blockade does not result in reduced oxidative stress
      and improved arterial stiffness.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Applied Physiology & Kinesiology, University of Florida,
      Gainesville, FL, USA.
FAU - Hwang, Moon-Hyon
AU  - Hwang MH
FAU - Yoo, Jeung-Ki
AU  - Yoo JK
FAU - Luttrell, Meredith
AU  - Luttrell M
FAU - Kim, Han-Kyul
AU  - Kim HK
FAU - Meade, Thomas H
AU  - Meade TH
FAU - English, Mark
AU  - English M
FAU - Nichols, Wilmer W
AU  - Nichols WW
FAU - Christou, Demetra D
AU  - Christou DD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Exp Gerontol
JT  - Experimental gerontology
JID - 0047061
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/14 [received]
PHST- 2013/05/10 [revised]
PHST- 2013/05/17 [accepted]
AID - S0531-5565(13)00192-7 [pii]
AID - 10.1016/j.exger.2013.05.058 [doi]
PST - aheadofprint
SO  - Exp Gerontol. 2013 May 23. pii: S0531-5565(13)00192-7. doi:
      10.1016/j.exger.2013.05.058.

PMID- 23707914
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1873-2976 (Electronic)
IS  - 0960-8524 (Linking)
VI  - 140C
DP  - 2013 May 2
TI  - Characterization of phenolics, in vitro reducing capacity and anti-glycation
      activity of red grape skins recovered from winemaking by-products.
PG  - 263-268
LID - S0960-8524(13)00716-5 [pii]
LID - 10.1016/j.biortech.2013.04.092 [doi]
AB  - Red grape skins recovered from ten winemaking processes were analyzed for total
      phenolic content (Folin Ciocalteu assay), proanthocyanidins (n-butanol/HCl
      assay), individual phenolics (UPLC-DAD-MS), in vitro ferric ion reducing capacity
      and anti-glycation activity by bovine serum albumin/fructose and bovine serum
      albumin/methylglyoxal model systems. The aim was to assess if these by-products
      have potential as dietary anti-glycation agents, to prevent the glyco-oxidative
      stress associated with type-2 diabetes. Variability was observed in total
      phenolics (12.1-53.6g gallic acid Eq/kg), proanthocyanidins (7.2-51.1g/kg),
      anthocyanins (2.5-13.8g malvidin 3-O glucoside Eq/kg), flavonols (0.3-2.6g
      quercetin 3-O glucoside Eq/kg) and reducing capacity (103-511mmol Fe(II) Eq/kg). 
      For all samples, the anti-glycation effectiveness was higher than that of
      commercial nutraceutical preparations. Hence, in spite of differences in
      cultivar, location of the vineyard and winemaking procedures, these by-products
      could be used as a source of cost-effective anti-glycation agent either as a food
      ingredient or as a nutraceutical preparation.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - DeFENS, Department of Food, Environmental and Nutritional Sciences, Universita
      degli Studi di Milano, via Celoria, 2, 20133 Milano, Italy.
FAU - Sri Harsha, P S C
AU  - Sri Harsha PS
FAU - Gardana, Claudio
AU  - Gardana C
FAU - Simonetti, Paolo
AU  - Simonetti P
FAU - Spigno, Giorgia
AU  - Spigno G
FAU - Lavelli, Vera
AU  - Lavelli V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Bioresour Technol
JT  - Bioresource technology
JID - 9889523
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/03/06 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/04/25 [accepted]
AID - S0960-8524(13)00716-5 [pii]
AID - 10.1016/j.biortech.2013.04.092 [doi]
PST - aheadofprint
SO  - Bioresour Technol. 2013 May 2;140C:263-268. doi: 10.1016/j.biortech.2013.04.092.

PMID- 23707907
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 23
TI  - Evaluation of membrane models and their composition for islet amyloid
      polypeptide-membrane aggregation.
LID - S0005-2736(13)00160-0 [pii]
LID - 10.1016/j.bbamem.2013.05.014 [doi]
AB  - Human islet amyloid polypeptide (IAPP) forms amyloid fibrils in the pancreatic
      islets of patients suffering from type 2 diabetes mellitus (T2DM). The formation 
      of IAPP fibrils has been shown to cause membrane damage which most likely is
      responsible for the death of pancreatic islet beta-cells during the pathogenesis 
      of T2DM. Several studies have demonstrated a clear interaction between IAPP and
      lipid membranes. However the effect of different lipid compositions and of
      various membrane mimetics (including micelles, bicelles, SUV and LUV) on fibril
      formation kinetics and fibril morphology has not yet systematically been
      analysed. Here we report that the interaction of IAPP with various membrane
      models promoted different processes of fibril formation. Our data reveal that in 
      SDS and DPC micelles, IAPP adopts a stable alpha-helical structure for several
      days, suggesting that the micelle models may stabilize monomeric or small
      oligomeric species of IAPP. In contrast, zwitterionic DMPC/DHPC bicelles and DOPC
      SUV accelerate the fibril formation compared to zwitterionic DOPC LUV, indicating
      that the size of the membrane model and its curvature influence the fibrillation 
      process. Negatively charged membranes decrease the lag-time of the fibril
      formation kinetics while phosphatidylethanolamine and cholesterol have an
      opposite effect, probably due to the modulation of the physical properties of the
      membrane and/or due to direct interactions with IAPP within the membrane core.
      Finally, our results show that the modulation of lipid composition influences not
      only the growth of fibrils at the membrane surface but also the interactions of
      beta-sheet oligomers with membranes.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - UPMC Univ Paris 06, UMR 7203 CNRS-UPMC-ENS, Laboratoire des Biomolecules, 4 place
      Jussieu, 75005 Paris, France.
FAU - Caillon, Lucie
AU  - Caillon L
FAU - Lequin, Olivier
AU  - Lequin O
FAU - Khemtemourian, Lucie
AU  - Khemtemourian L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/10/31 [received]
PHST- 2013/04/26 [revised]
PHST- 2013/05/13 [accepted]
AID - S0005-2736(13)00160-0 [pii]
AID - 10.1016/j.bbamem.2013.05.014 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 23. pii: S0005-2736(13)00160-0. doi:
      10.1016/j.bbamem.2013.05.014.

PMID- 23707905
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
DP  - 2013 May 23
TI  - Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia,
      hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in
      type 2 diabetic mice.
LID - S0014-2999(13)00399-3 [pii]
LID - 10.1016/j.ejphar.2013.05.014 [doi]
AB  - The sodium-glucose cotransporter (SGLT2) is responsible for most glucose
      reabsorption in the kidney and has been proposed as a novel therapeutic target
      for the treatment of type 2 diabetes. In the present study, the therapeutic
      effects of SGLT2 selective inhibitor ipragliflozin were examined in high-fat diet
      and streptozotocin-nicotinamide-induced type 2 diabetic mice which exhibit
      impaired insulin secretion, insulin resistance, hyperlipidemia, hepatic
      steatosis, and obesity. Single administration of ipragliflozin dose-dependently
      increased urinary glucose excretion, reduced blood glucose and plasma insulin
      levels, and improved glucose intolerance. Four-week repeated administration of
      ipragliflozin improved not only glucose tolerance, hyperglycemia, and
      hyperinsulinemia but also impaired insulin secretion, hyperlipidemia, hepatic
      steatosis, and obesity with a concomitant increase in urinary glucose excretion. 
      In addition, ipragliflozin reduced plasma and liver levels of oxidative stress
      biomarkers (thiobarbituric acid reactive substances and protein carbonyl) and
      inflammatory markers (interleukin 6, tumor necrosis factor alpha, monocyte
      chemotactic protein-1, and c-reactive protein), and improved liver injury as
      assessed by plasma levels of aminotransferases. These results demonstrate that
      SGLT2 selective inhibitor ipragliflozin improves not only hyperglycemia but also 
      diabetes/obesity-associated metabolic abnormalities in type 2 diabetic mice and
      suggest that ipragliflozin may be useful in treating type 2 diabetes with
      metabolic syndrome.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan. Electronic
      address: atsuo.tahara@jp.astellas.com.
FAU - Tahara, Atsuo
AU  - Tahara A
FAU - Kurosaki, Eiji
AU  - Kurosaki E
FAU - Yokono, Masanori
AU  - Yokono M
FAU - Yamajuku, Daisuke
AU  - Yamajuku D
FAU - Kihara, Rumi
AU  - Kihara R
FAU - Hayashizaki, Yuka
AU  - Hayashizaki Y
FAU - Takasu, Toshiyuki
AU  - Takasu T
FAU - Imamura, Masakazu
AU  - Imamura M
FAU - Qun, Li
AU  - Qun L
FAU - Tomiyama, Hiroshi
AU  - Tomiyama H
FAU - Kobayashi, Yoshinori
AU  - Kobayashi Y
FAU - Noda, Atsushi
AU  - Noda A
FAU - Sasamata, Masao
AU  - Sasamata M
FAU - Shibasaki, Masayuki
AU  - Shibasaki M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/07 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/05/11 [accepted]
AID - S0014-2999(13)00399-3 [pii]
AID - 10.1016/j.ejphar.2013.05.014 [doi]
PST - aheadofprint
SO  - Eur J Pharmacol. 2013 May 23. pii: S0014-2999(13)00399-3. doi:
      10.1016/j.ejphar.2013.05.014.

PMID- 23707792
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
VI  - 375
IP  - 1-2
DP  - 2013 May 22
TI  - Expression profiling of cell cycle genes in human pancreatic islets with and
      without type 2 diabetes.
PG  - 35-42
LID - S0303-7207(13)00206-2 [pii]
LID - 10.1016/j.mce.2013.05.003 [doi]
AB  - Microarray gene expression data were used to analyze the expression pattern of
      cyclin, cyclin-dependent kinase (CDKs) and cyclin-dependent kinase inhibitor
      (CDKIs) genes from human pancreatic islets with and without type 2 diabetes
      (T2D). Of the cyclin genes, CCNI was the most expressed. Data obtained from
      microarray and qRT-PCR showed higher expression of CCND1 in diabetic islets.
      Among the CDKs, CDK4, CDK8 and CDK9 were highly expressed, while CDK1 was
      expressed at low level. High expression of CDK18 was observed in diabetic islets.
      Of the CDKIs, CDKN1A expression was higher in diabetic islets in both microarray 
      and qRT-PCR. Expression of CDKN1A, CDKN2A, CCNI2, CDK3 and CDK16 was correlated
      with age. Finally, eight SNPs in these genes were associated with T2D in the
      DIAGRAM database. Our data provide a comprehensive expression pattern of cell
      cycle genes in human islets. More human studies are required to confirm and
      reproduce animal studies.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Lund University Diabetes Center, Department of Clinical Sciences, Diabetes &
      Endocrinology, Skane University Hospital, Lund University, Malmo 20502, Sweden.
      Electronic address: Jalal.Taneera@med.lu.se.
FAU - Taneera, Jalal
AU  - Taneera J
FAU - Fadista, Joao
AU  - Fadista J
FAU - Ahlqvist, Emma
AU  - Ahlqvist E
FAU - Zhang, Mengze
AU  - Zhang M
FAU - Wierup, Nils
AU  - Wierup N
FAU - Renstrom, Erik
AU  - Renstrom E
FAU - Groop, Leif
AU  - Groop L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/11/07 [received]
PHST- 2013/04/30 [revised]
PHST- 2013/05/01 [accepted]
AID - S0303-7207(13)00206-2 [pii]
AID - 10.1016/j.mce.2013.05.003 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 May 22;375(1-2):35-42. doi: 10.1016/j.mce.2013.05.003.

PMID- 23707791
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
VI  - 375
IP  - 1-2
DP  - 2013 May 21
TI  - Pharmacological activation of AMPK suppresses inflammatory response evoked by
      IL-6 signalling in mouse liver and in human hepatocytes.
PG  - 68-78
LID - S0303-7207(13)00217-7 [pii]
LID - 10.1016/j.mce.2013.05.013 [doi]
AB  - Interleukin-6 (IL-6) induces inflammatory signalling in liver, leading to
      impaired insulin action in hepatocytes. In this study, we demonstrate that
      pharmacological activation of AMP-activated protein kinase (AMPK) represses
      IL-6-stimulated expression of proinflammatory markers serum amyloid A (Saa) as
      well as suppressor of cytokine signalling 3 (Socs3) in mouse liver. Further
      studies using the human hepatocellular carcinoma cell line HepG2 suggest that
      AMPK inhibits IL-6 signalling by repressing IL-6-stimulated phosphorylation of
      several downstream components of the pathway such as Janus kinase 1 (JAK1),
      SH2-domain containing protein tyrosine phosphatase 2 (SHP2) and signal transducer
      and activator of transcription 3 (STAT3). In summary, inhibition of IL-6
      signalling cascade in liver by the metabolic master switch of the body, AMPK,
      supports the role of this kinase as a crucial point of convergence of metabolic
      and inflammatory pathways in hepatocytes.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - The Lundberg Laboratory for Diabetes Research, Department of Molecular and
      Clinical Medicine, University of Gothenburg, SE-413 45 Gothenburg, Sweden.
FAU - Nerstedt, Annika
AU  - Nerstedt A
FAU - Cansby, Emmelie
AU  - Cansby E
FAU - Amrutkar, Manoj
AU  - Amrutkar M
FAU - Smith, Ulf
AU  - Smith U
FAU - Mahlapuu, Margit
AU  - Mahlapuu M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/28 [received]
PHST- 2013/05/06 [revised]
PHST- 2013/05/14 [accepted]
AID - S0303-7207(13)00217-7 [pii]
AID - 10.1016/j.mce.2013.05.013 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 May 21;375(1-2):68-78. doi: 10.1016/j.mce.2013.05.013.

PMID- 23707775
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 16
IP  - 4
DP  - 2013 May 23
TI  - Preventive effects of andrographolide on the development of diabetes in
      autoimmune diabetic NOD mice by inducing immune tolerance.
PG  - 451-456
LID - S1567-5769(13)00182-3 [pii]
LID - 10.1016/j.intimp.2013.05.002 [doi]
AB  - Andrographolide, an active component in traditional anti-diabetic herbal plants, 
      is a diterpenoid lactone isolated from Andrographis paniculata because of its
      potent anti-inflammatory and hypoglycemic effects. However, the effect of
      andrographolide on the development of diabetes in autoimmune non-obese diabetic
      (NOD) mice remains unknown. This study aimed to investigate the protective
      effects of andrographolide on the development of autoimmune diabetes and clarify 
      the underlying mechanism. NOD mice were randomly divided into four groups and
      administered with water and andrographolide at 50, 100, and 150mg/kg body weight 
      for four weeks. ICR mice were also selected as the control group. Oral glucose
      tolerance and histopathological insulitis were examined. Th1/Th2/Th17 cytokine
      secretion was determined by ELISA. The transcriptional profiles of T-bet, GATA3, 
      and RORgammat in the pancreatic lymphatic node samples derived from the NOD mice 
      were detected by RT-PCR. After four weeks of oral supplementation,
      andrographolide significantly inhibited insulitis, delayed the onset, and
      suppressed the development of diabetes in 30-week-old NOD mice in a dose
      dependent manner. This protective status was correlated with a substantially
      decreased production of interferon (IFN)-gamma and interleukin (IL)-2, increased 
      IL-10 and transforming growth factor (TGF)-beta, and a reduced IL-17.
      Andrographolide also increased GATA3 mRNA expression but decreased T-bet and
      RORgammat mRNA expressions. Our results suggested that andrographolide prevented 
      type 1 diabetes by maintaining Th1/Th2/Th17 homeostasis.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, Wuhan 430033, China.
FAU - Zhang, Chengliang
AU  - Zhang C
FAU - Gui, Ling
AU  - Gui L
FAU - Xu, Yanjiao
AU  - Xu Y
FAU - Wu, Tao
AU  - Wu T
FAU - Liu, Dong
AU  - Liu D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/11/13 [received]
PHST- 2013/05/01 [revised]
PHST- 2013/05/01 [accepted]
AID - S1567-5769(13)00182-3 [pii]
AID - 10.1016/j.intimp.2013.05.002 [doi]
PST - aheadofprint
SO  - Int Immunopharmacol. 2013 May 23;16(4):451-456. doi:
      10.1016/j.intimp.2013.05.002.

PMID- 23707747
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-6971 (Electronic)
IS  - 0367-326X (Linking)
DP  - 2013 May 23
TI  - Inhibition of dipeptidyl peptidase activity by flavonol glycosides of guava
      (Psidium guajava L.): A key to the beneficial effects of guava in type II
      diabetes mellitus.
LID - S0367-326X(13)00135-4 [pii]
LID - 10.1016/j.fitote.2013.05.015 [doi]
AB  - Based on the traditional use in popular medicine, the effect of extracts from
      Psidium guajava L. leaves and of the main flavonol-glycoside components on
      dipeptidyl-peptidase IV (DP-IV), a key enzyme of blood glucose homoeostasis, has 
      been investigated in-vitro. An ethanolic extract was prepared from dried,
      powdered leaves of guava and was found to contain seven main flavonol-glycosides,
      which were isolated by semipreparative HPLC and tested individually. The
      ethanolic guava leave extract was shown to exert a dose-dependent inhibition of
      DP-IV, with an IC50 of 380mug/ml test assay solution. Also the individual
      flavonol-glycosides inhibited DP-IV dose-dependently, with variations of the
      effects by a factor of 10, and an overall effect accounting for 100% of that
      observed for the total guava extract. The recovery of individual
      flavonol-glycosides in CaCo-2 epithelial cells, a model of gastrointestinal tract
      absorption, amounted to 2.3-5.3% of the amount available for absorption over
      60min at 37 degrees C.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - University of Applied Science Upper Austria, Campus Wels, Stelzhamerstr. 23, 4600
      Wels, Austria. Electronic address: thomas.eidenberger@fh-wels.at.
FAU - Eidenberger, Thomas
AU  - Eidenberger T
FAU - Selg, Manuel
AU  - Selg M
FAU - Krennhuber, Klaus
AU  - Krennhuber K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Fitoterapia
JT  - Fitoterapia
JID - 16930290R
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/12/13 [received]
PHST- 2013/05/17 [revised]
PHST- 2013/05/19 [accepted]
AID - S0367-326X(13)00135-4 [pii]
AID - 10.1016/j.fitote.2013.05.015 [doi]
PST - aheadofprint
SO  - Fitoterapia. 2013 May 23. pii: S0367-326X(13)00135-4. doi:
      10.1016/j.fitote.2013.05.015.

PMID- 23707663
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 23
TI  - Inhibition of CYP2E1 leads to decreased advanced glycated end product formation
      in high glucose treated ADH and CYP2E1 over-expressing VL-17A cells.
LID - S0304-4165(13)00218-3 [pii]
LID - 10.1016/j.bbagen.2013.05.022 [doi]
AB  - BACKGROUND: In recent years, there has been a growing interest to explore the
      association between liver injury and diabetes. Advanced glycated end product
      (AGE) formation which characterizes diabetic complications is formed through
      hyperglycemia mediated oxidative stress and is itself a source for ROS. Further, 
      in VL-17A cells over-expressing ADH and CYP2E1, greatly increased oxidative
      stress and decreased viability have been observed with high glucose exposure.
      METHODS: In VL-17A cells treated with high glucose and pretreated with the
      different inhibitors of ADH and CYP2E1, the changes in cell viability, oxidative 
      stress parameters and formation of AGE, were studied. RESULTS: Inhibition of
      CYP2E1 with 10muM diallyl sulfide most effectively led to decreases in the
      oxidative stress and toxicity as compared with ADH inhibition with 2mM pyrazole
      or the combined inhibition of ADH and CYP2E1 with 5mM 4-methyl pyrazole. AGE
      formation was decreased in VL-17A cells when compared with HepG2 cells devoid of 
      the enzymes. Further, AGE formation was decreased to the greatest extent with the
      inhibitor for CYP2E1 suggesting that high glucose inducible CYP2E1 and the
      consequent ROS aid AGE formation. CONCLUSIONS: Thus, CYP2E1 plays a pivotal role 
      in the high glucose induced oxidative stress and toxicity in liver cells as
      observed through direct evidences obtained utilizing the different inhibitors for
      ADH and CYP2E1. GENERAL SIGNIFICANCE: The study demonstrates the role of CYP2E1
      mediated oxidative stress in aggravating hyperglycemic insult and suggests that
      CYP2E1 may be a vital component of hyperglycemia mediated oxidative injury in
      liver.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Life Science Division, AU-KBC Research Centre, MIT Campus of Anna University,
      Chromepet, Chennai-600044, India.
FAU - Swaminathan, Kavitha
AU  - Swaminathan K
FAU - Kumar, S Mathan
AU  - Kumar SM
FAU - Clemens, Dahn L
AU  - Clemens DL
FAU - Dey, Aparajita
AU  - Dey A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/03/08 [received]
PHST- 2013/05/13 [revised]
PHST- 2013/05/17 [accepted]
AID - S0304-4165(13)00218-3 [pii]
AID - 10.1016/j.bbagen.2013.05.022 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 23. pii: S0304-4165(13)00218-3. doi:
      10.1016/j.bbagen.2013.05.022.

PMID- 23707531
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1873-3913 (Electronic)
IS  - 0898-6568 (Linking)
DP  - 2013 May 22
TI  - Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting
      edge in understanding their additional therapeutic potentials.
LID - S0898-6568(13)00134-4 [pii]
LID - 10.1016/j.cellsig.2013.05.009 [doi]
AB  - Dipeptidyl peptidase 4 (DPP-4) is a serine protease enzyme expressed widely in
      many tissues, including the cardiovascular system. The incretin hormones such as 
      glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide 
      (GIP) are released from the small intestine into the vasculature during a meal,
      and these incretins have a potential to release insulin from pancreatic beta
      cells of islets of Langerhans, affording a glucose-lowering action. However, both
      incretins are hurriedly degraded by the DPP-4. Inhibitors of DPP-4, therefore,
      enhance the bioavailability of GLP-1 and GIP, and thus have been approved for
      better glycemic management in patients afflicted with type 2 diabetes mellitus
      (T2DM). Five different DPP-4 inhibitors, often called as 'gliptins', namely
      sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin have been
      approved hitherto for clinical use. These drugs are used along with diet and
      exercise to lower blood sugar in diabetic subjects. T2DM is intricately related
      with an increased risk of cardiovascular disease. Growing body of evidence
      suggests that gliptins, in addition to their persuasive anti-diabetic action,
      have a beneficial pleiotropic action on the heart and vessels. In view of the
      fact of cardiovascular disease susceptibility of patients afflicted with T2DM,
      gliptins might offer additional therapeutic benefits in treating diabetic
      cardiovascular complications. Exploring further the cardiovascular pleiotropic
      potentials of gliptins might open a panorama in impeccably employing these agents
      for the dual management of T2DM and T2DM-associated perilous cardiovascular
      complications. This review will shed lights on the newly identified beneficial
      pleiotropic actions of gliptins on the cardiovascular system.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, 
      Malaysia. Electronic address: pbala2006@gmail.com.
FAU - Balakumar, Pitchai
AU  - Balakumar P
FAU - Dhanaraj, Sokkalingam A
AU  - Dhanaraj SA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Cell Signal
JT  - Cellular signalling
JID - 8904683
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/03/29 [received]
PHST- 2013/05/06 [accepted]
AID - S0898-6568(13)00134-4 [pii]
AID - 10.1016/j.cellsig.2013.05.009 [doi]
PST - aheadofprint
SO  - Cell Signal. 2013 May 22. pii: S0898-6568(13)00134-4. doi:
      10.1016/j.cellsig.2013.05.009.

PMID- 23707515
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 22
TI  - Cellular and molecular players in adipose tissue inflammation in the development 
      of obesity-induced insulin resistance.
LID - S0925-4439(13)00179-8 [pii]
LID - 10.1016/j.bbadis.2013.05.017 [doi]
AB  - There is increasing evidence showing that inflammation is an important pathogenic
      mediator of the development of obesity-induced insulin resistance. It is now
      generally accepted that tissue-resident immune cells play a major role in the
      regulation of this obesity-induced inflammation. The roles that adipose tissue
      (AT)-resident immune cells play have been particularly extensively studied. AT
      contains most types of immune cells and obesity increases their numbers and
      activation levels, particularly in AT macrophages (ATMs). Other pro-inflammatory 
      cells found in AT include neutrophils, Th1 CD4 T cells, CD8 T cells, B cells,
      DCs, and mast cells. However, AT also contains anti-inflammatory cells that
      counter the pro-inflammatory immune cells that are responsible for the
      obesity-induced inflammation in this tissue. These anti-inflammatory cells
      include regulatory CD4 T cells (Tregs), Th2 CD4 T cells, and eosinophils. Hence, 
      AT inflammation is shaped by the regulation of pro- and anti-inflammatory immune 
      cell homeostasis, and obesity skews this balance towards a more pro-inflammatory 
      status. Recent genetic studies revealed several molecules that participate in the
      development of obesity-induced inflammation and insulin resistance. In this
      review, the cellular and molecular players that participate in the regulation of 
      obesity-induced inflammation and insulin resistance are discussed, with
      particular attention being placed on the roles of the cellular players in these
      pathogeneses. This article is part of a Special Issue entitled: Modulation of
      Adipose Tissue in Health and Disease.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - The Joslin Diabetes Center and Department of Medicine, Harvard Medical School,
      Boston, MA 02215, USA; Department of Internal Medicine, College of Korean
      Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-Ku, Seoul 130-702,
      Republic of Korea.
FAU - Lee, Byung-Cheol
AU  - Lee BC
FAU - Lee, Jongsoon
AU  - Lee J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/03/11 [received]
PHST- 2013/05/07 [revised]
PHST- 2013/05/13 [accepted]
AID - S0925-4439(13)00179-8 [pii]
AID - 10.1016/j.bbadis.2013.05.017 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 22. pii: S0925-4439(13)00179-8. doi:
      10.1016/j.bbadis.2013.05.017.

PMID- 23707471
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-6351 (Electronic)
IS  - 0278-6915 (Linking)
DP  - 2013 May 22
TI  - Lotus (Nelumbo nucifera Gaertn) plumule polysaccharide ameliorates pancreatic
      islets loss and serum lipid profiles in non-obese diabetic mice.
LID - S0278-6915(13)00322-0 [pii]
LID - 10.1016/j.fct.2013.05.018 [doi]
AB  - To unravel possible protective effects of a newly isolated lotus plumule
      polysaccharide (LPPS) on type 1 diabetes (T1D), this study isolated LPPS and
      administered it to non-obese diabetic (NOD) female mice for 15weeks. Oral glucose
      tolerance, serum ketone body, glucose, insulin, and lipid levels, as well as
      pancreatic islet cell numbers and the insulin secretion ability of the
      experimental mice were determined. The results showed that LPPS administration in
      vivo significantly (P<0.05) increased pancreatic islet cell numbers and slightly 
      enhanced the basal insulin secretion ability compared to the control group. LPPS 
      administration improved serum lipid profiles in the diabetic mice via relatively 
      increasing serum high density lipoprotein-cholesterol, but decreasing low density
      lipoprotein-cholesterol and total cholesterol levels. The present study suggests 
      that LPPS supplementation may ameliorate T1D progress and its complications
      through protecting pancreatic islets and modulating serum lipid profiles.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Department of Food Science and Biotechnology, National Chung Hsing University,
      250 Kuokuang Road, Taichung 40227, Taiwan, ROC.
FAU - Liao, Chun-Huei
AU  - Liao CH
FAU - Lin, Jin-Yuarn
AU  - Lin JY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Food Chem Toxicol
JT  - Food and chemical toxicology : an international journal published for the British
      Industrial Biological Research Association
JID - 8207483
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/01 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/05/13 [accepted]
AID - S0278-6915(13)00322-0 [pii]
AID - 10.1016/j.fct.2013.05.018 [doi]
PST - aheadofprint
SO  - Food Chem Toxicol. 2013 May 22. pii: S0278-6915(13)00322-0. doi:
      10.1016/j.fct.2013.05.018.

PMID- 23707370
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1600-0641 (Electronic)
IS  - 0168-8278 (Linking)
DP  - 2013 May 23
TI  - Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline
      mutation.
LID - S0168-8278(13)00355-3 [pii]
LID - 10.1016/j.jhep.2013.05.024 [doi]
AB  - BACKGROUND: Maturity onset diabetes of the young type 3 (MODY3) and
      hepatocellular adenomas (HCAs) are associated with mutations in the HNF1A gene.
      HNF1A codes for the transcription factor HNF1alpha, which interacts with DNA as a
      homodimer or a heterodimer with HNF1beta, to regulate multiple cellular functions
      including glucidic metabolism, lipidic transport and detoxication. METHODS AND
      RESULTS: We report three members of one family with a novel germline in-frame
      deletion of HNF1A exons 2-3 identified initially using array CGH and direct
      sequence analysis. All three family members have MODY3 in association with
      primary liver cell tumours (HCA, liver adenomatosis (LA), and hepatocellular
      carcinoma (HCC)). Additionally, a high rate of infant mortality was observed in
      the family. CONCLUSIONS: The described family demonstrate a novel HNF1A mutation 
      associated with both benign and malignant primary liver cell tumours and MODY3.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Surgical Sciences, Dunedin School of Medicine, University of Otago,
      Dunedin, New Zealand. Electronic address: john.mccall@otago.ac.nz.
FAU - Willson, J S B
AU  - Willson JS
FAU - Godwin, T D
AU  - Godwin TD
FAU - Wiggins, G A R
AU  - Wiggins GA
FAU - Guilford, P J
AU  - Guilford PJ
FAU - McCall, J L
AU  - McCall JL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Hepatol
JT  - Journal of hepatology
JID - 8503886
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/12/15 [received]
PHST- 2013/05/03 [revised]
PHST- 2013/05/10 [accepted]
AID - S0168-8278(13)00355-3 [pii]
AID - 10.1016/j.jhep.2013.05.024 [doi]
PST - aheadofprint
SO  - J Hepatol. 2013 May 23. pii: S0168-8278(13)00355-3. doi:
      10.1016/j.jhep.2013.05.024.

PMID- 23707334
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
DP  - 2013 May 21
TI  - Pharmacokinetic study of salvianolic acid A in beagle dog after oral
      administration by a liquid chromatography-mass spectrometry method: A study on
      bioavailability and dose proportionality.
LID - S0378-8741(13)00349-8 [pii]
LID - 10.1016/j.jep.2013.05.013 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Salvianolic acid A (SAA) is one of the main
      water-soluble components isolated from Salvia miltiorrhiza Bunge. Pharmacological
      researches revealed that it had various curative activities after oral and
      intravenous administration, including beneficial effects on diabetes and its
      complications, cardioprotective effect, anti-platelet aggregation, and so on.
      However, there is no report regarding the pharmacokinetics of SAA in beagle dogs 
      after oral administration up to now. AIM OF THE STUDY: To study the
      pharmacokinetics of different doses of SAA in beagle dogs and figure out the
      absolute bioavailability and dose proportionality of SAA after oral
      administration. MATERIALS AND METHODS: Male and female beagle dogs were orally
      administered SAA 5, 10 and 20mg/kg randomly. The plasma drug concentration was
      detected by a rapid, sensitive and reproducible liquid chromatography-mass
      spectrometry (LC-MS) method. The pharmacokinetic parameters were calculated from 
      plasma concentration-time data using the DAS pharmacokinetic software Data
      Analysis System Version 3.0 program. RESULTS: After single-dose oral
      administration of SAA, the mean peak plasma concentration (Cmax) values for
      groups treated with 5, 10 and 20mg/kg doses ranged from 14.38 to 38.18microg/L,
      and the mean area under the concentration-time curve (AUC(0-t)) values ranged
      from 38.77 to 130.33 (microg/Lh). SAA showed lack of dose proportionality over
      the dose range 5-20mg/kg, based on the power model. However, the increase in
      systemic exposure with dose appeared linear. The absolute bioavailability was
      calculated to range from 1.47% to 1.84%. CONCLUSION: The pharmacokinetic
      properties of SAA in beagle dogs after oral administration were characterized as 
      rapid oral absorption, quick clearance, and poor absolute bioavailability.
      Systemic exposure exhibited lack of dose proportionality over the dose range
      5-20mg/kg. Furthermore, a readily preparative LC-MS method was demonstrated in
      this study for the research of traditional Chinese medicine.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Beijing Key Laboratory of Drug Target Identification and Drug Screening,
      Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union
      Medical College, Beijing, China.
FAU - Sun, Jialin
AU  - Sun J
FAU - Zhang, Li
AU  - Zhang L
FAU - Song, Junke
AU  - Song J
FAU - Tian, Shuo
AU  - Tian S
FAU - Huang, Chao
AU  - Huang C
FAU - Feng, Zhangying
AU  - Feng Z
FAU - Lv, Yang
AU  - Lv Y
FAU - Du, Guanhua
AU  - Du G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/12/10 [received]
PHST- 2013/05/07 [revised]
PHST- 2013/05/14 [accepted]
AID - S0378-8741(13)00349-8 [pii]
AID - 10.1016/j.jep.2013.05.013 [doi]
PST - aheadofprint
SO  - J Ethnopharmacol. 2013 May 21. pii: S0378-8741(13)00349-8. doi:
      10.1016/j.jep.2013.05.013.

PMID- 23707222
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
DP  - 2013 May 23
TI  - Soluble serum Klotho levels in healthy subjects. Comparison of two different
      immunoassays.
LID - S0009-9120(13)00242-7 [pii]
LID - 10.1016/j.clinbiochem.2013.05.046 [doi]
AB  - OBJECTIVE: Soluble serum Klotho is a new biomarker linked to chronic kidney
      disease, cardiovascular disease and diabetes. This study describes the evaluation
      and comparison of two different immunoassays and establishment of assay specific 
      reference intervals in adults. DESIGN AND METHODS: Serum Klotho concentrations
      were determined in 120 healthy adults aged 19-66years. Blood samples were
      collected, and stored sera were assayed for Klotho according to age and gender.
      In addition several other clinical and laboratory characteristics were determined
      in the cohort and compared to the levels of serum Klotho. RESULTS: Serum Klotho
      levels were significantly higher in time-resolved fluorescence immunoassay (TRF) 
      compared to an ELISA (IBL) and no correlation was found between the assays. No
      signal was obtained in either assay when the standard curve was switched between 
      the two different immunoassays. The median serum Klotho concentration using TRF
      was 61ng/mL (2.5-97.5% reference limits; 11-181ng/mL) for males and 99ng/mL
      (2.5-97.5% reference limits; 19-316ng/mL) for females while the ELISA gave a mean
      value of 472pg/mL (2.5-97.5% reference limits; 204-741pg/mL) with no difference
      between genders. Concentrations of serum Klotho were independently associated
      with estimated glomerular filtration rate (eGFR) and body weight using TRF
      whereas serum Klotho concentrations were associated with age using the ELISA.
      CONCLUSION: Comparison of two different immunoassays for serum Klotho indicate,
      that the protein exists in human beings in different forms which may function as 
      independent factors and whose role and potential value as biomarkers needs to be 
      evaluated separately. Reference intervals specific for the different forms
      recognized by the different assays were calculated in this study.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Clinical Biochemistry and Pharmacology, Odense University Hospital,
      Odense, Denmark. Electronic address: Lise-Pedersen@ouh.regionsyddanmark.dk.
FAU - Pedersen, Lise
AU  - Pedersen L
FAU - Pedersen, Susanne Moller
AU  - Pedersen SM
FAU - Brasen, Claus Lohman
AU  - Brasen CL
FAU - Rasmussen, Lars Melholt
AU  - Rasmussen LM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/12/14 [received]
PHST- 2013/04/22 [revised]
PHST- 2013/05/14 [accepted]
AID - S0009-9120(13)00242-7 [pii]
AID - 10.1016/j.clinbiochem.2013.05.046 [doi]
PST - aheadofprint
SO  - Clin Biochem. 2013 May 23. pii: S0009-9120(13)00242-7. doi:
      10.1016/j.clinbiochem.2013.05.046.

PMID- 23706976
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
DP  - 2013 Apr 15
TI  - Associations between dietary patterns and kidney function indicators in type 2
      diabetes.
LID - S0261-5614(13)00110-6 [pii]
LID - 10.1016/j.clnu.2013.04.010 [doi]
AB  - BACKGROUND & AIMS: Dietary patterns link to risks for chronic diseases. Few
      studies explore relationships between dietary patterns and kidney function in
      adult type 2 diabetes in Asian. METHODS: Diabetic patients (n = 635) were
      selected from a cohort participating in a diabetic control study in Taiwan. Three
      dietary patterns, high fat (meats, processed meats, seafood, fatty foods, eggs), 
      vegetable and fish (light- or dark- colored vegetables, pond and marine fish) and
      traditional Chinese-snack (soy/gluten products, rice, noodles, root vegetables,
      nuts), were generated using factor analysis. Urinary albumin to creatinine (ACR),
      creatinine and estimated glomerular filtration rate (eGFR) served as clinical
      indicators of kidney function. RESULTS: After adjusting for confounders, tertile 
      scores of vegetable and fish dietary patterns correlated significantly (p-trend =
      0.032) and dose-responsively with multivariable-adjusted means of decreased
      creatinine and marginally with increased eGFR (p- trend = 0.065). Traditional
      Chinese-snack dietary pattern was marginally associated with creatinine (p-trend 
      = 0.065) and eGFR (p-trend = 0.064). High fat dietary patterns did not correlate 
      with any kidney function indicator. CONCLUSIONS: Healthy diets such as frequent
      intake of fish and vegetable may be related to indicators of better kidney
      function in type 2 diabetes. Further prospective studies with larger sample sizes
      and use of sensitive indicators for studying early renal function decline are
      needed to confirm this association.
CI  - Copyright (c) 2013 Elsevier Ltd and European Society for Clinical Nutrition and
      Metabolism. All rights reserved.
AD  - Division of Preventive Medicine and Health Services Research, Institute of
      Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan; 
      Department of Health Services Administration, China Medical University and
      Hospital, Taichung, Taiwan.
FAU - Hsu, Chih-Cheng
AU  - Hsu CC
FAU - Jhang, Huei-Ru
AU  - Jhang HR
FAU - Chang, Wen-Tsan
AU  - Chang WT
FAU - Lin, Chia-Huei
AU  - Lin CH
FAU - Shin, Shyi-Jang
AU  - Shin SJ
FAU - Hwang, Shang-Jyh
AU  - Hwang SJ
FAU - Huang, Meng-Chuan
AU  - Huang MC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/08/29 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/08 [accepted]
AID - S0261-5614(13)00110-6 [pii]
AID - 10.1016/j.clnu.2013.04.010 [doi]
PST - aheadofprint
SO  - Clin Nutr. 2013 Apr 15. pii: S0261-5614(13)00110-6. doi:
      10.1016/j.clnu.2013.04.010.

PMID- 23706960
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1879-2472 (Electronic)
IS  - 0049-3848 (Linking)
DP  - 2013 May 21
TI  - Relationship between Periodontal disease, Porphyromonas gingivalis, peripheral
      vascular resistance markers and Coronary Artery Disease in Asian Indians.
LID - S0049-3848(13)00155-2 [pii]
LID - 10.1016/j.thromres.2013.04.023 [doi]
AB  - INTRODUCTION: A close association exists between oral health and cardiovascular
      disease. Periodontal disease induces early vascular changes while oral pathogens 
      have been detected in sub gingival and atheromatous plaques. We examined the
      interrelationship between Periodontal disease, oral bacteria, surrogate
      sub-clinical markers and coronary artery disease (CAD) in a representative Asian 
      Indian cohort. MATERIALS AND METHODS: 532 Gingivitis cases and 282 Periodontitis 
      cases were assessed for early peripheral vascular changes, namely pulse wave
      velocity (PWV), arterial stiffness index (ASI) and ankle brachial index (ABI)
      using computerized oscillometry method. Relative quantitation (RQ) of
      Porphyromonas gingivalis (Pg) was estimated in saliva samples of 54
      Periodontitis, 25 Gingivitis and 51 CAD cases (38 also had oral disease) by
      Taqman assay by amplifying pathogen-specific gene targets, 16srRNA and IktA,
      respectively, and 16s universal bacterial rRNA as endogenous control. RESULTS:
      PWV and ASI were elevated in Periodontitis compared to Gingivitis cases
      (p<0.0001) and in those with diabetes and hypertension. Cases with Periodontitis 
      showed higher mean expression of Pg than Gingivitis (0.37+/-0.05 versus
      0.15+/-0.04, p<0.0001), while CAD patients with oral disease (N=38) showed lower 
      mean Pg expression than those without oral disease (N=13) (0.712+/-0.119 versus
      1.526+/-0.257, p=0.008). Higher Pg expression was recorded in subjects with
      diabetes and hypertension. CONCLUSION: Oral disease induces early changes in the 
      peripheral blood vessels. Further, common presence of Pg in subjects with oral
      disease, in those with established cardiovascular risk factors and in patients
      with symptomatic CAD reflects the importance of oral hygiene in the development
      of Coronary Artery Disease in Asian Indians.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Clinical Research Unit, Thrombosis Research Institute, India; Mary and Garry
      Weston Functional Genomics Unit, Thrombosis Research Institute, India. Electronic
      address: Jayashreeshanker@triindia.org.in.
FAU - Shanker, Jayashree
AU  - Shanker J
FAU - Setty, Priyanka
AU  - Setty P
FAU - Arvind, Prathima
AU  - Arvind P
FAU - Nair, Jiny
AU  - Nair J
FAU - Bhasker, Dhanalakshmi
AU  - Bhasker D
FAU - Balakrishna, G
AU  - Balakrishna G
FAU - Kakkar, Vijay V
AU  - Kakkar VV
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/23 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/18 [accepted]
AID - S0049-3848(13)00155-2 [pii]
AID - 10.1016/j.thromres.2013.04.023 [doi]
PST - aheadofprint
SO  - Thromb Res. 2013 May 21. pii: S0049-3848(13)00155-2. doi:
      10.1016/j.thromres.2013.04.023.

PMID- 23706945
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 May 6
TI  - Calcium-phosphorus product concentration is a risk factor of coronary artery
      disease in metabolic syndrome.
LID - S0021-9150(13)00270-0 [pii]
LID - 10.1016/j.atherosclerosis.2013.04.028 [doi]
AB  - BACKGROUND: High serum phosphorus and the calcium-phosphorus product
      concentration has been associated with increased mortality and cardiovascular
      events in patients with chronic kidney disease. OBJECTIVE: This study was
      designed to determine the relationship between calcium-phosphorus product
      concentration and the presence of coronary artery calcification in subjects with 
      metabolic syndrome (MetS). METHODS: We reviewed the medical records of 2056
      general subjects with a mean age of 55.1 +/- 9.9 years and a glomerular
      filtration rate of 88.9 +/- 16.2 mL/min/1.73 m2. The enrolled subjects consisted 
      of 384 (18.7%) subjects with MetS and 1672 (81.3%) subjects without MetS. The
      severity of coronary artery calcification was assessed by the coronary artery
      calcification score (CACS) using multi-detector computed tomography (MDCT).
      RESULTS: The CACS correlated with calcium-phosphorus product concentration in
      subjects with MetS (r = 0.184, P < 0.01). The odds ratio of calcium-phosphorus
      product concentration having CACS >50 was 1.053 in subjects with MetS (P < 0.05).
      After adjustment for age, sex, diabetes, and dyslipidemia, calcium-phosphorus
      product concentrations had a positive correlation with CACS in subjects with
      MetS. In single regression analysis, calcium-phosphorus product concentration as 
      independent variable was the significant predictor of CACS in subjects with MetS.
      Using a multivariate analysis, calcium-phosphorus product concentration remained 
      a significant factor associated with CACS in subjects with MetS. CONCLUSIONS:
      Calcium-phosphorus product concentration was weakly associated with CACS and an
      independent factor predicting for CACS by MDCT in subjects with MetS. These
      results suggest that calcium-phosphorus product concentration might be considered
      as a risk factor of coronary artery disease in subjects with MetS.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Internal Medicine, Graduate School, The Catholic University of
      Korea, Seoul, Republic of Korea.
FAU - Kim, Woo Shin
AU  - Kim WS
FAU - Lee, Dong-Hyun
AU  - Lee DH
FAU - Youn, Ho-Joong
AU  - Youn HJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/09/28 [received]
PHST- 2013/03/27 [revised]
PHST- 2013/04/18 [accepted]
AID - S0021-9150(13)00270-0 [pii]
AID - 10.1016/j.atherosclerosis.2013.04.028 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 May 6. pii: S0021-9150(13)00270-0. doi:
      10.1016/j.atherosclerosis.2013.04.028.

PMID- 23706880
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
DP  - 2013 May 24
TI  - Adipokines in the HIV/HAART-associated lipodystrophy syndrome.
LID - S0026-0495(13)00131-5 [pii]
LID - 10.1016/j.metabol.2013.04.014 [doi]
AB  - The use of highly active antiretroviral therapy (HAART) in the treatment of human
      immunodeficiency virus has dramatically altered both the landscape of this
      disease and the prognosis for those affected. With more patients now receiving
      HAART, adverse effects such as lipodystrophy and metabolic syndrome have emerged.
      In HIV/HAART-associated lipodystrophy syndrome (HALS), patients demonstrate fat
      maldistribution with dyslipidemia, insulin resistance, and other metabolic
      complications. Recent studies have contributed to the elucidation of the
      pathophysiological abnormalities seen in this syndrome and have provided guidance
      for the study and use of potential treatments for these patients, but widely
      accepted guidelines have not yet been established. Two adipokines, leptin and
      adiponectin, are decreased in patients with HALS and lipoatrophy or
      lipodystrophy. Further, recent proof-of-concept clinical trials have proven the
      efficacy of leptin replacement and medications that increase circulating
      adiponectin levels in improving the metabolic profile of HALS patients. This
      review article highlights recent evidence on leptin replacement and compares
      leptin's efficacy to that of other treatments, including metformin and
      thiazolidinediones, on metabolic abnormalities such as impaired insulin-glucose
      homeostasis associated with lipodystrophy in patients receiving HAART. It is
      hoped that forthcoming large phase III clinical trials will allow the addition of
      leptin to our therapeutic armamentarium for use in patients suffering from this
      disease state.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Internal Medicine, Division of Endocrinology, Diabetes and
      Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
      MA, USA; Department of Medicine, Mount Auburn Hospital, Harvard Medical School,
      Boston, MA, USA.
FAU - Paruthi, Jason
AU  - Paruthi J
FAU - Gill, Natasha
AU  - Gill N
FAU - Mantzoros, Christos S
AU  - Mantzoros CS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/23 [received]
PHST- 2013/04/15 [revised]
PHST- 2013/04/25 [accepted]
AID - S0026-0495(13)00131-5 [pii]
AID - 10.1016/j.metabol.2013.04.014 [doi]
PST - aheadofprint
SO  - Metabolism. 2013 May 24. pii: S0026-0495(13)00131-5. doi:
      10.1016/j.metabol.2013.04.014.

PMID- 23706874
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1532-6500 (Electronic)
IS  - 1058-2746 (Linking)
DP  - 2013 May 21
TI  - The incidence and risk factors for blood transfusion in revision shoulder
      arthroplasty: our institution's experience and review of the literature.
LID - S1058-2746(13)00156-0 [pii]
LID - 10.1016/j.jse.2013.03.010 [doi]
AB  - HYPOTHESIS: The purposes of this study were to determine the incidence of blood
      transfusion after revision shoulder arthroplasty and to assess risk factors
      associated with an increased risk of transfusion. MATERIALS AND METHODS: Between 
      1994 and 2008, 566 consecutive revision shoulder procedures were performed at our
      institution, which formed the basis of this study. The patient's age, sex, body
      mass index, comorbidities, preoperative and postoperative hemoglobin level,
      details of the surgery, operative time, and transfusion details were documented
      retrospectively from medical records. RESULTS: Overall, 11.3% of patients (64 of 
      566) required a transfusion. An increased transfusion rate was associated with
      age (odds ratio [OR] per 10 years, 1.5 [95% confidence interval (CI), 1.2 to
      2.0]; P = .002), operative time (</=5 hours vs >5 hours) (OR, 3.3 [95% CI, 1.9 to
      5.8]; P < .001), diabetes (OR, 2.3 [95% CI, 1.2 to 4.4]; P = .01), and cardiac
      disease (OR, 2.7 [95% CI, 1.5 to 5.0]; P < .001). There were significant
      associations between preoperative hemoglobin level (OR, 0.4 per 1 point [95% CI, 
      0.3 to 0.5]; P < .001) and a decreased odds of transfusion. The type of surgery
      (surgery on humeral component) also had an impact on the need for transfusion (P 
      < .001). CONCLUSIONS: Older age, low preoperative hemoglobin level, increased
      operative time, diabetes, presence of cardiac disease, and type of revision
      surgery are associated with higher postoperative transfusion rates. These factors
      should be taken into consideration to more accurately predict the need for
      transfusion and modify preoperative blood-ordering protocols.
CI  - Copyright (c) 2013 Journal of Shoulder and Elbow Surgery Board of Trustees.
      Published by Mosby, Inc. All rights reserved.
AD  - Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.
FAU - Ahmadi, Shahryar
AU  - Ahmadi S
FAU - Lawrence, Thomas M
AU  - Lawrence TM
FAU - Sahota, Shawn
AU  - Sahota S
FAU - Schleck, Cathy D
AU  - Schleck CD
FAU - Harmsen, William S
AU  - Harmsen WS
FAU - Cofield, Robert H
AU  - Cofield RH
FAU - Sperling, John W
AU  - Sperling JW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - J Shoulder Elbow Surg
JT  - Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... 
      [et al.]
JID - 9206499
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/10/01 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/03/17 [accepted]
AID - S1058-2746(13)00156-0 [pii]
AID - 10.1016/j.jse.2013.03.010 [doi]
PST - aheadofprint
SO  - J Shoulder Elbow Surg. 2013 May 21. pii: S1058-2746(13)00156-0. doi:
      10.1016/j.jse.2013.03.010.

PMID- 23706862
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1476-5616 (Electronic)
IS  - 0033-3506 (Linking)
DP  - 2013 May 22
TI  - Sex differences in the association between socio-economic status and type 2
      diabetes: data from the 2005 Korean National Health and Nutritional Examination
      Survey (KNHANES).
LID - S0033-3506(13)00068-1 [pii]
LID - 10.1016/j.puhe.2013.02.001 [doi]
AB  - OBJECTIVES: While socio-economic status (SES) is considered a key
      social-environment factor affecting health outcomes, sex differences in the
      association between SES and the risk of type 2 diabetes remain unclear. The aims 
      of this study were: (1) to identify risk factors associated with type 2 diabetes 
      in a representative sample of Korean adults with a focus on socio-economic
      determinants; and (2) to examine how the association between SES and type 2
      diabetes is affected by sex. STUDY DESIGN: Cross-sectional study. METHODS: This
      study used data obtained from 3870 Korean adults (age >/=35 years) who
      participated in the 2005 Korean National Health and Nutritional Examination
      Survey (KNHANES III). The risk of type 2 diabetes in relation to SES was
      calculated, after controlling for other risk factors such as medical
      characteristics (hypertension, family history, body mass index, triglyceride,
      total cholesterol, high-density lipoprotein cholesterol), lifestyle factors (body
      mass index, smoking, alcohol intake, exercise) and perceived stress. Odds ratios 
      (ORs) were calculated separately for Korean men and women using multivariate
      logistic regression. RESULTS: Compared with individuals with >/=13 years of
      education, those with </=6 years of education or 7-12 years of education had
      higher ORs for the risk of type 2 diabetes - 2.10 (95% confidence interval (CI)
      1.27-3.48) and 1.62 (95% CI 1.04-2.52), respectively - after adjusting for age,
      sex, medical characteristics, lifestyle factors and stress level. The OR for
      women with </=6 years of education was particularly high (OR 10.16, 95% CI
      2.08-49.53), even after adjusting for the study covariates. However, this
      increasing trend in the OR was not observed for men. CONCLUSIONS: SES
      significantly influences the risk of type 2 diabetes in Korean adults, and there 
      are interactions with sex. Korean women with a low level of education represent a
      particularly high-risk group for type 2 diabetes. Future interventions should
      incorporate more targeted diabetes prevention efforts for women with a low level 
      of education.
CI  - Copyright (c) 2013 The Royal Society for Public Health. Published by Elsevier
      Ltd. All rights reserved.
AD  - Department of Nursing, Kangwon National University, Chuncheon, Republic of Korea.
FAU - Lee, D S
AU  - Lee DS
FAU - Kim, Y J
AU  - Kim YJ
FAU - Han, H R
AU  - Han HR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Public Health
JT  - Public health
JID - 0376507
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2011/12/21 [received]
PHST- 2013/01/05 [revised]
PHST- 2013/02/01 [accepted]
AID - S0033-3506(13)00068-1 [pii]
AID - 10.1016/j.puhe.2013.02.001 [doi]
PST - aheadofprint
SO  - Public Health. 2013 May 22. pii: S0033-3506(13)00068-1. doi:
      10.1016/j.puhe.2013.02.001.

PMID- 23706830
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1527-3296 (Electronic)
IS  - 0196-6553 (Linking)
DP  - 2013 May 21
TI  - Predictors of methicillin-resistant Staphylococcus aureus colonization at
      hospital admission.
LID - S0196-6553(13)00291-5 [pii]
LID - 10.1016/j.ajic.2013.02.013 [doi]
AB  - BACKGROUND: The best strategy for active surveillance for methicillin-resistant
      Staphylococcus aureus (MRSA) remains unclear. We attempted to identify a risk
      factor score to predict MRSA colonization at hospital admission. METHODS: Data on
      9 variables reported as risk factors for MRSA colonization were analyzed, and a
      risk factor score to predict MRSA colonization was generated using multivariable 
      logistic regression and receiver operating characteristic curve analyses. This
      risk score was then prospectively validated. RESULTS: Four risk factors (nursing 
      home residence, diabetes, hospitalization in the past year, and chronic skin
      condition/infection) were significantly associated with MRSA colonization
      (c-statistic = 0.846). A cut-off score of 8 or greater would result in screening 
      20% of admissions and would detect 71% of MRSA-colonized patients. In the
      prospective validation study, a cut-off score of 8 or greater required screening 
      21% of admissions and detected 54% of MRSA. Nursing home residence was the best
      predictor of MRSA colonization. CONCLUSION: A similar risk factor-based screening
      strategy could be used to predict MRSA colonization in other institutions. Our
      data support routine screening of nursing home patients at hospital admission.
CI  - Copyright (c) 2013 Association for Professionals in Infection Control and
      Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.
AD  - Mayo Clinic, Department of Infectious Diseases, Rochester, MN.
FAU - Torres, Katherine
AU  - Torres K
FAU - Sampathkumar, Priya
AU  - Sampathkumar P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Am J Infect Control
JT  - American journal of infection control
JID - 8004854
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/09/29 [received]
PHST- 2013/02/16 [revised]
PHST- 2013/02/19 [accepted]
AID - S0196-6553(13)00291-5 [pii]
AID - 10.1016/j.ajic.2013.02.013 [doi]
PST - aheadofprint
SO  - Am J Infect Control. 2013 May 21. pii: S0196-6553(13)00291-5. doi:
      10.1016/j.ajic.2013.02.013.

PMID- 23706762
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1532-2661 (Electronic)
IS  - 0034-5288 (Linking)
DP  - 2013 May 21
TI  - Antioxidant and anti-inflammatory effects of quercetin in functional and
      morphological alterations in streptozotocin-induced diabetic rats.
LID - S0034-5288(13)00165-3 [pii]
LID - 10.1016/j.rvsc.2013.04.028 [doi]
AB  - The aim of this study was to investigate functional and morphological alterations
      caused by oxidative stress in streptozotocin (STZ)-induced diabetic rats and to
      evaluate the antioxidant effect of quercetin (QUE) in this disease. One hundred
      and thirty male Wistar rats, it were randomly distributed in 10 different
      experimental groups, with ten animals per group: Control Saline (CS), Control
      Ethanol (CE), Control QUE 5mg/kg (CQ5), Control QUE 25mg/kg (CQ25), Control QUE
      50mg/kg (CQ50), Diabetic Saline (DS), Diabetic Ethanol (DE), Diabetic QUE 5mg/kg 
      (DQ5), Diabetic QUE25mg/kg (DQ25), Diabetic QUE 50mg/kg (DQ50). Therefore,
      hyperglycemia is directly involved in oxidative stress production, as well as in 
      functional and morphological alterations caused by the excess of free radicals.
      QUE, specially at the dosage of 50mg/kg, can act as an antioxidant and
      anti-inflammatory agent, becoming a promising adjuvant in the treatment of
      diabetes mellitus.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Laboratorio de Analises Clinicas Veterinaria - LACVet, Universidade Federal de
      Santa Maria, Av. Roraima no 1000, Cidade Universitaria, Bairro Camobi, 97105-900 
      Santa Maria, RS, Brazil. Electronic address: roberto.marinho@uol.com.br.
FAU - Maciel, R M
AU  - Maciel RM
FAU - Costa, M M
AU  - Costa MM
FAU - Martins, D B
AU  - Martins DB
FAU - Franca, R T
AU  - Franca RT
FAU - Schmatz, R
AU  - Schmatz R
FAU - Graca, D L
AU  - Graca DL
FAU - Duarte, M M M F
AU  - Duarte MM
FAU - Danesi, C C
AU  - Danesi CC
FAU - Mazzanti, C M
AU  - Mazzanti CM
FAU - Schetinger, M R C
AU  - Schetinger MR
FAU - Paim, F C
AU  - Paim FC
FAU - Palma, H E
AU  - Palma HE
FAU - Abdala, F H
AU  - Abdala FH
FAU - Stefanello, N
AU  - Stefanello N
FAU - Zimpel, C K
AU  - Zimpel CK
FAU - Felin, D V
AU  - Felin DV
FAU - Lopes, S T A
AU  - Lopes ST
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Res Vet Sci
JT  - Research in veterinary science
JID - 0401300
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/08/22 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/04/25 [accepted]
AID - S0034-5288(13)00165-3 [pii]
AID - 10.1016/j.rvsc.2013.04.028 [doi]
PST - aheadofprint
SO  - Res Vet Sci. 2013 May 21. pii: S0034-5288(13)00165-3. doi:
      10.1016/j.rvsc.2013.04.028.

PMID- 23706759
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
DP  - 2013 May 22
TI  - Individualised treatment targets for elderly patients with type 2 diabetes using 
      vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised,
      double-blind, placebo-controlled study.
LID - S0140-6736(13)60995-2 [pii]
LID - 10.1016/S0140-6736(13)60995-2 [doi]
AB  - BACKGROUND: Guidelines suggest setting individualised targets for glycaemic
      control in elderly patients with type 2 diabetes, despite no evidence. We aimed
      to assess the feasibility of setting and achieving individualised targets over 24
      weeks along with conventional HbA1c reduction using vildagliptin versus placebo. 
      METHODS: In this multinational, double-blind, 24 week study, we enrolled
      drug-naive or inadequately controlled (glycosylated haemoglobin A1c [HbA1c]
      >/=7.0% to </=10.0%) patients with type 2 diabetes aged 70 years or older from 45
      outpatient centres in Europe. Investigators set individualised treatment targets 
      on the basis of age, baseline HbA1c, comorbidities, and frailty status before a
      validated automated system randomly assigned patients (1:1) to vildagliptin (50
      mg once or twice daily as per label) or placebo. Coprimary efficacy endpoints
      were proportion of patients reaching their investigator-defined HbA1c target and 
      HbA1c reduction from baseline to study end. The study is registered with
      ClinicalTrials.gov, number NCT01257451, and European Union Drug Regulating
      Authorities Clinical Trials database, number 2010-022658-18. FINDINGS: Between
      Dec 22, 2010, and March 14, 2012, we randomly assigned 139 patients each to the
      vildagliptin and placebo groups. 37 (27%) of 137 patients in the placebo group
      achieved their individualised targets by education and interactions with the
      study team alone and 72 (52.6%) of 137 patients achieved their target in the
      vildagliptin group (adjusted odds ratio 3.16, 96.2% CI 1.81-5.52; p<0.0001). This
      finding was accompanied by a clinically relevant 0.9% reduction in HbA1c from a
      baseline of 7.9% with vildagliptin and a between-group difference of -0.6% (98.8%
      CI -0.81 to -0.33; p<0.0001). The overall safety and tolerability was similar in 
      the vildagliptin and placebo groups, with low incidence of hypoglycaemia and no
      emergence of new safety signals. INTERPRETATION: This study is the first to
      introduce and show the feasibility of using individualised HbA1c targets as an
      endpoint in any type 2 diabetes population. Individualised glycaemic target
      levels are achievable with vildagliptin without any tolerability issues in the
      elderly type 2 diabetes population. FUNDING: Novartis Pharma AG.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Diabetes and Vascular Research Centre, University of Exeter Medical School,
      Exeter, UK. Electronic address: d.strain@exeter.ac.uk.
FAU - Strain, W David
AU  - Strain WD
FAU - Lukashevich, Valentina
AU  - Lukashevich V
FAU - Kothny, Wolfgang
AU  - Kothny W
FAU - Hoellinger, Marie-Jose
AU  - Hoellinger MJ
FAU - Paldanius, Paivi Maria
AU  - Paldanius PM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Lancet
JT  - Lancet
JID - 2985213R
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - S0140-6736(13)60995-2 [pii]
AID - 10.1016/S0140-6736(13)60995-2 [doi]
PST - aheadofprint
SO  - Lancet. 2013 May 22. pii: S0140-6736(13)60995-2. doi:
      10.1016/S0140-6736(13)60995-2.

PMID- 23706758
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
DP  - 2013 May 22
TI  - Individualising treatment for older people with diabetes.
LID - S0140-6736(13)61055-7 [pii]
LID - 10.1016/S0140-6736(13)61055-7 [doi]
AD  - Division of Geriatric Medicine and Endocrinology, Saint Louis University School
      of Medicine, St Louis, MO 63104, USA. Electronic address: morley@slu.edu.
FAU - Morley, John E
AU  - Morley JE
FAU - Sinclair, Alan
AU  - Sinclair A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Lancet
JT  - Lancet
JID - 2985213R
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - S0140-6736(13)61055-7 [pii]
AID - 10.1016/S0140-6736(13)61055-7 [doi]
PST - aheadofprint
SO  - Lancet. 2013 May 22. pii: S0140-6736(13)61055-7. doi:
      10.1016/S0140-6736(13)61055-7.

PMID- 23706645
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 4
IP  - 3
DP  - 2013 May 24
TI  - Preconditioning diabetic mesenchymal stem cells with myogenic medium increases
      their ability to repair diabetic heart.
PG  - 58
AB  - INTRODUCTION: Mesenchymal stem cells (MSCs) have the potential for treatment of
      diabetic cardiomyopathy, however the repair capability of MSCs declines with age 
      and disease. MSCs from diabetic animals exhibit impaired survival, proliferation 
      and differentiation and therefore require a strategy to improve their function.
      The aim of the study was to develop a preconditioning strategy to augment the
      ability of MSCs from diabetic patients to repair diabetic heart. METHOD: Diabetes
      was induced in C57BL/6 mice (6 to 8 weeks) with streptozotocin injections (55
      mg/kg) for 5 consecutive days. MSCs isolated from diabetic animals were
      preconditioned with medium from cardiomyocytes exposed to oxidative stress and
      high glucose (HG/H-CCM) RESULTS: Gene expression of VEGF, ANG-1, GATA-4, NKx2.5
      MEF2c, PCNA and eNOS was up-regulated after preconditioning with HG/H-CCM as
      evidenced by RT-PCR. Concurrently, increased AKT phosphorylation, proliferation, 
      angiogenic ability and reduced levels of apoptosis were observed in HG/H-CCM
      preconditioned diabetic MSCs compared to non-treated controls. HG/H-CCM
      preconditioned diabetic-mouse derived MSCs (dmMSCs) were transplanted in diabetic
      animals and demonstrated increased homing concomitant with augmented heart
      function. Gene expression of angiogenic and cardiac markers was significantly up 
      regulated in conjunction with paracrine factors (IGF-1, HGF, SDF-1, FGF-2) and in
      addition, reduced fibrosis, apoptosis and increased angiogenesis was observed in 
      diabetic hearts 4 weeks after transplantation of preconditioned dmMSCs compared
      to hearts with non-treated diabetic MSCs. CONCLUSIONS: Preconditioning with
      HG/H-CCM enhances survival, proliferation and angiogenic ability of dmMSCs
      augmenting their ability to improve function in a diabetic heart.
FAU - Khan, Mohsin
AU  - Khan M
FAU - Ali, Fatima
AU  - Ali F
FAU - Mohsin, Sadia
AU  - Mohsin S
FAU - Akhtar, Shoaib
AU  - Akhtar S
FAU - Mehmood, Azra
AU  - Mehmood A
FAU - Choudhery, Mahmood S
AU  - Choudhery MS
FAU - Khan, Shaheen N
AU  - Khan SN
FAU - Riazuddin, Sheikh
AU  - Riazuddin S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/11/22 [received]
PHST- 2013/05/24 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - scrt207 [pii]
AID - 10.1186/scrt207 [doi]
PST - aheadofprint
SO  - Stem Cell Res Ther. 2013 May 24;4(3):58.

PMID- 23706413
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 22
TI  - Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes
      mellitus with hypertension: A randomized controlled trial.
LID - S0168-8227(13)00161-7 [pii]
LID - 10.1016/j.diabres.2013.04.005 [doi]
AB  - AIMS: The aim of this study was to evaluate the effect of laparoscopic Roux-en-Y 
      gastric bypass (RYGB) surgery compared with usual care with and without Exenatide
      therapy in obese people with type 2 diabetes mellitus (T2DM) and hypertension.
      METHODS: 108 obese T2DM with hypertension were enrolled and randomly allocated to
      usual care (group A), usual care plus Exenatide (group B), and RYGB surgery
      (group C). Demographic characteristics, metabolic parameters and cardiac
      structure/function along with inflammatory cytokines were measured and compared
      before and after 12 months. RESULTS: At 12 months, diabetes remission had
      occurred in no patients in groups A and B versus 90% in group C, and there was a 
      significant decrease in requirement of antihypertensive drugs in group C compared
      with groups A and B (P<0.05). Other parameters (body mass index, hemoglobin A1c, 
      homeostasis model assessment of insulin resistance, lipids), inflammation index
      (high sensitivity C-reactive protein, tumor necrosis factor-alpha, high molecular
      weight adiponectin) and cardiac structure (left ventricular mass index) were
      significantly improved in groups B and C, but patients in group C had the
      greatest degree of improvement (P<0.05). CONCLUSION: RYGB surgery improves a
      number of parameters including cardiovascular function in obese hypertensive
      people with T2DM. This is likely to be due to, at least in part, an improvement
      in the abnormal metabolic panel and to reduced inflammation.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Endocrinology, Southwest Hospital of Third Military Medical
      University, Chongqing 400038, China; Section of Digestive Diseases, Department of
      Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. 
      Electronic address: ziwen.liang9@gmail.com.
FAU - Liang, Ziwen
AU  - Liang Z
FAU - Wu, Qinan
AU  - Wu Q
FAU - Chen, Bing
AU  - Chen B
FAU - Yu, Peiwu
AU  - Yu P
FAU - Zhao, Hongliang
AU  - Zhao H
FAU - Ouyang, Xinshou
AU  - Ouyang X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/31 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/22 [accepted]
AID - S0168-8227(13)00161-7 [pii]
AID - 10.1016/j.diabres.2013.04.005 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 22. pii: S0168-8227(13)00161-7. doi:
      10.1016/j.diabres.2013.04.005.

PMID- 23706362
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1097-6833 (Electronic)
IS  - 0022-3476 (Linking)
DP  - 2013 May 22
TI  - Threshold for Improvement in Insulin Sensitivity with Adolescent Weight Loss.
LID - S0022-3476(13)00420-4 [pii]
LID - 10.1016/j.jpeds.2013.04.003 [doi]
AB  - OBJECTIVES: To assess the association of weight loss and insulin sensitivity,
      glucose tolerance, and metabolic syndrome (MS) in obese adolescents following
      weight loss treatment, and to determine the threshold amount of weight loss
      required to observe improvements in these measures. STUDY DESIGN: A randomized,
      controlled behavioral weight loss trial was conducted with 113 obese adolescents.
      Changes in fasting insulin, homeostasis model assessment of insulin resistance,
      whole body insulin sensitivity index (WBISI), body mass index (BMI), and MS
      criteria were assessed at baseline and at month 4. RESULTS: There was significant
      improvement in all measures of insulin sensitivity at month 4. Mean fasting
      insulin dropped from 22.3 to 16.6 muU/mL (P < .0001). Homeostasis model
      assessment of insulin resistance decreased significantly from 4.9 to 3.7 (P =
      .001) and WBISI increased significantly from 2.87 to 3.98 (P < .0001). An 8%
      reduction in BMI led to a significant improvement in WBISI (P = .03) and was the 
      optimal threshold. Fewer individuals met criteria for MS after weight loss (P =
      .0038), although there were no significant changes in the individual features of 
      the syndrome. CONCLUSIONS: In this trial, weight loss at month 4 was associated
      with improved insulin sensitivity in obese adolescents. An approximate decrease
      in BMI of 8% was the threshold level at which insulin sensitivity improved. As
      more weight loss programs are designed for obese adolescents, it will be
      important to have reasonable weight loss goals that will yield improvements in
      metabolic and cardiovascular disease risk factors.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Division of Endocrinology and Diabetes, Department of Pediatrics, The Children's 
      Hospital of Philadelphia, Philadelphia, PA. Electronic address:
      abramsp@email.chop.edu.
FAU - Abrams, Pamela
AU  - Abrams P
FAU - Levitt Katz, Lorraine E
AU  - Levitt Katz LE
FAU - Moore, Renee H
AU  - Moore RH
FAU - Xanthopoulos, Melissa S
AU  - Xanthopoulos MS
FAU - Bishop-Gilyard, Chanelle T
AU  - Bishop-Gilyard CT
FAU - Wadden, Thomas A
AU  - Wadden TA
FAU - Berkowitz, Robert I
AU  - Berkowitz RI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/06/14 [received]
PHST- 2013/02/11 [revised]
PHST- 2013/04/03 [accepted]
AID - S0022-3476(13)00420-4 [pii]
AID - 10.1016/j.jpeds.2013.04.003 [doi]
PST - aheadofprint
SO  - J Pediatr. 2013 May 22. pii: S0022-3476(13)00420-4. doi:
      10.1016/j.jpeds.2013.04.003.

PMID- 23706335
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1556-5653 (Electronic)
IS  - 0015-0282 (Linking)
DP  - 2013 May 23
TI  - A common gene variant in STK11 is associated with metabolic risk markers and
      diabetes during gestation.
LID - S0015-0282(13)00551-7 [pii]
LID - 10.1016/j.fertnstert.2013.04.037 [doi]
AB  - OBJECTIVE: To assess whether the common rs8111699 (C528G) variant in STK11 is
      related to metabolic risk markers in pregnant women and to gestational diabetes
      mellitus (GDM). DESIGN: Cross-sectional study. SETTING: Hospital. PATIENT(S): A
      total of 561 pregnant women: 318 without and 243 with GDM (National Diabetes Data
      Group criteria). INTERVENTION(S): None. MAIN OUTCOME MEASURES(S): rs8111699
      variant in STK11 (Taqman technology). Fasting glucose, insulin (homeostatic model
      assessment of insulin resistance and beta-cell function [HOMA-IR and -beta]) and 
      C-peptide assessed at 24-28 weeks' gestation. RESULT(S): In non-GDM women, the G 
      allele in rs8111699 was associated with lower HOMA-IR (CC: 1.3 +/- 0.1 mIU/L; GG:
      0.9 +/- 0.1 mIU/L) and HOMA-beta (CC: 165 +/- 20 mIU/L; GG: 118 +/- 10 mIU/L). In
      GDM women, the G allele was related to lower body mass index (BMI; CC: 27.9 +/-
      1.0 kg/m2; GG: 24.5 +/- 0.6 kg/m2) and C-peptide (CC: 2.3 +/- 0.1 ng/mL; GG: 1.6 
      +/- 0.1 ng/mL). The GG genotype was less frequently observed in GDM women (18%
      vs. 26%), particularly in heavier GDM women (BMI > median: 14% vs. 28%).
      CONCLUSION(S): In pregnant women, the G allele for the rs8111699 variant in STK11
      is associated with a more favorable metabolic phenotype and may protect against
      the development of GDM, particularly in heavier women.
CI  - Copyright (c) 2013 American Society for Reproductive Medicine. Published by
      Elsevier Inc. All rights reserved.
AD  - Department of Pediatrics, Dr. Josep Trueta Hospital, Girona, Spain; Girona
      Institute for Biomedical Research, Girona, Spain.
FAU - Bassols, Judit
AU  - Bassols J
FAU - Megia, Ana
AU  - Megia A
FAU - Soriano-Rodriguez, Pilar
AU  - Soriano-Rodriguez P
FAU - Diaz, Marta
AU  - Diaz M
FAU - Prats-Puig, Anna
AU  - Prats-Puig A
FAU - Gifre, Magdalena
AU  - Gifre M
FAU - Simon-Muela, Inmaculada
AU  - Simon-Muela I
FAU - Torrent, Sara
AU  - Torrent S
FAU - Borrell, Anna C
AU  - Borrell AC
FAU - Riera-Socasau, Joan-Carles
AU  - Riera-Socasau JC
FAU - Vendrell, Joan
AU  - Vendrell J
FAU - de Zegher, Francis
AU  - de Zegher F
FAU - Ibanez, Lourdes
AU  - Ibanez L
FAU - Lopez-Bermejo, Abel
AU  - Lopez-Bermejo A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Fertil Steril
JT  - Fertility and sterility
JID - 0372772
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/04 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/04/24 [accepted]
AID - S0015-0282(13)00551-7 [pii]
AID - 10.1016/j.fertnstert.2013.04.037 [doi]
PST - aheadofprint
SO  - Fertil Steril. 2013 May 23. pii: S0015-0282(13)00551-7. doi:
      10.1016/j.fertnstert.2013.04.037.

PMID- 23706326
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 May 22
TI  - Long-term outcomes of patients receiving zotarolimus-eluting stents in ST
      elevation myocardial infarction, non-ST elevation acute coronary syndrome, and
      stable angina: Data from the Resolute program.
LID - S0167-5273(13)00908-X [pii]
LID - 10.1016/j.ijcard.2013.04.209 [doi]
AB  - BACKGROUND: Outcome data are limited in patients with ST-segment elevation acute 
      myocardial infarction (STEMI) or other acute coronary syndromes (ACSs) who
      receive a drug-eluting stent (DES). Data suggest that first generation DES is
      associated with an increased risk of stent thrombosis when used in STEMI. Whether
      this observation persists with newer generation DES is unknown. The study
      objective was to analyze the two-year safety and effectiveness of Resolute
      zotarolimus-eluting stents (R-ZESs) implanted for STEMI, ACS without ST segment
      elevation (non-STEACS), and stable angina (SA). METHODS: Data from the Resolute
      program (Resolute All Comers and Resolute International) were pooled and patients
      with R-ZES implantation were categorized by indication: STEMI (n=335), non-STEACS
      (n=1416), and SA (n=1260). RESULTS: Mean age was 59.8+/-11.3years (STEMI),
      63.8+/-11.6 (non-STEACS), and 64.9+/-10.1 (SA). Fewer STEMI patients had diabetes
      (19.1% vs. 28.5% vs. 29.2%; P<0.001), prior MI (11.3% vs. 27.2% vs. 29.4%;
      P<0.001), or previous revascularization (11.3% vs. 27.9% vs. 37.6%; P<0.001).
      Two-year definite/probable stent thrombosis occurred in 2.4% (STEMI), 1.2%
      (non-STEACS) and 1.1% (SA) of patients with late/very late stent thrombosis (days
      31-720) rates of 0.6% (STEMI and non-STEACS) and 0.4% (SA) (P=NS). The two-year
      mortality rate was 2.1% (STEMI), 4.8% (non-STEACS) and 3.7% (SA) (P=NS). Death or
      target vessel re-infarction occurred in 3.9% (STEMI), 8.7% (non-STEACS) and 7.3% 
      (SA) (P=0.012). CONCLUSION: R-ZES in STEMI and in other clinical presentations is
      effective and safe. Long term outcomes are favorable with an extremely rare
      incidence of late and very late stent thrombosis following R-ZES implantation
      across indications.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Cardiocenter, Third Faculty of Medicine, Charles University, Prague, Czech
      Republic. Electronic address: petr.widimsky@fnkv.cz.
FAU - Widimsky, Petr
AU  - Widimsky P
FAU - Motovska, Zuzana
AU  - Motovska Z
FAU - Belardi, Jorge
AU  - Belardi J
FAU - Serruys, Patrick
AU  - Serruys P
FAU - Silber, Sigmund
AU  - Silber S
FAU - Windecker, Stephan
AU  - Windecker S
FAU - Neumann, Franz-Josef
AU  - Neumann FJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/10/16 [received]
PHST- 2013/04/09 [revised]
PHST- 2013/04/30 [accepted]
AID - S0167-5273(13)00908-X [pii]
AID - 10.1016/j.ijcard.2013.04.209 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 May 22. pii: S0167-5273(13)00908-X. doi:
      10.1016/j.ijcard.2013.04.209.

PMID- 23706250
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1878-7436 (Electronic)
IS  - 1878-7436 (Linking)
DP  - 2013 May 23
TI  - Predictors of congruency between self-reported hypertension status and measured
      blood pressure in the stroke belt.
LID - S1933-1711(13)00075-2 [pii]
LID - 10.1016/j.jash.2013.04.007 [doi]
AB  - BACKGROUND: Few studies have comprehensively investigated the validity of
      self-reported hypertension (HTN) and assessed predictors of HTN status in the
      stroke belt. This study evaluates validity self-reporting as a tool to screen
      large study populations and determine predictors of congruency between
      self-reported HTN and clinical measures. METHODS: Community Initiative to
      Eliminate Stroke project (n = 16,598) was conducted in two counties of North
      Carolina in 2004 to 2007, which included collection of self-reported data and
      clinical data of stroke-related risk factors. Congruency between self-reported
      HTN status and clinical measures was based on epidemiological parameters of
      sensitivity, specificity, and predictive values. McNemar's test and Kappa
      agreement levels assessed differences in congruency, while odds ratios and
      logistic regression determined significant predictors of congruency. RESULTS:
      Sensitivity of self-reported HTN was low (33.3%), but specificity was high
      (89.5%). Prevalence of self-reported HTN was 16.15%. Kappa agreement between
      self-report and clinical measures for blood pressure was fair (k = 0.25).
      Females, whites, and young adults were most likely to be positively congruent,
      whereas individuals in high risk categories for total blood cholesterol, low
      density lipoproteins, triglycerides, and diabetes were least likely to accurately
      capture their HTN status. CONCLUSION: Self-report HTN information should be used 
      with caution as an epidemiological investigation tool.
CI  - Copyright (c) 2013 American Society of Hypertension. Published by Elsevier Inc.
      All rights reserved.
AD  - North Carolina Translational and Clinical Sciences (NC TraCS) Institute,
      University of North Carolina, Chapel Hill, NC, USA. Electronic address:
      gjdave@email.unc.edu.
FAU - Dave, Gaurav J
AU  - Dave GJ
FAU - Bibeau, Daniel L
AU  - Bibeau DL
FAU - Schulz, Mark R
AU  - Schulz MR
FAU - Aronson, Robert E
AU  - Aronson RE
FAU - Ivanov, Louise L
AU  - Ivanov LL
FAU - Black, Adina
AU  - Black A
FAU - Spann, Lapronda
AU  - Spann L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Am Soc Hypertens
JT  - Journal of the American Society of Hypertension : JASH
JID - 101312518
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/20 [received]
PHST- 2013/04/10 [revised]
PHST- 2013/04/11 [accepted]
AID - S1933-1711(13)00075-2 [pii]
AID - 10.1016/j.jash.2013.04.007 [doi]
PST - aheadofprint
SO  - J Am Soc Hypertens. 2013 May 23. pii: S1933-1711(13)00075-2. doi:
      10.1016/j.jash.2013.04.007.

PMID- 23706179
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1615-5947 (Electronic)
IS  - 0890-5096 (Linking)
DP  - 2013 May 22
TI  - Ruptured Cryptogenic Mycotic Abdominal Aortic Aneurysm by Salmonella enteritidis.
LID - S0890-5096(13)00090-3 [pii]
LID - 10.1016/j.avsg.2012.08.016 [doi]
AB  - BACKGROUND: The aim of this study is to describe a case of ruptured cryptogenic
      mycotic abdominal aortic aneurysm by Salmonella enteritidis (SE) and present a
      comprehensive review of the literature. METHODS: A 66-year-old man with a past
      medical history of coronary artery bypass graft (CABG) and polymylagia rheumatica
      (PMR) presented with a 2-day history of right-flank-to-groin pain and fever. He
      was found to have tenderness on the right of the umbilical region and laboratory 
      data showed leukocytosis, raised C-reactive protein, and a significant drop in
      hemoglobin level as compared with his first visit 17 days earlier, with no
      hemodynamic instability. An immediate computed tomography angiogram (CTA) was
      performed, which showed a 4-cm, fusiform, ruptured infrarenal aortic aneurysm.
      Exploratory laparatomy was performed and the aorta was isolated and excised from 
      the infrarenal level to the common iliac bificuration. A straight silver Dacron
      graft soaked in rifampicin was placed with an end-to-end anastomosis. The excised
      aorta and the lymph nodes were sent for histologic and microbiologic assessment. 
      RESULTS: Blood culture and specimen microbiology grew Salmonella enteritidis
      (SE). The histology exhibited atherosclerosis at the rupture point with
      decreasing neutrophil deposition from the intima to the adventitia layer,
      respectively. CONCLUSIONS: Infrarenal abdominal mycotic aneurysm (MA) by SE was
      observed and showed vague, nonspecific signs and symptoms. We recommend a high
      index of suspicion and low threshold for use of CT imaging in any infected
      patient of age >60 years with fever and abdominal pain on a background of
      diabetes and connective tissue disease. A comprehensive review of the literature 
      was performed due to a lack of consensus on the best surgical treatment and
      limited information on the path of SE-induced aortitis or MA from presentation to
      final outcome.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Vascular Surgery, Mid Essex Hospitals Services NHS Trust,
      Broomfield Hospital, Essex, UK. Electronic address: Alikordzadeh@gmail.com.
FAU - Kordzadeh, Ali
AU  - Kordzadeh A
FAU - Rhodes, Karen May
AU  - Rhodes KM
FAU - Hanif, Muhammad Asad
AU  - Hanif MA
FAU - Scott, Harriet
AU  - Scott H
FAU - Panayiotopoulos, Yiannis
AU  - Panayiotopoulos Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Ann Vasc Surg
JT  - Annals of vascular surgery
JID - 8703941
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/06/30 [received]
PHST- 2012/08/27 [revised]
PHST- 2012/08/31 [accepted]
AID - S0890-5096(13)00090-3 [pii]
AID - 10.1016/j.avsg.2012.08.016 [doi]
PST - aheadofprint
SO  - Ann Vasc Surg. 2013 May 22. pii: S0890-5096(13)00090-3. doi:
      10.1016/j.avsg.2012.08.016.

PMID- 23706129
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Prevalence of chronic diseases by immigrant status and disparities in chronic
      disease management in immigrants: a population-based cohort study, Valore
      Project.
PG  - 504
LID - 10.1186/1471-2458-13-504 [doi]
AB  - BACKGROUND: For chronic conditions, disparities can take effect cumulatively at
      various times as the disease progresses, even when care is provided. The aim of
      this study was to quantify the prevalence of diabetes, congestive heart failure
      (CHF) and coronary heart disease (CHD) in adults by citizenship, and to compare
      the performance of primary care services in managing these chronic conditions,
      again by citizenship. METHODS: This is a population-based retrospective cohort
      study on 1,948,622 people aged 16 years or more residing in Italy. A multilevel
      regression model was applied to analyze adherence to care processes using
      explanatory variables at both patient and district level. RESULTS: The
      age-adjusted prevalence of diabetes was found higher among immigrants from high
      migratory pressure countries (HMPC) than among Italians, while the age-adjusted
      prevalence of CHD and CHF was higher for Italians than for HMPC immigrants or
      those from highly-developed countries (HDC). Our results indicate lower levels in
      all quality management indicators for citizens from HMPC than for Italians, for
      all the chronic conditions considered. Patients from HDC did not differ from
      Italian in their adherence to disease management schemes. CONCLUSION: This study 
      revealed a different prevalence of chronic diseases by citizenship, implying a
      different burden of primary care by citizenship. Our findings show that more
      effort is needed to guarantee migrant-sensitive primary health care.
AD  - Department of Molecular Medicine, Laboratory for Public Health and Population
      Studies, University of Padova, Via Loredan 18, Padova 35128, Italy.
      alessandra.buja@unipd.it.
FAU - Buja, Alessandra
AU  - Buja A
FAU - Gini, Rosa
AU  - Gini R
FAU - Visca, Modesta
AU  - Visca M
FAU - Damiani, Gianfranco
AU  - Damiani G
FAU - Federico, Bruno
AU  - Federico B
FAU - Francesconi, Paolo
AU  - Francesconi P
FAU - Donato, Daniele
AU  - Donato D
FAU - Marini, Alessandro
AU  - Marini A
FAU - Donatini, Andrea
AU  - Donatini A
FAU - Brugaletta, Salvatore
AU  - Brugaletta S
FAU - Baldo, Vincenzo
AU  - Baldo V
FAU - Bellentani, Mariadonata
AU  - Bellentani M
CN  - Valore Project
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3673842
OID - NLM: PMC3673842
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/10/31 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 1471-2458-13-504 [pii]
AID - 10.1186/1471-2458-13-504 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 24;13:504. doi: 10.1186/1471-2458-13-504.

PMID- 23706067
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1471-2377 (Electronic)
IS  - 1471-2377 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 24
TI  - Predictors of long-term survival among first-ever ischemic and hemorrhagic stroke
      in a Brazilian stroke cohort.
PG  - 51
AB  - BACKGROUND: Few studies have examined both ischemic and hemorrhagic stroke to
      identify prognostic factors associated to long-term stroke survival. We
      investigated long-term survival and predictors that could adversely influence
      ischemic and hemorrhagic first-ever stroke prognosis. METHODS: We prospectively
      ascertained 665 consecutive first-ever ischemic and hemorrhagic stroke cases from
      "The Study of Stroke Mortality and Morbidity" (The EMMA Study) in a community
      hospital in Sao Paulo, Brazil. We evaluated cardiovascular risk factors and
      sociodemographic characteristics (age, gender, race and educational level).
      RESULTS: We found a lower survival rate among hemorrhagic cases compared to
      ischemic stroke cases at the end of 4 years of follow-up (52% vs. 44%, p = 0.04).
      The risk of death is two times higher among people with ischemic stroke without
      formal education. Also, we found consistently higher risk of death for diabetics 
      with ischemic stroke (HR = 1.45; 95% CI = 1.07-1.97) compared to no diabetics. As
      expected, age equally influenced on the high risk of poor survival, regardless of
      stroke subtype. CONCLUSIONS: For ischemic stroke, the lack of formal education
      and diabetes were significant independent predictors of poor long-term survival.
FAU - Goulart, Alessandra C
AU  - Goulart AC
FAU - Fernandes, Tiotrefis G
AU  - Fernandes TG
FAU - Santos, Itamar S
AU  - Santos IS
FAU - Alencar, Airlane P
AU  - Alencar AP
FAU - Bensenor, Isabela M
AU  - Bensenor IM
FAU - Lotufo, Paulo A
AU  - Lotufo PA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - BMC Neurol
JT  - BMC neurology
JID - 100968555
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/22 [received]
PHST- 2013/05/24 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 1471-2377-13-51 [pii]
AID - 10.1186/1471-2377-13-51 [doi]
PST - aheadofprint
SO  - BMC Neurol. 2013 May 24;13(1):51.

PMID- 23706016
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
DP  - 2013 May 26
TI  - Potential therapeutic use of deferoxamine and mesenchymal stem cells in type-1
      diabetes: assembling another piece of the jigsaw, in what is a complex puzzle.
AB  - Mesenchymal stem cells (MSCs) are recognized for their potential in regenerative 
      medicine. Due to long-term negative effects associated with insulin
      administration and difficulty with pancreas transplantation, patients with type-1
      diabetes could significantly benefit from organ-targeted cell-based therapy.
      Although several pharmacological agents increase the homing capacity of MSCs, the
      mechanisms regulating this process are still poorly understood. In this issue,
      Najafi et al. have demonstrated that pre-treatment of bone marrow-derived MSCs
      with the iron chelator and hypoxia mimetic, deferoxamine, can increase homing to 
      the pancreas in a rat model of diabetes. This effect appears to be driven through
      specific chemokines in addition to hypoxia-inducing factor 1-alpha. Results from 
      this study provide important clues in our endeavour to solve a complex process.
      Further studies will help determine whether these findings may offer potential
      therapeutic benefit to patients with diabetes.
AD  - Primula Multimedia SRL , Via G. Ravizza 22/b, Pisa, 56121 , Italy
      cegan@primulaedizioni.it.
FAU - Egan, Colin Gerard
AU  - Egan CG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - 10.1517/14712598.2013.804506 [doi]
PST - aheadofprint
SO  - Expert Opin Biol Ther. 2013 May 26.

PMID- 23705980
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
IP  - 1
DP  - 2013 May 25
TI  - HbA1c versus oral glucose tolerance test as a method to diagnose diabetes
      mellitus in vascular surgery patients.
PG  - 79
AB  - BACKGROUND: The diagnosis of diabetes mellitus (DM) is based on either fasting
      plasma glucose levels or an oral glucose tolerance test (OGTT). Recently, an
      HbA1c value of >= 48 mmol/mol (6.5%) has been included as an additional test to
      diagnose DM. The purpose of this study was to validate HbA1c versus OGTT as a
      method to diagnose DM in vascular surgery patients. METHODS: The study population
      consisted of 345 patients admitted consecutively due to peripheral arterial
      disease. Sixty-seven patients were previously diagnosed with DM. Glucose levels
      of OGTT and HbA1c values were analyzed in 275 patients. The OGTT results were
      categorized into three groups according to the World Health Organization 1999
      criteria: 1) DM defined as fasting plasma glucose (FPG) >= 7.0 mmol/L and/or
      two-hour value (2-h-value) >= 11.1 mmol/L; 2) intermediate hyperglycaemia, which 
      consists of IGT (FPG < 7.0 mmol/L and a 2-h-value between 7.8 mmol/L and 11.1
      mmol/L), and IFG (fasting glucose value between 6.1 mmol/L and 7.0 mmol/L with a 
      normal 2-h-value); and 3) normal glucose metabolism defined as FPG < 6.1 mmol/L
      and a 2-h-value < 7.8 mmol/L. RESULTS: Of the 275 patients on whom OGTT was
      performed, 33 were diagnosed with DM, 90 with intermediate hyperglycaemia and 152
      had normal glucose metabolism. An HbA1c value of >= 48 mmol/mol (6.5%) detected
      DM with a 45.5% sensitivity and a 90% specificity compared with the OGTT results.
      Combining the measurements of the HbA1c value with the fasting plasma glucose
      level (>=7.0 mmol/L) increased the sensitivity to 64%. The total prevalence of DM
      and intermediate hyperglycaemia was 85% based on HbA1c values and 45% based on
      the OGTT. CONCLUSIONS: Compared with the OGTT the HbA1c cut-off value of >= 48
      mmol/mol (6.5%) had a 45.5% sensitivity to diagnose DM in patients with
      peripheral arterial disease. OGTT and HbA1c categorized different individuals
      with DM and intermediate hyperglycaemia. The total prevalence of pathologic
      glucose metabolism was substantially higher based on HbA1c values than based on
      OGTT. The high prevalence of DM and intermediate hyperglycaemia when using HbA1c 
      in this study may reflect a high chronic glycaemic burden in patients with
      peripheral arterial disease. Further studies on vascular surgery patients are
      needed to identify which method, OGTT or HbA1c, is the better in predicting DM
      and future clinical development of vascular disease.Trial registration: REK vest 
      14109.
FAU - Hjellestad, Irene D
AU  - Hjellestad ID
FAU - Astor, Marianne C
AU  - Astor MC
FAU - Nilsen, Roy M
AU  - Nilsen RM
FAU - Softeland, Eirik
AU  - Softeland E
FAU - Jonung, Tobjorn
AU  - Jonung T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/05/10 [received]
PHST- 2013/05/25 [accepted]
PHST- 2013/05/25 [aheadofprint]
AID - 1475-2840-12-79 [pii]
AID - 10.1186/1475-2840-12-79 [doi]
PST - aheadofprint
SO  - Cardiovasc Diabetol. 2013 May 25;12(1):79.

PMID- 23705978
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1471-2296 (Electronic)
IS  - 1471-2296 (Linking)
VI  - 14
DP  - 2013
TI  - Effects of self-care, self-efficacy, social support on glycemic control in adults
      with type 2 diabetes.
PG  - 66
LID - 10.1186/1471-2296-14-66 [doi]
AB  - BACKGROUND: A number of studies have examined the influence of self-efficacy,
      social support and patient-provider communication (PPC) on self-care and glycemic
      control. Relatively few studies have tested the pathways through which these
      constructs operate to improve glycemic control, however. We used structural
      equation modeling to examine a conceptual model that hypothesizes how
      self-efficacy, social support and patient-provider communication influence
      glycemic control through self-care behaviors in Chinese adults with type 2
      diabetes. METHODS: We conducted a cross-sectional study of 222 Chinese adults
      with type 2 diabetes in one primary care center. We collected information on
      demographics, self-efficacy, social support, patient-provider communication (PPC)
      and diabetes self-care. Hemoglobin A1c (HbA1c) values were also obtained.
      Measured variable path analyses were used to determine the predicted pathways
      linking self-efficacy, social support and PPC to diabetes self-care and glycemic 
      control. RESULTS: Diabetes self-care had a direct effect on glycemic control
      (beta = -0.21, p = .007), No direct effect was observed for self-efficacy, social
      support or PPC on glycemic control. There were significant positive direct paths 
      from self-efficacy (beta = 0.32, p < .001), social support (beta = 0.17, p =
      .009) and PPC (beta = 0.14, p = .029) to diabetes self-care. All of them had an
      indirect effect on HbA1c (beta =-0.06, beta =-0.04, beta =-0.03 respectively).
      Additionally, PPC was positively associated with social support (gamma = 0.32, p 
      < .001). CONCLUSIONS: Having better provider-patient communication, having social
      support, and having higher self-efficacy was associated with performing diabetes 
      self-care behaviors; and these behaviors were directly linked to glycemic
      control. So longitudinal studies are needed to explore the effect of
      self-efficacy, social support and PPC on changes in diabetes self-care behaviors 
      and glycemic control.
AD  - School of Public Health, Fudan University, Key Laboratory of Public Health
      Safety, Ministry of Education, PO Box 248 138 Yixueyuan Road, Shanghai 200032,
      People's Republic of China. hfu@fudan.edu.cn.
FAU - Gao, Junling
AU  - Gao J
FAU - Wang, Jingli
AU  - Wang J
FAU - Zheng, Pinpin
AU  - Zheng P
FAU - Haardorfer, Regine
AU  - Haardorfer R
FAU - Kegler, Michelle C
AU  - Kegler MC
FAU - Zhu, Yaocheng
AU  - Zhu Y
FAU - Fu, Hua
AU  - Fu H
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - England
TA  - BMC Fam Pract
JT  - BMC family practice
JID - 100967792
SB  - IM
PMC - PMC3668988
OID - NLM: PMC3668988
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/09/09 [received]
PHST- 2013/05/20 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 1471-2296-14-66 [pii]
AID - 10.1186/1471-2296-14-66 [doi]
PST - epublish
SO  - BMC Fam Pract. 2013 May 24;14:66. doi: 10.1186/1471-2296-14-66.

PMID- 23705959
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - Sex-specific-differences in cardiometabolic risk in type 1 diabetes: a
      cross-sectional study.
PG  - 78
LID - 10.1186/1475-2840-12-78 [doi]
AB  - BACKGROUND: Little is known about the impact of sex-specific differences in the
      management of type 1 diabetes (T1DM).Thus, we evaluated the influence of gender
      on risk factors, complications, clinical care and adherence in patients with
      T1DM. METHODS: In a cross-sectional study, sex-specific disparities in glycaemic 
      control, cardiovascular risk factors, diabetic complications, concomitant
      medication use and adherence to treatment recommendations were evaluated in 225
      consecutive patients (45.3% women) who were comparable with respect to age,
      diabetes duration, and body mass index. RESULTS: Although women with T1DM had a
      higher total cholesterol than men, triglycerides were higher in obese men and
      males with HbA1c>7% than in their female counterparts. No sex differences were
      observed in glycaemic control and in micro- or macrovascular complications.
      However, the subgroup analysis showed that nephropathy was more common in obese
      men, hyperlipidaemic women and all hypertensive patients, whereas peripheral
      neuropathy was more common in hyperlipidaemic women. Retinopathy was found more
      frequently in women with HbA1c>7%, obese men and in both sexes with a long
      duration of diabetes. The multivariate analysis revealed that microvascular
      complications were associated with the duration of disease and BMI in both sexes 
      and with hyperlipidaemia in males. The overall adherence to interventions
      according to the guidelines was higher in men than in women. This adherence was
      concerned particularly with co-medication in patients diagnosed with
      hypertension, aspirin prescription in elderly patients and the achievement of
      target lipid levels following the prescription of statins. CONCLUSIONS: Our data 
      showed sex differences in lipids and overweight in patients with T1DM. Although
      glycaemic control and the frequency of diabetic complications were comparable
      between the sexes, the overall adherence to guidelines, particularly with respect
      to the prescription of statins and aspirin, was lower in women than in men.
AD  - Gender Medicine Unit, Department of Internal Medicine III, Division of
      Endocrinology and Metabolism, Medical University of Vienna, Waehringer Guertel
      18-20, 1090, Vienna, Austria. alexandra.kautzky-willer@meduniwien.ac.at.
FAU - Kautzky-Willer, Alexandra
AU  - Kautzky-Willer A
FAU - Stich, Kathrin
AU  - Stich K
FAU - Hintersteiner, Juliane
AU  - Hintersteiner J
FAU - Kautzky, Alexander
AU  - Kautzky A
FAU - Kamyar, Majid Reza
AU  - Kamyar MR
FAU - Saukel, Johannes
AU  - Saukel J
FAU - Johnson, Julienne
AU  - Johnson J
FAU - Lemmens-Gruber, Rosa
AU  - Lemmens-Gruber R
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3666903
OID - NLM: PMC3666903
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/02/14 [received]
PHST- 2013/05/19 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 1475-2840-12-78 [pii]
AID - 10.1186/1475-2840-12-78 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 May 24;12:78. doi: 10.1186/1475-2840-12-78.

PMID- 23705958
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1744-4160 (Electronic)
IS  - 1381-3455 (Linking)
DP  - 2013 May 24
TI  - So close and yet so far: mitochondria and peroxisomes are one but with specific
      talents.
AB  - Abstract Cellular compartmentalization of central metabolic pathways as lipid
      metabolism to mitochondria and peroxisomes enables high efficient control
      processes. The basis to understand mitochondrial or peroxisomal function is
      exactly to determine proteins physically present. For proteomic investigations of
      mouse liver organelles, we developed 2-DE reference maps covering the range pH
      4-9, available under ( www.diabesityprot.org ). MALDI-TOF-MS/MS analyses
      identified a total of 799 (mitochondria) and 681 (peroxisome) protein spots
      resembling 323 and 293 unique proteins, respectively. Direct comparison of
      mitochondrial and peroxisomal proteins indicated an approximate overlap of 2/3 of
      identified proteins. Gene Ontologies (GO) of the identified proteins in respect
      to physical presence confirmed functional specifications within the organelles.
      The 2-DE organelle reference maps will aid to point out functional differences
      and similarities. Our observations suggest that for functional analyses metabolic
      alterations focusing on one organelle are not sufficient and parallel comparison 
      of both organelles is to be preferred.
AD  - Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center 
      at the Heinrich-Heine-University Deusseldorf, Leibniz Center for Diabetes
      Research , 40225 Dusseldorf , Germany .
FAU - Hartwig, Sonja
AU  - Hartwig S
FAU - Knebel, Birgit
AU  - Knebel B
FAU - Goeddeke, Simon
AU  - Goeddeke S
FAU - Koellmer, Cornelia
AU  - Koellmer C
FAU - Jacob, Sylvia
AU  - Jacob S
FAU - Nitzgen, Ulrike
AU  - Nitzgen U
FAU - Passlack, Waltraud
AU  - Passlack W
FAU - Schiller, Martina
AU  - Schiller M
FAU - Dicken, Hans-Dieter
AU  - Dicken HD
FAU - Haas, Jutta
AU  - Haas J
FAU - Muller-Wieland, Dirk
AU  - Muller-Wieland D
FAU - Lehr, Stefan
AU  - Lehr S
FAU - Kotzka, Jorg
AU  - Kotzka J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Arch Physiol Biochem
JT  - Archives of physiology and biochemistry
JID - 9510153
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - 10.3109/13813455.2013.796994 [doi]
PST - aheadofprint
SO  - Arch Physiol Biochem. 2013 May 24.

PMID- 23705866
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 24
TI  - Patient and carer experience of obtaining regular prescribed medication for
      chronic disease in the English National Health Service: a qualitative study.
PG  - 192
AB  - BACKGROUND: The increasing burden of chronic disease is recognised globally.
      Within the English National Health Service, patients with chronic disease
      comprise of half of all consultations in primary care, and 70% of inpatient bed
      days. The cost of prescribing long-term medications for those with physical
      chronic diseases is rising and there is a drive to reduce medicine wastage and
      costs. While current policies in England are focused on the latter, there has
      been little previous research on patient experience of ordering and obtaining
      regular medication for their chronic disease. This paper presents findings from
      England of a qualitative study and survey of patients and their carers'
      experiences of community and primary care based services for physical chronic
      diseases. Although not the primary focus of the study, the results highlighted
      particular issues around service delivery of repeat prescriptions. METHODS: We
      conducted 21 qualitative in-depth interviews with 30 patients and family carers' 
      in two Primary Care Trusts in England. Participants were receiving community
      based care for diabetes, respiratory, neurological or complex co-morbidities, and
      ranged in age from 39-92 years old. We used a broadly inductive approach to
      enable themes around patient experience to emerge from the data. RESULTS: While
      the study sought to gain an overview of patient experience, the findings
      suggested that the processes associated with ordering and obtaining regular
      medication - the repeat prescription, was most frequently described as a
      recurring hassle of managing a long-term condition. Issues for patients and
      carers included multiple journeys to the surgery and pharmacy, lack of synchrony 
      and dissatisfaction with the length of prescriptions. CONCLUSION: Much literature
      exists around medication waste and cost, which led to encouragement from the NHS 
      in England to reduce dosage units to a 28-day supply. While there has been an
      acknowledgement that longer supplies may be suitable for people with stable
      chronic conditions, it appears that there is limited evidence on the impact of
      shorter length prescriptions on patient and carer experience, adherence and
      health outcomes. Recent policy documents within England also fail to address
      possible links between patient experience, adherence and flaws within repeat
      prescription service delivery.
FAU - Wilson, Patricia M
AU  - Wilson PM
FAU - Kataria, Neha
AU  - Kataria N
FAU - McNeilly, Elaine
AU  - McNeilly E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
PMC - PMC3671153
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2013/01/10 [received]
PHST- 2013/05/24 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 1472-6963-13-192 [pii]
AID - 10.1186/1472-6963-13-192 [doi]
PST - aheadofprint
SO  - BMC Health Serv Res. 2013 May 24;13(1):192.

PMID- 23705786
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 24
TI  - Association between vitamin b12 levels and melancholic depressive symptoms: a
      Finnish population-based study.
PG  - 145
AB  - BACKGROUND: An association between vitamin B12 levels and depressive symptoms
      (DS) has been reported in several epidemiological studies. The purpose of this
      study was to evaluate vitamin B12 levels in population-based samples with
      melancholic or non-melancholic DS as the relationship between vitamin B12 levels 
      and different subtypes of DS has not been evaluated in previous studies. METHODS:
      Subjects without previously known type 2 diabetes, aged 45--74 years were
      randomly selected from the National Population Register as a part of the Finnish 
      diabetes prevention programme (FIN-D2D). The study population (N = 2806,
      participation rate 62%) consisted of 1328 men and 1478 women. The health
      examinations were carried out between October and December 2007 according to the 
      WHO MONICA protocol. The assessment of DS was based on the Beck Depression
      Inventory (BDI, cut-off >=10 points). A DSM-IV- criteria based summary score of
      melancholic items in the BDI was used in dividing the participants with DS (N =
      429) into melancholic (N = 138) and non-melancholic DS (N = 291) subgroups. In
      the statistical analysis we used chi-squared test, t-test, permutation test,
      analysis of covariance, multivariate logistic regression analysis and multinomial
      regression model. RESULTS: The mean vitamin B12 level was 331+/-176 pmol/L in
      those without DS while the subjects with non-melancholic DS had a mean vitamin
      B12 level of 324 +/- 135 pmol/L, and those with melancholic DS had the lowest
      mean vitamin B12 level of 292+/-112 pmol/L (p < 0.001 after adjusted for age,
      sex, use of antidepressive medication and chronic diseases sum index). The
      adjusted difference of vitamin B12 levels between the non-melancholic and the
      melancholic group was 33 pmol/L (95%CI 8 to 57, p = 0.008). Melancholic DS and
      vitamin B12 levels showed an independent linearly inverse association. The
      relative risk ratio (RRR) for melancholic DS was 2.75 (95%CI 1.66 to 4.56) in the
      lowest vitamin B12 level tertile versus the highest (p for linearity <0.001) when
      those without DS formed the reference group. The RRR in the non-melancholic
      subgroup was nonsignificant. CONCLUSIONS: The vitamin B12 level was associated
      with melancholic DS but not with non-melancholic DS.
FAU - Seppala, Jussi
AU  - Seppala J
FAU - Koponen, Hannu
AU  - Koponen H
FAU - Kautiainen, Hannu
AU  - Kautiainen H
FAU - Eriksson, Johan G
AU  - Eriksson JG
FAU - Kampman, Olli
AU  - Kampman O
FAU - Leiviska, Jaana
AU  - Leiviska J
FAU - Mannisto, Satu
AU  - Mannisto S
FAU - Mantyselka, Pekka
AU  - Mantyselka P
FAU - Oksa, Heikki
AU  - Oksa H
FAU - Ovaskainen, Yrjo
AU  - Ovaskainen Y
FAU - Viikki, Merja
AU  - Viikki M
FAU - Vanhala, Mauno
AU  - Vanhala M
FAU - Seppala, Jussi
AU  - Seppala J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
PMC - PMC3674945
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/11/27 [received]
PHST- 2013/05/24 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 1471-244X-13-145 [pii]
AID - 10.1186/1471-244X-13-145 [doi]
PST - aheadofprint
SO  - BMC Psychiatry. 2013 May 24;13(1):145.

PMID- 23705645
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1475-2891 (Electronic)
IS  - 1475-2891 (Linking)
VI  - 12
DP  - 2013
TI  - Low glycaemic index diets improve glucose tolerance and body weight in women with
      previous history of gestational diabetes: a six months randomized trial.
PG  - 68
LID - 10.1186/1475-2891-12-68 [doi]
AB  - BACKGROUND: Gestational Diabetes Mellitus (GDM) increases risks for type 2
      diabetes and weight management is recommended to reduce the risk. Conventional
      dietary recommendations (energy-restricted, low fat) have limited success in
      women with previous GDM. The effect of lowering Glycaemic Index (GI) in managing 
      glycaemic variables and body weight in women post-GDM is unknown. OBJECTIVE: To
      evaluate the effects of conventional dietary recommendations administered with
      and without additional low-GI education, in the management of glucose tolerance
      and body weight in Asian women with previous GDM. METHOD: Seventy seven Asian,
      non-diabetic women with previous GDM, between 20- 40y were randomised into
      Conventional healthy dietary recommendation (CHDR) and low GI (LGI) groups. CHDR 
      received conventional dietary recommendations only (energy restricted, low in fat
      and refined sugars, high-fibre). LGI group received advice on lowering GI in
      addition. Fasting and 2-h post-load blood glucose after 75 g oral glucose
      tolerance test (2HPP) were measured at baseline and 6 months after intervention. 
      Anthropometry and dietary intake were assessed at baseline, three and six months 
      after intervention. The study is registered at the Malaysian National Medical
      Research Register (NMRR) with Research ID: 5183. RESULTS: After 6 months,
      significant reductions in body weight, BMI and waist-to-hip ratio were observed
      only in LGI group (P<0.05). Mean BMI changes were significantly different between
      groups (LGI vs. CHDR: -0.6 vs. 0 kg/m2, P= 0.03). More subjects achieved weight
      loss >/=5% in LGI compared to CHDR group (33% vs. 8%, P=0.01). Changes in 2HPP
      were significantly different between groups (LGI vs. CHDR: median (IQR):
      -0.2(2.8) vs. +0.8 (2.0) mmol/L, P=0.025). Subjects with baseline fasting
      insulin>/=2 muIU/ml had greater 2HPP reductions in LGI group compared to those in
      the CHDR group (-1.9+/-0.42 vs. +1.31+/-1.4 mmol/L, P<0.001). After 6 months, LGI
      group diets showed significantly lower GI (57+/-5 vs. 64+/-6, P<0.001), GL
      (122+/-33 vs. 142+/-35, P=0.04) and higher fibre content (17+/-4 vs.13+/-4 g,
      P<0.001). Caloric intakes were comparable between groups. CONCLUSION: In women
      post-GDM, lowering GI of healthy diets resulted in significant improvements in
      glucose tolerance and body weight reduction as compared to conventional low-fat
      diets with similar energy prescription.
AD  - School of Post Graduate Studies and Research, International Medical University,
      Kuala Lumpur, Malaysia. sangeeshyam@gmail.com.
FAU - Shyam, Sangeetha
AU  - Shyam S
FAU - Arshad, Fatimah
AU  - Arshad F
FAU - Abdul Ghani, Rohana
AU  - Abdul Ghani R
FAU - Wahab, Norasyikin A
AU  - Wahab NA
FAU - Safii, Nik Shanita
AU  - Safii NS
FAU - Nisak, Mohd Yusof Barakatun
AU  - Nisak MY
FAU - Chinna, Karuthan
AU  - Chinna K
FAU - Kamaruddin, Nor Azmi
AU  - Kamaruddin NA
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - England
TA  - Nutr J
JT  - Nutrition journal
JID - 101152213
SB  - IM
PMC - PMC3671161
OID - NLM: PMC3671161
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/12/10 [received]
PHST- 2013/05/15 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 1475-2891-12-68 [pii]
AID - 10.1186/1475-2891-12-68 [doi]
PST - epublish
SO  - Nutr J. 2013 May 24;12:68. doi: 10.1186/1475-2891-12-68.

PMID- 23705638
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 25
TI  - Forecasting future prevalence of type 2 diabetes mellitus in Syria.
PG  - 507
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is increasingly becoming a major
      public health problem worldwide. Estimating the future burden of diabetes is
      instrumental to guide the public health response to the epidemic. This study aims
      to project the prevalence of T2DM among adults in Syria over the period
      2003--2022 by applying a modelling approach to the country's own data. METHODS:
      Future prevalence of T2DM in Syria was estimated among adults aged 25 years and
      older for the period 2003--2022 using the IMPACT Diabetes Model (a discrete-state
      Markov model). RESULTS: According to our model, the prevalence of T2DM in Syria
      is projected to double in the period between 2003 and 2022 (from 10% to 21%). The
      projected increase in T2DM prevalence is higher in men (148%) than in women
      (93%). The increase in prevalence of T2DM is expected to be most marked in people
      younger than 55 years especially the 25--34 years age group. CONCLUSIONS: The
      future projections of T2DM in Syria put it amongst countries with the highest
      levels of T2DM worldwide. It is estimated that by 2022 approximately a fifth of
      the Syrian population aged 25 years and older will have T2DM.
FAU - Al Ali, Radwan
AU  - Al Ali R
FAU - Mzayek, Fawaz
AU  - Mzayek F
FAU - Rastam, Samer
AU  - Rastam S
FAU - M Fouad, Fouad
AU  - M Fouad F
FAU - O Flaherty, Martin
AU  - O Flaherty M
FAU - Capewell, Simon
AU  - Capewell S
FAU - Maziak, Wasim
AU  - Maziak W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130525
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
PMC - PMC3673829
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PHST- 2012/10/11 [received]
PHST- 2013/05/25 [accepted]
PHST- 2013/05/25 [aheadofprint]
AID - 1471-2458-13-507 [pii]
AID - 10.1186/1471-2458-13-507 [doi]
PST - aheadofprint
SO  - BMC Public Health. 2013 May 25;13(1):507.

PMID- 23705634
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 22
IP  - 6
DP  - 2013 Jun
TI  - Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes.
PG  - 751-63
LID - 10.1517/13543784.2013.802768 [doi]
AB  - Introduction: Some inhibitors of tyrosine kinase, as imatinib, erlotinib and
      sunitinib have antihyperglycemic effects but the mechanisms are not totally
      clear. Areas covered: It is well established that insulin resistance and
      beta-cell failure are hallmarks of type 2 diabetes mellitus (DM2). The present
      review will discuss the molecular mechanisms that account for insulin resistance 
      and beta-cell failure in DM2, and also the effect of tyrosine kinase inhibitors
      in these processes. Expert opinion: A better understanding of how these drugs
      improve the two most important mechanisms of DM2 associated with suggestions of
      clinical studies will lead to improve the treatment of this disease.
AD  - University of Campinas - UNICAMP, School of Applied Sciences , Limeira, SP,
      13484-350 , Brazil pprada@fcm.unicamp.br.
FAU - Prada, Patricia O
AU  - Prada PO
FAU - Saad, Mario Ja
AU  - Saad MJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - 10.1517/13543784.2013.802768 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2013 Jun;22(6):751-63. doi:
      10.1517/13543784.2013.802768.

PMID- 23705588
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
DP  - 2013 May 26
TI  - Interleukin-1 antagonists for diabetes.
AB  - Introduction: Diabetes is a currently incurable, epidemically growing global
      health concern. Contemporary symptomatic treatment targets acute and chronic
      metabolic consequences of relative or absolute insulin deficiency. Intensive
      multifactorial therapy is required to attenuate morbidity and mortality from late
      micro- and macrovascular complications, and despite current best clinical
      practice diabetes is still associated with shortened lifespan. There is an unmet 
      need for interventions targeting pathogenetic mechanisms in diabetes, and the
      market for such therapies is huge. Areas covered: Diabetes occurs when insulin
      secretion fails to meet tissue needs as a consequence of reduced functional
      beta-cell mass or reduced insulin sensitivity. Chronic inflammation contributes
      to beta-cell failure and insulin resistance. Molecular details are accumulating
      on the underlying cellular and molecular pathways. The testing of specific
      anti-inflammatory biologics targeting single pro-inflammatory cytokines has
      provided clinical proof-of-concept. Expert opinion: IL-1 antagonists have so far 
      failed to meet primary end points in recent-onset type 1 diabetes in Phase IIa,
      and promising Phase I and IIa trials in type 2 diabetes need confirmation in
      Phase III. The magnitude of response is variable and may relate to sub-phenotypes
      of these heterogeneous disorders. More studies are required to appreciate the
      potential of these drugs in diabetes.
AD  - University of Copenhagen, Panum Institute (12.2.10), Faculty of Health and
      Medical Sciences, Department of Biomedical Sciences, Section for Endocrinological
      Research , Blegdamsvej 3, DK-2200 Copenhagen N , Denmark.
FAU - Mandrup-Poulsen, Thomas
AU  - Mandrup-Poulsen T
CN  - on behalf of the AIDA study group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130526
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
AID - 10.1517/13543784.2013.804060 [doi]
PST - aheadofprint
SO  - Expert Opin Investig Drugs. 2013 May 26.

PMID- 23705556
OWN - NLM
STAT- In-Process
DA  - 20130527
IS  - 0001-5385 (Print)
IS  - 0001-5385 (Linking)
VI  - 68
IP  - 2
DP  - 2013 Apr
TI  - Heart rate variability and heart rate recovery in patients with type 1 diabetes
      mellitus.
PG  - 145-50
AB  - OBJECTIVE: Patients with diabetes mellitus (DM) are at an increased risk of
      sudden cardiac death (SCD) partly explained by cardiac autonomic neuropathy
      (CAN). There have been fewer studies to evaluate CAN using heart rate variability
      (HRV) and heart rate recovery (HRR) in patients with type 2 DM.To our knowledge, 
      there has been no study to investigate the association between HRR, HRV and type 
      1 DM. The purpose of this study was to examine the changes in HRR and HRV
      measurements in type 1 diabetic patients. METHODS: The study population consisted
      of 35 consecutive patients with type 1 diabetes and 35 sex- and age-matched
      non-diabetic controls. We performed electrocardiography, echocardiography, Holter
      analysis, exercise stress test, routine biochemical tests including haemoglobin
      Ale, high-sensitivity C-reactive protein and evaluated the clinical
      characteristics. HRR was calculated by subtracting the heart rate values at the
      first minute of the recovery phase from the peak heart rate. Abnormal HRR was
      defined as HRR < or = 18 beats.The HRV analysis was performed in both time domain
      and frequency domain. RESULTS: In HRV analysis, type 1 diabetic patients had
      significantly lower time domain [SDNN (P=0.041), SDANN (P=0.016), r-MSSD
      (P<0.001), pNN50 (P<0.001)] and frequency domain [total power (P=0.002), VLF
      (P<0.001), LF (P<0.001), HF (P=0.001), LF/HF (P=0.034)] HRV parameters as
      compared to controls. In logistic regression analysis, the HRR (OR 0.927, 95% CI 
      0.872 to 0.985, P= 0.014), METs (OR 0.562, 95% CI 0.355 to 0.890, P= 0.014),
      pNN50 (OR 0.729, 95% CI 0.566 to 0.941, P= 0.015) and HF (OR 0.952, 95% CI 0.911 
      to 0.994, P= 0.027) were independently associated with type 1 DM. CONCLUSION: The
      results of this study showed that HRV parameters and HRR were significantly
      reduced in patients with type 1 versus healthy controls. We found that HRV
      parameters correlated with HRR in type 1 diabetic patients. There is a
      relationship between CAN and inflammation and also, there may be a relationship
      between CAN and intensive glycaemic control according to this study.
AD  - Dept. of Cardiology, Faculty of Medicine, Duzce University, Duzce, Turkey.
      dryasinturker@hotmail.com
FAU - Turker, Yasin
AU  - Turker Y
FAU - Aslantas, Yusuf
AU  - Aslantas Y
FAU - Aydin, Yusuf
AU  - Aydin Y
FAU - Demirin, Hilmi
AU  - Demirin H
FAU - Kutlucan, Ali
AU  - Kutlucan A
FAU - Tibilli, Hakan
AU  - Tibilli H
FAU - Turker, Yasemin
AU  - Turker Y
FAU - Ozhan, Hakan
AU  - Ozhan H
LA  - eng
PT  - Journal Article
PL  - Belgium
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PST - ppublish
SO  - Acta Cardiol. 2013 Apr;68(2):145-50.

PMID- 23705521
OWN - NLM
STAT- In-Process
DA  - 20130527
IS  - 1934-4287 (Print)
IS  - 1934-4287 (Linking)
VI  - 24
IP  - 1
DP  - 2013 Apr
TI  - Updates in pediatric endocrinology.
PG  - 108-32, xii
AB  - There are rapid advances being made in the field of medicine! New research
      continues to investigate etiopathogenic mechanisms underlying many endocrine
      disorders, new tests to facilitate diagnosis, and newer treatment options. The
      discussion in this article focuses on a few of the important concerns in
      adolescent endocrinology and highlights some recent concepts that are important
      for the physicians taking care of these adolescents. This article also includes a
      brief update on diabetes mellitus types 1 and 2, obesity, and polycystic ovarian 
      syndrome; new thoughts and controversies about vitamin D and current management
      of the common thyroid disorders; adrenal insufficiency; and concerns with
      disorders of puberty in adolescents.
AD  - Wexner Medical Center at The Ohio State University, Section of Endocrinology,
      Metabolism and Diabetes, Nationwide Children's Hospital, 700 Children's Drive
      (ED425), Columbus, OH 43205, USA. Manmohan.Kamboj@Nationwidechildrens.org
FAU - Kamboj, Manmohan K
AU  - Kamboj MK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adolesc Med State Art Rev
JT  - Adolescent medicine: state of the art reviews
JID - 101314248
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PST - ppublish
SO  - Adolesc Med State Art Rev. 2013 Apr;24(1):108-32, xii.

PMID- 23705222
OWN - NLM
STAT- In-Process
DA  - 20130527
IS  - 1173-2032 (Print)
IS  - 1173-2032 (Linking)
VI  - 19
IP  - 3
DP  - 2013 Apr
TI  - Helping a teenager manage diabetes.
PG  - 36-8
AD  - Waikato Hospital.
FAU - Bennett, Sue
AU  - Bennett S
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Nurs N Z
JT  - Nursing New Zealand (Wellington, N.Z. : 1995)
JID - 9507374
SB  - N
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PST - ppublish
SO  - Nurs N Z. 2013 Apr;19(3):36-8.

PMID- 23705196
OWN - NLM
STAT- In-Process
DA  - 20130524
IS  - 0004-1254 (Print)
IS  - 0004-1254 (Linking)
VI  - 64
IP  - 1
DP  - 2013 Mar
TI  - Neurocognitive, mental health, and glucose disorders in farmers exposed to
      organophosphorus pesticides.
PG  - 1-8
AB  - About 25 million agricultural workers in the developing world suffer from at
      least one episode of poisoning each year, mainly by anticholinesterase-like
      organophosphates (OPs). The objective of this cross-sectional study was to
      establish the OP toxicity in 187 occupationally exposed farmers in terms of
      neurocognitive impairment, mental health status, clinical symptoms, diabetes, and
      haematological factors. The exposed group was compared to 187 healthy age-, sex-,
      and education-matching controls. Neurocognitive impairment was measured using the
      Subjective Neurocognition Inventory (SNI) and mental health status using the
      General Health Questionnaire-28 (GHQ-28). The subjects were also tested for
      fasting blood glucose (FBG), blood urea nitrogen (BUN), cholesterol (CL),
      triglycerides (TG), creatinine, oral glucose tolerance test (GTT), high-density
      lipoprotein (HDL), aspartate aminotransferase (AST), alanine aminotransferase
      (ALT), and alkaline phosphatase (ALP). The exposed farmers showed higher FBG
      (p<0.001), BUN (p=0.007), CL (p<0.001), oral GTT (p<0.001), and lower AST
      (p<0.001), ALP (p<0.001), and creatinine (p=0.004) than controls. The rates of
      anxiety/ insomnia and severe depression were also significantly higher in the
      farmers than in controls (p=0.015 and p<0.001, respectively). Meanwhile, the rate
      of social dysfunction was significantly lower than in controls (p<0.001).
      Disorders affecting psychomotor speed, selective attention, divided attention,
      verbal memory, nonverbal memory, prospective memory, spatial functioning, and
      initiative/energy were all lower in the farmers (p<0.001). Farmers showed
      clinical symptoms eczema, saliva secretion, fatigue, headache, sweating,
      abdominal pain, nausea, superior distal muscle weakness, inferior distal muscle
      weakness, inferior proximal muscle weakness, breath muscle weakness, hand
      tingling, foot tingling, epiphoria, polyuria, miosis, dyspnoea, bradycardia, and 
      rhinorrhoea, which all significantly correlated with the number of working years.
      These findings indicate that farmers who work with OPs are prone to
      neuropsychological disorders and diabetes.
AD  - Biology Department, Payame Noor University, Iran.
FAU - Malekirad, Ali Akbar
AU  - Malekirad AA
FAU - Faghih, Mahya
AU  - Faghih M
FAU - Mirabdollahi, Mansuoreh
AU  - Mirabdollahi M
FAU - Kiani, Mahdi
AU  - Kiani M
FAU - Fathi, Arezoo
AU  - Fathi A
FAU - Abdollahi, Mohammad
AU  - Abdollahi M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Croatia
TA  - Arh Hig Rada Toksikol
JT  - Arhiv za higijenu rada i toksikologiju
JID - 0373100
SB  - IM
EDAT- 2013/05/28 06:00
MHDA- 2013/05/28 06:00
CRDT- 2013/05/28 06:00
PST - ppublish
SO  - Arh Hig Rada Toksikol. 2013 Mar;64(1):1-8.

PMID- 23705058
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130524
DCOM- 20130527
LR  - 20130528
IS  - 2000-625X (Electronic)
IS  - 2000-625X (Linking)
VI  - 4
DP  - 2013
TI  - Etiology, pathophysiology and classifications of the diabetic Charcot foot.
LID - 10.3402/dfa.v4i0.20872 [doi]
AB  - In people with diabetes mellitus, the Charcot foot is a specific manifestation of
      peripheral neuropathy that may involve autonomic neuropathy with high blood flow 
      to the foot, leading to increased bone resorption. It may also involve peripheral
      somatic polyneuropathy with loss of protective sensation and high risk of
      unrecognized acute or chronic minor trauma. In both cases, there is excess local 
      inflammatory response to foot injury, resulting in local osteoporosis. In the
      Charcot foot, the acute and chronic phases have been described. The former is
      characterized by local erythema, edema, and marked temperature elevation, while
      pain is not a prominent symptom. In the latter, signs of inflammation gradually
      recede and deformities may develop, increasing the risk of foot ulceration. The
      most common anatomical classification describes five patterns, according to the
      localization of bone and joint pathology. This review article aims to provide a
      brief overview of the diabetic Charcot foot in terms of etiology,
      pathophysiology, and classification.
AD  - Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine,
      Democritus University of Thrace, Alexandroupolis, Greece.
FAU - Papanas, Nikolaos
AU  - Papanas N
FAU - Maltezos, Efstratios
AU  - Maltezos E
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - Sweden
TA  - Diabet Foot Ankle
JT  - Diabetic foot & ankle
JID - 101575215
PMC - PMC3661901
OID - NLM: PMC3661901
OTO - NOTNLM
OT  - Charcot foot
OT  - classification
OT  - diabetes mellitus
OT  - diabetic foot
OT  - neuropathy
OT  - osteoarthropathy
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:01
CRDT- 2013/05/25 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/17 [received]
PHST- 2013/04/18 [revised]
PHST- 2013/04/25 [accepted]
PHST- 2013/05/21 [epublish]
AID - 10.3402/dfa.v4i0.20872 [doi]
AID - 20872 [pii]
PST - epublish
SO  - Diabet Foot Ankle. 2013 May 21;4. doi: 10.3402/dfa.v4i0.20872. Print 2013.

PMID- 23705057
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130524
DCOM- 20130527
LR  - 20130528
IS  - 2000-625X (Electronic)
IS  - 2000-625X (Linking)
VI  - 4
DP  - 2013
TI  - Pressure pain perception in the diabetic Charcot foot: facts and hypotheses.
LID - 10.3402/dfa.v4i0.20981 [doi]
AB  - BACKGROUND: Reduced traumatic and posttraumatic (nociceptive) pain is a key
      feature of diabetic neuropathy. Underlying condition is a gradual degeneration of
      endings of pain nerves (A-delta fibers and C-fibers), which operate as receivers 
      of noxious stimuli (nociceptors). Hence, the absence of A-delta fiber mediated
      sharp pain ("first" pain), and of C-fiber mediated dull pain ("second" pain).
      However, patients with diabetic neuropathy and acute Charcot foot often
      experience deep dull aching in the Charcot foot while walking on it. AIM: To
      create a unifying hypothesis on the kind of pain in an acute Charcot foot.
      RESULT: Absence of punctuate (pinprick) pain perception at the sole of a Charcot 
      foot, as was shown recently, likely corresponds to vanished intraepidermal
      A-delta fiber endings. C-fiber nociceptors are reduced, according to
      histopathology studies. Both types of fibers contribute to posttraumatic
      hyperalgesia at the skin level, as studies show. Their deficiencies likely impact
      on posttraumatic hyperalgesia at the skin level and, probably, also at the
      skeletal level. CONCLUSION: It is hypothesised that deep dull aching in an acute 
      diabetic Charcot foot may represent faulty posttraumatic hyperalgesia involving
      cutaneous and skeletal tissues.
AD  - Diabetic Foot Clinic, Department of Endocrinology and Diabetes, Heinrich Heine
      University of Dusseldorf, Dusseldorf, Germany.
FAU - Chantelau, Ernst A
AU  - Chantelau EA
FAU - Wienemann, Tobias
AU  - Wienemann T
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - Sweden
TA  - Diabet Foot Ankle
JT  - Diabetic foot & ankle
JID - 101575215
PMC - PMC3661900
OID - NLM: PMC3661900
OTO - NOTNLM
OT  - Charcot neuroarthropathy
OT  - diabetic neuropathy
OT  - pain perception
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:01
CRDT- 2013/05/25 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/27 [received]
PHST- 2013/04/17 [revised]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/21 [epublish]
AID - 10.3402/dfa.v4i0.20981 [doi]
AID - 20981 [pii]
PST - epublish
SO  - Diabet Foot Ankle. 2013 May 21;4. doi: 10.3402/dfa.v4i0.20981. Print 2013.

PMID- 23705021
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Nov/Ccn3, a Novel Transcriptional Target of FoxO1, Impairs Pancreatic beta-Cell
      Function.
PG  - e64957
LID - 10.1371/journal.pone.0064957 [doi]
AB  - Type 2 diabetes is characterized by both insulin resistance and progressive
      deterioration of beta-cell function. The forkhead transcription factor FoxO1 is a
      prominent mediator of insulin signaling in beta-cells. We reasoned that
      identification of FoxO1 target genes in beta-cells could reveal mechanisms
      linking beta-cell dysfunction to insulin resistance. In this study, we report the
      characterization of Nov/Ccn3 as a novel transcriptional target of FoxO1 in
      pancreatic beta-cells. FoxO1 binds to an evolutionarily conserved response
      element in the Ccn3 promoter to regulate its expression. Accordingly, CCN3 levels
      are elevated in pancreatic islets of mice with overexpression of a constitutively
      active form of FoxO1 or insulin resistance. Our functional studies reveal that
      CCN3 impairs beta-cell proliferation concomitantly with a reduction in cAMP
      levels. Moreover, CCN3 decreases glucose oxidation, which translates into
      inhibition of glucose-stimulated Ca(2+) entry and insulin secretion. Our results 
      identify CCN3, a novel transcriptional target of FoxO1 in pancreatic beta-cells, 
      as a potential target for therapeutic intervention in the treatment of diabetes.
AD  - Department of Medicine, Universite Laval, Quebec, Canada.
FAU - Paradis, Renee
AU  - Paradis R
FAU - Lazar, Noureddine
AU  - Lazar N
FAU - Antinozzi, Peter
AU  - Antinozzi P
FAU - Perbal, Bernard
AU  - Perbal B
FAU - Buteau, Jean
AU  - Buteau J
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3660386
OID - NLM: PMC3660386
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013 [ppublish]
PHST- 2012/07/30 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/05/21 [epublish]
AID - 10.1371/journal.pone.0064957 [doi]
AID - PONE-D-12-22680 [pii]
PST - epublish
SO  - PLoS One. 2013 May 21;8(5):e64957. doi: 10.1371/journal.pone.0064957. Print 2013.

PMID- 23704975
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Protection against Myocardial Ischemia-Reperfusion Injury at Onset of Type 2
      Diabetes in Zucker Diabetic Fatty Rats Is Associated with Altered Glucose
      Oxidation.
PG  - e64093
LID - 10.1371/journal.pone.0064093 [doi]
AB  - BACKGROUND: Inhibition of glucose oxidation during initial reperfusion confers
      protection against ischemia-reperfusion (IR) injury in the heart. Mitochondrial
      metabolism is altered with progression of type 2 diabetes (T2DM). We hypothesized
      that the metabolic alterations present at onset of T2DM induce cardioprotection
      by metabolic shutdown during IR, and that chronic alterations seen in late T2DM
      cause increased IR injury. METHODS: Isolated perfused hearts from 6
      (prediabetic), 12 (onset of T2DM) and 24 (late T2DM) weeks old male Zucker
      diabetic fatty rats (ZDF) and their age-matched heterozygote controls were
      subjected to 40 min ischemia/120 min reperfusion. IR injury was assessed by
      TTC-staining. Myocardial glucose metabolism was evaluated by glucose tracer
      kinetics (glucose uptake-, glycolysis- and glucose oxidation rates), myocardial
      microdialysis (metabolomics) and tissue glycogen measurements. RESULTS: T2DM
      altered the development in sensitivity towards IR injury compared to controls. At
      late diabetes ZDF hearts suffered increased damage, while injury was decreased at
      onset of T2DM. Coincident with cardioprotection, oxidation of exogenous glucose
      was decreased during the initial and normalized after 5 minutes of reperfusion.
      Metabolomic analysis of citric acid cycle intermediates demonstrated that
      cardioprotection was associated with a reversible shutdown of mitochondrial
      glucose metabolism during ischemia and early reperfusion at onset of but not at
      late type 2 diabetes. CONCLUSIONS: The metabolic alterations of type 2 diabetes
      are associated with protection against IR injury at onset but detrimental effects
      in late diabetes mellitus consistent with progressive dysfunction of glucose
      oxidation. These findings may explain the variable efficacy of cardioprotective
      interventions in individuals with type 2 diabetes.
AD  - Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus N, Denmark ;
      Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
FAU - Povlsen, Jonas Agerlund
AU  - Povlsen JA
FAU - Lofgren, Bo
AU  - Lofgren B
FAU - Dalgas, Christian
AU  - Dalgas C
FAU - Birkler, Rune Isak Dupont
AU  - Birkler RI
FAU - Johannsen, Mogens
AU  - Johannsen M
FAU - Stottrup, Nicolaj Brejnholt
AU  - Stottrup NB
FAU - Botker, Hans Erik
AU  - Botker HE
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3660588
OID - NLM: PMC3660588
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/29 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/05/21 [epublish]
AID - 10.1371/journal.pone.0064093 [doi]
AID - PONE-D-13-04385 [pii]
PST - epublish
SO  - PLoS One. 2013 May 21;8(5):e64093. doi: 10.1371/journal.pone.0064093. Print 2013.

PMID- 23704966
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Effect of lipopolysaccharide on inflammation and insulin action in human muscle.
PG  - e63983
LID - 10.1371/journal.pone.0063983 [doi]
AB  - Accumulating evidence from animal studies suggest that chronic elevation of
      circulating intestinal-generated lipopolysaccharide (LPS) (i.e., metabolic
      endotoxemia) could play a role in the pathogenesis of insulin resistance.
      However, the effect of LPS in human muscle is unclear. Moreover, it is unknown
      whether blockade/down regulation of toll-like receptor (TLR)4 can prevent the
      effect of LPS on insulin action and glucose metabolism in human muscle cells. In 
      the present study we compared plasma LPS concentration in insulin resistant
      [obese non-diabetic and obese type 2 diabetic (T2DM)] subjects versus lean
      individuals. In addition, we employed a primary human skeletal muscle cell
      culture system to investigate the effect of LPS on glucose metabolism and whether
      these effects are mediated via TLR4. Obese non-diabetic and T2DM subjects had
      significantly elevated plasma LPS and LPS binding protein (LBP) concentrations.
      Plasma LPS (r = -0.46, P = 0.005) and LBP (r = -0.49, P = 0.005) concentrations
      negatively correlated with muscle insulin sensitivity (M). In human myotubes, LPS
      increased JNK phosphorylation and MCP-1 and IL-6 gene expression. This
      inflammatory response led to reduced insulin-stimulated IRS-1, Akt and AS160
      phosphorylation and impaired glucose transport. Both pharmacologic blockade of
      TLR4 with TAK-242, and TLR4 gene silencing, suppressed the inflammatory response 
      and insulin resistance caused by LPS in human muscle cells. Taken together, these
      findings suggest that elevations in plasma LPS concentration found in obese and
      T2DM subjects could play a role in the pathogenesis of insulin resistance and
      that antagonists of TLR4 may improve insulin action in these individuals.
AD  - Department of Medicine-Diabetes Division, University of Texas Health Science
      Center, San Antonio, Texas, United States of America ; Geriatric Research
      Education and Clinical Center, South Texas Veterans Health Care System, Audie L. 
      Murphy Division, San Antonio, Texas, United States of America ; Texas Diabetes
      Institute, San Antonio, Texas, United States of America.
FAU - Liang, Hanyu
AU  - Liang H
FAU - Hussey, Sophie E
AU  - Hussey SE
FAU - Sanchez-Avila, Alicia
AU  - Sanchez-Avila A
FAU - Tantiwong, Puntip
AU  - Tantiwong P
FAU - Musi, Nicolas
AU  - Musi N
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3660322
OID - NLM: PMC3660322
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/03 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/05/21 [epublish]
AID - 10.1371/journal.pone.0063983 [doi]
AID - PONE-D-12-37717 [pii]
PST - epublish
SO  - PLoS One. 2013 May 21;8(5):e63983. doi: 10.1371/journal.pone.0063983. Print 2013.

PMID- 23704946
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - High-Throughput Screening for GPR119 Modulators Identifies a Novel Compound with 
      Anti-Diabetic Efficacy in db/db Mice.
PG  - e63861
LID - 10.1371/journal.pone.0063861 [doi]
AB  - G protein-coupled receptor 119 (GPR119) is highly expressed in pancreatic beta
      cells and enteroendocrine cells. It is involved in glucose-stimulated insulin
      secretion and glucagon-like peptide-1 (GLP-1) release, thereby representing a
      promising target for the treatment of type 2 diabetes. Although a number of
      GPR119 agonists were developed, no positive allosteric modulator (PAM) to this
      receptor has been reported. Here we describe a high-throughput assay for
      screening GPR119 PAMs and agonists simultaneously. Following screening of a small
      molecule compound library containing 312,000 synthetic and natural
      product-derived samples, one potent GPR119 agonist with novel chemical structure,
      MW1219, was identified. Exposure of MIN6 and GLUTag cells to MW1219 enhanced
      glucose-stimulated insulin secretion and GLP-1 release; once-daily oral dosing of
      MW1219 for 6 weeks in diabetic db/db mice reduced hemoglobin A1c (HbA1c) and
      improved plasma glucose, insulin and GLP-1 levels; it also increased glucose
      tolerance. The results demonstrate that MW1219 is capable of effectively
      controlling blood glucose level and may have the potential to be developed as a
      new class of anti-diabetic agents.
AD  - The National Center for Drug Screening, State Key Laboratory of Drug Research,
      Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai,
      China.
FAU - Zhang, Meng
AU  - Zhang M
FAU - Feng, Yang
AU  - Feng Y
FAU - Wang, Jia
AU  - Wang J
FAU - Zhao, Jianwei
AU  - Zhao J
FAU - Li, Ting
AU  - Li T
FAU - He, Min
AU  - He M
FAU - Yang, Dehua
AU  - Yang D
FAU - Nosjean, Olivier
AU  - Nosjean O
FAU - Boutin, Jean
AU  - Boutin J
FAU - Renard, Pierre
AU  - Renard P
FAU - Wang, Ming-Wei
AU  - Wang MW
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3660563
OID - NLM: PMC3660563
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/23 [received]
PHST- 2013/04/06 [accepted]
PHST- 2013/05/21 [epublish]
AID - 10.1371/journal.pone.0063861 [doi]
AID - PONE-D-13-04051 [pii]
PST - epublish
SO  - PLoS One. 2013 May 21;8(5):e63861. doi: 10.1371/journal.pone.0063861. Print 2013.

PMID- 23704916
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - A Bispecific Protein Capable of Engaging CTLA-4 and MHCII Protects Non-Obese
      Diabetic Mice from Autoimmune Diabetes.
PG  - e63530
LID - 10.1371/journal.pone.0063530 [doi]
AB  - Crosslinking ligand-engaged cytotoxic T lymphocyte antigen-4 (CTLA-4) to the T
      cell receptor (TCR) with a bispecific fusion protein (BsB) comprised of a mutant 
      mouse CD80 and lymphocyte activation antigen-3 (LAG-3) has been shown to
      attenuate TCR signaling and to direct T-cell differentiation toward Foxp3(+)
      regulatory T cells (Tregs) in an allogenic mixed lymphocyte reaction (MLR). Here,
      we show that antigen-specific Tregs can also be induced in an antigen-specific
      setting in vitro. Treatment of non-obese diabetic (NOD) female mice between 9-12 
      weeks of age with a short course of BsB elicited a transient increase of Tregs in
      the blood and moderately delayed the onset of autoimmune type 1 diabetes (T1D).
      However, a longer course of treatment (10 weeks) of 4-13 weeks-old female NOD
      animals with BsB significantly delayed the onset of disease or protected animals 
      from developing diabetes, with only 13% of treated animals developing diabetes by
      35 weeks of age compared to 80% of the animals in the control group.
      Histopathological analysis of the pancreata of the BsB-treated mice that remained
      non-diabetic revealed the preservation of insulin-producing beta-cells despite
      the presence of different degrees of insulitis. Thus, a bifunctional protein
      capable of engaging CTLA-4 and MHCII and indirectly co-ligating CTLA-4 to the TCR
      protected NOD mice from developing T1D.
AD  - Genzyme, a Sanofi Company, Framingham, Massachusetts, United States of America.
FAU - Zhao, Hongmei
AU  - Zhao H
FAU - Karman, Jozsef
AU  - Karman J
FAU - Jiang, Ji-Lei
AU  - Jiang JL
FAU - Zhang, Jinhua
AU  - Zhang J
FAU - Gumlaw, Nathan
AU  - Gumlaw N
FAU - Lydon, John
AU  - Lydon J
FAU - Zhou, Qun
AU  - Zhou Q
FAU - Qiu, Huawei
AU  - Qiu H
FAU - Jiang, Canwen
AU  - Jiang C
FAU - Cheng, Seng H
AU  - Cheng SH
FAU - Zhu, Yunxiang
AU  - Zhu Y
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3660570
OID - NLM: PMC3660570
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/29 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/05/21 [epublish]
AID - 10.1371/journal.pone.0063530 [doi]
AID - PONE-D-12-37426 [pii]
PST - epublish
SO  - PLoS One. 2013 May 21;8(5):e63530. doi: 10.1371/journal.pone.0063530. Print 2013.

PMID- 23704847
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1552-5775 (Electronic)
IS  - 1552-5767 (Linking)
VI  - 17
IP  - 2
DP  - 2013 Spring
TI  - Understanding the social factors that contribute to diabetes: a means to
      informing health care and social policies for the chronically ill.
PG  - 67-72
LID - 10.7812/TPP/12-099 [doi]
AB  - Social determinants of health are the conditions in which individuals are born,
      grow, live, work, and age. Increasingly, they are being recognized for their
      relationship to the soaring incidence of Type 2 diabetes in the US, as well as
      the opportunities they present for us to counter it. Many current Type 2 diabetes
      interventions focus on biologic and behavioral factors, such as symptoms, diet,
      and physical activity. However, it is equally important to address the influence 
      of physical and social environments, which may include low income, employment
      insecurity, low educational attainment, and poor living conditions, on health
      outcomes. Section 4302 of the Patient Protection and Affordable Care Act of 2010 
      offers an opportunity to improve data collection and policy development to more
      effectively identify populations at high risk for developing Type 2 diabetes and 
      to proactively refer them to appropriate social support services that may
      ultimately support reduction of health disparities. Expanding the scope of this
      legislation to include data that incorporate social determinants would improve
      the ability of clinicians and health systems to engage and to treat patients with
      chronic conditions, such as Type 2 diabetes, while expanding policymakers'
      ability to conform to the legislation's intent of shaping efforts to reduce
      chronic conditions nationwide.
AD  - Director of Clinical Research in the Department of Radiology and a Doctoral
      Student in the Department of Health Policy and Management at the University of
      Kansas Medical Center in Kansas City. E-mail: jhill6@kumc.edu .
FAU - Hill, Jacqueline
AU  - Hill J
FAU - Nielsen, Marcia
AU  - Nielsen M
FAU - Fox, Michael H
AU  - Fox MH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perm J
JT  - The Permanente journal
JID - 9800474
SB  - IM
PMC - PMC3662286
OID - NLM: PMC3662286
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.7812/TPP/12-099 [doi]
AID - permj17_2p0067 [pii]
PST - ppublish
SO  - Perm J. 2013 Spring;17(2):67-72. doi: 10.7812/TPP/12-099.

PMID- 23704846
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1552-5775 (Electronic)
IS  - 1552-5767 (Linking)
VI  - 17
IP  - 2
DP  - 2013 Spring
TI  - Nutritional update for physicians: plant-based diets.
PG  - 61-6
LID - 10.7812/TPP/12-085 [doi]
AB  - The objective of this article is to present to physicians an update on
      plant-based diets. Concerns about the rising cost of health care are being voiced
      nationwide, even as unhealthy lifestyles are contributing to the spread of
      obesity, diabetes, and cardiovascular disease. For these reasons, physicians
      looking for cost-effective interventions to improve health outcomes are becoming 
      more involved in helping their patients adopt healthier lifestyles. Healthy
      eating may be best achieved with a plant-based diet, which we define as a regimen
      that encourages whole, plant-based foods and discourages meats, dairy products,
      and eggs as well as all refined and processed foods. We present a case study as
      an example of the potential health benefits of such a diet. Research shows that
      plant-based diets are cost-effective, low-risk interventions that may lower body 
      mass index, blood pressure, HbA1C, and cholesterol levels. They may also reduce
      the number of medications needed to treat chronic diseases and lower ischemic
      heart disease mortality rates. Physicians should consider recommending a
      plant-based diet to all their patients, especially those with high blood
      pressure, diabetes, cardiovascular disease, or obesity.
AD  - Regional Co-Lead for the Complete Care Program of the Southern California
      Permanente Medical Group and the National Physician Lead for the Care Management 
      Institute's Total Health Program. E-mail: phillip.j.tuso@kp.org .
FAU - Tuso, Philip J
AU  - Tuso PJ
FAU - Ismail, Mohamed H
AU  - Ismail MH
FAU - Ha, Benjamin P
AU  - Ha BP
FAU - Bartolotto, Carole
AU  - Bartolotto C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perm J
JT  - The Permanente journal
JID - 9800474
SB  - IM
PMC - PMC3662288
OID - NLM: PMC3662288
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.7812/TPP/12-085 [doi]
AID - permj17_2p0061 [pii]
PST - ppublish
SO  - Perm J. 2013 Spring;17(2):61-6. doi: 10.7812/TPP/12-085.

PMID- 23704841
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1552-5775 (Electronic)
IS  - 1552-5767 (Linking)
VI  - 17
IP  - 2
DP  - 2013 Spring
TI  - Epidemiology of diabetic foot infections in an eastern Caribbean population: a
      prospective study.
PG  - 37-40
LID - 10.7812/TPP/12-126 [doi]
AB  - INTRODUCTION: This study evaluates the epidemiology of diabetic foot infections
      in an Eastern Caribbean nation in order to direct public health preventive
      measures. METHODS: We prospectively identified all patients with diabetic foot
      infections who were admitted to tertiary care hospitals across Trinidad and
      Tobago from July 2011 to June 2012. A questionnaire was used to collect data on
      demographics, patient knowledge, avoidance of risk factors for chronic diseases
      (a proxy to unhealthy lifestyles), and glycosylated hemoglobin measurements on
      admission as an index of blood glucose control. The data were analyzed with
      statistical software. RESULTS: There were 446 patients with diabetic foot
      infections (mean age = 56.9 years, standard deviation = 12.4 years). Most
      patients had Type 2 diabetes (93.3%) and were of Indo-Trinidadian (49.1%) or
      Afro-Trinidadian (41.7%) descent. There were preexisting complications of
      diabetes in 82.9% of patients with Type 2 diabetes: foot infections requiring
      hospitalization (70.2%), ischemic heart disease (32.5%), renal impairment
      (13.7%), and retinopathy (22.1%). Despite most patients claiming compliance with 
      treatment, 75% had glycosylated hemoglobin levels above 7.1% at presentation, and
      49.3% continued unhealthy lifestyles. Despite the high prevalence of diabetic
      complications at admission, and despite 70% having had previous hospitalization
      for treatment of foot infections, only 57.4% of patients reported ever being
      counseled or taught about foot care by medical personnel. CONCLUSIONS: There is
      room for improvement in public health strategies to prevent diabetic foot
      complications in this setting. Such strategies should focus on patient education 
      with emphasis on lifestyle modification and compliance with medical therapy.
AD  - Resident in the Department of Surgery at the University of West Indies in San
      Fernando, Trinidad and Tobago. E-mail: ssI201190@yahoo.com .
FAU - Islam, Shariful
AU  - Islam S
FAU - Harnarayan, Patrick
AU  - Harnarayan P
FAU - Cawich, Shamir O
AU  - Cawich SO
FAU - Budhooram, Steve
AU  - Budhooram S
FAU - Bheem, Vinoo
AU  - Bheem V
FAU - Mahabir, Vijai
AU  - Mahabir V
FAU - Ramsewak, Shiva
AU  - Ramsewak S
FAU - Aziz, Imran
AU  - Aziz I
FAU - Naraynsingh, Vijay
AU  - Naraynsingh V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perm J
JT  - The Permanente journal
JID - 9800474
SB  - IM
PMC - PMC3662275
OID - NLM: PMC3662275
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.7812/TPP/12-126 [doi]
AID - permj17_2p0037 [pii]
PST - ppublish
SO  - Perm J. 2013 Spring;17(2):37-40. doi: 10.7812/TPP/12-126.

PMID- 23704837
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1552-5775 (Electronic)
IS  - 1552-5767 (Linking)
VI  - 17
IP  - 2
DP  - 2013 Spring
TI  - Analysis of Mitral Valve Replacement Outcomes is Enhanced by Meaningful Clinical 
      Use of Electronic Health Records.
PG  - 12-6
LID - 10.7812/TPP/12-113 [doi]
AB  - OBJECTIVE: Cardiac surgical mortality has improved during the last decade despite
      the aging of the population. An integrated US health plan developed a heart valve
      registry to track outcomes and complications of heart valve operations. This
      database was used for longitudinal evaluation of mitral valve (MV) outcomes from 
      1999 to 2008 at four affiliated hospitals. METHODS: We identified 3130 patients
      in the Apollo database who underwent 3180 initial MV procedures. Internal
      administrative and Social Security Administration databases were merged to
      determine survival rates. Electronic health records were searched to ascertain
      demographics, comorbidities, and postoperative complications. Cox regression was 
      used to evaluate mean survival and identify risk factors. RESULTS: The procedures
      included 1160 mechanical valve replacements, 1159 tissue valve replacements, and 
      861 annuloplasties. The mean age of patients undergoing these procedures was 58
      +/- 11 years, 69 +/- 12 years, and 62 +/- 12 years, respectively. Mean survival
      was 8.9 +/- 0.1 years for mechanical valve replacement, 7.0 +/- 0.1 years for
      tissue valve replacement, and 7.7 +/- 0.1 years for annuloplasty. Early in the
      study, there was a preference for implanting mechanical MVs. Beginning in 2003,
      more patients received tissue valve replacements rather than mechanical valves.
      Over time, there was an increasing trend of annuloplasty. Cox regression analysis
      identified the following risk factors for increased ten-year mortality: tissue
      valve implantation; advanced age; female sex; nonelective, nonisolated procedure;
      diabetes; postoperative use of banked blood products; previous cardiovascular
      intervention; dialysis; and longer perfusion time. Hospital location,
      reoperation, preoperative anticoagulation, and cardiogenic shock were not
      statistically significant risk factors. CONCLUSIONS: When controlling for other
      risk factors, we observed a lower long-term survival rate for tissue valve
      replacement compared with mechanical valve replacement. Integrating electronic
      health records with existing electronic databases provided near-real-time
      analysis of longitudinal cardiac surgical outcomes.
AD  - Cardiothoracic Surgeon at the Honolulu Medical Center in HI. E-mail:
      john.c.chen@kp.org .
FAU - Chen, John C
AU  - Chen JC
FAU - Pfeffer, Thomas
AU  - Pfeffer T
FAU - Johnstone, Shelley
AU  - Johnstone S
FAU - Chen, Yuexin
AU  - Chen Y
FAU - Kiley, Mary-Lou
AU  - Kiley ML
FAU - Richter, Richard
AU  - Richter R
FAU - Lee, Hon
AU  - Lee H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Perm J
JT  - The Permanente journal
JID - 9800474
SB  - IM
PMC - PMC3662282
OID - NLM: PMC3662282
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.7812/TPP/12-113 [doi]
AID - permj17_2p0012 [pii]
PST - ppublish
SO  - Perm J. 2013 Spring;17(2):12-6. doi: 10.7812/TPP/12-113.

PMID- 23704830
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 19
DP  - 2013 May 21
TI  - Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA
      expression in newly diagnosed diabetes subclinical vascular lesions.
PG  - 2963-8
LID - 10.3748/wjg.v19.i19.2963 [doi]
AB  - AIM: To investigate the effect of Danzhijiangtang capsule (DJC) on monocyte
      chemoattractant protein-1 (MCP-1) mRNA expression in newly diagnosed type 2
      diabetes mellitus (T2DM) subclinical vascular lesions. METHODS: Sixty-two
      patients with newly diagnosed T2DM subclinical vascular lesions were randomly
      divided into a control group and treatment group of 31 cases each. Oral
      antidiabetic therapy with routine western medicine was conducted in both groups, 
      and the treatment group was additionally treated with DJCs. The treatment course 
      for both groups was 12 wk. Before and after treatment, the total efficiency and
      traditional Chinese medicine (TCM) syndrome score were calculated. The fasting
      plasma glucose (FPG), 2-h plasma glucose (2hPG), fasting insulin (FINS), insulin 
      resistance index (IRI), hemoglobin (Hb)A1c, blood lipids, and hemorheology
      indices were determined. In addition, the levels of vascular endothelial growth
      factors including thrombomodulin (TM), von Willebrand factor (vWF), P-selectin
      and MCP-1 mRNA were determined. RESULTS: After 12 wk of treatment, the TCM
      syndrome score was significantly decreased compared to before treatment in both
      groups. After treatment, FPG, 2hPG, HbA1c, FINS, IRI, total cholesterol,
      triglycerides, low-density lipoprotein, high-density lipoprotein, whole blood low
      shear specific viscosity, plasma specific viscosity, TM, vWF, P-selectin and
      MCP-1 mRNA were significantly improved compared to before treatment in both
      groups. After treatment, the total efficiency and TCM syndrome score in the
      treatment group were better than in the control group. FINS, IRI, whole blood
      high shear specific viscosity, plasma specific viscosity, TM, vWF, P-selectin and
      MCP-1 mRNA level in the treatment group were significantly reduced after
      treatment compared with control group. CONCLUSION: DJCs are efficacious in
      supplementing qi, nourishing yin and invigorating blood circulation, and
      upregulate MCP-1 mRNA expression in patients with T2DM subclinical vascular
      lesions.
AD  - Zhao-Hui Fang, Yan Liu, Tao-Tao Bao, Ying-Qun Ni, Jian Liu, Guo-Bin Shi, Ji-Ping 
      Wu, Department of Endocrinology, the First Affiliated Hospital of Anhui College
      of Traditional Chinese Medicine, Hefei 230031, Anhui Province, China.
FAU - Fang, Zhao-Hui
AU  - Fang ZH
FAU - Liu, Yan
AU  - Liu Y
FAU - Bao, Tao-Tao
AU  - Bao TT
FAU - Ni, Ying-Qun
AU  - Ni YQ
FAU - Liu, Jian
AU  - Liu J
FAU - Shi, Guo-Bin
AU  - Shi GB
FAU - Wu, Ji-Ping
AU  - Wu JP
FAU - Yang, Jun-Ping
AU  - Yang JP
FAU - Zhang, Hong
AU  - Zhang H
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Gastroenterol
JT  - World journal of gastroenterology : WJG
JID - 100883448
SB  - IM
PMC - PMC3660822
OID - NLM: PMC3660822
OTO - NOTNLM
OT  - Danzhijiangtang capsule
OT  - Monocyte chemoattractant protein-1
OT  - Subclinical vascular lesions
OT  - Type 2 diabetes mellitus
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/12/25 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/02/28 [accepted]
AID - 10.3748/wjg.v19.i19.2963 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 May 21;19(19):2963-8. doi: 10.3748/wjg.v19.i19.2963.

PMID- 23704715
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
DP  - 2013 May 23
TI  - Nocturnal intermittent hypoxia as an associated risk factor for microalbuminuria 
      in Japanese patients with type 2 diabetes mellitus.
AB  - OBJECTIVEWE ESTIMATED THE PREVALENCE OF NOCTURNAL INTERMITTENT HYPOXIA, A
      SURROGATE MARKER OF OBSTRUCTIVE SLEEP APNOEA, AMONG TYPE 2 DIABETES MELLITUS
      (T2DM) PATIENTS, AND EXAMINED THE ASSOCIATION BETWEEN NOCTURNAL INTERMITTENT
      HYPOXIA AND MICROVASCULAR DISEASES.DESIGN AND METHODSWE RECRUITED 513 JAPANESE
      PATIENTS (292 MEN, 221 WOMEN) WITH T2DM. NOCTURNAL INTERMITTENT HYPOXIA WAS
      DIAGNOSED USING THE 3% OXYGEN DESATURATION INDEX (ODI), WITH 5 EVENTS/H
      CORRESPONDING TO NORMAL, AND 5 EVENTS/H CORRESPONDING TO NOCTURNAL INTERMITTENT
      HYPOXIA.RESULTSTHE PREVALENCE OF NOCTURNAL INTERMITTENT HYPOXIA WAS 45.4% AMONG
      T2DM PATIENTS. THE NOCTURNAL INTERMITTENT HYPOXIA GROUP WAS OLDER, HAD A HIGHER
      BMI, GREATER WEIGHT CHANGE SINCE THE AGE OF 20 YEARS, HIGHER SMOKING RATE, AND
      INCREASED PREVALENCE OF HYPERTENSION, HYPERLIPIDAEMIA, MICROALBUMINURIA, AND
      MACROALBUMINURIA. MICROALBUMINURIA (MODEL 1: OR, 3.41; 95% CI, 1.85-6.40; model
      2: OR, 3.69; 95% CI, 1.85-7.59; model 3: OR, 3.12; 95% CI, 1.45-6.95) and
      nephropathy (model 1: OR, 3.12; 95% CI, 1.45-6.95; model 2: OR, 7.31; 95% CI,
      2.11-31.6; model 3: OR, 5.23; 95% CI, 1.45-23.8) were derived as factors from all
      3 statistical models and constantly associated with nocturnal intermittent
      hypoxia only in women.ConclusionsNocturnal intermittent hypoxia was highly
      prevalent among T2DM patients, and may be an independent associated risk factor
      for microalbuminuria in Japanese women with T2DM.
AD  - S Furukawa, Department of Gastroenterology and Metabology, Ehime University
      Graduate School of Medicine, Toon, Japan.
FAU - Furukawa, Shinya
AU  - Furukawa S
FAU - Saito, Isao
AU  - Saito I
FAU - Yamamoto, Shin
AU  - Yamamoto S
FAU - Miyake, Teruki
AU  - Miyake T
FAU - Ueda, Teruhisa
AU  - Ueda T
FAU - Niiya, Tetsuji
AU  - Niiya T
FAU - Torisu, Masamoto
AU  - Torisu M
FAU - Kumagi, Teru
AU  - Kumagi T
FAU - Sakai, Takenori
AU  - Sakai T
FAU - Minami, Hisaka
AU  - Minami H
FAU - Miyaoka, Hiroaki
AU  - Miyaoka H
FAU - Sakurai, Susumu
AU  - Sakurai S
FAU - Matsuura, Bunzo
AU  - Matsuura B
FAU - Onji, Morikazu
AU  - Onji M
FAU - Tanigawa, Takeshi
AU  - Tanigawa T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - EJE-13-0086 [pii]
AID - 10.1530/EJE-13-0086 [doi]
PST - aheadofprint
SO  - Eur J Endocrinol. 2013 May 23.

PMID- 23704713
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
DP  - 2013 May 23
TI  - Characterization of oral and intravenous glucose handling in truncally
      vagotomised subjects with pyloroplasty.
AB  - OBJECTIVE: Glucagon-like peptide-1 (GLP-1) is rapidly inactivated by dipeptidyl
      peptidase 4, but may interact with vagal neurons at its site of secretion. We
      investigated the role of vagal innervation for handling of oral and iv glucose.
      Design and methods: Truncally vagotomised subjects (n=16) and matched controls
      (n=10) underwent 50g oral glucose tolerance test (OGTT)+/-vildagliptin, a DPP-4
      inhibitor (DPP-4i) and isoglycaemic iv glucose infusion (IIGI) copying the OGTT
      without DPP-4i. Results: Isoglycaemia was obtained with 25+/-2 g glucose in
      vagotomised subjects and 18+/-2 g in controls (P<0.03); thus,
      gastrointestinal-mediated glucose disposal (GIGD) - a measure of glucose handling
      [100% x (glucoseOGTT - glucoseIIGI/glucoseOGTT)], was reduced in the vagotomised 
      compared to the control group. Peak intact GLP-1 concentrations were higher in
      the vagotomised group. Gastric emptying was faster in vagotomised subjects after 
      OGTT and was unaffected by DPP-4i. The early GIP response was higher in
      vagotomised subjects. Despite this, the incretin effect was equal in both groups.
      DPP-4i enhanced insulin secretion in controls, but had no effect in the
      vagotomised subjects. Controls suppressed glucagon concentrations similarly,
      irrespective of the route of glucose administration, whereas vagotomised subjects
      showed suppression only during IIGI and exhibited hyperglucagonaemia following
      OGTT. DPP-4i further suppressed glucagon secretion in controls, and tended to
      normalise glucagon responses in vagotomised subjects. Conclusions: GIGD is
      diminished, but the incretin effect is unaffected in vagotomised subjects despite
      higher GLP-1 levels. This, together with small effect of DPP-4i, is compatible
      with the notion that part of the physiological effects of GLP-1 involves vagal
      transmission.
AD  - A Plamboeck, Department of Internal Medicine F, Diabetes Research Division,
      Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
FAU - Plamboeck, Astrid
AU  - Plamboeck A
FAU - Veedfald, Simon
AU  - Veedfald S
FAU - Deacon, Carolyn
AU  - Deacon C
FAU - Hartmann, Bolette
AU  - Hartmann B
FAU - Wettergren, Andre
AU  - Wettergren A
FAU - Svendsen, Lars Bo
AU  - Svendsen LB
FAU - Meisner, Soren
AU  - Meisner S
FAU - Hovendal, Claus
AU  - Hovendal C
FAU - Knop, Filip Krag
AU  - Knop FK
FAU - Vilsboll, Tina
AU  - Vilsboll T
FAU - Holst, Jens Juul
AU  - Holst JJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - EJE-13-0264 [pii]
AID - 10.1530/EJE-13-0264 [doi]
PST - aheadofprint
SO  - Eur J Endocrinol. 2013 May 23.

PMID- 23704696
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Response to yang and chan. Metformin and the risk of cancer: time-related biases 
      in observational studies. Diabetes care 2012;35:2665-2673.
PG  - e88
LID - 10.2337/dc13-0133 [doi]
AD  - Corresponding author: Samy Suissa, samy.suissa@mcgill.ca.
FAU - Suissa, Samy
AU  - Suissa S
FAU - Azoulay, Laurent
AU  - Azoulay L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661811
OID - NLM: PMC3661811 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e88 [pii]
AID - 10.2337/dc13-0133 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e88. doi: 10.2337/dc13-0133.

PMID- 23704695
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Suissa and Azoulay. Metformin and the Risk of Cancer: Time-Related
      Biases in Observational Studies. Diabetes Care 2012;35:2665-2673.
PG  - e87
LID - 10.2337/dc12-2561 [doi]
AD  - Corresponding author: Xilin Yang, yxl@hotmail.com.
FAU - Yang, Xilin
AU  - Yang X
FAU - Chan, Juliana C N
AU  - Chan JC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661801
OID - NLM: PMC3661801 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e87 [pii]
AID - 10.2337/dc12-2561 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e87. doi: 10.2337/dc12-2561.

PMID- 23704694
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Response to bodmer et Al. Metformin and the risk of cancer: time-related biases
      in observational studies. Diabetes care 2012;35:2665-2673.
PG  - e86
LID - 10.2337/dc13-0257 [doi]
AD  - Corresponding author: Samy Suissa, samy.suissa@mcgill.ca.
FAU - Suissa, Samy
AU  - Suissa S
FAU - Azoulay, Laurent
AU  - Azoulay L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661809
OID - NLM: PMC3661809 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e86 [pii]
AID - 10.2337/dc13-0257 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e86. doi: 10.2337/dc13-0257.

PMID- 23704693
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Suissa and Azoulay. Metformin and the Risk of Cancer: Time-Related
      Biases in Observational Studies. Diabetes Care 2012;35:2665-2673.
PG  - e85
LID - 10.2337/dc12-2693 [doi]
AD  - Corresponding author: Michael Bodmer, bodmerm@uhbs.ch.
FAU - Bodmer, Michael
AU  - Bodmer M
FAU - Jick, Susan S
AU  - Jick SS
FAU - Meier, Christoph R
AU  - Meier CR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661853
OID - NLM: PMC3661853 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e85 [pii]
AID - 10.2337/dc12-2693 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e85. doi: 10.2337/dc12-2693.

PMID- 23704692
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Response to Comment on: Richter et al. Serum Levels of the Adipokine Progranulin 
      Depend on Renal Function. Diabetes Care 2013;36:410-414.
PG  - e84
LID - 10.2337/dc12-2705 [doi]
AD  - Corresponding author: Mathias Fasshauer,
      mathias.fasshauer@medizin.uni-leipzig.de.
FAU - Richter, Judit
AU  - Richter J
FAU - Ebert, Thomas
AU  - Ebert T
FAU - Stolzenburg, Jens-Uwe
AU  - Stolzenburg JU
FAU - Dietel, Anja
AU  - Dietel A
FAU - Hopf, Lisa
AU  - Hopf L
FAU - Hindricks, Janka
AU  - Hindricks J
FAU - Kralisch, Susan
AU  - Kralisch S
FAU - Kratzsch, Jurgen
AU  - Kratzsch J
FAU - Fasshauer, Mathias
AU  - Fasshauer M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661818
OID - NLM: PMC3661818 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e84 [pii]
AID - 10.2337/dc12-2705 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e84. doi: 10.2337/dc12-2705.

PMID- 23704691
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Richter et al. Serum Levels of the Adipokine Progranulin Depend on
      Renal Function. Diabetes Care 2013;36:410-414.
PG  - e83
LID - 10.2337/dc12-2275 [doi]
AD  - Corresponding author: Jakob Triebel, jakob.triebel@gmx.de.
FAU - Triebel, Jakob
AU  - Triebel J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661840
OID - NLM: PMC3661840 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e83 [pii]
AID - 10.2337/dc12-2275 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e83. doi: 10.2337/dc12-2275.

PMID- 23704690
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Riazi et al. Can Ultrasound of the Tibial Nerve Detect Diabetic
      Peripheral Neuropathy? A Cross-Sectional Study. Diabetes Care 2012;35:2575-2579.
PG  - e82
LID - 10.2337/dc13-0176 [doi]
AD  - Corresponding author: D. Scott Nickerson, thenix@fiberpipe.net.
FAU - Nickerson, D Scott
AU  - Nickerson DS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661784
OID - NLM: PMC3661784 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e82 [pii]
AID - 10.2337/dc13-0176 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e82. doi: 10.2337/dc13-0176.

PMID- 23704689
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Davidson et al. High-Dose Vitamin D Supplementation in People With
      Prediabetes and Hypovitaminosis D. Diabetes Care 2013;36:260-266.
PG  - e81
LID - 10.2337/dc13-0332 [doi]
AD  - Corresponding author: Harald Sourij, ha.sourij@medunigraz.at.
FAU - Tripolt, Norbert J
AU  - Tripolt NJ
FAU - Eder, Michaela
AU  - Eder M
FAU - Stojakovic, Tatjana
AU  - Stojakovic T
FAU - Pilz, Stefan
AU  - Pilz S
FAU - Pieber, Thomas R
AU  - Pieber TR
FAU - Sourij, Harald
AU  - Sourij H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661852
OID - NLM: PMC3661852 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e81 [pii]
AID - 10.2337/dc13-0332 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e81. doi: 10.2337/dc13-0332.

PMID- 23704688
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by
      Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role 
      of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076-2082.
PG  - e80
LID - 10.2337/dc12-2220 [doi]
AD  - Corresponding author: Paresh Dandona, pdandona@kaleidahealth.org.
FAU - Makdissi, Antoine
AU  - Makdissi A
FAU - Chaudhuri, Ajay
AU  - Chaudhuri A
FAU - Kuhadiya, Nitesh
AU  - Kuhadiya N
FAU - Batra, Manav
AU  - Batra M
FAU - Dandona, Paresh
AU  - Dandona P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661805
OID - NLM: PMC3661805 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e80 [pii]
AID - 10.2337/dc12-2220 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e80. doi: 10.2337/dc12-2220.

PMID- 23704687
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Cohen et al. Effects of Gastric Bypass Surgery in Patients With Type 
      2 Diabetes and Only Mild Obesity. Diabetes Care 2012;35:1420-1428.
PG  - e79
LID - 10.2337/dc12-2244 [doi]
AD  - Corresponding author: L. Maria Belalcazar, lmbelalc@utmb.edu.
FAU - Thukunthla, Shwetha
AU  - Thukunthla S
FAU - Belalcazar, L Maria
AU  - Belalcazar LM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661791
OID - NLM: PMC3661791 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e79 [pii]
AID - 10.2337/dc12-2244 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e79. doi: 10.2337/dc12-2244.

PMID- 23704686
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Singer et al. Adiponectin and All-Cause Mortality in Elderly People
      With Type 2 Diabetes. Diabetes Care 2012;35:1858-1863.
PG  - e78
LID - 10.2337/dc12-1814 [doi]
AD  - Corresponding author: Su Chi Lim, lim.su.chi@alexandrahealth.com.sg.
FAU - Liu, Jian-Jun
AU  - Liu JJ
FAU - Tavintharan, Subramania
AU  - Tavintharan S
FAU - Sum, Chee Fang
AU  - Sum CF
FAU - Lim, Su Chi
AU  - Lim SC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661810
OID - NLM: PMC3661810 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e78 [pii]
AID - 10.2337/dc12-1814 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e78. doi: 10.2337/dc12-1814.

PMID- 23704685
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Anti-insulin receptor antibodies related to hypoglycemia in a previously diabetic
      patient.
PG  - e77
LID - 10.2337/dc12-2664 [doi]
AD  - Corresponding author: Jean-Christophe Maiza,
      jean-christophe.maiza@chu-reunion.fr.
FAU - Maiza, Jean-Christophe
AU  - Maiza JC
FAU - Caron-Debarle, Martine
AU  - Caron-Debarle M
FAU - Vigouroux, Corinne
AU  - Vigouroux C
FAU - Schneebeli, Stephane
AU  - Schneebeli S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661783
OID - NLM: PMC3661783 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e77 [pii]
AID - 10.2337/dc12-2664 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e77. doi: 10.2337/dc12-2664.

PMID- 23704684
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Diagnosis of gestational diabetes mellitus in china.
PG  - e76
LID - 10.2337/dc12-2624 [doi]
AD  - Corresponding author: Hui-xia Yang, yanghuixia@bjmu.edu.cn.
FAU - Zhu, Wei-Wei
AU  - Zhu WW
FAU - Yang, Hui-Xia
AU  - Yang HX
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661788
OID - NLM: PMC3661788 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e76 [pii]
AID - 10.2337/dc12-2624 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e76. doi: 10.2337/dc12-2624.

PMID- 23704683
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - State of diabetes, hypertension, and comorbidity in kuwait: showcasing the trends
      as seen in native versus expatriate populations.
PG  - e75
LID - 10.2337/dc12-2451 [doi]
AD  - Corresponding author: Thangavel Alphonse Thanaraj,
      alphonse.thangavel@dasmaninstitute.org.
FAU - Channanath, Arshad Mohamed
AU  - Channanath AM
FAU - Farran, Bassam
AU  - Farran B
FAU - Behbehani, Kazem
AU  - Behbehani K
FAU - Thanaraj, Thangavel Alphonse
AU  - Thanaraj TA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661797
OID - NLM: PMC3661797 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/e75 [pii]
AID - 10.2337/dc12-2451 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):e75. doi: 10.2337/dc12-2451.

PMID- 23704682
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Issues and events.
PG  - 1798
LID - 10.2337/dc13-ie06 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661795
OID - NLM: PMC3661795 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1798 [pii]
AID - 10.2337/dc13-ie06 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1798. doi: 10.2337/dc13-ie06.

PMID- 23704681
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin
      Response: A systematic review and meta-analysis.
PG  - 1789-96
LID - 10.2337/dc12-1235 [doi]
AB  - OBJECTIVE Human blood glucose levels have likely evolved toward their current
      point of stability over hundreds of thousands of years. The robust population
      stability of this trait is called canalization. It has been represented by a
      hyperbolic function of two variables: insulin sensitivity and insulin response.
      Environmental changes due to global migration may have pushed some human
      subpopulations to different points of stability. We hypothesized that there may
      be ethnic differences in the optimal states in the relationship between insulin
      sensitivity and insulin response. RESEARCH DESIGN AND METHODS We identified
      studies that measured the insulin sensitivity index (SI) and acute insulin
      response to glucose (AIRg) in three major ethnic groups: Africans, Caucasians,
      and East Asians. We identified 74 study cohorts comprising 3,813 individuals (19 
      African cohorts, 31 Caucasian, and 24 East Asian). We calculated the hyperbolic
      relationship using the mean values of SI and AIRg in the healthy cohorts with
      normal glucose tolerance. RESULTS We found that Caucasian subpopulations were
      located around the middle point of the hyperbola, while African and East Asian
      subpopulations are located around unstable extreme points, where a small change
      in one variable is associated with a large nonlinear change in the other
      variable. CONCLUSIONS Our findings suggest that the genetic background of
      Africans and East Asians makes them more and differentially susceptible to
      diabetes than Caucasians. This ethnic stratification could be implicated in the
      different natural courses of diabetes onset.
AD  - Corresponding authors: Keiichi Kodama, kkodama@stanford.edu.
FAU - Kodama, Keiichi
AU  - Kodama K
FAU - Tojjar, Damon
AU  - Tojjar D
FAU - Yamada, Satoru
AU  - Yamada S
FAU - Toda, Kyoko
AU  - Toda K
FAU - Patel, Chirag J
AU  - Patel CJ
FAU - Butte, Atul J
AU  - Butte AJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661854
OID - NLM: PMC3661854 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1789 [pii]
AID - 10.2337/dc12-1235 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1789-96. doi: 10.2337/dc12-1235.

PMID- 23704680
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Personalized management of hyperglycemia in type 2 diabetes: reflections from a
      diabetes care editors' expert forum.
PG  - 1779-88
LID - 10.2337/dc13-0512 [doi]
AB  - In June 2012, 13 thought leaders convened in a Diabetes Care Editors' Expert
      Forum to discuss the concept of personalized medicine in the wake of a recently
      published American Diabetes Association/European Association for the Study of
      Diabetes position statement calling for a patient-centered approach to
      hyperglycemia management in type 2 diabetes. This article, an outgrowth of that
      forum, offers a clinical translation of the underlying issues that need to be
      considered for effectively personalizing diabetes care. The medical management of
      type 2 diabetes has become increasingly complex, and its complications remain a
      great burden to individual patients and the larger society. The burgeoning
      armamentarium of pharmacological agents for hyperglycemia management should aid
      clinicians in providing early treatment to delay or prevent these complications. 
      However, trial evidence is limited for the optimal use of these agents,
      especially in dual or triple combinations. In the distant future, genotyping and 
      testing for metabolomic markers may help us to better phenotype patients and
      predict their responses to antihyperglycemic drugs. For now, a personalized ("n
      of 1") approach in which drugs are tested in a trial-and-error manner in each
      patient may be the most practical strategy for achieving therapeutic targets.
      Patient-centered care and standardized algorithmic management are conflicting
      approaches, but they can be made more compatible by recognizing instances in
      which personalized A1C targets are warranted and clinical circumstances that may 
      call for comanagement by primary care and specialty clinicians.
AD  - Corresponding author: William T. Cefalu, william.cefalu@pbrc.edu.
FAU - Raz, Itamar
AU  - Raz I
FAU - Riddle, Matthew C
AU  - Riddle MC
FAU - Rosenstock, Julio
AU  - Rosenstock J
FAU - Buse, John B
AU  - Buse JB
FAU - Inzucchi, Silvio E
AU  - Inzucchi SE
FAU - Home, Philip D
AU  - Home PD
FAU - Del Prato, Stefano
AU  - Del Prato S
FAU - Ferrannini, Ele
AU  - Ferrannini E
FAU - Chan, Juliana C N
AU  - Chan JC
FAU - Leiter, Lawrence A
AU  - Leiter LA
FAU - Leroith, Derek
AU  - Leroith D
FAU - Defronzo, Ralph
AU  - Defronzo R
FAU - Cefalu, William T
AU  - Cefalu WT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661796
OID - NLM: PMC3661796 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1779 [pii]
AID - 10.2337/dc13-0512 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1779-88. doi: 10.2337/dc13-0512.

PMID- 23704679
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Crisis in care: limited treatment options for type 2 diabetes in adolescents and 
      youth.
PG  - 1777-8
LID - 10.2337/dc13-0743 [doi]
AD  - Corresponding author: William V. Tamborlane, william.tamborlane@yale.edu.
FAU - Tamborlane, William V
AU  - Tamborlane WV
FAU - Klingensmith, Georgeanna
AU  - Klingensmith G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661850
OID - NLM: PMC3661850 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1777 [pii]
AID - 10.2337/dc13-0743 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1777-8. doi: 10.2337/dc13-0743.

PMID- 23704678
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - The TODAY Study: An NIH Perspective on Its Implications for Research.
PG  - 1775-6
LID - 10.2337/dc13-0707 [doi]
AD  - Corresponding author: Barbara L. Linder, linderb@mail.nih.gov.
FAU - Linder, Barbara L
AU  - Linder BL
FAU - Fradkin, Judith E
AU  - Fradkin JE
FAU - Rodgers, Griffin P
AU  - Rodgers GP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661792
OID - NLM: PMC3661792 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1775 [pii]
AID - 10.2337/dc13-0707 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1775-6. doi: 10.2337/dc13-0707.

PMID- 23704677
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Retinopathy in Youth With Type 2 Diabetes Participating in the TODAY Clinical
      Trial.
PG  - 1772-4
LID - 10.2337/dc12-2387 [doi]
AB  - OBJECTIVE To determine the prevalence of retinopathy in 517 youth with type 2
      diabetes of 2-8 years duration enrolled in the TODAY study. RESEARCH DESIGN AND
      METHODS Retinal photographs were graded centrally for retinopathy using
      established standards. RESULTS Retinopathy was identified in 13.7% of subjects.
      Prevalence increased with age, diabetes duration, and mean HbA1c. Subjects in the
      highest BMI tertile had the lowest prevalence of retinopathy. CONCLUSIONS
      Prevalence of retinopathy and its association with HbA1c and diabetes duration is
      similar to that previously reported in youth with type 1 diabetes and in adults
      with type 2 diabetes of known duration. The mechanism underlying the reduced risk
      of retinopathy in the most obese individuals is unknown. Follow-up of this cohort
      will help define the natural history of retinopathy in youth with type 2
      diabetes.
AD  - Corresponding author: Kimberly L. Drews, kdrews@bsc.gwu.edu.
CN  - TODAY Study Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661825
OID - NLM: PMC3661825 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1772 [pii]
AID - 10.2337/dc12-2387 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1772-4. doi: 10.2337/dc12-2387.

PMID- 23704676
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes: The
      TODAY experience.
PG  - 1765-71
LID - 10.2337/dc12-2390 [doi]
AB  - OBJECTIVE Data related to the safety and tolerability of treatments for pediatric
      type 2 diabetes are limited. The TODAY clinical trial assessed severe adverse
      events (SAEs) and targeted nonsevere adverse events (AEs) before and after
      treatment failure, which was the primary outcome (PO). RESEARCH DESIGN AND
      METHODS Obese 10- to 17-year-olds (N = 699) with type 2 diabetes for <2 years and
      hemoglobin A1c (A1C) </=8% on metformin monotherapy were randomized to one of
      three treatments: metformin, metformin plus rosiglitazone (M + R), or metformin
      plus lifestyle program (M + L). Participants were followed for 2-6.5 years.
      RESULTS Gastrointestinal (GI) disturbance was the most common AE (41%) and was
      lower in the M + R group (P = 0.018). Other common AEs included anemia (20%
      before PO, 14% after PO), abnormal liver transaminases (16, 15%), excessive
      weight gain (7, 9%), and psychological events (10, 18%); the AEs were similar
      across treatments. Permanent medication reductions/discontinuations occurred most
      often because of abnormal liver transaminases and were lowest in the M + R group 
      (P = 0.005). Treatment-emergent SAEs were uncommon and similar across treatments.
      Most (98%) were unrelated or unlikely related to the study intervention. There
      were no deaths and only 18 targeted SAEs (diabetic ketoacidosis, n = 12; severe
      hypoglycemia, n = 5; lactic acidosis, n = 1). There were 62 pregnancies occurring
      in 45 participants, and 6 infants had congenital anomalies. CONCLUSIONS The TODAY
      study represents extensive experience managing type 2 diabetes in youth and found
      that the three treatment approaches were generally safe and well tolerated.
      Adding rosiglitazone to metformin may reduce GI side effects and hepatotoxicity.
AD  - Corresponding author: Laura Pyle, lpyle@bsc.gwu.edu.
CN  - TODAY Study Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661822
OID - NLM: PMC3661822 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - dc12-2390 [pii]
AID - 10.2337/dc12-2390 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1765-71. doi: 10.2337/dc12-2390.

PMID- 23704675
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With
      Type 2 Diabetes: The TODAY clinical trial.
PG  - 1758-64
LID - 10.2337/dc12-2388 [doi]
AB  - OBJECTIVE Type 2 diabetes increases cardiovascular risk. We examined lipid
      profiles and inflammatory markers in 699 youth with recent-onset type 2 diabetes 
      in the TODAY clinical trial and compared changes across treatment groups:
      metformin alone (M), metformin plus rosiglitazone (M+R), and metformin plus
      intensive lifestyle program (M+L). RESEARCH DESIGN AND METHODS Multiethnic youth 
      with type 2 diabetes received M, M+R, or M+L. Statin drugs were begun for LDL
      cholesterol (LDL) >/=130 mg/dL or triglycerides >/=300 mg/dL. Lipids,
      apolipoprotein B (apoB), LDL particle size, high-sensitivity c-reactive protein
      (hsCRP), homocysteine, plasminogen activator inhibitor-1 (PAI-1), and HbA1c were 
      measured over 36 months or until loss of glycemic control. RESULTS LDL, apoB,
      triglycerides, and non-HDL cholesterol (HDL) rose over 12 months and then
      stabilized over the next 24 months. Participants with LDL >/=130 mg/dL or using
      LDL-lowering therapy increased from 4.5 to 10.7% over 36 months, while 55.9%
      remained at LDL goal (<100 mg/dL) over that time. Treatment group did not impact 
      LDL, apoB, or non-HDL. Small dense LDL (particle size, </=0.263 relative
      flotation rate) was most common in M. Triglycerides were lower in M+L than M, and
      M+L attenuated the negative effect of hyperglycemia on triglycerides and HDL in
      females. hsCRP, PAI-1, and homocysteine increased over time. However, hsCRP was
      lower in M+R compared with M or M+L. CONCLUSIONS Dyslipidemia and chronic
      inflammation were common in youth with type 2 diabetes and worsened over time.
      Diabetes treatment, despite some treatment group differences in lipid and
      inflammatory marker change over time, is generally inadequate to control this
      worsening risk.
AD  - Corresponding author: Kathryn Hirst, khirst@bsc.gwu.edu.
CN  - TODAY Study Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661790
OID - NLM: PMC3661790 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - dc12-2388 [pii]
AID - 10.2337/dc12-2388 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1758-64. doi: 10.2337/dc12-2388.

PMID- 23704674
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle 
      on Insulin Sensitivity and beta-Cell Function in TODAY.
PG  - 1749-57
LID - 10.2337/dc12-2393 [doi]
AB  - OBJECTIVE The Treatment Options for type 2 Diabetes in Adolescents and Youth
      (TODAY) trial demonstrated that combination therapy with metformin plus
      rosiglitazone provided superior durability of glycemic control compared with
      metformin alone, with significantly lower treatment failure rates (38.6 vs.
      51.7%), and metformin plus lifestyle was intermediate. Herein we describe the
      temporal changes in measures of beta-cell function and insulin sensitivity over a
      4-year period among the three treatments. RESEARCH DESIGN AND METHODS TODAY
      participants (699) were tested periodically with an oral glucose tolerance test
      to determine insulin sensitivity (1/fasting insulin [1/IF]), insulinogenic index 
      ( big up tri, openI30/ big up tri, openG30) or C-peptide index ( big up tri,
      openC30/ big up tri, openG30), and beta-cell function relative to insulin
      sensitivity (oral disposition index [oDI]). RESULTS During the first 6 months,
      metformin plus rosiglitazone exhibited a significantly greater improvement in
      insulin sensitivity and oDI versus metformin alone and versus metformin plus
      lifestyle; these improvements were sustained over 48 months of TODAY.
      Irrespective of treatment, those who failed to maintain glycemic control had
      significantly lower beta-cell function ( approximately 50%), higher fasting
      glucose concentration, and higher HbA1c at randomization compared with those who 
      did not fail. CONCLUSIONS The beneficial change in insulin sensitivity and the
      resultant lower burden on beta-cell function achieved in the first 6 months with 
      metformin plus rosiglitazone appear to be responsible for its superior glycemic
      durability over metformin alone and metformin plus lifestyle. However, initial
      beta-cell reserve and HbA1c at randomization are independent predictors of
      glycemic durability. Therefore, efforts to preserve beta-cell function before
      significant loss occurs and to reduce HbA1c may be beneficial in the treatment of
      youth with type 2 diabetes.
AD  - Corresponding author: Laura Pyle, lpyle@bsc.gwu.edu.
CN  - TODAY Study Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661836
OID - NLM: PMC3661836 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - dc12-2393 [pii]
AID - 10.2337/dc12-2393 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1749-57. doi: 10.2337/dc12-2393.

PMID- 23704673
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Treatment Effects on Measures of Body Composition in the TODAY Clinical Trial.
PG  - 1742-8
LID - 10.2337/dc12-2534 [doi]
AB  - OBJECTIVE The Treatment Options for type 2 Diabetes in Adolescents and Youth
      (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over
      metformin alone (M), with metformin plus lifestyle (M+L) intermediate in
      maintaining glycemic control. We report here treatment effects on measures of
      body composition and their relationships to demographic and metabolic variables
      including glycemia. RESEARCH DESIGN AND METHODS Measures of adiposity (BMI, waist
      circumference, abdominal height, percent and absolute fat, and bone mineral
      content [BMC] and density [BMD]) were analyzed as change from baseline at 6 and
      24 months. RESULTS Measures of fat accumulation were greatest in subjects treated
      with M+R and least in M+L. Although fat measures in M+L were less than those of
      M+R and M at 6 months, differences from M were no longer apparent at 24 months,
      whereas differences from M+R persisted at 24 months. The only body composition
      measure differing by race and/or ethnicity was waist circumference, greater in
      M+R than either M or M+L at both 6 and 24 months in whites. BMD and BMC increased
      in all groups, but increased less in M+R compared with the other two groups by 24
      months. Measures of adiposity (increases in BMI, waist circumference, abdominal
      height, and fat) were associated with reduced insulin sensitivity and increased
      hemoglobin A1c (HbA1c), although effects of adiposity on HbA1c were less evident 
      in those treated with M+R. CONCLUSIONS Despite differential effects on measures
      of adiposity (with M+R resulting in the most and M+L in the least fat
      accumulation), group differences generally were small and unrelated to treatment 
      effects in sustaining glycemic control.
AD  - Corresponding author: Laure El ghormli, elghorml@bsc.gwu.edu.
CN  - TODAY Study Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661839
OID - NLM: PMC3661839 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - dc12-2534 [pii]
AID - 10.2337/dc12-2534 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1742-8. doi: 10.2337/dc12-2534.

PMID- 23704672
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes: The
      TODAY clinical trial.
PG  - 1735-41
LID - 10.2337/dc12-2420 [doi]
AB  - OBJECTIVE Among adolescents with type 2 diabetes, there is limited information
      regarding incidence and progression of hypertension and microalbuminuria.
      Hypertension and microalbuminuria assessments made during the TODAY clinical
      trial were analyzed for effect of treatment, glycemic control, sex, and
      race/ethnicity. RESEARCH DESIGN AND METHODS A cohort of 699 adolescents, 10-17
      years of age, <2 years duration of type 2 diabetes, BMI >/=85%, HbA1c </=8% on
      metformin therapy, controlled blood pressure (BP), and calculated creatinine
      clearance >70 mL/min, were randomized to metformin, metformin plus rosiglitazone,
      or metformin plus intensive lifestyle intervention. Primary study outcome was
      loss of glycemic control for 6 months or sustained metabolic decompensation
      requiring insulin. Hypertension and microalbuminuria were managed aggressively
      with standardized therapy to maintain BP <130/80 or <95th percentile for age,
      sex, and height and microalbuminuria <30 mug/mg. RESULTS In this cohort, 319
      (45.6%) reached primary study outcome, and 11.6% were hypertensive at baseline
      and 33.8% by end of study (average follow-up 3.9 years). Male sex and higher BMI 
      significantly increased the risk for hypertension. Microalbuminuria was found in 
      6.3% at baseline and rose to 16.6% by end of study. Diagnosis of microalbuminuria
      was not significantly different between treatment arms, sex, or race/ethnicity,
      but higher levels of HbA1c were significantly related to risk of developing
      microalbuminuria. CONCLUSIONS Prevalence of hypertension and microalbuminuria
      increased over time among adolescents with type 2 diabetes regardless of diabetes
      treatment. The greatest risk for hypertension was male sex and higher BMI. The
      risk for microalbuminuria was more closely related to glycemic control.
AD  - Corresponding author: Laura Pyle, lpyle@bsc.gwu.edu.
CN  - TODAY Study Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661847
OID - NLM: PMC3661847 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - dc12-2420 [pii]
AID - 10.2337/dc12-2420 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1735-41. doi: 10.2337/dc12-2420.

PMID- 23704671
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - George s. Eisenbarth: insulin and type 1 diabetes.
PG  - 1437-42
LID - 10.2337/dc13-0753 [doi]
AD  - Corresponding author: Alberto Pugliese, apuglies@med.miami.edu.
FAU - Pugliese, Alberto
AU  - Pugliese A
FAU - Skyler, Jay S
AU  - Skyler JS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661806
OID - NLM: PMC3661806 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1437 [pii]
AID - 10.2337/dc13-0753 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1437-42. doi: 10.2337/dc13-0753.

PMID- 23704670
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Adiponectin: are measurements clinically useful in pregnancy?
PG  - 1434-6
LID - 10.2337/dc12-2532 [doi]
AD  - Corresponding author: Sylvie Hauguel-de Mouzon, shdemouzon@metrohealth.org.
FAU - Hauguel-de Mouzon, Sylvie
AU  - Hauguel-de Mouzon S
FAU - Catalano, Patrick
AU  - Catalano P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661841
OID - NLM: PMC3661841 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1434 [pii]
AID - 10.2337/dc12-2532 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1434-6. doi: 10.2337/dc12-2532.

PMID- 23704669
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - A special thanks to the reviewers of diabetes care.
PG  - 1433
LID - 10.2337/dc13-en06 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661829
OID - NLM: PMC3661829 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1433 [pii]
AID - 10.2337/dc13-en06 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1433. doi: 10.2337/dc13-en06.

PMID- 23704668
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - In this issue of diabetes care.
PG  - 1431-2
LID - 10.2337/dc13-ti06 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3661787
OID - NLM: PMC3661787 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 36/6/1431 [pii]
AID - 10.2337/dc13-ti06 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Jun;36(6):1431-2. doi: 10.2337/dc13-ti06.

PMID- 23704535
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years
      From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1
      Diabetes TrialNet Data. Diabetes 2012;61:2066-2073.
PG  - e8
LID - 10.2337/db13-0115 [doi]
AD  - Diabetes Program, Benaroya Research Institute, Seattle, Washington.
FAU - Greenbaum, Carla J
AU  - Greenbaum CJ
FAU - Beam, Craig A
AU  - Beam CA
CN  - Type 1 Diabetes TrialNet Study Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661623
OID - NLM: PMC3661623 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/e8 [pii]
AID - 10.2337/db13-0115 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):e8. doi: 10.2337/db13-0115.

PMID- 23704534
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From
      Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1
      Diabetes TrialNet Data. Diabetes 2012;61:2066-2073.
PG  - e7
LID - 10.2337/db13-0047 [doi]
AD  - Diabetes Unit, Department of Endocrinology, Institut d'Investigacions Biomediques
      August Pi i Sunyer, CIBERDEM, Hospital Clinic i Universitari, Barcelona, Spain.
FAU - Rios, Paola
AU  - Rios P
FAU - de Hollanda, Ana
AU  - de Hollanda A
FAU - Gimenez, Marga
AU  - Gimenez M
FAU - Conget, Ignacio
AU  - Conget I
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661624
OID - NLM: PMC3661624 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/e7 [pii]
AID - 10.2337/db13-0047 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):e7. doi: 10.2337/db13-0047.

PMID- 23704533
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Response to Comment on: Teeuwisse et al. Short-Term Caloric Restriction
      Normalizes Hypothalamic Neuronal Responsiveness to Glucose Ingestion in Patients 
      With Type 2 Diabetes. Diabetes 2012;61:3255-3259.
PG  - e6
LID - 10.2337/db13-0296 [doi]
AD  - Department of Radiology, Leiden University Medical Center, Leiden, the
      Netherlands.
FAU - Widya, Ralph L
AU  - Widya RL
FAU - Pijl, Hanno
AU  - Pijl H
FAU - van der Grond, Jeroen
AU  - van der Grond J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661638
OID - NLM: PMC3661638 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/e6 [pii]
AID - 10.2337/db13-0296 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):e6. doi: 10.2337/db13-0296.

PMID- 23704532
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Comment on: Teeuwisse et al. Short-Term Caloric Restriction Normalizes
      Hypothalamic Neuronal Responsiveness to Glucose Ingestion in Patients With Type 2
      Diabetes. Diabetes 2012;61:3255-3259.
PG  - e5
LID - 10.2337/db13-0054 [doi]
AD  - Division of Endocrinology, Department of Internal Medicine, Diabetology,
      Angiology, Nephrology and Clinical Chemistry, Eberhard Karls University,
      Tubingen, Germany.
FAU - Heni, Martin
AU  - Heni M
FAU - Kullmann, Stephanie
AU  - Kullmann S
FAU - Fritsche, Andreas
AU  - Fritsche A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661604
OID - NLM: PMC3661604 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/e5 [pii]
AID - 10.2337/db13-0054 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):e5. doi: 10.2337/db13-0054.

PMID- 23704531
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Highlights from the latest in diabetes research.
PG  - 2152-3
LID - 10.2337/db13-dd06 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661656
OID - NLM: PMC3661656 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/2152 [pii]
AID - 10.2337/db13-dd06 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):2152-3. doi: 10.2337/db13-dd06.

PMID- 23704530
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Issues and events.
PG  - 2151
LID - 10.2337/db13-ie06 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661650
OID - NLM: PMC3661650 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/2151 [pii]
AID - 10.2337/db13-ie06 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):2151. doi: 10.2337/db13-ie06.

PMID- 23704529
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Putting rac1 on the path to glucose uptake.
PG  - 1831-2
LID - 10.2337/db13-0381 [doi]
AD  - Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences,
      Ben-Gurion University of the Negev, Beer-Sheva, Israel.
FAU - Rudich, Assaf
AU  - Rudich A
FAU - Klip, Amira
AU  - Klip A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661647
OID - NLM: PMC3661647 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1831 [pii]
AID - 10.2337/db13-0381 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1831-2. doi: 10.2337/db13-0381.

PMID- 23704528
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Disrupting rhythms: diet-induced obesity impairs diurnal rhythms in metabolic
      tissues.
PG  - 1829-30
LID - 10.2337/db13-0353 [doi]
AD  - Department of Clinical Biochemistry, Institute of Metabolic Science, University
      of Cambridge, Addenbrooke's Hospital, Cambridge, U.K.
FAU - Wu, Lisa
AU  - Wu L
FAU - Reddy, Akhilesh B
AU  - Reddy AB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661628
OID - NLM: PMC3661628 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1829 [pii]
AID - 10.2337/db13-0353 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1829-30. doi: 10.2337/db13-0353.

PMID- 23704527
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Assessing multiple features of mitochondrial function.
PG  - 1826-8
LID - 10.2337/db13-0303 [doi]
AD  - Institute for Clinical Diabetology, German Diabetes Center, Dusseldorf, Germany.
FAU - Phielix, Esther
AU  - Phielix E
FAU - Roden, Michael
AU  - Roden M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661614
OID - NLM: PMC3661614 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1826 [pii]
AID - 10.2337/db13-0303 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1826-8. doi: 10.2337/db13-0303.

PMID- 23704526
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Sweet and Sour beta-Cells: ROS and Hif1alpha Induce Warburg-Like Lactate
      Production During Type 2 Diabetes.
PG  - 1823-5
LID - 10.2337/db13-0272 [doi]
AD  - Diabetes and Obesity Research Program, Garvan Institute of Medical Research,
      Darlinghurst, New South Wales, Australia.
FAU - Cantley, James
AU  - Cantley J
FAU - Biden, Trevor J
AU  - Biden TJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661644
OID - NLM: PMC3661644 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1823 [pii]
AID - 10.2337/db13-0272 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1823-5. doi: 10.2337/db13-0272.

PMID- 23704525
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - beta-Cells, Autoimmunity, and the Innate Immune System: "un Menage a Trois"?
PG  - 1821-2
LID - 10.2337/db13-0276 [doi]
AD  - Department of Immunohaematology and Blood Transfusion, Leiden University Medical 
      Center, Leiden, the Netherlands.
FAU - Roep, Bart O
AU  - Roep BO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661633
OID - NLM: PMC3661633 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1821 [pii]
AID - 10.2337/db13-0276 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1821-2. doi: 10.2337/db13-0276.

PMID- 23704524
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Opportunity "nox": a novel approach to preventing endothelial dysfunction in the 
      context of insulin resistance.
PG  - 1818-20
LID - 10.2337/db13-0255 [doi]
AD  - College of Health, University of Utah, Salt Lake City, Utah.
FAU - Symons, J David
AU  - Symons JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661632
OID - NLM: PMC3661632 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1818 [pii]
AID - 10.2337/db13-0255 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1818-20. doi: 10.2337/db13-0255.

PMID- 23704523
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Treatment of hyaluronan accumulation ameliorates high-fat diet-induced insulin
      resistance in mice.
PG  - 1816-7
LID - 10.2337/db13-0261 [doi]
AD  - Department of Molecular and Clinical Medicine/Wallenberg Laboratory, University
      of Gothenburg, Gothenburg, Sweden.
FAU - Fogelstrand, Per
AU  - Fogelstrand P
FAU - Boren, Jan
AU  - Boren J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661634
OID - NLM: PMC3661634 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1816 [pii]
AID - 10.2337/db13-0261 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1816-7. doi: 10.2337/db13-0261.

PMID- 23704522
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop
      Novel Therapies for Diabetic Retinopathy.
PG  - 1808-15
LID - 10.2337/db12-1744 [doi]
AB  - Therapies targeting vascular endothelial growth factor (VEGF) are revolutionizing
      the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME). In
      August 2012, ranibizumab, a monoclonal antibody fragment targeting VEGF designed 
      for ocular use, became the first and only U.S. Food and Drug
      Administration-approved medical therapy for DME and the first approved treatment 
      in over 25 years. This approval was based on strong preclinical data followed by 
      numerous clinical trials that demonstrate an essential role of VEGF in vascular
      permeability and angiogenesis in both normal physiology and disease pathology. In
      this Perspective, we will examine the experimental studies and scientific data
      that aided in the success of the development of therapies targeting VEGF and
      consider how these approaches may inform the development of future therapeutics
      for diabetic eye disease. A multipoint model is proposed, based on
      well-established drug development principles, with the goal of improving the
      success of clinical drug development. This model suggests that to provide a
      validated preclinical target, investigators should demonstrate the following: the
      role of the target in normal physiology, a causal link to disease pathogenesis,
      correlation to human disease, and the ability to elicit clinically relevant
      improvements of disease phenotypes in animal models with multiple, chemically
      diverse interventions. This model will provide a framework to validate the
      current preclinical targets and identify novel targets to improve drug
      development success for DR.
AD  - Department of Cellular and Molecular Physiology, Penn State University College of
      Medicine, Hershey, Pennsylvania.
FAU - Titchenell, Paul M
AU  - Titchenell PM
FAU - Antonetti, David A
AU  - Antonetti DA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661651
OID - NLM: PMC3661651 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1808 [pii]
AID - 10.2337/db12-1744 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1808-15. doi: 10.2337/db12-1744.

PMID- 23704521
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory: Bringing All the
      Strands Together.
PG  - 1800-7
LID - 10.2337/db12-1648 [doi]
AD  - Cardiology and Cardiovascular Research, University of Zurich, Zurich,
      Switzerland.
FAU - Paneni, Francesco
AU  - Paneni F
FAU - Volpe, Massimo
AU  - Volpe M
FAU - Luscher, Thomas Felix
AU  - Luscher TF
FAU - Cosentino, Francesco
AU  - Cosentino F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661615
OID - NLM: PMC3661615 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1800 [pii]
AID - 10.2337/db12-1648 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1800-7. doi: 10.2337/db12-1648.

PMID- 23704520
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Biochemical basis of the antidiabetic activity of oleanolic Acid and related
      pentacyclic triterpenes.
PG  - 1791-9
LID - 10.2337/db12-1215 [doi]
AB  - Oleanolic acid (OA), a natural component of many plant food and medicinal herbs, 
      is endowed with a wide range of pharmacological properties whose therapeutic
      potential has only partly been exploited until now. Throughout complex and
      multifactorial mechanisms, OA exerts beneficial effects against diabetes and
      metabolic syndrome. It improves insulin response, preserves functionality and
      survival of beta-cells, and protects against diabetes complications. OA may
      directly modulate enzymes connected to insulin biosynthesis, secretion, and
      signaling. However, its major contributions appear to be derived from the
      interaction with important transduction pathways, and many of its effects are
      consistently related to activation of the transcription factor Nrf2. Doing that, 
      OA induces the expression of antioxidant enzymes and phase II response genes,
      blocks NF-kappaB, and represses the polyol pathway, AGEs production, and
      hyperlipidemia. The management of type 2 diabetes requires an integrated
      approach, which includes the early intervention to prevent or delay the disease
      progression, and the use of therapies to control glycemia and lipidemia in its
      late stages. In this sense, the use of functional foods or drugs containing OA
      is, undoubtedly, an interesting path.
AD  - Instituto de la Grasa, Consejo Superior de Investigaciones Cientificas, Seville, 
      Spain.
FAU - Castellano, Jose M
AU  - Castellano JM
FAU - Guinda, Angeles
AU  - Guinda A
FAU - Delgado, Teresa
AU  - Delgado T
FAU - Rada, Mirela
AU  - Rada M
FAU - Cayuela, Jose A
AU  - Cayuela JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661625
OID - NLM: PMC3661625 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1791 [pii]
AID - 10.2337/db12-1215 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1791-9. doi: 10.2337/db12-1215.

PMID- 23704519
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Anatomical locations of human brown adipose tissue: functional relevance and
      implications in obesity and type 2 diabetes.
PG  - 1783-90
LID - 10.2337/db12-1430 [doi]
AB  - We will review information about and present hypotheses as to the anatomy of
      brown adipose tissue (BAT). Why is it located where it is in humans? Its
      anatomical distribution is likely to confer survival value by protecting critical
      organs from hypothermia by adaptive thermogenesis. Ultimately, the location and
      function will be important when considering therapeutic strategies for preventing
      and treating obesity and type 2 diabetes, in which case successful interventions 
      will need to have a significant effect on BAT function in subjects living in a
      thermoneutral environment. In view of the diverse locations and potential
      differences in responsiveness between BAT depots, it is likely that BAT will be
      shown to have much more subtle and thus previously overlooked functions and
      regulatory control mechanisms.
AD  - Endocrinology and Diabetes Division, VA Greater Los Angeles Healthcare System,
      Los Angeles, California.
FAU - Sacks, Harold
AU  - Sacks H
FAU - Symonds, Michael E
AU  - Symonds ME
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661606
OID - NLM: PMC3661606 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1783 [pii]
AID - 10.2337/db12-1430 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1783-90. doi: 10.2337/db12-1430.

PMID- 23704518
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - Banting lecture 2012: regulation of adipogenesis: toward new therapeutics for
      metabolic disease.
PG  - 1774-82
LID - 10.2337/db12-1665 [doi]
AB  - The Banting Medal for Scientific Achievement Award is the American Diabetes
      Association's highest scientific award and honors an individual who has made
      significant, long-term contributions to the understanding of diabetes, its
      treatment, and/or prevention.The award is named after Nobel Prize winner Sir
      Frederick Banting, who codiscovered insulin treatment for diabetes. Bruce M.
      Spiegelman, PhD, of Harvard Medical School and the Dana-Farber Cancer Institute
      in Boston, received the American Diabetes Association's Banting Medal for
      Scientific Achievement at the Association's 72nd Scientific Sessions, 8-12 June
      2012, Philadelphia, Pennsylvania. He presented the Banting Lecture,
      "Transcriptional Control of Adipogenesis-Toward a New Generation of Therapeutics 
      for Metabolic Disease," on Sunday, 10 June 2012. In his lecture, Dr. Spiegelman
      described the discovery of several transcriptional components that control
      adipose cell development: PPAR-gamma, PGC1-alpha, and PRDM16. He also described
      the cloning and characterization of beige fat cells, the thermogenic "brown-like"
      cells that can develop in white fat depots. Lastly, Dr. Spiegelman discussed
      irisin, a newly discovered regulatory hormone that converts white fat into the
      more thermogenic beige fat. Dr. Spiegelman's research has found that irisin,
      which is induced by exercise, appears to activate some of the same health
      benefits as exercise, including improvement of glycemic control. Understanding
      the regulation of adipose tissue, white, brown, and beige, can potentially lead
      to the development of a new generation of therapeutics for diabetes prevention
      and treatment.
AD  - Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
FAU - Spiegelman, Bruce M
AU  - Spiegelman BM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661621
OID - NLM: PMC3661621 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1774 [pii]
AID - 10.2337/db12-1665 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1774-82. doi: 10.2337/db12-1665.

PMID- 23704517
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - A special thanks to the reviewers of diabetes.
PG  - 1773
LID - 10.2337/db13-en06 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661657
OID - NLM: PMC3661657 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1773 [pii]
AID - 10.2337/db13-en06 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1773. doi: 10.2337/db13-en06.

PMID- 23704516
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 6
DP  - 2013 Jun
TI  - In this issue of diabetes.
PG  - 1771-2
LID - 10.2337/db13-ti06 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3661631
OID - NLM: PMC3661631 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
AID - 62/6/1771 [pii]
AID - 10.2337/db13-ti06 [doi]
PST - ppublish
SO  - Diabetes. 2013 Jun;62(6):1771-2. doi: 10.2337/db13-ti06.

PMID- 23704474
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
DP  - 2013 May 23
TI  - An assessment of the shared allelic architecture between type 2 diabetes and
      prostate cancer.
AB  - Background:To determine whether the alleles that influence type 2 diabetes risk
      and glycemic traits also influence prostate cancer risk. Methods:We used a
      multiple single nucleotide polymorphisms (SNP) genotypic risk score to assess the
      average effect of alleles that increase type 2 diabetes risk or worsen glycemic
      traits on risk of prostate cancer in 19,662 prostate cancer cases and 19,715
      controls from the PRACTICAL consortium and 5,504 prostate cancer cases and 5,834 
      controls from the CRUK prostate cancer study. Results:Calculating the average
      additive effect of type 2 diabetes or glycemic trait risk alleles on prostate
      cancer risk using a logistic model revealed no evidence of a shared allelic
      architecture between type 2 diabetes, or worsened glycemic status, with prostate 
      cancer risk (odds ratio for type 2 diabetes alleles: 1.00 (P=0.58), fasting
      glycemia alleles: 1.00 (P=0.67), HbA1c alleles: 1.00 (P=0.93), 2 hour OGTT
      alleles: 1.01 (P=0.14) and HOMA-B alleles: 0.99 (P=0.57)). Conclusions:Using
      genetic data from large consortia we found no evidence for a shared genetic
      etiology of type 2 diabetes, or glycemic risk, with prostate cancer. Impact:Our
      results showed that alleles influencing type 2 diabetes and related glycemic
      traits were not found to be associated with the risk of prostate cancer.
AD  - McGill University.
FAU - Yu, Oriana Hoi Yun
AU  - Yu OH
FAU - Foulkes, William D
AU  - Foulkes WD
FAU - Dastani, Zari
AU  - Dastani Z
FAU - Martin, Richard M
AU  - Martin RM
FAU - Eeles, Rosalind
AU  - Eeles R
FAU - Richards, J Brent
AU  - Richards JB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American
      Association for Cancer Research, cosponsored by the American Society of
      Preventive Oncology
JID - 9200608
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 1055-9965.EPI-13-0476 [pii]
AID - 10.1158/1055-9965.EPI-13-0476 [doi]
PST - aheadofprint
SO  - Cancer Epidemiol Biomarkers Prev. 2013 May 23.

PMID- 23704427
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - 'A one-sided affair': unilateral pulmonary oedema and the role of cardiac MRI in 
      diagnosing premature coronary artery disease in a patient with Prader-Willi
      syndrome.
LID - 10.1136/bcr-2013-008692 [doi]
LID - bcr2013008692 [pii]
AB  - There is no formal association between premature coronary artery disease (CAD)
      and Prader-Willi syndrome despite its association with hyperlipidaemia, diabetes 
      mellitus and hypertension. A 36-year-old man with Prader-Willi syndrome presented
      with acute breathlessness. Inflammatory markers were borderline elevated and
      chest radiography demonstrated unilateral diffuse alveolar shadowing.
      Bronchopneumonia was diagnosed and despite treatment with multiple courses of
      antimicrobial therapy, there was minimal symptomatic and radiographical
      improvement. A diagnosis of unilateral pulmonary oedema was suspected.
      Echocardiography was non-diagnostic due to body habitus and coronary angiography 
      was deemed inappropriate due to uncertainty in diagnosis, invasiveness and
      pre-existing chronic kidney disease. Therefore, cardiac magnetic resonance was
      performed, confirming severe triple-vessel CAD. This case demonstrates a
      presentation of heart failure with unilateral chest radiograph changes in a young
      patient with Prader-Willi syndrome and severe premature CAD detected by
      multiparametric cardiac magnetic resonance imaging.
AD  - Department of Cardiology, Glenfield Hospital, Leicester, UK.
FAU - Jabbar, Avais
AU  - Jabbar A
FAU - Khan, Jamal N
AU  - Khan JN
FAU - Singh, Anvesha
AU  - Singh A
FAU - McCann, Gerry P
AU  - McCann GP
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - bcr-2013-008692 [pii]
AID - 10.1136/bcr-2013-008692 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 22;2013. pii: bcr2013008692. doi: 10.1136/bcr-2013-008692.

PMID- 23704303
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Linking)
DP  - 2013 May 23
TI  - Association of Left Ventricular Longitudinal Strain with Mortality among Stable
      Hemodialysis Patients with Preserved Left Ventricular Ejection Fraction.
AB  - BACKGROUND AND OBJECTIVES: Little is known about the optimal echocardiographic
      parameters for risk stratification in stable dialysis patients with preserved
      left ventricular ejection fraction (LVEF) (ejection fraction >/=50%). Left
      ventricular (LV) global peak systolic longitudinal strain (GLS) is the ratio of
      the maximal change in myocardial longitudinal length in systole to the original
      length and reliably and accurately assesses LV function. During systole, LV
      myocardium in the longitudinal direction shortens and GLS is represented by a
      negative value. The more negative value of GLS, the better the LV function is.
      This study hypothesized that subtle abnormalities of GLS are associated with an
      adverse prognosis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This
      prospective study collected clinical and echocardiographic data (including GLS)
      from 88 stable hemodialysis patients (mean age 67.0+/-11.2 years; 35% men) with
      preserved LVEF. These patients were enrolled from December 2008 to January 2009
      and were followed-up for 25.6+/-9.9 months. The primary outcome was all-cause
      mortality. Multivariate Cox regression analysis was used to investigate risk
      factors for mortality. RESULTS: The mortality group (n=24) had lower albumin
      levels, less negative GLS, and higher prevalence of coronary artery disease and
      diabetes mellitus than the survival group. Using a GLS cutoff value of -15%, the 
      less negative GLS group (GLS >/=-15%) had a higher mortality rate. Cox regression
      analyses revealed that lower albumin level (hazard ratio, 0.16; 95% confidence
      interval, 0.05 to 0.53; P=0.003) and less negative GLS (hazard ratio, 3.57; 95%
      confidence interval, 1.41 to 9.04; P=0.01) were independent predictors of
      all-cause mortality. Furthermore, less negative GLS was associated with a higher 
      cardiovascular death rate. CONCLUSIONS: Less negative GLS is predictive of poor
      prognosis among stable hemodialysis patients with preserved LVEF.
AD  - Divisions of Cardiology and, double daggerNephrology, Department of Internal
      Medicine, National Cheng Kung University Medical College and Hospital, Tainan,
      Taiwan;, daggerDivision of Nephrology, Department of Internal Medicine, National 
      Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan;, section signGraduate
      Institute of Biomedical Engineering, National Cheng Kung University, Tainan,
      Taiwan;, ||Department of Statistics, National Cheng Kung University, Tainan,
      Taiwan, paragraph signDivision of Nephrology, Department of Internal Medicine,
      Catholic Fu-An Hospital, Yun-Lin, Taiwan.
FAU - Liu, Yen-Wen
AU  - Liu YW
FAU - Su, Chi-Ting
AU  - Su CT
FAU - Sung, Junne-Ming
AU  - Sung JM
FAU - Wang, Saprina P H
AU  - Wang SP
FAU - Su, Yu-Ru
AU  - Su YR
FAU - Yang, Chun-Shin
AU  - Yang CS
FAU - Tsai, Liang-Miin
AU  - Tsai LM
FAU - Chen, Jyh-Hong
AU  - Chen JH
FAU - Tsai, Wei-Chuan
AU  - Tsai WC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - CJN.10671012 [pii]
AID - 10.2215/CJN.10671012 [doi]
PST - aheadofprint
SO  - Clin J Am Soc Nephrol. 2013 May 23.

PMID- 23704171
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Risk of incident diabetes among patients treated with statins: population based
      study.
PG  - f2610
LID - 10.1136/bmj.f2610 [doi]
LID - bmj.f2610 [pii]
AB  - OBJECTIVE: To examine the risk of new onset diabetes among patients treated with 
      different HMG-CoA reductase inhibitors (statins). DESIGN: Population based cohort
      study with time to event analyses to estimate the relation between use of
      particular statins and incident diabetes. Hazard ratios were calculated to
      determine the effect of dose and type of statin on the risk of incident diabetes.
      SETTING: Ontario, Canada. PARTICIPANTS: All patients aged 66 or older without
      diabetes who started treatment with statins from 1 August 1997 to 31 March 2010. 
      The analysis was restricted to new users who had not been prescribed a statin in 
      at least the preceding year. Patients with established diabetes before the start 
      of treatment were excluded. INTERVENTIONS: Treatment with statins. MAIN OUTCOME
      MEASURE: Incident diabetes. RESULTS: Compared with pravastatin (the reference
      drug in all analyses), there was an increased risk of incident diabetes with
      atorvastatin (adjusted hazard ratio 1.22, 95% confidence interval 1.15 to 1.29), 
      rosuvastatin (1.18, 1.10 to 1.26), and simvastatin (1.10, 1.04 to 1.17). There
      was no significantly increased risk among people who received fluvastatin (0.95, 
      0.81 to 1.11) or lovastatin (0.99, 0.86 to 1.14). The absolute risk for incident 
      diabetes was about 31 and 34 events per 1000 person years for atorvastatin and
      rosuvastatin, respectively. There was a slightly lower absolute risk with
      simvastatin (26 outcomes per 1000 person years) compared with pravastatin (23
      outcomes per 1000 person years). Our findings were consistent regardless of
      whether statins were used for primary or secondary prevention of cardiovascular
      disease. Although similar results were observed when statins were grouped by
      potency, the risk of incident diabetes associated with use of rosuvastatin became
      non-significant (adjusted hazard ratio 1.01, 0.94 to 1.09) when dose was taken
      into account. CONCLUSIONS: Compared with pravastatin, treatment with higher
      potency statins, especially atorvastatin and simvastatin, might be associated
      with an increased risk of new onset diabetes.
AD  - Toronto General Hospital, Toronto, ON, Canada M5G 2C4.
FAU - Carter, Aleesa A
AU  - Carter AA
FAU - Gomes, Tara
AU  - Gomes T
FAU - Camacho, Ximena
AU  - Camacho X
FAU - Juurlink, David N
AU  - Juurlink DN
FAU - Shah, Baiju R
AU  - Shah BR
FAU - Mamdani, Muhammad M
AU  - Mamdani MM
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
PMC - PMC3662830
OID - NLM: PMC3662830
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - epublish
SO  - BMJ. 2013 May 23;346:f2610. doi: 10.1136/bmj.f2610.

PMID- 23704108
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
DP  - 2013 May 23
TI  - Diabetes Mellitus, Admission Glucose, and Outcomes After Stroke Thrombolysis: A
      Registry and Systematic Review.
AB  - BACKGROUND AND PURPOSE: The potential detrimental effect of diabetes mellitus and
      admission glucose level (AGL) on outcomes after stroke thrombolysis is unclear.
      We evaluated outcomes of patients treated by intravenous or intra-arterial
      therapy, according to diabetes mellitus and AGL. METHODS: We analyzed data from a
      patient registry (n=704) and conducted a systematic review of previous
      observational studies. The primary study outcome was the percentage of patients
      who achieved a favorable outcome (modified Rankin score </=2 at 3 months).
      RESULTS: We identified 54 previous reports that evaluated the effect of diabetes 
      mellitus or AGL on outcomes after thrombolysis. In an unadjusted meta-analysis
      that included our registry data and previous available observational data,
      diabetes mellitus was associated with less favorable outcome (odds ratio [OR],
      0.76; 95% confidence interval [CI], 0.73-0.79) and more symptomatic intracranial 
      hemorrhage (OR, 1.38; 95% CI, 1.21-1.56). However, in multivariable analysis,
      diabetes mellitus remained associated with less favorable outcome (OR, 0.77; 95% 
      CI, 0.69-0.87) but not with symptomatic intracranial hemorrhage (OR, 1.11; 95%
      CI, 0.83-1.48). In unadjusted and in adjusted meta-analysis, higher AGL was
      associated with less favorable outcome and more symptomatic intracranial
      hemorrhage; the adjusted OR (95% CI) per 1 mmol/L increase in AGL was 0.92
      (0.90-0.94) for favorable outcome, and 1.09 (1.04-1.14) for symptomatic
      intracranial hemorrhage. CONCLUSIONS: These results confirm that AGL and history 
      of diabetes mellitus are associated with poor clinical outcome after
      thrombolysis. AGL may be a surrogate marker of brain infarction severity rather
      than a causal factor. However, randomized controlled evidences are needed to
      address the significance of a tight glucose control during thrombolysis on
      clinical outcome.
AD  - From the Department of Neurology and Stroke Centre, Bichat University Hospital,
      Paris, France.
FAU - Desilles, Jean-Philippe
AU  - Desilles JP
FAU - Meseguer, Elena
AU  - Meseguer E
FAU - Labreuche, Julien
AU  - Labreuche J
FAU - Lapergue, Bertrand
AU  - Lapergue B
FAU - Sirimarco, Gaia
AU  - Sirimarco G
FAU - Gonzalez-Valcarcel, Jaime
AU  - Gonzalez-Valcarcel J
FAU - Lavallee, Philippa
AU  - Lavallee P
FAU - Cabrejo, Lucie
AU  - Cabrejo L
FAU - Guidoux, Celine
AU  - Guidoux C
FAU - Klein, Isabelle
AU  - Klein I
FAU - Amarenco, Pierre
AU  - Amarenco P
FAU - Mazighi, Mikael
AU  - Mazighi M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Stroke
JT  - Stroke; a journal of cerebral circulation
JID - 0235266
OTO - NOTNLM
OT  - acute stroke syndromes
OT  - diabetes mellitus
OT  - glucose
OT  - thrombolysis
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - STROKEAHA.111.000813 [pii]
AID - 10.1161/STROKEAHA.111.000813 [doi]
PST - aheadofprint
SO  - Stroke. 2013 May 23.

PMID- 23704064
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 81
IP  - 7
DP  - 2013 Jun 1
TI  - Drug-eluting stents and diabetes: A generation gap?
PG  - 1115-6
LID - 10.1002/ccd.24962 [doi]
AD  - Division of Cardiovascular Diseases, Mayo Clinic, Jacksonville, Florida.
FAU - Parikh, Pragnesh P
AU  - Parikh PP
FAU - Levy, Michael S
AU  - Levy MS
LA  - eng
PT  - Editorial
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the
      Society for Cardiac Angiography & Interventions
JID - 100884139
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/12 [received]
PHST- 2013/04/13 [accepted]
AID - 10.1002/ccd.24962 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1115-6. doi: 10.1002/ccd.24962.

PMID- 23704051
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 23
TI  - Serum visfatin levels and metabolic syndrome criteria in obese female subjects.
LID - 10.1002/dmrr.2430 [doi]
AB  - BACKGROUND: Serum visfatin are associated with cardiovascular risk factors and
      obesity. Relation of this adipokine with nmetabolic syndrome is unclear. We
      decide to investigate the association between metabolic syndrome and resistin
      levels in female obese subjects. SUBJECTS: A sample of 826 female obese subjects 
      was analyzed. A complete nutritional and biochemical evaluation was performed.
      Serum visfatin levels were measured and to estimate the prevalence of Metabolic
      Syndrome, the definitions of the ATPIII was considered RESULTS: Mean age was 48.1
      + 12.6 years. Patients were divided in three groups by tertiles of visfatin
      value, group I (< 7.94 ng/ml), group II (7.95 ng/ml- 11.78 ng/ml) and group 3 (> 
      11.79 ng/ml). A total of 350 females had metabolic syndrome (42.4%). Values of
      body mass index (BMI), weight, fat mass and waist circumference were lower in
      patients in the highest tertile group of visfatin than the lowest and middle
      tertiles of visfatin. Values of C reactive protein were higher in patients in the
      highest tertile group of visfatin than the lowest and middle tertiles of
      visfatin. Correlation analysis showed a significant correlation among serum
      visfatin levels and the independent variables; total cholesterol (r = 0.14;p <
      0.05) and C reactive protein (r = 0.12;p < 0.05). In the multivariate analysis,
      only visfatin concentration increase 0.123 ng/ml (CI95%:0.033-0.445) for each
      mg/dl of C reactive protein. CONCLUSION: Only C reactive protein remained
      associated, in an independent way. Serum visfatin was not associated with the
      accumulation of metabolic syndrome factors or the diagnosis of metabolic syndrome
      in obese female subjects. This article is protected by copyright. All rights
      reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Center of Investigation of Endocrinology and Clinical Nutrition, Medicine School 
      and Unit of Investigation, Hospital Rio Hortega, University of Valladolid,
      Valladolid, Spain.
FAU - de Luis, D A
AU  - de Luis DA
FAU - Aller, R
AU  - Aller R
FAU - Gonzalez Sagrado, M
AU  - Gonzalez Sagrado M
FAU - Conde, R
AU  - Conde R
FAU - Izaola, O
AU  - Izaola O
FAU - de la Fuente, B
AU  - de la Fuente B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/02/20 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/05/18 [accepted]
AID - 10.1002/dmrr.2430 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 23. doi: 10.1002/dmrr.2430.

PMID- 23704008
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 23
TI  - Cystic fibrosis-related diabetes compared to type 1 and type 2 diabetes in
      adults.
LID - 10.1002/dmrr.2429 [doi]
AB  - BACKGROUND: With increasing life expectancy of CF-patients, secondary diabetes
      becomes more prevalent. It appears to be the most common co-morbidity in persons 
      with cystic fibrosis. Therefore, the objective of our study was to describe
      characteristics of cystic fibrosis related diabetes (CFRD) compared to type 1 and
      2 diabetes (T1DM / T2DM) in adults. METHODS: Data from 218,436 patients >18 years
      with CFRD (n = 401), T1DM (n = 32,409) or T2DM (n = 185,626) in the multicenter
      DPV registry were analyzed. RESULTS: Diabetes onset (median [interquartile
      range]) in CFRD (18.70 [15.50-25.30] years) was between T1DM (16.40
      [10.50-31.80]) and T2DM (58.50 [48.80-68.00], with female preponderance. BMI and 
      HbA1c were lowest (19.6 [18.1 - 21.5] kg/m2 ) / 50 mmol/mol (6.73%) vs.T1DM: 24.4
      [22.1 - 27.4]) / 62 mmol/mol (7.83%) vs. T2DM: 29.6 [26.1 - 33.9]) / 54 mmol/mol 
      (7.06%); all p <0.01). 78.6% of CFRD patients received insulin. Insulin dose
      (0.74 IE per kilogram bodyweight) was not significantly different from T1DM
      (0.73) and T2DM (0.76). Frequency of vascular complications, adjusted for
      confounding effects, across the groups was different: Hypertension: (CFRD: 16.1% 
      vs. T1DM: 24.0% vs. T2DM: 32.2%; all p < 0.01), retinopathy: (CFRD: 10.7% vs.
      T1DM: 10.4% vs. T2DM 10.5%; n. s.), nephropathy: (CFRD: 25.2% vs. T1DM: 17.2% vs.
      T2DM: 24.7%; only T1DM / T2DM p < 0.01). CONCLUSION: CFRD is a uniquely complex
      entity with clear differences from T1DM and T2DM in adults. This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Pediatrics II, Pediatric Endocrinology and Diabetes, University
      Children's Hospital Essen, Essen, Germany.
FAU - Konrad, Katja
AU  - Konrad K
FAU - Scheuing, Nicole
AU  - Scheuing N
FAU - Badenhoop, Klaus
AU  - Badenhoop K
FAU - Borkenstein, Martin H
AU  - Borkenstein MH
FAU - Gohlke, Bettina
AU  - Gohlke B
FAU - Schofl, Christof
AU  - Schofl C
FAU - Seufert, Jochen
AU  - Seufert J
FAU - Thon, Angelika
AU  - Thon A
FAU - Holl, Reinhard W
AU  - Holl RW
CN  - for the German/Austrian DPV Initiative
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/03/13 [received]
PHST- 2013/05/18 [accepted]
AID - 10.1002/dmrr.2429 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 23. doi: 10.1002/dmrr.2429.

PMID- 23703931
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Linking)
DP  - 2013 May 23
TI  - Association of IL28B genotype with fibrosis progression and clinical outcomes in 
      patients with chronic hepatitis C: A longitudinal analysis.
LID - 10.1002/hep.26506 [doi]
AB  - Background: IL28B polymorphisms are associated with spontaneous clearance of HCV 
      infection and response to therapy. Whether IL28B genotype affects fibrosis
      progression or clinical outcome is unclear. Aims: To study the relationship
      between IL28B genotype and both histological and clinical outcomes in patients
      with chronic hepatitis C (CHC). Methods: Hepatic fibrosis was scored using the
      Ishak (0-6) scale; progression was defined as a 2-point increase in Ishak score
      between biopsies. Multiple logistic and Cox regressions were used to identify
      variables associated with fibrosis progression. Results: 1483 patients were
      included in a baseline cross-sectional analysis, from which 276 were eligible for
      a paired biopsy analysis (median time between biopsies-4 years), and 400 for a
      clinical outcome analysis. At baseline biopsy, patients with IL28B CC genotype
      had significantly higher portal inflammation (2.4 vs. 2.2) and ALT levels (133
      vs. 105 U/L), p <0.05 for all. In the paired biopsy analysis, there was no
      difference in the frequency of fibrosis progression between patients with IL28B
      CC and non-CC genotypes (17% vs. 23%). In logistic regression, only higher
      baseline alkaline phosphatase, lower platelets and greater hepatic steatosis were
      associated with fibrosis progression. Patients with IL28B CC were twice as likely
      to develop adverse clinical outcomes compared to non-CC (32% vs. 16%), P= 0.007. 
      Conclusions: IL28B CC genotype was associated with greater hepatic
      necroinflammation, higher ALT, and worse clinical outcomes in CHC patients. This 
      suggests that IL28B CC is associated with a state of enhanced immunity that on
      one hand can promote viral clearance, but alternately, can increase
      necroinflammation and hepatic decompensation without enhancing fibrosis
      progression. (HEPATOLOGY 2013.).
CI  - Copyright (c) 2013 American Association for the Study of Liver Diseases.
AD  - Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney
      Diseases.
FAU - Noureddin, Mazen
AU  - Noureddin M
FAU - Wright, Elizabeth C
AU  - Wright EC
FAU - Alter, Harvey
AU  - Alter H
FAU - Clark, Shauna
AU  - Clark S
FAU - Thomas, Emmanuel
AU  - Thomas E
FAU - Chen, Richard
AU  - Chen R
FAU - Zhao, Xiongce
AU  - Zhao X
FAU - Conry-Cantilena, Cathy
AU  - Conry-Cantilena C
FAU - Kleiner, David
AU  - Kleiner D
FAU - Liang, T Jake
AU  - Liang TJ
FAU - Ghany, Marc G
AU  - Ghany MG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/12/11 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/04/26 [accepted]
AID - 10.1002/hep.26506 [doi]
PST - aheadofprint
SO  - Hepatology. 2013 May 23. doi: 10.1002/hep.26506.

PMID- 23703906
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1757-4684 (Electronic)
IS  - 1757-4676 (Linking)
VI  - 5
IP  - 6
DP  - 2013 Jun
TI  - Wolfram Syndrome protein, Miner1, regulates sulphydryl redox status, the unfolded
      protein response, and Ca(2+) homeostasis.
PG  - 904-18
LID - 10.1002/emmm.201201429 [doi]
AB  - Miner1 is a redox-active 2Fe2S cluster protein. Mutations in Miner1 result in
      Wolfram Syndrome, a metabolic disease associated with diabetes, blindness,
      deafness, and a shortened lifespan. Embryonic fibroblasts from Miner1(-/-) mice
      displayed ER stress and showed hallmarks of the unfolded protein response. In
      addition, loss of Miner1 caused a depletion of ER Ca(2+) stores, a dramatic
      increase in mitochondrial Ca(2+) load, increased reactive oxygen and nitrogen
      species, an increase in the GSSG/GSH and NAD(+) /NADH ratios, and an increase in 
      the ADP/ATP ratio consistent with enhanced ATP utilization. Furthermore,
      mitochondria in fibroblasts lacking Miner1 displayed ultrastructural alterations,
      such as increased cristae density and punctate morphology, and an increase in O2 
      consumption. Treatment with the sulphydryl anti-oxidant N-acetylcysteine reversed
      the abnormalities in the Miner1 deficient cells, suggesting that sulphydryl
      reducing agents should be explored as a treatment for this rare genetic disease.
CI  - Copyright (c) 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf
      of EMBO.
AD  - Department of Pharmacology, University of California, San Diego, La Jolla, CA,
      USA.
FAU - Wiley, Sandra E
AU  - Wiley SE
FAU - Andreyev, Alexander Y
AU  - Andreyev AY
FAU - Divakaruni, Ajit S
AU  - Divakaruni AS
FAU - Karisch, Robert
AU  - Karisch R
FAU - Perkins, Guy
AU  - Perkins G
FAU - Wall, Estelle A
AU  - Wall EA
FAU - van der Geer, Peter
AU  - van der Geer P
FAU - Chen, Yi-Fan
AU  - Chen YF
FAU - Tsai, Ting-Fen
AU  - Tsai TF
FAU - Simon, Melvin I
AU  - Simon MI
FAU - Neel, Benjamin G
AU  - Neel BG
FAU - Dixon, Jack E
AU  - Dixon JE
FAU - Murphy, Anne N
AU  - Murphy AN
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - England
TA  - EMBO Mol Med
JT  - EMBO molecular medicine
JID - 101487380
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/04/01 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/03/27 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 10.1002/emmm.201201429 [doi]
PST - ppublish
SO  - EMBO Mol Med. 2013 Jun;5(6):904-18. doi: 10.1002/emmm.201201429. Epub 2013 May
      24.

PMID- 23703888
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Linking)
DP  - 2013 May 27
TI  - Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third
      National Health and Nutrition Examination Survey, 1988-1994.
AB  - Previous estimates of the prevalence of nonalcoholic fatty liver disease (NAFLD) 
      in the US population relied on measures of liver enzymes, potentially
      underestimating the burden of this disease. We used ultrasonography data from
      12,454 adults who participated in the Third National Health and Nutrition
      Examination Survey, conducted in the United States from 1988 to 1994. We defined 
      NAFLD as the presence of hepatic steatosis on ultrasonography in the absence of
      elevated alcohol consumption. In the US population, the rates of prevalence of
      hepatic steatosis and NAFLD were 21.4% and 19.0%, respectively, corresponding to 
      estimates of 32.5 (95% confidence interval: 29.9, 35.0) million adults with
      hepatic steatosis and 28.8 (95% confidence interval: 26.6, 31.2) million adults
      with NAFLD nationwide. After adjustment for age, income, education, body mass
      index (weight (kg)/height (m)2), and diabetes status, NAFLD was more common in
      Mexican Americans (24.1%) compared with non-Hispanic whites (17.8%) and
      non-Hispanic blacks (13.5%) (P = 0.001) and in men (20.2%) compared with women
      (15.8%) (P < 0.001). Hepatic steatosis and NAFLD were also independently
      associated with diabetes, with insulin resistance among people without diabetes, 
      with dyslipidemia, and with obesity. Our results extend previous national
      estimates of the prevalence of NAFLD in the US population and highlight the
      burden of this disease. Men, Mexican Americans, and people with diabetes and
      obesity are the most affected groups.
FAU - Lazo, Mariana
AU  - Lazo M
FAU - Hernaez, Ruben
AU  - Hernaez R
FAU - Eberhardt, Mark S
AU  - Eberhardt MS
FAU - Bonekamp, Susanne
AU  - Bonekamp S
FAU - Kamel, Ihab
AU  - Kamel I
FAU - Guallar, Eliseo
AU  - Guallar E
FAU - Koteish, Ayman
AU  - Koteish A
FAU - Brancati, Frederick L
AU  - Brancati FL
FAU - Clark, Jeanne M
AU  - Clark JM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130527
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
OTO - NOTNLM
OT  - ethnic variation
OT  - nonalcoholic fatty liver disease
OT  - population surveys
OT  - prevalence
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/05/23 [aheadofprint]
AID - kws448 [pii]
AID - 10.1093/aje/kws448 [doi]
PST - aheadofprint
SO  - Am J Epidemiol. 2013 May 27.

PMID- 23703881
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1523-4681 (Electronic)
IS  - 0884-0431 (Linking)
DP  - 2013 May 23
TI  - Kidney stones: A fetal origins hypothesis.
LID - 10.1002/jbmr.1993 [doi]
AB  - Kidney stones are common with a multifactorial aetiology involving dietary,
      environmental and genetic factors. In addition, patients with nephrolithiasis are
      at greater risk of hypertension, diabetes, metabolic syndrome, and osteoporosis
      although the basis for this is not fully understood. All of these renal stone
      associated conditions have also been linked with adverse early life events,
      including low birth weight, and it has been suggested that this developmental
      effect is due to excess exposure to maternal glucocorticoids in utero. This is
      proposed to result in long-term increased hypothalamic-pituitary-axis activation 
      and there are mechanisms through which this effect could also promote urinary
      lithogenic potential. We therefore hypothesise that the association between renal
      stone disease and hypertension, diabetes, metabolic syndrome and osteoporosis may
      be related by a common pathway of programming in early life which, if validated, 
      would implicate the developmental origins hypothesis in the aetiology of
      nephrolithiasis.
CI  - Copyright (c) 2013 American Society for Bone and Mineral Research.
AD  - Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United
      Kingdom; Radcliffe Department of Medicine, University of Oxford, Oxford, United
      Kingdom.
FAU - Howles, Sarah A
AU  - Howles SA
FAU - Edwards, Mark H
AU  - Edwards MH
FAU - Cooper, Cyrus
AU  - Cooper C
FAU - Thakker, Rajesh V
AU  - Thakker RV
LA  - ENG
GR  - MC_U147585819/Medical Research Council/United Kingdom
GR  - MC_UP_A620_1014/Medical Research Council/United Kingdom
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Bone Miner Res
JT  - Journal of bone and mineral research : the official journal of the American
      Society for Bone and Mineral Research
JID - 8610640
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/02/06 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/05/09 [accepted]
AID - 10.1002/jbmr.1993 [doi]
PST - aheadofprint
SO  - J Bone Miner Res. 2013 May 23. doi: 10.1002/jbmr.1993.

PMID- 23703842
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
DP  - 2013 May 22
TI  - Clinical effects of routine postdilatation of drug-eluting stents.
LID - 10.1002/ccd.24999 [doi]
AB  - Objectives To assess the clinical effects of postdilatation of DES Background
      Subotpimal stent expansion occurs after DES deployment. Postidlatation may
      improve DES expansion, but it is unclear whether postdilatation may also improve 
      clinical outcomes. Methods Since July 2009 we adopted a strategy of routine
      postdilatation with non-compliant balloons of all DES, while previously
      postdilatation was performed only for suboptimal results. The first 279
      consecutive patients (age 62+/-9 years, 231 men) who underwent routine
      postilatation were compared with 262 patients (age 61+/-9 years, 220 men) who
      received DES in the previous 6 months (standard treatment). Results The two
      groups were similar for age, sex, clinical presentation and main risk factors,
      including incidence of diabetes. Routine postdilatation resulted in an improved
      minimal lumen diameter at the end of the procedure (2.60+/-0.34 vs. 2.51+/-0.37
      mm, P=0.003). At 12-month follow-up incidence of MACE (including periprocedural
      myocardial infarction) was 19.5% in the standard treatment group and 12.5% in
      routine postdilatation group (P=0.04), with a significant difference in target
      vessel revascularization (10.7% vs. 5.4%, P=0.03), while incidence of myocardial 
      infarction was not significantly different between the two groups (10.7% vs.
      9.3%, P=0.70). Stent thrombosis (definite or probable) occurred in 3 patients in 
      standard treatment group, while no case of stent thrombosis occurred among
      patients treated with routine postdilatation (1.1% vs. 0%, P=0.11). Conclusions
      Our results suggest that a strategy of routine postdilatation with non compliant 
      balloons may improve clinical outcomes of DES. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc., a Wiley company.
AD  - Interventional Cardiology, San Filippo Neri Hospital, Rome, Italy.
FAU - Pasceri, Vincenzo
AU  - Pasceri V
FAU - Pelliccia, Francesco
AU  - Pelliccia F
FAU - Pristipino, Christian
AU  - Pristipino C
FAU - Roncella, Adriana
AU  - Roncella A
FAU - Irini, Diego
AU  - Irini D
FAU - Varveri, Antonio
AU  - Varveri A
FAU - Bisciglia, Andrea
AU  - Bisciglia A
FAU - Speciale, Giulio
AU  - Speciale G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the
      Society for Cardiac Angiography & Interventions
JID - 100884139
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2011/12/26 [received]
PHST- 2013/05/07 [revised]
PHST- 2013/05/12 [accepted]
AID - 10.1002/ccd.24999 [doi]
PST - aheadofprint
SO  - Catheter Cardiovasc Interv. 2013 May 22. doi: 10.1002/ccd.24999.

PMID- 23703648
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1537-1948 (Electronic)
IS  - 0025-7079 (Linking)
DP  - 2013 May 23
TI  - Potentially Avoidable Hospitalizations for Elderly Long-stay Residents in Nursing
      Homes.
AB  - BACKGROUND:: Hospitalizations of long-stay nursing home (NH) residents are
      common. The high estimates of potentially avoidable hospitalizations in NHs
      suggest that efforts to reduce avoidable hospitalizations may be effective in
      lowering health care expenditures as well as improving the quality of care for NH
      residents. OBJECTIVE:: To determine the relationship between clinical risk
      factors, facility characteristics and State policy variables, and both avoidable 
      and unavoidable hospitalizations. METHOD:: Hospitalization risk is estimated
      using competing risks proportional hazards regressions. Three hospitalization
      measures were constructed: (1) ambulatory care-sensitive conditions (ACSCs); (2) 
      additional NH-sensitive avoidable conditions (ANHACs); and (3) nursing home
      "unavoidable" conditions (NHUCs). In all models, we include clinical risk
      factors, facility characteristics, and State policy variables that may influence 
      the decision to hospitalize. SUBJECTS:: The population of interest is a cohort of
      long-stay NH residents. Data are from the Nursing Home Stay file, a sample of
      residents in 10% of certified NHs in the United States (2006-2008). RESULTS::
      Three fifths of hospitalizations were potentially avoidable and the majority was 
      for infections, injuries, and congestive heart failure. Clinical risk factors
      include renal disease, diabetes, and a high number of medications among others.
      Staffing, quality, and reimbursement affect avoidable, but not unavoidable
      hospitalizations. CONCLUSIONS:: A NH-sensitive measure of avoidable
      hospitalizations identifies both clinical facility and policy risk factors,
      emphasizing the potential for both reimbursement and clinical strategies to
      reduce hospitalizations from NHs.
AD  - *Agency for Healthcare Research & Quality, Rockville daggerSocial & Scientific
      Systems Inc., Silver Spring, MD double daggerAbt Associates, Durham, NC section
      signAbt Associates, Cambridge, MA.
FAU - Spector, William D
AU  - Spector WD
FAU - Limcangco, Rhona
AU  - Limcangco R
FAU - Williams, Christianna
AU  - Williams C
FAU - Rhodes, William
AU  - Rhodes W
FAU - Hurd, Donna
AU  - Hurd D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Med Care
JT  - Medical care
JID - 0230027
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1097/MLR.0b013e3182984bff [doi]
PST - aheadofprint
SO  - Med Care. 2013 May 23.

PMID- 23703631
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1476-5454 (Electronic)
IS  - 0950-222X (Linking)
DP  - 2013 May 24
TI  - Pathogenic conjunctival bacteria associated with systemic co-morbidities of
      patients undergoing cataract surgery.
LID - 10.1038/eye.2013.103 [doi]
AB  - PurposeTo identify the risk of patients undergoing cataract surgery of having
      pathogenic conjunctival bacteria associated with their systemic
      co-morbidities.MethodsRetrospective study of consecutive patients undergoing
      their first cataract operation from July 2005 to April 2010. Their preoperative
      conjunctival bacteria were cultured, identified, and classified in bacterial
      groups. Their co-morbidities were defined from their clinical data and the
      answers to systematic questions asked in the anaesthetic evaluation. The
      Microsoft Access databases of the two data sets were merged for carrying out the 
      statistical analysis. Univariate association of each bacterial group with each
      co-morbidity was studied by using chi2-test for categorical data and Student's
      t-test for continuous variables. Also, logistic regression models were used
      adjusting for age and sex. SPSS statistic programme, version 18 was used for all 
      these analyses. Endophthalmitis cases in this surgical series were
      searched.ResultsIn the 8333 selected patients, age was associated with increased 
      conjunctival bacteria in all groups except for Streptococcus pneumoniae and
      Propionibacteriae. However, male sex was associated with these two groups and
      also with coagulase-negative Staphylococci, Corynebacterium xerosis,
      Staphylococcus aureus, and Gram-negative rods. After adjusting for age and sex,
      S. aureus was associated with diabetes, lung diseases, and renal and heart
      insufficiency; Gram-negative rods with smoking habit; Enterococci with diabetes; 
      Streptococcus pneumoniae with kyphoscoliosis; and other Streptococci with
      diabetes and handicapped patients.ConclusionThe more pathogenic conjunctival
      bacteria were more likely associated with patients' co-morbidities, such as
      diabetes, lung diseases, renal and heart insufficiency, kyphoscoliosis, and
      smoking habit, than the less pathogenic ones.Eye advance online publication, 24
      May 2013; doi:10.1038/eye.2013.103.
AD  - Ophthalmic Institute Laboratory, Department of Ophthalmology, "Gregorio Maranon" 
      University General Hospital, Madrid, Spain.
FAU - Fernandez-Rubio, M-E
AU  - Fernandez-Rubio ME
FAU - Cuesta-Rodriguez, T
AU  - Cuesta-Rodriguez T
FAU - Urcelay-Segura, J-L
AU  - Urcelay-Segura JL
FAU - Cortes-Valdes, C
AU  - Cortes-Valdes C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/05/24 [aheadofprint]
AID - eye2013103 [pii]
AID - 10.1038/eye.2013.103 [doi]
PST - aheadofprint
SO  - Eye (Lond). 2013 May 24. doi: 10.1038/eye.2013.103.

PMID- 23703573
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 2092-6413 (Electronic)
IS  - 1226-3613 (Linking)
VI  - 45
DP  - 2013
TI  - B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin
      secretion via induction of PDX-1 in pancreatic beta-cells.
PG  - e25
LID - 10.1038/emm.2013.47 [doi]
AB  - Glucagon-like peptide-1 (GLP-1) is a potent glucoincretin hormone and an
      important agent for the treatment of type 2 diabetes. Here we demonstrate that
      B-cell translocation gene 2 (BTG2) is a crucial regulator in GLP-1-induced
      insulin gene expression and insulin secretion via upregulation of pancreatic
      duodenal homeobox-1 (PDX-1) in pancreatic beta-cells. GLP-1 treatment
      significantly increased BTG2, PDX-1 and insulin gene expression in pancreatic
      beta-cells. Notably, adenovirus-mediated overexpression of BTG2 significantly
      elevated insulin secretion, as well as insulin and PDX-1 gene expression.
      Physical interaction studies showed that BTG2 is associated with increased PDX-1 
      occupancy on the insulin gene promoter via a direct interaction with PDX-1.
      Exendin-4 (Ex-4), a GLP-1 agonist, and GLP-1 in pancreatic beta-cells increased
      insulin secretion through the BTG2-PDX-1-insulin pathway, which was blocked by
      endogenous BTG2 knockdown using a BTG2 small interfering RNA knockdown system.
      Finally, we revealed that Ex-4 and GLP-1 significantly elevated insulin secretion
      via upregulation of the BTG2-PDX-1 axis in pancreatic islets, and this phenomenon
      was abolished by endogenous BTG2 knockdown. Collectively, our current study
      provides a novel molecular mechanism by which GLP-1 positively regulates insulin 
      gene expression via BTG2, suggesting that BTG2 has a key function in insulin
      secretion in pancreatic beta-cells.
AD  - College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
FAU - Hwang, Seung-Lark
AU  - Hwang SL
FAU - Kwon, Okyun
AU  - Kwon O
FAU - Kim, Sun-Gyun
AU  - Kim SG
FAU - Lee, In-Kyu
AU  - Lee IK
FAU - Kim, Yong Deuk
AU  - Kim YD
LA  - eng
PT  - Journal Article
DEP - 20130524
PL  - United States
TA  - Exp Mol Med
JT  - Experimental & molecular medicine
JID - 9607880
SB  - IM
PMC - PMC3674408
OID - NLM: PMC3674408
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - emm201347 [pii]
AID - 10.1038/emm.2013.47 [doi]
PST - epublish
SO  - Exp Mol Med. 2013 May 24;45:e25. doi: 10.1038/emm.2013.47.

PMID- 23703557
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1016-5169 (Print)
IS  - 1016-5169 (Linking)
VI  - 41
IP  - 3
DP  - 2013 May
TI  - [The prevalence of alternative herbal medicine and nutritional complementary
      product intake in patients admitted to out-patient cardiology departments].
PG  - 218-24
LID - 10.5543/tkda.2013.15146 [doi]
AB  - Objectives: To detect the prevalence of alternative herbal medicine and
      nutritional complementary product intake in patients admitted to outpatient
      cardiology clinics and to determine demographic characteristics, comorbidities
      and medical properties of those patients. Study design: Patients admitted to
      outpatient cardiology clinics between June 2011 and March 2012 were given
      questionnaires involving age, gender, education, occupation, chronic illness,
      medication, herbs, nutritional complementary products, the index purpose and
      motivation for using herbs and nutritional complementary products. The data of
      those questionnaires were analyzed. Results: A total of 454 questionnaires were
      collected. The mean age was 49+/-13 and 48% of the participants were female. Of
      those patients, 12% had diabetes, 34% had hypertension, 26% had coronary artery
      disease, 7% had heart failure, 58% had chronic illness, 49% had cardiovascular
      disease, and 57% had history of drug intake. Including vitamins and minerals,
      there were 75 (16%) patients taking alternative and complementary medicine. When 
      vitamins and minerals were excluded, 56 (12%) patients were using at least one
      product, while 24 (5%) patients were using more than one. Garlic (n=33), flaxseed
      (n=13), ginger (n=12), omega 3 (n=12), and turmeric (n=11) were the most popular 
      products. Of those 56 patients, 32% were using alternative medicine for
      hypertension and 23% for hyperlipidemia treatment, while 20% were using those
      products to be healthier in general. Alternative medicine was more prominent in
      females (p=0.04), and older patients (p=0.004). Education level, drug intake, and
      the presence of chronic illnesses, hypertension and cardiovascular disease were
      significantly higher in those patients. Conclusion: Alternative and complementary
      products were common in patients admitted to outpatient cardiology clinics.
      Female gender, advanced age, higher education level, drug intake, and having a
      chronic illness were predisposing factors.
AD  - Clinic of Cardiology, Polatli State Hospital, Ankara, Turkey.
      esragucuk@hotmail.com.
FAU - Gucuk Ipek, Esra
AU  - Gucuk Ipek E
FAU - Guray, Yesim
AU  - Guray Y
FAU - Demirkan, Burcu
AU  - Demirkan B
FAU - Guray, Umit
AU  - Guray U
FAU - Kafes, Habibe
AU  - Kafes H
FAU - Basyigit, Funda
AU  - Basyigit F
LA  - tur
PT  - English Abstract
PT  - Journal Article
TT  - Kardiyoloji poliklinigine basvuran hastalarda bitkisel kokenli alternatif
      tedavilerin ve tamamlayici besin urunlerinin tuketim prevalansi
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2013 May;41(3):218-24. doi: 10.5543/tkda.2013.15146.

PMID- 23703555
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1016-5169 (Print)
IS  - 1016-5169 (Linking)
VI  - 41
IP  - 3
DP  - 2013 May
TI  - Clinical and morphological evaluation of coronary bifurcation lesions.
PG  - 207-11
LID - 10.5543/tkda.2013.38073 [doi]
AB  - Objectives: We aimed to investigate the anatomical and morphological
      characterization of coronary bifurcation lesions. Study design: The study
      population consisted of 542 stable patients who underwent coronary angiography.
      Bifurcation lesions were defined as a lesion >=50% diameter stenosis involving a 
      main branch and/or contiguous side branch with a diameter of >=2.5 mm. Using
      these criteria, the presence and number of bifurcation lesions, bifurcation
      lesion location, lesion classification according to Medina classification and the
      angle of the bifurcation lesion were determined. Results: According to the
      bifurcation definition 19.3% (n=105) of our patients had bifurcation lesions. In 
      77% of all bifurcation lesions, the bifurcation angle was <70 degrees . About 37%
      of all lesions were concordant with the Medina 1.1.1 classification.
      Approximately 56% of bifurcation lesions were in the LAD region, 25.4% in the Cx 
      region, and 12.5% in the RCA region. Medina 1.1.1 was the most frequently
      observed in the LAD and RCA regions, while it was least common in the Cx and LMCA
      regions. Diabetes was observed to be significantly higher in those with
      bifurcation lesions than in those without. Conclusion: Bifurcation lesions are
      frequently observed in coronary angiography practice. Angiographic
      characteristics and the relationship of these lesions with clinical conditions
      may be a crucial factor in choosing the appropriate interventional procedure.
AD  - Department of Cardiology, Mustafa Kemal University, Faculty of Medicine, Hatay,
      Turkey. drmustafakurt@yahoo.com.
FAU - Kurt, Mustafa
AU  - Kurt M
FAU - Tanboga, Ibrahim Halil
AU  - Tanboga IH
FAU - Karakas, Mehmet Fatih
AU  - Karakas MF
FAU - Buyukkaya, Eyup
AU  - Buyukkaya E
FAU - Akcay, Adnan Burak
AU  - Akcay AB
FAU - Sen, Nihat
AU  - Sen N
FAU - Aksakal, Enbiya
AU  - Aksakal E
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2013 May;41(3):207-11. doi: 10.5543/tkda.2013.38073.

PMID- 23703521
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 0091-3847 (Print)
IS  - 0091-3847 (Linking)
VI  - 41
IP  - 2
DP  - 2013 May
TI  - Letter to the Editor: AAP clinical guidelines on nutrition and fitness for people
      with diabetes.
PG  - 87-8
LID - 10.3810/psm.2013.05.2012 [doi]
AD  - Pediatrician, Pediatric Medical Associates, Vista, CA Senior Health Strategist,
      American Council on Exercise.
FAU - Muth, Natalie Digate
AU  - Muth ND
FAU - Bryant, Cedric X
AU  - Bryant CX
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Phys Sportsmed
JT  - The Physician and sportsmedicine
JID - 0427461
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.3810/psm.2013.05.2012 [doi]
PST - ppublish
SO  - Phys Sportsmed. 2013 May;41(2):87-8. doi: 10.3810/psm.2013.05.2012.

PMID- 23703503
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1437-1588 (Electronic)
VI  - 56
IP  - 5-6
DP  - 2013 May
TI  - [Socioeconomic status and health : Results of the German Health Interview and
      Examination Survey for Adults (DEGS1)].
PG  - 814-21
LID - 10.1007/s00103-013-1695-4 [doi]
AB  - The analysis focuses on the connection between socioeconomic status (SES) and
      five health outcomes in the 18 to 79-year-old population of Germany. It uses data
      from the "German Health Interview and Examination Survey for Adults" (DEGS1)
      which the Robert Koch Institute conducted in the period from 2008 to 2011
      (n=8152). Socioeconomic status is recorded via a multidimensional index which
      includes information on education attainment, occupational status and household
      income. The results show that persons with a low socioeconomic status have a
      self-rated health status which is worse than that of persons with a medium or
      high socioeconomic status, and that they have diabetes more frequently. They also
      have a higher risk of depressive symptoms, obesity and physical inactivity. The
      results illustrate that health chances and the risk of illness are still very
      socially uneven distributed, thus emphasising the significance of political
      interventions to reduce health inequalities. An English full-text version of this
      article is available at SpringerLink as supplemental.
AD  - Abteilung fur Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut,
      General-Pape-Str. 62-66, 12101, Berlin, Deutschland, t.lampert@rki.de.
FAU - Lampert, T
AU  - Lampert T
FAU - Kroll, L E
AU  - Kroll LE
FAU - von der Lippe, E
AU  - von der Lippe E
FAU - Muters, S
AU  - Muters S
FAU - Stolzenberg, H
AU  - Stolzenberg H
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Soziookonomischer Status und Gesundheit : Ergebnisse der Studie zur Gesundheit
      Erwachsener in Deutschland (DEGS1).
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1007/s00103-013-1695-4 [doi]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013
      May;56(5-6):814-21. doi: 10.1007/s00103-013-1695-4.

PMID- 23703485
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1437-1588 (Electronic)
VI  - 56
IP  - 5-6
DP  - 2013 May
TI  - [Prevalence and temporal trend of known diabetes mellitus : Results of the German
      Health Interview and Examination Survey for Adults (DEGS1)].
PG  - 668-77
LID - 10.1007/s00103-012-1662-5 [doi]
AB  - The first wave of the "German Health Interview and Examination Survey for Adults"
      (DEGS1, 2008-2011) allows for up-to-date, representative prevalence estimates of 
      known diabetes amongst the 18- to 79-year-old resident population of Germany.
      Temporal trends can be shown by comparing the survey findings with those of the
      "German National Health Interview and Examination Survey 1998" (GNHIES98). The
      definition of known diabetes was based on self-reports in physician-administered 
      interviews that asked respondents if they had ever been diagnosed with diabetes
      by a doctor or were on anti-diabetic medication. Overall, diabetes had been
      diagnosed in 7.2 % of the adults (7.4 % of the women; 7.0 % of the men). The
      prevalence increased substantially with advancing age and was higher in persons
      of low than of high socioeconomic status. Prevalence varied depending on the type
      of health insurance held and was highest amongst those insured with AOK health
      insurance funds. In comparison with GNHIES98, there was a 38 % increase in
      prevalence, of which approximately one third is to be attributed to demographic
      ageing. In the context of other nationwide studies, the results indicate a figure
      of at least 4.6 million 18- to 79-year-olds having been diagnosed with diabetes
      at some point. Planned analyses of undiagnosed diabetes will contribute to the
      interpretation of the observed increase in the prevalence of known diabetes. An
      English full-text version of this article is available at SpringerLink as
      supplemental.
AD  - Abteilung fur Epidemiologie und Gesundheitsmonitoring, Robert Koch-Institut,
      General-Pape-Str. 62-66, 12101, Berlin, Deutschland, HeidemannC@rki.de.
FAU - Heidemann, C
AU  - Heidemann C
FAU - Du, Y
AU  - Du Y
FAU - Schubert, I
AU  - Schubert I
FAU - Rathmann, W
AU  - Rathmann W
FAU - Scheidt-Nave, C
AU  - Scheidt-Nave C
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Pravalenz und zeitliche Entwicklung des bekannten Diabetes mellitus : Ergebnisse 
      der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1).
PL  - Germany
TA  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
JT  - Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
JID - 101181368
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1007/s00103-012-1662-5 [doi]
PST - ppublish
SO  - Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013
      May;56(5-6):668-77. doi: 10.1007/s00103-012-1662-5.

PMID- 23703380
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1532-6551 (Electronic)
IS  - 1071-3581 (Linking)
DP  - 2013 May 24
TI  - Risk stratification among diabetic patients undergoing stress myocardial
      perfusion imaging.
AB  - BACKGROUND: Previous studies have suggested that diabetic patients undergoing
      single photon emission computed tomography (SPECT) myocardial perfusion imaging
      (MPI) are at greater risk for cardiac events than non-diabetic patients with both
      normal and abnormal imaging results. However, the impact of stress modality on
      outcomes in this patient group has not been examined. METHODS: The data on all
      patients undergoing exercise stress or vasodilator stress SPECT MPI from 1996 to 
      2005 were reviewed. After excluding patients based on our predefined criteria, we
      subcategorized the study population into diabetic patients and non-diabetic
      patients. Among the diabetic patients, we identified patients with known coronary
      artery disease (CAD) and no known CAD. All studies were interpreted using the
      17-segment ASNC model. The presence, extent, and severity of perfusion defects
      were calculated using the summed stress score (SSS), and patients were classified
      into normal (SSS < 4), mildly abnormal (SSS 4-8), and moderate-severely abnormal 
      (SSS > 8) categories. The annualized cardiac event rate including cardiac death
      and non-fatal myocardial infarction was calculated over a mean follow-up period
      of 2.4 +/- 1.4 years with a maximum of 6 years. RESULTS: The cardiac event rate
      was statistically significantly lower in diabetic patients undergoing exercise
      stress MPI when compared to the diabetic patients undergoing pharmacological
      stress MPI across all three perfusion categories (1.3% vs 3.4%, 2.3% vs 5.7%,
      4.2% vs 10.7%, respectively). Diabetic patients with no known CAD, who underwent 
      exercise stress MPI had significantly lower cardiac events across all three
      perfusion categories as compared to the remainder of the diabetic population.
      Ability to perform exercise stress test was the strongest multivariate predictor 
      of favorable outcome, whereas ejection fraction < 50%, abnormal perfusion imaging
      on SPECT MPI, and increasing age stood out as independent predictors of adverse
      outcome in the diabetic patients. Within the abnormal perfusion category, the
      annualized cardiac event rate among patients undergoing exercise stress SPECT MPI
      was not statistically different between the diabetic and non-diabetic cohorts.
      CONCLUSION: Diabetic patients undergoing exercise SPECT MPI have a significantly 
      better prognosis than those undergoing pharmacological stress, more similar to
      patients without diabetes. In patients with diabetes exercise stress test MPI
      identifies low risk patients and provides precise risk stratification.
AD  - Division of Cardiovascular Medicine, University of Miami Miller School of
      Medicine, 1600 NW 10th Avenue, Miami, FL, 33136, USA, abhijitghatak@yahoo.com.
FAU - Ghatak, Abhijit
AU  - Ghatak A
FAU - Padala, Santosh
AU  - Padala S
FAU - Katten, Deborah M
AU  - Katten DM
FAU - Polk, Donna M
AU  - Polk DM
FAU - Heller, Gary V
AU  - Heller GV
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - J Nucl Cardiol
JT  - Journal of nuclear cardiology : official publication of the American Society of
      Nuclear Cardiology
JID - 9423534
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/05/31 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 10.1007/s12350-013-9731-1 [doi]
PST - aheadofprint
SO  - J Nucl Cardiol. 2013 May 24.

PMID- 23703373
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1573-2789 (Electronic)
IS  - 0010-3853 (Linking)
DP  - 2013 May 24
TI  - Characteristics of Homeless Adults with Serious Mental Illness Served by a State 
      Mental Health Transitional Shelter.
AB  - Specialized transitional shelters are available in various cities to provide
      assistance to homeless individuals with serious mental illness. Little is known
      about the population using such shelters. The authors conducted a retrospective
      chart review to collect demographic, social, and clinical data of residents in a 
      state-operated mental health transitional shelter in Massachusetts. A total of 74
      subjects were included. Schizophrenia-spectrum disorders were present in 67.6 %
      of the sample and mood disorders in 35.1 %. Substance use disorders were
      documented in 44.6 %. Chronic medical illness (mostly hypertension, dyslipidemia,
      asthma, and diabetes) was found in 82.4 %. The co-occurrence of a psychiatric and
      substance use disorder and chronic medical illness was found in 36.5 %. The
      majority (75.7 %) of patients had a history of legal charges. Homeless
      individuals with serious mental illness served by specialized transitional
      shelters represent a population with complex psychiatric, medical and social
      needs.
AD  - Massachusetts Mental Health Center, 75 Fenwood Rd, Boston, MA, 02115, USA,
      mark.viron@state.ma.us.
FAU - Viron, Mark
AU  - Viron M
FAU - Bello, Iruma
AU  - Bello I
FAU - Freudenreich, Oliver
AU  - Freudenreich O
FAU - Shtasel, Derri
AU  - Shtasel D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Community Ment Health J
JT  - Community mental health journal
JID - 0005735
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/04/10 [received]
PHST- 2013/05/16 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 10.1007/s10597-013-9607-5 [doi]
PST - aheadofprint
SO  - Community Ment Health J. 2013 May 24.

PMID- 23703342
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 137
IP  - 4
DP  - 2013 Apr
TI  - Correlation between reactive oxygen metabolites & atherosclerotic risk factors in
      patients with type 2 diabetes mellitus.
PG  - 742-8
AB  - Background & objectives: Oxidative stress plays important roles in the
      pathophysiology of type 2 diabetes mellitus (T2DM). The diacron reactive oxygen
      metabolites (d-ROMs) test has been used in the clinics. The present study was
      aimed to investigate the correlation of the oxidative stress status, as evaluated
      by the d-ROMs, with atherosclerotic risk factors in T2DM patients, in comparison 
      to controls. Methods: The study included 200 subjects (100 patients with T2DM and
      100 controls; 86 males/114 females; mean age 59.0 yr). Clinical variables
      including the body mass index, blood pressure (BP), glucose and lipid panels, in 
      addition to the d-ROMs, were measured. Results: Patients with T2DM showed
      significantly higher d-ROMs levels than controls (322 +/- 60 vs. 345 +/- 64 U.
      Carr., P<0.05). A multiple linear regression analysis revealed that systolic BP
      (beta=0.26, P<0.05) and high-density lipoprotein cholesterol (HDL-C: beta= -0.30,
      P<0.05) were independently and significantly correlated with the d-ROMs levels in
      patients with T2DM, although these correlations were not significant in the
      controls. The gender-based analysis showed that systolic BP (beta = 0.44, P<0.05)
      and HDL-C (beta = -0.36, P<0.05) were independently and significantly correlated 
      with the d-ROMs levels in females with T2DM, while there was a marginally
      significant correlation between HDL-C and the d-ROMs levels (beta = -0.36,
      P=0.06) in males with T2DM. Interpretation & conclusions: The present findings
      may reinforce the importance of BP control in female patients with T2DM, as well 
      as the management of HDL-C in male and female patients with T2DM, under the
      linkage between oxidative stress and atherosclerosis.
AD  - Department of Clinical Laboratory Medicine, Jichi Medical University,
      Shimotsuke-City, Tochigi; Division of Preventive Medicine, Clinical Research
      Institute,National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
FAU - Kotani, Kazuhiko
AU  - Kotani K
FAU - Tsuzaki, Kokoro
AU  - Tsuzaki K
FAU - Taniguchi, Nobuyuki
AU  - Taniguchi N
FAU - Sakane, Naoki
AU  - Sakane N
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - IndianJMedRes_2013_137_4_742_112115 [pii]
PST - ppublish
SO  - Indian J Med Res. 2013 Apr;137(4):742-8.

PMID- 23703340
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 137
IP  - 4
DP  - 2013 Apr
TI  - Prevalence of gestational diabetes mellitus & associated risk factors at a
      tertiary care hospital in Haryana.
PG  - 728-33
AB  - Background & objectives: Prevalence of gestational diabetes mellitus (GDM) is
      known to vary widely depending on the region of the country, dietary habits, and 
      socio-economic status. This study was undertaken to determine the prevalence of
      GDM and risk factors associated with it, in women attending an antenatal care
      (ANC) clinic at a tertiary care hospital in Haryana. Methods: This study enrolled
      women, with their estimated gestational age between 24 th and 28 th week,
      attending antenatal care (ANC) clinic at a tertiary care hospital in Rohtak.
      After informing, women who consented to participate were given a standardized 2-h
      75 g oral glucose tolerance test (OGTT). A proforma containing general
      information on demographic characteristics, socio-economic status, education
      level, parity, family history of diabetes and/or hypertension and past history of
      GDM was filled up. American Diabetes Association (ADA) criteria for 75 g 2-h OGTT
      was used for diagnosing GDM. Results: A total of 607 women participated in the
      study and GDM was diagnosed in 43 (7.1%) women. A single abnormal value was
      observed in additional 66 (10.87%) women. On bivariate analysis risk factors
      found to be significantly associated with GDM were age, educational level,
      socio-economic status, pre-pregnancy weight and BMI, weight gain, acanthosis
      nigricans, family history of diabetes or hypertension and past history of GDM but
      on multivariate analysis only upper middle class and presence of acanthosis
      nigricans were found to be significantly associated with GDM. Interpretation &
      conclusions: The prevalence of GDM was found to be 7.1 per cent in a tertiary
      care hospital in Haryana. Appropriate interventions are required for control and 
      risk factor modifications.
AD  - Department of Medicine VI & Endocrinology, Community Medicine, Pt. B.D.S. Post
      Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
FAU - Rajput, Rajesh
AU  - Rajput R
FAU - Yadav, Yogesh
AU  - Yadav Y
FAU - Nanda, Smiti
AU  - Nanda S
FAU - Rajput, Meena
AU  - Rajput M
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - IndianJMedRes_2013_137_4_728_112095 [pii]
PST - ppublish
SO  - Indian J Med Res. 2013 Apr;137(4):728-33.

PMID- 23703336
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 137
IP  - 4
DP  - 2013 Apr
TI  - Genes involved in pancreatic islet cell rejuvenation.
PG  - 695-703
AB  - Pancreas plays an important role in maintaining the glucose homeostasis. The
      deterioration of beta-cells in the pancreas is a crucial factor in the
      progression of diabetes mellitus; therefore, the restoration of beta-cell mass
      and its function is of vital importance for effective therapeutic strategies. The
      precise mechanism for increase in functional beta-cell mass is still unknown.
      This review focuses on the importance of certain genes which are involved in the 
      rejuvenation of pancreas. These genes are divided according to their functions
      into three categories: participate either in proliferation (mitotic division of
      differentiated beta-cells), neogenesis/transdifferentiation (development from
      precursor cells) or inhibition of beta-cell apoptosis (programmed cell death).
      The rate of beta-cell rejuvenation is the balance among the rates of beta-cell
      proliferation, neogenesis and apoptosis. Understanding these genes and their
      pathways may lead to the discovery of new drugs, target based gene delivery and
      development of safer antidiabetic drugs.
AD  - Centre of Bio-Separation Technology (CBST), VIT University, Vellore, India.
FAU - Bansal, Vinay S
AU  - Bansal VS
FAU - Raja, C Prasanna
AU  - Raja CP
FAU - Venkataraman, Krishnan
AU  - Venkataraman K
FAU - Vijayalakshmi, M A
AU  - Vijayalakshmi MA
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - IndianJMedRes_2013_137_4_695_112022 [pii]
PST - ppublish
SO  - Indian J Med Res. 2013 Apr;137(4):695-703.

PMID- 23703316
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1472-1465 (Electronic)
IS  - 0007-1250 (Linking)
DP  - 2013 May 23
TI  - Cardiovascular and metabolic risk profile in young people at familial risk of
      depression.
AB  - BACKGROUND: Depression is associated with increased risk of several general
      medical conditions, including diabetes and cardiovascular disease. The nature of 
      the association is complex and may involve bidirectional causation or a common
      pathophysiology. AIMS: To determine whether young people without depression but
      at increased familial risk have altered metabolic and blood pressure markers
      relative to matched controls. METHOD: We studied young people (n = 85), who had a
      parent with depression but no personal history of depressive illness (FH+) and
      healthy controls (n = 69). Cardiovascular risk profile was assessed by a fasting 
      blood sample to measure insulin, glucose, lipids and high-sensitivity C-reactive 
      protein (CRP) and blood pressure was measured centrally and peripherally.
      Arterial stiffness and waking cortisol concentration were also measured. RESULTS:
      Compared with controls, the FH+ group demonstrated increased peripheral and
      central systolic blood pressure, increased arterial stiffness and diminished
      insulin sensitivity but they did not differ from controls in measures of lipids, 
      CRP or waking cortisol. CONCLUSIONS: Our data suggest that young people at
      increased familial risk of depression show evidence of altered cardiovascular
      risk profile in young adulthood even in the absence of depressive symptoms. It is
      possible therefore that vulnerability to conditions such as hypertension and
      diabetes may precede the onset of major depression and may share common risk
      factors.
AD  - MSc, PhD, Clare Williams, RMN, BSc, Psychopharmacology Research Unit, University 
      Department of Psychiatry, Warneford Hospital, Oxford; Jonathan Diesch, Oxford
      Cardiovascular Clinical Research Facility, John Radliffe Hospital, Oxford; Andrew
      Steptoe, DSc, Institute of Epidemiology and Health Care, University College
      London; Paul Leeson, PhD, FRCP, Oxford Cardiovascular Clinical Research Facility,
      John Radliffe Hospital, Oxford; Philip J. Cowen, MD, FRCPsych, Psychopharmacology
      Research Unit, University Department of Psychiatry, Warneford Hospital, Oxford,
      UK.
FAU - Mannie, Zola N
AU  - Mannie ZN
FAU - Williams, Clare
AU  - Williams C
FAU - Diesch, Jonathan
AU  - Diesch J
FAU - Steptoe, Andrew
AU  - Steptoe A
FAU - Leeson, Paul
AU  - Leeson P
FAU - Cowen, Philip J
AU  - Cowen PJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Br J Psychiatry
JT  - The British journal of psychiatry : the journal of mental science
JID - 0342367
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - bjp.bp.113.126987 [pii]
AID - 10.1192/bjp.bp.113.126987 [doi]
PST - aheadofprint
SO  - Br J Psychiatry. 2013 May 23.

PMID- 23703232
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1533-4112 (Electronic)
IS  - 1095-0680 (Linking)
VI  - 29
IP  - 2
DP  - 2013 Jun
TI  - Development of central diabetes insipidus following electroconvulsive therapy:
      results of a prospective pilot study.
PG  - e29-30
LID - 10.1097/YCT.0b013e3182839069 [doi]
AB  - OBJECTIVES: The objective of this study was to examine the occurrence of
      laboratory abnormalities and symptoms of central diabetes insipidus (CDI) in
      patients receiving acute electroconvulsive therapy (ECT) series. METHODS: We
      prospectively investigated adult psychiatric inpatients for objective and
      subjective evidence of CDI at baseline and after their sixth ECT. RESULTS:
      Although participants did not report any CDI symptoms, two thirds had clinically 
      important decreases in urine osmolality (>200 mOsm/kg), and two thirds had serum 
      sodium increases of 5 mmol/L following exposure to ECT. CONCLUSION: Our findings 
      suggest that objective evidence of CDI can occur following the administration of 
      ECT series, even in the absence of symptomatic complaints.
AD  - From the *McGill University and daggerDepartment of Psychiatry, McGill
      University; and double daggerDepartment of Psychiatry and section signGeriatric
      Psychiatry, Jewish General Hospital, Montreal, Quebec, Canada.
FAU - Senouci, Soumia Imene
AU  - Senouci SI
FAU - Rej, Soham
AU  - Rej S
FAU - Looper, Karl
AU  - Looper K
FAU - Segal, Marilyn
AU  - Segal M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J ECT
JT  - The journal of ECT
JID - 9808943
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1097/YCT.0b013e3182839069 [doi]
AID - 00124509-201306000-00027 [pii]
PST - ppublish
SO  - J ECT. 2013 Jun;29(2):e29-30. doi: 10.1097/YCT.0b013e3182839069.

PMID- 23703153
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
DP  - 2013 May 23
TI  - Satisfaction with Current Status at Work and Lack of Motivation to Improve It
      During Midlife is Associated with Increased Risk for Dementia in Subjects who
      Survived Thirty-Seven Years Later.
AB  - The present study aimed to assess the relationship of midlife Motivation to
      Improve Status at work (MIS) with dementia more than three decades later. In
      1963, 9,920 out of 10,059 male participants of the Israel Ischemic Heart disease 
      (IIHD) study, aged 40-65 years, were questioned about their MIS as follows: "Do
      you want to improve your status at work and do you believe it is possible?". One 
      of four answers was possible: trying to change status and believe it is possible 
      (MIS1) (n = 3,060); trying but unsure of success (MIS2) (n = 2,618); not trying, 
      unlikely to succeed (MIS3) (n = 2,020); not trying, satisfied (MIS4) (n = 2,222).
      Dementia was assessed over three decades later in 1,714 survivors of the original
      cohort, including 1,691 who responded in 1963 to the questionnaire regarding MIS.
      Controlling for age, the estimated odds for dementia relative to MIS1 were 1.45
      (95% CI 1.06-2.01) in MIS2, 1.52 (95% CI 1.04-2.23) in MIS3, and 1.96 (95% CI
      1.38-2.81) in MIS4. Further adjustment for age and socioeconomic status index
      resulted in adjusted estimated odds for dementia relative to MIS1 were 1.26 (95% 
      CI 0.90-1.75) in MIS2, 1.10 (95% CI 0.74-1.64) in MIS3, and 1.78 (95% CI
      1.23-2.56) in MIS4. These results were not attenuated when midlife diabetes,
      blood pressure values, serum-cholesterol levels, and coronary heart disease were 
      controlled for in the analysis. Among tenured working men, lack of MIS together
      with satisfaction with current status was associated with higher risk for
      dementia among survivors several decades later. This association was partially
      attenuated by socioeconomic status.
AD  - Memory Clinic, Department of Psychiatry, Sheba Medical Center, Tel Hashomer,
      Israel.
FAU - Ravona-Springer, Ramit
AU  - Ravona-Springer R
FAU - Beeri, Michal Schnaider
AU  - Beeri MS
FAU - Goldbourt, Uri
AU  - Goldbourt U
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - Q95406145V285UH3 [pii]
AID - 10.3233/JAD-122422 [doi]
PST - aheadofprint
SO  - J Alzheimers Dis. 2013 May 23.

PMID- 23703097
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 0393-2249 (Print)
IS  - 0393-2249 (Linking)
VI  - 65
IP  - 2
DP  - 2013 Jun
TI  - Nephrolithiasis-related end stage renal disease.
PG  - 101-7
AB  - There is graded association between episodes of kidney stones and chronic kidney 
      disease, and the prevalence of nephrolithiasis leading to end stage renal disease
      (ESRD), although low, is still unavoidable. The marginal causes of
      nephrolithiasis-related ESRD continue to be metabolic and infection stones. Few
      lines of investigation account for a higher risk of ESRD in stone formers than in
      general population, being influenced by hypertension, diabetes, dyslipidemia,
      gout and recurrent urinary tract infections. Moreover, the risk for ESRD seems to
      be higher among women over 50 years old who presented more than one episodes of
      renal colic. However, the evaluation of these studies is limited by the fact that
      most of them are retrospective, mainly originating from single centre
      experiences. Additional work on consistent and active patient surveillance will
      hopefully give information about the association between kidney stones and ESRD, 
      clarifying also the diagnostic dilemmas that have been reported worldwide. This
      paper addresses the current data for nephrolithiasis-associated ESRD, an
      interesting topic, the awareness of which should be enhanced.
AD  - "Laiki Merimna" Department of Nephrology Athens, Greece - chrysapi2001@gmail.com.
FAU - Pipili, C
AU  - Pipili C
FAU - Kiriakoutzik, I
AU  - Kiriakoutzik I
FAU - Petychaki, F
AU  - Petychaki F
FAU - Koutsovasili, A
AU  - Koutsovasili A
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Urol Nefrol
JT  - Minerva urologica e nefrologica = The Italian journal of urology and nephrology
JID - 8503649
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - R19Y2013N02A0101 [pii]
PST - ppublish
SO  - Minerva Urol Nefrol. 2013 Jun;65(2):101-7.

PMID- 23702932
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1678-2674 (Electronic)
IS  - 0102-8650 (Linking)
VI  - 28
IP  - 5
DP  - 2013 May
TI  - Experimental diabetes exacerbates skin transplant rejection in rats.
PG  - 323-6
LID - S0102-86502013000500001 [pii]
AB  - PURPOSE: To investigate the effect of chronic experimental diabetes on skin
      allografts in rats as a simple model that could clarify some basic aspects and
      mechanisms involved in transplant rejection in diabetes compared to normal
      animals. METHODS: Skin grafting was performed with fragments of tail skin from
      sex matched non diabetic Wistar rats engrafted onto the thoracic area of diabetic
      and non diabetic recipients. Grafts were scored for rejection every other day and
      were removed on day 14. Skin grafts were graded according to the following itens:
      no rejection; or rejection including: acute, chronic and humoral and/or cellular 
      rejection. Statistical analysis was performed using JMP 5.1 software with ANOVA
      test. Diabetes was induced with IV injection of alloxan 40 mg/kg. RESULTS:
      Inflammatory vascular infiltrate compromising the endothelium with areas of
      fibrinoid necrosis and thrombosis characteristics of acute humoral rejection and 
      subendothelial lymphocyte infiltrate typical of acute cellular rejection were
      significantly (p<0.003) higher in diabetic than in non diabetic recipients as the
      inflammatory infiltrate in the epidermis (p<0.002). CONCLUSION: Skin transplant
      acute rejection from chronic alloxan diabetic rats to normal tissue was
      significantly more intense than the acute rejection between normal rats.
AD  - Department of Pathology, Santos Metropolitan University.
FAU - Reis, Flavio Pola Dos
AU  - Reis FP
FAU - Sementilli, Angelo
AU  - Sementilli A
FAU - Gagliardi, Antonio Ricardo de Toledo
AU  - Gagliardi AR
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Acta Cir Bras
JT  - Acta cirurgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em
      Cirurgia
JID - 9103983
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/01/14 [received]
PHST- 2013/04/16 [accepted]
AID - S0102-86502013000500001 [pii]
PST - ppublish
SO  - Acta Cir Bras. 2013 May;28(5):323-6.

PMID- 23702909
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 May 24
TI  - Amelioration in Hepatic Insulin Sensitivity by Reduced Hepatic Lipid Accumulation
      at Short-Term After Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetic Rats.
AB  - BACKGROUND: Previous studies showed that early after Roux-en-Y gastric bypass
      (RYGB), there is a remarkable improvement in type 2 diabetes, which is
      characterized by insulin resistance. This study aims to gain insight into the
      underlying mechanisms of this effect. We determined the acute effects of RYGB on 
      hepatic and peripheral insulin sensitivity. METHODS: A rat model of type 2
      diabetes was established using high-fat diet combined with streptozotocin (30
      mg/kg, ip). Animals were divided into four groups: diabetic, diabetic RYGB,
      diabetic RYGB sham, and control rats. Hyperinsulinemic-euglycemic clamps with
      tracer infusion were completed at 2 weeks postoperatively to assess insulin
      sensitivity. Triglyceride concentration in liver and muscle tissues was
      determined. Protein kinase C (PKC) membrane translocation, protein expression of 
      phospho-c-Jun NH2-terminal kinase (JNK), and phospho-IkappaB kinase beta
      (IKKbeta) were assessed with western blot. Malondialdehyde (MDA) and superoxide
      dismutase (SOD) activities in the liver were also measured. RESULTS: RYGB surgery
      significantly improved hepatic insulin sensitivity index and decreased hepatic
      triglyceride concentration (P < 0.05), without an improvement in peripheral
      insulin sensitivity. Membrane translocation of PKC-epsilon, PKC-delta, and
      PKC-theta; the ratio of MDA to SOD; and the expression of p-JNK and p-IKKbeta in 
      the liver were lower in the diabetic RYGB group than in the diabetic group.
      CONCLUSIONS: Diabetes remission was induced at short term after RYGB. The
      improvement of hepatic tissue lipotoxicity decreased the activation of certain
      PKC isoforms, the activity of JNK and IKK inflammatory signaling pathways, and
      the degree of oxidative stress. Furthermore, the hepatic insulin sensitivity was 
      ameliorated, which is possibly a mechanism for early diabetes remission.
AD  - Department of Endocrinology, Shengjing Hospital of China Medical University,
      Shenyang, China, litong909@hotmail.com.
FAU - He, Bing
AU  - He B
FAU - Piao, Dongxu
AU  - Piao D
FAU - Yu, Chong
AU  - Yu C
FAU - Wang, Yong
AU  - Wang Y
FAU - Han, Ping
AU  - Han P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1007/s11695-013-0997-9 [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 May 24.

PMID- 23702908
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 May 24
TI  - Diagnosis of Diabetes Remission After Bariatic Surgery May be Jeopardized by
      Remission Criteria and Previous Hypoglycemic Treatment.
AB  - BACKGROUND: Controversy exists regarding type 2 diabetes (T2D) remission rates
      after bariatric surgery (BS) due to heterogeneity in its definition and patients'
      baseline features. We evaluate T2D remission using recent criteria, according to 
      preoperative characteristics and insulin therapy (IT). METHODS: We performed a
      retrospective study from a cohort of 657 BS from a single center (2006-2011), of 
      which 141 (57.4 % women) had T2D. We evaluated anthropometric and glucose
      metabolism parameters before surgery and at 1-year follow-up. T2D remission was
      defined according to 2009 consensus criteria: HbA1c <6 %, fasting glucose (FG)
      <100 mg/dL, and absence of pharmacologic treatment. We analyzed diabetes
      remission according to previous treatment. RESULTS: Preoperative characteristic
      were (mean +/- SD): age 53.9 +/- 9.8 years, BMI 43.7 +/- 5.6 kg/m2, T2D duration 
      7.4 +/- 7.6 years, FG 160.0 +/- 54.6 mg/dL, HbA1c 7.6 +/- 1.6 %. Fifty-six (39.7 
      %) individuals had IT. At 1-year follow-up, 74 patients (52.5 %) had diabetes
      remission. Percentage weight loss (%WL) and percentage excess weight loss (%EWL) 
      were associated to remission (35.5 +/- 8.1 vs. 30.2 +/- 9.5 %, p = 0.001; 73.6
      +/- 18.4 vs. 66.3 +/- 22.8 %, p = 0.037, respectively). Duration of diabetes,
      age, and female sex were associated to nonremission: 10.3 +/- 9.4 vs. 4.7 +/- 3.8
      years, p < 0.001; 55.1 +/- 9.3 vs. 51.2 +/- 9.9 years, p = 0.017; 58.9 vs. 33.3
      %, p = 0.004, respectively. Prior treatment revealed differences in remission
      rates: 67.1 % in case of oral therapy (OT) vs. 30.4 % in IT, p < 0.001. OR for
      T2D remission in patients with previous IT, compared to those with only OT, were 
      0.157-0.327 (p < 0.05), adjusting by different models. CONCLUSIONS: Consensus
      criteria reveal lower T2D remission rates after BS than previously reported.
      Prior insulin use is a main setback for remission.
AD  - Department of Endocrinology and Nutrition, Hospital Clinico San Carlos, Instituto
      de Investigacion Sanitaria San Carlos (IdISSC), Facultad de Medicina, Universidad
      Complutense, C/ Prof. Martin Lagos s/n., Madrid, 28040, Spain,
      ana_ramoslevi@hotmail.com.
FAU - Ramos-Levi, Ana
AU  - Ramos-Levi A
FAU - Sanchez-Pernaute, Andres
AU  - Sanchez-Pernaute A
FAU - Matia, Pilar
AU  - Matia P
FAU - Cabrerizo, Lucio
AU  - Cabrerizo L
FAU - Barabash, Ana
AU  - Barabash A
FAU - Hernandez, Carmen
AU  - Hernandez C
FAU - Calle-Pascual, Alfonso
AU  - Calle-Pascual A
FAU - Torres, Antonio
AU  - Torres A
FAU - Rubio, Miguel
AU  - Rubio M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1007/s11695-013-0995-y [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 May 24.

PMID- 23702788
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1745-9206 (Electronic)
IS  - 1742-3953 (Linking)
DP  - 2013 May 23
TI  - The association of diabetes complications with physical activity in a
      representative sample of older adults in the United States.
AB  - OBJECTIVE: Most adults with diabetes do not engage in the level of physical
      activity recommended for optimal disease management. Diabetes complications are
      not generally considered a clinical contraindication to exercise. No prior
      national studies have examined the associations of these complications with
      physical activity. METHODS: Data are from the 2003 Diabetes Supplement to the
      nationally representative US Health and Retirement Study (n = 1811; age >50
      years). Multiple logistic regression was used to examine the association between 
      diabetes complications and the odds of meeting physical activity guidelines.
      RESULTS: Forty-three percent of the sample met physical activity guidelines.
      Adjusting for sociodemographic variables, retinopathy (odds ratios (OR) OR =
      0.54, 95% confidence intervals (CI) = 0.36-0.81), nephropathy (OR = 0.70, 95% CI 
      = 0.50-0.99), neuropathy (OR = 0.75, 95% CI = 0.59-0.95), and heart disease (OR =
      0.69, 95% CI = 0.51-0.94) were all independently associated with reduced odds of 
      meeting guidelines. A borderline significant association was observed for stroke.
      DISCUSSION: Adults with diabetes with complications of the eyes, kidneys, or
      nerves and those with heart disease are less likely to meet physical activity
      guidelines compared to those without these complications. These individuals may
      require additional support from health professionals to achieve recommended
      amounts of physical activity. More studies are needed to clarify the barriers and
      benefits to engaging in physical activity in the presence of diabetes
      complications.
AD  - Center for Managing Chronic Disease, University of Michigan, Ann Arbor, MI, USA.
FAU - Janevic, Mary R
AU  - Janevic MR
FAU - McLaughlin, Sara J
AU  - McLaughlin SJ
FAU - Connell, Cathleen M
AU  - Connell CM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Chronic Illn
JT  - Chronic illness
JID - 101253019
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 1742395313475461 [pii]
AID - 10.1177/1742395313475461 [doi]
PST - aheadofprint
SO  - Chronic Illn. 2013 May 23.

PMID- 23702782
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
DP  - 2013 May 23
TI  - LOSS OF PROTEIN TYROSINE PHOSPHATASE 1B INCREASES IGF-I RECEPTOR TYROSINE
      PHOSPHORYLATION BUT DOES NOT RESCUE RETINAL DEFECTS IN IRS2-DEFICIENT MICE.
LID - iovs.12-11438v1 [pii]
LID - 10.1167/iovs.12-11438 [doi]
AB  - PURPOSE: Mice with deletion of insulin receptor substrate (IRS) 2 develop type 2 
      diabetes and photoreceptor degeneration. Loss of protein tyrosine phosphatase 1B 
      (PTP1B) in diabetic IRS2-/- mice restores insulin sensitivity and normalizes
      glucose homeostasis. Since IGF-IR promotes survival of photoreceptors and is a
      substrate of PTP1B, we investigated IGF-IR-mediated survival signaling and visual
      function in PTP1B-/- and double mutant IRS2-/-/PTP1B-/- mice. METHODS:
      IGF-IR-mediated Akt signaling was evaluated in IGF-I-stimulated retinal explants.
      Histological and electroretinogram analysis was performed in wild-type, IRS2-/-, 
      PTP1B-/- and the double mutant IRS2-/-/PTP1B-/- mice. RESULTS: IGF-I stimulated
      the tyrosine phosphorylation of its receptor and Akt activation in retinal
      explants of wild-type mice. In PTP1B-/- retinal explants, these responses were
      enhanced. Conversely, in retinas from IRS2-/- mice, expression of PTP1B was
      increased, coincident with decreased IGF-I-mediated Akt serine 473
      phosphorylation. PTP1B deletion in IRS2-/- mice also enhanced IGF-IR tyrosine
      phosphorylation but, unexpectedly, did not rescue Akt activation in response to
      IGF-I. One potential explanation is that PTEN was increased in retinas of both
      IRS2-/- and IRS2-/-/PTP1B-/- mice. Histological evaluation revealed alterations
      in various structures of the retina in both IRS2-/- and IRS2-/-/PTP1B-/- mice,
      specifically in the outer nuclear layer (ONL) and retinal outer segments (ROS).
      ERG analysis confirmed that PTP1B deficiency did not restore visual function in
      IRS2-/- mice. CONCLUSIONS: Although loss of PTP1B enhances tyrosine
      phosphorylation of the IGF-IR in retinal explants of IRS2-/- mice, Akt activation
      remains defective owing to elevated PTEN levels and thus, structural and
      functional visual defects persist in this model.
AD  - Instituto de Investigaciones Biomedicas Alberto Sols (Centro mixto CSIC/UAM),
      C/Arturo Duperier 4, Madrid, 28029, Spain.
FAU - Arroba, Ana I
AU  - Arroba AI
FAU - Revuelta-Cervantes, Jesus
AU  - Revuelta-Cervantes J
FAU - Menes, Lorena
AU  - Menes L
FAU - Gonzalez-Rodriguez, Agueda
AU  - Gonzalez-Rodriguez A
FAU - Pardo, Virginia
AU  - Pardo V
FAU - de la Villa, Pedro
AU  - de la Villa P
FAU - Burks, Deborah J
AU  - Burks DJ
FAU - Valverde, Angela M
AU  - Valverde AM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - iovs.12-11438 [pii]
AID - 10.1167/iovs.12-11438 [doi]
PST - aheadofprint
SO  - Invest Ophthalmol Vis Sci. 2013 May 23. pii: iovs.12-11438v1. doi:
      10.1167/iovs.12-11438.

PMID- 23702738
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1433-0350 (Electronic)
IS  - 0256-7040 (Linking)
DP  - 2013 May 24
TI  - Suprasellar pediatric craniopharyngioma resection via endonasal endoscopic
      approach.
AB  - PURPOSE: Purely endoscopic endonasal approaches to surgical resection of
      pediatric suprasellar craniopharyngiomas are uncommonly performed. The aim of the
      study is to assess the feasibility and to describe the short-term outcomes of
      endonasal endoscopic approaches for the gross total resection of suprasellar
      craniopharyngiomas in the pediatric population. METHODS: A combined
      neurosurgical-otolaryngologic team performed gross total resection of
      craniopharyngiomas in seven pediatric patients (mean age 9.6 years) at The
      Children's Hospital of Philadelphia over 2011-2012. Short-term outcomes were
      analyzed over a mean follow-up period of 6.3 months. RESULTS: All tumors involved
      the sellar and/or suprasellar space and contained some cystic component. The mean
      maximal tumor diameter was 31.5 mm (range 18.5-62.0 mm). Using a binostril
      approach, gross total tumor resection was obtained in all patients (100 %). All
      patients with preoperative visual dysfunction demonstrated improvement in visual 
      acuity. New or stable panhypopituitarism was observed in all cases. All patients 
      developed postoperative diabetes insipidus, and cerebrospinal fluid leak occurred
      in one patient (15 %). CONCLUSIONS: Complete radiographic resection of pediatric 
      craniopharyngioma can be achieved via a purely endoscopic endonasal approach. In 
      particular, this approach can be performed safely using the
      "two-nostrils-four-hands" technique with intraoperative neuronavigation. This
      approach should be highly considered in patients with progressive visual
      dysfunction. Further studies are needed to characterize the long-term surgical
      and clinical outcome of pediatric patients treated with this surgical approach.
AD  - Department of Neurosurgery, University of Pennsylvania, 3400 Spruce Street, 3rd
      Floor Silverstein Pavilion, Philadelphia, PA, 19104, USA,
      Zarina.Ali@uphs.upenn.edu.
FAU - Ali, Zarina S
AU  - Ali ZS
FAU - Lang, Shih-Shan
AU  - Lang SS
FAU - Kamat, Ameet R
AU  - Kamat AR
FAU - Adappa, Nithin D
AU  - Adappa ND
FAU - Palmer, James N
AU  - Palmer JN
FAU - Storm, Phillip B
AU  - Storm PB
FAU - Lee, John Y K
AU  - Lee JY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Childs Nerv Syst
JT  - Child's nervous system : ChNS : official journal of the International Society for
      Pediatric Neurosurgery
JID - 8503227
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/02 [received]
PHST- 2013/05/07 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 10.1007/s00381-013-2153-1 [doi]
PST - aheadofprint
SO  - Childs Nerv Syst. 2013 May 24.

PMID- 23702721
OWN - NLM
STAT- In-Process
DA  - 20130524
IS  - 0969-0700 (Print)
IS  - 0969-0700 (Linking)
VI  - 22
IP  - 5
DP  - 2013 May
TI  - Use of maggot debridement therapy for tropical diabetic hand syndrome.
PG  - 244-7
AB  - Diabetic patients with infectious hand ulceration, known as tropical diabetic
      hand syndrome (TDHS), are generally less well recognised than those with foot
      ulcers. Maggot debridement therapy (MDT) is usually used for the treatment of
      diabetic foot ulcers and, in these wounds, the remarkable wound cleansing
      properties can be of considerable value. However, it is less commonly used in
      TDHS. Here we present a case of TDHS in a 51-year-old man with type II diabetes, 
      hypertension and dilated cardiomyopathy, in which conventional therapy had
      minimal effect, but significant wound debridement was achieved with MDT. This
      suggests that MDT may be a cost-effective alternative to conventional treatments 
      for the debridement of TDHS.
AD  - Department of Endocrinology, Nanjing PLA General Hospital, Jiangsu Province,
      People's Republic of China.
FAU - Jiang, K C
AU  - Jiang KC
FAU - Luo, N
AU  - Luo N
FAU - Chen, Y C
AU  - Chen YC
FAU - Wang, A P
AU  - Wang AP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Wound Care
JT  - Journal of wound care
JID - 9417080
SB  - N
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - ppublish
SO  - J Wound Care. 2013 May;22(5):244-7.

PMID- 23702657
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
DP  - 2013 May 23
TI  - Resistin-Like Molecule beta Is Abundantly Expressed in Foam Cells and Is Involved
      in Atherosclerosis Development.
AB  - OBJECTIVE: Resistin-like molecule (RELM) beta is a secretory protein homologous
      to resistin and reportedly contributes to local immune response regulation in gut
      and bronchial epithelial cells. However, we found that activated macrophages also
      express RELMbeta and thus investigated the role of RELMbeta in the development of
      atherosclerosis. APPROACH AND RESULTS: It was demonstrated that foam cells in
      atherosclerotic lesions of the human coronary artery abundantly express RELMbeta.
      RELMbeta knockout (-/-) and wild-type mice were mated with apolipoprotein
      E-deficient background mice. RELMbeta-/- apolipoprotein E-deficient mice
      exhibited less lipid accumulation in the aortic root and wall than RELMbeta+/+
      apolipoprotein E-deficient mice, without significant changes in serum lipid
      parameters. In vitro, RELMbeta-/- peritoneal macrophages (PCPMs) exhibited weaker
      lipopolysaccharide-induced nuclear factor-kappaB classical pathway activation and
      inflammatory cytokine secretion than RELMbeta+/+, whereas stimulation with
      RELMbeta upregulated inflammatory cytokine expressions and increased expressions 
      of many lipid transporters and scavenger receptors in PCPMs. Flow cytometric
      analysis revealed inflammatory stimulation-induced RELMbeta in F4/80(+) CD11c(+) 
      PCPMs. In contrast, the expressions of CD11c and tumor necrosis factor were lower
      in RELMbeta-/- PCPMs, but both were restored by stimulation with recombinant
      RELMbeta. CONCLUSIONS: RELMbeta is abundantly expressed in foam cells within
      plaques and contributes to atherosclerosis development via lipid accumulation and
      inflammatory facilitation.
AD  - From the Department of Internal Medicine, The Institute for Adult Diseases, Asahi
      Life Foundation, Tokyo, Japan (A.K., T.K., S.K.); Department of Internal
      Medicine, Graduate School of Medicine (H.S., M.F.), Department of Physiological
      Chemistry and Metabolism, Graduate School of Medicine (K.N., S.K., H.K.), and
      Research Center for Advanced Science and Technology (H.A.), University of Tokyo, 
      Tokyo, Japan; Department of Molecular Pathology, Hiroshima University Graduate
      School of Biomedical Sciences, Hiroshima, Japan (N.O., K.S., W.Y.); Department of
      Medical Chemistry, Division of Molecular Medical Science (M.O., Y.N., H.O., T.F.,
      H.K., Y.H., T.A.) and Department of Dental Science for Health Promotion, Division
      of Cervico-Gnathostomatology (F.N.), Graduate School of Biomedical Sciences,
      Hiroshima University, Hiroshima, Japan; Department of Molecular and Cellular
      Biology, Kobe Pharma Research Institute, Nippon Boehringer-Ingelheim Co Ltd,
      Hyogo, Japan (M.I., N.T., J.E.); RIKEN BioResource Center, Tsukuba, Japan (N.O., 
      A.O.); and Division of Molecular Metabolism and Diabetes, Tohoku University
      Graduate School of Medicine, Sendai, Japan (H.K.).
FAU - Kushiyama, Akifumi
AU  - Kushiyama A
FAU - Sakoda, Hideyuki
AU  - Sakoda H
FAU - Oue, Naohide
AU  - Oue N
FAU - Okubo, Masamichi
AU  - Okubo M
FAU - Nakatsu, Yusuke
AU  - Nakatsu Y
FAU - Ono, Haruya
AU  - Ono H
FAU - Fukushima, Toshiaki
AU  - Fukushima T
FAU - Kamata, Hideaki
AU  - Kamata H
FAU - Nishimura, Fusanori
AU  - Nishimura F
FAU - Kikuchi, Takako
AU  - Kikuchi T
FAU - Fujishiro, Midori
AU  - Fujishiro M
FAU - Nishiyama, Koichi
AU  - Nishiyama K
FAU - Aburatani, Hiroyuki
AU  - Aburatani H
FAU - Kushiyama, Sakura
AU  - Kushiyama S
FAU - Iizuka, Masaki
AU  - Iizuka M
FAU - Taki, Naoyuki
AU  - Taki N
FAU - Encinas, Jeffrey
AU  - Encinas J
FAU - Sentani, Kazuhiro
AU  - Sentani K
FAU - Ogonuki, Narumi
AU  - Ogonuki N
FAU - Ogura, Atsuo
AU  - Ogura A
FAU - Kawazu, Shoji
AU  - Kawazu S
FAU - Yasui, Wataru
AU  - Yasui W
FAU - Higashi, Yukihito
AU  - Higashi Y
FAU - Kurihara, Hiroki
AU  - Kurihara H
FAU - Katagiri, Hideki
AU  - Katagiri H
FAU - Asano, Tomoichiro
AU  - Asano T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
OTO - NOTNLM
OT  - atherosclerosis
OT  - inflammation
OT  - macrophage
OT  - resistin-like molecule β, mouse
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - ATVBAHA.113.301546 [pii]
AID - 10.1161/ATVBAHA.113.301546 [doi]
PST - aheadofprint
SO  - Arterioscler Thromb Vasc Biol. 2013 May 23.

PMID- 23702607
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 24
TI  - The association of the mitochondrial DNA OriB variant (16184-16193 polycytosine
      tract) with type 2 diabetes in Europid populations.
AB  - AIMS/HYPOTHESIS: The association between the mitochondrial DNA 16181-16193
      polycytosine variant (known as the OriB variant as it maps to the OriB origin of 
      replication) and type 2 diabetes has not been reliably characterised, with
      studies reporting conflicting results. We report a systematic review of published
      literature in Europid populations, new data from the Norfolk Diabetes
      Case-Control Study and a meta-analysis to help quantify this association.
      METHODS: We performed a systematic review identifying all the studies of the OriB
      variant and type 2 diabetes in Europid populations published before January 2013.
      We typed the OriB variant by pyrosequencing and sequencing in the Norfolk
      Diabetes Case-Control Study, which comprised 5,574 type 2 diabetes cases and
      6,950 population-based controls. RESULTS: Overall, the meta-analysis included
      eight published studies plus the current new results, with a total of 11,794 type
      2 diabetes cases and 14,465 controls. In the Norfolk Diabetes Case-Control Study,
      the OR for type 2 diabetes for the OriB variant was 1.09 (95% CI 0.96, 1.24). In 
      a combined analysis, the relative risk for type 2 diabetes for the OriB variant
      in Europid populations was 1.10 (95% CI 1.01, 1.20; p = 0.03)
      CONCLUSIONS/INTERPRETATION: Results from this systematic review and meta-analysis
      suggest that the mitochondrial DNA OriB variant is modestly associated with an
      increased risk of type 2 diabetes in Europid populations, with an effect size
      comparable with that of recently identified variants from genome-wide association
      studies.
AD  - Medical Research Council Epidemiology Unit, Institute of Metabolic Science,
      Addenbrooke's Hospital, PO Box 285, Hills Road, Cambridge, CB2 0QQ, UK,
      zheng.ye@mrc-epid.cam.ac.uk.
FAU - Ye, Zheng
AU  - Ye Z
FAU - Gillson, Christopher
AU  - Gillson C
FAU - Sims, Matt
AU  - Sims M
FAU - Khaw, Kay-Tee
AU  - Khaw KT
FAU - Plotka, Magdalena
AU  - Plotka M
FAU - Poulton, Joanna
AU  - Poulton J
FAU - Langenberg, Claudia
AU  - Langenberg C
FAU - Wareham, Nicholas J
AU  - Wareham NJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/03/15 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/05/24 [aheadofprint]
AID - 10.1007/s00125-013-2945-6 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 24.

PMID- 23702602
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1745-7270 (Electronic)
IS  - 1672-9145 (Linking)
DP  - 2013 May 23
TI  - The association of adipose-derived dimethylarginine dimethylaminohydrolase-2 with
      insulin sensitivity in experimental type 2 diabetes mellitus.
AB  - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide
      synthase (NOS), which can be hydrolyzed by
      dimethylarginine-dimethylaminohydrolase (DDAH). It has been reported that
      adipocytes can produce DDAH/ADMA, but its role remains unknown. In the present
      study, we examined the effects of adipocyte-derived DDAH/ADMA on insulin
      sensitivity using animal and cell models. Results showed that in adipose tissue
      of high fat diet-fed diabetic rats, as well as in high glucose (25 mM) plus
      insulin (100 nM)-treated 3T3-L1 adipocytes, expression levels of insulin receptor
      substance-1 (IRS-1), glucose transporter-4 (GLUT-4), and DDAH isoform-2 (DDAH-2) 
      were down-regulated compared with control, although DDAH-1 expression showed no
      significant changes. We also observed that nitric oxide bioavailability, DDAH and
      NOS activities were subsequently decreased, while the local ADMA content was
      elevated in diabetic adipose tissue. Transfection of human DDAH-2 gene into high 
      glucose- and insulin-treated 3T3-L1 adipocytes significantly ameliorated DDAH
      activity, reduced ADMA contents, and up-regulated the mRNA expression levels of
      IRS-1 and GLUT-4. These findings suggested that in the development of type 2
      diabetes mellitus, local DDAH-2 in adipocytes might play an important role in
      regulating insulin sensitivity.
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Central South
      University, Changsha 410078, China.
FAU - Zheng, Jie
AU  - Zheng J
FAU - Wang, Kuansong
AU  - Wang K
FAU - Jin, Ping
AU  - Jin P
FAU - Dong, Changsheng
AU  - Dong C
FAU - Yuan, Qiong
AU  - Yuan Q
FAU - Li, Yuanjian
AU  - Li Y
FAU - Yang, Zhichun
AU  - Yang Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Acta Biochim Biophys Sin (Shanghai)
JT  - Acta biochimica et biophysica Sinica
JID - 101206716
OTO - NOTNLM
OT  - adipocyte
OT  - diabetes mellitus
OT  - dimethylarginine dimethylaminohydrolase
OT  - insulin resistance
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - gmt058 [pii]
AID - 10.1093/abbs/gmt058 [doi]
PST - aheadofprint
SO  - Acta Biochim Biophys Sin (Shanghai). 2013 May 23.

PMID- 23702482
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
DP  - 2013 May 20
TI  - Chloroquine stimulates glucose uptake and glycogen synthase in muscle cells
      through activation of Akt.
LID - S0006-291X(13)00830-9 [pii]
LID - 10.1016/j.bbrc.2013.05.047 [doi]
AB  - Chloroquine is a pharmaceutical agent that has been widely used to treat patients
      with malaria. Chloroquine has also been reported to have hypoglycemic effects on 
      humans and animal models of diabetes. Despite many previous studies, the
      mechanism responsible for its hypoglycemic effect is still unclear. Chloroquine
      was recently reported to be an activator of ATM, the protein deficient in the
      Ataxia-telagiectasia (A-T) disease. Since ATM is also known as an insulin
      responsive protein that mediates Akt activation, we tested the effect of
      chloroquine on the activity of Akt and its downstream targets. In L6 muscle cells
      treated with insulin and chloroquine, the phosphorylation of Akt and glucose
      uptake were dramatically increased compared to cells treated with insulin alone, 
      suggesting that chloroquine is a potent activator of Akt and glucose uptake in
      these cells. We also found that the reduction of insulin-mediated Akt activity in
      muscle tissues of insulin resistant rats was partially reversed by chloroquine
      treatment. Moreover, insulin-mediated phosphorylation of glycogen synthase
      kinase-3beta in L6 cells was greatly enhanced by chloroquine. A substantial
      decrease in phosphorylation of glycogen synthase was also observed in
      chloroquine-treated L6 cells, indicating enhanced activity of glycogen synthase. 
      Taken together, our results not only show that chloroquine is a novel activator
      of Akt that stimulates glucose uptake and glycogen synthase, but also validate
      chloroquine as a potential therapeutic agent for patients with type 2 diabetes
      mellitus.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - The Hormel Institute, University of Minnesota, Austin, MN, USA.
FAU - Halaby, Marie-Jo
AU  - Halaby MJ
FAU - Kastein, Brandon K
AU  - Kastein BK
FAU - Yang, Da-Qing
AU  - Yang DQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/29 [received]
PHST- 2013/05/11 [accepted]
AID - S0006-291X(13)00830-9 [pii]
AID - 10.1016/j.bbrc.2013.05.047 [doi]
PST - aheadofprint
SO  - Biochem Biophys Res Commun. 2013 May 20. pii: S0006-291X(13)00830-9. doi:
      10.1016/j.bbrc.2013.05.047.

PMID- 23702410
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1558-4410 (Electronic)
IS  - 0889-8529 (Linking)
VI  - 42
IP  - 2
DP  - 2013 Jun
TI  - Preface.
PG  - xvii-xviii
LID - 10.1016/j.ecl.2013.04.001 [doi]
LID - S0889-8529(13)00024-8 [pii]
AD  - Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine,
      University of Pennsylvania, Smilow Center for Translational Research, 12th Floor,
      3400 Civic Center Blvd, Building 421, Philadelphia, PA 19104-5160, USA.
      Electronic address: acappola@med.upenn.edu.
FAU - Cappola, Anne R
AU  - Cappola AR
LA  - eng
PT  - Editorial
DEP - 20130409
PL  - United States
TA  - Endocrinol Metab Clin North Am
JT  - Endocrinology and metabolism clinics of North America
JID - 8800104
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/09 [aheadofprint]
AID - S0889-8529(13)00024-8 [pii]
AID - 10.1016/j.ecl.2013.04.001 [doi]
PST - ppublish
SO  - Endocrinol Metab Clin North Am. 2013 Jun;42(2):xvii-xviii. doi:
      10.1016/j.ecl.2013.04.001. Epub 2013 Apr 9.

PMID- 23702405
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1558-4410 (Electronic)
IS  - 0889-8529 (Linking)
VI  - 42
IP  - 2
DP  - 2013 Jun
TI  - Diabetes and altered glucose metabolism with aging.
PG  - 333-47
LID - 10.1016/j.ecl.2013.02.010 [doi]
LID - S0889-8529(13)00020-0 [pii]
AB  - Diabetes and impaired glucose tolerance affect a substantial proportion of older 
      adults. Abnormal glucose metabolism is not a necessary component of aging. Older 
      adults with diabetes and altered glucose status likely represent a subset of the 
      population at high risk for complications and adverse geriatric syndromes. Goals 
      for treatment of diabetes in the elderly include control of hyperglycemia,
      prevention and treatment of diabetic complications, avoidance of hypoglycemia,
      and preservation of quality of life. Research exploring associations of
      dysglycemia and insulin resistance with the development of adverse outcomes in
      the elderly may ultimately inform use of future glucose-lowering therapies in
      this population.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins
      University School of Medicine, The Johns Hopkins University, 1830 East Monument
      Street, Suite 333, Baltimore, MD 21287, USA. Electronic address:
      rrastogi@jhmi.edu.
FAU - Kalyani, Rita Rastogi
AU  - Kalyani RR
FAU - Egan, Josephine M
AU  - Egan JM
LA  - eng
GR  - K23 DK093583/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130322
PL  - United States
TA  - Endocrinol Metab Clin North Am
JT  - Endocrinology and metabolism clinics of North America
JID - 8800104
SB  - IM
PMC - PMC3664017
MID - NIHMS447319
OID - NLM: NIHMS447319 [Available on 06/01/14]
OID - NLM: PMC3664017 [Available on 06/01/14]
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PMCR- 2014/06/01 00:00
PHST- 2013/03/22 [aheadofprint]
AID - S0889-8529(13)00020-0 [pii]
AID - 10.1016/j.ecl.2013.02.010 [doi]
PST - ppublish
SO  - Endocrinol Metab Clin North Am. 2013 Jun;42(2):333-47. doi:
      10.1016/j.ecl.2013.02.010. Epub 2013 Mar 22.

PMID- 23702388
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-2763 (Electronic)
IS  - 1873-2763 (Linking)
VI  - 56
IP  - 1
DP  - 2013 May 20
TI  - C-reactive protein and fracture risk: European Prospective Investigation into
      Cancer Norfolk Study.
PG  - 67-72
LID - S8756-3282(13)00191-9 [pii]
LID - 10.1016/j.bone.2013.05.009 [doi]
AB  - BACKGROUND: Serum C-reactive protein (CRP) is a marker of general systemic
      inflammation. It has been suggested that inflammation may have a role in
      osteoporosis and subsequent fracture risk. We examined the prospective
      relationship between CRP and fracture risk in a large cohort study. METHODS: The 
      study populations were 18,586 men and women aged 40-79 enrolled between 1993 and 
      1997 in the European Prospective Investigation into Cancer in Norfolk study
      (EPIC-Norfolk), who had high sensitivity serum CRP measured in frozen serum from 
      baseline. After 261,563 person-years of follow up (Median (inter-quartile range) 
      follow-up time was 14.8 (13.6-16.1) years), 792 incident fractures (291 hip
      fractures) were ascertained by hospital record linkage. All multivariate
      regression models were adjusted for age, sex, body mass index, smoking, alcohol
      intake, physical activity, past history of fractures, history of osteoporosis,
      use of NSAIDs and corticosteroid medication, medical history of arthritis,
      cancer, myocardial infarction, stroke and diabetes, and in women only menopausal 
      status and postmenopausal Hormone Replacement Therapy. RESULTS: We found a
      U-shaped association for CRP and fracture risk. The lowest risk of fracture was
      observed for men and women with baseline CRP levels in the range of 1.1-2mg/L in 
      fractional polynomial Cox-proportional hazards regression analysis. Hazard ratios
      of all-fractures for participants with CRP levels 0.1-0.5; 0.6-1; 1.1-2; 2.1-3;
      3.1-10; and above 10mg/L were 1.31 (1.03, 1.66); 1.21 (0.98, 1.51); 1.00
      (referent category); 1.06 (0.82, 1.35); 1.22 (1.00, 1.51); and 1.29 (0.91, 1.81) 
      respectively. Although a similar U-shaped association was observed for hip
      fractures, the corresponding hazard ratios were not statistically significant.
      CONCLUSION: A U-shaped association was observed between CRP and fracture risk.
      The increased risk of fracture observed at lower end of CRP compared to
      intermediate levels require further exploration, confirmation in other
      populations, and investigation into potential biological mechanisms.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK. Electronic address: sa540@medschl.cam.ac.uk.
FAU - Ahmadi-Abhari, Sara
AU  - Ahmadi-Abhari S
FAU - Luben, Robert N
AU  - Luben RN
FAU - Wareham, Nicholas J
AU  - Wareham NJ
FAU - Khaw, Kay-Tee
AU  - Khaw KT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Bone
JT  - Bone
JID - 8504048
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/11/21 [received]
PHST- 2013/05/09 [revised]
PHST- 2013/05/11 [accepted]
AID - S8756-3282(13)00191-9 [pii]
AID - 10.1016/j.bone.2013.05.009 [doi]
PST - aheadofprint
SO  - Bone. 2013 May 20;56(1):67-72. doi: 10.1016/j.bone.2013.05.009.

PMID- 23702383
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
DP  - 2013 May 20
TI  - Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in
      diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling
      independently of FGF21 pathway.
LID - S0026-0495(13)00084-X [pii]
LID - 10.1016/j.metabol.2013.03.004 [doi]
AB  - OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is a common liver disease
      which has no standard treatment. In this regard, we sought to evaluate the
      effects of extracts of Artemisia santolinaefolia (SANT) and Artemisia scoparia
      (SCO) on hepatic lipid deposition and cellular signaling in a diet-induced
      obesity (DIO) animal model. MATERIALS/METHODS: DIO C57/B6J mice were randomly
      divided into three groups, i.e. HFD, SANT and SCO. Both extracts were
      incorporated into HFD at a concentration of 0.5% (w/w). Fasting plasma glucose,
      insulin, adiponectin, and FGF21 concentrations were measured. RESULTS: At the end
      of the 4-week intervention, liver tissues were collected for analysis of insulin,
      AMPK, and FGF21 signaling. SANT and SCO supplementation significantly increased
      plasma adiponectin levels when compared with the HFD mice (P<0.001). Fasting
      insulin levels were significantly lower in the SCO than HFD mice, but not in SANT
      group. Hepatic H&E staining showed fewer lipid droplets in the SCO group than in 
      the other two groups. Cellular signaling data demonstrated that SCO significantly
      increased liver IRS-2 content, phosphorylation of IRS-1, IR beta, Akt1 and Akt2, 
      AMPK alpha1 and AMPK activity and significantly reduced PTP 1B abundance when
      compared with the HFD group. SCO also significantly decreased fatty acid synthase
      (FAS), HMG-CoA Reductase (HMGR), and Sterol regulatory element-binding protein 1c
      (SREBP1c), but not Carnitine palmitoyltransferase I (CPT-1) when compared with
      HFD group. Neither SANT nor SCO significantly altered plasma FGF21 concentrations
      and liver FGF21 signaling. CONCLUSION: This study suggests that SCO may attenuate
      liver lipid accumulation in DIO mice. Contributing mechanisms were postulated to 
      include promotion of adiponectin expression, inhibition of hepatic lipogenesis,
      and/or enhanced insulin and AMPK signaling independent of FGF21 pathway.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Nutrition and Diabetes Research Laboratory, Pennington Biomedical Research
      Center, LSU System, Baton Rouge, LA 70808, USA.
FAU - Wang, Zhong Q
AU  - Wang ZQ
FAU - Zhang, Xian H
AU  - Zhang XH
FAU - Yu, Yongmei
AU  - Yu Y
FAU - Tipton, Russell C
AU  - Tipton RC
FAU - Raskin, Ilya
AU  - Raskin I
FAU - Ribnicky, David
AU  - Ribnicky D
FAU - Johnson, William
AU  - Johnson W
FAU - Cefalu, William T
AU  - Cefalu WT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/11/28 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/21 [accepted]
AID - S0026-0495(13)00084-X [pii]
AID - 10.1016/j.metabol.2013.03.004 [doi]
PST - aheadofprint
SO  - Metabolism. 2013 May 20. pii: S0026-0495(13)00084-X. doi:
      10.1016/j.metabol.2013.03.004.

PMID- 23702357
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
VI  - 29
IP  - 6
DP  - 2013 Jun
TI  - Impactful clinical trials of 2012: what clinicians need to know.
PG  - 747-50
LID - 10.1016/j.cjca.2013.03.003 [doi]
LID - S0828-282X(13)00143-8 [pii]
AB  - The results of clinical trials serve to inform cardiovascular (CV) practice. In
      2012, a number of clinical trials were reported that have an immediate effect on 
      patient management. We highlight the results of key trials in several areas:
      interventional cardiology, acute coronary syndromes (ACS), and pharmacologic
      therapy. The FREEDOM trial, which demonstrated a significant benefit on hard
      outcomes of coronary artery bypass grafting vs multivessel percutaneous coronary 
      intervention (PCI) in patients with diabetes, answered a long-debated question.
      The MADIT-RIT trial demonstrated an impressive reduction in inappropriate shocks 
      and mortality in stable implantable cardioverter defibrillator (ICD) patients by 
      altering ICD programming variables. In ACS, prolonged dual antiplatelet therapy
      (DAPT) with acetylsalicylic acid (ASA) and prasugrel in medically managed
      patients was not superior to ASA plus clopidogrel, and ongoing trials will assess
      if there are benefits to use of DAPT beyond 1 year. The WOEST trial compared
      warfarin plus DAPT vs warfarin plus ASA alone in PCI patients who had an
      indication for ongoing anticoagulation. Not surprisingly, the major bleeding rate
      was lower with double compared with triple therapy. However, major CV events were
      unexpectedly lower with double therapy as well, a finding that warrants
      confirmation in larger studies. One of the most exciting developments in 2012 was
      with PCSK9 inhibitors, injectable monoclonal antibodies, that were shown to lower
      low-density lipoprotein cholesterol by 40%-70% above the effects of maximal dose 
      statin therapy. We now await the results of large outcome trials with this
      promising class of drugs.
CI  - Copyright (c) 2013 Canadian Cardiovascular Society. Published by Elsevier Inc.
      All rights reserved.
AD  - Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Canadian 
      Cardiovascular Research Network, Brampton, Ontario, Canada. Electronic address:
      mkgupta@rogers.com.
FAU - Gupta, Milan
AU  - Gupta M
FAU - Singh, Narendra
AU  - Singh N
LA  - eng
PT  - Journal Article
PL  - England
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/02/13 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/03/05 [accepted]
AID - S0828-282X(13)00143-8 [pii]
AID - 10.1016/j.cjca.2013.03.003 [doi]
PST - ppublish
SO  - Can J Cardiol. 2013 Jun;29(6):747-50. doi: 10.1016/j.cjca.2013.03.003.

PMID- 23702312
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1095-953X (Electronic)
IS  - 0969-9961 (Linking)
VI  - 58C
DP  - 2013 May 20
TI  - Role of HIF-1alpha-activated Epac1 on HSC-mediated neuroplasticity in stroke
      model.
PG  - 76-91
LID - S0969-9961(13)00148-4 [pii]
LID - 10.1016/j.nbd.2013.05.006 [doi]
AB  - Exchange protein activated by cAMP-1 (Epac1) plays an important role in cell
      proliferation, cell survival and neuronal signaling, and activation of Epac1 in
      endothelial progenitor cells increases their homing to ischemic muscles and
      promotes neovascularization in a model of hind limb ischemia. Moreover,
      upregulation of Epac1 occurs during organ development and in diseases such as
      myocardial hypertrophy, diabetes, and Alzheimer's disease. We report here that
      hypoxia upregulated Epac1 through HIF-1alpha induction in the CD34-immunosorted
      human umbilical cord blood hematopoietic stem cells (hUCB34). Importantly,
      implantation of hUCB34 subjected to hypoxia-preconditioning (HP-hUCB34) improved 
      stroke outcome, more than did implantation of untreated hUCB34, in rodents
      subjected to cerebral ischemia, and this required Epac1-to-matrix metalloprotease
      (MMP) signaling. This improved therapeutic efficacy correlated with better
      engraftment and differentiation of these cells in the ischemic host brain. In
      addition, more than did implantation of untreated HP-hUCB34, implantation of
      HP-hUCB34 improved cerebral blood flow into the ischemic brain via induction of
      angiogenesis, facilitated proliferation/recruitment of endogenous neural
      progenitor cells in the ischemic brain, and promoted neurite outgrowth following 
      cerebral ischemia. Consistent with our proposed role of Epac1-to-MMP signaling in
      hypoxia-preconditioning, the above mentioned effects of implanting HP-hUCB34
      could be abolished by pharmacological inhibition and genetic disruption/deletion 
      of Epac1 or MMPs. We have discovered a HIF-1alpha-to-Epac1-to-MMP signaling
      pathway that is required for the improved therapeutic efficacy resulting from
      hypoxia preconditioning of hUCB34 in vitro prior to their implantation into the
      host brain in vivo.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Center for Neuropsychiatry and Department of Neurology, China Medical University 
      Hospital, Taichung 40440, Taiwan.
FAU - Lin, Chen-Huan
AU  - Lin CH
FAU - Lee, Hsu-Tung
AU  - Lee HT
FAU - Lee, Shin-Da
AU  - Lee SD
FAU - Lee, Wei
AU  - Lee W
FAU - Cho, Chin-Wen Chental
AU  - Cho CW
FAU - Lin, Shinn-Zong
AU  - Lin SZ
FAU - Wang, Hsiao-Jung
AU  - Wang HJ
FAU - Okano, Hideyuki
AU  - Okano H
FAU - Su, Ching-Yuan
AU  - Su CY
FAU - Yu, Yung-Luen
AU  - Yu YL
FAU - Hsu, Chung-Y
AU  - Hsu CY
FAU - Shyu, Woei-Cherng
AU  - Shyu WC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Neurobiol Dis
JT  - Neurobiology of disease
JID - 9500169
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/02/07 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/10 [accepted]
AID - S0969-9961(13)00148-4 [pii]
AID - 10.1016/j.nbd.2013.05.006 [doi]
PST - aheadofprint
SO  - Neurobiol Dis. 2013 May 20;58C:76-91. doi: 10.1016/j.nbd.2013.05.006.

PMID- 23702284
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 11
IP  - 1
DP  - 2013 May 23
TI  - Middle-preserving pancreatectomy: report of two cases and review of the
      literature.
PG  - 106
AB  - BACKGROUND: Middle-preserving pancreatectomy (MPP) is a parenchyma-sparing
      surgical procedure which has recently been sporadically reported for the
      treatment of multicentric periampullary-pancreatic lesions. However, a
      comprehensive recognition of this procedure has not been clearly elucidated. CASE
      PRESENTATION: We herein report two patients undergoing MPP due to synchronous
      multicentric pancreatic neoplasm. Patient one was a 24-year-old woman with a
      multicentre solid pseudopapillary neoplasm (SPN) and patient two was a
      36-year-old woman with a multicentric serous cystic neoplasm (SCN). Simultaneous 
      atypical pancreaticoduodenectomy and atypical left pancreatectomy were performed 
      in patient one; simultaneous standard pancreaticoduodenectomy and atypical left
      pancreatectomy with spleen preservation were performed in patient two.
      Approximately 6 cm and 5 cm segments of the middle portion of the pancreas were
      preserved, respectively. At follow-up at 36 months and 6 months respectively,
      patient one had developed diabetes and malabsorption requiring dietary control,
      exercise and pancreatic enzyme supplement whereas patient two showed normal
      fasting blood glucose without diarrhea. Both patients were disease-free and in
      good nutritional condition. We reviewed twenty cases of MPP that were previously 
      reported in the literature. Patient characteristics, surgical techniques and
      short- and long-term outcomes were analyzed. CONCLUSION: MPP is mainly beneficial
      for multicentric noninvasive periampullary-pancreatic lesions. However, for
      multicentric periampullary-pancreatic lesions involving even primary invasive
      cancers, as long as the invasive cancers affect only one side of the pancreas
      (proximal or distal), MPP could serve as a rational choice in well-selected
      patients.
FAU - Cheng, Kun
AU  - Cheng K
FAU - Shen, Bai-Yong
AU  - Shen BY
FAU - Peng, Cheng-Hong
AU  - Peng CH
FAU - Na, Li-Ma
AU  - Na LM
FAU - Cheng, Dong-Feng
AU  - Cheng DF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/10/18 [received]
PHST- 2013/05/23 [accepted]
PHST- 2013/05/23 [aheadofprint]
AID - 1477-7819-11-106 [pii]
AID - 10.1186/1477-7819-11-106 [doi]
PST - aheadofprint
SO  - World J Surg Oncol. 2013 May 23;11(1):106.

PMID- 23702241
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 0870-2551 (Print)
IS  - 0870-2551 (Linking)
VI  - 32
IP  - 5
DP  - 2013 May
TI  - Left ventricular mechanical dyssynchrony in patients with impaired left
      ventricular function undergoing gated SPECT myocardial perfusion imaging.
PG  - 387-94
LID - 10.1016/j.repc.2012.09.010 [doi]
LID - S0870-2551(13)00080-2 [pii]
AB  - INTRODUCTION: Gated SPECT myocardial perfusion imaging (MPI) has been used to
      quantify mechanical dyssynchrony. Mechanical dyssynchrony appears to be related
      to response to cardiac resynchronization therapy. OBJECTIVE: To evaluate the
      presence and predictors of mechanical dyssynchrony in patients with impaired left
      ventricular function (LVEF) </=50%. METHODS: The study included 143 consecutive
      patients referred for gated SPECT MPI with LVEF </=50%. Gated SPECT MPI was
      performed according to a stress/rest protocol acquiring images with Tc
      99m-tetrofosmin. Emory Cardiac Toolbox software was used for phase analysis and a
      standard deviation (SD) >/=43 degrees was considered to indicate mechanical
      dyssynchrony. RESULTS: Mechanical dyssynchrony was present in 53.1% of the
      patients. Its predictors were diabetes (OR 2.0, p</=0.05), summed stress score
      (OR 1.1, p</=0.0005), summed rest score (OR 1.1, p</=0.0001), end-diastolic
      volume (OR 1.0, p</=0.0001), LVEF (OR 0.9, p</=0.0001), LVEF </=35% (OR 3.1,
      p</=0.005) and LVEF </=35% and QRS >/=120 ms (OR 3.5, p</=0.05). In this study
      QRS width and QRS >/=120 ms were not predictors of mechanical dyssynchrony.
      CONCLUSIONS: Myocardial perfusion imaging can be used to assess mechanical
      dyssynchrony. In patients with impaired ventricular function mechanical
      dyssynchrony was highly prevalent and was related to parameters of left
      ventricular function and perfusion.
CI  - Copyright (c) 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier
      Espana. All rights reserved.
AD  - Faculdade de Medicina, Universidade de Coimbra, Centro Hospitalar e Universitario
      de Coimbra (HUC), Servico de Cardiologia, Coimbra, Portugal. Electronic address: 
      mjvidigal@netc.pt.
FAU - Vidigal Ferreira, Maria Joao
AU  - Vidigal Ferreira MJ
FAU - Silva, Rodolfo
AU  - Silva R
FAU - Cabanelas, Nuno
AU  - Cabanelas N
FAU - Cunha, Maria Joao
AU  - Cunha MJ
FAU - Ramos, Domingos
AU  - Ramos D
FAU - Albuquerque, Anabela
AU  - Albuquerque A
FAU - Teixeira, Rogerio
AU  - Teixeira R
FAU - Moreira, Ana Paula
AU  - Moreira AP
FAU - Costa, Gracinda
AU  - Costa G
FAU - Lima, Joao
AU  - Lima J
FAU - Providencia, Luis Augusto
AU  - Providencia LA
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20130520
PL  - Portugal
TA  - Rev Port Cardiol
JT  - Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de
      Cardiologia = Portuguese journal of cardiology : an official journal of the
      Portuguese Society of Cardiology
JID - 8710716
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/06/17 [received]
PHST- 2012/08/12 [revised]
PHST- 2012/09/04 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - S0870-2551(13)00080-2 [pii]
AID - 10.1016/j.repc.2012.09.010 [doi]
PST - ppublish
SO  - Rev Port Cardiol. 2013 May;32(5):387-94. doi: 10.1016/j.repc.2012.09.010. Epub
      2013 May 20.

PMID- 23702239
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 May 20
TI  - Assessment guidance of carbohydrate counting method in patients with type 2
      diabetes mellitus.
LID - S1751-9918(13)00050-8 [pii]
LID - 10.1016/j.pcd.2013.04.009 [doi]
AB  - AIMS: We evaluated the application of the method of carbohydrate counting
      performed by 21 patients with type 2 diabetes, 1 year later attending a guidance 
      course. METHODS: Participants answered a questionnaire to assess patients'
      adhesion to carbohydrate counting as well as to identify habit changes and the
      method's applicability, and values of glycated hemoglobin were also analyzed.
      RESULTS: Most participants (76%) were females, and 25% of them had obesity degree
      III. There was a statistically significant decrease in glycated hemoglobin from
      8.42+/-0.02% to 7.66+/-0.01% comparing values before and after counseling. We
      observed that although patients stated that the method was difficult they
      understood that carbohydrate counting could allow them make choices and have more
      freedom in their meals; we also verified if they understood accurately how to
      replace some foods used regularly in their diets and most patients correctly
      chose replacements for the groups of bread (76%), beans (67%) and noodles (67%). 
      CONCLUSIONS: We concluded that participation in the course led to improved blood 
      glucose control with a significant reduction of glycated hemoglobin, better
      understanding of food groups and the adoption of healthier eating habits.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Division of Nutrition and Dietetics, Hospital das Clinicas, University of Sao
      Paulo School of Medicine, Brazil.
FAU - Martins, Michelle R
AU  - Martins MR
FAU - Ambrosio, Ana Cristina T
AU  - Ambrosio AC
FAU - Nery, Marcia
AU  - Nery M
FAU - Aquino, Rita de Cassia
AU  - Aquino RD
FAU - Queiroz, Marcia S
AU  - Queiroz MS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/11/20 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/19 [accepted]
AID - S1751-9918(13)00050-8 [pii]
AID - 10.1016/j.pcd.2013.04.009 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 May 20. pii: S1751-9918(13)00050-8. doi:
      10.1016/j.pcd.2013.04.009.

PMID- 23702217
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1879-0380 (Electronic)
IS  - 0959-437X (Linking)
DP  - 2013 May 20
TI  - Artificial induction and disease-related conversion of the hepatic fate.
LID - S0959-437X(13)00060-9 [pii]
LID - 10.1016/j.gde.2013.04.006 [doi]
AB  - Under normal physiological conditions, the fates of cells that compose various
      parts of organs are determined during development, and never change to those of
      other cell types. However, recent advances in induction of cellular reprogramming
      provide chances to generate a completely different cell type from an original
      cell source by artificially modulating the microenvironments or gene expressions 
      pattern of cells. Although hepatocytes normally only reside in the liver, the
      hepatic program can be induced in skin-derived fibroblasts by expressing defined 
      extrinsic transcription factors. These induced hepatocyte-like cells have
      hepatocyte-specific properties and functionally restore damaged hepatic tissues
      after transplantation. On the other hand, hepatocytes themselves can be converted
      into biliary lineage cells as a causative factor of hepatic diseases. Thus,
      blockade of such disease-related reprogramming of the hepatic fate will become a 
      new therapeutic strategy for refractory diseases in the liver. Moreover,
      hepatocytes could partially accept the pancreatic program by expressing
      transcription factors required for pancreas development, suggesting that
      insulin-producing cells could be generated from hepatocytes and used to treat
      diabetes. The above-mentioned progress will stimulate studies on the molecular
      nature of cellular identity and plasticity in hepatocytes, and contribute to the 
      development of potential therapies for liver diseases.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Division of Organogenesis and Regeneration, Medical Institute of Bioregulation,
      Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan; Core
      Research for Evolutional Science and Technology (CREST), Japan Science and
      Technology Agency, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan. Electronic
      address: suzukicks@bioreg.kyushu-u.ac.jp.
FAU - Suzuki, Atsushi
AU  - Suzuki A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Curr Opin Genet Dev
JT  - Current opinion in genetics & development
JID - 9111375
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/03/12 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/05 [accepted]
AID - S0959-437X(13)00060-9 [pii]
AID - 10.1016/j.gde.2013.04.006 [doi]
PST - aheadofprint
SO  - Curr Opin Genet Dev. 2013 May 20. pii: S0959-437X(13)00060-9. doi:
      10.1016/j.gde.2013.04.006.

PMID- 23702182
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1532-3374 (Electronic)
IS  - 0959-289X (Linking)
DP  - 2013 May 20
TI  - Serum uric acid as a novel marker for uterine atony and post-spinal vasopressor
      use during cesarean delivery.
LID - S0959-289X(13)00053-8 [pii]
LID - 10.1016/j.ijoa.2013.04.005 [doi]
AB  - INTRODUCTION: Serum uric acid is a marker for oxidative stress in preeclampsia.
      Because oxidative stress can result in diminished uterine contractility and
      impaired vascular relaxation, we hypothesized that an elevated serum uric acid
      level in women undergoing neuraxial anesthesia for cesarean delivery would be
      associated with greater uterine atony, as measured by supplemental uterotonic
      agent use and blood loss, and less hypotension, as measured by total vasopressor 
      use. METHODS: All records of patients (n=2527) undergoing cesarean delivery in
      2009 were reviewed. Serum uric acid was measured within 24h of delivery in 509
      patients; data from 345 patients with singleton pregnancies undergoing neuraxial 
      anesthesia were analyzed. Demographic data, medical and obstetric history,
      anesthetic management and peripartum course were evaluated. ANOVA, Chi-square,
      and multivariate logistic and linear regression analyses were performed. RESULTS:
      Increased serum uric acid correlated positively with preeclampsia and the need
      for supplemental uterotonic agents (odds ratio 1.53, 95%CI 1.2-2.0, P=0.002), but
      not blood loss. The presence of preeclampsia also correlated with greater
      supplemental uterotonic agent use (P=0.01). The correlation between serum uric
      acid and post-spinal vasopressor use (i.e., none, moderate, and high) was of
      borderline significance (P=0.05). In patients without diabetes, serum uric acid
      levels correlated inversely with post-spinal vasopressor use (P=0.04).
      CONCLUSIONS: Elevated serum uric acid in parturients undergoing cesarean delivery
      with neuraxial anesthesia correlated with increased use of supplemental
      uterotonic agents and decreased use of post-spinal vasopressors. Further
      validation of this study is required to determine if serum uric acid in
      parturients can serve as a reliable predictor for higher and lower occurrences of
      uterine atony and spinal-induced hypotension, respectively.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and
      Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Kovacheva, V P
AU  - Kovacheva VP
FAU - Soens, M A
AU  - Soens MA
FAU - Tsen, L C
AU  - Tsen LC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Int J Obstet Anesth
JT  - International journal of obstetric anesthesia
JID - 9200430
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/09/16 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/04/05 [accepted]
AID - S0959-289X(13)00053-8 [pii]
AID - 10.1016/j.ijoa.2013.04.005 [doi]
PST - aheadofprint
SO  - Int J Obstet Anesth. 2013 May 20. pii: S0959-289X(13)00053-8. doi:
      10.1016/j.ijoa.2013.04.005.

PMID- 23702159
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1879-3649 (Electronic)
IS  - 1537-1891 (Linking)
DP  - 2013 May 20
TI  - Is Type 2 Diabetes Really a Coronary Heart Disease Risk Equivalent?
LID - S1537-1891(13)00072-4 [pii]
LID - 10.1016/j.vph.2013.05.003 [doi]
AB  - The concept of diabetes as a coronary heart risk (CHD) equivalent postulates that
      patients with diabetes who do not yet have CHD are at an equally high
      cardiovascular risk as non-diabetic patients with CHD. This implies important
      therapeutic, psychological, and economical consequences. However, whereas several
      reports support the concept of diabetes as a CHD risk equivalent, others refute
      it, and several investigations find that the cardiovascular risk conferred by
      diabetes is strongly modulated by sex (with diabetes conferring a greater risk
      increase in women), diabetes duration, concomitant risk factors, or the presence 
      of subclinical atherosclerosis. A detailed review of the literature shows that
      the concept of diabetes as a CHD risk equivalent is overly simplistic, because
      not all patients with diabetes are at the same cardiovascular risk. An
      individualized approach to cardiovascular risk estimation and management appears 
      mandatory in patients with diabetes.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch,
      Austria; Department of Medicine and Cardiology, Academic Teaching Hospital
      Feldkirch, Feldkirch, Austria; Private University of the Principality of
      Liechtenstein, Triesen, Liechtenstein.
FAU - Saely, Christoph H
AU  - Saely CH
FAU - Drexel, Heinz
AU  - Drexel H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Vascul Pharmacol
JT  - Vascular pharmacology
JID - 101130615
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/25 [received]
PHST- 2013/05/08 [revised]
PHST- 2013/05/11 [accepted]
AID - S1537-1891(13)00072-4 [pii]
AID - 10.1016/j.vph.2013.05.003 [doi]
PST - aheadofprint
SO  - Vascul Pharmacol. 2013 May 20. pii: S1537-1891(13)00072-4. doi:
      10.1016/j.vph.2013.05.003.

PMID- 23702127
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1557-9832 (Electronic)
IS  - 0272-2712 (Linking)
VI  - 33
IP  - 2
DP  - 2013 Jun
TI  - Diabetes, hematology/coagulation in pregnancy.
PG  - xiii-xiv
LID - 10.1016/j.cll.2013.03.026 [doi]
LID - S0272-2712(13)00035-8 [pii]
AD  - University of Connecticut Health Center School of Medicine, John Dempsey
      Hospital, 263 Farmington Avenue-CG 214, Farmington, CT 06030-4946, USA.
      Electronic address: wcampbell@nso2.uchc.edu.
FAU - Campbell, Winston A
AU  - Campbell WA
LA  - eng
PT  - Editorial
DEP - 20130419
PL  - United States
TA  - Clin Lab Med
JT  - Clinics in laboratory medicine
JID - 8100174
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/19 [aheadofprint]
AID - S0272-2712(13)00035-8 [pii]
AID - 10.1016/j.cll.2013.03.026 [doi]
PST - ppublish
SO  - Clin Lab Med. 2013 Jun;33(2):xiii-xiv. doi: 10.1016/j.cll.2013.03.026. Epub 2013 
      Apr 19.

PMID- 23702117
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1557-9832 (Electronic)
IS  - 0272-2712 (Linking)
VI  - 33
IP  - 2
DP  - 2013 Jun
TI  - Impact of diabetes on aneuploidy screening.
PG  - 271-80
LID - 10.1016/j.cll.2013.03.022 [doi]
LID - S0272-2712(13)00031-0 [pii]
AB  - Maternal pregestational diabetes mellitus is a known risk factor for multiple
      nonchromosomal congenital anomalies, but there is no clear evidence that diabetes
      increases the risk for aneuploidy. However, diabetes affects maternal serum
      analyte concentrations that are used for aneuploidy screening and can alter the
      false-positive rates of the screening tests. Correction factors are used for
      women with pregestational diabetes for second-trimester serum analytes used in
      aneuploidy screening. There is considerable variation in the reported literature 
      regarding the effect of diabetes on first-trimester serum analytes and how it
      might have an impact on aneuploidy screening.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of
      Connecticut Health Center School of Medicine, John Dempsey Hospital, 263
      Farmington Avenue, Room CG 214, Farmington, CT 06030, USA. Electronic address:
      PGurram@resident.uchc.edu.
FAU - Gurram, Padmalatha
AU  - Gurram P
FAU - Benn, Peter
AU  - Benn P
FAU - Campbell, Winston A
AU  - Campbell WA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Lab Med
JT  - Clinics in laboratory medicine
JID - 8100174
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - S0272-2712(13)00031-0 [pii]
AID - 10.1016/j.cll.2013.03.022 [doi]
PST - ppublish
SO  - Clin Lab Med. 2013 Jun;33(2):271-80. doi: 10.1016/j.cll.2013.03.022.

PMID- 23702115
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1557-9832 (Electronic)
IS  - 0272-2712 (Linking)
VI  - 33
IP  - 2
DP  - 2013 Jun
TI  - Management of pregnant patients with diabetes with ischemic heart disease.
PG  - 243-56
LID - 10.1016/j.cll.2013.03.020 [doi]
LID - S0272-2712(13)00029-2 [pii]
AB  - Management of pregnant patients with diabetes who have ischemic heart disease
      (IHD) remains a challenging clinical dilemma for obstetricians and maternal fetal
      specialist alike. The diagnosis of women with IHD is difficult, primarily because
      of a lack of awareness of the atypical characteristics at presentation by both
      patient and provider. Counseling of women regarding pregnancy when they are
      diabetic with IHD is best done before conception. Management by trimester should 
      focus on careful monitoring of maternal cardiac status and stabilization of
      glycemic control without hypoglycemia. Delivery and postpartum care remain
      critical in the avoidance of complications and mortality.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Obstetrics and Gynecology, Oakwood Hospital and Medical Center,
      18101 Oakwood Boulevard, PO Box 2500, Dearborn, MI 48124, USA. Electronic
      address: theodore.jones@oakwood.org.
FAU - Jones, Theodore B
AU  - Jones TB
FAU - Savasan, Zeynep Alpay
AU  - Savasan ZA
FAU - Johnson, Quinetta
AU  - Johnson Q
FAU - Bahado-Singh, Ray
AU  - Bahado-Singh R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Lab Med
JT  - Clinics in laboratory medicine
JID - 8100174
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - S0272-2712(13)00029-2 [pii]
AID - 10.1016/j.cll.2013.03.020 [doi]
PST - ppublish
SO  - Clin Lab Med. 2013 Jun;33(2):243-56. doi: 10.1016/j.cll.2013.03.020.

PMID- 23702114
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1557-9832 (Electronic)
IS  - 0272-2712 (Linking)
VI  - 33
IP  - 2
DP  - 2013 Jun
TI  - Use of oral hypoglycemic and insulin agents in pregnant patients.
PG  - 235-42
LID - 10.1016/j.cll.2013.03.015 [doi]
LID - S0272-2712(13)00024-3 [pii]
AB  - Although insulin remains the standard medication for the treatment of all types
      of patients with diabetes during pregnancy, oral hypoglycemics may be considered 
      as alternative medications in the treatment of some types of diabetes in
      pregnancy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology,
      Hartford Hospital, 85 Jefferson Street, Hartford, CT 06102, USA.
FAU - Feldman, Deborah M
AU  - Feldman DM
FAU - Fang, Yu Ming Victor
AU  - Fang YM
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - Clin Lab Med
JT  - Clinics in laboratory medicine
JID - 8100174
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/19 [aheadofprint]
AID - S0272-2712(13)00024-3 [pii]
AID - 10.1016/j.cll.2013.03.015 [doi]
PST - ppublish
SO  - Clin Lab Med. 2013 Jun;33(2):235-42. doi: 10.1016/j.cll.2013.03.015. Epub 2013
      Apr 19.

PMID- 23702113
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1557-9832 (Electronic)
IS  - 0272-2712 (Linking)
VI  - 33
IP  - 2
DP  - 2013 Jun
TI  - New concepts in diabetic embryopathy.
PG  - 207-33
LID - 10.1016/j.cll.2013.03.017 [doi]
LID - S0272-2712(13)00026-7 [pii]
AB  - Diabetes mellitus is responsible for nearly 10% of fetal anomalies in diabetic
      pregnancies. Although aggressive perinatal care and glycemic control are
      available in developed countries, the birth defect rate in diabetic pregnancies
      remains higher than that in the general population. Major cellular activities
      (ie, proliferation and apoptosis) and intracellular metabolic conditions (ie,
      nitrosative, oxidative, and endoplasmic reticulum stress) have been shown to be
      associated with diabetic embryopathy using animal models. Translating advances
      made in animal studies into clinical applications in humans requires
      collaborative efforts across the basic research, preclinical, and clinical
      communities.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Obstetrics, Gynecology and Reproductive Sciences, University of
      Maryland School of Medicine, 655 West Baltimore Street, BRB 11-041, Baltimore, MD
      21201, USA. Electronic address: zzhao@fpi.umaryland.edu.
FAU - Zhao, Zhiyong
AU  - Zhao Z
FAU - Reece, E Albert
AU  - Reece EA
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - Clin Lab Med
JT  - Clinics in laboratory medicine
JID - 8100174
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/19 [aheadofprint]
AID - S0272-2712(13)00026-7 [pii]
AID - 10.1016/j.cll.2013.03.017 [doi]
PST - ppublish
SO  - Clin Lab Med. 2013 Jun;33(2):207-33. doi: 10.1016/j.cll.2013.03.017. Epub 2013
      Apr 19.

PMID- 23702038
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
DP  - 2013 May 20
TI  - Cuscuta chinensis seeds water extraction protecting murine osteoblastic MC3T3-E1 
      cells against tertiary butyl hydroperoxide induced injury.
LID - S0378-8741(13)00340-1 [pii]
LID - 10.1016/j.jep.2013.05.005 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Cuscuta chinensis (C. chinensis) is a well-known 
      traditional Chinese herb that has been used to treat heart disease, diabetes,
      liver injury, cancer, and aging. MATERIALS AND METHODS: Murine osteoblastic
      MC3T3-E1 cells were treated with various concentrations of C. chinensis water
      extraction at different time intervals. The antioxidant effect of C. chinensis on
      MC3T3-E1 cells was evaluated using MTT and TUNEL assays. The effect of C.
      chinensis on cell cycle was analyzed by flow cytometry with propidium iodide.
      Lipid peroxidation was measured by the HPLC method. The cellular redox status was
      determined from the reduced glutathione to oxidized glutathione ratio (GSH/GSSG) 
      and the enzymes involved in glutathione metabolism, including glutathione
      reductase (GR), Glutathione S-transferase (GST), and Glucose-6-phosphate
      dehydrogenase (G6PD). The changes in relative mitochondrial transmembrane
      potential (DeltaPsim) in the MC3T3-E1 cells were analyzed with rhodamine 123
      staining. Western blot analysis was used to evaluate the levels of cytochrome c
      (cyto c), Bax, Bcl-2, caspase 3, Sirt3, and IDH2 expressions. RESULTS: The C.
      chinensis water extraction protects tertiary butyl hydroperoxide (TBHP)-treated
      MC3T3-E1 cells from death in a dose-dependent manner. C. chinensis treatment
      significantly inhibited the reactive oxygen species (ROS) generation,
      malondialdehyde (MDA) production, and increased the activity of superoxide
      dismutase (SOD), GR, GST, and G6PD. The release of cyto c from mitochondria was
      reduced by C. chinensis, which increased the expression of antiapoptotic IDH2,
      Sirt3, and Bcl-2 and decreased the expression of Bax, cyto c, and caspase 3.
      CONCLUSIONS: C. chinensis modulated the oxidative stress-induced apoptosis in
      MC3T3-E1 cells, probably due to its antioxidant activity and functioning via
      mitochondria-dependent pathways.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road,
      Shenyang 110016, China; Department of Medical Science, Shandong Wanjie Medical
      University, 246 Xiwaihuan Road, Zibo 255213, China.
FAU - Gao, Jian-Mei
AU  - Gao JM
FAU - Li, Ran
AU  - Li R
FAU - Zhang, Lei
AU  - Zhang L
FAU - Jia, Li-Long
AU  - Jia LL
FAU - Ying, Xi-Xiang
AU  - Ying XX
FAU - Dou, De-Qiang
AU  - Dou DQ
FAU - Li, Jian-Chun
AU  - Li JC
FAU - Li, Hai-Bo
AU  - Li HB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/11/07 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/05/04 [accepted]
AID - S0378-8741(13)00340-1 [pii]
AID - 10.1016/j.jep.2013.05.005 [doi]
PST - aheadofprint
SO  - J Ethnopharmacol. 2013 May 20. pii: S0378-8741(13)00340-1. doi:
      10.1016/j.jep.2013.05.005.

PMID- 23702029
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 20
TI  - Socioeconomic status and gender affects utilization of Medical Nutrition Therapy.
LID - S0168-8227(13)00167-8 [pii]
LID - 10.1016/j.diabres.2013.04.011 [doi]
AB  - AIMS: To identify socioeconomic status and gender inequalities in long and
      short-term Medical Nutrition Therapy among Israeli adult patients with diabetes. 
      METHODS: An analysis of data was performed on 90,900 patients over the age of 18 
      who were registered as patients with diabetes mellitus in Maccabi Healthcare
      Service Register which is the second largest health maintenance organization in
      Israel. Socioeconomic Rank for each patient was determined from the Israel
      Central Bureau of Statistics by geographical area of residence. Medical Nutrition
      Therapy was defined by the number of visits with registered dietitians.
      Short-term therapy was defined as one visit and long term therapy as two or more 
      visits during the previous two years. Newly diagnosed patients were compared with
      veteran patients. RESULTS: Only 25.8% of the patients with diabetes received
      nutrition therapy during the previous two years. Newly diagnosed patients
      received therapy more frequently than veterans. We found that long term therapy
      was positively dependent on socioeconomic rank. Women under the age of seventy
      five had a higher chance of receiving therapy compared to men. CONCLUSIONS: A
      nationwide nutritional counseling service is available and accessible to all
      patients with diabetes. However, the patients with higher socioeconomic rank have
      a higher rate of persistence with long-term nutritional therapy.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Maccabi Healthcare Services, Faculty of Social Welfare and Health Studies,
      University of Haifa, Israel; School of Public Health, Faculty of Social Welfare
      and Health Studies, University of Haifa, Israel.
FAU - Endevelt, Ronit
AU  - Endevelt R
FAU - Baron-Epel, Orna
AU  - Baron-Epel O
FAU - Viner, Anna
AU  - Viner A
FAU - Heymann, Anthony David
AU  - Heymann AD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/06/15 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/25 [accepted]
AID - S0168-8227(13)00167-8 [pii]
AID - 10.1016/j.diabres.2013.04.011 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 20. pii: S0168-8227(13)00167-8. doi:
      10.1016/j.diabres.2013.04.011.

PMID- 23701967
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
DP  - 2013 May 20
TI  - Soluble epoxide hydrolase: Gene structure, expression and deletion.
LID - S0378-1119(13)00617-3 [pii]
LID - 10.1016/j.gene.2013.05.008 [doi]
AB  - Mammalian soluble epoxide hydrolase (sEH) converts epoxides to their
      corresponding diols through the addition of a water molecule. sEH readily
      hydrolyzes lipid signaling molecules, including the epoxyeicosatrienoic acids
      (EETs), epoxidized lipids produced from arachidonic acid by the action of
      cytochrome p450s. Through its metabolism of the EETs and other lipid mediators,
      sEH contributes to the regulation of vascular tone, nociception, angiogenesis and
      the inflammatory response. Because of its central physiological role in disease
      states such as cardiac hypertrophy, diabetes, hypertension, and pain sEH is being
      investigated as a therapeutic target. This review begins with a brief
      introduction to sEH protein structure and function. sEH evolution and gene
      structure are then discussed before human small nucleotide polymorphisms and
      mammalian gene expression are described in the context of several disease models.
      The review ends with an overview of studies that have employed the sEH knockout
      mouse model.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Entomology and Comprehensive Cancer Center, University of
      California, Davis, CA, USA.
FAU - Harris, Todd R
AU  - Harris TR
FAU - Hammock, Bruce D
AU  - Hammock BD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Gene
JT  - Gene
JID - 7706761
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/12/11 [received]
PHST- 2013/03/29 [revised]
PHST- 2013/05/09 [accepted]
AID - S0378-1119(13)00617-3 [pii]
AID - 10.1016/j.gene.2013.05.008 [doi]
PST - aheadofprint
SO  - Gene. 2013 May 20. pii: S0378-1119(13)00617-3. doi: 10.1016/j.gene.2013.05.008.

PMID- 23701965
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1618-0372 (Electronic)
IS  - 0065-1281 (Linking)
DP  - 2013 May 20
TI  - Activation profile of dorsal root ganglia Iba-1 (+) macrophages varies with the
      type of lesion in rats.
LID - S0065-1281(13)00079-2 [pii]
LID - 10.1016/j.acthis.2013.04.007 [doi]
AB  - The interactions between neurons, immune and immune-like glial cells can initiate
      the abnormal processes that underlie neuropathic pain. In the peripheral nervous 
      system the resident macrophages may play an important role. In this study we
      investigated in experimental adult Sprague-Dawley rats how Iba-1 (ionized calcium
      binding adaptor molecule 1) (+) resident macrophages in the dorsal root ganglion 
      (DRG) are activated after a spinal nerve ligation (SNL) or streptozotocin
      (STZ)-induced diabetes. The activation profile was defined by comparing the
      responses of resident macrophages against microglia in the spinal cord as they
      share a common origin. After SNL, the Iba-1 (+) macrophages in L5 DRG reached
      their activation peak 5 days later, clustered as satellite cells around large
      A-neurons, expressed the MHC-II marker, but did not show p-p38 and p-ERK1/2
      activation and did not secrete IL-18. After STZ-induced diabetes, the Iba-1 (+)
      macrophages reached their activation peak 1 week later in L4 and L5 DRG, remained
      scattered between neurons, expressed the MHC-II marker only in L5 DRG, did not
      show p-p38 and p-ERK1/2 activation and did not secrete any of the investigated
      cytokines/chemokines. These responses suggest that depending on the type of
      lesion DRG Iba-1 (+) resident macrophages have different activation mechanisms,
      which are dissimilar to those in microglia.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
AD  - Department of Anatomy, Physiology and Biophysics, Faculty of Biology, University 
      of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania; Department 
      of Anatomy and Physiology, Faculty of Biology, Vinh University, 182 Le Duan, Nghe
      An, Vietnam.
FAU - Ton, Bich-Hoai Thi
AU  - Ton BH
FAU - Chen, Qingmin
AU  - Chen Q
FAU - Gaina, Gisela
AU  - Gaina G
FAU - Tucureanu, Catalin
AU  - Tucureanu C
FAU - Georgescu, Adriana
AU  - Georgescu A
FAU - Strungaru, Carmen
AU  - Strungaru C
FAU - Flonta, Maria-Luiza
AU  - Flonta ML
FAU - Sah, Dinah
AU  - Sah D
FAU - Ristoiu, Violeta
AU  - Ristoiu V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Acta Histochem
JT  - Acta histochemica
JID - 0370320
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/01/03 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/04/07 [accepted]
AID - S0065-1281(13)00079-2 [pii]
AID - 10.1016/j.acthis.2013.04.007 [doi]
PST - aheadofprint
SO  - Acta Histochem. 2013 May 20. pii: S0065-1281(13)00079-2. doi:
      10.1016/j.acthis.2013.04.007.

PMID- 23701944
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 0156-5788 (Print)
IS  - 0156-5788 (Linking)
VI  - 37
IP  - 3
DP  - 2013 Jun
TI  - Do people with existing chronic conditions benefit from telephone coaching? A
      rapid review.
PG  - 381-8
LID - 10.1071/AH13005 [doi]
AB  - Objective. To examine the effectiveness of telephone-based coaching services for 
      the management of patients with chronic diseases. Methods. A rapid scoping review
      of the published peer reviewed literature, using Medline, Embase, CINAHL,
      PsychNet and Scopus. We included studies involving people aged 18 years or over
      with one or more of the following chronic conditions: type 2 diabetes, congestive
      cardiac failure, coronary artery disease, chronic obstructive pulmonary disease
      and hypertension. Patients were identified as having multi-morbidity if they had 
      an index chronic condition plus one or more other chronic condition. To be
      included in this review, the telephone coaching had to involve two-way
      conversations by telephone or video phone between a patient and a provider.
      Behaviour change, goal setting and empowerment are essential features of
      coaching. Results. The review found 1756 papers, which was reduced to 30 after
      screening and relevance checks. Most coaching services were planned, as opposed
      to reactive, and targeted patients with complex needs who had one or more chronic
      disease. Several studies reported improvements in health behaviour,
      self-efficacy, health status and satisfaction with the service. More than
      one-third of the papers targeted vulnerable people and telephone coaching was
      found to be effective for these people. Conclusions. Telephone coaching for
      people with chronic conditions can improve health behaviour, self-efficacy and
      health status. This is especially true for vulnerable populations who had
      difficulty accessing health services. There is less evidence for improvements in 
      quality of life and patient satisfaction with the service. The evidence for
      improvements in health service use was limited. This rapid scoping review found
      that telephone-based coaching can enhance the management of chronic disease,
      especially for vulnerable groups. Further work is needed to identify what models 
      of telephone coaching are most effective according to patients' level of risk and
      co-morbidity. What is known about the topic? With the increasing prevalence of
      chronic diseases more demands are being made of limited health services and
      resources. Telephone health coaching for people with or at risk of chronic
      diseases is seen as a means of supporting people to manage their health and
      reducing the burden on the healthcare system. What does this paper add? Telephone
      coaching interventions were effective for vulnerable people with chronic
      disease(s). Often the vulnerable populations had worse control of their chronic
      condition at baseline and demonstrated the greatest improvement compared with
      those with better control at baseline. Planned (i.e. weekly or monthly telephone 
      calls to support the patients with chronic disease) and unscripted telephone
      coaching interventions appear to be most effective for improving self-management 
      skills in people from vulnerable groups: the planned telephone coaching services 
      had the advantage of regular contact and helping people develop their skills over
      time, whereas the unscripted aspect allowed the coach to tailor support to the
      patient's individual needs What are the implications for practitioners? Telephone
      coaching is an effective means of supporting people with chronic diseases to
      manage their own health. Further work is needed to embed telephone coaching
      within existing services. Good linkages with the patient's general practitioner
      are important. This might be a regular report, updates via the patient e-health
      record, or provision for contact if a problem is identified or linking to the
      patient e-health record.
AD  - Centre for Primary Health Care and Equity, University of New South Wales, Sydney,
      NSW 2052, Australia. Emails: ; ; ; ;
FAU - Dennis, Sarah M
AU  - Dennis SM
FAU - Harris, Mark
AU  - Harris M
FAU - Lloyd, Jane
AU  - Lloyd J
FAU - Powell Davies, Gawaine
AU  - Powell Davies G
FAU - Faruqi, Nighat
AU  - Faruqi N
FAU - Zwar, Nicholas
AU  - Zwar N
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust Health Rev
JT  - Australian health review : a publication of the Australian Hospital Association
JID - 8214381
SB  - H
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/08/07 [received]
PHST- 2013/01/29 [accepted]
AID - AH13005 [pii]
AID - 10.1071/AH13005 [doi]
PST - ppublish
SO  - Aust Health Rev. 2013 Jun;37(3):381-8. doi: 10.1071/AH13005.

PMID- 23701924
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1748-1716 (Electronic)
IS  - 1748-1708 (Linking)
DP  - 2013 May 23
TI  - Increased susceptibility to streptozotocin and impeded regeneration capacity of
      beta-cells in adult offspring of malnourished rats.
LID - 10.1111/apha.12121 [doi]
AB  - Epidemiological studies related poor maternal nutrition and subsequent growth
      retardation in the progeny to the development of diabetes later in life. Low
      protein diet during gestation altered the beta-cell development of the rat
      progeny, by decreasing beta-cells proliferation, and increasing their sensitivity
      to nitric oxide and cytokines in the foetus. This disturbed maternal environment 
      had lasting consequences since the higher beta-cell vulnerability was maintained 
      at adulthood. AIM: The aim was to determine whether early malnutrition influences
      the vulnerability and the regeneration capacity of beta-cells after
      streptozotocin (STZ) damage at adulthood. METHODS: Gestating rats were fed either
      a control or a low protein diet until weaning. Adult female offspring received
      weekly during five weeks, injections of Freund's adjuvant followed 24h later by
      STZ. Half of the cohort was killed at d34 whereas the other half was maintained
      until d48 to analyse the regeneration capacity of the beta-cells. RESULTS:
      Although control and low protein rats had equivalent pancreatic insulin content
      and beta-cell volume density at d34, hyperglycaemia appeared earlier and was more
      dramatic in low protein than in control rats. STZ treatment increased beta-cell
      proliferation similarly in both groups. At d48, apoptotic rate was higher in the 
      low protein group. Regeneration appeared in control but not in the low protein
      rats, where beta-cell aggregates/surface area and Reg1-positive area were
      decreased compared to control. CONCLUSION: Maternal malnutrition programs a more 
      vulnerable endocrine pancreas in the progeny which is unable to regenerate after 
      injury therefore predisposing it to develop glucose intolerance and diabetes
      later in life. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Laboratory of Cell Biology, Universite catholique de Louvain, Louvain-la-Neuve,
      Belgium.
FAU - Goosse, Kevin
AU  - Goosse K
FAU - Bouckenooghe, Thomas
AU  - Bouckenooghe T
FAU - Sisino, Giorgia
AU  - Sisino G
FAU - Aurientis, Sandra
AU  - Aurientis S
FAU - Remacle, Claude
AU  - Remacle C
FAU - Reusens, Brigitte
AU  - Reusens B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Acta Physiol (Oxf)
JT  - Acta physiologica (Oxford, England)
JID - 101262545
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/01/10 [received]
PHST- 2013/02/22 [revised]
PHST- 2013/04/29 [revised]
PHST- 2013/05/16 [accepted]
AID - 10.1111/apha.12121 [doi]
PST - aheadofprint
SO  - Acta Physiol (Oxf). 2013 May 23. doi: 10.1111/apha.12121.

PMID- 23701900
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130606
DCOM- 20130607
IS  - 2045-3701 (Electronic)
IS  - 2045-3701 (Linking)
VI  - 3
IP  - 1
DP  - 2013
TI  - Monoubiquitination of EEA1 regulates endosome fusion and trafficking.
PG  - 24
LID - 10.1186/2045-3701-3-24 [doi]
AB  - BACKGROUND: Early endosomal autoantigen 1 (EEA1) is a membrane tethering factor
      required for the fusion and maturation of early endosomes in endocytosis. How the
      activity of EEA1 is regulated in cells is unclear. RESULTS: Here we show that
      endogenous EEA1 is prone to monoubiquitination at multiple sites, owing to an
      intrinsic affinity to ubiquitin conjugating enzymes (E2). The E2 interactions
      enable a ubiquitin ligase (E3) independent mechanism that decorate EEA1 with
      multiple mono-ubiquitin moieties. Expression of an ubiquitin-EEA1 chimera that
      mimics native mono-ubiquitinated EEA1 generates giant endosomes abutting the
      nucleus. Several lines of evidence suggest that this phenotype is due to
      increased endosome fusion and a simultaneous blockade on an endosome recycling
      pathway. The latter is likely caused by diminished endosome fission in cells
      expressing ubiquitin-EEA1. CONCLUSION: Our results demonstrate that
      ubiquitination may dramatically affect the activity of an endosome fusion factor 
      to alter endosome morphology and trafficking pattern, and thereby implicating an 
      unexpected role of ubiquitin signaling in endocytosis.
AD  - Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and
      Kidney Diseases, National Institutes of Health, 5 center drive, Bethesda, MD
      20892, USA. yihongy@mail.nih.gov.
FAU - Ramanathan, Harish N
AU  - Ramanathan HN
FAU - Zhang, Guofeng
AU  - Zhang G
FAU - Ye, Yihong
AU  - Ye Y
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - England
TA  - Cell Biosci
JT  - Cell & bioscience
JID - 101561195
PMC - PMC3673817
OID - NLM: PMC3673817
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:01
CRDT- 2013/05/25 06:00
PHST- 2013/03/13 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/23 [aheadofprint]
AID - 2045-3701-3-24 [pii]
AID - 10.1186/2045-3701-3-24 [doi]
PST - epublish
SO  - Cell Biosci. 2013 May 23;3(1):24. doi: 10.1186/2045-3701-3-24.

PMID- 23701881
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1873-7544 (Electronic)
IS  - 0306-4522 (Linking)
DP  - 2013 May 20
TI  - Food-intake dysregulation in type 2 diabetic Goto-Kakizaki rats: Hypothesized
      role of dysfunctional brainstem thyrotropin-releasing hormone and impaired vagal 
      output.
LID - S0306-4522(13)00429-6 [pii]
LID - 10.1016/j.neuroscience.2013.05.017 [doi]
AB  - Thyrotropin-releasing hormone (TRH), a neuropeptide contained in neural terminals
      innervating brainstem vagal motor neurons, enhances vagal outflow to modify
      multisystemic visceral functions and food intake. Type 2 diabetes (T2D) and
      obesity are accompanied by impaired vagal functioning. We examined the
      possibility that impaired brainstem TRH action may contribute to the vagal
      dysregulation of food intake in Goto-Kakizaki (GK) rats, a T2D model with
      hyperglycemia and impaired central vagal activation by TRH. Food intake induced
      by intracisternal injection of TRH analog was reduced significantly by 50% in GK 
      rats, compared to Wistar rats. Similarly, natural food intake in the dark phase
      or food intake after an overnight fast was reduced by 56-81% in GK rats. Fasting 
      (48h) and refeeding (2h)-associated changes in serum ghrelin, insulin, peptide
      YY, pancreatic polypeptide and leptin, and the concomitant changes in orexigenic 
      or anorexigenic peptide expression in the brainstem and hypothalamus, all
      apparent in Wistar rats, were absent or markedly reduced in GK rats, with hormone
      release stimulated by vagal activation, such as ghrelin and pancreatic
      polypeptide, decreased substantially. Fasting-induced Fos expression accompanying
      endogenous brainstem TRH action decreased by 66% and 91%, respectively, in the
      nucleus tractus solitarius (NTS) and the dorsal motor nucleus of the vagus (DMV) 
      in GK rats, compared to Wistar rats. Refeeding abolished fasting-induced
      Fos-expression in the NTS, while that in the DMV remained in Wistar but not GK
      rats. These findings indicate that dysfunctional brainstem TRH-elicited vagal
      impairment contributes to the disturbed food intake in T2D GK rats, and may
      provide a pathophysiological mechanism which prevents further weight gain in T2D 
      and obesity.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Research & Development, Department of Veterans Affairs, Greater Los Angeles
      Health Care System, Los Angeles, CA 90073, USA.
FAU - Zhao, K
AU  - Zhao K
FAU - Ao, Y
AU  - Ao Y
FAU - Harper, R M
AU  - Harper RM
FAU - Go, V L W
AU  - Go VL
FAU - Yang, H
AU  - Yang H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/01/29 [received]
PHST- 2013/04/25 [revised]
PHST- 2013/05/02 [accepted]
AID - S0306-4522(13)00429-6 [pii]
AID - 10.1016/j.neuroscience.2013.05.017 [doi]
PST - aheadofprint
SO  - Neuroscience. 2013 May 20. pii: S0306-4522(13)00429-6. doi:
      10.1016/j.neuroscience.2013.05.017.

PMID- 23701836
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 63
IP  - 2
DP  - 2013 Aug
TI  - Interpersonal violence, PTSD, and inflammation: Potential psychogenic pathways to
      higher C-reactive protein levels.
PG  - 172-8
LID - 10.1016/j.cyto.2013.04.030 [doi]
LID - S1043-4666(13)00211-1 [pii]
AB  - Interpersonal violence (IPV) is major public health concern with wide-ranging
      sequelae including depression, posttraumatic stress disorder (PTSD), and possible
      alterations of immune and inflammation processes. There is a need to identify the
      psycho-biological pathways through which IPV may translate to altered
      inflammatory processes since both PTSD and inflammation are associated with
      serious physical health conditions such as obesity, diabetes, and cardiovascular 
      disease. This study investigated the relationships between IPV, psychological
      distress, and the inflammatory marker C-reactive protein (CRP), in a sample of
      139 urban women who have a high likelihood for having experienced IPV.
      Participants were recruited from an outpatient gynecology clinic to complete
      self-report measures about their IPV histories and psychological symptoms, as
      well as to have their blood sampled using a finger stick. Results indicated that 
      exposure to IPV predicted the presence of probable depression and PTSD diagnoses.
      Individuals who experience clinical levels of PTSD exhibited higher CRP levels,
      and this relationship held after adjusting for comorbid depression. Correlational
      analyses suggested that reexperiencing symptoms may explain the link between PTSD
      diagnosis and higher levels of CRP. Follow-up path analytic models provided good 
      fit to the overall data, and indicated that the relationship between probable
      PTSD status and CRP is not explained by higher BMI. Overall, these findings call 
      for increased attention to the role of PTSD in explaining links between trauma
      and diminished health.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Behavioral Sciences, Rush University Medical Center, 1645 W.
      Jackson, Suite 400, Chicago, IL 60612, United States. Electronic address:
      Nicole_Heath@rush.edu.
FAU - Heath, Nicole M
AU  - Heath NM
FAU - Chesney, Samantha A
AU  - Chesney SA
FAU - Gerhart, James I
AU  - Gerhart JI
FAU - Goldsmith, Rachel E
AU  - Goldsmith RE
FAU - Luborsky, Judith L
AU  - Luborsky JL
FAU - Stevens, Natalie R
AU  - Stevens NR
FAU - Hobfoll, Stevan E
AU  - Hobfoll SE
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - United States
TA  - Cytokine
JT  - Cytokine
JID - 9005353
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/01/04 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - S1043-4666(13)00211-1 [pii]
AID - 10.1016/j.cyto.2013.04.030 [doi]
PST - ppublish
SO  - Cytokine. 2013 Aug;63(2):172-8. doi: 10.1016/j.cyto.2013.04.030. Epub 2013 May
      20.

PMID- 23701589
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1545-4312 (Electronic)
IS  - 0199-9885 (Linking)
DP  - 2013 May 22
TI  - Making, Baking, and Breaking: The Synthesis, Storage, and Hydrolysis of Neutral
      Lipids.
AB  - The esterification of amphiphilic alcohols with fatty acids is a ubiquitous
      strategy implemented by eukaryotes and some prokaryotes to conserve energy and
      membrane progenitors and simultaneously detoxify fatty acids and other lipids.
      This key reaction is performed by at least four evolutionarily unrelated
      multigene families. The synthesis of this "neutral lipid" leads to the formation 
      of a lipid droplet, which despite the clear selective advantage it confers is
      also a harbinger of cellular and organismal malaise. Neutral lipid deposition as 
      a cytoplasmic lipid droplet may be thermodynamically favored but nevertheless is 
      elaborately regulated. Optimal utilization of these resources by lipolysis is
      similarly multigenic in determination and regulation. We present here a
      perspective on these processes that originates from studies in model organisms,
      and we include our thoughts on interventions that target reductions in neutral
      lipids as therapeutics for human diseases such as obesity and diabetes. Expected 
      final online publication date for the Annual Review of Nutrition Volume 33 is
      July 17, 2013. Please see http://www.annualreviews.org/catalog/pubdates.aspx for 
      revised estimates.
AD  - Institute of Human Nutrition Columbia University Medical Center, New York, New
      York 10032; email: kelly.ruggles@nyumc.org.
FAU - Ruggles, Kelly V
AU  - Ruggles KV
FAU - Turkish, Aaron
AU  - Turkish A
FAU - Sturley, Stephen L
AU  - Sturley SL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Annu Rev Nutr
JT  - Annual review of nutrition
JID - 8209988
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1146/annurev-nutr-071812-161254 [doi]
PST - aheadofprint
SO  - Annu Rev Nutr. 2013 May 22.

PMID- 23701495
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
DP  - 2013 May 24
TI  - Hoof Nail Deformity: a previously unknown hereditary nail malformation.
LID - 10.1111/bjd.12445 [doi]
AB  - A 54-year-old man who was followed by dermatology regarding a personal history of
      malignant melanoma was found to have an incidental nail abnormality affecting his
      bilateral second toenails. The malformed nails were present since birth, were
      non-progressive, and were not associated with any symptoms. The patient denied
      any history of hair, teeth, or sweating abnormalities. The patient also had a
      history of porphyria cutanea tarda, hepatitis C acquired via a blood transfusion,
      diabetes mellitus type II, and a 40 pack-year smoking history. His medications
      included metformin and sitagliptin. This article is protected by copyright. All
      rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Division of Dermatology and Cutaneous Sciences, Department of Medicine,
      University of Alberta, Edmonton, Alberta.
FAU - Jung, G W
AU  - Jung GW
FAU - Salopek, T G
AU  - Salopek TG
LA  - ENG
PT  - LETTER
DEP - 20130524
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/03/25 [received]
PHST- 2013/04/22 [revised]
PHST- 2013/05/11 [accepted]
AID - 10.1111/bjd.12445 [doi]
PST - aheadofprint
SO  - Br J Dermatol. 2013 May 24. doi: 10.1111/bjd.12445.

PMID- 23701472
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1525-6006 (Electronic)
IS  - 1064-1963 (Linking)
DP  - 2013 May 23
TI  - Association of the -262C/T polymorphism in the catalase gene promoter and the
      C242T polymorphism of the NADPH oxidase P22phox gene with essential arterial
      hypertension in patients with diabetes mellitus type 2.
AB  - Abstract Aim: The aim of the present study was to test the association between
      genetic polymorphisms with functional effects on redox regulation: the -262C/T of
      the catalase gene promoter (rs1001179), the C242T of the nicotinamide adenine
      dinucleotide phosphate (NADPH) oxidase P22phox gene (rs4673), and the 594C/T
      polymorphism of the glutathione peroxidase gene (rs1050450) and arterial
      hypertension (AH) in patients with type 2 diabetes. Methods: 810 Slovenian
      subjects (Caucasians) with type 2 diabetes were enrolled in the cross-sectional
      study. Genotypes were determined by real-time PCR. Results: Univariate analysis
      failed to demonstrate an association between either the -262C/T of the catalase
      gene promoter (rs1001179) or the C242T polymorphism of the P22phox gene (rs4673) 
      or the 594C/T polymorphism of the glutathione peroxidase gene (rs1050450) and AH.
      After adjustment for age, body mass index, fibrinogen level and high sensitivity 
      C-reactive protein level, rs4673 was found to be an independent risk factor for
      AH in subjects with type 2 diabetes, whereas rs1001179 and rs1050450 were not.
      Conclusion: According to the results of cross-sectional study, the tested
      polymorphism of the NADPH oxidase P22phox gene (rs4673) was found to be
      associated with the development of AH, indicating that the oxidative stress gene 
      NADPH oxidase might be implicated in the pathogenesis of AH in subjects with type
      2 diabetes.
AD  - Medical Faculty Ljubljana, University Ljubljana , Ljubljana , Slovenia.
FAU - Petrovic, Daniel
AU  - Petrovic D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Clin Exp Hypertens
JT  - Clinical and experimental hypertension (New York, N.Y. : 1993)
JID - 9305929
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.3109/10641963.2013.783051 [doi]
PST - aheadofprint
SO  - Clin Exp Hypertens. 2013 May 23.

PMID- 23701456
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1743-8942 (Electronic)
IS  - 0167-482X (Linking)
VI  - 34
IP  - 2
DP  - 2013 Jun
TI  - An investigation of psycho-social factors associated with the uptake of
      pre-pregnancy care in Australian women with type 1 and type 2 diabetes.
PG  - 75-81
LID - 10.3109/0167482X.2013.793664 [doi]
AB  - Abstract Pre-pregnancy care (PPC) reduces adverse pregnancy outcomes for women
      with pre-existing diabetes. Yet, despite the compelling case for PPC,
      participation rates remain poor. The reasons for poor participation are as yet
      unclear. The aim of this study was to further our understanding of the
      factors-associated PPC uptake, particularly attitudes and beliefs towards PPC
      using models of health behaviour: The Health Belief Model, Social Cognitive
      Theory, and Theory of Reasoned Action. Participants comprised 123 women with type
      1 and 2 diabetes attending outpatient clinics for diabetes and pregnancy, who
      completed questionnaires. Logistic regression analysis indicated that after
      adjusting for socio-demographic factors, exposure to a greater number of cues was
      a significant predictor of PPC participation (odds ratio [OR]: 1.93; 95%
      confidence interval [95% CI]: 1.13-3.28). Other significant predictors of PPC
      uptake were older age (OR: 1.13; 95% CI: 1.01-1.26) and not having children (OR: 
      3.93; 95% CI: 1.28-12.06). The findings from this study support initiatives to
      provide cues to PPC for women with diabetes to enhance PPC uptake. Further, some 
      groups such as younger women as well as women with children may possibly be
      considered for the focus of more vigorous intervention efforts.
AD  - Department of Psychiatry, The University of Melbourne .
FAU - Komiti, A
AU  - Komiti A
FAU - Jackson, H J
AU  - Jackson HJ
FAU - Nankervis, A
AU  - Nankervis A
FAU - Conn, J
AU  - Conn J
FAU - Allan, C
AU  - Allan C
FAU - Judd, F
AU  - Judd F
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - England
TA  - J Psychosom Obstet Gynaecol
JT  - Journal of psychosomatic obstetrics and gynaecology
JID - 8308648
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/05/23 [aheadofprint]
AID - 10.3109/0167482X.2013.793664 [doi]
PST - ppublish
SO  - J Psychosom Obstet Gynaecol. 2013 Jun;34(2):75-81. doi:
      10.3109/0167482X.2013.793664. Epub 2013 May 23.

PMID- 23701432
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1743-8942 (Electronic)
IS  - 0167-482X (Linking)
VI  - 34
IP  - 2
DP  - 2013 Jun
TI  - A study of postpartum depression and maternal risk factors in Qatar.
PG  - 90-7
LID - 10.3109/0167482X.2013.786036 [doi]
AB  - Abstract Objective: The objective of this study was to investigate the
      association between maternal complications and postpartum depression (PPD) among 
      postpartum women in Qatar by using the Edinburgh Postnatal Depression Scale
      (EPDS) as well as a structured questionnaire. Methods: This is a cross-sectional 
      study of PPD of 1379 postpartum women within 6 months of delivery attending the
      primary healthcare centers of the State of Qatar. Results: The prevalence of PPD 
      was 17.6% in the studied mothers. The results of the logistic regression analysis
      showed that the risk factors for PPD included various socio-demographic risk
      factors such as education, occupation, consanguinity and access to
      transportation. Amongst the maternal factors studied, history of unplanned
      pregnancy and infertility and other medical complications such as gestational
      diabetes, heart disease, threatened abortion and cesarean section were found to
      be risk factors for PPD. Amongst the postpartum women with maternal
      complications, items related to feeling scared and panicky and feeling sad and
      miserable were the most frequently reported symptoms of depression. These women
      were also more likely to be experiencing sleep difficulty (p = 0.029) compared to
      women without maternal complications. Conclusion: While socio-demographic risk
      factors are well studied in the PPD literature, there is much less information on
      the impact of maternal complications on the psychological status of postpartum
      women. Postpartum women, especially those with maternal complications, need close
      screening and have quick access to mental healthcare within integrated
      reproductive health services.
AD  - Department of Psychiatry, Weill Cornell Medical College , New York, NY , USA .
FAU - Burgut, F Tuna
AU  - Burgut FT
FAU - Bener, Abdulbari
AU  - Bener A
FAU - Ghuloum, Suheila
AU  - Ghuloum S
FAU - Sheikh, Javaid
AU  - Sheikh J
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - England
TA  - J Psychosom Obstet Gynaecol
JT  - Journal of psychosomatic obstetrics and gynaecology
JID - 8308648
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/05/23 [aheadofprint]
AID - 10.3109/0167482X.2013.786036 [doi]
PST - ppublish
SO  - J Psychosom Obstet Gynaecol. 2013 Jun;34(2):90-7. doi:
      10.3109/0167482X.2013.786036. Epub 2013 May 23.

PMID- 23701408
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1554-8937 (Electronic)
IS  - 1554-8929 (Linking)
DP  - 2013 May 23
TI  - Proteome-Wide Reactivity Profiling Identifies Diverse Carbamate Chemotypes Tuned 
      for Serine Hydrolase Inhibition.
AB  - Serine hydrolases are one of the largest and most diverse enzyme classes in
      Nature. Inhibitors of serine hydrolases are used to treat many diseases,
      including obesity, diabetes, cognitive dementia, and bacterial and viral
      infections. Nonetheless, the majority of the 200+ serine hydrolases in mammals
      still lack selective inhibitors for their functional characterization. We and
      others have shown that activated carbamates, through covalent reaction with the
      conserved serine nucleophile of serine hydrolases, can serve as useful inhibitors
      for members of this enzyme family. The extent to which carbamates, however,
      cross-react with other protein classes remains mostly unexplored. Here, we
      address this problem by investigating the proteome-wide reactivity of a diverse
      set of activated carbamates in vitro and in vivo, using a combination of
      competitive and click chemistry (CC)-activity-based protein profiling (ABPP). We 
      identify multiple classes of carbamates, including O-aryl, O-hexafluoroisopropyl 
      (HFIP), and O-N-hydroxysuccinimidyl (NHS) carbamates that react selectively with 
      serine hydrolases across entire mouse tissue proteomes in vivo. We exploit the
      proteome-wide specificity of HFIP carbamates to create in situ imaging probes for
      the endocannabinoid hydrolases monoacylglycerol lipase (MAGL) and alpha-beta
      hydrolase-6 (ABHD6). These findings, taken together, designate the carbamate as a
      privileged reactive group for serine hydrolases that can accommodate diverse
      structural modifications to produce inhibitors that display exceptional potency
      and selectivity across the mammalian proteome.
AD  - The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, 
      The Scripps Research Institute , La Jolla, California, The United States of
      America.
FAU - Chang, Jae Won
AU  - Chang JW
FAU - Cognetta, Armand B 3rd
AU  - Cognetta AB 3rd
FAU - Niphakis, Micah J
AU  - Niphakis MJ
FAU - Cravatt, Benjamin F
AU  - Cravatt BF
LA  - ENG
GR  - P01 DA017259/DA/NIDA NIH HHS/United States
GR  - R01 DA033760/DA/NIDA NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - ACS Chem Biol
JT  - ACS chemical biology
JID - 101282906
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1021/cb400261h [doi]
PST - aheadofprint
SO  - ACS Chem Biol. 2013 May 23.

PMID- 23701311
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 23
TI  - Diabetes distress in Type 1 diabetes-a new measurement fit for purpose.
LID - 10.1111/dme.12241 [doi]
AB  - AIMS: To examine and assess (1) the internal consistency and validity of a Danish
      translation of the Diabetes Distress Scale (DDS17) among adults with Type 1
      diabetes mellitus, (2) the properties of the brief version of DDS17 and (3) cut
      points for the DDS17. METHODS: Cross-sectional survey of 2419 adults with Type 1 
      diabetes mellitus. Validated scales and questions measured diabetes distress
      (DDS17), diabetes empowerment (DES-SF), healthy diet, physical activity,
      self-rated health (SF-12) and quality of life (WHOQoL-BREF). An electronic
      patient record provided information about glycaemic control (HbA1c ). We examined
      internal consistency, construct validity, subscale construction and cut points
      for determining clinically relevant diabetes distress, as well as two- and
      four-item brief versions of the DDS17. RESULTS: The DDS17 had a Cronbach's alpha 
      of 0.92; subscale alphas were 0.83-0.89. A four-factor division into subscales
      was appropriate and the division corresponded closely to the four domains
      described in the development of the DDS17. The DDS17 correlated well with
      relevant measures; higher distress was correlated with low diabetes empowerment, 
      low quality of life, unhealthy diet, not being physically active, poor glycaemic 
      control and low scores on the mental component score of the SF-12. A two-item
      brief scale performed as well as a four-item version. The relationship between
      DDS17 and outcomes did not suggest distinct cut points for DDS17. CONCLUSIONS:
      Our results provide support for the use of this Danish adaptation of the DDS17
      for assessing psychosocial distress among adults with Type 1 diabetes mellitus.
      This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Steno Health Promotion Center, Steno Diabetes Center, Gentofte.
FAU - Joensen, L E
AU  - Joensen LE
FAU - Tapager, I
AU  - Tapager I
FAU - Willaing, I
AU  - Willaing I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/01/30 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/05/21 [accepted]
AID - 10.1111/dme.12241 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 23. doi: 10.1111/dme.12241.

PMID- 23701286
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 23
TI  - Differences between men and women in the regulation of adipose 11beta-HSD1 and in
      its association with adiposity and insulin resistance.
LID - 10.1111/dom.12137 [doi]
AB  - This study explored sex differences in 11beta-hydroxysteroid dehydrogenases type 
      1 (11beta-HSD1) activity and gene expression in isolated adipocytes and adipose
      tissue (AT), obtained via subcutaneous biopsies from non-diabetic subjects (58M, 
      64F; age 48.3 +/- 15.3 yr, BMI 27.2 +/- 3.9 kg/m2 ). Relationships with adiposity
      and insulin resistance (IR) were addressed. Males exhibited higher 11beta-HSD1
      activity in adipocytes than females, but there was no such difference for AT. In 
      both men and women, adipocyte 11beta-HSD1 activity correlated positively with
      BMI, waist circumference, % body fat, adipocyte size and with serum glucose,
      triglycerides and LDL:HDL ratio. Positive correlations with insulin, HOMA-IR and 
      HbA1c and a negative correlation with HDL-cholesterol were significant only in
      males. Conversely, 11beta-HSD1 activity in AT correlated with several markers of 
      IR and adiposity in females but not in males, but the opposite pattern was found 
      with respect to 11beta-HSD1 mRNA expression. This study suggests that there are
      sex differences in 11beta-HSD1 regulation and in its associations with markers of
      obesity and IR.
CI  - This article is protected by copyright. All rights reserved.
AD  - AstraZeneca R&D, Macclesfield, United Kingdon.
FAU - Deschoolmeester, Joanne
AU  - Deschoolmeester J
FAU - Palming, Jenny
AU  - Palming J
FAU - Persson, Tore
AU  - Persson T
FAU - Pereira, Maria J
AU  - Pereira MJ
FAU - Wallerstedt, Emelie
AU  - Wallerstedt E
FAU - Brown, Henry
AU  - Brown H
FAU - Gill, Debra
AU  - Gill D
FAU - Renstrom, Frida
AU  - Renstrom F
FAU - Lundgren, Magdalena
AU  - Lundgren M
FAU - Svensson, Maria K
AU  - Svensson MK
FAU - Rees, Amanda
AU  - Rees A
FAU - Eriksson, Jan W
AU  - Eriksson JW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/02/13 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/10 [accepted]
AID - 10.1111/dom.12137 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 23. doi: 10.1111/dom.12137.

PMID- 23701274
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 23
TI  - A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks
      benfotiamine treatment on postprandial vascular function and variables of
      autonomic nerve function in Type 2 diabetes.
LID - 10.1111/dme.12240 [doi]
AB  - AIMS: In a pilot study we suggested that benfotiamine, a thiamine prodrug,
      prevents postprandial endothelial dysfunction in people with Type 2 diabetes
      mellitus. The aim of this study was to test these effects in a larger population.
      METHODS: In a double-blind, placebo-controlled, randomized, crossover study, 31
      people with Type 2 diabetes received 900 mg/day benfotiamine or a placebo for 6
      weeks (with a washout period of 6 weeks between). At the end of each treatment
      period, macrovascular and microvascular function were assessed, together with
      variables of autonomic nervous function in a fasting state, as well as 2, 4 and 6
      h following a heated, mixed test meal. RESULTS: Participants had an impaired
      baseline flow-mediated dilatation (2.63 +/- 2.49%). Compared with the fasting
      state, neither variable changed postprandially following the placebo treatment.
      The 6 weeks' treatment with high doses of benfotiamine did not alter this
      pattern, either in the fasting state or postprandially. Among a subgroup of
      patients with the highest flow-mediated dilatation, following placebo treatment
      there was a significant postprandial flow-mediated dilatation decrease, while
      this effect was attenuated by benfotiamine pretreatment. CONCLUSIONS: In people
      with Type 2 diabetes and markedly impaired fasting flow-mediated dilatation, a
      mixed test meal does not further deteriorate flow-mediated dilatation or
      variables of microvascular or autonomic nervous function. Because no significant 
      deterioration of postprandial flow-mediated dilatation, microvascular or
      autonomic nervous function tests occurred after placebo treatment, a prevention
      of the postprandial deterioration of these variables with benfotiamine was not
      feasible. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Diabetes Clinic, Heart and Diabetes Center NRW, Bad Oeynhausen, Neuss, Germany;
      Profil Institute for Metabolic Research GmbH, Neuss, Germany.
FAU - Stirban, A
AU  - Stirban A
FAU - Pop, A
AU  - Pop A
FAU - Tschoepe, D
AU  - Tschoepe D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/02/26 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/05/21 [accepted]
AID - 10.1111/dme.12240 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 23. doi: 10.1111/dme.12240.

PMID- 23701262
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 22
TI  - GSK256073, a Selective Agonist of G-protein Coupled Receptor 109A (GPR109A)
      Reduces Serum Glucose in Subjects with Type 2 Diabetes Mellitus.
LID - 10.1111/dom.12132 [doi]
AB  - AIMS: This clinical trial assessed whether a potent, selective GPR109A agonist,
      GSK256073, could, through inhibition of lipolysis, acutely improve glucose
      homeostasis in subjects with type 2 diabetes mellitus. MATERIALS AND METHODS:
      Thirty-nine diabetic subjects were enrolled in the randomized, single-blind,
      placebo-controlled, three-period crossover trial. Each subject received placebo
      and two of four regimens of GSK256073 for two days. GSK256073 was dosed 5 mg
      every 12 hours before breakfast and supper (BID), 10 mg every 24 hours before
      breakfast (QD), 25 mg BID, and 50 mg QD. RESULTS: The change from baseline
      weighted mean glucose concentration for an interval from 24 to 48 hour after the 
      initial drug dose was significantly reduced for all GSK256073 regimens, reaching 
      a maximum of -0.87 mmol/L (-1.20, -0.52) with the 25 mg BID dose. Sustained
      suppression of non-esterified fatty acid (NEFA) and glycerol concentrations was
      observed with all GSK256073 doses throughout the 48-hour dosing period. Serum
      insulin and C-peptide concentrations fell in concert with glucose concentrations 
      and calculated HOMA-IR scores decreased 27 to 47%, consistent with insulin
      sensitization. No marked differences were evident between either 10 and 50 mg
      total daily doses or QD vs. BID dosing. CONCLUSIONS: Administration of a GPR109A 
      agonist for two days significantly decreased serum NEFA and glucose
      concentrations in diabetic subjects. Glucose improvements were associated with
      decreased insulin concentrations and measures of enhanced insulin sensitivity.
      Improved glucose control occurred with GSK256073 doses that were generally safe
      and not associated with events of flushing or gastrointestinal disturbances.
CI  - This article is protected by copyright. All rights reserved.
AD  - GlaxoSmithKline, Drug Discovery, Research Triangle Park, North Carolina, USA.
FAU - Dobbins, Robert L
AU  - Dobbins RL
FAU - Shearn, Shawn P
AU  - Shearn SP
FAU - Byerly, Robert L
AU  - Byerly RL
FAU - Gao, Feng F
AU  - Gao FF
FAU - Mahar, Kelly M
AU  - Mahar KM
FAU - Napolitano, Antonella
AU  - Napolitano A
FAU - Nachbaur, Gaelle J
AU  - Nachbaur GJ
FAU - Le Monnier de Gouville, Anne-Charlotte
AU  - Le Monnier de Gouville AC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/12/14 [received]
PHST- 2013/03/24 [revised]
PHST- 2013/05/06 [accepted]
AID - 10.1111/dom.12132 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 22. doi: 10.1111/dom.12132.

PMID- 23701260
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
DP  - 2013 Jun 7
TI  - Cost-effectiveness of lurasidone vs aripiprazole among patients with
      schizophrenia who have previously failed on an atypical antipsychotic: an
      indirect comparison of outcomes from clinical trial data.
AB  - Abstract Objective: Compare long-term costs and outcomes of lurasidone to
      aripiprazole among adults with schizophrenia in the US who previously failed >/=1
      atypical antipsychotic (olanzapine, risperidone, quetiapine, or ziprasidone)
      based on an indirect comparison of outcomes data from clinical trials. Methods: A
      5-year Markov cohort model was developed to compare long-term effectiveness of
      lurasidone to aripiprazole, including total discontinuations, relapse rates, and 
      hospitalization rates. Cost inputs included pharmacy, mental health, and medical 
      costs associated with cardiometabolic risks (diabetes and cardiovascular [CV]
      events). Effectiveness inputs were derived from an indirect comparison of
      aripiprazole and lurasidone using common comparators from CATIE. Cardiometabolic 
      risks were derived from claims data analysis for diabetes, weight change and CV
      events, and Framingham body mass index (BMI) risk equation. Cost inputs were
      derived from published sources and Red Book. Costs and outcomes were discounted
      at 3% and tested with sensitivity analyses. Results: Over 5 years, total
      discounted costs for lurasidone and aripiprazole patients were $86,480 and
      $90,500, respectively. During this period, the number of relapses per patient,
      hospitalizations per patient, diabetes rates, and CV events per 1000 patients,
      respectively, were estimated to be lower for lurasidone (0.442, 0.245, 7.29%, and
      37.3) than aripiprazole (0.478, 0.369, 7.36%, and 37.8). Results were sensitive
      to lurasidone and aripiprazole hospitalization rates. At a willingness-to-pay
      threshold of $50,000 per hospitalization avoided, lurasidone had a 100%
      probability of being more cost-effective than aripiprazole. Limitations: The
      model was based on results from various comparative clinical trials. Differences 
      in patient population and study methods may change estimates from the model. The 
      model does not account for patient heterogeneity. Conclusions: Based on this
      model, when switching from another atypical antipsychotic, lurasidone had fewer
      relapses and hospitalizations with a lower incidence of diabetes and CV events
      than aripiprazole. Additionally, lurasidone may be less costly than aripiprazole 
      among adults with schizophrenia.
AD  - Sunovion Pharmaceuticals Inc. , Marlborough, MA , USA.
FAU - Rajagopalan, Krithika
AU  - Rajagopalan K
FAU - Hassan, Mariam
AU  - Hassan M
FAU - O'Day, Ken
AU  - O'Day K
FAU - Meyer, Kellie
AU  - Meyer K
FAU - Grossman, Fred
AU  - Grossman F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130607
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.3111/13696998.2013.807813 [doi]
PST - aheadofprint
SO  - J Med Econ. 2013 Jun 7.

PMID- 23701236
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 23
TI  - WITHDRAWN: The Diabetes Attitudes, Wishes and Needs second study(DAWN2)
      cross-national benchmarking indicators for family members living with people with
      diabetes.
LID - 10.1111/dme.12239 [doi]
AD  - Edmonton Clinic Health Academy, University of Alberta, Edmonton, AB, Canada.
FAU - Kovacs Burns, K
AU  - Kovacs Burns K
FAU - Nicolucci, A
AU  - Nicolucci A
FAU - Holt, R I G
AU  - Holt RI
FAU - Willaing, I
AU  - Willaing I
FAU - Hermanns, N
AU  - Hermanns N
FAU - Kalra, S
AU  - Kalra S
FAU - Wens, J
AU  - Wens J
FAU - Pouwer, F
AU  - Pouwer F
FAU - Skovlund, S E
AU  - Skovlund SE
FAU - Peyrot, M
AU  - Peyrot M
CN  - The DAWN2 Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.1111/dme.12239 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 23. doi: 10.1111/dme.12239.

PMID- 23701223
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
DP  - 2013 May 23
TI  - Postural orthostatic tachycardia syndrome (POTS) in a child with type 1 diabetes.
LID - 10.1111/jpc.12243 [doi]
AD  - Starship Children's Hospital, Auckland District Health Board, Auckland, New
      Zealand.
FAU - Su, Jennifer
AU  - Su J
FAU - Lee, James
AU  - Lee J
FAU - Gunn, Alistair Jan
AU  - Gunn AJ
FAU - Jefferies, Craig
AU  - Jefferies C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/12 [accepted]
AID - 10.1111/jpc.12243 [doi]
PST - aheadofprint
SO  - J Paediatr Child Health. 2013 May 23. doi: 10.1111/jpc.12243.

PMID- 23701217
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
DP  - 2013 Apr 12
TI  - Combination of Daidzein, Hemin and Bms182874 Halts the Progression of
      Diabetes-Induced Experimental Nephropathy.
AB  - The present study has been designed to investigated the combined effect of
      daidzein (caveolin inhibitor), hemin (hemoxygenase activator) and BMS182874
      (endothelin receptor antagonist) in diabetic nephropathy in wistar rats. Diabetic
      nephropathy was induced by administering single dose of streptozotocin in wistar 
      rats. DN was clinically assessed by estimation of various biochemical parameters 
      and histopathological studies of renal tissue. DN was assessed by measuring serum
      creatinine, blood urea nitrogen, proteinuria, renal cortical collagen content,
      lipid profile, serum nitrite/nitrate ratio, renal TBARS, reduced glutathione
      levels. The combination of daidzein, hemin and BMS182874 showed significant
      improvement in (BUN, serum creatinine, proteinuria, urinary output, kidney
      weight/ body weight, renal cortical collagen content, nitrite/ nitrate level,
      renal TBARS, reduced glutathione) renal parameters studied for DN in comparison
      with single drug administration as well as combination of two drugs. L-NAME
      (NG-nitro-L-arginine methyl ester) a selective eNOS inhibitor abolished the
      ameliorative effect of combination of daidzein, hemin and BMS182874 in DN in
      rats. It may be concluded that Daidzein in combination with hemin may enhance the
      level of renal nitric oxide by decreasing the expression of caveolin. BMS182874
      shows renoprotection by inhibiting RAAS system & by reactivation of NO synthesis.
      These finding provide mechanistic insights to explain renoprotective effect of
      this combined therapy in diabetes.
AD  - Indo Soviet Friendship College of pharmacy, Moga, Punjab. tarunakatyal@gmail.com.
FAU - Katyal, Taruna
AU  - Katyal T
FAU - Garg, Arun
AU  - Garg A
FAU - Budhiraja, R D
AU  - Budhiraja RD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/01/10 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/12 [accepted]
AID - CDTIEMD-EPUB-20130412-2 [pii]
PST - aheadofprint
SO  - Endocr Metab Immune Disord Drug Targets. 2013 Apr 12.

PMID- 23701209
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1475-097X (Electronic)
IS  - 1475-0961 (Linking)
DP  - 2013 Apr 2
TI  - Women with metabolic syndrome present different autonomic modulation and blood
      pressure response to an acute resistance exercise session compared with women
      without metabolic syndrome.
LID - 10.1111/cpf.12038 [doi]
AB  - Metabolic syndrome (MetS) is a cluster of risk factors in individuals with high
      risk of diabetes and heart disease. Resistance training (RT) has been proposed to
      be a safe, effective and worthwhile method for the prevention and treatment of
      metabolic and cardiovascular diseases. However, no study has analysed the acute
      response of blood pressure (BP) and autonomic control of heart rate (HR) after a 
      RT session in female patients with MetS. The aim of the present study was to
      analyse the response of laboratory assessed and ambulatory BP and cardiac
      autonomic modulation after a RT session in women with MetS. Nine women without
      MetS (35.0 +/- 6.7 years) and 10 women with MetS (34.1 +/- 9.4 years) completed
      one experimental exercise session and a control session. Laboratory BP, heart
      rate variability (HRV) and ambulatory BP of each subject were measured at rest,
      over 60 min, and for 24 h after the end of the sessions, respectively. There was 
      a significant reduction in systolic blood pressure (SBP), night time diastolic
      blood pressure (DBP) and mean blood pressure (MBP) only for women with MetS, for 
      all periods after the RT session when compared with the control session (P<0.05).
      Significantly lower laboratory values of SBP and DBP (10, 30 and 40 min
      postexercise) and MBP (10, 40 and 50 min postexercise) were observed in women
      with MetS (P<0.05). Patients with MetS exhibited significant lower basal HRV and 
      a lower autonomic responsiveness during the 60 min of acute recovery. These
      results confirmed that an acute session of resistance exercise induced a lower BP
      during day time and sleeping hours in women with MetS that may offer a
      cardio-protective effect. Women with MetS exhibited an impaired autonomic
      modulation at rest and a lower acute autonomic responsiveness to a RT session.
      The dissociation between BP and HRV responses suggests that other factors than
      autonomic control could be involved in the hypotensive effect of a RT session in 
      MetS patients.
CI  - (c) 2013 Scandinavian Society of Clinical Physiology and Nuclear Medicine.
      Published by Blackwell Publishing Ltd.
AD  - Graduation Program on Physical Education, Catholic University of Brasilia,
      Brasilia, Brazil; Department of Physical Education, Euro-American University
      Center (UNIEURO), Brasilia, Brazil.
FAU - Tibana, Ramires A
AU  - Tibana RA
FAU - Boullosa, Daniel A
AU  - Boullosa DA
FAU - Leicht, Anthony S
AU  - Leicht AS
FAU - Prestes, Jonato
AU  - Prestes J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130402
TA  - Clin Physiol Funct Imaging
JT  - Clinical physiology and functional imaging
JID - 101137604
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2012/09/11 [received]
PHST- 2013/02/26 [accepted]
AID - 10.1111/cpf.12038 [doi]
PST - aheadofprint
SO  - Clin Physiol Funct Imaging. 2013 Apr 2. doi: 10.1111/cpf.12038.

PMID- 23701078
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1546-3141 (Electronic)
IS  - 0361-803X (Linking)
VI  - 200
IP  - 6
DP  - 2013 Jun
TI  - Liver abscess after transarterial chemoembolization in patients with bilioenteric
      anastomosis: frequency and risk factors.
PG  - 1370-7
LID - 10.2214/AJR.12.9630 [doi]
AB  - OBJECTIVE. The purpose of this study was to clarify the frequency of and risk
      factors for liver abscess formation after transarterial chemoembolization (TACE) 
      in patients with hepatocellular carcinoma or metastatic hepatic tumors after
      undergoing bilioenteric anastomosis. MATERIALS AND METHODS. From January 1996 to 
      June 2012, 25 patients (21 men, four women; age range, 34-74 years) with
      hepatocellular carcinoma (n = 12) or metastatic hepatic tumors (n = 13) with an
      underlying bilioenteric anastomosis underwent 65 TACE procedures. The incidence
      of liver abscess, predisposing factors (diabetes, Child-Pugh class, leukopenia,
      tumor number, tumor size, tumor burden, tumor type, portal vein thrombus,
      lipiodol dose, particulate embolization, embolization selectivity, oily
      portogram, antibiotic prophylaxis, and occurrence of liver abscess at initial
      TACE), and clinical outcome were evaluated. Statistical analysis for relations
      between liver abscess and predisposing factors was performed by Fisher exact test
      and linear-by-linear association. RESULTS. Liver abscess developed after 17 of 65
      (26.2%) TACE procedures performed on 12 of 25 (48%) patients. Two patients died
      of progression of liver abscess into sepsis. Univariate and multivariate analyses
      showed that leukopenia (p = 0.029), occurrence of liver abscess at initial TACE
      (p = 0.082), and particulate embolization or oily portogram (grade 2) (p = 0.001)
      were associated with a higher incidence of liver abscess. CONCLUSION. The
      incidence of liver abscess was high among patients with bilioenteric anastomoses 
      who underwent TACE. Leukopenia, occurrence of liver abscess at initial session of
      TACE, and particulate embolization or oily portogram (grade 2) were associated
      with the development of liver abscess.
AD  - 1 All authors: Department of Radiology, Seoul National University College of
      Medicine, 101 Daehak-ro, Jongnogu, Seoul 110-744, Korea.
FAU - Woo, Sungmin
AU  - Woo S
FAU - Chung, Jin Wook
AU  - Chung JW
FAU - Hur, Saebeom
AU  - Hur S
FAU - Joo, Seung-Moon
AU  - Joo SM
FAU - Kim, Hyo-Cheol
AU  - Kim HC
FAU - Jae, Hwan Jun
AU  - Jae HJ
FAU - Park, Jae Hyung
AU  - Park JH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AJR Am J Roentgenol
JT  - AJR. American journal of roentgenology
JID - 7708173
SB  - AIM
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
AID - 10.2214/AJR.12.9630 [doi]
PST - ppublish
SO  - AJR Am J Roentgenol. 2013 Jun;200(6):1370-7. doi: 10.2214/AJR.12.9630.

PMID- 23700968
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1365-2796 (Electronic)
IS  - 0954-6820 (Linking)
DP  - 2013 May 23
TI  - Long-term coeliac disease influences risk of death in patients with type 1
      diabetes.
LID - 10.1111/joim.12092 [doi]
AB  - AIM: The aim of this study was to examine mortality in patients with both type 1 
      diabetes (T1D) and coeliac disease (CD). METHODS: Between 1969 and 2008, we
      identified individuals with CD through biopsy reports from all pathology
      departments (n = 28) in Sweden. T1D was defined as a diagnosis of diabetes
      recorded in the Swedish National Patient Register between 1964 and 2009 in
      individuals aged </=30 years. During follow-up, we identified 960 patients with
      both T1D and CD. For each individual with T1D and CD, we selected up to five
      subjects with T1D alone (i.e. no CD), matched for sex, age and calendar period of
      diagnosis, as the reference group (n = 4608). Using a stratified Cox regression
      analysis with CD as a time-dependent covariate, we estimated the risk of death in
      patients with both T1D and CD compared to those with T1D alone. RESULTS:
      Stratifying for time since CD diagnosis, CD was not a risk factor for death in
      patients with T1D during the first 5 years after CD diagnosis [hazard ratio (HR) 
      0.87, 95% confidence interval (CI) 0.43-1.73], but thereafter the HR for
      mortality increased as a function of follow-up time (5 to <10 years, HR 1.44, 95%
      CI 0.74- 2.79; 10 to <15 years, HR 1.88, 95% CI 0.81-4.36). Having a CD diagnosis
      for >/=15 years was associated with a 2.80-fold increased risk of death in
      individuals with T1D (95% CI 1.28-6.12). CONCLUSION: A diagnosis of CD for >/=15 
      years increases the risk of death in patients with T1D. This article is protected
      by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet,
      Stockholm, Sweden; St. Erik Eye Hospital, Karolinska Institutet, Stockholm,
      Sweden.
FAU - Mollazadegan, Kaziwe
AU  - Mollazadegan K
FAU - Sanders, David S
AU  - Sanders DS
FAU - Ludvigsson, Johnny
AU  - Ludvigsson J
FAU - Ludvigsson, Jonas F
AU  - Ludvigsson JF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PHST- 2013/04/18 [accepted]
AID - 10.1111/joim.12092 [doi]
PST - aheadofprint
SO  - J Intern Med. 2013 May 23. doi: 10.1111/joim.12092.

PMID- 23700849
OWN - NLM
STAT- In-Process
DA  - 20130524
IS  - 0017-0011 (Print)
IS  - 0017-0011 (Linking)
VI  - 84
IP  - 3
DP  - 2013 Mar
TI  - Somatic and non-somatic problems connected with psoriasis in pregnancy.
PG  - 211-3
AB  - Hormonal, metabolic and immunological changes occurring during pregnancy have
      significant effects on the function of the skin. Psoriasis is one of the most
      common dermatological diseases and it is known as a nonspecific dermatosis in
      pregnancy. The aim of this article is to present the importance of support in the
      course of psoriasis in pregnant women. Psoriasis may cause recurrent
      miscarriages, chronic hypertension, diabetes or obesity leading to perinatal
      complications and premature birth. The coexistence of psoriasis and pregnancy
      requires emotional prophylaxis, as well as support and psychotherapeutic care.
      Medical staff requires knowledge of skin diseases and skills to assess a
      patient's mental state.
AD  - Samodzielna Pracownia Zdrowia Psychicznego, Uniwersytet Medyczny w Lublinie,
      Polska. mlewicka13@wp.pl
FAU - Makara-Studzinska, Marta
AU  - Makara-Studzinska M
FAU - Pietrzak, Aldona
AU  - Pietrzak A
FAU - Lewicka, Magdalena
AU  - Lewicka M
FAU - Sulima, Magdalena
AU  - Sulima M
FAU - Kowalczyk, Karolina
AU  - Kowalczyk K
FAU - Michalak-Stoma, Anna
AU  - Michalak-Stoma A
FAU - Paszkowski, Tomasz
AU  - Paszkowski T
FAU - Chodorowska, Grazyna
AU  - Chodorowska G
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Ginekol Pol
JT  - Ginekologia polska
JID - 0374641
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - ppublish
SO  - Ginekol Pol. 2013 Mar;84(3):211-3.

PMID- 23700798
OWN - NLM
STAT- In-Process
DA  - 20130524
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 68
IP  - 4
DP  - 2013 Apr
TI  - alpha-Glucosidase and alpha-amylase inhibitory activities of saponins from
      traditional Chinese medicines in the treatment of diabetes mellitus.
PG  - 300-4
AB  - Extracts of eleven traditional Chinese medicines (TCM) with a reputation of
      usefulness in treating diabetes mellitus were examined for alpha-glucosidase and 
      alpha-amylase inhibitory activities in vitro. The extract with the highest
      activity was selected for further characterization. The extract of the root bark 
      of Aralia taibaiensis (EAT) outperformed other extracts in the assays with IC50
      values of 0.48 +/- 0.01 mg/mL (BSG), 0.41 +/- 0.02mg/mL (SCG), 0.61 +/- .03mg/mL 
      (BLA) and 0.77 +/- 0.03mg/mL (PPA), respectively. To identify which constituents 
      were responsible for the activities, thirteen triterpenoid saponins were isolated
      from EAT and examined for their inhibitory effects against alpha-glucosidase and 
      alpha-amylase. The results revealed that saponins 2, 3, 4 (IC50: 0.83 +/- 0.05
      microM for BSG and IC50: 0.72 +/- 0.03 microM for SCG), 5, 6, 7, 9, 10, 11 and 12
      (IC50: 1.07 +/- 0.04 micro.M for BSG and IC50: 0.93 +/- 0.05 micro.M for SCG)
      showed alpha-glucosidase inhibitory activities, while 2, 3, 4 (IC50: 0.93 +/-
      0.04 micro.M for PPA), 5, 6, 7, 9, 10, 11 and 12 (IC50: 1.02 +/- 0.03 micro.M for
      PPA) possessed significant alpha-amylase inhibitory activities. In addition, the 
      structure-activity relationship of the thirteen saponins was discussed based on
      their structure features and diabetes mellitus related activities. It is
      suggested that the glucuronic acid unit at C-3 of the aglycone is the imperative 
      functional group of the antidiabetic activities, and two characteristic
      structural features are responsible for the remarkable alpha-glucosidase and
      alpha-amylase inhibitory activities.
AD  - Department of Pharmacy, Xijing Hospital, Fourth Military Medical University,
      Yangling, PR China.
FAU - Dou, Fang
AU  - Dou F
FAU - Xi, Miaomiao
AU  - Xi M
FAU - Wang, Junxian
AU  - Wang J
FAU - Tian, Xiangrong
AU  - Tian X
FAU - Hong, Liangjian
AU  - Hong L
FAU - Tang, Haifeng
AU  - Tang H
FAU - Wen, Aidong
AU  - Wen A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - ppublish
SO  - Pharmazie. 2013 Apr;68(4):300-4.

PMID- 23700793
OWN - NLM
STAT- In-Process
DA  - 20130524
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 68
IP  - 4
DP  - 2013 Apr
TI  - Pioglitazone ameliorates palmitate induced impairment of mitochondrial morphology
      and function and restores insulin level in beta cells.
PG  - 270-3
AB  - This study aimed to investigate the effect of pioglitazone (PIO) on insulin
      secretion and mitochondrial ultrastructure and function in 3 cells. HIT-T15 cells
      were treated with control or palmitate (free fat acids, FFA) or/and PIO and
      divided into 7 groups: Control group; 0.5 mmol/l FFA (LF); 0.5 mmol/l FFA plus
      10-7 mol/I PIO (LFLP); 0.5 mmol/l FFA plus 10-5mol/I PIO (LFHP); 1.0 mmol/l FFA
      (HF); 1.0 mmol/l FFA plus 10-7mol/I PIO (HFLP); 1.0 mmol/l FFA plus 10-5 mol/I
      PIO (HFHP). Apoptotic peaks, mitochondrial ultrastructure, ATP/ADP, mRNA levels
      of peroxisome proliferater activated receptor gamma coactivator-1 (PGC-1) and
      nucleus respiratory factor-1 (NRF-1) as well as insulin secretion were measured. 
      The results showed that palmitate impaired mitochondrion structure, which could
      be alleviated by PIO. Palmitate could increase apoptotic peaks, decrease ATP/ADP 
      ratio, enhance the expression of PGC-1 mRNA and NRF-1 mRNA, and decrease glucose 
      stimulated insulin secretion (GSIS). In contrast, PIO could decrease apoptotic
      peaks, restore partly ATP/ADP ratio, decrease the expression of PGC-1 mRNA and
      NRF-1 mRNA, and increase GSIS level. These results demonstrate that PIO could
      ameliorate palmitate induced damage to mitochondrion ultrastructure and function 
      and restore GSIS, accompanied by the modulation of PGC-1 and NRF-1 expression.
      These findings provide new insight into the hypoglycemic effects of PIO and help 
      develop new agents for diabetes therapy.
AD  - The First Affiliated Hospital of Chengdu Medical College, Huaxi Hospital of
      Sichuan University, Chengdu, China.
FAU - Li, Yao
AU  - Li Y
FAU - Zhang, Xinxia
AU  - Zhang X
FAU - Tong, Nanwei
AU  - Tong N
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - ppublish
SO  - Pharmazie. 2013 Apr;68(4):270-3.

PMID- 23700781
OWN - NLM
STAT- In-Process
DA  - 20130524
IS  - 0945-1129 (Print)
IS  - 0945-1129 (Linking)
VI  - 66
IP  - 5
DP  - 2013 May
TI  - [In Process Citation].
PG  - 301
LA  - ger
PT  - Journal Article
TT  - Experten entwickeln Diabetes-Schulungsprogramm.
PL  - Germany
TA  - Pflege Z
JT  - Pflege Zeitschrift
JID - 9430463
SB  - N
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - ppublish
SO  - Pflege Z. 2013 May;66(5):301.

PMID- 23700756
OWN - NLM
STAT- In-Process
DA  - 20130524
IS  - 1068-8838 (Print)
IS  - 1068-8838 (Linking)
VI  - 87
IP  - 4
DP  - 2013 Apr
TI  - Diabetes: five keys to better care.
PG  - 34-7
AB  - Hospitals that are pushing the envelope on diabetes care are taking a population 
      health mangement approach that involves five critical components. This is the
      latest installment in our yearlong Diabetes Management series.
FAU - Aston, Geri
AU  - Aston G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hosp Health Netw
JT  - Hospitals & health networks / AHA
JID - 9312077
SB  - AIM
SB  - IM
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/25 06:00
PST - ppublish
SO  - Hosp Health Netw. 2013 Apr;87(4):34-7.

PMID- 23690393
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1544-1717 (Electronic)
IS  - 1544-1709 (Linking)
VI  - 11 Suppl 1
DP  - 2013 May-Jun
TI  - A positive deviance approach to understanding key features to improving diabetes 
      care in the medical home.
PG  - S99-S107
LID - 10.1370/afm.1473 [doi]
AB  - PURPOSE The medical home has gained national attention as a model to reorganize
      primary care to improve health outcomes. Pennsylvania has undertaken one of the
      largest state-based, multipayer medical home pilot projects. We used a positive
      deviance approach to identify and compare factors driving the care models of
      practices showing the greatest and least improvement in diabetes care in a sample
      of 25 primary care practices in southeast Pennsylvania. METHODS We ranked
      practices into improvement quintiles on the basis of the average absolute
      percentage point improvement from baseline to 18 months in 3 registry-based
      measures of performance related to diabetes care: glycated hemoglobin
      concentration, blood pressure, and low-density lipoprotein cholesterol level. We 
      then conducted surveys and key informant interviews with leaders and staff in the
      5 most and least improved practices, and compared their responses. RESULTS The
      most improved/higher-performing practices tended to have greater structural
      capabilities (eg, electronic health records) than the least
      improved/lower-performing practices at baseline. Interviews revealed striking
      differences between the groups in terms of leadership styles and shared vision;
      sense, use, and development of teams; processes for monitoring progress and
      obtaining feedback; and presence of technologic and financial distractions.
      CONCLUSIONS Positive deviance analysis suggests that primary care practices'
      baseline structural capabilities and abilities to buffer the stresses of change
      may be key facilitators of performance improvement in medical home
      transformations. Attention to the practices' structural capabilities and factors 
      shaping successful change, especially early in the process, will be necessary to 
      improve the likelihood of successful medical home transformation and better care.
AD  - Penn State College of Medicine, Hershey, Pennsylvania.
FAU - Gabbay, Robert A
AU  - Gabbay RA
FAU - Friedberg, Mark W
AU  - Friedberg MW
FAU - Miller-Day, Michelle
AU  - Miller-Day M
FAU - Cronholm, Peter F
AU  - Cronholm PF
FAU - Adelman, Alan
AU  - Adelman A
FAU - Schneider, Eric C
AU  - Schneider EC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Fam Med
JT  - Annals of family medicine
JID - 101167762
SB  - IM
OTO - NOTNLM
OT  - change
OT  - organizational
OT  - patient-centered medical home
OT  - positive deviance
OT  - practice-based research
OT  - primary care
OT  - quality improvement
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/22 06:00
AID - 11/Suppl_1/S99 [pii]
AID - 10.1370/afm.1473 [doi]
PST - ppublish
SO  - Ann Fam Med. 2013 May-Jun;11 Suppl 1:S99-S107. doi: 10.1370/afm.1473.

PMID- 23690389
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1544-1717 (Electronic)
IS  - 1544-1709 (Linking)
VI  - 11 Suppl 1
DP  - 2013 May-Jun
TI  - Becoming a patient-centered medical home: a 9-year transition for a network of
      federally qualified health centers.
PG  - S68-73
LID - 10.1370/afm.1547 [doi]
AB  - PURPOSE The patient-centered medical home (PCMH) model has great potential for
      optimizing the care of chronically ill patients, yet there is much to be learned 
      about various implementations of this model and their impact on patient care
      processes and outcomes. METHODS We examined changes in patterns of health care
      use in a network of Federally Qualified Health Centers throughout a 9-year period
      of practice transformation that included recognition of all centers by the
      National Committee for Quality Assurance (NCQA) as Level 3 PCMH practices. We
      analyzed deidentified data from electronic health records for the period 2003 to 
      2011 to identify patterns of service use for all 4,595 patients with diabetes. We
      also examined a subsample of 545 patients who were in care throughout the study
      period to track improvement in glycated hemoglobin levels as a clinical measure
      over time. RESULTS Through the transition to a PCMH, the mean number of
      encounters with outreach, diabetes educators, and psychosocial services increased
      for all diabetic patients; virtually all patients had visits with a primary care 
      clinician, but the mean number of visits decreased slightly. Among patients in
      the subsample, mean annual levels of glycated hemoglobin decreased steadily
      during the 9-year study period, mainly driven by a reduction in patients having
      baseline levels exceeding 9%. CONCLUSIONS This retrospective study conducted in a
      real-world setting using electronic health record data demonstrates a shift in
      resource use by diabetic patients from the primary care clinician to other
      members of the care team. The findings suggest that PCMH implementation has the
      potential to alter processes of care and improve outcomes of care, especially
      among those with higher disease burden.
AD  - The Institute for Family Health, New York, New York.
FAU - Calman, Neil S
AU  - Calman NS
FAU - Hauser, Diane
AU  - Hauser D
FAU - Weiss, Linda
AU  - Weiss L
FAU - Waltermaurer, Eve
AU  - Waltermaurer E
FAU - Molina-Ortiz, Elizabeth
AU  - Molina-Ortiz E
FAU - Chantarat, Tongtan
AU  - Chantarat T
FAU - Bozack, Anne
AU  - Bozack A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Fam Med
JT  - Annals of family medicine
JID - 101167762
SB  - IM
OTO - NOTNLM
OT  - certification
OT  - change
OT  - diabetes
OT  - organizational
OT  - patient-centered medical home
OT  - practice-based research
OT  - primary care
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/22 06:00
AID - 11/Suppl_1/S68 [pii]
AID - 10.1370/afm.1547 [doi]
PST - ppublish
SO  - Ann Fam Med. 2013 May-Jun;11 Suppl 1:S68-73. doi: 10.1370/afm.1547.

PMID- 23690383
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1544-1717 (Electronic)
IS  - 1544-1709 (Linking)
VI  - 11 Suppl 1
DP  - 2013 May-Jun
TI  - Facilitators of transforming primary care: a look under the hood at practice
      leadership.
PG  - S27-33
LID - 10.1370/afm.1492 [doi]
AB  - PURPOSE This study examined how characteristics of practice leadership affect the
      change process in a statewide initiative to improve the quality of diabetes and
      asthma care. METHODS We used a mixed methods approach, involving analyses of
      existing quality improvement data on 76 practices with at least 1 year of
      participation and focus groups with clinicians and staff in a 12-practice
      subsample. Existing data included monthly diabetes or asthma measures (clinical
      measures) and monthly practice implementation, leadership, and practice
      engagement scores rated by an external practice coach. RESULTS Of the 76
      practices, 51 focused on diabetes and 25 on asthma. In aggregate, 50% to 78% made
      improvements within in each clinical measure in the first year. The odds of
      making practice changes were greater for practices with higher leadership scores 
      (odds ratios = 2.41-4.20). Among practices focused on diabetes, those with higher
      leadership scores had higher odds of performing nephropathy screening (odds ratio
      = 1.37, 95% CI, 1.08-1.74); no significant associations were seen for the
      intermediate outcome measures of hemoglobin A1c, blood pressure, and cholesterol.
      Focus groups revealed the importance of a leader, typically a physician, who
      believed in the transformation work (ie, a visionary leader) and promoted
      practice engagement through education and cross-training. Practices with greater 
      change implementation also mentioned the importance of a midlevel operational
      leader who helped to create and sustain practice changes. This person
      communicated and interacted well with, and was respected by both clinicians and
      staff. CONCLUSIONS In the presence of a vision for transformation, operational
      leaders within practices can facilitate practice changes that are associated with
      clinical improvement.
AD  - University of North Carolina Department of Family Medicine, Chapel Hill, North
      Carolina.
FAU - Donahue, Katrina E
AU  - Donahue KE
FAU - Halladay, Jacqueline R
AU  - Halladay JR
FAU - Wise, Alison
AU  - Wise A
FAU - Reiter, Kristin
AU  - Reiter K
FAU - Lee, Shoou-Yih Daniel
AU  - Lee SY
FAU - Ward, Kimberly
AU  - Ward K
FAU - Mitchell, Madeline
AU  - Mitchell M
FAU - Qaqish, Bahjat
AU  - Qaqish B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Fam Med
JT  - Annals of family medicine
JID - 101167762
SB  - IM
OTO - NOTNLM
OT  - change
OT  - coaching
OT  - innovation
OT  - organizational
OT  - practice facilitator
OT  - practice-based research
OT  - primary care
OT  - quality improvement
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/22 06:00
AID - 11/Suppl_1/S27 [pii]
AID - 10.1370/afm.1492 [doi]
PST - ppublish
SO  - Ann Fam Med. 2013 May-Jun;11 Suppl 1:S27-33. doi: 10.1370/afm.1492.

PMID- 23690379
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1544-1717 (Electronic)
IS  - 1544-1709 (Linking)
VI  - 11 Suppl 1
DP  - 2013 May-Jun
TI  - Medical home transformation: a gradual process and a continuum of attainment.
PG  - S108-14
LID - 10.1370/afm.1478 [doi]
AB  - PURPOSE The patient-centered medical home is often discussed as though there
      exist either traditional practices or medical homes, with marked differences
      between them. We analyzed data from an evaluation of certified medical homes in
      Minnesota to study this topic. METHODS We obtained publicly reported composite
      measures for quality of care outcomes pertaining to diabetes and vascular disease
      for all clinics in Minnesota from 2008 to 2010. The extent of and change in
      practice systems over that same time period for the first 120 clinics serving
      adults certified as health care homes (HCHs) was measured by the Physician
      Practice Connections Research Survey (PPC-RS), a self-report tool similar to the 
      National Committee for Quality Assurance standards for patient-centered medical
      homes. Measures were compared between these clinics and 518 non-HCH clinics in
      the state. RESULTS Among the 102 clinics for which we had precertification and
      postcertification scores for both the PPC-RS and either diabetes or vascular
      disease measures, the mean increase in systems score over 3 years was an absolute
      29.1% (SD = 16.7%) from a baseline score of 38.8% (SD = 16.5%, P </=.001). The
      proportion of clinics in which all patients had optimal diabetes measures
      improved by an absolute 2.1% (SD = 5.5%, P </=.001) and the proportion in which
      all had optimal cardiovascular disease measures by 4.4% (SD = 7.5%, P </=.001),
      but all measures varied widely among clinics. Mean performance rates of HCH
      clinics were higher than those of non-HCH clinics, but there was extensive
      overlap, and neither group changed much over this time period. CONCLUSIONS The
      extensive variation among HCH clinics, their overlap with non-HCH clinics, and
      the small change in performance over time suggest that medical homes are not
      similar, that change in outcomes is slow, and that there is a continuum of
      transformation.
AD  - HealthPartners Institute for Education and Research, Minneapolis Minnesota.
FAU - Solberg, Leif I
AU  - Solberg LI
FAU - Crain, A Lauren
AU  - Crain AL
FAU - Tillema, Juliana
AU  - Tillema J
FAU - Scholle, Sarah Hudson
AU  - Scholle SH
FAU - Fontaine, Patricia
AU  - Fontaine P
FAU - Whitebird, Robin
AU  - Whitebird R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Fam Med
JT  - Annals of family medicine
JID - 101167762
SB  - IM
OTO - NOTNLM
OT  - certification
OT  - change
OT  - organizational
OT  - patient-centered medical home
OT  - practice-based research
OT  - primary care
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/22 06:00
AID - 11/Suppl_1/S108 [pii]
AID - 10.1370/afm.1478 [doi]
PST - ppublish
SO  - Ann Fam Med. 2013 May-Jun;11 Suppl 1:S108-14. doi: 10.1370/afm.1478.

PMID- 23678503
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1757-9767 (Electronic)
IS  - 1757-9759 (Linking)
VI  - 20
IP  - 2 Suppl
DP  - 2013 Jun
TI  - Therapeutic education among adults with type 2 diabetes: effects of a three-day
      intervention on perceived competence, self-management behaviours and glycaemic
      control.
PG  - 94-8
LID - 10.1177/1757975913483331 [doi]
AB  - The purpose of this study was to evaluate the impact of a three-day therapeutic
      education programme on perceived competence, self-management behaviours (i.e.
      physical activity, diet and medication) and glycaemic control among adults with
      type 2 diabetes. A total of 120 participants were included in this randomized,
      wait list control group trial. The results confirm that therapeutic education may
      be a powerful healthcare intervention to improve lifestyle and health status of
      people with type 2 diabetes. We observed that the education programme used in
      this study generated positive changes in glycaemic control and adherence to
      physical activity and diet after three months follow-up. Furthermore, the
      intervention positively impacted participants' perceived competence towards
      physical activity and diet. The latter finding is of particular importance, given
      that perceived competence has been found to be involved in long-term adherence to
      self-management behaviours.
AD  - 1.Laboratoire Sport et Environnement Social, Universite de Grenoble, France.
FAU - Trouilloud, David
AU  - Trouilloud D
FAU - Regnier, Jennifer
AU  - Regnier J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Glob Health Promot
JT  - Global health promotion
JID - 101497462
SB  - IM
OTO - NOTNLM
OT  - diabetes
OT  - diet
OT  - glycaemic control
OT  - perceived competence
OT  - physical activity
OT  - self-management
OT  - therapeutic education
EDAT- 2013/05/25 06:00
MHDA- 2013/05/25 06:00
CRDT- 2013/05/17 06:00
AID - 20/2_suppl/94 [pii]
AID - 10.1177/1757975913483331 [doi]
PST - ppublish
SO  - Glob Health Promot. 2013 Jun;20(2 Suppl):94-8. doi: 10.1177/1757975913483331.

PMID- 23700634
STAT- Publisher
DA  - 20130524
PB  - Agency for Healthcare Research and Quality (US)
CTI - AHRQ Comparative Effectiveness Reviews
DP  - 2013 Apr
BTI - Interventions To Improve Cardiovascular Risk Factors in People With Serious
      Mental Illness
AB  - Individuals with serious mental illness (SMI) have excess mortality from
      cardiovascular disease (CVD) and high rates of CVD risk factors such as diabetes,
      obesity, and hyperlipidemia. We conducted a systematic review to evaluate
      interventions to improve CVD risk factors in adults with SMI. We searched
      PubMed(R), Embase(R), PsycINFO(R), and the Cochrane Database of Systematic
      Reviews for English-language trials published since 1980 that evaluated
      patient-focused behavioral interventions, peer or family support interventions,
      pharmacological treatments, and multicondition lifestyle interventions, or their 
      combination, that targeted weight control, glucose levels, lipid levels, or CVD
      risk profile among adults with SMI at elevated risk of CVD. Two investigators
      screened each abstract and full-text article for inclusion, abstracted data, and 
      performed quality ratings, efficacy-effectiveness ratings, and evidence grading. 
      Qualitative and quantitative methods, using random-effects models, were used to
      summarize results. Of 35 eligible studies, most enrolled patients with
      schizophrenia who were prescribed antipsychotics. Most studies were designed to
      control weight (n=28); one study specifically addressed diabetes management, none
      targeted hyperlipidemia, and three were multicondition interventions. Most
      studies were efficacy trials comparing behavioral interventions with control;
      none evaluated peer and family support. There were few direct comparisons of
      active interventions; effects on overall CVD risk, physical functioning, or
      cardiovascular events were reported rarely. Compared with controls, behavioral
      interventions (mean difference [MD] -3.13 kg; 95% CI, -4.21 to -2.05), metformin 
      (MD -4.13 kg; CI, -6.58 to -1.68), the anticonvulsive medications topiramate and 
      zonisamide (MD -5.11kg; CI, -9.48 to -0.74), and adjunctive or antipsychotic
      switching to aripiprazole improved weight control. However, aripiprazole
      switching may be associated with higher rates of treatment failure. Nizatidine
      did not improve any outcome. The evidence was insufficient for all other
      interventions and effects on glucose and lipid control. Few studies have
      evaluated interventions to address one or more CVD risk factors in patients with 
      SMI. Comparative effectiveness studies are needed to test multimodal strategies, 
      agents known to be effective in non-SMI populations, and antipsychotic-management
      strategies.
FAU - Gierisch, Jennifer M
AU  - Gierisch JM
FAU - Nieuwsma, Jason A
AU  - Nieuwsma JA
FAU - Bradford, Daniel W
AU  - Bradford DW
FAU - Wilder, Christine M
AU  - Wilder CM
FAU - Mann-Wrobel, Monica C
AU  - Mann-Wrobel MC
FAU - McBroom, Amanda J
AU  - McBroom AJ
FAU - Wing, Liz
AU  - Wing L
FAU - Musty, Michael D
AU  - Musty MD
FAU - Chobot, Megan M
AU  - Chobot MM
FAU - Hasselblad, Vic
AU  - Hasselblad V
FAU - Williams, John W John W
AU  - Williams JW
LA  - eng
PT  - Book
PL  - Rockville (MD)
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CDAT- 2013/05/24 06:00
AID - NBK138237 [bookaccession]

PMID- 23700495
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130523
DCOM- 20130524
LR  - 20130527
IS  - 2005-6737 (Print)
IS  - 2005-6737 (Linking)
VI  - 54
IP  - 5
DP  - 2013 May
TI  - Predictive preoperative factors for renal insufficiency in patients followed for 
      more than 5 years after radical nephrectomy.
PG  - 303-10
LID - 10.4111/kju.2013.54.5.303 [doi]
AB  - PURPOSE: We assessed the predictive factors for renal insufficiency in patients
      followed for more than 5 years after radical nephrectomy. MATERIALS AND METHODS: 
      Age, gender, history of diabetes, history of hypertension, body mass index,
      preoperative estimated glomerular filtration rate (eGFR), serum uric acid, urine 
      albumin, normal renal parenchymal volume, tumor size, and ratio of normal
      parenchymal volume of the removed kidney to that of the remaining kidney were
      evaluated retrospectively in 89 patients who underwent radical nephrectomy from
      January 2001 to December 2005. Patients were included whose renal parenchymal
      volume was measurable by use of perioperative imaging (computed tomography or
      magnetic resonance imaging), whose preoperative eGFR was greater than 60
      mL/min/1.73 m(2), and who were followed for more than 5 years. To measure renal
      parenchymal volume from imaging, we integrated the extent of the normal renal
      parenchyma from axial slides of images. RESULTS: In univariate and multivariate
      binary regression analysis, the parenchymal volume of the remnant kidney
      (p=0.001), a history of diabetes (p=0.035), and preoperative eGFR (p=0.011) were 
      independent factors for renal insufficiency. By use of a receiver operating
      characteristic curve, a volume of 170 mL was determined to be an appropriate
      cutoff value, with sensitivity of 58.7% and specificity of 74.4% for the
      parenchymal volume of the remnant kidney for predicting eGFR less than 60
      mL/min/1.73 m(2) (area under the curve, 0.678). The parenchymal volume of the
      remnant kidney was also an independent factor for the downgrading of the chronic 
      kidney disease category in the multivariate linear regression analysis (p=0.021).
      CONCLUSIONS: Preoperative eGFR, a history of diabetes, and the radiologic volume 
      of the remaining kidney parenchyma could be useful factors for predicting
      postoperative renal function. Patients with parenchymal volumes of less than 170 
      mL have a higher risk of postoperative renal insufficiency, which should be
      considered carefully when choosing a treatment modality.
AD  - Department of Urology, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, Seoul, Korea.
FAU - Ahn, Joong Seo
AU  - Ahn JS
FAU - Kim, Hyung Joon
AU  - Kim HJ
FAU - Jeon, Hwang Gyun
AU  - Jeon HG
FAU - Jeong, Byong Chang
AU  - Jeong BC
FAU - Seo, Seong Il
AU  - Seo SI
FAU - Lee, Hyun Moo
AU  - Lee HM
FAU - Choi, Han Yong
AU  - Choi HY
FAU - Jeon, Seong Soo
AU  - Jeon SS
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - Korea (South)
TA  - Korean J Urol
JT  - Korean journal of urology
JID - 101499376
PMC - PMC3659223
OID - NLM: PMC3659223
OTO - NOTNLM
OT  - Kidney
OT  - Nephrectomy
OT  - Organ size
OT  - Renal insufficiency
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:01
CRDT- 2013/05/24 06:00
PHST- 2013/01/23 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/05/14 [epublish]
AID - 10.4111/kju.2013.54.5.303 [doi]
PST - ppublish
SO  - Korean J Urol. 2013 May;54(5):303-10. doi: 10.4111/kju.2013.54.5.303. Epub 2013
      May 14.

PMID- 23700469
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - The value of genetic information for diabetes risk prediction - differences
      according to sex, age, family history and obesity.
PG  - e64307
LID - 10.1371/journal.pone.0064307 [doi]
AB  - BACKGROUND: Genome-wide association studies have identified numerous single
      nucleotide polymorphisms associated with type 2 diabetes through the past years. 
      In previous studies, the usefulness of these genetic markers for prediction of
      diabetes was found to be limited. However, differences may exist between
      substrata of the population according to the presence of major diabetes risk
      factors. This study aimed to investigate the added predictive value of genetic
      information (42 single nucleotide polymorphisms) in subgroups of sex, age, family
      history of diabetes, and obesity. METHODS: A case-cohort study (random subcohort 
      N = 1,968; incident cases: N = 578) within the European Prospective Investigation
      into Cancer and Nutrition Potsdam study was used. Prediction models without and
      with genetic information were evaluated in terms of the area under the receiver
      operating characteristic curve and the integrated discrimination improvement.
      Stratified analyses included subgroups of sex, age (<50 or >/=50 years), family
      history (positive if either father or mother or a sibling has/had diabetes), and 
      obesity (BMI< or >/=30 kg/m(2)). RESULTS: A genetic risk score did not improve
      prediction above classic and metabolic markers, but - compared to a non-invasive 
      prediction model - genetic information slightly improved the area under the
      receiver operating characteristic curve (difference [95%-CI]: 0.007
      [0.002-0.011]). Stratified analyses showed stronger improvement in the older age 
      group (0.010 [0.002-0.018]), the group with a positive family history (0.012
      [0.000-0.023]) and among obese participants (0.015 [-0.005-0.034]) compared to
      the younger participants (0.005 [-0.004-0.014]), participants with a negative
      family history (0.003 [-0.001-0.008]) and non-obese (0.007 [0.000-0.014]),
      respectively. No difference was found between men and women. CONCLUSION: There
      was no incremental value of genetic information compared to standard non-invasive
      and metabolic markers. Our study suggests that inclusion of genetic variants in
      diabetes risk prediction might be useful for subgroups with already manifest risk
      factors such as older age, a positive family history and obesity.
AD  - Department of Molecular Epidemiology, German Institute of Human Nutrition
      Potsdam-Rehbruecke, Nuthetal, Germany ; German Center for Diabetes Research,
      Neuherberg, Germany.
FAU - Muhlenbruch, Kristin
AU  - Muhlenbruch K
FAU - Jeppesen, Charlotte
AU  - Jeppesen C
FAU - Joost, Hans-Georg
AU  - Joost HG
FAU - Boeing, Heiner
AU  - Boeing H
FAU - Schulze, Matthias B
AU  - Schulze MB
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3658960
OID - NLM: PMC3658960
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/14 [received]
PHST- 2013/04/13 [accepted]
PHST- 2013/05/20 [epublish]
AID - 10.1371/journal.pone.0064307 [doi]
AID - PONE-D-13-03684 [pii]
PST - epublish
SO  - PLoS One. 2013 May 20;8(5):e64307. doi: 10.1371/journal.pone.0064307. Print 2013.

PMID- 23700440
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Munc18c in adipose tissue is downregulated in obesity and is associated with
      insulin.
PG  - e63937
LID - 10.1371/journal.pone.0063937 [doi]
AB  - OBJECTIVE: Munc18c is associated with glucose metabolism and could play a
      relevant role in obesity. However, little is known about the regulation of
      Munc18c expression. We analyzed Munc18c gene expression in human visceral (VAT)
      and subcutaneous (SAT) adipose tissue and its relationship with obesity and
      insulin. MATERIALS AND METHODS: We evaluated 70 subjects distributed in 12
      non-obese lean subjects, 23 overweight subjects, 12 obese subjects and 23
      nondiabetic morbidly obese patients (11 with low insulin resistance and 12 with
      high insulin resistance). RESULTS: The lean, overweight and obese persons had a
      greater Munc18c gene expression in adipose tissue than the morbidly obese
      patients (p<0.001). VAT Munc18c gene expression was predicted by the body mass
      index (B = -0.001, p = 0.009). In SAT, no associations were found by different
      multiple regression analysis models. SAT Munc18c gene expression was the main
      determinant of the improvement in the HOMA-IR index 15 days after bariatric
      surgery (B = -2148.4, p = 0.038). SAT explant cultures showed that insulin
      produced a significant down-regulation of Munc18c gene expression (p = 0.048).
      This decrease was also obtained when explants were incubated with liver X
      receptor alpha (LXRalpha) agonist, either without (p = 0.038) or with insulin (p 
      = 0.050). However, Munc18c gene expression was not affected when explants were
      incubated with insulin plus a sterol regulatory element-binding protein-1c
      (SREBP-1c) inhibitor (p = 0.504). CONCLUSIONS: Munc18c gene expression in human
      adipose tissue is down-regulated in morbid obesity. Insulin may have an effect on
      the Munc18c expression, probably through LXRalpha and SREBP-1c.
AD  - Endocrinology and Diabetes Unit, Joan XXIII University Hospital, IISPV,
      Universitat Rovira i Virgili, Tarragona, Spain ; CIBER de Diabetes y Enfermedades
      Metabolicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Tarragona,
      Spain.
FAU - Garrido-Sanchez, Lourdes
AU  - Garrido-Sanchez L
FAU - Escote, Xavier
AU  - Escote X
FAU - Coin-Araguez, Leticia
AU  - Coin-Araguez L
FAU - Fernandez-Garcia, Jose Carlos
AU  - Fernandez-Garcia JC
FAU - El Bekay, Rajaa
AU  - El Bekay R
FAU - Vendrell, Joan
AU  - Vendrell J
FAU - Garcia-Fuentes, Eduardo
AU  - Garcia-Fuentes E
FAU - Tinahones, Francisco J
AU  - Tinahones FJ
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3659121
OID - NLM: PMC3659121
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/21 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/05/20 [epublish]
AID - 10.1371/journal.pone.0063937 [doi]
AID - PONE-D-12-36577 [pii]
PST - epublish
SO  - PLoS One. 2013 May 20;8(5):e63937. doi: 10.1371/journal.pone.0063937. Print 2013.

PMID- 23700410
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Activation of TrkB with TAM-163 Results in Opposite Effects on Body Weight in
      Rodents and Non-Human Primates.
PG  - e62616
LID - 10.1371/journal.pone.0062616 [doi]
AB  - Strong genetic data link the Tyrosine kinase receptor B (TrkB) and its major
      endogenous ligand brain-derived neurotrophic factor (BDNF) to the regulation of
      energy homeostasis, with loss-of-function mutations in either gene causing severe
      obesity in both mice and humans. It has previously been reported that peripheral 
      administration of the endogenous TrkB agonist ligand neurotrophin-4 (NT-4)
      profoundly decreases food intake and body weight in rodents, while paradoxically 
      increasing these same parameters in monkeys. We generated a humanized TrkB
      agonist antibody, TAM-163, and characterized its therapeutic potential in several
      models of type 2 diabetes and obesity. In vitro, TAM-163 bound to human and
      rodent TrkB with high affinity, activated all aspects of the TrkB signaling
      cascade and induced TrkB internalization and degradation in a manner similar to
      BDNF. In vivo, peripheral administration of TAM-163 decreased food intake and/or 
      body weight in mice, rats, hamsters, and dogs, but increased food intake and body
      weight in monkeys. The magnitude of weight change was similar in rodents and
      non-human primates, occurred at doses where there was no appreciable penetration 
      into deep structures of the brain, and could not be explained by differences in
      exposures between species. Rather, peripherally administered TAM-163 localized to
      areas in the hypothalamus and the brain stem located outside the blood-brain
      barrier in a similar manner between rodents and non-human primates, suggesting
      differences in neuroanatomy across species. Our data demonstrate that a TrkB
      agonist antibody, administered peripherally, causes species-dependent effects on 
      body weight similar to the endogenous TrkB ligand NT-4. The possible clinical
      utility of TrkB agonism in treating weight regulatory disorder, such as obesity
      or cachexia, will require evaluation in man.
AD  - Cardiovascular and Metabolic Diseases Research Unit, Pfizer Inc., Cambridge,
      Massachusetts, United States of America.
FAU - Perreault, Mylene
AU  - Perreault M
FAU - Feng, Guo
AU  - Feng G
FAU - Will, Sarah
AU  - Will S
FAU - Gareski, Tiffany
AU  - Gareski T
FAU - Kubasiak, David
AU  - Kubasiak D
FAU - Marquette, Kimberly
AU  - Marquette K
FAU - Vugmeyster, Yulia
AU  - Vugmeyster Y
FAU - Unger, Thaddeus J
AU  - Unger TJ
FAU - Jones, Juli
AU  - Jones J
FAU - Qadri, Ariful
AU  - Qadri A
FAU - Hahm, Seung
AU  - Hahm S
FAU - Sun, Ying
AU  - Sun Y
FAU - Rohde, Cynthia M
AU  - Rohde CM
FAU - Zwijnenberg, Raphael
AU  - Zwijnenberg R
FAU - Paulsen, Janet
AU  - Paulsen J
FAU - Gimeno, Ruth E
AU  - Gimeno RE
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3659094
OID - NLM: PMC3659094
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/04 [received]
PHST- 2013/03/23 [accepted]
PHST- 2013/05/20 [epublish]
AID - 10.1371/journal.pone.0062616 [doi]
AID - PONE-D-12-40522 [pii]
PST - epublish
SO  - PLoS One. 2013 May 20;8(5):e62616. doi: 10.1371/journal.pone.0062616. Print 2013.

PMID- 23700409
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Combined Use of Waist and Hip Circumference to Identify Abdominally Obese
      HIV-Infected Patients at Increased Health Risk.
PG  - e62538
LID - 10.1371/journal.pone.0062538 [doi]
AB  - OBJECTIVES: To determine whether for a given waist circumference (WC), a larger
      hip circumference (HC) was associated with a reduced risk of insulin resistance, 
      type 2 diabetes (T2D), hypertension and cardiovascular disease (CVD) in
      HIV-infected patients. A second objective was to determine whether, for a given
      WC, the addition of HC improved upon estimates of abdominal adiposity, in
      particular visceral adipose tissue (VAT), compared to those obtained by WC alone.
      METHODS: HIV-infected men (N = 1481) and women (N = 841) were recruited between
      2005 and 2009. WC and HC were obtained using standard techniques and abdominal
      adiposity was measured using computed tomography. RESULTS: After control for WC
      and covariates, HC was negatively associated with risk of insulin resistance
      (p<0.05) and T2D [Men: OR = 0.91 (95% CI: 0.86-0.96); Women: OR = 0.91 (95% CI:
      0.84-0.98)]. For a given WC, HC was also negatively associated with a lower risk 
      of hypertension (p<0.05) and CVD [OR = 0.94 (95% CI: 0.88-0.99)] in men, but not 
      women. Although HC was negatively associated with VAT in men and women after
      control for WC (p<0.05), the addition of HC did not substantially improve upon
      the prediction of VAT compared to WC alone. CONCLUSIONS: The identification of
      HIV-infected individuals at increased health risk by WC alone is substantially
      improved by the addition of HC. Estimates of visceral adipose tissue by WC are
      not substantially improved by the addition of HC and thus variation in visceral
      adiposity may not be the conduit by which HC identifies increased health risk.
AD  - School of Kinesiology and Health Studies, Queen's University, Kingston, Ontario, 
      Canada.
FAU - O'Neill, Trevor
AU  - O'Neill T
FAU - Guaraldi, Giovanni
AU  - Guaraldi G
FAU - Orlando, Gabriella
AU  - Orlando G
FAU - Carli, Federica
AU  - Carli F
FAU - Garlassi, Elisa
AU  - Garlassi E
FAU - Zona, Stefano
AU  - Zona S
FAU - Despres, Jean-Pierre
AU  - Despres JP
FAU - Ross, Robert
AU  - Ross R
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3659108
OID - NLM: PMC3659108
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/15 [received]
PHST- 2013/03/21 [accepted]
PHST- 2013/05/20 [epublish]
AID - 10.1371/journal.pone.0062538 [doi]
AID - PONE-D-12-35702 [pii]
PST - epublish
SO  - PLoS One. 2013 May 20;8(5):e62538. doi: 10.1371/journal.pone.0062538. Print 2013.

PMID- 23700406
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse
      models.
PG  - e61477
LID - 10.1371/journal.pone.0061477 [doi]
AB  - Obesity is important for the development of type-2 diabetes as a result of
      obesity-induced insulin resistance accompanied by impaired compensation of
      insulin secretion from pancreatic beta cells. Here, based on a randomized pilot
      clinical trial, we report that intranasal oxytocin administration over an 8-week 
      period led to effective reduction of obesity and reversal of related prediabetic 
      changes in patients. Using mouse models, we further systematically evaluated
      whether oxytocin and its analogs yield therapeutic effects against prediabetic or
      diabetic disorders regardless of obesity. Our results showed that oxytocin and
      two analogs including [Ser4, Ile8]-oxytocin or [Asu1,6]-oxytocin worked in mice
      to reverse insulin resistance and glucose intolerance prior to reduction of
      obesity. In parallel, using streptozotocin-induced diabetic mouse model, we found
      that treatment with oxytocin or its analogs reduced the magnitude of glucose
      intolerance through improving insulin secretion. The anti-diabetic effects of
      oxytocin and its analogs in these animal models can be produced similarly whether
      central or peripheral administration was used. In conclusion, oxytocin and its
      analogs have multi-level effects in improving weight control, insulin sensitivity
      and insulin secretion, and bear potentials for being developed as therapeutic
      peptides for obesity and diabetes.
AD  - Department of Molecular Pharmacology, Diabetes Research Center, Institute of
      Aging, Albert Einstein College of Medicine, Bronx, New York, United States of
      America.
FAU - Zhang, Hai
AU  - Zhang H
FAU - Wu, Chenguang
AU  - Wu C
FAU - Chen, Qiaofen
AU  - Chen Q
FAU - Chen, Xiaoluo
AU  - Chen X
FAU - Xu, Zhigang
AU  - Xu Z
FAU - Wu, Jing
AU  - Wu J
FAU - Cai, Dongsheng
AU  - Cai D
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3658979
OID - NLM: PMC3658979
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/23 [received]
PHST- 2013/03/09 [accepted]
PHST- 2013/05/20 [epublish]
AID - 10.1371/journal.pone.0061477 [doi]
AID - PONE-D-12-32438 [pii]
PST - epublish
SO  - PLoS One. 2013 May 20;8(5):e61477. doi: 10.1371/journal.pone.0061477. Print 2013.

PMID- 23700340
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1541-6100 (Electronic)
IS  - 0022-3166 (Linking)
DP  - 2013 May 22
TI  - Zinc Deficiency Augments Leptin Production and Exacerbates Macrophage
      Infiltration into Adipose Tissue in Mice Fed a High-Fat Diet.
AB  - Zinc (Zn) deficiency and obesity are global public health problems. Zn deficiency
      is associated with obesity and comorbid conditions that include insulin
      resistance and type 2 diabetes. However, the function of Zn in obesity remains
      unclear. Using a mouse model of combined high-fat and low-Zn intake (0.5-1.5
      mg/kg), we investigated whether Zn deficiency exacerbates the extent of adiposity
      as well as perturbations in metabolic and immune function. C57BL/6 mice were
      randomly assigned to receive either a high-fat diet (HFD) or a control (C) diet
      for 6 wk, followed by further subdivision into 2 additional groups fed
      Zn-deficient diets (C-Zn, HFD-Zn), along with a C diet and an HFD, for 3 wk (n = 
      8-9 mice/group). The extent of visceral fat, insulin resistance, or systemic
      inflammation was unaffected by Zn deficiency. Strikingly, Zn deficiency
      significantly augmented circulating leptin concentrations (HFD-Zn vs. HFD: 3.15
      +/- 0.16 vs. 2.59 +/- 0.12 mug/L, respectively) and leptin signaling in the liver
      of obese mice. Furthermore, gene expression of macrophage-specific markers ADAM8 
      (A disintegrin and metalloproteinase domain-containing protein 8) and CD68
      (cluster of differentiation 68) was significantly greater in adipose tissue in
      the HFD-Zn group than in the HFD group, as confirmed by CD68 protein analysis,
      indicative of increased macrophage infiltration. Inspection of Zn content and
      mRNA profiles of all Zn transporters in the adipose tissue revealed alterations
      of Zn metabolism to obesity and Zn deficiency. Our results demonstrate that Zn
      deficiency increases leptin production and exacerbates macrophage infiltration
      into adipose tissue in obese mice, indicating the importance of Zn in metabolic
      and immune dysregulation in obesity.
AD  - Dorothy M. Davis Heart and Lung Research Institute.
FAU - Liu, Ming-Jie
AU  - Liu MJ
FAU - Bao, Shengying
AU  - Bao S
FAU - Bolin, Eric R
AU  - Bolin ER
FAU - Burris, Dara L
AU  - Burris DL
FAU - Xu, Xiaohua
AU  - Xu X
FAU - Sun, Qinghua
AU  - Sun Q
FAU - Killilea, David W
AU  - Killilea DW
FAU - Shen, Qiwen
AU  - Shen Q
FAU - Ziouzenkova, Ouliana
AU  - Ziouzenkova O
FAU - Belury, Martha A
AU  - Belury MA
FAU - Failla, Mark L
AU  - Failla ML
FAU - Knoell, Daren L
AU  - Knoell DL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - J Nutr
JT  - The Journal of nutrition
JID - 0404243
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - jn.113.175158 [pii]
AID - 10.3945/jn.113.175158 [doi]
PST - aheadofprint
SO  - J Nutr. 2013 May 22.

PMID- 23700320
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
DP  - 2013 May 22
TI  - The Effect of Leptin Administration on Mammary Tumor Growth in Diabetic Mice.
AB  - Obesity is associated with hyperleptinemia and this has led to the suggestion
      that leptin maybe a factor in cancer progression. To study the effect of leptin
      on cancer progression we used a mouse model of diabetes that was shown to enhance
      tumor progression and thereby determine if leptin affects cancer progression
      despite improvements in metabolic status. Mammary tumors were allowed to develop 
      in male and female mice following orthotopic injection of cells expressing
      oncogenes. After 2 weeks leptin was administered to the mice using Alzet pumps.
      In these mice leptin failed to stimulate tumor progression; indeed, in those
      studies where glucose tolerance improved tumor growth was actually inhibited.
      Thus, the possibility exists that the effect of leptin on tumor progression maybe
      opposed by improvements in metabolism.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Diabetes and Metabolism Clinical Research Center of Excellence, Clinical Research
      Institute at Rambam (CRIR) and the Ruth and Bruce Rappaport Faculty of Medicine, 
      Technion, Haifa, Israel.
FAU - Bitton-Worms, K
AU  - Bitton-Worms K
FAU - Rostoker, R
AU  - Rostoker R
FAU - Braun, S
AU  - Braun S
FAU - Shen-Orr, Z
AU  - Shen-Orr Z
FAU - Leroith, D
AU  - Leroith D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/05/22 [epublish]
AID - 10.1055/s-0033-1345151 [doi]
PST - aheadofprint
SO  - Horm Metab Res. 2013 May 22.

PMID- 23700236
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 May 23
TI  - Duodenal-Jejunal Bypass Surgery Up-Regulates the Expression of the Hepatic
      Insulin Signaling Proteins and the Key Regulatory Enzymes of Intestinal
      Gluconeogenesis in Diabetic Goto-Kakizaki Rats.
AB  - BACKGROUND: Duodenal-jejunal bypass (DJB), which is not routinely applied in
      metabolic surgery, is an effective surgical procedure in terms of type 2 diabetes
      mellitus resolution. However, the underlying mechanisms are still undefined. Our 
      aim was to investigate the diabetic improvement by DJB and to explore the changes
      in hepatic insulin signaling proteins and regulatory enzymes of gluconeogenesis
      after DJB in a non-obese diabetic rat model. METHODS: Sixteen adult male
      Goto-Kakizaki rats were randomly divided into DJB and sham-operated groups. The
      body weight, food intake, hormone levels, and glucose metabolism were measured.
      The levels of protein expression and phosphorylation of insulin receptor-beta
      (IR-beta) and insulin receptor substrate 2 (IRS-2) were evaluated in the liver.
      We also detected the expression of key regulatory enzymes of gluconeogenesis
      [phosphoenoylpyruvate carboxykinase-1 (PCK1), glucose-6-phosphatase-alpha
      (G6Pase-alpha)] in small intestine and liver. RESULTS: DJB induced significant
      diabetic improvement with higher postprandial glucagons-like peptide 1, peptide
      YY, and insulin levels, but without weight loss. The DJB group exhibited
      increased expression and phosphorylation of IR-beta and IRS-2 in liver,
      up-regulated the expression of PCK1 and G6Pase-alpha in small intestine, and
      down-regulated the expression of these enzymes in liver. CONCLUSIONS: DJB is
      effective in up-regulating the expression of the key proteins in the hepatic
      insulin signaling pathway and the key regulatory enzymes of intestinal
      gluconeogenesis and down-regulating the expression of the key regulatory enzymes 
      of hepatic gluconeogenesis without weight loss. Our study helps to reveal the
      potential role of hepatic insulin signaling pathway and intestinal
      gluconeogenesis in ameliorating insulin resistance after metabolic surgery.
AD  - Department of General Surgery, Qilu Hospital of Shandong University, #107 Wenhua 
      Xi Road, Jinan, 250012, Shandong, People's Republic of China.
FAU - Sun, Dong
AU  - Sun D
FAU - Wang, Kexin
AU  - Wang K
FAU - Yan, Zhibo
AU  - Yan Z
FAU - Zhang, Guangyong
AU  - Zhang G
FAU - Liu, Shaozhuang
AU  - Liu S
FAU - Liu, Fengjun
AU  - Liu F
FAU - Hu, Chunxiao
AU  - Hu C
FAU - Hu, Sanyuan
AU  - Hu S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1007/s11695-013-0985-0 [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 May 23.

PMID- 23700220
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1438-8359 (Electronic)
IS  - 0913-8668 (Linking)
DP  - 2013 May 23
TI  - Risk factors for postoperative mortality and morbidities in emergency surgeries.
AB  - BACKGROUND: Emergency surgery itself induces high risk for postoperative
      mortality and morbidities; however, it remains unknown which concomitant
      pathological conditions of emergency surgeries are causative factors of
      deteriorating outcomes. This study examined the causal factors of postoperative
      mortality and morbidity in cases of emergency surgery. METHODS: Patients
      undergoing emergency surgery from January to December 2007 were enrolled in this 
      retrospective cohort study. Causal relationships were analyzed by stepwise
      multivariate logistic regression analysis between possible independent factors
      (sex, age, kind of surgical department, timing of surgery, duration of surgery,
      blood transfusion, deteriorated consciousness level, shock state, abnormal
      coagulate state, and history of hypertension, diabetes, ischemic heart disease,
      chronic obstructive pulmonary disease, renal failure, and anemia) and
      postoperative mortality or morbidities (failure of removal of tracheal tube after
      operation, tracheotomy, cerebral infarction, massive hemorrhage, severe
      hypotension, severe hypoxemia, and severe arrhythmia during or after surgery).
      RESULTS: Shock, deteriorated consciousness level, chronic obstructive lung
      disease, and ischemic heart disease were significant risk factors for mortality
      (OR 14.2, 7.9, 6.4, and 3.8, respectively), and deteriorated consciousness level,
      blood transfusion, shock, chronic obstructive lung disease, diabetes,
      cardiovascular surgery, and operation longer than 2 h were significant risk
      factors for morbidity (OR 19.1, 3.3, 3.0, 2.5, 2.4, 2.4, and 1.8, respectively). 
      CONCLUSION: State of shock, deteriorated consciousness level, chronic obstructive
      lung disease, ischemic heart disease, hemorrhage requiring blood transfusion, age
      over 80 years, cardiovascular surgery, surgeries at night, and surgeries of
      duration more than 2 h cause patients to be strongly susceptible to postoperative
      mortality or morbidity in emergency surgeries.
AD  - Department of Anesthesia, Kyoto University Hospital, 54 Kawaharacho, Shogoin,
      Sakyo-ku, Kyoto, 606-8507, Japan.
FAU - Matsuyama, Tomonori
AU  - Matsuyama T
FAU - Iranami, Hiroshi
AU  - Iranami H
FAU - Fujii, Keisuke
AU  - Fujii K
FAU - Inoue, Mariko
AU  - Inoue M
FAU - Nakagawa, Reiko
AU  - Nakagawa R
FAU - Kawashima, Kohei
AU  - Kawashima K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Anesth
JT  - Journal of anesthesia
JID - 8905667
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2012/09/27 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/23 [aheadofprint]
AID - 10.1007/s00540-013-1639-z [doi]
PST - aheadofprint
SO  - J Anesth. 2013 May 23.

PMID- 23700217
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1432-1440 (Electronic)
IS  - 0946-2716 (Linking)
DP  - 2013 May 23
TI  - Imaging beta-cell mass and function in situ and in vivo.
AB  - Glucose-stimulated insulin secretion (GSIS) from pancreatic beta-cells is
      critical to the maintenance of blood glucose homeostasis in animals. Both
      decrease in pancreatic beta-cell mass and defects in beta-cell function
      contribute to the onset of diabetes, although the underlying mechanisms remain
      largely unknown. Molecular imaging techniques can help beta-cell study in a
      number of ways. High-resolution fluorescence imaging techniques provide novel
      insights into the fundamental mechanisms underlying GSIS in isolated beta-cells
      or in situ in pancreatic islets, and dynamic changes of beta-cell mass and
      function can be noninvasively monitored in vivo by imaging techniques such as
      positron emission tomography and single-photon emission computed tomography. All 
      these techniques will contribute to the better understanding of the progression
      of diabetes and the search for the optimized therapeutic measures that reverse
      deficits in beta-cell mass and function.
AD  - The State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of 
      Molecular Medicine, Peking University and National Center for Nanoscience and
      Technology, Beijing, China, yanglu130@gmail.com.
FAU - Yang, Lu
AU  - Yang L
FAU - Ji, Wei
AU  - Ji W
FAU - Xue, Yanhong
AU  - Xue Y
FAU - Chen, Liangyi
AU  - Chen L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Mol Med (Berl)
JT  - Journal of molecular medicine (Berlin, Germany)
JID - 9504370
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/01/28 [received]
PHST- 2013/05/15 [accepted]
PHST- 2013/05/07 [revised]
PHST- 2013/05/23 [aheadofprint]
AID - 10.1007/s00109-013-1056-7 [doi]
PST - aheadofprint
SO  - J Mol Med (Berl). 2013 May 23.

PMID- 23700212
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1867-108X (Electronic)
IS  - 1867-1071 (Linking)
DP  - 2013 May 23
TI  - CT features of myocardial fat and correlation with clinical background in
      patients without cardiac disease.
AB  - OBJECTIVE: To evaluate the frequency and common locations of myocardial fat and
      its associated factors using coronary CT angiography (CCTA) in patients without
      cardiac disease. METHODS: Using CCTA findings for 298 consecutive patients
      without cardiac disease, we categorized the myocardium into nine locations,
      scored fat in those locations, and correlated the fat score with the thickness of
      the right ventricular (RV) free wall and factors including gender, age, and body 
      mass index (BMI) as well as history of diabetes mellitus, hypertension (HT), and 
      dyslipidemia. RESULTS: We observed myocardial fat in 68.5 % of patients, most
      commonly in the RV outflow tract (RVOT, 64.1 %), followed by the base (42.3 %)
      and middle (28.9 %) of the RV free wall, RV trabeculations (22.5 %), and the left
      ventricular apex (11.4 %). The RV free wall thickened significantly with
      increasing fat score. Dependent variables for myocardial fat were female gender
      (P < 0.0001), age >/=65 years (P = 0.0043), BMI >/=25 (P = 0.0050), and HT (P =
      0.0139). CONCLUSION: Myocardial fat is a common finding on CCTA in patients
      without cardiac disease, is often observed in the RVOT, and is more frequent in
      female patients, those older than 65 years, those with BMI >/=25, and those with 
      HT.
AD  - Department of Diagnostic Radiology, Saitama Medical University International
      Medical Center, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan.
FAU - Matsuo, Yuka
AU  - Matsuo Y
FAU - Kimura, Fumiko
AU  - Kimura F
FAU - Nakajima, Takatomo
AU  - Nakajima T
FAU - Inoue, Kaiji
AU  - Inoue K
FAU - Mizukoshi, Waka
AU  - Mizukoshi W
FAU - Kozawa, Eito
AU  - Kozawa E
FAU - Sakai, Fumikazu
AU  - Sakai F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Jpn J Radiol
JT  - Japanese journal of radiology
JID - 101490689
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2012/09/27 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/05/23 [aheadofprint]
AID - 10.1007/s11604-013-0212-x [doi]
PST - aheadofprint
SO  - Jpn J Radiol. 2013 May 23.

PMID- 23700194
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1869-6953 (Print)
DP  - 2013 May 23
TI  - Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 
      Clinical Studies.
AB  - INTRODUCTION: In a previous pooled analysis of 19 double-blind clinical studies
      conducted by Merck, which included data available as of July 2009 on 10,246
      patients with type 2 diabetes (T2DM), treatment with sitagliptin was shown to be 
      generally well tolerated compared with treatment with control agents. As the
      sitagliptin clinical development program continues, additional studies with
      sitagliptin have been completed. The present analysis updates the safety and
      tolerability assessment of sitagliptin by examining pooled data from 25
      double-blind clinical studies. METHODS: The present analysis included data from
      14,611 patients in 25 studies with T2DM who received either sitagliptin 100
      mg/day (n = 7,726; sitagliptin group) or a comparator agent (n = 6,885;
      non-exposed group). These studies represent all randomized, double-blind trials
      conducted by Merck that included patients treated with the usual clinical dose of
      sitagliptin (100 mg/day) for between 12 weeks and 2 years, and for which results 
      were available as of December 2011. These studies assessed sitagliptin, versus
      comparator agents, taken as monotherapy, initial combination therapy with
      metformin or pioglitazone, or as add-on combination therapy with other
      antihyperglycemic agents (metformin, pioglitazone, a sulfonylurea +/- metformin, 
      insulin +/- metformin, or metformin + pioglitazone or rosiglitazone).
      Patient-level data from each study were used to evaluate between-group
      differences in the exposure-adjusted incidence rates of adverse events (AEs).
      RESULTS: Overall incidence rates of AEs and drug-related AEs were higher in the
      non-exposed group compared with the sitagliptin group. Incidence rates of
      specific AEs were generally similar between the two groups, except for higher
      incidence rates of hypoglycemia related to the greater use of a sulfonylurea and 
      diarrhea related to the greater use of metformin in the non-exposed group, and of
      constipation in the sitagliptin group. Treatment with sitagliptin was not
      associated with an increased risk of major adverse cardiovascular events,
      malignancy, or pancreatitis. CONCLUSION: In this updated pooled safety analysis
      of data from 14,611 patients with T2DM, sitagliptin 100 mg/day was generally well
      tolerated in clinical trials of up to 2 years in duration.
AD  - Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, samuel.engel@merck.com.
FAU - Engel, Samuel S
AU  - Engel SS
FAU - Round, Elizabeth
AU  - Round E
FAU - Golm, Gregory T
AU  - Golm GT
FAU - Kaufman, Keith D
AU  - Kaufman KD
FAU - Goldstein, Barry J
AU  - Goldstein BJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/03/29 [received]
PHST- 2013/05/23 [aheadofprint]
AID - 10.1007/s13300-013-0024-0 [doi]
PST - aheadofprint
SO  - Diabetes Ther. 2013 May 23.

PMID- 23700164
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1559-0283 (Electronic)
IS  - 1085-9195 (Linking)
DP  - 2013 May 23
TI  - Topology Mapping of Insulin-Regulated Glucose Transporter GLUT4 Using
      Computational Biology.
AB  - The type 2 diabetes is increasing rapidly around the globe. The primary cause for
      this is insulin resistance due to the disruption of the insulin signal
      transduction mechanism. Insulin signal transduction stimulates glucose transport 
      through the glucose transporter GLUT4, by promoting the exocytosis process.
      Understanding the structural topology of GLUT4 mechanism will increase our
      understanding of the dynamic activities about glucose transport and its
      regulation in the membrane environment. However, little is known about the
      topology of GLUT4. In this article, we have determined the amino acid
      composition, disulfide topology, structure conformation pattern of GLUT4. The
      amino acid composition portrays that leucine composition is the highest
      contributing to 15.5 % among all other amino acids. Three cysteine residues such 
      as Cys223, Cys361, and Cys363 were observed and the last two were associated with
      one disulfide bond formation. We have generated surface cavities to know the
      clefts/pockets on the surface of this protein that showed few irregular cavities 
      placed mostly in the transmembrane-helical part. Besides, topology mapping of 12 
      transmembrane-helixes was done to predict N- and O-glycosylation sites and to
      show the highly glycosylated GLUT4 that includes both N- and O-glycosylation
      sites. Furthermore, hydrophobic segment and molecular charge distribution were
      analyzed. This article shows that bioinformatics tools can provide a rapid
      methodology to predict the topology of GLUT4. It also provides insights into the 
      structural details and structural functioning relationships in the human GLUT4.
      The results can be of great help to advance future drug development research
      using GLUT4 as a target protein.
AD  - Department of Bioinformatics, School of Computer and Information Sciences,
      Galgotias University, Noida, India.
FAU - Chakraborty, Chiranjib
AU  - Chakraborty C
FAU - Bandyopadhyay, Sanghamitra
AU  - Bandyopadhyay S
FAU - Maulik, Ujjwal
AU  - Maulik U
FAU - Agoramoorthy, Govindasamy
AU  - Agoramoorthy G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Cell Biochem Biophys
JT  - Cell biochemistry and biophysics
JID - 9701934
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1007/s12013-013-9644-2 [doi]
PST - aheadofprint
SO  - Cell Biochem Biophys. 2013 May 23.

PMID- 23700152
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 2168-6084 (Electronic)
DP  - 2013 May 22
TI  - Autoimmune, Atopic, and Mental Health Comorbid Conditions Associated With
      Alopecia Areata in the United States.
PG  - 1-5
LID - 10.1001/jamadermatol.2013.3049 [doi]
AB  - OBJECTIVE To evaluate the prevalence of comorbid conditions among patients with
      alopecia areata (AA) seen at tertiary care hospitals in Boston, Massachusetts,
      during an 11-year period. DESIGN Retrospective cross-sectional study. SETTING
      Tertiary care hospitals in Boston, including Brigham and Women's Hospital and
      Massachusetts General Hospital. PARTICIPANTS We identified 3568 individuals with 
      AA seen in the Partners health care system in Boston between January 1, 2000, and
      January 1, 2011. We performed comprehensive searches of the Research Patient Data
      Repository using International Classification of Diseases, Ninth Revision code
      704.01. We randomly selected 350 patients and manually reviewed their medical
      records to train and validate a novel artificial intelligence program. This
      program then used natural language processing to review free-text medical records
      and confirm a diagnosis of AA. To confirm the algorithm, we manually reviewed a
      subset of records and found 93.9% validity. MAIN OUTCOMES AND MEASURES The
      prevalence of comorbid conditions was assessed. RESULTS Common comorbid
      conditions included autoimmune diagnoses (thyroid disease in 14.6%, diabetes
      mellitus in 11.1%, inflammatory bowel disease in 6.3%, systemic lupus
      erythematosus in 4.3%, rheumatoid arthritis in 3.9%, and psoriasis and psoriatic 
      arthritis in 2.0%), atopy (allergic rhinitis, asthma, and/or eczema in 38.2% and 
      contact dermatitis and other eczema in 35.9%), and mental health problems
      (depression or anxiety in 25.5%). We also found high prevalences of
      hyperlipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease
      (17.3%). This profile was different from that seen in a comparison psoriasis and 
      psoriatic arthritis group. CONCLUSIONS AND RELEVANCE We found a high prevalence
      of comorbid conditions among individuals with AA presenting to academic medical
      centers in Boston. Physicians caring for patients with AA should consider
      screening for comorbid conditions.
FAU - Huang, Kathie P
AU  - Huang KP
FAU - Mullangi, Samyukta
AU  - Mullangi S
FAU - Guo, Ye
AU  - Guo Y
FAU - Qureshi, Abrar A
AU  - Qureshi AA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - JAMA Dermatol
JT  - JAMA dermatology (Chicago, Ill.)
JID - 101589530
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 1690841 [pii]
AID - 10.1001/jamadermatol.2013.3049 [doi]
PST - aheadofprint
SO  - JAMA Dermatol. 2013 May 22:1-5. doi: 10.1001/jamadermatol.2013.3049.

PMID- 23700151
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1432-0878 (Electronic)
IS  - 0302-766X (Linking)
DP  - 2013 May 23
TI  - Melatonin-receptor-1-deficiency affects neurogenic differentiation factor
      immunoreaction in pancreatic islets and enteroendocrine cells of mice.
AB  - Neurogenic differentiation factor (NeuroD) is a transcription factor involved in 
      the differentiation of neurons and in the control of energy balance and
      metabolism. It plays a key role in type 1 and type 2 diabetes. Melatonin is an
      important rhythmic endocrine signal within the circadian system of mammals and
      modulates insulin secretion and glucose metabolism. In the mouse pars tuberalis, 
      NeuroD mRNA levels show day/night variation, which is independent of the
      molecular clock gene mPER1 but depends on the functional melatonin receptor 1
      (MT1). So far, little is known about the effect of melatonin on NeuroD synthesis 
      in the gastrointestinal tract. Thus, NeuroD protein levels and cellular
      localization were analyzed by immunohistochemistry in pancreatic islets and
      duodenal enteroendocrine cells of MT1- and mPER1-deficienct mice. In addition,
      the localization of NeuroD-positive cells was analyzed by
      double-immunofluorescence and confocal laser microscopy. In duodenal
      enteroendocrine cells and pancreatic islets of WT and PER1-deficient mice, NeuroD
      immunoreaction showed a peak during the early subjective night. In contrast, this
      peak was absent in MT1-deficent mice. These data suggest that melatonin, by
      acting on MT1 receptors, affects NeuroD expression in the gastrointestinal tract 
      and thus might contribute to circadian regulation in metabolic functions.
AD  - Dr. Senckenbergische Anatomie, Institut fur Anatomie II,
      Johann-Wolfgang-Goethe-Universitat, Theodor-Stern-Kai 7, 60590, Frankfurt/M,
      Germany.
FAU - Shalabi, Andree
AU  - Shalabi A
FAU - Fischer, Claudia
AU  - Fischer C
FAU - Korf, Horst-Werner
AU  - Korf HW
FAU - von Gall, Charlotte
AU  - von Gall C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Cell Tissue Res
JT  - Cell and tissue research
JID - 0417625
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2012/12/21 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/23 [aheadofprint]
AID - 10.1007/s00441-013-1647-1 [doi]
PST - aheadofprint
SO  - Cell Tissue Res. 2013 May 23.

PMID- 23700014
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 2168-6114 (Electronic)
IS  - 2168-6106 (Linking)
VI  - 173
IP  - 9
DP  - 2013 May 13
TI  - Error in Table in: Communication and Medication Refill Adherence: The Diabetes
      Study of Northern California.
PG  - 731
LID - 10.1001/jamainternmed.2013.6768 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA Intern Med
JT  - JAMA internal medicine
JID - 101589534
SB  - AIM
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 1687641 [pii]
AID - 10.1001/jamainternmed.2013.6768 [doi]
PST - ppublish
SO  - JAMA Intern Med. 2013 May 13;173(9):731. doi: 10.1001/jamainternmed.2013.6768.

PMID- 23699990
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 23
TI  - Maternal smoking during pregnancy and daughters' risk of gestational diabetes and
      obesity.
AB  - AIMS/HYPOTHESIS: The primary aim of the study was to investigate the risk of
      developing gestational diabetes in women who were exposed to tobacco smoke in
      utero. Secondary aims were to assess the risk of obesity and non-gestational
      diabetes. METHODS: Data were retrieved from the Medical Birth Register of Sweden 
      for women who were born in 1982 (when smoking data were first registered) or
      later and who had given birth to at least one child; 80,189 pregnancies were
      included. The associations between in utero smoking exposure (three categories:
      non-smokers, 1-9 cigarettes/day [moderately exposed] and >9 cigarettes/day
      [heavily exposed]) and subsequent gestational diabetes (n = 291), non-gestational
      diabetes (n = 280) and obesity (n = 7,300) were assessed. RESULTS: The adjusted
      ORs (aORs) of gestational diabetes were increased among women who were moderately
      (1.62, 95% CI 1.24, 2.13) and heavily (1.52, 95% CI 1.12, 2.06) exposed. The
      corresponding aORs of obesity were 1.36 (95% CI 1.28, 1.44) and 1.58 (95% CI
      1.48, 1.68), respectively. A reduced OR for non-gestational diabetes was seen in 
      the offspring of heavy smokers (aOR 0.66, 95% CI 0.45, 0.96).
      CONCLUSIONS/INTERPRETATION: Women exposed to smoking during fetal life were at
      higher risk of developing gestational diabetes and obesity.
AD  - Division of Occupational and Environmental Medicine, Institute of Laboratory
      Medicine, Lund University, SE-221 85, Lund, Sweden, kristina.mattsson@med.lu.se.
FAU - Mattsson, K
AU  - Mattsson K
FAU - Kallen, K
AU  - Kallen K
FAU - Longnecker, M P
AU  - Longnecker MP
FAU - Rignell-Hydbom, A
AU  - Rignell-Hydbom A
FAU - Rylander, L
AU  - Rylander L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/02/19 [received]
PHST- 2013/04/26 [accepted]
PHST- 2013/05/23 [aheadofprint]
AID - 10.1007/s00125-013-2936-7 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 23.

PMID- 23699989
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 23
TI  - Double deficiency in IL-17 and IFN-gamma signalling significantly suppresses the 
      development of diabetes in the NOD mouse.
AB  - AIMS/HYPOTHESIS: T helper type (Th) 17 cells have been shown to play important
      roles in mouse models of several autoimmune diseases that have been classified as
      Th1 diseases. In the NOD mouse, the relevance of Th1 and Th17 is controversial,
      because single-cytokine-deficient NOD mice develop diabetes similarly to
      wild-type NOD mice. METHODS: We studied the impact of IL-17/IFN-gamma receptor
      double deficiency in NOD mice on the development of insulitis/diabetes compared
      with IL-17 single-deficient mice and wild-type mice by monitoring
      diabetes-related phenotypes. The lymphocyte phenotypes were determined by flow
      cytometric analysis. RESULTS: IL-17 single-deficient NOD mice showed delayed
      onset of diabetes and reduced severity of insulitis, but the cumulative incidence
      of longstanding diabetes in the IL-17-deficient mice was similar to that in
      wild-type mice. The IL-17/IFN-gamma receptor double-deficient NOD mice showed an 
      apparent decline in longstanding diabetes onset, but not in insulitis compared
      with that in the IL-17 single-deficient mice. We also found that double-deficient
      NOD mice had a severe lymphopenic phenotype and preferential increase in
      regulatory T cells among CD4+ T cells compared with the IL-17 single-deficient
      mice and wild-type NOD mice. An adoptive transfer study with CD4+CD25- T cells
      from young non-diabetic IL-17 single-deficient NOD mice, but not those from older
      mice, showed significantly delayed disease onset in immune-deficient hosts
      compared with the corresponding wild-type mice. CONCLUSIONS/INTERPRETATION: These
      results indicate that IL-17/Th17 participates in the development of insulitis and
      that both IL-17 and IFN-gamma signalling may synergistically contribute to the
      development of diabetes in NOD mice.
AD  - Department of Endocrinology and Metabolism, Unit of Translational Medicine,
      Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto,
      Nagasaki, 852-8501, Japan.
FAU - Kuriya, G
AU  - Kuriya G
FAU - Uchida, T
AU  - Uchida T
FAU - Akazawa, S
AU  - Akazawa S
FAU - Kobayashi, M
AU  - Kobayashi M
FAU - Nakamura, K
AU  - Nakamura K
FAU - Satoh, T
AU  - Satoh T
FAU - Horie, I
AU  - Horie I
FAU - Kawasaki, E
AU  - Kawasaki E
FAU - Yamasaki, H
AU  - Yamasaki H
FAU - Yu, L
AU  - Yu L
FAU - Iwakura, Y
AU  - Iwakura Y
FAU - Sasaki, H
AU  - Sasaki H
FAU - Nagayama, Y
AU  - Nagayama Y
FAU - Kawakami, A
AU  - Kawakami A
FAU - Abiru, N
AU  - Abiru N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2012/12/06 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/23 [aheadofprint]
AID - 10.1007/s00125-013-2935-8 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 23.

PMID- 23699841
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 2168-6173 (Electronic)
IS  - 2168-6165 (Linking)
VI  - 131
IP  - 5
DP  - 2013 May 1
TI  - Forniceal conjunctival pedicle flap for the treatment of complex glaucoma
      drainage device tube erosion.
PG  - 662-6
LID - 10.1001/jamaophthalmol.2013.2315 [doi]
AB  - This retrospective study evaluated the safety and efficacy of the forniceal
      conjunctival pedicle flap for repair of conjunctival-deficient tube erosions.
      Additionally, we report the split-lid technique, a procedural improvement if
      fornix access is difficult. We identified 15 eyes of 14 consecutive patients with
      complex tube erosions. The mean age was 72.8 years and 33.3% had diabetes
      mellitus. Most patients were functionally monocular and 80% had undergone 4 or
      more prior ocular surgical procedures. There was no difference between the
      following preoperative and postoperative values: visual acuity, intraocular
      pressure, or number of glaucoma medications. The mean follow-up time after
      pedicle flap repair was 49 months. There were no recurrent erosions allowing for 
      preservation of the drainage implant with excellent intraocular pressure control.
      This study demonstrates the relative long-term safety and success of this novel
      technique.
FAU - Grover, Davinder S
AU  - Grover DS
FAU - Merritt, James
AU  - Merritt J
FAU - Godfrey, David G
AU  - Godfrey DG
FAU - Fellman, Ronald L
AU  - Fellman RL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA Ophthalmol
JT  - JAMA ophthalmology
JID - 101589539
SB  - AIM
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 1686199 [pii]
AID - 10.1001/jamaophthalmol.2013.2315 [doi]
PST - ppublish
SO  - JAMA Ophthalmol. 2013 May 1;131(5):662-6. doi: 10.1001/jamaophthalmol.2013.2315.

PMID- 23699750
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1465-735X (Electronic)
IS  - 0146-8693 (Linking)
DP  - 2013 May 22
TI  - A Multicomponent Motivational Intervention to Improve Adherence Among Adolescents
      With Poorly Controlled Type 1 Diabetes: A Pilot Study.
AB  - OBJECTIVE: To adapt and pilot test a multicomponent motivational intervention
      that includes family-based contingency management (CM) for adolescents with
      poorly controlled type 1 diabetes. METHODS: A total of 17 adolescents, age 12-17 
      years (M = 14.8, SD = 1.5), with type 1 diabetes (duration M = 6.2 years, SD =
      4.5) and mean HbA1c of 11.6% (SD = 2.5%) were enrolled. Adolescents and their
      parents received 14 weeks of motivational interviewing, clinic-based CM, and
      parent-directed CM that targeted increased blood glucose monitoring (BGM).
      RESULTS: Adolescents significantly increased their BGM (p < .001) and showed
      significantly improved HbA1c levels (glycemic control) from pre-to posttreatment 
      (p < .0001). CONCLUSIONS: The magnitude of improvements in the frequency of BGM
      and glycemic control in adolescents with type 1 diabetes is encouraging and will 
      be tested in a randomized controlled trial.
AD  - Department of Psychiatry, Geisel School of Medicine at Dartmouth, University of
      Texas Health Science Center at San Antonio, University of Arkansas for Medical
      Sciences, and Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center.
FAU - Stanger, Catherine
AU  - Stanger C
FAU - Ryan, Stacy R
AU  - Ryan SR
FAU - Delhey, Leanna M
AU  - Delhey LM
FAU - Thrailkill, Kathryn
AU  - Thrailkill K
FAU - Li, Zhongze
AU  - Li Z
FAU - Li, Zhigang
AU  - Li Z
FAU - Budney, Alan J
AU  - Budney AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - J Pediatr Psychol
JT  - Journal of pediatric psychology
JID - 7801773
OTO - NOTNLM
OT  - cognitive behavior therapy
OT  - contingency management
OT  - motivational interviewing
OT  - type 1 diabetes
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - jst032 [pii]
AID - 10.1093/jpepsy/jst032 [doi]
PST - aheadofprint
SO  - J Pediatr Psychol. 2013 May 22.

PMID- 23699675
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1544-3450 (Electronic)
IS  - 1086-5802 (Linking)
VI  - 53
IP  - 3
DP  - 2013 May 1
TI  - Medication adherence program: Adherence challenges and interventions in type 2
      diabetes.
PG  - 267-72
LID - 10.1331/JAPhA.2013.12065 [doi]
AB  - OBJECTIVES To describe medication adherence problems for adults with type 2
      diabetes and to assess the nature and frequency of pharmacist activities in
      addressing them and proximate outcomes. DESIGN Pre-post analysis. SETTING Four
      community chain pharmacies located in Seattle, WA, from April 2008 to October
      2009. PATIENTS 120 patients (mean age &gt;60 years) with type 2 diabetes taking
      oral diabetes medications and who were 6 or more days late for refills.
      INTERVENTION Pharmacist telephone-initiated adherence support. MAIN OUTCOMES
      MEASURES Nature and frequency of adherence-related problems and intervention
      activities and impact on reduction in refill gaps. RESULTS The primary adherence 
      challenge was difficulty taking medications (27.1%). Failure to remember doses
      and forgetting refills were reported by 24.6% and 26.3% of patients at baseline, 
      respectively. Pharmacists provided support through some form of patient education
      (35.6% of encounters) or other adherence support (40.7%). Pharmacist time
      averaged slightly greater than 5 minutes per intervention and 12.6 +/- 10.7
      minutes (mean +/- SD) over 12 months, with 3.4 +/- 2.4 interventions per patient.
      Patient-specific education and adherence support by pharmacists and total
      intervention time were positively correlated, with a modest but significant
      reduction in refill gaps during 12 months of follow-up. CONCLUSION Not
      remembering to refill medications was the most commonly reported problem. Patient
      encounters averaged 4 to 6 minutes for the first visit and 12 to 13 minutes over 
      12 months. Phone calls by pharmacists to adults who were late for oral diabetes
      medication refills were effective in identifying adherence-related problems and
      developing support strategies to promote medication self-management in busy urban
      community chain pharmacy settings.
FAU - Odegard, Peggy Soule
AU  - Odegard PS
FAU - Carpinito, Gina
AU  - Carpinito G
FAU - Christensen, Dale B
AU  - Christensen DB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Pharm Assoc (2003)
JT  - Journal of the American Pharmacists Association : JAPhA
JID - 101176252
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 1686688 [pii]
AID - 10.1331/JAPhA.2013.12065 [doi]
PST - ppublish
SO  - J Am Pharm Assoc (2003). 2013 May 1;53(3):267-72. doi: 10.1331/JAPhA.2013.12065.

PMID- 23699674
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1544-3450 (Electronic)
IS  - 1086-5802 (Linking)
VI  - 53
IP  - 3
DP  - 2013 May 1
TI  - Comparing point-of-care A1C and random plasma glucose for screening diabetes in
      migrant farm workers.
PG  - 261-6
LID - 10.1331/JAPhA.2013.12102 [doi]
AB  - OBJECTIVE To compare point-of-care (POC) glycosylated hemoglobin (A1C) and random
      plasma glucose (RPG) as a POC screening tool for prediabetes and diabetes in
      migrant farm workers of eastern North Carolina. DESIGN Prospective,
      observational, single-center study. SETTING Federally qualified community health 
      center in eastern North Carolina, from August to October 2011. PARTICIPANTS
      Migrant farm workers 18 years or older who resided in a migrant camp in eastern
      North Carolina. INTERVENTION Diabetes screening using POC A1C and RPG via
      fingerstick followed by venipuncture A1C and basic metabolic panel in individuals
      with a positive screening. MAIN OUTCOME MEASURES Positive predictive value (PPV) 
      of POC A1C and RPG, incidence of positive screening, incidence of confirmed
      diagnosis, concordance rate of the screening tools, and correlation between POC
      A1C and laboratory A1C. RESULTS 206 workers participated in the screenings;
      screening identified 39 individuals with a POC A1C greater than 5.7% and 1
      individual with both an RPG of 200 mg/dL or more and a POC A1C greater than 5.7%.
      Of the 39 individuals found to have a positive screening, 24 presented to
      Carolina Family Health Centers, Inc., for follow-up venipuncture; however, 1
      participant did not have a venipuncture A1C, leaving 23 individuals with complete
      data. Two participants were diagnosed with diabetes and 17 with prediabetes. POC 
      A1C had a PPV of 82.6%; however, the PPV of RPG could not be calculated due to
      the number of participants lost to follow-up. POC A1C correlated well with
      laboratory A1C regardless of time to follow-up. CONCLUSION POC A1C should be
      considered for diabetes screening in high-risk populations. If the screening had 
      been performed with RPG alone, 38 individuals would have gone undetected. Early
      identification of individuals with elevated blood glucose will likely decrease
      the risk of long-term complications.
FAU - Wensil, Ashley M
AU  - Wensil AM
FAU - Smith, Jennifer D
AU  - Smith JD
FAU - Pound, Melanie W
AU  - Pound MW
FAU - Herring, Charles
AU  - Herring C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Pharm Assoc (2003)
JT  - Journal of the American Pharmacists Association : JAPhA
JID - 101176252
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 1686687 [pii]
AID - 10.1331/JAPhA.2013.12102 [doi]
PST - ppublish
SO  - J Am Pharm Assoc (2003). 2013 May 1;53(3):261-6. doi: 10.1331/JAPhA.2013.12102.

PMID- 23699598
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
DP  - 2013 May 22
TI  - Diabetes is associated with post-translational modifications in plasminogen
      resulting in reduced plasmin generation and enzyme specific activity.
AB  - Diabetes is associated with hypofibrinolysis by mechanisms that are only
      partially understood. We investigated the effects of in vivo plasminogen
      glycation on fibrinolysis, plasmin generation, protein proteolytic activity and
      plasminogen-fibrin interactions. Plasma was collected from healthy controls and
      individuals with type 1 diabetes before and after improving glycemia.
      Plasma-purified plasmin(ogen) functional activity was evaluated by chromogenic,
      turbidimetric and plasmin conversion assays, with surface plasmon resonance
      employed for fibrin-plasminogen interactions. Plasminogen post-translational
      modifications were quantified by mass spectrometry and glycation sites located by
      peptide mapping. Diabetes was associated with impaired plasma fibrin network
      lysis, which partly normalized upon improving glycaemia. Purified plasmin(ogen)
      from diabetes subjects had impaired fibrinolytic activity compared with controls 
      (723+/-16 and 317+/-4 s, respectively; p<0.01), mainly related to decreased
      fibrin-dependent plasmin generation and reduced protease activity (Kcat/KM
      2.57+/-1.02x10-3 and 5.67+/-0.98x10-3 M-1s-1, respectively; p<0.05).
      Nepsilon-fructosyl-lysine (FL) residue on plasminogen was increased in diabetes
      compared with controls (6.26+/-3.43 and 1.82+/-0.95 %mol, respectively; p<0.01)
      with preferential glycation of lysines 107 and 557, sites involved in fibrin
      binding and plasmin(ogen) cleavage, respectively. Glycation of plasminogen in
      diabetes directly affects fibrinolysis by decreasing plasmin generation and
      reducing protein specific activity; changes that are reversible with modest
      improvement in glycemic control.
AD  - Division of Cardiovascular and Diabetes Research, Leeds Institute for Genetics,
      Health and Therapeutics, Multidisciplinary Cardiovascular Research Centre,
      University of Leeds, Leeds, United Kingdom;
FAU - Ajjan, Ramzi A
AU  - Ajjan RA
FAU - Gamlen, Toby
AU  - Gamlen T
FAU - Standeven, Kristina F
AU  - Standeven KF
FAU - Mughal, Salihah
AU  - Mughal S
FAU - Hess, Katharina
AU  - Hess K
FAU - Smith, Kerrie A
AU  - Smith KA
FAU - Dunn, Emma J
AU  - Dunn EJ
FAU - Anwar, M Maqsud
AU  - Anwar MM
FAU - Rabbani, Naila
AU  - Rabbani N
FAU - Thornalley, Paul J
AU  - Thornalley PJ
FAU - Philippou, Helen
AU  - Philippou H
FAU - Grant, Peter J
AU  - Grant PJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Blood
JT  - Blood
JID - 7603509
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - blood-2013-04-494641 [pii]
AID - 10.1182/blood-2013-04-494641 [doi]
PST - aheadofprint
SO  - Blood. 2013 May 22.

PMID- 23699514
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Linking)
VI  - 33
IP  - 21
DP  - 2013 May 22
TI  - Promoted Interaction of Nuclear Factor-kappaB with Demethylated
      Cystathionine-beta-Synthetase Gene Contributes to Gastric Hypersensitivity in
      Diabetic Rats.
PG  - 9028-9038
AB  - Patients with long-standing diabetes frequently demonstrate gastric
      hypersensitivity with an unknown mechanism. The present study was designed to
      investigate roles for nuclear factor-kappaB (NF-kappaB) and the endogenous
      H2S-producing enzyme cystathionine-beta-synthetase (CBS) signaling pathways by
      examining cbs gene methylation status in adult rats with diabetes.
      Intraperitoneal injection of streptozotocin (STZ) produced gastric
      hypersensitivity in female rats in response to gastric balloon distention.
      Treatment with the CBS inhibitor aminooxyacetic acid significantly attenuated
      STZ-induced gastric hypersensitivity in a dose-dependent fashion. Aminooxyacetic 
      acid treatment also reversed hyperexcitability of gastric-specific dorsal root
      ganglion (DRG) neurons labeled by the dye DiI in diabetic rats. Conversely, the
      H2S donor NaHS enhanced neuronal excitability of gastric DRG neurons. Expression 
      of CBS and p65 were markedly enhanced in gastric DRGs in diabetic rats. Blockade 
      of NF-kappaB signaling using pyrrolidine dithiocarbamate reversed the
      upregulation of CBS expression. Interestingly, STZ treatment led to a significant
      demethylation of CpG islands in the cbs gene promoter region, as determined by
      methylation-specific PCR and bisulfite sequencing. STZ treatment also remarkably 
      downregulated the expression of DNA methyltransferase 3a and 3b. More
      importantly, STZ treatment significantly enhanced the ability of cbs to bind DNA 
      at the p65 consensus site, as shown by chromatin immunoprecipitation assays. Our 
      findings suggest that upregulation of cbs expression is attributed to cbs
      promoter DNA demethylation and p65 activation and that the enhanced interaction
      of the cbs gene and p65 contributes to gastric hypersensitivity in diabetes. This
      finding may guide the development and evaluation of new treatment modalities for 
      patients with diabetic gastric hypersensitivity.
AD  - Division of Endocrinology, the Second Affiliated Hospital, Soochow University,
      Suzhou 215000, P.R. China, Institute of Neuroscience, Suzhou Key Laboratory of
      Pain Research and Therapy, Department of Neurobiology, Soochow University, Suzhou
      215123, P.R. China, Hand Surgery Research Center, Department of Hand Surgery,
      Affiliated Hospital of Nantong University, Nantong 226001, P.R. China, and
      Department of Neuroscience and Cell Biology, University of Texas Medical Branch, 
      Galveston, Texas 77555-1069.
FAU - Zhang, Hong-Hong
AU  - Zhang HH
FAU - Hu, Ji
AU  - Hu J
FAU - Zhou, You-Lang
AU  - Zhou YL
FAU - Hu, Shufen
AU  - Hu S
FAU - Wang, Yong-Meng
AU  - Wang YM
FAU - Chen, Wei
AU  - Chen W
FAU - Xiao, Ying
AU  - Xiao Y
FAU - Huang, Li-Yen Mae
AU  - Huang LY
FAU - Jiang, Xinghong
AU  - Jiang X
FAU - Xu, Guang-Yin
AU  - Xu GY
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for
      Neuroscience
JID - 8102140
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 33/21/9028 [pii]
AID - 10.1523/JNEUROSCI.1068-13.2013 [doi]
PST - ppublish
SO  - J Neurosci. 2013 May 22;33(21):9028-9038.

PMID- 23698804
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1348-4214 (Electronic)
IS  - 0916-9636 (Linking)
DP  - 2013 May 23
TI  - Prevalence of microalbuminuria and associated risk factors among adult Korean
      hypertensive patients in a primary care setting.
LID - 10.1038/hr.2013.44 [doi]
AB  - Microalbuminuria is an early sign of nephropathy and an independent predictor of 
      end-stage renal disease. The purpose of this study was to assess microalbuminuria
      prevalence and its contributing factors in Korean hypertensive patients. This
      cross-sectional study enrolled male and female patients of >/=35 years old with
      an essential hypertension diagnosis as made by 841 physicians in primary care
      clinics and 17 in general hospitals in the Republic of Korea between November
      2008 and July 2009. To assess microalbuminuria prevalence, urine
      albumin/creatinine ratio (UACR) was measured in patients with a positive dipstick
      test. Of the 40 473 enrolled patients, 5713 (14.1%) had a positive dipstick test.
      Of 5393 patients with a positive dipstick test and valid UACR values, 2657 (6.6%)
      had significantly elevated UACR (>/=30 mug mg-1), 2158 (5.4%) had
      microalbuminuria (30 mug mg-1</=UACR <300 mug mg-1) and 499 (1.2%) had
      macroalbuminuria (UACR >/=300 mug mg-1). Based on multivariate analysis,
      independent factors associated with elevated UACR included low adherence to
      antihypertensive medication (23% higher; P=0.042), poorly controlled blood
      pressure (BP; 38% higher for systolic BP/diastolic BP >/=130 mm Hg/>/=80 mm Hg;
      P<0.001), obesity (47% higher for body mass index (BMI) >/=25.0 kg m-2; P<0.001),
      age (17% lower and 58% higher for age categories 35-44 years (P=0.043) and >75
      years (P<0.001), respectively) and a prior history of diabetes (151% higher;
      P<0.001) and kidney-related disease (71% higher; P<0.001). The prevalences of
      elevated UACR and microalbuminuria were 6.6% and 5.4%, respectively. Age,
      increased BMI, presence of comorbidities, poor medication adherence and
      inadequately controlled BP were independent predictors of elevated UACR after
      controlling for potential confounders.Hypertension Research advance online
      publication, 23 May 2013; doi:10.1038/hr.2013.44.
AD  - Division of Nephrology, Department of Internal Medicine, Seoul National
      University College of Medicine, Seoul, Korea.
FAU - Kim, Yon Su
AU  - Kim YS
FAU - Kim, Han Soo
AU  - Kim HS
FAU - Oh, Ha Young
AU  - Oh HY
FAU - Lee, Moon-Kyu
AU  - Lee MK
FAU - Kim, Cheol Ho
AU  - Kim CH
FAU - Kim, Yong Soo
AU  - Kim YS
FAU - Wu, David
AU  - Wu D
FAU - Johnson-Levonas, Amy O
AU  - Johnson-Levonas AO
FAU - Oh, Byung-Hee
AU  - Oh BH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/05/23 [aheadofprint]
AID - hr201344 [pii]
AID - 10.1038/hr.2013.44 [doi]
PST - aheadofprint
SO  - Hypertens Res. 2013 May 23. doi: 10.1038/hr.2013.44.

PMID- 23698776
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130523
DCOM- 20130524
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 14
IP  - 5
DP  - 2013
TI  - Obesity-associated oxidative stress: strategies finalized to improve redox state.
PG  - 10497-538
LID - 10.3390/ijms140510497 [doi]
AB  - Obesity represents a major risk factor for a plethora of severe diseases,
      including diabetes, cardiovascular disease, non-alcoholic fatty liver disease,
      and cancer. It is often accompanied by an increased risk of mortality and, in the
      case of non-fatal health problems, the quality of life is impaired because of
      associated conditions, including sleep apnea, respiratory problems,
      osteoarthritis, and infertility. Recent evidence suggests that oxidative stress
      may be the mechanistic link between obesity and related complications. In obese
      patients, antioxidant defenses are lower than normal weight counterparts and
      their levels inversely correlate with central adiposity; obesity is also
      characterized by enhanced levels of reactive oxygen or nitrogen species.
      Inadequacy of antioxidant defenses probably relies on different factors: obese
      individuals may have a lower intake of antioxidant- and phytochemical-rich foods,
      such as fruits, vegetables, and legumes; otherwise, consumption of antioxidant
      nutrients is normal, but obese individuals may have an increased utilization of
      these molecules, likewise to that reported in diabetic patients and smokers. Also
      inadequate physical activity may account for a decreased antioxidant state. In
      this review, we describe current concepts in the meaning of obesity as a state of
      chronic oxidative stress and the potential interventions to improve redox
      balance.
AD  - Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 
      Via Montpellier 1, 00133 Rome, Italy. savini@uniroma2.it.
FAU - Savini, Isabella
AU  - Savini I
FAU - Catani, Maria Valeria
AU  - Catani MV
FAU - Evangelista, Daniela
AU  - Evangelista D
FAU - Gasperi, Valeria
AU  - Gasperi V
FAU - Avigliano, Luciana
AU  - Avigliano L
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:01
CRDT- 2013/05/24 06:00
PHST- 2013/02/16 [received]
PHST- 2013/04/18 [revised]
PHST- 2013/05/06 [accepted]
AID - ijms140510497 [pii]
AID - 10.3390/ijms140510497 [doi]
PST - epublish
SO  - Int J Mol Sci. 2013 May 21;14(5):10497-538. doi: 10.3390/ijms140510497.

PMID- 23698636
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1460-2180 (Electronic)
IS  - 0143-3334 (Linking)
DP  - 2013 May 22
TI  - Prospective Evaluation of Serum Sarcosine and Risk of Prostate Cancer in the
      Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
AB  - Metabolomic profiling has identified, sarcosine, a derivative of the amino acid
      glycine, as an important metabolite involved in the etiology or natural history
      of prostate cancer. We examined the association between serum sarcosine levels
      and risk of prostate cancer in 1,122 cases (813 non-aggressive and 309
      aggressive) and 1,112 controls in the Prostate, Lung, Colorectal and Ovarian
      (PLCO) Cancer Screening Trial. Sarcosine was quantified using high-throughput
      liquid chromatography-mass spectrometry. A significantly increased risk of
      prostate cancer was observed with increasing levels of sarcosine (Odds Ratio (OR)
      for the highest quartile of exposure (Q4) versus the lowest quartile (Q1) = 1.30,
      95% CI: 1.02, 1.65; P-trend 0.03). When stratified by disease aggressiveness, we 
      observed a stronger association for nonaggressive cases (OR for Q4 vs Q1 = 1.44, 
      95% CI: 1.11, 1.88; P-trend 0.006) but no association for aggressive prostate
      cancer (OR for Q4 vs Q1 = 1.03, 95% CI: 0.73, 1.47; P-trend 0.89). Although not
      statistically significant, temporal analyses showed a stronger association
      between sarcosine and prostate cancer for serum collected closer to diagnosis,
      suggesting that sarcosine may be an early biomarker of disease. Interestingly,
      the association between sarcosine and prostate cancer risk was stronger among men
      with diabetes (OR= 2.66, 95% CI: 1.04, 6.84) compared to those without reported
      diabetes (OR=1.23, 95% CI: 0.95-1.59, p-interaction=0.01). This study found that 
      elevated levels of serum sarcosine are associated with an increased prostate
      cancer risk and evidence to suggest that sarcosine may be an early biomarker for 
      this disease.
AD  - Division of Cancer Epidemiology and Genetics, National Cancer Institute.
      Rockville, MD.
FAU - Koutros, Stella
AU  - Koutros S
FAU - Meyer, Tamra E
AU  - Meyer TE
FAU - Fox, Stephen D
AU  - Fox SD
FAU - Issaq, Haleem J
AU  - Issaq HJ
FAU - Veenstra, Timothy D
AU  - Veenstra TD
FAU - Huang, Wen-Yi
AU  - Huang WY
FAU - Yu, Kai
AU  - Yu K
FAU - Albanes, Demetrius
AU  - Albanes D
FAU - Chu, Lisa W
AU  - Chu LW
FAU - Andriole, Gerald
AU  - Andriole G
FAU - Hoover, Robert N
AU  - Hoover RN
FAU - Hsing, Ann W
AU  - Hsing AW
FAU - Berndt, Sonja I
AU  - Berndt SI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - bgt176 [pii]
AID - 10.1093/carcin/bgt176 [doi]
PST - aheadofprint
SO  - Carcinogenesis. 2013 May 22.

PMID- 23698601
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
DP  - 2013 May 22
TI  - Extended family history of autoimmune diseases and phenotype and genotype of
      children with newly diagnosed type 1 diabetes.
AB  - OBJECTIVE: Based on the concept of clustering autoimmunity, children with a
      positive family history for autoimmunity could be expected to have a different
      pathogenetic form of type 1 diabetes and thus a stronger autoimmune reactivity
      against beta cells and increased prevalence of the HLA-DR3-DQ2 haplotype. DESIGN 
      AND METHODS: We tested this hypothesis in a cross-sectional observational study
      from the Finnish Pediatric Diabetes Register. HLA class II genotypes and
      beta-cell autoantibodies were analyzed, and data on the extended family history
      of autoimmunity and clinical markers at diagnosis were collected with a
      structured questionnaire from 1,488 children diagnosed with type 1 diabetes under
      the age of 15 years (57% male). RESULTS: Only 23 children (1.5%) had another
      autoimmune disease known at diagnosis, and they had milder metabolic
      decompensation at diabetes presentation. One third (31.4%) had at least one
      relative with an autoimmune disease other than type 1 diabetes with affected
      mothers overrepresented (8.2%) compared to fathers (2.8%). The children with a
      positive family history of other autoimmune diseases had higher levels of islet
      cell antibodies (P=0.003), and the HLA-DR3-DQ2 haplotype in the child was
      associated with celiac disease in the extended family (P<0.001) but not with an
      increased frequency of autoimmune disorders in general. CONCLUSIONS: Around one
      third of children with newly diagnosed type 1 diabetes have a first and/or
      second-degree relative affected by an autoimmune disease. Our data do not
      consistently support the hypothesis of differential pathogenetic mechanisms in
      such children.
AD  - A Parkkola, Childrens' Hospital, University of Helsinki, Helsinki, Finland.
FAU - Parkkola, Anna
AU  - Parkkola A
FAU - Harkonen, Taina
AU  - Harkonen T
FAU - Ryhanen, Samppa J
AU  - Ryhanen SJ
FAU - Ilonen, Jorma
AU  - Ilonen J
FAU - Knip, Mikael
AU  - Knip M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - EJE-13-0089 [pii]
AID - 10.1530/EJE-13-0089 [doi]
PST - aheadofprint
SO  - Eur J Endocrinol. 2013 May 22.

PMID- 23698590
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 May 22
TI  - Associations between two single nucleotide polymorphisms of the Adiponectin gene,
      its circulating concentrations and cardiometabolic risk factors in prepubertal
      children with and without abdominal obesity.
AB  - Background: The adiponectin gene has been identified as a susceptibility locus
      for metabolic syndrome, diabetes and cardiovascular disease. Aim: To examine the 
      influence of two single nucleotide polymorphisms (SNPs) of this gene (+276G>T and
      +45T>G) on circulating adiponectin concentrations, and to evaluate their
      relationship with adiposity and cardiometabolic risk factors in prepubertal
      children with and without abdominal obesity. Material and methods: 168 children
      (78M, 6-10 years) were examined, divided into three groups based on waist
      circumference (WC). Auxological and biochemical parameters were measured by
      standard procedures. Adiponectin SNPs were genotyped using TaqMan allelic
      discrimination assays. Results: Adiponectin concentration correlated inversely
      with measures of adiposity (rBMIzscore=- 0.211, pBMIz-score=0.007; rwc=-0.210,
      pwc=0.008; rwc/height=-0.215, pwc/height=0.006), and was significantly influenced
      by blood glucose, insulin and systolic blood pressure (SBP). The +276T-allele
      carriers had higher SBP and diastolic BP compared to GG-homozygotes (p<0.05), and
      expressed higher obesity-related measures and lower adiponectin concentrations.
      As to the +45T>G SNP, the GG-subject had higher total cholesterol and LDLC
      concentrations compared to the T-allele carriers (p<0.05), showing worse obesity 
      measures, higher triglyceride, glucose and insulin and lower serum adiponectin
      values. Conclusion: Genetic variants of the adiponectin gene had an impact on
      adiposity, adiponectin concentrations and some cardiometabolic variables among
      prepubertal children.
AD  - Department of Paediatrics and Medical Genetics, Varna Medical University, Varna, 
      Bulgaria.
FAU - Galcheva, S V
AU  - Galcheva SV
FAU - Martorana, D
AU  - Martorana D
FAU - Iotova, V M
AU  - Iotova VM
FAU - Yotov, Y
AU  - Yotov Y
FAU - Neri, T M
AU  - Neri TM
FAU - Street, M E
AU  - Street ME
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 8972 [pii]
AID - 10.3275/8972 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 May 22.

PMID- 23698396
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 22
TI  - Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in
      Type 2 Diabetes Inadequately Controlled on Metformin: A 24-Week, Randomized,
      Open-Label, Active-Controlled Study (GetGoal-X).
AB  - OBJECTIVETo compare efficacy and safety of lixisenatide once daily versus
      exenatide twice daily in type 2 diabetes inadequately controlled with
      metformin.RESEARCH DESIGN AND METHODSAdults with diabetes inadequately controlled
      (HbA1c 7-10%) with metformin were randomized to lixisenatide 20 mug once daily (n
      = 318) or exenatide 10 mug twice daily (n = 316) in a 24-week (main period),
      open-label, parallel-group, multicenter study. The primary objective was a
      noninferiority assessment of lixisenatide versus exenatide in HbA1c change from
      baseline to week 24.RESULTSLixisenatide once daily demonstrated noninferiority in
      HbA1c reduction versus exenatide twice daily. The LS mean change was -0.79% (mean
      decrease 7.97 to 7.17%) for lixisenatide versus -0.96% (mean +/- SD 7.96 to
      7.01%) for exenatide, and treatment difference was 0.17% (95% CI, 0.033-0.297),
      meeting a predefined noninferiority upper CI margin of 0.4%. Responder rate
      (HbA1c <7.0%) and improvements in fasting plasma glucose were comparable. Both
      agents induced weight loss (from 94.5 to 91.7 kg and from 96.7 to 92.9 kg with
      lixisenatide and exenatide, respectively). Incidence of adverse events (AEs) was 
      similar for lixisenatide and exenatide, as was incidence of serious AEs (2.8 and 
      2.2%, respectively). Discontinuations attributable to AEs occurred in 33
      lixisenatide (10.4%) and 41 exenatide (13.0%) patients. In the lixisenatide
      group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P <
      0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P <
      0.05).CONCLUSIONSAdd-on lixisenatide once daily in type 2 diabetes inadequately
      controlled with metformin demonstrated noninferior improvements in HbA1c, with
      slightly lower mean weight loss, lower incidence of hypoglycemia, and better
      gastrointestinal tolerability compared with exenatide twice daily.
AD  - Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas.
FAU - Rosenstock, Julio
AU  - Rosenstock J
FAU - Raccah, Denis
AU  - Raccah D
FAU - Koranyi, Laszlo
AU  - Koranyi L
FAU - Maffei, Laura
AU  - Maffei L
FAU - Boka, Gabor
AU  - Boka G
FAU - Miossec, Patrick
AU  - Miossec P
FAU - Gerich, John E
AU  - Gerich JE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - dc12-2709 [pii]
AID - 10.2337/dc12-2709 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 22.

PMID- 23698246
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1530-0315 (Electronic)
IS  - 0195-9131 (Linking)
DP  - 2013 May 21
TI  - Exercise Training in PCOS Enhances FMD in the Absence of Changes in Fatness.
AB  - INTRODUCTION: Polycystic ovarian syndrome (PCOS) is associated with an adverse
      cardiovascular (CVD) profile. A surrogate marker for CVD risk is endothelial
      dysfunction. Limited studies exist examining the cardiovascular and metabolic
      effects of exercise in PCOS, and specifically its impact on endothelial function.
      Therefore the aim of the current study was to investigate the impact of exercise 
      on endothelial function, in parallel with body composition, insulin resistance
      and cardiopulmonary fitness in PCOS. METHODS: Ten women with PCOS [27y (95% CI = 
      23, 32), 31kg/m (95% CI = 28, 34)] completed a 16-week exercise (EX) programme
      while 7 women with PCOS [29y (95% CI = 24, 35), 35kg/m (95% CI = 31, 40)]
      undertook conventional care (CC) following lifestyle advice. Brachial artery
      endothelial function was assessed pre- and post intervention using flow-mediated 
      dilation (FMD) adjusted for variability in baseline diameter. Visceral (VAT) and 
      abdominal subcutaneous adipose tissue (SAT) was assessed using whole body
      magnetic resonance imaging and H magnetic resonance spectroscopy quantified liver
      fat. Cardiorespiratory fitness, glycaemic control, hormone and lipid profiles
      were also assessed. Data were analysed using covariate-controlled generalised
      estimating equations. RESULTS: At follow-up, EX improved FMD by 3.6% (95% CI =
      0.5, 6.7), P = 0.03) more than CC. There was a parallel improvement in
      cardiorespiratory fitness of 4.7ml/kg/min (95% CI = 1.4, 7.9, P < 0.001) with EX 
      vs. CC. These changes were not explained by changes in VAT, SAT, liver fat or
      insulin resistance. CONCLUSION: Supervised exercise in women with PCOS improves
      endothelial function, an adaptation associated with reduced CVD risk. This change
      occurs independently of changes in body weight or composition. The success of
      public health interventions in this patient group should not be solely judged by 
      weight loss.
AD  - 1Research Institute for Sport and Exercise Sciences, Liverpool John Moores
      University, Liverpool, UK, 2Department of Diabetes and Endocrinology, University 
      Hospital Aintree, Liverpool, UK, 3Department of Gynaecology, Liverpool Women's
      Hospital, Liverpool, UK, 4Magnetic Resonance and Image Analysis Research Centre
      (MARIARC) and Department of Musculoskeletal Biology, University of Liverpool, UK,
      5School of Sports Science, Exercise and Health, The University of Western
      Australia, Crawley, Western Australia, Australia.
FAU - Sprung, Victoria S
AU  - Sprung VS
FAU - Cuthbertson, Daniel J
AU  - Cuthbertson DJ
FAU - Pugh, Christopher J A
AU  - Pugh CJ
FAU - Aziz, Nabil
AU  - Aziz N
FAU - Kemp, Graham J
AU  - Kemp GJ
FAU - Daousi, Christina
AU  - Daousi C
FAU - Green, Daniel J
AU  - Green DJ
FAU - Tim Cable, N
AU  - Tim Cable N
FAU - Jones, Helen
AU  - Jones H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Med Sci Sports Exerc
JT  - Medicine and science in sports and exercise
JID - 8005433
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1249/MSS.0b013e31829ba9a1 [doi]
PST - aheadofprint
SO  - Med Sci Sports Exerc. 2013 May 21.

PMID- 23698229
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
DP  - 2013 May 22
TI  - Report on ISN Forefronts, Melbourne, Australia, 4-7 October 2012:
      tubulointerstitial disease in diabetic nephropathy.
LID - 10.1038/ki.2013.89 [doi]
AB  - The mechanisms involved in expansion of the tubulointerstitial compartment of the
      kidney in individuals with diabetes are not well understood. Given that
      tubulointerstitial damage is an important predictor of progression to end-stage
      kidney disease in most forms of chronic kidney disease it is imperative to gain a
      greater understanding of the processes involved. With this in mind, a very clear 
      objective for the scientific content of this meeting was to spend more than half 
      the program outside the comfort zone of nephrology, gaining insights from sources
      such as neurodegenerative and mitochondrial diseases, stem cells, cancer and
      high-level computing to reconstruct organ systems. The meeting also aimed to
      place the new concepts presented in the context of current knowledge in diabetic 
      kidney disease and the milestones achieved to date in this area. The presenters
      were all extremely generous, giving not only their time, but also showing a large
      proportion of unpublished data to stimulate discussions, questions and
      innovation.Kidney International advance online publication, 22 May 2013;
      doi:10.1038/ki.2013.89.
AD  - 1] Mater Medical Research Institute, South Brisbane, Queensland, Australia [2]
      Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
FAU - Forbes, Josephine M
AU  - Forbes JM
FAU - Harris, David C H
AU  - Harris DC
FAU - Cooper, Mark E
AU  - Cooper ME
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/05/22 [aheadofprint]
AID - ki201389 [pii]
AID - 10.1038/ki.2013.89 [doi]
PST - aheadofprint
SO  - Kidney Int. 2013 May 22. doi: 10.1038/ki.2013.89.

PMID- 23698228
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
DP  - 2013 May 22
TI  - Adherence to antihypertensive agents improves risk reduction of end-stage renal
      disease.
LID - 10.1038/ki.2013.103 [doi]
AB  - Uncontrolled hypertension is associated with an increased risk of end-stage renal
      disease (ESRD). Intensified blood pressure control may slow progression of
      chronic kidney disease; however, the impact of antihypertensive agent adherence
      on the prevention of ESRD has never been evaluated. Here we assessed the impact
      of antihypertensive agent adherence on the risk of ESRD in 185,476 patients in
      the RAMQ databases age 45 to 85 and newly diagnosed/treated for hypertension
      between 1999 and 2007. A case cohort study design was used to assess the risk of 
      and multivariate Cox proportional models were used to estimate the adjusted
      hazard ratio of ESRD. Adherence level was reported as a medication possession
      ratio. Mean patient age was 63 years, 42.2% male, 14.0% diabetic, 30.3%
      dyslipidemic, and mean follow-up was 5.1 years. A high adherence level of 80% or 
      more to antihypertensive agent(s) compared to a lower one was related to a risk
      reduction of ESRD (hazard ratio 0.67; 95% confidence intervals 0.54-0.83).
      Sensitivity analysis revealed that the effect is mainly in those without chronic 
      kidney disease. Risk factors for ESRD were male, diabetes, peripheral artery
      disease, chronic heart failure, gout, previous chronic kidney disease, and use of
      more than one agent. Thus, our study suggests that a better adherence to
      antihypertensive agents is related to a risk reduction of ESRD and this adherence
      needs to be improved to optimize benefits.Kidney International advance online
      publication, 22 May 2013; doi:10.1038/ki.2013.103.
AD  - Faculte de Medecine, Universite de Montreal, Montreal, Quebec, Canada.
FAU - Roy, Louise
AU  - Roy L
FAU - White-Guay, Brian
AU  - White-Guay B
FAU - Dorais, Marc
AU  - Dorais M
FAU - Dragomir, Alice
AU  - Dragomir A
FAU - Lessard, Myriam
AU  - Lessard M
FAU - Perreault, Sylvie
AU  - Perreault S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/05/22 [aheadofprint]
AID - ki2013103 [pii]
AID - 10.1038/ki.2013.103 [doi]
PST - aheadofprint
SO  - Kidney Int. 2013 May 22. doi: 10.1038/ki.2013.103.

PMID- 23698218
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1972-6007 (Electronic)
IS  - 0009-9074 (Linking)
VI  - 164
IP  - 2
DP  - 2013 Mar-Apr
TI  - Myocardial infarction in young adults: risk factors, clinical characteristics and
      prognosis according to our experience.
PG  - e77-82
LID - 10.7417/CT.2013.1535 [doi]
AB  - Objectives. Myocardial infarction is a relatively unusual phenomenon in young
      subjects. The aim if this work is to characterize the risk profile and factors
      influencing outcomes of these patients since it makes possible to manage
      prevention interventions. Patients and Methods. We examined cardiovascular risk
      factors, clinical presentation, angiographic picture and outcome of a group of
      young patients hospitalized for a myocardial infarction. We enrolled 121 young
      patients consecutively admitted to our hospital for a myocardial infarction and
      examined them not only at the initial stage, but also after 3 months and one
      year; finally a long-term telephonic follow up was performed, when possible.
      Results. We found some peculiarity making these patients quite different from the
      older ones who develop a myocardial infarction: cigarettes smoking, family
      history of ischemic heart disease and hyperlipidemia were the most frequent
      cardiovascular risk factors, while diabetes and hypertension were less
      represented; moreover coronary angiography showed more frequently a less
      extensive coronary atherosclerosis. Patients who developed a cardiovascular event
      at follow-up presented a significantly higher prevalence of hypertension and
      obesity and a significantly lower frequency of healthy coronary arteries and of
      previous revascularization. Conclusions. Myocardial infarction in young adults
      presents several peculiarities, represented not only by the risk profile, but
      also by the angiographic picture and the prognosis. Considering the long life
      expectancy of the involved population, the essential role of preventive
      interventions should be strongly underlined. Clin Ter 2013; 164(2):e77-82. doi:
      10.7417/CT.2013.1535.
AD  - Department of Internal and Specialistic Medicine, University of Palermo, Palermo 
      Italy.
FAU - Incalcaterra, E
AU  - Incalcaterra E
FAU - Caruso, M
AU  - Caruso M
FAU - Lo Presti, R
AU  - Lo Presti R
FAU - Caimi, G
AU  - Caimi G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Ter
JT  - La Clinica terapeutica
JID - 0372604
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PST - ppublish
SO  - Clin Ter. 2013 Mar-Apr;164(2):e77-82. doi: 10.7417/CT.2013.1535.

PMID- 23698202
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1972-6007 (Electronic)
IS  - 0009-9074 (Linking)
VI  - 164
IP  - 2
DP  - 2013 Mar-Apr
TI  - The effectiveness of oral goat colostrum in the treatment of patients with type 2
      diabetes mellitus: Our preliminary experience.
PG  - 111-4
LID - 10.7417/CT.2013.1527 [doi]
AB  - Introduction. The properties of colostrum were recognized and investigated more
      thoroughly in the first half of the eighties, when the immune factors and growth 
      factors it contains were pointed out. Numerous studies show that the
      administration of colostrum benefits the subjects with type 2 diabetes mellitus
      as it gradually regulates appetite, improves utilization of nutrients, especially
      glucose, and leads to a significant decrease in body fat. Materials and Methods. 
      The following study is aimed at verifying a possible reduction in the use of
      insulin in 27 subjects with type 2 diabetes, treated with goat colostrum in the
      form gastro-resistant tablets of 300 mg (4/die). Results. In subjects with type 2
      diabetes treated with insulin, the administration of colostrum has obtained a
      significant reduction of insulin dosage and normalization of blood glucose
      levels. Conclusions. The effects of colostrum are presumably linked to increased 
      levels of IGF-1 that improves the utilization of glucose, stimulates glycogen and
      protein synthesis. Clin Ter 2013; 164(2):111-114. doi: 10.7417/CT.2013.1527.
AD  - Clinical and Molecular Medicine Dept., Faculty of Medicine and Psycology,
      "Sapienza" University of Rome, S. Camillo-Forlanini Hospital. Rome, Italy.
FAU - Guaragna, M A
AU  - Guaragna MA
FAU - Albanesi, M
AU  - Albanesi M
FAU - Stefani, S
AU  - Stefani S
FAU - Pasqualone, A
AU  - Pasqualone A
FAU - Angelini, A
AU  - Angelini A
FAU - Alfieri, S
AU  - Alfieri S
FAU - Paparo Barbaro, S
AU  - Paparo Barbaro S
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Clin Ter
JT  - La Clinica terapeutica
JID - 0372604
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PST - ppublish
SO  - Clin Ter. 2013 Mar-Apr;164(2):111-4. doi: 10.7417/CT.2013.1527.

PMID- 23698186
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
DP  - 2013 May 21
TI  - Effect of Aliskiren and Valsartan Combination Versus Aliskiren Monotherapy on
      Hemostatic Biomarkers in Hypertensive Diabetics: Aliskiren and Valsartan Impact
      in Diabetics Pilot Trial.
AB  - Valsartan is known to inhibit platelet activity in both in vitro and ex vivo
      clinical setting, whereas aliskiren in vitro modulates antithrombin-III in
      plasma. The authors tested how aliskiren and valsartan combination versus
      aliskiren monotherapy will affect hemostatic biomarkers in mild-to-moderate
      hypertensive diabetics in the frame of the Aliskiren and Valsartan Impact in
      Diabetics (AVID) trial. A total of 52 patients with type 2 diabetes and
      mild-to-moderate hypertension were equally randomized to aliskiren (150-300 mg/d)
      and valsartan (160 mg/d) versus aliskiren (150-300 mg/d) alone for 4 weeks. A
      total of 25 biomarkers were serially measured, of which 16 are related to
      platelet function, 6 to coagulation, and 3 to fibrinolysis. Aliskiren monotherapy
      has no significant impact on any of the assessed biomarkers. In contrast,
      valsartan on top of aliskiren provided significant inhibition of ADP-induced
      platelet aggregation (P = 0.032), decreased shear-induced activation measured
      with PFA-100 analyzer (P = 0.041), and diminished expression of GP IIb/IIIa
      activity (P = 0.027) measured by PAC-1 antibody, GP Ib (CD42b, P = 0.033),
      vitronectin receptor (CD51/61, P = 0.046), P-selectin (CD62p, P = 0.026),
      lysosome-associated membrane protein (CD107a, P = 0.042), and CD40-ligand (CD154,
      P = 0.048). In AVID trial, valsartan in combination with aliskiren mildly but
      significantly inhibited platelets, confirming previous observations. In contrast,
      aliskiren monotherapy does not enhance antithrombin activity, suggesting that
      previous data probably represent a laboratory artifact. Importantly, these
      randomized data were generated on top of low-dose daily aspirin, supporting extra
      benefit for combination use of angiotensin receptor blockers and renin inhibitors
      in high-risk diabetic population.
AD  - 1HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD; 2Heart
      Institute, University of Pecs, Pecs, Hungary; 3Wegmans Pharmacy, Ithaca, NY;
      4Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway; and
      5Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
FAU - Serebruany, Victor L
AU  - Serebruany VL
FAU - Pokov, Alex N
AU  - Pokov AN
FAU - Aradi, Daniel
AU  - Aradi D
FAU - Can, Mehmet
AU  - Can M
FAU - Dinicolantonio, James
AU  - Dinicolantonio J
FAU - Kipshidze, Nodar
AU  - Kipshidze N
FAU - Atar, Dan
AU  - Atar D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1097/MJT.0b013e31826915ab [doi]
PST - aheadofprint
SO  - Am J Ther. 2013 May 21.

PMID- 23698181
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1537-1948 (Electronic)
IS  - 0025-7079 (Linking)
DP  - 2013 May 23
TI  - Profiling Individual Physicians Using Administrative Data From a Single Insurer: 
      Variance Components, Reliability, and Implications for Performance Improvement
      Efforts.
AB  - BACKGROUND:: Individual physicians are increasingly being subjected to
      comparative performance assessments. When single-insurer data are used to profile
      individual physicians' performance, reliable measurements are uncertain because
      of small sample sizes. METHODS:: Administrative data (2006-2008) from a Dutch
      insurer are used to examine variation in general practitioners' (GPs) performance
      on expenses (5 measures), utilization of hospital care (2 measures), and clinical
      quality for diabetes and chronic obstructive pulmonary disease (6 measures).
      Unadjusted and adjusted multilevel models are used to separate total variance in 
      between-GP and within-GP components. The components are used to calculate
      intraclass correlation coefficients (ICCs), reliability, and sample size
      requirements at common reliability thresholds. RESULTS:: Average ICCs varied
      between 0.07% (hospital admissions) and 8.34% (physiotherapy for chronic
      obstructive pulmonary disease patients). Risk-adjustment often greatly changed
      the relative size of variance components and often led to lower ICCs. In
      addition, ICCs and thus reliability generally decreased over time. Eight measures
      had reliabilities > 0.70, and 3 of these (all GP-related expenses) > 0.90.
      Measures related to utilization of hospital care had reliabilities < 0.60 or even
      0.50. For 5 measures, the vast majority of GPs had sufficient patients to reach
      0.70 reliability. At a reliability of 0.90, however, there were no measures for
      which all GPs met the sample size requirements. CONCLUSIONS:: Reliable
      measurement of individual physicians' performance using single-purchaser data is 
      challenging. For most measures reliability was insufficient to allow for
      high-stakes applications or even any application of profiling. Future research
      should continue to explore methods for enhancing the reliability of individual
      physicians' profiles.
AD  - Institute of Health Policy and Management, Erasmus University Rotterdam,
      Rotterdam, The Netherlands.
FAU - Eijkenaar, Frank
AU  - Eijkenaar F
FAU - van Vliet, Rene C J A
AU  - van Vliet RC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Med Care
JT  - Medical care
JID - 0230027
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1097/MLR.0b013e3182992bc1 [doi]
PST - aheadofprint
SO  - Med Care. 2013 May 23.

PMID- 23698174
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1680-5348 (Electronic)
IS  - 1020-4989 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Apr
TI  - Barriers to prevention of cardiovascular disease in primary care settings in
      Argentina.
PG  - 259-66
LID - S1020-49892013000400004 [pii]
AB  - OBJECTIVE: To identify main barriers to preventing cardiovascular disease and
      implementing clinical practice guidelines in primary care, to pilot
      implementation of a tailored enactment of the adapted World Health Organization
      guidelines to prevent cardiovascular disease, and to assess the impact of the
      intervention in risk stratification. METHODS: A qualitative study was done with
      decision makers, health professionals, and staff from five primary health care
      centers, who were interviewed to identify the main barriers. A tailored
      intervention to apply the guidelines was then designed and implemented. To assess
      the impact of the intervention on risk factor screening, a before-and-after
      analysis was performed through a records review of independent samples of
      patients aged 40 years or older attending each center. RESULTS: The main barriers
      identified were lack of awareness of guidelines and lack of knowledge about
      preventing cardiovascular disease, communication problems within health teams,
      lack of motivation, and organizational problems. Before (n = 226) and after (n = 
      234) the intervention, screening of the main risk factors increased: blood
      pressure measurement from 44.3% to 72.6%, cholesterol measurement from 20.7% to
      49.7%, smoking status assessment from 20.4% to 56.1%, diabetes status assessment 
      from 25.5% to 93.6%, and previous vascular event status from 33.2% to 74.3%.
      Global risk stratification was not done at baseline, compared with 45.1% after
      the intervention. CONCLUSIONS: The main barriers identified were useful in
      designing a tailored intervention. Although no clinical outcomes were evaluated, 
      this study shows that the implementation is feasible, with increased risk
      stratification as a first step at better patient management.
AD  - Programa Nacional de Prevencion y Control de Enfermedades Cardiovasculares,
      Ministerio de Salud, Buenos Aires, Argentina.
FAU - Ferrante, Daniel
AU  - Ferrante D
FAU - Konfino, Jonatan
AU  - Konfino J
FAU - Linetzky, Bruno
AU  - Linetzky B
FAU - Tambussi, Ana
AU  - Tambussi A
FAU - Laspiur, Sebastian
AU  - Laspiur S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Rev Panam Salud Publica
JT  - Revista panamericana de salud publica = Pan American journal of public health
JID - 9705400
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2012/04/19 [received]
PHST- 2012/12/15 [accepted]
AID - S1020-49892013000400004 [pii]
PST - ppublish
SO  - Rev Panam Salud Publica. 2013 Apr;33(4):259-66.

PMID- 23698123
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1522-1466 (Electronic)
IS  - 1522-1466 (Linking)
DP  - 2013 May 22
TI  - (Pro)renin Receptor is Required for Prorenin-Dependent and -Independent
      Regulation of Vacuolar H+-ATPase Activity in MDCK.C11 Collecting Duct Cells.
AB  - Prorenin binding to the prorenin receptor ((P)RR) results in non-proteolytic
      activation of prorenin, but also directly (i.e., independent of angiotensin
      generation) activates signal transduction cascades that can lead to upregulation 
      of profibrotic factors. The (P)RR is an accessory protein of the vacuolar-type
      H+-ATPase (V-ATPase) and is required for V-ATPase integrity. In addition, in
      collecting duct cells prorenin-induced activation of the extracellular
      signal-regulated kinase depends on V-ATPase activity. However, whether prorenin
      binding to the (P)RR directly regulates V-ATPase activity is as yet unknown.
      Here, we studied the effect of prorenin on plasma membrane V-ATPase activity in
      Madin Darby Canine Kidney clone 11 (MDCK.C11) cells, which resemble the
      intercalated cells of the collecting duct. Prorenin increased V-ATPase activity
      at low nanomolar concentrations, and the V-ATPase inhibitor bafilomycin A1, but
      not the angiotensin II type 1 and 2 receptor blockers irbesartan and PD123319,
      prevented this. Increased, but not basal V-ATPase activity was abolished by siRNA
      depletion of the (P)RR. Unexpectedly, the putative peptidic (P)RR blocker Handle 
      Region Peptide (HRP) also increasedV-ATPase activity in a (P)RR-dependent manner.
      Finally, [Arg8]-vasopressin-stimulated V-ATPase activity and cAMP production were
      also abolished by (P)RR depletion. Our results show that in MDCK.C11 cells, the
      (P)RR is required for prorenin-dependent and -independent regulation of V-ATPase 
      activity.
AD  - 1Erasmus MC.
FAU - Lu, Xifeng
AU  - Lu X
FAU - Garrelds, Ingrid M
AU  - Garrelds IM
FAU - Wagner, Carsten A
AU  - Wagner CA
FAU - Danser, A H Jan
AU  - Danser AH
FAU - Meima, Marcel E
AU  - Meima ME
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Am J Physiol Renal Physiol
JT  - American journal of physiology. Renal physiology
JID - 100901990
OTO - NOTNLM
OT  - cAMP
OT  - diabetes
OT  - handle region peptide
OT  - kidney
OT  - renin-angiotensin system
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - ajprenal.00037.2013 [pii]
AID - 10.1152/ajprenal.00037.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Renal Physiol. 2013 May 22.

PMID- 23698113
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1522-1466 (Electronic)
IS  - 1522-1466 (Linking)
DP  - 2013 May 22
TI  - Insulin Directly Stimulates VEGF-A production in the Glomerular Podocyte.
AB  - Podocytes are critically important for maintaining integrity of the glomerular
      filtration barrier and preventing albuminuria. Recently it has become clear that 
      to achieve this they need to be insulin sensitive, and produce an optimal amount 
      of vascular endothelial growth factor-A (VEGF-A). In other tissues insulin has
      been shown to regulate VEGF-A release but this has not been previously examined
      in the podocyte. Using an in-vitro and in-vivo approach we now show that insulin 
      regulates VEGF-A in the podocyte in both mouse and man via the insulin receptor
      (IR). Insulin directly increases VEGF-A messenger RNA levels and protein
      production in conditionally immortalized wild-type human and murine podocytes.
      Furthermore, when podocytes are rendered insulin resistant in vitro (using stable
      short hairpin RNA knockdown of the IR) or in vivo (using transgenic podocyte
      specific IR knockout mice) podocyte VEGF-A production is impaired. Importantly,
      in vivo this occurs prior to the development of any podocyte damage due to
      podocyte insulin resistance. Modulation of VEGF-A by insulin in the podocyte may 
      be another important factor in the development of glomerular disease associated
      with conditions in which insulin signaling to the podocyte is deranged.
AD  - 1Bristol University.
FAU - Hale, Lorna J
AU  - Hale LJ
FAU - Hurcombe, Jennifer
AU  - Hurcombe J
FAU - Lay, Abigail
AU  - Lay A
FAU - Santamaria, Beatriz
AU  - Santamaria B
FAU - Valverde, Angela M
AU  - Valverde AM
FAU - Saleem, Moin A
AU  - Saleem MA
FAU - Mathieson, Peter W
AU  - Mathieson PW
FAU - Welsh, Gavin I
AU  - Welsh GI
FAU - Coward, Richard John Mark
AU  - Coward RJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Am J Physiol Renal Physiol
JT  - American journal of physiology. Renal physiology
JID - 100901990
OTO - NOTNLM
OT  - VEGF-A
OT  - diabetes
OT  - insulin
OT  - podocyte
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - ajprenal.00548.2012 [pii]
AID - 10.1152/ajprenal.00548.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Renal Physiol. 2013 May 22.

PMID- 23698110
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1347-8648 (Electronic)
IS  - 1347-8613 (Linking)
DP  - 2013 May 22
TI  - Inhibition of the TNF-alpha-Induced Serine Phosphorylation of IRS-1 at 636/639 by
      AICAR.
AB  - AMP-activated protein kinase (AMPK) contributes to the acceleration of insulin
      signaling. However, the mechanism by which AMPK regulates insulin signaling
      remains unclear. Serine phosphorylation of insulin receptor substrate (IRS)-1
      negatively regulates insulin signaling. Here we investigated the role of AMPK in 
      serine phosphorylation of IRS-1 at 636/639 and 307, which is induced by tumor
      necrosis factor (TNF)-alpha in 3T3L1 adipocytes. We demonstrated that the AMPK
      activator 5-aminoimidazole-4-carboxamide-1-d-ribofuranoside (AICAR) significantly
      inhibited the TNF-alpha-induced serine phosphorylation of IRS-1 at 636/639 and
      307 by suppression of extracellular signal-regulated kinase (ERK) phosphorylation
      but not c-Jun-NH2-terminal kinase (JNK) phosphorylation. In addition, AICAR
      stimulation resulted in enhanced interaction between ERK and MAP kinase
      phosphatase-4 (DUSP9/MKP-4) without affecting DUSP9/MPK4 mRNA synthesis.
      Moreover, intraperitoneal administration (0.25 g/kg) of AICAR to db/db mice
      improved blood glucose levels and inhibited the phosphorylation of ERK in adipose
      tissue. In conclusion, we propose a new mechanism in which AICAR suppresses
      TNF-alpha-induced serine phosphorylation of IRS-1 at 636/639 and 307 by enhancing
      the interaction between ERK and DUSP9/MKP-4. Taken together, these findings
      provide evidence that AMPK plays a crucial role in improving of type 2 diabetes.
AD  - Division of Pharmacology, Hokkaido Pharmaceutical University School of Pharmacy, 
      Japan.
FAU - Shibata, Tomohito
AU  - Shibata T
FAU - Takaguri, Akira
AU  - Takaguri A
FAU - Ichihara, Kazuo
AU  - Ichihara K
FAU - Satoh, Kumi
AU  - Satoh K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - J Pharmacol Sci
JT  - Journal of pharmacological sciences
JID - 101167001
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - DN/JST.JSTAGE/jphs/12270FP [pii]
PST - aheadofprint
SO  - J Pharmacol Sci. 2013 May 22.

PMID- 23698095
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1756-2651 (Electronic)
IS  - 0021-924X (Linking)
DP  - 2013 May 21
TI  - Evolutionarily conserved regulation of TOR signaling.
AB  - The target of rapamycin (TOR) is an evolutionarily conserved protein kinase that 
      regulates cell growth in response to various environmental as well as
      intracellular cues through the formation of two distinct TOR complexes (TORC),
      TORC1 and TORC2. Dysregulation of TORC1 and TORC2 activity is closely associated 
      with various diseases, including diabetes, cancer, and neurodegenerative
      disorders. Over the past few years, new regulatory mechanisms of TORC1 and TORC2 
      activity have been elucidated. Furthermore, recent advances in the study of TOR
      inhibitors have revealed previously unrecognized cellular functions of TORC1. In 
      this review, we briefly summarize the current understanding of the evolutionarily
      conserved TOR signaling from upstream regulators to downstream events.
AD  - Institute of Molecular and Cellular Biosciences, The University of Tokyo.
FAU - Takahara, Terunao
AU  - Takahara T
FAU - Maeda, Tatsuya
AU  - Maeda T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - J Biochem
JT  - Journal of biochemistry
JID - 0376600
OTO - NOTNLM
OT  - TOR complex
OT  - amino acid
OT  - cell growth
OT  - stress granule
OT  - target of rapamycin
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - mvt047 [pii]
AID - 10.1093/jb/mvt047 [doi]
PST - aheadofprint
SO  - J Biochem. 2013 May 21.

PMID- 23697979
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Linking)
DP  - 2013 May 23
TI  - Pharmacogenomics of anti-platelet therapy: how much evidence is enough for
      clinical implementation?
LID - 10.1038/jhg.2013.41 [doi]
AB  - Pharmacogenomics, the study of the genomics of drug response and adverse effects,
      holds great promise for more effective individualized (personalized) medicine.
      Recent evidence supports a role of loss-of-function (LOF) variants in the
      cytochrome P450 enzyme CYP2C19 as a determinant of clopidogrel response. Patients
      given clopidogrel after percutaneous coronary intervention who carry LOF variants
      do not metabolize clopidogrel, a prodrug, into its active form resulting in
      decreased inhibition of platelet function and a higher likelihood of recurrent
      cardiovascular events. Despite a large body of evidence supporting clinical
      utility, adoption of anti-platelet pharmacogenetics into clinical practice has
      been slow. In this review, we summarize the pharmacokinetic, pharmacodynamic and 
      clinical evidence, identify gaps in knowledge and other barriers that appear to
      be slowing adoption, and describe CYP2C19 pharmacogenetics implementation
      projects currently underway. Only when we surmount these barriers will clinicians
      be able to use pharmacogenetic information in conjunction with the history,
      physical examination and other medical tests and information to choose the most
      efficacious anti-platelet therapy for each individual patient.Journal of Human
      Genetics advance online publication, 23 May 2013; doi:10.1038/jhg.2013.41.
AD  - Program in Personalized and Genomic Medicine, and the Division of Endocrinology, 
      Diabetes and Nutrition, Department of Medicine, University of Maryland School of 
      Medicine, Baltimore, MD, USA.
FAU - Perry, Christina G
AU  - Perry CG
FAU - Shuldiner, Alan R
AU  - Shuldiner AR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/05/23 [aheadofprint]
AID - jhg201341 [pii]
AID - 10.1038/jhg.2013.41 [doi]
PST - aheadofprint
SO  - J Hum Genet. 2013 May 23. doi: 10.1038/jhg.2013.41.

PMID- 23697968
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1465-3419 (Electronic)
IS  - 1355-7858 (Linking)
DP  - 2013 May 22
TI  - Racial/ethnic disparities in association between dietary quality and incident
      diabetes in postmenopausal women in the United States: the Women's Health
      Initiative 1993-2005.
AB  - Objective. To examine the association of dietary quality and risk of incident
      diabetes overall and by race/ethnicity among postmenopausal women enrolled in the
      Women's Health Initiative (WHI). Research methods and procedures. The WHI
      recruited 161,808 postmenopausal women between 1993 and 1998, and followed them
      until 2005. Incident diabetes was determined annually over an average of 7.6
      years from enrollment. At baseline, all participants completed a Food Frequency
      Questionnaire (FFQ). Dietary quality was assessed by the Alternate Healthy Eating
      Index (AHEI), calculated from the baseline FFQ responses. Results. There were
      10,307 incident cases of self-reported treated diabetes over 1,172,761
      person-years of follow-up. Most participants did not meet the AHEI dietary goals;
      that is, only 0.1% of women met or exceeded the recommended consumption of
      vegetables, and few (17.3%) met or exceeded the recommended level for total
      fiber. After adjusting for potential confounders, women in the highest quintile
      of the AHEI score were 24% less likely to develop diabetes relative to women in
      the lowest quintile of AHEI [hazard ratio (HR) = 0.76 (95% CI: 0.70-0.82)]. This 
      association was observed in Whites [HR = 0.74 (95% CI: 0.68-0.82)] and Hispanics 
      [HR = 0.68 (95% CI: 0.46-0.99)], but not in Blacks [HR = 0.85 (95% CI:
      0.69-1.05)] or Asians [HR = 0.88 (95% CI: 0.57-1.38)]. Conclusion. These findings
      support a protective role of healthful eating choices in reducing the risk of
      developing diabetes, after adjusting for other lifestyle factors, in White and
      Hispanic postmenopausal women. Future studies are needed to investigate the
      relationship between dietary quality and risk of diabetes among Blacks and Asians
      in relationship to other lifestyle factors.
AD  - a School of Public Health , Shanghai Jiaotong University , Shanghai , China.
FAU - Qiao, Yongxia
AU  - Qiao Y
FAU - Tinker, Lesley
AU  - Tinker L
FAU - Olendzki, Barbara C
AU  - Olendzki BC
FAU - Hebert, James R
AU  - Hebert JR
FAU - Balasubramanian, Raji
AU  - Balasubramanian R
FAU - Rosal, Milagros C
AU  - Rosal MC
FAU - Hingle, Melanie
AU  - Hingle M
FAU - Song, Yiqing
AU  - Song Y
FAU - Schneider, Kristin L
AU  - Schneider KL
FAU - Liu, Simin
AU  - Liu S
FAU - Sims, Stacy
AU  - Sims S
FAU - Ockene, Judith K
AU  - Ockene JK
FAU - Sepavich, Deidre M
AU  - Sepavich DM
FAU - Shikany, James M
AU  - Shikany JM
FAU - Persuitte, Gioia
AU  - Persuitte G
FAU - Ma, Yunsheng
AU  - Ma Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Ethn Health
JT  - Ethnicity & health
JID - 9608374
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1080/13557858.2013.797322 [doi]
PST - aheadofprint
SO  - Ethn Health. 2013 May 22.

PMID- 23697964
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 May 21
TI  - Renal nerve ablation reduces augmentation index in patients with resistant
      hypertension.
AB  - OBJECTIVE:: Renal denervation (RDN) has been demonstrated to reduce muscle
      sympathetic nerve activity (MSNA) and blood pressure (BP) in patients with
      resistant hypertension. Whether alterations of arterial stiffness may contribute 
      to BP-lowering effects of RDN is unknown. METHODS:: We measured office BP and
      arterial stiffness using fingertip tonometry-derived augmentation index
      (EndoPAT2000) at baseline and at 3-month follow-up in 50 consecutive patients
      with resistant hypertension. Forty patients received RDN and 10 patients served
      as controls. MSNA was obtained in 20 RDN and 10 non-RDN patients. RESULTS::
      Baseline BP averaged 170/92 +/- 19/15 mmHg (RDN) and 171/93 +/- 14/8 mmHg
      (non-RDN) despite the use of 4.9 +/- 1.9 and 4.4 +/- 2.0 antihypertensive drugs, 
      respectively. RDN significantly reduced SBP (170 +/- 19 vs. 154 +/- 25 mmHg; P < 
      0.001) and DBP (92 +/- 15 vs. 84 +/- 16 mmHg; P < 0.001), augmentation index
      (30.6 +/- 23.8 vs. 22.7 +/- 22.4%; P = 0.002), AI@75 corrected for heart rate
      (22.4 +/- 21.6 vs. 14.4 +/- 20.7; P = 0.002) and MSNA (80 +/- 15 vs. 71 +/- 18
      bursts/100 heartbeats; P < 0.01). Changes in AI@75 with RDN were unrelated to SBP
      (r = 0.043; P = 0.79), and DBP (r = 0.092; P = 0.57) and MSNA changes (r = -0.17;
      P = 0.49). No changes in BP, augmentation index, AI@75 or MSNA were observed in
      the non-RDN group. CONCLUSION:: RDN results in a substantial and rapid reduction 
      in augmentation index, which appears to be independent of BP and MSNA changes.
      These findings are indicative of a beneficial effect of RDN on arterial stiffness
      in patients with resistant hypertension and may contribute to the sustained
      BP-lowering effect of RDN.
AD  - aNeurovascular Hypertension & Kidney Disease Laboratory, Baker IDI Heart &
      Diabetes Institute, Melbourne, Victoria, Australia bDepartment of Hypertension
      and Diabetology, Medical University of Gdansk, Gdansk, Poland cHeart Centre
      Alfred Hospital dDepartment of Epidemiology & Preventive Medicine eFaculty of
      Medicine, Nursing and Health Sciences and Department of Physiology, Monash
      University, Melbourne, Victoria, Australia fDepartment of Medicine and
      Cardiology, Hennepin County Medical Center, University of Minnesota, Minneapolis,
      Minnesota gMedtronic ARDIAN Inc., Mountain View, California, USA
      hUniversitatsklinikum des Saarlandes, Homburg/Saar, Germany.
FAU - Hering, Dagmara
AU  - Hering D
FAU - Lambert, Elisabeth A
AU  - Lambert EA
FAU - Marusic, Petra
AU  - Marusic P
FAU - Ika-Sari, Carolina
AU  - Ika-Sari C
FAU - Walton, Antony S
AU  - Walton AS
FAU - Krum, Henry
AU  - Krum H
FAU - Sobotka, Paul A
AU  - Sobotka PA
FAU - Mahfoud, Felix
AU  - Mahfoud F
FAU - Bohm, Michael
AU  - Bohm M
FAU - Lambert, Gavin W
AU  - Lambert GW
FAU - Esler, Murray D
AU  - Esler MD
FAU - Schlaich, Markus P
AU  - Schlaich MP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1097/HJH.0b013e3283622e58 [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 May 21.

PMID- 23697963
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 May 21
TI  - Blood pressure response with fixed-dose combination therapy: comparing
      hydrochlorothiazide with amlodipine through individual-level meta-analysis.
AB  - BACKGROUND:: Although fixed-dose combination drug therapy is commonly used to
      treat hypertension, the efficacy of head-to-head comparisons of dual fixed-dose
      combinations has not been well described. We hypothesized that when used in
      combination with an angiotensin receptor blocker (ARB) olmesartan medoxomil,
      hydrochlorothiazide (HCTZ) will be as effective as the dihydropyridine calcium
      channel blocker (CCB) amlodipine to lower both clinic and 24-h ambulatory blood
      pressure (BP). Furthermore, we hypothesized that response to ARB along with HCTZ 
      or ARB along with CCB may be heterogeneous depending on clinical characteristics.
      METHODS:: An individual-level meta-analysis was performed among 559 individuals
      treated with dual combination therapy in five trials. A forced titration scheme
      was used in each of these trials and blood BP was measured both in the clinic and
      outside using 24-h ambulatory BP monitors. RESULTS:: The mean age was 62 years,
      55% were men, 46% had diabetes mellitus, 17% were black, clinic BP averaged
      159.5/89.5 mmHg and 24-h ambulatory BP 145.0/82.5 mmHg. Overall,
      baseline-adjusted lowering of mean 24-h ambulatory BP was 22.0/11.7 mmHg. BP
      reductions were similar between ARB along with HCTZ and ARB along with CCB
      groups. However, clinic BP was lowered 4.3/1.8 mmHg more with ARB along with CCB 
      combination (28.4/13.0 mmHg drop) than with ARB along with HCTZ combination
      (24.1/11.2 mmHg drop). The white coat effect (WCE) was therefore mitigated
      3.8/1.7 mmHg more with ARB along with CCB combination. Heterogeneity in
      ambulatory BP response was noted. Compared with men, women had a greater
      ambulatory and clinic BP lowering with either combination. ARB along with HCTZ
      produced a greater BP-lowering effect among men, elderly, nonobese and
      nondiabetic. On the contrary, ARB along with CCB produced a greater BP-lowering
      effect among women, young, obese and diabetic individuals. This heterogeneity in 
      response was often undetectable with clinic BP measurements. In multivariable
      analysis, sex and diabetes mellitus remained independent measures of
      heterogeneity. CONCLUSION:: Overall, the combination of olmesartan and HCTZ is as
      effective as olmesartan and CCB in lowering 24-h, daytime, and night-time
      ambulatory BP. However, greater lowering is noted with the olmesartan and CCB
      combination for clinic BP. Thus, out-of-office BP monitoring is necessary to
      provide better assessment of overall BP and response to treatment. Women and
      diabetic individuals may have slightly better 24-h ambulatory BP response with
      the olmesartan and CCB combination therapy.
AD  - aIndiana University School of Medicine and Richard L. Roudebush Veterans
      Administration Medical Center, Indianapolis, Indiana bDepartment of Medicine,
      University of Maryland, Baltimore, Maryland, USA.
FAU - Agarwal, Rajiv
AU  - Agarwal R
FAU - Weir, Matthew R
AU  - Weir MR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1097/HJH.0b013e32836157be [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 May 21.

PMID- 23697958
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1549-4713 (Electronic)
IS  - 0161-6420 (Linking)
DP  - 2013 May 19
TI  - Subfoveal Choroidal Thickness in Diabetes and Diabetic Retinopathy.
LID - S0161-6420(13)00233-9 [pii]
LID - 10.1016/j.ophtha.2013.03.009 [doi]
AB  - PURPOSE: To examine subfoveal choroidal thickness (SFCT) in patients with
      diabetes mellitus and patients with diabetic retinopathy. DESIGN:
      Population-based, cross-sectional study. PARTICIPANTS: The population-based
      Beijing Eye Study 2011 included 3468 individuals with a mean age of 64.6+/-9.8
      years (range, 50-93 years). METHODS: A detailed ophthalmic examination was
      performed including spectral-domain optical coherence tomography (OCT) with
      enhanced depth imaging for measurement of SFCT and fundus photography for the
      assessment of diabetic retinopathy. MAIN OUTCOME MEASURES: Subfoveal choroidal
      thickness. RESULTS: Fasting blood samples, fundus photographs, and choroidal OCT 
      images were available for 2041 subjects (58.8%), with 246 subjects (12.1+/-0.7%) 
      fulfilling the diagnosis of diabetes mellitus and 23 subjects having diabetic
      retinopathy. Mean SFCT did not differ significantly between patients with
      diabetes mellitus and nondiabetic subjects (266+/-108 vs. 261+/-103 mum; P =
      0.43) nor between patients with diabetic retinopathy and subjects without
      retinopathy (249+/-86 vs. 262+/-104 mum; P = 0.56). After adjustment for age,
      sex, axial length, lens thickness, anterior chamber depth, corneal curvature
      radius, and best-corrected visual acuity, SFCT was associated with a higher
      glycosylated hemoglobin (HbA1c) value (P<0.001; regression coefficient B, 8.18;
      95% confidence interval [CI], 4.02-12.3); standardized coefficient beta, 0.08) or
      with the presence of diabetes mellitus (P = 0.001; B, 21.3; 95% CI, 9.12-33.5)
      but not with presence of diabetic retinopathy (P = 0.61) or stage of diabetic
      retinopathy (P = 0.14). As a corollary, after adjusting for age, region of
      habitation, body mass index, systolic and diastolic blood pressure, and level of 
      education, diabetes mellitus was associated with a thicker SFCT (P<0.001). In
      contrast, neither presence of diabetic retinopathy (P = 0.61) nor stage of
      diabetic retinopathy (P = 0.09) were associated significantly with SFCT after
      adjusting for body mass index, diastolic and systolic blood pressure, and level
      of education and after adjusting for blood glucose concentrations, HbA1c value,
      diagnosis of diabetes mellitus, and systolic and diastolic blood pressure,
      respectively. CONCLUSIONS: Patients with diabetes mellitus had a slightly, but
      statistically significantly, thicker subfoveal choroid, whereas presence and
      stage of diabetic retinopathy were not associated additionally with an abnormal
      SFCT. Whereas diabetes mellitus as a systemic disease leads to a slight
      thickening of the choroid, diabetic retinopathy as an ocular disorder was not
      associated with choroidal thickness abnormalities after adjusting for the
      presence of diabetes mellitus. FINANCIAL DISCLOSURE(S): The author(s) have no
      proprietary or commercial interest in any materials discussed in this article.
CI  - Copyright (c) 2013 American Academy of Ophthalmology. Published by Elsevier Inc. 
      All rights reserved.
AD  - Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University,
      Beijing, China.
FAU - Xu, Jie
AU  - Xu J
FAU - Xu, Liang
AU  - Xu L
FAU - Du, Kui Fang
AU  - Du KF
FAU - Shao, Lei
AU  - Shao L
FAU - Chen, Chang Xi
AU  - Chen CX
FAU - Zhou, Jin Qiong
AU  - Zhou JQ
FAU - Wang, Ya Xing
AU  - Wang YX
FAU - You, Qi Sheng
AU  - You QS
FAU - Jonas, Jost B
AU  - Jonas JB
FAU - Wei, Wen Bin
AU  - Wei WB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130519
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2012/12/11 [received]
PHST- 2013/02/20 [revised]
PHST- 2013/03/07 [accepted]
AID - S0161-6420(13)00233-9 [pii]
AID - 10.1016/j.ophtha.2013.03.009 [doi]
PST - aheadofprint
SO  - Ophthalmology. 2013 May 19. pii: S0161-6420(13)00233-9. doi:
      10.1016/j.ophtha.2013.03.009.

PMID- 23697940
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1470-8752 (Electronic)
IS  - 0300-5127 (Linking)
VI  - 41
IP  - 3
DP  - 2013 Jun 1
TI  - Could lncRNAs contribute to beta-cell identity and its loss in Type 2 diabetes?
PG  - 797-801
LID - 10.1042/BST20120355 [doi]
AB  - The progression of Type 2 diabetes is accompanied by diminishing islet beta-cell 
      mass and function. It has been proposed that beta-cells are lost not only through
      apoptosis, but also by dedifferentiating into progenitor-like cells. There is
      therefore much interest in the mechanisms which define and maintain beta-cell
      identity. The advent of genome-wide analyses of chromatin modifications has
      highlighted the role of epigenetic factors in determining cell identity. There is
      also evidence from both human populations and animal models for an epigenetic
      component in susceptibility to Type 2 diabetes. The mechanisms responsible for
      defining the epigenetic landscape in individual cell types are poorly understood,
      but there is growing evidence of a role for lncRNAs (long non-coding RNAs) in
      this process. In the present paper, we discuss some of the mechanisms through
      which lncRNAs may contribute to beta-cell identity and Type 2 diabetes risk.
AD  - Section of Cell Biology, Department of Medicine, Imperial College London,
      Exhibition Road, London SW7 2AZ, U.K.
FAU - Pullen, Timothy J
AU  - Pullen TJ
FAU - Rutter, Guy A
AU  - Rutter GA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Biochem Soc Trans
JT  - Biochemical Society transactions
JID - 7506897
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - BST20120355 [pii]
AID - 10.1042/BST20120355 [doi]
PST - ppublish
SO  - Biochem Soc Trans. 2013 Jun 1;41(3):797-801. doi: 10.1042/BST20120355.

PMID- 23697847
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1364-6915 (Electronic)
IS  - 1360-7863 (Linking)
DP  - 2013 May 22
TI  - Correlates of cognitive impairment in older Vietnamese.
AB  - Objectives: This study examined correlates of cognitive functioning and possible 
      cognitive impairment among older adults living in Da Nang, Vietnam and
      surrounding rural areas. Methods: The analytic sample consisted of 489 adults, 55
      and older stratified by gender, age, and residence in a rural or urban area. The 
      sample was 46% rural, 44% women, with a mean age of 69.04. Interviews were
      conducted in individuals' homes by trained interviewers. The dependent variable
      was a Vietnamese version of the mini mental status examination (MMSE). A multiple
      linear regression was run with the MMSE continuous scores reflecting cognitive
      functioning, while a binary logistic regression was conducted with an
      education-adjusted cut-off score reflecting possible cognitive impairment. Age,
      gender, education, material hardship, depressive symptoms Center for
      Epidemiologic Studies - Depression Scale, war injury, head trauma, diabetes,
      cardiovascular and cerebrovascular disease conditions served as correlates,
      controlling for marital status and rural/urban residence. Results: About 33% of
      the sample scored below the standard cutoff of 23 on the MMSE. However, only
      12.9% of the sample would be considered impaired using the education-adjusted
      cut-off score. Cognitive functioning and possible cognitive impairment as
      indicated by MMSE scores were significantly associated with being older,
      completing fewer years of education, and material hardship. Gender, depressive
      symptoms, and cerebrovascular disease were associated with cognitive functioning,
      but not cognitive impairment. Conclusion: These results show that social
      characteristics, physical illness, and mental health are associated with
      cognitive functioning. The study also raises questions about the need for
      standardization of screening measures on Vietnamese populations.
AD  - a Human Development and Family Studies, State College , The Pennsylvania State
      University , PA , USA.
FAU - Leggett, Amanda
AU  - Leggett A
FAU - Zarit, Steven H
AU  - Zarit SH
FAU - Hoang, Chuong N
AU  - Hoang CN
FAU - Nguyen, Ha T
AU  - Nguyen HT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Aging Ment Health
JT  - Aging & mental health
JID - 9705773
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1080/13607863.2013.799116 [doi]
PST - aheadofprint
SO  - Aging Ment Health. 2013 May 22.

PMID- 23697733
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1930-8264 (Electronic)
IS  - 1930-8264 (Linking)
VI  - 103
IP  - 3
DP  - 2013 May-Jun
TI  - Diabetes, Damp Casts, and Hair Dryers are Not a Good Combination.
PG  - 243-5
AB  - Second- and third-degree burns of the toes resulted when a 69-year-old man with
      Charcot foot and a recent fractured ankle followed the advice of his local
      podiatrist. The man got his fiberglass cast wet while showering and was told to
      dry his cast using the low setting on a blow dryer. The following presents a
      literature review of cast drying, hair dryers, and this unfortunate man's case.
AD  - Department of Endocrinology, Wilmington VA Medical Center, Wilmington, Delaware.
FAU - Henderson, Bernardine C
AU  - Henderson BC
FAU - Lawson, Derek
AU  - Lawson D
FAU - Conley, G Reid
AU  - Conley GR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Podiatr Med Assoc
JT  - Journal of the American Podiatric Medical Association
JID - 8501423
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 103/3/243 [pii]
PST - ppublish
SO  - J Am Podiatr Med Assoc. 2013 May-Jun;103(3):243-5.

PMID- 23697729
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1930-8264 (Electronic)
IS  - 1930-8264 (Linking)
VI  - 103
IP  - 3
DP  - 2013 May-Jun
TI  - Impact of diabetes and comorbidities on split-thickness skin grafts for foot
      wounds.
PG  - 223-32
AB  - Background: Split-thickness skin grafts can be used for foot wound closure in
      diabetic and nondiabetic patients. It is unknown whether this procedure is
      reliable for all diabetic patients, with or without comorbidities of diabetes,
      including cardiovascular disease, neuropathy, retinopathy, and nephropathy.
      Methods: We retrospectively reviewed 203 patients who underwent this procedure to
      determine significant differences in healing time, postoperative infection, and
      need for revisional surgery and to create a predictive model to identify diabetic
      patients who are likely to have a successful outcome. Results: Overall, compared 
      with nondiabetic patients, diabetic patients experienced a significantly higher
      risk of delayed healing time and postoperative complication/infection and, hence,
      are more likely to require revisional surgery after undergoing the initial
      split-thickness skin graft procedure. These differences seemed to be related more
      to the presence of comorbidities than to diabetic status itself. Diabetic
      patients with preexisting comorbidities experienced a significantly increased
      risk of delayed healing time and postoperative infection and a higher need for
      revisional surgery compared with nondiabetic patients or diabetic patients
      without comorbidities. However, there were no significant differences in outcome 
      between diabetic patients without comorbidities and nondiabetic patients.
      Conclusions: For individuals with diabetes but without exclusionary
      comorbidities, split-thickness skin grafting may be considered an effective
      surgical alternative to other prolonged treatment options currently used in this 
      patient population.
AD  - Division of Podiatric Medicine and Surgery, Department of Orthopaedic Surgery,
      University of Texas Health Science Center at San Antonio, San Antonio, TX.
FAU - Ramanujam, Crystal L
AU  - Ramanujam CL
FAU - Han, David
AU  - Han D
FAU - Fowler, Sharon
AU  - Fowler S
FAU - Kilpadi, Krista
AU  - Kilpadi K
FAU - Zgonis, Thomas
AU  - Zgonis T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Podiatr Med Assoc
JT  - Journal of the American Podiatric Medical Association
JID - 8501423
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 103/3/223 [pii]
PST - ppublish
SO  - J Am Podiatr Med Assoc. 2013 May-Jun;103(3):223-32.

PMID- 23697719
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1930-8264 (Electronic)
IS  - 1930-8264 (Linking)
VI  - 103
IP  - 3
DP  - 2013 May-Jun
TI  - The impact of footwear and walking distance on gait stability in diabetic
      patients with peripheral neuropathy.
PG  - 165-73
AB  - Background: We explored gait differences in patients with diabetes and peripheral
      neuropathy (DPN) and aged-matched controls over short and long walking distances.
      The potential benefit of footwear for improving gait in patients with DPN was
      also explored. Methods: Twelve patients with DPN and eight controls walked at
      their habitual speed over short (7 m) and long (20 m) distances under two
      conditions: barefoot and regular shoes. A validated system of body-worn sensors
      was used to extract spatiotemporal gait parameters. Neuropathy severity was
      quantified using vibratory perception threshold measured at the great toe.
      Results: Gait deterioration in the DPN group was observed during all of the
      walking trials. However, the difference between patients with DPN and
      participants in the control group achieved statistical significance only during
      long walking distance trials. Shod and barefoot double support times were longer 
      in the DPN group during long walking distances (>20%, P = .03). Gait
      unsteadiness, defined as coefficient of variation of gait velocity, was also
      significantly higher in the DPN group when barefoot walking over long distances
      (83%, P = .008). Furthermore, there was a high correlation between neuropathy
      severity and gait unsteadiness best demonstrated during the barefoot walking/long
      walking distance condition (r = 0.77, P < .001). The addition of footwear
      improved gait steadiness in the DPN group by 46% (P = .02). All differences were 
      independent of age, sex, and body mass index (P > .05). Conclusions: This study
      suggests that gait alteration in patients with DPN is most pronounced while
      walking barefoot over longer distances and that footwear may improve gait
      steadiness in patients with DPN.
AD  - Southern Arizona Limb Salvage Alliance, Interdisciplinary Consortium for Advanced
      Motion Performance, University of Arizona College of Medicine, Tucson, AZ.
FAU - Najafi, Bijan
AU  - Najafi B
FAU - Khan, Tahir
AU  - Khan T
FAU - Fleischer, Adam
AU  - Fleischer A
FAU - Wrobel, James
AU  - Wrobel J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Podiatr Med Assoc
JT  - Journal of the American Podiatric Medical Association
JID - 8501423
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 103/3/165 [pii]
PST - ppublish
SO  - J Am Podiatr Med Assoc. 2013 May-Jun;103(3):165-73.

PMID- 23697717
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
DP  - 2013 May 19
TI  - Obesity and diabetes related plasma amino acid alterations.
LID - S0009-9120(13)00241-5 [pii]
LID - 10.1016/j.clinbiochem.2013.05.045 [doi]
AB  - OBJECTIVES: The objective of the study is to evaluate whether plasma amino acid
      (AA) differences are related with obesity or diabetes. DESIGN AND METHODS: In 126
      diabetes and 100 non-diabetes participants, the plasma concentrations of 42 (AAs)
      were analyzed with a liquid chromatography tandem mass spectrometry technology
      (LC-MS/MS). Both groups were divided into obese and lean individuals and we
      compared intra- and inter-group differences between the groups. RESULTS: In obese
      non-diabetic participants, 19 AA plasma concentrations were different compared to
      lean non-diabetic individuals, from which 15 were essential AAs, whereas in the
      diabetic group only three AAs differed in the obese compared to the lean
      patients. When comparing the overall AA differences between diabetics and
      non-diabetics, 16 AA concentrations were enhanced and 11 AA concentrations were
      reduced in the diabetic patients. A multivariate linear regression analysis
      revealed correlations between: FBG and Cystathionine, Proline and Citrulline;
      HbA1c and Glycine, Proline and Sarcosine; Cholesterol and Serine, beta-alanine,
      Proline and Cystathionine; HDL-C and beta-alanine, 1-methylhistidine and Proline;
      and LDL-C and alpha-Amino n-butyric acid and Hydroxyproline. Triglycerides were
      related with gamma-aminobutyric acid, Serine and Alanine. Fasting insulin was
      related with 3-methylhistidine, Asparagine, Alanine, gamma-aminobutyric acid and 
      Cystathionine. CONCLUSIONS: The concentrations of 19 plasma AAs differed between 
      non-diabetic obese and lean individuals, which were mostly superimposed by
      diabetes. Between diabetic and non-diabetic participants plasma AA concentration 
      differences were obvious and some of these alterations were correlated to other
      factors like blood glucose, lipids, insulin and hemoglobin status.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Endocrinology, Dahua Hospital, No.901 Old Hu Min Road, Shanghai
      200237, China. Electronic address: shzhouyy@163.com.
FAU - Zhou, Yong
AU  - Zhou Y
FAU - Qiu, Ling
AU  - Qiu L
FAU - Xiao, Qian
AU  - Xiao Q
FAU - Wang, Yi
AU  - Wang Y
FAU - Meng, Xiangying
AU  - Meng X
FAU - Xu, Rong
AU  - Xu R
FAU - Wang, Siyang
AU  - Wang S
FAU - Na, Risu
AU  - Na R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130519
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/03/13 [received]
PHST- 2013/05/04 [revised]
PHST- 2013/05/06 [accepted]
AID - S0009-9120(13)00241-5 [pii]
AID - 10.1016/j.clinbiochem.2013.05.045 [doi]
PST - aheadofprint
SO  - Clin Biochem. 2013 May 19. pii: S0009-9120(13)00241-5. doi:
      10.1016/j.clinbiochem.2013.05.045.

PMID- 23697655
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
DP  - 2013 May 22
TI  - Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor?
AB  - Intensive glucose control is widely practiced in patients with diabetes mellitus 
      and patients acutely admitted to hospitals with concomitant stress-induced
      hyperglycaemia. Such a strategy increases the risk of hypoglycaemia by
      several-fold. Hypoglycaemia leads to a surge in catecholamine levels with a
      profound haemodynamic response. In patients with a decreased cardiac reserve,
      such significant changes can culminate in serious or even fatal cardiovascular
      outcomes. This review is aimed at discussing in depth the evidence to date that
      links hypoglycaemia with cardiovascular mortality, reviewing the likely
      mechanisms underlying this association, as well as summarising these from a
      cardiologist's perspective.
AD  - University of Southampton and Southampton University Hospitals NHS Foundation
      Trust, , Southampton, Hampshire, UK.
FAU - Rana, Omar A
AU  - Rana OA
FAU - Byrne, Christopher D
AU  - Byrne CD
FAU - Greaves, Kim
AU  - Greaves K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
OTO - NOTNLM
OT  - MYOCARDIAL ISCHAEMIA AND INFARCTION (IHD)
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - heartjnl-2013-303871 [pii]
AID - 10.1136/heartjnl-2013-303871 [doi]
PST - aheadofprint
SO  - Heart. 2013 May 22.

PMID- 23697612
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130530
DCOM- 20130531
LR  - 20130531
IS  - 1758-5996 (Electronic)
VI  - 5
IP  - 1
DP  - 2013
TI  - Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment.
PG  - 25
LID - 10.1186/1758-5996-5-25 [doi]
AB  - Type 2 diabetes mellitus (T2DM) has a high prevalence and incidence around the
      world. The complex pathophysiology mechanism is among the barriers for diabetes
      treatment. Type 2 diabetes patients have dysfunction in incretin hormones (as
      glucagon-like peptide-1 or GLP-1, and glucose-dependent insulinotropic
      polypeptide or GIP). By inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, it 
      is possible to slow the inactivation of GLP-1 and GIP, promoting blood glucose
      level reduction in a glucose-dependent manner. Linagliptin is a highly specific
      and potent inhibitor of DPP-4 that is currently indicated for the treatment of
      type 2 diabetes. Clinical studies with linagliptin demonstrated efficacy in
      reducing glycated hemoglobin (HbA1c) levels in type 2 diabetes patients, while
      maintaining a placebo-like safety and tolerability profile. Linagliptin has an
      interesting pharmacokinetic profile in terms of its predominantly non-renal
      elimination and the main implication of this characteristic is that no dose
      adjustment is necessary in patients with renal disease. Also, no dose adjustment 
      is required in patients with hepatic insufficiency, as well in elderly or obese
      patients. This article will review the pharmacokinetic profile, efficacy data and
      safety aspects of linagliptin in type 2 diabetes patients.
AD  - Endocrinologist Board of Metabolism Outpatient Clinic from the 481 State
      Institute for Diabetes and Endocrinology (IEDE/RJ), Rio de Janeiro, RJ, Brazil.
      erikapaniago@uol.com.br.
FAU - Guedes, Erika Paniago
AU  - Guedes EP
FAU - Hohl, Alexandre
AU  - Hohl A
FAU - de Melo, Thais Gomes
AU  - de Melo TG
FAU - Lauand, Felipe
AU  - Lauand F
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC3667107
OID - NLM: PMC3667107
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:01
CRDT- 2013/05/24 06:00
PHST- 2013/02/08 [received]
PHST- 2013/05/13 [accepted]
PHST- 2013/05/22 [aheadofprint]
AID - 1758-5996-5-25 [pii]
AID - 10.1186/1758-5996-5-25 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2013 May 22;5(1):25. doi: 10.1186/1758-5996-5-25.

PMID- 23697589
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1871-403X (Print)
IS  - 1871-403X (Linking)
VI  - 7
IP  - 3
DP  - 2013 May-Jun
TI  - The adipokines and inflammatory marker in young type 2 diabetics with metabolic
      syndrome: A pilot study.
PG  - e206-10
LID - 10.1016/j.orcp.2011.12.002 [doi]
LID - S1871-403X(11)00228-6 [pii]
AB  - Summary: Objective: The purpose of the metabolic syndrome (MetS) concept was to
      early identify subjects having risk for developing cardiovascular diseases and
      diabetes, which of both are involved in low grade inflammation and obesity. We
      wish to explore the role of adipokines and inflammatory marker in young type 2
      diabetics (YDM) with MetS. Methods: Forty-eight YDM patients were divided to 2
      and 3 groups according to the presence of the MetS (MetS+ and MetS-), and the
      numbers of MetS component (MetS-2 to MetS-4 with 1-2, 3, and 4-5 components)
      respectively. Plasma adipokines (tumor necrosis factor-alpha; TNF-alpha and
      adiponectin) and C-reactive protein (CRP) were measured and compared among
      groups. Results: Blood pressure (BP), body mass index (BMI), and plasma
      triglyceride (TG) levels were higher in the group with MetS+ than that of MetS-. 
      Except for diastolic BP, BMI, waist, and plasma TG levels, which were generally
      lower in the MetS-2 group, the rest demographic characteristics were not
      different among these three groups. Finally, the plasma adiponectin, CRP and
      TNF-alphalevels were not different between both groups with or without MetS; and 
      also among these three groups regardless the component numbers they had.
      Conclusion: YDM with MetS might have non-significant lower adiponectin and higher
      CRP levels compared to subjects without MetS. It needs prospective study with
      larger scale to explicit the role of cytokines and inflammatory markers in YDM
      with MetS.
CI  - (c) 2011 Asian Oceanian Association for the Study of Obesity. Published by
      Elsevier Ltd. All rights reserved.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      Tri-Service General Hospital, Taipei, Taiwan, ROC.
FAU - Wen, Min-Jie
AU  - Wen MJ
FAU - Hsieh, Chang-Hsun
AU  - Hsieh CH
FAU - Wu, Chung-Ze
AU  - Wu CZ
FAU - Hsiao, Fone-Ching
AU  - Hsiao FC
FAU - Hsia, Te-Lin
AU  - Hsia TL
FAU - Hung, Yi-Jen
AU  - Hung YJ
FAU - Pei, Dee
AU  - Pei D
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Obes Res Clin Pract
JT  - Obesity research & clinical practice
JID - 101303911
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2011/06/02 [received]
PHST- 2011/11/11 [revised]
PHST- 2011/12/08 [accepted]
AID - S1871-403X(11)00228-6 [pii]
AID - 10.1016/j.orcp.2011.12.002 [doi]
PST - ppublish
SO  - Obes Res Clin Pract. 2013 May-Jun;7(3):e206-10. doi: 10.1016/j.orcp.2011.12.002.

PMID- 23697585
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1871-403X (Print)
IS  - 1871-403X (Linking)
VI  - 7
IP  - 3
DP  - 2013 May-Jun
TI  - Dietary supplementation with long chain omega-3 polyunsaturated fatty acids and
      weight loss in obese adults.
PG  - e173-81
LID - 10.1016/j.orcp.2011.11.001 [doi]
LID - S1871-403X(11)00219-5 [pii]
AB  - Summary: Background: Obesity is associated with elevated levels of inflammation
      and metabolic abnormalities, with increased risk of developing insulin
      resistance, type 2 diabetes, stroke and CVD. Nutrients that can assist in weight 
      loss may also reduce the risk of obesity related co-morbidities. Aim: The aim of 
      this study was to investigate whether LCn-3PUFA, combined with a reduced energy
      diet, facilitated weight loss and improvements in blood lipids and inflammatory
      mediators. Design: A double blind randomised controlled trial with two parallel
      groups. Both groups followed a low energy diet for 12 weeks, one group consumed 6
      x 1 g capsules/d monounsaturated oil (Placebo) (n = 18), the other 6 x 1 g
      capsules/d LCn-3PUFA (fish oil) (n = 17). Fasting blood samples, anthropometric
      measurements and 3-day food diaries were collected at baseline and post
      intervention. Results: There was a two-fold increase in plasma levels of EPA and 
      DHA in the fish oil group (p < 0.001). There were no significant difference
      within and between the placebo and the fish oil groups for weight reduction
      (3.37% and 4.35% respectively), fat mass reduction (8.95% and 9.76%
      respectively), or changes in inflammatory biomarkers and blood lipids apart from 
      triglycerides, reduced by 27% in fish oil group (p < 0.05). For fish oil group
      there were significant correlations between leptin and weight loss (p = 0.01) and
      leptin and EPA and DHA (p < 0.05 for both). Conclusion: Dietary LCn-3PUFA
      supplementation during a weight loss program does not appear to assist weight
      loss. Poor dietary compliance may be a contributing factor in accurate assessment
      of the role of these fatty acids in weight loss.
CI  - Crown Copyright (c) 2011 Published by Elsevier Ltd on behalf of Asian Oceanian
      Association for the Study of Obesity. All rights reserved.
AD  - Nutraceuticals Research Group, School of Biomedical Sciences and Pharmacy, The
      University of Newcastle, Callaghan NSW 2308 Australia.
FAU - Munro, Irene A
AU  - Munro IA
FAU - Garg, Manohar L
AU  - Garg ML
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Obes Res Clin Pract
JT  - Obesity research & clinical practice
JID - 101303911
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2011/04/29 [received]
PHST- 2011/11/09 [accepted]
AID - S1871-403X(11)00219-5 [pii]
AID - 10.1016/j.orcp.2011.11.001 [doi]
PST - ppublish
SO  - Obes Res Clin Pract. 2013 May-Jun;7(3):e173-81. doi: 10.1016/j.orcp.2011.11.001.

PMID- 23697584
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1871-403X (Print)
IS  - 1871-403X (Linking)
VI  - 7
IP  - 3
DP  - 2013 May-Jun
TI  - Natural food science based novel approach toward prevention and treatment of
      obesity and type 2 diabetes: Recent studies on brown rice and gamma-oryzanol.
PG  - e165-72
LID - 10.1016/j.orcp.2013.02.003 [doi]
LID - S1871-403X(13)00025-2 [pii]
AB  - Summary: The prevalences of obesity and type 2 diabetes mellitus are dramatically
      increasing, and there is a strong need for more effective and safer therapies.
      However, some of drugs show limited efficacy and considerable adverse effects.
      Furthermore, artificial energy-dense foods and non-caloric foods may promote
      overeating and weight gain. In this context, a natural food-based approach may
      represent a valuable means of tackling the obesity-diabetes syndrome. Although
      recent studies have shown that brown rice improves glucose intolerance and
      prevents obesity and type 2 diabetes in humans, the underlying molecular
      mechanisms remain unclear. We found that one of the major components of brown
      rice, gamma-oryzanol (Orz), plays an important role in the metabolically
      beneficial effects of brown rice. Orz acts as a chemical chaperone and decreases 
      high fat diet (HFD)-induced endoplasmic reticulum (ER) stress in the
      hypothalamus, thereby leading to a significant shift in preference from fatty to 
      healthy foods. Orz also decreases HFD-induced ER stress in pancreatic beta-cells 
      and improves beta-cell function. Notably, Orz directly acts on pancreatic islets 
      and enhances glucose-stimulated insulin secretion (GSIS). This evidence
      highlights food preference as a promising therapeutic target in obesity-diabetes 
      syndrome and suggests that brown rice and Orz may have potential for the
      treatment of obesity and type 2 diabetes in humans.
CI  - (c) 2013 Asian Oceanian Association for the Study of Obesity. Published by
      Elsevier Ltd. All rights reserved.
AD  - Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology
      (Second Department of Internal Medicine), Graduate School of Medicine, University
      of the Ryukyus, Okinawa, Japan.
FAU - Kozuka, Chisayo
AU  - Kozuka C
FAU - Yabiku, Kouichi
AU  - Yabiku K
FAU - Takayama, Chitoshi
AU  - Takayama C
FAU - Matsushita, Masayuki
AU  - Matsushita M
FAU - Shimabukuro, Michio
AU  - Shimabukuro M
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Obes Res Clin Pract
JT  - Obesity research & clinical practice
JID - 101303911
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/01/16 [received]
PHST- 2013/02/14 [revised]
PHST- 2013/02/25 [accepted]
AID - S1871-403X(13)00025-2 [pii]
AID - 10.1016/j.orcp.2013.02.003 [doi]
PST - ppublish
SO  - Obes Res Clin Pract. 2013 May-Jun;7(3):e165-72. doi: 10.1016/j.orcp.2013.02.003.

PMID- 23697580
OWN - NLM
STAT- Publisher
DA  - 20130523
IS  - 1744-4160 (Electronic)
IS  - 1381-3455 (Linking)
DP  - 2013 May 23
TI  - Incretin hormones and beta-cell mass expansion: what we know and what is missing?
AB  - Abstract Pancreatic beta-cell mass expands through beta-cell proliferation and
      neogenesis while it decreases mainly via apoptosis. The loss of balance between
      beta-cell death and regeneration leads to a reduction of beta-cell functional
      mass, thus contributing to the pathogenesis of type 2 diabetes mellitus (T2DM).
      The pathogenetic mechanisms causing T2DM are complex, and also include a
      significant reduction of the incretin effect. A better understanding of the role 
      of incretin hormones in glucose homeostasis has led to the development of
      incretin-based therapies. Recently, incretin hormones have been shown to
      stimulate the beta-cell growth and differentiation from pancreas-derived
      stem/progenitor cells, as well as to exert cytoprotective, antiapoptotic effects 
      on beta-cells. However, the role and the molecular mechanisms by which GLP-1 and 
      its agonists regulate beta-cell mass have not been fully investigated. This
      review focuses the current findings and the missing understanding of the effects 
      of incretin hormones on beta-cell mass expansion.
AD  - Department of Emergency and Organ Transplantation, Section of Internal Medicine, 
      Endocrinology, Andrology and Metabolic Diseases, University of Bari School of
      Medicine , Bari , Italy and.
FAU - Tortosa, Federica
AU  - Tortosa F
FAU - Dotta, Francesco
AU  - Dotta F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - Arch Physiol Biochem
JT  - Archives of physiology and biochemistry
JID - 9510153
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.3109/13813455.2013.795175 [doi]
PST - aheadofprint
SO  - Arch Physiol Biochem. 2013 May 23.

PMID- 23697477
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1944-706X (Electronic)
IS  - 1083-4087 (Linking)
VI  - 19
IP  - 5
DP  - 2013 Jun
TI  - Reducing cardiovascular medication complexity in a german university hospital:
      effects of a structured pharmaceutical management intervention on adherence.
PG  - 396-407
AB  - BACKGROUND: Patient adherence is necessary for successful medication therapy.
      However, highly complex medication regimens may lead to poor adherence, which
      decreases the effectiveness of treatment and often results in treatment failure, 
      excessive morbidity and mortality, and higher costs. OBJECTIVE: To examine
      whether patient adherence can be increased indirectly through reducing medication
      complexity by (a) pharmaceutical counseling of hospital medical staff and (b)
      additional information in the discharge letter for the primary care provider
      (PCP) about the simplified discharge medication. METHODS: At the Medical Center
      Hamburg-Eppendorf, a tertiary care university hospital in Germany, 240
      chronically ill inpatients with hypertension, diabetes, and/or dyslipidemia were 
      enrolled in this prospective, semirandomized study. For the intervention group,
      hospital doctors were counseled by a clinical pharmacist on feasible
      simplifications of cardiovascular and antidiabetic medications. In 1 randomized
      subgroup, the PCP received additional explanatory information in the discharge
      letter. Adherence (self-reporting using the Medication Adherence Rating Scale
      [MARS-D]) and medication complexity (using the Medication Regimen Complexity
      Index [MRCI-D]) were recorded at admission to the hospital, discharge from the
      hospital, and 6 weeks after discharge. Patient quality of life (QoL) and
      satisfaction with information about medications were assessed at admission and
      after discharge. RESULTS: At discharge, the medication regimen in the
      intervention group was significantly less complex than in the comparison group.
      Yet, 6 weeks after discharge, the complexity of the outpatient medication had
      increased to values similar to the comparison group, unless the PCP received
      additional information in the discharge letter. Propensity adjusted complete
      adherence rates at discharge were slightly, but not significantly, higher in the 
      intervention group than in the comparison group. Within the intervention group,
      complete adherence was more frequent in the subgroup with additional information 
      for the PCP. Patient QoL and satisfaction with information were comparable in
      both groups. CONCLUSION: The complexity of cardiovascular and antidiabetic
      hospital medications can be reduced by counseling the hospital doctors. However, 
      for a sustainable simplification of outpatient medication, the PCPs must receive 
      explicit information about the modifications. Patient adherence was not
      significantly influenced by this intervention. To verify these results, further
      research with objective measures of adherence and in patients with other diseases
      is needed.
AD  - University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg,
      Germany. d.stange@uke3.de.
FAU - Stange, Dorit
AU  - Stange D
FAU - Kriston, Levente
AU  - Kriston L
FAU - von-Wolff, Alessa
AU  - von-Wolff A
FAU - Baehr, Michael
AU  - Baehr M
FAU - Dartsch, Dorothee C
AU  - Dartsch DC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Manag Care Pharm
JT  - Journal of managed care pharmacy : JMCP
JID - 9605854
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 2013(19)5: 396-407 [pii]
PST - ppublish
SO  - J Manag Care Pharm. 2013 Jun;19(5):396-407.

PMID- 23697475
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1944-706X (Electronic)
IS  - 1083-4087 (Linking)
VI  - 19
IP  - 5
DP  - 2013 Jun
TI  - Retrospective database analysis of the impact of prior authorization for type 2
      diabetes medications on health care costs in a medicare advantage prescription
      drug plan population.
PG  - 374-84
AB  - BACKGROUND: Health plans and pharmacy benefit managers have implemented
      utilization management strategies for newer type 2 diabetes mellitus (T2DM)
      medications to control pharmacy expenditures. Little is known about the impact of
      utilization management strategies on overall health care costs and subsequent use
      of T2DM medications among members who request, but do not receive, a T2DM
      medication requiring prior authorization (PA). OBJECTIVE: To examine the
      relationship between the receipt of a T2DM medication requiring PA, health care
      costs, and subsequent treatment for T2DM. METHODS: A retrospective cohort study
      using pharmacy, medical, and laboratory claims data was conducted among Medicare 
      Advantage Prescription Drug plan members with a denied claim for a T2DM
      medication requiring PA (sitagliptin, a dipeptidyl peptidase-4 inhibitor
      [DPP-4i], and exenatide, an incretin mimetic) between January 1, 2008, and June
      30, 2009. Subjects were required to have 12 months of continuous enrollment both 
      before and after the index date. The entire study period was 24 months in
      duration, including a 12-month pre-index and 12-month post-index period. Three
      cohorts were identified: 1 that received a medication requiring PA (denied claim,
      subsequent fill) and 2 nonfilling control groups. Both control groups requested a
      medication requiring PA, as evidenced by the denied claim, but neither received
      the medication, either because the medication was not authorized or the member
      chose not to fill. Claims-based estimates were used to infer whether the
      individual likely met the criteria for PA, with 1 control group designated as
      having met the claims-based criteria (qualifying nonfilling cohort) and the other
      not having done so (nonqualifying nonfilling cohort.) The primary endpoint
      evaluated was the relationship between PA medication fill status and plan-paid
      costs (medical [including laboratory] and pharmacy) over the 12-month post-denial
      period, with generalized linear models adjusting for key covariates including
      demographics, concomitant medications, pre-index costs, pre-index adherence, and 
      comorbidities. The secondary endpoint of T2DM medication use (post-denial) among 
      the 2 nonfilling control groups was also evaluated. RESULTS: There were 1,728
      members identified who received medication for T2DM requiring PA (the received
      authorization cohort) and 2,373 who did not (606 qualifying nonfilling cohort;
      1,767 nonqualifying nonfilling cohort.) Cohorts were similar with regard to age
      and gender, but the nonfilling cohort had more comorbidities. Total unadjusted
      plan-paid 12-month costs were lowest among the received authorization cohort
      ($11,739), slightly higher ($11,980) for the qualifying nonfilling cohort, and
      notably higher for the nonqualifying nonfilling cohort ($12,962), although no
      differences were statistically significant. After adjusting for key covariates,
      the difference between the nonqualifying nonfilling cohort ($11,980) and the
      received authorization cohort ($11,729) was statistically significant (P =
      0.034). Large differences in plan-paid medical costs ($10,127 for the
      nonqualifying nonfilling cohort vs. $8,192 for the received authorization cohort)
      appeared to drive the overall cost totals and were significant in both the
      unadjusted (P = 0.005) and adjusted models (P less than 0.001). Pharmacy costs
      were significantly lower for the nonqualifying nonfilling cohort in the adjusted 
      model and for the qualifying nonfilling cohort in both models (all P less than
      0.001), but the lower pharmacy costs were not offset by the higher medical costs.
      In examining the use of medication for treatment of T2DM following the denied
      claim, 10.6% of the qualifying nonfilling cohort and 13.4% of the nonqualifying
      nonfilling cohort added another oral therapy, 10.2% and 5.8% added insulin, and
      11.9% and 7.1% had treatment intensification, respectively. More than half
      (56.1%) of the qualifying nonfilling cohort, but only 32.1% of the nonqualifying 
      nonfilling cohort, maintained current therapy. CONCLUSIONS: This study found
      higher plan-paid health care costs (overall and medical alone) among members who 
      requested a type 2 diabetes medication requiring PA, but never received it,
      compared with those who qualified for and received the requested medication. A
      notable number of individuals who were assumed to have met the criteria based on 
      a claims-based equivalent, but who never received the medication, made no change 
      to their current therapy. Failure of a member to take medication deemed necessary
      by his or her physician could translate to inadequate control of the diabetic
      condition and result in an excess of resource utilization and costs for treating 
      the disease and associated comorbidities. In light of the present findings,
      health plans should consider not only the impact of utilization management
      strategies on reducing pharmacy costs, but the broader implication for overall
      health care costs and subsequent treatment patterns among members.
AD  - Comprehensive Health Insights, 325 W. Main St. WFP6W, Louisville, KY 40202, USA. 
      kworley@humana.com.
FAU - Bergeson, Joette Gdovin
AU  - Bergeson JG
FAU - Worley, Karen
AU  - Worley K
FAU - Louder, Anthony
AU  - Louder A
FAU - Ward, Melea
AU  - Ward M
FAU - Graham, John
AU  - Graham J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Manag Care Pharm
JT  - Journal of managed care pharmacy : JMCP
JID - 9605854
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 2013(19)5: 374-384 [pii]
PST - ppublish
SO  - J Manag Care Pharm. 2013 Jun;19(5):374-84.

PMID- 23697472
OWN - NLM
STAT- MEDLINE
DA  - 20130530
DCOM- 20130606
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 368
IP  - 22
DP  - 2013 May 30
TI  - Case records of the Massachusetts General Hospital. Case 17-2013. A 56-year-old
      woman with poorly controlled diabetes mellitus and fatigue.
PG  - 2126-36
LID - 10.1056/NEJMcpc1215971 [doi]
AD  - Department of Medicine, Massachusetts General Hospital, Boston, USA.
FAU - Florez, Jose C
AU  - Florez JC
FAU - Shepard, Jo-Anne O
AU  - Shepard JA
FAU - Kradin, Richard L
AU  - Kradin RL
LA  - eng
PT  - Case Reports
PT  - Clinical Conference
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 50-23-7 (Hydrocortisone)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
SB  - AIM
SB  - IM
MH  - Adrenocorticotropic Hormone/*secretion
MH  - Algorithms
MH  - Carcinoid Tumor/complications/*pathology/secretion
MH  - Chest Pain/etiology
MH  - Diabetes Mellitus, Type 2/complications
MH  - Fatigue/etiology
MH  - Female
MH  - Humans
MH  - Hydrocortisone/*urine
MH  - Hyperglycemia/etiology
MH  - Lung Neoplasms/complications/*pathology/secretion
MH  - Middle Aged
MH  - Pituitary ACTH Hypersecretion/*diagnosis/etiology
MH  - Solitary Pulmonary Nodule/complications/*pathology/radiography
EDAT- 2013/05/24 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/05/24 06:00
PHST- 2013/05/22 [aheadofprint]
AID - 10.1056/NEJMcpc1215971 [doi]
PST - ppublish
SO  - N Engl J Med. 2013 May 30;368(22):2126-36. doi: 10.1056/NEJMcpc1215971. Epub 2013
      May 22.

PMID- 23697377
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1520-5118 (Electronic)
IS  - 0021-8561 (Linking)
DP  - 2013 Jun 3
TI  - Inhibition of Human Intestinal alpha-Glucosidases by Calystegines.
AB  - Calystegines are polyhydroxylated nortropane alkaloids found in Convolvulaceae,
      Solanaceae, and other plant families. These plants produce common fruits and
      vegetables. The calystegine structures resemble sugars and suggest interaction
      with enzymes of carbohydrate metabolism. Maltase and sucrase are
      alpha-glucosidases contributing to human carbohydrate degradation in the small
      intestine. Inhibition of these enzymes by orally administered drugs is one option
      for treatment of diabetes mellitus type 2. In this study, inhibition of maltase
      and sucrase by calystegines A3 and B2 purified from potatoes was investigated. In
      silico docking studies confirmed binding of both calystegines to the active sites
      of the enzymes. Calystegine A3 showed low in vitro enzyme inhibition; calystegine
      B2 inhibited mainly sucrose activity. Both compounds were not transported by
      Caco-2 cells indicating low systemic availability. Vegetables rich in calystegine
      B2 should be further investigated as possible components of a diet preventing a
      steep increase in blood glucose after a carbohydrate-rich meal.
AD  - Institute of Pharmacy, Faculty of Sciences I, Martin-Luther-University
      Halle-Wittenberg , Hoher Weg 8, 06120 Halle (Saale), Germany.
FAU - Jockovic, Nebojsa
AU  - Jockovic N
FAU - Fischer, Wiebke
AU  - Fischer W
FAU - Brandsch, Matthias
AU  - Brandsch M
FAU - Brandt, Wolfgang
AU  - Brandt W
FAU - Drager, Birgit
AU  - Drager B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - J Agric Food Chem
JT  - Journal of agricultural and food chemistry
JID - 0374755
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
AID - 10.1021/jf4010737 [doi]
PST - aheadofprint
SO  - J Agric Food Chem. 2013 Jun 3.

PMID- 23697274
OWN - NLM
STAT- In-Process
DA  - 20130523
IS  - 0350-6134 (Print)
IS  - 0350-6134 (Linking)
VI  - 37
IP  - 1
DP  - 2013 Mar
TI  - Prevalence of the metabolic syndrome in the old institutionalized people in
      Zagreb, Croatia.
PG  - 203-6
AB  - Metabolic syndrome (MeS) is defined by a cluster of abnormalities comprising
      obesity, hypertension, carbohydrate intolerance and dyslipidemia. MeS increases
      the risk of developing various diseases, including coronary heart disease,
      stroke, peripheral angiopathy and type 2 diabetes. In our study, the subjects
      were 561 persons, residents of 11 homes for the elderly in Zagreb, Croatia. There
      were 160 men (28.5%) and 401 women (71.5%), aged from 56 to 96 years (the average
      being 79 years). Physical examination was conducted, which included blood
      pressure measurement, and body height and weight. Blood samples were taken for
      biochemical analysis. Along with other biochemical parameters, the levels of
      glucose, triglycerides and cholesterol (LDL, HDL-C) were also measured. The
      results have shown the prevalence of MeS in the elderly instutionalised people to
      be in the range of 20.8%, according to WHO criteria. The most common MeS
      component was hypertension, and it was significantly more frequent in women than 
      in men; also, the elevated triglyceride levels were more often found in women;
      the difference between men and women was also statistically significant. MeS is a
      serious and growing health problem not only in Croatia but worldwide as well.
      Further studies are needed to verify the prevalence of MeS in Croatia, as it is a
      major risk for CVD and many other severe diseases.
AD  - University of Zagreb, Dubrava University Hospital, Department of Neurology,
      Zagreb, Croatia. bnevajda@zvu.hr
FAU - Nevajda, Branimir
AU  - Nevajda B
FAU - Havelka-Mestrovic, Ana
AU  - Havelka-Mestrovic A
FAU - Bilic, Morana
AU  - Bilic M
FAU - Nevajda, Andreja Podvez
AU  - Nevajda AP
FAU - Romic, Dominik
AU  - Romic D
FAU - Vuletic, Vladimira
AU  - Vuletic V
FAU - Cukljek, Snjezana
AU  - Cukljek S
FAU - Sicaja, Mario
AU  - Sicaja M
FAU - Bocina, Zeljko
AU  - Bocina Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Croatia
TA  - Coll Antropol
JT  - Collegium antropologicum
JID - 8003354
SB  - IM
EDAT- 2013/05/24 06:00
MHDA- 2013/05/24 06:00
CRDT- 2013/05/24 06:00
PST - ppublish
SO  - Coll Antropol. 2013 Mar;37(1):203-6.

PMID- 23696946
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 6
IP  - 6
DP  - 2013
TI  - Novel detection of pancreatic and duodenal homeobox 1 autoantibodies (PAA) in
      human sera using luciferase immunoprecipitation systems (LIPS) assay.
PG  - 1202-10
AB  - We have previously identified pancreatic and duodenal homeobox 1 (Pdx1)
      autoantibodies (PAA) in sera from both non-obese diabetic (NOD) mice and human
      type 1 diabetic (T1D) patients. A suitable non-radioactive, sensitive and
      specific assay is needed for large-scale testing to determine the clinical
      utility of PAA. Here we reported a liquid-phase luciferase immunoprecipitation
      system (LIPS) assay by generating a renilla luciferase (Rluc)-Pdx1 fusion protein
      as a sensitive non-radioactive antigen from mammalian cells combined with
      immunoprecipitation to detect PAA in human sera. Sera from healthy donors and the
      University of Florida Pathology Laboratories, Endocrine Autoantibody Laboratory
      were used to validate the LIPS assay for PAA. Antigenic specificity to Pdx1 was
      confirmed by using a Rluc-only control compared to Rluc-Pdx1 fusion antigen and
      by competition assays using purified recombinant Pdx1 protein. We then used the
      LIPS assay to assess the prevalence of triple autoantibodies (GADA, IA-2A, and
      IA-2betaA), and PAA in non-T1D control sera, recent onset (RO)-T1D sera (mean
      duration of T1D = 9.5 weeks), and long standing (LS)-T1D sera. Compared to
      clinical radioimmunoprecipitation assays (RIPA), the LIPS assay showed comparable
      sensitivity and specificity for detection of GADA and IA-2A. PAA were detectable 
      in human serum samples and higher in triple-positive T1D autoantibodies (21% PAA 
      positive in triple positive sera and 4% PAA positive in triple negative sera).
      Interestingly, PAA were found to be highest in the non-T1D population, suggesting
      that PAA might have a clinical utility in screening high-risk population
      susceptible for developing T1D. In conclusion, we have developed a liquid-phase, 
      non-radioactive, sensitive and specific LIPS assay to detect PAA in human sera,
      providing a useful tool for evaluating the clinical relevance of PAA.
AD  - Department of Pathology, Immunology and Laboratory Medicine Gainesville, Florida 
      32610, USA.
FAU - Donelan, William
AU  - Donelan W
FAU - Wang, Hai
AU  - Wang H
FAU - Li, Shi-Wu
AU  - Li SW
FAU - Pittman, David
AU  - Pittman D
FAU - Li, Yi
AU  - Li Y
FAU - Han, Shuhong
AU  - Han S
FAU - Sun, Yu
AU  - Sun Y
FAU - Carter, Christopher
AU  - Carter C
FAU - Atkinson, Mark
AU  - Atkinson M
FAU - Reeves, Westley
AU  - Reeves W
FAU - Winter, William E
AU  - Winter WE
FAU - Yang, Li-Jun
AU  - Yang LJ
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
SB  - IM
PMC - PMC3657381
OID - NLM: PMC3657381
OTO - NOTNLM
OT  - Pancreatic and duodenal homeobox 1 (Pdx1)
OT  - Pdx1 autoantibodies (PAA)
OT  - luciferase immunoprecipitation systems (LIPS) assay
OT  - type I diabetes
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/24 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/05/15 [epublish]
PST - epublish
SO  - Int J Clin Exp Pathol. 2013 May 15;6(6):1202-10. Print 2013.

PMID- 23696845
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Transient and Stable Expression of the Neurotensin Receptor NTS1: A Comparison of
      the Baculovirus-Insect Cell and the T-REx-293 Expression Systems.
PG  - e63679
LID - 10.1371/journal.pone.0063679 [doi]
AB  - Nowadays, baculovirus-infected insect cells and tetracycline-inducible mammalian 
      cell lines (T-REx-293) are intensively used for G protein-coupled receptor (GPCR)
      production for crystallography purposes. Here we constructed a suspension
      T-REx-293 cell line to stably express an engineered neurotensin receptor 1 (NTS1)
      mutant and we quantitatively compared this cell line with the transient
      baculovirus-insect cell system throughout a milligram-scale NTS1 expression and
      purification process. The two systems were comparable with respect to functional 
      NTS1 expression levels and receptor binding affinity for the agonist [(3)H]
      neurotensin. However, NTS1 surface display on T-REx-293 cells determined by
      radio-ligand binding assays was 2.8 fold higher than that on insect cells. This
      work demonstrates two approaches for preparing milligram quantities of purified
      NTS1 suitable for structural studies and provides useful input to users in
      choosing and optimizing an appropriate expression host for other GPCRs.
AD  - Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and
      Kidney Diseases, Bethesda, Maryland, United States of America ; Department of
      Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore,
      Maryland, United States of America.
FAU - Xiao, Su
AU  - Xiao S
FAU - White, Jim F
AU  - White JF
FAU - Betenbaugh, Michael J
AU  - Betenbaugh MJ
FAU - Grisshammer, Reinhard
AU  - Grisshammer R
FAU - Shiloach, Joseph
AU  - Shiloach J
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3656039
OID - NLM: PMC3656039
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/20 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/16 [epublish]
AID - 10.1371/journal.pone.0063679 [doi]
AID - PONE-D-13-03780 [pii]
PST - epublish
SO  - PLoS One. 2013 May 16;8(5):e63679. doi: 10.1371/journal.pone.0063679. Print 2013.

PMID- 23696840
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown
      adipose tissue uncoupling protein levels in mice with diet-induced obesity.
PG  - e63626
LID - 10.1371/journal.pone.0063626 [doi]
AB  - OBJECTIVE: Dipeptidyl peptidase (DPP)-4 is responsible for the degradation of
      several peptides that contain an alanine or proline at the penultimate position
      or position P1. DPP-4 inhibitors (DPP-4is) have protective effects against type-2
      diabetes and several metabolic disorders. METHODS: In the present study, we
      examined the effects of des-fluoro-sitagliptin (DFS), a DDP-4i, on body adiposity
      and levels of peroxisome proliferator-activated receptor (PPAR)-alpha, PPAR-gamma
      coactivator-1 (PGC-1), and uncoupling proteins (UCPs) in mice with diet-induced
      obesity. RESULTS: Treatment with DFS dose-dependently decreased the weight of
      white adipose tissue and serum levels of glucose, compared with controls, without
      influencing food intake (P<0.05). Additionally, DFS treatment increased the
      levels of PPAR-alpha, PGC-1, and UCPs in brown adipose tissue (BAT), and of
      PPAR-alpha and UCP3 in skeletal muscle (P<0.05). Furthermore, the effects on BAT 
      PGC-1 and muscle PPAR-alpha levels were attenuated by treatment with the
      glucagon-like peptide 1 (GLP-1) antagonist exendin (9-39). Interestingly,
      hypothalamic levels of proopiomelanocortin (POMC) were increased by DFS treatment
      and the effects of DFS on PPAR-alpha, PGC-1, and UCP levels were attenuated in
      melanocortin (MC)-4 receptor-deficient mice. CONCLUSIONS: In conclusion,
      high-dose DFS appeared to regulate body adiposity and UCPs in mice with
      diet-induced obesity, at least partly through a GLP-1 and/or MC-4 pathway.
AD  - Department of Internal Medicine 1, Faculty of Medicine, Oita University, Yufu,
      Japan.
FAU - Shimasaki, Takanobu
AU  - Shimasaki T
FAU - Masaki, Takayuki
AU  - Masaki T
FAU - Mitsutomi, Kimihiko
AU  - Mitsutomi K
FAU - Ueno, Daisuke
AU  - Ueno D
FAU - Gotoh, Koro
AU  - Gotoh K
FAU - Chiba, Seiichi
AU  - Chiba S
FAU - Kakuma, Tetsuya
AU  - Kakuma T
FAU - Yoshimatsu, Hironobu
AU  - Yoshimatsu H
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3656085
OID - NLM: PMC3656085
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/30 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/05/16 [epublish]
AID - 10.1371/journal.pone.0063626 [doi]
AID - PONE-D-12-37801 [pii]
PST - epublish
SO  - PLoS One. 2013 May 16;8(5):e63626. doi: 10.1371/journal.pone.0063626. Print 2013.

PMID- 23696784
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - The Association between Dietary Energy Density and Type 2 Diabetes in Europe:
      Results from the EPIC-InterAct Study.
PG  - e59947
LID - 10.1371/journal.pone.0059947 [doi]
AB  - BACKGROUND: Observational studies implicate higher dietary energy density (DED)
      as a potential risk factor for weight gain and obesity. It has been hypothesized 
      that DED may also be associated with risk of type 2 diabetes (T2D), but limited
      evidence exists. Therefore, we investigated the association between DED and risk 
      of T2D in a large prospective study with heterogeneity of dietary intake.
      METHODOLOGYPRINCIPAL FINDINGS: A case-cohort study was nested within the European
      Prospective Investigation into Cancer (EPIC) study of 340,234 participants
      contributing 3.99 million person years of follow-up, identifying 12,403 incident 
      diabetes cases and a random subcohort of 16,835 individuals from 8 European
      countries. DED was calculated as energy (kcal) from foods (except beverages)
      divided by the weight (gram) of foods estimated from dietary questionnaires.
      Prentice-weighted Cox proportional hazard regression models were fitted by
      country. Risk estimates were pooled by random effects meta-analysis and
      heterogeneity was evaluated. Estimated mean (sd) DED was 1.5 (0.3) kcal/g among
      cases and subcohort members, varying across countries (range 1.4-1.7 kcal/g).
      After adjustment for age, sex, smoking, physical activity, alcohol intake, energy
      intake from beverages and misreporting of dietary intake, no association was
      observed between DED and T2D (HR 1.02 (95% CI: 0.93-1.13), which was consistent
      across countries (I (2) = 2.9%). CONCLUSIONSSIGNIFICANCE: In this large European 
      case-cohort study no association between DED of solid and semi-solid foods and
      risk of T2D was observed. However, despite the fact that there currently is no
      conclusive evidence for an association between DED and T2DM risk, choosing low
      energy dense foods should be promoted as they support current WHO recommendations
      to prevent chronic diseases.
CN  - InterAct Consortium
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3655954
OID - NLM: PMC3655954
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/17 [received]
PHST- 2013/02/20 [accepted]
PHST- 2013/05/16 [epublish]
AID - 10.1371/journal.pone.0059947 [doi]
AID - PONE-D-12-32480 [pii]
PST - epublish
SO  - PLoS One. 2013 May 16;8(5):e59947. doi: 10.1371/journal.pone.0059947. Print 2013.

PMID- 23696780
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Correction: Genetic Variant Is Associated with Risk of Cardiovascular Disease -
      Assessing the Individual and Cumulative Effect of 46 Type 2 Diabetes Related
      Genetic Variants.
LID - 10.1371/annotation/77e1d9b0-2b94-4a1b-95d5-4336258cecef [doi]
AB  - [This corrects the article on p. e50418 in vol. 7.].
FAU - Borglykke, Anders
AU  - Borglykke A
FAU - Grarup, Niels
AU  - Grarup N
FAU - Sparso, Thomas
AU  - Sparso T
FAU - Linneberg, Allan
AU  - Linneberg A
FAU - Fenger, Mogens
AU  - Fenger M
FAU - Jeppesen, Jorgen
AU  - Jeppesen J
FAU - Hansen, Torben
AU  - Hansen T
FAU - Pedersen, Oluf
AU  - Pedersen O
FAU - Jorgensen, Torben
AU  - Jorgensen T
LA  - ENG
PT  - PUBLISHED ERRATUM
DEP - 20130515
TA  - PLoS One
JT  - PloS one
JID - 101285081
PMC - PMC3656163
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/15 [epublish]
AID - 10.1371/annotation/77e1d9b0-2b94-4a1b-95d5-4336258cecef [doi]
PST - epublish
SO  - PLoS One. 2013 May 15;8(5). doi:
      10.1371/annotation/77e1d9b0-2b94-4a1b-95d5-4336258cecef. Print 2013.

PMID- 23696724
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1553-7358 (Electronic)
IS  - 1553-734X (Linking)
VI  - 9
IP  - 5
DP  - 2013 May
TI  - Interface-resolved network of protein-protein interactions.
PG  - e1003065
LID - 10.1371/journal.pcbi.1003065 [doi]
AB  - We define an interface-interaction network (IIN) to capture the specificity and
      competition between protein-protein interactions (PPI). This new type of network 
      represents interactions between individual interfaces used in functional protein 
      binding and thereby contains the detail necessary to describe the competition and
      cooperation between any pair of binding partners. Here we establish a general
      framework for the construction of IINs that merges computational structure-based 
      interface assignment with careful curation of available literature. To complement
      limited structural data, the inclusion of biochemical data is critical for
      achieving the accuracy and completeness necessary to analyze the specificity and 
      competition between the protein interactions. Firstly, this procedure provides a 
      means to clarify the information content of existing data on purported protein
      interactions and to remove indirect and spurious interactions. Secondly, the IIN 
      we have constructed here for proteins involved in clathrin-mediated endocytosis
      (CME) exhibits distinctive topological properties. In contrast to PPI networks
      with their global and relatively dense connectivity, the fragmentation of the IIN
      into distinctive network modules suggests that different functional pressures act
      on the evolution of its topology. Large modules in the IIN are formed by
      interfaces sharing specificity for certain domain types, such as SH3 domains
      distributed across different proteins. The shared and distinct specificity of an 
      interface is necessary for effective negative and positive design of highly
      selective binding targets. Lastly, the organization of detailed structural data
      in a network format allows one to identify pathways of specific binding
      interactions and thereby predict effects of mutations at specific surfaces on a
      protein and of specific binding inhibitors, as we explore in several examples.
      Overall, the endocytosis IIN is remarkably complex and rich in features masked in
      the coarser PPI, and collects relevant detail of protein association in a readily
      interpretable format.
AD  - Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and 
      Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States
      of America.
FAU - Johnson, Margaret E
AU  - Johnson ME
FAU - Hummer, Gerhard
AU  - Hummer G
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - United States
TA  - PLoS Comput Biol
JT  - PLoS computational biology
JID - 101238922
SB  - IM
PMC - PMC3656101
OID - NLM: PMC3656101
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05 [ppublish]
PHST- 2012/12/14 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/05/16 [epublish]
AID - 10.1371/journal.pcbi.1003065 [doi]
AID - PCOMPBIOL-D-12-01964 [pii]
PST - ppublish
SO  - PLoS Comput Biol. 2013 May;9(5):e1003065. doi: 10.1371/journal.pcbi.1003065. Epub
      2013 May 16.

PMID- 23696712
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130522
DCOM- 20130523
LR  - 20130527
IS  - 1178-7015 (Electronic)
IS  - 1178-7015 (Linking)
VI  - 6
DP  - 2013
TI  - The skin landscape in diabetes mellitus. Focus on dermocosmetic management.
PG  - 127-35
LID - 10.2147/CCID.S43141 [doi]
AB  - BACKGROUND: Some relationships are established between diabetes mellitus (DM) and
      a series of cutaneous disorders. Specific dermatoses are markers for undiagnosed 
      DM. Other disorders represent supervening complications in an already treated DM 
      patient. OBJECTIVE: To review the information about dermocosmetic care products
      and their appropriate use in the management and prevention of dermatoses related 
      to DM. METHOD: The peer-reviewed literature and empiric findings are covered.
      Owing to the limited clinical evidence available for the use of dermocosmetics, a
      review of the routine practices and common therapies in DM-related dermatoses was
      conducted. RESULTS: Some DM-related dermatoses (acanthosis nigricans, pigmented
      purpuric dermatosis) are markers of macrovascular complications. The same
      disorders and some others (xerosis, Dupuytren's disease) have been found to be
      more frequently associated with microangiopathy. Other skin diseases (alopecia
      areata, vitiligo) were found to be markers of autoimmunity, particularly in type 
      1 DM. Unsurprisingly, using dermocosmetics and appropriate skin care has shown
      objective improvements of some DM-related dermatoses, such effects improve the
      quality of life. The most common skin manifestations of DM fall along continuum
      between "dry skin," xerosis, and acquired ichthyosis, occurring predominately on 
      the shins and feet. Dermocosmetic products improve the feeling of well-being for 
      DM patients.
AD  - Laboratory of Skin Bioengineering and Imaging (LABIC), University of Liege,
      Liege, Belgium.
FAU - Pierard, Gerald E
AU  - Pierard GE
FAU - Seite, Sophie
AU  - Seite S
FAU - Hermanns-Le, Trinh
AU  - Hermanns-Le T
FAU - Delvenne, Philippe
AU  - Delvenne P
FAU - Scheen, Andre
AU  - Scheen A
FAU - Pierard-Franchimont, Claudine
AU  - Pierard-Franchimont C
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - New Zealand
TA  - Clin Cosmet Investig Dermatol
JT  - Clinical, cosmetic and investigational dermatology
JID - 101543449
PMC - PMC3658433
OID - NLM: PMC3658433
OTO - NOTNLM
OT  - dermocosmetics
OT  - diabetes mellitus
OT  - diabetic xerosis
OT  - skin
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:01
CRDT- 2013/05/23 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/15 [epublish]
AID - 10.2147/CCID.S43141 [doi]
AID - ccid-6-127 [pii]
PST - epublish
SO  - Clin Cosmet Investig Dermatol. 2013 May 15;6:127-35. doi: 10.2147/CCID.S43141.
      Print 2013.

PMID- 23696709
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130522
DCOM- 20130523
LR  - 20130527
IS  - 1178-6981 (Electronic)
IS  - 1178-6981 (Linking)
VI  - 5
DP  - 2013
TI  - Glycemic control and diabetes-related health care costs in type 2 diabetes;
      retrospective analysis based on clinical and administrative databases.
PG  - 193-201
LID - 10.2147/CEOR.S41846 [doi]
AB  - BACKGROUND: Diabetes is one of the most prevalent chronic diseases, and its
      prevalence is predicted to increase in the next two decades. Diabetes imposes a
      staggering financial burden on the health care system, so information about the
      costs and experiences of collecting and reporting quality measures of data is
      vital for practices deciding whether to adopt quality improvements or monitor
      existing initiatives. The aim of this study was to quantify the association
      between health care costs and level of glycemic control in patients with type 2
      diabetes using clinical and administrative databases. METHODS: A retrospective
      analysis using a large administrative database and a clinical registry containing
      laboratory results was performed. Patients were subdivided according to their
      glycated hemoglobin level. Multivariate analyses were used to control for
      differences in potential confounding factors, including age, gender, Charlson
      comorbidity index, presence of dyslipidemia, hypertension, or cardiovascular
      disease, and degree of adherence with antidiabetic drugs among the study groups. 
      RESULTS: Of the total population of 700,000 subjects, 31,022 were identified as
      being diabetic (4.4% of the entire population). Of these, 21,586 met the study
      inclusion criteria. In total, 31.5% of patients had very poor glycemic control
      and 25.7% had excellent control. Over 2 years, the mean diabetes-related cost per
      person was: euro1291.56 in patients with excellent control; euro1545.99 in those 
      with good control; euro1584.07 in those with fair control; euro1839.42 in those
      with poor control; and euro1894.80 in those with very poor control. After
      adjustment, compared with the group having excellent control, the estimated
      excess cost per person associated with the groups with good control, fair
      control, poor control, and very poor control was euro219.28, euro264.65,
      euro513.18, and euro564.79, respectively. CONCLUSION: Many patients showed
      suboptimal glycemic control. Lower levels of glycated hemoglobin were associated 
      with lower diabetes-related health care costs. Integration of administrative
      databases and a laboratory database appears to be suitable for showing that
      appropriate management of diabetes can help to achieve better resource
      allocation.
AD  - CliCon Srl, Health, Economics and Outcomes Research, Ravenna, Italy.
FAU - Degli Esposti, Luca
AU  - Degli Esposti L
FAU - Saragoni, Stefania
AU  - Saragoni S
FAU - Buda, Stefano
AU  - Buda S
FAU - Sturani, Alessandra
AU  - Sturani A
FAU - Degli Esposti, Ezio
AU  - Degli Esposti E
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - New Zealand
TA  - Clinicoecon Outcomes Res
JT  - ClinicoEconomics and outcomes research : CEOR
JID - 101560564
PMC - PMC3658432
OID - NLM: PMC3658432
OTO - NOTNLM
OT  - HbA1c
OT  - diabetes mellitus
OT  - glycemic control
OT  - health expenditure
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:01
CRDT- 2013/05/23 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/14 [epublish]
AID - 10.2147/CEOR.S41846 [doi]
AID - ceor-5-193 [pii]
PST - epublish
SO  - Clinicoecon Outcomes Res. 2013 May 14;5:193-201. doi: 10.2147/CEOR.S41846. Print 
      2013.

PMID- 23696677
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1460-2393 (Electronic)
IS  - 1460-2393 (Linking)
DP  - 2013 Jun 6
TI  - Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National 
      Diabetes Audit.
AB  - BACKGROUND: Obesity is increasingly prevalent in many countries. Obesity is a
      major risk factor for the development of type 2 diabetes but its relationship
      with diabetic kidney disease (DKD) remains unclear. Some studies have suggested
      that the metabolic syndrome (including obesity) may be associated with DKD in
      type 1 diabetes. AIM: To investigate the association between obesity and DKD.
      DESIGN: Retrospective cross-sectional study. METHODS: National Diabetes Audit
      data were available for the 2007-08 cycle. Type 1 and 2 diabetes patients with
      both a valid serum creatinine and urinary albumin:creatinine ratio were included.
      DKD was defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73
      m2, albuminuria or both. Logistic regression was used to analyse associations of 
      obesity (body mass index >/=30 kg/m2) and other variables including year of
      birth, year of diagnosis, ethnicity and stage of kidney disease. RESULTS: A total
      of 58 791 type 1 and 733 769 type 2 diabetes patients were included in the
      analysis. After adjustment, when compared with type 1 diabetes patients with
      normal renal function those with DKD were up to twice as likely to be obese. Type
      2 DKD patients were also more likely to be obese. For example, type 2 diabetes
      patients with an eGFR <15 ml/min/1.73 m2 and normoalbuminuria, microalbuminuria
      or macroalbuminuria were all more likely to be obese; odds ratios (95% CI) 1.65
      (1.3-2.1), 1.56 (1.28-1.92) and 1.27 (1.05-1.54), respectively. CONCLUSION: This 
      study has highlighted a strong association between obesity and kidney disease in 
      type 1 diabetes and confirmed their association in type 2 diabetes.
AD  - From the Centre for Public Health, Royal Victoria Hospital, Belfast, UK, Regional
      Nephrology Unit, Belfast City Hospital, Belfast, UK, National Diabetes Audit and 
      National Diabetes Information Service, Salford Royal Foundation NHS Trust, Stott 
      Lane, Salford, M6 8HD, UK, NHS Kidney Care, New Croft House, Market Street,
      Newcastle-upon-Tyne, NE1 6ND, UK and Department of Health, 404 Wellington House, 
      133-155 Waterloo Road, London, SE1 8UG, UK.
FAU - Hill, C J
AU  - Hill CJ
FAU - Cardwell, C R
AU  - Cardwell CR
FAU - Maxwell, A P
AU  - Maxwell AP
FAU - Young, R J
AU  - Young RJ
FAU - Matthews, B
AU  - Matthews B
FAU - O'Donoghue, D J
AU  - O'Donoghue DJ
FAU - Fogarty, D G
AU  - Fogarty DG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/20 [aheadofprint]
AID - hct123 [pii]
AID - 10.1093/qjmed/hct123 [doi]
PST - aheadofprint
SO  - QJM. 2013 Jun 6.

PMID- 23696663
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 110
IP  - 22
DP  - 2013 May 28
TI  - Brief demethylation step allows the conversion of adult human skin fibroblasts
      into insulin-secreting cells.
PG  - 8948-53
LID - 10.1073/pnas.1220637110 [doi]
AB  - The differentiated state of mature cells of adult organisms is achieved and
      maintained through the epigenetic regulation of gene expression, which consists
      of several mechanisms including DNA methylation. The advent of induced
      pluripotent stem cell technology enabled the conversion of adult cells into any
      other cell type passing through a stable pluripotency state. However, indefinite 
      pluripotency is unphysiological, inherently labile, and makes cells prone to
      culture-induced alterations. The direct conversion of one cell type to another
      without an intermediate pluripotent stage is also possible but, at present,
      requires the viral transfection of appropriate transcription factors, limiting
      its therapeutic potential. The aim of this study was to investigate whether it is
      possible to achieve the direct conversion of an adult cell by exposing it to a
      demethylating agent immediately followed by differentiating culture conditions.
      Adult human skin fibroblasts were exposed for 18 h to the DNA methyltransferase
      inhibitor 5-azacytidine, followed by a three-step protocol for the induction of
      endocrine pancreatic differentiation that lasted 36 d. At the end of this
      treatment, 35 +/- 8.9% fibroblasts became pancreatic converted cells that
      acquired an epithelial morphology, produced insulin, and then released the
      hormone in response to a physiological glucose challenge in vitro. Furthermore,
      pancreatic converted cells were able to protect recipient mice against
      streptozotocin-induced diabetes, restoring a physiological response to glucose
      tolerance tests. This work shows that it is possible to convert adult fibroblasts
      into insulin-secreting cells, avoiding both a stable pluripotent stage and any
      transgenic modification.
AD  - Laboratory of Biomedical Embryology, UniStem, Center for Stem Cell Research,
      Department of Clinical and Community Sciences, and Istituto di Ricerca e Cura a
      Carattere Scientifico Maggiore Hospital, Mangiagalli and Regina Elena Foundation,
      Universita degli Studi di Milano, Italy.
FAU - Pennarossa, Georgia
AU  - Pennarossa G
FAU - Maffei, Sara
AU  - Maffei S
FAU - Campagnol, Marino
AU  - Campagnol M
FAU - Tarantini, Letizia
AU  - Tarantini L
FAU - Gandolfi, Fulvio
AU  - Gandolfi F
FAU - Brevini, Tiziana A L
AU  - Brevini TA
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
OTO - NOTNLM
OT  - cell plasticity
OT  - pancreatic beta cell
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/21 [aheadofprint]
AID - 1220637110 [pii]
AID - 10.1073/pnas.1220637110 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2013 May 28;110(22):8948-53. doi:
      10.1073/pnas.1220637110. Epub 2013 May 21.

PMID- 23696565
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 21
TI  - Inducible Brown Adipose Tissue, or Beige Fat, Is Anabolic for the Skeleton.
AB  - It is known that insulin resistance and type 2 diabetes mellitus are associated
      with increased fractures and that brown adipose tissue (BAT) counteracts many if 
      not all of the symptoms associated with type 2 diabetes. By the use of
      FoxC2AD+/Tg mice, a well-established model for induction of BAT, or beige fat, we
      present data extending the beneficial action of beige fat to also include a
      positive effect on bone. FoxC2AD+/Tg mice are lean and insulin-sensitive and have
      high bone mass due to increased bone formation associated with high bone
      turnover. Inducible BAT is linked to activation of endosteal osteoblasts whereas 
      osteocytes have decreased expression of the SOST transcript encoding sclerostin
      and elevated expression of RANKL. Conditioned media (CM) collected from
      FoxC2-induced beige adipocytes activated the osteoblast phenotype and increased
      levels of phospho-Akt and beta-catenin in recipient cells. In osteocytes, the
      same media decreased SOST expression. Immunodepletion of CM with antibodies
      against Wnt10b and IGFBP2 resulted in the loss of pro-osteoblastic activity, and 
      the loss of increase in the levels of phospho-Akt and beta-catenin. Conversely,
      CM derived from cells overexpressing IGFBP2 or Wnt10b restores osteoblastic
      activity in recipient cells. In conclusion, beige fat secretes
      endocrine/paracrine activity that is beneficial for the skeleton.
AD  - Departments of Orthopaedic Surgery (S.R., Y.L., P.J.C., B.L.-C.) and Department
      of Physiology and Pharmacology (B.L.-C.) and Center for Diabetes and Endocrine
      Research (S.R., B.L.-C.), University of Toledo Health Sciences Campus, Toledo,
      Ohio 43614; Maine Medical Center Research Institute (C.J.R.), Scarborough, Maine;
      and Department of Medical and Clinical Genetics (S.E.), Institute of Biomedicine,
      The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Rahman, Sima
AU  - Rahman S
FAU - Lu, Yalin
AU  - Lu Y
FAU - Czernik, Piotr J
AU  - Czernik PJ
FAU - Rosen, Clifford J
AU  - Rosen CJ
FAU - Enerback, Sven
AU  - Enerback S
FAU - Lecka-Czernik, Beata
AU  - Lecka-Czernik B
LA  - ENG
GR  - R01 AR061164/AR/NIAMS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - en.2012-2162 [pii]
AID - 10.1210/en.2012-2162 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 21.

PMID- 23696563
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 21
TI  - Endogenous Somatostatin Is Critical in Regulating the Acute Effects of l-Arginine
      on Growth Hormone and Insulin Release in Mice.
AB  - l-arginine (l-Arg) rapidly stimulates GH and insulin release in vivo. It has been
      hypothesized that l-Arg stimulates GH release by lowering hypothalamic
      somatostatin (SST) tone. l-Arg may also act directly at the pituitary to
      stimulate GH release. Moreover, l-Arg has a direct stimulatory effect on
      beta-cells, which is thought to be blunted by the release of SST from pancreatic 
      delta-cells. To confirm the role of endogenous SST on l-Arg-induced GH and
      insulin release, wild-type (WT) and SST-knockout (SST-KO) mice were injected with
      l-Arg (ip; 0.8 g/kg), and pre-/post-injection GH, insulin, and glucose levels
      were measured. In WT mice, l-Arg evoked a 6-fold increase in circulating GH.
      However, there was only a modest increase in GH levels in WT pituitary cell
      cultures treated with l-Arg. In contrast, l-Arg failed to increase GH in SST-KO
      beyond their already elevated levels. These results further support the
      hypothesis that the primary mechanism by which l-Arg acutely increases GH in vivo
      is by lowering hypothalamic SST input to the pituitary and not via direct
      pituitary effects. Additionally, l-Arg induced a clear first-phase insulin
      secretion in WT mice, but not in SST-KO. However, SST-KO, but not WT mice,
      displayed a robust and sustained second-phase insulin release. These results
      further support a role for endogenous SST in regulating l-Arg-mediated insulin
      release.
AD  - Department of Cell Biology, Physiology, and Immunology (J.C.-C., M.D.G.,
      A.I.P.-S., J.P.C., R.M.L.), University of Cordoba, Instituto Maimonides de
      Investigacion Biomedica de Cordoba (IMIBIC), Reina Sofia University Hospital, and
      Centro de Investigacion Biomedica en Red de la Fisiopatologia de la Obesidad y
      Nutricion (CIBERobn), Cordoba 14014, Spain; Research and Development Division
      (J.C.-C., R.D.K.), Jesse Brown Veterans Affairs Medical Center, Chicago,
      Illinois; and Section of Endocrinology, Diabetes and Metabolism (J.C.-C.,
      R.D.K.), Department of Medicine, University of Illinois at Chicago, Chicago,
      Illinois 60612.
FAU - Cordoba-Chacon, Jose
AU  - Cordoba-Chacon J
FAU - Gahete, Manuel D
AU  - Gahete MD
FAU - Pozo-Salas, Ana I
AU  - Pozo-Salas AI
FAU - Castano, Justo P
AU  - Castano JP
FAU - Kineman, Rhonda D
AU  - Kineman RD
FAU - Luque, Raul M
AU  - Luque RM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - en.2013-1136 [pii]
AID - 10.1210/en.2013-1136 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 21.

PMID- 23696562
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 21
TI  - Cardiac-specific Overexpression of CYP2J2 Attenuates Diabetic cardiomyopathy in
      Male Streptozotocin-induced Diabetic Mice.
AB  - Cytochrome P450 epoxygenases metabolize arachidonic acid to biologically active
      cis-epoxyeicosatrienoic acids which have potent vasodilatory, anti-inflammatory, 
      anti-apoptotic and anti-diabetes properties. Here we showed the effects of
      cardiac-specific overexpression of CYP2J2 on diabetic cardiomyopathy and insulin 
      resistance in high fat diet fed, low dose streptozotocin-treated mice. Diabetic
      cardiomyopathy was induced by high fat and streptozotocin in cardiac-specific
      CYP2J2 transgenic mice. Physiological parameters and systemic metabolic
      parameters were monitored using ELISA kits. Intraperitoneal injection glucose
      tolerance test and hyperinsulinemic-euglycemic clamp study were implied to
      indicate insulin resistance. Cardiac function was assessed by echocardiography
      and Millar Catheter System. Real-time PCR and western blot were used in signal
      pathway detection. alphaMHC-CYP2J2 transgenic mice showed significantly lower
      plasma glucose and insulin levels, improved glucose tolerance and increased
      cardiac glucose uptake. Furthermore, alphaMHC-CYP2J2 transgenic mice were
      significantly protected from high fat-streptozotocin-induced diabetic
      cardiomyopathy. Strikingly, CYP2J2 overexpression attenuated myocardial
      hypertrophy induced by diabetes. We conclude that cardiac-specific overexpression
      of CYP2J2 significantly protects against diabetic cardiomyopathy, which may be
      due to improved cardiac insulin resistance, glucose uptake and reversal of
      cardiac hypertrophy. Relevant mechanisms may include upregulation of PPARgamma,
      activation of insulin receptor and AMPK signaling pathways, as well as inhibition
      of NFATc3 signal by enhanced ANP production. These results suggest that CYP2J2
      epoxygenase metabolites likely play an important role in plasma glucose
      homeostasis and enhancement of epoxyeicosatrienoic acids activation may serve as 
      an effective therapeutic strategy to prevent diabetic cardiomyopathy.
AD  - 1The Institute of Hypertension and Department of Internal Medicine, Tongji
      Hospital, Tongji Medical College, Huazhong University of Science and Technology.
FAU - Ma, Ben
AU  - Ma B
FAU - Xiong, Xiaojv
AU  - Xiong X
FAU - Chen, Chen
AU  - Chen C
FAU - Li, Huaping
AU  - Li H
FAU - Xu, Xizhen
AU  - Xu X
FAU - Li, Xuguang
AU  - Li X
FAU - Li, Rui
AU  - Li R
FAU - Chen, Guangzhi
AU  - Chen G
FAU - Dackor, Ryan T
AU  - Dackor RT
FAU - Zeldin, Darryl C
AU  - Zeldin DC
FAU - Wang, Dao Wen
AU  - Wang DW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - en.2012-2166 [pii]
AID - 10.1210/en.2012-2166 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 21.

PMID- 23696553
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
DP  - 2013 May 21
TI  - Outflow graft abrasion due to bend relief detachment in a HeartMate II device.
AD  - Department of Cardiothoracic Surgery, Heart and Diabetes Center North
      Rhine-Westphalia, Bad Oeynhausen, Germany.
FAU - Furukawa, Nobuyuki
AU  - Furukawa N
FAU - Morshuis, Michiel
AU  - Morshuis M
FAU - Gummert, Jan Fritz
AU  - Gummert JF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European
      Association for Cardio-thoracic Surgery
JID - 8804069
OTO - NOTNLM
OT  - Cardiomyopathy
OT  - Device failure
OT  - Left ventricular assist device
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - ezt274 [pii]
AID - 10.1093/ejcts/ezt274 [doi]
PST - aheadofprint
SO  - Eur J Cardiothorac Surg. 2013 May 21.

PMID- 23696491
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Linking)
DP  - 2013 May 20
TI  - Hepatocellular cancer risk in diabetes: Not all diabetics are the same.
LID - 10.1002/hep.26452 [doi]
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine,
      Mayo Clinic, Rochester. singh.siddharth2@mayo.edu.
FAU - Singh, Siddharth
AU  - Singh S
FAU - Singh, Preet Paul
AU  - Singh PP
LA  - ENG
PT  - LETTER
DEP - 20130520
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/02/20 [received]
PHST- 2013/03/04 [accepted]
AID - 10.1002/hep.26452 [doi]
PST - aheadofprint
SO  - Hepatology. 2013 May 20. doi: 10.1002/hep.26452.

PMID- 23696480
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
DP  - 2013 May 21
TI  - The Increase in Thyroid Cancer Incidence is not only due to Papillary
      Microcarcinomas: a 40-year Study in 1 778 Patients.
AB  - Thyroid cancer incidence has been increased over the last decades. The aims of
      the present study were: (a) to identify a changing trend in thyroid cancer in
      Northern Greece, (b) to examine patients' and tumoral characteristics and (c) to 
      investigate the increase of papillary microcarcinomas and that of invasive or
      larger cancers.We retrospectively analyzed the records of 1 778 patients who were
      diagnosed with thyroid cancer between January 1971 and December 2010. The study
      period was divided into 4 decades: 1971-1980, 1981-1990, 1991-2000, 2001-2010.
      Patients were separated into 2 groups: in Group A we have included papillary
      thyroid microcarcinomas (PTM) and in Group B all cancers with diameter >10 mm as 
      well as invasive cancers </=10 mm.Patients diagnosed with thyroid cancer
      increased substantially per decade. The relative frequency of papillary thyroid
      cancer cases increased (from 60% up to 84.6% in the last decade) and follicular
      cancers decreased (from 40% down to 11.6%). During the study period, cancer size 
      declined. Frequency of PTM (Group A) increased from 0% up to 19.3% in the last
      decade, but cancers of this group represent only a minority of total cancers.The 
      increase of thyroid cancer in this cohort was mainly due to tumors larger than 1 
      cm and also to smaller in size but invasive thyroid tumors. This increase
      outnumbers the increase in papillary thyroid microcarcinomas.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Department of Endocrinology & Endocrine Oncology, Theagenio Cancer Hospital,
      Thessaloniki, Greece.
FAU - Pazaitou-Panayiotou, K
AU  - Pazaitou-Panayiotou K
FAU - Iliadou, P Kappa
AU  - Iliadou PK
FAU - Chrisoulidou, A
AU  - Chrisoulidou A
FAU - Mitsakis, P
AU  - Mitsakis P
FAU - Doumala, E
AU  - Doumala E
FAU - Fotareli, A
AU  - Fotareli A
FAU - Boudina, M
AU  - Boudina M
FAU - Mathiopoulou, L
AU  - Mathiopoulou L
FAU - Patakiouta, F
AU  - Patakiouta F
FAU - Tziomalos, K
AU  - Tziomalos K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/21 [epublish]
AID - 10.1055/s-0033-1345125 [doi]
PST - aheadofprint
SO  - Exp Clin Endocrinol Diabetes. 2013 May 21.

PMID- 23696479
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
DP  - 2013 May 21
TI  - Performance of Abdominal Bioelectrical Impedance Analysis and Comparison with
      Other Known Parameters in Predicting the Metabolic Syndrome.
AB  - Although obesity is a powerful risk factor for metabolic syndrome (MetS) it is
      not present in all obese individuals. Increased visceral adipose tissue is the
      hallmark of this syndrome. In this cross sectional survey we aimed to use
      abdominal bioelectrical impedance analysis to measure the visceral adipose tissue
      (VAT) and trunk fat percentages (TF%) in the study population, correlate these
      findings with traditional anthropometric measures and biochemical parameters of
      metabolic syndrome and estimate a cut-off value of visceral fat for development
      of MetS. A total of 285 subjects were enrolled. VAT and TF% were measured by the 
      AB-140 device via abdominal bioelectrical impedance analysis. Fat% was measured
      by a body composition analyzer (TBF-300). VAT was significantly positively
      correlated with body mass index, waist circumference, TF%, HOMA IR, fat
      percentage, fasting plasma glucose and triglycerides. Strongest correlations were
      between VAT and TF%, VAT and device measured waist circumference and between VAT 
      and manual waist circumference (r=0.95, r=0.93, r=0.92 respectively).
      Correlations of VAT and TF% with metabolic parameters were significant but weak. 
      The mean VAT and TF% in MetS (+) groups were significantly higher than patients
      in MetS (-) groups in both sexes. The areas under the ROC curves were 0.730 (95% 
      CI: 0.661-0.791) for female VAT and 0.702 (95% CI: 0.654-0.749) for male VAT in
      predicting MetS which were similar to the areas under ROC curves calculated for
      device and manually measured waist circumference, HOMA IR and TF% in predicting
      MetS (p>0.05 for all comparisons). The accuracy of VAT and TF% for predicting
      MetS was not sufficient. From our results we can deduce that the performance of
      abdominal BIA in predicting MetS is weak but could be used in the follow-up of
      patients with obesity and/or MetS. This has to be confirmed in future studies.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - From the Department of Endocrinology and Metabolism, Baskent University Faculty
      of Medicine, Ankara, Turkey.
FAU - Mousa, U
AU  - Mousa U
FAU - Kut, A
AU  - Kut A
FAU - Bozkus, Y
AU  - Bozkus Y
FAU - Cicek Demir, C
AU  - Cicek Demir C
FAU - Anil, C
AU  - Anil C
FAU - Bascil Tutuncu, N
AU  - Bascil Tutuncu N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/21 [epublish]
AID - 10.1055/s-0033-1341473 [doi]
PST - aheadofprint
SO  - Exp Clin Endocrinol Diabetes. 2013 May 21.

PMID- 23696478
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
DP  - 2013 May 21
TI  - Transgenerational Metabolic Determinants of Fetal Birth Weight.
AB  - Infants born with a higher birth weight have long been associated with an
      increased incidence of developing the metabolic syndrome starting from early
      childhood and persisting into adult life. Such risk factors include genetic
      tendencies as well as environmental factors. Of these, certain maternal
      anthropometric characteristics such as obesity or carbohydrate intolerance alter 
      the intrauterine environment to one of nutritional plenty, thus impacting on
      intrauterine development. This hypernutrition pathway has led to the hypothesis
      of fuel mediated teratogenesis' and an obesogenic environment.The aim was to
      identify a relationship across 3 generations relating to body weight and birth
      weight in order to identify whether a genetic and/or nutritional role are
      involved in the observed transmission.The study utilized 2 clinical databases.
      The first consisted of a cohort of 182 women born in 1987 and who delivered a
      child between 2004-2010 [2nd Generation]. A total of 233 infants were born [3rd
      Generation]. This was further linked to another database of women who had
      delivered a child in 1987 [1st Generation]. The birth weight of the 2nd and 3rd
      generations and the pre-pregnancy body mass index (BMI) of the 1st and 2nd
      generation were registered as was the development of features of the metabolic
      syndrome in the 1st generation population. The 1st generation population was
      subdivided into 2 groups based on the BMI: BMI <25 kg/m2 (n=76) and BMI >=25
      kg/m2 (n=106). The mean birth weights and pre-pregnancy BMI of the subsequent
      generations were compared using the student t-test.There was no direct
      transgenerational link between the first generation BMI and third generation
      birth weight. Rather, birth weight was directly linked to maternal BMI.
      Furthermore in this study we also studied the presence of metabolic syndrome in
      first generation mothers. The presence or absence of metabolic syndrome did not
      cause any statistically significant difference in the birth weight of 2nd and 3rd
      generations.This study supports previous reports that environmental factors play 
      a key role in determining fetal birth weight. Identifying women with a higher
      pre-pregnancy BMI and educating them with regards to dietary modification in
      order to reduce body weight prior to pregnancy would contribute towards less
      adverse outcomes to the mother and her child in both the short and the long term.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Division of Diabetes and Endocrinology, Mater Dei Hospital, Msida, Malta.
FAU - Agius, R
AU  - Agius R
FAU - Savona-Ventura, C
AU  - Savona-Ventura C
FAU - Vassallo, J
AU  - Vassallo J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/21 [epublish]
AID - 10.1055/s-0033-1345121 [doi]
PST - aheadofprint
SO  - Exp Clin Endocrinol Diabetes. 2013 May 21.

PMID- 23696430
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
DP  - 2013 May 21
TI  - The Effect of Maternal Body Mass Index on Perinatal Outcomes in Women with
      Diabetes.
AB  - Objective To determine the effect of increasing maternal obesity, including
      superobesity (body mass index [BMI] >/= 50 kg/m2), on perinatal outcomes in women
      with diabetes.Study Design Retrospective cohort study of birth records for all
      live-born nonanomalous singleton infants >/= 37 weeks' gestation born to Missouri
      residents with diabetes from 2000 to 2006. Women with either pregestational or
      gestational diabetes were included.Results There were 14,595 births to women with
      diabetes meeting study criteria, including 7,082 women with a BMI > 30 kg/m2
      (48.5%). Compared with normal-weight women with diabetes, increasing BMI
      category, especially superobesity, was associated with a significantly increased 
      risk for preeclampsia (adjusted relative risk [aRR] 3.6, 95% confidence interval 
      [CI] 2.5, 5.2) and macrosomia (aRR 3.0, 95% CI 1.8, 5.40). The majority of
      nulliparous obese women with diabetes delivered via cesarean including 50.5% of
      obese, 61.4% of morbidly obese, and 69.8% of superobese women. The incidence of
      primary elective cesarean among nulliparous women with diabetes increased
      significantly with increasing maternal BMI with over 33% of morbidly obese and
      39% of superobese women with diabetes delivering electively by
      cesarean.Conclusion Increasing maternal obesity in women with diabetes is
      significantly associated with higher risks of perinatal complications, especially
      cesarean delivery.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
AD  - Department of Obstetrics and Gynecology, Oregon Health and Science University,
      Portland, Oregon.
FAU - Marshall, Nicole E
AU  - Marshall NE
FAU - Guild, Camelia
AU  - Guild C
FAU - Cheng, Yvonne W
AU  - Cheng YW
FAU - Caughey, Aaron B
AU  - Caughey AB
FAU - Halloran, Donna R
AU  - Halloran DR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/21 [epublish]
AID - 10.1055/s-0033-1347363 [doi]
PST - aheadofprint
SO  - Am J Perinatol. 2013 May 21.

PMID- 23696424
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 100
IP  - 8
DP  - 2013 Jul
TI  - Association between operative approach and complications in patients undergoing
      Hartmann's reversal.
PG  - 1094-9
LID - 10.1002/bjs.9153 [doi]
AB  - BACKGROUND: Complications following reversal of Hartmann's procedure are common, 
      with morbidity rates of up to 50 per cent, and a mortality rate as high as 10 per
      cent. This is based on case series with heterogeneous data collection and
      analysis. This study determined risk factors for complications following
      Hartmann's reversal. METHODS: Patients who underwent elective open and
      laparoscopic Hartmann's reversal were identified from the American College of
      Surgeons National Surgical Quality Improvement Program database (2005-2010). The 
      programme collects patient demographics, preoperative medical history, clinical
      findings and laboratory investigations. Postdischarge data were obtained by a
      certified reviewer. Complications were categorized as major, septic or
      incisional. Risk-adjusted 30-day outcomes were assessed by univariable and
      multivariable analyses, adjusting for patient characteristics, co-morbidity and
      operative approach. RESULTS: During the study period 7996 patients had a
      Hartmann's procedure and 2567 cases of Hartmann's reversal were identified,
      including 336 laparoscopic procedures (13.1 per cent). Major, septic and
      incisional complication rates were 13.3, 8.5 and 15.7 per cent respectively, with
      a mortality rate of 0.5 per cent. A laparoscopic approach was found to be
      independently associated with fewer major (odds ratio (OR) 0.53, 95 per cent
      confidence interval 0.34 to 0.81), septic (OR 0.48, 0.27 to 0.83) and incisional 
      (OR 0.54, 0.37 to 0.80) complications. A history of chronic obstructive pulmonary
      disease (OR 1.78-2.00), steroid use (OR 1.75), body mass index at least 30
      kg/m(2) (OR 1.48), diabetes (OR 1.40), smoking (OR 1.33-1.40), American Society
      of Anesthesiologists fitness grade III and IV (OR 1.46-1.48) and prolonged
      operating time (OR 1.02) were other factors associated with complications.
      CONCLUSION: A laparoscopic approach to Hartmann's reversal was associated with
      fewer complications than open surgery in this highly selected group of patients.
CI  - (c) 2013 British Journal of Surgery Society Ltd. Published by John Wiley & Sons
      Ltd.
AD  - Division of Colorectal Surgery and Surgical Health Outcomes & Research Enterprise
      (SHORE), University of Rochester Medical Center, Rochester, New York, USA.
FAU - Cellini, C
AU  - Cellini C
FAU - Deeb, A-P
AU  - Deeb AP
FAU - Sharma, A
AU  - Sharma A
FAU - Monson, J R T
AU  - Monson JR
FAU - Fleming, F J
AU  - Fleming FJ
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - AIM
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/03/21 [accepted]
PHST- 2013/05/21 [aheadofprint]
AID - 10.1002/bjs.9153 [doi]
PST - ppublish
SO  - Br J Surg. 2013 Jul;100(8):1094-9. doi: 10.1002/bjs.9153. Epub 2013 May 21.

PMID- 23696423
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1477-0903 (Electronic)
IS  - 0960-3271 (Linking)
VI  - 32
IP  - 5
DP  - 2013 May
TI  - Antiapoptotic effects of cerium oxide and yttrium oxide nanoparticles in isolated
      rat pancreatic islets.
PG  - 544-53
LID - 10.1177/0960327112468175 [doi]
AB  - Type I diabetes mellitus is a metabolic disease caused by the impairment of
      pancreatic beta-cells mainly mediated through oxidative stress and related
      apoptosis. Islets transplantation seems a promising treatment for these patients,
      but during islets transplant, various types of stresses related to the isolation 
      and transplantation procedure compromise the function and viability of islets. We
      recently hypothesized that the combination of cerium oxide (CeO2) and yttrium
      oxide (Y2O3) nanoparticles with a potential free radical scavenger behavior
      should be useful to make isolated islets survive until transplanted. In the
      present study, oxidative stress-induced apoptosis in isolated rat pancreatic
      islets exposed to hydrogen peroxide (H2O2) and the protective effects of CeO2 and
      Y2O3 nanoparticles were investigated. Exposure of islets to H2O2 (50 microm, 2 h)
      increased intracellular oxidant formation such as reactive oxygen species and
      subsequently apoptosis and decreased viability, glucose-induced adenosine
      triphosphate (ATP) production and glucose-stimulated insulin secretion.
      Pretreatment with CeO2 and/or Y2O3 nanoparticles reduced the oxidant formation
      and apoptosis and increased viability, glucose-induced ATP production and
      glucose-stimulated insulin secretion. These results suggest that this combination
      may protect beta-cell apoptosis by improving the oxidative stress-mediated
      apoptotic pathway.
AD  - 1Razi Drug Research Center, Faculty of Medicine, Tehran University of Medical
      Sciences, Tehran, Islamic Republic of Iran.
FAU - Hosseini, A
AU  - Hosseini A
FAU - Baeeri, M
AU  - Baeeri M
FAU - Rahimifard, M
AU  - Rahimifard M
FAU - Navaei-Nigjeh, M
AU  - Navaei-Nigjeh M
FAU - Mohammadirad, A
AU  - Mohammadirad A
FAU - Pourkhalili, N
AU  - Pourkhalili N
FAU - Hassani, S
AU  - Hassani S
FAU - Kamali, M
AU  - Kamali M
FAU - Abdollahi, M
AU  - Abdollahi M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Exp Toxicol
JT  - Human & experimental toxicology
JID - 9004560
SB  - IM
OTO - NOTNLM
OT  - Cerium oxide nanoparticles
OT  - apoptosis
OT  - oxidative stress
OT  - yttrium oxide nanoparticles
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 32/5/544 [pii]
AID - 10.1177/0960327112468175 [doi]
PST - ppublish
SO  - Hum Exp Toxicol. 2013 May;32(5):544-53. doi: 10.1177/0960327112468175.

PMID- 23696415
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1098-1004 (Electronic)
IS  - 1059-7794 (Linking)
DP  - 2013 May 20
TI  - Pathogenic mitochondrial tRNA point mutations: nine novel mutations affirm their 
      importance as a cause of mitochondrial disease.
LID - 10.1002/humu.22358 [doi]
AB  - Mutations in the mitochondrial genome, and in particular the mt-tRNAs, are an
      important cause of human disease. Accurate classification of the pathogenicity of
      novel variants is vital to allow accurate genetic counselling for patients and
      their families. The use of weighted criteria based on functional studies -
      outlined in a validated pathogenicity scoring system - are therefore invaluable
      in determining whether novel or rare mt-tRNA variants are pathogenic. Here we
      describe the identification of 9 novel mt-tRNA variants in nine families, in
      which the probands presented with a diverse range of clinical phenotypes
      including mitochondrial encephalomyopathy, lactic acidosis and stroke-like
      episodes (MELAS), isolated progressive external ophthalmoplegia (PEO), epilepsy, 
      deafness and diabetes. Each of the variants identified (m.4289T>C, MT-TI;
      m.5541C>T, MT-TW; m.5690A>G, MT-TN; m.7451A>T, MT-TS1; m.7554G>A, MT-TD;
      m.8304G>A, MT-TK; m.12206C>T, MT-TH; m.12317T>C, MT-TL2; m.16023G>A, MT-TP) was
      present in a different tRNA, with evidence in support of pathogenicity, and where
      possible, details of mutation transmission documented. Through the application of
      the pathogenicity scoring system, we have classified six of these variants as
      'definitely pathogenic' mutations (m.5541C>T, m.5690A>G, m.7451A>T, m.12206C>T,
      m.12317T>C and m.16023G>A), whilst the remaining three currently lack sufficient 
      evidence and are therefore classed as 'possibly pathogenic'(m.4289T>C, m.7554G>A 
      and m.8304G>A). This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Wellcome Trust Centre for Mitochondrial Research, Institute for Ageing and
      Health, Newcastle University, Newcastle upon Tyne, UK.
FAU - Blakely, Emma L
AU  - Blakely EL
FAU - Yarham, John W
AU  - Yarham JW
FAU - Alston, Charlotte L
AU  - Alston CL
FAU - Craig, Kate
AU  - Craig K
FAU - Poulton, Joanna
AU  - Poulton J
FAU - Brierley, Charlotte
AU  - Brierley C
FAU - Park, Soo-Mi
AU  - Park SM
FAU - Dean, Andrew
AU  - Dean A
FAU - Xuereb, John H
AU  - Xuereb JH
FAU - Anderson, Kirstie N
AU  - Anderson KN
FAU - Compston, Alistair
AU  - Compston A
FAU - Allen, Chris
AU  - Allen C
FAU - Sharif, Saba
AU  - Sharif S
FAU - Enevoldson, Peter
AU  - Enevoldson P
FAU - Wilson, Martin
AU  - Wilson M
FAU - Hammans, Simon R
AU  - Hammans SR
FAU - Turnbull, Douglass M
AU  - Turnbull DM
FAU - McFarland, Robert
AU  - McFarland R
FAU - Taylor, Robert W
AU  - Taylor RW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Hum Mutat
JT  - Human mutation
JID - 9215429
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/02/28 [received]
PHST- 2013/05/03 [revised]
PHST- 2013/05/10 [accepted]
AID - 10.1002/humu.22358 [doi]
PST - aheadofprint
SO  - Hum Mutat. 2013 May 20. doi: 10.1002/humu.22358.

PMID- 23696233
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1175-0561 (Electronic)
IS  - 1175-0561 (Linking)
DP  - 2013 May 22
TI  - Etiology, Diagnosis, and Therapeutic Management of Granuloma Annulare: An Update.
AB  - Granuloma annulare (GA) is a common cutaneous disorder classically presenting as 
      annular groups of skin-colored to erythematous papules without epidermal change
      localized to the dorsal hands and/or feet. In addition to the localized form,
      there are variants including generalized (including generalized annular GA,
      disseminated papular GA, and atypical generalized GA), subcutaneous, and
      perforating GA, providing for a wide spectrum of clinical lesions. The etiology
      of GA remains unknown and several systemic associations have been proposed but
      not proven, including diabetes mellitus, malignancy, thyroid disease, and
      dyslipidemia. The diagnosis of GA relies on clinicopathological correlation, with
      a skin biopsy confirming the histological features of the disease, including
      palisading granulomas, collagen degeneration, mucin, and a lymphohistiocytic
      infiltrate. Localized GA is often asymptomatic and self-limited within 2 years;
      however, the patient may desire treatment for cosmetic reasons, with topical and 
      intralesional corticosteroids as the mainstays of therapy. When GA is
      generalized, disseminated, or atypical, a more thorough medical workup for
      underlying diseases may be considered depending on the physical examination, a
      thorough review of systems, comorbidities, and clinical suspicion. Treatment is
      often challenging for generalized GA, especially because of its recalcitrant
      nature and a lack of evidence-based therapy. Over 30 different treatments have
      been described for GA with variable results; however, the majority of these have 
      been single case reports, small case series, or retrospective studies. Reported
      treatments for GA include topical, intralesional, intramuscular, and oral
      medications (steroidal vs. non-steroidal); biologic agents; surgical
      interventions; phototherapy; and laser treatments. When selecting a systemic
      therapy for a patient with GA, multiple variables must be considered, such as
      baseline blood evaluations, comorbidities, drug interactions, compliance, adverse
      effect profiles, prior treatments, and reproductive status. This evidence-based
      review will focus on the advances made in the twenty-first century regarding the 
      etiology, diagnosis, and therapeutic management of GA.
AD  - Department of Dermatology, University of Pittsburgh, 200 Lothrop St., Presby
      South Tower Suite 3880, Pittsburgh, PA, 15213, USA.
FAU - Thornsberry, Laura A
AU  - Thornsberry LA
FAU - English, Joseph C 3rd
AU  - English JC 3rd
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Am J Clin Dermatol
JT  - American journal of clinical dermatology
JID - 100895290
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1007/s40257-013-0029-5 [doi]
PST - aheadofprint
SO  - Am J Clin Dermatol. 2013 May 22.

PMID- 23696124
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1862-8354 (Electronic)
IS  - 1862-8346 (Linking)
DP  - 2013 May 21
TI  - Mass Spectrometric Immunoassay and Multiple Reaction Monitoring as Targeted
      MS-based Quantitative Approaches in Biomarker Development: Potential Applications
      to Cardiovascular Disease and Diabetes.
LID - 10.1002/prca.201200028 [doi]
AB  - Type 2 diabetes (T2DM) is an important risk factor for cardiovascular disease
      (CVD)-the leading cause of death in the US. Yet not all subjects with T2DM are at
      equal risk for CVD complications; the challenge lies in identifying those at
      greatest risk. Therapies directed towards treating conventional risk factors have
      failed to significantly reduce this residual risk in T2DM patients. Thus newer
      targets and markers are needed for the development and testing of novel
      therapies. Herein we review two complementary mass spectrometry-based
      approaches-Mass Spectrometric Immunoassay (MSIA) and tandem mass spectrometry as 
      multiple reaction monitoring (MRM)-for the analysis of plasma proteins and post
      translational modifications (PTMs) of relevance to T2DM and CVD. Together, these 
      complementary approaches allow for high-throughput monitoring of many PTMs and
      the absolute quantification of proteins near the low picomolar range. In this
      review article, we discuss the clinical relevance of the HDL proteome and
      Apolipoprotein A-I PTMs to T2DM and CVD as well as provide illustrative MSIA and 
      MRM data on high density lipoprotein (HDL) proteins from T2DM patients to provide
      examples of how these mass spectrometry approaches can be applied to gain new
      insight regarding cardiovascular risk factors. Also discussed are the
      reproducibility, interpretation and limitations of each technique with an
      emphasis on their capacities to facilitate the translation of new biomarkers into
      clinical practice. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - University of Southern California, Los Angeles, CA.
FAU - Yassine, Hussein
AU  - Yassine H
FAU - Borges, Chad R
AU  - Borges CR
FAU - Schaab, Matthew R
AU  - Schaab MR
FAU - Billheimer, Dean
AU  - Billheimer D
FAU - Stump, Craig
AU  - Stump C
FAU - Reaven, Peter
AU  - Reaven P
FAU - Lau, Serrine S
AU  - Lau SS
FAU - Nelson, Randall
AU  - Nelson R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Proteomics Clin Appl
JT  - Proteomics. Clinical applications
JID - 101298608
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/04/25 [received]
PHST- 2013/02/04 [revised]
PHST- 2013/03/30 [accepted]
AID - 10.1002/prca.201200028 [doi]
PST - aheadofprint
SO  - Proteomics Clin Appl. 2013 May 21. doi: 10.1002/prca.201200028.

PMID- 23695953
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1473-6810 (Electronic)
IS  - 1356-5524 (Linking)
DP  - 2013 May 21
TI  - Should metformin be preferred over insulin therapy in the management of
      gestational diabetes (GDM)?
AD  - Department of Endocrinology & Metabolism, Medstar Washington Hospital Center, ,
      Washington, DC, USA.
FAU - Sullivan, Shannon D
AU  - Sullivan SD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Evid Based Med
JT  - Evidence-based medicine
JID - 9608386
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - eb-2013-101329 [pii]
AID - 10.1136/eb-2013-101329 [doi]
PST - aheadofprint
SO  - Evid Based Med. 2013 May 21.

PMID- 23695824
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 May 21
TI  - Assessment of skeletal muscle microcirculation in type 2 diabetes mellitus using 
      dynamic contrast-enhanced ultrasound: A pilot study.
AB  - Purpose:To investigate muscular micro-perfusion by employing dynamic
      contrast-enhanced ultrasound (CEUS) and performing transient arterial occlusion
      in patients with type 2 diabetes mellitus (DM-2).Methods:Twenty DM-2 patients
      (mean age, 58 +/- 8.6 years; duration of diabetes, 15.4 +/- 12.1 years) and 20
      healthy volunteers (mean age, 54 +/- 5.4 years) participated. CEUS was applied to
      the calf, while 4.8 mL of SonoVue(R) was injected intravenously. At the thigh
      level, arterial occlusion (60 s) was performed. CEUS parameters (tmax, max,
      AUCpost and m) were evaluated and Pearson-product-moment correlation coefficients
      were computed.Results:A moderate negative correlation of HbA1c and max was
      established (-0.53). Max in patients with DM-2 >10 years was 79.89 +/- 37.4. Max 
      in patients with DM-2 duration <10 years was 137.62 +/- 71.72 (p = 0.04). AUCpost
      in patients with DM-2 duration >10 years was 3924.01 +/- 1630.52. AUCpost in
      patients with DM-2 duration <10 years was 6453.59 +/- 3206.23 (p =
      0.04).Conclusion:Patients with long history of DM-2 present with impaired
      muscular perfusion. CEUS and transient arterial occlusion may provide appropriate
      methods for semi-quantitative evaluation of muscular micro-perfusion in patients 
      with DM-2.
AD  - Department of Diagnostic and Interventional Radiology, University Hospital of
      Heidelberg, Heidelberg, Germany.
FAU - Amarteifio, Erick
AU  - Amarteifio E
FAU - Wormsbecher, Stephanie
AU  - Wormsbecher S
FAU - Demirel, Serdar
AU  - Demirel S
FAU - Krix, Martin
AU  - Krix M
FAU - Braun, Simone
AU  - Braun S
FAU - Rehnitz, Christoph
AU  - Rehnitz C
FAU - Delorme, Stefan
AU  - Delorme S
FAU - Kauczor, Hans-Ulrich
AU  - Kauczor HU
FAU - Weber, Marc-Andre
AU  - Weber MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
OTO - NOTNLM
OT  - Muscle perfusion
OT  - contrast-enhanced ultrasound
OT  - diabetes mellitus
OT  - transient arterial occlusion
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 1479164113484165 [pii]
AID - 10.1177/1479164113484165 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 May 21.

PMID- 23695818
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 21
TI  - Improved Plasma FFA/Insulin Homeostasis Is Independently Associated With Improved
      Glucose Tolerance After a One-Year Lifestyle Intervention in Viscerally Obese
      Men.
AB  - OBJECTIVESElevated plasma free fatty acids (FFAs) are one important link between 
      excess visceral adiposity, insulin resistance, and the development of type 2
      diabetes. Effects of lifestyle interventions on FFA metabolism are poorly known. 
      This open-label study was conducted to test the effects of a 1-year healthy
      eating/physical activity intervention program on plasma FFA homeostasis in 117
      viscerally obese men with dyslipidemia associated with insulin resistance (waist 
      circumference >/=90 cm; triglycerides >/=1.69 mmol/L; and/or HDL-cholesterol
      <1.03 mmol/L).RESEARCH DESIGN AND METHODSBody weight, body composition, and fat
      distribution were assessed by dual-energy X-ray absorptiometry/computed
      tomography. Oral loads of lipid (60 g fat/m2 body surface area) and glucose (75
      g) were measured before and after the intervention.RESULTSAfter 1 year of
      lifestyle intervention, visceral adiposity was reduced by -26% (95% CI -29 to
      -23), whereas cardiorespiratory fitness improved by +20% (95% CI +16 to +24).
      After 1 year, the suppression of FFAs after the glucose load improved, whereas
      insulin concentrations were drastically reduced. After the oral lipid load, the
      late increase in FFA was reduced together with reduced circulating insulin. We
      calculated an insulin sensitivity index to reflect the concentration of insulin
      needed to manage plasma FFAs after the oral lipid load, which increased after the
      intervention and was associated with improved glucose tolerance, independent of
      changes in visceral or total adiposity.CONCLUSIONSA 1-year healthy
      eating/physical activity intervention improved the suppression of FFAs after oral
      glucose and lipid load tests in viscerally obese men, possibly due to improved
      responsiveness to insulin. This insulin-mediated regulation of postprandial
      plasma FFA levels could be a link between visceral obesity and impaired glucose
      homeostasis.
AD  - Institut universitaire de cardiologie et de pneumologie de Quebec, Quebec, QC,
      Canada.
FAU - Borel, Anne-Laure
AU  - Borel AL
FAU - Boulet, Genevieve
AU  - Boulet G
FAU - Nazare, Julie-Anne
AU  - Nazare JA
FAU - Smith, Jessica
AU  - Smith J
FAU - Almeras, Natalie
AU  - Almeras N
FAU - Tremblay, Angelo
AU  - Tremblay A
FAU - Bergeron, Jean
AU  - Bergeron J
FAU - Poirier, Paul
AU  - Poirier P
FAU - Carpentier, Andre C
AU  - Carpentier AC
FAU - Despres, Jean-Pierre
AU  - Despres JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - dc12-2353 [pii]
AID - 10.2337/dc12-2353 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 21.

PMID- 23695817
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 21
TI  - Interpreting Adverse Signals in Diabetes Drug Development Programs.
AB  - Detection and interpretation of adverse signals during preclinical and clinical
      stages of drug development inform the benefit-risk assessment that determines
      suitability for use in real-world situations. This review considers some recent
      signals associated with diabetes therapies, illustrating the difficulties in
      ascribing causality and evaluating absolute risk, predictability, prevention, and
      containment. Individual clinical trials are necessarily restricted for patient
      selection, number, and duration; they can introduce allocation and ascertainment 
      bias and they often rely on biomarkers to estimate long-term clinical outcomes.
      In diabetes, the risk perspective is inevitably confounded by emergent comorbid
      conditions and potential interactions that limit therapeutic choice, hence the
      need for new therapies and better use of existing therapies to address the
      consequences of protracted glucotoxicity. However, for some therapies, the
      adverse effects may take several years to emerge, and it is evident that faint
      initial signals under trial conditions cannot be expected to foretell all
      eventualities. Thus, as information and experience accumulate with time, it
      should be accepted that benefit-risk deliberations will be refined, and
      adjustments to prescribing indications may become appropriate.
AD  - School of Life and Health Sciences, Aston University, Birmingham, U.K.
FAU - Bailey, Clifford J
AU  - Bailey CJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - dc13-0182 [pii]
AID - 10.2337/dc13-0182 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 21.

PMID- 23695816
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 21
TI  - Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides
      the rationale for revamping epidemiologic pharmacovigilance.
AD  - Joint Program on Diabetes, Endocrinology and Metabolism, Pennington Biomedical
      Research Center, Louisiana State University System, Baton Rouge, Louisiana, and
      Louisiana State University Health Sciences Center School of Medicine, New
      Orleans, Louisiana.
FAU - Cefalu, William T
AU  - Cefalu WT
FAU - Rosenstock, Julio
AU  - Rosenstock J
FAU - Henry, Robert R
AU  - Henry RR
FAU - Riddle, Matthew
AU  - Riddle M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - dc13-0895 [pii]
AID - 10.2337/dc13-0895 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 21.

PMID- 23695815
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 21
TI  - Assessing the Benefit-Risk for New Drugs: Are the FDA's Endocrinologic and
      Metabolic Drugs Advisory Committee and the Division of Metabolism and
      Endocrinology Products in sync?
AD  - Department of Medicine, Harbor-UCLA Medical Center, Torrance, California.
FAU - Brass, Eric P
AU  - Brass EP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - dc13-0891 [pii]
AID - 10.2337/dc13-0891 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 21.

PMID- 23695772
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
DP  - 2013 May 20
TI  - Effects of Direct Renin Inhibition on Atherosclerotic Biomarkers in Patients With
      Stable Coronary Artery Disease and Type 2 Diabetes Mellitus.
AB  - OBJECTIVES: To evaluate whether the direct renin inhibitor, aliskiren, has a more
      favorable effect compared to amlodipine on atherosclerotic biomarkers in patients
      with stable coronary artery disease and diabetes currently receiving standard
      secondary prevention therapy. METHODS: A total of 38 patients were randomly
      assigned initially to either aliskiren (150 mg daily) or amlodipine (5 mg daily) 
      for 2 weeks after which the dose of either medication was increased to its
      maximum daily dose for 4 additional weeks. Baseline and 6-week blood samples were
      analyzed for changes from baseline and between treatment groups for vascular and 
      intracellular cell adhesion molecule, C-reactive protein, nitric oxide,
      plasminogen activator inhibitor 1, 8-isoprostane, and thiobarbituric acid
      reactive substances. RESULTS: Thirty-one patients completed the study. More of
      the dropouts occurred in patients receiving aliskiren. Systolic blood pressure
      decreased in both treatment arms with no differences between the groups being
      noted. Plasminogen activator inhibitor 1, nitric oxide, and C-reactive protein
      concentrations increased in both groups from baseline but changes from baseline
      or between groups were not significant. Vascular and intracellular cell adhesion 
      molecule, thiobarbituric acid reactive substances, and isoprostane concentrations
      decreased in each treatment arm from baseline, but these changes were not
      significant and no differences were noted between the groups. CONCLUSIONS:
      Treatment with either aliskiren or amlodipine did not significantly alter
      surrogate biomarkers of atherosclerosis in patients with both diabetes and
      established cardiovascular disease already receiving appropriate secondary
      cardiovascular prevention therapy. The study is limited in its size and duration 
      to see an effect.
AD  - 1Department of Pharmacy Practice, Texas Tech University Health Sciences
      Center-School of Pharmacy, Department of Pharmacy Practice, Lubbock, TX, USA.
FAU - Irons, Brian K
AU  - Irons BK
FAU - Trujillo, Alex
AU  - Trujillo A
FAU - Seifert, Charles F
AU  - Seifert CF
FAU - Simoni, Jan S
AU  - Simoni JS
FAU - Doctolero, Susan
AU  - Doctolero S
FAU - Meyerrose, Gary E
AU  - Meyerrose GE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
OTO - NOTNLM
OT  - C-reactive protein
OT  - aliskiren
OT  - amlodipine
OT  - atherosclerosis
OT  - biomarkers
OT  - nitric oxide
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 1074248413489772 [pii]
AID - 10.1177/1074248413489772 [doi]
PST - aheadofprint
SO  - J Cardiovasc Pharmacol Ther. 2013 May 20.

PMID- 23695708
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1538-8662 (Electronic)
IS  - 0361-1817 (Linking)
VI  - 38
IP  - 6
DP  - 2013 Jun 10
TI  - Management of type 2 diabetes.
PG  - 13-6
LID - 10.1097/01.NPR.0000430282.47467.5a [doi]
AD  - Stacey Seggelke is a Clinical Nurse Specialist with an Inpatient Glucose
      Management Team at University of Colorado Hospital, Aurora, Colo. Bridget
      Everhart is an Inpatient Diabetes Advanced Practice Nurse Educator at University 
      of Colorado Hospital, Aurora, Colo.
FAU - Seggelke, Stacey
AU  - Seggelke S
FAU - Everhart, Bridget
AU  - Everhart B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nurse Pract
JT  - The Nurse practitioner
JID - 7603663
SB  - IM
SB  - N
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1097/01.NPR.0000430282.47467.5a [doi]
AID - 00006205-201306000-00004 [pii]
PST - ppublish
SO  - Nurse Pract. 2013 Jun 10;38(6):13-6. doi: 10.1097/01.NPR.0000430282.47467.5a.

PMID- 23695383
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1433-3023 (Electronic)
IS  - 0937-3462 (Linking)
DP  - 2013 May 22
TI  - Differences in sacral neuromodulation device infection rates based on
      preoperative antibiotic selection.
AB  - INTRODUCTION AND HYPOTHESIS: After SNM implantation the most significant
      complication that can occur is wound infection, which typically requires removal 
      of all components. Such infections have been reported in 5-11 % of patients, but 
      little is known about risk factors. The objective of this analysis is to
      determine our postoperative wound infection rate after SNM implantation, and
      examined various potential predictive factors. Our hypothesis is that
      perioperative antibiotic selection is related to the risk of infections. METHODS:
      A retrospective review was performed of all patients who underwent SNM
      implantation by one of three surgeons from 2007 to 2010. Preoperative antibiotics
      were administered according to surgeon preference, and included cefazolin alone, 
      vancomycin alone, or vancomycin with gentamicin. Predictors of wound infection
      were evaluated using multivariate techniques. Variables examined included
      preoperative antibiotic regimen, surgeon, location (outpatient surgery center vs 
      university hospital), gender, comorbidities (diabetes mellitus, immunosuppression
      and smoking), history of urinary tract infections, and preoperative skin
      preparation. RESULTS: A total of 136 patients underwent SNM implantation, and 8
      (5.9 %) experienced infections that required device explantation. Cefazolin alone
      was less effective in preventing infection compared with the other antibiotic
      regimens (p = 0.03). The odds of having an infection in cefazolin-treated
      patients was 7.3 times that of other patients treated with another antibiotic
      regimen. Seven out of the eight infections with explant grew Staphylococcus
      aureus resistant to cephalosporins. None of the other variables proved to be a
      statistically significant contributor. CONCLUSIONS: Preoperative antibiotic
      selection was a significant factor in preventing subsequent infection and
      explantation following SNM placement.
AD  - University of Michigan Department of Urology, 3875 Taubman Center 1500 E. Medical
      Center Drive, Ann Arbor, MI, 48109-5330, USA.
FAU - Haraway, Allen M
AU  - Haraway AM
FAU - Clemens, J Quentin
AU  - Clemens JQ
FAU - He, Chang
AU  - He C
FAU - Stroup, Cynthia
AU  - Stroup C
FAU - Atiemo, Humphrey O
AU  - Atiemo HO
FAU - Cameron, Anne P
AU  - Cameron AP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Int Urogynecol J
JT  - International urogynecology journal
JID - 101567041
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/02/07 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/22 [aheadofprint]
AID - 10.1007/s00192-013-2121-z [doi]
PST - aheadofprint
SO  - Int Urogynecol J. 2013 May 22.

PMID- 23695257
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1399-0047 (Electronic)
IS  - 0907-4449 (Linking)
VI  - 69
IP  - Pt 6
DP  - 2013 Jun
TI  - Mapping the conformational space accessible to BACE2 using surface mutants and
      cocrystals with Fab fragments, Fynomers and Xaperones.
PG  - 1124-37
LID - 10.1107/S0907444913006574 [doi]
AB  - The aspartic protease BACE2 is responsible for the shedding of the transmembrane 
      protein Tmem27 from the surface of pancreatic beta-cells, which leads to
      inactivation of the beta-cell proliferating activity of Tmem27. This role of
      BACE2 in the control of beta-cell maintenance suggests BACE2 as a drug target for
      diabetes. Inhibition of BACE2 has recently been shown to lead to improved control
      of glucose homeostasis and to increased insulin levels in insulin-resistant mice.
      BACE2 has 52% sequence identity to the well studied Alzheimer's disease target
      enzyme beta-secretase (BACE1). High-resolution BACE2 structures would contribute 
      significantly to the investigation of this enzyme as either a drug target or
      anti-target. Surface mutagenesis, BACE2-binding antibody Fab fragments,
      single-domain camelid antibody VHH fragments (Xaperones) and Fyn-kinase-derived
      SH3 domains (Fynomers) were used as crystallization helpers to obtain the first
      high-resolution structures of BACE2. Eight crystal structures in six different
      packing environments define an ensemble of low-energy conformations available to 
      the enzyme. Here, the different strategies used for raising and selecting BACE2
      binders for cocrystallization are described and the crystallization success,
      crystal quality and the time and resources needed to obtain suitable crystals are
      compared.
AD  - pRED Pharma Research and Early Development, Small Molecule Research, Discovery
      Technologies, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
FAU - Banner, David W
AU  - Banner DW
FAU - Gsell, Bernard
AU  - Gsell B
FAU - Benz, Jorg
AU  - Benz J
FAU - Bertschinger, Julian
AU  - Bertschinger J
FAU - Burger, Dominique
AU  - Burger D
FAU - Brack, Simon
AU  - Brack S
FAU - Cuppuleri, Simon
AU  - Cuppuleri S
FAU - Debulpaep, Maja
AU  - Debulpaep M
FAU - Gast, Alain
AU  - Gast A
FAU - Grabulovski, Dragan
AU  - Grabulovski D
FAU - Hennig, Michael
AU  - Hennig M
FAU - Hilpert, Hans
AU  - Hilpert H
FAU - Huber, Walter
AU  - Huber W
FAU - Kuglstatter, Andreas
AU  - Kuglstatter A
FAU - Kusznir, Eric
AU  - Kusznir E
FAU - Laeremans, Toon
AU  - Laeremans T
FAU - Matile, Hugues
AU  - Matile H
FAU - Miscenic, Christian
AU  - Miscenic C
FAU - Rufer, Arne C
AU  - Rufer AC
FAU - Schlatter, Daniel
AU  - Schlatter D
FAU - Steyaert, Jan
AU  - Steyaert J
FAU - Stihle, Martine
AU  - Stihle M
FAU - Thoma, Ralf
AU  - Thoma R
FAU - Weber, Martin
AU  - Weber M
FAU - Ruf, Armin
AU  - Ruf A
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - Acta Crystallogr D Biol Crystallogr
JT  - Acta crystallographica. Section D, Biological crystallography
JID - 9305878
SB  - IM
OTO - NOTNLM
OT  - antibodies
OT  - drug discovery and design
OT  - protein crystallization
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/01/25 [received]
PHST- 2013/03/07 [accepted]
PHST- 2013/05/15 [epublish]
AID - S0907444913006574 [pii]
AID - 10.1107/S0907444913006574 [doi]
PST - ppublish
SO  - Acta Crystallogr D Biol Crystallogr. 2013 Jun;69(Pt 6):1124-37. doi:
      10.1107/S0907444913006574. Epub 2013 May 15.

PMID- 23695216
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 May 21
TI  - Interferon Regulatory Factor 7 Deficiency Prevents Diet-induced Obesity and
      Insulin Resistance.
AB  - ABSTRACT Obesity-related inflammation has been implicated in the pathogenesis of 
      insulin resistance and type 2 diabetes. In this study, we addressed the potential
      role of interferon regulatory factor 7 (IRF7), a master regulator of type I
      interferon-dependent immune responses, in the regulation of energy metabolism.
      The expression levels of IRF7 were increased in white adipose tissue (WAT), liver
      tissue and gastrocnemius muscle of both diet-induced obese mice and ob/ob mice
      compared with their lean counterparts. After feeding a high fat diet (HFD) for 24
      weeks, IRF7 knockout (KO) mice showed less weight gain and adiposity than
      wild-type (WT) controls. KO of IRF7 improved glucose and lipid homeostasis and
      insulin sensitivity. Additionally, KO of IRF7 ameliorated diet-induced hepatic
      steatosis. Then, we assessed the inflammatory state of the IRF7 KO mice on the
      HFD. These mice showed less macrophage infiltration into multiple organs and were
      protected from local and systemic inflammation. This study demonstrates a role
      for IRF7 in diet-induced alterations in energy metabolism and insulin
      sensitivity. Our results also suggest that IRF7 is involved in the etiology of
      metabolic abnormalities, which suggests a new strategy for treating obesity and
      type 2 diabetes. KEY WORDS interferon regulatory factor 7; obesity; insulin
      resistance; type 2 diabetes; inflammation.
AD  - 1Cardiovascular Research Institute of Wuhan University.
FAU - Wang, Xin-An
AU  - Wang XA
FAU - Zhang, Ran
AU  - Zhang R
FAU - Zhang, Shumin
AU  - Zhang S
FAU - Deng, Shan
AU  - Deng S
FAU - Jiang, Dingsheng
AU  - Jiang D
FAU - Zhong, Jinfeng
AU  - Zhong J
FAU - Yang, Li
AU  - Yang L
FAU - Wang, Tao
AU  - Wang T
FAU - Hong, Shufen
AU  - Hong S
FAU - Guo, Sen
AU  - Guo S
FAU - She, Zhi-Gang
AU  - She ZG
FAU - Zhang, Xiao-Dong
AU  - Zhang XD
FAU - Li, Hongliang
AU  - Li H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - inflammation
OT  - insulin resistance
OT  - interferon regulatory factor 7
OT  - obesity
OT  - type 2 diabetes
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - ajpendo.00505.2012 [pii]
AID - 10.1152/ajpendo.00505.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 May 21.

PMID- 23695212
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 May 21
TI  - Melatonin acts through MT1/MT2 receptors to activate hypothalamic AKT and
      suppress hepatic gluconeogenesis in rats.
AB  - Melatonin can contribute to glucose homeostasis either by decreasing
      gluconeogenesis or by counteracting insulin resistance in distinct models of
      obesity. However, the precise mechanism through which melatonin controls glucose 
      homeostasis is not completely understood. Male Wistar rats were administered an
      intracerebroventricular (icv) injection of melatonin and one of following: an icv
      injection of a phosphatidylinositol 3-kinase (PI3K) inhibitor, an icv injection
      of a melatonin receptor (MT) antagonist or an ip injection of a muscarinic
      receptor antagonist. Anesthetized rats were subjected to pyruvate tolerance test 
      to estimate in vivo glucose clearance after pyruvate load and to in situ liver
      perfusion to assess hepatic gluconeogenesis. The hypothalamus was removed to
      determine AKT phosphorylation. Melatonin injections in the central nervous system
      suppressed hepatic gluconeogenesis and increased hypothalamic AKT
      phosphorylation. These effects of melatonin were suppressed either by icv
      injections of PI3K inhibitors and MT antagonists and by ip injection of a
      muscarinic receptor antagonist. We conclude that melatonin activates
      hypothalamus-liver communication that may contribute to circadian adjustments of 
      gluconeogenesis. These data further suggest a physiopathological relationship
      between the circadian disruptions in metabolism and reduced levels of melatonin
      found in type 2 diabetes patients.
AD  - 1State University of Campinas.
FAU - Faria, Juliana A
AU  - Faria JA
FAU - Kinote, Andrezza
AU  - Kinote A
FAU - Ignacio-Souza, Leticia M
AU  - Ignacio-Souza LM
FAU - de Araujo, Thiago M
AU  - de Araujo TM
FAU - Razolli, Daniela S
AU  - Razolli DS
FAU - Doneda, Diego L
AU  - Doneda DL
FAU - Paschoal, Livia B
AU  - Paschoal LB
FAU - Lellis-Santos, Camilo
AU  - Lellis-Santos C
FAU - Bertolini, Gisele L
AU  - Bertolini GL
FAU - Velloso, Licio A
AU  - Velloso LA
FAU - Bordin, Silvana
AU  - Bordin S
FAU - Anhe, Gabriel F
AU  - Anhe GF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - gluconeogenesis
OT  - liver
OT  - melatonin
OT  - melatonin receptors
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - ajpendo.00094.2013 [pii]
AID - 10.1152/ajpendo.00094.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 May 21.

PMID- 23695207
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1476-5640 (Electronic)
IS  - 0954-3007 (Linking)
DP  - 2013 May 22
TI  - A multicenter randomized controlled trial of a plant-based nutrition program to
      reduce body weight and cardiovascular risk in the corporate setting: the GEICO
      study.
LID - 10.1038/ejcn.2013.92 [doi]
AB  - Background/objectives:To determine the effects of a low-fat plant-based diet
      program on anthropometric and biochemical measures in a multicenter corporate
      setting.Subjects/methods:Employees from 10 sites of a major US company with body 
      mass index >/=25 kg/m2 and/or previous diagnosis of type 2 diabetes were
      randomized to either follow a low-fat vegan diet, with weekly group support and
      work cafeteria options available, or make no diet changes for 18 weeks. Dietary
      intake, body weight, plasma lipid concentrations, blood pressure and glycated
      hemoglobin (HbA1C) were determined at baseline and 18 weeks.Results:Mean body
      weight fell 2.9 kg and 0.06 kg in the intervention and control groups,
      respectively (P<0.001). Total and low-density lipoprotein (LDL) cholesterol fell 
      8.0 and 8.1 mg/dl in the intervention group and 0.01 and 0.9 mg/dl in the control
      group (P<0.01). HbA1C fell 0.6 percentage point and 0.08 percentage point in the 
      intervention and control group, respectively (P<0.01).Among study completers,
      mean changes in body weight were -4.3 kg and -0.08 kg in the intervention and
      control groups, respectively (P<0.001). Total and LDL cholesterol fell 13.7 and
      13.0 mg/dl in the intervention group and 1.3 and 1.7 mg/dl in the control group
      (P<0.001). HbA1C levels decreased 0.7 percentage point and 0.1 percentage point
      in the intervention and control group, respectively (P<0.01).Conclusions:An
      18-week dietary intervention using a low-fat plant-based diet in a corporate
      setting improves body weight, plasma lipids, and, in individuals with diabetes,
      glycemic control.European Journal of Clinical Nutrition advance online
      publication, 22 May 2013; doi:10.1038/ejcn.2013.92.
AD  - Clinical Research, Physicians Committee for Responsible Medicine, Washington, DC,
      USA.
FAU - Mishra, S
AU  - Mishra S
FAU - Xu, J
AU  - Xu J
FAU - Agarwal, U
AU  - Agarwal U
FAU - Gonzales, J
AU  - Gonzales J
FAU - Levin, S
AU  - Levin S
FAU - Barnard, N D
AU  - Barnard ND
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Eur J Clin Nutr
JT  - European journal of clinical nutrition
JID - 8804070
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/22 [aheadofprint]
AID - ejcn201392 [pii]
AID - 10.1038/ejcn.2013.92 [doi]
PST - aheadofprint
SO  - Eur J Clin Nutr. 2013 May 22. doi: 10.1038/ejcn.2013.92.

PMID- 23694999
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1473-5857 (Electronic)
IS  - 0268-1315 (Linking)
DP  - 2013 May 20
TI  - Open-label pilot study on vitamin D3 supplementation for antipsychotic-associated
      metabolic anomalies.
AB  - Previous studies have linked vitamin D deficiency to hypertension, dyslipidemia, 
      diabetes mellitus, and cardiovascular disease. The aim of this study was to
      investigate the short-term effects of vitamin D3 supplementation on weight and
      glucose and lipid metabolism in antipsychotic-treated patients. A total of 19
      schizophrenic or schizoaffective patients (BMI>27 kg/m) taking atypical
      antipsychotics were recruited and dispensed a 2000 IU daily dose of vitamin D3.
      On comparing baseline with week 8 (study end) results, we found a statistically
      significant increase in vitamin D3 and total vitamin D levels but no
      statistically significant changes in weight, glucose, or lipids measurements.
      Patients whose vitamin D3 level at week 8 was 30 ng/ml or more achieved a
      significantly greater decrease in total cholesterol levels compared with those
      whose week 8 vitamin D3 measurement was less than 30 ng/ml. These results suggest
      that a randomized trial with a longer follow-up period would be helpful in
      further evaluating the effects of vitamin D3 on weight, lipid metabolism, and on 
      components of metabolic syndrome in antipsychotic-treated patients.
AD  - aSchizophrenia Clinical and Research Program, Massachusetts General Hospital
      bHarvard Medical School cBeth Israel Deaconess Medical Center dPublic Psychiatry 
      Division, Massachusetts Mental Health Center eDepartment of Psychiatry,
      Massachusetts General Hospital, Boston fDepartment of Mathematics and Computer
      Science, College of the Holy Cross, Worcester, Massachusetts, USA.
FAU - Thakurathi, Neelam
AU  - Thakurathi N
FAU - Stock, Shannon
AU  - Stock S
FAU - Oppenheim, Claire E
AU  - Oppenheim CE
FAU - Borba, Christina P C
AU  - Borba CP
FAU - Vincenzi, Brenda
AU  - Vincenzi B
FAU - Seidman, Larry J
AU  - Seidman LJ
FAU - Stone, William S
AU  - Stone WS
FAU - Henderson, David C
AU  - Henderson DC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Int Clin Psychopharmacol
JT  - International clinical psychopharmacology
JID - 8609061
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1097/YIC.0b013e3283628f98 [doi]
PST - aheadofprint
SO  - Int Clin Psychopharmacol. 2013 May 20.

PMID- 23694989
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 0219-1032 (Electronic)
IS  - 1016-8478 (Linking)
DP  - 2013 May 20
TI  - Nutrient regulation of the mTOR Complex 1 signaling pathway.
AB  - The mammalian target of rapamycin (mTOR) is an evolutionally conserved kinase
      which exists in two distinct structural and functional complexes, mTOR complex 1 
      (mTORC1) and mTOR complex 2 (mTORC2). Of the two complexes, mTORC1 couples
      nutrient abundance to cell growth and proliferation by sensing and integrating a 
      variety of inputs arising from amino acids, cellular stresses, energy status, and
      growth factors. Defects in mTORC1 regulation are implicated in the development of
      many metabolic diseases, including cancer and diabetes. Over the past decade,
      significant advances have been made in deciphering the complexity of the
      signaling processes contributing to mTORC1 regulation and function, but the
      mechanistic details are still not fully understood. In particular, how amino acid
      availability is sensed by cells and signals to mTORC1 remains unclear. In this
      review, we discuss the current understanding of nutrient-dependent control of
      mTORC1 signaling and will focus on the key components involved in amino acid
      signaling to mTORC1.
AD  - Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA,
      SangGyun_Kim@hms.harvard.edu.
FAU - Kim, Sang Gyun
AU  - Kim SG
FAU - Buel, Gwen R
AU  - Buel GR
FAU - Blenis, John
AU  - Blenis J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Mol Cells
JT  - Molecules and cells
JID - 9610936
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/03 [received]
PHST- 2013/05/06 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - 10.1007/s10059-013-0138-2 [doi]
PST - aheadofprint
SO  - Mol Cells. 2013 May 20.

PMID- 23694982
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1525-1438 (Electronic)
IS  - 1048-891X (Linking)
VI  - 23
IP  - 5
DP  - 2013 Jun
TI  - A randomized comparison of Cisplatin and oral vinorelbine as radiosensitizers in 
      aged or comorbid locally advanced cervical cancer patients.
PG  - 884-9
LID - 10.1097/IGC.0b013e3182915c69 [doi]
AB  - OBJECTIVE: Chemoradiation with cisplatin is considered the standard of care for
      patients with locally advanced cervical cancer; however, cisplatin could be
      difficult to use in aged patients or patients with comorbidities such as diabetes
      mellitus and blood hypertension; hence, it is important to investigate
      nonplatinum drugs for radiosensitization. In addition, oral cytotoxics may
      overcome the drawbacks of intravenous infusions and could be of easier
      administration. METHODS: In this small randomized trial, we tested cisplatin
      against oral vinorelbine as radiosensitizers in these patients. A total of 39
      patients 65 years or older or diabetic and hypertensive patients of any age were 
      randomized to cisplatin or oral vinorelbine at 40 mg/m or 60 mg/m, respectively. 
      Both drugs were administered weekly for 6 courses during pelvic external-beam
      radiotherapy and brachytherapy radiation. Efficacy and safety were assessed.
      RESULTS: Nineteen patients received oral vinorelbine, and 20 patients received
      cisplatin. The median cumulative dose to point A was 80.8 Gy for both groups, and
      the overall treatment time was 48 (42-54) and 50 (43-55) days for vinorelbine and
      cisplatin groups, respectively. Patients in both arms received a median of 5
      applications of chemotherapy. Treatment was well tolerated in both arms. The most
      frequent toxicity in both arms was lymphopenia grades 2 and 3. At a median
      follow-up time of 16 months (4-19), there were no differences in either
      progression-free survival or overall survival between groups. CONCLUSIONS: Our
      results suggest that these patient populations can safely be treated with either 
      cisplatin or navelbine as radiosensitizers; however, a larger randomized study is
      needed to demonstrate the noninferiority of oral vinorelbine as an easier and
      practical alternative for radiosensitization in cervical cancer.
AD  - *Division of Clinical Research, daggerDepartment of Radiotherapy, anddouble
      daggerUnit of Biomedical Research on Cancer, Instituto de Investigaciones
      Biomedicas, Universidad Nacional Autonoma de Mexico, Instituto Nacional de
      Cancerologia, Mexico City, Mexico.
FAU - Coronel, Jaime Alberto
AU  - Coronel JA
FAU - Cetina, Lucely Del Carmen
AU  - Cetina Ldel C
FAU - Cantu, David
AU  - Cantu D
FAU - Cerezo, Oscar
AU  - Cerezo O
FAU - Hernandez, Cintia Sanchez
AU  - Hernandez CS
FAU - Rivera, Lesbia
AU  - Rivera L
FAU - Chacon, Adela Poitevin
AU  - Chacon AP
FAU - Duenas-Gonzalez, Alfonso
AU  - Duenas-Gonzalez A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the
      International Gynecological Cancer Society
JID - 9111626
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1097/IGC.0b013e3182915c69 [doi]
AID - 00009577-201306000-00018 [pii]
PST - ppublish
SO  - Int J Gynecol Cancer. 2013 Jun;23(5):884-9. doi: 10.1097/IGC.0b013e3182915c69.

PMID- 23694765
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
DP  - 2013 May 18
TI  - An atlas and functional analysis of G-protein coupled receptors in human islets
      of Langerhans.
LID - S0163-7258(13)00119-8 [pii]
LID - 10.1016/j.pharmthera.2013.05.004 [doi]
AB  - G-protein coupled receptors (GPCRs) regulate hormone secretion from islets of
      Langerhans, and recently developed therapies for type-2 diabetes target islet
      GLP-1 receptors. However, the total number of GPCRs expressed by human islets, as
      well as their function and interactions with drugs, is poorly understood. In this
      review we have constructed an atlas of all GPCRs expressed by human islets: the
      'islet GPCRome'. We have used this atlas to describe how islet GPCRs interact
      with their endogenous ligands, regulate islet hormone secretion, and interact
      with drugs known to target GPCRs, with a focus on drug/receptor interactions that
      may affect insulin secretion. The islet GPCRome consists of 293 GPCRs, a majority
      of which have unknown effects on insulin, glucagon and somatostatin secretion.
      The islet GPCRs are activated by 271 different endogenous ligands, at least 131
      of which are present in islet cells. A large signalling redundancy was also
      found, with 119 ligands activating more than one islet receptor. Islet GPCRs are 
      also the targets of a large number of clinically used drugs, and based on their
      coupling characteristics and effects on receptor signalling we identified 107
      drugs predicted to stimulate and 184 drugs predicted to inhibit insulin
      secretion. The islet GPCRome highlights knowledge gaps in the current
      understanding of islet GPCR function, and identifies GPCR/ligand/drug
      interactions that might affect insulin secretion, which are important for
      understanding the metabolic side effects of drugs. This approach may aid in the
      design of new safer therapeutic agents with fewer detrimental effects on islet
      hormone secretion.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Diabetes Research Group, Division of Diabetes & Nutritional Sciences, King's
      College London School of Medicine, London, UK. Electronic address:
      stefan.amisten@kcl.ac.uk.
FAU - Amisten, Stefan
AU  - Amisten S
FAU - Salehi, Albert
AU  - Salehi A
FAU - Rorsman, Patrik
AU  - Rorsman P
FAU - Jones, Peter M
AU  - Jones PM
FAU - Persaud, Shanta J
AU  - Persaud SJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/02 [received]
PHST- 2013/05/03 [accepted]
AID - S0163-7258(13)00119-8 [pii]
AID - 10.1016/j.pharmthera.2013.05.004 [doi]
PST - aheadofprint
SO  - Pharmacol Ther. 2013 May 18. pii: S0163-7258(13)00119-8. doi:
      10.1016/j.pharmthera.2013.05.004.

PMID- 23693131
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1941-0042 (Electronic)
IS  - 1057-7149 (Linking)
DP  - 2013 May 17
TI  - An Automatic Graph-based Approach for Artery/Vein Classification in Retinal
      Images.
AB  - The classification of retinal vessels into artery/vein (A/V) is an important
      phase for automating the detection of vascular changes, and for the calculation
      of characteristic signs associated with several systemic diseases such as
      diabetes, hypertension, and other cardiovascular conditions. This paper presents 
      an automatic approach for A/V classification based on the analysis of a graph
      extracted from the retinal vasculature. The proposed method classifies the entire
      vascular tree by deciding on the type of each intersection point (graph nodes)
      and assigning one of two labels to each vessel segment (graph links). Final
      classification of a vessel segment as an artery or a vein is performed through
      the combination of the graph-based labeling results with a set of intensity
      features. The results of this proposed method are compared with manual labeling
      for three public databases. Accuracy values of 88.3%, 87.4% and 89.8% are
      obtained for the images of the INSPIRE-AVR, DRIVE and VICAVR databases,
      respectively. These results demonstrate that our method outperforms recent
      approaches for A/V classification.
FAU - Dashtbozorg, Behdad
AU  - Dashtbozorg B
FAU - Mendonca, A-M
AU  - Mendonca AM
FAU - Campilho, Aurelio
AU  - Campilho A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - IEEE Trans Image Process
JT  - IEEE transactions on image processing : a publication of the IEEE Signal
      Processing Society
JID - 9886191
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1109/TIP.2013.2263809 [doi]
PST - aheadofprint
SO  - IEEE Trans Image Process. 2013 May 17.

PMID- 23693076
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 18
TI  - ATP-binding cassette transporter G1 protects against endothelial dysfunction
      induced by high glucose.
LID - S0168-8227(13)00165-4 [pii]
LID - 10.1016/j.diabres.2013.04.009 [doi]
AB  - AIMS: ATP binding cassette transporter G1 (ABCG1), a regulator of cholesterol
      efflux to HDL, has been shown to decrease in macrophages and smooth muscle cells 
      under high glucose conditions. Endothelial cells have a high capacity to efflux
      sterols and express ABCG1. In the present study we explored the role of ABCG1 in 
      high glucose-induced endothelial dysfunction. METHODS: Human aortic endothelial
      cells (HAECs) were cultured under high glucose conditions. ABCG1 mRNA and protein
      expression in HAECs were measured by real time PCR and Western blot. Cholesterol 
      efflux and NO synthesis (NOS) activity were determined by means of scintillation 
      counting. Total intracellular cholesterol was determined by gas-liquid
      chromatography. The secretion of IL-6 and ICAM-1 was measured using ELISA. The
      generation of intracellular reactive oxygen species (ROS) was measured using a
      fluorescence microscope. RESULTS: We observed that high glucose suppressed ABCG1 
      expression and intracellular cholesterol efflux to HDL. Furthermore, high glucose
      increased the secretion of IL-6 and ICAM, as well as decreased phospho-eNOS
      protein expression and NOS activity. These processes were reversed by the
      up-regulation of ABCG1 using the liver X receptor (LXR) agonist T0901307 and an
      ABCG1 expression vector. In addition, high glucose-induced oxidative stress was
      reduced by the upregulation of ABCG1. In contrast, knock-down of ABCG1 in HAECs
      significantly increased the secretion of IL-6 and ICAM, as well as decreased
      phospho-eNOS protein expression and NOS activity. CONCLUSIONS: The present
      results suggest that ABCG1 plays an important role in protecting against
      endothelial dysfunction induced by high glucose.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Cardiovascular Medicine, Second Affiliated Hospital of Medical
      School, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China. Electronic
      address: xjh1224@163.com.
FAU - Xue, Jiahong
AU  - Xue J
FAU - Wang, Congxia
AU  - Wang C
FAU - Zhu, Canzhan
AU  - Zhu C
FAU - Li, Yongqin
AU  - Li Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/02/01 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/04/25 [accepted]
AID - S0168-8227(13)00165-4 [pii]
AID - 10.1016/j.diabres.2013.04.009 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 18. pii: S0168-8227(13)00165-4. doi:
      10.1016/j.diabres.2013.04.009.

PMID- 23692921
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 14
IP  - 1
DP  - 2013 May 21
TI  - Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of
      diabetes and improves beta cell preservation and function in male ZDF rats.
PG  - 28
AB  - BACKGROUND: The role of G protein-coupled receptor (GPR40), which is highly
      expressed in pancreatic beta cells, has been studied extensively in the
      amelioration of beta cell dysfunction in T2D using rat and mouse islets, beta
      cell lines and in animal models of diabetes. But its potential as a therapeutic
      target has not been fully explored. This aim of the study is to evaluate the
      therapeutic potential of CNX-011-67, a highly selective, potent and orally
      bioavailable GPR40 agonist, in controlling diabetes and other metabolic
      parameters. METHODS: Seven week old male ZDF rats were treated with either
      vehicle or CNX-011-67, 5 mg/kg twice daily, for seven weeks. The animals were
      subjected to oral glucose tolerance and insulin tolerance tests. Plasma glucose, 
      insulin, triglyceride, HbA1c, fructosamine and free fatty acids were measured at 
      selected time points. Pancreas from control and treated animals were subjected to
      insulin and pancreatic and duodenal homeobox 1 (PDX1) immunohistochemistry and
      were also evaluated by electron microscopy. Also the potential impact of
      CNX-011-67 on islet insulin secretion, content, ATP levels and markers of both
      glucose oxidation, beta cell health in rat islets under chronic glucolipotoxic
      conditions was evaluated. RESULTS: Treatment of male ZDF rats with CNX-011-67 for
      7 weeks significantly enhanced insulin secretion in response to oral glucose
      load, delayed the onset of fasting hyperglycemia by 3 weeks, reduced nonfasting
      glucose excursions, fasting free fatty acids and triglyceride levels. A
      significant increase in PDX1 expression and insulin content and reduction in
      plasma fructosamine, HOMA-IR, and beta cell apoptosis were observed. CNX-011-67
      improves glucose mediated insulin secretion, insulin gene transcription and islet
      insulin content in cultured rat islets under chronic glucolipotoxic condition.
      Also enhanced glucose oxidation in the form of increased islet ATP content and
      overall improvement in beta cell health in the form of reduced expression of
      stress markers (TXNIP and CHOP mRNA) were observed. CONCLUSIONS: These findings, 
      suggest that long-term oral therapy with CNX-011-67 could be of clinical value to
      provide good glycemic control and improve islet beta cell function.
FAU - Gowda, Nagesh
AU  - Gowda N
FAU - Dandu, Anilkumar
AU  - Dandu A
FAU - Singh, Jaideep
AU  - Singh J
FAU - Biswas, Sanghamitra
AU  - Biswas S
FAU - Raghav, Vijaya
AU  - Raghav V
FAU - Lakshmi, Mudigere N
AU  - Lakshmi MN
FAU - Shilpa, Pavagada C
AU  - Shilpa PC
FAU - Sunil, Venkategowda
AU  - Sunil V
FAU - Reddy, Ashokkumar
AU  - Reddy A
FAU - Sadasivuni, Manojkumar
AU  - Sadasivuni M
FAU - Aparna, Kumaraswamy
AU  - Aparna K
FAU - Verma, Mahesh Kumar
AU  - Verma MK
FAU - Moolemath, Yoganand
AU  - Moolemath Y
FAU - Anup, Mammen O
AU  - Anup MO
FAU - Venkataranganna, Marikunte V
AU  - Venkataranganna MV
FAU - Somesh, Baggavalli P
AU  - Somesh BP
FAU - Jagannath, Madanahalli R
AU  - Jagannath MR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
PMC - PMC3668190
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/01/04 [received]
PHST- 2013/05/21 [accepted]
PHST- 2013/05/21 [aheadofprint]
AID - 2050-6511-14-28 [pii]
AID - 10.1186/2050-6511-14-28 [doi]
PST - aheadofprint
SO  - BMC Pharmacol Toxicol. 2013 May 21;14(1):28.

PMID- 23692648
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 21
TI  - Multifactorial intervention for children with asthma and overweight (Mikado):
      study design of a randomised controlled trial.
PG  - 494
AB  - BACKGROUND: In children, the prevalence's of both obesity and asthma are
      disconcertingly high. Asthmatic children with obesity are characterised by less
      asthma control and a high need for asthma medication. As the obese asthmatic
      child is becoming more common in the clinical setting and the disease burden of
      the asthma-obesity phenotype is high, there is an increasing need for effective
      treatment in these children. In adults, weight reduction resulted in improved
      lung function, better asthma control and less need for asthma medication. In
      children this is hardly studied. The Mikado study aims to evaluate the
      effectiveness of a long term multifactorial weight reduction intervention, on
      asthma characteristics in children with asthma and a high body
      weight.Methods/design: The Mikado study is a two-armed, randomised controlled
      trial. In total, 104 participants will be recruited via online questionnaires,
      pulmonary paediatricians, the youth department of the Municipal Health Services
      and cohorts of existing studies. All participants will be aged 6--16 years, will 
      have current asthma, a Body Mass Index in the overweight or obesity range, and no
      serious comorbidities (such as diabetes, heart diseases). Participants in the
      intervention arm will receive a multifactorial intervention of 18 months
      consisting of sessions concerning sports, parental involvement, individual
      counselling and lifestyle advices including dietary advices and cognitive
      behavioural therapy. The control group will receive usual care. The primary
      outcome variables will include Forced Expiratory Volume in one second and Body
      Mass Index - Standard Deviation Score. Secondary outcomes will include other lung
      function parameters (including dynamic and static lung function parameters),
      asthma control, asthma-specific quality of life, use of asthma medication and
      markers of systemic inflammation and airway inflammation. DISCUSSION: In this
      randomised controlled trial we will study the potential of a multifactorial
      weight reduction intervention to improve asthma-related outcome measures in
      asthmatic children with overweight. Moreover, it will provide information about
      the underlying mechanisms in the relationship between asthma and a high body
      weight in children. These findings can contribute to optimal management programs 
      and better clinical guidelines for children with asthma and overweight.Trial
      registration: Clinicaltrial.gov NCT00998413.
FAU - Willeboordse, Maartje
AU  - Willeboordse M
FAU - van de Kant, Kim D
AU  - van de Kant KD
FAU - de Laat, Maroeska N
AU  - de Laat MN
FAU - van Schayck, Onno C
AU  - van Schayck OC
FAU - Mulkens, Sandra
AU  - Mulkens S
FAU - Dompeling, Edward
AU  - Dompeling E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/05/13 [received]
PHST- 2013/05/21 [accepted]
PHST- 2013/05/21 [aheadofprint]
AID - 1471-2458-13-494 [pii]
AID - 10.1186/1471-2458-13-494 [doi]
PST - aheadofprint
SO  - BMC Public Health. 2013 May 21;13(1):494.

PMID- 23692620
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1475-097X (Electronic)
IS  - 1475-0961 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Jul
TI  - Heat-washout - an objective method for diagnosing neuropathy and atherosclerosis 
      in diabetic patients.
PG  - 302-6
LID - 10.1111/cpf.12028 [doi]
AB  - BACKGROUND: The heat-washout method is an objective method that measures
      cutaneous blood flow rate (BFR) in ml (100 g. min)(-1) , previously found useful 
      for measuring toe BFR in non-diabetic patients with claudication. AIM: The method
      is used for evaluating the presence of a veno-arteriolar reflex (VAR) in the
      forefoot and signs of atherosclerosis in the first toe in type 2 diabetics.
      METHODS: Nine type 2 diabetics for +10 years, peripheral neuropathy, median age
      62, and 9 healthy subjects without diabetes, median age 52 were examined for the 
      presence of a VAR in the forefoot. A VAR was present when BFR decreased 25% or
      more with the foot 50 cm below heart level. Examinations for atherosclerosis were
      made in the pulp of the first toe. An increase in BFR of 50% or more with the
      foot 50 cm below heart level indicated the presence of atherosclerosis. RESULTS: 
      The VAR was significantly attenuated in type 2 diabetics with neuropathy compared
      to controls, (P<0.01). Only one patient with known neuropathy and diabetes showed
      a reflex compared to eight out of nine controls (P<0.01). The VAR was correlated 
      to the vibration perception threshold measured with biothesiometry (r = -0.661, P
      = 0.0003). Two patients with type 2 diabetes and neuropathy without clinical sign
      of peripheral artery disease (PAD) had an abnormal response similar to that seen 
      in subjects with intermittent claudication. CONCLUSION: The heat-washout method
      seems useful as and objective method for evaluating as well the presence of a VAR
      as atherosclerosis in type 2 diabetics.
CI  - (c) 2013 The Authors Clinical Physiology and Functional Imaging (c) 2013
      Scandinavian Society of Clinical Physiology and Nuclear Medicine.
AD  - Department of Geriatrics, Copenhagen University Hospital Hvidovre, Hvidovre,
      Denmark.
FAU - Midttun, M
AU  - Midttun M
FAU - Snorgaard, O
AU  - Snorgaard O
LA  - eng
PT  - Journal Article
DEP - 20130213
PL  - England
TA  - Clin Physiol Funct Imaging
JT  - Clinical physiology and functional imaging
JID - 101137604
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/09/21 [received]
PHST- 2013/01/08 [accepted]
PHST- 2013/02/13 [aheadofprint]
AID - 10.1111/cpf.12028 [doi]
PST - ppublish
SO  - Clin Physiol Funct Imaging. 2013 Jul;33(4):302-6. doi: 10.1111/cpf.12028. Epub
      2013 Feb 13.

PMID- 23692619
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1475-097X (Electronic)
IS  - 1475-0961 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Jul
TI  - Choline treatment affects the liver reticuloendothelial system and plasma fatty
      acid composition in diabetic rats.
PG  - 293-301
LID - 10.1111/cpf.12027 [doi]
AB  - PURPOSE: This study investigated effects of choline treatment on hepatic
      reticuloendothelial and biliary functions and plasma fatty acid composition in
      diabetic rats. METHODS: Diabetes was induced by streptozotocin (STZ). Choline was
      administered to untreated rats and a portion of STZ-treated rats for two
      sequences of five consecutive days, separated by a 2-day interval. Hepatic
      functions were studied using (99m) Tc Tin (II) colloid (TIN) and 99 mTc
      mebrofenin [bromo-iminodiacetic acid (BrIDA)] imaging. The TIN-uptake ratios
      (organ/whole body) of heart, liver and spleen, and the BrIDA-uptake ratios (organ
      or tissue/whole body) of liver, biliary tree and abdomen were obtained following 
      imaging studies. Fatty acids were analysed by GC/MS. RESULTS: Choline treatment
      did not attenuate hyperglycaemic development. Diabetic rats showed (i) a
      decreased TIN-uptake ratio in liver with co-increased ratios in heart and spleen;
      choline treatment diminished these changes, (ii) elevated BrIDA-uptake ratios in 
      biliary tree and abdomen but not in liver; choline treatment did not attenuate
      the elevations and (iii) decreases in plasma palmitoleic acid and oleic acid,
      reflecting an impaired stearoyl-CoA desaturase function; choline treatment did
      not affect the diminutions, but caused a decrease in arachidonic acid with a
      co-increase in linoleic acid. Some rats developed hypoproteinemia (HPO). HPO rats
      also exhibited decreases in plasma palmitoleic acid and oleic acid. Diabetes
      caused almost absence of palmitoleic acid in HPO rats. Choline treatment exerted 
      no effect on the plasma fatty acid composition of diabetic HPO rats. CONCLUSIONS:
      Choline treatment affected hepatic reticuloendothelial function and plasma fatty 
      acid composition, but not hepatobiliary function, in diabetic rats. Whether
      choline treatment is beneficial requires further studies.
CI  - (c) 2013 The Authors Clinical Physiology and Functional Imaging (c) 2013
      Scandinavian Society of Clinical Physiology and Nuclear Medicine.
AD  - Nuclear Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
FAU - Al-Saeedi, Fatma J
AU  - Al-Saeedi FJ
FAU - Cheng, Behling
AU  - Cheng B
LA  - eng
PT  - Journal Article
DEP - 20130124
PL  - England
TA  - Clin Physiol Funct Imaging
JT  - Clinical physiology and functional imaging
JID - 101137604
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/03/16 [received]
PHST- 2012/12/27 [accepted]
PHST- 2013/01/24 [aheadofprint]
AID - 10.1111/cpf.12027 [doi]
PST - ppublish
SO  - Clin Physiol Funct Imaging. 2013 Jul;33(4):293-301. doi: 10.1111/cpf.12027. Epub 
      2013 Jan 24.

PMID- 23692524
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1747-4949 (Electronic)
IS  - 1747-4930 (Linking)
DP  - 2013 May 22
TI  - Aortic stiffness and plasma brain natriuretic peptide predicts mortality in acute
      ischemic stroke.
LID - 10.1111/ijs.12049 [doi]
AB  - BACKGROUND: The study aimed to evaluate the prognostic role and discriminative
      power of aortic stiffness and plasma brain natriuretic peptide levels in a cohort
      of patients hospitalized for acute ischemic stroke. METHODS AND RESULTS: Three
      hundred and ten consecutive patients aged 50 years and older with a first episode
      of acute ischemic stroke were prospectively evaluated. All patients were admitted
      to the hospital within 24 h of the onset of stroke symptoms. The type of acute
      ischemic stroke was classified according to the Trial of Org 10172 in Acute
      Stroke Treatment classification. Blood samples were taken for measurement of
      brain natriuretic peptide levels at admission. Aortic stiffness indices, aortic
      strain and distensibility, were calculated from the aortic diameters measured by 
      transthoracic echocardiography. The patients were followed for one-year or until 
      death, whichever came first. Death occurred in 51 (16.5%) patients. On
      multivariate logistic regression analysis, National Institutes of Health Stroke
      Scale score >13, diabetes, brain natriuretic peptide >235 pg/mL, aortic
      distensibility, and aortic strain were associated with all-cause mortality. The
      optimal cutoff level of brain natriuretic peptide to distinguish the deceased
      group from the survival group was 235 pg/mL (sensitivity 71.0% and specificity
      63.0%) and to distinguish cardioembolic stroke from noncardioembolic stroke was
      155 pg/mL (sensitivity 81% and specificity 63%). CONCLUSIONS: Aortic stiffness
      and brain natriuretic peptide predict mortality in patients with first-ever acute
      ischemic stroke. Brain natriuretic peptide also differentiates cardioembolic
      stroke from noncardioembolic stroke.
CI  - (c) 2013 The Authors. International Journal of Stroke (c) 2013 World Stroke
      Organization.
AD  - Department of Cardiology, Haydarpasa Numune Education and Research Hospital,
      Istanbul, Turkey.
FAU - Biteker, Murat
AU  - Biteker M
FAU - Ozden, Temel
AU  - Ozden T
FAU - Dayan, Akin
AU  - Dayan A
FAU - Tekkesin, Ahmet Ilker
AU  - Tekkesin AI
FAU - Misirli, Cemile Handan
AU  - Misirli CH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Int J Stroke
JT  - International journal of stroke : official journal of the International Stroke
      Society
JID - 101274068
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1111/ijs.12049 [doi]
PST - aheadofprint
SO  - Int J Stroke. 2013 May 22. doi: 10.1111/ijs.12049.

PMID- 23692499
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
DP  - 2013 May 21
TI  - The value of routine screening for peripheral arterial disease in stable
      outpatients with a history of coronary artery or cerebrovascular disease.
LID - 10.1111/ijcp.12148 [doi]
AB  - BACKGROUND: Frequently unrecognised, PAD is associated with reduced quality of
      life and an increased mortality rate because of a greater propensity for fatal
      ischaemic events. PAD commonly coexists with coronary and cerebrovascular disease
      and is associated with poorer outcomes in such patients. The Edinburgh
      Claudication Questionnaire (ECQ) and the ankle-brachial index (ABI) are screening
      methods to identify the presence of PAD. This study used these methods to
      estimate the rate of previously undiagnosed PAD and to validate the ECQ against
      ABI in a Canadian outpatient population with manifest cerebrovascular or coronary
      disease. METHODS: At a regular office visit, patients completed the ECQ and were 
      categorised as ECQ(+) or ECQ(-). All ECQ(+) and a randomly selected 25% of ECQ(-)
      patients were referred for ABI measurement. An ABI < 0.9 was considered positive.
      The prevalence of PAD in the patient population and the sensitivity and
      specificity of the ECQ score against the ABI were assessed. RESULTS: Of 2235
      patients enrolled, 815 were selected for an ABI [ECQ(-), n = 478; ECQ(+), n =
      337]. Extrapolated PAD prevalence in the total population was 12.3% (highest
      arterial pressure [HAP] method) and 20.8% (lowest arterial pressure [LAP]
      method), with a significantly higher prevalence found in diabetic patients than
      non-diabetic patients (p < 0.0001). Because ECQ is only a measure of symptomatic 
      disease, it had poor sensitivity (35.3% and 25.8%), but high specificity (88.2%
      and 88.3%) using the HAP and LAP methods of ABI measurement, respectively.
      CONCLUSIONS: Undiagnosed PAD is common in stable outpatients with a prior history
      of manifest cardiovascular disease, particularly in those with diabetes. The ECQ 
      does not possess the diagnostic value of the ABI in detecting PAD in this
      high-risk population, but may be useful to raise suspicion of PAD to be confirmed
      by ABI assessment.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Family and Community Medicine, University of Toronto, Toronto, ON, 
      Canada.
FAU - Bell, A D
AU  - Bell AD
FAU - Roussin, A
AU  - Roussin A
FAU - Popovici-Toma, D
AU  - Popovici-Toma D
FAU - Girard, M
AU  - Girard M
FAU - Chiu, J F
AU  - Chiu JF
FAU - Huckell, V
AU  - Huckell V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/06/04 [received]
PHST- 2013/01/25 [accepted]
AID - 10.1111/ijcp.12148 [doi]
PST - aheadofprint
SO  - Int J Clin Pract. 2013 May 21. doi: 10.1111/ijcp.12148.

PMID- 23692476
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 22
TI  - Breastfeeding in women with diabetes: lower rates despite greater rewards. A
      population-based study.
LID - 10.1111/dme.12238 [doi]
AB  - AIMS: To explore intention to breastfeed and breastfeeding rates in hospital and 
      on discharge across women with pre-gestational or gestational diabetes mellitus, 
      or no diabetes. METHODS: A retrospective cohort analysis was conducted using data
      from four Ontario hospitals. Women who delivered a viable infant between 1 April 
      2008 and 31 March 2010 were included in the study. Unadjusted and adjusted odds
      ratios were calculated for each outcome measure and were used to compare the
      breastfeeding rates among women with and without diabetes. RESULTS: After
      controlling for potential confounders, women with insulin-treated diabetes were
      less likely to intend to breastfeed, when compared with women without diabetes
      (adjusted odds ratio 0.49, 95% CI 0.27-0.89). In hospital, women with
      insulin-treated diabetes were least likely to breastfeed (odds ratio 0.42, 95% CI
      0.26-0.67), followed by women with non-insulin-treated diabetes (odds ratio 0.50,
      95% CI 0.26-0.96) and women with gestational diabetes (odds ratio 0.77, 95% CI
      0.68-0.87) when compared with women without diabetes. On discharge, women with
      insulin-treated diabetes were least likely to breastfeed (odds ratio 0.38, 95% CI
      0.24-0.60), followed by women with gestational diabetes (odds ratio 0.75, 95% CI 
      0.66-0.85); rates of breastfeeding among women with non-insulin-treated diabetes 
      were comparable on discharge with those of women without diabetes. Women seeking 
      care from an antenatal provider other than a physician were 2-3 times more likely
      to breastfeed in hospital and on discharge. CONCLUSIONS: Women with
      insulin-treated diabetes had the poorest outcomes with respect to breastfeeding
      rates. Gestational and non-insulin-treated diabetes were associated with lower
      rates of breastfeeding in hospital, while gestational diabetes was additionally
      associated with lower breastfeeding rates on discharge. This article is protected
      by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Obstetrics and Maternal Newborn Investigations (OMNI) Research Group, Ottawa
      Hospital Research Institute, The Ottawa Hospital, Ottawa, ON; Faculty of
      Medicine, University of Calgary, Calgary, AB.
FAU - Finkelstein, S A
AU  - Finkelstein SA
FAU - Keely, E
AU  - Keely E
FAU - Feig, D S
AU  - Feig DS
FAU - Tu, X
AU  - Tu X
FAU - Yasseen, A S 3rd
AU  - Yasseen AS 3rd
FAU - Walker, M
AU  - Walker M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/06/29 [received]
PHST- 2013/03/31 [revised]
PHST- 2013/05/15 [accepted]
AID - 10.1111/dme.12238 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 22. doi: 10.1111/dme.12238.

PMID- 23692438
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 22
TI  - Association between KCNQ1 genetic variants and QT interval in a Chinese
      population.
LID - 10.1111/dme.12237 [doi]
AB  - AIMS: There is a close link between electrocardiographic ventricular
      repolarization QT parameters and Type 2 diabetes. The aim of the present study
      was to assess the effects of QT-related and diabetes-related variants in KCNQ1 on
      QT interval in a Chinese population. METHODS: We recruited 2415 patients with
      Type 2 diabetes and 1163 subjects with normal glucose regulation in the present
      study. QT interval was obtained and the heart rate-corrected QT interval (QTc)
      was calculated using Bazett's formula. Four single nucleotide polymorphisms in
      KCNQ1 were selected (rs12296050, rs12576239, rs2237892 and rs2237895) and
      genotyped. RESULTS: In participants with normal glucose regulation, the minor
      allele T of rs12296050 was associated with a 3.46-ms QTc prolongation under an
      additive model (P = 0.0109, empirical P = 0.0498). In patients with Type 2
      diabetes, we did not find any association for the single nucleotide
      polymorphisms. CONCLUSIONS: Our findings indicate that KCNQ1 is associated with
      QT interval in a Chinese population with normal glucose regulation. This article 
      is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai
      Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes.
FAU - Yu, W
AU  - Yu W
FAU - Zhang, F
AU  - Zhang F
FAU - Hu, W
AU  - Hu W
FAU - Zhang, R
AU  - Zhang R
FAU - Wang, C
AU  - Wang C
FAU - Lu, J
AU  - Lu J
FAU - Jiang, F
AU  - Jiang F
FAU - Tang, S
AU  - Tang S
FAU - Peng, D
AU  - Peng D
FAU - Chen, M
AU  - Chen M
FAU - Bao, Y
AU  - Bao Y
FAU - Xiang, K
AU  - Xiang K
FAU - Hu, C
AU  - Hu C
FAU - Jia, W
AU  - Jia W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/10/08 [received]
PHST- 2013/04/12 [revised]
PHST- 2013/05/15 [accepted]
AID - 10.1111/dme.12237 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 22. doi: 10.1111/dme.12237.

PMID- 23692400
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 22
TI  - Relationship between HbA and risk of all-cause hospital admissions among people
      with Type 2 diabetes.
LID - 10.1111/dme.12235 [doi]
AB  - AIM: To investigate the relationship between HbA1c and the 2-year risk of
      hospitalization among people with Type 2 diabetes. METHODS: In total, 4704
      patients from 18 general practices in Cambridgeshire were included. Glycaemic
      exposure was assessed in 2008-2009. The primary outcome was all-cause hospital
      admissions in 2010-2011. Adjusted relative risks for each HbA1c quintile were
      estimated using Cox models. Further relationships between HbA1c and risks were
      explored using spline models. RESULTS: There was a non-linear relationship
      between HbA1c and the risk of all-cause, diabetes and vascular admissions (all P 
      < 0.001 for linearity test) with an HbA1c threshold of 61 (95% CI 55-66) mmol/mol
      [7.7 (95% CI 7.2-8.2)%]. For every 11 mmol/mol (1%) HbA1c above the threshold,
      the risks increased by 6.3% for all-cause admission, 6.4% for a diabetes
      admission and 15.9% for a cardiovascular admission (all P < 0.001). The overall
      hospitalization risks of having an HbA1c above, rather than at, the threshold,
      were 19.1 16.3 and 54.3% greater, respectively. There were non-significantly
      greater risks of hospital admission below the threshold. CONCLUSION: In people
      with Type 2 diabetes, a non-linear relationship exists between HbA1c and the risk
      of hospitalization. A threshold of 61 mmol/mol (7.7%) was associated with the
      lowest rate of all-cause hospital admissions. Further research should investigate
      the causes of admissions below and above this threshold, with a view to
      developing strategies to reduce the excess hospitalization among patients with
      diabetes. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Institute of Metabolic Science, Cambridge University Hospitals NHS Foundation
      Trust, Cambridge, UK.
FAU - Yu, D
AU  - Yu D
FAU - Simmons, D
AU  - Simmons D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/01/11 [received]
PHST- 2013/04/15 [revised]
PHST- 2013/05/15 [accepted]
AID - 10.1111/dme.12235 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 22. doi: 10.1111/dme.12235.

PMID- 23692373
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 22
TI  - Late effects of childhood cancer treatment: severe hypertriglyceridaemia, central
      obesity, non alcoholic fatty liver disease and diabetes as complications of
      childhood total body irradiation.
LID - 10.1111/dme.12234 [doi]
AB  - BACKGROUND: Childhood cancer survivors may develop a number of endocrine
      complications linked to organ failure, such as hypogonadism, diabetes and growth 
      hormone deficiency. However, increasing evidence now suggests that total body
      irradiation treatment, specifically, is linked with future risk of insulin
      resistance, hepatic steatosis and dyslipidaemia, possibly because total body
      irradiation affects adipocyte differentiation and impairs subcutaneous adipose
      tissue depot expansion during times of positive energy balance. CASE REPORT: We
      describe a 20-year-old woman who developed pancreatitis with severe
      hypertriglyceridaemia (serum triglycerides > 300 mmol/l) that required
      plasmapheresis. She had received total body irradiation prior to her bone marrow 
      transplant at age 6 years for relapsed acute lymphoblastic leukaemia. She
      developed ovarian failure at age 12 years. At age 15 years she was noted to have 
      hyperglycaemia, increased blood pressure, hepatic steatosis and mild
      hypertriglyceridaemia. She presented with severe hypertriglyceridaemia and
      eruptive xanthoma, and developed pancreatitis 12 h after admission. She was
      treated with plasmapheresis and intravenous insulin and made an excellent
      recovery. We implicate and discuss total body irradiation as the major
      contributing factor to her severe hypertriglyceridaemia, compounded by worsening 
      glycaemic control, oestrogen deficiency and a changing adult lifestyle.
      CONCLUSION: Children who have received total body irradiation are at risk of
      diabetes and an exaggerated form of the metabolic syndrome with
      hypertriglyceridaemia, which can be life-threatening. We suggest that survivors
      of total body irradiation treatment require careful lifelong monitoring of their 
      metabolic status. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Diabetes and Endocrinology, University Hospitals of Southampton NHS
      Foundation Trust.
FAU - Rajendran, R
AU  - Rajendran R
FAU - Abu, E
AU  - Abu E
FAU - Fadl, A
AU  - Fadl A
FAU - Byrne, C D
AU  - Byrne CD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/01/16 [received]
PHST- 2013/05/15 [accepted]
AID - 10.1111/dme.12234 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 22. doi: 10.1111/dme.12234.

PMID- 23692363
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1557-8100 (Electronic)
IS  - 1536-2310 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun
TI  - Identification of Key Nodes of Type 2 Diabetes Mellitus Protein Interactome and
      Study of their Interactions with Phloridzin.
PG  - 302-17
LID - 10.1089/omi.2012.0115 [doi]
AB  - Abstract Network biology-inspired approaches could be used effectively in probing
      regulatory processes by which small molecules intervene with disease mechanisms. 
      The present study aims at identification of key targets of type 2 diabetes
      mellitus (T2DM) by network analysis of the underlying protein interactome, and
      probing for mechanisms by which phloridzin could be critical at altering the
      disease phenotype. Towards this goal, we constructed a protein-protein
      interaction network associated with T2DM, starting from candidate genes and
      systems-level interactions data available. The relevance of the network
      constructed was verified with the help of gene ontology, node deletion, and
      biological essentiality studies. Using a network analysis method, MAPK1, EP300,
      and SMAD2 were identified as the most central proteins of potential therapeutic
      value. Phloridzin, a known antidiabetic agent, potentially interacts with
      proteins central to T2DM mechanisms. The structural understanding of interaction 
      of phloridzin with these proteins of relevance to T2DM could provide better
      insight into its regulatory mechanisms and help in developing better therapeutic 
      agents. The molecular docking results suggest that phloridzin is potentially
      involved in making critical interactions with MAPK1. These results could further 
      be validated by experimental studies and could be used to design therapeutic
      agents for T2DM intervention.
AD  - Biotechnology Division, Institute of Himalayan Bioresource Technology, Council of
      Scientific and Industrial Research (CSIR-IHBT) , Palampur, India .
FAU - Randhawa, Vinay
AU  - Randhawa V
FAU - Sharma, Purnima
AU  - Sharma P
FAU - Bhushan, Shashi
AU  - Bhushan S
FAU - Bagler, Ganesh
AU  - Bagler G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - OMICS
JT  - Omics : a journal of integrative biology
JID - 101131135
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1089/omi.2012.0115 [doi]
PST - ppublish
SO  - OMICS. 2013 Jun;17(6):302-17. doi: 10.1089/omi.2012.0115.

PMID- 23692346
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Vitamin D levels during and after resolution of ketoacidosis in children with new
      onset Type 1 diabetes.
LID - 10.1111/dme.12200 [doi]
AB  - AIM: To study the effect of ketoacidosis on measured 25-hydroxyvitamin D3 in
      children with new onset Type 1 diabetes. METHODS: Measurement of pH and
      bicarbonate levels was carried out in children with newly diagnosed Type 1
      diabetes at presentation with ketoacidosis. 25-hydroxyvitamin D3 estimation was
      carried out at presentation (timepoint 1) and 1 month later (timepoint 2). There 
      was no significant difference in the mean (+/-sd) 25-hydroxyvitamin D3 levels
      [35.39 (+/-25.79) vs 39.63 (+/-48.03) nmol/L; P = 0.661) at the two timepoints in
      the study. RESULTS: Correlation analysis revealed a positive correlation between 
      bicarbonate levels and timepoint 1, i.e. the lower the bicarbonate levels, the
      lower were the timepoint 1 levels and vice versa (correlation coefficient 0.538, 
      P = 0.001). Timepoint 2 levels also showed a positive correlation with serum
      bicarbonate levels with a correlation coefficient of 0.379 (P = 0.032). None of
      the variables other than bicarbonate,.(age, gender, BMI, pH or time), was found
      to have the predictive ability for timepoint1 levels. Similarly for predicting
      timepoint 2 levels, BMI was found to have independent predictive ability in
      addition to bicarbonate. CONCLUSIONS: Severe ketoacidosis, as judged by
      bicarbonate but not pH, may transiently lower 25-hydroxyvitamin D3 levels in
      children with new onset Type 1 diabetes. Persistence of low 25-hydroxyvitamin D3 
      levels after resolution of ketoacidosis suggests a state of permanent vitamin D
      deficiency in our patient population.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Department of Paediatrics, Postgraduate Institute of Medical Education and
      Research, Chandigarh, India.
FAU - Devidayal
AU  - Devidayal
FAU - Singh, M K
AU  - Singh MK
FAU - Sachdeva, N
AU  - Sachdeva N
FAU - Singhi, S
AU  - Singhi S
FAU - Attri, S V
AU  - Attri SV
FAU - Jayashree, M
AU  - Jayashree M
FAU - Bhalla, A K
AU  - Bhalla AK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/03/14 [accepted]
AID - 10.1111/dme.12200 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12200.

PMID- 23692306
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
DP  - 2013 May 21
TI  - BCG/DNAhsp65 prime-boost is protective against diabetes in NOD mice but not in
      the STZ model of type 1 diabetes.
LID - 10.1111/cei.12140 [doi]
AB  - Diabetes type I is a disease caused by autoimmune destruction of the beta cells
      in the pancreas that leads to a deficiency in insulin production. The aim of this
      study was to evaluate the prophylactic potential of a prime-boost strategy
      involving BCG and the pVAXhs65 vaccine (BCG/DNAhsp65) in diabetes induced by
      streptozotocin (STZ) in C57BL/6 mice and also in spontaneous type 1 diabetes in
      NOD mice. BCG/DNAhsp65 vaccination in NOD mice determined weight gain, protection
      against hyperglycaemia, decreased islet inflammation, higher levels of cytokine
      production by the spleen and reduced number of regulatory T cells in the spleen
      compared with non-immunized NOD mice. In the STZ model, however, there was no
      significant difference in the clinical parameters. Although this vaccination
      strategy did not protect mice in the STZ model, it was very effective in NOD
      mice. This is the first report demonstrating that a prime-boost strategy could be
      explored as an immunomodulatory procedure in autoimmune diseases.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Microbiology and Immunology, Biosciences Institute, Univ. Estadual 
      Paulista (UNESP), Botucatu, Sao Paulo, Brazil.
FAU - da Rosa, Larissa Camargo
AU  - da Rosa LC
FAU - Chiuso-Minicucci, Fernanda
AU  - Chiuso-Minicucci F
FAU - Zorzella-Pezavento, Sofia Fernanda Goncalves
AU  - Zorzella-Pezavento SF
FAU - Franca, Thais Graziela Donega
AU  - Franca TG
FAU - Ishikawa, Larissa Lumi Watanabe
AU  - Ishikawa LL
FAU - Colavite, Priscila Maria
AU  - Colavite PM
FAU - Balbino, Bianca
AU  - Balbino B
FAU - Tavares, Lais Calissi Brisolla
AU  - Tavares LC
FAU - Silva, Celio Lopes
AU  - Silva CL
FAU - Marques, Camila
AU  - Marques C
FAU - Ikoma, Maura Rosane Valerio
AU  - Ikoma MR
FAU - Sartori, Alexandrina
AU  - Sartori A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/04/30 [accepted]
AID - 10.1111/cei.12140 [doi]
PST - aheadofprint
SO  - Clin Exp Immunol. 2013 May 21. doi: 10.1111/cei.12140.

PMID- 23692212
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1442-2018 (Electronic)
IS  - 1441-0745 (Linking)
DP  - 2013 May 21
TI  - Supporting adolescents with type 1 diabetes mellitus: A qualitative study.
LID - 10.1111/nhs.12070 [doi]
AB  - Without sufficient support, type 1 diabetes mellitus often disturbs patients'
      normal lives. This study describes and explores the support that Iranian
      adolescents with type 1 diabetes mellitus experienced. Semistructured interviews 
      were conducted with ten adolescents, seven family members, one dietitian, one
      nurse, and one school nurse. Participants were chosen using purposive sampling
      from two teaching hospitals and one high school in two urban areas of Iran. Using
      standard procedures for content analysis, three main themes were identified:
      maintaining a normal life; receiving tangible, informational, and emotional
      support from the family and society; and advancement of life toward
      normalization. The cornerstone of maintaining a normal life for adolescents with 
      type 1 diabetes mellitus is to adopt an active role in taking care of themselves 
      within their systems of support.
CI  - (c) 2013 Wiley Publishing Asia Pty Ltd.
AD  - Nursing, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Rostami, Shahnaz
AU  - Rostami S
FAU - Parsa-Yekta, Zohreh
AU  - Parsa-Yekta Z
FAU - Najafi Ghezeljeh, Tahereh
AU  - Najafi Ghezeljeh T
FAU - Vanaki, Zohreh
AU  - Vanaki Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Nurs Health Sci
JT  - Nursing & health sciences
JID - 100891857
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/11/03 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/05 [accepted]
AID - 10.1111/nhs.12070 [doi]
PST - aheadofprint
SO  - Nurs Health Sci. 2013 May 21. doi: 10.1111/nhs.12070.

PMID- 23692178
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1029-2470 (Electronic)
IS  - 1029-2470 (Linking)
DP  - 2013 May 21
TI  - Molecular effects of advanced glycation end products (AGEs) on cell signalling
      pathways, ageing and pathophysiology.
AB  - ABSTRACT Advanced glycation end-products (AGEs) are a heterogeneous group of
      compounds formed by the Maillard chemical process of non-enzymatic glycation of
      free amino groups of proteins, lipids and nucleic acids. This chemical
      modification of biomolecules is triggered by endogenous hyperglycaemic or
      oxidative stress-related processes. Additionally, AGEs can derive from exogenous,
      mostly diet-related, sources. Considering that AGE accumulation in tissues
      correlates with ageing and is a hallmark in several age-related diseases it is
      not surprising that the role of AGEs in ageing and pathology has become
      increasingly evident. The receptor for AGEs (RAGE) is a single transmembrane
      protein being expressed in a wide variety of human cells. RAGE binds a broad
      repertoire of extracellular ligands and mediates responses to stress conditions
      by activating multiple signal transduction pathways being mostly responsible for 
      acute and/or chronic inflammation. RAGE activation has been implicated in ageing 
      as well as in a number of age-related diseases, including atherosclerosis,
      neurodegeneration, arthritis, stoke, diabetes and cancer. Here we present a
      synopsis of findings that relate to AGEs reported implication in cell signalling 
      pathways and ageing, as well as in pathology. Potential implications and
      opportunities for translational research and the development of new therapies are
      also discussed.
FAU - Nedic, Olgica
AU  - Nedic O
FAU - Rattan, Suresh I S
AU  - Rattan SI
FAU - Grune, Tilman
AU  - Grune T
FAU - Trougakos, Ioannis P
AU  - Trougakos IP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Free Radic Res
JT  - Free radical research
JID - 9423872
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.3109/10715762.2013.806798 [doi]
PST - aheadofprint
SO  - Free Radic Res. 2013 May 21.

PMID- 23692152
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
DP  - 2013 May 21
TI  - Factors associated with post-stroke anger proneness in ischaemic stroke patients.
LID - 10.1111/ene.12199 [doi]
AB  - BACKGROUND AND PURPOSE: Factors related to post- stroke anger proneness (PSAP)
      are poorly studied. The aim of the present study was to determine the frequency
      of, and the factors related to, PSAP in the acute stage of stroke. Serotonin
      transporter protein genes and monoamine oxidase A (MAO-A) gene polymorphisms were
      also examined. METHODS: A total of 508 patients with acute IS were screened for
      PSAP at admission after stroke, using the modified Spielberger Trait Anger Scale.
      Blood samples were collected from each participant for DNA extraction and
      genotyping. The promoter of serotonin transporter protein (5-HTTLPR), the
      variable number of tandem repeat polymorphisms within intron 2 (VNTR STin2), and 
      the 30-bp functional VNTR polymorphism in the promoter region of the MAO-A gene
      (MAOA-uVNTR) were genotyped. RESULTS: Post- stroke anger proneness was present in
      15.1% of patients at admission. The factors related to PSAP were diabetes
      mellitus (P < 0.05), previous stroke (P < 0.01), motor and sensory dysfunction (P
      < 0.01), National Institutes of Health Stroke Scale (NIHSS) at admission (P <
      0.01), and MAO-A gene polymorphism (P < 0.05). Multiple logistic regression
      analyses showed that previous stroke (95% CI: 1.33-4.25, P < 0.01), NIHSS at
      admission (95% CI: 1.09-1.26, P < 0.01), and low MAO-A activity (95% CI:
      1.19-3.47, P = 0.01) were the factors related to PSAP. CONCLUSIONS: Our results
      show that PSAP is relatively prevalent and that previous stroke, neurological
      dysfunction and the MAO-A gene are involved in the development of PSAP.
CI  - (c) 2013 The Author(s) European Journal of Neurology (c) 2013 EFNS.
AD  - College of Nursing, Research Institute of Nursing Science, Seoul National
      University, Seoul, Korea.
FAU - Choi-Kwon, S
AU  - Choi-Kwon S
FAU - Han, K
AU  - Han K
FAU - Cho, K-H
AU  - Cho KH
FAU - Choi, S
AU  - Choi S
FAU - Suh, M
AU  - Suh M
FAU - Nah, H-W
AU  - Nah HW
FAU - Kim, J S
AU  - Kim JS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Eur J Neurol
JT  - European journal of neurology : the official journal of the European Federation
      of Neurological Societies
JID - 9506311
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/11/29 [received]
PHST- 2013/04/18 [accepted]
AID - 10.1111/ene.12199 [doi]
PST - aheadofprint
SO  - Eur J Neurol. 2013 May 21. doi: 10.1111/ene.12199.

PMID- 23692133
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1442-2018 (Electronic)
IS  - 1441-0745 (Linking)
DP  - 2013 May 21
TI  - Factors related to prediabetes among postpartum Thai women with a history of
      gestational diabetes mellitus.
LID - 10.1111/nhs.12055 [doi]
AB  - Women with a history of gestational diabetes mellitus are at risk of developing
      prediabetes. Using a cross-sectional analytic design, the factors related to
      prediabetes among Thai women (n = 210) with a history of gestational diabetes
      mellitus were investigated. The main outcomes measured were two-hour plasma
      glucose after taking a 75 g oral glucose tolerance test at a six week postpartum 
      visit. Data were analyzed using descriptive statistics and Pearson's correlation.
      The study showed that the incidence of prediabetes among postpartum Thai women
      was 26.67%. Factors associated with prediabetes were: (i) being over 35 years of 
      age; (ii) three or more pregnancies; (iii) recurrent gestational diabetes
      mellitus; (iv) high plasma glucose before taking a 100 g glucose tolerance test
      and high postprandial plasma glucose during pregnancy; and (v) being overweight
      or obese at six weeks' postpartum. The results showed that nursing interventions 
      need to be implemented to reduce plasma glucose and body mass index in order to
      prevent or reverse prediabetes.
CI  - (c) 2013 Wiley Publishing Asia Pty Ltd.
AD  - Department of Obstetric Nursing and Midwifery, Prince of Songkla University, Hat 
      Yai, Songkhla, Thailand.
FAU - Youngwanichsetha, Sununta
AU  - Youngwanichsetha S
FAU - Phumdoung, Sasitorn
AU  - Phumdoung S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Nurs Health Sci
JT  - Nursing & health sciences
JID - 100891857
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2012/08/04 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/02/26 [accepted]
AID - 10.1111/nhs.12055 [doi]
PST - aheadofprint
SO  - Nurs Health Sci. 2013 May 21. doi: 10.1111/nhs.12055.

PMID- 23692012
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1466-7657 (Electronic)
IS  - 0020-8132 (Linking)
VI  - 60
IP  - 2
DP  - 2013 Jun
TI  - Development and validation of diabetes empowerment questionnaire in Iranian
      people with type 2 diabetes.
PG  - 267-73
LID - 10.1111/inr.12007 [doi]
AB  - BACKGROUND: Diabetes self-management education programmes which have been
      reported to improve the self-efficacy of diabetic people can lead to their
      empowerment. Specialized diabetes nurses also play a fundamental role in
      empowering patients with diabetes through improving their knowledge and
      self-care. AIM: The purpose of this study was to develop a valid and reliable
      questionnaire to measure empowerment in Iranian people with type 2 diabetes.
      METHODS: Important subscales of patient empowerment were identified by an expert 
      panel. The subscales included active self-care, coping with personal and social
      concerns, basic knowledge related to diabetes management and patient-physician
      communication. Questions related to each subscale were generated and the expert
      panel renewed the questionnaire to ensure relevance and clarity of the items.
      Patient focus groups were conducted to establish the face validity of the
      questionnaire. The final questionnaire consisted of 15 items organized in three
      subscales. In a population-based study, a sample of 378 people with type 2
      diabetes was recruited. Reliability coefficient (Cronbach's alpha) was calculated
      for all of the subscales. Convergent validity was assessed by Pearson's product
      moment correlation. The scree test was used to select significant subscales.
      FINDINGS: Two hundred forty-seven female and 131 male subjects with type 2
      diabetes filled out the questionnaire. Three subscales were derived from factor
      analysis considering item-component loading of 0.4 as significant: 'active
      self-care' (Cronbach's alpha: 0.78), 'basic knowledge related to diabetes
      management' (Cronbach's alpha: 0.72) and 'coping with personal and social
      concerns' (Cronbach's alpha: 0.51). The scree plot of the eigenvalues of 15 items
      proposed three subscale solutions. Internal consistency reliabilities for the
      three subscales were acceptable (alpha: 0.51-0.78). CONCLUSIONS: The Diabetes
      Empowerment Questionnaire is a reliable and valid tool to assess patient
      empowerment in Iranian people with type 2 diabetes.
CI  - (c) 2013 The Authors. International Nursing Review (c) 2013 International Council
      of Nurses.
AD  - Endocrine Research Center (Firouzgar), Institute of Endocrinology and Metabolism,
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Aghili, R
AU  - Aghili R
FAU - Khamseh, M E
AU  - Khamseh ME
FAU - Malek, M
AU  - Malek M
FAU - Banikarimi, A S
AU  - Banikarimi AS
FAU - Baradaran, H R
AU  - Baradaran HR
FAU - Ebrahim Valojerdi, A
AU  - Ebrahim Valojerdi A
LA  - eng
PT  - Journal Article
DEP - 20130220
PL  - England
TA  - Int Nurs Rev
JT  - International nursing review
JID - 7808754
SB  - IM
SB  - N
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/02/20 [aheadofprint]
AID - 10.1111/inr.12007 [doi]
PST - ppublish
SO  - Int Nurs Rev. 2013 Jun;60(2):267-73. doi: 10.1111/inr.12007. Epub 2013 Feb 20.

PMID- 23691979
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1744-7631 (Electronic)
IS  - 1472-8222 (Linking)
DP  - 2013 May 22
TI  - Non-glycemic effects of pioglitazone and incretin-based therapies.
AB  - Atherosclerosis and cardiovascular events are highly prevalent and represent the 
      major cause of mortality in patients with type 2 diabetes. Therefore, there is
      significant interest in the non-glycemic properties of anti-diabetic agents,
      particularly on those that are effective on cardiovascular risk factors.
      Thiazolidinediones and incretin-based therapies (IBTs) represent some of the most
      recent treatment options approved for the management of type 2 diabetes; these
      agents have shown important glycemic effects, as well as a number of non-glycemic
      effects. The latter include those on body weight, inflammation, hypertension and 
      dyslipidemia, thus impacting the different components of the metabolic syndrome. 
      Pioglitazone has been shown to significantly reduce cardiovascular adverse
      outcomes, while preliminary data on IBTs are very encouraging as well. Although
      highlighting the non-glycemic effects of pioglitazone and incretin-based
      therapies is of potential significance, clinical practice and patient care must
      be based largely on evidence-based medicine. Therefore, definitive opinions will 
      await additional data from ongoing studies evaluating the effects of both GLP-1
      agonists and DPP-4 inhibitors on cardiovascular morbidity and mortality.
AD  - University of Palermo, Biomedical Department of Internal Medicine and Medical
      Specialties (DiBiMIS) , Via del Vespro, 141, 90127, Palermo , Italy +39 091
      6552945 ; +39 091 6552945 ; manfredi.rizzo@unipa.it.
FAU - Rizzo, Manfredi
AU  - Rizzo M
FAU - Avogaro, Angelo
AU  - Avogaro A
FAU - Montalto, Giuseppe
AU  - Montalto G
FAU - Rizvi, Ali A
AU  - Rizvi AA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130522
TA  - Expert Opin Ther Targets
JT  - Expert opinion on therapeutic targets
JID - 101127833
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1517/14728222.2013.804067 [doi]
PST - aheadofprint
SO  - Expert Opin Ther Targets. 2013 May 22.

PMID- 23691971
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1557-9077 (Electronic)
IS  - 1050-7256 (Linking)
DP  - 2013 May 21
TI  - The State of U.S. Iodine Nutrition: How can we Ensure Adequate Iodine for All?
AB  - na.
AD  - Boston University Medical Center, Sectionof Endocrinology, Diabetes, and
      Nutrition, 88 East newton Street, eVANS 201, Boston, Massachusetts, United
      States, 02118, 617-414-1348, 617-638-7221 ; elizabeth.pearce@bmc.org.
FAU - Pearce, Elizabeth N
AU  - Pearce EN
FAU - Leung, Angela M
AU  - Leung AM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Thyroid
JT  - Thyroid : official journal of the American Thyroid Association
JID - 9104317
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
AID - 10.1089/thy.2013.0295 [doi]
PST - aheadofprint
SO  - Thyroid. 2013 May 21.

PMID- 23691962
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 May 20
TI  - 2013 Update on the worldwide standardization of the hemoglobin A measurement.
LID - 10.1111/pedi.12047 [doi]
AD  - Department of Pediatrics, Uddevalla Hospital, Uddevalla, Sweden; The Sahlgrenska 
      Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Hanas, Ragnar
AU  - Hanas R
CN  - W. Garry John on behalf of the International HbA1c Consensus Committee
LA  - ENG
PT  - LETTER
DEP - 20130520
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PHST- 2013/04/04 [received]
PHST- 2013/04/04 [accepted]
AID - 10.1111/pedi.12047 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 May 20. doi: 10.1111/pedi.12047.

PMID- 23691735
OWN - NLM
STAT- In-Process
DA  - 20130522
IS  - 0010-6178 (Print)
IS  - 0010-6178 (Linking)
VI  - 77
IP  - 4
DP  - 2013 Apr
TI  - Clinical correlates of obesity in an inner-city adult medicine clinic.
PG  - 219-22
AB  - This cross-sectional study was done to assess the association of obesity with
      multiple conditions in an inner-city adult medicine clinic. Data were gathered to
      assess the relationship of obesity to multiple variables. Logistic regression was
      used to adjust for age, gender, ethnicity and tobacco use. Of 2,081 patients, 62%
      were minorities; 41% lacked insurance, and 38% had Medicaid. Forty-two percent
      were obese, with 9% morbidly obese. Out of 25 conditions, 20 had statistically
      significant correlations with obesity (two-sided P < 0.05): four cardiovascular, 
      two pulmonary, three musculoskeletal, three metabolic syndrome conditions
      (metabolic syndrome is defined by the presence of three or more of the following:
      Fasting glucose > 110 mg/dL, BP > 130/85, Waist circumference in men > 40 inches 
      or in women > 35 inches, HDL < 40 mg/dL in men or < 50 mg/dL in women,
      triglycerides > 150 mg/dL), four other clinical conditions, multiple ED visits,
      multiple clinic visits, unemployment, and disability. Body mass index (BMI)
      predicted coronary artery disease (P < 0.001), stroke (P = 0.011) and peripheral 
      arterial disease (P = 0.013), but these associations were no longer statistically
      significant after adjustment for hypertension, diabetes and dyslipidemia. In
      conclusion, obesity was associated with many diseases, as well as with healthcare
      utilization, unemployment and disability in this predominantly minority
      inner-city population.
AD  - St. Vincent's Medical Center, Bridgeport, USA. dr.shahla@gmail.com
FAU - Yassir, Shahla
AU  - Yassir S
FAU - Chopra, Ravi
AU  - Chopra R
FAU - Roush, George
AU  - Roush G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Conn Med
JT  - Connecticut medicine
JID - 0372745
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PST - ppublish
SO  - Conn Med. 2013 Apr;77(4):219-22.

PMID- 23691725
OWN - NLM
STAT- In-Process
DA  - 20130522
IS  - 0028-7571 (Print)
IS  - 0028-7571 (Linking)
VI  - 79
IP  - 2
DP  - 2013 Mar
TI  - Smoking and diabetes. Epigenetics involvement in osseointegration.
PG  - 27-30
AB  - Bone quality is a poorly defined parameter for successful implant placement,
      which largely depends upon many environmental and genetic factors unique to every
      individual. Smoking and diabetes are among the environmental factors that most
      impact osseointegration. However, there is an inter-individual variability of
      bone response in smokers and diabetic patients. Recent data on gene-environment
      interactions highlight the major role of epigenetic changes to induce a specific 
      phenotype. Histone acetylation and DNA methylation are the main events that occur
      and modulate the gene expression. In this paper, we emphasize the impact of
      epigenetics on diabetes and smoking and describe their significance in bone
      healing. Also, we underscore the importance of adopting a new approach in
      clinical management for implant placement by customizing the treatment according 
      to the patient's specific characteristics.
AD  - Department of Periodontology and Implant Dentistry, New York University College
      of Dentistry, New York, NY, USA. razzos01@nyu.edu
FAU - Razzouk, Sleiman
AU  - Razzouk S
FAU - Sarkis, Rami
AU  - Sarkis R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Y State Dent J
JT  - The New York state dental journal
JID - 0414634
SB  - D
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PST - ppublish
SO  - N Y State Dent J. 2013 Mar;79(2):27-30.

PMID- 23691694
OWN - NLM
STAT- In-Process
DA  - 20130522
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 96
IP  - 4
DP  - 2013 Apr
TI  - Comparison of low density lipoprotein cholesterol concentrations by direct
      measurement and Friedewald formula in diabetic patients with and without
      hemoglobin E disorders.
PG  - 407-15
AB  - BACKGROUND: Low density lipoprotein cholesterol (LDL) levels were significantly
      lower in diabetic patients with homozygous hemoglobin E (HbEE) measured by a
      homogeneous assay. OBJECTIVE: Comparison of direct measurement of LDL (dLDL)
      determined by a homogeneous assay and calculated LDL (cLDL) determined by the
      Friedewald formula in diabetic patients with and without hemoglobin E disorders. 
      MATERIAL AND METHOD: The hemoglobin E (HbE) screening test and hemoglobin (Hb)
      typing were conducted in diabetic patients at Surin Hospital. In 2,973 cases with
      triglyceride (TG) levels under 400 mg/dL, classification was determined into
      three groups, negative screening (NS), HbE trait (HbEA), and HbEE. The
      measurements of total cholesterol (TC) and TG were performed using enzymatic
      methods. The direct measurements of high density lipoprotein cholesterol (HDL)
      andLDL were performed using homogeneous methods. RESULTS: The prevalence of HbEE 
      and HbEA were 7.6% and 35.7% respectively. The means of TG, CHOL, dLDL, cLDL, and
      non-HDL cholesterol (non-HDL-C) were significantly lower in HbEE (p = 0.009,
      p<0.001, p< 0.001, p< 0.001, and p< 0.001 respectively). The mean of cLDL in each
      group was significantly lower than the mean of dLDL (p< 0.001 at all). By the
      Passing-Bablok regression, the interception with 95% confidence interval (95% CI)
      ofNS, HbEA, and HbEE were 4.322 (3.082 to 5.485), 6.625 (5.094 to 7.981), and
      6.60 (3.347 to 10.356) respectively. The slope with 95% CI were 1.017 (1.007 to
      1.027), 1.002 (0.991 to 1.016), and 1.0 (0.963 to 1.033) respectively. Using the 
      Bland-Altman method, the mean with standard deviation of the difference between
      dLDL and cLDL in NS, HbEA, and HbEE were 6.758 (7.856) mg/dL, 7.350 (8.212)
      mg/dL, and 7.225 (7.129) mg/dL respectively. The 95% limits of agreement between 
      the dLDL and cLDL in NS, HbEA, and HbEE were -8.640 to 22.156 mg/dL, -8.746 to
      23.446 mg/dL, and-6.748 to 21.197 mg/dL respectively. The statistically
      significant difference of having more patients with cLDL <100 mg/dL than dLDL
      <100 mg/dL in each group were observed in most of the subgroups of TG levels at
      100 mg/dL to <200 mg/dL and higher HbEE had more patients of dLDL <100 mg/dL and 
      cLDL <100 mg/dL than NS. The adjusted odds ratio and 95% CI were 1.383 (1.022 to 
      1.871) with p = 0. 036 and 1.838 (1.375 to 2.456) with p< 0.001 respectively.
      CONCLUSION: The direct homogeneous method showed a higher LDL concentration than 
      the Friedewald formula indicated in diabetes and diabetes with HbE disorders. The
      percentage of higher LDL levels by direct method than Friedewald formula
      significantly increased along the subgroups of higher TG levels. The dissociation
      occurred at TG levels of 100 mg/dL and higher Systematic biases between both
      methods were found in all groups but the proportional difference between both
      methods was only observed in diabetes without HbE disorders.
AD  - Department of Medicine, Surin Hospital, Suranaree University of Technology,
      Surin, Thailand. wasuntsrisurin@gmail.com
FAU - Srisurin, Wasunt
AU  - Srisurin W
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PST - ppublish
SO  - J Med Assoc Thai. 2013 Apr;96(4):407-15.

PMID- 23691642
OWN - NLM
STAT- In-Process
DA  - 20130522
IS  - 0125-1562 (Print)
IS  - 0125-1562 (Linking)
VI  - 44
IP  - 2
DP  - 2013 Mar
TI  - Synergism between obesity and poor oral health associated with diabetes in an
      elderly human population.
PG  - 318-31
AB  - We investigated associations between type 2 diabetes (DM) and several variables, 
      including poor oral health and overweight/obesity, among a group of elderly Hmong
      subjects (60 years and older) who emigrated to the United States following the
      Vietnam conflict. Each subject was interviewed and their weight, height and waist
      circumference were measured. Each subject had an oral health examination. Each
      subject's saliva was analyzed for seven components related to inflammation. The
      presence of DM was correlated with poor oral health (POH) and overweight/obesity 
      (OW) separately. There was a strong correlation between concurrent POH and OW and
      the presence of DM: all subjects with both POH and OW had DM. Logistic
      multivariate analysis of OW, POH, age, years of residence in California, and
      stress level revealed a significant association between the presence of DM and
      concurrent OW and POH. A change in diet after immigration was excluded as an
      explanatory variable. Subjects with DM and concurrent OW and POH had
      significantly elevated salivary levels of five analyses related to chronic
      inflammation. The association between POH and OW and the presence of DM needs
      further study.
AD  - International Relief and Development, Inc, Health Division, Arlington, VA, USA.
      jalbright@ird-dc.org
FAU - Albright, Julia W
AU  - Albright JW
FAU - Woo, Perry H
AU  - Woo PH
FAU - Ji, Shaoquan
AU  - Ji S
FAU - Sun, Binggang
AU  - Sun B
FAU - Lang, Kathleen
AU  - Lang K
FAU - Albright, Joseph F
AU  - Albright JF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Southeast Asian J Trop Med Public Health
JT  - The Southeast Asian journal of tropical medicine and public health
JID - 0266303
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PST - ppublish
SO  - Southeast Asian J Trop Med Public Health. 2013 Mar;44(2):318-31.

PMID- 23691641
OWN - NLM
STAT- In-Process
DA  - 20130522
IS  - 0125-1562 (Print)
IS  - 0125-1562 (Linking)
VI  - 44
IP  - 2
DP  - 2013 Mar
TI  - Prevalence of ultrasound diagnosed nonalcoholic fatty liver disease among rural
      indigenous community of Sarawak and its association with biochemical and
      anthropometric measures.
PG  - 309-17
AB  - Although the association between non-alcoholic fatty liver disease (NAFLD) and
      metabolic syndrome has been previously firmly established, the prevalence of
      NAFLD and its risk factors in rural communities remains incompletely defined.
      This study aimed to determine the prevalence and factors associated with
      ultrasound-diagnosed NAFLD amongst a rural community in Sarawak. An indigenous
      village was randomly selected where all adults aged 21 years and above underwent 
      an abdominal ultrasound, biochemical tests and an anthropometric assessment.
      Respondents with a score > or =8 on an alcohol-use disorders-identification test 
      (AUDIT) indicating harmful or hazardous drinking were excluded. Seventy-seven
      respondents (46.8% male, mean age 48.4 SD 16.64), met inclusion criteria. The
      prevalence of ultrasound diagnosed NAFLD was 44.2% (n=34), among them 52.9% had
      moderate NAFLD. There were no significant age or gender differences between
      respondents with and without NAFLD, although those with NAFLD were older.
      Respondents with NAFLD had a significantly higher BMI t,han those without NAFLD
      (p<0.001). Both male and female respondents with NAFLD had a significantly higher
      waist circumference than those without NAFLD (p<0.001). Prevalence of diabetes,
      hypertension, hyperglycemia and hypertriglyceridemia were significantly higher
      among those with NAFLD. However, there were no significant differences in terms
      of percentage of unhealthy body fat and muscle, and serum HDL levels. Risk
      factors independently associated with NAFLD included male gender (odd ratio 0.06;
      95% CI 0.008-0.523) and waist circumference (odd ratio 1.2; 95% CI 1.036-1.421). 
      There was a high prevalence of NAFLD and the presence of more severe stages of
      disease in this indigenous population. Life-style related diseases, such as fatty
      liver disease, can occur in rural as well as urban populations.
AD  - Universiti Malaysia Sarawak, Kuching, Sarawak, Malaysia. wlcheah@fmhs.unimas.my
FAU - Cheah, Whye Lian
AU  - Cheah WL
FAU - Lee, Ping Yein
AU  - Lee PY
FAU - Chang, Ching Thon
AU  - Chang CT
FAU - Mohamed, Hamid Jan
AU  - Mohamed HJ
FAU - Wong, Siong Long
AU  - Wong SL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Southeast Asian J Trop Med Public Health
JT  - The Southeast Asian journal of tropical medicine and public health
JID - 0266303
SB  - IM
EDAT- 2013/05/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/23 06:00
PST - ppublish
SO  - Southeast Asian J Trop Med Public Health. 2013 Mar;44(2):309-17.

PMID- 23691535
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1533-7294 (Electronic)
IS  - 0094-3509 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Self-management of type 2 diabetes: A good idea--or not ?
PG  - 244-8
AB  - The evidence supports the use of some measures but is questionable on others,
      including routine self-monitoring of blood glucose.
AD  - Department of Family Medicine, University of Rochester School of Medicine and
      Dentistry, NY, USA. Email: Michael_Mendoza@urmc.rochester.edu.
FAU - Mendoza, Michael
AU  - Mendoza M
FAU - Rosenberg, Tziporah
AU  - Rosenberg T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Fam Pract
JT  - The Journal of family practice
JID - 7502590
SB  - AIM
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - jfp_6205f [pii]
PST - ppublish
SO  - J Fam Pract. 2013 May;62(5):244-8.

PMID- 23691527
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Notch Signaling Molecules Activate TGF- beta in Rat Mesangial Cells under High
      Glucose Conditions.
PG  - 979702
LID - 10.1155/2013/979702 [doi]
AB  - The involvement of the Notch signaling pathway in the cellular differentiation of
      the mammalian kidney is established. Recently, the dysregulation of Notch
      signaling molecules has been identified in acute and chronic renal injuries,
      fibrosis models, and diabetic kidney biopsies. The canonical Notch ligand ,
      Jagged1, is upregulated in a transforming growth factor-beta- (TGF- beta -)
      dependent manner during chronic kidney disease. TGF- beta , a central mediator of
      renal fibrosis, also is a major contributor to the development of diabetic
      nephropathy. To explore the roles and possible mechanisms of Notch signaling
      molecules in the pathogenesis of diabetic nephropathy, we exposed cultured rat
      mesangial cells to a gamma -secretase inhibitor (DAPT) or high glucose and
      measured the expression of Notch signaling molecules and the fibrosis index.
      Notch pathway-related molecules, TGF- beta , and fibronectin increased with
      exposure to high glucose and decreased with DAPT treatment. Our results suggest
      that the Notch signaling pathway may precipitate diabetic nephropathy via TGF-
      beta activation.
AD  - Department of Endocrinology, The Affiliated Hospital of Luzhou Medical College,
      Luzhou, Sichuan, China ; Department of Endocrinology, The People's Hospital of
      Yongchuan, Yongchuan, Chongqing, China.
FAU - Liu, Li
AU  - Liu L
FAU - Gao, Chenlin
AU  - Gao C
FAU - Chen, Guo
AU  - Chen G
FAU - Li, Xia
AU  - Li X
FAU - Li, Jia
AU  - Li J
FAU - Wan, Qin
AU  - Wan Q
FAU - Xu, Yong
AU  - Xu Y
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3652152
OID - NLM: PMC3652152
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/11/27 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/03/31 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.1155/2013/979702 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:979702. doi: 10.1155/2013/979702. Epub 2013 Apr 18.

PMID- 23691525
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Effect of V(IV)O(dipic-Cl)(H2O)2 on Lipid Metabolism Disorders in the Liver of
      STZ-Induced Diabetic Rats.
PG  - 956737
LID - 10.1155/2013/956737 [doi]
AB  - Vanadium complexes are potent antidiabetic agents for therapeutical treatment of 
      diabetes. In the present study, we investigated the hypolipidemic effect of
      V(IV)O(dipic-Cl)(H2O)2 (V4dipic-Cl) in liver of streptozotocin- (STZ-)-induced
      diabetic rats. We found that diabetic animals exhibited hepatic inflammatory
      infiltration and impaired liver function along with triglyceride (TG)
      accumulation in the liver. V4dipic-Cl treatment not only ameliorated liver
      pathological state but also reduced hepatic TG level. Moreover, the upregulation 
      of fatty acid translocase (FAT/CD36) mRNA (4.0-fold) and protein (8.2-fold)
      levels in the liver of diabetic rats were significantly reversed after V4dipic-Cl
      treatment. However, no significant effects of V4dipic-Cl on the mRNA expression
      of fatty acid metabolism-related fatty acid bounding protein 1 (FABP1) and fatty 
      acid transporter 5 (FATP5) were observed. These results suggest that the
      modification of lipid metabolism-related FAT/CD36 in the liver of diabetic rats
      is likely involved in the hypolipidemic effects of V4dipic-Cl.
AD  - College of Life Sciences, University of Chinese Academy of Sciences, No. 19A
      YuQuan Road, Beijing 100049, China.
FAU - Liu, Fang
AU  - Liu F
FAU - Xie, Mingxia
AU  - Xie M
FAU - Chen, Deliang
AU  - Chen D
FAU - Li, Jian
AU  - Li J
FAU - Ding, Wenjun
AU  - Ding W
LA  - eng
PT  - Journal Article
DEP - 20130320
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647472
OID - NLM: PMC3647472
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/12/21 [received]
PHST- 2013/02/24 [accepted]
PHST- 2013/03/20 [epublish]
AID - 10.1155/2013/956737 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:956737. doi: 10.1155/2013/956737. Epub 2013 Mar 20.

PMID- 23691523
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Foxp3(+) regulatory T cells in mouse models of type 1 diabetes.
PG  - 940710
LID - 10.1155/2013/940710 [doi]
AB  - Studies on human type 1 diabetes (T1D) are facilitated by the availability of
      animal models such as nonobese diabetic (NOD) mice that spontaneously develop
      autoimmune diabetes, as well as a variety of genetically engineered mouse models 
      with reduced genetic and pathogenic complexity, as compared to the spontaneous
      NOD model. In recent years, increasing evidence has implicated CD4(+)CD25(+)
      regulatory T (Treg) cells expressing the transcription factor Foxp3 in both the
      breakdown of self-tolerance and the restoration of immune homeostasis in T1D. In 
      this paper, we provide an overview of currently available mouse models to study
      the role of Foxp3(+) Treg cells in the control of destructive beta cell
      autoimmunity, including a novel NOD model that allows specific and temporally
      controlled deletion of Foxp3(+) Treg cells.
AD  - Center for Regenerative Therapies Dresden, 01307 Dresden, Germany.
FAU - Petzold, Cathleen
AU  - Petzold C
FAU - Riewaldt, Julia
AU  - Riewaldt J
FAU - Watts, Deepika
AU  - Watts D
FAU - Sparwasser, Tim
AU  - Sparwasser T
FAU - Schallenberg, Sonja
AU  - Schallenberg S
FAU - Kretschmer, Karsten
AU  - Kretschmer K
LA  - eng
PT  - Journal Article
DEP - 20130314
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647588
OID - NLM: PMC3647588
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/12/21 [received]
PHST- 2013/02/03 [accepted]
PHST- 2013/03/14 [epublish]
AID - 10.1155/2013/940710 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:940710. doi: 10.1155/2013/940710. Epub 2013 Mar 14.

PMID- 23691522
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Increased Small Dense LDL and Decreased Paraoxonase Enzyme Activity Reveals
      Formation of an Atherogenic Risk in Streptozotocin-Induced Diabetic Guinea Pigs.
PG  - 860190
LID - 10.1155/2013/860190 [doi]
AB  - This study aimed to investigate LDL subfraction distribution as well as serum
      cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase
      (LCAT), and paraoxonase (PON1) activity in streptozotocin-induced diabetic guinea
      pigs. Materials/Methods. Guinea pigs were given a single intraperitoneal (ip)
      injection of streptozotocin (STZ) and animals having fasting blood glucose levels
      greater than 200 mg/dl, were considered diabetic. Protein levels of LCAT and CETP
      were determined via ELISA. Paraoxonase activity was measured kinetically by the
      formation of phenol while LDL subfraction analysis was done by disc
      polyacrylamide gel electrophoresis. Results. Plasma glucose and high-density
      lipoprotein (HDL) cholesterol were significantly increased while total
      cholesterol and LDL cholesterol were significantly decreased in diabetic guinea
      pigs compared to controls. LDL subfraction analysis revealed a significant
      decrease in nonatherogenic LDL-2 subfraction and a significant increase in
      atherogenic LDL-4 subfraction in diabetic guinea pigs compared to controls.
      Plasma CETP and PON1 levels were significantly decreased while LCAT showed no
      significant difference in diabetic guinea pigs compared to controls. Conclusion. 
      Decreased non-atherogenic LDL-1, LDL-2 subfractions, increased small dense LDL-4 
      subfraction, and decreased PON1 activity, reveals formation of an atherogenic
      risk in diabetic guinea pigs. Decrease in CETP levels supports the observed
      increase in HDL cholesterol levels in diabetic guinea pigs.
AD  - Department of Medical Biochemistry, Akdeniz University, Faculty of Medicine,
      07070 Antalya, Turkey.
FAU - Aslan, Mutay
AU  - Aslan M
FAU - Ozcan, Filiz
AU  - Ozcan F
FAU - Kucuksayan, Ertan
AU  - Kucuksayan E
LA  - eng
PT  - Journal Article
DEP - 20130327
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647573
OID - NLM: PMC3647573
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013/01/29 [received]
PHST- 2013/02/25 [accepted]
PHST- 2013/03/27 [epublish]
AID - 10.1155/2013/860190 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:860190. doi: 10.1155/2013/860190. Epub 2013 Mar 27.

PMID- 23691521
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Effects of glucose load and nateglinide intervention on endothelial function and 
      oxidative stress.
PG  - 849295
LID - 10.1155/2013/849295 [doi]
AB  - We analysed endothelial function and oxidative stress in patients with abnormal
      glucose metabolism, the effect of glucose load, and the impact of nateglinide.
      109 participants were grouped into newly diagnosed diabetes, prediabetes, and
      control. Fasting plasma glucose (FPG), postprandial plasma glucose (PPG),
      glycosylated haemoglobin (HbA1c), and glycated albumin (GA) varied significantly 
      among the study groups (P < 0.01). Nitric oxide (NO) and insulin resistance index
      (HOMA-IRI) levels were markedly different between the newly diagnosed diabetes
      and the control (P < 0.01). Glucose loading lowered flow-mediated
      endothelium-dependent dilation (FMEDD), NO, and superoxide dismutase (SOD) (P <
      0.01). Fasting and glucose loading FMEDD, FPG, PPG, HbA1c, and GA were negatively
      correlated (r = -0.4573, -0.4602, -0.3895, -0.3897, and r = -0.4594, -0.4803,
      -0.4494, -0.3885; P < 0.01), whereas NO, SOD, and HOMA- beta were positively
      correlated (r = 0.2983, 0.3211, 0.311, and r = 0.1954, 0.361, 0.2569; P < 0.05). 
      After the treatment with nateglinide, significant decreases in FPG, PPG, GA,
      HbA1C, endothelin-1(ET-1), malondialdehyde (MDA), and HOMA-IRI were observed,
      whereas FMEDD, NO, and SOD increased (P < 0.01). Thus, the study demonstrated the
      adverse effect of glucose load on endothelial function and oxidative stress.
      Nateglinide lowers blood glucose, reduces insulin resistance and oxidative
      stress, and improves endothelial function in newly diagnosed diabetes.
AD  - VIP Department, Beijing Hospital of the Ministry of Health, Dongdan Dahua, Road
      Number One, Beijing 100730, China.
FAU - Wang, Leilei
AU  - Wang L
FAU - Guo, Lixin
AU  - Guo L
FAU - Zhang, Lina
AU  - Zhang L
FAU - Zhou, Yan
AU  - Zhou Y
FAU - He, Qinghua
AU  - He Q
FAU - Zhang, Zheng
AU  - Zhang Z
FAU - Wang, Meng
AU  - Wang M
LA  - eng
PT  - Journal Article
DEP - 20130407
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647564
OID - NLM: PMC3647564
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/11/14 [received]
PHST- 2013/02/17 [revised]
PHST- 2013/02/18 [accepted]
PHST- 2013/04/07 [epublish]
AID - 10.1155/2013/849295 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:849295. doi: 10.1155/2013/849295. Epub 2013 Apr 7.

PMID- 23691520
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - The Effect of Dantonic Pill on beta -Catenin Expression in a Rat Model of
      Streptozotocin-Induced Early Stage of Diabetic Nephropathy.
PG  - 848679
LID - 10.1155/2013/848679 [doi]
AB  - Diabetic nephropathy (DN) is one of the most common causes of end-stage renal
      failure. This study was performed to determine the effect of Dantonic Pill (DP)
      treatment on beta -catenin expression in a rat model of streptozotocin- (STZ-)
      induced early-stage DN, with irbesartan treatment as a positive control.
      Including an analysis of the general metabolic index and renal function,
      immunohistochemical staining and reverse transcription real-time PCR for beta
      -catenin were performed in the renal cortex of the rat models every 4 weeks.
      After the treatments of DP and irbesartan, the albuminuria level, kidney
      weight/body weight, and thickness of the glomerular basement membrane were
      decreased, but the expression of beta -catenin was not downregulated in the renal
      cortex. The effective drug target of DP to ameliorate albuminuria and renal
      hypertrophy should not inhibit the upregulated expression of beta -catenin in
      rats with STZ-induced early-stage diabetic damage.
AD  - Department of Endocrinology, the First Affiliated Hospital of Xi'an Jiaotong
      University School of Medicine, Xi'an 710061, China.
FAU - Shuhong, Zhou
AU  - Shuhong Z
FAU - Hongjun, Lv
AU  - Hongjun L
FAU - Bo, Cui
AU  - Bo C
FAU - Li, Xu
AU  - Li X
FAU - Bingyin, Shi
AU  - Bingyin S
LA  - eng
PT  - Journal Article
DEP - 20130414
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3652155
OID - NLM: PMC3652155
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013/01/17 [received]
PHST- 2013/03/12 [accepted]
PHST- 2013/04/14 [epublish]
AID - 10.1155/2013/848679 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:848679. doi: 10.1155/2013/848679. Epub 2013 Apr 14.

PMID- 23691519
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Features analysis of lower extremity arterial lesions in 162 diabetes patients.
PG  - 781360
LID - 10.1155/2013/781360 [doi]
AB  - Objective. This study aimed to investigate the angiographic manifestations of
      lower extremity atherosclerotic steno-occlusive disease in patients with
      diabetes. Materials and Methods. A total of 162 patients with diabetes were
      enrolled in this study. The angiographic findings of lower extremity arterial
      lesions were evaluated according to location (iliac, femoral, popliteal, and
      crural artery), type (stenosis or occlusion), and length (<5 cm, 5-10 cm, and >5 
      cm). Results. A total of 131 of 162 (80.9%) diabetics showed multiple segmental
      lesions, and 19.1% (31/162) presented single segmental lesions in the lower
      extremity artery. Crural artery was the mainly involved location (39/162, 85.8%).
      Among the recorded 660 lesions of 162 cases, 437 (66.2%) were occlusion lesions, 
      while 223 (33.8%) were stenosis lesions. Of 437 occlusion lesions, 308 lesions
      (70.5%) were in crural artery. More than 10 cm occlusion lesion (242/392, 61.7%) 
      was the main manifestation in crural artery, especially in anterior (92/127,
      67.2%) and posterior tibial arteries (91/124, 73.4%), which was higher than that 
      in iliac artery (8/33, 24.2%), popliteal artery (53/157, 33.8%), and femoral
      artery (11/78, 14.1%). Conclusion. In diabetic subjects with lower limb artery
      ischemia, the vascular involvement is extremely diffuse and particularly severe
      in crural arteries, with high prevalence of more than 10 cm occlusion lesions.
AD  - Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai
      Jiaotong University, Shanghai 200001, China.
FAU - Guo, Xiangjiang
AU  - Guo X
FAU - Shi, Yaxue
AU  - Shi Y
FAU - Huang, Xiaozhong
AU  - Huang X
FAU - Ye, Meng
AU  - Ye M
FAU - Xue, Guanhua
AU  - Xue G
FAU - Zhang, Jiwei
AU  - Zhang J
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3652182
OID - NLM: PMC3652182
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/11/12 [received]
PHST- 2013/01/18 [revised]
PHST- 2013/01/21 [accepted]
PHST- 2013/04/15 [epublish]
AID - 10.1155/2013/781360 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:781360. doi: 10.1155/2013/781360. Epub 2013 Apr 15.

PMID- 23691518
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Cardiovascular changes in animal models of metabolic syndrome.
PG  - 761314
LID - 10.1155/2013/761314 [doi]
AB  - Metabolic syndrome has been defined as a group of risk factors that directly
      contribute to the development of cardiovascular disease and/or type 2 diabetes.
      Insulin resistance seems to have a fundamental role in the genesis of this
      syndrome. Over the past years to the present day, basic and translational
      research has used small animal models to explore the pathophysiology of metabolic
      syndrome and to develop novel therapies that might slow the progression of this
      prevalent condition. In this paper we discuss the animal models used for the
      study of metabolic syndrome, with particular focus on cardiovascular changes,
      since they are the main cause of death associated with the condition in humans.
AD  - Laboratorio de Experimentacao Animal e Laboratorio de Cardiologia Celular e
      Molecular, Instituto de Cardiologia do Rio Grande do Sul/Fundacao Universitaria
      de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil ; Divisao de
      Endocrinologia, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio
      Grande do Sul, Porto Alegre, Brazil.
FAU - Lehnen, Alexandre M
AU  - Lehnen AM
FAU - Rodrigues, Bruno
AU  - Rodrigues B
FAU - Irigoyen, Maria Claudia
AU  - Irigoyen MC
FAU - De Angelis, Katia
AU  - De Angelis K
FAU - Schaan, Beatriz D'Agord
AU  - Schaan BD
LA  - eng
PT  - Journal Article
DEP - 20130314
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647579
OID - NLM: PMC3647579
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/12/12 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/02/12 [accepted]
PHST- 2013/03/14 [epublish]
AID - 10.1155/2013/761314 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:761314. doi: 10.1155/2013/761314. Epub 2013 Mar 14.

PMID- 23691517
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - The Missing Heritability in T1D and Potential New Targets for Prevention.
PG  - 737485
LID - 10.1155/2013/737485 [doi]
AB  - Type 1 diabetes (T1D) is a T cell-mediated disease. It is strongly associated
      with susceptibility haplotypes within the major histocompatibility complex, but
      this association accounts for an estimated 50% of susceptibility. Other studies
      have identified as many as 50 additional susceptibility loci, but the effect of
      most is very modest (odds ratio (OR) <1.5). What accounts for the "missing
      heritability" is unknown and is often attributed to environmental factors. Here
      we review new data on the cognate ligand of MHC molecules, the T cell receptor
      (TCR). In rats, we found that one allele of a TCR variable gene, V beta 13A, is
      strongly associated with T1D (OR >5) and that deletion of V beta 13+ T cells
      prevents diabetes. A role for the TCR is also suspected in NOD mice, but TCR
      regions have not been associated with human T1D. To investigate this disparity,
      we tested the hypothesis in silico that previous studies of human T1D genetics
      were underpowered to detect MHC-contingent TCR susceptibility. We show that
      stratifying by MHC markedly increases statistical power to detect potential TCR
      susceptibility alleles. We suggest that the TCR regions are viable candidates for
      T1D susceptibility genes, could account for "missing heritability," and could be 
      targets for prevention.
AD  - Program in Bioinformatics and Integrative Biology, University of Massachusetts
      Medical School, Worcester, MA 01605, USA.
FAU - Pierce, Brian G
AU  - Pierce BG
FAU - Eberwine, Ryan
AU  - Eberwine R
FAU - Noble, Janelle A
AU  - Noble JA
FAU - Habib, Michael
AU  - Habib M
FAU - Shulha, Hennady P
AU  - Shulha HP
FAU - Weng, Zhiping
AU  - Weng Z
FAU - Blankenhorn, Elizabeth P
AU  - Blankenhorn EP
FAU - Mordes, John P
AU  - Mordes JP
LA  - eng
PT  - Journal Article
DEP - 20130313
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647582
OID - NLM: PMC3647582
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013/01/07 [received]
PHST- 2013/02/13 [accepted]
PHST- 2013/03/13 [epublish]
AID - 10.1155/2013/737485 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:737485. doi: 10.1155/2013/737485. Epub 2013 Mar 13.

PMID- 23691516
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Nearby Construction Impedes the Progression to Overt Autoimmune Diabetes in NOD
      Mice.
PG  - 620313
LID - 10.1155/2013/620313 [doi]
AB  - Construction nearby animal houses has sporadically been reported to affect
      various aspects of animal health. Most of the reports have focussed on the impact
      on stress hormone levels and the hypersensitivity of animals relative to humans. 
      There has also been an anecdotal report on the impact of construction on
      autoimmune diabetes in NOD mice. Here, we describe that nearby construction
      significantly impedes the progression to overt diabetes in female NOD mice
      offspring. We demonstrate that this was not due to a genetic drift or to
      particularities associated with our specific mouse colony. Interestingly,
      although the glycemia levels remained low in mice born from mothers subject to
      construction stress during gestation, we detected an active autoimmune reaction
      towards pancreatic islet cells, as measured by both the degree of insulitis and
      the presence of insulin autoantibody levels in the serum. These results suggest
      that the external stress imposed during embryonic development does not prevent
      but significantly delays the autoimmune process. Together, our findings emphasize
      the impact of surrounding factors during in vivo studies and are in agreement
      with the hypothesis that both environmental and genetic cues contribute to
      autoimmune diabetes development.
AD  - Maisonneuve-Rosemont Hospital Research Center, Montreal, QC, Canada H1T 2M4 ;
      Department of Microbiology and Immunology, University of Montreal, Montreal, QC, 
      Canada H3C 3J7.
FAU - Hillhouse, Erin E
AU  - Hillhouse EE
FAU - Collin, Roxanne
AU  - Collin R
FAU - Chabot-Roy, Genevieve
AU  - Chabot-Roy G
FAU - Guyon, Marie-Josee
AU  - Guyon MJ
FAU - Tessier, Nathalie
AU  - Tessier N
FAU - Boulay, Maryse
AU  - Boulay M
FAU - Liscourt, Patricia
AU  - Liscourt P
FAU - Lesage, Sylvie
AU  - Lesage S
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3652156
OID - NLM: PMC3652156
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/12/19 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/03/29 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.1155/2013/620313 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:620313. doi: 10.1155/2013/620313. Epub 2013 Apr 18.

PMID- 23691349
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 2090-4630 (Print)
IS  - 2090-4630 (Linking)
VI  - 2013
DP  - 2013
TI  - Effect of polyherbal mixtures on the treatment of diabetes.
PG  - 934797
LID - 10.1155/2013/934797 [doi]
AB  - The study focuses on polyherbal antidiabetic formulations of different plants
      used in the treatment of diabetes mixed in different concentrations. In the
      present study eleven medicinal plants with proven antidiabetic and related
      beneficial effects were selected for the preparation of five mixtures. The
      efficacy of prepared mixtures has been tested on streptozotocin- (STZ-) induced
      diabetic rats and compared with a commercially available drug glibenclamide. The 
      mixtures at the dose levels of 400 mg/kg b.w. produced a significant decrease in 
      blood glucose level by 69.6%, 70.97%, 64.45%, 71.82%, and 64.44% after 21 days of
      treatment. The elevated level of SGPT, SGOT, and ALP in the diabetic controlled
      group reflected the significant alteration of liver function by STZ induction and
      was found to be equipotent to glibenclamide in restoration of the elevated enzyme
      levels to normal. The elevated lipid levels (triglyceride and total cholesterol) 
      were restored to near normal by these mixtures for all the estimated parameters. 
      The results of the mixtures on treated group were found to restore the glycemic
      level to the near normal level thereby indicating antihyperglycemic activity of
      the formulated mixtures.
AD  - Hi-Tech Research and Development Centre, Konark Institute of Science and
      Technology, Bhubaneswar, Odisha 752050, India.
FAU - Panda, Aparajeya
AU  - Panda A
FAU - Jena, Somanatha
AU  - Jena S
FAU - Sahu, Pramod Kumar
AU  - Sahu PK
FAU - Nayak, Sanghamitra
AU  - Nayak S
FAU - Padhi, Payodhar
AU  - Padhi P
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - ISRN Endocrinol
JT  - ISRN endocrinology
JID - 101568096
PMC - PMC3654233
OID - NLM: PMC3654233
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/27 [received]
PHST- 2013/03/20 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.1155/2013/934797 [doi]
PST - epublish
SO  - ISRN Endocrinol. 2013 Apr 16;2013:934797. doi: 10.1155/2013/934797. Print 2013.

PMID- 23691293
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 2090-1283 (Print)
IS  - 2090-1283 (Linking)
VI  - 2013
DP  - 2013
TI  - Current views on genetics and epigenetics of cholesterol gallstone disease.
PG  - 298421
LID - 10.1155/2013/298421 [doi]
AB  - Cholesterol gallstone disease, one of the commonest digestive diseases in western
      countries, is induced by an imbalance in cholesterol metabolism, which involves
      intestinal absorption, hepatic biosynthesis, and biliary output of cholesterol,
      and its conversion to bile acids. Several components of the metabolic syndrome
      (e.g., obesity, type 2 diabetes, dyslipidemia, and hyperinsulinemia) are also
      well-known risk factors for gallstones, suggesting the existence of interplay
      between common pathophysiological pathways influenced by insulin resistance,
      genetic, epigenetic, and environmental factors. Cholesterol gallstones may be
      enhanced, at least in part, by the abnormal expression of a set of the genes that
      affect cholesterol homeostasis and lead to insulin resistance. Additionally,
      epigenetic mechanisms (mainly DNA methylation, histone acetylation/deacetylation,
      and noncoding microRNAs) may modify gene expression in the absence of an altered 
      DNA sequence, in response to different lithogenic environmental stimuli, such as 
      diet, lifestyle, pollutants, also occurring in utero before birth. In this
      review, we will comment on various steps of the pathogenesis of cholesterol
      gallstones and interaction between environmental and genetic factors. The
      epigenomic approach may offer new options for therapy of gallstones and better
      possibilities for primary prevention in subjects at risk.
AD  - Division of Internal Medicine Hospital of Bisceglie, 76011 Bisceglie, Italy.
FAU - Di Ciaula, Agostino
AU  - Di Ciaula A
FAU - Wang, David Q-H
AU  - Wang DQ
FAU - Bonfrate, Leonilde
AU  - Bonfrate L
FAU - Portincasa, Piero
AU  - Portincasa P
LA  - eng
PT  - Journal Article
DEP - 20130414
PL  - United States
TA  - Cholesterol
JT  - Cholesterol
JID - 101540641
PMC - PMC3649201
OID - NLM: PMC3649201
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013/01/28 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/20 [accepted]
PHST- 2013/04/14 [epublish]
AID - 10.1155/2013/298421 [doi]
PST - ppublish
SO  - Cholesterol. 2013;2013:298421. doi: 10.1155/2013/298421. Epub 2013 Apr 14.

PMID- 23691290
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 2090-0724 (Print)
IS  - 2090-0724 (Linking)
VI  - 2013
DP  - 2013
TI  - Potential mechanisms of exercise in gestational diabetes.
PG  - 285948
LID - 10.1155/2013/285948 [doi]
AB  - Gestational diabetes mellitus (GDM) is defined as glucose intolerance first
      diagnosed during pregnancy. This condition shares same array of underlying
      abnormalities as occurs in diabetes outside of pregnancy, for example, genetic
      and environmental causes. However, the role of a sedentary lifestyle and/or
      excess energy intake is more prominent in GDM. Physically active women are less
      likely to develop GDM and other pregnancy-related diseases. Weight gain in
      pregnancy causes increased release of adipokines from adipose tissue; many
      adipokines increase oxidative stress and insulin resistance. Increased
      intramyocellular lipids also increase cellular oxidative stress with subsequent
      generation of reactive oxygen species. A well-planned program of exercise is an
      important component of a healthy lifestyle and, in spite of old myths, is also
      recommended during pregnancy. This paper briefly reviews the role of adipokines
      in gestational diabetes and attempts to shed some light on the mechanisms by
      which exercise can be beneficial as an adjuvant therapy in GDM. In this regard,
      we discuss the mechanisms by which exercise increases insulin sensitivity,
      changes adipokine profile levels, and boosts antioxidant mechanisms.
AD  - Department of Pharmacology and Therapeutics, Faculty of Medicine, University of
      British Columbia, Vancouver, BC, Canada V6T 1Z3.
FAU - Golbidi, Saeid
AU  - Golbidi S
FAU - Laher, Ismail
AU  - Laher I
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - United States
TA  - J Nutr Metab
JT  - Journal of nutrition and metabolism
JID - 101526296
PMC - PMC3649306
OID - NLM: PMC3649306
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/09/25 [received]
PHST- 2013/01/31 [revised]
PHST- 2013/02/10 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1155/2013/285948 [doi]
PST - ppublish
SO  - J Nutr Metab. 2013;2013:285948. doi: 10.1155/2013/285948. Epub 2013 Apr 9.

PMID- 23691279
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 2090-004X (Print)
IS  - 2090-004X (Linking)
VI  - 2013
DP  - 2013
TI  - Cental Macular Thickness in Patients with Type 2 Diabetes Mellitus without
      Clinical Retinopathy.
PG  - 767931
LID - 10.1155/2013/767931 [doi]
AB  - Objective. To compare central macular thickness (CMT) of diabetic patients with
      type 2 diabetes without clinical retinopathy and healthy subjects. Materials and 
      Methods. Optical coherence tomography (OCT) measurements were performed in 124
      eyes of 62 subjects with diabetes mellitus without clinical retinopathy (study
      group: 39 females, 23 males; mean age: 55.06 +/- 9.77 years) and in 120 eyes of
      60 healthy subjects (control group: 35 females, 25 males; mean age: 55.78 +/-
      10.34 years). Blood biochemistry parameters were analyzed in all cases. The data 
      for central macular thickness (at 1 mm), the levels of fasting plasma glucose,
      and glycosylated hemoglobin (HbA1c) were compared in both groups. Results. The
      mean central macular thickness was 232.12 +/- 24.41 microm in the study group and
      227.19 +/- 29.94 microm in the control group. The mean HbA1c level was 8.92 +/-
      2.58% in the study group and 5.07 +/- 0.70% in the control group (P = 0.001). No 
      statistically significant relationship was found between CMT, HbA1c, and fasting 
      plasma glucose level in either group (P > 0.05). Conclusions. Central macular
      thickness was not significantly thicker in patients with type 2 diabetes without 
      clinical retinopathy than in healthy subjects.
AD  - Department of Ophthalmology, Sisli Etfal Training and Research Hospital,
      Istanbul, Turkey ; Sisli Etfal Hastanesi, Halaskargazi Caddesi Etfal Sokak No.
      10, 34400 Sisli, Istanbul, Turkey.
FAU - Demir, Mehmet
AU  - Demir M
FAU - Dirim, Burcu
AU  - Dirim B
FAU - Acar, Zeynep
AU  - Acar Z
FAU - Yilmaz, Murat
AU  - Yilmaz M
FAU - Sendul, Yekta
AU  - Sendul Y
LA  - eng
PT  - Journal Article
DEP - 20130403
PL  - United States
TA  - J Ophthalmol
JT  - Journal of ophthalmology
JID - 101524199
PMC - PMC3649345
OID - NLM: PMC3649345
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/12/09 [received]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/03 [epublish]
AID - 10.1155/2013/767931 [doi]
PST - ppublish
SO  - J Ophthalmol. 2013;2013:767931. doi: 10.1155/2013/767931. Epub 2013 Apr 3.

PMID- 23691267
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1942-0994 (Electronic)
VI  - 2013
DP  - 2013
TI  - Increased nitroxidative stress promotes mitochondrial dysfunction in alcoholic
      and nonalcoholic Fatty liver disease.
PG  - 781050
LID - 10.1155/2013/781050 [doi]
AB  - Increased nitroxidative stress causes mitochondrial dysfunctions through
      oxidative modifications of mitochondrial DNA, lipids, and proteins. Persistent
      mitochondrial dysfunction sensitizes the target cells/organs to other
      pathological risk factors and thus ultimately contributes to the development of
      more severe disease states in alcoholic and nonalcoholic fatty liver disease. The
      incidences of nonalcoholic fatty liver disease continuously increase due to high 
      prevalence of metabolic syndrome including hyperlipidemia, hypercholesterolemia, 
      obesity, insulin resistance, and diabetes. Many mitochondrial proteins including 
      the enzymes involved in fat oxidation and energy supply could be oxidatively
      modified (including S-nitrosylation/nitration) under increased nitroxidative
      stress and thus inactivated, leading to increased fat accumulation and ATP
      depletion. To demonstrate the underlying mechanism(s) of mitochondrial
      dysfunction, we employed a redox proteomics approach using biotin-N-maleimide
      (biotin-NM) as a sensitive biotin-switch probe to identify oxidized Cys residues 
      of mitochondrial proteins in the experimental models of alcoholic and acute liver
      disease. The aims of this paper are to briefly describe the mechanisms,
      functional consequences, and detection methods of mitochondrial dysfunction. We
      also describe advantages and limitations of the Cys-targeted redox proteomics
      method with alternative approaches. Finally, we discuss various applications of
      this method in studying oxidatively modified mitochondrial proteins in
      extrahepatic tissues or different subcellular organelles and translational
      research.
AD  - Section of Molecular Pharmacology and Toxicology, Laboratory of Membrane
      Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, 
      9000 Rockville Pike, Bethesda, MD 20892, USA.
FAU - Song, Byoung-Joon
AU  - Song BJ
FAU - Abdelmegeed, Mohamed A
AU  - Abdelmegeed MA
FAU - Henderson, Lauren E
AU  - Henderson LE
FAU - Yoo, Seong-Ho
AU  - Yoo SH
FAU - Wan, Jie
AU  - Wan J
FAU - Purohit, Vishnudutt
AU  - Purohit V
FAU - Hardwick, James P
AU  - Hardwick JP
FAU - Moon, Kwan-Hoon
AU  - Moon KH
LA  - eng
PT  - Journal Article
DEP - 20130403
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
SB  - IM
PMC - PMC3649774
OID - NLM: PMC3649774
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/09 [received]
PHST- 2013/02/27 [accepted]
PHST- 2013/04/03 [epublish]
AID - 10.1155/2013/781050 [doi]
PST - ppublish
SO  - Oxid Med Cell Longev. 2013;2013:781050. doi: 10.1155/2013/781050. Epub 2013 Apr
      3.

PMID- 23691264
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1942-0994 (Electronic)
VI  - 2013
DP  - 2013
TI  - A review of pterostilbene antioxidant activity and disease modification.
PG  - 575482
LID - 10.1155/2013/575482 [doi]
AB  - Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a natural dietary
      compound and the primary antioxidant component of blueberries. It has increased
      bioavailability in comparison to other stilbene compounds, which may enhance its 
      dietary benefit and possibly contribute to a valuable clinical effect. Multiple
      studies have demonstrated the antioxidant activity of pterostilbene in both in
      vitro and in vivo models illustrating both preventative and therapeutic benefits.
      The antioxidant activity of pterostilbene has been implicated in
      anticarcinogenesis, modulation of neurological disease, anti-inflammation,
      attenuation of vascular disease, and amelioration of diabetes. In this review, we
      explore the antioxidant properties of pterostilbene and its relationship to
      common disease pathways and give a summary of the clinical potential of
      pterostilbene in the prevention and treatment of various medical conditions.
AD  - Mailman School of Public Health, Columbia University, Allan Rosenfield Building, 
      722 West 168th Street, New York, NY 10032, USA.
FAU - McCormack, Denise
AU  - McCormack D
FAU - McFadden, David
AU  - McFadden D
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
SB  - IM
PMC - PMC3649683
OID - NLM: PMC3649683
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/02/13 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1155/2013/575482 [doi]
PST - ppublish
SO  - Oxid Med Cell Longev. 2013;2013:575482. doi: 10.1155/2013/575482. Epub 2013 Apr
      4.

PMID- 23691262
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1942-0994 (Electronic)
VI  - 2013
DP  - 2013
TI  - Assessment of endothelial dysfunction in childhood obesity and clinical use.
PG  - 174782
LID - 10.1155/2013/174782 [doi]
AB  - The association of obesity with noncommunicable diseases, such as cardiovascular 
      complications and diabetes, is considered a major threat to the management of
      health care worldwide. Epidemiological findings show that childhood obesity is
      rapidly rising in Western society, as well as in developing countries. This
      pandemic is not without consequences and can affect the risk of future
      cardiovascular disease in these children. Childhood obesity is associated with
      endothelial dysfunction, the first yet still reversible step towards
      atherosclerosis. Advanced research techniques have added further insight on how
      childhood obesity and associated comorbidities lead to endothelial dysfunction.
      Techniques used to measure endothelial function were further brought to
      perfection, and novel biomarkers, including endothelial progenitor cells, were
      discovered. The aim of this paper is to provide a critical overview on both in
      vivo as well as in vitro markers for endothelial integrity. Additionally, an
      in-depth description of the mechanisms that disrupt the delicate balance between 
      endothelial damage and repair will be given. Finally, the effects of lifestyle
      interventions and pharmacotherapy on endothelial dysfunction will be reviewed.
AD  - Laboratory of Cellular and Molecular Cardiology, University Hospital Antwerp,
      Wilrijkstraat 10, 2650 Edegem, Belgium ; Cardiovascular Diseases, Department of
      Translational Pathophysiological Research, Faculty of Medicine and Health
      Sciences, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium ;
      Department of Pediatrics, University Hospital Antwerp, Wilrijkstraat 10, 2650
      Edegem, Belgium.
FAU - Bruyndonckx, Luc
AU  - Bruyndonckx L
FAU - Hoymans, Vicky Y
AU  - Hoymans VY
FAU - Van Craenenbroeck, Amaryllis H
AU  - Van Craenenbroeck AH
FAU - Vissers, Dirk K
AU  - Vissers DK
FAU - Vrints, Christiaan J
AU  - Vrints CJ
FAU - Ramet, Jose
AU  - Ramet J
FAU - Conraads, Viviane M
AU  - Conraads VM
LA  - eng
PT  - Journal Article
DEP - 20130403
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
SB  - IM
PMC - PMC3649697
OID - NLM: PMC3649697
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/18 [received]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/03 [epublish]
AID - 10.1155/2013/174782 [doi]
PST - ppublish
SO  - Oxid Med Cell Longev. 2013;2013:174782. doi: 10.1155/2013/174782. Epub 2013 Apr
      3.

PMID- 23691256
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Association between Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Anxiety 
      Disorder: A Population-Based Study.
PG  - e64630
LID - 10.1371/journal.pone.0064630 [doi]
AB  - BACKGROUND: this case-control study utilized a population-based dataset to
      examine the association of chronic prostatitis/chronic pelvic pain syndrome
      (CP/CPPS) with prior anxiety disorder (AD) by comparing the risk of prior AD
      between subjects with CP/CPPS and matched controls in Taiwan. METHODS: We study
      used data sourced from the Taiwan Longitudinal Health Insurance Database. The
      cases comprised 8,088 subjects with CP/CPPS and 24,264 randomly matched subjects 
      as controls. We used a conditional logistic regression to calculate the odds
      ratio (OR) for having been previously diagnosed with AD between subjects with and
      without CP/CPPS. RESULTS: Of the 24,264 sampled subjects, 2309 (7.1%) had
      received an AD diagnosis before the index date; AD was found in 930 (11.5%) cases
      and 1379 (5.7%) controls (p<0.001). The conditional logistic regression analysis 
      revealed that compared to controls, the OR for prior AD among cases was 2.10 (95%
      CI = 1.92 approximately 2.29, p<0.001) after adjusting for diabetes,
      hypertension, hyperlipidemia, and sexually transmitted diseases. Our results show
      that CP/CPPS was consistently and significantly associated with prior AD in all
      age groups (18 approximately 39, 40 approximately 59, and >59 years). In
      particular, subjects aged 40 approximately 59 years had the highest adjusted OR
      (of 2.53) for prior AD among cases compared to controls. CONCLUSIONS: We
      concluded that CP/CPPS is associated with previously diagnosed AD. Urologists
      should be alert for the association between CP/CPPS and AD in subjects suffering 
      from AD.
AD  - Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, New
      Taipei City, Taiwan ; Sleep Research Center, Taipei Medical University Hospital, 
      Taipei, Taiwan.
FAU - Chung, Shiu-Dong
AU  - Chung SD
FAU - Lin, Herng-Ching
AU  - Lin HC
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3654910
OID - NLM: PMC3654910
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/11 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.1371/journal.pone.0064630 [doi]
AID - PONE-D-13-10715 [pii]
PST - epublish
SO  - PLoS One. 2013 May 15;8(5):e64630. doi: 10.1371/journal.pone.0064630. Print 2013.

PMID- 23691192
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Combined Anti-Inflammatory and Anti-AGE Drug Treatments Have a Protective Effect 
      on Intervertebral Discs in Mice with Diabetes.
PG  - e64302
LID - 10.1371/journal.pone.0064302 [doi]
AB  - OBJECTIVE: Diabetes and low back pain are debilitating diseases and modern
      epidemics. Diabetes and obesity are also highly correlated with intervertebral
      disc (IVD) degeneration and back pain. Advanced-glycation-end-products (AGEs)
      increase reactive-oxygen-species (ROS) and inflammation, and are one cause for
      early development of diabetes mellitus. We hypothesize that diabetes results in
      accumulation of AGEs in spines and associated spinal pathology via increased
      catabolism. We present a mouse model showing that: 1) diabetes induces
      pathological changes to structure and composition of IVDs and vertebrae; 2)
      diabetes is associated with accumulation of AGEs, TNFalpha, and increased
      catabolism spinal structures; and 3) oral-treatments with a combination of
      anti-inflammatory and anti-AGE drugs mitigate these diabetes-induced degenerative
      changes to the spine. METHODS: Three age-matched groups of ROP-Os mice were
      compared: non-diabetic, diabetic (streptozotocin (STZ)-induced), or diabetic mice
      treated with pentosan-polysulfate (anti-inflammatory) and pyridoxamine
      (AGE-inhibitor). Mice were euthanized and vertebra-IVD segments were analyzed by 
      muCT, histology and Immunohistochemistry. RESULTS: Diabetic mice exhibited
      several pathological changes including loss in IVD height, decreased vertebral
      bone mass, decreased glycosaminoglycan content and morphologically altered IVDs
      with focal deposition of tissues highly expressing TNFalpha, MMP-13 and ADAMTS-5.
      Accumulation of larger amounts of methylglyoxal suggested that AGE accumulation
      was associated with these diabetic degenerative changes. However, treatment
      prevented or reduced these pathological effects on vertebrae and IVD. CONCLUSION:
      This is the first study to demonstrate specific degenerative changes to nucleus
      pulposus (NP) morphology and their association with AGE accumulation in a
      diabetic mouse model. Furthermore, this is the first study to demonstrate that
      oral-treatments can inhibit AGE-induced ROS and inflammation in spinal structures
      and provide a potential treatment to slow progression of degenerative spine
      changes in diabetes. Since diabetes, IVD degeneration, and accumulation of AGEs
      are frequent consequences of aging, early treatments to reduce AGE-induced ROS
      and Inflammation may have broad public-health implications.
AD  - Leni & Peter May Dept. of Orthopaedics, Mount Sinai School of Medicine, New York,
      New York, United States of America.
FAU - Illien-Junger, Svenja
AU  - Illien-Junger S
FAU - Grosjean, Fabrizio
AU  - Grosjean F
FAU - Laudier, Damien M
AU  - Laudier DM
FAU - Vlassara, Helen
AU  - Vlassara H
FAU - Striker, Gary E
AU  - Striker GE
FAU - Iatridis, James C
AU  - Iatridis JC
LA  - eng
PT  - Journal Article
DEP - 20130517
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3656842
OID - NLM: PMC3656842
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/14 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/17 [epublish]
AID - 10.1371/journal.pone.0064302 [doi]
AID - PONE-D-13-02430 [pii]
PST - epublish
SO  - PLoS One. 2013 May 17;8(5):e64302. doi: 10.1371/journal.pone.0064302. Print 2013.

PMID- 23691167
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Identifying parameters to distinguish non-diabetic renal diseases from diabetic
      nephropathy in patients with type 2 diabetes mellitus: a meta-analysis.
PG  - e64184
LID - 10.1371/journal.pone.0064184 [doi]
AB  - BACKGROUND: Renal injuries in patients with diabetes include diabetic nephropathy
      (DN) and non-diabetic renal diseases (NDRD). The value of a clinical diagnosis of
      DN and NDRD remains inconclusive. We conducted a meta-analysis of the literature 
      to identify predictive factors of NDRD and to compare the clinical
      characteristics of DN and NDRD for differential diagnosis. METHODS: We searched
      PubMed (1990 to January 2012), Embase (1990 to February 2009), and CNKI (1990 to 
      January 2012) to identify studies that enrolled patients with DN and NDRD. Then, 
      the quality of the studies was assessed, and data were extracted. The results
      were summarized as odds ratios (ORs) for dichotomous outcomes and weighted mean
      differences (WMDs) for continuous outcomes. RESULTS: Twenty-six relevant studies 
      with 2,322 patients were included. The meta-analysis showed that the absence of
      diabetic retinopathy (DR) predicts NDRD (OR, 0.15; 95% confidence interval [CI], 
      0.09-0.26, p<0.00001). A shorter duration of diabetes mellitus (DM) also
      predicted NDRD (weighted mean difference, -34.67; 95% CI, -45.23--24.11,
      p<0.00001). The levels of glycosylated hemoglobin (HbA1C%), blood pressure (BP), 
      and total cholesterol were lower in patients with NDRD, whereas triglycerides and
      body mass index were higher. Other clinical parameters, including age, 24-h
      urinary protein excretion, serum creatinine, creatinine clearance, blood urea
      nitrogen, and glomerular filtration rate were not different between patients with
      NDRD and DN. CONCLUSIONS: We identified that the absence of DR, shorter duration 
      of DM, lower HbA1C, and lower BP may help to distinguish NDRD from DN in patients
      with diabetes. This could assist clinicians in making a safe and sound diagnosis 
      and lead to more effective treatments.
AD  - Department of Nephrology, State Key Laboratory of Kidney Diseases, Chinese PLA
      General Hospital, Beijing, China.
FAU - Liang, Shuang
AU  - Liang S
FAU - Zhang, Xue-Guang
AU  - Zhang XG
FAU - Cai, Guang-Yan
AU  - Cai GY
FAU - Zhu, Han-Yu
AU  - Zhu HY
FAU - Zhou, Jian-Hui
AU  - Zhou JH
FAU - Wu, Jie
AU  - Wu J
FAU - Chen, Pu
AU  - Chen P
FAU - Lin, Shu-Peng
AU  - Lin SP
FAU - Qiu, Qiang
AU  - Qiu Q
FAU - Chen, Xiang-Mei
AU  - Chen XM
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3653878
OID - NLM: PMC3653878
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2012/07/24 [received]
PHST- 2013/04/13 [accepted]
PHST- 2013/05/14 [epublish]
AID - 10.1371/journal.pone.0064184 [doi]
AID - PONE-D-12-22286 [pii]
PST - epublish
SO  - PLoS One. 2013 May 14;8(5):e64184. doi: 10.1371/journal.pone.0064184. Print 2013.

PMID- 23691124
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Increased plasma citrulline in mice marks diet-induced obesity and may predict
      the development of the metabolic syndrome.
PG  - e63950
LID - 10.1371/journal.pone.0063950 [doi]
AB  - In humans, plasma amino acid concentrations of branched-chain amino acids (BCAA) 
      and aromatic amino acids (AAA) increase in states of obesity, insulin resistance 
      and diabetes. We here assessed whether these putative biomarkers can also be
      identified in two different obesity and diabetic mouse models. C57BL/6 mice with 
      diet-induced obesity (DIO) mimic the metabolic impairments of obesity in humans
      characterized by hyperglycemia, hyperinsulinemia and hepatic triglyceride
      accumulation. Mice treated with streptozotocin (STZ) to induce insulin deficiency
      were used as a type 1 diabetes model. Plasma amino acid profiling of two high fat
      (HF) feeding trials revealed that citrulline and ornithine concentrations are
      elevated in obese mice, while systemic arginine bioavailability (ratio of plasma 
      arginine to ornithine + citrulline) is reduced. In skeletal muscle, HF feeding
      induced a reduction of arginine levels while citrulline levels were elevated.
      However, arginine or citrulline remained unchanged in their key metabolic organs,
      intestine and kidney. Moreover, the intestinal conversion of labeled arginine to 
      ornithine and citrulline in vitro remained unaffected by HF feeding excluding the
      intestine as prime site of these alterations. In liver, citrulline is mainly
      derived from ornithine in the urea cycle and DIO mice displayed reduced hepatic
      ornithine levels. Since both amino acids share an antiport mechanism for
      mitochondrial import and export, elevated plasma citrulline may indicate impaired
      hepatic amino acid handling in DIO mice. In the insulin deficient mice, plasma
      citrulline and ornithine levels also increased and additionally these animals
      displayed elevated BCAA and AAA levels like insulin resistant and diabetic
      patients. Therefore, type 1 diabetic mice but not DIO mice show the "diabetic
      fingerprint" of plasma amino acid changes observed in humans. Additionally,
      citrulline may serve as an early indicator of the obesity-dependent metabolic
      impairments.
AD  - Molecular Nutrition Unit, Research Center for Nutrition and Food Sciences,
      Technische Universitat Munchen, Freising-Weihenstephan, Germany.
FAU - Sailer, Manuela
AU  - Sailer M
FAU - Dahlhoff, Christoph
AU  - Dahlhoff C
FAU - Giesbertz, Pieter
AU  - Giesbertz P
FAU - Eidens, Mena K
AU  - Eidens MK
FAU - de Wit, Nicole
AU  - de Wit N
FAU - Rubio-Aliaga, Isabel
AU  - Rubio-Aliaga I
FAU - Boekschoten, Mark V
AU  - Boekschoten MV
FAU - Muller, Michael
AU  - Muller M
FAU - Daniel, Hannelore
AU  - Daniel H
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3653803
OID - NLM: PMC3653803
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/19 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/14 [epublish]
AID - 10.1371/journal.pone.0063950 [doi]
AID - PONE-D-12-31988 [pii]
PST - epublish
SO  - PLoS One. 2013 May 14;8(5):e63950. doi: 10.1371/journal.pone.0063950. Print 2013.

PMID- 23691063
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Singlet Oxygen Induced Products of Linoleates, 10- and
      12-(Z,E)-Hydroxyoctadecadienoic Acids (HODE), Can Be Potential Biomarkers for
      Early Detection of Type 2 Diabetes.
PG  - e63542
LID - 10.1371/journal.pone.0063542 [doi]
AB  - Current diagnostic tests such as glycemic indicators have limitations for early
      detection of impaired glucose tolerance (IGT), which leads to diabetes. Oxidative
      stress induced by various oxidants in a random and destructive manner is
      considered to play an important role in the pathophysiology of a number of human 
      disorders and diseases such as impaired glucose tolerance. We have developed an
      improved method for the measurement of in vivo lipid peroxidation, where the
      presence of 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha), hydroxyoctadecadienoic
      acids (HODEs), hydroxyeicosatetraenoic acids (HETEs), and 7-hydroxycholesterol
      (7-OHCh), as well as their parent molecules, linoleic acid (LA) and cholesterol
      (Ch), was determined by performing LC-MS/MS (for 8-iso-PGF2alpha, HODE, and HETE)
      and GC-MS (for 7-OHCh, LA, and Ch) after reduction with triphenyl phosphine and
      saponification by potassium hydroxide. We then applied this method to volunteers 
      (n = 57), including normal type (n = 43), "high-normal" (fasting plasma glucose, 
      100-109 mg/dL, n = 7), pre-diabetic type (IGT, n = 5), and diabetic type (n = 2) 
      subjects who are diagnosed by performing oral glucose tolerance tests (OGTTs).
      Several biomarkers in plasma, such as insulin, leptin, adiponectin,
      interleukin-6, tumor necrosis factor-alpha, high sensitivity-C-reactive protein, 
      HbA1c, and glucose levels were measured during OGTT. We found that the fasting
      levels of (10- and 12-(Z,E)- HODE)/LA increased significantly with increasing
      levels of HbA1c and glucose during OGTT and with insulin secretion and resistance
      index. In conclusion, 10- and 12-(Z,E)-HODE may be prominent biomarkers for the
      early detection of IGT and "high-normal" type without OGTT.
AD  - Health Research Institute, National Institute of Advanced Industrial Science and 
      Technology, Takamatsu, Kagawa, Japan.
FAU - Umeno, Aya
AU  - Umeno A
FAU - Shichiri, Mototada
AU  - Shichiri M
FAU - Ishida, Noriko
AU  - Ishida N
FAU - Hashimoto, Yoshiko
AU  - Hashimoto Y
FAU - Abe, Kaori
AU  - Abe K
FAU - Kataoka, Masatoshi
AU  - Kataoka M
FAU - Yoshino, Kohzoh
AU  - Yoshino K
FAU - Hagihara, Yoshihisa
AU  - Hagihara Y
FAU - Aki, Nanako
AU  - Aki N
FAU - Funaki, Makoto
AU  - Funaki M
FAU - Asada, Yasuhiko
AU  - Asada Y
FAU - Yoshida, Yasukazu
AU  - Yoshida Y
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3655182
OID - NLM: PMC3655182
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/28 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.1371/journal.pone.0063542 [doi]
AID - PONE-D-13-09266 [pii]
PST - epublish
SO  - PLoS One. 2013 May 15;8(5):e63542. doi: 10.1371/journal.pone.0063542. Print 2013.

PMID- 23691032
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Identification of adiponectin receptor agonist utilizing a fluorescence
      polarization based high throughput assay.
PG  - e63354
LID - 10.1371/journal.pone.0063354 [doi]
AB  - Adiponectin, the adipose-derived hormone, plays an important role in the
      suppression of metabolic disorders that can result in type 2 diabetes, obesity,
      and atherosclerosis. It has been shown that up-regulation of adiponectin or
      adiponectin receptor has a number of therapeutic benefits. Given that it is hard 
      to convert the full size adiponectin protein into a viable drug, adiponectin
      receptor agonists could be designed or identified using high-throughput
      screening. Here, we report on the development of a two-step screening process to 
      identify adiponectin agonists. First step, we developed a high throughput
      screening assay based on fluorescence polarization to identify adiponectin
      ligands. The fluorescence polarization assay reported here could be adapted to
      screening against larger small molecular compound libraries. A natural product
      library containing 10,000 compounds was screened and 9 hits were selected for
      validation. These compounds have been taken for the second-step in vitro tests to
      confirm their agonistic activity. The most active adiponectin receptor 1 agonists
      are matairesinol, arctiin, (-)-arctigenin and gramine. The most active
      adiponectin receptor 2 agonists are parthenolide, taxifoliol, deoxyschizandrin,
      and syringin. These compounds may be useful drug candidates for hypoadiponectin
      related diseases.
AD  - Chengdu Medical College, Pharmacy School, Chengdu, Sichuan Province, China.
FAU - Sun, Yiyi
AU  - Sun Y
FAU - Zang, Zhihe
AU  - Zang Z
FAU - Zhong, Ling
AU  - Zhong L
FAU - Wu, Min
AU  - Wu M
FAU - Su, Qing
AU  - Su Q
FAU - Gao, Xiurong
AU  - Gao X
FAU - Zan, Wang
AU  - Zan W
FAU - Lin, Dong
AU  - Lin D
FAU - Zhao, Yan
AU  - Zhao Y
FAU - Zhang, Zhonglin
AU  - Zhang Z
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3653934
OID - NLM: PMC3653934
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/16 [received]
PHST- 2013/03/30 [accepted]
PHST- 2013/05/14 [epublish]
AID - 10.1371/journal.pone.0063354 [doi]
AID - PONE-D-13-02775 [pii]
PST - epublish
SO  - PLoS One. 2013 May 14;8(5):e63354. doi: 10.1371/journal.pone.0063354. Print 2013.

PMID- 23691013
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Efferocytosis Promotes Suppressive Effects on Dendritic Cells through
      Prostaglandin E2 Production in the Context of Autoimmunity.
PG  - e63296
LID - 10.1371/journal.pone.0063296 [doi]
AB  - INTRODUCTION: Efferocytosis is a crucial process by which apoptotic cells are
      cleared by phagocytes, maintaining immune tolerance to self in the absence of
      inflammation. Peripheral tolerance, lost in autoimmune processes, may be restored
      by the administration of autologous dendritic cells loaded with islet apoptotic
      cells in experimental type 1 diabetes. OBJECTIVE: To evaluate tolerogenic
      properties in dendritic cells induced by the clearance of apoptotic islet cells, 
      thus explaining the re-establishment of tolerance in a context of autoimmunity.
      METHODS: Bone marrow derived dendritic cells from non-obese diabetic mice, a
      model of autoimmune diabetes, were generated and pulsed with islet apoptotic
      cells. The ability of these cells to induce autologous T cell proliferation and
      to suppress mature dendritic cell function was assessed, together with cytokine
      production. Microarray experiments were performed using dendritic cells to
      identify differentially expressed genes after efferocytosis. RESULTS: Molecular
      and functional changes in dendritic cells after the capture of apoptotic cells
      were observed. 1) Impaired ability of dendritic cells to stimulate autologous T
      cell proliferation after the capture of apoptotic cells even after
      proinflammatory stimuli, with a cytokine profile typical for immature dendritic
      cells. 2) Suppressive ability of mature dendritic cell function. 3)
      Microarray-based gene expression profiling of dendritic cells showed differential
      expression of genes involved in antigen processing and presentation after
      efferocytosis. 4) Prostaglandin E2 increased production was responsible for
      immunosuppressive mechanism of dendritic cells after the capture of apoptotic
      cells. CONCLUSIONS: The tolerogenic behaviour of dendritic cells after islet
      cells efferocytosis points to a mechanism of silencing potential autoreactive T
      cells in the microenvironment of autoimmunity. Our results suggest that dendritic
      cells may be programmed to induce specific immune tolerance using apoptotic
      cells; this is a viable strategy for a variety of autoimmune diseases.
AD  - Department of Immunology, Germans Trias i Pujol Research Institute, Autonomous
      University of Barcelona, Badalona, Spain.
FAU - Pujol-Autonell, Irma
AU  - Pujol-Autonell I
FAU - Ampudia, Rosa-Maria
AU  - Ampudia RM
FAU - Planas, Raquel
AU  - Planas R
FAU - Marin-Gallen, Silvia
AU  - Marin-Gallen S
FAU - Carrascal, Jorge
AU  - Carrascal J
FAU - Sanchez, Alex
AU  - Sanchez A
FAU - Marin, Ana
AU  - Marin A
FAU - Puig-Domingo, Manuel
AU  - Puig-Domingo M
FAU - Pujol-Borrell, Ricardo
AU  - Pujol-Borrell R
FAU - Verdaguer, Joan
AU  - Verdaguer J
FAU - Vives-Pi, Marta
AU  - Vives-Pi M
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3654963
OID - NLM: PMC3654963
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/11 [received]
PHST- 2013/04/02 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.1371/journal.pone.0063296 [doi]
AID - PONE-D-12-39267 [pii]
PST - epublish
SO  - PLoS One. 2013 May 15;8(5):e63296. doi: 10.1371/journal.pone.0063296. Print 2013.

PMID- 23690989
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Factors associated with blood pressure control in hypertensive patients with
      coronary heart disease: evidence from the chinese cholesterol education program.
PG  - e63135
LID - 10.1371/journal.pone.0063135 [doi]
AB  - Blood pressure (BP) remains poorly controlled among hypertensive patients with
      coronary heart disease (CHD) in China. Improvement of its management will require
      an understanding of the patient characteristics and treatment factors associated 
      with uncontrolled hypertension. A cross-sectional survey of 3,279 patients from
      52 centers in China was performed to examine potential barriers to adequate blood
      pressure control of hypertensive patients with CHD. Uncontrolled hypertension was
      defined as blood pressure >/=130/or 80 mmHg. Multivariable logistic regression
      was used to identify factors associated with poor blood pressure control. Mean
      age of the patients was 65 years, 40% were women, and mean BMI was 25 kg/m(2).
      Mean systolic blood pressure was 136+/-18 mmHg and mean diastolic blood pressure 
      was 80+/-11 mmHg. Only 18% of patients had a mean blood pressure <130/80 mmHg
      during the study period. Multivariate analysis revealed several independent
      factors of poor blood pressure control: body mass index >/=23 kg/m(2), the
      presence of stable angina pectoris (SAP), family history of diabetes, and use of 
      calcium channel blockers (CCB). Further analysis showed that non-dihydropyridine 
      calcium antagonist was significantly correlated with low BP control rate. Some of
      these may be amenable to modification. The results of our study suggest that
      overweight, the presence of SAP and family history of diabetes are important
      factors for tight BP control in primary care. In addition, non-dihydropyridine
      calcium channel blockers appear less effective than other therapies in control of
      blood pressure and should not be the first choice among hypertensive patients
      with CHD. Further identification of patients at risk of poor BP control can lead 
      to targeted interventions to improve management.
AD  - Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University
      School of Medicine, Shanghai, China ; Heart, Lung and Blood Vessel Center, Tongji
      University School of Medicine, Shanghai, China.
FAU - Xu, Dachun
AU  - Xu D
FAU - Chen, Wei
AU  - Chen W
FAU - Li, Xiankai
AU  - Li X
FAU - Zhang, Yi
AU  - Zhang Y
FAU - Li, Xin
AU  - Li X
FAU - Lei, Hou
AU  - Lei H
FAU - Wei, Yidong
AU  - Wei Y
FAU - Li, Weiming
AU  - Li W
FAU - Hu, Dayi
AU  - Hu D
FAU - Wedick, Nicole M
AU  - Wedick NM
FAU - Wang, Jinsong
AU  - Wang J
FAU - Xu, Yawei
AU  - Xu Y
FAU - Li, Jue
AU  - Li J
FAU - Ma, Yunsheng
AU  - Ma Y
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3655186
OID - NLM: PMC3655186
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/16 [received]
PHST- 2013/03/28 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.1371/journal.pone.0063135 [doi]
AID - PONE-D-12-39900 [pii]
PST - epublish
SO  - PLoS One. 2013 May 15;8(5):e63135. doi: 10.1371/journal.pone.0063135. Print 2013.

PMID- 23690974
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Shared effects of genetic and intrauterine and perinatal environment on the
      development of metabolic syndrome.
PG  - e63021
LID - 10.1371/journal.pone.0063021 [doi]
AB  - Genetic and environmental factors, including the in utero environment, contribute
      to Metabolic Syndrome. Exposure to high fat diet exposure in utero and lactation 
      increases incidence of Metabolic Syndrome in offspring. Using GLUT4 heterozygous 
      (G4+/-) mice, genetically predisposed to Type 2 Diabetes Mellitus, and wild-type 
      littermates we demonstrate genotype specific differences to high fat in utero and
      lactation. High fat in utero and lactation increased adiposity and impaired
      insulin and glucose tolerance in both genotypes. High fat wild type offspring had
      increased serum glucose and PAI-1 levels and decreased adiponectin at 6 wks of
      age compared to control wild type. High fat G4+/- offspring had increased
      systolic blood pressure at 13 wks of age compared to all other groups. Potential 
      fetal origins of adult Metabolic Syndrome were investigated. Regardless of
      genotype, high fat in utero decreased fetal weight and crown rump length at
      embryonic day 18.5 compared to control. Hepatic expression of genes involved in
      glycolysis, gluconeogenesis, oxidative stress and inflammation were increased
      with high fat in utero. Fetal serum glucose levels were decreased in high fat
      G4+/- compared to high fat wild type fetuses. High fat G4+/-, but not high fat
      wild type fetuses, had increased levels of serum cytokines (IFN-gamma, MCP-1,
      RANTES and M-CSF) compared to control. This data demonstrates that high fat
      during pregnancy and lactation increases Metabolic Syndrome male offspring and
      that heterozygous deletion of GLUT4 augments susceptibility to increased systolic
      blood pressure. Fetal adaptations to high fat in utero that may predispose to
      Metabolic Syndrome in adulthood include changes in fetal hepatic gene expression 
      and alterations in circulating cytokines. These results suggest that the
      interaction between in utero-perinatal environment and genotype plays a critical 
      role in the developmental origin of health and disease.
AD  - Division of Pediatric Endocrinology, Children's Hospital at Montefiore, Bronx,
      New York, United States of America.
FAU - Vuguin, Patricia M
AU  - Vuguin PM
FAU - Hartil, Kirsten
AU  - Hartil K
FAU - Kruse, Michael
AU  - Kruse M
FAU - Kaur, Harpreet
AU  - Kaur H
FAU - Lin, Chia-Lei Vivian
AU  - Lin CL
FAU - Fiallo, Ariana
AU  - Fiallo A
FAU - Glenn, Alan Scott
AU  - Glenn AS
FAU - Patel, Avanee
AU  - Patel A
FAU - Williams, Lyda
AU  - Williams L
FAU - Seki, Yoshinori
AU  - Seki Y
FAU - Katz, Ellen B
AU  - Katz EB
FAU - Charron, Maureen J
AU  - Charron MJ
LA  - eng
GR  - F31 DK093332/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130517
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3656882
OID - NLM: PMC3656882
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/09 [received]
PHST- 2013/03/28 [accepted]
PHST- 2013/05/17 [epublish]
AID - 10.1371/journal.pone.0063021 [doi]
AID - PONE-D-13-01793 [pii]
PST - epublish
SO  - PLoS One. 2013 May 17;8(5):e63021. doi: 10.1371/journal.pone.0063021. Print 2013.

PMID- 23690966
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - The bitter fate of the sweet heart: impairment of iron homeostasis in diabetic
      heart leads to failure in myocardial protection by preconditioning.
PG  - e62948
LID - 10.1371/journal.pone.0062948 [doi]
AB  - Cardiovascular dysfunction is a major complication of diabetes. Examining
      mechanistic aspects underlying the incapacity of the diabetic heart to respond to
      ischemic preconditioning (IPC), we could show that the alterations in iron
      homeostasis can explain this phenomenon. Correlating the hemodynamic parameters
      with levels of ferritin, the main iron storage and detoxifying protein, without
      and with inhibitors of protein degradation, substantiated this explanation.
      Diabetic hearts were less sensitive to ischemia-reperfusion stress, as indicated 
      by functional parameters and histology. Mechanistically, since ferritin has been 
      shown to provide cellular protection against insults, including
      ischemia-reperfusion stress and as the basal ferritin level in diabetic heart was
      2-fold higher than in controls, these are in accord with the greater resistance
      of the diabetic heart to ischemia-reperfusion. Additionally, during
      ischemia-reperfusion, preceded by IPC, a rapid and extensive loss in ferritin
      levels, during the prolonged ischemia, in diabetic heart but not in non-diabetic 
      controls, provide additional substantiation to the explanation for loss of
      respond to IPC. Current research is shedding light on the mechanism behind
      ferritin degradation as well, suggesting a novel explanation for diabetes-induced
      loss of cardioprotection.
AD  - Department of Biochemistry and Molecular Biology, Institute of Medical Research
      Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Jerusalem, Israel ;
      Department of Otolaryngology, Hadassah-University Hospital, Jerusalem, Israel.
FAU - Vinokur, Vladimir
AU  - Vinokur V
FAU - Berenshtein, Eduard
AU  - Berenshtein E
FAU - Bulvik, Baruch
AU  - Bulvik B
FAU - Grinberg, Leonid
AU  - Grinberg L
FAU - Eliashar, Ron
AU  - Eliashar R
FAU - Chevion, Mordechai
AU  - Chevion M
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3655153
OID - NLM: PMC3655153
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/12 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/05/15 [epublish]
AID - 10.1371/journal.pone.0062948 [doi]
AID - PONE-D-13-06379 [pii]
PST - epublish
SO  - PLoS One. 2013 May 15;8(5):e62948. doi: 10.1371/journal.pone.0062948. Print 2013.

PMID- 23690953
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Association of plasma Angiotensin-(1-7) level and left ventricular function in
      patients with type 2 diabetes mellitus.
PG  - e62788
LID - 10.1371/journal.pone.0062788 [doi]
AB  - BACKGROUND: We recently found that overexpression of angiotensin (Ang)-converting
      enzyme 2, which metabolizes Ang-II to Ang-(1-7) and Ang-I to Ang-(1-9), may
      prevent diabetes-induced left ventricular remodeling and dysfunction in rats. Our
      objective was to evaluate the association of plasma Ang-(1-7) level and left
      ventricular function in patients with type 2 diabetes mellitus.
      METHODOLOGYPRINCIPAL FINDINGS: We measured the left ventricular ejection fraction
      (EF), ratio of early to late left ventricular filling velocity (E/A) and ratio of
      early diastolic mitral inflow to annular velocity (E/Ea) by ultrasonography in
      110 patients with type 2 diabetes mellitus for more than 5 years. Anthropometric 
      and fasting blood values were obtained from medical records. The plasma Ang-(1-7)
      level in patients with a poor EF (<50%) was significantly lower than that in
      patients with EF >/=50%; the level in patients with E/A <1 was significantly
      lower than that in patients with E/A >/=1; and the level in patients with E/Ea
      >15 was significantly lower than that in patients with E/Ea </=15. Ang-(1-7)
      level was negatively correlated with E/Ea and Log-N-terminal pro-B-type
      natriuretic peptide and positively with EF and E/A. Stepwise multiple regression 
      analysis revealed that Ang-(1-7), hemoglobin A1c and Ang-II levels as well as
      duration of diabetes predicted EF; Ang-(1-7) level, fasting blood glucose,
      low-density lipoprotein cholesterol level and duration of diabetes predicted E/A;
      and Ang-(1-7) and hemoglobin A1c levels predicted E/Ea. CONCLUSIONSSIGNIFICANCE: 
      Plasma Ang-(1-7) level is independently associated with left ventricular function
      in patients with type 2 diabetes mellitus and may be a biomarker for assessing
      cardiac function in such patients.
AD  - Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese
      Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital,
      Shandong University, Jinan, Shandong, China.
FAU - Hao, Pan-Pan
AU  - Hao PP
FAU - Chen, Yu-Guo
AU  - Chen YG
FAU - Liu, Yan-Ping
AU  - Liu YP
FAU - Zhang, Ming-Xiang
AU  - Zhang MX
FAU - Yang, Jian-Min
AU  - Yang JM
FAU - Gao, Fei
AU  - Gao F
FAU - Zhang, Yun
AU  - Zhang Y
FAU - Zhang, Cheng
AU  - Zhang C
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3653917
OID - NLM: PMC3653917
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/05 [received]
PHST- 2013/03/24 [accepted]
PHST- 2013/05/14 [epublish]
AID - 10.1371/journal.pone.0062788 [doi]
AID - PONE-D-13-05362 [pii]
PST - epublish
SO  - PLoS One. 2013 May 14;8(5):e62788. doi: 10.1371/journal.pone.0062788. Print 2013.

PMID- 23690884
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1748-6718 (Electronic)
IS  - 1748-670X (Linking)
VI  - 2013
DP  - 2013
TI  - Clinical outcome prediction in aneurysmal subarachnoid hemorrhage using bayesian 
      neural networks with fuzzy logic inferences.
PG  - 904860
LID - 10.1155/2013/904860 [doi]
AB  - Objective. The novel clinical prediction approach of Bayesian neural networks
      with fuzzy logic inferences is created and applied to derive prognostic decision 
      rules in cerebral aneurysmal subarachnoid hemorrhage (aSAH). Methods. The
      approach of Bayesian neural networks with fuzzy logic inferences was applied to
      data from five trials of Tirilazad for aneurysmal subarachnoid hemorrhage (3551
      patients). Results. Bayesian meta-analyses of observational studies on aSAH
      prognostic factors gave generalizable posterior distributions of population mean 
      log odd ratios (ORs). Similar trends were noted in Bayesian and linear regression
      ORs. Significant outcome predictors include normal motor response, cerebral
      infarction, history of myocardial infarction, cerebral edema, history of diabetes
      mellitus, fever on day 8, prior subarachnoid hemorrhage, admission angiographic
      vasospasm, neurological grade, intraventricular hemorrhage, ruptured aneurysm
      size, history of hypertension, vasospasm day, age and mean arterial pressure.
      Heteroscedasticity was present in the nontransformed dataset. Artificial neural
      networks found nonlinear relationships with 11 hidden variables in 1 layer, using
      the multilayer perceptron model. Fuzzy logic decision rules (centroid
      defuzzification technique) denoted cut-off points for poor prognosis at greater
      than 2.5 clusters. Discussion. This aSAH prognostic system makes use of existing 
      knowledge, recognizes unknown areas, incorporates one's clinical reasoning, and
      compensates for uncertainty in prognostication.
AD  - Divisions of Neurosurgery & Critical Care Medicine, St. Michael's Hospital,
      University of Toronto, 30 Bond Street, 3 Bond Wing, Toronto, ON, Canada M5B 1W8.
FAU - Lo, Benjamin W Y
AU  - Lo BW
FAU - Macdonald, R Loch
AU  - Macdonald RL
FAU - Baker, Andrew
AU  - Baker A
FAU - Levine, Mitchell A H
AU  - Levine MA
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - United States
TA  - Comput Math Methods Med
JT  - Computational and mathematical methods in medicine
JID - 101277751
SB  - IM
PMC - PMC3639630
OID - NLM: PMC3639630
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/24 [received]
PHST- 2013/03/23 [accepted]
PHST- 2013/04/10 [epublish]
AID - 10.1155/2013/904860 [doi]
PST - ppublish
SO  - Comput Math Methods Med. 2013;2013:904860. doi: 10.1155/2013/904860. Epub 2013
      Apr 10.

PMID- 23690868
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Resveratrol is not as effective as physical exercise for improving reproductive
      and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary
      syndrome.
PG  - 964070
LID - 10.1155/2013/964070 [doi]
AB  - Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disorder
      associated with obesity and insulin resistance that often precedes the
      development of type-2 diabetes. Rats continuously exposed to dihydrotestosterone 
      from prepuberty display typical reproductive and metabolic PCOS characteristics
      including anovulation, polycystic ovaries, insulin resistance, and obesity. Our
      aim was to investigate if resveratrol improves reproductive and metabolic
      functions in PCOS rats. The effect was compared to exercise. Control and PCOS
      rats were treated with vehicle or resveratrol (400 mg . kg(-1) . day(-1)) for 5-6
      weeks. Another group of PCOS rats received vehicle treatment and exercised for
      5-6 weeks. Insulin sensitivity was determined by euglycemic-hyperinsulinemic
      clamp. The glucose infusion rate was lower in the PCOS-vehicle group compared to 
      control-vehicle rats (P < 0.05). Exercise increased insulin sensitivity compared 
      with PCOS-vehicle rats (P < 0.05), but resveratrol did not. Resveratrol treatment
      and exercise resulted in smaller adipocytes, upregulated estrogen-related
      receptor alpha gene expression in subcutaneous fat, and improved estrus cyclicity
      in the previously acyclic PCOS rats. Although resveratrol had positive effects on
      adiposity and cyclicity in a similar manner to exercise, resveratrol does not
      seem to be a good candidate for treating insulin resistance associated with PCOS 
      because no improvement in insulin sensitivity was observed in PCOS rats on normal
      chow.
AD  - Department of Physiology, Institute of Neuroscience and Physiology, The
      Sahlgrenska Academy at the University of Gothenburg, Box 434, 405 30 Gothenburg, 
      Sweden.
FAU - Benrick, Anna
AU  - Benrick A
FAU - Maliqueo, Manuel
AU  - Maliqueo M
FAU - Miao, Sun
AU  - Miao S
FAU - Villanueva, Jesus A
AU  - Villanueva JA
FAU - Feng, Yi
AU  - Feng Y
FAU - Ohlsson, Claes
AU  - Ohlsson C
FAU - Duleba, Antoni J
AU  - Duleba AJ
FAU - Stener-Victorin, Elisabet
AU  - Stener-Victorin E
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3638597
OID - NLM: PMC3638597
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/13 [received]
PHST- 2013/03/04 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1155/2013/964070 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:964070. doi: 10.1155/2013/964070.
      Epub 2013 Apr 8.

PMID- 23690865
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Eleutheroside E, An Active Component of Eleutherococcus senticosus, Ameliorates
      Insulin Resistance in Type 2 Diabetic db/db Mice.
PG  - 934183
LID - 10.1155/2013/934183 [doi]
AB  - Eleutheroside E (EE), a principal component of Eleutherococcus senticosus (ES),
      has anti-inflammatory and protective effects in ischemia heart. However, it is
      unknown whether it ameliorates insulin resistance and reduces hyperglycemia in
      diabetes. This study investigated the effect of EE-containing ES extracts, as
      well as EE, on hyperglycemia and insulin resistance in db/db mice. EE increased
      the insulin-provoked glucose uptake in C2C12 myotubes. Moreover, EE improved TNF-
      alpha -induced suppression of glucose uptake in 3T3-L1 adipocytes. Five-week-old 
      db/db mice were fed a diet consisting of ES extract or EE for 5 weeks. Both were 
      effective in improving serum lipid profiles and significantly decreased blood
      glucose and serum insulin levels. ES and EE supplementation effectively
      attenuated HOMA-IR. Glucose tolerance and insulin tolerance tests showed that EE 
      increased insulin sensitivity. Immunohistochemical staining indicated that ES and
      EE protected pancreatic alpha and beta cells from diabetic damage. In addition,
      ES and EE improved hepatic glucose metabolism by upregulating glycolysis and
      downregulating gluconeogenesis in obese type 2 diabetic mice. These data suggest 
      that EE mediates the hyperglycemic effects of ES by regulating insulin signaling 
      and glucose utilization. The beneficial effects of EE may provide an effective
      and powerful strategy to alleviate diabetes.
AD  - Metabolism and Nutrition Research Group, Korea Food Research Institute, 516
      Baekhyun, Bundang, Seongnam, Gyeonggi 463-746, Republic of Korea.
FAU - Ahn, Jiyun
AU  - Ahn J
FAU - Um, Min Young
AU  - Um MY
FAU - Lee, Hyunjung
AU  - Lee H
FAU - Jung, Chang Hwa
AU  - Jung CH
FAU - Heo, Seok Hyun
AU  - Heo SH
FAU - Ha, Tae Youl
AU  - Ha TY
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3638629
OID - NLM: PMC3638629
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/16 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/10 [epublish]
AID - 10.1155/2013/934183 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:934183. doi: 10.1155/2013/934183.
      Epub 2013 Apr 10.

PMID- 23690860
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Boehmeria nivea Stimulates Glucose Uptake by Activating Peroxisome
      Proliferator-Activated Receptor Gamma in C2C12 Cells and Improves Glucose
      Intolerance in Mice Fed a High-Fat Diet.
PG  - 867893
LID - 10.1155/2013/867893 [doi]
AB  - We examined the antidiabetic property of Boehmeria nivea (L.) Gaud. Ethanolic
      extract of Boehmeria nivea (L.) Gaud. (EBN) increased the uptake of
      2-[N-(nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-d-glucose in C2C12 myotubes.
      To examine the mechanisms underlying EBN-mediated increase in glucose uptake, we 
      examined the transcriptional activity and expression of peroxisome
      proliferator-activated receptor gamma (PPAR- gamma ), a pivotal target for
      glucose metabolism in C2C12 myotubes. We found that the EBN increased both the
      transcriptional activity and mRNA expression levels of PPAR- gamma . In addition,
      we measured phosphorylation and expression levels of other targets of glucose
      metabolism, such as AMP-activated protein kinase (AMPK) and protein kinase B
      (Akt/PKB). We found that EBN did not alter the phosphorylation or expression
      levels of these proteins in a time- or dose-dependent manner, which suggested
      that EBN stimulates glucose uptake through a PPAR- gamma -dependent mechanism.
      Further, we investigated the antidiabetic property of EBN using mice fed a
      high-fat diet (HFD). Administration of 0.5% EBN reduced the HFD-induced increase 
      in body weight, total cholesterol level, and fatty liver and improved the
      impaired fasting glucose level, blood insulin content, and glucose intolerance.
      These results suggest that EBN had an antidiabetic effect in cell culture and
      animal systems and may be useful for preventing diabetes.
AD  - Korea Food Research Institute, 516 Baekhyun-dong, Bundang-ku, Seongnam,
      Gyeonggi-do 463-746, Republic of Korea.
FAU - Kim, Sung Hee
AU  - Kim SH
FAU - Sung, Mi Jeong
AU  - Sung MJ
FAU - Park, Jae Ho
AU  - Park JH
FAU - Yang, Hye Jeong
AU  - Yang HJ
FAU - Hwang, Jin-Taek
AU  - Hwang JT
LA  - eng
PT  - Journal Article
DEP - 20130403
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3638624
OID - NLM: PMC3638624
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/09 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/12 [accepted]
PHST- 2013/04/03 [epublish]
AID - 10.1155/2013/867893 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:867893. doi: 10.1155/2013/867893.
      Epub 2013 Apr 3.

PMID- 23690849
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Validation of the Antidiabetic and Hypolipidemic Effects of Hawthorn by
      Assessment of Gluconeogenesis and Lipogenesis Related Genes and AMP-Activated
      Protein Kinase Phosphorylation.
PG  - 597067
LID - 10.1155/2013/597067 [doi]
AB  - Since with the increased use of antidiabetic and antihyperlipidemic effect of
      phytonutrients for daily supplement has gained considerable attention worldwide, 
      we examine the effect and molecular mechanism of Crataegus pinnatifida Bge. var. 
      major N.E. Br. (hawthorn) by quantifying the expression of hepatic
      gluconeogenesis and lipogenesis on diabetes and dyslipidemia in high-fat (HF)-fed
      C57BL/6J mice. Firstly, mice were divided randomly into two groups: the control
      (CON) group was fed with a low-fat diet, whereas the experimental group was fed a
      45% HF diet for 8 weeks. Afterwards, the CON group was treated with vehicle,
      whereas the HF group was subdivided into five groups and was given orally
      hawthorn extract (including 0.2, 0.5, 1.0 g/kg/day extracts) or rosiglitazone
      (Rosi) or vehicle for 4 weeks afterward. Diabetic mice showed an increase in
      plasma glucose and insulin. Glucose lowering was comparable with Rosi-treated
      mice. This study demonstrated that hawthorn was effective in ameliorating the HF 
      diet-induced hyperglycemia, hypertriglyceridemia and hypercholesterolaemia.
      Hawthorn extract significantly increases the hepatic protein contents of
      AMP-activated protein kinase (AMPK) phosphorylation and reduces expression of
      phosphenol pyruvate carboxykinase (PEPCK) and glucose production. Furthermore,
      hawthorn decreased in hepatic triacylglycerol and cholesterol synthesis
      (including sterol regulatory element binding protein-1c (SREBP-1c), fatty acid
      synthase (FAS), SREBP2). An increase in expressions of apoA-I gene and
      high-density lipoprotein cholesterol (HDL-C) was detected in HF-fed mice treated 
      with high dose hawthorn. Our data suggest that hawthorn extract are capable of
      decreasing glucose production and triacylglycerol synthesis by inducing
      AMPK-phosphorylation and hawthorn is a candidate source of antidiabetic and
      antihyperlipidemic phytonutrients factors.
AD  - Graduate Institute of Pharmaceutical Science and Technology, College of Health
      Science, Central Taiwan University of Science and Technology, No. 666, Buzih
      Road, Beitun District, Taichung City 40601, Taiwan.
FAU - Shih, Chun-Ching
AU  - Shih CC
FAU - Lin, Cheng-Hsiu
AU  - Lin CH
FAU - Lin, Yih-Jiun
AU  - Lin YJ
FAU - Wu, Jin-Bin
AU  - Wu JB
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3652187
OID - NLM: PMC3652187
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/05/24 [received]
PHST- 2013/02/20 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.1155/2013/597067 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:597067. doi: 10.1155/2013/597067.
      Epub 2013 Apr 16.

PMID- 23690839
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Pharmacometrics of 3-methoxypterostilbene: a component of traditional chinese
      medicinal plants.
PG  - 261468
LID - 10.1155/2013/261468 [doi]
AB  - 3-Methoxypterostilbene is a naturally occurring stilbene with potential in the
      treatment of diabetes. The preclinical pharmacokinetics and pharmacodynamics of
      3-methoxypterostilbene were evaluated in the present study. The right jugular
      veins of male Sprague-Dawley rats were cannulated. The rats were dosed 10 mg/kg
      or 100 mg/kg of 3-methoxypterostilbene intravenously (IV) or orally (PO),
      respectively. Serum and urine samples were analyzed using a previously validated 
      reversed-phase HPLC method. Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd 
      for IV dosing were 48.1 +/- 23.8 mu g/h/mL, 18.9 +/- 10.9 h, 9.54 +/- 1.51 h,
      47.8 +/- 23.7 L/h/kg, and 5.11 +/- 0.38 L/kg, respectively (mean +/- SEM, n = 4) 
      . Serum AUC, serum t 1/2, urine t 1/2, Cltotal, and Vd for PO dosing were 229 +/-
      44.6 mu g/h/mL, 73.3 +/- 8.91 h, 20.6 +/- 3.01 h, 0.48 +/- 0.008 L/h/kg, and 52.0
      +/- 10.5 L/kg, respectively (mean +/- SEM, n = 4). Bioavailability of the
      stilbene was determined to be 50.6% +/- 10.0%. A 3-methoxypterostilbene
      glucuronidated metabolite was detected in both serum and urine.
      3-Methoxypterostilbene exhibited antidiabetic activity including
      alpha-glucosidase and alpha-amylase inhibition as well as concentration-dependent
      antioxidant capacity similar to resveratrol. 3-Methoxypterostilbene also
      exhibited anti-inflammatory activity. 3-Methoxypterostilbene appears to be a
      bioactive compound and may be useful in reducing postprandial hyperglycemia.
AD  - Faculty of Pharmacy, Apotex Centre University of Manitoba, Winnipeg, MB, Canada
      R3E 0T5.
FAU - Martinez, Stephanie E
AU  - Martinez SE
FAU - Sayre, Casey L
AU  - Sayre CL
FAU - Davies, Neal M
AU  - Davies NM
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3652196
OID - NLM: PMC3652196
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/02/09 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.1155/2013/261468 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:261468. doi: 10.1155/2013/261468.
      Epub 2013 Apr 16.

PMID- 23690811
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 1735-3955 (Print)
IS  - 1735-3955 (Linking)
VI  - 9
IP  - 2
DP  - 2013 Mar
TI  - Risk factors of short-term stroke recurrence in patients with minor ischemic
      cerebrovascular events.
PG  - 119-27
AB  - BACKGROUND: Assessing the risk of recurrent ischemic events in patients with
      transient ischemic attack (TIA) and minor ischemic stroke (MIS) is of a great
      importance in clinical practice. METHODS: Consecutive patients with TIA or MIS
      who were visited in Ghaem Hospital, (Mashhad, Iran) were enrolled in a
      prospective cohort study during 2010 to 2011. Diagnosis of TIA or MIS was
      accomplished by a stroke neurologist. Only those who presented within 24 hours
      from the onset of symptoms were recruited. MIS was considered as an ischemic
      stroke with National Institutes of Health Stroke Scale (NIHSS) < 4. The endpoint 
      of the study was a new ischemic cerebrovascular event or vascular death in 90
      days and additionally in 3 days. The decision to admit and type of treatment in
      each case was left to the discretion of the stroke neurologist. The association
      between 20 potential factors with recurrent ischemic events in 3 and 90 days was 
      investigated using univariate and multivariate analysis (MVA). RESULTS: 393 TIA
      patients (238 males and 155 females) and 118 MIS patients (77 males and 41
      females) were enrolled in the study. Stroke occurred in 117 (23.2%) patients, TIA
      in 99 (19.6%), and there was 11 (2.2%) vascular deaths within 3 months in the
      total 511 patients with minor ischemic events. Crescendo TIAs and multiple TIAs
      were associated with greater risk of stroke in 3 days in a univariate analysis
      (OR = 5.12, P < 0.001) and (OR = 3.98, P = 0.003), respectively. Patients with
      index stroke had 11.5% lower risk of recurrent stroke in 3 days than patients
      with index TIA in multivariate analysis (OR = 0.115, P = 0.039). Diabetes was
      independently associated with 3 months stroke recurrence in the patients with
      minor ischemic events (OR = 2.65, P = 0.039). CONCLUSION: Multiple and crescendo 
      TIAs are the main predictors of stroke recurrence, derived from the univariate
      analysis of the patients with minor ischemic events.
AD  - Professor, Cerebrovascular Research Center, Mashhad University of Medical
      Sciences, Mashhad, Iran.
FAU - Ghandehari, Kavian
AU  - Ghandehari K
FAU - Khajedaluei, Mohammad Reza
AU  - Khajedaluei MR
FAU - Yazdankhah, Zahra
AU  - Yazdankhah Z
FAU - Ghandehari, Kosar
AU  - Ghandehari K
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - ARYA Atheroscler
JT  - ARYA atherosclerosis
JID - 101487337
PMC - PMC3653243
OID - NLM: PMC3653243
OTO - NOTNLM
OT  - Brain
OT  - Infarction
OT  - Recurrence
OT  - Risk
OT  - Transient Ischemic Attacks
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/06/06 [received]
PHST- 2013/01/30 [accepted]
PST - ppublish
SO  - ARYA Atheroscler. 2013 Mar;9(2):119-27.

PMID- 23690804
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1687-9813 (Electronic)
IS  - 1687-9805 (Linking)
VI  - 2013
DP  - 2013
TI  - Active transport and health outcomes: findings from a population study in
      jiangsu, china.
PG  - 624194
LID - 10.1155/2013/624194 [doi]
AB  - To investigate the prevalence of active transport (AT, defined as walking or
      bicycling for transport) and to explore the association between AT and health
      outcomes, we conducted a population-based cross-sectional study in Jiangsu,
      China, where walking and bicycling are still the main modes of transport. In this
      study, 8400 community residents aged 18 or above were interviewed following a
      multistage random sampling method (100% response rate). Face-to-face
      questionnaire survey data, anthropometric measurements, and biochemical data from
      blood tests were collected. Results show that 49.6% of the subjects, as part of
      daily transport, actively traveled on average 5.3 days per week, 53.5 minutes per
      day, and 300.3 minutes per week. There was an inverse correlation between AT and 
      some health outcomes: AT respondents had a higher prevalence of cholesterol
      disorder; AT respondents who actively travelled every day had a higher risk of
      diabetes, whilst AT respondents with shorter daily or weekly duration had a lower
      risk of obesity, central obesity, and cholesterol disorder. Moreover, AT
      influences more health aspects among urban residents than among rural residents. 
      Findings of this study do not support the notion that AT is beneficial to
      population health. Further research is needed in determining the negative side
      effects of AT.
AD  - Chronic Disease Department of Jiangsu Provincial Center for Disease Control and
      Prevention, 172 Jiangsu Road, Nanjing 210009, China.
FAU - Lu, Shu-Rong
AU  - Lu SR
FAU - Su, Jian
AU  - Su J
FAU - Xiang, Quan-Yong
AU  - Xiang QY
FAU - Zhang, Feng-Yun
AU  - Zhang FY
FAU - Wu, Ming
AU  - Wu M
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - United States
TA  - J Environ Public Health
JT  - Journal of environmental and public health
JID - 101516361
SB  - IM
PMC - PMC3649642
OID - NLM: PMC3649642
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/12/14 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/17 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1155/2013/624194 [doi]
PST - ppublish
SO  - J Environ Public Health. 2013;2013:624194. doi: 10.1155/2013/624194. Epub 2013
      Apr 4.

PMID- 23690773
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Subetta treatment increases adiponectin secretion by mature human adipocytes in
      vitro.
PG  - 925874
LID - 10.1155/2013/925874 [doi]
AB  - Purpose. To investigate the mechanism of action in peripheral tissues of novel
      complex drug containing release-active dilutions of antibodies to the beta
      subunit of the insulin receptor and antibodies to endothelial nitric oxide
      synthase (Subetta), which has shown efficacy in animal models of diabetes.
      Methods. Human mature adipocytes were incubated either with Subetta, with one of 
      negative controls (placebo or vehicle), with one of nonspecific controls
      (release-active dilutions of antibodies to cannabinoid receptor type I or
      release-active dilutions of rabbit nonimmune serum), or with dimethyl sulfoxide
      (DMSO) at 37 degrees C in a humidified incubator at 5% CO2 for three days.
      Rosiglitazone was used as reference drug. Secretion of adiponectin was measured
      by quantitative enzyme-linked immunosorbent assay (ELISA). Results. Only Subetta 
      significantly stimulates adiponectin production by mature human adipocytes.
      Nonspecific controls did not significantly affect adiponectin secretion,
      resulting in adiponectin levels comparable to background values of the negative
      controls and DMSO. Conclusion. Increasing adiponectin production in absence of
      insulin by Subetta probably via modulating effect on the beta subunit of the
      insulin receptor might serve as one of the mechanisms of the antidiabetic effect 
      of this drug. These in vitro results give first insight on possible mechanism of 
      action of Subetta and serve as a background for further studies.
AD  - Zen-Bio, Inc., 3200 Chapel Hill-Nelson Boulevard, Street 100, Research Triangle
      Park, NC 27709, USA.
FAU - Nicoll, Jim
AU  - Nicoll J
FAU - Gorbunov, Evgeniy A
AU  - Gorbunov EA
FAU - Tarasov, Sergey A
AU  - Tarasov SA
FAU - Epstein, Oleg I
AU  - Epstein OI
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3652171
OID - NLM: PMC3652171
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013/03/04 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.1155/2013/925874 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:925874. doi: 10.1155/2013/925874. Epub 2013 Apr 18.

PMID- 23690772
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Obesity and inflammation: epidemiology, risk factors, and markers of
      inflammation.
PG  - 678159
LID - 10.1155/2013/678159 [doi]
AB  - Obesity is a public health problem that has reached epidemic proportions with an 
      increasing worldwide prevalence. The global emergence of obesity increases the
      risk of developing chronic metabolic disorders. Thus, it is an economic issue
      that increased the costs of the comorbidities associated. Moreover, in recent
      years, it has been demonstrated that obesity is associated with chronic systemic 
      inflammation, this status is conditioned by the innate immune system activation
      in adipose tissue that promotes an increase in the production and release of
      pro-inflammatory cytokines that contribute to the triggering of the systemic
      acute-phase response which is characterized by elevation of acute-phase protein
      levels. On this regard, low-grade chronic inflammation is a characteristic of
      various chronic diseases such as metabolic syndrome, cardiovascular disease,
      diabetes, hypertension, non-alcoholic fatty liver disease, and some cancers,
      among others, which are also characterized by obesity condition. Thus, a growing 
      body of evidence supports the important role that is played by the inflammatory
      response in obesity condition and the pathogenesis of chronic diseases related.
AD  - Biomedical Research Unit of the Mexican Social Security Institute at Durango,
      Predio Canoas 100, Los Angeles, 34067 Durango, DGO, Mexico ; Faculty of Medicine 
      and Nutrition, Juarez University of Durango State, Av. Universidad and Fanny
      Anitua s/n, Zona Centro, 34000 Durango, DGO, Mexico.
FAU - Rodriguez-Hernandez, Heriberto
AU  - Rodriguez-Hernandez H
FAU - Simental-Mendia, Luis E
AU  - Simental-Mendia LE
FAU - Rodriguez-Ramirez, Gabriela
AU  - Rodriguez-Ramirez G
FAU - Reyes-Romero, Miguel A
AU  - Reyes-Romero MA
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3652163
OID - NLM: PMC3652163
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013/01/14 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/17 [epublish]
AID - 10.1155/2013/678159 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:678159. doi: 10.1155/2013/678159. Epub 2013 Apr 17.

PMID- 23690771
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Changes in Adipokines following Laparoscopic Roux-en-Y Gastric Bypass Surgery in 
      Chinese Individuals with Type 2 Diabetes Mellitus and BMI of 22-30 kg.m(-2.).
PG  - 240971
LID - 10.1155/2013/240971 [doi]
AB  - Aims. Although altered endocrine changes following bariatric surgery in morbidly 
      obese patients with diabetes have been demonstrated by previous studies, little
      is known about their effects on low BMI patients of T2DM. We investigated the
      changes in adipokines and sICAM-1 in Chinese subjects with low BMI and T2DM after
      LRYGB and explored their relationship with postsurgical insulin sensitivity.
      Methods. Plasma levels of adiponectin, sICAM-1, fasting glucose, glycated
      hemoglobin, and fasting insulin and serum levels of visfatin were measured before
      and at three months after LRYGB in 33 T2DM patients with BMI of 22-30 kg.m(-2).
      Results. Significant reductions in anthropometric measurements and indicators of 
      glucose and lipid metabolism and moderate reductions in insulin resistance and
      fasting insulin were observed at three months after LRYGB. Postoperative
      adiponectin level (P < 0.001) was increased compared to the preoperative level,
      whereas visfatin (P < 0.001) and sICAM-1 (P < 0.001) were lower than that before 
      surgery. Serum adiponectin negatively correlated with HOMA-IR and FIns both
      preoperatively and at three months after surgery, and visfatin positively
      correlated with HOMA-IR and FIns both preoperatively and postoperatively.
      Conclusion. Changes in adipokines were related to an improvement in postsurgical 
      insulin sensitivity, which was predicted by weight loss after LRYGB even in low
      BMI patients with T2DM.
AD  - Department of Endocrinology and Metabolism, The Third Xiangya Hospital, Central
      South University, Changsha, Hunan 410013, China.
FAU - Shrestha, Chandrama
AU  - Shrestha C
FAU - He, Honghui
AU  - He H
FAU - Liu, Yiqun
AU  - Liu Y
FAU - Zhu, Shaihong
AU  - Zhu S
FAU - Xiong, Jing
AU  - Xiong J
FAU - Mo, Zhaohui
AU  - Mo Z
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3652206
OID - NLM: PMC3652206
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/11/22 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/17 [epublish]
AID - 10.1155/2013/240971 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:240971. doi: 10.1155/2013/240971. Epub 2013 Apr 17.

PMID- 23690768
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130523
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Osteoporosis associated with antipsychotic treatment in schizophrenia.
PG  - 167138
LID - 10.1155/2013/167138 [doi]
AB  - Schizophrenia is one of the most common global mental diseases, with prevalence
      of 1%. Patients with schizophrenia are predisposed to diabetes, coronary heart
      disease, hypertension, and osteoporosis, than the normal. In comparison with the 
      metabolic syndrome, for instance, there are little reports about osteoporosis
      which occurs secondary to antipsychotic-induced hyperprolactinaemia. There are
      extensive recent works of literature indicating that osteoporosis is associated
      with schizophrenia particularly in patients under psychotropic medication
      therapy. As osteoporotic fractures cause significantly increased morbidity and
      mortality, it is quite necessary to raise the awareness and understanding of the 
      impact of antipsychotic-induced hyperprolactinaemia on physical health in
      schizophrenia. In this paper, we will review the relationship between
      schizophrenia, antipsychotic medication, hyperprolactinaemia, and osteoporosis.
AD  - Institute of Mental Health, Second Xiangya Hospital, Central South University,
      Changsha 410011, China.
FAU - Wu, Haishan
AU  - Wu H
FAU - Deng, Lu
AU  - Deng L
FAU - Zhao, Lipin
AU  - Zhao L
FAU - Zhao, Jingping
AU  - Zhao J
FAU - Li, Lehua
AU  - Li L
FAU - Chen, Jindong
AU  - Chen J
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3652172
OID - NLM: PMC3652172
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2012/12/19 [received]
PHST- 2013/02/20 [revised]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/17 [epublish]
AID - 10.1155/2013/167138 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:167138. doi: 10.1155/2013/167138. Epub 2013 Apr 17.

PMID- 23690696
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 6
DP  - 2013
TI  - Impact of admission blood glucose level on outcomes in community-acquired
      pneumonia in older adults.
PG  - 341-4
LID - 10.2147/IJGM.S42854 [doi]
AB  - BACKGROUND: Community-acquired pneumonia (CAP) is a common cause of morbidity and
      mortality in older adults. Although diabetes mellitus is a risk factor for
      pneumonia, the clinical impact of blood glucose level at the time of admission is
      not clear. Our goal was to examine the association between admission
      hyperglycemia and subsequent mortality, length of stay, and readmission outcomes 
      in older adults with CAP. METHODS: A retrospective observational study was
      conducted using hospital data for community-acquired pneumonia admissions in 857 
      persons from January 1, 2008 to December 31, 2010. We examined the effects of
      admission glucose level on mortality, length of stay, and 30 day readmission,
      adjusted for demographic factors and comorbidity. RESULTS: The mean age of the
      sample was 64 years, and 51% of the subjects were female. Inpatient mortality
      occurred in 4.6% and the median length of stay was 5 days (interquartile range
      3-9 days). Readmission within 30 days occurred in 17%. We found little impact of 
      first glucose measures on in-hospital mortality (P = 0.94), length of stay (P =
      0.95), and 30-day readmission (P = 0.56). Subjects 65 years and older trended
      towards higher in-hospital mortality. Older age, cancer, heart failure, and
      cirrhosis were associated with adverse outcomes. CONCLUSION: Glucose level upon
      admission for community-acquired pneumonia was not associated with adverse
      outcomes within 30 days in older adults.
AD  - University of Kansas School of Medicine, Kansas City, KS, USA.
FAU - Bhattacharya, Rajib K
AU  - Bhattacharya RK
FAU - Mahnken, Jonathan D
AU  - Mahnken JD
FAU - Rigler, Sally K
AU  - Rigler SK
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC3656812
OID - NLM: PMC3656812
OTO - NOTNLM
OT  - community-acquired pneumonia
OT  - hospital mortality
OT  - hyperglycemia
OT  - readmission rates
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/06 [epublish]
AID - 10.2147/IJGM.S42854 [doi]
AID - ijgm-6-341 [pii]
PST - epublish
SO  - Int J Gen Med. 2013 May 6;6:341-4. doi: 10.2147/IJGM.S42854. Print 2013.

PMID- 23690694
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130527
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 6
DP  - 2013
TI  - Management of limited joint mobility in diabetic patients.
PG  - 197-207
LID - 10.2147/DMSO.S33943 [doi]
AB  - Several rheumatologic manifestations are more pronounced in subjects with
      diabetes, ie, frozen shoulder, rotator cuff tears, Dupuytren's contracture,
      trigger finger, cheiroarthropathy in the upper limb, and Achilles tendinopathy
      and plantar fasciitis in the lower limb. These conditions can limit the range of 
      motion of the affected joint, thereby impairing function and ability to perform
      activities of daily living. This review provides a short description of
      diabetes-related joint diseases, the specific pathogenetic mechanisms involved,
      and the role of inflammation, overuse, and genetics, each of which activates a
      complex sequence of biochemical alterations. Diabetes is a causative factor in
      tendon diseases and amplifies the damage induced by other agents as well.
      According to an accepted hypothesis, damaged joint tissue in diabetes is caused
      by an excess of advanced glycation end products, which forms covalent cross-links
      within collagen fibers and alters their structure and function. Moreover, they
      interact with a variety of cell surface receptors, activating a number of
      effects, including pro-oxidant and proinflammatory events. Adiposity and advanced
      age, commonly associated with type 2 diabetes mellitus, are further pathogenetic 
      factors. Prevention and strict control of this metabolic disorder is essential,
      because it has been demonstrated that limited joint motion is related to duration
      of the disease and hyperglycemia. Several treatments are used in clinical
      practice, but their mechanisms of action are not completely understood, and their
      efficacy is also debated.
AD  - Department of Medicine and Science of Aging, University G d'Annunzio,
      Chieti-Pescara, Italy.
FAU - Abate, Michele
AU  - Abate M
FAU - Schiavone, Cosima
AU  - Schiavone C
FAU - Salini, Vincenzo
AU  - Salini V
FAU - Andia, Isabel
AU  - Andia I
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3656815
OID - NLM: PMC3656815
OTO - NOTNLM
OT  - diabetes mellitus
OT  - diabetic complication
OT  - joint mobility
OT  - tendon
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:01
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/07 [epublish]
AID - 10.2147/DMSO.S33943 [doi]
AID - dmso-6-197 [pii]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2013 May 7;6:197-207. doi: 10.2147/DMSO.S33943. Print 
      2013.

PMID- 23690689
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Red blood cell count as an indicator of microvascular complications in Chinese
      patients with type 2 diabetes mellitus.
PG  - 237-43
LID - 10.2147/VHRM.S43211 [doi]
AB  - BACKGROUND: Rheological disorders of red blood cells (RBC) and decreased RBC
      deformability have been involved in the development of diabetic microangiopathy. 
      However, few studies have evaluated the association of RBC count with
      microvascular complications in patients with type 2 diabetes mellitus (T2DM). The
      purpose of this study was to investigate the association of RBC count with
      microvascular complications in patients with T2DM. METHODS: This study involved
      369 patients with T2DM: 243 with one or more microvascular complications and 126 
      without microvascular complications. Anticoagulated blood was collected and
      analyzed in an automated blood cell counter. The presence of risk factors for
      microvascular complications was determined. RESULTS: The proportion of patients
      with microvascular complications increased as the RBC count decreased (P <
      0.001). After adjustment for known risk factors for microvascular complications
      by logistic regression analysis, lower quartiles of RBC count were associated
      with a higher risk of microvascular complications compared with the reference
      group composed of the highest quartile (first quartile, odds ratio 4.98, 95%
      confidence interval 1.54-6.19, P = 0.008; second quartile, odds ratio 3.21, 95%
      confidence interval 1.17-5.28, P = 0.024). CONCLUSION: A decreased RBC count is
      associated with microvascular complications in Chinese patients with T2DM. The
      RBC count is a potential marker to improve further the ability to identify
      diabetic patients at high risk of microvascular complications.
AD  - Department of Cardiology, First Affiliated Hospital of China Medical University, 
      Shenyang, People's Republic of China ; Second Department of Cardiology, Fourth
      People's Hospital of Shenyang, Shenyang, People's Republic of China.
FAU - Wang, Zhan-Sheng
AU  - Wang ZS
FAU - Song, Zhan-Chun
AU  - Song ZC
FAU - Bai, Jing-Hui
AU  - Bai JH
FAU - Li, Fei
AU  - Li F
FAU - Wu, Tao
AU  - Wu T
FAU - Qi, Ji
AU  - Qi J
FAU - Hu, Jian
AU  - Hu J
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
SB  - IM
PMC - PMC3656917
OID - NLM: PMC3656917
OTO - NOTNLM
OT  - microvascular complication
OT  - red blood cell count
OT  - type 2 diabetes mellitus
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/14 [epublish]
AID - 10.2147/VHRM.S43211 [doi]
AID - vhrm-9-237 [pii]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:237-43. doi: 10.2147/VHRM.S43211. Epub 2013 May
      14.

PMID- 23690533
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 20
TI  - Renal Function Following Three Distinct Weight Loss Dietary Strategies During 2
      Years of Randomized Controlled Trial.
AB  - OBJECTIVEThis study addressed the long-term effect of various diets, particularly
      low-carbohydrate high-protein, on renal function on participants with or without 
      type 2 diabetes.RESEARCH DESIGN AND METHODSIn the 2-year Dietary Intervention
      Randomized Controlled Trial (DIRECT), 318 participants (age, 51 years; 86% men;
      BMI, 31 kg/m2; mean estimated glomerular filtration rate [eGFR], 70.5 mL/min/1.73
      m2; mean urine microalbumin-to-creatinine ratio, 12:12) with serum creatinine
      <176 mumol/L (eGFR >/=30 mL/min/1.73 m2) were randomized to low-fat,
      Mediterranean, or low-carbohydrate diets. The 2-year compliance was 85%, and the 
      proportion of protein intake significantly increased to 22% of energy only in the
      low-carbohydrate diet (P < 0.05 vs. low-fat and Mediterranean). We examined
      changes in urinary microalbumin and eGFR, estimated by Modification of Diet in
      Renal Disease and Chronic Kidney Disease Epidemiology Collaboration
      formulas.RESULTSSignificant (P < 0.05 within groups) improvements in eGFR were
      achieved in low-carbohydrate (+5.3% [95% CI 2.1-8.5]), Mediterranean (+5.2%
      [3.0-7.4]), and low-fat diets (+4.0% [0.9-7.1]) with similar magnitude (P > 0.05)
      across diet groups. The increased eGFR was at least as prominent in participants 
      with (+6.7%) or without (+4.5%) type 2 diabetes or those with lower baseline
      renal function of eGFR <60 mL/min/1.73 m2 (+7.1%) versus eGFR >/=60 mL/min/1.73
      m2 (+3.7%). In a multivariable model adjusted for age, sex, diet-group, type 2
      diabetes, use of ACE inhibitors, 2-year weight loss, and change in protein intake
      (confounders and univariate predictors), only a decrease in fasting insulin (beta
      = -0.211; P = 0.004) and systolic blood pressure (beta = -0.25; P < 0.001) were
      independently associated with increased eGFR. The urine
      microalbumin-to-creatinine ratio improved similarly across the diets,
      particularly among participants with baseline sex-adjusted microalbuminuria, with
      a mean change of -24.8 (P < 0.05).CONCLUSIONSA low-carbohydrate diet is as safe
      as Mediterranean or low-fat diets in preserving/improving renal function among
      moderately obese participants with or without type 2 diabetes, with baseline
      serum creatinine <176 mumol/L. Potential improvement is likely to be mediated by 
      weight loss-induced improvements in insulin sensitivity and blood pressure.
AD  - Brigham and Women's Hospital, Harvard School of Public Health Boston,
      Massachusetts, and the Talpiot Medical Leadership Program, Chaim Sheba Medical
      Center, Tel-Hashomer, Israel.
FAU - Tirosh, Amir
AU  - Tirosh A
FAU - Golan, Rachel
AU  - Golan R
FAU - Harman-Boehm, Ilana
AU  - Harman-Boehm I
FAU - Henkin, Yaakov
AU  - Henkin Y
FAU - Schwarzfuchs, Dan
AU  - Schwarzfuchs D
FAU - Rudich, Assaf
AU  - Rudich A
FAU - Kovsan, Julia
AU  - Kovsan J
FAU - Fiedler, Georg M
AU  - Fiedler GM
FAU - Bluher, Matthias
AU  - Bluher M
FAU - Stumvoll, Michael
AU  - Stumvoll M
FAU - Thiery, Joachim
AU  - Thiery J
FAU - Stampfer, Meir J
AU  - Stampfer MJ
FAU - Shai, Iris
AU  - Shai I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - dc12-1846 [pii]
AID - 10.2337/dc12-1846 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 20.

PMID- 23690532
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 20
TI  - Circulating Estrone Levels Are Associated Prospectively With Diabetes Risk in Men
      of the Framingham Heart Study.
AB  - OBJECTIVEIn postmenopausal women and preclinical murine models, estrogen
      administration reduces diabetes risk; however, the relationship of estradiol and 
      estrone to diabetes in men is poorly understood. We determined the relationship
      between circulating estradiol and estrone levels and diabetes risk in
      community-dwelling men of the Framingham Heart Study (FHS).METHODSCross-sectional
      relationships of estradiol and estrone levels with diabetes were assessed at
      examination 7 (1998-2001) in FHS generation 2 men (n = 1,458); prospective
      associations between hormone levels at examination 7 and incident diabetes were
      assessed 6.8 years later at examination 8. Type 2 diabetes mellitus was defined
      as fasting glucose >125 mg/dL, medication use, or both. Estradiol, estrone, and
      testosterone levels were measured with liquid chromatography tandem mass
      spectrometry, and free estradiol and estrone were calculated.RESULTSIn
      cross-sectional models, men with elevated estrone and estradiol had 40% and 62%
      increased likelihoods of existing diabetes per cross-sectional doubling of
      estrone and estradiol levels, respectively. Free estrone (cross-sectional odds
      ratio 1.28 [95% CI 1.02-1.62], P = 0.04) was associated with impaired fasting
      glucose at examination 7. There was an increase in risk of existing diabetes with
      increasing quartiles of total and free estrone and estradiol and an increase in
      risk of incident diabetes with increasing quartiles of estrone levels. In
      multivariate longitudinal analyses, a twofold increase in total or free estrone
      levels at examination 7 was associated with 77 and 93% increases, respectively,
      in odds of incident diabetes at examination 8.CONCLUSIONSAlthough both estradiol 
      and estrone exhibit cross-sectional associations with diabetes in men, in
      longitudinal analyses estrone is a more sensitive marker of diabetes risk than
      estradiol.
AD  - Department of Mathematics, Boston University, Boston, Massachusetts.
FAU - Jasuja, Guneet Kaur
AU  - Jasuja GK
FAU - Travison, Thomas G
AU  - Travison TG
FAU - Davda, Maithili
AU  - Davda M
FAU - Rose, Adam J
AU  - Rose AJ
FAU - Zhang, Anqi
AU  - Zhang A
FAU - Kushnir, Mark M
AU  - Kushnir MM
FAU - Rockwood, Alan L
AU  - Rockwood AL
FAU - Meikle, Wayne
AU  - Meikle W
FAU - Coviello, Andrea D
AU  - Coviello AD
FAU - D'Agostino, Ralph
AU  - D'Agostino R
FAU - Vasan, Ramachandran S
AU  - Vasan RS
FAU - Bhasin, Shalender
AU  - Bhasin S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - dc12-2477 [pii]
AID - 10.2337/dc12-2477 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 20.

PMID- 23690531
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 20
TI  - Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A
      Comparative Effectiveness Study (GRADE).
AB  - OBJECTIVEThe epidemic of type 2 diabetes (T2DM) threatens to become the major
      public health problem of this century. However, a comprehensive comparison of the
      long-term effects of medications to treat T2DM has not been conducted. GRADE, a
      pragmatic, unmasked clinical trial, aims to compare commonly used diabetes
      medications, when combined with metformin, on glycemia-lowering effectiveness and
      patient-centered outcomes.RESEARCH DESIGN AND METHODSGRADE was designed with
      support from a U34 planning grant from the National Institute of Diabetes and
      Digestive and Kidney Diseases (NIDDK). The consensus protocol was approved by
      NIDDK and the GRADE Research Group. Eligibility criteria for the 5,000
      metformin-treated subjects include <5 years' diabetes duration, >/=30 years of
      age at time of diagnosis, and baseline hemoglobin A1c (A1C) of 6.8-8.5% (51-69
      mmol/mol). Medications representing four classes (sulfonylureas, dipeptidyl
      peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, and insulin)
      will be randomly assigned and added to metformin (minimum-maximum 1,000-2,000
      mg/day). The primary metabolic outcome is the time to primary failure defined as 
      an A1C >/=7% (53 mmol/mol), subsequently confirmed, over an anticipated mean
      observation period of 4.8 years (range 4-7 years). Other long-term metabolic
      outcomes include the need for the addition of basal insulin after a confirmed A1C
      >7.5% (58 mmol/mol) and, ultimately, the need to implement an intensive
      basal/bolus insulin regimen. The four drugs will also be compared with respect to
      selected microvascular complications, cardiovascular disease risk factors,
      adverse effects, tolerability, quality of life, and
      cost-effectiveness.CONCLUSIONSGRADE will compare the long-term effectiveness of
      major glycemia-lowering medications and provide guidance to clinicians about the 
      most appropriate medications to treat T2DM. GRADE begins recruitment at 37
      centers in the U.S. in 2013.
AD  - Diabetes Research Center, Massachusetts General Hospital and Harvard School of
      Medicine, Boston, Massachusetts.
FAU - Nathan, David M
AU  - Nathan DM
FAU - Buse, John B
AU  - Buse JB
FAU - Kahn, Steven E
AU  - Kahn SE
FAU - Krause-Steinrauf, Heidi
AU  - Krause-Steinrauf H
FAU - Larkin, Mary E
AU  - Larkin ME
FAU - Staten, Myrlene
AU  - Staten M
FAU - Wexler, Deborah
AU  - Wexler D
FAU - Lachin, John M
AU  - Lachin JM
CN  - the GRADE Study Research Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - dc13-0356 [pii]
AID - 10.2337/dc13-0356 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 20.

PMID- 23690530
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 20
TI  - Aggressive Blood Pressure Control Increases Coronary Heart Disease Risk Among
      Diabetic Patients.
AB  - OBJECTIVEBlood pressure control can reduce the risk of coronary heart disease
      (CHD) among diabetic patients; however, it is not known whether the lowest risk
      of CHD is among diabetic patients with the lowest blood pressure level.RESEARCH
      DESIGN AND METHODSWe performed a prospective cohort study (2000-2009) on diabetic
      patients including 17,536 African American and 12,618 white. Cox proportional
      hazards regression models were used to estimate the association of blood pressure
      with CHD risk.RESULTSDuring a mean follow-up of 6.0 years, 7,260 CHD incident
      cases were identified. The multivariable-adjusted hazard ratios of CHD associated
      with different levels of systolic/diastolic blood pressure at baseline (<110/65, 
      110-119/65-69, 120-129/70-80, and 130-139/80-90 mmHg [reference group];
      140-159/90-100; and >/=160/100 mmHg) were 1.73, 1.16, 1.04, 1.00, 1.06, and 1.11 
      (P trend <0.001), respectively, for African American diabetic patients, and 1.60,
      1.27, 1.08, 1.00, 0.95, and 0.99 (P trend<0.001) for white diabetic patients,
      respectively. A U-shaped association of isolated systolic and diastolic blood
      pressure at baseline as well as blood pressure during follow-up with CHD risk was
      observed among both African American and white diabetic patients (all P trend
      <0.001). The U-shaped association was present in the younger age-group (30-49
      years), and this U-shaped association changed to an inverse association in the
      older age-group (>/=60 years).CONCLUSIONSOur study suggests that there is a
      U-shaped or inverse association between blood pressure and the risk of CHD, and
      aggressive blood pressure control (blood pressure <120/70 mmHg) is associated
      with an increased risk of CHD among both African American and white patients with
      diabetes.
AD  - Pennington Biomedical Research Center, Baton Rouge, Louisiana.
FAU - Zhao, Wenhui
AU  - Zhao W
FAU - Katzmarzyk, Peter T
AU  - Katzmarzyk PT
FAU - Horswell, Ronald
AU  - Horswell R
FAU - Wang, Yujie
AU  - Wang Y
FAU - Li, Wei
AU  - Li W
FAU - Johnson, Jolene
AU  - Johnson J
FAU - Heymsfield, Steven B
AU  - Heymsfield SB
FAU - Cefalu, William T
AU  - Cefalu WT
FAU - Ryan, Donna H
AU  - Ryan DH
FAU - Hu, Gang
AU  - Hu G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - dc13-0189 [pii]
AID - 10.2337/dc13-0189 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 20.

PMID- 23690508
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1479-6813 (Electronic)
IS  - 0952-5041 (Linking)
DP  - 2013 May 20
TI  - High glucose and insulin differentially modulates proliferation in MCF-7 and
      MDA-MB-231 cells.
AB  - Various pre-clinical and clinical studies have linked diabetes and breast cancer,
      but, little is known regarding the molecular mechanism involved. The present
      study was aimed to investigate the effect of high glucose and insulin in breast
      cancer cells (MCF-7; non-invasive, hormone dependent and MDA-MB-231; invasive,
      hormone independent). In contrast to MCF-7 cells, high glucose augmented
      proliferation of MDA-MB-231 cells as observed by MTT and BrdU assay. High glucose
      condition led to increased expression of Cyclin D1, de-phosphorylation of p38 and
      increased phosphorylation of ERK in MDA-MB-231 cells and not in MCF-7 cells.
      Interestingly, we observed increased phosphorylation of GSK-3beta, NF-kappaB and 
      ERalpha only in MCF-7 cells, highlighting their role as potential targets in
      preventing progression of breast cancer under high glucose and insulin condition.
      Furthermore, insulin treatment under high glucose condition resulted in increased
      histone H3 phosphorylation and de-acetylation only in MDA-MB-231 cells. Taken
      together, we provide first evidence that high glucose and insulin promotes
      proliferation of MDA-MB-231 cells, by differential alteration of GSK-3beta,
      NF-kappaB, ERalpha expression and histone H3 modifications, which may directly or
      indirectly modulate the expression of genes involved in its proliferation.
AD  - C Gupta, Pharmacology and Toxicology, National Institute of Pharmaceutical
      Education and Research, Mohali, India.
FAU - Gupta, Chanchal
AU  - Gupta C
FAU - Tikoo, Kulbhushan
AU  - Tikoo K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Mol Endocrinol
JT  - Journal of molecular endocrinology
JID - 8902617
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - JME-13-0062 [pii]
AID - 10.1530/JME-13-0062 [doi]
PST - aheadofprint
SO  - J Mol Endocrinol. 2013 May 20.

PMID- 23690410
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
DP  - 2013 May 20
TI  - Effects of a Telephone-Delivered Multiple Health Behavior Change Intervention
      (CanChange) on Health and Behavioral Outcomes in Survivors of Colorectal Cancer: 
      A Randomized Controlled Trial.
AB  - PURPOSEColorectal cancer survivors are at risk for poor health outcomes because
      of unhealthy lifestyles, but few studies have developed translatable health
      behavior change interventions. This study aimed to determine the effects of a
      telephone-delivered multiple health behavior change intervention (CanChange) on
      health and behavioral outcomes among colorectal cancer survivors. METHODSIn this 
      two-group randomized controlled trial, 410 colorectal cancer survivors were
      randomly assigned to the health coaching intervention (11 theory-based
      telephone-delivered health coaching sessions delivered over 6 months focusing on 
      physical activity, weight management, dietary habits, alcohol, and smoking) or
      usual care. Assessment of primary (ie, physical activity [Godin Leisure Time
      Index], health-related quality of life [HRQoL; Short Form-36], and cancer-related
      fatigue [Functional Assessment of Chronic Illness Therapy Fatigue Scale]) and
      secondary outcomes (ie, body mass index [kg/m2], diet and alcohol intake [Food
      Frequency Questionnaire], and smoking) were conducted at baseline and 6 and 12
      months.ResultsAt 12 months, significant intervention effects were observed for
      moderate physical activity (28.5 minutes; P = .003), body mass index (-0.9 kg/m2;
      P = .001), energy from total fat (-7.0%; P = .006), and energy from saturated fat
      (-2.8%; P = .016). A significant intervention effect was reported for vegetable
      intake (0.4 servings per day; P = .001) at 6 months. No significant group
      differences were found at 6 or 12 months for HRQoL, cancer-related fatigue,
      fruit, fiber, or alcohol intake, or smoking. CONCLUSIONThe CanChange intervention
      was effective for improving physical activity, dietary habits, and body mass
      index in colorectal cancer survivors. The intervention is translatable through
      existing telephone cancer support and information services in Australia and other
      countries.
AD  - Anna L. Hawkes, Tania A. Patrao, Peter D. Baade, and Joanne F. Aitken, Viertel
      Centre for Research in Cancer Control, Cancer Council Queensland; Anna L. Hawkes 
      and Peter D. Baade, School of Public Health and Social Work, Queensland
      University of Technology; Suzanne K. Chambers and Peter D. Baade, Griffith
      Institute for Health and Medical Research, Griffith University; Kenneth I.
      Pakenham, School of Psychology, University of Queensland, Brisbane, Queensland;
      Brigid M. Lynch, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria;
      Xingqiong Meng, School of Public Health, Curtin University, Perth, Western
      Australia, Australia; and Kerry S. Courneya, University of Alberta, Edmonton,
      Alberta, Canada.
FAU - Hawkes, Anna L
AU  - Hawkes AL
FAU - Chambers, Suzanne K
AU  - Chambers SK
FAU - Pakenham, Kenneth I
AU  - Pakenham KI
FAU - Patrao, Tania A
AU  - Patrao TA
FAU - Baade, Peter D
AU  - Baade PD
FAU - Lynch, Brigid M
AU  - Lynch BM
FAU - Aitken, Joanne F
AU  - Aitken JF
FAU - Meng, Xingqiong
AU  - Meng X
FAU - Courneya, Kerry S
AU  - Courneya KS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - JCO.2012.45.5873 [pii]
AID - 10.1200/JCO.2012.45.5873 [doi]
PST - aheadofprint
SO  - J Clin Oncol. 2013 May 20.

PMID- 23690376
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 2159-3000 (Print)
IS  - 2159-3000 (Linking)
VI  - 408
DP  - 2013 May
TI  - Diabetes update: population management.
PG  - 25-33
AB  - To optimally care for diabetes patients, physicians must adopt a systematic
      approach to managing the entire panel. At the heart of excellent care is a
      multidisciplinary health care team working in a patient-centered environment.
      Options to supplement traditional office visits include shared medical
      appointments (ie, group visits), patient self-management education, and social
      media for patient support and education. Educating patients about diabetes is
      associated with more frequent recommended screening, improved objective measures,
      cost savings, and improved short-term quality of life, especially when behavioral
      goal setting is incorporated. Participation in a nurse-led diabetes management
      program or an outreach program is associated with reduced health care costs and
      increased receipt of recommended screening and testing for patients with
      diabetes; implementation of an electronic database or registry system also is
      associated with these benefits. Some studies show that these interventions are
      associated with improvements in A1c; however, outcomes data are limited. Formats 
      for group visits vary. Evidence suggests that patients with diabetes who
      participate in a group education program have lower A1c levels, improved lipid
      profiles, higher quality of life scores, and improved knowledge about diabetes
      and problem-solving ability.
CI  - Written permission from the American Academy of Family Physicians is required for
      reproduction of this material in whole or in part in any form or medium.
AD  - Tufts University, 136 Harrison Avenue, Boston, MA 02111,
      deborah.erlich@tufts.edu.
FAU - Erlich, Deborah R
AU  - Erlich DR
FAU - Slawson, David C
AU  - Slawson DC
FAU - Shaughnessy, Allen
AU  - Shaughnessy A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - FP Essent
JT  - FP essentials
JID - 101578821
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PST - ppublish
SO  - FP Essent. 2013 May;408:25-33.

PMID- 23690375
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 2159-3000 (Print)
IS  - 2159-3000 (Linking)
VI  - 408
DP  - 2013 May
TI  - Diabetes update: new drugs to manage type 2 diabetes.
PG  - 20-4
AB  - Metformin is the first-line treatment for patients with diabetes because it
      reduces mortality rates. If metformin is contraindicated or is not tolerated, any
      one of the other available antihyperglycemic drugs may be used as monotherapy.
      These drugs are equally effective for glucose control, lowering A1c by
      approximately 1%. Evidence of their benefit for reducing mortality or morbidity, 
      or improving health-related quality of life is lacking. A sulfonylurea,
      pioglitazone, or exenatide can be added to maximally dosed metformin if
      additional glycemic control is necessary. Sulfonylureas and pioglitazone often
      cause weight gain. The combination of metformin plus a sulfonylurea is associated
      with a greater risk of hypoglycemia and mortality than the combination of
      metformin and a thiazolidinedione (ie, glitazone). Thiazolidinediones are
      contraindicated in patients with severe heart failure or liver disease. Newer
      drug classes target incretin, the hormone that stimulates food-dependent insulin 
      secretion. The incretin mimetic exenatide, a high-cost injectable drug, is
      similar to metformin for reduction of A1c and body mass index. Incretin-enhancing
      dipeptidyl-peptidase 4 inhibitors (ie, gliptins) are inferior to metformin for
      lowering A1c and body mass index; little is known about their effect on all-cause
      mortality. Fixed combination products might improve ease of use and adherence;
      they might also reduce cost and risk of adverse effects.
CI  - Written permission from the American Academy of Family Physicians is required for
      reproduction of this material in whole or in part in any form or medium.
AD  - Tufts University, 136 Harrison Avenue, Boston, MA 02111,
      deborah.erlich@tufts.edu.
FAU - Erlich, Deborah R
AU  - Erlich DR
FAU - Slawson, David C
AU  - Slawson DC
FAU - Shaughnessy, Allen
AU  - Shaughnessy A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - FP Essent
JT  - FP essentials
JID - 101578821
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PST - ppublish
SO  - FP Essent. 2013 May;408:20-4.

PMID- 23690374
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 2159-3000 (Print)
IS  - 2159-3000 (Linking)
VI  - 408
DP  - 2013 May
TI  - Diabetes update: long-term treatment of adults.
PG  - 14-9
AB  - Current evidence supports a less interventional, less aggressive, and more
      patient-oriented approach to the care of patients with diabetes than is commonly 
      followed. When treating an adult patient with type 2 diabetes, the physician must
      focus on the following (in order of importance): smoking cessation and other
      lifestyle interventions, blood pressure control, metformin use, lipid control,
      and glycemic control. Patients also should receive influenza and pneumococcal
      vaccinations. Management goals should be individualized, but general target
      values are blood pressure of 140/80 mm Hg, low-density lipoprotein less than 100 
      mg/dL (or 70 mg/dL in a patient with diabetes and coronary artery disease,
      according to consensus opinion), and A1c less than 8%. Hypertension control is
      important; a thiazide or angiotensin-converting enzyme inhibitor might be the
      best first-line treatment. Metformin is the foundation of treatment for most
      patients with type 2 diabetes; in patients who are overweight, use of metformin
      delays premature mortality regardless of achieved glucose levels. Statin drugs
      are superior to other drugs for cholesterol reduction. The use of combination or 
      high-intensity drugs does not appear to confer additional benefit.
CI  - Written permission from the American Academy of Family Physicians is required for
      reproduction of this material in whole or in part in any form or medium.
AD  - Tufts University, 136 Harrison Avenue, Boston, MA 02111,
      deborah.erlich@tufts.edu.
FAU - Erlich, Deborah R
AU  - Erlich DR
FAU - Slawson, David C
AU  - Slawson DC
FAU - Shaughnessy, Allen
AU  - Shaughnessy A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - FP Essent
JT  - FP essentials
JID - 101578821
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PST - ppublish
SO  - FP Essent. 2013 May;408:14-9.

PMID- 23690373
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 2159-3000 (Print)
IS  - 2159-3000 (Linking)
VI  - 408
DP  - 2013 May
TI  - Diabetes update: screening and diagnosis.
PG  - 11-3
AB  - Busy primary care physicians who want their patients with type 2 diabetes to live
      longer and better should, as much as possible, base screening and management
      decisions on patient-oriented evidence that affects morbidity and mortality.
      Because patients with dual diagnoses of diabetes and hypertension have a high
      risk of cardiovascular mortality, asymptomatic patients with hypertension should 
      be screened for type 2 diabetes. Screening is conducted using a fasting plasma
      glucose test, a random A1c test, or a 2-hour oral glucose tolerance test. For
      obese patients, efforts to prevent diabetes focus on weight reduction and
      moderate physical activity. In high-risk patients, use of metformin could delay
      diabetes onset. Diabetes is diagnosed on the basis of an abnormal A1c level,
      fasting plasma glucose level, or 2-hour oral glucose tolerance test or a
      symptomatic random plasma glucose level. After diabetes is diagnosed, the
      physician should obtain blood pressure, body mass index, a lipid panel (fasting
      not required), kidney function tests, and A1c test, and review vaccination and
      smoking status. Increased exercise and dietary modification should be
      recommended. For most patients with newly diagnosed diabetes, metformin should be
      initiated. Risk factors for cardiovascular disease should be evaluated; use of
      daily low-dose aspirin may be considered. Patients who meet treatment criteria
      for high cholesterol levels should take a statin, and patients with unacceptably 
      elevated blood pressure should take an antihypertensive drug.
CI  - Written permission from the American Academy of Family Physicians is required for
      reproduction of this material in whole or in part in any form or medium.
AD  - Tufts University, 136 Harrison Avenue, Boston, MA 02111,
      deborah.erlich@tufts.edu.
FAU - Erlich, Deborah R
AU  - Erlich DR
FAU - Slawson, David C
AU  - Slawson DC
FAU - Shaughnessy, Allen
AU  - Shaughnessy A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - FP Essent
JT  - FP essentials
JID - 101578821
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PST - ppublish
SO  - FP Essent. 2013 May;408:11-3.

PMID- 23690345
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
DP  - 2013 May 20
TI  - Recent Clinical Trials of Hypertension Management.
AD  - Baker IDI Heart and Diabetes Institute, Melbourne 3004, Australia.
FAU - Jennings, Garry L R
AU  - Jennings GL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Hypertension
JT  - Hypertension
JID - 7906255
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - HYPERTENSIONAHA.113.00863 [pii]
AID - 10.1161/HYPERTENSIONAHA.113.00863 [doi]
PST - aheadofprint
SO  - Hypertension. 2013 May 20.

PMID- 23690324
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1544-1717 (Electronic)
IS  - 1544-1709 (Linking)
VI  - 11
IP  - 3
DP  - 2013 May-Jun
TI  - Association of depression with increased risk of severe hypoglycemic episodes in 
      patients with diabetes.
PG  - 245-50
LID - 10.1370/afm.1501 [doi]
AB  - PURPOSE Although psychosocial and clinical factors have been found to be
      associated with hypoglycemic episodes in patients with diabetes, few studies have
      examined the association of depression with severe hypoglycemic episodes. This
      study examined the prospective association of depression with risk of
      hypoglycemic episodes requiring either an emergency department visit or
      hospitalization. METHODS In a longitudinal cohort study, a sample of 4,117
      patients with diabetes enrolled between 2000 and 2002 were observed from 2005 to 
      2007. Meeting major depression criteria on the Patient Health Questionnaire-9 was
      the exposure of interest, and the outcome of interest was an International
      Classification of Disease, Ninth Revision code for a hypoglycemic episode
      requiring an emergency department visit or hospitalization. Proportional hazard
      models were used to analyze the association of baseline depression and risk of
      one or more severe hypoglycemic episodes. Poisson regression was used to
      determine whether depression status was associated with the number of
      hypoglycemic episodes. RESULTS After adjusting for sociodemographic, clinical
      measures of diabetes severity, non-diabetes-related medical comorbidity, prior
      hypoglycemic episodes, and health risk behaviors, depressed compared with
      nondepressed patients who had diabetes had a significantly higher risk of a
      severe hypoglycemic episode (hazard ratio = 1.42, 95% CI, 1.03-1.96) and a
      greater number of hypoglycemic episodes (odds ratio = 1.34, 95% CI, 1.03-1.74).
      CONCLUSION Depression was significantly associated with time to first severe
      hypoglycemic episode and number of hypoglycemic episodes. Research assessing
      whether recognition and effective treatment of depression among persons with
      diabetes prevents severe hypoglycemic episodes is needed.
AD  - Department of Psychiatry, University of Washington Medical School, Seattle,
      Washington.
FAU - Katon, Wayne J
AU  - Katon WJ
FAU - Young, Bessie A
AU  - Young BA
FAU - Russo, Joan
AU  - Russo J
FAU - Lin, Elizabeth H B
AU  - Lin EH
FAU - Ciechanowski, Paul
AU  - Ciechanowski P
FAU - Ludman, Evette J
AU  - Ludman EJ
FAU - Von Korff, Michael R
AU  - Von Korff MR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Fam Med
JT  - Annals of family medicine
JID - 101167762
SB  - IM
PMC - PMC3659141
OID - NLM: PMC3659141 [Available on 11/01/13]
OTO - NOTNLM
OT  - depression
OT  - diabetes
OT  - hypoglycemia
OT  - mental health
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PMCR- 2013/11/01 00:00
AID - 11/3/245 [pii]
AID - 10.1370/afm.1501 [doi]
PST - ppublish
SO  - Ann Fam Med. 2013 May-Jun;11(3):245-50. doi: 10.1370/afm.1501.

PMID- 23690314
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 20
TI  - ACUTE GLUCOCORTICOID DEFICIENCY AND DIABETES INSIPIDUS ARE COMMON FOLLOWING ACUTE
      TRAUMATIC BRAIN INJURY AND PREDICT MORTALITY.
AB  - Context:Published data demonstrates that hypopituitarism is common following
      traumatic brain injury (TBI). Hormone deficiencies are transient in many but the 
      natural history of the acute changes following TBI has not been documented. In
      addition, it is not clear whether there are any early parameters which accurately
      predict the development of permanent hypopituitarism.Objectives:1. To describe
      the natural history of plasma cortisol (PC) changes and sodium balance following 
      TBI2. To identify whether acute hypocortisolaemia or cranial diabetes insipidus
      (CDI) predict mortality3. To identify whether acute pituitary dysfunction
      predicts the development of chronic anterior hypopituitarismDesign:Each TBI
      patient underwent sequential measurement of PC, plasma sodium, urine osmolality
      and fluid balance following TBI. All other anterior pituitary hormones were
      measured on day 10 following TBI. The results from 15 surgical comparisons
      defined a PC < 300nmol/L as inappropriately low for an acutely ill patient. CDI
      was diagnosed according to the Seckl and Dunger criteria (1). Surviving TBI
      patients underwent dynamic anterior pituitary testing at least 6 months following
      TBI.Setting:The patients were recruited from the Irish National Neurosurgery
      Centre.Patients:100 sequential TBI patients were recruited. 15 patients admitted 
      to ITU following major surgery were recruited as comparisons.Main Outcome
      Measures:PC in TBI patients was compared with that of comparisons. Mortality rate
      was compared between TBI patients with and without acute hypocortisolaemia.
      Results of follow-up dynamic pituitary testing were compared between those with
      and without acute hypocortisolaemia.Results:78% of TBI patients developed
      inappropriately low PC following TBI. Low PC and CDI were predictive of
      mortality. 39% of patients who had follow-up testing had at least one pituitary
      hormone deficit, all of whom had had previous acute hypocortisolaemia or
      CDI.Conclusions:Acute hypocortisolaemia and CDI are predictive of mortality and
      long term pituitary deficits in TBI.
AD  - 1Departments of Endocrinology.
FAU - Hannon, Mj
AU  - Hannon M
FAU - Crowley, Rk
AU  - Crowley R
FAU - Behan, LA
AU  - Behan L
FAU - O'Sullivan, Ep
AU  - O'Sullivan E
FAU - O'Brien, Mmc
AU  - O'Brien M
FAU - Sherlock, M
AU  - Sherlock M
FAU - Rawluk, D
AU  - Rawluk D
FAU - O'Dwyer, R
AU  - O'Dwyer R
FAU - Tormey, W
AU  - Tormey W
FAU - Thompson, Cj
AU  - Thompson C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - jc.2013-1555 [pii]
AID - 10.1210/jc.2013-1555 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 20.

PMID- 23690310
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 20
TI  - Skeletal and Soft Tissue Involvement in Mazabraud Syndrome.
AB  - Abstract Not Available.
AD  - Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine
      III, Technical University Medical Center (ET, LCH), Dresden, Germany, Division of
      Orthopedics, Technical University Medical Center (CH) Dresden, and Center of
      Regenerative Therapies Dresden, Germany (LCH).
FAU - Tsourdi, Elena
AU  - Tsourdi E
FAU - Hamann, Christine
AU  - Hamann C
FAU - Hofbauer, Lorenz C
AU  - Hofbauer LC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - jc.2013-2186 [pii]
AID - 10.1210/jc.2013-2186 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 20.

PMID- 23690306
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 20
TI  - Role of HDL cholesterol and estimates of HDL particle composition in future
      development of type 2 diabetes in the general population: The PREVEND Study.
AB  - Background and aimsHigh density lipoproteins (HDL) may directly stimulate
      beta-cell function and glucose metabolism. We determined relationships of fasting
      HDL-cholesterol, plasma apolipoprotein (apo) A-I, apoA-II and of
      HDL-cholesterol/apoA-I and HDL-cholesterol/apoA-II ratios, as estimates of HDL
      particle composition, with incident type 2 diabetes mellitus.MethodsA prospective
      study was carried out in the PREVEND cohort after excluding subjects with
      diabetes at baseline (n=6,820; age 28-75 years). The association of HDL-related
      variables with incident type 2 diabetes was determined by multivariate logistic
      regression analyses.ResultsAfter a median follow-up of 7.7 years, 394 incident
      cases of type 2 diabetes mellitus were ascertained (5.8 %). After adjustment for 
      age, sex, family history of diabetes, body mass index, hypertension, alcohol and 
      smoking, odd ratios (ORs) for diabetes were 0.55 (95 % CI: 0.47-0.64; P<0.001),
      0.81 (0.71-0.93; P=0.002), 0.02 (0.01-0.06; P<0.001) and 0.03 (0.01-0.060;
      P<0.001) per 1-SD increase in HDL-cholesterol, apoA-I and in the
      HDL-cholesterol/apoA-I and the HDL-cholesterol/apoA-II ratios, respectively. In
      contrast, apoA-II was not related to incident diabetes (OR: 1.02 (0.90-1.16;
      P=0.71). The relationships of HDL-cholesterol and the ratios of
      HDL-cholesterol/apoA-I and HDL-cholesterol/apoA-II remained significant after
      further adjustment for baseline glucose and triglycerides (ORHDL = 0.74
      (0.61-0.88), ORHDL/APOA-I = 0.14 (0.04-0.44), ORHDL/APOA-II = 0.12 (0.04-0.36),
      all P</=0.001).ConclusionsHigher HDL cholesterol, as well as higher
      HDL-cholesterol/apoA-I and HDL-cholesterol/apoA-II ratios are strongly and
      independently related to lower risk of future type 2 diabetes.
AD  - 1Department of Epidemiology.
FAU - Abbasi, Ali
AU  - Abbasi A
FAU - Corpeleijn, Eva
AU  - Corpeleijn E
FAU - Gansevoort, Ron T
AU  - Gansevoort RT
FAU - Gans, Rijk O B
AU  - Gans RO
FAU - Hillege, Hans L
AU  - Hillege HL
FAU - Stolk, Ronald P
AU  - Stolk RP
FAU - Navis, Gerjan
AU  - Navis G
FAU - Bakker, Stephan J L
AU  - Bakker SJ
FAU - Dullaart, Robin P F
AU  - Dullaart RP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - jc.2013-1680 [pii]
AID - 10.1210/jc.2013-1680 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 20.

PMID- 23690305
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1460-2369 (Electronic)
IS  - 1355-4786 (Linking)
DP  - 2013 May 19
TI  - Genetic variants and the risk of gestational diabetes mellitus: a systematic
      review.
AB  - BACKGROUNDSeveral studies have examined associations between genetic variants and
      the risk of gestational diabetes mellitus (GDM). However, inferences from these
      studies were often hindered by limited statistical power and conflicting results.
      We aimed to systematically review and quantitatively summarize the association of
      commonly studied single nucleotide polymorphisms (SNPs) with GDM risk and to
      identify important gaps that remain for consideration in future
      studies.METHODSGenetic association studies of GDM published through 1 October
      2012 were searched using the HuGE Navigator and PubMed databases. A SNP was
      included if the SNP-GDM associations were assessed in three or more independent
      studies. Two reviewers independently evaluated the eligibility for inclusion and 
      extracted the data. The allele-specific odds ratios (ORs) and 95% confidence
      intervals (CIs) were pooled using random effects models accounting for
      heterogeneity.RESULTSOverall, 29 eligible articles capturing associations of 12
      SNPs from 10 genes were included for the systematic review. The minor alleles of 
      rs7903146 (TCF7L2), rs12255372 (TCF7L2), rs1799884 (-30G/A, GCK), rs5219 (E23K,
      KCNJ11), rs7754840 (CDKAL1), rs4402960 (IGF2BP2), rs10830963 (MTNR1B), rs1387153 
      (MTNR1B) and rs1801278 (Gly972Arg, IRS1) were significantly associated with a
      higher risk of GDM. Among them, genetic variants in TCF7L2 showed the strongest
      association with GDM risk, with ORs (95% CIs) of 1.44 (1.29-1.60, P < 0.001) per 
      T allele of rs7903146 and 1.46 (1.15-1.84, P = 0.002) per T allele of
      rs12255372.CONCLUSIONSIn this systematic review, we found significant
      associations of GDM risk with nine SNPs in seven genes, most of which have been
      related to the regulation of insulin secretion.
AD  - Epidemiology Branch, Division of Epidemiology, Statistics and Prevention
      Research, Eunice Kennedy Shriver National Institute of Child Health and Human
      Development, National Institutes of Health, 6100 Executive Blvd, Rockville, MD
      20852, USA.
FAU - Zhang, Cuilin
AU  - Zhang C
FAU - Bao, Wei
AU  - Bao W
FAU - Rong, Ying
AU  - Rong Y
FAU - Yang, Huixia
AU  - Yang H
FAU - Bowers, Katherine
AU  - Bowers K
FAU - Yeung, Edwina
AU  - Yeung E
FAU - Kiely, Michele
AU  - Kiely M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130519
TA  - Hum Reprod Update
JT  - Human reproduction update
JID - 9507614
OTO - NOTNLM
OT  - gene
OT  - genetic factors
OT  - gestational diabetes mellitus
OT  - single nucleotide polymorphism
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - dmt013 [pii]
AID - 10.1093/humupd/dmt013 [doi]
PST - aheadofprint
SO  - Hum Reprod Update. 2013 May 19.

PMID- 23690199
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 9
DP  - 2013 May
TI  - Clavicular fracture: its incidence and predisposing factors in term uncomplicated
      pregnancy.
PG  - 1269-72
LID - 1348 [pii]
AB  - BACKGROUND AND OBJECTIVES: Our aim was to evaluate fetal and maternal
      predisposing factors associated with clavicular fracture. PATIENTS AND METHODS:
      In this study we reviewed all term uncomplicated deliveries in our Hospital
      between January 2009 and April 2010. The diagnosis of clavicular fracture was
      established by physical examination and in clinically diagnosed patients
      confirmed by radiology. We compared deliveries with clavicular fracture (study
      group) with a sample of 150 patients (control group) matched for time at active
      phase of labor from all vaginal deliveries. The data included maternal age,
      gestational age, fetal weight, and infant sex, presence of gestational diabetes, 
      labor duration and induction and shoulder dystocia. RESULTS: In the Unit 16819
      deliveries occurred during the period. The study included 9700 uncomplicated
      pregnancies at > or = 37 weeks of gestation delivered vaginally. We identified 73
      cases of clavicular fracture with an prevalence of (73/9700) 0.75%. The study
      group had a significantly higher prevalence of shoulder dystocia (6.8% vs. 0.6%).
      Logistic regression analysis revealed maternal age and fetal weight as
      significant risk factors influencing clavicular fractures. CONCLUSIONS: Main risk
      factors for clavicular fracture identified from our study seem as maternal age
      and birth weight.
AD  - Zekai Tahir Burak Women's Health Education and Research Hospital, Cankaya,
      Ankara, Turkey. ustunyaprak@yahoo.com.
FAU - Ozdener, T
AU  - Ozdener T
FAU - Engin-Ustun, Y
AU  - Engin-Ustun Y
FAU - Aktulay, A
AU  - Aktulay A
FAU - Turkcapar, F
AU  - Turkcapar F
FAU - Oguz, S
AU  - Oguz S
FAU - Yapar Eyi, E G
AU  - Yapar Eyi EG
FAU - Mollamahmutoglu, L
AU  - Mollamahmutoglu L
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 May;17(9):1269-72.

PMID- 23690197
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 9
DP  - 2013 May
TI  - The effect of diet on pregnancy outcomes among pregnants with abnormal glucose
      challenge test.
PG  - 1258-61
LID - 3648 [pii]
AB  - OBJECTIVES: Gestational diabetes mellitus (GDM) is defined as glucose
      intolerance, first time detected in pregnancy. Diagnostic criteria for GDM have
      changed over the decades. The aim of the study was to examine the effect of diet 
      on birth weight, number of large for gestational age (LGA) (birth weight > 90th
      percentile) babies, total maternal weight gain, gestational age and route of
      delivery among patients with positive 50 g glucose challenge test (GCT) and
      negative 100 g oral glucose tolerance test (OGTT). PATIENTS AND METHODS: A
      prospective randomized controlled study was conducted among patients with
      positive 50 g GCT and negative 100 g OGTT. A plasma glucose value of 140 mg/dL
      was used as the threshold to define an abnormal GCT result. In group 1 50
      patients were given a caloric diet and compared with group 2 with 50 patients
      without a given diet. Patients were followed up until delivery and evaluated for 
      birth weight, number of LGA babies, total maternal weight gain, gestational age
      and route of delivery. RESULTS: There were no significant differences between the
      groups in maternal age, parity, body mass index and gestational age at delivery. 
      There were significant differences in birth weight, number of LGA babies, total
      maternal weight gain during pregnancy. The mean gestational age at delivery was
      38.7+/-1.2 weeks in group 1 and 38.9+/-1.1 weeks in group 2 (p = 0.615). The mean
      birth weight in group 1 was 3328+/-399 g and 3623+/-485 g in group 2 (p = 0.007),
      cesarean rate was 32% in group 1 and 40% in group 2 (p = 0.405). CONCLUSIONS: In 
      the management of patients with positive 50 g GCT and negative 100 g OGTT,
      patients who were prescribed medical nutrition therapy by a dietitian experienced
      in GDM management had better perinatal outcomes.
AD  - Zekai Tahir Burak Women Health Education and Research Hospital, Ankara, Turkey.
      deveer3@hotmail.com.
FAU - Deveer, R
AU  - Deveer R
FAU - Deveer, M
AU  - Deveer M
FAU - Akbaba, E
AU  - Akbaba E
FAU - Engin-Ustun, Y
AU  - Engin-Ustun Y
FAU - Aydogan, P
AU  - Aydogan P
FAU - Celikkaya, H
AU  - Celikkaya H
FAU - Danisman, N
AU  - Danisman N
FAU - Mollamahmutoglu, L
AU  - Mollamahmutoglu L
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 May;17(9):1258-61.

PMID- 23690196
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 9
DP  - 2013 May
TI  - Influence of admission glucose profile and hemoglobin A1c on complications of
      acute myocardial infarction in diabetic patients.
PG  - 1252-7
LID - 4095 [pii]
AB  - BACKGROUND: Diabetic patients have a double higher short-term mortality rate
      after acute myocardial infarction (AMI) than non-diabetic ones. Admission glucose
      level has been already concerned as an independent risk factor for the long-term 
      prognosis after myocardial infarction. The aim of this study is to evaluate the
      influence of admission glucose profile (AGP) and glycosylated hemoglobin (HbA1c) 
      on complications of the AMI in patients with type 2 diabetes. PATIENTS AND
      METHODS: The study was based on 76 diabetic patients hospitalized with first-ever
      AMI. Admission glucose profile was estimated as mean value of the first six blood
      glucose values, since HbA1c was measured from the blood sampled in the first
      morning after the admission to hospital. All post-infarction complications are
      divided into electrical and mechanical ones. ROC curves are used to analyze
      predictive values of admission glucose profile and HbA1c for developing
      post-infarction complications. RESULTS: Admission glucose profile is a
      significant (p = 0.001) predictor of electrical complications with 12.25 mmol/L
      cut-off value (sensitivity 77.3%; specificity 64.5%), while it is not significant
      (p > 0.05) for mechanical complication (cut-off value 16.85 mmol/L; sensitivity
      45.2%; specificity 77.8%). HbA1c is not enough good for the complication
      prediction (p > 0.05). Considering electrical and mechanical complications
      aggregately, AGP is even more significant (p = 0.000) with 14.85 mmol/L cut-off
      value (sensitivity 54.4%; specificity 94.7%), and HbA1c is significant, as well
      (p = 0.013, too with 9.07 % cut-off value (sensitivity 57.9%; specificity 78.8%).
      CONCLUSIONS: Comparing the predictability between AGP and HbA1c, in our sample,
      the first one seems to be the better one. Admission glucose profile and HbA1c
      should be the obligatory laboratory tests performed at the time of hospital
      admission after the heart attack.
AD  - Clinical Centre of Montenegro, School of Medicine, University of Montenegro,
      Podgorica, Montenegro. com_nr@yahoo.com.
FAU - Vujosevic, S
AU  - Vujosevic S
FAU - Radojevic, N
AU  - Radojevic N
FAU - Belada, N
AU  - Belada N
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 May;17(9):1252-7.

PMID- 23690192
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 9
DP  - 2013 May
TI  - Vitamin D deficiency in HIV infection: an underestimated and undertreated
      epidemic.
PG  - 1218-32
LID - 4071 [pii]
AB  - Hypovitaminosis D is a very common disorder, regarding both Western and
      developing countries. A growing amount of data over the last years have shown
      vitamin D deficiency to be high prevalent among HIV-positive subjects. In
      addition to "classic" risk factors, such as female sex, low dietary intake, dark 
      skin pigmentation and low sun exposure, HIV-related factors, including immune
      activation and antiretroviral adverse effects, may affect vitamin D status. Even 
      if both protease inhibitors and non-nucleoside reverse transcriptase inhibitors
      have been associated with low vitamin D levels, available evidences have failed
      to univocally associate hypovitaminosis D with specific antiretroviral class
      effects. Low vitamin D is known to have a negative impact not only on bone
      health, but also on neurocognitive, metabolic, cardiovascular and immune
      functions. Similarly to the general population, several studies conducted on
      HIV-infected subjects have associated hypovitaminosis D with a greater risk of
      developing osteopenia/osteoporosis and fragility fractures. Analogously, vitamin 
      D deficiency has been described as an independent risk factor for cardiovascular 
      disease and metabolic disorders, such as insulin resistance and type 2 diabetes
      mellitus. Last EACS guidelines suggest to screen for hypovitaminosis D every
      HIV-positive subject having a history of bone disease, chronic kidney disease or 
      other known risk factors for vitamin D deficiency. Vitamin D repletion is
      recommended when 25-hydroxyvitamin D levels are below 10 ng/ml. Furthermore, it
      may be indicated in presence of 25OHD values between 10 and 30 ng/ml, if
      associated with osteoporosis, osteomalacia or increased parathyroid hormone
      levels. The optimal repletion and maintenance dosing regimens remain to be
      established, as well as the impact of vitamin D supplementation in preventing
      comorbidities.
AD  - Department of Clinical and Molecular Biomedicine, Division of Infectious
      Diseases, University of Catania, Italy. gnunnari@hotmail.com.
FAU - Pinzone, M R
AU  - Pinzone MR
FAU - Di Rosa, M
AU  - Di Rosa M
FAU - Malaguarnera, M
AU  - Malaguarnera M
FAU - Madeddu, G
AU  - Madeddu G
FAU - Foca, E
AU  - Foca E
FAU - Ceccarelli, G
AU  - Ceccarelli G
FAU - d'Ettorre, G
AU  - d'Ettorre G
FAU - Vullo, V
AU  - Vullo V
FAU - Fisichella, R
AU  - Fisichella R
FAU - Cacopardo, B
AU  - Cacopardo B
FAU - Nunnari, G
AU  - Nunnari G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 May;17(9):1218-32.

PMID- 23690106
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 51
IP  - 4
DP  - 2013
TI  - Quality of Life in Elderly Diabetic: Comparison between Home and Nursing Home.
PG  - 254-9
AB  - Research and planning to improve the quality of life for elderly seems to be
      essential, as the population of this age group has shown an increasing trend. Any
      chronic disease including diabetes has an impact on lifestyle of the patient. The
      objective of this study was to compare the quality of life between two groups of 
      elderly diabetic patients who were residence of home as well as nursing home. A
      descriptive-analytical random study was conducted during 2010-2011 on two groups 
      of 93 elderly diabetic patients, who were living in Kahrizak nursing home of
      Tehran (Iran), and home residents as well by interview for their demographical
      information and one standard questionnaire provided by world health organization.
      SPSS 16 was employed for data analysis. Significant differences were found in
      physical, psychological and social domains between two groups (P&lt;0.05). In
      physical and social domains the elderly diabetic patients of nursing home had a
      higher mean score but in psychological domain the result was in contrast.
      Regarding the difference between scores in two studied groups it is necessary to 
      study the weak points of each group individually and try to resolve the problems.
AD  - Department of Rehabilitation Management, School of Rehabilitation, Ahvaz
      Jundishapur University of Medical Sciences, Ahvaz, Iran. nasseh2002@yahoo.com.
FAU - Ghassemzadeh, Roya
AU  - Ghassemzadeh R
FAU - Nasseh, Homa
AU  - Nasseh H
FAU - Arastoo, Ali Asghar
AU  - Arastoo AA
FAU - Kamali, Mohammad
AU  - Kamali M
FAU - Rahimi Foroushani, Abbas
AU  - Rahimi Foroushani A
FAU - Arzaghi, Masoud
AU  - Arzaghi M
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/07 [received]
PHST- 2013/05/07 [accepted]
PST - epublish
SO  - Acta Med Iran. 2013 May 7;51(4):254-9.

PMID- 23690101
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 51
IP  - 4
DP  - 2013
TI  - Positive Correlation between Microalbuminuria and Severity of Coronary Artery
      Stenosis in Patients with Type 2 Diabetes Mellitus.
PG  - 231-5
AB  - Diabetes mellitus (DM) is the most prevalent metabolic disease worldwide and is
      associated with coronary artery disease (CAD). Therefore it is very important to 
      find a clue to diagnose the presence of CAD as early as possible in DM patients. 
      The aim of this study was to find any correlation between microalbuminuria (MAU) 
      and the severity of CAD in patients with DM type 2. This was a cross sectional
      study that included 77 DM type 2 patients with suspected CAD that all of whom
      were performed coronary angiography in our hospital (from 2010 to 2011). Patients
      were divided into two groups, the case group (group 1) that includes patients
      with MAU and the control group (group 2) that include patients without MAU.
      Severity of CAD was estimated by using Gensini score and MAU was defined as the
      ratio of urine albumin to urine creatinine. Of 77 patients forty three (55.8%)
      were female, mean +/- SD of their ages was 55.8 +/- 10.3 and sixteen (21%) of
      them had MAU. Gensini score of case group was significantly higher than control
      group (94.94 +/- 12 versus 33.25 +/- 25.4, P&lt;0.001). The linear regression
      analysis revealed urinary albumin to creatinine ratio (UA/CR) as an independent
      predictor for the severity of CAD (P&lt;0.001). Based on the ROC curve, 10.25 was
      the best albumin level cut off point for differentiating Gensini score over and
      below 70. Area under curve was 0.9; sensitivity and specificity were 72% and 80%,
      respectively (P&lt;0.001). According to this study, in patients with DM type2,
      MAU is an independent predictor of severity of coronary artery stenosis and
      reveals a positive correlation between MAU and the Gensini score.
AD  - Department of Cardiology, School of Medicine, Tehran University of Medical
      Sciences, Tehran, Iran. zandparsa@tums.ac.ir.
FAU - Zand Parsa, Amir Farhang
AU  - Zand Parsa AF
FAU - Ghadirian, Laleh
AU  - Ghadirian L
FAU - Rajabzadeh Kanafi, Sahar
AU  - Rajabzadeh Kanafi S
FAU - Moradi Farsani, Ehsan
AU  - Moradi Farsani E
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/06 [received]
PHST- 2013/05/06 [accepted]
PST - epublish
SO  - Acta Med Iran. 2013 May 7;51(4):231-5.

PMID- 23689972
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1557-1920 (Electronic)
IS  - 1557-1912 (Linking)
DP  - 2013 May 21
TI  - Everyday Discrimination, Diabetes-Related Distress, and Depressive Symptoms Among
      African Americans and Latinos with Diabetes.
AB  - It is not known how discrimination might affect diabetes-related distress (DRD), 
      an important correlate of diabetes outcomes. We examined correlates of
      discrimination and the influence of discrimination on DRD and depressive symptoms
      (DS) for African Americans and Latinos with type 2 diabetes. We analyzed survey
      data (n = 157) collected at enrollment into a diabetes management intervention.
      Using multiple linear regression, we examined correlates of discrimination and
      the association between discrimination and DRD and DS. Discrimination was
      significantly associated with higher DRD for Latinos (b 1.58, 95 % CI 1.08, 2.31,
      p < 0.05), but not significant for African Americans (b 0.96, 95 % CI 0.59,
      1.57). Discrimination was marginally significantly associated with more DS for
      Latinos (b 1.43, 95 % CI 0.97, 2.12, p < 0.10), but not significant for African
      Americans (b 1.21, 95 % CI 0.87, 1.70). These findings suggest the need to
      address stressors unique to racial/ethnic minorities to improve diabetes-related 
      outcomes.
AD  - Department of Health Behavior and Health Education, University of Michigan School
      of Public Health, 1415 Washington Heights, Ann Arbor, MI, 48109, USA,
      alanamw@umich.edu.
FAU - Lebron, Alana M W
AU  - Lebron AM
FAU - Valerio, Melissa A
AU  - Valerio MA
FAU - Kieffer, Edith
AU  - Kieffer E
FAU - Sinco, Brandy
AU  - Sinco B
FAU - Rosland, Ann-Marie
AU  - Rosland AM
FAU - Hawkins, Jaclynn
AU  - Hawkins J
FAU - Espitia, Nicolaus
AU  - Espitia N
FAU - Palmisano, Gloria
AU  - Palmisano G
FAU - Spencer, Michael
AU  - Spencer M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - J Immigr Minor Health
JT  - Journal of immigrant and minority health / Center for Minority Public Health
JID - 101256527
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 10.1007/s10903-013-9843-3 [doi]
PST - aheadofprint
SO  - J Immigr Minor Health. 2013 May 21.

PMID- 23689816
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 May 21
TI  - Diabetes: A lipidomic profile for the prediction of type 1 diabetes mellitus.
LID - 10.1038/nrendo.2013.101 [doi]
FAU - Wilson, Carol
AU  - Wilson C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/21 [aheadofprint]
AID - nrendo.2013.101 [pii]
AID - 10.1038/nrendo.2013.101 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 May 21. doi: 10.1038/nrendo.2013.101.

PMID- 23689796
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 21
TI  - Predicted impact of extending the screening interval for diabetic retinopathy:
      the Scottish Diabetic Retinopathy Screening programme.
AB  - AIMS/HYPOTHESIS: The aim of our study was to identify subgroups of patients
      attending the Scottish Diabetic Retinopathy Screening (DRS) programme who might
      safely move from annual to two yearly retinopathy screening. METHODS: This was a 
      retrospective cohort study of screening data from the DRS programme collected
      between 2005 and 2011 for people aged >/=12 years with type 1 or type 2 diabetes 
      in Scotland. We used hidden Markov models to calculate the probabilities of
      transitions to referable diabetic retinopathy (referable background or
      proliferative retinopathy) or referable maculopathy. RESULTS: The study included 
      155,114 individuals with no referable diabetic retinopathy or maculopathy at
      their first DRS examination and with one or more further DRS examinations. There 
      were 11,275 incident cases of referable diabetic eye disease (9,204 referable
      maculopathy, 2,071 referable background or proliferative retinopathy). The
      observed transitions to referable background or proliferative retinopathy were
      lower for people with no visible retinopathy vs mild background retinopathy at
      their prior examination (respectively, 1.2% vs 8.1% for type 1 diabetes and 0.6% 
      vs 5.1% for type 2 diabetes). The lowest probability for transitioning to
      referable background or proliferative retinopathy was among people with two
      consecutive screens showing no visible retinopathy, where the probability was
      <0.3% for type 1 and <0.2% for type 2 diabetes at 2 years.
      CONCLUSIONS/INTERPRETATION: Transition rates to referable diabetic eye disease
      were lowest among people with type 2 diabetes and two consecutive screens showing
      no visible retinopathy. If such people had been offered two yearly screening the 
      DRS service would have needed to screen 40% fewer people in 2009.
AD  - Population Health Sciences, University of Dundee, The MacKenzie Building, Kirsty 
      Semple Way, Dundee, DD2 4BF, UK, h.c.looker@dundee.ac.uk.
FAU - Looker, H C
AU  - Looker HC
FAU - Nyangoma, S O
AU  - Nyangoma SO
FAU - Cromie, D T
AU  - Cromie DT
FAU - Olson, J A
AU  - Olson JA
FAU - Leese, G P
AU  - Leese GP
FAU - Philip, S
AU  - Philip S
FAU - Black, M W
AU  - Black MW
FAU - Doig, J
AU  - Doig J
FAU - Lee, N
AU  - Lee N
FAU - Briggs, A
AU  - Briggs A
FAU - Hothersall, E J
AU  - Hothersall EJ
FAU - Morris, A D
AU  - Morris AD
FAU - Lindsay, R S
AU  - Lindsay RS
FAU - McKnight, J A
AU  - McKnight JA
FAU - Pearson, D W M
AU  - Pearson DW
FAU - Sattar, N A
AU  - Sattar NA
FAU - Wild, S H
AU  - Wild SH
FAU - McKeigue, P
AU  - McKeigue P
FAU - Colhoun, H M
AU  - Colhoun HM
CN  - on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group and
      the Scottish Diabetic Retinopathy Collaborative
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/29 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/21 [aheadofprint]
AID - 10.1007/s00125-013-2928-7 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 21.

PMID- 23689783
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 158
IP  - 10
DP  - 2013 May 21
TI  - An intensive lifestyle intervention increased remission from type 2 diabetes in
      overweight adults.
PG  - JC4
LID - 10.7326/0003-4819-158-10-201305210-02004 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
SB  - AIM
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 1687007 [pii]
AID - 10.7326/0003-4819-158-10-201305210-02004 [doi]
PST - ppublish
SO  - Ann Intern Med. 2013 May 21;158(10):JC4. doi:
      10.7326/0003-4819-158-10-201305210-02004.

PMID- 23689685
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1421-9670 (Electronic)
IS  - 0250-8095 (Linking)
VI  - 37
IP  - 6
DP  - 2013 May 15
TI  - Association between Dietary Sodium and Potassium Intake with Chronic Kidney
      Disease in US Adults: A Cross-Sectional Study.
PG  - 526-533
AB  - Background/Aims: Clinical guidelines recommend a diet low in sodium and high in
      potassium to reduce blood pressure and cardiovascular events. Little is known
      about the relationship between dietary sodium and potassium intake and chronic
      kidney disease (CKD). Methods: 13,917 participants from the National Health and
      Nutrition Examination Survey (2001-2006) were examined. Sodium and potassium
      intake were calculated from 24-hour recall and evaluated in quartiles. CKD was
      defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2 or eGFR
      >/=60 ml/min/1.73 m2 with albuminuria (>30 mg/g creatinine). Results: The mean
      (SE) age and eGFR of participants were 45.0 +/- 0.4 years and 88.0 +/- 0.60
      ml/min/1.73 m2, respectively. 2,333 (14.2%) had CKD: 1,146 (7.3%) had an eGFR <60
      ml/min/1.73 m2 and 1,514 (8.4%) had an eGFR >/=60 ml/min/1.73 m2 and albuminuria.
      After adjustment for age, sex, race, BMI, diabetes, hypertension, cardiovascular 
      disease and congestive heart failure, subjects in the highest quartile of sodium 
      intake had lower odds of CKD compared to subjects in the lowest quartile
      (adjusted OR: 0.79; 95% CI: 0.66-0.96; p < 0.016). Compared to the highest
      quartile, the odds of CKD increased 44% for participants in the lowest quartile
      of potassium intake (adjusted OR: 1.44; 95% CI: 1.16-1.79; p = 0.0011).
      Conclusions: Higher intake of sodium and potassium is associated with lower odds 
      of CKD among US adults. These results should be corroborated through longitudinal
      studies and clinical trials designed specifically to examine the effects of
      dietary sodium and potassium intake on kidney disease and its progression.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Division of Renal Diseases and Hypertension, University of Colorado Denver,
      Denver, Colo., USA.
FAU - Sharma, Shailendra
AU  - Sharma S
FAU - McFann, Kim
AU  - McFann K
FAU - Chonchol, Michel
AU  - Chonchol M
FAU - de Boer, Ian H
AU  - de Boer IH
FAU - Kendrick, Jessica
AU  - Kendrick J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/08 [received]
PHST- 2013/03/31 [accepted]
PHST- 2013/05/15 [aheadofprint]
AID - 000351178 [pii]
AID - 10.1159/000351178 [doi]
PST - aheadofprint
SO  - Am J Nephrol. 2013 May 15;37(6):526-533.

PMID- 23689678
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1538-9235 (Electronic)
IS  - 1040-5488 (Linking)
VI  - 90
IP  - 6
DP  - 2013 Jun
TI  - Hemolacria in a patient with severe systemic diseases.
PG  - e161-6
LID - 10.1097/OPX.0b013e318294c172 [doi]
AB  - PURPOSE: Hemolacria is a rare phenomenon of bloody tears caused by various ocular
      and systemic conditions, as well as psychological, pharmacologic, and idiopathic 
      etiologies. Hemolacria is typically a benign process; however, serious systemic
      associations can exist. It is predominantly unilateral and self-limiting, but
      because of limited literature, its prevalence and predilection toward a specific 
      gender, race, or age is not known. CASE REPORT: An 82-year-old Caucasian male
      presented for an emergent eye examination with an acute onset of hemolacria of
      the right eye (OD). Patient medical history was extensive with coronary artery
      disease, atrial fibrillation, lipidemia, insulin-dependent diabetes, uncontrolled
      hypertension, and untreated severe renal failure. Before the incident, patient
      medication included warfarin, 81 mg of aspirin, insulin, glipizide, and blood
      pressure regime with which the patient was noncompliant. The patient was
      forwarded to urgent care to address his stage 2 hypertension and referred for a
      medical evaluation, which included a complete blood count, an International
      Normalized Ratio, a prothrombin time, and a glycated hemoglobin. CONCLUSIONS:
      Spontaneous resolution of the hemolacria occurred within 24 hr after evaluation
      and restoration of blood pressure to normal range. Before follow-up, the patient 
      died because of kidney failure. After a review of pertinent laboratory results
      and literature, the etiology of this patient's hemolacria could be attributed to 
      either uncontrolled hypertension, chronic renal failure, aggressive anticoagulant
      therapy, and/or diabetes. An extensive literature review of documented etiologies
      and management is included.
AD  - *OD, FAAO William Jennings Bryan Dorn Veterans Affairs Medical Center, Columbia, 
      SC.
FAU - Dillivan, Kimberly M
AU  - Dillivan KM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Optom Vis Sci
JT  - Optometry and vision science : official publication of the American Academy of
      Optometry
JID - 8904931
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 10.1097/OPX.0b013e318294c172 [doi]
PST - ppublish
SO  - Optom Vis Sci. 2013 Jun;90(6):e161-6. doi: 10.1097/OPX.0b013e318294c172.

PMID- 23689661
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1662-2782 (Electronic)
IS  - 0302-5144 (Linking)
VI  - 182
DP  - 2013
TI  - Cardiorenal Syndrome Type 4: Insights on Clinical Presentation and
      Pathophysiology from the Eleventh Consensus Conference of the Acute Dialysis
      Quality Initiative (ADQI).
PG  - 158-73
LID - 10.1159/000349972 [doi]
AB  - In developed countries, the continuing rise in the prevalence of hypertension,
      hyperlipidemia and diabetes has contributed to an overall increase in the
      incidence of both cardiovascular disease (CVD) and chronic kidney disease (CKD). 
      The observation that even modest reductions in renal function correlate with
      increased CVD morbidity and mortality has led to the recognition that CKD is an
      independent risk factor for CVD. Conversely, there is a growing recognition that 
      many pathologic conditions that contribute to CVD, including coronary artery
      disease, left ventricular hypertrophy and diastolic dysfunction, can accelerate
      the decline in renal function. In addition, physiologic mechanisms designed to
      compensate for reduced glomerular filtration rate including activation of the
      renin-angiotensin-aldosterone axis, the release of fibroblastic growth factor 23 
      and other mechanisms for calcium-phosphate homeostasis as well as and the
      pathophysiologic effects of uremic toxins can also directly contribute to CVD.
      The end result of the interaction between changes in pressure and volume overload
      and the physiologic compensation for the loss of function in both the heart and
      the kidney leads to accelerated decline in both organ systems. This complex
      physiologic and pathophysiologic interplay between the cardiovascular and renal
      systems is collectively referred to as the cardiorenal syndrome. The discussion
      which follows is aimed at outlining the pathophysiologic mechanisms linking
      advanced CKD (4 and 5) to the development of cardiac abnormalities which occur
      with unique frequency and severity in patients with severe impairment of renal
      function.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Medicine, College of Medicine, University of Tennessee,
      Chattanooga, Tenn., USA Midwest Heart Foundation, Edward Heart Hospital,
      Naperville, Ill., USA.
FAU - Tumlin, James A
AU  - Tumlin JA
FAU - Costanzo, Maria R
AU  - Costanzo MR
FAU - Chawla, Lakhmir S
AU  - Chawla LS
FAU - Herzog, Charles A
AU  - Herzog CA
FAU - Kellum, John A
AU  - Kellum JA
FAU - McCullough, Peter A
AU  - McCullough PA
FAU - Ronco, Claudio
AU  - Ronco C
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - Switzerland
TA  - Contrib Nephrol
JT  - Contributions to nephrology
JID - 7513582
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/13 [aheadofprint]
AID - 000349972 [pii]
AID - 10.1159/000349972 [doi]
PST - ppublish
SO  - Contrib Nephrol. 2013;182:158-73. doi: 10.1159/000349972. Epub 2013 May 13.

PMID- 23689658
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1662-2782 (Electronic)
IS  - 0302-5144 (Linking)
VI  - 182
DP  - 2013
TI  - Pathogenesis of Cardiorenal Syndrome Type 1 in Acute Decompensated Heart Failure:
      Workgroup Statements from the Eleventh Consensus Conference of the Acute Dialysis
      Quality Initiative (ADQI).
PG  - 99-116
LID - 10.1159/000349969 [doi]
AB  - Pathophysiological mechanisms of cardiorenal syndromes (CRS) types 1-5 are still 
      sparsely characterized. In an attempt to address this issue, a consensus
      conference on CRS was held in Venice, Italy, in November 2012 under the auspices 
      of the Acute Dialysis Quality Initiative (ADQI). Working group 1 discussed
      monodirectional mechanisms of CRS type 1 which is characterized by a rapid
      worsening of cardiac function leading to acute kidney injury (AKI).
      Pre-conference we performed a systematic search and review of the available
      literature using a modified Delphi analysis. Hereby identified and in this review
      discussed questions were: (i) What are the predominant pathophysiologic
      mechanisms of CRS type 1 in acute decompensated heart failure? (ii) Could
      biomarker profiling identify pathomechanisms or hemodynamic phenotype of patients
      with CRS type 1? Could predictive biomarkers improve renal safety of therapy in
      CRS type 1? (iii) How do the timing, severity and duration relate to the
      mechanisms and outcomes of CRS type 1? In summary, after discussion and appraisal
      of the best available evidence, working group 1 makes consensus recommendations
      for future research on pathologic mechanisms of CRS type 1 and recommendations
      for clinical practice where treatment is in either proof or disproof of a
      mechanism.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Nephrology and Hypertension, Diabetes and Endocrinology, Otto von
      Guericke University Magdeburg, Magdeburg, Germany.
FAU - Haase, Michael
AU  - Haase M
FAU - Muller, Christian
AU  - Muller C
FAU - Damman, Kevin
AU  - Damman K
FAU - Murray, Patrick T
AU  - Murray PT
FAU - Kellum, John A
AU  - Kellum JA
FAU - Ronco, Claudio
AU  - Ronco C
FAU - McCullough, Peter A
AU  - McCullough PA
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - Switzerland
TA  - Contrib Nephrol
JT  - Contributions to nephrology
JID - 7513582
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/13 [aheadofprint]
AID - 000349969 [pii]
AID - 10.1159/000349969 [doi]
PST - ppublish
SO  - Contrib Nephrol. 2013;182:99-116. doi: 10.1159/000349969. Epub 2013 May 13.

PMID- 23689646
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1423-0356 (Electronic)
IS  - 0025-7931 (Linking)
DP  - 2013 May 8
TI  - Impact of Diabetes on Treatment Outcomes and Long-Term Survival in
      Multidrug-Resistant Tuberculosis.
AB  - Background: Few studies have investigated the impact of diabetes mellitus (DM), a
      globally increasing metabolic disease, on treatment outcomes and long-term
      survival in patients with multidrug-resistant forms of tuberculosis (MDR-TB).
      Objectives: We analyzed outcomes in a large cohort to assess the impact of DM on 
      treatment outcomes of patients with MDR-TB. Methods: MDR-TB patients newly
      diagnosed or retreated between 2000 and 2002 and followed for 8-11 years were
      retrospectively analyzed with respect to the effect of DM as a comorbidity on
      their treatment outcome and long-term survival. Results: Of 1,407 patients with
      MDR-TB, 239 (17.0%) had coexisting DM. The mean age and body mass index were
      higher in MDR-TB patients with DM [MDR-TBDM(+)] than in those without DM
      [MDR-TBDM(-)]. Patients with MDR-TB and a comorbidity of DM had a significantly
      lower treatment success rate than those without a history of DM (36.0 vs. 47.2%, 
      p = 0.002). In addition, DM was the negative predictor for MDR-TB treatment
      success in multivariate analyses [odds ratio 0.51, 95% confidence interval (CI)
      0.26-0.99]. Mean survival times were also lower in MDR-TBDM(+) than in
      MDR-TBDM(-) patients (102 vs. 114 months, p = 0.001), with DM as a significant
      predictor of poor long-term survival in multivariate analyses (hazard ratio 1.59,
      95% CI 1.01-2.50). Conclusions: Among MDR-TB patients, DM was a relatively common
      comorbidity. In patients undergoing treatment for MDR-TB and followed for 8-11
      years, it was found to be independently associated with an increased risk of both
      treatment failure and death.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul,
      South Korea.
FAU - Kang, Young Ae
AU  - Kang YA
FAU - Kim, Song Yee
AU  - Kim SY
FAU - Jo, Kyung-Wook
AU  - Jo KW
FAU - Kim, Hee Jin
AU  - Kim HJ
FAU - Park, Seung-Kyu
AU  - Park SK
FAU - Kim, Tae-Hyung
AU  - Kim TH
FAU - Kim, Eun Kyung
AU  - Kim EK
FAU - Lee, Ki Man
AU  - Lee KM
FAU - Lee, Sung Soon
AU  - Lee SS
FAU - Park, Jae Seuk
AU  - Park JS
FAU - Koh, Won-Jung
AU  - Koh WJ
FAU - Kim, Dae Yun
AU  - Kim DY
FAU - Shim, Tae Sun
AU  - Shim TS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Respiration
JT  - Respiration; international review of thoracic diseases
JID - 0137356
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/09/28 [received]
PHST- 2013/01/24 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 000348374 [pii]
AID - 10.1159/000348374 [doi]
PST - aheadofprint
SO  - Respiration. 2013 May 8.

PMID- 23689643
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1537-453X (Electronic)
IS  - 0277-3732 (Linking)
DP  - 2013 May 17
TI  - Treating Gynecologic Malignancies in Elderly Patients.
AB  - AIM:: To determine the relative benefits of full and partial treatment for
      gynecologic malignancies in elderly patients. METHODS:: A retrospective cohort
      study of all consecutive patients (n=169) aged 79 and older (median age 82 y;
      range, 79 to 94 y), diagnosed between 1971 and 2007 with various types of
      gynecologic malignancies (endometrial, 52%; ovarian, 26%; vulvar, 11%; cervical, 
      5%; other, 6%) was conducted. Stages were I to II (47%), III to IV (35.5%), and
      unknown (17.5%). Major comorbidities were hypertension (51%), diabetes (17%),
      cardiac diseases (34%), and other malignancy (12%). Regardless of age or chronic 
      illnesses, patients were grouped on the basis of having been treated optimally
      (100 patients; 59.2%), defined as the accepted standard for each diagnosis and
      stage including surgery and adjuvant radiation or chemotherapy as indicated; or
      suboptimally (69 patients; 40.8%), that is, no or only partial treatment.
      Kaplan-Meier survival analysis and Cox proportional hazard models, univariate and
      multivariable were conducted. RESULTS:: For all patients with suboptimal
      treatment, the age-and-stage-adjusted hazard ratio for death was 1.76 (95% CI,
      1.203-2.570; P=0.004) compared with optimal treatment. Age-adjusted hazard ratio 
      was 2.15 (95% CI, 1.127-4.114; P=0.02) and 2.3 (95% CI, 1.415-3.779; P=0.001) for
      ovarian and endometrial cancer patients, respectively. Age-adjusted and
      stage-adjusted hazard ratio was 2.8 (95% CI, 1.099-5.157; P=0.028) and 1.53 (95% 
      CI, 0.867-2.702; P=0.1420) for ovarian and endometrial cancer patients,
      respectively. CONCLUSIONS:: Optimal treatment in patients with gynecologic
      malignancies evidently improves survival in elderly patients at any age, and in
      patients with ovarian cancer at any stage. Regardless of chronological age, the
      aim should be to deliver optimal treatment.
AD  - *Department of Gynecologic Oncology, Sheba Medical Center, Tel Hashomer
      daggerSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Perri, Tamar
AU  - Perri T
FAU - Katz, Tanya
AU  - Katz T
FAU - Korach, Jacob
AU  - Korach J
FAU - Beiner, Mario E
AU  - Beiner ME
FAU - Jakobson-Setton, Ariella
AU  - Jakobson-Setton A
FAU - Ben-Baruch, Gilad
AU  - Ben-Baruch G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 10.1097/COC.0b013e318297d464 [doi]
PST - aheadofprint
SO  - Am J Clin Oncol. 2013 May 17.

PMID- 23689598
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Linking)
DP  - 2013 May 21
TI  - Genetically Engineered Human Islets Protected From CD8-mediated Autoimmune
      Destruction In Vivo.
LID - 10.1038/mt.2013.105 [doi]
AB  - Islet transplantation is a promising therapy for type 1 diabetes, but graft
      function and survival are compromised by recurrent islet autoimmunity.
      Immunoprotection of islets will be required to improve clinical outcome. We
      engineered human beta cells to express herpesvirus-encoded immune-evasion
      proteins, "immunevasins." The capacity of immunevasins to protect beta cells from
      autoreactive T-cell killing was evaluated in vitro and in vivo in humanized mice.
      Lentiviral vectors were used for efficient genetic modification of primary human 
      beta cells without impairing their function. Using a novel beta-cell-specific
      reporter gene assay, we show that autoreactive cytotoxic CD8+ T-cell clones
      isolated from patients with recent onset diabetes selectively destroyed human
      beta cells, and that coexpression of the human cytomegalovirus-encoded US2
      protein and serine proteinase inhibitor 9 offers highly efficient protection in
      vitro. Moreover, coimplantation of these genetically modified pseudoislets with
      beta-cell-specific cytotoxic T cells into immunodeficient mice achieves preserved
      human insulin production and C-peptide secretion. Collectively, our data provide 
      proof of concept that human beta cells can be efficiently genetically modified to
      provide protection from killing mediated by autoreactive T cells and retain their
      function in vitro and in vivo.Molecular Therapy (2013); doi:10.1038/mt.2013.105.
AD  - Department of Molecular Cell Biology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - Zaldumbide, Arnaud
AU  - Zaldumbide A
FAU - Alkemade, Gonnie
AU  - Alkemade G
FAU - Carlotti, Francoise
AU  - Carlotti F
FAU - Nikolic, Tatjana
AU  - Nikolic T
FAU - Abreu, Joana Rf
AU  - Abreu JR
FAU - Engelse, Marten A
AU  - Engelse MA
FAU - Skowera, Anja
AU  - Skowera A
FAU - de Koning, Eelco J
AU  - de Koning EJ
FAU - Peakman, Mark
AU  - Peakman M
FAU - Roep, Bart O
AU  - Roep BO
FAU - Hoeben, Rob C
AU  - Hoeben RC
FAU - Wiertz, Emmanuel Jhj
AU  - Wiertz EJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/21 [aheadofprint]
AID - mt2013105 [pii]
AID - 10.1038/mt.2013.105 [doi]
PST - aheadofprint
SO  - Mol Ther. 2013 May 21. doi: 10.1038/mt.2013.105.

PMID- 23689571
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1662-2782 (Electronic)
IS  - 0302-5144 (Linking)
VI  - 181
DP  - 2013
TI  - Screening of ACTN4 and TRPC6 Mutations in a Chinese Cohort of Patients with
      Adult-Onset Familial Focal Segmental Glomerulosclerosis.
PG  - 91-100
LID - 10.1159/000348471 [doi]
AB  - Objectives: Familial focal segmental glomerulosclerosis (FSGS) has been widely
      reported as having an underlining genetic component to its pathogenesis.
      Recently, mutations in TRPC6 and ACTN4 were identified to be associated with
      familial FSGS, however few studies have reported the mutation rates of these two 
      genes in Chinese familial FSGS patients. The aim of this study was to determine
      the prevalence of TRPC6 and ACTN4 mutations in Chinese adult-onset familial FSGS.
      Methods: 80 FSGS pedigrees with Chinese ancestry who were admitted to our
      hospital from September 1997 to January 2012 were screened for TRPC6 and ACTN4
      mutations. There was at least one biopsy-proven FSGS in each family. An
      additional family member with renal function insufficiency, obvious proteinuria, 
      or end-stage renal disease was required if there was only 1 biopsy-proven FSGS
      case in the family. FSGS secondary to systemic diseases, such as obesity,
      hypertension, diabetes, or virus infection, were excluded. Other hereditary renal
      diseases, such as Alport's disease and Fabry disease, were also excluded by
      related tests. Genomic DNA was extracted from peripheral blood cells, and Sanger 
      sequencing was performed for all exons and exon-intron boundaries of TRPC6 and
      ACTN4 in the probands of all FSGS pedigrees enrolled in this study. Results: Of
      the total index patients, 33 were female and 47 were male. The median age at
      disease onset was 39 years (range 15-67). The median proteinuria level was 1,324 
      mg/day and the median serum creatinine level was 114.5 mumol/l (range 41-1,040)
      at diagnosis. A missense mutation (Q889K) of TRPC6 was found in two independent
      families. No mutation was found in ACTN4. Accordingly, the mutation rate of TRPC6
      was 2.5% and of ACTN4 it was 0%. Conclusion: Mutations of TRPC6 and ACTN4 occur
      in only a minor portion of Chinese familial FSGS patients. Further genetic
      studies conducted in these patients will be helpful to increase our understanding
      of the pathogenesis of FSGS.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
FAU - Zhang, Qianying
AU  - Zhang Q
FAU - Ma, Jun
AU  - Ma J
FAU - Xie, Jingyuan
AU  - Xie J
FAU - Wang, Zhaohui
AU  - Wang Z
FAU - Zhu, Bin
AU  - Zhu B
FAU - Hao, Xu
AU  - Hao X
FAU - Yang, Li
AU  - Yang L
FAU - Ren, Hong
AU  - Ren H
FAU - Chen, Nan
AU  - Chen N
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - Switzerland
TA  - Contrib Nephrol
JT  - Contributions to nephrology
JID - 7513582
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/08 [aheadofprint]
AID - 000348471 [pii]
AID - 10.1159/000348471 [doi]
PST - ppublish
SO  - Contrib Nephrol. 2013;181:91-100. doi: 10.1159/000348471. Epub 2013 May 8.

PMID- 23689510
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 May 20
TI  - Structural and Pharmacological Characterisation of Novel Potent and Selective
      Monoclonal Antibody Antagonists of Glucose-Dependent Insulinotropic Polypeptide
      Receptor.
AB  - Glucose-dependent insulinotropic polypeptide (GIP) is an endogenous hormonal
      factor (incretin) that upon binding to its receptor (GIPr; a class B GPCR),
      stimulates insulin secretion by beta cells in the pancreas, There has been a lack
      of potent inhibitors of the GIPr with prolonged in vivo exposure, to investigate 
      GIP biology. Here we describe here the generation of an antagonizing antibody to 
      the GIPr, using phage and ribosome display libraries. Gipg013 is a specific
      competitive antagonist with equally high potencies to mouse, rat, dog and human
      GIP receptors with a Ki of 7 nM for the human GIPr. Gipg013 antagonises the GIP
      receptor and inhibits GIP induced insulin secretion in vivo. A crystal structure 
      of Gipg013 Fab in complex with the human GIPr ECD indicates that the antibody
      binds through a series of hydrogen bonds from the CDRs of Gipg013 Fab to the
      N-terminal alpha-helix of GIPr extracellular domain (ECD) as well as to residues 
      around its highly conserved glucagon receptor sub-family recognition fold. The
      antibody epitope overlaps with the GIP binding site on GIPr ECD ensuring
      competitive antagonism of the receptor. This well characterized antagonizing
      antibody to the GIPr will be useful as a tool to further understand the
      biological roles of GIP.
AD  - MedImmune, United Kingdom;
FAU - Ravn, Peter
AU  - Ravn P
FAU - Madhurantakam, Chaithanya
AU  - Madhurantakam C
FAU - Kunze, Susan
AU  - Kunze S
FAU - Matthews, Evelyn
AU  - Matthews E
FAU - Priest, Claire
AU  - Priest C
FAU - O'brien, Siobhan
AU  - O'brien S
FAU - Collinson, Andie
AU  - Collinson A
FAU - Papworth, Monika
AU  - Papworth M
FAU - Fritsch-Fredin, Maria
AU  - Fritsch-Fredin M
FAU - Jermutus, Lutz
AU  - Jermutus L
FAU - Benthem, Lambertus
AU  - Benthem L
FAU - Gruetter, Marcus
AU  - Gruetter M
FAU - Jackson, Ronald H
AU  - Jackson RH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Antagonist
OT  - Antibody engineering
OT  - Crystal structure
OT  - Diabetes
OT  - G protein coupled receptors (GPCR)
OT  - GIP receptor (GIPr)
OT  - Glucose-dependent Insulinotropic Polypeptide (GIP)
OT  - Incretin
OT  - Phage display
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - M112.426288 [pii]
AID - 10.1074/jbc.M112.426288 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 May 20.

PMID- 23689408
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1678-4227 (Electronic)
IS  - 0004-282X (Linking)
VI  - 71
IP  - 5
DP  - 2013 May
TI  - Clinical and laboratorial characterization and post-surgical follow-up of 87
      patients with non-functioning pituitary macroadenomas.
PG  - 307-12
LID - S0004-282X2013000500307 [pii]
AB  - Objective: It was to assess the main characteristics of patients undergoing
      pituitary tumor surgery. Method: Eighty-seven patients (44 men; 44.8+/-13 years
      old) were included. Results: The main symptoms were visual alterations (87.3%),
      headache (70.1%), diminished libido (34.4%), galactorrhea (22.9%) and hair loss
      (19.5%). The axes affected were gonadotropic (72.6%), thyrotropic (48.4%) and
      corticotropic (38.7%), without significant changes after surgery. The average
      largest tumor diameter was 3.1 cm before surgery and 1.56 cm after surgery. The
      most frequent postoperative complications were hydro-electrolyte and acid-base
      disorders (12%), diabetes insipidus (9%), visual field alterations (9%), liquoric
      fistula (8%) and nasal obstruction (7%). The patients were affected by more than 
      one complication. Conclusion: Although a decrease in tumor volume was achieved
      through surgery, hormonal deficiencies persisted in most of the patients and new 
      surgical approaches were necessary for dealing with tumor recurrence or
      persistence.
FAU - Mello, Paulo Andrade de
AU  - Mello PA
FAU - Naves, Luciana Ansaneli
AU  - Naves LA
FAU - Pereira Neto, Aldo
AU  - Pereira Neto A
FAU - Oliveira, Eduardo Henrique
AU  - Oliveira EH
FAU - Ferreira, Ivan Coelho
AU  - Ferreira IC
FAU - Araujo Junior, Antonio Santos de
AU  - Araujo Junior AS
FAU - Onishi, Franz Jooji
AU  - Onishi FJ
FAU - Casulari, Luiz Augusto
AU  - Casulari LA
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Arq Neuropsiquiatr
JT  - Arquivos de neuro-psiquiatria
JID - 0125444
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/11/28 [received]
PHST- 2012/12/05 [accepted]
AID - S0004-282X2013000500307 [pii]
PST - ppublish
SO  - Arq Neuropsiquiatr. 2013 May;71(5):307-12.

PMID- 23689382
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 20
IP  - 3
DP  - 2013
TI  - Wnt signalling in pituitary development and tumorigenesis.
PG  - R101-11
LID - 10.1530/ERC-13-0005 [doi]
AB  - Wnt signalling is activated in both pituitary organogenesis and its mature
      function. Wnt ligands and Wnt signalling pathways are critical for the regulation
      of the formation of the pituitary. In the mature pituitary, Wnt signalling
      pathways control cell activity and may stimulate cell proliferation in both
      physiological and pathological processes. This review compares Wnt signalling
      pathways active in the developing and mature pituitary and explores how this
      gives us further insight into the development of pituitary adenomas.
AD  - Endocrinology and Diabetes Group, Faculty of Medical and Human Sciences, Centre
      for Endocrinology and Diabetes, Institute of Human Development, University of
      Manchester, AV Hill Building, Oxford Road, Manchester M13 9PT, UK Experimental
      and Clinical Endocrinology, Med Clinic I, University of Lubeck, Lubeck, Germany.
FAU - Chambers, T J G
AU  - Chambers TJ
FAU - Giles, A
AU  - Giles A
FAU - Brabant, G
AU  - Brabant G
FAU - Davis, J R E
AU  - Davis JR
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
SB  - IM
OTO - NOTNLM
OT  - Wnt
OT  - adenoma
OT  - development
OT  - pituitary
OT  - tumorigenesis
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013 [ppublish]
AID - ERC-13-0005 [pii]
AID - 10.1530/ERC-13-0005 [doi]
PST - epublish
SO  - Endocr Relat Cancer. 2013 May 20;20(3):R101-11. doi: 10.1530/ERC-13-0005. Print
      2013.

PMID- 23689376
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1661-6758 (Electronic)
IS  - 1661-6499 (Linking)
VI  - 6
IP  - 2
DP  - 2013 May 9
TI  - The rs9939609 Polymorphism in the FTO Gene Is Associated with Fat and Fiber
      Intakes in Patients with Type 2 Diabetes.
PG  - 97-106
AB  - Background/Aims: The common polymorphism in the FTO gene (rs9939609) has been
      associated with obesity, type 2 diabetes, and appetite regulation. The aim of
      this study was to evaluate possible associations of FTO rs9939609 with dietary
      factors in patients with type 2 diabetes. Methods: This was a cross-sectional
      study of 236 patients with type 2 diabetes (age 60.0 +/- 10.3 years; diabetes
      duration 12.7 +/- 8.2 years; 53.4% females) who were genotyped for FTO rs9939609.
      Patients underwent clinical and laboratory evaluations and 3-day weighed diet
      records. Data on dietary intake were categorized as high or low, based on median 
      values. Results: The AA genotype in the FTO gene was positively associated with
      high fat (>34% energy; OR = 2.17; 95% CI 1.02-4.63) and low fiber intakes (<16
      g/day; OR = 2.42; 95% CI 1.05-5.57), adjusted for gender, BMI, total energy
      intake, systolic blood pressure, and HbA1c. When gender was taken into account,
      AA females had higher fat (37.4 +/- 5.3 vs. 32.6 +/- 7.5 and 32.2 +/- 6.2%
      energy; p = 0.005) and lower fiber intakes (12.4 +/- 4.4 vs. 15.1 +/- 6.3 and
      16.7 +/- 5.6 g/day; p = 0.023) than patients with TT and AT genotypes. Multiple
      logistic regression models confirmed female associations for high fat (OR = 9.73;
      95% CI 2.12-44.66) and low fiber intakes (OR = 4.28; 95% CI 1.14-16.06; p < 0.05 
      for all models). Conclusions: Patients with type 2 diabetes, who were carriers of
      the AA genotype of the FTO rs9939609, had increased fat and decreased fiber
      consumption, independently of BMI.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Endocrine Division, Hospital de Clinicas de Porto Alegre, Universidade Federal do
      Rio Grande do Sul, Porto Alegre, Brazil.
FAU - Steemburgo, Thais
AU  - Steemburgo T
FAU - Azevedo, Mirela J
AU  - Azevedo MJ
FAU - Gross, Jorge L
AU  - Gross JL
FAU - Milagro, Fermin I
AU  - Milagro FI
FAU - Campion, Javier
AU  - Campion J
FAU - Martinez, Jose Alfredo
AU  - Martinez JA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - J Nutrigenet Nutrigenomics
JT  - Journal of nutrigenetics and nutrigenomics
JID - 101299758
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/08/23 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 000350741 [pii]
AID - 10.1159/000350741 [doi]
PST - aheadofprint
SO  - J Nutrigenet Nutrigenomics. 2013 May 9;6(2):97-106.

PMID- 23689355
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 Apr 24
TI  - Obesity development in caspase-1-deficient mice.
LID - 10.1038/ijo.2013.59 [doi]
AB  - Caspase-1 is a member of the intracellular cysteine protease family that mediates
      inflammation through the activation of the cytokines interleukin-1beta (IL-1beta)
      and interleukin-18 (IL-18). As mice lacking IL-18 become obese and insulin
      resistant, and both IL-18 and IL-1beta have a role in overall energy balance, we 
      sought to determine whether caspase-1 deficiency also causes obesity. Male and
      female caspase-1-deficient (caspase-1-/-) and control (wild-type (WT)) mice were 
      fed either a high-fat (HF, 45% of kcal) or a low-fat (LF, 10% of kcal) synthetic 
      diet starting at 6 weeks of age. Caspase-1-/- mice maintained lower but
      detectable levels of IL-18 compared with WT mice. Plasma IL-1beta levels were
      below the detection limit for both KO and WT mice. Male caspase-1-/- mice gained 
      extra fat mass by 16 weeks on the HF diet, but not until 40 weeks on the LF diet.
      Female capase-1-/- mice gained more fat by 28 weeks but only on the HF diet.
      These data indicate that caspase-1-/- mice develop obesity with an age and
      sex-dependent differences, and only male mice display obesity on LF diet.
      Overall, this study suggests that the lower level of IL-18 in caspase-1-/- mice
      might be causing obesity development similarly to IL-18-deficient
      mice.International Journal of Obesity advance online publication, 21 May 2013;
      doi:10.1038/ijo.2013.59.
AD  - Division of Endocrinology, Metabolism and Diabetes, Department of Medicine,
      University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
FAU - Wang, H
AU  - Wang H
FAU - Capell, W
AU  - Capell W
FAU - Yoon, J H
AU  - Yoon JH
FAU - Faubel, S
AU  - Faubel S
FAU - Eckel, R H
AU  - Eckel RH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/04/24 [aheadofprint]
PHST- 2013/05/21 [aheadofprint]
AID - ijo201359 [pii]
AID - 10.1038/ijo.2013.59 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 Apr 24. doi: 10.1038/ijo.2013.59.

PMID- 23689277
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1748-7838 (Electronic)
IS  - 1001-0602 (Linking)
VI  - 23
IP  - 6
DP  - 2013 Jun
TI  - Sirtuin deacetylases in neurodegenerative diseases of aging.
PG  - 746-58
LID - 10.1038/cr.2013.70 [doi]
AB  - Sirtuin enzymes are a family of highly conserved protein deacetylases that depend
      on nicotinamide adenine dinucleotide (NAD+) for their activity. There are seven
      sirtuins in mammals and these proteins have been linked with caloric restriction 
      and aging by modulating energy metabolism, genomic stability and stress
      resistance. Sirtuin enzymes are potential therapeutic targets in a variety of
      human diseases including cancer, diabetes, inflammatory disorders and
      neurodegenerative disease. Modulation of sirtuin activity has been shown to
      impact the course of several aggregate-forming neurodegenerative disorders
      including Alzheimer's disease, Parkinson's disease, Huntington's disease,
      amyotrophic lateral sclerosis and spinal and bulbar muscular atrophy. Sirtuins
      can influence the progression of neurodegenerative disorders by modulating
      transcription factor activity and directly deacetylating proteotoxic species.
      Here, we describe sirtuin protein targets in several aggregate-forming
      neurodegenerative diseases and discuss the therapeutic potential of compounds
      that modulate sirtuin activity in these disorders.
AD  - 1] Department of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston,
      MA 02115, USA [2] Department of Biology, Massachusetts Institute of Technology,
      77 Massachusetts Avenue, 68-280 Cambridge, MA 02139, USA.
FAU - Herskovits, Adrianna Z
AU  - Herskovits AZ
FAU - Guarente, Leonard
AU  - Guarente L
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - England
TA  - Cell Res
JT  - Cell research
JID - 9425763
SB  - IM
PMC - PMC3674397
OID - NLM: PMC3674397
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/21 [aheadofprint]
AID - cr201370 [pii]
AID - 10.1038/cr.2013.70 [doi]
PST - ppublish
SO  - Cell Res. 2013 Jun;23(6):746-58. doi: 10.1038/cr.2013.70. Epub 2013 May 21.

PMID- 23689181
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1873-2054 (Electronic)
IS  - 1353-8292 (Linking)
VI  - 22
DP  - 2013 Jul
TI  - The contextual influence of coal abandoned mine lands in communities and type 2
      diabetes in Pennsylvania.
PG  - 115-22
LID - 10.1016/j.healthplace.2013.03.012 [doi]
LID - S1353-8292(13)00061-0 [pii]
AB  - Coal abandoned mine lands (AMLs), persistent and prevalent across Pennsylvania,
      offer an instructive evaluation of potential contextual influences of chronic
      environmental contamination (CEC) on individual health. We evaluated associations
      between the burden of AMLs, represented by 10 contextual metrics at the community
      level, and individual-level type 2 diabetes using hemoglobin A1c (HbA1c) as a
      biomarker. Cross-sectional and longitudinal multilevel analyses were conducted
      with over 28,000 diabetic primary care patients of the Geisinger Clinic. Adjusted
      models revealed five AML burden measures were associated (p<0.05), and three
      additional were borderline associated (0.05</=p</=0.10), with higher and/or
      change in HbA1c levels. This study provides key empirical evidence of adverse
      impacts of CEC in communities on an important chronic disease, illustrating the
      contextual effects of living in long-term degraded landscapes and communities.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of
      Public Health, 615 N Wolfe St, Baltimore, MD 21205, United States. Electronic
      address: aliu@jhsph.edu.
FAU - Liu, Ann Y
AU  - Liu AY
FAU - Curriero, Frank C
AU  - Curriero FC
FAU - Glass, Thomas A
AU  - Glass TA
FAU - Stewart, Walter F
AU  - Stewart WF
FAU - Schwartz, Brian S
AU  - Schwartz BS
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - England
TA  - Health Place
JT  - Health & place
JID - 9510067
SB  - T
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/11/24 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/03/31 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - S1353-8292(13)00061-0 [pii]
AID - 10.1016/j.healthplace.2013.03.012 [doi]
PST - ppublish
SO  - Health Place. 2013 Jul;22:115-22. doi: 10.1016/j.healthplace.2013.03.012. Epub
      2013 Apr 25.

PMID- 23689158
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1735-8604 (Electronic)
IS  - 1735-8582 (Linking)
VI  - 7
IP  - 3
DP  - 2013
TI  - Severe high anion gap metabolic acidosis in pregnancy.
PG  - 235-6
AB  - Ketoacidosis can occur most often as a result of uncontrolled diabetes mellitus. 
      However, it can be seen with fasting and alcohol consumption, as well.
      Ketoacidosis in association with fasting has less severity, and ketoacid levels
      do not exceed 10 mEq/L. In the literature, there are a few reports about severe
      high anion gap acidosis that were associated with fasting. We report a case of
      pregnancy associated with high anion gap acidosis as a result of fasting.
AD  - Division of Nephrology, Department of Internal Medicine, Mashhad University of
      Medical Sciences, Mashhad, Iran. maryamhami@yahoo.com.
FAU - Hami, Maryam
AU  - Hami M
FAU - Hasanzadeh Mofrad, Maliheh
AU  - Hasanzadeh Mofrad M
FAU - Takallo, Reihaneh
AU  - Takallo R
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - Iran
TA  - Iran J Kidney Dis
JT  - Iranian journal of kidney diseases
JID - 101316967
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/01/15 [received]
PHST- 2012/08/04 [accepted]
AID - 752/542 [pii]
PST - epublish
SO  - Iran J Kidney Dis. 2013 May 21;7(3):235-6.

PMID- 23689156
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1735-8604 (Electronic)
IS  - 1735-8582 (Linking)
VI  - 7
IP  - 3
DP  - 2013
TI  - Hyperglycemia after kidney transplantation: frequency and risk factors.
PG  - 226-30
AB  - Introduction. Kidney transplantation and its conventional treatment can lead to
      increased risk of diabetes mellitus outbreak in normoglycemic recipients. Also,
      uncontrolled hyperglycemia may increase allograft loss and decrease patient
      survival. We aimed to assess the frequency of hyperglycemia in transplant
      patients and its risk factors. Materials and Methods. A retrospective study was
      performed on 3342 adult kidney transplant recipients between 2008 and 2010.
      Demographic and laboratory data were collected. All laboratory tests were done in
      a one laboratory, and hyperglycemia was defined as a fasting plasma glucose level
      greater than 125 mg/dL.&nbsp; Univariable and multivariable logistic regression
      analyses were used to determine the risk factors of hyperglycemia following
      kidney transplantation. Results. There were 2120 men (63.4%) and 1212 women
      (36.3%) included in the study. The prevalence of hyperglycemia was 22.5%.
      Hyperglycemia was significantly higher in patients with cytomegalovirus infection
      (P = .001), elevated serum creatinine (P &lt; .001), low high-density lipoprotein
      cholesterol (P = .01), and increased blood levels of cyclosporine (P &lt; .001). 
      After adjusting for covariates by multivariate logistic regression, the
      hyperglycemia rate was significantly higher for patients with a cyclosporine
      trough level greater than 250 ng/mL (P &lt; .001), a serum creatinine level
      greater than 1.5 mg/dL (P &lt; .001), and a high-density lipoprotein cholesterol 
      less than 45 mg/dL&nbsp; (P = .03). Conclusions. This study indicated that
      hyperglycemia is a common metabolic disorder in Iranian kidney transplant
      patients. Risk factors for hyperglycemia were higher cyclosporine level, impaired
      kidney function, and reduced high-density lipoprotein cholesterol values.
AD  - Nephrology and Urology Research Center, Baqiyatallah University of Medical
      Sciences, Tehran, Iran. rostami@ijnu.ir.
FAU - Khalili, Nahid
AU  - Khalili N
FAU - Rostami, Zohreh
AU  - Rostami Z
FAU - Kalantar, Ebrahim
AU  - Kalantar E
FAU - Einollahi, Behzad
AU  - Einollahi B
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - Iran
TA  - Iran J Kidney Dis
JT  - Iranian journal of kidney diseases
JID - 101316967
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/01/05 [received]
PHST- 2012/10/10 [accepted]
AID - 735/540 [pii]
PST - epublish
SO  - Iran J Kidney Dis. 2013 May 21;7(3):226-30.

PMID- 23689152
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1735-8604 (Electronic)
IS  - 1735-8582 (Linking)
VI  - 7
IP  - 3
DP  - 2013 May
TI  - Correlation between ankle-brachial index and microalbuminuria in type 2 diabetes 
      mellitus.
PG  - 204-9
AB  - Introduction. Microalbuminuria is a reliable marker of diabetic nephropathy.
      Establishment of peripheral vascular complications leads to early diagnosis,
      prevention, and treatment of renal and cardiovascular complications. This study
      investigated the value of ankle-brachial index (ABI) for prediction of
      microalbuminuria in type 2 diabetic patients. Materials and Methods.&nbsp;
      Measurement of ABI with color Doppler ultrasonography was carried out for 206
      patients with type 2 diabetes mellitus. An ABI Index less than 0.9 was defined as
      a predictive marker for atherosclerosis. Microalbuminuria and risk factors of
      atherosclerosis were compared between the patients categorized based on the ABI
      values. Results. The mean ABI was 1.1 &plusmn; 0.2 (range, 0.052 to 1.6), and 41 
      (20%) had an abnormal ABI (&lt;&nbsp; 0.9). The correlations were significant
      between abnormal ABI and duration of disease (P = .04), cardiovascular event and 
      cardiac care unit admission (P = .001), hypertension (P = .01), and dyslipidemia 
      (P = .01). There was a significant correlation between ABI and microalbuminuria
      (odds ratio, 0.05; 95% confidence interval, 0.038 to 0.630; P &lt; .001). A
      cutoff point of an ABI less than or equal to 1.04 had a sensitivity of 71.6% and 
      a specificity of 64.2% for prediction of microalbuminuria. Conclusions. The ABI
      is a noninvasive and reliable assay for detection of peripheral and
      cardiovascular complications, and also early stage of nephropathy in diabetic
      patients. In patients with an abnormal ABI, long-term follow-up for earlier
      detection and prevention of complications is helpful.
AD  - Nephrology and Kidney Transplant Research Center and Department of Nephrology,
      Urmia University of Medical Sciences, Urmia, Iran. makhdoomikhadijeh@yahoo.com.
FAU - Makhdoomi, Khadijeh
AU  - Makhdoomi K
FAU - Mohammadi, Afshin
AU  - Mohammadi A
FAU - Yekta, Zahra
AU  - Yekta Z
FAU - Aghasi, Mohammad Reza
AU  - Aghasi MR
FAU - Zamani, Nader
AU  - Zamani N
FAU - Vossughian, Sara
AU  - Vossughian S
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Kidney Dis
JT  - Iranian journal of kidney diseases
JID - 101316967
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/04/29 [received]
PHST- 2012/12/09 [accepted]
AID - 849/535 [pii]
PST - ppublish
SO  - Iran J Kidney Dis. 2013 May;7(3):204-9.

PMID- 23689071
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
DP  - 2013 May 17
TI  - Differences Between Office and 24-Hour Blood Pressure Control in Hypertensive
      Patients With CKD: A 5,693-Patient Cross-sectional Analysis From Spain.
LID - S0272-6386(13)00702-6 [pii]
LID - 10.1053/j.ajkd.2013.03.025 [doi]
AB  - BACKGROUND: Previous studies have examined control rates of office blood pressure
      (BP) in chronic kidney disease (CKD). However, recent evidence suggests major
      discrepancies between office and 24-hour BP values in hypertensive populations.
      This study examined concordance/discordance between office- and ambulatory-based 
      BP control in a large cohort of patients with CKD. STUDY DESIGN: Cross-sectional.
      SETTING & PARTICIPANTS: 5,693 hypertensive individuals with CKD stages 1-5 from
      the Spanish ABPM (ambulatory BP monitoring) Registry. PREDICTORS: Thresholds of
      140/90 and 130/80 mm Hg for office BP and 24-hour ambulatory BP, respectively.
      Age, sex, body mass index, waist circumference, hypertension duration, kidney
      measures, diabetes, dyslipidemia, target-organ damage, and cardiovascular
      comorbid conditions. OUTCOMES: Misclassification of BP control as "white-coat"
      hypertension (office BP >/=140/90 mm Hg, 24-hour BP <130/80 mm Hg) or masked
      hypertension (office BP <140/90 mm Hg, 24-hour BP >/=130/80 mm Hg). MEASUREMENTS:
      Standardized office-based BP and 24-hour ABPM. RESULTS: Mean age was 61.0 +/-
      13.9 (SD) years and 52.6% were men. The proportion with white-coat hypertension
      was 28.8% (36.8% of patients with office BP >/=140/90 mm Hg) and that of masked
      hypertension was 7.0% (but 32.1% of patients with office BP <140/90 mm Hg). Male 
      sex, aging, obesity, and target-organ damage were associated with white-coat
      hypertension; aging and obesity were associated with masked hypertension. Only
      21.7% and 8.1% of the CKD population had office BP <140/90 and <130/80 mm Hg,
      respectively. In contrast, 43.5% of individuals had average 24-hour BP <130/80 mm
      Hg. LIMITATIONS: Cross-sectional design, longitudinal associations cannot be
      established. CONCLUSIONS: Misclassification of BP control at the office was
      observed in 1 of 3 hypertensive patients with CKD. Ambulatory-based control rates
      were far better than office-based rates. Nevertheless, the burden of uncontrolled
      ambulatory BP and misclassification of BP control at the office constitutes a
      call for wider use of ABPM to evaluate the success of hypertension treatment in
      patients with CKD.
CI  - Copyright (c) 2013 National Kidney Foundation, Inc. Published by Elsevier Inc.
      All rights reserved.
AD  - Department of Nephrology, Hospital Universitario Central de Asturias, Oviedo,
      Spain. Electronic address: manuel.gorostidi@sespa.princast.es.
FAU - Gorostidi, Manuel
AU  - Gorostidi M
FAU - Sarafidis, Pantelis A
AU  - Sarafidis PA
FAU - de la Sierra, Alejandro
AU  - de la Sierra A
FAU - Segura, Julian
AU  - Segura J
FAU - de la Cruz, Juan J
AU  - de la Cruz JJ
FAU - Banegas, Jose R
AU  - Banegas JR
FAU - Ruilope, Luis M
AU  - Ruilope LM
CN  - Spanish ABPM Registry Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/06/15 [received]
PHST- 2013/03/07 [accepted]
AID - S0272-6386(13)00702-6 [pii]
AID - 10.1053/j.ajkd.2013.03.025 [doi]
PST - aheadofprint
SO  - Am J Kidney Dis. 2013 May 17. pii: S0272-6386(13)00702-6. doi:
      10.1053/j.ajkd.2013.03.025.

PMID- 23689065
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1421-9697 (Electronic)
IS  - 0250-6807 (Linking)
VI  - 62
IP  - 4
DP  - 2013 May 16
TI  - Dietary Intakes and Familial Correlates of Overweight/Obesity: A Four-Cities
      Study in India.
PG  - 279-290
AB  - Background: The prevalence of overweight and obesity among children is increasing
      in India. However, knowledge of, attitude towards and practice of health and
      nutrition in mothers and children have not been researched. Objective: To assess 
      knowledge of, attitude towards and practice of nutrition, physical activity and
      other lifestyle practices in a nationally representative sample of urban children
      and mothers in India. Methods: A cross-sectional observational study of 1,800
      children aged 9-18 years and their mothers, using qualitative (focus group) and
      quantitative (semi-structured survey) data. Results: The overall prevalence of
      overweight/obesity among the children was 19.2% in males and 18.1% in females;
      64.8% of mothers were either overweight [body mass index (BMI) 23.0-24.9; 23.3%] 
      or obese (BMI >25.0; 41.5%). Household family income, related socioeconomic
      factors, and overweight in mothers were most significantly associated with
      obesity in children (all p </= 0.001). Dietary consumption patterns (snacking,
      fast food etc.) showed a marked association between mothers and children (all p
      </= 0.000). Focus group discussion revealed several interesting attitudes and
      misconceptions among children ('home-cooked food is old fashioned') and mothers
      ('a child with chubby cheeks is healthy, not fat'). Importantly, only a few
      mothers understood that excess weight or diets are contributory factors of
      morbidities in children or themselves. Conclusions: This study highlights the
      poor knowledge, faulty attitudes and practices of urban Asian Indian mothers and 
      their children in a highly correlated manner. These knowledge gaps must be
      addressed to formulate effective strategies for the prevention of obesity and
      related metabolic disorders.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - National Diabetes, Obesity and Cholesterol Foundation, Fortis Hospital, New
      Delhi, India.
FAU - Gulati, Seema
AU  - Gulati S
FAU - Misra, Anoop
AU  - Misra A
FAU - Colles, Susan L
AU  - Colles SL
FAU - Kondal, Dimple
AU  - Kondal D
FAU - Gupta, Nidhi
AU  - Gupta N
FAU - Goel, Kashish
AU  - Goel K
FAU - Bansal, Sunil
AU  - Bansal S
FAU - Mishra, Mamatha
AU  - Mishra M
FAU - Madkaikar, Vaishali
AU  - Madkaikar V
FAU - Bhardwaj, Swati
AU  - Bhardwaj S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Ann Nutr Metab
JT  - Annals of nutrition & metabolism
JID - 8105511
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/07/13 [received]
PHST- 2012/12/16 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 000346554 [pii]
AID - 10.1159/000346554 [doi]
PST - aheadofprint
SO  - Ann Nutr Metab. 2013 May 16;62(4):279-290.

PMID- 23689053
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
DP  - 2013 May 17
TI  - Predictors of Long-term Mortality After Severe Sepsis in the Elderly.
AB  - BACKGROUND:: Mortality rates after severe sepsis are extremely high, and the main
      focus of most research is short-term mortality, which may not be associated with 
      long-term outcomes. The purpose of this study was to examine long-term mortality 
      after a severe sepsis and identify factors associated with this mortality.
      METHODS:: The authors performed a population-based study using Veterans' Affairs 
      administrative data of patients aged 65 years and older. The outcome of interest 
      was mortality > 90 days following hospitalization. Our primary analyses were Cox 
      proportional hazard models to examine specific risk factors for long-term
      mortality. RESULTS:: There were 2,727 patients that met the inclusion criteria.
      Overall mortality was 55%, and 1- and 2-year mortality rates were 31% and 43%,
      respectively. Factors significantly associated with long-term mortality included 
      congestive heart failure, peripheral vascular disease, dementia, diabetes with
      complications and use of mechanical ventilation. Smoking cessation and cardiac
      medications were associated with decreased long-term mortality rates.
      CONCLUSIONS:: The authors identified several factors, including receipt of
      mechanical ventilation, which were significantly associated with increased
      long-term mortality for survivors of severe sepsis. This information will help
      clinicians discuss prognosis with patients and their families.
AD  - VERDICT research program, and South Texas Veterans Health Care System, Audie L.
      Murphy Division (MIR, EMM), University of Texas Health Science Center at San
      Antonio, San Antonio, Texas; and Divisions of Hospital Medicine (ACL, EMM) and
      Pulmonary/Critical Care Medicine (MIR, AA), Department of Medicine, University of
      Texas Health Science Center at San Antonio, San Antonio, Texas.
FAU - Lemay, Allyson C
AU  - Lemay AC
FAU - Anzueto, Antonio
AU  - Anzueto A
FAU - Restrepo, Marcos I
AU  - Restrepo MI
FAU - Mortensen, Eric M
AU  - Mortensen EM
LA  - ENG
GR  - R01 NR010828/NR/NINR NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 10.1097/MAJ.0b013e318295a147 [doi]
PST - aheadofprint
SO  - Am J Med Sci. 2013 May 17.

PMID- 23689049
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
DP  - 2013 May 17
TI  - Community-acquired Methicillin-resistant Staphylococcus aureus Prostatic
      Abscesses.
AB  - : We describe 2 men with prostatic abscesses due to community-acquired
      methicillin-resistant Staphylococcus aureus. Neither of them had diabetes
      mellitus, prior prostate disease, recent health care exposure or urinary
      instrumentation and had no evidence of bloodstream infection at the time of
      presentation. Both were treated with surgical drainage and prolonged antibiotics.
AD  - Department of Neurology (PK), University of Kentucky, Lexington, Kentucky;
      Division of Infectious Diseases (TS), Department of Medicine, Veterans Affairs
      Medical Center, Lexington, Kentucky; Division of Infectious Diseases (LMB, MNA), 
      Department of Medicine, Mayo Clinic, Rochester, Minnesota; and Division of
      Infectious Diseases (MNA), Department of Medicine, University of South Carolina
      School of Medicine, Columbia, South Carolina.
FAU - Krishnamohan, Prashanth
AU  - Krishnamohan P
FAU - Schaninger, Takako
AU  - Schaninger T
FAU - Baddour, Larry M
AU  - Baddour LM
FAU - Al-Hasan, Majdi N
AU  - Al-Hasan MN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 10.1097/MAJ.0b013e318294f53a [doi]
PST - aheadofprint
SO  - Am J Med Sci. 2013 May 17.

PMID- 23688961
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1873-4529 (Electronic)
IS  - 0952-8180 (Linking)
VI  - 25
IP  - 3
DP  - 2013 May
TI  - Perioperative management of a neurosurgical patient with a meningioma and recent 
      coronary artery stent.
PG  - 228-31
LID - 10.1016/j.jclinane.2012.11.007 [doi]
LID - S0952-8180(13)00069-X [pii]
AB  - Patients who undergo placement of a drug-eluting coronary artery stent are
      prescribed dual antiplatelet therapy for one year. Early cessation of this
      therapy is a risk factor for a major adverse cardiac event, especially in
      high-risk patients. The perioperative physician team must evaluate the risk of
      surgical bleeding relative to the thrombotic risk during the perioperative period
      in patients taking dual antiplatelet therapy who must undergo intracranial
      neurosurgery. A 67 year old woman presented with right-sided hearing loss.
      Neurologic examination was significant for early papilledema and decreased
      hearing in the right ear. Magnetic resonance imaging showed a > 5 cm
      contrast-enhancing mass within her right-middle fossa with surrounding vasogenic 
      edema and midline shift. Additional medical history was significant for diabetes,
      hypertension, and placement of a drug-eluting stent for coronary artery disease
      three months before her initial presentation. Medications included aspirin and
      clopidogrel. She underwent embolization of the middle meningeal arterial supply
      to the meningioma, then was admitted to the hospital for perioperative management
      of her antiplatelet therapy and telemetry monitoring. Her clopidogrel was stopped
      and aspirin continued perioperatively. An intravenous infusion of the
      antiplatelet drug, eptifibatide, replaced clopidogrel and was continued until 8
      hours prior to surgical incision. During resection of the meningioma, no unusual 
      surgical bleeding was noted. The patient was discharged on postoperative day 3
      with satisfactory recovery.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Anesthesia and Perioperative Care, University of California, San
      Francisco, San Francisco, CA 94143-0648, USA. Electronic address:
      rouinerk@anesthesia.ucsf.edu.
FAU - Rouine-Rapp, Kathryn
AU  - Rouine-Rapp K
FAU - McDermott, Michael W
AU  - McDermott MW
LA  - eng
PT  - Journal Article
DEP - 20130322
PL  - United States
TA  - J Clin Anesth
JT  - Journal of clinical anesthesia
JID - 8812166
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/03/19 [received]
PHST- 2012/10/14 [revised]
PHST- 2012/11/11 [accepted]
PHST- 2013/03/22 [aheadofprint]
AID - S0952-8180(13)00069-X [pii]
AID - 10.1016/j.jclinane.2012.11.007 [doi]
PST - ppublish
SO  - J Clin Anesth. 2013 May;25(3):228-31. doi: 10.1016/j.jclinane.2012.11.007. Epub
      2013 Mar 22.

PMID- 23688916
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
DP  - 2013 May 17
TI  - Major depressive episode among Brazilian adults: A cross-sectional
      population-based study.
LID - S0165-0327(13)00304-2 [pii]
LID - 10.1016/j.jad.2013.04.031 [doi]
AB  - BACKGROUND: Despite the fact that there is extensive scientific research on
      depression very few population-based studies have been conducted in Brazilian
      cities. METHODS: A sampling design of two-stage conglomerates with probability
      proportional to size. All adults aged 20 or more living in the selected
      households were invited to participate in the study. Depression was assessed
      using the Patient Health Questionnaire-9 (PHQ-9) with a cutoff >/=9. RESULTS: The
      study sample comprised 2925 respondents. The prevalence of depression in the
      sample studied was 20.4% (95% CI 18.9;21.8). After adjustment for confounding
      factors according to a conceptual analysis model the following variables were
      associated with a higher prevalence of depression: female gender; younger age;
      white skin color; lower socioeconomic condition; lower education; smoking; being 
      single or separated; being unemployed; and reporting a heart condition. Alcohol
      use, arterial hypertension, and diabetes mellitus were not found to be associated
      with depression. LIMITATIONS: The difference in the proportion of males among
      losses and refusals compared to that in the sample analyzed. Another limitation
      is reverse causality bias that is a problem inherent to cross-sectional studies. 
      CONCLUSIONS: Our findings support the relevance of depression as a prevalent
      condition among adults. It also provided evidence of the factors associated with 
      depression, and that some are potentially modifiable risk factors may have
      implications for policy and health service planning.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas,
      Brazil. Electronic address: tyagomunhoz@hotmail.com.
FAU - Munhoz, Tiago N
AU  - Munhoz TN
FAU - Santos, Ina S
AU  - Santos IS
FAU - Matijasevich, Alicia
AU  - Matijasevich A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/02/05 [received]
PHST- 2013/04/19 [accepted]
AID - S0165-0327(13)00304-2 [pii]
AID - 10.1016/j.jad.2013.04.031 [doi]
PST - aheadofprint
SO  - J Affect Disord. 2013 May 17. pii: S0165-0327(13)00304-2. doi:
      10.1016/j.jad.2013.04.031.

PMID- 23688786
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
DP  - 2013 May 8
TI  - Sartorius transposition during inguinal lymphadenectomy for melanoma.
LID - S0022-4804(13)00409-5 [pii]
LID - 10.1016/j.jss.2013.04.033 [doi]
AB  - BACKGROUND: Inguinal lymph node dissection (ILND) for melanoma has been
      associated with high rates of wound complication (WC). Sartorius transposition
      (ST) is a technique that has been proposed to minimize morbidity. We report the
      frequency of utilization of ST and associated clinical outcomes in a national
      sample. MATERIALS AND METHODS: Patients undergoing ILND for melanoma were
      identified in the American College of Surgeons National Surgical Quality
      Improvement Program Participant Use File (2005-2011). ST status was determined.
      Univariate logistic regression analyses were performed. Propensity score matching
      was used to control for operative time. Conditional logistic regression was used 
      to determine the likelihood of a WC following ST in the matched cohort. RESULTS: 
      Of the 381 patients identified, 13% had a WC. By univariate analysis, increasing 
      body mass index (P = 0.006), diabetes (P = 0.02), and longer operative time (P = 
      0.005) were associated with WC. Sixty-three patients received a prophylactic ST
      (16.5%). ST use was significantly associated with deep nodal dissection (P =
      0.03) and increased operative time (P < 0.0001) but not with any preoperative
      risk factors. WC rates were similar between ST and non-ST patients (10% versus
      14%, P = 0.39). In the multivariate analysis of patients matched for operative
      time, ST was the only factor significantly associated with lower WC rate. The WC 
      rate was 23% in non-ST compared with 8% in ST patients (P = 0.05). CONCLUSIONS:
      Nationally, ST is used infrequently at the time of ILND. Moreover, patients
      undergoing ST do not appear to be selected based on the patient factors
      associated with increased risk of WC. Risk factors for wound complication should 
      be considered in the selective use of ST.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.
      Electronic address: edmund.bartlett@uphs.upenn.edu.
FAU - Bartlett, Edmund K
AU  - Bartlett EK
FAU - Meise, Chelsey
AU  - Meise C
FAU - Bansal, Neha
AU  - Bansal N
FAU - Fischer, John P
AU  - Fischer JP
FAU - Low, David W
AU  - Low DW
FAU - Czerniecki, Brian J
AU  - Czerniecki BJ
FAU - Roses, Robert E
AU  - Roses RE
FAU - Fraker, Douglas L
AU  - Fraker DL
FAU - Kelz, Rachel R
AU  - Kelz RR
FAU - Karakousis, Giorgos C
AU  - Karakousis GC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/05 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/04/17 [accepted]
AID - S0022-4804(13)00409-5 [pii]
AID - 10.1016/j.jss.2013.04.033 [doi]
PST - aheadofprint
SO  - J Surg Res. 2013 May 8. pii: S0022-4804(13)00409-5. doi:
      10.1016/j.jss.2013.04.033.

PMID- 23688782
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 17
TI  - Role of adipose specific lipid droplet proteins in maintaining whole body energy 
      homeostasis.
LID - S0925-4439(13)00161-0 [pii]
LID - 10.1016/j.bbadis.2013.05.007 [doi]
AB  - Excess or insufficient lipid storage in white adipose tissue lipid droplets is
      associated with dyslipidemia, insulin resistance and increased risk for diabetes 
      type 2. Thus, maintenance of adipose lipid droplet growth and function is
      critical to preserve whole body insulin sensitivity and energy homeostasis.
      Progress in understanding biology of lipid droplets has underscored the role of
      proteins that interact with lipid droplets. Here, we review the current knowledge
      of adipose specific lipid droplet proteins, which share unique functions
      controlling adipocyte lipid storage, limiting lipid spill-over and lipotoxic
      effects thought to contribute to disease. This article is part of a Special Issue
      entitled: Modulation of Adipose Tissue in Health and Disease.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Medicine, Division of Endocrinology, School of Medicine, University
      of Maryland, Baltimore, MD 21201, USA.
FAU - Konige, Manige
AU  - Konige M
FAU - Wang, Hong
AU  - Wang H
FAU - Sztalryd, Carole
AU  - Sztalryd C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/02/12 [received]
PHST- 2013/04/10 [revised]
PHST- 2013/05/03 [accepted]
AID - S0925-4439(13)00161-0 [pii]
AID - 10.1016/j.bbadis.2013.05.007 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 17. pii: S0925-4439(13)00161-0. doi:
      10.1016/j.bbadis.2013.05.007.

PMID- 23688738
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
DP  - 2013 May 17
TI  - Is type 1 diabetes a food-induced disease?
LID - S0306-9877(13)00170-9 [pii]
LID - 10.1016/j.mehy.2013.03.046 [doi]
AB  - The incidence of type 1 diabetes among children has almost doubled during the
      last decades in Sweden. Type 1 diabetes is considered as an autoimmune disease
      with unknown aetiology. Here we propose that the immune reaction may be initiated
      by food-derived mechanisms. The incidence of diabetes parallels an increased
      consumption of pasta, white bread, meat, cheese, low-fat milk, exotic fruits,
      soda, and snacks. Simultaneously, the consumption of potatoes, butter, high-fat
      milk, and domestic fruit has decreased. Three categories of food related reaction
      mechanisms are discussed against the following items (1) proteins from wheat,
      meat, and milk, (2) fat from processed food, and (3) exotic fruits. The current
      food consumption is suggested to initiate a pro-inflammatory reaction in the
      intestine and thereby reduce the intestinal barrier function. This may influence 
      tolerance development and thus pave the way for an autoimmune attack on
      pancreatic beta cells.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Dept. of Medicine, Helsingborg Hospital, Sweden; Dept. of Clinical Sciences in
      Lund, Lund University, Sweden. Electronic address: mona.landin-olsson@med.lu.se.
FAU - Landin-Olsson, Mona
AU  - Landin-Olsson M
FAU - Hillman, Magnus
AU  - Hillman M
FAU - Erlanson-Albertsson, Charlotte
AU  - Erlanson-Albertsson C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/10/08 [received]
PHST- 2013/03/29 [accepted]
AID - S0306-9877(13)00170-9 [pii]
AID - 10.1016/j.mehy.2013.03.046 [doi]
PST - aheadofprint
SO  - Med Hypotheses. 2013 May 17. pii: S0306-9877(13)00170-9. doi:
      10.1016/j.mehy.2013.03.046.

PMID- 23688720
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1873-2585 (Electronic)
IS  - 1047-2797 (Linking)
DP  - 2013 May 17
TI  - Physical health indicators among lesbian, gay, and bisexual U.S. veterans.
LID - S1047-2797(13)00099-9 [pii]
LID - 10.1016/j.annepidem.2013.04.009 [doi]
AB  - PURPOSE: To provide information about lesbian, gay, and bisexual (LGB) veterans' 
      health status, diagnoses, and health screening behaviors compared with
      heterosexual veterans. METHODS: Data are from 10 states' 2010 Behavioral Risk
      Factor Surveillance System surveys that contained sexual orientation data for
      veterans (n = 11,665). chi2 tests and multiple logistic regression were used to
      examine outcomes among LGB and heterosexual veterans. RESULTS: More LGB than
      heterosexual veterans reported current smoking, not seeking medical care owing to
      cost, and activity limitations. Compared with heterosexual veterans, LGB veterans
      had greater odds of ever having an human immunodeficiency virus test (odds ratio 
      [OR], 5.42; 95% confidence interval [CI], 3.28-8.96) but lower odds of diabetes
      diagnosis (OR, 0.55; 95% CI, 0.34-0.89). CONCLUSIONS: Findings from this sample
      suggest patterns of health behaviors and outcomes among LGB veterans that are
      both unique from and similar to results from general samples of LGB persons. With
      the formal end of the "Don't Ask, Don't Tell" policy that discriminated against
      LGB people in the military, institutions such as the Department of Veterans
      Affairs are likely to see an increase in its current population of LGB veterans. 
      The Department of Veterans Affairs stands in a unique place to meet the health
      equity needs of this minority population.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Veterans Affairs, VISN-2 Center of Excellence for Suicide
      Prevention, Canandaigua, NY; Department of Psychiatry, Center for the Study and
      Prevention of Suicide, University of Rochester, Rochester, NY. Electronic
      address: john.blosnich@va.gov.
FAU - Blosnich, John R
AU  - Blosnich JR
FAU - Silenzio, Vincent M B
AU  - Silenzio VM
LA  - ENG
GR  - T32 MH020061/MH/NIMH NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Ann Epidemiol
JT  - Annals of epidemiology
JID - 9100013
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/12/12 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/04/16 [accepted]
AID - S1047-2797(13)00099-9 [pii]
AID - 10.1016/j.annepidem.2013.04.009 [doi]
PST - aheadofprint
SO  - Ann Epidemiol. 2013 May 17. pii: S1047-2797(13)00099-9. doi:
      10.1016/j.annepidem.2013.04.009.

PMID- 23688639
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1527-3792 (Electronic)
IS  - 0022-5347 (Linking)
DP  - 2013 May 17
TI  - Can We Change Patient Behaviors to Improve Urological Health?
LID - S0022-5347(13)04362-0 [pii]
LID - 10.1016/j.juro.2013.05.025 [doi]
AD  - National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda,
      Maryland.
FAU - Kirkali, Ziya
AU  - Kirkali Z
LA  - ENG
PT  - EDITORIAL
DEP - 20130517
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/09 [accepted]
AID - S0022-5347(13)04362-0 [pii]
AID - 10.1016/j.juro.2013.05.025 [doi]
PST - aheadofprint
SO  - J Urol. 2013 May 17. pii: S0022-5347(13)04362-0. doi: 10.1016/j.juro.2013.05.025.

PMID- 23688630
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
DP  - 2013 May 17
TI  - The toe-brachial index in the diagnosis of peripheral arterial disease.
LID - S0741-5214(13)00710-6 [pii]
LID - 10.1016/j.jvs.2013.03.044 [doi]
AB  - BACKGROUND: Peripheral arterial disease (PAD) can be diagnosed noninvasively by
      segmental blood pressure measurement and calculating an ankle-brachial index
      (ABI) or toe-brachial index (TBI). The ABI is known to be unreliable in patients 
      with vascular stiffness and fails to detect the early phase of arteriosclerotic
      development. The toe vessels are less susceptible to vessel stiffness, which
      makes the TBI useful. However, the diagnostic limits used in guidelines, clinical
      settings, and experimental studies vary substantially. This review provides an
      overview of the evidence supporting the clinical use of the TBI. METHODS: A
      review of the literature identified studies reporting the use of the TBI
      regarding guideline recommendations, normal populations, correlations to
      angiographic findings, and prognostic implications. RESULTS: Eight studies
      conducted in a normal population were identified, of which only one study used
      imaging techniques to rule out arterial stenosis. A reference value of 0.71 was
      estimated as the lowest limit of normal based on the weighted average in studies 
      with preheating of the limbs. A further seven studies showed correlations of the 
      TBI with angiographic findings. The TBI had a sensitivity of 90% to 100% and a
      specificity of 65% to 100% for the detection of vessel stenosis. Few studies
      investigated the value of the TBI as a prognostic marker for cardiovascular
      mortality and morbidity, and no firm conclusions could be made. Studies have,
      however, shown correlation between the TBI and comorbidities such as kidney
      disease, diabetes, and microvasculature disease. CONCLUSIONS: In contrast to the 
      well-defined and evidence-based limits of the ABI, the diagnostic criteria for a 
      pathologic TBI remain ambiguous. Although several guidelines and reviews of PAD
      diagnostics recommend a TBI <0.70 as cutoff, it is not strictly evidence-based.
      The current literature is not sufficient to conclude a specific cutoff as
      diagnostic for PAD. The current studies in normal populations and the correlation
      with angiography are sparse, and additional trials are needed to further validate
      the limits. Large-scale trials are needed to establish the risk of morbidity and 
      mortality for the various diagnostic limits of the TBI.
CI  - Copyright (c) 2013 Society for Vascular Surgery. Published by Mosby, Inc. All
      rights reserved.
AD  - Department of Clinical Physiology, Viborg Regional Hospital, Viborg, Denmark;
      Department of Health Science and Technology, Aalborg University, Aalborg,
      Denmark. Electronic address: ch@hst.aau.dk.
FAU - Hoyer, Christian
AU  - Hoyer C
FAU - Sandermann, Jes
AU  - Sandermann J
FAU - Petersen, Lars J
AU  - Petersen LJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/09 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/03/24 [accepted]
AID - S0741-5214(13)00710-6 [pii]
AID - 10.1016/j.jvs.2013.03.044 [doi]
PST - aheadofprint
SO  - J Vasc Surg. 2013 May 17. pii: S0741-5214(13)00710-6. doi:
      10.1016/j.jvs.2013.03.044.

PMID- 23688574
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
DP  - 2013 May 18
TI  - Opioid mu-receptors as ne0077 target for insulin resistance.
LID - S0163-7258(13)00117-4 [pii]
LID - 10.1016/j.pharmthera.2013.05.002 [doi]
AB  - Type-2 diabetes is one of the fastest growing public health problems worldwide
      resulting from both environmental and genetic factors. Activation of mu-opioid
      receptor (MOR) could result in reversal of the impairment of insulin-stimulated
      glucose disposal in genetically obese Zucker rats via exercise training. This
      improvement of insulin resistance was associated with an elevation of circulating
      beta-endorphin to ameliorate the post-receptor insulin signaling cascade,
      including downstream effectors of the phosphatidylinositol 3-kinase (PI3-kinase) 
      signaling pathway. In insulin resistant rats, Loperamide treatment effected on
      the insulin receptor substrate (IRS)-1/PI3-kinase/Akt signaling cascade and
      subsequent insulin-stimulated glucose transport trafficking on skeletal muscle,
      which were all suppressed by MOR antagonism. In addition, induction of insulin
      resistance by the intake of high fructose is more rapid in MOR knockout mice than
      in wild-type mice. Improvements in insulin sensitivity through the peripheral MOR
      activation overcoming defects related to the post-receptor in IRS-1-associated
      PI3-kinase step have been defined. Opioid receptor activation, especially of the 
      mu-subtype, may provide merits in the amelioration of defective insulin action.
      Atypical zeta (zeta) isoform of protein kinase C serves as a factor that
      integrates with peripheral MOR pathway and insulin signals for glucose
      utilization. The developments call new insights into the chemical compounds
      and/or herbal products that might enhance opioid peptide secretion and/or
      stimulate MOR in peripheral insulin-sensitive tissues to serve as potential
      agents or adjuvants for helping the glucose metabolism. In the present review, we
      update these topics and discuss the concept of targeting peripheral MOR pathway
      for the treatment of insulin resistance.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Psychosomatic Internal Medicine, Kagoshima University Graduate
      School of Medical and Dental Sciences, Kagoshima 890-8520, Japan.
FAU - Cheng, Kai-Chun
AU  - Cheng KC
FAU - Asakawa, Akihiro
AU  - Asakawa A
FAU - Li, Ying-Xiao
AU  - Li YX
FAU - Liu, I-Min
AU  - Liu IM
FAU - Amitani, Haruka
AU  - Amitani H
FAU - Cheng, Juei-Tang
AU  - Cheng JT
FAU - Inui, Akio
AU  - Inui A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/04/11 [received]
PHST- 2013/04/12 [accepted]
AID - S0163-7258(13)00117-4 [pii]
AID - 10.1016/j.pharmthera.2013.05.002 [doi]
PST - aheadofprint
SO  - Pharmacol Ther. 2013 May 18. pii: S0163-7258(13)00117-4. doi:
      10.1016/j.pharmthera.2013.05.002.

PMID- 23688559
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1464-3391 (Electronic)
IS  - 0968-0896 (Linking)
DP  - 2013 May 7
TI  - Development of time resolved fluorescence resonance energy transfer-based assay
      for FXR antagonist discovery.
LID - S0968-0896(13)00408-2 [pii]
LID - 10.1016/j.bmc.2013.04.069 [doi]
AB  - FXR (farnesoid X receptor, NRIH4), a nuclear receptor, plays a major role in the 
      control of cholesterol metabolism. FXR ligands have been investigated in
      preclinical studies for targeted therapy against metabolic diseases, but have
      shown limitations. Therefore, there is a need for new agonist or antagonist
      ligands of FXR, both for potential clinical applications, as well as to further
      elucidate its biological functions. Here we describe the use of the X-ray crystal
      structure of FXR complexed with the potent small molecule agonist GW4064 to
      design and synthesize a novel fluorescent, high-affinity probe (DY246) for time
      resolved fluorescence resonance energy transfer (TR-FRET) assays. We then used
      the TR-FRET assay for high throughput screening of a library of over 5000
      bioactive compounds. From this library, we identified 13 compounds that act as
      putative FXR transcriptional antagonists.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Diabetes, Endocrinology and Metabolism, Beckman Research Institute,
      City of Hope National Medical Center, Duarte, CA 91010, USA. Electronic address: 
      dyu@coh.org.
FAU - Yu, Donna D
AU  - Yu DD
FAU - Lin, Wenwei
AU  - Lin W
FAU - Chen, Taosheng
AU  - Chen T
FAU - Forman, Barry M
AU  - Forman BM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Bioorg Med Chem
JT  - Bioorganic & medicinal chemistry
JID - 9413298
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/02/11 [received]
PHST- 2013/04/17 [revised]
PHST- 2013/04/26 [accepted]
AID - S0968-0896(13)00408-2 [pii]
AID - 10.1016/j.bmc.2013.04.069 [doi]
PST - aheadofprint
SO  - Bioorg Med Chem. 2013 May 7. pii: S0968-0896(13)00408-2. doi:
      10.1016/j.bmc.2013.04.069.

PMID- 23688538
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 5
DP  - 2013 May
TI  - Diabetes education: looking through the kaleidoscope.
PG  - 734-9
LID - 10.1016/j.clinthera.2013.02.028 [doi]
LID - S0149-2918(13)00181-1 [pii]
AB  - BACKGROUND: Diabetes self-management education (DSME) is a critical element of
      care for all people with diabetes and those at risk for developing diabetes. In
      spite of growing evidence of the value of DSME in reducing hospitalization costs,
      improvement in glucose, weight and medication adherence, DSME remains an
      underutilized insurance benefit and access to qualified diabetes educators is
      problematic. PURPOSE: This paper reviews the current challenges, principles and
      evidence of DSME, importance of integration of diabetes education with clinical
      care, and the future of diabetes educators and education in the emerging health
      care delivery models. DATA SOURCES: Scientific literature review, Pub Med, EBP
      websites and other online literature databases and resources. LIMITATIONS: This
      is not a systematic literature review or meta-analysis of diabetes education.
      CONCLUSION: Because diabetes is a complex condition reaching pandemic
      proportions, which requires self-management of the chronic disease on a daily
      basis, the future of DSME faces challenges in the current fee for service
      environment. The National Standards for Diabetes self-management education and
      support and the American Association of Diabetes Educators Practice Guidelines
      offers new concepts for meeting the future demand of diabetes educators and
      education.
CI  - Copyright (c) 2013 Elsevier HS Journals, Inc. All rights reserved.
AD  - Endocrinology and Diabetes Education, ABQ Health Partners, Albuquerque, New
      Mexico. Electronic address: dtomky@xmission.com.
FAU - Tomky, Donna
AU  - Tomky D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/02/20 [received]
PHST- 2013/04/19 [accepted]
AID - S0149-2918(13)00181-1 [pii]
AID - 10.1016/j.clinthera.2013.02.028 [doi]
PST - ppublish
SO  - Clin Ther. 2013 May;35(5):734-9. doi: 10.1016/j.clinthera.2013.02.028.

PMID- 23688537
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 5
DP  - 2013 May
TI  - Inpatient management of diabetes and hyperglycemia.
PG  - 724-33
LID - 10.1016/j.clinthera.2013.04.008 [doi]
LID - S0149-2918(13)00180-X [pii]
AB  - Illness, particularly when severe, leads to increased concentrations of
      counter-regulatory factors which induce insulin resistance and predispose
      patients to stress hyperglycemia. Elevated glucose concentrations are common in
      hospitalized patients, both those with as well as without recognized diabetes.
      Substantial data has emerged over the past decade that quality glucose management
      in these individuals actually improves clinical outcomes. Controlling glucose in 
      this setting is challenging, given the phenotypic variability amongst patients,
      with fluctuating courses of acute illnesses and unpredictable nutritional
      schedules. We review the evidence basis that has informed national standards and 
      glucose targets in both critically and non-critically ill patients. In the
      intensive care setting, insulin infusions are now widely endorsed to quickly
      achieve and maintain glucose control. On the hospital wards, physiological
      subcutaneous insulin therapy, incorporating both basal and nutritional
      components, is emerging as the optimal treatment strategy. The transition to
      outpatient care is another important aspect of any hospital glycemic management
      program.
CI  - Copyright (c) 2013. Published by EM Inc USA.
AD  - Section of Endocrinology, Yale University School of Medicine, New Haven,
      Connecticut.
FAU - Bogun, Magdalena
AU  - Bogun M
FAU - Inzucchi, Silvio E
AU  - Inzucchi SE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/04/19 [received]
PHST- 2013/04/19 [accepted]
AID - S0149-2918(13)00180-X [pii]
AID - 10.1016/j.clinthera.2013.04.008 [doi]
PST - ppublish
SO  - Clin Ther. 2013 May;35(5):724-33. doi: 10.1016/j.clinthera.2013.04.008.

PMID- 23688536
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 5
DP  - 2013 May
TI  - Diabetes mellitus in the next decade: novel pipeline medications to treat
      hyperglycemia.
PG  - 714-23
LID - 10.1016/j.clinthera.2013.04.007 [doi]
LID - S0149-2918(13)00179-3 [pii]
AB  - Despite a rapid increase in the number of drugs available to treat hyperglycemia 
      there remain several unmet needs in the prevention and treatment of diabetes.
      There have also been tremendous advances in our understanding of the
      pathophysiology of type 2 diabetes, allowing the recognition of novel treatment
      targets. The purpose of this review is to highlight some of the novel approaches 
      that are being developed to improve glucose control in patients with diabetes.
CI  - Copyright (c) 2013. Published by EM Inc USA.
AD  - Tulane University Health Sciences Center, New Orleans, Louisiana. Electronic
      address: vfonseca@tulane.edu.
FAU - Fonseca, Vivian
AU  - Fonseca V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/04 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/04/19 [accepted]
AID - S0149-2918(13)00179-3 [pii]
AID - 10.1016/j.clinthera.2013.04.007 [doi]
PST - ppublish
SO  - Clin Ther. 2013 May;35(5):714-23. doi: 10.1016/j.clinthera.2013.04.007.

PMID- 23688535
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 5
DP  - 2013 May
TI  - Collaboration designed to increase translation of diabetes research outcomes into
      clinical practice.
PG  - 712-3
LID - 10.1016/j.clinthera.2013.04.010 [doi]
LID - S0149-2918(13)00183-5 [pii]
AD  - Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania;
      Division of Endocrinology, Diabetes and Metabolic Disease, Thomas Jefferson
      University Hospital, Philadelphia, Pennsylvania.
FAU - Jabbour, Serge
AU  - Jabbour S
FAU - Miller, Jeffrey L
AU  - Miller JL
LA  - eng
PT  - Editorial
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/04/18 [received]
PHST- 2013/04/19 [accepted]
AID - S0149-2918(13)00183-5 [pii]
AID - 10.1016/j.clinthera.2013.04.010 [doi]
PST - ppublish
SO  - Clin Ther. 2013 May;35(5):712-3. doi: 10.1016/j.clinthera.2013.04.010.

PMID- 23688528
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1477-1128 (Electronic)
IS  - 1463-4236 (Linking)
VI  - 14
IP  - 3
DP  - 2013 Jul
TI  - Approaches to diabetes: empowerment, control or both?
PG  - 221-3
LID - 10.1017/S1463423613000236 [doi]
AD  - Department of Public Health and Primary Care Universtiy of Cambridge, Cambridge
      Cambridgeshire, UK.
FAU - Graffy, Jonathan
AU  - Graffy J
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - England
TA  - Prim Health Care Res Dev
JT  - Primary health care research & development
JID - 100897390
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/21 [aheadofprint]
AID - S1463423613000236 [pii]
AID - 10.1017/S1463423613000236 [doi]
PST - ppublish
SO  - Prim Health Care Res Dev. 2013 Jul;14(3):221-3. doi: 10.1017/S1463423613000236.
      Epub 2013 May 21.

PMID- 23688357
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
IP  - 1
DP  - 2013 May 20
TI  - Association between non-alcoholic fatty pancreatic disease (nafpd) and the
      metabolic syndrome: case--control retrospective study.
PG  - 77
AB  - BACKGROUND: Fatty liver is associated with insulin resistance, dyslipidemia, and 
      obesity and is therefore considered a phenotype of metabolic syndrome. However,
      less is known regarding the metabolic abnormalities associated with non-alcoholic
      fatty pancreatic disease (NAFPD; fatty pancreas). The present study was performed
      to ascertain whether fatty pancreas is associated with specific metabolic risk
      factors and with metabolic syndrome as defined by the Adult Treatment Panel III. 
      METHODS: Five-hundred-fifty-seven healthy and consecutive subjects without known 
      hypertension or diabetes and who received a health investigation at the National 
      Taiwan University Hospital Health Management Center were enrolled in this
      retrospective study. Fatty pancreas was diagnosed via trans-abdominal
      ultrasonographic findings. RESULTS: Seventy-two (12.9%) subjects diagnosed with
      fatty pancreas comprised the fatty pancreas group, and remaining subjects
      comprised the normal pancreas group. The presence of various demographic and
      metabolic risk factors was recorded for all subjects, and the two groups were
      examined for statistically significant differences in these factors. As compared 
      to the absence of fatty pancreas, the presence of the disease was associated with
      older age and with higher values for each of the following: BMI, abdominal
      girth/height, abdominal girth (both genders), fasting and postprandial blood
      glucose, HbA1c, total cholesterol, triglycerides, LDL-cholesterol, systolic blood
      pressure, and platelet count. In contrast to previously reported findings, serum 
      amylase values were lower in the fatty pancreas as compared to the control group.
      CONCLUSION: The presence of fatty pancreas represents a meaningful manifestation 
      of metabolic syndrome together with obesity.
FAU - Wu, Wan-Chen
AU  - Wu WC
FAU - Wang, Chih-Yuan
AU  - Wang CY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/12/31 [received]
PHST- 2013/05/20 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - 1475-2840-12-77 [pii]
AID - 10.1186/1475-2840-12-77 [doi]
PST - aheadofprint
SO  - Cardiovasc Diabetol. 2013 May 20;12(1):77.

PMID- 23688340
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Lipid-lowering pharmacotherapy and socioeconomic status: atherosclerosis risk in 
      communities (ARIC) surveillance study.
PG  - 488
LID - 10.1186/1471-2458-13-488 [doi]
AB  - BACKGROUND: Lipid-reduction pharmacotherapy is often employed to reduce morbidity
      and mortality risk for patients with dyslipidemia or established cardiovascular
      disease. Associations between socioeconomic factors and the prescribing and use
      of lipid-lowering agents have been reported in several developed countries.
      METHODS: We evaluated the association of census tract-level neighborhood
      household income (nINC) and lipid-lowering medications received during
      hospitalization or at discharge among 3,546 (5,335 weighted) myocardial
      infarction (MI) events in the United States (US) Atherosclerosis Risk In
      Communities (ARIC) surveillance study (1999-2002). Models included neighborhood
      household income, race, gender, age, study community, year of MI, hospital type
      (teaching vs. nonteaching), current or past history of hypertension, diabetes or 
      heart failure, and presence of cardiac pain. RESULTS: About fifty-nine percent of
      patients received lipid-lowering pharmacotherapy during hospitalization or at
      discharge. Low nINC was associated with a lower likelihood (prevalence ratio
      0.89, 95% confidence interval: 0.79, 1.01) of receiving lipid-lowering
      pharmacotherapy compared to high neighborhood household income, and no
      significant change in this association resulted when adjusted for the
      above-mentioned covariates. CONCLUSION: Patient's socioeconomic status appeared
      to influence whether they were prescribed a lipid-lowering pharmacotherapy after 
      hospitalization for myocardial infarction in the US ARIC surveillance study
      (1999-2002).
AD  - Department of Epidemiology, Gillings School of Global Public Health, University
      of North Carolina, 135 Dauer Drive, Chapel Hill, NC, 27599, USA.
      kathy_rose@sra.com.
FAU - Kitzmiller, Joseph P
AU  - Kitzmiller JP
FAU - Foraker, Randi E
AU  - Foraker RE
FAU - Rose, Kathy M
AU  - Rose KM
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3663719
OID - NLM: PMC3663719
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/12/02 [received]
PHST- 2013/05/16 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - 1471-2458-13-488 [pii]
AID - 10.1186/1471-2458-13-488 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 20;13:488. doi: 10.1186/1471-2458-13-488.

PMID- 23688324
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1749-8090 (Electronic)
IS  - 1749-8090 (Linking)
VI  - 8
DP  - 2013
TI  - Deep sternal wound infection after cardiac surgery.
PG  - 132
LID - 10.1186/1749-8090-8-132 [doi]
AB  - BACKGROUND: Deep sternal wound infection (DSWI) is a serious postoperative
      complication of cardiac surgery. In this study we investigated the incidence of
      DSWI and effect of re-exploration for bleeding on DSWI mortality. METHODS: We
      reviewed 73,700 cases registered in the Japan Adult Cardiovascular Surgery
      Database (JACVSD) during the period from 2004 to 2009 and divided them into five 
      groups: 26,597 of isolated coronary artery bypass graft (CABG) cases, 23,136
      valvular surgery cases, 17,441 thoracic aortic surgery cases, 4,726 valvular
      surgery plus CABG cases, and 1,800 thoracic aortic surgery plus CABG cases. We
      calculated the overall incidence of postoperative DSWI, incidence of
      postoperative DSWI according to operative procedure, 30-day mortality and
      operative mortality of postoperative DSWI cases according to operative procedure,
      30-day mortality and operative mortality of postoperative DSWI according to
      whether re-exploration for bleeding, and the intervals between the operation and 
      deaths according to whether re-exploration for bleeding were investigated.
      Operative mortality is defined as in-hospital or 30-day mortality. Risk factors
      for DSWI were also examined. RESULTS: The overall incidence of postoperative DSWI
      was 1.8%. The incidence of postoperative DSWI was 1.8% after isolated CABG, 1.3% 
      after valve surgery, 2.8% after valve surgery plus CABG, 1.9% after thoracic
      aortic surgery, and 3.4% after thoracic aortic surgery plus CABG. The 30-day and 
      operative mortality in patients with DSWI was higher after more complicated
      operative procedures. The incidence of re-exploration for bleeding in DSWI cases 
      was 11.1%. The overall 30-day/operative mortality after DSWI with re-exploration 
      for bleeding was 23.0%/48.0%, and it was significantly higher than in the absence
      of re-exploration for bleeding (8.1%/22.0%). The difference between the intervals
      between the operation and death according to whether re-exploration for bleeding 
      had been performed was not significant. Age and cardiogenic shock were
      significant risk factors related to re-exploration for bleeding, and diabetes
      control was a significant risk factor related to DSWI for all surgical groups.
      Previous CABG was a significant risk factor related to both re-exploration for
      bleeding and DSWI for all surgical groups. CONCLUSIONS: The incidence of DSWI
      after cardiac surgery according to the data entered in the JACVSD registry during
      the period from 2004 to 2009 was 1.8%, and more complicated procedures were
      followed by higher incidence and mortality. When re-exploration for bleeding was 
      performed, mortality was significantly higher than when it was not performed.
      Prevention of DSWI and establishment of an effective appropriate treatment for
      DSWI may improve the outcome of cardiac surgery.
AD  - Department of Cardiovascular Surgery, Kyorin University, 6-20-2, Shinkawa,
      Mitaka, Tokyo, Japan. kub@ks.kyorin-u.ac.jp.
FAU - Kubota, Hiroshi
AU  - Kubota H
FAU - Miyata, Hiroaki
AU  - Miyata H
FAU - Motomura, Noboru
AU  - Motomura N
FAU - Ono, Minoru
AU  - Ono M
FAU - Takamoto, Shinichi
AU  - Takamoto S
FAU - Harii, Kiyonori
AU  - Harii K
FAU - Oura, Norihiko
AU  - Oura N
FAU - Hirabayashi, Shinichi
AU  - Hirabayashi S
FAU - Kyo, Shunei
AU  - Kyo S
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - England
TA  - J Cardiothorac Surg
JT  - Journal of cardiothoracic surgery
JID - 101265113
SB  - IM
PMC - PMC3663691
OID - NLM: PMC3663691
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/02/13 [received]
PHST- 2013/05/10 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - 1749-8090-8-132 [pii]
AID - 10.1186/1749-8090-8-132 [doi]
PST - epublish
SO  - J Cardiothorac Surg. 2013 May 20;8:132. doi: 10.1186/1749-8090-8-132.

PMID- 23688317
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 20
TI  - Pharmacological primary and secondary cardiovascular prevention among diabetic
      patients in a multiethnic general practice population: still room for
      improvements.
PG  - 182
AB  - BACKGROUND: Ethnic minority groups have higher prevalence of cardiovascular
      disease (CVD) and type 2 diabetes mellitus (T2DM). We assessed general
      practitioners' (GPs') performance with respect to the pharmacological prevention 
      of CVD in patients with T2DM from different ethnic backgrounds in Oslo. METHODS: 
      Of 1653 T2DM patients cared for by 49 GPs in 2005, 380 had a diagnosis of CVD.
      Ethnicity was categorized as Norwegian, South Asian and other. Risk factor
      levels, medication use, achievement of treatment targets (HbA1c <= 7.5%, systolic
      blood pressure (SBP) <= 140 mmHg, total cholesterol/HDL-cholesterol < 4) and
      therapeutic intensity (number of drugs targeting each risk factor) were recorded.
      Chi-square, Wald tests and multiple linear regression analyses were used.
      RESULTS: Of the 1273 patients receiving primary prevention, 1.5% had their Hb1Ac,
      4.8% SBP and 12.7% lipids levels above treatment thresholds without relevant
      prescriptions. Among patients on pharmacological therapy, 66% reached the HbA1c, 
      62% SBP and 62% lipid target. Proportions not achieving the HbA1c target were 26%
      in Norwegians, 38% in South Asians and 29% in others (p = 0.008). Proportions not
      achieving the SBP target were 42% in Norwegians, 22% in South Asians and 25% in
      others (p <= 0.001). Of those not achieving the HbA1c and SBP targets, 43% and
      35% respectively, used only one agent.In secondary prevention, 0.8% of the
      patients had their HbA1c, 0.5% SBP and 7.4% lipid levels above treatment
      thresholds without relevant prescriptions. Among patients on pharmacological
      therapy, 65% reached the HbA1c, 64% SBP and 66% lipid target. Proportions not
      achieving the HbA1c target were 26% in Norwegians, 47% in South Asians and 40% in
      others (p = 0.03). Proportions not achieving the SBP target were 36% in
      Norwegians, 22% in South Asians and 56% in others (p = 0.050). Of those not
      achieving HbA1c and SBP targets, 49% and 21% respectively, were on mono-therapy. 
      CONCLUSIONS: Norwegian GPs comply reasonably well with guidelines for
      pharmacological prevention of CVD in T2DM patients across ethnic groups. However,
      lipid-lowering therapy was generally underused, and the achievement of treatment 
      targets for HbA1c in ethnic minorities and for BP in Norwegians could be
      improved.
FAU - Tran, Anh T
AU  - Tran AT
FAU - Straand, Jorund
AU  - Straand J
FAU - Dalen, Ingvild
AU  - Dalen I
FAU - Birkeland, Kare I
AU  - Birkeland KI
FAU - Claudi, Tor
AU  - Claudi T
FAU - Cooper, John G
AU  - Cooper JG
FAU - Meyer, Haakon E
AU  - Meyer HE
FAU - Jenum, Anne K
AU  - Jenum AK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
PMC - PMC3664587
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/12/11 [received]
PHST- 2013/05/20 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - 1472-6963-13-182 [pii]
AID - 10.1186/1472-6963-13-182 [doi]
PST - aheadofprint
SO  - BMC Health Serv Res. 2013 May 20;13(1):182.

PMID- 23688259
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 13
DP  - 2013
TI  - Pragmatic controlled trial to prevent childhood obesity in maternity and child
      health care clinics: pregnancy and infant weight outcomes (The VACOPP Study).
PG  - 80
LID - 10.1186/1471-2431-13-80 [doi]
AB  - BACKGROUND: According to current evidence, the prevention of obesity should start
      early in life. Even the prenatal environment may expose a child to unhealthy
      weight gain; maternal gestational diabetes is known to be among the prenatal risk
      factors conducive to obesity. Here we report the effects of antenatal dietary and
      physical activity counselling on pregnancy and infant weight gain outcomes.
      METHODS: The study was a non-randomised controlled pragmatic trial aiming to
      prevent childhood obesity, the setting being municipal maternity health care
      clinics. The participants (n = 185) were mothers at risk of developing
      gestational diabetes mellitus and their offspring. The children of the
      intervention group mothers were born between 2009 and 2010, and children of the
      control group in 2008. The intervention started between 10-17 gestational weeks
      and consisted of individual counselling on diet and physical activity by a public
      health nurse, and two group counselling sessions by a dietician and a
      physiotherapist. The expectant mothers also received a written information
      leaflet to motivate them to breastfeed their offspring for at least 6 months. We 
      report the proportion of mothers with pathological glucose tolerance at 26-28
      weeks' gestation, the mother's gestational weight gain (GWG) and newborn
      anthropometry. Infant weight gain from 0 to 12 months of age was assessed as
      weight-for-length standard deviation scores (SDS) and mixed effect linear
      regression models. RESULTS: Intervention group mothers had fewer pathological
      oral glucose tolerance test results (14.6% vs. 29.2%; 95% CI 8.9 to 23.0% vs.
      20.8 to 39.4%; p-value 0.016) suggesting that the intervention improved
      gestational glucose tolerance. Mother's GWG, newborn anthropometry or infant
      weight gain did not differ significantly between the groups. CONCLUSION: Since
      the intervention reduced the prevalence of gestational diabetes mellitus, it may 
      have the potential to diminish obesity risk in offspring. However, results from
      earlier studies suggest that the possible effect on the offspring's weight gain
      may manifest only later in childhood. TRIAL REGISTRATION: Clinical Trials gov:
      NCT00970710.
AD  - Seinajoki Central Hospital, Hanneksenrinne 7, 60220 Seinajoki, Finland.
      taina.mustila@fimnet.fi.
FAU - Mustila, Taina
AU  - Mustila T
FAU - Raitanen, Jani
AU  - Raitanen J
FAU - Keskinen, Paivi
AU  - Keskinen P
FAU - Saari, Antti
AU  - Saari A
FAU - Luoto, Riitta
AU  - Luoto R
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
SB  - IM
PMC - PMC3664621
OID - NLM: PMC3664621
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/01/29 [received]
PHST- 2013/05/15 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - 1471-2431-13-80 [pii]
AID - 10.1186/1471-2431-13-80 [doi]
PST - epublish
SO  - BMC Pediatr. 2013 May 20;13:80. doi: 10.1186/1471-2431-13-80.

PMID- 23688199
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1520-6904 (Electronic)
IS  - 0022-3263 (Linking)
DP  - 2013 Jun 5
TI  - C-Branched Iminosugars: alpha-Glucosidase Inhibition by Enantiomers of isoDMDP,
      isoDGDP, and isoDAB-l-isoDMDP Compared to Miglitol and Miglustat.
AB  - The Ho crossed aldol condensation provides access to a series of carbon branched 
      iminosugars as exemplified by the synthesis of enantiomeric pairs of isoDMDP,
      isoDGDP, and isoDAB, allowing comparison of their biological activities with
      three linear isomeric natural products DMDP, DGDP, and DAB and their enantiomers.
      l-IsoDMDP [(2S,3S,4R)-2,4-bis(hydroxymethyl)pyrrolidine-3,4-diol], prepared in 11
      steps in an overall yield of 45% from d-lyxonolactone, is a potent specific
      competitive inhibitor of gut disaccharidases [Ki 0.081 muM for rat intestinal
      maltase] and is more effective in the suppression of hyperglycaemia in a maltose 
      loading test than miglitol, a drug presently used in the treatment of late onset 
      diabetes. The partial rescue of the defective F508del-CFTR function in CF-KM4
      cells by l-isoDMDP is compared with miglustat and isoLAB in an approach to the
      treatment of cystic fibrosis.
AD  - Chemistry Research Laboratory, Department of Chemistry, University of Oxford ,
      Mansfield Road, Oxford OX1 3TA, U.K.
FAU - Jenkinson, Sarah F
AU  - Jenkinson SF
FAU - Best, Daniel
AU  - Best D
FAU - Saville, A Waldo
AU  - Saville AW
FAU - Mui, James
AU  - Mui J
FAU - Martinez, R Fernando
AU  - Martinez RF
FAU - Nakagawa, Shinpei
AU  - Nakagawa S
FAU - Kunimatsu, Takahito
AU  - Kunimatsu T
FAU - Alonzi, Dominic S
AU  - Alonzi DS
FAU - Butters, Terry D
AU  - Butters TD
FAU - Norez, Caroline
AU  - Norez C
FAU - Becq, Frederic
AU  - Becq F
FAU - Bleriot, Yves
AU  - Bleriot Y
FAU - Wilson, Francis X
AU  - Wilson FX
FAU - Weymouth-Wilson, Alexander C
AU  - Weymouth-Wilson AC
FAU - Kato, Atsushi
AU  - Kato A
FAU - Fleet, George W J
AU  - Fleet GW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Org Chem
JT  - The Journal of organic chemistry
JID - 2985193R
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 10.1021/jo4005487 [doi]
PST - aheadofprint
SO  - J Org Chem. 2013 Jun 5.

PMID- 23688116
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1525-6073 (Electronic)
IS  - 0742-0528 (Linking)
DP  - 2013 May 20
TI  - Reduced preprandial dipping accounts for rapid elevation of blood pressure and
      renal sympathetic nerve activity in rabbits fed a high-fat diet.
AB  - Consumption of a high-fat diet (HFD) by rabbits results in increased blood
      pressure (BP), heart rate (HR), and renal sympathetic nerve activity (RSNA)
      within 1 wk. Here, we determined how early this activation occurred and whether
      it was related to changes in cardiovascular and neural 24-h rhythms. Rabbits were
      meal-fed a HFD for 3 wks, then a normal-fat diet (NFD) for 1 wk. BP, HR, and RSNA
      were measured daily in the home cage via implanted telemeters. Baseline BP, HR,
      and RSNA over 24 h were 71 +/- 1 mm Hg, 205 +/- 4 beats/min and 7 +/- 1
      normalized units (nu). The 24-h pattern was entrained to the feeding cycle and
      values increased from preprandial minimum to postprandial maximum by 4 +/- 1 mm
      Hg, 51 +/- 6 beats/min, and 1.6 +/- .6 nu each day. Feeding of a HFD markedly
      diminished the preprandial dip after 2 d (79-125% of control; p < 0.05) and this 
      reduction lasted for 3 wks of HFD. Twenty-four-hour BP, HR, and RSNA concurrently
      increased by 2%, 18%, and 22%, respectively. Loss of preprandial dipping
      accounted for all of the BP increase and 50% of the RSNA increase over 3 wks and 
      the 24-h rhythm became entrained to the light-dark cycle. Resumption of a NFD did
      not alter the BP preprandial dip. Thus, elevated BP induced by a HFD and mediated
      by increased sympathetic nerve activity results from a reduction in preprandial
      dipping, from the first day. Increased calories, glucose, insulin, and leptin may
      account for early changes, whereas long-term loss of dipping may be related to
      increased sensitivity of sympathetic pathways. (Author correspondence:
      geoff.head@baker.edu.au).
AD  - Neuropharmacology Laboratory, Baker IDI Heart and Diabetes Institute , Melbourne 
      , Australia .
FAU - Burke, Sandra L
AU  - Burke SL
FAU - Prior, Larissa J
AU  - Prior LJ
FAU - Lukoshkova, Elena V
AU  - Lukoshkova EV
FAU - Lim, Kyungjoon
AU  - Lim K
FAU - Barzel, Benjamin
AU  - Barzel B
FAU - Davern, Pamela J
AU  - Davern PJ
FAU - Armitage, James A
AU  - Armitage JA
FAU - Head, Geoffrey A
AU  - Head GA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Chronobiol Int
JT  - Chronobiology international
JID - 8501362
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 10.3109/07420528.2013.784771 [doi]
PST - aheadofprint
SO  - Chronobiol Int. 2013 May 20.

PMID- 23688109
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1475-2891 (Electronic)
IS  - 1475-2891 (Linking)
VI  - 12
DP  - 2013
TI  - Ethnic differences in grains consumption and their contribution to intake of
      B-vitamins: results of the Multiethnic Cohort Study.
PG  - 65
LID - 10.1186/1475-2891-12-65 [doi]
AB  - BACKGROUND: Research indicates that a diet rich in whole grains may reduce the
      risk of prevalent chronic diseases, including cardiovascular disease, diabetes,
      and some cancers, and that risk for these diseases varies by ethnicity. The
      objective of the current study was to identify major dietary sources of grains
      and describe their contribution to B vitamins in five ethnic groups. METHODS: A
      cross-sectional mail survey was used to collect data from participants in the
      Multiethnic Cohort Study in Hawaii and Los Angeles County, United States, from
      1993 to 1996. Dietary intake data collected using a quantitative food frequency
      questionnaire was available for 186,916 participants representing five ethnic
      groups (African American, Latino, Japanese American, Native Hawaiian and
      Caucasian) aged 45-75 years. The top sources of grain foods were determined, and 
      their contribution to thiamin, riboflavin, niacin, vitamin B6, and folic acid
      intakes were analyzed. RESULTS: The top source of whole grains was whole
      wheat/rye bread for all ethnic-sex groups, followed by popcorn and cooked
      cereals, except for Native Hawaiian men and Japanese Americans, for whom
      brown/wild rice was the second top source; major contributors of refined grains
      were white rice and white bread, except for Latinos. Refined grain foods
      contributed more to grain consumption (27.1-55.6%) than whole grain foods
      (7.4-30.8%) among all ethnic-sex groups, except African American women. Grain
      foods made an important contribution to the intakes of thiamin (30.2-45.9%),
      riboflavin (23.1-29.2%), niacin (27.1-35.8%), vitamin B6 (22.9-27.5%), and folic 
      acid (23.3-27.7%). CONCLUSIONS: This is the first study to document consumption
      of different grain sources and their contribution to B vitamins in five ethnic
      groups in the U.S. Findings can be used to assess unhealthful food choices, to
      guide dietary recommendations, and to help reduce risk of chronic diseases in
      these populations.
AD  - Department of Medicine, Aboriginal and Global Health Research Group, University
      of Alberta, 5-10 University Terrace, 8303 112 Street, Edmonton, Alberta T6G 2T4, 
      Canada. gita.sharma@ualberta.ca.
FAU - Sharma, Sangita
AU  - Sharma S
FAU - Sheehy, Tony
AU  - Sheehy T
FAU - Kolonel, Laurence N
AU  - Kolonel LN
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - England
TA  - Nutr J
JT  - Nutrition journal
JID - 101152213
SB  - IM
PMC - PMC3665444
OID - NLM: PMC3665444
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/10/12 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - 1475-2891-12-65 [pii]
AID - 10.1186/1475-2891-12-65 [doi]
PST - epublish
SO  - Nutr J. 2013 May 20;12:65. doi: 10.1186/1475-2891-12-65.

PMID- 23688034
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1471-2350 (Electronic)
IS  - 1471-2350 (Linking)
VI  - 14
DP  - 2013
TI  - Risk interaction of obesity, insulin resistance and hormone-sensitive lipase
      promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver.
PG  - 54
LID - 10.1186/1471-2350-14-54 [doi]
AB  - BACKGROUND: Hormone sensitive lipase (HSL) promoter (LIPE-60 C > G) polymorphism 
      has been found to be involved in hepatic steatosis, obesity, diabetes and
      dyslipidemia. The precise interactions between these risk factors and genetic
      susceptibility that may affect non-alcoholic fatty liver disease (NAFLD) are
      still not fully determined. METHODS: A cross-sectional study was conducted in
      1056 men. To avoid the confounding effect of plasma glucose, the study population
      was classified into normal glucose tolerance (NGT, n = 729) and glucose
      intolerance (GI, n = 299) groups. NAFLD was diagnosed by abdominal ultrasound
      after ruling out any history of alcohol abuse. A multivariate regression model
      was used to estimate the impact of these factors on NAFLD. RESULTS: In the NGT
      group, subjects with NAFLD often have complicated metabolic abnormalities. The
      coexistence of NAFLD and GI has been demonstrated to have a synergistic effect
      raising BMI, serum insulin and HOMA-insulin resistance (HOMA-IR). BMI and
      adipose-insulin resistance (Adipo-IR), but not HOMA-IR, significantly contributed
      to a greater risk of developing NAFLD. Serum triglyceride was significantly
      up-regulated in men with the (CG + GG) genotype of HSL promoter polymorphism,
      NAFLD and Adiopo-IR in sequence. CONCLUSION: Adipo-IR, rather than HOMA-IR,
      appears to be a consistent insulin resistance index in the study of NAFLD. G
      allele of the HSL promoter polymorphism may contribute the greatest impact
      raising serum triglyceride in a state of glucose intolerance.
AD  - Department of Surgery, Hepatobiliary Division, Kaohsiung Medical University
      Hospital, Kaohsiung, Taiwan. kuoksfo@yahoo.com.tw.
FAU - Hsiao, Pi-Jung
AU  - Hsiao PJ
FAU - Chen, Zhih-Cherg
AU  - Chen ZC
FAU - Hung, Wei-Wen
AU  - Hung WW
FAU - Yang, Yi-Hsin Connie
AU  - Yang YH
FAU - Lee, Mei-Yueh
AU  - Lee MY
FAU - Huang, Jee-Fu
AU  - Huang JF
FAU - Kuo, Kung-Kai
AU  - Kuo KK
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - England
TA  - BMC Med Genet
JT  - BMC medical genetics
JID - 100968552
SB  - IM
PMC - PMC3673851
OID - NLM: PMC3673851
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/09/09 [received]
PHST- 2013/05/09 [accepted]
PHST- 2013/05/20 [aheadofprint]
AID - 1471-2350-14-54 [pii]
AID - 10.1186/1471-2350-14-54 [doi]
PST - epublish
SO  - BMC Med Genet. 2013 May 20;14:54. doi: 10.1186/1471-2350-14-54.

PMID- 23688029
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Linking)
VI  - 45
IP  - 4
DP  - 2013 Jun
TI  - Comparison of normal fasting and one-hour glucose levels as predictors of future 
      diabetes during a 34-year follow-up.
PG  - 336-40
LID - 10.3109/07853890.2013.785233 [doi]
AB  - Abstract Introduction. Early identification of those at risk of developing type 2
      diabetes (T2DM) is essential. We examined how normoglycemic levels of fasting
      blood glucose (FBG) and 1-hour glucose predict the development of diabetes among 
      men initially at low risk. Methods. In the Helsinki Businessmen Study (men born
      in 1919- 1934), 1,145 men had normal FBG (< 5.0 mmol/L) in 1974, and 1-hour
      glucose values available. Multivariate, adjusted models were used to investigate 
      how fasting and 1-hour glucose at baseline related to new-onset diabetes during a
      follow-up of 34 years. Results. The median FBG and 1-hour glucose values at
      baseline were 4.4 and 6.6 mmol/L, respectively. During follow-up, 108 men
      developed diabetes. The risk of incident diabetes was doubled for the highest
      quintile of FBG (fully adjusted relative risk (RR) 2.22, 95% confidence interval 
      (CI) 1.10-4.50), and quadrupled for that of 1-hour glucose (RR 4.23, 95% CI
      2.49-7.17). FBG could not separate the risk for those with higher levels of
      glucose in the range < 5.0 mmol/L, whereas 1-hour glucose discriminated the risk 
      better at higher values. Conclusions. Higher values in the normoglycemic range
      for both fasting and 1-hour glucose predicted long-term incidence of diabetes in 
      healthy middle-aged men.
AD  - Department of Medicine, Geriatric Clinic, University of Helsinki , Helsinki ,
      Finland.
FAU - Strandberg, Arto Y
AU  - Strandberg AY
FAU - Pienimaki, Tuula
AU  - Pienimaki T
FAU - Pitkala, Kaisu H
AU  - Pitkala KH
FAU - Tilvis, Reijo S
AU  - Tilvis RS
FAU - Salomaa, Veikko V
AU  - Salomaa VV
FAU - Strandberg, Timo E
AU  - Strandberg TE
LA  - eng
PT  - Journal Article
DEP - 20130520
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
SB  - IM
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/20 [aheadofprint]
AID - 10.3109/07853890.2013.785233 [doi]
PST - ppublish
SO  - Ann Med. 2013 Jun;45(4):336-40. doi: 10.3109/07853890.2013.785233. Epub 2013 May 
      20.

PMID- 23688014
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
DP  - 2013 May 14
TI  - What Fans the Fire: Insights Into Mechanisms of Leptin in Metabolic
      Syndrome-Associated Heart Diseases.
AB  - Obesity and metabolic syndrome are one of the most devastating risk factors for
      cardiovascular diseases. The obesity gene product leptin plays a central role in 
      the regulation of food intake and energy expenditure. The physiological and
      pathophysiological roles of leptin in cardiovascular system have been
      investigated extensively since its discovery in 1994. In addition to its
      well-established metabolic effects, more recent evidence have depicted a rather
      pivotal role of leptin in inflammation, oxidative stress, endoplasmic reticulum
      stress, apoptosis and tissue remodeling en route to the pathogenesis of type 2
      diabetes mellitus, hypertension, atherosclerosis, and insulin resistance. Under
      physiological condition, leptin is known to reduce appetite, promote energy
      expenditure, increase sympathetic activity, facilitate glucose utilization and
      improve insulin sensitivity. In addition, leptin may regulate cardiac and
      vascular function through a nitric oxide-dependent mechanism. However,
      hyperleptinemia usually occurs with progressively increased body weight and
      metabolic syndrome development, leading to a state of global or selective leptin 
      resistance. Both central and peripheral leptin resistance may be present under
      pathophysiological conditions such as inflammation, insulin resistance,
      hyperlipidemia and a cadre of other cardiovascular diseases including
      hypertension, atherosclerosis, obesity, ischemic heart disease and heart failure.
      In this review, we will discuss cardiovascular actions of leptin related to
      various components of metabolic syndrome. Particular emphasis will be given to
      insights derived from therapeutic interventions with lifestyle modification,
      cardiovascular drugs, anti-diabetic and anti-obesity drugs.
AD  - Center for Cardiovascular Research and Alternative Medicine, University of
      Wyoming College of Health Sciences Laramie, WY 82071, USA. jren@uwyo.edu.
FAU - Dong, Maolong
AU  - Dong M
FAU - Ren, Jun
AU  - Ren J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/04/03 [received]
PHST- 2013/05/13 [accepted]
AID - CPD-EPUB-20130514-8 [pii]
PST - aheadofprint
SO  - Curr Pharm Des. 2013 May 14.

PMID- 23687960
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
DP  - 2013 May 15
TI  - Iron Overload and Glucose Metabolism in Subjects With beta-Thalassaemia Major :
      An Overview.
AB  - Thalassaemia is one of the most common genetic disorders caused by a reduction of
      the globin chains leading to chronic haemolytic anaemia from birth. The mainstay 
      of treatment is blood transfusion to maintain adequate levels of the haemoglobin.
      Iron overload in beta-thalassaemia major patients is secondary to multiple blood 
      transfusions and increased iron absorption. Excess iron potentially catalyzes
      free-radicals generation and impairment in cellular function and integrity.
      Extensive iron-induced injury develops in the heart, liver, pancreas and
      endocrine system. Pancreatic iron loading in thalassaemia major patients begins
      at early childhood, and the prevalence of diabetes mellitus (DM) ranges from 6.4%
      to 14.1% in cross-sectional studies. Both insulin resistance and decreased
      insulin secretion contribute to DM in thalassaemia major patients. This has been 
      shown by oral glucose tolerance test, euglycemic insulin clamp, homeostatic model
      assessment, intravenous glucose tolerance test and continuous glucose monitoring 
      system. The prevalence of DM in thalassaemia has been shown to correlate with
      serum ferritin concentration, hepatitis C infection, and pancreatic and cardiac
      iron measured by imaging techniques. Therefore the incidence of disturbed glucose
      homeostasis depends on adherence to chelation treatment, the adequacy of the
      dosage, the chemical properties of the chelating agent and the prevention of
      liver infections.
AD  - Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, 44121 Ferrara
      (Italy). vdesanctis@libero.it.
FAU - De Sanctis, Vincenzo
AU  - De Sanctis V
FAU - Soliman, Ashraf
AU  - Soliman A
FAU - Yassin, Mohamed
AU  - Yassin M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
PHST- 2012/11/05 [received]
PHST- 2013/05/01 [revised]
PHST- 2013/05/02 [accepted]
AID - CDR-EPUB-20130515-1 [pii]
PST - aheadofprint
SO  - Curr Diabetes Rev. 2013 May 15.

PMID- 23687948
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
DP  - 2013 May 21
TI  - Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA
      and spikes of high glucose values in the third trimester.
AB  - Abstract Objective: To analyse data from a randomised, controlled study of
      prandial insulin aspart vs. human insulin, both with NPH insulin, in pregnant
      women with type 1 diabetes for potential factors predicting poor pregnancy
      outcomes. Research design/methods: Post hoc analysis including 91 subjects
      randomised prior to pregnancy with known outcome in early pregnancy and 259
      subjects randomised prior to pregnancy/during pregnancy of <10 weeks' gestation
      with known late-pregnancy outcomes. Poor early-pregnancy outcomes included fetal 
      loss <22 gestational weeks and/or congenital malformation (n = 18). Poor
      late-pregnancy outcomes included: composite endpoint including pre-eclampsia,
      preterm delivery and perinatal death (n = 78); preterm delivery (n = 63); and
      excessive fetal growth (n = 88). Results: 18 patients experienced a
      malformed/lost fetus in early pregnancy - none preceded by severe hypoglycaemia. 
      Albuminuria in early pregnancy was a significant predictor of poor late-pregnancy
      outcome (composite endpoint; p = 0.012). In the third trimester, elevated HbA1c, 
      >/=1 plasma glucose (PG) measurement >11 mmol/L (198 mg/dL) and %PG values
      outside 3.9-7.0 mmol/L (70-126 mg/dL) were significant predictors of poor
      late-pregnancy outcomes (all p < 0.05). Conclusions: Elevated HbA1c, high glucose
      spikes and out-of-range %PG in the third trimester, and albuminuria in early
      pregnancy, are associated with poor late-pregnancy outcomes.
AD  - Center for Pregnant Women with Diabetes, Departments of Endocrinology and
      Obstetrics, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Damm, Peter
AU  - Damm P
FAU - Mersebach, Henriette
AU  - Mersebach H
FAU - Rastam, Jacob
AU  - Rastam J
FAU - Kaaja, Risto
AU  - Kaaja R
FAU - Hod, Moshe
AU  - Hod M
FAU - McCance, David R
AU  - McCance DR
FAU - Mathiesen, Elisabeth R
AU  - Mathiesen ER
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the
      European Association of Perinatal Medicine, the Federation of Asia and Oceania
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
EDAT- 2013/05/22 06:00
MHDA- 2013/05/22 06:00
CRDT- 2013/05/22 06:00
AID - 10.3109/14767058.2013.806896 [doi]
PST - aheadofprint
SO  - J Matern Fetal Neonatal Med. 2013 May 21.

PMID- 23687558
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1948-5875 (Print)
VI  - 4
IP  - 5
DP  - 2013 May 9
TI  - Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40)
      Agonist for Treatment of Type 2 Diabetes.
PG  - 441-445
AB  - Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin
      secretion from pancreatic beta-cells and currently attracts high interest as a
      new target for the treatment of type 2 diabetes. We here report the discovery of 
      a highly potent FFA1 agonist with favorable physicochemical and pharmacokinetic
      properties. The compound efficiently normalizes glucose tolerance in diet-induced
      obese mice, an effect that is fully sustained after 29 days of chronic dosing.
AD  - Department of Physics, Chemistry and Pharmacy, University of Southern Denmark ,
      Campusvej 55, DK-5230 Odense M, Denmark.
FAU - Christiansen, Elisabeth
AU  - Christiansen E
FAU - Hansen, Steffen V F
AU  - Hansen SV
FAU - Urban, Christian
AU  - Urban C
FAU - Hudson, Brian D
AU  - Hudson BD
FAU - Wargent, Edward T
AU  - Wargent ET
FAU - Grundmann, Manuel
AU  - Grundmann M
FAU - Jenkins, Laura
AU  - Jenkins L
FAU - Zaibi, Mohamed
AU  - Zaibi M
FAU - Stocker, Claire J
AU  - Stocker CJ
FAU - Ullrich, Susanne
AU  - Ullrich S
FAU - Kostenis, Evi
AU  - Kostenis E
FAU - Kassack, Matthias U
AU  - Kassack MU
FAU - Milligan, Graeme
AU  - Milligan G
FAU - Cawthorne, Michael A
AU  - Cawthorne MA
FAU - Ulven, Trond
AU  - Ulven T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130408
TA  - ACS Med Chem Lett
JT  - ACS medicinal chemistry letters
JID - 101521073
PMC - PMC3654565
OTO - NOTNLM
OT  - FFA1 agonist
OT  - GPR40 agonist
OT  - TUG-770
OT  - Type 2 diabetes
OT  - free fatty acid receptor
OT  - insulin secretagogue
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/17 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1021/ml4000673 [doi]
PST - ppublish
SO  - ACS Med Chem Lett. 2013 May 9;4(5):441-445. Epub 2013 Apr 8.

PMID- 23687511
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130520
DCOM- 20130521
LR  - 20130522
IS  - 1664-5529 (Electronic)
VI  - 3
IP  - 1
DP  - 2013 Jan
TI  - Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? 
      A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for
      Renoprotective Agents.
PG  - 36-49
LID - 10.1159/000351044 [doi]
AB  - In the June 2011 issue of the New England Journal of Medicine, the BEAM
      (Bardoxolone Methyl Treatment: Renal Function in CKD/Type 2 Diabetes) trial
      investigators rekindled new interest and also some controversy regarding the
      concept of renoprotection and the role of renoprotective agents, when they
      reported significant increases in the mean estimated glomerular filtration rate
      (eGFR) in diabetic chronic kidney disease (CKD) patients with an eGFR of 20-45
      ml/min/1.73 m(2) of body surface area at enrollment who received the trial drug
      bardoxolone methyl versus placebo. Unfortunately, subsequent phase IIIb trials
      failed to show that the drug is a safe alternative renoprotective agent. Current 
      renoprotection paradigms depend wholly and entirely on angiotensin blockade;
      however, these agents [angiotensin converting enzyme (ACE) inhibitors and
      angiotensin receptor blockers (ARBs)] have proved to be imperfect renoprotective 
      agents. In this review, we examine the mechanistic limitations of the various
      previous randomized controlled trials on CKD renoprotection, including the
      paucity of veritable, elaborate and systematic assessment methods for the
      documentation and reporting of individual patient-level, drug-related adverse
      events. We review the evidence base for the presence of putative, multiple
      independent and unrelated pathogenetic mechanisms that drive (diabetic and
      non-diabetic) CKD progression. Furthermore, we examine the validity, or lack
      thereof, of the hyped notion that the blockade of a single molecule (angiotensin 
      II), which can only antagonize the angiotensin cascade, would veritably
      successfully, consistently and unfailingly deliver adequate and qualitative
      renoprotection results in (diabetic and non-diabetic) CKD patients. We clearly
      posit that there is this overarching impetus to arrive at the inference that
      multiple, disparately diverse and independent pathways, including any veritable
      combination of the mechanisms that we examine in this review, and many more
      others yet to be identified, do concurrently and asymmetrically contribute to CKD
      initiation and propagation to end-stage renal disease (ESRD) in our CKD patients.
      We conclude that current knowledge of CKD initiation and progression to ESRD, the
      natural history of CKD and the impacts of acute kidney injury on this continuum
      remain in their infancy and call for more research. Finally, we suggest a new
      classification scheme for renoprotective agents: (1) the single-pathway blockers 
      that block a single putative pathogenetic pathway involved in CKD progression, as
      typified by ACE inhibitors and/or ARBs, and (2) the multiple-pathway blockers
      that are able to block or antagonize the effects of multiple pathogenetic
      pathways through their ability to simultaneously block, downstream, the effects
      of several pathways or mechanisms of CKD to ESRD progression and could therefore 
      concurrently interfere with several unrelated upstream pathways or mechanisms. We
      surmise that maybe the ideal and truly renoprotective agent, clearly a
      multiple-pathway blocker, is on the horizon. This calls for more research efforts
      from all.
AD  - College of Medicine, Mayo Clinic, Rochester, Minn., and Mayo Health System
      Practice-Based Research Network, and Department of Nephrology, Mayo Clinic Health
      System, Eau Claire, Wisc., USA.
FAU - Onuigbo, Macaulay
AU  - Onuigbo M
LA  - eng
PT  - Journal Article
DEP - 20130427
PL  - Switzerland
TA  - Nephron Extra
JT  - Nephron extra
JID - 101571879
PMC - PMC3656681
OID - NLM: PMC3656681
OTO - NOTNLM
OT  - Angiotensin converting enzyme inhibitors
OT  - Angiotensin receptor blockers
OT  - Chronic kidney disease
OT  - Diabetes mellitus
OT  - Novel classification scheme
OT  - Renoprotection
OT  - Renoprotective agents
OT  - Revisionist view
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:01
CRDT- 2013/05/21 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/27 [epublish]
AID - 10.1159/000351044 [doi]
AID - nne-0003-0036 [pii]
PST - epublish
SO  - Nephron Extra. 2013 Apr 27;3(1):36-49. doi: 10.1159/000351044. Print 2013 Jan.

PMID- 23687510
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130520
DCOM- 20130521
LR  - 20130522
IS  - 1664-5510 (Electronic)
IS  - 1664-5510 (Linking)
VI  - 3
IP  - 1
DP  - 2013 Jan
TI  - Hyponatremia - a rare but serious complication of amiodarone: a case report and
      review of the literature.
PG  - 46-50
LID - 10.1159/000350910 [doi]
AB  - INTRODUCTION: Hyponatremia secondary to the syndrome of inappropriate
      antidiuretic hormone secretion (SIADH) during amiodarone therapy is a rare but
      potentially lethal adverse effect. We report a case of severe hyponatremia
      associated with amiodarone, and discuss its clinical implications. CASE REPORT:
      An 84-year-old Caucasian man with a past medical history of hypertension and
      diabetes was admitted to the hospital with a non-ST elevation myocardial
      infarction. He underwent coronary artery bypass graft and developed atrial
      fibrillation on postoperative day 2. A loading dose of amiodarone followed by a
      maintenance dose was started. The serum sodium level was 136 mmol/l at discharge 
      and subsequently decreased to 105 mmol/l 11 days later, at which time the patient
      represented with altered mental status. The diagnosis of SIADH was made based on 
      euvolemic hypoosmotic hyponatremia, lack of any other medication known to cause
      SIADH and urine that was less than maximally dilute. The serum sodium increased
      gradually to 123 mmol/l after 36 h of treatment with hypertonic saline,
      demeclocycline and fluid restriction. CONCLUSION: SIADH-induced hyponatremia
      associated with amiodarone occurs rarely. Since severe hyponatremia is associated
      with significant neurological damage and mortality, clinicians should carefully
      monitor serum sodium during amiodarone therapy.
AD  - Department of Medicine, St. Elizabeth Health Center, Youngstown, Ohio, USA.
FAU - Pham, Linh
AU  - Pham L
FAU - Shaer, Andrea J
AU  - Shaer AJ
FAU - Marnejon, Thomas
AU  - Marnejon T
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - Switzerland
TA  - Case Rep Nephrol Urol
JT  - Case reports in nephrology and urology
JID - 101591817
PMC - PMC3656677
OID - NLM: PMC3656677
OTO - NOTNLM
OT  - Amiodarone
OT  - Hyponatremia
OT  - Side effect
OT  - Syndrome of inappropriate antidiuretic hormone secretion
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:01
CRDT- 2013/05/21 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/19 [epublish]
AID - 10.1159/000350910 [doi]
AID - cru-0003-0046 [pii]
PST - epublish
SO  - Case Rep Nephrol Urol. 2013 Apr 19;3(1):46-50. doi: 10.1159/000350910. Print 2013
      Jan.

PMID- 23687478
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130520
DCOM- 20130521
LR  - 20130522
IS  - 1568-4156 (Electronic)
VI  - 13
DP  - 2013 Jan
TI  - Evaluation of complex integrated care programmes: the approach in North West
      London.
PG  - e006
AB  - BACKGROUND: Several local attempts to introduce integrated care in the English
      National Health Service have been tried, with limited success. The Northwest
      London Integrated Care Pilot attempts to improve the quality of care of the
      elderly and people with diabetes by providing a novel integration process across 
      primary, secondary and social care organisations. It involves predictive risk
      modelling, care planning, multidisciplinary management of complex cases and an
      information technology tool to support information sharing. This paper sets out
      the evaluation approach adopted to measure its effect. STUDY DESIGN: We present a
      mixed methods evaluation methodology. It includes a quantitative approach
      measuring changes in service utilization, costs, clinical outcomes and quality of
      care using routine primary and secondary data sources. It also contains a
      qualitative component, involving observations, interviews and focus groups with
      patients and professionals, to understand participant experiences and to
      understand the pilot within the national policy context. THEORY AND DISCUSSION:
      This study considers the complexity of evaluating a large, multi-organisational
      intervention in a changing healthcare economy. We locate the evaluation within
      the theory of evaluation of complex interventions. We present the specific
      challenges faced by evaluating an intervention of this sort, and the responses
      made to mitigate against them. CONCLUSIONS: We hope this broad, dynamic and
      responsive evaluation will allow us to clarify the contribution of the pilot, and
      provide a potential model for evaluation of other similar interventions. Because 
      of the priority given to the integrated agenda by governments internationally,
      the need to develop and improve strong evaluation methodologies remains
      strikingly important.
AD  - Department of Primary Care and Public Health, Reynolds Building, Charing Cross
      Campus, Imperial College London, London, UK W6 8RP.
FAU - Greaves, Felix
AU  - Greaves F
FAU - Pappas, Yannis
AU  - Pappas Y
FAU - Bardsley, Martin
AU  - Bardsley M
FAU - Harris, Matthew
AU  - Harris M
FAU - Curry, Natasha
AU  - Curry N
FAU - Holder, Holly
AU  - Holder H
FAU - Blunt, Ian
AU  - Blunt I
FAU - Soljak, Michael
AU  - Soljak M
FAU - Gunn, Laura
AU  - Gunn L
FAU - Majeed, Azeem
AU  - Majeed A
FAU - Car, Josip
AU  - Car J
LA  - eng
PT  - Journal Article
DEP - 20130308
PL  - Netherlands
TA  - Int J Integr Care
JT  - International journal of integrated care
JID - 101214424
PMC - PMC3653284
OID - NLM: PMC3653284
OTO - NOTNLM
OT  - complexity
OT  - delivery
OT  - evaluation
OT  - integrated
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:01
CRDT- 2013/05/21 06:00
PHST- 2013 [ppublish]
PHST- 2012/06/22 [received]
PHST- 2012/11/01 [revised]
PHST- 2013/01/15 [accepted]
PHST- 2013/03/08 [epublish]
PST - epublish
SO  - Int J Integr Care. 2013 Mar 8;13:e006. Print 2013 Jan.

PMID- 23687360
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1533-3450 (Electronic)
IS  - 1046-6673 (Linking)
DP  - 2013 May 16
TI  - Renal Lesions Predict Progression of Diabetic Nephropathy in Type 1 Diabetes.
AB  - Whether early glomerular, tubulointerstitial, vascular, and global
      glomerulosclerotic lesions can predict progression of diabetic nephropathy is not
      well defined. Here, we sought to determine whether renal structural parameters
      predict the development of proteinuria or ESRD after long-term follow-up. We
      measured several renal structures in kidney biopsies from 94 normoalbuminuric
      patients with longstanding type 1 diabetes using unbiased morphometric methods.
      Greater width of the glomerular basement membrane and higher levels of glycated
      hemoglobin were independent predictors of progression to diabetic nephropathy in 
      this normoalbuminuric cohort. Moreover, none of these patients with type 1
      diabetes who had glomerular basement membrane widths within the normal range
      developed proteinuria and/or ESRD. In conclusion, careful quantitative assessment
      of kidney biopsies in normoalbuminuric patients with type 1 diabetes adds
      substantially to the prediction of progression to clinical diabetic nephropathy.
AD  - Departments of *Medicine and.
FAU - Caramori, M Luiza
AU  - Caramori ML
FAU - Parks, Alicia
AU  - Parks A
FAU - Mauer, Michael
AU  - Mauer M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - J Am Soc Nephrol
JT  - Journal of the American Society of Nephrology : JASN
JID - 9013836
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - ASN.2012070739 [pii]
AID - 10.1681/ASN.2012070739 [doi]
PST - aheadofprint
SO  - J Am Soc Nephrol. 2013 May 16.

PMID- 23687356
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1533-3450 (Electronic)
IS  - 1046-6673 (Linking)
DP  - 2013 May 16
TI  - A Combined Epidemiologic and Metabolomic Approach Improves CKD Prediction.
AB  - Metabolomic approaches have begun to catalog the metabolic disturbances that
      accompany CKD, but whether metabolite alterations can predict future CKD is
      unknown. We performed liquid chromatography/mass spectrometry-based metabolite
      profiling on plasma from 1434 participants in the Framingham Heart Study (FHS)
      who did not have CKD at baseline. During the following 8 years, 123 individuals
      developed CKD, defined by an estimated GFR of <60 ml/min per 1.73 m2. Numerous
      metabolites were associated with incident CKD, including 16 that achieved the
      Bonferroni-adjusted significance threshold of P</=0.00023. To explore how the
      human kidney modulates these metabolites, we profiled arterial and renal venous
      plasma from nine individuals. Nine metabolites that predicted CKD in the FHS
      cohort decreased more than creatinine across the renal circulation, suggesting
      that they may reflect non-GFR-dependent functions, such as renal metabolism and
      secretion. Urine isotope dilution studies identified citrulline and choline as
      markers of renal metabolism and kynurenic acid as a marker of renal secretion. In
      turn, these analytes remained associated with incident CKD in the FHS cohort,
      even after adjustment for eGFR, age, sex, diabetes, hypertension, and proteinuria
      at baseline. Addition of a multimarker metabolite panel to clinical variables
      significantly increased the c-statistic (0.77-0.83, P<0.0001); net
      reclassification improvement was 0.78 (95% confidence interval, 0.60 to 0.95;
      P<0.0001). Thus, the addition of metabolite profiling to clinical data may
      significantly improve the ability to predict whether an individual will develop
      CKD by identifying predictors of renal risk that are independent of estimated
      GFR.
AD  - *Nephrology Division.
FAU - Rhee, Eugene P
AU  - Rhee EP
FAU - Clish, Clary B
AU  - Clish CB
FAU - Ghorbani, Anahita
AU  - Ghorbani A
FAU - Larson, Martin G
AU  - Larson MG
FAU - Elmariah, Sammy
AU  - Elmariah S
FAU - McCabe, Elizabeth
AU  - McCabe E
FAU - Yang, Qiong
AU  - Yang Q
FAU - Cheng, Susan
AU  - Cheng S
FAU - Pierce, Kerry
AU  - Pierce K
FAU - Deik, Amy
AU  - Deik A
FAU - Souza, Amanda L
AU  - Souza AL
FAU - Farrell, Laurie
AU  - Farrell L
FAU - Domos, Carly
AU  - Domos C
FAU - Yeh, Robert W
AU  - Yeh RW
FAU - Palacios, Igor
AU  - Palacios I
FAU - Rosenfield, Kenneth
AU  - Rosenfield K
FAU - Vasan, Ramachandran S
AU  - Vasan RS
FAU - Florez, Jose C
AU  - Florez JC
FAU - Wang, Thomas J
AU  - Wang TJ
FAU - Fox, Caroline S
AU  - Fox CS
FAU - Gerszten, Robert E
AU  - Gerszten RE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - J Am Soc Nephrol
JT  - Journal of the American Society of Nephrology : JASN
JID - 9013836
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - ASN.2012101006 [pii]
AID - 10.1681/ASN.2012101006 [doi]
PST - aheadofprint
SO  - J Am Soc Nephrol. 2013 May 16.

PMID- 23687126
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1464-3685 (Electronic)
IS  - 0300-5771 (Linking)
DP  - 2013 May 18
TI  - Cohort Profile: The Japan Diabetes Complications Study: a long-term follow-up of 
      a randomised lifestyle intervention study of type 2 diabetes.
AB  - The Japan Diabetes Complications Study, a randomised lifestyle intervention study
      of type 2 diabetes conducted at 59 institutes throughout Japan that enrolled 2033
      eligible patients from January 1995 to March 1996, was directed at: (i)
      determining the incidence and progression rates of complications of diabetes;
      (ii) exploring clinical risk factors for complications of diabetes; and (iii)
      determining the association between lifestyle factors, including diet and
      physical activity, and complications of diabetes, in addition to comparing, in a 
      randomised manner, the effects on type 2 diabetes of an extensive lifestyle
      intervention and conventional treatment. The protocol for the study originally
      specified four study populations according to primary outcomes, consisting of:
      (1) a macroangiopathy group (N = 1771); (ii) a nephropathy group (N = 1607);
      (iii) a retinopathy-incident group (N = 1221); and (iv) a retinopathy-progression
      group (N = 410). The primary outcomes were: (i) development of retinopathy; (ii) 
      progression of retinopathy; (iii) development of overt nephropathy; and (iv)
      occurrence of macroangiopathic events including proven coronary heart disease and
      stroke. The study was originally planned to follow patients for 8 years, and an
      extended follow-up is ongoing. Information about primary outcomes, laboratory
      tests, and other clinical variables for each patient was collected at a central
      data centre through an annual report from each investigator. Additionally,
      extensive lifestyle surveys were conducted at baseline and 5 years after the
      beginning of the study intervention in both the intervention and conventional
      treatment groups. A description of the occurrence of complications of diabetes
      and of all-cause mortality, provided in this paper, demonstrated a clear
      gender-based difference in cardiovascular disease and all-cause mortality. The
      data set of the study is not freely available, but collaborative ideas are
      welcome. Potential collaborators should discuss ideas informally with the
      principal investigator by e-mail.
AD  - Department of Clinical Trial Design and Management, Translational Research
      Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto
      University Graduate School of Medicine, Kyoto, Japan, Department of
      Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan,
      Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata,
      Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama
      Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life
      Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba 
      Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of
      Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
FAU - Tanaka, Shiro
AU  - Tanaka S
FAU - Tanaka, Sachiko
AU  - Tanaka S
FAU - Iimuro, Satoshi
AU  - Iimuro S
FAU - Yamashita, Hidetoshi
AU  - Yamashita H
FAU - Katayama, Shigehiro
AU  - Katayama S
FAU - Ohashi, Yasuo
AU  - Ohashi Y
FAU - Akanuma, Yasuo
AU  - Akanuma Y
FAU - Yamada, Nobuhiro
AU  - Yamada N
FAU - Sone, Hirohito
AU  - Sone H
CN  - on behalf of the Japan Diabetes Complications Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Int J Epidemiol
JT  - International journal of epidemiology
JID - 7802871
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - dietary survey
OT  - nephropathy
OT  - physical activity
OT  - retinopathy
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - dyt057 [pii]
AID - 10.1093/ije/dyt057 [doi]
PST - aheadofprint
SO  - Int J Epidemiol. 2013 May 18.

PMID- 23687105
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Integrated care scheme for older people and people with diabetes has not reduced 
      emergency admissions in its first year.
PG  - f3255
LID - 10.1136/bmj.f3255 [doi]
LID - bmj.f3255 [pii]
AD  - BMJ.
FAU - Iacobucci, Gareth
AU  - Iacobucci G
LA  - eng
PT  - Journal Article
DEP - 20130517
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PST - epublish
SO  - BMJ. 2013 May 17;346:f3255. doi: 10.1136/bmj.f3255.

PMID- 23687074
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1468-3296 (Electronic)
IS  - 0040-6376 (Linking)
DP  - 2013 May 18
TI  - Cavitating pulmonary nodules growing in a favourable medium.
LID - 10.1136/thoraxjnl-2013-203663 [doi]
AB  - Pulmonary involvement due to Nocardia is generally associated with cell-mediated 
      immunosuppressive conditions and risk factors like HIV infection,
      lymphoproliferative diseases, diabetes and steroid therapy. Pulmonary alveolar
      proteinosis (PAP) is a well-known risk factor for Nocardia infection and is
      usually easily detectable on a high-resolution CT scan as ground-glass opacities 
      with geographical distribution, crazy paving pattern and varying amounts of
      pulmonary consolidation. Pulmonary nocardiosis should be considered in apparently
      immunocompetent patients who present with PAP and a suspected opportunistic
      infection. We report a case of pulmonary nocardiosis occurring in a patient with 
      radiologically inapparent PAP. The serendipitous finding of PAP on transbronchial
      biopsy further increased the likelihood of a Nocardia infection, subsequently
      confirmed by a surgical biopsy.
AD  - Pulmonology Unit, Department of Cardiology, Thoracic and Vascular Surgery and
      Critical Care Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a
      Carattere Scientifico, , Reggio Emilia, Italy.
FAU - Carbonelli, Cristiano
AU  - Carbonelli C
FAU - Prati, Francesca
AU  - Prati F
FAU - Carretto, Edoardo
AU  - Carretto E
FAU - Cavazza, Alberto
AU  - Cavazza A
FAU - Spaggiari, Lucia
AU  - Spaggiari L
FAU - Magnani, Giacomo
AU  - Magnani G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Thorax
JT  - Thorax
JID - 0417353
OTO - NOTNLM
OT  - Bronchoscopy
OT  - GM-CSF autoantibody
OT  - Imaging/CT MRI etc
OT  - Opportunist lung infections
OT  - Pulmonary alveolar proteinosis
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - thoraxjnl-2013-203663 [pii]
AID - 10.1136/thoraxjnl-2013-203663 [doi]
PST - aheadofprint
SO  - Thorax. 2013 May 18. doi: 10.1136/thoraxjnl-2013-203663.

PMID- 23686896
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 2047-2927 (Electronic)
DP  - 2013 May 20
TI  - Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy 
      for non-metastatic prostate cancer: implementation of standardized management
      guidelines.
LID - 10.1111/j.2047-2927.2013.00093.x [doi]
AB  - Our objective was to evaluate the effectiveness of implementing standardized
      guidelines to mitigate metabolic and bone side effects of androgen deprivation
      therapy (ADT) in men with non-metastatic prostate cancer. We conducted a 2-year
      prospective cohort study at a tertiary referral teaching hospital. Overall, 236
      men (mean age 69.8 +/- 7.1) commencing ADT for non-metastatic prostate cancer
      attended a baseline clinic visit between 2007 and 2011, and 153 men were eligible
      for follow-up after 2 years of continuous ADT. Of these, 113 men had data
      available for analysis at 2 years. At baseline, 87% of the men were overweight or
      obese, 61% had hypertension, 56% had hypercholesterolaemia, 27% prior
      cardiovascular disease, 11% osteoporosis and 40% osteopaenia. After 2 years of
      ADT, there was an increase in waist circumference (+2.8 +/- 6.3 cm, p = 0.002),
      and, in men without diabetes, in HbA1c (+0.13 +/- 0.34%, p = 0.019). Despite
      this, due to treatment, there were significant reductions in total cholesterol
      (-0.35 +/- 1.00 mmol/L, p < 0.001), and blood pressure (systolic -7.6 +/- 19.3
      mmHg; diastolic -4.7 +/- 11.6 mmHg, p < 0.001). After 2 years, men not receiving 
      anti-resorptive therapy experienced a significant decline in lumbar spine (-0.042
      +/- 0.134 g/cm2 , p = 0.012) and total hip bone mineral density (BMD) (-0.026 +/-
      0.036 g/cm2 , p < 0.001), whereas bisphosphonate treatment maintained stable BMD.
      Prevalence of anaemia increased from 13.8 to 32.5%. Older age independently
      predicted a greater drop in haemoglobin (p = 0.005). We conclude that a
      structured approach to assess and treat men undergoing ADT effectively improves
      cardiovascular risk factors and prevents bone decay. Larger studies are needed to
      determine effects on cardiovascular outcomes, fracture prevention and survival.
CI  - (c) 2013 American Society of Andrology and European Academy of Andrology.
AD  - Department of Medicine Austin Health, The University of Melbourne, Heidelberg,
      Vic., Australia; Department of Endocrinology, Austin Health, Heidelberg, Vic.,
      Australia.
FAU - Cheung, A S
AU  - Cheung AS
FAU - Pattison, D
AU  - Pattison D
FAU - Bretherton, I
AU  - Bretherton I
FAU - Hoermann, R
AU  - Hoermann R
FAU - Lim Joon, D
AU  - Lim Joon D
FAU - Ho, E
AU  - Ho E
FAU - Jenkins, T
AU  - Jenkins T
FAU - Hamilton, E J
AU  - Hamilton EJ
FAU - Bate, K
AU  - Bate K
FAU - Chan, I
AU  - Chan I
FAU - Zajac, J D
AU  - Zajac JD
FAU - Grossmann, M
AU  - Grossmann M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Andrology
JT  - Andrology
JID - 101585129
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/13 [received]
PHST- 2013/03/22 [revised]
PHST- 2013/04/02 [accepted]
AID - 10.1111/j.2047-2927.2013.00093.x [doi]
PST - aheadofprint
SO  - Andrology. 2013 May 20. doi: 10.1111/j.2047-2927.2013.00093.x.

PMID- 23686810
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 18
TI  - Automated Analysis of Diabetic Retinopathy Images: Principles, Recent
      Developments, and Emerging Trends.
AB  - Diabetic retinopathy (DR) is a vision-threatening complication of diabetes.
      Timely diagnosis and intervention are essential for treatment that reduces the
      risk of vision loss. A good color retinal (fundus) photograph can be used as a
      surrogate for face-to-face evaluation of DR. The use of computers to assist or
      fully automate DR evaluation from retinal images has been studied for many years.
      Early work showed promising results for algorithms in detecting and classifying
      DR pathology. Newer techniques include those that adapt machine learning
      technology to DR image analysis. Challenges remain, however, that must be
      overcome before fully automatic DR detection and analysis systems become
      practical clinical tools.
AD  - School of Computing, Informatics & Decision Systems Engineering, Arizona State
      University, 699 S Mill AVE #553, Tempe, AZ, 85281, USA, Baoxin.Li@asu.edu.
FAU - Li, Baoxin
AU  - Li B
FAU - Li, Helen K
AU  - Li HK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.1007/s11892-013-0393-9 [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 18.

PMID- 23686641
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1527-3350 (Electronic)
IS  - 0270-9139 (Linking)
DP  - 2013 May 17
TI  - Effect of type 2 diabetes on risk for hepatocellular carcinoma in chronic
      hepatitis C.
LID - 10.1002/hep.26456 [doi]
AD  - Department of Hepatology and Okinaka Memorial Institute for Medical Research,
      Toranomon Hospital, Tokyo, Japan.
FAU - Arase, Yasuji
AU  - Arase Y
FAU - Kobayashi, Mariko
AU  - Kobayashi M
FAU - Kumada, Hiromitsu
AU  - Kumada H
LA  - ENG
PT  - LETTER
DEP - 20130517
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/03/14 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/07 [accepted]
AID - 10.1002/hep.26456 [doi]
PST - aheadofprint
SO  - Hepatology. 2013 May 17. doi: 10.1002/hep.26456.

PMID- 23686640
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2013 May 18
TI  - New technologies aiding dietary programmes for weight control: the oral glucose
      spray.
AB  - To determine whether the administration of small amounts of glucose through an
      oral spray device (GSD) facilitates weight loss in overweight/obese subjects
      involved in a lifestyle modification programme. We randomly assigned 56
      overweight/obese subjects to either the treatment group (n = 32) or the control
      group (n = 24). All subjects in both groups followed a structured dietary
      programme of 6,280.2 kJ (1,500 kcal)/day and exercised minimum 150 min a week and
      were followed-up for a period of 60 days. Subjects assigned to the treatment
      group were asked to spray, during early symptoms of neuroglycopenia, 10 puffs by 
      GSD. GSD is a device that delivers to the buccal mucosa 50 mg of glucose per
      puff. A mean weight loss of 3.5 +/- 3.0 kg in GSD-treated group compared to 1.7
      +/- 2.1 kg in control group (p = 0.01) was observed. Significant differences
      regarding reduction of BMI (-1.3 +/- 1.0 vs -0.7 +/- 0.8 kg/m2; p = 0.01) and
      waist circumference (-3.5 +/- 3.2 vs -0.9 +/- 3.5 cm; p = 0.02) were also
      detected. A short-term use of GSD, in association with dietary restriction and
      exercise, is helpful in improving weight loss and in reducing waist circumference
      in overweight/obese subjects.
AD  - Department of Endocrinology and Diabetes, University Campus Bio-Medico of Rome,
      Via Alvaro del Portillo, 21, 00128, Rome, Italy, m.khazrai@unicampus.it.
FAU - Khazrai, Yeganeh Manon
AU  - Khazrai YM
FAU - Maddaloni, Ernesto
AU  - Maddaloni E
FAU - Altomare, Maria
AU  - Altomare M
FAU - Cacciapaglia, Fabio
AU  - Cacciapaglia F
FAU - Pozzilli, Paolo
AU  - Pozzilli P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Endocrine
JT  - Endocrine
JID - 9434444
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/26 [received]
PHST- 2013/05/13 [accepted]
PHST- 2013/05/18 [aheadofprint]
AID - 10.1007/s12020-013-9987-x [doi]
PST - aheadofprint
SO  - Endocrine. 2013 May 18.

PMID- 23686639
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2013 May 18
TI  - Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem
      cells from umbilical cord with sitagliptin in type 2 diabetic rats.
AB  - Type 2 diabetes mellitus is the most common endocrine disease all over the world,
      while existing therapies can only ameliorate hyperglycemia or temporarily improve
      the response to insulin in target tissues, they cannot retard or improve the
      progressive beta-cell dysfunction persistently. Combined therapy of stem cells
      and sitagliptin might resolve this problem, we verified this hypothesis in a
      diabetic rat model. Except ten Wistar rats in normal control group, diabetic rats
      were divided into diabetic control group, WJ-MSCs group, sitagliptin group and
      WJ-MSCs + sitagliptin group and received homologous therapy. Ten weeks after
      therapy, diabetic symptoms, FPG and GHbA1c in WJ-MSCs group, sitagliptin group
      and WJ-MSCs + sitagliptin group were significantly less than those in diabetic
      control group (P < 0.05), while fasting C-peptide and number of beta cells in
      WJ-MSCs group and WJ-MSCs + sitagliptin group was significantly higher than those
      in diabetic control and sitagliptin group (P < 0.01). Glucagon and number of
      alpha cells in sitagliptin group and WJ-MSCs + sitagliptin group were
      significantly lower than those in WJ-MSCs group and diabetic control group (P <
      0.01). No symptoms of rejection and toxic effect were observed. Combined therapy 
      of WJ-MSCs and sitagliptin can effectively ameliorate hyperglycemia, promote
      regeneration of islet beta cells and suppress generation of islet alpha cells in 
      diabetic rats, presenting a new therapy for type 2 diabetes although the exact
      mechanisms are unclear.
AD  - Stem Cell Research Center, The Affiliated Hospital of Medical College, Qingdao
      University, No. 16, Jiangsu Road, Qingdao, 266003, China.
FAU - Hu, Jianxia
AU  - Hu J
FAU - Wang, Fang
AU  - Wang F
FAU - Sun, Ruixia
AU  - Sun R
FAU - Wang, Zhongchao
AU  - Wang Z
FAU - Yu, Xiaolong
AU  - Yu X
FAU - Wang, Li
AU  - Wang L
FAU - Gao, Hong
AU  - Gao H
FAU - Zhao, Wenjuan
AU  - Zhao W
FAU - Yan, Shengli
AU  - Yan S
FAU - Wang, Yangang
AU  - Wang Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Endocrine
JT  - Endocrine
JID - 9434444
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/06 [received]
PHST- 2013/05/07 [accepted]
PHST- 2013/05/18 [aheadofprint]
AID - 10.1007/s12020-013-9984-0 [doi]
PST - aheadofprint
SO  - Endocrine. 2013 May 18.

PMID- 23686638
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May-Jun
TI  - Looking ahead.
PG  - 278
LID - 10.1177/0145721713491075 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
SB  - N
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 39/3/278 [pii]
AID - 10.1177/0145721713491075 [doi]
PST - ppublish
SO  - Diabetes Educ. 2013 May-Jun;39(3):278. doi: 10.1177/0145721713491075.

PMID- 23686637
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May-Jun
TI  - AADE News.
PG  - 273-4
LID - 10.1177/0145721713487150 [doi]
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
SB  - N
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 39/3/273 [pii]
AID - 10.1177/0145721713487150 [doi]
PST - ppublish
SO  - Diabetes Educ. 2013 May-Jun;39(3):273-4. doi: 10.1177/0145721713487150.

PMID- 23686529
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1557-1920 (Electronic)
IS  - 1557-1912 (Linking)
DP  - 2013 May 18
TI  - Lifestyle Physical Activity Behavior Among South Asian Indian Immigrants.
AB  - Little is known of the physical activity behavior of South Asian Indian
      immigrants (SAIs), though they have more than twice the risk for cardiovascular
      disease and diabetes than Whites. This was a cross-sectional descriptive
      face-to-face survey design, comparing between men and women in leisure time
      (LTPA), household (HPA), and occupational physical activity (OPA). Participants
      also wore a Lifecorder EX (NL2200) accelerometer for 7 days. Just over half (51.8
      %) of the participants met the recommended PA guidelines (>/=150 min
      moderate-intensity or >/=75 min vigorous-intensity) through LTPA. The average
      number of daily steps was 6,904.3, which is in the "low active" classification.
      Increasing lifestyle PA among SAIs is important; PA interventions appealing to
      gender and culture and with an aerobic component are needed.
AD  - College of Nursing, Rush University, Chicago, IL, USA, daniel.manju@yahoo.com.
FAU - Daniel, Manju
AU  - Daniel M
FAU - Wilbur, Joellen
AU  - Wilbur J
FAU - Marquez, David
AU  - Marquez D
FAU - Farran, Carol
AU  - Farran C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - J Immigr Minor Health
JT  - Journal of immigrant and minority health / Center for Minority Public Health
JID - 101256527
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.1007/s10903-013-9842-4 [doi]
PST - aheadofprint
SO  - J Immigr Minor Health. 2013 May 18.

PMID- 23686473
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1559-0291 (Electronic)
IS  - 0273-2289 (Linking)
DP  - 2013 May 18
TI  - High Levels of Glucose Induces a Dose-Dependent Apoptosis in Human Periodontal
      Ligament Fibroblasts by Activating Caspase-3 Signaling Pathway.
AB  - Periodontitis is one of the main complications of diabetes mellitus and many
      researches have been done on the relationship between periodontitis and diabetes 
      mellitus, but too much are still unclear, especially the mechanisms by which high
      glucose induces damage of periodontal ligament fibroblasts. So in this study, we 
      investigated the effects of different concentration of high glucose on apoptosis 
      in human periodontal ligament fibroblasts and the possible mechanisms involved.
      Human periodontal ligament fibroblasts were cultured and subjected to glucose of 
      different concentration (5.5, 15, 25, and 35 mM) for 24 h. Apoptosis was studied 
      by flow cytometry, caspase assays, fluorescent real-time PCR and Western blot. We
      also determined Fas/FasL expression was by Western blot. The application of
      different concentration of high glucose induced a concentration-dependent
      increase of apoptosis and the activity of caspase-3 in cultured human periodontal
      ligament fibroblasts. Furthermore, inhibitor of caspase-3 could prevent the
      high-glucose-induced apoptosis in human periodontal ligament fibroblasts. Protein
      levels of Fas and FasL remained unchanged. These data indicate that high glucose 
      induces a concentration- and caspase-3-dependent increase of apoptosis in
      cultured human periodontal ligament fibroblasts in vitro. Activation of caspase-3
      caused by high glucose is independent of Fas/FasL signaling pathways system.
      These results suggest a novel mechanism for the regulation of human periodontal
      ligament fibroblasts apoptosis by high glucose.
AD  - Department of Stomatology, Chinese PLA General Hospital, No. 28 Fuxing Road,
      Beijing, 100853, People's Republic of China, liujqmj@163.com.
FAU - Liu, Jiaqiang
AU  - Liu J
FAU - Jiang, Yi
AU  - Jiang Y
FAU - Mao, Jing
AU  - Mao J
FAU - Gu, Bin
AU  - Gu B
FAU - Liu, Hongchen
AU  - Liu H
FAU - Fang, Bing
AU  - Fang B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Appl Biochem Biotechnol
JT  - Applied biochemistry and biotechnology
JID - 8208561
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/13 [received]
PHST- 2013/05/06 [accepted]
PHST- 2013/05/18 [aheadofprint]
AID - 10.1007/s12010-013-0287-y [doi]
PST - aheadofprint
SO  - Appl Biochem Biotechnol. 2013 May 18.

PMID- 23686250
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1527-3172 (Electronic)
IS  - 1527-3172 (Linking)
VI  - 15
IP  - 2
DP  - 2013 Apr
TI  - Diabetes risk in a cuban primary care setting in persons with no known glucose
      abnormalities.
PG  - 16-9
AB  - INTRODUCTION With 333 million cases worldwide predicted for 2015, type 2 diabetes
      mellitus presents an important global health challenge. Its rising tide calls for
      health policies emphasizing prevention at the primary care level, including
      public education as well as early risk identification and intervention.
      OBJECTIVES Estimate risk of developing type 2 diabetes in persons with no known
      glucose abnormalities, registered in a primary care setting in Pinar del Rio
      city, Cuba, using FINDRISK. METHODS A descriptive, cross-sectional study applied 
      FINDRISK to 620 persons aged >/=18 years randomly selected from a universe of
      1058 patients with no known glucose abnormalities, registered in
      family-doctor-and-nurse office No. 23 in the Turcios Lima Teaching Polyclinic
      health area, Pinar del Rio city. RESULTS The study population was predominantly
      aged </=45 years (53.5%) and 80.2% was overweight or obese. At least moderate
      risk of diabetes was found in 74.4% of the sample, and 10.5% was at very high
      risk, meaning an estimated 120 patients in the sample could be expected to
      develop type 2 diabetes within the next 10 years. CONCLUSIONS Type 2 diabetes
      prevalence can be expected to increase substantially in this population over the 
      next decade. We recommend design and timely implementation of intensive lifestyle
      change programs to eliminate or slow development of type 2 diabetes in at-risk
      individuals. We propose following cohorts identified by FINDRISK to assess its
      prognostic value in the Cuban population. KEYWORDS Diabetes mellitus, risk
      factors, risk prediction, prevention, Cuba.
AD  - Turcios Lima Teaching Polyclinic, Pinar del Rio, Cuba.
      adrian90@princesa.pri.sld.cu.
FAU - Naranjo, Adrian A
AU  - Naranjo AA
FAU - Rodriguez, Angel Y
AU  - Rodriguez AY
FAU - Llera, Rosa E
AU  - Llera RE
FAU - Aroche, Ronald
AU  - Aroche R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - MEDICC Rev
JT  - MEDICC review
JID - 100964771
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PST - ppublish
SO  - MEDICC Rev. 2013 Apr;15(2):16-9.

PMID- 23686249
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1527-3172 (Electronic)
IS  - 1527-3172 (Linking)
VI  - 15
IP  - 2
DP  - 2013 Apr
TI  - Contextual and individual influences on diabetes and heart disease in havana
      primary care catchment areas.
PG  - 10-5
AB  - INTRODUCTION A population health profile is a cumulative product of
      socioenvironmental and political factors that create the contexts in which health
      problems arise, as well as opportunities and barriers to addressing them.
      Research on context has focused on demonstrating its effects, direct or indirect,
      on health indicators, but has made few incursions into assessing its role as a
      mediator of other factors. While individual risk factors for chronic diseases are
      well known, the same cannot be said for the complex of contextual factors
      operating at various levels and over the lifespan.OBJECTIVES Estimate relative
      influences by contextual versus individual factors as determinants of diabetes
      type 2 and heart disease. METHODS A cross-sectional study was carried out in
      populations served by 12 family doctor-and-nurse practices in Havana, in 840
      families selected by simple random sampling, 70 per practice. Principal
      components analysis was used, as well as contextual logistic regression models
      with a nested model strategy, whose fit was meant to estimate the relative
      contributions of contextual compared to individual risk factors for diabetes and 
      heart disease. Context was described and analyzed at two levels: that of the
      family or household and that of the catchment area served by a family
      doctor-and-nurse practice (geographically defined as a neighborhood). RESULTS For
      diabetes, the contextual effect of neighborhood was modified when household
      effect was removed; that is, the effect of neighborhood was indirect and mediated
      by household. Individual coefficients were practically invariant; the principal
      effect of household changed noticeably on removal of individual effects, while
      age maintained its effect without variation. For heart disease, the effect of
      neighborhood was slightly modified when household effect was controlled for.
      Individual coefficients showed little change. There was an important direct
      effect of household on risk of heart disease. Age and high blood pressure
      coefficients hardly varied. CONCLUSIONS We confirmed interactions between
      individual and contextual (neighborhood and household) factors, whose effects on 
      individual health are not entirely mediated by individual factors. Research needs
      to pay more attention to context beyond its direct effect on individual risk
      factors. KEYWORDS Risk factors, risk reduction, community, neighborhood, type 2
      diabetes mellitus, heart disease, logistic models, Cuba.
AD  - Atherosclerosis Research and Reference Center (CIRAH), Havana, Cuba.
      georgia.diazperera@infomed.sld.cu.
FAU - Diaz-Perera, Georgia
AU  - Diaz-Perera G
FAU - Bacallao, Jorge
AU  - Bacallao J
FAU - Alemany, Eduardo
AU  - Alemany E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - MEDICC Rev
JT  - MEDICC review
JID - 100964771
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PST - ppublish
SO  - MEDICC Rev. 2013 Apr;15(2):10-5.

PMID- 23686112
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1944-9917 (Electronic)
IS  - 0888-8809 (Linking)
DP  - 2013 May 17
TI  - The Helix 1-3 Loop in the Glucocorticoid Receptor LBD is a Regulatory Element for
      FKBP Cochaperones.
AB  - The Hsp90 cochaperone FKBP52 upregulates, whereas FKBP51 inhibits,
      hormone-binding and nuclear targeting of the glucocorticoid receptor (GR).
      Decreased cortisol sensitivity in the guinea pig is attributed to changes within 
      the helix 1 to helix 3 (H1-H3) loop of the guinea pig GR (gpGR) ligand-binding
      domain (LBD). It has been proposed that this loop serves as a contact point for
      FKBP52 and/or FKBP51 with receptor. We examined the role of the H1-H3 loop in GR 
      activation by FKBP52 using a Saccharomyces cerevisiae model. The activity of rat 
      GR (rGR) containing the gpGR H1-H3 loop substitutions was still potentiated by
      FKBP52, confirming the loop is not involved in primary FKBP52 interactions.
      Additional assays also excluded a role for other intervening loops between LBD
      helices in direct interactions with FKBP52 associated with enhanced receptor
      activity. Complementary studies in FKBP51-deficient mouse embryo fibroblasts and 
      HEK293 cells demonstrated that substitution of the gpGR H1-H3 loop residues into 
      rGR dramatically increased receptor repression by FKBP51 without enhancing
      receptor-FKBP51 interaction and did not alter recruitment of endogenous Hsp90 and
      the p23 cochaperone to receptor complexes. FKBP51 suppression of the mutated rGR 
      did not require FKPB51 PPIase activity and was not disrupted by mutation of the
      FK1 proline-rich loop thought to mediate reciprocal FKBP influences on receptor
      activity. We conclude that the gpGR-specific mutations within the H1-H3 loop
      confer global changes within the GR-Hsp90 complex that favour FKBP51 repression
      over FKBP52 potentiation, thus identifying the loop as an important target for GR
      regulation by the FKBP cochaperones.
AD  - 1Laboratory for Molecular Endocrinology, Western Australian Institute for Medical
      Research and the UWA Centre for Medical Research, The University of Western
      Australia; Department of Endocrinology & Diabetes, Sir Charles Gairdner Hospital,
      Nedlands WA 6009 and.
FAU - Cluning, Carmel
AU  - Cluning C
FAU - Ward, Bryan K
AU  - Ward BK
FAU - Rea, Sarah L
AU  - Rea SL
FAU - Arulpragasam, Ajanthy
AU  - Arulpragasam A
FAU - Fuller, Peter J
AU  - Fuller PJ
FAU - Ratajczak, Thomas
AU  - Ratajczak T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Mol Endocrinol
JT  - Molecular endocrinology (Baltimore, Md.)
JID - 8801431
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - me.2012-1023 [pii]
AID - 10.1210/me.2012-1023 [doi]
PST - aheadofprint
SO  - Mol Endocrinol. 2013 May 17.

PMID- 23686080
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 May 20
TI  - The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male
      patients.
AB  - Introduction No data on the prevalence of erectile dysfunction (ED) in subjects
      with newly diagnosed DM type 2 are currently available. Aim The aim of the
      present study was to estimate the prevalence of ED and its associated causes in a
      sample of male patients with recently diagnosed DM (<24 months) attending a
      diabetes care center. Methods The study comprised two phases: a cross-sectional
      analysis and a longitudinal reassessment of the data collected during the first
      phase. During the first phase 1503 subjects (mean age, 58.7+/-8.9 years) from 27 
      centers were interviewed: 666 (43.3%) reported experiencing ED, 499 of which
      (mean age, 58.8+/-8.8 years) agreed to participate in the study (final enrolment 
      rate, 33.3%). Concurrent morbidities were hypertension (55.3%), dyslipidemia
      (39.5%), and coronary heart disease (7.8%); chronic complications were neuropathy
      (8.9%), nephropathy (12.6%) and retinopathy (7.6%) in about one third of the
      sample at enrolment. Results Overall, about 20% of the patients reported having
      used ED drugs, but more than 50% had abandoned therapy because of the drug's
      ineffectiveness or high cost. The prevalence of hypogonadism was 46.9% (total
      testosterone level, 3.5 ng/ml). Some 20% of patients reported symptoms suggestive
      of depression. Conclusion The present study provides data showing a high
      prevalence of ED, hypogonadism and depressive symptoms among male patients with
      newly diagnosed DM type 2. Further analysis of the data will elucidate the
      specific determinants of such conditions and their longitudinal significance.
AD  - Endocrinoly Unit, Medical Department, Azienda Usl Bologna, Maggiore-Bellaria
      Hospital, Bologna.
FAU - Corona, G
AU  - Corona G
FAU - Giorda, C B
AU  - Giorda CB
FAU - Cucinotta, D
AU  - Cucinotta D
FAU - Guida, P
AU  - Guida P
FAU - Nada, E
AU  - Nada E
CN  - Gruppo di studio SUBITO-DE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 8969 [pii]
AID - 10.3275/8969 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 May 20.

PMID- 23686079
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
DP  - 2013 May 16
TI  - Fasting Glucose Level Modulates Cell Surface Expression of CD11b and CD66b in
      Granulocytes and Monocytes of Patients With Type 2 Diabetes.
AB  - INTRODUCTION: Cardiovascular complications are the leading cause of mortality in 
      type 2 diabetes (T2DM), in which onset and progression of atherosclerosis is
      linked to chronic inflammation. Activation status of innate immune cells
      (granulocytes [Gc], monocytes [Mc]), as reflected by increased CD11b, CD66b, and 
      other surface markers, increases their endothelial and cytokines/chemokines
      release. Whereas this inflammatory activation seems inversely related to poor
      glycemic control, the effect of acute spontaneous hyperglycemia on innate immune 
      cell activation remains unclear. METHODS: Expression of key markers (CD11b, CD14,
      CD16, CD62L, and CD66b) was therefore determined by flow cytometry on whole blood
      of healthy subjects and patients with T2DM with spontaneous fasting euglycemia or
      hyperglycemia both at baseline and after 30, 90, and 240 minutes of incubation at
      room temperature. RESULTS: Hyperglycemic patients with T2DM had significantly
      higher Gc and Mc CD11b and Gc CD66b surface mean fluorescence intensity compared 
      with the euglycemic patients with T2DM whose values were similar to those of the 
      healthy controls. CD16 expression in CD14+CD16+ Mc was elevated in all patients
      with T2DM, regardless of glycemic levels. CONCLUSION: Our data suggest that
      whereas the presence of diabetes per se may have a proinflammatory effect,
      hyperglycemia seems to further acutely exacerbate innate cell inflammatory status
      and their consequent endothelial adhesion and vascular damage potential.
AD  - From the *Department of Pharmacology, School of Medicine, University of
      California, Irvine, Irvine, CA; and daggerInstitute for Clinical Translational
      Science, Department of Pediatrics, University of California, Irvine, Orange, CA.
FAU - Horvath, Peter
AU  - Horvath P
FAU - Oliver, Stacy R
AU  - Oliver SR
FAU - Ganesan, Goutham
AU  - Ganesan G
FAU - Zaldivar, Frank P Jr
AU  - Zaldivar FP Jr
FAU - Radom-Aizik, Shlomit
AU  - Radom-Aizik S
FAU - Galassetti, Pietro R
AU  - Galassetti PR
LA  - ENG
GR  - K24 DK085223/DK/NIDDK NIH HHS/United States
GR  - M01 RR000827/RR/NCRR NIH HHS/United States
GR  - P01 HD048721/HD/NICHD NIH HHS/United States
GR  - UL1 TR000153/TR/NCATS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American
      Federation for Clinical Research
JID - 9501229
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.231/JIM.0b013e3182961517 [doi]
PST - aheadofprint
SO  - J Investig Med. 2013 May 16.

PMID- 23686023
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1758-5341 (Electronic)
IS  - 0016-9013 (Linking)
DP  - 2013 May 18
TI  - Chronic Illness Intrusion: Role Impairment and Time Out of Role in Racially and
      Ethnically Diverse Older Adults.
AB  - Purpose of the study:Little is known about the effects of chronic illness on
      social role participation among racially and ethnically diverse older adults.
      This study was undertaken to better understand disruptions in role among African 
      American, black Caribbean, white, Latino, and Asian older adults with arthritis, 
      heart disease, or diabetes. DESIGN AND METHODS: This study consisted of a
      cross-sectional secondary data analysis of the Collaborative Psychiatric
      Epidemiology Surveys. Role disruption was operationalized using time out of role 
      and role impairment in the past 30 days. Data from participants aged 65 and older
      were used in negative binomial regression analyses. RESULTS: Overall, prevalence 
      of role impairment occurred more often than time out of role. Race and ethnicity 
      were not associated with time out of role, but they were for role impairment.
      Whites experienced more role impairment than any other racial or ethnic group.
      Within-group analyses identified that chronic illness, role participation, and
      socioeconomic factors are related in different ways depending on race or
      ethnicity. It appears that for some racially and ethnically diverse older adults,
      higher income and education are protective against role disruption. IMPLICATIONS:
      Race and ethnicity are factors in how the social roles of older adults are
      affected by chronic illness, and it appears that role disruption varies with type
      of illness. Interventions to support older adults with chronic illness should
      take into account the cultural factors related to role disruption.
AD  - *Address correspondence to Anne K. Hughes, MSW, School of Social Work, Michigan
      State University, 655 Auditorium Rd, Baker Hall, East Lansing, MI 48824. E-mail: 
      hughesa@msu.edu.
FAU - Hughes, Anne K
AU  - Hughes AK
FAU - Toler Woodward, Amanda
AU  - Toler Woodward A
FAU - Velez-Ortiz, Daniel
AU  - Velez-Ortiz D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Gerontologist
JT  - The Gerontologist
JID - 0375327
OTO - NOTNLM
OT  - Chronic illness
OT  - Diversity and ethnicity
OT  - Social roles and social factors
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - gnt041 [pii]
AID - 10.1093/geront/gnt041 [doi]
PST - aheadofprint
SO  - Gerontologist. 2013 May 18.

PMID- 23685996
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 May 20
TI  - ADIPOCYTOKINES DURING PREGNANCY AND POSTPARTUM IN WOMEN WITH GESTATIONAL DIABETES
      AND HEALTHY CONTROLS.
AD  - Medical University Sofia, Clinical Center of Endocrinology.
FAU - Boyadzhieva, Maria
AU  - Boyadzhieva M
FAU - Atanasova, Iliana
AU  - Atanasova I
FAU - Zacharieva, Sabina
AU  - Zacharieva S
FAU - Kedikova, Sesil
AU  - Kedikova S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 8968 [pii]
AID - 10.3275/8968 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 May 20.

PMID- 23685946
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Linking)
DP  - 2013 May 16
TI  - Comparison of Risk Factors and Outcomes in HIV Immune Complex Kidney Disease and 
      HIV-Associated Nephropathy.
AB  - BACKGROUND AND OBJECTIVES: HIV-associated nephropathy (HIVAN) is well described, 
      but the clinical features of a group of renal pathologies characterized by Ig or 
      immune complex depositions referred to as HIV-associated immune complex kidney
      disease (HIVICK) have not been well established. The objective of this study is
      to assess risk factors for HIVICK compared with contemporaneous control
      participants. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A nested
      case-control study of 751 HIV-infected patients followed from January 1996 to
      June 2010 was conducted. Groups were compared using the chi-squared test or
      rank-sum analysis. Conditional logistic regression was used to estimate odds
      ratios (ORs) for HIVICK. Incidences of overall ESRD and with/without combined
      antiretroviral therapy (cART) exposure were calculated. RESULTS: HIVICK patients 
      were predominantly African American (92%). Compared with matched controls,
      patients with HIVICK were more likely to have HIV RNA >400 copies/ml (OR, 2.5;
      95% confidence interval [95% CI], 1.2 to 5.2), diabetes (OR, 2.8; 95% CI, 1.1 to 
      6.8), and hypertension (OR, 2.3; 95% CI, 1.2 to 4.5). Compared with HIVAN,
      patients with HIVICK had more antiretroviral therapy exposure, lower HIV viral
      loads, and higher CD4 and estimated GFR. ESRD was less common in the HIVICK
      versus the HIVAN group (30% versus 82%; P<0.001), and the use of cART was not
      associated with ESRD in HIVICK patients (25% versus 26; P=0.39). CONCLUSIONS:
      HIVICK was predominantly observed in African-American patients and associated
      with advanced HIV disease. ESRD incidence is lower in HIVICK patients compared
      with those with HIVAN. Unlike HIVAN, cART use was not associated with the
      incidence of ESRD in HIVICK.
AD  - Division of Internal Medicine, Louisiana State University Health Science Center, 
      Baton Rouge, Louisiana;, Divisions of double daggerNephrology,, daggerInfectious 
      Diseases, and, ||General Internal Medicine, Johns Hopkins University School of
      Medicine, Baltimore, Maryland, section signDow University of Health Sciences,
      Karachi, Pakistan.
FAU - Foy, Matthew C
AU  - Foy MC
FAU - Estrella, Michelle M
AU  - Estrella MM
FAU - Lucas, Gregory M
AU  - Lucas GM
FAU - Tahir, Faryal
AU  - Tahir F
FAU - Fine, Derek M
AU  - Fine DM
FAU - Moore, Richard D
AU  - Moore RD
FAU - Atta, Mohamed G
AU  - Atta MG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - CJN.10991012 [pii]
AID - 10.2215/CJN.10991012 [doi]
PST - aheadofprint
SO  - Clin J Am Soc Nephrol. 2013 May 16.

PMID- 23685845
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Linking)
DP  - 2013 May 19
TI  - Low nitric oxide bioavailability is associated with better responses to
      sildenafil in patients with erectile dysfunction.
AB  - Erectile dysfunction (ED) is a multifactorial disease associated with vascular
      dysfunction, low nitric oxide (NO) bioavailability, and oxidative stress.
      However, it is not known whether low NO bioavailability and oxidative stress
      affect the responsiveness of ED patients to sildenafil. We tested this hypothesis
      by studying 28 healthy subjects (control group), 26 patients with ED without
      comorbidities (ED group), and 18 patients with ED and diabetes mellitus (ED/DM
      group). The International Index for Erectile Function (IIEF) questionnaire was
      used to assess the erectile function of all participants, and their
      responsiveness to sildenafil was assessed as the percentage of change in the
      five-item version of IIEF score before and after sildenafil treatment. Levels of 
      whole blood nitrite, antioxidants markers (ferric reducing ability of plasma
      (FRAP) and reduced glutathione), and oxidative stress markers (thiobarbituric
      acid reactive substance and protein carbonyl) were determined. We found a
      negative correlation between whole blood nitrite levels and the responses to
      sildenafil in both ED groups (P < 0.05). FRAP correlated negatively with the
      responses to sildenafil in the ED/DM group (P < 0.05). No other significant
      associations were found. Our findings show evidence that low NO bioavailability
      is associated with better responses to sildenafil in patients with ED (with or
      without DM).
AD  - Department of Pharmacology, State University of Campinas, Campinas, Sao Paulo,
      Brazil.
FAU - Muniz, Jaqueline J
AU  - Muniz JJ
FAU - Lacchini, Riccardo
AU  - Lacchini R
FAU - Sertorio, Jonas T C
AU  - Sertorio JT
FAU - Jordao, Alceu A Jr
AU  - Jordao AA Jr
FAU - Nobre, Yuri T D A
AU  - Nobre YT
FAU - Tucci, Silvio Jr
AU  - Tucci S Jr
FAU - Martins, Antonio C P
AU  - Martins AC
FAU - Tanus-Santos, Jose E
AU  - Tanus-Santos JE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130519
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/01 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/19 [aheadofprint]
AID - 10.1007/s00210-013-0882-z [doi]
PST - aheadofprint
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2013 May 19.

PMID- 23685839
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 19
IP  - 6
DP  - 2013 Jun
TI  - Hypothalamic glucagon signaling inhibits hepatic glucose production.
PG  - 766-72
LID - 10.1038/nm.3115 [doi]
AB  - Glucagon activates hepatic protein kinase A (PKA) to increase glucose production,
      but the gluco-stimulatory effect is transient even in the presence of continuous 
      intravenous glucagon infusion. Continuous intravenous infusion of insulin,
      however, inhibits glucose production through its sustained actions in both the
      liver and the mediobasal hypothalamus (MBH). In a pancreatic clamp setting, MBH
      infusion with glucagon activated MBH PKA and inhibited hepatic glucose production
      (HGP) in rats, as did central glucagon infusion in mice. Inhibition of glucagon
      receptor-PKA signaling in the MBH and hepatic vagotomy each negated the effect of
      MBH glucagon in rats, whereas the central effect of glucagon was diminished in
      glucagon receptor knockout mice. A sustained rise in plasma glucagon
      concentrations transiently increased HGP, and this transiency was abolished in
      rats with negated MBH glucagon action. In a nonclamp setting, MBH glucagon
      infusion improved glucose tolerance, and inhibition of glucagon receptor-PKA
      signaling in the MBH enhanced the ability of intravenous glucagon injection to
      increase plasma glucose concentrations. We also detected a similar enhancement of
      glucose concentrations that was associated with a disruption in MBH glucagon
      signaling in rats fed a high-fat diet. We show that hypothalamic glucagon
      signaling inhibits HGP and suggest that hypothalamic glucagon resistance
      contributes to hyperglycemia in diabetes and obesity.
AD  - 1] Toronto General Research Institute, University Health Network, Toronto,
      Ontario, Canada. [2] Department of Physiology, University of Toronto, Toronto,
      Ontario, Canada. [3].
FAU - Mighiu, Patricia I
AU  - Mighiu PI
FAU - Yue, Jessica T Y
AU  - Yue JT
FAU - Filippi, Beatrice M
AU  - Filippi BM
FAU - Abraham, Mona A
AU  - Abraham MA
FAU - Chari, Madhu
AU  - Chari M
FAU - Lam, Carol K L
AU  - Lam CK
FAU - Yang, Clair S
AU  - Yang CS
FAU - Christian, Nikita R
AU  - Christian NR
FAU - Charron, Maureen J
AU  - Charron MJ
FAU - Lam, Tony K T
AU  - Lam TK
LA  - eng
PT  - Journal Article
DEP - 20130519
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/08 [received]
PHST- 2013/01/31 [accepted]
PHST- 2013/05/19 [aheadofprint]
AID - nm.3115 [pii]
AID - 10.1038/nm.3115 [doi]
PST - ppublish
SO  - Nat Med. 2013 Jun;19(6):766-72. doi: 10.1038/nm.3115. Epub 2013 May 19.

PMID- 23685806
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1757-9708 (Electronic)
IS  - 1757-9694 (Linking)
DP  - 2013 May 20
TI  - Molecular network analysis of phosphotyrosine and lipid metabolism in hepatic
      PTP1b deletion mice.
AB  - Metabolic syndrome describes a set of obesity-related disorders that increase
      diabetes, cardiovascular, and mortality risk. Studies of liver-specific
      protein-tyrosine phosphatase 1b (PTP1b) deletion mice (L-PTP1b-/-) suggest that
      hepatic PTP1b inhibition would mitigate metabolic-syndrome through amelioration
      of hepatic insulin resistance, endoplasmic-reticulum stress, and whole-body lipid
      metabolism. However, the altered molecular-network states underlying these
      phenotypes are poorly understood. We used mass spectrometry to quantify
      protein-phosphotyrosine network changes in L-PTP1b-/- mouse livers relative to
      control mice on normal and high-fat diets. We applied a
      phosphosite-set-enrichment analysis to identify known and novel pathways
      exhibiting PTP1b- and diet-dependent phosphotyrosine regulation. Detection of a
      PTP1b-dependent, but functionally uncharacterized, set of phosphosites on
      lipid-metabolic proteins motivated global lipidomic analyses that revealed
      altered polyunsaturated-fatty-acid (PUFA) and triglyceride metabolism in
      L-PTP1b-/- mice. To connect phosphosites and lipid measurements in a unified
      model, we developed a multivariate-regression framework, which accounts for
      measurement noise and systematically missing proteomics data. This analysis
      resulted in quantitative models that predict roles for phosphoproteins involved
      in oxidation-reduction in altered PUFA and triglyceride metabolism.
AD  - Computational and Systems Biology, Massachusetts Institute of Technology,
      Cambridge, MA 02139, USA.
FAU - Miraldi, Emily R
AU  - Miraldi ER
FAU - Sharfi, Hadar
AU  - Sharfi H
FAU - Friedline, Randall H
AU  - Friedline RH
FAU - Johnson, Hannah
AU  - Johnson H
FAU - Zhang, Tejia
AU  - Zhang T
FAU - Lau, Ken S
AU  - Lau KS
FAU - Ko, Hwi Jin
AU  - Ko HJ
FAU - Curran, Timothy G
AU  - Curran TG
FAU - Haigis, Kevin M
AU  - Haigis KM
FAU - Yaffe, Michael B
AU  - Yaffe MB
FAU - Bonneau, Richard
AU  - Bonneau R
FAU - Lauffenburger, Douglas A
AU  - Lauffenburger DA
FAU - Kahn, Barbara B
AU  - Kahn BB
FAU - Kim, Jason K
AU  - Kim JK
FAU - Neel, Benjamin G
AU  - Neel BG
FAU - Saghatelian, Alan
AU  - Saghatelian A
FAU - White, Forest M
AU  - White FM
LA  - ENG
GR  - R01 CA049152/CA/NCI NIH HHS/United States
GR  - R01 DK080756/DK/NIDDK NIH HHS/United States
GR  - R24 DK090963/DK/NIDDK NIH HHS/United States
GR  - U24 DK093000/DK/NIDDK NIH HHS/United States
GR  - U54 CA112967/CA/NCI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Integr Biol (Camb)
JT  - Integrative biology : quantitative biosciences from nano to macro
JID - 101478378
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.1039/c3ib40013a [doi]
PST - aheadofprint
SO  - Integr Biol (Camb). 2013 May 20.

PMID- 23685789
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1940-087X (Electronic)
IS  - 1940-087X (Linking)
IP  - 75
DP  - 2013
TI  - Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of
      Diabetogenic CD4+ T Cells.
LID - 10.3791/50389 [doi]
AB  - The nonobese diabetic (NOD) mouse spontaneously develops autoimmune diabetes
      after 12 weeks of age and is the most extensively studied animal model of human
      Type 1 diabetes (T1D). Cell transfer studies in irradiated recipient mice have
      established that T cells are pivotal in T1D pathogenesis in this model. We
      describe herein a simple method to rapidly induce T1D by adoptive transfer of
      purified, primary CD4+ T cells from pre-diabetic NOD mice transgenic for the
      islet-specific T cell receptor (TCR) BDC2.5 into NOD.SCID recipient mice. The
      major advantages of this technique are that isolation and adoptive transfer of
      diabetogenic T cells can be completed within the same day, irradiation of the
      recipients is not required, and a high incidence of T1D is elicited within 2
      weeks after T cell transfer. Thus, studies of pathogenesis and therapeutic
      interventions in T1D can proceed at a faster rate than with methods that rely on 
      heterogenous T cell populations or clones derived from diabetic NOD mice.
AD  - Department of Microbiology & Immunology, Pennsylvania State University College of
      Medicine.
FAU - Berry, Gregory
AU  - Berry G
FAU - Waldner, Hanspeter
AU  - Waldner H
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - United States
TA  - J Vis Exp
JT  - Journal of visualized experiments : JoVE
JID - 101313252
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.3791/50389 [doi]
PST - epublish
SO  - J Vis Exp. 2013 May 6;(75). doi: 10.3791/50389.

PMID- 23685786
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1529-2916 (Electronic)
IS  - 1529-2908 (Linking)
DP  - 2013 May 19
TI  - T cell regulation mediated by interaction of soluble CD52 with the inhibitory
      receptor Siglec-10.
LID - 10.1038/ni.2610 [doi]
AB  - Functionally diverse T cell populations interact to maintain homeostasis of the
      immune system. We found that human and mouse antigen-activated T cells with high 
      expression of the lymphocyte surface marker CD52 suppressed other T cells.
      CD52hiCD4+ T cells were distinct from CD4+CD25+Foxp3+ regulatory T cells. Their
      suppression was mediated by soluble CD52 released by phospholipase C. Soluble
      CD52 bound to the inhibitory receptor Siglec-10 and impaired phosphorylation of
      the T cell receptor-associated kinases Lck and Zap70 and T cell activation.
      Humans with type 1 diabetes had a lower frequency and diminished function of
      CD52hiCD4+ T cells responsive to the autoantigen GAD65. In diabetes-prone mice of
      the nonobese diabetic (NOD) strain, transfer of lymphocyte populations depleted
      of CD52hi cells resulted in a substantially accelerated onset of diabetes. Our
      studies identify a ligand-receptor mechanism of T cell regulation that may
      protect humans and mice from autoimmune disease.
AD  - 1] Walter & Eliza Hall Institute of Medical Research, Parkville, Australia. [2]
      Department of Medical Biology, University of Melbourne, Parkville, Australia.
      [3].
FAU - Bandala-Sanchez, Esther
AU  - Bandala-Sanchez E
FAU - Zhang, Yuxia
AU  - Zhang Y
FAU - Reinwald, Simone
AU  - Reinwald S
FAU - Dromey, James A
AU  - Dromey JA
FAU - Lee, Bo-Han
AU  - Lee BH
FAU - Qian, Junyan
AU  - Qian J
FAU - Bohmer, Ralph M
AU  - Bohmer RM
FAU - Harrison, Leonard C
AU  - Harrison LC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130519
TA  - Nat Immunol
JT  - Nature immunology
JID - 100941354
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/31 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/19 [aheadofprint]
AID - ni.2610 [pii]
AID - 10.1038/ni.2610 [doi]
PST - aheadofprint
SO  - Nat Immunol. 2013 May 19. doi: 10.1038/ni.2610.

PMID- 23685686
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1538-8689 (Electronic)
IS  - 0360-4039 (Linking)
VI  - 43
IP  - 6
DP  - 2013 Jun
TI  - An algorithm for care: Managing type 2 diabetes.
PG  - 14-7
LID - 10.1097/01.NURSE.0000427993.46812.c3 [doi]
AD  - Gloria P. Beecher is the director of Clinical Performance Improvement at Grady
      Health System in Atlanta, Ga. Susan J. Appel is a professor at the Capstone
      College of Nursing at the University of Alabama in Tuscaloosa, Ala.
FAU - Beecher, Gloria P
AU  - Beecher GP
FAU - Appel, Susan J
AU  - Appel SJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nursing
JT  - Nursing
JID - 7600137
SB  - N
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.1097/01.NURSE.0000427993.46812.c3 [doi]
AID - 00152193-201306000-00007 [pii]
PST - ppublish
SO  - Nursing. 2013 Jun;43(6):14-7. doi: 10.1097/01.NURSE.0000427993.46812.c3.

PMID- 23685666
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1552-6127 (Electronic)
IS  - 1090-1981 (Linking)
DP  - 2013 May 24
TI  - Why Culture Matters in Health Interventions: Lessons From HIV/AIDS Stigma and
      NCDs.
AB  - Theories about health behavior are commonly used in public health and often frame
      problems as ascribed or related to individuals' actions or inaction. This framing
      suggests that poor health occurs because individuals are unable or unwilling to
      heed preventive messages or recommended treatment actions. The recent United
      Nations call for strategies to reduce the global disease burden of
      noncommunicable diseases like diabetes requires a reassessment of
      individual-based approaches to behavior change. We argue that public health and
      health behavior intervention should focus more on culture than behavior to
      achieve meaningful and sustainable change resulting in positive health outcomes. 
      To change negative health behaviors, one must first identify and promote positive
      health behaviors within the cultural logic of its contexts. To illustrate these
      points, we discuss stigma associated with obesity and human immunodeficiency
      virus and acquired immune deficiency syndrome. We conclude that focusing on
      positive behaviors and sustaining cultural and personal transformations requires 
      a culturally grounded approach to public health interventions, such as that
      provided by the PEN-3 model.
AD  - 1Penn State University, University Park, PA, USA.
FAU - Airhihenbuwa, Collins O
AU  - Airhihenbuwa CO
FAU - Ford, Chandra L
AU  - Ford CL
FAU - Iwelunmor, Juliet I
AU  - Iwelunmor JI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - Health Educ Behav
JT  - Health education & behavior : the official publication of the Society for Public 
      Health Education
JID - 9704962
OTO - NOTNLM
OT  - HIV/AIDS
OT  - PEN-3 model
OT  - behavioral theories
OT  - culture
OT  - global health
OT  - obesity
OT  - social determinants
OT  - stigma
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/05/17 [aheadofprint]
AID - 1090198113487199 [pii]
AID - 10.1177/1090198113487199 [doi]
PST - aheadofprint
SO  - Health Educ Behav. 2013 May 24.

PMID- 23685658
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1109-9666 (Print)
IS  - 1109-9666 (Linking)
VI  - 54
IP  - 3
DP  - 2013 May-Jun
TI  - The impact of bariatric surgery procedures on type 2 diabetes, hyperlipidemia and
      hypertension.
PG  - 212-7
AD  - Second Department of Endocrinology and Metabolism, "Alexandra General Hospital"
      Athens, Greece.
FAU - Polymeris, Antonis
AU  - Polymeris A
FAU - Karoutsou, Eftychia
AU  - Karoutsou E
FAU - Michalakis, Konstantinos
AU  - Michalakis K
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Hellenic J Cardiol
JT  - Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
JID - 101257381
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PST - ppublish
SO  - Hellenic J Cardiol. 2013 May-Jun;54(3):212-7.

PMID- 23685624
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1758-535X (Electronic)
IS  - 1079-5006 (Linking)
DP  - 2013 May 16
TI  - Longer Lived Parents: Protective Associations With Cancer Incidence and Overall
      Mortality.
AB  - BACKGROUND: Children of centenarians have lower cardiovascular disease prevalence
      and live longer. We aimed to estimate associations between the full range of
      parental attained ages and health status in a middle-aged U.S. representative
      sample. METHODS: Using Health and Retirement Study data, models estimated disease
      incidence and mortality hazards for respondents aged 51-61 years at baseline,
      followed up for 18 years. Full adjustment included sex, race, smoking, wealth,
      education, body mass index, and childhood socioeconomic status. Mother's and
      father's attained age distributions were used to define short-, intermediate-,
      and long-lived groups, yielding a ranked parental longevity score (n = 6,055,
      excluding short-long discordance). Linear models (n = 8,340) tested mother's or
      father's attained ages, adjusted for each other. RESULTS: With increasing
      mother's or father's survival (>65 years), all-cause mortality declined 19%
      (hazard ratio [HR] = 0.81, 95% CI: 0.76-0.86, p < .001) and 14% per decade (HR = 
      0.87, 95% CI: 0.81-0.92, p < .001). Estimates changed only modestly when fully
      adjusted. Parent-in-law survival was not associated with mortality (n = 1,809, HR
      = 1.00, 95% CI: 0.90-1.12, p = .98). Offspring with one or two long-lived parents
      had lower cancer incidence (938 cases, HR per parental longevity score = 0.76,
      95% CI: 0.61-0.94, p = .01) versus two intermediate parents. Similar HRs for
      diabetes (HR = 0.89, 95% CI: 0.84-0.96, p = .001), heart disease (HR = 0.88, 95% 
      CI: 0.82-0.93, p < .001), and stroke (HR = 0.86, 95% CI: 0.78-0.95, p = .002)
      were significant, but there was no trend for arthritis. CONCLUSIONS: The results 
      provide the first robust evidence that increasing parental attained age is
      associated with lower cancer incidence in offspring. Health advantages of having 
      centenarian parents extend to a wider range of parental longevity and may provide
      a quantitative trait of slower aging.
AD  - MBBCH, Medical School, Barrack Road, Exeter, EX2 5DW, UK. d.melzer@exeter.ac.uk.
FAU - Dutta, Ambarish
AU  - Dutta A
FAU - Henley, William
AU  - Henley W
FAU - Robine, Jean-Marie
AU  - Robine JM
FAU - Langa, Kenneth M
AU  - Langa KM
FAU - Wallace, Robert B
AU  - Wallace RB
FAU - Melzer, David
AU  - Melzer D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - J Gerontol A Biol Sci Med Sci
JT  - The journals of gerontology. Series A, Biological sciences and medical sciences
JID - 9502837
OTO - NOTNLM
OT  - Cancer
OT  - Cardiovascular disease
OT  - Centenarian.
OT  - Family history
OT  - Parental longevity
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - glt061 [pii]
AID - 10.1093/gerona/glt061 [doi]
PST - aheadofprint
SO  - J Gerontol A Biol Sci Med Sci. 2013 May 16.

PMID- 23685555
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
DP  - 2013 May 16
TI  - Dkk1 and Msx2-Wnt7b Signaling Reciprocally Regulate the Endothelial-Mesenchymal
      Transition in Aortic Endothelial Cells.
AB  - OBJECTIVE: Endothelial cells (ECs) can undergo an endothelial-mesenchymal
      transition with tissue fibrosis. Wnt- and Msx2-regulated signals participate in
      arteriosclerotic fibrosis and calcification. We studied the impact of Wnt7, Msx2,
      and Dkk1, a Wnt7 antagonist, on endothelial-mesenchymal transition in primary
      aortic ECs. APPROACH AND RESULTS: Transduction of aortic ECs with vectors
      expressing Dkk1 suppressed EC differentiation and induced a mineralizing
      myofibroblast phenotype. Dkk1 suppressed claudin 5, PECAM, cadherin 5 (Cdh5),
      Tie1, and Tie2. Dkk1 converted the cuboidal cell monolayer into a spindle-shaped 
      multilayer and inhibited EC cord formation. Myofibroblast and osteogenic markers,
      SM22, type I collagen, Osx, Runx2, and alkaline phosphatase, were upregulated by 
      Dkk1 via activin-like kinase/Smad pathways. Dkk1 increased fibrotic
      mineralization of aortic ECs cultured under osteogenic conditions-the opposite of
      mesenchymal cell responses. Msx2 and Wnt7b maintained morphology and upregulated 
      markers of differentiated ECs. Deleting EC Wnt7b with the Cdh5-Cre transgene in
      Wnt7b(fl/fl);LDLR-/- mice upregulated aortic osteogenic genes (Osx, Sox9, Runx2, 
      and Msx2) and nuclear phospho-Smad1/5, and increased collagen and calcium
      accumulation. CONCLUSIONS: Dkk1 enhances endothelial-mesenchymal transition in
      aortic ECs, whereas Wnt7b and Msx2 signals preserve EC phenotype. EC responses to
      Dkk1, Wnt7b, and Msx2 are the opposite of mesenchymal responses, coupling EC
      phenotypic stability with osteofibrogenic predilection during arteriosclerosis.
AD  - From the Diabetes and Obesity Research Center, Sanford-Burnham Medical Research
      Institute, Orlando, FL (S.-L.C., A.B., K.K., D.A.T.); and Department of Internal 
      Medicine, Washington University, St. Louis, MO (J.-S.S.).
FAU - Cheng, Su-Li
AU  - Cheng SL
FAU - Shao, Jian-Su
AU  - Shao JS
FAU - Behrmann, Abraham
AU  - Behrmann A
FAU - Krchma, Karen
AU  - Krchma K
FAU - Towler, Dwight A
AU  - Towler DA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
OTO - NOTNLM
OT  - endothelial cells
OT  - mesenchymal stem transition
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - ATVBAHA.113.300647 [pii]
AID - 10.1161/ATVBAHA.113.300647 [doi]
PST - aheadofprint
SO  - Arterioscler Thromb Vasc Biol. 2013 May 16.

PMID- 23685497
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1998-3689 (Electronic)
IS  - 0301-4738 (Linking)
VI  - 61
IP  - 4
DP  - 2013 Apr
TI  - Assessing Framingham cardiovascular risk scores in subjects with diabetes and
      their correlation with diabetic retinopathy-Comment.
PG  - 187
LID - 10.4103/0301-4738.112172 [doi]
AD  - Clinical Biochemistry, Apollo Speciality Hospitals, Chennai, India.
FAU - Vivekanandan, Sachidanandam
AU  - Vivekanandan S
LA  - eng
PT  - Letter
PL  - India
TA  - Indian J Ophthalmol
JT  - Indian journal of ophthalmology
JID - 0405376
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - IndianJOphthalmol_2013_61_4_187_112172 [pii]
AID - 10.4103/0301-4738.112172 [doi]
PST - ppublish
SO  - Indian J Ophthalmol. 2013 Apr;61(4):187. doi: 10.4103/0301-4738.112172.

PMID- 23685457
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 18
TI  - Glucose regulation of a cell cycle gene module is selectively lost in mouse
      pancreatic islets during ageing.
AB  - AIMS/HYPOTHESIS: Transcriptional networks in beta cells are modulated by
      extracellular signals such as glucose, thereby ensuring beta cell adaptation to
      systemic insulin demands. Ageing is a main risk factor for type 2 diabetes and
      has been associated with perturbed expression of genes essential for beta cell
      function. We aimed to uncover glucose-dependent gene modules in mouse pancreatic 
      islets and investigate how this regulation is affected by ageing. METHODS: Global
      gene expression was assessed in pancreatic islets from young and aged wild-type
      and Cdkn2a (Ink4a/Arf)-deficient mice exposed to different glucose
      concentrations. Gene modules were identified by gene ontology and gene set
      enrichment analysis. RESULTS: Gene expression profiling revealed that variations 
      in glucose levels have a widespread and highly dynamic impact on the islet
      transcriptome. Stimulatory glucose levels induced the expression of highly beta
      cell-selective genes and repressed the expression of ubiquitous genes involved in
      stress and antiproliferative responses, and in organelle biogenesis.
      Interestingly, a module comprising cell cycle genes was significantly induced
      between non-stimulatory and stimulatory glucose concentrations. Unexpectedly,
      glucose regulation of gene expression was broadly maintained in islets from old
      mice. However, glucose induction of mitotic genes was selectively lost in aged
      islets and was not even restored in the absence of the cell cycle inhibitors
      p16INK4a and p19ARF, which have been implicated in the restricted proliferative
      capacity of beta cells with advanced age. CONCLUSIONS/INTERPRETATION:
      Glucose-dependent transcriptional networks in islets are globally conserved
      during ageing, with the exception of the ability of stimulatory glucose levels to
      induce a cell cycle gene module.
AD  - Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomediques
      August Pi i Sunyer (IDIBAPS), Centre Esther Koplowitz, Rossello 153, 08036,
      Barcelona, Spain.
FAU - Moreno-Asso, A
AU  - Moreno-Asso A
FAU - Castano, C
AU  - Castano C
FAU - Grilli, A
AU  - Grilli A
FAU - Novials, A
AU  - Novials A
FAU - Servitja, J-M
AU  - Servitja JM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/18 [aheadofprint]
AID - 10.1007/s00125-013-2930-0 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 18.

PMID- 23685372
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1876-2891 (Electronic)
IS  - 1876-2883 (Linking)
DP  - 2013 May 17
TI  - A novel cobiotic containing a prebiotic and an antioxidant augments the glucose
      control and gastrointestinal tolerability of metformin: a case report.
PG  - 1-4
AB  - The gut microbiome plays an important role in regulation of metabolic processes, 
      including digestion, absorption, and synthesis of bioactive molecules that signal
      physiological host mechanisms. Changes in the human gut microbiome are associated
      with type 2 diabetes and insulin resistance. Water-soluble dietary fibres like
      inulin and beta-glucan are fermented in the colon, and beta-glucan increases
      viscosity. Blueberries improve insulin sensitivity through an antioxidant effect.
      A cobiotic, consisting of purified inulin, sugar-free blueberry pomace extract,
      and an oat preparation of purified beta-glucan was developed for twice a day
      (bid) consumption as a smoothie drink to repair the gastrointestinal dysbiosis in
      type 2 diabetes. A 30-year-old man presented with new onset type 2 diabetes and a
      fasting glucose (FBS) of 375 mg/dl. Metformin 500 mg bid was initiated and
      increased to 1 g bid after 1 week. During the first 9 days of metformin
      treatment, he developed diarrhoea, but his FBS only dropped to 325 mg/dl. The
      cobiotic bid was added on the 9th day of metformin treatment, and after 2 days,
      his FBS dropped to 175 mg/dl. After 8 weeks on metformin and the cobiotic, his
      blood sugar was 100 mg/dl and he lost 5.5 kg. His stools became soft and formed
      on the cobiotic, reverted to diarrhoea when off of it for 2 days, and returned to
      normal on resuming the cobiotic formulation. Metformin is a safe, effective and
      inexpensive generic medication favouring weight loss, recommended as initial
      treatment of type 2 diabetes by the American Diabetes Association. However, a 20%
      incidence of diarrhoea limits its tolerability. A safe food supplement that can
      increase the efficacy of metformin and its tolerability, as occurred in this case
      report, would have significant positive public health consequences. A controlled 
      clinical trial of the cobiotic with metformin is planned.
AD  - Pennington Biomedical Research Center, Outpatient Clinic, Louisiana State
      University System, 6400 Perkins Road, Baton Rouge, LA 70808, USA.
FAU - Greenway, F
AU  - Greenway F
FAU - Wang, S
AU  - Wang S
FAU - Heiman, M
AU  - Heiman M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Benef Microbes
JT  - Beneficial microbes
JID - 101507616
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - FG7642372U410742 [pii]
AID - 10.3920/BM2012.0063 [doi]
PST - aheadofprint
SO  - Benef Microbes. 2013 May 17:1-4.

PMID- 23685312
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 16
TI  - Increased proton leak and SOD2 expression in myotubes from obese non-diabetic
      subjects with a family history of type 2 diabetes.
LID - S0925-4439(13)00162-2 [pii]
LID - 10.1016/j.bbadis.2013.05.008 [doi]
AB  - Muscle insulin resistance is linked to oxidative stress and decreased
      mitochondrial function. However, the exact cause of muscle insulin resistance is 
      still unknown. Since offspring of patients with type 2 diabetes mellitus (T2DM)
      are susceptible to developing insulin resistance, they are ideal for studying the
      early development of insulin resistance. By using primary muscle cells derived
      from obese non-diabetic subjects with (FH+) or without (FH-) a family history of 
      T2DM, we aimed to better understand the link between mitochondrial function,
      oxidative stress, and muscle insulin resistance. Insulin-stimulated glucose
      uptake and glycogen synthesis were normal in FH+ myotubes. Resting oxygen
      consumption rate was not different between groups. However, proton leak was
      higher in FH+ myotubes. This was associated with lower ATP content and decreased 
      mitochondrial membrane potential in FH+ myotubes. Surprisingly, mtDNA content was
      higher in FH+ myotubes. Oxidative stress level was not different between FH+ and 
      FH- groups. Reactive oxygen species content was lower in FH+ myotubes when
      differentiated in high glucose/insulin (25mM/150pM), which could be due to higher
      oxidative stress defenses (SOD2 expression and uncoupled respiration). The
      increased antioxidant defenses and mtDNA content in FH+ myotubes suggest the
      existence of compensatory mechanisms, which may provisionally prevent the
      development of insulin resistance.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine,
      University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada.
FAU - Aguer, Celine
AU  - Aguer C
FAU - Pasqua, Melissa
AU  - Pasqua M
FAU - Thrush, A Brianne
AU  - Thrush AB
FAU - Moffat, Cynthia
AU  - Moffat C
FAU - McBurney, Michael
AU  - McBurney M
FAU - Jardine, Karen
AU  - Jardine K
FAU - Zhang, Rui
AU  - Zhang R
FAU - Beauchamp, Brittany
AU  - Beauchamp B
FAU - Dent, Robert
AU  - Dent R
FAU - McPherson, Ruth
AU  - McPherson R
FAU - Harper, Mary-Ellen
AU  - Harper ME
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/28 [received]
PHST- 2013/05/06 [revised]
PHST- 2013/05/07 [accepted]
AID - S0925-4439(13)00162-2 [pii]
AID - 10.1016/j.bbadis.2013.05.008 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 16. pii: S0925-4439(13)00162-2. doi:
      10.1016/j.bbadis.2013.05.008.

PMID- 23685222
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
DP  - 2013 May 16
TI  - Measurement of urinary TGF-beta1 in patients with diabetes mellitus and normal
      controls.
LID - S0009-9120(13)00237-3 [pii]
LID - 10.1016/j.clinbiochem.2013.05.041 [doi]
AB  - OBJECTIVE: Increasing evidence links TGF-beta1 to progression of renal fibrosis
      including its association with diabetic nephropathy (DN). Current ELISA assays
      are not sensitive enough to measure TGF-beta1 in the urine of many clinically
      healthy individuals, even those with established renal disease. The objective of 
      this study was to validate a sensitive urinary assay for TGF-beta1 and compare
      levels between healthy controls and patients with established DN. DESIGN AND
      METHODS: An ELISA method (R&D Systems) was utilized together with an
      amplification step to assay TGF-beta1 in urine samples from 190 patients with DN 
      and 80 healthy controls. RESULTS: Using an ELAST (Perkin Elmer, Inc)
      amplification step, the ELISA for urinary TGF-beta1 had a limit of quantification
      of 15.6pg/mL and limit of detection of 7pg/mL. Preliminary studies demonstrated
      that TGF-beta1 was stable if urine was frozen promptly at -70 degrees C without
      preservatives. Using this assay, 22/80 controls (27%) had detectable levels of
      urinary TGF-beta1 (range <7 to 40.9pg/mL; mean+/-SD 6.4+/-11.1pg/mL). This was
      significantly lower (p<0.0001) than in the DN group in whom 114/190 (60%) had
      detectable levels of urinary TGF-beta1 (range <7 to 526.4pg/mL; mean+/-SD
      20.4+/-45.8pg/mL). Urinary protein and TGF-beta1 concentrations demonstrated
      modest correlation in patients with DN (r=0.47, P<0.001). TGF-beta1 measurement
      in patients with DN did not demonstrate significant association with progression 
      of proteinuria or increase in serum creatinine during the next 12months of
      follow-up. CONCLUSION: We have validated a sensitive ELISA assay for urinary
      TGF-beta1, and demonstrated correlations with the degree of proteinuria and
      higher levels in patients with DN compared to controls. Additional study will be 
      necessary in order to determine if serial testing can predict renal prognosis
      independent of known prognostic factors for patients with DN.
CI  - Copyright (c) 2013 The Canadian Society of Clinical Chemists. Published by
      Elsevier Inc. All rights reserved.
AD  - Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo
      Clinic, Rochester, MN, USA.
FAU - Tsapenko, Mykola V
AU  - Tsapenko MV
FAU - Nwoko, Rosemary E
AU  - Nwoko RE
FAU - Borland, Timothy M
AU  - Borland TM
FAU - Voskoboev, Nikolay V
AU  - Voskoboev NV
FAU - Pflueger, Axel
AU  - Pflueger A
FAU - Rule, Andrew D
AU  - Rule AD
FAU - Lieske, John C
AU  - Lieske JC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/14 [received]
PHST- 2013/05/04 [revised]
PHST- 2013/05/09 [accepted]
AID - S0009-9120(13)00237-3 [pii]
AID - 10.1016/j.clinbiochem.2013.05.041 [doi]
PST - aheadofprint
SO  - Clin Biochem. 2013 May 16. pii: S0009-9120(13)00237-3. doi:
      10.1016/j.clinbiochem.2013.05.041.

PMID- 23685187
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1528-8447 (Electronic)
IS  - 1526-5900 (Linking)
DP  - 2013 May 16
TI  - Increased Axonal Regeneration and Swellings in Intraepidermal Nerve Fibers
      Characterize Painful Phenotypes of Diabetic Neuropathy.
LID - S1526-5900(13)00910-3 [pii]
LID - 10.1016/j.jpain.2013.03.005 [doi]
AB  - We examined changes in intraepidermal nerve fibers (IENFs) to differentiate
      patients with diabetic neuropathy (DN) and diabetic neuropathic pain (DN-P) from 
      those with DN without pain (DN-NOP). Punch skin biopsies were collected from the 
      proximal thigh (PT) and distal leg (DL) of normal subjects, patients with type 2 
      diabetes without evidence of DN (DM), or DN-P and DN-NOP patients. Protein gene
      product 9.5-positive (PGP+) immunohistochemistry was used to quantify total IENF,
      and growth-associated protein 43 (GAP43) for regenerating IENF. Compared to
      normal subjects and patients with type 2 diabetes without evidence of DN, both
      DN-P and DN-NOP have reduced PGP+ IENF densities in DL and PT. Although GAP43+
      IENF densities were also reduced in DL for both DN-P and DN-NOP, the GAP43+ IENF 
      densities in PT of DN-P remained at the control levels. Higher GAP43/PGP ratios
      were detected in DN-P compared to DN-NOP in the DL and PT. In parallel, increased
      numbers of axonal swellings per PGP+ fiber (axonal swelling/PGP) were detected in
      DN-P compared to normal subjects, patients with type 2 diabetes without evidence 
      of DN, and DN-NOP in the DL. These axonal swellings were positive for
      tropomyosin-receptor-kinase A and substance P, suggesting that they are
      associated with nociception. PERSPECTIVE: Among patients with DN, the ratios of
      GAP43/PGP and axonal swelling/PGP are likely to differentiate painful from
      painless phenotypes.
CI  - Copyright (c) 2013 American Pain Society. Published by Elsevier Inc. All rights
      reserved.
AD  - Department of Neurology, University of Michigan Medical Center, Ann Arbor,
      Michigan. Electronic address: chengt@umich.edu.
FAU - Cheng, Hsinlin T
AU  - Cheng HT
FAU - Dauch, Jacqueline R
AU  - Dauch JR
FAU - Porzio, Michael T
AU  - Porzio MT
FAU - Yanik, Brandon M
AU  - Yanik BM
FAU - Hsieh, Wilson
AU  - Hsieh W
FAU - Smith, A Gordon
AU  - Smith AG
FAU - Singleton, J Robinson
AU  - Singleton JR
FAU - Feldman, Eva L
AU  - Feldman EL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - J Pain
JT  - The journal of pain : official journal of the American Pain Society
JID - 100898657
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/08/24 [received]
PHST- 2013/01/23 [revised]
PHST- 2013/03/11 [accepted]
AID - S1526-5900(13)00910-3 [pii]
AID - 10.1016/j.jpain.2013.03.005 [doi]
PST - aheadofprint
SO  - J Pain. 2013 May 16. pii: S1526-5900(13)00910-3. doi:
      10.1016/j.jpain.2013.03.005.

PMID- 23685153
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
DP  - 2013 May 16
TI  - Potential roles of adenosine deaminase-2 in diabetic retinopathy.
LID - S0006-291X(13)00794-8 [pii]
LID - 10.1016/j.bbrc.2013.05.023 [doi]
AB  - The early activation of microglia that induces retinal inflammation in DR may
      serve as a target for therapeutic intervention of DR. Our demonstration that
      retinal inflammation is attenuated via adenosine receptor A2AAR supports the
      hypothesis that a mechanism to maintain extracellular concentrations of adenosine
      important in normal physiology is impaired in DR. Extracellular concentrations of
      adenosine are regulated by the interplay of equiliberative nucleoside transporter
      (ENT)s with enzymes of adenosine metabolism including adenosine deaminase-1
      (ADA1), adenosine kinase (AK) and CD73. In the vertebrates but not rodents, a
      macrophage-associated ADA2 is identified. The role of ADA2 is, therefore,
      understudied as the sequencing probes or antibodies to mouse ADA2 are not
      available. We identified increased ADA2 expression and activity in human and
      porcine retinas with diabetes, and in Amadori glycated albumin (AGA)- or
      hyperglycemia-treated porcine and human microglia. In rodent as well as porcine
      cells, modulation of TNF-alpha release is mediated by A2AAR. Quantitative
      analysis of normal and diabetic porcine retinas reveals that while the expression
      levels of ADA2, A2AAR, ENT1, TNF-alpha and MMP9 are increased, the levels of AK
      are reduced during inflammation as an endogenous protective mechanism. To
      determine the role of ADA2, we found that AGA induces ADA2 expression, ADA2
      activity and TNF-alpha release, and that TNF-alpha release is blocked by
      ADA2-neutralizing antibody or ADA2 siRNA, but not by scrambled siRNA. These
      results suggest that retinal inflammation in DR is mediated by ADA2, and that the
      anti-inflammatory activity of A2AAR signaling is impaired in diabetes due to
      increased ADA2 activity.
CI  - Published by Elsevier Inc.
AD  - Department of Ophthalmology, Georgia Regents University, Augusta, GA, United
      States; Department of Clinical Biochemistry, Faculty of Pharmacy, Mansoura
      University, Mansoura, Egypt.
FAU - Elsherbiny, Nehal M
AU  - Elsherbiny NM
FAU - Naime, Mohammad
AU  - Naime M
FAU - Ahmad, Saif
AU  - Ahmad S
FAU - Elsherbini, Ahmed M
AU  - Elsherbini AM
FAU - Mohammad, Shuaib
AU  - Mohammad S
FAU - Fulzele, Sadanand
AU  - Fulzele S
FAU - El-Remessy, Azza B
AU  - El-Remessy AB
FAU - Al-Gayyar, Mohammed M
AU  - Al-Gayyar MM
FAU - Eissa, Laila A
AU  - Eissa LA
FAU - El-Shishtawy, Mamdouh M
AU  - El-Shishtawy MM
FAU - Han, Guichun
AU  - Han G
FAU - White, Richard
AU  - White R
FAU - Haroldo, Toque Flores
AU  - Haroldo TF
FAU - Liou, Gregory I
AU  - Liou GI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/04/30 [received]
PHST- 2013/05/06 [accepted]
AID - S0006-291X(13)00794-8 [pii]
AID - 10.1016/j.bbrc.2013.05.023 [doi]
PST - aheadofprint
SO  - Biochem Biophys Res Commun. 2013 May 16. pii: S0006-291X(13)00794-8. doi:
      10.1016/j.bbrc.2013.05.023.

PMID- 23685112
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1872-9177 (Electronic)
IS  - 1769-7255 (Linking)
DP  - 2013 May 16
TI  - [Evolution of the diet from the paleolithic to today: Progress or regress?]
LID - S1769-7255(13)00065-5 [pii]
LID - 10.1016/j.nephro.2013.03.011 [doi]
AB  - The changes in eating habits and decreased physical activity have been
      responsible for part of the high prevalence of chronic diseases such as
      hypertension or diabetes, currently observed in the so-called civilized
      societies. These diseases are less prevalent in previous civilizations and
      several decades of nutrition research have enabled better understanding of the
      eating habits of our ancestors, and have demonstrated the value of diet called
      "Mediterranean or Paleolithic". This review provides an update on the latest
      research. What dietary changes since the Paleolithic period, and finally how can 
      we adapt our current diet? Several animal studies or human clinical demonstrate
      the value of historical research and nutrition.
CI  - Copyright (c) 2013. Published by Elsevier SAS.
AD  - Service de nephrologie, hopital Pellegrin, CHU de Bordeaux, place Amelie
      Raba-Leon, 33000 Bordeaux, France; Aurad-Aquitaine, 2, allee des demoiselles,
      33170 Gradignan, France. Electronic address: ph.chauveau@gmail.com.
FAU - Chauveau, Philippe
AU  - Chauveau P
FAU - Fouque, Denis
AU  - Fouque D
FAU - Combe, Christian
AU  - Combe C
FAU - Aparicio, Michel
AU  - Aparicio M
LA  - FRE
PT  - JOURNAL ARTICLE
TT  - Evolution de l'alimentation du paleolithique a nos jours : progression ou
      regression ?
DEP - 20130516
TA  - Nephrol Ther
JT  - Nephrologie & therapeutique
JID - 101248950
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/11 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/18 [accepted]
AID - S1769-7255(13)00065-5 [pii]
AID - 10.1016/j.nephro.2013.03.011 [doi]
PST - aheadofprint
SO  - Nephrol Ther. 2013 May 16. pii: S1769-7255(13)00065-5. doi:
      10.1016/j.nephro.2013.03.011.

PMID- 23685025
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 May 16
TI  - Does insulin resistance in type 2 diabetes alter vitamin D status?
LID - S1751-9918(13)00049-1 [pii]
LID - 10.1016/j.pcd.2013.04.008 [doi]
AB  - AIMS: Data on changes of vitamin D due to insulin resistance are conflicting. We 
      assessed vitamin D concentrations and parameters of glycemia and mineral
      homeostasis in patients with insulin resistant type 2 diabetes and in matched
      normal controls. METHODS: Sixty-nine patients with type 2 diabetes and 60 matched
      normal control subjects were studied. After an overnight fast, blood was
      collected for measuring the parameters of glycemia (glucose, insulin and HbA1c), 
      mineral profile (corrected calcium, phosphate and alkaline phosphatase), total
      25(OH) vitamin D and parathyroid hormone (PTH) levels. RESULTS: Patients had
      significantly elevated fasting glucose (P=0.0001), insulin (P=0.0003) and HbA1c
      (P=0.0005) than the controls had. They had significantly raised calculated
      insulin resistance compared with control subjects (P=0.0001). Patients and
      controls had similar levels of serum corrected calcium and ALP, whereas serum
      phosphate was significantly lower in the patients compared with controls
      (P=0.001). Patients and controls had similar levels of 25(OH)D, but the levels of
      25(OH)D in both were in the deficiency range. Intact PTH was similar in the
      patients and controls. Levels of 25(OH)D did not demonstrate any relation with
      fasting insulin, insulin resistance, or HbA1c, but correlated negatively with
      intact PTH (r=-0.4, P=0.02). CONCLUSION: This study demonstrated prevalent
      vitamin D deficiency in insulin resistant type 2 diabetic and normal subjects.
      Insulin resistance did not influence the status of vitamin D.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Division of Endocrinology & Metabolic Medicine, Department of Medicine, Faculty
      of Medicine, Kuwait University, Jabriya, Kuwait; Mubarak Al Kabeer Hospital,
      Jabriya, Kuwait. Electronic address: kshoumer@gmail.com.
FAU - Al-Shoumer, Kamal Abdul Aziz Sulaiman
AU  - Al-Shoumer KA
FAU - Al-Asoosi, Adnan Ali
AU  - Al-Asoosi AA
FAU - Ali, Aida Hussain
AU  - Ali AH
FAU - Nair, Vasanthy Sudheer
AU  - Nair VS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/07 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/03 [accepted]
AID - S1751-9918(13)00049-1 [pii]
AID - 10.1016/j.pcd.2013.04.008 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 May 16. pii: S1751-9918(13)00049-1. doi:
      10.1016/j.pcd.2013.04.008.

PMID- 23685024
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 May 16
TI  - Trends in cardiovascular risk factors among people with diabetes in a population 
      based study, Health Survey for England 1994-2009.
LID - S1751-9918(13)00051-X [pii]
LID - 10.1016/j.pcd.2013.04.010 [doi]
AB  - AIMS: We evaluated trends in cardiovascular risk factors in a population-based
      sample of people with diabetes in England from 1994 to 2009. METHODS: Data were
      obtained from Health Survey for England for 1994, 1998, 2003, 2006, 2008 and
      2009. Participants were aged >/=30 years with self-reported diabetes. RESULTS:
      The standerdised prevalence of diabetes increased from 2.8% in 1994 to 6.4% in
      2009 and the prevalence among males was higher than females throughout. The trend
      in prevalence was more apparent in manual workers. From 1994 to 2009, mean
      systolic blood pressure declined from 148mmHg to 137mmHg; mean diastolic pressure
      declined from 80mmHg to 70mmHg; mean total cholesterol declined from 6.1mmol/L to
      4.5mmol/L over the 15 years with linear trends. The proportion prescribed lipid
      lowering drugs increased from 2.2% to 47.4%. The percentage of current smokers
      declined from 17.5% to 13.4%. Mean body mass index increased from 27.7kg/m2 to
      31.6kg/m2 with an overall increase of 0.24kg/m2 per year. Risk factor trends were
      generally similar between genders and social classes but the decline in smoking
      was not significant for men or for manual workers. CONCLUSIONS: People with
      clinical diabetes have experienced substantial reductions in blood pressure,
      total cholesterol and smoking over 15 years. Increasing body mass index and
      persistence of smoking in lower socioeconomic groups, may compromise these
      improvements.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. All rights reserved.
AD  - King's College London, Department of Primary Care and Public Health Sciences,
      Capital House, 42, Weston Street, London SE1 3QD, United Kingdom; Department of
      Family Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, 
      Sri Lanka. Electronic address: shyamalee.samaranayaka@kcl.ac.uk.
FAU - Samaranayaka, Shyamalee
AU  - Samaranayaka S
FAU - Gulliford, Martin C
AU  - Gulliford MC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/05/15 [received]
PHST- 2013/04/18 [revised]
PHST- 2013/04/19 [accepted]
AID - S1751-9918(13)00051-X [pii]
AID - 10.1016/j.pcd.2013.04.010 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 May 16. pii: S1751-9918(13)00051-X. doi:
      10.1016/j.pcd.2013.04.010.

PMID- 23685023
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 May 16
TI  - Association of HbA with emotion regulation, intolerance of uncertainty, and
      purpose in life in type 2 diabetes mellitus.
LID - S1751-9918(13)00047-8 [pii]
LID - 10.1016/j.pcd.2013.04.006 [doi]
AB  - BACKGROUND: The extant literature lacks breadth on psychological variables
      associated with health outcome for type 2 diabetes mellitus (T2DM). This
      investigation extends the scope of psychological information by reporting on
      previously unpublished factors. OBJECTIVE: To investigate if intolerance of
      uncertainty, emotion regulation, or purpose in life differentiate T2DM adults
      with sustained high HbA1c (HH) vs. sustained acceptable HbA1c (AH). SUBJECTS AND 
      METHODS: Cross-sectional observational study. Adult patients with diagnosed T2DM 
      meeting inclusionary criteria for AH, HH, or a nondiabetic reference group (NDR) 
      were randomly selected and invited to participate. Patients who consented and
      participated resulted in a final sample of 312 subgrouped as follows: HH (n=108);
      AH (n=98); and NDR (n=106). Data sources included a survey, self-report
      questionnaires, and electronic medical record (EMR). RESULTS: HH individuals with
      T2DM reported lower purpose in life satisfaction (p=0.005) compared to the NDR
      group. The effect size for this finding is in the small-to-medium range using
      Cohen's guidelines for estimating clinical relevance. The HH-AH comparison on
      purpose in life was nonsignificant. The emotion regulation and intolerance of
      uncertainty comparisons across the three groups were not significant.
      CONCLUSIONS: The present study determined that lower purpose in life satisfaction
      is associated with higher HbA1c. In a T2DM patient with sustained high HbA1c, the
      primary care clinician is encouraged to consider screening for purpose in life
      satisfaction by asking a single question such as "Do the things you do in your
      life seem important and worthwhile?" The patient's response will assist the
      clinician in determining if meaning or purpose in life distress may be
      interferring with diabetes self-care. If this is the case, the clinician can
      shift the conversation to the value of behavioral and emotional health
      counseling.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Department of Psychiatry and Psychology, Division of Integrated Behavioral
      Healthcare, Mayo Clinic, Rochester, MN, USA; Department of Family Medicine, Mayo 
      Clinic, Rochester, MN, USA. Electronic address: rasmussen.norman@mayo.edu.
FAU - Rasmussen, Norman H
AU  - Rasmussen NH
FAU - Smith, Steven A
AU  - Smith SA
FAU - Maxson, Julie A
AU  - Maxson JA
FAU - Bernard, Matthew E
AU  - Bernard ME
FAU - Cha, Stephen S
AU  - Cha SS
FAU - Agerter, David C
AU  - Agerter DC
FAU - Shah, Nilay D
AU  - Shah ND
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/19 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/04/16 [accepted]
AID - S1751-9918(13)00047-8 [pii]
AID - 10.1016/j.pcd.2013.04.006 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 May 16. pii: S1751-9918(13)00047-8. doi:
      10.1016/j.pcd.2013.04.006.

PMID- 23684983
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
DP  - 2013 May 16
TI  - Increased vitamin D receptor expression in dorsal root ganglia neurons of
      diabetic rats.
LID - S0304-3940(13)00444-8 [pii]
LID - 10.1016/j.neulet.2013.05.023 [doi]
AB  - The effects of vitamin D on the nervous system have been studied extensively. In 
      spite of accumulating data about the substantial changes in the vitamin D
      receptor (VDR) signaling system, during different types of neuroinflammatory
      diseases, its role in diabetic neuropathy has not been investigated in detail. To
      assess the role of VDR signaling in diabetic neuropathy, we examined expression
      of VDRs in dorsal root ganglia (DRG) neurons in a rat model of
      streptozotocin-induced diabetes mellitus type 1. Diabetes mellitus (DM) type 1
      was induced with streptozotocin in male Sprague-Dawley rats. After two months,
      expression of VDRs was analyzed immunohistochemically in the cytoplasm of L4 and 
      L5 DRG neurons of diabetic rats. Semi-quantitative analysis for the determination
      of staining in nuclei and plasma-membranes of DRG neurons was performed. A
      significant increase in VDR expression was observed in DRG neurons of diabetic
      rats. Expression of VDRs was increased in the cytoplasm, nuclei and in cell
      membranes of neurons. An increase in VDR expression occurred in all neurons, but 
      the greatest increase of fluorescence intensity in cytoplasm was observed in
      neurons of small diameter. Results of the present study indicate that the VDR
      signaling system could be a potential therapeutic target for diabetic neuropathy.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - School of Medicine in Split, Department of Anatomy, Histology and Embriology,
      Soltanska 2, 21000 Split, Croatia. Electronic address:
      natalija.filipovic@mefst.hr.
FAU - Filipovic, Natalija
AU  - Filipovic N
FAU - Ferhatovic, Lejla
AU  - Ferhatovic L
FAU - Marelja, Ivana
AU  - Marelja I
FAU - Puljak, Livia
AU  - Puljak L
FAU - Grkovic, Ivica
AU  - Grkovic I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/04/15 [received]
PHST- 2013/05/05 [revised]
PHST- 2013/05/06 [accepted]
AID - S0304-3940(13)00444-8 [pii]
AID - 10.1016/j.neulet.2013.05.023 [doi]
PST - aheadofprint
SO  - Neurosci Lett. 2013 May 16. pii: S0304-3940(13)00444-8. doi:
      10.1016/j.neulet.2013.05.023.

PMID- 23684905
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-507X (Electronic)
IS  - 0031-9384 (Linking)
VI  - 118C
DP  - 2013 May 15
TI  - Insulin concentrations in cerebellum and body balance in diabetic male rats:
      Aerobic training effects.
PG  - 58-62
LID - S0031-9384(13)00149-2 [pii]
LID - 10.1016/j.physbeh.2013.05.008 [doi]
AB  - Brain insulin has had widespread metabolic, neurotrophic, and neuromodulatory
      functions and has been involved in the central regulation of food intake and body
      weight, learning and memory, neuronal development, and neuronal apoptosis.
      PURPOSE: The present study investigated the role of swimming training on cerebral
      metabolism on insulin concentrations in cerebellum and the body balance
      performance of diabetic rats. METHODS: Forty Male Wistar rats were divided in
      four groups: sedentary control (SC), trained control (TC), sedentary diabetic
      (SD), and trained diabetic (TD). Diabetes was induced by alloxan (32mgkg b.w.),
      single dose injection. The mean blood glucose of diabetic groups was
      367+/-40mg/dl. Training program consisted in swimming 5days/week, 1h/day, 8weeks,
      supporting a workload corresponding to 90% of maximal lactate steady state
      (MLSS). For the body balance testing rats were trained to traverse for 5min daily
      for 5-7days. All dependent variables were analyzed by one-way analysis of
      variance (ANOVA) and a significance level of p<0.05 was used for all comparisons.
      RESULTS: The body balance testing scores were different between groups. Insulin
      concentrations in cerebellum were not different between groups. CONCLUSION: It
      was concluded that in diabetic rats, aerobic training does not induce alterations
      on cerebellum insulin but induces important metabolic, hormonal and behavioral
      alterations which are associated with an improvement in glucose homeostasis,
      serum insulin concentrations and body balance.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - UNESP - Sao Paulo State University, Rio Claro, Brazil. Electronic address:
      umarantes@hotmail.com.
FAU - Arantes, Luciana Mendonca
AU  - Arantes LM
FAU - Bertolini, Natalia Oliveira
AU  - Bertolini NO
FAU - de Moura, Rodrigo Ferreira
AU  - de Moura RF
FAU - de Mello, Maria Alice Rostom
AU  - de Mello MA
FAU - Luciano, Eliete
AU  - Luciano E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/10/17 [received]
PHST- 2013/01/21 [revised]
PHST- 2013/05/06 [accepted]
AID - S0031-9384(13)00149-2 [pii]
AID - 10.1016/j.physbeh.2013.05.008 [doi]
PST - aheadofprint
SO  - Physiol Behav. 2013 May 15;118C:58-62. doi: 10.1016/j.physbeh.2013.05.008.

PMID- 23684887
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
DP  - 2013 May 16
TI  - Decursin inhibited proliferation and angiogenesis of endothelial cells to
      suppress diabetic retinopathy via VEGFR2.
LID - S0303-7207(13)00198-6 [pii]
LID - 10.1016/j.mce.2013.04.021 [doi]
AB  - Diabetes induces pathologic proliferation and angiogenesis in the retina that
      leads to catastrophic loss of vision. Decursin is a novel therapeutic that
      targets the vascular endothelial growth factor (VEGF) receptor (VEGFR) with
      putative anti-proliferative and anti-angiogenic activities. Thereby we utilized
      human retinal microvascular endothelial cells (HRMEC) and human umbilical vein
      endothelial cells (HUVEC) under conditions of excess glucose to explore
      dose-dependent responses of decursin on markers of migration, angiogenesis, and
      proliferation. Decursin dose-dependently inhibited tube formation, VEGFR-2
      expression, along with relative metabolic activity and 5-bromo-2'-deoxy-uridine
      (BrdU) activity in both cell lines. We then correlated our findings to the
      streptozotocin-induced rat model of diabetes. Following three months of decursin 
      treatment VEGFR-2 expression was significantly inhibited. Our data would suggest 
      that decursin may be a potent anti-angiogenic and anti-proliferative agent
      targeting the VEGFR-2 signaling pathway, which significantly inhibits diabetic
      retinal neovascularization.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Endocrinology and Metabolism, Yunnan Province 2nd Hospital, Kunming
      650031, China; Department of Internal Medicine, Division of Endocrinology, HSC
      Diabetes Center, University of Missouri, Columbia, MO 65201, USA; Laboratory for 
      Conservation and Utilization of Bio-resources Yunnan University, Kunming 650021, 
      China. Electronic address: yangying2072@126.com.
FAU - Yang, Ying
AU  - Yang Y
FAU - Yang, Ke
AU  - Yang K
FAU - Li, Yiping
AU  - Li Y
FAU - Li, Xianli
AU  - Li X
FAU - Sun, Qiangming
AU  - Sun Q
FAU - Meng, Hua
AU  - Meng H
FAU - Zeng, Ying
AU  - Zeng Y
FAU - Hu, Yong
AU  - Hu Y
FAU - Zhang, Ying
AU  - Zhang Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/17 [received]
PHST- 2013/04/26 [revised]
PHST- 2013/04/26 [accepted]
AID - S0303-7207(13)00198-6 [pii]
AID - 10.1016/j.mce.2013.04.021 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 May 16. pii: S0303-7207(13)00198-6. doi:
      10.1016/j.mce.2013.04.021.

PMID- 23684884
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
DP  - 2013 May 17
TI  - Canonical and non-canonical roles of the histone methyltransferase EZH2 in
      mammary development and cancer.
LID - S0303-7207(13)00205-0 [pii]
LID - 10.1016/j.mce.2013.05.002 [doi]
AB  - Although hormones and downstream transcription factors are considered main
      drivers directing mammary gland development and oncogenic transformation, an
      emerging body of evidence suggests these processes are modulated by dynamic
      histone methylation landscapes. The methyltransferase EZH2 catalyzes the
      formation of trimethyl groups on lysine 27 of histone 3 (H3K27me3) and loss- and 
      gain-of-function studies have provided insight into its role in normal mammary
      development and oncogenic transformation. EZH2 controls the homeostasis of mouse 
      mammary stem cells, and mammary epithelium devoid of EZH2 does not undergo
      functional development during pregnancy, possibly due to a paucity of stem cells.
      EZH2 levels are frequently elevated in breast cancer suggesting a link between
      H3K27me3 and cell proliferation. In addition to its role as epigenetic regulator,
      recent studies have placed EZH2 into the category of transcriptional
      co-activators and thus opened the possibility of non-canonical signaling
      pathways. In contrast to solid tumors, loss of EZH2 from hematopoietic cells has 
      been linked to malignancies (Fig. 1). The challenge will be to understand not
      only cell-specific functions of EZH2, but also the extent to which it relies on
      its enzymatic activity versus its ability to serve as a transcriptional
      co-factor.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights
      reserved.
AD  - Laboratory of Genetics and Physiology, National Institute of Diabetes and
      Digestive and Kidney Diseases, National Institutes of Health, 8 Center Drive,
      Bethesda, MD, 20892-0822, USA; Department of Hematology and Oncology, Chonnam
      National University, Hwasun Hospital, Hwasun-gun, Jeollanamdo, South Korea.
      Electronic address: wookyun.bae@mail.nih.gov.
FAU - Bae, Woo Kyun
AU  - Bae WK
FAU - Hennighausen, Lothar
AU  - Hennighausen L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/04/19 [received]
PHST- 2013/05/01 [accepted]
AID - S0303-7207(13)00205-0 [pii]
AID - 10.1016/j.mce.2013.05.002 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 May 17. pii: S0303-7207(13)00205-0. doi:
      10.1016/j.mce.2013.05.002.

PMID- 23684841
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 16
TI  - Sex dimorphism and depot differences in adipose tissue function.
LID - S0925-4439(13)00160-9 [pii]
LID - 10.1016/j.bbadis.2013.05.006 [doi]
AB  - Obesity, characterized by excessive adiposity, is a risk factor for many
      metabolic pathologies, such as type 2 diabetes mellitus (T2DM). Numerous studies 
      have shown that adipose tissue distribution may be a greater predictor of
      metabolic health. Upper-body fat (visceral and subcutaneous abdominal) is
      commonly associated with the unfavorable complications of obesity, while
      lower-body fat (gluteal-femoral) may be protective. Current research
      investigations are focused on analyzing the metabolic properties of adipose
      tissue, in order to better understand the mechanisms that regulate fat
      distribution in both men and women. This review will highlight the adipose tissue
      depot- and sex-dependent differences in white adipose tissue function, including 
      adipogenesis, adipose tissue developmental patterning, the storage and release of
      fatty acids, and secretory function. This article is part of a Special Issue
      entitled: Modulation of Adipose Tissue in Health and Disease.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Pennington Biomedical Research Center, Louisiana State University System, Baton
      Rouge, LA, USA.
FAU - White, Ursula A
AU  - White UA
FAU - Tchoukalova, Yourka D
AU  - Tchoukalova YD
LA  - ENG
GR  - R01 DK090607/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/21 [received]
PHST- 2013/04/18 [revised]
PHST- 2013/05/03 [accepted]
AID - S0925-4439(13)00160-9 [pii]
AID - 10.1016/j.bbadis.2013.05.006 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 16. pii: S0925-4439(13)00160-9. doi:
      10.1016/j.bbadis.2013.05.006.

PMID- 23684761
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 16
TI  - Intense physical activity is associated with better metabolic control in patients
      with type 1 diabetes.
LID - S0168-8227(13)00162-9 [pii]
LID - 10.1016/j.diabres.2013.04.006 [doi]
AB  - OBJECTIVES: To analyze the association between adherence to physical activity
      guideline recommendations and metabolic control in patients with type 1 diabetes 
      (DM1). METHODS: An observational, cross-sectional study was conducted in 130
      adult DM1 patients from Spain with a mean age of 33.9+/-11.5 years and disease
      duration of 16.5+/-9.5 years. We analyzed several clinical, anthropometric and
      laboratory variables together with information obtained from the Minnesota
      Leisure Time Physical Activity Questionnaire. RESULTS: Evaluated patients
      reported an average of 850.6+/-493.2min of physical activity per week, being
      classified as light (567.4+/-425.4min/week), moderate (169.9+/-212.1min/week) and
      intense activities (120.6+/-184.2). Patients who dedicated more time to intense
      physical activity were younger, had university studies and were males more often 
      than those who spent none or less time on intense physical activity. We observed 
      no differences in HbA1c levels in relation to time dedicated to moderate physical
      activities. However, patients who dedicated more than 150min to intense physical 
      activity per week had lower levels of HbA1c (HbA1c: 7.2+/-1.0% versus 7.8+/-1.1% 
      versus 8.0+/-1.0% in more than 149min, between 0 and 149min or 0min of intense
      physical activity per week, respectively). CONCLUSION: Performing more than
      150min of intense physical activity a week is associated with better metabolic
      control in type 1 Spanish patients. No positive impact in metabolic control was
      observed in relation to the time spent in moderate physical activity.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Endocrinology Service of Puerto Real University Hospital, Cadiz, Spain.
      Electronic address: florencarral@hotmail.com.
FAU - Carral, Florentino
AU  - Carral F
FAU - Gutierrez, Jose Vicente
AU  - Gutierrez JV
FAU - Ayala, Maria Del Carmen
AU  - Ayala MD
FAU - Garcia, Gloria
AU  - Garcia G
FAU - Aguilar, Manuel
AU  - Aguilar M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/14 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/04/22 [accepted]
AID - S0168-8227(13)00162-9 [pii]
AID - 10.1016/j.diabres.2013.04.006 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 16. pii: S0168-8227(13)00162-9. doi:
      10.1016/j.diabres.2013.04.006.

PMID- 23684754
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
DP  - 2013 May 16
TI  - Effects of Exenatide on Kidney Function, Adverse Events, and Clinical End Points 
      of Kidney Disease in Type 2 Diabetes.
LID - S0272-6386(13)00703-8 [pii]
LID - 10.1053/j.ajkd.2013.03.026 [doi]
AD  - Providence Sacred Heart Medical Center & University of Washington School of
      Medicine, Spokane, Washington.
FAU - Tuttle, Katherine R
AU  - Tuttle KR
FAU - Heilmann, Cory
AU  - Heilmann C
FAU - Hoogwerf, Byron J
AU  - Hoogwerf BJ
FAU - Brown, Carl
AU  - Brown C
FAU - Anderson, Pamela W
AU  - Anderson PW
LA  - ENG
PT  - LETTER
DEP - 20130516
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/15 [received]
PHST- 2013/03/07 [accepted]
AID - S0272-6386(13)00703-8 [pii]
AID - 10.1053/j.ajkd.2013.03.026 [doi]
PST - aheadofprint
SO  - Am J Kidney Dis. 2013 May 16. pii: S0272-6386(13)00703-8. doi:
      10.1053/j.ajkd.2013.03.026.

PMID- 23684753
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
DP  - 2013 May 16
TI  - Cystatin-Based Estimated GFR Versus Creatinine-Based and Creatinine- and
      Cystatin-Based Estimated GFR for ESRD and Mortality Risk in Diabetes.
LID - S0272-6386(13)00709-9 [pii]
LID - 10.1053/j.ajkd.2013.03.029 [doi]
AD  - Joslin Diabetes Center, Boston, Massachusetts; Harvard Medical School, Boston,
      Massachusetts; Jagiellonian University Medical College, Krakow, Poland.
FAU - Skupien, Jan
AU  - Skupien J
FAU - Warram, James H
AU  - Warram JH
FAU - Groop, Per-Henrik
AU  - Groop PH
FAU - Krolewski, Andrzej S
AU  - Krolewski AS
LA  - ENG
PT  - LETTER
DEP - 20130516
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/30 [received]
PHST- 2013/03/22 [accepted]
AID - S0272-6386(13)00709-9 [pii]
AID - 10.1053/j.ajkd.2013.03.029 [doi]
PST - aheadofprint
SO  - Am J Kidney Dis. 2013 May 16. pii: S0272-6386(13)00709-9. doi:
      10.1053/j.ajkd.2013.03.029.

PMID- 23684685
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 May 15
TI  - Brief episodes of silent atrial fibrillation were associated with an increased
      risk of silent cerebral infarct and stroke in type 2 diabetic patients.
LID - S0735-1097(13)01881-0 [pii]
LID - 10.1016/j.jacc.2013.02.091 [doi]
AB  - OBJECTIVE: We evaluated whether subclinical episodes of atrial fibrillation (AF) 
      were associated with an increased risk of silent cerebral infarct (SCI) and
      stroke in diabetic patients younger than 60 years who did not have other clinical
      evidence of AF and cerebrovascular disease at baseline. BACKGROUND: In type 2
      diabetic patients, one quarter of strokes are of unknown cause, and subclinical
      episodes AF may be a common etiologic factor. METHODS: Longitudinal,
      observational study was performed on 464 type 2 diabetic patients younger than 60
      years and matched them to patients without diabetes. Patients underwent to
      quarterly 48-hour ECG Holter monitoring (48HM) to detect brief subclinical
      episodes of AF (AF durations <48 hours.) and followed them for 37 months. The
      outcomes were a SCI, assessed by brain MRI, and stroke events during the
      follow-up. RESULTS: Prevalence of subclinical episodes of AF was significantly
      greater among patients with diabetes compared with matched healthy subjects (9%
      vs. 1.6%, P<0.0001). During an average duration of 37 months, 43 stroke events
      occurred in diabetic population, whereas no events occurred in healthy subjects. 
      Diabetic patients with silent episodes of AF (SAFE-group, n=176) had higher
      baseline prevalence of SCI (61% versus 29%, P<0.01) and higher stroke events
      (17.3% versus 5.9%, P<0.01) during the follow-up period than the others
      (non-SAFE-group, n=288). Episode of silent AF was an independent determinant of
      SCI (OR 4.441, P<0.001 C.I=2.42 to 8.16) and independent predictors for the
      occurrence of stroke in diabetic patients (HR, 4.6; P<0.01 C.I 2.7-9.1).
      CONCLUSION: Subclinical episodes of AF occurred frequently in type 2 diabetic
      patients and were associated with a significantly increased risk of SCI and
      stroke.
CI  - Copyright (c) 2013 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
AD  - Department of Geriatrics and Metabolic Diseases Second University of Naples,
      Italy. Electronic address: raffaele.marfella@unina2.it.
FAU - Marfella, Raffaele
AU  - Marfella R
FAU - Sasso, Ferdinando Carlo
AU  - Sasso FC
FAU - Siniscalchi, Mario
AU  - Siniscalchi M
FAU - Cirillo, Mario
AU  - Cirillo M
FAU - Paolisso, Pasquale
AU  - Paolisso P
FAU - Sardu, Celestino
AU  - Sardu C
FAU - Barbieri, Michelangela
AU  - Barbieri M
FAU - Rizzo, Maria Rosaria
AU  - Rizzo MR
FAU - Mauro, Ciro
AU  - Mauro C
FAU - Paolisso, Giuseppe
AU  - Paolisso G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/12 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/02/26 [accepted]
AID - S0735-1097(13)01881-0 [pii]
AID - 10.1016/j.jacc.2013.02.091 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 May 15. pii: S0735-1097(13)01881-0. doi:
      10.1016/j.jacc.2013.02.091.

PMID- 23684677
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 May 15
TI  - A Novel Paradigm for Heart Failure with Preserved Ejection Fraction:
      Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary
      Microvascular Endothelial Inflammation.
LID - S0735-1097(13)01890-1 [pii]
LID - 10.1016/j.jacc.2013.02.092 [doi]
AB  - Over the last decennium, myocardial structure, cardiomyocyte function and
      intramyocardial signaling were shown to be specifically altered in heart failure 
      with preserved ejection fraction (HFPEF). A new paradigm for HFPEF development is
      therefore proposed, which identifies a systemic proinflammatory state induced by 
      comorbidities as the cause of myocardial structural and functional alterations.
      The new paradigm presumes the following sequence of events in HFPEF: 1) A high
      prevalence of comorbidities such as overweight/obesity, diabetes mellitus,
      chronic obstructive pulmonary disease and salt sensitive hypertension induce a
      systemic proinflammatory state; 2) A systemic proinflammatory state causes
      coronary microvascular endothelial inflammation; 3) Coronary microvascular
      endothelial inflammation reduces nitric oxide (NO) bioavailability, cyclic
      guanosine monophosphate (cGMP) content and protein kinase G (PKG) activity in
      adjacent cardiomyocytes; 4) Low PKG activity favours hypertrophy development and 
      raises resting tension because of hypophosphorylation of titin; 5) Both stiff
      cardiomyocytes and interstitial fibrosis contribute to high diastolic left
      ventricular (LV) stiffness and HF development. The new HFPEF paradigm shifts
      emphasis from left ventricular (LV) afterload excess to coronary microvascular
      inflammation. This shift is supported by a favourable Laplace relationship in
      concentric LV hypertrophy and by all cardiac chambers showing similar remodeling 
      and dysfunction. Myocardial remodeling in HFPEF differs from heart failure with
      reduced ejection fraction (HFREF), where remodeling is driven by loss of
      cardiomyocytes. The new HFPEF paradigm proposes comorbidities, plasma markers of 
      inflammation or vascular hyperaemic responses to be included in diagnostic
      algorithms and aims at restoring myocardial PKG activity with NO-donors,
      phosphodiesterase 5 inhibitors and statins.
CI  - Copyright (c) 2013 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
AD  - Institute for Cardiovascular Research VU (ICaR-VU), VU University Medical Center 
      Amsterdam, Amsterdam, the Netherlands. Electronic address: wj.paulus@vumc.nl.
FAU - Paulus, Walter J
AU  - Paulus WJ
FAU - Tschope, Carsten
AU  - Tschope C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/26 [received]
PHST- 2013/01/07 [revised]
PHST- 2013/02/05 [accepted]
AID - S0735-1097(13)01890-1 [pii]
AID - 10.1016/j.jacc.2013.02.092 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 May 15. pii: S0735-1097(13)01890-1. doi:
      10.1016/j.jacc.2013.02.092.

PMID- 23684663
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1095-953X (Electronic)
IS  - 0969-9961 (Linking)
DP  - 2013 May 16
TI  - Diabetic neuropathic pain development in type 2 diabetic mouse model and the
      prophylactic and therapeutic effects of coenzyme Q10.
LID - S0969-9961(13)00145-9 [pii]
LID - 10.1016/j.nbd.2013.05.003 [doi]
AB  - The early onset of type 2 diabetes mellitus (DM), driven by increasing obesity,
      is associated with peripheral neuropathy. Here, we characterize diabetic
      neuropathic pain in New Zealand obese diabetic mice (NZO/HILtJ) as a polygenic
      model of obesity with type 2 diabetes and investigate the role of coenzyme Q10
      (CoQ10) in the prevention and treatment of diabetic neuropathic pain. Since the
      overexpression of mitogen-activated protein kinase (MAPK), nuclear factor-kappaB 
      proteins (NF-Kb), toll-like receptor 4 (TLR4) and downstream cytokines (such as
      CCL2, CXCL10) are considered important factors contributing to the development of
      neuropathic pain, the expression of these factors and the inhibitory effects of
      CoQ10 were evaluated. NZO/HILtJ mice spontaneously developed type 2 DM and
      increased body mass with diabetic neuropathic pain. CoQ10 treatment decreased
      pain hypersensitivity and long-term supplementation prevented the development of 
      diabetic neuropathic pain but did not attenuate diabetes. Spinal cord, blood
      serum, liver tissue, and dorsal root ganglia (DRG) from diabetic mice
      demonstrated increased lipid peroxidation, which was decreased by CoQ10
      treatment. The percentage of positive neurons of p65 (the activated marker of
      NF-KB) and MAPK in DRG were significantly higher in DM mice compared to controls.
      However, CoQ10 treatment significantly decreased p65 and MAPK positive neurons in
      the DRG of DM mice. RT-PCR demonstrated that elevated levels of mRNA of CCL2,
      CXCL10 or TLR4 in the spinal cord of DM mice decreased significantly when DM mice
      were treated with CoQ10. CONCLUSION: This model may be useful in understanding
      the mechanisms of neuropathic pain in type 2 DM induced neuropathic pain and may 
      facilitate preclinical testing of therapies. CoQ10 may decrease oxidative stress 
      in the central and peripheral nervous system by acting as an anti-oxidant and
      free-radical scavenger. These results suggest that CoQ10 might be a reasonable
      preventative strategy for long-term use and using CoQ10 treatment may be a safe
      and effective long-term approach in the treatment of diabetic neuropathy.
CI  - Published by Elsevier Inc.
AD  - Department of Anesthesiology, Perioperative Medicine and Pain Management,
      University of Miami Miller School of Medicine, Miami, FL, USA.
FAU - Zhang, Yan Ping
AU  - Zhang YP
FAU - Song, Chun Yu
AU  - Song CY
FAU - Yuan, Yue
AU  - Yuan Y
FAU - Eber, Ariel
AU  - Eber A
FAU - Rodriguez, Yiliam
AU  - Rodriguez Y
FAU - Levitt, Roy C
AU  - Levitt RC
FAU - Takacs, Peter
AU  - Takacs P
FAU - Yang, Zhe
AU  - Yang Z
FAU - Goldberg, Ronald
AU  - Goldberg R
FAU - Candiotti, Keith A
AU  - Candiotti KA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Neurobiol Dis
JT  - Neurobiology of disease
JID - 9500169
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/10/24 [received]
PHST- 2013/05/05 [revised]
PHST- 2013/05/08 [accepted]
AID - S0969-9961(13)00145-9 [pii]
AID - 10.1016/j.nbd.2013.05.003 [doi]
PST - aheadofprint
SO  - Neurobiol Dis. 2013 May 16. pii: S0969-9961(13)00145-9. doi:
      10.1016/j.nbd.2013.05.003.

PMID- 23684628
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Linking)
DP  - 2013 May 16
TI  - The role of the complement system in metabolic organs and metabolic diseases.
LID - S1044-5323(13)00019-5 [pii]
LID - 10.1016/j.smim.2013.04.003 [doi]
AB  - Emerging evidence points to a close crosstalk between metabolic organs and innate
      immunity in the course of metabolic disorders. In particular, cellular and
      humoral factors of innate immunity are thought to contribute to metabolic
      dysregulation of the adipose tissue or the liver, as well as to dysfunction of
      the pancreas; all these conditions are linked to the development of insulin
      resistance and diabetes mellitus. A central component of innate immunity is the
      complement system. Interestingly, the classical view of complement as a major
      system of host defense that copes with infections is changing to that of a
      multi-functional player in tissue homeostasis, degeneration, and regeneration. In
      the present review, we will discuss the link between complement and metabolic
      organs, focusing on the pancreas, adipose tissue, and liver and the diverse
      effects of complement system on metabolic disorders.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Internal Medicine, University Dresden, Dresden, Germany; Institute 
      of Physiology, University Dresden, Dresden, Germany.
FAU - Phieler, Julia
AU  - Phieler J
FAU - Garcia-Martin, Ruben
AU  - Garcia-Martin R
FAU - Lambris, John D
AU  - Lambris JD
FAU - Chavakis, Triantafyllos
AU  - Chavakis T
LA  - ENG
GR  - P01 AI068730/AI/NIAID NIH HHS/United States
GR  - R01 AI030040/AI/NIAID NIH HHS/United States
GR  - R01 AI072106/AI/NIAID NIH HHS/United States
GR  - R01 EY020633/EY/NEI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/03/25 [received]
PHST- 2013/04/13 [accepted]
AID - S1044-5323(13)00019-5 [pii]
AID - 10.1016/j.smim.2013.04.003 [doi]
PST - aheadofprint
SO  - Semin Immunol. 2013 May 16. pii: S1044-5323(13)00019-5. doi:
      10.1016/j.smim.2013.04.003.

PMID- 23684623
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun 4
TI  - Pharmacology, physiology, and mechanisms of incretin hormone action.
PG  - 819-37
LID - 10.1016/j.cmet.2013.04.008 [doi]
LID - S1550-4131(13)00150-2 [pii]
AB  - Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion,
      glucose concentrations, lipid metabolism, gut motility, appetite and body weight,
      and immune function, providing a scientific basis for utilizing incretin-based
      therapies in the treatment of type 2 diabetes. Activation of GLP-1 and GIP
      receptors also leads to nonglycemic effects in multiple tissues, through direct
      actions on tissues expressing incretin receptors and indirect mechanisms mediated
      through neuronal and endocrine pathways. Here we contrast the pharmacology and
      physiology of incretin hormones and review recent advances in mechanisms coupling
      incretin receptor signaling to pleiotropic metabolic actions in preclinical
      studies. We discuss whether mechanisms identified in preclinical studies have
      potential translational relevance for the treatment of human disease and
      highlight controversies and uncertainties in incretin biology that require
      resolution in future studies.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai
      Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.
FAU - Campbell, Jonathan E
AU  - Campbell JE
FAU - Drucker, Daniel J
AU  - Drucker DJ
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/05/16 [aheadofprint]
AID - S1550-4131(13)00150-2 [pii]
AID - 10.1016/j.cmet.2013.04.008 [doi]
PST - ppublish
SO  - Cell Metab. 2013 Jun 4;17(6):819-37. doi: 10.1016/j.cmet.2013.04.008. Epub 2013
      May 16.

PMID- 23684622
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun 4
TI  - Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2.
PG  - 1009-20
LID - 10.1016/j.cmet.2013.04.010 [doi]
LID - S1550-4131(13)00152-6 [pii]
AB  - A major challenge of the post-genomics era is to define the connectivity of
      protein phosphorylation networks. Here, we quantitatively delineate the insulin
      signaling network in adipocytes by high-resolution mass spectrometry-based
      proteomics. These data reveal the complexity of intracellular protein
      phosphorylation. We identified 37,248 phosphorylation sites on 5,705 proteins in 
      this single-cell type, with approximately 15% responding to insulin. We
      integrated these large-scale phosphoproteomics data using a machine learning
      approach to predict physiological substrates of several diverse insulin-regulated
      kinases. This led to the identification of an Akt substrate, SIN1, a core
      component of the mTORC2 complex. The phosphorylation of SIN1 by Akt was found to 
      regulate mTORC2 activity in response to growth factors, revealing topological
      insights into the Akt/mTOR signaling network. The dynamic phosphoproteome
      described here contains numerous phosphorylation sites on proteins involved in
      diverse molecular functions and should serve as a useful functional resource for 
      cell biologists.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst,
      New South Wales 2010, Australia; Biological Mass Spectrometry Unit, Garvan
      Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia.
FAU - Humphrey, Sean J
AU  - Humphrey SJ
FAU - Yang, Guang
AU  - Yang G
FAU - Yang, Pengyi
AU  - Yang P
FAU - Fazakerley, Daniel J
AU  - Fazakerley DJ
FAU - Stockli, Jacqueline
AU  - Stockli J
FAU - Yang, Jean Y
AU  - Yang JY
FAU - James, David E
AU  - James DE
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/26 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/04/17 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - S1550-4131(13)00152-6 [pii]
AID - 10.1016/j.cmet.2013.04.010 [doi]
PST - ppublish
SO  - Cell Metab. 2013 Jun 4;17(6):1009-20. doi: 10.1016/j.cmet.2013.04.010. Epub 2013 
      May 16.

PMID- 23684602
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 May 16
TI  - Distinctive profile of sudden cardiac arrest in middle-aged vs. older adults: A
      community-based study.
LID - S0167-5273(13)00890-5 [pii]
LID - 10.1016/j.ijcard.2013.04.207 [doi]
AB  - BACKGROUND: While sudden cardiac arrest (SCA) rates increase with age,
      middle-aged adults (35-59years) may comprise a significant proportion of SCA
      cases in the community (30-40%). However, there is a lack of studies evaluating
      SCA risk factors specifically associated with this age-group of the population.
      METHODS: Using prospective multiple-source surveillance methodology we identified
      cases of SCA >/=35years in the ongoing Oregon Sudden Unexpected Death Study
      (Portland, Oregon metropolitan area, population approximately 1,000,000).
      Out-of-hospital SCA cases, aged 35-59years were compared to older SCA cases
      (>/=60years) in a comprehensive analysis of clinical profile of SCA. RESULTS: The
      middle-aged (n=753) compared to older (n=1251) cases were more likely to be male,
      obese, have sleep apnea and seizure disorder (all p</=0.001); and were less
      likely to have a history of hypertension, diabetes mellitus, known coronary
      artery disease, congestive heart failure and syncope (all p<0.01). In
      multivariable analyses the middle-aged group had higher likelihood of male sex
      (O.R. 1.67, 95% C.I. 1.29-2.18), obesity (2.20, 1.52-3.19), sleep apnea (2.30,
      1.44-3.68) and seizure disorder (2.69, 1.64-4.42); and lower rates of known
      coronary artery disease (0.57, 0.43-0.74) and congestive heart failure (0.35,
      0.25-0.48). CONCLUSIONS: SCA in the middle-aged adult was distinguishable from
      older subjects by higher rates of obesity, sleep apnea and seizure disorder; and 
      lower prevalence of traditional clinical risk markers. With the growing epidemic 
      of obesity, these findings have implications for SCA burden; and suggest the need
      for a clinical and investigational focus on SCA prediction and prevention in the 
      middle-aged adult, that is distinct from older adults.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - The Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
FAU - Noheria, Amit
AU  - Noheria A
FAU - Teodorescu, Carmen
AU  - Teodorescu C
FAU - Uy-Evanado, Audrey
AU  - Uy-Evanado A
FAU - Reinier, Kyndaron
AU  - Reinier K
FAU - Mariani, Ronald
AU  - Mariani R
FAU - Gunson, Karen
AU  - Gunson K
FAU - Jui, Jonathan
AU  - Jui J
FAU - Chugh, Sumeet S
AU  - Chugh SS
LA  - ENG
GR  - R01 HL088416/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/30 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/04/25 [accepted]
AID - S0167-5273(13)00890-5 [pii]
AID - 10.1016/j.ijcard.2013.04.207 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 May 16. pii: S0167-5273(13)00890-5. doi:
      10.1016/j.ijcard.2013.04.207.

PMID- 23684540
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1875-9777 (Electronic)
DP  - 2013 May 15
TI  - Generation of Functional Thymic Epithelium from Human Embryonic Stem Cells that
      Supports Host T Cell Development.
LID - S1934-5909(13)00140-9 [pii]
LID - 10.1016/j.stem.2013.04.004 [doi]
AB  - Inducing immune tolerance to prevent rejection is a key step toward successful
      engraftment of stem-cell-derived tissue in a clinical setting. Using human
      pluripotent stem cells to generate thymic epithelial cells (TECs) capable of
      supporting T cell development represents a promising approach to reach this goal;
      however, progress toward generating functional TECs has been limited. Here, we
      describe a robust in vitro method to direct differentiation of human embryonic
      stem cells (hESCs) into thymic epithelial progenitors (TEPs) by precise
      regulation of TGFbeta, BMP4, RA, Wnt, Shh, and FGF signaling. The hESC-derived
      TEPs further mature into functional TECs that support T cell development upon
      transplantation into thymus-deficient mice. Importantly, the engrafted TEPs
      produce T cells capable of in vitro proliferation as well as in vivo immune
      responses. Thus, hESC-derived TEP grafts may have broad applications for
      enhancing engraftment in cell-based therapies as well as restoring age- and
      stress-related thymic decline.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Diabetes Center, Department of Medicine, University of California, San Francisco,
      San Francisco, CA 94143-0540, USA.
FAU - Parent, Audrey V
AU  - Parent AV
FAU - Russ, Holger A
AU  - Russ HA
FAU - Khan, Imran S
AU  - Khan IS
FAU - Laflam, Taylor N
AU  - Laflam TN
FAU - Metzger, Todd C
AU  - Metzger TC
FAU - Anderson, Mark S
AU  - Anderson MS
FAU - Hebrok, Matthias
AU  - Hebrok M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Cell Stem Cell
JT  - Cell stem cell
JID - 101311472
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/09/12 [received]
PHST- 2013/02/26 [revised]
PHST- 2013/03/29 [accepted]
AID - S1934-5909(13)00140-9 [pii]
AID - 10.1016/j.stem.2013.04.004 [doi]
PST - aheadofprint
SO  - Cell Stem Cell. 2013 May 15. pii: S1934-5909(13)00140-9. doi:
      10.1016/j.stem.2013.04.004.

PMID- 23684503
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1578-1283 (Electronic)
IS  - 0213-9111 (Linking)
DP  - 2013 May 16
TI  - Changes of age at onset in patients with type 1 diabetes during the last two
      decades.
LID - S0213-9111(13)00082-4 [pii]
LID - 10.1016/j.gaceta.2013.03.011 [doi]
AD  - Endocrinology Department, Complejo Hospitalario de Navarra, Pamplona, Navarra,
      Spain. Electronic address: lforgall@cfnavarra.es.
FAU - Forga, Luis
AU  - Forga L
FAU - Goni, Maria Jose
AU  - Goni MJ
FAU - Cambra, Koldo
AU  - Cambra K
FAU - Ibanez, Berta
AU  - Ibanez B
FAU - Mozas, David
AU  - Mozas D
FAU - Chueca, Maria
AU  - Chueca M
LA  - ENG
PT  - LETTER
DEP - 20130516
TA  - Gac Sanit
JT  - Gaceta sanitaria / S.E.S.P.A.S
JID - 8901623
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/05 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/03/29 [accepted]
AID - S0213-9111(13)00082-4 [pii]
AID - 10.1016/j.gaceta.2013.03.011 [doi]
PST - aheadofprint
SO  - Gac Sanit. 2013 May 16. pii: S0213-9111(13)00082-4. doi:
      10.1016/j.gaceta.2013.03.011.

PMID- 23684449
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 15
TI  - Effect of indomethacin on cerebrovascular reactivity in patients with type 2
      diabetes mellitus.
LID - S0168-8227(13)00160-5 [pii]
LID - 10.1016/j.diabres.2013.04.004 [doi]
AB  - AIM: Impaired cerebral vasoreactivity to endothelium-dependent stimuli were
      described in type 2 diabetes mellitus (T2DM), but the mechanisms underlying that 
      impairment are still unclear. The aim of this study was to investigate the role
      of cyclooxygenases' metabolites in response to acute hypercapnic stimulus in
      cerebral vessels, in patients with T2DM. METHODS: Vascular responses in the
      breath-holding test (BHT) were assessed in the absence/presence of a
      non-selective, reversible-inhibitor of cyclooxygenases, indomethacin (INDO), by
      functional transcranial Doppler sonography of the middle cerebral artery (N of
      patients=50; 33 men and 17 women). The functional hemodynamic parameter mean flow
      velocity (MFV) was assessed at rest, before and 90min after 100mg of INDO, and
      during the BHT. Breath holding index (BHI) [(MFV at the end of BHT minus MFV at
      rest)/MFV at rest)x100/s of breath-holding] was calculated after BHT performed
      before and 90min after INDO. RESULTS: MFV at rest significantly decreased after
      INDO administration compared with a control condition before INDO (at rest before
      INDO from 49.36+/-15.09 to 36.72+/-8.45 after INDO, p<0.001) However, overall
      cerebral vessel vasoreactivity to hypercapnia, evaluated with BHI, was
      significantly improved after INDO administration compared with the BHI before
      INDO administration (from 0.68+/-0.4 to 1.27+/-0.42, p<0.001). CONCLUSIONS: The
      improvement in cerebral vasoreactivity in response to BHT after INDO
      administration suggests that the production of a vasoconstrictor metabolite of
      cyclooxygenase in diabetic patients was reduced by indomethacin consumption.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Neurology, Dubrava University Hospital, Zagreb, Croatia. Electronic
      address: vvuletic@kbd.hr.
FAU - Vuletic, Vladimira
AU  - Vuletic V
FAU - Drenjancevic, Ines
AU  - Drenjancevic I
FAU - Rahelic, Dario
AU  - Rahelic D
FAU - Demarin, Vida
AU  - Demarin V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/29 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/04/22 [accepted]
AID - S0168-8227(13)00160-5 [pii]
AID - 10.1016/j.diabres.2013.04.004 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 15. pii: S0168-8227(13)00160-5. doi:
      10.1016/j.diabres.2013.04.004.

PMID- 23684448
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 15
TI  - HbA1c in the diagnosis of diabetes and abnormal glucose tolerance in patients
      with Graves' hyperthyroidism.
LID - S0168-8227(13)00164-2 [pii]
LID - 10.1016/j.diabres.2013.04.008 [doi]
AB  - OBJECTIVE: To assess the suitability of HbA1c as a criterion for the diagnosis of
      diabetes in patients with Graves' disease. METHODS: This study enrolled 310
      patients with untreated newly diagnosed Graves' disease, 208 patients with
      euthyroid goiter and 329 age-matched (control) subjects without thyroid disease
      from Fuzhou, China. The performance of HbA1c against the OGTT for diagnosing
      diabetes was determined. The Framingham risk score was used to assess general
      cardiovascular disease (CVD) risk. RESULTS: The percentage of patients with
      abnormal glucose metabolism as classified by HbA1c levels was lower than by OGTT 
      criteria in patients with Graves' disease-33.2% vs. 41.3% for pre-diabetes and
      4.5% vs. 11.3% for diabetes, respectively. The sensitivity of HbA1c for
      diagnosing diabetes in patients with Graves' disease was lower than in patients
      with euthyroid goiter and subjects without thyroid disease (34.9%, 63.2% and
      60.6% respectively), while the specificity was similar (99.3%, 98.6%, 97.4%).
      Approximately 7.4% of patients with Graves' disease diagnosed with diabetes
      according to OGTT criteria were misdiagnosed as not having the disease by HbA1c, 
      much higher than that for the other two groups. Patients with Graves' disease
      with diabetes not diagnosed with the disease by HbA1c showed a high risk for CVD.
      CONCLUSIONS: The low sensitivity of the HbA1c criterion underestimated the
      percentage of diabetes in patients with Graves' disease. Patients with diabetes
      who were misdiagnosed as not having the disease by HbA1c were at high risk for
      CVD.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Endocrinology Department, The First Affiliated Hospital of Fujian Medical
      University, Fuzhou 350005, Fujian, China. Electronic address: liyongy@yahoo.com.
FAU - Yang, Liyong
AU  - Yang L
FAU - Shen, Ximei
AU  - Shen X
FAU - Yan, Sunjie
AU  - Yan S
FAU - Yuan, Xin
AU  - Yuan X
FAU - Lu, Juanjuan
AU  - Lu J
FAU - Wei, Wenfeng
AU  - Wei W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/03/20 [received]
PHST- 2013/04/22 [accepted]
AID - S0168-8227(13)00164-2 [pii]
AID - 10.1016/j.diabres.2013.04.008 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 15. pii: S0168-8227(13)00164-2. doi:
      10.1016/j.diabres.2013.04.008.

PMID- 23684438
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1879-0739 (Electronic)
IS  - 0271-5317 (Linking)
VI  - 33
IP  - 5
DP  - 2013 May
TI  - Daily flaxseed consumption improves glycemic control in obese men and women with 
      pre-diabetes: a randomized study.
PG  - 367-75
LID - 10.1016/j.nutres.2013.02.012 [doi]
LID - S0271-5317(13)00048-1 [pii]
AB  - The study hypothesis was that fasting glucose, insulin, fructosamine, C-reactive 
      protein, and interleukin-6 decrease and adiponectin increases with daily flaxseed
      consumption in overweight or obese individuals with pre-diabetes. In this
      randomized, cross-over study overweight or obese men and postmenopausal women (n 
      = 25) with pre-diabetes consumed 0, 13, or 26 g ground flaxseed for 12 weeks.
      Glucose, insulin, homeostatic model assessment (HOMA-IR), and normalized percent 
      of alpha-linolenic fatty acid (ALA) were significantly different by treatment
      (multiple analysis of variance, P = .036, P = .013, P = .008, P = .024
      respectively). Paired t tests showed glucose decreased on the 13 g intervention
      compared to the 0 g period [13g = -2.10 +/- 1.66 mg/L (mean +/- SEM), 0 g = 9.22 
      +/- 4.44 mg/L, P = .036]. Insulin decreased on the 13 g intervention but not the 
      26 g (P = .021) and 0 g (P = .013) periods (13 g = -2.12 +/- 1.00 mU/L, 26 g =
      0.67 +/- 0.84 mU/L, 0g = 1.20 +/- 1.16 mU/L). HOMA-IR decreased on the 13 g
      period but not on the 26 g (P = .012) and 0 g (P = .008) periods (13g = -0.71 +/-
      0.31, 26g = 0.27 +/- 0.24, 0g = 0.51 +/- 0.35). The alpha-linolenic fatty acid
      decrease for the 0 g period was different than the 13 g (P = .024) and 26 g (P = 
      .000) periods (13 g = 0.20 +/- 0.04, 26g = 0.35 +/- 0.07, 0g = -0.01 +/- 0.07).
      Fructosamine, high sensitivity C-reactive protein, adiponectin, and
      high-sensitivity interleukin-6 had no significant differences. Flaxseed intake
      decreased glucose and insulin and improved insulin sensitivity as part of a
      habitual diet in overweight or obese individuals with pre-diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - University of Colorado Colorado Springs, Colorado Springs, CO. Electronic
      address: andrea.hutchins@uccs.edu.
FAU - Hutchins, Andrea M
AU  - Hutchins AM
FAU - Brown, Blakely D
AU  - Brown BD
FAU - Cunnane, Stephen C
AU  - Cunnane SC
FAU - Domitrovich, Stephanie G
AU  - Domitrovich SG
FAU - Adams, Earle R
AU  - Adams ER
FAU - Bobowiec, Courtney E
AU  - Bobowiec CE
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - United States
TA  - Nutr Res
JT  - Nutrition research (New York, N.Y.)
JID - 8303331
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/10/08 [received]
PHST- 2013/02/26 [revised]
PHST- 2013/02/28 [accepted]
PHST- 2013/04/01 [aheadofprint]
AID - S0271-5317(13)00048-1 [pii]
AID - 10.1016/j.nutres.2013.02.012 [doi]
PST - ppublish
SO  - Nutr Res. 2013 May;33(5):367-75. doi: 10.1016/j.nutres.2013.02.012. Epub 2013 Apr
      1.

PMID- 23684435
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1879-0739 (Electronic)
IS  - 0271-5317 (Linking)
VI  - 33
IP  - 5
DP  - 2013 May
TI  - Pomegranate and type 2 diabetes.
PG  - 341-8
LID - 10.1016/j.nutres.2013.03.003 [doi]
LID - S0271-5317(13)00056-0 [pii]
AB  - Over the last decade, various studies have linked pomegranate (Punica granatum
      Linn), a fruit native to the Middle East, with type 2 diabetes prevention and
      treatment. This review focuses on current laboratory and clinical research
      related to the effects of pomegranate fractions (peels, flowers, and seeds) and
      some of their active components on biochemical and metabolic variables associated
      with the pathologic markers of type 2 diabetes. This review systematically
      presents findings from cell culture and animal studies as well as clinical human 
      research. One key mechanism by which pomegranate fractions affect the type 2
      diabetic condition is by reducing oxidative stress and lipid peroxidation. This
      reduction may occur by directly neutralizing the generated reactive oxygen
      species, increasing certain antioxidant enzyme activities, inducing metal
      chelation activity, reducing resistin formation, and inhibiting or activating
      certain transcriptional factors, such as nuclear factor kappaB and peroxisome
      proliferator-activated receptor gamma. Fasting blood glucose levels were
      decreased significantly by punicic acid, methanolic seed extract, and pomegranate
      peel extract. Known compounds in pomegranate, such as punicalagin and ellagic,
      gallic, oleanolic, ursolic, and uallic acids, have been identified as having
      anti-diabetic actions. Furthermore, the juice sugar fraction was found to have
      unique antioxidant polyphenols (tannins and anthocyanins), which could be
      beneficial to control conditions in type 2 diabetes. These findings provide
      evidence for the anti-diabetic activity of pomegranate fruit; however, before
      pomegranate or any of its extracts can be medically recommended for the
      management of type 2 diabetes, controlled, clinical studies, are needed.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Medical Laboratory Sciences, Jordan University of Science and
      Technology, Irbid 22110, Jordan. Electronic address: sabanihani@just.edu.jo.
FAU - Banihani, Saleem
AU  - Banihani S
FAU - Swedan, Samer
AU  - Swedan S
FAU - Alguraan, Ziyad
AU  - Alguraan Z
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Nutr Res
JT  - Nutrition research (New York, N.Y.)
JID - 8303331
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/07/12 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S0271-5317(13)00056-0 [pii]
AID - 10.1016/j.nutres.2013.03.003 [doi]
PST - ppublish
SO  - Nutr Res. 2013 May;33(5):341-8. doi: 10.1016/j.nutres.2013.03.003. Epub 2013 Apr 
      15.

PMID- 23684419
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 15
TI  - Liver enzymes and type 2 diabetes: A complex two-way relationship.
LID - S1056-8727(13)00104-9 [pii]
LID - 10.1016/j.jdiacomp.2013.04.009 [doi]
AD  - Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada;
      Division of Endocrinology, University of Toronto, Toronto, Canada.
FAU - Kramer, Caroline K
AU  - Kramer CK
FAU - Retnakaran, Ravi
AU  - Retnakaran R
LA  - ENG
PT  - EDITORIAL
DEP - 20130515
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/04/15 [received]
PHST- 2013/04/15 [accepted]
AID - S1056-8727(13)00104-9 [pii]
AID - 10.1016/j.jdiacomp.2013.04.009 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 15. pii: S1056-8727(13)00104-9. doi:
      10.1016/j.jdiacomp.2013.04.009.

PMID- 23684416
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 May 15
TI  - Original research: Postpartum testing rates among women with a history of
      gestational diabetes-Systematic review.
LID - S1751-9918(13)00048-X [pii]
LID - 10.1016/j.pcd.2013.04.007 [doi]
AB  - AIMS: Gestational diabetes mellitus (GDM) is increasing and 30% have persistent
      postpartum dysglycemia. Reported compliance with recommended postpartum testing
      ranges 9-95% without a clear explanation for this wide variation. Small and
      conflicting differences in testing rates are associated with some demographics
      (race, use of insulin), but system factors likely play a larger role. A
      systematic literature review was performed to identify system based factors that 
      could explain the broad variation in postpartum GDM testing rates. METHODS:
      Original articles reporting postpartum testing rates among women with GDM were
      identified within PubMed, OVID, EMBASE, and the Cochrane Database of systematic
      reviews. Articles that did not report rates for the entire GDM cohort were
      excluded. RESULTS: 54/307 citations met inclusion criteria. The use of proactive 
      patient contact programs increased postpartum testing rates from an average of
      33% (range 9-71%) up to 60% (range 14-95%). CONCLUSIONS: Proactively contacting
      patients via phone calls, education programs, or postal reminders was associated 
      with higher postpartum testing rates. Rather than working to identifying
      individual demographic factors, systems based approaches were associated with a
      larger potential impact, and appear easily generalizable. Clinicians should think
      beyond individual habits and consider systematic approaches to improving testing 
      rates.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - UMDNJ-Robert Wood Johnson Medical School, Jersey Shore University Medical Center,
      Department of Medicine, Ackerman 3, 1945 Route 33, Neptune, NJ 07753, United
      States. Electronic address: MPCarson@meridianhealth.com.
FAU - Carson, Michael P
AU  - Carson MP
FAU - Frank, Matthew I
AU  - Frank MI
FAU - Keely, Erin
AU  - Keely E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/21 [received]
PHST- 2013/04/13 [revised]
PHST- 2013/04/16 [accepted]
AID - S1751-9918(13)00048-X [pii]
AID - 10.1016/j.pcd.2013.04.007 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 May 15. pii: S1751-9918(13)00048-X. doi:
      10.1016/j.pcd.2013.04.007.

PMID- 23684393
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
DP  - 2013 May 9
TI  - The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US 
      Adults.
LID - S0002-9343(13)00200-3 [pii]
LID - 10.1016/j.amjmed.2013.03.002 [doi]
AB  - BACKGROUND: There are limited data regarding the relationship between
      cannabinoids and metabolic processes. Epidemiologic studies have found lower
      prevalence rates of obesity and diabetes mellitus in marijuana users compared
      with people who have never used marijuana, suggesting a relationship between
      cannabinoids and peripheral metabolic processes. To date, no study has
      investigated the relationship between marijuana use and fasting insulin, glucose,
      and insulin resistance. METHODS: We included 4657 adult men and women from the
      National Health and Nutrition Examination Survey from 2005 to 2010. Marijuana use
      was assessed by self-report in a private room. Fasting insulin and glucose were
      measured via blood samples after a 9-hour fast, and homeostasis model assessment 
      of insulin resistance (HOMA-IR) was calculated to evaluate insulin resistance.
      Associations were estimated using multiple linear regression, accounting for
      survey design and adjusting for potential confounders. RESULTS: Of the
      participants in our study sample, 579 were current marijuana users and 1975 were 
      past users. In multivariable adjusted models, current marijuana use was
      associated with 16% lower fasting insulin levels (95% confidence interval [CI],
      -26, -6) and 17% lower HOMA-IR (95% CI, -27, -6). We found significant
      associations between marijuana use and smaller waist circumferences. Among
      current users, we found no significant dose-response. CONCLUSIONS: We found that 
      marijuana use was associated with lower levels of fasting insulin and HOMA-IR,
      and smaller waist circumference.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - University of Nebraska College of Medicine, Omaha; Department of Epidemiology,
      Harvard School of Public Health, Boston, Mass.
FAU - Penner, Elizabeth A
AU  - Penner EA
FAU - Buettner, Hannah
AU  - Buettner H
FAU - Mittleman, Murray A
AU  - Mittleman MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/03/01 [received]
PHST- 2013/03/02 [accepted]
AID - S0002-9343(13)00200-3 [pii]
AID - 10.1016/j.amjmed.2013.03.002 [doi]
PST - aheadofprint
SO  - Am J Med. 2013 May 9. pii: S0002-9343(13)00200-3. doi:
      10.1016/j.amjmed.2013.03.002.

PMID- 23684366
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1873-5134 (Electronic)
IS  - 0738-3991 (Linking)
DP  - 2013 May 16
TI  - Using a robot to personalise health education for children with diabetes type 1: 
      A pilot study.
LID - S0738-3991(13)00170-5 [pii]
LID - 10.1016/j.pec.2013.04.012 [doi]
AB  - OBJECTIVE: Assess the effects of personalised robot behaviours on the enjoyment
      and motivation of children (8-12) with diabetes, and on their acquisition of
      health knowledge, in educational play. METHODS: Children (N=5) played diabetes
      quizzes against a personal or neutral robot on three occasions: once at the
      clinic, twice at home. The personal robot asked them about their names, sports
      and favourite colours, referred to these data during the interaction, and engaged
      in small talk. Fun, motivation and diabetes knowledge was measured. Child-robot
      interaction was observed. RESULTS: Children said the robot and quiz were fun, but
      this appreciation declined over time. With the personal robot, the children
      looked more at the robot and spoke more. The children mimicked the robot.
      Finally, an increase in knowledge about diabetes was observed. CONCLUSION: The
      study provides strong indication for how a personal robot can help children to
      improve health literacy in an enjoyable way. Children mimic the robot. When the
      robot is personal, they follow suit. Our results are positive and establish a
      good foundation for further development and testing in a larger study. PRACTICE
      IMPLICATIONS: Using a robot in health care could contribute to self-management in
      children and help them to cope with their illness.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - TNO Lifestyle, Leiden, The Netherlands. Electronic address:
      Olivier.BlansonHenkemans@TNO.nl.
FAU - Blanson Henkemans, Olivier A
AU  - Blanson Henkemans OA
FAU - Bierman, Bert P B
AU  - Bierman BP
FAU - Janssen, Joris
AU  - Janssen J
FAU - Neerincx, Mark A
AU  - Neerincx MA
FAU - Looije, Rosemarijn
AU  - Looije R
FAU - van der Bosch, Hanneke
AU  - van der Bosch H
FAU - van der Giessen, Jeanine A M
AU  - van der Giessen JA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Patient Educ Couns
JT  - Patient education and counseling
JID - 8406280
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/06/29 [received]
PHST- 2013/04/09 [revised]
PHST- 2013/04/18 [accepted]
AID - S0738-3991(13)00170-5 [pii]
AID - 10.1016/j.pec.2013.04.012 [doi]
PST - aheadofprint
SO  - Patient Educ Couns. 2013 May 16. pii: S0738-3991(13)00170-5. doi:
      10.1016/j.pec.2013.04.012.

PMID- 23684298
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 2212-2672 (Print)
VI  - 113
IP  - 6
DP  - 2013 Jun
TI  - Diagnosing and managing gestational diabetes: where do we stand?
PG  - 876
LID - 10.1016/j.jand.2013.04.008 [doi]
LID - S2212-2672(13)00355-9 [pii]
FAU - Marcason, Wendy
AU  - Marcason W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Acad Nutr Diet
JT  - Journal of the Academy of Nutrition and Dietetics
JID - 101573920
SB  - AIM
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/04/06 [received]
AID - S2212-2672(13)00355-9 [pii]
AID - 10.1016/j.jand.2013.04.008 [doi]
PST - ppublish
SO  - J Acad Nutr Diet. 2013 Jun;113(6):876. doi: 10.1016/j.jand.2013.04.008.

PMID- 23684257
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
DP  - 2013 May 16
TI  - Non-communicable diseases and injuries in Pakistan: strategic priorities.
LID - S0140-6736(13)60646-7 [pii]
LID - 10.1016/S0140-6736(13)60646-7 [doi]
AB  - Non-communicable diseases, including cardiovascular diseases, cancers,
      respiratory diseases, diabetes, and mental disorders, and injuries have become
      the major causes of morbidity and mortality in Pakistan. Tobacco use and
      hypertension are the leading attributable risk factors for deaths due to
      cardiovascular diseases, cancers, and respiratory diseases. Pakistan has the
      sixth highest number of people in the world with diabetes; every fourth adult is 
      overweight or obese; cigarettes are cheap; antismoking and road safety laws are
      poorly enforced; and a mixed public-private health-care system provides
      suboptimum care. Furthermore, almost three decades of exposure to sociopolitical 
      instability, economic uncertainty, violence, regional conflict, and dislocation
      have contributed to a high prevalence of mental health disorders. Projection
      models based on the Global Burden of Disease 2010 data suggest that there will be
      about 3.87 million premature deaths by 2025 from cardiovascular diseases,
      cancers, and chronic respiratory diseases in people aged 30-69 years in Pakistan,
      with serious economic consequences. Modelling of risk factor reductions also
      indicate that Pakistan could achieve at least a 20% reduction in the number of
      these deaths by 2025 by targeting of the major risk factors. We call for policy
      and legislative changes, and health-system interventions to target readily
      preventable non-communicable diseases in Pakistan.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Health Services and Systems Research, Duke-NUS Graduate Medical School,
      Singapore; Department of Community Health Sciences and Department of Medicine,
      Aga Khan University, Karachi, Pakistan. Electronic address:
      tazeen.jafar@duke-nus.edu.sg.
FAU - Jafar, Tazeen H
AU  - Jafar TH
FAU - Haaland, Benjamin A
AU  - Haaland BA
FAU - Rahman, Atif
AU  - Rahman A
FAU - Razzak, Junaid A
AU  - Razzak JA
FAU - Bilger, Marcel
AU  - Bilger M
FAU - Naghavi, Mohsen
AU  - Naghavi M
FAU - Mokdad, Ali H
AU  - Mokdad AH
FAU - Hyder, Adnan A
AU  - Hyder AA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Lancet
JT  - Lancet
JID - 2985213R
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - S0140-6736(13)60646-7 [pii]
AID - 10.1016/S0140-6736(13)60646-7 [doi]
PST - aheadofprint
SO  - Lancet. 2013 May 16. pii: S0140-6736(13)60646-7. doi:
      10.1016/S0140-6736(13)60646-7.

PMID- 23684248
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1579-2242 (Electronic)
IS  - 0300-8932 (Linking)
DP  - 2013 May 14
TI  - Delayed Diagnosis of Hypertension in Diabetic Patients Monitored in Primary Care.
LID - S0300-8932(13)00134-6 [pii]
LID - 10.1016/j.recesp.2013.01.020 [doi]
AB  - INTRODUCTION AND OBJECTIVES: Delayed diagnosis of hypertension may result in
      inadequate blood pressure control and increased cardiovascular risk. The aim of
      this study was to estimate the delay in hypertension diagnosis in patients with
      type 2 diabetes and the likelihood of a diagnosis within a suitable period (first
      6 months), and to analyze the patient and physician characteristics associated
      with delayed diagnosis. METHODS: Retrospective dynamic cohort study, with a
      7-year follow-up in primary care, of 8074 adult patients with diabetes who met
      the diagnostic criteria for hypertension. Two thresholds were considered:
      140/90mmHg and 130/80 mmHg. The time elapsed between meeting these criteria and
      recording the diagnosis was estimated; the time course of the likelihood of a
      missed diagnosis and the variables associated with correct diagnosis were
      assessed by Kaplan-Meier survival analysis and logistic regression analysis,
      respectively. RESULTS: The mean diagnostic delay was 8.9 (15.4) months in
      patients with blood pressure>/=140/90 mmHg compared to 15.2 (19.6) months for
      those with <140/90 mmHg (P<.001). The main variables associated with correct
      diagnosis were baseline blood pressure >/=140/90 mmHg (odds ratio=2.77; 95%
      confidence interval, 2.44-3.15), no history of acute myocardial infarction (odds 
      ratio=2.23; 95% confidence interval, 1.67-2.99), obesity (odds ratio=1.70; 95%
      confidence interval, 1.44-1.99), absence of depression (odds ratio=1.63; 95%
      confidence interval, 1.27-2.08), female sex (odds ratio=1.29; 95% confidence
      interval, 1.14-1.46), older age, and taking more intensive antidiabetic therapy. 
      There was an inverse relationship with the age of physicians and a direct
      relationship with their professional stability. CONCLUSIONS: The mean diagnostic 
      delay in hypertension among diabetic patients was greater than 6 months and
      varied according to the diagnostic threshold used. Patients with baseline blood
      pressure>/=140/90mmHg were more likely to receive a timely diagnosis. Full
      English text available from:www.revespcardiol.org/en.
CI  - Copyright (c) 2013 Sociedad Espanola de Cardiologia. Publicado por Elsevier
      Espana. All rights reserved.
AD  - Unidad de Epidemiologia Clinica e Investigacion, Hospital Carlos III, Servicio
      Madrileno de Salud, Madrid, Espana. Electronic address: carmenblunar@hotmail.com.
FAU - de Burgos-Lunar, Carmen
AU  - de Burgos-Lunar C
FAU - Del Cura-Gonzalez, Isabel
AU  - Del Cura-Gonzalez I
FAU - Salinero-Fort, Miguel A
AU  - Salinero-Fort MA
FAU - Gomez-Campelo, Paloma
AU  - Gomez-Campelo P
FAU - Perez de Isla, Leopoldo
AU  - Perez de Isla L
FAU - Jimenez-Garcia, Rodrigo
AU  - Jimenez-Garcia R
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Retraso diagnostico de la hipertension arterial en pacientes diabeticos atendidos
      en atencion primaria.
DEP - 20130514
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/08/16 [received]
PHST- 2013/01/22 [accepted]
AID - S0300-8932(13)00134-6 [pii]
AID - 10.1016/j.recesp.2013.01.020 [doi]
PST - aheadofprint
SO  - Rev Esp Cardiol. 2013 May 14. pii: S0300-8932(13)00134-6. doi:
      10.1016/j.recesp.2013.01.020.

PMID- 23684219
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130531
DCOM- 20130603
LR  - 20130603
IS  - 1749-8546 (Electronic)
IS  - 1749-8546 (Linking)
VI  - 8
IP  - 1
DP  - 2013
TI  - Anti-hyperglycaemic activity of swietenia macrophylla king (meliaceae) seed
      extracts in normoglycaemic rats undergoing glucose tolerance tests.
PG  - 11
LID - 10.1186/1749-8546-8-11 [doi]
AB  - BACKGROUND: Swietenia macrophylla King (Meliaceae) is used to treat diabetes
      mellitus in Malaysia. This study aims to evaluate the anti-hyperglycaemic
      potential of petroleum ether (PE), chloroform (CE) and methanol (ME) extracts of 
      S. macrophylla seeds, in normoglycaemic and streptozotocin (STZ)-induced diabetic
      rats. METHODS: Following treatment of normoglycaemic rats with S. macrophylla
      seed extracts, hypoglycaemic and intraperitoneal glucose tolerance tests (IPGTT) 
      were performed, and blood glucose concentrations were measured. Similarly,
      glucose concentrations were measured after 1 and 14 days of extract treatment of 
      STZ-induced diabetic rats. Glucose absorption by isolated everted intestine and
      glucose uptake by isolated abdominal muscle were tested after treatment with seed
      extracts. Gas chromatography mass spectrometry (GC-MS) analysis was performed on 
      PE of S. macrophylla seeds to identify the compounds responsible for its
      activity. RESULTS: None of the extracts had a significant effect on the blood
      glucose levels of 60 randomly selected normoglycaemic (normal) and diabetic rats 
      undergoing hypoglycaemic tests. PE, however, significantly reduced blood glucose 
      levels in 30 randomly selected normoglycaemic rats undergoing IPGTT tests 30-120 
      minutes after glucose administration. Repeated doses of 1000 mg/kg and 500 mg/kg 
      PE to STZ-induced diabetic rats for 14 days did not reduce blood glucose levels
      significantly. PE did not significantly reduced the intestinal absorption of
      glucose, but significantly increased glucose uptake by abdominal muscle in the
      absence or presence of insulin. GC-MS analysis indicated that diterpenes,
      triterpenoids, fatty acid methyl esters, aldehydes and phytosterols may be
      responsible for the glucose lowering effects of PE. CONCLUSION: PE extracts of S.
      macrophylla seeds showed anti-hyperglycaemic activity on IPGTTs . GC-MS analysis 
      on the PE revealed that several compounds, including fucosterol and
      beta-sitosterol, may be responsible for these anti-hyperglycaemic properties.
AD  - School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Pulau Pinang,
      Malaysia. mal_roteiro85@yahoo.com.my.
FAU - Hashim, Mohd Akmal
AU  - Hashim MA
FAU - Yam, Mun Fei
AU  - Yam MF
FAU - Hor, Sook Yee
AU  - Hor SY
FAU - Lim, Chung Pin
AU  - Lim CP
FAU - Asmawi, Mohd Zaini
AU  - Asmawi MZ
FAU - Sadikun, Amirin
AU  - Sadikun A
LA  - eng
PT  - Journal Article
DEP - 20130517
PL  - England
TA  - Chin Med
JT  - Chinese medicine
JID - 101265109
PMC - PMC3668191
OID - NLM: PMC3668191
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:01
CRDT- 2013/05/21 06:00
PHST- 2012/09/02 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 1749-8546-8-11 [pii]
AID - 10.1186/1749-8546-8-11 [doi]
PST - epublish
SO  - Chin Med. 2013 May 17;8(1):11. doi: 10.1186/1749-8546-8-11.

PMID- 23684214
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0104-4230 (Print)
IS  - 0104-4230 (Linking)
VI  - 59
IP  - 3
DP  - 2013 May-Jun
TI  - Cardiovascular risk in individuals with depression.
PG  - 298-304
LID - 10.1016/j.ramb.2012.12.006 [doi]
LID - S0104-4230(13)00056-0 [pii]
AB  - Depression and cardiovascular diseases (CVD) are both common illnesses. Several
      studies demonstrated that depressed individuals have higher mortality compared to
      age- and gender-matched population, with an excess of cardiovascular deaths.
      There is a bidirectional association between depression and CVD. Several factors 
      can interact and influence this relationship: poverty and social inequality,
      reduced accessibility to health care, biological alterations (as reduced heart
      rate variability, endothelial dysfunction, increased inflammation and platelet
      function, and hyperactivity of hypothalamic-pituitary-adrenal axis), side effects
      of psychiatric medication, lower adherence to medical treatments, and higher
      frequency of cardiovascular risk factors (higher tobacco use, physical
      inactivity, obesity, diabetes mellitus). This article aims to update the current 
      evidence of the possible mechanisms involved in the association between
      depression and CVD.
CI  - Copyright (c) 2013 Elsevier Editora Ltda. All rights reserved.
AD  - Centro de Saude Escola Barra Funda "Dr. Alexandre Vranjac", Irmandade da Santa
      Casa de Misericordia de Sao Paulo, Sao Paulo, SP, Brazil. Electronic address:
      danielle.bivanco@gmail.com.
FAU - Bivanco-Lima, Danielle
AU  - Bivanco-Lima D
FAU - de Souza Santos, Itamar
AU  - de Souza Santos I
FAU - Vannucchi, Ana Maria Cortez
AU  - Vannucchi AM
FAU - de Almeida Ribeiro, Manoel Carlos Sampaio
AU  - de Almeida Ribeiro MC
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - Brazil
TA  - Rev Assoc Med Bras
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/09/29 [received]
PHST- 2012/11/08 [revised]
PHST- 2012/12/02 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - S0104-4230(13)00056-0 [pii]
AID - 10.1016/j.ramb.2012.12.006 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras. 2013 May-Jun;59(3):298-304. doi: 10.1016/j.ramb.2012.12.006. 
      Epub 2013 May 16.

PMID- 23684064
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
DP  - 2013 May 16
TI  - Ifosfamide-induced Fanconi Syndrome and Desmopressin-responsive Nephrogenic
      Diabetes Insipidus.
LID - S0002-9343(13)00145-9 [pii]
LID - 10.1016/j.amjmed.2013.02.005 [doi]
AD  - Harvard Medical School, Boston, Mass.
FAU - Kamran, Sophia C
AU  - Kamran SC
FAU - Pendergraft, William F
AU  - Pendergraft WF
FAU - Harmon, David C
AU  - Harmon DC
FAU - Rubin, Mario F
AU  - Rubin MF
LA  - ENG
PT  - LETTER
DEP - 20130516
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/05 [received]
PHST- 2013/02/05 [accepted]
AID - S0002-9343(13)00145-9 [pii]
AID - 10.1016/j.amjmed.2013.02.005 [doi]
PST - aheadofprint
SO  - Am J Med. 2013 May 16. pii: S0002-9343(13)00145-9. doi:
      10.1016/j.amjmed.2013.02.005.

PMID- 23684049
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1887-1364 (Electronic)
IS  - 1134-282X (Linking)
DP  - 2013 May 14
TI  - [Relationship between process indicators measured using electronic records and
      intermediate health outcomes in patients with diabetes.]
LID - S1134-282X(13)00044-4 [pii]
LID - 10.1016/j.cali.2013.03.006 [doi]
AB  - OBJECTIVE: To study relationship between institutional process indicators
      (measured using electronic records) and intermediate outcomes of patients with
      diabetes. METHOD: Cross-sectional epidemiological study. Setting Primary care
      health district 1. Madrid. 2010. Patients: all patients with diabetes; n=16.652. 
      Main measures variables. Independent. Institutional process indicators.
      Dependent. Intermediate outcomes: GHb, BP, LDL, tobacco and weight within target 
      limits and detected complications. Confounding. Age, gender, type and years for
      DM, co-morbidity, drugs and professional variables. RESULTS: GHb of 55,9% (SE
      0,4) of patients was within target limits. Bivariate analysis and multivariate
      logistic regression showed that the recording of some process indicators was
      associated with an increase in the probability to achieve targets in intermediate
      outcomes: reviewing personal and family history, lifestyle and drug therapy,
      creatinine, GHb, BP and weight measurement, smoking advice, EKG, ankle-arm index,
      and eye examination. OR were from 1,15 (CI95%:1,01-1,32) to 2,05
      (CI95%:1,76-2,39). Relationship among other indicators and higher probability to 
      achieve targets was not found: classification, reviewing care plan, glucose, BMI,
      LDL and microalbuminury measurement. CONCLUSIONS: In diabetes, a lot of
      institutional process indicators measured on electronic records was associated
      with increase of probability to achieve targets in intermediate outcomes. It
      suggests to maintain process and outcome measurement, to include other outcomes, 
      to include other interventions, to prioritize improvements in process indicators 
      that show low performance and high impact and to keep out or to change process
      indicators that relationship was not found.
CI  - Copyright (c) 2012 SECA. Published by Elsevier Espana. All rights reserved.
AD  - Area Unica de Atencion Primaria, Servicio Madrileno de Salud, Madrid, Espana.
      Electronic address: ggarzon.gapm01@salud.madrid.org.
FAU - Garzon, G
AU  - Garzon G
FAU - Gil, A
AU  - Gil A
FAU - Alvaro, A
AU  - Alvaro A
FAU - Rodrigo, R
AU  - Rodrigo R
FAU - Cerezo, M J
AU  - Cerezo MJ
FAU - Dominguez, C
AU  - Dominguez C
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Asociacion entre indicadores de proceso medidos sobre historia electronica y
      resultados intermedios en salud, en pacientes con diabetes.
DEP - 20130514
TA  - Rev Calid Asist
JT  - Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad
      Asistencial
JID - 9601664
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/31 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/03/21 [accepted]
AID - S1134-282X(13)00044-4 [pii]
AID - 10.1016/j.cali.2013.03.006 [doi]
PST - aheadofprint
SO  - Rev Calid Asist. 2013 May 14. pii: S1134-282X(13)00044-4. doi:
      10.1016/j.cali.2013.03.006.

PMID- 23684029
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1525-3198 (Electronic)
IS  - 0022-0302 (Linking)
DP  - 2013 May 15
TI  - Short communication: Validation of a point-of-care glucometer for use in dairy
      cows.
LID - S0022-0302(13)00362-7 [pii]
LID - 10.3168/jds.2012-6533 [doi]
AB  - The purpose of this study was to evaluate the diagnostic performance of a
      hand-held electronic glucometer (Precision Xtra; Abbott Diabetes Care Inc.,
      Mississauga, ON, Canada) for cow-side use in dairy cattle. This device has been
      validated for measuring blood concentrations of beta-hydroxybutyrate in dairy
      cows. This study was designed to assess the accuracy of whole-blood glucose
      measurements from the glucose meter relative to a reference chemical analyzer in 
      a diagnostic laboratory. Duplicate samples were taken from the same cows at the
      same time, into blood tubes with either the glycolysis-inhibiting preservative
      sodium fluoride (NaF) or without preservative. Glucometer readings were taken on 
      whole blood with no preservative, and laboratory measurements were conducted on
      serum preserved with NaF. Blood samples were collected from cows between 3 wk
      before and 5 wk after calving, including during a glucose tolerance test
      conducted 1 wk before expected calving. Passing-Bablok and Bland-Altman data
      analyses were used to evaluate the performance of the glucometer relative to the 
      laboratory results. A strong correlation was observed in 709 samples from 81 cows
      between the hand-held meter and serum from samples preserved with NaF (R2 =
      0.95). Overall, 96% of measurements with the glucometer fell within the 95%
      confidence limits of analysis in the laboratory, although at
      higher-than-physiologic glucose concentrations (>5.2 mmol/L) the glucometer
      tended to overestimate. The hand-held glucometer appears suitable for rapid
      measurement of glucose under field conditions in dairy cattle.
CI  - Copyright (c) 2013 American Dairy Science Association. Published by Elsevier Inc.
      All rights reserved.
AD  - Department of Population Medicine, Ontario Veterinary College, University of
      Guelph, Guelph, Ontario, N1G 2W1, Canada. Electronic address:
      julie.wittrock@gmail.com.
FAU - Wittrock, J A M
AU  - Wittrock JA
FAU - Duffield, T F
AU  - Duffield TF
FAU - Leblanc, S J
AU  - Leblanc SJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Dairy Sci
JT  - Journal of dairy science
JID - 2985126R
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/28 [received]
PHST- 2013/04/02 [accepted]
AID - S0022-0302(13)00362-7 [pii]
AID - 10.3168/jds.2012-6533 [doi]
PST - aheadofprint
SO  - J Dairy Sci. 2013 May 15. pii: S0022-0302(13)00362-7. doi: 10.3168/jds.2012-6533.

PMID- 23684008
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
DP  - 2013 May 14
TI  - GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent
      manner, through the Akt, Src and PKC pathways.
LID - S0026-0495(13)00117-0 [pii]
LID - 10.1016/j.metabol.2013.04.010 [doi]
AB  - INTRODUCTION: Novel anti-diabetic medications that mimic or augment the
      physiological actions of GLP-1 improve cardiovascular risk factors in diabetics
      and GLP-1 has been proposed to have a beneficial role in the cardiovascular
      system. GLP-1 may have a direct cardioprotective role by decreasing infarct size 
      and protecting from ischemia-reperfusion injury while prolonging survival in
      rodent models. The mechanisms underlying these observations remain largely
      unknown. In vitro studies suggest that GLP-1 may promote endothelial cell
      proliferation, but no study to date has evaluated a potential direct effect of
      GLP-1 on angiogenesis. SPECIFIC AIM: To evaluate whether GLP-1 affects
      angiogenesis in humans and to elucidate underlying molecular mechanisms. MATERIAL
      AND METHODS: We utilized a 3D culture system where spherules of human umbilical
      vein endothelial cells (HUVECs) embedded in a collagen scaffold were treated with
      escalating doses of human recombinant GLP-1 (50-2000nmol/L) and the formation of 
      new vessels was observed and quantified. Signaling inhibitors were utilized to
      identify molecular pathways through which GLP-1 promotes angiogenesis. RESULTS:
      We demonstrate that GLP-1 promotes angiogenesis in a dose-dependent manner. The
      maximum effect on angiogenesis was observed at a GLP-1 dose of 500nmol/L, while
      increased angiogenesis occurred in response to doses ranging from 200nmol/L to
      1000nmol/L. Pre-treatment of the system with Akt inhibitor IV,
      Bisindolylmaleimide (PKC inhibitor) and src inhibitor I resulted in a significant
      decrease of the GLP-1 induced angiogenesis. CONCLUSIONS: This is the first study 
      to demonstrate that GLP-1 promotes angiogenesis in a HUVEC three dimensional in
      vitro model. This effect requires pharmacological doses and is mediated through
      the Akt, PKC and src pathways.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Endocrinology, Diabetes & Metabolism, Beth Israel Deaconess Medical
      Center, Harvard Medical School, Boston, MA, USA; Section of Endocrinology, Boston
      VA Healthcare System, Harvard Medical School, Boston, MA, USA; Department of
      Medicine, Boston Medical Center, Boston University, Boston, MA, USA. Electronic
      address: konstantinos.aronis@bmc.org.
FAU - Aronis, Konstantinos N
AU  - Aronis KN
FAU - Chamberland, John P
AU  - Chamberland JP
FAU - Mantzoros, Christos S
AU  - Mantzoros CS
LA  - ENG
GR  - K24 DK081913/DK/NIDDK NIH HHS/United States
GR  - R01 DK079929/DK/NIDDK NIH HHS/United States
GR  - R56 DK058785/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/14 [received]
PHST- 2013/04/10 [revised]
PHST- 2013/04/11 [accepted]
AID - S0026-0495(13)00117-0 [pii]
AID - 10.1016/j.metabol.2013.04.010 [doi]
PST - aheadofprint
SO  - Metabolism. 2013 May 14. pii: S0026-0495(13)00117-0. doi:
      10.1016/j.metabol.2013.04.010.

PMID- 23683969
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 0025-7753 (Electronic)
IS  - 0025-7753 (Linking)
DP  - 2013 May 14
TI  - [Prevalence of type 2 diabetes mellitus in overweight or obese patients attended 
      ambulatorly in Spain. OBEDIA Study.]
LID - S0025-7753(13)00255-8 [pii]
LID - 10.1016/j.medcli.2013.03.013 [doi]
AB  - BACKGROUND AND OBJECTIVE: The increase in the prevalence of type 2 diabetes
      mellitus (T2DM) is related to the increase of obesity. We aimed to determine the 
      Spanish prevalence of T2DM in patients with overweight or obesity attended by
      either family or specialist physicians. PATIENTS AND METHOD: Cross-sectional,
      multicenter and simultaneous 2-phase design, performed under clinical conditions.
      Phase A was designed to determine T2DM prevalence: 169,023 patients were
      recruited. Phase B was designed to define socio-demographic, clinical and
      metabolic profile of T2DM according to the body mass index (BMI): 7,754 patients 
      were included. RESULTS: T2DM prevalence in overweight or obese patients was
      23.6%; 17.8% of overweight patients were diabetic and T2DM was present in 34.8%
      of obese people. According to sex, 20.2% of men and 16.4% of women had T2DM.
      Overall, the mean of risk factors related to T2DM was 4.4 (SD 0,8); out of them, 
      92.6% patients had dyslipidemia, 73.7% hypertension and 62.5% performed a low
      physical activity. 37.8% of diabetic patients had vascular involvement. Only
      43.1% of patients showed a proper metabolic control of T2DM (glycosilated
      hemoglobin<7%). CONCLUSIONS: T2DM is related to overweight and obesity and higher
      the BMI is, higher the T2DM prevalence. Dyslipidemia, hypertension and a low
      physical activity in diabetic patients are more frequent when BMI increases.
      Patients with inadequate metabolic control have a higher BMI.
CI  - Copyright (c) 2012 Elsevier Espana, S.L. All rights reserved.
AD  - Servicio de Endocrinologia, Hospital Clinic de Barcelona, Universitat de
      Barcelona, Barcelona, Espana. Electronic address: rgomis@clinic.ub.es.
FAU - Gomis, Ramon
AU  - Gomis R
FAU - Artola, Sara
AU  - Artola S
FAU - Conthe, Pedro
AU  - Conthe P
FAU - Vidal, Josep
AU  - Vidal J
FAU - Casamor, Ricard
AU  - Casamor R
FAU - Font, Beatriu
AU  - Font B
CN  - en representacion de los investigadores del Grupo de Estudio OBEDIA
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Prevalencia en consultas de diabetes mellitus tipo 2 en pacientes con sobrepeso u
      obesidad en Espana. Estudio OBEDIA.
DEP - 20130514
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/11/28 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/03/07 [accepted]
AID - S0025-7753(13)00255-8 [pii]
AID - 10.1016/j.medcli.2013.03.013 [doi]
PST - aheadofprint
SO  - Med Clin (Barc). 2013 May 14. pii: S0025-7753(13)00255-8. doi:
      10.1016/j.medcli.2013.03.013.

PMID- 23683967
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 0025-7753 (Electronic)
IS  - 0025-7753 (Linking)
DP  - 2013 May 14
TI  - [Patients' characteristics and clinical management of atrial fibrillation in
      primary healthcare in Spain: FIATE Study.]
LID - S0025-7753(13)00266-2 [pii]
LID - 10.1016/j.medcli.2012.12.023 [doi]
AB  - BACKGROUND AND OBJECTIVES: The main therapeutic objective in atrial fibrillation 
      (AF) patients is stroke prevention. This study is aimed to determine whether the 
      anticoagulant therapy may be appropriate regarding to the Guidelines and
      patients' profile in primary healthcare in Spain. PATIENTS AND METHODS: A
      national, multicenter, cross-sectional study of AF patients attended in primary
      healthcare in Spain has been conducted. The study involved 185 family physicians 
      whose patients were randomized. RESULTS: A total of 3,759 AF patients were
      randomized from the clinical records, and 2,070 were included in the study, at an
      average age of 74 (11) years old (50.7% female). Most of them (78%) had permanent
      AF and high comorbidity rates (hypertension 75%, obesity 30%, diabetes 27%, heart
      failure 20%, coronary heart disease 17%, and social risk 15%). Patients diagnosed
      in primary healthcare were more frequently asymptomatic than in hospital setting 
      (36%; P<.001). The therapeutic strategy was based on the heart rate control in 4 
      out of 5 patients. Anticoagulation therapy was widely used (84%), more frequently
      in patients with permanent vs. non-permanent AF (91 vs. 60%, P<.001). Follow-up
      and monitoring was mainly performed in primary care (72%). The anticoagulation
      control was suboptimal, with a 66% of the international normalized ratio (INR) in
      therapeutic range, dropping to 33% when the last 3 available INR were included
      (P<.001). CONCLUSIONS: A high rate of patients with anticoagulant therapy in
      primary healthcare has been found in this research. INR control, however, remains
      suboptimal. Heart rate control is the most commonly used strategy. The decision
      about the anticoagulation should be based on the thromboembolic risk rather than 
      in the arrhytmia type.
CI  - Copyright (c) 2012 Elsevier Espana, S.L. All rights reserved.
AD  - Centro de Salud Jazmin, Area Este, Atencion Primaria, Madrid, Espana. Electronic 
      address: jmlobos@telefonica.net.
FAU - Lobos-Bejarano, Jose Maria
AU  - Lobos-Bejarano JM
FAU - Del Castillo-Rodriguez, Jose Carlos
AU  - Del Castillo-Rodriguez JC
FAU - Mena-Gonzalez, Amparo
AU  - Mena-Gonzalez A
FAU - Aleman-Sanchez, Jose J
AU  - Aleman-Sanchez JJ
FAU - Cabrera de Leon, Antonio
AU  - Cabrera de Leon A
FAU - Baron-Esquivias, Gonzalo
AU  - Baron-Esquivias G
FAU - Pastor-Fuentes, Agustin
AU  - Pastor-Fuentes A
CN  - en nombre de los Investigadores del Estudio FIATE (Situacion actual de la
      FIbrilacion auricular en ATencion primaria en Espana)
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Caracteristicas de los pacientes y abordaje terapeutico de la fibrilacion
      auricular en atencion primaria en Espana: Estudio FIATE.
DEP - 20130514
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/09/24 [received]
PHST- 2012/11/30 [revised]
PHST- 2012/12/13 [accepted]
AID - S0025-7753(13)00266-2 [pii]
AID - 10.1016/j.medcli.2012.12.023 [doi]
PST - aheadofprint
SO  - Med Clin (Barc). 2013 May 14. pii: S0025-7753(13)00266-2. doi:
      10.1016/j.medcli.2012.12.023.

PMID- 23683965
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1578-1860 (Electronic)
IS  - 0014-2565 (Linking)
DP  - 2013 May 14
TI  - Community-based incidence rate of cardiovascular disease and mortality in 50-75
      year old adults.
LID - S0014-2565(13)00066-0 [pii]
LID - 10.1016/j.rce.2013.01.007 [doi]
AB  - BACKGROUNDS AND OBJECTIVES: Updated information on the incidence of the principal
      cardiovascular diseases (CVD) and cardiovascular mortality is not available in
      Spain. We have studied the incidence rate of new cases of myocardial infarction, 
      heart failure, stroke and cardiovascular mortality in the adult population in
      Sanlucar de Barrameda (Spain). MATERIAL AND METHODS: A community-based
      prospective follow-up study was conducted. The study enrolled 858 participants
      aged 50-75 years who were randomly selected from the population and followed-up
      for 5 years. Age and gender-adjusted incidence rates of cardiovascular disease
      and cardiovascular mortality were calculated, obtaining complete information for 
      855 participants. Prognostic risk factors of new cases of cardiovascular disease 
      were obtained using Cox proportional hazard modeling. RESULTS: The
      community-based incidence rate of heart failure was 455/100.000 persons-year. The
      incidence of myocardial infarction, stroke and cardiovascular mortality (506, 216
      and 225/100.000 persons-year, respectively) was also very elevated. Male gender, 
      family history of early cardiovascular disease, diabetes, hypertension and
      sedentary life style were independent risk factors of cardiovascular disease.
      CONCLUSIONS: The community-based incidence rate of heart failure in Sanlucar de
      Barrameda (Spain) is very high, and it is the first to be reported in Spain. The 
      incidence of myocardial infarction is among the highest in Spain.
CI  - Copyright (c) 2012 Elsevier Espana, S.L. All rights reserved.
AD  - Servicio de Medicina Interna, Hospital Virgen del Camino, Sanlucar de Barrameda, 
      Cadiz, Espana. Electronic address: a.lopez.ssl@gmail.com.
FAU - Lopez-Suarez, A
AU  - Lopez-Suarez A
FAU - Bascunana-Quirell, A
AU  - Bascunana-Quirell A
FAU - Elvira-Gonzalez, J
AU  - Elvira-Gonzalez J
FAU - Beltran-Robles, M
AU  - Beltran-Robles M
FAU - Aboza-Lobaton, A
AU  - Aboza-Lobaton A
FAU - Solis-Diaz, R
AU  - Solis-Diaz R
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Incidencia poblacional de enfermedad cardiovascular y mortalidad en los adultos
      de 50-75 anos.
DEP - 20130514
TA  - Rev Clin Esp
JT  - Revista clinica espanola
JID - 8608576
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/19 [received]
PHST- 2013/01/22 [revised]
PHST- 2013/01/27 [accepted]
AID - S0014-2565(13)00066-0 [pii]
AID - 10.1016/j.rce.2013.01.007 [doi]
PST - aheadofprint
SO  - Rev Clin Esp. 2013 May 14. pii: S0014-2565(13)00066-0. doi:
      10.1016/j.rce.2013.01.007.

PMID- 23683963
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1578-1860 (Electronic)
IS  - 0014-2565 (Linking)
DP  - 2013 May 14
TI  - Hospitalizations due to severe hypoglycemia in patients with diabetes mellitus in
      Spain.
LID - S0014-2565(13)00123-9 [pii]
LID - 10.1016/j.rce.2013.02.015 [doi]
AB  - Background and objectives One of the most important therapeutic complications in 
      patients with diabetes mellitus (DM) is hypoglycemia. This study has estimated
      the number of hospitalizations due to severe hypoglycemia in patients with type
      DM1 and DM2. PATIENTS AND METHODS: The study hospital population was defined
      using the National Catalogue of Hospitals (CNH) 2007 (last available data), and
      has included 260 general hospitals of the National Health System. The number of
      hospitalizations due to severe hypoglycemia was obtained from the Basic Minimum
      Data Set (BMDS) for the 183 hospitals. For the remaining 77 hospitals, this
      number was estimated based on the available information. RESULTS: In 2007, there 
      were 26,701 (0.82%) hospitalizations with hypoglycemia. In DM2 patients, 8,242
      (0.25%) episodes were reported as primary diagnosis and 16,649 (0.51%) as
      secondary. In DM1 patients, 1,157 (0.04%) and 653 (0.02%) episodes were reported 
      as primary and secondary diagnosis, respectively. Overall incidence in DM2 was
      1.82 episodes/10,000 inhabitants-year, this ranging between 1.10 episodes/10,000 
      inhabitants-year in the Islas Canarias to 3.37 in Castilla y Leon. CONCLUSIONS:
      Severe hypoglycemia is an important reason for hospitalization of patients with
      DM in Spain, there being great variability according to the Autonomous Regions.
CI  - Copyright (c) 2013 Elsevier Espana, S.L. All rights reserved.
AD  - HEOR-IMS Health, Barcelona, Espana.
FAU - Lindner, L
AU  - Lindner L
FAU - Garcia-Sanchez, R
AU  - Garcia-Sanchez R
FAU - Alvarez, C
AU  - Alvarez C
FAU - Betegon, L
AU  - Betegon L
FAU - Badia, X
AU  - Badia X
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Hospitalizaciones por hipoglucemia grave en pacientes con diabetes mellitus en
      Espana.
DEP - 20130514
TA  - Rev Clin Esp
JT  - Revista clinica espanola
JID - 8608576
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/31 [received]
PHST- 2013/02/21 [revised]
PHST- 2013/02/22 [accepted]
AID - S0014-2565(13)00123-9 [pii]
AID - 10.1016/j.rce.2013.02.015 [doi]
PST - aheadofprint
SO  - Rev Clin Esp. 2013 May 14. pii: S0014-2565(13)00123-9. doi:
      10.1016/j.rce.2013.02.015.

PMID- 23683953
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 May 16
TI  - Relation of Short-Term Heart Rate Variability to Incident Heart Failure (from the
      Multi-Ethnic Study of Atherosclerosis).
LID - S0002-9149(13)00992-2 [pii]
LID - 10.1016/j.amjcard.2013.04.018 [doi]
AB  - Whether autonomic dysfunction predates the development of symptomatic heart
      failure (HF) or is simply a consequence of severe HF is unknown. We hypothesized 
      that reduced heart rate variability (a marker of abnormal autonomic function) at 
      baseline is associated with incident HF in subjects free of clinically recognized
      cardiovascular disease. In the Multi-Ethnic Study of Atherosclerosis (MESA), a
      population-based study of subclinical cardiovascular disease in adults aged 45 to
      84 years, we measured the heart rate variability using a standard 30-second,
      12-lead electrocardiogram to measure the standard deviation of normal-to-normal
      intervals (SDNN) and the root mean square of successive differences in RR
      intervals (RMSSD). During a median follow-up of 7.6 years, 95 participants
      developed HF (incidence rate 2.7/1,000 person-years). After adjusting for age,
      gender, and ethnicity, the hazard ratio for incident HF stratified by the RMSSD
      tertile was 2.4 (95% confidence interval 1.4 to 4.2) for the lowest tertile and
      1.7 (95% confidence interval 1.0 to 3.2) for the middle tertile (highest tertile 
      was the referent group; p for trend <0.001). The inverse association between the 
      RMSSD and incident HF persisted after adjustment for additional covariates,
      including diabetes, systolic blood pressure, heart rate, subclinical
      atherosclerosis, left ventricular end-systolic volume, interim myocardial
      infarction, and high-sensitivity C-reactive protein (p for trend = 0.009). A
      similarly significant inverse association was also observed for SDNN. In
      conclusion, baseline autonomic dysfunction was a risk factor for the development 
      of HF in a multiethnic cohort. These population-based findings implicate
      autonomic dysfunction in the pathogenesis of HF, and decreased short-term heart
      rate variability might be a novel form of stage B (asymptomatic) HF.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Cardiology, Department of Medicine, Wake Forest University,
      Winston-Salem, North Carolina.
FAU - Shah, Sidharth A
AU  - Shah SA
FAU - Kambur, Thomas
AU  - Kambur T
FAU - Chan, Cheeling
AU  - Chan C
FAU - Herrington, David M
AU  - Herrington DM
FAU - Liu, Kiang
AU  - Liu K
FAU - Shah, Sanjiv J
AU  - Shah SJ
LA  - ENG
GR  - R01 HL107577/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/03/02 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/03 [accepted]
AID - S0002-9149(13)00992-2 [pii]
AID - 10.1016/j.amjcard.2013.04.018 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 May 16. pii: S0002-9149(13)00992-2. doi:
      10.1016/j.amjcard.2013.04.018.

PMID- 23683946
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1532-8201 (Electronic)
IS  - 0897-1897 (Linking)
DP  - 2013 May 14
TI  - A Structural Equation Model of Quality of Life in Adults with Type 2 Diabetes in 
      Korea.
LID - S0897-1897(13)00035-9 [pii]
LID - 10.1016/j.apnr.2013.04.001 [doi]
AB  - PURPOSE: The purpose of this study was to test a structural equation model in
      which self-efficacy and self-care activity predicts the quality of life (QOL) of 
      individuals with type 2 diabetes in Korea. METHOD: A survey about self-care
      activity, self-efficacy, glucose control, and QOL was completed by 132 diabetic
      patients from public health centers in Korea. Data were analyzed using SPSSWIN
      18.0 and AMOS 19.0. RESULTS: The mean age of the participants was 63.2years. The 
      proposed model was a good fit for the data based on the model fit indices.
      Self-efficacy had a significant effect on self-care activity (95%), and this
      model explained 25% of the variance in QOL. CONCLUSIONS: The findings indicate
      that self-efficacy and self-care activity play important roles in explaining QOL 
      in adults with type 2 diabetes. Nursing strategies to increase QOL in this
      population should contain self-efficacy enhancement to promote the performance of
      self-care activity.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Chungnam National University, College of Nursing, Daejeon, South Korea.
FAU - Song, Rhayun
AU  - Song R
FAU - Ahn, Sukhee
AU  - Ahn S
FAU - Oh, Hyunkyoung
AU  - Oh H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Appl Nurs Res
JT  - Applied nursing research : ANR
JID - 8901557
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/09/16 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/10 [accepted]
AID - S0897-1897(13)00035-9 [pii]
AID - 10.1016/j.apnr.2013.04.001 [doi]
PST - aheadofprint
SO  - Appl Nurs Res. 2013 May 14. pii: S0897-1897(13)00035-9. doi:
      10.1016/j.apnr.2013.04.001.

PMID- 23683774
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
DP  - 2013 May 14
TI  - Urine miRNAs: Potential biomarkers for monitoring progression of early stages of 
      diabetic nephropathy.
LID - S0306-9877(13)00201-6 [pii]
LID - 10.1016/j.mehy.2013.04.031 [doi]
AB  - With a steep increase in the incidence of type 1 and 2 diabetes globally,
      diabetic nephropathy (DN) has now become the leading cause of renal failure in
      the world. There are no suitable biomarkers for the diagnosis of early stages of 
      DN. In recent years, tremendous efforts are being made worldwide to delineate the
      role of micro RNAs in the pathogenesis of DN. Circulating miRNAs in serum,
      plasma, urine and other body fluids, which reflect a response to various
      pathophysiological stresses, are being investigated in the context of diabetic
      nephropathy. Delineation of the changes in miRNA levels in patients with DN may
      lead to a better understanding of the progression of the disease. We present here
      an exhaustive survey of the miRNA literature, highlighting various studies
      performed over the last decade. The aim is to assess if changes in various miRNAs
      could correlate with the progression of diabetic nephropathy. Based on the
      survey, we found that miRNA-377, miRNA-192, miRNA-216/217 and miRNA-144 are
      increased in body fluids of patients with DN, while miRNA-21 and miRNA-375 are
      decreased. Overall, there are a very few miRNAs that are kidney specific, and
      although significant differences were observed in the urinary excretion of
      certain miRNAs, they were not correlative to their levels in the blood or plasma.
      Thus, it is completely plausible that urine-specific miRNAs could serve as novel 
      biomarkers for the diagnosis of early stages of diabetic nephropathy.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Nephropathy, The Second Xiangya Hospital, Kidney Institute of
      Nephrology, Central South University, Changsha, Hunan Province 410011, China.
FAU - Yang, Yeyi
AU  - Yang Y
FAU - Xiao, Li
AU  - Xiao L
FAU - Li, Jun
AU  - Li J
FAU - Kanwar, Yashpal S
AU  - Kanwar YS
FAU - Liu, Fuyou
AU  - Liu F
FAU - Sun, Lin
AU  - Sun L
LA  - ENG
GR  - R01 DK060635/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/08/11 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/04/16 [accepted]
AID - S0306-9877(13)00201-6 [pii]
AID - 10.1016/j.mehy.2013.04.031 [doi]
PST - aheadofprint
SO  - Med Hypotheses. 2013 May 14. pii: S0306-9877(13)00201-6. doi:
      10.1016/j.mehy.2013.04.031.

PMID- 23683754
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1578-1852 (Electronic)
IS  - 0213-005X (Linking)
DP  - 2013 May 15
TI  - [Skin and soft-tissue infections in hospitalized patients: Epidemiology,
      microbiological, clinical and prognostic factors.]
LID - S0213-005X(13)00077-3 [pii]
LID - 10.1016/j.eimc.2013.03.004 [doi]
AB  - INTRODUCTION: Skin and soft-tissue infections (SSTIs) are a frequent cause of
      consultation in emergence services, and complicated cases require
      hospitalization. However there are few data in our setting about the clinical
      characteristics of these infections. MATERIAL AND METHODS: A retrospective review
      of hospital admitted patients with a diagnosis of folliculitis, cellulitis,
      erysipelas, abscesses, hidradenitis, furuncle, impetigo, fasciitis and Fournier's
      gangrene. Cases were extracted from the data base of diagnostic codes of the
      Archive and Clinical Documentation Department of Son Llatzer Hospital from
      January 2002 to November 2011. RESULTS: We studied 996episodes in 841hospitalized
      patients with any diagnosis of SSTIs. Cellulitis/erysipelas (66.7%) was the most 
      frequently diagnosed condition, with 77% of all SSTIs being community acquired,
      and the majority of patients had comorbidities, mainly diabetes (33%) and heart
      failure (17.7%). The most frequent isolated microorganism was S.aureus (35.1%),
      in 19 (12.9%) cases with methicillin-resistance (MRSA), 84.2% of them were
      nosocomial or health care acquired. Monotherapy with aminopenicillin with
      clavulanic acid was the empiric treatment most frequently used (35.5%). New
      antibiotics for Gram-positive cocci (linezolid, daptomycin, and tigecycline) were
      used in patients with comorbidities that presented more complications (P<.001)
      and more risk of mortality (P=.001). During admission 10.9% of patients died, but
      only in 2.7% of them mortality was related to the SSTIs. CONCLUSIONS: SSTIs
      attended most frequently in hospitalized patients are mainly
      cellulitis/erysipela, the majority community acquired. MRSA infections are mainly
      health care related. Use of new antibiotic for Gram-positive cocci was limited.
CI  - Copyright (c) 2012 Elsevier Espana, S.L. All rights reserved.
AD  - Servicio de Medicina Interna y Enfermedades Infecciosas, Hospital Son Llatzer,
      Palma de Mallorca, Espana. Electronic address: manuelraya@hotmail.com.
FAU - Raya-Cruz, Manuel
AU  - Raya-Cruz M
FAU - Ferullo, Ignacio
AU  - Ferullo I
FAU - Arrizabalaga-Asenjo, Maria
AU  - Arrizabalaga-Asenjo M
FAU - Nadal-Nadal, Antonio
AU  - Nadal-Nadal A
FAU - Diaz-Antolin, Maria Paz
AU  - Diaz-Antolin MP
FAU - Garau-Colom, Margarita
AU  - Garau-Colom M
FAU - Payeras-Cifre, Antonio
AU  - Payeras-Cifre A
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Infecciones de piel y partes blandas en pacientes hospitalizados: factores
      epidemiologicos, microbiologicos, clinicos y pronosticos.
DEP - 20130515
TA  - Enferm Infecc Microbiol Clin
JT  - Enfermedades infecciosas y microbiologia clinica
JID - 9104081
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/06 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/03/04 [accepted]
AID - S0213-005X(13)00077-3 [pii]
AID - 10.1016/j.eimc.2013.03.004 [doi]
PST - aheadofprint
SO  - Enferm Infecc Microbiol Clin. 2013 May 15. pii: S0213-005X(13)00077-3. doi:
      10.1016/j.eimc.2013.03.004.

PMID- 23683740
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1532-2653 (Electronic)
IS  - 0967-5868 (Linking)
DP  - 2013 May 15
TI  - Can lower risk patients presenting with transient ischaemic attack be safely
      managed as outpatients?
LID - S0967-5868(13)00234-8 [pii]
LID - 10.1016/j.jocn.2013.02.028 [doi]
AB  - This study aimed to examine outcome in low risk transient ischaemic attack (TIA) 
      patients presenting to emergency departments (ED) in a regional Australian
      setting discharged on antiplatelet therapy with expedited neurology review. All
      patients presenting to Gosford or Wyong Hospital ED with TIA, for whom faxed
      referrals to the neurology department were received between October 2008 and July
      2010, were included in this prospective cohort study. Classification of low risk 
      was based on an age, blood pressure, clinical features, duration of symptoms and 
      diabetes (ABCD2) score <4 and the absence of high risk features, including known 
      carotid disease, crescendo TIA, or atrial fibrillation. Patients with ABCD2
      scores 4 or with high risk features were discussed with the neurologist on call
      (a decision regarding discharge or admission was then made at the neurologist's
      discretion). Patients were investigated with a brain CT scan and/or CT
      angiography, routine pathology, and an electrocardiogram. All discharged patients
      were commenced on antiplatelet therapy and asked to follow up with their local
      medical officer within 7days. The patients were contacted by the neurology
      department to arrange follow-up. Our primary outcome was the number of subsequent
      strokes occurring within 90days. Of 200 discharged patients for whom referrals
      were received, three patients had a stroke within 90days. None of these would
      have been prevented through hospitalisation. In conclusion, medical assessment,
      expedited investigation with immediate commencement of secondary prevention and
      outpatient neurology review may be a reasonable alternative to admission for low 
      risk patients presenting to the ED with TIA.
CI  - Crown Copyright (c) 2013. Published by Elsevier Ltd. All rights reserved.
AD  - Department of Neurology, Royal North Shore Hospital, Pacific Hwy, St Leonards,
      NSW 2065, Australia. Electronic address: daynagriffiths@yahoo.ca.
FAU - Griffiths, D
AU  - Griffiths D
FAU - Sturm, J
AU  - Sturm J
FAU - Heard, R
AU  - Heard R
FAU - Reyneke, E
AU  - Reyneke E
FAU - Whyte, S
AU  - Whyte S
FAU - Clarke, T
AU  - Clarke T
FAU - O'Brien, W
AU  - O'Brien W
FAU - Crimmins, D
AU  - Crimmins D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Clin Neurosci
JT  - Journal of clinical neuroscience : official journal of the Neurosurgical Society 
      of Australasia
JID - 9433352
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/07/29 [received]
PHST- 2013/02/05 [revised]
PHST- 2013/02/10 [accepted]
AID - S0967-5868(13)00234-8 [pii]
AID - 10.1016/j.jocn.2013.02.028 [doi]
PST - aheadofprint
SO  - J Clin Neurosci. 2013 May 15. pii: S0967-5868(13)00234-8. doi:
      10.1016/j.jocn.2013.02.028.

PMID- 23683663
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 14
TI  - Elevated liver enzymes in individuals with undiagnosed diabetes in the U.S.
LID - S1056-8727(13)00073-1 [pii]
LID - 10.1016/j.jdiacomp.2013.04.005 [doi]
AB  - OBJECTIVE: We investigated the association of diabetes diagnosis and medication
      type with liver injury in individuals with clinical diabetes. METHODS: We
      analyzed 2426 patients with clinical diabetes in the National Health and
      Nutrition Examination Survey conducted from 1999 to 2008. Elevated alanine
      transaminase (ALT) and aspartate transaminase (AST) levels were used as markers
      of liver injury. Participants were categorized into one of three categories: 1)
      clinical diabetes without physician's diagnosis or diabetes medication; 2)
      diagnosed diabetes without diabetes medication; or 3) diagnosed diabetes with
      diabetes medication, further divided by classes of diabetes medications
      prescribed. We conducted logistic regression analysis to examine the relationship
      between diabetes diagnosis and medication type and elevated ALT and AST,
      adjusting for race/ethnicity, education, health insurance status, BMI category,
      alcohol consumption, physical activity, antihyperlipidemic agents,
      glycohemoglobin, C-reactive protein, viral hepatitis and liver disease. RESULTS: 
      Participants with undiagnosed diabetes were more likely to have elevated ALT and 
      AST levels (OR=1.82, 95% CI 1.47, 2.42; OR=1.99, 95% CI 1.46, 2.71,
      respectively). In contrast, there was no association between specific diabetes
      medication (i.e., sulfonylureas, biguanides/thiazolidinediones) and elevated ALT 
      or AST levels among the treated. Our findings were confirmed in sensitivity
      analyses employing a lower threshold for ALT, and excluding individuals with
      viral hepatitis or liver disease. CONCLUSION: We found that undiagnosed diabetes 
      is associated with liver injury, compared to diagnosed diabetes with treatment.
      The effect of diabetes treatment on liver injury in individuals with diabetes
      remains uncertain.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Center for Cancer Prevention and Control Research, Fielding School of Public
      Health, University of California Los Angeles, Los Angeles, CA. Electronic
      address: cyjeon@ucla.edu.
FAU - Jeon, Christie Y
AU  - Jeon CY
FAU - Roberts, Christian K
AU  - Roberts CK
FAU - Crespi, Catherine M
AU  - Crespi CM
FAU - Zhang, Zuo-Feng
AU  - Zhang ZF
LA  - ENG
GR  - R21 ES011667/ES/NIEHS NIH HHS/United States
GR  - UL1 TR000124/TR/NCATS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/02 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/04/08 [accepted]
AID - S1056-8727(13)00073-1 [pii]
AID - 10.1016/j.jdiacomp.2013.04.005 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 14. pii: S1056-8727(13)00073-1. doi:
      10.1016/j.jdiacomp.2013.04.005.

PMID- 23683590
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 23
IP  - 13
DP  - 2013 Jul 1
TI  - Design and synthesis of 6,7-dimethoxyquinazoline analogs as multi-targeted
      ligands for alpha1- and AII-receptors antagonism.
PG  - 3959-66
LID - 10.1016/j.bmcl.2013.04.054 [doi]
LID - S0960-894X(13)00535-0 [pii]
AB  - Multiple-targeted ligands can have certain advantages for the management of
      hypertension which has multiple controls. Molecules with dual bioactivities are
      available in literature for treating metabolic disorders like diabetes,
      hypertension and hypercholesterolemia. After scrutinizing the SAR of
      prazosin-type alpha1-blockers and AII-antagonists it was planned to develop dual 
      alpha1- and AII-antagonists. Five series of quinazoline derivatives were
      synthesized and evaluated as dual alpha1- and AII-antagonists on rat aortic
      strips for the blockade of known alpha1- and AII-agonist mediated contractions.
      Many compounds showed balanced activity on both the receptors but compound (22)
      was found to be the most active derivative having higher antagonistic activity on
      both the receptors. In the in vivo experiments the chosen compound (22) was
      slightly less active than prazosin but was found to be equipotent to losartan.
      These findings shed a new light on the structural requirements for both alpha1-
      as well as AII-receptor antagonists.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Pharmacy Department, Faculty of Tech. & Engg., The M.S. University of Baroda,
      Vadodara 390001, Gujarat, India. Electronic address: mryadav11@yahoo.co.in.
FAU - Yadav, M R
AU  - Yadav MR
FAU - Naik, P P
AU  - Naik PP
FAU - Gandhi, H P
AU  - Gandhi HP
FAU - Chauhan, B S
AU  - Chauhan BS
FAU - Giridhar, R
AU  - Giridhar R
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/14 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/19 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - S0960-894X(13)00535-0 [pii]
AID - 10.1016/j.bmcl.2013.04.054 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2013 Jul 1;23(13):3959-66. doi: 10.1016/j.bmcl.2013.04.054.
      Epub 2013 Apr 30.

PMID- 23683575
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1555-3892 (Electronic)
IS  - 0963-6897 (Linking)
DP  - 2013 May 15
TI  - Automated Digital Image Analysis of islet cell mass using Nikon's inverted
      Eclipse Ti microscope and software to improve engraftment may help to advance the
      therapeutic efficacy and accessibility of islet transplantation across centers.
AB  - Reliable assessment of islet viability, mass and purity must be met prior to
      transplanting anislet preparation into patients with type 1 diabetes. The
      standard method for quantifyinghuman islet preparations is by direct microscopic 
      analysis of dithizone-stained islet samples,but this technique may be susceptible
      to inter / intra observer variability, which may inducefalse positive / negative 
      islet counts. Here we describe a simple, reliable, automated digitalimage
      analysis (ADIA) technique, for accurately quantifying islets into total islet
      number,islet equivalent number (IEQ), and islet purity before islet
      transplantation.Islets were isolated and purified from n=42 human pancreata
      according to the automatedmethod of Ricordi et al. For each preparation, three
      islet samples were stained with dithizone,and expressed as IEQ number. Islets
      were analyzed manually by microscopy, or automaticallyquantified using Nikon's
      inverted Eclipse Ti microscope, with built in NIS-Elements Advanced Research (AR)
      software.The AIDA method significantly enhanced the number of islet preparations 
      eligible forengraftment compared to the standard manual method (P<0.001).
      Comparisons of individualmethods showed good correlations between mean values of 
      IEQ number (r(2)</=0.91), and totalislet number (r(2)</=0.88), and thus,
      increased to (r(2)</=0.93) when islet surface area was estimatedcomparatively
      with IEQ number. The ADIA method showed very high intra-observerreproducibility
      compared to the standard manual method (P<0.001). However, islet purity
      wasroutinely estimated as significantly higher with the manual method vs. the
      ADIA method(p<0.001).The ADIA method also detected small islets between 10-50 mum
      in size.Automated digital image analysis utilizing the Nikon Instruments (Nikon) 
      software is anunbiased, simple, and reliable teaching tool to comprehensively
      assess the individual size ofeach islet cell preparation prior to
      transplantation. Implementation of this technology toimprove engraftment may help
      to advance the therapeutic efficacy and accessibility of islet transplantation
      across centers.
FAU - Gmyr, Valery
AU  - Gmyr V
FAU - Bonner, Caroline
AU  - Bonner C
FAU - Lukowiak, Bruno
AU  - Lukowiak B
FAU - Pawlowski, Valerie
AU  - Pawlowski V
FAU - Dellaleau, Nathalie
AU  - Dellaleau N
FAU - Belaich, Sandrine
AU  - Belaich S
FAU - Aluka, Isanga
AU  - Aluka I
FAU - Moermann, Ericka
AU  - Moermann E
FAU - Thevenet, Julien
AU  - Thevenet J
FAU - Ezzouaoui, Rimed
AU  - Ezzouaoui R
FAU - Queniat, Gurvan
AU  - Queniat G
FAU - Pattou, Francois
AU  - Pattou F
FAU - Kerr-Conte, Julie
AU  - Kerr-Conte J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - ct1018rgmyr [pii]
AID - 10.3727/096368913X667493 [doi]
PST - aheadofprint
SO  - Cell Transplant. 2013 May 15.

PMID- 23683548
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
VI  - 46
IP  - 9
DP  - 2013 Jun
TI  - Role of the laboratory in diabetes diagnosis and screening-The 2013 CDA CPGs.
PG  - 707-9
LID - 10.1016/j.clinbiochem.2013.04.019 [doi]
LID - S0009-9120(13)00159-8 [pii]
AD  - Endocrinology & Metabolism, McMaster University, Hamilton, Ontario, Canada.
      Electronic address: zubin.punthakee@mcmaster.ca.
FAU - Punthakee, Zubin
AU  - Punthakee Z
LA  - eng
PT  - Editorial
PL  - United States
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - S0009-9120(13)00159-8 [pii]
AID - 10.1016/j.clinbiochem.2013.04.019 [doi]
PST - ppublish
SO  - Clin Biochem. 2013 Jun;46(9):707-9. doi: 10.1016/j.clinbiochem.2013.04.019.

PMID- 23683523
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1872-8952 (Electronic)
IS  - 1388-2457 (Linking)
DP  - 2013 May 14
TI  - Mechanisms of axonal dysfunction in diabetic and uraemic neuropathies.
LID - S1388-2457(13)00307-6 [pii]
LID - 10.1016/j.clinph.2013.04.012 [doi]
AB  - The global burden imposed by metabolic diseases and associated complications
      continue to escalate. Neurological complications, most commonly peripheral
      neuropathy, represent a significant cause of morbidity and disability in patients
      with diabetes and chronic kidney disease. Furthermore, health care costs are
      substantially increased by the presence of complications making investigation
      into treatment a matter of high priority. Over the last decade nerve excitability
      techniques have entered the clinical realm and enabled in vivo assessment of
      biophysical properties and function of peripheral nerves in health and disease.
      Studies of excitability in diabetic neuropathy have demonstrated alteration in
      biophysical properties, including changes in Na+ conductances and Na+/K+ pump
      function, which may contribute to the development of neuropathic symptoms.
      Interventional studies have demonstrated that these changes are responsive to
      pharmacological agents. Excitability studies in patients with chronic kidney
      disease have demonstrated prominent changes that may contribute to the
      development of uraemic neuropathy. In particular, these studies have demonstrated
      strong correlation between hyperkalaemia and the development of nerve
      dysfunction. These studies have provided a basis for future work assessing the
      benefits of potassium restriction as a therapeutic strategy in this condition.
CI  - Copyright (c) 2013 International Federation of Clinical Neurophysiology.
      Published by Elsevier Ireland Ltd. All rights reserved.
AD  - Translational Neuroscience Facility, School of Medical Sciences, University of
      New South Wales, Sydney, Australia.
FAU - Arnold, Ria
AU  - Arnold R
FAU - Kwai, Natalie C G
AU  - Kwai NC
FAU - Krishnan, Arun V
AU  - Krishnan AV
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Clin Neurophysiol
JT  - Clinical neurophysiology : official journal of the International Federation of
      Clinical Neurophysiology
JID - 100883319
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/08 [received]
PHST- 2013/04/12 [revised]
PHST- 2013/04/13 [accepted]
AID - S1388-2457(13)00307-6 [pii]
AID - 10.1016/j.clinph.2013.04.012 [doi]
PST - aheadofprint
SO  - Clin Neurophysiol. 2013 May 14. pii: S1388-2457(13)00307-6. doi:
      10.1016/j.clinph.2013.04.012.

PMID- 23683482
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1847-6538 (Electronic)
IS  - 1330-027X (Linking)
VI  - 21
IP  - 1
DP  - 2013 May
TI  - Frequency of onychomycoses in chronic renal failure patients undergoing
      hemodialysis in porto alegre, Brazil.
PG  - 19-23
AB  - Onychomycosis is one of the most frequent infections affecting the fingernails or
      the toenails and it is caused mainly by dermatophytes. The aim of the study was
      to assess the frequency of onychomycoses in hemodialysis patients and to relate
      sex, age, duration of hemodialysis and causes of renal failure to the development
      of nail disorders. The study included 100 patients with chronic renal failure
      undergoing hemodialysis. The patients underwent detailed clinical examination of 
      the toenails and those with any kind of clinical finding had nail scraping for
      mycological testing. In the study population, the frequency of onychomycosis was 
      39%. The most commonly isolated fungi were dermatophytes (69.23%), Candida spp.
      (15.38%) and nondermatophyte molds (15.38%). T. interdigitale was the most
      prevalent fungus followed by Candida ssp. and T. rubrum. The risk of
      onychomycosis increases by 1.9% for each additional year in age and diabetic
      patients are 88% more likely to develop onychomycosis than nondiabetic ones. The 
      duration of hemodialysis treatment and sex were not associated with the
      development of onychomycosis. In conclusion, in hemodialysis patients, the
      frequency of onychomycosis was higher in those at advanced age and with diabetes.
AD  - Flavia Maria Lamb, MD, Rua Mostardeiro 5, sala 711, Porto Alegre, RS CEP
      90430-001, Brazil; flalamb@gmail.com; scrofern@ufrgs.br.
FAU - Lamb, Flavia Maria
AU  - Lamb FM
FAU - Ottonelli Stopiglia, Cheila Denise
AU  - Ottonelli Stopiglia CD
FAU - Vetoratto, Gerson
AU  - Vetoratto G
FAU - Goldani, Joao Carlos
AU  - Goldani JC
FAU - Scroferneker, Maria Lucia
AU  - Scroferneker ML
LA  - eng
PT  - Journal Article
PL  - Croatia
TA  - Acta Dermatovenerol Croat
JT  - Acta dermatovenerologica Croatica : ADC
JID - 9433781
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PST - ppublish
SO  - Acta Dermatovenerol Croat. 2013 May;21(1):19-23.

PMID- 23683449
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1806-907X (Electronic)
IS  - 0034-7094 (Linking)
VI  - 63
IP  - 3
DP  - 2013 May-Jun
TI  - Use of simple clinical predictors on preoperative diagnosis of difficult
      endotracheal intubation in obese patients.
PG  - 262-6
LID - 10.1016/S0034-7094(13)70228-9 [doi]
LID - S0034-7094(13)70228-9 [pii]
AB  - BACKGROUND AND OBJECTIVES: Although the incidence of difficult laryngoscopy is
      similar in obese and non-obese patients, there are more reports of difficult
      intubation in obese individuals. Alternatives for the diagnosis and prediction of
      difficult intubation in the preoperative period may help reduce anesthetic
      complications in obese patients. The aim of this study was to identify predictors
      for the diagnosis of difficult airway in obese patients, correlating with the
      clinical methods of pre-anesthetic evaluation and polysomnography. We also
      compared the incidence of difficult facemask ventilation and difficult
      laryngoscopy between obese and non-obese patients, identifying the most prevalent
      predictors. METHODS: Observational, prospective and comparative study, with 88
      adult patients undergoing general anesthesia. In the preoperative period, we
      evaluated a questionnaire on the clinical predictors of the obstructive sleep
      apnea syndrome (OSAS) and anatomical parameters. During anesthesia, we evaluated 
      difficult facemask ventilation and laryngoscopy. Descriptive statistics and
      correlation test were used for analysis. RESULTS: Patients were allocated into
      two groups: obese group (n=43) and non-obese group (n=45). Physical status,
      prevalence of snoring, hypertension, diabetes mellitus, neck circumference, and
      Mallampati index were higher in the obese group. Obese patients had a higher
      incidence of difficult facemask ventilation and laryngoscopy. There was no
      correlation between anatomical or clinical variable and difficult facemask
      ventilation in both groups. In obese patients, the diagnosis of OSAS showed
      strong correlation with difficult laryngoscopy. CONCLUSIONS: The clinical and
      polysomnographic diagnosis of OSA proved useful in the preoperative diagnosis of 
      difficult laryngoscopy. Obese patients are more prone to difficult facemask
      ventilation and laryngoscopy.
CI  - Copyright (c) 2013 Elsevier Editora Ltda. All rights reserved.
AD  - Responsible for CET /SBA, Anesthesiology Center, Universidade de Brasilia.
      Electronic address: ednomag@gmail.com.
FAU - Magalhaes, Edno
AU  - Magalhaes E
FAU - Oliveira Marques, Felipe
AU  - Oliveira Marques F
FAU - Sousa Goveia, Catia
AU  - Sousa Goveia C
FAU - Araujo Ladeira, Luis Claudio
AU  - Araujo Ladeira LC
FAU - Lagares, Jader
AU  - Lagares J
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Rev Bras Anestesiol
JT  - Revista brasileira de anestesiologia
JID - 0401316
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/01/26 [received]
PHST- 2012/05/07 [accepted]
AID - S0034-7094(13)70228-9 [pii]
AID - 10.1016/S0034-7094(13)70228-9 [doi]
PST - ppublish
SO  - Rev Bras Anestesiol. 2013 May-Jun;63(3):262-6. doi:
      10.1016/S0034-7094(13)70228-9.

PMID- 23683386
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 0755-4982 (Electronic)
IS  - 0755-4982 (Linking)
DP  - 2013 May 15
TI  - A case of inguinal hernia stone alongwith diabetes and pathophysiology.
LID - S0755-4982(13)00547-2 [pii]
LID - 10.1016/j.lpm.2012.11.022 [doi]
AD  - Maharishi Markandeshwer Institute of Medical Sciences and Research, Department of
      Surgery, Mullana (Distt-Ambala), Haryana, India. Electronic address:
      singalsurgery@yahoo.com.
FAU - Singal, Rikki
AU  - Singal R
LA  - ENG
PT  - LETTER
DEP - 20130515
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/09/24 [received]
PHST- 2012/10/22 [revised]
PHST- 2012/11/19 [accepted]
AID - S0755-4982(13)00547-2 [pii]
AID - 10.1016/j.lpm.2012.11.022 [doi]
PST - aheadofprint
SO  - Presse Med. 2013 May 15. pii: S0755-4982(13)00547-2. doi:
      10.1016/j.lpm.2012.11.022.

PMID- 23683380
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
DP  - 2013 May 14
TI  - Clinical presentation and outcome after failed infrainguinal endovascular and
      open revascularization in patients with chronic limb ischemia.
LID - S0741-5214(13)00135-3 [pii]
LID - 10.1016/j.jvs.2012.12.076 [doi]
AB  - OBJECTIVE: Failure of prior endovascular (EV) interventions for chronic limb
      ischemia has been reported to negatively affect patency and limb salvage after
      subsequent revascularization procedures. The goal of our study was to compare the
      clinical presentation of patients who failed infrainguinal EV and open
      revascularizations (OR) and the effect of the initial intervention on final
      outcomes. METHODS: From June 2001 to October 2010, 216 patients (237 limbs; 66
      disabling claudication [DC], 171 critical limb ischemia [CLI]) presented with
      failed infrainguinal OR or EV revascularization for chronic limb ischemia.
      Clinical presentation, reinterventions, patency and limb salvage rates, and final
      outcomes were analyzed. RESULTS: The EV group (n = 143) had more diabetes (44% vs
      57%; P = .048) and ulcers (26% vs 38%; P = .039), whereas the OR group (n = 94)
      had more multilevel revascularizations (59% vs 33%; P < .001), rest pain (23% vs 
      9%; P = .002), and infrapopliteal interventions (58% vs 38%; P = .038).
      Presentation at time of failure was non-limb-threatening ischemia in 70% of DC
      and 16% of CLI patients (P < .001), with no difference in those initially treated
      with EV or OR. In CLI, 23% presented with acute limb ischemia in the OR group vs 
      10% in the EV group (P = .024). Early failure (<3 months) occurred in 15% of DC
      and in 36% of CLI patients and was more in the OR than in the EV group (30% vs 7%
      for DC [P = .011] and 71% vs 38% for CLI [P = .024]). Overall, 195 (82%) had
      attempted reinterventions (79% in DC and 85% in CLI; P = .245). In DC patients,
      48% of OR had OR + EV and 26% had EV; 32% of EV had OR + EV and 47% had EV
      reinterventions. In CLI patients, 40% of OR had OR + EV and 42% had EV; 17% of EV
      had OR + EV; and 70% had EV reinterventions. A patent revascularized limb was
      achieved in 66% of OR and in 92% of EV patients (P < .001). Patency and limb
      salvage were significantly better in the EV group, mainly due to the difference
      in CLI patients, whereas survival was identical. CONCLUSIONS: Clinical
      presentation after failed infrainguinal revascularization is determined by the
      initial indication. CLI patients are more likely to present early with acute limb
      ischemia, especially after OR. EV reinterventions play a significant role in the 
      management of patients with failed revascularization, and EV failure is
      associated with better outcomes than those after OR failure, likely due to OR
      patients having more disadvantaged anatomy and advanced disease at the time of
      their initial presentation.
CI  - Copyright (c) 2013 Society for Vascular Surgery. Published by Mosby, Inc. All
      rights reserved.
AD  - Division of Vascular Surgery, VA Western NY Healthcare System, Buffalo, NY;
      Division of Vascular Surgery, Department of Surgery, State University of New York
      at Buffalo, Buffalo, NY. Electronic address: dosluoglu@yahoo.com.
FAU - Dosluoglu, Hasan H
AU  - Dosluoglu HH
FAU - Lall, Purandath
AU  - Lall P
FAU - Blochle, Raphael
AU  - Blochle R
FAU - Harris, Linda M
AU  - Harris LM
FAU - Dryjski, Maciej L
AU  - Dryjski ML
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/09/04 [received]
PHST- 2012/12/21 [revised]
PHST- 2012/12/24 [accepted]
AID - S0741-5214(13)00135-3 [pii]
AID - 10.1016/j.jvs.2012.12.076 [doi]
PST - aheadofprint
SO  - J Vasc Surg. 2013 May 14. pii: S0741-5214(13)00135-3. doi:
      10.1016/j.jvs.2012.12.076.

PMID- 23683372
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 17
TI  - Using web-based familial risk information for diabetes prevention: a randomized
      controlled trial.
PG  - 485
AB  - BACKGROUND: It has been suggested that family history information may be
      effective in motivating people to adopt health promoting behaviour. The aim was
      to determine if diabetic familial risk information by using a web-based tool
      leads to improved self-reported risk-reducing behaviour among individuals with a 
      diabetic family history, without causing false reassurance among those without a 
      family history. METHODS: An online sample of 1,174 healthy adults aged 35--65
      years with a BMI >= 25 was randomized into two groups receiving an online
      diabetes risk assessment. Both arms received general tailored diabetes prevention
      information, whilst the intervention arm also received familial risk information 
      after completing a detailed family history questionnaire. Separate analysis was
      performed for four groups (family history group: 286 control versus 288
      intervention group; no family history: 269 control versus 266 intervention
      group). Primary outcomes were self-reported behavioural outcomes: fat intake,
      physical activity, and attitudes towards diabetes testing. Secondary outcomes
      were illness and risk perceptions. RESULTS: For individuals at familial risk
      there was no overall intervention effect on risk-reducing behaviour after three
      months, except for a decrease in self-reported saturated fat intake among
      low-educated individuals (Beta (b) -1.01, 95% CI -2.01 to 0.00). Familial risk
      information resulted in a decrease of diabetes risk worries (b -0.21, -0.40 to
      -0.03). For individuals without family history no effect was found on
      risk-reducing behaviour and perceived risk. A detailed family history assessment 
      resulted in a greater percentage of individuals reporting a familial risk for
      diabetes compared to a simple enquiry. CONCLUSIONS: Web-based familial risk
      information reduced worry related to diabetes risk and decreased saturated fat
      intake of those at greatest need of preventative care. However, the intervention 
      was not effective for the total study population on improving risk-reducing
      behaviour. The emphasis on familial risk does not seem to result in false
      reassurance among individuals without family history. Additionally, a detailed
      family history questionnaire identifies more individuals at familial risk than a 
      simple enquiry.Trial registration: NTR1938,
      http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1938.
FAU - Wijdenes, Miranda
AU  - Wijdenes M
FAU - Henneman, Lidewij
AU  - Henneman L
FAU - Qureshi, Nadeem
AU  - Qureshi N
FAU - Kostense, Piet J
AU  - Kostense PJ
FAU - Cornel, Martina C
AU  - Cornel MC
FAU - Timmermans, Danielle Rm
AU  - Timmermans DR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/10/31 [received]
PHST- 2013/05/17 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 1471-2458-13-485 [pii]
AID - 10.1186/1471-2458-13-485 [doi]
PST - aheadofprint
SO  - BMC Public Health. 2013 May 17;13(1):485.

PMID- 23683260
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Linking)
VI  - 76
IP  - 5
DP  - 2013 May
TI  - Risk factors for acute kidney injury in the elderly undergoing contrast-enhanced 
      computed tomography in the emergency department.
PG  - 271-6
LID - 10.1016/j.jcma.2013.01.007 [doi]
LID - S1726-4901(13)00024-5 [pii]
AB  - BACKGROUND: There have been few studies focusing on the incidence and risk
      factors for elderly patients undergoing computed tomography (CT) scans with
      intravascular contrast medium, who develop contrast-induced nephropathy (CIN) in 
      the emergency department (ED). Our objective was to investigate the incidence of 
      and risk factors for, CIN in elderly patients seen in the ED, who receive
      intravenous contrast media for CT examination. METHODS: Patients >/=65 years of
      age who received contrast-enhanced CT were eligible for inclusion in this
      retrospective analysis. CIN was defined as an increase in serum creatinine (sCr) 
      >/=0.5 mg/dL 48 to 72 hours after intravenous contrast administration. Multiple
      logistic regression analysis for risk factors for CIN and Chi-square test were
      performed for trend analysis for CIN incidence and mortality of different risk
      scores. RESULTS: A total of 594 patients, with a mean age of 79.8 +/- 6.8 years
      were included. The overall incidence of CIN was 8.6%. In multivariate analyses,
      CIN was associated with diabetes mellitus [adjusted odds ratio (OR) = 1.93; 95%
      confidence interval (CI) = 1.04-3.62], precontrast sCr >1.5 mg/dL (OR = 2.72; 95%
      CI = 1.44-5.13), and acute hypotension (OR = 3.56; 95% CI = 1.29-9.84). CIN and
      mortality increased with increasing risk score (p < 0.001 and p = 0.001,
      respectively). The all-cause in-hospital mortality rate was 13.1%, and the
      mortality rates for patients with and without CIN (p < 0.001) were 47.1% and
      9.9%, respectively. CONCLUSION: Our investigation confirmed diabetes mellitus,
      precontrast sCr >1.5 mg/dL and acute hypotension as risk factors for CIN, and
      also developed a simple risk score for elderly patients seen in the ED.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Emergency Medicine, Mackay Memorial Hospital, Taipei, Taiwan, ROC.
FAU - Huang, Ming-Kun
AU  - Huang MK
FAU - Hsu, Teh-Fu
AU  - Hsu TF
FAU - Chiu, Yu-Hui
AU  - Chiu YH
FAU - Chiang, Shu-Chiung
AU  - Chiang SC
FAU - Kao, Wei-Fong
AU  - Kao WF
FAU - Yen, David Hung-Tsang
AU  - Yen DH
FAU - Huang, Mu-Shun
AU  - Huang MS
LA  - eng
PT  - Journal Article
DEP - 20130321
PL  - China (Republic : 1949- )
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/03/19 [received]
PHST- 2012/08/25 [accepted]
PHST- 2013/03/21 [aheadofprint]
AID - S1726-4901(13)00024-5 [pii]
AID - 10.1016/j.jcma.2013.01.007 [doi]
PST - ppublish
SO  - J Chin Med Assoc. 2013 May;76(5):271-6. doi: 10.1016/j.jcma.2013.01.007. Epub
      2013 Mar 21.

PMID- 23683134
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 17
TI  - Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
LID - 10.1111/dom.12135 [doi]
AB  - AIM: Assess influences of demographics and co-morbidities of gout patients with
      or without diabetes on safety and efficacy of urate-lowering agents. MATERIALS
      AND METHODS: Post-hoc analysis of 312 diabetic and 1,957 non-diabetic gout
      patients (baseline serum urate levels [sUA] >/=8.0 mg/dL) enrolled in a 6-month
      randomized controlled trial comparing urate-lowering efficacy (ULE) and safety of
      daily xanthine oxidase inhibitors (XOIs) febuxostat (40 mg or 80 mg) and
      allopurinol (200 mg or 300 mg). We compared baseline demographic, gout, and
      co-morbid characteristics, ULE, and safety of XOI treatment in diabetic and
      non-diabetic gout patients. ULE was measured by the proportion of diabetic and
      non-diabetic patients in each treatment group achieving final visit sUA
      <6.0mg/dL. Safety was monitored throughout the trial. RESULTS: Diabetic gout
      patients were older, more frequently female, and had longer gout duration.
      Co-morbidities were more frequent among diabetic patients: cardiovascular
      disease; impaired renal function; hyperlipidemia; and obesity (BMI >30 kg/m2 ) (p
      < 0.001 for all comparisons). Febuxostat 80 mg ULE exceeded that of febuxostat 40
      mg or allopurinol (p <0.050) at all levels of renal function, achieving sUA goal 
      range in the majority of diabetic and non-diabetic patients. Diabetics and
      non-diabetics reported self-limiting diarrhea and URIs as the most common AEs.
      CONCLUSIONS: Despite higher co-morbidity rates in diabetic patients, febuxostat
      and allopurinol were safe in both groups at the doses tested. Febuxostat 80 mg
      achieved sUA <6.0 mg/dL more often than febuxostat 40 mg or allopurinol at
      commonly prescribed doses.
CI  - This article is protected by copyright. All rights reserved.
AD  - The University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
FAU - Becker, M A
AU  - Becker MA
FAU - Macdonald, P A
AU  - Macdonald PA
FAU - Hunt, B J
AU  - Hunt BJ
FAU - Jackson, R L
AU  - Jackson RL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/11 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/05/14 [accepted]
AID - 10.1111/dom.12135 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 17. doi: 10.1111/dom.12135.

PMID- 23683113
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1364-6915 (Electronic)
IS  - 1360-7863 (Linking)
DP  - 2013 May 20
TI  - Vascular depression and frailty: a compound threat to longevity among older-old
      women.
AB  - Objectives: The vascular depression hypothesis posits that cerebrovascular burden
      contributes to the development of depression symptoms in late life. Building on
      work that suggests that vascular depression is a prodrome for frailty, this paper
      tests a theoretical framework that vascular depression symptoms are an early
      marker of a broader pattern of decline characterized by more frailty symptoms and
      shortened lifespan, and that vascular depression symptoms predict mortality
      through frailty. Methods: The sample was drawn from the Health and Retirement
      Study and included 1361 stroke-free women over the age of 80. Data were included 
      from six biannual waves from 1998 to 2008 (waves 4-9). A vascular depression
      symptomatology variable was based on Center for Epidemiological Studies
      Depression Scale (CES-D) scores and number of cerebrovascular risk factors
      (hypertension, diabetes, cardiac disease, and smoking). Frailty was measured
      based on wasting, slowness, weakness, fatigue, and falls. Vascular depression and
      frailty symptoms were modeled using slope and intercept terms. Mortality was
      modeled using a discrete-time survival term. Results: The data supported the
      proposed model (RMSEA = 0.051; CFI = 0.971; X 2 = 234.84, p < 0.001). Higher
      vascular depression symptom slope and intercept scores significantly predicted
      higher frailty slope and intercept scores, respectively. Frailty intercept scores
      significantly predicted mortality. The vascular depression symptoms indirectly
      predicted mortality through frailty symptoms. A second model testing the
      competing hypothesis - that frailty symptoms lead to vascular depression symptoms
      and indirectly to mortality - was not supported by the data. Conclusions: Results
      suggest that vascular depression symptoms are associated with a clinical
      trajectory that includes greater frailty and shortened remaining lifespan.
AD  - a Department of Psychology and Institute of Gerontology , Wayne State University 
      , United States.
FAU - Paulson, Daniel
AU  - Paulson D
FAU - Lichtenberg, Peter A
AU  - Lichtenberg PA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - Aging Ment Health
JT  - Aging & mental health
JID - 9705773
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.1080/13607863.2013.799115 [doi]
PST - aheadofprint
SO  - Aging Ment Health. 2013 May 20.

PMID- 23683111
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 17
TI  - A comparison of the assessment and management of cardiometabolic risk in patients
      with and without type 2 diabetes mellitus in Canadian primary care.
LID - 10.1111/dom.12134 [doi]
AB  - AIM: To investigate the cardiometabolic risk assessment and management patterns
      for individuals with and without type 2 diabetes mellitus (T2DM) in Canadian
      primary care practices. METHODS: Between April 2011 and March 2012, physicians
      from 9 primary care teams and 88 traditional non-team practices completed a
      practice assessment on the management of 2461 patients >40 years old with no
      clinical evidence of cardiovascular disease and diagnosed with at least one of
      the following risk factor - T2DM, dyslipidemia or hypertension. RESULTS: There
      were 1304 individuals with T2DM and 1157 without. Pharmacotherapy to manage
      hyperglycemia, dyslipidemia and hypertension was widely prescribed. Fifty-eight
      percent of individuals with T2DM had an HbA1c </=7.0%. Amongst individuals with
      dyslipidemia, median LDL-C was 1.8 mmol/L for those with T2DM and 2.8 mmol/L for 
      those without. Amongst individuals with hypertension, 30% of those with T2DM
      achieved the <130/80 mmHg target while 60% of those without met the <140/90 mmHg 
      target. The composite glycemic, LDL-C and blood pressure (BP) target outcome was 
      achieved by 12% of individuals with T2DM. Only 17% of individuals with T2DM and
      11% without were advised to increase their physical activity. Dietary
      modifications were recommended to 32% and 10% of those with and without T2DM
      respectively. CONCLUSIONS: Patients at elevated cardiometabolic risk were
      sub-optimally managed in the primary care practices surveyed. There was low
      attainment of recommended therapeutic glycemic, lipid and BP targets. Advice on
      healthy lifestyle changes was infrequently dispensed, representing a missed
      opportunity to educate patients on the long-term benefits of lifestyle
      modification.
CI  - This article is protected by copyright. All rights reserved.
AD  - Divisions of Endocrinology & Metabolism, Keenan Research Centre in the Li Ka
      Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada;
      Divisions of Cardiac Surgery, Keenan Research Centre in the Li Ka Shing Knowledge
      Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
FAU - Teoh, H
AU  - Teoh H
FAU - Despres, J-P
AU  - Despres JP
FAU - Dufour, R
AU  - Dufour R
FAU - Fitchett, D H
AU  - Fitchett DH
FAU - Goldin, L
AU  - Goldin L
FAU - Goodman, S G
AU  - Goodman SG
FAU - Harris, S B
AU  - Harris SB
FAU - Langer, A
AU  - Langer A
FAU - Lau, D C W
AU  - Lau DC
FAU - Lonn, E M
AU  - Lonn EM
FAU - Mancini, G B J
AU  - Mancini GB
FAU - McFarlane, P A
AU  - McFarlane PA
FAU - Poirier, P
AU  - Poirier P
FAU - Rabasa-Lhoret, R
AU  - Rabasa-Lhoret R
FAU - Tan, Mary K
AU  - Tan MK
FAU - Leiter, L A
AU  - Leiter LA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/02/12 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/05/14 [accepted]
AID - 10.1111/dom.12134 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 17. doi: 10.1111/dom.12134.

PMID- 23683104
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 30
IP  - 6
DP  - 2013 Jun
TI  - Systematic review of the development, implementation and availability of
      smart-phone applications for assessing Type 2 diabetes risk.
PG  - 758-60
LID - 10.1111/dme.12115 [doi]
AD  - Department of Health Sciences, University of Leicester, Leicester, UK.
FAU - Gray, L J
AU  - Gray LJ
FAU - Leigh, T
AU  - Leigh T
FAU - Davies, M J
AU  - Davies MJ
FAU - Patel, N
AU  - Patel N
FAU - Stone, M
AU  - Stone M
FAU - Bonar, M
AU  - Bonar M
FAU - Badge, R
AU  - Badge R
FAU - Khunti, K
AU  - Khunti K
LA  - eng
PT  - Letter
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/09 [accepted]
AID - 10.1111/dme.12115 [doi]
PST - ppublish
SO  - Diabet Med. 2013 Jun;30(6):758-60. doi: 10.1111/dme.12115.

PMID- 23683103
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 30
IP  - 6
DP  - 2013 Jun
TI  - Assessment of insulin action on carbohydrate metabolism: physiological and
      non-physiological methods.
PG  - 664-70
LID - 10.1111/dme.12189 [doi]
AB  - Carbohydrate metabolism in humans is regulated by insulin secretion from
      pancreatic beta-cells and glucose disposal by insulin-sensitive tissues. Insulin 
      facilitates glucose utilization in peripheral tissues and suppresses hepatic
      glucose production. Any defects in insulin action predispose an individual to
      glucose intolerance and Type 2 diabetes mellitus. Early detection of defects in
      insulin action could provide opportunities to prevent or delay progression of the
      disease state. There are different approaches to assess insulin action. Initial
      methods, such as peripheral insulin concentration and simple indices, have
      several limitations. Subsequently, researchers developed methodologies using
      intravenous glucose infusion to determine glucose fluxes. However, these
      methodologies are limited by being non-physiological. Newer, innovative
      techniques that have been developed are more sophisticated and physiological. By 
      modelling glucose kinetics using isotope dilution techniques, several robust
      parameters can be obtained that are physiologically relevant and sound. This
      brief review summarizes most of the non-physiological and physiological
      methodologies used to measure the variables of insulin action.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of
      Internal Medicine, Mayo Clinic and Foundation, Rochester, MN, USA.
FAU - Dube, S
AU  - Dube S
FAU - Errazuriz, I
AU  - Errazuriz I
FAU - Cobelli, C
AU  - Cobelli C
FAU - Basu, R
AU  - Basu R
FAU - Basu, A
AU  - Basu A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
SB  - IM
PMC - PMC3662485
MID - NIHMS459542
OID - NLM: NIHMS459542 [Available on 06/01/14]
OID - NLM: PMC3662485 [Available on 06/01/14]
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PMCR- 2014/06/01 00:00
PHST- 2013/03/14 [accepted]
AID - 10.1111/dme.12189 [doi]
PST - ppublish
SO  - Diabet Med. 2013 Jun;30(6):664-70. doi: 10.1111/dme.12189.

PMID- 23683102
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 30
IP  - 6
DP  - 2013 Jun
TI  - Professor Harry Keen, champion of people with diabetes worldwide.
PG  - 638-9
LID - 10.1111/dme.12221_1 [doi]
LA  - eng
PT  - Journal Article
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.1111/dme.12221_1 [doi]
PST - ppublish
SO  - Diabet Med. 2013 Jun;30(6):638-9. doi: 10.1111/dme.12221_1.

PMID- 23683069
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 17
TI  - Liraglutide suppresses postprandial triglyceride and apolipoprotein B48
      elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, 
      double-blind, placebo-controlled, crossover trial.
LID - 10.1111/dom.12133 [doi]
AB  - AIMS: Postprandial triglyceridaemia is a risk factor for cardiovascular disease. 
      This study investigated the effects of steady-state liraglutide 1.8 mg versus
      placebo on postprandial plasma lipid concentrations after 3 weeks of treatment in
      patients with type 2 diabetes. METHODS: In a cross-over trial, patients with type
      2 diabetes (n=20, 18-75 years, BMI 18.5-40 kg/m2 ) were randomized to once-daily 
      subcutaneous liraglutide (weekly dose-escalation from 0.6 to 1.8 mg) and placebo.
      After each 3-week period, a standardized fat-rich meal was provided, and the
      effects of liraglutide on triglyceride (primary endpoint AUC0 -8h ),
      apolipoprotein B48, nonesterified fatty acids, glycaemic responses and gastric
      emptying were assessed. ClinicalTrials.gov ID: NCT00993304. Funding: Novo Nordisk
      A/S. RESULTS: After 3 weeks, mean postprandial triglyceride (AUC0 -8h
      liraglutide/placebo treatment-ratio 0.72, 95% CI [0.62-0.83], p = 0.0004) and
      apolipoprotein B48 (AUC0 -8h ratio 0.65 [0.58-0.73], p < 0.0001) significantly
      decreased with liraglutide 1.8 mg versus placebo, as did iAUC0 -8h and Cmax (p < 
      0.001). No significant treatment differences were observed for nonesterified
      fatty acids. Mean postprandial glucose and glucagon AUC0 -8h and Cmax were
      significantly reduced with liraglutide versus placebo. Postprandial gastric
      emptying rate (assessed by paracetamol absorption [liquid phase] and the 13
      C-octanoate breath test [solid phase]) displayed no treatment differences. Mean
      low-density lipoprotein and total cholesterol decreased significantly with
      liraglutide versus placebo. CONCLUSIONS: Liraglutide treatment in patients with
      type 2 diabetes significantly reduced postprandial excursions of triglyceride and
      apolipoprotein B48 after a fat-rich meal, independently of gastric emptying.
      Results indicate liraglutide's potential to reduce cardiovascular disease risk
      via improvement of postprandial lipaemia.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Medicine and Endocrinology MEA, Aarhus University Hospital,
      DK-8000, Aarhus C, Denmark.
FAU - Hermansen, K
AU  - Hermansen K
FAU - Baekdal, T A
AU  - Baekdal TA
FAU - During, M
AU  - During M
FAU - Pietraszek, A
AU  - Pietraszek A
FAU - Mortensen, L S
AU  - Mortensen LS
FAU - Jorgensen, H
AU  - Jorgensen H
FAU - Flint, A
AU  - Flint A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2012/12/06 [received]
PHST- 2013/04/18 [revised]
PHST- 2013/05/14 [accepted]
AID - 10.1111/dom.12133 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 17. doi: 10.1111/dom.12133.

PMID- 23683065
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 May 20
TI  - DPP-4 inhibitors: Multi-target drugs, not only anti-diabetes.
LID - 10.1111/1753-0407.12063 [doi]
AB  - Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a new class of anti-diabetic agents
      that reduce blood glucose by preventing the degradation of the endogenous
      incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent
      insulinotropic polypeptide (GIP). The protection of DPP-4 inhibitors on beta-cell
      function has been demonstrated in patients with type 2 diabetes (T2D). Because
      DPP-4 is an enzyme widely expressed in humans, DPP-4 inhibitors are speculated to
      be multi-target agents. However, the other potential therapeutic value of DPP-4
      inhibitors remains unknown. Recently, some therapeutic effects of DPP-4
      inhibitors, such as immune regulation, cardiovascular protection and
      anti-inflammatory effect have been gradually observed. This article provides a
      systematic and comprehensive review of current researches on the newly-found
      effect and mechanism of DPP-4 inhibitors in therapy.
CI  - This article is protected by copyright. All rights reserved.
AD  - Diabetes Center, Institute of Metabolism and Endocrinology, The Second Xiangya
      Hospital and Key Laboratory of Diabetes Immunology, Ministry of Education,
      Central South University, Changsha, China.
FAU - Zhao, Yunjuan
AU  - Zhao Y
FAU - Yang, Lin
AU  - Yang L
FAU - Zhou, Zhiguang
AU  - Zhou Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130520
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/05/10 [accepted]
AID - 10.1111/1753-0407.12063 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 May 20. doi: 10.1111/1753-0407.12063.

PMID- 23683002
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 17
TI  - Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes
      treated with insulin glargine or NPH insulin.
LID - 10.1111/dom.12131 [doi]
AB  - AIM: To compare the impact of diabetes duration on hypoglycaemia in patients with
      type 2 diabetes mellitus (T2DM) treated with insulin glargine or NPH insulin.
      METHODS: A pooled analysis of 24-week patient level data from randomized
      controlled studies comparing once-daily insulin glargine with once-daily NPH
      insulin in insulin-naive adult patients with T2DM was performed, stratifying
      patients into quartiles by duration of diabetes: < 5.8 years; 5.8 to < 9.2 years;
      9.2 to < 14 years and >/= 14 years. Daytime and nocturnal hypoglycaemia events
      were evaluated. RESULTS: Data from 2,330 patients in four randomized controlled
      trials were included in the analysis; 1,258 treated with insulin glargine and
      1,072 with NPH insulin. The rates of daytime hypoglycaemia were similar for
      insulin glargine and NPH insulin, irrespective of disease duration. Patients with
      longer T2DM duration treated with glargine experienced greater glycated
      haemoglobin A1c (HbA1c) reductions. Rates of severe nocturnal hypoglycaemia and
      nocturnal hypoglycaemia (self-monitored blood glucose < 70 mg/dL [3.89 mmol/L]
      and < 50 mg/dL [2.78 mmol/L]) were all significantly and positively correlated
      with the duration of diabetes for patients treated with NPH insulin but not with 
      insulin glargine. Despite improvements in HbA1c, rates of symptomatic nocturnal
      hypoglycaemia were significantly lower with insulin glargine than with NPH
      insulin in patients with longer T2DM duration. CONCLUSION: There is a lower risk 
      for nocturnal hypoglycaemia with insulin glargine than with NPH insulin. When
      considering diabetes duration, insulin glargine (compared to NPH insulin) may be 
      particularly beneficial in patients with a longer duration of T2DM.
CI  - This article is protected by copyright. All rights reserved.
AD  - Scripps Clinic, La Jolla, CA.
FAU - Dailey, G E
AU  - Dailey GE
FAU - Gao, L
AU  - Gao L
FAU - Aurand, L
AU  - Aurand L
FAU - Garg, S K
AU  - Garg SK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/03/20 [received]
PHST- 2013/05/14 [accepted]
AID - 10.1111/dom.12131 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 17. doi: 10.1111/dom.12131.

PMID- 23682974
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
DP  - 2013 May 18
TI  - White-Coat Hypertension.
LID - 10.1111/1440-1681.12114 [doi]
AB  - AIM: A number of studies have examined if WCHT is associated with increased
      cardiovascular risk but with definitions of WCHT that were not sufficiently
      robust, and results have been inconsistent. This review aims to standardise the
      evidence by only including studies which used a definition of WCHT consistent
      with international guidelines. METHOD: Published studies were reviewed for data
      on vascular dysfunction, target organ damage, risk of future sustained
      hypertension and cardiovascular events. FINDINGS: WCHT has a population
      prevalence of approximately 15% and is associated with non-smoking and slightly
      elevated clinic blood pressure. Compared to normotensives, subjects with WCHT are
      at increased cardiovascular risk due to a higher prevalence of glucose
      dysregulation, increased left ventricular mass index and increased risk of future
      diabetes and hypertension. CONCLUSION: Management of a subject with WCHT should
      focus on cardiovascular risk factors, particularly glucose intolerance, not blood
      pressure alone. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Monash University, Clayton, Australia; Monash Health, Dandenong, Australia;
      Australian Catholic University, Fitzroy, Australia.
FAU - Martin, Catherine A
AU  - Martin CA
FAU - McGrath, Barry P
AU  - McGrath BP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/22 [received]
PHST- 2013/04/28 [revised]
PHST- 2013/05/12 [accepted]
AID - 10.1111/1440-1681.12114 [doi]
PST - aheadofprint
SO  - Clin Exp Pharmacol Physiol. 2013 May 18. doi: 10.1111/1440-1681.12114.

PMID- 23682909
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1439-0272 (Electronic)
IS  - 0303-4569 (Linking)
DP  - 2013 May 19
TI  - Men and women, so different, so similar: observations from cross-sex hormone
      treatment of transsexual subjects.
LID - 10.1111/and.12111 [doi]
AB  - Sexual differentiation in mammals is largely driven by the presence of androgen
      in males and their absence in females. The presence of androgens induces a number
      of irreversible changes in males: prenatally, the genital differentiation; during
      puberty, the development of secondary sex characteristics - the larger facial
      bones, hand, feet and height in males. A large number of metabolic variables are 
      influenced by sex hormones and consequently show difference between men and
      women, and this helps to explain differences in pathologies, such as
      cardiovascular disease, bone fractures and auto immune disease. There is some
      recent evidence that some sex differences in brain functions are not mediated by 
      sex hormones, but by-products of genes located on the X and Y chromosomes. This
      communication reviews the results of administration of cross-sex hormone
      treatment to transsexual persons transitioning to the other sex. Natal males are 
      treated with anti-androgens+oestrogens and natal females with testosterone. This 
      provides a unique opportunity to study which metabolic functions are not
      irreversibly sex-differentiated but are determined by the prevailing milieu of
      sex steroids. The insights gained with these studies should lead to a better
      appreciation of the role of sex steroids in cardiovascular disease and diabetes
      mellitus which presently do not receive due attention.
CI  - (c) 2013 Blackwell Verlag GmbH.
AD  - Emeritus VU University Medical Center, Amsterdam, The Netherlands.
FAU - Gooren, L J
AU  - Gooren LJ
FAU - Giltay, E J
AU  - Giltay EJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130519
TA  - Andrologia
JT  - Andrologia
JID - 0423506
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/03/25 [accepted]
AID - 10.1111/and.12111 [doi]
PST - aheadofprint
SO  - Andrologia. 2013 May 19. doi: 10.1111/and.12111.

PMID- 23682854
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1471-2164 (Electronic)
IS  - 1471-2164 (Linking)
VI  - 14
DP  - 2013
TI  - Integrative genomic analysis of CREB defines a critical role for transcription
      factor networks in mediating the fed/fasted switch in liver.
PG  - 337
LID - 10.1186/1471-2164-14-337 [doi]
AB  - BACKGROUND: Metabolic homeostasis in mammals critically depends on the regulation
      of fasting-induced genes by CREB in the liver. Previous genome-wide analysis has 
      shown that only a small percentage of CREB target genes are induced in response
      to fasting-associated signaling pathways. The precise molecular mechanisms by
      which CREB specifically targets these genes in response to alternating hormonal
      cues remain to be elucidated. RESULTS: We performed chromatin immunoprecipitation
      coupled to high-throughput sequencing of CREB in livers from both fasted and
      re-fed mice. In order to quantitatively compare the extent of CREB-DNA
      interactions genome-wide between these two physiological conditions we developed 
      a novel, robust analysis method, termed the 'single sample independence' (SSI)
      test that greatly reduced the number of false-positive peaks. We found that CREB 
      remains constitutively bound to its target genes in the liver regardless of the
      metabolic state. Integration of the CREB cistrome with expression microarrays of 
      fasted and re-fed mouse livers and ChIP-seq data for additional transcription
      factors revealed that the gene expression switches between the two metabolic
      states are associated with co-localization of additional transcription factors at
      CREB sites. CONCLUSIONS: Our results support a model in which CREB is
      constitutively bound to thousands of target genes, and combinatorial interactions
      between DNA-binding factors are necessary to achieve the specific transcriptional
      response of the liver to fasting. Furthermore, our genome-wide analysis
      identifies thousands of novel CREB target genes in liver, and suggests a
      previously unknown role for CREB in regulating ER stress genes in response to
      nutrient influx.
AD  - Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine at
      the University of Pennsylvania, Philadelphia, PA, USA.
      kaestner@mail.med.upenn.edu.
FAU - Everett, Logan J
AU  - Everett LJ
FAU - Lay, John Le
AU  - Lay JL
FAU - Lukovac, Sabina
AU  - Lukovac S
FAU - Bernstein, Diana
AU  - Bernstein D
FAU - Steger, David J
AU  - Steger DJ
FAU - Lazar, Mitchell A
AU  - Lazar MA
FAU - Kaestner, Klaus H
AU  - Kaestner KH
LA  - eng
PT  - Journal Article
DEP - 20130517
PL  - England
TA  - BMC Genomics
JT  - BMC genomics
JID - 100965258
SB  - IM
PMC - PMC3671974
OID - NLM: PMC3671974
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/14 [received]
PHST- 2013/05/13 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 1471-2164-14-337 [pii]
AID - 10.1186/1471-2164-14-337 [doi]
PST - epublish
SO  - BMC Genomics. 2013 May 17;14:337. doi: 10.1186/1471-2164-14-337.

PMID- 23682852
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1439-0272 (Electronic)
IS  - 0303-4569 (Linking)
DP  - 2013 May 19
TI  - Altered expression of mitofusin 2 in penile tissues of diabetic rats.
LID - 10.1111/and.12108 [doi]
AB  - Diabetic erectile dysfunction (ED) is a common complication in diabetes mellitus,
      and the efficacy of first-line therapies is not satisfactory. Recent studies
      revealed that corporal apoptosis was responsible for the nonresponsiveness of
      severe ED to phosphodiesterase type 5 inhibitors. Mitofusin 2 (Mfn2) is a
      versatile protein, regulating mitochondrial morphology and playing an important
      role in apoptosis. Several studies showed that expression of Mfn2 was decreased
      in STZ-induced diabetic rats' kidney, myocardium and retina, which was associated
      with diabetic nephropathy, cardiomyopathy and retinopathy respectively. In this
      study, our aim was to explore the expression of Mfn2 and apoptosis in diabetic
      rats' penes. We found that erectile function (ICP/MAP) elicited by electrical
      stimulation of cavernous nerve was markedly impaired in diabetic rats compared
      with the normal rats. The mRNA and protein levels of Mfn2 were found to be
      significantly reduced in diabetic rats' penile tissues. Compared with normal
      rats, the content of smooth muscle and B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated
      X protein (Bax) ratio were dramatically decreased, and penile apoptotic index and
      expression of activated-caspase-3 were dramatically increased in diabetic rats.
      This data indicated that repression of Mfn2 in diabetic rats' penes might be
      associated with excessive apoptosis in diabetes-induced severe ED.
CI  - (c) 2013 Blackwell Verlag GmbH.
AD  - Department of Urology, Tongji Medical College, Tongji Hospital, Huazhong
      University of Science and Technology, Wuhan, Hubei, China.
FAU - Yang, J
AU  - Yang J
FAU - Wang, T
AU  - Wang T
FAU - Zhang, Y
AU  - Zhang Y
FAU - Li, R
AU  - Li R
FAU - Wang, S
AU  - Wang S
FAU - Xu, H
AU  - Xu H
FAU - Liu, J
AU  - Liu J
FAU - Ye, Z
AU  - Ye Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130519
TA  - Andrologia
JT  - Andrologia
JID - 0423506
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/03/18 [accepted]
AID - 10.1111/and.12108 [doi]
PST - aheadofprint
SO  - Andrologia. 2013 May 19. doi: 10.1111/and.12108.

PMID- 23682840
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1557-7716 (Electronic)
IS  - 1523-0864 (Linking)
DP  - 2013 May 18
TI  - Mn PORPHYRIN REGULATION OF AEROBIC GLYCOLYSIS: IMPLICATIONS ON THE ACTIVATION OF 
      DIABETOGENIC IMMUNE CELLS.
AB  - AIMS: The immune system is critical for protection against infections and cancer,
      but requires scrupulous regulation to limit self-reactivity and autoimmunity. Our
      group has utilized a manganese porphyrin catalytic antioxidant (MnTE-2-PyP5+,
      MnP) as a potential immunoregulatory therapy for type 1 diabetes. MnP has
      previously been shown to modulate diabetogenic immune responses through decreases
      in proinflammatory cytokine production from antigen-presenting cells (APC) and T 
      cells and to reduce diabetes onset in NOD mice. However, it is unclear whether or
      not MnP treatment can act beyond the reported inflammatory mediators. Therefore, 
      the hypothesis that MnP may be affecting the redox-dependent bioenergetics of
      diabetogenic splenocytes was investigated. RESULTS: MnP treatment enhanced
      glucose oxidation, reduced fatty acid oxidation, but only slightly decreased
      overall oxidative phosphorylation. These alterations occurred because of
      increased tricarboxylic acid (TCA) cycle aconitase enzyme efficiency and were not
      due to changes in mitochondrial abundance. MnP treatment also displayed decreased
      aerobic glycolysis, which promotes activated immune cell proliferation, as
      demonstrated by reduced lactate production and Glut1 levels and inactivation of
      key signaling molecules, such as mTOR, c-myc and G6PD. INNOVATION: This work
      highlights the importance of redox signaling by demonstrating that modulation of 
      reactive oxygen species (ROS) can supplant complex downstream regulation, thus
      affecting metabolic programming towards aerobic glycolysis. CONCLUSION: MnP
      treatment promotes metabolic quiescence, impeding diabetogenic autoimmune
      responses by restricting the metabolic pathways for energy production and
      affecting anabolic processes necessary for cell proliferation.
AD  - University of Pittsburgh SOM, Immunology, Pittsburgh, Pennsylvania, United States
      ; mmd33@pitt.edu.
FAU - Delmastro-Greenwood, Meghan M
AU  - Delmastro-Greenwood MM
FAU - Votyakova, Tatyana
AU  - Votyakova T
FAU - Goetzman, Eric
AU  - Goetzman E
FAU - Marre, Meghan L
AU  - Marre ML
FAU - Previte, Dana M
AU  - Previte DM
FAU - Tovmasyan, Artak
AU  - Tovmasyan A
FAU - Batinic-Haberle, Ines
AU  - Batinic-Haberle I
FAU - Trucco, Massimo
AU  - Trucco M
FAU - Piganelli, Jon D
AU  - Piganelli JD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Antioxid Redox Signal
JT  - Antioxidants & redox signaling
JID - 100888899
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.1089/ars.2012.5167 [doi]
PST - aheadofprint
SO  - Antioxid Redox Signal. 2013 May 18.

PMID- 23682836
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1557-8542 (Electronic)
IS  - 1545-8547 (Linking)
VI  - 10
IP  - 2
DP  - 2013 Jun
TI  - Imaging Beta cell regeneration and interactions with islet vasculature in
      transparent adult zebrafish.
PG  - 249-57
LID - 10.1089/zeb.2012.0813 [doi]
AB  - Abstract Blood vessel networks provide nutrients and gaseous exchange that are
      essential for functions. Pancreatic islet capillaries deliver oxygen to endocrine
      cells while transporting hormones to organs and peripheral locations throughout
      the body. We have developed a zebrafish diabetes model in which adult islets can 
      be followed in vivo during beta cell regeneration while calibrating changes in
      beta cell mass and fasting blood glucose levels. After genetic ablation, beta
      cells are initially dysfunctional or dying, and blood glucose levels increase
      fourfold. During a 2-week period, hyperglycemia eventually normalizes as beta
      cell mass regenerates. We show that mCherry-fluorescent, insulin-positive beta
      cells re-emerge in close contact with the vascular endothelium. Alterations in
      the dense vascular network of zebrafish islets were visualized by the expression 
      of green fluorescent protein (GFP) in endothelial cells derived from the Fli
      transcription factor promoter. The rapid destruction and regeneration of beta
      cell mass was evaluated in the same animal over time, providing a functional
      model for investigating the interactions of islet cell types with vascular cells 
      as well as the consequences of hyperglycemia on other tissues. Regenerating adult
      zebrafish can be utilized as vertebrate, metabolically active models for
      generating new insights into treatments for type 2 diabetes.
AD  - Division of Endocrinology, Metabolism and Nutrition, Sarah W. Stedman Nutrition
      and Metabolism Center, Duke University Medical Center , Durham, North Carolina.
FAU - Moss, Larry G
AU  - Moss LG
FAU - Caplan, Tanner V
AU  - Caplan TV
FAU - Moss, Jennifer B
AU  - Moss JB
LA  - eng
PT  - Journal Article
DEP - 20130519
PL  - United States
TA  - Zebrafish
JT  - Zebrafish
JID - 101225070
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/05/19 [aheadofprint]
AID - 10.1089/zeb.2012.0813 [doi]
PST - ppublish
SO  - Zebrafish. 2013 Jun;10(2):249-57. doi: 10.1089/zeb.2012.0813. Epub 2013 May 19.

PMID- 23682797
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 18
TI  - Effect of lifestyle modification on serum chemerin concentration and its
      association with insulin sensitivity in overweight and obese adults with type 2
      diabetes.
LID - 10.1111/cen.12249 [doi]
AB  - OBJECTIVE: Chemerin, a recently identified adipokine, has been linked to
      adiposity, insulin resistance, metabolic syndrome risk factors and inflammation. 
      Here, we evaluated whether a 12-week lifestyle intervention in overweight and
      obese adults with type 2 diabetes could significantly affect the average blood
      glucose and serum chemerin levels over time. DESIGN: Thirty-five overweight or
      obese subjects with type 2 diabetes were randomized to receive intensive
      lifestyle modification including supervised exercise sessions or usual care for
      12 weeks. Anthropometric and clinical data were collected before the intervention
      and after 12 weeks. RESULTS: Lifestyle intervention induced a significant
      decrease in HbA1c (-1.0 +/- 0.5 vs. 0.1 +/- 0.6%, p<0.001), BMI, total body fat
      content, serum lipocalin-2 and chemerin levels (-8.1 +/- 21.6 vs. +8.2 +/- 15.9
      ng/ml, p=0.021) and a significant increase in VO2max after 12 weeks compared to
      the usual care group. Baseline chemerin levels were positively correlated with
      the homeostasis model of assessment of insulin resistance (HOMA-IR), fasting
      insulin, and the high-sensitivity C-reactive protein (hsCRP) and negatively
      correlated with insulin sensitivity index (ISI). Changes in the chemerin
      concentration during 12weeks was independently negatively correlated with changes
      in ISI and positively correlated with changes in fasting plasma glucose, total
      cholesterol, and lipocalin-2 levels. CONCLUSIONS: A 12 week intensive lifestyle
      intervention significantly decreased serum chemerin level compared to usual care.
      Decrease in serum chemerin level was associated with improved insulin sensitivity
      and this may be involved in the beneficial effects of lifestyle intervention in
      overweight and obese type 2 diabetic patients. This article is protected by
      copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Internal Medicine, Inha University School of Medicine, Incheon,
      Korea.
FAU - Kim, So Hun
AU  - Kim SH
FAU - Lee, Seung Hwan
AU  - Lee SH
FAU - Ahn, Ki Yong
AU  - Ahn KY
FAU - Lee, Dong Hoon
AU  - Lee DH
FAU - Suh, Young Ju
AU  - Suh YJ
FAU - Cho, Soon Gu
AU  - Cho SG
FAU - Choi, Yun Jin
AU  - Choi YJ
FAU - Lee, Dae Hyung
AU  - Lee DH
FAU - Lee, Seung Youn
AU  - Lee SY
FAU - Hong, Seong Bin
AU  - Hong SB
FAU - Kim, Yong Seong
AU  - Kim YS
FAU - Jeon, Justin Y
AU  - Jeon JY
FAU - Nam, Moonsuk
AU  - Nam M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/01/25 [received]
PHST- 2013/05/06 [revised]
PHST- 2013/05/14 [revised]
PHST- 2013/05/15 [accepted]
AID - 10.1111/cen.12249 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 18. doi: 10.1111/cen.12249.

PMID- 23682738
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1557-8976 (Electronic)
IS  - 0882-8245 (Linking)
DP  - 2013 May 17
TI  - Relation Between Ljungan Virus Antibodies, HLA-DQ8, and Insulin Autoantibodies in
      Newly Diagnosed Type 1 Diabetes Children.
AB  - Abstract Environmental factors, including viral infections, may explain an
      increasing and fluctuating incidence of childhood type 1 diabetes (T1D). Ljungan 
      virus (LV) isolated from bank voles have been implicated, but it is unclear
      whether LV contributes to islet autoimmunity, progression to clinical onset, or
      both, of T1D. The aim was to test whether LV antibodies (LVAb) were related to
      HLA-DQ and islet autoantibodies in newly diagnosed T1D patients (n=676) and
      controls (n=309). Patients, 0-18 years of age, diagnosed with T1D in 1996-2005
      were analyzed for LVAb, HLA-DQ genotypes, and all seven known islet
      autoantibodies (GADA, IA-2A, IAA, ICA, ZnT8RA, ZnT8WA, and ZnT8QA). LVAb at 75th 
      percentile, defined as cut off, was 90 (range 6-3936) U/mL and 4th quartile LVAb 
      were found in 25% (170/676) of which 64% were <10 (n=108, p<0.0001), and 27%
      were<5 (n=45; p<0.0001) years old. The 4th quartile LVAb in children <10 years of
      age correlated to HLA DQ2/8, 8/8, and 8/X (p<0.0001). Furthermore, in the group
      with 4th quartile LVAb, 55% were IAA positive (p=0.01) and correlation was found 
      between 4th quartile LVAb and IAA in children <10 years of age (p=0.035). It is
      concluded that 1) LVAb were common among the young T1D patients and LVAb levels
      were higher in the younger age groups; 2) 4th quartile LVAb correlated with IAA; 
      and 3) there was a correlation between 4th quartile LVAb and HLA-DQ8,
      particularly in the young patients. The presence of LVAb supports the notion that
      prior exposure to LV may be associated with T1D.
AD  - 1 Department of Paediatrics, Ostersund Hospital , Ostersund, Sweden .
FAU - Nilsson, Anna-Lena
AU  - Nilsson AL
FAU - Vaziri-Sani, Fariba
AU  - Vaziri-Sani F
FAU - Andersson, Cecilia
AU  - Andersson C
FAU - Larsson, Karin
AU  - Larsson K
FAU - Carlsson, Anneli
AU  - Carlsson A
FAU - Cedervall, Elisabeth
AU  - Cedervall E
FAU - Jonsson, Bjorn
AU  - Jonsson B
FAU - Neiderud, Jan
AU  - Neiderud J
FAU - Elding Larsson, Helena
AU  - Elding Larsson H
FAU - Ivarsson, Sten-Anders
AU  - Ivarsson SA
FAU - Lernmark, Ake
AU  - Lernmark A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Viral Immunol
JT  - Viral immunology
JID - 8801552
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.1089/vim.2013.0008 [doi]
PST - aheadofprint
SO  - Viral Immunol. 2013 May 17.

PMID- 23682710
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
VI  - 1287
IP  - 1
DP  - 2013 May
TI  - Vitamin D: beyond bone.
PG  - 45-58
LID - 10.1111/nyas.12129 [doi]
AB  - In recent years, vitamin D has been received increased attention due to the
      resurgence of vitamin D deficiency and rickets in developed countries and the
      identification of extraskeletal effects of vitamin D, suggesting unexpected
      benefits of vitamin D in health and disease, beyond bone health. The possibility 
      of extraskeletal effects of vitamin D was first noted with the discovery of the
      vitamin D receptor (VDR) in tissues and cells that are not involved in
      maintaining mineral homeostasis and bone health, including skin, placenta,
      pancreas, breast, prostate and colon cancer cells, and activated T cells.
      However, the biological significance of the expression of the VDR in different
      tissues is not fully understood, and the role of vitamin D in extraskeletal
      health has been a matter of debate. This report summarizes recent research on the
      roles for vitamin D in cancer, immunity and autoimmune diseases, cardiovascular
      and respiratory health, pregnancy, obesity, erythropoiesis, diabetes, muscle
      function, and aging.
CI  - (c) 2013 New York Academy of Sciences.
AD  - Department of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical
      School, Newark, New Jersey.
FAU - Christakos, Sylvia
AU  - Christakos S
FAU - Hewison, Martin
AU  - Hewison M
FAU - Gardner, David G
AU  - Gardner DG
FAU - Wagner, Carol L
AU  - Wagner CL
FAU - Sergeev, Igor N
AU  - Sergeev IN
FAU - Rutten, Erica
AU  - Rutten E
FAU - Pittas, Anastassios G
AU  - Pittas AG
FAU - Boland, Ricardo
AU  - Boland R
FAU - Ferrucci, Luigi
AU  - Ferrucci L
FAU - Bikle, Daniel D
AU  - Bikle DD
LA  - eng
PT  - Journal Article
DEP - 20130517
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PHST- 2013/05/17 [aheadofprint]
AID - 10.1111/nyas.12129 [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2013 May;1287(1):45-58. doi: 10.1111/nyas.12129. Epub 2013 May 
      17.

PMID- 23682642
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
DP  - 2013 May 17
TI  - Intermittent Absent End Diastolic Velocity of the Umbilical Artery: Antenatal and
      Neonatal Characteristics and Indications for Delivery.
AB  - Objective Is there there is a difference in indications for delivery, antepartum 
      and neonatal characteristics in intermittent absent end diastolic velocity
      (iAEDV) compared to persistent absent or reversed end diastolic velocity
      (pA/REDV). Methods A retrospective study of 109 patients with iAEDV or pA/REDV
      from 19-39 weeks. The delivery indication was classified as maternal or fetal.
      The primary antepartum and maternal characteristic were age, parity, AMA, chronic
      hypertension, PEC, thrombophilia, lupus, diabetes, smoker, placenta previa,
      gestational age (GA) at diagnosis of IUGR and/or SGA, GA at diagnosis of elevated
      S/D, iAEDV or pA/REDV, GA at delivery, minimal/absent variability day of
      delivery, BPP </= 6 prior to delivery. The primary neonatal outcomes were birth
      weight, arterial cord pH, neonatal demise, necrotizing enterocolitis,
      intraventricular hemorrhage and length of stay in the NICU. Results Fetuses with 
      iAEDV were diagnosed with an elevated S/D at a later GA (29.6 vs 27.5 weeks, P < 
      0.03), delivered at a later GA (31.6 vs 29.7 weeks, P < 0.01), had a higher birth
      weight (1336.6 vs 933g, P < 0.0004), were more likely to be delivered for
      maternal indications (42.9% vs 20.27%, P<0.01), had a higher cord arterial pH
      (7.28 vs 7.21, P<0.002) and were less likely to have an arterial pH at birth <7.2
      (0% vs 34.1%, P < 0.002). Conclusions Although fetuses with iAEDV have an
      improved antenatal course as compared with pA/REDV, indications for delivery are 
      more likely to be maternal and adverse outcome is common.
AD  - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, New
      York University Langone Medical Center, NYC, NY, USA.
FAU - Rosner, J
AU  - Rosner J
FAU - Rochelson, B
AU  - Rochelson B
FAU - Rosen, L
AU  - Rosen L
FAU - Roman, A
AU  - Roman A
FAU - Vohra, N
AU  - Vohra N
FAU - Tam Tam, H
AU  - Tam Tam H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the
      European Association of Perinatal Medicine, the Federation of Asia and Oceania
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.3109/14767058.2013.806475 [doi]
PST - aheadofprint
SO  - J Matern Fetal Neonatal Med. 2013 May 17.

PMID- 23682611
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
DP  - 2013 May 17
TI  - Racial Disparities in Pregnancy Outcomes in Obese Women.
AB  - Abstract Objective: To estimate the effect of race on perinatal outcomes in obese
      women. Methods: Retrospective cohort study of birth records linked to hospital
      discharge data for all live born singleton infants >/=37 weeks gestation born to 
      African-American or Caucasian Missouri residents from 2000-2006. We excluded
      major congenital anomalies and women with diabetes or chronic hypertension.
      Obesity was defined as pre-pregnancy body mass index >/= 30 kg/m2. Results: There
      were 312,412 births meeting study criteria. 27.1% (11,776) of African-American
      mothers and 19.1% (49,415) of Caucasian mothers were obese. There were no
      differences in cesarean delivery or preeclampsia between obese African- American 
      and obese Caucasian women. Infants of obese African-American women were
      significantly less likely to be macrosomic (0.9% vs. 2.2%, adjusted odds ratio
      [aOR] 0.5, 95% confidence interval [CI] 0.4 0.6) and more likely to be low birth 
      weight (3.4% vs. 1.8%, aOR 1.9, 95% CI 1.7, 2.2) compared to infants of obese
      Caucasian women. Compared to their normal weight peers, obese Caucasian women had
      a greater relative risk of developing preeclampsia (aOR 3.1, 95% CI 2.9, 3.2)
      than obese African-American women (aOR 2.1, 95% CI 1.9, 2.4). Conclusion: Racial 
      disparities impact obesity-related maternal and neonatal complications of
      pregnancy.
AD  - Department of Obstetrics & Gynecology, Oregon Health & Science University,
      Portland, OR;
FAU - Marshall, Nicole E
AU  - Marshall NE
FAU - Guild, Camelia
AU  - Guild C
FAU - Cheng, Yvonne W
AU  - Cheng YW
FAU - Caughey, Aaron B
AU  - Caughey AB
FAU - Halloran, Donna R
AU  - Halloran DR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the
      European Association of Perinatal Medicine, the Federation of Asia and Oceania
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
AID - 10.3109/14767058.2013.806478 [doi]
PST - aheadofprint
SO  - J Matern Fetal Neonatal Med. 2013 May 17.

PMID- 23682543
OWN - NLM
STAT- MEDLINE
DA  - 20130520
DCOM- 20130521
IS  - 1066-2936 (Print)
IS  - 1066-2936 (Linking)
VI  - 40
IP  - 2
DP  - 2013 Mar-Apr
TI  - Different oxygen treatment pressures alter inflammatory gene expression in human 
      endothelial cells.
PG  - 115-23
AB  - Hyperbaric oxygen has proven to be a useful treatment for chronic wounds.
      However, therapeutic conditions vary between treatment centers, and we wished to 
      investigate the effects of different treatment pressures on cells under
      inflammatory conditions. Endothelial cells were exposed to a chronic wound model 
      comprising hypoxia (2% O2 at 1 atmosphere absolute (atm abs); PO2 approximately 2
      kPa) in the presence of 0.5 microg/ml lipopolysaccharide and 1 ng/ml TNF-alpha
      for 24 hours, then treated with normobaric oxygen (NBO2; 95%O2/5%CO2 at 1.0 atm
      abs; PO2 approximately 96.3 kPa), hyperbaric oxygen (HBO2) at 1.5 atm abs
      (1.5HBO2; 96.7%O2/3.3%CO2 at 1.5 atm abs; PO2 approximately 147 kPa), and HBO2 at
      2.4 atm abs (2.4HBO2; 97.9%O2/2.1%CO2 at 2.4 atm abs; PO2 approximately 238 kPa).
      The mRNA expression of 92 inflammatory genes was then analyzed, and we identified
      changes in genes involved in adhesion molecule expression, angiogenesis and
      tissue remodeling, intracellular signaling, and cellular oxygen responses and
      redox signaling. We noted differences in expression between different treatment
      pressures, highlighting the need for further research into the use of different
      therapeutic protocols in the treatment of inflammatory conditions such as chronic
      wounds.
AD  - University of Exeter Medical School, University of Exeter, Devon, UK.
FAU - Kendall, Alexandra C
AU  - Kendall AC
FAU - Whatmore, Jacqueline L
AU  - Whatmore JL
FAU - Harries, Lorna W
AU  - Harries LW
FAU - Winyard, Paul G
AU  - Winyard PG
FAU - Eggleton, Paul
AU  - Eggleton P
FAU - Smerdon, Gary R
AU  - Smerdon GR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Undersea Hyperb Med
JT  - Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical
      Society, Inc
JID - 9312954
RN  - 0 (Antigens, CD31)
RN  - 0 (ED-B fibronectin protein, human)
RN  - 0 (Fibronectins)
RN  - 0 (Inflammation Mediators)
RN  - 0 (RNA, Messenger)
SB  - IM
SB  - S
MH  - Antigens, CD31/metabolism
MH  - Apoptosis/genetics
MH  - Atmospheric Pressure
MH  - Cell Hypoxia/physiology
MH  - Chronic Disease
MH  - Diabetic Foot/genetics/therapy
MH  - Fibronectins/metabolism
MH  - Gene Expression/physiology
MH  - Gene Expression Profiling/*methods
MH  - Human Umbilical Vein Endothelial Cells/*metabolism
MH  - Humans
MH  - Hyperbaric Oxygenation/*standards
MH  - Inflammation Mediators/*metabolism
MH  - Neovascularization, Physiologic/physiology
MH  - Oxidation-Reduction
MH  - RNA, Messenger/*metabolism
MH  - Wounds and Injuries/genetics/metabolism/*therapy
EDAT- 2013/05/21 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/21 06:00
PST - ppublish
SO  - Undersea Hyperb Med. 2013 Mar-Apr;40(2):115-23.

PMID- 23682534
OWN - NLM
STAT- In-Process
DA  - 20130520
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 96 Suppl 3
DP  - 2013 Mar
TI  - Fulminant type I diabetes: the first case report in Thailand.
PG  - S114-7
AB  - Type 1 diabetes is classified as either autoimmune (type IA) or idiopathic (type 
      IB) diabetes. Fulminant type 1 diabetes is a recently-discovered subtype of
      idiopathic type 1 diabetes. It is defined as diabetes with complete abrupt onset 
      of beta cell destruction and progression to hyperglycemia and ketoacidosis within
      a short period of time, but with a near-normal HbA1c level. The patients often
      have flu-like or abdominal symptoms at onset and elevated levels of pancreatic
      exocrine enzymes. Their diabetes-related autoantibodies are usually negative. In 
      the present report, the authors present a case of fulminant type 1 diabetes in a 
      43-year-old Thai woman who presented with sudden onset of flu-like symptoms and
      abdominal pain. Findings on admission included a high blood glucose level and
      ketoacidosis, but a prediabetes range ofHbA1c level. Autoantibodies to glutamic
      acid decarboxylase (GAD) were negative. This subtype of type 1 diabetes was first
      identified in 2000 and there have been case reports from Japan, Korea, the
      Philippines and the Netherlands. Nonetheless, no case had been reported in
      Thailand until the present study. Here the authors report the first case of
      fulminant type 1 diabetes in Bangkok, Thailand.
AD  - Department of Medicine, Rajavithi Hospital, College of Medicine, Rangsit
      University, Bangkok, Thailand. navapornnapa@gmail.com
FAU - Napartivaumnuay, Navaporn
AU  - Napartivaumnuay N
FAU - Suthornthepvarakul, Thongkum
AU  - Suthornthepvarakul T
FAU - Deerochanawong, Chaicharn
AU  - Deerochanawong C
FAU - Sarinnapakorn, Veerasak
AU  - Sarinnapakorn V
FAU - Niramitmahapanya, Sathit
AU  - Niramitmahapanya S
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PST - ppublish
SO  - J Med Assoc Thai. 2013 Mar;96 Suppl 3:S114-7.

PMID- 23682526
OWN - NLM
STAT- In-Process
DA  - 20130520
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 96 Suppl 3
DP  - 2013 Mar
TI  - Maternal 25 hydroxyvitamin D level and its correlation in Thai gestational
      diabetes patients.
PG  - S69-76
AB  - OBJECTIVE: To identify 25 hydroxyvitamin D (250HD) levels in Thai pregnant women 
      with gestational diabetes and nongestational diabetes. MATERIAL AND METHOD: This 
      prospective study was conducted on 197 pregnant women at Rajavithi Hospital, a
      tertiary care medical center in Bangkok from October 2010 to July 2011. Plasma 25
      hydroxyvitamin D concentration and HbA1c level during the 75 g OGTT in
      gestational diabetes mellitus (GDM) and non-GDM were evaluated. The
      recommendations of the International Association of Diabetes and Pregnancy Study 
      Groups (IADPSG) were used for diagnosis of GDM in the present study. RESULTS: In 
      the selected 197 Thai pregnant women aged from 18 to 49 years, the mean age was
      32.1 years, and the mean plasma 250OHD level was 34.3 ng/dl. The percentages of
      patients classified as having 25OHD deficiency (< 20 ng/dl), 25OHD insufficiency 
      and normal 25OHD were 3.1%, 22.3% and 74.6%, respectively. Among the 197 women,
      70 patients (34.8%) had GDM. In the GDM group, 29 patients (41.4%) had abnormal
      25OHD level of which 5.7% had 25OHD deficiency and 35.7% had 25OHD insufficiency.
      Among those with GDM, plasma 25OHD concentration was significantly lower than in 
      the non-GDM subjects (32.3 +/- 10.3 vs. 35.5 +/- 6.7 ng/dl, p = 0.001). Fasting
      blood glucose and HbA1C independently predicted low 25OHD levels in Thai GDM
      subjects after applying regression model and adjusting for age, BMI, trimester
      and family history of DM (p = 0.031, p = 0.014 respectively). Higher
      pre-pregnancy BMI was associated with GDM and lower 25OHD level. CONCLUSION: Thai
      pregnant women with GDM had lower levels of 25OHD compared to those without GDM. 
      Only fasting plasma glucose independently predicted low 25OHD levels in GDM
      subjects.
AD  - Department of lnternal Medicine, Rajavithi Hospital, Medical College of Rangsit
      University, Bangkok, Thailand. navapornnapa@gmail.com
FAU - Napartivaumnuay, Navaporn
AU  - Napartivaumnuay N
FAU - Niramitmahapanya, Sathit
AU  - Niramitmahapanya S
FAU - Deerochanawong, Chaicharn
AU  - Deerochanawong C
FAU - Suthornthepavarakul, Thongkum
AU  - Suthornthepavarakul T
FAU - Sarinnapakorn, Veerasak
AU  - Sarinnapakorn V
FAU - Jaruyawongs, Prapon
AU  - Jaruyawongs P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PST - ppublish
SO  - J Med Assoc Thai. 2013 Mar;96 Suppl 3:S69-76.

PMID- 23682523
OWN - NLM
STAT- In-Process
DA  - 20130520
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 96 Suppl 3
DP  - 2013 Mar
TI  - Association between hs-CRP and Hba1c in overweight type 2 diabetic female
      patients.
PG  - S54-8
AB  - BACKGROUND AND OBJECTIVE: High-sensitive C-reactive protein (hs-CRP) is
      associated with atherosclerosis. Previous studies have shown that hs-CRP is
      associated with insulin resistance, type 2 diabetes and higher HbA1c levels. As
      type 2 diabetes is often found in overweight women, the present study
      investigated the relationship between hs-CRP and HbA1c levels in such patients.
      MATERIAL AND METHOD: This was a retrospective study of type 2 diabetic patients
      in Rajavithi Hospital from January 2009 until June 2011. All the subjects were
      females aged 40 years or more who had body mass index (BMI) of more than 25
      kilograms per square metre. The patients were examined and blood was collected in
      order to check hs-CRP and HbA1c levels. RESULTS: Data from 75 cases, classified
      the patients into 2 groups by their levels of hs-CRP and risk of coronary artery 
      disease. Of the 75 patients, 35 had hs-CRP levels less than 1 mg/L, and the
      remaining 40 patients had hs-CRP levels of 1 mg/ L or more, representing 46.67%
      and 53.33% respectively, and it was found that hs-CRP values correlated with
      HbA1c levels. The group with hs-CRP of less than 1 milligram per liter had a mean
      HbA1c of 7.36 +/- 1.23%, while the group with hs-CRP of 1 mg/L or more had a mean
      HbA1c of 8.77 +/- 1.78%, with statistical significance at p-value < 0.001.
      CONCLUSION: In the present study of patients with type 2 diabetes, the authors
      found that hs-CRP levels correlated with HbA1c levels. Mean HbA1c levels were
      significantly higher in patients who had hs-CRP levels of 1 mg/L or more (p-value
      < 0.001). Other factors such as age, blood pressure, BMI, LDL-C, serum creatinine
      were not correlated with hs-CRP level.
AD  - Department of Medicine, College of Medicine, Rajavithi Hospital, Rangsit
      University, Bangkok, Thailand. veerasak_sarin@yahoo.co.th
FAU - Sarinnapakorn, Veerasak
AU  - Sarinnapakorn V
FAU - Wanicagool, Warangkana
AU  - Wanicagool W
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
SB  - IM
EDAT- 2013/05/21 06:00
MHDA- 2013/05/21 06:00
CRDT- 2013/05/21 06:00
PST - ppublish
SO  - J Med Assoc Thai. 2013 Mar;96 Suppl 3:S54-8.

PMID- 23682228
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Linking)
VI  - 28
IP  - 3
DP  - 2013 May
TI  - Low glibenclamide concentrations affect endoplasmic reticulum stress in INS-1
      cells under glucotoxic or glucolipotoxic conditions.
PG  - 339-46
LID - 10.3904/kjim.2013.28.3.339 [doi]
AB  - BACKGROUNDAIMS: beta-Cell apoptosis caused by increased endoplasmic reticulum
      (ER) stress is an important pathogenic component of type 2 diabetes mellitus. In 
      theory, sulfonylureas, used for the treatment of diabetes, can contribute to ER
      stress. We assessed changes in ER stress in pancreatic beta-cells under
      glucotoxic or glucolipotoxic conditions using low concentrations of the
      sulfonylurea, glibenclamide (GB). METHODS: Low concentrations of GB (10 or 100
      nM) were added to INS-1 cells cultured under glucotoxic or glucolipotoxic
      conditions. The degree of viability, level of apoptosis and levels of markers
      associated with ER stress were measured. RESULTS: Apoptosis decreased in response
      to low concentrations of GB under glucolipotoxic but not glucotoxic conditions.
      Most ER stress markers decreased upon the addition of GB. Under glucotoxic
      conditions, changes in the levels of ER stress markers were not consistent.
      However, all decreased significantly under glucolipotoxic conditions.
      CONCLUSIONS: Low concentrations of GB exerted antiapoptotic effects through the
      attenuation of ER stress under glucolipotoxic conditions.
AD  - Paik Diabetes Center, Department of Internal Medicine, Inje University College of
      Medicine, Busan, Korea. ; Molecular Therapy Lab, Paik Memorial Institute for
      Clinical Research, Inje University College of Medicine, Busan, Korea.
FAU - Kwon, Min Jeong
AU  - Kwon MJ
FAU - Chung, Hye Suk
AU  - Chung HS
FAU - Yoon, Chang Shin
AU  - Yoon CS
FAU - Lee, Eun Ju
AU  - Lee EJ
FAU - Kim, Tae Kyun
AU  - Kim TK
FAU - Lee, Soon Hee
AU  - Lee SH
FAU - Ko, Kyung Soo
AU  - Ko KS
FAU - Rhee, Byoung Doo
AU  - Rhee BD
FAU - Kim, Mi Kyung
AU  - Kim MK
FAU - Park, Jeong Hyun
AU  - Park JH
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
SB  - IM
PMC - PMC3654132
OID - NLM: PMC3654132
OTO - NOTNLM
OT  - Endoplasmic reticulum stress
OT  - Glucolipotoxicity
OT  - Glucotoxicity
OT  - Glyburide
OT  - Insulin-secreting cells
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2011/12/29 [received]
PHST- 2012/04/05 [revised]
PHST- 2012/04/17 [accepted]
PHST- 2013/05/01 [epublish]
AID - 10.3904/kjim.2013.28.3.339 [doi]
PST - ppublish
SO  - Korean J Intern Med. 2013 May;28(3):339-46. doi: 10.3904/kjim.2013.28.3.339. Epub
      2013 May 1.

PMID- 23682224
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Linking)
VI  - 28
IP  - 3
DP  - 2013 May
TI  - Insulin secretion and insulin resistance in Korean women with gestational
      diabetes mellitus and impaired glucose tolerance.
PG  - 306-13
LID - 10.3904/kjim.2013.28.3.306 [doi]
AB  - BACKGROUNDAIMS: The aim was to compare the insulin sensitivity and secretion
      index of pregnant Korean women with normal glucose tolerance (NGT), gestational
      impaired glucose tolerance (GIGT; only one abnormal value according to the
      Carpenter and Coustan criteria), and gestational diabetes mellitus (GDM).
      METHODS: A cross-sectional study was performed with 1,163 pregnant women with
      positive (1-hour plasma glucose >/= 7.2 mmol/L) in a 50-g oral glucose challenge 
      test (OGCT). The 100-g oral glucose tolerance test (OGTT) was used to stratify
      the participants into three groups: NGT (n = 588), GIGT (n = 294), and GDM (n =
      281). RESULTS: The GDM group had higher homeostasis model assessment of insulin
      resistance and lower insulin sensitivity index (ISOGTT), quantitative insulin
      sensitivity check index, homeostasis model assessment for estimation of index
      beta-cell secretion (HOMA-B), first and second phase insulin secretion, and
      insulin secretion-sensitivity index (ISSI) than the NGT group (p </= 0.001 for
      all). Moreover, the GIGT group had lower ISOGTT, HOMA-B, first and second phase
      insulin secretion, and ISSI than the NGT group (p < 0.001 for all). Among the
      GIGT subjects, the 1-hour plasma glucose abnormal levels group showed
      significantly greater weight gain during pregnancy and higher values in the 50-g 
      OGCT than the other two groups. Moreover, the 1-hour and 2-hour abnormal levels
      groups had poorer insulin secretion status than the 3-hour abnormal levels group.
      CONCLUSIONS: Korean women with GDM show impairments of both insulin secretion and
      insulin sensitivity. In addition, GIGT is associated with both beta-cell
      dysfunction and insulin resistance.
AD  - Department of Internal Medicine, Korea University College of Medicine, Seoul,
      Korea.
FAU - Yang, Sae Jeong
AU  - Yang SJ
FAU - Kim, Tae Nyun
AU  - Kim TN
FAU - Baik, Sei Hyun
AU  - Baik SH
FAU - Kim, Tae Sun
AU  - Kim TS
FAU - Lee, Kwan Woo
AU  - Lee KW
FAU - Nam, Moonsuk
AU  - Nam M
FAU - Park, Yong Soo
AU  - Park YS
FAU - Woo, Jeong-Teak
AU  - Woo JT
FAU - Kim, Young Seol
AU  - Kim YS
FAU - Kim, Sung-Hoon
AU  - Kim SH
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
SB  - IM
PMC - PMC3654128
OID - NLM: PMC3654128
OTO - NOTNLM
OT  - Gestational diabetes mellitus
OT  - Gestational impaired glucose tolerance
OT  - Insulin resistance
OT  - Insulin secretion
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/03/19 [received]
PHST- 2012/04/04 [revised]
PHST- 2012/06/08 [accepted]
PHST- 2013/05/01 [epublish]
AID - 10.3904/kjim.2013.28.3.306 [doi]
PST - ppublish
SO  - Korean J Intern Med. 2013 May;28(3):306-13. doi: 10.3904/kjim.2013.28.3.306. Epub
      2013 May 1.

PMID- 23682123
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1530-6860 (Electronic)
IS  - 0892-6638 (Linking)
DP  - 2013 May 16
TI  - Vascular endothelial growth factor is important for brown adipose tissue
      development and maintenance.
AB  - Vascular endothelial growth factor (VEGF) is critical for angiogenesis, but also 
      has pleiotropic effects on several nonvascular cells. Our aim was to investigate 
      the role of VEGF in brown adipose tissue (BAT). We show that VEGF expression
      increases 2.5-fold during differentiation of cultured murine brown adipocytes and
      that VEGF receptor-2 is phosphorylated, indicating VEGF signaling. VEGF increased
      proliferation in brown preadipocytes in vitro by 70%, and blockade of VEGF
      signaling using anti-VEGFR2 antibody DC101 increased brown adipocyte apoptosis,
      as determined by cell number and activation of caspase 3. Systemic VEGF
      neutralization in mice, accomplished by adenoviral expression of soluble Flt1,
      resulted in 7-fold increase in brown adipocyte apoptosis, mitochondrial
      degeneration, and increased mitophagy compared to control mice expressing a null 
      adenovirus. Absence of the heparan sulfate-binding VEGF isoforms, VEGF164 and
      VEGF188, resulted in abnormal BAT development in mice at E15.5, with fewer brown 
      adipocytes and lower mitochondrial protein compared to wild-type littermates.
      These results suggest a role for VEGF in brown adipocytes and preadipocytes to
      promote survival, proliferation, and normal mitochondria and development.-Bagchi,
      M., Kim, L A., Boucher, J., Walshe, T. E., Kahn, C. R., D'Amore, P. A. Vascular
      endothelial growth factor is important for brown adipose tissue development and
      maintenance.
AD  - *Department of Pathology, daggerDepartment of Ophthalmology, and double
      daggerSection on Integrative Physiology and Metabolism, Joslin Diabetes Center,
      Harvard Medical School, Boston, Massachusetts, USA; and.
FAU - Bagchi, Mandrita
AU  - Bagchi M
FAU - Kim, Leo A
AU  - Kim LA
FAU - Boucher, Jeremie
AU  - Boucher J
FAU - Walshe, Tony E
AU  - Walshe TE
FAU - Kahn, C Ronald
AU  - Kahn CR
FAU - D'Amore, Patricia A
AU  - D'Amore PA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
OTO - NOTNLM
OT  - apoptosis
OT  - mitochondria
OT  - proliferation
OT  - sFlt1
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - fj.12-221812 [pii]
AID - 10.1096/fj.12-221812 [doi]
PST - aheadofprint
SO  - FASEB J. 2013 May 16.

PMID- 23682087
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Aceclofenac-induced acute tubulointerstitial nephritis in a patient with
      diabetes.
LID - 10.1136/bcr-2013-009217 [doi]
LID - bcr2013009217 [pii]
AB  - We describe a case of a 40-year-old lady diabetic and hypertensive, who presented
      with increasing fatigue and decreased physical endurance attributable to
      deterioration in renal function. The renal biopsy revealed drug-induced acute
      tubulointerstitial nephritis and the chronology of the events suggested the
      aetiology to be a recent intake of aceclofenac for knee pain. The patient
      improved with oral corticosteroids and the renal functions returned to baseline
      in 3 weeks. We did not come across a case of aceclofenac-induced acute
      tubulointerstitial nephritis on extensive electronic search of literature. This
      is probably the first case report of acute tubulointerstitial nephritis
      associated with the use of aceclofenac, a newer potent non-steroidal
      anti-inflammatory drug.
AD  - Department of Medicine, Government Medical College and Hospital, Chandigarh,
      India.
FAU - Gupta, Monica
AU  - Gupta M
FAU - Cruz, Sanjay D
AU  - Cruz SD
FAU - Nada, Ritambhara
AU  - Nada R
FAU - Aggarwal, Purnima
AU  - Aggarwal P
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - bcr-2013-009217 [pii]
AID - 10.1136/bcr-2013-009217 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 15;2013. pii: bcr2013009217. doi: 10.1136/bcr-2013-009217.

PMID- 23682079
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - HACEK-induced endocarditis.
LID - 10.1136/bcr-2012-007359 [doi]
LID - bcr2012007359 [pii]
AB  - A 61-year-old patient with diabetes had a bio-prosthetic aortic valve replacement
      3 years before admission. He complained of lethargy, night sweats, decreased
      appetite and erratic blood glucose with no weight loss. He had splinter
      haemorrhage and a systolic ejection murmur at the aortic area. Chest and
      abdominal examination revealed no abnormality. The erythrocyte sedimentation rate
      and C reactive protein were raised. He had several sets of blood cultures and he 
      was started on empirical vancomycin, rifampicin and gentamicin. Transthoracic
      echocardiography showed vegetation on the base of the anterior mitral leaflet,
      which was confirmed by a trans-oesophageal echocardiography. Blood culture was
      positive for Haemophilus aphrophilus, and he was started on ceftriaxone for 6
      weeks instead of vancomycin and rifampicin and continued gentamicin for 2 weeks. 
      Follow-up echocardiography showed no evidence of vegetations. The patient
      recovered completely and he was discharged home.
AD  - Department of Cardiology, Kettering General Hospital, Kettering, UK.
FAU - Wassef, Nancy
AU  - Wassef N
FAU - Rizkalla, Essam
AU  - Rizkalla E
FAU - Shaukat, Naeem
AU  - Shaukat N
FAU - Sluka, Martin
AU  - Sluka M
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - bcr-2012-007359 [pii]
AID - 10.1136/bcr-2012-007359 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 15;2013. pii: bcr2012007359. doi: 10.1136/bcr-2012-007359.

PMID- 23682019
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 0231-5882 (Print)
IS  - 0231-5882 (Linking)
DP  - 2013 May 15
TI  - Ischemia-reperfusion injury of the isolated diabetic rat heart: effect of the
      antioxidant stobadine.
AB  - The etiology of diabetic complications is strongly associated with increased
      oxidative stress. The aim of the present study was to evaluate the effect of the 
      potent antioxidant stobadine (STB) on global ischemia-reperfusion cardiac injury 
      in the rat model of diabetes mellitus (DM). Diabetes was induced by multiple low 
      doses of streptozotocin. The effect of STB was compared with that of a high dose 
      of alpha-lipoic acid (ALA). All experiments were performed on isolated
      Langendorff-perfused hearts 10 weeks after streptozotocin administration.
      Diabetic hearts showed to be more resistant to ischemia-reperfusion than the
      control hearts, as shown by the reduced number of reperfusion dysrhythmias. The
      effect of the therapy with ALA (100 mg/kg i.p., 5 times a week during 8 weeks)
      was comparable to that of STB (25 mg/kg i.p., 5 times a week during 8 weeks)
      resulting in lowering the heart rate and coronary flow as well as the number of
      serious reperfusion dysrhythmias. Though the protective effect of STB on the
      reperfusion-induced dysrhythmias was comparable with that of ALA, both substances
      failed to enhance functional recovery of the diabetic rat heart.
AD  - Institute of Experimental Pharmacology and Toxicology, Slovak Academy of
      Sciences, Dubravska cesta 9, 841 04 Bratislava, Slovak Republic.
      zuzana.broskova@savba.sk.
FAU - Broskova, Zuzana
AU  - Broskova Z
FAU - Kyselova, Zuzana
AU  - Kyselova Z
FAU - Knezl, Vladimir
AU  - Knezl V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Gen Physiol Biophys
JT  - General physiology and biophysics
JID - 8400604
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/07/23 [received]
PHST- 2013/01/09 [accepted]
AID - 10.4149/gpb_2013028 [doi]
PST - aheadofprint
SO  - Gen Physiol Biophys. 2013 May 15.

PMID- 23681922
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1466-1268 (Electronic)
IS  - 1355-8145 (Linking)
DP  - 2013 May 17
TI  - Heat shock protein 70 and albuminuria in patients with type 2 diabetes: a matched
      case control study.
AB  - Here, we aimed to study serum heat shock protein (HSP) 70 levels in diabetic
      patients with and without albuminuria. We performed a 1:1 matched case control
      study on 40 diabetic patients with albuminuria as cases and 40 age, sex, body
      mass index matched diabetic patients without albuminuria (normoalbuminuria) as
      controls. Normoalbuminuria was defined as urinary albumin excretion rate <15
      mg/12 h, and albuminuria was defined as urinary albumin excretion rate between
      100-400 mg/12 h. Patients with albuminuria had a higher HSP70 than controls (0.83
      +/- 0.50 vs. 0.63 +/- 0.06; p = 0.02), while they did not differ in any other
      studied variables. In ten of the studied pairs, the controls had higher HSP70
      levels than cases (reverse relationship). Patients in the "direct relationship
      group" had higher HbA1c values than the patients in the "reverse relationship
      group" (8.9 +/- 0.3 vs. 7.3 +/- 0.6, p = 0.04). Cases in the reverse pairs had a 
      lower low density lipoprotein cholesterol levels than their controls. The odds
      ratio of HSP70 in the prediction of albuminuria was (28.69 (3.2-250.1), p =
      0.002). In conclusion, we have shown an increased HSP70 levels in diabetic
      patients with albuminuria.
AD  - Endocrinology and Diabetes Division, Vali-Asr Hospital, Tehran University of
      Medical Sciences, P.O. Box: 13145-784, Tehran, Iran, aafsaneh03@gmail.com.
FAU - Morteza, Afsaneh
AU  - Morteza A
FAU - Nakhjavani, Manouchehr
AU  - Nakhjavani M
FAU - Larry, Mehrdada
AU  - Larry M
FAU - Nargesi, Arash Aghajani
AU  - Nargesi AA
FAU - Esteghamati, Alireza
AU  - Esteghamati A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Cell Stress Chaperones
JT  - Cell stress & chaperones
JID - 9610925
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/02/16 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/04/25 [revised]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s12192-013-0435-x [doi]
PST - aheadofprint
SO  - Cell Stress Chaperones. 2013 May 17.

PMID- 23681864
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1470-2118 (Print)
IS  - 1470-2118 (Linking)
VI  - 13
IP  - 2
DP  - 2013 Apr
TI  - Managing hyperglycaemic emergencies: an illustrative case and review of recent
      British guidelines.
PG  - 160-2
LID - 10.7861/clinmedicine.13-2-160 [doi]
AB  - Diabetic ketoacidosis and hyperosmolar hyperglycaemic syndrome are important
      hyperglycaemic emergencies seen in patients with diabetes. Occasionally,
      differentiation between the two conditions can be difficult. We present the case 
      of a patient whose hyperglycaemic emergency was managed in a way that could have 
      adversely influenced the outcome. We also discuss important aspects of the new
      Joint British Diabetes Societies Guidelines on the management of hyperglycaemic
      emergencies.
AD  - Department of Diabetes and Metabolism, The Royal London Hospital, London, UK.
FAU - Gouveia, Catherine F
AU  - Gouveia CF
FAU - Chowdhury, Tahseen A
AU  - Chowdhury TA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Med
JT  - Clinical medicine (London, England)
JID - 101092853
SB  - IM
OTO - NOTNLM
OT  - Joint British Diabetes Societies Guidelines
OT  - diabetic ketoacidosis
OT  - hyperosmolar hyperglycaemic syndrome
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 13/2/160 [pii]
AID - 10.7861/clinmedicine.13-2-160 [doi]
PST - ppublish
SO  - Clin Med. 2013 Apr;13(2):160-2. doi: 10.7861/clinmedicine.13-2-160.

PMID- 23681859
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1470-2118 (Print)
IS  - 1470-2118 (Linking)
VI  - 13
IP  - 2
DP  - 2013 Apr
TI  - Erectile dysfunction in general medicine.
PG  - 136-40
LID - 10.7861/clinmedicine.13-2-136 [doi]
AB  - Erectile dysfunction (ED) affects millions of men worldwide with implications
      that go far beyond sexual activity. ED is now recognised as an early marker of
      cardiovascular disease, diabetes mellitus (DM) and depression. The risk factors
      that are associated with ED (sedentary lifestyle, obesity, smoking,
      hypercholesterolaemia and the metabolic syndrome) are very similar to those for
      cardiovascular disease (CVD). Arguably, the awareness of ED as a symptomatic
      entity in the post-Viagra age is on the rise. Nevertheless, ED is commonly missed
      when evaluating patients in the hospital setting, either because of lack of
      consideration or awareness, or through simple embarrassment (of both clinician
      and patient). This article provides an overview of the aetiology, assessment and 
      importance of ED and hopes to promote its consideration in day-to-day clinical
      practice.
AD  - 1Maidstone & Tunbridge Wells Hospitals Trust.
FAU - Grant, Paul
AU  - Grant P
FAU - Jackson, Graham
AU  - Jackson G
FAU - Baig, Irfan
AU  - Baig I
FAU - Quin, John
AU  - Quin J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Med
JT  - Clinical medicine (London, England)
JID - 101092853
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 13/2/136 [pii]
AID - 10.7861/clinmedicine.13-2-136 [doi]
PST - ppublish
SO  - Clin Med. 2013 Apr;13(2):136-40. doi: 10.7861/clinmedicine.13-2-136.

PMID- 23681842
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
DP  - 2013 May 17
TI  - Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for
      Primary Prevention in Men.
AB  - BACKGROUND: Recent data suggest that aspirin may be effective for reducing cancer
      mortality. OBJECTIVE: To examine whether including a cancer mortality-reducing
      effect influences which men would benefit from aspirin for primary prevention.
      DESIGN: We modified our existing Markov model that examines the effects of
      aspirin among middle-aged men with no previous history of cardiovascular disease 
      or diabetes. For our base case scenario of 45-year-old men, we examined costs and
      life-years for men taking aspirin for 10 years compared with men who were not
      taking aspirin over those 10 years; after 10 years, we equalized treatment and
      followed the cohort until death. We compared our results depending on whether or 
      not we included a 22 % relative reduction in cancer mortality, based on a recent 
      meta-analysis. We discounted costs and benefits at 3 % and employed a third party
      payer perspective. MAIN MEASURE: Cost per quality-adjusted life year (QALY)
      gained. KEY RESULTS: When no effect on cancer mortality was included, aspirin had
      a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD)
      risk; at 2.5 % risk or below, no treatment was favored. When we included a
      reduction in cancer mortality, aspirin became cost-effective for men at 2.5 %
      risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility
      of taking aspirin daily; risk of death after myocardial infarction; and effects
      of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin
      remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic
      analyses (59 % with no cancer effect included; 96 % with cancer effect) for men
      at 5 % risk. CONCLUSIONS: Including an effect of aspirin on cancer mortality
      influences the threshold for prescribing aspirin for primary prevention in men.
      If such an effect is real, many middle-aged men at low cardiovascular risk would 
      become candidates for regular aspirin use.
AD  - Cecil Sheps Center for Health Services Research, University of North Carolina,
      Chapel Hill, NC, USA, pignone@med.unc.edu.
FAU - Pignone, Michael
AU  - Pignone M
FAU - Earnshaw, Stephanie
AU  - Earnshaw S
FAU - McDade, Cheryl
AU  - McDade C
FAU - Pletcher, Mark J
AU  - Pletcher MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/10/31 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/01/01 [revised]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s11606-013-2465-6 [doi]
PST - aheadofprint
SO  - J Gen Intern Med. 2013 May 17.

PMID- 23681754
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1099-1166 (Electronic)
IS  - 0885-6230 (Linking)
DP  - 2013 May 17
TI  - Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the
      Cache County Study.
LID - 10.1002/gps.3980 [doi]
AB  - OBJECTIVE: Knowledge of potentially modifiable risk factors for neuropsychiatric 
      symptoms (NPS) in Alzheimer's disease (AD) is important. This study
      longitudinally explores modifiable vascular risk factors for NPS in AD. METHODS: 
      Participants enrolled in the Cache County Study on Memory in Aging with no
      dementia at baseline were subsequently assessed over three additional waves, and 
      those with incident (new onset) dementia were invited to join the Dementia
      Progression Study for longitudinal follow-up. A total of 327 participants with
      incident AD were identified and assessed for the following vascular factors:
      atrial fibrillation, hypertension, diabetes mellitus, angina, coronary artery
      bypass surgery, myocardial infarction, cerebrovascular accident, and use of
      antihypertensive or diabetes medicines. A vascular index (VI) was also
      calculated. NPS were assessed over time using the Neuropsychiatric Inventory
      (NPI). Affective and Psychotic symptom clusters were assessed separately. The
      association between vascular factors and change in NPI total score was analyzed
      using linear mixed model and in symptom clusters using a random effects model.
      RESULTS: No individual vascular risk factors or the VI significantly predicted
      change in any individual NPS. The use of antihypertensive medications more than
      four times per week was associated with higher total NPI and Affective cluster
      scores. CONCLUSIONS: Use of antihypertensive medication was associated with
      higher total NPI and Affective cluster scores. The results of this study do not
      otherwise support vascular risk factors as modifiers of longitudinal change in
      NPS in AD. Copyright (c) 2013 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
AD  - Department of Psychiatry and Behavioral Sciences, Johns Hopkins Bayview Medical
      Center, Baltimore, MD, USA.
FAU - Steinberg, Martin
AU  - Steinberg M
FAU - Hess, Kyle
AU  - Hess K
FAU - Corcoran, Chris
AU  - Corcoran C
FAU - Mielke, Michelle M
AU  - Mielke MM
FAU - Norton, Maria
AU  - Norton M
FAU - Breitner, John
AU  - Breitner J
FAU - Green, Robert
AU  - Green R
FAU - Leoutsakos, Jeannie
AU  - Leoutsakos J
FAU - Welsh-Bohmer, Kathleen
AU  - Welsh-Bohmer K
FAU - Lyketsos, Constantine
AU  - Lyketsos C
FAU - Tschanz, Joann
AU  - Tschanz J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Int J Geriatr Psychiatry
JT  - International journal of geriatric psychiatry
JID - 8710629
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/10/01 [received]
PHST- 2013/04/03 [accepted]
AID - 10.1002/gps.3980 [doi]
PST - aheadofprint
SO  - Int J Geriatr Psychiatry. 2013 May 17. doi: 10.1002/gps.3980.

PMID- 23681682
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1938-3800 (Electronic)
IS  - 0742-3225 (Linking)
VI  - 45
IP  - 5
DP  - 2013 May
TI  - Patient-provider communication about diabetes self-care activities.
PG  - 319-22
AB  - BACKGROUND AND OBJECTIVES: Controlling diabetes requires sustained
      self-management on the part of patients. Health care providers can support
      patients' self-care efforts through communication and problem solving. We
      conducted this study to determine the frequency with which self-care activities
      were discussed during office visits for follow-up care of diabetes and how much
      time was spent on these discussions. METHODS: Audio recordings of 28 patient
      encounters in five primary care clinics were analyzed. We determined the
      frequency of self-care discussions and the amount of time devoted to these
      discussions. RESULTS: Self-care was discussed in all 28 encounters. Median
      encounter times for each clinic ranged from 19.8 to 37.6 minutes, with self-care 
      discussions taking from 0.1 to 17.2 minutes. Median discussion time devoted to
      all self-care activities was 5.2 minutes, representing 23.5% of a visit of median
      length. Blood sugar testing was discussed longer than the other activities. The
      least time was devoted to eye and foot examinations. Discussions were usually
      initiated by providers and did not differ in length according to who initiated
      the discussion. CONCLUSIONS: Patients with diabetes regularly discussed self-care
      activities during follow-up visits at family medicine clinics. Providers varied
      in their capacity to incorporate self-care planning into routine medical care for
      patients with diabetes. Interventions are needed that help improve goal-setting
      and documentation. Documentation of self-care discussions will be important for
      meeting Meaningful Use criteria.
AD  - Department of Family and Community Medicine, University of Missouri, Columbia.
FAU - Kruse, Robin L
AU  - Kruse RL
FAU - Olsberg, Joshua E
AU  - Olsberg JE
FAU - Oliver, Debra Parker
AU  - Oliver DP
FAU - Shigaki, Cheryl L
AU  - Shigaki CL
FAU - Vetter-Smith, Molly J
AU  - Vetter-Smith MJ
FAU - Lemaster, Joseph W
AU  - Lemaster JW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Fam Med
JT  - Family medicine
JID - 8306464
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PST - ppublish
SO  - Fam Med. 2013 May;45(5):319-22.

PMID- 23681558
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 May 17
TI  - A 7-year follow-up retrospective, international, multicenter study of insulin
      pump therapy in children and adolescents with type 1 diabetes.
AB  - We evaluated the long-term glycemic control in children with type 1 diabetes,
      using continuous subcutaneous insulin infusion (CSII) for at least 5 years in
      three diabetes centers from three different countries: Canada, Italy and Spain.
      This was an observational retrospective multicenter cohort study. Subjects were
      included if they were followed at one of the participating centers, had type 1
      diabetes, age 5-20 years at time of data collection and used CSII for more than 5
      years. Data collected included gender, age, disease duration, age at CSII
      initiation, body mass index (BMI), hemoglobin A1c (HbA1c), insulin requirement
      and serious adverse events (SAE) at baseline and every 12 months during
      follow-up. One hundred fifteen patients were included in the study (55 % males), 
      aged 5-20 years (mean: 13.5 +/- 3.8 years), with mean diabetes duration of 6.3
      +/- 3.4 years, using CSII for mean of 6.9 +/- 1.2 years (range 5-12 years.).
      HbA1c significantly improved after 1 year of CSII treatment and during follow-up 
      (p = 0.02). When HbA1c was compared between countries, a difference was observed,
      with slightly lower values in Italy than in Canada and Spain (p = 0.04). When
      evaluated by gender, HbA1c was similar at baseline, but significantly improved
      only in males during all follow-up (p = 0.004). No significant differences were
      observed for BMI, insulin requirement or SAE. Insulin pump therapy is safe and
      effective in the pediatric population, although in this study, the major benefit 
      in HbA1c was seen in males. The use of advanced pump features was associated with
      greater improvement in HbA1c.
AD  - Department of Pediatrics, Azienda Ospedaliera, University of Milano, "Ospedale
      Luigi Sacco," Via G.B. Grassi 74, 20154, Milan, Italy.
FAU - Mameli, Chiara
AU  - Mameli C
FAU - Scaramuzza, Andrea E
AU  - Scaramuzza AE
FAU - Ho, Josephine
AU  - Ho J
FAU - Cardona-Hernandez, Roque
AU  - Cardona-Hernandez R
FAU - Suarez-Ortega, Larisa
AU  - Suarez-Ortega L
FAU - Zuccotti, Gian Vincenzo
AU  - Zuccotti GV
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/15 [received]
PHST- 2013/05/06 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s00592-013-0481-y [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 May 17.

PMID- 23681557
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 May 17
TI  - CD2AP is associated with end-stage renal disease in patients with type 1
      diabetes.
AB  - CD2-associated protein (CD2AP) is essential for podocyte function. CD2AP
      mutations have been found in patients with focal segmental glomerulosclerosis, a 
      disease histologically resembling diabetic nephropathy and often progressing to
      end-stage renal disease (ESRD). We hypothesised that variations in the CD2AP gene
      may contribute to susceptibility to glomerular injury in diabetes and
      investigated if single-nucleotide polymorphisms (SNPs) in CD2AP are associated
      with diabetic nephropathy in patients with type 1 diabetes. The discovery cohort 
      consisted of 2,251 Finnish patients with type 1 diabetes. SNPs were selected from
      the HapMap database to cover the CD2AP gene. The associations between genotyped
      SNPs and diabetic nephropathy or ESRD were analysed with the chi-squared test and
      logistic regression. Three SNPs were selected for replication in cohorts from
      Denmark, Italy, the United Kingdom and Ireland. None of the 15 successfully
      genotyped SNPs were associated with diabetic nephropathy when compared to
      patients with normal albumin excretion rate. However, when genotype frequencies
      in patients with ESRD were compared with all other patients, two CD2AP SNPs,
      rs9369717 and rs9349417, were found to be associated with ESRD. The meta-analysis
      of the original and two additional European cohorts resulted in significant p
      values <0.01 for these SNPs. A third SNP, rs6936632, was suggestively associated 
      with ESRD in the Finnish patients and in the meta-analysis of four cohorts. CD2AP
      gene variants may contribute to susceptibility to ESRD in patients with type 1
      diabetes.
AD  - Department of Pathology, Haartman Institute, University of Helsinki, Helsinki,
      Finland, mervi.hyvonen@helsinki.fi.
FAU - Hyvonen, Mervi E
AU  - Hyvonen ME
FAU - Ihalmo, Pekka
AU  - Ihalmo P
FAU - Sandholm, Niina
AU  - Sandholm N
FAU - Stavarachi, Monica
AU  - Stavarachi M
FAU - Forsblom, Carol
AU  - Forsblom C
FAU - McKnight, Amy Jayne
AU  - McKnight AJ
FAU - Lajer, Maria
AU  - Lajer M
FAU - Maestroni, Anna
AU  - Maestroni A
FAU - Lewis, Gareth
AU  - Lewis G
FAU - Tarnow, Lise
AU  - Tarnow L
FAU - Maestroni, Silvia
AU  - Maestroni S
FAU - Zerbini, Gianpaolo
AU  - Zerbini G
FAU - Parving, Hans-Henrik
AU  - Parving HH
FAU - Maxwell, Alexander P
AU  - Maxwell AP
FAU - Groop, Per-Henrik
AU  - Groop PH
FAU - Lehtonen, Sanna
AU  - Lehtonen S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/02/12 [received]
PHST- 2013/04/06 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s00592-013-0475-9 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 May 17.

PMID- 23681496
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1432-0711 (Electronic)
IS  - 0932-0067 (Linking)
DP  - 2013 May 17
TI  - Pregnancy outcomes amongst thalassemia traits.
AB  - OBJECTIVE: To compare the pregnancy outcome between pregnancies affected and not 
      affected by thalassemia trait. METHODS: A retrospective case-control cohort study
      was conducted on singleton pregnant women who attended antenatal care and
      delivered at Songklanagarind Hospital. All of the participating thalassemia trait
      pregnant women were diagnosed based on hemoglobin typing and/or DNA analysis. A
      ratio of around 1-1 was used to compare their pregnancy outcomes with normal
      pregnant women. RESULTS: Seven hundred thirty-nine thalassemia trait and 799
      normal pregnant women were included in the study. All of the women were Thai
      nationals living in the Southern Region of Thailand and nearly all of them had
      spontaneously conceived. Maternal complication rates of gestational diabetes,
      preterm birth, antepartum bleeding, postpartum bleeding, shoulder dystocia and
      puerperal morbidity, and the rates of neonatal complications: macrosomia, fetal
      weight <2,000 g, intrauterine growth restriction (IUGR), stillbirth, low Apgar
      score (<7) at 1 and 5 min and NICU admission, were not significantly different
      between the two groups. The rate of pre-eclampsia, however, was significantly
      different, with RRs of 1.73 (CI 1.01-3.00). CONCLUSION: The thalassemia trait
      condition did not affect the risk of gestational diabetes, postpartum hemorrhage,
      stillbirth, preterm birth and puerperal morbidity. However, pre-eclampsia should 
      be warranted especially among nulliparous and high-BMI pregnant women.
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine Prince of Songkla
      University, Hat Yai, Songkhla, 90110, Thailand, htharang@medicine.psu.ac.th.
FAU - Hanprasertpong, Tharangrut
AU  - Hanprasertpong T
FAU - Kor-Anantakul, Ounjai
AU  - Kor-Anantakul O
FAU - Leetanaporn, Roengsak
AU  - Leetanaporn R
FAU - Suntharasaj, Thitima
AU  - Suntharasaj T
FAU - Suwanrath, Chitkasaem
AU  - Suwanrath C
FAU - Pruksanusak, Ninlapa
AU  - Pruksanusak N
FAU - Pranpanus, Savitree
AU  - Pranpanus S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/11/14 [received]
PHST- 2013/05/06 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s00404-013-2886-9 [doi]
PST - aheadofprint
SO  - Arch Gynecol Obstet. 2013 May 17.

PMID- 23681491
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 17
TI  - Neurovascular Function and Sudorimetry in Health and Disease.
AB  - In this review of thermoregulatory function in health and disease, we review the 
      basic mechanisms controlling skin blood flow of the hairy and glabrous skin and
      illustrate the major differences in blood flow to glabrous skin, which is, in
      essence, sympathetically mediated, while hairy skin is dependent upon
      neuropeptidergic signals, nitric oxide, and prostaglandin, among others. Laser
      Doppler methods of quantification of blood flow-in response to iontophoresis of
      acetylcholine or heat-and nociceptor-mediated blood flow have relatively
      uniformly demonstrated an impaired capacity to increase blood flow to the skin in
      diabetes and in its forerunners, prediabetes and the metabolic syndrome. This
      reduced capacity is likely to be a significant contributor to the development of 
      foot ulcerations and amputations in diabetes, and means of increasing blood flow 
      are clearly needed. Understanding the pathogenic mechanisms is likely to provide 
      a means of identifying a valuable therapeutic target. Thermoregulatory control of
      sweating is intimately linked to the autonomic nervous system via sympathetic C
      fibers, and sweat glands are richly endowed with a neuropeptidergic innervation. 
      Sweating disturbances are prevalent in diabetes and its precursors, and
      quantification of sweating may be useful as an index of diagnosis of somatic and,
      probably, autonomic dysfunction. Moreover, quantifying this disturbance in
      sweating by various methods may be useful in identifying the risk of progression 
      from prediabetes to diabetes, as well as responses to therapeutic intervention.
      We now have the technological power to take advantage of this physiological
      arrangement to better understand, monitor, and treat disorders of small nerve
      fibers and the somatic and autonomic nervous system (ANS). Newer methods of
      sudomotor function testing are rapid, noninvasive, not technically demanding, and
      accessible to the outpatient clinic. Whether the potential applications are
      screening for diabetes, following poorly controlled diabetes subjects during
      alteration of their treatment regimen, or simply monitoring somatic and autonomic
      function throughout the course of treatment, sudorimetry can be an invaluable
      tool for today's clinicians.
AD  - Strelitz Diabetes Center for Endocrine and Metabolic Disorders, Eastern Virginia 
      Medical School, 855 W Brambleton Avenue, Norfolk, VA, 23510, USA,
      vinikai@evms.edu.
FAU - Vinik, Aaron I
AU  - Vinik AI
FAU - Nevoret, Marie
AU  - Nevoret M
FAU - Casellini, Carolina
AU  - Casellini C
FAU - Parson, Henri
AU  - Parson H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1007/s11892-013-0392-x [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 17.

PMID- 23681419
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
DP  - 2013 May 17
TI  - Fetal Left and Right Ventricle Myocardial Performance Index: Defining Normal
      Values for the Second and Third Trimesters-Single Tertiary Center Experience.
AB  - Myocardial performance index (MPI), or Tei index, has become a commonly used
      parameter for the noninvasive, Doppler-derived assessment of global systolic and 
      diastolic performance of the heart in both adults and children. Normal values
      have been established in adults and children; however, limited data exist in
      fetal hearts. The aim of this study was to further elucidate normal values of
      fetal left (LV) and right ventricle (RV) MPI values in second- and
      third-trimester fetuses and compare these values with other previously published 
      data. This was a retrospective study to measure MPI in healthy fetuses. After
      Institutional Review Board approval, 2000 fetal echocardiography studies (FES)
      were acquired during a period of 4 years. Demographic parameters examined
      included gestational age (GA), maternal age (MA), and indication for fetal
      echocardiography. Fetuses with congenital heart disease, arrhythmias, or
      significant noncardiac fetal anomalies were excluded. The following
      echocardiography parameters were collected: LV ejection time (LVET), mitral valve
      close-to-open time (MVCO), RVET, tricuspid valve CO (TVCO), and fetal heart rate.
      For simplicity, LV and RV MPI values were calculated as follows: LV MPI = MVCO - 
      LVET/LVET and RV MPI = TVCO - RVET/RVET. Four hundred twenty FES met the study
      criteria. LV MPI was evaluated in 230 and 190 FES in the second and third
      trimester, respectively. Of the 420 FES, 250 (150 in the second trimester and 100
      in the third trimester) had all of the measurements required for RV MPI
      calculation. MA ranged between 16 and 49 years. Indications for FES included
      diabetes mellitus (N = 140; 33 %), suspected fetal anomalies on routine
      obstetrical ultrasound (N = 80; 20 %), autoimmune disorder (N = 60; 14 %), family
      history of CHD (N = 76; 18 %), medication exposure (N = 22; 5 %), increase nuchal
      thickness (N = 13; 3 %), and other indications (N = 29; 6 %). Averaged LV and RV 
      MPI values were 0.464 +/- 0.08 and 0.466 +/- 0.09, respectively. Further analysis
      based on gestational period showed slightly greater LV and RV MPI values during
      the third compared with the second trimester, i.e., 0.48 and 0.49, respectively, 
      with no statistically significant difference. There was no significant
      association of LV and RV MPI with heart rate. To our knowledge, this is the first
      study to establish normal values of fetal MPI based on a large fetal population
      from a single tertiary center. LV and RV MPI values were independent of GA and
      fetal heart rate. MPI is a useful parameter for the assessment of global cardiac 
      function in the fetus and demonstrates good reproducibility with narrow
      interobserver and intraobserver variability. Its usefulness should be studied in 
      fetal hearts with complex congenital anomalies.
AD  - Rush Center for Congenital & Structural Heart Disease, Rush University Medical
      Center, 1653 West Congress Parkway, Jones 770, Chicago, IL, 60612, USA.
FAU - Ghawi, Hani
AU  - Ghawi H
FAU - Gendi, Salwa
AU  - Gendi S
FAU - Mallula, Kiran
AU  - Mallula K
FAU - Zghouzi, Mohammed
AU  - Zghouzi M
FAU - Faza, Nadeen
AU  - Faza N
FAU - Awad, Sawsan
AU  - Awad S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/27 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s00246-013-0709-1 [doi]
PST - aheadofprint
SO  - Pediatr Cardiol. 2013 May 17.

PMID- 23681352
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1432-1424 (Electronic)
IS  - 0022-2631 (Linking)
DP  - 2013 May 17
TI  - The Effect of Glutathione Treatment on the Biochemical and Immunohistochemical
      Profile in Streptozotocin-Induced Diabetic Rats.
AB  - This study investigated the possible role of glutathione (GSH) in diabetic
      complications and its biochemical safety in experimental diabetic rats. Serum
      biochemical parameters and the histology of the pancreas were investigated. Seven
      rats were separated as controls. To create the diabetes in rats, 45 mg/kg
      single-dose streptozotocin (STZ) was administered i.p. The treatment was
      continued for 1 month. STZ was administered to the diabetes + GSH group, then
      reduced GSH, dissolved in isotonic salt solution (200 mg/kg), was applied i.p.
      two times a week. The GSH group received i.p. GSH. Serum biochemical parameters
      were determined by autoanalyzer. Immunohistochemical procedures were used to
      determine the percentage of the insulin-immunoreactive beta-cell area in the
      islets of Langerhans. The biochemical parameters changed to different degrees or 
      did not change. Pancreatic cells of the control and GSH groups were healthy, but 
      in the diabetic and GSH-treated diabetic groups we found damage in different
      numbers. The results from these analyses show that GSH supplementation can exert 
      beneficial effects on pancreatic cells in STZ-induced diabetic rats and can
      safely be used for therapy in and protection from diabetes and complications of
      diabetes.
AD  - Biochemistry Department, Faculty of Veterinary Medicine, Yuzuncu Yil University, 
      Van, Turkey.
FAU - Yur, Fatmagul
AU  - Yur F
FAU - Dede, Semiha
AU  - Dede S
FAU - Karaca, Turan
AU  - Karaca T
FAU - Ciftci Yegin, Sevim
AU  - Ciftci Yegin S
FAU - Deger, Yeter
AU  - Deger Y
FAU - Ozdemir, Hulya
AU  - Ozdemir H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - J Membr Biol
JT  - The Journal of membrane biology
JID - 0211301
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/12/16 [received]
PHST- 2013/03/22 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s00232-013-9541-z [doi]
PST - aheadofprint
SO  - J Membr Biol. 2013 May 17.

PMID- 23681349
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1948-965X (Electronic)
IS  - 1682-3141 (Linking)
VI  - 21
IP  - 2
DP  - 2013 Jun
TI  - Correlations Among Social Support, Depression, and Anxiety in Patients With
      Type-2 Diabetes.
PG  - 129-138
AB  - BACKGROUND:: Social support is related to patient self-care and health status.
      Patients' psychosocial issues play an important role in diabetes care. PURPOSE:: 
      This study investigates correlations among social support, depression, and
      anxiety in patients with diabetes. METHODS:: A cross-sectional study design and
      purposive sampling were used. One hundred eleven patients with type-2 diabetes
      were recruited from three regional teaching hospitals in northern, central, and
      southern Taiwan, respectively. Questionnaires used included the social support
      and psychological referral inventory, Beck depression inventory, and Beck anxiety
      inventory. RESULTS:: Approximately 12.6% of the study population had depression, 
      and 27.0% had anxiety. Depression and anxiety were positively correlated (r =
      .65, p < .01), whereas depression was negatively correlated with the sum of
      disease control types (r = -0.26, p < .01) and social support (r = -0.27, p
      <.01). The sum of disease control types and social support were the most
      important explanatory factors for depression in patients, explaining 45.5% of
      variance. Anxiety was correlated positively with age (r = .26, p < .01), total
      number of complications (r = .31, p < .01), and depression (r = .65, p < .01).
      Anxiety correlated negatively with weight (r = -0.20, p < .05) and sum of disease
      control types (r = -0.25, p < .05). The above variables were important
      explanatory factors for anxiety, accounting for 15.2% of variance.
      CONCLUSIONS/IMPLICATIONS FOR PRACTICE:: Psychological factors, such as depression
      and anxiety, are common symptoms in patients with diabetes. If social support can
      be strengthened in these patients, then psychological factors can be improved.
      Professional care providers should focus on reducing the patient depression and
      anxiety levels, strengthening social support, and providing referrals to
      psychology-related professionals.
AD  - 1PhD, RN, Associate Professor, School of Nursing, National Taipei University of
      Nursing and Health Sciences 2MSN, RN, Director, Department of Nursing, En Chu
      Kong Hospital 3MSN, RN, Deputy Director, Department of Nursing, Kuang Tien
      General Hospital 4MSN, RN, Instructor, Department of Nursing, Chang Gung
      University of Science and Technology 5MSN, RN, Instructor, Department of Early
      Childhood Educare, Wu Feng University 6MSN, RN, Instructor, School of Nursing,
      National Taipei University of Nursing and Health Sciences.
FAU - Wu, Shu-Fang Vivienne
AU  - Wu SF
FAU - Young, Li-Sei
AU  - Young LS
FAU - Yeh, Fang-Chih
AU  - Yeh FC
FAU - Jian, Yu-Mei
AU  - Jian YM
FAU - Cheng, Kuei-Chen
AU  - Cheng KC
FAU - Lee, Mei-Chen
AU  - Lee MC
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - J Nurs Res
JT  - The journal of nursing research : JNR
JID - 101128757
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1097/jnr.0b013e3182921fe1 [doi]
AID - 00134372-201306000-00008 [pii]
PST - ppublish
SO  - J Nurs Res. 2013 Jun;21(2):129-138.

PMID- 23681273
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1615-2573 (Electronic)
IS  - 0910-8327 (Linking)
DP  - 2013 May 17
TI  - Greater insulin resistance indicates decreased diurnal variation in the QT
      interval in patients with type 2 diabetes.
AB  - Circadian variations in the QT interval (QT) and QT dispersion are decreased in
      patients with type 2 diabetes because of cardioneuropathy. Insulin resistance has
      been recently identified as an independent determinant of QT prolongation in
      normoglycemic women. However, the relationship between QT prolongation and the
      degree of insulin resistance as well as circadian variation remains unclear in
      diabetic patients. This study was designed to assess the relationship between
      insulin resistance and the circadian variation in QT measurements in patients
      with type 2 diabetes. In 14 patients with diabetes, QT, corrected QT (QTc), QT
      dispersion, QTc dispersion, and RR interval (RR) were analyzed using 12-lead
      Holter monitoring and commercial software. The degree of diurnal variation in
      each measurement was defined as the amplitude between the maximum and mean values
      on curves fitted using the mean cosinor method (A_QT, A_QTc, A_QT dispersion,
      A_QTc dispersion, and A_RR). The cosine curve was fitted to all measured values
      in each QT measurement and RR for 24 h. Insulin resistance (glucose infusion rate
      (GIR)) was measured using the euglycemic hyperinsulinemic glucose clamp method.
      The maximum QT, QTc, QT dispersion, and QTc dispersion were >450 ms. GIR was
      significantly correlated with A_QT only (r = 0.59, P < 0.05). GIR was not
      correlated with other variables, and was dependent only on the circadian
      variation in QT.
AD  - Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine,
      Department of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo,
      113-8603, Japan.
FAU - Tanaka, Kotoko
AU  - Tanaka K
FAU - Yodogawa, Kenji
AU  - Yodogawa K
FAU - Ono, Takuya
AU  - Ono T
FAU - Yana, Kazuo
AU  - Yana K
FAU - Miyamoto, Masaaki
AU  - Miyamoto M
FAU - Atarashi, Hirotsugu
AU  - Atarashi H
FAU - Kato, Takao
AU  - Kato T
FAU - Mizuno, Kyoichi
AU  - Mizuno K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Heart Vessels
JT  - Heart and vessels
JID - 8511258
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/11/07 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s00380-013-0356-8 [doi]
PST - aheadofprint
SO  - Heart Vessels. 2013 May 17.

PMID- 23681139
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 0026-4725 (Print)
IS  - 0026-4725 (Linking)
VI  - 61
IP  - 3
DP  - 2013 Jun
TI  - Why interventional cardiologists may be the most suitable specialists for the
      endovascular management of peripheral artery disease.
PG  - 367-70
AB  - Peripheral artery disease has a major morbidity and mortality burden worldwide,
      and its impact is going to increase even further given the obesity and diabetes
      pandemic. Whereas medical therapy and open surgical therapy (e.g. bypass,
      endarterectomy, and aneurysmectomy) remain mainstays in the management of
      peripheral artery disease, endovascular (i.e. percutaneous or transcatheter)
      therapy is gaining ever increasing success among patients and physicians alike.
      However, endovascular interventions can be performed by cardiologists,
      radiologists, vascular surgeons and, possibly, others as well. Are all these
      specialists similarly likely to perform endovascular procedures in a safe and
      effective fashion? Can we identify a subset of specialists ideally equipped to
      perform endovascular interventions in the best manner? We indeed make the case in
      this article for the possible superiority of interventional cardiologists, for
      their background, training and clinical experience, in performing endovascular
      procedures.
AD  - Department of Medico-Surgical Sciences and Biotechnologies La Sapienza
      University, RomeLatina, Italy - gbiondizoccai@gmail.com.
FAU - Biondi-Zoccai, G
AU  - Biondi-Zoccai G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - R05Y2013N03A0367 [pii]
PST - ppublish
SO  - Minerva Cardioangiol. 2013 Jun;61(3):367-70.

PMID- 23681134
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 0026-4725 (Print)
IS  - 0026-4725 (Linking)
VI  - 61
IP  - 3
DP  - 2013 Jun
TI  - Early vascular healing with biodegradable polymer coated sirolimus-eluting
      coronary stent implantation: assessed by optical coherence tomography results at 
      4-month follow-up.
PG  - 313-22
AB  - Aim: The aim of this study was to evaluate the strut apposition and neointimal
      coverage of Supralimus-Core stent struts at 4 months after implantation using
      optical coherence tomography (OCT). Methods: The Supralimus-Core OCT study is a
      retrospective, single-center study evaluating strut apposition and neointimal
      coverage with OCT at 4 months after stent implantation. A total of 12 patients,
      who had 15 stents implanted were included in the study. The OCT was obtained
      using a C7-XR FD-OCT (frequency-domain OCT) intravascular imaging system. Strut
      apposition, neointimal hyperplasia (NIH) thickness and stent coverage on each
      stent strut were evaluated. Results: A total of 2870 struts and 1950 frames were 
      analyzed from 15 stents. Average stent length was 29.3 mm. Average reference
      vessel diameter was 2.64 mm. Among 12 patients, 3 (25.0%) patients were with
      diabetes, 4 (26.7%) type B2 and 10 (66.7%) type C lesions. The apposed and
      covered struts were 2787 (97.11%), whereas malapposed and covered struts were 3
      (0.10%), apposed and uncovered 49 (1.71%) and malapposed and uncovered 31
      (1.08%). Mean NIH thickness was 155.1+/-55.2 microm. Conclusion: The present
      study suggests that Supralimus-Core stent has a favorable vascular healing
      pattern at 4 months after stent implantation in terms of stent-strut coverage and
      strut apposition. This information indicates that the Supralimus-Core stent is a 
      promising solution for decreasing late stent restenosis and preventing stent
      thrombosis.
AD  - Shree B.D. Mehta Mahavir Heart Institute Athwagate, Surat, India -
      atulda@hotmail.com.
FAU - Abhyankar, A
AU  - Abhyankar A
FAU - Prajapati, J
AU  - Prajapati J
FAU - Reddy, S
AU  - Reddy S
FAU - Reddy, S
AU  - Reddy S
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - R05Y2013N03A0313 [pii]
PST - ppublish
SO  - Minerva Cardioangiol. 2013 Jun;61(3):313-22.

PMID- 23681133
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 0026-4725 (Print)
IS  - 0026-4725 (Linking)
VI  - 61
IP  - 3
DP  - 2013 Jun
TI  - Circulating endothelial progenitor cells are inversely correlated with in-stent
      restenosis in patients with non-ST-segment elevation acute coronary syndromes
      treated with EPC-capture stents (JACK-EPC trial).
PG  - 301-11
AB  - Aim: Aim of the study was to evaluate the association between circulating
      endothelial progenitor cells (EPCs) and angiographic outcomes after implantation 
      of GenousTM stent in patients with non-ST-segment elevation acute coronary
      syndromes (ACS) (NSTE-ACS) undergoing urgent percutaneous coronary intervention
      (PCI). Methods: Sixty patients treated with EPC-capture stent (N.=30) or bare
      metal stents (BMS) (N.=30) receiving 80 mg atorvastatin and dual antiplatelet
      therapy (DAT) for 12 months. Restenosis was assessed after 6 months by
      quantitative coronary angiography (QCA) and major acute coronary events (MACE)
      evaluated after 6 and 12 months. Inclusion criteria: de novo lesion >70% in
      native vessel, diameter 2.5-4 mm, lesion length <30 mm. Exclusion criteria:
      diabetes, previous revascularization, significant left main stenosis, chronic
      total occlusions (CTO) and multivessel disease. Results: Majority of patients in 
      EPC-capture stent and BMS groups presented with NSTEMI (73.3% and 70%,
      respectively). Mean stent length was 20.1+/-8 and 19.9+/-10 mm, diameter 3+/-0.97
      and 3.1+/-0.88 mm in respective groups. The binary restenosis was significantly
      lower in GenousTM (13 vs. 26.6%, P=0.04). Risk of MACE after 6 and 12 months were
      comparable in both groups. There was no stent thrombosis. Numbers of circulating 
      EPCs were significantly approximately 2-fold higher during the ACS than after 6
      months. Mobilization of EPCs during acute ischemia was significantly lower in
      patients who developed restenosis after 6 months (3 vs. 4.5 cells/muL, P=0.002)
      and it was negatively correlated with late-loss after 6 months (R=-0.42; P<0.03).
      Conclusion: Use of GenousTM stents in NSTE-ACS is associated with lower
      restenosis rate than BMS at 6 months. There was no ST through 1 year. The number 
      of circulating EPCs is inversely correlated with in-stent late loss (LL).
AD  - Third Division of Cardiology Medical University of Silesia, Katowice, Poland -
      wojtek.wojakowski@gmail.com.
FAU - Wojakowski, W
AU  - Wojakowski W
FAU - Pyrlik, A
AU  - Pyrlik A
FAU - Krol, M
AU  - Krol M
FAU - Buszman, P
AU  - Buszman P
FAU - Ochala, A
AU  - Ochala A
FAU - Milewski, K
AU  - Milewski K
FAU - Smolka, G
AU  - Smolka G
FAU - Kawecki, D
AU  - Kawecki D
FAU - Rudnik, A
AU  - Rudnik A
FAU - Pawlowski, T
AU  - Pawlowski T
FAU - Jadczyk, T
AU  - Jadczyk T
FAU - Wyderka, R
AU  - Wyderka R
FAU - Cybulski, W
AU  - Cybulski W
FAU - Dworowy, S
AU  - Dworowy S
FAU - Tendera, M
AU  - Tendera M
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Cardioangiol
JT  - Minerva cardioangiologica
JID - 0400725
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - R05Y2013N03A0301 [pii]
PST - ppublish
SO  - Minerva Cardioangiol. 2013 Jun;61(3):301-11.

PMID- 23681126
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1569-9285 (Electronic)
IS  - 1569-9285 (Linking)
DP  - 2013 May 16
TI  - Simple adaptations of surgical technique to critically reduce the risk of
      postoperative sternal complications in patients receiving bilateral internal
      thoracic arteries.
AB  - OBJECTIVESLimited blood supply to the thoracic chest wall is a known risk factor 
      for sternal wound complications after CABG. Therefore, bilateral internal
      thoracic arteries are still rarely utilized despite their proven superior graft
      patency. The aim of our study was to analyse whether modification of the surgical
      technique is able to limit the risk of sternal wound complications in patients
      receiving bilateral internal thoracic artery grafting.METHODSAll 418 non-emergent
      CABG patients receiving bilateral internal thoracic artery CABG procedures (BITA)
      from January 2001 to January 2012 were analysed for sternal wound complications. 
      Surgical technique together with known risk factors and relevant comorbidity were
      analysed for their effect on the occurrence of sternal wound complications by
      means of multivariate logistic regression analysis.RESULTSSternal wound
      complications occurred in 25 patients (5.9%), with a sternal dehiscence rate of
      2.4% (10 patients). In multivariate analysis, diabetes (odds ratio [OR]: 4.8, 95%
      CI: 1.9-11.7, P = 0.001), but not obesity (OR: 1.6, 95% CI: 0.7-4.2, P = 0.28) or
      chronic obstructive pulmonary disease (OR: 2.2, 95% CI: 0.87-5.6, P = 0.1) was a 
      relevant comorbid condition for sternal complications. Skeletonization of ITA
      grafts (OR: 0.17, 95% CI: 0.06-0.5, P = 0.001) and the augmented use of sternal
      wires (OR: 0.24, 95% CI: 0.06-0.95, P = 0.04) were highly effective in preventing
      sternal complications. The use of platelet-enriched-fibrin glue (PRF) sealant,
      however, was associated with more superficial sternal infections (OR: 3.7, 95%
      CI: 1.3-10.5, P = 0.02).CONCLUSIONAdjusted for common risk factors,
      skeletonization of BITA grafts together with augmented sternal wires is effective
      in preventing sternal complications. The use of PRF sealant, however, increased
      the risk for superficial wound complications.
AD  - Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria.
FAU - Sakic, Adel
AU  - Sakic A
FAU - Chevtchik, Orest
AU  - Chevtchik O
FAU - Kilo, Juliane
AU  - Kilo J
FAU - Schistek, Roland
AU  - Schistek R
FAU - Mueller, Ludwig C
AU  - Mueller LC
FAU - Ulmer, Hanno
AU  - Ulmer H
FAU - Grimm, Michael
AU  - Grimm M
FAU - Ruttmann, Elfriede
AU  - Ruttmann E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Interact Cardiovasc Thorac Surg
JT  - Interactive cardiovascular and thoracic surgery
JID - 101158399
OTO - NOTNLM
OT  - Bilateral internal thoracic artery
OT  - Coronary artery bypass grafting
OT  - Sternal complications
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - ivt089 [pii]
AID - 10.1093/icvts/ivt089 [doi]
PST - aheadofprint
SO  - Interact Cardiovasc Thorac Surg. 2013 May 16.

PMID- 23681078
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
DP  - 2013 May 15
TI  - Adrenal Cortical Adenoma: The Fourth Component of the Carney Triad and an
      Association With Subclinical Cushing Syndrome.
AB  - The Carney triad is the combination of gastric stromal sarcoma, pulmonary
      chondroma, and extra-adrenal paraganglioma. Herein, we describe the clinical,
      imaging, pathologic, and follow-up findings from 14 patients for a fourth
      component of the syndrome, adrenal adenoma. The adrenal neoplasm was asymptomatic
      and usually a late finding. Results of adrenocortical function tests were normal.
      Computed tomography revealed low-density adrenal masses that were consistent with
      adenomas. Bilateral lesions were present in 4 patients. In 13 of the 14 patients 
      who underwent surgery, resected adrenal glands and biopsy specimens featured 1 or
      more circumscribed, yellow tumors, up to 3.5 cm in diameter, composed of
      well-differentiated polygonal cells with clear vacuolated cytoplasm and a smaller
      component of eosinophilic cells. The extratumoral cortex had combinations of
      normal histologic features, discrete clear cell micronodules, zonal clear cell
      hypertrophy, and marked atrophy. The lesion in the 14th patient was different,
      grossly and microscopically resembling the usual sporadic cortisol-secreting
      adenoma. After the tumor was excised, the patient required glucocorticoid
      support. None of the tumors recurred or metastasized. Fourteen additional
      patients had unilateral or bilateral adrenal tumors consistent with adenomas
      detected by imaging studies.
AD  - *Department of Laboratory Medicine and Pathology double daggerDivision of
      Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN
      daggerSection on Endocrinology & Genetics, Program on Developmental Endocrinology
      and Genetics, NICHD, NIH, Bethesda, MD.
FAU - Carney, J Aidan
AU  - Carney JA
FAU - Stratakis, Constantine A
AU  - Stratakis CA
FAU - Young, William F Jr
AU  - Young WF Jr
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1097/PAS.0b013e318285f6a2 [doi]
PST - aheadofprint
SO  - Am J Surg Pathol. 2013 May 15.

PMID- 23681066
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
DP  - 2013 May 16
TI  - Prognostic Value of the Index of Microcirculatory Resistance Measured after
      Primary Percutaneous Coronary Intervention.
AB  - BACKGROUND: Most methods for assessing microvascular function are not readily
      available in the cardiac catheterization laboratory. The aim of this study is to 
      determine whether the Index of Microcirculatory Resistance (IMR), measured at the
      time of primary percutaneous coronary intervention (PCI) is predictive of death
      and rehospitalization for heart failure. METHODS AND RESULTS: IMR was measured
      immediately after primary PCI in 253 patients from 3 institutions using a
      pressure-temperature sensor wire. The primary endpoint was the rate of death or
      rehospitalization for heart failure. The prognostic value of IMR was compared to 
      coronary flow reserve, TIMI myocardial perfusion grade and clinical variables.
      The mean IMR was 40.3 +/-32.5. Patients with an IMR>40 had a higher rate of the
      primary end point at one year compared to patients with an IMR</=40 (17.1% vs.
      6.6%, p=0.027). During a median follow-up period of 2.8 years, 13.8% suffered the
      primary end point and 4.3% died. An IMR>40 was associated with an increased risk 
      of death or rehospitalization for heart failure (HR 2.1, p=0.034) and of death
      alone (HR 3.95, p=0.028). On multivariate analysis, independent predictors of
      death or rehospitalization for heart failure included IMR>40 (HR 2.2, p=0.026),
      fractional flow reserve </=0.8 (HR 3.24, p=0.008) and diabetes (HR 4.4, p<0.001).
      An IMR>40 was the only independent predictor of death alone (HR 4.3, p=0.02).
      CONCLUSIONS: An elevated IMR at the time of primary PCI predicts poor long term
      outcomes.
AD  - 1Stanford University Medical Center, Stanford, CA.
FAU - Fearon, William F
AU  - Fearon WF
FAU - Low, Adrian F
AU  - Low AF
FAU - Yong, Andy C
AU  - Yong AC
FAU - McGeoch, Ross
AU  - McGeoch R
FAU - Berry, Colin
AU  - Berry C
FAU - Shah, Maulik G
AU  - Shah MG
FAU - Ho, Michael
AU  - Ho M
FAU - Kim, Hyun-Sook
AU  - Kim HS
FAU - Loh, Joshua P
AU  - Loh JP
FAU - Oldroyd, Keith G
AU  - Oldroyd KG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Circulation
JT  - Circulation
JID - 0147763
OTO - NOTNLM
OT  - microvascular dysfunction
OT  - myocardial infarction
OT  - physiology
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - CIRCULATIONAHA.112.000298 [pii]
AID - 10.1161/CIRCULATIONAHA.112.000298 [doi]
PST - aheadofprint
SO  - Circulation. 2013 May 16.

PMID- 23680948
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1708-8283 (Electronic)
IS  - 0883-0738 (Linking)
DP  - 2013 May 16
TI  - Treatment of Diabetes and Diabetic Complications With a Ketogenic Diet.
AB  - Accumulating evidence suggests that low-carbohydrate, high-fat diets are safe and
      effective to reduce glycemia in diabetic patients without producing significant
      cardiovascular risks. Most of these studies have been carried out specifically
      restricting carbohydrates, which tends to lead to increased protein intake, thus 
      reducing the ketosis. However, diets that limit protein as well as carbohydrates,
      entailing a composition very high in fat, appear even more effective to reduce
      glucose and whole-body glucose metabolism in humans. In animal models,
      low-carbohydrate, high-protein diets do not produce ketosis or reduce glycemia
      but rather cause obesity. However, limiting both protein and carbohydrates as in 
      a classic ketogenic diet remarkably reduces blood glucose in animal models of
      type 1 and type 2 diabetes and reverses diabetic nephropathy. Future studies
      should assess if ketogenic diets would be effective to reverse diabetic
      complications in humans.
AD  - 1The Graduate School of the Icahn School of Medicine at Mount Sinai, New York,
      NY, USA.
FAU - Mobbs, Charles V
AU  - Mobbs CV
FAU - Mastaitis, Jason
AU  - Mastaitis J
FAU - Isoda, Fumiko
AU  - Isoda F
FAU - Poplawski, Michal
AU  - Poplawski M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - J Child Neurol
JT  - Journal of child neurology
JID - 8606714
OTO - NOTNLM
OT  - low carbohydrate
OT  - nephropathy
OT  - type 1 diabetes
OT  - type 2 diabetes mellitus
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 0883073813487596 [pii]
AID - 10.1177/0883073813487596 [doi]
PST - aheadofprint
SO  - J Child Neurol. 2013 May 16.

PMID- 23680929
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
DP  - 2013 May 15
TI  - Racial Differences and Income Disparities Are Associated with Poor Outcomes in
      Kidney Transplant Recipients with Lupus Nephritis.
AB  - BACKGROUND: An analysis of income and racial/ethnic disparities on renal
      transplant outcomes in recipients with lupus nephritis (LN) has not been
      reported. We analyzed the United States Renal Data System database to assess the 
      impact of these disparities on graft loss and death in the LN and non-LN cohorts.
      METHODS: We identified 4214 patients with LN as the cause of end-stage renal
      disease in a retrospective cohort of 150,118 patients first transplanted from
      January 1, 1995 to July 1, 2006. We merged data on median household income from
      the United States Census based on the ZIP code. RESULTS: In multivariate Cox
      regression analyses, African-Americans (AF) recipients with LN (vs. non-AF) had
      an increased risk of graft loss (adjusted hazard ratio [AHR], 1.39; 95%
      confidence interval [CI], 1.21-1.60) and death (AHR, 1.33; 95% CI, 1.09-1.63).
      Furthermore, there were significant associations of lower-income quintiles with
      higher risk for graft loss and death among AF with LN. In comparison, among
      non-AF recipients with LN, income levels did not predict risk for transplant
      outcomes. The racial disparity for both graft loss and death outcomes among AF
      with LN was greater than among AF without LN (AHR, 1.32; 95% CI, 1.29-1.36 for
      graft loss and AHR, 1.02; 95% CI, 0.99-1.05 for death). CONCLUSIONS: AF kidney
      transplant recipients with LN were at increased risk for graft loss and death
      compared with non-AF. Income levels were associated with the risk of graft loss
      and death in AF but not in non-AF recipients with LN.
AD  - 1 Nephrology, Walter Reed National Military Medical Center, Bethesda, MD. 2
      Department of Surgery, Walter Reed National Military Medical Center and Uniformed
      Services University of Health Sciences, Bethesda, MD. 3 Division of Rheumatology,
      Northwestern University Feinberg School of Medicine, Chicago, IL. 4 National
      Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
      Health, Bethesda, MD. 5 Address correspondence to: Rahul M. Jindal, M.D., Ph.D., 
      M.B.A., Department of Transplantation, Walter Reed National Military Medical
      Center, 8901 Wisconsin Avenue, Bethesda, MD 20889.
FAU - Nee, Robert
AU  - Nee R
FAU - Jindal, Rahul M
AU  - Jindal RM
FAU - Little, Dustin
AU  - Little D
FAU - Ramsey-Goldman, Rosalind
AU  - Ramsey-Goldman R
FAU - Agodoa, Lawrence
AU  - Agodoa L
FAU - Hurst, Frank P
AU  - Hurst FP
FAU - Abbott, Kevin C
AU  - Abbott KC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Transplantation
JT  - Transplantation
JID - 0132144
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1097/TP.0b013e318292520e [doi]
PST - aheadofprint
SO  - Transplantation. 2013 May 15.

PMID- 23680916
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 17
TI  - Prediction of mortality and macrovascular complications in type 2 diabetes:
      validation of the UKPDS Outcomes Model in the Casale Monferrato Survey, Italy.
AB  - AIMS/HYPOTHESIS: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes
      Model can be used to estimate the lifetime occurrence of major diabetes-related
      complications in order to calculate health economic outcomes. The aim of the
      study was to assess the performance of the model by comparing the predicted and
      observed mortality and the incidence of macrovascular complications in an Italian
      population-based cohort with type 2 diabetes. METHODS: We used data from the
      Casale Monferrato Survey, a cohort enrolled in 1988 and surveyed in 1991 (n =
      1,967) to assess the prevalence of cardiovascular risk factors. In 2000, a new
      survey included all the members of the original cohort who were still alive (n = 
      860), and in addition all individuals identified with a new diagnosis of type 2
      diabetes since 1993 (n = 2,389). We compared the mortality predicted by the model
      for the 1991 survey over the subsequent 17-year period with the observed risk.
      The following outcomes were analysed in the 2000 survey: myocardial infarction
      (MI), other ischaemic heart disease, stroke, congestive heart failure (CHF) and
      amputation. RESULTS: For all-cause mortality, the predictions from the model at 5
      and 10 years (23% and 47%, respectively) were identical to the observed risks. At
      15 years, the risk of death was slightly overestimated (an estimate of 67% vs 64%
      observed, 95% CI 61%, 66%). The performance of the model was best for patients
      with a recent history of disease (duration <6 years). Among the complications,
      the predicted cumulative incidences of MI and CHF were very close to those
      observed. CONCLUSIONS/INTERPRETATION: External validation is essential to assess 
      the accuracy of simulation models. The UKPDS Outcomes Model satisfactorily
      predicted a set of actual incidences of mortality and complications in an Italian
      diabetes cohort up to a duration of approximately 12 years. The longer term
      performance of such models should be carefully evaluated.
AD  - Unit of Cancer Epidemiology and CPO Piemonte, Azienda Ospedaliera Citta della
      Salute e della Scienza and University of Turin, Via Santena 7, 10126, Turin,
      Italy, evapagano@yahoo.com.
FAU - Pagano, E
AU  - Pagano E
FAU - Gray, A
AU  - Gray A
FAU - Rosato, R
AU  - Rosato R
FAU - Gruden, G
AU  - Gruden G
FAU - Perin, P Cavallo
AU  - Perin PC
FAU - Merletti, F
AU  - Merletti F
FAU - Bruno, G
AU  - Bruno G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/01/31 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s00125-013-2933-x [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 17.

PMID- 23680915
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 17
TI  - Impact of impaired insulin secretion and insulin resistance on the incidence of
      type 2 diabetes mellitus in a Japanese population: the Saku study.
AB  - AIMS/HYPOTHESIS: To assess the impact of impaired insulin secretion (IIS) and
      insulin resistance (IR) on type 2 diabetes incidence in a Japanese population.
      METHODS: This 4 year cohort study included 3,059 participants aged 30-69 without 
      diabetes at baseline who underwent comprehensive medical check-ups between April 
      2006 and March 2007 at Saku Central Hospital. Based on their insulinogenic index 
      and HOMA-IR values, participants were classified by the criteria of the Japan
      Diabetes Society into four categories: normal; isolated IIS (i-IIS); isolated IR 
      (i-IR); and IIS plus IR. They were followed up until March 2011. The incidence of
      type 2 diabetes was determined from fasting and 2 h post-load plasma glucose
      concentrations and from receiving medical treatment for diabetes. RESULTS: At
      baseline, 1,550 individuals (50.7%) were classified as normal, 900 (29.4%) i-IIS,
      505 (16.5%) i-IR, and 104 (3.4%) IIS plus IR. During 10,553 person-years of
      follow-up, 219 individuals developed type 2 diabetes, with 126 (57.5%) having
      i-IIS at baseline. Relative to the normal group, the multivariable-adjusted HRs
      for type 2 diabetes in the i-IIS, i-IR and IIS plus IR groups were 8.27 (95% CI
      5.33, 12.83), 4.90 (95% CI 2.94, 8.17) and 16.93 (95% CI 9.80, 29.25),
      respectively. The population-attributable fractions of type 2 diabetes onset due 
      to i-IIS, i-IR, and IIS plus IR were 50.6% (95% CI 46.7%, 53.0%), 14.2% (95% CI
      11.8%, 15.6%) and 12.9% (95% CI 12.3%, 13.2%), respectively.
      CONCLUSIONS/INTERPRETATION: Compared with IR, IIS had a greater impact on the
      incidence of type 2 diabetes in a Japanese population.
AD  - Department of Clinical Nursing, Shiga University of Medical Science,
      Tsukinowa-cho Seta, Otsu, Shiga, 520-2192, Japan, aki62@belle.shiga-med.ac.jp.
FAU - Morimoto, Akiko
AU  - Morimoto A
FAU - Tatsumi, Yukako
AU  - Tatsumi Y
FAU - Deura, Kijyo
AU  - Deura K
FAU - Mizuno, Shoichi
AU  - Mizuno S
FAU - Ohno, Yuko
AU  - Ohno Y
FAU - Miyamatsu, Naomi
AU  - Miyamatsu N
FAU - Watanabe, Shaw
AU  - Watanabe S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/12/30 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s00125-013-2932-y [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 17.

PMID- 23680913
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 18
TI  - Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor
      gamma (PPARgamma) agonist with potent glucose-lowering properties.
AB  - AIMS/HYPOTHESIS: The nuclear receptor peroxisome proliferator-activated receptor 
      gamma (PPARgamma) is an important gene regulator in glucose and lipid metabolism.
      Unfortunately, PPARgamma-activating drugs of the thiazolidinedione class provoke 
      adverse side effects. As recently shown, amorfrutin A1 is a natural
      glucose-lowering compound that selectively modulates PPARgamma. In this study we 
      aimed to characterise, in vitro, a large spectrum of the amorfrutins and similar 
      molecules, which we isolated from various plants. We further studied in vivo the 
      glucose-lowering effects of the so far undescribed amorfrutin B, which featured
      the most striking PPARgamma-binding and pharmacological properties of this family
      of plant metabolites. METHODS: Amorfrutins were investigated in vitro by binding 
      and cofactor recruitment assays and by transcriptional activation assays in
      primary human adipocytes and murine preosteoblasts, as well as in vivo using
      insulin-resistant high-fat-diet-fed C57BL/6 mice treated for 27 days with 100 mg 
      kg-1 day-1 amorfrutin B. RESULTS: Amorfrutin B showed low nanomolar binding
      affinity to PPARgamma, and micromolar binding to the isotypes PPARalpha and
      PPARbeta/delta. Amorfrutin B selectively modulated PPARgamma activity at low
      nanomolar concentrations. In insulin-resistant mice, amorfrutin B considerably
      improved insulin sensitivity, glucose tolerance and blood lipid variables after
      several days of treatment. Amorfrutin B treatment did not induce weight gain and 
      furthermore showed liver-protecting properties. Additionally, amorfrutins had no 
      adverse effects on osteoblastogenesis and fluid retention.
      CONCLUSIONS/INTERPRETATION: The application of plant-derived amorfrutins or
      synthetic analogues thereof constitutes a promising approach to prevent or treat 
      complex metabolic diseases such as insulin resistance or type 2 diabetes.
AD  - Otto Warburg Laboratory, Max Planck Institute for Molecular Genetics, Ihnestrasse
      63-73, 14195, Berlin, Germany.
FAU - Weidner, C
AU  - Weidner C
FAU - Wowro, S J
AU  - Wowro SJ
FAU - Freiwald, A
AU  - Freiwald A
FAU - Kawamoto, K
AU  - Kawamoto K
FAU - Witzke, A
AU  - Witzke A
FAU - Kliem, M
AU  - Kliem M
FAU - Siems, K
AU  - Siems K
FAU - Muller-Kuhrt, L
AU  - Muller-Kuhrt L
FAU - Schroeder, F C
AU  - Schroeder FC
FAU - Sauer, S
AU  - Sauer S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130518
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/11/22 [received]
PHST- 2013/03/20 [accepted]
PHST- 2013/05/18 [aheadofprint]
AID - 10.1007/s00125-013-2920-2 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 18.

PMID- 23680897
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1556-3871 (Electronic)
IS  - 1547-5271 (Linking)
DP  - 2013 May 13
TI  - Resting heart rate and risk of sudden cardiac death in the general population:
      Influence of left ventricular systolic dysfunction and heart rate-modulating
      drugs.
LID - S1547-5271(13)00517-1 [pii]
LID - 10.1016/j.hrthm.2013.05.009 [doi]
AB  - BACKGROUND: Higher levels of resting heart rate (HR) have been associated with
      sudden cardiac death (SCD) but mechanisms are poorly understood. We hypothesized 
      that severe left ventricular systolic dysfunction (LVSD) and HR-modulating drugs 
      explain the HR-SCD relationship. OBJECTIVE: To evaluate the relationship between 
      HR, severe LVSD, HR-affecting medications, and SCD in the community by using a
      case-control approach. METHODS: From the ongoing Oregon Sudden Unexpected Death
      Study, SCD cases (n = 378) aged >/=35 years and with electrocardiogram-documented
      resting HR were compared to 378 age- and gender-matched control subjects with
      coronary artery disease (mean age 68 +/- 13 years; 69% man). Associations with
      SCD were assessed by using multivariable logistic regression. RESULTS: Mean
      resting HR was significantly higher among SCD cases compared to controls (7.5
      beats/min difference; P < .0001). HR was a significant determinant of SCD after
      adjustment for significant comorbidities and medications (odds ratio for 10
      beats/min increase 1.26; 95% confidence interval 1.14-1.38; P < .0001). After
      considering LVSD, resting HR was slightly attenuated but remained significantly
      associated with SCD (P = .005). In addition to diabetes and digoxin as well as
      pulmonary and renal disease, LVSD was also independently associated with SCD
      (odds ratio 1.79; 95% confidence interval 1.11-2.87; P = .02). CONCLUSIONS:
      Contrary to expectations, the significant relationship between increased resting 
      HR and SCD persisted even after adjustment for LVSD and HR-modulating drugs.
      These findings suggest a potential role for additional novel
      interventions/therapies that modulate autonomic tone.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
FAU - Teodorescu, Carmen
AU  - Teodorescu C
FAU - Reinier, Kyndaron
AU  - Reinier K
FAU - Uy-Evanado, Audrey
AU  - Uy-Evanado A
FAU - Gunson, Karen
AU  - Gunson K
FAU - Jui, Jonathan
AU  - Jui J
FAU - Chugh, Sumeet S
AU  - Chugh SS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Heart Rhythm
JT  - Heart rhythm : the official journal of the Heart Rhythm Society
JID - 101200317
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/26 [received]
AID - S1547-5271(13)00517-1 [pii]
AID - 10.1016/j.hrthm.2013.05.009 [doi]
PST - aheadofprint
SO  - Heart Rhythm. 2013 May 13. pii: S1547-5271(13)00517-1. doi:
      10.1016/j.hrthm.2013.05.009.

PMID- 23680892
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
DP  - 2013 May 16
TI  - The 10 'Best Buys' to combat heart disease, diabetes and stroke in Africa.
FAU - Mayosi, Bongani M
AU  - Mayosi BM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
OTO - NOTNLM
OT  - Infection
OT  - Myocardial Disease
OT  - Myocardial Ischaemia and Infarction (IHD)
OT  - Pericardial Disease
OT  - Valvular Disease
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - heartjnl-2013-304130 [pii]
AID - 10.1136/heartjnl-2013-304130 [doi]
PST - aheadofprint
SO  - Heart. 2013 May 16.

PMID- 23680891
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
DP  - 2013 May 16
TI  - New insights on diabetes mellitus and obesity in Africa-Part 1: prevalence,
      pathogenesis and comorbidities.
AB  - Evidence continues to accumulate on the rising burden of diabetes mellitus at a
      higher pace in Africa. In a series of two papers, we sought to summarise recent
      evidence on diabetes and obesity in Africa based on a systematic review of
      studies published between January 2002 and October 2012. This first paper on the 
      prevalence, pathogenesis and comorbidities shows that the increase in diabetes
      prevalence has paralleled that of obesity in Africa. Recent surveys on diabetes
      and obesity have been largely suboptimal. Hence, the need for more representative
      and robust continent-wide prevalence figures, which may be somehow achieved
      through pooling of existing data. Prospective studies linking environmental risk 
      factors to disease occurrence and outcomes remain scarce, and genetic factors for
      diabetes or obesity have not been extensively assessed. The health consequences
      of diabetes are manifold, and include a complex interaction with other conditions
      like HIV infection and sickle cell disease/trait.
AD  - University of Cape Town and South African Medical Research Council, , Cape Town, 
      South Africa.
FAU - Kengne, Andre Pascal
AU  - Kengne AP
FAU - Echouffo-Tcheugui, Justin-Basile
AU  - Echouffo-Tcheugui JB
FAU - Sobngwi, Eugene
AU  - Sobngwi E
FAU - Mbanya, Jean-Claude
AU  - Mbanya JC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
OTO - NOTNLM
OT  - Metabolic medicine
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - heartjnl-2012-303316 [pii]
AID - 10.1136/heartjnl-2012-303316 [doi]
PST - aheadofprint
SO  - Heart. 2013 May 16.

PMID- 23680890
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
DP  - 2013 May 16
TI  - New insights on diabetes mellitus and obesity in Africa-Part 2: prevention,
      screening and economic burden.
AB  - Evidence has been accumulating on the importance of the rising burden of diabetes
      mellitus on the African continent at an increasingly higher pace. In the first
      paper of this series of two companion papers, recent evidence on the prevalence, 
      pathogenesis and comorbidities of obesity and diabetes mellitus in Africa were
      summarised. In this second paper, we focus on recent developments pertaining to
      the prevention, screening and the economic burden of diabetes and obesity on the 
      continent. There are indications that awareness on diabetes and chronic diseases 
      at large has increased in Africa in recent times. However, the care for diabetes 
      largely remains suboptimal in most countries, which are not adequately prepared
      to face the prevention and control of diabetes, as the costs of caring for the
      condition pose a tremendous challenge to most local economies. Moreover,
      translation strategies to prevent and control diabetes and obesity, on the
      continent, are still to be evaluated.
AD  - University of Cape Town and South African Medical Research Council, , Cape Town, 
      South Africa.
FAU - Kengne, Andre Pascal
AU  - Kengne AP
FAU - Sobngwi, Eugene
AU  - Sobngwi E
FAU - Echouffo-Tcheugui, Justin-Basile
AU  - Echouffo-Tcheugui JB
FAU - Mbanya, Jean-Claude
AU  - Mbanya JC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
OTO - NOTNLM
OT  - Metabolic medicine
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - heartjnl-2013-303773 [pii]
AID - 10.1136/heartjnl-2013-303773 [doi]
PST - aheadofprint
SO  - Heart. 2013 May 16.

PMID- 23680809
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1535-2811 (Electronic)
IS  - 1535-2811 (Linking)
VI  - 12
IP  - 2
DP  - 2013 Jun
TI  - The "Rule of Halves" Does Not Apply in Peru: Awareness, Treatment, and Control of
      Hypertension and Diabetes in Rural, Urban, and Rural-to-Urban Migrants.
PG  - 53-58
AB  - OBJECTIVE:: To determine the awareness, treatment, and control of hypertension
      and diabetes by migration status. DESIGN:: Cross-sectional study, secondary
      analyses of the PERU MIGRANT study. PATIENTS:: Rural, rural-to-urban migrants,
      and urban participants. MAIN OUTCOME MEASURES:: Awareness, treatment, and control
      of hypertension and diabetes mellitus were calculated using weights to account
      for participant's group size. RESULTS:: Of 205 of the 987 (weighted prevalence
      24.1%, 95% confidence interval: 21.1%-27.1%) participants identified as
      hypertensive, 48.3% were aware of their diagnosis, 40% of them were receiving
      treatment, and 30.4% of those receiving treatment were controlled. Diabetes was
      present in 33 of the 987 (weighted prevalence 4.6%, 95% confidence interval:
      3.1%-6%), and diabetes awareness, treatment, and control were 71.1%, 40.6%, and
      7.7%, respectively. Suboptimal control rates, defined as those not meeting blood 
      pressure or glycaemia targets among those with the condition, were 95.1% for
      hypertension and 97% for diabetes. Higher awareness, treatment, and control
      rates, for both hypertension and diabetes, were observed in rural-to-urban
      migrants and urban participants compared with rural participants. However,
      treatment rates were much lower among migrants compared with the urban group.
      CONCLUSIONS:: These results identify major unmet needs in awareness, treatment,
      and control of hypertension and diabetes. Particular challenges are lack of
      awareness of both hypertension and diabetes in rural areas, and poor levels of
      treatment and control among people who have migrated from rural into urban areas.
AD  - From the *CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana 
      Cayetano Heredia, Lima, Peru; daggerVanderbilt Institute for Global Health,
      Vanderbilt University, Nashville, TN; double daggerEpidemiology Unit, School of
      Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima,
      Peru; section signDepartment of International Health, Johns Hopkins Bloomberg
      School of Public Health, Baltimore, MD; paragraph signArea de Investigacion y
      Desarrollo, A.B. PRISMA, Lima, Peru; ||Faculty of Epidemiology and Population
      Health, London School of Hygiene and Tropical Medicine, London, United Kingdom;
      and **Department of Medicine, School of Medicine, Universidad Peruana Cayetano
      Heredia, Lima, Peru.
FAU - Lerner, Alana G
AU  - Lerner AG
FAU - Bernabe-Ortiz, Antonio
AU  - Bernabe-Ortiz A
FAU - Gilman, Robert H
AU  - Gilman RH
FAU - Smeeth, Liam
AU  - Smeeth L
FAU - Miranda, J Jaime
AU  - Miranda JJ
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - Crit Pathw Cardiol
JT  - Critical pathways in cardiology
JID - 101165286
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1097/HPC.0b013e318285ef60 [doi]
AID - 00132577-201306000-00005 [pii]
PST - ppublish
SO  - Crit Pathw Cardiol. 2013 Jun;12(2):53-58.

PMID- 23680756
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1531-7021 (Electronic)
IS  - 1040-8738 (Linking)
VI  - 24
IP  - 4
DP  - 2013 Jul
TI  - Hormones and dry eye syndrome: an update on what we do and don't know.
PG  - 348-55
LID - 10.1097/ICU.0b013e32836227bf [doi]
AB  - PURPOSE OF REVIEW: Dry eye syndrome (DES) prevalence is large and its
      relationship with hormonal diseases is becoming clearer, although more complex.
      This review provides insight to this association as well as clarifying what
      remains unanswered about how to interpret and treat findings common to both DES
      and hormonal diseases. RECENT FINDINGS: Several sex hormone-related diseases are 
      associated with DES. Hormone replacement therapy to correct such conditions has
      conflicting outcomes based on epidemiologic studies and clinical trials.
      Thyroid-associated diseases are frequently involved in DES and must be
      investigated in cases where the cause of the ocular disease is undetermined.
      Diabetes mellitus is one of the major causes of DES, whereas correcting the
      metabolic imbalance minimizes its ocular symptomology. Gene therapy to treat
      DES-related hormonal diseases is a promising option based on animal studies.
      SUMMARY: Diagnosis and management of hormonal diseases can minimize the ocular
      surface damage and severity of DES. Clinical care of DES includes patient
      evaluation of hormonal status. Future research requires clarification of the
      underlying disease mechanisms and identifying novel strategies to reprogram the
      endocrine system rather than chronic medication usage.
AD  - aUniversity of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil bIRCCS Fondazione GB 
      Bietti cDepartment of Ophthalmology, University of Rome, Rome, Italy.
FAU - Rocha, Eduardo Melani
AU  - Rocha EM
FAU - Mantelli, Flavio
AU  - Mantelli F
FAU - Nominato, Luis Fernando
AU  - Nominato LF
FAU - Bonini, Stefano
AU  - Bonini S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Opin Ophthalmol
JT  - Current opinion in ophthalmology
JID - 9011108
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1097/ICU.0b013e32836227bf [doi]
PST - ppublish
SO  - Curr Opin Ophthalmol. 2013 Jul;24(4):348-55. doi: 10.1097/ICU.0b013e32836227bf.

PMID- 23680744
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 2154-8331 (Print)
IS  - 2154-8331 (Linking)
VI  - 41
IP  - 2
DP  - 2013 Apr
TI  - Pleiotropic effects of thiazolidinediones: implications for the treatment of
      patients with type 2 diabetes mellitus.
PG  - 132-47
LID - 10.3810/hp.2013.04.1062 [doi]
AB  - Thiazolidinediones (TZDs) are insulin-sensitizing antidiabetes agents that act
      through the peroxisome proliferator-activated receptor-gamma to cause a durable
      improvement in glycemic control in patients with type 2 diabetes mellitus.
      Although less well recognized, TZDs also exert a protective effect on beta-cell
      function. In addition to their beneficial effects on glucose homeostasis,
      TZDs-especially pioglitazone-exert a number of other pleiotropic effects that
      make them ideal agents as monotherapy or in combination with other oral agents,
      glucagon-like peptide-1 analogs, or insulin. Pioglitazone improves endothelial
      dysfunction, reduces blood pressure, corrects diabetic dyslipidemia, and reduces 
      circulating levels of inflammatory cytokines and prothrombotic factors.
      Pioglitazone also redistributes fat and toxic lipid metabolites in muscle, liver,
      beta cells, and arteries, and deposits the fat in subcutaneous adipocytes where
      it cannot exert its lipotoxic effects. Consistent with these antiatherogenic
      effects, pioglitazone reduced major adverse cardiac event endpoints (ie,
      mortality, myocardial infarction, and stroke) in the Prospective Pioglitazone
      Clinical Trial in Macrovascular Events and in a meta-analysis of all other
      published pioglitazone trials. Pioglitazone also mobilizes fat out of the liver, 
      improving liver function and histologic abnormalities in patients with
      nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Pioglitazone
      also reduces proteinuria, all-cause mortality, and cardiovascular events in
      patients with type 2 diabetes mellitus with a reduced glomerular filtration rate.
      These benefits must be weighed against the side effects of the drug, including
      weight gain, fluid retention, atypical fractures, and, possibly, bladder cancer. 
      When low doses of pioglitazone are used (eg, 7.5-30 mg/d) with gradual titration,
      and physician recognition of the potential side effects are applied, the
      risk-to-benefit ratio is very favorable. Despite having similar effects on
      glycemic control, pioglitazone and rosiglitazone appear to have different effects
      on cardiovascular outcomes. Rosiglitazone has been associated with an increased
      risk of myocardial infarction, and its use in the United States is restricted
      because of cardiovascular safety concerns.
AD  - 1Diabetes Division, The University of Texas Health Science Center, San Antonio,
      TX. albarado@uthscsa.edu.
FAU - Defronzo, Ralph A
AU  - Defronzo RA
FAU - Mehta, Rucha J
AU  - Mehta RJ
FAU - Schnure, Joel J
AU  - Schnure JJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hosp Pract (1995)
JT  - Hospital practice (1995)
JID - 101268948
SB  - AIM
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.3810/hp.2013.04.1062 [doi]
PST - ppublish
SO  - Hosp Pract (1995). 2013 Apr;41(2):132-47. doi: 10.3810/hp.2013.04.1062.

PMID- 23680741
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 2154-8331 (Print)
IS  - 2154-8331 (Linking)
VI  - 41
IP  - 2
DP  - 2013 Apr
TI  - Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2
      Diabetes Mellitus: What Is the Evidence?
PG  - 93-107
LID - 10.3810/hp.2013.04.1059 [doi]
AB  - As type 2 diabetes mellitus (T2DM) progresses, most patients will require insulin
      replacement therapy. Whether oral antidiabetic drug (OAD) therapy should be
      retained when initiating insulin is still debated. While the rationale to keep
      metformin with insulin is strong (mostly as an insulin-sparing agent to limit
      weight gain), the evidence is less clear for other OADs. In particular, the
      question now comes up what the expected benefit could be of combining the newer
      agents, such as the dipeptidyl peptidase-4 (DPP-4) inhibitors with insulin.
      Additionally, when metformin is no longer a treatment option, as in the case of
      patients with severe renal impairment, insulin is often used as monotherapy, with
      little evidence of benefit in maintaining other OADs. In this specific situation,
      it is also of interest to evaluate the potential benefit of combined treatment
      with a DPP-4 inhibitor and insulin. Among the classic limitations of insulin
      therapy in patients with T2DM, hypoglycemia remains a major barrier to glycemic
      control, along with weight gain exacerbation. The oral DPP-4 inhibitors improve
      glycemic control by increasing the sensitivity of the islet cells to glucose, and
      thus are not associated with an increased risk for hypoglycemia and are weight
      neutral. In addition to the expected benefits associated with limiting insulin
      dose and regimen complexity, the specific advantages the DPP-4 inhibitor drug
      class on hypoglycemia and weight gain could justify combining DPP-4 inhibitors
      with insulin; additionally, a DPP-4 inhibitor may be of special value to decrease
      glycemic excursions that are not properly addressed by basal insulin therapy and 
      metformin use, even after optimizing titration of the basal insulin. However,
      given the common original perception that treatment with DPP-4 inhibitors may be 
      less beneficial with increasing disease progression because of the loss of
      beta-cell function, the potential relevance of these agents in the setting of
      advanced T2DM treated with insulin was not necessarily anticipated. Promising
      data from studies on the use of these new agents in insulin-treated patients with
      T2DM have started to emerge. Our article provides a comprehensive overview of the
      currently available evidence from controlled randomized clinical trials and we
      discuss the potential role of DPP-4 inhibitors in the this setting. Further
      clinical experience will allow to fully assess the positioning of these agents in
      insulin-treated T2DM populations.
AD  - Department of Endocrinology, University of Nantes, Hopital Laennec, Nantes,
      France.
FAU - Charbonnel, Bernard
AU  - Charbonnel B
FAU - Schweizer, Anja
AU  - Schweizer A
FAU - Dejager, Sylvie
AU  - Dejager S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hosp Pract (1995)
JT  - Hospital practice (1995)
JID - 101268948
SB  - AIM
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.3810/hp.2013.04.1059 [doi]
PST - ppublish
SO  - Hosp Pract (1995). 2013 Apr;41(2):93-107. doi: 10.3810/hp.2013.04.1059.

PMID- 23680739
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 2154-8331 (Print)
IS  - 2154-8331 (Linking)
VI  - 41
IP  - 2
DP  - 2013 Apr
TI  - Efficacy and safety of canagliflozin treatment in older subjects with type 2
      diabetes mellitus: a randomized trial.
PG  - 72-84
LID - 10.3810/hp.2013.04.1020 [doi]
AB  - Introduction: Canagliflozin is a sodium glucose co-transporter 2 inhibitor
      developed for the treatment of patients with type 2 diabetes mellitus (T2DM). Our
      randomized, double-blind, placebo-controlled, phase 3 study
      (www.clinicaltrials.gov: NCT01106651) evaluated the efficacy and safety of
      canagliflozin therapy in older subjects (aged 55-80 years) with T2DM inadequately
      controlled on their current regimen of blood glucose-lowering agents (any
      approved oral or injectable treatment). Methods: Subjects (N = 716) aged 55 to 80
      years (mean, 63.6 years) with glycated hemoglobin (HbA1c) levels >/= 7.0% to </= 
      10.0% were randomized. Seven hundred fourteen received canagliflozin 100 mg or
      300 mg or placebo (1:1:1) daily. The prespecified primary endpoint was change
      from baseline in HbA1c level at week 26. Prespecified secondary endpoints
      included proportion of subjects achieving HbA1c levels < 7.0%, change from
      baseline in fasting plasma glucose (FPG) level and systolic blood pressure (BP), 
      and percent change from baseline in body weight, triglyceride levels, and
      high-density lipoprotein cholesterol (HDL-C) level. Adverse events (AEs) were
      reported throughout the study. Results: At week 26, treatment with canagliflozin 
      100 mg and 300 mg significantly reduced HbA1c levels compared with placebo
      (-0.60%, -0.73%, -0.03%, respectively; P < 0.001); more subjects achieved HbA1c
      levels < 7.0% with both canagliflozin doses compared with placebo (P < 0.001).
      Both canagliflozin doses significantly reduced body weight, FPG level, and
      systolic BP, and increased HDL-C level compared with placebo (P < 0.001);
      low-density lipoprotein cholesterol level was increased with both canagliflozin
      doses compared with placebo. The overall AE incidence was slightly higher with
      canagliflozin 300 mg than with canagliflozin 100 mg or placebo (78.0%, 72.2%,
      73.4%, respectively). Serious AE and AE-related discontinuation rates were low
      across groups. Both canagliflozin doses were associated with higher rates than
      placebo of genital mycotic infections, urinary tract infections, and osmotic
      diuresis-related AEs (ie, pollakiuria, polyuria). Documented hypoglycemia rates
      were modestly higher with both canagliflozin doses compared with placebo.
      Conclusion: Canagliflozin improved glycemic control, reduced body weight and
      systolic BP, and was generally well tolerated in older subjects with T2DM who
      were on background therapy with a variety of blood glucose-lowering agents.
AD  - Atlanta Diabetes Associates, Atlanta, GA. bbode001@aol.com.
FAU - Bode, Bruce
AU  - Bode B
FAU - Stenlof, Kaj
AU  - Stenlof K
FAU - Sullivan, Daniel
AU  - Sullivan D
FAU - Fung, Albert
AU  - Fung A
FAU - Usiskin, Keith
AU  - Usiskin K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hosp Pract (1995)
JT  - Hospital practice (1995)
JID - 101268948
SB  - AIM
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.3810/hp.2013.04.1020 [doi]
PST - ppublish
SO  - Hosp Pract (1995). 2013 Apr;41(2):72-84. doi: 10.3810/hp.2013.04.1020.

PMID- 23680736
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 2154-8331 (Print)
IS  - 2154-8331 (Linking)
VI  - 41
IP  - 2
DP  - 2013 Apr
TI  - Practical approach to management of inpatient hyperglycemia in select patient
      populations.
PG  - 45-53
LID - 10.3810/hp.2013.04.1025 [doi]
AB  - Hospitalized patients frequently transition between various levels of care and
      changing clinical situations. Optimal management of hospitalized patients with
      hyperglycemia includes awareness of situations that may significantly affect
      glucose and/or insulin metabolism. A review of published clinical trials reveals 
      practical approaches to the management of hyperglycemia in select patient
      populations that may prove useful for the hospital clinician. We outline
      approaches to the management of hyperglycemia in hospitalized patients receiving 
      glucocorticoids, patients with severe or end-stage renal disease undergoing hemo-
      or peritoneal dialysis, and patients receiving total parenteral or enteral
      feeding, in addition to patients transitioning from intravenous insulin infusion 
      to subcutaneously administered insulin. Key considerations underlying these
      management methods include a proactive approach, frequent blood glucose
      monitoring, daily review of blood glucose patterns, and daily reassessment of the
      insulin regimen and associated orders.
AD  - Department of Medicine, Division of Endocrinology, Metabolism and Diabetes,
      University of Colorado School of Medicine, Aurora, CO. cecilia.wang@UCDenver.edu.
FAU - Low Wang, Cecilia C
AU  - Low Wang CC
FAU - Draznin, Boris
AU  - Draznin B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Hosp Pract (1995)
JT  - Hospital practice (1995)
JID - 101268948
SB  - AIM
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.3810/hp.2013.04.1025 [doi]
PST - ppublish
SO  - Hosp Pract (1995). 2013 Apr;41(2):45-53. doi: 10.3810/hp.2013.04.1025.

PMID- 23680701
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1873-7528 (Electronic)
IS  - 0149-7634 (Linking)
DP  - 2013 May 13
TI  - Effects of diabetes on hippocampal neurogenesis: Links to cognition and
      depression.
LID - S0149-7634(13)00070-5 [pii]
LID - 10.1016/j.neubiorev.2013.03.010 [doi]
AB  - Diabetes often leads to a number of complications involving brain function,
      including cognitive decline and depression. In addition, depression is a risk
      factor for developing diabetes. A loss of hippocampal neuroplasticity, which
      impairs the ability of the brain to adapt and reorganize key behavioral and
      emotional functions, provides a framework for understanding this reciprocal
      relationship. The effects of diabetes on brain and behavioral functions in
      experimental models of type 1 and type 2 diabetes are reviewed, with a focus on
      the negative impact of impaired hippocampal neurogenesis, dendritic remodeling
      and increased apoptosis. Mechanisms shown to regulate neuroplasticity and
      behavior in diabetes models, including stress hormones, neurotransmitters,
      neurotrophins, inflammation and aging, are integrated within this framework.
      Pathological changes in hippocampal function can contribute to the brain symptoms
      of diabetes-associated complications by failing to regulate the
      hypothalamic-pituitary-axis, maintain learning and memory and govern emotional
      expression. Further characterization of alterations in neuroplasticity along with
      glycemic control will facilitate the development and evaluation of
      pharmacological interventions that could successfully prevent and/or reverse the 
      detrimental effects of diabetes on brain and behavior.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia,
      PA 19104, USA.
FAU - Ho, Nancy
AU  - Ho N
FAU - Sommers, Marilyn S
AU  - Sommers MS
FAU - Lucki, Irwin
AU  - Lucki I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/08/06 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/03/14 [accepted]
AID - S0149-7634(13)00070-5 [pii]
AID - 10.1016/j.neubiorev.2013.03.010 [doi]
PST - aheadofprint
SO  - Neurosci Biobehav Rev. 2013 May 13. pii: S0149-7634(13)00070-5. doi:
      10.1016/j.neubiorev.2013.03.010.

PMID- 23680671
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1878-5875 (Electronic)
IS  - 1357-2725 (Linking)
DP  - 2013 May 13
TI  - The orphan nuclear receptor small heterodimer partner negatively regulates
      pancreatic beta cell survival and hyperglycemia in multiple low-dose
      streptozotocin-induced type 1 diabetic mice.
LID - S1357-2725(13)00141-6 [pii]
LID - 10.1016/j.biocel.2013.05.004 [doi]
AB  - The small heterodimer partner (SHP; NR0B2) regulates the transcription of a
      variety of target genes and controls a variety of physiological functions in
      various tissues. However, the role of SHP in beta cell has not been fully
      determined yet. We used SHP knockout (SHP KO) mice to investigate the role of SHP
      in multiple low-dose streptozotocin (MLDS)-induced diabetes. Blood glucose and
      insulin levels were measured until 20 days, and intraperitoneal glucose tolerance
      and glucose-stimulated insulin secretion tests were performed. The expression of 
      apoptotic genes and beta cell markers were detected by quantitative
      realtime-polymerase chain reaction, immunostaining and western blot analysis. SHP
      KO mice showed significantly lower blood glucose, higher insulin levels, and
      enhanced glucose tolerance compared with wild type (WT) mice after MLDS
      treatment. Moreover, beta cell mass and pancreatic insulin content were
      remarkably increased in SHP KO mice. In the response to glucose stimulation,
      islets of SHP KO showed increased insulin secretion via up-regulation of beta
      cell enriched transcription factors compared to WT mice after streptozotocin
      (STZ) treatment. In quantification for beta cell apoptosis at day 1 post STZ
      treatment, the SHP KO mice showed significantly increased anti-apoptotic gene
      expression and decreased release of apoptotic markers cytochrome c, smac/diablo, 
      and only a few apoptotic beta cells were found in SHP KO pancreas through
      inactivation of caspase-3, compared to those of WT. These data demonstrate that
      SHP deficiency ameliorates hyperglycemia and preserves islet function by
      inhibiting apoptosis of pancreatic beta cells and up-regulating of their enriched
      transcriptional factors.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Laboratory Animal Center, Korea Research Institute of Bioscience and
      Biotechnology, University of Science and Technology, Daejeon 305-806, Republic of
      Korea.
FAU - Noh, Jung-Ran
AU  - Noh JR
FAU - Hwang, Jung Hwan
AU  - Hwang JH
FAU - Kim, Yong-Hoon
AU  - Kim YH
FAU - Kim, Kyoung-Shim
AU  - Kim KS
FAU - Gang, Gil-Tae
AU  - Gang GT
FAU - Kim, Sang-Woo
AU  - Kim SW
FAU - Kim, Don-Kyu
AU  - Kim DK
FAU - Shong, Minho
AU  - Shong M
FAU - Lee, In-Kyu
AU  - Lee IK
FAU - Choi, Hueng-Sik
AU  - Choi HS
FAU - Lee, Chul-Ho
AU  - Lee CH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Int J Biochem Cell Biol
JT  - The international journal of biochemistry & cell biology
JID - 9508482
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/27 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/06 [accepted]
AID - S1357-2725(13)00141-6 [pii]
AID - 10.1016/j.biocel.2013.05.004 [doi]
PST - aheadofprint
SO  - Int J Biochem Cell Biol. 2013 May 13. pii: S1357-2725(13)00141-6. doi:
      10.1016/j.biocel.2013.05.004.

PMID- 23680665
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 435
IP  - 3
DP  - 2013 Jun 7
TI  - Neuronal nitric oxide synthase is phosphorylated in response to insulin
      stimulation in skeletal muscle.
PG  - 501-5
LID - 10.1016/j.bbrc.2013.05.020 [doi]
LID - S0006-291X(13)00790-0 [pii]
AB  - Type 2 Diabetes (T2DM) is the seventh leading cause of death in the United
      States, and is quickly becoming a global pandemic. T2DM results from reduced
      insulin sensitivity coupled with a relative failure of insulin secretion. Reduced
      insulin sensitivity has been associated with reduced nitric oxide synthase (NOS) 
      activity and impaired glucose uptake in T2DM skeletal muscle. Upon insulin
      stimulation, NO synthesis increases in normal adult skeletal muscle, whereas no
      such increase is observed in T2DM adults. Endothelial NOS is activated by
      phosphorylation in the C-terminal tail in response to insulin. Neuronal NOS
      (nNOS), the primary NOS isoform in skeletal muscle, contains a homologous
      phosphorylation site, raising the possibility that nNOS, too, may undergo an
      activating phosphorylation event upon insulin treatment. Yet it remains unknown
      if or how nNOS is regulated by insulin in skeletal muscle. Data shown herein
      indicate that nNOS is phosphorylated in response to insulin in skeletal muscle
      and that this phosphorylation event occurs rapidly in C2C12 myotubes, resulting
      in increased NO production. In vivo phosphorylation of nNOS was also observed in 
      response to insulin in mouse skeletal muscle. These results indicate, for the
      first time, that nNOS is phosphorylated in skeletal muscle in response to insulin
      and in association with increased NO production.
CI  - Published by Elsevier Inc.
AD  - Department of Biochemistry, The University of Texas Health Science Center at San 
      Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78229-7760, USA.
FAU - Hinchee-Rodriguez, Kathryn
AU  - Hinchee-Rodriguez K
FAU - Garg, Neha
AU  - Garg N
FAU - Venkatakrishnan, Priya
AU  - Venkatakrishnan P
FAU - Roman, Madeline G
AU  - Roman MG
FAU - Adamo, Martin L
AU  - Adamo ML
FAU - Masters, Bettie Sue
AU  - Masters BS
FAU - Roman, Linda J
AU  - Roman LJ
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/04/30 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - S0006-291X(13)00790-0 [pii]
AID - 10.1016/j.bbrc.2013.05.020 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2013 Jun 7;435(3):501-5. doi:
      10.1016/j.bbrc.2013.05.020. Epub 2013 May 14.

PMID- 23680515
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 13
TI  - Neural melanocortin receptors in obesity and related metabolic disorders.
LID - S0925-4439(13)00158-0 [pii]
LID - 10.1016/j.bbadis.2013.05.004 [doi]
AB  - Obesity is a global health issue, as it is associated with increased risk of
      developing chronic conditions associated with disorders of metabolism such as
      type 2 diabetes and cardiovascular disease. A better understanding of how
      excessive fat accumulation develops and causes diseases of the metabolic syndrome
      is urgently needed. The hypothalamic melanocortin system is an important point of
      convergence connecting signals of metabolic status with the neural circuitry that
      governs appetite and the autonomic and neuroendocrine system controling
      metabolism. This system has a critical role in the defense of body weight and
      maintenance of homeostasis. Two neural melanocortin receptors, melanocortin 3 and
      4 receptors (MC3R and MC4R), play crucial roles in the regulation of energy
      balance. Mutations in the MC4R gene are the most common cause of monogenic
      obesity in humans, and a large literature indicates a role in regulating both
      energy intake through the control of satiety and energy expenditure. In contrast,
      MC3Rs have a more subtle role in energy homeostasis. Results from our lab
      indicate an important role for MC3Rs in synchronizing rhythms in foraging
      behavior with caloric cues and maintaining metabolic homeostasis during periods
      of nutrient scarcity. However, while deletion of the Mc3r gene in mice alters
      nutrient partitioning to favor accumulation of fat mass no obvious role for MC3R 
      haploinsufficiency in human obesity has been reported. This article is part of a 
      Special Issue entitled: Modulation of Adipose Tissue in Health and Disease.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Metabolism and Aging, The Scripps Research Institute, 130 Scripps
      Way, Jupiter, FL 33458, USA.
FAU - Girardet, Clemence
AU  - Girardet C
FAU - Butler, Andrew A
AU  - Butler AA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/01 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/05/03 [accepted]
AID - S0925-4439(13)00158-0 [pii]
AID - 10.1016/j.bbadis.2013.05.004 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 13. pii: S0925-4439(13)00158-0. doi:
      10.1016/j.bbadis.2013.05.004.

PMID- 23680469
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
DP  - 2013 Apr 10
TI  - Increased levels of CD34+ cells are associated in patients with abdominal aortic 
      aneurysms compared with patients with peripheral vascular disease.
LID - S0022-4804(13)00289-8 [pii]
LID - 10.1016/j.jss.2013.03.070 [doi]
AB  - BACKGROUND: Circulating progenitor cells are integral to vascular health and
      effectively predict vascular reactivity. CD34 is a known marker of circulating
      progenitor cells. Few studies have examined the role of CD34+ cells in abdominal 
      aortic aneurysm (AAA) disease and peripheral vascular disease (PVD). The aim of
      this study was to compare the percentage of CD34+ cells between patients with AAA
      versus PVD. MATERIALS AND METHODS: We collected peripheral whole blood from AAA
      or PVD patients. The blood was stained with fluorescently labeled antibodies
      against CD34 or isotype controls. We collected data using a flow cytometer and
      analyzed them. We also recorded risk factors such as hypertension, diabetes,
      total cholesterol, serum white blood cells, serum creatinine, body mass index,
      blood pressure, statin use, current smoking status, coronary artery disease,
      cerebral vascular accident, and chronic obstructive pulmonary disease. RESULTS:
      We enrolled 24 patients in this study (AAA, n = 12; PVD, n = 12). The AAA
      patients had a greater percentage of CD34+ cells compared with PVD patients. (r =
      0.84; P = 0.016). There were no significant risk factors differences between AAA 
      and PVD patients. CONCLUSIONS: Based on CD34+ cell counts, AAA is a less severe
      vascular disease than PVD. Whether CD34+ cells can serve as a biomarker for risk 
      stratification or a potential therapy warrants further study.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, Sacramento VA Medical Center, Mather, California.
FAU - Van Spyk, Elyse N
AU  - Van Spyk EN
FAU - Chun, Kevin C
AU  - Chun KC
FAU - Samadzadeh, Kiana M
AU  - Samadzadeh KM
FAU - Peters, John H
AU  - Peters JH
FAU - Lee, Eugene S
AU  - Lee ES
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130410
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/01/11 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/20 [accepted]
AID - S0022-4804(13)00289-8 [pii]
AID - 10.1016/j.jss.2013.03.070 [doi]
PST - aheadofprint
SO  - J Surg Res. 2013 Apr 10. pii: S0022-4804(13)00289-8. doi:
      10.1016/j.jss.2013.03.070.

PMID- 23680413
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1527-3288 (Electronic)
IS  - 0147-9563 (Linking)
DP  - 2013 May 14
TI  - Pulmonary nocardiosis in an immunocompetent patient with COPD: The role of
      defective innate response.
LID - S0147-9563(13)00117-9 [pii]
LID - 10.1016/j.hrtlng.2013.03.007 [doi]
AB  - OBJECTIVES: Pulmonary nocardiosis is an uncommon opportunistic infection
      affecting mainly immunocompromised patients. We herein present a case of
      nocardiosis without profound underlying immunodeficiency. BACKGROUND: A female,
      84-years' old patient with stage IV chronic obstructive pulmonary disease (COPD) 
      is presented. No profound causes of immunodeficiency existed, such as HIV
      infection, diabetes mellitus, malignancy, alcoholism, chemotherapy or previous
      corticosteroid intake. The patient recovered after treatment with
      trimethoprim/sulfamethoxazole for 6 months. RESULTS: One year after infection
      resolution, stimulation of the patient's blood monocytes with Nocardia antigens
      revealed defective production of tumor necrosis factor-alpha, interleukin (IL)-6 
      and IL-17. CONCLUSION: We provide preliminary evidence for a link between
      defective innate immune responses and predisposition for Nocardia infections.
      Further studies must be conducted in order to fully investigate this mechanism of
      infection acquisition.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - 2nd Department of Critical Care Medicine, Medical School, National and
      Kapodistrian University of Athens, "Attikon" General Hospital, 1 Rimini st.,
      Haidari, Athens 12462, Greece. Electronic address: Kontoloi@otenet.gr.
FAU - Kontogiorgi, Marina
AU  - Kontogiorgi M
FAU - Opsimoulis, Panagiotis
AU  - Opsimoulis P
FAU - Kopterides, Petros
AU  - Kopterides P
FAU - Savva, Athina
AU  - Savva A
FAU - Kalodimou, Vasiliki E
AU  - Kalodimou VE
FAU - Belesiotou, Elina
AU  - Belesiotou E
FAU - Giamarellos-Bourboulis, Evangelos
AU  - Giamarellos-Bourboulis E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Heart Lung
JT  - Heart & lung : the journal of critical care
JID - 0330057
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/01/04 [received]
PHST- 2013/03/29 [revised]
PHST- 2013/03/29 [accepted]
AID - S0147-9563(13)00117-9 [pii]
AID - 10.1016/j.hrtlng.2013.03.007 [doi]
PST - aheadofprint
SO  - Heart Lung. 2013 May 14. pii: S0147-9563(13)00117-9. doi:
      10.1016/j.hrtlng.2013.03.007.

PMID- 23680377
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
DP  - 2013 May 13
TI  - Renal GLUT1 reduction depends on angiotensin-converting enzyme inhibition in
      diabetic hypertensive rats.
LID - S0024-3205(13)00265-8 [pii]
LID - 10.1016/j.lfs.2013.05.001 [doi]
AB  - AIMS: Angiotensin-converting enzyme (ACE) inhibitors are used in diabetic kidney 
      disease to reduce systemic/intra-glomerular pressure. The objective of this study
      was to investigate whether reducing blood pressure (BP) could modulate renal
      glucose transporter expression, and urinary markers of diabetic nephropathy in
      diabetic hypertensive rats treated with ramipril or amlodipine. MAIN METHODS:
      Diabetes was induced in spontaneously-hypertensive rats (~210g) by streptozotocin
      (50mg/kg). Thirty days later, animals received ramipril 15mug/kg/day (R, n=10),
      or amlodipine 10mg/kg/day (A, n=8,) or water (C, n=10) by gavage. After 30-day
      treatment, body weight, glycaemia, urinary albumin and TGF-beta1 (enzyme-linked
      immunosorbent assay) and BP (tail-cuff pressure method) were evaluated. Kidneys
      were removed for evaluation of renal cortex glucose transporters (Western
      blotting) and renal tissue ACE activity (fluorometric assay). KEY FINDINGS: After
      treatments, body weight (p=0.77) and glycaemia (p=0.22) were similar among the
      groups. Systolic BP was similarly reduced (p<0.001) in A and R vs. C
      (172.4+/-3.2; 186.7+/-3.7 and 202.2+/-4.3mmHg; respectively). ACE activity (C:
      0.903+/-0.086; A: 0.654+/-0.025, and R: 0.389+/-0.057mU/mg), albuminuria (C:
      264.8+/-15.4; A: 140.8+/-13.5 and R: 102.8+/-6.7mg/24h), and renal cortex GLUT1
      content (C: 46.81+/-4.54; A: 40.30+/-5.39 and R: 26.89+/-0.79AU) decreased only
      in R (p<0.001, p<0.05 and p<0.001; respectively). SIGNIFICANCE: We concluded that
      the blockade of the renin-angiotensin system with ramipril reduced early markers 
      of diabetic nephropathy, a phenomenon that cannot be specifically related to
      decreased BP levels.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Instituto de Cardiologia do Rio Grande do Sul/Fundacao Universitaria de
      Cardiologia (IC/FUC), Porto Alegre, RS, Brazil.
FAU - da Silva, Ariel S
AU  - da Silva AS
FAU - Dias, Lucinara D
AU  - Dias LD
FAU - Borges, Julia F
AU  - Borges JF
FAU - Markoski, Melissa M
AU  - Markoski MM
FAU - de Souza, Martina S
AU  - de Souza MS
FAU - Irigoyen, Maria C
AU  - Irigoyen MC
FAU - Machado, Ubiratan F
AU  - Machado UF
FAU - Schaan, Beatriz D
AU  - Schaan BD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Life Sci
JT  - Life sciences
JID - 0375521
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/02/02 [received]
PHST- 2013/04/15 [revised]
PHST- 2013/05/01 [accepted]
AID - S0024-3205(13)00265-8 [pii]
AID - 10.1016/j.lfs.2013.05.001 [doi]
PST - aheadofprint
SO  - Life Sci. 2013 May 13. pii: S0024-3205(13)00265-8. doi:
      10.1016/j.lfs.2013.05.001.

PMID- 23680358
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1475-2719 (Electronic)
IS  - 0029-6651 (Linking)
DP  - 2013 May 17
TI  - Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal
      microbiota for the management of digestive disorders.
PG  - 1-11
AB  - The gastrointestinal microbiota is a complex ecosystem with each human individual
      hosting at least 160 different bacterial strains. Our understanding of its role
      is rapidly expanding as a result of the molecular microbiological techniques that
      can accurately characterise its composition and 'omics' technologies that measure
      its metabolic activity. Since 1995, extensive research has investigated the
      prebiotic concept, which describes how supplementation of some non-digestible
      oligosaccharides can stimulate the growth and/or activity of specific genera
      including bifidobacteria. However, the vast majority of studies are in healthy
      human subjects, with few undertaken in patients with disorders relevant to
      clinical nutrition. Marked alterations of the luminal microbiota have been
      demonstrated in patients with digestive disorders, highlighting mechanisms
      through which they might be involved in their pathogenesis, including higher
      clostridia in patients who develop diarrhoea during enteral nutrition and the
      influence of bifidobacteria on intestinal dendritic cell phenotype in Crohn's
      disease. The impact of prebiotics on the intestinal microbiota of healthy people 
      has not been consistently replicated in patients with digestive disorders. For
      example, a number of studies show that inulin/oligofructose do not increase
      bifidobacteria in enteral nutrition and Crohn's disease. Indeed, in Crohn's
      disease and irritable bowel syndrome there is evidence that some prebiotics in
      high doses worsen functional symptoms. Unlike healthy human subjects, patients
      experience a number of issues that may alter their gastrointestinal microbiota
      (disease, antibiotics and inflammation) and the use of microbiota modifying
      therapies, such as prebiotics, do not always elicit the same effects in patients 
      as they do in healthy people.
AD  - King's College London, School of Medicine, Diabetes and Nutritional Sciences
      Division, London SE1 9NN, UK.
FAU - Whelan, Kevin
AU  - Whelan K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Proc Nutr Soc
JT  - The Proceedings of the Nutrition Society
JID - 7505881
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - S0029665113001262 [pii]
AID - 10.1017/S0029665113001262 [doi]
PST - aheadofprint
SO  - Proc Nutr Soc. 2013 May 17:1-11.

PMID- 23680271
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0104-4230 (Print)
IS  - 0104-4230 (Linking)
VI  - 59
IP  - 3
DP  - 2013 May-Jun
TI  - Serum magnesium and proton-pump inhibitors use: a cross-sectional study.
PG  - 276-9
LID - 10.1016/j.ramb.2012.12.007 [doi]
LID - S0104-4230(13)00057-2 [pii]
AB  - OBJECTIVE: The aim of this study was to evaluate the association of serum
      magnesium levels with proton pump inhibitors (PPIs) use and other factors.
      METHODS: This was a cross-sectional study of 151 patients admitted with acute
      diseases in the Internal Medicine Division of the Hospital de Clinicas de Porto
      Alegre, after the exclusion of conditions that are commonly associated with
      hypomagnesemia: diarrhea; vomiting; chronic alcohol use; severely uncompensated
      diabetes mellitus; and chronic use of laxatives, diuretics or other drugs causing
      magnesium deficiency. RESULTS: All patients had normal serum magnesium levels.
      Serum albumin and creatinine levels were positively associated with serum
      magnesium levels, after adjusting for confounders. There was no difference
      between mean serum magnesium levels of PPI users and non-users, nor between men
      and women; there was also no correlation among age, serum phosphorus, and
      potassium levels with serum magnesium levels. Limitations of this study include
      the absence of an instrument for measuring adherence to PPI use and the sample
      size. CONCLUSION: The association of PPI use and hypomagnesemia is uncommon.
      Congenital defects in the metabolism of magnesium may be responsible for
      hypomagnesemia in some patients using this drug class.
CI  - Copyright (c) 2013 Elsevier Editora Ltda. All rights reserved.
AD  - Postgraduate Program in Medicine, Universidade Federal do Rio Grande do Sul
      (UFRGS), Porto Alegre, RS, Brazil; Internal Medicine Division, Hospital de
      Clinicas de Porto Alegre, UFRGS, Porto Alegre, RS, Brazil.
FAU - Faulhaber, Gustavo Adolpho Moreira
AU  - Faulhaber GA
FAU - Ascoli, Bruna Maria
AU  - Ascoli BM
FAU - Lubini, Adriano
AU  - Lubini A
FAU - Mossmann, Marcio
AU  - Mossmann M
FAU - Rossi, Gabriela
AU  - Rossi G
FAU - Geib, Guilherme
AU  - Geib G
FAU - Furlanetto, Tania Weber
AU  - Furlanetto TW
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - Brazil
TA  - Rev Assoc Med Bras
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/10/02 [received]
PHST- 2012/11/04 [revised]
PHST- 2012/12/02 [accepted]
PHST- 2013/05/13 [aheadofprint]
AID - S0104-4230(13)00057-2 [pii]
AID - 10.1016/j.ramb.2012.12.007 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras. 2013 May-Jun;59(3):276-9. doi: 10.1016/j.ramb.2012.12.007.
      Epub 2013 May 13.

PMID- 23680254
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - HbA1c and iron deficiency: A review.
PG  - 118-22
LID - 10.1016/j.dsx.2013.02.004 [doi]
LID - S1871-4021(13)00005-2 [pii]
AB  - Conditions that affect erythrocyte turnover influence HbA1c concentrations and
      the International Expert Committee has warned clinicians to be aware of any
      conditions that could affect the turnover of red blood cells. Although many forms
      of anemia are associated with lowering of HbA1c, iron deficiency has been shown
      to shift HbA1c slightly upward. The exact mechanism through which iron deficiency
      anemia affects HbA1c levels, however still remains unclear. The explanations
      provided above are merely speculations, warranting further studies to confirm and
      elucidate the role of these factors. As little work has been done in this field
      so future and large scale studies are required which may address HbA1c enhancing 
      effect and the mechanism of increased HbA glycation in iron deficiency properly.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Centre for Diabetes and Endocrinology, Faculty of Medicine, J.N. Medical College,
      Aligarh Muslim University, Aligarh 202002, India. Electronic address:
      jamalahmad11@rediffmail.com.
FAU - Ahmad, Jamal
AU  - Ahmad J
FAU - Rafat, Dalia
AU  - Rafat D
LA  - eng
PT  - Journal Article
DEP - 20130315
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/15 [aheadofprint]
AID - S1871-4021(13)00005-2 [pii]
AID - 10.1016/j.dsx.2013.02.004 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):118-22. doi: 10.1016/j.dsx.2013.02.004.
      Epub 2013 Mar 15.

PMID- 23680253
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Alopecia due to common metabolic diseases.
PG  - 116-7
LID - 10.1016/j.dsx.2013.02.022 [doi]
LID - S1871-4021(13)00023-4 [pii]
AB  - Alopecia is an important condition presenting with excessive hair loss. The
      problem of alopecia is important concern in trichology. Sometimes, alopecia can
      be due to complicated etiologies. The good examples are metabolic diseases. In
      this article, the authors will present the details of alopecia due to some
      important metabolic diseases. Special focus is made on diagnosis and treatment.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Wiwanitkit House, Bangkhae, Bangkok, Thailand. Electronic address:
      somsriwiwan@hotmail.com.
FAU - Wiwanitkit, Somsri
AU  - Wiwanitkit S
FAU - Wiwanitkit, Viroj
AU  - Wiwanitkit V
LA  - eng
PT  - Journal Article
DEP - 20130315
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/15 [aheadofprint]
AID - S1871-4021(13)00023-4 [pii]
AID - 10.1016/j.dsx.2013.02.022 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):116-7. doi: 10.1016/j.dsx.2013.02.022.
      Epub 2013 Mar 15.

PMID- 23680252
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Ferroportin Q248H mutation, hyperferritinemia and atypical type 2 diabetes
      mellitus in South Kivu.
PG  - 112-5
LID - 10.1016/j.dsx.2013.02.017 [doi]
LID - S1871-4021(13)00018-0 [pii]
AB  - BACKGROUND: The ferroportin Q248H mutation is relatively common in sub-Saharan
      Africa. No previous study examined its relationship with atypical diabetes
      mellitus (DM) in this area. OBJECTIVE: To determine the potential interactions
      between ferroportin Q248H mutation, hyperferritinemia and DM in South Kivu (RDC).
      METHODOLOGY: Presence of ferroportin Q248H mutation and iron status were
      investigated in diabetic patients (n=179, age (mean) 57.7 years, CRP (median)
      0.16mg/L) and non-diabetic subjects (n=86, age 44.5 years, CRP 0.07mg/L) living
      in the city of Bukavu. Hyperferritinemia was considered for values greater than
      200 and 300mug/L in women and in men, respectively. RESULTS: The prevalence of
      ferroportin Q248H mutation [12.1%] was non-significantly higher in diabetics than
      non-diabetics [14.0% vs. 8.1%, p=0.17]. Similarly, hyperferritinemia frequency
      was higher in diabetic patients with Q248H mutation [44.0% vs. 14.3%, p=0.16] and
      in mutation carriers [37.0% vs 16.5%, p=0.001] than in the control groups,
      respectively. The association between Q248H mutation and DM was nevertheless not 
      significant [adjusted OR 1.70 (95% CI: 0.52-5.58), p=0.37], whereas
      hyperferritinemia [OR 2.72 (1.24-5.98), p=0.01] showed an independent effect
      after adjustment for age and metabolic syndrome. CONCLUSIONS: The present work
      suggests a potential association between abnormal iron metabolism, ferroportin
      Q248H mutation and atypical DM in Africans, which may be modulated by
      environmental factors.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Faculty of Medicine NCD's Observatory, Catholic University of Bukavu/VLIR-UOS, PO
      Box 235, Bukavu, The Democratic Republic of the Congo. Electronic address:
      philkatch@yahoo.fr.
FAU - Katchunga, Philippe Bianga
AU  - Katchunga PB
FAU - Baguma, Marius
AU  - Baguma M
FAU - M'buyamba-Kabangu, Jean-Rene
AU  - M'buyamba-Kabangu JR
FAU - Philippe, Jan
AU  - Philippe J
FAU - Hermans, Michel P
AU  - Hermans MP
FAU - Delanghe, Joris
AU  - Delanghe J
LA  - eng
PT  - Journal Article
DEP - 20130314
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/14 [aheadofprint]
AID - S1871-4021(13)00018-0 [pii]
AID - 10.1016/j.dsx.2013.02.017 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):112-5. doi: 10.1016/j.dsx.2013.02.017.
      Epub 2013 Mar 14.

PMID- 23680251
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Paraoxonase 1: A better atherosclerotic risk predictor than HDL in type 2
      diabetes mellitus.
PG  - 108-11
LID - 10.1016/j.dsx.2013.02.007 [doi]
LID - S1871-4021(13)00008-8 [pii]
AB  - INTRODUCTION: Type 2 diabetes mellitus is a state of glycative stress and
      oxidative stress. Lower level of serum PON 1 has been correlated to higher
      morbidity and mortality related to cardiovascular complications in type 2
      diabetes mellitus. OBJECTIVES: To estimate and compare the serum PON 1 levels in 
      type 2 diabetes mellitus and controls and to predict which one is the better
      atherosclerotic risk predictor among HDL and PON 1 in T2DM patients. MATERIALS
      AND METHODS: An observational analytical case-control study was conducted with a 
      sample size of 30 in two groups like group I (30 cases of type 2 diabetes
      mellitus diagnosed by ADA 2010 criteria) and group II (30 age and sex matched
      controls). Human serum paroxonase 1 levels were measured by ELISA. RESULTS: Both 
      HDL and PON 1 were negatively correlated with the various atherogenic indices
      (AIP, AC, CRI I, CRI II) but the strength of negative correlation is always
      greater for PON 1. In multiple linear regression analysis, we found that the
      regression coefficient (beta) is always higher for PON 1 than for HDL while
      taking the atherogenic indices as outcome variable. CONCLUSION: PON 1 can be a
      better predictor than HDL for atherosclerotic risk in type 2 diabetes mellitus.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Department of Clinical Biochemistry, Lady Hardinge Medical College, New Delhi,
      India. Electronic address: drsurajeetlhmc@gmail.com.
FAU - Patra, Surajeet Kumar
AU  - Patra SK
FAU - Singh, Kamna
AU  - Singh K
FAU - Singh, Ritu
AU  - Singh R
LA  - eng
PT  - Journal Article
DEP - 20130315
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/15 [aheadofprint]
AID - S1871-4021(13)00008-8 [pii]
AID - 10.1016/j.dsx.2013.02.007 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):108-11. doi: 10.1016/j.dsx.2013.02.007.
      Epub 2013 Mar 15.

PMID- 23680250
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - The diabetic foot infections: Biofilms and antimicrobial resistance.
PG  - 101-7
LID - 10.1016/j.dsx.2013.02.006 [doi]
LID - S1871-4021(13)00007-6 [pii]
AB  - AIM: To study the difference in antimicrobial resistance profile among biofilm
      producing and non-producing microorganisms isolated from diabetic foot ulcer in a
      tertiary care hospital in North India. METHODOLOGY: We performed a prospective
      study on 162 DFU in patients treated in a multidisciplinary based diabetes and
      endocrinology center of JNMCH, AMU, Aligarh, India during the period of December 
      2008-March 2011. Detailed history and physical examination was carried out for
      every subject. Patient's profile, grade of DFU, co-morbidities and complications,
      laboratory data and final outcome were collected. Standard methods of sample
      collection and identification of microorganism were adopted. Risk factors for
      biofilm producing infections were determined by univariate analysis with 95% of
      CI. P value <0.05 were considered as significant. RESULTS: The overall biofilm
      producing infection rate among DFU was 67.9%. On univariate analysis, significant
      risk factors for biofilm producing infection were male sex [P=0.015, OR 2.35, RR 
      1.71], duration of diabetes [P<0.006, OR 4.0, RR 2.7], duration of ulcer >1 month
      [P<0.02, OR 2.26, RR 1.72], size of ulcer >4cm(2) [P<0.05, OR 2.03, RR 1.54],
      Grade II ulcer [P<0.06, OR 1.87, RR 1.63], necrotic ulcer [P<0.002, OR 5.79, RR
      3.59], previous antibiotic use [P<0.007, OR 4.24, RR 2.74], subcutaneous
      infection [P<0.06, OR 1.87, RR 1.63], HbA1c >7% [P<0.04, OR 3.19, RR1.87] and
      polymicrobial infection [P<0.001, OR 6.64, RR 3.21] were significant risk
      factors. CONCLUSIONS: Treating the DFU by shifting from the planktonic model of
      microbiology to the biofilm model was recommended. With this new scientific
      approaches along with coordination of clinical and laboratory efforts, education,
      and research, it is possible to imagine overcoming much of biofilm disease.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Department of Microbiology, Faculty of Medicine, J.N. Medical College, Aligarh
      Muslim University, Aligarh 202002, India. Electronic address:
      abidamailik2k@gmail.com.
FAU - Malik, Abida
AU  - Malik A
FAU - Mohammad, Zubair
AU  - Mohammad Z
FAU - Ahmad, Jamal
AU  - Ahmad J
LA  - eng
PT  - Journal Article
DEP - 20130315
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/15 [aheadofprint]
AID - S1871-4021(13)00007-6 [pii]
AID - 10.1016/j.dsx.2013.02.006 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):101-7. doi: 10.1016/j.dsx.2013.02.006.
      Epub 2013 Mar 15.

PMID- 23680249
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Pattern and predictors of dyslipidemia in patients with type 2 diabetes mellitus.
PG  - 95-100
LID - 10.1016/j.dsx.2013.02.011 [doi]
LID - S1871-4021(13)00012-X [pii]
AB  - Dyslipidemia is a major risk factor for macro-vascular complications in patients 
      with type 2 diabetes mellitus (T2DM). Present study explored pattern and
      predictors of dyslipidemia in Bangladeshi T2DM patients. The cross-sectional
      study is conducted among 366 consecutive eligible T2DM patients aged >30 years,
      BIRDEM diabetic hospital, during July-to-December 2010. Physical examination,
      diabetic profile, lipid profile and serum createnine was performed. Adjusted odds
      ratio and confidence limit were generated through binary logistic regression.
      Most frequent form (59.3%) of dyslipidemia is low HDL. Duration of T2DM is
      significantly correlated with TC (P<0.05), HDL (P<0.05) and LDL (P<0.05) in both 
      male and female. Glycemic control in terms of HbA1c >7% appeared as predictor of 
      dyslipidemia (P<0.01). Duration T2DM is associated with increased risk of having 
      higher TC (P<0.05), LDL (P<0.05) and lower HDL (P<0.01) and does not seem to
      affect triglyceride (P>0.05). T2DM with comorbid hypertension seems to predict
      hyper tri-glyceridemia and lower HDL. Both TC-HDL ratio and LDL-HDL ratio
      appeared as good predictor of all four parameters of dyslipidemia (P<0.01). The
      characteristic features of diabetic dyslipidemia are low HDL, high triglyceride
      and LDL cholesterol level. Low HDL level is the most frequent type of
      abnormality. Poor glycemic control, prolonged duration, coexisting hypertension
      predicts dyslipidemia in T2DM.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Directorate General of Health Services, Bangladesh.
FAU - Karim, Md N
AU  - Karim MN
FAU - Ahmed, Kazi R
AU  - Ahmed KR
FAU - Bukht, Mohammad S
AU  - Bukht MS
FAU - Akter, Jesmin
AU  - Akter J
FAU - Chowdhury, Hasina A
AU  - Chowdhury HA
FAU - Hossain, Sharmin
AU  - Hossain S
FAU - Anwar, Nazneen
AU  - Anwar N
FAU - Selim, Shajada
AU  - Selim S
FAU - Chowdhury, Shahabul H
AU  - Chowdhury SH
FAU - Hossain, Fawzia
AU  - Hossain F
FAU - Ali, Liaquat
AU  - Ali L
LA  - eng
PT  - Journal Article
DEP - 20130327
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/27 [aheadofprint]
AID - S1871-4021(13)00012-X [pii]
AID - 10.1016/j.dsx.2013.02.011 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):95-100. doi: 10.1016/j.dsx.2013.02.011.
      Epub 2013 Mar 27.

PMID- 23680248
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Relationship between socioeconomic status and metabolic syndrome among Nigerian
      adults.
PG  - 91-4
LID - 10.1016/j.dsx.2013.02.014 [doi]
LID - S1871-4021(13)00015-5 [pii]
AB  - The study determined the diastolic and systolic pressure, anthropometric
      parameters, serological parameters comprising fasting blood glucose (FBG),
      triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) as well as the
      socio-economic status (SES) of inhabitants of Ilora with a view to providing
      information on impact of SES on metabolic syndrome (MetS). One hundred
      participants (54 males and 46 females) whose ages ranged from 30 and 70 years,
      participated in the study. Participants were recruited from the three wards of
      the town using multi-stage random sampling procedure. Subjects' weights, height, 
      blood pressure, waist circumference (WC) were measured using standard
      instruments. Fasting blood glucose (FBG) was measured using a glucometer on
      participants' blood samples taken after at least 8h of fasting. Serum
      triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) were analyzed 
      using enzyme colometric assay kits in the laboratory. SES of the participants was
      determined by using a questionnaire, which sought information on annual income,
      occupation and education. Participants who had MetS were determined using the new
      International Diabetes Foundation definition of MetS. Both descriptive and
      inferential statistics were used to analyze the data. The mean scores for the
      males and females systolic blood pressure (SBP) were 123.20+/-20.72mmHg and
      117.78+/-14.64mmHg, and the diastolic blood pressure (DBP), 78.63+/-11.72mmHg and
      75.98+/-13.06mmHg, respectively. The mean of serological variables scores for the
      males and females, respectively, were FBG (4.95+/-0.81mmol/L and
      4.84+/-1.36mmol/L), TG (1.28+/-0.75mmol/L and 1.35+/-1.05mmol/L), HDL-C
      (1.26+/-0.21mmol/L and 2.32+/-7.34mmol/L). The mean SES scores for the males and 
      females were 14.35+/-4.75 and 13.13+/-4.66, respectively. The prevalence of MetS 
      was 43.5% in females and 9.3% in males. Significant differences were found in SBP
      and FBG across the three SES groups (F=3.148 and 3.862, respectively, p<0.05).
      The high SES group was found to have significantly higher SBP and FBG than the
      low and middle SES groups. There were significant correlations between SES scores
      and SBP (r=0.255; p<0.05), FBG (r=0.270; p<0.01), and BMI (r=0.210; p<0.05).
      Also, significant relationships were found between weight and TG (r=0.282;
      p<0.05), waist circumference (WC) and FBG (r=0.264; p<0.05), and WC and TG
      (r=0.414; p<0.01). The study concluded that SES has significant relationship with
      metabolic syndrome components such as SBP and fasting blood glucose among adult
      population in Nigeria.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Department of Medical Rehabilitation, Obafemi Awolowo University, Ile-Ife,
      Nigeria. Electronic address: radedoyi@yahoo.com.
FAU - Adedoyin, Rufus A
AU  - Adedoyin RA
FAU - Afolabi, Abiodun
AU  - Afolabi A
FAU - Adegoke, Olajire O
AU  - Adegoke OO
FAU - Akintomide, Anthony O
AU  - Akintomide AO
FAU - Awotidebe, Taofeek O
AU  - Awotidebe TO
LA  - eng
PT  - Journal Article
DEP - 20130314
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/14 [aheadofprint]
AID - S1871-4021(13)00015-5 [pii]
AID - 10.1016/j.dsx.2013.02.014 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):91-4. doi: 10.1016/j.dsx.2013.02.014.
      Epub 2013 Mar 14.

PMID- 23680247
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - A novel endocrinology-based wellness program to reduce medication expenditures
      and improve glycemic outcomes.
PG  - 87-90
LID - 10.1016/j.dsx.2013.02.016 [doi]
LID - S1871-4021(13)00017-9 [pii]
AB  - AIMS: The purpose of this study was to determine the difference in
      diabetes-related medication expenditures as a result of a 16-week lifestyle
      intervention program. Medical expenditures for patients with diabetes are twice
      as high compared to patients without this condition. Secondary objectives were
      changes in HbA1C, BMI, weight, body fat, and program satisfaction. METHODS: The
      Wellness Life! Program includes educational sessions focused on nutrition,
      fitness, and behavioral therapy. Medication costs were based on Average Wholesale
      Prices, tabulated from the 2010 Red Book. RESULTS: A total of 36 patients (49-80 
      years old) enrolled, of which 27 patients have diabetes mellitus (Type 2=26, Type
      1=1). Mean 30-day anti-diabetic medication costs decreased by $142.92. Clinical
      mean parameters improved in both the overall group and the diabetic subgroup,
      respectively: HbA1C (%) -0.69, -0.82; weight (lbs) -16.94, -17.11; BMI -2.73,
      -2.88; and body fat (%) -1.71, -1.79. Participants were generally satisfied with 
      the program. CONCLUSIONS: Employing a multidisciplinary wellness program within
      an endocrinology practice can reduce anti-diabetic medication expenses; however, 
      long term follow-up is needed to determine if medication reductions and improved 
      clinical parameters persist.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Northeast Florida Endocrine & Diabetes Associates, Jacksonville, FL, United
      States. Electronic address: john.evans12@comcast.net.
FAU - Evans, J Gary
AU  - Evans JG
FAU - Sutton, David R
AU  - Sutton DR
FAU - Dajani, Lorraine H
AU  - Dajani LH
FAU - Magee, J Sample
AU  - Magee JS
FAU - Silva, Ricardo A
AU  - Silva RA
FAU - Roura, Miguel F
AU  - Roura MF
FAU - Wadud, Khurram
AU  - Wadud K
FAU - Purcell, John A
AU  - Purcell JA
FAU - Travaglini, Stefano
AU  - Travaglini S
FAU - Segel, Scott A
AU  - Segel SA
FAU - Sultan, Senan
AU  - Sultan S
FAU - Roffman, Melissa S
AU  - Roffman MS
FAU - Ayad, Salwa S
AU  - Ayad SS
FAU - Borja-Hart, Nancy L
AU  - Borja-Hart NL
FAU - Smith, Steven M
AU  - Smith SM
LA  - eng
PT  - Journal Article
DEP - 20130322
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/22 [aheadofprint]
AID - S1871-4021(13)00017-9 [pii]
AID - 10.1016/j.dsx.2013.02.016 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):87-90. doi: 10.1016/j.dsx.2013.02.016.
      Epub 2013 Mar 22.

PMID- 23680246
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - A study evaluating prevalence of hypertension and risk factors affecting on blood
      pressure control among type 2 diabetes patients attending teaching hospital in
      Malaysia.
PG  - 83-6
LID - 10.1016/j.dsx.2013.02.019 [doi]
LID - S1871-4021(13)00020-9 [pii]
AB  - INTRODUCTION: Hypertension is extremely common disease found in patients with
      diabetes mellitus. Eighty to 90% of patients with type 2 diabetes mellitus will
      develop hypertension, and about 20% of hypertensive patients develop diabetes.
      The aim of this study was designed to assess the prevalence of hypertension and
      factors affecting the control of hypertension among type 2 diabetic patients.
      MATERIALS AND METHODS: A total of 1077 type 2 diabetes mellitus patients were
      included in this study who attended at diabetes clinic of Universiti Sains
      Malaysia (USM) teaching hospital in Kelantan. All these patients were
      prospectively followed from January to December 2008. Logistic regression
      analysis was used to assess the independent effect of variables on hypertension. 
      RESULTS: The prevalence of hypertension (BP>130/80 or on medication for high
      blood pressure) was 92.7%. A total 471 (47.2%) patients had achieved blood
      pressure targets </=130/80mmHg. The logistic regression indicated that
      hypertension was positively associated with age (P=0.040), BMI (P=0.027), HbA1c
      (P=0.046), and level of education (P=0.039). CONCLUSION: Hypertension is a common
      co-morbidity among diabetic patients. Hypertension was not controlled to the
      recommended levels of blood pressure in about one-half (52.8%) of diabetes
      patients. Age, BMI, HbA1c and level of education are factors affecting on
      hypertension.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Discipline of Clinical Pharmacy, Qassim University, Pharmacy College, Qassim,
      Saudi Arabia. Electronic address: SALWASL2005@yahoo.com.
FAU - Abougalambou, Salwa Selim Ibrahim
AU  - Abougalambou SS
FAU - Abougalambou, Ayman S
AU  - Abougalambou AS
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/04/15 [aheadofprint]
AID - S1871-4021(13)00020-9 [pii]
AID - 10.1016/j.dsx.2013.02.019 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):83-6. doi: 10.1016/j.dsx.2013.02.019.
      Epub 2013 Apr 15.

PMID- 23680245
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Morphofunctional characteristics of the foot in patients with diabetes mellitus
      and diabetic neuropathy.
PG  - 78-82
LID - 10.1016/j.dsx.2013.02.029 [doi]
LID - S1871-4021(13)00030-1 [pii]
AB  - AIMS: To determine the structural and biomechanical characteristics associated
      with the conditions diabetes mellitus and diabetic neuropathy. METHODS:
      Observational study of 788 patients conducted between February 2007 and February 
      2009, which included subjects with and without diabetes mellitus who had no
      active ulcer at enrollment. Demographic variables and the general and specific
      history of diabetes mellitus were recorded. The patient's foot type according to 
      the Foot Posture Index, joint mobility and deformity were recorded. RESULTS: No
      associations were found between the different foot types (neutral, pronated and
      supinated) and the structural and demographic variables at a general level,
      except for the pronated foot that was associated with a higher body mass index,
      longer suffering from diabetes and the presence of neuropathy [p<0.001, OR (95%
      CI): 6.017 (4.198-8.624); p<0.001, OR (95% CI): 1.710 (1.266-2.309); p=0.010, OR 
      (95% CI): 0.759 (0.615-0.937), respectively]. CONCLUSIONS: The confluence of risk
      factors such as neuropathy, body mass index, duration of diabetes and limited
      joint mobility in patients with diabetes mellitus and pronated foot may be a
      high-risk anthropometric pattern for developing associated complications such as 
      Charcot foot. A prospective analysis of these patients is required to define the 
      risk for developing Charcot neuroarthropathy.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Unidad de Pie Diabetico, Facultad de Medicina, Universidad Complutense de Madrid,
      Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC),
      Madrid, Spain. Electronic address: ygarci01@pdi.ucm.es.
FAU - Garcia-Alvarez, Yolanda
AU  - Garcia-Alvarez Y
FAU - Lazaro-Martinez, Jose Luis
AU  - Lazaro-Martinez JL
FAU - Garcia-Morales, Esther
AU  - Garcia-Morales E
FAU - Cecilia-Matilla, Almudena
AU  - Cecilia-Matilla A
FAU - Aragon-Sanchez, Javier
AU  - Aragon-Sanchez J
FAU - Carabantes-Alarcon, David
AU  - Carabantes-Alarcon D
LA  - eng
PT  - Journal Article
DEP - 20130315
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/15 [aheadofprint]
AID - S1871-4021(13)00030-1 [pii]
AID - 10.1016/j.dsx.2013.02.029 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):78-82. doi: 10.1016/j.dsx.2013.02.029.
      Epub 2013 Mar 15.

PMID- 23680244
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Comparison of DEXA-derived body fat measurement to two race-specific
      bioelectrical impedance equations in healthy Indians.
PG  - 72-7
LID - 10.1016/j.dsx.2013.02.031 [doi]
LID - S1871-4021(13)00032-5 [pii]
AB  - AIM: Prevalence of obesity is increasing in Asian Indians. Reliable, precise and 
      convenient methods to estimate body composition are required. This study aimed to
      test the accuracy of bioelectrical impedance analysis (BIA) estimates of body
      composition among Asian Indians according to two BIA equations - one developed
      for Asians, the other for Caucasians. METHODS: Two hundred apparently healthy
      Asian Indians (100 males, 100 females; mean age 36.6+/-7.6 years; mean BMI
      16.6-46.7kg/m(2)) underwent BIA assessment of fat mass (FM), fat free mass (FFM) 
      and percentage body fat (%BF) using Tanita Multi-Frequency Body Composition
      Analyzer MC-180MA (Tanita Corporation, Tokyo, Japan). One set of BIA values was
      automatically calculated by the analyzer (Caucasian figures), the other set by
      Tanita (Japanese Asian figures). Results were compared to dual X-ray
      absorptiometry (DEXA) as the standard measure. RESULTS: A moderate level of
      relative agreement was found between the DEXA-derived measurement of %BF and the 
      estimate from both the Caucasian (r(2)=0.75; p<0.001) and Asian equation
      (r(2)=0.7; p<0.001). Despite this, the level of absolute agreement was poor, with
      large bias and wide limits of agreement. According to the Caucasian equation the 
      mean difference between methods was -8.3+/-3.9 (95% limits of agreement -20.10 to
      9.40), for the Asian equations mean difference was -5.4+/-4.3 (95% limits of
      agreement -20.63 to 11.41). INTERPRETATION AND CONCLUSIONS: When compared to
      DEXA, the current Asian and Caucasian Tanita formulae significantly
      under-estimate the %BF of Asian Indians.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Diabetes Foundation (India), SDA, New Delhi 110016, India.
FAU - Nigam, Priyanka
AU  - Nigam P
FAU - Misra, Anoop
AU  - Misra A
FAU - Colles, Susan L
AU  - Colles SL
LA  - eng
PT  - Journal Article
DEP - 20130314
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/14 [aheadofprint]
AID - S1871-4021(13)00032-5 [pii]
AID - 10.1016/j.dsx.2013.02.031 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):72-7. doi: 10.1016/j.dsx.2013.02.031.
      Epub 2013 Mar 14.

PMID- 23680243
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Pregnancy outcome and glycemic control in women with type 1 diabetes: A
      retrospective comparison between CSII and MDI treatment.
PG  - 68-71
LID - 10.1016/j.dsx.2013.02.032 [doi]
LID - S1871-4021(13)00033-7 [pii]
AB  - AIM: Present study was aimed to evaluate glycemic control and maternal-fetal
      outcome in pregnant type 1 diabetic patient treated with continuous subcutaneous 
      insulin infusion (CSII) or multiple daily injections of insulin (MDI). PATIENTS
      AND METHODS: A retrospective observational study included thirty-four pregnant
      type 1 diabetic patients. Patients were divided into two group, CSII treated
      group (n=14) and MDI treated group (n=20). The HbA1c level and maternal-fetal
      outcome were evaluated in both the treatment group. Outcome parameters such as
      glycemic control (HbA1c), hypoglycemic events, time and mode of delivery and
      labor results (abortion, premature labor, perinatal mortality, neonatal weight,
      Apgar score, neonatal hypoglycaemia, presence of congenital abnormalities) were
      analyzed. RESULTS: Pregnancy outcome and glycemic control in pregnant type 1
      diabetic patients treated with CSII and MDI were evaluated and compared. Two
      groups were compared for their epidemiological parameters, although patients on
      CSII treatment had longer duration of diabetes compared to MDI treated group.
      Reduction in HbA1c level was higher in CSII treated patients at first (CSII: 0.9%
      vs MDI: 0.46%), second (CSII: 1.58% vs MDI: 0.78%) and third trimester (CSII:
      1.74% vs MDI: 1.09%) of pregnancy compared to MDI treated patients. Duration of
      pregnancy and new born baby weight were founded similar in both group. Moreover, 
      the rate of abortion, preterm labor, cesarean section and hypoglycemia in new
      born were founded less in CSII treated group compared to MDI treated group and
      Apgar score was significantly (p<0.05) higher in CSII treated group compared to
      MDI treated group. CONCLUSION: Results of present study revealed that the CSII
      gives better glycemic control and pregnancy outcome in pregnant type 1 diabetic
      patients compared to MDI treatment. CSII also decreases the daily insulin
      requirement compared MDI.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Dia Care - Diabetes Care and Hormone Clinic, Ahmedabad, India.
FAU - Talaviya, Praful A
AU  - Talaviya PA
FAU - Saboo, Banshi D
AU  - Saboo BD
FAU - Joshi, Shashank R
AU  - Joshi SR
FAU - Padhiyar, Jayendra N
AU  - Padhiyar JN
FAU - Chandarana, Hardik K
AU  - Chandarana HK
FAU - Shah, Smita J
AU  - Shah SJ
FAU - Vyas, Chintal K
AU  - Vyas CK
FAU - Shah, Asha N
AU  - Shah AN
LA  - eng
PT  - Journal Article
DEP - 20130330
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/30 [aheadofprint]
AID - S1871-4021(13)00033-7 [pii]
AID - 10.1016/j.dsx.2013.02.032 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):68-71. doi: 10.1016/j.dsx.2013.02.032.
      Epub 2013 Mar 30.

PMID- 23680242
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Prevalence and risk factors of microalbuminuria in type 2 diabetes mellitus
      outpatients at University Sains Malaysia Hospital.
PG  - 64-7
LID - 10.1016/j.dsx.2013.02.034 [doi]
LID - S1871-4021(13)00035-0 [pii]
AB  - BACKGROUND AND OBJECTIVE: Microalbuminuria is early stage of diabetic nephropathy
      as well as a marker of cardiovascular disease. The objective of this study is to 
      determine the prevalence of microalbuminuria and associated risk factors among
      type 2 diabetic outpatients, attending a diabetic clinic in University Sains
      Malaysia Hospital (HUSM). PATIENTS AND METHODS: Prospective study design was used
      in the data collection process. The study sample consists of 1066 type 2 diabetes
      mellitus outpatients who fit the inclusion criteria. All the patients were
      recruited from the diabetic outpatient clinics from HUSM. The study period was
      from January till December 2008. Microalbuminuria was diagnosed if the urinary
      albumin excretion more than 30mg/g of creatinine. RESULTS: A total of 1661
      patients were included in this study. Microalbuminuria was diagnosed in 273
      (25.4%) patients. Multivariate logistic regression analysis indicated that
      microalbuminuria was positively associated with duration of hypertension
      (P=0.044), HbA1c (P=0.004), systolic blood pressure (<0.001), creatinine
      clearance (P=0.007) and the presence of neuropathy (P=0.004). CONCLUSION: High
      prevalence of microalbuminuria was in type 2 diabetic outpatients. Predictive
      factors for microalbuminuria were duration of hypertension, HbA1c, systolic blood
      pressure, creatinine clearance and the presence of neuropathy. The study suggests
      the need to screen for microalbuminuria early and the active management of
      modifiable risk factors in particular, hyperglycemia, hypertension and creatinine
      clearance, to reduce the burden of end-stage renal disease in the future.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Qassim University, Pharmacy School, Discipline of Clinical Pharmacy, Saudi
      Arabia. Electronic address: SALWASL2005@YAHOO.COM.
FAU - Abougalambou, Salwa Selim Ibrahim
AU  - Abougalambou SS
FAU - Abougalambou, Ayman S
AU  - Abougalambou AS
LA  - eng
PT  - Journal Article
DEP - 20130314
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/14 [aheadofprint]
AID - S1871-4021(13)00035-0 [pii]
AID - 10.1016/j.dsx.2013.02.034 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):64-7. doi: 10.1016/j.dsx.2013.02.034.
      Epub 2013 Mar 14.

PMID- 23680241
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr-Jun
TI  - Periodontal disease and type 1 diabetes mellitus: Associations with glycemic
      control and complications: An Indian perspective.
PG  - 61-3
LID - 10.1016/j.dsx.2013.03.001 [doi]
LID - S1871-4021(13)00036-2 [pii]
AB  - AIM: To evaluate the frequency of periodontal disease in a group of patients with
      type 1 diabetes mellitus and its relationship with diabetic metabolic control,
      duration and complications. MATERIALS AND METHODS: A comparison was made of
      periodontal parameters (plaque index, bleeding index, pocket depth and attachment
      loss) in a group of diabetic patients versus a group of non-diabetics (n=20).
      Statistical analysis was performed to evaluate the relationship between
      periodontal parameters and degree of metabolic control, the duration of the
      disease and the appearance of complications. RESULTS: Diabetics had greater
      bleeding index (p<0.001), probing pocket depth (p<0.001) and clinical attachment 
      level (p=0.001). Patients diagnosed for diabetes for shorter duration of time
      (4-7 years) showed bleeding index-disease severity correlation to be
      1.760+/-0.434. CONCLUSION: Patients with type 1 diabetes have increased
      periodontal disease susceptibility. Periodontal inflammation is greatly increased
      in subjects with longer disease course, poor metabolic control and diabetic
      complications.
CI  - Copyright (c) 2013 Diabetes India. Published by Elsevier Ltd. All rights
      reserved.
AD  - Department of Periodontics, BBD College of Dental Sciences and Research Centre,
      Lucknow 226 010, Uttar Pradesh, India; Department of General Medicine, BBDCODS,
      BBD University, Lucknow 226 010, India.
FAU - Ajita, Meenawat
AU  - Ajita M
FAU - Karan, Punn
AU  - Karan P
FAU - Vivek, Govila
AU  - Vivek G
FAU - S, Meenawat Anand
AU  - S MA
FAU - Anuj, Maheshwari
AU  - Anuj M
LA  - eng
PT  - Journal Article
DEP - 20130326
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/26 [aheadofprint]
AID - S1871-4021(13)00036-2 [pii]
AID - 10.1016/j.dsx.2013.03.001 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2013 Apr-Jun;7(2):61-3. doi: 10.1016/j.dsx.2013.03.001.
      Epub 2013 Mar 26.

PMID- 23680095
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-2933 (Electronic)
IS  - 0009-9120 (Linking)
DP  - 2013 May 14
TI  - A quick look at biochemistry: Carbohydrate metabolism.
LID - S0009-9120(13)00167-7 [pii]
LID - 10.1016/j.clinbiochem.2013.04.027 [doi]
AB  - In mammals, there are different metabolic pathways in cells that break down fuel 
      molecules to transfer their energy into high energy compounds such as
      adenosine-5'-triphosphate (ATP), guanosine-5'-triphosphate (GTP), reduced
      nicotinamide adenine dinucleotide (NADH2), reduced flavin adenine dinucleotide
      (FADH2) and reduced nicotinamide adenine dinucleotide phosphate (NADPH). This
      process is called cellular respiration. In carbohydrate metabolism, the breakdown
      starts from digestion of food in the gastrointestinal tract and is followed by
      absorption of carbohydrate components by the enterocytes in the form of
      monosaccharides. Monosaccharides are transferred to cells for aerobic and
      anaerobic respiration via glycolysis, citric acid cycle and pentose phosphate
      pathway to be used in the starvation state. In the normal state, the skeletal
      muscle and liver cells store monosaccharides in the form of glycogen. In the
      obesity state, the extra glucose is converted to triglycerides via lipogenesis
      and is stored in the lipid droplets of adipocytes. In the lipotoxicity state, the
      lipid droplets of other tissues such as the liver, skeletal muscle and pancreatic
      beta cells also accumulate triacylglycerol. This event is the axis of the
      pathogenesis of metabolic dysregulation in insulin resistance, metabolic syndrome
      and type 2 diabetes. In this paper a summary of the metabolism of carbohydrates
      is represented in a way that researchers can follow the biochemical processes
      easily.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Cell Biology, University Medical Center Groningen, University of
      Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. Electronic
      address: M.Dashti.Rahmatabadi@med.umcg.nl.
FAU - Dashty, Monireh
AU  - Dashty M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Clin Biochem
JT  - Clinical biochemistry
JID - 0133660
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/10/17 [received]
PHST- 2013/04/18 [revised]
PHST- 2013/04/20 [accepted]
AID - S0009-9120(13)00167-7 [pii]
AID - 10.1016/j.clinbiochem.2013.04.027 [doi]
PST - aheadofprint
SO  - Clin Biochem. 2013 May 14. pii: S0009-9120(13)00167-7. doi:
      10.1016/j.clinbiochem.2013.04.027.

PMID- 23680083
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1744-8603 (Electronic)
IS  - 1744-8603 (Linking)
VI  - 9
DP  - 2013
TI  - Screening for diabetes and hypertension in a rural low income setting in western 
      Kenya utilizing home-based and community-based strategies.
PG  - 21
LID - 10.1186/1744-8603-9-21 [doi]
AB  - BACKGROUND: The burdens of hypertension and diabetes are increasing in low- and
      middle-income countries (LMICs). It is important to identify patients with these 
      conditions early in the disease process. The goal of this study, therefore, is to
      compare community- versus home-based screening for hypertension and diabetes in
      Kenya. METHODS: This was a feasibility study conducted by the Academic Model
      Providing Access to Healthcare (AMPATH) program in Webuye, a town in western
      Kenya. Home-based (door-to-door) screening occurred in March 2010 and
      community-based screening in November 2011. HIV counselors were trained to screen
      for diabetes and hypertension in the home-based screening with local district
      hospital based staff conducting the community-based screening. Participants >18
      years old qualified for screening in both groups. Counselors referred all
      participants with a systolic blood pressure (SBP) >/=160 mmHg and/or a random
      blood glucose >/=7 mmol/L (126 mg/dL) to a local clinic for follow-up.
      Differences in likelihood of screening positive between the two strategies were
      compared using Fischer's Exact Test. Logistic regression models were used to
      identify factors associated with the likelihood of following-up after a positive 
      screening. RESULTS: There were 236 participants in home-based screening: 13 (6%) 
      had a SBP >/=160 mmHg, and 54 (23%) had a random glucose >/= 7 mmol/L. There were
      346 participants in community-based screening: 35 (10%) had a SBP >/=160 mmHg,
      and 27 (8%) had a random glucose >/= 7 mmol/L. Participants in community-based
      screening were twice as likely to screen positive for hypertension compared to
      home-based screening (OR=1.93, P=0.06). In contrast, participants were 3.5 times 
      more likely to screen positive for a random blood glucose >/=7 mmol/L with
      home-based screening (OR=3.51, P<0.01). Rates for following-up at the clinic
      after a positive screen were low for both groups with 31% of patients with an
      elevated SBP returning for confirmation in both the community-based and
      home-based group (P=1.0). Follow-up after a random glucose was also low with 23% 
      returning in the home-based group and 22% in the community-based group (P=1.0).
      CONCLUSION: Community- or home-based screening for diabetes and hypertension in
      LMICs is feasible. Due to low rates of follow-up, screening efforts in rural
      settings should focus on linking cases to care.
AD  - Purdue University College of Pharmacy, W7555 Myers Building, 1001 W, 10th Street,
      Indianapolis, Indiana, USA. spastaki@gmail.com.
FAU - Pastakia, Sonak D
AU  - Pastakia SD
FAU - Ali, Shamim M
AU  - Ali SM
FAU - Kamano, Jemima H
AU  - Kamano JH
FAU - Akwanalo, Constantine O
AU  - Akwanalo CO
FAU - Ndege, Samson K
AU  - Ndege SK
FAU - Buckwalter, Victor L
AU  - Buckwalter VL
FAU - Vedanthan, Rajesh
AU  - Vedanthan R
FAU - Bloomfield, Gerald S
AU  - Bloomfield GS
LA  - eng
GR  - K01 TW008407/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20130516
PL  - England
TA  - Global Health
JT  - Globalization and health
JID - 101245734
SB  - IM
PMC - PMC3662603
OID - NLM: PMC3662603
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/01/08 [received]
PHST- 2013/05/10 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 1744-8603-9-21 [pii]
AID - 10.1186/1744-8603-9-21 [doi]
PST - epublish
SO  - Global Health. 2013 May 16;9:21. doi: 10.1186/1744-8603-9-21.

PMID- 23680062
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1545-7206 (Electronic)
IS  - 0033-3182 (Linking)
VI  - 54
IP  - 3
DP  - 2013 May-Jun
TI  - A case of ziprasidone associated with acutely worsened diabetes mellitus.
PG  - 304-5
LID - 10.1016/j.psym.2012.08.011 [doi]
LID - S0033-3182(12)00161-2 [pii]
AD  - Harvard Medical School, Boston, MA.
FAU - Honigberg, Michael C
AU  - Honigberg MC
FAU - Bui, Melissa P
AU  - Bui MP
FAU - Coconcea, Cristinel
AU  - Coconcea C
LA  - eng
PT  - Letter
PL  - England
TA  - Psychosomatics
JT  - Psychosomatics
JID - 0376506
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/08/21 [received]
PHST- 2012/08/22 [revised]
PHST- 2012/08/23 [accepted]
AID - S0033-3182(12)00161-2 [pii]
AID - 10.1016/j.psym.2012.08.011 [doi]
PST - ppublish
SO  - Psychosomatics. 2013 May-Jun;54(3):304-5. doi: 10.1016/j.psym.2012.08.011.

PMID- 23680059
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 13
TI  - Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND.
LID - S1056-8727(13)00068-8 [pii]
LID - 10.1016/j.jdiacomp.2013.03.005 [doi]
AB  - OBJECTIVE: To examine the relationship of cognitive performance to exposure to
      insulin (INS) and thiazolidinediones (TZD) in the ACCORD-MIND cohort. METHODS:
      Participants (55-80years) with type 2 diabetes (T2D), hemoglobin A1c (HbA1c)
      >7.5% (>58mmol/mol), and a high risk of cardiovascular events were randomly
      assigned to receive intensive control targeting HbA1c to <6.0% (42mmol/mol) or a 
      standard strategy targeting HbA1c to 7.0%-7.9% (53-63mmol/mol). The Digit Symbol 
      Substitution Test (DSST) was assessed at baseline and at 20 and 40months.
      Exposure to INS was calculated as average daily dose/kg of body weight; exposure 
      to rosiglitazone (ROS) was calculated as days of ROS prescription in the
      intervals preceding the 20- and 40-month DSSTs. RESULTS: At baseline, INS use was
      associated with reduced DSST performance, but not after controlling for
      comorbidities and lab values. There was no relationship between use of a TZD and 
      DSST performance on at baseline. ROS but not INS exposure was associated with
      greater decline in DSST performance over 40months in subjects randomized to the
      intensive but not the standard group. CONCLUSIONS: Exposure to a TZD may increase
      cognitive decline in some patients with T2D. However, these results may be
      confounded by unexplained differences between participants.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
      Electronic address: seaqu001@umn.edu.
FAU - Seaquist, Elizabeth R
AU  - Seaquist ER
FAU - Miller, Michael E
AU  - Miller ME
FAU - Fonseca, Vivian
AU  - Fonseca V
FAU - Ismail-Beigi, Faramarz
AU  - Ismail-Beigi F
FAU - Launer, Lenore J
AU  - Launer LJ
FAU - Punthakee, Zubin
AU  - Punthakee Z
FAU - Sood, Ajay
AU  - Sood A
LA  - ENG
GR  - M01 RR000400/RR/NCRR NIH HHS/United States
GR  - N01 HC095181/HC/NHLBI NIH HHS/United States
GR  - N01 HC095182/HC/NHLBI NIH HHS/United States
GR  - N01 HC095183/HC/NHLBI NIH HHS/United States
GR  - N01 HC095184/HC/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/11/06 [received]
PHST- 2013/02/12 [revised]
PHST- 2013/03/29 [accepted]
AID - S1056-8727(13)00068-8 [pii]
AID - 10.1016/j.jdiacomp.2013.03.005 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 13. pii: S1056-8727(13)00068-8. doi:
      10.1016/j.jdiacomp.2013.03.005.

PMID- 23680037
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1573-2509 (Electronic)
VI  - 147
IP  - 2-3
DP  - 2013 Jul
TI  - Open-label salsalate for the treatment of pre-diabetes in people with
      schizophrenia.
PG  - 408-9
LID - 10.1016/j.schres.2013.04.028 [doi]
LID - S0920-9964(13)00228-4 [pii]
AD  - Maryland Psychiatric Research Center, University of Maryland School of Medicine, 
      Baltimore, MD, USA.
FAU - Keller, William R
AU  - Keller WR
FAU - Fischer, Bernard A
AU  - Fischer BA
FAU - McMahon, Robert P
AU  - McMahon RP
FAU - Meyer, Walter
AU  - Meyer W
FAU - Buchanan, Robert W
AU  - Buchanan RW
LA  - eng
PT  - Letter
DEP - 20130513
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/10/25 [received]
PHST- 2013/04/09 [revised]
PHST- 2013/04/11 [accepted]
PHST- 2013/05/13 [aheadofprint]
AID - S0920-9964(13)00228-4 [pii]
AID - 10.1016/j.schres.2013.04.028 [doi]
PST - ppublish
SO  - Schizophr Res. 2013 Jul;147(2-3):408-9. doi: 10.1016/j.schres.2013.04.028. Epub
      2013 May 13.

PMID- 23680007
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1475-2891 (Electronic)
IS  - 1475-2891 (Linking)
VI  - 12
IP  - 1
DP  - 2013 May 17
TI  - Effect of consumption of micronutrient enriched wheat steamed bread on
      postprandial plasma glucose in healthy and type 2 diabetic subjects.
PG  - 64
AB  - BACKGROUND: Steamed wheat bread have previously been shown to induce
      comparatively high postprandial plasma glucose responses, on the contrary,
      buckwheat products induced lower postprandial plasma glucose. The present study
      was to assess the effects of micronutrient enriched bread wheat variety Jizi439
      and buckwheat on postprandial plasma glucose in healthy and diabetic subjects
      comparing with buckwheat and other bread wheat varieties. METHODS: Two
      experiments were conducted to study the effects of bread wheat variety Jizi439 on
      the postprandial plasma glucose levels of the randomly selected subjects. The
      first experiment involved three types of steamed bread with equivalent of 50g
      available carbohydrate fed to 10 normal weight young healthy subjects. Two types 
      of steamed bread were made from two purple-grain bread wheat varieties, Jizi439
      and Chu20, respectively, and the third type was made from the mixture of
      different white grain wheat varieties. Plasma glucose levels of each subject were
      measured at 15, 30, 45, 60, 120 min after eating. Glucose was used as a
      reference, the total area under curve (AUC) and glycemic index (GI) was
      calculated for test meal. The second experiment was performed among ten type 2
      diabetics who were served equivalent of 50g available carbohydrate of steamed
      bread made from Jizi 439, the mixture of white grain bread wheat and buckwheat,
      respectively. The plasma glucose increment was determined two hours thereafter.
      RESULTS: In the first experiment, consumption of the steamed bread made from
      Jizi439 resulted in the least increase in plasma glucose and the GI was
      significantly lower than that of Chu20 and the mixture. In the second experiment,
      the average of postprandial 2h plasma glucose increment of Jizi439 was 2.46mmol/L
      which was significantly lower than that of the mixture of white wheat but was not
      significantly different from buckwheat. CONCLUSIONS: The results indicated that
      consumption of Jizi439 steamed bread resulted in significantly lower plasma
      glucose in both healthy and diabetic subjects, compared with other types of test 
      foods, except buckwheat bread. The steam bread made from Jizi439 would be an
      ideal food for preventing and treatment of diabetes.
FAU - Lan, Su-Que
AU  - Lan SQ
FAU - Meng, Ya-Ning
AU  - Meng YN
FAU - Li, Xing-Pu
AU  - Li XP
FAU - Zhang, Ye-Lun
AU  - Zhang YL
FAU - Song, Guang-Yao
AU  - Song GY
FAU - Ma, Hui-Juan
AU  - Ma HJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Nutr J
JT  - Nutrition journal
JID - 101152213
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/09/07 [received]
PHST- 2013/05/17 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 1475-2891-12-64 [pii]
AID - 10.1186/1475-2891-12-64 [doi]
PST - aheadofprint
SO  - Nutr J. 2013 May 17;12(1):64.

PMID- 23679968
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1097-685X (Electronic)
IS  - 0022-5223 (Linking)
VI  - 145
IP  - 6
DP  - 2013 Jun
TI  - Transfusions and morbidity after surgery of congenital heart disease: Pure
      statistics or time for a paradigm shift?
PG  - 1679
LID - 10.1016/j.jtcvs.2013.01.046 [doi]
LID - S0022-5223(13)00176-1 [pii]
AD  - Institute of Anesthesiology, Heart and Diabetes Center NRW, Ruhr-University of
      Bochum, Bad Oeynhausen, Germany.
FAU - Koster, Andreas
AU  - Koster A
FAU - Zittermann, Armin
AU  - Zittermann A
FAU - Sandica, Eugen
AU  - Sandica E
LA  - eng
PT  - Letter
PL  - United States
TA  - J Thorac Cardiovasc Surg
JT  - The Journal of thoracic and cardiovascular surgery
JID - 0376343
SB  - AIM
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/12/27 [received]
PHST- 2013/01/11 [accepted]
AID - S0022-5223(13)00176-1 [pii]
AID - 10.1016/j.jtcvs.2013.01.046 [doi]
PST - ppublish
SO  - J Thorac Cardiovasc Surg. 2013 Jun;145(6):1679. doi: 10.1016/j.jtcvs.2013.01.046.

PMID- 23679962
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 0156-5788 (Print)
IS  - 0156-5788 (Linking)
VI  - 37
IP  - 3
DP  - 2013 Jun
TI  - Health for all? Patterns and predictors of allied health service use in
      Australia.
PG  - 389-96
LID - 10.1071/AH12040 [doi]
AB  - Objective To examine patterns and predictors of allied health service use among
      the Australian population. Methods Data from the 2007-08 longitudinal National
      Health Survey conducted by the Australian Bureau of Statistics in Australia were 
      used to examine differences in use of allied health services among the
      population. The survey is based on 15779 adult respondents. Multivariate logistic
      regression models were used to model the probability of visiting an allied health
      service contingent on multiple factors of interest. Results Men, less educated
      people and people from non-English speaking backgrounds were low users compared
      with other groups. Interestingly, people with type 2 diabetes were substantially 
      higher users compared with people with other chronic diseases, or no reported
      chronic disease, and ancillary health insurance had a strong positive effect on
      use. Discussion Further investigation of the social and economic circumstances
      surrounding allied health service use is required to determine areas of under use
      or unmet need. High use among people with diabetes might indicate the impact of
      policy incentives to enhance use. Yet, whether all those in need are able to
      access services is unknown. Further investigation of use among groups with
      different health needs and by type of financing will enhance policy. What is
      known about the topic? Inequities and variations in access to allied health
      services are commonplace. Effective policy initiatives to improve access,
      particularly among patients with chronic disease, will depend on improving the
      knowledge base about patterns of use of allied health services, and what
      determines use. What does this paper add? This paper reveals the high and low
      users of allied health services among the Australian population, those population
      groups who might be missing out and what might explain these patterns. This
      information will enable policy makers to target areas of potential unmet need.
      What are the implications for practitioners? Multidisciplinary team care is
      advocated in the management of chronic disease. Practitioners have a vital role
      in framing the benefits of allied health services to patients and in developing
      the evidence base about best practice in the management of chronic disease for
      diverse patient groups.
AD  - School of Social Work and Human Services, The University of Queensland, St Lucia,
      Qld 4072, Australia.
FAU - Foster, Michele
AU  - Foster M
FAU - O'Flaherty, Martin
AU  - O'Flaherty M
FAU - Haynes, Michele
AU  - Haynes M
FAU - Mitchell, Geoffrey
AU  - Mitchell G
FAU - Haines, Terrence P
AU  - Haines TP
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Aust Health Rev
JT  - Australian health review : a publication of the Australian Hospital Association
JID - 8214381
SB  - H
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/07/23 [received]
PHST- 2013/02/05 [accepted]
AID - AH12040 [pii]
AID - 10.1071/AH12040 [doi]
PST - ppublish
SO  - Aust Health Rev. 2013 Jun;37(3):389-96. doi: 10.1071/AH12040.

PMID- 23679955
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
DP  - 2013 May 30
TI  - Antagonists for the Orphan G-Protein-Coupled Receptor GPR55 Based on a Coumarin
      Scaffold.
AB  - The orphan G-protein-coupled receptor GPR55, which is activated by
      1-lysophosphatidylinositol and interacts with cannabinoid (CB) receptor ligands, 
      has been proposed as a new potential drug target for the treatment of diabetes,
      Parkinson's disease, neuropathic pain, and cancer. We applied beta-arrestin
      assays to identify 3-substituted coumarins as a novel class of antagonists and
      performed an extensive structure-activity relationship study for GPR55.
      Selectivity versus the related receptors CB1, CB2, and GPR18 was assessed. Among 
      the 7-unsubstituted coumarins selective, competitive GPR55 antagonists were
      identified, such as 3-(2-hydroxybenzyl)-5-isopropyl-8-methyl-2H-chromen-2-one
      (12, PSB-SB-489, IC50 = 1.77 muM, pA2 = 0.547 muM). Derivatives with long alkyl
      chains in position 7 were potent, possibly allosteric GPR55 antagonists which
      showed ancillary CB receptor affinity.
      7-(1,1-Dimethyloctyl)-5-hydroxy-3-(2-hydroxybenzyl)-2H-chromen-2-one (69,
      PSB-SB-487, IC50 = 0.113 muM, KB = 0.561 muM) and
      7-(1,1-dimethylheptyl)-5-hydroxy-3-(2-hydroxybenzyl)-2H-chromen-2-one (67,
      PSB-SB-1203, IC50 = 0.261 muM) were the most potent GPR55 antagonists of the
      present series.
AD  - PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I,
      University of Bonn , An der Immenburg 4, D-53121 Bonn, Germany.
FAU - Rempel, Viktor
AU  - Rempel V
FAU - Volz, Nicole
AU  - Volz N
FAU - Glaser, Franziska
AU  - Glaser F
FAU - Nieger, Martin
AU  - Nieger M
FAU - Brase, Stefan
AU  - Brase S
FAU - Muller, Christa E
AU  - Muller CE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1021/jm4005175 [doi]
PST - aheadofprint
SO  - J Med Chem. 2013 May 30.

PMID- 23679951
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130521
DCOM- 20130522
LR  - 20130522
IS  - 1560-8115 (Print)
IS  - 1560-8115 (Linking)
VI  - 21
IP  - 1
DP  - 2013
TI  - Renoprotective effects of metformin.
PG  - 36
LID - 10.1186/2008-2231-21-36 [doi]
AB  - Metformin as a biguanid drug entered to the market 50 years ago and now is
      generally recommended as the first-line treatment in type 2 diabetes, especially 
      in overweight patients, however in recent years new indications for its use have 
      emerged . It improves peripheral and liver sensitivity to insulin, reduces basal 
      hepatic glucose production, increases insulin-stimulated uptake and utilization
      of glucose by peripheral tissues, decreases hunger and causes weight
      reduction.Recently, much attention has been made toward the possible kidney
      protective efficacy of metformin. Recent studies have proven that metformin,
      possesses antioxidant properties, too.
AD  - Department of Nephrology, Division of Nephropathology, Isfahan University of
      Medical Sciences, Isfahan, Iran. hamidnasri@med.mui.ac.ir.
FAU - Nasri, Running Hamid
AU  - Nasri RH
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - England
TA  - Daru
JT  - Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences
JID - 101125969
PMC - PMC3658943
OID - NLM: PMC3658943
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:01
CRDT- 2013/05/18 06:00
PHST- 2013/02/21 [received]
PHST- 2013/05/11 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 2008-2231-21-36 [pii]
AID - 10.1186/2008-2231-21-36 [doi]
PST - epublish
SO  - Daru. 2013 May 16;21(1):36. doi: 10.1186/2008-2231-21-36.

PMID- 23679924
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1475-2891 (Electronic)
IS  - 1475-2891 (Linking)
VI  - 12
DP  - 2013
TI  - The potential role of phytochemicals in wholegrain cereals for the prevention of 
      type-2 diabetes.
PG  - 62
LID - 10.1186/1475-2891-12-62 [doi]
AB  - Diets high in wholegrains are associated with a 20-30% reduction in risk of
      developing type-2 diabetes (T2D), which is attributed to a variety of wholegrain 
      components, notably dietary fibre, vitamins, minerals and phytochemicals. Most
      phytochemicals function as antioxidants in vitro and have the potential to
      mitigate oxidative stress and inflammation which are implicated in the
      pathogenesis of T2D. In this review we compare the content and bioavailability of
      phytochemicals in wheat, barley, rice, rye and oat varieties and critically
      evaluate the evidence for wholegrain cereals and cereal fractions increasing
      plasma phytochemical concentrations and reducing oxidative stress and
      inflammation in humans. Phytochemical content varies considerably within and
      among the major cereal varieties. Differences in genetics and agro-climatic
      conditions explain much of the variation. For a number of the major
      phytochemicals, such as phenolics and flavanoids, their content in grains may be 
      high but because these compounds are tightly bound to the cell wall matrix, their
      bioavailability is often limited. Clinical trials show that postprandial plasma
      phenolic concentrations are increased after consumption of wholegrain wheat or
      wheat bran however the magnitude of the response is usually modest and transient.
      Whether this is sufficient to bolster antioxidant defences and translates into
      improved health outcomes is still uncertain. Increased phytochemical
      bioavailability may be achieved through bio-processing of grains but the
      improvements so far are small and have not yet led to changes in clinical or
      physiological markers associated with reduced risk of T2D. Furthermore, the
      effect of wholegrain cereals and cereal fractions on biomarkers of oxidative
      stress or strengthening antioxidant defence in healthy individuals is generally
      small or nonexistent, whereas biomarkers of systemic inflammation tend to be
      reduced in people consuming high intakes of wholegrains. Future dietary
      intervention studies seeking to establish a direct role of phytochemicals in
      mediating the metabolic health benefits of wholegrains, and their potential for
      mitigating disease progression, should consider using varieties that deliver the 
      highest possible levels of bioavailable phytochemicals in the context of whole
      foods and diets. Both postprandial and prolonged responses in systemic
      phytochemical concentrations and markers of inflammation and oxidative stress
      should be assessed along with changes related to health outcomes in healthy
      individuals as well as those with metabolic disease.
AD  - Commonwealth Scientific & Industrial Research Organisation (CSIRO) Food Futures
      National Flagship, GPO BOX 10041, Adelaide, SA, 5000, Australia.
      damien.belobrajdic@csiro.au.
FAU - Belobrajdic, Damien P
AU  - Belobrajdic DP
FAU - Bird, Anthony R
AU  - Bird AR
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - England
TA  - Nutr J
JT  - Nutrition journal
JID - 101152213
SB  - IM
PMC - PMC3658901
OID - NLM: PMC3658901
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/02/27 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 1475-2891-12-62 [pii]
AID - 10.1186/1475-2891-12-62 [doi]
PST - epublish
SO  - Nutr J. 2013 May 16;12:62. doi: 10.1186/1475-2891-12-62.

PMID- 23679876
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Linking)
VI  - 52
IP  - 6
DP  - 2013 Jun
TI  - First reported case of subcutaneous hyalohyphomycosis caused by Paecilomyces
      variotii.
PG  - 711-3
LID - 10.1111/j.1365-4632.2012.05761.x [doi]
AB  - BACKGROUND: Hyalohyphomycosis is a rare opportunistic fungal infection caused by 
      saprophytes of genera such as Fusarium, Paecilomyces, Scedosporium, Penicillium, 
      Scopulariopsis Acremonium, and similar fungi. The literature includes only one
      previous report of Paecilomyces variotii human infection and very few reports of 
      subcutaneous mycosis caused by any of the hyalohyphomycosis group of fungi.
      METHODS: We report an instance of fungal infection in a 50-year-old woman, known 
      to have diabetes, who presented with multiple raised lesions on the upper back of
      two years' duration. Dermatological examination revealed a 20 x 22-cm, swollen,
      indurated area on the upper back with multiple violaceous, exophytic nodules on
      the surface. RESULTS: Microscopy from pus and tissue smear revealed septate
      branching fungi. Periodic acid Schiff (PAS) stain was positive for fungal
      elements. Culture on three occasions yielded P. variotii. Slide culture mounts
      showed septate hyaline hyphae of P. variotii with elongated phialides
      demonstrating bulbous bases and tapering apices attached to the conidiophores.
      The patient was treated with itraconazole, to which she responded well.
      CONCLUSIONS: This is the first reported case of subcutaneous hyalohyphomycosis
      caused by P. variotii. It appears that this relatively rare fungal pathogen may
      be starting to assert itself as an important cause of infection in humans.
CI  - (c) 2013 The International Society of Dermatology.
AD  - Department of Dermatology, Command Hospital and Armed Forces Medical College,
      Pune, India.
FAU - Vasudevan, Biju
AU  - Vasudevan B
FAU - Hazra, Nandita
AU  - Hazra N
FAU - Verma, Rajesh
AU  - Verma R
FAU - Srinivas, Vadlamannati
AU  - Srinivas V
FAU - Vijendran, Pragasam
AU  - Vijendran P
FAU - Badad, Ambresh
AU  - Badad A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1111/j.1365-4632.2012.05761.x [doi]
PST - ppublish
SO  - Int J Dermatol. 2013 Jun;52(6):711-3. doi: 10.1111/j.1365-4632.2012.05761.x.

PMID- 23679869
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Do socioeconomic inequalities in mortality vary between different Spanish cities?
      a pooled cross-sectional analysis.
PG  - 480
LID - 10.1186/1471-2458-13-480 [doi]
AB  - BACKGROUND: The relationship between deprivation and mortality in urban settings 
      is well established. This relationship has been found for several causes of death
      in Spanish cities in independent analyses (the MEDEA project). However, no joint 
      analysis which pools the strength of this relationship across several cities has 
      ever been undertaken. Such an analysis would determine, if appropriate, a joint
      relationship by linking the associations found. METHODS: A pooled cross-sectional
      analysis of the data from the MEDEA project has been carried out for each of the 
      causes of death studied. Specifically, a meta-analysis has been carried out to
      pool the relative risks in eleven Spanish cities. Different deprivation-mortality
      relationships across the cities are considered in the analysis (fixed and random 
      effects models). The size of the cities is also considered as a possible factor
      explaining differences between cities. RESULTS: Twenty studies have been carried 
      out for different combinations of sex and causes of death. For nine of them (men:
      prostate cancer, diabetes, mental illnesses, Alzheimer's disease, cerebrovascular
      disease; women: diabetes, mental illnesses, respiratory diseases, cirrhosis) no
      differences were found between cities in the effect of deprivation on mortality; 
      in four cases (men: respiratory diseases, all causes of mortality; women: breast 
      cancer, Alzheimer's disease) differences not associated with the size of the city
      have been determined; in two cases (men: cirrhosis; women: lung cancer)
      differences strictly linked to the size of the city have been determined, and in 
      five cases (men: lung cancer, ischaemic heart disease; women: ischaemic heart
      disease, cerebrovascular diseases, all causes of mortality) both kinds of
      differences have been found. Except for lung cancer in women, every significant
      relationship between deprivation and mortality goes in the same direction:
      deprivation increases mortality. Variability in the relative risks across cities 
      was found for general mortality for both sexes. CONCLUSIONS: This study provides 
      a general overview of the relationship between deprivation and mortality for a
      sample of large Spanish cities combined. This joint study allows the exploration 
      of and, if appropriate, the quantification of the variability in that
      relationship for the set of cities considered.
AD  - Centro Superior de Investigacion en Salud Publica, Av, Cataluna, 21, 46020
      Valencia, Spain. miguel.a.martinez@uv.es.
FAU - Martinez-Beneito, Miguel A
AU  - Martinez-Beneito MA
FAU - Zurriaga, Oscar
AU  - Zurriaga O
FAU - Botella-Rocamora, Paloma
AU  - Botella-Rocamora P
FAU - Mari-Dell'olmo, Marc
AU  - Mari-Dell'olmo M
FAU - Nolasco, Andreu
AU  - Nolasco A
FAU - Moncho, Joaquin
AU  - Moncho J
FAU - Daponte, Antonio
AU  - Daponte A
FAU - Dominguez-Berjon, M Felicitas
AU  - Dominguez-Berjon MF
FAU - Gandarillas, Ana
AU  - Gandarillas A
FAU - Martos, Carmen
AU  - Martos C
FAU - Montoya, Imanol
AU  - Montoya I
FAU - Sanchez-Villegas, Pablo
AU  - Sanchez-Villegas P
FAU - Taracido, Margarita
AU  - Taracido M
FAU - Borrell, Carme
AU  - Borrell C
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3659018
OID - NLM: PMC3659018
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/05/02 [received]
PHST- 2013/05/10 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 1471-2458-13-480 [pii]
AID - 10.1186/1471-2458-13-480 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 16;13:480. doi: 10.1186/1471-2458-13-480.

PMID- 23679221
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1600-0412 (Electronic)
IS  - 0001-6349 (Linking)
DP  - 2013 May 16
TI  - Pregnancy outcomes in a cohort of women with a preconception body mass index >50 
      kg/m
LID - 10.1111/aogs.12174 [doi]
AB  - We describe characteristics and risk factors regarding pregnancy outcome in women
      with a preconception body mass index (BMI) >50 kg/m2 compared with women with BMI
      </=50 kg/m2 in a retrospective population cohort study in singleton pregnancies
      from the Danish Medical Birth Registry. Results were analyzed as relative risks
      by a two-proportion z-test. Women with preconception BMI >50 kg/m2 smoked,
      developed gestational diabetes and pre-eclampsia, and needed induction of labor
      more frequently than mothers with BMI </=50 kg/m2 . Examination of the case
      records showed that many attempted vaginal delivery without epidural analgesia,
      21% needed an emergency cesarean section (compared with 12% among women with BMI 
      </=50 kg/m2 ), and 25% underwent general anesthesia in this context. Many
      neonates were macrosomic and 34% needed neonatal intensive care and early feeding
      compared with 6% of neonates from women with BMI </=50 kg/m2 . Women with an
      extremely high preconception BMI develop more pregnancy complications and their
      neonates appear affected by this as well.
CI  - (c) 2013 Nordic Federation of Societies of Obstetrics and Gynecology.
AD  - Department of Gynecology and Obstetrics, Holbaek Hospital, Holbaek, Denmark.
FAU - Bonnesen, Barbara
AU  - Bonnesen B
FAU - Secher, Niels J
AU  - Secher NJ
FAU - Moller, Lars K
AU  - Moller LK
FAU - Rasmussen, Steen
AU  - Rasmussen S
FAU - Andreasen, Kirsten R
AU  - Andreasen KR
FAU - Renault, Kristina
AU  - Renault K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Acta Obstet Gynecol Scand
JT  - Acta obstetricia et gynecologica Scandinavica
JID - 0370343
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/04/08 [received]
PHST- 2013/05/10 [accepted]
AID - 10.1111/aogs.12174 [doi]
PST - aheadofprint
SO  - Acta Obstet Gynecol Scand. 2013 May 16. doi: 10.1111/aogs.12174.

PMID- 23679188
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 16
TI  - Ghrelin suppression is associated with weight loss and insulin action following
      gastric bypass surgery at 12 months in obese adults with type 2 diabetes.
LID - 10.1111/dom.12118 [doi]
AB  - Roux-en-Y gastric bypass (RYGB) surgery reverses type 2 diabetes mellitus (T2DM) 
      in approximately 80% of patients. Ghrelin regulates glucose homeostasis, but its 
      role in T2DM remission after RYGB surgery is unclear. Nine obese T2DM subjects
      underwent a mixed meal tolerance test before and at 1 and 12 months after RYGB
      surgery. Changes in ghrelin, body weight, glucagon-like polypeptide-1 (GLP-1,
      glucose tolerance and insulin sensitivity (IS) were measured. At 1 month, body
      weight, glycaemia and IS were improved, while ghrelin concentrations were reduced
      (p < 0.05). After 12 months, body weight and fasting glucose were reduced (30 and
      16%, respectively; p < 0.05) and IS was enhanced (threefold; p < 0.05). Ghrelin
      suppression improved by 32% at 12 months (p < 0.05), and this was associated with
      weight loss (r = 0.72, p = 0.03), enhanced IS (r = -0.78, p = 0.01) and peak
      postprandial GLP-1 (r = -0.73, p = 0.03). These data suggest that postprandial
      ghrelin suppression may be part of the mechanism that contributes to diabetes
      remission after RYGB surgery.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic,
      Cleveland, OH, USA.
FAU - Samat, A
AU  - Samat A
FAU - Malin, S K
AU  - Malin SK
FAU - Huang, H
AU  - Huang H
FAU - Schauer, P R
AU  - Schauer PR
FAU - Kirwan, J P
AU  - Kirwan JP
FAU - Kashyap, S R
AU  - Kashyap SR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/11/15 [received]
PHST- 2012/12/27 [revised]
PHST- 2013/03/26 [accepted]
AID - 10.1111/dom.12118 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 16. doi: 10.1111/dom.12118.

PMID- 23679181
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1442-200X (Electronic)
VI  - 55
IP  - 2
DP  - 2013 Apr
TI  - Japanese boy with maturity-onset diabetes of the young type 3 who developed
      diabetes at 19 months old.
PG  - e32-4
LID - 10.1111/j.1442-200X.2012.03741.x [doi]
AB  - Maturity-onset diabetes of the young type 3 (MODY3) is caused by hepatocyte
      nuclear factor 1alpha gene mutation and is clinically characterized by young
      onset and insufficient insulin secretion. We report a 19-month-old Japanese boy
      with a family history of young-onset diabetes who was initially diagnosed with
      type 1 diabetes. Mutational analysis of the hepatocyte nuclear factor 1alpha gene
      revealed a novel heterozygous frameshift mutation (c.593delA p.Lys198fs)
      resulting in a truncated protein in the patient and his father. The patient was
      diagnosed as having MODY3 and was successfully treated with insulin glargine. We 
      could not determine the genetic or environmental factors to explain the
      difference in the age of disease onset within the same family. This is the
      youngest case of a MODY3 child presenting with overt diabetes. Our experience
      suggests that clinicians should always consider the possible diagnosis of MODY3
      in a diabetic child with a family history of young-onset diabetes and should
      perform molecular investigations.
CI  - (c) 2013 The Authors. Pediatrics International (c) 2013 Japan Pediatric Society.
AD  - Department of Pediatrics, University of Tsukuba, Ibaraki, Japan.
FAU - Iwabuchi, Atsushi
AU  - Iwabuchi A
FAU - Kamoda, Tomohiro
AU  - Kamoda T
FAU - Shinohara, Hiroyuki
AU  - Shinohara H
FAU - Sumazaki, Ryo
AU  - Sumazaki R
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Pediatr Int
JT  - Pediatrics international : official journal of the Japan Pediatric Society
JID - 100886002
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2012/06/03 [received]
PHST- 2012/08/13 [revised]
PHST- 2012/09/19 [accepted]
AID - 10.1111/j.1442-200X.2012.03741.x [doi]
PST - ppublish
SO  - Pediatr Int. 2013 Apr;55(2):e32-4. doi: 10.1111/j.1442-200X.2012.03741.x.

PMID- 23679132
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 16
TI  - Habitual snoring and depressive symptoms during pregnancy.
PG  - 113
AB  - BACKGROUND: Depression is frequently observed in patients with untreated
      sleep-disordered breathing (SDB) in the general population. Pregnant women are
      particularly vulnerable since pregnancy increases the risk of both SDB and
      depressive symptoms. However, no study has investigated whether SDB symptoms
      prior to or in early pregnancy are associated with such mood problems. METHODS: A
      retrospective chart review of pregnant women. Women were included if they
      attended prenatal clinics between June 2007 and July 2010, were >=18 years old,
      pregnant with a single fetus, and had been screened for habitual snoring as well 
      as depressive symptoms using the Edinburgh Postnatal Depression Scales (EPDS).
      RESULTS: In total, 362 women were included and 32.3% reported habitual snoring.
      Twenty-nine percent of women had an EPDS score >=10. Significantly more snoring
      women, compared to non-snorers, had an EPDS score >=10 (42.7% vs. 22.9%, p <
      0.001) despite the mean EPDS values not reaching statistical significance (6.1
      +/- 4.9 vs. 5.4 +/- 5.0, p = 0.2). In a logistic regression model controlling for
      parity, the presence of pre-pregnancy obesity, presence of a partner, sleep
      quality, African American race, maternal educational level, pre-eclampsia, and
      diabetes, snoring was independently associated with a prenatal EPDS score >=10
      (O.R. 2.0, 95%CI 1.13-3.46; p = 0.023). CONCLUSION: Maternal snoring may be a
      risk factor for prenatal depressive symptoms. Further investigation of the
      temporal relationship between maternal snoring and depressive symptoms is
      warranted.
FAU - O Brien, Louise M
AU  - O Brien LM
FAU - Owusu, Jocelynn T
AU  - Owusu JT
FAU - Swanson, Leslie M
AU  - Swanson LM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
PMC - PMC3660222
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/02/28 [received]
PHST- 2013/05/16 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 1471-2393-13-113 [pii]
AID - 10.1186/1471-2393-13-113 [doi]
PST - aheadofprint
SO  - BMC Pregnancy Childbirth. 2013 May 16;13(1):113.

PMID- 23679086
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 Apr 23
TI  - Hepatoselectivity and the evolution of insulin.
LID - 10.1111/dom.12117 [doi]
AB  - In spite of major developments in insulin production, purification,
      pharmaceutical formulation and methods of delivery, problems remain both in the
      day to day management of insulin-treated diabetes and with regard to its
      long-term complications. The risks of hypoglycaemia and weight gain are major
      concerns particularly for the patient, and the persistence of microvascular and
      premature macrovascular complications as the main causes of morbidity and
      mortality in both type 1 and type 2 diabetes is a constant reminder that our
      therapeutic and management strategies are inadequate. One clear and striking
      difference between currently available insulin treatments and normal physiology
      is the relative difference in exposure to insulin of the liver versus peripheral 
      tissues. Hepatoselective insulin analogues have the potential to restore the
      normal hepatic to peripheral gradient in insulin action. Here, we discuss the
      possible therapeutic potential that such analogues may have over currently
      available insulin preparations. These benefits could include a lower risk of
      hypoglycaemia, less weight gain and a potential reduction in microvascular and
      macrovascular complications. We explore the evolution of insulin with
      hepatoselectivity in mind and possible strategies to create hepatoselective
      insulins.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Centre for Endocrinology, Diabetes and Research, Royal Surrey County Hospital,
      Guildford, UK.
FAU - Herring, R
AU  - Herring R
FAU - Jones, R H
AU  - Jones RH
FAU - Russell-Jones, D L
AU  - Russell-Jones DL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PHST- 2013/03/21 [received]
PHST- 2013/04/09 [revised]
PHST- 2013/04/15 [accepted]
AID - 10.1111/dom.12117 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 Apr 23. doi: 10.1111/dom.12117.

PMID- 23678871
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
DP  - 2013 Jun 6
TI  - Discovery of a Highly Potent, Nonabsorbable Apical Sodium-Dependent Bile Acid
      Transporter Inhibitor (GSK2330672) for Treatment of Type 2 Diabetes.
AB  - The apical sodium-dependent bile acid transporter (ASBT) transports bile salts
      from the lumen of the gastrointestinal (GI) tract to the liver via the portal
      vein. Multiple pharmaceutical companies have exploited the physiological link
      between ASBT and hepatic cholesterol metabolism, which led to the clinical
      investigation of ASBT inhibitors as lipid-lowering agents. While modest lipid
      effects were demonstrated, the potential utility of ASBT inhibitors for treatment
      of type 2 diabetes has been relatively unexplored. We initiated a lead
      optimization effort that focused on the identification of a potent, nonabsorbable
      ASBT inhibitor starting from the first-generation inhibitor 264W94 (1). Extensive
      SAR studies culminated in the discovery of GSK2330672 (56) as a highly potent,
      nonabsorbable ASBT inhibitor which lowers glucose in an animal model of type 2
      diabetes and shows excellent developability properties for evaluating the
      potential therapeutic utility of a nonabsorbable ASBT inhibitor for treatment of 
      patients with type 2 diabetes.
AD  - GlaxoSmithKline Research & Development, Five Moore Drive, Research Triangle Park,
      North Carolina 27709, United States.
FAU - Wu, Yulin
AU  - Wu Y
FAU - Aquino, Christopher J
AU  - Aquino CJ
FAU - Cowan, David J
AU  - Cowan DJ
FAU - Anderson, Don L
AU  - Anderson DL
FAU - Ambroso, Jeff L
AU  - Ambroso JL
FAU - Bishop, Michael J
AU  - Bishop MJ
FAU - Boros, Eric E
AU  - Boros EE
FAU - Chen, Lihong
AU  - Chen L
FAU - Cunningham, Alan
AU  - Cunningham A
FAU - Dobbins, Robert L
AU  - Dobbins RL
FAU - Feldman, Paul L
AU  - Feldman PL
FAU - Harston, Lindsey T
AU  - Harston LT
FAU - Kaldor, Istvan W
AU  - Kaldor IW
FAU - Klein, Ryan
AU  - Klein R
FAU - Liang, Xi
AU  - Liang X
FAU - McIntyre, Maggie S
AU  - McIntyre MS
FAU - Merrill, Christine L
AU  - Merrill CL
FAU - Patterson, Kristin M
AU  - Patterson KM
FAU - Prescott, Judith S
AU  - Prescott JS
FAU - Ray, John S
AU  - Ray JS
FAU - Roller, Shane G
AU  - Roller SG
FAU - Yao, Xiaozhou
AU  - Yao X
FAU - Young, Andrew
AU  - Young A
FAU - Yuen, Josephine
AU  - Yuen J
FAU - Collins, Jon L
AU  - Collins JL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
AID - 10.1021/jm400459m [doi]
PST - aheadofprint
SO  - J Med Chem. 2013 Jun 6.

PMID- 23678712
OWN - NLM
STAT- In-Process
DA  - 20130517
IS  - 1009-3591 (Print)
IS  - 1009-3591 (Linking)
VI  - 19
IP  - 4
DP  - 2013 Apr
TI  - [Sexual function of middle-aged and older males in Beijing: urban versus suburban
      area].
PG  - 328-31
AB  - OBJECTIVE: To investigate and compare the prevalence of erectile dysfunction,
      hyposexuality and ejaculation disorder among middle-aged and older males in the
      urban and suburban areas of Beijing. METHODS: Using the random sampling method,
      we selected 1 656 men aged > or = 50 years from 15 communities in Beijing. We
      recorded their scores on the International Index of Erectile Function-5 (IIEF-5) 
      and Brief Male Sexual Function Inventory for Urology (O'Leary 1995), and analyzed
      the obtained data using SPSS 17.0. RESULTS: Totally, 1 644 of the subjects were
      qualified for the study, 1 244 from the urban area and the other 400 from the
      suburbs. The median scores on IIEF-5, sexual desire and ejaculation were 5, 2 and
      4 in the urban males as compared with 13, 2 and 5 in the suburban men, with
      statistically significant differences between the two groups (P < 0.01). The
      IIEF-5 score was significantly correlated with age, diabetes,
      cardiocerebrovascular diseases, drinking and administration of 5alpha-reductase
      inhibitor in both the urban and suburban groups (P < 0.01). CONCLUSION: The
      sexual function of the middle-aged and older males is better in the suburbs than 
      in the urban area of Beijing. The main reasons might be the lower incidences of
      diabetes and cardiocerebrovascular diseases, moderate drinking and less use of
      5alpha-reductase inhibitor among the suburban men. Natl J Androl, 2013, 19 (4) : 
      328 -331
AD  - Department of Urology, Beijing Changping Hospital, Beijing 102200, China.
      magumiao@163.com
FAU - Yang, Dong-Quan
AU  - Yang DQ
FAU - Sui, Wen-Xue
AU  - Sui WX
FAU - Ma, Ran
AU  - Ma R
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Nan Ke Xue
JT  - Zhonghua nan ke xue = National journal of andrology
JID - 101093592
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PST - ppublish
SO  - Zhonghua Nan Ke Xue. 2013 Apr;19(4):328-31.

PMID- 23678598
OWN - NLM
STAT- In-Process
DA  - 20130516
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 71
IP  - 4
DP  - 2013 Apr
TI  - [Quetiapine].
PG  - 673-7
AB  - Quetiapine is a unique antipsychotic drug characterized by the weakest affinity
      for dopamine D2 receptors of all the antipsychotics. This drug certainly binds D2
      receptors, but rapidly dissociates from them. Therefore, it is necessary to
      establish how to use quetiapine in the different way from potent and sustained D2
      receptor antagonists such as haloperidol. Plenty dose of quetiapine is effective 
      for schizophrenia patients suffered from severe insomnia, catatonia, emotional
      instability, impulsiveness and aggressiveness. However, in order to avoid
      metabolic side effects including weight gain and diabetes mellitus, we have to
      continue a longitudinal blood glucose monitoring in schizophrenia patients
      treated with quetiapine.
AD  - Department of Psychiatry, Hokkaido University Graduate School of Medicine.
FAU - Kusumi, Ichiro
AU  - Kusumi I
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
SB  - IM
EDAT- 2013/05/18 06:00
MHDA- 2013/05/18 06:00
CRDT- 2013/05/18 06:00
PST - ppublish
SO  - Nihon Rinsho. 2013 Apr;71(4):673-7.

PMID- 23678475
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130516
DCOM- 20130517
LR  - 20130520
IS  - 2233-7385 (Print)
IS  - 2233-7393 (Linking)
VI  - 49
IP  - 1
DP  - 2013 Apr
TI  - Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin 
      in patients with mild to moderate hypertension.
PG  - 31-7
LID - 10.4068/cmj.2013.49.1.31 [doi]
AB  - The effects of statins on insulin resistance and new-onset diabetes are unclear. 
      The purpose of this study was to evaluate the effects of rosuvastatin on insulin 
      resistance and adiponectin in patients with mild to moderate hypertension. In a
      randomized, prospective, single-blind study, 53 hypertensive patients were
      randomly assigned to the control group (n=26) or the rosuvastatin (20 mg once
      daily) group (n=27) during an 8-week treatment period. Both groups showed
      significant improvements in systolic blood pressure and flow-mediated dilation
      (FMD) after 8 weeks of treatment. Rosuvastatin treatment improved total
      cholesterol, low-density lipoprotein (LDL)-cholesterol, and triglyceride levels. 
      The control and rosuvastatin treatment groups did not differ significantly in the
      change in HbA1c (3.0+/-10.1% vs. -1.3+/-12.7%; p=0.33), fasting glucose
      (-1.3+/-18.0% vs. 2.5+/-24.1%; p=0.69), or fasting insulin levels (5.2+/-70.5%
      vs. 22.6+/-133.2%; p=0.27) from baseline. Furthermore, the control and
      rosuvastatin treatment groups did not differ significantly in the change in the
      QUICKI insulin sensitivity index (mean change, 2.2+/-11.6% vs. 3.6+/-11.9%;
      p=0.64) or the HOMA index (11.6+/-94.9% vs. 32.4+/-176.7%; p=0.44). The plasma
      adiponectin level increased significantly in the rosuvastatin treatment group
      (p=0.046), but did not differ significantly from that in the control group (mean 
      change, 23.2+/-28.4% vs. 23.1+/-27.6%; p=0.36). Eight weeks of rosuvastatin (20
      mg) therapy resulted in no significant improvement or deterioration in fasting
      glucose levels, insulin resistance, or adiponectin levels in patients with mild
      to moderate hypertension.
AD  - Cardiology Division, Department of Internal Medicine, Kyung Hee University School
      of Medicine, Seoul, Korea.
FAU - Kim, Weon
AU  - Kim W
FAU - Hong, Myong Joo
AU  - Hong MJ
FAU - Woo, Jong Shin
AU  - Woo JS
FAU - Kang, Won Yu
AU  - Kang WY
FAU - Hwang, Sun Ho
AU  - Hwang SH
FAU - Kim, Wan
AU  - Kim W
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Korea (South)
TA  - Chonnam Med J
JT  - Chonnam medical journal
JID - 101564659
PMC - PMC3651984
OID - NLM: PMC3651984
OTO - NOTNLM
OT  - Adiponectin
OT  - Blood glucose
OT  - Hydroxymethylglutaryl-CoA reductase inhibitors
OT  - Insulin resistance
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:01
CRDT- 2013/05/17 06:00
PHST- 2013/01/10 [received]
PHST- 2013/03/04 [revised]
PHST- 2013/03/05 [accepted]
PHST- 2013/04/25 [epublish]
AID - 10.4068/cmj.2013.49.1.31 [doi]
PST - ppublish
SO  - Chonnam Med J. 2013 Apr;49(1):31-7. doi: 10.4068/cmj.2013.49.1.31. Epub 2013 Apr 
      25.

PMID- 23678392
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130516
DCOM- 20130517
LR  - 20130520
IS  - 2093-2278 (Print)
IS  - 2093-2278 (Linking)
VI  - 43
IP  - 2
DP  - 2013 Apr
TI  - The expression of a nitric oxide derivative, tissue inhibitors of
      metalloproteinase-3, and tissue inhibitors of metalloproteinase-4 in chronic
      periodontitis with type 2 diabetes mellitus.
PG  - 87-95
LID - 10.5051/jpis.2013.43.2.87 [doi]
AB  - PURPOSE: The purpose of this study was to analyze the expression of inducible
      nitric oxide synthases (iNOS), tissue inhibitors of metalloproteinase (TIMP)-3,
      and TIMP-4 in the gingival tissues of periodontal patients with or without type 2
      diabetes mellitus (DM). METHODS: Depending on the patient's systemic condition
      and clinical criteria of the gingiva, each gingival sample was classified into
      one of three groups. Sixteen clinically, systemically healthy patients (group 1),
      16 periodontal patients (group 2), and 16 periodontal patients with DM (group 3) 
      were included. Tissue samples in each group were collected, prepared, and
      analyzed by western blotting. Quantification of the relative amount of TIMP-3,
      TIMP-4, and iNOS was performed. RESULTS: The expression levels of iNOS and TIMP-3
      both increased in group 1, group 2, and group 3 in increasing order, and were
      significantly higher in both group 2 and group 3 as compared to group 1 (P<0.05).
      The expression levels of TIMP-4 increased in the same order, but significantly
      increased in group 2 as compared to group 1, in group 3 as compared to group 1,
      and group 3 as compared to group 2 (P<0.05). CONCLUSIONS: This study demonstrated
      that iNOS, TIMP-3, and TIMP-4 might be involved in the progression of periodontal
      inflammation associated with type 2 DM. It is thought that further study of these
      factors can be applied practically for the diagnosis and control of periodontitis
      in diabetics.
AD  - Department of Periodontology, Kyungpook National University School of Dentistry, 
      Daegu, Korea.
FAU - Jung, Hyun-Yub
AU  - Jung HY
FAU - Kim, Yong-Gun
AU  - Kim YG
FAU - Park, Jin-Woo
AU  - Park JW
FAU - Suh, Jo-Young
AU  - Suh JY
FAU - Lee, Jae-Mok
AU  - Lee JM
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Korea (South)
TA  - J Periodontal Implant Sci
JT  - Journal of periodontal & implant science
JID - 101526931
PMC - PMC3651942
OID - NLM: PMC3651942
OTO - NOTNLM
OT  - Chronic periodontitis
OT  - Diabetes mellitus
OT  - Nitric oxide synthase
OT  - Tissue inhibitor of metalloproteinases
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:01
CRDT- 2013/05/17 06:00
PHST- 2012/12/20 [received]
PHST- 2013/03/10 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.5051/jpis.2013.43.2.87 [doi]
PST - ppublish
SO  - J Periodontal Implant Sci. 2013 Apr;43(2):87-95. doi: 10.5051/jpis.2013.43.2.87. 
      Epub 2013 Apr 30.

PMID- 23678391
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130516
DCOM- 20130517
LR  - 20130520
IS  - 2093-2278 (Print)
IS  - 2093-2278 (Linking)
VI  - 43
IP  - 2
DP  - 2013 Apr
TI  - Effect of scaling and root planing combined with systemic doxycycline therapy on 
      glycemic control in diabetes mellitus subjects with chronic generalized
      periodontitis: a clinical study.
PG  - 79-86
LID - 10.5051/jpis.2013.43.2.79 [doi]
AB  - PURPOSE: The purpose of study was to compare glycemic control using glycated
      hemoglobin levels (HbA1c) in diabetic patients with chronic generalized
      periodontitis (CGP) undergoing scaling and root planing (SRP) with and without
      systemic doxycycline. METHODS: Fifty subjects with type 2 diabetes mellitus
      (T2DM) and CGP receiving antidiabetic therapy were selected for study. The
      selected subjects were randomly assigned to two groups (test group [TG] and
      control group [CG]) comprising 25 patients each. The TG received SRP followed by 
      systemic doxycycline. The CG received treatment with SRP only. The periodontal
      parameters were recorded at baseline (day zero), and every 1 month for 4 months
      and included probing depth, clinical attachment level, plaque index, gingival
      index, and HbA1c level were recorded at baseline (day zero) and at the end of 4
      months. RESULTS: A statistically significant effect was demonstrated for the
      periodontal parameters for both the TG and CG. HbA1c values did not show a
      statistically significant difference in the treatment group as compared to the
      CG. CONCLUSIONS: The authors concluded that nonsurgical periodontal therapy
      improved glycemic control in patients with T2DM in both groups, but no
      statistical difference was observed with adjunctive systemic doxycycline therapy.
      A further study with a larger sample size is required.
AD  - Department of Periodontics, Tatyasaheb Kore Dental College and Research Centre,
      Kolhapur, India.
FAU - Gaikwad, Subodh P
AU  - Gaikwad SP
FAU - Gurav, Abhijit N
AU  - Gurav AN
FAU - Shete, Abhijeet R
AU  - Shete AR
FAU - Desarda, Hitesh M
AU  - Desarda HM
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Korea (South)
TA  - J Periodontal Implant Sci
JT  - Journal of periodontal & implant science
JID - 101526931
PMC - PMC3651941
OID - NLM: PMC3651941
OTO - NOTNLM
OT  - Chronic periodontitis
OT  - Diabetes mellitus
OT  - Glycosylated hemoglobin A
OT  - Periodontal debridement
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:01
CRDT- 2013/05/17 06:00
PHST- 2013/01/15 [received]
PHST- 2013/03/05 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.5051/jpis.2013.43.2.79 [doi]
PST - ppublish
SO  - J Periodontal Implant Sci. 2013 Apr;43(2):79-86. doi: 10.5051/jpis.2013.43.2.79. 
      Epub 2013 Apr 30.

PMID- 23678154
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 0315-162X (Electronic)
IS  - 0315-162X (Linking)
DP  - 2013 May 15
TI  - Serum Urate and Incidence of Kidney Disease Among Veterans with Gout.
AB  - OBJECTIVE: To study the association between serum urate level (sUA) and the risk 
      of incident kidney disease among US veterans with gouty arthritis. METHODS: From 
      2002 through 2011 adult male patients with gout who were free of kidney disease
      were identified in the data from the Veterans Administration VISN 16 database and
      were followed until incidence of kidney disease, death, or the last available
      observation. Accumulated hazard curves for time to kidney disease were estimated 
      for patients with average sUA levels > 7 mg/dl (high) versus </= 7 mg/dl (low)
      based on Kaplan-Meier analyses; and statistical comparison was conducted using a 
      log-rank test. A Cox proportional hazard model with time-varying covariates was
      used to estimate the unadjusted and adjusted hazard ratios for kidney disease.
      RESULTS: Eligible patients (n = 2116) were mostly white (53%), with average age
      62.6 years, mean body mass index 31.2 kg/m2, and high baseline prevalence of
      hypertension (93%), hyperlipidemia (67%), and diabetes (20%). Mean followup time 
      was 6.5 years. The estimated rates of all incident kidney disease in the overall 
      low versus high sUA groups were 2% versus 4% at Year 1, 3% versus 6% at Year 2,
      and 5% versus 9% at Year 3, respectively (p < 0.0001). After adjustment, high sUA
      continued to predict a significantly higher risk of kidney disease development
      (HR 1.43, 95% CI 1.20-1.70). CONCLUSION: Male veterans with gout and sUA levels >
      7 mg/dl had an increased incidence of kidney disease.
AD  - From Stanford University, Stanford, California; Takeda Pharmaceuticals
      International Inc., Deerfield, Illinois; Analysis Group Inc., Boston,
      Massachusetts; Tulane University, New Orleans, Louisiana; and Southeast Louisiana
      Veterans Health Care System, New Orleans, Louisiana, USA.
FAU - Krishnan, Eswar
AU  - Krishnan E
FAU - Akhras, Kasem S
AU  - Akhras KS
FAU - Sharma, Hari
AU  - Sharma H
FAU - Marynchenko, Maryna
AU  - Marynchenko M
FAU - Wu, Eric
AU  - Wu E
FAU - Tawk, Rima H
AU  - Tawk RH
FAU - Liu, Jinan
AU  - Liu J
FAU - Shi, Lizheng
AU  - Shi L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - jrheum.121061 [pii]
AID - 10.3899/jrheum.121061 [doi]
PST - aheadofprint
SO  - J Rheumatol. 2013 May 15.

PMID- 23678086
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - The usefulness of metformin for diabetes control in older people.
PG  - f3077
LID - 10.1136/bmj.f3077 [doi]
LID - bmj.f3077 [pii]
AD  - Institute for Genetic Medicine, University of Newcastle on Tyne, Endocrine Unit, 
      Royal Victoria Infirmary, Newcastle NE1 4LP, UK.
FAU - Quinton, Richard
AU  - Quinton R
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PST - epublish
SO  - BMJ. 2013 May 15;346:f3077. doi: 10.1136/bmj.f3077.

PMID- 23678081
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Funding ignores clinical aspects of diabetes targets.
PG  - f3046
LID - 10.1136/bmj.f3046 [doi]
LID - bmj.f3046 [pii]
AD  - Canterbury Road Surgery, Sittingbourne ME10 4JA, UK.
FAU - Beerstecher, Hendrik J
AU  - Beerstecher HJ
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PST - epublish
SO  - BMJ. 2013 May 15;346:f3046. doi: 10.1136/bmj.f3046.

PMID- 23678045
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1522-1466 (Electronic)
IS  - 1522-1466 (Linking)
DP  - 2013 May 15
TI  - ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex
      of OVE26 mice.
AB  - Matrix protein accumulation is a prominent feature of diabetic nephropathy that
      contributes to renal fibrosis and decline in renal function. The pathogenic
      mechanisms of matrix accumulation are incompletely characterized. We investigated
      if the matrix metalloprotease A Disintegrin And Metalloprotease17 (ADAM17), known
      to cleave growth factors and cytokines, is activated in the kidney cortex of
      OVE26 type 1 diabetic mice and potential mechanisms by which ADAM17 mediates
      extracellular matrix accumulation. Protein expression and activity of ADAM17 were
      increased in OVE26 kidney cortex. Using a pharmacological inhibitor to ADAM17,
      TMI-005, we determined that ADAM17 activation results in increased type IV
      collagen, Nox4, and NADPH oxidase activity in the kidney cortex of diabetic mice.
      In cultured mouse proximal tubular epithelial cells (MCTs), high glucose
      increases ADAM17 activity, Nox4 and fibronectin expression, cellular collagen
      content, and NADPH oxidase activity. These effects of glucose were inhibited when
      cells were pretreated with TMI-005 and/or transfected with siADAM17.
      Collectively, these data indicate a novel mechanism whereby hyperglycemia in
      diabetes increases extracellular matrix protein expression in the kidney cortex
      through activation of ADAM17 and enhanced oxidative stress through Nox enzyme
      activation. Additionally, our study is the first to provide evidence that Nox4 is
      downstream of ADAM17.
AD  - 1University of Texas Health Science Center at San Antonio.
FAU - Ford, Bridget M
AU  - Ford BM
FAU - Eid, Assaad A
AU  - Eid AA
FAU - Gooz, Monika
AU  - Gooz M
FAU - Barnes, Jeffrey L
AU  - Barnes JL
FAU - Gorin, Yves C
AU  - Gorin YC
FAU - Abboud, Hanna E
AU  - Abboud HE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Am J Physiol Renal Physiol
JT  - American journal of physiology. Renal physiology
JID - 100901990
OTO - NOTNLM
OT  - ADAM17
OT  - Nox4
OT  - OVE26 mice
OT  - diabetic nephropathy
OT  - extracellular matrix
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - ajprenal.00522.2012 [pii]
AID - 10.1152/ajprenal.00522.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Renal Physiol. 2013 May 15.

PMID- 23678028
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1522-1490 (Electronic)
IS  - 0363-6119 (Linking)
DP  - 2013 May 15
TI  - Does endoplasmic reticulum stress mediate endothelin-1-induced renal
      inflammation?
AB  - Endothelin-1 (ET-1) is the most potent vasoconstrictor peptide known. It exerts
      its actions through two pharmacologically different receptors: ETA and ETB
      receptors. In the renal vasculature, there is a majority of ETB receptors in the 
      efferent arteriole, while a greater amount of ETA receptors are located in the
      afferent arteriole. The nephron is rich in ETB receptors, especially in the thick
      ascending limb and collecting ducts, while containing a smaller amount of ETA
      receptors. High levels of circulating or renal ET-1 have been described in
      cardiovascular diseases such as hypertension or diabetes, diseases also
      associated to renal inflammation. Despite extensive evidence associating high
      levels of ET-1 to increased renal inflammation, the molecular mechanism(s) by
      which ET-1 leads to renal immune infiltration and/or immune activation remains
      unknown. In this mini-review, we propose that the ET-1/ETA pathway mediates an
      increase in renal endoplasmic reticulum (ER) stress, initially a survival
      mechanism that if prolonged, leads to the eventual death of the cell via
      apoptosis.
AD  - 1Georgia Regents University.
FAU - De Miguel, Carmen
AU  - De Miguel C
FAU - Pollock, Jennifer S
AU  - Pollock JS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Am J Physiol Regul Integr Comp Physiol
JT  - American journal of physiology. Regulatory, integrative and comparative
      physiology
JID - 100901230
OTO - NOTNLM
OT  - ER stress
OT  - endothelin-1
OT  - renal inflammation
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - ajpregu.00184.2013 [pii]
AID - 10.1152/ajpregu.00184.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Regul Integr Comp Physiol. 2013 May 15.

PMID- 23677932
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 15
TI  - CRTC2 is required for beta cell function and proliferation.
AB  - Previous work in insulinoma cell lines has established that calcineurin plays a
      critical role in the activation of Creb, a key transcription factor required for 
      beta cell function and survival, by dephosphorylating the Creb coactivator Crtc2 
      at two regulatory sites, Ser171 and Ser275. Here we report that Crtc2 is
      essential both for glucose-stimulated insulin secretion and cell survival in the 
      beta cell. Endogenous Crtc2 activation is achieved via increasing glucose levels 
      to the physiological feeding range, indicating that Crtc2 is a sensor that
      couples ambient glucose concentrations to Creb activity in the beta cell.
      Immunosuppressant drugs such as CsA and FK506 that target the protein phosphatase
      calcineurin are commonly administered following organ transplantation. Chronic
      use is associated with reduced insulin secretion and new onset diabetes,
      suggestive of pancreatic beta cell dysfunction. Importantly, we show that
      overexpression of a Crtc2 mutant rendered constitutively active by introduction
      of non-phosphorylatable alanine residues at Ser171 and Ser275 permits Creb target
      gene activation under conditions when calcineurin is inhibited. Taken together,
      these data suggest promoting Crtc2-Creb activity is required for beta cell
      function and proliferation and promoting this pathway could ameliorate symptoms
      of new onset diabetes after transplantation (NODAT).
AD  - 1Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Rd, Ottawa,
      K1H 8L1, Canada;
FAU - Eberhard, Chandra E
AU  - Eberhard CE
FAU - Fu, Accalia
AU  - Fu A
FAU - Reeks, Courtney
AU  - Reeks C
FAU - Screaton, Robert A
AU  - Screaton RA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - en.2012-2088 [pii]
AID - 10.1210/en.2012-2088 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 15.

PMID- 23677929
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 15
TI  - Implication of Insulin Receptor A Isoform and IRA/IGF-IR Hybrid Receptors in the 
      Aortic Vascular Smooth Muscle Cell Proliferation: Role of TNF-alpha and IGF-II.
AB  - To assess the role of insulin receptor (IR) isoforms (IRA and IRB) in the
      proliferation of vascular smooth muscle cells (VSMCs) involved in the
      atherosclerotic process, we generated new VSMC lines bearing IR (wild-type VSMCs;
      IRLoxP+/+ VSMCs), lacking IR (IR-/- VSMCs) or expressing IRA (IRA VSMCs) or IRB
      (IRB VSMCs). Insulin and different proatherogenic stimuli induced a significant
      increase of IRA expression in IRLoxP+/+ VSMCs. Moreover, insulin, through ERK
      signaling, and the proatherogenic stimuli, through ERK and p38 signaling, induced
      a higher proliferation in IRA than IRB VSMCs. The latter effect might be due to
      IRA cells showing a higher expression of Ang II, ET-1, and TXA2 receptors and
      basal association between IRA and these receptors. Furthermore, TNF-alpha induced
      in a ligand-dependent manner a higher association between IRA and TNF-alpha
      receptor 1 (TNF-R1). On the other hand, IRA overexpression might favor the
      atherogenic actions of IGF-II. Thereby, IGF-II or TNF-alpha induced IRA and IGF-I
      receptor (IGF-IR) overexpression as well as an increase of IRA/IGF-IR hybrid
      receptors in VSMCs. More importantly, we observed a significant increase of IRA, 
      TNF-R1, and IGF-IR expression as well as higher association of IRA with TNF-R1 or
      IGF-IR in the aorta from ApoE-/- and BATIRKO mice, 2 models showing vascular
      damage. In addition, anti-TNF-alpha treatment prevented those effects in BATIRKO 
      mice. Finally, our data suggest that the IRA isoform and its association with
      TNF-R1 or IGF-IR confers proliferative advantage to VSMCs, mainly in response to 
      TNF-alpha or IGF-II, which might be of significance in the early atherosclerotic 
      process.
AD  - Biochemistry and Molecular Biology Department, School of Pharmacy, Complutense
      University of Madrid, IdISHCSC, CIBER of Diabetes and Associated Metabolic
      Diseases, Instituto de Salud Carlos III, Madrid 28040, Spain.
FAU - Gomez-Hernandez, Almudena
AU  - Gomez-Hernandez A
FAU - Escribano, Oscar
AU  - Escribano O
FAU - Perdomo, Liliana
AU  - Perdomo L
FAU - Otero, Yolanda F
AU  - Otero YF
FAU - Garcia-Gomez, Gema
AU  - Garcia-Gomez G
FAU - Fernandez, Silvia
AU  - Fernandez S
FAU - Beneit, Nuria
AU  - Beneit N
FAU - Benito, Manuel
AU  - Benito M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - en.2012-2161 [pii]
AID - 10.1210/en.2012-2161 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 15.

PMID- 23677924
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1941-3297 (Electronic)
IS  - 1941-3289 (Linking)
DP  - 2013 May 15
TI  - Physical Fitness and Risk for Heart Failure and Coronary Artery Disease.
AB  - BACKGROUND: -Multiple studies have demonstrated strong associations between
      cardiorespiratory fitness and lower cardiovascular disease mortality. In
      contrast, little is known about associations of fitness with non-fatal
      cardiovascular events. METHODS AND RESULTS: -Linking individual participant data 
      from the Cooper Center Longitudinal Study with Medicare claims files, we studied 
      20,642 participants (21% women) with fitness measured at mean age 49 years and
      who survived to receive Medicare coverage from 1999 to 2009. Fitness was
      categorized into age- and sex-specific quintiles (Q) according to Balke protocol 
      treadmill time with Q1 as low fitness. Fitness was also estimated in metabolic
      equivalents according to treadmill time. Associations between midlife fitness and
      hospitalizations for heart failure and acute myocardial infarction after age 65
      were assessed by applying a proportional hazards model to the multivariate
      failure time data. After 133,514 person-years of Medicare follow-up, we observed 
      1,051 hospitalizations for heart failure and 832 hospitalizations for acute
      myocardial infarction. Compared to high fitness (Q4-5), low fitness (Q1) was
      associated with a higher rate of heart failure hospitalization (14.3% vs. 4.2%)
      and hospitalization for myocardial infarction (9.7% vs. 4.5%). After
      multivariable adjustment for baseline age, blood pressure, diabetes, body mass
      index, smoking status and total cholesterol, a 1 unit greater fitness level in
      metabolic equivalents (METs) achieved in midlife was associated with
      approximately a 20% lower risk for heart failure hospitalization after age 65
      [Men, hazard ratio (95% confidence intervals): 0.79 (0.75-0.83), p<0.001; Women: 
      0.81 (0.68-0.96), P=0.01] but just a 10% lower risk for acute myocardial
      infarction in men [0.91 (0.87-0.95), p< 0.001] and no association in women [0.97 
      (0.83-1.13), p=0.68]. CONCLUSIONS: -Fitness in healthy, middle-aged adults is
      more strongly associated with heart failure hospitalization than acute myocardial
      infarction outcomes decades later in older age.
AD  - 1University of Texas Southwestern Medical Center, Dallas, TX.
FAU - Berry, Jarett D
AU  - Berry JD
FAU - Pandey, Ambarish
AU  - Pandey A
FAU - Gao, Ang
AU  - Gao A
FAU - Leonard, David
AU  - Leonard D
FAU - Farzaneh-Far, Ramin
AU  - Farzaneh-Far R
FAU - Ayers, Colby
AU  - Ayers C
FAU - Defina, Laura
AU  - Defina L
FAU - Willis, Benjamin
AU  - Willis B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Circ Heart Fail
JT  - Circulation. Heart failure
JID - 101479941
OTO - NOTNLM
OT  - acute myocardial infarction
OT  - cardiorespiratory fitness
OT  - heart failure
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - CIRCHEARTFAILURE.112.000054 [pii]
AID - 10.1161/CIRCHEARTFAILURE.112.000054 [doi]
PST - aheadofprint
SO  - Circ Heart Fail. 2013 May 15.

PMID- 23677911
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
DP  - 2013 May 14
TI  - Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1
      in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of
      Healthy Individuals.
AB  - It is implicated that diabetic patients are more resistant to aspirin therapy
      than patients with other diseases or healthy individuals. We evaluated the
      inhibitory effects of aspirin on aggregation and the cyclooxygenase activity of
      platelets of 10 patients with severe type-2 diabetes mellitis (DM) and compared
      the results with those of healthy individuals. Although platelet aggregation had 
      a tendency to be more resistant to aspirin with the DM group, there was no
      significant difference in half maximal inhibitory concentration 50 values of
      aspirin on the cyclooxygenase activity between the patients with DM and healthy
      individuals. Thus, the residual platelet aggregability uninhibited by aspirin
      appears to be independent of the cyclooxygenase activity. Since adenosine
      diphosphate (ADP) receptor blocking almost completely inhibited the residual
      platelet aggregability, it is suggested that hyperreactivity to ADP is more
      prevalent in patients with DM.
FAU - Kimura, Yukio
AU  - Kimura Y
FAU - Takano, Katsuhiro
AU  - Takano K
FAU - Satoh, Kaneo
AU  - Satoh K
FAU - Aida, Kaoru
AU  - Aida K
FAU - Kobayashi, Tetsuro
AU  - Kobayashi T
FAU - Ozaki, Yukio
AU  - Ozaki Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 1076029613488934 [pii]
AID - 10.1177/1076029613488934 [doi]
PST - aheadofprint
SO  - Clin Appl Thromb Hemost. 2013 May 14.

PMID- 23677864
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1541-6100 (Electronic)
IS  - 0022-3166 (Linking)
DP  - 2013 May 15
TI  - Dietary Resistant Starch Prevents Urinary Excretion of 25-Hydroxycholecalciferol 
      and Vitamin D-Binding Protein in Type 1 Diabetic Rats.
AB  - Diabetes is a rapidly growing epidemic affecting millions of Americans and has
      been implicated in a number of devastating secondary complications. We previously
      demonstrated that type 2 diabetic rats exhibit vitamin D deficiency due to
      aberrant megalin-mediated endocytosis and excessive urinary excretion of
      25-hydroxycholecalciferol (25D3) and vitamin D-binding protein (DBP). Here, we
      examined whether a model of type 1 diabetes [T1D; streptozotocin (STZ)-treated
      Sprague-Dawley rats] would similarly excrete abnormally high concentrations of
      25D3 and DBP due to renal damage and compromised expression of megalin and its
      endocytic partner, disabled-2 (Dab2). Moreover, we tested whether feeding
      diabetic rats starch that is resistant to digestion could alleviate these
      abnormalities. Control (n = 12) rats were fed a standard, semipurified diet
      (AIN-93G) containing 55% total dietary starch and STZ-treated rats were fed the
      AIN-93G diet (n = 12) or a diet containing 55% high-amylose maize that is
      partially resistant to digestion [20% total dietary resistant starch (RS); n =
      12] for 2 and 5 wk. The RS diet attenuated weight loss and polyuria in
      STZ-treated rats. Histology and immunohistochemistry revealed that dietary RS
      also attenuated the loss of Dab2 expression in renal proximal tubules. Moreover, 
      urinary concentrations of both 25D3 and DBP were elevated approximately 10-fold
      in STZ-treated rats (5 wk post STZ injection), which was virtually prevented by
      the RS. We also observed a approximately 1.5-fold increase in megalin mRNA
      expression in STZ-treated rats, which was attenuated by feeding rats the RS diet 
      for 2 wk. Taken together, these studies indicate that consumption of low-glycemic
      carbohydrates can attenuate disruption of vitamin D homeostasis in T1D through
      the rescue of megalin-mediated endocytosis in the kidney.
AD  - Department of Food Science and Human Nutrition.
FAU - Smazal, Anne L
AU  - Smazal AL
FAU - Borcherding, Nicholas C
AU  - Borcherding NC
FAU - Anderegg, Alysse S
AU  - Anderegg AS
FAU - Schalinske, Kevin L
AU  - Schalinske KL
FAU - Whitley, Elizabeth M
AU  - Whitley EM
FAU - Rowling, Matthew J
AU  - Rowling MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Nutr
JT  - The Journal of nutrition
JID - 0404243
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - jn.112.173278 [pii]
AID - 10.3945/jn.112.173278 [doi]
PST - aheadofprint
SO  - J Nutr. 2013 May 15.

PMID- 23677857
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1179-2000 (Electronic)
IS  - 1177-1062 (Linking)
DP  - 2013 May 16
TI  - Do MDR1 and SLCO1B1 Polymorphisms Influence the Therapeutic Response to
      Atorvastatin? A Study on a Cohort of Egyptian Patients with Hypercholesterolemia.
AB  - BACKGROUND: Statins are among the most prescribed drugs worldwide to reduce the
      risk of cardiovascular events. Interindividual variability in drug response is a 
      major clinical problem and is of concern during drug development. Statins, such
      as atorvastatin, are taken orally and access to their site of action in the liver
      is greatly facilitated by both intestinal and hepatic transporters. OBJECTIVE: To
      examine the impact of polymorphisms of the multidrug resistance 1(MDR1) and
      solute carrier organic anion transporter 1B1 (SLCO1B1) genes on the therapeutic
      response to atorvastatin as well as the presence of gender-gene interaction.
      METHODS: Serum lipid levels were determined at baseline and 4 weeks following 40 
      mg/day atorvastatin treatment in 50 Egyptian hypercholesterolemic patients (27
      males and 23 females). Identification of MDR1 C3435T and SLCO1B1 A388G gene
      polymorphisms was performed using a polymerase chain reaction-restriction
      fragment length polymorphism (PCR-RFLP) method. RESULTS: Treatment with
      atorvastatin resulted in a mean reduction of total cholesterol (TC), low density 
      lipoprotein cholesterol (LDL-C), and triglyceride (TG) of 8.7 %, 9.2 %, and 4.1
      %, respectively, and a mean increase of high density lipoprotein cholesterol
      (HDL-C) of 1 %. Baseline and post-treatment HDL-C levels were statistically
      significantly higher in the MDR 1 TT homozygotes when compared with the CC wild
      type. The percentage change in TC, LDL-C, TG, and HDL-C did not show any
      statistically significant difference when compared among the different MDR 1
      C3435T or SLCO1B1 A388G genotypes. The SLCO1B1 GG homozygotes showed a decrease
      in TG, whereas there was an increase in TG following atorvastatin treatment in AA
      and AG carriers in females; however, males did not show any statistically
      significant difference. There was no statistically significant association
      between either the coronary artery disease (CAD) risk factors (family history of 
      CAD, hypertension, diabetes mellitus, smoking) or concomitant medications with
      the percentage change in different lipid parameters. CONCLUSION: MDR1 C3435T was 
      associated with baseline and post-treatment HDL-C variation. SLCO1B1 A388G showed
      gender-related effects on TG change following atorvastatin treatment. None of the
      comorbidities or the concomitant medications influenced the percentage change of 
      lipid parameters following atorvastatin treatment. The results of this study may 
      lead to an improved understanding of the genetic determinants of lipid response
      to atorvastatin treatment.
AD  - Department of Pharmacology, Faculty of Medicine, Fayoum University, Fayoum,
      Egypt.
FAU - Shabana, Mona F
AU  - Shabana MF
FAU - Mishriki, Amal A
AU  - Mishriki AA
FAU - Issac, Marianne Samir M
AU  - Issac MS
FAU - Bakhoum, Sameh W G
AU  - Bakhoum SW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Mol Diagn Ther
JT  - Molecular diagnosis & therapy
JID - 101264260
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.1007/s40291-013-0038-3 [doi]
PST - aheadofprint
SO  - Mol Diagn Ther. 2013 May 16.

PMID- 23677849
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1559-0720 (Electronic)
IS  - 0163-4984 (Linking)
DP  - 2013 May 17
TI  - The Antioxidant Activity of Copper(II) (3,5-Diisopropyl Salicylate) and Its
      Protective Effect Against Streptozotocin-Induced Diabetes Mellitus in Rats.
AB  - Oxidative stress has been suggested as a potential contributor to the development
      of diabetic complications. In this study, we investigated the protective effect
      of a strong antioxidant copper complex against streptozotocin (STZ)-induced
      diabetes in animals. Out of four copper complexes used, copper(II)
      (3,5-diisopropyl salicylate)4 (Cu(II)DIPS) was found to be the most potent
      antioxidant-copper complex. Pretreatment with Cu(II)DIPS (5 mg/kg) twice a week
      prior to the injection of streptozotocin (50 mg/kg) has reduced the level of
      hyperglycemia by 34 % and the mortality rate by 29 %. Injection of the same
      dosage of the ligand 3,5-diisopropyl salicylate has no effect on
      streptozotocin-induced hyperglycemia. The same copper complex has neither
      hypoglycemic activity when injected in normal rats nor antidiabetic activity when
      injected in STZ-induced diabetic rats. The protective effect of Cu(II)DIPS could 
      be related to its strong antioxidant activity compared to other copper complexes 
      median effective concentration (MEC) = 23.84 mug/ml and to Trolox MEC = 29.30
      mug/ml. In addition, it reduced serum 8-hydroxy-2'-deoxyguanosine, a biomarker of
      oxidative DNA damage, by 29 %. This effect may explain why it was not effective
      against diabetic rats, when beta Langerhans cells were already destroyed. Similar
      protective activities were reported by other antioxidants like Trolox.
AD  - Faculty of Nursing and Allied Health Professions, Birzeit University, Birzeit,
      Palestine, mqazzaz@birzeit.edu.
FAU - Qazzaz, Munir
AU  - Qazzaz M
FAU - Abdul-Ghani, Rula
AU  - Abdul-Ghani R
FAU - Metani, Munther
AU  - Metani M
FAU - Husein, Rateb
AU  - Husein R
FAU - Abu-Hijleh, Abdul-Latif
AU  - Abu-Hijleh AL
FAU - Abdul-Ghani, Abdul-Salam
AU  - Abdul-Ghani AS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/02/27 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/05/17 [aheadofprint]
AID - 10.1007/s12011-013-9697-5 [doi]
PST - aheadofprint
SO  - Biol Trace Elem Res. 2013 May 17.

PMID- 23677831
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1867-0687 (Electronic)
VI  - 9
IP  - 2
DP  - 2013 May
TI  - Status and trends of diabetes in Chinese children: analysis of data from 14
      medical centers.
PG  - 127-34
LID - 10.1007/s12519-013-0414-4 [doi]
AB  - BACKGROUND: Childhood diabetes has become a growing concern. We conducted a study
      to evaluate the status and trend of diabetes from 14 medical centers in China.
      Pre-diabetic status among obese children was also noted. METHODS: Hospital
      medical records were reviewed, and data of diabetes were collected from 1995
      through 2010. We took every five years as a calculation unit to analyze the trend
      of new-onset diabetes. Data on obesity were collected in the recent five years.
      RESULTS: A total of 4 337 836 patients aged 0-18 years were discharged from the
      14 centers. The prevalence (per 100 000 persons) of new-onset type 1 diabetes,
      type 2 diabetes and other types of diabetes were 96.8, 8.0, and 3.3,
      respectively. The prevalence of type 1 diabetes increased from 90.9 to 92.9 and
      101.4, while type 2 diabetes increased from 4.1 to 7.1 and 10.0 in every five
      years (P<0.0001). The increasing trend was significant from Southwest to East and
      North China (type 1 diabetes from 59.76 to 80.02 and 120.45, type 2 diabetes from
      2.52 to 3.77 and 15.64 (per 100 000 persons) (all P<0.0001). Well developed areas
      in China had a higher prevalence compared to less developed areas [type 1
      diabetes: 151.51 vs. 32.2 (per 100 000 persons); type 2 diabetes: 15.16 vs. 1.64 
      and others: 7.54 vs. 0.42 (per 100 000 persons)]. Of the 3153 obese children,
      18.24% had impaired fasting glucose (IFG), 5.99% had impaired gulose tolerance
      (IGT), and 4% had combined IFG and IGT. CONCLUSIONS: The prevalence of childhood 
      diabetes in China has increased dramatically, with type 2 diabetes exceeding type
      1 diabetes. The incidence rate of abnormal glucose metabolism in obese children
      has reached 28.26%.
AD  - Key Laboratory of Reproductive Genetics, Children's Hospital, Zhejiang University
      School of Medicine, Hangzhou, China.
FAU - Fu, Jun-Fen
AU  - Fu JF
FAU - Liang, Li
AU  - Liang L
FAU - Gong, Chun-Xiu
AU  - Gong CX
FAU - Xiong, Feng
AU  - Xiong F
FAU - Luo, Fei-Hong
AU  - Luo FH
FAU - Liu, Ge-Li
AU  - Liu GL
FAU - Li, Pin
AU  - Li P
FAU - Liu, Li
AU  - Liu L
FAU - Xin, Ying
AU  - Xin Y
FAU - Yao, Hui
AU  - Yao H
FAU - Cui, Lan-Wei
AU  - Cui LW
FAU - Shi, Xing
AU  - Shi X
FAU - Yang, Yu
AU  - Yang Y
FAU - Chen, Lin-Qi
AU  - Chen LQ
FAU - Wei, Hai-Yan
AU  - Wei HY
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - China
TA  - World J Pediatr
JT  - World journal of pediatrics : WJP
JID - 101278599
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2012/08/23 [received]
PHST- 2012/11/26 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 10.1007/s12519-013-0414-4 [doi]
PST - ppublish
SO  - World J Pediatr. 2013 May;9(2):127-34. doi: 10.1007/s12519-013-0414-4. Epub 2013 
      May 16.

PMID- 23677827
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1867-0687 (Electronic)
VI  - 9
IP  - 2
DP  - 2013 May
TI  - Childhood obesity and type 2 diabetes: the frightening epidemic.
PG  - 101-2
LID - 10.1007/s12519-013-0410-8 [doi]
AD  - Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA,
      nicola.santoro@yale.edu.
FAU - Santoro, Nicola
AU  - Santoro N
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - China
TA  - World J Pediatr
JT  - World journal of pediatrics : WJP
JID - 101278599
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2012/11/21 [received]
PHST- 2012/11/25 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 10.1007/s12519-013-0410-8 [doi]
PST - ppublish
SO  - World J Pediatr. 2013 May;9(2):101-2. doi: 10.1007/s12519-013-0410-8. Epub 2013
      May 16.

PMID- 23677752
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
DP  - 2013 May 16
TI  - Anthropometric, socioeconomic, and maternal health determinants of placental
      transfer of organochlorine compounds.
AB  - The aim of this study was to relate placental transfer, quantified by the cord to
      maternal serum concentration ratio (C/M), of five organochlorine pesticides (OCP)
      hexachlorobenzene (HCB), beta-hexachlorocyclohexane (beta-HCH),
      gamma-hexachlorocyclohexane (gamma-HCH) , p,p'-DDT, p,p'-DDE and 15
      polychlorinated biphenyl (PCB) congeners (28, 52, 101, 105, 114, 118, 123+149,
      138+163, 153, 156+171, 157, 167, 170, 180, and 189) to anthropometric,
      socioeconomic, and maternal health characteristics. We included into the study
      1,134 births during the period 2002-2004 from two districts in eastern Slovakia
      with high organochlorine concentrations relative to other areas of the world.
      Only concentrations >LOD were taken into account. Variables as age, weight and
      height of mothers, parity, ethnicity, alcohol consumption, illness during
      pregnancy, smoking during pregnancy, hypertension, respiratory diseases,
      rheumatoid arthritis and diabetes mellitus, and birth weight were related to C/M.
      Results of regression analyses showed that C/M was predicted by several factors
      studied. Positive associations were observed for gestational alcohol consumption,
      fewer illnesses during pregnancy, maternal age, and maternal weight. Caucasians
      had a greater C/M compared to Romani for wet weight data of congeners 170 and 180
      and in contrast C/M for HCB was greater in Romani. Our results show that drinking
      mothers compared to abstaining expose their fetuses not only to alcohol but to an
      increased level of several PCB congeners. A straightforward explanation of
      associations between C/M shifts and factors studied is very difficult, however,
      with regard to the high lipophilicity of OCPs and PCBs, changes in their kinetics
      probably reflect lipid kinetics.
AD  - Department of Environmental Medicine, Slovak Medical University, Limbova 12,
      83303, Bratislava, Slovakia.
FAU - Patayova, Henrieta
AU  - Patayova H
FAU - Wimmerova, Sona
AU  - Wimmerova S
FAU - Lancz, Kinga
AU  - Lancz K
FAU - Palkovicova, Lubica
AU  - Palkovicova L
FAU - Drobna, Beata
AU  - Drobna B
FAU - Fabisikova, Anna
AU  - Fabisikova A
FAU - Kovac, Jan
AU  - Kovac J
FAU - Hertz-Picciotto, Irva
AU  - Hertz-Picciotto I
FAU - Jusko, Todd A
AU  - Jusko TA
FAU - Trnovec, Tomas
AU  - Trnovec T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2012/12/29 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 10.1007/s11356-013-1786-7 [doi]
PST - aheadofprint
SO  - Environ Sci Pollut Res Int. 2013 May 16.

PMID- 23677746
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 80
IP  - 21
DP  - 2013 May 21
TI  - Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk.
PG  - 1966-72
LID - 10.1212/WNL.0b013e3182941990 [doi]
AB  - OBJECTIVE: To explore the association of nonmelanoma skin cancer (NMSC) and
      Alzheimer disease (AD) in the Einstein Aging Study, an epidemiologic study of
      aging in New York City. METHODS: Community-residing volunteers aged 70 years or
      older were assessed annually, followed by multidisciplinary diagnostic consensus.
      Cancer status and type was obtained by self-report. Cox proportional hazards
      models were used to test associations between NMSC and subsequent risk of
      developing a neurocognitive disorder. To deduce a biologically specific
      association between AD and NMSC, we considered 3 nested outcomes groups: only AD 
      (probable or possible AD as the sole diagnosis), any AD (probable AD or possible 
      AD, as well as mixed AD/vascular dementia), and all-cause dementia. RESULTS: We
      followed 1,102 adults with a mean age of 79 years at enrollment. Prevalent NMSC
      was associated with reduced risk of only AD (hazard ratio = 0.21; 95% confidence 
      interval = 0.051-0.87; p = 0.031) among subjects after adjustment for
      demographics, hypertension, diabetes, and coronary heart disease. APOE epsilon4
      genotypes were available in 769 individuals. The association was similar in
      magnitude, but nonsignificant, when the number of APOE epsilon4 alleles was
      included in the model. No significant association was found between NMSC and
      subsequent development of any AD or all-cause dementia. CONCLUSIONS: This
      population-based longitudinal study shows that individuals older than 70 years
      with NMSC have a significantly reduced risk of developing AD compared with
      individuals without NMSC. We deduce Alzheimer-specific neuroprotection, because
      the effect is attenuated or eliminated when considering less-specific diagnoses
      such as AD with another diagnosis (any AD) or all-cause dementia.
AD  - From the Saul B. Korey Department of Neurology (R.S.W., R.B.L., C.B.H., J.R.S.), 
      Department of Epidemiology and Population Health (R.S.W., R.B.L., C.B.H.) and the
      Einstein Aging Study (R.S.W., R.B.L., C.B.H.), Albert Einstein College of
      Medicine; and ProGevity Neuroscience, Inc. (J.R.S.), Bronx, NY.
FAU - White, Robert S
AU  - White RS
FAU - Lipton, Richard B
AU  - Lipton RB
FAU - Hall, Charles B
AU  - Hall CB
FAU - Steinerman, Joshua R
AU  - Steinerman JR
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - AIM
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/15 [aheadofprint]
AID - WNL.0b013e3182941990 [pii]
AID - 10.1212/WNL.0b013e3182941990 [doi]
PST - ppublish
SO  - Neurology. 2013 May 21;80(21):1966-72. doi: 10.1212/WNL.0b013e3182941990. Epub
      2013 May 15.

PMID- 23677728
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1897-5593 (Electronic)
IS  - 1898-018X (Linking)
DP  - 2013 May 15
TI  - Factor XIII Val34Leu polymorphism in patients with Cardiac Syndrome X.
LID - 10.5603/CJ.a2013.0046 [doi]
AB  - Aims: To examine the frequency of Factor XIII polymorphism among patients with
      cardiac syndrome X (CSX). Methods: This study was designed as a cross-sectional
      and observational study. Forty-eight female patients with CSX and 36 controls
      matched by age, gender, diabetes, and hypertension were studied. Cardiac syndrome
      X was defined as typical chest pain during rest or effort, abnormal test result
      for exercise ECG, and presence of angiographically normal epicardial coronary
      arteries after ruling out inducible spasm. Factor XIII gene polymorphism was
      investigated by using CVD Strip Assay (ViennaLab Diagnostic GmbH) commercial kit.
      Results: The frequency of Factor XIII (Val/Leu + Leu/Leu) mutation was
      significantly higher in patients with CSX (43%) was significantly higher than
      than in controls (19%) (p = 0.02). Frequency of the Leu allele was significantly 
      higher in the patient group (23.5% vs. 11.1%, p = 0.04). Factor XIII (Val/Leu +
      Leu/Leu) mutation (p = 0.01, OR = 3.42; 95% CI [1.22-9.58]) and smoking (p =
      0.04, OR = 3.33, 95% CI [1.05, 10.58]) were identified as independent predictors 
      of the disease in multivariate regression analysis.Conclusion: This study
      indicates that there is an evidence for association between factor XIII Val34Leu 
      polymorphism and CSX.
AD  - Istinye State Hospital. gamzebabur@hotmail.com.
FAU - Guler, Gamze Babur
AU  - Guler GB
FAU - Batgerel, Ulaankhuu
AU  - Batgerel U
FAU - Guler, Ekrem
AU  - Guler E
FAU - Karaca, Oguz
AU  - Karaca O
FAU - Gecmen, Cetin
AU  - Gecmen C
FAU - Gunes, Haci Murat
AU  - Gunes HM
FAU - Agus, Hicaz Zencirkiran
AU  - Agus HZ
FAU - Esen, Ali Metin
AU  - Esen AM
FAU - Turkmen, Mehmet Muhsin
AU  - Turkmen MM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/02/17 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/04/13 [revised]
AID - VM/OJS/J/26121 [pii]
AID - 10.5603/CJ.a2013.0046 [doi]
PST - aheadofprint
SO  - Cardiol J. 2013 May 15. doi: 10.5603/CJ.a2013.0046.

PMID- 23677720
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1897-5593 (Electronic)
IS  - 1898-018X (Linking)
DP  - 2013 May 29
TI  - The metabolic syndrome entanglement: cutting the Gordian knot.
LID - 10.5603/CJ.a2013.0054 [doi]
AB  - Questions have been raised concerning the clinical value of the metabolic
      syndrome (MS). The negative opinion regarding MS is basically anchored on a
      separate analysis of four conditions: obesity, dyslipidemia, hypertension and
      glucose intolerance. The common denominator of these four sets of arguments is
      that they represent an utterly simplistic view of MS as a solely predictive tool 
      of morbidity or mortality. We believe that it is inequitable to compare it with
      statistically constructed predictive tools, including stronger prognostic
      variables even unrelated to each other from the biological point of view. Several
      recent large meta-analyses - one of them including near one million patients -
      had systematically shown that people with MS are at increased risk of
      cardiovascular events. MS was associated with a 2-fold increase in cardiovascular
      outcomes and a 1.5-fold increase in all-cause mortality rates. A very important
      finding was that cardiovascular risk remained still high in patients with MS but 
      without diabetes. The presence of MS possesses a definite predictive value, but
      first of all it is a widely accepted concept regarding a biological condition
      based on the complex and interrelated pathophysiological mechanisms emanating
      from excess central adiposity and insulin resistance. The risk factors are
      multiplicative, meaning that the risk for cardiovascular disease from risk
      factors rises geometrically, not linearly, as the number of risk factors
      increases. Therefore, currently available evidences strongly support the concept 
      of the MS as a critical clustering of cardiovascular risk factors and diabetes,
      representing a true and solid evolving clinical entity.
AD  - Cardiovascular Diabetology Research Foundation Holon, Israel.
      zfisman@post.tau.ac.il.
FAU - Fisman, Enrique Z
AU  - Fisman EZ
FAU - Tenenbaum, Alexander
AU  - Tenenbaum A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/04/02 [received]
PHST- 2013/04/02 [accepted]
AID - VM/OJS/J/33931 [pii]
AID - 10.5603/CJ.a2013.0054 [doi]
PST - aheadofprint
SO  - Cardiol J. 2013 May 29. doi: 10.5603/CJ.a2013.0054.

PMID- 23677717
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1945-239X (Electronic)
IS  - 0021-9665 (Linking)
DP  - 2013 May 14
TI  - Determination of
      2-(3-Benzoyl)-4-Hydroxy-1,1-Dioxo-2H-1,2-Benzothiazine-2-yl-1-Phenylethanone by
      Liquid Chromatography-Tandem Mass Spectrometry.
AB  - 2-(3-Benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone
      (KR-66344), a 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor,
      is newly developed for the control of type 2 diabetes mellitus (T2DM) and
      metabolic syndrome. A method for the determination of KR-66344 in rat plasma was 
      developed by liquid chromatography-electrospray ionization tandem mass
      spectrometry (LC-ESI-MS-MS) to evaluate the pharmacokinetics of KR-66344. Plasma 
      samples were processed by a liquid-liquid extraction method with ethyl acetate
      and introduced onto the LC-MS-MS system. The analyte and imipramine (internal
      standard) were analyzed by multiple reaction monitoring based on transitions at
      m/z 420.1 --> 105.0 and 282.2 --> 86.0, respectively. The calibration curve was
      linear (r = 0.9993) over the concentration range of 1.0-1,000 ng/mL. The mean
      recovery values for KR-66344 and imipramine were 83.8 and 86.2%, respectively.
      The mean inter-day and intra-day assay precision values were 3.9 and 2.4%,
      respectively. KR-66344 was stable under various handling and storage conditions. 
      This developed method was applied to a pharmacokinetic study after the oral
      administration of KR-66344 in rats. The concentration of KR-66344 was readily
      measurable in rat plasma up to 24 h post-dose after an oral administration,
      suggesting that current assay is applicable to pharmacokinetic studies for
      KR-66344.
AD  - 1Drug Discovery Platform Technology Research Group, Korea Research Institute of
      Chemical Technology (KRICT), Yuseong-gu, Daejeon, 305-600, Korea.
FAU - Zheng, Zhi
AU  - Zheng Z
FAU - Song, Jin Sook
AU  - Song JS
FAU - Lee, Byung Hoi
AU  - Lee BH
FAU - Ahn, Sung-Hoon
AU  - Ahn SH
FAU - Ahn, Jin-Hee
AU  - Ahn JH
FAU - Woo, Jaechun
AU  - Woo J
FAU - Park, Ji-Young
AU  - Park JY
FAU - Yoo, Dae Seok
AU  - Yoo DS
FAU - Bae, Myung Ae
AU  - Bae MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - J Chromatogr Sci
JT  - Journal of chromatographic science
JID - 0173225
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - bmt050 [pii]
AID - 10.1093/chromsci/bmt050 [doi]
PST - aheadofprint
SO  - J Chromatogr Sci. 2013 May 14.

PMID- 23677561
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1432-2323 (Electronic)
IS  - 0364-2313 (Linking)
DP  - 2013 May 16
TI  - Effect of Diabetes on Outcomes in Patients Undergoing Emergent Cholecystectomy
      for Acute Cholecystitis.
AB  - BACKGROUND: The purpose of the present study was to determine the prevalence of
      diabetes and its effect on surgical outcomes in patients undergoing emergent,
      in-patient cholecystectomy for acute cholecystitis. Some 8.3 % of the U.S.
      population has diabetes and this number is projected to rise to 21-33 % by 2050. 
      Diabetes is considered to be associated with a higher incidence of acute
      cholecystitis; however, its impact on outcomes is unknown. METHODS: The American 
      College of Surgeons National Surgical Quality Improvement Program database was
      queried to identify all patients with acute cholecystitis who underwent emergent 
      in-patient cholecystectomy from 2004 to 2010. The study population was divided
      into two groups: diabetics and non-diabetics. Diabetics were further subdivided
      into those taking oral medication and those on insulin. Demographics,
      co-morbidities, and wound classification were compared with univariate analysis, 
      and 30-day outcomes were compared with univariate and multivariate analyses.
      RESULTS: A total of 5,460 patients met the inclusion criteria. Of these 770
      (14.10 %) had a diagnosis of diabetes. Mortality was higher for diabetics than
      for non-diabetics [4.4 vs 1.4 %, adjusted odds ratio (AOR) (95 % CI): 1.79 (1.09,
      2.94), adj-p = 0.022]. Preoperative perforation rates were 25.1 and 13.0 %,
      respectively [AOR (95 % CI): 1.34 (1.09, 1.65), adj-p = 0.005]. The adjusted risk
      of cardiovascular events and renal failure was significantly higher for
      diabetics. Insulin treatment, but not oral medication, was associated with a
      significant increase in mortality, preoperative perforation, superficial surgical
      site infection, septic shock, cardiovascular incidents, and renal insufficiency. 
      CONCLUSIONS: In patients undergoing cholecystectomy for acute cholecystitis,
      diabetes increases the risk of mortality, cardiovascular events, and renal
      failure. Insulin-treated diabetics have more co-morbidities and poorer outcomes.
AD  - Division of Acute Care Surgery, Keck School of Medicine, University of Southern
      California, Los Angeles, CA, USA, ef.karamanos@gmail.com.
FAU - Karamanos, Efstathios
AU  - Karamanos E
FAU - Sivrikoz, Emre
AU  - Sivrikoz E
FAU - Beale, Elizabeth
AU  - Beale E
FAU - Chan, Linda
AU  - Chan L
FAU - Inaba, Kenji
AU  - Inaba K
FAU - Demetriades, Demetrios
AU  - Demetriades D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - World J Surg
JT  - World journal of surgery
JID - 7704052
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.1007/s00268-013-2086-6 [doi]
PST - aheadofprint
SO  - World J Surg. 2013 May 16.

PMID- 23677545
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 May 16
TI  - Sexual dysfunction in pre-menopausal diabetic women: clinical, metabolic,
      psychological, cardiovascular, and neurophysiologic correlates.
AB  - An increased prevalence of female sexual dysfunction (FSD) has been reported in
      women with diabetes mellitus (DM). Our aim was to evaluate correlates
      (psychological, cardiovascular, and neurophysiologic) of FSD in DM women without 
      chronic diabetic complications. Female Sexual Function Index (FSFI), Beck
      Depression Inventory (BDI), Michigan Diabetic Neuropathy Index (DNI), and the
      symptoms of diabetic neuropathy (SDN) questionnaires, metabolic variables,
      endothelial vascular function (flow-mediated dilation, FMD), echocardiography,
      and electromyography were studied. 109 pre-menopausal women (18-50 years) [48
      with DM (14 type 1 DM, 34 type 2 DM, duration 12.6 +/- 1.91 years), and 61
      healthy women] received the above questionnaires; physical activity, smoking
      habits, parity, BMI, waist circumference, HOMA-IR index, fibrinogen, cholesterol 
      (total, HDL, LDL), triglycerides, HbA1c, high-sensitivity C-reactive protein,
      total testosterone, and estradiol were measured; echocardiography, assessment of 
      intima-media thickness (IMT), FMD, ECG (heart rate and Qtc, indexes of
      sympathetic activity), and electromyography were performed. FSFI total score and 
      score for arousal, lubrication, and orgasm domains were lower in DM women than in
      controls (P < 0.05); DM women had higher BDI, Doppler A wave peak velocity, DNI, 
      and SDN score (P < 0.001 to P < 0.04). Doppler E wave peak velocity, peroneal,
      posterior tibial and sural nerves conduction velocity and amplitude were lower in
      diabetic women than in controls (P < 0.05 to P < 0.001). FSFI score was
      positively correlated with physical activity, Doppler E wave peak velocity, and
      peroneal nerve amplitude and negatively with BDI, parity, IMT, SDN, and HbA1c (P 
      < 0.05 to P < 0.001). At stepwise regression, SDN score (negatively) and Doppler 
      E wave peak velocity (positively) predicted FSFI score (r = 507, P < 0.001). In
      conclusion, cardiovascular and neurological impairments are associated with FSD
      in diabetic women. Follow-up studies are required to evaluate sexual dysfunction 
      as a risk factor for future cardiovascular or neurological events.
AD  - Dipartimento di Scienze della Salute, Universita degli Studi di Milano, Ospedale 
      San Paolo, via Antonio Di Rudini 8, 20142, Milan, Italy.
FAU - Cortelazzi, Donatella
AU  - Cortelazzi D
FAU - Marconi, Annamaria
AU  - Marconi A
FAU - Guazzi, Marco
AU  - Guazzi M
FAU - Cristina, Maurizio
AU  - Cristina M
FAU - Zecchini, Barbara
AU  - Zecchini B
FAU - Veronelli, Annamaria
AU  - Veronelli A
FAU - Cattalini, Claudio
AU  - Cattalini C
FAU - Innocenti, Alessandro
AU  - Innocenti A
FAU - Bosco, Giovanna
AU  - Bosco G
FAU - Pontiroli, Antonio E
AU  - Pontiroli AE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/04/05 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 10.1007/s00592-013-0482-x [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 May 16.

PMID- 23677506
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 21
DP  - 2013 May
TI  - [Diabetes treatment in patients with chronic kidney disease].
PG  - 1109-22
LID - 10.1055/s-0032-1332954 [doi]
AD  - Medizinische Klinik I, Universitatsklinikum Schleswig-Holstein, Campus Lubeck.
FAU - Sufke, S
AU  - Sufke S
FAU - Steinhoff, J
AU  - Steinhoff J
FAU - Schutt, M
AU  - Schutt M
LA  - ger
PT  - Journal Article
TT  - Diabetestherapie bei chronischer Niereninsuffizienz.
DEP - 20130515
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/15 [epublish]
AID - 10.1055/s-0032-1332954 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(21):1109-22. doi: 10.1055/s-0032-1332954. Epub
      2013 May 15.

PMID- 23677504
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 21
DP  - 2013 May
TI  - [Medial calcific sclerosis under long-term anticoagulation with vitamin K
      antagonists].
PG  - 1102-6
LID - 10.1055/s-0033-1343136 [doi]
AB  - Background: Vitamin K antagonists not only influence the synthesis of coagulation
      factors but also the activation of other vitamin K dependent proteins. Among
      other possible side effects, arterial calcification has been focused on in recent
      years. History and findings: Four patients under long-term anticoagulation for
      more than 10 years developed medial calcific sclerosis. In case 1 we identified
      an unexplained medial calcific sclerosis on x-ray after a trauma by chance. After
      that we examined the ankle-brachial index of blood pressure in all patients who
      had received long-term anticoagulation for more than 10 years. Where the index
      exceeded 1,3 we performed a x-ray-examination of the forefoot. Of the four
      described patients no one suffered from diabetes mellitus, renal failure or
      hyperparathyreoidism. Serum calcium was normal in all patients. The severity of
      the medial calcific sclerosis could not be explained by the initial vascular risk
      factors. Conclusion: In certain patients, even at low vascular risk, a medial
      calcific sclerosis can appear under long-term anticoagulation with vitamin K
      antagonists. We conclude that vitamin K antagonists inhibit several proteins
      which protect the vessels from calcification leading to medial calcific
      sclerosis.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Internistische Praxis, Munchen.
FAU - Walther, B
AU  - Walther B
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Mediasklerose als Folge der Langzeitantikoagulation mit Vitamin-K-Antagonisten.
DEP - 20130515
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/15 [epublish]
AID - 10.1055/s-0033-1343136 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(21):1102-6. doi: 10.1055/s-0033-1343136. Epub 
      2013 May 15.

PMID- 23677493
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 0340-6245 (Electronic)
IS  - 0340-6245 (Linking)
VI  - 110
IP  - 1
DP  - 2013 May 16
TI  - Factors associated with diagnosis and operability of chronic thromboembolic
      pulmonary hypertension. A case-control study.
AB  - Chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary
      hypertension (IPAH) share a similar clinical presentation, and a differential
      diagnosis requires a thorough workup. Once CTEPH is confirmed, patients who can
      be safely operated have to be identified. We investigated risk factors associated
      with CTEPH and IPAH, and the criteria for the selection of operable CTEPH
      patients. This case-control study included 436 consecutive patients with CTEPH
      and 158 with IPAH in eight European centres, between 2006 and 2010. Conditions
      identified as risk factors for CTEPH included history of acute venous
      thromboembolism (p < 0.0001), large size of previous pulmonary embolism (p =
      0.0040 in univariate analysis), blood groups non-O (p < 0.0001 in univariate
      analysis), and older age (p = 0.0198), whereas diabetes mellitus (p = 0.0006),
      female gender (p = 0.0197) and higher mean pulmonary artery pressure (p = 0.0103)
      were associated with increased likelihood for an IPAH diagnosis. Operability of
      CTEPH patients was associated with younger age (p = 0.0108), proximal lesions (p 
      </= 0.0001), and pulmonary vascular resistance below 1200 dyn.s.cm(-)(5) (p =
      0.0080). Non-operable CTEPH patients tended to be less differentiable from IPAH
      patients by risk factor analysis than operable patients. This study confirmed the
      association of CTEPH with history of acute venous thromboembolism and blood
      groups non-O, and identified diabetes mellitus and higher mean pulmonary artery
      pressure as factors suggesting an IPAH diagnosis. Non-operable CTEPH is more
      similar to IPAH than operable CTEPH regarding risk factors.
AD  - Irene Lang, Department of Cardiology, Medical University of Vienna, Wahringer
      Gurtel 18 - 20, 1090 Vienna, Austria, Tel.: +43 140 400 61 35, Fax: +43 140 400
      78 42, E-mail: irene.lang@meduniwien.ac.at.
FAU - Lang, I M
AU  - Lang IM
FAU - Simonneau, G
AU  - Simonneau G
FAU - Pepke-Zaba, J W
AU  - Pepke-Zaba JW
FAU - Mayer, E
AU  - Mayer E
FAU - Ambroz, D
AU  - Ambroz D
FAU - Blanco, I
AU  - Blanco I
FAU - Torbicki, A
AU  - Torbicki A
FAU - Mellemkjaer, S
AU  - Mellemkjaer S
FAU - Yaici, A
AU  - Yaici A
FAU - Delcroix, M
AU  - Delcroix M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/02/04 [received]
PHST- 2013/04/04 [accepted]
AID - 13-02-0097 [pii]
AID - 10.1160/TH13-02-0097 [doi]
PST - aheadofprint
SO  - Thromb Haemost. 2013 May 16;110(1).

PMID- 23677470
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 190
IP  - 12
DP  - 2013 Jun 15
TI  - Accelerated Turnover of MHC Class II Molecules in Nonobese Diabetic Mice Is
      Developmentally and Environmentally Regulated In Vivo and Dispensable for
      Autoimmunity.
PG  - 5961-71
LID - 10.4049/jimmunol.1300551 [doi]
AB  - The H2-A(g7) (A(g7)) MHC class II (MHCII) allele is required for type 1 diabetes 
      (T1D) in NOD mice. A(g7) not only has a unique peptide-binding profile, it was
      reported to exhibit biochemical defects, including accelerated protein turnover. 
      Such defects were proposed to impair Ag presentation and, thus, self-tolerance.
      Here, we report measurements of MHCII protein synthesis and turnover in vivo. NOD
      mice and BALB/c controls were labeled continuously with heavy water, and splenic 
      B cells and dendritic cells were isolated. MHCII molecules were
      immunoprecipitated and digested with trypsin. Digests were analyzed by liquid
      chromatography/mass spectrometry to quantify the fraction of newly synthesized
      MHCII molecules and, thus, turnover. MHCII turnover was faster in dendritic cells
      than in B cells, varying slightly between mouse strains. Some A(g7) molecules
      exhibited accelerated turnover in B cells from young, but not older, prediabetic 
      female NOD mice. This acceleration was not detected in a second NOD colony with a
      high incidence of T1D. Turnover rates of A(g7) and H2-A(d) were indistinguishable
      in (NOD x BALB/c) F1 mice. In conclusion, accelerated MHCII turnover may occur in
      NOD mice, but it reflects environmental and developmental regulation, rather than
      a structural deficit of the A(g7) allele. Moreover, this phenotype wanes before
      the onset of overt T1D and is dispensable for the development of autoimmune
      diabetes. Our observations highlight the importance of in vivo studies in
      understanding the role of protein turnover in genotype/phenotype relationships
      and offer a novel approach for addressing this fundamental research challenge.
AD  - Department of Medicine, University of Cambridge, Addenbrooke's Hospital,
      Cambridge CB2 0QQ, United Kingdom;
FAU - De Riva, Alessandra
AU  - De Riva A
FAU - Varley, Mark C
AU  - Varley MC
FAU - Bluck, Leslie J
AU  - Bluck LJ
FAU - Cooke, Anne
AU  - Cooke A
FAU - Deery, Michael J
AU  - Deery MJ
FAU - Busch, Robert
AU  - Busch R
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
SB  - AIM
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/15 [aheadofprint]
AID - jimmunol.1300551 [pii]
AID - 10.4049/jimmunol.1300551 [doi]
PST - ppublish
SO  - J Immunol. 2013 Jun 15;190(12):5961-71. doi: 10.4049/jimmunol.1300551. Epub 2013 
      May 15.

PMID- 23677466
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 190
IP  - 12
DP  - 2013 Jun 15
TI  - B lymphocyte "original sin" in the bone marrow enhances islet autoreactivity in
      type 1 diabetes-prone nonobese diabetic mice.
PG  - 5992-6003
LID - 10.4049/jimmunol.1201359 [doi]
AB  - Effective central tolerance is required to control the large extent of
      autoreactivity normally present in the developing B cell repertoire.
      Insulin-reactive B cells are required for type 1 diabetes in the NOD mouse,
      because engineered mice lacking this population are protected from disease. The
      Cg-Tg(Igh-6/Igh-V125)2Jwt/JwtJ (VH125Tg) model is used to define this population,
      which is found with increased frequency in the periphery of NOD mice versus
      nonautoimmune C57BL/6 VH125Tg mice; however, the ontogeny of this disparity is
      unknown. To better understand the origins of these pernicious B cells,
      anti-insulin B cells were tracked during development in the polyclonal repertoire
      of VH125Tg mice. An increased proportion of insulin-binding B cells is apparent
      in NOD mice at the earliest point of Ag commitment in the bone marrow. Two
      predominant L chains were identified in B cells that bind heterologous insulin.
      Interestingly, Vkappa4-57-1 polymorphisms that confer a CDR3 Pro-Pro motif
      enhance self-reactivity in VH125Tg/NOD mice. Despite binding circulating
      autoantigen in vivo, anti-insulin B cells transition from the parenchyma to the
      sinusoids in the bone marrow of NOD mice and enter the periphery unimpeded.
      Anti-insulin B cells expand at the site of autoimmune attack in the pancreas and 
      correlate with increased numbers of IFN-gamma-producing cells in the repertoire. 
      These data identify the failure to cull autoreactive B cells in the bone marrow
      as the primary source of anti-insulin B cells in NOD mice and suggest that
      dysregulation of central tolerance permits their escape into the periphery to
      promote disease.
AD  - Division of Rheumatology and Immunology, Department of Medicine, Vanderbilt
      University, Nashville TN 37232;
FAU - Henry-Bonami, Rachel A
AU  - Henry-Bonami RA
FAU - Williams, Jonathan M
AU  - Williams JM
FAU - Rachakonda, Amita B
AU  - Rachakonda AB
FAU - Karamali, Mariam
AU  - Karamali M
FAU - Kendall, Peggy L
AU  - Kendall PL
FAU - Thomas, James W
AU  - Thomas JW
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
SB  - AIM
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/15 [aheadofprint]
AID - jimmunol.1201359 [pii]
AID - 10.4049/jimmunol.1201359 [doi]
PST - ppublish
SO  - J Immunol. 2013 Jun 15;190(12):5992-6003. doi: 10.4049/jimmunol.1201359. Epub
      2013 May 15.

PMID- 23677420
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1432-0711 (Electronic)
IS  - 0932-0067 (Linking)
DP  - 2013 May 16
TI  - Copeptin concentrations are not elevated in gestational diabetes mellitus.
AB  - PURPOSE: To investigate copeptin levels in women with GDM and women with
      uncomplicated pregnancies. METHODS: This case-control study was conducted on 45
      women with GDM and 40 women with uncomplicated pregnancies. The maternal serum
      levels of copeptin were measured with enzyme-linked immunosorbent assay. RESULTS:
      Copeptin levels were not different among groups (0.93 +/- 0.75 vs. 1.15 +/- 0.93 
      ng/ml, p: 0.24). HOMA-IR and insulin levels were significantly higher in woman
      with GDM when compared with control group (2.90 +/- 1.88 vs. 1.91 +/- 0.50, p:
      0.002; 11.74 +/- 6.43 vs. 8.52 +/- 2.28, p: 0.004, respectively). The copeptin
      concentrations were significantly correlated with insulin levels and HOMA-IR
      values (r = 0.329 p = 0.002, r = 0.289 p = 0.007, respectively). CONCLUSIONS: The
      present study shows that serum copeptin concentrations did not differ in woman
      with GDM and non-GDM patients. However, we found a significant correlation
      between copeptin and HOMA-IR. Future studies are needed with larger populations
      in gestational diabetic patients on copeptin secretion, metabolism and action.
AD  - Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa Medical 
      Faculty, Istanbul, Turkey.
FAU - Oncul, Mahmut
AU  - Oncul M
FAU - Tuten, Abdullah
AU  - Tuten A
FAU - Kucur, Mine
AU  - Kucur M
FAU - Imamoglu, Metehan
AU  - Imamoglu M
FAU - Ekmekci, Ozlem Balci
AU  - Ekmekci OB
FAU - Acikgoz, Abdullah Serdar
AU  - Acikgoz AS
FAU - Madazli, Riza
AU  - Madazli R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Arch Gynecol Obstet
JT  - Archives of gynecology and obstetrics
JID - 8710213
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/02/15 [received]
PHST- 2013/05/07 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 10.1007/s00404-013-2887-8 [doi]
PST - aheadofprint
SO  - Arch Gynecol Obstet. 2013 May 16.

PMID- 23677380
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 0340-6245 (Electronic)
IS  - 0340-6245 (Linking)
VI  - 110
IP  - 1
DP  - 2013 May 16
TI  - Combined and independent impact of diabetes mellitus and chronic kidney disease
      on residual platelet reactivity.
AB  - Patients with both chronic kidney disease (CKD) and diabetes mellitus (DM) are at
      increased risk for thrombotic events compared to those with one abnormality
      alone. Whether this can be attributed to changes in platelet reactivity among
      those with both CKD and DM is unknown. We prospectively studied 438
      clopidogrel-naive patients undergoing percutaneous coronary intervention (PCI).
      Platelet function tests were performed 4-6 hours after loading with 600 mg of
      clopidogrel. Platelet reactivity was assessed using the VerifyNow system and
      expressed as P2Y12 reaction units (PRU). High residual platelet reactivity (HRPR)
      was defined as PRU > 230. Patients were categorised into four groups by the
      presence or absence of CKD and DM. Among those without CKD or DM (n=166), DM
      alone (n=150), CKD alone (n=60) and both CKD and DM (n=62) the mean PRU levels
      were 201.6 +/- 96.3, 220.5 +/- 101.1, 254.9 +/- 106.7 and 275.0 +/- 94.5,
      respectively (p<0.001). Analogously, the prevalence of HRPR was 42.3%, 50.7%,
      63.3% and 75.8%, respectively (p< 0.001). Associations between either CKD or DM
      alone and HRPR were attenuated after multivariable adjustment while the odds for 
      HRPR associated with both CKD and DM remained significant (OR [95% CI]: 2.61
      [1.16 - 5.86]). In conclusion, the presence of both CKD and DM confers a
      synergistic impact on residual platelet reactivity when compared to either
      condition alone. Whether more potent platelet inhibitors may improve outcomes
      among patients with both abnormalities warrants investigation.
AD  - Samin K. Sharma, Cardiac Catheterization Laboratory, Mount Sinai Medical Center, 
      One Gustave L. Levy Place, New York, NY 10029, USA, E-mail:
      samin.sharma@mountsinai.org.
FAU - Baber, U
AU  - Baber U
FAU - Bander, J
AU  - Bander J
FAU - Karajgikar, R
AU  - Karajgikar R
FAU - Yadav, K
AU  - Yadav K
FAU - Hadi, A
AU  - Hadi A
FAU - Theodoropolous, K
AU  - Theodoropolous K
FAU - Gukathasan, N
AU  - Gukathasan N
FAU - Roy, S
AU  - Roy S
FAU - Sayeneni, S
AU  - Sayeneni S
FAU - Scott, S A
AU  - Scott SA
FAU - Kovacic, J C
AU  - Kovacic JC
FAU - Yu, J
AU  - Yu J
FAU - Sartori, S
AU  - Sartori S
FAU - Mehran, R
AU  - Mehran R
FAU - Uribarri, J
AU  - Uribarri J
FAU - Badimon, J
AU  - Badimon J
FAU - Muntner, P
AU  - Muntner P
FAU - Moreno, P
AU  - Moreno P
FAU - Kini, A S
AU  - Kini AS
FAU - Sharma, S K
AU  - Sharma SK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/01/03 [received]
PHST- 2013/04/20 [accepted]
AID - 13-01-0004 [pii]
AID - 10.1160/TH13-01-0004 [doi]
PST - aheadofprint
SO  - Thromb Haemost. 2013 May 16;110(1).

PMID- 23677087
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 2168-6084 (Electronic)
VI  - 149
IP  - 5
DP  - 2013 May 1
TI  - Association of androgenetic alopecia with mortality from diabetes mellitus and
      heart disease.
PG  - 601-6
LID - 10.1001/jamadermatol.2013.130 [doi]
AB  - IMPORTANCE Identifying predictors of mortality from diabetes mellitus (DM) and
      heart disease can help shape treatment strategies. Presence of androgenetic
      alopecia (AGA) might be such a predictor. OBJECTIVE To determine whether the
      presence of AGA is associated with an elevated rate of mortality from DM and
      heart disease in both sexes after adjustment for potential confounders. DESIGN A 
      population-based prospective cohort study. SETTING Community-based integrated
      screening in Taiwan. PARTICIPANTS A total of 7252 subjects aged 30 to 95 years
      participated in the baseline AGA survey using the Norwood and Ludwig
      classifications between April and June 2005. Baseline information on metabolic
      syndrome (MetS) and other possible risk factors was also collected. We then
      followed this cohort over time to ascertain death and cause of death until
      December 2010. INTERVENTIONS OR EXPOSURES Application of Norwood and Ludwig ALA
      classifications to study population. MAIN OUTCOMES AND MEASURES Deaths from DM
      and heart disease. RESULTS Among the 7126 subjects (2429 men and 4697 women) who 
      provided complete data, there were 70 deaths from DM and heart disease during the
      57-month follow-up period. Subjects with moderate to severe AGA vs normal or mild
      AGA had a significantly higher risk of mortality from DM (adjusted hazard ratio
      [HR], 2.97; 95% CI, 1.26-7.01) (P = .01) and heart disease (adjusted HR, 2.28;
      95% CI, 1.00-5.23) (P = .05) after adjusting for age, family history of DM or
      heart disease, and MetS. CONCLUSIONS AND RELEVANCE AGA is an independent
      predictor of mortality from DM and heart disease in both sexes. This finding may 
      have significant implications for the identification of risk factors for DM and
      heart disease in patients with moderate or severe AGA, regardless of whether MetS
      is present.
FAU - Su, Lin-Hui
AU  - Su LH
FAU - Chen, Li-Sheng
AU  - Chen LS
FAU - Lin, Sheng-Che
AU  - Lin SC
FAU - Chen, Hsiu-Hsi
AU  - Chen HH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - JAMA Dermatol
JT  - JAMA dermatology (Chicago, Ill.)
JID - 101589530
SB  - AIM
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 1688048 [pii]
AID - 10.1001/jamadermatol.2013.130 [doi]
PST - ppublish
SO  - JAMA Dermatol. 2013 May 1;149(5):601-6. doi: 10.1001/jamadermatol.2013.130.

PMID- 23677052
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
DP  - 2013 May 13
TI  - Factors Affecting Transplant Outcomes in Diabetic Nude Mice Receiving Human,
      Porcine, and Nonhuman Primate Islets: Analysis of 335 Transplantations.
AB  - BACKGROUND: In the absence of a reliable islet potency assay, nude mice (NM)
      transplantation is the criterion standard to assess islet quality for clinical
      transplantation. There are factors other than islet quality that affect the
      transplant outcome. METHODS: Here, we analyzed the transplant outcomes in 335 NM 
      receiving islets from human (n=103), porcine (n=205), and nonhuman primate (NHP; 
      n=27) donors. The islets (750, 1000, and 2000 islet equivalents [IEQ]) were
      transplanted under the kidney capsule of streptozotocin-induced diabetic NM.
      RESULTS: The proportion of mice that achieved normoglycemia was significantly
      higher in the group implanted with 2000 IEQ of human, porcine, or NHP islets (75%
      normoglycemic) versus groups that were implanted with 750 IEQ (7% normoglycemic) 
      and 1000 IEQ (30% normoglycemic). In this study, we observed that the purity of
      porcine islet preparations (P</=0.001), islet pellet size in porcine preparations
      (P</= 0.01), and mice recipient body weight for human islet preparations
      (P=0.013) were independently associated with successful transplant outcome. NHP
      islets of 1000 IEQ were sufficient to achieve normoglycemic condition (83%). An
      islet mass of 2000 IEQ, high islet purity, increased recipient body weight, and
      high islet pellet volume increased the likelihood of successful reversal of
      diabetes in transplanted mice. Also, higher insulin secretory status of islets at
      basal stimulus was associated with a reduced mouse cure rate. The cumulative
      incidence of graft failure was significantly greater in human islets (56.12%)
      compared with porcine islets (35.57%; P</=0.001). CONCLUSION: Factors affecting
      NM bioassay were identified (islet mass, islet purity, pellet size, in vitro
      insulin secretory capability, and mouse recipient body weight) and should be
      considered when evaluating islet function.
AD  - 1 Schulze Diabetes Institute, Department of Surgery, University of Minnesota,
      Minneapolis, MN. 2 Department of Surgery, University of Minnesota, Minneapolis,
      MN. 3 Currently, Department of Surgery, Fukushima Medical University, Fukushima, 
      Japan. 4 Currently, Institute of Cellular Transplantation, Department of Surgery,
      University of Arizona, Tucson, AZ. 5 Address correspondence to: A.N. Balamurugan,
      Ph.D., Schulze Diabetes Institute, Department of Surgery, University of
      Minnesota, Minneapolis, MN 55455.
FAU - Loganathan, Gopalakrishnan
AU  - Loganathan G
FAU - Graham, Melanie L
AU  - Graham ML
FAU - Radosevich, David M
AU  - Radosevich DM
FAU - Soltani, Sajjad M
AU  - Soltani SM
FAU - Tiwari, Mukesh
AU  - Tiwari M
FAU - Anazawa, Takayuki
AU  - Anazawa T
FAU - Papas, Klearchos K
AU  - Papas KK
FAU - Sutherland, David E R
AU  - Sutherland DE
FAU - Hering, Bernhard J
AU  - Hering BJ
FAU - Balamurugan, A N
AU  - Balamurugan AN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Transplantation
JT  - Transplantation
JID - 0132144
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.1097/TP.0b013e318293b7b8 [doi]
PST - aheadofprint
SO  - Transplantation. 2013 May 13.

PMID- 23677041
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Global trends in the incidence and prevalence of type 2 diabetes in children and 
      adolescents: a systematic review and evaluation of methodological approaches.
PG  - 1471-88
LID - 10.1007/s00125-013-2915-z [doi]
AB  - AIMS/HYPOTHESIS: This study aimed to systematically review what has been reported
      on the incidence and prevalence of type 2 diabetes in children and adolescents,
      to scrutinise the methodological issues observed in the included studies and to
      prepare recommendations for future research and surveillances. METHODS: PubMed,
      the Cochrane Database of Systematic Reviews, Scopus, EMBASE and Web of Science
      were searched from inception to February 2013. Population-based studies on
      incidence and prevalence of type 2 diabetes in children and adolescents were
      summarised and methodologically evaluated. Owing to substantial methodological
      heterogeneity and considerable differences in study populations a quantitative
      meta-analysis was not performed. RESULTS: Among 145 potentially relevant studies,
      37 population-based studies met the inclusion criteria. Variations in the
      incidence and prevalence rates of type 2 diabetes in children and adolescents
      were mainly related to age of the study population, calendar time, geographical
      regions and ethnicity, resulting in a range of 0-330 per 100,000 person-years for
      incidence rates, and 0-5,300 per 100,000 population for prevalence rates.
      Furthermore, a substantial variation in the methodological characteristics was
      observed for response rates (60-96%), ascertainment rates (53-99%), diagnostic
      tests and criteria used to diagnose type 2 diabetes. CONCLUSIONS/INTERPRETATION: 
      Worldwide incidence and prevalence of type 2 diabetes in children and adolescents
      vary substantially among countries, age categories and ethnic groups and this can
      be explained by variations in population characteristics and methodological
      dissimilarities between studies.
AD  - Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for
      Pharmaceutical Sciences (UIPS), Utrecht University, P.O. Box 80082, 3508 TB,
      Utrecht, the Netherlands.
FAU - Fazeli Farsani, S
AU  - Fazeli Farsani S
FAU - van der Aa, M P
AU  - van der Aa MP
FAU - van der Vorst, M M J
AU  - van der Vorst MM
FAU - Knibbe, C A J
AU  - Knibbe CA
FAU - de Boer, A
AU  - de Boer A
LA  - eng
PT  - Journal Article
DEP - 20130516
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/01/16 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/05/16 [aheadofprint]
AID - 10.1007/s00125-013-2915-z [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1471-88. doi: 10.1007/s00125-013-2915-z. Epub 2013
      May 16.

PMID- 23676986
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 0340-6245 (Electronic)
IS  - 0340-6245 (Linking)
VI  - 110
IP  - 2
DP  - 2013 May 16
TI  - Role of plasma kallikrein in diabetes and metabolism.
AB  - Plasma kallikrein (PK) is a serine protease generated from plasma prekallikrein, 
      an abundant circulating zymogen expressed by the Klkb1 gene. The physiological
      actions of PK have been primarily attributed to its production of bradykinin and 
      activation of coagulation factor XII, which promotes inflammation and the
      intrinsic coagulation pathway. Recent genetic, molecular, and pharmacological
      studies of PK have provided further insight into its role in physiology and
      disease. Genetic analyses have revealed common Klkb1 variants that are
      association with blood metabolite levels, hypertension, and coagulation.
      Characterisation of animal models with Klkb1 deficiency and PK inhibition have
      demonstrated effects on inflammation, vascular function, blood pressure
      regulation, thrombosis, haemostasis, and metabolism. These reports have also
      identified a host of PK substrates and interactions, which suggest an expanded
      physiological role for this protease beyond the bradykinin system and
      coagulation. The review summarises the mechanisms that contribute to PK
      activation and its emerging role in diabetes and metabolism.
AD  - Edward P. Feener, PhD, Joslin Diabetes Center, One Joslin Place, Boston,
      Massachusetts 02215, USA, Tel.: +1 617 309 2599, Fax: +1 617 309 2637, E-mail:
      edward.feener@joslin.harvard.edu.
FAU - Feener, E P
AU  - Feener EP
FAU - Zhou, Q
AU  - Zhou Q
FAU - Fickweiler, W
AU  - Fickweiler W
LA  - ENG
GR  - P30 DK036836/DK/NIDDK NIH HHS/United States
GR  - R01 EY019029/EY/NEI NIH HHS/United States
GR  - R01 NS077006/NS/NINDS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/02/27 [received]
PHST- 2013/04/03 [accepted]
AID - 13-02-0179 [pii]
AID - 10.1160/TH13-02-0179 [doi]
PST - aheadofprint
SO  - Thromb Haemost. 2013 May 16;110(2).

PMID- 23676937
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1008-8830 (Print)
IS  - 1008-8830 (Linking)
VI  - 15
IP  - 5
DP  - 2013 May
TI  - [Non-high-density-cholesterol as a predictor of non-lipid cardiovascular disease 
      risk factors in obese children].
PG  - 356-60
AB  - OBJECTIVE: To investigate the role of non-high density lipoprotein cholesterol
      (non-HDL-C) in the assessment of cardiovascular disease (CVD) risk factors such
      as hypertension, pre-diabetes and diabetes in obese children. METHODS: According 
      to the presence of complications (hypertension, pre-diabetes and diabetes), 810
      children with central obesity were divided into two groups: one group with
      complications (n=499) and one group without complications (n=311). One hundred
      and sixty-four age- and sex-matched children served as the control group.
      Logistic regression analysis and receiver operating characteristic (ROC) curves
      were used to analyze the detection of non-lipid CVD risk factors by seven lipid
      markers. RESULTS: The prevalence rates of hypertension and pre-diabetes were
      significantly higher in obese children with high non-HDL-C concentrations
      (>/=3.76 mmol/L). After adjusting for waist circumference Z-scores, the area
      under the ROC curve for non-HDL-C was 0.680 to detect non-lipid CVD risk factors,
      while the areas for low-density lipoprotein cholesterol, total cholesterol and
      apoprotein B were 0.659, 0.669 and 0.647 respectively. CONCLUSIONS: Compared with
      the other lipid markers, non-HDL-C is a better predictor for non-lipid CVD risk
      factors in obese children. Measurement of non-HDL-C concentations is recommended 
      for obese children.
AD  - Department of Endocrinology, Children's Hospital of Zhejiang University School of
      Medicine, Hangzhou 310003, China. zdliangli@163.com.
FAU - Chen, Lian-Hui
AU  - Chen LH
FAU - Zhu, Wei-Fen
AU  - Zhu WF
FAU - Liang, Li
AU  - Liang L
FAU - Fu, Jun-Fen
AU  - Fu JF
FAU - Wang, Chun-Lin
AU  - Wang CL
FAU - Fang, Yan-Lan
AU  - Fang YL
FAU - Chen, Xue-Feng
AU  - Chen XF
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Dang Dai Er Ke Za Zhi
JT  - Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
JID - 100909956
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.7499/j.issn.1008-8830.2013.05.009 [pii]
PST - ppublish
SO  - Zhongguo Dang Dai Er Ke Za Zhi. 2013 May;15(5):356-60.

PMID- 23676813
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1478-7083 (Electronic)
IS  - 0035-8843 (Linking)
VI  - 95
IP  - 4
DP  - 2013 May
TI  - Diabetes is predictive of longer hospital stay and increased rate of
      complications in spinal surgery in the UK.
PG  - 275-9
LID - 10.1308/003588413X13511609958299 [doi]
AB  - INTRODUCTION: Diabetes is a common co-morbidity of patients undergoing spinal
      surgery in the UK but there are no published studies from the UK, particularly
      with respect to length of hospital stay and complications. The aims of this study
      were to identify complications and length of hospital stay in patients with
      diabetes undergoing spinal surgery. METHODS: Data were collected retrospectively 
      for 111 consecutive patients with diabetes (and 97 age and sex matched control
      patients, identified using computer records) who underwent spinal surgery between
      2004 and 2010 in a single centre. The data collected included operative time,
      blood loss, details of surgery, Clavien complications and length of hospital
      stay. RESULTS: No significant differences were found by group in operative time, 
      blood loss, instrumentation, use of graft or revision surgery. Overall
      complication rates were higher in the patients with diabetes than in the controls
      (28.8% vs 15.5%). The mean hospital stay was significantly longer for patients
      with diabetes than for control patients (4.6 vs 3.2 days, p<0.001). CONCLUSIONS: 
      This study identified a significantly higher Clavien grade I complication rate
      and length of hospital stay in patients with diabetes undergoing spinal surgery
      than control patients (p=0.02). This has resulted in a predictive model being
      generated. Of note, no infections were seen in patients with diabetes, suggesting
      that infection rates in this particular group of patients undergoing spinal
      surgery might not be as high as considered previously.
AD  - Oxford University Hospitals NHS Trust, UK.
FAU - Sharma, A
AU  - Sharma A
FAU - Muir, R
AU  - Muir R
FAU - Johnston, R
AU  - Johnston R
FAU - Carter, E
AU  - Carter E
FAU - Bowden, G
AU  - Bowden G
FAU - Wilson-Macdonald, J
AU  - Wilson-Macdonald J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ann R Coll Surg Engl
JT  - Annals of the Royal College of Surgeons of England
JID - 7506860
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.1308/003588413X13511609958299 [doi]
PST - ppublish
SO  - Ann R Coll Surg Engl. 2013 May;95(4):275-9. doi:
      10.1308/003588413X13511609958299.

PMID- 23676796
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130516
DCOM- 20130517
LR  - 20130522
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 5
DP  - 2013
TI  - Predictive models to assess risk of type 2 diabetes, hypertension and
      comorbidity: machine-learning algorithms and validation using national health
      data from Kuwait--a cohort study.
LID - 10.1136/bmjopen-2012-002457 [doi]
LID - e002457 [pii]
AB  - OBJECTIVE: We build classification models and risk assessment tools for diabetes,
      hypertension and comorbidity using machine-learning algorithms on data from
      Kuwait. We model the increased proneness in diabetic patients to develop
      hypertension and vice versa. We ascertain the importance of ethnicity (and
      natives vs expatriate migrants) and of using regional data in risk assessment.
      DESIGN: Retrospective cohort study. Four machine-learning techniques were used:
      logistic regression, k-nearest neighbours (k-NN), multifactor dimensionality
      reduction and support vector machines. The study uses fivefold cross validation
      to obtain generalisation accuracies and errors. SETTING: Kuwait Health Network
      (KHN) that integrates data from primary health centres and hospitals in Kuwait.
      PARTICIPANTS: 270 172 hospital visitors (of which, 89 858 are diabetic, 58 745
      hypertensive and 30 522 comorbid) comprising Kuwaiti natives, Asian and Arab
      expatriates. OUTCOME MEASURES: Incident type 2 diabetes, hypertension and
      comorbidity. RESULTS: Classification accuracies of >85% (for diabetes) and >90%
      (for hypertension) are achieved using only simple non-laboratory-based
      parameters. Risk assessment tools based on k-NN classification models are able to
      assign 'high' risk to 75% of diabetic patients and to 94% of hypertensive
      patients. Only 5% of diabetic patients are seen assigned 'low' risk.
      Asian-specific models and assessments perform even better. Pathological
      conditions of diabetes in the general population or in hypertensive population
      and those of hypertension are modelled. Two-stage aggregate classification models
      and risk assessment tools, built combining both the component models on diabetes 
      (or on hypertension), perform better than individual models. CONCLUSIONS: Data on
      diabetes, hypertension and comorbidity from the cosmopolitan State of Kuwait are 
      available for the first time. This enabled us to apply four different
      case-control models to assess risks. These tools aid in the preliminary
      non-intrusive assessment of the population. Ethnicity is seen significant to the 
      predictive models. Risk assessments need to be developed using regional data as
      we demonstrate the applicability of the American Diabetes Association online
      calculator on data from Kuwait.
AD  - Integrative Informatics, Dasman Diabetes Institute, Dasman, Kuwait.
FAU - Farran, Bassam
AU  - Farran B
FAU - Channanath, Arshad Mohamed
AU  - Channanath AM
FAU - Behbehani, Kazem
AU  - Behbehani K
FAU - Thanaraj, Thangavel Alphonse
AU  - Thanaraj TA
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3657675
OID - NLM: PMC3657675
OTO - NOTNLM
OT  - Kuwait
OT  - Machine learning
OT  - Risk assessment
OT  - predictive models
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:01
CRDT- 2013/05/17 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2012-002457 [pii]
AID - 10.1136/bmjopen-2012-002457 [doi]
PST - epublish
SO  - BMJ Open. 2013 May 14;3(5). pii: e002457. doi: 10.1136/bmjopen-2012-002457. Print
      2013.

PMID- 23676771
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1543-5474 (Electronic)
IS  - 1543-3080 (Linking)
DP  - 2013 May 10
TI  - Should Physical Activity Intervention Efforts Take a Whole Population, High-Risk 
      or Middle Road Strategy?
AB  - PURPOSE: To compare theoretical strategies for changing physical activity (PA) in
      terms of their potential to reduce the incidence of chronic conditions in mid-age
      women: (1) whole population: + 30 minutes/week in all; (2) high-risk: +60
      minutes/week in the lowest 25% of the PA distribution; and (3) middle road: shift
      all those not meeting guidelines to a level commensurate with meeting guidelines.
      METHODS: 10,854 participants (50-55 years in 2001) in the Australian Longitudinal
      Study of Women's Health completed mail surveys in 2001, 2004, 2007 and 2010. PA
      was calculated as MET.minutes/week spent in walking, moderate and vigorous PA in 
      the previous week. Incidence rates per 1000 person-years for diabetes, heart
      disease, hypertension, cancer and depression were calculated for the actual
      distribution and after modelled shifts in PA. RESULTS: The incidence rates were
      10.6 for diabetes, 7.0 for heart disease, 30.7 for hypertension, 8.0 for cancer
      and 28.4 for depression. Greater reductions in incidence were found for the
      middle road strategy than for the whole population and high-risk strategies, with
      reductions ranging from -6.3% for cancer to -12.3% for diabetes. DISCUSSION: This
      theoretical modelling showed that a middle road strategy to increasing PA was
      superior to the whole population and high-risk strategies, in terms of reducing
      incidence rates of chronic conditions in middle-aged women.
AD  - School of Human Movement Studies, The University of Queensland, Brisbane,
      Queensland, Australia.
FAU - Peeters, Geeske
AU  - Peeters G
FAU - Hockey, Richard
AU  - Hockey R
FAU - Brown, Wendy
AU  - Brown W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Phys Act Health
JT  - Journal of physical activity & health
JID - 101189457
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 2012-0275 [pii]
PST - aheadofprint
SO  - J Phys Act Health. 2013 May 10.

PMID- 23676648
OWN - NLM
STAT- In-Process
DA  - 20130516
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 54
IP  - 3
DP  - 2013 Mar
TI  - [Central intravenous catheter-related bacteremia due to Chryseobacterium
      indologenes after cord blood transplantation].
PG  - 305-10
AB  - A 3-year-old girl with acute myeloid leukemia underwent unrelated cord blood stem
      cell transplantation (UCBT) due to primary induction failure. Fourteen days after
      UCBT, she developed central venous catheter (CVC)-related bloodstream infection
      due to Chryseobacterium indologenes. Despite ciprofloxacin and minocycline being 
      administered according to the results of susceptibility, a high grade fever
      recurred. Therefore, the CVC was removed 21 days after UCBT and symptoms related 
      to CVC infection improved. Although C. indologenes is widely distributed in
      nature, it is a rare pathogen in humans. Most cases of C. indologenes bacteremia 
      have been found in immunocompromised patients with malignancies and diabetes
      mellitus. C. indologenes exhibits specific characteristics, including the
      progression of resistance to antibiotics and the formation of a biofilm.
      Therefore, removal of the CVC appears to be the most reasonable treatment for CVC
      infection due to C. indologenes in patients undergoing hematopoietic stem cell
      transplantation if clinical symptoms do not improve after appropriate antibiotic 
      therapy.
AD  - Department of Pediatrics, National Kyushu Cancer Center, Japan.
FAU - Kodama, Yuichi
AU  - Kodama Y
FAU - Nishimura, Miho
AU  - Nishimura M
FAU - Nakashima, Kentaro
AU  - Nakashima K
FAU - Ito, Nobuhiro
AU  - Ito N
FAU - Fukano, Reiji
AU  - Fukano R
FAU - Okamura, Jun
AU  - Okamura J
FAU - Inagaki, Jiro
AU  - Inagaki J
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - DN/JST.JSTAGE/rinketsu/54.305 [pii]
PST - ppublish
SO  - Rinsho Ketsueki. 2013 Mar;54(3):305-10.

PMID- 23676599
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 52
IP  - 10
DP  - 2013
TI  - Central Diabetes Insipidus in an HHV6 Encephalitis Patient with a Posterior
      Pituitary Lesion that Developed after Tandem Cord Blood Transplantation.
PG  - 1107-10
AB  - A 60-year-old myelodysplastic syndrome patient underwent tandem cord blood
      transplantation. The primary cord blood graft was rejected, and human herpesvirus
      6 (HHV6) encephalitis developed after engraftment of secondary cord blood.
      Polyuria and adipsic hypernatremia were observed during treatment of the
      encephalitis. The patient died of bacteremia caused by methicillin-resistant
      Streptococcus epidermis. HHV6 infection in the posterior pituitary was confirmed 
      on autopsy, as was infection of the hippocampus, but not of the hypothalamus.
      This is the first case report of central diabetes insipidus caused by an HHV6
      posterior pituitary infection demonstrated on a pathological examination.
AD  - Department of Internal Medicine, Rinku General Medical Center, Japan.
FAU - Kawamoto, Shinichiro
AU  - Kawamoto S
FAU - Hatanaka, Kazuo
AU  - Hatanaka K
FAU - Imakita, Masami
AU  - Imakita M
FAU - Tamaki, Toshiharu
AU  - Tamaki T
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/15 [epublish]
AID - DN/JST.JSTAGE/internalmedicine/52.9432 [pii]
PST - ppublish
SO  - Intern Med. 2013;52(10):1107-10. Epub 2013 May 15.

PMID- 23676586
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 52
IP  - 10
DP  - 2013
TI  - Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight,
      Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes
      Mellitus.
PG  - 1029-34
AB  - Objective To evaluate the effects of six-month liraglutide treatment on body
      weight, visceral and subcutaneous fat and related markers in Japanese type 2
      diabetic patients. Methods A total of 59 patients with type 2 diabetes were
      treated with liraglutide (0.3 mg/day for >/=1 week and then 0.6 mg/day for >/=1
      week, gradually increasing the dose to 0.9 mg/day) for six months. Changes in
      body weight, body mass index (BMI), HbA1c, the fasting blood glucose level,
      visceral and subcutaneous fat areas, hepatic and renal CT values and the
      associated markers proinsulin, adiponectin and pentraxin (PTX) 3 were measured.
      Results The study included one treatment-naive patient, 10 patients who were
      switched from oral antidiabetic drugs and 35 patients who were switched from
      insulin therapy. At six months after treatment, the preprandial blood glucose
      levels were higher (148.8+/-40.5 mg/dL) than the baseline values (130.8+/-36.7,
      p<0.05); however, body weight, BMI and abdominal circumference were lower, and
      the liver/kidney CT ratio improved significantly from 1.64+/-0.44 at baseline to 
      1.78+/-0.42. An analysis of the patients who were not pretreated with insulin
      resistance ameliorators showed that six months of liraglutide treatment
      significantly decreased the subcutaneous but not visceral fat areas,
      significantly decreased the serum adiponectin levels and significantly increased 
      the serum PTX3 levels. Conclusion In addition to its glucose-lowering effects,
      liraglutide exhibits weight loss promotion actions, reducing subcutaneous fat
      areas in particular. The weight and total fat area reduction properties of
      liraglutide are likely to be beneficial when this medication is used in
      combination with other oral antidiabetic drugs and insulin.
AD  - Division of Nephrology, Endocrinology and Metabolism, Department of Internal
      Medicine, Tokai University School of Medicine, Japan.
FAU - Suzuki, Daisuke
AU  - Suzuki D
FAU - Toyoda, Masao
AU  - Toyoda M
FAU - Kimura, Moritugu
AU  - Kimura M
FAU - Miyauchi, Masaaki
AU  - Miyauchi M
FAU - Yamamoto, Naoyuki
AU  - Yamamoto N
FAU - Sato, Hiroki
AU  - Sato H
FAU - Tanaka, Eitaro
AU  - Tanaka E
FAU - Kuriyama, Yusuke
AU  - Kuriyama Y
FAU - Miyatake, Han
AU  - Miyatake H
FAU - Abe, Makiko
AU  - Abe M
FAU - Umezono, Tomoya
AU  - Umezono T
FAU - Fukagawa, Masafumi
AU  - Fukagawa M
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/15 [epublish]
AID - DN/JST.JSTAGE/internalmedicine/52.8961 [pii]
PST - ppublish
SO  - Intern Med. 2013;52(10):1029-34. Epub 2013 May 15.

PMID- 23676525
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1543-5474 (Electronic)
IS  - 1543-3080 (Linking)
DP  - 2013 May 10
TI  - Physical Activity, Measures of Obesity, and Cardiometabolic Risk: The
      Multi-Ethnic Study of Atherosclerosis (MESA).
AB  - BACKGROUND: The influence of higher physical activity on the relationship between
      adiposity and cardiometabolic risk is not completely understood. METHODS: Between
      2000 and 2002 data were collected on 6795 Multi-Ethnic Study of Atherosclerosis
      (MESA) participants. Self-reported intentional physical activity in the lowest
      quartile (0-105 MET-minutes/wk) was categorized as inactive and the upper three
      quartiles (123-37,260 MET-minutes/wk) as active. Associations of body mass index 
      (BMI) and waist circumference categories, stratified by physical activity status 
      (inactive or active) with cardiometabolic risk factors (dyslipidemia,
      hypertension, upper quartile of homeostasis model assessment of insulin
      resistance [HOMA-IR] for population, and impaired fasting glucose or diabetes)
      were assessed using logistic regression analysis adjusting for age, gender,
      race/ethnicity, and current smoking. RESULTS: Among obese participants, those who
      were physically active had reduced odds of insulin resistance (47% lower;
      p<0.001) and impaired fasting glucose/diabetes (23% lower; p=0.04). These
      associations were weaker for central obesity. However, among participants with a 
      normal waist circumference, those who were inactive were 63% more likely to have 
      insulin resistance (OR [95% CI] 1.63 [1.24-2.15]) compared to the active
      reference group. CONCLUSIONS: Physical activity was inversely related to the
      cardiometabolic risk associated with obesity and central obesity.
AD  - Human Performance and Sport Sciences, Winston-Salem State University,
      Winston-Salem, NC.
FAU - McAuley, Paul A
AU  - McAuley PA
FAU - Chen, Haiying
AU  - Chen H
FAU - Lee, Duck-Chul
AU  - Lee DC
FAU - Artero, Enrique Garcia
AU  - Artero EG
FAU - Bluemke, David A
AU  - Bluemke DA
FAU - Burke, Gregory L
AU  - Burke GL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Phys Act Health
JT  - Journal of physical activity & health
JID - 101189457
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 2012-0326 [pii]
PST - aheadofprint
SO  - J Phys Act Health. 2013 May 10.

PMID- 23676484
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1512-0112 (Print)
IS  - 1512-0112 (Linking)
IP  - 217
DP  - 2013 Apr
TI  - [Post-operational acute iridocyclitis and immune shifts in intraocular humor of
      patients with cataracts].
PG  - 30-4
AB  - The negative tendency of cataracts growth, which is a consequence of various
      diseases of the organism including those of eyes, combined in the concept "the
      complicated cataract" is clearly traced now. In the concept of such a
      complication of cataracts as the acute autoimmune iridocyclitis, the important
      role, in our opinion, should be given to regional immunopathological disorders,
      which testify to the withdrawal of the known phenomenon underlying in the
      immunological tolerance of post-barrier eye membrane "a syndrome of eye anterior 
      chamber-associated immune deviation (ACAID). Microcoaxial phacoemulsification was
      carried in three hundred patients with senile and complicated cataracts. The
      intraocular humor of the operated patients was subjected to immune-enzyme
      immunomorphological analysis for capital ES, CyrillicD4, capital ES, CyrillicD8, 
      IgG and B-lymphocytic populations. On the base of performed clinical-laboratory
      research we found that the gravest inflammatory process in eye tissues manifested
      in the form of autoimmune aseptic iridocyclitis was observed particularly in
      patients with complicated cataracts, proceeding on the background of glaucoma,
      diabetes and the previous trauma of an eye. The high indicators of IgG, capital
      ES, CyrillicD4 were registered on the background of low capital ES, CyrillicD8
      indicators in the intraocular humour at these patients. The revealed regional
      inflammatory reaction in eye tissues testifies, in our opinion, in favour of in
      situ withdrawal of ACAID; this latter brings to origination of acute aseptic
      autoimmune iridocyclitis in the early post-operational course of the complicated 
      cataracts.
AD  - Scientific-Research Center of Yerevan State Medical University, Yerevan;
      "Shengavit" Medical Center, Yerevan, Armenia.
FAU - Zilfyan, A
AU  - Zilfyan A
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Georgia (Republic)
TA  - Georgian Med News
JT  - Georgian medical news
JID - 101218222
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PST - ppublish
SO  - Georgian Med News. 2013 Apr;(217):30-4.

PMID- 23676463
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 123
IP  - 6
DP  - 2013 Jun 3
TI  - Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
PG  - 2737-41
LID - 10.1172/JCI68775 [doi]
LID - 68775 [pii]
AB  - Multiple sclerosis (MS) is a genetically mediated autoimmune disease of the
      central nervous system. B cells have recently emerged as major contributors to
      disease pathogenesis, but the mechanisms responsible for the loss of B cell
      tolerance in patients with MS are largely unknown. In healthy individuals,
      developing autoreactive B cells are removed from the repertoire at 2 tolerance
      checkpoints during early B cell development. Both of these central and peripheral
      B cell tolerance checkpoints are defective in patients with rheumatoid arthritis 
      (RA) and type 1 diabetes (T1D). Here, we found that only the peripheral, but not 
      the central, B cell tolerance checkpoint is defective in patients with MS. We
      show that this specific defect is accompanied by increased activation and
      homeostatic proliferation of mature naive B cells. Interestingly, all of these MS
      features parallel defects observed in FOXP3-deficient IPEX patients, who harbor
      nonfunctional Tregs. We demonstrate that in contrast to patients with RA or T1D, 
      bone marrow central B cell selection in MS appears normal in most patients. In
      contrast, patients with MS suffer from a specific peripheral B cell tolerance
      defect that is potentially attributable to impaired Treg function and that leads 
      to the accumulation of autoreactive B cell clones in their blood.
FAU - Kinnunen, Tuure
AU  - Kinnunen T
FAU - Chamberlain, Nicolas
AU  - Chamberlain N
FAU - Morbach, Henner
AU  - Morbach H
FAU - Cantaert, Tineke
AU  - Cantaert T
FAU - Lynch, Megan
AU  - Lynch M
FAU - Preston-Hurlburt, Paula
AU  - Preston-Hurlburt P
FAU - Herold, Kevan C
AU  - Herold KC
FAU - Hafler, David A
AU  - Hafler DA
FAU - O'Connor, Kevin C
AU  - O'Connor KC
FAU - Meffre, Eric
AU  - Meffre E
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
SB  - AIM
SB  - IM
PMC - PMC3668812
OID - NLM: PMC3668812
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/01/11 [received]
PHST- 2013/03/21 [accepted]
PHST- 2013/05/15 [aheadofprint]
PHST- 2013/05/15 [epublish]
AID - 68775 [pii]
AID - 10.1172/JCI68775 [doi]
PST - ppublish
SO  - J Clin Invest. 2013 Jun 3;123(6):2737-41. doi: 10.1172/JCI68775. Epub 2013 May
      15.

PMID- 23676423
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1938-3207 (Electronic)
IS  - 0002-9165 (Linking)
DP  - 2013 May 15
TI  - Egg consumption in relation to risk of cardiovascular disease and diabetes: a
      systematic review and meta-analysis.
AB  - BACKGROUND: The associations of egg consumption with cardiovascular disease (CVD)
      and diabetes are still unclear. OBJECTIVE: We aimed to quantitatively summarize
      the literature on egg consumption and risk of CVD, cardiac mortality, and type 2 
      diabetes by conducting a meta-analysis of prospective cohort studies. DESIGN: A
      systematic literature review was conducted for published studies in PubMed and
      EMBASE through March 2012. Additional information was retrieved through Google or
      a hand review of the reference from relevant articles. Studies were included if
      they had a prospective study design, were published in English-language journals,
      and provided HRs and 95% CIs for the associations of interest. Data were
      independently extracted by 2 investigators, and the weighted HRs and 95% CIs for 
      the associations of interest were estimated by using a random-effects model.
      RESULTS: A total of 22 independent cohorts from 16 studies were identified,
      including participants ranging in number from 1600 to 90,735 and in follow-up
      time from 5.8 to 20.0 y. Comparison of the highest category (>/=1 egg/d) of egg
      consumption with the lowest (<1 egg/wk or never) resulted in a pooled HR (95% CI)
      of 0.96 (0.88, 1.05) for overall CVD, 0.97 (0.86, 1.09) for ischemic heart
      disease, 0.93 (0.81, 1.07) for stroke, 0.98 (0.77, 1.24) for ischemic heart
      disease mortality, 0.92 (0.56, 1.50) for stroke mortality, and 1.42 (1.09, 1.86) 
      for type 2 diabetes. Of the studies conducted in diabetic patients, the pooled HR
      (95% CI) was 1.69 (1.09, 2.62) for overall CVD. CONCLUSION: This meta-analysis
      suggests that egg consumption is not associated with the risk of CVD and cardiac 
      mortality in the general population. However, egg consumption may be associated
      with an increased incidence of type 2 diabetes among the general population and
      CVD comorbidity among diabetic patients.
AD  - Departments of Nutrition and Epidemiology, Gillings Schools of Global Public
      Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
FAU - Shin, Jang Yel
AU  - Shin JY
FAU - Xun, Pengcheng
AU  - Xun P
FAU - Nakamura, Yasuyuki
AU  - Nakamura Y
FAU - He, Ka
AU  - He K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - ajcn.112.051318 [pii]
AID - 10.3945/ajcn.112.051318 [doi]
PST - aheadofprint
SO  - Am J Clin Nutr. 2013 May 15.

PMID- 23676359
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
DP  - 2013 May 12
TI  - The Prevalence and Predictors of Androgen Deficiency in Taiwanese Men With Type 2
      Diabetes.
LID - S0090-4295(13)00390-7 [pii]
LID - 10.1016/j.urology.2013.03.023 [doi]
AB  - OBJECTIVE: To evaluate the prevalence and predictors of androgen deficiency (AD) 
      in Taiwanese men with type 2 diabetes mellitus (T2DM). METHODS: A recent
      hospital-based series of Western populations showed that 30%-50% of men with T2DM
      have low testosterone, and AD links to DM and obesity bidirectionally. However,
      data of AD from other ethnicities with character of less obesity are rarely
      reported. AD was defined as having a total testosterone level less than 300
      ng/dL. The clinical variables and diabetes-associated complications of the risk
      of AD were evaluated. RESULTS: Of 766 consecutive subjects (mean age 62.2 years, 
      mean body mass index [BMI] 26.0) attending out-patient diabetic clinics, 32.5%
      have AD. The AD group was older, had higher BMI, waist circumference, higher
      proportion of metabolic syndrome and stroke, higher levels of triglyceride, high 
      sensitivity C-reactive protein (hsCRP), uric acid, and lower levels of total
      cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL)
      than the normal testosterone group. After age adjustment, AD was positively
      associated with metabolic syndrome (odds ratio [OR] = 2.142), serum high
      sensitivity C-reactive protein (OR = 1.120), uric acid (OR = 1.118), BMI (OR =
      1.083), waist circumference (OR = 1.038), triglyceride (OR = 1.028), and
      inversely associated with serum low-density lipoprotein (OR = 0.931) and
      high-density lipoprotein (OR = 0.826) in logistic regression analysis. There were
      no significant differences in retinopathy, neuropathy, nephropathy, or coronary
      artery disease between patients with or without AD. CONCLUSION: One third of
      Taiwanese men with T2DM have AD. The major predictors of AD are linked to
      obesity, which is a potentially modifiable risk factor, and may represent an
      important avenue for intervention.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Metabolism, Kaohsiung Chang Gung Memorial Hospital, Chang Gung
      University College of Medicine, Taiwan.
FAU - Liu, Rue-Tsuan
AU  - Liu RT
FAU - Chung, Min-Shen
AU  - Chung MS
FAU - Wang, Pei-Wen
AU  - Wang PW
FAU - Chen, Chung-Dar
AU  - Chen CD
FAU - Lee, Jong-Jer
AU  - Lee JJ
FAU - Lee, Wei-Chia
AU  - Lee WC
FAU - Chancellor, Michael B
AU  - Chancellor MB
FAU - Yang, Kuender D
AU  - Yang KD
FAU - Chuang, Yao-Chi
AU  - Chuang YC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Urology
JT  - Urology
JID - 0366151
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/02/05 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/12 [accepted]
AID - S0090-4295(13)00390-7 [pii]
AID - 10.1016/j.urology.2013.03.023 [doi]
PST - aheadofprint
SO  - Urology. 2013 May 12. pii: S0090-4295(13)00390-7. doi:
      10.1016/j.urology.2013.03.023.

PMID- 23676341
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1880-3873 (Electronic)
IS  - 1340-3478 (Linking)
DP  - 2013 May 16
TI  - Correlations Between the Level of High-Sensitivity C-Reactive Protein and
      Cardiovascular Risk Factors in Korean Adults with Cardiovascular Disease or
      Diabetes Mellitus: The CALLISTO Study.
AB  - Aim: We assessed the relationship between the level of high-sensitivity
      C-reactive protein (hsCRP) and cardiovascular risk factors in Korean
      adults.Methods: We reviewed 1,561 patients with cardiovascular disease or
      diabetes mellitus with hsCRP levels measured within the past year. Four
      cardiovascular risk groups were determined: low (<10%, 0-1 risk), moderate (<10%,
      >2 risk), high (10-20%) and very high (>20%) risk, according to the number of
      risk factors and the Framingham/NCEP ATP III risk score. The correlations between
      the hsCRP level and cardiovascular risk factors (age, smoking, hypertension,
      lipid profiles and familial history of premature coronary heart disease) were
      investigated.Results: The mean and median hsCRP (mg/L) levels were 1.32+/-9.69
      and 0.29 (range: 0.01-7.48), respectively. Men had a higher median level of hsCRP
      than women (p<0.001). The levels of hs CRP significantly increased from the low
      to the very high risk group (0.15, 0.23, 0.27 and 0.47, respectively) and were
      significantly correlated with age, the level of glycosylated hemoglobin, body
      mass index (BMI), the level of high-density lipoprotein cholesterol (HDL-C), the 
      low-density lipoprotein cholesterol (LDL-C)/HDL-C ratio, the LDL-C/total
      cholesterol (TC) ratio, the HDL-C/TC ratio, the HDL-C/triglyceride (TG) ratio and
      the TC/TG ratio. Neither smoking, the LDL-C level nor the TG level affected the
      hsCRP level. In a multivariate regression analysis, age, the HDL-C level, the
      LDL-C/TC ratio and BMI were found to be independently correlated with the hsCRP
      level.Conclusions: There is a significant relationship between the degree of
      cardiovascular risk and the hsCRP level in Korean adults with cardiovascular
      disease or diabetes mellitus. Assessing the hsCRP levels may thus provide
      additive value in predicting cardiovascular risks.
AD  - Division of Cardiovascular Medicine, Seoul St. Mary's Hospital, The Catholic
      University of Korea.
FAU - Seo, Suk Min
AU  - Seo SM
FAU - Baek, Sang Hong
AU  - Baek SH
FAU - Jeon, Hui Kyung
AU  - Jeon HK
FAU - Kang, Seok-Min
AU  - Kang SM
FAU - Kim, Dong-Soo
AU  - Kim DS
FAU - Kim, Woo-Shik
AU  - Kim WS
FAU - Kim, Hyung Seop
AU  - Kim HS
FAU - Rha, Seung Woon
AU  - Rha SW
FAU - Park, Jong Seon
AU  - Park JS
FAU - Seong, In Whan
AU  - Seong IW
FAU - Ahn, Young Keun
AU  - Ahn YK
FAU - Yoon, Jung Han
AU  - Yoon JH
FAU - Cha, Tae Joon
AU  - Cha TJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130516
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - DN/JST.JSTAGE/jat/16089 [pii]
PST - aheadofprint
SO  - J Atheroscler Thromb. 2013 May 16.

PMID- 23676315
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
DP  - 2013 May 14
TI  - Improvement in Myocardial Function by Terminalia arjuna in Streptozotocin-Induced
      Diabetic Rats: Possible Mechanisms.
AB  - Vascular complications are a leading cause of mortality and morbidity in diabetic
      patients. Herbal drugs are increasingly being used in the treatment of
      cardiovascular disorders. The present study was designed to examine the
      therapeutic potential of Terminalia arjuna bark extract in improving myocardial
      function in streptozotocin (STZ)-induced diabetic rats. After 8 weeks of STZ
      administration, rats showed a decline in left ventricular pressure (LVP), maximal
      rate of rise and fall in LVP (LV [dP/dt] max and LV [dP/dt] min), cardiac
      contractility index (LV [dP/dt] max/LVP), and rise in LV end-diastolic pressure. 
      Altered lipid profile, oxidative stress, and increased levels of endothelin 1
      (ET-1), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6) along
      with histological changes in heart and pancreas were observed in diabetic rats. T
      arjuna significantly attenuated cardiac dysfunction and myocardial injury in
      diabetic rats. It also reduced oxidative stress, ET-1, and inflammatory cytokine 
      levels. The decreased body weight, heart rate blood pressure, and raised blood
      sugar in diabetic rats did not improve after T arjuna therapy. Results suggest
      that T arjuna bark extract improves the altered myocardial function in diabetic
      rats possibly through maintaining endogenous antioxidant enzyme activities,
      decreasing ET-1 and cytokine levels.
AD  - 1Department of Physiology, University College of Medical Sciences, Delhi
      University, Delhi, India.
FAU - Khaliq, Farah
AU  - Khaliq F
FAU - Parveen, Adila
AU  - Parveen A
FAU - Singh, Savita
AU  - Singh S
FAU - Gondal, Ranjana
AU  - Gondal R
FAU - Hussain, M Eijaz
AU  - Hussain ME
FAU - Fahim, Mohammad
AU  - Fahim M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
OTO - NOTNLM
OT  - Terminalia arjuna
OT  - cytokines
OT  - diabetes
OT  - endothelin 1
OT  - myocardial function
OT  - oxidative stress
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 1074248413488831 [pii]
AID - 10.1177/1074248413488831 [doi]
PST - aheadofprint
SO  - J Cardiovasc Pharmacol Ther. 2013 May 14.

PMID- 23676285
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1938-2707 (Electronic)
IS  - 0009-9228 (Linking)
DP  - 2013 May 14
TI  - Effects of Hypothetical Type 2 Diabetes Genetic Testing on Parents' Efforts to
      Prevent Diabetes in Children.
AB  - Objective. To examine the effect of hypothetical genetic susceptibility test
      results on diabetic parents' intention to prevent type 2 diabetes (T2D) in their 
      children. Methods. Parents with T2D indicated their intention to prevent T2D in
      their youngest child at baseline and after a hypothetical positive and negative
      T2D genetic test result. We calculated mean/median "preventive intention scores" 
      for each scenario and examined the association between parents' score change and 
      parent/child characteristics. Results. A total of 63% of parents reported that
      their child had "almost no risk" or "slight risk" of developing T2D. Parents'
      median baseline preventive intention score was 8. It increased to 10 after a
      positive test result and decreased to 5 after a negative test result.
      Conclusions. Negative T2D genetic susceptibility test results may decrease
      diabetic parents' intentions to prevent T2D for their children. Future research
      studies in a real-life clinical context should examine this phenomenon.
AD  - 1University of Michigan, Ann Arbor, MI, USA.
FAU - Tarini, Beth A
AU  - Tarini BA
FAU - Herman, William H
AU  - Herman WH
FAU - Lee, Joyce M
AU  - Lee JM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Clin Pediatr (Phila)
JT  - Clinical pediatrics
JID - 0372606
OTO - NOTNLM
OT  - children
OT  - diabetes mellitus
OT  - genetic testing
OT  - type 2 diabetes
OT  - vignettes
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 0009922813488644 [pii]
AID - 10.1177/0009922813488644 [doi]
PST - aheadofprint
SO  - Clin Pediatr (Phila). 2013 May 14.

PMID- 23676268
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1531-5487 (Electronic)
IS  - 1044-3983 (Linking)
VI  - 24
IP  - 4
DP  - 2013 Jul
TI  - Hyperuricemia after exposure to polychlorinated dibenzo-p-dioxins and
      dibenzofurans near a highly contaminated area.
PG  - 582-9
LID - 10.1097/EDE.0b013e318294ef68 [doi]
AB  - BACKGROUND: : Hyperuricemia (too much uric acid in the blood) is the predisposing
      condition for gout and is associated with hypertriglyceridemia, diabetes
      mellitus, and coronary artery disease. Polychlorinated dibenzo-p-dioxins and
      dibenzo-furans (PCDD/Fs) cause renal toxicity and elevate uric acid. The aim of
      this analysis was to investigate and clarify the effect of moderate-to-high
      PCDD/F exposure on hyperuricemia risk. METHODS: : In this cross-sectional study, 
      we recruited 1531 healthy participants living near a deserted pentachlorophenol
      factory. We measured serum levels of 17 2,3,7,8-substituted PCDD/Fs, and then
      examined associations between the main predictor variable, serum TEQDF-2005
      (total PCDD/Fs 2005 World Health Organization [WHO] toxic equivalency [TEQ]), and
      dependent variables such as uric acid, glomerular filtration rates, and
      hyperuricemia risk. RESULTS: : We observed a strong monotonic inverse
      relationship between serum TEQDF-2005 quartiles and the estimated glomerular
      filtration rate after adjusting for confounding factors (Men: beta were 0, -4.7, 
      -6.2, and -14.8; Women: beta were 0, -6.7, -12.9, and -21.5). In addition, we
      observed a suggestive positive trend between serum TEQDF-2005 quartiles and uric 
      acid only in men after adjusting for confounding factors (Men: beta were 0, 0.40,
      0.36, and 0.59; Pfor trend <0.05). Men with serum TEQDF-2005 higher than the
      reference group's (<7.4 pg WHO2005-TEQDF/g lipid) had a higher hyperuricemia risk
      after adjusting for confounding factors (25th to <50th percentile, adjusted odds 
      ratio [AOR] = 2.20 [95% confidence interval {CI} = 1.30-3.73]; 50th to <75th
      percentile, AOR = 1.86 [95% CI = 1.08-3.22]; >/=75th percentile, AOR = 3.00 [95% 
      CI = 1.69-5.31]). CONCLUSIONS: : We conclude that serum TEQDF-2005 is an
      important determinant of serum uric acid levels and heightens the risk of
      hyperuricemia in general populations.
AD  - From the aDepartment of Environmental and Occupational Health, College of
      Medicine, National Cheng Kung University, Tainan, Taiwan; bDivision of
      Endocrinology and Metabolism, Department of Internal Medicine, National Cheng
      Kung University Hospital, Tainan, Taiwan; cDepartment of Industrial Safety and
      Health, Hung Kuang University, Taichung, Taiwan; and dResearch Center for
      Environmental Trace Toxic Substances, National Cheng Kung University, Tainan,
      Taiwan.
FAU - Chang, Jung-Wei
AU  - Chang JW
FAU - Ou, Horng-Yih
AU  - Ou HY
FAU - Chen, Hsiu-Ling
AU  - Chen HL
FAU - Su, Huey-Jen
AU  - Su HJ
FAU - Lee, Ching-Chang
AU  - Lee CC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Epidemiology
JT  - Epidemiology (Cambridge, Mass.)
JID - 9009644
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.1097/EDE.0b013e318294ef68 [doi]
PST - ppublish
SO  - Epidemiology. 2013 Jul;24(4):582-9. doi: 10.1097/EDE.0b013e318294ef68.

PMID- 23676243
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1527-974X (Electronic)
IS  - 1067-5027 (Linking)
DP  - 2013 May 15
TI  - Patient-provider communication and trust in relation to use of an online patient 
      portal among diabetes patients: The Diabetes and Aging Study.
AB  - Patient-provider relationships influence diabetes care; less is known about their
      impact on online patient portal use. Diabetes patients rated provider
      communication and trust. In this study, we linked responses to electronic medical
      record data on being a registered portal user and using secure messaging (SM). We
      specified regression models to evaluate main effects on portal use, and subgroup 
      analyses by race/ethnicity and age. 52% of subjects were registered users; among 
      those, 36% used SM. Those reporting greater trust were more likely to be
      registered users (relative risk (RR)=1.14) or SM users (RR=1.29). In subgroup
      analyses, increased trust was associated with being a registered user among
      white, Latino, and older patients, as well as SM use among white patients. Better
      communication ratings were also related to being a registered user among older
      patients. Since increased trust and communication were associated with portal use
      within subgroups, this suggests that patient-provider relationships encourage
      portal engagement.
AD  - Division of General Internal Medicine and Center for Vulnerable Populations,
      University of California, San Francisco, San Francisco, CA, USA.
FAU - Lyles, Courtney R
AU  - Lyles CR
FAU - Sarkar, Urmimala
AU  - Sarkar U
FAU - Ralston, James D
AU  - Ralston JD
FAU - Adler, Nancy
AU  - Adler N
FAU - Schillinger, Dean
AU  - Schillinger D
FAU - Moffet, Howard H
AU  - Moffet HH
FAU - Huang, Elbert S
AU  - Huang ES
FAU - Karter, Andrew J
AU  - Karter AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Am Med Inform Assoc
JT  - Journal of the American Medical Informatics Association : JAMIA
JID - 9430800
OTO - NOTNLM
OT  - age
OT  - diabetes
OT  - patient portals
OT  - patient-provider relationship
OT  - race/ethnicity
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - amiajnl-2012-001567 [pii]
AID - 10.1136/amiajnl-2012-001567 [doi]
PST - aheadofprint
SO  - J Am Med Inform Assoc. 2013 May 15.

PMID- 23676183
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1524-4571 (Electronic)
IS  - 0009-7330 (Linking)
DP  - 2013 May 15
TI  - Effects of HDL Elevation with CETP Inhibition on Insulin Secretion.
AB  - Rationale: High-density lipoprotein (HDL) cholesterol elevation via cholesteryl
      ester transfer protein (CETP) inhibition represents a novel therapy for
      atherosclerosis, which may also have relevance for type 2 diabetes. Objective:
      The current study assessed the effects of a CETP inhibitor (CETPi) on
      postprandial insulin, ex vivo insulin secretion and cholesterol efflux from
      pancreatic beta-cells. Methods and Results: Healthy participants received a daily
      dose of CETPi (n=10) or placebo (n=15) for 14 days in a randomized, double-blind 
      study. Insulin secretion and cholesterol efflux from MIN6N8 beta-cells was
      determined following incubation with treated plasma. CETP inhibition increased
      plasma HDL cholesterol, apoAI and postprandial insulin. MIN6N8 beta-cells
      incubated with plasma from CETPi-treated individuals (vs placebo) exhibited an
      increase in both glucose-stimulated insulin secretion (GSIS) and cholesterol
      efflux over the 14 day treatment period. Conclusions: CETP inhibition increased
      postprandial insulin and promoted ex vivo beta-cell GSIS, potentially via
      enhanced beta-cell cholesterol efflux.
AD  - Metabolic & Vascular Physiology, Baker IDI Heart and Diabetes Institute, 75
      Commercial Rd, Melbourne, N/A, 3004, AUSTRALIA.
FAU - Siebel, Andrew L
AU  - Siebel AL
FAU - Natoli, Alaina K
AU  - Natoli AK
FAU - Yap, Felicia Y
AU  - Yap FY
FAU - Carey, Andrew L
AU  - Carey AL
FAU - Reddy-Luthmoodoo, Medini
AU  - Reddy-Luthmoodoo M
FAU - Sviridov, Dmitri
AU  - Sviridov D
FAU - Weber, Chek Ing Kiu
AU  - Weber CI
FAU - Meneses-Lorente, Georgina
AU  - Meneses-Lorente G
FAU - Maugeais, Cyrille
AU  - Maugeais C
FAU - Forbes, Josephine M
AU  - Forbes JM
FAU - Kingwell, Bronwyn A
AU  - Kingwell BA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Circ Res
JT  - Circulation research
JID - 0047103
OTO - NOTNLM
OT  - cholesterol homeostasis
OT  - high-density lipoprotein cholesterol
OT  - insulin secretion
OT  - oxidized low-density lipoprotein
OT  - type 2 diabetes mellitus
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - CIRCRESAHA.113.300689 [pii]
AID - 10.1161/CIRCRESAHA.113.300689 [doi]
PST - aheadofprint
SO  - Circ Res. 2013 May 15.

PMID- 23676123
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1365-2850 (Electronic)
IS  - 1351-0126 (Linking)
DP  - 2013 May 15
TI  - Provision of health promotion programmes to people with serious mental illness: a
      mapping exercise of four South London boroughs.
LID - 10.1111/jpm.12057 [doi]
AB  - ACCESSIBLE SUMMARY: Background: People with serious mental illness (SMI) are at
      increased risk of developing various physical health diseases, contributing to
      significantly reduced life expectancies compared with the general population. In 
      light of this, the Department of Health have set the physical health of people
      with mental health problems as a priority for improvement. Additionally, the UK
      government encourages the NHS and local authorities to develop health promotion
      programmes (HPPs) for people with SMI. Aims: To document how many and what types 
      of HPPs were available to people with SMI across four South London boroughs, UK. 
      Results: We found 145 HPPs were available to people with SMI across the four
      boroughs, but with an inequitable distribution. We also found that certain HPPs
      set admission criteria that were likely to act as a barrier to improving health. 
      Conclusions: A more integrated approach of documenting and providing information 
      regarding the provision of HPPs for or inclusive of people with SMI is needed.
      ABSTRACT: People with serious mental illness (SMI) such as schizophrenia,
      schizoaffective disorders and bipolar disorder are at increased risk of
      developing diabetes, cardiovascular disease and respiratory disease, contributing
      to significantly reduced life expectancies. As a result, emphasis has been placed
      on developing Health Promotion Programmes (HPPs) to modify the risk of poor
      physical health in SMI. We examined how many and what types of HPPs are available
      for or inclusive of people with SMI across four borough in South London, UK. A
      cross-sectional mapping study was carried out to identify the number of HPPs
      available to people with SMI. We found 145 HPPs available to people with SMI
      existed across the four boroughs but with an inequitable distribution, which in
      some boroughs we anticipate may not meet need. In some cases, HPPs set admission 
      conditions which were likely to further impede access. We recommend that accurate
      and readily available information on the provision of HPPs for or inclusive of
      people with SMI is needed.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Psychosis Studies, King's College London, London.
FAU - O'Brien, C
AU  - O'Brien C
FAU - Gardner-Sood, P
AU  - Gardner-Sood P
FAU - Corlett, S K
AU  - Corlett SK
FAU - Ismail, K
AU  - Ismail K
FAU - Smith, S
AU  - Smith S
FAU - Atakan, Z
AU  - Atakan Z
FAU - Greenwood, K
AU  - Greenwood K
FAU - Joseph, C
AU  - Joseph C
FAU - Gaughran, F
AU  - Gaughran F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Psychiatr Ment Health Nurs
JT  - Journal of psychiatric and mental health nursing
JID - 9439514
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/02/17 [accepted]
AID - 10.1111/jpm.12057 [doi]
PST - aheadofprint
SO  - J Psychiatr Ment Health Nurs. 2013 May 15. doi: 10.1111/jpm.12057.

PMID- 23675990
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1557-7600 (Electronic)
IS  - 1096-620X (Linking)
VI  - 16
IP  - 5
DP  - 2013 May
TI  - Diabetes-ameliorating effects of fermented red ginseng and causal effects on
      hormonal interactions: testing the hypothesis by multiple group path analysis.
PG  - 383-95
LID - 10.1089/jmf.2012.2583 [doi]
AB  - Abstract Although diagnostic criteria for metabolic syndrome (MtS) vary among
      various health professionals and organizations, blood glucose dysregulation and
      insulin resistance are common to all definitions. Red ginseng is beneficial for
      glucose regulation and insulin sensitivity but the mechanism is not yet
      elucidated. Ginsenosides Rh1 and Rg3 act as ligands of the estrogen receptor, and
      Rh2 and compound K act as ligands of the glucocorticoid receptors, which may
      influence the diabetes markers. The objective of this study was to test the
      hypothesis that there are significant causal relationships among diabetes-related
      markers and several hormones, and assess whether or not the consumption of
      fermented red ginseng (FRG) influences these causal relationships by multiple
      group path analysis and conventional statistical analyses. The 93 postmenopausal 
      women were randomly divided into two groups for a double-blind trial. FRG powder 
      and placebo were provided for 2 weeks. The data were analyzed by multiple group
      path analysis and the mean between groups were compared. The model's goodness of 
      fit was excellent, with a root mean square error of approximation of 0.00, and
      comparative fit index of 1.00. The FRG group exhibited significantly increased
      levels of dehydroepiandrosterone sulfate (DHEAS), growth hormone (GH), and
      estradiol (E2), and they exhibited decreased levels of glycosylated hemoglobin
      (HbA1c), insulin, and homeostatic model assessment of insulin resistance. With
      regard to the hypothesis, the blood glucose lowering effects of FRG were due to
      the negative effects of aldosterone and increased GH, which was associated with
      DHEAS and E2. Even though the differences of variables between both groups were
      small, the total effects of these variables may indicate beneficial changes for
      the prevention of diabetes in healthy postmenopausal women.
AD  - 1 Department of Food and Nutrition, Research of Institute of Human Ecology, Seoul
      National University , Seoul, Korea.
FAU - Lee, Kwang Jo
AU  - Lee KJ
FAU - Lee, Sook Yeon
AU  - Lee SY
FAU - Ji, Geun Eog
AU  - Ji GE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med Food
JT  - Journal of medicinal food
JID - 9812512
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.1089/jmf.2012.2583 [doi]
PST - ppublish
SO  - J Med Food. 2013 May;16(5):383-95. doi: 10.1089/jmf.2012.2583.

PMID- 23675839
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Linking)
VI  - 51
IP  - 6
DP  - 2013 Jun
TI  - Therapeutic potential of octyl gallate isolated from fruits of Terminalia
      bellerica in streptozotocin-induced diabetic rats.
PG  - 798-805
LID - 10.3109/13880209.2013.766894 [doi]
AB  - Abstract Context: Medicinal plants are a potential source of antidiabetic drugs. 
      Terminalia bellerica Roxb. (Combretaceae) is used in Indian traditional systems
      of medicine to treat diabetes mellitus. Objective: The aim of this study was to
      isolate and identify antihyperglycemic principle(s) from the fruits of T.
      bellerica and assess the bioactivity in streptozotocin (STZ)-induced diabetic
      rats. Materials and methods: Bioassay-guided fractionation was followed to
      isolate the active compound(s), structure was elucidated using (1)H and (13)C
      NMR, IR and mass spectrometry and administered intragastrically to diabetic
      Wistar rats at different doses (5, 10 and 20 mg/kg, body weight) for 28 d. Plasma
      glucose, insulin, C-peptide and other biochemical parameters were studied.
      Results: Octyl gallate (OG) isolated first time from the fruit rind of T.
      bellerica significantly (p < 0.05) reduced plasma glucose to near normal values
      (108.47 +/- 6.9 mg/dl) after 14 d at the dose of 20 mg/kg. In addition, OG
      significantly increased plasma insulin, C-peptide, total protein, albumin, tissue
      glycogen, body weight and markedly decreased serum total cholesterol,
      triglyceride, LDL-cholesterol, urea, uric acid and creatinine in diabetic rats.
      Also OG restored the altered regulatory enzymes of carbohydrate metabolism.
      Discussion and conclusion: OG might have augmented the secretion of insulin by
      the modulation of cAMP and intracellular calcium levels in the beta cells of the 
      pancreas. Our findings indicate that OG isolated first time from the fruit rind
      of T. bellerica has potential antidiabetic effect as it augments insulin
      secretion and normalizes the altered biochemical parameters in experimental
      diabetic rat models.
AD  - Department of Biotechnology and.
FAU - Latha, R Cecily Rosemary
AU  - Latha RC
FAU - Daisy, P
AU  - Daisy P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.3109/13880209.2013.766894 [doi]
PST - ppublish
SO  - Pharm Biol. 2013 Jun;51(6):798-805. doi: 10.3109/13880209.2013.766894.

PMID- 23675824
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 16
IP  - 6
DP  - 2013
TI  - A study of regional variation in the inpatient cost of lower extremity amputation
      among patients with diabetes in the United States.
PG  - 820-7
LID - 10.3111/13696998.2013.801349 [doi]
AB  - Abstract Objective: Understanding of the effects of providers' cost on regional
      variation in healthcare spending is still very limited. The objective of this
      study is to assess cross-state and cross-region variations in inpatient cost of
      lower extremity amputation among diabetic patients (DLEA) in relation to patient,
      hospital, and state factors. Methods: Patient and hospital level data were
      obtained from the 2007 US Agency for Healthcare Research and Quality Healthcare
      Cost and Utilization Project (HCUP). State level data were obtained from the US
      Census Bureau and the Kaiser Family Foundation websites. Regression models were
      implemented to analyze the association between in-patient cost and variables at
      patient, hospital, and state levels. Results: This study analyzed data on 9066
      DLEA hospitalizations from 39 states. The mean cost per in-patient stay was
      $17,103. Four out of the five most costly states were located on the East and
      West coasts (NY and NJ, CA and OR). Age, race, length of stay, level of
      amputation, in-patient mortality, primary payer, co-morbidities, and type of
      hospital were significantly correlated with in-patient costs and explained 55.3% 
      of the cost variance. Based on the means of costs unexplained by those factors,
      the three West coast states had the highest costs, followed by five Midwestern
      states, and four Southern states, and Kansas were the least costly. Conclusions: 
      Over 40% of the variations in DLEA hospital costs could not be explained by major
      patient-, hospital-, and state-level variables. Further research is needed to
      examine whether similar patterns exist for other costly surgical procedures among
      diabetic patients.
AD  - Philadelphia College of Osteopathic Medicine, Georgia Campus , Suwanee, GA , USA.
FAU - Yin, Hongjun
AU  - Yin H
FAU - Radican, Larry
AU  - Radican L
FAU - Kong, Sheldon X
AU  - Kong SX
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
SB  - IM
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/05/15 [aheadofprint]
AID - 10.3111/13696998.2013.801349 [doi]
PST - ppublish
SO  - J Med Econ. 2013;16(6):820-7. doi: 10.3111/13696998.2013.801349. Epub 2013 May
      15.

PMID- 23675775
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1554-8937 (Electronic)
IS  - 1554-8929 (Linking)
DP  - 2013 May 29
TI  - Identification of Alverine and Benfluorex as HNF4alpha Activators.
AB  - The principal finding of this study is that two drugs, alverine and benfluorex,
      used in vastly different clinical settings, activated the nuclear receptor
      transcription factor HNF4alpha. Both were hits in a high-throughput screen for
      compounds that reversed the inhibitory effect of the fatty acid palmitate on
      human insulin promoter activity. Alverine is used in the treatment of irritable
      bowel syndrome, while benfluorex (Mediator) was used to treat hyperlipidemia and 
      type II diabetes. Benfluorex was withdrawn from the market recently because of
      serious cardiovascular side effects related to fenfluramine-like activity.
      Strikingly, alverine and benfluorex have a previously unrecognized structural
      similarity, consistent with a common mechanism of action. Gene expression and
      biochemical studies revealed that they both activate HNF4alpha. This novel
      mechanism of action should lead to a reinterpretation of previous studies with
      these drugs and suggests a path toward the development of therapies for diseases 
      such as inflammatory bowel and diabetes that may respond to HNF4alpha activators.
AD  - Sanford Children's Health Research Center, Sanford-Burnham Medical Research
      Institute , La Jolla, California, 92037, United States.
FAU - Lee, Seung-Hee
AU  - Lee SH
FAU - Athavankar, Sonalee
AU  - Athavankar S
FAU - Cohen, Tom
AU  - Cohen T
FAU - Piran, Ron
AU  - Piran R
FAU - Kiselyuk, Alice
AU  - Kiselyuk A
FAU - Levine, Fred
AU  - Levine F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - ACS Chem Biol
JT  - ACS chemical biology
JID - 101282906
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.1021/cb4000986 [doi]
PST - aheadofprint
SO  - ACS Chem Biol. 2013 May 29.

PMID- 23675752
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Linking)
DP  - 2013 May 15
TI  - Inpatient dermatology: profile of patients and characteristics of admissions to a
      tertiary dermatology inpatient unit in Sao Paulo, Brazil.
LID - 10.1111/j.1365-4632.2012.05818.x [doi]
AB  - BACKGROUND: Dermatology is primarily an outpatient clinical and surgical
      specialty, but substantial numbers of patients are admitted to hospital for
      inpatient treatment in dermatology wards. METHODS: We performed a retrospective
      study of patients admitted to dermatology beds between September 1, 2002, and
      September 30, 2010. Patient data were analyzed for age, gender, ethnicity, length
      of stay (LoS), dermatologic disease, comorbidities, hospital-acquired infection
      (HAI), transfer to the intensive care unit (ICU), and mortality. RESULTS: A total
      of 3308 patients admitted during this 8-year period were identified for analysis.
      The most frequent admissions were for eczema/dermatitis (17.5%) and cutaneous
      infections (15.9%). The mean LoS was 13.0 days. The mean +/- standard deviation
      (SD) number of comorbidities per patient was 1.0 +/- 1.2, among the most frequent
      of which were hypertension and diabetes mellitus. The rate of HAI was 6.2%;
      bloodstream infection was regarded as the most commonly acquired type and
      Staphylococcus aureus as the infectious agent most commonly found in culture. Of 
      the patients admitted, 3.7% were transferred to the ICU and 2.5% died. In these
      latter two groups, the most common dermatologic diagnoses were immunobullous
      diseases, and the mean hospital LoS and rate of HAI were higher than in the total
      admissions cohort. CONCLUSIONS: Higher value should be placed on dermatology
      inpatient services in order to expand the availability of dermatology beds,
      mainly in tertiary hospitals, in view of the potentially high severity of the
      dermatologic diseases found in many patients referred to this type of service.
CI  - (c) 2013 The International Society of Dermatology.
AD  - Department of Dermatology, Hospital das Clinicas of the University of Sao Paulo
      Medical School, Sao Paulo, SP, Brazil.
FAU - de Paula Samorano-Lima, Luciana
AU  - de Paula Samorano-Lima L
FAU - Quiterio, Ligia M
AU  - Quiterio LM
FAU - Sanches, Jose A Jr
AU  - Sanches JA Jr
FAU - Neto, Cyro Festa
AU  - Neto CF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
AID - 10.1111/j.1365-4632.2012.05818.x [doi]
PST - aheadofprint
SO  - Int J Dermatol. 2013 May 15. doi: 10.1111/j.1365-4632.2012.05818.x.

PMID- 23675742
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 15
TI  - The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010.
LID - 10.1111/dom.12123 [doi]
AB  - AIMS: To characterize the incidence of type 2 diabetes in the UK over the
      previous 20 years; and determine if there has been an increase in people aged 40 
      years or less at diagnosis. METHODS: For this retrospective cohort study,
      patients newly diagnosed with type 2 diabetes between 1991 and 2010 were
      identified from the UK Clinical Practice Research Datalink (CPRD). Patient data
      were grouped into 5-year intervals by year of diagnosis and age at diagnosis. A
      standardized incidence ratio (SIR) was determined (1991-1995 = 100). The
      percentage of newly diagnosed patients for each age group and aged </=40 years
      was calculated for each 5-year calendar period. The incidence rate by age and
      5-year calendar period was also determined. RESULTS: In 2010, the crude incidence
      rate of type 2 diabetes was 515 per 100,000 population. The overall SIR increased
      to 158 (95% CI 157-160, p < 0.001), 237 (235-238, p < 0.001) and 275 (273-276, p 
      < 0.001) for 1996-2000, 2001-2005 and 2006-2010, respectively. For those </=40,
      the respective values were 217 (209-226, p < 0.001), 327 (320-335, p < 0.001) and
      598 (589-608, p < 0.001). An increase in incidence occurred with increasing
      5-year calendar period. The incidence of type 2 diabetes was higher for males
      after the age of 40 and higher for females aged </=40. The percentage of patients
      aged </=40 years at diagnosis increased with each increasing 5-year calendar
      period (5.9, 8.4, 8.5 and 12.4%, respectively). CONCLUSIONS: There was a
      significant increase in the incidence of diagnosed type 2 diabetes between 1991
      and 2010 and the proportion of people diagnosed at a relatively early age has
      increased markedly.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Primary Care and Public Health, School of Medicine, Cardiff
      University, The Pharma Research Centre, Cardiff MediCentre, Cardiff, UK.
FAU - Holden, S H
AU  - Holden SH
FAU - Barnett, A H
AU  - Barnett AH
FAU - Peters, J R
AU  - Peters JR
FAU - Jenkins-Jones, S
AU  - Jenkins-Jones S
FAU - Poole, C D
AU  - Poole CD
FAU - Morgan, C L
AU  - Morgan CL
FAU - Currie, C J
AU  - Currie CJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2012/09/11 [received]
PHST- 2012/10/28 [revised]
PHST- 2013/04/23 [accepted]
AID - 10.1111/dom.12123 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 15. doi: 10.1111/dom.12123.

PMID- 23675676
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 15
TI  - The Influence Of Physical Activity On Vascular Complications And Mortality In
      Patients With Type 2 Diabetes Mellitus.
LID - 10.1111/dom.12122 [doi]
AB  - AIMS: There is limited evidence regarding the association between physical
      activity and vascular complications, particularly microvascular disease, in
      patients with type 2 diabetes. MATERIALS AND METHODS: From the 11,140 patients in
      the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron
      modified release Controlled Evaluation) trial the effect of physical activity,
      categorized as none, mild, moderate or vigorous, and the number of sessions
      within a week, was examined in multivariable regression models adjusted for
      potential confounders. The study end-points were major cardiovascular events,
      microvascular complications and all-cause mortality. RESULTS: Forty-six percent
      of participants reported undertaking moderate to vigorous physical activity for
      >15 minutes at least once in the previous week. During a median of 5 years of
      follow up, 1,031 patients died, 1,147 experienced a major cardiovascular event
      and 1,136 a microvascular event. Compared to patients who undertook no or mild
      physical activity, those reporting moderate to vigorous activity had a decreased 
      risk of cardiovascular events (HR 0.78, 95% CI 0.69-0.88, p < 0.0001),
      microvascular events (HR 0.85, 95% CI 0.76-0.96, p0.010) and all-cause mortality 
      (HR 0.83, 95% CI 0.73-0.94, p0.0044). CONCLUSIONS: Moderate to vigorous, but not 
      mild, physical activity is associated with a reduced incidence of cardiovascular 
      events, microvascular complications and all-cause mortality in patients with type
      2 diabetes.
CI  - This article is protected by copyright. All rights reserved.
AD  - The George Institute for Global Health and University of Sydney, Sydney,
      Australia; University of Turku, Turku, Finland.
FAU - Blomster, Juuso I
AU  - Blomster JI
FAU - Chow, Clara K
AU  - Chow CK
FAU - Zoungas, Sophia
AU  - Zoungas S
FAU - Woodward, Mark
AU  - Woodward M
FAU - Patel, Anushka
AU  - Patel A
FAU - Poulter, Neil R
AU  - Poulter NR
FAU - Marre, Michel
AU  - Marre M
FAU - Harrap, Stephen
AU  - Harrap S
FAU - Chalmers, John
AU  - Chalmers J
FAU - Hillis, Graham S
AU  - Hillis GS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/17 06:00
MHDA- 2013/05/17 06:00
CRDT- 2013/05/17 06:00
PHST- 2013/02/04 [received]
PHST- 2013/04/10 [revised]
PHST- 2013/04/23 [accepted]
AID - 10.1111/dom.12122 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 15. doi: 10.1111/dom.12122.

PMID- 23675659
OWN - NLM
STAT- MEDLINE
DA  - 20130516
DCOM- 20130528
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 368
IP  - 20
DP  - 2013 May 16
TI  - Current and future therapies for hepatitis C virus infection.
PG  - 1907-17
LID - 10.1056/NEJMra1213651 [doi]
AD  - Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney
      Diseases, National Institutes of Health, Bethesda, MD 20892-1800,USA.
      jakel@bldg10.niddk.nih.gov
FAU - Liang, T Jake
AU  - Liang TJ
FAU - Ghany, Marc G
AU  - Ghany MG
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
SB  - AIM
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hepacivirus/*genetics/growth & development
MH  - Hepatitis C/*drug therapy
MH  - Humans
MH  - Interferon-alpha/therapeutic use
MH  - Standard of Care
EDAT- 2013/05/17 06:00
MHDA- 2013/05/29 06:00
CRDT- 2013/05/17 06:00
AID - 10.1056/NEJMra1213651 [doi]
PST - ppublish
SO  - N Engl J Med. 2013 May 16;368(20):1907-17. doi: 10.1056/NEJMra1213651.

PMID- 23675523
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Perinatal bisphenol a exposure and adult glucose homeostasis: identifying
      critical windows of exposure.
PG  - e64143
LID - 10.1371/journal.pone.0064143 [doi]
AB  - Bisphenol A (BPA) is a widespread endocrine-disrupting chemical used as the
      building block for polycarbonate plastics. Epidemiological evidence has
      correlated BPA exposure with higher risk of heart disease and type 2 diabetes.
      However, it remains unknown whether there are critical windows of susceptibility 
      to BPA exposure on the development of dysglycemia. This study was an attempt to
      investigate the critical windows and the long-term consequences of perinatal
      exposure to BPA on glucose homeostasis. Pregnant mice were given either vehicle
      or BPA (100 microg/kg/day) at different time of perinatal stage: 1) on days 1-6
      of pregnancy (P1-P6, preimplantation exposure); 2) from day 6 of pregnancy until 
      postnatal day (PND) 0 (P6-PND0, fetal exposure); 3) from lactation until weaning 
      (PND0-PND21, neonatal exposure); and 4) from day 6 of gestation until weaning
      (P6-PND21, fetal and neonatal exposure). At 3, 6 and 8 months of age, offspring
      in each group were challenged with glucose and insulin tolerance tests. Then
      islet morphometry and beta-cell function were measured. The glucose homeostasis
      was impaired in P6-PND0 mice from 3 to 6 months of age, and this continued to 8
      months in males, but not females. While in PND0-PND21 and P6-PND21 BPA-treated
      groups, only the 3-month-old male offspring developed glucose intolerance.
      Moreover, at the age of 3 months, perinatal exposure to BPA resulted in the
      increase of beta-cell mass mainly due to the coordinate changes in cell
      replication, neogenesis, and apoptosis. The alterations of insulin secretion and 
      insulin sensitivity, rather than beta-cell mass, were consistent with the
      development of glucose intolerance. Our findings suggest that BPA may contribute 
      to metabolic disorders relevant to glucose homeostasis and the effects of BPA
      were dose, sex, and time-dependent. Fetal development stage may be the critical
      window of susceptibility to BPA exposure.
AD  - Department of Toxicology, School of Public Health, Nanjing Medical University,
      Nanjing, China.
FAU - Liu, Jingli
AU  - Liu J
FAU - Yu, Pan
AU  - Yu P
FAU - Qian, Wenyi
AU  - Qian W
FAU - Li, Yan
AU  - Li Y
FAU - Zhao, Jingjing
AU  - Zhao J
FAU - Huan, Fei
AU  - Huan F
FAU - Wang, Jun
AU  - Wang J
FAU - Xiao, Hang
AU  - Xiao H
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3651242
OID - NLM: PMC3651242
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/20 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/05/10 [epublish]
AID - 10.1371/journal.pone.0064143 [doi]
AID - PONE-D-12-40596 [pii]
PST - epublish
SO  - PLoS One. 2013 May 10;8(5):e64143. doi: 10.1371/journal.pone.0064143. Print 2013.

PMID- 23675517
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Interaction of osteopontin with IL-18 in obese individuals: implications for
      insulin resistance.
PG  - e63944
LID - 10.1371/journal.pone.0063944 [doi]
AB  - BACKGROUNDOBJECTIVE: Osteopontin (OPN) and IL-18 are known inflammatory mediators
      and both participate in a wide range of biological processes linked to
      immunological disorders. Since an interaction between OPN and IL-18 has not been 
      studied in obesity, we investigated whether: (i) their levels were simultaneously
      elevated in obese individuals; (ii) OPN was associated with IL-18 in obese
      individuals and (iii) their levels associated with fasting blood glucose (FBG)
      and BMI. SUBJECTS AND METHODS: PBMCs and plasma samples were isolated from 60
      individuals including lean as well as overweight and obese individuals.
      Subcutaneous adipose tissue samples were obtained. OPN and IL-18 were measured by
      ELISA. OPN and IL-18 mRNA expression was quantified by real time quantitative
      RT-PCR. RESULTS: Obese individuals exhibited significantly increased circulating 
      OPN levels as compared with lean individuals (obese 2865+/-101; lean 1681+/-116
      pg/ml; P<0.0001). IL-18 levels were also high in obese individuals (obese
      491+/-39, lean 301+/-26 pg/ml; P = 0.0009). OPN and IL-18 expression were
      simultaneously up-regulated (OPN: 5.4-Fold; IL-18: 8.9-Fold; P<0.05) in PBMCs
      from obese individuals compared to lean group. Adipose tissue from obese
      individuals had high expression of OPN (7.3-Fold) and IL-18 (9.6-Fold). Plasma
      OPN levels correlated positively with FBG levels (r = 0.32, P = 0.02). Similarly,
      IL-18 correlated positively with FBG levels (r = 0.406, P = 0.0042). Stepwise
      multiple regression analysis showed an independent association of BMI with OPN
      and IL-18. Interestingly, OPN levels increased progressively with an increase in 
      IL-18 levels (r = 0.52, P = 0.0004). We also examined the regulatory role of
      IL-18 in OPN secretion from PBMCs. Neutralizing anti-IL-18Ralpha mAb reduced OPN 
      secretion. CONCLUSION: These findings represent the first observation that
      plasma, PBMC and adipose tissue OPN and IL-18 are simultaneously increased and
      correlate with each other in overweight/obese individuals which may trigger the
      development of obesity-associated insulin resistance. Moreover, these results
      provide the direct evidence that IL-18 regulates OPN production in PBMCs.
AD  - Immunology and Innovative Cell Therapy Unit, Dasman Diabetes Institute, Kuwait
      City, Kuwait.
FAU - Ahmad, Rasheed
AU  - Ahmad R
FAU - Al-Mass, Anfal
AU  - Al-Mass A
FAU - Al-Ghawas, Dalal
AU  - Al-Ghawas D
FAU - Shareif, Nada
AU  - Shareif N
FAU - Zghoul, Nadia
AU  - Zghoul N
FAU - Melhem, Motasem
AU  - Melhem M
FAU - Hasan, Amal
AU  - Hasan A
FAU - Al-Ghimlas, Fahad
AU  - Al-Ghimlas F
FAU - Dermime, Said
AU  - Dermime S
FAU - Behbehani, Kazem
AU  - Behbehani K
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3652828
OID - NLM: PMC3652828
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/09/12 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/13 [epublish]
AID - 10.1371/journal.pone.0063944 [doi]
AID - PONE-D-12-27852 [pii]
PST - epublish
SO  - PLoS One. 2013 May 13;8(5):e63944. doi: 10.1371/journal.pone.0063944. Print 2013.

PMID- 23675477
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - The global burden of visual difficulty in low, middle, and high income countries.
PG  - e63315
LID - 10.1371/journal.pone.0063315 [doi]
AB  - PURPOSE: Using a world-wide, population-based dataset of adults, we sought to
      determine the frequency of far visual difficulty and its associated risk factors.
      METHODS: The World Health Survey (WHS) was conducted in 70 countries throughout
      the world in 2003 using a random, multi-stage, stratified, cluster sampling
      design of adults ages 18 years and older. Far vision was assessed by asking "In
      the last 30 days, how much difficulty did you have in seeing and recognizing a
      person you know across the road (i.e. from a distance of about 20 meters)?".
      Responses included none, mild, moderate, severe, or extreme/unable. The income
      status of countries was estimated using gross national income per capita data
      from 2003 from the World Bank. Prevalence and regression estimates were adjusted 
      to account for the complex sample design. RESULTS: 21% of adults reported any
      visual difficulty. The rate varied by the income status of the country with the
      percentage who had any visual difficulty being 24%, 23%, and 13% in low, middle, 
      and high income countries, respectively. Five percent of people reported severe
      or extreme visual difficulty with rates in low, middle, and high income countries
      of 6%, 5%, and 2% respectively. Risk factors for visual difficulty included older
      age, female sex, poorer socioeconomic status, little to no formal education, and 
      diabetes (P<0.05). CONCLUSIONS: One out of five adults in the WHS reported some
      degree of far visual difficulty. Given the importance of vision to living an
      independent life, better access to quality eye care services and life course
      factors affecting vision health (e.g. repeated eye infections, diet lacking
      vitamin A) must receive adequate attention and resources, especially in low and
      middle income countries.
AD  - Department of Ophthalmology, Universite de Montreal, Montreal, Quebec, Canada ;
      Centre de Recherche, Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
FAU - Freeman, Ellen E
AU  - Freeman EE
FAU - Roy-Gagnon, Marie-Helene
AU  - Roy-Gagnon MH
FAU - Samson, Elodie
AU  - Samson E
FAU - Haddad, Slim
AU  - Haddad S
FAU - Aubin, Marie-Josee
AU  - Aubin MJ
FAU - Vela, Claudia
AU  - Vela C
FAU - Zunzunegui, Maria Victoria
AU  - Zunzunegui MV
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3651198
OID - NLM: PMC3651198
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/20 [received]
PHST- 2013/04/01 [accepted]
PHST- 2013/05/10 [epublish]
AID - 10.1371/journal.pone.0063315 [doi]
AID - PONE-D-12-40489 [pii]
PST - epublish
SO  - PLoS One. 2013 May 10;8(5):e63315. doi: 10.1371/journal.pone.0063315. Print 2013.

PMID- 23675460
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Orthostatic hypotension and the risk of congestive heart failure: a meta-analysis
      of prospective cohort studies.
PG  - e63169
LID - 10.1371/journal.pone.0063169 [doi]
AB  - BACKGROUND: Orthostatic hypotension (OH) has been related to the increased risk
      of future congestive heart failure (CHF) events. However, the overall
      quantitative estimate of predictive ability of OH for CHF has not been
      determined. We therefore performed a meta-analysis to investigate the association
      between OH and incident CHF. METHODS: Prospective cohort studies relevant to the 
      aim of the study were identified by searching of Medline and Embase databases up 
      to December 25, 2012 without restrictions and by reviewing the reference lists
      from retrieved articles. RESULTS: A total of 51270 subjects and 3603 incident CHF
      cases from 4 prospective cohorts were included in the meta-analysis. Using random
      effect model, the pooled result indicated that presence of OH at baseline was
      significantly associated with an increased risk for future CHF outcomes (adjusted
      hazard ratio: 1.30, 95% confidence interval 1.09-1.55; p = 0.004). Results of
      stratified analysis suggested that the association between OH and CHF incidence
      seemed to be significant in middle-age subjects, or the individuals with
      hypertension and diabetes at baseline, but did not significant in the elderly
      subjects or those without hypertension or diabetes. CONCLUSIONS: Our
      meta-analysis confirmed that presence of OH is related to a significant increased
      risk for development of CHF in the future. Studies are needed to explore the
      potential mechanisms underlying this association. More importantly, screen for OH
      may be of great clinical significance for the early identification of subjects at
      higher risk for development of CHF.
AD  - First Department of Geriatric Cardiovascular Medicine, Chinese PLA General
      Hospital, Beijing, China.
FAU - Xin, Wei
AU  - Xin W
FAU - Lin, Zhiqin
AU  - Lin Z
FAU - Li, Xiaoying
AU  - Li X
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3652866
OID - NLM: PMC3652866
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/24 [received]
PHST- 2013/03/29 [accepted]
PHST- 2013/05/13 [epublish]
AID - 10.1371/journal.pone.0063169 [doi]
AID - PONE-D-13-04318 [pii]
PST - epublish
SO  - PLoS One. 2013 May 13;8(5):e63169. doi: 10.1371/journal.pone.0063169. Print 2013.

PMID- 23675368
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130515
DCOM- 20130516
LR  - 20130517
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 4
DP  - 2013
TI  - Mechanisms of obesity-induced inflammation and insulin resistance: insights into 
      the emerging role of nutritional strategies.
PG  - 52
LID - 10.3389/fendo.2013.00052 [doi]
AB  - Obesity and associated chronic inflammation initiate a state of insulin
      resistance (IR). The secretion of chemoattractants such as MCP-1 and MIF and of
      cytokines IL-6, TNF-alpha, and IL-1beta, draw immune cells including dendritic
      cells, T cells, and macrophages into adipose tissue (AT). Dysfunctional AT lipid 
      metabolism leads to increased circulating free fatty acids, initiating
      inflammatory signaling cascades in the population of infiltrating cells. A
      feedback loop of pro-inflammatory cytokines exacerbates this pathological state, 
      driving further immune cell infiltration and cytokine secretion and disrupts the 
      insulin signaling cascade. Disruption of normal AT function is causative of
      defects in hepatic and skeletal muscle glucose homeostasis, resulting in systemic
      IR and ultimately the development of type 2 diabetes. Pharmaceutical strategies
      that target the inflammatory milieu may have some potential; however there are a 
      number of safety concerns surrounding such pharmaceutical approaches. Nutritional
      anti-inflammatory interventions could offer a more suitable long-term
      alternative; whilst they may be less potent than some pharmaceutical
      anti-inflammatory agents, this may be advantageous for long-term therapy. This
      review will investigate obese AT biology, initiation of the inflammatory, and
      insulin resistant environment; and the mechanisms through which dietary
      anti-inflammatory components/functional nutrients may be beneficial.
AD  - Nutrigenomics Research Group, UCD Conway Institute, School of Public Health,
      Physiotherapy and Population Science, University College Dublin Dublin, Republic 
      of Ireland.
FAU - McArdle, Maeve A
AU  - McArdle MA
FAU - Finucane, Orla M
AU  - Finucane OM
FAU - Connaughton, Ruth M
AU  - Connaughton RM
FAU - McMorrow, Aoibheann M
AU  - McMorrow AM
FAU - Roche, Helen M
AU  - Roche HM
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC3650620
OID - NLM: PMC3650620
OTO - NOTNLM
OT  - PUFA
OT  - immune cell infiltration
OT  - inflammation
OT  - insulin resistance
OT  - nutrient sensing
OT  - obesity
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:01
CRDT- 2013/05/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/10 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/10 [epublish]
AID - 10.3389/fendo.2013.00052 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2013 May 10;4:52. doi: 10.3389/fendo.2013.00052.
      Print 2013.

PMID- 23675313
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130515
DCOM- 20130516
LR  - 20130517
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 7
DP  - 2013
TI  - Revisiting the Ventral Medial Nucleus of the Hypothalamus: The Roles of SF-1
      Neurons in Energy Homeostasis.
PG  - 71
LID - 10.3389/fnins.2013.00071 [doi]
AB  - Obesity, diabetes, and other metabolic complications are growing concerns for
      public health and could lead to detrimental life-threatening conditions. Neurons 
      whose activities are required for energy and glucose homeostasis are found in a
      number of hypothalamic nuclei. In the early twentieth century, the ventral medial
      nucleus of the hypothalamus (VMH) was the first site reported to play a prominent
      role in the regulation of energy homeostasis through control of food intake and
      energy expenditure. Recent studies using sophisticated genetic tools have further
      highlighted the importance of the VMH and have extended our understanding of the 
      physiological role of the nucleus in regulation of energy homeostasis. These
      genetic studies were preceded by the identification of steroidogenic factor-1
      (SF-1) as a marker of the VMH. This review focuses on the emerging homeostatic
      roles of the SF-1 neurons in the VMH discovered through the use of genetic
      models, particularly highlighting the control of energy, and glucose homeostasis.
AD  - Division of Hypothalamic Research, Department of Internal Medicine, University of
      Texas Southwestern Medical Center Dallas, TX, USA ; Department of Pharmacology,
      University of Texas Southwestern Medical Center Dallas, TX, USA.
FAU - Choi, Yun-Hee
AU  - Choi YH
FAU - Fujikawa, Teppei
AU  - Fujikawa T
FAU - Lee, Jiwon
AU  - Lee J
FAU - Reuter, Anne
AU  - Reuter A
FAU - Kim, Ki Woo
AU  - Kim KW
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC3646253
OID - NLM: PMC3646253
OTO - NOTNLM
OT  - arcuate nucleus of the hypothalamus
OT  - energy homeostasis
OT  - glucose homeostasis
OT  - knockout
OT  - obesity
OT  - steroidogenic factor-1
OT  - ventral medial hypothalamic nucleus
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:01
CRDT- 2013/05/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/24 [received]
PHST- 2013/04/18 [accepted]
PHST- 2013/05/07 [epublish]
AID - 10.3389/fnins.2013.00071 [doi]
PST - epublish
SO  - Front Neurosci. 2013 May 7;7:71. doi: 10.3389/fnins.2013.00071. Print 2013.

PMID- 23674886
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130515
DCOM- 20130516
LR  - 20130517
IS  - 1177-5467 (Print)
IS  - 1177-5467 (Linking)
VI  - 7
DP  - 2013
TI  - Rapid anterior capsular contraction after phacoemulsification surgery in a
      patient with retinitis pigmentosa.
PG  - 839-42
LID - 10.2147/OPTH.S42122 [doi]
AB  - A decrease in the anterior capsule opening after cataract surgery has been
      observed in eyes with weakened lens zonules. It commonly occurs in diabetes
      mellitus, uveitis, pseudoexfoliation syndrome, high myopia, and elderly patients.
      Herein, we report the case of a middle-aged man with advanced retinitis
      pigmentosa who developed a rapid contraction of the anterior capsule after an
      uneventful phacoemulsification surgery that resulted in severe visual loss during
      the early postoperative period.
AD  - Department of Ophthalmology, School of Medical Sciences, Universiti Sains
      Malaysia, Kubang Kerian, Malaysia.
FAU - Jin-Poi, Tan
AU  - Jin-Poi T
FAU - Shatriah, Ismail
AU  - Shatriah I
FAU - Khairy-Shamel, Sonny Teo
AU  - Khairy-Shamel ST
FAU - Zunaina, Embong
AU  - Zunaina E
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC3652515
OID - NLM: PMC3652515
OTO - NOTNLM
OT  - contraction of anterior capsule
OT  - early postoperative period
OT  - phacoemulsification surgery
OT  - retinitis pigmentosa
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:01
CRDT- 2013/05/16 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/06 [epublish]
AID - 10.2147/OPTH.S42122 [doi]
AID - opth-7-839 [pii]
PST - ppublish
SO  - Clin Ophthalmol. 2013;7:839-42. doi: 10.2147/OPTH.S42122. Epub 2013 May 6.

PMID- 23674856
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 16
DP  - 2013 Apr 28
TI  - ABO blood type, long-standing diabetes, and the risk of pancreatic cancer.
PG  - 2537-42
LID - 10.3748/wjg.v19.i16.2537 [doi]
AB  - AIM: To retrospectively study pancreatic cancer patients with respect to their
      ABO blood type and diabetes. METHODS: Our analysis included a cohort of 1017
      patients with pancreatic ductal cancer diagnosed at our hospital in Tokyo. They
      were divided into two groups: 114 patients with long-standing type 2 diabetes (DM
      group, defined as diabetes lasting for at least three years before the diagnosis 
      of pancreatic cancer) and 903 patients without diabetes (non-DM group).
      Multivariate analysis was performed to identify factors that are associated with 
      long-standing diabetes. The DM group was further divided into three subgroups
      according to the duration of diabetes (3-5 years, 5.1-14.9 years, and 15 years or
      more) and univariate analyses were performed. RESULTS: Of the 883 pancreatic
      cancer patients with serologically assessed ABO blood type, 217 (24.6%) had blood
      type O. Compared with the non-DM group, the DM group had a higher frequency of
      blood type B [odds ratio (OR) = 2.61, 95%CI: 1.24-5.47; reference group: blood
      type A]. Moreover, male (OR = 3.17, 95%CI: 1.67-6.06), older than 70 years of age
      (OR = 2.19, 95%CI: 1.20-3.98) and presence of a family history of diabetes (OR = 
      6.21, 95%CI: 3.38-11.36) were associated with long-standing type 2 diabetes. The 
      mean ages were 64.8 +/- 9.2 years, 67.1 +/- 9.8 years, and 71.7 +/- 7.0 years in 
      the subgroups with the duration of diabetes, 3-5 years, 5.1-14.9 years, and 15
      years or more, respectively (P = 0.007). A comparison of ABO blood type
      distribution among the subgroups also showed a significant difference (P = 0.03).
      CONCLUSION: The association of pancreatic cancer with blood type and duration of 
      diabetes needs to be further examined in prospective studies.
AD  - Naoto Egawa, Taku Tabata, Sawako Kuruma, Seiichi Hara, Ken Kubota, Terumi
      Kamisawa, Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, 
      Tokyo 113-8677, Japan.
FAU - Egawa, Naoto
AU  - Egawa N
FAU - Lin, Yingsong
AU  - Lin Y
FAU - Tabata, Taku
AU  - Tabata T
FAU - Kuruma, Sawako
AU  - Kuruma S
FAU - Hara, Seiichi
AU  - Hara S
FAU - Kubota, Ken
AU  - Kubota K
FAU - Kamisawa, Terumi
AU  - Kamisawa T
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Gastroenterol
JT  - World journal of gastroenterology : WJG
JID - 100883448
SB  - IM
PMC - PMC3646145
OID - NLM: PMC3646145
OTO - NOTNLM
OT  - ABO blood type
OT  - Diabetes mellitus
OT  - Pancreatic cancer
OT  - Risk factor
OT  - Screening
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/12/04 [received]
PHST- 2013/01/16 [revised]
PHST- 2013/01/23 [accepted]
AID - 10.3748/wjg.v19.i16.2537 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 Apr 28;19(16):2537-42. doi: 10.3748/wjg.v19.i16.2537.

PMID- 23674807
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 2156-5376 (Electronic)
IS  - 2161-8313 (Linking)
VI  - 4
IP  - 3
DP  - 2013
TI  - Magnesium in disease prevention and overall health.
PG  - 378S-83S
LID - 10.3945/an.112.003483 [doi]
AB  - Magnesium is the fourth most abundant mineral and the second most abundant
      intracellular divalent cation and has been recognized as a cofactor for >300
      metabolic reactions in the body. Some of the processes in which magnesium is a
      cofactor include, but are not limited to, protein synthesis, cellular energy
      production and storage, reproduction, DNA and RNA synthesis, and stabilizing
      mitochondrial membranes. Magnesium also plays a critical role in nerve
      transmission, cardiac excitability, neuromuscular conduction, muscular
      contraction, vasomotor tone, blood pressure, and glucose and insulin metabolism. 
      Because of magnesium's many functions within the body, it plays a major role in
      disease prevention and overall health. Low levels of magnesium have been
      associated with a number of chronic diseases including migraine headaches,
      Alzheimer's disease, cerebrovascular accident (stroke), hypertension,
      cardiovascular disease, and type 2 diabetes mellitus. Good food sources of
      magnesium include unrefined (whole) grains, spinach, nuts, legumes, and white
      potatoes (tubers). This review presents recent research in the areas of magnesium
      and chronic disease, with the goal of emphasizing magnesium's role in disease
      prevention and overall health.
AD  - Department of Nutrition Sciences, Center for Integrated Nutrition & Performance
      College of Nursing and Health Professions Drexel University, Philadelphia, PA.
FAU - Volpe, Stella Lucia
AU  - Volpe SL
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - Adv Nutr
JT  - Advances in nutrition (Bethesda, Md.)
JID - 101540874
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 4/3/378S [pii]
AID - 10.3945/an.112.003483 [doi]
PST - epublish
SO  - Adv Nutr. 2013 May 1;4(3):378S-83S. doi: 10.3945/an.112.003483.

PMID- 23674796
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 2156-5376 (Electronic)
IS  - 2161-8313 (Linking)
VI  - 4
IP  - 3
DP  - 2013
TI  - A novel approach localizes the association of vitamin d status with insulin
      resistance to one region of the 25-hydroxyvitamin d continuum.
PG  - 303-10
LID - 10.3945/an.113.003731 [doi]
AB  - Vitamin D status has been implicated in insulin resistance, type 2 diabetes
      mellitus, and hypertension, but the range of vitamin D status values over which
      the association can be found is unknown. Our objective was to define this range
      in a cohort of nondiabetic adult Canadians. We used a regression modeling
      strategy, first adjusting insulin-response variables and systolic and diastolic
      blood pressure for BMI, waist circumference, weight, age, and sex. The resulting 
      residuals were regressed against serum 25-hydroxyvitamin D [25(OH)D]
      concentration using successive 40% data blocks ranging from the 0th to the 60th
      percentile of 25(OH)D values. All of the predictor variables were significantly
      associated with each of the dependent variables, with BMI and waist circumference
      accounting for >98% of the explained variance. The vitamin D association was
      localized to the serum 25(OH)D range extending from approximately 40 to
      approximately 90 nmol/L (16-36 mug/L). We conclude that vitamin D status is
      inversely associated with insulin responsiveness and blood pressure. Consistent
      with the threshold response characteristic typical of nutrients, the association 
      was strongest in a circumscribed region of the range of 25(OH)D values. There was
      no association at 25(OH)D values >80-90 nmol/L (32-36 mug/L), indicating that the
      vitamin D association applied principally to values below that level. The
      differences observed, if they can be further confirmed in prospective studies,
      are of a magnitude that would be clinically important.
AD  - Creighton University, Omaha, NE.
FAU - Heaney, Robert P
AU  - Heaney RP
FAU - French, Christine B
AU  - French CB
FAU - Nguyen, Stacie
AU  - Nguyen S
FAU - Ferreira, Mia
AU  - Ferreira M
FAU - Baggerly, Leo L
AU  - Baggerly LL
FAU - Brunel, Ludovic
AU  - Brunel L
FAU - Veugelers, Paul
AU  - Veugelers P
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - Adv Nutr
JT  - Advances in nutrition (Bethesda, Md.)
JID - 101540874
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 4/3/303 [pii]
AID - 10.3945/an.113.003731 [doi]
PST - epublish
SO  - Adv Nutr. 2013 May 1;4(3):303-10. doi: 10.3945/an.113.003731.

PMID- 23674788
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1527-1315 (Electronic)
IS  - 0033-8419 (Linking)
DP  - 2013 May 14
TI  - Ischemic Stroke: Measurement of Intracranial Artery Calcifications Can Improve
      Prediction of Asymptomatic Coronary Artery Disease.
AB  - Purpose:To examine the associations between intracranial artery calcifications
      (IACs) and coronary artery calcifications (CACs) in patients with ischemic stroke
      and to assess the predictive value of IAC for asymptomatic coronary artery
      disease (CAD).Materials and Methods:This retrospective study, approved by an
      institutional review board that waived the need for informed consent, included
      314 consecutive patients who had acute ischemic stroke and who underwent both
      brain and coronary computed tomography (CT) within 1 month of stroke. IAC was
      quantified semiautomatically by calculating both Agatston scores (area of
      calcification multiplied by a weighted value assigned to its highest Hounsfield
      unit) and volumes on thin-section unenhanced images and was correlated with
      coronary calcium scores and volumes. Quartiles were created for IAC scores and
      were used for logistic regression analysis. An optimal IAC score cutoff value was
      determined and used to predict the presence of asymptomatic CAD. Independent
      factors for asymptomatic CAD were assessed by using multiple logistic regression 
      analysis. Receiver operating characteristic curve analysis was performed to
      evaluate the added value of IAC scores for prediction of asymptomatic
      CAD.Results:IAC and CAC were significantly correlated for both Agatston scores
      and volumes (R = 0.665 and 0.663, respectively; P < .001). A graded association
      was found between IAC scores and presence of asymptomatic CAD. Both IAC scores of
      120.11 or greater (odds ratio [OR], 2.57; 95% confidence interval [CI]: 1.45,
      4.55) and diabetes mellitus (OR, 4.23; 95% CI: 2.42, 7.4) were independent
      predictors for asymptomatic CAD. Adding the IAC score to analytic models
      significantly improved the ability to predict asymptomatic CAD.Conclusion:The IAC
      scores quantified by using unenhanced CT correlate significantly with coronary
      calcium scores and may serve as an independent predictor of asymptomatic CAD in
      patients with ischemic stroke.(c) RSNA, 2013.
AD  - Department of Radiology, Research Institute of Radiological Science, Department
      of Neurology, and Biostatistics Collaboration Unit, Medical Research Center,
      Yonsei University College of Medicine, Seoul, Korea; Department of Radiology,
      University Hospital, 234 Goodman St, Cincinnati, OH 45219.
FAU - Ahn, Sung Soo
AU  - Ahn SS
FAU - Nam, Hyo Suk
AU  - Nam HS
FAU - Heo, Ji Hoe
AU  - Heo JH
FAU - Kim, Young Dae
AU  - Kim YD
FAU - Lee, Seung-Koo
AU  - Lee SK
FAU - Han, Kyung Hwa
AU  - Han KH
FAU - Choi, Byoung Wook
AU  - Choi BW
FAU - Kim, Eung Yeop
AU  - Kim EY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Radiology
JT  - Radiology
JID - 0401260
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - radiol.13122417 [pii]
AID - 10.1148/radiol.13122417 [doi]
PST - aheadofprint
SO  - Radiology. 2013 May 14.

PMID- 23674606
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 14
TI  - Exercise Prevents Fructose-Induced Hypertriglyceridemia in Healthy Young
      Subjects.
AB  - Excess fructose intake causes hypertriglyceridemia and hepatic insulin resistance
      in sedentary humans. Since exercise improves insulin sensitivity in
      insulin-resistant patients, we hypothesized that it would also prevent
      fructose-induced hypertriglyceridemia. This study was therefore designed to
      evaluate the effects of exercise on circulating lipids in healthy subjects fed a 
      weight-maintenance, high-fructose diet. Eight healthy males were studied on three
      occasions after 4 days of 1) a diet low in fructose and no exercise (C), 2) a
      diet with 30% fructose and no exercise (HFr), or 3) a diet with 30% fructose and 
      moderate aerobic exercise (HFrEx). On all three occasions, a 9-h oral
      [13C]-labeled fructose loading test was performed on the fifth day to measure
      [13C]palmitate in triglyceride-rich lipoprotein (TRL)-triglycerides (TG).
      Compared with C, HFr significantly increased fasting glucose, total TG, TRL-TG
      concentrations, and apolipoprotein (apo)B48 concentrations as well as
      postfructose glucose, total TG, TRL-TG, and [13C]palmitate in TRL-TG. HFrEx
      completely normalized fasting and postfructose TG, TRL-TG, and [13C]palmitate
      concentration in TRL-TG and apoB48 concentrations. In addition, it increased
      lipid oxidation and plasma nonesterified fatty acid concentrations compared with 
      HFr. These data indicate that exercise prevents the dyslipidemia induced by high 
      fructose intake independently of energy balance.
AD  - Department of Physiology, University of Lausanne, Lausanne, Switzerland.
FAU - Egli, Leonie
AU  - Egli L
FAU - Lecoultre, Virgile
AU  - Lecoultre V
FAU - Theytaz, Fanny
AU  - Theytaz F
FAU - Campos, Vanessa
AU  - Campos V
FAU - Hodson, Leanne
AU  - Hodson L
FAU - Schneiter, Philippe
AU  - Schneiter P
FAU - Mittendorfer, Bettina
AU  - Mittendorfer B
FAU - Patterson, Bruce W
AU  - Patterson BW
FAU - Fielding, Barbara A
AU  - Fielding BA
FAU - Gerber, Philipp A
AU  - Gerber PA
FAU - Giusti, Vittorio
AU  - Giusti V
FAU - Berneis, Kaspar
AU  - Berneis K
FAU - Tappy, Luc
AU  - Tappy L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - db12-1651 [pii]
AID - 10.2337/db12-1651 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 14.

PMID- 23674605
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 14
TI  - The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin 
      pathway.
AB  - The incretin hormone glucagon-like-peptide 1 (GLP-1) promotes glucose homeostasis
      and enhances beta-cell function. GLP-1 receptor agonists (GLP-1 RA) and
      dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological
      inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. 
      Using the Metabochip we identified three novel genetic loci with large effects
      (30-40%) on GLP-1 stimulated insulin secretion during hyperglycemic clamps in
      non-diabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n=232, all
      p</=8.8*10-7). rs7202877 near CTRB1/2, a known diabetes risk locus, also
      associated with an absolute 0.51+/-0.16% (5.6+/-1.7 mmol/mol) lower A1C response 
      to DPP-4 inhibitor treatment in G allele carriers but there was no effect on
      GLP-1 RA treatment in type 2 diabetes patients (n=527). Furthermore, in
      pancreatic tissue we show that rs7202877 acts as expression quantitative trait
      locus for CTRB1 and CTRB2, encoding chymotrypsinogen, and increases fecal
      chymotrypsin activity in healthy carriers. Chymotrypsin is one of the most
      abundant digestive enzymes in the gut where it cleaves food proteins into smaller
      peptide fragments.Our data identify chymotrypsin in the regulation of the
      incretin pathway, development of diabetes and response to DPP-4 inhibitor
      treatment.
AD  - Department of Molecular Cell Biology, Leiden University Medical Center, Leiden,
      The Netherlands.
FAU - 't Hart, Leen M
AU  - 't Hart LM
FAU - Fritsche, Andreas
AU  - Fritsche A
FAU - Nijpels, Giel
AU  - Nijpels G
FAU - van Leeuwen, Nienke
AU  - van Leeuwen N
FAU - Donnelly, Louise A
AU  - Donnelly LA
FAU - Dekker, Jacqueline M
AU  - Dekker JM
FAU - Alssema, Marjan
AU  - Alssema M
FAU - Fadista, Joao
AU  - Fadista J
FAU - Carlotti, Francoise
AU  - Carlotti F
FAU - Gjesing, Anette P
AU  - Gjesing AP
FAU - Palmer, Colin N A
AU  - Palmer CN
FAU - van Haeften, Timon W
AU  - van Haeften TW
FAU - Herzberg-Schafer, Silke A
AU  - Herzberg-Schafer SA
FAU - Simonis-Bik, Annemarie M C
AU  - Simonis-Bik AM
FAU - Houwing-Duistermaat, Jeanine J
AU  - Houwing-Duistermaat JJ
FAU - Helmer, Quinta
AU  - Helmer Q
FAU - Deelen, Joris
AU  - Deelen J
FAU - Guigas, Bruno
AU  - Guigas B
FAU - Hansen, Torben
AU  - Hansen T
FAU - Machicao, Fausto
AU  - Machicao F
FAU - Willemsen, Gonneke
AU  - Willemsen G
FAU - Heine, Robert J
AU  - Heine RJ
FAU - Kramer, Mark H H
AU  - Kramer MH
FAU - Holst, Jens J
AU  - Holst JJ
FAU - de Koning, Eelco J P
AU  - de Koning EJ
FAU - Haring, Hans-Ulrich
AU  - Haring HU
FAU - Pedersen, Oluf
AU  - Pedersen O
FAU - Groop, Leif
AU  - Groop L
FAU - de Geus, Eco J C
AU  - de Geus EJ
FAU - Slagboom, P Eline
AU  - Slagboom PE
FAU - Boomsma, Dorret I
AU  - Boomsma DI
FAU - Eekhoff, Elisabeth M W
AU  - Eekhoff EM
FAU - Pearson, Ewan R
AU  - Pearson ER
FAU - Diamant, Michaela
AU  - Diamant M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - db13-0227 [pii]
AID - 10.2337/db13-0227 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 14.

PMID- 23674518
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1952-4005 (Electronic)
IS  - 1148-5493 (Linking)
VI  - 24
IP  - 1
DP  - 2013 Mar 1
TI  - The lost correlation between leptin and CRP in type 2 diabetes.
PG  - 53-9
LID - 10.1684/ecn.2013.0329 [doi]
AB  - C reactive protein (CRP) is an inflammatory marker believed to be of value in the
      early prediction of type 2 diabetes (T2DM). Recent studies have shown a positive 
      correlation between leptin and CRP levels. Here, we aimed to study the
      correlation between leptin and CRP in patients with T2DM. We also studied the
      effect of metformin therapy on the CRP-leptin correlation in patients with newly 
      diagnosed diabetes. We performed a follow-up study on three groups of
      participants defined as 1: patients with newly diagnosed T2DM, 2: patients with
      long-standing T2DM, and 3: healthy controls. Patients with newly diagnosed
      diabetes were followed for three months after the initiation of metformin
      therapy. The homeostatic model assessment of insulin resistance (HOMA-IR)
      decreased, while leptin levels (15.9 +/- 1.6 versus 21.4 +/- 2.5, p<0.01)
      increased after metformin therapy. Leptin levels correlated significantly with
      CRP in healthy controls (r = 0.48; p<0.01); patients with newly diagnosed
      diabetes before (r = 0.35; p<0.05), and after (r = 0.55, p<0.001) metformin
      therapy, while there was no significant correlation between leptin and CRP in
      patients with long-standing diabetes (r = 0.15; p = 0.55). After multiple
      adjustments for potential confounders, leptin was the best predictor of CRP in
      controls (beta coefficient = 0.433, p<0.01), and patients with newly diagnosed
      T2DM who received metformin (beta coefficient = 0.584, p<0.01). Statin treatment 
      did not have any significant effect on the results. This is the first report
      demonstrating the restorative role of metformin on the leptin-CRP correlation in 
      patients with newly diagnosed diabetes.
AD  - Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran
      University of Medical Sciences, Tehran, Iran.
FAU - Morteza, Afsaneh
AU  - Morteza A
FAU - Nakhjavani, Manouchehr
AU  - Nakhjavani M
FAU - Asgarani, Firuzeh
AU  - Asgarani F
FAU - Ghaneei, Azam
AU  - Ghaneei A
FAU - Esteghamati, Alireza
AU  - Esteghamati A
FAU - Mirmiranpour, Hossein
AU  - Mirmiranpour H
LA  - eng
PT  - Journal Article
PL  - France
TA  - Eur Cytokine Netw
JT  - European cytokine network
JID - 9100879
SB  - IM
OTO - NOTNLM
OT  - C reactive protein (CRP)
OT  - inflammation
OT  - leptin
OT  - type 2 diabetes
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - ecn.2013.0329 [pii]
AID - 10.1684/ecn.2013.0329 [doi]
PST - ppublish
SO  - Eur Cytokine Netw. 2013 Mar 1;24(1):53-9. doi: 10.1684/ecn.2013.0329.

PMID- 23674506
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1552-9924 (Electronic)
IS  - 0091-6765 (Linking)
DP  - 2013 May 14
TI  - Diabetes, Metabolic Syndrome, and Obesity in Relation to Serum Dioxin
      Concentrations: The Seveso Women's Health Study.
AB  - Background: In animal studies, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) alters 
      glucose transport and increases lipids and blood pressure. Epidemiologic evidence
      suggests an association between TCDD and metabolic disease. Objectives: On July
      10, 1976, a chemical explosion in Seveso, Italy, resulted in the highest known
      residential exposure to TCDD. Using data from the Seveso Women's Health Study
      (SWHS), a cohort study of the health of the women, we examined the relation of
      serum TCDD to diabetes, metabolic syndrome, and obesity over 30 years later.
      Methods: In 1996, we enrolled 981 women who were newborn to 40 years in 1976 and 
      resided in the most contaminated areas. Individual TCDD concentration was
      measured in archived serum collected soon after the explosion. In 2008, 833 women
      participated in a follow-up study. Diabetes was classified based on self-report
      or fasting serum glucose and glycated hemoglobin levels. Metabolic syndrome was
      defined by International Diabetes Federation criteria. Obesity was defined as
      body mass index >/=30 kg/m2. Results: A 10-fold increase in serum TCDD
      (log10TCDD) was not associated with diabetes (adjusted hazard ratio = 0.76; 95%
      confidence interval (CI): 0.45, 1.28) or obesity (adjusted odds ratio = 0.80; 95%
      CI: 0.58, 1.10). Log10TCDD was associated with metabolic syndrome, but only among
      women who were </= 12 years at explosion (adjusted odds ratio = 2.03; 95% CI:
      1.25, 3.29; p-interaction = 0.01). Conclusions: We found an increase in metabolic
      syndrome associated with TCDD, but only among women who were youngest at
      exposure. Continued follow-up of the SWHS cohort will be informative.
AD  - Center for Environmental Research and Children's Health (CERCH), School of Public
      Health, University of California at Berkeley, Berkeley, California, USA.
FAU - Warner, Marcella
AU  - Warner M
FAU - Mocarelli, Paolo
AU  - Mocarelli P
FAU - Brambilla, Paolo
AU  - Brambilla P
FAU - Wesselink, Amelia
AU  - Wesselink A
FAU - Samuels, Steven
AU  - Samuels S
FAU - Signorini, Stefano
AU  - Signorini S
FAU - Eskenazi, Brenda
AU  - Eskenazi B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Environ Health Perspect
JT  - Environmental health perspectives
JID - 0330411
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/10/08 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/05/13 [accepted]
AID - 10.1289/ehp.1206113 [doi]
PST - aheadofprint
SO  - Environ Health Perspect. 2013 May 14.

PMID- 23674484
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 14
TI  - Methods, quality control and specimen management in an international multi-center
      investigation of type 1 diabetes: TEDDY.
LID - 10.1002/dmrr.2427 [doi]
AB  - The Environmental Determinants of Diabetes in the Young (TEDDY) is a
      multi-center, international prospective study (n = 8,677) designed to identify
      environmental triggers of type 1 diabetes (T1D) in genetically at-risk children
      from age 3 months until 15 years. The study is conducted through six primary
      clinical centers located in four countries. As of May 2012, over three million
      biological samples and 250 million total data points have been collected which
      will be analyzed to assess autoimmunity status, presence of inflammatory
      biomarkers, genetic factors, exposure to infectious agents, dietary biomarkers,
      and other potentially important environmental exposures in relation to
      autoimmunity and progression to T1D. The vast array and quantity of longitudinal 
      samples collected in the TEDDY study present a series of challenges in terms of
      quality control procedures and data validity. To address this, pilot studies have
      been conducted to standardize and enhance both biospecimen collection and sample 
      obtainment in terms of autoantibody collection, stool sample preservation, RNA,
      biomarker stability, metabolic biomarkers, and T-cell viability. This paper
      details the procedures utilized to standardize both data harmonization and
      management when handling a large quantity of longitudinal samples obtained from
      multiple locations. In addition, we provide a description of the available
      specimens that serve as an invaluable repository for the elucidation of
      determinants in T1D focusing on autoantibody concordance and harmonization,
      transglutaminase autoantibody (tGA), inflammatory biomarkers (T-cells), genetic
      proficiency testing, RNA lab internal quality control testing, infectious agents 
      (monitoring cross contamination, virus preservation, and nasal swab collection
      validity), and HbA1c testing. This article is protected by copyright. All rights 
      reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Pediatrics Epidemiology Center, Morsani College of Medicine, University of South 
      Florida, Tampa, Florida.
FAU - Vehik, Kendra
AU  - Vehik K
FAU - Fiske, Steven W
AU  - Fiske SW
FAU - Logan, Chad A
AU  - Logan CA
FAU - Agardh, Daniel
AU  - Agardh D
FAU - Cilio, Corrado M
AU  - Cilio CM
FAU - Hagopian, William
AU  - Hagopian W
FAU - Simell, Olli
AU  - Simell O
FAU - Roivainen, Merja
AU  - Roivainen M
FAU - She, Jin-Xiong
AU  - She JX
FAU - Briese, Thomas
AU  - Briese T
FAU - Oikarinen, Sami
AU  - Oikarinen S
FAU - Hyoty, Heikki
AU  - Hyoty H
FAU - Ziegler, Anette-G
AU  - Ziegler AG
FAU - Rewers, Marian
AU  - Rewers M
FAU - Lernmark, Ake
AU  - Lernmark A
FAU - Akolkar, Beena
AU  - Akolkar B
FAU - Krischer, Jeffrey P
AU  - Krischer JP
FAU - Burkhardt, Brant R
AU  - Burkhardt BR
CN  - the TEDDY Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/09/17 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1002/dmrr.2427 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 14. doi: 10.1002/dmrr.2427.

PMID- 23674445
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130515
DCOM- 20130516
LR  - 20130522
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 5
DP  - 2013
TI  - The relationship between osteoarthritis and cardiovascular disease in a
      population health survey: a cross-sectional study.
LID - 10.1136/bmjopen-2013-002624 [doi]
LID - e002624 [pii]
AB  - OBJECTIVES: Our objective was to determine the relationship between
      osteoarthritis (OA) and heart diseases (myocardial infarction (MI), angina,
      congestive heart failure (CHF)) and stroke using population-based survey data.
      DESIGN: Cross-sectional study. SETTING: Canadian Community Health Survey (CCHS). 
      PARTICIPANTS: Adult participants in the CCHS cycles 1.1, 2.1 and 3.1 were
      included. CCHS provides nationally representative data on health determinants,
      health status and health system utilisation. We have identified 40 817
      self-reported OA subjects and selected 1:1 matched non-OA respondents by age, sex
      and CCHS cycles. MAIN OUTCOME MEASURES: Self-reported heart disease was the
      primary outcome and MI, angina, CHF and stroke were considered as secondary
      outcomes. Multivariable logistic regression models were used to estimate the ORs 
      after adjusting for sociodemographic status, obesity, physical activity, smoking 
      status, fruit and vegetable consumption, medication use, diabetes, hypertension
      and chronic obstructive pulmonary disease. RESULTS: The mean age of OA cases was 
      66 years and 71.6% were women. OA exhibited increased odds of prevalent heart
      disease, and adjusted overall OR (95% CI) was 1.45 (1.36 to 1.54), 1.35 (1.21 to 
      1.50) among men and 1.51 (1.39 to 1.64) among women with OA. OA showed increased 
      ORs for angina and CHF in both men and women, and for MI in women. ORs (95% CI)
      for men and women, respectively, were 1.08 (0.91 to 1.28) and 1.49 (1.28 to 1.75)
      for MI, 1.76 (1.43 to 2.17) and 1.84 (1.59 to 2.14) for angina, 1.50 (1.13 to
      1.97) and 1.81 (1.49 to 2.21) for CHF, and 1.08 (0.83 to 1.40) and 1.13 (0.93 to 
      1.37) for stroke. CONCLUSIONS: Prevalent OA was associated with self-reported
      heart disease, particularly angina, and CHF in both men and women, after
      controlling for established risk factors for these conditions. This study
      provides a rationale for further investigation of the association between OA and 
      heart disease in longitudinal studies for investigating possible biological and
      behavioural mechanisms.
AD  - School of Population and Public Health, University of British Columbia Vancouver,
      British Columbia, Canada.
FAU - Rahman, M Mushfiqur
AU  - Rahman MM
FAU - Kopec, Jacek A
AU  - Kopec JA
FAU - Cibere, Jolanda
AU  - Cibere J
FAU - Goldsmith, Charlie H
AU  - Goldsmith CH
FAU - Anis, Aslam H
AU  - Anis AH
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3657665
OID - NLM: PMC3657665
OTO - NOTNLM
OT  - Epidemiology
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:01
CRDT- 2013/05/16 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2013-002624 [pii]
AID - 10.1136/bmjopen-2013-002624 [doi]
PST - epublish
SO  - BMJ Open. 2013 May 14;3(5). pii: e002624. doi: 10.1136/bmjopen-2013-002624. Print
      2013.

PMID- 23674398
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
DP  - 2013 May 14
TI  - High-Dose Statin Therapy in Patients with Stable Coronary Artery Disease:
      Treating the Right Patients Based on Individualized Prediction of Treatment
      Effect.
AB  - BACKGROUND: Clinicians need to identify coronary artery disease patients for whom
      the benefits of high-dose versus usual-dose statin therapy outweigh potential
      harm. We therefore aimed to develop and validate a model for prediction of the
      incremental treatment effect of high-dose statins for individual patients in
      terms of reduction of 5-year absolute risk for myocardial infarction, stroke,
      coronary death or cardiac resuscitation. METHODS AND RESULTS: Based on data from 
      the Treating to New Targets trial (TNT; n=10,001), a Cox proportional hazards
      model was developed comprising 13 easy-to-measure clinical predictors: age, sex, 
      smoking, diabetes mellitus, total cholesterol, high-density lipoprotein
      cholesterol, systolic blood pressure, history of myocardial infarction, coronary 
      artery bypass grafting, congestive heart failure or abdominal aortic aneurysm,
      glomerular filtration rate, and treatment status (i.e. atorvastatin 80mg or
      10mg). External validation in the Incremental Decrease in End Points Through
      Aggressive Lipid Lowering trial (IDEAL; n=8,888) confirmed adequate
      goodness-of-fit and calibration, but moderate discrimination (C-statistic 0.63;
      95%CI 0.62-0.65). Still, among participants of both trials combined, the model
      identified a group of 11.7% whose predicted 5-year number needed to treat (NNT)
      was 25 or lower and a group of 41.9% whose predicted NNT was 50 or higher. A
      decision curve shows that making treatment decisions on the basis of predictions 
      using our model may improve net benefit. CONCLUSIONS: Estimation of the
      incremental treatment effect of high-dose versus usual-dose statin therapy in
      individual coronary artery disease patients enables selection of high-risk
      patients that benefit most from more aggressive therapy. CLINICAL TRIAL
      REGISTRATION INFORMATION: www.clinicaltrials.gov. Identifiers: NCT00327691 and
      NCT00159835.
AD  - 1University Medical Center Utrecht, Utrecht, the Netherlands.
FAU - Dorresteijn, Johannes A N
AU  - Dorresteijn JA
FAU - Boekholdt, S Matthijs
AU  - Boekholdt SM
FAU - van der Graaf, Yolanda
AU  - van der Graaf Y
FAU - Kastelein, John J P
AU  - Kastelein JJ
FAU - Larosa, John C
AU  - Larosa JC
FAU - Pedersen, Terje R
AU  - Pedersen TR
FAU - Demicco, David A
AU  - Demicco DA
FAU - Ridker, Paul M
AU  - Ridker PM
FAU - Cook, Nancy R
AU  - Cook NR
FAU - Visseren, Frank L J
AU  - Visseren FL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Circulation
JT  - Circulation
JID - 0147763
OTO - NOTNLM
OT  - coronary
OT  - prediction
OT  - prevention
OT  - statin
OT  - treatment effectiveness
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - CIRCULATIONAHA.112.000712 [pii]
AID - 10.1161/CIRCULATIONAHA.112.000712 [doi]
PST - aheadofprint
SO  - Circulation. 2013 May 14.

PMID- 23674378
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1098-108X (Electronic)
IS  - 0276-3478 (Linking)
DP  - 2013 May 15
TI  - Detecting intentional insulin omission for weight loss in girls with type 1
      diabetes mellitus.
LID - 10.1002/eat.22138 [doi]
AB  - OBJECTIVE: Intentional insulin omission is a unique inappropriate compensatory
      behavior that occurs in patients with type 1 diabetes mellitus, mostly in
      females, who omit or restrict their required insulin doses in order to lose
      weight. Diagnosis of this underlying disorder is difficult. We aimed to use
      clinical and laboratory criteria to create an algorithm to assist in the
      detection of intentional insulin omission. METHOD: The distribution of HbA1c
      levels from 287 (181 females) patients with type 1 diabetes were used as
      reference. Data from 26 patients with type 1 diabetes and intentional insulin
      omission were analysed. The Weka (Waikato Environment for Knowledge Analysis)
      machine learning software, decision tree classifier with 10-fold cross validation
      was used to developed prediction models. Model performance was assessed by
      cross-validation in a further 43 patients. RESULTS: Adolescents with intentional 
      insulin omission were discriminated by: female sex, HbA1c>9.2%, more than 20% of 
      HbA1c measurements above the 90th percentile, the mean of 3 highest delta HbA1c
      z-scores>1.28, current age and age at diagnosis. The models developed showed good
      discrimination (sensitivity and specificity 0.88 and 0.74, respectively). The
      external test dataset revealed good performance of the model with a sensitivity
      and specificity of 1.00 and 0.97, respectively. DISCUSSION: Using data mining
      methods we developed a clinical prediction model to determine an individual's
      probability of intentionally omitting insulin. This model provides a decision
      support system for the detection of intentional insulin omission for weight loss 
      in adolescent females with type 1 diabetes mellitus. (c) 2013 Wiley Periodicals, 
      Inc. (Int J Eat Disord 2013;).
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Maccabi Health Care Services, Juvenile Diabetes Center, Raanana, Israel;
      Pediatric Endocrine and Diabetes Unit, Edmond and Lily Safra Children's Hospital,
      Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv
      University, Tel-Aviv, Israel.
FAU - Pinhas-Hamiel, Orit
AU  - Pinhas-Hamiel O
FAU - Hamiel, Uri
AU  - Hamiel U
FAU - Greenfield, Yuval
AU  - Greenfield Y
FAU - Boyko, Valentina
AU  - Boyko V
FAU - Graph-Barel, Chana
AU  - Graph-Barel C
FAU - Rachmiel, Marianna
AU  - Rachmiel M
FAU - Lerner-Geva, Liat
AU  - Lerner-Geva L
FAU - Reichman, Brian
AU  - Reichman B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Int J Eat Disord
JT  - The International journal of eating disorders
JID - 8111226
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/03/24 [revised]
PHST- 2013/03/25 [accepted]
AID - 10.1002/eat.22138 [doi]
PST - aheadofprint
SO  - Int J Eat Disord. 2013 May 15. doi: 10.1002/eat.22138.

PMID- 23674375
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 May 14
TI  - Celiac Disease in Patients With Type 1 Diabetes: Screening and Diagnostic
      Practices.
AB  - ObjectiveThe purpose of this study was to investigate screening practices for
      celiac disease in patients with type 1 diabetes across North America. The
      research question investigated was whether diabetes centers screen for celiac
      disease in type 1 diabetes more frequently than other facilities.Research Design 
      and MethodsA survey with 27 questions on screening practices for celiac disease
      in patients with type 1 diabetes was designed by experts in celiac disease and
      diabetes. Surveys were sent by email to diabetes educators and dietitians
      throughout the United States and Canada between December 2010 and May
      2011.ResultsThere were 514 respondents from 484 endocrine clinics, diabetes
      clinics, private practices, community nutrition centers, and inpatient centers.
      Thirty-five percent of work locations screened for celiac disease, with endocrine
      clinics reporting screening at the highest frequency (80%). Tissue
      transglutaminase was the most common screening test used. The most frequently
      recommended treatment of confirmed celiac disease was a gluten-free diet.
      However, only 71% of respondents recommended biopsy in patients with positive
      serologies. Most respondents (55.3%) reported that the gluten-free diet resulted 
      in symptom improvement in the majority of patients.ConclusionsStaff at endocrine 
      clinics were more likely to suggest screening for celiac disease in patients with
      type 1 diabetes. Both low screening frequency as well as inconsistency in
      management of positive celiac disease serological tests indicated an increase in 
      education regarding celiac disease in patients with type 1 diabetes is required. 
      In addition uniform guidelines should be developed.
AD  - Celiac Disease Center at Columbia University, New York, New York (Ms Simpson, Mr 
      Ciaccio, Dr Mahadev, Dr Lebwohl, Dr Green).
FAU - Simpson, Suzanne M
AU  - Simpson SM
FAU - Ciaccio, Edward J
AU  - Ciaccio EJ
FAU - Case, Shelley
AU  - Case S
FAU - Jaffe, Nancee
AU  - Jaffe N
FAU - Mahadov, Srihari
AU  - Mahadov S
FAU - Lebwohl, Benjamin
AU  - Lebwohl B
FAU - Green, Peter H
AU  - Green PH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 0145721713487998 [pii]
AID - 10.1177/0145721713487998 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 May 14.

PMID- 23674374
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 May 14
TI  - Population Management of Diabetes in a High-Need Urban Community in the Bronx:
      The Experience of Montefiore Medical Center.
AB  - PurposeThe purpose of this study is to examine the impact of a Care Management
      Organization (CMO) Diabetes Disease Management Program (DDMP) in improving
      diabetes outcomes among high-risk patients with type 2 diabetes (T2DM) in the
      Bronx, New York.MethodsAn interventional, nonrandomized study design was used to 
      assess the effectiveness of the DDMP. Patients older than 18 years who had T2DM
      and an A1C persistently 8% or greater or with a cardiovascular comorbidity were
      characterized as high risk and received intensive disease management. Patients
      served as their own controls, with data collection and analysis occurring 12
      months prior to and 12 months after enrollment in DDMP. Data collection included 
      screening rates for A1C, low-density lipoprotein (LDL) cholesterol, depression,
      smoking status, and annual influenza vaccine administration. Changes in A1C and
      LDL cholesterol were also analyzed. Statistical analyses were conducted using
      Minitab. McNemar's chi-square and paired t tests were used to assess within-group
      changes from baseline to final outcomes.ResultsSignificant improvements in
      screening rates for A1C, LDL, depression, smoking status, and annual influenza
      vaccine administration were found among high-risk/intensively managed patients in
      the DDMP. Improvements in clinical measures were also achieved in this group.
      Provider and patient satisfaction surveys were positive, with 92% of patients
      believing that the program helped them better understand their
      disease.ConclusionsA DDMP among high-risk patients has shown promise in improving
      the quality of care for patients with diabetes. This program has relevance for
      other integrated delivery systems that are developing accountable care
      approaches.
AD  - Montefiore CMO, Yonkers, NY (Ms Farrell, Ms Barnaby, Ms Galarza, Ms Figueira, Ms 
      Felleman, Ms Meara, Dr Chung).
FAU - Farrell, Patricia
AU  - Farrell P
FAU - Barnaby, Sandra
AU  - Barnaby S
FAU - Galarza, Tahnee
AU  - Galarza T
FAU - Simonson, Julie K
AU  - Simonson JK
FAU - Zonszein, Joel
AU  - Zonszein J
FAU - Meara, Anne
AU  - Meara A
FAU - Chung, Henry
AU  - Chung H
FAU - Figueira, Rhonda
AU  - Figueira R
FAU - Felleman, Sheila
AU  - Felleman S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 0145721713487259 [pii]
AID - 10.1177/0145721713487259 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 May 14.

PMID- 23674344
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
DP  - 2013 May 15
TI  - A prospective analysis of telomere length and pancreatic cancer in the
      Alpha-Tocopherol Beta-Carotene cancer prevention (ATBC) study.
LID - 10.1002/ijc.28272 [doi]
AB  - Smoking and diabetes, consistent risk factors for pancreatic cancer, are also
      factors that influence telomere length maintenance. To test whether telomere
      length is associated with pancreatic cancer risk, we conducted a nested
      case-control study in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention
      (ATBC) Study cohort of male smokers, aged 50-69 years at baseline. Between 1992
      and 2004, 193 incident cases of pancreatic adenocarcinoma occurred (mean
      follow-up from blood draw: 6.3 years) among participants with whole blood samples
      available for telomere length assays. For these cases and 660 controls, we
      calculated odds ratios (OR) and 95% confidence intervals using unconditional
      logistic regression, adjusting for age, number of years smoked regularly, and
      history of diabetes mellitus. Telomere length was categorized into quartiles
      (shortest to longest) and analyzed as both a categorical and a continuous normal 
      variable (reported per 0.2 unit increase in telomere length). All statistical
      tests were two-sided. Longer telomere length was significantly associated with
      increased pancreatic cancer risk (continuous OR=1.26 95% CI=1.09-1.46; highest
      quartile compared to lowest, OR=1.57, 95% CI=1.01-2.43, p-trend=0.007). This
      association remained for subjects diagnosed within the first five years of blood 
      draw(continuous OR=1.46, 95% CI=1.19-1.79 highest quartile OR=2.92,
      95%CI=1.47-5.77, p-trend=0.002), but not those diagnosed greater than five years 
      after blood draw (continuous OR=1.03, 95%CI=0.85-1.22; highest quartile OR=1.04, 
      95%CI=0.60-1.79). This is the first prospective study to suggest an association
      between longer blood leukocyte telomere length and increased pancreatic cancer
      risk. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 UICC.
AD  - Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics,
      National Cancer Institute, Bethesda, MD; Center for Clinical Epidemiology and
      Biostatistics, Center for Genetics and Complex Traits, University of
      Pennsylvania, Philadelphia, PA.
FAU - Lynch, Shannon M
AU  - Lynch SM
FAU - Major, Jacqueline M
AU  - Major JM
FAU - Cawthon, Richard
AU  - Cawthon R
FAU - Weinstein, Stephanie J
AU  - Weinstein SJ
FAU - Virtamo, Jarmo
AU  - Virtamo J
FAU - Lan, Qing
AU  - Lan Q
FAU - Rothman, Nathaniel
AU  - Rothman N
FAU - Albanes, Demetrius
AU  - Albanes D
FAU - Stolzenberg-Solomon, Rachael Z
AU  - Stolzenberg-Solomon RZ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Int J Cancer
JT  - International journal of cancer. Journal international du cancer
JID - 0042124
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/09/03 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/04/15 [accepted]
AID - 10.1002/ijc.28272 [doi]
PST - aheadofprint
SO  - Int J Cancer. 2013 May 15. doi: 10.1002/ijc.28272.

PMID- 23674307
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1941-7705 (Electronic)
IS  - 1941-7713 (Linking)
VI  - 6
IP  - 3
DP  - 2013 May 1
TI  - Diabetes mellitus and cardiovascular events in older patients with myocardial
      infarction prescribed intensive-dose and moderate-dose statins.
PG  - 315-22
LID - 10.1161/CIRCOUTCOMES.111.000015 [doi]
AB  - Background- Practice guidelines recommend intensive-dose statins for patients
      with acute coronary syndrome, but recent data about the risk of new-onset
      diabetes mellitus have raised concerns about its use. Our main objective was to
      evaluate the association between intensive statin therapy and new-onset diabetes 
      mellitus in patients with myocardial infarction and to evaluate the association
      of intensive statin therapy with long-term adverse clinical outcomes. Methods and
      Results- A propensity score-matched cohort was created consisting of 17 080
      patients with myocardial infarction aged >65 years old, hospitalized in Ontario, 
      Canada, from 2004 to 2010. Clinical outcomes were compared in patients prescribed
      intensive-dose versus moderate-dose statins at hospital discharge. At 5 years,
      13.6% of patients receiving intensive-dose statins and 13.0% of patients
      receiving moderate-dose statins had new-onset diabetes, which was not
      significantly different (P=0.19). By contrast, the 5-year rate of death or acute 
      coronary syndrome was significantly lower at 44.8% in the intensive-dose statin
      group compared with 46.5% in the moderate-dose group (P=0.044). The reduction in 
      combined clinical outcome was driven mainly by a significantly lower rate of
      acute coronary syndrome (P=0.039) associated with intensive-dose statins. No
      significant difference in mortality rates (34.8% in both groups) was observed
      between the treatment groups during the study period (P=0.89). Conclusions- In
      older patients with myocardial infarction, we found intensive-dose statin therapy
      to be effective in reducing repeat hospitalization for acute coronary syndrome.
      The rate of new-onset diabetes mellitus at long term was not significantly
      different between intensive-dose and moderate-dose statins.
AD  - Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
FAU - Ko, Dennis T
AU  - Ko DT
FAU - Wijeysundera, Harindra C
AU  - Wijeysundera HC
FAU - Jackevicius, Cynthia A
AU  - Jackevicius CA
FAU - Yousef, Altayyeb
AU  - Yousef A
FAU - Wang, Julie
AU  - Wang J
FAU - Tu, Jack V
AU  - Tu JV
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - United States
TA  - Circ Cardiovasc Qual Outcomes
JT  - Circulation. Cardiovascular quality and outcomes
JID - 101489148
SB  - IM
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - intensive-dose statins
OT  - new-onset diabetes mellitus
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/05/14 [aheadofprint]
AID - CIRCOUTCOMES.111.000015 [pii]
AID - 10.1161/CIRCOUTCOMES.111.000015 [doi]
PST - ppublish
SO  - Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):315-22. doi:
      10.1161/CIRCOUTCOMES.111.000015. Epub 2013 May 14.

PMID- 23674208
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1619-7089 (Electronic)
IS  - 1619-7070 (Linking)
DP  - 2013 May 15
TI  - Predictive variables for hard cardiac events and coronary revascularization in
      patients with normal left ventricular myocardial perfusion and systolic function.
AB  - BACKGROUND: The objective of this study was to investigate the impact of
      clinical, electrocardiographic and stress testing variables in predicting hard
      cardiac events (HE) and coronary revascularization (CR) in patients with normal
      stress-rest gated SPECT. MATERIALS AND METHODS: Included in the study were 2,004 
      patients (63.5 +/- 12.5 years, 41.6 % men) with normal myocardial perfusion and
      left ventricular ejection fraction (LVEF) >50 % on gated SPECT who were followed 
      for HE (cardiovascular death or acute myocardial infarction) and CR. RESULTS:
      During a follow-up of 4.3 +/- 2.4 years, 33 patients (1.6 %; 0.4 %/year) had HE
      and 50 patients (2.5 %; 0.6 %/year) underwent CR. In a univariate analysis, age
      >/=65 years, insulin-dependent diabetes mellitus (IDDM), left bundle branch block
      (LBBB), and pharmacological stress were associated with HE. Independent
      predictors of HE were age >/=65 years (p < 0.001; HR 6.9), IDDM (p = 0.014; HR
      3.4), and LBBB (p = 0.002; HR 4.6). In the univariate analysis, male gender,
      LVEF, known coronary artery disease (CAD), LBBB, and a positive stress test were 
      associated with CR. Independent predictors of CR were known CAD (p = 0.016; HR
      2.1), and a positive stress test (p = 0.006; HR 2.3). CONCLUSION: Age >/=65
      years, IDDM, and LBBB are HE-independent predictors in patients with normal
      myocardial perfusion and normal LVEF on gated SPECT. The presence of known CAD or
      a positive stress test significantly increases the probability of CR during
      follow-up.
AD  - Cardiology Department, Hospital Universitari Vall d'Hebron. Institut de Recerca
      (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain,
      guirom@adinet.com.uy.
FAU - Romero-Farina, Guillermo
AU  - Romero-Farina G
FAU - Candell-Riera, Jaume
AU  - Candell-Riera J
FAU - Aguade-Bruix, Santiago
AU  - Aguade-Bruix S
FAU - Cuberas-Borros, Gemma
AU  - Cuberas-Borros G
FAU - Ferreira-Gonzalez, Ignacio
AU  - Ferreira-Gonzalez I
FAU - Nazarena Pizzi, Maria
AU  - Nazarena Pizzi M
FAU - de Leon, Gustavo
AU  - de Leon G
FAU - Santos, Alba
AU  - Santos A
FAU - Garcia-Dorado, David
AU  - Garcia-Dorado D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Eur J Nucl Med Mol Imaging
JT  - European journal of nuclear medicine and molecular imaging
JID - 101140988
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/02/17 [received]
PHST- 2013/04/18 [accepted]
PHST- 2013/05/15 [aheadofprint]
AID - 10.1007/s00259-013-2438-3 [doi]
PST - aheadofprint
SO  - Eur J Nucl Med Mol Imaging. 2013 May 15.

PMID- 23674172
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 15
TI  - Identification of circulating microRNAs in HNF1A-MODY carriers.
AB  - AIMS/HYPOTHESIS: HNF1A-MODY is a monogenic form of diabetes caused by mutations
      in the HNF1A gene. Here we identify, for the first time, HNF1A-MODY-associated
      microRNAs (miRNAs) that can be detected in the serum of HNF1A-MODY carriers.
      METHODS: An miRNA array was carried out in rat INS-1 insulinoma cells inducibly
      expressing the common human Pro291fsinsC-HNF1A frame shift mutation.
      Differentially expressed miRNAs were validated by quantitative real-time PCR.
      Expression of miRNAs in the serum of HNF1A-MODY carriers (n = 31), MODY-negative 
      family members (n = 10) and individuals with type 2 diabetes mellitus (n = 17)
      was quantified by absolute real-time PCR analysis. RESULTS: Inducible expression 
      of Pro291fsinsC-HNF1A in INS-1 cells caused a significant upregulation of three
      miRNAs (miR-103, miR-224, miR-292-3p). The differential expression of two miRNAs 
      (miR-103 and miR-224) was validated in vitro. Strongly elevated levels of miR-103
      and miR-224 could be detected in the serum of HNF1A-MODY carriers compared with
      MODY-negative family controls. Serum levels of miR-103 distinguished HNF1A-MODY
      carriers from HbA1c-matched individuals with type 2 diabetes mellitus.
      CONCLUSIONS/INTERPRETATION: Our study demonstrates that the pathophysiology of
      HNF1A-MODY is associated with the overexpression of miR-103 and miR-224.
      Furthermore, our study demonstrates that these miRNAs can be readily detected in 
      the serum of HNF1A-MODY carriers.
AD  - Department of Physiology and Medical Physics, Royal College of Surgeons in
      Ireland, 123 St Stephen's Green, Dublin 2, Ireland.
FAU - Bonner, C
AU  - Bonner C
FAU - Nyhan, K C
AU  - Nyhan KC
FAU - Bacon, S
AU  - Bacon S
FAU - Kyithar, M P
AU  - Kyithar MP
FAU - Schmid, J
AU  - Schmid J
FAU - Concannon, C G
AU  - Concannon CG
FAU - Bray, I M
AU  - Bray IM
FAU - Stallings, R L
AU  - Stallings RL
FAU - Prehn, J H M
AU  - Prehn JH
FAU - Byrne, M M
AU  - Byrne MM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/12/22 [received]
PHST- 2013/04/25 [accepted]
PHST- 2013/05/15 [aheadofprint]
AID - 10.1007/s00125-013-2939-4 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 15.

PMID- 23674160
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 121
IP  - 5
DP  - 2013 May
TI  - AIP Mutation Identified in a Patient with Acromegaly Caused by Pituitary
      Somatotroph Adenoma with Neuronal Choristoma.
PG  - 295-9
LID - 10.1055/s-0032-1331697 [doi]
AB  - Pituitary adenoma with neuronal choristoma (PANCH) is a rare condition that
      includes ganglion cells and GH-producing tumor that is characterized by sparsely 
      granulated somatotroph cell type. However, the pathophysiology of this condition 
      remains to be elucidated. We report a case of 46-year-old woman with acromegaly
      caused by PANCH. The patient had a large and invasive macroadenoma that was
      resistant to preoperative therapy with somatostatin analogue (SSA) and dopamine
      agonist. Histological examination showed typical diffuse, chromophobe-type
      adenoma containing ganglion cells, and sparsely granulated somatotroph cell type,
      which were consistent with PANCH. Genetic analysis showed heterozygous germline
      missense mutation in the AIP gene that results in Y261X amino acid substitution. 
      The clinical characteristics of acromegaly associated with AIP mutations are
      reportedly macroadenomas with tumor extension and invasion, lower decreases in GH
      and IGF-I and less tumor shrinkage with SSA treatment, and sparsely granulated
      somatotroph cell type, which are comparable with those observed in PANCH. Taken
      together, the mutation in AIP gene may explain the clinical characteristics and
      pathogenesis of PANCH.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe
      University Graduate School of Medicine, Chuo-ku, Kobe, Japan.
FAU - Nishizawa, H
AU  - Nishizawa H
FAU - Fukuoka, H
AU  - Fukuoka H
FAU - Iguchi, G
AU  - Iguchi G
FAU - Inoshita, N
AU  - Inoshita N
FAU - Yamada, S
AU  - Yamada S
FAU - Takahashi, Y
AU  - Takahashi Y
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/05/14 [epublish]
AID - 10.1055/s-0032-1331697 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2013 May;121(5):295-9. doi: 10.1055/s-0032-1331697.
      Epub 2013 May 14.

PMID- 23674159
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 121
IP  - 5
DP  - 2013 May
TI  - Feasibility and Efficacy of an Isocaloric High-Protein vs. Standard Diet on
      Insulin Requirement, Body Weight and Metabolic Parameters in Patients with Type 2
      Diabetes on Insulin Therapy.
PG  - 286-94
LID - 10.1055/s-0033-1341472 [doi]
AB  - To determine the feasibility and efficacy of a high-protein diet compared with a 
      standard diet aiming for weight maintenance in insulin treated type-2 diabetic
      patients on insulin requirement, body weight and metabolic parameters over 12
      weeks.In a randomized controlled trial we assigned 44 type-2 diabetic patients on
      insulin therapy either to high-protein or standard diet over 12 weeks. Parameters
      were evaluated at baseline and monthly.After 12 weeks, the high protein diet
      significantly decreased insulin requirement (9.4+/-16.3 vs. +0.8+/-4.8 IU,
      mean+/-SD; p=0.007), fasting plasma glucose (41.7+/-62.5 vs. 2.1+/-39.0 mg dl- 1;
      p=0.02), body mass index (1.1+/-0.8 vs. 0.3+/-0.7 kg m- 2; p=0.003), fat-free
      (0.8+/-0.5 vs. 0.2+/-0.5kg; p=0.001), fat mass (2.6+/-1.7 vs. 0.8+/-1.6kg;
      p=0.001) and increased serum folate (4.2+/-8.3 vs. - 0.8+/-5.5 nmol l-1; p=0.04) 
      compared to the standard diet. These beneficial metabolic effects are most likely
      related to the achieved weight loss. No significant differences between groups in
      renal function were observed.In this study we demonstrate that a high protein
      diet with emphasis on plant source protein vs. a standard diet is feasible in
      insulin-treated type-2 diabetic patients and reduces insulin requirement and body
      weight and improves metabolic parameters up to 12 weeks. A high protein diet can 
      thus be considered as an appropriate diet choice for type-2 diabetic patients.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Department of Medicine 3, Division of Endocrinology and Metabolism, Medical
      University of Vienna, Vienna, Austria.
FAU - Luger, M
AU  - Luger M
FAU - Holstein, B
AU  - Holstein B
FAU - Schindler, K
AU  - Schindler K
FAU - Kruschitz, R
AU  - Kruschitz R
FAU - Ludvik, B
AU  - Ludvik B
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/05/14 [epublish]
AID - 10.1055/s-0033-1341472 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2013 May;121(5):286-94. doi:
      10.1055/s-0033-1341472. Epub 2013 May 14.

PMID- 23674158
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 121
IP  - 5
DP  - 2013 May
TI  - Inhibition of Calcitonin Gene-related Peptide (CGRP) has the Potential to Extend 
      First-phase Insulin Secretion.
PG  - 280-5
LID - 10.1055/s-0033-1341441 [doi]
AB  - The neuropeptide calcitonin gene-related peptide (CGRP), known to have a strong
      vasodilation effect, has also been reported to inhibit insulin secretion.
      However, the physiological effect of CGRP related to insulin secretion is still
      unknown. Here, we evaluated the effect of whole-body CGRP inhibition by anti-CGRP
      antibodies in mice using an oral glucose tolerance test. CGRP has 2 isotypes,
      alpha-CGRP and beta-CGRP, and we confirmed the antibody used in this study
      inhibits function of both. Then, we evaluated the effect of CGRP inhibition on
      insulin secretion and discovered that CGRP inhibition lead to extend first-phase 
      insulin secretion in an antibody dose-dependent manner and nearly plateaued at 10
      mg/kg, although the effect was not so large and didn't affect plasma glucose
      level. We then measured the plasma antibody concentration and it was increased
      depending on administration dose. So, the effect of first-phase insulin secretion
      extension was determined to be the result of complete inhibition of CGRP by the
      antibody. These results indicate that CGRP has the potential to inhibit insulin
      secretion and shorten first-phase insulin secretion. However the effect of CGRP
      inhibition was not so large at least on healthy condition, and it indicates the
      effect of CGRP related to insulin secretion on healthy physiological condition
      may be limited.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Molecular Medicine Research Labs. Drug Discovery Research, Astellas Pharma Inc., 
      Tsukuba, Ibaraki, Japan.
FAU - Tanaka, H
AU  - Tanaka H
FAU - Kashiwagi, R
AU  - Kashiwagi R
FAU - Koizumi, T
AU  - Koizumi T
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/05/14 [epublish]
AID - 10.1055/s-0033-1341441 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2013 May;121(5):280-5. doi: 10.1055/s-0033-1341441.
      Epub 2013 May 14.

PMID- 23674157
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 121
IP  - 5
DP  - 2013 May
TI  - And the Winner is....
PG  - 247
LID - 10.1055/s-0033-1345143 [doi]
AD  - Editorial Director, Georg Thieme Verlag, Stuttgart, Germany.
FAU - Wiegers, W
AU  - Wiegers W
FAU - Wenzel, R
AU  - Wenzel R
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/05/14 [epublish]
AID - 10.1055/s-0033-1345143 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2013 May;121(5):247. doi: 10.1055/s-0033-1345143.
      Epub 2013 May 14.

PMID- 23673977
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1557-1904 (Electronic)
IS  - 1557-1890 (Linking)
DP  - 2013 May 15
TI  - The Immune System in Stroke: Clinical Challenges and Their Translation to
      Experimental Research.
AB  - Stroke represents an unresolved challenge for both developed and developing
      countries and has a huge socio-economic impact. Although considerable effort has 
      been made to limit stroke incidence and improve outcome, strategies aimed at
      protecting injured neurons in the brain have all failed. This failure is likely
      to be due to both the incompleteness of modelling the disease and its causes in
      experimental research, and also the lack of understanding of how systemic
      mechanisms lead to an acute cerebrovascular event or contribute to outcome.
      Inflammation has been implicated in all forms of brain injury and it is now clear
      that immune mechanisms profoundly influence (and are responsible for the
      development of) risk and causation of stroke, and the outcome following the onset
      of cerebral ischemia. Until very recently, systemic inflammatory mechanisms, with
      respect to common comorbidities in stroke, have largely been ignored in
      experimental studies. The main aim is therefore to understand interactions
      between the immune system and brain injury in order to develop novel therapeutic 
      approaches. Recent data from clinical and experimental research clearly show that
      systemic inflammatory diseases -such as atherosclerosis, obesity, diabetes or
      infection - similar to stress and advanced age, are associated with dysregulated 
      immune responses which can profoundly contribute to cerebrovascular inflammation 
      and injury in the central nervous system. In this review, we summarize recent
      advances in the field of inflammation and stroke, focusing on the challenges of
      translation between pre-clinical and clinical studies, and potential
      anti-inflammatory/immunomodulatory therapeutic approaches.
AD  - Stroke and Vascular Research Centre, Institute of Cardiovascular Sciences,
      University of Manchester, Manchester Academic Health Science Centre, Salford
      Royal Foundation Trust, Salford, M6 8HD, UK, Craig.Smith-2@manchester.ac.uk.
FAU - Smith, Craig J
AU  - Smith CJ
FAU - Lawrence, Catherine B
AU  - Lawrence CB
FAU - Rodriguez-Grande, Beatriz
AU  - Rodriguez-Grande B
FAU - Kovacs, Krisztina J
AU  - Kovacs KJ
FAU - Pradillo, Jesus M
AU  - Pradillo JM
FAU - Denes, Adam
AU  - Denes A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Neuroimmune Pharmacol
JT  - Journal of neuroimmune pharmacology : the official journal of the Society on
      NeuroImmune Pharmacology
JID - 101256586
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/11/30 [received]
PHST- 2013/04/28 [accepted]
PHST- 2013/05/15 [aheadofprint]
AID - 10.1007/s11481-013-9469-1 [doi]
PST - aheadofprint
SO  - J Neuroimmune Pharmacol. 2013 May 15.

PMID- 23673903
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 4
IP  - 6
DP  - 2013 Jun 28
TI  - Monascin improves diabetes and dyslipidemia by regulating PPARgamma and
      inhibiting lipogenesis in fructose-rich diet-induced C57BL/6 mice.
PG  - 950-9
LID - 10.1039/c3fo60062a [doi]
AB  - Monascin (MS) is a yellow compound isolated from Monascus-fermented products that
      has pancreatic protective, anti-inflammatory, anti-oxidative, and hypolipidemic
      activity. We recently found that MS also acts as a peroxisome
      proliferator-activated receptor-gamma (PPARgamma) agonist, thereby promoting
      insulin sensitivity in C2C12 cells. However, the attenuation of hyperglycemia by 
      MS treatment in vivo remains uncertain. In the present study, both MS and
      pioglitazone significantly down-regulated blood glucose and hyperinsulinemia in
      fructose-rich diet (FRD)-induced C57BL/6 mice (8 weeks). In addition, inhibitions
      of inflammatory factor production, serum dyslipidemia, and hepatic fatty acid
      accumulation by MS and pioglitazone were attenuated by GW9662 (PPARgamma
      antagonist). These results were mediated by MS-suppressing FRD-elevated lipogenic
      transcription factors, including sterol regulatory element-binding protein-1c
      (SREBP-1c), carbohydrate response element-binding protein (ChREBP), PPARgamma
      coactivator-1alpha (PGC-1alpha), and PPARgamma coactivator-1beta (PGC-1beta).
      Taken together, de novo lipogenesis results in hyperlipidemia and hyperglycemia
      by fructose induction thereby leading to diabetes development; we found that MS
      may inhibit lipogenesis in FRD-induced mice. These findings suggest that MS acts 
      as an antidiabetic agent and thus may have therapeutic potential for prevention
      of diabetes.
AD  - Department of Biochemical Science & Technology, College of Life Science, National
      Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei, 10617, Taiwan.
      tmpan@ntu.edu.tw.
FAU - Lee, Bao-Hong
AU  - Lee BH
FAU - Hsu, Wei-Hsuan
AU  - Hsu WH
FAU - Huang, Tao
AU  - Huang T
FAU - Chang, Yu-Yin
AU  - Chang YY
FAU - Hsu, Ya-Wen
AU  - Hsu YW
FAU - Pan, Tzu-Ming
AU  - Pan TM
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/05/14 [aheadofprint]
PHST- 2013/05/28 [epublish]
AID - 10.1039/c3fo60062a [doi]
PST - ppublish
SO  - Food Funct. 2013 Jun 28;4(6):950-9. doi: 10.1039/c3fo60062a. Epub 2013 May 14.

PMID- 23673729
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1531-2267 (Electronic)
IS  - 1094-8341 (Linking)
DP  - 2013 May 14
TI  - Allelic expression imbalance screening of genes in chromosome 1q21-24 region to
      identify functional variants for type 2 diabetes susceptibility.
AB  - Type-2 diabetes (T2D)-associated SNPs are more likely to be eQTLs. The allelic
      expression imbalance (AEI) analysis is the measure of relative expression between
      two allelic transcripts and is the most sensitive measurement to detect
      cis-regulatory effects. We performed AEI screening to detect cis-regulators for
      genes expressed in transformed lymphocytes of 190 Caucasian (CA) and African
      American (AA) subjects to identify functional variants for T2D susceptibility in 
      the chromosome1q21-24 region of linkage. Among transcribed SNPs studied in 115
      genes, significant AEI (p<0.001) occurred in 28 and 30 genes in CA and AA
      subjects, respectively. Analysis of the effect of selected AEI-SNPs (>/=10% mean 
      AEI) on total gene expression further established the cis-eQTLs in THEM4
      (rs13320, p=0.027), and IGSF8 (rs1131891, p=0.02). Examination of published
      genome-wide association data identified significant associations (p<0.01) of
      three AEI-SNPs with T2D in the DIAGRAM-v3 dataset. Six AEI-SNPs, including
      rs13320 (p=1.35E-04) in THEM4, were associated with glucose homeostasis traits in
      the MAGIC dataset. Evaluation of AEI-SNPs for association with glucose
      homeostasis traits in 611 nondiabetic subjects showed lower AIRG (p=0.005) in
      those with TT/TC-genotype for rs13320. THEM4 expression in adipose was higher
      (p=0.005) in subjects carrying the T-allele; in vitro analysis with luciferase
      construct confirmed the higher expression of the T-allele. Resequencing of THEM4 
      exons in 192 CA subjects revealed four coding non-synonymous variants, but did
      not explain transmission of T2D in 718 subjects from 67 Caucasian pedigrees. Our 
      study indicates the role of a cis-regulatory SNP in THEM4 that may influence T2D 
      predisposition by modulating glucose homeostasis.
AD  - Wake Forest School of Medicine.
FAU - Mondal, Ashis Kumar
AU  - Mondal AK
FAU - Sharma, Neeraj Kumar
AU  - Sharma NK
FAU - Elbein, Steven C Deceased
AU  - Elbein SC Deceased
FAU - Das, Swapan Kumar
AU  - Das SK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Physiol Genomics
JT  - Physiological genomics
JID - 9815683
OTO - NOTNLM
OT  - Allelic expression imbalance
OT  - SNP
OT  - Type 2 diabetes
OT  - eQTL
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - physiolgenomics.00048.2013 [pii]
AID - 10.1152/physiolgenomics.00048.2013 [doi]
PST - aheadofprint
SO  - Physiol Genomics. 2013 May 14.

PMID- 23673658
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 May 14
TI  - A metabolomics driven elucidation of the anti-obesity mechanisms of xanthohumol.
AB  - Mild, mitochondrial uncoupling increases energy expenditure and can reduce the
      generation of reactive oxygen species (ROS). Activation of cellular, adaptive
      stress response pathways can result in an enhanced capacity to reduce oxidative
      damage. Together, these strategies target energy imbalance and oxidative stress, 
      both underlying factors of obesity and related conditions such as type 2
      diabetes. Here we describe a metabolomics driven effort to uncover the
      anti-obesity mechanism(s) of xanthohumol (XN), a prenylated flavonoid from hops. 
      Metabolomics analysis of fasting plasma from obese, Zucker rats treated with XN
      revealed decreases in products of dysfunctional fatty acid oxidation and ROS,
      prompting us to explore the effects of XN on muscle cell bioenergetics. At low
      micromolar concentrations, XN acutely increased uncoupled respiration in several 
      different cell types, including myocytes. Tetrahydroxanthohumol also increased
      respiration, suggesting electrophilicty did not play a role. At higher
      concentrations, XN inhibited respiration in a ROS dependent manner. In myocytes, 
      time course metabolomics revealed acute activation of glutathione recycling and
      long-term induction of glutathione synthesis as well as several other changes
      indicative of short term elevated cellular stress and a concerted adaptive
      response. Based on these findings, we hypothesize that XN may ameliorate
      metabolic syndrome, at least in part, through mitochondrial uncoupling and stress
      response induction. In addition, time course metabolomics appears to be an
      effective strategy for uncovering metabolic events that occur during a stress
      response.
AD  - Oregon State University, United States.
FAU - Kirkwood, Jay S
AU  - Kirkwood JS
FAU - Legette, Leecole L
AU  - Legette LL
FAU - Miranda, Cristobal L
AU  - Miranda CL
FAU - Jiang, Yuan
AU  - Jiang Y
FAU - Stevens, Jan Frederik
AU  - Stevens JF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Flavonoids
OT  - Mass spectrometry (MS)
OT  - Metabolism
OT  - Metabolomics
OT  - Obesity
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - M112.445452 [pii]
AID - 10.1074/jbc.M112.445452 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 May 14.

PMID- 23673393
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1537-1948 (Electronic)
IS  - 0025-7079 (Linking)
VI  - 51
IP  - 6
DP  - 2013 Jun
TI  - Is Medical Home Enrollment Associated With Receipt of Guideline-Concordant
      Follow-up Care Among Low-Income Breast Cancer Survivors?
PG  - 494-502
LID - 10.1097/MLR.0b013e31828d4d0c [doi]
AB  - BACKGROUND: : Community Care of North Carolina (CCNC) initiated an innovative
      medical home program in the 1990s to improve primary care in Medicaid-insured
      populations. CCNC has been successful in improving asthma, diabetes, and
      cardiovascular outcomes but has not been evaluated in the context of cancer care.
      We explored whether CCNC enrollment was associated with guideline-concordant
      follow-up care among breast cancer survivors. METHODS: : Using state cancer
      registry records matched to Medicaid claims, we identified women 18 to 64 years
      old who were diagnosed with stage 0, I, II, or unstaged breast cancer from 2003
      to 2007 and tracked their monthly CCNC enrollment. Using published American
      Society for Clinical Oncology guidelines to define our outcomes, we employed
      multivariate logistic regressions to examine, as a function of CCNC enrollment,
      receipt of mammogram and at least 2 physical examinations/history-taking visits
      within observational windows consistent with the guidelines. RESULTS: : Of the
      840 women, approximately half were enrolled into the CCNC for some time during
      the study period. Between 40% and 85% received follow-up mammogram in accordance 
      with guidelines, with significant variation by CCNC status, and 95% of women
      received at least 2 physical examinations/history-taking visits. In multivariate 
      models, increasing months of CCNC enrollment was significantly positively
      associated with receipt of follow-up mammogram but not with physical
      examinations/history-taking visits. CONCLUSIONS: : Results suggest that CCNC
      enrollment is associated with guideline-concordant follow-up care for
      Medicaid-insured survivors. Given the growing population of cancer survivors and 
      increased emphasis on primary care medical homes, future studies should explore
      what factors are associated with medical home participation and whether similar
      findings are observed with extended follow-up.
AD  - *Department of Health Policy and Management daggerLineberger Comprehensive Cancer
      Center double daggerCecil G. Sheps Center for Health Services Research section
      signDepartment of Family Medicine, University of North Carolina, Chapel Hill, NC 
      parallelCollege of Medicine, Medical University of South Carolina, Charleston,
      SC.
FAU - Wheeler, Stephanie B
AU  - Wheeler SB
FAU - Kohler, Racquel E
AU  - Kohler RE
FAU - Goyal, Ravi K
AU  - Goyal RK
FAU - Lich, Kristen H
AU  - Lich KH
FAU - Lin, Ching-Ching
AU  - Lin CC
FAU - Moore, Alexis
AU  - Moore A
FAU - Smith, Timothy W
AU  - Smith TW
FAU - Melvin, Cathy L
AU  - Melvin CL
FAU - Reeder-Hayes, Katherine
AU  - Reeder-Hayes K
FAU - Domino, Marisa E
AU  - Domino ME
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Care
JT  - Medical care
JID - 0230027
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.1097/MLR.0b013e31828d4d0c [doi]
AID - 00005650-201306000-00004 [pii]
PST - ppublish
SO  - Med Care. 2013 Jun;51(6):494-502. doi: 10.1097/MLR.0b013e31828d4d0c.

PMID- 23673378
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 May 14
TI  - Endothelial dysfunction in patients with type 2 diabetes post acute coronary
      syndrome.
AB  - This single visit study examined whether endothelial function, in addition to
      cardiovascular (CV) risk factors and plasma microparticle content, was normalised
      in 15 patients with type 2 diabetes + acute coronary syndrome (ACS) (6 weeks-6
      months post cardiac event) undergoing standard clinical care compared to 16 sex- 
      and age-matched healthy controls.Results:While total and low-density lipoprotein 
      (LDL) cholesterol levels were well controlled in the patients with type 2
      diabetes + ACS, residual CV risk profiles such as increased body mass index
      (BMI), systolic blood pressure, glucose levels and triglycerides and lower
      high-density lipoprotein (HDL) levels were still apparent. Endothelium-dependent 
      responses to acetylcholine (ACh) were significantly lower in type 2 diabetes +
      ACS patients compared to controls. Correspondingly, the reactive hyperaemic index
      (RHI) was lower in the patient cohort. Endothelial microparticle (EMP) levels
      (CD31+, CD41-) were 40% lower in the patient cohort. Simultaneous analysis of
      platelet microparticle (PMP) levels (CD41+) showed no difference between
      cohorts.Conclusions:Patients with type 2 diabetes suffering from recent ACS
      exhibit residual CV risk factors despite being on standard clinical care. In
      addition, these patients continue to present with endothelial dysfunction despite
      having lower levels of EMPs.
AD  - Vascular Pharmacology and Heart Failure, Baker IDI Heart and Diabetes Institute, 
      Melbourne, VIC, Australia.
FAU - Lumsden, Natalie G
AU  - Lumsden NG
FAU - Andrews, Karen L
AU  - Andrews KL
FAU - Bobadilla, Maria
AU  - Bobadilla M
FAU - Moore, Xiao L
AU  - Moore XL
FAU - Sampson, Amanda K
AU  - Sampson AK
FAU - Shaw, James A
AU  - Shaw JA
FAU - Mizrahi, Jacques
AU  - Mizrahi J
FAU - Kaye, David M
AU  - Kaye DM
FAU - Dart, Anthony M
AU  - Dart AM
FAU - Chin-Dusting, Jaye Pf
AU  - Chin-Dusting JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
OTO - NOTNLM
OT  - Type 2 diabetes
OT  - acute coronary syndrome
OT  - endothelial dysfunction
OT  - endothelial microparticles
OT  - peripheral arterial tonometry
OT  - plethysmography
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 1479164113482593 [pii]
AID - 10.1177/1479164113482593 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 May 14.

PMID- 23673377
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 May 14
TI  - Self-rated health predicts outcome in patients with type 2 diabetes and
      myocardial infarction: A DIGAMI 2 quality of life sub-study.
AB  - The Diabetes mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction
      (DIGAMI) 2 Quality of Life (QoL) sub-study included 465 patients with type 2
      diabetes and acute myocardial infarction (AMI) followed for 2 years. Self-rated
      health was reported by the rating scale (RS), graded 0 = death to 100 = perfect
      health. Prospective associations between RS and all-cause mortality,
      cardiovascular (CV) death and cardiovascular events (CVEs = CV death, non-fatal
      AMI, stroke) were assessed. Median age was 68 years (range 59-74), 68% male.
      Patients experiencing CVE (n = 132) or death (n = 71) had lower RS compared with 
      patients free from events: 60 (50-79) versus 70 (55-81) (p < 0.001) and 60
      (50-75) versus 70 (51-80) (p = 0.008). The RS score predicted CVE [hazard ratio
      (HR); 95% confidence interval (CI): 0.87; 0.80-0.95] and all-cause mortality
      (0.86; 0.76-0.97), and corresponding HRs after adjustment were 0.90; 0.83-0.99
      and 0.90; 0.79-1.02, respectively. A low self-rated health is of prognostic
      importance in patients with type 2 diabetes and AMI and may serve as an easily
      obtainable indicator of high risk for CVEs supplementing traditional risk
      factors.
AD  - Department of Medicine, Cardiology Unit, Karolinska University Hospital,
      Stockholm, Sweden.
FAU - Venskutonyte, Laura
AU  - Venskutonyte L
FAU - Brismar, Kerstin
AU  - Brismar K
FAU - Ohrvik, John
AU  - Ohrvik J
FAU - Ryden, Lars
AU  - Ryden L
FAU - Kjellstrom, Barbro
AU  - Kjellstrom B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
OTO - NOTNLM
OT  - Self-rated health
OT  - gender
OT  - quality of life
OT  - rating scale
OT  - survival
OT  - type 2 diabetes
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 1479164113482694 [pii]
AID - 10.1177/1479164113482694 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 May 14.

PMID- 23673376
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 May 14
TI  - The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease
      via effects on atherogenesis, plaque stability and endothelial function in an
      ApoE-/- mouse model.
AB  - Liraglutide, a once-daily glucagon-like peptide-1 receptor (GLP-1R) agonist, has 
      been approved as a new treatment for type 2 diabetes and is the subject of a
      clinical trial programme to evaluate the effects on cardiovascular disease and
      safety. The current study aimed to determine the in vivo effect of liraglutide on
      progression of atherosclerotic vascular disease in the apolipoprotein E-deficient
      (ApoE-/-) mouse model and identify underlying mechanisms responsible. Liraglutide
      treatment inhibited progression of early onset, low-burden atherosclerotic
      disease in a partially GLP-1R-dependent manner in the ApoE-/- mouse model. In
      addition, liraglutide treatment inhibited progression of atherosclerotic plaque
      formation and enhanced plaque stability, again in a partially GLP-1R-dependent
      manner. No significant effect of liraglutide on progression of late onset,
      high-burden atherosclerotic disease was observed. In addition, no significant
      endothelial cell dysfunction was identified in ApoE-/- mice with early onset,
      low-burden atherosclerotic disease, although significant prevention of weight
      gain was observed in liraglutide-treated mice using this dietary protocol. Taken 
      together, these results suggest a potential role for liraglutide in the
      prevention and stabilisation of atherosclerotic vascular disease together with
      possible protection against major cardiovascular events.
AD  - Department of Pharmacology, Monash University, Melbourne, VIC, Australia.
FAU - Gaspari, Tracey
AU  - Gaspari T
FAU - Welungoda, Iresha
AU  - Welungoda I
FAU - Widdop, Robert E
AU  - Widdop RE
FAU - Simpson, Richard W
AU  - Simpson RW
FAU - Dear, Anthony E
AU  - Dear AE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
OTO - NOTNLM
OT  - Incretin
OT  - atherosclerosis
OT  - endothelial dysfunction
OT  - glucagon-like peptide-1
OT  - liraglutide
OT  - plaque stability
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 1479164113481817 [pii]
AID - 10.1177/1479164113481817 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 May 14.

PMID- 23673350
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 May 13
TI  - Predictive power of home blood pressure and clinic blood pressure in hypertensive
      patients with impaired glucose metabolism and diabetes.
AB  - OBJECTIVES:: We evaluated the predictive power of home blood pressure and clinic 
      blood pressure based on the long-term cardiovascular outcome in hypertensive
      patients with and without impaired glucose metabolism (IGM). METHOD:: The
      multicentre Hypertension Objective Treatment Based on Measurement by Electrical
      Devices Blood Pressure trial (HOMED-BP) involved 3080 patients (50.5% women; mean
      age 59.7 years) with a baseline, untreated home/clinic blood pressure as well as 
      follow-up, on-treatment blood pressure. Of those, 979 had IGM and 475 of these
      patients had diabetes. We applied Cox regression pooling all participants in a
      cohort analysis in which IGM and normal glucose metabolism (NGM) were separated. 
      RESULTS:: During median 5.45 years follow-up, cardiovascular events occurred in
      48 patients with IGM and 53 patients with NGM. Baseline home SBP significantly
      predicted cardiovascular outcome among IGM group [hazard ratio 1.68, 95% CI
      1.26-2.26, P = 0.0005]. On-treatment home blood pressure was a significant
      predictor for cardiovascular risk even after the further adjustment of baseline
      blood pressure level (P </= 0.027), whereas on-treatment clinic blood pressure
      was not in NGM group (P >/= 0.37). The event rate in IGM was approximately two
      times higher than that in NGM (9.95 vs. 4.88 per 1000 patient-years), resulted to
      the low 5-year number needed to treat in IGM patients [83 vs. 121 for 1-SD (13.1 
      mmHg) home SBP reduction, and 62 vs. 104 for 1-SD (9.5 mmHg) home DBP reduction).
      CONCLUSION:: The present findings suggest that long-term cardiovascular risk in
      IGM patients should be assessed based on home blood pressure, not on clinic blood
      pressure.
AD  - aDepartment of Endocrinology and Diabetes, School of Medicine, Saitama Medical
      University, Moroyama, Japan bDepartment of Cardiovascular Sciences, Studies
      Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, 
      University of Leuven, Leuven, Belgium cDepartment of Planning for Drug
      Development and Clinical Evaluation, Tohoku University Graduate School of
      Pharmaceutical Sciences, Sendai, Japan dDepartment of Epidemiology, Maastricht
      University, Maastricht, The Netherlands eDepartment of Health Science, Shiga
      University of Medical Science, Otsu fDepartment of Hygiene and Public Health,
      Teikyo University School of Medicine, Tokyo gDivision of Health Sciences, Osaka
      University Graduate School of Medicine, Suita, Japan.
FAU - Noguchi, Yuichi
AU  - Noguchi Y
FAU - Asayama, Kei
AU  - Asayama K
FAU - Staessen, Jan A
AU  - Staessen JA
FAU - Inaba, Munemichi
AU  - Inaba M
FAU - Ohkubo, Takayoshi
AU  - Ohkubo T
FAU - Hosaka, Miki
AU  - Hosaka M
FAU - Satoh, Michihiro
AU  - Satoh M
FAU - Kamide, Kei
AU  - Kamide K
FAU - Awata, Takuya
AU  - Awata T
FAU - Katayama, Shigehiro
AU  - Katayama S
FAU - Imai, Yutaka
AU  - Imai Y
CN  - the HOMED-BP study group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.1097/HJH.0b013e328361732c [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 May 13.

PMID- 23673349
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 May 13
TI  - Use of electronic health records to evaluate the quality of care for hypertensive
      patients in Mexican family medicine clinics.
AB  - OBJECTIVES:: Patients with hypertension require life-long care and should be
      monitored to identify whether they are receiving the appropriate healthcare and
      reach their expected health outcomes. Our objectives were to develop quality of
      healthcare indicators (QCI) and evaluate the quality of care that hypertensive
      patients receive in family medicine clinics at the Mexican Institute of Social
      Security. METHOD:: We used a two-stage mixed methods approach: development of
      QCIs following the RAND-UCLA method; quality of care evaluation using electronic 
      health record (EHR) data from 47 150 hypertensive patients who received care in
      2009. We developed 15 QCIs, which were possible to construct using EHR data. The 
      QCIs evaluated the process of care and health outcomes. RESULTS:: Most
      hypertensive patients were women (64%) more than 60 years old; 79% were
      overweight/obese and 31% had diabetes. On average, these patients attended
      regularly to the family doctor (>/=7 visits a year); however, they received only 
      27% of recommended care. Among the hypertensive patients without comorbidity, 62%
      had achieved blood pressure (BP) control, whereas in the group of hypertensive
      patients with diabetes or chronic kidney disease, only 7% had achieved BP
      control. CONCLUSION:: EHR can become a source of information to evaluate
      routinely quality of care in developing countries that are beginning to modernize
      their health information systems.
AD  - aEpidemiology and Health Services Research Unit CMN Siglo XXI, Mexican Institute 
      of Social Security, Mexico DF bCenter for Evaluation Research and Surveys.
      National Institute of Public Health, Cuernavaca cDivision of Social Protection
      and Health. Inter American Development Bank, Mexico DF, Mexico.
FAU - Doubova, Svetlana V
AU  - Doubova SV
FAU - Lamadrid-Figueroa, Hector
AU  - Lamadrid-Figueroa H
FAU - Perez-Cuevas, Ricardo
AU  - Perez-Cuevas R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.1097/HJH.0b013e3283613090 [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 May 13.

PMID- 23673263
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 2245-1919 (Electronic)
IS  - 2245-1919 (Linking)
VI  - 60
IP  - 5
DP  - 2013 May
TI  - Traditional SCORE-based health check fails to identify individuals who develop
      acute myocardial infarction.
PG  - A4629
AB  - INTRODUCTION: Atherosclerotic cardiovascular disease (CVD), including acute
      myocardial infarction (AMI), is caused by well-known risk factors. They
      constitute important therapeutic targets, but their predictive value is disputed.
      We evaluated the effectiveness of the risk scoring system (SCORE) and thresholds 
      for pharmacotherapy re-commended in the European guidelines on CVD prevention.
      MATERIAL AND METHODS: The medical records of 605 consecutive patients
      hospitalized for a first AMI were reviewed. Patients with pre-existing CVD,
      diabetes, or incomplete information on risk factors were excluded. Those not
      treated with statin before AMI were risk stratified based on risk factors. A
      SCORE >/= 5% or >/= 10% was considered to qualify for preventive medication in
      young adults (age </= 60 years) or elderly (age > 60 years), respectively.
      RESULTS: Before AMI, 40 (9%) used statin. Among non-statin users, only five of
      the 109 young adults had a SCORE >/= 5%, and 23 of the 284 elderly had a SCORE
      >/= 10%. Among women, only three elderly qualified for treatment. More than four 
      times more patients would have qualified for treatment with the high-risk country
      chart used in 2011. The incremental value of the novel high-density lipoprotein
      adjusted SCORE charts was limited. CONCLUSION: Few patients admitted with a first
      AMI used statin. Among non-statin users, SCORE and the recommended thresholds for
      pharmacotherapy identified no women and less than one out of ten men who
      untreated were destined for an AMI before 61 years of age. The preventive
      potential of a traditional risk factor-based health check is limited. FUNDING:
      not relevant. TRIAL REGISTRATION: not relevant.
AD  - Kardiologisk Afdeling, Aarhus Universitetshospital, 8200 Aarhus N, Denmark.
      martin.bodtker.mortensen@ki.au.dk.
FAU - Mortensen, Martin B
AU  - Mortensen MB
FAU - Sivesgaard, Kim
AU  - Sivesgaard K
FAU - Jensen, Helle K
AU  - Jensen HK
FAU - Comuth, Willemijn
AU  - Comuth W
FAU - Kanstrup, Helle
AU  - Kanstrup H
FAU - Gotzsche, Ole
AU  - Gotzsche O
FAU - May, Ole
AU  - May O
FAU - Bertelsen, Jette
AU  - Bertelsen J
FAU - Falk, Erling
AU  - Falk E
LA  - eng
PT  - Journal Article
PL  - Denmark
TA  - Dan Med J
JT  - Danish medical journal
JID - 101576205
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - A4629 [pii]
PST - ppublish
SO  - Dan Med J. 2013 May;60(5):A4629.

PMID- 23673238
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 12
TI  - Glycated albumin and diabetes mellitus.
LID - S0304-4165(13)00206-7 [pii]
LID - 10.1016/j.bbagen.2013.05.010 [doi]
AB  - BACKGROUND: Diabetes is a growing worldwide problem that is strongly associated
      with atherosclerosis. Screening and intervention for diabetes in the earliest
      stages are advocated for the prevention of diabetic complications and
      cardiovascular disease. SCOPE OF REVIEW: This review gives a background of and
      discusses the potential clinical utility of glycated albumin (GA) in diabetes.
      MAJOR CONCLUSIONS: GA is a ketoamine formed via a non-enzymatic glycation
      reaction of serum albumin and it reflects mean glycemia over two to three weeks. 
      GA can be used for patients with anemia or hemoglobinopathies for whom the
      clinically measured hemoglobin A1c level may be inaccurate. Because both serum
      and plasma samples can be used, GA can be analyzed from the same samples as
      common biological markers. GA is a useful marker for the screening of diabetes in
      a medical evaluation. It can be also used to determine the effectiveness of
      treatment before initiating or changing medications for diabetic patients. GA is 
      potentially an atherogenic protein in the development of diabetic
      atherosclerosis. GENERAL SIGNIFICANCE: GA measurement is useful as part of a
      routine examination to screen for both diabetes and atherosclerosis. This article
      is part of a Special Issue entitled Serum Albumin.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of General Internal Medicine, Kyushu University Hospital, Fukuoka,
      Japan. Electronic address: furusyo@gim.med.kyushu-u.ac.jp.
FAU - Furusyo, Norihiro
AU  - Furusyo N
FAU - Hayashi, Jun
AU  - Hayashi J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/03/10 [received]
PHST- 2013/05/02 [revised]
PHST- 2013/05/06 [accepted]
AID - S0304-4165(13)00206-7 [pii]
AID - 10.1016/j.bbagen.2013.05.010 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 12. pii: S0304-4165(13)00206-7. doi:
      10.1016/j.bbagen.2013.05.010.

PMID- 23673207
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130517
DCOM- 20130520
LR  - 20130521
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Retraction: the association between depression, socio-economic factors and
      dietary intake in mothers having primary school children living in Rey, South of 
      Tehran, Iran.
PG  - 21
LID - 10.1186/2251-6581-12-21 [doi]
AD  - School of Public Health & Institute of Public Health Researches, Tehran
      University of Medical Sciences, Tehran, Iran. dorostim@tums.ac.ir.
FAU - Payab, Moloud
AU  - Payab M
FAU - Dorosty Motlagh, Ahmad-Reza
AU  - Dorosty Motlagh AR
FAU - Eshraghian, Mohammadreza
AU  - Eshraghian M
FAU - Rostami, Reza
AU  - Rostami R
FAU - Siassi, Fereydoun
AU  - Siassi F
FAU - Abbasi, Behnood
AU  - Abbasi B
FAU - Ahmadi, Mehrnaz
AU  - Ahmadi M
FAU - Karimi, Tina
AU  - Karimi T
FAU - Mahjouri, Mohammad Yoosef
AU  - Mahjouri MY
FAU - Seifirad, Soroush
AU  - Seifirad S
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3654979
OID - NLM: PMC3654979
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:01
CRDT- 2013/05/16 06:00
PHST- 2013/04/22 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 2251-6581-12-21 [pii]
AID - 10.1186/2251-6581-12-21 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 May 14;12(1):21. doi: 10.1186/2251-6581-12-21.

PMID- 23673161
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130524
DCOM- 20130527
LR  - 20130606
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Mediating factors of coping process in parents of children with type 1 diabetes.
PG  - 20
LID - 10.1186/2251-6581-12-20 [doi]
AB  - BACKGROUND: Type 1 diabetes is a lifelong condition for children and their
      parents, the management for which imposes a vast responsibility. This study
      explores the mediating factors that affect Iranian parents' coping processes with
      their children's type 1 diabetes. METHODS: Research was conducted using the
      grounded theory method. Participants were selected purposefully, and we continued
      with theoretical sampling. Constant comparative analysis was used to analyze the 
      data. RESULTS: The mediating factors of the parental coping process with their
      child's diabetes consist of the child's cooperation, crises and experiences,
      economic challenges, and parental participation in care. CONCLUSION: Findings
      highlight the necessity of well-informed nurses with insightful understanding of 
      the mediating factors in parental coping with juvenile diabetes in order to meet 
      the particular needs of this group.
AD  - School of Nursing and Midwifery, Shahroud University of Medical Sciences,
      Shahroud, Iran. h_ebrahimi43@yahoo.com.
FAU - Oskouie, Fatemeh
AU  - Oskouie F
FAU - Mehrdad, Neda
AU  - Mehrdad N
FAU - Ebrahimi, Hossein
AU  - Ebrahimi H
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3662580
OID - NLM: PMC3662580
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:01
CRDT- 2013/05/16 06:00
PHST- 2013/01/15 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 2251-6581-12-20 [pii]
AID - 10.1186/2251-6581-12-20 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 May 14;12(1):20. doi: 10.1186/2251-6581-12-20.

PMID- 23673159
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 May 14
TI  - Adaptive beta cell proliferation increases early in high fat feeding in mice,
      concurrent with metabolic changes, with induction of islet cyclin D2 expression.
AB  - Type 2 diabetes (T2D) is caused by relative insulin deficiency, due in part to
      reduced beta cell mass (11, 60). Therapies aimed at expanding beta cell mass may 
      be useful to treat T2D (13). Although feeding rodents a high fat diet (HFD) for
      an extended period (3-6 months) increases beta cell mass by inducing beta cell
      proliferation (15, 19, 51, 52), evidence suggests that adult human beta cells may
      not meaningfully proliferate in response to obesity. The timing and identity of
      the earliest initiators of the rodent compensatory growth response, possible
      therapeutic targets to drive proliferation in refractory human beta cells, are
      not known. To develop a system to identify early drivers of beta cell
      proliferation, we studied mice during the first week of HFD exposure, determining
      the onset of proliferation in the context of diet-related physiological changes. 
      Within the first week of HFD mice consumed more kCal, gained weight and fat mass,
      and developed hyperglycemia, hyperinsulinemia and glucose intolerance due to
      impaired insulin secretion. The beta cell proliferative response also began
      within the first week of HFD feeding. Intriguingly, beta cell proliferation
      increased before insulin resistance was detected. Cyclin D2 protein expression
      was increased in islets by day 7, suggesting it may be an early effector driving 
      compensatory beta cell proliferation in mice. This study defines the time frame
      and physiology to identify novel upstream regulatory signals driving mouse beta
      cell mass expansion, in order to explore their efficacy, or reasons for
      inefficacy, in initiating human beta cell proliferation.
AD  - 1University of Pittsburgh.
FAU - Stamateris, Rachel E
AU  - Stamateris RE
FAU - Sharma, Rohit B
AU  - Sharma RB
FAU - Hollern, Douglas A
AU  - Hollern DA
FAU - Alonso, Laura C
AU  - Alonso LC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - diet induced obesity
OT  - islet replication
OT  - overnutrition
OT  - pancreatic beta cell mitosis
OT  - short term hypercaloric diet
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - ajpendo.00040.2013 [pii]
AID - 10.1152/ajpendo.00040.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 May 14.

PMID- 23673156
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 May 14
TI  - High-glucose levels reduce fatty acid oxidation and increase triglyceride
      accumulation in human placenta.
AB  - Aim/hypothesis: Placenta of women with gestational diabetes mellitus (GDM)
      exhibits an altered lipid metabolism. The mechanism by which GDM is linked to
      alterations in placental lipid metabolism remains obscure. We hypothesized that
      high-glucose levels reduce mitochondrial fatty acid oxidation (FAO) and increase 
      triglyceride accumulation in human placenta. Methods: To test this hypothesis, we
      measured FAO, fatty acid esterification, de novo fatty acid synthesis,
      triglyceride levels and carnitine palmitoyltransferase activities (CPT) in
      placental explants of women with GDM or with no pregnancy complication. Results: 
      In women with GDM, FAO was reduced by ~30%, and triglyceride content was 3-fold
      higher than control group. Likewise, in placental explants of women with no
      complication high-glucose levels reduced by ~20% FAO and esterification increased
      linearly with increasing fatty acids concentrations. However, de novo fatty acid 
      synthesis remained unchanged between high-and-low glucose levels. In addition,
      high-glucose levels increased triglycerides content ~2-fold compared to
      low-glucose levels. Furthermore, etomoxir-mediated inhibition of FAO enhanced by 
      ~40% esterification capacity, and elevated by 1.5-fold triglycerides content in
      placental explants of women with no complications. Finally, high-glucose levels
      reduced ~70% CPT-I activity, and ~25% phosphorylation levels of acetyl-CoA
      carboxylase in placental explants of women with no complications. Conclusion: We 
      reveal an unrecognized regulatory mechanism on placental fatty acid metabolism by
      which high-glucose levels reduce mitochondrial FAO through inhibition of CPT-I,
      shifting flux of fatty acids away from oxidation towards the esterification
      pathway, leading to accumulation of placental triglycerides.
AD  - 1University Hospital "Puerta del Mar"
FAU - Visiedo, Francisco
AU  - Visiedo F
FAU - Bugatto, Fernando
AU  - Bugatto F
FAU - Sanchez, Viviana
AU  - Sanchez V
FAU - Cozar-Castellano, Irene
AU  - Cozar-Castellano I
FAU - Bartha, Jose L
AU  - Bartha JL
FAU - Perdomo, German
AU  - Perdomo G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - Carnitine Palmitoyltransferase 1
OT  - fatty acid metabolism
OT  - gestational diabetes
OT  - macrosomy
OT  - placenta
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - ajpendo.00032.2013 [pii]
AID - 10.1152/ajpendo.00032.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 May 14.

PMID- 23673084
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 4
IP  - 3
DP  - 2013 May 14
TI  - Monitoring neurodegeneration in diabetes using adult neural stem cells derived
      from the olfactory bulb.
PG  - 51
AB  - INTRODUCTION: Neurons have the intrinsic capacity to produce insulin, similar to 
      pancreatic cells. Adult neural stem cells (NSCs), which give rise to functional
      neurons, can be established and cultured not only by intracerebral collection,
      which requires difficult surgery, but also by collection from the olfactory bulb 
      (OB), which is relatively easy. Adult neurogenesis in the hippocampus (HPC) is
      significantly decreased in diabetes patients. As a result, learning and memory
      functions, for which the HPC is responsible, decrease. METHODS: In the present
      study, we compared the effect of diabetes on neurogenesis and insulin expression 
      in adult NSCs. Adult NSCs were derived from the HPC or OB of
      streptozotocin-induced diabetic rats. Comparative gene-expression analyses were
      carried out by using extracted tissues and established adult NSC cultures from
      the HPC or OB in diabetic rats. RESULTS: Diabetes progression influenced
      important genes that were required for insulin expression in both OB- and
      HPC-derived cells. Additionally, we found that the expression levels of several
      genes, such as voltage-gated sodium channels, glutamate transporters, and
      glutamate receptors, were significantly different in OB and HPC cells collected
      from diabetic rats. CONCLUSIONS: By using identified diabetes-response genes, OB 
      NSCs from diabetes patients can be used during diabetes progression to monitor
      processes that cause neurodegeneration in the central nervous system (CNS).
      Because hippocampal NSCs and OB NSCs exhibited similar gene-expression profiles
      during diabetes progression, OB NSCs, which are more easily collected and
      established than HPC NSCs, may potentially be used for screening of effective
      drugs for neurodegenerative disorders that cause malignant damage to CNS
      functions.
AD  - Research Center for Stem Cell Engineering, National Institute of Advanced
      Industrial Science and Technology (AIST), Central 4, 1-1-4 Higashi, Tsukuba
      Science City 305-8562, Japan. t.warashina@aist.go.jp.
FAU - Hidaka, Ryo
AU  - Hidaka R
FAU - Machida, Masanao
AU  - Machida M
FAU - Fujimaki, Shin
AU  - Fujimaki S
FAU - Terashima, Kazuyuki
AU  - Terashima K
FAU - Asashima, Makoto
AU  - Asashima M
FAU - Kuwabara, Tomoko
AU  - Kuwabara T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/06/29 [received]
PHST- 2013/01/30 [revised]
PHST- 2013/05/09 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - scrt201 [pii]
AID - 10.1186/scrt201 [doi]
PST - aheadofprint
SO  - Stem Cell Res Ther. 2013 May 14;4(3):51.

PMID- 23672990
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 May 11
TI  - Relation of Elevated Serum Uric Acid Levels to Incidence of Atrial Fibrillation
      in Patients With Type 2 Diabetes Mellitus.
LID - S0002-9149(13)00986-7 [pii]
LID - 10.1016/j.amjcard.2013.04.012 [doi]
AB  - The association between serum uric acid (SUA) levels and atrial fibrillation (AF)
      is currently poorly known. We examined the association between SUA levels and
      risk of incident AF in patients with type 2 diabetes mellitus. We followed for 10
      years a random sample of 400 type 2 diabetic outpatients, who were free from AF
      at baseline. A standard 12-lead electrocardiography was undertaken annually and a
      diagnosis of incident AF was confirmed in affected participants by a single
      cardiologist. Over 10 years, there were 42 incident AF cases (cumulative
      incidence of 10.5%). Elevated SUA level was associated with an increased risk of 
      incident AF (odds ratio 2.43, 95% confidence interval 1.8 to 3.4, p <0.0001 for
      each 1-SD increase in SUA level). Adjustments for age, gender, body mass index,
      hypertension, chronic kidney disease, electrocardiographic features (left
      ventricular hypertrophy and PR interval), and use of diuretics and allopurinol
      did not attenuate the association between SUA and incident AF (adjusted odds
      ratio 2.44, 95% confidence interval 1.6 to 3.9, p <0.0001). Further adjustment
      for variables that were included in the 10-year Framingham Heart Study-derived AF
      risk score did not appreciably weaken this association. Results remained
      unchanged even when SUA was modeled as a categorical variable (stratifying by
      either SUA median or hyperuricemia), and when patients with previous coronary
      heart disease or heart failure were excluded from analysis. In conclusion, our
      findings suggest that elevated SUA levels are strongly associated with an
      increased incidence of AF in patients with type 2 diabetes mellitus even after
      adjustment for multiple clinical risk factors for AF.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Internal Medicine, "Sacro Cuore" Hospital of Negrar, Verona, Italy.
FAU - Valbusa, Filippo
AU  - Valbusa F
FAU - Bertolini, Lorenzo
AU  - Bertolini L
FAU - Bonapace, Stefano
AU  - Bonapace S
FAU - Zenari, Luciano
AU  - Zenari L
FAU - Zoppini, Giacomo
AU  - Zoppini G
FAU - Arcaro, Guido
AU  - Arcaro G
FAU - Byrne, Christopher D
AU  - Byrne CD
FAU - Targher, Giovanni
AU  - Targher G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130511
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/03/13 [received]
PHST- 2013/04/08 [revised]
PHST- 2013/04/08 [accepted]
AID - S0002-9149(13)00986-7 [pii]
AID - 10.1016/j.amjcard.2013.04.012 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 May 11. pii: S0002-9149(13)00986-7. doi:
      10.1016/j.amjcard.2013.04.012.

PMID- 23672987
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 May 11
TI  - Procedural Outcomes of Revascularization of Chronic Total Occlusion of Native
      Coronary Arteries (from a Multicenter United States Registry).
LID - S0002-9149(13)00981-8 [pii]
LID - 10.1016/j.amjcard.2013.04.008 [doi]
AB  - Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is a 
      rapidly evolving area of interventional cardiology. We sought to examine the
      immediate procedural and in-hospital clinical outcomes of native coronary artery 
      CTO PCI from a multicenter United States (US) registry. We retrospectively
      examined the procedural outcomes of 1,361 consecutive native coronary artery CTO 
      PCIs performed at 3 US institutions from January 2006 to November 2011. Mean age 
      was 65 +/- 11 years, 85% of patients were men, 40% had diabetes, 37% had previous
      coronary artery bypass graft surgery, and 42% had previous PCI. The CTO target
      vessel was the right coronary artery (55%), circumflex (23%), left anterior
      descending artery (21%), and left main or bypass graft (1%). The retrograde
      approach was used in 34% of all procedures. The technical and procedural success 
      rates were 85.5% and 84.2%, respectively. The mean procedural time, fluoroscopy
      time, and contrast utilization were 113 +/- 61 minutes, 42 +/- 29 minutes, and
      294 +/- 158 ml, respectively. In multivariate analysis, female gender, no
      previous coronary artery bypass surgery, and years since initiation of CTO PCI at
      each center were independent predictors of procedural success. Major
      complications occurred in 24 patients (1.8%). In conclusion, among selected
      US-based institutions with experienced operators, native coronary artery CTO PCI 
      can be performed with high success and low major complication rates.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - VA North Texas Healthcare System, Dallas, Texas; University of Texas Southwestern
      Medical Center, Dallas, Texas.
FAU - Michael, Tesfaldet T
AU  - Michael TT
FAU - Karmpaliotis, Dimitri
AU  - Karmpaliotis D
FAU - Brilakis, Emmanouil S
AU  - Brilakis ES
FAU - Fuh, Eric
AU  - Fuh E
FAU - Patel, Vishal G
AU  - Patel VG
FAU - Mogabgab, Owen
AU  - Mogabgab O
FAU - Alomar, Mohammed
AU  - Alomar M
FAU - Kirkland, Ben L
AU  - Kirkland BL
FAU - Lembo, Nicholas
AU  - Lembo N
FAU - Kalynych, Anna
AU  - Kalynych A
FAU - Carlson, Harold
AU  - Carlson H
FAU - Banerjee, Subhash
AU  - Banerjee S
FAU - Lombardi, William
AU  - Lombardi W
FAU - Kandzari, David E
AU  - Kandzari DE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130511
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/02/21 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/03 [accepted]
AID - S0002-9149(13)00981-8 [pii]
AID - 10.1016/j.amjcard.2013.04.008 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 May 11. pii: S0002-9149(13)00981-8. doi:
      10.1016/j.amjcard.2013.04.008.

PMID- 23672960
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1873-6750 (Electronic)
IS  - 0160-4120 (Linking)
VI  - 57-58
DP  - 2013 Jul
TI  - Organohalogenated contaminants in domestic cats' plasma in relation to
      spontaneous acromegaly and type 2 diabetes mellitus: A clue for endocrine
      disruption in humans?
PG  - 60-7
LID - 10.1016/j.envint.2013.04.004 [doi]
LID - S0160-4120(13)00084-6 [pii]
AB  - It was recently hypothesized that pets may serve as sentinels to explore human
      exposure to organohalogenated chemicals (OHCs) via indoor environments and
      adverse health effects. The current study investigates OHCs contamination in
      domestic cats suffering from diabetes mellitus (DM), particularly DM induced by
      acromegaly and a form of DM akin to human type 2 DM (T2DM). Plasma from three
      groups of domestic cats was analyzed: acromegaly induced DM, T2DM and age matched
      control cats without DM. Analytes targeted included organochlorine pesticides,
      polychlorinated biphenyls (PCBs), and polybrominated diphenyl ethers (PBDEs),
      together with their hydroxylated (HO-) metabolites. Similar PCB profiles were
      measured in cat plasma compared to humans, while the PBDE profile (dominated by
      BDE-99 (48%-55%) and BDE-47 (19%-25%)), the PCB and PBDE metabolite profiles were
      different in cat plasma than found in humans. Significantly higher OHC
      concentrations were recorded in plasma of acromegalic cats compared to the other 
      two groups. Group differences in the PCBs/HO-PCBs ratios suggest that acromegalic
      cats have a lower capacity to metabolize persistent OHCs, like PCBs, than
      diabetic cats or cats without an endocrinopathy. As pituitary tumorigenesis in
      animals can be induced by estrogens, and PCBs may act as xenoestrogens, further
      investigation into whether there could be a causative link with the induction of 
      feline acromegaly is warranted. Interestingly, BDE-47/BDE-99 ratios in cats were 
      similar to the ratios in house dust. The results of this study suggest that
      domestic cats may represent a good model to assess human exposure to chemicals
      present in indoor dust.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Toxicological Centre, University of Antwerp, Wilrijk, Antwerp, Belgium.
FAU - Dirtu, Alin C
AU  - Dirtu AC
FAU - Niessen, Stijn J M
AU  - Niessen SJ
FAU - Jorens, Philippe G
AU  - Jorens PG
FAU - Covaci, Adrian
AU  - Covaci A
LA  - eng
PT  - Journal Article
DEP - 20130511
PL  - Netherlands
TA  - Environ Int
JT  - Environment international
JID - 7807270
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/02/02 [received]
PHST- 2013/03/30 [revised]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/11 [aheadofprint]
AID - S0160-4120(13)00084-6 [pii]
AID - 10.1016/j.envint.2013.04.004 [doi]
PST - ppublish
SO  - Environ Int. 2013 Jul;57-58:60-7. doi: 10.1016/j.envint.2013.04.004. Epub 2013
      May 11.

PMID- 23672955
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
DP  - 2013 May 14
TI  - Requirement for age-specific peak cortisol responses to insulin-induced
      hypoglycaemia in children.
AB  - OBJECTIVE: Based on adult data, a peak cortisol >/=500 nmol/L to insulin induced 
      hypoglycaemia constitutes a normal response. Age-specific reference ranges for
      basal morning cortisol have been developed for clinical use in the paediatric
      population. Such reference ranges are not clearly established for peak cortisol
      response to insulin-induced hypoglycaemia despite limited data suggesting an
      effect of age on peak cortisol. To assess factors affecting the cortisol response
      to insulin induced hypoglycaemia in children and determine whether peak cortisol 
      was related to age. DESIGN: Retrospective cohort study METHODS: Retrospective
      analysis of Children and adolescents </=18 years undergoing Insulin tolerance
      Test with adequate hypoglycaemia. Patients with hypopituitarism, severe
      hypothalamic-pituitary-adrenal axis impairment (peak cortisol <400 nmol/L) or
      using systemic glucocorticoids were excluded. RESULTS: Two hundred and twenty
      three (223) tests were analysed. Peak cortisol >/=500 nmol/L occurred in 183
      (82%) tests. Age was negatively associated with peak cortisol (r = -0.15, p =
      0.03). Peak cortisol <500nmol/L was significantly less common in patients <12
      years (9/97 (9 %) vs. 31/126 (25 %); p=0.004). In children <12 years the median
      (5th - 95th centiles) peak cortisol values were 610 (480-806) nmol/L compared to 
      574 (442 - 789) nmol/L in children >/=12 years (p < 0.004). Similarly, median
      cortisol increment was significantly higher in younger patients (301 nmol/L
      compared to 226 nmol/L (p = 0.0004)). CONCLUSIONS: Use of a single peak cortisol 
      threshold in children of all ages is not appropriate and will result in
      over-diagnosis of adrenal insufficiency in adolescents.
AD  - M O'Grady, Department of Endocrinology and Diabetes, Our Lady's Childrens
      Hospital, Dublin, Ireland.
FAU - O'Grady, Michael J
AU  - O'Grady MJ
FAU - Hensey, Conor
AU  - Hensey C
FAU - Fallon, Miriam
AU  - Fallon M
FAU - Hoey, Hilary
AU  - Hoey H
FAU - Murphy, Nuala
AU  - Murphy N
FAU - Costigan, Colm
AU  - Costigan C
FAU - Cody, Declan
AU  - Cody D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - EJE-13-0084 [pii]
AID - 10.1530/EJE-13-0084 [doi]
PST - aheadofprint
SO  - Eur J Endocrinol. 2013 May 14.

PMID- 23672733
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Effects of lifestyle education program for type 2 diabetes patients in clinics: a
      cluster randomized controlled trial.
PG  - 467
LID - 10.1186/1471-2458-13-467 [doi]
AB  - BACKGROUND: The prevalence of type 2 diabetes is rising worldwide, as has been
      the global mean fasting plasma glucose level. This study aimed to evaluate the
      effectiveness of a structured individual-based lifestyle education (SILE) program
      to reduce the hemoglobin A1c (HbA1c) level in type 2 diabetes patients delivered 
      by registered dietitians in primary care clinical settings. METHODS: This was a
      6-month prospective cluster randomized controlled trial in a primary care setting
      with randomization at the practice level. Twenty general practitioners in 20
      clinics in Kanagawa prefecture, Japan, were involved. 193 adults (51% men, mean
      age 61.3 years) with type 2 diabetes and HbA1c >/=6.5% who received treatment in 
      medical clinics were the participants. A SILE program was implemented through 4
      sessions with trained registered dietitians during the 6-month study period.
      Results were compared with those of a control group who received usual care. The 
      primary endpoint was the change in HbA1c levels at 6 months from baseline.
      Secondary endpoints were the changes at 6 months from baseline in fasting plasma 
      glucose, lipid profile, blood pressure, BMI, energy, and nutrient intakes (whole 
      day and each meal). Intention-to-treat analysis was conducted. Mixed-effects
      linear models were used to examine the effects of the treatment. RESULTS: The
      mean change at 6 months from baseline in HbA1c was a 0.7% decrease in the
      intervention group (n = 100) and a 0.2% decrease in the control group (n = 93)
      (difference -0.5%, 95%CI: -0.2% to -0.8%, p = 0.004). After adjusting for
      baseline values and other factors, the difference was still significant (p =
      0.003 ~ 0.011). The intervention group had a significantly greater decrease in
      mean energy intake at dinner compared with the control group and a greater
      increase in mean vegetable intake for the whole day, breakfast, and lunch as
      shown in crude and adjusted models. A tendency toward improvement was observed in
      the other secondary endpoints but the improvement was not statistically
      significant. These results were confirmed by several sensitivity analyses.
      CONCLUSIONS: The SILE program that was provided in primary care settings for
      patients with type 2 diabetes resulted in greater improvement in HbA1c levels
      than usual diabetes care and education. TRIAL REGISTRATION: http://UMIN000004049.
AD  - Teikyo University, Graduate School of Public Health, 2-11-1 Kaga, Itabashi-ku,
      Tokyo, 173-8605, Japan. kazue@med.teikyo-u.ac.jp.
FAU - Adachi, Misa
AU  - Adachi M
FAU - Yamaoka, Kazue
AU  - Yamaoka K
FAU - Watanabe, Mariko
AU  - Watanabe M
FAU - Nishikawa, Masako
AU  - Nishikawa M
FAU - Kobayashi, Itsuro
AU  - Kobayashi I
FAU - Hida, Eisuke
AU  - Hida E
FAU - Tango, Toshiro
AU  - Tango T
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3658890
OID - NLM: PMC3658890
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/06/15 [received]
PHST- 2013/05/06 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 1471-2458-13-467 [pii]
AID - 10.1186/1471-2458-13-467 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 14;13:467. doi: 10.1186/1471-2458-13-467.

PMID- 23672639
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1742-2094 (Electronic)
IS  - 1742-2094 (Linking)
VI  - 10
IP  - 1
DP  - 2013 May 14
TI  - Neurogenic factor-induced Langerhans cell activation in diabetic mice with
      mechanical allodynia.
PG  - 64
AB  - BACKGROUND: Langerhans cells (LCs) are antigen-presenting dendritic cells located
      in the skin. It has been reported that LC activation is associated with painful
      diabetic neuropathy (PDN); however, the mechanism of LC activation is still
      unclear. METHODS: The db/db mouse, a rodent model of PDN, was used to study the
      roles of LCs in the development of PDN in type 2 diabetes. Hind foot pads from
      db/db and control db/+ mice from 5 to 24 weeks of age (encompassing the period of
      mechanical allodynia development and its abatement) were collected and processed 
      for immunohistochemistry studies. LCs were identified with immunohistochemistry
      using an antibody against CD207 (Langerin). The intraepidermal nerve fibers and
      subepidermal nerve plexus were identified by immunohistochemistry of protein gene
      product 9.5 (PGP 9.5) and tropomyosin-receptor kinase (Trk) A, the high affinity 
      nerve growth factor receptor. RESULTS: CD207-positive LCs increased in the db/db 
      mouse during the period of mechanical allodynia, from 8 to 10 weeks of age, in
      both the epidermis and subepidermal plexus. At 16 weeks of age, when mechanical
      allodynia diminishes, LC populations were reduced in the epidermis and
      subepidermal plexus. Epidermal LCs (ELCs) were positive for Trk A. Subepidermal
      LCs (SLCs) were positive for CD68, suggesting that they are immature LCs.
      Additionally, these SLCs were positive for the receptor of advanced glycation end
      products (RAGE) and were in direct contact with TNF-alpha-positive nerve fibers
      in the subepidermal nerve plexus during the period of mechanical allodynia.
      Intrathecal administration of SB203580, a p38 kinase inhibitor, significantly
      reduced mechanical allodynia, TNF-alpha expression in the subepidermal plexus,
      and increased both ELC and SLC populations during the period of mechanical
      allodynia. CONCLUSIONS: Our data support the hypothesis that increased LC
      populations in PDN are activated by p38-dependent neurogenic factors and may be
      involved in the pathogenesis of PDN.
FAU - Dauch, Jacqueline R
AU  - Dauch JR
FAU - Bender, Diane E
AU  - Bender DE
FAU - Luna-Wong, Lucia A
AU  - Luna-Wong LA
FAU - Hsieh, Wilson
AU  - Hsieh W
FAU - Yanik, Brandon M
AU  - Yanik BM
FAU - Kelly, Zachary A
AU  - Kelly ZA
FAU - Cheng, Hsinlin T
AU  - Cheng HT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - J Neuroinflammation
JT  - Journal of neuroinflammation
JID - 101222974
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/02/12 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 1742-2094-10-64 [pii]
AID - 10.1186/1742-2094-10-64 [doi]
PST - aheadofprint
SO  - J Neuroinflammation. 2013 May 14;10(1):64.

PMID- 23672632
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
DP  - 2013 Jun 4
TI  - Efficacy and safety of linagliptin added to metformin and sulphonylurea in
      Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised
      clinical trial.
AB  - Abstract Objectives: To evaluate the efficacy and safety of linagliptin in
      Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled by 
      metformin and sulphonylurea. Research design and methods: Data for a pre-defined 
      Chinese subgroup who participated in a Phase III randomised, placebo-controlled, 
      24 week trial (NCT00602472) were analysed. The primary endpoint was change in
      HbA1c from baseline to 24 weeks. Apart from safety endpoints, secondary endpoints
      included changes in FPG and measures of insulin secretion and resistance.
      Results: A total of 192 Chinese patients with T2DM participated in the
      pre-defined analysis; 144 and 48 patients received linagliptin or placebo,
      respectively, added to metformin and sulphonylurea. Baseline characteristics
      (mean [+/-SD]) for linagliptin and placebo were similar: HbA1c: 8.1% (+/-0.85)
      and 8.1% (+/-0.84); body mass index: 25.9 (+/-3.2) and 25.6 (+/-3.4) kg/m2,
      respectively. Placebo-corrected mean (+/-SE) change in HbA1c from baseline at 24 
      weeks was -0.68% (0.14) with linagliptin-based treatment (95% CI: -0.96 to -0.39;
      P < 0.0001). Placebo-corrected mean (+/-SE) change in FPG from baseline at 24
      weeks with linagliptin was -18.8 (6.5) mg/dL (-1.0 [0.4] mmol/L; 95% CI: -31.7 to
      -5.9; P = 0.0044). Overall adverse event (AE) rates with linagliptin and placebo 
      including background medication were similar (38.9% and 43.8%, respectively).
      Drug-related AEs were reported by 12.5% and 2.1% of linagliptin and placebo
      patients, respectively. Differences were due to hypoglycaemia (10.4% and 0.0%,
      respectively). No severe hypoglycaemia was reported in either group of this
      sub-population. Conclusion: Linagliptin in combination with metformin and
      sulphonylurea has a favourable safety profile and is an efficacious and well
      tolerated treatment option for Chinese patients with inadequately controlled
      T2DM. Reduction of sulphonylurea dose should be considered to minimise risk of
      hypoglycaemia. Although the findings of this pre-specified sub-analysis may be
      limited by the number of patients in the subgroup, the results were generally
      consistent with those for the overall population. ClinicalTrials identifier:
      NCT00602472.
AD  - Peking Union Medical College Hospital , Beijing , China.
FAU - Zeng, Zhengpei
AU  - Zeng Z
FAU - Yang, Jin-Kui
AU  - Yang JK
FAU - Tong, Nanwei
AU  - Tong N
FAU - Yan, Shengli
AU  - Yan S
FAU - Zhang, Xiling
AU  - Zhang X
FAU - Gong, Yan
AU  - Gong Y
FAU - Woerle, Hans-Juergen
AU  - Woerle HJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130604
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.1185/03007995.2013.805123 [doi]
PST - aheadofprint
SO  - Curr Med Res Opin. 2013 Jun 4.

PMID- 23672628
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1741-7015 (Electronic)
IS  - 1741-7015 (Linking)
VI  - 11
DP  - 2013
TI  - Understanding the somatic consequences of depression: biological mechanisms and
      the role of depression symptom profile.
PG  - 129
LID - 10.1186/1741-7015-11-129 [doi]
AB  - Depression is the most common psychiatric disorder worldwide. The burden of
      disease for depression goes beyond functioning and quality of life and extends to
      somatic health. Depression has been shown to subsequently increase the risk of,
      for example, cardiovascular, stroke, diabetes and obesity morbidity. These
      somatic consequences could partly be due to metabolic, immuno-inflammatory,
      autonomic and hypothalamic-pituitary-adrenal (HPA)-axis dysregulations which have
      been suggested to be more often present among depressed patients. Evidence
      linking depression to metabolic syndrome abnormalities indicates that depression 
      is especially associated with its obesity-related components (for example,
      abdominal obesity and dyslipidemia). In addition, systemic inflammation and
      hyperactivity of the HPA-axis have been consistently observed among depressed
      patients. Slightly less consistent observations are for autonomic dysregulation
      among depressed patients. The heterogeneity of the depression concept seems to
      play a differentiating role: metabolic syndrome and inflammation up-regulations
      appear more specific to the atypical depression subtype, whereas
      hypercortisolemia appears more specific for melancholic depression. This review
      finishes with potential treatment implications for the downward spiral in which
      different depressive symptom profiles and biological dysregulations may impact on
      each other and interact with somatic health decline.
AD  - Department of Psychiatry, EMGO+ Institute and Neuroscience Campus Amsterdam, VU
      University Medical Center, Amsterdam, The Netherlands. b.penninx@vumc.nl.
FAU - Penninx, Brenda Wjh
AU  - Penninx BW
FAU - Milaneschi, Yuri
AU  - Milaneschi Y
FAU - Lamers, Femke
AU  - Lamers F
FAU - Vogelzangs, Nicole
AU  - Vogelzangs N
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - England
TA  - BMC Med
JT  - BMC medicine
JID - 101190723
SB  - IM
PMC - PMC3661358
OID - NLM: PMC3661358
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/11/14 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/05/15 [aheadofprint]
AID - 1741-7015-11-129 [pii]
AID - 10.1186/1741-7015-11-129 [doi]
PST - epublish
SO  - BMC Med. 2013 May 15;11:129. doi: 10.1186/1741-7015-11-129.

PMID- 23672623
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 18
TI  - Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi
      effect-more fiction than fact?
LID - 10.1111/dme.12175 [doi]
AB  - AIMS: The Somogyi effect postulates that nocturnal hypoglycaemia causes fasting
      hyperglycaemia attributable to counter-regulatory hormone release. Although most 
      published evidence has failed to support this hypothesis, this concept remains
      firmly embedded in clinical practice and often prevents patients and
      professionals from optimizing overnight insulin. Previous observational data
      found lower fasting glucose was associated with nocturnal hypoglycaemia, but did 
      not assess the probability of infrequent individual episodes of rebound
      hypoglycaemia. We analysed continuous glucose monitoring data to explore its
      prevalence. METHODS: We analysed data from 89 patients with Type 1 diabetes who
      participated in the UK Hypoglycaemia study. We compared fasting capillary glucose
      following nights with and without nocturnal hypoglycaemia (sensor glucose < 3.5
      mmol/l). RESULTS: Fasting capillary blood glucose was lower after nights with
      hypoglycaemia than without [5.5 (3.0) vs. 14.5 (4.5) mmol/l, P < 0.0001], and was
      lower on nights with more severe nocturnal hypoglycaemia [5.5 (3.0) vs. 8.2 (2.3)
      mmol/l; P = 0.018 on nights with nadir sensor glucose of < 2.2 mmol/l vs. 3.5
      mmol/l]. There were only two instances of fasting capillary blood glucose > 10
      mmol/l after nocturnal hypoglycaemia, both after likely treatment of the episode.
      When fasting capillary blood glucose is < 5 mmol/l, there was evidence of
      nocturnal hypoglycaemia on 94% of nights. CONCLUSION: Our data indicate that, in 
      clinical practice, the Somogyi effect is rare. Fasting capillary blood glucose
      </= 5 mmol/l appears an important indicator of preceding silent nocturnal
      hypoglycaemia.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield,
      Sheffield, UK.
FAU - Choudhary, P
AU  - Choudhary P
FAU - Davies, C
AU  - Davies C
FAU - Emery, C J
AU  - Emery CJ
FAU - Heller, S R
AU  - Heller SR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130318
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/09/13 [received]
PHST- 2013/01/09 [revised]
PHST- 2013/03/13 [accepted]
AID - 10.1111/dme.12175 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 18. doi: 10.1111/dme.12175.

PMID- 23672597
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 14
TI  - Chinese herbal medicine for impaired glucose tolerance: a randomized placebo
      controlled trial.
PG  - 104
AB  - BACKGROUND: Diabetes remains a major health problem worldwide. Low-risk low-cost 
      alternatives to pharmaceutical interventions are needed where lifestyle
      modifications have failed. We conducted a double-blind randomised placebo
      controlled trial to investigate the efficacy of a Chinese herbal formula,
      Jiangtang Xiaozhi, in treating impaired glucose control and insulin resistance in
      persons with prediabetes and controlled diabetes. METHODS: Seventy-one patients
      with prediabetes or 'controlled' diabetes were randomised to receive 3 capsules
      of Jiangtang Xiaozhi (n = 39) or placebo (n = 32) three times daily for 16 weeks 
      with a follow up eight weeks later (week 24). The primary outcome was change in
      glycaemic control as evidenced by fasting blood glucose (FBG), post-prandial
      plasma glucose and glycosylated haemoglobin (HbA1c). Other measures included
      change in fasting insulin, insulin resistance and sensitivity, lipids, C-reactive
      protein (CRP), body mass index (BMI), waist girth, blood pressure (BP), health
      related quality of life (HRQoL) and safety. Analysis of covariance (ANCOVA) was
      used to model outcomes at 16 weeks, by treatment group corrected for baseline
      level of the outcome variable. RESULTS: In patients receiving Jiangtang Xiaozhi, 
      FBG was not significantly different (p =0.73) compared to placebo after 16 weeks 
      of treatment (6.3 +/- 1.1 mmol/L vs 6.7 +/- 1.3 mmol/L). There was a significant 
      difference (p = 0.04) in the mean levels of fasting insulin between the treatment
      group (11.6 +/- 5.5 mmol/L) and the placebo group (22.1 +/- 25.9 mmol/L). Insulin
      resistance slightly decreased in the treatment group (1.58 +/- 0.74) compared to 
      that of the placebo group (2.43 +/- 1.59) but this change did not reach
      statistical significance (p = 0.06). Patients taking Jiangtang Xiaozhi had a
      significant improvement in high-density lipoprotein (HDL) level compared to the
      placebo group at week 16 (p = 0.03). Mean levels of cholesterol, triglycerides,
      BMI, waist-girth, HRQoL, BP, CRP and insulin sensitivity were not significantly
      different between the two groups. The herbal medicine was well tolerated.
      CONCLUSIONS: In the current study, the 16 week Jiangtang Xiaozhi treatment did
      not lower fasting blood glucose, but it improved serum insulin and HDL
      cholesterol in a Western population with prediabetes or controlled diabetes. Our 
      trial may have been underpowered. Dosage needs to be considered before commencing
      a longer adequately powered trial.Trial registration: Australian New Zealand
      Clinical Trials Registry ACTRN12612000128897;
      https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=362005.
FAU - Grant, Suzanne J
AU  - Grant SJ
FAU - Chang, Dennis Hsu-Tung
AU  - Chang DH
FAU - Liu, Jianxun
AU  - Liu J
FAU - Wong, Vincent
AU  - Wong V
FAU - Kiat, Hosen
AU  - Kiat H
FAU - Bensoussan, Alan
AU  - Bensoussan A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
PMC - PMC3659077
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/06/16 [received]
PHST- 2013/05/14 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 1472-6882-13-104 [pii]
AID - 10.1186/1472-6882-13-104 [doi]
PST - aheadofprint
SO  - BMC Complement Altern Med. 2013 May 14;13(1):104.

PMID- 23672564
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 61
IP  - 5
DP  - 2013 May
TI  - Alzheimer's disease: how far have we progressed? Lessons learned from diabetes
      mellitus, metabolic syndrome, and inflammation.
PG  - 845-6
LID - 10.1111/jgs.12242 [doi]
AD  - Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and
      Geriatric Sciences, Sapienza University of Rome, Rome, Italy.
FAU - Viscogliosi, Giovanni
AU  - Viscogliosi G
FAU - Marigliano, Vincenzo
AU  - Marigliano V
LA  - eng
PT  - Letter
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.1111/jgs.12242 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2013 May;61(5):845-6. doi: 10.1111/jgs.12242.

PMID- 23672561
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 61
IP  - 5
DP  - 2013 May
TI  - The real research question about diabetes mellitus in older adults.
PG  - 843
LID - 10.1111/jgs.12238 [doi]
AD  - Johns Hopkins Bayview Medical Center, Baltimore, MD.
FAU - Finucane, Thomas E
AU  - Finucane TE
LA  - eng
PT  - Letter
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.1111/jgs.12238 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2013 May;61(5):843. doi: 10.1111/jgs.12238.

PMID- 23672556
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 61
IP  - 5
DP  - 2013 May
TI  - Gas-forming pyogenic liver abscess in an elderly adult with diabetes mellitus.
PG  - 837-8
LID - 10.1111/jgs.12235 [doi]
AD  - Department of Emergency Medicine, Far Eastern Memorial Hospital, New Taipei City,
      Taiwan.
FAU - Ho, Min-Po
AU  - Ho MP
FAU - Chou, An-Hsun
AU  - Chou AH
FAU - Cheung, Wing-Keung
AU  - Cheung WK
LA  - eng
PT  - Letter
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.1111/jgs.12235 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2013 May;61(5):837-8. doi: 10.1111/jgs.12235.

PMID- 23672502
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Linking)
DP  - 2013 May 15
TI  - Mechanobiological dysregulation of the epidermis and dermis in skin disorders and
      in degeneration.
LID - 10.1111/jcmm.12060 [doi]
AB  - During growth and development, the skin expands to cover the growing skeleton and
      soft tissues by constantly responding to the intrinsic forces of underlying
      skeletal growth as well as to the extrinsic mechanical forces from body movements
      and external supports. Mechanical forces can be perceived by two types of skin
      receptors: (1) cellular mechanoreceptors/mechanosensors, such as the
      cytoskeleton, cell adhesion molecules and mechanosensitive (MS) ion channels, and
      (2) sensory nerve fibres that produce the somatic sensation of mechanical force. 
      Skin disorders in which there is an abnormality of collagen [e.g. Ehlers-Danlos
      syndrome (EDS)] or elastic (e.g. cutis laxa) fibres or a malfunction of cutaneous
      nerve fibres (e.g. neurofibroma, leprosy and diabetes mellitus) are also
      characterized to some extent by deficiencies in mechanobiological processes.
      Recent studies have shown that mechanotransduction is crucial for skin
      development, especially hemidesmosome maturation, which implies that the
      pathogenesis of skin disorders such as bullous pemphigoid is related to skin
      mechanobiology. Similarly, autoimmune diseases, including scleroderma and mixed
      connective tissue disease, and pathological scarring in the form of keloids and
      hypertrophic scars would seem to be clearly associated with the mechanobiological
      dysfunction of the skin. Finally, skin ageing can also be considered as a
      degenerative process associated with mechanobiological dysfunction. Clinically, a
      therapeutic strategy involving mechanoreceptors or MS nociceptor inhibition or
      acceleration together with a reduction or augmentation in the relevant mechanical
      forces is likely to be successful. The development of novel approaches such as
      these will allow the treatment of a broad range of cutaneous diseases.
CI  - (c) 2013 The Authors. Published by Foundation for Cellular and Molecular
      Medicine/Blackwell Publishing Ltd.
AD  - Department of Plastic, Reconstructive and Aesthetic Surgery, Nippon Medical
      School, Tokyo, Japan.
FAU - Ogawa, Rei
AU  - Ogawa R
FAU - Hsu, Chao-Kai
AU  - Hsu CK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2012/09/29 [received]
PHST- 2013/03/01 [accepted]
AID - 10.1111/jcmm.12060 [doi]
PST - aheadofprint
SO  - J Cell Mol Med. 2013 May 15. doi: 10.1111/jcmm.12060.

PMID- 23672413
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 14
DP  - 2013
TI  - Model-driven diabetes care: study protocol for a randomized controlled trial.
PG  - 139
LID - 10.1186/1745-6215-14-139 [doi]
AB  - BACKGROUND: People with type 1 diabetes who use electronic self-help tools
      register a large amount of information about their disease on their participating
      devices; however, this information is rarely utilized beyond the immediate
      investigation. We have developed a diabetes diary for mobile phones and a
      statistics-based feedback module, which we have named Diastat, to give
      data-driven feedback to the patient based on their own data. METHOD: In this
      study, up to 40 participants will be given a smartphone on which is loaded a
      diabetes self-help application (app), the Few Touch Application (FTA).
      Participants will be randomized into two groups to be given access to Diastat 4
      or 12 weeks, respectively after receiving the smartphone, and will use the FTA
      with Diastat for 8 weeks after this point. The primary endpoint is the frequency 
      of high and low blood-glucose measurements. DISCUSSION: The study will
      investigate the effect of data-driven feedback to patients. Our hypothesis is
      that this will improve glycemic control and reduce variability. The endpoints are
      robust indicators that can be assembled with minimal effort by the patient beyond
      normal routine. TRIAL REGISTRATION: Clinicaltrials.gov: NCT01774149.
AD  - Norwegian Centre for Integrated Care and Telemedicine, University Hospital of
      North Norway, Tromso, 9038, Norway. stein.olav.skrovseth@telemed.no.
FAU - Skrovseth, Stein Olav
AU  - Skrovseth SO
FAU - Arsand, Eirik
AU  - Arsand E
FAU - Godtliebsen, Fred
AU  - Godtliebsen F
FAU - Joakimsen, Ragnar M
AU  - Joakimsen RM
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
PMC - PMC3655925
OID - NLM: PMC3655925
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/02/15 [received]
PHST- 2013/04/26 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 1745-6215-14-139 [pii]
AID - 10.1186/1745-6215-14-139 [doi]
PST - epublish
SO  - Trials. 2013 May 14;14:139. doi: 10.1186/1745-6215-14-139.

PMID- 23672265
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1521-0758 (Electronic)
IS  - 0191-3123 (Linking)
DP  - 2013 May 14
TI  - Albumin Stabilizes Fibrin Fiber Ultrastructure in Low Serum Albumin Type 2
      Diabetes.
AB  - Abstract Serum albumin is an essential plasma protein that serves an important
      function in maintaining osmotic pressure. Low levels of this protein are
      associated with the kidney failure and hemodialysis that are often seen in
      diabetic patients who are at high risk of thrombotic events. In diabetes, fibrin 
      fiber nets are changed to form dense matted deposits (DMDs, or parafibrin). Here 
      the authors investigate whether parafibrin is also present in diagnosed
      low-albumin diabetes patients and whether the addition of human albumin to plasma
      from low-albumin diabetes type 2 individuals may change the architecture of the
      fibrin nets. The authors show that the addition of albumin to plasma of
      low-albumin diabetes patients progressively caused the DMDs typically found in
      these patients to revert back to ultrastructure typically seen in healthy
      individuals. This disease has an extremely complicated pathophysiology and thus
      cannot be considered as a simple condition. This study shows that serum albumin
      levels may play an important role in the structure of fibrin fibrils, making them
      more susceptible to the fibrinolytic degradation and elimination from the
      circulation.
AD  - Department of Physiology, Faculty of Health Sciences, University of Pretoria ,
      Pretoria , South Africa and.
FAU - Pretorius, Etheresia
AU  - Pretorius E
FAU - Lipinski, Boguslaw
AU  - Lipinski B
FAU - Bester, Janette
AU  - Bester J
FAU - Vermeulen, Natasha
AU  - Vermeulen N
FAU - Soma, Prashilla
AU  - Soma P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Ultrastruct Pathol
JT  - Ultrastructural pathology
JID - 8002867
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.3109/01913123.2013.778929 [doi]
PST - aheadofprint
SO  - Ultrastruct Pathol. 2013 May 14.

PMID- 23672237
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1742-481X (Electronic)
IS  - 1742-4801 (Linking)
DP  - 2013 May 15
TI  - Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular
      disease.
LID - 10.1111/iwj.12085 [doi]
AB  - Diabetic patients are at the high risk of foot ulcerations that may lead to limb 
      amputations with important socio economic impact. Peripheral vascular disease may
      be frequently associated in diabetes mellitus type II with its main symptom,
      intermittent claudication. Many studies reported the known efficacy of cilostazol
      in treating vascular claudication. Metalloproteinase-9 (MMP-9) seems to be a
      biochemical marker implicated in chronic wounds and in particular in diabetic
      foot ulcers. Cilostazol seems to have also a lowering effect on levels of MMP-9
      and this may suggest a beneficial effect in order to prevent or retard the onset 
      of foot ulcer in diabetic patients. In our study two groups of diabetic patients,
      with peripheral vascular disease were divided into two groups according to the
      presence of claudication in order to receive cilostazol. Group A (31 patients
      without claudication) were not eligible to receive cilostazol whereas Group B (47
      patients with claudication) received cilostazol administration for 24 weeks (100 
      mg orally twice daily). Median follow up was of 16 months. During the follow up
      4.25% of patients of Group B and 35.48% of patients of Group A (P < 0.01) showed 
      the onset of foot ulceration. Although further randomised and controlled studies 
      are required cilostazol seems to show beneficial effects for primary prevention
      of diabetic foot ulcers.
CI  - (c) 2013 The Authors. International Wound Journal (c) 2013 John Wiley & Sons Ltd 
      and Medicalhelplines.com Inc.
AD  - Department of Medical and Surgical Science, University Magna Graecia of
      Catanzaro, Catanzaro, Italy; Interuniversity Center of Phlebolymphology,
      International Research and Educational Program in Clinical and Experimental
      Biotechnology, University Magna Gracia of Catanzaro, Catanzaro, Italy.
FAU - de Franciscis, Stefano
AU  - de Franciscis S
FAU - Gallelli, Luca
AU  - Gallelli L
FAU - Battaglia, Luigi
AU  - Battaglia L
FAU - Molinari, Vincenzo
AU  - Molinari V
FAU - Montemurro, Rossella
AU  - Montemurro R
FAU - Stillitano, Domenico M
AU  - Stillitano DM
FAU - Buffone, Gianluca
AU  - Buffone G
FAU - Serra, Raffaele
AU  - Serra R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - Int Wound J
JT  - International wound journal
JID - 101230907
EDAT- 2013/05/16 06:00
MHDA- 2013/05/16 06:00
CRDT- 2013/05/16 06:00
AID - 10.1111/iwj.12085 [doi]
PST - aheadofprint
SO  - Int Wound J. 2013 May 15. doi: 10.1111/iwj.12085.

PMID- 23671888
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Hypermethylation of the PRKCZ Gene in Type 2 Diabetes Mellitus.
PG  - 721493
LID - 10.1155/2013/721493 [doi]
AB  - Objectives. To study the correlation between the methylation of protein kinase C 
      epsilon zeta (PRKCZ) gene promoters and type 2 diabetes mellitus (T2DM). Methods.
      The case-control method was implemented in 272 unrelated to one another cases in 
      Shiyan People's Hospital. Of those, 152 were diagnosed as T2DM cases, and the
      other 120 cases were healthy individuals visiting the hospital for a physical
      examination. The subjects were first divided into two groups: the T2DM group and 
      the normal control (NC) group. Next, methylated DNA immunoprecipitation chip
      (MeDIP-chip) was used for detection. Bisulfite sequencing PCR (BSP) and gene
      sequencing were then performed to detect and analyze the correlation between
      PRKCZ gene promoter methylation and T2DM. Finally, Western blotting was applied
      to determine the serum level of PRKCZ. The data were then analyzed with the
      statistics analyzing software SPSS 17.0. Results. In contrast with cases in NC,
      T2DM patients showed a high level of methylation, with 7 of 9 CpG sites were
      shown to be methylated, whereas, in the control group, only one CpG site was
      found to be methylated. The methylated CpG sites for the two groups showed marked
      differences (P < 0.01). Additionally, the level of PRKCZ was decreased in T2DM
      subjects, and the difference between the two groups was statistically significant
      (P < 0.05). Discussion. This study suggests that the PRKCZ gene is the
      hypermethylated gene of T2DM and the hypermethylation PRKCZ gene may be involved 
      in the pathogenesis of T2DM.
AD  - Clinical Laboratory of Renmin Hospital, The Third Affiliated Hospital of Hubei
      University of Medicine, 39 Chaoyang Road, Shiyan, Hubei Province 442000, China.
FAU - Zou, Li
AU  - Zou L
FAU - Yan, Shirong
AU  - Yan S
FAU - Guan, Xueping
AU  - Guan X
FAU - Pan, Yunjun
AU  - Pan Y
FAU - Qu, Xin
AU  - Qu X
LA  - eng
PT  - Journal Article
DEP - 20130316
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647574
OID - NLM: PMC3647574
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/11/07 [received]
PHST- 2013/02/21 [accepted]
PHST- 2013/03/16 [epublish]
AID - 10.1155/2013/721493 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:721493. doi: 10.1155/2013/721493. Epub 2013 Mar 16.

PMID- 23671887
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Reduction of methylglyoxal-induced glycation by pyridoxamine improves adipose
      tissue microvascular lesions.
PG  - 690650
LID - 10.1155/2013/690650 [doi]
AB  - Background and Aims. Adipose tissue dysfunction results from many factors,
      including glycation-induced microvascular damages. We tested the usefulness of
      inhibiting methylglyoxal-induced glycation to adipose tissue microvasculature in 
      this work, using the antioxidant and dicarbonyl scavenger drug pyridoxamine.
      Methods. A group of Wistar rats was treated daily with methylglyoxal (MG, 75
      mg/Kg/day, 8 weeks). Half of this group was treated with pyridoxamine in the
      following 4 weeks (Pyr) (100 mg/Kg/day) and the other half did not have any
      further treatment (MG). A group of Wistar rats without MG treatment was used as
      control (C). Results. MG group showed decreased HDL cholesterol and increased
      plasma free fatty acids levels, what was reverted by pyridoxamine. MG also caused
      an increase of tissue CEL levels (glycation marker), as well as increased
      staining of PAS and Masson Trichrome-positive components. Pyridoxamine led to CEL
      and TGF- beta levels similar to those observed in control rats and inhibited the 
      accumulation of PAS and Masson Trichrome-positive components. MG caused a
      decrease of Bcl-2/Bax ratio (marker of apoptosis) and vWF staining (microvascular
      marker), what was partially reverted by the treatment with pyridoxamine.
      Conclusions. Preventing methylglyoxal-induced accumulation of glycated and
      fibrotic materials using pyridoxamine improves the microvascular lesions of the
      adipose tissue.
AD  - Laboratory of Physiology, Institute of Biomedical Research on Light and Image
      (IBILI), Faculty of Medicine, University of Coimbra, 3000-354 Coimbra, Portugal.
FAU - Rodrigues, Tiago
AU  - Rodrigues T
FAU - Matafome, Paulo
AU  - Matafome P
FAU - Santos-Silva, Daniela
AU  - Santos-Silva D
FAU - Sena, Cristina
AU  - Sena C
FAU - Seica, Raquel
AU  - Seica R
LA  - eng
PT  - Journal Article
DEP - 20130407
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647595
OID - NLM: PMC3647595
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/14 [received]
PHST- 2013/02/26 [revised]
PHST- 2013/03/01 [accepted]
PHST- 2013/04/07 [epublish]
AID - 10.1155/2013/690650 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:690650. doi: 10.1155/2013/690650. Epub 2013 Apr 7.

PMID- 23671886
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - The ERK1/2 Inhibitor U0126 Attenuates Diabetes-Induced Upregulation of MMP-9 and 
      Biomarkers of Inflammation in the Retina.
PG  - 658548
LID - 10.1155/2013/658548 [doi]
AB  - This study was conducted to determine the expression of matrix
      metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) 
      in a time-dependent manner and the effect of extracellular-signal-regulated
      kinases-1/2 (ERK1/2) inhibition on the expressions of MMP-9, TIMP-1, and
      inflammatory biomarkers in the retinas of diabetic rats. The expression of MMP-9 
      was quantified by zymography, and the mRNA level of MMP-9 and TIMP-1 was
      quantified by RT-PCR. The expression of inducible nitric oxide synthase (iNOS),
      interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF- alpha ) was examined 
      by Western blot analysis. MMP-9 expression was significantly higher in diabetic
      rat retinas compared to controls at all time points.TIMP-1 expression was
      nonsignificantly upregulated at 1week of diabetes and was significantly
      downregulated at 4 and 12 weeks of diabetes. Intravitreal administration of the
      ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2
      activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and
      TNF- alpha and upregulated TIMP-1 expression. In MMP-9 knockout mice, diabetes
      had no effect on retinal iNOS expression and its level remained unchanged. These 
      data provide evidence that ERK1/2 signaling pathway is involved in MMP-9, iNOS,
      IL-6, and TNF- alpha induction in diabetic retinas and suggest that ERK1/2 can be
      a novel therapeutic target in diabetic retinopathy.
AD  - Department of Ophthalmology, College of Medicine, King Saud University, P.O. Box 
      245, Riyadh 11411, Saudi Arabia.
FAU - Mohammad, Ghulam
AU  - Mohammad G
FAU - Mairaj Siddiquei, Mohammad
AU  - Mairaj Siddiquei M
FAU - Imtiaz Nawaz, Mohammad
AU  - Imtiaz Nawaz M
FAU - Abu El-Asrar, Ahmed M
AU  - Abu El-Asrar AM
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647581
OID - NLM: PMC3647581
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/21 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/10 [epublish]
AID - 10.1155/2013/658548 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:658548. doi: 10.1155/2013/658548. Epub 2013 Apr 10.

PMID- 23671885
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Skin autofluorescence relates to soluble receptor for advanced glycation
      end-products and albuminuria in diabetes mellitus.
PG  - 650694
LID - 10.1155/2013/650694 [doi]
AB  - The aim of this study was to compare skin autofluorescence caused by advanced
      glycation end-products (AGEs) with biochemical markers of endothelial dysfunction
      and soluble receptor for AGEs (sRAGE) in patients with diabetes. Skin
      autofluorescence (AF) assessed by AGE-Reader was evaluated with sRAGE and other
      biochemical parameters in 88 patients with diabetes (47 Type 1/T1DM/ and 41 Type 
      2/T2DM/) and 20 controls. Skin AF was significantly higher in T1DM and T2DM in
      comparison to controls (2.39 +/- 0.54, 2.63 +/- 0.73 versus 1.96 +/- 0.33 AU; P <
      0.0001). Positive correlation of AF with sRAGE was detected in T1DM and T2DM (r =
      0.37, P < 0.02 and r = 0.60, P < 0.0001), but not in controls. Significantly
      higher AF values were found in patients with positive albuminuria as compared to 
      those with normal albuminuria. Similarly, higher AF was detected in patients with
      endothelial dysfunction expressed by vWF, ICAM-1, and VCAM-1. Multiple regression
      analysis revealed independent association of skin AF with age, sRAGE, and
      albumin-creatinine ratio in patients with diabetes (R (2) = 0.38). Our study
      confirms that AF is elevated in patients with diabetes, especially with positive 
      albuminuria and endothelial dysfunction. The strong and independent relationship 
      between AF and sRAGE supports the idea that AF may reflect AGEs/RAGE
      interactions. The exact mechanism remains to be established.
AD  - Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of
      Medicine, Charles University in Prague, General University Hospital in Prague,
      128 08 Prague 2, Czech Republic ; 3rd Department of Internal Medicine, First
      Faculty of Medicine, Charles University in Prague, General University Hospital in
      Prague, 128 08 Prague 2, Czech Republic.
FAU - Skrha, J Jr
AU  - Skrha J Jr
FAU - Soupal, J
AU  - Soupal J
FAU - Loni Ekali, G
AU  - Loni Ekali G
FAU - Prazny, M
AU  - Prazny M
FAU - Kalousova, M
AU  - Kalousova M
FAU - Kvasnicka, J
AU  - Kvasnicka J
FAU - Landova, L
AU  - Landova L
FAU - Zima, T
AU  - Zima T
FAU - Skrha, J
AU  - Skrha J
LA  - eng
PT  - Journal Article
DEP - 20130310
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647585
OID - NLM: PMC3647585
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/21 [received]
PHST- 2013/02/12 [revised]
PHST- 2013/02/14 [accepted]
PHST- 2013/03/10 [epublish]
AID - 10.1155/2013/650694 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:650694. doi: 10.1155/2013/650694. Epub 2013 Mar 10.

PMID- 23671884
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Transplantation of bone marrow-derived mesenchymal stem cells promotes delayed
      wound healing in diabetic rats.
PG  - 647107
LID - 10.1155/2013/647107 [doi]
AB  - In this paper, we established a delayed wound healing model on diabetic rat to
      mimic the pathophysiology of clinical patients who suffered from diabetic foot
      ulcers. We also evaluated if transplantation of allogeneic bone marrow-derived
      mesenchymal stem cells could promote the delayed wound healing and investigated
      the possible underlying biological mechanisms and stem cell behavior involved in 
      this process. The results showed that bone marrow-derived mesenchymal stem cells 
      had a positive effect on delayed wound healing in diabetic rats. Intramuscular
      transplantation demonstrated the best efficacy. This effect is associated with
      granulation tissue formation, angiogenesis, cellular proliferation, and high
      vascular endothelial growth factor expression in wound tissues. In addition, bone
      marrow-derived mesenchymal stem cells have been shown to mobilize and find home
      for ischemic and wounded tissues to participate in the process of wound healing. 
      Intramuscular transplantation of exogenous isogeneic stem cells may be suitable
      for clinical application in the treatment of diabetic foot ulcers although the
      safety of this therapy should be considered.
AD  - Department of Burns and Plastic Surgery, Lanzhou General Hospital of Lanzhou
      Command, 333 Binhe Road, Lanzhou, Gansu 730050, China.
FAU - Wan, Jiangbo
AU  - Wan J
FAU - Xia, Liulu
AU  - Xia L
FAU - Liang, Wenjia
AU  - Liang W
FAU - Liu, Yi
AU  - Liu Y
FAU - Cai, Qian
AU  - Cai Q
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647567
OID - NLM: PMC3647567
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/11 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1155/2013/647107 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:647107. doi: 10.1155/2013/647107. Epub 2013 Apr 9.

PMID- 23671883
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Therapeutic Potential of Dioscorea Extract (DA-9801) in Comparison with Alpha
      Lipoic Acid on the Peripheral Nerves in Experimental Diabetes.
PG  - 631218
LID - 10.1155/2013/631218 [doi]
AB  - DA-9801, a mixture of extracts from Dioscorea japonica Thunb. and Dioscorea
      nipponica Makino, was reported to have neurotrophic activity. Therefore, we
      investigated the therapeutic potential of DA-9801, in comparison with alpha
      lipoic acid (ALA), for peripheral nerves preservation in experimental diabetes.
      Experimental animals were divided into 4 groups, and each group was designated
      according to the type of treatment administered as follows: normal, DM,
      DM+DA-9801, and DM+ALA. After 16 weeks, response thresholds to tactile and
      thermal stimuli were higher in DM+DA-9801 group than in nontreated DM group. This
      degree of increase in DM+DA-9801 group indicates more therapeutic potency of
      DA-9801 than ALA. Western blot analysis showed more significant increase in NGF
      and decrease in TNF-alpha and IL-6 in DM+DA-9801 group than in DM or DM+ALA
      groups (P < 0.05). IENF density was reduced less significantly in the DM+DA-9801 
      group than in other DM groups (7.61 +/- 0.32, 4.2 +/- 0.26, and 6.5 +/- 0.30 in
      DM+DA-9801, DM, and DM+ALA, resp., P < 0.05). Mean myelinated axonal area in the 
      sciatic nerves was significantly greater in DM+DA-9801 group than in other DM
      groups (69.2 +/- 5.76, 54.0 +/- 6.32, and 63.1 +/- 5.41 in DM+DA-9801, DM, and
      DM+ALA, resp., P < 0.05). Results of this study demonstrated potential
      therapeutic applications of DA-9801 for the treatment of diabetic peripheral
      neuropathy.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      Research Institute of Clinical Medicine of Chonbuk National University,
      Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk
      National University Medical School, 634-18, Keum-Am Dong, Jeonju 561-712,
      Republic of Korea.
FAU - Jin, Heung Yong
AU  - Jin HY
FAU - Kim, Sun Hee
AU  - Kim SH
FAU - Yu, Hea Min
AU  - Yu HM
FAU - Baek, Hong Sun
AU  - Baek HS
FAU - Park, Tae Sun
AU  - Park TS
LA  - eng
PT  - Journal Article
DEP - 20130312
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647555
OID - NLM: PMC3647555
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/10/16 [received]
PHST- 2013/01/25 [revised]
PHST- 2013/02/03 [accepted]
PHST- 2013/03/12 [epublish]
AID - 10.1155/2013/631218 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:631218. doi: 10.1155/2013/631218. Epub 2013 Mar 12.

PMID- 23671882
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic
      Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway.
PG  - 630537
LID - 10.1155/2013/630537 [doi]
AB  - Aim. This study aimed to investigate whether the glucagon-like peptide-1 analog
      liraglutide (LIRA) can protect against diabetic cardiomyopathy and explore the
      related mechanism. Methods. Rats were divided into 6 groups: a nondiabetic group,
      diabetic cardiomyopathy rats without LIRA treatment, diabetic cardiomyopathy rats
      with LIRA treatment (with high-, medium-, and low-dose, resp.), and diabetic
      cardiomyopathy rats treated with insulin. Cardiac function was examined by
      echocardiography before and after treatment. The histopathology of the heart was 
      examined with H&E staining. The mRNA levels of XBP1, ATF4, and TRAF2 were
      analyzed by RT-PCR, and the expression of glucose-regulated protein 78 (Grp78),
      enhancer-binding protein homologous protein (CHOP), caspase-3, and caspase-12 was
      detected by western blot. Results. LIRA strongly improved cardiac function from
      both echocardiographic and histopathologic analyses, but insulin only partly
      increased cardiac function by improving FS and LVPW values. LIRA treatment can
      significantly decrease the expression of XBP1, ATF4, and TRAF2 (P < 0.01). LIRA
      also significantly downregulates the expression of Grp78, caspase-3 (P < 0.01),
      CHOP, and caspase-12 (P < 0.05). Conclusions. LIRA can protect against diabetic
      cardiomyopathy by inactivating the ER stress pathway. The improvement in cardiac 
      function by LIRA is independent of glucose control.
AD  - Department of the Endocrinology, The Second Hospital of Jilin University, Jilin
      University, Changchun 130041, China.
FAU - Liu, Jieyu
AU  - Liu J
FAU - Liu, Yu
AU  - Liu Y
FAU - Chen, Li
AU  - Chen L
FAU - Wang, Yuehui
AU  - Wang Y
FAU - Li, Junqi
AU  - Li J
LA  - eng
PT  - Journal Article
DEP - 20130305
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647568
OID - NLM: PMC3647568
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/03 [received]
PHST- 2013/02/11 [revised]
PHST- 2013/02/13 [accepted]
PHST- 2013/03/05 [epublish]
AID - 10.1155/2013/630537 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:630537. doi: 10.1155/2013/630537. Epub 2013 Mar 5.

PMID- 23671881
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Serum concentrations of transforming growth factor-Beta 1 in predicting the
      occurrence of diabetic retinopathy in juvenile patients with type 1 diabetes
      mellitus.
PG  - 614908
LID - 10.1155/2013/614908 [doi]
AB  - In the present study, we have decided to evaluate if serum transforming growth
      factor-beta 1 (TGF- beta 1) concentrations may have diagnostic value in
      predicting the occurrence of diabetic retinopathy (DR) in juvenile patients with 
      type 1 diabetes mellitus (T1DM). The study included 81 children and adolescents
      with T1DM and 19 control subjects. All study participants had biochemical
      parameters examined, underwent an eye examination, and 24-hour blood pressure
      monitoring. Moreover, serum concentrations of TGF- beta 1 were measured. The
      group of patients with T1DM and nonproliferative diabetic retinopathy (NPDR) had 
      statistically significant higher serum levels of TGF- beta 1 (P = 0.001) as
      compared to T1DM patients without retinopathy as well as the healthy control
      subject. The threshold serum TGF- beta 1 concentrations which had a
      discriminative ability to predict the presence of DR were calculated using the
      receiver operating characteristic (ROC) curves analysis and amounted to 443
      pg/ml. The area under the ROC curve (AUCROC) was 0.80, and its population value
      was in the range of 0.66 to 0.94. The sensitivity and specificity were calculated
      to be 72% and 88%, respectively. Our results suggest that TGF- beta 1 serum
      concentrations may be an additional parameter in predicting the occurrence of DR 
      in juvenile patients with T1DM.
AD  - Department of Clinical and Experimental Endocrinology, Institute of Maritime and 
      Tropical Medicine, Medical University of Gdansk, Powstania Styczniowego 9b,
      81-519 Gdynia, Poland.
FAU - Zorena, Katarzyna
AU  - Zorena K
FAU - Malinowska, Ewa
AU  - Malinowska E
FAU - Raczynska, Dorota
AU  - Raczynska D
FAU - Mysliwiec, Malgorzata
AU  - Mysliwiec M
FAU - Raczynska, Krystyna
AU  - Raczynska K
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647575
OID - NLM: PMC3647575
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/11/30 [received]
PHST- 2013/02/20 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.1155/2013/614908 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:614908. doi: 10.1155/2013/614908. Epub 2013 Mar 31.

PMID- 23671879
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Evaluation of the Effects of STZ-Induced Diabetes on In Vitro Fertilization and
      Early Embryogenesis Processes.
PG  - 603813
LID - 10.1155/2013/603813 [doi]
AB  - The aim of this study was to investigate the effects of experimentally induced
      diabetes on (a) germ cells, (b) in vitro fertilization (IVF) success rate, and
      (c) gap junction and cell adhesion molecule gene and protein expressions during
      the early blastocyst period. Germ cells were obtained from healthy and diabetic
      rats, analyzed for number, motility, and morphology, and used for IVF. After
      reaching the early blastocyst stage, the expressions of genes encoding gap
      junction proteins and cell adhesion molecules were analyzed by quantitative
      RT-PCR. Histomorphologically and immunohistochemically analyses were also
      performed. Diabetes significantly affected sperm number and motility and the
      development of oocytes. Gene expressions of beta -catenin and connexin family
      members and protein expressions of E-cadherin and connexin-43 significantly
      decreased in groups including germ cells isolated from diabetic rats. Connective 
      tissue growth factor expression increased in groups that included sperm cells
      isolated from diabetic male rats, whereas mucin-1 expression increased in the
      group that included oocytes isolated from diabetic female rats paired with sperm 
      cells isolated from healthy male rats. In summary, experimentally induced
      diabetes was found to influence gap junctions, cell adhesion molecules, and
      associated proteins which all have important roles in germ cell maturation,
      fertilization, and development.
AD  - Department of Histology and Embryology, Ege University Medical School, 35100
      Izmir, Turkey.
FAU - Aktug, Huseyin
AU  - Aktug H
FAU - Bozok Cetintas, Vildan
AU  - Bozok Cetintas V
FAU - Uysal, Aysegul
AU  - Uysal A
FAU - Oltulu, Fatih
AU  - Oltulu F
FAU - Yavasoglu, Altug
AU  - Yavasoglu A
FAU - Akarca, Saadet Ozen
AU  - Akarca SO
FAU - Kosova, Buket
AU  - Kosova B
LA  - eng
PT  - Journal Article
DEP - 20130324
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647572
OID - NLM: PMC3647572
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/07 [received]
PHST- 2013/02/12 [revised]
PHST- 2013/02/25 [accepted]
PHST- 2013/03/24 [epublish]
AID - 10.1155/2013/603813 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:603813. doi: 10.1155/2013/603813. Epub 2013 Mar 24.

PMID- 23671878
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood 
      Brain Barrier of a Rat.
PG  - 598603
LID - 10.1155/2013/598603 [doi]
AB  - Major problem for diabetic patients represents damage of blood vessels and the
      oxidative stress of the brain cells due to increased concentration of free
      radicals and poor nutrition of brain cells. Gliclazide has antioxidative
      properties and poor blood brain barrier (BBB) penetration. Bile acids are known
      for their hypoglycemic effect and as promoters of drug penetration across
      biological membranes. Accordingly, the aim of this study is to investigate
      whether the bile acid (deoxycholic acid) can change the permeation of gliclazide,
      through the blood brain barrier of a rat model type-1 diabetes. Twenty-four male 
      Wistar rats were randomly allocated to four groups, of which, two were given
      alloxan intraperitoneally (100 mg/kg) to induce diabetes. One diabetic group and 
      one healthy group were given a bolus gliclazide intra-arterially (20 mg/kg),
      while the other two groups apart from gliclazide got deoxycholic acid (4 mg/kg)
      subcutaneously. Blood samples were collected 30, 60, 150, and 240 seconds after
      dose, brain tissues were immediately excised and blood glucose and gliclazide
      concentrations were measured. Penetration of gliclazide in groups without
      deoxycholic acid pretreatment was increased in diabetic animals compared to
      healthy animals. Also in both, the healthy and diabetic animals, deoxycholic acid
      increased the permeation of gliclazide through that in BBB.
AD  - Department of Pharmacy, Medical Faculty, University of Novi Sad, 2100 Novi Sad,
      Serbia.
FAU - Lalic-Popovic, Mladena
AU  - Lalic-Popovic M
FAU - Vasovic, Velibor
AU  - Vasovic V
FAU - Milijasevic, Boris
AU  - Milijasevic B
FAU - Golocorbin-Kon, Svetlana
AU  - Golocorbin-Kon S
FAU - Al-Salami, Hani
AU  - Al-Salami H
FAU - Mikov, Momir
AU  - Mikov M
LA  - eng
PT  - Journal Article
DEP - 20130313
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647598
OID - NLM: PMC3647598
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/10/30 [received]
PHST- 2013/02/13 [revised]
PHST- 2013/02/15 [accepted]
PHST- 2013/03/13 [epublish]
AID - 10.1155/2013/598603 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:598603. doi: 10.1155/2013/598603. Epub 2013 Mar 13.

PMID- 23671877
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Sex disparities in diabetes process of care measures and self-care in high-risk
      patients.
PG  - 575814
LID - 10.1155/2013/575814 [doi]
AB  - Patients with chronic diabetic complications experience high morbidity and
      mortality. Sex disparities in modifiable factors such as processes of care or
      self-care activities have not been explored in detail, particularly in these
      high-risk patients. Sex differences in processes of care and self-care activities
      were assessed in a cross-sectional analysis of the Pathways Study, an
      observational cohort of primary care diabetic patients from a managed care
      organization (N = 4,839). Compared to men, women had decreased odds of
      dyslipidemia screening (adjusted odds ratio (AOR) 0.73, 95% CI 0.62-0.85),
      reaching low-density lipoprotein goal (AOR 0.70, 95% CI 0.58-0.86), and statin
      use (AOR 0.69, 95% CI 0.58-0.81); women had 19% greater odds of reaching
      hemoglobin A1c <7% (95% CI 1.02-1.41). There were no sex differences in
      hemoglobin A1c testing, microalbuminuria screening, or angiotensin-converting
      enzyme inhibitor use. Women were less likely to report regular exercise but had
      better adherence to healthy diet, glucose monitoring, and self-foot examination
      compared to men. Patterns of sex differences were consistent in subjects with
      diabetic complications. Significant sex disparities exist in diabetes process of 
      care measures and self-care, even amongst patients known to have chronic diabetic
      complications.
AD  - Division of Nephrology, University of Washington, 1959 NE Pacific Street,
      Seattle, WA 98195, USA ; Department of Epidemiology, University of Washington,
      1959 NE Pacific Street, Seattle, WA 98195, USA ; Kidney Research Institute, 325
      9th Avenue, P. O. Box 359606, Seattle, WA 98104, USA.
FAU - Yu, Margaret K
AU  - Yu MK
FAU - Lyles, Courtney Rees
AU  - Lyles CR
FAU - Bent-Shaw, Luis A
AU  - Bent-Shaw LA
FAU - Young, Bessie A
AU  - Young BA
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647593
OID - NLM: PMC3647593
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/12 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/12 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.1155/2013/575814 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:575814. doi: 10.1155/2013/575814. Epub 2013 Mar 31.

PMID- 23671874
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Angiogenic and vasculogenic factors in the vitreous from patients with
      proliferative diabetic retinopathy.
PG  - 539658
LID - 10.1155/2013/539658 [doi]
AB  - This study was conducted to determine levels of angiogenic and endothelial
      progenitor cell mobilizing (vasculogenic) factors in vitreous fluid from
      proliferative diabetic retinopathy (PDR) patients and correlate their levels with
      clinical disease activity. Vascular endothelial growth factor (VEGF), soluble
      vascular endothelial growth factor receptor-2 (sVEGFR-2), stem cell factor (SCF),
      soluble c-kit (s-kit), endothelial nitric oxide synthase (eNOS), and
      prostaglandin E2 (PGE2) levels were measured by ELISA in vitreous samples from 34
      PDR and 15 nondiabetic patients. eNOS was not detected. VEGF, sVEGFR-2, SCF, and 
      s-kit levels were significantly higher in PDR with active neovascularization
      compared with quiescent PDR and nondiabetic patients (P < 0.001; 0.007; 0.001;
      <0.001, resp.). In contrast, PGE2 levels were significantly higher in nondiabetic
      patients compared with PDR patients (P < 0.001). There were significant
      correlations between levels of sVEGFR-2 versus SCF (r = 0.950, P < 0.001),
      sVEGFR-2 versus s-kit (r = 0.941, P < 0.001), and SCF versus s-kit (r = 0.970, P 
      < 0.001). Our findings suggest that upregulation of VEGF, sVEGFR-2, SCF, and
      s-kit supports the contributions of angiogenesis and vasculogenesis in
      pathogenesis of PDR.
AD  - Department of Ophthalmology, College of Medicine, King Saud University, Riyadh,
      Saudi Arabia ; Department of Ophthalmology, King Abdulaziz University Hospital,
      Old Airport Road, P.O. Box 245, Riyadh 11411, Saudi Arabia.
FAU - Abu El-Asrar, Ahmed M
AU  - Abu El-Asrar AM
FAU - Nawaz, Mohd Imtiaz
AU  - Nawaz MI
FAU - Kangave, Dustan
AU  - Kangave D
FAU - Mairaj Siddiquei, Mohammed
AU  - Mairaj Siddiquei M
FAU - Geboes, Karel
AU  - Geboes K
LA  - eng
PT  - Journal Article
DEP - 20130310
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647558
OID - NLM: PMC3647558
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/22 [received]
PHST- 2013/02/12 [accepted]
PHST- 2013/03/10 [epublish]
AID - 10.1155/2013/539658 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:539658. doi: 10.1155/2013/539658. Epub 2013 Mar 10.

PMID- 23671870
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Zinc and diabetic retinopathy.
PG  - 425854
LID - 10.1155/2013/425854 [doi]
AB  - Zinc (Zn) is an important nutrient that is involved in various physiological
      metabolisms. Zn dyshomeostasis is often associated with various pathogeneses of
      chronic diseases, such as metabolic syndrome, diabetes, and related
      complications. Zn is present in ocular tissue in high concentrations,
      particularly in the retina and choroid. Zn deficiencies have been shown to affect
      ocular development, cataracts, age-related macular degeneration, and even
      diabetic retinopathy. However, the mechanism by which Zn deficiency increases the
      prevalence of diabetic retinopathy remains unclear. In addition, due to the
      negative effect of Zn deficiency on the eye, Zn supplementation should prevent
      diabetic retinopathy; however, limited available data do not always support this 
      notion. Therefore, the goal of this paper was to summarize these pieces of
      available information regarding Zn prevention of diabetic retinopathy. Current
      theories and possible mechanisms underlying the role of Zn in the eye-related
      diseases are discussed. The possible factors that affect the preventive effect of
      Zn supplementation on diabetic retinopathy were also discussed.
AD  - The Second Hospital of Jilin University, Changchun 130021, China ; Department of 
      Ophthalmology, The Second Hospital of Jilin University, 218 Ziqiang Street,
      Changchun 130041, China.
FAU - Miao, Xiao
AU  - Miao X
FAU - Sun, Weixia
AU  - Sun W
FAU - Miao, Lining
AU  - Miao L
FAU - Fu, Yaowen
AU  - Fu Y
FAU - Wang, Yonggang
AU  - Wang Y
FAU - Su, Guanfang
AU  - Su G
FAU - Liu, Quan
AU  - Liu Q
LA  - eng
PT  - Journal Article
DEP - 20130317
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647550
OID - NLM: PMC3647550
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/11 [received]
PHST- 2013/02/08 [accepted]
PHST- 2013/03/17 [epublish]
AID - 10.1155/2013/425854 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:425854. doi: 10.1155/2013/425854. Epub 2013 Mar 17.

PMID- 23671869
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Angiotensin-Converting Enzyme 2 Deficiency Aggravates Glucose Intolerance via
      Impairment of Islet Microvascular Density in Mice with High-Fat Diet.
PG  - 405284
LID - 10.1155/2013/405284 [doi]
AB  - The aim of this study was to evaluate the effects of angiotensin-converting
      enzyme 2 (ACE2) on glucose homeostasis and islet function in mice. Male wildtype 
      (WT) and ACE2 knockout (ACE2 KO) mice were divided into chow diet group and
      long-term high-fat diet (HFD) group. After 16 weeks of feeding, the islet
      function of the animals was evaluated by intraperitoneal glucose tolerance test
      (IPGTT) and intraperitoneal insulin releasing test (IPIRT). The pancreas was
      immunohistochemically stained to analyze the relative content of insulin (IRC),
      vascular endothelial growth factor (VEGF), and microvessel density (MVD) in
      islets. There was no difference of body weight, area under curve of glucose
      (AUCG), area under curve of insulin from 0 to 5 min (AUGI0-5), MVD, and RVC
      (relative content of VEGF) between WT and ACE2 KO mice with regular chow diet.
      Under the condition of long-term HFD, the AUCG of ACE2 KO mice was increased
      obviously in comparison with the WT mice, with decreased IRC, MVD, AUGI0-5,
      AUCI0-30, and RVC (all P < 0.05). In conclusion, these results show that ACE2
      deficiency deteriorates islet function of mice with long-term HFD via impairment 
      of islet microvasculature.
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College of HuaZhong, 
      University of Science & Technology, Wuhan 430022, China.
FAU - Yuan, Li
AU  - Yuan L
FAU - Wang, Ying
AU  - Wang Y
FAU - Lu, Chunli
AU  - Lu C
FAU - Li, Xiaoya
AU  - Li X
LA  - eng
PT  - Journal Article
DEP - 20130319
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647559
OID - NLM: PMC3647559
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/15 [received]
PHST- 2013/02/20 [accepted]
PHST- 2013/03/19 [epublish]
AID - 10.1155/2013/405284 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:405284. doi: 10.1155/2013/405284. Epub 2013 Mar 19.

PMID- 23671867
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - The Relationship between Type 2 Diabetes Mellitus and Related Thyroid Diseases.
PG  - 390534
LID - 10.1155/2013/390534 [doi]
AB  - Type 2 diabetes mellitus (T2DM) has an intersecting underlying pathology with
      thyroid dysfunction. The literature is punctuated with evidence indicating a
      contribution of abnormalities of thyroid hormones to type 2 DM. The most probable
      mechanism leading to T2DM in thyroid dysfunction could be attributed to perturbed
      genetic expression of a constellation of genes along with physiological
      aberrations leading to impaired glucose utilization and disposal in muscles,
      overproduction of hepatic glucose output, and enhanced absorption of splanchnic
      glucose. These factors contribute to insulin resistance. Insulin resistance is
      also associated with thyroid dysfunction. Hyper- and hypothyroidism have been
      associated with insulin resistance which has been reported to be the major cause 
      of impaired glucose metabolism in T2DM. The state-of-art evidence suggests a
      pivotal role of insulin resistance in underlining the relation between T2DM and
      thyroid dysfunction. A plethora of preclinical, molecular, and clinical studies
      have evidenced an undeniable role of thyroid malfunctioning as a comorbid
      disorder of T2DM. It has been investigated that specifically designed thyroid
      hormone analogues can be looked upon as the potential therapeutic strategies to
      alleviate diabetes, obesity, and atherosclerosis. These molecules are in final
      stages of preclinical and clinical evaluation and may pave the way to unveil a
      distinct class of drugs to treat metabolic disorders.
AD  - Department of Endocrinology, Shanghai Pudong Hospital, Fudan University Pudong
      Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai 201399, China.
FAU - Wang, Chaoxun
AU  - Wang C
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647563
OID - NLM: PMC3647563
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/20 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1155/2013/390534 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:390534. doi: 10.1155/2013/390534. Epub 2013 Apr 4.

PMID- 23671866
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Serum Proteome Changes in Healthy Subjects with Different Genotypes of NOS1AP in 
      the Chinese Population.
PG  - 357630
LID - 10.1155/2013/357630 [doi]
AB  - Type 2 diabetes and its chronic complications have become a worldwide epidemic
      nowadays. However, its molecular mechanism is still unknown. We have previously
      identified a novel variant rs12742393 of NOS1AP for type 2 diabetes
      susceptibility in the Chinese population. In this study, we analyzed the total
      serum profiling among three genotypes of rs12742393 to discover potential
      crosstalk under the variant and the disease through proteomic analyses for the
      first time. We used OFFGEL peptide fractionation, LC-MS/MS analysis, and
      label-free quantification to profile the fasting human serum samples of the
      genotypes in rs12742393 (n = 4, for CC, AC, and AA, resp.). Four proteins were
      identified, including apoA4, alpha1-ACT, HABP2, and keratin 10, with blood levels
      changed significantly between CC and AA homozygotes of rs12742393. Compared with 
      AA group, the levels of apoA4 increased (P = 0.000265), whereas the concentration
      of alpha1-ACT, HABP2, and keratin 10 decreased in CC group (P = 0.011116,
      0.021175, and 0.015661, resp.). Then we selected additional fasting serum samples
      for ELISA and western blot validation. However, no significant differences were
      identified by neither ELISA nor western blot (P > 0.05). The protein profiling
      changes between the genotypes of rs12742393 indicated that this SNP might play a 
      role in the development of type 2 diabetes.
AD  - Department of Endocrinology and Metabolism, Shanghai Jiao Tong University
      Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Key
      Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, 600
      Yishan Road, Shanghai 200233, China.
FAU - Jiang, Feng
AU  - Jiang F
FAU - Wang, Congrong
AU  - Wang C
FAU - Li, Rongxia
AU  - Li R
FAU - Sheng, Quanhu
AU  - Sheng Q
FAU - Hu, Cheng
AU  - Hu C
FAU - Zhang, Rong
AU  - Zhang R
FAU - Fang, Qichen
AU  - Fang Q
FAU - Bao, Yuqian
AU  - Bao Y
FAU - Xiang, Kunsan
AU  - Xiang K
FAU - Zeng, Rong
AU  - Zeng R
FAU - Jia, Weiping
AU  - Jia W
LA  - eng
PT  - Journal Article
DEP - 20130407
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647583
OID - NLM: PMC3647583
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/29 [received]
PHST- 2013/03/12 [accepted]
PHST- 2013/04/07 [epublish]
AID - 10.1155/2013/357630 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:357630. doi: 10.1155/2013/357630. Epub 2013 Apr 7.

PMID- 23671865
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Bone marrow stem cell as a potential treatment for diabetes.
PG  - 329596
LID - 10.1155/2013/329596 [doi]
AB  - Diabetes mellitus (DM) is a group of metabolic diseases in which a person has
      high blood glucose levels resulting from defects in insulin secretion and insulin
      action. The chronic hyperglycemia damages the eyes, kidneys, nerves, heart, and
      blood vessels. Curative therapies mainly include diet, insulin, and oral
      hypoglycemic agents. However, these therapies fail to maintain blood glucose
      levels in the normal range all the time. Although pancreas or islet-cell
      transplantation achieves better glucose control, a major obstacle is the shortage
      of donor organs. Recently, research has focused on stem cells which can be
      classified into embryonic stem cells (ESCs) and tissue stem cells (TSCs) to
      generate functional beta cells. TSCs include the bone-marrow-, liver-, and
      pancreas-derived stem cells. In this review, we focus on treatment using bone
      marrow stem cells for type 1 and 2 DM.
AD  - Department of Stem Cell Disorders, Kansai Medical University, Moriguchi, Osaka
      570-8506, Japan.
FAU - Li, Ming
AU  - Li M
FAU - Ikehara, Susumu
AU  - Ikehara S
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647566
OID - NLM: PMC3647566
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/11 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/10 [epublish]
AID - 10.1155/2013/329596 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:329596. doi: 10.1155/2013/329596. Epub 2013 Apr 10.

PMID- 23671858
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Relationship between Stage of Diabetic Retinopathy and Pulse Wave Velocity in
      Japanese Patients with Type 2 Diabetes.
PG  - 193514
LID - 10.1155/2013/193514 [doi]
AB  - Objectives. We investigated the relationship between the stage of diabetic
      retinopathy and pulse wave velocity (PWV). Methods. This was a cross-sectional
      study of 689 patients (406 men and 283 women) with type 2 diabetes who were
      admitted to our hospital from 2004 to 2007. Brachial-ankle pulse wave velocity
      (baPWV) was measured by an arterial pressure measurement device as PWV/ABI.
      Diagnosis of diabetic retinopathy was made by ophthalmologists based on the Davis
      classification: no diabetic retinopathy (NDR), simple retinopathy (SDR),
      pre-proliferative retinopathy (pre-PDR), and proliferative retinopathy (PDR).
      Results. There was a significant difference in PWV between patients without
      diabetic retinopathy (1657.0 +/- 417.9 m/s (mean +/- SD)) and with diabetic
      retinopathy (1847.1 +/- 423.9 m/s) (P < 0.001). In addition, the stage of
      diabetic retinopathy was associated with aortic PWV (1657.0 +/- 417.9 m/s in NDR 
      (n = 420), 1819.4 +/- 430.3 m/s in SDR (n = 152), 1862.1 +/- 394.0 m/s in pre-PDR
      (n = 54), and 1901.1 +/- 433.5 m/s in PDR (n = 63) (P < 0.001)). Conclusions. In 
      patients with diabetic retinopathy, even in those with SDR, PWV was higher than
      that in patients without diabetic retinopathy. Physicians should therefore pay
      attention to the value of PWV and macroangiopathy regardless of the stage of
      diabetic retinopathy.
AD  - Department of Internal Medicine, School of Medicine, Keio University, 35
      Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
FAU - Tanaka, Kumiko
AU  - Tanaka K
FAU - Kawai, Toshihide
AU  - Kawai T
FAU - Saisho, Yoshifumi
AU  - Saisho Y
FAU - Meguro, Shu
AU  - Meguro S
FAU - Harada, Kana
AU  - Harada K
FAU - Satoh, Yuka
AU  - Satoh Y
FAU - Kobayashi, Kaori
AU  - Kobayashi K
FAU - Mizushima, Kei
AU  - Mizushima K
FAU - Abe, Takayuki
AU  - Abe T
FAU - Itoh, Hiroshi
AU  - Itoh H
LA  - eng
PT  - Journal Article
DEP - 20130320
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647565
OID - NLM: PMC3647565
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/25 [received]
PHST- 2013/02/20 [revised]
PHST- 2013/02/20 [accepted]
PHST- 2013/03/20 [epublish]
AID - 10.1155/2013/193514 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:193514. doi: 10.1155/2013/193514. Epub 2013 Mar 20.

PMID- 23671857
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Stress and Its Effects on Glucose Metabolism and 11beta-HSD Activities in Rats
      Fed on a Combination of High-Fat and High-Sucrose Diet with Glycyrrhizic Acid.
PG  - 190395
LID - 10.1155/2013/190395 [doi]
AB  - Chronic stress has been shown to have a strong link towards metabolic syndrome
      (MetS). Glycyrrhizic acid (GA) meanwhile has been shown to improve MetS symptoms 
      caused by an unhealthy diet by inhibiting 11 beta -HSD 1. This experiment aimed
      to determine the effects of continuous, moderate-intensity stress on rats with
      and without GA intake on systolic blood pressure (SBP) across a 28-day period, as
      well as glucose metabolism, and 11 beta -HSD 1 and 2 activities at the end of the
      28-day period. Adaptation to the stressor (as shown by SBP) resulted in no
      significant defects in glucose metabolism by the end of the experimental
      duration. However, a weakly significant increase in renal 11 beta -HSD 1 and a
      significant increase in subcutaneous adipose tissue 11 beta -HSD 1 activities
      were observed. GA intake did not elicit any significant benefit in glucose
      metabolism, indicating that the stress response may block its effects. However,
      GA-induced improvements in 11 beta -HSD activities in certain tissues were
      observed, although it is uncertain if these effects are manifested after
      adaptation due to the withdrawal of the stress response. Hence the ability of GA 
      to improve stress-induced disturbances in the absence of adaptation needs to be
      investigated further.
AD  - Monash University Sunway Campus, Jalan Lagoon Selatan, Bandar Sunway, 46150
      Selangor Darul Ehsan, Malaysia.
FAU - Fernando, Hamish Alexander
AU  - Fernando HA
FAU - Chin, Hsien-Fei
AU  - Chin HF
FAU - Ton, So Ha
AU  - Ton SH
FAU - Abdul Kadir, Khalid
AU  - Abdul Kadir K
LA  - eng
PT  - Journal Article
DEP - 20130318
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647599
OID - NLM: PMC3647599
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/20 [received]
PHST- 2013/01/29 [accepted]
PHST- 2013/03/18 [epublish]
AID - 10.1155/2013/190395 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:190395. doi: 10.1155/2013/190395. Epub 2013 Mar 18.

PMID- 23671856
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Protective Effects of Resveratrol on TNF-alpha-Induced Endothelial Cytotoxicity
      in Baboon Femoral Arterial Endothelial Cells.
PG  - 185172
LID - 10.1155/2013/185172 [doi]
AB  - Endothelial injury induced by inflammatory factors plays a critical role in the
      pathogenesis of cardiovascular disease. Endothelial cell (EC) apoptosis,
      proliferation, migration, and cellular adhesion molecule (CAM) expression
      contribute to the development of atherosclerosis. We investigated the effects of 
      resveratrol (0.1-100 mu M) on the proliferation, migration, and CAM expression of
      primary cultures of baboon arterial endothelial cells (BAECs). In addition, we
      tested its effects under normal conditions as well as under inflammatory
      conditions induced by tumour necrosis factor-alpha (TNF-alpha) administered
      either by cotreatment, pretreatment, or posttreatment. Immunocytochemistry, MTT, 
      wound-healing, and flow cytometry assays were performed. The resveratrol
      treatment significantly enhanced BAEC proliferation and attenuated
      TNF-alpha-induced impairment of proliferation at the optimal doses of 1-50
      microM. Resveratrol at a high dose (100 mu M) and TNF-alpha impaired BAEC
      migration, while low doses of resveratrol (1-50 mu M) attenuated
      TNF-alpha-induced impairment of BAEC migration. Moreover, resveratrol inhibited
      TNF-alpha-induced ICAM-1 and VCAM-1 expression. Taken together, our results
      suggest that the resveratrol protects BAECs after inflammatory stimulation as
      well as ameliorates inflammatory effects at low concentrations. Consequently,
      resveratrol should be considered as a candidate drug for the prevention and
      treatment of inflammatory vascular diseases.
AD  - Department of Endocrinology, Qilu Hospital, Shandong University, 107 Wen Hua Xi
      Lu, Jinan, Shandong 250012, China ; Southwest National Primate Research Center,
      Texas Biomedical Research Institute, P.O. Box 760549, San Antonio, TX 78245-0549,
      USA.
FAU - Xiao, Juan
AU  - Xiao J
FAU - Song, Jun
AU  - Song J
FAU - Hodara, Vida
AU  - Hodara V
FAU - Ford, Allen
AU  - Ford A
FAU - Wang, Xing Li
AU  - Wang XL
FAU - Shi, Qiang
AU  - Shi Q
FAU - Chen, Li
AU  - Chen L
FAU - Vandeberg, John L
AU  - Vandeberg JL
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647561
OID - NLM: PMC3647561
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/05 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/03/01 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.1155/2013/185172 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:185172. doi: 10.1155/2013/185172. Epub 2013 Mar 31.

PMID- 23671855
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Effects of long-term treatment with ranirestat, a potent aldose reductase
      inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii
      rats.
PG  - 175901
LID - 10.1155/2013/175901 [doi]
AB  - We evaluated ranirestat, an aldose reductase inhibitor, in diabetic cataract and 
      neuropathy (DN) in spontaneously diabetic Torii (SDT) rats compared with
      epalrestat, the positive control. Animals were divided into groups and treated
      once daily with oral ranirestat (0.1, 1.0, 10 mg/kg) or epalrestat (100 mg/kg)
      for 40 weeks, normal Sprague-Dawley rats, and untreated SDT rats. Lens
      opacification was scored from 0 (normal) to 3 (mature cataract). The combined
      scores (0-6) from both lenses represented the total for each animal. DN was
      assessed by measuring the motor nerve conduction velocity (MNCV) in the sciatic
      nerve. Sorbitol and fructose levels were measured in the lens and sciatic nerve
      40 weeks after diabetes onset. Cataracts developed more in untreated rats than
      normal rats (P < 0.01). Ranirestat significantly (P < 0.01) inhibited rapid
      cataract development; epalrestat did not. Ranirestat significantly reversed the
      MNCV decrease (40.7 +/- 0.6 m/s) in SDT rats dose-dependently (P < 0.01).
      Epalrestat also reversed the prevented MNCV decrease (P < 0.05). Sorbitol levels 
      in the sciatic nerve increased significantly in SDT rats (2.05 +/- 0.10 nmol/g), 
      which ranirestat significantly suppressed dose-dependently, (P < 0.05, <0.01, and
      <0.01); epalrestat did not. Ranirestat prevents DN and cataract; epalrestat
      prevents DN only.
AD  - Department of Ophthalmology, Jichi Medical University, Saitama Medical Center,
      1-847 Amanuma-cho, Omiya-ku, Saitama-shi 330-8503, Japan.
FAU - Ota, Ayumi
AU  - Ota A
FAU - Kakehashi, Akihiro
AU  - Kakehashi A
FAU - Toyoda, Fumihiko
AU  - Toyoda F
FAU - Kinoshita, Nozomi
AU  - Kinoshita N
FAU - Shinmura, Machiko
AU  - Shinmura M
FAU - Takano, Hiroko
AU  - Takano H
FAU - Obata, Hiroto
AU  - Obata H
FAU - Matsumoto, Takafumi
AU  - Matsumoto T
FAU - Tsuji, Junichi
AU  - Tsuji J
FAU - Dobashi, Yoh
AU  - Dobashi Y
FAU - Fujimoto, Wilfred Y
AU  - Fujimoto WY
FAU - Kawakami, Masanobu
AU  - Kawakami M
FAU - Kanazawa, Yasunori
AU  - Kanazawa Y
LA  - eng
PT  - Journal Article
DEP - 20130313
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647549
OID - NLM: PMC3647549
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/22 [received]
PHST- 2013/01/29 [accepted]
PHST- 2013/03/13 [epublish]
AID - 10.1155/2013/175901 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:175901. doi: 10.1155/2013/175901. Epub 2013 Mar 13.

PMID- 23671854
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Comparison of Two New Mouse Models of Polygenic Type 2 Diabetes at the Jackson
      Laboratory, NONcNZO10Lt/J and TALLYHO/JngJ.
PG  - 165327
LID - 10.1155/2013/165327 [doi]
AB  - This review compares two novel polygenic mouse models of type 2 diabetes (T2D),
      TALLYHO/JngJ and NONcNZO10/LtJ, and contrasts both with the well-known
      C57BLKS/J-Lepr(db) (db/db) monogenic diabesity model. We posit that the new
      polygenic models are more representative of the "garden variety" obesity
      underlying human T2D in terms of their polygenetic rather than monogenic
      etiology. Moreover, the clinical phenotypes in these new models are less extreme,
      for example, more moderated development of obesity coupled with less extreme
      endocrine disturbances. The more progressive development of obesity produces a
      maturity-onset development of hyperglycemia in contrast to the juvenile-onset
      diabetes observed in the morbidly obese db/db model. Unlike the leptin
      receptor-deficient db/db models with central leptin resistance, the new models
      develop a progressive peripheral leptin resistance and are able to maintain
      reproductive function. Although the T2D pathophysiology in both TALLYHO/JngJ and 
      NONcNZO10/LtJ is remarkably similar, their genetic etiologies are clearly
      different, underscoring the genetic heterogeneity underlying T2D in humans.
AD  - The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA.
FAU - Leiter, Edward H
AU  - Leiter EH
FAU - Strobel, Marjorie
AU  - Strobel M
FAU - O'Neill, Adam
AU  - O'Neill A
FAU - Schultz, David
AU  - Schultz D
FAU - Schile, Andrew
AU  - Schile A
FAU - Reifsnyder, Peter C
AU  - Reifsnyder PC
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647594
OID - NLM: PMC3647594
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/02/04 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1155/2013/165327 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:165327. doi: 10.1155/2013/165327. Epub 2013 Apr 8.

PMID- 23671852
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Impact of serum retinol-binding protein 4 levels on regulation of remnant-like
      particles triglyceride in type 2 diabetes mellitus.
PG  - 143515
LID - 10.1155/2013/143515 [doi]
AB  - Background. Although retinol-binding protein 4 (RBP4) associates with insulin
      resistance and remnant-like particles triglyceride (RLP-TG) elevated in the
      insulin resistant state, few data exist regarding the relationship between RBP4
      and RLP-TG. Subjects and Methods. The study included 92 Japanese type 2 diabetic 
      mellitus (T2DM) male patients (age 60.5 +/- 13.6 years, body mass index (BMI)
      24.7 +/- 4.1 kg/m(2), waist circumference (WC) 88.4 +/- 10.7 cm, and HbA1c (NGSP)
      7.2 +/- 1.9%). Patients on medications affecting insulin sensitivity, including
      fibrates, biguanides, and thiazolidinedione, were excluded. Visceral fat area
      (VFA) and subcutaneous fat area (SFA) were measured by computed tomography.
      Results. RBP4 levels showed a significant positive correlation with RLP-TG (r =
      0.2544 and P = 0.0056), TG (r = 0.1852 and P = 0.041), RLP-TG/TG (r = 0.23765 and
      P = 0.0241), and age (r = -0.2082 and P = 0.0219), although there was no
      significant correlation with VFA, SFA, adiponectin levels, or homeostasis model
      of assessment insulin resistance (HOMA-R). Multiple regression analysis revealed 
      that RBP4 was an independent determinant of RLP-TG (P = 0.0193) but was not a
      determinant of TG. Conclusions. RBP4 correlates positively with serum RLP-TG
      independent of fat accumulation in T2DM. RBP4 may regulate remnant metabolism
      independent of glycemic control in T2DM.
AD  - Department of Internal Medicine, Graduate School of Medical Science, Kanazawa
      University, 13-1 Takaramachi, Kanazawa 920-8640, Japan.
FAU - Yamaaki, Naoto
AU  - Yamaaki N
FAU - Yagi, Kunimasa
AU  - Yagi K
FAU - Kobayashi, Junji
AU  - Kobayashi J
FAU - Nohara, Atsushi
AU  - Nohara A
FAU - Ito, Naoko
AU  - Ito N
FAU - Asano, Akimichi
AU  - Asano A
FAU - Nakano, Kaoru
AU  - Nakano K
FAU - Liu, Jianhui
AU  - Liu J
FAU - Okamoto, Takuya
AU  - Okamoto T
FAU - Mori, Yukiko
AU  - Mori Y
FAU - Ohbatake, Azusa
AU  - Ohbatake A
FAU - Okazaki, Satoko
AU  - Okazaki S
FAU - Takeda, Yoshiyu
AU  - Takeda Y
FAU - Yamagishi, Masakazu
AU  - Yamagishi M
LA  - eng
PT  - Journal Article
DEP - 20130319
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647570
OID - NLM: PMC3647570
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/25 [received]
PHST- 2013/02/12 [accepted]
PHST- 2013/03/19 [epublish]
AID - 10.1155/2013/143515 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:143515. doi: 10.1155/2013/143515. Epub 2013 Mar 19.

PMID- 23671851
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Rodent models for investigating the dysregulation of immune responses in type 1
      diabetes.
PG  - 138412
LID - 10.1155/2013/138412 [doi]
AB  - Type 1 diabetes (T1D) is an autoimmune disease mediated by T cells that
      selectively destroy the insulin-producing beta cells. Previous reports based on
      epidemiological and animal studies have demonstrated that both genetic factors
      and environmental parameters can either promote or attenuate the progression of
      autoimmunity. In recent decades, several inbred rodent strains that spontaneously
      develop diabetes have been applied to the investigation of the pathogenesis of
      T1D. Because the genetic manipulation of mice is well developed (transgenic,
      knockout, and conditional knockout/transgenic), most studies are performed using 
      the nonobese diabetic (NOD) mouse model. This paper will focus on the use of
      genetically manipulated NOD mice to explore the pathogenesis of T1D and to
      develop potential therapeutic approaches.
AD  - Department and Graduate Institute of Microbiology and Immunology, National
      Defense Medical Center, R8324, 161, Section 6, MinChuan East Road, Neihu, Taipei 
      114, Taiwan.
FAU - Chou, Feng-Cheng
AU  - Chou FC
FAU - Chen, Heng-Yi
AU  - Chen HY
FAU - Chen, Shyi-Jou
AU  - Chen SJ
FAU - Fang, Mei-Cho
AU  - Fang MC
FAU - Sytwu, Huey-Kang
AU  - Sytwu HK
LA  - eng
PT  - Journal Article
DEP - 20130311
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647569
OID - NLM: PMC3647569
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/23 [received]
PHST- 2013/02/07 [accepted]
PHST- 2013/03/11 [epublish]
AID - 10.1155/2013/138412 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:138412. doi: 10.1155/2013/138412. Epub 2013 Mar 11.

PMID- 23671849
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Short-term exercise training improves insulin sensitivity but does not inhibit
      inflammatory pathways in immune cells from insulin-resistant subjects.
PG  - 107805
LID - 10.1155/2013/107805 [doi]
AB  - Background. Exercise has an anti-inflammatory effect against, and immune cells
      play critical roles in the development, of insulin resistance and atherosclerotic
      vascular disease (AVD). Thus, the goal of this study was to determine whether
      exercise improves insulin sensitivity in insulin-resistant subjects by
      downregulating proinflammatory signaling in immune cells. Methods. Seventeen
      lean, 8 obese nondiabetic, and 11 obese type 2 diabetic individuals underwent an 
      aerobic exercise program for 15 days and an insulin clamp before and after
      exercise. Peripheral mononuclear cells (PMNC) were obtained for determination of 
      Toll-like receptor (TLR) 2 and 4 protein content and mitogen-activated protein
      kinase phosphorylation. Results. Compared with that in lean individuals, TLR4
      protein content was increased by 4.2-fold in diabetic subjects. This increase in 
      TLR4 content was accompanied by a 3.0-fold increase in extracellular
      signal-regulated kinase (ERK) phosphorylation. Exercise improved insulin
      sensitivity in the lean, obese, and type 2 diabetes groups. However, exercise did
      not affect TLR content or ERK phosphorylation. Conclusions. TLR4 content and ERK 
      phosphorylation are increased in PMNC of type 2 diabetic individuals. While
      exercise improves insulin sensitivity, this effect is not related to changes in
      TLR2/TLR4 content or ERK phosphorylation in PMNC of type 2 diabetic individuals.
AD  - Medical Research Division, Regional Academic Health Center, 1214 W. Schunior
      Street, Edinburg, TX 78541, USA ; Diabetes Division, University of Texas Health
      Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA 
      ; Texas Diabetes Institute, 701 S. Zarzamora, San Antonio, TX 78207, USA.
FAU - Reyna, Sara M
AU  - Reyna SM
FAU - Tantiwong, Puntip
AU  - Tantiwong P
FAU - Cersosimo, Eugenio
AU  - Cersosimo E
FAU - Defronzo, Ralph A
AU  - Defronzo RA
FAU - Sriwijitkamol, Apiradee
AU  - Sriwijitkamol A
FAU - Musi, Nicolas
AU  - Musi N
LA  - eng
PT  - Journal Article
DEP - 20130313
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647562
OID - NLM: PMC3647562
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/11/02 [received]
PHST- 2013/01/16 [accepted]
PHST- 2013/03/13 [epublish]
AID - 10.1155/2013/107805 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:107805. doi: 10.1155/2013/107805. Epub 2013 Mar 13.

PMID- 23671848
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 2314-6745 (Print)
VI  - 2013
DP  - 2013
TI  - Protection effect of endomorphins on advanced glycation end products induced
      injury in endothelial cells.
PG  - 105780
LID - 10.1155/2013/105780 [doi]
AB  - Endomorphins (EMs) have a very important bridge-function in cardiovascular,
      endocrinological, and neurological systems. This study is to investigate the
      effects of EMs on the synthesis and secretion of vasoactive substances induced by
      advanced glycation end products in primary cultured human umbilical vein
      endothelial cells (HUVECs). Firstly, HUVECs were stimulated with AGEs-bovine
      serum albumin (AGEs-BSA), bovine serum albumin (BSA), or both AGEs-BSA and EMs
      together, respectively. Then, HUVEC survival rate was calculated by MTT assay,
      the levels of NO, endothelial nitric oxide synthase (eNOS), and inducible nitric 
      oxide synthase (iNOS) were detected by colorimetric analysis, and the contents of
      endothelin-1 (ET-1) were detected by ELISA. The mRNA levels of eNOS and ET-1 were
      measured by RT-PCR. The expression of p38 mitogen-activated protein kinase (p38
      MAPK) was detected by immunofluorescence assay. The results showed that the mRNA 
      expression and secretion of eNOS were significantly enhanced after incubation
      with EMs compared to those with AGEs-BSA, while the secretion of NO and iNOS,
      mRNA expression, and secretion of ET-1 had opposite changes. The fluorescence
      intensity of p38MAPK in nuclear was decreased after pretreatment with EMs
      compared to incubation with AGEs-BSA. Conclusion. The present study suggests that
      EMs have certain protection effect on AGEs-BSA-induced injury in HUVEC.
AD  - Department of Endocrinology, Gansu Provincial People's Hospital, 204 West
      Donggang Road, Lanzhou City 730000, Gansu Province, China.
FAU - Liu, Jing
AU  - Liu J
FAU - Yan, Liping
AU  - Yan L
FAU - Niu, Ruilan
AU  - Niu R
FAU - Tian, Limin
AU  - Tian L
FAU - Zhang, Qi
AU  - Zhang Q
FAU - Quan, Jinxing
AU  - Quan J
FAU - Liu, Hua
AU  - Liu H
FAU - Wei, Suhong
AU  - Wei S
FAU - Guo, Qian
AU  - Guo Q
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - Egypt
TA  - J Diabetes Res
JT  - Journal of diabetes research
JID - 101605237
PMC - PMC3647545
OID - NLM: PMC3647545
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/01/11 [received]
PHST- 2013/03/03 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1155/2013/105780 [doi]
PST - ppublish
SO  - J Diabetes Res. 2013;2013:105780. doi: 10.1155/2013/105780. Epub 2013 Apr 8.

PMID- 23671836
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 2242-3982 (Electronic)
IS  - 1239-9736 (Linking)
VI  - 72
DP  - 2013
TI  - Utilizing harmonization and common surveillance methods to consolidate 4 cohorts:
      the Western Alaska Tribal Collaborative for Health (WATCH) study.
LID - 10.3402/ijch.v72i0.20572 [doi]
AB  - BACKGROUND: According to health status reports, chronic disease prevalence
      appears to be rising in western Alaska Native (AN) people, and accurate
      population-based data are needed. Four cohort studies of western AN people were
      conducted in the Norton Sound and Yukon-Kuskokwim regions, but none have been
      large enough to allow reliable estimates of rates of chronic diseases and
      evaluate their risk factors. OBJECTIVE: In this article, the methods used to
      combine 4 major cohort studies of rural western AN people are described and the
      benefits and challenges encountered in combining data and standardizing
      surveillance methods for these studies are discussed. DESIGN: Tribal permission
      was obtained for each cohort study and the consolidated study. Data from baseline
      exams were directly combined or harmonized into new variables. Common
      surveillance methods were developed and implemented to identify incidence and
      risk factors for cardiovascular disease (CVD) events and type 2 diabetes.
      RESULTS: A cohort of 4,569 western AN participants (2,116 men and 2,453 women),
      aged 18-95 years, was established to study CVD and diabetes prevalence.
      Prospective surveillance data over an average 6.7-year follow-up can now be used 
      to study CVD and diabetes incidence and associated risk factors in a subset of
      2,754 western AN participants (1,218 men and 1,536 women) who consented to
      initial surveillance. CONCLUSIONS: The combined cohort provides statistical power
      to examine incidence rates and risk factors for CVD and diabetes and allows for
      analyses by geographic region. The data can be used to develop intervention
      programmes in these populations and others.
AD  - Division of Community Health Services, Alaska Native Tribal Health Consortium,
      Anchorage, AK, USA.
FAU - Koller, Kathryn R
AU  - Koller KR
FAU - Wolfe, Abbie W
AU  - Wolfe AW
FAU - Metzger, Jesse S
AU  - Metzger JS
FAU - Austin, Melissa A
AU  - Austin MA
FAU - Hopkins, Scarlett E
AU  - Hopkins SE
FAU - Kaufmann, Cristiane
AU  - Kaufmann C
FAU - Jolly, Stacey E
AU  - Jolly SE
FAU - Ebbesson, Sven O E
AU  - Ebbesson SO
FAU - Umans, Jason G
AU  - Umans JG
FAU - Howard, Barbara V
AU  - Howard BV
FAU - Boyer, Bert B
AU  - Boyer BB
LA  - eng
GR  - K23 DK091363/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130502
PL  - Sweden
TA  - Int J Circumpolar Health
JT  - International journal of circumpolar health
JID - 9713056
SB  - IM
PMC - PMC3644062
OID - NLM: PMC3644062
OTO - NOTNLM
OT  - Alaska Native
OT  - cardiovascular disease
OT  - cohort study
OT  - risk factors
OT  - statistical power
OT  - type 2 diabetes
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/05 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/04/02 [accepted]
PHST- 2013/05/02 [epublish]
AID - 10.3402/ijch.v72i0.20572 [doi]
AID - 20572 [pii]
PST - epublish
SO  - Int J Circumpolar Health. 2013 May 2;72. doi: 10.3402/ijch.v72i0.20572. Print
      2013.

PMID- 23671819
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 2213-1779 (Print)
VI  - 1
IP  - 2
DP  - 2013 Apr 1
TI  - Heart Failure with Preserved Ejection Fraction in African-Americans - The
      Atherosclerosis Risk in Communities (ARIC) Study.
PG  - 156-163
AB  - In an entirely African-American cohort, we compared clinical characteristics,
      cardiac structure and function, and all cause mortality in heart failure (HF)
      with preserved ejection fraction (HFpEF) in relation to HF with reduced ejection 
      fraction (HFrEF) and those without HF. African-Americans are at increased risk
      for HF. Nevertheless, there are limited phenotypic and prognostic data in
      African-Americans with HFpEF compared to those with HFrEF and those without HF.
      Middle-aged African-Americans from the Jackson cohort of the Atherosclerosis Risk
      in Communities study (n=2,445) underwent echocardiography between 1993 and 1995. 
      HF prevalence was available in 1,962 for whom left ventricular ejection fraction 
      (LVEF) could be quantified. Participants with HF were categorized as having HFpEF
      (LVEF >/= 50%) or HFrEF (LVEF < 50%), or no HF, with comparisons made between
      groups. HF was identified in 116 (5.9%) participants (n=85 [73%] HFpEF; n=31
      [27%] HFrEF). Compared to those without HF, those with HFpEF were older, more
      likely to be female, had more frequent comorbidities, and concentric hypertrophy.
      In relation to HFrEF, those with HFpEF were more likely female, but less likely
      to have coronary heart disease, diabetes mellitus, chronic kidney disease, left
      atrial enlargement, and eccentric hypertrophy. Over a median 13.7 years of follow
      up, risk of death differed between groups, with age and sex adjusted hazard
      ratios of 1.51 (95%CI 1.01-2.25) for HFpEF vs. those without HF, and 2.50 (95%CI 
      1.37-4.58) for HFrEF vs. HFpEF. In this cohort of middle-aged African-Americans, 
      HFpEF was the most common form of HF, and was associated with a substantially
      better prognosis than HFrEF, but worse than those without HF.
AD  - Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States.
FAU - Gupta, Deepak K
AU  - Gupta DK
FAU - Shah, Amil M
AU  - Shah AM
FAU - Castagno, Davide
AU  - Castagno D
FAU - Takeuchi, Madoka
AU  - Takeuchi M
FAU - Loehr, Laura R
AU  - Loehr LR
FAU - Fox, Ervin R
AU  - Fox ER
FAU - Butler, Kenneth R
AU  - Butler KR
FAU - Mosley, Thomas H
AU  - Mosley TH
FAU - Kitzman, Dalane W
AU  - Kitzman DW
FAU - Solomon, Scott D
AU  - Solomon SD
LA  - ENG
GR  - HHSN268201100011C/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
TA  - JACC Heart Fail
JT  - JACC. Heart failure
JID - 101598241
PMC - PMC3650857
MID - NIHMS440898
OTO - NOTNLM
OT  - African-Americans
OT  - echocardiography
OT  - heart failure with preserved ejection fraction
OT  - heart failure with reduced ejection fraction
OT  - mortality
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PMCR- 2014/04/01 00:00
AID - 10.1016/j.jchf.2013.01.003 [doi]
PST - ppublish
SO  - JACC Heart Fail. 2013 Apr 1;1(2):156-163.

PMID- 23671718
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 1948-0210 (Electronic)
IS  - 1948-0210 (Linking)
VI  - 5
IP  - 2
DP  - 2013 Apr 26
TI  - In utero transplantation: Disparate ramifications.
PG  - 43-52
LID - 10.4252/wjsc.v5.i2.43 [doi]
AB  - In utero stem cell transplantation, which promises treatment for a host of
      genetic disorders early in gestation before disease effect stems from Ray Owen's 
      seminal observation that self-tolerance, is acquired during gestation. To date,
      in utero transplantation (IUT) has proved useful in characterizing the
      hematopoietic stem cell. Recent observations support its use as an in vivo method
      to further understanding of self-tolerance. Preclinical development continues for
      its application as a treatment for childhood hematolymphoid diseases. In
      addition, IUT may offer therapeutic options in the treatment of diabetes among
      other diseases. Thus IUT serves as a technique or system important in both a
      basic and applied format. This review summarizes these findings.
AD  - John S Pixley, Rheumatology/Immunology Division, Department of Medicine, VA
      Sierra Health Care System and the University of Nevada School of Medicine, Reno, 
      NV 89557, United States.
FAU - Pixley, John S
AU  - Pixley JS
FAU - Zanjani, Esmail D
AU  - Zanjani ED
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Stem Cells
JT  - World journal of stem cells
JID - 101535826
PMC - PMC3648645
OID - NLM: PMC3648645
OTO - NOTNLM
OT  - Immune ontogeny
OT  - Self non-self discrimination
OT  - Stem cell transplantation
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/12/03 [received]
PHST- 2013/01/07 [revised]
PHST- 2013/01/23 [accepted]
AID - 10.4252/wjsc.v5.i2.43 [doi]
PST - ppublish
SO  - World J Stem Cells. 2013 Apr 26;5(2):43-52. doi: 10.4252/wjsc.v5.i2.43.

PMID- 23671705
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Making and maintaining lifestyle changes after participating in group based type 
      2 diabetes self-management educations: a qualitative study.
PG  - e64009
LID - 10.1371/journal.pone.0064009 [doi]
AB  - BACKGROUND: Disease management is crucial in type 2 diabetes. Diabetes
      self-management education aims to provide the knowledge necessary to make and
      maintain lifestyle changes. However, few studies have investigated the processes 
      after such courses. The aim of this study was to investigate how participants
      make and maintain lifestyle changes after participating in group-based type 2
      diabetes self-management education. METHODS: Data was collected through
      qualitative semi-structured interviews with 23 patients who attended educational 
      group programs in Central Norway. The participants were asked how they had used
      the advice given and what they had changed after the course. RESULTS: Knowledge
      was essential for making lifestyle changes following education. Three factors
      affected whether lifestyle changes were implemented: obtaining new knowledge,
      taking responsibility, and receiving confirmation of an already healthy
      lifestyle. Four factors motivated individuals to maintain changes: support from
      others, experiencing an effect, fear of complications, and the formation of new
      habits. CONCLUSION: Knowledge was used to make and maintain changes in diet,
      medication and physical activity. Knowledge also acted as confirmation of an
      already adequate lifestyle. Knowledge led to no changes if diabetes appeared "not
      that scary" or if changes appeared too time consuming. Those involved in diabetes
      education need to be aware of the challenges in convincing asymptomatic patients 
      about the benefits of adherence to self-management behaviour.
AD  - Department of Public Health and General Practice, Norwegian University of Science
      and Technology, Trondheim, Norway.
FAU - Rise, Marit B
AU  - Rise MB
FAU - Pellerud, Anneli
AU  - Pellerud A
FAU - Rygg, Lisbeth O
AU  - Rygg LO
FAU - Steinsbekk, Aslak
AU  - Steinsbekk A
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3650057
OID - NLM: PMC3650057
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/21 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/05/09 [epublish]
AID - 10.1371/journal.pone.0064009 [doi]
AID - PONE-D-12-36371 [pii]
PST - epublish
SO  - PLoS One. 2013 May 9;8(5):e64009. doi: 10.1371/journal.pone.0064009. Print 2013.

PMID- 23671645
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Smoking and risk of kidney failure in the singapore chinese health study.
PG  - e62962
LID - 10.1371/journal.pone.0062962 [doi]
AB  - BACKGROUND: The relationship between smoking and risk of kidney failure,
      especially in people of Chinese origin, is not clear. We analyzed data from the
      Singapore Chinese Health Study to investigate whether smoking increases the risk 
      of kidney failure. METHODS: The Singapore Chinese Health Study is a
      population-based cohort of 63,257 Chinese adults enrolled between 1993 and 1998. 
      Information on smoking status was collected at baseline. Incidence of kidney
      failure was identified via record linkage with the nationwide Singapore Renal
      Registry until 2008. Kidney failure was defined by one of the following: 1) serum
      creatinine level of more than or equal to 500 micromol/l (5.7 mg/dl), 2)
      estimated glomerular filtration rate of less than 15 ml/min/1.73 m(2), 3)
      undergoing hemodialysis or peritoneal dialysis, 4) undergone kidney
      transplantation. Cox proportional hazard regression analysis was performed for
      the outcome of kidney failure after adjusting for age, education, dialect, herbal
      medications, body mass index, sex, physician-diagnosed hypertension and diabetes 
      mellitus. RESULTS: The mean age of subjects was 55.6 years at baseline, and 44%
      were men. Overall 30.6% were ever smokers (current or former) at baseline. A
      total of 674 incident cases of kidney failure occurred during a median follow-up 
      of 13.3 years. Among men, smokers had a significant increase in the adjusted risk
      of kidney failure [hazard ratio (HR): 1.29; 95% CI: 1.02-1.64] compared to never 
      smokers. There was a strong dose-dependent association between number of years of
      smoking and kidney failure, (p for trend = 0.011). The risk decreased with
      prolonged cessation (quitting >/=10 years since baseline). The number of women
      smokers was too few for conclusive relationship. LIMITATION: Information on
      baseline kidney function was not available. CONCLUSIONS: Cigarette smoking is
      associated with increased risk of kidney failure among Chinese men. The risk
      appears to be dose- and duration-dependent and modifiable after long duration of 
      cessation.
AD  - National Registry of Diseases Office, Health Promotion Board, Singapore,
      Singapore.
FAU - Jin, Aizhen
AU  - Jin A
FAU - Koh, Woon-Puay
AU  - Koh WP
FAU - Chow, Khuan Yew
AU  - Chow KY
FAU - Yuan, Jian-Min
AU  - Yuan JM
FAU - Jafar, Tazeen Hasan
AU  - Jafar TH
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3650019
OID - NLM: PMC3650019
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/15 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/05/09 [epublish]
AID - 10.1371/journal.pone.0062962 [doi]
AID - PONE-D-13-06671 [pii]
PST - epublish
SO  - PLoS One. 2013 May 9;8(5):e62962. doi: 10.1371/journal.pone.0062962. Print 2013.

PMID- 23671624
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - A Comparison of the Clinical and Epidemiological Characteristics of Adult
      Patients with Laboratory-Confirmed Influenza A or B during the 2011-2012
      Influenza Season in Korea: A Multi-Center Study.
PG  - e62685
LID - 10.1371/journal.pone.0062685 [doi]
AB  - BACKGROUND: During the 2011/2012 winter influenza season in the Republic of
      Korea, influenza A (H3N2) was the predominant virus in the first peak period of
      influenza activity during the second half of January 2012. On the other hand,
      influenza B was the predominant virus in the second peak period of influenza
      activity during the second half of March 2012. The objectives of this study were 
      to compare the clinical and epidemiological characteristics of patients with
      laboratory-confirmed influenza A or influenza B. METHODOLOGYPRINCIPAL FINDINGS:
      We analyzed data from 2,129 adult patients with influenza-like illnesses who
      visited the emergency rooms of seven university hospitals in Korea from October
      2011 to May 2012. Of 850 patients with laboratory-confirmed influenza, 656
      (77.2%) had influenza A (H3N2), and 194 (22.8%) influenza B. Age, and the
      frequencies of cardiovascular disorders, diabetes, hypertension were
      significantly higher in patients with influenza A (H3N2) (P<0.05). The
      frequencies of leukopenia or thrombocytopenia in patients with influenza B at
      initial presentation were statistically higher than those in patients with
      influenza A (H3N2) (P<0.05). The rate of hospitalization, and length of hospital 
      stay were statistically higher in patients with influenza A (H3N2) (P<0.05), and 
      of the 79 hospitalized patients, the frequency of diabetes, hypertension, cases
      having at least one of the comorbid conditions, and the proportion of elderly
      were significantly higher in patients with influenza A (H3N2) (P<0.05).
      CONCLUSIONS: The proportion of males to females and elderly population were
      significantly higher for influenza A (H3N2) patients group compared with
      influenza B group. Hypertension, diabetes, chronic lung diseases, cardiovascular 
      disorders, and neuromuscular diseases were independently associated with
      hospitalization due to influenza. Physicians should assess and treat the
      underlying comorbid conditions as well as influenza viral infections for the
      appropriate management of patients with influenza.
AD  - Division of Infectious Diseases, Department of Internal Medicine, St. Vincent's
      Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
FAU - Wie, Seong-Heon
AU  - Wie SH
FAU - So, Byung Hak
AU  - So BH
FAU - Song, Joon Young
AU  - Song JY
FAU - Cheong, Hee Jin
AU  - Cheong HJ
FAU - Seo, Yu Bin
AU  - Seo YB
FAU - Choi, Sung Hyuk
AU  - Choi SH
FAU - Noh, Ji Yun
AU  - Noh JY
FAU - Baek, Ji Hyeon
AU  - Baek JH
FAU - Lee, Jin Soo
AU  - Lee JS
FAU - Kim, Hyo Youl
AU  - Kim HY
FAU - Kim, Young Keun
AU  - Kim YK
FAU - Choi, Won Suk
AU  - Choi WS
FAU - Lee, Jacob
AU  - Lee J
FAU - Jeong, Hye Won
AU  - Jeong HW
FAU - Kim, Woo Joo
AU  - Kim WJ
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3643978
OID - NLM: PMC3643978
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/05 [received]
PHST- 2013/03/22 [accepted]
PHST- 2013/05/03 [epublish]
AID - 10.1371/journal.pone.0062685 [doi]
AID - PONE-D-12-38164 [pii]
PST - epublish
SO  - PLoS One. 2013 May 3;8(5):e62685. doi: 10.1371/journal.pone.0062685. Print 2013.

PMID- 23671618
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Towards renewed health economic simulation of type 2 diabetes: risk equations for
      first and second cardiovascular events from Swedish register data.
PG  - e62650
LID - 10.1371/journal.pone.0062650 [doi]
AB  - OBJECTIVE: Predicting the risk of future events is an essential part of health
      economic simulation models. In pursuit of this goal, the current study aims to
      predict the risk of developing first and second acute myocardial infarction,
      heart failure, non-acute ischaemic heart disease, and stroke after diagnosis in
      patients with type 2 diabetes, using data from the Swedish National Diabetes
      Register. MATERIAL AND METHODS: Register data on 29,034 patients with type 2
      diabetes were analysed over five years of follow up (baseline 2003). To develop
      and validate the risk equations, the sample was randomly divided into training
      (75%) and test (25%) subsamples. The Weibull proportional hazard model was used
      to estimate the coefficients of the risk equations, and these were validated in
      both the training and the test samples. RESULTS: In total, 4,547 first and 2,418 
      second events were observed during the five years of follow up. Experiencing a
      first event substantially elevated the risk of subsequent events. There were
      heterogeneities in the effects of covariates within as well as between events;
      for example, while for females the hazard ratio of having a first acute
      myocardial infarction was 0.79 (0.70-0.90), the hazard ratio of a second was 1.21
      (0.98-1.48). The hazards of second events decreased as the time since first
      events elapsed. The equations showed adequate calibration and discrimination (C
      statistics range: 0.70-0.84 in test samples). CONCLUSION: The accuracy of health 
      economic simulation models of type 2 diabetes can be improved by ensuring that
      they account for the heterogeneous effects of covariates on the risk of first and
      second cardiovascular events. Thus it is important to extend such models by
      including risk equations for second cardiovascular events.
AD  - Division of Health Economics, Department of Clinical Sciences, Malmo University
      Hospital, Lund University, Malmo, Sweden ; Health Economics & Management,
      Institute of Economic Research, Lund University, Lund, Sweden ; Department of
      Health Management and Economics, School of Public Health, Tehran University of
      Medical Sciences, Tehran, Iran.
FAU - Ahmad Kiadaliri, Aliasghar
AU  - Ahmad Kiadaliri A
FAU - Gerdtham, Ulf-G
AU  - Gerdtham UG
FAU - Nilsson, Peter
AU  - Nilsson P
FAU - Eliasson, Bjorn
AU  - Eliasson B
FAU - Gudbjornsdottir, Soffia
AU  - Gudbjornsdottir S
FAU - Carlsson, Katarina Steen
AU  - Carlsson KS
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3650043
OID - NLM: PMC3650043
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/20 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/05/09 [epublish]
AID - 10.1371/journal.pone.0062650 [doi]
AID - PONE-D-12-39930 [pii]
PST - epublish
SO  - PLoS One. 2013 May 9;8(5):e62650. doi: 10.1371/journal.pone.0062650. Print 2013.

PMID- 23671610
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - The Association between Nonalcoholic Fatty Pancreas Disease and Diabetes.
PG  - e62561
LID - 10.1371/journal.pone.0062561 [doi]
AB  - BACKGROUND: Fatty infiltration of the pancreas has been shown to interfere with
      insulin secretion. Both insulin sensitivity and secretion are important in the
      pathogenesis of diabetes and prediabetes. However, the relationship between
      diabetes, prediabetes, and fatty pancreas remains unknown. We aim to investigate 
      the relationships that fatty pancreas and nonalcoholic fatty liver disease
      (NAFLD) have with prediabetes and diabetes in a Chinese population. PATIENTS AND 
      METHODS: This was a cross-sectional study. A total of 7,464 subjects were
      recruited. NAFLD and fatty pancreas were assessed by sonography.
      Clinico-metabolic parameters were compared among subjects with normoglycemia,
      prediabetes, and diabetes. Multinomial logistic regression was used to evaluate
      the relationship between fatty pancreas and NAFLD and diabetes or prediabetes
      with adjustment for cardiometabolic risk factors. RESULTS: With an increase in
      glycemia, a significantly greater proportion of subjects had NAFLD and fatty
      pancreas (test for trend p<0.05). Similar trends were also found for
      hypertension, general and central obesity, low-HDL cholesterol, and
      hypertriglyceridemia. In the logistic regression analysis, age, hypertension,
      male gender, hypertriglyceridemia, and central obesity were significantly
      associated with prediabetes and diabetes. Furthermore, the ORs of prediabetes and
      diabetes for NAFLD were 1.798 (95% CI 1.544-2.094) and 2.578 (95% CI
      2.024-3.284), respectively. In addition, fatty pancreas was independently related
      to diabetes (OR, 1.379; 95% CI, 1.047-1.816) and prediabetes (OR, 1.222; 95% CI, 
      1.002-1.491) in male subjects. CONCLUSIONS: Both NAFLD and fatty pancreas were
      associated with diabetes independent of age, gender, adiposity, and other
      cardiometabolic risk factors. Fatty pancreas was also related to prediabetes in
      males.
AD  - Department of Internal Medicine, National Cheng-Kung University Hospital, College
      of Medicine, National Cheng-Kung University, Tainan, Taiwan.
FAU - Ou, Horng-Yih
AU  - Ou HY
FAU - Wang, Chih-Yuan
AU  - Wang CY
FAU - Yang, Yi-Ching
AU  - Yang YC
FAU - Chen, Ming-Fong
AU  - Chen MF
FAU - Chang, Chih-Jen
AU  - Chang CJ
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3643962
OID - NLM: PMC3643962
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/05 [received]
PHST- 2013/03/22 [accepted]
PHST- 2013/05/03 [epublish]
AID - 10.1371/journal.pone.0062561 [doi]
AID - PONE-D-13-01143 [pii]
PST - epublish
SO  - PLoS One. 2013 May 3;8(5):e62561. doi: 10.1371/journal.pone.0062561. Print 2013.

PMID- 23671599
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Factors Associated with Prevalence, Awareness, Treatment and Control of
      Hypertension among Adults in Southern China: A Community-Based, Cross-Sectional
      Survey.
PG  - e62469
LID - 10.1371/journal.pone.0062469 [doi]
AB  - The aim of this study was to investigate factors associated with prevalence,
      awareness, treatment and control of hypertension in southern China. A
      cross-sectional, population-based survey was conducted in 180 villages across 15 
      counties in southern China from July to November 2010. Totally, 17437 persons
      completed all of the questionnaires, measurement examination and blood specimen
      collection. Adjusted rate of hypertension was 22.59% (95%CI: 22.52%-22.66%), for 
      men 23.36% (95%CI: 23.25%-23.47%) and for women 21.77% (95%CI: 21.68%-21.86%).
      Multivariate logistic regression showed that old age, education attainment,
      alcohol use, diabetes, obesity, high TC and high TG were associated with
      hypertension. Among the hypertensive individuals, 54.33% were aware of their
      hypertension, and 46.34% were currently taking antihypertensive medication, but
      only 18.26% had their blood pressure controlled. Among all the hypertensive
      subjects, awareness was more common in those who were female, living in the
      urban, old age, low education attainment, diabetes, overweight, obese, Low HDL-C.
      Among the subjects aware of their diagnosis of hypertension, medication treatment
      was more common in those living in the urban, old age, nonsmoker and diabetes.
      Among the individuals who receiving medication treatment, controlled hypertension
      were less common in those living in the urban, young age, low education
      attainment, overweight and obese. Despite high rate of hypertension, awareness,
      treatment and control of hypertension still need to be strengthened.
AD  - Department of Chronic Non-Communicable Diseases Control and Prevention, Zhejiang 
      Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.
FAU - Wang, Hao
AU  - Wang H
FAU - Zhang, Xinwei
AU  - Zhang X
FAU - Zhang, Jie
AU  - Zhang J
FAU - He, Qingfang
AU  - He Q
FAU - Hu, Ruying
AU  - Hu R
FAU - Wang, Lixin
AU  - Wang L
FAU - Su, Danting
AU  - Su D
FAU - Xiao, Yuanyuan
AU  - Xiao Y
FAU - Pan, Jin
AU  - Pan J
FAU - Ye, Zhen
AU  - Ye Z
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3650037
OID - NLM: PMC3650037
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/28 [received]
PHST- 2013/03/20 [accepted]
PHST- 2013/05/09 [epublish]
AID - 10.1371/journal.pone.0062469 [doi]
AID - PONE-D-12-37272 [pii]
PST - epublish
SO  - PLoS One. 2013 May 9;8(5):e62469. doi: 10.1371/journal.pone.0062469. Print 2013.

PMID- 23671547
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 1918-3003 (Print)
IS  - 1918-3003 (Linking)
VI  - 5
IP  - 3
DP  - 2013 Jun
TI  - Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93
      patients with type 2 diabetes treated for 1.5 years or longer.
PG  - 217-21
LID - 10.4021/jocmr1256w [doi]
AB  - BACKGROUND: Several studies have shown the effectiveness of sitagliptin, a
      dipeptidyl peptidase-4 inhibitor, for type 2 diabetes, with a hypoglycemic effect
      being demonstrated both when it is administered alone or in combination with
      other oral antidiabetic agents. However, there are few reports about its
      long-term efficacy, although medications for diabetes need to be effective over
      the long term. This study (as part of ASSET-K) aimed to investigate the efficacy 
      and safety of sitagliptin when it was administered for 1.5 years or longer, and
      to explore factors associated with reduction of the therapeutic response.
      METHODS: Out of 375 patients treated with sitagliptin (50 mg/day) at Kanamori
      Diabetes Clinic between December 2009 and March 2012, 133 could be followed up
      for 72 weeks without interruption. After excluding 40 patients in whom the dosage
      and/or types of concomitant medications were modified during that period, the
      remaining 93 were included in this analysis. Clinical indices, such as blood
      glucose, HbA1c, and body weight, were investigated retrospectively. Compliance
      with diet and exercise therapy at 48 weeks was checked by a questionnaire.
      RESULTS: In the 93 patients analyzed (sitagliptin monotherapy, n = 9; combination
      therapy, n = 77; and switching from an alpha-glucosidase inhibitor or glinide, n 
      = 7), hemoglobin A1c (HbA1c) showed a significant decrease after 24 weeks (7.70
      +/- 0.73% at baseline vs. 6.90 +/- 0.55% at 24 weeks), but then showed a slight
      increase at 48 weeks. HbA1c was subsequently maintained in the same range with no
      significant changes until 72 weeks. A positive correlation was noted between the 
      changes of HbA1c and body weight from 24 to 48 weeks. Compliance with diet and
      exercise therapy was worse in patients showing a >/= 0.3% increase of HbA1c (n = 
      37) from 24 to 48 weeks than in the others (n = 56). Multiple logistic regression
      analysis showed that both factors were independent determinants of the increase
      of HbA1c from 24 weeks onward. CONCLUSIONS: Sitagliptin showed good efficacy and 
      safety when administered for 18 months as both monotherapy and combination
      therapy. Inadequate compliance with diet/exercise therapy and weight again may be
      associated with an increase of HbA1c over time during treatment with sitagliptin.
AD  - Kanamori Diabetes Clinic, First floor, Prestige Sagami Yume Odori, 8-1-1
      Sagamihara, Sagamihara City, Kanagawa 229-0031, Japan.
FAU - Kanamori, Akira
AU  - Kanamori A
FAU - Matsuba, Ikuro
AU  - Matsuba I
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Canada
TA  - J Clin Med Res
JT  - Journal of clinical medicine research
JID - 101538301
PMC - PMC3651072
OID - NLM: PMC3651072
OTO - NOTNLM
OT  - Hemoglobin A1c
OT  - Long-term administration
OT  - Sitagliptin
OT  - Type 2 diabetes
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013/02/19 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.4021/jocmr1256w [doi]
PST - ppublish
SO  - J Clin Med Res. 2013 Jun;5(3):217-21. doi: 10.4021/jocmr1256w. Epub 2013 Apr 23.

PMID- 23671529
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130528
IS  - 1911-6470 (Print)
IS  - 1911-6470 (Linking)
VI  - 7
IP  - 3-4
DP  - 2013 Mar-Apr
TI  - Preoperative hydronephrosis and diabetes mellitus predict poor prognosis in upper
      urinary tract urothelial carcinoma.
PG  - E215-20
LID - 10.5489/cuaj.11236 [doi]
AB  - INTRODUCTION: We assess the impact of traditional prognostic factors, tumour
      location, degree of hydronephrosis and diabetes mellitus (DM) on the survival of 
      patients treated for upper urinary tract urothelial carcinoma (UUTUC). METHODS:
      From January 2004 to March 2010, we analyzed data from 114 patients with UUTUC
      who underwent nephroureterectomy with a bladder cuff excision. Median patient age
      was 71 years and median follow-up was 26.5 months. The influence of traditional
      prognostic factors, including DM, tumour stage, grade, location and degree of
      hydronephrosis, on recurrence-free survival (RFS) rates were analyzed using
      Kaplan-Meier analysis and Cox proportional hazards regression model. RESULTS:
      Among 61 renal pelvis and 53 ureteral tumour cases, recurrence was identified in 
      71 cases (62.3%). Kaplan-Meier analysis showed that degree of hydronephrosis was 
      associated with RFS (p = 0.001). DM and degree of hydronephrosis were independent
      factors for RFS in Cox proportional regression analysis (HR=1.8 CI: 1.01-3.55, p 
      = 0.04), (HR=3.7, CI: 2.0-6.5, p = 0.001). All patients with ureteral tumour had 
      no worse prognosis than those with renal pelvis tumour, but the pT2 patients with
      ureteral tumour had a worse prognosis than those with renal pelvis tumour with a 
      median RFS of 9 months (range: 2.6-15.3 months) and 29 months (range: 8.0-13.2
      months), respectively (p = 0.028). CONCLUSIONS: Tumour location is not a factor
      influencing RFS, except in the pT2 stage. However, severe hydronephrosis is
      associated with a higher recurrence in UUTUC. Also, DM is related to disease
      recurrence. Further prospective studies are needed to establish the prognostic
      significance of DM in large populations.
AD  - Department of Urology, Chonnam National University Medical School, Gwangju,
      Republic of Korea.
FAU - Hwang, Insang
AU  - Hwang I
FAU - Jung, Seung Il
AU  - Jung SI
FAU - Nam, Deok-Hyun
AU  - Nam DH
FAU - Hwang, Eu Chang
AU  - Hwang EC
FAU - Kang, Taek Won
AU  - Kang TW
FAU - Kwon, Dong Deuk
AU  - Kwon DD
FAU - Ryu, Soo Bang
AU  - Ryu SB
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can Urol Assoc J
JT  - Canadian Urological Association journal = Journal de l'Association des urologues 
      du Canada
JID - 101312644
PMC - PMC3650762
OID - NLM: PMC3650762
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
AID - 10.5489/cuaj.11236 [doi]
AID - cuaj-3-4-e215 [pii]
PST - ppublish
SO  - Can Urol Assoc J. 2013 Mar-Apr;7(3-4):E215-20. doi: 10.5489/cuaj.11236.

PMID- 23671455
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 1734-1922 (Print)
IS  - 1734-1922 (Linking)
VI  - 9
IP  - 2
DP  - 2013 Apr 20
TI  - Infection caused by Aeromonas sobria, complicated by lower extremity paraplegia
      and the cauda equine syndrome in a patient with well-controlled type 2 diabetes.
PG  - 384-5
LID - 10.5114/aoms.2012.30832 [doi]
AD  - Department of Endocrinology and Diabetology, Nicolaus Copernicus University,
      Ludwik Rydygier Collegium Medicum , Bydgoszcz, Poland.
FAU - Szafranska, Malgorzata
AU  - Szafranska M
FAU - Szafranski, Jacek
AU  - Szafranski J
FAU - Bronisz, Agata
AU  - Bronisz A
FAU - Junik, Roman
AU  - Junik R
LA  - eng
PT  - Journal Article
DEP - 20121008
PL  - Poland
TA  - Arch Med Sci
JT  - Archives of medical science : AMS
JID - 101258257
PMC - PMC3648811
OID - NLM: PMC3648811
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2011/07/05 [received]
PHST- 2011/08/15 [revised]
PHST- 2011/08/25 [accepted]
PHST- 2012/10/08 [epublish]
AID - 10.5114/aoms.2012.30832 [doi]
AID - 19488 [pii]
PST - ppublish
SO  - Arch Med Sci. 2013 Apr 20;9(2):384-5. doi: 10.5114/aoms.2012.30832. Epub 2012 Oct
      8.

PMID- 23671434
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 1734-1922 (Print)
IS  - 1734-1922 (Linking)
VI  - 9
IP  - 2
DP  - 2013 Apr 20
TI  - Metabolic syndrome prevalence according to ATP III and IDF criteria and related
      factors in Turkish adults.
PG  - 243-53
LID - 10.5114/aoms.2013.34560 [doi]
AB  - INTRODUCTION: The aim of this study is to investigate the prevalence of metabolic
      syndrome (MS) and its components according to Adult Treatment Panel III (ATP III)
      and International Diabetes Federation (IDF) criteria and the risk factors
      affecting MS. Metabolic syndrome prevalence was evaluated according to certain
      quintet age groups, altitude, location and demographic features. MATERIAL AND
      METHODS: This study was a cross-sectional survey conducted in 24 provinces from
      the 7 regions of Turkey. A total of 4309 adults from 7 regions participated in
      the study (1947 males, 45.2%). RESULTS: The mean age of participants was 47 +/-14
      years. Metabolic syndrome prevalence was found as 36.6% according to ATP III and 
      44.0% according to IDF. The MS rate was found to be higher in females compared to
      males in both groups (p < 0.01). According to both criteria, MS prevalence was
      found to be higher in subjects who lived in coastal regions when evaluated
      according to altitude and in subjects who lived in district centers when
      evaluated according to location. The MS risk is 1.62-fold higher in females
      compared to males. Metabolic syndrome risk increases as age increases and is
      highest in the 61-65 age group. Metabolic syndrome risk increases 2.75-fold in
      the overweight compared to normal weighing subjects and 7.80-fold in the obese.
      CONCLUSIONS: Metabolic syndrome prevalence was found to be high in Turkey
      according to both criteria. Metabolic syndrome prevalence increases as age and
      body mass index (BMI) increase. Age, female gender and obesity are independent
      risk factors for MS development.
AD  - Department of Intensive Care, Faculty of Medicine, Erciyes University, Kayseri,
      Turkey.
FAU - Gundogan, Kursat
AU  - Gundogan K
FAU - Bayram, Fahri
AU  - Bayram F
FAU - Gedik, Vedia
AU  - Gedik V
FAU - Kaya, Ahmet
AU  - Kaya A
FAU - Karaman, Ahmet
AU  - Karaman A
FAU - Demir, Ozgur
AU  - Demir O
FAU - Sabuncu, Tevfik
AU  - Sabuncu T
FAU - Kocer, Derya
AU  - Kocer D
FAU - Coskun, Ramazan
AU  - Coskun R
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - Poland
TA  - Arch Med Sci
JT  - Archives of medical science : AMS
JID - 101258257
PMC - PMC3648836
OID - NLM: PMC3648836
OTO - NOTNLM
OT  - age groups
OT  - altitude
OT  - metabolic syndrome
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/05/28 [received]
PHST- 2012/07/19 [revised]
PHST- 2012/08/29 [accepted]
PHST- 2013/04/12 [epublish]
AID - 10.5114/aoms.2013.34560 [doi]
AID - 20604 [pii]
PST - ppublish
SO  - Arch Med Sci. 2013 Apr 20;9(2):243-53. doi: 10.5114/aoms.2013.34560. Epub 2013
      Apr 12.

PMID- 23671432
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 1734-1922 (Print)
IS  - 1734-1922 (Linking)
VI  - 9
IP  - 2
DP  - 2013 Apr 20
TI  - Association of rs1800471 polymorphism of TGFB1 gene with chronic kidney disease
      occurrence and progression and hypertension appearance.
PG  - 230-7
LID - 10.5114/aoms.2013.34418 [doi]
AB  - INTRODUCTION: Transforming growth factor beta1 (TGF-beta1) is a cytokine involved
      in the process of pathological tissue sclerosis, which is part of the
      pathophysiological mechanism of end stage renal disease development. The aim of
      the study was to evaluate the association of the single nucleotide polymorphism
      rs1800471 of the TGFB1 gene with chronic kidney disease (CKD) occurrence and
      progression as well as hypertension appearance. MATERIAL AND METHODS: It was a
      case-control study where 109 patients with CKD and 111 very old people were
      enrolled. The association of the studied polymorphism with mentioned diseases was
      assessed in the whole study group as well as in the subgroups stratified
      according to the underlying etiology of CKD: nephropathy in type 1 diabetes (n = 
      13), chronic glomerulonephritis (n = 50) and chronic interstitial nephritis (n = 
      46). RESULTS: No association of CKD progression with rs1800471 polymorphism was
      observed. The C allele was identified as the one associated with higher risk of
      the disease occurrence in the dominant model of inheritance (p = 0.035). The C
      allele in women, opposite to male gender, was associated with higher risk of CKD 
      development (p = 0.038). GG genotype was associated with elevated risk of
      hypertension appearance (p = 0,0021). CONCLUSIONS: Due to the lack of accordance 
      with previously performed studies it is still impossible to state an unequivocal 
      conclusion regarding the association between rs1800471 polymorphism of the TGFB1 
      gene and risk of CKD occurrence and progression as well as hypertension
      appearance. That is why it is necessary to perform further studies in this field.
AD  - Department of Internal Diseases, Diabetology and Nephrology, Medical University
      of Silesia, Zabrze, Poland.
FAU - Nabrdalik, Katarzyna
AU  - Nabrdalik K
FAU - Gumprecht, Janusz
AU  - Gumprecht J
FAU - Adamczyk, Piotr
AU  - Adamczyk P
FAU - Gorczynska-Kosiorz, Sylwia
AU  - Gorczynska-Kosiorz S
FAU - Zywiec, Joanna
AU  - Zywiec J
FAU - Grzeszczak, Wladyslaw
AU  - Grzeszczak W
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - Poland
TA  - Arch Med Sci
JT  - Archives of medical science : AMS
JID - 101258257
PMC - PMC3648826
OID - NLM: PMC3648826
OTO - NOTNLM
OT  - case-control study
OT  - genetic risk factors
OT  - kidney diseases
OT  - very old people
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2012/06/20 [received]
PHST- 2012/09/26 [revised]
PHST- 2012/11/16 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.5114/aoms.2013.34418 [doi]
AID - 20581 [pii]
PST - ppublish
SO  - Arch Med Sci. 2013 Apr 20;9(2):230-7. doi: 10.5114/aoms.2013.34418. Epub 2013 Apr
      9.

PMID- 23671395
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130517
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 6
DP  - 2013
TI  - Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.
PG  - 187-95
LID - 10.2147/DMSO.S35682 [doi]
AB  - Dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged as a new class of
      antidiabetic that show favorable results in improving glycemic control with a
      minimal risk of hypoglycemia and weight gain. Teneligliptin, a novel DPP-4
      inhibitor, exhibits a unique structure characterized by five consecutive rings,
      which produce a potent and long-lasting effect. Teneligliptin is currently used
      in cases showing insufficient improvement in glycemic control even after diet
      control and exercise or a combination of diet control, exercise, and
      sulfonylurea- or thiazolidine-class drugs. In adults, teneligliptin is orally
      administered at a dosage of 20 mg once daily, which can be increased up to 40 mg 
      per day. Because the metabolites of this drug are eliminated via renal and
      hepatic excretion, no dose adjustment is necessary in patients with renal
      impairment. The safety profile of teneligliptin is similar to those of other
      available DPP-4 inhibitors. However, caution needs to be exercised when
      administering teneligliptin to patients who are prone to QT prolongation. One
      study has reported that the postprandial blood glucose-lowering effects of
      teneligliptin administered prior to breakfast were sustained throughout the day, 
      and the effects observed after dinner were similar to those observed after
      breakfast or lunch. Thus, although clinical data for this new drug are limited,
      this drug shows promise in stabilizing glycemic fluctuations throughout the day
      and consequently suppressing the progression of diabetic complications. However, 
      continued evaluation in long-term studies and clinical trials is required to
      evaluate the efficacy and safety of the drug as well as to identify additional
      indications for its clinical use.
AD  - Department of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan;
      Diabetes and Metabolism Information Center, Diabetes Research Center, National
      Center for Global Health and Medicine, Tokyo, Japan.
FAU - Kishimoto, Miyako
AU  - Kishimoto M
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3650886
OID - NLM: PMC3650886
OTO - NOTNLM
OT  - DPP-4 inhibitor
OT  - diabetes
OT  - teneligliptin
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/06 [epublish]
AID - 10.2147/DMSO.S35682 [doi]
AID - dmso-6-187 [pii]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2013 May 6;6:187-95. doi: 10.2147/DMSO.S35682. Print
      2013.

PMID- 23671314
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 13
TI  - The relationship between TSH and free T4 in a large population is complex,
      non-linear and differs by age and gender.
AB  - Context:The relationship between TSH and T4 is thought to be inverse log-linear, 
      but recent studies have challenged this. There are limited data regarding age and
      gender differences in the TSH-T4 relationship.Objective:To evaluate the TSH-free 
      T4 relationship in a large sample.Methods:In a cross-sectional, retrospective
      study we analyzed TSH and free T4 results from 152,261 subjects collected over 12
      years by a single laboratory. For each free T4 value (in pmol/L), the median TSH 
      was calculated and analyzed by gender and age (in 20 year bands).Results:The
      relationship between log TSH and free T4 was nonlinear. Mathematical modeling
      confirmed that it was described by two sigmoid curves with inflexion points at
      free T4 concentrations of 7 and 21 pmol/L. For free T4 within the reference range
      (10 - 20 pmol/L), median TSH was higher in males than females (p<0.001) and
      increased across age bands with the highest values in those aged over 80 years
      (p<0.001). By contrast, in overt hypothyroidism (n= 4403), TSH was lower in older
      age groups compared with those aged 20 to 39 years (p<0.001).Conclusions:The
      TSH-free T4 relationship is not inverse log-linear but can be described by two
      overlapping negative sigmoid curves. At physiological free T4 concentrations, TSH
      is higher in males and in older people, whereas the TSH response to
      hypothyroidism is more robust in younger people. These results advance
      understanding of the TSH-free T4 relationship, which is central to thyroid
      pathophysiology and laboratory diagnosis of thyroid disease.
AD  - Department of Clinical Biochemistry, PathWest Laboratory Medicine, Queen
      Elizabeth II Medical Centre, Nedlands 6009 (N. C. H., K.M.R., R.W., E.M.L)
      Australia; Western Diagnostic Pathology, Myaree 6154, Australia (N. C. H.);
      School of Pathology and Laboratory Medicine, The University of Western Australia,
      Crawley 6009, Australia (N.C.H); Department of Endocrinology and Diabetes, Sir
      Charles Gairdner Hospital, Nedlands 6009, Australia (K.M.R., S.J.B., E.M.L,
      J.P.W); and School of Medicine and Pharmacology, The University of Western
      Australia, Crawley 6009, Australia (J.P.W).
FAU - Hadlow, Narelle C
AU  - Hadlow NC
FAU - Rothacker, Karen M
AU  - Rothacker KM
FAU - Wardrop, Robert
AU  - Wardrop R
FAU - Brown, Suzanne J
AU  - Brown SJ
FAU - Lim, Ee Mun
AU  - Lim EM
FAU - Walsh, John P
AU  - Walsh JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - jc.2012-4223 [pii]
AID - 10.1210/jc.2012-4223 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 13.

PMID- 23671265
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
DP  - 2013 May 12
TI  - Renin-angiotensin system blockade in heart failure patients on long-term
      haemodialysis in Taiwan.
AB  - AIMS: Heart failure is among the most frequent complications of patients on
      long-term haemodialysis. The benefits of renin-angiotensin system (RAS) blockade 
      on the outcomes of these patients have yet to be determined. METHODS AND RESULTS:
      We conducted a nationwide observational study using data from the Taiwan National
      Health Insurance claims database, between 1999 and 2010. We enrolled patients
      aged >/=35 years with new-onset heart failure [diagnosed by International
      Classification of Diseases, 9th revision, clinical modification (ICD-9-CM) codes]
      under treatment with medications. New users of a RAS blocker (RASB; i.e. an ACE
      inhibitor or an ARB used as monotherapy or dual therapy) were selected to compare
      with non-RASB users. We used Cox proportional hazards regression with and without
      propensity score adjustment to compare the risk of 3-year all-cause and
      cardiovascular mortality. Stratified analyses and RASB therapy duration as a
      time-dependent covariate were also performed. In all, 4771 were treated with an
      RASB (n = 3024) or without an RASB (n = 1747). RASB users had a higher prevalence
      of hypertension and diabetes, and a higher number of hospitalization. Among RASB 
      users, 1148 deaths (38.0%) occurred during 5272 person-years of follow-up
      compared with 734 deaths (42.0%) among non-RASB users during 2683 person-years of
      follow-up. Three-year mortality rates were 45.4% and 49.1% for patients receiving
      and those not receiving an RASB, respectively (log-rank test, P < 0.001).
      Adjusted hazard analysis revealed that RASB therapeutic effects remained
      significant on all-cause [hazard ratio (HR) 0.8; 95% confidence interval (CI)
      0.72-0.89; P < 0.001] and cardiovascular mortality (HR 0.76; 95% CI 0.64-0.90; P 
      < 0.01). CONCLUSIONS: RASB therapy reduced all-cause and cardiovascular mortality
      in heart failure patients on long-term haemodialysis.
AD  - School of Health Care Administration, Taipei Medical University, Taipei, Taiwan.
FAU - Tang, Chao-Hsiun
AU  - Tang CH
FAU - Chen, Tso-Hsiao
AU  - Chen TH
FAU - Wang, Chia-Chen
AU  - Wang CC
FAU - Hong, Chuang-Ye
AU  - Hong CY
FAU - Huang, Kuan-Chih
AU  - Huang KC
FAU - Sue, Yuh-Mou
AU  - Sue YM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
OTO - NOTNLM
OT  - ACE inhibitor
OT  - ARB
OT  - Haemodialysis
OT  - Heart failure
OT  - Mortality
OT  - Renin–angiotensin system
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - hft082 [pii]
AID - 10.1093/eurjhf/hft082 [doi]
PST - aheadofprint
SO  - Eur J Heart Fail. 2013 May 12.

PMID- 23671259
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 13
TI  - Redefining the initiation and maintenance of zebrafish interrenal steroidogenesis
      by characterizing the key enzyme Cyp11a2.
AB  - Zebrafish are emerging as a model to study steroid hormone action and associated 
      disease. However, steroidogenesis in zebrafish is not well characterized.
      Mammalian P450 side-chain cleavage enzyme (CYP11A1) catalyzes the first step of
      steroidogenesis, the conversion of cholesterol to pregnenolone. Previous studies 
      describe an essential role for zebrafish Cyp11a1 during early development.
      Cyp11a1 has been suggested to be the functional equivalent of mammalian CYP11A1
      in the zebrafish interrenal gland (equivalent to the mammalian adrenal), gonad
      and brain. However, reported cyp11a1 expression is inconsistent in zebrafish
      larvae, after active cortisol synthesis commences. Recently, a duplicated cyp11a 
      gene, cyp11a2, has been described, which shares an 85% identity with cyp11a1. We 
      aimed to elucidate the specific role of the two cyp11a paralogs. cyp11a1 was
      expressed from 0-48 hours post-fertilization (hpf), whilst cyp11a2 expression
      started after development of the interrenal primordium (32 hpf), and was the only
      paralog in larvae. cyp11a2 is expressed in adult steroidogenic tissues, such as
      the interrenal, gonads, and brain. In contrast, cyp11a1 was mainly restricted to 
      the gonads. Anti-sense morpholino knockdown studies confirmed abnormal
      gastrulation in cyp11a1 morphants. cyp11a2 morphants showed impaired
      steroidogenesis and a phenotype indicative of metabolic abnormalities. The
      phenotype was rescued by pregnenolone replacement in cyp11a2 morphants. Thus, we 
      conclude that cyp11a1 is required for early development, whereas cyp11a2 is
      essential for initiation and maintenance of zebrafish interrenal steroidogenesis.
      Importantly, this study highlights the need for a comprehensive characterization 
      of steroidogenesis in zebrafish prior its implementation as a model organism in
      translational research of adrenal disease.
AD  - Centre for Endocrinology, Diabetes and Metabolism (S.P., A.G., A.E.T., I.T.R,
      W.A., C.S., N.K.), and Medical and Molecular Genetics (I.M.E., Y.H., F.M.),
      School of Clinical & Experimental Medicine, University of Birmingham, Birmingham,
      United Kingdom.
FAU - Parajes, Silvia
AU  - Parajes S
FAU - Griffin, Aliesha
AU  - Griffin A
FAU - Taylor, Angela E
AU  - Taylor AE
FAU - Rose, Ian T
AU  - Rose IT
FAU - Miguel-Escalada, Irene
AU  - Miguel-Escalada I
FAU - Hadzhiev, Yavor
AU  - Hadzhiev Y
FAU - Arlt, Wiebke
AU  - Arlt W
FAU - Shackleton, Cedric
AU  - Shackleton C
FAU - Muller, Ferenc
AU  - Muller F
FAU - Krone, Nils
AU  - Krone N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - en.2013-1145 [pii]
AID - 10.1210/en.2013-1145 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 13.

PMID- 23671156
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
DP  - 2013 May 21
TI  - Long-term survival in patients with refractory angina.
AB  - AIMS: An increasing number of patients with severe coronary artery disease (CAD) 
      are not candidates for traditional revascularization and experience angina in
      spite of excellent medical therapy. Despite limited data regarding the natural
      history and predictors of adverse outcome, these patients have been considered at
      high risk for early mortality. METHODS AND RESULTS: The OPtions In Myocardial
      Ischemic Syndrome Therapy (OPTIMIST) program at the Minneapolis Heart Institute
      offers traditional and investigational therapies for patients with refractory
      angina. A prospective clinical database includes detailed baseline and yearly
      follow-up information. Death status and cause were determined using the Social
      Security Death Index, clinical data, and death certificates. Time to death was
      analysed using survival analysis methods. For 1200 patients, the mean age was
      63.5 years (77.5% male) with 72.4% having prior coronary artery bypass grafting, 
      74.4% prior percutaneous coronary intervention, 72.6% prior myocardial
      infarction, 78.3% 3-vessel CAD, 23.0% moderate-to-severe left-ventricular (LV)
      dysfunction, and 32.6% congestive heart failure (CHF). Overall, 241 patients died
      (20.1%: 71.8% cardiovascular) during a median follow-up 5.1 years (range 0-16,
      14.7% over 9). By Kaplan-Meier analysis, mortality was 3.9% (95% CI 2.8-5.0) at 1
      year and 28.4% (95% CI 24.9-32.0) at 9 years. Multivariate predictors of
      all-cause mortality were baseline age, diabetes, angina class, chronic kidney
      disease, LV dysfunction, and CHF. CONCLUSION: Long-term mortality in patients
      with refractory angina is lower than previously reported. Therapeutic options for
      this distinct and growing group of patients should focus on angina relief and
      improved quality of life.
AD  - Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, 920 East 
      28th Street, Suite 100, Minneapolis, MN 55407, USA.
FAU - Henry, Timothy D
AU  - Henry TD
FAU - Satran, Daniel
AU  - Satran D
FAU - Hodges, James S
AU  - Hodges JS
FAU - Johnson, Randall K
AU  - Johnson RK
FAU - Poulose, Anil K
AU  - Poulose AK
FAU - Campbell, Alex R
AU  - Campbell AR
FAU - Garberich, Ross F
AU  - Garberich RF
FAU - Bart, Bradley A
AU  - Bart BA
FAU - Olson, Rachel E
AU  - Olson RE
FAU - Boisjolie, Charlene R
AU  - Boisjolie CR
FAU - Harvey, Karen L
AU  - Harvey KL
FAU - Arndt, Theresa L
AU  - Arndt TL
FAU - Traverse, Jay H
AU  - Traverse JH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130521
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
OTO - NOTNLM
OT  - Chronic coronary artery disease
OT  - Refractory angina
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/05/12 [aheadofprint]
AID - eht165 [pii]
AID - 10.1093/eurheartj/eht165 [doi]
PST - aheadofprint
SO  - Eur Heart J. 2013 May 21.

PMID- 23671105
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 110
IP  - 22
DP  - 2013 May 28
TI  - Cross-talk between Akkermansia muciniphila and intestinal epithelium controls
      diet-induced obesity.
PG  - 9066-71
LID - 10.1073/pnas.1219451110 [doi]
AB  - Obesity and type 2 diabetes are characterized by altered gut microbiota,
      inflammation, and gut barrier disruption. Microbial composition and the
      mechanisms of interaction with the host that affect gut barrier function during
      obesity and type 2 diabetes have not been elucidated. We recently isolated
      Akkermansia muciniphila, which is a mucin-degrading bacterium that resides in the
      mucus layer. The presence of this bacterium inversely correlates with body weight
      in rodents and humans. However, the precise physiological roles played by this
      bacterium during obesity and metabolic disorders are unknown. This study
      demonstrated that the abundance of A. muciniphila decreased in obese and type 2
      diabetic mice. We also observed that prebiotic feeding normalized A. muciniphila 
      abundance, which correlated with an improved metabolic profile. In addition, we
      demonstrated that A. muciniphila treatment reversed high-fat diet-induced
      metabolic disorders, including fat-mass gain, metabolic endotoxemia, adipose
      tissue inflammation, and insulin resistance. A. muciniphila administration
      increased the intestinal levels of endocannabinoids that control inflammation,
      the gut barrier, and gut peptide secretion. Finally, we demonstrated that all
      these effects required viable A. muciniphila because treatment with heat-killed
      cells did not improve the metabolic profile or the mucus layer thickness. In
      summary, this study provides substantial insight into the intricate mechanisms of
      bacterial (i.e., A. muciniphila) regulation of the cross-talk between the host
      and gut microbiota. These results also provide a rationale for the development of
      a treatment that uses this human mucus colonizer for the prevention or treatment 
      of obesity and its associated metabolic disorders.
AD  - Metabolism and Nutrition Research Group, Walloon Excellence in Life sciences and 
      BIOtechnology (WELBIO), Louvain Drug Research Institute, Universite catholique de
      Louvain, B-1200 Brussels, Belgium.
FAU - Everard, Amandine
AU  - Everard A
FAU - Belzer, Clara
AU  - Belzer C
FAU - Geurts, Lucie
AU  - Geurts L
FAU - Ouwerkerk, Janneke P
AU  - Ouwerkerk JP
FAU - Druart, Celine
AU  - Druart C
FAU - Bindels, Laure B
AU  - Bindels LB
FAU - Guiot, Yves
AU  - Guiot Y
FAU - Derrien, Muriel
AU  - Derrien M
FAU - Muccioli, Giulio G
AU  - Muccioli GG
FAU - Delzenne, Nathalie M
AU  - Delzenne NM
FAU - de Vos, Willem M
AU  - de Vos WM
FAU - Cani, Patrice D
AU  - Cani PD
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
OTO - NOTNLM
OT  - LPS
OT  - Lactobacillus plantarum
OT  - RegIIIγ
OT  - antimicrobial peptides
OT  - gut permeability
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/05/13 [aheadofprint]
AID - 1219451110 [pii]
AID - 10.1073/pnas.1219451110 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71. doi:
      10.1073/pnas.1219451110. Epub 2013 May 13.

PMID- 23671083
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 110
IP  - 23
DP  - 2013 Jun 4
TI  - Biodegradable synthetic high-density lipoprotein nanoparticles for
      atherosclerosis.
PG  - 9445-50
LID - 10.1073/pnas.1301929110 [doi]
AB  - Atherosclerosis remains one of the most common causes of death in the United
      States and throughout the world because of the lack of early detection.
      Macrophage apoptosis is a major contributor to the instability of atherosclerotic
      lesions. Development of an apoptosis targeted high-density lipoprotein
      (HDL)-mimicking nanoparticle (NP) to carry contrast agents for early detection of
      vulnerable plaques and the initiation of preventative therapies that exploit the 
      vascular protective effects of HDL can be attractive for atherosclerosis. Here,
      we report the construction of a synthetic, biodegradable HDL-NP platform for
      detection of vulnerable plaques by targeting the collapse of mitochondrial
      membrane potential that occurs during apoptosis. This HDL mimic contains a core
      of biodegradable poly(lactic-co-glycolic acid), cholesteryl oleate, and a
      phospholipid bilayer coat that is decorated with triphenylphosphonium (TPP)
      cations for detection of mitochondrial membrane potential collapse. The lipid
      layer provides the surface for adsorption of apolipoprotein (apo) A-I mimetic 4F 
      peptide, and the core contains diagnostically active quantum dots (QDs) for
      optical imaging. In vitro uptake, detection of apoptosis, and cholesterol binding
      studies indicated promising detection ability and therapeutic potential of
      TPP-HDL-apoA-I-QD NPs. In vitro studies indicated the potential of these NPs in
      reverse cholesterol transport. In vivo biodistribution and pharmacokinetics
      indicated favorable tissue distribution, controlled pharmacokinetic parameters,
      and significant triglyceride reduction for i.v.-injected TPP-HDL-apoA-I-QD NPs in
      rats. These HDL NPs demonstrate excellent biocompatibility, stability, nontoxic, 
      and nonimmunogenic properties, which prove to be promising for future translation
      in early plaque diagnosis and might find applications to prevent vulnerable
      plaque progression.
AD  - NanoTherapeutics Research Laboratory, Department of Chemistry, and Department of 
      Physiology and Pharmacology, University of Georgia, Athens, GA 30602.
FAU - Marrache, Sean
AU  - Marrache S
FAU - Dhar, Shanta
AU  - Dhar S
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
OTO - NOTNLM
OT  - atheroprotection
OT  - coronary heart disease
OT  - diabetes
OT  - good cholesterol
OT  - obesity
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/05/13 [aheadofprint]
AID - 1301929110 [pii]
AID - 10.1073/pnas.1301929110 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9445-50. doi:
      10.1073/pnas.1301929110. Epub 2013 May 13.

PMID- 23671028
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1521-6551 (Electronic)
IS  - 1521-6543 (Linking)
DP  - 2013 May 14
TI  - Role of energy- and nutrient-sensing kinases AMP-activated protein kinase (AMPK) 
      and mammalian target of rapamycin (mTOR) in adipocyte differentiation.
LID - 10.1002/iub.1170 [doi]
AB  - Recent advances have demonstrated that the adipose tissue plays a central role in
      regulating overall energy balance. Obesity results from a chronic deregulation of
      energy balance, with energy intake exceeding energy expenditure. Recently, new
      mechanisms that control the obesity phenotype such as the equilibrium between
      white and brown adipose tissue function has been identified. In this context, it 
      is becoming increasingly clear that in addition to cellular growth, AMP-activated
      protein kinase (AMPK) and mammalian target of rapamycin (mTOR) also regulate
      lipid metabolism and adipogenesis. Here, we review recent advances in the
      understanding of the molecular mechanisms involved in white and brown
      differentiation programs focusing on AMPK and mTOR signaling pathways, which may 
      play differential roles in white adipose tissue and brown adipose tissue
      development. In view of the worldwide epidemic of obesity and its associated
      metabolic disorders such as insulin resistance and type 2 diabetes, targeting
      these kinases may represent a potential approach for reducing adiposity and
      improving obesity-related diseases. (c) 2013 IUBMB Life, 2013.
CI  - Copyright (c) 2013 International Union of Biochemistry and Molecular Biology,
      Inc.
AD  - Research Unit, Hospital Universitari de Tarragona Joan XXIII. IISPV. Universitat 
      Rovira i Virgili, Tarragona, Spain; CIBER de Diabetes y Enfermedades Metabolicas 
      Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
FAU - Fernandez-Veledo, Sonia
AU  - Fernandez-Veledo S
FAU - Vazquez-Carballo, Ana
AU  - Vazquez-Carballo A
FAU - Vila-Bedmar, Rocio
AU  - Vila-Bedmar R
FAU - Ceperuelo-Mallafre, Victoria
AU  - Ceperuelo-Mallafre V
FAU - Vendrell, Joan
AU  - Vendrell J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - IUBMB Life
JT  - IUBMB life
JID - 100888706
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/01/15 [received]
PHST- 2013/03/14 [accepted]
AID - 10.1002/iub.1170 [doi]
PST - aheadofprint
SO  - IUBMB Life. 2013 May 14. doi: 10.1002/iub.1170.

PMID- 23671024
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1860-7187 (Electronic)
IS  - 1860-7179 (Linking)
DP  - 2013 May 13
TI  - Design and Synthesis of 4-(2,4,5-Trifluorophenyl)butane-1,3-diamines as
      Dipeptidyl Peptidase IV Inhibitors.
LID - 10.1002/cmdc.201300104 [doi]
AB  - The worldwide prevalence of diabetes has spurred numerous studies on the
      development of new antidiabetic medicines. As a result, dipeptidyl peptidase IV
      (DPP4) has been recognized as a validated target. In our efforts to discover new 
      DPP4 inhibitors, we analyzed the complexed structures of DPP4 available in
      Protein Data Bank and designed a series of triazole compounds. After enzyme
      activity assays and crystallographic verification of the binding interaction
      patterns, we found that the triazole compounds can inhibit DPP4 with micromolar
      IC50 values. Liver microsome stability and cytochrome P450 metabolic tests were
      performed on this series, revealing undesirable pharmacokinetic profiles for the 
      triazole compounds. To overcome this liability, we substituted the triazole ring 
      with an amide or urea group to produce a new series of DPP4 inhibitors. Based on 
      its enzyme activity, metabolic stability, and selectivity over DPP8 and DPP9, we 
      selected compound 21 r for further study of its in vivo effects in mice using an 
      oral glucose tolerance test (OGTT). The results show that 21 r has efficacy
      similar to that of sitagliptin at a dose of 3 mg kg-1 . The crystal structure of 
      21 r bound to DPP4 also reveals that the trifluoromethyl group is directed toward
      a subpocket different from the subsite bound by sitagliptin, providing clues for 
      the design of new DPP4 inhibitors.
CI  - Copyright (c) 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
AD  - State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica,
      Chinese Academy of Sciences, 555 Zuchongzhi Road, Zhangjiang Hi-Tech Park,
      Shanghai 201203 (China).
FAU - Zhu, Linrong
AU  - Zhu L
FAU - Li, Yuanyuan
AU  - Li Y
FAU - Qiu, Ling
AU  - Qiu L
FAU - Su, Mingbo
AU  - Su M
FAU - Wang, Xin
AU  - Wang X
FAU - Xia, Chunmei
AU  - Xia C
FAU - Qu, Yi
AU  - Qu Y
FAU - Li, Jingya
AU  - Li J
FAU - Li, Jia
AU  - Li J
FAU - Xiong, Bing
AU  - Xiong B
FAU - Shen, Jingkang
AU  - Shen J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - ChemMedChem
JT  - ChemMedChem
JID - 101259013
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/03/04 [received]
AID - 10.1002/cmdc.201300104 [doi]
PST - aheadofprint
SO  - ChemMedChem. 2013 May 13. doi: 10.1002/cmdc.201300104.

PMID- 23670996
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 13
TI  - Effects of Low-Dose Prednisolone on Hepatic and Peripheral Insulin Sensitivity,
      Insulin Secretion, and Abdominal Adiposity in Patients With Inflammatory
      Rheumatologic Disease.
AB  - OBJECTIVESThe metabolic effects of low-dose prednisolone and optimal management
      of glucocorticoid-induced diabetes are poorly characterized. The aims were to
      investigate the acute effects of low-dose prednisolone on carbohydrate metabolism
      and whether long-term low-dose prednisolone administration increases visceral
      adiposity, amplifying metabolic perturbations.RESEARCH DESIGN AND METHODSSubjects
      with inflammatory rheumatologic disease without diabetes mellitus were recruited.
      Nine subjects (age, 59 +/- 11 years) not using oral glucocorticoids were studied 
      before and after a 7- to 10-day course of oral prednisolone 6 mg daily. Baseline 
      data were compared with 12 subjects (age, 61 +/- 8 years) using continuous
      long-term prednisolone (6.3 +/- 2.2 mg/day). Basal endogenous glucose production 
      (EGP) was estimated by 6,6-2H2 glucose infusion, insulin sensitivity was
      estimated by two-step hyperinsulinemic-euglycemic clamp, insulin secretion was
      estimated by intravenous glucose tolerance test, and adipose tissue areas were
      estimated by computed tomography.RESULTSPrednisolone acutely increased basal EGP 
      (2.44 +/- 0.46 to 2.65 +/- 0.35 mg/min/kg; P = 0.05) and reduced insulin
      suppression of EGP (79 +/- 7 to 67 +/- 14%; P = 0.03), peripheral glucose
      disposal (8.2 +/- 2.4 to 7.0 +/- 1.6 mg/kg/min; P = 0.01), and first-phase (5.9
      +/- 2.0 to 3.9 +/- 1.6 mU/mmol; P = 0.01) and second-phase (4.6 +/- 1.7 to 3.6
      +/- 1.4 mU/mmol; P = 0.02) insulin secretion. Long-term prednisolone users had
      attenuated insulin suppression of EGP (66 +/- 14 vs. 79 +/- 7%; P = 0.03) and
      nonoxidative glucose disposal (44 +/- 24 vs. 62 +/- 8%; P = 0.02) compared with
      nonglucocorticoid users, whereas basal EGP, insulin secretion, and adipose tissue
      areas were not significantly different.CONCLUSIONLow-dose prednisolone acutely
      perturbs all aspects of carbohydrate metabolism. Long-term low-dose prednisolone 
      induces hepatic insulin resistance and reduces peripheral nonoxidative glucose
      disposal. We conclude that hepatic and peripheral insulin sensitivity should be
      targeted by glucose-lowering therapy for glucocorticoid-induced diabetes.
AD  - Faculty of Health Sciences, Flinders University, Adelaide, Australia.
FAU - Petersons, Carolyn J
AU  - Petersons CJ
FAU - Mangelsdorf, Brenda L
AU  - Mangelsdorf BL
FAU - Jenkins, Arthur B
AU  - Jenkins AB
FAU - Poljak, Anne
AU  - Poljak A
FAU - Smith, Malcolm D
AU  - Smith MD
FAU - Greenfield, Jerry R
AU  - Greenfield JR
FAU - Thompson, Campbell H
AU  - Thompson CH
FAU - Burt, Morton G
AU  - Burt MG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - dc12-2617 [pii]
AID - 10.2337/dc12-2617 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 13.

PMID- 23670995
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 13
TI  - Changes in Body Fat Distribution and Fitness Are Associated With Changes in
      Hemoglobin A1c After 9 Months of Exercise Training: Results From the HART-D
      Study.
AB  - OBJECTIVETo investigate the associations between changes in body composition and 
      fitness after exercise training and changes in hemoglobin A1c (HbA1c) in
      individuals with type 2 diabetes.RESEARCH DESIGN AND METHODSParticipants (n =
      201) were randomized to aerobic, resistance, or combined training for 9 months.
      HbA1c, waist circumference, total and trunk fat mass, appendicular fat mass, lean
      body mass, isokinetic leg muscle strength, peak O2 uptake, and estimated METs
      were assessed at baseline and follow-up. Change in HbA1c was evaluated across
      quartiles of change in body composition and fitness.RESULTSChange in HbA1c was
      associated with changes in body weight (r = 0.13, P = 0.052), waist circumference
      (r = 0.17, P = 0.013), trunk fat mass (r = 0.19, P = 0.005), and estimated METs
      (r = -0.16, P = 0.023). There was a trend in change in HbA1c across quartiles of 
      waist circumference (P = 0.011), trunk fat mass (P = 0.020), and estimated METs
      (P = 0.011). Participants with increased estimated METs and reduced trunk fat
      mass had greater odds of having reduced HbA1c after training (3.48, 1.46-8.31).
      Finally, participants with increased estimated METs and reduced waist
      circumference were 2.81 (1.13-6.98) times more likely to have reduced HbA1c and
      type 2 diabetes medication use than those who without improved fitness and
      central adiposity.CONCLUSIONSIn patients with type 2 diabetes, a reduction in
      central adiposity and increase in fitness were the most prominent predictors of
      the change in HbA1c in response to exercise training.
AD  - Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada.
FAU - Senechal, Martin
AU  - Senechal M
FAU - Swift, Damon L
AU  - Swift DL
FAU - Johannsen, Neil M
AU  - Johannsen NM
FAU - Blair, Steven N
AU  - Blair SN
FAU - Earnest, Conrad P
AU  - Earnest CP
FAU - Lavie, Carl J
AU  - Lavie CJ
FAU - Church, Timothy S
AU  - Church TS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - dc12-2428 [pii]
AID - 10.2337/dc12-2428 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 13.

PMID- 23670975
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 13
TI  - Quality Control Culture System Restores Diabetic Endothelial Progenitor Cell
      Vasculogenesis and Accelerates Wound Closure.
AB  - Delayed diabetic (DM) wound healing is, in part, the result of inadequate
      endothelial progenitor cell (EPC) proliferation, mobilization, and trafficking.
      Recently, we developed a serum free functional culture system called quantity and
      quality control culture system (QQc) which enhances the number and vasculogenic
      potential of EPCs. We hypothesize that QQc restoration of DM EPC function will
      improve wound closure. In order to test this hypothesis, we measured pre/post-QQc
      DM KSL (e.g. c-kit+Sca-1+lin-) cell activity in vitro as well as the effect of
      KSL cell adoptive transfer on the rate of euglycemic wound closure. KSL cells
      were magnetically sorted from control and streptozotocin-induced Type I DM
      C57BL6J bone marrow. Freshly isolated control and DM KSL cells were cultured in
      QQc for 7 days and pre/post-QQc KSL function was tested. The number of KSLs
      significantly increased post QQc for both DM and controls and also increasing DM 
      -KSL vasculogenic potential above fresh control KSL level. Similarly, fresh DM
      cells form fewer tubules, but QQc increases DM tubule formation to greater than
      fresh control cell levels (p<0.05). Adoptive transfer of post-QQc DM KSL cells
      significantly enhance wound closure compared to fresh DM KSL cells and equaled
      wound closure of post-QQc control KSL cells. Post-QQc DM KSL enhancement of wound
      closure is mediated, in part, via a vasculogenic mechanism. This study
      demonstrates that QQc can reverse DM EPC dysfunction and achieve control-levels
      of EPC function. Finally, post-QQc DM EPC therapy effectively improved euglycemic
      wound closure and may improve DM wound healing.
AD  - Tokai University School of Medicine Division of Regenerative Med, Department of
      Basic Clinical Science.
FAU - Tanaka, Rica
AU  - Tanaka R
FAU - Vaynrub, Max
AU  - Vaynrub M
FAU - Masuda, Haruchika
AU  - Masuda H
FAU - Ito, Rie
AU  - Ito R
FAU - Kobori, Michiru
AU  - Kobori M
FAU - Miyasaka, Muneo
AU  - Miyasaka M
FAU - Mizuno, Hiroshi
AU  - Mizuno H
FAU - Warren, Stephen M
AU  - Warren SM
FAU - Asahara, Takayuki
AU  - Asahara T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - db12-1621 [pii]
AID - 10.2337/db12-1621 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 13.

PMID- 23670974
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 13
TI  - Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin
      resistance in mice.
AB  - Circulating interleukin (IL)-18 is elevated in obesity, but paradoxically causes 
      hypophagia. We hypothesized that IL-18 may attenuate high fat diet induced
      insulin resistance by activating AMP activated protein kinase (AMPK). We studied 
      mice with a global deletion of the alpha isoform of the IL-18 receptor
      (IL-18R-/-), fed a standard chow or high fat diet (HFD). We next performed gain
      of function experiments in skeletal muscle, in vitro, ex vivo and in vivo. We
      show that IL-18 is implicated in metabolic homeostasis, inflammation and insulin 
      resistance via mechanisms involving the activation of AMPK in skeletal muscle.
      IL-18R-/- mice display increased weight gain, and ectopic lipid deposition,
      inflammation and reduced AMPK signaling in skeletal muscle. Treating myotubes or 
      skeletal muscle strips with IL-18 activated AMPK and increased fat oxidation.
      Moreover, in vivo electroporation of IL-18 into skeletal muscle activated AMPK
      and concomitantly inhibited high fat diet-induced weight gain. In summary IL-18
      enhances AMPK signaling and lipid oxidation in skeletal muscle implicating IL-18 
      in metabolic homeostasis.
AD  - The Centre of Inflammation and Metabolism, Rigshospitalet.
FAU - Lindegaard, Birgitte
AU  - Lindegaard B
FAU - Matthews, Vance B
AU  - Matthews VB
FAU - Brandt, Claus
AU  - Brandt C
FAU - Hojman, Pernille
AU  - Hojman P
FAU - Allen, Tamara L
AU  - Allen TL
FAU - Estevez, Emma
AU  - Estevez E
FAU - Watt, Matthew J
AU  - Watt MJ
FAU - Bruce, Clinton R
AU  - Bruce CR
FAU - Mortensen, Ole
AU  - Mortensen O
FAU - Syberg, Susanne
AU  - Syberg S
FAU - Rudnicka, Caroline
AU  - Rudnicka C
FAU - Abildgaard, Julie
AU  - Abildgaard J
FAU - Pilegaard, Henriette
AU  - Pilegaard H
FAU - Hidalgo, Juan
AU  - Hidalgo J
FAU - Ditlevsen, Susanne
AU  - Ditlevsen S
FAU - Alsted, Thomas J
AU  - Alsted TJ
FAU - Madsen, Andreas N
AU  - Madsen AN
FAU - Pedersen, Bente K
AU  - Pedersen BK
FAU - Febbraio, Mark A
AU  - Febbraio MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - db12-1095 [pii]
AID - 10.2337/db12-1095 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 13.

PMID- 23670973
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 13
TI  - Relation between Serum Free Fatty Acids and Adiposity, Insulin Resistance and
      Cardiovascular Risk Factors from Adolescence to Adulthood.
AB  - The objective of this study was to describe longitudinal relations of serum total
      free fatty acids (FFA) to insulin resistance (IR) and cardiovascular (CV) risk
      factors from adolescence into adulthood. The cohort included participants in a
      longitudinal study of obesity and IR with complete data, including anthropometric
      measures, FFA, IR measured by euglycemic clamp, blood pressure, fasting serum
      lipids and insulin at mean-ages 15 and 22 (N=207) and their parents (N=272). FFA 
      and IR were not significantly related at mean-age 15 but were significantly
      related at mean-age 22. FFA did not relate to BMI at either age. FFA at age 15
      estimated IR at age 22. In parents (mean-age 51) FFA was significantly correlated
      with BMI, percent body fat, systolic blood pressure, LDL, and IR. Associations
      with all risk factors except IR in parents were attenuated by adjustment for BMI.
      Most age 22 correlations with parents were higher than corresponding age 15
      correlations. This study finds that FFA is associated with IR starting in young
      adulthood. The relation between FFA and CV risk factors does not become
      significant until later adulthood. The results support a significant impact of
      early metabolic dysfunction on later CV risk.
AD  - Department of Pediatrics, Medical School and.
FAU - Frohnert, Brigitte I
AU  - Frohnert BI
FAU - Jacobs, David R Jr
AU  - Jacobs DR Jr
FAU - Steinberger, Julia
AU  - Steinberger J
FAU - Moran, Antoinette
AU  - Moran A
FAU - Steffen, Lyn M
AU  - Steffen LM
FAU - Sinaiko, Alan R
AU  - Sinaiko AR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - db12-1122 [pii]
AID - 10.2337/db12-1122 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 13.

PMID- 23670972
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 13
TI  - Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes.
AB  - Administration of low-dose IL-2 alone or combined with rapamycin (RAPA) prevents 
      hyperglycemia in NOD mice. Also, low-dose IL-2 cures recent onset type 1 diabetes
      (T1D) in NOD mice, partially by boosting pancreatic regulatory T cells (Treg
      cells). These approaches are currently being evaluated in humans. Our objective
      was to study the effect of higher IL-2 doses (250,000-500,000 IU, daily) as well 
      as low-dose IL-2 (25,000 IU, daily) and RAPA (1mg/kg, daily) (RAPA/IL-2)
      combination. We show that despite further boosting Treg cells, high doses of IL-2
      rapidly precipitated T1D in pre-diabetic female and male mice and increased
      myeloid cells in the pancreas. Also, we observed that RAPA counteracted IL-2
      effects on Treg cells, failed to control IL-2-boosted NK cells and broke
      IL-2-induced tolerance in a reversible way. Notably, RAPA/IL-2 combination
      failure to cure T1D was associated to an unexpected deleterious effect on glucose
      homeostasis at multiple levels, including beta-cell division, glucose tolerance
      and liver glucose metabolism. Our data help understand the therapeutic
      limitations of IL-2 alone or RAPA/IL-2 combination and could lead to the design
      of improved therapies for T1D.
AD  - Universite Pierre et Marie Curie Univ Paris 06.
FAU - Baeyens, Audrey
AU  - Baeyens A
FAU - Perol, Louis
AU  - Perol L
FAU - Fourcade, Gwladys
AU  - Fourcade G
FAU - Cagnard, Nicolas
AU  - Cagnard N
FAU - Carpentier, Wassila
AU  - Carpentier W
FAU - Woytschak, Janine
AU  - Woytschak J
FAU - Boyman, Onur
AU  - Boyman O
FAU - Hartemann, Agnes
AU  - Hartemann A
FAU - Piaggio, Eliane
AU  - Piaggio E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - db13-0214 [pii]
AID - 10.2337/db13-0214 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 13.

PMID- 23670971
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 13
TI  - Induction of cytosolic phospholipase A2alpha is required for adipose neutrophil
      infiltration and hepatic insulin resistance early in the course of high fat
      feeding.
AB  - In established obesity inflammation and macrophage recruitment likely contribute 
      to the development of insulin resistance. In the present study, we set to explore
      whether adipose tissue infiltration by neutrophils that occurs early (3 days)
      after initiating high-fat diet (3dHFD) could contribute to the early occurrence
      of hepatic insulin resistance, and to determine the role of cytosolic
      phospholipaseA2alpha (cPLA2alpha) in this process. 3dHFD caused a significant
      upregulation of cPLA2alpha in peri-epididymal fat and in the liver. A specific
      antisense oligonucleotide (AS) effectively prevented cPLA2alpha induction,
      neutrophil infiltration into adipose tissue (likely involving MIP-2), and
      protected against 3dHFD-induced impairment in hepatic insulin signaling and
      glucose over-production from pyruvate. To sort out the role of adipose neutrophil
      infiltration independent of cPLA2alpha induction in the liver, mice were injected
      intraperitoneally with anti-ICAM-1 antibodies. This effectively prevented
      neutrophil infiltration without affecting cPLA2alpha or MIP-2, but like AS,
      prevented impairment in hepatic insulin signaling, the enhanced
      glucose-to-pyruvate flux, and the impaired insulin-mediated suppression of
      hepatic glucose production (assessed by clamp), which were induced by 3dHFD.
      Adipose tissue secretion of TNFalpha was increased by 3dHFD, but not if mice were
      treated with AS or ICAM-1 antibodies. Moreover, systemic TNFalpha neutralization 
      prevented 3dHFD-induced hepatic insulin resistance, suggesting its mediatory
      role. We propose that an acute, cPLA2alpha-dependent, neutrophil-dominated
      inflammatory response of adipose tissue contributes to hepatic insulin resistance
      and glucose overproduction in the early adaptation to high-fat feeding.
AD  - Infectious Diseases and Immunology Laboratory.
FAU - Hadad, Nurit
AU  - Hadad N
FAU - Burgazliev, Olga
AU  - Burgazliev O
FAU - Elgazar-Carmon, Vered
AU  - Elgazar-Carmon V
FAU - Solomonov, Yulia
AU  - Solomonov Y
FAU - Wueest, Stephan
AU  - Wueest S
FAU - Item, Flurin
AU  - Item F
FAU - Konrad, Daniel
AU  - Konrad D
FAU - Rudich, Assaf
AU  - Rudich A
FAU - Levy, Rachel
AU  - Levy R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - db12-1300 [pii]
AID - 10.2337/db12-1300 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 13.

PMID- 23670970
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 13
TI  - Genetic modifiers of cystic fibrosis-related diabetes.
AB  - Diabetes is a common age-dependent complication of cystic fibrosis (CF) that is
      strongly influenced by modifier genes. We conducted a genome-wide association
      study in 3059 individuals with CF (644 with CFRD) and identified single
      nucleotide polymorphisms (SNPs) within and 5' to the SLC26A9 gene which
      associated with CFRD (hazard ratio=1.38, P=3.6x10-8). Replication was
      demonstrated in 694 individuals (124 with CFRD) (hazard ratio=1.47, P=0.007) with
      combined analysis significant at P=9.8x10-10. SLC26A9 is an epithelial
      chloride/bicarbonate channel that can interact with CFTR, the protein mutated in 
      CF. We also hypothesized that common SNPs associated with type 2 diabetes (T2D
      SNPs) might also affect risk for CF-related diabetes (CFRD). A previous
      association of CFRD with SNPs in TCF7L2 was replicated in this study (P=0.004;
      combined analysis P=3.8x10-6), and T2D SNPs at/near CDKAL1, CDKN2A/B, and IGF2BP2
      associated with CFRD (P<0.004). These 5 loci accounted for 8.3% of the phenotypic
      variance in CFRD onset and had a combined population attributable risk of 68%.
      Diabetes is a highly prevalent complication of CF whose susceptibility is
      determined in part by variants at SLC26A9 (which mediates processes proximate to 
      the CF disease-causing gene), and at 4 susceptibility loci for type 2 diabetes in
      the general population.
AD  - Division of Pediatric Endocrinology, Johns Hopkins University School of Medicine,
      Baltimore, MD.
FAU - Blackman, Scott M
AU  - Blackman SM
FAU - Commander, Clayton W
AU  - Commander CW
FAU - Watson, Christopher
AU  - Watson C
FAU - Arcara, Kristin M
AU  - Arcara KM
FAU - Strug, Lisa J
AU  - Strug LJ
FAU - Stonebraker, Jaclyn R
AU  - Stonebraker JR
FAU - Wright, Fred A
AU  - Wright FA
FAU - Rommens, Johanna M
AU  - Rommens JM
FAU - Sun, Lei
AU  - Sun L
FAU - Pace, Rhonda G
AU  - Pace RG
FAU - Norris, Sarah A
AU  - Norris SA
FAU - Durie, Peter R
AU  - Durie PR
FAU - Drumm, Mitchell L
AU  - Drumm ML
FAU - Knowles, Michael R
AU  - Knowles MR
FAU - Cutting, Garry R
AU  - Cutting GR
LA  - ENG
GR  - K23 DK083551/DK/NIDDK NIH HHS/United States
GR  - R01 HL068890/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - db13-0510 [pii]
AID - 10.2337/db13-0510 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 13.

PMID- 23670948
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
DP  - 2013 May 13
TI  - A Clinician's Guide to the ABCs of Cardiovascular Disease Prevention: The Johns
      Hopkins Ciccarone Center for the Prevention of Heart Disease and American College
      of Cardiology Cardiosource Approach to the Million Hearts Initiative.
LID - 10.1002/clc.22137 [doi]
AB  - Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the
      United States and worldwide. Fortunately, it is often preventable with early
      adoption of lifestyle modification, prevention of risk factor onset, and
      aggressive treatment of existing risk factors. The Million Hearts Initiative is
      an effort by the Centers for Disease Control that aims to prevent 1 million
      myocardial infarctions and strokes over the next 5 years. As part of this
      initiative, we present a simply organized "ABCDE" approach for guiding a
      consistent comprehensive approach to managing cardiovascular risk in daily
      clinical practice. ABCDE stands for assessment of risk, antiplatelet therapy,
      blood pressure management, cholesterol management, cigarette/tobacco cessation,
      diet and weight management, diabetes prevention and treatment, and exercise,
      interventions regularly used to reduce cardiovascular (CV) risk. Throughout this 
      article we summarize recommendations related to each topic and reference landmark
      trials and data that support our approach. We believe that the ABCDE approach
      will be the core framework for addressing CV risk in our effort to prevent CVD.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Ciccarone Center for the Prevention of Heart Disease, The Johns Hopkins School of
      Medicine, Baltimore, Maryland.
FAU - Hsu, Steven
AU  - Hsu S
FAU - Ton, Van-Khue
AU  - Ton VK
FAU - Dominique Ashen, M
AU  - Dominique Ashen M
FAU - Martin, Seth S
AU  - Martin SS
FAU - Gluckman, Ty J
AU  - Gluckman TJ
FAU - Kohli, Payal
AU  - Kohli P
FAU - Sisson, Stephen D
AU  - Sisson SD
FAU - Blumenthal, Roger S
AU  - Blumenthal RS
FAU - Blaha, Michael J
AU  - Blaha MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/03/04 [received]
PHST- 2013/04/10 [revised]
AID - 10.1002/clc.22137 [doi]
PST - aheadofprint
SO  - Clin Cardiol. 2013 May 13. doi: 10.1002/clc.22137.

PMID- 23670940
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
DP  - 2013 May 13
TI  - Statin Therapy in the Reduction of Cardiovascular Events in Patients Undergoing
      Intermediate-Risk Noncardiac, Nonvascular Surgery.
LID - 10.1002/clc.22135 [doi]
AB  - BACKGROUND: Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins)
      reduce perioperative cardiac events in high-risk patients undergoing
      cardiovascular surgery. However, there is paucity of data on the role of statins 
      in patients undergoing intermediate-risk noncardiac, nonvascular surgery (NCNVS).
      HYPOTHESIS: Statins are cardioprotective in intermediate-risk NCNVS. METHODS: We 
      identified a retrospective cohort of patients undergoing intermediate risk NCNVS.
      Our composite end point (CEP) included 30-day all-cause mortality, atrial
      fibrillation (AF), and nonfatal myocardial infarction (MI). A stepwise logistic
      regression with adjustment using propensity scores was performed to determine if 
      statin therapy was independently associated with the risk reduction of adverse
      postoperative cardiovascular outcomes. RESULTS: We identified 752 patients.
      Seventy-five of them (9.97%) developed composite end points; 10 (1.33%) had
      in-hospital nonfatal MI, 44 (5.85%) developed AF, and 35 (4.65%) died within 30
      days. The 30-day all-cause mortality was 31/478 (6.48%) among statin nonusers vs 
      4/274 (1.45%) for statin users (P < 0.002). As compared with nonusers, patients
      on statin therapy had a 5-fold reduced risk of 30-day all-cause mortality. Statin
      therapy was associated with decreased CEP after adjusting for baseline
      characteristics, with a propensity score to predict use of statins (odds ratio
      [OR]: 0.54, 95% confidence interval [CI]: 0.30-0.97, P = 0.039). After further
      adjustment for propensity score, diabetes mellitus, percutaneous coronary
      intervention, and prior coronary artery bypass grafting, statin therapy proved
      beneficial (OR: 0.51, 95% CI: 0.28-0.92, P = 0.026). CONCLUSIONS: Statin use in
      the perioperative period was associated with a reduction in cardiovascular
      adverse events and 30-day all-cause mortality in patients undergoing
      intermediate-risk NCNVS.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland,
      Ohio; Section of Vascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio.
FAU - Raju, Manjunath G
AU  - Raju MG
FAU - Pachika, Ajay
AU  - Pachika A
FAU - Punnam, Sujeeth R
AU  - Punnam SR
FAU - Gardiner, Joseph C
AU  - Gardiner JC
FAU - Shishehbor, Mehdi H
AU  - Shishehbor MH
FAU - Kapadia, Samir R
AU  - Kapadia SR
FAU - Abela, George S
AU  - Abela GS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/01/31 [received]
PHST- 2013/04/03 [revised]
AID - 10.1002/clc.22135 [doi]
PST - aheadofprint
SO  - Clin Cardiol. 2013 May 13. doi: 10.1002/clc.22135.

PMID- 23670879
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1545-5017 (Electronic)
IS  - 1545-5009 (Linking)
DP  - 2013 May 14
TI  - Predictors of neoplastic disease in children with isolated pituitary stalk
      thickening.
LID - 10.1002/pbc.24577 [doi]
AB  - BACKGROUND: The significance of pituitary stalk thickening (PST) on magnetic
      resonance imaging (MRI) is often unclear. We evaluated presenting symptoms, MRI
      findings, clinical course, and outcome predictors of patients with PST.
      PROCEDURE: We used a computerized search of the medical record from 1995 to 2008 
      to identify patients with PST without pituitary mass on MRI. Baseline and
      follow-up MRIs were reviewed in a blinded fashion. Relevant clinical data were
      abstracted. RESULTS: 69 patients with reported PST and adequate imaging for
      review were identified; 42 met study criteria. Median age at first abnormal MRI
      was 13.6 years (range: 0.8-19.7); 43% were male. Median follow-up was 3.4 years
      (range 0-12.8). Patients with diabetes insipidus (DI) were significantly more
      likely to have a neoplastic process than those without (P = 0.0008). Of 16
      patients with DI, 8 (50%) had a neoplastic process, including germ cell tumor (n 
      = 4), Langerhans cell histiocytosis (n = 3), and lymphoma (n = 1). Among patients
      with DI, 7 (44%) also developed anterior pituitary hormone dysfunction (APD),
      either at presentation or on pre-biopsy follow-up, including 6/8 patients with
      stalk neoplasm and only 1/8 patients with non-neoplastic PST (P = 0.04).
      Twenty-six patients presented without DI; none was found to have neoplasm of the 
      stalk except one patient with craniopharyngioma. Progression of PST on follow-up 
      imaging was significantly associated with a subsequent neoplastic diagnosis (P = 
      0.04). CONCLUSION: Patients with PST without DI are unlikely to have a neoplastic
      process. Among patients with DI, APD or progressive stalk increase over time are 
      predictive of neoplasia. Pediatr Blood Cancer (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's
      Hospital, Boston, Massachusetts; Division of Hematology/Oncology, Boston
      Children's Hospital, Boston, Massachusetts.
FAU - Robison, Nathan J
AU  - Robison NJ
FAU - Prabhu, Sanjay P
AU  - Prabhu SP
FAU - Sun, Pengling
AU  - Sun P
FAU - Chi, Susan N
AU  - Chi SN
FAU - Kieran, Mark W
AU  - Kieran MW
FAU - Manley, Peter E
AU  - Manley PE
FAU - Cohen, Laurie E
AU  - Cohen LE
FAU - Goumnerova, Liliana
AU  - Goumnerova L
FAU - Smith, Edward R
AU  - Smith ER
FAU - Scott, R Michael
AU  - Scott RM
FAU - London, Wendy B
AU  - London WB
FAU - Ullrich, Nicole J
AU  - Ullrich NJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Pediatr Blood Cancer
JT  - Pediatric blood & cancer
JID - 101186624
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/03/12 [received]
PHST- 2013/04/05 [accepted]
AID - 10.1002/pbc.24577 [doi]
PST - aheadofprint
SO  - Pediatr Blood Cancer. 2013 May 14. doi: 10.1002/pbc.24577.

PMID- 23670858
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
DP  - 2013 May 13
TI  - A specific and sensitive assay for blood levels of glycated CD59: A novel
      biomarker for diabetes.
LID - 10.1002/ajh.23478 [doi]
AB  - Increasing evidence links the complement system with complications of human
      diabetes. The complement regulatory protein CD59, an inhibitor of formation of
      membrane attack complex (MAC), is inhibited by hyperglycemia-induced glycation
      fostering increased deposition of MAC, a major effector of complement-mediated
      tissue damage. CD59, an ubiquitous GPI-anchored membrane protein, is shed from
      cell membranes by phospholipases generating a soluble form present in blood and
      urine. Methods: We established an ELISA to measure serum/plasma glycated hCD59
      (GCD59) and evaluated its potential as a diabetes biomarker. We used a synthetic 
      peptide strategy to generate a) a mouse monoclonal antibody to capture hCD59, b) 
      a rabbit monoclonal antibody to detect GCD59, and c) a GCD59 surrogate for assay 
      standardization. ELISA conditions were optimized for precision, reproducibility
      and clinical sensitivity. The clinical utility of the assay was initially
      evaluated in 24 subjects with or without diabetes and further validated in a
      study that included 100 subjects with and 90 subjects without a diagnosis of
      diabetes. Results: GCD59 a) was significantly higher in individuals with than in 
      individual without diabetes, b) was independently associated with HbA1c, and )
      identified individuals with diabetes with high specificity and sensitivity.
      Conclusions: We report the development and standardization of a novel, sensitive,
      and specific ELISA for measuring GCD59 in blood. The assay distinguished
      individuals with diabetes from those without, and showed strong correlation
      between GCD59 and HbA1c. Because GCD59 likely contributes to the pathogenesis of 
      diabetes complications, measurement of blood levels of GCD59 may be useful in the
      diagnosis and management of diabetes.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc., A Wiley Company.
AD  - Division of Hematology, Department of Medicine, Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA, USA.
FAU - Ghosh, Pamela
AU  - Ghosh P
FAU - Sahoo, Rupam
AU  - Sahoo R
FAU - Vaidya, Anand
AU  - Vaidya A
FAU - Cantel, Sonia
AU  - Cantel S
FAU - Kavishwar, Amol
AU  - Kavishwar A
FAU - Goldfine, Allison
AU  - Goldfine A
FAU - Herring, Neil
AU  - Herring N
FAU - Bry, Lynn
AU  - Bry L
FAU - Chorev, Michael
AU  - Chorev M
FAU - Halperin, Jose A
AU  - Halperin JA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/04/29 [received]
PHST- 2013/05/02 [accepted]
AID - 10.1002/ajh.23478 [doi]
PST - aheadofprint
SO  - Am J Hematol. 2013 May 13. doi: 10.1002/ajh.23478.

PMID- 23670848
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1699-5848 (Electronic)
IS  - 0213-3911 (Linking)
DP  - 2013 May 14
TI  - SPARC is up-regulated during skeletal muscle regeneration and inhibits myoblast
      differentiation.
AB  - Skeletal muscle repair is mediated primarily by the muscle stem cell, the
      satellite cell. Several factors, including extracellular matrix, are known to
      regulate satellite cell function and regeneration. One factor, the matricellular 
      Secreted Protein Acidic and Rich in Cysteine (SPARC) is highly up-regulated
      during skeletal muscle disease, but its function remains elusive. In the present 
      study, we demonstrate a prominent yet transient increase in SPARC mRNA and
      protein content during skeletal muscle regeneration that correlates with the
      expression profile of specific muscle factors like MyoD, Myf5, Myf6, Myogenin,
      NCAM, CD34, and M-Cadherin, all known to be implicated in satellite cell
      activation/proliferation following muscle damage. This up regulation was detected
      in more cell types. Ectopic expression of SPARC in the muscle progenitor cell
      line C2C12 was performed to mimic the high levels of SPARC seen in muscle
      disease. SPARC overexpression almost completely abolished myogenic
      differentiation in these cultures as determined by substantially reduced levels
      of myogenic factors (Pax7, Myf5, Myod, Mef2B, Myogenin, and Myostatin) and a lack
      of multinucleated myotubes. These results demonstrate that there is a delicate
      temporal regulation of SPARC to which more sources in the micro environment
      contribute, and that disturbances in this, such as extensive up regulation, may
      have an adverse effect on muscle regeneration.
AD  - Department of Clinical Pathology, and Department of Endocrinology, Section for
      Molecular Diabetes and Metabolism, Institute of Clinical Research, University of 
      Southern Denmark and Odense University Hospital, Odense, Denmark.
FAU - Petersson, Stine Juhl
AU  - Petersson SJ
FAU - Jorgensen, Louise Helskov
AU  - Jorgensen LH
FAU - Andersen, Ditte C
AU  - Andersen DC
FAU - Norgaard, Rikke C
AU  - Norgaard RC
FAU - Jensen, Charlotte Harken
AU  - Jensen CH
FAU - Schroder, Henrik Daa
AU  - Schroder HD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - HH-11-340 [pii]
PST - aheadofprint
SO  - Histol Histopathol. 2013 May 14.

PMID- 23670794
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
DP  - 2013 May 13
TI  - Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial.
AB  - OBJECTIVE: Previous observational studies reported beneficial effects of the
      Mediterranean diet (MedDiet) on cognitive function, but results were
      inconsistent. We assessed the effect on cognition of a nutritional intervention
      using MedDiets in comparison with a low-fat control diet. METHODS: We assessed
      522 participants at high vascular risk (44.6% men, age 74.6 +/- 5.7 years at
      cognitive evaluation) enrolled in a multicentre, randomised, primary prevention
      trial (PREDIMED), after a nutritional intervention comparing two MedDiets
      (supplemented with either extra-virgin olive oil (EVOO) or mixed nuts) versus a
      low-fat control diet. Global cognitive performance was examined by Mini-Mental
      State Examination (MMSE) and Clock Drawing Test (CDT) after 6.5 years of
      nutritional intervention. Researchers who assessed the outcome were blinded to
      group assignment. We used general linear models to control for potential
      confounding. RESULTS: After adjustment for sex, age, education, Apolipoprotein E 
      genotype, family history of cognitive impairment/dementia, smoking, physical
      activity, body mass index, hypertension, dyslipidaemia, diabetes, alcohol and
      total energy intake, participants allocated to the MedDiet+EVOO showed higher
      mean MMSE and CDT scores with significant differences versus control (adjusted
      differences: +0.62 95% CI +0.18 to +1.05, p=0.005 for MMSE, and +0.51 95% CI
      +0.20 to +0.82, p=0.001 for CDT). The adjusted means of MMSE and CDT scores were 
      also higher for participants allocated to the MedDiet+Nuts versus control
      (adjusted differences: +0.57 (95% CI +0.11 to +1.03), p=0.015 for MMSE and +0.33 
      (95% CI +0.003 to +0.67), p=0.048 for CDT). These results did not differ after
      controlling for incident depression. CONCLUSIONS: An intervention with MedDiets
      enhanced with either EVOO or nuts appears to improve cognition compared with a
      low-fat diet.ISRCTN:35739639.
AD  - Department of Preventive Medicine and Public Health, Medical School-Clinica,
      University of Navarra, , Pamplona, Spain.
FAU - Martinez-Lapiscina, Elena H
AU  - Martinez-Lapiscina EH
FAU - Clavero, Pedro
AU  - Clavero P
FAU - Toledo, Estefania
AU  - Toledo E
FAU - Estruch, Ramon
AU  - Estruch R
FAU - Salas-Salvado, Jordi
AU  - Salas-Salvado J
FAU - San Julian, Beatriz
AU  - San Julian B
FAU - Sanchez-Tainta, Ana
AU  - Sanchez-Tainta A
FAU - Ros, Emilio
AU  - Ros E
FAU - Valls-Pedret, Cinta
AU  - Valls-Pedret C
FAU - Martinez-Gonzalez, Miguel A
AU  - Martinez-Gonzalez MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
OTO - NOTNLM
OT  - COGNITION
OT  - COGNITIVE NEUROPSYCHOLOGY
OT  - RANDOMISED TRIALS
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - jnnp-2012-304792 [pii]
AID - 10.1136/jnnp-2012-304792 [doi]
PST - aheadofprint
SO  - J Neurol Neurosurg Psychiatry. 2013 May 13.

PMID- 23670707
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 53
IP  - 6
DP  - 2013 Jun
TI  - Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose
      co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
PG  - 601-10
LID - 10.1002/jcph.88 [doi]
AB  - This study characterized single- and multiple-dose pharmacokinetics of
      canagliflozin and its O-glucuronide metabolites (M5 and M7) and pharmacodynamics 
      (renal threshold for glucose [RTG ], urinary glucose excretion [UGE0-24h ], and
      24-hour mean plasma glucose [MPG0-24h ]) of canagliflozin in subjects with type 2
      diabetes. Thirty-six randomized subjects received canagliflozin 50, 100, or 300
      mg/day or placebo for 7 days. On Days 1 and 7, area under the plasma
      concentration-time curve and maximum observed plasma concentration (Cmax ) for
      canagliflozin and its metabolites increased dose-dependently. Half-life and time 
      at which Cmax was observed were dose-independent. Systemic molar M5 exposure was 
      half that of canagliflozin; M7 exposure was similar to canagliflozin.
      Steady-state plasma canagliflozin concentrations were reached by Day 4 in all
      active treatment groups. Pharmacodynamic effects were dose- and
      exposure-dependent. All canagliflozin doses decreased RTG , increased UGE0-24h , 
      and reduced MPG0-24h versus placebo on Days 1 and 7. On Day 7, placebo-subtracted
      least-squares mean decreases in MPG0-24h ranged from 42-57 mg/dL with
      canagliflozin treatment. Adverse events (AEs) were balanced between treatments;
      no treatment-related serious AEs, AE-related discontinuations, or clinically
      meaningful adverse changes in routine safety evaluations occurred. The observed
      pharmacokinetic/pharmacodynamic profile of canagliflozin in subjects with type 2 
      diabetes supports a once-daily dosing regimen.
CI  - Copyright (c) The Author(s) 2013.
AD  - Janssen Research & Development, LLC, Raritan, NJ, USA.
FAU - Devineni, Damayanthi
AU  - Devineni D
FAU - Curtin, Christopher R
AU  - Curtin CR
FAU - Polidori, David
AU  - Polidori D
FAU - Gutierrez, Maria J
AU  - Gutierrez MJ
FAU - Murphy, Joseph
AU  - Murphy J
FAU - Rusch, Sarah
AU  - Rusch S
FAU - Rothenberg, Paul L
AU  - Rothenberg PL
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/10/27 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 10.1002/jcph.88 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2013 Jun;53(6):601-10. doi: 10.1002/jcph.88. Epub 2013 May 14.

PMID- 23670660
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Implementation of self management support for long term conditions in routine
      primary care settings: cluster randomised controlled trial.
PG  - f2882
LID - 10.1136/bmj.f2882 [doi]
LID - bmj.f2882 [pii]
AB  - OBJECTIVE: To determine the effectiveness of an intervention to enhance self
      management support for patients with chronic conditions in UK primary care.
      DESIGN: Pragmatic, two arm, cluster randomised controlled trial. SETTING: General
      practices, serving a population in northwest England with high levels of
      deprivation. PARTICIPANTS: 5599 patients with a diagnosis of diabetes (n=2546),
      chronic obstructive pulmonary disease (n=1634), and irritable bowel syndrome
      (n=1419) from 43 practices (19 intervention and 22 control practices).
      INTERVENTION: Practice level training in a whole systems approach to self
      management support. Practices were trained to use a range of resources: a tool to
      assess the support needs of patients, guidebooks on self management, and a web
      based directory of local self management resources. Training facilitators were
      employed by the health management organisation. MAIN OUTCOME MEASURES: Primary
      outcomes were shared decision making, self efficacy, and generic health related
      quality of life measured at 12 months. Secondary outcomes were general health,
      social or role limitations, energy and vitality, psychological wellbeing, self
      care activity, and enablement. RESULTS: We randomised 44 practices and recruited 
      5599 patients, representing 43% of the eligible population on the practice lists.
      4533 patients (81.0%) completed the six month follow-up and 4076 (72.8%) the 12
      month follow-up. No statistically significant differences were found between
      patients attending trained practices and those attending control practices on any
      of the primary or secondary outcomes. All effect size estimates were well below
      the prespecified threshold of clinically important difference. CONCLUSIONS: An
      intervention to enhance self management support in routine primary care did not
      add noticeable value to existing care for long term conditions. The active
      components required for effective self management support need to be better
      understood, both within primary care and in patients' everyday lives. TRIAL
      REGISTRATION: Current Controlled Trials ISRCTN90940049.
AD  - Faculty of Health Sciences, University of Southampton, Highfield Campus,
      Southampton SO17 1BJ, UK.
FAU - Kennedy, Anne
AU  - Kennedy A
FAU - Bower, Peter
AU  - Bower P
FAU - Reeves, David
AU  - Reeves D
FAU - Blakeman, Tom
AU  - Blakeman T
FAU - Bowen, Robert
AU  - Bowen R
FAU - Chew-Graham, Carolyn
AU  - Chew-Graham C
FAU - Eden, Martin
AU  - Eden M
FAU - Fullwood, Catherine
AU  - Fullwood C
FAU - Gaffney, Hannah
AU  - Gaffney H
FAU - Gardner, Caroline
AU  - Gardner C
FAU - Lee, Victoria
AU  - Lee V
FAU - Morris, Rebecca
AU  - Morris R
FAU - Protheroe, Joanne
AU  - Protheroe J
FAU - Richardson, Gerry
AU  - Richardson G
FAU - Sanders, Caroline
AU  - Sanders C
FAU - Swallow, Angela
AU  - Swallow A
FAU - Thompson, David
AU  - Thompson D
FAU - Rogers, Anne
AU  - Rogers A
CN  - Salford National Institute for Health Research Gastrointestinal programme Grant
      Research Group
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
PMC - PMC3652644
OID - NLM: PMC3652644
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PST - epublish
SO  - BMJ. 2013 May 13;346:f2882. doi: 10.1136/bmj.f2882.

PMID- 23670643
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1573-3521 (Electronic)
IS  - 0160-7715 (Linking)
DP  - 2013 May 14
TI  - Theory-based predictors of multiple clinician behaviors in the management of
      diabetes.
AB  - Behavioral theory is often tested on one behavior in isolation from other
      behaviors and theories. We aimed to test the predictive validity of constructs
      from motivation and action theories of behavior across six diabetes-related
      clinician behaviors, within the same sample of primary care clinicians.
      Physicians and nurses (n = 427 from 99 practices in the United Kingdom) completed
      questionnaires at baseline and 12 months. Primary outcomes: six self-reported
      clinician behaviors related to advising, prescribing and examining measured at 12
      months; secondary outcomes: baseline intention and patient-scenario-based
      simulated behavior. Across six behaviors, each theory accounted for a medium
      amount of variance for 12-month behavior (median R adj 2 = 0.15), large and
      medium amount of variance for two intention measures (median R adj 2 = 0.66;
      0.34), and small amount of variance for simulated behavior (median R adj 2 =
      0.05). Intention/proximal goals, self-efficacy, and habit predicted all
      behaviors. Constructs from social cognitive theory (self-efficacy), learning
      theory (habit) and action and coping planning consistently predicted multiple
      clinician behaviors and should be targeted by quality improvement interventions.
AD  - Institute of Health and Society, Newcastle University, Baddiley-Clark Building,
      Richardson Road, Newcastle upon Tyne, NE2 4AX, UK, justin.presseau@ncl.ac.uk.
FAU - Presseau, Justin
AU  - Presseau J
FAU - Johnston, Marie
AU  - Johnston M
FAU - Francis, Jill J
AU  - Francis JJ
FAU - Hrisos, Susan
AU  - Hrisos S
FAU - Stamp, Elaine
AU  - Stamp E
FAU - Steen, Nick
AU  - Steen N
FAU - Hawthorne, Gillian
AU  - Hawthorne G
FAU - Grimshaw, Jeremy M
AU  - Grimshaw JM
FAU - Elovainio, Marko
AU  - Elovainio M
FAU - Hunter, Margaret
AU  - Hunter M
FAU - Eccles, Martin P
AU  - Eccles MP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - J Behav Med
JT  - Journal of behavioral medicine
JID - 7807105
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/08/20 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 10.1007/s10865-013-9513-x [doi]
PST - aheadofprint
SO  - J Behav Med. 2013 May 14.

PMID- 23670542
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
DP  - 2013 May 13
TI  - The physical anthropometry, lifestyle habits and blood pressure of people
      presenting with a first clinical demyelinating event compared to controls: The
      Ausimmune study.
AB  - INTRODUCTION: Lifestyle factors prior to a first clinical demyelinating event
      (FCD), a disorder often preceding the development of clinically definite multiple
      sclerosis (MS), have not previously been examined in detail. Past tobacco smoking
      has been consistently associated with MS. METHODS: This was a multicentre
      incident case-control study. Cases (n = 282) were aged 18-59 years with an FCD
      and resident within one of four Australian centres (from latitudes 27 degrees S
      to 43 degrees S), from 1 November 2003 to 31 December 2006. Controls (n = 558)
      were matched to cases on age, sex and study region, without CNS demyelination.
      Exposures measured included current and past tobacco and marijuana, alcohol and
      beverage use, physical activity patterns, blood pressure and physical
      anthropometry. RESULTS: A history of smoking ever was associated with FCD risk
      (AOR 1.89 (95%CL 1.82, 3.52)). Marijuana use was not associated with FCD risk
      after adjusting for confounders such as smoking ever but the estimates were
      imprecise because of a low prevalence of use. Alcohol consumption was common and 
      not associated with FCD risk. No case-control differences in blood pressure or
      physical anthropometry were observed. CONCLUSIONS: Past tobacco smoking was
      positively associated with a risk of FCD but most other lifestyle factors were
      not. Prevention efforts against type 2 diabetes and cardiovascular disease by
      increasing physical activity and reducing obesity are unlikely to alter MS
      incidence, and more targeted campaigns will be required.
AD  - Murdoch Childrens Research Institute, Australia.
FAU - Ponsonby, Anne-Louise
AU  - Ponsonby AL
FAU - Lucas, Robyn M
AU  - Lucas RM
FAU - Dear, Keith
AU  - Dear K
FAU - van der Mei, Ingrid
AU  - van der Mei I
FAU - Taylor, Bruce
AU  - Taylor B
FAU - Chapman, Caron
AU  - Chapman C
FAU - Coulthard, Alan
AU  - Coulthard A
FAU - Dwyer, Terence
AU  - Dwyer T
FAU - Kilpatrick, Trevor J
AU  - Kilpatrick TJ
FAU - McMichael, Anthony J
AU  - McMichael AJ
FAU - Pender, Michael P
AU  - Pender MP
FAU - Valery, Patricia C
AU  - Valery PC
FAU - Williams, David
AU  - Williams D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
OTO - NOTNLM
OT  - Multiple sclerosis
OT  - demyelination
OT  - lifestyle
OT  - marijuana
OT  - obesity
OT  - tobacco
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 1352458513483887 [pii]
AID - 10.1177/1352458513483887 [doi]
PST - aheadofprint
SO  - Mult Scler. 2013 May 13.

PMID- 23670404
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
DP  - 2013 May 14
TI  - Post-marketing surveillance of the safety and effectiveness of tacrolimus in
      3,267 Japanese patients with rheumatoid arthritis.
AB  - OBJECTIVES: A post-marketing surveillance (PMS) program was implemented to assess
      the safety and effectiveness of tacrolimus (TAC) in Japanese rheumatoid arthritis
      (RA) patients and to identify risk factors related to adverse drug reactions
      (ADRs). METHODS: Patients were registered centrally and monitored for all adverse
      events (AEs) for 24 weeks. Effectiveness was evaluated using the Disease Activity
      Score 28-CRP (DAS28-CRP). RESULTS: Data from 3,172 patients (mean age 62.2 years)
      were evaluated in the safety analysis. Of the safety population, 78.5 %were
      female and 25.9 % were in Steinbrocker's functional class 3 or 4. TAC was
      prescribed as monotherapy in 52.5 % and the most common concomitant disease
      modifying antirheumatic drug (DMARD) was methotrexate, used in 28.9 % of the
      patients. The incidence of AEs, serious AEs (SAEs), ADRs and serious ADRs were
      41.2, 6.4, 36.0, and 4.9 %, respectively. The most frequent serious ADR category 
      was infections and infestations. Age >/=65 years, concurrent renal dysfunction,
      and concurrent diabetes mellitus were identified as significant risk factors for 
      ADR. Based on EULAR response criteria, 65.4 % of the patients showed moderate or 
      good response. CONCLUSIONS: The results demonstrate that TAC is well tolerated by
      Japanese patients with active RA, including those receiving concomitant
      methotrexate, in the real world.
AD  - Division of Rheumatology, Department of Internal Medicine, Keio University School
      of Medicine, 35 Shinanomachi, Shinjyuku-ku, Tokyo, 160-8582, Japan,
      tsutake@z5.keio.jp.
FAU - Takeuchi, Tsutomu
AU  - Takeuchi T
FAU - Kawai, Shinichi
AU  - Kawai S
FAU - Yamamoto, Kazuhiko
AU  - Yamamoto K
FAU - Harigai, Masayoshi
AU  - Harigai M
FAU - Ishida, Kota
AU  - Ishida K
FAU - Miyasaka, Nobuyuki
AU  - Miyasaka N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Mod Rheumatol
JT  - Modern rheumatology / the Japan Rheumatism Association
JID - 100959226
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 10.1007/s10165-013-0887-y [doi]
PST - aheadofprint
SO  - Mod Rheumatol. 2013 May 14.

PMID- 23670380
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1678-4561 (Electronic)
IS  - 1413-8123 (Linking)
VI  - 18
IP  - 4
DP  - 2013 Apr
TI  - [The prevalence of morbidity and symptoms among the elderly: a comparative study 
      between rural and urban areas].
PG  - 1029-40
LID - S1413-81232013000400016 [pii]
AB  - A cross-sectional study was conducted with the elderly population in rural and
      urban areas characterized by the prevalence of morbidity and symptoms, and 229
      elderly people were interviewed. The average age was 72.3, of which 57.2% lived
      in the rural zone and 56.3% were female. The morbidities most reported were
      insomnia (37.7%), anxiety (32.1%), depression (26.7%), and in the rural zone it
      was diabetes (13.3%). In this zone, Alzheimer s disease was more prevalent among 
      the elderly who handled pesticides (21.7%). The most prevalent symptoms among
      urban zone residents were: cough/runny nose and sight alterations (41.2%),
      allergy/itching (11.4%). In the rural zone, dry mouth (25.4%), sight alterations 
      (35.6%) and leg pain (66.1%) were also more prevalent among those who used
      pesticides. The inadequate use of Individual Protection Equipment was 85.4%, and 
      45.1% also disposed of pesticide packaging inappropriately. The setting up of
      public health programs is necessary to promote health among the elderly and the
      potential exposure to pesticides for this population should be seen as a health
      risk determinant.
AD  - Universidade Luterna do Brasil, Canoas, RS, 92425-900,
      evelinefronza@yahoo.com.br.
FAU - Silva, Eveline Fronza da
AU  - Silva EF
FAU - Paniz, Vera Maria Vieira
AU  - Paniz VM
FAU - Laste, Gabriela
AU  - Laste G
FAU - Torres, Iraci Lucena da Silva
AU  - Torres IL
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Prevalencia de morbidades e sintomas em idosos: um estudo comparativo entre zonas
      rural e urbana.
PL  - Brazil
TA  - Cien Saude Colet
JT  - Ciencia & saude coletiva
JID - 9713483
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2011/10/12 [received]
PHST- 2011/10/20 [accepted]
AID - S1413-81232013000400016 [pii]
PST - ppublish
SO  - Cien Saude Colet. 2013 Apr;18(4):1029-40.

PMID- 23670354
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1752-8976 (Electronic)
IS  - 1470-3203 (Linking)
DP  - 2013 May 13
TI  - Aliskiren improves vascular smooth muscle function in the skin microcirculation
      of type 2 diabetic patients with normal renal function.
AB  - OBJECTIVE: The objective of this paper is to study the effect of aliskiren on
      metabolic parameters and micro- and macrovascular reactivity in individuals
      diagnosed with or at high risk for developing type 2 diabetes mellitus
      (T2DM).Research design and methods:We studied 47 T2DM and 41 at-risk individuals 
      in a randomized, double-blinded, placebo-controlled trial. All subjects were
      treated with 150 mg aliskiren or placebo daily for 12 weeks. Twenty-six (55%) of 
      T2DM and four (8%) at-risk subjects were also treated with angiotensin-converting
      enzyme (ACE) inhibitors or angiotensin II receptor blockers. RESULTS: Aliskiren
      treatment was associated with improvement in systolic and diastolic blood
      pressure and endothelium-independent vasodilation at the skin microcirculation in
      those with T2DM but not in those at risk. There were no incidences of hypotension
      and no significant changes in serum potassium or creatinine levels with aliskiren
      treatment in either study group. CONCLUSIONS: Aliskiren improves blood pressure
      and vascular smooth muscle function in the skin microcirculation of T2DM
      patients.
AD  - 1Joslin-Beth Israel Deaconess Foot Center and Microcirculation Laboratory, USA.
FAU - Dushay, Jody R
AU  - Dushay JR
FAU - Tecilazich, Francesco
AU  - Tecilazich F
FAU - Kafanas, Antonios
AU  - Kafanas A
FAU - Magargee, Mary L
AU  - Magargee ML
FAU - Auster, Michael E
AU  - Auster ME
FAU - Gnardellis, Charalambos
AU  - Gnardellis C
FAU - Dinh, Thanh
AU  - Dinh T
FAU - Veves, Aristidis
AU  - Veves A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Renin Angiotensin Aldosterone Syst
JT  - Journal of the renin-angiotensin-aldosterone system : JRAAS
JID - 100971636
OTO - NOTNLM
OT  - Type 2 diabetes
OT  - aliskiren
OT  - prediabetes
OT  - vascular smooth muscle
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 1470320313489060 [pii]
AID - 10.1177/1470320313489060 [doi]
PST - aheadofprint
SO  - J Renin Angiotensin Aldosterone Syst. 2013 May 13.

PMID- 23670348
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
DP  - 2013 May 13
TI  - Adiponectin-induced Inhibition of Intrinsic and Extrinsic Apoptotic Pathways
      Protects Pancreatic beta-Cells Against Apoptosis.
AB  - Apoptosis is the main form of beta-cell death in type 2 diabetes mellitus. There 
      are 2 major pathways leading to apoptosis, 'intrinsic and extrinsic pathways'.
      Adiponectin is an adipocyte-derived hormone, which plays an important role in
      glucose and lipid metabolism. The main aims of this study were to investigate
      related apoptotic pathways in diabetes and the anti-apoptosis effects of
      adiponectin on pancreatic beta-cell and the underlying mechanisms. Diabetic mice 
      were generated by intraperitoneal injection of streptozotocin (STZ, 50 mg/kg/d
      for 5 days) and high-fat diet. Adiponectin overexpressing mice were developed by 
      injecting lentivirus expressing mouse full length adiponectin (plenti-acdc-EGFP) 
      through tail vein. Fourteen days after plenti-acdc-EGFP lentivirus injection,
      plasma adiponectin protein levels were increased 2-fold. Plasma triglyceride and 
      glucose levels, but not total cholesterol, were significantly reduced in
      plenti-acdc-EGFP-treated mice. Pancreatic beta-cell apoptotic numbers and the
      expression of caspase-8, -9, -3 in islet increased in diabetic mice, which was
      reversed by elevated adiponectin in plenti-acdc-EGFP-treated mice. These results 
      suggest that both intrinsic and extrinsic apoptotic pathways have an important
      role in diabetic beta-cell apoptosis. Adiponectin has antidiabetic and
      anti-apoptotic effects by regulating glucose and lipid metabolisms and inhibiting
      intrinsic and extrinsic apoptotic pathway in pancreatic beta-cells.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Department of Endocrinology, The First Affiliated Hospital, Chongqing Medical
      University, Chongqing, China.
FAU - Jian, L
AU  - Jian L
FAU - Su, Y X
AU  - Su YX
FAU - Deng, H C
AU  - Deng HC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/05/13 [epublish]
AID - 10.1055/s-0033-1341500 [doi]
PST - aheadofprint
SO  - Horm Metab Res. 2013 May 13.

PMID- 23670279
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1432-1750 (Electronic)
IS  - 0341-2040 (Linking)
DP  - 2013 May 14
TI  - Intima-Media Thickness in Patients With Obstructive Sleep Apnea Without
      Comorbidities.
AB  - BACKGROUND: Obstructive sleep apnea (OSA) is associated with elevated risk of
      cardiovascular events. The early stages of vascular complications can be
      visualized by means of ultrasound. Intima-media thickness (IMT) correlates with
      the presence of risk factors of cardiovascular diseases such as hypertension,
      diabetes, tobacco smoking, or hyperlipidemia. However, little is known whether
      OSA itself may be the cause of IMT thickening. METHODS: The study group was
      composed of 28 patients (6 women, 22 men; mean age = 53.8 years, mean BMI = 27.1 
      kg/m2, mean AHI = 22.4/h) with OSA who had no comorbidities. The control group
      consisted of 28 healthy subjects (6 women, 22 men; mean age = 53.9 years; mean
      BMI = 27.5 kg/m2). In both groups IMT was assessed in common carotid arteries
      with the use of ultrasonography. Additionally, in patients with OSA, pulse wave
      velocity, echocardiography, 24-h automated blood pressure monitoring, clinical
      signs and symptoms, and blood tests were performed to investigate possible
      correlations with IMT. RESULTS: Median IMT was 0.41 mm in OSA patients and 0.46
      mm in the control group (p = 0.087). Echocardiography revealed left ventricle
      hypertrophy in 21 %, systolic disorders in 8 %, and diastolic disorders in 57 %
      of the patients. In a large majority of patients, pulse wave velocity was found
      to be normal. IMT correlated with age (r = 0.446, p = 0.017), total cholesterol
      (r = 0.518, p = 0.005), daytime systolic blood pressure (r = 0.422, p = 0.025),
      pulse pressure 24 h and daytime (r = 0.424, p = 0.027 and r = 0.449, p = 0.019), 
      early mitral flow/atrial mitral flow (E/A) (r = -0.429, p = 0.023), and posterior
      wall diameter (PWD) (r = 0.417, p = 0.270). CONCLUSION: In a relatively nonobese 
      group of patients, no significant differences were found in the intima-media
      thickness between OSA patients without concomitant cardiovascular diseases and
      healthy controls. This may lead to the conclusion that IMT does not reflect
      increased risk of cardiovascular events in patients with isolated OSA.
AD  - Department of Pneumonology, Medical University of Gdansk, ul. Debinki 7, 80-952, 
      Gdansk, Poland.
FAU - Gorzewska, Agnieszka
AU  - Gorzewska A
FAU - Specjalski, Krzysztof
AU  - Specjalski K
FAU - Drozdowski, Jacek
AU  - Drozdowski J
FAU - Kunicka, Katarzyna
AU  - Kunicka K
FAU - Swierblewska, Ewa
AU  - Swierblewska E
FAU - Bieniaszewski, Leszek
AU  - Bieniaszewski L
FAU - Slominski, Jan M
AU  - Slominski JM
FAU - Jassem, Ewa
AU  - Jassem E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Lung
JT  - Lung
JID - 7701875
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/01/21 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 10.1007/s00408-013-9471-7 [doi]
PST - aheadofprint
SO  - Lung. 2013 May 14.

PMID- 23670256
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1476-5608 (Electronic)
IS  - 1365-7852 (Linking)
DP  - 2013 May 14
TI  - Oxidative stress in prostate cancer: changing research concepts towards a novel
      paradigm for prevention and therapeutics.
LID - 10.1038/pcan.2013.13 [doi]
AB  - A mounting body of evidence suggests that increased production of reactive oxygen
      species (ROS) is linked to aging processes and to the etiopathogenesis of
      aging-related diseases, such as cancer, diabetes, atherosclerosis and
      degenerative diseases like Parkinson's and Alzheimer's. Excess ROS are
      deleterious to normal cells, while in cancer cells, they can lead to accelerated 
      tumorigenesis. In prostate cancer (PC), oxidative stress, an innate key event
      characterized by supraphysiological ROS concentrations, has been identified as
      one of the hallmarks of the aggressive disease phenotype. Specifically, oxidative
      stress is associated with PC development, progression and the response to
      therapy. Nevertheless, a thorough understanding of the relationships between
      oxidative stress, redox homeostasis and the activation of proliferation and
      survival pathways in healthy and malignant prostate remains elusive. Moreover,
      the failure of chemoprevention strategies targeting oxidative stress reduced the 
      level of interest in the field after the recent negative results of the Selenium 
      and Vitamin E Cancer Prevention Trial (SELECT) trial. Therefore, a revisit of the
      concept is warranted and several key issues need to be addressed: The
      consequences of changes in ROS levels with respect to altered redox homeostasis
      and redox-regulated processes in PC need to be established. Similarly, the key
      molecular events that cause changes in the generation of ROS in PC and the role
      for therapeutic strategies aimed at ameliorating oxidative stress need to be
      identified. Moreover, the issues whether genetic/epigenetic susceptibility for
      oxidative stress-induced prostatic carcinogenesis is an individual phenomenon and
      what measurements adequately quantify prostatic oxidative stress are also
      crucial. Addressing these matters will provide a more rational basis to improve
      the design of redox-related clinical trials in PC. This review summarizes
      accepted concepts and principles in redox research, and explores their
      implications and limitations in PC.Prostate Cancer and Prostatic Disease advance 
      online publication, 14 May 2013; doi:10.1038/pcan.2013.13.
AD  - Department of Surgery, McMaster University and Juravinski Cancer Centre,
      Hamilton, Ontario, Canada.
FAU - Paschos, A
AU  - Paschos A
FAU - Pandya, R
AU  - Pandya R
FAU - Duivenvoorden, W C M
AU  - Duivenvoorden WC
FAU - Pinthus, J H
AU  - Pinthus JH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Prostate Cancer Prostatic Dis
JT  - Prostate cancer and prostatic diseases
JID - 9815755
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/05/14 [aheadofprint]
AID - pcan201313 [pii]
AID - 10.1038/pcan.2013.13 [doi]
PST - aheadofprint
SO  - Prostate Cancer Prostatic Dis. 2013 May 14. doi: 10.1038/pcan.2013.13.

PMID- 23670244
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1708-8283 (Electronic)
IS  - 0883-0738 (Linking)
DP  - 2013 May 13
TI  - Worldwide Dietary Therapies for Adults With Epilepsy and Other Disorders.
AB  - During the 3rd International Symposium on Dietary Therapies held in Chicago,
      Illinois, there was a first-ever, half-day session devoted to the management of
      adults with epilepsy and other disorders with dietary treatments. Speakers from 3
      different continents shared their successes, challenges, and future directions in
      their management of these patients. Diets used to treat adults included the
      classic ketogenic diet, the modified Atkins diet, and a low glycemic index
      treatment. The utility of dietary therapies was demonstrated not only in patients
      with epilepsy but also patients with propriospinal myoclonus, astrocytoma, type 2
      diabetes, obesity, hyperlipidemia, and metabolic disorder. The session provided
      evidence that dietary therapies are safe and effective in adults.
AD  - 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore,
      MD, USA.
FAU - Cervenka, Mackenzie C
AU  - Cervenka MC
FAU - Henry, Bobbie
AU  - Henry B
FAU - Nathan, Janak
AU  - Nathan J
FAU - Wood, Susan
AU  - Wood S
FAU - Volek, Jeff S
AU  - Volek JS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Child Neurol
JT  - Journal of child neurology
JID - 8606714
OTO - NOTNLM
OT  - Atkins
OT  - adult
OT  - epilepsy
OT  - ketogenic diet
OT  - seizure
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 0883073813488671 [pii]
AID - 10.1177/0883073813488671 [doi]
PST - aheadofprint
SO  - J Child Neurol. 2013 May 13.

PMID- 23670225
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130605
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - Discordances in the application of different criteria for quantification of
      paediatric abdominal obesity: an analysis of two Swiss studies.
PG  - e67
LID - 10.1038/nutd.2013.7 [doi]
AB  - Several definitions of paediatric abdominal obesity have been proposed but it is 
      unclear whether they lead to similar results. We assessed the prevalence of
      abdominal obesity using five different waist circumference-based definitions and 
      their agreement with total body fat (TBF) and abdominal fat (AF). Data from 190
      girls and 162 boys (Ballabeina), and from 134 girls and 113 boys
      (Kinder-Sportstudie, KISS) aged 5-11 years were used. TBF was assessed by
      bioimpedance (Ballabeina) or dual energy X-ray absorption (KISS). On the basis of
      the definition used, the prevalence of abdominal obesity varied between 3.1 and
      49.4% in boys, and 4.7 and 55.5% in girls (Ballabeina), and between 1.8 and 36.3%
      in boys and 4.5 and 37.3% in girls (KISS). Among children considered as
      abdominally obese by at least one definition, 32.0 (Ballabeina) and 44.7% (KISS) 
      were considered as such by at least two (out of five possible) definitions. Using
      excess TBF or AF as reference, the areas under the receiver operating curve
      varied between 0.577 and 0.762 (Ballabeina), and 0.583 and 0.818 (KISS). We
      conclude that current definitions of abdominal obesity in children lead to wide
      prevalence estimates and should not be used until a standard definition can be
      proposed.
AD  - 1] Medical Faculty of Lisbon, University of Lisbon, Lisbon, Portugal [2]
      Institute of Social and Preventive Medicine (IUMSP), Lausanne University
      Hospital, Lausanne, Switzerland.
FAU - Pinto, A M
AU  - Pinto AM
FAU - Puder, J
AU  - Puder J
FAU - Burgi, F
AU  - Burgi F
FAU - Ebenegger, V
AU  - Ebenegger V
FAU - Nydegger, A
AU  - Nydegger A
FAU - Niederer, I
AU  - Niederer I
FAU - Kriemler, S
AU  - Kriemler S
FAU - Marques-Vidal, P
AU  - Marques-Vidal P
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
PMC - PMC3671749
OID - NLM: PMC3671749
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
AID - nutd20137 [pii]
AID - 10.1038/nutd.2013.7 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 May 13;3:e67. doi: 10.1038/nutd.2013.7.

PMID- 23670224
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130605
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - Human mediastinal adipose tissue displays certain characteristics of brown fat.
PG  - e66
LID - 10.1038/nutd.2013.6 [doi]
AB  - Background:The amount of intra-thoracic fat, of which mediastinal adipose tissue 
      comprises the major depot, is related to various cardiometabolic risk factors.
      Autopsy and imaging studies indicate that the mediastinal depot in adult humans
      could contain brown adipose tissue (BAT). To gain a better understanding of this 
      intra-thoracic fat depot, we examined possible BAT characteristics of human
      mediastinal in comparison with subcutaneous adipose tissue.Materials and
      methods:Adipose tissue biopsies from thoracic subcutaneous and mediastinal depots
      were obtained during open-heart surgery from 33 subjects (26 male, 63.7+/-13.8
      years, body mass index 29.3+/-5.1 kg m(-2)). Microarray analysis was performed on
      10 patients and genes of interest confirmed by quantitative PCR (qPCR) in samples
      from another group of 23 patients. Adipocyte size was determined and uncoupling
      protein 1 (UCP1) protein expression investigated with
      immunohistochemistry.Results:The microarray data showed that a number of
      BAT-specific genes had significantly higher expression in the mediastinal depot
      than in the subcutaneous depot. Higher expression of UCP1 (24-fold, P<0.001) and 
      PPARGC1A (1.7-fold, P=0.0047), and lower expression of SHOX2 (0.12-fold, P<0.001)
      and HOXC8 (0.14-fold, P<0.001) in the mediastinal depot was confirmed by qPCR.
      Gene set enrichment analysis identified two gene sets related to mitochondria,
      which were significantly more highly expressed in the mediastinal than in the
      subcutaneous depot (P<0.01). No significant changes in UCP1 gene expression were 
      observed in the subcutaneous or mediastinal depots following lowering of body
      temperature during surgery. UCP1 messenger RNA levels in the mediastinal depot
      were lower than those in murine BAT and white adipose tissue. In some mediastinal
      adipose tissue biopsies, a small number of multilocular adipocytes that stained
      positively for UCP1 were observed. Adipocytes were significantly smaller in the
      mediastinal than the subcutaneous depot (cross-sectional area 2400+/-810 versus
      3260+/-980 mum(2), P<0.001).Conclusions:Human mediastinal adipose tissue displays
      some characteristics of BAT when compared with the subcutaneous depot at
      microscopic and molecular levels.
AD  - Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
FAU - Cheung, L
AU  - Cheung L
FAU - Gertow, J
AU  - Gertow J
FAU - Werngren, O
AU  - Werngren O
FAU - Folkersen, L
AU  - Folkersen L
FAU - Petrovic, N
AU  - Petrovic N
FAU - Nedergaard, J
AU  - Nedergaard J
FAU - Franco-Cereceda, A
AU  - Franco-Cereceda A
FAU - Eriksson, P
AU  - Eriksson P
FAU - Fisher, R M
AU  - Fisher RM
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
PMC - PMC3671748
OID - NLM: PMC3671748
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
AID - nutd20136 [pii]
AID - 10.1038/nutd.2013.6 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 May 13;3:e66. doi: 10.1038/nutd.2013.6.

PMID- 23670223
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130514
DCOM- 20130515
LR  - 20130605
IS  - 2044-4052 (Electronic)
IS  - 2044-4052 (Linking)
VI  - 3
DP  - 2013
TI  - Sleep duration and metabolic syndrome in adult populations: a meta-analysis of
      observational studies.
PG  - e65
LID - 10.1038/nutd.2013.8 [doi]
AB  - Objective:Epidemiological studies have repeatedly investigated the association
      between sleep duration and metabolic syndrome. However, the results have been
      inconsistent. This meta-analysis aimed to summarize the current evidence from
      cross-sectional and prospective cohort studies that evaluated this.Data
      sources:Relevant studies were identified by systematically searching the PubMed, 
      Cochrane CENTRAL, EMBASE and PsycINFO databases through November 2012 without
      language restriction.Study selection:We identified 12 cross-sectional studies
      with 76 027 participants including 14 404 cases of metabolic syndrome, and 3
      cohort studies with 2055 participants and 283 incident cases of metabolic
      syndrome.Results:For short sleep durations (<5 to 6 h), the odds ratios (OR) was 
      1.27 (95% confidence interval (CI)=1.10-1.48, I(2)=75.5%) in the 12
      cross-sectional studies and 1.62 (95% CI=0.74-3.55, I(2)=71.4%) in the 3 cohort
      studies; for long sleep durations (>8 to 10 h), the OR was 1.23 (95%
      CI=1.02-1.49, I(2)=75.8%) in the 11 cross-sectional studies and 1.62 (95%
      CI=0.86-3.04, I(2)=0.0%) in the 2 cohort studies.Conclusions:Short and long sleep
      durations are risky behaviors for increasing the risk of metabolic syndrome and
      thus have important public health implications, as sleep habits are amenable to
      behavioral interventions. The available data are sparse, and further studies,
      especially longitudinal studies, are needed to facilitate a better understanding 
      of these associations.
AD  - Department of Family Medicine, Yeouido St Mary's Hospital, College of Medicine,
      The Catholic University of Korea, Seoul, Korea.
FAU - Ju, S-Y
AU  - Ju SY
FAU - Choi, W-S
AU  - Choi WS
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - England
TA  - Nutr Diabetes
JT  - Nutrition & diabetes
JID - 101566341
PMC - PMC3671750
OID - NLM: PMC3671750
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/15 06:00
AID - nutd20138 [pii]
AID - 10.1038/nutd.2013.8 [doi]
PST - epublish
SO  - Nutr Diabetes. 2013 May 13;3:e65. doi: 10.1038/nutd.2013.8.

PMID- 23670221
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 Apr 19
TI  - Fat depot-specific mRNA expression of novel loci associated with waist-hip ratio.
LID - 10.1038/ijo.2013.56 [doi]
AB  - Objective:We hypothesized that genes within recently identified loci associated
      with waist-hip ratio (WHR) exhibit fat depot-specific mRNA expression, which
      correlates with obesity-related traits.Methods:Adipose tissue (AT) mRNA
      expression of 6 genes (TBX15/WARS2, STAB1, PIGC, ZNRF3 and GRB14) within these
      loci showing coincident cis-expression quantitative trait loci was measured in
      222 paired samples of human visceral (vis) and subcutaneous (sc) AT. The
      relationship of mRNA expression levels with obesity-related quantitative traits
      was assessed by Pearson's correlation analyses. Multivariate linear relationships
      were assessed by generalized linear regression models.Results:Whereas only PIGC, 
      ZNFR3 and STAB1 mRNA expression in sc AT correlated nominally with WHR (P<0.05,
      adjusted for age and sex), mRNA expression of all studied genes in at least one
      of the fat depots correlated significantly with vis and/or sc fat area (P ranging
      from 0.05 to 4.0 x 106, adjusted for age and sex). Consistently, the transcript
      levels of WARS, PIGC and GRB14 were nominally associated with body mass index
      (BMI) (P ranging from 0.02 to 9.2 x 105, adjusted for age and sex). Moreover,
      independent of sex, obesity and diabetes status, differential expression between 
      vis and sc AT was observed for all tested genes (P<0.01). Finally, the rs10195252
      T-allele was nominally associated with increased GRB14 sc mRNA expression
      (P=0.025 after adjusting for age, sex and BMI).Conclusions:Our data including the
      inter-depot variability of mRNA expression suggests that genes within the
      WHR-associated loci might be involved in the regulation of fat
      distribution.International Journal of Obesity advance online publication, 14 May 
      2013; doi:10.1038/ijo.2013.56.
AD  - Interdisciplinary Centre for Clinical Research, Medical Faculty, University of
      Leipzig, Leipzig, Germany.
FAU - Schleinitz, D
AU  - Schleinitz D
FAU - Kloting, N
AU  - Kloting N
FAU - Lindgren, C M
AU  - Lindgren CM
FAU - Breitfeld, J
AU  - Breitfeld J
FAU - Dietrich, A
AU  - Dietrich A
FAU - Schon, M R
AU  - Schon MR
FAU - Lohmann, T
AU  - Lohmann T
FAU - Dressler, M
AU  - Dressler M
FAU - Stumvoll, M
AU  - Stumvoll M
FAU - McCarthy, M I
AU  - McCarthy MI
FAU - Bluher, M
AU  - Bluher M
FAU - Kovacs, P
AU  - Kovacs P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/04/19 [aheadofprint]
PHST- 2013/05/14 [aheadofprint]
AID - ijo201356 [pii]
AID - 10.1038/ijo.2013.56 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 Apr 19. doi: 10.1038/ijo.2013.56.

PMID- 23670205
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1869-6953 (Print)
DP  - 2013 May 14
TI  - Safety and Effectiveness of Insulin Aspart in Basal-Bolus Regimens Regardless of 
      Age: Achieve Study Results.
AB  - INTRODUCTION: Hypoglycemia is a complication in the management of type 2
      diabetes, and elderly people are at greater risk of experiencing hypoglycemia
      events than younger patients. Insulin analogs achieve glycemic control with
      minimal risk of hypoglycemia and may therefore be a good treatment option for all
      patients. METHODS: A1chieve was an international, multicenter, prospective,
      open-label, non-interventional, 24-week study in people with type 2 diabetes who 
      started/switched to therapy with biphasic insulin aspart 30, insulin detemir or
      insulin aspart (alone/in combination) in routine clinical practice. This
      sub-analysis evaluated clinical safety and effectiveness of insulin aspart as
      part of a basal-bolus regimen (+/-oral glucose-lowering drugs) in three
      age-groups (</=40, >40-65, and >65 years) of insulin-experienced and
      insulin-naive people with type 2 diabetes. RESULTS: In total, 4,032 patients were
      included in the sub-analysis. After 24 weeks of insulin aspart treatment,
      significant improvements versus baseline were observed in all age-groups for:
      proportion of people with >/=1 hypoglycemia events (18.3-27.1% and 11.0-12.7%, at
      baseline and 24 weeks, respectively), >/=1 major hypoglycemia events (3.3-6.7%
      and 0-0.2%), and >/=1 nocturnal hypoglycemia events (9.2-13.7% and 2.9-4.9%);
      glycated hemoglobin (9.6-9.8% and 7.4%); fasting plasma glucose (change from
      baseline ranged from -3.6 to -4.4 mmol/l); and post-breakfast post-prandial
      plasma glucose (change from baseline ranged from -5.5 to -5.9 mmol/l). Fourteen
      serious adverse drug reactions were reported. Health-related quality of life was 
      significantly improved for all age-groups (all, p < 0.001). CONCLUSION: All
      age-groups showed improved glycemic control and reduced risk of hypoglycemia when
      starting/switching to insulin aspart therapy within a basal-bolus regimen; this
      may be particularly important for elderly patients given their greater risk of
      hypoglycemia versus younger patients.
AD  - Department of Endocrinology, Bangladesh Institute of Research and Rehabilitation 
      for Diabetes, Endocrine and Metabolic Disorders, Dhaka, Bangladesh.
FAU - Latif, Zafar A
AU  - Latif ZA
FAU - Hussein, Zanariah
AU  - Hussein Z
FAU - Litwak, Leon
AU  - Litwak L
FAU - El Naggar, Nabil
AU  - El Naggar N
FAU - Chen, Jian-Wen
AU  - Chen JW
FAU - Soewondo, Pradana
AU  - Soewondo P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/02/01 [received]
PHST- 2013/05/14 [aheadofprint]
AID - 10.1007/s13300-013-0023-1 [doi]
PST - aheadofprint
SO  - Diabetes Ther. 2013 May 14.

PMID- 23670204
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1869-6953 (Print)
DP  - 2013 May 14
TI  - Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the
      Achieve Study.
AB  - INTRODUCTION: Diabetes therapy should balance glycemic control with risk of
      adverse events. This sub-analysis of the A1chieve study evaluated clinical safety
      and effectiveness of insulin detemir in different age-groups (</=40 years, >40-65
      years, and >65 years) of insulin-experienced and insulin-naive people with type 2
      diabetes. METHODS: A1chieve was an international, open-label, non-interventional,
      24-week study in 66,726 people with type 2 diabetes starting/switching to therapy
      with biphasic insulin aspart 30, insulin detemir or insulin aspart (alone/in
      combination) in routine clinical practice. This sub-analysis evaluated clinical
      safety and effectiveness in patients starting/switching to insulin detemir
      (+/-oral glucose-lowering drugs). RESULTS: In total, 15,241 patients were
      included in the sub-analysis. In all age-groups, the proportion of participants
      experiencing any, major or nocturnal hypoglycemia was significantly (all p <
      0.05) reduced relative to baseline, except in insulin-naive patients for any and 
      nocturnal hypoglycemia, where there was a significant increase or no significant 
      change in patients aged >65 years and >40-65 years, respectively, and no
      significant change in major hypoglycemia in insulin-naive patients aged </=40
      years. Seven serious adverse drug reactions were reported. Body weight was
      significantly reduced in patients aged </=40 years and >40-65 years and
      significantly increased in insulin-naive patients aged >65 years at 24 weeks. At 
      24 weeks, glycated hemoglobin was reduced by 2.3%, 2.0%, and 1.8%, in the </=40
      years, >40-65 years, and >65 years age-groups, respectively (all p < 0.001).
      Fasting and post-prandial plasma glucose were significantly reduced and
      health-related quality of life (HRQoL) significantly improved across all patient 
      cohorts (all p < 0.001). CONCLUSION: After 24-week treatment with insulin
      detemir, all age-groups of insulin-experienced and insulin-naive patients had
      significantly improved glycemic control and HRQoL. The proportion of patients
      experiencing hypoglycemia was reduced in all age-groups but unchanged in
      insulin-naive patients aged >40-65 years and increased in insulin-naive patients 
      aged >65 years. The safety and effectiveness of insulin detemir may benefit all
      age-groups.
AD  - Internal Medicine, CHU Setif, Setif, Algeria.
FAU - Malek, Rachid
AU  - Malek R
FAU - Gonzalez-Galvez, Guillermo
AU  - Gonzalez-Galvez G
FAU - El Naggar, Nabil
AU  - El Naggar N
FAU - Shah, Siddharth
AU  - Shah S
FAU - Prusty, Vinay
AU  - Prusty V
FAU - Litwak, Leon
AU  - Litwak L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/02/04 [received]
PHST- 2013/05/14 [aheadofprint]
AID - 10.1007/s13300-013-0021-3 [doi]
PST - aheadofprint
SO  - Diabetes Ther. 2013 May 14.

PMID- 23670046
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1554-8635 (Electronic)
IS  - 1554-8627 (Linking)
VI  - 9
IP  - 7
DP  - 2013 May 2
TI  - What the N-terminal domain of Atg13 looks like and what it does: A HORMA fold
      required for PtdIns 3-kinase recruitment.
AB  - Atg13 is a subunit of the Atg1 complex that is involved in autophagy. The middle 
      and C-terminal regions of Atg13 are intrinsically disordered and rich in
      regulatory phosphorylation sites. Thus far, there have been no structural data
      for any part of Atg13, and no function assigned to its N-terminal domain. We
      crystallized this domain, and found that it has a HORMA (Hop1, Rev7, Mad2) fold. 
      We showed that the Atg13 HORMA domain is required for autophagy and for
      recruitment of the phosphatidylinositol (PtdIns) 3-kinase subunit Atg14, but is
      not required for Atg1 interaction or Atg13 recruitment to the PAS. The HORMA
      domain of Atg13 is similar to the closed conformation of the spindle checkpoint
      protein Mad2. A pair of conserved arginines was identified in the structure, and 
      tested functionally in yeast. These residues are important for autophagy, as
      mutations abrogate autophagy and block Atg14 recruitment. The location of these
      Arg residues in the structure suggests that the Atg13 HORMA domain could act as a
      phosphorylation-dependent conformational switch.
AD  - Laboratory of Molecular Biology; National Institute of Diabetes and Digestive and
      Kidney Diseases; National Institutes of Health; Bethesda, MD USA.
FAU - Jao, Christine C
AU  - Jao CC
FAU - Ragusa, Michael J
AU  - Ragusa MJ
FAU - Stanley, Robin E
AU  - Stanley RE
FAU - Hurley, James H
AU  - Hurley JH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Autophagy
JT  - Autophagy
JID - 101265188
OTO - NOTNLM
OT  - Atg13
OT  - Atg14
OT  - HORMA
OT  - protein crystallography
OT  - protein degradation
OT  - protein structure
OT  - yeast genetics
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 24896 [pii]
PST - aheadofprint
SO  - Autophagy. 2013 May 2;9(7).

PMID- 23670025
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1533-4112 (Electronic)
IS  - 1095-0680 (Linking)
DP  - 2013 May 10
TI  - Resolution of Electroconvulsive Therapy Refractory Major Depressive Disorder With
      Unintentional Hypoglycemic Seizure: A Case Report.
AB  - We report a 74-year-old white woman with type 1 diabetes and major depressive
      disorder refractory to multiple medications who received 15 electroconvulsive
      therapy treatments with minimal improvement. After an accidental hypoglycemic
      seizure, the patient's symptoms completely resolved. In conclusion, the present
      case reveals an instance where electroconvulsive therapy-induced seizures
      appeared to be minimally effective, whereas a single accidental
      hypoglycemia-induced seizure was incredibly effective for the resolutions of
      depressive symptoms. Although this case presents a single efficacious use of
      accidental insulin coma therapy, the applicability is limited because of the
      known risks of insulin coma therapy.
AD  - From Western University, Chatham, Ontario, Canada .
FAU - Rosenblat, Joshua D
AU  - Rosenblat JD
FAU - Devarajan, Sivakumaran
AU  - Devarajan S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J ECT
JT  - The journal of ECT
JID - 9808943
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.1097/YCT.0b013e318290fc20 [doi]
PST - aheadofprint
SO  - J ECT. 2013 May 10.

PMID- 23669883
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 May 14
TI  - In vitro effects of resveratrol on oxidative stress in diabetic platelets.
AB  - To evaluate the in vitro effects of resveratrol (RSV) incubation on platelets
      from compensated and decompensated diabetic patients in order to use it as an
      adjuvant therapy. The study was performed on 77 diabetic patients and divided
      into two phases: 29 compensated and 48 decompensated diabetic platelets were
      analyzed at recruitment (T 0) and after in vitro RSV incubation (20 mug/ml) for 3
      h at 37 degrees C (T 1). Lipoperoxide and nitric oxide (NO) levels, superoxide
      dismutase (SOD) and Na+/K+ ATPase activities, total antioxidant capacity (TAC),
      and membrane fluidity tested by anisotropy of fluorescent probes TMA-DPH and DPH 
      were determined. In vitro RSV incubation counteracts oxidative damage associated 
      with diabetes and its complications; it is able to improve platelet function
      through augmented membrane fluidity and Na+/K+ ATPase activity; it enhances
      antioxidant systems' functionality by increasing NO levels, SOD activity, and TAC
      and by decreasing lipoperoxide levels in both compensated and decompensated
      patients. Such platelet functionality enhancement suggests a new method of
      secondary prevention of complications associated with platelet dysfunction. Being
      free from one of the major risks associated with many antidiabetic agents, it can
      be assumed that RSV utilization in the diabetic diet may have a preventive and
      protective role in the progression of diabetic oxidative damage.
AD  - Section of Biochemistry, Biology and Physics, Department of Clinical Sciences,
      Faculty of Medicine, Marche Polytechnic University, Via Tronto 10, 60128, Ancona,
      Italy.
FAU - Raffaelli, F
AU  - Raffaelli F
FAU - Vignini, A
AU  - Vignini A
FAU - Giulietti, A
AU  - Giulietti A
FAU - Alidori, A
AU  - Alidori A
FAU - Borroni, F
AU  - Borroni F
FAU - Sforza, G
AU  - Sforza G
FAU - Faloia, E
AU  - Faloia E
FAU - Mazzanti, L
AU  - Mazzanti L
FAU - Nanetti, L
AU  - Nanetti L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/11/27 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 10.1007/s00592-013-0480-z [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 May 14.

PMID- 23669882
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1530-0315 (Electronic)
IS  - 0195-9131 (Linking)
DP  - 2013 May 10
TI  - Soccer Training Improves Cardiac Function in Men with Type 2 Diabetes.
AB  - INTRODUCTION: Patients with type 2 diabetes (T2DM) have an increased risk of
      cardiovascular disease which is worsened by physical inactivity. Subclinical
      myocardial dysfunction is associated with increased risk of heart failure and
      impaired prognosis in T2DM; however, it is not clear if exercise training can
      counteract the early signs of diabetic heart disease. PURPOSE: To evaluate the
      effects of soccer training on cardiac function, exercise capacity and blood
      pressure in middle-aged men with T2DM. METHODS: Twenty-one men aged 49.8+/-1.7
      yrs with T2DM and no history of cardiovascular disease, participated in a soccer 
      training group (STG; n=12) that trained one h twice a week or a control group
      (CG; n=9) with no change in lifestyle. Examinations included comprehensive
      transthoracic echocardiography, measurements of blood pressure, maximal oxygen
      consumption (VO2max) and intermittent endurance capacity before and after 12 and 
      24 wks. Two-way repeated-measures ANOVA was applied. RESULTS: After 24 wks of
      soccer training, left ventricular (LV) end-diastolic diameter and volume were
      increased (P<0.001) compared to baseline. LV longitudinal systolic displacement
      was augmented by 23% (P<0.001) and global longitudinal 2D strain increased by 10%
      (P<0.05). LV diastolic function, determined by mitral inflow (E/A-ratio) and peak
      diastolic velocity E were increased by 18% (P<0.01) and 29% (P<0.001),
      respectively while LV filling pressure E/E was reduced by 15% (P=0.05). Systolic,
      diastolic and mean arterial pressures were all reduced by 8 mmHg (P<0.01, P<0.001
      and P<0.001, respectively). VO2max and intermittent endurance capacity was 12%
      and 42% (P<0.001) higher, respectively. No changes in any of the measured
      parameters were observed in CG. CONCLUSION: Regular soccer training improves
      cardiac function, increases exercise capacity and lowers blood pressure in men
      with T2DM.
AD  - 1Copenhagen Centre for Team Sports and Health, Department of Nutrition, Exercise 
      and Sports, University of Copenhagen, Denmark, 2Department of Cardiology,
      Gentofte Hospital, Denmark, 3Department of Cardiology, Herlev Hospital, Denmark, 
      4Steno Diabetes Center, Copenhagen and Health, Aarhus University, Denmark, 5Sport
      and Health Sciences, College of Life and Environmental Sciences, St. Luke's
      Campus, University of Exeter, UK.
FAU - Friis Schmidt, Jakob
AU  - Friis Schmidt J
FAU - Rostgaard Andersen, Thomas
AU  - Rostgaard Andersen T
FAU - Horton, Joshua
AU  - Horton J
FAU - Brix, Jonathan
AU  - Brix J
FAU - Tarnow, Lise
AU  - Tarnow L
FAU - Krustrup, Peter
AU  - Krustrup P
FAU - Juel Andersen, Lars
AU  - Juel Andersen L
FAU - Bangsbo, Jens
AU  - Bangsbo J
FAU - Riis Hansen, Peter
AU  - Riis Hansen P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Med Sci Sports Exerc
JT  - Medicine and science in sports and exercise
JID - 8005433
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.1249/MSS.0b013e31829ab43c [doi]
PST - aheadofprint
SO  - Med Sci Sports Exerc. 2013 May 10.

PMID- 23669877
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1530-0315 (Electronic)
IS  - 0195-9131 (Linking)
DP  - 2013 May 10
TI  - A Comparison of Energy Expenditure Estimation of Several Physical Activity
      Monitors.
AB  - Accurately and precisely estimating free-living energy expenditure (EE) is
      important for monitoring energy balance and quantifying physical activity.
      Recently, single and multi-sensor devices have been developed that can classify
      physical activities, potentially resulting in improved estimates of EE. PURPOSE: 
      To determine the validity of EE estimation of a footwear-based physical activity 
      monitor and to compare this validity against a variety of research and consumer
      physical activity monitors. METHODS: Nineteen healthy young adults (10 male, 9
      female), completed a four-hour stay in a room calorimeter. Participants wore a
      footwear-based physical activity monitor, as well as Actical, Actigraph, IDEEA,
      DirectLife and Fitbit devices. Each individual performed a series of
      postures/activities. We developed models to estimate EE from the footwear-based
      device, and we used the manufacturer's software to estimate EE for all other
      devices. RESULTS: Estimated EE using the shoe-based device was not significantly 
      different than measured EE (476(20) vs. 478(18) kcal) (Mean (SE)), respectively, 
      and had a root mean square error (RMSE) of (29.6 kcal (6.2%)). The IDEEA and
      DirectLlife estimates of EE were not significantly different than the measured EE
      but the Actigraph and Fitbit devices significantly underestimated EE. Root mean
      square errors were 93.5 (19%), 62.1 kcal (14%), 88.2 kcal (18%), 136.6 kcal
      (27%), 130.1 kcal (26%), and 143.2 kcal (28%) for Actical, DirectLife, IDEEA,
      Actigraph and Fitbit respectively. CONCLUSIONS: The shoe based physical activity 
      monitor provides a valid estimate of EE while the other physical activity
      monitors tested have a wide range of validity when estimating EE. Our results
      also demonstrate that estimating EE based on classification of physical
      activities can be more accurate and precise than estimating EE based on total
      physical activity.
AD  - 1Health and Exercise Science, Colorado State University, Fort Collins, CO;
      2Electrical and Computer Engineering, University of Alabama, Tuscaloosa, AL;
      3Division of Endocrinology, Metabolism and Diabetes, 4Division of Geriatrics,
      University of Colorado Anschutz Medical Campus, Denver, CO.
FAU - Dannecker, Kathryn L
AU  - Dannecker KL
FAU - Sazonova, Nadezhda A
AU  - Sazonova NA
FAU - Melanson, Edward L
AU  - Melanson EL
FAU - Sazonov, Edward S
AU  - Sazonov ES
FAU - Browning, Raymond C
AU  - Browning RC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Med Sci Sports Exerc
JT  - Medicine and science in sports and exercise
JID - 8005433
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.1249/MSS.0b013e318299d2eb [doi]
PST - aheadofprint
SO  - Med Sci Sports Exerc. 2013 May 10.

PMID- 23669782
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1523-2859 (Electronic)
IS  - 0025-732X (Linking)
VI  - 55
IP  - 1416
DP  - 2013 May 13
TI  - Canaglifozin (Invokana) for type 2 diabetes.
PG  - 37-9
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Med Lett Drugs Ther
JT  - The Medical letter on drugs and therapeutics
JID - 2985240R
SB  - AIM
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PST - ppublish
SO  - Med Lett Drugs Ther. 2013 May 13;55(1416):37-9.

PMID- 23669655
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Linking)
DP  - 2013 May 12
TI  - Chicago Healthy Aging Study: Objectives and Design.
AB  - Investigators in the Chicago Healthy Aging Study (CHAS) reexamined 1,395
      surviving participants aged 65-84 years (28% women) from the Chicago Heart
      Association Detection Project in Industry (CHA) 1967-1973 cohort whose
      cardiovascular disease (CVD) risk profiles were originally ascertained at ages
      25-44 years. CHAS investigators reexamined 421 participants who were low-risk
      (LR) at baseline and 974 participants who were non-LR at baseline. LR was defined
      as having favorable levels of 4 major CVD risk factors: serum total cholesterol
      level <200 mg/dL and no use of cholesterol-lowering medication; blood pressure
      <120/</=80 mm Hg and no use of antihypertensive medication; no current smoking;
      and no history of diabetes or heart attack. While the potential of LR status in
      overcoming the CVD epidemic is being recognized, the long-term association of LR 
      with objectively measured health in older age has not been examined. It is
      hypothesized that persons who were LR in 1967-1973 and have survived to older age
      will have less clinical and subclinical CVD, lower levels of inflammatory
      markers, and better physical performance/functioning and sleep quality. Here we
      describe the rationale, objectives, design, and implementation of this
      longitudinal epidemiologic study, compare baseline and follow-up characteristics 
      of participants and nonparticipants, and highlight the feasibility of reexamining
      study participants after an extended period postbaseline with minimal interim
      contact.
FAU - Pirzada, Amber
AU  - Pirzada A
FAU - Reid, Kathryn
AU  - Reid K
FAU - Kim, Daniel
AU  - Kim D
FAU - Garside, Daniel B
AU  - Garside DB
FAU - Lu, Brandon
AU  - Lu B
FAU - Vu, Thanh-Huyen T
AU  - Vu TH
FAU - Lloyd-Jones, Donald M
AU  - Lloyd-Jones DM
FAU - Zee, Phyllis
AU  - Zee P
FAU - Liu, Kiang
AU  - Liu K
FAU - Stamler, Jeremiah
AU  - Stamler J
FAU - Daviglus, Martha L
AU  - Daviglus ML
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
OTO - NOTNLM
OT  - cardiovascular disease
OT  - epidemiologic studies
OT  - follow-up examination
OT  - risk factors
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - kwt020 [pii]
AID - 10.1093/aje/kwt020 [doi]
PST - aheadofprint
SO  - Am J Epidemiol. 2013 May 12.

PMID- 23669614
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1554-6179 (Electronic)
IS  - 1539-4182 (Linking)
DP  - 2013 May 13
TI  - Breast and Prostate Cancer Survivors in a Diabetic Cohort: Results from the
      Living With Diabetes Study.
AB  - ObjectiveDiabetes is more common in cancer survivors than in the general
      population. The objective of the present study was to determine cancer frequency 
      in a cohort of patients with diabetes and to examine demographic, clinical, and
      quality of life differences between cancer survivors and their cancer-free peers 
      to inform better individualized care.MethodsSelf-reported survey data from 3,466 
      registrants with type 2 diabetes from Australia's National Diabetes Services
      Scheme (NDSS) were analyzed to compare relevant variables between cancer
      survivors and cancer-free patients. Analyses were focused on breast and prostate 
      cancer to reflect the most common cancers in women and men,
      respectively.ResultsFive percent of diabetic women reported a history of breast
      cancer and 4.2% of men reported a history of prostate cancer. Diabetic patients
      with a history of breast or prostate cancer were older at time of survey and
      diabetes diagnosis, less likely to report metformin use (women), and more likely 
      to have two or more comorbidities than their cancer-free peers. More diabetic
      prostate cancer survivors also reported problems with mobility and performing
      usual tasks. However, cancer-free diabetic subjects reported a lower
      diabetes-dependent quality of life than diabetic cancer survivors. There was no
      association between cancer survivorship and duration of diabetes, indices of
      glycemic control, obesity, or diabetic complications.ConclusionsCancer survivors 
      comprise a significant minority of diabetic patients that are particularly
      vulnerable and may benefit from interventions to increase screening and treatment
      of other comorbidities and promote a healthy lifestyle.
AD  - *School of Population Health, University of Queensland, Brisbane, Queensland,
      Australia.
FAU - Onitilo, Adedayo A
AU  - Onitilo AA
FAU - Donald, Maria
AU  - Donald M
FAU - Stankowski, Rachel V
AU  - Stankowski RV
FAU - Engel, Jessica M
AU  - Engel JM
FAU - Williams, Gail
AU  - Williams G
FAU - Doi, Suhail A R
AU  - Doi SA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Clin Med Res
JT  - Clinical medicine & research
JID - 101175887
OTO - NOTNLM
OT  - Diabetes
OT  - cancer
OT  - cross-sectional survey
OT  - metformin
OT  - patient characteristics
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - cmr.2013.1156 [pii]
AID - 10.3121/cmr.2013.1156 [doi]
PST - aheadofprint
SO  - Clin Med Res. 2013 May 13.

PMID- 23669476
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1590-8577 (Electronic)
IS  - 1590-8577 (Linking)
VI  - 14
IP  - 3
DP  - 2013
TI  - Refractory idiopathic non-insulinoma pancreatogenous hypoglycemia in an adult:
      case report and review of the literature.
PG  - 264-8
LID - 10.6092/1590-8577/1319 [doi]
AB  - CONTEXT: Non-insulinoma pancreatogenous hypoglycemia is a rare cause of
      spontaneous hypoglycemia in adults. The ideal diagnostic and therapeutic approach
      is still controversial, not least because most reported cases lack long-term
      follow-up. CASE REPORT: We describe the case of a 58-year-old woman, who was
      diagnosed with idiopathic non-insulinoma pancreatogenous hypoglycemia in 2001.
      After resection of 75% of the distal pancreas, she initially experienced no
      additional hypoglycemic episodes and did not suffer from diabetes mellitus.
      However, after one month, recurrent hypoglycemia occurred. After resection of the
      larger part of the remaining pancreatic tissue, the patient suffered from
      hypoglycemic as well as hyperglycemic episodes. Octreotide and diazoxide were not
      successful in preventing the hypoglycemic attacks, whereas continuous insulin
      therapy with an insulin pump helped to stabilize the blood glucose level
      temporarily. Finally, all remaining pancreatic tissue had to be removed.
      CONCLUSION: This long-term follow-up of non-insulinoma pancreatogenous
      hypoglycemia treatment in an adult patient indicates that lateral pancreatectomy 
      may not be sufficient for permanent blood glucose control and emphasizes the need
      of follow-up data after subtotal pancreatectomy.
AD  - Diabetes Center, Clinic and Polyclinic IV, "Ludwig-Maximilians" University.
      Munich, Germany. cornelia.then@med.uni-muenchen.de.
FAU - Then, Cornelia
AU  - Then C
FAU - Nam-Apostolopoulos, Yun-Chung
AU  - Nam-Apostolopoulos YC
FAU - Seissler, Jochen
AU  - Seissler J
FAU - Lechner, Andreas
AU  - Lechner A
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - Italy
TA  - JOP
JT  - JOP : Journal of the pancreas
JID - 101091810
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/12/06 [received]
PHST- 2013/03/20 [accepted]
PHST- 2013/02/02 [revised]
PST - epublish
SO  - JOP. 2013 May 10;14(3):264-8. doi: 10.6092/1590-8577/1319.

PMID- 23669472
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1590-8577 (Electronic)
IS  - 1590-8577 (Linking)
VI  - 14
IP  - 3
DP  - 2013
TI  - Duration of Diabetes and Pancreatic Cancer in a Case-Control Study in the Midwest
      and the Iowa Women's Health Study (IWHS) Cohort.
PG  - 243-9
LID - 10.6092/1590-8577/1317 [doi]
AB  - CONTEXT: Studies have shown a relationship between history of diabetes and the
      risk of pancreatic cancer; however, the temporal relation between diabetes and
      pancreatic cancer is not clearly established. OBJECTIVES: Diabetes and diabetes
      duration were examined in relation to pancreatic cancer in a population-based
      case-control study and prospective cohort. METHODS: Case-control study:
      pancreatic cancer cases (n=200) from the Midwest were frequency matched by age
      and sex to population controls (n=673). Logistic regression yielded odds ratios
      (ORs) and 95% confidence intervals (95% CI). Iowa Women's Health Study (IWHS)
      cohort: 292 incident pancreatic cancer cases occurred between 1986-2008 among
      36,084 post-menopausal, initially cancer-free women. Diabetes status and
      diagnosis age were ascertained at baseline and follow-ups. Proportional hazards
      regression yielded hazard ratios (HR, 95% CI) for pancreatic cancer in relation
      to baseline diabetes. Time-dependent analyses accounted for diabetes diagnosed
      after baseline. A nested-case control analysis assessed diabetes duration as a
      risk factor. RESULTS: In the case-control study, compared to participants without
      diabetes, the multivariate ORs (95% CI) for pancreatic cancer were 2.35
      (1.24-4.47) for those with diabetes and 4.00 (0.94-16.9), 2.79 (0.97-8.04), and
      2.40 (0.97-5.98) for diabetes durations of 2-5 years, 5.1-10 years, and more than
      10 years, respectively. In IWHS, compared to no diabetes, multivariate-adjusted
      HRs for pancreatic cancer were 1.86 (1.23-2.83) for baseline diabetes and 1.94
      (1.40-2.69) adding diabetes during follow-up. In an IWHS nested case-control
      analysis, ORs were 1.70 (0.78-3.67), 2.62 (1.48-4.65), and 2.10 (1.36-3.24) for
      diabetes durations of 2-5 years, 5.1-10 years and more than 10 years,
      respectively, versus no diabetes. CONCLUSIONS: Diabetes is associated with
      pancreatic cancer risk and this is similar across different duration categories.
AD  - Division of Epidemiology and Community Health, School of Public Health,
      University of Minnesota; University of Minnesota Masonic Cancer Center.
      Minneapolis, MN, USA. ander116@umn.edu.
FAU - Henry, Sarah A
AU  - Henry SA
FAU - Prizment, Anna E
AU  - Prizment AE
FAU - Anderson, Kristin E
AU  - Anderson KE
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - Italy
TA  - JOP
JT  - JOP : Journal of the pancreas
JID - 101091810
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/12/05 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/04/03 [revised]
PST - epublish
SO  - JOP. 2013 May 10;14(3):243-9. doi: 10.6092/1590-8577/1317.

PMID- 23669470
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1590-8577 (Electronic)
IS  - 1590-8577 (Linking)
VI  - 14
IP  - 3
DP  - 2013
TI  - Effects of fungal pancreatic enzymes on the function of islet cells in Syrian
      golden hamsters.
PG  - 228-336
LID - 10.6092/1590-8577/903 [doi]
AB  - CONTEXT: Our previous studies showed that porcine pancreatic enzymes in Syrian
      golden hamsters with peripheral insulin resistance normalizes the plasma insulin 
      level, reduces the size of enlarged islets and inhibits the increased DNA
      synthesis in the beta-cell of islets. OBJECTIVE: In order to exclude the
      possibility that these effects was attributed to some contaminants of this crude 
      material, we tested the effect of purified fungal pancreatic enzyme (FPE) that
      contains primarily amylase and lipase without (FPE) and with addition of
      chymotrypsin (FPE+chy). MATERIAL AND METHODS: In a pilot study we tested the
      effect of different doses of FPE given in drinking water on insulin level, islet 
      size and DNA synthesis of islet cells in hamsters with induced peripheral insulin
      resistance by a high fat diet. The most effective dose of FPE on these parameters
      was used in a long-term experiment with FPE and FPE+chy in hamsters fed a
      high-fat diet for 36 or 40 weeks. RESULTS: In the pilot study a dose of 2 g/kg
      body weight was found to be optimal for controlling the body weight, normalizing 
      plasma insulin level, the size of islets, the DNA synthesis and the number of
      insulin cells in the islets. These data were produced in the long-term study,
      where steatorrhea was also inhibited. Addition of chymotrypsin had no effects on 
      these parameters. CONCLUSION: Pancreatic lipase and amylase appear to be
      responsible for the observed effects and offer a safe and effective natural
      product for the treatment of pancreatic diseases, including acute pancreatitis,
      chronic pancreatic, cystic fibrosis and any conditions associated with peripheral
      insulin resistance, including obesity and type 2 diabetes. The possible mechanism
      of the action is discussed.
AD  - Eppley Institute for Research in Cancer and Allied Diseases. Omaha, NE, USA.
      ppour@unmc.edu.
FAU - Nozawa, Fumiaki
AU  - Nozawa F
FAU - Yalniz, Mehmet
AU  - Yalniz M
FAU - Saruc, Murat
AU  - Saruc M
FAU - Standop, Jens
AU  - Standop J
FAU - Egami, Hiroshi
AU  - Egami H
FAU - Pour, Parviz M
AU  - Pour PM
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - Italy
TA  - JOP
JT  - JOP : Journal of the pancreas
JID - 101091810
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/06/04 [received]
PHST- 2013/03/22 [accepted]
PHST- 2013/02/07 [revised]
PST - epublish
SO  - JOP. 2013 May 10;14(3):228-336. doi: 10.6092/1590-8577/903.

PMID- 23669376
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 81
IP  - 1
DP  - 2013 Jul
TI  - Is laterality of malignant otitis externa related to handedness?
PG  - 142-3
LID - 10.1016/j.mehy.2013.04.020 [doi]
LID - S0306-9877(13)00190-4 [pii]
AB  - Malignant otitis externa (MOE) usually affect patients with systemic diseases,
      especially diabetes mellitus. MOE is a mainly unilateral disease. Given that
      around 90% of human adults are right-handed we hypothesized that hand preference 
      might be one of the factors involved in the development of MOE. All 38 of the
      patients whom we treated for MOE between August 2009 and November 2012 (28 males 
      and 10 females, age range 43-91years) had poorly controlled diabetes mellitus,
      and all of them reported itching in the involved ear. The difference in the
      laterality of MOE among our right- and left-handed subjects was significant:
      right hand dominance was associated mostly with right-sided MOE (24/34) and left 
      hand dominance was associated with occurrence of MOE only in the left ears (4/4, 
      p=0.006). These findings point to an unexpectedly strong relationship between the
      patient's handedness and laterality of his/her MOE, leading us to hypothesize
      that the development of MOE might be attributable to self-inflicted local trauma 
      to the ear canal on the same side as the dominant hand.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Otolaryngology Head & Neck Surgery, Sheba Medical Center,
      Affiliated to the Sackler School of Medicine, Tel Aviv University, Israel.
      Electronic address: migirovl@gmail.com.
FAU - Migirov, Lela
AU  - Migirov L
FAU - Lipshitz, Noga
AU  - Lipshitz N
FAU - Dagan, Elad
AU  - Dagan E
FAU - Wolf, Michael
AU  - Wolf M
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/12/17 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - S0306-9877(13)00190-4 [pii]
AID - 10.1016/j.mehy.2013.04.020 [doi]
PST - ppublish
SO  - Med Hypotheses. 2013 Jul;81(1):142-3. doi: 10.1016/j.mehy.2013.04.020. Epub 2013 
      May 10.

PMID- 23669362
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-3468 (Electronic)
IS  - 0014-5793 (Linking)
DP  - 2013 May 10
TI  - Diabetes mellitus due to the toxic misfolding of proinsulin variants.
LID - S0014-5793(13)00339-6 [pii]
LID - 10.1016/j.febslet.2013.04.044 [doi]
AB  - Dominant mutations in the human insulin gene can lead to pancreatic beta-cell
      dysfunction and diabetes mellitus due to toxic folding of a mutant proinsulin.
      Analogous to a classical mouse model (the Akita mouse), this monogenic syndrome
      highlights the susceptibility of human beta-cells to endoreticular stress due to 
      protein misfolding and aberrant aggregation. The clinical mutations directly or
      indirectly perturb native disulfide pairing. Whereas the majority of mutations
      introduce or remove a cysteine (leading in either case to an unpaired residue),
      non-cysteine-related mutations identify key determinants of folding efficiency.
      Studies of such mutations suggest that the evolution of insulin has been
      constrained not only by its structure and function, but also by the
      susceptibility of its single-chain precursor to impaired foldability.
CI  - Copyright (c) 2013 Federation of European Biochemical Societies. Published by
      Elsevier B.V. All rights reserved.
AD  - Department of Biochemistry, Case Western Reserve University, Cleveland, OH 44106,
      United States. Electronic address: michael.weiss@case.edu.
FAU - Weiss, Michael A
AU  - Weiss MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - FEBS Lett
JT  - FEBS letters
JID - 0155157
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/04/17 [received]
PHST- 2013/04/29 [revised]
PHST- 2013/04/30 [accepted]
AID - S0014-5793(13)00339-6 [pii]
AID - 10.1016/j.febslet.2013.04.044 [doi]
PST - aheadofprint
SO  - FEBS Lett. 2013 May 10. pii: S0014-5793(13)00339-6. doi:
      10.1016/j.febslet.2013.04.044.

PMID- 23669275
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1470-2738 (Electronic)
IS  - 0143-005X (Linking)
DP  - 2013 May 13
TI  - Residential proximity to major roadways and renal function.
AB  - BACKGROUND: Living near major roadways has been associated with increased risk of
      cardiovascular events, but little is known about its impact on renal function.
      METHODS: We calculated the estimated glomerular filtration rate (eGFR) for 1103
      consecutive Boston-area patients hospitalised with confirmed acute ischaemic
      stroke between 1999 and 2004. We used linear regression to evaluate the
      association between eGFR and categories of residential distance to major roadway 
      (0 to </=50, >50 to </=100, >100 to </=200, >200 to </=400, >400 to </=1000 and
      >1000 m) adjusting for age, sex, race, smoking, comorbid conditions, treatment
      with ACE inhibitor and neighbourhood-level socioeconomic characteristics. In a
      second analysis, we considered the log of distance to major roadway as a
      continuous variable. RESULTS: Patients living closer to a major roadway had lower
      eGFR than patients living farther away (Ptrend=0.01). Comparing patients living
      50 m versus 1000 m from a major roadway was associated with a 3.9 ml/min/1.73 m2 
      lower eGFR (95% CI 1.0 to 6.7; p=0.007): a difference comparable in magnitude to 
      the reduction in eGFR observed for a 4-year increase in age in population-based
      studies. The magnitude of this association did not differ significantly across
      categories of age, sex, race, history of hypertension, diabetes or socioeconomic 
      status. CONCLUSIONS: Living near a major roadway is associated with lower eGFR in
      a cohort of patients presenting with acute ischaemic stroke. If causal, these
      results imply that exposures associated with living near a major roadway
      contribute to reduced renal function, an important risk factor for cardiovascular
      events.
AD  - Beth Israel Deaconess Medical Center, , Boston, Massachusetts, USA.
FAU - Lue, Shih-Ho
AU  - Lue SH
FAU - Wellenius, Gregory A
AU  - Wellenius GA
FAU - Wilker, Elissa H
AU  - Wilker EH
FAU - Mostofsky, Elizabeth
AU  - Mostofsky E
FAU - Mittleman, Murray A
AU  - Mittleman MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Epidemiol Community Health
JT  - Journal of epidemiology and community health
JID - 7909766
OTO - NOTNLM
OT  - Air pollution
OT  - Epidemiology
OT  - Vascular disease
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - jech-2012-202307 [pii]
AID - 10.1136/jech-2012-202307 [doi]
PST - aheadofprint
SO  - J Epidemiol Community Health. 2013 May 13.

PMID- 23669259
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1943-2720 (Electronic)
IS  - 0889-5899 (Linking)
VI  - 59
IP  - 5
DP  - 2013 May
TI  - The Effect of a Cellulose Dressing and Topical Vancomycin on
      Methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive Organisms in
      Chronic Wounds: A Case Series .
PG  - 34-44
AB  - High levels of persistent bacteria may contribute to wound chronicity and delayed
      healing. A prospective study was conducted to: 1) evaluate the effect of applying
      vancomycin topically on appropriately cultured chronic lower leg wounds,
      specifically methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive
      bacteria, and 2) evaluate its effect in combination with a cellulose dressing on 
      healing. Twenty-three (23) outpatients (11 men, 12 women, average age 65 years
      [range 39-89 years]) with lower extremity wounds (15 venous ulcers, six chronic
      open wounds with a history of diabetes, and two chronic open trauma wounds)
      averaging 43.58 weeks' (range 5-121 weeks) duration and swab-cultured positive
      for MRSA or Gram-positive bacteria were provided 1 g vancomycin delivered by a
      cellulose dressing and changed every 72 hours. Patients served as their own
      control, and all wounds were debrided once a week. Wound surface area and
      bacterial and exudate levels were recorded weekly during the 3-week pretreatment 
      period and compared to 3-week treatment period levels. Patients were followed
      until healed. Mean change in wound surface area was +14.5% (SD 71.91) per week
      before and -24.6% (SD 13.59) during the vancomycin treatment period (P = 0.014), 
      average exudate levels decreased from 2.75 (range 1-4) to 1.81 (range 0-3) (P =
      0.016), and the number of patients with positive wound cultures for MRSA or
      Gram-positive bacteria decreased from 23 to four after the 3-week study period.
      All wounds healed after an average of 8.18 weeks (SD 4.76, range 2-17 weeks). The
      results of this study suggest topical vancomycin applied using a dressing that
      retains moisture reduces wound bacterial load and may facilitate healing.
      Randomized, controlled clinical studies to evaluate the effectiveness and
      efficacy of this treatment modality and explore the relationship between wound
      culture results and healing are warranted.
AD  - Neumann University, Aston, PA; email:albaughk@neumann.edu.
FAU - Albaugh, Karen W
AU  - Albaugh KW
FAU - Biely, Scott A
AU  - Biely SA
FAU - Cavorsi, Joseph P
AU  - Cavorsi JP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ostomy Wound Manage
JT  - Ostomy/wound management
JID - 8912029
SB  - N
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PST - ppublish
SO  - Ostomy Wound Manage. 2013 May;59(5):34-44.

PMID- 23669253
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
DP  - 2013 May 10
TI  - Vitamin D supplementation modulates inflammatory responses from the muscle damage
      induced by high-intensity exercise in SD rats.
LID - S1043-4666(13)00137-3 [pii]
LID - 10.1016/j.cyto.2013.03.018 [doi]
AB  - Vitamin D is an important factor for calcium and phosphorus homeostasis. A
      negative relationship has been observed between vitamin D status and diseases
      such as cancer, arthritis, diabetes, and muscle fiber atrophy. However, the
      relationship between vitamin D and prevention of skeletal muscle damage has not
      been clearly elucidated. The purpose of this study was to investigate the effects
      of vitamin D on exercise-induced muscle changes. Rats were divided into 3 groups:
      (1) sedentary control (C: n=10), (2) high-intensity exercise (HE: n=10), and (3) 
      high-intensity exercise with vitamin D supplementation (HED: n=10; i.p. 1000IU/kg
      body weight). Rats were trained for 30min/day on treadmills (5days/week for
      8weeks) with the running speed gradually increased up to 30m/min at a 3 degrees
      incline. At the end of the training period, the running speed was 38m/min at a 5 
      degrees incline. The high-intensity exercise significantly increased plasma
      creatine kinase (CK) and lactate dehydrogenase (LDH) activity. In addition, IL-6 
      and TNF-alpha levels as well as phosphorylation of AMPK, p38, ERK1/2, IKK, and
      IkappaB were significantly increased. Vitamin D-treated rats showed a significant
      decrease in plasma CK level, phosphorylation of AMPK, p38, ERK1/2, IKK, and
      IkappaB, and gene expression of IL-6 and TNF-alpha. Furthermore, the protein
      expression of vitamin D receptor (VDR) was highly increased in the muscles of
      HED-treated rats, respectively. Therefore, we concluded that vitamin D may play a
      pivotal role in exercise-induced muscle damage and inflammation through the
      modulation of MAPK and NF-kappaB involved with VDR.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Dept. of Food and Nutrition and Research Institute of Obesity Sciences, Sungshin 
      Women's University, Seoul, Republic of Korea.
FAU - Choi, Munji
AU  - Choi M
FAU - Park, Hyon
AU  - Park H
FAU - Cho, Seongsuk
AU  - Cho S
FAU - Lee, Myoungsook
AU  - Lee M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Cytokine
JT  - Cytokine
JID - 9005353
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/05/08 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/03/19 [accepted]
AID - S1043-4666(13)00137-3 [pii]
AID - 10.1016/j.cyto.2013.03.018 [doi]
PST - aheadofprint
SO  - Cytokine. 2013 May 10. pii: S1043-4666(13)00137-3. doi:
      10.1016/j.cyto.2013.03.018.

PMID- 23669195
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
DP  - 2013 May 13
TI  - Revision Surgery for Diabetic Foot Infections: Giving Another Chance to the
      Patient.
AB  - Revision surgery (RS) is frequently needed to control diabetic foot infections.
      It is the aim of this retrospective observational study to analyze the variables 
      associated with undergoing RS and the variables associated with undergoing a
      major amputation when RS was required. We conducted a retrospective study of
      patients with diabetes treated in our department during 10 years (January 1, 2000
      to January 1, 2010) who had foot infections identifying those who required RS. In
      all, 167 out of 417 patients (40%) with diabetes who underwent surgery for foot
      infections underwent RS for persistent infection. The predictive variables
      related to undergoing revision surgery were erythrocyte sedimentation rate >70
      mm/h (odds ratio [OR] = 1.6, 95% confidence interval [CI] = 1.1-2.6),
      leukocytosis (OR = 1.6, 95% CI = 1.1-2.5), peripheral arterial disease (OR = 1.5,
      95% CI = 1.0-2.4), and isolation of gram-negative rods from tissue biopsy (OR =
      2.2, 95% CI = 1.5-3.4). Seventy-nine out of 167 patients (47.3) who underwent RS 
      required a higher level of surgery achieving a limb salvage rate of 70.7%.
      Predictive variables related to undergoing a major amputation after RS were
      persistent infection located in the bone (OR = 0.08, 95% CI = 0.03-0.22),
      ischemic heart disease (OR = 3.4, 95% CI = 1.4-8.5), 2 or more reoperations (OR =
      3.0, 95% CI = 1.2-7.1), isolation of gram-negative rods from tissue biopsy (OR = 
      3.3, 95% CI = 1.3-8.4), and peripheral arterial disease (OR = 6.5, 95% CI =
      1.9-22.8). Despite the fact that 40% of patients underwent reoperations for
      diabetic foot infections and 47.3% of them required a higher level of surgery, a 
      high rate of limb salvage could be achieved.
AD  - 1Surgery, Diabetic Foot Unit, La Paloma Hospital, Las Palmas de Gran Canaria,
      Spain.
FAU - Aragon-Sanchez, Javier
AU  - Aragon-Sanchez J
FAU - Lazaro-Martinez, Jose L
AU  - Lazaro-Martinez JL
FAU - Molines-Barroso, Raul
AU  - Molines-Barroso R
FAU - Garcia Alvarez, Yolanda
AU  - Garcia Alvarez Y
FAU - Quintana-Marrero, Yurena
AU  - Quintana-Marrero Y
FAU - Hernandez-Herrero, Maria J
AU  - Hernandez-Herrero MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
OTO - NOTNLM
OT  - diabetic foot
OT  - diabetic foot infection
OT  - foot ulcer
OT  - osteomyelitis
OT  - revision surgery
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 1534734613486155 [pii]
AID - 10.1177/1534734613486155 [doi]
PST - aheadofprint
SO  - Int J Low Extrem Wounds. 2013 May 13.

PMID- 23669189
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1464-3391 (Electronic)
IS  - 0968-0896 (Linking)
VI  - 21
IP  - 13
DP  - 2013 Jul 1
TI  - Pseudoperoxidase investigations of hydroperoxides and inhibitors with human
      lipoxygenases.
PG  - 3894-9
LID - 10.1016/j.bmc.2013.04.016 [doi]
LID - S0968-0896(13)00333-7 [pii]
AB  - Understanding the mode of action for lipoxygenase (LOX) inhibitors is critical to
      determining their efficacy in the cell. The pseudoperoxidase assay is an
      important tool for establishing if a LOX inhibitor is reductive in nature,
      however, there have been difficulties identifying the proper conditions for each 
      of the many human LOX isozymes. In the current paper, both the 234nM
      decomposition (UV) and iron-xylenol orange (XO) assays are shown to be effective 
      methods of detecting pseudoperoxidase activity for 5-LOX, 12-LOX, 15-LOX-1 and
      15-LOX-2, but only if 13-(S)-HPODE is used as the hydroperoxide substrate. The AA
      products, 12-(S)-HPETE and 15-(S)-HPETE, are not consistent hydroperoxide
      substrates since they undergo a competing transformation to the di-HETE products.
      Utilizing the above conditions, the selective 12-LOX and 15-LOX-1 inhibitors,
      probes for diabetes, stroke and asthma, are characterized for their inhibitory
      nature. Interestingly, ascorbic acid also supports the pseudoperoxidase assay,
      suggesting that it may have a role in maintaining the inactive ferrous form of
      LOX in the cell. In addition, it is observed that nordihydroguaiaretic acid
      (NDGA), a known reductive LOX inhibitor, appears to generate radical species
      during the pseudoperoxidase assay, which are potent inhibitors against the human 
      LOX isozymes, producing a negative pseudoperoxidase result. Therefore, inhibitors
      that do not support the pseudoperoxidase assay with the human LOX isozymes,
      should also be investigated for rapid inactivation, to clarify the negative
      pseudoperoxidase result.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
AD  - Chemistry and Biochemistry Department, University of California, Santa Cruz, CA
      95064, USA.
FAU - Hoobler, Eric K
AU  - Hoobler EK
FAU - Holz, Charles
AU  - Holz C
FAU - Holman, Theodore R
AU  - Holman TR
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - England
TA  - Bioorg Med Chem
JT  - Bioorganic & medicinal chemistry
JID - 9413298
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/01/23 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - S0968-0896(13)00333-7 [pii]
AID - 10.1016/j.bmc.2013.04.016 [doi]
PST - ppublish
SO  - Bioorg Med Chem. 2013 Jul 1;21(13):3894-9. doi: 10.1016/j.bmc.2013.04.016. Epub
      2013 Apr 18.

PMID- 23669164
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
DP  - 2013 May 10
TI  - Predictors and pregnancy outcomes associated with a newborn birth weight of 4000 
      g or more in Lusaka, Zambia.
LID - S0020-7292(13)00183-5 [pii]
LID - 10.1016/j.ijgo.2013.03.010 [doi]
AB  - OBJECTIVE: To identify predictors and outcomes associated with a birth weight of 
      4000g or more in Lusaka, Zambia. METHODS: Data from women who delivered between
      February 2006 and August 2011 were obtained from electronic perinatal records at 
      25 public sector facilities in Lusaka. Macrosomia was defined as a birth weight
      of 4000g or more and normal birth weight as 2500-3999g. Maternal and newborn
      characteristics were analyzed for association with macrosomia. RESULTS: There
      were 4717 macrosomic and 187 117 normal birth weight newborns. The strongest
      predictors of macrosomia were high BMI (adjusted odds ratio [AOR], 2.88; 95%
      confidence interval [CI], 1.95-4.24), prior macrosomic newborn (AOR, 7.60; 95%
      CI, 6.81-8.49), and history of diabetes (AOR, 3.09; 95% CI, 1.36-6.98).
      Macrosomic newborns were at increased risk for cesarean delivery (AOR, 1.63; 95% 
      CI, 1.35-1.96), fresh stillbirth (AOR, 2.24; 95% CI, 1.56-3.21), Apgar score of
      under 7 at 5minutes (AOR, 2.03; 95% CI, 1.33-3.11), and neonatal intensive care
      admission (AOR, 2.07; 95% CI, 1.32-3.23). CONCLUSION: Screening for macrosomia
      should be considered for high-risk patients in Sub-Saharan Africa. Institutional 
      delivery at facilities with operating rooms and neonatal intensive care services 
      should be encouraged.
CI  - Copyright (c) 2013 International Federation of Gynecology and Obstetrics.
      Published by Elsevier Ireland Ltd. All rights reserved.
AD  - Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; Department of
      Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of 
      Medicine, Chapel Hill, USA. Electronic address: cherry.liu@cidrz.org.
FAU - Liu, Katherine C
AU  - Liu KC
FAU - Joseph, Jessica A
AU  - Joseph JA
FAU - Nkole, Theresa B
AU  - Nkole TB
FAU - Kaunda, Eugine
AU  - Kaunda E
FAU - Stringer, Jeffrey S A
AU  - Stringer JS
FAU - Chi, Benjamin H
AU  - Chi BH
FAU - Stringer, Elizabeth M
AU  - Stringer EM
LA  - ENG
GR  - R24 TW007988/TW/FIC NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the
      International Federation of Gynaecology and Obstetrics
JID - 0210174
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/11/12 [received]
PHST- 2013/02/15 [revised]
PHST- 2013/04/12 [accepted]
AID - S0020-7292(13)00183-5 [pii]
AID - 10.1016/j.ijgo.2013.03.010 [doi]
PST - aheadofprint
SO  - Int J Gynaecol Obstet. 2013 May 10. pii: S0020-7292(13)00183-5. doi:
      10.1016/j.ijgo.2013.03.010.

PMID- 23669130
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 0736-4679 (Electronic)
IS  - 0736-4679 (Linking)
DP  - 2013 May 10
TI  - Octreotide for the Treatment of Hypoglycemia After Insulin Glargine Overdose.
LID - S0736-4679(13)00099-1 [pii]
LID - 10.1016/j.jemermed.2012.11.099 [doi]
AB  - BACKGROUND: Intentional insulin glargine overdose is rarely reported in the
      literature, but usually results in prolonged hypoglycemia requiring intensive
      care unit admission. OBJECTIVE: We report a case of using octreotide to treat
      prolonged hypoglycemia after a large insulin glargine overdose. CASE REPORT: A
      56-year-old man with type 2 diabetes mellitus presented to the Emergency
      Department after a multidrug overdose including up to 3,300 units insulin
      glargine. He required admission to the intensive care unit for mechanical
      ventilation and blood-glucose monitoring every 30 to 60 min. He received a
      continuous dextrose infusion for > 100 h for persistent hypoglycemia. Octreotide,
      a somatostatin analogue, was given on day 4 of admission in an attempt to inhibit
      any insulin secretion from the pancreas that might be occurring in response to
      the dextrose infusion and to minimize the amount of fluid being given. After
      three doses, improvements in the patient's blood glucoses were seen, however,
      this could have coincided with complete absorption of the insulin. CONCLUSIONS:
      Prolonged hypoglycemia often occurs after large overdoses of insulin glargine due
      to a depot effect at the site of injection. Octreotide is a potential adjunctive 
      treatment to dextrose in patients with a functioning pancreas.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Pharmacy, University of Rochester Medical Center, Rochester, New
      York.
FAU - Groth, Christine M
AU  - Groth CM
FAU - Banzon, Eleanor R
AU  - Banzon ER
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Emerg Med
JT  - The Journal of emergency medicine
JID - 8412174
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/03/20 [received]
PHST- 2012/06/25 [revised]
PHST- 2012/11/05 [accepted]
AID - S0736-4679(13)00099-1 [pii]
AID - 10.1016/j.jemermed.2012.11.099 [doi]
PST - aheadofprint
SO  - J Emerg Med. 2013 May 10. pii: S0736-4679(13)00099-1. doi:
      10.1016/j.jemermed.2012.11.099.

PMID- 23669073
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1555-8584 (Electronic)
IS  - 1547-6286 (Linking)
VI  - 10
IP  - 6
DP  - 2013 Apr 30
TI  - Drosophila miR-277 controls branched-chain amino acid catabolism and affects
      lifespan.
AB  - Development, growth and adult survival are coordinated with available metabolic
      resources, ascertaining that the organism responds appropriately to environmental
      conditions. MicroRNAs are short (21-23 nt) regulatory RNAs that confer
      specificity on the RNA-induced silencing complex (RISC) to inhibit a given set of
      mRNA targets. We profiled changes in miRNA expression during adult life in
      Drosophila melanogaster and determined that miR-277 is downregulated during adult
      life. Molecular analysis revealed that this miRNA controls branched-chain amino
      acid (BCAA) catabolism and as a result it can modulate the activity of the TOR
      kinase, a central growth regulator, in cultured cells. Metabolite analysis in
      cultured cells as well as flies suggests that the mechanistic basis may be an
      accumulation of branched-chain alpha-keto-acids (BCKA), rather than BCAAs, thus
      avoiding potentially detrimental consequences of increased branched chain amino
      acid levels on e.g., translational fidelity. Constitutive miR-277 expression
      shortens lifespan and is synthetically lethal with reduced insulin signaling,
      indicating that metabolic control underlies this phenotype. Transgenic inhibition
      with a miRNA sponge construct also shortens lifespan, in particular on
      protein-rich food. Thus, optimal metabolic adaptation appears to require tuning
      of cellular BCAA catabolism by miR-277.
AD  - Gene Center and Department of Biochemistry; Ludwig-Maximilians-Universitat
      Munchen; Feodor-Lynen-Strasse 25; Munchen, Germany.
FAU - Esslinger, Stephanie Maria
AU  - Esslinger SM
FAU - Schwalb, Bjorn
AU  - Schwalb B
FAU - Helfer, Stephanie
AU  - Helfer S
FAU - Michalik, Katharina Maria
AU  - Michalik KM
FAU - Witte, Heidi
AU  - Witte H
FAU - Maier, Kerstin C
AU  - Maier KC
FAU - Martin, Dietmar
AU  - Martin D
FAU - Michalke, Bernhard
AU  - Michalke B
FAU - Tresch, Achim
AU  - Tresch A
FAU - Cramer, Patrick
AU  - Cramer P
FAU - Forstemann, Klaus
AU  - Forstemann K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - RNA Biol
JT  - RNA biology
JID - 101235328
OTO - NOTNLM
OT  - ageing
OT  - diabetes
OT  - longevity
OT  - maple syrup urine disease (MSUD)
OT  - metabolic syndrome
OT  - miRNA
OT  - miRNA target validation
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 24810 [pii]
PST - aheadofprint
SO  - RNA Biol. 2013 Apr 30;10(6).

PMID- 23669053
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1532-4036 (Electronic)
IS  - 0964-3397 (Linking)
DP  - 2013 May 10
TI  - Can factors related to mortality be used to predict the follow-up health-related 
      quality of life (HRQoL) in cardiac surgery patients?
LID - S0964-3397(13)00038-4 [pii]
LID - 10.1016/j.iccn.2013.04.003 [doi]
AB  - BACKGROUND: Optimal selection of patients and choice of treatment methods in
      cardiac surgery calls for methods to predict outcome both in terms of mortality
      and health-related quality of life (HRQoL). Our target was to evaluate whether
      indicators predicting mortality can also be used to predict follow-up HRQoL.
      METHODS: Preoperative and intensive care-related data of 571 elective cardiac
      surgery patients treated in the Helsinki University Central Hospital were used to
      predict, in a stepwise (forward) binary logistic regression, the probability of
      being dead at six months after operation. Furthermore, Tobit regression models
      were employed to predict the follow-up HRQoL of patients using also treatment
      complications and patients' experiences of pain and restlessness during treatment
      as explanatory variables. RESULTS: The EuroSCORE, renal, respiratory and
      neurological complications as well as urgent sternotomy were all statistically
      significant predictors of mortality. By contrast, follow-up HRQoL was predicted
      by the baseline HRQoL, diabetes and male gender as well as experience of pain and
      restlessness during the ICU stay. CONCLUSION: Mortality and HRQoL after cardiac
      surgery appear to be explained by different factors. Pain and restlessness during
      ICU treatment affect follow-up HRQoL in a negative manner and as potentially
      modifiable factors, need attention during treatment.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Helsinki and Uusimaa Hospital District, Helsinki, Finland. Electronic address:
      tvainiol@mappi.helsinki.fi.
FAU - Vainiola, Tarja
AU  - Vainiola T
FAU - Roine, Risto P
AU  - Roine RP
FAU - Suojaranta-Ylinen, Raili
AU  - Suojaranta-Ylinen R
FAU - Vento, Antti
AU  - Vento A
FAU - Sintonen, Harri
AU  - Sintonen H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Intensive Crit Care Nurs
JT  - Intensive & critical care nursing : the official journal of the British
      Association of Critical Care Nurses
JID - 9211274
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/05/02 [received]
PHST- 2013/04/10 [revised]
PHST- 2013/04/12 [accepted]
AID - S0964-3397(13)00038-4 [pii]
AID - 10.1016/j.iccn.2013.04.003 [doi]
PST - aheadofprint
SO  - Intensive Crit Care Nurs. 2013 May 10. pii: S0964-3397(13)00038-4. doi:
      10.1016/j.iccn.2013.04.003.

PMID- 23668976
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
DP  - 2013 May 13
TI  - Predicting End-Stage Renal Disease After Liver Transplant.
LID - 10.1111/ajt.12257 [doi]
AB  - Few equations have been developed to predict end-stage renal disease (ESRD) after
      deceased donor liver transplant. This retrospective observational cohort study
      analyzed all adult deceased donor liver transplant recipients in the Scientific
      Registry of Transplant Recipients (SRTR) database, 1995-2010. The prediction
      equation for ESRD was developed using candidate predictor variables available in 
      SRTR after implementation of the allocation policy based on the model for
      end-stage liver disease. ESRD was defined as initiation of maintenance dialysis
      therapy, kidney transplant or registration on the kidney transplant waiting list.
      We used Cox proportional hazard models to develop separate equations for
      assessing risk of ESRD by 6 months posttransplant and between 6 months and 5
      years posttransplant. Variables in the 6-month equation included recipient age,
      history of diabetes, history of dialysis before liver transplant, history of
      malignancy, body mass index, serum creatinine and liver donor risk index.
      Variables in the 6-month to 5-year equation included recipient race, history of
      diabetes, hepatitis C status, serum albumin, serum bilirubin and serum
      creatinine. The prediction equations have good calibration and discrimination (C 
      statistics 0.74-0.78). We have produced risk prediction equations that can be
      used to aid in understanding the risk of ESRD after liver transplant.
CI  - (c) Copyright 2013 The American Society of Transplantation and the American
      Society of Transplant Surgeons.
AD  - Department of Medicine, Hennepin County Medical Center, University of Minnesota, 
      Minneapolis, MN; Chronic Disease Research Group, Minneapolis Medical Research
      Foundation, Minneapolis, MN; Division of Epidemiology and Community Health,
      School of Public Health, University of Minnesota, Minneapolis, MN.
FAU - Israni, A K
AU  - Israni AK
FAU - Xiong, H
AU  - Xiong H
FAU - Liu, J
AU  - Liu J
FAU - Salkowski, N
AU  - Salkowski N
FAU - Trotter, J F
AU  - Trotter JF
FAU - Snyder, J J
AU  - Snyder JJ
FAU - Kasiske, B L
AU  - Kasiske BL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/10/31 [received]
PHST- 2013/02/25 [revised]
PHST- 2013/03/13 [accepted]
AID - 10.1111/ajt.12257 [doi]
PST - aheadofprint
SO  - Am J Transplant. 2013 May 13. doi: 10.1111/ajt.12257.

PMID- 23668834
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
DP  - 2013 May 14
TI  - Effect of an educational intervention in primary care physicians on the
      compliance of indicators of good clinical practice in the treatment of type 2
      diabetes mellitus [OBTEDIGA project].
LID - 10.1111/ijcp.12145 [doi]
AB  - AIM: To evaluate the effect of an educational intervention among primary care
      physicians on several indicators of good clinical practice in diabetes care.
      METHODS: Two groups of physicians were randomly assigned to the intervention or
      control group (IG and CG). Every physician randomly selected two samples of
      patients from all type 2 diabetic patients aged 40 years and above and diagnosed 
      more than a year ago. Baseline and final information were collected
      cross-sectionally 12 months apart, in two independent samples of 30 patients per 
      physician. The educational intervention comprised: distribution of educational
      materials and physicians' specific bench-marking information, an on-line course
      and three on-site educational workshops on diabetes. External observers collected
      information directly from the physicians and from the medical records of the
      patients on personal and family history of disease and on the evolution and
      treatment of their disease. Baseline information was collected retrospectively in
      the control group. RESULTS: Intervention group comprised 53 physicians who
      included a total of 3018 patients in the baseline and final evaluations. CG
      comprised 50 physicians who included 2868 patients in the same evaluations.
      Measurement of micro-albuminuria in the last 12 months (OR = 1.6, 95% CI:
      1.1-2.4) and foot examination in the last year (OR = 2.0, 95% CI: 1.1-3.6) were
      the indicators for which greater improvement was found in the IG. No other
      indicator considered showed statistically significant improvement between groups.
      CONCLUSIONS: The identification of indicators with very low level of compliance
      and the implementation of a simple intervention in physicians to correct them is 
      effective in improving the quality of care of diabetic patients.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Servicio de Endocrinoloxia, Complexo Hospitalario Lucus Augusti. Servicio Galego 
      de Saude, Lugo, Spain.
FAU - Vidal-Pardo, J I
AU  - Vidal-Pardo JI
FAU - Perez-Castro, T R
AU  - Perez-Castro TR
FAU - Lopez-Alvarez, X L
AU  - Lopez-Alvarez XL
FAU - Santiago-Perez, M I
AU  - Santiago-Perez MI
FAU - Garcia-Soidan, F J
AU  - Garcia-Soidan FJ
FAU - Muniz, J
AU  - Muniz J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/11/09 [received]
PHST- 2013/01/27 [accepted]
AID - 10.1111/ijcp.12145 [doi]
PST - aheadofprint
SO  - Int J Clin Pract. 2013 May 14. doi: 10.1111/ijcp.12145.

PMID- 23668815
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1470-8744 (Electronic)
IS  - 0885-4513 (Linking)
DP  - 2013 May 13
TI  - Attachment of alginate microcapsules onto plasma-treated PDMS sheet for retrieval
      after transplantation.
LID - 10.1002/bab.1124 [doi]
AB  - Although transplantation of microencapsulated islets has been proposed as a
      therapy for the treatment of diabetes mellitus, limited retrievability of the
      cells has impeded its medical usage. To achieve retrieval of microencapsulated
      islets, capsules were attached to polydimethylsiloxane(PDMS) with a biocompatible
      adhesive. Because the hydrophobic nature of the PDMS surface prevents attachment,
      surface modification is essential. Alginate microcapsules were attached to
      modified PDMS sheets, and the mechanical stability of the resulting constructs
      was determined. Acrylic acid (AA) and acrylamide (AM) mixtures were grafted on
      the surfaces of PDMS sheets using a two-step oxygen plasma treatment (TSPT).
      TSPT-PDMS was characterized according to water contact angle and zeta-potential
      measurements. The contact angle was altered by changing the ratio of AM to AA to 
      generate hydrophilic surface. Evaluation of the surface charge at pH 2, 7, and 12
      confirmed the presence of polar groups on the modified surface. Microcapsules
      were attached to TSPT-PDMS using Histoacryl(R) and shown to be in a mono-layered 
      and half-exposed state. The shear stress resistance of alginate capsules attached
      to the PDMS sheet indicates the possibility of transplantation of encapsulated
      cells without scattering in vivo. This method is applicable to retrieve
      microencapsulated porcine islets when required. This article is protected by
      copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - School of Chemical and Biological Engineering, Seoul National University, Seoul, 
      151-742, Korea.
FAU - Shin, Soojeong
AU  - Shin S
FAU - Shin, Jeong Eun
AU  - Shin JE
FAU - Yoo, Young Je
AU  - Yoo YJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Biotechnol Appl Biochem
JT  - Biotechnology and applied biochemistry
JID - 8609465
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.1002/bab.1124 [doi]
PST - aheadofprint
SO  - Biotechnol Appl Biochem. 2013 May 13. doi: 10.1002/bab.1124.

PMID- 23668772
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 13
TI  - Clinical, metabolic and psychological outcomes and treatment costs of a
      prospective randomized trial based on different educational strategies to improve
      diabetes care (PRODIACOR).
LID - 10.1111/dme.12230 [doi]
AB  - AIM: To evaluate the effect of system interventions (formalized data collection
      and 100% coverage of medications and supplies) combined with physician and/or
      patient education on therapeutic indicators and costs in Type 2 diabetes.
      METHODS: This was a randomized 2 x 2 design in public health, social security or 
      private prepaid primary care clinics in Corrientes, Argentina. Thirty-six general
      practitioners and 468 adults with Type 2 diabetes participated. Patients of nine 
      participating physicians were selected randomly and assigned to one of four
      structured group education programmes (117 patients each): control (group 1),
      physician education (group 2), patient education (group 3), and both physician
      education and patient education (group 4), with identical system interventions in
      all four groups. Outcome measures included HbA1c , BMI, blood pressure, fasting
      glucose, lipid profile, drug consumption, resource use and patient well-being at 
      baseline and every 6 months up to 42 months. RESULTS: HbA1c decreased
      significantly from 4 mmol/mol to 10 mmol/mol by 42 months (P < 0.05); the largest
      and more consistent decrease was in the groups where patients and physicians were
      educated. Blood pressure and triglycerides decreased significantly in all groups;
      the largest changes were recorded in the combined education group. The World
      Health Organization-5 Lowe score showed significant improvements, without
      differences among groups. The lowest treatment cost was seen in the combined
      education group. CONCLUSIONS: In a primary care setting, educational
      interventions combined with comprehensive care coverage resulted in long-term
      improvement in clinical, metabolic and psychological outcomes at the best
      cost-effectiveness ratio.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - CENEXA-Centro de Endocrinologia Experimental y Aplicada (UNLP-CONICET LA PLATA,
      Centro Colaborador de la OPS/OMS), Facultad de Ciencias Medicas UNLP, La Plata,
      Argentina.
FAU - Gagliardino, J J
AU  - Gagliardino JJ
FAU - Lapertosa, S
AU  - Lapertosa S
FAU - Pfirter, G
AU  - Pfirter G
FAU - Villagra, M
AU  - Villagra M
FAU - Caporale, J E
AU  - Caporale JE
FAU - Gonzalez, C D
AU  - Gonzalez CD
FAU - Elgart, J
AU  - Elgart J
FAU - Gonzalez, L
AU  - Gonzalez L
FAU - Cernadas, C
AU  - Cernadas C
FAU - Rucci, E
AU  - Rucci E
FAU - Clark, C Jr
AU  - Clark C Jr
CN  - the PRODIACOR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/07/30 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dme.12230 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 13. doi: 10.1111/dme.12230.

PMID- 23668743
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 9
IP  - 3
DP  - 2013 May
TI  - Management of the patient with diabetes and coronary artery disease: a
      contemporary review.
PG  - 387-403
LID - 10.2217/fca.13.22 [doi]
AB  - Diabetes mellitus is a metabolic disease with microvascular and macrovascular
      complications, and is well known to increase the risk of coronary
      atherosclerosis. Despite recent reductions in the prevalence of coronary artery
      disease and cardiovascular events in the USA, persons with diabetes remain up to 
      four-times as likely to die of cardiovascular disease than the general
      population. Diabetes is associated with an atherogenic lipid profile, induces a
      hypercoagulable state, and increases coronary plaque volume, progression and
      instability. Medicinal and procedural treatments in the patient with diabetes
      should be multifactorial, targeting and managing the many coexisting risk factors
      that contribute to atherosclerosis. This type of treatment is complex and should 
      be individualized, and guided by a careful review of recent literature. Here we
      discuss important clinical data and their impact on up-to-date recommendations
      for the management of coronary artery disease in the patient with Type 2 diabetes
      mellitus.
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue,
      Cleveland, OH 44195, USA.
FAU - Raymond, Timothy
AU  - Raymond T
FAU - Raymond, Russell
AU  - Raymond R
FAU - Lincoff, A Michael
AU  - Lincoff AM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.2217/fca.13.22 [doi]
PST - ppublish
SO  - Future Cardiol. 2013 May;9(3):387-403. doi: 10.2217/fca.13.22.

PMID- 23668723
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1475-2719 (Electronic)
IS  - 0029-6651 (Linking)
DP  - 2013 May 14
TI  - Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
PG  - 1-8
AB  - Non-alcoholic fatty liver disease (NAFLD) is now recognised as the hepatic
      component of metabolic syndrome (MetS). NAFLD is an example of ectopic fat
      accumulation in a visceral organ that causes organ-specific disease, and affects 
      risk of other related diseases such as type 2 diabetes and CVD. NAFLD is a
      spectrum of fat-associated liver conditions that can culminate in end stage liver
      disease, hepatocellular carcinoma and the need for liver transplantation. Simple 
      steatosis, or fatty liver, occurs early in NAFLD and may progress to
      non-alcoholic steatohepatitis, fibrosis and cirrhosis with increased risk of
      hepatocellular carcinoma. Prevalence estimates for NAFLD range from 2 to 44% in
      the general population and it has been estimated that NAFLD exists in up to 70%
      of people with type 2 diabetes. Although many obese people have NAFLD, there are 
      many obese people who do not develop ectopic liver fat. The aim of this review
      which is based on a presentation at the Royal Society of Medicine, UK in December
      2012 is to discuss development of NAFLD, ectopic fat accumulation and insulin
      resistance. The review will also describe the relationships between NAFLD, type 2
      diabetes and CVD.
AD  - Endocrinology and Metabolism, Nutrition and Metabolism, Faculty of Medicine,
      University of Southampton, and Southampton National Institute for Health Research
      Biomedical Research Centre, University Hospital of Southampton, UK.
FAU - Byrne, Christopher D
AU  - Byrne CD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Proc Nutr Soc
JT  - The Proceedings of the Nutrition Society
JID - 7505881
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - S0029665113001249 [pii]
AID - 10.1017/S0029665113001249 [doi]
PST - aheadofprint
SO  - Proc Nutr Soc. 2013 May 14:1-8.

PMID- 23668717
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 13
TI  - Early-pregnancy maternal vitamin D status and maternal hyperglycaemia.
LID - 10.1111/dme.12229 [doi]
AB  - AIMS: To estimate the association between serum 25-hydroxyvitamin D
      concentrations and maternal hyperglycaemia (post-load glucose concentration >/=
      7.5 mmol/l). METHODS: Pregnant women (n = 429; 61% black, 36% obese, 45% smokers)
      enrolled in a cohort study at <16 weeks gestation. Non-fasting blood samples were
      assayed for serum 25-hydroxyvitamin D at enrolment. At 24-28 weeks gestation,
      maternal hyperglycaemia was determined using a 50-g 1-h oral glucose challenge
      test. RESULTS: A total of 67% of women had 25-hydroxyvitamin D concentrations <
      50 nmol/l and 11% had maternal hyperglycaemia. Among smokers, each 23-nmol/l
      increase in serum 25-hydroxyvitamin D was associated with a reduction in the odds
      of maternal hyperglycaemia [odds ratio: 0.30 (95% CI: 0.13, 0.68)] after
      adjustment for parity, race/ethnicity, age, pre-pregnancy BMI, marital status,
      income, family history of diabetes, and gestational age of gestational diabetes
      mellitus screening. Among non-smokers, we found no association between early
      pregnancy vitamin D status and maternal hyperglycaemia. CONCLUSIONS: Smoking
      status may modify the relationship between poor maternal vitamin D status and
      maternal hyperglycaemia. This article is protected by copyright. All rights
      reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Epidemiology, University of Pittsburgh Graduate School of Public
      Health.
FAU - Tomedi, L E
AU  - Tomedi LE
FAU - Simhan, H N
AU  - Simhan HN
FAU - Bodnar, L M
AU  - Bodnar LM
LA  - ENG
GR  - T32 HD055162/HD/NICHD NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/12/03 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dme.12229 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 13. doi: 10.1111/dme.12229.

PMID- 23668688
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Linking)
VI  - 45
IP  - 4
DP  - 2013 Jun
TI  - Inhibition of the mTOR pathway: A possible protective role in coronary artery
      disease.
PG  - 348-56
LID - 10.3109/07853890.2013.770333 [doi]
AB  - Abstract The main approach to obesity and type-II diabetes is to unravel the
      mechanisms involved in nutrient absorption and fuel allocation. In conditions of 
      over-nutrition, cells must cope with a multitude of extracellular signals
      generated by changes in nutrient load, hormonal milieu, adverse
      cytokine/adipokine profile, and apoptosis/anti-apoptosis processes. To date
      studies have demonstrate that among all nutrients, lipids and carbohydrates play 
      a major regulatory role in the gene transcription of glycolytic and lipogenic
      enzymes, insulin, and adipokines. These nutrients mainly exert their effects
      through the gene expression of sterol responsive binding protein 1 and 2 (SREBP) 
      and the mammalian target of rapamycin (mTOR). Excess of adipose tissue is known
      to confer a significantly higher risk of coronary artery disease. Administration 
      of rapamycin effectively attenuated inflammation, inhibited progression, and
      enhanced stability of atherosclerotic plaques in animal models. Herein we discuss
      the mTOR pathway and the molecular mechanisms of mTOR inhibitors, hypothesizing a
      possible protective role in atherosclerosis, taking into account also previous
      clinical studies emphasizing their opposite role.
AD  - Department of Clinical Medicine and Surgery, Federico II University Medical
      School of Naples , Italy , and CROM (Oncology Research Centre of Mercogliano)
      "Fiorentino Lo Vuolo" , Mercogliano , Italy.
FAU - Tarantino, Giovanni
AU  - Tarantino G
FAU - Capone, Domenico
AU  - Capone D
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/05/13 [aheadofprint]
AID - 10.3109/07853890.2013.770333 [doi]
PST - ppublish
SO  - Ann Med. 2013 Jun;45(4):348-56. doi: 10.3109/07853890.2013.770333. Epub 2013 May 
      13.

PMID- 23668675
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 13
TI  - A randomized crossover study to assess the effect of an oat-rich diet on
      glycaemic control, plasma lipids and postprandial glycaemia, inflammation and
      oxidative stress in Type 2 diabetes.
LID - 10.1111/dme.12228 [doi]
AB  - AIMS: In the UK, lifestyle intervention is first-line management in Type 2
      diabetes. It is unclear what type of diet is most efficacious for improving
      glycaemic control. This study investigated the effects of an oat-enriched diet on
      glycaemic control, postprandial glycaemia, inflammation and oxidative stress
      compared with standard dietary advice. METHODS: In a randomized crossover design,
      27 volunteers with Type 2 diabetes, managed on diet and lifestyle only, were
      observed for two consecutive 8-week periods following either the oat-enriched
      diet or re-enforced standard dietary advice. Volunteers attended at baseline
      (habitual intake) and 8 and 16 weeks. Measurements included basic clinical
      measurements and fasted and postprandial (3-h) glucose and insulin in response to
      a healthy test meal. Markers of inflammation and oxidative stress, including
      high-sensitivity C-reactive protein, interleukin 6, interleukin 18, tumour
      necrosis factor-alpha, adiponectin, thiobarbituric acid reactive substances,
      oxygen radical antioxidant capacity, oxidized LDL and urinary isoprostanes, were 
      also measured at fasting and in the postprandial period. RESULTS: There were no
      diet-related effects on glycaemic control or glycaemic or insulinaemic responses 
      to the test meal. Total cholesterol (5.1 +/- 1.0 vs. 4.9 +/- 0.8, P = 0.019)
      concentrations declined following the oat-enriched diet compared with standard
      dietary advice. There was a postprandial decline in adiponectin concentration (P 
      = 0.009), but no effect of dietary intervention. None of the measures of
      oxidative stress or inflammation were altered by the oat-enriched diet compared
      with standard dietary advice. CONCLUSION: The oat-enriched diet had a modest
      impact on lipid lowering, but did not impact on oxidative stress or inflammation 
      in these volunteers with Type 2 diabetes. This article is protected by copyright.
      All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - The Rowett Institute of Nutrition and Health, University of Aberdeen; Department 
      of Diabetes, Aberdeen Royal Infirmary, Aberdeen.
FAU - McGeoch, S C
AU  - McGeoch SC
FAU - Johnstone, A M
AU  - Johnstone AM
FAU - Lobley, G E
AU  - Lobley GE
FAU - Adamson, J
AU  - Adamson J
FAU - Hickson, K
AU  - Hickson K
FAU - Holtrop, G
AU  - Holtrop G
FAU - Fyfe, C
AU  - Fyfe C
FAU - Clark, L F
AU  - Clark LF
FAU - Pearson, D W M
AU  - Pearson DW
FAU - Abraham, P
AU  - Abraham P
FAU - Megson, I L
AU  - Megson IL
FAU - Macrury, S M
AU  - Macrury SM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/11/28 [received]
PHST- 2013/03/07 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dme.12228 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 13. doi: 10.1111/dme.12228.

PMID- 23668671
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Linking)
DP  - 2013 May 14
TI  - Genetic predisposition to obesity and lifestyle factors - the combined analyses
      of twenty-six known BMI- and fourteen known waist:hip ratio (WHR)-associated
      variants in the Finnish Diabetes Prevention Study.
PG  - 1-10
AB  - Recent genome-wide association studies have identified multiple loci associated
      with BMI or the waist:hip ratio (WHR). However, evidence on gene-lifestyle
      interactions is still scarce, and investigation of the effects of well-documented
      dietary and other lifestyle data is warranted to assess whether genetic risk can 
      be modified by lifestyle. We assessed whether previously established BMI and WHR 
      genetic variants associate with obesity and weight change in the Finnish Diabetes
      Prevention Study, and whether the associations are modified by dietary factors or
      physical activity. Individuals (n 459) completed a 3 d food record and were
      genotyped for twenty-six BMI- and fourteen WHR-related variants. The effects of
      the variants individually and in combination were investigated in relation to
      obesity and to 1- and 3-year weight change by calculating genetic risk scores
      (GRS). The GRS were separately calculated for BMI and the WHR by summing the
      increasing alleles weighted by their published effect sizes. At baseline, the GRS
      were not associated with total intakes of energy, macronutrients or fibre. The
      mean 1- and 3-year weight changes were not affected by the BMI or WHR GRS. During
      the 3-year follow-up, a trend for higher BMI by the GRS was detected especially
      in those who reported a diet low in fibre (P for interaction = 0.065). Based on
      the present findings, it appears unlikely that obesity-predisposing variants
      substantially modify the effect of lifestyle modification on the success of
      weight reduction in the long term. In addition, these findings suggest that the
      association between the BMI-related genetic variants and obesity could be
      modulated by the diet.
AD  - Department of Clinical Nutrition, Institute of Public Health and Clinical
      Nutrition, University of Eastern Finland, Kuopio Campus, PO Box 1627, FI-70211
      Kuopio, Finland.
FAU - Jaaskelainen, Tiina
AU  - Jaaskelainen T
FAU - Paananen, Jussi
AU  - Paananen J
FAU - Lindstrom, Jaana
AU  - Lindstrom J
FAU - Eriksson, Johan G
AU  - Eriksson JG
FAU - Tuomilehto, Jaakko
AU  - Tuomilehto J
FAU - Uusitupa, Matti
AU  - Uusitupa M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - S0007114513001116 [pii]
AID - 10.1017/S0007114513001116 [doi]
PST - aheadofprint
SO  - Br J Nutr. 2013 May 14:1-10.

PMID- 23668634
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 14
IP  - 1
DP  - 2013 May 13
TI  - First human dose-escalation study with remogliflozin etabonate, a selective
      inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in
      subjects with type 2 diabetes mellitus.
PG  - 26
AB  - BACKGROUND: Remogliflozin etabonate (RE) is the prodrug of remogliflozin, a
      selective inhibitor of the renal sodium-dependent glucose transporter 2 (SGLT2), 
      which could increase urine glucose excretion (UGE) and lower plasma glucose in
      humans. METHODS: This double-blind, randomized, placebo-controlled, single-dose, 
      dose-escalation, crossover study is the first human trial designed to evaluate
      safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RE. All
      subjects received single oral doses of either RE or placebo separated by
      approximately 2 week intervals. In Part A, 10 healthy subjects participated in 5 
      dosing periods where they received RE (20 mg, 50 mg, 150 mg, 500 mg, or 1000 mg) 
      or placebo (4:1 active to placebo ratio per treatment period). In Part B, 6
      subjects with type 2 diabetes mellitus (T2DM) participated in 3 dose periods
      where they received RE (50 mg and 500 mg) or placebo (2:1 active to placebo per
      treatment period). The study protocol was registered with the NIH clinical trials
      data base with identifier NCT01571661. RESULTS: RE was generally well-tolerated; 
      there were no serious adverse events. In both populations, RE was rapidly
      absorbed and converted to remogliflozin (time to maximum plasma concentration
      [Cmax;Tmax] approximately 1 h). Generally, exposure to remogliflozin was
      proportional to the administered dose. RE was rapidly eliminated (mean T1/2 of
      ~25 min; mean plasma T1/2 for remogliflozin was 120 min) and was independent of
      dose. All subjects showed dose-dependent increases in 24-hour UGE, which
      plateaued at approximately 200 to 250 mmol glucose with RE doses >=150 mg. In
      T2DM subjects, increased plasma glucose following OGTT was attenuated by RE in a 
      drug-dependent fashion, but there were no clear trends in plasma insulin. There
      were no apparent effects of treatment on plasma or urine electrolytes.
      CONCLUSIONS: The results support progression of RE as a potential treatment for
      T2DM.Trial registration: ClinicalTrials.gov NCT01571661.
FAU - Kapur, Anita
AU  - Kapur A
FAU - O Connor-Semmes, Robin
AU  - O Connor-Semmes R
FAU - Hussey, Elizabeth K
AU  - Hussey EK
FAU - Dobbins, Robert L
AU  - Dobbins RL
FAU - Tao, Wenli
AU  - Tao W
FAU - Hompesch, Marcus
AU  - Hompesch M
FAU - Smith, Glenn A
AU  - Smith GA
FAU - Polli, Joseph W
AU  - Polli JW
FAU - James Jr, Charles D
AU  - James Jr CD
FAU - Mikoshiba, Imao
AU  - Mikoshiba I
FAU - Nunez, Derek J
AU  - Nunez DJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/02/17 [received]
PHST- 2013/05/13 [accepted]
PHST- 2013/05/13 [aheadofprint]
AID - 2050-6511-14-26 [pii]
AID - 10.1186/2050-6511-14-26 [doi]
PST - aheadofprint
SO  - BMC Pharmacol Toxicol. 2013 May 13;14(1):26.

PMID- 23668625
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1432-2277 (Electronic)
IS  - 0934-0874 (Linking)
VI  - 26
IP  - 7
DP  - 2013 Jul
TI  - Evaluation of domino liver transplantations in Germany.
PG  - 715-23
LID - 10.1111/tri.12110 [doi]
AB  - A retrospective multicenter study has been conducted to evaluate domino liver
      transplantations (DLTs) in Germany. The study provides insight into survival and 
      features having an impact on the assessment of neuropathy after DLT. In addition,
      a neurologic follow-up program with a scheme to estimate the likelihood of de
      novo amyloidosis is presented. A series of 61 DLTs at seven transplant centers in
      Germany was enrolled. The mean age of domino recipients at the time of
      transplantation was 58 years, 46 of them being men, and 15 being women. The
      median follow-up was 46 months. The overall 1-, 3-, and 5-year survival of domino
      recipients was 81.6%, 70.8% and 68.8%, respectively. Causes of death were
      primarily not related to familial amyloidosis. The main indication of DLT was
      hepatocellular carcinoma. Two of the reported domino recipients developed
      symptoms and signs of de novo amyloidosis within 10 years after transplantation. 
      A total of 30 domino graft recipients (49.18%) presented with diabetes post
      transplantation. In conclusion, an advanced follow-up program is crucial to
      evaluate the risk of transmitting familial amyloidosis by DLT and to establish
      more strict selection criteria for domino recipients.
CI  - (c) 2013 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
AD  - Klinik fur Transplantationsmedizin, Universitatsklinikum Munster, Munster,
      Germany.
FAU - Bolte, Fabian Johannes
AU  - Bolte FJ
FAU - Schmidt, Hartmut H-J
AU  - Schmidt HH
FAU - Becker, Thomas
AU  - Becker T
FAU - Braun, Felix
AU  - Braun F
FAU - Pascher, Andreas
AU  - Pascher A
FAU - Klempnauer, Jurgen
AU  - Klempnauer J
FAU - Schmidt, Jan
AU  - Schmidt J
FAU - Nadalin, Silvio
AU  - Nadalin S
FAU - Otto, Gerd
AU  - Otto G
FAU - Barreiros, Ana Paula
AU  - Barreiros AP
LA  - eng
PT  - Journal Article
DEP - 20130514
PL  - England
TA  - Transpl Int
JT  - Transplant international : official journal of the European Society for Organ
      Transplantation
JID - 8908516
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/12/20 [received]
PHST- 2013/02/11 [revised]
PHST- 2013/04/06 [accepted]
PHST- 2013/05/14 [aheadofprint]
AID - 10.1111/tri.12110 [doi]
PST - ppublish
SO  - Transpl Int. 2013 Jul;26(7):715-23. doi: 10.1111/tri.12110. Epub 2013 May 14.

PMID- 23668598
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 13
TI  - Treat-to-Target Trials: Uses, Interpretation, and Review of Concepts.
LID - 10.1111/dom.12129 [doi]
AB  - Treat-to-target trial designs compare investigational insulins with a standard
      insulin. Treat-to-target trials force-titrate insulin dosages to achieve a
      prespecified treatment goal. With comparable glycemic control, comparisons of
      safety endpoints such as hypoglycemia can be made to establish the risk-benefit
      profile of the new insulin. Glargine vs NPH showed comparable A1C reductions;
      however, A1C <7% without associated nocturnal hypoglycemia was reached in more
      patients on glargine and overall hypoglycemia was lower. Detemir vs glargine
      demonstrated noninferiority between the groups; however, with less weight gain
      and more injection site reactions with detemir. Detemir/aspart vs glargine/aspart
      demonstrated noninferiority between the treatments, however, with less weight
      gain in the detemir group but comparable risk of hypoglycemia. Degludec in
      combination with aspart vs glargine/aspart showed comparable A1C reductions.
      However, degludec-treated patients had less overall hypoglycemia and less
      nocturnal hypoglycemia. Because insulin titrations are guided by goal attainment 
      with each treatment, treat-to-target trials enable clinicians to determine
      differences in non-glycemic treatment effects, such as rates of hypoglycemia and 
      weight gain, at the same level of glycemic control.
CI  - This article is protected by copyright. All rights reserved.
AD  - Departments of Medicine, Biochemistry and Molecular Biology and Molecular and
      Cellular Biology, Baylor College of Medicine, Houston, Texas.
FAU - Garber, Alan J
AU  - Garber AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.1111/dom.12129 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 13. doi: 10.1111/dom.12129.

PMID- 23668584
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 381
IP  - 9871
DP  - 2013 Mar 23
TI  - UK health performance: findings of the Global Burden of Disease Study 2010.
PG  - 997-1020
LID - 10.1016/S0140-6736(13)60355-4 [doi]
LID - S0140-6736(13)60355-4 [pii]
AB  - BACKGROUND: The UK has had universal free health care and public health
      programmes for more than six decades. Several policy initiatives and structural
      reforms of the health system have been undertaken. Health expenditure has
      increased substantially since 1990, albeit from relatively low levels compared
      with other countries. We used data from the Global Burden of Diseases, Injuries, 
      and Risk Factors Study 2010 (GBD 2010) to examine the patterns of health loss in 
      the UK, the leading preventable risks that explain some of these patterns, and
      how UK outcomes compare with a set of comparable countries in the European Union 
      and elsewhere in 1990 and 2010. METHODS: We used results of GBD 2010 for 1990 and
      2010 for the UK and 18 other comparator nations (the original 15 members of the
      European Union, Australia, Canada, Norway, and the USA; henceforth EU15+). We
      present analyses of trends and relative performance for mortality, causes of
      death, years of life lost (YLLs), years lived with disability (YLDs),
      disability-adjusted life-years (DALYs), and healthy life expectancy (HALE). We
      present results for 259 diseases and injuries and for 67 risk factors or clusters
      of risk factors relevant to the UK. We assessed the UK's rank for
      age-standardised YLLs and DALYs for their leading causes compared with EU15+ in
      1990 and 2010. We estimated 95% uncertainty intervals (UIs) for all measures.
      FINDINGS: For both mortality and disability, overall health has improved
      substantially in absolute terms in the UK from 1990 to 2010. Life expectancy in
      the UK increased by 4.2 years (95% UI 4.2-4.3) from 1990 to 2010. However, the UK
      performed significantly worse than the EU15+ for age-standardised death rates,
      age-standardised YLL rates, and life expectancy in 1990, and its relative
      position had worsened by 2010. Although in most age groups, there have been
      reductions in age-specific mortality, for men aged 30-34 years, mortality rates
      have hardly changed (reduction of 3.7%, 95% UI 2.7-4.9). In terms of premature
      mortality, worsening ranks are most notable for men and women aged 20-54 years.
      For all age groups, the contributions of Alzheimer's disease (increase of 137%,
      16-277), cirrhosis (65%, ?15 to 107), and drug use disorders (577%, 71-942) to
      premature mortality rose from 1990 to 2010. In 2010, compared with EU15+, the UK 
      had significantly lower rates of age-standardised YLLs for road injury, diabetes,
      liver cancer, and chronic kidney disease, but significantly greater rates for
      ischaemic heart disease, chronic obstructive pulmonary disease, lower respiratory
      infections, breast cancer, other cardiovascular and circulatory disorders,
      oesophageal cancer, preterm birth complications, congenital anomalies, and aortic
      aneurysm. Because YLDs per person by age and sex have not changed substantially
      from 1990 to 2010 but age-specific mortality has been falling, the importance of 
      chronic disability is rising. The major causes of YLDs in 2010 were mental and
      behavioural disorders (including substance abuse; 21.5% [95 UI 17.2-26.3] of
      YLDs), and musculoskeletal disorders (30.5% [25.5-35.7]). The leading risk factor
      in the UK was tobacco (11.8% [10.5-13.3] of DALYs), followed by increased blood
      pressure (9.0 % [7.5-10.5]), and high body-mass index (8.6% [7.4-9.8]). Diet and 
      physical inactivity accounted for 14.3% (95% UI 12.8-15.9) of UK DALYs in 2010.
      INTERPRETATION: The performance of the UK in terms of premature mortality is
      persistently and significantly below the mean of EU15+ and requires additional
      concerted action. Further progress in premature mortality from several major
      causes, such as cardiovascular diseases and cancers, will probably require
      improved public health, prevention, early intervention, and treatment activities.
      The growing burden of disability, particularly from mental disorders, substance
      use, musculoskeletal disorders, and falls deserves an integrated and strategic
      response. FUNDING: Bill & Melinda Gates Foundation.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Institute for Health Metrics and Evaluation, University of Washington, Seattle,
      WA, USA. Electronic address: cjlm@uw.edu.
FAU - Murray, Christopher Jl
AU  - Murray CJ
FAU - Richards, Michael A
AU  - Richards MA
FAU - Newton, John N
AU  - Newton JN
FAU - Fenton, Kevin A
AU  - Fenton KA
FAU - Anderson, H Ross
AU  - Anderson HR
FAU - Atkinson, Charles
AU  - Atkinson C
FAU - Bennett, Derrick
AU  - Bennett D
FAU - Bernabe, Eduardo
AU  - Bernabe E
FAU - Blencowe, Hannah
AU  - Blencowe H
FAU - Bourne, Rupert
AU  - Bourne R
FAU - Braithwaite, Tasanee
AU  - Braithwaite T
FAU - Brayne, Carol
AU  - Brayne C
FAU - Bruce, Nigel G
AU  - Bruce NG
FAU - Brugha, Traolach S
AU  - Brugha TS
FAU - Burney, Peter
AU  - Burney P
FAU - Dherani, Mukesh
AU  - Dherani M
FAU - Dolk, Helen
AU  - Dolk H
FAU - Edmond, Karen
AU  - Edmond K
FAU - Ezzati, Majid
AU  - Ezzati M
FAU - Flaxman, Abraham D
AU  - Flaxman AD
FAU - Fleming, Tom D
AU  - Fleming TD
FAU - Freedman, Greg
AU  - Freedman G
FAU - Gunnell, David
AU  - Gunnell D
FAU - Hay, Roderick J
AU  - Hay RJ
FAU - Hutchings, Sally J
AU  - Hutchings SJ
FAU - Ohno, Summer Lockett
AU  - Ohno SL
FAU - Lozano, Rafael
AU  - Lozano R
FAU - Lyons, Ronan A
AU  - Lyons RA
FAU - Marcenes, Wagner
AU  - Marcenes W
FAU - Naghavi, Mohsen
AU  - Naghavi M
FAU - Newton, Charles R
AU  - Newton CR
FAU - Pearce, Neil
AU  - Pearce N
FAU - Pope, Dan
AU  - Pope D
FAU - Rushton, Lesley
AU  - Rushton L
FAU - Salomon, Joshua A
AU  - Salomon JA
FAU - Shibuya, Kenji
AU  - Shibuya K
FAU - Vos, Theo
AU  - Vos T
FAU - Wang, Haidong
AU  - Wang H
FAU - Williams, Hywel C
AU  - Williams HC
FAU - Woolf, Anthony D
AU  - Woolf AD
FAU - Lopez, Alan D
AU  - Lopez AD
FAU - Davis, Adrian
AU  - Davis A
LA  - eng
PT  - Journal Article
DEP - 20130305
PL  - England
TA  - Lancet
JT  - Lancet
JID - 2985213R
SB  - AIM
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/03/05 [aheadofprint]
AID - S0140-6736(13)60355-4 [pii]
AID - 10.1016/S0140-6736(13)60355-4 [doi]
PST - ppublish
SO  - Lancet. 2013 Mar 23;381(9871):997-1020. doi: 10.1016/S0140-6736(13)60355-4. Epub 
      2013 Mar 5.

PMID- 23668534
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 13
TI  - Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 
      diabetes: rationale and evidence.
LID - 10.1111/dom.12128 [doi]
AB  - The main pathogenesis of type 2 diabetes mellitus (T2DM) includes insulin
      resistance and pancreatic islet dysfunction. Metformin, which attenuates insulin 
      resistance, has been recommended as the first-line antidiabetic medication.
      Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral hypoglycaemic agents
      that protect glucagon-like peptide-1 (GLP-1) from degradation, maintain the
      bioactivity of endogenous GLP-1, and thus improve islet dysfunction. Results from
      clinical trials have shown that the combination therapy of DPP-4 inhibitors and
      metformin [as an add-on, an initial combination or a fixed-dose combination
      (FDC)] provides excellent efficacy and safety in patients with T2DM. Moreover,
      recent studies have suggested that metformin enhances the biological effect of
      GLP-1 by increasing GLP-1 secretion, suppressing activity of DPP-4 and
      upregulating the expression of GLP-1 receptor in pancreatic beta-cells.
      Conversely, DPP-4 inhibitors have a favourable effect on insulin sensitivity in
      patients with T2DM. Therefore, the combination of DPP-4 inhibitors and metformin 
      provides an additive or even synergistic effect on metabolic control in patients 
      with T2DM. This article provides an overview of clinical evidence and discusses
      the rationale for the combination therapy of DPP-4 inhibitors and metformin.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Endocrinology and Metabolism, Peking University Third Hospital,
      Beijing, China.
FAU - Liu, Y
AU  - Liu Y
FAU - Hong, T
AU  - Hong T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/01/11 [received]
PHST- 2013/02/25 [revised]
PHST- 2013/05/06 [accepted]
AID - 10.1111/dom.12128 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 13. doi: 10.1111/dom.12128.

PMID- 23668519
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1439-0507 (Electronic)
IS  - 0933-7407 (Linking)
DP  - 2013 May 14
TI  - Onychomycosis in close quarter living review of the literature.
LID - 10.1111/myc.12088 [doi]
AB  - Onychomycosis is defined as a fungal infection of the nail bed and/or nail plate.
      The prevalence of onychomycosis has increased dramatically as a worldwide
      condition in the twentieth century due to occlusive footwear, global wars and
      natural migration. Risk factors generally leading to onychomycosis development
      include bodily spread of dermatophyte and non-dermatophyte tinea pedis,
      peripheral vascular disease, damaged nails via sports and trauma, older age,
      genetics, immunodeficiency and diabetes. Many publications discuss prevalence,
      symptoms and treatment of the disease in individual cases, hospitals or specific 
      locations, but few strongly link the cause of onychomycosis to living
      environments. This is a review of the current literature on the prevalence of
      onychomycosis and its relationship to surrounding living environments of those
      infected. A Pubmed search was performed with 'onychomycosis'. Articles were
      selected based on the relevance to close quarter living environments. All ages
      can be affected with onychomycosis, ranging from children in boarding schools to 
      elderly in nursing homes. Although not directly linking living environments to
      transmission and infection in all articles reviewed, onychomycosis was very
      prevalent in many different close quarter living settings, including within
      families, boarding schools, military quarters and nursing homes. This review
      demonstrates that various close quarter living environments are highly associated
      with increased transmission and infection with onychomycosis.
CI  - (c) 2013 Blackwell Verlag GmbH.
AD  - New York College of Podiatric Medicine, New York, NY, USA; Mount Sinai School of 
      Medicine, New York, NY, USA.
FAU - Gazes, Michael I
AU  - Gazes MI
FAU - Zeichner, Joshua
AU  - Zeichner J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130514
TA  - Mycoses
JT  - Mycoses
JID - 8805008
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/10/15 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/17 [accepted]
AID - 10.1111/myc.12088 [doi]
PST - aheadofprint
SO  - Mycoses. 2013 May 14. doi: 10.1111/myc.12088.

PMID- 23668478
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 13
TI  - Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with
      type 2 diabetes.
LID - 10.1111/dom.12127 [doi]
AB  - AIMS: Sodium-glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the
      renal proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia 
      in type 2 diabetes by increasing renal glucose excretion. To investigate whether 
      the parallel occurring sodium loss would have diuretic-like physiologic effects, 
      we compared dapagliflozin and hydrochlorothiazide (HCTZ) effects on 24-h blood
      pressure (BP), body weight, plasma volume and glomerular filtration rate (GFR).
      METHODS: In this randomized, placebo-controlled, double-blind trial, 75 subjects 
      with type 2 diabetes were assigned placebo, dapagliflozin 10 mg/day, or HCTZ 25
      mg/day. Changes from baseline BP, body weight, plasma volume and GFR were
      assessed after 12 weeks of treatment. RESULTS: Subjects' mean age was 56 years,
      type 2 diabetes mellitus (T2DM) duration 6.3 years, and haemoglobin A1c (HbA1c)
      7.5%. Treatment with placebo, dapagliflozin or HCTZ resulted in changes from
      baseline in 24-h ambulatory mean systolic blood pressure (SBP) of -0.9 (95%CI
      -4.2, +2.4), -3.3 (95%CI -6.8, +0.2), and -6.6 (95%CI -9.9, -3.2) mmHg,
      respectively at week 12, adjusted for baseline SBP. Body weight decreased with
      dapagliflozin and HCTZ. In a sub-study plasma volume appeared to decrease with
      dapagliflozin but did not change with placebo or HCTZ treatment. Dapagliflozin
      induced a greater reduction in GFR (-10.8%; 95%CI -14.6, -6.7) relative to
      placebo (-2.9%; 95% CI -6.9, +1.2) or HCTZ (-3.4%; 95%CI -7.3, +0.6).
      CONCLUSIONS: Dapagliflozin-induced SGLT2 inhibition for 12 weeks is associated
      with reductions in 24-h BP, body weight, GFR and possibly plasma volume.
      Cumulatively, these effects suggest that dapagliflozin may have a diuretic-like
      capacity to lower BP in addition to beneficial effects on glycaemic control.
CI  - (c) 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
AD  - Department of Clinical Pharmacology, University Medical Center Groningen,
      University of Groningen, Groningen, The Netherlands.
FAU - Lambers Heerspink, H J
AU  - Lambers Heerspink HJ
FAU - de Zeeuw, D
AU  - de Zeeuw D
FAU - Wie, L
AU  - Wie L
FAU - Leslie, B
AU  - Leslie B
FAU - List, J
AU  - List J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/02/18 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/05/08 [accepted]
AID - 10.1111/dom.12127 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 13. doi: 10.1111/dom.12127.

PMID- 23668447
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1532-0650 (Electronic)
IS  - 0002-838X (Linking)
VI  - 87
IP  - 8
DP  - 2013 Apr 15
TI  - Diabetes: treating hypertension.
PG  - 574-5
AD  - University of Michigan Health System, Ann Arbor, MI, USA.
FAU - Vijan, Sandeep
AU  - Vijan S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am Fam Physician
JT  - American family physician
JID - 1272646
SB  - AIM
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - d10828 [pii]
PST - ppublish
SO  - Am Fam Physician. 2013 Apr 15;87(8):574-5.

PMID- 23668425
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 13
TI  - Are users of sulfonylureas at the time of an acute coronary syndrome at risk of
      poorer outcomes?
LID - 10.1111/dom.12126 [doi]
AB  - AIMS: Adenosine triphosphate sensitive potassium (KATP ) channel activity is
      cardioprotective during ischaemia. One of the purported mechanisms for
      sulfonylurea adverse effects is through inhibition of these channels. The purpose
      of this study is to examine whether patients using KATP channel inhibitors at the
      time of an acute coronary syndrome are at greater risk of death or heart failure 
      (HF) than those not exposed. METHODS: Using linked administrative databases we
      identified all adults who had an acute coronary syndrome between April 2002 and
      October 2006 (n = 21 023). RESULTS: Within 30 days of acute coronary syndrome,
      5.3% of our cohort died and 15.6% were diagnosed with HF. Individuals with
      diabetes exhibited significantly higher risk of death (adjusted OR: 1.20, 95% CI:
      1.03-1.40) and death or HF (aOR: 1.73, 95% CI: 1.59-1.89) than individuals
      without diabetes. However, there was no significantly increased risk of death
      (aOR: 1.00, 95% CI: 0.76-1.33) or death/HF (aOR: 1.06, 95% CI: 0.89-1.26) in
      patients exposed to KATP channel inhibitors versus patients not exposed to KATP
      channel inhibitors prior to their acute coronary syndrome. CONCLUSIONS: Diabetes 
      is associated with an increased risk of death or HF within 30 days of an acute
      coronary syndrome. However, we did not find any excess risk of death or HF
      associated with use of KATP channel inhibitors at the time of an acute coronary
      syndrome, raising doubts about the hypothesis that sulfonylureas inhibit the
      cardioprotective effects of myocardial KATP channels.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Division of Cardiac Surgery, Department of Surgery, Mazankowski Alberta Heart
      Institute, University of Alberta, Edmonton, Alberta, Canada; Cardiovascular
      Research Centre, Faculty of Medicine and Dentistry, Mazankowski Alberta Heart
      Institute, University of Alberta, Edmonton, Alberta, Canada.
FAU - Nagendran, J
AU  - Nagendran J
FAU - Oudit, G Y
AU  - Oudit GY
FAU - Bakal, J A
AU  - Bakal JA
FAU - Light, P E
AU  - Light PE
FAU - Dyck, J R B
AU  - Dyck JR
FAU - McAlister, F A
AU  - McAlister FA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/03/19 [received]
PHST- 2013/03/24 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dom.12126 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 13. doi: 10.1111/dom.12126.

PMID- 23668423
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
DP  - 2013 May 13
TI  - Intensive Weight Loss Intervention in Older Individuals: Results from the Action 
      for Health in Diabetes Type 2 Diabetes Mellitus Trial.
LID - 10.1111/jgs.12271 [doi]
AB  - OBJECTIVES: To compare the effects of 4 years of intensive lifestyle intervention
      on weight, fitness, and cardiovascular disease risk factors in older and younger 
      individuals. DESIGN: Randomized controlled clinical trial. SETTING: Sixteen U.S. 
      clinical sites. PARTICIPANTS: Individuals with type 2 diabetes mellitus: 1,053
      aged 65 to 76 and 4,092 aged 45 to 64. INTERVENTIONS: An intensive behavioral
      intervention designed to promote and maintain weight loss through caloric
      restriction and increased physical activity was compared with diabetes mellitus
      support and education. MEASUREMENTS: Standardized assessments of weight, fitness 
      (based on graded exercise testing), and cardiovascular disease risk factors.
      RESULTS: Over 4 years, older individuals had greater intervention-related mean
      weight losses (6.2%) than younger participants (5.1%; interaction P = .006) and
      comparable relative mean increases in fitness (0.56 vs 0.53 metabolic
      equivalents; interaction P = .72). These benefits were seen consistently across
      subgroups of older adults formed according to many demographic and health
      factors. Of a panel of age-related health conditions, only self-reported
      worsening vision was associated with poorer intervention-related weight loss in
      older individuals. The intensive lifestyle intervention produced mean increases
      in high-density lipoprotein cholesterol (2.03 mg/dL; P < .001) and decreases in
      glycated hemoglobin (0.21%; P < .001) and waist circumference (3.52 cm; P < .001)
      over 4 years that were at least as large in older as in younger individuals.
      CONCLUSION: Intensive lifestyle intervention targeting weight loss and increased 
      physical activity is effective in overweight and obese older individuals to
      produce sustained weight loss and improvements in fitness and cardiovascular risk
      factors.
CI  - (c) 2013, Copyright the Authors Journal compilation (c) 2013, The American
      Geriatrics Society.
AD  - Department of Biostatistical Sciences, School of Medicine, Wake Forest
      University, Winston-Salem, North Carolina.
FAU - Espeland, Mark A
AU  - Espeland MA
FAU - Rejeski, W Jack
AU  - Rejeski WJ
FAU - West, Delia S
AU  - West DS
FAU - Bray, George A
AU  - Bray GA
FAU - Clark, Jeanne M
AU  - Clark JM
FAU - Peters, Anne L
AU  - Peters AL
FAU - Chen, Haiying
AU  - Chen H
FAU - Johnson, Karen C
AU  - Johnson KC
FAU - Horton, Edward S
AU  - Horton ES
FAU - Hazuda, Helen P
AU  - Hazuda HP
CN  - for the Action for Health in Diabetes Research Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.1111/jgs.12271 [doi]
PST - aheadofprint
SO  - J Am Geriatr Soc. 2013 May 13. doi: 10.1111/jgs.12271.

PMID- 23668396
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 May 13
TI  - Diabetes And Cancer: Two Diseases With Obesity As A Common Risk Factor.
LID - 10.1111/dom.12124 [doi]
AB  - There is a growing body of evidence to support a connection between diabetes
      (predominantly type 2), obesity and cancer. Multiple meta-analyses of
      epidemiological data show that people with diabetes are at increased risk of
      developing many different types of cancers, along with an increased risk of
      cancer mortality. Several pathophysiological mechanisms for this relationship
      have been postulated, including insulin resistance and hyperinsulinaemia,
      enhanced inflammatory processes, dysregulation of sex hormone production and
      hyperglycemia. In addition to these potential mechanisms, a number of common risk
      factors, including obesity, may be behind the association between diabetes and
      cancer. Indeed, obesity is associated with an increased risk of cancer and
      diabetes. Abdominal adiposity has been shown to play a role in creating a
      systemic pro-inflammatory environment, which could result in the development of
      both diabetes and cancer. Here, we examine the relationship between diabetes,
      obesity and cancer, and investigate the potential underlying causes of increased 
      cancer risk in individuals with diabetes. Current treatment recommendations for
      reducing the overall disease burden are also explored and possible areas for
      future research are considered.
CI  - This article is protected by copyright. All rights reserved.
AD  - Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO,
      USA; Editor-in-Chief, Diabetes Technology and Therapeutics; Professor of Medicine
      and Pediatrics, University of Colorado Denver, Aurora, CO, USA.
FAU - Garg, Satish K
AU  - Garg SK
FAU - Maurer, Heather
AU  - Maurer H
FAU - Reed, Kathryne
AU  - Reed K
FAU - Selagamsetty, Rajendranath
AU  - Selagamsetty R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.1111/dom.12124 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 May 13. doi: 10.1111/dom.12124.

PMID- 23668393
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
DP  - 2013 May 13
TI  - Stroke-Associated Differences in Rates of Activity of Daily Living Loss Emerge
      Years Before Stroke Onset.
LID - 10.1111/jgs.12270 [doi]
AB  - OBJECTIVES: To compare typical age-related changes in activities of daily living 
      (ADLs) independence in stroke-free adults with long-term ADL trajectories before 
      and after stroke. DESIGN: Prospective, observational study. SETTING:
      Community-dwelling Health and Retirement Study (HRS) cohort. PARTICIPANTS: HRS
      participants who were stroke free in 1998 and were followed through 2008 (average
      follow-up 7.9 years) (N = 18,441). MEASUREMENTS: Strokes were assessed using
      self- or proxy-report of a doctor's diagnosis and month and year of event.
      Logistic regression was used to compare within-person changes in odds of
      self-reported independence in five ADLs in those who remained stroke free
      throughout follow-up (n = 16,816), those who survived a stroke (n = 1,208), and
      those who had a stroke and did not survive to participate in another interview (n
      = 417). Models were adjusted for demographic and socioeconomic covariates.
      RESULTS: Even before stroke, those who later developed stroke had significantly
      lower ADL independence and were experiencing faster independence losses than
      similar-aged individuals who remained stroke free. Of those who developed a
      stroke, survivors experienced slower pre-stroke loss of ADL independence than
      those who died. ADL independence declined at the time of stroke and decline
      continued afterwards. CONCLUSION: In adults at risk of stroke, disproportionate
      ADL limitations emerge well before stroke onset. Excess disability in stroke
      survivors should not be entirely attributed to effects of acute stroke or quality
      of acute stroke care. Although there are many possible causal pathways between
      ADL and stroke, the association may be noncausal. For example, ADL limitations
      may be a consequence of stroke risk factors (e.g., diabetes mellitus) or early
      cerebrovascular ischemia.
CI  - (c) 2013, Copyright the Authors Journal compilation (c) 2013, The American
      Geriatrics Society.
AD  - Department of Social and Behavioral Sciences, Harvard School of Public Health,
      Boston, Massachusetts; Carolina Population Center, University of North Carolina, 
      Chapel Hill, North Carolina.
FAU - Capistrant, Benjamin D
AU  - Capistrant BD
FAU - Wang, Qianyi
AU  - Wang Q
FAU - Liu, Sze Y
AU  - Liu SY
FAU - Glymour, M Maria
AU  - Glymour MM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
AID - 10.1111/jgs.12270 [doi]
PST - aheadofprint
SO  - J Am Geriatr Soc. 2013 May 13. doi: 10.1111/jgs.12270.

PMID- 23668283
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 43
IP  - 5
DP  - 2013 May
TI  - Statistical issues in the interpretation of diabetes as a risk factor for
      dementia.
PG  - 612
LID - 10.1111/imj.12028 [doi]
AD  - Department of Pharmacy Practice, National Institute of Pharmaceutical Education
      and Research, Mohali, India.
FAU - Bansal, D
AU  - Bansal D
FAU - Gudala, K
AU  - Gudala K
LA  - eng
PT  - Letter
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2012/08/29 [received]
PHST- 2012/10/16 [accepted]
AID - 10.1111/imj.12028 [doi]
PST - ppublish
SO  - Intern Med J. 2013 May;43(5):612. doi: 10.1111/imj.12028.

PMID- 23668278
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 43
IP  - 5
DP  - 2013 May
TI  - Contraception advice in women with pulmonary arterial hypertension.
PG  - 608
LID - 10.1111/imj.12120 [doi]
AD  - QLD Diabetes Centre, Mater Hospital, South Brisbane, Queensland, Australia.
FAU - Morton, A P
AU  - Morton AP
LA  - eng
PT  - Letter
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PHST- 2013/02/07 [received]
PHST- 2013/02/14 [accepted]
AID - 10.1111/imj.12120 [doi]
PST - ppublish
SO  - Intern Med J. 2013 May;43(5):608. doi: 10.1111/imj.12120.

PMID- 23668175
OWN - NLM
STAT- In-Process
DA  - 20130514
IS  - 1438-3276 (Print)
IS  - 1438-3276 (Linking)
VI  - 155
IP  - 7
DP  - 2013 Apr 18
TI  - [Antidiabetic drug therapy in overweight and obese adults with type 2 diabetes].
PG  - 43-6
AD  - Jocelyn.deHeer@med.uni-muenchen.de
FAU - de Heer, Jocelyn
AU  - de Heer J
FAU - Parhofer, Klaus
AU  - Parhofer K
LA  - ger
PT  - Journal Article
TT  - Das ist die optimale Therapie bei ubergewichtigen Typ-2-Diabetikern.
PL  - Germany
TA  - MMW Fortschr Med
JT  - MMW Fortschritte der Medizin
JID - 100893959
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/15 06:00
PST - ppublish
SO  - MMW Fortschr Med. 2013 Apr 18;155(7):43-6.

PMID- 23667888
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 155
IP  - 1
DP  - 2013 Apr
TI  - Measurement of plasma hemoglobin peroxidase activity.
PG  - 118-21
AB  - We described a spectrophotometric method for measuring hemoglobin peroxidase
      activity in human plasma using o-dianisidine (o-DA) as the substrate and
      myeloperoxidase specific inhibitor 4-aminobensoic acid hydrazide (ruling out the 
      probable contribution of myeloperoxidase to the measured parameter value). The
      optimal conditions (pH 5.5; 2 mM H2O2) have been determined, at which hemoglobin 
      makes the main contribution to plasma oxidation of o-DA. A significant positive
      correlation between hemoglobin peroxidase activity measured by the
      spectrophotometric method and hemoglobin level measured by the pyridine
      hemochromogenic method has been detected (r=0.624; p<0.01) in plasma specimens
      from 16 donors. Plasma hemoglobin peroxidase activities were measured in healthy 
      individuals and patients with type 2 diabetes mellitus and coronary heart
      disease. High plasma hemoglobin peroxidase activities in both groups of patients 
      indicates disorders in the mechanisms of clearance of hemoglobin and its highly
      reactive derivatives and can serve as specific markers of diseases associated
      with oxidative stress.
AD  - Belarusian State University, Minsk; Institute of Physicochemical Medicine,
      Federal Biomedical Agency of Russia, Moscow; A. N. Bach Institute of
      Biochemistry, Russian Academy of Sciences, Moscow; Cardiology Research and
      Practical Center, Minsk, Belarus. irinagorudko@rambler.ru.
FAU - Grigorieva, D V
AU  - Grigorieva DV
FAU - Gorudko, I V
AU  - Gorudko IV
FAU - Sokolov, A V
AU  - Sokolov AV
FAU - Kosmachevskaya, O V
AU  - Kosmachevskaya OV
FAU - Topunov, A F
AU  - Topunov AF
FAU - Buko, I V
AU  - Buko IV
FAU - Konstantinova, E E
AU  - Konstantinova EE
FAU - Cherenkevich, S N
AU  - Cherenkevich SN
FAU - Panasenko, O M
AU  - Panasenko OM
LA  - eng
LA  - rus
PT  - Journal Article
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PST - ppublish
SO  - Bull Exp Biol Med. 2013 Apr;155(1):118-21.

PMID- 23667872
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 155
IP  - 1
DP  - 2013 Apr
TI  - Cerebroprotective effects of emoxipin, reamberin, and mexidol in alloxan
      diabetes.
PG  - 56-64
AB  - The effects of original Russian preparations, derivatives of 3-hydroxypyridine
      and succinic acid (emoxipin, reamberin, mexidol), on the cellular composition of 
      the cerebrocortical and diencephalic structures were studied and correlations of 
      shifts in the cellular composition with changes in the severity of hyperglycemia 
      in rats with alloxan diabetes were analyzed. The efficiency of 3-hydroxypyridine 
      and succinic acid derivatives was evaluated in comparison with alpha-lipoic acid.
      Seven injections of the optimal doses of all the studied drugs prevented the
      neuron loss in layers I-III of the primary somatosensory cortex. In addition,
      emoxipin, reamberin, and alpha-lipoic acid prevented astrocyte loss in the
      neocortical surface layers and of neurons in the hypothalamic paraventricular
      nucleus. Reamberin limited microglial infiltration of the hippocampal field CA1. 
      Injection of alpha-lipoic acid augmented the increase in astrocyte count in the
      paraventricular nucleus and potentiated the reduction of tigroid granularity of
      CA1 field neurons. Emoxipin and mexidol caused an increase in the counts of
      neurons and oligodendrocytes in CA1 field. By contrast, reamberin and
      alpha-lipoic acid reduced the counts of neurons and oligodendrocytes,
      respectively, in this hippocampal zone. More favorable effects of emoxipin and
      mexidol vs. reamberin and alpha-lipoic acid on the cellular composition of the
      hippocampus of rats with alloxan diabetes were explained by more effective
      correction of hyperglycemia under the effect of 3-hydroxypyridine derivatives.
AD  - Department of Pharmacology, Chelyabinsk State Medical Academy, Russia.
      volcheg@yandex.ru.
FAU - Volchegorskii, I A
AU  - Volchegorskii IA
FAU - Rassokhina, L M
AU  - Rassokhina LM
FAU - Miroshnichenko, I Yu
AU  - Miroshnichenko IY
LA  - eng
LA  - rus
PT  - Journal Article
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PST - ppublish
SO  - Bull Exp Biol Med. 2013 Apr;155(1):56-64.

PMID- 23667870
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 155
IP  - 1
DP  - 2013 Apr
TI  - Autoantibodies to Neuron-Specific Proteins S100, GFAP, MBP and NGF in the Serum
      of Rats with Streptozotocin-Induced Diabetes.
PG  - 48-51
AB  - The appearance of autoantibodies to neuronal proteins (S100, GFAP, MBP, and NGF) 
      in rat serum was analyzed by ELISA on days 5, 10, 17, 25, and 32 after
      streptozotocin injection. Simultaneously, blood glucose and insulin
      autoantibodies were assayed. Serum glucose level increased on the next day after 
      streptozotocin injection and the level of autoantibodies to insulin significantly
      increased on day 5 indicating the development of diabetes. The levels of
      antibodies to specific neuronal proteins (S100, GFAP, MBP, and NGF) also
      increased at this term. It is concluded that diabetes with streptozotocin is
      associated with damage to the blood-brain barrier.
AD  - Institute of Biomedical Problems; Institute of Human Morphology, Russian Academy 
      of Medical Sciences; M.V. Lomonosov State University, Moscow, Russia.
      almostvelvet@rambler.ru.
FAU - Lotosh, N G
AU  - Lotosh NG
FAU - Savel'eva, E K
AU  - Savel'eva EK
FAU - Selishcheva, A A
AU  - Selishcheva AA
FAU - Savel'ev, S V
AU  - Savel'ev SV
LA  - eng
LA  - rus
PT  - Journal Article
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PST - ppublish
SO  - Bull Exp Biol Med. 2013 Apr;155(1):48-51.

PMID- 23667864
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1573-8221 (Electronic)
IS  - 0007-4888 (Linking)
VI  - 155
IP  - 1
DP  - 2013 Apr
TI  - Dynamics of Lipid Peroxidation-Antioxidant Defense System during Alloxan Diabetes
      in Rats.
PG  - 26-9
AB  - We studied the dynamics of lipid peroxidation-antioxidant defense system in rat
      model of alloxan diabetes and compared it with disorders of carbohydrate and
      lipid metabolism. It was found that rats not treated with insulin developed
      hyperglycemia, hypertriglyceridemia, hypocholesterolemia, and hypotocoferolemia
      with simultaneous accumulation of circulating LPO products 96 h after the
      administration of alloxan. The severity of hyperglycemia and hypertriglyceridemia
      decreased, hypercholesterolemia developed, hypotocoferolemia returned to normal, 
      and the tendency to LPO inhibition was observed in rats 10 days after alloxan
      administration against the background of previous one-week treatment with
      insulin. In 17 days after the induction of alloxan diabetes preceded by two-week 
      insulin therapy, the content of lipoperoxides reduced below the normal values
      with simultaneous progression of hypercholesterolemia, hypertriglyceridemia and
      the increase in serum fructosamine.
AD  - Department of Pharmacology, Chelyabinsk State Medical Academy, Russia.
      volcheg@yandex.ru.
FAU - Volchegorskii, I A
AU  - Volchegorskii IA
FAU - Rassokhina, L M
AU  - Rassokhina LM
FAU - Miroshnichenko, I Yu
AU  - Miroshnichenko IY
LA  - eng
LA  - rus
PT  - Journal Article
PL  - United States
TA  - Bull Exp Biol Med
JT  - Bulletin of experimental biology and medicine
JID - 0372557
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PST - ppublish
SO  - Bull Exp Biol Med. 2013 Apr;155(1):26-9.

PMID- 23667747
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130513
DCOM- 20130514
LR  - 20130517
IS  - 2093-0879 (Print)
IS  - 2093-0879 (Linking)
VI  - 19
IP  - 2
DP  - 2013 Apr
TI  - Gastrointestinal motility changes and myenteric plexus alterations in
      spontaneously diabetic biobreeding rats.
PG  - 161-70
LID - 10.5056/jnm.2013.19.2.161 [doi]
AB  - BACKGROUNDAIMS: Type 1 diabetes is often accompanied by gastrointestinal motility
      disturbances. Vagal neuropathy, hyperglycemia, and alterations in the myenteric
      plexus have been proposed as underlying mechanism. We therefore studied the
      relationship between vagal function, gastrointestinal motiliy and characteristics
      of the enteric nervous system in the biobreeding (BB) rat known as model for
      spontaneous type 1 diabetes. METHODS: Gastric emptying breath test, small
      intestinal electromyography, relative risk-interval variability, histology and
      immunohistochemistry on antral and jejunal segments were performed at 1, 8 and 16
      weeks after diabetes onset and on age-matched controls. RESULTS: We observed no
      consistent changes in relative risk-interval variability and gastric emptying
      rate. There was however, a loss of phases 3 with longer duration of diabetes on
      small intestinal electromyography. We found a progressive decrease of nitrergic
      neurons in the myenteric plexus of antrum and jejunum, while numbers of
      cholinergic nerve were not altered. In addition, a transient inflammatory
      infiltrate in jejunal wall was found in spontaneous diabetic BB rats at 8 weeks
      of diabetes. CONCLUSIONS: In diabetic BB rats, altered small intestinal motor
      control associated with a loss of myenteric nitric oxide synthase expression
      occurs, which does not depend on hyperglycemia or vagal dysfunction, and which is
      preceded by transient intestinal inflammation.
AD  - Translational Research Center for Gastrointestinal Disorders, University of
      Leuven, Leuven, Belgium.
FAU - Demedts, Ingrid
AU  - Demedts I
FAU - Masaoka, Tatsuhiro
AU  - Masaoka T
FAU - Kindt, Sebastien
AU  - Kindt S
FAU - De Hertogh, Gert
AU  - De Hertogh G
FAU - Geboes, Karel
AU  - Geboes K
FAU - Farre, Ricard
AU  - Farre R
FAU - Vanden Berghe, Pieter
AU  - Vanden Berghe P
FAU - Tack, Jan
AU  - Tack J
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - Korea (South)
TA  - J Neurogastroenterol Motil
JT  - Journal of neurogastroenterology and motility
JID - 101530189
PMC - PMC3644652
OID - NLM: PMC3644652
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Electromyography
OT  - Enteric nervous system
OT  - Gastric empyting
OT  - Rats, inbred BB
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/14 06:00
PHST- 2012/08/27 [received]
PHST- 2012/12/17 [revised]
PHST- 2013/01/02 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.5056/jnm.2013.19.2.161 [doi]
PST - ppublish
SO  - J Neurogastroenterol Motil. 2013 Apr;19(2):161-70. doi:
      10.5056/jnm.2013.19.2.161. Epub 2013 Apr 16.

PMID- 23667742
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130513
DCOM- 20130514
LR  - 20130517
IS  - 2093-0879 (Print)
IS  - 2093-0879 (Linking)
VI  - 19
IP  - 2
DP  - 2013 Apr
TI  - Impact of myenteric plexus alterations on diabetes related gastrointestinal
      dysmotility.
PG  - 121-3
LID - 10.5056/jnm.2013.19.2.121 [doi]
AD  - Department of Internal Medicine, Keimyung University School of Medicine, Daegu,
      Korea.
FAU - Park, Kyung Sik
AU  - Park KS
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - Korea (South)
TA  - J Neurogastroenterol Motil
JT  - Journal of neurogastroenterology and motility
JID - 101530189
PMC - PMC3644647
OID - NLM: PMC3644647
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/14 06:00
PHST- 2012/12/26 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/02/06 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.5056/jnm.2013.19.2.121 [doi]
PST - ppublish
SO  - J Neurogastroenterol Motil. 2013 Apr;19(2):121-3. doi: 10.5056/jnm.2013.19.2.121.
      Epub 2013 Apr 16.

PMID- 23667714
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1932-9520 (Print)
IS  - 1932-9520 (Linking)
VI  - 7
IP  - 3
DP  - 2013 Jun
TI  - Type 2 diabetes in older people; the importance of blood pressure control.
PG  - 233-237
AB  - Diabetes and hypertension often coexist and their coexistence substantially
      promote cardiovascular disease (CVD) and chronic kidney disease. Control of blood
      pressure to a level of 140/90 mm Hg in people with diabetes can prevent or at
      least delay CVD and chronic kidney disease.. In the past many society treatment
      guidelines have stressed tight blood pressure control (=< 130/80) for people with
      diabetes. But recommendations for such tight blood pressure control have not been
      supported by recent large randomized control trials, especially in in elderly.
      Here we review the recent literature regarding the benefits of blood pressure
      control in elderly patients with diabetics. We further focus on evidence for
      specific levels of blood pressure treatment goals, in this population subset..
AD  - Department of Internal Medicine, Division of Hospital Medicine, School of
      Medicine, Univeristy of Missouri, One Hospital Drive, Coulumbia, MO 65212.
FAU - Jindal, Ankur
AU  - Jindal A
FAU - Whaley-Connell, Adam
AU  - Whaley-Connell A
FAU - Sowers, James R
AU  - Sowers JR
LA  - ENG
GR  - R01 HL073101/HL/NHLBI NIH HHS/United States
GR  - R01 HL107910/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
TA  - Curr Cardiovasc Risk Rep
JT  - Current cardiovascular risk reports
JID - 101463024
PMC - PMC3647695
MID - NIHMS461207
OTO - NOTNLM
OT  - Blood pressure control
OT  - Diabetes
OT  - Diabetes complications
OT  - Hypertension
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PMCR- 2014/06/01 00:00
AID - 10.1007/s12170-013-0301-5 [doi]
PST - ppublish
SO  - Curr Cardiovasc Risk Rep. 2013 Jun;7(3):233-237.

PMID- 23667692
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Low Concentrations of Metformin Selectively Inhibit CD133(+) Cell Proliferation
      in Pancreatic Cancer and Have Anticancer Action.
PG  - e63969
LID - 10.1371/journal.pone.0063969 [doi]
AB  - Pancreatic cancer is the fourth leading cause of cancer related deaths in the
      United States. The prognosis remains dismal with little advance in treatment.
      Metformin is a drug widely used for the treatment of type II diabetes. Recent
      epidemiologic data revealed that oral administration of metformin is associated
      with a reduced risk of pancreatic cancer, suggesting its potential as a novel
      drug for this disease. Many studies have demonstrated the in vitro anticancer
      action of metformin, but the typically used concentrations were much higher than 
      the in vivo plasma and tissue concentrations achieved with recommended
      therapeutic doses of metformin, and low concentrations of metformin had little
      effect on the proliferation of pancreatic cancer cells. We examined the effect of
      low concentrations of metformin on different subpopulations of pancreatic cancer 
      cells and found that these selectively inhibited the proliferation of CD133(+)
      but not CD24(+)CD44(+)ESA(+) cells. We also examined the effect of low
      concentrations of metformin on cell invasion and in vivo tumor formation,
      demonstrating in vitro and in vivo anticancer action. Metformin was associated
      with a reduction of phospho-Erk and phospho-mTOR independent of Akt and AMPK
      phosphorylation. CD133(+) pancreatic cancer cells are considered to be cancer
      stem cells that contribute to recurrence, metastasis and resistance to adjuvant
      therapies in pancreatic cancer. Our results provide a basis for combination of
      metformin with current therapies to improve the prognosis of this disease.
AD  - Pancreatic Disease Institute, Department of General Surgery, Union Hospital,
      HUST, Wuhan, P. R. China.
FAU - Gou, Shanmiao
AU  - Gou S
FAU - Cui, Pengfei
AU  - Cui P
FAU - Li, Xiangsheng
AU  - Li X
FAU - Shi, Pengfei
AU  - Shi P
FAU - Liu, Tao
AU  - Liu T
FAU - Wang, Chunyou
AU  - Wang C
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3648476
OID - NLM: PMC3648476
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/10 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/08 [epublish]
AID - 10.1371/journal.pone.0063969 [doi]
AID - PONE-D-13-05876 [pii]
PST - epublish
SO  - PLoS One. 2013 May 8;8(5):e63969. doi: 10.1371/journal.pone.0063969. Print 2013.

PMID- 23667671
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Functional Characterization of a Novel KCNJ11 in Frame Mutation-Deletion
      Associated with Infancy-Onset Diabetes and a Mild Form of Intermediate DEND: A
      Battle between KATP Gain of Channel Activity and Loss of Channel Expression.
PG  - e63758
LID - 10.1371/journal.pone.0063758 [doi]
AB  - ATP-sensitive potassium (KATP) channels are widely distributed in various tissues
      and cell types where they couple cell metabolism to cell excitability. Gain of
      channel function (GOF) mutations in the genes encoding Kir6.2 (KCNJ11) or the
      associated regulatory ssulfonylurea receptor 1 subunit (ABCC8), cause
      developmental delay, epilepsy and neonatal diabetes (DEND) due to suppressed cell
      excitability in pancreatic beta-cells and neurons. The objective of this study
      was to determine the molecular basis of infancy-onset diabetes and a mild form of
      intermediate DEND, resulting from a novel KCNJ11 in frame mutation plus deletion.
      The naturally occurring Kir6.2 mutation plus deletion (Ser225Thr,
      Pro226_Pro232del) as well as the isolated S225T mutation or isolated del226-232
      deletion were coexpressed with SUR1 in COS cells in homozygous or heterozygous
      states. The protein expression and gating effects of the resulting channels were 
      assessed biochemically and electrophysiologically. For both the deletion and
      point mutations, simulated heterozygous expression resulted in overall increased 
      conductance in intact cells in basal conditions and rightward shifted ATP
      dose-response curves in excised patches, due to increased intrinsic open
      probability. Interestingly, homomeric channels for the combined
      deletion/mutation, or for the deletion alone, showed dramatically reduced channel
      expression at the cell membrane, which would underlie a reduced function in vivo.
      These results demonstrate that both the mis-sense mutation and the deleted region
      in the Kir6.2 subunit are important for control of the intrinsic channel gating
      and suggest that the clinical presentation could be affected by the competition
      between loss-of-function by reduced trafficking and enhanced channel gating.
AD  - Department of Cell Biology and Physiology, and Center for the Investigation of
      Membrane Excitability Diseases, Washington University School of Medicine, St.
      Louis, Missouri, United States of America.
FAU - Lin, Yu-Wen
AU  - Lin YW
FAU - Li, Anlong
AU  - Li A
FAU - Grasso, Valeria
AU  - Grasso V
FAU - Battaglia, Domenica
AU  - Battaglia D
FAU - Crino, Antonino
AU  - Crino A
FAU - Colombo, Carlo
AU  - Colombo C
FAU - Barbetti, Fabrizio
AU  - Barbetti F
FAU - Nichols, Colin G
AU  - Nichols CG
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3646792
OID - NLM: PMC3646792
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/28 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/07 [epublish]
AID - 10.1371/journal.pone.0063758 [doi]
AID - PONE-D-13-00467 [pii]
PST - epublish
SO  - PLoS One. 2013 May 7;8(5):e63758. doi: 10.1371/journal.pone.0063758. Print 2013.

PMID- 23667661
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Obesity and Staphylococcus aureus Nasal Colonization among Women and Men in a
      General Population.
PG  - e63716
LID - 10.1371/journal.pone.0063716 [doi]
AB  - BACKGROUND: Obesity and diabetes mellitus (DM) have been linked to increased risk
      of infections, and Staphylococcus aureus nasal colonization is a major risk
      factor for developing infections with the microbe. We therefore sought to find
      whether body mass index (BMI) and waist circumference (WC) could be associated
      with S. aureus colonization independent of DM. METHODOLOGY: S. aureus
      colonization was assessed by nasal swab cultures among 2,169 women and 1,709 men,
      aged 30-87 years, in the population-based Tromso Staph and Skin Study in 2007-08.
      Height (cm), weight (kg), WC (cm), and glycated haemoglobin (HbA1c,%) were
      measured. Multivariable logistic regression analyses including information on DM,
      HbA1c, hormonal contraceptive use and other potential confounders were used.
      RESULTS: In the female population, each 2.5 kg/m(2) increase in BMI was
      associated with a 7% higher odds of S. aureus nasal colonization (P = 0.01). When
      comparing obese and lean women aged 30-43 years, we observed that BMI >/=32.5
      versus <22.5 kg/m(2) and WC >/=101 versus <80 cm was associated with a 2.60 and
      2.12 times higher odds of S. aureus colonization, respectively (95% confidence
      intervals 1.35-4.98 and 1.17-3.85). Among men, high WC was also associated with
      S. aureus nasal colonization. The associations did not change significantly when 
      the analysis was restricted to participants without signs of pre-diabetes (HbA1c 
      <6.0%) among women and men, and to non-users of hormonal contraceptives among
      women. CONCLUSION: Our results support that obesity is a possible determinant for
      S. aureus nasal colonization independent of DM, in particular for premenopausal
      women. The role of obesity at different ages and by sex should be addressed in
      future prospective studies of S. aureus colonization.
AD  - Department of Microbiology and Infection Control, University Hospital of North
      Norway, Tromso, Norway ; Department of Community Medicine, Faculty of Health
      Sciences, University of Tromso, Tromso, Norway.
FAU - Olsen, Karina
AU  - Olsen K
FAU - Danielsen, Kjersti
AU  - Danielsen K
FAU - Wilsgaard, Tom
AU  - Wilsgaard T
FAU - Sangvik, Maria
AU  - Sangvik M
FAU - Sollid, Johanna U E
AU  - Sollid JU
FAU - Thune, Inger
AU  - Thune I
FAU - Eggen, Anne E
AU  - Eggen AE
FAU - Simonsen, Gunnar S
AU  - Simonsen GS
FAU - Furberg, Anne-Sofie
AU  - Furberg AS
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3646820
OID - NLM: PMC3646820
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/20 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/07 [epublish]
AID - 10.1371/journal.pone.0063716 [doi]
AID - PONE-D-12-36426 [pii]
PST - epublish
SO  - PLoS One. 2013 May 7;8(5):e63716. doi: 10.1371/journal.pone.0063716. Print 2013.

PMID- 23667629
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Acute Exercise Induces FGF21 Expression in Mice and in Healthy Humans.
PG  - e63517
LID - 10.1371/journal.pone.0063517 [doi]
AB  - Fibroblast growth factor 21 (FGF21) plays an important role in the regulation of 
      energy homeostasis during starvation and has an excellent therapeutic potential
      for the treatment of type 2 diabetes in rodents and monkeys. Acute exercise
      affects glucose and lipid metabolism by increasing glucose uptake and lipolysis. 
      However, it is not known whether acute exercise affects FGF21 expression. Here,
      we showed that serum FGF21 level is increased in mice after a single bout of
      acute exercise, and that this is accompanied by increased serum levels of free
      fatty acid, glycerol and ketone body. FGF21 gene expression was induced in the
      liver but not in skeletal muscle and white adipose tissue of mice after acute
      exercise, and further, the gene expression levels of hepatic peroxisome
      proliferator-activated receptor alpha (PPARalpha) and activating transcription
      factor 4 (ATF4) were also increased. In addition, we observed increased FGF21
      level in serum of healthy male volunteers performing a treadmill run at 50 or 80%
      VO2max. These results suggest that FGF21 may also be associated with
      exercise-induced lipolysis in addition to increased catecholamines and reduced
      insulin.
AD  - Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of
      Medicine, 50 Irwon-dong Gangnam-gu, Seoul, Korea ; Samsung Advanced Institute for
      Health Sciences and Technology, Sungkyunkwan University School of Medicine, 50
      Irwon-dong Gangnam-gu, Seoul, Korea.
FAU - Kim, Kook Hwan
AU  - Kim KH
FAU - Kim, Seong Hun
AU  - Kim SH
FAU - Min, Young-Ki
AU  - Min YK
FAU - Yang, Hun-Mo
AU  - Yang HM
FAU - Lee, Jeong-Beom
AU  - Lee JB
FAU - Lee, Myung-Shik
AU  - Lee MS
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3646740
OID - NLM: PMC3646740
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/02 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/05/07 [epublish]
AID - 10.1371/journal.pone.0063517 [doi]
AID - PONE-D-13-00822 [pii]
PST - epublish
SO  - PLoS One. 2013 May 7;8(5):e63517. doi: 10.1371/journal.pone.0063517. Print 2013.

PMID- 23667618
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Independent and supra-additive effects of alcohol consumption, cigarette smoking,
      and metabolic syndrome on the elevation of serum liver enzyme levels.
PG  - e63439
LID - 10.1371/journal.pone.0063439 [doi]
AB  - We investigated the independent and combined effects of alcohol consumption,
      cigarette smoking and metabolic syndrome on abnormal liver function, i.e., the
      elevation of serum liver enzyme levels. Participants of a Korean population-based
      prospective cohort aged >/=30 years without liver disease, diabetes, or
      cardiovascular diseases were included. Information on alcohol consumption,
      smoking status, and metabolic syndrome, defined as per the criteria of the Adult 
      Treatment Panel III, were applied to evaluate their impact on serum levels of
      aspartate aminotransferase (AST), alanine aminotransferase (ALT), and
      gamma-glutamyl transferase (GGT). Alcohol consumption, cigarette smoking and
      metabolic syndrome were the significant individual factors that elevated serum
      liver enzyme levels. Supra-additive effects of metabolic syndrome and either
      alcohol consumption or cigarette smoking were also identified. The combination of
      heavy drinking (>/=24 g/day) and metabolic syndrome conferred an effect that was 
      higher than the sum of the two individual effects (Synergic Index (SI): AST, 2.37
      [1.20-4.67]; GGT, 1.91 [1.17-3.13]). Only GGT level (odds ratio 6.04 [3.68-9.94],
      SI 2.33 [1.24-4.41]) was significantly elevated when the effect of moderate
      drinking (<24 g/day) and metabolic syndrome was combined. The combined effect of 
      any level of alcohol consumption and cigarette smoking was also supra-additive on
      the elevation of GGT level with SIs of 5.57 for drinking <24 g/day and smoking
      </=20 pack years, 5.12 for <24 g/day and >20 pack years, 1.80 for >/=24 g/day and
      </=20 pack years, 2.03 for >/=24 g/day and >20 pack years, while only the
      combined effect of drinking >/=24 g/day and smoking >20 pack years elevated the
      AST level (SI 4.55 [3.12-6.61]). The combined effect of cigarette smoking and
      metabolic syndrome was not supra-additive. To prevent fatty liver disease and
      other related diseases, a multifactorial prevention strategy that includes
      limited alcohol consumption, smoking cessation and rectification of adverse
      metabolic profiles is required.
AD  - National Cancer Control Institute, National Cancer Center, Goyang, Republic of
      Korea ; Department of Preventive Medicine, Seoul National University College of
      Medicine, Seoul, Republic of Korea.
FAU - Park, Eun Young
AU  - Park EY
FAU - Lim, Min Kyung
AU  - Lim MK
FAU - Oh, Jin-Kyoung
AU  - Oh JK
FAU - Cho, Heeyoun
AU  - Cho H
FAU - Bae, Mi Jin
AU  - Bae MJ
FAU - Yun, E Hwa
AU  - Yun EH
FAU - Kim, Dong-Il
AU  - Kim DI
FAU - Shin, Hai-Rim
AU  - Shin HR
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3646757
OID - NLM: PMC3646757
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2012/09/12 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/07 [epublish]
AID - 10.1371/journal.pone.0063439 [doi]
AID - PONE-D-12-28618 [pii]
PST - epublish
SO  - PLoS One. 2013 May 7;8(5):e63439. doi: 10.1371/journal.pone.0063439. Print 2013.

PMID- 23667557
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Screening for diabetic retinopathy and nephropathy in patients with diabetes: a
      nationwide survey in Korea.
PG  - e62991
LID - 10.1371/journal.pone.0062991 [doi]
AB  - This study was performed to identify factors associated with screening for
      diabetic retinopathy and nephropathy. Data from the Korean National Health and
      Nutrition Examination Survey between 2007 and 2009 were analyzed. Of 24,871
      participants, 1,288 patients diagnosed with diabetes at >/=30 years of age were
      included. 36.3% received screening for diabetic retinopathy, and 40.5% received
      screening for diabetic nephropathy during the previous year. Patients living in
      rural areas, those with less education, those who had not received education
      about diabetes care, and those who did not receive medical care for diabetes were
      screened less often for retinopathy or nephropathy. Patients with poorer
      self-reported health status were screened more often. Occupation, smoking status,
      and diabetes duration were associated with retinopathy screening. Lower family
      income was associated with decreased nephropathy screening. Receiving education
      about diabetes care and receiving medical care for diabetes were significant
      factors in patients with a shorter duration of diabetes (the significant odds
      ratio [OR] of not receiving education varied between 0.27 and 0.51, and that of
      not receiving medical care varied between 0.34 and 0.42). Sociodemographic
      factors and health-related factors as well as education and medical care
      influenced screening for diabetic complications among those with a longer
      duration of diabetes (for retinopathy and nephropathy, the significant OR of
      living in a rural area varied between 0.56 and 0.61; for retinopathy, the
      significant OR of current smokers was 0.55, and the p-trend of subjective health 
      status was <0.001; for nephropathy, the significant OR of a monthly household
      income of <3000 dollars was 0.61 and the p-trends of education and subjective
      health status were 0.030 and 0.007, respectively). Efforts to decrease
      sociodemographic disparities should be combined with education about diabetes
      care to increase the screening, especially for those with a longer duration of
      diabetes.
AD  - Department of Preventive Medicine, Seoul National University College of Medicine,
      Seoul, Korea.
FAU - Byun, Sang-Ho
AU  - Byun SH
FAU - Ma, Seung Hyun
AU  - Ma SH
FAU - Jun, Jae Kwan
AU  - Jun JK
FAU - Jung, Kyu-Won
AU  - Jung KW
FAU - Park, Boyoung
AU  - Park B
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3648467
OID - NLM: PMC3648467
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/10 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/05/08 [epublish]
AID - 10.1371/journal.pone.0062991 [doi]
AID - PONE-D-13-01878 [pii]
PST - epublish
SO  - PLoS One. 2013 May 8;8(5):e62991. doi: 10.1371/journal.pone.0062991. Print 2013.

PMID- 23667441
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Housework reduces all-cause and cancer mortality in chinese men.
PG  - e61529
LID - 10.1371/journal.pone.0061529 [doi]
AB  - BACKGROUND: Leisure time physical activity has been extensively studied. However,
      the health benefits of non-leisure time physical activity, particular those
      undertaken at home on all-cause and cancer mortality are limited, particularly
      among the elderly. METHODS: We studied physical activity in relation to all-cause
      and cancer mortality in a cohort of 4,000 community-dwelling elderly aged 65 and 
      older. Leisure time physical activity (sport/recreational activity and lawn
      work/yard care/gardening) and non-leisure time physical activity (housework, home
      repairs and caring for another person) were self-reported on the Physical
      Activity Scale for the Elderly. Subjects with heart diseases, stroke, cancer or
      diabetes at baseline were excluded (n = 1,133). RESULTS: Among the 2,867 subjects
      with a mean age of 72 years at baseline, 452 died from all-cause and 185 died
      from cancer during the follow-up period (2001-2012). With the adjustment for age,
      education level and lifestyle factors, we found an inverse association between
      risk of all-cause mortality and heavy housework among men, with the adjusted
      hazard ratio (HR) of 0.72 (95%CI = 0.57-0.92). Further adjustment for BMI,
      frailty index, living arrangement, and leisure time activity did not change the
      result (HR = 0.71, 95%CI = 0.56-0.91). Among women, however, heavy housework was 
      not associated with all-cause mortality. The risk of cancer mortality was
      significantly lower among men who participated in heavy housework (HR = 0.52,
      95%CI = 0.35-0.78), whereas among women the risk was not significant. Men
      participated in light housework also were at lower risk of cancer mortality than 
      were their counterparts, however, the association was not significant. Leisure
      time physical activity was not related to all-cause or cancer mortality in either
      men or women. CONCLUSION: Heavy housework is associated with reduced mortality
      and cancer deaths over a 9-year period. The underlying mechanism needs further
      study.
AD  - Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
      Hong Kong, China.
FAU - Yu, Ruby
AU  - Yu R
FAU - Leung, Jason
AU  - Leung J
FAU - Woo, Jean
AU  - Woo J
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3647044
OID - NLM: PMC3647044
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/10 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/05/07 [epublish]
AID - 10.1371/journal.pone.0061529 [doi]
AID - PONE-D-12-39367 [pii]
PST - epublish
SO  - PLoS One. 2013 May 7;8(5):e61529. doi: 10.1371/journal.pone.0061529. Print 2013.

PMID- 23667317
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130513
DCOM- 20130514
LR  - 20130517
IS  - 1178-7104 (Electronic)
IS  - 1178-7104 (Linking)
VI  - 6
DP  - 2013
TI  - Cardio-ankle vascular index (CAVI) as an indicator of arterial stiffness.
PG  - 27-38
LID - 10.2147/IBPC.S34423 [doi]
AB  - Arterial stiffness has been identified as an independent predictor of prognostic 
      outcomes for patients with cardiovascular disease. Although measurement of pulse 
      wave velocity has been a widely accepted noninvasive approach to the assessment
      of arterial stiffness, its accuracy is hampered by changes in blood pressure.
      Taking the exponential relation between intravascular pressure and arterial
      diameter into consideration, a stiffness parameter can be obtained by plotting
      the natural logarithm of systolic-diastolic pressure ratio against the arterial
      wall extensibility. Cardio-ankle vascular index (CAVI), which is calculated based
      on the stiffness parameter thus obtained, is theoretically independent of changes
      in blood pressure. With this distinct advantage, CAVI has been widely applied
      clinically to assess arterial stiffness in subjects with known cardiovascular
      diseases including those with diagnosed atherosclerosis, coronary heart disease, 
      and stroke as well as those at risk, including those with hypertension, diabetes,
      the elderly, and the obese. Because of its enhanced sensitivity, not only has the
      index been used to discern subtle changes in the disease process, it has also
      been utilized in studying normal individuals to assess their potential risks of
      developing cardiovascular diseases. The primary aims of assessing arterial
      stiffness using CAVI are not only to aid in early detection of arteriosclerosis
      to allow timely treatment and change in lifestyle, but also to quantitatively
      evaluate the progression of disease and the effectiveness of treatment. Despite
      its merit of being unaffected by blood pressure, discretion in data
      interpretation is suggested because an elevated CAVI represents not just vascular
      stiffness caused by pathological changes in the arterial wall, but can also be
      attributed to an increased vascular tone brought about by smooth muscle
      contraction. Moreover, certain patient populations, such as those with an
      ankle-brachial index < 0.9, may give falsely low CAVI and are suggested to be
      excluded from study.
AD  - Department of Emergency Medicine, Department of Medical Education, E-Da Hospital,
      I-Shou University, Kaohsiung, Taiwan.
FAU - Sun, Cheuk-Kwan
AU  - Sun CK
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - New Zealand
TA  - Integr Blood Press Control
JT  - Integrated blood pressure control
JID - 101562709
PMC - PMC3650513
OID - NLM: PMC3650513
OTO - NOTNLM
OT  - arteriosclerosis
OT  - atherosclerosis
OT  - cardio-ankle vascular index
OT  - cardiovascular disease
OT  - pulse wave velocity
OT  - stiffness parameter
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/30 [epublish]
AID - 10.2147/IBPC.S34423 [doi]
AID - ibpc-6-027 [pii]
PST - epublish
SO  - Integr Blood Press Control. 2013 Apr 30;6:27-38. doi: 10.2147/IBPC.S34423. Print 
      2013.

PMID- 23667315
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130513
DCOM- 20130514
LR  - 20130517
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 6
DP  - 2013
TI  - Treatment outcomes after initiation of exenatide twice daily or insulin in
      clinical practice: 12-month results from CHOICE in six European countries.
PG  - 171-85
LID - 10.2147/DMSO.S41827 [doi]
AB  - OBJECTIVE: The CHanges to treatment and Outcomes in patients with type 2 diabetes
      initiating InjeCtablE therapy (CHOICE) study assessed time to, and reasons for,
      significant treatment change after patients with type 2 diabetes (T2DM) initiated
      their first injectable glucose-lowering therapy (exenatide twice daily [BID] or
      insulin) in routine clinical practice, and these patients' clinical outcomes, in 
      six European countries. This paper reports interim data from the first 12 months 
      of the study. RESEARCH DESIGN AND METHODS: CHOICE (NCT00635492) is a prospective,
      noninterventional, observational study. Clinical data were collected at
      initiation of first injectable therapy and after approximately 3, 6, and 12
      months. RESULTS: Of 2497 patients enrolled in CHOICE, 1096 in the exenatide BID
      and 1239 in the insulin cohorts had >/=1 post-baseline assessment and were
      included in this analysis. Overall, 32.2% of the exenatide BID cohort and 29.1%
      of the insulin cohort (Kaplan-Meier estimates) had significant treatment change
      during the first 12 months, most commonly discontinuing injectable therapy or
      adding new T2DM therapy, respectively. Glycemic control improved in both cohorts,
      but weight loss occurred only in the exenatide BID cohort (mean change -3.3 kg). 
      Hypoglycemia occurred in 13.2% of the exenatide BID cohort and 28.6% of the
      insulin cohort (82.8% and 55.6% of these patients, respectively, received
      sulfonylureas). The post hoc endpoint of glycated hemoglobin < 7%, no weight
      gain, and no hypoglycemia was attained at 12 months by 24.3% and 10.3% of
      patients who had data at 12 months and who were receiving exenatide BID and
      insulin, respectively. CONCLUSION: About 30% of patients in CHOICE changed
      treatment in the first 12 months after initiation of first injectable therapy
      (exenatide BID or insulin). Overall, both cohorts achieved improved glycemic
      control, which was accompanied by a mean weight loss in the exenatide BID cohort.
AD  - Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm,
      Sweden;
FAU - Ostenson, Claes-Goran
AU  - Ostenson CG
FAU - Matthaei, Stephan
AU  - Matthaei S
FAU - Reaney, Matthew
AU  - Reaney M
FAU - Krarup, Thure
AU  - Krarup T
FAU - Guerci, Bruno
AU  - Guerci B
FAU - Kiljanski, Jacek
AU  - Kiljanski J
FAU - Salaun-Martin, Carole
AU  - Salaun-Martin C
FAU - Sapin, Helene
AU  - Sapin H
FAU - Bruhn, David
AU  - Bruhn D
FAU - Mathieu, Chantal
AU  - Mathieu C
FAU - Theodorakis, Michael
AU  - Theodorakis M
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3650573
OID - NLM: PMC3650573
OTO - NOTNLM
OT  - exenatide
OT  - injectable therapy
OT  - insulin
OT  - type 2 diabetes mellitus
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/14 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/25 [received]
PHST- 2013/04/26 [epublish]
AID - 10.2147/DMSO.S41827 [doi]
AID - dmso-6-171 [pii]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2013 Apr 26;6:171-85. doi: 10.2147/DMSO.S41827. Print 
      2013.

PMID- 23667218
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Lactococcus lactis cremoris infection: not rare anymore?
LID - 10.1136/bcr-2012-008479 [doi]
LID - bcr2012008479 [pii]
AB  - A middle-aged female patient with diabetes was admitted with a right neck
      abscess. Ultrasound scan revealed a necrotic abscess suspicious of malignancy and
      biopsy showed evidence of chronic inflammation. In order to isolate the primary
      source of malignancy, we performed MRI and positron emission tomography scans but
      neither had conclusive results. Subsequently, we performed an incision and
      drainage of the mass in order to alleviate pressure symptoms. The ensuing
      histological examination revealed that the mass was caused by Lactococcus lactis 
      cremoris. As such, the patient was treated with antibiotics and made a complete
      recovery. This report reinforces the scarce existing evidence that L lactis
      cremoris is a potential pathogen in adults. The case shows that atypical
      organisms should always be considered in the working diagnosis of an atypical
      neck abscess especially due to the rise in popularity of organic farming.
AD  - Department of ENT, Luton and Dunstable NHS Trust, London, UK.
FAU - Hadjisymeou, Simone
AU  - Hadjisymeou S
FAU - Loizou, Peter
AU  - Loizou P
FAU - Kothari, Prasad
AU  - Kothari P
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - bcr-2012-008479 [pii]
AID - 10.1136/bcr-2012-008479 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 9;2013. pii: bcr2012008479. doi: 10.1136/bcr-2012-008479.

PMID- 23667105
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
DP  - 2013 May 9
TI  - Secondary Prevention of Diabetic Foot Infections in a Caribbean Nation: A Call
      for Improved Patient Education.
AB  - Most countries have instituted measures to limit the complications of diabetes.
      We evaluate secondary prevention strategies for diabetic foot infections in a
      Caribbean country. We performed a prospective questionnaire study evaluating all 
      patients admitted to tertiary care hospitals across Trinidad and Tobago from July
      2011 to June 2012. Primary study end points were the number of patient-detected
      injuries and the time interval between injury and presentation. Secondary end
      points included the practice of regular foot inspection (>/=2 foot examinations
      per week) for early detection and the use of self-directed nonmedical therapies
      to treat foot infections. There were 446 patients admitted with diabetic foot
      infections at an average age of 56.9 +/- 12.4 years. Three hundred and fifty-six 
      (80%) were previously hospitalized with foot infections and 226 (51%) had already
      sustained end organ injury from diabetes. There were 163 (36.6%) patients walking
      barefoot at the time of injury and 189 (42.4%) had footwear-related injuries. In 
      257 (57.6%) cases, patients identified their foot injury shortly after the event.
      Despite early detection, they presented to hospital after a mean interval of 6.2 
      +/- 5.03 days, with 78 (30.4%) having tried some form of home therapy first.
      Overall, 190 (42.6%) patients did not practice regular foot examinations. There
      is room for improvement in secondary preventative measures for diabetic foot
      infections in this setting. Educational campaigns may be beneficial to educate
      diabetics on the dangers of walking barefoot, the importance of appropriate
      footwear, regular foot inspection, and the importance of seeking immediate
      medical attention instead of experimenting with home remedies.
AD  - 1San Fernando General Hospital, Trinidad and Tobago, West Indies.
FAU - Islam, Shariful
AU  - Islam S
FAU - Harnarayan, Patrick
AU  - Harnarayan P
FAU - Cawich, Shamir
AU  - Cawich S
FAU - Mahabir, Vijai
AU  - Mahabir V
FAU - Budhooram, Steve
AU  - Budhooram S
FAU - Bheem, Vinoo
AU  - Bheem V
FAU - Ramsewak, Shivaa
AU  - Ramsewak S
FAU - Naraynsingh, Vijay
AU  - Naraynsingh V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
OTO - NOTNLM
OT  - diabetes
OT  - epidemiology
OT  - foot infection
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 1534734613486151 [pii]
AID - 10.1177/1534734613486151 [doi]
PST - aheadofprint
SO  - Int J Low Extrem Wounds. 2013 May 9.

PMID- 23667104
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
DP  - 2013 May 9
TI  - Current Achievements With Topical Negative Pressure to Improve Wound Healing in
      Dehiscent Ischemic Stumps of Diabetic Patients: A Case Series.
AB  - Negative pressure wound therapy has been increasingly used either as a primary or
      as an adjunctive therapeutic measure to treat a variety of recalcitrant wounds
      during the past years. It is thought to act by creating a local environment that 
      promotes cell proliferation, angiogenesis, and granulation tissue formation,
      leading to accelerated wound healing to the point of spontaneous closure or
      reducing the wound size to facilitate significantly further surgical
      reconstruction. This case series presents our preliminary experience with the use
      of a Topical Negative Pressure system in the treatment of challenging ischemic
      wounds of diabetic patients. It aims to underscore its beneficial effects and
      explore its potential role in the management of ischemic amputated stumps to
      avoid ipsilateral re-amputation at a higher level.
AD  - 1Department of Vascular Surgery, University Hospital of Alexandroupolis,
      Democritus University of Thrace, Greece.
FAU - Georgakarakos, Efstratios
AU  - Georgakarakos E
FAU - Charalampidis, Dimitris
AU  - Charalampidis D
FAU - Kakagia, Despoina
AU  - Kakagia D
FAU - Georgiadis, George S
AU  - Georgiadis GS
FAU - Lazarides, Miltos K
AU  - Lazarides MK
FAU - Papanas, Nikolaos
AU  - Papanas N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
OTO - NOTNLM
OT  - diabetes
OT  - granulation
OT  - ischemia
OT  - negative pressure treatment
OT  - wound healing
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 1534734613483769 [pii]
AID - 10.1177/1534734613483769 [doi]
PST - aheadofprint
SO  - Int J Low Extrem Wounds. 2013 May 9.

PMID- 23667103
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
DP  - 2013 May 9
TI  - Hyperbaric Oxygen Therapy as Adjunctive Treatment for Diabetic Foot Ulcers.
AB  - Hyperbaric oxygen therapy (HBOT) has been suggested to improve healing of
      hard-to-heal diabetic foot ulcers. Although the wide use of HBOT as a treatment
      for diabetic foot ulcers has been founded on weak scientific ground, 2
      well-designed randomized, double-blind, placebo-controlled studies have in recent
      years put HBOT on firmer ground as treatment for diabetic patients with chronic
      foot ulcers. The recognition of inclusion criteria in these studies may help
      identify a select group of diabetic patients with hard-to-heal ulcers who might
      benefit from HBOT. In this review, we discuss the rationale behind the use of
      HBOT, its clinical application, and possible treatment complications.
AD  - 1Lund University, Lund, Sweden.
FAU - Londahl, Magnus
AU  - Londahl M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
OTO - NOTNLM
OT  - HBO
OT  - diabetes
OT  - foot ulcer
OT  - hyperbaric oxygen therapy
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 1534734613486154 [pii]
AID - 10.1177/1534734613486154 [doi]
PST - aheadofprint
SO  - Int J Low Extrem Wounds. 2013 May 9.

PMID- 23667102
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
DP  - 2013 May 9
TI  - The Performance of Serum Inflammatory Markers for the Diagnosis and Follow-up of 
      Patients With Osteomyelitis.
AB  - Serum inflammatory markers, C-reactive protein (CRP), erythrocyte sedimentation
      rate (ESR), white blood cells (WBC), and procalcitonin (PCT), have been used for 
      the diagnosis of foot infections in patients with diabetes. However, little is
      known about their changes during treatment of patients with foot infections. The 
      aim of this prospective study was to examine the performance of serum
      inflammatory markers for the diagnosis and follow-up of patients with
      osteomyelitis. A total of 61 patients (age 63.1 +/- 7.0 years, 45 men and 16
      women, 7 with type 1 and 54 with type 2 diabetes) with untreated foot infection
      (34 with soft-tissue infection and 27 with osteomyelitis) were recruited.
      Diagnosis of osteomyelitis was based on clinical examination and was confirmed by
      imaging studies (X-ray, scintigraphy, magnetic resonance imaging). Determination 
      of the inflammatory markers was performed at baseline, after 1 week, after 3
      weeks, and after 3 months of treatment. At baseline, the values of CRP, ESR, WBC,
      and PCT were significantly higher in patients with osteomyelitis than in those
      with soft-tissue infections. The sensitivity and specificity for the diagnosis of
      osteomyelitis of CRP (cutoff value >14 mg/L) were 0.85 and 0.83, of ESR (cutoff
      value >67 mm/h) 0.84 and 0.75, of WBC (cutoff value >14 x 109/L) 0.75 and 0.79,
      and of PCT (cutoff value >0.30 ng/mL) 0.81 and 0.71, respectively. All values
      declined after initiation of treatment with antibiotics; the WBC, CRP, and PCT
      values returned to near-normal levels at day 7, whereas the values of ESR
      remained high until month 3 only in patients with bone infection. From the
      inflammatory markers, ESR is recommended to be used for the follow-up of patients
      with osteomyelitis.
AD  - 1Athens University Medical School, Laiko General Hospital, Athens, Greece.
FAU - Michail, Marios
AU  - Michail M
FAU - Jude, Edward
AU  - Jude E
FAU - Liaskos, Christos
AU  - Liaskos C
FAU - Karamagiolis, Spyridon
AU  - Karamagiolis S
FAU - Makrilakis, Konstantinos
AU  - Makrilakis K
FAU - Dimitroulis, Dimitrios
AU  - Dimitroulis D
FAU - Michail, Othon
AU  - Michail O
FAU - Tentolouris, Nicholas
AU  - Tentolouris N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
OTO - NOTNLM
OT  - C-reactive protein
OT  - erythrocyte sedimentation rate
OT  - osteomyelitis
OT  - procalcitonin
OT  - serum inflammatory markers
OT  - white blood cells
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 1534734613486152 [pii]
AID - 10.1177/1534734613486152 [doi]
PST - aheadofprint
SO  - Int J Low Extrem Wounds. 2013 May 9.

PMID- 23667101
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
DP  - 2013 May 9
TI  - Managing Diabetic Foot Infection in India.
AB  - The burden of diabetic foot complications, in terms of both physical and
      socioeconomical constraints, poses a heavy challenge both to the patient and the 
      physician, especially in developing countries, where the number of people living 
      with diabetes is increasing at an alarming rate compared with the developed
      world. In developing countries like India, there are specific causes and risk
      factors that increase the burden of diabetic foot infections (DFIs), for example,
      sociocultural risk factors such as barefoot walking, using improper footwear,
      poor knowledge of foot care practices, lack of adequate and timely access to
      podiatry services, and poor health care resources. Management of DFI in light of 
      these limitations is quite a challenge to health care professionals. Several
      techniques and strategies are required to address this problem and should be
      combined with a multidisciplinary team effort to reduce the burgeoning epidemic
      of diabetic foot disease. This review is intended to address some of the major
      aspects of management of DFI in India.
AD  - 1MV Hospital for Diabetes and Prof M. Viswanathan Diabetes Research Centre (WHO
      Collaborating Centre for Research, Education and Training in Diabetes), Chennai. 
      Tamil Nadu, India.
FAU - Viswanathan, Vijay
AU  - Viswanathan V
FAU - Rao, V Narayan
AU  - Rao VN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
OTO - NOTNLM
OT  - India
OT  - diabetic foot infection
OT  - foot care education
OT  - neuropathic foot
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 1534734613486153 [pii]
AID - 10.1177/1534734613486153 [doi]
PST - aheadofprint
SO  - Int J Low Extrem Wounds. 2013 May 9.

PMID- 23667099
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1552-6941 (Electronic)
IS  - 1534-7346 (Linking)
DP  - 2013 May 9
TI  - Tissue and Swab Culture in Diabetic Foot Infections: Neuropathic Versus
      Neuroischemic Ulcers.
AB  - We evaluated the diagnostic performance of swabs versus tissue cultures in 28
      diabetic patients with neuropathic (group A) and 22 diabetic patients with
      neuroischemic foot ulcer (group B) and the differences in bacterial isolates
      between the 2 groups. In group A, sensitivity, specificity, positive predictive
      value (PPV), and negative predictive value (NPV) of swab cultures for the
      diagnosis of infection were 100%, 40%, 88.5%, and 100%, respectively. In group B,
      the corresponding values were 100%, 22.2%, 65%, and 100%. In group A,
      sensitivity, specificity, PPV, and NPV of swab cultures for the identification of
      pathogens were 100%, 14.3%, 53.8%, and 100%, respectively. In group B, the
      corresponding values were 100%, 18.2%, 55%, and 100%. In each group,
      Staphylococcus aureus and Pseudomonas aeruginosa were the most common isolates.
      The number of isolates was significantly higher on swab versus tissue cultures
      only in group A (P = .033). No differences were observed between groups in number
      of isolates and colony forming units. In conclusion, swab cultures are highly
      sensitive but less specific and have an excellent NPV both in diabetic patients
      with neuropathic and in those with neuroischemic foot ulcer. There are no
      differences between the groups in microbial load.
AD  - 1Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
FAU - Demetriou, Maria
AU  - Demetriou M
FAU - Papanas, Nikolaos
AU  - Papanas N
FAU - Panopoulou, Maria
AU  - Panopoulou M
FAU - Papatheodorou, Konstantinos
AU  - Papatheodorou K
FAU - Bounovas, Anastasios
AU  - Bounovas A
FAU - Maltezos, Efstratios
AU  - Maltezos E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Int J Low Extrem Wounds
JT  - The international journal of lower extremity wounds
JID - 101128359
OTO - NOTNLM
OT  - culture
OT  - diabetes mellitus
OT  - diabetic foot
OT  - diagnosis
OT  - infection
OT  - ischemia
OT  - neuropathy
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 1534734613481975 [pii]
AID - 10.1177/1534734613481975 [doi]
PST - aheadofprint
SO  - Int J Low Extrem Wounds. 2013 May 9.

PMID- 23667001
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1473-0480 (Electronic)
IS  - 0306-3674 (Linking)
VI  - 47
IP  - 9
DP  - 2013 Jun
TI  - Ultrasound tissue characterisation, an innovative technique for injury-prevention
      and monitoring of tendinopathy.
PG  - e2
LID - 10.1136/bjsports-2013-092459.27 [doi]
AB  - Ultrasonography (US) is used to visualise tendon structure. However, its capacity
      to detect early disintegration, to reproducibly monitor progress of pathology or 
      repair, and to objectively evaluate effect of therapies and exercise is poor.
      Furthermore, US is not able to reliably assess tissue integrity as its limits of 
      resolution means that every US image is a mixture of reflections (of relatively
      large structures like secondary tendon bundles, fasciculi) and interfering echoes
      (generated by smaller entities like fibrils and cells) that cannot be
      discriminated by the eye. Therefore, a method for computerised 'ultrasound tissue
      characterisation' (UTC) was created. A high-resolution probe is fixed in a
      tracking device and moves automatically along a tendon's long axis, collecting
      transverse images at even distances of 0.2 mm. By compounding contiguous
      transverse images, a 3-D ultrasound data-block is created that can be used for
      (A) tomographic visualisation in 3 planes of view plus a 3-D rendered view, and
      for (B) tissue characterisation and quantification of 3-D architecture of the
      tendon matrix. Dedicated UTC-Algorithms can discriminate four different
      echo-types, namely: echo-type I, generated by reflections at intact and aligned
      tendon bundles, echo-type II, generated by reflections at discontinuous or wavy
      tendon bundles, echo-type III, generated by interfering echoes from mainly
      fibrillar components, and echo-type IV, generated by mainly cellular components
      and fluid in amorphous tissue. Initially, UTC was validated by precisely matching
      UTC-processed images with corresponding tendon specimens, sampled from isolated
      flexor tendons in the horse. These four echo-types appeared to be highly
      correlated with histo-morphological characteristics, showing the discriminative
      power of UTC for tissue characterisation. Since 2005, UTC is implemented for
      human Achilles and patellar tendons and has been used in multiple research
      projects too. Some relevant observations in these studies are: Inter-and
      intra-observer reproducibility of both data-collection and analysis appeared to
      be high (ICC over 0.90), indicating an excellent reliability for longitudinal
      monitoring. Observational studies of UTC parameters related to age revealed that 
      Achilles tendons of young persons (24-30 years of age) are characterised by
      80-85% echo-type I, 10-15% echo-type II and only 2-5% type III plus IV echoes.
      Initial deterioration, mostly asymptomatic, was characterised by increasing
      percentages of echo-types II (remodelling or fibrosis) and/or III plus IV
      (fibrillar and cellular disintegration), mainly localised in the postero-medial
      quadrant of the Achilles tendon. In patients with diabetes type II and in persons
      with lateral foot-landing pattern, the Achilles tendons demonstrated
      significantly more changes on UTC compared to matched controls. Patients
      suffering tendinopathy (avg. age 45 years) have significantly higher percentages 
      of echo-types II, III and/or IV, compared with a matching group of asymptomatic
      control persons.1 Significant increases of echo-type II and III can be observed
      in normal tendons 24-48 h after maximal loads: these changes appear reversible
      within 4 days.2 On the other hand, preliminary results in a group of
      high-performance athletes indicate that athletes with persistent changes on UTC
      are at risk of developing symptoms within the same season. Ultra-structural
      effects of rehabilitation exercises can be quantitatively evaluated within 14
      days. It is concluded that UTC is utmost suitable for (a) detection of in-situ
      tendon responses to load, (b) early diagnosis of injury or degeneration, (c)
      staging of histo-pathological stage of lesions, and for (d) objective evaluation 
      of longitudinal effects of regenerative therapies.
AD  - UTC Imaging, Wassenaar, Netherlands.
FAU - van Schie, H T M
AU  - van Schie HT
FAU - Docking, S I
AU  - Docking SI
FAU - Daffy, J
AU  - Daffy J
FAU - Praet, S E
AU  - Praet SE
FAU - Rosengarten, S
AU  - Rosengarten S
FAU - Cook, J L
AU  - Cook JL
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Sports Med
JT  - British journal of sports medicine
JID - 0432520
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 47/9/e2-s [pii]
AID - 10.1136/bjsports-2013-092459.27 [doi]
PST - ppublish
SO  - Br J Sports Med. 2013 Jun;47(9):e2. doi: 10.1136/bjsports-2013-092459.27.

PMID- 23666976
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 10
TI  - Extent and determinants of thermogenic responses to 24 hours of fasting, energy
      balance, and five different overfeeding diets in humans.
AB  - Context:Individual variation in the ability to convert excess calories to heat
      and the effects of dietary macronutrient composition are
      unclear.Objective:Stability and determinants of the energy expenditure (EE)
      response to overconsumption were assessed.Design, Setting, and
      Participants:Twenty subjects (75% male) with normal glucose regulation were
      evaluated during 24 hours each of energy balance, fasting, and five different
      diets with 200% energy requirements in a clinical research
      unit.Interventions:Five 1-day overfeeding diets were given in random order: high 
      carbohydrate (75%), low protein (3%); high carbohydrate, normal protein (20%);
      high fat (46%), low protein; high fat (60%), normal protein; and balanced (50%
      carbohydrates, 20% protein).Main Outcome Measures:The 24h-EE, sleeping EE, and
      thermic effect of food (TEF) during each diet were measured with a metabolic
      chamber. Appetitive hormones were measured before and after the diets.Results:The
      EE response to overfeeding exhibited good intraindividual reproducibility.
      Similar increases above eucaloric feeding in 24h-EE (mean: 10.7+/-5.7%, p<0.001; 
      range: 2.9-18.8%) and sleeping EE (14.4+/-11.3%, p<0.001; range: 1.0-45.1%)
      occurred when overfeeding diets containing 20% protein, despite differences in
      fat and carbohydrate content, but the EE response during overfeeding diets
      containing 3% protein was attenuated. Percent body fat negatively correlated with
      TEF during normal protein overfeeding (r=-0.53, p<0.01). Fasting peptide YY
      negatively correlated with TEF (r=-0.56, p<0.01) and the increase in sleeping EE 
      (r=-0.54, p<0.01) during overfeeding.Conclusions:There is an intrinsic EE
      response to overfeeding that negatively associates with adiposity, although it
      represents a small percentage of consumed calories.
AD  - 1Phoenix Epidemiology and Clinical Research Branch, National Institute of
      Diabetes and Digestive and Kidney Diseases, National Institutes of Health,
      Phoenix, AZ, USA.
FAU - Thearle, Marie S
AU  - Thearle MS
FAU - Pannacciulli, Nicola
AU  - Pannacciulli N
FAU - Bonfiglio, Susan
AU  - Bonfiglio S
FAU - Pacak, Karel
AU  - Pacak K
FAU - Krakoff, Jonathan
AU  - Krakoff J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - jc.2013-1289 [pii]
AID - 10.1210/jc.2013-1289 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 10.

PMID- 23666972
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 10
TI  - Biliopancreatic diversion in nonobese patients with type 2 diabetes: impact and
      mechanisms.
AB  - Context.Diabetes remission is frequent after biliopancreatic diversion (BPD) in
      morbidly obese patients with type 2 diabetes (T2D). Data, mechanisms, and
      clinical indications in nonobese T2D patients are scanty.Objective.To assess
      remission and investigate insulin sensitivity and ss-cell function after BPD in
      nonobese patients with long-standing T2D.Design, setting and patients.Clinical
      research study comparing 15 T2D patients (age 55+/-1 years, duration 16+/-2
      years, BMI=28.3+/-0.6 kg/m2, HbA1c=8.6+/-1.3%) with 15 gender-, age-, and
      BMI-matched nondiabetic controls. Before surgery, and 2 months and one year
      later, a 3-hour OGTT, a 5-hour mixed meal test, and a 3-hour euglycemic clamp
      were performed.Intervention.BPD (distal gastrectomy, proximal ileum anastomosed
      to remaining stomach, biliopancreatic limb anastomosed to ileum 50 cm from the
      ileocecal valve).Results.Glycemia improved in all patients, but remission
      (HbA1c<6.5% and normal OGTT) occurred in 6/15. Insulin resistance (19.8+/-0.8
      mumol.min-1.kgffm-1, p<0.001 vs 40.9+/-5.3 of controls) resolved already at 2
      months (34.2+/-2.8) and was sustained at one year (34.7+/-1.6), although
      insulin-mediated suppression of endogenous glucose production remained impaired. 
      In contrast, ss-cell glucose sensitivity (19[12] pmol.min-1.m-2.mM-1 vs 96[73] of
      controls, p<0.0001) rose (p=0.02) only to 31[26] at one year, and was lower in
      non-remitters (16[18]) than remitters (46[33]).Conclusions.In nonobese patients
      with long-standing T2D, BPD improves metabolic control but induces remission in
      only approximately 40% of patients. Peripheral insulin sensitivity is restored
      early after surgery, and similarly in remitters and non-remitters, indicating a
      weight-independent effect of the operation. The initial extent of ss-cell
      incompetence is the main predictor of the metabolic outcome.
AD  - 1Department of Medicine, University of Pisa School of Medicine, Pisa, Italy.
FAU - Astiarraga, Brenno
AU  - Astiarraga B
FAU - Gastaldelli, Amalia
AU  - Gastaldelli A
FAU - Muscelli, Elza
AU  - Muscelli E
FAU - Baldi, Simona
AU  - Baldi S
FAU - Camastra, Stefania
AU  - Camastra S
FAU - Mari, Andrea
AU  - Mari A
FAU - Papadia, Francesco
AU  - Papadia F
FAU - Camerini, Giovanni
AU  - Camerini G
FAU - Adami, Gianfranco
AU  - Adami G
FAU - Scopinaro, Nicola
AU  - Scopinaro N
FAU - Ferrannini, Ele
AU  - Ferrannini E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - jc.2013-1476 [pii]
AID - 10.1210/jc.2013-1476 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 10.

PMID- 23666893
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 12
TI  - Corneal Confocal Microscopy: A New Technique for Early Detection of Diabetic
      Neuropathy.
AB  - Corneal confocal microscopy (CCM) is a noninvasive method for the study of human 
      cornea in vivo. It has increasingly been used to assess the morphology of the
      sub-basal corneal nerve plexus. CCM has good reproducibility and may contribute
      to the early diagnosis of diabetic polyneuropathy. It may also be useful to
      document favorable changes in nerve fiber structure early after therapeutic
      intervention. Corneal nerve pathology is more pronounced in patients with
      diabetic polyneuropathy and is associated with its clinical severity. The
      sensitivity and specificity of CCM for the diagnosis of polyneuropathy is
      moderate to high. CCM now merits further use in large longitudinal studies to
      provide more information on the natural history of diabetic neuropathy and
      effects of treatment. Moreover, there is a need for a larger normative database. 
      Finally, technical progress is expected to enable visualization of larger corneal
      areas and improve nerve fiber quantification, increasing diagnostic accuracy.
AD  - Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine 
      University, Auf'm Hennekamp 65, 40225, Dusseldorf, Germany.
FAU - Papanas, N
AU  - Papanas N
FAU - Ziegler, D
AU  - Ziegler D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1007/s11892-013-0390-z [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 12.

PMID- 23666892
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 12
TI  - Emerging Roles for miRNAs in the Development, Diagnosis, and Treatment of
      Diabetic Nephropathy.
AB  - Although the causes of diabetic nephropathy are not yet fully known, emerging
      evidence suggests a role for epigenetic factors in the development of the
      disease. In particular, microRNAs (miRNAs) are becoming recognized as important
      mediators of biological processes relevant to diabetic nephropathy. Until
      recently, investigations of miRNAs in the development of diabetic nephropathy
      have remained relatively limited; however, the number of reports identifying
      potential new candidates and mechanisms of impact is presently expanding at a
      rapid pace. This review seeks to summarize these recent findings, focusing on new
      candidates and/or novel mechanisms, including the intersection between genetic
      variation and miRNA function in modulating disease expression, emerging in the
      field. We also review the latest advances in the diagnostic and therapeutic
      potential of miRNAs in the treatment of diabetic nephropathy.
AD  - Diabetes, Cardiovascular and Metabolic Diseases Division, Translational Genomics 
      Research Institute, 445 North Fifth Street, Phoenix, AZ, 85004, USA,
      jdistefano@tgen.org.
FAU - Distefano, Johanna K
AU  - Distefano JK
FAU - Taila, Matthew
AU  - Taila M
FAU - Alvarez, M Lucrecia
AU  - Alvarez ML
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1007/s11892-013-0386-8 [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 12.

PMID- 23666769
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2013 May 11
TI  - Effects of alkali supplementation and vitamin D insufficiency on rat skeletal
      muscle.
AB  - Data on the independent and potential combined effects of acid-base balance and
      vitamin D status on muscle mass and metabolism are lacking. We investigated
      whether alkali supplementation with potassium bicarbonate (KHCO3), with or
      without vitamin D3 (+/-VD3), alters urinary nitrogen (indicator of muscle
      proteolysis), muscle fiber cross-sectional area (FCSA), fiber number (FN), and
      anabolic (IGF-1, Akt, p70s6k) and catabolic (FOXO3a, MURF1, MAFbx) signaling
      pathways regulating muscle mass. Thirty-six, 20-month-old, Fischer
      344/Brown-Norway rats were randomly assigned in a 2 x 2 factorial design to one
      of two KHCO3-supplemented diets (+/-VD3) or diets without KHCO3 (+/-VD3) for 12
      weeks. Soleus, extensor digitorum longus (EDL), and plantaris muscles were
      harvested at 12 weeks. Independent of VD3 group, KHCO3 supplementation resulted
      in 35 % lower mean urinary nitrogen to creatinine ratio, 10 % higher mean type I 
      FCSA (adjusted to muscle weight), but no statistically different mean type II
      FCSA (adjusted to muscle weight) or FN compared to no KHCO3. Among VD3-replete
      rats, phosphorylated-Akt protein expression was twofold higher in the KHCO3
      compared to no KHCO3 groups, but this effect was blunted in rats on VD3-deficient
      diets. Neither intervention significantly affected serum or intramuscular IGF-1
      expression, p70s6k or FOXO3a activation, or MURF1 and MAFbx gene expression.
      These findings provide support for alkali supplementation as a promising
      intervention to promote preservation of skeletal muscle mass, particularly in the
      setting of higher vitamin D status. Additional research is needed in defining the
      muscle biological pathways that are being targeted by alkali and vitamin D
      supplementation.
AD  - Division of Endocrinology, Diabetes, and Metabolism, Tufts Medical Center, Box
      268, 800 Washington Street, Boston, MA, 02111, USA, lisa.ceglia@tufts.edu.
FAU - Ceglia, Lisa
AU  - Ceglia L
FAU - Rivas, Donato A
AU  - Rivas DA
FAU - Pojednic, Rachele M
AU  - Pojednic RM
FAU - Price, Lori Lyn
AU  - Price LL
FAU - Harris, Susan S
AU  - Harris SS
FAU - Smith, Donald
AU  - Smith D
FAU - Fielding, Roger A
AU  - Fielding RA
FAU - Dawson-Hughes, Bess
AU  - Dawson-Hughes B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130511
TA  - Endocrine
JT  - Endocrine
JID - 9434444
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/03/14 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/05/11 [aheadofprint]
AID - 10.1007/s12020-013-9976-0 [doi]
PST - aheadofprint
SO  - Endocrine. 2013 May 11.

PMID- 23666677
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1522-1539 (Electronic)
IS  - 0363-6135 (Linking)
DP  - 2013 May 10
TI  - Apolipoprotein A-1 Mimetic D-4F Enhances Isoflurane-Induced eNOS Signaling and
      Cardioprotection During Acute Hyperglycemia.
AB  - Acute hyperglycemia (AHG) decreases the availability of nitric oxide (NO), and
      impairs anesthetic preconditioning (APC)-elicited protection against myocardial
      infarction. We investigated whether D-4F, an apolipoprotein A-1 mimetic, rescues 
      myocardium by promoting APC-induced endothelial NO signaling during AHG.
      Myocardial infarct size was measured in mice in the absence or presence of APC
      (isoflurane 1.4%), with or without AHG (dextrose 2 g/kg intraperitoneal) and D-4F
      (0.12 or 0.6 mg/kg intraperitoneal). NO production, superoxide generation,
      protein compartmentalization, and post-translational eNOS modifications were
      assessed in human coronary artery endothelial cells cultured in 5.5 or 20 mM
      glucose with or without isoflurane (0.5 mM) in the presence or absence of D-4F
      (0.5 microg/ml). Myocardial infarct size was significantly decreased by APC
      (36+/-3% of risk area) compared to control (54+/-3%) in the absence, but not
      presence, of AHG (49+/-4%). D-4F restored the cardioprotective effect of APC
      during AHG (36+/-3% and 30+/-3%; 0.12 and 0.6 mg/kg, respectively), although D-4F
      alone had no effect on infarct size (53+/-3%). Isoflurane promoted Cav-1 and eNOS
      compartmentalization within endothelial cell caveolae and eNOS dimerization,
      concomitant with increased NO production (411+/-28 pmol/mg protein versus control
      68+/-10 pmol/mg protein). These actions were attenuated by AHG (NO production
      264+/-18 pmol/mg protein). D-4F reduced superoxide generation and enhanced Cav-1 
      and eNOS caveolar compartmentalization and post-translational eNOS modifications,
      thus restoring NO production during isoflurane and AHG (418+/-36 pmol/mg
      protein). In conclusion, D-4F restored the cardioprotective effect of APC during 
      AHG, possibly by decreasing superoxide generation that promoted
      isoflurane-induced eNOS signaling and NO biosynthesis.
AD  - 1Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic
      Diseases, Zagreb, Croatia.
FAU - Baotic, Ines
AU  - Baotic I
FAU - Ge, Zhi-Dong
AU  - Ge ZD
FAU - Sedlic, Filip
AU  - Sedlic F
FAU - Coon, Adrian
AU  - Coon A
FAU - Weihrauch, Dorothee
AU  - Weihrauch D
FAU - Warltier, David C
AU  - Warltier DC
FAU - Kersten, Judy R
AU  - Kersten JR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
OTO - NOTNLM
OT  - Anesthetic preconditioning
OT  - Cardioprotection
OT  - D-4F
OT  - Hyperglycemia
OT  - Nitric oxide
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - ajpheart.00850.2012 [pii]
AID - 10.1152/ajpheart.00850.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Heart Circ Physiol. 2013 May 10.

PMID- 23666642
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1559-0291 (Electronic)
IS  - 0273-2289 (Linking)
DP  - 2013 May 12
TI  - Antioxidant, Anti-inflammatory, and Hypoglycemic Effects of the Leaf Extract from
      Passiflora nitida Kunth.
AB  - Diabetes mellitus is a metabolic disease characterized by abnormally high plasma 
      glucose levels, leading to major complications, such as insulin resistance,
      obesity, hyperlipidemia, and hypertension, also with alterations in the immune
      and neuronal systems. Brazilian plants have been studied as important sources for
      new molecules with medicinal properties. The genus Passiflora known as "Maracuja"
      has been used as a traditional folk medicine for a long time, so an investigation
      was performed regarding an endemic kind of passion fruit (Passiflora nitida
      Kunth) from Amazonas, Brazil. Here, we aimed to determine its potential
      biological activity against metabolic syndrome, oxidative stress, pain, and
      inflammation. The hydroethanol leaf extract revealed an in vitro
      alpha-glucosidase inhibitory activity of 50 % inhibitory concentration (IC50) =
      6.78 +/- 0.31 mug/mL and an alpha-amylase inhibition of IC50 = 93.36 +/- 4.37. In
      vivo, experiments of different saccharide tolerance resulted in significant
      glycemia control and, with alloxan-diabetic mice, resulted in a decrease of total
      cholesterol, a hypoglycemic effect, and an antioxidant activity by thiobarbituric
      acid-reactive substances measurement. Also, it decreased the carrageenan-induced 
      edema volume and the rate of writhing as a nociceptive response. These results
      indicate positive effects of P. nitida extract and its potential to inhibit
      metabolic syndrome.
AD  - Laboratory of Biological Activity, Faculty of Pharmaceutical Sciences, Amazonas
      Federal University, Alexandre Amorim Street, 330, 69010-300, Aparecida, Manaus,
      Amazonas, Brazil.
FAU - Montefusco-Pereira, Carlos Victor
AU  - Montefusco-Pereira CV
FAU - de Carvalho, Maria Jose
AU  - de Carvalho MJ
FAU - de Araujo Boleti, Ana Paula
AU  - de Araujo Boleti AP
FAU - Teixeira, Lorisa Simas
AU  - Teixeira LS
FAU - Matos, Humberto Reis
AU  - Matos HR
FAU - Lima, Emerson Silva
AU  - Lima ES
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Appl Biochem Biotechnol
JT  - Applied biochemistry and biotechnology
JID - 8208561
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/06/28 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/05/12 [aheadofprint]
AID - 10.1007/s12010-013-0271-6 [doi]
PST - aheadofprint
SO  - Appl Biochem Biotechnol. 2013 May 12.

PMID- 23666605
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1531-4995 (Electronic)
IS  - 0023-852X (Linking)
VI  - 123
IP  - 6
DP  - 2013 Jun
TI  - Chronic rhinosinusitis increased the risk of chronic periodontitis: A
      population-based matched-cohort study.
PG  - 1323-7
LID - 10.1002/lary.23720 [doi]
AB  - OBJECTIVES/HYPOTHESIS: Although chronic periodontitis (CP) and chronic
      rhinosinusitis (CRS) both share immunological disturbances as pathological
      factors, no prior study has investigated the risk for CP among patients with CRS.
      This study set out to provide an estimation of risk by utilizing a cohort study
      design to leverage the statistical power of a population-based dataset in Taiwan.
      STUDY DESIGN: A retrospective cohort study. METHODS: In total, 13,782 CRS
      subjects were included in the study cohort and 41,346 subjects were randomly
      extracted for the comparison cohort. We individually tracked each subject in this
      study (N = 55,128) for a 5-year period following their index date to identify
      those subjects who received a subsequent diagnosis of CP. Cox proportional
      hazards regression analysis was conducted to calculate the 5-year risk of
      subsequent CP following a diagnosis of CRS among the sampled subjects. RESULTS:
      The incidence rate of CP during the 5-year follow-up period was 5.12 (95%
      confidence interval [CI], 4.95-5.30) per 100 person-years and 3.24 (95% CI,
      3.17-3.30) per 100 person-years for the study and comparison cohort,
      respectively. Cox proportional hazards regression revealed that the hazard ratio 
      for CP during the 5-year follow-up period for subjects with CRS was 1.59 times
      (95% CI, 1.52-1.67) that of comparison subjects after adjusting for monthly
      income, geographic region, hypertension, diabetes, coronary heart disease, and
      hyperlipidemia, and censoring for cases who died during the 5-year follow-up
      period. CONCLUSIONS: This study detected an increased risk for CP among patients 
      suffering from CRS. CRS patients should be alerted to pay particular attention to
      their oral hygiene practices to prevent both CP and its downstream sequelae.
CI  - Copyright (c) 2013 The American Laryngological, Rhinological, and Otological
      Society, Inc.
AD  - School of Public Health, Taipei Medical University Hospital, Taipei.
FAU - Keller, Joseph J
AU  - Keller JJ
FAU - Wu, Chuan-Song
AU  - Wu CS
FAU - Lin, Herng-Ching
AU  - Lin HC
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/06/08 [received]
PHST- 2012/07/22 [revised]
PHST- 2012/08/13 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - 10.1002/lary.23720 [doi]
PST - ppublish
SO  - Laryngoscope. 2013 Jun;123(6):1323-7. doi: 10.1002/lary.23720. Epub 2013 May 10.

PMID- 23666595
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1689-1392 (Electronic)
IS  - 1425-8153 (Linking)
VI  - 18
IP  - 2
DP  - 2013 Jun
TI  - Enhancement of wound closure in diabetic mice by ex vivo expanded cord blood
      CD34(+) cells.
PG  - 263-83
LID - 10.2478/s11658-013-0089-9 [doi]
AB  - Diabetes can impair wound closure, which can give rise to major clinical
      problems. Most treatments for wound repair in diabetes remain ineffective. This
      study aimed to investigate the influence on wound closure of treatments using
      expanded human cord blood CD34(+) cells (CB-CD34(+) cells), freshly isolated
      CB-CD34(+) cells and a cytokine cocktail. The test subjects were mice with
      streptozotocin-induced diabetes. Wounds treated with fresh CB-CD34(+) cells
      showed more rapid repair than mice given the PBS control. Injection of expanded
      CB-CD34(+) cells improved wound closure significantly, whereas the injection of
      the cytokine cocktail alone did not improve wound repair. The results also
      demonstrated a significant decrease in epithelial gaps and advanced
      re-epithelialization over the wound bed area after treatment with either expanded
      CB-CD34(+) cells or freshly isolated cells compared with the control. In
      addition, treatments with both CB-CD34(+) cells and the cytokine cocktail were
      shown to promote recruitment of CD31(+)-endothelial cells in the wounds. Both the
      CB-CD34(+) cell population and the cytokine treatments also enhanced the
      recruitment of CD68-positive cells in the early stages (day 3) of treatment
      compared with PBS control, although the degree of this enhancement was found to
      decline in the later stages (day 9). These results demonstrated that expanded
      CB-CD34(+) cells or freshly isolated CB-CD34(+) cells could accelerate wound
      repair by increasing the recruitment of macrophages and capillaries and the
      reepithelialization over the wound bed area. Our data suggest an effective role
      in wound closure for both ex vivo expanded CB-CD34(+) cells and freshly isolated 
      cells, and these may serve as therapeutic options for wound treatment for
      diabetic patients. Wound closure acceleration by expanded CB-CD34(+) cells also
      breaks the insufficient quantity obstacle of stem cells per unit of cord blood
      and other stem cell sources, which indicates a broader potential for autologous
      transplantation.
AD  - Stem Cell Therapy and Transplantation Research Group, Suranaree University of
      Technology, Suranaree, Thailand.
FAU - Chotinantakul, Kamonnaree
AU  - Chotinantakul K
FAU - Dechsukhum, Chavaboon
AU  - Dechsukhum C
FAU - Dejjuy, Duangnapa
AU  - Dejjuy D
FAU - Leeanansaksiri, Wilairat
AU  - Leeanansaksiri W
LA  - eng
PT  - Journal Article
DEP - 20130515
PL  - Poland
TA  - Cell Mol Biol Lett
JT  - Cellular & molecular biology letters
JID - 9607427
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/22 [received]
PHST- 2013/04/18 [accepted]
PHST- 2013/05/15 [aheadofprint]
AID - 10.2478/s11658-013-0089-9 [doi]
PST - ppublish
SO  - Cell Mol Biol Lett. 2013 Jun;18(2):263-83. doi: 10.2478/s11658-013-0089-9. Epub
      2013 May 15.

PMID- 23666569
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1536-3694 (Electronic)
IS  - 0163-4356 (Linking)
VI  - 35
IP  - 3
DP  - 2013 Jun
TI  - Inosine monophosphate dehydrogenase expression and activity are significantly
      lower in kidney transplant recipients with diabetes mellitus.
PG  - 374-83
LID - 10.1097/FTD.0b013e3182852697 [doi]
AB  - BACKGROUND: : Inosine 5'-monophosphate dehydrogenase (IMPDH) is a target of the
      immunosuppressive drug, mycophenolic acid (MPA). A 12-hour clinical
      pharmacokinetic and pharmacodynamic study was conducted to compare IMPDH1 and
      IMPDH2 gene expression, IMPDHI and IMPDHII protein levels, and enzyme activity
      between kidney transplant recipients with respect to diabetes status. METHODS: : 
      Nondiabetic (ND, n = 11) and diabetic (D, n = 9) kidney transplant recipients and
      on nontransplant nondiabetic (n = 10) and diabetic (n = 10) volunteers were
      included in the study. RESULTS: : Area under the effect curve values for gene
      expression: IMPDH1 [ND: 22.1 (13.8-31.3) versus D: 4.5 (2.3-6.5), P < 0.001] and 
      IMPDH2 [ND: 15.3 (11.0-21.7) versus D: 6.1 (4.6-8.6), P < 0.001], protein level: 
      IMPDHI [ND: 1.0 (0.5-1.3) versus 0.5 (0.4-0.7), P = 0.002] and IMPDHII [ND: 1.0
      (0.6-1.6) versus D: 0.7 (0.6-0.8) P < 0.001] and enzyme activity [ND: 180
      (105-245) versus D: 29.9 (15.3-35.6) micromole.s.mole adenosine monophosphate, P 
      < 0.001] was significantly lower in transplant recipients with diabetes. Similar 
      results were observed in nontransplanted volunteers. Kinetic studies of
      MPA-mediated suppression of IMPDH activity in nontransplanted individuals
      revealed an approximately 2.5-fold lower half-maximum effective concentration
      (EC50) for diabetic as compared with nondiabetic [ND: 50.2 (49.8-50.7) versus D: 
      15.8 (15.6-16.3) nmole/L, P = 0.004] volunteers. This difference was not related 
      to several IMPDH gene variants. CONCLUSIONS: : This study indicates a
      significantly lower IMPDH gene expression, protein level, and enzyme activity in 
      diabetic patients. Further clinical studies in a larger number of patients are
      warranted to verify whether MPA dosing must be optimized for kidney transplant
      recipients with diabetes mellitus.
AD  - *Department of Biomedical and Pharmaceutical Sciences, University of Rhode
      Island, Kingston, RI; and daggerDivision of Organ Transplantation, Rhode Island
      Hospital, Warren Alpert Medical School of Brown University, Providence, RI.
FAU - Dostalek, Miroslav
AU  - Dostalek M
FAU - Gohh, Reginald Y
AU  - Gohh RY
FAU - Akhlaghi, Fatemeh
AU  - Akhlaghi F
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ther Drug Monit
JT  - Therapeutic drug monitoring
JID - 7909660
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1097/FTD.0b013e3182852697 [doi]
PST - ppublish
SO  - Ther Drug Monit. 2013 Jun;35(3):374-83. doi: 10.1097/FTD.0b013e3182852697.

PMID- 23666500
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 May 10
TI  - Development of diabetic nephropathy in nude mice.
AB  - Background-Immune dysfunction is very common in diabetes mellitus (DM). However, 
      there is no evidence whether such immune dysfunction can influence the
      development of DM, especially, the development of diabetic nephropathy (DN).
      Aim-To investigate the influence of absence of T cells on DN. Materials and
      Methods-Balb/c nude mice and Balb/c wide type nude (WT) mice were injected with
      streptozotocin (STZ). Serum TNF-alpha, blood glucose, body weight, urine
      albumin/creatinine ratio and rate of kidney weight to body weight (KW/BW) were
      measured. Results-After modeling, there was no difference of blood glucose level 
      between nude mice and WT mice except at week 2 (28.3+/-4.9 mmol/L vs. 23.1+/-3.9 
      mmol/L, P<0.01). At week 4, the serum TNF-alpha level of nude mice got to
      175.08+/-46.03 pg/mL (P<0.05, compared with baseline level 80.19+/-8.46 pg/mL),
      whereas the TNF-alpha levels of WT mice kept stable. At week 4, the body weight
      of nude mice was lower than that of WT mice (14.7+/-3.15 g vs. 17.97+/-2.85 g,
      p<0.05); the urine Alb/Cr of nude mice was higher than that of WT mice
      (50.96+/-5.57 mg/mmol vs. 41.09+/-5.79 mg/mmol, P<0.05); the KW/BW of nude mice
      was higher than that of WT mice (0.01352+/-0.00163 vs. 0.01173+/-0.00131,
      P<0.05). Correlation analysis showed urine Alb/Cr positively correlated with
      serum TNF-alpha level at week 4 (r=0.588, P<0.01). At week 4, the increase of
      type IV collagen in the glomeruli was more prominent in diabetic nude mice than
      in diabetic WT mice (P<0.05). Conclusions-Absence of T cells in DM might
      influence the development of DN.
AD  - Department of Nephrology; General Hospital of Tianjin Medical University; Tianjin
      300052, China.
FAU - Lin, Shan
AU  - Lin S
FAU - Xu, Peng-Cheng
AU  - Xu PC
FAU - Huang, Qian-E
AU  - Huang QE
FAU - Jia, Jun-Ya
AU  - Jia JY
FAU - Jia, Zhong-Hui
AU  - Jia ZH
FAU - Wei, Li
AU  - Wei L
FAU - Zheng, Zhen-Feng
AU  - Zheng ZF
FAU - Shang, When-Ya
AU  - Shang WY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 8962 [pii]
AID - 10.3275/8962 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 May 10.

PMID- 23666487
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1474-1784 (Electronic)
IS  - 1474-1776 (Linking)
VI  - 12
IP  - 6
DP  - 2013 May
TI  - Pharmacological approaches to restore mitochondrial function.
PG  - 465-83
LID - 10.1038/nrd4023 [doi]
AB  - Mitochondrial dysfunction is not only a hallmark of rare inherited mitochondrial 
      disorders but also implicated in age-related diseases, including those that
      affect the metabolic and nervous system, such as type 2 diabetes and Parkinson's 
      disease. Numerous pathways maintain and/or restore proper mitochondrial function,
      including mitochondrial biogenesis, mitochondrial dynamics, mitophagy and the
      mitochondrial unfolded protein response. New and powerful phenotypic assays in
      cell-based models as well as multicellular organisms have been developed to
      explore these different aspects of mitochondrial function. Modulating
      mitochondrial function has therefore emerged as an attractive therapeutic
      strategy for several diseases, which has spurred active drug discovery efforts in
      this area.
AD  - Laboratory of Integrative and Systems Physiology, Ecole Polytechnique Federale de
      Lausanne, CH-1015 Lausanne, Switzerland.
FAU - Andreux, Penelope A
AU  - Andreux PA
FAU - Houtkooper, Riekelt H
AU  - Houtkooper RH
FAU - Auwerx, Johan
AU  - Auwerx J
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - England
TA  - Nat Rev Drug Discov
JT  - Nature reviews. Drug discovery
JID - 101124171
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/05/13 [aheadofprint]
AID - nrd4023 [pii]
AID - 10.1038/nrd4023 [doi]
PST - ppublish
SO  - Nat Rev Drug Discov. 2013 May;12(6):465-83. doi: 10.1038/nrd4023. Epub 2013 May
      13.

PMID- 23666447
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 0026-1270 (Electronic)
IS  - 0026-1270 (Linking)
VI  - 52
IP  - 4
DP  - 2013 May 13
TI  - Developing Topic-specific Search Filters for PubMed with Click-through Data.
AB  - Objectives: Search filters have been developed and demonstrated for better
      information access to the immense and ever-growing body of publications in the
      biomedical domain. However, to date the number of filters remains quite limited
      because the current filter development methods require significant human efforts 
      in manual document review and filter term selection. In this regard, we aim to
      investigate automatic methods for generating search filters. Methods: We present 
      an automated method to develop topic-specific filters on the basis of users'
      search logs in PubMed. Specifically, for a given topic, we first detect its
      relevant user queries and then include their corresponding clicked articles to
      serve as the topic-relevant document set accordingly. Next, we statistically
      identify informative terms that best represent the topic-relevant document set
      using a background set composed of topic irrelevant articles. Lastly, the
      selected representative terms are combined with Boolean operators and evaluated
      on benchmark datasets to derive the final filter with the best performance.
      Results: We applied our method to develop filters for four clinical topics:
      nephrology, diabetes, pregnancy, and depression. For the nephrology filter, our
      method obtained performance comparable to the state of the art (sensitivity of
      91.3%, specificity of 98.7%, precision of 94.6%, and accuracy of 97.2%).
      Similarly, high-performing results (over 90% in all measures) were obtained for
      the other three search filters. Conclusion: Based on PubMed click-through data,
      we successfully developed a high-performance method for generating topic-specific
      search filters that is significantly more efficient than existing manual methods.
      All data sets (topic-relevant and irrelevant document sets) used in this study
      and a demonstration system are publicly available at
      http://www.ncbi.nlm.nih.gov/CBBresearch/Lu/downloads/CQ_filter/
AD  - Dr. Zhiyong Lu, NCBI/NLM/NIH, 8600 Rockville Pike, Building 38A, Room 1003A,
      Bethesda, MD, 20894, USA, E-mail: zhiyong.lu@nih.gov.
FAU - Li, J
AU  - Li J
FAU - Lu, Z
AU  - Lu Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Methods Inf Med
JT  - Methods of information in medicine
JID - 0210453
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/06/12 [received]
PHST- 2013/02/27 [accepted]
AID - 12-01-0054 [pii]
AID - 10.3414/ME12-01-0054 [doi]
PST - aheadofprint
SO  - Methods Inf Med. 2013 May 13;52(4).

PMID- 23666423
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 May 9
TI  - Prevalence, awareness, and control of hypertension among Asian Indians living in 
      urban Singapore and rural India.
AB  - BACKGROUND:: Hypertension is a major modifiable risk factor associated with
      cardiovascular morbidity and mortality. We compared the epidemiology of
      hypertension in South Asian Indians living in two geographic regions with vastly 
      different socioeconomic settings (urban Singapore and rural India). METHODS:: We 
      analyzed data from two large population-based studies: the Singapore Indian Eye
      Study (SINDI, n = 3228, aged 40-80 years, 49.2% women) and the Central India Eye 
      and Medical Study (CIEMS, n = 3591, aged >/=40 years, 52.6% women). Hypertension 
      was defined as SBP at least 140 or DBP at least 90 mmHg or self-reported
      history/treatment for hypertension. RESULTS:: The age-adjusted prevalence of
      hypertension in SINDI and CIEMS were 58.6 and 25.3%. After adjusting for
      potential confounders, increasing age, overweight/obese, and diabetes status
      showed a positive association and 'never drinking alcohol' showed a protective
      association with hypertension in both populations. Current smoking and being
      female showed a protective association and no formal education showed a positive 
      association with hypertension in SINDI. Among those with hypertension in SINDI
      and CIEMS, 72.4 and 25.3% were aware of their condition of whom 85 and 31.6% were
      on treatment for hypertension. The blood pressure control was similar between the
      two populations (48.7% in SINDI and 46.9% in CIEMS). CONCLUSION:: The prevalence 
      of hypertension, the level of awareness, and treatment for hypertension was
      higher in Indians living in Singapore than in rural Indians. Socioeconomic and
      metabolic factors explain some of the observed differences between the two
      populations, which may provide insights to develop public health strategies.
AD  - aSingapore Eye Research Institute bDepartment of Ophthalmology, Yong Loo Lin
      School of Medicine, National University of Singapore and National University
      Health System, Singapore, Singapore cCentre for Eye Research Australia,
      University of Melbourne, Melbourne, Australia dSuraj Eye Institute, Nagpur, India
      eDepartment of Ophthalmology, Universitatsmedizin Mannheim, Medical Faculty
      Mannheim, Heidelberg University, Mannheim, Germany fOffice of Clinical Sciences, 
      Duke-NUS Graduate Medical School, Singapore, Singapore.
FAU - Yip, Wanfen
AU  - Yip W
FAU - Wong, Tien Y
AU  - Wong TY
FAU - Jonas, Jost B
AU  - Jonas JB
FAU - Zheng, Yingfeng
AU  - Zheng Y
FAU - Lamoureux, Ecosse L
AU  - Lamoureux EL
FAU - Nangia, Vinay
AU  - Nangia V
FAU - Sabanayagam, Charumathi
AU  - Sabanayagam C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1097/HJH.0b013e328361d52b [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 May 9.

PMID- 23666421
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 May 9
TI  - Silencing of Atp2b1 increases blood pressure through vasoconstriction.
AB  - BACKGROUND:: Recent genome-wide association studies (GWASs) have identified 30
      genetic loci that regulate blood pressure, increasing our understanding of the
      cause of hypertension. However, it has been difficult to define the causative
      genes at these loci due to a lack of functional analyses. METHOD:: In this study,
      we aimed to validate the candidate gene ATP2B1 in 12q21, variants near which have
      the strongest association with blood pressure in Asians and Europeans. ATP2B1
      functions as a calcium pump to fine-tune calcium concentrations - necessary for
      repolarization following muscular contractions. We silenced Atp2b1 using an siRNA
      complex, injected into mouse tail veins. RESULTS:: In treated mice, blood
      pressure rose and the mesenteric arteries increased in wall : lumen ratio.
      Moreover, the arteries showed enhanced myogenic responses to pressure, and
      contractile responses to phenylephrine increased compared with the control,
      suggesting that blood pressure is regulated by ATP2B1 through the contraction and
      dilation of the vessel, likely by controlling calcium concentrations in the
      resting state. CONCLUSION:: These results support that ATP2B1 is the causative
      gene in the blood pressure-associated 12q21 locus and demonstrate that ATP2B1
      expression in the vessel influences blood pressure.
AD  - aDepartment of Biomedical Engineering, School of Medicine, Kyung Hee University
      bDepartment of Physiology, College of Medicine, BK 21 Project for Medical
      Sciences, Yonsei University, Seoul, Korea cWellcome Trust Centre for Human
      Genetics, University of Oxford dOxford Centre for Diabetes Endocrinology and
      Metabolism, Churchill Hospital, Oxford, UK *Young-Bin Shin and Ji Eun Lim
      contributed equally to the writing of this work.
FAU - Shin, Young-Bin
AU  - Shin YB
FAU - Lim, Ji Eun
AU  - Lim JE
FAU - Ji, Su-Min
AU  - Ji SM
FAU - Lee, Hyeon-Ju
AU  - Lee HJ
FAU - Park, So-Yon
AU  - Park SY
FAU - Hong, Kyung-Won
AU  - Hong KW
FAU - Lim, Mihwa
AU  - Lim M
FAU - McCarthy, Mark I
AU  - McCarthy MI
FAU - Lee, Young-Ho
AU  - Lee YH
FAU - Oh, Bermseok
AU  - Oh B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1097/HJH.0b013e32836189e9 [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 May 9.

PMID- 23666376
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
DP  - 2013 May 10
TI  - Excessive negative venous line pressures and increased arterial air bubble counts
      during miniaturized cardiopulmonary bypass: an experimental study comparing
      miniaturized with conventional perfusion systems.
AB  - OBJECTIVES: Miniaturized cardiopulmonary bypass (MCPB) is increasingly used in
      cardiac surgery, because it can lower clinically significant complications such
      as systemic inflammatory response, haemolysis and high transfusion requirements. 
      A limitation of MCPB is the risk of excessive negative pressure in the venous
      line during volume depletion, probably leading to gaseous microembolism. METHODS:
      In an experimental study with 24 pigs, we compared conventional open
      cardiopulmonary bypass (CCPB group, n = 11) with MCPB (n = 13). The same pump and
      identical tubing materials were used in both groups. Primary endpoints were
      pressure values in the venous line and the right atrium as well as the amount of 
      air bubbles >500 microm. Secondary endpoints were biochemical parameters of
      systemic inflammatory response, ischaemia, haemodilution and haemolysis. RESULTS:
      Nearly 20% of venous pressure values were below -150 mmHg and approximately 10%
      of the right atrial pressure values were below -100 mmHg in the MCPB group,
      during the experiment. No such low values were observed in the CCPB group. In
      addition, the number of large arterial air bubbles was higher in the MCPB group
      compared with the CCPB group (mean +/- standard deviation [SD]: 13 444 +/- 5709
      vs 0.9 +/- 0.6, respectively; P < 0.001). Bubble volume was also significantly
      larger during MCPB compared with CCPB (mean +/- SD: 1522 +/- 654 vs 4.1 +/- 2.5
      microl, respectively; P < 0.001). Blood levels of interleukin-6, free haemoglobin
      and creatine kinase were significantly higher in the CCPB group compared with the
      MCPB group. CONCLUSIONS: Despite the benefits of MCPB regarding systemic
      inflammatory response and haemolysis, this technique is associated with excessive
      negative venous line pressures and a significant increase in the number and
      volume of arterial air bubbles compared with CCPB. Mini-perfusion systems and the
      management of MCPB require further refinements to avoid such adverse effects.
AD  - Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW,
      Ruhr University Bochum, Bad Oeynhausen, Germany.
FAU - Aboud, Anas
AU  - Aboud A
FAU - Liebing, Kai
AU  - Liebing K
FAU - Borgermann, Jochen
AU  - Borgermann J
FAU - Ensminger, Stephan
AU  - Ensminger S
FAU - Zittermann, Armin
AU  - Zittermann A
FAU - Renner, Andre
AU  - Renner A
FAU - Hakim-Meibodi, Kavous
AU  - Hakim-Meibodi K
FAU - Gummert, Jan
AU  - Gummert J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European
      Association for Cardio-thoracic Surgery
JID - 8804069
OTO - NOTNLM
OT  - Cardiopulmonary bypass
OT  - Gaseous microembolism
OT  - Haemodilution
OT  - Haemolysis
OT  - Systemic inflammatory response
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - ezt257 [pii]
AID - 10.1093/ejcts/ezt257 [doi]
PST - aheadofprint
SO  - Eur J Cardiothorac Surg. 2013 May 10.

PMID- 23666370
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 19
DP  - 2013
TI  - What is more damaging to vascular endothelial function: Diabetes, age, high BMI, 
      or all of the above?
PG  - 257-63
LID - 10.12659/MSM.883878 [doi]
AB  - Background It is well established that there is a reduction in the skin blood
      flow (SBF) in response to heat with age and diabetes. While it is known that high
      BMI creates a stress on the cardiovascular system and increases the risk of all
      cause of morbidity and mortality, little is known of the effect of high BMI on
      SBF response to heat. Since diabetes is associated with age and a higher BMI, the
      interrelationship between age, BMI and SBF needs to be investigated to better
      understand the contribution diabetes alone has to endothelial impairment.
      Material and Methods This study examined the SBF to heat in young and old people 
      with low and high BMI and people with diabetes with high BMI to determine the
      contribution these variables have on SBF. Subjects were ten young and older
      people with BMI <20 and ten young and older people with BMI >20 and ten subjects 
      with diabetes with BMI >20. The SBF response, above the quadriceps, was
      determined during a 6 minutes exposure to heat at 44 degrees C. Results Even in
      young people, SBF after the stress of heat exposure was reduced in subjects with 
      a high BMI. The effect of BMI was greatest in young people and lowest in older
      people and people with diabetes; in people with diabetes, BMI was a more
      significant variable than diabetes in causing impairment of blood flow to heat.
      BMI, for example, was responsible for 49% of the reduction in blood flow after
      stress heat exposure (R=-0.7) while ageing only accounted for 16% of the blood
      flow reduction (R=-0.397). Conclusions These results would suggest the importance
      of keeping BMI low not only in people with diabetes to minimize further
      circulatory vascular damage, but also in young people to diminish long term
      circulatory vascular compromise.
AD  - Department of Physical Therapy, School of Allied Health Professions, Loma Linda
      University, Loma LInda, CA, U.S.A.
FAU - Petrofsky, Jerrold Scott
AU  - Petrofsky JS
FAU - Alshammari, Faris
AU  - Alshammari F
FAU - Bains, Gurinder Singh
AU  - Bains GS
FAU - Khowailed, Iman Akef
AU  - Khowailed IA
FAU - Lee, Haneul
AU  - Lee H
FAU - Kuderu, Yashvanth Nagarajamurthy
AU  - Kuderu YN
FAU - Lodha, Riya D
AU  - Lodha RD
FAU - Rodrigues, Sophia
AU  - Rodrigues S
FAU - Nguyen, Diamond
AU  - Nguyen D
FAU - Potnis, Pooja Ashok
AU  - Potnis PA
FAU - Deshpande, Pooja P
AU  - Deshpande PP
FAU - Yim, Jong Eun
AU  - Yim JE
FAU - Berk, Lee
AU  - Berk L
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and
      clinical research
JID - 9609063
SB  - IM
PMC - PMC3659113
OID - NLM: PMC3659113
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 883878 [pii]
AID - 10.12659/MSM.883878 [doi]
PST - epublish
SO  - Med Sci Monit. 2013 Apr 10;19:257-63. doi: 10.12659/MSM.883878.

PMID- 23666276
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 19
DP  - 2013
TI  - Obesity in hospitalized type 2 diabetes patients: A descriptive study.
PG  - 359-65
LID - 10.12659/MSM.889119 [doi]
AB  - Background The association between obesity and type 2 diabetes has been well
      documented in epidemiological studies. Patients with type 2 diabetes have a
      higher body weight than control populations. Relatively few studies, however,
      have examined the prevalence of obesity in a cohort of hospitalized type 2
      diabetes mellitus patients using an electronic health records database. This
      study measured the prevalence of obesity in hospitalized type 2 diabetes patients
      and described demographic and clinical characteristics using electronic health
      records from Convergence CT sites located in the southwestern United States.
      Material and Methods Hospitalized patients with type 2 diabetes mellitus were
      identified in electronic health records from the Convergence Global Research
      Network. Demographic and clinical characteristics were examined for hospitalized 
      patients with type 2 diabetes. Comparisons were made between males and females
      across different clinical characteristics as well as between obese patients (BMI 
      >/=30 kg/m2) and patients with BMI <30 kg/m2. Results Approximately 26.8% of
      hospitalized type 2 diabetes patients were overweight (BMI=25-29.9 kg/m2) and
      57.7% were obese (BMI >/=30 kg/m2). A higher percentage of females (61.3%) were
      obese compared to males (54.6%) (p=0.002). Obese patients with type 2 diabetes
      were younger, appeared to have inadequate glycemic control, exhibited higher
      blood pressure, and had worse lipid profiles compared to type 2 diabetes patients
      with BMI <30 kg/m2. Conclusions Approximately 84.5% of the hospitalized type 2
      diabetes patients identified in this study were overweight or obese (BMI >/=25
      kg/m2), suggesting the need for effective weight loss intervention in this
      population.
AD  - Shionogi Inc., New Jersey, U.S.A.
FAU - Blumentals, William A
AU  - Blumentals WA
FAU - Hwu, Peter
AU  - Hwu P
FAU - Kobayashi, Norihiro
AU  - Kobayashi N
FAU - Ogura, Eriko
AU  - Ogura E
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and
      clinical research
JID - 9609063
SB  - IM
PMC - PMC3658866
OID - NLM: PMC3658866
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 889119 [pii]
AID - 10.12659/MSM.889119 [doi]
PST - epublish
SO  - Med Sci Monit. 2013 May 13;19:359-65. doi: 10.12659/MSM.889119.

PMID- 23666249
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
DP  - 2013 May 10
TI  - Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction
      in obesity.
AD  - Division of Endocrinology, Diabetes and Hypertension, Department of Medicine,
      Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
FAU - Pojoga, Luminita H
AU  - Pojoga LH
FAU - Baudrand, Rene
AU  - Baudrand R
FAU - Adler, Gail K
AU  - Adler GK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - eht158 [pii]
AID - 10.1093/eurheartj/eht158 [doi]
PST - aheadofprint
SO  - Eur Heart J. 2013 May 10.

PMID- 23666224
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 54
IP  - 4
DP  - 2013 Apr
TI  - Acute myeloid leukemia with monosomy 7 and inv(3)(q21q26.2) complicated with
      central diabetes insipidus.
PG  - 397-402
AB  - A 20-year-old female presented with thirst, polyposia, and polyuria and was
      referred to our hospital because of leukocytosis and anemia. Bone marrow
      aspiration revealed 66.8% myeloperoxidase-positive blasts and trilineage
      myelodysplasia. The karyotype was 45, XX, inv(3)(q21q26.2), -7[19]. Therefore, a 
      diagnosis of AML with inv(3)(q21q26.2) complicated by -7 was made. Moreover,
      hyposthenuria and a low anti-diuretic hormone (ADH) level were observed. Although
      cerebrospinal fluid analysis was normal, magnetic resonance imaging (MRI)
      revealed the absence of hyperintensity in the neurohypophysis in T1-weighted
      images. Therefore, she was also diagnosed with diabetes insipidus. After she was 
      administered a desmopressin nasal spray, the volume of urine produced decreased. 
      Following treatment with second induction therapy containing high-dose cytarabine
      for AML, she achieved complete remission in the bone marrow. Moreover, when the
      abnormality on MRI and the volume of urine were normalized, she discontinued
      desmopressin. Although diabetes insipidus is a rare complication of AML, the
      majority of AML patients who have diabetes insipidus have the abnormal karyotypes
      with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and monosomy 7. Further study is required
      to clarify the pathogenesis and develop a strategy for the treatment of this
      category of AML.
AD  - Department of Hematology, Graduate School of Medicine, Osaka City University.
FAU - Nanno, Satoru
AU  - Nanno S
FAU - Hagihara, Kiyoyuki
AU  - Hagihara K
FAU - Sakabe, Manami
AU  - Sakabe M
FAU - Okamura, Hiroshi
AU  - Okamura H
FAU - Inaba, Akiko
AU  - Inaba A
FAU - Nagata, Yuki
AU  - Nagata Y
FAU - Nishimoto, Mitsutaka
AU  - Nishimoto M
FAU - Koh, Hideo
AU  - Koh H
FAU - Nakao, Yoshitaka
AU  - Nakao Y
FAU - Nakane, Takahiko
AU  - Nakane T
FAU - Nakamae, Hirohisa
AU  - Nakamae H
FAU - Shimono, Taro
AU  - Shimono T
FAU - Hino, Masayuki
AU  - Hino M
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - DN/JST.JSTAGE/rinketsu/54.397 [pii]
PST - ppublish
SO  - Rinsho Ketsueki. 2013 Apr;54(4):397-402.

PMID- 23666211
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 12
TI  - Thyroid autoimmunity in relation to islet autoantibodies and HLA-DQ genotype in
      newly diagnosed type 1 diabetes in children and adolescents.
AB  - AIMS/HYPOTHESIS: The aim of this work was to investigate, in children newly
      diagnosed with type 1 diabetes: (1) the prevalence of autoantibodies against
      thyroid peroxidase (TPOAb) and thyroglobulin (TGAb); and (2) the association
      between TPOAb, TGAb or both, with either islet autoantibodies or HLA-DQ genes.
      METHODS: Blood samples from 2,433 children newly diagnosed with type 1 diabetes
      were analysed for TPOAb and TGAb in addition to autoantibodies against arginine
      zinc transporter 8 (ZnT8RA), tryptophan zinc transporter 8 (ZnT8WA), glutamine
      zinc transporter 8 (ZnT8QA), glutamic acid decarboxylase (GADA), insulin (IAA),
      insulinoma-associated protein-2 (IA-2A), HLA-DQA-B1 genotypes,
      thyroid-stimulating hormone (TSH) and free thyroxine (T4). RESULTS: At type 1
      diabetes diagnosis, 12% of the children had thyroid autoantibodies (60% were
      girls; p < 0.0001). GADA was positively associated with TPOAb (p < 0.001) and
      with TGAb (p < 0.001). In addition, ZnT8A was associated with both TPOAb (p =
      0.039) and TGAb (p = 0.015). DQB1*05:01 in any genotype was negatively associated
      with TPOAb (OR 0.55, 95% CI 0.37, 0.83, p value corrected for multiple
      comparisons (p c) = 0.012) and possibly with TGAb (OR 0.55, 95% CI 0.35, 0.87, p 
      c = 0.07). Thyroid autoimmunity in children newly diagnosed with type 1 diabetes 
      was rarely (0.45%) associated with onset of clinical thyroid disease based on TSH
      and free T4. CONCLUSIONS/INTERPRETATION: GADA and ZnT8A increased the risk for
      thyroid autoimmunity at the time of clinical diagnosis of type 1 diabetes, while 
      HLA-DQB1*05:01 reduced the risk. However, the associations between thyroid
      autoimmunity and HLA-DQ genotype were weak and did not fully explain the
      co-occurrence of islet and thyroid autoimmunity.
AD  - Lund University/CRC, Department of Clinical Sciences, Skane University Hospital
      SUS, Jan Waldenstroms gata 35, 20502, Malmo, Sweden,
      berglind.jonsdottir@gmail.com.
FAU - Jonsdottir, B
AU  - Jonsdottir B
FAU - Andersson, C
AU  - Andersson C
FAU - Carlsson, A
AU  - Carlsson A
FAU - Delli, A
AU  - Delli A
FAU - Forsander, G
AU  - Forsander G
FAU - Ludvigsson, J
AU  - Ludvigsson J
FAU - Marcus, C
AU  - Marcus C
FAU - Samuelsson, U
AU  - Samuelsson U
FAU - Ortqvist, E
AU  - Ortqvist E
FAU - Lernmark, A
AU  - Lernmark A
FAU - Ivarsson, S-A
AU  - Ivarsson SA
FAU - Larsson, H Elding
AU  - Larsson HE
CN  - for the Better Diabetes Diagnosis (BDD) study group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/12/20 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/12 [aheadofprint]
AID - 10.1007/s00125-013-2934-9 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 12.

PMID- 23666166
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 11
TI  - Long-term exposure to traffic-related air pollution and insulin resistance in
      children: results from the GINIplus and LISAplus birth cohorts.
AB  - AIMS/HYPOTHESIS: Epidemiological studies that have examined associations between 
      long-term exposure to traffic-related air pollution and type 2 diabetes mellitus 
      in adults are inconsistent, and studies on insulin resistance are scarce. We
      aimed to assess the association between traffic-related air pollution and insulin
      resistance in children. METHODS: Fasting blood samples were collected from 397
      10-year-old children in two prospective German birth cohort studies.
      Individual-level exposures to traffic-related air pollutants at the birth address
      were estimated by land use regression models. The association between air
      pollution and HOMA of insulin resistance (HOMA-IR) was analysed using a linear
      model adjusted for several covariates including birthweight, pubertal status and 
      BMI. Models were also further adjusted for second-hand smoke exposure at home.
      Sensitivity analyses that assessed the impact of relocating, study design and sex
      were performed. RESULTS: In all crude and adjusted models, levels of insulin
      resistance were greater in children with higher exposure to air pollution.
      Insulin resistance increased by 17.0% (95% CI 5.0, 30.3) and 18.7% (95% CI 2.9,
      36.9) for every 2SDs increase in ambient NO2 and particulate matter </=10 mum in 
      diameter, respectively. Proximity to the nearest major road increased insulin
      resistance by 7.2% (95% CI 0.8, 14.0) per 500 m. CONCLUSIONS/INTERPRETATION:
      Traffic-related air pollution may increase the risk of insulin resistance. Given 
      the ubiquitous nature of air pollution and the high incidence of insulin
      resistance in the general population, the associations examined here may have
      potentially important public health effects despite the small/moderate effect
      sizes observed.
AD  - Institute of Epidemiology I, Helmholtz Zentrum Munchen, German Research Center
      for Environmental Health, Ingolstadter Landstrasse 1, 85764, Neuherberg, Germany.
FAU - Thiering, E
AU  - Thiering E
FAU - Cyrys, J
AU  - Cyrys J
FAU - Kratzsch, J
AU  - Kratzsch J
FAU - Meisinger, C
AU  - Meisinger C
FAU - Hoffmann, B
AU  - Hoffmann B
FAU - Berdel, D
AU  - Berdel D
FAU - von Berg, A
AU  - von Berg A
FAU - Koletzko, S
AU  - Koletzko S
FAU - Bauer, C-P
AU  - Bauer CP
FAU - Heinrich, J
AU  - Heinrich J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130511
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/12 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/11 [aheadofprint]
AID - 10.1007/s00125-013-2925-x [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 11.

PMID- 23666024
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 154
IP  - 20
DP  - 2013 May 1
TI  - [Comparison of the effectivity of two internationally recommended screening
      methods for the recognition of gestational diabetes].
PG  - 776-83
LID - 10.1556/OH.2013.29615 [doi]
AB  - Introduction: Early diagnosis and adequate care of gestational diabetes is of
      great importance for both the mother and her fetus. Although several national and
      international guidelines are known on the methodology for screening gestational
      diabetes, a not negligible part of the cases remain unrecognized when applying
      even the most widely used criteria recommended by the World Health Organization
      (1st recommendation). A connection has been found between the maternal blood
      glucose values and the prevalence of still-birth, preeclampsia and large for
      gestational age neonates in several studies, from which the Hyperglycaemia and
      Adverse Pregnancy Outcomes study has come into prominence. According to
      conclusions of this study the International Association of Diabetic Pregnancy
      Study Groups suggested new numeric criteria for the evaluation of the 75-gramm
      oral glucose tolerance test (2nd rercommendation), which differs from the
      evaluation used in the afore mentioned screening system. Aims: The aim of the
      study was to compare the effectiveness of the two screening systems by evaluation
      of the pregnancy outcomes. Methods: By following non-twin pregnancies of 1107
      pregnant mothers (831 with normal glucose tolerance, 276 with gestational
      diabetes based on any of the applied screening methods) the maternal (pre- and
      postterminal birth, caesarean section, toxaemia) and newborns pregnancy outcomes 
      (infants small and large for gestational age, hypoglycaemia) were analysed.
      Results: With the exception of the prevalence of large for gestational age
      infants - which was higher among women screened by the new evaluation - no
      substantial difference in the efficacy of the two investigated methods was found.
      Conclusion: The decision whether the screening of gestational diabetes using the 
      new criteria results in safer recognition of the disturbances of glucose
      metabolism during pregnancy requires further investigations including a large
      number of cases. Orv. Hetil., 2013, 154, 776-783.
AD  - Szent Janos Korhaz II. Belgyogyaszat-Diabetologia Budapest Dios arok 1-3. 1125.
FAU - Salamon, Monika
AU  - Salamon M
FAU - Soos, Zsuzsanna
AU  - Soos Z
FAU - Olah, Roland
AU  - Olah R
FAU - Hazai, Mate
AU  - Hazai M
FAU - Sovago, Laszlo
AU  - Sovago L
FAU - Kovacs, Dora
AU  - Kovacs D
FAU - Pal, Borbala
AU  - Pal B
FAU - Baranyi, Eva
AU  - Baranyi E
FAU - Lintner, Ferenc
AU  - Lintner F
FAU - Winkler, Gabor
AU  - Winkler G
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - A gestatios diabetes szuresere ajanlott ket nemzetkozi eljaras hatekonysaganak
      osszehasonlitasa.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
SB  - IM
OAB - Publisher: Abstract available from the publisher.
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 9R27207T45R6T462 [pii]
AID - 10.1556/OH.2013.29615 [doi]
PST - ppublish
SO  - Orv Hetil. 2013 May 1;154(20):776-83. doi: 10.1556/OH.2013.29615.

PMID- 23665884
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
DP  - 2013 May 9
TI  - Vildagliptin With Metformin Once-Daily Regimen-Insights From a Single-Center
      Analysis.
AB  - Dipeptidyl peptidase-4 (DPP-4) inhibitors have been well established as an
      adjunctive treatment to metformin. Most guidelines recommend treatment with a
      DPP-4 inhibitor, vildagliptin, in addition to metformin in a twice-daily regimen.
      However, the twice-daily regimen has difficulty with medication adherence,
      increased cost of therapy, and possibility of more side effects. Our objective
      was to evaluate, by means of retrospective analysis, the efficacy of once-daily
      metformin and vildagliptin (a DPP-4 inhibitor) in reducing blood glucose for
      patients on combination therapy. We analyzed data from our database of
      outpatients attending the diabetic clinic at a tertiary care center in Kolkata,
      India. We had data on once-daily combination of metformin and vildagliptin for
      154 patients between September 2008 and May 2012. We followed up these patients
      for a median of 17.6 months and evaluated posttherapy glucose levels and
      hemoglobin A1c. Continuous variables were compared with t tests. Once-daily
      metformin-vildagliptin combination was found to be associated with a mean
      reduction of 27.52 mg/dL of fasting plasma glucose, 71.70 mg/dL of postprandial
      plasma glucose, and 1.41% reduction of HbA1c (P < 0.05 for all).
      Metformin-vildagliptin combination in a once-daily regimen seems to be associated
      with significant reductions in plasma glucose and HbA1c and may be a viable and
      cost-effective alternative to a twice-daily regimen as starting therapy.
AD  - 1Consultant Physician, Diabetes Clinical Nutrition, Apollo Gleneagles Hospital,
      Kolkata, India; and 2Fellow, Preventive Cardiology, Brown University & VA Medical
      Center, Providence, RI.
FAU - Chatterjee, Sanjay
AU  - Chatterjee S
FAU - Chatterjee, Saurav
AU  - Chatterjee S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1097/MJT.0b013e3182811a8b [doi]
PST - aheadofprint
SO  - Am J Ther. 2013 May 9.

PMID- 23665842
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1880-3873 (Electronic)
IS  - 1340-3478 (Linking)
DP  - 2013 May 10
TI  - N-terminal Pro-B-Type Natriuretic Peptide is Associated with Arterial Stiffness
      Measured Using the Cardio-Ankle Vascular Index in Renal Transplant Recipients.
AB  - Aim: Arterial stiffness is an established cardiovascular risk marker and an
      independent predictor of cardiovascular events and mortality in various groups of
      patients, including renal transplant recipients. Recent studies have noted that
      B-type natriuretic peptide (BNP) acts as a local paracrine molecule that
      modulates endothelial permeability and regeneration. The aim of this study was to
      evaluate the relationship between the serum N-terminal pro-BNP (NT-pro-BNP) level
      and arterial stiffness in renal transplant recipients.Methods: Fasting blood
      samples were obtained from 66 renal transplant recipients. The cardio-ankle
      vascular index was calculated using the waveform device (CAVI-VaSera VS-1000).
      The serum NTpro-BNP levels were measured using an electrochemiluminescence
      immunoassay. A CAVI value of >/=9 was used to define a high level of arterial
      stiffness.Results: Thirty-two patients (48.5%) were classified into the high
      arterial stiffness group. Diabetes (p=0.030), smoking (p<0.001), duration of
      kidney transplantation (p=0.001), body weight (p=0.014), waist circumference
      (p=0.022), body mass index (p=0.001) and the fasting glucose (p=0.021) and serum 
      NT-pro-BNP (p<0.001) levels were higher in the high arterial stiffness group than
      in the low arterial stiffness group. A multivariate forward stepwise linear
      regression analysis showed that the log-NT-pro-BNP level (beta: 0.459, p<0.001)
      remained an independent predictor of the CAVI value in the renal transplant
      recipients.Conclusions: The serum fasting NT-pro-BNP level is associated with
      arterial stiffness in renal transplant recipients.
AD  - Department of Surgery, Buddhist Tzu Chi General Hospital.
FAU - Chen, Yen-Cheng
AU  - Chen YC
FAU - Lee, Ming-Che
AU  - Lee MC
FAU - Lee, Chung-Jen
AU  - Lee CJ
FAU - Ho, Guan-Jin
AU  - Ho GJ
FAU - Yin, Wen-Yao
AU  - Yin WY
FAU - Chang, Yao-Jen
AU  - Chang YJ
FAU - Hsu, Bang-Gee
AU  - Hsu BG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - DN/JST.JSTAGE/jat/17780 [pii]
PST - aheadofprint
SO  - J Atheroscler Thromb. 2013 May 10.

PMID- 23665775
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
DP  - 2013 May 11
TI  - A case of malignant insulinoma: successful control of glycemic fluctuation by
      replacing octreotide injections with octreotide LAR injections.
AB  - A 73-year-old woman with malignant insulinoma was treated with 100 mug/day
      octreotide for unresected insulinoma and liver metastases. The daily
      administration of the drug induced hyperglycemia after dinner in addition to
      existing fasting hypoglycemia possibly because this drug suppressed both insulin 
      and glucagon secretion and its blood concentration was unstable. After replacing 
      a daily injection of octreotide with a monthly injection of octreotide
      long-acting repeatable (LAR), blood glucose levels stabilized within the normal
      range. The findings of the present study showed that octreotide LAR could be
      useful for the long-term treatment of unresectable insulinomas.
AD  - Department of Diabetes and Metabolic Medicine, Center Hospital, National Center
      for Global Health and Medicine, Tokyo 162-8655, Japan.
FAU - Okamoto, Masahide
AU  - Okamoto M
FAU - Kishimoto, Miyako
AU  - Kishimoto M
FAU - Takahashi, Yoshihiko
AU  - Takahashi Y
FAU - Osame, Keiichiro
AU  - Osame K
FAU - Noto, Hiroshi
AU  - Noto H
FAU - Yamamoto-Honda, Ritsuko
AU  - Yamamoto-Honda R
FAU - Kajio, Hiroshi
AU  - Kajio H
FAU - Tokuhara, Makoto
AU  - Tokuhara M
FAU - Edamoto, Yoshihiro
AU  - Edamoto Y
FAU - Endo, Hisako
AU  - Endo H
FAU - Igari, Toru
AU  - Igari T
FAU - Kubota, Kazuo
AU  - Kubota K
FAU - Noda, Mitsuhiko
AU  - Noda M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130511
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - DN/JST.JSTAGE/endocrj/EJ13-0025 [pii]
PST - aheadofprint
SO  - Endocr J. 2013 May 11.

PMID- 23665770
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1432-8798 (Electronic)
IS  - 0304-8608 (Linking)
DP  - 2013 May 12
TI  - Ljungan virus is endemic in rodents in the UK.
AB  - Ljungan virus is a recently identified member of the family Picornaviridae that
      was isolated from bank voles in Sweden. It has been shown to cause type 1
      diabetes-like symptoms and myocarditis in bank voles (Myodes glareolus), and it
      has been suggested that it has zoonotic potential. Here, we show for the first
      time that Ljungan virus is prevalent (20-27 % positive by PCR) in four species of
      UK rodent (Myodes glareolus [bank vole], Apodemus sylvaticus [wood mouse],
      Microtus agrestis [field vole] and Mus musculus [house mouse]). Sequence analysis
      showed that Ljungan virus of genotypes 1 and 2 were present, although genotype 1 
      was more prevalent and more frequently associated with brain tissue. This study
      highlights the prevalence of Ljungan virus in the UK and the need for
      confirmation of its zoonotic potential.
AD  - Department of Infection Biology, University of Liverpool, Liverpool Science Park 
      IC2, 146 Brownlow Hill, Liverpool, L3 5RF, UK.
FAU - Salisbury, Anne-Marie
AU  - Salisbury AM
FAU - Begon, Michael
AU  - Begon M
FAU - Dove, Winifred
AU  - Dove W
FAU - Niklasson, Bo
AU  - Niklasson B
FAU - Stewart, James P
AU  - Stewart JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Arch Virol
JT  - Archives of virology
JID - 7506870
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/13 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/05/12 [aheadofprint]
AID - 10.1007/s00705-013-1731-6 [doi]
PST - aheadofprint
SO  - Arch Virol. 2013 May 12.

PMID- 23665609
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 0974-7559 (Electronic)
IS  - 0019-6061 (Linking)
VI  - 50
IP  - 4
DP  - 2013 Apr 8
TI  - Glibenclamide for neonatal diabetes.
PG  - 428-9
AD  - Departments of Pediatrics and Adolescent Endocrinology, and *Endocrinology,
      Indraprastha Apollo Hospital, New Delhi, India. inderpal_kochar@yahoo.com.
FAU - Kochar, I Ps
AU  - Kochar IP
FAU - Jindal, Radhika
AU  - Jindal R
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian Pediatr
JT  - Indian pediatrics
JID - 2985062R
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PST - ppublish
SO  - Indian Pediatr. 2013 Apr 8;50(4):428-9.

PMID- 23665587
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 May 10
TI  - Calorimetric analysis of the plasma proteome: Identification of type 1 diabetes
      patients with early renal function decline.
LID - S0304-4165(13)00203-1 [pii]
LID - 10.1016/j.bbagen.2013.05.007 [doi]
AB  - BACKGROUND: Microalbuminuria (MA) has been questioned as a predictor of
      progressive renal dysfunction in patients with type 1 diabetes (T1D).
      Consequently, new clinical end points are needed that identify or predict
      patients that are at risk for early renal function decline (ERFD). The potential 
      clinical utility of differential scanning calorimetry (DSC) analysis of blood
      plasma and other biofluids has recently been reported. This method provides an
      alternate physical basis with which to study disease-associated changes in the
      bulk plasma proteome. METHODS: DSC analysis of blood plasma was applied to
      identify unique signatures of ERFD in subjects enrolled in the 1st Joslin Study
      of the Natural History of Microalbuminuria in Type 1 Diabetes, a prospective
      cohort study of T1D patients. Recent data suggests that differences in the plasma
      peptidome of these patients correlate with longitudinal measures of renal
      function. Differences in DSC profile (thermogram) features were evaluated between
      T1D MA individuals exhibiting ERFD (n=15) and matched control subjects (n=14).
      RESULTS: The average control group thermogram resembled a previously defined
      healthy thermogram. Differences were evident between ERFD and control
      individuals. Heat capacity values of the main two transitions were found to be
      significant discriminators of patient status. CONCLUSIONS: Results from this
      pilot study suggest the potential utility of DSC proteome analysis to prognostic 
      indicators of renal disease in T1D. GENERAL SIGNIFICANCE: DSC shows sensitivity
      to changes in the bulk plasma proteome that correlate with clinical status in T1D
      providing additional support for the utility of DSC profiling in clinical
      diagnostics.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - James Graham Brown Cancer Center, University of Louisville Health Sciences
      Center, Louisville, KY 40202, USA. Electronic address:
      nichola.garbett@louisville.edu.
FAU - Garbett, Nichola C
AU  - Garbett NC
FAU - Merchant, Michael L
AU  - Merchant ML
FAU - Chaires, Jonathan B
AU  - Chaires JB
FAU - Klein, Jon B
AU  - Klein JB
LA  - ENG
GR  - R01 DK067638/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/28 [received]
PHST- 2013/04/29 [revised]
PHST- 2013/05/02 [accepted]
AID - S0304-4165(13)00203-1 [pii]
AID - 10.1016/j.bbagen.2013.05.007 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 May 10. pii: S0304-4165(13)00203-1. doi:
      10.1016/j.bbagen.2013.05.007.

PMID- 23665564
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 May 12
TI  - Reinterpreting the action of ATP analogs on KATP channels.
AB  - Neuroendocrine-type KATP channels, (SUR1/Kir6.2)4, couple the transmembrane flux 
      of K+, and thus membrane potential, with cellular metabolism in various cell
      types including insulin secreting beta-cells. Mutant channels with reduced
      activity are a cause of congenital hyperinsulinism, while hyperactive channels
      are a cause of neonatal diabetes (ND). A current regulatory model proposes that
      ATP hydrolysis is required to switch SUR1 into post-hydrolytic conformations able
      to antagonize the inhibitory action of nucleotide binding at the Kir6.2 pore thus
      coupling enzymatic and channel activities. Alterations in SUR1 ATPase activity
      are proposed to contribute to ND and type 2 diabetes risk. The regulatory model
      is partly based on the reduced ability of ATP analogs like AMP-PNP and ATPgammaS 
      to stimulate channel activity, presumably by reducing hydrolysis. This study uses
      a substitution at the catalytic glutamate, SUR1E1507Q, with a significantly
      increased affinity for ATP, to probe the action of these ATP analogs on
      conformational switching. ATPgammaS, a slowly hydrolysable analog, switches SUR1 
      conformations, albeit with reduced affinity. Non-hydrolysable AMP-PNP and AMP-PCP
      alone fail to switch SUR1, but do reverse ATP-induced switching. AMP-PCP
      displaces [32P] 8-azido ATP from the non-canonical Nucleotide-Binding-Domain-1
      (NBD1) of SUR1. This is consistent with structural data on an asymmetric
      bacterial ABC protein that shows AMP-PNP binds selectively to the non-canonical
      NBD to prevent conformational switching. The results imply AMP-PxP fail to
      activate KATP channels because they do not support NBD dimerization and
      conformational switching, rather than by limiting enzymatic activity.
AD  - Pacific Northwest Diabetes Research Institute, United States;
FAU - Ortiz, David
AU  - Ortiz D
FAU - Gossack, Lindsay
AU  - Gossack L
FAU - Quast, Ulrich
AU  - Quast U
FAU - Bryan, Joseph
AU  - Bryan J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - ABC Transporter
OT  - ABCC8
OT  - ATP Analogs
OT  - Allosteric regulation
OT  - KATP Channels
OT  - Ligand binding protein
OT  - Neonatal Diabetes
OT  - Nucleoside nucleotide analogs
OT  - Potassium channels
OT  - Sulfonylureas
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - M113.476887 [pii]
AID - 10.1074/jbc.M113.476887 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 May 12.

PMID- 23665535
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 May 10
TI  - Improvement of Insulin Resistance Following Transsphenoidal Surgery in Patients
      with Acromegaly: Correlation with Serum IGF-1 Levels.
AB  - Aim: The aim of this study was to determine the correlation between the growth
      hormone (GH)-insulin-like growth factor-1 (IGF-1) axis and glucose intolerance in
      acromegaly during the early postoperative period. Subjects and Methods: The study
      included 20 patients with acromegaly caused by GH-secreting pituitary adenoma who
      received transsphenoidal surgery in our hospital. Glucose tolerance was evaluated
      with oral glucose tolerance tests (OGTTs) performed pre- and early postoperative 
      periods (9 [7-18] days after surgery). Homeostasis model assessment of insulin
      resistance (HOMA-R) and insulinogenic index (IGI) were calculated, and
      correlation analyses were performed between these values and the GH- IGF-1 axis. 
      Patients were divided according to postoperative changes of the axis, and glucose
      tolerance was compared between the groups. Results: In preoperative OGTTs, nine
      patients had impaired glucose tolerance and two had diabetes mellitus patterns.
      Postoperatively, significant reduction was observed both in fasting plasma
      glucose levels (p < 0.01) and in HOMA-R (p < 0.01), whereas IGI showed no
      significant change. HOMA-R was significantly correlated with serum IGF-1 levels
      both before (r = 0.83, p < 0.01) and after (r = 0.57, p < 0.01) surgery, although
      it was not correlated with serum GH levels. Patients who achieved more than 50%
      postoperative reduction in serum IGF-1 levels showed significant improvement in
      OGTTs results (p < 0.05). Conclusions: In patients with acromegaly, serum IGF-1
      levels, but not GH levels, were significantly correlated with insulin resistance.
      Early postoperative improvement of glucose tolerance is observed in patients who 
      achieved postoperative reduction in serum IGF-1 levels.
AD  - Center for Diabetes and Endocrinology, The Tazuke Kofukai Foundation Medical
      Research Institute Kitano Hospital, Osaka, Japan.
FAU - Mori, K
AU  - Mori K
FAU - Iwasaki, Y
AU  - Iwasaki Y
FAU - Kawasaki-Ogita, Y
AU  - Kawasaki-Ogita Y
FAU - Honjo, S
AU  - Honjo S
FAU - Hamamoto, Y
AU  - Hamamoto Y
FAU - Tatsuoka, H
AU  - Tatsuoka H
FAU - Fujimoto, K
AU  - Fujimoto K
FAU - Ikeda, H
AU  - Ikeda H
FAU - Wada, Y
AU  - Wada Y
FAU - Takahashi, Y
AU  - Takahashi Y
FAU - Takahashi, J
AU  - Takahashi J
FAU - Koshiyama, H
AU  - Koshiyama H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 8964 [pii]
AID - 10.3275/8964 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 May 10.

PMID- 23665496
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 713
IP  - 1-3
DP  - 2013 May 9
TI  - Pentamethylquercetin ameliorates fibrosis in diabetic Goto-Kakizaki rat kidneys
      and mesangial cells with suppression of TGF-beta/Smads signaling.
PG  - 6-15
LID - S0014-2999(13)00351-8 [pii]
LID - 10.1016/j.ejphar.2013.04.045 [doi]
AB  - Pentamethylquercetin (PMQ) has been shown to possess glucose-lowering properties,
      but its effect on renal fibrosis in diabetes is still unclear. This study was
      designed to investigate the effect of PMQ on renal fibrosis and the underlying
      mechanisms in spontaneous type II diabetic Goto-Kakizaki rats and mesangial cells
      in high glucose. We found that in Goto-Kakizaki rats, PMQ treatment attenuated
      glomerular volume, glycogen deposition, renal collagen and fibronectin
      accumulation, in addition to amelioration of diabetic symptoms, including
      reduction of urine volume and urine glucose levels. In mesangial cells, PMQ
      remarkably inhibited the cell proliferation and total collagen accumulation, and 
      suppressed cell hypertrophy. Further experiments showed that PMQ treatment
      down-regulated the expression of TGF-beta1, up-regulated Smad7 and inhibited
      Smad2/3 activation in vivo and vitro. Our results demonstrated that PMQ
      ameliorated renal fibrosis in diabetes, which may be associated with suppressed
      TGF-beta/Smads signaling.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Pharmacology, Tongji Medical College, Huazhong University of
      Science and Technology, 13 Hangkong Road, Wuhan 430030, China; The Key Laboratory
      for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province,
      Wuhan, China.
FAU - Xin, Xin
AU  - Xin X
FAU - Li, Xian-Hui
AU  - Li XH
FAU - Wu, Jian-Zhao
AU  - Wu JZ
FAU - Chen, Kui-Hao
AU  - Chen KH
FAU - Liu, Yi
AU  - Liu Y
FAU - Nie, Chun-Jie
AU  - Nie CJ
FAU - Hu, Yan
AU  - Hu Y
FAU - Jin, Man-Wen
AU  - Jin MW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/22 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/04/26 [accepted]
AID - S0014-2999(13)00351-8 [pii]
AID - 10.1016/j.ejphar.2013.04.045 [doi]
PST - aheadofprint
SO  - Eur J Pharmacol. 2013 May 9;713(1-3):6-15. doi: 10.1016/j.ejphar.2013.04.045.

PMID- 23665494
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 713
IP  - 1-3
DP  - 2013 May 9
TI  - Male hypogonadism induced by high fat diet and low dose streptozotocin is
      mediated by activated endoplasmic reticulum stress and IkappaBbeta and attenuated
      by argirein and valsartan.
PG  - 78-88
LID - S0014-2999(13)00335-X [pii]
LID - 10.1016/j.ejphar.2013.04.030 [doi]
AB  - Male hypogonadism is frequently accompanied with type 2 diabetes due to
      testicular dysfunction, but the origin of the pathogenesis is not known. We
      measured whether pro-inflammatory factors including endoplasmic reticulum (ER)
      stress chaperones and inhibitory kappaBbeta (IkappaBbeta) contribute to testis
      damage in type 2 diabetic rats produced by a high-fat diet (HFD) and low dose
      streptozotocin (STZ). We determined whether these can be attenuated by the
      anti-inflammatory activity of argirein a derivative of rhein as compared to
      valsartan. Reduced testosterone and LH (luteinizing hormone) levels in serum were
      significant in association with a decrease in the levels of mRNA and
      steroidogenic acute regulatory protein (StAR), insulin receptor substrate
      (IRS-1), activated IkappaBbeta and ER stress chaperone C/EBP homologous protein
      (CHOP) in the diabetic testis and sperm count, motility and sexual behaviors were
      reduced in vivo. Additionally, Leydig cells cultured with high glucose showed
      upregulated IkappaBbeta, ER stress sensor PERK (PKR-like ER kinase) and p-Akt/Akt
      in vitro. These changes may be due to a component of inflammation linked to
      activated NADPH oxidase and were significantly alleviated by either argirein or
      valsartan. In conclusion, diabetic testopathy induced by a HFD and low STZ is
      characterized by an entity of inflammation and is alleviated by argirein and
      valsartan through normalizing activated IkappaBbeta and ER stress.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Research Division of Pharmacology, China Pharmaceutical University, Nanjing
      210009, China.
FAU - Liu, Gui-Lai
AU  - Liu GL
FAU - Zhang, Yu-Mao
AU  - Zhang YM
FAU - Dai, De-Zai
AU  - Dai DZ
FAU - Ding, Ming-Jian
AU  - Ding MJ
FAU - Cong, Xiao-Dong
AU  - Cong XD
FAU - Dai, Yin
AU  - Dai Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/08/19 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/04/26 [accepted]
AID - S0014-2999(13)00335-X [pii]
AID - 10.1016/j.ejphar.2013.04.030 [doi]
PST - aheadofprint
SO  - Eur J Pharmacol. 2013 May 9;713(1-3):78-88. doi: 10.1016/j.ejphar.2013.04.030.

PMID- 23665486
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1872-8278 (Electronic)
IS  - 1567-7249 (Linking)
DP  - 2013 May 9
TI  - Lipidomic characterization of streptozotocin-induced heart mitochondrial
      dysfunction.
LID - S1567-7249(13)00075-5 [pii]
LID - 10.1016/j.mito.2013.05.001 [doi]
AB  - Myocardial mitochondria dysfunction seems to represent an important pathogenic
      factor underlying cardiomyopathy, a common complication of type 1 diabetes
      mellitus (T1DM). Despite significant progress in the understanding of the
      molecular mechanisms of mitochondrial function in the heart, the interplay
      between phospholipids and membrane proteins of this organelle is still poorly
      comprehended. Using a well-characterized animal model of T1DM obtained by the
      administration of streptozotocin, phospholipid profiling of isolated mitochondria
      was performed using MS-based approaches, which was analyzed together with
      oxidative phosphorylation (OXPHOS) complexes activities and their susceptibility 
      to oxidation, and the expression of cytochrome c, the uncoupling protein UCP-3
      and the mitochondrial transcription factor Tfam. Although in higher amounts,
      mitochondria from T1DM heart presented lower OXPHOS activity and lower
      transcription ability. This profile was related to phospholipid (PL) remodeling
      characterized by higher phosphatidylcholine levels, lower phosphatidylglycerol,
      phosphatidylinositol and sphingomyelin content, higher amounts of long fatty acyl
      side chains and increased lipid peroxidation, particularly of cardiolipin (CL).
      CL peroxidation was paralleled by lower cytochrome c content. Though in higher
      levels, UCP-3 does not seem to protect heart mitochondrial PL and membrane
      proteins from the oxidative damage induced by four weeks of hyperglycemia. Taken 
      together, our data suggest that PL remodeling of heart mitochondria is an early
      event in T1DM pathogenesis and is related with OXPHOS dysfunction.
CI  - Copyright (c) 2013 (c) Elsevier B.V. and Mitochondria Research Society. All
      rights reserved. Published by Elsevier B.V. All rights reserved.
AD  - QOPNA, Department of Chemistry, University of Aveiro, Aveiro, Portugal.
      Electronic address: ritaferreira@ua.pt.
FAU - Ferreira, Rita
AU  - Ferreira R
FAU - Guerra, Gabriela
AU  - Guerra G
FAU - Padrao, Ana Isabel
AU  - Padrao AI
FAU - Melo, Tania
AU  - Melo T
FAU - Vitorino, Rui
AU  - Vitorino R
FAU - Duarte, Jose Alberto
AU  - Duarte JA
FAU - Remiao, Fernando
AU  - Remiao F
FAU - Domingues, Pedro
AU  - Domingues P
FAU - Amado, Francisco
AU  - Amado F
FAU - Domingues, M Rosario
AU  - Domingues MR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Mitochondrion
JT  - Mitochondrion
JID - 100968751
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/16 [received]
PHST- 2013/03/27 [revised]
PHST- 2013/05/02 [accepted]
AID - S1567-7249(13)00075-5 [pii]
AID - 10.1016/j.mito.2013.05.001 [doi]
PST - aheadofprint
SO  - Mitochondrion. 2013 May 9. pii: S1567-7249(13)00075-5. doi:
      10.1016/j.mito.2013.05.001.

PMID- 23665469
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 74C
DP  - 2013 May 7
TI  - Homocysteine is a novel risk factor for suboptimal response of blood platelets to
      acetylsalicylic acid in coronary artery disease: A randomized multicenter study.
PG  - 7-22
LID - S1043-6618(13)00084-4 [pii]
LID - 10.1016/j.phrs.2013.04.010 [doi]
AB  - The incomplete inhibition of platelet function by acetylsalicylic acid (ASA),
      despite the patients are receiving therapeutic doses of the drug
      ('aspirin-resistance'), is caused by numbers of risk factors. In this study we
      verified the idea that plasma homocysteine (Hcy) contributes to
      'aspirin-resistance' in patients with coronary artery disease (CAD) and with or
      without type 2 diabetes mellitus (T2DM). A cross-designed randomized controlled
      intervention study has been performed (126 CAD pts incl. 26 with T2DM) to
      determine whether increasing ASA dose from 75mg to 150mg daily may result in the 
      increased antiplatelet effect, in the course of four-week treatment. Platelet
      response to collagen (coll) or arachidonic acid (AA) was monitored with whole
      blood aggregometry, plasma thromboxane (Tx), and Hcy levels were determined
      immunochemically. The ASA-mediated reductions in platelet response to coll (by
      12+/-3%) or AA (by 10+/-3%) and in plasma Tx (by 20+/-9%; p<0.02 or less) were
      significantly greater for higher ASA dose and significantly correlated with
      plasma Hcy, which was significantly lower in "good" ASA responders compared to
      "poor" responders (p<0.001). Higher plasma Hcy appeared a significant risk factor
      for blood platelet refractoriness to low ASA dose (OR=1.11; +/-95%CI: 1.02-1.20, 
      p<0.02, adjusted to age, sex and CAD risk factors). Hcy diminished in vitro
      antiplatelet effect of low ASA concentration and augmented platelet aggregation
      (by up to 62% (p<0.005) for coll and up to 15% (p<0.005) for AA), whereas its
      acetyl derivative acted oppositely. Otherwise, Hcy intensified antiplatelet
      action of high ASA. Hyperhomocysteinaemia may be a novel risk factor for the
      suppressed blood platelet response to ASA, and homocysteine may act as a specific
      sensitizer of blood platelets to some agonists. While homocysteine per se acts as
      a proaggregatory agent to blood platelets, its acetylated form is able to reverse
      this effect. Thus, these findings reveal a possibly new challenging potential of 
      the acetylating properties of ASA therapy.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Haemostatic Disorders, Medical University of Lodz, 113 Zeromski
      Street, 90-549 Lodz, Poland. Electronic address: kamil.karolczak@umed.lodz.pl.
FAU - Karolczak, Kamil
AU  - Karolczak K
FAU - Kamysz, Wojciech
AU  - Kamysz W
FAU - Karafova, Anna
AU  - Karafova A
FAU - Drzewoski, Jozef
AU  - Drzewoski J
FAU - Watala, Cezary
AU  - Watala C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Pharmacol Res
JT  - Pharmacological research : the official journal of the Italian Pharmacological
      Society
JID - 8907422
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/28 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/04/25 [accepted]
AID - S1043-6618(13)00084-4 [pii]
AID - 10.1016/j.phrs.2013.04.010 [doi]
PST - aheadofprint
SO  - Pharmacol Res. 2013 May 7;74C:7-22. doi: 10.1016/j.phrs.2013.04.010.

PMID- 23665451
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1873-2399 (Electronic)
IS  - 0301-472X (Linking)
DP  - 2013 May 9
TI  - Efficient transduction of human hematopoietic repopulating cells with a chimeric 
      HIV1-based vector including SIV capsid.
LID - S0301-472X(13)00206-3 [pii]
LID - 10.1016/j.exphem.2013.04.014 [doi]
AB  - OBJECTIVE: Innate immune factors, such as TRIM5alpha and cyclophilin A (CypA),
      act as a major restriction factor of retroviral infection among species. When
      HIV1 infects human cells, HIV1 capsid binds to human CypA to escape from human
      TRIM5alpha restriction. However, in rhesus cells, the mismatch between HIV1
      capsid and rhesus CypA is recognized by rhesus TRIM5alpha to reduce HIV1
      infectivity through proteasomal degradation. To circumvent this block, we
      previously developed a chimeric HIV1 vector (chiHIV) which substituted HIV1
      capsid with SIV capsid, and it significantly increased transduction efficiency
      for non-human primate cells. In this study, we evaluated whether the chiHIV
      vector efficiently transduces human cells, and the transduction efficiency might 
      increase by a CypA inhibitor (cyclosporine) and a proteasome inhibitor (MG132).
      RESULTS: The chiHIV vector could transduce human CD34+ cells, as efficiently as
      the HIV1 vector, in vitro and in xenograft mice, even in the mismatch between SIV
      capsid and human CypA. Cyclosporine decreased transduction efficiency with the
      HIV1 vector, while it slightly increased transduction efficiency with the chiHIV 
      vector in human CD34+ cells. MG132 increased transduction efficiency with both
      chiHIV and HIV1 vectors in the same manner. However, MG132 was toxic to human
      CD34+ cells at high concentrations, and both drugs had a small range of effective
      dosage. CONCLUSIONS: These findings demonstrate that both chiHIV and HIV1 vectors
      have similar transduction efficiency for human hematopoietic repopulating cells, 
      and suggest that the chiHIV vector escapes from TRIM5alpha restriction, which is 
      independent of human CypA.
CI  - Copyright (c) 2013 ISEH - Society for Hematology and Stem Cells. Published by
      Elsevier Inc. All rights reserved.
AD  - Molecular and Clinical Hematology Branch, National Heart Lung and Blood Institute
      (NHLBI) / National Institute of Diabetes and Digestive and Kidney Diseases
      (NIDDK), National Institutes of Health (NIH), Bethesda, Maryland USA.
FAU - Uchida, Naoya
AU  - Uchida N
FAU - Hsieh, Matthew M
AU  - Hsieh MM
FAU - Washington, Kareem N
AU  - Washington KN
FAU - Tisdale, John F
AU  - Tisdale JF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Exp Hematol
JT  - Experimental hematology
JID - 0402313
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/07 [received]
PHST- 2013/03/05 [revised]
PHST- 2013/04/03 [accepted]
AID - S0301-472X(13)00206-3 [pii]
AID - 10.1016/j.exphem.2013.04.014 [doi]
PST - aheadofprint
SO  - Exp Hematol. 2013 May 9. pii: S0301-472X(13)00206-3. doi:
      10.1016/j.exphem.2013.04.014.

PMID- 23665415
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1872-7786 (Electronic)
IS  - 0009-2797 (Linking)
VI  - 204
IP  - 2
DP  - 2013 May 9
TI  - Alterations in hepatic metabolism of sulfur amino acids in non-obese type-2
      diabetic Goto-Kakizaki rats.
PG  - 80-87
LID - S0009-2797(13)00100-2 [pii]
LID - 10.1016/j.cbi.2013.04.014 [doi]
AB  - Elevated plasma homocysteine has been identified as a risk factor for
      cardiovascular disease and non-alcoholic liver disease, which are major
      complications of diabetes. Hence, hepatic homocysteine metabolism has become a
      major focus of diabetes research. However, little information is available
      regarding plasma homocysteine levels in non-obese diabetic animals. Therefore, we
      investigated the hepatic metabolism of sulfur-amino acids in non-obese type-2
      diabetic Goto-Kakizaki rats. The experiments were performed using 9-week-old
      Goto-Kakizaki rats and age-matched Wistar rats. The major finding of this study
      is that homocysteine levels in the liver and plasma are maintained by a balance
      between the up-regulation of betaine homocysteine methyltransferase and the
      inhibition of cystathionine beta-synthase in non-obese type-2 diabetic rats.
      Hepatic levels of cysteine and its metabolites, such as hypotaurine, taurine, and
      glutathione, were increased despite inhibition of the transsulfuration of
      homocysteine to cysteine. The elevated hepatic taurine and glutathione levels may
      be attributed to the up-regulation of cysteine dioxygenase expression and
      increased cysteine availability for glutathione synthesis. Inhibition of hepatic 
      methionine adenosyltransferase activity in Goto-Kakizaki rats was associated with
      a decrease in hepatic S-adenosylmethionine, which serves as an allosteric
      activator of cystathionine beta-synthase. The non-obese type-2 diabetic condition
      results in profound changes in hepatic sulfur-amino acid metabolism and raises
      the possibility that sulfur-amino acid metabolism may be regulated by obesity- as
      well as diabetes-associated factors. Further study to elucidate the pathological 
      significance of sulfur-amino acid metabolism in chronic liver disease in type-2
      diabetic animals is underway in this laboratory.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - Department of Pathology, Wayne State University, School of Medicine, Detroit, MI 
      48201, United States.
FAU - Jung, Young Suk
AU  - Jung YS
FAU - Yun, Kang Uk
AU  - Yun KU
FAU - Ryu, Chang Seon
AU  - Ryu CS
FAU - Oh, Jung Min
AU  - Oh JM
FAU - Kwak, Hui Chan
AU  - Kwak HC
FAU - Lee, Ji-Yoon
AU  - Lee JY
FAU - Park, Song-Kyu
AU  - Park SK
FAU - Kim, Bong Hee
AU  - Kim BH
FAU - Oh, Soo Jin
AU  - Oh SJ
FAU - Kim, Sang Kyum
AU  - Kim SK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/12/31 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/04/28 [accepted]
AID - S0009-2797(13)00100-2 [pii]
AID - 10.1016/j.cbi.2013.04.014 [doi]
PST - aheadofprint
SO  - Chem Biol Interact. 2013 May 9;204(2):80-87. doi: 10.1016/j.cbi.2013.04.014.

PMID- 23665412
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
DP  - 2013 May 9
TI  - Statins modulate feedback regulation mechanisms between advanced glycation
      end-products and C-reactive protein: Evidence in patients with acute myocardial
      infarction.
LID - S0928-0987(13)00175-9 [pii]
LID - 10.1016/j.ejps.2013.05.001 [doi]
AB  - OBJECTIVE: High sensitivity C-reactive protein (hsCRP) and advanced glycation
      end-products (AGEs) have been proposed as mediators in inflammation and
      atherosclerosis. Therefore, we studied the relation between AGE and hsCRP in
      patients with acute myocardial infarction (AMI). METHODS: Patients with AMI
      diagnosis and satisfying our inclusion criteria were included during 2009-2011 in
      an unicentre registry of AMI patients for a cross-sectional study. The final
      cohort was composed of 156 patients (46.2% STEMI and 27.6% with type-2 diabetes).
      AGE and hsCRP were measured in plasma. RESULTS: Diabetic patients were older than
      non-diabetics (68.6+/-10.6 vs. 60.4+/-13.9years; p<0.05), presented more
      incidence of hypertension (62.8 vs. 36.3%; p<0.05) and were in a higher Killip
      class (p<0.05). The mean values of fluorescent AGE and hsCRP levels were
      61.3+/-49.8 AU and 2.4+/-4.0mg/L, respectively, and there were no differences in 
      these parameters between diabetic and non-diabetic patients. A direct association
      between AGE and hsCRP levels was observed, mainly in diabetic patients (r=0.258; 
      p=0.018). Importantly, this association disappeared in patients who had been
      treated with statins before their AMI (r=-0.055; p=0.845), but it was maintained 
      in non-diabetic patients naive for statins treatment (r=0.634; p<0.001),
      independently of other treatments and confounding parameters. CONCLUSIONS: This
      is the first evidence in humans of a feedback regulation mechanism between CRP
      and the AGE-RAGE axis modulated by statins.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Instituto de Investigacion Sanitaria de Santiago de Compostela, Santiago de
      Compostela, Spain.
FAU - Paradela-Dobarro, Beatriz
AU  - Paradela-Dobarro B
FAU - Raposeiras-Roubin, Sergio
AU  - Raposeiras-Roubin S
FAU - Rodino-Janeiro, Bruno K
AU  - Rodino-Janeiro BK
FAU - Grigorian-Shamagian, Lilian
AU  - Grigorian-Shamagian L
FAU - Garcia-Acuna, Jose M
AU  - Garcia-Acuna JM
FAU - Aguiar-Souto, Pablo
AU  - Aguiar-Souto P
FAU - Jacquet-Hervet, Michel
AU  - Jacquet-Hervet M
FAU - Reino-Maceiras, Maria V
AU  - Reino-Maceiras MV
FAU - Gonzalez-Juanatey, Jose R
AU  - Gonzalez-Juanatey JR
FAU - Alvarez, Ezequiel
AU  - Alvarez E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European
      Federation for Pharmaceutical Sciences
JID - 9317982
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/22 [received]
PHST- 2013/05/01 [accepted]
AID - S0928-0987(13)00175-9 [pii]
AID - 10.1016/j.ejps.2013.05.001 [doi]
PST - aheadofprint
SO  - Eur J Pharm Sci. 2013 May 9. pii: S0928-0987(13)00175-9. doi:
      10.1016/j.ejps.2013.05.001.

PMID- 23665365
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 May 8
TI  - Glycemic Control and Risk of Cardiovascular Disease Hospitalization and All-Cause
      Mortality.
LID - S0735-1097(13)01792-0 [pii]
LID - 10.1016/j.jacc.2013.04.031 [doi]
AB  - OBJECTIVE: This study evaluated the relationship between glycemic control and
      cardiovascular disease (CVD) hospitalizations and all-cause mortality among type 
      2 diabetes patients in a real-world setting. BACKGROUND: Clinical trials have not
      established that tight glycemic control reduces CVD events and may be associated 
      with increased mortality. Observational studies of specific cohorts have reported
      increased risk of those outcomes at both high and low glycated hemoglobin (A1C)
      levels. METHODS: Using the mean of all A1C measures over mean follow-up of 6
      years, we created categories of A1C (<6%, 6%-6.4%, 6.5%-6.9%, 7%-7.4%, 7.5%-7.9%,
      8%-8.4%, 8.5%-8.9%, >9.0% to estimate the risk of CVD hospitalization and
      all-cause mortality associated with glycemic control adjusting for demographic
      and clinical characteristics among 26,646 members of Kaiser Permanente Northwest 
      with type 2 diabetes. RESULTS: Compared with patients with mean A1C 7.0%-7.4%,
      those with mean A1C <6.0% had a 75% increased risk of CVD hospitalization (hazard
      ratio [HR] 1.68, 95% CI 1.39-2.04, p<0.001) after adjustment for demographic and 
      clinical characteristics. Those with A1C 6.0%-6.4% (1.18, 1.00-1.40, p=0.048) and
      6.5%-6.9% (1.18, 1.02-1.37, p=0.031) also had significantly higher risk relative 
      to the reference group of 7.0%-7.4%, as did patients with A1C 8.5%-8.9% (HR 1.55,
      1.24-1.94, p<0.001) and >9.0% (HR 1.83, 1.50-2.22, p<0.001). Risk of all-cause
      mortality was significantly greater than the reference group among A1C categories
      <6.0%, 6.0%-6.4%, 6.5%-6.9%, and >9.0%. CONCLUSION: The relationship between mean
      A1C and CVD hospitalizations and all-cause mortality is U-shaped, with greater
      risk at both higher and lower A1C levels.
CI  - Copyright (c) 2013 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
AD  - Kaiser Permanente Center for Health Research, Portland, Oregon. Electronic
      address: greg.nichols@kpchr.org.
FAU - Nichols, Gregory A
AU  - Nichols GA
FAU - Joshua-Gotlib, Sandra
AU  - Joshua-Gotlib S
FAU - Parasuraman, Shreekant
AU  - Parasuraman S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/12/10 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/04/07 [accepted]
AID - S0735-1097(13)01792-0 [pii]
AID - 10.1016/j.jacc.2013.04.031 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 May 8. pii: S0735-1097(13)01792-0. doi:
      10.1016/j.jacc.2013.04.031.

PMID- 23665301
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1527-3792 (Electronic)
IS  - 0022-5347 (Linking)
DP  - 2013 May 8
TI  - Risk Factors for Renal Cell Carcinoma in the Vitamin and Lifestyle (VITAL) Study.
LID - S0022-5347(13)04319-X [pii]
LID - 10.1016/j.juro.2013.04.130 [doi]
AB  - PURPOSE: The incidence of renal cell carcinoma (RCC) is increasing worldwide.
      Cited risk factors include obesity, smoking and hypertension, but few others have
      been confirmed by prospective studies. We used a prospective cohort to validate
      established RCC risk factors and to evaluate more controversial risk factors for 
      incident RCC. MATERIALS/METHODS: 77,260 residents of Washington aged 50-76 years 
      completed a questionnaire between 2000-2002 on demographic, lifestyle and health 
      data. Incident RCC cases were determined through linkage to the regional cancer
      registry through Dec 31, 2009. Multivariate methods using covariates and cut offs
      selecteda priori analyzed the association between RCC and previously studied
      factors related to lifestyle (body mass index [BMI], smoking,
      alcohol/fruit/vegetable consumption) and health (hypertension, diabetes, kidney
      disease, viral hepatitis). RESULTS: There were 249 incident cases of RCC.
      Independent RCC risk factors in the fully adjusted model with HR and 95% CIs
      were: BMI (HR 1.71, CI 1.06, 2.79, for >=35 kg/m2 vs. <25 kg/m2), smoking (HR
      1.67, CI 1.16, 2.42, for >=37.5 pack-years vs. none), hypertension (HR 1.70, CI
      1.30, 2.22), kidney disease (HR 2.58, CI 1.21, 5.50), viral hepatitis (HR 1.80,
      CI 1.03, 3.14). Diabetes was associated with RCC (HR 1.83, CI 1.26, 2.65) in a
      base model adjusting for age and gender, but not in the multivariate model. We
      found no association between alcohol, fruit, or vegetable intake and RCC.
      CONCLUSIONS: We identified significant association between RCC and obesity,
      smoking, hypertension, renal disease and viral hepatitis. Identification of risk 
      factors offers an opportunity for targeted education and intervention.
CI  - Copyright (c) 2013 American Urological Association Education and Research, Inc.
      Published by Elsevier Inc. All rights reserved.
AD  - University of Washington Medical Center, Department of Urology, 1959 NE Pacific
      St., BB-1121, Seattle WA 98195, phone 206.535.5886 or 206.685.1982, fax
      206.543.3272.
FAU - Macleod, Liam C
AU  - Macleod LC
FAU - Hotaling, James M
AU  - Hotaling JM
FAU - Wright, Jonathan L
AU  - Wright JL
FAU - Davenport, Michael T
AU  - Davenport MT
FAU - Gore, John L
AU  - Gore JL
FAU - Harper, Jonathan
AU  - Harper J
FAU - White, Emily
AU  - White E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/04/29 [accepted]
AID - S0022-5347(13)04319-X [pii]
AID - 10.1016/j.juro.2013.04.130 [doi]
PST - aheadofprint
SO  - J Urol. 2013 May 8. pii: S0022-5347(13)04319-X. doi: 10.1016/j.juro.2013.04.130.

PMID- 23665299
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1095-8304 (Electronic)
IS  - 0195-6663 (Linking)
VI  - 68C
DP  - 2013 May 9
TI  - Food label education does not reduce sodium intake in people with type 2 diabetes
      mellitus. A randomised controlled trial.
PG  - 147-151
LID - S0195-6663(13)00191-8 [pii]
LID - 10.1016/j.appet.2013.04.028 [doi]
AB  - BACKGROUND: Sodium intake is high in people with type 2 diabetes (T2DM). The aim 
      of this study was to investigate whether urinary sodium excretion can be reduced 
      by educating people with T2DM to read food labels and choose low sodium products.
      METHOD: In a 3month randomised controlled trial, 78 men (n=49) and women (n=29)
      with T2DM were recruited from a Diabetes Centre at a University teaching
      hospital. The intervention group was educated in a single session to use the
      nutrition information panel on food labels to choose products which complied with
      the Food Standards Australia New Zealand (FSANZ) guideline of <120mg sodium/100g 
      food. The control group continued on their usual diet. The primary outcome
      measure was 24h urinary sodium excretion which was performed at baseline and
      3months. Data was analysed using repeated measures analysis of variance,
      independent samples t-test and Pearson's correlations. RESULTS: At 3months mean
      urinary sodium excretion was unchanged in the intervention (174+/-13mmol/24h and 
      175+/-13mmol/24h) and control group (167+/-15mmol/24h and 161+/-13mmol/24h), and 
      there was no between group difference (p>0.05). CONCLUSION: Sodium excretion was 
      not reduced following the label reading education provided to this group of
      people with T2DM.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Nutrition and Dietetics, School of Medicine, Flinders University, Australia;
      University of South Australia, School of Pharmacy and Medical Sciences, Division 
      of Health Sciences, GPO Box 2471, Adelaide, SA 5000, Australia.
FAU - Petersen, Kristina S
AU  - Petersen KS
FAU - Torpy, David J
AU  - Torpy DJ
FAU - Chapman, Ian M
AU  - Chapman IM
FAU - Guha, Sanghamitra
AU  - Guha S
FAU - Clifton, Peter M
AU  - Clifton PM
FAU - Turner, Kirsty
AU  - Turner K
FAU - Keogh, Jennifer B
AU  - Keogh JB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Appetite
JT  - Appetite
JID - 8006808
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/10 [received]
PHST- 2013/04/29 [revised]
PHST- 2013/04/30 [accepted]
AID - S0195-6663(13)00191-8 [pii]
AID - 10.1016/j.appet.2013.04.028 [doi]
PST - aheadofprint
SO  - Appetite. 2013 May 9;68C:147-151. doi: 10.1016/j.appet.2013.04.028.

PMID- 23665288
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1600-0641 (Electronic)
IS  - 0168-8278 (Linking)
DP  - 2013 May 8
TI  - A systematic review of follow-up biopsies reveals disease progression in patients
      with non-alcoholic fatty liver.
LID - S0168-8278(13)00282-1 [pii]
LID - 10.1016/j.jhep.2013.04.027 [doi]
AB  - BACKGROUND & AIMS: Disease progression in nonalcoholic fatty liver disease
      (NAFLD) is not well understood and there is controversy whether nonalcoholic
      fatty liver (NAFL, i.e. steatosis alone or with mild inflammation not qualifying 
      for steatohepatitis) can evolve towards steatohepatitis (NASH) with fibrosis.
      METHODS: We reviewed 70 patients with untreated NAFLD and with two biopsies
      performed more than one year apart. Clinical and biological data were recorded at
      the time of both biopsies. Alcohol consumption did not change during follow-up.
      RESULTS: Initially 25 patients had NAFL and 45 had NASH and/or advanced fibrosis.
      After a mean follow-up of 3.7 years (s.d. 2.1), 16 NAFL patients developed NASH, 
      eight with severe ballooning and six with bridging fibrosis on the follow-up
      biopsy. Patients with mild lobular inflammation or any degree of fibrosis were at
      higher risk of progression than those with steatosis alone. Those with
      unambiguous disease progression were older and had worsening of their metabolic
      risk factors (higher weight and more diabetes at baseline and during follow-up). 
      In the whole cohort, ballooning progression and bridging fibrosis often occurred 
      together and coexisted with a reduction in ALT, higher weight gain and a higher
      incidence of diabetes during follow-up. CONCLUSIONS: A substantial proportion of 
      patients with NAFL can progress towards well-defined NASH with bridging fibrosis,
      especially if metabolic risk factors deteriorate. Even mild inflammation or
      fibrosis could substantially increase the risk of progression when compared to
      steatosis alone. Current monitoring practices of these patients should be
      revised.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Universite Pierre et Marie Curie, Assistance Publique Hopitaux de Paris, Hopital 
      Pitie Salpetriere, Paris, France.
FAU - Pais, Raluca
AU  - Pais R
FAU - Charlotte, Frederic
AU  - Charlotte F
FAU - Fedchuk, Larissa
AU  - Fedchuk L
FAU - Bedossa, Pierre
AU  - Bedossa P
FAU - Lebray, Pascal
AU  - Lebray P
FAU - Poynard, Thierry
AU  - Poynard T
FAU - Ratziu, Vlad
AU  - Ratziu V
CN  - for the LIDO Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Hepatol
JT  - Journal of hepatology
JID - 8503886
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/07/11 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/25 [accepted]
AID - S0168-8278(13)00282-1 [pii]
AID - 10.1016/j.jhep.2013.04.027 [doi]
PST - aheadofprint
SO  - J Hepatol. 2013 May 8. pii: S0168-8278(13)00282-1. doi:
      10.1016/j.jhep.2013.04.027.

PMID- 23665283
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1600-0641 (Electronic)
IS  - 0168-8278 (Linking)
DP  - 2013 May 8
TI  - Irisin is inversely associated with intrahepatic triglyceride contents in obese
      adults.
LID - S0168-8278(13)00285-7 [pii]
LID - 10.1016/j.jhep.2013.04.030 [doi]
AB  - BACKGROUND & AIMS: Obesity is closely related with nonalcoholic fatty liver
      disease (NAFLD), which has become an important public health problem because of
      its high prevalence and association with metabolic syndromes. Irisin was recently
      identified as a novel peptide to improve obesity and glucose homeostasis, and
      considered to be therapeutic for human metabolic diseases. The aim of this study 
      was to examine the association of serum irisin concentration and liver
      triglyceride contents in obese Chinese adults. METHODS: Serum irisin levels were 
      measured and liver fat contents determined by 1H MRS in 296 obese adults.
      Anthropometric parameters and blood biochemical indexes including liver enzymes, 
      glucose, and lipid profiles were detected. The liver triglyceride contents of
      subjects were measured by 1H MRS. The protein levels of irisin were determined by
      quantitative ELISA. RESULTS: We found that serum irisin levels were reduced in
      obese adults with NAFLD. By dividing the distribution of intrahepatic
      triglyceride (IHTG) contents into quartiles, serum irisin levels were reduced
      gradually with the increase of IHTG contents (p<0.01). Higher serum irisin levels
      were associated with preferable TG levels. Serum ALT and AST concentrations were 
      inversely correlated with serum irisin levels. Multivariate linear regression
      analysis demonstrated that serum irisin levels were independently associated with
      liver fat (p<0.01). By logistic regression analysis the odds ratio for higher
      IHTG contents was reduced by 12.4% per 1 SD increase in serum irisin
      concentrations after adjustment for multivariate metabolic factors [OR (95% CI); 
      0.876 (0.777-0.987)]. CONCLUSIONS: These results demonstrated that serum irisin
      concentrations were inversely associated with the triglyceride contents in the
      liver and liver enzymes in obese Chinese adults.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Key
      Laboratory of Endocrine Tumor, Shanghai Institute of Endocrinology and
      Metabolism, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine,
      197 RuiJin 2nd Road, Shanghai 200025, China; Xiamen Diabetes Institute,
      Department of Endocrinology and Metabolism, The First Hospital of Xiamen, Xiamen 
      University, 55 Zhenhai Road, Xiamen 361003, China.
FAU - Zhang, Hui-Jie
AU  - Zhang HJ
FAU - Zhang, Xian-Feng
AU  - Zhang XF
FAU - Ma, Zhi-Min
AU  - Ma ZM
FAU - Pan, Ling-Ling
AU  - Pan LL
FAU - Chen, Zheng
AU  - Chen Z
FAU - Han, Hai-Wei
AU  - Han HW
FAU - Han, Cheng-Kun
AU  - Han CK
FAU - Zhuang, Xiong-Jie
AU  - Zhuang XJ
FAU - Lu, Yan
AU  - Lu Y
FAU - Li, Xue-Jun
AU  - Li XJ
FAU - Yang, Shu-Yu
AU  - Yang SY
FAU - Li, Xiao-Ying
AU  - Li XY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Hepatol
JT  - Journal of hepatology
JID - 8503886
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/11/28 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/19 [accepted]
AID - S0168-8278(13)00285-7 [pii]
AID - 10.1016/j.jhep.2013.04.030 [doi]
PST - aheadofprint
SO  - J Hepatol. 2013 May 8. pii: S0168-8278(13)00285-7. doi:
      10.1016/j.jhep.2013.04.030.

PMID- 23665164
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1872-7573 (Electronic)
IS  - 0378-8741 (Linking)
DP  - 2013 May 7
TI  - Argyreia nervosa (Burm. f.): Receptor profiling of lysergic acid amide and other 
      potential psychedelic LSD-like compounds by computational and binding assay
      approaches.
LID - S0378-8741(13)00323-1 [pii]
LID - 10.1016/j.jep.2013.04.044 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: The convolvulacea Argyreia nervosa (Burm. f.) is 
      well known as an important medical plant in the traditional Ayurvedic system of
      medicine and it is used in numerous diseases (e.g. nervousness, bronchitis,
      tuberculosis, arthritis, and diabetes). Additionally, in the Indian state of
      Assam and in other regions Argyreia nervosa is part of the traditional tribal
      medicine (e.g. the Santali people, the Lodhas, and others). In the western
      hemisphere, Argyreia nervosa has been brought in attention as so called "legal
      high". In this context, the seeds are used as source of the psychoactive
      ergotalkaloid lysergic acid amide (LSA), which is considered as the main active
      ingredient. AIM OF THE STUDY: As the chemical structure of LSA is very similar to
      that of lysergic acid diethylamide (LSD), the seeds of Argyreia nervosa (Burm.
      f.) are often considered as natural substitute of LSD. In the present study, LSA 
      and LSD have been compared concerning their potential pharmacological profiles
      based on the receptor binding affinities since our recent human study with four
      volunteers on p.o. application of Argyreia nervosa seeds has led to some
      ambiguous effects. MATERIAL AND METHODS: In an initial step computer-aided in
      silico prediction models on receptor binding were employed to screen for
      serotonin, norepinephrine, dopamine, muscarine, and histamine receptor subtypes
      as potential targets for LSA. In addition, this screening was extended to
      accompany ergotalkaloids of Argyreia nervosa (Burm. f.). In a verification step, 
      selected LSA screening results were confirmed by in vitro binding assays with
      some extensions to LSD. RESULTS: In the in silico model LSA exhibited the highest
      affinity with a pKi of about 8.0 at alpha1A, and alpha1B. Clear affinity with
      pKi>7 was predicted for 5-HT1A, 5-HT1B, 5-HT1D, 5-HT6, 5-HT7, and D2. From these 
      receptors the 5-HT1D subtype exhibited the highest pKi with 7.98 in the
      prediction model. From the other ergotalkaloids, agroclavine and festuclavine
      also seemed to be highly affine to the 5-HT1D-receptor with pKi>8. In general,
      the ergotalkaloids of Argyreia nervosa seem to prefer serotonin and dopamine
      receptors (pKi>7). However, with exception of ergometrine/ergometrinine only for 
      5-HT3A, and histamine H2 and H4 no affinities were predicted. Compared to LSD,
      LSA exhibited lower binding affinities in the in vitro binding assays for all
      tested receptor subtypes. However, with a pKi of 7.99, 7.56, and 7.21 a clear
      affinity for 5-HT1A, 5-HT2, and alpha2 could be demonstrated. For DA receptor
      subtypes and the alpha1-receptor the pKi ranged from 6.05 to 6.85. CONCLUSION:
      Since the psychedelic activity of LSA in the recent human study was weak and
      although LSA from Argyreia nervosa is often considered as natural exchange for
      LSD, LSA should not be regarded as LSD-like psychedelic drug. However, vegetative
      side effects and psychotropic effects may be triggered by serotonin or dopamine
      receptor subtypes.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - Institute of Legal Medicine, Goethe University of Frankfurt/Main, Kennedyallee
      104, D-60596 Frankfurt/Main, Germany. Electronic address:
      paulke@em.uni-frankfurt.de.
FAU - Paulke, Alexander
AU  - Paulke A
FAU - Kremer, Christian
AU  - Kremer C
FAU - Wunder, Cora
AU  - Wunder C
FAU - Achenbach, Janosch
AU  - Achenbach J
FAU - Djahanschiri, Bardya
AU  - Djahanschiri B
FAU - Elias, Anderson
AU  - Elias A
FAU - Stefan Schwed, J
AU  - Stefan Schwed J
FAU - Hubner, Harald
AU  - Hubner H
FAU - Gmeiner, Peter
AU  - Gmeiner P
FAU - Proschak, Ewgenij
AU  - Proschak E
FAU - Toennes, Stefan W
AU  - Toennes SW
FAU - Stark, Holger
AU  - Stark H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - J Ethnopharmacol
JT  - Journal of ethnopharmacology
JID - 7903310
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/22 [revised]
PHST- 2013/04/25 [accepted]
AID - S0378-8741(13)00323-1 [pii]
AID - 10.1016/j.jep.2013.04.044 [doi]
PST - aheadofprint
SO  - J Ethnopharmacol. 2013 May 7. pii: S0378-8741(13)00323-1. doi:
      10.1016/j.jep.2013.04.044.

PMID- 23665100
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 May 8
TI  - The Effects of Bariatric Surgery on Human Small Artery Function: Evidence for
      Reduction in Perivascular Adipocyte Inflammation, and the Restoration of Normal
      Anticontractile Activity Despite Persistent Obesity.
LID - S0735-1097(13)01788-9 [pii]
LID - 10.1016/j.jacc.2013.04.027 [doi]
AB  - OBJECTIVES: The aim of this study was to investigate the effects of bariatric
      surgery on small artery function and the mechanisms underlying this. BACKGROUND: 
      In lean healthy humans, perivascular adipose tissue (PVAT) exerts an
      anticontractile effect on adjacent small arteries, but this is lost in
      obesity-associated conditions such as the Metabolic Syndrome and Type II Diabetes
      where there is evidence of adipocyte inflammation and increased oxidative stress.
      METHODS: Segments of small subcutaneous artery and perivascular fat were
      harvested from severely obese individuals before (n = 20) and 6 months after
      bariatric surgery (n = 15). Small artery contractile function was examined
      in-vitro using wire myography and perivascular adipose tissue (PVAT) morphology
      was assessed using immunohistochemistry. RESULTS: The anticontractile activity of
      PVAT was lost in obese patients before surgery when compared with healthy
      volunteers, and was restored 6 months after bariatric surgery. In-vitro protocols
      using superoxide dismutase and catalase rescued PVAT anticontractile function in 
      tissue from obese individuals prior to surgery. The improvement in
      anticontractile function following surgery was accompanied by improvements in
      insulin sensitivity, serum glycaemic indices, inflammatory cytokines, adipokine
      profile, and systolic blood pressure together with increased PVAT adiponectin and
      nitric oxide bioavailability and reduced macrophage infiltration and
      inflammation. These changes were observed despite the patients remaining severely
      obese. CONCLUSIONS: Bariatric surgery and its attendant improvements in weight,
      blood pressure, inflammation and metabolism collectively reverse the
      obesity-induced alteration to PVAT anticontractile function. This reversal is
      attributable to reductions in local adipose inflammation and oxidative stress
      with improved adiponectin and nitric oxide bioavailability.
CI  - Copyright (c) 2013 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
AD  - Cardiovascular Research Group, University of Manchester, UK; Manchester Wellcome 
      Trust Clinical Research Facility, UK, double dagger: Department of Clinical
      Biochemistry, Manchester Royal Infirmary, UK. Electronic address:
      reza.zadeh@manchester.ac.uk.
FAU - Aghamohammadzadeh, Reza
AU  - Aghamohammadzadeh R
FAU - Greenstein, Adam S
AU  - Greenstein AS
FAU - Yadav, Rahul
AU  - Yadav R
FAU - Jeziorska, Maria
AU  - Jeziorska M
FAU - Hama, Salam
AU  - Hama S
FAU - Soltani, Fardad
AU  - Soltani F
FAU - Pemberton, Phil W
AU  - Pemberton PW
FAU - Ammori, Basil
AU  - Ammori B
FAU - Malik, Rayaz A
AU  - Malik RA
FAU - Soran, Handrean
AU  - Soran H
FAU - Heagerty, Anthony M
AU  - Heagerty AM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/12/13 [received]
PHST- 2013/04/11 [revised]
PHST- 2013/04/16 [accepted]
AID - S0735-1097(13)01788-9 [pii]
AID - 10.1016/j.jacc.2013.04.027 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 May 8. pii: S0735-1097(13)01788-9. doi:
      10.1016/j.jacc.2013.04.027.

PMID- 23665095
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 May 8
TI  - Effects of Nitric Oxide on Cell Proliferation: Novel Insights.
LID - S0735-1097(13)01785-3 [pii]
LID - 10.1016/j.jacc.2013.03.070 [doi]
AB  - Nitric oxide (NO) has been suggested to be a pathophysiological modulator of cell
      proliferation, cell cycle arrest and apoptosis. In this context, opposite effects
      can be exerted by NO under diverse conditions. Indeed, several studies have
      indicated that low relative concentrations of NO seem to favour cell
      proliferation and anti-apoptotic responses whereas higher levels of NO favour
      pathways inducing cell cycle arrest, mitochondria respiration, senescence or
      apoptosis. Here, we report the NO effects on both promotion and inhibition of
      cell proliferation with particular concern on cardiovascular disease, diabetes
      and stem cells. Moreover, we focus on molecular mechanisms of action involved in 
      the control of cell cycle progression, which include both cGMP-dependent and
      -independent pathways. This growing field may lead to broad and novel targeted
      therapies against cardiovascular diseases especially during concomitant type 2
      diabetes, as well as novel bioimaging NO-based diagnostic tools.
CI  - Copyright (c) 2013 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
AD  - Department of General Pathology, Excellence Research Centre on Cardiovascular
      Diseases Chair of Clinical Pathology, U.O.C. Immunohematology, Second University 
      of Naples, 80138 Naples, Italy; Fondazione SDN, IRCCS, 80134 Naples, Italy.
      Electronic address: claunap@tin.it.
FAU - Napoli, Claudio
AU  - Napoli C
FAU - Paolisso, Giuseppe
AU  - Paolisso G
FAU - Casamassimi, Amelia
AU  - Casamassimi A
FAU - Al-Omran, Mohammed
AU  - Al-Omran M
FAU - Barbieri, Michelangela
AU  - Barbieri M
FAU - Sommese, Linda
AU  - Sommese L
FAU - Infante, Teresa
AU  - Infante T
FAU - Ignarro, Louis J
AU  - Ignarro LJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/15 [received]
PHST- 2013/03/19 [accepted]
AID - S0735-1097(13)01785-3 [pii]
AID - 10.1016/j.jacc.2013.03.070 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 May 8. pii: S0735-1097(13)01785-3. doi:
      10.1016/j.jacc.2013.03.070.

PMID- 23665085
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1872-7786 (Electronic)
IS  - 0009-2797 (Linking)
VI  - 204
IP  - 2
DP  - 2013 May 7
TI  - Evaluation of antioxidant efficacy of vanadium-3-hydroxyflavone complex in
      streptozotocin-diabetic rats.
PG  - 67-74
LID - S0009-2797(13)00098-7 [pii]
LID - 10.1016/j.cbi.2013.04.012 [doi]
AB  - Since 1985, when Heyliger et al., first demonstrated that oral administration of 
      sodium orthovanadate (0.8mg/ml) to STZ induced diabetic rats resulted in
      normoglycemia, numerous extensive studies have been reported on the antidiabetic 
      actions of vanadium. The acceptance of vanadium compounds as promising
      therapeutic antidiabetic drugs has been slowed due to the concern for chronic
      toxicity associated with vanadium accumulation. In order to circumvent the toxic 
      effects of vanadium, a combinational approach wherein a novel V3HF complex was
      synthesized, characterized and its toxic as well as antidiabetic potential were
      evaluated in STZ diabetic rats. Experimental and clinical studies suggest that
      hyperglycemia-induced oxidative stress primarily contributes to the pathogenesis 
      and progression of both primary as well as secondary complications of diabetes.
      It is possible to reduce the risks caused by excessive generation of free
      radicals by either enhancing the body's natural antioxidant defenses or by
      supplementing with proven antioxidants. The present study was aimed to study the 
      role of V3HF complex on hyperglycemia mediated oxidative stress in STZ-diabetic
      rats and the results indicate that the complex improves pancreatic beta cell
      function. Histological and ultrastructural studies also evidenced that the
      complex protect the beta cells from hyperglycemia-induced oxidative stress.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Inorganic Chemistry, School of Chemical Science, University of
      Madras, Guindy Campus, Chennai 600 025, India.
FAU - Pillai, Subramanian Iyyam
AU  - Pillai SI
FAU - Subramanian, Sorimuthu Pillai
AU  - Subramanian SP
FAU - Kandaswamy, Muthusamy
AU  - Kandaswamy M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/26 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/04/26 [accepted]
AID - S0009-2797(13)00098-7 [pii]
AID - 10.1016/j.cbi.2013.04.012 [doi]
PST - aheadofprint
SO  - Chem Biol Interact. 2013 May 7;204(2):67-74. doi: 10.1016/j.cbi.2013.04.012.

PMID- 23665027
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-1686 (Electronic)
IS  - 0167-0115 (Linking)
VI  - 185C
DP  - 2013 May 9
TI  - Effects of lixisenatide once daily on gastric emptying in type 2 diabetes -
      Relationship to postprandial glycemia.
PG  - 1-8
LID - S0167-0115(13)00077-3 [pii]
LID - 10.1016/j.regpep.2013.04.001 [doi]
AB  - OBJECTIVES: To determine the effects of lixisenatide, a new once-daily (QD)
      glucagon-like peptide-1 receptor agonist, on postprandial glucose (PPG) and
      gastric emptying, and the relationship between these effects in patients with
      type 2 diabetes mellitus (T2DM). METHODS: Data were obtained from a randomized,
      double-blind, placebo-controlled, parallel-group study with treatment duration of
      28days in patients with T2DM receiving </=2 oral antidiabetic drugs. Lixisenatide
      was injected subcutaneously using an ascending dose range (5-20mug) increased
      every fifth day in increments of 2.5mug. Blood glucose was determined before and 
      after three standardized meals (breakfast, lunch, and dinner). Gastric emptying
      of the standardized breakfast was determined by a 13C-octanoic acid breath test
      at baseline (Day-1) and at Day 28. RESULTS: A total of 21 and 22 patients were
      randomized to lixisenatide 20mug QD and placebo, respectively. With lixisenatide 
      20mug QD, there was a reduction in PPG when compared with placebo after breakfast
      (p<0.0001), lunch (p<0.001) and dinner (p<0.05). Hence, lixisenatide 20mug
      administered in the morning exhibited a pharmacodynamic effect on blood glucose
      throughout the day. Gastric emptying (50% emptying time) increased substantially 
      from baseline with lixisenatide 20mug QD, but not with placebo (change from
      baseline+/-SD: -24.1+/-133.1min for placebo and 211.5+/-278.5min for
      lixisenatide; p<0.01). There was an inverse relationship between PPG area under
      the curve after breakfast and gastric emptying with lixisenatide 20mug QD (n=17, 
      r2=0.51, p<0.05), but not with placebo. CONCLUSIONS: In this study, lixisenatide 
      at a dose of 20mug QD reduced postprandial glycemic excursions in patients with
      T2DM, possibly as a result of sustained slowing of gastric emptying.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Sanofi, Frankfurt am Main, Germany. Electronic address: martin.lorenz@sanofi.com.
FAU - Lorenz, Martin
AU  - Lorenz M
FAU - Pfeiffer, Claudia
AU  - Pfeiffer C
FAU - Steinstrasser, Axel
AU  - Steinstrasser A
FAU - Becker, Reinhard H A
AU  - Becker RH
FAU - Rutten, Hartmut
AU  - Rutten H
FAU - Ruus, Peter
AU  - Ruus P
FAU - Horowitz, Michael
AU  - Horowitz M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Regul Pept
JT  - Regulatory peptides
JID - 8100479
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/11/28 [received]
PHST- 2013/03/22 [revised]
PHST- 2013/04/26 [accepted]
AID - S0167-0115(13)00077-3 [pii]
AID - 10.1016/j.regpep.2013.04.001 [doi]
PST - aheadofprint
SO  - Regul Pept. 2013 May 9;185C:1-8. doi: 10.1016/j.regpep.2013.04.001.

PMID- 23665024
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 435
IP  - 2
DP  - 2013 May 31
TI  - Fasudil inhibits ER stress-induced VCAM-1 expression by modulating unfolded
      protein response in endothelial cells.
PG  - 171-5
LID - 10.1016/j.bbrc.2013.04.091 [doi]
LID - S0006-291X(13)00745-6 [pii]
AB  - The process of atherosclerosis is affected by interactions among numerous
      biological pathways. Accumulating evidence shows that endoplasmic reticulum (ER) 
      stress plays a crucial role in the development of atherosclerosis. Rho-kinase is 
      an effector of small GTP-binding protein Rho, and has been implicated as an
      atherogenic factor. Previous studies demonstrated that fasudil, a specific
      Rho-kinase inhibitor, exerts a cardioprotective effect by downregulating ER
      stress signaling. However, the molecular link between ER stress and Rho-kinase in
      endothelial cells has not been elucidated. In this study, we investigated the
      mechanisms by which fasudil regulates endothelial inflammation during ER stress. 
      Tunicamycin, an established ER stress inducer, increased vascular cellular
      adhesion molecule (VCAM)-1 expression in endothelial cells. Intriguingly, fasudil
      inhibited VCAM-1 induction. From a mechanistic stand point, fasudil inhibited
      expression of activating transcription factor (ATF)4 and subsequent C/EBP
      homologous protein (CHOP) induction by tunicamycin. Furthermore, fasudil
      attenuated tunicamycin-induced phophorylation of p38MAPK that is crucial for the 
      atherogenic response during ER stress. These findings indicate that Rho-kinase
      regulates ER stress-mediated VCAM-1 induction by ATF4- and p38MAPK-dependent
      signaling pathways. Rho-kinase inhibition by fasudil would be an important
      therapeutic approach against atherosclerosis, in particular, under conditions of 
      ER stress.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Diabetes, Metabolism and Endocrinology, Department of Internal
      Medicine, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku,
      Tokyo 105-8461, Japan. Electronic address: daijika@jikei.ac.jp.
FAU - Kawanami, Daiji
AU  - Kawanami D
FAU - Matoba, Keiichiro
AU  - Matoba K
FAU - Okada, Rina
AU  - Okada R
FAU - Tsukamoto, Masami
AU  - Tsukamoto M
FAU - Kinoshita, Jun
AU  - Kinoshita J
FAU - Ishizawa, Sho
AU  - Ishizawa S
FAU - Kanazawa, Yasushi
AU  - Kanazawa Y
FAU - Yokota, Tamotsu
AU  - Yokota T
FAU - Utsunomiya, Kazunori
AU  - Utsunomiya K
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/04/15 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - S0006-291X(13)00745-6 [pii]
AID - 10.1016/j.bbrc.2013.04.091 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2013 May 31;435(2):171-5. doi:
      10.1016/j.bbrc.2013.04.091. Epub 2013 May 7.

PMID- 23665021
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 435
IP  - 2
DP  - 2013 May 31
TI  - Inhibition of sorbitol dehydrogenase by nucleosides and nucleotides.
PG  - 202-8
LID - 10.1016/j.bbrc.2013.04.081 [doi]
LID - S0006-291X(13)00735-3 [pii]
AB  - Sorbitol dehydrogenase inhibitors have been found to prevent, or alleviate,
      various secondary complications of diabetes mellitus. In the present study, the
      effects of nucleosides and nucleotides on the rate of sorbitol oxidation
      catalyzed by the sheep liver enzyme were studied by steady-state kinetics at pH
      7.4. Various such compounds, including ATP and the 2'-deoxy-analogues of ATP, ADP
      and AMP, reversibly inhibit enzyme activity by formation of
      enzyme-coenzyme-inhibitor ternary complexes. In each case, no deviations from
      linearity were seen in the double-reciprocal plots using sorbitol or NAD(+) as
      the varied substrate and there was a linear relationship between inhibitor
      concentration and the observed inhibitory effects. Sorbitol was docked into a
      model of the sheep SDH-NAD(+) complex based upon the structure of the human
      SDH-NAD(+) holoenzyme. The resulting structure of the ternary complex of sheep
      SDH, NAD(+) and sorbitol (PMDB ID code PM 0078068) shows that the reactive C-2
      hydroxyl group of sorbitol is oriented toward the 4'-position of the nicotinamide
      moiety of the coenzyme, and that the adjacent primary hydroxyl group of sorbitol 
      interacts with the catalytic zinc. The results indicate that the ribose moiety of
      the inhibitor structures is an important determinant for the observed effects.
      Specifically, the 2'-position of the ribose ring exerts an effect with respect to
      inhibitor potency.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Institute of Chemistry, Biotechnology and Food Science (IKBM), Norwegian
      University of Life Sciences, Box 5003, N-1432 As, Norway.
FAU - Lindstad, Rune I
AU  - Lindstad RI
FAU - Teigen, Knut
AU  - Teigen K
FAU - Skjeldal, Lars
AU  - Skjeldal L
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/04/02 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - S0006-291X(13)00735-3 [pii]
AID - 10.1016/j.bbrc.2013.04.081 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2013 May 31;435(2):202-8. doi:
      10.1016/j.bbrc.2013.04.081. Epub 2013 May 7.

PMID- 23664978
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 525
IP  - 1
DP  - 2013 Aug 1
TI  - Genetic structure of Mexican Mestizos with type 2 diabetes mellitus based on
      three STR loci.
PG  - 41-6
LID - 10.1016/j.gene.2013.04.063 [doi]
LID - S0378-1119(13)00560-X [pii]
AB  - BACKGROUND: The aims of this population genetics study were: 1) to ascertain
      whether Mexicans with type 2 diabetes mellitus (DM) were genetically homogeneous 
      and 2) to compare the genetic structure of this selected population with the
      previously reported data of four random populations (Nuevo Leon, Hispanics,
      Chihuahua, and Central Region of Mexico). METHODS: A sample of 103 unrelated
      individuals with DM and whose 4 grandparents were born in five zones of Mexico
      was interviewed in 32 Medical Units in the Mexican Institute of Social Security
      (IMSS). The non-coding STRs D16S539, D7S820, and D13S317 were analyzed. RESULTS: 
      Genotype distribution was in agreement with Hardy-Weinberg expectations for all
      three markers. Allele frequencies were found to be similar between the selected
      population and the four random populations. Gene diversity analysis suggested
      that more than 99.57% of the total gene diversity could be attributed to
      variation between individuals within the population and 0.43% between the
      populations. CONCLUSIONS: According to the present and previous studies using
      molecular and non-molecular nuclear DNA markers not associated with any disease, 
      the Mexican Mestizo population is found to be genetically homogeneous and
      therefore the genetic causes of DM are less heterogeneous, thereby simplifying
      genetic epidemiological studies as has been found in a previous study with the
      same design in Mexican women with breast cancer.
CI  - Published by Elsevier B.V.
AD  - Universidad Autonoma de Nuevo Leon, Facultad de Enfermeria, Monterrey, Mexico.
      Electronic address: ricardocerda_mx@yahoo.com.mx.
FAU - Cerda-Flores, Ricardo M
AU  - Cerda-Flores RM
FAU - Rivera-Prieto, Roxana A
AU  - Rivera-Prieto RA
FAU - Pereyra-Alferez, Benito
AU  - Pereyra-Alferez B
FAU - Calderon-Garciduenas, Ana L
AU  - Calderon-Garciduenas AL
FAU - Barrera-Saldana, Hugo A
AU  - Barrera-Saldana HA
FAU - Gallardo-Blanco, Hugo L
AU  - Gallardo-Blanco HL
FAU - Ortiz-Lopez, Rocio
AU  - Ortiz-Lopez R
FAU - Flores-Pena, Yolanda
AU  - Flores-Pena Y
FAU - Cardenas-Villarreal, Velia M
AU  - Cardenas-Villarreal VM
FAU - Rivas, Fernando
AU  - Rivas F
FAU - Figueroa, Andres
AU  - Figueroa A
FAU - Kshatriya, Gautam
AU  - Kshatriya G
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/31 [received]
PHST- 2013/04/09 [revised]
PHST- 2013/04/20 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - S0378-1119(13)00560-X [pii]
AID - 10.1016/j.gene.2013.04.063 [doi]
PST - ppublish
SO  - Gene. 2013 Aug 1;525(1):41-6. doi: 10.1016/j.gene.2013.04.063. Epub 2013 May 8.

PMID- 23664882
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
DP  - 2013 May 9
TI  - Superior renoprotective effects of the combination of breviscapine with enalapril
      and its mechanism in diabetic rats.
LID - S0944-7113(13)00136-0 [pii]
LID - 10.1016/j.phymed.2013.03.027 [doi]
AB  - Breviscapine is a flavonoid extracted from a Chinese herb Erigeron breviscapus,
      previously it was shown that treatment with breviscapine attenuated renal injury 
      in the diabetic rats. The purpose of this study was to investigate whether
      breviscapine combined with enalapril (an ACE inhibitor) have superior
      renoprotective effects against diabetic nephropathy. Rats were randomly separated
      into five groups: control, diabetes, diabetes treated with enalapril, diabetes
      treated with breviscapine, or diabetes treated with combined enalapril with
      breviscapine. Twenty-four hours urinary AER and the levels of 3-NT in renal
      tissue and MDA in renal tissue and urine as well as activities and expression of 
      PKC in renal tissue were determined, and renal tissue morphology were observed by
      light microscopy after 8 weeks. Expression of TGFbeta1 protein was performed by
      immunohistochemistry method. Increased AER and kidney pathologic injury were
      attenuated by treatment with either enalapril or breviscapine and further reduced
      by the combination of the two. Elevated 3-NT in renal tissue and MDA levels in
      renal tissue and urine were reduced by enalapril or breviscapine and, more
      effectively, by combined enalapril with breviscapine. PKC activities and
      expression were higher in renal tissue in diabetic rats than those of the control
      group, which were reduced by both monotherapies, and further abrogated by
      combination therapy in both cases. Overexpression of TGFbeta1 protein observed in
      the glomeruli and tubulointerstitium of diabetic rats was attenuated by enalapril
      or breviscapine to a similar lever and further reduced by the combination of the 
      two. The combination of enalapril and breviscapine confers superiority over
      monotherapies on renoprotection, which mechanism may be at least partly
      correlated with synergetic suppression on increased oxidative stress and PKC
      activities as well as overexpression of TGFbeta1 in renal tissue.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
AD  - Department of Nephrology, The First Affiliated Hospital, Anhui Medical
      University, Hefei, Anhui, PR China.
FAU - Xu, Xing-Xin
AU  - Xu XX
FAU - Zhang, Wei
AU  - Zhang W
FAU - Zhang, Pei
AU  - Zhang P
FAU - Qi, Xiang-Ming
AU  - Qi XM
FAU - Wu, Yong-Gui
AU  - Wu YG
FAU - Shen, Ji-Jia
AU  - Shen JJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/20 [received]
PHST- 2013/03/28 [accepted]
AID - S0944-7113(13)00136-0 [pii]
AID - 10.1016/j.phymed.2013.03.027 [doi]
PST - aheadofprint
SO  - Phytomedicine. 2013 May 9. pii: S0944-7113(13)00136-0. doi:
      10.1016/j.phymed.2013.03.027.

PMID- 23664855
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1532-2742 (Electronic)
IS  - 0163-4453 (Linking)
DP  - 2013 May 9
TI  - A nationwide study of comorbidity and risk of reinfection after Staphylococcus
      aureus bacteraemia.
LID - S0163-4453(13)00107-2 [pii]
LID - 10.1016/j.jinf.2013.04.018 [doi]
AB  - BACKGROUND: Data on risk factors and rates of reinfection associated with
      Staphylococcus aureus bacteraemia (SAB) are sparse. METHODS: We conducted a
      nationwide cohort study of cases of SAB diagnosed between 1995 and 2008.
      Reinfection was defined as an episode of SAB more than 90 days after the initial 
      episode of SAB. Comorbidity was evaluated by the Charlson Comorbidity Index
      (CCI). Cox proportional hazards modelling was used to estimate hazard rates (HR).
      RESULTS: Of 10,891 eligible patients, 774 (7.1%) experienced reinfection a median
      of 458 days (range 90-5021 days) after their primary SAB episode corresponding to
      a reinfection rate of 1459 (95% confidence interval (CI): 1357-1562) per 100,000 
      personyears. In multivariate analysis, sex, origin, a vascular or peritoneal
      device, endocarditis and comorbidity were associated with reinfection. The
      association was more than two-fold higher among patients in dialysis and for
      patients with severe comorbidity (CCI>/=2). HIV infection (Hazard ratio (HR)
      6.18, 95% CI: 4.17-9.16), renal disease (HR 3.92, 95% CI: 3.22-4.78), diabetes
      with complications (HR 2.11, 95% CI: 1.69-2.62), diabetes without complications
      (HR 1.61, 95% CI: 1.34-1.93), mild (HR: 1.94, 95% CI: 1.36-2.76) and severe liver
      disease (HR 2.08, 95% CI: 1.08-4.03), peptic ulcer (HR 1.33, 95% CI: 1.03-1.72), 
      and paraplegia (HR 2.15, 95% CI: 1.02-4.54) were each associated with an
      increased risk of reinfection. CONCLUSIONS: Patients with previous SAB have a
      60-fold higher risk of SAB compared to the general population. Patients with HIV 
      infection, renal disease, diabetes, liver disease, peptic ulcer and paraplegia
      had the highest rates of reinfection.
CI  - Copyright (c) 2013 The British Infection Association. Published by Elsevier Ltd. 
      All rights reserved.
AD  - Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre,
      Denmark. Electronic address: wiese@dadlnet.dk.
FAU - Wiese, L
AU  - Wiese L
FAU - Mejer, N
AU  - Mejer N
FAU - Schonheyder, H C
AU  - Schonheyder HC
FAU - Westh, H
AU  - Westh H
FAU - Jensen, A G
AU  - Jensen AG
FAU - Larsen, A R
AU  - Larsen AR
FAU - Skov, R
AU  - Skov R
FAU - Benfield, T
AU  - Benfield T
CN  - Danish Staphylococcal Bacteraemia Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - J Infect
JT  - The Journal of infection
JID - 7908424
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/23 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/20 [accepted]
AID - S0163-4453(13)00107-2 [pii]
AID - 10.1016/j.jinf.2013.04.018 [doi]
PST - aheadofprint
SO  - J Infect. 2013 May 9. pii: S0163-4453(13)00107-2. doi:
      10.1016/j.jinf.2013.04.018.

PMID- 23664849
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 May 9
TI  - Evaluation of clinical tools and their diagnostic use in distal symmetric
      polyneuropathy.
LID - S1751-9918(13)00045-4 [pii]
LID - 10.1016/j.pcd.2013.04.004 [doi]
AB  - AIMS: To compare the diagnostic usefulness of tuning fork, monofilament,
      biothesiometer and skin biopsies in peripheral neuropathy in individuals with
      varying glucose metabolism. METHODS: Normoglycaemic, impaired glucose tolerance
      (IGT) and type 2 diabetes (T2DM) individuals were recruited. Nerve conduction
      studies (NCS) and thermal threshold tests were performed. Vibrotactile sense was 
      tested with a biothesiometer and a 128-Hz tuning fork. Touch/pressure perception 
      was examined with a 10-g monofilament. Skin biopsies were performed and
      intraepidermal nerve fibres were quantified. Distal symmetric polyneuropathy
      (DSPN) was defined as neuropathy disability score >/=2 and abnormal NCS. Thermal 
      threshold tests were used to define small nerve fibre neuropathy (sDSPN) in cases
      where NCS (large nerve fibres) were normal. RESULTS: The prevalence of DSPN and
      sDSPN in the whole group (n=119) was 18% and 23%, respectively. For the
      biothesiometer, a cut-off of >/=24.5V had a sensitivity of 82% and specificity of
      70% (AUC=0.81, 95% CI 0.71-0.91) when evaluating DSPN. An intraepidermal nerve
      fibre density cut-off of </=3.39fibres/mm showed a sensitivity of 74% and
      specificity of 70% in the detection of sDSPN, whereas the sensitivity of the
      tuning fork and the biothesiometer were relatively low, 46% and 67%,
      respectively. When combining skin biopsies with the tuning fork, 10 more sDSPN
      cases were identified. Adding skin biopsy to the combination of the tuning fork
      and biothesiometer increased the sensitivity of finding sDSPN cases, but not
      DSPN, from 81% to 93%. CONCLUSION: Using a biothesiometer in clinical routine
      might be a sensitive method to detect large nerve fibre dysfunction in the lower 
      extremity, whereas skin biopsies in combination with methods measuring
      vibrotactile sense could increase the diagnostic sensitivity of detecting
      peripheral neuropathy at an early stage.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Department of Public Health and Clinical Medicine, Family Medicine, Umea
      University, Umea, Sweden. Electronic address: kaveh.pourhamidi@fammed.umu.se.
FAU - Pourhamidi, Kaveh
AU  - Pourhamidi K
FAU - Dahlin, Lars B
AU  - Dahlin LB
FAU - Englund, Elisabet
AU  - Englund E
FAU - Rolandsson, Olov
AU  - Rolandsson O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/31 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/03 [accepted]
AID - S1751-9918(13)00045-4 [pii]
AID - 10.1016/j.pcd.2013.04.004 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 May 9. pii: S1751-9918(13)00045-4. doi:
      10.1016/j.pcd.2013.04.004.

PMID- 23664787
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1872-6976 (Electronic)
IS  - 0167-4943 (Linking)
VI  - 57
IP  - 2
DP  - 2013 Sep-Oct
TI  - Comparison of functional autonomy with associated sociodemographic factors,
      lifestyle, chronic diseases (CD) and neuropsychiatric factors in elderly patients
      with or without the metabolic syndrome (MS).
PG  - 151-5
LID - 10.1016/j.archger.2013.04.005 [doi]
LID - S0167-4943(13)00065-4 [pii]
AB  - The objective of this study was to compare autonomy and its associated factors in
      the elderly with and without MS. This study was a cross-sectional evaluation
      comprised of 402 subjects aged 60 years or older, of both sexes, consulting at
      the Family Health program, in Vicosa/MG. Autonomy was classified according to the
      Group of Latin American Development to Maturity (GDLAM) protocol and MS according
      to classification of the International Diabetes Federation. The independent
      variables were sociodemographic gender, age, marital status, education, those
      related to lifestyle including levels of physical activity and sedentary
      behavior, neuropsychological aspects included depressive symptoms, level of
      cognition and the presence of CD. A multiple linear regression model was used to 
      estimate associations of variables with autonomy in the elderly with or without
      the MS. In the elderly group without MS, autonomy was associated with increasing 
      age, sedentary behavior and depressive symptoms. In the group of elderly patients
      with MS, in addition to these factors, autonomy was also associated with being
      illiterate, not being physically active and presenting chronic illness. It was
      concluded that the presence of MS worsened the functional autonomy of elderly
      persons.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Federal University of Vicosa, Department of Nutrition and Health, Laboratory of
      Epidemiology, Av PH Rolfs, s/n, CCB-II, CEP: 36570-000 Vicosa, MG, Brazil.
      Electronic address: karina.martinho@ufv.br.
FAU - Martinho, Karina Oliveira
AU  - Martinho KO
FAU - Dantas, Estelio Henrique Martin
AU  - Dantas EH
FAU - Longo, Giana Zarbato
AU  - Longo GZ
FAU - Ribeiro, Andreia Queiroz
AU  - Ribeiro AQ
FAU - Pereira, Eveline Torres
AU  - Pereira ET
FAU - Franco, Fernanda Silva
AU  - Franco FS
FAU - Goncalves, Meirele Rodrigues
AU  - Goncalves MR
FAU - de Morais, Keila Bacelar Duarte
AU  - de Morais KB
FAU - Martins, Marcos Vidal
AU  - Martins MV
FAU - Danesio, Jacqueline
AU  - Danesio J
FAU - Tinoco, Adelson Luiz Araujo
AU  - Tinoco AL
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - Netherlands
TA  - Arch Gerontol Geriatr
JT  - Archives of gerontology and geriatrics
JID - 8214379
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/17 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/04/13 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - S0167-4943(13)00065-4 [pii]
AID - 10.1016/j.archger.2013.04.005 [doi]
PST - ppublish
SO  - Arch Gerontol Geriatr. 2013 Sep-Oct;57(2):151-5. doi:
      10.1016/j.archger.2013.04.005. Epub 2013 May 10.

PMID- 23664771
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 63
IP  - 2
DP  - 2013 Aug
TI  - Administration of IL-1 Trap prolongs survival of transplanted pancreatic islets
      to type 1 diabetic NOD mice.
PG  - 123-9
LID - 10.1016/j.cyto.2013.04.020 [doi]
LID - S1043-4666(13)00185-3 [pii]
AB  - We previously reported that IL-1 Trap (a hybrid molecule consisting of the
      extracellular domain of IL-1 receptor accessory protein and IL-1 receptor type 1 
      arranged inline and fused to the Fc-portion of IgG1) can protect rat pancreatic
      islets in vitro against noxious effects induced by IL-1beta. In this study we
      tested the effect of administration of a murine IL-1 Trap on the recurrence of
      disease (ROD) model in non-obese diabetic (NOD) mice. Spontaneously diabetic
      female NOD mice received implantation of a curative number (600) of syngeneic
      pancreatic islets beneath their left kidney capsule from young healthy NOD mouse 
      donors. Once a day, the mice were injected subcutaneously with IL-1 Trap (30mg/kg
      bodyweight), or an equimolar dose Fc-control protein (8.4mg/kg bodyweight) or
      saline. The treatments were maintained until ROD (i.e. a blood glucose value
      11.1mM for 2 consecutive days) or until 5days after transplantation. 3 out of 11 
      mice treated with IL-1 Trap showed a significantly increased graft survival
      compared to all other mice, and analysis of relative cytokine mRNA levels in
      isolated spleen cells showed elevated IL-4 mRNA levels, but no differences in
      FoxP3 or iNOS staining of grafts, from mice treated with IL-1 Trap, at both
      endpoints, compared to both control groups. Administration of IL-1 Trap
      counteracts islet cell destruction in the NOD mouse model of type 1 diabetes. In 
      part this could be due to a shift towards Th2 cytokine production seen in IL-1
      Trap treated animals.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Medical Cell Biology, Uppsala University, Biomedicum, P.O. Box 571,
      SE-75123 Uppsala, Sweden. Electronic address: Tobias.Rydgren@mcb.uu.se.
FAU - Rydgren, Tobias
AU  - Rydgren T
FAU - Oster, Elin
AU  - Oster E
FAU - Sandberg, Monica
AU  - Sandberg M
FAU - Sandler, Stellan
AU  - Sandler S
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - United States
TA  - Cytokine
JT  - Cytokine
JID - 9005353
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/11/22 [received]
PHST- 2013/03/22 [revised]
PHST- 2013/04/13 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - S1043-4666(13)00185-3 [pii]
AID - 10.1016/j.cyto.2013.04.020 [doi]
PST - ppublish
SO  - Cytokine. 2013 Aug;63(2):123-9. doi: 10.1016/j.cyto.2013.04.020. Epub 2013 May 9.

PMID- 23664770
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
DP  - 2013 May 8
TI  - Increases in inflammatory mediators in DRG implicate in the pathogenesis of
      painful neuropathy in Type 2 diabetes.
LID - S1043-4666(13)00174-9 [pii]
LID - 10.1016/j.cyto.2013.04.009 [doi]
AB  - BACKGROUND: Painful neuropathy is a common, difficult to treat complication of
      both Types 1 and 2 diabetes (T1D and T2D). Reports have shown that activation of 
      inflammatory cascades play an important role in the development and persistence
      of neuropathic pain states, but it is not well established in painful diabetic
      neuropathy (PDN). Previously, studies have shown increased inflammatory cytokines
      in the serum of the diabetic patients with painful neuropathy. This study focuses
      on the changes in the levels of inflammatory mediators such as TNFalpha,
      interleukins, chemokines and cell adhesion molecules with the development of pain
      in the DRG of the Zucker diabetic fatty (ZDF) rat, an established model for T2D. 
      This study also demonstrates an alteration in the levels of voltage gated sodium 
      channel 1.7 (NaV1.7) with the development of pain in DRG of the ZDF rats.
      RESULTS: Pre-diabetic ZDF animals at 8-9weeks of age showed no thermal and
      mechanical hyperalgesia compared to their respective lean controls. Diabetic-ZDF 
      animals tested for pain related behaviors showed significant thermal and
      mechanical hyperalgesia at 4 and 6weeks after the onset of diabetes when compared
      with their age matched lean controls. These ZDF animals with PDN also showed
      changes in a large number of inflammatory mediators in the DRG as assessed by
      Western blot as well as by cytokine antibody array compared to their age matched 
      lean controls. Further analysis by Rat cytokine antibody array of DRG of the ZDF 
      animals with PDN at 6weeks after diabetes when compared with ZDF animals with no 
      pain revealed an elevation of a significant number of inflammatory mediators
      including, the pro-inflammatory cytokines such as TNFalpha, interleukin-1, 6, 13 
      and 17, chemokines such as MIP1 and 3, RANTES, Fractalkine and cell adhesion
      molecule sICAM that are associated with pain phenotype. The ZDF animals with PDN 
      also demonstrated an increase in the protein levels of voltage gated sodium
      channel NaV1.7 in DRG compared to lean controls with no pain. CONCLUSIONS: The
      rise in inflammatory markers in the DRG of Type 2 diabetic animals and increases 
      in voltage gated sodium channel NaV1.7 in DRG with the onset of pain in PDN
      suggest that inflammation in the DRG may play an important role in the
      development of pain in this model.
CI  - Published by Elsevier Ltd.
AD  - Department of Neurology, University of Michigan, Ann Arbor, MI, USA; VA Ann Arbor
      Healthcare System, Ann Arbor, MI, USA.
FAU - Galloway, Christina
AU  - Galloway C
FAU - Chattopadhyay, Munmun
AU  - Chattopadhyay M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Cytokine
JT  - Cytokine
JID - 9005353
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/05/16 [received]
PHST- 2013/04/08 [revised]
PHST- 2013/04/10 [accepted]
AID - S1043-4666(13)00174-9 [pii]
AID - 10.1016/j.cyto.2013.04.009 [doi]
PST - aheadofprint
SO  - Cytokine. 2013 May 8. pii: S1043-4666(13)00174-9. doi:
      10.1016/j.cyto.2013.04.009.

PMID- 23664642
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1879-0828 (Electronic)
IS  - 0953-6205 (Linking)
DP  - 2013 May 7
TI  - Left ventricular hypertrophy detected by echocardiography in HIV-infected
      patients.
LID - S0953-6205(13)00110-6 [pii]
LID - 10.1016/j.ejim.2013.04.007 [doi]
AB  - BACKGROUND: Left ventricular hypertrophy (LVH) is a predictor of overall
      mortality in the general population. The most sensitive diagnostic method is
      transthoracic echocardiography (TTE). In this study, we describe the prevalence
      of LVH, and the factors associated with it, in a group of patients with HIV
      infection. METHODS: TTE was offered to all patients attending the outpatient
      clinic of the Hospital Costa del Sol (Marbella, Spain) between 1 December 2009
      and 28 February 2011. The corresponding demographic and clinical data were
      obtained. The left ventricular mass (LVM) was calculated and indexed by
      height2.7. LVH was defined as LVM >48g/m2.7 in men or >44g/m2.7 in women.
      RESULTS: We examined 388 individuals (75.5% male, mean age 45.38years). Of these,
      76.1% were receiving HAART; 11.9% had hypertension, 6.2% had diabetes mellitus,
      23.2% had dyslipidaemia and 53.6% were tobacco users. The risk of cardiovascular 
      disease at 10years (RV10) was 12.15% (95%CI: 10.99-13.31%). 19.1% of these
      patients had a high RV10. A total of 69 patients (19.8%) presented high LVM. Age,
      hypertension, dyslipidaemia, RV10 and the use of nevirapine were associated with 
      a greater presence of LVH in the univariate analysis. In the logistic regression 
      analysis performed, the factors retained in the model were the presence of high
      RV10 (OR: 2.92, 95%CI: 1.39-6.15) and the use of nevirapine (OR 2.20, 95%CI:
      1.18-4.14). CONCLUSIONS: In this group of patients, the use of nevirapine and the
      presence of high RV10 were associated with LVH. The use of nevirapine might be
      related to its prescription for patients with higher RV10.
CI  - Copyright (c) 2013 European Federation of Internal Medicine. Published by
      Elsevier B.V. All rights reserved.
AD  - Area de Cardiologia, Agencia Hospitalaria Costa del Sol, Marbella, Spain.
FAU - Pombo, Marta
AU  - Pombo M
FAU - Olalla, Julian
AU  - Olalla J
FAU - Del Arco, Alfonso
AU  - Del Arco A
FAU - De La Torre, Javier
AU  - De La Torre J
FAU - Urdiales, Daniel
AU  - Urdiales D
FAU - Aguilar, Ana
AU  - Aguilar A
FAU - Prada, Jose Luis
AU  - Prada JL
FAU - Garcia-Alegria, Javier
AU  - Garcia-Alegria J
FAU - Ruiz-Mateas, Francisco
AU  - Ruiz-Mateas F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Eur J Intern Med
JT  - European journal of internal medicine
JID - 9003220
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/11/13 [received]
PHST- 2013/03/22 [revised]
PHST- 2013/04/14 [accepted]
AID - S0953-6205(13)00110-6 [pii]
AID - 10.1016/j.ejim.2013.04.007 [doi]
PST - aheadofprint
SO  - Eur J Intern Med. 2013 May 7. pii: S0953-6205(13)00110-6. doi:
      10.1016/j.ejim.2013.04.007.

PMID- 23664596
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1532-2823 (Electronic)
IS  - 0952-3278 (Linking)
DP  - 2013 May 7
TI  - Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in
      adults with diabetes mellitus.
LID - S0952-3278(13)00054-9 [pii]
LID - 10.1016/j.plefa.2013.03.005 [doi]
AB  - INTRODUCTION: Many diabetics are insensitive to aspirin's platelet
      anti-aggregation effects. The possible modulating effects of co-administration of
      aspirin and fish oil in subjects with diabetes are poorly characterized.
      PARTICIPANTS AND METHODS: Thirty adults with type 2 diabetes mellitus were
      treated with aspirin 81mg/d for 7 days, then with fish oil 4g/day for 28 days,
      then the combination of fish oil and aspirin for another 7 days. RESULTS: Aspirin
      alone and in combination with fish oil reduced platelet aggregation in most
      participants. Five of 7 participants classified as aspirin insensitive 1 week
      after daily aspirin ingestion were sensitive after the combination. Although some
      platelet aggregation measures correlated positively after aspirin and fish oil
      ingestion alone and (in combination) in all individuals, correlation was only
      observed in those who were aspirin insensitive after ingestion of the
      combination. CONCLUSIONS: Co-administration of aspirin and fish oil may reduce
      platelet aggregation more than aspirin alone in adults with diabetes mellitus.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Public Health Sciences, The University of Rochester School of
      Medicine and Dentistry, Rochester, New York, United States. Electronic address:
      robert_block@urmc.rochester.edu.
FAU - Block, Robert C
AU  - Block RC
FAU - Abdolahi, Amir
AU  - Abdolahi A
FAU - Smith, Brian
AU  - Smith B
FAU - Meednu, N
AU  - Meednu N
FAU - Thevenet-Morrison, Kelly
AU  - Thevenet-Morrison K
FAU - Cai, Xueya
AU  - Cai X
FAU - Cui, Huadong
AU  - Cui H
FAU - Mousa, Shaker
AU  - Mousa S
FAU - Thomas Brenna, J
AU  - Thomas Brenna J
FAU - Georas, S
AU  - Georas S
LA  - ENG
GR  - KL2 RR024136/RR/NCRR NIH HHS/United States
GR  - R01 AT007003/AT/NCCAM NIH HHS/United States
GR  - R01 HL071933/HL/NHLBI NIH HHS/United States
GR  - R21 HL102582/HL/NHLBI NIH HHS/United States
GR  - T32 HL007937/HL/NHLBI NIH HHS/United States
GR  - UL1 RR024160/RR/NCRR NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Prostaglandins Leukot Essent Fatty Acids
JT  - Prostaglandins, leukotrienes, and essential fatty acids
JID - 8802730
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/29 [received]
PHST- 2013/03/10 [revised]
PHST- 2013/03/11 [accepted]
AID - S0952-3278(13)00054-9 [pii]
AID - 10.1016/j.plefa.2013.03.005 [doi]
PST - aheadofprint
SO  - Prostaglandins Leukot Essent Fatty Acids. 2013 May 7. pii: S0952-3278(13)00054-9.
      doi: 10.1016/j.plefa.2013.03.005.

PMID- 23664565
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
DP  - 2013 May 8
TI  - The change of insulin levels after six weeks antidepressant use in drug-naive
      major depressive patients.
LID - S0165-0327(13)00263-2 [pii]
LID - 10.1016/j.jad.2013.04.008 [doi]
AB  - BACKGROUND: A reciprocal relationship between diabetes risk and depression has
      been reported. There are few studies investigating glucose-insulin homeostasis
      before and after short-term antidepressant treatment in drug-naive major
      depressive disorder (MDD) patients. METHODS: This study included 104 healthy
      controls and 50 drug-naive MDD patients diagnosed according to the DSM-IV
      criteria. These MDD patients were randomly assigned to receive fluoxetine or
      venlafaxine for six weeks. Depressive symptoms, body mass index, fasting plasma
      levels of glucose and insulin were measured. RESULTS: Compared to the healthy
      controls, the fasting plasma insulin and the homeostasis model of assessment for 
      pancreatic beta-cell secretory function (HOMA-beta) was significantly lower in
      the MDD patients before antidepressant treatment (7.7+/-4.8muIU/mL vs.
      5.1+/-4.2muIU/mL, p=0.006; 114.2+/-72.3% vs. 74.8+/-52.0%, p=0.005,
      respectively). However, these indices were not correlated with depression
      severity. After 6 weeks of fluoxetine or venlafaxine treatment, the level of
      HOMA-beta borderline significantly increased (108.1+/-75.5%, p=0.059).
      LIMITATIONS: The study was limited by the follow-up duration and lack of a
      placebo group. CONCLUSIONS: Antidepressants might affect insulin secretion
      independently of the therapeutic effects on MDD. Further studies are needed to
      investigate the long-term effects of antidepressants on insulin regulation in MDD
      patients.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan.
FAU - Chang, Hui Hua
AU  - Chang HH
FAU - Chi, Mei Hung
AU  - Chi MH
FAU - Lee, I Hui
AU  - Lee IH
FAU - Tsai, Hsin Chun
AU  - Tsai HC
FAU - Gean, Po Wu
AU  - Gean PW
FAU - Yang, Yen Kuang
AU  - Yang YK
FAU - Lu, Ru-Band
AU  - Lu RB
FAU - Chen, Po See
AU  - Chen PS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/23 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/03 [accepted]
AID - S0165-0327(13)00263-2 [pii]
AID - 10.1016/j.jad.2013.04.008 [doi]
PST - aheadofprint
SO  - J Affect Disord. 2013 May 8. pii: S0165-0327(13)00263-2. doi:
      10.1016/j.jad.2013.04.008.

PMID- 23664547
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
DP  - 2013 May 9
TI  - Out-of-Hospital Use of Proton Pump Inhibitors and Hypomagnesemia at Hospital
      Admission: A Nested Case-Control Study.
LID - S0272-6386(13)00600-8 [pii]
LID - 10.1053/j.ajkd.2013.02.373 [doi]
AB  - BACKGROUND: Case series suggest that long-term use of proton pump inhibitors
      (PPIs) is associated with hypomagnesemia, but the current literature lacks
      systematically collected data. Our aim was to examine whether hypomagnesemia at
      the time of hospital admission is associated with out-of-hospital use of PPIs.
      STUDY DESIGN: Nested case-control study matched for age and sex. SETTING &
      PARTICIPANTS: Data were collected retrospectively from a tertiary acute-care
      facility. Eligible cases consisted of 402 adults with hypomagnesemia (serum
      magnesium <1.4 mEq/L) at the time of hospital admission to medical services, age-
      and sex-matched with 402 control individuals with normal serum magnesium levels
      (1.4-2.0 mEq/L). PREDICTOR: Out-of-hospital PPI use was identified in the
      hospital record. An omeprazole equivalent dose was calculated when possible.
      Covariates included the Charlson-Deyo comorbidity index, diabetes, diuretic use, 
      estimated glomerular filtration rate, and gastroesophageal reflux. OUTCOME:
      Multivariable conditional logistic regression analyses were used to examine the
      association of PPI use with hypomagnesemia at the time of hospital admission.
      RESULTS: PPI use was not associated with hypomagnesemia (adjusted OR, 0.82; 95%
      CI, 0.61-1.11). Neither PPI type nor omeprazole equivalent daily dose was
      associated with hypomagnesemia. Sensitivity analyses of PPI use restricted to
      patients with esophageal disorders (adjusted OR, 1.00; 95% CI, 0.69-1.45), severe
      hypomagnesemia (magnesium, </=1.0 mEq/L; adjusted OR, 0.78; 95% CI, 0.13-4.61),
      or estimated glomerular filtration rate >/=60 mL/min/1.73 m2 (adjusted OR, 0.84; 
      95% CI, 0.53-1.34) were unrevealing. LIMITATIONS: Exposure misclassification;
      hospitalized patients on medical services may not be representative of a broader 
      ambulatory-based population. CONCLUSIONS: In a hospital-based adult population,
      out-of-hospital PPI use is not associated with hypomagnesemia at the time of
      hospital admission to medical services. In light of these inconclusive results,
      prospective cohort studies are needed to address this rare potential
      medication-related adverse effect.
CI  - Copyright (c) 2013 National Kidney Foundation, Inc. Published by Elsevier Inc.
      All rights reserved.
AD  - Department of Medicine, Division of Nephrology, Kidney and Dialysis Research
      Laboratory, St. Elizabeth's Medical Center, Boston, MA; Department of Medicine,
      Tufts University School of Medicine, Boston, MA.
FAU - Koulouridis, Ioannis
AU  - Koulouridis I
FAU - Alfayez, Mansour
AU  - Alfayez M
FAU - Tighiouart, Hocine
AU  - Tighiouart H
FAU - Madias, Nicolaos E
AU  - Madias NE
FAU - Kent, David M
AU  - Kent DM
FAU - Paulus, Jessica K
AU  - Paulus JK
FAU - Jaber, Bertrand L
AU  - Jaber BL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/30 [received]
PHST- 2013/02/26 [accepted]
AID - S0272-6386(13)00600-8 [pii]
AID - 10.1053/j.ajkd.2013.02.373 [doi]
PST - aheadofprint
SO  - Am J Kidney Dis. 2013 May 9. pii: S0272-6386(13)00600-8. doi:
      10.1053/j.ajkd.2013.02.373.

PMID- 23664468
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1549-4713 (Electronic)
IS  - 0161-6420 (Linking)
DP  - 2013 May 9
TI  - Correction of Visual Impairment by Cataract Surgery and Improved Survival in
      Older Persons: The Blue Mountains Eye Study Cohort.
LID - S0161-6420(13)00143-7 [pii]
LID - 10.1016/j.ophtha.2013.02.009 [doi]
AB  - OBJECTIVE: We assessed whether correction of visual impairment (VI) by cataract
      surgery was associated with improved long-term survival in an older Australian
      population. DESIGN: Population-based cohort study. PARTICIPANTS: In the Blue
      Mountains Eye Study, 354 participants, aged >/=49 years, had both cataract and VI
      or had undergone cataract surgery before baseline examinations. They were
      subsequently examined after 5- and 10-year follow-ups. METHODS: Associations
      between the mortality risk and the surgical correction of VI (visual acuity [VA] 
      <20/40, attributable to cataract) were assessed in Cox proportional hazard
      regression models, after multivariate adjustment, using time-dependent variables 
      for the study factor. MAIN OUTCOME MEASURES: All-cause mortality. RESULTS: The
      15-year crude mortality of participants who had undergone cataract surgery at
      baseline with no subsequent VI (71.8%) was relatively similar to that in
      participants with cataract-related VI who had not yet undergone surgery (79.4%). 
      However, after adjusting for age and sex, participants who underwent cataract
      surgery before baseline or during follow-up and no longer had VI had
      significantly lower long-term mortality risk (hazard ratio [HR], 0.60; 95%
      confidence interval [CI], 0.46-0.77) than participants with VI due to cataract
      who had not undergone cataract surgery. This lower mortality risk in the group
      with surgically corrected VI (HR, 0.54; 95% CI, 0.41-0.73) persisted after
      further adjustment for smoking, body mass index, home ownership, qualifications, 
      poor self-rated health, the presence of poor mobility, hypertension, diabetes,
      self-reported history of angina, myocardial infarction, stroke, cancer, asthma,
      and arthritis. This finding remained significant (HR, 0.55; 95% CI, 0.41-0.73)
      after additional adjustment for the number of medications taken (continuous
      variable) and the number (>/=5 vs. <5) of comorbid conditions (poor mobility,
      hypertension, diabetes, angina, myocardial infarction, stroke, cancer, asthma, or
      arthritis) as indicators of frailty. CONCLUSIONS: Surgical correction of VI due
      to cataract was associated with significantly better long-term survival of older 
      persons after accounting for known cataract and mortality risk factors, and
      indicators of general health. Whether some uncontrolled factors (frailty or
      general health) could have influenced decisions not to perform cataract surgery
      in some participants is unknown. However, this finding strongly supports many
      previous reports linking VI with poor survival. FINANCIAL DISCLOSURE(S):
      Proprietary or commercial disclosure may be found after the references.
CI  - Copyright (c) 2013 American Academy of Ophthalmology. Published by Elsevier Inc. 
      All rights reserved.
AD  - Centre for Vision Research, Department of Ophthalmology and Westmead Millennium
      Institute, University of Sydney, Sydney, Australia.
FAU - Fong, Calvin Sze-Un
AU  - Fong CS
FAU - Mitchell, Paul
AU  - Mitchell P
FAU - Rochtchina, Elena
AU  - Rochtchina E
FAU - Teber, Erdahl T
AU  - Teber ET
FAU - Hong, Thomas
AU  - Hong T
FAU - Wang, Jie Jin
AU  - Wang JJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/09/05 [received]
PHST- 2013/01/10 [revised]
PHST- 2013/02/11 [accepted]
AID - S0161-6420(13)00143-7 [pii]
AID - 10.1016/j.ophtha.2013.02.009 [doi]
PST - aheadofprint
SO  - Ophthalmology. 2013 May 9. pii: S0161-6420(13)00143-7. doi:
      10.1016/j.ophtha.2013.02.009.

PMID- 23664317
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
VI  - 75
IP  - 3
DP  - 2013 Jul
TI  - Pregnancy-induced hypertension is associated with maternal history and a risk of 
      cardiovascular disease in later life: A Japanese cross-sectional study.
PG  - 227-31
LID - 10.1016/j.maturitas.2013.04.002 [doi]
LID - S0378-5122(13)00106-0 [pii]
AB  - OBJECTIVE: To clarify the associations between pregnancy-induced hypertension
      (PIH) with heritability of PIH from mother to daughter and the risk of
      cardiovascular disease in later life in Japanese women. STUDY DESIGN: The Japan
      Nurses' Health Study (JNHS) is a cohort study of Japanese women's health. Data
      from the JNHS baseline survey between 2001 and 2007 were used to conduct a
      cross-sectional analysis. Of the 49,927 respondents in the baseline survey,
      10,456 parous women who were >/=45 years old at baseline were included in the
      analysis. MAIN OUTCOME MEASURES: The age-adjusted odds ratio (OR) of PIH in women
      whose mother had a history of PIH, and the age-adjusted OR of PIH in participants
      for hypertension, hypercholesterolemia and diabetes mellitus (DM). RESULTS: The
      age-adjusted OR of PIH was 2.72 (95% confidence interval [CI]: 2.14-3.46) in
      women whose mother had a history of PIH compared with those whose mother did not 
      have PIH. PIH was a risk factor for hypertension (age adjusted OR: 2.85, 95% CI: 
      2.45-3.11), hypercholesterolemia (age-adjusted OR: 1.49, 95% CI: 1.29-1.72) and
      DM (age-adjusted OR: 1.53, 95% CI: 1.11-2.11), as determined by logistic
      regression analysis. CONCLUSIONS: In Japanese women, the risk of PIH is
      approximately 2.7-fold greater in those whose mothers also had PIH compared with 
      those whose mothers did not. PIH is a risk factor for hypertension,
      hypercholesterolemia, and diabetes mellitus in later life.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Obstetrics and Gynecology, Niigata City General Hospital, Niigata
      950-1197, Japan. Electronic address: takumi@hosp.niigata.niigata.jp.
FAU - Kurabayashi, Takumi
AU  - Kurabayashi T
FAU - Mizunuma, Hideki
AU  - Mizunuma H
FAU - Kubota, Toshiro
AU  - Kubota T
FAU - Kiyohara, Yutaka
AU  - Kiyohara Y
FAU - Nagai, Kazue
AU  - Nagai K
FAU - Hayashi, Kunihiko
AU  - Hayashi K
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - Ireland
TA  - Maturitas
JT  - Maturitas
JID - 7807333
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/03/07 [received]
PHST- 2013/04/02 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - S0378-5122(13)00106-0 [pii]
AID - 10.1016/j.maturitas.2013.04.002 [doi]
PST - ppublish
SO  - Maturitas. 2013 Jul;75(3):227-31. doi: 10.1016/j.maturitas.2013.04.002. Epub 2013
      May 8.

PMID- 23664294
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 May 7
TI  - Impact of Age on Long-Term Outcome After Primary Angioplasty With Bare-Metal or
      Drug-Eluting Stent (From the DESERT Cooperation).
LID - S0002-9149(13)00808-4 [pii]
LID - 10.1016/j.amjcard.2013.03.012 [doi]
AB  - Despite mechanical reperfusion, elderly patients with ST-segment elevation
      myocardial infarction (STEMI) still experience unsatisfactory outcomes.
      Drug-eluting stents (DES) have significantly reduced target-vessel
      revascularization (TVR), but concerns have emerged about the higher risk of late 
      stent thrombosis, which may be more pronounced in elderly patients. Therefore,
      the aim of this study was to evaluate the impact of age on outcome in patients
      with STEMI who underwent primary angioplasty with bare-metal stents (BMS) or DES.
      Our population comprised 6,298 patients who underwent primary angioplasty and
      stent implantation included in the Drug-Eluting Stent in Primary Angioplasty
      (DESERT) Cooperation database. Age was significantly associated with female
      gender (p <0.001), diabetes (p <0.001), hypertension (p <0.001), previous
      myocardial infarction (MI; p <0.001), ischemia time (p <0.001), and anterior MI
      (p <0.001) but inversely related to smoking (p <0.001). Elderly patients most
      often had infarct-related artery located in the descending artery (p = 0.014) and
      impaired postprocedural thrombolysis in myocardial infarction flow (p <0.001).
      Elderly patients were less often on clopidogrel at follow-up. At long-term
      follow-up, age was associated with a higher rate of death (hazard ratio [95%
      confidence interval] = 2.17 [1.97 to 2.39], p <0.0001), whereas no impact was
      observed on reinfarction (p = 0.36), stent thrombosis (p = 0.84), and TVR (p =
      0.54). These results were confirmed in patients receiving both BMS and DES. The
      impact of age on mortality was confirmed after correction for baseline
      confounding factors (gender, diabetes hypertension, hypercholesterolemia,
      smoking, ischemia time, anterior MI, infarct-related artery location, and
      postprocedural thrombolysis in myocardial infarction 3 flow; adjusted hazard
      ratio [95% confidence interval] = 2.13 [1.78 to 2.56], p <0.001). In conclusion, 
      this study shows that in patients with STEMI who underwent primary angioplasty,
      age is independently associated with higher mortality, observed with both BMS and
      DES, whereas no impact was observed on the rate of reinfarction, stent
      thrombosis, and TVR.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Cardiology, Ospedale "Maggiore della Carita," Eastern Piedmont
      University, Novara, Italy; Centro di Biotecnologie per la Ricerca Medica
      Applicata, Eastern Piedmont University, Novara, Italy. Electronic address:
      giuseppe.deluca@maggioreosp.novara.it.
FAU - De Luca, Giuseppe
AU  - De Luca G
FAU - Dirksen, Maurits T
AU  - Dirksen MT
FAU - Spaulding, Christian
AU  - Spaulding C
FAU - Kelbaek, Henning
AU  - Kelbaek H
FAU - Schalij, Martin
AU  - Schalij M
FAU - Thuesen, Leif
AU  - Thuesen L
FAU - van der Hoeven, Bas
AU  - van der Hoeven B
FAU - Vink, Marteen A
AU  - Vink MA
FAU - Kaiser, Christoph
AU  - Kaiser C
FAU - Musto, Carmine
AU  - Musto C
FAU - Chechi, Tania
AU  - Chechi T
FAU - Spaziani, Gaia
AU  - Spaziani G
FAU - Diaz de la Llera, Luis Salvador
AU  - Diaz de la Llera LS
FAU - Pasceri, Vincenzo
AU  - Pasceri V
FAU - Di Lorenzo, Emilio
AU  - Di Lorenzo E
FAU - Violini, Roberto
AU  - Violini R
FAU - Suryapranata, Harry
AU  - Suryapranata H
FAU - Stone, Gregg W
AU  - Stone GW
CN  - DESERT cooperation
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/30 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/08 [accepted]
AID - S0002-9149(13)00808-4 [pii]
AID - 10.1016/j.amjcard.2013.03.012 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 May 7. pii: S0002-9149(13)00808-4. doi:
      10.1016/j.amjcard.2013.03.012.

PMID- 23664235
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 9
TI  - Meta-analysis of methylcobalamin alone and in combination with lipoic acid in
      patients with diabetic peripheral neuropathy.
LID - S0168-8227(13)00132-0 [pii]
LID - 10.1016/j.diabres.2013.03.033 [doi]
AB  - AIMS: To compare the efficacy and safety of daily lipoic acid (300-600mg i.v.)
      plus methylcobalamin (500-1000mg i.v. or im.) (LA-MC) with that of
      methylcobalamin alone (MC) on diabetic peripheral neuropathy (DPN). METHODS:
      Electronic database were searched for studies published up to November 1, 2012
      and study quality was assessed in duplicate. A random or a fixed effect model was
      used to analyse outcomes which were expressed as risk ratios (RRs) or mean
      difference (MD). I2 statistic was used to assess heterogeneity. RESULTS:
      Seventeen studies were included. Combined data from all studies showed that the
      LA-MC combination therapy was significantly superior to MC monotherapy (RR=1.47; 
      95% CI: 1.37-1.58). Superiority of the LA-MC combination was shown in nerve
      conduction velocity (NCV) with WMDs of 6.89 (95% CI: 4.24-9.73) for median motor 
      nerve conduction velocity (MNCV), 5.24 (4.14-6.34) for median sensory nerve
      conduction velocity (SNCV), 4.34 (3.03-5.64) for peroneal MNCV, and 4.53
      (3.2-5.85) for peroneal SNCV. There were no serious adverse events associated
      with treatment. CONCLUSIONS: The results of the meta-analysis show that treatment
      with LA-MC for 2-4weeks is associated with better outcomes in NCV and neuropathic
      symptoms relative to MC treatment. However larger well-designed studies are
      required to confirm this conclusion.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Pharmacy, Zhu-Jiang Hospital, Southern Medical University,
      Guangzhou, China. Electronic address: xiaoqian7666@163.com.
FAU - Xu, Qian
AU  - Xu Q
FAU - Pan, Jianhong
AU  - Pan J
FAU - Yu, Jingwen
AU  - Yu J
FAU - Liu, Xiaoxia
AU  - Liu X
FAU - Liu, Li
AU  - Liu L
FAU - Zuo, Xialin
AU  - Zuo X
FAU - Wu, Ping
AU  - Wu P
FAU - Deng, Houliang
AU  - Deng H
FAU - Zhang, Jingjing
AU  - Zhang J
FAU - Ji, Aimin
AU  - Ji A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/11/19 [received]
PHST- 2013/02/12 [revised]
PHST- 2013/03/25 [accepted]
AID - S0168-8227(13)00132-0 [pii]
AID - 10.1016/j.diabres.2013.03.033 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 9. pii: S0168-8227(13)00132-0. doi:
      10.1016/j.diabres.2013.03.033.

PMID- 23664193
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1579-2021 (Electronic)
IS  - 1575-0922 (Linking)
DP  - 2013 May 7
TI  - Diabetes mellitus and depressive disorder, an undesirable association.
LID - S1575-0922(13)00092-2 [pii]
LID - 10.1016/j.endonu.2013.01.011 [doi]
AB  - Type 2 diabetes and depressive disorder are 2 chronic diseases highly prevalent
      in developed countries and with a negative impact on quality of life and life
      expectancy. In recent years, both conditions have been shown to be strongly
      associated. Thus, diabetics have an increased risk of suffering depressive
      disorder, as well as impaired glucose homeostasis, if they experience depression.
      In diabetic patients, concurrent depression is associated to greater difficulties
      in disease management and metabolic control, increased risk of developing chronic
      complications, decreased quality of life, and higher healthcare expenses. As a
      result, the interest of diabetic scientific societies in this association has
      increased, and they recommend regular mood assessment in diabetic patients.
      However, the limited clinical experience available and the conflicting results
      reported to date make it difficult to draw conclusions.
CI  - Copyright (c) 2012 SEEN. Published by Elsevier Espana. All rights reserved.
AD  - Servicio de Endocrinologia y Nutricion, Hospital Son Llatzer, Palma de Mallorca, 
      Espana. Electronic address: jnicolauramis@gmail.com.
FAU - Nicolau, Joana
AU  - Nicolau J
FAU - Masmiquel, Lluis
AU  - Masmiquel L
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Diabetes mellitus y trastorno depresivo, un mal binomio.
DEP - 20130507
TA  - Endocrinol Nutr
JT  - Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y
      Nutricion
JID - 100886482
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/11/07 [received]
PHST- 2013/01/09 [revised]
PHST- 2013/01/14 [accepted]
AID - S1575-0922(13)00092-2 [pii]
AID - 10.1016/j.endonu.2013.01.011 [doi]
PST - aheadofprint
SO  - Endocrinol Nutr. 2013 May 7. pii: S1575-0922(13)00092-2. doi:
      10.1016/j.endonu.2013.01.011.

PMID- 23664146
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
DP  - 2013 May 7
TI  - Pharmacological concentrations of irisin increase cell proliferation without
      influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7
      hippocampal cell lines.
LID - S0026-0495(13)00114-5 [pii]
LID - 10.1016/j.metabol.2013.04.007 [doi]
AB  - AIMS/HYPOTHESIS: Irisin is a novel, myocyte secreted, hormone that has been
      proposed to mediate the beneficial effects of exercise on metabolism. Irisin is
      expressed, at lower levels, in human brains and knock-down of the precursor of
      irisin, FNDC5, decreases neural differentiation of mouse embryonic stem cells. No
      previous studies have evaluated whether irisin may directly regulate hippocampal 
      neurogenesis in mouse hippocampal neuronal (HN) cells. METHODS: Hippocampal
      neurogenesis and irisin signaling were studied in vitro using mouse H19-7 HN cell
      lines. RESULTS: We observed that cell proliferation is regulated by irisin in a
      dose-dependent manner in mouse H19-7 HN cells. Specifically, physiological
      concentrations of irisin, 5 to 10nmol/L, had no effect on cell proliferation when
      compared to control. By contrast, pharmacological concentrations of irisin, 50 to
      100nmol/L, increased cell proliferation when compared to control. Similar to
      these results regarding irisin's effects on cell proliferation, we also observed 
      that only pharmacological concentrations of irisin increased STAT3, but not AMPK 
      and/or ERK, activation. Finally, we observed that irisin did not activate either 
      microtubule-associated protein 2, a specific neurite outgrowth marker, or
      Synapsin, a specific synaptogenesis marker in mouse H19-7 HN cells.
      CONCLUSIONS/INTERPRETATIONS: Our data suggest that irisin, in pharmacological
      concentrations, increases cell proliferation in mouse H19-7 HN cells via STAT3,
      but not AMPK and/or ERK, signaling pathways. By contrast, neither physiological
      nor pharmacological concentrations of irisin alter markers of hippocampal
      neurogenesis in mouse H19-7 HN cell lines.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess
      Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic
      address: hmoon@bidmc.harvard.edu.
FAU - Moon, Hyun-Seuk
AU  - Moon HS
FAU - Dincer, Fadime
AU  - Dincer F
FAU - Mantzoros, Christos S
AU  - Mantzoros CS
LA  - ENG
GR  - K24 DK081913/DK/NIDDK NIH HHS/United States
GR  - R01 DK079929/DK/NIDDK NIH HHS/United States
GR  - R56 DK058785/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/03/21 [received]
PHST- 2013/04/06 [accepted]
AID - S0026-0495(13)00114-5 [pii]
AID - 10.1016/j.metabol.2013.04.007 [doi]
PST - aheadofprint
SO  - Metabolism. 2013 May 7. pii: S0026-0495(13)00114-5. doi:
      10.1016/j.metabol.2013.04.007.

PMID- 23664112
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
DP  - 2013 May 8
TI  - Reducing the Health Consequences of Opioid Addiction in Primary Care.
LID - S0002-9343(13)00138-1 [pii]
LID - 10.1016/j.amjmed.2012.11.031 [doi]
AB  - Addiction to prescription opioids is prevalent in primary care settings.
      Increasing prescription opioid use is largely responsible for a parallel increase
      in overdose nationally. Many patients most at risk for addiction and overdose
      come into regular contact with primary care providers. Lack of routine addiction 
      screening results in missed treatment opportunities in this setting. We reviewed 
      the literature on screening and brief interventions for addictive disorders in
      primary care settings, focusing on opioid addiction. Screening and brief
      interventions can improve health outcomes for chronic illnesses including
      diabetes, hypertension, and asthma. Similarly, through the use of screening and
      brief interventions, patients with addiction can achieve improved health outcome.
      A spectrum of low-threshold care options can reduce the negative health
      consequences among individuals with opioid addiction. Screening in primary care
      coupled with short interventions, including motivational interviewing, syringe
      distribution, naloxone prescription for overdose prevention, and buprenorphine
      treatment are effective ways to manage addiction and its associated risks and
      improve health outcomes for individuals with opioid addiction.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Internal Medicine, Rhode Island Hospital, Providence.
FAU - Bowman, Sarah
AU  - Bowman S
FAU - Eiserman, Julie
AU  - Eiserman J
FAU - Beletsky, Leo
AU  - Beletsky L
FAU - Stancliff, Sharon
AU  - Stancliff S
FAU - Bruce, R Douglas
AU  - Bruce RD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/18 [received]
PHST- 2012/11/03 [revised]
PHST- 2012/11/12 [accepted]
AID - S0002-9343(13)00138-1 [pii]
AID - 10.1016/j.amjmed.2012.11.031 [doi]
PST - aheadofprint
SO  - Am J Med. 2013 May 8. pii: S0002-9343(13)00138-1. doi:
      10.1016/j.amjmed.2012.11.031.

PMID- 23664053
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 May 9
TI  - Stress cardiac magnetic resonance reveals myocardial perfusion impairment in
      asymptomatic diabetes mellitus type I, missed by the routine non-invasive
      evaluation.
LID - S0167-5273(13)00837-1 [pii]
LID - 10.1016/j.ijcard.2013.04.170 [doi]
AD  - Onassis Cardiac Surgery Center, Athens, Greece. Electronic address:
      soma13@otenet.gr.
FAU - Mavrogeni, Sophie
AU  - Mavrogeni S
FAU - Bratis, Konstantinos
AU  - Bratis K
FAU - Gavra, Paraskevi
AU  - Gavra P
FAU - Fousteris, Evangelos
AU  - Fousteris E
FAU - Markussis, Vyron
AU  - Markussis V
FAU - Kolovou, Genovefa
AU  - Kolovou G
FAU - van Wijk, Kees
AU  - van Wijk K
FAU - Hautemann, David
AU  - Hautemann D
FAU - Reiber, Johan H C
AU  - Reiber JH
FAU - Melidonis, Andreas
AU  - Melidonis A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/04/13 [received]
PHST- 2013/04/20 [accepted]
AID - S0167-5273(13)00837-1 [pii]
AID - 10.1016/j.ijcard.2013.04.170 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 May 9. pii: S0167-5273(13)00837-1. doi:
      10.1016/j.ijcard.2013.04.170.

PMID- 23663891
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1405-9940 (Print)
VI  - 83
IP  - 2
DP  - 2013 Apr-Jun
TI  - [Orthostatic response of blood pressure in patients with early Parkinson's
      disease].
PG  - 93-9
LID - 10.1016/j.acmx.2013.02.003 [doi]
LID - S1405-9940(13)00043-8 [pii]
AB  - OBJECTIVE: To evaluate orthostatic blood pressure response in patients with early
      Parkinson's disease and mild to moderate disease treated at the National
      Institute of Neurology and Neurosurgery. METHOD: A cross-sectional study with
      control group was carried out. Patients with Parkinson's disease with a disease
      duration of less than 5 years and mild to moderate severity along with healthy
      controls of the same age group were included. Those subjects with diabetes
      mellitus, hypertension or diagnosis of dysautonomia were excluded. Blood pressure
      was measured in supine position as well as after 3 and 5 min of standing.
      RESULTS: Seventy subjects with Parkinson's disease and 145 controls were
      included. There were no statistically significant differences in gender and age
      between both groups. There was no difference in systolic blood pressure change
      between groups at 3 minutes but at 5 minutes a statistically significant
      difference was found (P=.03). For diastolic blood pressure a difference between
      both groups was present at three and five minutes (P=.02 and P=.007). CONCLUSION:
      Patients with early Parkinson's disease have differences in orthostatic responses
      compared to healthy controls, these differences are more relevant at 5 minutes of
      standing.
CI  - Copyright (c) 2012 Instituto Nacional de Cardiologia Ignacio Chavez. Published by
      Masson Doyma Mexico S.A. All rights reserved.
AD  - Laboratorio Clinico de Enfermedades Neurodegenerativas, Instituto Nacional de
      Neurologia y Neurocirugia, DF, Mexico; Clinica de Movimientos Anormales,
      Instituto Nacional de Neurologia y Neurocirugia, DF, Mexico. Electronic address: 
      mrodriguez@innn.edu.mx.
FAU - Rodriguez-Violante, Mayela
AU  - Rodriguez-Violante M
FAU - Cervantes-Arriaga, Amin
AU  - Cervantes-Arriaga A
FAU - Garcia-Ibarra, Daniela
AU  - Garcia-Ibarra D
FAU - Corona, Teresa
AU  - Corona T
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Respuesta ortostatica de la tension arterial de pacientes con enfermedad de
      Parkinson inicial.
PL  - Mexico
TA  - Arch Cardiol Mex
JT  - Archivos de cardiologia de Mexico
JID - 101126728
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/02/03 [received]
PHST- 2013/01/31 [revised]
PHST- 2013/02/01 [accepted]
AID - S1405-9940(13)00043-8 [pii]
AID - 10.1016/j.acmx.2013.02.003 [doi]
PST - ppublish
SO  - Arch Cardiol Mex. 2013 Apr-Jun;83(2):93-9. doi: 10.1016/j.acmx.2013.02.003.

PMID- 23663869
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
DP  - 2013 May 7
TI  - The essential role of endothelial nitric oxide synthase activation in
      insulin-mediated neuroprotection against ischemic stroke in diabetes.
LID - S0741-5214(13)00636-8 [pii]
LID - 10.1016/j.jvs.2013.03.023 [doi]
AB  - BACKGROUND: Stroke patients with diabetes have a higher mortality rate, worse
      neurologic outcome, and more severe disability than those without diabetes.
      Results from clinical trials comparing the outcomes of stroke seen with intensive
      glycemic control in diabetic individuals are conflicting. Therefore, the present 
      study was aimed to identify the key factor involved in the neuroprotective action
      of insulin beyond its hypoglycemic effects in streptozotocin-diabetic rats with
      ischemic stroke. METHODS: Long-Evans male rats were divided into three groups
      (control, diabetes, and diabetes treated with insulin) and subjected to focal
      cerebral ischemia-reperfusion (FC I/R) injury. RESULTS: Hyperglycemia aggravated 
      FC I/R injuries with an increase in cerebral infarction and neurologic deficits, 
      inhibition of glucose uptake and membrane-trafficking activity of glucose
      transporter 1, and reduction of Akt and endothelial nitric oxide synthase (eNOS) 
      phosphorylation in the cerebrum. Insulin treatment alleviated hyperglycemia and
      the symptoms of diabetes in streptozotocin-diabetic rats. Insulin administration 
      also significantly decreased cerebral infarction and neurologic deficits and
      increased phosphorylation of Akt and eNOS protein in the cerebrum of FC
      I/R-injured diabetic rats. However, the glucose uptake and membrane trafficking
      activity of glucose transporter 1 in the cerebrum were not restored by insulin
      treatment. Coadministration of the eNOS inhibitor, N-iminoethyl-L-ornithine, with
      insulin abrogated beneficial effects of insulin on cerebral infarct volume and
      neurologic deficits in FC I/R-injured diabetic rats without affecting the
      hypoglycemic action of insulin. CONCLUSIONS: These results suggest that eNOS
      activation is required for the neuroprotection of insulin against ischemic stroke
      in patients with diabetes.
CI  - Copyright (c) 2013 Society for Vascular Surgery. Published by Mosby, Inc. All
      rights reserved.
AD  - Department of Pharmacology and Institute of Medicine, Chung Shan Medical
      University and Department of Pharmacy, Chung Shan Medical University Hospital,
      Taichung.
FAU - Huang, Shiang-Suo
AU  - Huang SS
FAU - Lu, Yi-Jhu
AU  - Lu YJ
FAU - Huang, Jiung-Pang
AU  - Huang JP
FAU - Wu, Yang-Tzu
AU  - Wu YT
FAU - Day, Yuan-Ji
AU  - Day YJ
FAU - Hung, Li-Man
AU  - Hung LM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/12/16 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/15 [accepted]
AID - S0741-5214(13)00636-8 [pii]
AID - 10.1016/j.jvs.2013.03.023 [doi]
PST - aheadofprint
SO  - J Vasc Surg. 2013 May 7. pii: S0741-5214(13)00636-8. doi:
      10.1016/j.jvs.2013.03.023.

PMID- 23663856
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1527-3296 (Electronic)
IS  - 0196-6553 (Linking)
DP  - 2013 May 7
TI  - Risk factors for and impact of methicillin-resistant Staphylococcus aureus nasal 
      colonization in patients in a medical intensive care unit.
LID - S0196-6553(13)00198-3 [pii]
LID - 10.1016/j.ajic.2013.01.035 [doi]
AB  - This retrospective cohort study investigated the impact and predictive factors of
      methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in 180
      patients admitted to a medical intensive care unit between July 2009 and June
      2010. No significant associations between MRSA nasal colonization and the
      incidence of health care-associated multidrug-resistant-related infections,
      intensive care unit length of stay, or inpatient mortality were found.
      Significant risk factors for MRSA colonization included previous medical history 
      of diabetes mellitus and congestive heart failure.
CI  - Copyright (c) 2013 Association for Professionals in Infection Control and
      Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.
AD  - Department of Pharmacy Services, Dallas VA Medical Center, Dallas, TX; Department
      of Pharmacy Practice, Texas Tech University Health Sciences Center School of
      Pharmacy, Dallas, TX. Electronic address: CChenUT@gmail.com.
FAU - Chen, Christina C
AU  - Chen CC
FAU - Pass, Steven E
AU  - Pass SE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Am J Infect Control
JT  - American journal of infection control
JID - 8004854
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/06/24 [received]
PHST- 2013/01/10 [revised]
PHST- 2013/01/10 [accepted]
AID - S0196-6553(13)00198-3 [pii]
AID - 10.1016/j.ajic.2013.01.035 [doi]
PST - aheadofprint
SO  - Am J Infect Control. 2013 May 7. pii: S0196-6553(13)00198-3. doi:
      10.1016/j.ajic.2013.01.035.

PMID- 23663750
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1471-2288 (Electronic)
IS  - 1471-2288 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 10
TI  - Recruitment strategies and yields for the Pathobiology of Prediabetes in a
      Biracial Cohort: a prospective natural history study of incident dysglycemia.
PG  - 64
AB  - BACKGROUND: The Pathobiology of Prediabetes in A Biracial Cohort study is a
      prospective evaluation of the transition from normal to impaired glucose
      regulation among African American and Caucasian adults with parental type 2
      diabetes. This report describes recruitment strategies and relative yields for
      the 376 enrolled subjects. METHODS: Recruitment occurred over 3.4 years, with
      clinical and metabolic assessments during 2.1-5.5 years of quarterly follow-up.
      The major recruitment sources were advertisements, community outreach, and
      clinical facilities. Advertisements included newspaper, television, radio,
      Internet, distributed brochures, utility bill inserts, and direct mailing.
      Community outreach included screening events during religious gatherings and
      health fairs, and referral by friends and families. The category of clinical
      facilities covered all subjects referred by health workers or recruited through
      area clinics and hospitals. RESULTS: 57.7% of participants were African American 
      and 42.3% were Caucasian; the mean age (+/- SD) was 44.2 +/- 10.6 years, and ~70%
      were female. Advertisements yielded 52.4% of all participants, compared to 34.8% 
      from community outreach and 12.8% from clinical facilities (P for trend <
      0.0001). More Caucasians than African Americans cited advertising as the source
      of study information, whereas more African Americans than Caucasians cited
      community outreach. The accrual from clinical facilities was similar in both
      groups. CONCLUSIONS: Advertisements and community outreach were robust
      recruitment sources for assembling a diverse longitudinal diabetes offspring
      cohort, but each had differential yields in African Americans and Caucasians.
      Thus, a multifaceted approach comprising passive and active components is needed 
      to recruit a multiracial clinical research population.
FAU - Ebenibo, Sotonte
AU  - Ebenibo S
FAU - Edeoga, Chimaroke
AU  - Edeoga C
FAU - Ammons, Ann
AU  - Ammons A
FAU - Egbuonu, Nonso
AU  - Egbuonu N
FAU - Dagogo-Jack, Samuel
AU  - Dagogo-Jack S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - BMC Med Res Methodol
JT  - BMC medical research methodology
JID - 100968545
PMC - PMC3654922
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/04 [received]
PHST- 2013/05/10 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - 1471-2288-13-64 [pii]
AID - 10.1186/1471-2288-13-64 [doi]
PST - aheadofprint
SO  - BMC Med Res Methodol. 2013 May 10;13(1):64.

PMID- 23663742
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 5
DP  - 2013 May 7
TI  - An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action
      in Mice.
PG  - 790-7
LID - 10.1016/j.cmet.2013.03.019 [doi]
LID - S1550-4131(13)00153-8 [pii]
AB  - FGF21, a member of the fibroblast growth factor (FGF) superfamily, has recently
      emerged as a regulator of metabolism and energy utilization. However, the exact
      mechanism(s) whereby FGF21 mediates its actions have not been elucidated. There
      is considerable evidence that insulin resistance may arise from aberrant
      accumulation of intracellular lipids in insulin-responsive tissues due to
      lipotoxicity. In particular, the sphingolipid ceramide has been implicated in
      this process. Here, we show that FGF21 rapidly and robustly stimulates
      adiponectin secretion in rodents while diminishing accumulation of ceramides in
      obese animals. Importantly, adiponectin-knockout mice are refractory to changes
      in energy expenditure and ceramide-lowering effects evoked by FGF21
      administration. Moreover, FGF21 lowers blood glucose levels and enhances insulin 
      sensitivity in diabetic Lep(ob/ob) mice and diet-induced obese (DIO) mice only
      when adiponectin is functionally present. Collectively, these data suggest that
      FGF21 is a potent regulator of adiponectin secretion and that FGF21 critically
      depends on adiponectin to exert its glycemic and insulin sensitizing effects.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Touchstone Diabetes Center, Department of Internal Medicine, The University of
      Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
FAU - Holland, William L
AU  - Holland WL
FAU - Adams, Andrew C
AU  - Adams AC
FAU - Brozinick, Joseph T
AU  - Brozinick JT
FAU - Bui, Hai H
AU  - Bui HH
FAU - Miyauchi, Yukiko
AU  - Miyauchi Y
FAU - Kusminski, Christine M
AU  - Kusminski CM
FAU - Bauer, Steven M
AU  - Bauer SM
FAU - Wade, Mark
AU  - Wade M
FAU - Singhal, Esha
AU  - Singhal E
FAU - Cheng, Christine C
AU  - Cheng CC
FAU - Volk, Katherine
AU  - Volk K
FAU - Kuo, Ming-Shang
AU  - Kuo MS
FAU - Gordillo, Ruth
AU  - Gordillo R
FAU - Kharitonenkov, Alexei
AU  - Kharitonenkov A
FAU - Scherer, Philipp E
AU  - Scherer PE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
PMC - PMC3667496
MID - NIHMS471510
OID - NLM: NIHMS471510 [Available on 05/07/14]
OID - NLM: PMC3667496 [Available on 05/07/14]
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PMCR- 2014/05/07 00:00
PHST- 2012/10/13 [received]
PHST- 2013/01/22 [revised]
PHST- 2013/03/29 [accepted]
AID - S1550-4131(13)00153-8 [pii]
AID - 10.1016/j.cmet.2013.03.019 [doi]
PST - ppublish
SO  - Cell Metab. 2013 May 7;17(5):790-7. doi: 10.1016/j.cmet.2013.03.019.

PMID- 23663740
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 5
DP  - 2013 May 7
TI  - Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose 
      production.
PG  - 768-78
LID - 10.1016/j.cmet.2013.04.012 [doi]
LID - S1550-4131(13)00155-1 [pii]
AB  - Proper control of hepatic glucose production is central to whole-body glucose
      homeostasis, and its disruption plays a major role in diabetes. Here, we
      demonstrate that although established as an intracellular lipid chaperone, aP2 is
      in fact actively secreted from adipocytes to control liver glucose metabolism.
      Secretion of aP2 from adipocytes is regulated by fasting- and lipolysis-related
      signals, and circulating aP2 levels are markedly elevated in mouse and human
      obesity. Recombinant aP2 stimulates glucose production and gluconeogenic activity
      in primary hepatocytes in vitro and in lean mice in vivo. In contrast,
      neutralization of secreted aP2 reduces glucose production and corrects the
      diabetic phenotype of obese mice. Hyperinsulinemic-euglycemic and pancreatic
      clamp studies upon aP2 administration or neutralization demonstrated actions of
      aP2 in liver. We conclude that aP2 is an adipokine linking adipocytes to hepatic 
      glucose production and that neutralizing secreted aP2 may represent an effective 
      therapeutic strategy against diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Genetics and Complex Diseases, Harvard School of Public Health,
      Boston, MA 02115, USA.
FAU - Cao, Haiming
AU  - Cao H
FAU - Sekiya, Motohiro
AU  - Sekiya M
FAU - Ertunc, Meric Erikci
AU  - Ertunc ME
FAU - Burak, M Furkan
AU  - Burak MF
FAU - Mayers, Jared R
AU  - Mayers JR
FAU - White, Ariel
AU  - White A
FAU - Inouye, Karen
AU  - Inouye K
FAU - Rickey, Lisa M
AU  - Rickey LM
FAU - Ercal, Baris C
AU  - Ercal BC
FAU - Furuhashi, Masato
AU  - Furuhashi M
FAU - Tuncman, Gurol
AU  - Tuncman G
FAU - Hotamisligil, Gokhan S
AU  - Hotamisligil GS
LA  - eng
GR  - R01 DK052539/DK/NIDDK NIH HHS/United States
GR  - R01 DK056894/DK/NIDDK NIH HHS/United States
GR  - R01 DK064360/DK/NIDDK NIH HHS/United States
GR  - R56 DK064360/DK/NIDDK NIH HHS/United States
GR  - RC4 DK090942/DK/NIDDK NIH HHS/United States
GR  - T32 ES007155/ES/NIEHS NIH HHS/United States
GR  - T35 ES007300/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/15 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/04/17 [accepted]
AID - S1550-4131(13)00155-1 [pii]
AID - 10.1016/j.cmet.2013.04.012 [doi]
PST - ppublish
SO  - Cell Metab. 2013 May 7;17(5):768-78. doi: 10.1016/j.cmet.2013.04.012.

PMID- 23663738
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 5
DP  - 2013 May 7
TI  - Hyperglycemia promotes myelopoiesis and impairs the resolution of
      atherosclerosis.
PG  - 695-708
LID - 10.1016/j.cmet.2013.04.001 [doi]
LID - S1550-4131(13)00143-5 [pii]
AB  - Diabetes is a major risk factor for atherosclerosis. Although atherosclerosis is 
      initiated by deposition of cholesterol-rich lipoproteins in the artery wall, the 
      entry of inflammatory leukocytes into lesions fuels disease progression and
      impairs resolution. We show that diabetic mice have increased numbers of
      circulating neutrophils and Ly6-C(hi) monocytes, reflecting hyperglycemia-induced
      proliferation and expansion of bone marrow myeloid progenitors and release of
      monocytes into the circulation. Increased neutrophil production of S100A8/S100A9,
      and its subsequent interaction with the receptor for advanced glycation end
      products on common myeloid progenitor cells, leads to enhanced myelopoiesis.
      Treatment of hyperglycemia reduces monocytosis, entry of monocytes into
      atherosclerotic lesions, and promotes regression. In patients with type 1
      diabetes, plasma S100A8/S100A9 levels correlate with leukocyte counts and
      coronary artery disease. Thus, hyperglycemia drives myelopoiesis and promotes
      atherogenesis in diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Preventive Medicine and Nutrition, Department of Medicine, Columbia
      University, New York, NY 10032, USA.
FAU - Nagareddy, Prabhakara R
AU  - Nagareddy PR
FAU - Murphy, Andrew J
AU  - Murphy AJ
FAU - Stirzaker, Roslynn A
AU  - Stirzaker RA
FAU - Hu, Yunying
AU  - Hu Y
FAU - Yu, Shiquing
AU  - Yu S
FAU - Miller, Rachel G
AU  - Miller RG
FAU - Ramkhelawon, Bhama
AU  - Ramkhelawon B
FAU - Distel, Emilie
AU  - Distel E
FAU - Westerterp, Marit
AU  - Westerterp M
FAU - Huang, Li-Shin
AU  - Huang LS
FAU - Schmidt, Ann Marie
AU  - Schmidt AM
FAU - Orchard, Trevor J
AU  - Orchard TJ
FAU - Fisher, Edward A
AU  - Fisher EA
FAU - Tall, Alan R
AU  - Tall AR
FAU - Goldberg, Ira J
AU  - Goldberg IJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/11/20 [received]
PHST- 2013/02/19 [revised]
PHST- 2013/03/29 [accepted]
AID - S1550-4131(13)00143-5 [pii]
AID - 10.1016/j.cmet.2013.04.001 [doi]
PST - ppublish
SO  - Cell Metab. 2013 May 7;17(5):695-708. doi: 10.1016/j.cmet.2013.04.001.

PMID- 23663737
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 5
DP  - 2013 May 7
TI  - Metabolic Stress Modulates Alzheimer's beta-Secretase Gene Transcription via
      SIRT1-PPARgamma-PGC-1 in Neurons.
PG  - 685-94
LID - 10.1016/j.cmet.2013.03.016 [doi]
LID - S1550-4131(13)00140-X [pii]
AB  - Classic cardio-metabolic risk factors such as hypertension, stroke, diabetes, and
      hypercholesterolemia all increase the risk of Alzheimer's disease. We found
      increased transcription of beta-secretase/BACE1, the rate-limiting enzyme for
      Abeta generation, in eNOS-deficient mouse brains and after feeding mice a
      high-fat, high-cholesterol diet. Up- or downregulation of PGC-1alpha reciprocally
      regulated BACE1 in vitro and in vivo. Modest fasting in mice reduced BACE1
      transcription in the brains, which was accompanied by elevated PGC-1 expression
      and activity. Moreover, the suppressive effect of PGC-1 was dependent on
      activated PPARgamma, likely via SIRT1-mediated deacetylation in a
      ligand-independent manner. The BACE1 promoter contains multiple PPAR-RXR sites,
      and direct interactions among SIRT1-PPARgamma-PGC-1 at these sites were enhanced 
      with fasting. The interference on the BACE1 gene identified here represents a
      unique noncanonical mechanism of PPARgamma-PGC-1 in transcriptional repression in
      neurons in response to metabolic signals that may involve recruitment of
      corepressor NCoR.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Pharmacology, University of Tennessee Health Science Center,
      College of Medicine, 874 Union Avenue, Memphis, TN 38163, USA.
FAU - Wang, Ruishan
AU  - Wang R
FAU - Li, Jing Jing
AU  - Li JJ
FAU - Diao, Shiyong
AU  - Diao S
FAU - Kwak, Young-Don
AU  - Kwak YD
FAU - Liu, Li
AU  - Liu L
FAU - Zhi, Lianteng
AU  - Zhi L
FAU - Bueler, Hansruedi
AU  - Bueler H
FAU - Bhat, Narayan R
AU  - Bhat NR
FAU - Williams, Robert W
AU  - Williams RW
FAU - Park, Edwards A
AU  - Park EA
FAU - Liao, Francesca-Fang
AU  - Liao FF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/08/30 [received]
PHST- 2013/01/22 [revised]
PHST- 2013/03/28 [accepted]
AID - S1550-4131(13)00140-X [pii]
AID - 10.1016/j.cmet.2013.03.016 [doi]
PST - ppublish
SO  - Cell Metab. 2013 May 7;17(5):685-94. doi: 10.1016/j.cmet.2013.03.016.

PMID- 23663733
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1932-7420 (Electronic)
IS  - 1550-4131 (Linking)
VI  - 17
IP  - 5
DP  - 2013 May 7
TI  - Hyperglycemia-stimulated myelopoiesis causes impaired regression of
      atherosclerosis in type 1 diabetes.
PG  - 631-3
LID - 10.1016/j.cmet.2013.04.015 [doi]
LID - S1550-4131(13)00158-7 [pii]
AB  - People with type 1 diabetes (T1D) have a high risk of early morbidity and
      mortality from coronary artery disease. A study in this issue of Cell Metabolism 
      (Nagareddy et al., 2013) now identifies a mechanism causing impaired regression
      of atherosclerosis in T1D.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Diabetes Research Center and Departments of Internal Medicine and Pathology,
      Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461,
      USA. Electronic address: michael.brownlee@einstein.yu.edu.
FAU - Brownlee, Michael
AU  - Brownlee M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cell Metab
JT  - Cell metabolism
JID - 101233170
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - S1550-4131(13)00158-7 [pii]
AID - 10.1016/j.cmet.2013.04.015 [doi]
PST - ppublish
SO  - Cell Metab. 2013 May 7;17(5):631-3. doi: 10.1016/j.cmet.2013.04.015.

PMID- 23663655
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1463-1318 (Electronic)
IS  - 1462-8910 (Linking)
DP  - 2013 May 13
TI  - Re: Luo et al, Diabetes mellitus and the incidence and mortality of colorectal
      cancer: a meta-analysis of 24 cohort studies.
LID - 10.1111/codi.12280 [doi]
AB  - We read the recent meta-analysis by Luo et al(1) that reported a link between
      diabetes mellitus and an increased risk of colorectal cancer and increased
      mortality. The authors have included twenty four studies that span a considerable
      geographic area and time frame and have performed subgroup analysis to help avoid
      the various confounding factors. However, no adjustments have been made to take
      into account differing diabetic treatments among the patients studied. There is
      now increasing evidence that the commonly used anti-diabetic drug Metformin may
      be associated with a reduced incidence of cancer including colorectal cancer (2).
      This has been found in both population studies (3) and also in animal and human
      models where surrogate markers for early colorectal carcinogenesis have been
      used(4, 5). This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Academic Unit of Surgery, University of Glasgow, 4th Floor Walton Building,
      Glasgow Royal Infirmary, G4 0SF.
FAU - Mansouri, D
AU  - Mansouri D
FAU - McMillan, Dc
AU  - McMillan D
FAU - Crighton, Em
AU  - Crighton E
FAU - Horgan, Pg
AU  - Horgan P
LA  - ENG
PT  - LETTER
DEP - 20130513
TA  - Colorectal Dis
JT  - Colorectal disease : the official journal of the Association of Coloproctology of
      Great Britain and Ireland
JID - 100883611
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/22 [received]
PHST- 2013/01/25 [accepted]
AID - 10.1111/codi.12280 [doi]
PST - aheadofprint
SO  - Colorectal Dis. 2013 May 13. doi: 10.1111/codi.12280.

PMID- 23663556
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1745-6215 (Electronic)
IS  - 1745-6215 (Linking)
VI  - 14
DP  - 2013
TI  - Update on the collaborative interventions for circulation and depression
      (COINCIDE) trial: changes to planned methodology of a cluster randomized
      controlled trial of collaborative care for depression in people with diabetes
      and/or coronary heart disease.
PG  - 136
LID - 10.1186/1745-6215-14-136 [doi]
AB  - BACKGROUND: The COINCIDE trial aims to evaluate the effectiveness and
      cost-effectiveness of a collaborative care intervention for depression in people 
      with diabetes and/or coronary heart disease attending English general practices. 
      DESIGN: This update details changes to the cluster and patient recruitment
      strategy for the COINCIDE study. The original protocol was published in Trials
      (http://www.trialsjournal.com/content/pdf/1745-6215-13-139.pdf). Modifications
      were made to the recruitment targets in response to lower-than-expected patient
      recruitment at the first ten general practices recruited into the study. In order
      to boost patient numbers and retain statistical power, the number of general
      practices recruited was increased from 30 to 36. Follow-up period was shortened
      from 6 months to 4 months to ensure that patients recruited to the trial could be
      followed up by the end of the study. RESULTS: Patient recruitment began on the
      01/05/2012 and is planned to be completed by the 30/04/2013. Recruitment for
      general practices was completed on 31/10/2012, by which time the target of 36
      practices had been recruited. The main trial results will be published in a
      peer-reviewed journal. CONCLUSION: The data from the trial will provide evidence 
      on the effectiveness and cost-effectiveness of collaborative care for depression 
      in people with diabetes and/or coronary heart disease. TRIAL REGISTRATION: Trial 
      registration number: ISRCTN80309252.
AD  - Greater Manchester Collaboration for Leadership in Applied Health Research and
      Care, Institute of Population Health and Manchester Academic Health Science
      Centre, University of Manchester, Manchester M13 9PL, UK.
      peter.a.coventry@manchester.ac.uk.
FAU - Coventry, Peter A
AU  - Coventry PA
FAU - Lovell, Karina
AU  - Lovell K
FAU - Dickens, Chris
AU  - Dickens C
FAU - Bower, Peter
AU  - Bower P
FAU - Chew-Graham, Carolyn
AU  - Chew-Graham C
FAU - Cherrington, Andrea
AU  - Cherrington A
FAU - Garrett, Charlotte
AU  - Garrett C
FAU - Gibbons, Chris J
AU  - Gibbons CJ
FAU - Baguley, Clare
AU  - Baguley C
FAU - Roughley, Kate
AU  - Roughley K
FAU - Adeyemi, Isabel
AU  - Adeyemi I
FAU - Keyworth, Chris
AU  - Keyworth C
FAU - Waheed, Waquas
AU  - Waheed W
FAU - Hann, Mark
AU  - Hann M
FAU - Davies, Linda
AU  - Davies L
FAU - Jeeva, Farheen
AU  - Jeeva F
FAU - Roberts, Chris
AU  - Roberts C
FAU - Knowles, Sarah
AU  - Knowles S
FAU - Gask, Linda
AU  - Gask L
LA  - eng
PT  - Journal Article
DEP - 20130511
PL  - England
TA  - Trials
JT  - Trials
JID - 101263253
SB  - IM
PMC - PMC3660180
OID - NLM: PMC3660180
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/01/19 [received]
PHST- 2013/04/18 [accepted]
PHST- 2013/05/11 [aheadofprint]
AID - 1745-6215-14-136 [pii]
AID - 10.1186/1745-6215-14-136 [doi]
PST - epublish
SO  - Trials. 2013 May 11;14:136. doi: 10.1186/1745-6215-14-136.

PMID- 23663483
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 13
DP  - 2013
TI  - Metformin-mediated growth inhibition involves suppression of the IGF-I receptor
      signalling pathway in human pancreatic cancer cells.
PG  - 235
LID - 10.1186/1471-2407-13-235 [doi]
AB  - BACKGROUND: Epidemiological studies have shown direct associations between type 2
      diabetes and obesity, both conditions associated with hyperglycaemia and
      hyperinsulinemia, and the risk of pancreatic cancer. Up to 80% of pancreatic
      cancer patients present with either new-onset type 2 diabetes or impaired glucose
      tolerance at the time of diagnosis. Recent population studies indicate that the
      incidence of pancreatic cancer is reduced among diabetics taking metformin. In
      this study, the effects of exposure of pancreatic cancer cells to high glucose
      levels on their growth and response to metformin were investigated. METHODS: The 
      human pancreatic cancer cell lines AsPC-1, BxPC-3, PANC-1 and MIAPaCa-2 were
      grown in normal (5 mM) or high (25 mM) glucose conditions, with or without
      metformin. The influence by metformin on proliferation, apoptosis and the AMPK
      and IGF-IR signalling pathways were evaluated in vitro. RESULTS: Metformin
      significantly reduced the proliferation of pancreatic cancer cells under normal
      glucose conditions. Hyperglycaemia however, protected against the
      metformin-induced growth inhibition. The anti-proliferative actions of metformin 
      were associated with an activation of AMP-activated protein kinase AMPKThr172
      together with an inhibition of the insulin/insulin-like growth factor-I (IGF-I)
      receptor activation and downstream signalling mediators IRS-1 and phosphorylated 
      Akt. Furthermore, exposure to metformin during normal glucose conditions led to
      increased apoptosis as measured by poly(ADP-ribose) polymerase (PARP) cleavage.
      In contrast, exposure to high glucose levels promoted a more robust IGF-I
      response and Akt activation which correlated to stimulated AMPKSer485
      phosphorylation and impaired AMPKThr172 phosphorylation, resulting in reduced
      anti-proliferative and apoptotic effects by metformin. CONCLUSION: Our results
      indicate that metformin has direct anti-tumour activities in pancreatic cancer
      cells involving AMPKThr172 activation and suppression of the insulin/IGF
      signalling pathways. However, hyperglycaemic conditions enhance the insulin/IGF-I
      responses resulting in an altered AMPK activation profile and prevent metformin
      from fully switching off the growth promoting signals in pancreatic cancer cells.
AD  - Department of Surgery, Clinical Sciences Lund, Skane University Hospital and Lund
      University, Lund SE-221 84, Sweden. roland.andersson@med.lu.se.
FAU - Karnevi, Emelie
AU  - Karnevi E
FAU - Said, Katarzyna
AU  - Said K
FAU - Andersson, Roland
AU  - Andersson R
FAU - Rosendahl, Ann H
AU  - Rosendahl AH
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
PMC - PMC3661399
OID - NLM: PMC3661399
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/09 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - 1471-2407-13-235 [pii]
AID - 10.1186/1471-2407-13-235 [doi]
PST - epublish
SO  - BMC Cancer. 2013 May 10;13:235. doi: 10.1186/1471-2407-13-235.

PMID- 23663478
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130524
DCOM- 20130527
LR  - 20130606
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - The effect of cigarette smoke exposure on vitamin D level and biochemical
      parameters of mothers and neonates.
PG  - 19
LID - 10.1186/2251-6581-12-19 [doi]
AB  - BACKGROUND: Exposure to cigarette smoke during pregnancy leads to several adverse
      effects on mother and child. The purpose of this study was to evaluate the effect
      of being a passive smoker during pregnancy on vitamin D level and related
      biochemical indices including parathyroid hormone, calcium, phosphorus and
      alkaline phosphatase in mothers and newborns. METHODS: One hundred eight pregnant
      women and their newborns participated in a historical cohort study in two equal
      groups (n = 54) with and without cigarette smoke exposure. Maternal blood and
      urine samples and blood samples of umbilical cord were obtained in the delivery
      room. Concentration of 25-hydroxy vitamin D and related biochemical indices in
      samples of maternal and cord blood were investigated. Exposure to cigarette smoke
      was evaluated through questionnaire and maternal urine and umbilical cord serum
      cotinine levels. RESULTS: The mean level of 25-hydroxyvitamin D in maternal serum
      was 9.28 +/- 5.19 ng/mlin exposed and 10.75 +/- 5.26 ng/ml in non-exposed group(p
      > 0.05). The mean concentration of 25-hydroxy vitamin D in cord serum was 10.83
      +/- 6.68 ng/ml in the exposed and 11.05 +/- 4.99 ng/ml in the non-exposed group(p
      > 0.05). The exposed mothers had significantly higher parathyroid hormone level
      (p = 0.013), lower serum calcium (p = 0.024) and higher serum alkaline
      phosphatase (p = 0.024). There was a significant correlation between maternal and
      umbilical cord serum 25-hydroxyvitamin D within both exposed and non-exposed
      groups (p < 0.001). CONCLUSION: Maternal exposure to cigarette smoking during
      pregnancy negatively influences serum calcium level and increase parathyroid
      hormone and alkaline phosphatase in mothers.
AD  - Endocrinology and Metabolism Research Center, Endocrinology and Metabolism
      Clinical Sciences Institute, Endocrinology and Metabolism Research Institute,
      Tehran University of Medical Sciences, Tehran, Iran. nshirzad@tums.ac.ir.
FAU - Banihosseini, Seyede Zahra
AU  - Banihosseini SZ
FAU - Baheiraei, Azam
AU  - Baheiraei A
FAU - Shirzad, Nooshin
AU  - Shirzad N
FAU - Heshmat, Ramin
AU  - Heshmat R
FAU - Mohsenifar, Afshin
AU  - Mohsenifar A
LA  - eng
PT  - Journal Article
DEP - 20130511
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3662582
OID - NLM: PMC3662582
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/14 06:00
PHST- 2013/01/05 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/05/11 [aheadofprint]
AID - 2251-6581-12-19 [pii]
AID - 10.1186/2251-6581-12-19 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 May 11;12(1):19. doi: 10.1186/2251-6581-12-19.

PMID- 23663445
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130517
DCOM- 20130520
LR  - 20130520
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Patient centred care in diabetology: an Islamic perspective from Iran.
PG  - 18
LID - 10.1186/2251-6581-12-18 [doi]
AB  - Patient-centred system of care is essential in managing many disorders such as
      diabetes mellitus. The cultural and religious context can influence the
      involvement of patients and their families in such a care. We intend to discuss
      patient-centred care in diabetology in view of Islam. For more clarification, we 
      will take into consideration a few illustrative lines of argument in detail about
      situation in Iran. In conclusion, dynamic spirit of Islamic jurisprudence is
      reflected in its adaptability to change in medical practice. In recent decades,
      Iranian religious scholars have provided scientists in new fields of science and 
      research with appropriate directions and guidelines. Decree issued by Iranian
      religious leaders permitting research on stem cells for therapeutic purposes in
      many disorders including diabetes mellitus is one example. Understanding of the
      nature of Islam is importance for communication with patients in Islamic
      countries.
AD  - Endocrinology and Metabolism Research Centre, Endocrinology and Metabolism
      Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
      fzahedi@sina.tums.ac.ir.
FAU - Larijani, Bagher
AU  - Larijani B
FAU - Zahedi, Farzaneh
AU  - Zahedi F
LA  - eng
PT  - Editorial
DEP - 20130510
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3655888
OID - NLM: PMC3655888
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/14 06:00
PHST- 2013/05/08 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - 2251-6581-12-18 [pii]
AID - 10.1186/2251-6581-12-18 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 May 10;12(1):18. doi: 10.1186/2251-6581-12-18.

PMID- 23663412
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130524
DCOM- 20130527
LR  - 20130528
IS  - 2191-219X (Electronic)
VI  - 3
IP  - 1
DP  - 2013
TI  - Imaging receptor for advanced glycation end product expression in mouse model of 
      hind limb ischemia.
PG  - 37
LID - 10.1186/2191-219X-3-37 [doi]
AB  - BACKGROUND: The purpose of this study is to image the effect of diabetes on
      expression of receptor for advanced glycation endproducts (RAGE) in limb ischemia
      in live animals. METHODS: Male wild-type C57BL/6 mice were either made diabetic
      or left as control. Two months later, diabetic and non-diabetic mice underwent
      left femoral artery ligation. The right leg served as lesion control. Five days
      later, mice were injected with 15.1 +/- 4.4 MBq 99mTc-anti-RAGE F(ab')2 and 4 to 
      5 h later (blood pool clearance) underwent SPECT/CT imaging. At the completion of
      imaging, mice were euthanized, hind limbs counted and sectioned, and scans
      reconstructed. Regions of interest were drawn on serial transverse sections
      comprising the hind limbs and activity in millicuries summed and divided by the
      injected dose (ID). Quantitative histology was performed for RAGE staining and
      angiogenesis. RESULTS: Uptake of 99mTc-anti-RAGE F(ab')2 as %ID x 10-3 was higher
      in the left (ischemic) limbs for the diabetic mice (n = 8) compared to
      non-diabetic mice (n = 8) (1.20 +/- 0.44% vs. 0.49 +/- 0.40%; P = 0.0007) and
      corresponded to less angiogenesis in the diabetic mice. Uptake was also higher in
      the right limbs of diabetic compared to non-diabetic animals (0.82 +/- 0.33% vs. 
      0.40 +/- 0.14%; P = 0.0004). CONCLUSIONS: These data show the feasibility of
      imaging and quantifying the effect of diabetes on RAGE expression in limb
      ischemia.
AD  - Department of Medicine, Columbia University Medical Center, 622 West 168th St, PH
      10 room 203, New York, NY 10032, USA. lj2129@columbia.edu.
FAU - Tekabe, Yared
AU  - Tekabe Y
FAU - Kollaros, Maria
AU  - Kollaros M
FAU - Li, Chong
AU  - Li C
FAU - Zhang, Geping
AU  - Zhang G
FAU - Schmidt, Ann Marie
AU  - Schmidt AM
FAU - Johnson, Lynne
AU  - Johnson L
LA  - eng
PT  - Journal Article
DEP - 20130511
PL  - Germany
TA  - EJNMMI Res
JT  - EJNMMI research
JID - 101560946
PMC - PMC3662588
OID - NLM: PMC3662588
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:01
CRDT- 2013/05/14 06:00
PHST- 2013/01/02 [received]
PHST- 2013/04/20 [accepted]
PHST- 2013/05/11 [aheadofprint]
AID - 2191-219X-3-37 [pii]
AID - 10.1186/2191-219X-3-37 [doi]
PST - epublish
SO  - EJNMMI Res. 2013 May 11;3(1):37. doi: 10.1186/2191-219X-3-37.

PMID- 23663292
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1442-2018 (Electronic)
IS  - 1441-0745 (Linking)
DP  - 2013 May 13
TI  - American rural women's exercise self-efficacy and awareness of exercise benefits 
      and safety during pregnancy.
LID - 10.1111/nhs.12057 [doi]
AB  - Though the positive link between physical activity and maternal health is well
      documented, physical activity declines during pregnancy and, internationally,
      rural mothers are less likely than urban mothers to engage in physical activity. 
      Some evidence suggests that self-efficacy is related to sustained engagement in
      physical activity. The purpose of this study was to examine self-efficacy,
      perceived benefits, and knowledge of safe exercise among 88 rural pregnant women 
      in a southeastern region of the United States. Exercise self-efficacy was
      significantly related to maternal age and gestation. Women over age 26 years, and
      those in the second and third trimesters, scored significantly higher than
      younger women or those in the first trimester. Fifty-two percent (n = 46) of
      participants perceived that activity would decrease energy levels, 37.5% (n = 33)
      did not know that exercise can decrease the risk of gestational diabetes, and
      47.6% (n = 41) were unaware that a mother who is overweight is more likely to
      have an overweight child. Results confirm a need for education to improve women's
      knowledge about health benefits and safety information related to physical
      activity during pregnancy.
CI  - (c) 2013 Wiley Publishing Asia Pty Ltd.
AD  - Department of Health & Kinesiology, Georgia Southern University.
FAU - Melton, Bridget
AU  - Melton B
FAU - Marshall, Elaine
AU  - Marshall E
FAU - Bland, Helen
AU  - Bland H
FAU - Schmidt, Michael
AU  - Schmidt M
FAU - Guion, W Kent
AU  - Guion WK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Nurs Health Sci
JT  - Nursing & health sciences
JID - 100891857
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/04/28 [received]
PHST- 2013/02/26 [revised]
PHST- 2013/03/01 [accepted]
AID - 10.1111/nhs.12057 [doi]
PST - aheadofprint
SO  - Nurs Health Sci. 2013 May 13. doi: 10.1111/nhs.12057.

PMID- 23663156
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 11
TI  - Sulphonylureas and risk of cardiovascular disease: systematic review and
      meta-analysis.
LID - 10.1111/dme.12232 [doi]
AB  - AIMS: Sulphonylurea use has been linked with increased cardiovascular disease
      risk; however, previous studies have been inconsistent. Type 2 diabetes
      independently increases risk for cardiovascular disease, so understanding the
      link between longer-term use of anti-diabetic medications and cardiovascular
      disease has important clinical implications. METHODS: Literature search in
      MEDLINE and CENTRAL was conducted throughout December 2011 for clinical and
      observational studies that reported the association between sulphonylurea and
      cardiovascular disease events. Ratios (relative risk, odds ratios or hazard
      ratios) adjusted for potential confounders (e.g. concomitant medications,
      baseline cardiovascular risk, diabetes severity) were pooled using a
      random-effects model to yield relative risks and associated 95% confidence
      intervals. RESULTS: This meta-analysis included 33 studies (n = 1,325,446
      patients), followed for a range of 0.46-10.4 years. In all studies, compared with
      other oral diabetes drugs, sulphonylurea use was associated with a significantly 
      increased risk of cardiovascular death (relative risk 1.27, 95% confidence
      interval 1.18-1.34, n = 27 comparisons) and composite cardiovascular event
      (including myocardial infarction, stroke, cardiovascular-related hospitalization 
      or cardiovascular death) (relative risk 1.10, 95% confidence interval 1.04-1.16, 
      n = 43 comparisons). In studies comparing sulphonylurea vs. metformin, these
      relative risks were 1.26 (95% confidence interval 1.17-1.35, n = 17 comparisons) 
      and 1.18 (95%confidence interval 1.13-1.24, n = 16 comparisons), respectively.
      CONCLUSIONS: Results suggest that sulphonylurea use may elevate the risk of
      cardiovascular disease among patients with diabetes. This meta-analysis expands
      the pool of studies evaluating cardiovascular mortality compared with prior
      observations while using adjusted estimates, and assessing an additional outcome 
      of a composite cardiovascular event. This finding warrants consideration in
      clinical practice when other treatment options may be available. This article is 
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Western University of Health Sciences, College of Pharmacy, Pomona, CA; Western
      Diabetes Institute, Pomona, CA.
FAU - Phung, O J
AU  - Phung OJ
FAU - Schwartzman, E
AU  - Schwartzman E
FAU - Allen, R W
AU  - Allen RW
FAU - Engel, S S
AU  - Engel SS
FAU - Rajpathak, S N
AU  - Rajpathak SN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130511
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/09/19 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/05/08 [accepted]
AID - 10.1111/dme.12232 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 11. doi: 10.1111/dme.12232.

PMID- 23663133
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 14
IP  - 9
DP  - 2013 Jun
TI  - Pathophysiology and pharmacotherapy of gastroparesis: current and future
      perspectives.
PG  - 1171-86
LID - 10.1517/14656566.2013.795948 [doi]
AB  - Introduction: Gastroparesis is an important clinical disorder characterised by
      delayed gastric emptying in the absence of mechanical outlet obstruction.
      Idiopathic, diabetes and postsurgical causes represent the most common
      aetiologies. The condition commonly manifests as upper gastrointestinal symptoms,
      including nausea, vomiting, postprandial fullness, early satiety, abdominal pain 
      and bloating. Areas covered: This paper provides a review of the prevalence,
      pathophysiology and clinical features associated with gastroparesis, with a
      particular focus on current pharmacological management options and novel and
      emerging therapies. A literature search was undertaken using the search terms:
      gastroparesis, diabetic gastroparesis, idiopathic gastroparesis, gastric
      emptying, prokinetic, metoclopramide, domperidone, erythromycin, motilin,
      alemcinal, KC11458, mitemcinal, ghrelin, TZP-101, TZP-102, RM-131, tegaserod,
      prucalopride, naronapride, velusetrag, levosulpiride, itopride, botulinum toxin, 
      gastric electrical stimulation, Enterra. Expert opinion: Strategies for the
      management of gastroparesis include correction of malnutrition, dehydration and
      electrolyte imbalance, relief of symptoms by appropriate use of prokinetic and
      antiemetic agents and, in patients with gastroparesis associated with diabetes or
      critical illness-induced hyperglycaemia, optimisation of glycaemic control.
      Conventional prokinetic agents form the mainstay of treatment. While novel
      pharmacotherapies are in development, compelling evidence for their efficacy,
      particularly in symptom relief, remains to be established.
AD  - University of South Australia, School of Pharmacy and Medical Sciences , GPO Box 
      2471 Adelaide SA 5001 , Australia julie.stevens@unisa.edu.au.
FAU - Stevens, Julie E
AU  - Stevens JE
FAU - Jones, Karen L
AU  - Jones KL
FAU - Rayner, Christopher K
AU  - Rayner CK
FAU - Horowitz, Michael
AU  - Horowitz M
LA  - eng
PT  - Journal Article
DEP - 20130511
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/05/11 [aheadofprint]
AID - 10.1517/14656566.2013.795948 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2013 Jun;14(9):1171-86. doi:
      10.1517/14656566.2013.795948. Epub 2013 May 11.

PMID- 23663130
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
DP  - 2013 May 29
TI  - Results of the CAPPS: COPD - Assessment of Practice in Primary Care Study.
AB  - Abstract Objective: Since many patients with COPD in the US are managed by
      primary care physicians, we evaluated adherence to the Global Initiative for
      Chronic Obstructive Lung Disease (GOLD) guidelines in a primary care setting.
      Methods: A cross-sectional study was conducted using a random sample of patients 
      (n = 50-150 per site) aged 40-89 years with diagnosed COPD. Patients were
      identified for study inclusion (N = 1517) from 11 US primary care sites.
      Demographic and clinical information was extracted from primary care medical
      records via retrospective chart review. The main outcome measures were adherence 
      to GOLD primary care guidelines, assessed via three components as follows: 1. Is 
      there a current diagnostic spirometry test measurement available within the
      patient's medical record during the prior calendar year? 2. Are comorbid
      conditions, if present, being treated appropriately? 3. Are adequate risk
      reduction measures being taken? Results: Mean patient age was 67.2 (SD +/- 11.3) 
      years, 54% were female, and 34% were current smokers. Overall, 19% of patients
      had comorbid asthma, 66% hypertension, 61% dyslipidemia, 30% cardiovascular
      disease, and 28% diabetes. Mean duration of COPD was approximately 4.8 years.
      Only 27% of patients had a spirometry test result documented within the past
      year. More than half (52%) of patients did not have a documented COPD stage; 20% 
      were classified as stage I, 13% stage II, 12% stage III, 3% stage IV. About 63%
      of patients met at least one guideline component, while only 3% of patients met
      all components; 27% met diagnostic, 25% comorbid conditions management, and 32%
      met risk reduction criteria. Limitations: The retrospective design of our study
      did not allow evaluation of some possible covariates or causal assessment, and
      spirometry measurements were unavailable for many patients. Conclusions: Results 
      suggest that treatment per COPD primary care guidelines was not consistently
      applied among participating practices (range 0.0%-8.7% for meeting all three
      components). Educational initiatives may increase primary care providers'
      knowledge of and adherence to COPD treatment guidelines and recommended patient
      management strategies.
AD  - Novartis Pharmaceuticals Corporation , East Hanover, NJ , USA.
FAU - Belletti, Daniel
AU  - Belletti D
FAU - Liu, Jia
AU  - Liu J
FAU - Zacker, Christopher
AU  - Zacker C
FAU - Wogen, Jenifer
AU  - Wogen J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1185/03007995.2013.803957 [doi]
PST - aheadofprint
SO  - Curr Med Res Opin. 2013 May 29.

PMID- 23663119
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 11
TI  - Thirty days of resveratrol supplementation does not affect postprandial incretin 
      hormone responses, but suppresses postprandial glucagon in obese subjects.
LID - 10.1111/dme.12231 [doi]
AB  - AIMS: Resveratrol, a natural polyphenolic compound produced by various plants
      (e.g. red grapes) and found in red wine, has glucose-lowering effects in humans
      and rodent models of obesity and/or diabetes. The mechanisms behind these effects
      have been suggested to include resveratrol-induced secretion of the gut incretin 
      hormone glucagon-like peptide-1. We investigated postprandial incretin hormone
      and glucagon responses in obese human subjects before and after 30 days of
      resveratrol supplementation. METHODS: Postprandial plasma responses of the
      incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic
      polypeptide and glucagon were evaluated in 10 obese men [subjects characteristics
      (mean +/- standard error of the mean): age 52 +/- 2 years; BMI 32 +/- 1 kg/m2 ,
      fasting plasma glucose 5.5 +/- 0.1 mmol/l] who had been given a dietary
      supplement of resveratrol (Resvida(R) 150 mg/day) or placebo for 30 days in a
      randomized, double-blind, crossover design with a 4-week washout period. At the
      end of each intervention period a standardized meal test (without
      co-administration of resveratrol) was performed. RESULTS: Resveratrol
      supplementation had no impact on fasting plasma concentrations or postprandial
      plasma responses (area under curve values) of glucose-dependent insulinotropic
      polypeptide (11.2 +/- 2.1 vs. 11.8 +/- 2.2 pmol/l, P = 0.87; 17.0 +/- 2.2 vs.
      14.8 +/- 1.6 min x nmol/l, P = 0.20) or glucagon-like peptide-1 (15.4 +/- 1.0 vs.
      15.2 +/- 0.9 pmol/l, P = 0.84; 5.6 +/- 0.4 vs. 5.7 +/- 0.3 min x nmol/l, P =
      0.73). Resveratrol supplementation significantly suppressed postprandial glucagon
      responses (4.4 +/- 0.4 vs. 3.9 +/- 0.4 min x nmol/l, P = 0.01) without affecting 
      fasting glucagon levels (15.2 +/- 2.2 vs. 14.5 +/- 1.5 pmol/l, P = 0.56).
      CONCLUSIONS: Our data suggest that 30 days of resveratrol supplementation does
      not affect fasting or postprandial incretin hormone plasma levels in obese
      humans, but suppresses postprandial glucagon responses.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital,
      University of Copenhagen, Hellerup, Denmark; Department of Biomedical Sciences,
      University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for
      Basic Metabolic Research, The Panum Institute, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Knop, F K
AU  - Knop FK
FAU - Konings, E
AU  - Konings E
FAU - Timmers, S
AU  - Timmers S
FAU - Schrauwen, P
AU  - Schrauwen P
FAU - Holst, J J
AU  - Holst JJ
FAU - Blaak, E E
AU  - Blaak EE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130511
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/04/08 [accepted]
AID - 10.1111/dme.12231 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 11. doi: 10.1111/dme.12231.

PMID- 23663085
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 2042-3306 (Electronic)
IS  - 0425-1644 (Linking)
DP  - 2013 Apr 12
TI  - Severe hypertriglyceridaemia in horses and ponies with endocrine disorders.
LID - 10.1111/evj.12089 [doi]
AB  - REASONS FOR PERFORMING THE STUDY: Severe hypertriglyceridaemia in horses and
      ponies with endocrine disorders has been reported anecdotally but has not been
      documented in the literature. OBJECTIVES: To describe historical and
      clinicopathological findings as well as progression and outcome in horses and
      ponies with severe hypertriglyceridaemia (serum triglyceride concentration >5.65 
      mmol/l) secondary to an endocrine disorder that were otherwise apparently
      healthy. METHODS: Cases from 6 participating institutions were identified and
      case details extracted from the medical records. RESULTS: Case details of 3
      horses and 4 ponies were available. Presenting complaints included weight loss
      despite good appetite in 4 animals while in 3 hypertriglyceridaemia was
      identified incidentally. All animals were bright and alert and showed a normal or
      increased appetite. Serum triglyceride concentrations ranged from 10.5-57.9
      mmol/l. Other abnormalities included hyperglycaemia in 6 animals, suspected
      insulin resistance and mild to severe increases in hepatic enzyme activities. In 
      2 animals moderate hepatic lipidosis was confirmed histologically. Three horses
      and 3 ponies were diagnosed with pituitary pars intermedia dysfunction (PPID)
      based on clinical signs and basal ACTH concentrations or dexamethasone
      suppression test results. In 5 of these, type II diabetes mellitus was also
      confirmed while one pony suffered from type II diabetes mellitus without
      concurrent PPID. Laboratory abnormalities improved in 4 animals with treatment
      (pergolide and/or insulin), in one horse specific treatment was not attempted and
      in 2 ponies treatment was impaired by the owner or only partially effective. In
      one of the latter cases biochemical abnormalities persisted for 7 years without
      apparent ill effects. CONCLUSIONS AND POTENTIAL RELEVANCE: Horses and ponies may 
      develop severe hypertriglyceridaemia secondary to endocrine disorders that are
      associated with insulin resistance. Hypertriglyceridaemia can resolve with
      treatment of the endocrinopathy. Although biochemical evidence of hepatic
      compromise was present, clinical abnormalities were not noted in these animals.
CI  - This article is protected by copyright. All rights reserved.
AD  - Dept. of Veterinary Clinical Sciences, The Royal Veterinary College, North Mymms,
      Herts, AL9 7TA, UK.
FAU - Dunkel, B
AU  - Dunkel B
FAU - Wilford, S A
AU  - Wilford SA
FAU - Parkinson, N J
AU  - Parkinson NJ
FAU - Ward, C
AU  - Ward C
FAU - Smith, P
AU  - Smith P
FAU - Grahame, L
AU  - Grahame L
FAU - Brazil, T
AU  - Brazil T
FAU - Schott, H C 2nd
AU  - Schott HC 2nd
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Equine Vet J
JT  - Equine veterinary journal
JID - 0173320
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1111/evj.12089 [doi]
PST - aheadofprint
SO  - Equine Vet J. 2013 Apr 12. doi: 10.1111/evj.12089.

PMID- 23663075
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
DP  - 2013 May 13
TI  - Genetic deletion of Granzyme B does not confer resistance to the development of
      spontaneous diabetes in NOD mice.
LID - 10.1111/cei.12134 [doi]
AB  - Granzyme-B (GzmB) and perforin are proteins, secreted mainly by natural killer
      cells and cytotoxic T lymphocytes that are largely responsible for the induction 
      of apoptosis in target cells. Since type 1 diabetes results from the selective
      destruction of beta cells and perforin deficiency effectively reduces diabetes in
      non-obese diabetic (NOD) mice, it can be deduced that beta-cell apoptosis
      involves the GzmB/perforin pathway. However, the relevance of GzmB remains
      totally unknown in NOD mice. We here focused on GzmB and examined the consequence
      of GzmB deficiency in NOD mice. We found that NOD.GzmB-/- mice spontaneously
      developed diabetes with kinetics similar to those of wild-type NOD (wt-NOD) mice.
      Adoptive transfer study with Treg-depleted SPCs into NOD-SCID mice or in vivo
      Treg-depletion by anti-CD25 antibody at 4 weeks of age comparably induced the
      rapid progression of diabetes in the NOD.GzmB-/- mice and wt-NOD mice. Expression
      of GzmA and Fas was enhanced in the islets from pre-diabetic NOD.GzmB-/- mice. In
      contrast to spontaneous diabetes, GzmB deficiency suppressed the development of
      cyclophosphamide-promoted diabetes in male NOD mice. Cyclophosphamide treatment
      led to a significantly lower percentage of apoptotic CD4+, CD8+ and CD4+CD25+ T
      cells in SPCs from NOD.GzmB-/- mice than those from wt-NOD mice. In conclusion,
      GzmB, in contrast to perforin, is not essentially involved in the effector
      mechanisms for beta-cell destruction in NOD mice.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Endocrinology and Metabolism, Unit of Translational Medicine,
      Graduate School of Biomedical Science, Nagasaki University, 1-7-1 Sakamoto,
      Nagasaki 852-8501, Japan.
FAU - Kobayashi, Masakazu
AU  - Kobayashi M
FAU - Kaneko-Koike, Chieko
AU  - Kaneko-Koike C
FAU - Abiru, Norio
AU  - Abiru N
FAU - Uchida, Takahiro
AU  - Uchida T
FAU - Akazawa, Satoru
AU  - Akazawa S
FAU - Nakamura, Kan
AU  - Nakamura K
FAU - Kuriya, Genpei
AU  - Kuriya G
FAU - Satoh, Tsuyoshi
AU  - Satoh T
FAU - Ida, Hiroaki
AU  - Ida H
FAU - Kawasaki, Eiji
AU  - Kawasaki E
FAU - Yamasaki, Hironori
AU  - Yamasaki H
FAU - Nagayama, Yuji
AU  - Nagayama Y
FAU - Sasaki, Hitoshi
AU  - Sasaki H
FAU - Kawakami, Atsushi
AU  - Kawakami A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/04/15 [accepted]
AID - 10.1111/cei.12134 [doi]
PST - aheadofprint
SO  - Clin Exp Immunol. 2013 May 13. doi: 10.1111/cei.12134.

PMID- 23662975
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 10
TI  - Giant prolactinomas: the therapeutic approach.
LID - 10.1111/cen.12242 [doi]
AB  - BACKGROUND: Giant prolactinomas are an unusual subset of macroprolactinomas and
      are more commonly found in men. The goal of this review is to propose a giant
      prolactinoma definition and discuss the available therapeutic options for
      biochemical and tumour volume control. METHODS: A comprehensive search of all
      published studies was performed between April and November 2012 in electronic
      databases (PubMed and Ovid). RESULTS: A giant prolactinoma should be defined as
      an adenoma with a maximum diameter of more than 4 cm that is associated with
      serum prolactin above 5300 mIU/L. Regarding treatment, cabergoline is the
      preferred dopamine agonist for medical management of giant prolactinomas because 
      of its excellent efficacy and tolerability. Normalisation of prolactin level and 
      significant tumour reduction may be achieved in the majority of patients.
      Combined therapy, particularly cabergoline and surgery, may be necessary due to
      the large tumour load. Radiotherapy and temozolomide may be used for patients
      with aggressive giant prolactinomas in whom tumour volume control is not achieved
      with cabergoline and surgery. CONCLUSION: There is a scarcity of large studies
      about the management of giant prolactinoma. Cabergoline is the first-line
      treatment. However, caution should be exercised when comparing efficacy rates
      among the different treatment modalities due to the variability in study design
      and data quality. In this scenario, a "standard" definition for giant
      prolactinomas and larger series may be helpful to assess the real efficacy and
      safety of each therapeutic modality. This article is protected by copyright. All 
      rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Internal Medicine and Endocrine Unit, Medical School and Clementino
      Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de
      Janeiro, Brazil; Psychoneuroendocrinology Unit, State Institute of Diabetes and
      Endocrinology of Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Moraes, Aline Barbosa
AU  - Moraes AB
FAU - Marques Dos Santos Silva, Cintia
AU  - Marques Dos Santos Silva C
FAU - Vieira Neto, Leonardo
AU  - Vieira Neto L
FAU - Gadelha, Monica R
AU  - Gadelha MR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2012/10/22 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/05/02 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/cen.12242 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 10. doi: 10.1111/cen.12242.

PMID- 23662945
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1744-5086 (Electronic)
IS  - 0928-6586 (Linking)
DP  - 2013 May 10
TI  - Factors Contributing to Diabetes Patients Not Receiving Annual Dilated Eye
      Examinations.
AB  - Abstract Purpose: Early detection of diabetic eye disease by dilated eye exam can
      limit potential vision loss from diabetic retinopathy. The purpose of this study 
      was to examine what variables contribute to diabetes patients not receiving
      annual dilated eye examinations. Methods: This study used national 2009
      Behavioral Risk Factor Surveillance System survey data. Variables used in the
      analysis included sociodemographics, insurance status, mentally unhealthy days,
      receipt of annual dilated eye exams, insulin dependence, a history of diabetes
      education classes, timely annual diabetic foot exams, and history of
      cardiovascular disease. Survey proportions were calculated, and survey logistic
      regression was performed with the consideration of survey strata and weight to
      correct for biases. Results: The likelihood of receiving annual dilated eye exams
      was correlated with eight statistically significant variables. These variables
      included age category, income level, education level, health insurance status,
      mentally unhealthy days within the past month, insulin dependence, a history of
      diabetic education classes, and timeliness of annual diabetic foot examinations. 
      Conclusions: This study provides a snapshot of variables that may have a bearing 
      on diabetes patients seeking annual dilated retinal examinations. Eight variables
      were statistically significant in affecting the timeliness of diabetic eye
      examinations. Thus, resolutions for these factors could be implemented for future
      improvement of comprehensive health care provided to those with diabetes.
AD  - Robert J. Dole VA Medical Center - Wichita , KS , USA and.
FAU - Paksin-Hall, Arraya
AU  - Paksin-Hall A
FAU - Dent, Michelle L
AU  - Dent ML
FAU - Dong, Frank
AU  - Dong F
FAU - Ablah, Elizabeth
AU  - Ablah E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Ophthalmic Epidemiol
JT  - Ophthalmic epidemiology
JID - 9435674
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.3109/09286586.2013.789531 [doi]
PST - aheadofprint
SO  - Ophthalmic Epidemiol. 2013 May 10.

PMID- 23662939
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 10
TI  - Relation of insulin-like growth factor-I and IGF binding protein 3 with markers
      of inflammation: results of a population-based study.
LID - 10.1111/cen.12241 [doi]
AB  - OBJECTIVE: Previous studies in acromegaly and growth hormone deficiency observed 
      inverse associations between insulin-like growth factor-I (IGF-I) levels and
      inflammatory biomarkers including high-sensitive C-reactive protein (hsCRP),
      interleukin-6 or fibrinogen. We aimed to assess the relations between IGF-I or
      IGF binding protein 3 (IGFBP-3) levels and hsCRP, interleukin-6, fibrinogen and
      white blood cell count (WBC) in a population-based sample. DESIGN AND PATIENTS:
      Data from 3480 subjects from the population-based Study of Health in Pomerania
      (SHIP) were used. IGF-I, IGFBP-3 and inflammatory biomarkers were measured.
      Analysis of variance (anova), quantile regression models and logistic regression 
      models, adjusted for age, smoking, diabetes mellitus and waist circumference,
      were performed. MEASUREMENTS AND RESULTS: anova and/or quantile regression showed
      inverse associations between IGF-I and hsCRP as well as positive associations
      between IGF-I and fibrinogen among both sexes. Furthermore, the odds of elevated 
      fibrinogen levels increased with increasing IGF-I levels (per SD IGF-I increase: 
      men: odds ratio (OR) 1.35 [95% confidence interval (CI) 1.04, 1.55]; women: OR
      1.44 [95% CI 1.21, 1.71]) in both sexes, whereas the odds of increased hsCRP
      (women: OR 0.46 [95% CI 0.36, 0.58]) and interleukin-6 (men: odds ratio (OR) 0.77
      [95% CI 0.61, 0.96]; women: OR 0.69 [95% CI 0.55, 0.86]) decreased. CONCLUSION:
      Serum IGF-I levels are associated with inflammatory biomarkers including hsCRP,
      interleukin-6 and fibrinogen. Further experimental studies are needed to
      elucidate the mechanisms underlying the relation between the GH/IGF axis and the 
      inflammatory system.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Institute of Clinical Chemistry and Laboratory Medicine, University Medicine
      Greifswald, Greifswald, Germany.
FAU - Lohr, Johannes
AU  - Lohr J
FAU - Grotevendt, Anne
AU  - Grotevendt A
FAU - Nauck, Matthias
AU  - Nauck M
FAU - Volzke, Henry
AU  - Volzke H
FAU - Wallaschofski, Henri
AU  - Wallaschofski H
FAU - Friedrich, Nele
AU  - Friedrich N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/02/26 [received]
PHST- 2013/04/25 [revised]
PHST- 2013/04/26 [revised]
PHST- 2013/05/06 [accepted]
AID - 10.1111/cen.12241 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 10. doi: 10.1111/cen.12241.

PMID- 23662913
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 10
TI  - Developing long-acting growth hormone formulations.
LID - 10.1111/cen.12240 [doi]
AB  - Daily recombinant growth hormone (GH) restores normal growth and body composition
      in GH deficient children and adults, however daily injections are inconvenient
      and can be distressing for some children. On top of this compliance is a problem 
      in up to 75% of children. Developing long-acting GH formulations has proved
      challenging and questions remain regarding safety and efficacy. In this review we
      focus on the rationale for generating long-acting GH agonists and the
      technologies being developed to deliver prolonged exposure to GH. This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Academic Unit of Diabetes, Endocrinology and Reproduction, University of
      Sheffield, Sheffield, UK.
FAU - Cawley, Pippa
AU  - Cawley P
FAU - Wilkinson, Ian
AU  - Wilkinson I
FAU - Ross, Richard J
AU  - Ross RJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PHST- 2013/04/23 [received]
PHST- 2013/04/30 [revised]
PHST- 2013/05/07 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/cen.12240 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 10. doi: 10.1111/cen.12240.

PMID- 23662778
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1545-4274 (Electronic)
IS  - 1523-9829 (Linking)
DP  - 2013 May 6
TI  - Cardiovascular Magnetic Resonance: Deeper Insights Through Bioengineering.
AB  - Heart disease is the main cause of morbidity and mortality worldwide, with
      coronary artery disease, diabetes, and obesity being major contributing factors. 
      Cardiovascular magnetic resonance (CMR) can provide a wealth of quantitative
      information on the performance of the heart, without risk to the patient.
      Quantitative analyses of these data can substantially augment the diagnostic
      quality of CMR examinations and can lead to more effective characterization of
      disease and quantification of treatment benefit. This review provides an overview
      of the current state of the art in CMR with particular regard to the
      quantification of motion, both microscopic and macroscopic, and the application
      of bioengineering analysis for the evaluation of cardiac mechanics. We discuss
      the current clinical practice and the likely advances in the next 5-10 years, as 
      well as the ways in which clinical examinations can be augmented by
      bioengineering analysis of strain, compliance, and stress. Expected final online 
      publication date for the Annual Review of Biomedical Engineering Volume 15 is
      July 11, 2013. Please see http://www.annualreviews.org/catalog/pubdates.aspx for 
      revised estimates.
AD  - Department of Anatomy with Radiology, School of Medical Science, Faculty of
      Medical and Health Sciences, Auckland, 1023 New Zealand; email:
      a.young@auckland.ac.nz.
FAU - Young, A A
AU  - Young AA
FAU - Prince, J L
AU  - Prince JL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Annu Rev Biomed Eng
JT  - Annual review of biomedical engineering
JID - 100883581
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
AID - 10.1146/annurev-bioeng-071812-152346 [doi]
PST - aheadofprint
SO  - Annu Rev Biomed Eng. 2013 May 6.

PMID- 23662374
OWN - NLM
STAT- In-Process
DA  - 20130513
IS  - 1565-1088 (Print)
VI  - 15
IP  - 3
DP  - 2013 Mar
TI  - Health ramifications of the Gush Katif evacuation.
PG  - 137-42
AB  - BACKGROUND: Following the 2005 evacuation of Gush Katif, a community of Jewish
      settlements located in the greater Gaza Strip, many evacuees reported a
      deterioration in their health status. OBJECTIVES: To determine if and to what
      degree the evacuation of Gush Katif caused a worsening in the health status of
      the evacuees. METHODS: In this retrospective cohort study we assessed the medical
      records of 2962 evacuees for changes in prevalence of diabetes, hypertension and 
      ischemic heart disease in the period beginning 1 year before and ending 5 years
      after the evacuation. The findings were compared to those for the general israeli
      population. A questionnaire was distributed to 64 individuals to assess lifestyle
      and social change. RESULTS: An increase in diabetes and hypertension was found in
      men aged 45-64. The prevalence of diabetes mellitus in the 45-54 male group rose 
      from 8.7% in 2004 to 12.6% in 2007 to 18.7% in 2010; in the 55-64 age group it
      rose from 24.6% in 2004 to 29.9% in 2007 to 32.9% in 2010. Hypertension in 45-64 
      year old men rose from 27.1% in 2004 to 35.12% in 2010. The increases in diabetes
      were significant and higher than those in the general population. The increases
      in hypertension were of similar magnitude. The prevalence of heart disease did
      not change and is similar to that in the general population. The questionnaire
      sample showed an increase in depression and overweight. CONCLUSIONS: The Gush
      Katif evacuation appears to be associated with increased morbidity of chronic
      disease. This may be attributed to any of several mechanisms, with unemployment, 
      depression, inactivity and overweight playing significant roles. Preventive
      medical interventions and measures should be employed to screen and treat this
      population which underwent a major stressful event and as a result seem at
      greater risk than their peers.
AD  - Department of Internal Medicine, Shaarei Zedek Medical Center, Jerusalem, Israel.
FAU - Kory, Ronen
AU  - Kory R
FAU - Carney, Alon
AU  - Carney A
FAU - Naimer, Sody
AU  - Naimer S
LA  - eng
PT  - Journal Article
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/05/14 06:00
PST - ppublish
SO  - Isr Med Assoc J. 2013 Mar;15(3):137-42.

PMID- 23510522
OWN - NLM
STAT- In-Process
DA  - 20130320
IS  - 0767-0974 (Print)
IS  - 0767-0974 (Linking)
VI  - 29 Spec No 1
DP  - 2013 Mar
TI  - [Mucormycosis: therapeutic news].
PG  - 25-30
LID - 10.1051/medsci/201329s106 [doi]
AB  - Mucormycosis is a life-threatening invasive fungal infection that arises among
      immunocompromised patients (haematological malignancies, solid organ
      transplantation, diabetes mellitus). The most frequent sites of infection are
      pulmonary, rhinocerebral, cutaneous and disseminated. Reversal of the underlying 
      conditions is mandatory for controlling mucormycosis. Another cornerstone of
      mucormycosis treatment is prompt and aggressive surgery. It is achieved by
      extensive surgical debridement of necrotic tissues. Finally an antifungal therapy
      is needed. The first-line chemotherapy of mucormycosis includes high-dose
      liposomal amphotericin B (>/= 5 mg/kg/day). The duration of antifungal
      chemotherapy is not defined but guided by the resolution of all associated
      symptoms and findings (usually 6-8 weeks). Maintenance therapy/secondary
      prophylaxis by posaconazole has to be considered in persistently immuno
      compromised patients.
CI  - (c) 2013 medecine/sciences - Inserm / SRMS.
AD  - Universite Paris-Descartes, Hopital Necker-Enfants malades, Service des maladies 
      infectieuses et tropicales, Centre d'Infectiologie Necker-Pasteur, Paris, France.
FAU - Pilmis, Benoit
AU  - Pilmis B
FAU - Lanternier, Fanny
AU  - Lanternier F
FAU - Lortholary, Olivier
AU  - Lortholary O
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Mucormycoses - Actualites therapeutiques.
DEP - 20130313
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
SB  - IM
EDAT- 2013/05/15 06:00
MHDA- 2013/05/15 06:00
CRDT- 2013/03/21 06:00
PHST- 2013/03/13 [epublish]
AID - 10.1051/medsci/201329s106 [doi]
AID - medsci2013291sp25 [pii]
PST - ppublish
SO  - Med Sci (Paris). 2013 Mar;29 Spec No 1:25-30. doi: 10.1051/medsci/201329s106.
      Epub 2013 Mar 13.

PMID- 23662341
OWN - NLM
STAT- In-Process
DA  - 20130510
IS  - 0954-4119 (Print)
IS  - 0954-4119 (Linking)
VI  - 227
IP  - 3
DP  - 2013 Mar
TI  - Decision support system for diabetic retinopathy using discrete wavelet
      transform.
PG  - 251-61
AB  - Prolonged duration of the diabetes may affect the tiny blood vessels of the
      retina causing diabetic retinopathy. Routine eye screening of patients with
      diabetes helps to detect diabetic retinopathy at the early stage. It is very
      laborious and time-consuming for the doctors to go through many fundus images
      continuously. Therefore, decision support system for diabetic retinopathy
      detection can reduce the burden of the ophthalmologists. In this work, we have
      used discrete wavelet transform and support vector machine classifier for
      automated detection of normal and diabetic retinopathy classes. The wavelet-based
      decomposition was performed up to the second level, and eight energy features
      were extracted. Two energy features from the approximation coefficients of two
      levels and six energy values from the details in three orientations (horizontal, 
      vertical and diagonal) were evaluated. These features were fed to the support
      vector machine classifier with various kernel functions (linear, radial basis
      function, polynomial of orders 2 and 3) to evaluate the highest classification
      accuracy. We obtained the highest average classification accuracy, sensitivity
      and specificity of more than 99% with support vector machine classifier
      (polynomial kernel of order 3) using three discrete wavelet transform features.
      We have also proposed an integrated index called Diabetic Retinopathy Risk Index 
      using clinically significant wavelet energy features to identify normal and
      diabetic retinopathy classes using just one number. We believe that this
      (Diabetic Retinopathy Risk Index) can be used as an adjunct tool by the doctors
      during the eye screening to cross-check their diagnosis.
AD  - Department of Electronics & Communication, Manipal Institute of Technology,
      Manipal, India. kevinkurkal@yahoo.co.in
FAU - Noronha, K
AU  - Noronha K
FAU - Acharya, U R
AU  - Acharya UR
FAU - Nayak, K P
AU  - Nayak KP
FAU - Kamath, S
AU  - Kamath S
FAU - Bhandary, S V
AU  - Bhandary SV
LA  - eng
PT  - Journal Article
PL  - England
TA  - Proc Inst Mech Eng H
JT  - Proceedings of the Institution of Mechanical Engineers. Part H, Journal of
      engineering in medicine
JID - 8908934
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PST - ppublish
SO  - Proc Inst Mech Eng H. 2013 Mar;227(3):251-61.

PMID- 23662249
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 2168-8761 (Print)
VI  - 1
IP  - 1
DP  - 2013 Mar 1
TI  - Natural Polyphenols Inhibit Lysine-Specific Demethylase-1
PG  - 56-63
AB  - Natural polyphenols, such as resveratrol, have beneficial functions on major
      human diseases such as cancer, diabetes, and cardiovascular disease. Besides
      acting as antioxidants, some of these polyphenols can also target proteins to
      modulate specific biological pathways. The lysine-specific histone demethylase
      LSD1 plays important roles in cell growth, differentiation and nutrient
      metabolism. Here, we studied the effect of natural polyphenols resveratrol,
      curcumin, quercetin and analogs on LSD1. Using in vitro LSD1 enzymatic assays, we
      show that resveratrol, curcumin and quercetin displayed a potent inhibitory
      effect on the LSD1 activity and were more potent than the known LSD1 inhibitor
      trans-2-phenylcyclopropylamine (TCP). The new function of resveratrol, curcumin
      and quercetin is independent of their antioxidant properties, as other
      antioxidants had no effect on LSD1 under the similar conditions. In C2C12
      fibroblasts, resveratrol and curcumin can efficiently inhibit myogenic expression
      and differentiation, for which LSD1 is required. Thus, our study has identified
      LSD1 as a novel target of bioactive natural compounds, such as resveratrol,
      curcumin and quercetin, and such finding suggests that LSD1 inhibition can at
      least partially contribute to some of the previously observed beneficial effects 
      of these compounds.
AD  - Department of Medicine, Developmental and Molecular Biology, Diabetes Research
      and Training Center, Albert Einstein College of Medicine, 1301 Morris Park
      Avenue, Bronx NY 10461, USA.
FAU - Abdulla, Arian
AU  - Abdulla A
FAU - Zhao, Xiaoping
AU  - Zhao X
FAU - Yang, Fajun
AU  - Yang F
LA  - ENG
GR  - P60 DK020541/DK/NIDDK NIH HHS/United States
GR  - R01 DK093623/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
TA  - J Biochem Pharmacol Res
JT  - Journal of biochemical and pharmacological research
JID - 101604121
PMC - PMC3646376
MID - NIHMS465947
OTO - NOTNLM
OT  - LSD1
OT  - curcumin
OT  - demethylation
OT  - myogenesis
OT  - polyphenol
OT  - quercetin
OT  - resveratrol
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PST - ppublish
SO  - J Biochem Pharmacol Res. 2013 Mar 1;1(1):56-63.

PMID- 23662142
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130510
DCOM- 20130513
LR  - 20130513
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - An Aqueous Extract of Radix Astragali, Angelica sinensis, and Panax notoginseng
      Is Effective in Preventing Diabetic Retinopathy.
PG  - 578165
LID - 10.1155/2013/578165 [doi]
AB  - Diabetic retinopathy (DR), in which inflammation has been implicated playing
      important roles, is one of the most common diabetes complications. Dang Gui Bu
      Xue Tang (DBT), an aqueous extract of Radix Astragali and Radix Angelica
      sinensis, is a classical prescription in Traditional Chinese Medicine for
      treating inflammation and ischemic diseases. Here, we investigated the effects of
      a modified recipe of DBT, with addition of Panax notoginseng, in treating
      diabetic retinopathy. An aqueous extract of Radix Astragali, Radix Angelica
      sinensis, and Panax notoginseng (RRP) was given to Goto-Kakizaki (GK) rats and
      streptozotocin-induced Sprague-Dawley (SD) rats. Leukostasis, vascular leakage,
      and acellular capillaries in retinal vasculature of animals were determined.
      Expression of retinal inflammatory biomarkers was assessed. We found that RRP
      reduced leukostasis, acellular capillaries, and vascular leakage compared to
      diabetic control rats. We also found that RRP decreased the expression of
      inflammatory factors including IL-1 beta , IL-6, TNF- alpha , NF- kappa B, MCP-1,
      ICAM-1, or VCAM-1 in the retinas of GK rats and reversed high glucose-induced
      inhibition of endothelial cell migration and proliferation in vitro. We conclude 
      that RRP has a potent effect in preventing the pathogenesis and/or progression of
      DR and thus may serve as a promising nontoxic therapeutic approach of DR.
AD  - Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University,
      Xiamen 361003, China.
FAU - Gao, Dehong
AU  - Gao D
FAU - Guo, Yijuan
AU  - Guo Y
FAU - Li, Xuejun
AU  - Li X
FAU - Li, Xiumin
AU  - Li X
FAU - Li, Zhipeng
AU  - Li Z
FAU - Xue, Mei
AU  - Xue M
FAU - Ou, Zhimin
AU  - Ou Z
FAU - Liu, Ming
AU  - Liu M
FAU - Yang, Mingxing
AU  - Yang M
FAU - Liu, Suhuan
AU  - Liu S
FAU - Yang, Shuyu
AU  - Yang S
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3638602
OID - NLM: PMC3638602
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:01
CRDT- 2013/05/11 06:00
PHST- 2012/12/18 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1155/2013/578165 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:578165. doi: 10.1155/2013/578165.
      Epub 2013 Apr 8.

PMID- 23662138
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130510
DCOM- 20130513
LR  - 20130513
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Rhinacanthus nasutus Ameliorates Cytosolic and Mitochondrial Enzyme Levels in
      Streptozotocin-Induced Diabetic Rats.
PG  - 486047
LID - 10.1155/2013/486047 [doi]
AB  - The present study was conducted to evaluate the therapeutic efficacy of
      Rhinacanthus nasutus (R. nasutus) on mitochondrial and cytosolic enzymes in
      streptozotocin-induced diabetic rats. The rats were divided into five groups with
      6 rats in each group. The methanolic extract of R. nasutus was orally
      administered at a dose of 200 mg/kg/day, and glibenclamide was administered at a 
      dose of 50 mg/kg/day. All animals were treated for 30 days and were sacrificed.
      The activities of both intra- and extramitochondrial enzymes including
      glucose-6-phosphate dehydrogenase (G6PDH), succinate dehydrogenase (SDH),
      glutamate dehydrogenase (GDH), and lactate dehydrogenase (LDH) were measured in
      the livers of the animals. The levels of G6PDH, SDH, and GDH were significantly
      reduced in the diabetic rats but were significantly increased after 30 days of R.
      nasutus treatment. The increased LDH level in diabetic rats exhibited a
      significant reduction after treatment with R. nasutus. These results indicate
      that the administration of R. nasutus altered the activities of oxidative enzymes
      in a positive manner, indicating that R. nasutus improves mitochondrial energy
      production. Our data suggest that R. nasutus should be further explored for its
      role in the treatment of diabetes mellitus.
AD  - Department of Biotechnology, Sri Venkateswara University, Tirupati 517502, Andhra
      Pradesh, India ; Human Genome Centre, School of Medical Sciences, Universiti
      Sains Malaysia, 16150 Kubang Kerian, Malaysia.
FAU - Visweswara Rao, Pasupuleti
AU  - Visweswara Rao P
FAU - Madhavi, K
AU  - Madhavi K
FAU - Dhananjaya Naidu, M
AU  - Dhananjaya Naidu M
FAU - Gan, Siew Hua
AU  - Gan SH
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3638636
OID - NLM: PMC3638636
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:01
CRDT- 2013/05/11 06:00
PHST- 2013/02/13 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/03/16 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1155/2013/486047 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:486047. doi: 10.1155/2013/486047.
      Epub 2013 Apr 9.

PMID- 23662132
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130510
DCOM- 20130513
LR  - 20130513
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential 
      application of selected plants and compounds.
PG  - 378657
LID - 10.1155/2013/378657 [doi]
AB  - Diabetes mellitus has been recognized since antiquity. It currently affects as
      many as 285 million people worldwide and results in heavy personal and national
      economic burdens. Considerable progress has been made in orthodox antidiabetic
      drugs. However, new remedies are still in great demand because of the limited
      efficacy and undesirable side effects of current orthodox drugs. Nature is an
      extraordinary source of antidiabetic medicines. To date, more than 1200 flowering
      plants have been claimed to have antidiabetic properties. Among them, one-third
      have been scientifically studied and documented in around 460 publications. In
      this review, we select and discuss blood glucose-lowering medicinal herbs that
      have the ability to modulate one or more of the pathways that regulate insulin
      resistance, beta-cell function, GLP-1 homeostasis, and glucose (re)absorption.
      Emphasis is placed on phytochemistry, anti-diabetic bioactivities, and likely
      mechanism(s). Recent progress in the understanding of the biological actions,
      mechanisms, and therapeutic potential of compounds and extracts of plant origin
      in type 2 diabetes is summarized. This review provides a source of up-to-date
      information for further basic and clinical research into herbal therapy for type 
      2 diabetes. Emerging views on therapeutic strategies for type 2 diabetes are also
      discussed.
AD  - Department of Veterinary Medicine, National Chung Hsing University, Taichung 402,
      Taiwan.
FAU - Chang, Cicero L T
AU  - Chang CL
FAU - Lin, Yenshou
AU  - Lin Y
FAU - Bartolome, Arlene P
AU  - Bartolome AP
FAU - Chen, Yi-Ching
AU  - Chen YC
FAU - Chiu, Shao-Chih
AU  - Chiu SC
FAU - Yang, Wen-Chin
AU  - Yang WC
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3638592
OID - NLM: PMC3638592
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:01
CRDT- 2013/05/11 06:00
PHST- 2013/02/06 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1155/2013/378657 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:378657. doi: 10.1155/2013/378657.
      Epub 2013 Apr 4.

PMID- 23662125
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130510
DCOM- 20130513
LR  - 20130513
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - A Small Molecule Swertisin from Enicostemma littorale Differentiates NIH3T3 Cells
      into Islet-Like Clusters and Restores Normoglycemia upon Transplantation in
      Diabetic Balb/c Mice.
PG  - 280392
LID - 10.1155/2013/280392 [doi]
AB  - Aim. Stem cell therapy is one of the upcoming therapies for the treatment of
      diabetes. Discovery of potent differentiating agents is a prerequisite for
      increasing islet mass. The present study is an attempt to screen the potential of
      novel small biomolecules for their differentiating property into pancreatic islet
      cells using NIH3T3, as representative of extra pancreatic stem cells/progenitors.
      Methods. To identify new agents that stimulate islet differentiation, we screened
      various compounds isolated from Enicostemma littorale using NIH3T3 cells and
      morphological changes were observed. Characterization was performed by
      semiquantitative RT-PCR, Q-PCR, immunocytochemistry, immunoblotting, and insulin 
      secretion assay for functional response in newly generated islet-like cell
      clusters (ILCC). Reversal of hyperglycemia was monitored after transplanting ILCC
      in STZ-induced diabetic mice. Results. Among various compounds tested, swertisin,
      an isolated flavonoid, was the most effective in differentiating NIH3T3 into
      endocrine cells. Swertisin efficiently changed the morphology of NIH3T3 cells
      from fibroblastic to round aggregate cell cluster in huge numbers. Dithizone
      (DTZ) stain primarily confirmed differentiation and gene expression studies
      signified rapid onset of differentiation signaling cascade in swertisin-induced
      ILCC. Molecular imaging and immunoblotting further confirmed presence of islet
      specific proteins. Moreover, glucose induced insulin release (in vitro) and
      decreased fasting blood glucose (FBG) (in vivo) in transplanted diabetic BALB/c
      mice depicted functional maturity of ILCC. Insulin and glucagon expression in
      excised islet grafts illustrated survival and functional integrity. Conclusions. 
      Rapid induction for islet differentiation by swertisin, a novel herbal
      biomolecule, provides low cost and readily available differentiating agent that
      can be translated as a therapeutic tool for effective treatment in diabetes.
AD  - Department of Biochemistry, Faculty of Science, The M.S. University of Baroda,
      Vadodara Gujarat, 390 002, India.
FAU - Dadheech, Nidheesh
AU  - Dadheech N
FAU - Soni, Sanket
AU  - Soni S
FAU - Srivastava, Abhay
AU  - Srivastava A
FAU - Dadheech, Sucheta
AU  - Dadheech S
FAU - Gupta, Shivika
AU  - Gupta S
FAU - Gopurappilly, Renjitha
AU  - Gopurappilly R
FAU - Bhonde, Ramesh R
AU  - Bhonde RR
FAU - Gupta, Sarita
AU  - Gupta S
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3639639
OID - NLM: PMC3639639
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:01
CRDT- 2013/05/11 06:00
PHST- 2012/10/21 [received]
PHST- 2013/01/15 [revised]
PHST- 2013/02/03 [accepted]
PHST- 2013/04/15 [epublish]
AID - 10.1155/2013/280392 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:280392. doi: 10.1155/2013/280392.
      Epub 2013 Apr 15.

PMID- 23662103
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130510
DCOM- 20130513
LR  - 20130513
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Calcium activity of upper thoracic dorsal root ganglion neurons in zucker
      diabetic Fatty rats.
PG  - 532850
LID - 10.1155/2013/532850 [doi]
AB  - The aim of the present study was to examine the calcium activity of C8-T5 dorsal 
      root ganglion (DRG) neurons from Zucker diabetic fatty rats. In total, 8 diabetic
      ZDF fatty animals and 8 age-matched control ZDF lean rats were employed in the
      study. C8-T5 dorsal root ganglia were isolated bilaterally from 14 to 18 weeks
      old rats, and a primary culture was prepared. Calcium activity was measured
      ratiometrically using the fluorescent Ca(2+)-indicator Fura-2 acetoxymethyl
      ester. All neurons were stimulated twice with 20 mM K(+), followed by stimulation
      with either 0.3 or 0.5 mu M Capsaicin, alone or in combination with algogenic
      chemicals (bradykinin, serotonin, prostaglandin E2 (all 10(-5) M), and adenosine 
      (10(-3) M)) at pH 7.4 and 6.0. Neurons from diabetic animals exhibited an overall
      increased response to stimulation with 20 mM K(+) compared to neurons from
      control. Stimulation with Capsaicin alone caused an augmented response in neurons
      from diabetic animals compared to control animals. When stimulated with a
      combination of Capsaicin and algogenic chemicals, no differences between the two 
      groups of neurons were measured, neither at pH 7.4 nor 6.0. In conclusion,
      diabetes-induced alterations in calcium activity of the DRG neurons were found,
      potentially indicating altered neuronal responses during myocardial ischemia.
AD  - Department of Drug Design and Pharmacology, Faculty of Health and Medical
      Sciences, University of Copenhagen, 2100 Copenhagen, Denmark.
FAU - Ghorbani, Marie Louise
AU  - Ghorbani ML
FAU - Nyborg, Niels C B
AU  - Nyborg NC
FAU - Fjalland, Bjarne
AU  - Fjalland B
FAU - Sheykhzade, Majid
AU  - Sheykhzade M
LA  - eng
PT  - Journal Article
DEP - 20130414
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3639628
OID - NLM: PMC3639628
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:01
CRDT- 2013/05/11 06:00
PHST- 2012/12/14 [received]
PHST- 2013/02/19 [revised]
PHST- 2013/02/20 [accepted]
PHST- 2013/04/14 [epublish]
AID - 10.1155/2013/532850 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:532850. doi: 10.1155/2013/532850. Epub 2013 Apr 14.

PMID- 23662064
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Platelet function testing to predict hyporesponsiveness to clopidogrel in
      patients with chest pain seen in the emergency department.
PG  - 187-93
LID - 10.2147/VHRM.S43909 [doi]
AB  - BACKGROUND: A dual antiplatelet regimen has been shown to reduce the risk of
      major adverse cardiovascular events after percutaneous coronary intervention.
      However, there is little information available on inhibition of platelet
      aggregation in patients with a prior coronary stent presenting with chest pain.
      This study evaluated the prevalence of hyporesponsiveness to clopidogrel and
      factors associated with this in patients presenting to our emergency department
      with chest pain who had previously undergone coronary stent placement and were
      prescribed dual antiplatelet therapy. METHODS: Responsiveness to clopidogrel was 
      evaluated in a cohort of 533 consecutive stented patients presenting to the
      emergency department with chest pain. P2Y12 reaction units (PRU) and percent
      P2Y12 inhibition with clopidogrel were measured in all patients. Of 533 patients,
      221 (41.6%) had PRU >/= 230. A multivariate logistic regression model was used to
      determine the relationship between hyporesponsiveness to clopidogrel (defined as 
      PRU >/= 230) and several potential risk factors, ie, gender, age, race, type 1 or
      type 2 diabetes, hypertension, smoking, chronic renal failure, and obesity.
      RESULTS: There was a greater risk of hyporesponsiveness in African Americans than
      in non-African American patients (adjusted odds ratio [OR] = 2.165), in patients 
      with type 2 diabetes than in those without (adjusted OR = 2.109), and in women
      than in men (adjusted OR = 1.813), as well as a greater risk of
      hyporesponsiveness with increasing age (adjusted OR = 1.167 per decade).
      CONCLUSION: There was a high prevalence of hyporesponsiveness to clopidogrel in
      patients presenting with chest pain and a prior coronary stent.
      Non-insulin-dependent diabetes mellitus and African American race were the
      strongest predictors of hyporesponsiveness to clopidogrel, followed by gender and
      age.
AD  - Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences,
      Little Rock.
FAU - Sharma, Rakesh K
AU  - Sharma RK
FAU - Erickson, Stephen W
AU  - Erickson SW
FAU - Sharma, Rohit
AU  - Sharma R
FAU - Voelker, Donald J
AU  - Voelker DJ
FAU - Reddy, Hanumanth K
AU  - Reddy HK
FAU - Dod, Harvinder
AU  - Dod H
FAU - Marsh, James D
AU  - Marsh JD
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
SB  - IM
PMC - PMC3646472
OID - NLM: PMC3646472
OTO - NOTNLM
OT  - chest pain
OT  - clopidogrel
OT  - emergency department
OT  - platelet function testing
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013 [ppublish]
PHST- 2013/05/01 [epublish]
AID - 10.2147/VHRM.S43909 [doi]
AID - vhrm-9-187 [pii]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:187-93. doi: 10.2147/VHRM.S43909. Epub 2013 May 1.

PMID- 23662063
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Awareness, treatment, and control of major cardiovascular risk factors in a
      small-scale Italian community: results of a screening campaign.
PG  - 177-85
LID - 10.2147/VHRM.S40925 [doi]
AB  - INTRODUCTION: Hypertension, hypercholesterolemia, and diabetes are the main
      causes of cardiovascular diseases in developed countries. However, these
      conditions are still poorly recognized and treated. OBJECTIVE: This study aimed
      at estimating the prevalence, awareness, treatment, and control rates of major
      cardiovascular risk factors in an unselected sample of individuals of a small
      community located in northern Italy. METHODS: We screened 344 sequential subjects
      in this study. Data collection included family and clinical history,
      anthropometric data, blood pressure, blood glucose, and serum cholesterol values.
      Individual cardiovascular risk profiles were assessed by risk charts of the
      Progetto Cuore. RESULTS: Based on personal history and/or measured values, 78.2% 
      of subjects had hypercholesterolemia (total cholesterol levels > 190 mg/dL),
      61.0% had central obesity (waist circumference >/= 94 cm for men and >/=80 cm for
      women), 51.2% had arterial hypertension (blood pressure >/= 140/90 mmHg), 8.1%
      had diabetes (blood glucose >/= 126 mg/dL), 22.7% had impaired fasting glucose
      (blood glucose 100-125 mg/dL), and 35.5% were overweight (body mass index 25-29
      kg/m(2)). Alcohol drinkers and smokers accounted for 46.2% and 22.4% of subjects,
      respectively. Awareness of hypertension, hypercholesterolemia, and diabetes was
      poor, and control of these risk factors, except for diabetes, was even worse.
      Prevalence of high blood pressure, high serum cholesterol, overweight, and
      obesity significantly increased with aging. Hypercholesterolemia and obesity were
      significantly more common in women, while overweight and diabetes in men. In
      15.4% of participants, the risk of a major cardiovascular event in the next 10
      years was either high or very high. CONCLUSION: In a small community in a wealthy
      region of Italy, the prevalence of major cardiovascular risk factors is high,
      while awareness, treatment, and control are poor. Such a result highlights the
      importance of screening campaigns as a strategy to improve early diagnosis and
      access to treatment, and thus effective prevention of cardiovascular diseases in 
      the general population.
AD  - Italian Institute of Telemedicine and Association for Research and Development of
      Biomedical Technologies and for Continuing Medical Education (ARSMED), Varese,
      Italy.
FAU - Omboni, Stefano
AU  - Omboni S
FAU - Carabelli, Giorgia
AU  - Carabelli G
FAU - Ghirardi, Edoardo
AU  - Ghirardi E
FAU - Carugo, Stefano
AU  - Carugo S
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
SB  - IM
PMC - PMC3646473
OID - NLM: PMC3646473
OTO - NOTNLM
OT  - Italy
OT  - cardiovascular risk
OT  - diabetes
OT  - hypercholesterolemia
OT  - hypertension
OT  - obesity
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/30 [epublish]
AID - 10.2147/VHRM.S40925 [doi]
AID - vhrm-9-177 [pii]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:177-85. doi: 10.2147/VHRM.S40925. Epub 2013 Apr
      30.

PMID- 23662062
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Long-term safety and efficacy of telmisartan/amlodipine single pill combination
      in the treatment of hypertension.
PG  - 95-104
LID - 10.2147/VHRM.S40963 [doi]
AB  - The use of multiple drug regimens is increasingly recognized as a tacit
      requirement for the management of hypertension, a necessity fueled in part by
      rising rates of metabolic syndrome and diabetes. By targeting complementary
      pathways, combinations of antihypertensive drugs can be applied to provide
      effective blood pressure control while minimizing side effects and reducing
      exposure to high doses of individual medications. In addition, combination
      therapies, including angiotensin converting enzyme (ACE) inhibitors and calcium
      channel blockers (CCBs), have the added benefit of reducing cardiovascular
      mortality and morbidity over other dual therapies while providing equivalent
      blood pressure control. It is possible that angiotensin receptor blockers (ARBs),
      which unlike ACE inhibitors are minimally affected by upregulation of alternative
      pathways for angiotensin II accumulation following long-term treatment, would
      also provide such outcome benefits. At issue, however, is maintaining patient
      compliance, as adding medications is known to reduce adherence to treatment
      regimens. The purpose of this review is to summarize existing trial data for the 
      long-term safety and efficacy of a recent addition to the armamentarium of
      dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill
      combination. The areas where long-term data are lacking, notably clinical
      information regarding minorities and women, will also be discussed.
AD  - Beaumont Health System, Ministrelli Women's Heart Center, Royal Oak, MI, USA.
FAU - Billecke, Scott S
AU  - Billecke SS
FAU - Marcovitz, Pamela A
AU  - Marcovitz PA
LA  - eng
PT  - Journal Article
DEP - 20130316
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
SB  - IM
PMC - PMC3606043
OID - NLM: PMC3606043
OTO - NOTNLM
OT  - Angiotensin receptor blocker
OT  - antihypertensive
OT  - calcium channel blocker
OT  - clinical trial
OT  - combination pill
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/16 [epublish]
AID - 10.2147/VHRM.S40963 [doi]
AID - vhrm-9-095 [pii]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:95-104. doi: 10.2147/VHRM.S40963. Epub 2013 Mar
      16.

PMID- 23661723
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
DP  - 2013 May 9
TI  - Quantifying Options for Reducing Coronary Heart Disease Mortality By 2020.
AB  - BACKGROUND: The AHA 2020 Strategic Impact Goal proposes a 20% improvement in
      cardiovascular health of all Americans. We aimed to estimate the potential
      reduction in coronary heart disease (CHD) deaths. METHODS AND RESULTS: We used
      data on 40,373 CVD-free adults from NHANES (1988-2010). We quantified recent
      trends for six metrics (total cholesterol [TC]; systolic blood pressure [SBP];
      physical inactivity; smoking; diabetes; obesity) and generated linear projections
      to 2020. We projected the expected number of CHD deaths in 2020 if 2006 age- and 
      sex-specific CHD death rates remained constant, which would result in
      approximately 480,000 CHD deaths in 2020 (12% increase). We used the previously
      validated IMPACT CHD model to project numbers of CHD deaths in 2020 under two
      different scenarios. A) Assuming a 20% improvement in each CVH metric, we project
      365,000 CHD deaths in 2020, (range 327,000-403,000) a 24% decrease reflecting
      modest reductions in TC (-41,000), SBP (-36,000), physical inactivity (-12,000), 
      smoking (-10,000), diabetes (-10,000), and obesity (-5,000). B) Assuming that
      recent risk factor trends continue to 2020, we project 335,000 CHD deaths (range 
      274,000-386,000), a 30% decrease reflecting improvements in TC, SBP, smoking and 
      physical activity (~167,000 fewer deaths), offset by increases in diabetes and
      BMI (~24,000 more deaths). CONCLUSIONS: Two contrasting scenarios of change in
      CVH metrics could prevent 24-30% of the CHD deaths expected in 2020, though with 
      differing impacts by age. Unfavorable continuing trends in obesity and diabetes
      would have substantial adverse effects. This analysis demonstrates the utility of
      modelling to inform health policy.
AD  - 1Northwestern University Feinberg School of Medicine, Chicago, IL.
FAU - Huffman, Mark D
AU  - Huffman MD
FAU - Lloyd-Jones, Donald M
AU  - Lloyd-Jones DM
FAU - Ning, Hongyan
AU  - Ning H
FAU - Labarthe, Darwin R
AU  - Labarthe DR
FAU - Guzman Castillo, Maria
AU  - Guzman Castillo M
FAU - O'Flaherty, Martin
AU  - O'Flaherty M
FAU - Ford, Earl S
AU  - Ford ES
FAU - Capewell, Simon
AU  - Capewell S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Circulation
JT  - Circulation
JID - 0147763
OTO - NOTNLM
OT  - 2020 Strategic Impact Goal
OT  - American Heart Association
OT  - epidemiology
OT  - heart disease
OT  - risk factor
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - CIRCULATIONAHA.112.000769 [pii]
AID - 10.1161/CIRCULATIONAHA.112.000769 [doi]
PST - aheadofprint
SO  - Circulation. 2013 May 9.

PMID- 23661720
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1470-2738 (Electronic)
IS  - 0143-005X (Linking)
DP  - 2013 May 9
TI  - Epidemiological evidence on association between ambient air pollution and stroke 
      mortality.
AB  - BACKGROUND: Inconsistent results have been found on the association between air
      pollution and stroke mortality. Additionally, evidence on people who are
      potentially sensitive to air pollution-associated stroke mortality is limited.
      METHODS: Daily stroke mortality of adults aged over 65 between 2003 and 2008 in
      Shanghai, China were collected. The time-stratified case-crossover approach was
      used to assess the association between daily concentrations of air pollutants
      including particles with size <10 microm, sulfur dioxide (SO2) and nitrogen
      dioxide (NO2) and stroke mortality. RESULTS: Both total-stroke and
      ischaemic-stroke mortalities were found to be significantly associated with all
      three air pollutants. Haemorrhagic stroke was significantly associated with SO2
      and NO2 only. Substantial differences were observed for effect estimates of
      ischaemic-stroke mortality in relation to NO2 among people with cardiac diseases 
      compared with those without; for an increase of 10 mug/m3 in NO2, the increase in
      ischaemic-stroke mortality was 7.05% (95% CI 1.92% to 12.17%) for people with
      comorbid cardiac diseases versus 0.60% (95% CI -0.49% to 1.68%) for those
      without. We did not find evidence of effect modification by hypertension and
      diabetes. CONCLUSIONS: This study provides new evidence for the association
      between exposure to ambient air pollution and stroke mortality. Our results also 
      suggest that underlying cardiac disorder may increase the risk for
      ischaemic-stroke mortality in relation to air pollution exposure, especially
      NO2..
AD  - , Shanghai, China.
FAU - Qian, Yifeng
AU  - Qian Y
FAU - Zhu, Meiying
AU  - Zhu M
FAU - Cai, Binxin
AU  - Cai B
FAU - Yang, Qing
AU  - Yang Q
FAU - Kan, Haidong
AU  - Kan H
FAU - Song, Guixiang
AU  - Song G
FAU - Jin, Wenzheng
AU  - Jin W
FAU - Han, Ming
AU  - Han M
FAU - Wang, Chunfang
AU  - Wang C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - J Epidemiol Community Health
JT  - Journal of epidemiology and community health
JID - 7909766
OTO - NOTNLM
OT  - Air Pollution
OT  - Environmental Health
OT  - Mortality
OT  - Stroke
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - jech-2012-201096 [pii]
AID - 10.1136/jech-2012-201096 [doi]
PST - aheadofprint
SO  - J Epidemiol Community Health. 2013 May 9.

PMID- 23661600
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1099-0844 (Electronic)
IS  - 0263-6484 (Linking)
DP  - 2013 May 10
TI  - Ferulic acid in the treatment of post-diabetes testicular damage: relevance to
      the down regulation of apoptosis correlates with antioxidant status via
      modulation of TGF-beta1, IL-1beta and Akt signalling.
LID - 10.1002/cbf.2983 [doi]
AB  - The aim of this study was to investigate the protective effect of ferulic acid at
      different doses (50 mg kg-1 alternative day and 50 mg kg-1 daily) on the
      streptozotocin (STZ)-induced post-diabetes rat testicular damage. Diabetes was
      induced by a single intraperitoneal injection of STZ (50 mg/kg). Rats treated
      with ferulic acid were given once a day orally for 10 weeks, starting 3 days
      after STZ injection. Testis tissue and blood samples were collected for
      investigating biochemical analysis, antioxidant status, sperm parameters, and
      histopathological, immunohistochemical and apoptotic studies. Treatment with
      ferulic acid to diabetic rats significantly improved the body weight, testis
      weight, serum insulin level, serum testosterone level and sperm parameters
      (viability, motility and count). Histopathological study also revealed that
      ferulic acid-treated diabetic rats showed an improved histological appearance.
      Our data indicated that significant reduction in the activity of apoptosis by
      using terminal deoxyuridine triphosphate nick end-labelling and reduced
      expression of transforming growth factor-beta1 and interleukin-1beta in the
      testis tissue of ferulic acid-treated diabetic rats. Conversely, it was also
      revealed that ferulic acid-treated diabetic rats markedly enhanced the
      serine/threonine protein kinase protein expression in the testis tissue. Our
      result suggests that ferulic acid inhibits testicular damage in diabetic rats by 
      declining oxidative stress. Copyright (c) 2013 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
AD  - Department of Pharmaceutical Technology, NSHM Knowledge Campus, Kolkata, West
      Bengal, India.
FAU - Roy, Souvik
AU  - Roy S
FAU - Metya, Satyajit Kumar
AU  - Metya SK
FAU - Rahaman, Noorjaman
AU  - Rahaman N
FAU - Sannigrahi, Santanu
AU  - Sannigrahi S
FAU - Ahmed, Faiqa
AU  - Ahmed F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Cell Biochem Funct
JT  - Cell biochemistry and function
JID - 8305874
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/08 [received]
PHST- 2013/04/14 [revised]
PHST- 2013/04/19 [accepted]
AID - 10.1002/cbf.2983 [doi]
PST - aheadofprint
SO  - Cell Biochem Funct. 2013 May 10. doi: 10.1002/cbf.2983.

PMID- 23661202
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1117-1936 (Print)
VI  - 20
IP  - 1
DP  - 2013 Mar
TI  - Changing trend in the incidence of myocardial infarction among medical admissions
      in Ilorin, north-central Nigeria.
PG  - 5-8
AB  - AIMS AND OBJECTIVES: This study aimed at reviewing cases of myocardial infarction
      managed between January 2006 and June 2009. MATERIALS AND METHODS: Records of all
      patients managed for acute MI during the period were studied. Diagnosis was based
      on presence of ischemic type of chest discomfort, serial electrocardiographic
      (ECG) changes compatible with MI, a rise in troponin I level and
      echocardiographic abnormalities. RESULTS: Fourteen patients consisting of 13
      (92.9%) males and 1 (7.1%) female had MI. They were all Nigerians, their ages
      ranged from 40 to 82 years with a mean of 55.6 +/-12.7 years; and 85.7% of them
      belonged to social class 1. MI accounted for 0.21% of the total 6647 admissions
      during the period. Present hospital incidence (0.21%) is significantly higher
      (Chi2=6.8, p=0.01) than previously reported incidence of 0.075%. Twelve patients 
      had systemic hypertension, 8 had high body mass index, 6 had dyslipidaemia, 5
      smoked cigarette and 2 had diabetes mellitus. Three patients died giving a case
      fatality rate of 21.4% and another 3 developed chronic left ventricular systolic 
      failure. CONCLUSION: Incidence of MI is increasing among hospital admissions in
      Ilorin and there is an urgent need for community interventions targeted at early 
      detection and treatment of hypertension, diabetes mellitus, dyslipidaemia and
      obesity. Campaigns against cigarette smoking should be sustained.
AD  - Cardiology Unit, Department of Medicine, University of Ilorin Teaching Hospital, 
      P.M.B 1459, Ilorin Nigeria.
FAU - Kolo, P M
AU  - Kolo PM
FAU - Fasae, A J
AU  - Fasae AJ
FAU - Aigbe, I F
AU  - Aigbe IF
FAU - Ogunmodede, J A
AU  - Ogunmodede JA
FAU - Omotosho, A B
AU  - Omotosho AB
LA  - eng
PT  - Journal Article
PL  - Nigeria
TA  - Niger Postgrad Med J
JT  - The Nigerian postgraduate medical journal
JID - 9613595
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PST - ppublish
SO  - Niger Postgrad Med J. 2013 Mar;20(1):5-8.

PMID- 23661111
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Investigating hypocalcaemia.
PG  - f2213
LID - 10.1136/bmj.f2213 [doi]
LID - bmj.f2213 [pii]
AD  - Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and
      Metabolism, Nuffield Department of Clinical Medicine, University of Oxford,
      Churchill Hospital, Oxford OX3 7LJ, UK.
FAU - Hannan, Fadil M
AU  - Hannan FM
FAU - Thakker, Rajesh V
AU  - Thakker RV
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PST - epublish
SO  - BMJ. 2013 May 9;346:f2213. doi: 10.1136/bmj.f2213.

PMID- 23661106
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 10
TI  - Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001-2007.
AB  - AIMS/HYPOTHESIS: The objective of this study was to use Scottish national data to
      assess the influence of type 2 diabetes on the risk of cancer at 16 different
      sites, while specifically investigating the role of confounding by socioeconomic 
      status in the diabetes-cancer relationship. METHODS: All people in Scotland aged 
      55-79 years diagnosed with any of the cancers of interest during the period
      2001-2007 were identified and classified by the presence/absence of co-morbid
      type 2 diabetes. The influence of diabetes on cancer risk for each site was
      assessed via Poisson regression, initially with adjustment for age only, then
      adjusted for both age and socioeconomic status. RESULTS: There were 4,285
      incident cancers in people with type 2 diabetes. RR for any cancers (adjusted for
      age only) was 1.11 (95% CI 1.05, 1.17) for men and 1.33 (1.28, 1.40) for women.
      Corresponding values after additional adjustment for socioeconomic status were
      1.10 (1.04, 1.15) and 1.31 (1.25, 1.38), respectively. RRs for individual cancer 
      sites varied markedly. CONCLUSIONS/INTERPRETATION: Socioeconomic status was found
      to have little influence on the association between type 2 diabetes and cancer.
AD  - Centre for Population Health Sciences, The University of Edinburgh, Medical
      School, Teviot Place, Edinburgh, EH8 9AG, UK, jeremy.walker@ed.ac.uk.
FAU - Walker, J J
AU  - Walker JJ
FAU - Brewster, D H
AU  - Brewster DH
FAU - Colhoun, H M
AU  - Colhoun HM
FAU - Fischbacher, C M
AU  - Fischbacher CM
FAU - Leese, G P
AU  - Leese GP
FAU - Lindsay, R S
AU  - Lindsay RS
FAU - McKnight, J A
AU  - McKnight JA
FAU - Philip, S
AU  - Philip S
FAU - Sattar, N
AU  - Sattar N
FAU - Stockton, D L
AU  - Stockton DL
FAU - Wild, S H
AU  - Wild SH
CN  - on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/10/25 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - 10.1007/s00125-013-2937-6 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 10.

PMID- 23661104
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
DP  - 2013 May 8
TI  - Gelatinases and Their Tissue Inhibitors in a Group of Subjects With Metabolic
      Syndrome.
AB  - AIM: To evaluate matrix metalloproteases (MMP)-2 and MMP-9 and tissue inhibitor
      of metalloproteases (TIMP)-1 and TIMP-2 in a group of subjects with metabolic
      syndrome (MS) subdivided according to the presence or absence of diabetes
      mellitus. METHODS: We examined in 90 subjects (51 men and 39 women) with MS,
      defined following the International Diabetes Federation criteria, and
      subsequently subdivided into diabetic subjects (22 men and 11 women) and
      nondiabetic subjects s (29 men and 28 women), the plasma concentrations of MMP-2 
      and MMP-9 and of TIMP-1 and TIMP-2 using specific enzyme-linked immunosorbent
      assay kits. RESULTS: We found a significant increase in plasma concentrations of 
      MMP-2, MMP-9, TIMP-1, and TIMP-2 in the whole group of MS subjects (P < 0.001)
      and in both subgroups of MS subjects with diabetes mellitus (P < 0.001) and
      without diabetes mellitus (P < 0.001) in comparison with healthy controls. We
      also noted higher concentrations of all the examined parameters in the MS
      subjects with diabetes mellitus in comparison with the MS subjects without
      diabetes mellitus. Matrix metalloproteases and TIMPs showed some significant
      correlations with body mass index and waist circumference and with metabolic
      parameters in the whole group of MS subjects. CONCLUSION: An altered pattern of
      MMPs and their inhibitors is demonstrated in MS; the presence of diabetes
      mellitus strongly influences the concentration of MMP and TIMP, contributing
      probably to the increased cardiovascular risk of MS subjects.
AD  - From the Dipartimento Biomedico di Medicina Interna e Specialistica, Universita
      degli Studi di Palermo, Italy.
FAU - Hopps, Eugenia
AU  - Hopps E
FAU - Lo Presti, Rosalia
AU  - Lo Presti R
FAU - Montana, Maria
AU  - Montana M
FAU - Noto, Davide
AU  - Noto D
FAU - Averna, Maurizio R
AU  - Averna MR
FAU - Caimi, Gregorio
AU  - Caimi G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American
      Federation for Clinical Research
JID - 9501229
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - 10.231/JIM.0b013e318294e9da [doi]
PST - aheadofprint
SO  - J Investig Med. 2013 May 8.

PMID- 23661004
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 2041-4889 (Electronic)
VI  - 4
DP  - 2013
TI  - Protein tyrosine phosphatase 1B modulates GSK3beta/Nrf2 and IGFIR signaling
      pathways in acetaminophen-induced hepatotoxicity.
PG  - e626
LID - 10.1038/cddis.2013.150 [doi]
AB  - Acute hepatic failure secondary to acetaminophen (APAP) poisoning is associated
      with high mortality. Protein tyrosine phosphatase 1B (PTP1B) is a negative
      regulator of tyrosine kinase growth factor signaling. In the liver, this pathway 
      confers protection against injury. However, the involvement of PTP1B in the
      intracellular networks activated by APAP is unknown. We have assessed PTP1B
      expression in APAP-induced liver failure in humans and its role in the molecular 
      mechanisms that regulate the balance between cell death and survival in human and
      mouse hepatocytes, as well as in a mouse model of APAP-induced hepatotoxicity.
      PTP1B expression was increased in human liver tissue removed during liver
      transplant from patients for APAP overdose. PTP1B was upregulated by APAP in
      primary human and mouse hepatocytes together with the activation of c-jun (NH2)
      terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK),
      resulting in cell death. Conversely, Akt phosphorylation and the antiapoptotic
      Bcl2 family members BclxL and Mcl1 were decreased. PTP1B deficiency in mouse
      protects hepatocytes against APAP-induced cell death, preventing glutathione
      depletion, reactive oxygen species (ROS) generation and activation of JNK and p38
      MAPK. APAP-treated PTP1B(-/-) hepatocytes showed enhanced antioxidant defense
      through the glycogen synthase kinase 3 (GSK3)beta/Src kinase family (SKF) axis,
      delaying tyrosine phosphorylation of the transcription factor nuclear
      factor-erythroid 2-related factor (Nrf2) and its nuclear exclusion,
      ubiquitination and degradation. Insulin-like growth factor-I receptor-mediated
      signaling decreased in APAP-treated wild-type hepatocytes, but was maintained in 
      PTP1B(-/-) cells or in wild-type hepatocytes with reduced PTP1B levels by RNA
      interference. Likewise, both signaling cascades were modulated in mice, resulting
      in less severe APAP hepatotoxicity in PTP1B(-/-) mice. Our results demonstrated
      that PTP1B is a central player of the mechanisms triggered by APAP in
      hepatotoxicity, suggesting a novel therapeutic target against APAP-induced liver 
      failure.
AD  - 1] Instituto de Investigaciones Biomedicas Alberto Sols (CSIC-UAM), Madrid 28029,
      Spain [2] Centro de Investigacion Biomedica en Red de Diabetes y Enfermedades
      Metabolicas Asociadas (CIBERDEM), ISCIII, Madrid, Spain.
FAU - Mobasher, M A
AU  - Mobasher MA
FAU - Gonzalez-Rodriguez, A
AU  - Gonzalez-Rodriguez A
FAU - Santamaria, B
AU  - Santamaria B
FAU - Ramos, S
AU  - Ramos S
FAU - Martin, M A
AU  - Martin MA
FAU - Goya, L
AU  - Goya L
FAU - Rada, P
AU  - Rada P
FAU - Letzig, L
AU  - Letzig L
FAU - James, L P
AU  - James LP
FAU - Cuadrado, A
AU  - Cuadrado A
FAU - Martin-Perez, J
AU  - Martin-Perez J
FAU - Simpson, K J
AU  - Simpson KJ
FAU - Muntane, J
AU  - Muntane J
FAU - Valverde, A M
AU  - Valverde AM
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - England
TA  - Cell Death Dis
JT  - Cell death & disease
JID - 101524092
SB  - IM
PMC - PMC3674359
OID - NLM: PMC3674359
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - cddis2013150 [pii]
AID - 10.1038/cddis.2013.150 [doi]
PST - epublish
SO  - Cell Death Dis. 2013 May 9;4:e626. doi: 10.1038/cddis.2013.150.

PMID- 23661000
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1873-4626 (Electronic)
IS  - 1091-255X (Linking)
DP  - 2013 May 10
TI  - Identification and Validation of Risk Factors for Postoperative Infectious
      Complications Following Hepatectomy.
AB  - Postoperative infectious complications (PICs) are associated with significant
      morbidity after abdominal surgery. Using multivariate analysis of data from a
      prospective database, our study focused on the risk factors for PICs and the
      prevention of these complications after hepatectomy, with the goal of improving
      outcomes and reducing the length of hospital stays. BACKGROUND: PICs following
      surgery are associated with significant morbidity, increase the length of
      hospital stays, and have a negative impact on long-term oncological outcome. The 
      aim of this study was to determine the risk factors for PICs following partial
      hepatectomy and to validate these results with an external database. METHODS:
      Between January 2006 and December 2009, 555 patients underwent elective partial
      hepatectomy. We prospectively collected and retrospectively analyzed demographic 
      data, pathological variables, associated pathological conditions, and
      preoperative, intraoperative, and postoperative variables. The dependent
      variables studied were the occurrence of PICs, defined as development of one or
      more of the following conditions: pneumonia, sepsis, Central line-associated
      bloodstream infection, urinary tract infection, wound infection, and infected
      intra-abdominal fluid collection. PICs were devised in medical (PIMCs) and
      surgical (PISCs) complications. The incidence of PICs and validation of the
      predictive score were determined using an external prospective database of 342
      patients. RESULTS: The multivariate analysis identified three independent risk
      factors for PICs: the presence of a nasogastric tube (OR = 1.8), blood
      transfusion (OR = 1.9), and diabetes (OR = 2.4). The multivariate analysis
      identified only one independent risk factor for PISCs: an associated portal
      venous resection (OR = 5.5). The multivariate analysis identified four
      independent risk factors for PIMCs: presence of a biliary drainage (OR = 1.9),
      blood transfusion (OR = 2.1), diabetes (OR = 2.9), and presence of atrial
      fibrillation (OR = 3.6). According to the three predictive factors, the observed 
      rates of PICs ranged from 18.8 % to 77.8 % and ranged from 24.2 % to 100 % in the
      external database. Predicted and observed risks of PICs were not statistically
      different. CONCLUSIONS: The correction of modifiable risk factors among the
      identified factors could reduce the incidence of PICs and, as a consequence,
      improve patient outcomes and reduce the length of hospital stays.
AD  - Department of Hepato-Biliary and Pancreatic Surgery, Nouvel Hopital Civil,
      Universite de Strasbourg, IHU MixSurg, IRCAD, 1 place de l'hopital, 67091,
      Strasbourg, France, patrick.pessaux@chru-strasbourg.fr.
FAU - Pessaux, Patrick
AU  - Pessaux P
FAU - van den Broek, Maartje A J
AU  - van den Broek MA
FAU - Wu, Tao
AU  - Wu T
FAU - Damink, Steven W M Olde
AU  - Damink SW
FAU - Piardi, Tullio
AU  - Piardi T
FAU - Dejong, Cornelis H C
AU  - Dejong CH
FAU - Ntourakis, Dimitrios
AU  - Ntourakis D
FAU - van Dam, Ronald M
AU  - van Dam RM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - J Gastrointest Surg
JT  - Journal of gastrointestinal surgery : official journal of the Society for Surgery
      of the Alimentary Tract
JID - 9706084
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/03/10 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - 10.1007/s11605-013-2226-1 [doi]
PST - aheadofprint
SO  - J Gastrointest Surg. 2013 May 10.

PMID- 23660945
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
DP  - 2013 May 9
TI  - Prevalence of the metabolic syndrome and cardiovascular disease risk in
      chemotherapy-treated testicular germ cell tumour survivors.
LID - 10.1038/bjc.2013.226 [doi]
AB  - Background:Testicular cancer patients have an increased risk for cardiovascular
      disease (CVD), which might be related to the increased prevalence of the
      metabolic syndrome (MetS) in this group of patients.Methods:We assessed the
      prevalence of MetS and calculated the 10-year CVD risk in a cohort of 255
      testicular germ cell tumour survivors (median age, 38.7 years; interquartile
      range, 31-48) at a mean of 7.8 years after anti-cancer treatment, and compared
      these with data obtained from 360 healthy men.Results:Survivors had an
      age-adjusted increased risk for MetS of 1.9 compared with that of healthy
      controls. The risk for MetS was highest in survivors treated with combination
      chemotherapy (CT) 2.4 (Adult Treatment Panel of the National Cholesterol
      Education Program classification) and 2.2 (International Diabetes Federation
      classification). The risk of MetS was especially increased in survivors with
      testosterone levels in the lowest quartile (OR, 2.5). Ten-year cardiovascular
      risk as assessed by the Framingham Risk Score (3.0%) and Systemic Coronary Risk
      Evaluation (1.7%) algorithms was low, independent of treatment, and was
      comparable to controls.Conclusion:Testicular germ cell tumour survivors have an
      increased prevalence of MetS, with hypogonadism and CT treatment being clear risk
      factors for the development of the syndrome. The increased prevalence of MetS was
      not associated with an increased 10-year cardiovascular risk.British Journal of
      Cancer advance online publication, 9 May 2013; doi:10.1038/bjc.2013.226
      www.bjcancer.com.
AD  - Department of Clinical Oncology, Leiden University Medical Center, Albinusdreef
      2, 2333 ZA Leiden, The Netherlands.
FAU - Willemse, P M
AU  - Willemse PM
FAU - Burggraaf, J
AU  - Burggraaf J
FAU - Hamdy, N A T
AU  - Hamdy NA
FAU - Weijl, N I
AU  - Weijl NI
FAU - Vossen, C Y
AU  - Vossen CY
FAU - van Wulften, L
AU  - van Wulften L
FAU - van Steijn-van Tol, A Q M J
AU  - van Steijn-van Tol AQ
FAU - Rosendaal, F R
AU  - Rosendaal FR
FAU - Osanto, S
AU  - Osanto S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/05/09 [aheadofprint]
AID - bjc2013226 [pii]
AID - 10.1038/bjc.2013.226 [doi]
PST - aheadofprint
SO  - Br J Cancer. 2013 May 9. doi: 10.1038/bjc.2013.226.

PMID- 23660828
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 2325-4416 (Electronic)
VI  - 19
DP  - 2013
TI  - Effect of the administration of Solanum nigrum fruit on blood glucose, lipid
      profiles, and sensitivity of the vascular mesenteric bed to phenylephrine in
      streptozotocin-induced diabetic rats.
PG  - 133-40
LID - 10.12659/MSMBR.883892 [doi]
AB  - Background Solanum nigrum fruit is traditionally used in Asia to manage, control,
      and treat diabetes but there is no scientific evidence of the efficacy of Solanum
      nigrum fruit in treatment of diabetes. We designed this study to investigate the 
      effect of the administration of oral doses of aqueous extract from Solanum nigrum
      fruit on plasma glucose, lipid profiles, and the sensitivity of the vascular
      mesenteric bed to Phenylephrine in diabetic and non-diabetic rats. Material and
      Methods Animals were divided into 5 groups (n=10): 2 groups served as
      non-diabetic controls (NDC), and the other groups had diabetes induced with a
      single injection of streptozotocin (STZ). Solanum nigrum-treated chronic diabetic
      (CD-SNE) and Solanum nigrum-treated controls (ND-SNE) received 1g/l of Solanum
      nigrum added to drinking water for 8 weeks. The mesenteric vascular beds were
      prepared using the McGregor method. Results Administration of Solanum nigrum
      caused Ca/Mg ratio, plasma glucose, high-density lipoprotein (HDL), low-density
      lipoprotein (LDL), very low-density lipoprotein (VLDL), total cholesterol, and
      triglyceride concentrations to return to normal levels, and was shown to decrease
      alteration in vascular reactivity to vasoconstrictor agents. Conclusions Our
      results support the hypothesis that Solanum nigrum could play a role in the
      management of diabetes and the prevention of vascular complications in
      STZ-induced diabetic rats.
AD  - Department of Physiology, School of Medicine and Research Center for Molecular
      Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
FAU - Sohrabipour, Shahla
AU  - Sohrabipour S
FAU - Kharazmi, Fatemah
AU  - Kharazmi F
FAU - Soltani, Nepton
AU  - Soltani N
FAU - Kamalinejad, Mohammad
AU  - Kamalinejad M
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - Med Sci Monit Basic Res
JT  - Medical science monitor basic research
JID - 101597444
SB  - IM
PMC - PMC3659129
OID - NLM: PMC3659129
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - 883892 [pii]
AID - 10.12659/MSMBR.883892 [doi]
PST - epublish
SO  - Med Sci Monit Basic Res. 2013 Apr 22;19:133-40. doi: 10.12659/MSMBR.883892.

PMID- 23660643
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 169
IP  - 1
DP  - 2013 Jul
TI  - Mortality outcomes of different sulphonylurea drugs: the results of a 14-year
      cohort study of type 2 diabetic patients.
PG  - 117-26
LID - 10.1530/EJE-13-0299 [doi]
AB  - OBJECTIVE: Available data about mortality of type 2 diabetic patients treated
      with different sulphonylureas are scarce and contradictory. DESIGN: We evaluated 
      the associations between all-cause and cause-specific mortality and treatments
      with different sulphonylureas in a retrospective cohort of type 2 diabetic
      patients from a diabetes clinic. METHODS: ALL 1277 PATIENTS TREATED WITH
      SULPHONYLUREAS DURING 19961997 WERE ENROLLED: 159 patients were treated with
      tolbutamide, 977 glibenclamide and 141 gliclazide. The baseline data (centralised
      laboratory parameters, anthropometric data and presence of chronic complications)
      were abstracted from the clinical records. Information on vital status was
      collected from demographic files after 14-year follow-up. Adjusted hazard ratios 
      (HR) were estimated with Cox (all-cause mortality) or Fine and Gray models
      (cause-specific mortality), including several potential confounders. RESULTS:
      FIVE HUNDRED AND FIFTY-SIX PATIENTS DIED DURING THE FOLLOW-UP: 262 from
      cardiovascular causes, 158 from cancer and 136 from other causes. When compared
      with the glibenclamide users, the gliclazide and tolbutamide users showed a
      significantly lower cancer mortality (HR=0.30; 95% CI 0.16-0.55, and HR=0.48; 95%
      CI 0.29-0.79 respectively). These results were strongly confirmed in the 555
      patients on sulphonylurea monotherapy. None of the patients who were treated with
      gliclazide monotherapy died from cancer during the follow-up, and the patients on
      tolbutamide treatment exhibited a lower cancer mortality than the glibenclamide
      users (HR=0.40; 95% CI 0.22-0.71). Data did not change after stratification for
      the duration of sulphonylurea treatment from diabetes diagnosis to the study
      enrolment. CONCLUSIONS: Cancer mortality was markedly reduced in the patients on 
      gliclazide and tolbutamide treatment. These results suggest additional benefits
      for these drugs beyond their blood glucose-lowering effect and strongly advocate 
      for further investigation.
AD  - , Department of Internal Medicine.
FAU - Bo, Simona
AU  - Bo S
FAU - Castiglione, Anna
AU  - Castiglione A
FAU - Ghigo, Ezio
AU  - Ghigo E
FAU - Gentile, Luigi
AU  - Gentile L
FAU - Durazzo, Marilena
AU  - Durazzo M
FAU - Cavallo-Perin, Paolo
AU  - Cavallo-Perin P
FAU - Ciccone, Giovannino
AU  - Ciccone G
LA  - eng
PT  - Journal Article
DEP - 20130607
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013 [ppublish]
AID - EJE-13-0299 [pii]
AID - 10.1530/EJE-13-0299 [doi]
PST - epublish
SO  - Eur J Endocrinol. 2013 Jun 7;169(1):117-26. doi: 10.1530/EJE-13-0299. Print 2013 
      Jul.

PMID- 23660641
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 169
IP  - 1
DP  - 2013 Jul
TI  - Effects of medical therapies for acromegaly on glucose metabolism.
PG  - 99-108
LID - 10.1530/EJE-13-0032 [doi]
AB  - OBJECTIVE: Abnormalities of glucose metabolism are common findings of acromegaly.
      However, robust evidence on whether therapy with somatostatin analogs (SSAs) or
      pegvisomant (PEG) differently affects glucose metabolism is lacking. The purpose 
      of this study was to evaluate the effects of therapy with SSAs, PEG, or their
      combination on glucose metabolism in a large series of acromegalic patients.
      DESIGN: This was a historical-prospective study. Among 50 consecutive acromegalic
      patients under SSA therapy, acromegaly in 19 patients was controlled. PEG used in
      combination with SSA therapy allowed the control of acromegaly in the remaining
      31 patients and was then continued as monotherapy in 18 patients. METHODS: THE
      FOLLOWING PARAMETERS WERE EVALUATED AT THE DIAGNOSIS OF ACROMEGALY AND DURING
      DIFFERENT TREATMENTS: fasting plasma glucose (FPG) and insulin concentrations,
      insulin sensitivity (QUICK-I), homeostasis model assessment of insulin resistance
      (HOMA2-IR), and plasma glucose and insulin concentrations during the oral glucose
      tolerance test (OGTT). Comparison was made using analysis for paired data.
      RESULTS: Insulin resistance improved when acromegaly was controlled with therapy 
      with SSAs, PEG, or SSA+PEG. However, FPG concentrations were higher during SSA
      therapy (alone or combined with PEG) than at the diagnosis of acromegaly, even
      when corrected for disease activity, whereas they were reduced during PEG
      therapy. Mean glucose concentrations during the OGTT were higher in patients
      receiving SSA therapy than in those receiving PEG therapy. In addition, the
      prevalence of diabetes or impaired glucose tolerance was higher during SSA
      therapy than at diagnosis or during PEG therapy and was not influenced by disease
      control. CONCLUSIONS: Medical therapies for acromegaly reduce insulin resistance 
      and increase insulin sensitivity; on the contrary, glucose indexes may be
      differently affected by SSA or PEG therapy.
AD  - Department of Endocrinology and Metabolism, University of Pisa, Ospedale
      Cisanello, Via Paradisa 2, 56124 Pisa, Italy.
FAU - Urbani, C
AU  - Urbani C
FAU - Sardella, C
AU  - Sardella C
FAU - Calevro, A
AU  - Calevro A
FAU - Rossi, G
AU  - Rossi G
FAU - Scattina, I
AU  - Scattina I
FAU - Lombardi, M
AU  - Lombardi M
FAU - Lupi, I
AU  - Lupi I
FAU - Manetti, L
AU  - Manetti L
FAU - Martino, E
AU  - Martino E
FAU - Bogazzi, F
AU  - Bogazzi F
LA  - eng
PT  - Journal Article
DEP - 20130607
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013 [ppublish]
AID - EJE-13-0032 [pii]
AID - 10.1530/EJE-13-0032 [doi]
PST - epublish
SO  - Eur J Endocrinol. 2013 Jun 7;169(1):99-108. doi: 10.1530/EJE-13-0032. Print 2013 
      Jul.

PMID- 23660596
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1944-9917 (Electronic)
IS  - 0888-8809 (Linking)
DP  - 2013 May 9
TI  - Preventing p38 MAPK-mediated MafA degradation ameliorates beta cell dysfunction
      under oxidative stress.
AB  - The reduction in the expression of glucose-responsive insulin gene transcription 
      factor MafA accompanies the development of beta-cell dysfunction under oxidative 
      stress/diabetic milieu. Humans with type 2 diabetes have reduced MafA expression,
      and thus preventing this reduction could overcome beta-cell dysfunction and
      diabetes. We previously showed that p38 MAPK, but not GSK3, is a major regulator 
      of MafA degradation under oxidative stress. Here, we examined the mechanisms of
      this degradation and whether preventing MafA degradation under oxidative stress
      will overcome beta-cell dysfunction. We show that under oxidative and
      non-oxidative conditions p38 MAPK directly binds to MafA and triggers MafA
      degradation via ubiquitin proteasomal pathway. However, unlike non-oxidative
      conditions, MafA degradation under oxidative stress depended on p38 MAPK-mediated
      phosphorylation at Threonin(T) 134, and not T57. Furthermore the expression of
      Alanine(A) 134-MafA, but not A57-MafA, reduced the oxidative stress-mediated loss
      of glucose-stimulated insulin secretion, which was independent of p38 MAPK action
      on protein kinase D, a regulator of insulin secretion. Interestingly, the
      expression of proteasomal activator PA28gamma that degrades GSK3-phosphorylated
      (including T57) MafA was reduced under oxidative stress explaining the dominance 
      of p38 MAPK than GSK3 pathway in regulating MafA stability under oxidative
      stress. These results identify two distinct pathways mediating p38 MAPK-dependent
      MafA degradation under oxidative and non-oxidative conditions, and show that
      inhibiting MafA degradation under oxidative stress ameliorates beta-cell
      dysfunction, and could lead to novel therapies for diabetes.
AD  - Section of Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard
      Medical School, One Joslin Pl, Boston, MA 02215.
FAU - El Khattabi, Ilham
AU  - El Khattabi I
FAU - Sharma, Arun
AU  - Sharma A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Mol Endocrinol
JT  - Molecular endocrinology (Baltimore, Md.)
JID - 8801431
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - me.2012-1346 [pii]
AID - 10.1210/me.2012-1346 [doi]
PST - aheadofprint
SO  - Mol Endocrinol. 2013 May 9.

PMID- 23660551
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
DP  - 2013 May 9
TI  - Early and mid-term outcomes of combined aortic valve replacement and coronary
      artery bypass grafting in elderly patients.
AB  - OBJECTIVES: Although the number of elderly patients undergoing combined aortic
      valve replacement (AVR) and coronary artery bypass grafting (CABG) is increasing,
      the early and mid-term outcomes of this combined procedure remain to be
      determined. We sought to elucidate the early and mid-term outcomes of elderly
      (>/=75 years) vs non-elderly (<75 years) patients who underwent combined AVR and 
      CABG. METHODS: Between September 2004 and September 2011, 259 patients underwent 
      combined AVR and CABG at our institute, including 155 elderly patients (59.8%;
      Elderly group) with a mean age of 79.8 +/- 3.6 years and 104 non-elderly patients
      (40.2%; Non-elderly group) with a mean age of 67.3 +/- 5.8 years. Early and
      mid-term outcomes were compared, and multivariate analyses were performed to
      determine the risk factors for morbidity and mortality. The mean follow-up times 
      were 33.1 +/- 21.7 and 37.4 +/- 22.2 months in the Elderly and Non-elderly
      groups, respectively. RESULTS: The mean number of anastomoses and the frequency
      of use of the internal thoracic artery were similar between the two groups. The
      use of a mechanical valve was less frequent in the Elderly group than in the
      Non-elderly group (11.6 vs 60.6%, P < 0.001). The Elderly and Non-elderly groups 
      had similar rates of operative death (1.9 vs 1.0%, P = 0.651), early stroke (2.6 
      vs 1.0%, P = 0.651), 5-year overall survival (83.1 +/- 4.8 vs 87.2 +/- 5.2%, P = 
      0.358), 5-year freedom from cardiac death (92.3 +/- 2.7 vs 94.8 +/- 3.4%, P =
      0.570) and 5-year freedom from stroke (94.0 +/- 2.6 vs 99.0 +/- 1.0%, P = 0.097).
      Cox proportional hazards analyses identified diabetes, creatinine level and
      EuroSCORE II, but not age, as independent predictors of overall mortality rate.
      CONCLUSIONS: Early and mid-term outcomes of combined AVR and CABG were similar
      between elderly and non-elderly patients. Older age was not a risk factor for
      mortality in patients undergoing combined AVR plus CABG, and this procedure
      should be recommended in properly selected elderly patients.
AD  - Department of Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo, Japan.
FAU - Fukui, Toshihiro
AU  - Fukui T
FAU - Bando, Ko
AU  - Bando K
FAU - Tanaka, Sachiko
AU  - Tanaka S
FAU - Uchimuro, Tomoya
AU  - Uchimuro T
FAU - Tabata, Minoru
AU  - Tabata M
FAU - Takanashi, Shuichiro
AU  - Takanashi S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European
      Association for Cardio-thoracic Surgery
JID - 8804069
OTO - NOTNLM
OT  - Aortic valve replacement
OT  - Coronary artery bypass grafting
OT  - Elderly
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - ezt242 [pii]
AID - 10.1093/ejcts/ezt242 [doi]
PST - aheadofprint
SO  - Eur J Cardiothorac Surg. 2013 May 9.

PMID- 23660512
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
DP  - 2013 May 6
TI  - The association of elective hormone therapy with changes in lipids among glucose 
      intolerant postmenopausal women in the diabetes prevention program.
LID - S0026-0495(13)00102-9 [pii]
LID - 10.1016/j.metabol.2013.04.005 [doi]
AB  - OBJECTIVE: It is unclear how lipids change in response to lifestyle modification 
      or metformin among postmenopausal glucose intolerant women using and not using
      hormone therapy (HT). We examined the one-year changes in lipids among
      postmenopausal, prediabetic women in the Diabetes Prevention Program (DPP), and
      whether changes were mediated by sex hormones. MATERIALS/METHODS: We performed a 
      secondary analysis of a randomized controlled trial of 342 women who used HT at
      baseline and year 1 and 382 women who did not use HT at either time point.
      Interventions included intensive lifestyle (ILS) with goals of weight reduction
      of at least 7% of initial weight and 150minutes per week of moderate intensity
      exercise, or metformin or placebo administered 850mg up to twice a day. Women
      were not randomized to HT. Main outcome measures were changes between baseline
      and study year 1 in low-density lipoprotein cholesterol (LDL-C), high-density
      lipoprotein cholesterol (HDL-C), and triglycerides. RESULTS: Compared to placebo,
      both ILS and metformin significantly reduced LDL-C and raised HDL-C among HT
      users, changes partially explained by change in estradiol and testosterone but
      independent of changes in waist circumference and 1/fasting insulin. In contrast,
      DPP interventions had no effect on LDL-C and HDL-C among non-HT users. ILS
      significantly lowered triglycerides among non-users but did not significantly
      change triglycerides among HT users. Metformin did not significantly change
      triglycerides among non-users but increased triglycerides among HT users.
      CONCLUSIONS: The beneficial effects of ILS and metformin on lowering LDL-C and
      raising HDL-C differ depending upon concurrent HT use.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Johns Hopkins University, Baltimore, MD, USA. Electronic address:
      sahill@jhmi.edu.
FAU - Golden, Sherita Hill
AU  - Golden SH
FAU - Kim, Catherine
AU  - Kim C
FAU - Barrett-Connor, Elizabeth
AU  - Barrett-Connor E
FAU - Nan, Bin
AU  - Nan B
FAU - Kong, Shengchun
AU  - Kong S
FAU - Goldberg, Ronald
AU  - Goldberg R
CN  - the Diabetes Prevention Program Research Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/14 [received]
PHST- 2013/03/24 [revised]
PHST- 2013/04/03 [accepted]
AID - S0026-0495(13)00102-9 [pii]
AID - 10.1016/j.metabol.2013.04.005 [doi]
PST - aheadofprint
SO  - Metabolism. 2013 May 6. pii: S0026-0495(13)00102-9. doi:
      10.1016/j.metabol.2013.04.005.

PMID- 23660496
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1873-6300 (Electronic)
IS  - 0891-0618 (Linking)
DP  - 2013 May 6
TI  - Changes of calcium binding proteins, c-Fos and COX in hippocampal formation and
      cerebellum of Niemann-Pick, type C mouse.
LID - S0891-0618(13)00053-7 [pii]
LID - 10.1016/j.jchemneu.2013.04.006 [doi]
AB  - Niemann-Pick disease, type C (NPC) is an intractable disease that is accompanied 
      by ataxia, dystonia, neurodegeneration, and dementia due to an NPC gene defect.
      Disruption of calcium homeostasis in neurons is important in patients with NPC.
      Thus, we used immunohistochemistry to assess the expression levels of calcium
      binding proteins (calbindin D28K, parvalbumin, and calretinin), c-Fos and
      cyclooxygenase-1,2 (COX-1,2) in the hippocampal formation and cerebellum of 4 and
      8 week old NPC+/+, NPC+/-, and NPC-/- mice. General expression of these proteins 
      decreased in the hippocampus and cerebellum of NPC-/- compared to that in both
      young and adult NPC+/+ or NPC+/- mice. Parvalbumin, COX-1,2 or
      c-Fos-immunoreactive neurons were widely detected in the CA1, CA3, and DG of the 
      hippocampus, but the immunoreactivities were decreased sharply in all areas of
      hippocampus of NPC-/- compared to NPC+/+ and NPC+/- mice. Taken together,
      reduction of these proteins may be one of the strong phenotypes related to the
      neuronal degeneration in NPC-/- mice.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Center for Regenerative Medicine, Lee Gil Ya Cancer and Diabetes Institute,
      Gachon University, Incheon 406-840, South Korea; Department of Anatomy and Cell
      Biology, Gachon University Graduate School of Medicine, Incheon 406-799, South
      Korea.
FAU - Byun, Kyunghee
AU  - Byun K
FAU - Kim, Daesik
AU  - Kim D
FAU - Bayarsaikhan, Enkhjaigal
AU  - Bayarsaikhan E
FAU - Oh, Jeehyun
AU  - Oh J
FAU - Kim, Jisun
AU  - Kim J
FAU - Kwak, Grace
AU  - Kwak G
FAU - Jeong, Goo-Bo
AU  - Jeong GB
FAU - Jo, Seung-Mook
AU  - Jo SM
FAU - Lee, Bonghee
AU  - Lee B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - J Chem Neuroanat
JT  - Journal of chemical neuroanatomy
JID - 8902615
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/10/08 [received]
PHST- 2013/04/09 [revised]
PHST- 2013/04/25 [accepted]
AID - S0891-0618(13)00053-7 [pii]
AID - 10.1016/j.jchemneu.2013.04.006 [doi]
PST - aheadofprint
SO  - J Chem Neuroanat. 2013 May 6. pii: S0891-0618(13)00053-7. doi:
      10.1016/j.jchemneu.2013.04.006.

PMID- 23660462
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1465-3648 (Electronic)
IS  - 0268-1153 (Linking)
VI  - 28
IP  - 3
DP  - 2013 Jun
TI  - Impact of targeted health promotion on cardiovascular knowledge among American
      Indians and Alaska Natives.
PG  - 437-49
LID - 10.1093/her/cyt054 [doi]
AB  - The National Heart, Lung, and Blood Institute developed the Honoring the Gift of 
      Heart Health (HGHH) curriculum to promote cardiovascular knowledge and
      heart-healthy lifestyles among American Indians and Alaska Natives (AI/ANs).
      Using data from a small randomized trial designed to reduce diabetes and
      cardiovascular disease (CVD) risk among overweight/obese AI/ANs, we evaluated the
      impact of an adapted HGHH curriculum on cardiovascular knowledge. We also
      assessed whether the curriculum was effective across levels of health literacy
      (defined as the 'capacity to obtain, process and understand basic health
      information and services needed to make appropriate health decisions'). We
      examined change in knowledge from baseline to 3 months for two groups: HGHH (N = 
      89) and control (N = 50). Compared with controls, HGHH participants showed
      significant improvement in heart attack knowledge and marginally significant
      improvement in stroke and general CVD knowledge. HGHH participants attending >/=1
      class showed significantly greater improvement than controls on all three
      measures. Although HGHH participants with inadequate health literacy had worse
      heart attack and stroke knowledge at baseline and 3 months than did participants 
      with adequate skills, the degree of improvement in knowledge did not differ by
      health literacy level. HGHH appears to improve cardiovascular knowledge among
      AI/ANs across health literacy levels.
AD  - Centers for American Indian and Alaska Native Health, Colorado School of Public
      Health, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA and
      Department of Epidemiology and Biostatistics, School of Rural Public Health,
      Texas A&M Health Sciences Center, College Station, TX 77845, USA.
FAU - Brega, Angela G
AU  - Brega AG
FAU - Pratte, Katherine A
AU  - Pratte KA
FAU - Jiang, Luohua
AU  - Jiang L
FAU - Mitchell, Christina M
AU  - Mitchell CM
FAU - Stotz, Sarah A
AU  - Stotz SA
FAU - Loudhawk-Hedgepeth, Crystal
AU  - Loudhawk-Hedgepeth C
FAU - Morse, Brad D
AU  - Morse BD
FAU - Noe, Tim
AU  - Noe T
FAU - Moore, Kelly R
AU  - Moore KR
FAU - Beals, Janette
AU  - Beals J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Health Educ Res
JT  - Health education research
JID - 8608459
SB  - T
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - cyt054 [pii]
AID - 10.1093/her/cyt054 [doi]
PST - ppublish
SO  - Health Educ Res. 2013 Jun;28(3):437-49. doi: 10.1093/her/cyt054.

PMID- 23660449
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1095-6840 (Electronic)
IS  - 0016-6480 (Linking)
DP  - 2013 May 6
TI  - The effect of experimentally induced chronic hyperglycaemia on serum and
      pancreatic insulin, pancreatic islet IGF-I and plasma and urinary ketones in the 
      domestic cat (Felis felis).
LID - S0016-6480(13)00205-0 [pii]
LID - 10.1016/j.ygcen.2013.04.029 [doi]
AB  - Like in humans, diabetes mellitus is on the rise in cats. Feline diabetes is a
      suitable model for human type-2 diabetes. We investigated magnitude and timing of
      insulin suppression with induced hyperglycaemia and its relationship to plasma
      and urinary ketones and to pancreatic islet insulin. IGF-I is under discussion as
      a protective mechanism but little is known about its role in diabetes in general 
      and its distinct localisation in feline pancreatic islets in particular. Thirteen
      healthy, adult cats were allocated to 2 groups and infused with glucose to
      maintain their blood glucose at a high or moderate concentration for 42days
      resulting in insulin secretion suppression. After initial increase, insulin
      levels declined to baseline but were still detectable in the blood at a very low 
      level after 6weeks of glucose infusion and then increased after a 3week recovery 
      period. While IGF-I in healthy cats was primarily located in glucagon cells, in
      hyperglycaemia-challenge IGF-I was pronounced in the beta-cells 3weeks after
      ceasation of infusion. Six/8 cats developing glucose toxicity became ketonuric
      after 3-4weeks. Gross lipaemia occurred approx 1week prior to ketonuria.
      Ketonuric cats required 1-2weeks of insulin therapy after-infusion until
      beta-cell recovery. In conclusion, ketosis and hyperlipidaemia are likely to
      occur in diabetic cats with glucose at 30mmol/L, especially after 2weeks. Three
      weeks after ceasation of infusions, clinical and morphological recovery occurred.
      We propose a local protective effect of IGF-I to support survival and insulin
      production in the hyperglycaemic state and recovery period.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Centre for Evolutionary Medicine (ZEM), Institute of Anatomy, University of
      Zurich, Zurich, Switzerland; School of Veterinary Science, The University of
      Queensland, St Lucia, Brisbane, Australia.
FAU - Link, Karl R J
AU  - Link KR
FAU - Allio, Ileana
AU  - Allio I
FAU - Rand, Jacqueline S
AU  - Rand JS
FAU - Eppler, Elisabeth
AU  - Eppler E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Gen Comp Endocrinol
JT  - General and comparative endocrinology
JID - 0370735
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/02/26 [received]
PHST- 2013/04/17 [revised]
PHST- 2013/04/19 [accepted]
AID - S0016-6480(13)00205-0 [pii]
AID - 10.1016/j.ygcen.2013.04.029 [doi]
PST - aheadofprint
SO  - Gen Comp Endocrinol. 2013 May 6. pii: S0016-6480(13)00205-0. doi:
      10.1016/j.ygcen.2013.04.029.

PMID- 23660364
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1879-0445 (Electronic)
IS  - 0960-9822 (Linking)
VI  - 23
IP  - 9
DP  - 2013 May 6
TI  - An evolutionary perspective on food and human taste.
PG  - R409-18
LID - 10.1016/j.cub.2013.04.010 [doi]
LID - S0960-9822(13)00418-1 [pii]
AB  - The sense of taste is stimulated when nutrients or other chemical compounds
      activate specialized receptor cells within the oral cavity. Taste helps us decide
      what to eat and influences how efficiently we digest these foods. Human taste
      abilities have been shaped, in large part, by the ecological niches our
      evolutionary ancestors occupied and by the nutrients they sought. Early hominoids
      sought nutrition within a closed tropical forest environment, probably eating
      mostly fruit and leaves, and early hominids left this environment for the
      savannah and greatly expanded their dietary repertoire. They would have used
      their sense of taste to identify nutritious food items. The risks of making poor 
      food selections when foraging not only entail wasted energy and metabolic harm
      from eating foods of low nutrient and energy content, but also the harmful and
      potentially lethal ingestion of toxins. The learned consequences of ingested
      foods may subsequently guide our future food choices. The evolved taste abilities
      of humans are still useful for the one billion humans living with very low food
      security by helping them identify nutrients. But for those who have easy access
      to tasty, energy-dense foods our sensitivities for sugary, salty and fatty foods 
      have also helped cause over nutrition-related diseases, such as obesity and
      diabetes.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Rutgers University, Department of Nutrition, New Brunswick, NJ, USA; Monell
      Chemical Senses Center, Philadelphia, PA, USA. Electronic address:
      Breslin@aesop.rutgers.edu.
FAU - Breslin, Paul A S
AU  - Breslin PA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Biol
JT  - Current biology : CB
JID - 9107782
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - S0960-9822(13)00418-1 [pii]
AID - 10.1016/j.cub.2013.04.010 [doi]
PST - ppublish
SO  - Curr Biol. 2013 May 6;23(9):R409-18. doi: 10.1016/j.cub.2013.04.010.

PMID- 23660359
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1879-0445 (Electronic)
IS  - 0960-9822 (Linking)
VI  - 23
IP  - 9
DP  - 2013 May 6
TI  - Nutrient sensors.
PG  - R369-73
LID - 10.1016/j.cub.2013.04.002 [doi]
LID - S0960-9822(13)00410-7 [pii]
AB  - Elucidating the cellular and molecular basis of nutrient metabolism and
      regulation of feeding has become a major focus in scientific research over the
      last twenty years. Because of the increasing number of overweight and obese
      people in western and other societies, research efforts have initially been
      directed towards the basic metabolic processes that regulate nutrient uptake of
      cells and organ systems. One of the major goals of this research is to better
      understand the physiological and molecular processes that are disrupted or
      deregulated in various diseases, including diabetes, obesity, metabolic syndrome 
      and heart disease. But research efforts have expanded to include the neural and
      molecular underpinnings of feeding behavior. It has become apparent that a
      central role in nutrient metabolism and, by extension, the regulation of feeding 
      behavior, is the sensing of different classes of nutrients. Our goal is to
      provide an overview of what is currently known about nutrient sensors both in
      mammals and the invertebrate model system Drosophila melanogaster.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Molecular and Cellular Medicine, Texas A&M Health Science Center,
      College Station, TX, USA.
FAU - Miyamoto, Tetsuya
AU  - Miyamoto T
FAU - Wright, Geraldine
AU  - Wright G
FAU - Amrein, Hubert
AU  - Amrein H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Biol
JT  - Current biology : CB
JID - 9107782
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - S0960-9822(13)00410-7 [pii]
AID - 10.1016/j.cub.2013.04.002 [doi]
PST - ppublish
SO  - Curr Biol. 2013 May 6;23(9):R369-73. doi: 10.1016/j.cub.2013.04.002.

PMID- 23660331
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 May 6
TI  - Six-monthly diabetes monitoring of well-controlled patients: Experiences of
      primary care providers.
LID - S1751-9918(13)00046-6 [pii]
LID - 10.1016/j.pcd.2013.04.005 [doi]
AB  - AIMS: To examine experiences of primary care providers with six-monthly diabetes 
      monitoring of well-controlled patients. METHODS: This study was part of the
      EFFIMODI study, examining whether six-monthly monitoring of well-controlled
      (HbA1c </=58mmol/mol, systolic blood pressure </=145mmHg and total cholesterol
      </=5.2mmol/l) type 2 diabetes patients results in equivalent cardiometabolic
      control compared to three-monthly monitoring. Primary care providers completed a 
      questionnaire about their experiences with six-monthly diabetes monitoring,
      whether they want to continue six-monthly monitoring and for which type of
      patients six-monthly monitoring is sufficient. RESULTS: Of 163 questionnaires,
      157 (96.3%) were completed and returned. Only 14 (8.9%) primary care providers
      were negative about the six-monthly monitoring and 102 (65.0%) would like to
      continue six-monthly monitoring. Primary care providers disagreed about patients'
      ability to determine their own monitoring frequency and whether six-monthly
      monitoring was suitable for all well-controlled type 2 diabetes patients.
      Practical concerns emerged such as the inability to declare healthcare costs and 
      the unsuitability of electronic health record systems. CONCLUSIONS: Almost two
      out of three primary care providers would like to continue six-monthly monitoring
      of well-controlled type 2 diabetes patients. However, some diabetes care
      providers should be convinced and some practical concerns should be solved.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center
      Utrecht, STR 6.131, PO Box 85500, 3508 GA Utrecht, The Netherlands. Electronic
      address: P.Wermeling@umcutrecht.nl.
FAU - Wermeling, Paulien R
AU  - Wermeling PR
FAU - Janssen, Jolien
AU  - Janssen J
FAU - Gorter, Kees J
AU  - Gorter KJ
FAU - Beulens, Joline W J
AU  - Beulens JW
FAU - Rutten, Guy E H M
AU  - Rutten GE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/02/14 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/04/09 [accepted]
AID - S1751-9918(13)00046-6 [pii]
AID - 10.1016/j.pcd.2013.04.005 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 May 6. pii: S1751-9918(13)00046-6. doi:
      10.1016/j.pcd.2013.04.005.

PMID- 23660251
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 34
IP  - 23
DP  - 2013 Jul
TI  - Enhanced function of immuno-isolated islets in diabetes therapy by
      co-encapsulation with an anti-inflammatory drug.
PG  - 5792-801
LID - 10.1016/j.biomaterials.2013.04.016 [doi]
LID - S0142-9612(13)00460-2 [pii]
AB  - Immuno-isolation of islets has the potential to enable the replacement of
      pancreatic function in diabetic patients. However, host response to the
      encapsulated islets frequently leads to fibrotic overgrowth with subsequent
      impairment of the transplanted grafts. Here, we identified and incorporated
      anti-inflammatory agents into islet-containing microcapsules to address this
      challenge. In vivo subcutaneous screening of 16 small molecule anti-inflammatory 
      drugs was performed to identify promising compounds that could minimize the
      formation of fibrotic cell layers. Using parallel non-invasive fluorescent and
      bioluminescent imaging, we identified dexamethasone and curcumin as the most
      effective drugs in inhibiting the activities of inflammatory proteases and
      reactive oxygen species in the host response to subcutaneously injected
      biomaterials. Next, we demonstrated that co-encapsulating curcumin with
      pancreatic rat islets in alginate microcapsules reduced fibrotic overgrowth and
      improved glycemic control in a mouse model of chemically-induced type I diabetes.
      These results showed that localized administration of anti-inflammatory drug can 
      improve the longevity of encapsulated islets and may facilitate the translation
      of this technology toward a long-term cure for type I diabetes.
CI  - Published by Elsevier Ltd.
AD  - Department of Chemical Engineering, Massachusetts Institute of Technology, 77
      Massachusetts Avenue, Cambridge, MA 02139, USA; David H. Koch Institute for
      Integrative Cancer Research, Massachusetts Institute of Technology, 77
      Massachusetts Avenue, Cambridge, MA 02139, USA; Department of Anesthesiology,
      Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA.
FAU - Dang, Tram T
AU  - Dang TT
FAU - Thai, Anh V
AU  - Thai AV
FAU - Cohen, Joshua
AU  - Cohen J
FAU - Slosberg, Jeremy E
AU  - Slosberg JE
FAU - Siniakowicz, Karolina
AU  - Siniakowicz K
FAU - Doloff, Joshua C
AU  - Doloff JC
FAU - Ma, Minglin
AU  - Ma M
FAU - Hollister-Lock, Jennifer
AU  - Hollister-Lock J
FAU - Tang, Katherine M
AU  - Tang KM
FAU - Gu, Zhen
AU  - Gu Z
FAU - Cheng, Hao
AU  - Cheng H
FAU - Weir, Gordon C
AU  - Weir GC
FAU - Langer, Robert
AU  - Langer R
FAU - Anderson, Daniel G
AU  - Anderson DG
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/29 [received]
PHST- 2013/04/06 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - S0142-9612(13)00460-2 [pii]
AID - 10.1016/j.biomaterials.2013.04.016 [doi]
PST - ppublish
SO  - Biomaterials. 2013 Jul;34(23):5792-801. doi: 10.1016/j.biomaterials.2013.04.016. 
      Epub 2013 May 7.

PMID- 23660191
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 435
IP  - 2
DP  - 2013 May 31
TI  - Curcumin stimulates glucagon-like peptide-1 secretion in GLUTag cells via
      Ca(2+)/calmodulin-dependent kinase II activation.
PG  - 165-70
LID - 10.1016/j.bbrc.2013.04.092 [doi]
LID - S0006-291X(13)00746-8 [pii]
AB  - Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine
      L-cells. Enhancing GLP-1 action is an important target for prevention and
      treatment of type 2 diabetes. Several approaches (GLP-1 analogs, dipeptidyl
      peptidase IV inhibitors) are being used to develop therapeutic agents using GLP-1
      action for the treatment of diabetes. However, an alternative approach is to
      increase endogenous GLP-1 secretion through modulation of the secretory mechanism
      in intestinal L cells by pharmaceutical agents or dietary ingredients. In the
      present study, we demonstrate that curcumin, a yellow pigment isolated from the
      rhizomes of Curcuma longa L, significantly increases GLP-1 secretion in GLUTag
      cells, and we clarified the structure-activity relationship using curcumin
      derivatives. Also, concerning the secretory mechanism, the significant increase
      in GLP-1 secretion by curcumin involved the Ca(2+)-Ca(2+)/calmodulin-dependent
      kinase II pathway, and was independent of extracellular signal-regulated kinase, 
      PKC, and the cAMP/PKA-related pathway. These findings provide a molecular
      mechanism for GLP-1 secretion mediated by foods or drugs, and demonstrate a novel
      biological function of curcumin in regards to GLP-1 secretion.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - College of Bioscience and Biotechnology, Chubu University, Kasugai, Aichi
      487-8501, Japan.
FAU - Takikawa, Masahito
AU  - Takikawa M
FAU - Kurimoto, Yuta
AU  - Kurimoto Y
FAU - Tsuda, Takanori
AU  - Tsuda T
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/04/20 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/06 [aheadofprint]
AID - S0006-291X(13)00746-8 [pii]
AID - 10.1016/j.bbrc.2013.04.092 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2013 May 31;435(2):165-70. doi:
      10.1016/j.bbrc.2013.04.092. Epub 2013 May 6.

PMID- 23660189
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 435
IP  - 3
DP  - 2013 Jun 7
TI  - Loss of beta-arrestin2 mediates pancreatic-islet dysfunction in mice.
PG  - 345-9
LID - 10.1016/j.bbrc.2013.04.079 [doi]
LID - S0006-291X(13)00733-X [pii]
AB  - Insulin resistance and defective insulin secretion are two major factors
      contributing to the pathogenesis of type 2 diabetes. beta-Arrestin2 is known to
      interact with numerous signaling molecules. Our previous study demonstrated that 
      beta-arrestin2 regulates insulin sensitivity in both skeletal muscle and liver,
      yet its role in insulin secretion remains elusive. In this study, we found that
      beta-arrestin2 was abundantly expressed in mouse pancreatic beta cells, while its
      expression was significantly decreased in obese and diabetic mouse models.
      Hyperglycemic clamp study showed that the acute and late phase of insulin
      secretion were impaired in beta-arrestin2 knockout mice. Ex vivo study showed
      that beta-arrestin2 deficient pancreatic islets exhibited blunted
      glucose-stimulated insulin secretion. Further analysis demonstrated the number of
      docked insulin granules in beta-arrestin2 deficient islets was markedly decreased
      compared to wild-type islets, while insulin content and beta cell mass remained
      unchanged. Our study establishes a new role for beta-arrestin2 in beta-cell
      functions, and suggests that the down regulation of beta-arrestin2 may contribute
      to impaired insulin secretion in type 2 diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Endocrinology and Metabolism, Shanghai Jiao Tong University
      Affiliated Sixth People's Hospital, Shanghai, People's Republic of China;
      Diabetes Institute, Shanghai Jiao Tong University, Shanghai, People's Republic of
      China; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, People's Republic 
      of China.
FAU - Zhang, Mingliang
AU  - Zhang M
FAU - Zhu, Yunxia
AU  - Zhu Y
FAU - Mu, Kaida
AU  - Mu K
FAU - Li, Ling
AU  - Li L
FAU - Lu, Junxi
AU  - Lu J
FAU - Zhao, Jian
AU  - Zhao J
FAU - Huang, Xinyi
AU  - Huang X
FAU - Wang, Chen
AU  - Wang C
FAU - Jia, Weiping
AU  - Jia W
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/04/12 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/05/06 [aheadofprint]
AID - S0006-291X(13)00733-X [pii]
AID - 10.1016/j.bbrc.2013.04.079 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2013 Jun 7;435(3):345-9. doi:
      10.1016/j.bbrc.2013.04.079. Epub 2013 May 6.

PMID- 23660113
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
VI  - 375
IP  - 1-2
DP  - 2013 May 6
TI  - The polymorphism in the let-7 targeted region of the Lin28 gene is associated
      with increased risk of type 2 diabetes mellitus.
PG  - 53-57
LID - S0303-7207(13)00199-8 [pii]
LID - 10.1016/j.mce.2013.04.022 [doi]
AB  - Genetic polymorphisms in the miRNAs pathway of the pathogenesis of disease might 
      contribute to the risk of disease. However, it is unclear whether these
      polymorphisms about miRNAs are associated with the risk of type 2 diabetes
      mellitus (T2DM). We performed a case-control study to investigate two
      polymorphisms in the let-7/Lin28 pathway based on 588 T2DM patients and 588 age
      and sex matched controls. The results showed that the rs3811463 polymorphism was 
      associated with increased risk of T2DM (odds ratio (OR)=1.47, 95% confidence
      inference (95%CI)=1.13-1.93, P=0.005), while the rs3811464 not (OR=1.04,
      95%CI=0.79-1.36, P=0.78). For the rs3811463 polymorphism, the variant genotypes
      were associated with increased risk of disease in females; statistically
      differences were observed in the clinical features of age at diagnosis,
      hypertension and peripheral neuropathy for the variant and wild genotype of the
      rs3811463 in T2DM. In summary, the results indicated that the rs3811463
      polymorphism in the let-7/Lin28 pathway could significantly increase the risk of 
      T2DM.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial
      Key Laboratory of Medical Genetics, Wenzhou Medical College, Wenzhou, Zhejiang
      325035, China.
FAU - Zhang, Jie
AU  - Zhang J
FAU - Zhang, Longyi
AU  - Zhang L
FAU - Fan, Runping
AU  - Fan R
FAU - Guo, Nengneng
AU  - Guo N
FAU - Xiong, Chunhui
AU  - Xiong C
FAU - Wang, Lin
AU  - Wang L
FAU - Jin, Sheng
AU  - Jin S
FAU - Li, Wei
AU  - Li W
FAU - Lu, Jianxin
AU  - Lu J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/11/08 [received]
PHST- 2013/04/24 [revised]
PHST- 2013/04/26 [accepted]
AID - S0303-7207(13)00199-8 [pii]
AID - 10.1016/j.mce.2013.04.022 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 May 6;375(1-2):53-57. doi: 10.1016/j.mce.2013.04.022.

PMID- 23659990
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1097-6868 (Electronic)
IS  - 0002-9378 (Linking)
DP  - 2013 May 6
TI  - Factors associated with persistent urinary incontinence.
LID - S0002-9378(13)00474-2 [pii]
LID - 10.1016/j.ajog.2013.05.002 [doi]
AB  - OBJECTIVE: Many women with urinary incontinence (UI) have symptoms that continue 
      over many years; however, virtually nothing is known about factors that are
      associated with persistent UI. STUDY DESIGN: We studied 36,843 participants of
      the Nurses' Health Study, aged 54-79 years at baseline for the UI study, who
      provided UI information on biennial questionnaires from 2000 through 2008;
      follow-up in the Nurses' Health Study is 90%. In total, 18,347 women had
      "persistent UI," defined as urine leakage >/=1/mo reported on all 5 biennial
      questionnaires during this 8-year period; 18,496 women had no UI during this
      period. Using multivariable-adjusted logistic regression, we estimated odds
      ratios (ORs) of persistent UI vs no UI across various demographic, lifestyle, and
      health-related factors, which were derived from reports in 2000. RESULTS:
      Increasing age group, white race, greater parity, greater body mass index (BMI), 
      and lower physical activity levels were each associated with greater odds of
      persistent UI, as were several health-related factors (ie, stroke, type 2
      diabetes, and hysterectomy). Associations with persistent UI were particularly
      strong for increasing age group (P trend < .0001; OR, 2.75; 95% confidence
      interval [CI], 2.54-2.98 comparing women aged >/=75 vs <60 years) and greater BMI
      (P trend < .0001; OR, 3.14; 95% CI, 2.95-3.33 comparing women with BMI >/=30 vs
      <25 kg/m2); moreover, black women had much lower odds of persistent UI compared
      to white women (OR, 0.27; 95% CI, 0.21-0.34). CONCLUSION: Factors associated with
      persistent UI were generally consistent with those identified in previous studies
      of UI over shorter time periods; however, older age, white race, and obesity were
      particularly strongly related to persistent UI.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital and Harvard Medical School, Boston, MA. Electronic address:
      nheed@channing.harvard.edu.
FAU - Devore, Elizabeth E
AU  - Devore EE
FAU - Minassian, Vatche A
AU  - Minassian VA
FAU - Grodstein, Francine
AU  - Grodstein F
LA  - ENG
GR  - P01 CA087969/CA/NCI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Am J Obstet Gynecol
JT  - American journal of obstetrics and gynecology
JID - 0370476
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/02/06 [received]
PHST- 2013/04/17 [revised]
PHST- 2013/05/01 [accepted]
AID - S0002-9378(13)00474-2 [pii]
AID - 10.1016/j.ajog.2013.05.002 [doi]
PST - aheadofprint
SO  - Am J Obstet Gynecol. 2013 May 6. pii: S0002-9378(13)00474-2. doi:
      10.1016/j.ajog.2013.05.002.

PMID- 23659916
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 0755-4982 (Electronic)
IS  - 0755-4982 (Linking)
DP  - 2013 May 6
TI  - [Detainees in police custody in Seine-Saint-Denis (France): Medical data and
      high-risk situations, a descriptive study.]
LID - S0755-4982(13)00500-9 [pii]
LID - 10.1016/j.lpm.2013.01.055 [doi]
AB  - OBJECTIVES: The number of detainees held in police custody in France increased up
      to 792,000 yearly in 2009. Medical examination is a right for every detainee. Our
      objective was to assess medical characteristics and addictive behaviours of
      arrestees. METHODS: In this study, we systematically evaluated arrestees detained
      in police custody in Seine-Saint-Denis, a suburban area near Paris over one year 
      (June 1, 2010-May 31, 2011). RESULTS: A total of 22,379 medical examinations were
      performed. Males accounted for 94% of detainees. Median age was 23 (range:
      13-78). In 2968 of 18,466 cases (16%), the detainee had at least one chronic
      somatic disease. Asthma, diabetes, and arterial hypertension were the most
      commonly encountered. A history of psychiatric disorder was reported in 819 of
      16,697 cases (5%). Daily alcohol consumption was reported by 14% of detainees and
      77% smoked tobacco. Drug use was reported by 40% of detainees, cannabis in most
      cases (38%), infrequently cocaine or crack (4%) or heroine (1%). Assaults were
      reported by 20% of detainees, at the time of arrest in most cases (11%).
      PERSPECTIVES: The present study showed the high frequency of addictive behaviours
      and reported assaults or traumatic injuries in arrestees. Attending physicians
      should pay particular attention to addictive disorders and recent traumatic
      lesions in arrestees, both for immediate care and for prevention.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - AP-HP, hopital Jean-Verdier, service de medecine legale, 93140 Bondy, France.
FAU - Gilard-Pioc, Severine
AU  - Gilard-Pioc S
FAU - Dang-Hauter, Catherine
AU  - Dang-Hauter C
FAU - Denis, Celine
AU  - Denis C
FAU - Boraud, Cyril
AU  - Boraud C
FAU - Chariot, Patrick
AU  - Chariot P
LA  - FRE
PT  - JOURNAL ARTICLE
TT  - Personnes placees en garde a vue en Seine-Saint-Denis : donnees medicales et
      situations a risque, etude descriptive.
DEP - 20130506
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/12/06 [received]
PHST- 2013/01/08 [revised]
PHST- 2013/01/13 [accepted]
AID - S0755-4982(13)00500-9 [pii]
AID - 10.1016/j.lpm.2013.01.055 [doi]
PST - aheadofprint
SO  - Presse Med. 2013 May 6. pii: S0755-4982(13)00500-9. doi:
      10.1016/j.lpm.2013.01.055.

PMID- 23659872
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 20
TI  - A novel lamin A/C mutation in a Dutch family with premature atherosclerosis.
LID - S0021-9150(13)00256-6 [pii]
LID - 10.1016/j.atherosclerosis.2013.04.016 [doi]
AB  - OBJECTIVE: We report a novel lamin A/C (LMNA) mutation, p.Glu223Lys, in a family 
      with extensive atherosclerosis, diabetes mellitus and steatosis hepatis. METHODS:
      Sequence analysis of LMNA (using Alamut version 2.2), co-segregation analysis,
      electron microscopy, extensive phenotypic evaluation of the mutation carriers and
      literature comparison were used to determine the loss of function of this
      mutation. RESULTS: The father of three siblings died at the age of 45 years. The 
      three siblings and the brother and sister of the father were referred to the
      cardiovascular genetics department, because of the premature atherosclerosis and 
      dysmorphic characteristics observed in the father at autopsy. The novel LMNA
      mutation, p.Glu223Lys, was identified in the proband and his two sons. Clinical
      evaluation revealed atherosclerosis, insulin resistance and hypertension in the
      proband and dyslipidemia and hepatic steatosis in all the patients with the
      mutation. CONCLUSION: Based on the facts that in silico analysis predicts a
      possibly pathogenic mutation, the mutation co-segregates with the disease, only
      fibroblasts from mutation carriers show nuclear blebbing and a similar phenotype 
      was reported to be due to missense mutations in LMNA we conclude that we deal
      with a pathogenic mutation. We conclude that the phenotype is similar to
      Dunnigan-type familial partial lipodystrophy.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Vascular Medicine, Academic Medical Center, University of
      Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands; Department of
      Clinical Epidemiology, Biostatistics and Bio-informatics, Academic Medical
      Center, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The
      Netherlands.
FAU - Weterings, A A W
AU  - Weterings AA
FAU - van Rijsingen, I A W
AU  - van Rijsingen IA
FAU - Plomp, A S
AU  - Plomp AS
FAU - Zwinderman, A H
AU  - Zwinderman AH
FAU - Lekanne Deprez, R H
AU  - Lekanne Deprez RH
FAU - Mannens, M M
AU  - Mannens MM
FAU - van den Bergh Weerman, M A
AU  - van den Bergh Weerman MA
FAU - van der Wal, A C
AU  - van der Wal AC
FAU - Pinto-Sietsma, S J
AU  - Pinto-Sietsma SJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/24 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/10 [accepted]
AID - S0021-9150(13)00256-6 [pii]
AID - 10.1016/j.atherosclerosis.2013.04.016 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 20. pii: S0021-9150(13)00256-6. doi:
      10.1016/j.atherosclerosis.2013.04.016.

PMID- 23659871
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 18
TI  - Hypertension in pregnancy is a risk factor for peripheral arterial disease
      decades after pregnancy.
LID - S0021-9150(13)00252-9 [pii]
LID - 10.1016/j.atherosclerosis.2013.04.012 [doi]
AB  - BACKGROUND: An ankle-brachial index (ABI) (the ratio of ankle to brachial artery 
      systolic blood pressure) value </=0.9 identifies patients with peripheral
      arterial disease (PAD) and elevated cardiovascular event risk. This study
      examined whether women with a history of hypertension in pregnancy are more
      likely to have an ABI </=0.9 decades after pregnancy. METHODS AND RESULTS: ABI
      was measured in nulliparous women (n = 144), and women with a history of
      normotensive (n = 1272) or hypertensive (n = 281) pregnancies who participated in
      the Genetic Epidemiology Network of Arteriopathy (GENOA) study [non-Hispanic
      white (39%) and black (61%) women, 60 (mean) +/- 10 (SD) years of age].
      Relationships between PAD and pregnancy history were examined by logistic
      regression. Compared to women with a history of normotensive pregnancy, women
      with a history of hypertensive pregnancy had greater odds of PAD (1.61 (odds
      ratio); 1.04-2.49 (95% confidence interval), p = 0.03, adjusted for age, race,
      height and heart rate). Additional adjustment for ever smoking, hypertension,
      diabetes, dyslipidemia, a family history of hypertension or coronary heart
      disease, body mass index and education did not attenuate this relationship (1.63;
      1.02-2.62, p = 0.04). PAD risk did not differ between women with a history of
      normotensive pregnancy and nulliparous women (1.06; 0.52-2.14, p = 0.87).
      CONCLUSIONS: Hypertension in pregnancy is an independent risk factor for PAD
      decades after pregnancy after adjusting for race, age, height, heart rate, ever
      smoking, hypertension, diabetes, dyslipidemia, a family history of hypertension
      or coronary heart disease, body mass index and education.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - Division of Nephrology and Hypertension, Mayo Clinic, 200 First Street SW,
      RO-MA-19-E19NEP, Rochester, MN 55905, USA.
FAU - Weissgerber, Tracey L
AU  - Weissgerber TL
FAU - Turner, Stephen T
AU  - Turner ST
FAU - Bailey, Kent R
AU  - Bailey KR
FAU - Mosley, Thomas H Jr
AU  - Mosley TH Jr
FAU - Kardia, Sharon L R
AU  - Kardia SL
FAU - Wiste, Heather J
AU  - Wiste HJ
FAU - Miller, Virginia M
AU  - Miller VM
FAU - Kullo, Iftikhar J
AU  - Kullo IJ
FAU - Garovic, Vesna D
AU  - Garovic VD
LA  - ENG
GR  - K08 HD051714/HD/NICHD NIH HHS/United States
GR  - P50 AG044170/AG/NIA NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/17 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/04/07 [accepted]
AID - S0021-9150(13)00252-9 [pii]
AID - 10.1016/j.atherosclerosis.2013.04.012 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 18. pii: S0021-9150(13)00252-9. doi:
      10.1016/j.atherosclerosis.2013.04.012.

PMID- 23659870
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 22
TI  - Common variants in and near IRS1 and subclinical cardiovascular disease in the
      Framingham Heart Study.
LID - S0021-9150(13)00213-X [pii]
LID - 10.1016/j.atherosclerosis.2013.03.037 [doi]
AB  - OBJECTIVE: Common variants at the 2q36.3-IRS1 locus are associated with insulin
      resistance (IR), type 2 diabetes (T2D) and coronary artery disease (CAD) in
      large-scale association studies. We tested the hypothesis that variants at this
      locus are associated with subclinical atherosclerosis traits. METHODS: We studied
      2740 Framingham Heart Study participants (54.9% women; mean age 57.8 years) with 
      measures of coronary artery or abdominal aortic calcium, internal and common
      carotid intima-media thickness, and ankle-brachial index (ABI). We tested 1) four
      SNPs previously shown to be associated with IR (rs2972146, rs2943650), T2D
      (rs2943641) or CAD (rs2943634) and 2) any SNP at 2q36.3-IRS1, for association
      with subclinical atherosclerosis traits, adjusting for atherosclerosis risk
      factors. We set type 1 error rate for test 1) as 0.05/5 traits = P < 0.01, and
      for test 2) as 0.05 divided by the effective number of independent tests, divided
      by 5 for the number of traits analyzed. RESULTS: We found no association between 
      the four known SNPs and subclinical atherosclerosis, but identified one SNP
      (rs10167219, r2 with rs2943634 = 0.07) at 2q36.3 that was significantly
      associated with ABI (corrected P = 0.009). However, rs10167219 was not associated
      with ABI (P = 0.70) in 35,404 participants in a published ABI association study. 
      CONCLUSION: Common variants at the 2q36.3-IRS1 locus were not associated with
      subclinical atherosclerosis traits in this study which was adequately powered to 
      find associations with moderate effect size. Although IR and T2D may be
      mechanistically linked to CAD via subclinical atherosclerosis, an alternate
      mechanism for the IR-T2D-CAD associations at 2q36.3-IRS1 must be postulated.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - General Medicine Division, Department of Medicine, Massachusetts General Hospital
      and Harvard Medical School, Boston, MA, USA; Department of Internal Medicine,
      Seoul National University College of Medicine, Seoul National University Bundang 
      Hospital, Seongnam, South Korea.
FAU - Lim, Soo
AU  - Lim S
FAU - Hong, Jaeyoung
AU  - Hong J
FAU - Liu, Ching-Ti
AU  - Liu CT
FAU - Hivert, Marie-France
AU  - Hivert MF
FAU - White, Charles C
AU  - White CC
FAU - Murabito, Joanne M
AU  - Murabito JM
FAU - O'Donnell, Christopher J
AU  - O'Donnell CJ
FAU - Dupuis, Josee
AU  - Dupuis J
FAU - Florez, Jose C
AU  - Florez JC
FAU - Meigs, James B
AU  - Meigs JB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/10/17 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/29 [accepted]
AID - S0021-9150(13)00213-X [pii]
AID - 10.1016/j.atherosclerosis.2013.03.037 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 22. pii: S0021-9150(13)00213-X. doi:
      10.1016/j.atherosclerosis.2013.03.037.

PMID- 23659822
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1873-6130 (Electronic)
IS  - 1570-677X (Linking)
DP  - 2013 Apr 17
TI  - An investigation into the effect of type I and type II diabetes duration on
      employment and wages.
LID - S1570-677X(13)00039-7 [pii]
LID - 10.1016/j.ehb.2013.04.004 [doi]
AB  - Using data from the National Longitudinal Survey of Youth 1979, the current study
      examines the effect of type I and type II diabetes on employment status and
      wages. The results suggest that both the probability of employment and wages are 
      negatively related to the number of years since the initial diagnosis of
      diabetes. Moreover, the effect of diabetes duration on the probability of
      employment appears to be nonlinear, peaking around 16 years for females and 10
      years for males. A similar negative effect on wages is found only in male
      diabetics. Finally, the results suggest that failure to distinguish between type 
      I and type II diabetics may lead to some counterintuitive results.
CI  - Published by Elsevier B.V.
AD  - Food and Drug Administration/Center for Food Safety and Applied Nutrition, United
      States. Electronic address: Travis.Minor@fda.hhs.gov.
FAU - Minor, Travis
AU  - Minor T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Econ Hum Biol
JT  - Economics and human biology
JID - 101166135
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2011/09/24 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/01 [accepted]
AID - S1570-677X(13)00039-7 [pii]
AID - 10.1016/j.ehb.2013.04.004 [doi]
PST - aheadofprint
SO  - Econ Hum Biol. 2013 Apr 17. pii: S1570-677X(13)00039-7. doi:
      10.1016/j.ehb.2013.04.004.

PMID- 23659818
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1558-1357 (Electronic)
IS  - 0029-6465 (Linking)
VI  - 48
IP  - 2
DP  - 2013 Jun
TI  - Implementation of a clinical practice guideline for identification of
      microalbuminuria in the pediatric patient with type 1 diabetes.
PG  - 343-52
LID - 10.1016/j.cnur.2013.01.003 [doi]
LID - S0029-6465(13)00004-2 [pii]
AB  - Evidence-based practice is a shift in the health care culture from basing
      decisions on consensus opinion, past practice, and precedent toward the use of
      rigorous analysis of scientific evidence using outcomes research and clinical
      evidence to guide clinical decision making. The development of evidence-based
      clinical practice guidelines (CPG) is critical to guide the assessment and
      management of children with diabetes. This article provides an overview of the
      infrastructure and processes that are crucial to providing evidence-based care in
      a large urban pediatric diabetes center. Development of a CPG to identify
      microalbuminuria in children with type 1 diabetes is discussed.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, 
      34th and Civic Center Boulevard, Philadelphia, PA 19104, USA. Electronic address:
      montgomery@email.chop.edu.
FAU - Montgomery, Kathleen A
AU  - Montgomery KA
FAU - Ratcliffe, Sarah J
AU  - Ratcliffe SJ
FAU - Baluarte, H Jorge
AU  - Baluarte HJ
FAU - Murphy, Kathryn M
AU  - Murphy KM
FAU - Willi, Steven
AU  - Willi S
FAU - Lipman, Terri H
AU  - Lipman TH
LA  - eng
PT  - Journal Article
DEP - 20130222
PL  - United States
TA  - Nurs Clin North Am
JT  - The Nursing clinics of North America
JID - 0042033
SB  - AIM
SB  - IM
SB  - N
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/02/22 [aheadofprint]
AID - S0029-6465(13)00004-2 [pii]
AID - 10.1016/j.cnur.2013.01.003 [doi]
PST - ppublish
SO  - Nurs Clin North Am. 2013 Jun;48(2):343-52. doi: 10.1016/j.cnur.2013.01.003. Epub 
      2013 Feb 22.

PMID- 23659817
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1558-1357 (Electronic)
IS  - 0029-6465 (Linking)
VI  - 48
IP  - 2
DP  - 2013 Jun
TI  - Developmental mastery of diabetes-related tasks in children.
PG  - 329-42
LID - 10.1016/j.cnur.2013.01.015 [doi]
LID - S0029-6465(13)00026-1 [pii]
AB  - The goal of managing diabetes in childhood is to assist the child in becoming a
      physically healthy and emotionally mature adult, free from complications
      associated with diabetes. Gradual achievement of self-care independence occurs as
      developmental changes evolve during childhood. Inappropriate expectations related
      to self-care competence may lead to impaired diabetes control. It is important to
      have an understanding of child development and cognitive development in order
      ensure adequate expectations of self-care skill acquisition and the appropriate
      transition of self-care skills. Numerous steps can be taken to assist the child
      with diabetes in attaining developmentally appropriate, self-management skills.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - College of Nursing, University of Kentucky, 425A College of Nursing Building, 801
      Rose Street, Lexington, KY 40536, USA. Electronic address: lkscot0@uky.edu.
FAU - Scott, Leslie K
AU  - Scott LK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nurs Clin North Am
JT  - The Nursing clinics of North America
JID - 0042033
SB  - AIM
SB  - IM
SB  - N
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - S0029-6465(13)00026-1 [pii]
AID - 10.1016/j.cnur.2013.01.015 [doi]
PST - ppublish
SO  - Nurs Clin North Am. 2013 Jun;48(2):329-42. doi: 10.1016/j.cnur.2013.01.015.

PMID- 23659816
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1558-1357 (Electronic)
IS  - 0029-6465 (Linking)
VI  - 48
IP  - 2
DP  - 2013 Jun
TI  - Promoting normal development and self-efficacy in school-age children managing
      chronic conditions.
PG  - 319-28
LID - 10.1016/j.cnur.2013.01.009 [doi]
LID - S0029-6465(13)00010-8 [pii]
AB  - Chronic conditions can affect school-age children in more ways than just
      physically. Normal childhood maturation is critical at this age, yet daily
      management of chronic symptoms can be challenging. This article describes 4
      common childhood chronic illnesses (asthma, seizure disorders, diabetes, and
      cystic fibrosis), and the impact these conditions have on the developing child.
      Self-efficacy, the belief that one can effectively perform necessary skills, is
      essential to self-management of chronic conditions and contributes in a positive 
      way to the child's normal development. Implications for clinical practice and
      future research are discussed.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - 202 College of Nursing, University of Kentucky, 751 Rose Street, Lexington, KY
      40536-0232, USA; Pediatric Intensive Care Unit, Kentucky Children's Hospital,
      Lexington, KY 40536-0232, USA. Electronic address: klmick2@uky.edu.
FAU - Mickley, Kristyn L
AU  - Mickley KL
FAU - Burkhart, Patricia V
AU  - Burkhart PV
FAU - Sigler, April N
AU  - Sigler AN
LA  - eng
PT  - Journal Article
DEP - 20130222
PL  - United States
TA  - Nurs Clin North Am
JT  - The Nursing clinics of North America
JID - 0042033
SB  - AIM
SB  - IM
SB  - N
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/02/22 [aheadofprint]
AID - S0029-6465(13)00010-8 [pii]
AID - 10.1016/j.cnur.2013.01.009 [doi]
PST - ppublish
SO  - Nurs Clin North Am. 2013 Jun;48(2):319-28. doi: 10.1016/j.cnur.2013.01.009. Epub 
      2013 Feb 22.

PMID- 23659777
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 6
TI  - Are diabetes risk scores useful for the prediction of cardiovascular diseases?
      Assessment of seven diabetes risk scores in the KORA S4/F4 cohort study.
LID - S1056-8727(13)00067-6 [pii]
LID - 10.1016/j.jdiacomp.2013.03.004 [doi]
AB  - AIM: To evaluate the utility of diabetes prediction models for CVD prediction as 
      stated in two earlier studies. METHODS: 845 subjects from the population based
      German KORA (Cooperative Health Research in the Region of Augsburg) S4/F4 cohort 
      study (aged 55 to 74years, without diabetes, former stroke, and former myocardial
      infarction at baseline) were followed for up to ten years for incident stroke and
      myocardial infarction. Seven diabetes risk scores developed from four different
      studies were applied to the KORA cohort to assess their predictive ability for
      CVD. RESULTS: Areas under the receiver-operating curve (AROCs) for the prediction
      of CVD ranged from 0.60 to 0.65 when diabetes risk scores were applied to the
      KORA cohort. When diabetes risk scores were used to predict CVD and type 2
      diabetes, respectively, AROCs for the prediction of CVD were 0.09 to 0.24 lower
      than AROCs for the prediction of type 2 diabetes. Furthermore, we used KORA data 
      to develop prediction models for either diabetes or CVD, and found that they
      differed widely in selected predictor variables. CONCLUSION: In the older
      population, diabetes risk scores are not useful for the prediction of CVD, and
      prediction models for diabetes and CVD, respectively, require different
      parameters.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Center 
      for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany.
      Electronic address: bernd.kowall@ddz.uni-duesseldorf.de.
FAU - Kowall, Bernd
AU  - Kowall B
FAU - Rathmann, Wolfgang
AU  - Rathmann W
FAU - Bongaerts, Brenda
AU  - Bongaerts B
FAU - Thorand, Barbara
AU  - Thorand B
FAU - Belcredi, Petra
AU  - Belcredi P
FAU - Heier, Margit
AU  - Heier M
FAU - Huth, Cornelia
AU  - Huth C
FAU - Ruckert, Ina-Maria
AU  - Ruckert IM
FAU - Stockl, Doris
AU  - Stockl D
FAU - Peters, Annette
AU  - Peters A
FAU - Meisinger, Christa
AU  - Meisinger C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/16 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/24 [accepted]
AID - S1056-8727(13)00067-6 [pii]
AID - 10.1016/j.jdiacomp.2013.03.004 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 6. pii: S1056-8727(13)00067-6. doi:
      10.1016/j.jdiacomp.2013.03.004.

PMID- 23659776
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 7
TI  - Irisin in obesity and type 2 diabetes.
LID - S1056-8727(13)00070-6 [pii]
LID - 10.1016/j.jdiacomp.2013.04.002 [doi]
AD  - Department of Endocrinology, Odense University Hospital & Section of Molecular
      Diabetes & Metabolism, Institute of Molecular Medicine, University of Southern
      Denmark, Odense, Denmark. Electronic address: k.hojlund@dadlnet.dk.
FAU - Hojlund, Kurt
AU  - Hojlund K
FAU - Bostrom, Pontus
AU  - Bostrom P
LA  - ENG
PT  - EDITORIAL
DEP - 20130507
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/04/02 [received]
PHST- 2013/04/02 [accepted]
AID - S1056-8727(13)00070-6 [pii]
AID - 10.1016/j.jdiacomp.2013.04.002 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 7. pii: S1056-8727(13)00070-6. doi:
      10.1016/j.jdiacomp.2013.04.002.

PMID- 23659775
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 6
TI  - Lowering blood pressure limits in patients with type 2 diabetes: Is it still
      warranted?
LID - S1056-8727(13)00069-X [pii]
LID - 10.1016/j.jdiacomp.2013.04.001 [doi]
AD  - ASH Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and
      Metabolism, The University of Chicago Medicine, Chicago, IL USA. Electronic
      address: gbakris@gmail.com.
FAU - Bakris, George L
AU  - Bakris GL
LA  - ENG
PT  - EDITORIAL
DEP - 20130506
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/03/29 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/02 [accepted]
AID - S1056-8727(13)00069-X [pii]
AID - 10.1016/j.jdiacomp.2013.04.001 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 6. pii: S1056-8727(13)00069-X. doi:
      10.1016/j.jdiacomp.2013.04.001.

PMID- 23659774
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 6
TI  - The influence of subclinical cardiovascular disease and related risk factors on
      cognition in type 2 diabetes mellitus: The DHS-Mind study.
LID - S1056-8727(13)00072-X [pii]
LID - 10.1016/j.jdiacomp.2013.04.004 [doi]
AB  - We hypothesized that measures of coronary artery calcified plaque (CAC) collected
      at baseline from the Diabetes Heart Study (DHS) would explain associations
      between cognition and diabetes collected at follow-up approximately 7years later.
      The DHS is a sibling study of cardiovascular disease (CVD) in a cohort with a
      high prevalence of type 2 diabetes (~80%). Associations between baseline CAC and 
      cognitive performance were tested using generalized estimating equations and
      mixed effects models to adjust for familial relationships. Diabetes status was
      associated (p<0.05) with poorer performance on tests of verbal memory, processing
      speed, and semantic fluency adjusting for age, sex, education, and hypertension
      status. As hypothesized, including CAC in the statistical model attenuated this
      association. Additionally, CAC and fasting glucose predicted performance in tasks
      not associated with diabetes status in this study (Stroop Task, Phonemic
      Fluency). These results confirm work attributing the heterogeneity of cognitive
      outcomes in type 2 diabetes to subclinical risk factors that combine to affect
      different aspects of brain function. Importantly, these results imply that risk
      factor intervention should begin before comorbidities, particularly CVD, become
      clinically apparent.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Internal Medicine, Section on Gerontology and Geriatric Medicine,
      Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address:
      chugensc@wakehealth.edu.
FAU - Hugenschmidt, Christina E
AU  - Hugenschmidt CE
FAU - Hsu, Fang-Chi
AU  - Hsu FC
FAU - Hayasaka, Satoru
AU  - Hayasaka S
FAU - Carr, J Jeffrey
AU  - Carr JJ
FAU - Freedman, Barry I
AU  - Freedman BI
FAU - Nyenhuis, David L
AU  - Nyenhuis DL
FAU - Williamson, Jeff D
AU  - Williamson JD
FAU - Bowden, Donald W
AU  - Bowden DW
LA  - ENG
GR  - R01 NS058700/NS/NINDS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/10/02 [received]
PHST- 2013/04/04 [revised]
PHST- 2013/04/05 [accepted]
AID - S1056-8727(13)00072-X [pii]
AID - 10.1016/j.jdiacomp.2013.04.004 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 6. pii: S1056-8727(13)00072-X. doi:
      10.1016/j.jdiacomp.2013.04.004.

PMID- 23659762
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
VI  - 9999
IP  - 9999
DP  - 2013 May 9
TI  - Vascular function and glucose variability improve transiently following
      initiation of continuous subcutaneous insulin infusion in children with type 1
      diabetes.
LID - 10.1111/pedi.12050 [doi]
AB  - OBJECTIVE: The effect of continuous subcutaneous insulin infusion (CSII) and
      glucose variability on vascular health in type 1 diabetes (T1D) is not known. We 
      aimed to determine whether initiation of CSII improves vascular function and
      reduces glucose variability, independent of changes in HbA1c. METHODS: Twenty-two
      children with T1D (12.5 +/- 2.9 yr) were reviewed immediately prior, 3 wk, and 12
      months after initiation of CSII. Vascular function [flow-mediated dilatation
      (FMD), glyceryl trinitrate-mediated dilatation (GTN)], glucose variability [mean 
      of daily differences (MODD), mean amplitude of glycaemic excursions (MAGE) and
      continuous overlapping net glycaemic action (CONGA)], and clinical and
      biochemical data were measured at each visit. Results for the first two visits
      were compared to a previously studied cohort of 31 children with T1D who remained
      on multiple daily injections (MDI). RESULTS: FMD, GTN, blood pressure, HbA1c,
      fructosamine, and glucose variability significantly improved 3 wk after CSII
      commencement (all p < 0.05), but there was no change in the MDI control group. At
      3 wk, vascular function related to glucose variability [(FMD: MODD, r = -0.62, p 
      = 0.002) and (GTN: MAGE, r = -0.59, p = 0.004; CONGA-4, r = -0.51, p = 0.01;
      MODD, r = -0.62, p = 0.002)] but not to blood pressure, HbA1c, or fructosamine.
      At 12 months, FMD, GTN, blood pressure, and glucose variability returned to
      baseline levels, while HbA1c deteriorated. Carotid intima media thickness was
      unchanged over 12 months. CONCLUSIONS: Initiation of CSII rapidly improves
      vascular function in association with decreased glucose variability; however, the
      effects are not sustained with deterioration of metabolic control and glucose
      variability.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Endocrinology and Diabetes Department.
FAU - Harrington, Jennifer
AU  - Harrington J
FAU - Pena, Alexia S
AU  - Pena AS
FAU - Wilson, Louise
AU  - Wilson L
FAU - Gent, Roger
AU  - Gent R
FAU - Dowling, Kate
AU  - Dowling K
FAU - Baghurst, Peter
AU  - Baghurst P
FAU - Couper, Jennifer
AU  - Couper J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/12/29 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/10 [accepted]
AID - 10.1111/pedi.12050 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 May 9;9999(9999). doi: 10.1111/pedi.12050.

PMID- 23659710
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1502-7724 (Electronic)
IS  - 0281-3432 (Linking)
VI  - 31
IP  - 2
DP  - 2013 Jun
TI  - No identifiable Hb1Ac or lifestyle change after a comprehensive diabetes
      programme including motivational interviewing: A cluster randomised trial.
PG  - 119-27
LID - 10.3109/02813432.2013.797178 [doi]
AB  - Abstract Objective. To study the effectiveness of a comprehensive diabetes
      programme in general practice that integrates patient-centred lifestyle
      counselling into structured diabetes care. Design and setting. Cluster randomised
      trial in general practices. Intervention. Nurse-led structured diabetes care with
      a protocol, record keeping, reminders, and feedback, plus training in
      motivational interviewing and agenda setting. Subjects. Primary care nurses in 58
      general practices and their 940 type 2 diabetes patients with an HbA1c
      concentration above 7%, and a body mass index (BMI) above 25 kg/m(2). Main
      outcome measures. HbA1c, diet, and physical activity (medical records and patient
      questionnaires). Results. Multilevel linear and logistic regression analyses
      adjusted for baseline outcomes showed that despite active nurse participation in 
      the intervention, the comprehensive programme was no more effective than usual
      care after 14 months, as shown by HbA1c levels (difference between groups = 0.13;
      CI 20.8-0.35) and diet (fat (difference between groups = 0.19; CI 20.82-1.21);
      vegetables (difference between groups = 0.10; CI-0.21-0.41); fruit (difference
      between groups = 20.02; CI 20.26-0.22)), and physical activity (difference
      between groups = 21.15; CI 212.26-9.97), or any of the other measures of clinical
      parameters, patient's readiness to change, or quality of life. Conclusion. A
      comprehensive programme that integrated lifestyle counselling based on
      motivational interviewing principles integrated into structured diabetes care did
      not alter HbA1c or the lifestyle related to diet and physical activity. We thus
      question the impact of motivational interviewing in terms of its ability to
      improve routine diabetes care in general practice.
AD  - Scientific Institute for Quality of Healthcare, Radboud University Nijmegen
      Medical Centre , Nijmegen , the Netherlands.
FAU - Jansink, Renate
AU  - Jansink R
FAU - Braspenning, Joze
AU  - Braspenning J
FAU - Keizer, Ellen
AU  - Keizer E
FAU - van der Weijden, Trudy
AU  - van der Weijden T
FAU - Elwyn, Glyn
AU  - Elwyn G
FAU - Grol, Richard
AU  - Grol R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Scand J Prim Health Care
JT  - Scandinavian journal of primary health care
JID - 8510679
SB  - IM
PMC - PMC3656395
OID - NLM: PMC3656395
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - 10.3109/02813432.2013.797178 [doi]
PST - ppublish
SO  - Scand J Prim Health Care. 2013 Jun;31(2):119-27. doi:
      10.3109/02813432.2013.797178.

PMID- 23659706
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 May 9
TI  - Use of glycosylated hemoglobin increases diabetes screening for at-risk
      adolescents in primary care settings.
LID - 10.1111/pedi.12037 [doi]
AB  - OBJECTIVE: To examine rates of diabetes screening in obese adolescents in an
      ethnically diverse primary care health care system before and after an internal
      recommendation to use HbA1c-based screening. RESEARCH DESIGN AND METHODS:
      Adolescents 12-18-years old with BMI > 95% were identified through electronic
      medical record review during two 18-month periods in 8 community health clinics
      and 13 school-based health centers: period 1 (P1, 19 April 2008 to 19 October
      2009) and period 2 (P2, 3 May 2010 to 3 November 2011). Testing for diabetes in
      the 2 yr preceding the most recently elevated BMI was reviewed. RESULTS: A total 
      of 2870 obese adolescents were identified in P1 and 3940 in P2. Ethnicity was
      primarily Hispanic, with smaller populations of Black and White youth. The
      percent of obese teens screened for diabetes increased from 40% in P1 to 47% in
      P2. Use of HbA1c increased 493% during P2. Older teens (>15 yr), those seen
      during P2, and those with BMI >/= 30 kg/m2 were more likely to be screened.
      Record review confirmed equal rates of type 2 diabetes in the two periods: 8
      incident (0.7%) cases in P1 and 13 (0.7%) in P2. CONCLUSIONS: The use of HbA1c, a
      non-fasting and logistically simpler test, was associated with increased diabetes
      screening in primary care. The percentage of screened patients with confirmed
      type 2 diabetes remained unchanged. Thus, despite potential pitfalls, the use of 
      HbA1c for screening appears to be as successful as previous approaches in
      identifying adolescents with diabetes.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Pediatrics/Adolescent Medicine, Denver Health and Hospitals and University of
      Colorado School of Medicine, Denver, CO, 80205, USA.
FAU - Love-Osborne, Kathryn A
AU  - Love-Osborne KA
FAU - Sheeder, Jeanelle
AU  - Sheeder J
FAU - Svircev, Anna
AU  - Svircev A
FAU - Chan, Christine
AU  - Chan C
FAU - Zeitler, Phil
AU  - Zeitler P
FAU - Nadeau, Kristen J
AU  - Nadeau KJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/11/06 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/14 [accepted]
AID - 10.1111/pedi.12037 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 May 9. doi: 10.1111/pedi.12037.

PMID- 23659685
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 8
DP  - 2013
TI  - Deletion mutation in BSCL2 gene underlies congenital generalized lipodystrophy in
      a Pakistani family.
PG  - 78
LID - 10.1186/1746-1596-8-78 [doi]
AB  - BACKGROUND: Congenital generalized lipodystrophy (CGL) also known as
      Berardinelli-Seip Congenital Lipodystrophy (BSCL) is a genetically heterogeneous 
      disorder characterized by loss of adipose tissues, Acanthosis nigricans, diabetes
      mellitus, muscular hypertrophy, hepatomegaly and hypertriglyceridemia. There are 
      four subclinical phenotypes of CGL (CGL1-4) and mutations in four genes AGPAT2,
      BSCL2, CAV1 and PTRF have been assigned to each type. METHODS: The study included
      clinical and molecular investigations of CGL disease in a consanguineous
      Pakistani family. For mutation screening all the coding exons including splice
      junctions of AGPAT2, BSCL2, CAV1 and PTRF genes were PCR amplified and sequenced 
      directly using an automated DNA sequencer ABI3730. RESULTS: Sequence analysis
      revealed a single base pair deletion mutation (c.636delC; p.Tyr213ThrfsX20) in
      exon 5 of BSCL2 gene causing a frame shift and premature termination codon.
      CONCLUSION: Mutation identified here in BSCL2 gene causing congenital generalized
      lipodystrophy is the first report in Pakistani population. The patients exhibited
      characteristic features of generalized lipodystrophy, Acanthosis nigricans,
      diabetes mellitus and hypertrophic cardiomyopathy. VIRTUAL SLIDES: The virtual
      slide(s) for this article can be found here:
      http://www.diagnosticpathology.diagnomx.eu/vs/1913913076864247.
AD  - Medical Genetics and Molecular Biology Unit, Biochemistry Department, Institute
      of Basic Medical Sciences, Khyber Medical University, Peshawar 25000, Pakistan.
      mjelani.ibms@kmu.edu.pk.
FAU - Rahman, Obaid Ur
AU  - Rahman OU
FAU - Khawar, Nadeem
AU  - Khawar N
FAU - Khan, Muhammad Aman
AU  - Khan MA
FAU - Ahmed, Jawad
AU  - Ahmed J
FAU - Khattak, Kamran
AU  - Khattak K
FAU - Al-Aama, Jumana Yousuf
AU  - Al-Aama JY
FAU - Naeem, Muhammad
AU  - Naeem M
FAU - Jelani, Musharraf
AU  - Jelani M
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
SB  - IM
PMC - PMC3655832
OID - NLM: PMC3655832
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/12/05 [received]
PHST- 2013/05/06 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 1746-1596-8-78 [pii]
AID - 10.1186/1746-1596-8-78 [doi]
PST - epublish
SO  - Diagn Pathol. 2013 May 9;8:78. doi: 10.1186/1746-1596-8-78.

PMID- 23659636
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1749-6632 (Electronic)
IS  - 0077-8923 (Linking)
VI  - 1287
IP  - 1
DP  - 2013 May
TI  - Application of combined omics platforms to accelerate biomedical discovery in
      diabesity.
PG  - 1-16
LID - 10.1111/nyas.12116 [doi]
AB  - Diabesity has become a popular term to describe the specific form of diabetes
      that develops late in life and is associated with obesity. While there is a
      correlation between diabetes and obesity, the association is not universally
      predictive. Defining the metabolic characteristics of obesity that lead to
      diabetes, and how obese individuals who develop diabetes different from those who
      do not, are important goals. The use of large-scale omics analyses (e.g.,
      metabolomic, proteomic, transcriptomic, and lipidomic) of diabetes and obesity
      may help to identify new targets to treat these conditions. This report discusses
      how various types of omics data can be integrated to shed light on the changes in
      metabolism that occur in obesity and diabetes.
CI  - (c) 2013 New York Academy of Sciences.
AD  - Department of Medicine, Stable Isotope and Metabolomics Core Facility, Albert
      Einstein College of Medicine Diabetes Center, Bronx, New York.
FAU - Kurland, Irwin J
AU  - Kurland IJ
FAU - Accili, Domenico
AU  - Accili D
FAU - Burant, Charles
AU  - Burant C
FAU - Fischer, Steven M
AU  - Fischer SM
FAU - Kahn, Barbara B
AU  - Kahn BB
FAU - Newgard, Christopher B
AU  - Newgard CB
FAU - Ramagiri, Suma
AU  - Ramagiri S
FAU - Ronnett, Gabriele V
AU  - Ronnett GV
FAU - Ryals, John A
AU  - Ryals JA
FAU - Sanders, Mark
AU  - Sanders M
FAU - Shambaugh, Joe
AU  - Shambaugh J
FAU - Shockcor, John
AU  - Shockcor J
FAU - Gross, Steven S
AU  - Gross SS
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/05/09 [aheadofprint]
AID - 10.1111/nyas.12116 [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2013 May;1287(1):1-16. doi: 10.1111/nyas.12116. Epub 2013 May
      9.

PMID- 23659590
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 10
TI  - Diabetes care provision: barriers, enablers and service needs of young adults
      with Type 1 diabetes from a region of social disadvantage.
LID - 10.1111/dme.12227 [doi]
AB  - AIMS: To determine the barriers to and enablers of engaging with specialist
      diabetes care and the service requirements of young adults with Type 1 diabetes
      mellitus from a low socio-economic, multicultural region. METHODS: A
      cross-sectional survey targeted 357 young adults with Type 1 diabetes, aged 18-30
      years. Participants completed questions about barriers/enablers to accessing
      diabetes care and service preferences, self-reported HbA1c , plus measures of
      diabetes-related distress (Problem Areas in Diabetes), depression/anxiety
      (Hospital Anxiety and Depression Scale), and illness perceptions (Brief Illness
      Perceptions Questionnaire). RESULTS: Eighty-six (24%) responses were received [55
      (64%) female; mean +/- sd age 24 +/- 4 years; diabetes duration 12 +/- 7 years;
      HbA1c 68 +/- 16 mmol/mol (8.4 +/- 1.5%)]. Logistical barriers to attending
      diabetes care were reported; for example, time constraints (30%), transportation 
      (26%) and cost (21%). However, 'a previous unsatisfactory diabetes health
      experience' was cited as a barrier by 27%. Enablers were largely matched to
      overcoming these barriers. Over 90% preferred a multidisciplinary team
      environment, close to home, with after-hours appointment times. Forty per cent
      reported severe diabetes-related distress, 19% reported moderate-to-severe
      depressive symptoms and 50% reported moderate-to-severe anxiety. CONCLUSIONS:
      Among these young adults with Type 1 diabetes, glycaemic control was suboptimal
      and emotional distress common. They had identifiable logistical barriers to
      accessing and maintaining contact with diabetes care services, which can be
      addressed with flexible service provision. A substantial minority were
      discouraged by previous unsatisfactory experiences, suggesting health providers
      need to improve their interactions with young adults. This research will inform
      the design of life-stage-appropriate diabetes services targeting optimal
      engagement, access, attendance and ultimately improved healthcare outcomes in
      this vulnerable population.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Diabetes Unit, Southern Health, Melbourne, Australia.
FAU - Kibbey, K J
AU  - Kibbey KJ
FAU - Speight, J
AU  - Speight J
FAU - Wong, J L A
AU  - Wong JL
FAU - Smith, L A
AU  - Smith LA
FAU - Teede, H J
AU  - Teede HJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/11/28 [received]
PHST- 2013/02/13 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dme.12227 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 10. doi: 10.1111/dme.12227.

PMID- 23659572
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 10
TI  - Pre-diabetes in adults 45 years and over in Ireland: the Survey of Lifestyle,
      Attitudes and Nutrition in Ireland 2007.
LID - 10.1111/dme.12226 [doi]
AB  - OBJECTIVES: Pre-diabetes is an important indicator of future diabetes burden and 
      many countries are reporting prevalence estimates of pre-diabetes. To date in
      Ireland, estimates of the prevalence of pre-diabetes were unavailable. Our
      objectives were to estimate the prevalence of pre-diabetes in a nationally
      representative sample of Irish adults and to explore determinants of
      pre-diabetes. METHODS: The Survey of Lifestyle Attitudes and Nutrition 2007 was a
      cross-sectional survey on health and lifestyle in a nationally representative
      sample of Irish adults. Analysis was performed on a subsample of 1132
      participants >/= 45 years who provided blood samples. Determination of
      pre-diabetes was based on American Diabetes Association HbA1c cut points of 39-46
      mmol/mol (5.7-6.4%). To explore determinants, we modelled pre-diabetes prevalence
      as a function of a set of health system and socio-demographic variables using
      logistic regression. RESULTS: The overall weighted prevalence estimate of
      pre-diabetes in participants >/= 45 years was 19.8% (95% CI 16.4-23.9). There was
      no significant difference between age or gender-specific prevalence rates.
      Obesity was significantly associated with pre-diabetes on univariate and
      multivariate analysis. Population attributable fraction estimates for excess BMI,
      physical inactivity and poor diet as causes of pre-diabetes were 31.3% (95% CI
      -3.9 to 54.5), 10.0% (95% CI -2.7 to 21.3) and 6.1% (95% CI -4.9 to 15.9),
      respectively. CONCLUSIONS: The high levels of pre-diabetes detected in this study
      are worrying. Population level interventions to address diet and lifestyle
      factors are needed urgently to prevent progression to diabetes in high-risk
      individuals. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of General Practice, University College Cork (UCC); Department of
      Epidemiology and Public Health, University College Cork (UCC), Cork.
FAU - Buckley, C M
AU  - Buckley CM
FAU - Madden, J
AU  - Madden J
FAU - Balanda, K
AU  - Balanda K
FAU - Barron, S
AU  - Barron S
FAU - Fahy, L
AU  - Fahy L
FAU - Harrington, J
AU  - Harrington J
FAU - Perry, I J
AU  - Perry IJ
FAU - Kearney, P M
AU  - Kearney PM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2012/12/03 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dme.12226 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 10. doi: 10.1111/dme.12226.

PMID- 23659564
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
DP  - 2013 May 9
TI  - Clinical Outcomes after 24 Months of Insulin Therapy in Patients with Type 2
      Diabetes in 5 Countries: Results from the TREAT Study.
AB  - Abstract Objective: To assess factors associated with insulin regimens at
      initiation, changes in treatment and metabolic control over 2 years of insulin
      therapy in patients with type 2 diabetes in 5 countries. Research design and
      methods: TREAT was a prospective, 24-month, observational study in patients with 
      type 2 diabetes initiating insulin in clinical practice. Patient characteristics 
      were collected at baseline and metabolic outcomes at 3, 6, 12, 18 and 24 months
      after initiation. Results: A total of 985 patients were enrolled, 886 assessed at
      baseline and 734 (82.8%) at 24 months. Baseline characteristics varied between
      countries; 52.8% of patients were men; mean age was 60.4 years; body mass index, 
      29.7 kg/m2; time since diagnosis, 10.1 years; HbA1c, 9.6%. Less than 25% of
      patients met ADA/IDF targets for blood pressure/LDL cholesterol. Overall, 50.1%
      of patients were initiated on long/intermediate insulin, 39.3% on mixture and
      7.8% on basal-bolus; distribution varied between countries. Patients on
      long/intermediate were more likely to have lower baseline HbA1c and be
      intensified to other regimens (19.4%). No oral antidiabetic medication was used
      for 16.4% initiating on long/intermediate, 47.4% on mixture and 62.3% with
      basal-bolus. Overall, mean HbA1c decreased from 9.6% to 7.6%, with little
      difference between regimens at endpoint. Percentage of patients with
      hypoglycaemia was highest at six months and with basal-bolus. Limitations: Sites 
      were not selected at random. Drop-out of patients prior to 24 months may have
      introduced a bias that favoured responders. Conclusions: Mean baseline HbA1c was 
      high, indicating delayed initiation of insulin treatment. Blood pressure and
      lipids were suboptimally controlled. Insulin regimens varied between countries,
      changed little and resulted in similar HbA1c levels after 24 months.
AD  - Department of Internal Medicine, Istanbul Medeniyet University, Goztepe Education
      and Research Hospital, Istanbul, Turkey.
FAU - Oguz, A
AU  - Oguz A
FAU - Benroubi, M
AU  - Benroubi M
FAU - Brismar, K
AU  - Brismar K
FAU - Melo, P
AU  - Melo P
FAU - Morar, C
AU  - Morar C
FAU - Cleall, S P
AU  - Cleall SP
FAU - Giaconia, J
AU  - Giaconia J
FAU - Schmitt, H
AU  - Schmitt H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - 10.1185/03007995.2013.803053 [doi]
PST - aheadofprint
SO  - Curr Med Res Opin. 2013 May 9.

PMID- 23659561
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 29
IP  - 7
DP  - 2013 Jul
TI  - Treatment adherence with vildagliptin compared to sulphonylurea as add-on to
      metformin in Muslim patients with type 2 diabetes mellitus fasting during
      Ramadan.
PG  - 807-11
LID - 10.1185/03007995.2013.803054 [doi]
AB  - Abstract Objective: To assess treatment adherence to dipeptidyl peptidase-4
      inhibitor vildagliptin compared with sulphonylureas (SU) in Muslim patients with 
      type 2 diabetes mellitus who were fasting during Ramadan in the UK. Research
      design and methods: This prospective, observational cohort study was conducted in
      four UK centres. Patients already taking vildagliptin (50 mg twice a day) or an
      SU as add-on therapy to metformin were followed up for </=16 weeks. They were
      asked to record all missed doses of anti-diabetes medications. Results: Of the 72
      patients enrolled (vildagliptin, n = 30; SU, n = 41; not allocated to treatment, 
      n = 1), 59 (81.9%) completed the study (vildagliptin, n = 23; SU, n = 36),
      including one patient in the SU arm who completed but failed to provide
      information on missed doses; all patients in the SU arm were taking gliclazide.
      In the vildagliptin arm one patient (4.3%) missed a total of four doses while in 
      the SU arm 10 patients (27.8%) missed a total of 266 doses (mean [SD] number of
      doses missed per patient: 26.6 [16.5]). The mean (SD) proportions of doses missed
      during fasting were 0.2% (0.9) and 10.4% (21.7) in the vildagliptin and SU arms, 
      respectively, with a significant mean between-group difference of -10.2% (95% CI:
      -19.3%, -1.1%; p = 0.0292). There were no patients in the vildagliptin arm who
      missed more than 20% of OAD doses compared with 19.4% in the SU arm (p = 0.0358).
      Of the patients receiving an SU, 15 (42%) collectively reported 34 hypoglycaemic 
      events (HEs) and one grade 2 HE; of these, fewer were non-adherent (n = 6, 40%)
      than adherent (n = 9, 60%). No patients reported HEs in the vildagliptin arm.
      Conclusion: During Ramadan fasting, treatment with vildagliptin resulted in
      better treatment adherence compared with SU in Muslim patients with type 2
      diabetes mellitus. Study limitations are the sample size and the lack of diet and
      exercise data.
AD  - University of Birmingham , Birmingham , UK.
FAU - Hanif, W
AU  - Hanif W
FAU - Malik, W
AU  - Malik W
FAU - Hassanein, M
AU  - Hassanein M
FAU - Kamal, A
AU  - Kamal A
FAU - Geransar, P
AU  - Geransar P
FAU - Andrews, C
AU  - Andrews C
FAU - Azam, M
AU  - Azam M
FAU - Barnett, A H
AU  - Barnett AH
LA  - eng
PT  - Journal Article
DEP - 20130531
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
SB  - IM
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/05/31 [aheadofprint]
AID - 10.1185/03007995.2013.803054 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2013 Jul;29(7):807-11. doi: 10.1185/03007995.2013.803054. Epub
      2013 May 31.

PMID- 23659525
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 10
TI  - Blood pressure levels but not hypertensive complications have increased in Type 1
      diabetes pregnancies during 1989-2010.
LID - 10.1111/dme.12224 [doi]
AB  - AIMS: The pre-pregnancy BMI and the third trimester HbA1c levels increased in
      Finnish parturients with Type 1 diabetes during 1989-2008. The aim of the present
      study was to investigate whether these trends have been accompanied by increases 
      in blood pressure or hypertensive complications. Hypertension trends were
      analysed using the definitions of hypertension of both the American College of
      Obstetricians and Gynecologists and the American Diabetes Association. The
      associations of hypertension, as defined by the latter criteria, with perinatal
      complications were also studied. METHODS: The records of a cohort of 1007
      consecutive patients with Type 1 diabetes with a singleton live childbirth during
      1989-2010 at the Helsinki University Central Hospital were studied. RESULTS: The 
      frequencies of hypertensive pregnancy complications did not change, but the mean 
      diastolic blood pressure increased in normotensive parturients in all trimesters.
      The proportion of patients with systolic blood pressure > 130 mmHg or diastolic
      blood pressure > 80 mmHg in the first, second and third trimesters of pregnancy
      increased from 25 to 33%, from 26 to 35% and from 57 to 71%, respectively.
      Systolic blood pressure of 131-139 mmHg or diastolic blood pressure of 81-89 mmHg
      in the third trimester was associated with umbilical artery pH < 7.15.
      CONCLUSIONS: Blood pressure of patients with Type 1 diabetes during pregnancy is 
      increasing. A growing proportion of women with Type 1 diabetes exceed the
      American Diabetes Association's definition of hypertension during pregnancy.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Department of Obstetrics and Gynaecology, Helsinki University Central Hospital,
      Helsinki, Finland; Department of Medical Genetics, Haartman Institute, Helsinki, 
      Finland; National Graduate School of Clinical Investigation (CLIGS), Biomedicum
      Helsinki, Helsinki, Finland; Research Programs Unit, Women's Health, University
      of Helsinki, Helsinki, Finland.
FAU - Klemetti, M M
AU  - Klemetti MM
FAU - Teramo, K
AU  - Teramo K
FAU - Nuutila, M
AU  - Nuutila M
FAU - Tikkanen, M
AU  - Tikkanen M
FAU - Hiilesmaa, V
AU  - Hiilesmaa V
FAU - Laivuori, H
AU  - Laivuori H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/08 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dme.12224 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 10. doi: 10.1111/dme.12224.

PMID- 23659477
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 10
TI  - Epidemiology of blindness attributable to diabetes in Scotland: change over 20
      years in a defined population.
LID - 10.1111/dme.12223 [doi]
AB  - AIMS: To establish the incidence and prevalence of blindness attributable to
      diabetes in a defined population in Scotland during the period 2000-2009, and to 
      compare these figures with published data from the previous decade in the same
      population. METHODS: All blind registrations during 2000-2009 in Fife, Scotland, 
      UK were examined and included if diabetic retinopathy/maculopathy was the main
      cause of blindness. The annual incidence and point prevalence on 31 December 2009
      of registered blindness attributable to diabetes were calculated in both the
      total population and the population with diabetes. These data were compared with 
      figures for the period 1990-1999, using a two-tailed t-test, and subjected to
      Poisson regression analysis. RESULTS: In the population with diabetes, the mean
      incidence of blindness attributable to diabetes was 42.7 (sd 24.2, 95% CI 25- 60)
      per 100 000 per year for 2000-2009, compared with 64.3 for 1990-1999 (P = 0.062).
      The relative risk of developing blindness per year was 0.894 (95% CI 0.811-
      0.988, P = 0.028) for 2000- 2009. The point prevalence on 31 December 2009 was
      167 per 100 000 in the population with diabetes, vs 210 on 31 December 1999.
      CONCLUSION: Compared with the previous decade, the prevalence of blindness
      attributable to diabetes has decreased in the population with diabetes, with a
      trend towards a decrease in its incidence. This may be a consequence of an
      increased denominator population, resulting from better recording of diabetes and
      changes to the diagnostic criteria. Over the decade 2000-2009, the incidence of
      blindness attributable to diabetes fell by a mean of 10.6% per year in the
      population with diabetes.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Department of Ophthalmology, Queen Margaret Hospital, Dunfermline, Fife, UK.
FAU - Hall, H N
AU  - Hall HN
FAU - Chinn, D J
AU  - Chinn DJ
FAU - Sinclair, A
AU  - Sinclair A
FAU - Styles, C J
AU  - Styles CJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/01/25 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dme.12223 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 10. doi: 10.1111/dme.12223.

PMID- 23659458
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 May 10
TI  - Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 
      diabetes.
LID - 10.1111/dme.12222 [doi]
AB  - AIMS: To determine the prevalence and clinical characteristics of absolute
      insulin deficiency in long-standing Type 2 diabetes, using a strategy based on
      home urinary C-peptide creatinine ratio measurement. METHODS: We assessed the
      urinary C-peptide creatinine ratios, from urine samples taken at home 2 h after
      the largest meal of the day, in 191 insulin-treated subjects with Type 2 diabetes
      (diagnosis age >/=45 years, no insulin in the first year). If the initial urinary
      C-peptide creatinine ratio was </=0.2 nmol/mmol (representing absolute insulin
      deficiency), the assessment was repeated. A standardized mixed-meal tolerance
      test with 90-min stimulated serum C-peptide measurement was performed in nine
      subjects with a urinary C-peptide creatinine ratio </= 0.2nmol/mmol (and in nine 
      controls with a urinary C-peptide creatinine ratio >0.2nmol/mmol) to confirm
      absolute insulin deficiency. RESULTS: A total of 2.7% of participants had
      absolute insulin deficiency confirmed by a mixed-meal tolerance test. They were
      identified initially using urinary C-peptide creatinine ratio: 11/191 subjects
      (5.8%) had two consistent urinary C-peptide creatinine ratios </= 0.2 nmol/mmol; 
      9/11 subjects completed a mixed-meal tolerance test and had a median stimulated
      serum C-peptide of 0.18nmol/l. Five out of nine subjects had stimulated serum
      C-peptide <0.2 nmol/l and 9/9 subjects with urinary C-peptide creatinine ratio
      >0.2 had endogenous insulin secretion confirmed by the mixed-meal tolerance test.
      Compared with subjects with a urinary C-peptide creatinine ratio >0.2 nmol/mmol, 
      those with confirmed absolute insulin deficiency had a shorter time to insulin
      treatment (median 2.5 vs. 6 years, P=0.005) and lower BMI (25.1 vs. 29.1kg/m2 ,
      P=0.04). Two out of five patients were glutamic acid decarboxylase
      autoantibody-positive. CONCLUSIONS: Absolute insulin deficiency may occur in
      long-standing Type 2 diabetes, and cannot be reliably predicted by clinical
      features or autoantibodies. Its recognition should help guide treatment,
      education and management. The urinary C-peptide creatinine ratio is a practical
      non-invasive method to aid detection of absolute insulin deficiency, with a
      urinary C-peptide creatinine ratio > 0.2nmol/mmol being a reliable indicator of
      retained endogenous insulin secretion. This article is protected by copyright.
      All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Geriatrics, Royal Devon and Exeter NHS Foundation Trust; NIHR
      Exeter Clinical Research Facility, University of Exeter.
FAU - Hope, S V
AU  - Hope SV
FAU - Jones, A G
AU  - Jones AG
FAU - Goodchild, E
AU  - Goodchild E
FAU - Shepherd, M
AU  - Shepherd M
FAU - Besser, R E J
AU  - Besser RE
FAU - Shields, B
AU  - Shields B
FAU - McDonald, T
AU  - McDonald T
FAU - Knight, B A
AU  - Knight BA
FAU - Hattersley, A
AU  - Hattersley A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/02/01 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/05/07 [accepted]
AID - 10.1111/dme.12222 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 May 10. doi: 10.1111/dme.12222.

PMID- 23659427
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - Role of Kir6.2 subunits of ATP-sensitive potassium channels in
      endotoxemia-induced cardiac dysfunction.
PG  - 75
LID - 10.1186/1475-2840-12-75 [doi]
AB  - BACKGROUND: Cardiac dysfunction is well-described in endotoxemia and diagnosed in
      up to 60% of patients with endotoxic shock. ATP-sensitive potassium (KATP)
      channels are critical to cardiac function. This study investigates the role of
      Kir6.2 subunits of KATP channels on cardiac dysfunction in lipopolysaccharide
      (LPS)-induced endotoxemia. METHODS: Kir6.2 subunits knockout (Kir6.2-/-) and
      wild-type (WT) mice were injected with LPS to induce endotoxemia. Cardiac
      function was monitored by echocardiography. Left ventricles were taken for
      microscopy (both light and electron) and TUNEL examination. Serum lactate
      dehydrogenase (LDH) and creatine kinase (CK) activities, and tumor necrosis
      factor-alpha (TNF-alpha) levels in both serum and left ventricular tissues were
      determined. RESULTS: Compared to WT, Kir6.2-/- mice showed significantly declined
      cardiac function 360 min after LPS administration, aggravated myocardial damage
      and elevated serum LDH and CK activities. Apoptotic cells were obviously
      increased in heart tissues from Kir6.2-/- mice at 90, 180 and 360 min. TNF-alpha 
      expression in both serum and heart tissues of Kir6.2-/- mice was significantly
      increased. CONCLUSIONS: We conclude that Kir6.2 subunits are critical in
      resistance to endotoxemia-induced cardiac dysfunction through reducing myocardial
      damage by inhibition of apoptosis and inflammation. KATP channels blockers are
      extensively used in the treatment of diabetes, their potential role should
      therefore be considered in the clinic when patients treated with antidiabetic
      sulfonylureas are complicated by endotoxemia.
AD  - Department of Pharmacology, School of Pharmacy, Second Military Medical
      University, Shanghai 200433, China. jiangguojun999@163.com.
FAU - Yang, Zhong-Wei
AU  - Yang ZW
FAU - Chen, Ji-Kuai
AU  - Chen JK
FAU - Ni, Min
AU  - Ni M
FAU - Zhao, Ting
AU  - Zhao T
FAU - Deng, Ya-Ping
AU  - Deng YP
FAU - Tao, Xia
AU  - Tao X
FAU - Jiang, Guo-Jun
AU  - Jiang GJ
FAU - Shen, Fu-Ming
AU  - Shen FM
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3654940
OID - NLM: PMC3654940
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
PHST- 2013/02/08 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 1475-2840-12-75 [pii]
AID - 10.1186/1475-2840-12-75 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 May 9;12:75. doi: 10.1186/1475-2840-12-75.

PMID- 23659201
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
DP  - 2013 May 31
TI  - The cost-effectiveness of exenatide once weekly compared with exenatide twice
      daily and insulin glargine for the treatment of patients with type two diabetes
      and body mass index >/=30 kg/m in Spain.
AB  - Abstract Objective: The objective of this analysis was to estimate the
      cost-effectiveness of exenatide once weekly (EQW) for the treatment of type two
      diabetes mellitus (T2DM) in Spain. EQW was compared against exenatide twice daily
      (EBID) and insulin glargine (IG). Methods: The IMS CORE Diabetes Model was used
      to project clinical and economic outcomes for patients with T2DM treated with
      EQW, EBID, and IG. Treatment effects and patient baseline characteristics were
      taken from the DURATION 3 and pooled DURATION 1 and 5 studies, in the comparison 
      against IG and EBID, respectively. Unit costs and health state utility values
      were derived from published sources. To reflect diabetes progression, patients
      started on EQW or EBID, switching to insulin glargine after 3 years. The analysis
      was conducted from the perspective of the Spanish National Health Service over a 
      time horizon of 35 years with costs and outcomes discounted at 3%. The base case 
      included patients with a BMI > 30 kg/m2, which is in line with current
      prescription restrictions in Spain. Uncertainty was addressed through extensive
      one-way sensitivity analyses around key model parameters and a comprehensive
      probabilistic sensitivity analysis. Results: When compared with EBID, EQW was the
      dominant strategy, i.e., less costly and more effective. When compared to IG, the
      incremental cost-effectiveness ratio was estimated at euro12,084 per QALY gained.
      Sensitivity analysis indicated that the model projections were robust to the
      various scenarios tested. Limitations: Primary limitations of the analysis are
      common to other T2DM analyses and include the extrapolation of short-term
      clinical data to the 35 year time horizon and uncertainty around optimum
      treatment durations. Conclusion: The analyses indicate that EQW is a
      cost-effective option for the treatment of T2DM patients in Spain for patients
      with a BMI > 30 kg/m2 considering a willingness-to-pay threshold of euro30,000
      per QALY gained.
AD  - IMS Health, Health Economics and Outcomes Research , London , UK.
FAU - Fonseca, Tiago
AU  - Fonseca T
FAU - Clegg, John
AU  - Clegg J
FAU - Caputo, Giuseppe
AU  - Caputo G
FAU - Norrbacka, Kirsi
AU  - Norrbacka K
FAU - Dilla, Tatiana
AU  - Dilla T
FAU - Alvarez, Maria
AU  - Alvarez M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130531
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
EDAT- 2013/05/11 06:00
MHDA- 2013/05/11 06:00
CRDT- 2013/05/11 06:00
AID - 10.3111/13696998.2013.803110 [doi]
PST - aheadofprint
SO  - J Med Econ. 2013 May 31.

PMID- 23658849
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Linking)
VI  - 7
IP  - 5
DP  - 2013 May
TI  - Review of dengue hemorrhagic Fever fatal cases seen among adults: a retrospective
      study.
PG  - e2194
LID - 10.1371/journal.pntd.0002194 [doi]
AB  - BACKGROUND: Dengue is a mosquito-borne viral disease endemic in many countries in
      the tropics and sub-tropics. The disease affects mainly children, but in recent
      years it is becoming more of an adult disease. Malaysia experienced a large
      dengue outbreak in 2006 to 2007, involving mostly adults, with a high number of
      deaths. METHODOLOGYPRINCIPAL FINDINGS: We undertook a retrospective study to
      examine dengue death cases in our hospital from June 2006 to October 2007 with a 
      view to determine if there have been changes in the presentation of severe to
      fatal dengue. Nine of ten fatal cases involved adult females with a median age of
      32 years. All had secondary dengue infection. The mean duration of illness prior 
      to hospitalization was 4.7 days and deaths occurred at an average of 2.4 days
      post-admission. Gastrointestinal pain, vomiting, diarrhea, intravascular leakages
      and bleeding occurred in the majority of cases. DSS complicated with severe
      bleeding, multi-organ failure and coagulopathy were the primary causes of deaths.
      Seven patients presented with thrombocytopenia and hypoalbuminemia, five of which
      had hemoconcentration and increased ALT and AST indicative of liver damage.
      Co-morbidities particularly diabetes mellitus was common in our cohort. Prominent
      unusual presentations included acute renal failure, acute respiratory distress
      syndrome, myocarditis with pericarditis, and hemorrhages over the brain and
      heart. CONCLUSIONS: In our cohort, dengue fatalities are seen primarily in adult 
      females with secondary dengue infection. The majority of the patients presented
      with common clinical and laboratory warning signs of severe dengue. Underlying
      co-morbidities may contribute to the rapid clinical deterioration in severe
      dengue. The uncommon presentations of dengue are likely a reflection of the
      changing demographics where adults are now more likely to contract dengue in
      dengue endemic regions.
AD  - Tropical Infectious Diseases Research and Education Center (TIDREC), Department
      of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur,
      Malaysia.
FAU - Sam, Sing-Sin
AU  - Sam SS
FAU - Omar, Sharifah Faridah Syed
AU  - Omar SF
FAU - Teoh, Boon-Teong
AU  - Teoh BT
FAU - Abd-Jamil, Juraina
AU  - Abd-Jamil J
FAU - Abubakar, Sazaly
AU  - Abubakar S
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
SB  - IM
PMC - PMC3642057
OID - NLM: PMC3642057
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/05 [ppublish]
PHST- 2012/08/03 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/05/02 [epublish]
AID - 10.1371/journal.pntd.0002194 [doi]
AID - PNTD-D-12-00967 [pii]
PST - epublish
SO  - PLoS Negl Trop Dis. 2013 May 2;7(5):e2194. doi: 10.1371/journal.pntd.0002194.
      Print 2013 May.

PMID- 23658831
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - The Protective Effects of Beta-Casomorphin-7 against Glucose -Induced Renal
      Oxidative Stress In Vivo and Vitro.
PG  - e63472
LID - 10.1371/journal.pone.0063472 [doi]
AB  - Oxidative stress is implicated in the pathogenesis of diabetic nephropathy. The
      present study aimed to investigate the effect of beta-casomorphin-7 (BCM7) on the
      oxidative stress occurring in kidney tissue in streptozotocin (STZ)-induced
      diabetic rats and proximal tubular epithelial cells (NRK-52E) exposure to high
      glucose (HG) by using biochemical methods. There is a significant decrease in
      plasma insulin and a significant increase in plasma glucagon in the rats of
      diabetic group. Oral administration of BCM7 for 30 days to rats with STZ-induced 
      diabetes resulted in a significant increase in serum level of insulin, and a
      decrease in the level of glucagon. Moreover, rats with STZ-induced diabetes had
      lower levels of superoxide dismutase (SOD), glutathione peroxidase (GPx) and
      total antioxidative capacity (T-AOC), higher levels of malondialdehyde (MDA) and 
      hydrogen peroxide (H2O2) in the kidney than that in the control rats. The
      administration of BCM7 altered the changes of SOD, GPx, T-AOC, MDA and H2O2 in
      the kidney of diabetic rats. Furthermore, BCM7 alleviated high glucose-induced
      decreasement in SOD and GPx activity, increasement in MDA contents in the NRK-52E
      cells. BCM7 ameliorated the changes of angiotensin converting enzyme (ACE) and
      ACE2 levels in the kidney of diabetic rats and BCM7 lowered the levels of
      angiotensin (Ang)II in the kidney of diabetic rats and culture medium for cells. 
      Moreover losartan (antagonist of angiotensin II type I receptor) lowered the high
      glucose-induced oxidative stress in the NRK-52E cells. Our results suggest that
      administration of BCM7 would alleviate high glucose-induced renal oxidative
      stress in vivo and in vitro, which may be associated with down regulation of the 
      concentration of Ang II partly.
AD  - Key Lab of Animal Physiology and Biochemistry, Ministry of Agriculture, Nanjing
      Agriculture University, Nanjing, People's Republic of China.
FAU - Zhang, Wei
AU  - Zhang W
FAU - Miao, Jinfeng
AU  - Miao J
FAU - Wang, Shanshan
AU  - Wang S
FAU - Zhang, Yuanshu
AU  - Zhang Y
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3643933
OID - NLM: PMC3643933
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/22 [received]
PHST- 2013/04/02 [accepted]
PHST- 2013/05/03 [epublish]
AID - 10.1371/journal.pone.0063472 [doi]
AID - PONE-D-12-40329 [pii]
PST - epublish
SO  - PLoS One. 2013 May 3;8(5):e63472. doi: 10.1371/journal.pone.0063472. Print 2013.

PMID- 23658808
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Analyzing Recent Coronary Heart Disease Mortality Trends in Tunisia between 1997 
      and 2009.
PG  - e63202
LID - 10.1371/journal.pone.0063202 [doi]
AB  - BACKGROUND: In Tunisia, Cardiovascular Diseases are the leading causes of death
      (30%), 70% of those are coronary heart disease (CHD) deaths and population
      studies have demonstrated that major risk factor levels are increasing.
      OBJECTIVE: To explain recent CHD trends in Tunisia between 1997 and 2009.
      METHODS: DATA SOURCES: Published and unpublished data were identified by
      extensive searches, complemented with specifically designed surveys. ANALYSIS:
      Data were integrated and analyzed using the previously validated IMPACT CHD
      policy model. Data items included: (i)number of CHD patients in specific groups
      (including acute coronary syndromes, congestive heart failure and chronic
      angina)(ii) uptake of specific medical and surgical treatments, and(iii)
      population trends in major cardiovascular risk factors (smoking, total
      cholesterol, systolic blood pressure (SBP), body mass index (BMI), diabetes and
      physical inactivity). RESULTS: CHD mortality rates increased by 11.8% for men and
      23.8% for women, resulting in 680 additional CHD deaths in 2009 compared with the
      1997 baseline, after adjusting for population change. Almost all (98%) of this
      rise was explained by risk factor increases, though men and women differed. A
      large rise in total cholesterol level in men (0.73 mmol/L) generated 440
      additional deaths. In women, a fall (-0.43 mmol/L), apparently avoided about 95
      deaths. For SBP a rise in men (4 mmHg) generated 270 additional deaths. In women,
      a 2 mmHg fall avoided 65 deaths. BMI and diabetes increased substantially
      resulting respectively in 105 and 75 additional deaths. Increased treatment
      uptake prevented about 450 deaths in 2009. The most important contributions came 
      from secondary prevention following Acute Myocardial Infarction (AMI) (95 fewer
      deaths), initial AMI treatments (90), antihypertensive medications (80) and
      unstable angina (75). CONCLUSIONS: Recent trends in CHD mortality mainly
      reflected increases in major modifiable risk factors, notably SBP and
      cholesterol, BMI and diabetes. Current prevention strategies are mainly focused
      on treatments but should become more comprehensive.
AD  - Cardiovascular Epidemiology and Prevention Research Laboratory, Faculty of
      Medicine of Tunis-Tunisia, Tunis, Tunisia.
FAU - Saidi, Olfa
AU  - Saidi O
FAU - Ben Mansour, Nadia
AU  - Ben Mansour N
FAU - O'Flaherty, Martin
AU  - O'Flaherty M
FAU - Capewell, Simon
AU  - Capewell S
FAU - Critchley, Julia A
AU  - Critchley JA
FAU - Romdhane, Habiba Ben
AU  - Romdhane HB
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3643918
OID - NLM: PMC3643918
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2012/07/23 [received]
PHST- 2013/04/02 [accepted]
PHST- 2013/05/03 [epublish]
AID - 10.1371/journal.pone.0063202 [doi]
AID - PONE-D-12-21994 [pii]
PST - epublish
SO  - PLoS One. 2013 May 3;8(5):e63202. doi: 10.1371/journal.pone.0063202. Print 2013.

PMID- 23658749
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Quantitatively Different, yet Qualitatively Alike: A Meta-Analysis of the Mouse
      Core Gut Microbiome with a View towards the Human Gut Microbiome.
PG  - e62578
LID - 10.1371/journal.pone.0062578 [doi]
AB  - BACKGROUND: A number of human diseases such as obesity and diabetes are
      associated with changes or imbalances in the gut microbiota (GM). Laboratory mice
      are commonly used as experimental models for such disorders. The introduction and
      dynamic development of next generation sequencing techniques have enabled
      detailed mapping of the GM of both humans and animal models. Nevertheless there
      is still a significant knowledge gap regarding the human and mouse common GM core
      and thus the applicability of the latter as an animal model. The aim of the
      present study was to identify inter- and intra-individual differences and
      similarities between the GM composition of particular mouse strains and humans.
      METHODOLOGYPRINCIPAL FINDINGS: A total of 1509428 high quality tag-encoded
      partial 16S rRNA gene sequences determined using 454/FLX Titanium (Roche)
      pyro-sequencing reflecting the GM composition of 32 human samples from 16
      individuals and 88 mouse samples from three laboratory mouse strains commonly
      used in diabetes research were analyzed using Principal Coordinate Analysis
      (PCoA), nonparametric multivariate analysis of similarity (ANOSIM) and alpha
      diversity measures. A reliable cutoff threshold for low abundant taxa estimated
      on the basis of the present study is recommended for similar trials.
      CONCLUSIONSSIGNIFICANCE: Distinctive quantitative differences in the relative
      abundance of most taxonomic groups between the examined categories were found.
      All investigated mouse strains clustered separately, but with a range of shared
      features when compared to the human GM. However, both mouse fecal, caecal and
      human fecal samples shared to a large extent not only representatives of the same
      phyla, but also a substantial fraction of common genera, where the number of
      shared genera increased with sequencing depth. In conclusion, the GM of mice and 
      humans is quantitatively different (in terms of abundance of specific phyla and
      species) but share a large qualitatively similar core.
AD  - Department of Food Science, Faculty of Science, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Krych, Lukasz
AU  - Krych L
FAU - Hansen, Camilla H F
AU  - Hansen CH
FAU - Hansen, Axel K
AU  - Hansen AK
FAU - van den Berg, Frans W J
AU  - van den Berg FW
FAU - Nielsen, Dennis S
AU  - Nielsen DS
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3641060
OID - NLM: PMC3641060
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/07 [received]
PHST- 2013/03/22 [accepted]
PHST- 2013/05/01 [epublish]
AID - 10.1371/journal.pone.0062578 [doi]
AID - PONE-D-13-05537 [pii]
PST - epublish
SO  - PLoS One. 2013 May 1;8(5):e62578. doi: 10.1371/journal.pone.0062578. Print 2013.

PMID- 23658727
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Increased risk of dementia in patients with mild traumatic brain injury: a
      nationwide cohort study.
PG  - e62422
LID - 10.1371/journal.pone.0062422 [doi]
AB  - BACKGROUND: It is known that the risk of dementia in patients with moderate to
      severe traumatic brain injury (TBI) is higher. However, the relationship between 
      mild traumatic brain injury (mTBI) and dementia has never been established.
      OBJECTIVES: We investigated the incidences of dementia among patients with mTBI
      in Taiwan to evaluate if there is higher risk compared with general population.
      METHODS: We utilized a sampled National Health Insurance (NHI) claims data
      containing one million beneficiaries. We followed all adult beneficiaries from
      January 1, 2005 till December 31, 2009 to see if they had been diagnosed with
      dementia. We further identify patients with mTBI and compared their risk of
      dementia with the general population. RESULTS: We identified 28551 patients with 
      mTBI and 692382 without. After controlled for age, gender, urbanization level,
      socioeconomic status, diabetes, hypertension, coronary artery disease,
      hyperlipidemia, history of alcohol intoxication, history of ischemic stroke,
      history of intracranial hemorrhage and Charlson Comorbidity Index Score, the
      adjusted hazard ratio is 3.26 (95% Confidence interval, 2.69-3.94). CONCLUSIONS: 
      TBI is an independent significant risk factor of developing dementia even in the 
      mild type.
AD  - Emergency Department, Buddhist Tzu Chi Dalin General Hospital, Chiayi, Taiwan ;
      School of Medicine, Tzu Chi University, Hualien, Taiwan.
FAU - Lee, Yi-Kung
AU  - Lee YK
FAU - Hou, Sheng-Wen
AU  - Hou SW
FAU - Lee, Ching-Chih
AU  - Lee CC
FAU - Hsu, Chen-Yang
AU  - Hsu CY
FAU - Huang, Yung-Sung
AU  - Huang YS
FAU - Su, Yung-Cheng
AU  - Su YC
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3641064
OID - NLM: PMC3641064
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/17 [received]
PHST- 2013/03/21 [accepted]
PHST- 2013/05/01 [epublish]
AID - 10.1371/journal.pone.0062422 [doi]
AID - PONE-D-13-02962 [pii]
PST - epublish
SO  - PLoS One. 2013 May 1;8(5):e62422. doi: 10.1371/journal.pone.0062422. Print 2013.

PMID- 23658699
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Insulin-mediated activation of the L-arginine nitric oxide pathway in man, and
      its impairment in diabetes.
PG  - e61840
LID - 10.1371/journal.pone.0061840 [doi]
AB  - AIMSHYPOTHESIS: Impaired L-arginine transport has been reported in cardiovascular
      diseases, providing a possible mechanism for reduced nitric oxide (NO)
      production. Given that cardiovascular diseases are also associated with insulin
      resistance, and insulin is known to induce vasodilation via a NO-dependent
      pathway, we hypothesised that abnormal insulin modulation of L-arginine transport
      may contribute to vascular dysfunction in diabetes. METHODS: Forearm blood flow
      (FBF) responses to insulin and sodium nitroprusside (SNP) were measured in
      control and type 2 diabetic volunteers using venous occlusion plethysmography.
      Effects of intra-arterial insulin on the forearm veno-arterial flux of arginine
      and related amino acids were determined by HPLC. The effect of locally delivered 
      insulin on arginine transport was assessed during an intra-arterial infusion of
      [4,5-(3)H] L-arginine. RESULTS: In controls, intrabrachial infusion of 5
      mUnits/min insulin lead to a progressive rise in FBF (p<0.001) while this was not
      evident in diabetics. In support of this observation, we observed a concomitant, 
      significant increase in the flux of N-hydroxy-L-arginine (the NO precursor) in
      controls (baseline vs. 60 mins insulin: 16.2+/-12.2 vs. 33.0+/-13.1 nmol/100 ml
      tissue/min; p<0.01), whilst no increase was observed in diabetics. Moreover,
      insulin augmented the clearance of [(3)H]L-arginine from the forearm circulation 
      in controls (baseline vs insulin: 123+/-22 vs. 150+/-28 ml/min; p<0.05) but not
      in diabetics. CONCLUSION: These findings suggest that insulin resistance may
      contribute substantially to the onset and development of cardiovascular disease
      in type 2 diabetics via abnormal insulin-mediated regulation of L-arginine
      transport.
AD  - Heart Failure Research Group, Baker IDI Heart and Diabetes Institute, Melbourne, 
      Australia ; Department of Physiology, Monash University, Melbourne, Australia.
FAU - Rajapakse, Niwanthi W
AU  - Rajapakse NW
FAU - Chong, Abigail L
AU  - Chong AL
FAU - Zhang, Wei-Zheng
AU  - Zhang WZ
FAU - Kaye, David M
AU  - Kaye DM
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3642141
OID - NLM: PMC3642141
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/10 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/05/02 [epublish]
AID - 10.1371/journal.pone.0061840 [doi]
AID - PONE-D-13-01770 [pii]
PST - epublish
SO  - PLoS One. 2013 May 2;8(5):e61840. doi: 10.1371/journal.pone.0061840. Print 2013.

PMID- 23658698
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Primary medication non-adherence after discharge from a general internal medicine
      service.
PG  - e61735
LID - 10.1371/journal.pone.0061735 [doi]
AB  - BACKGROUND: Medication non-adherence frequently leads to suboptimal patient
      outcomes. Primary non-adherence, which occurs when a patient does not fill an
      initial prescription, is particularly important at the time of hospital discharge
      because new medications are often being prescribed to treat an illness rather
      than for prevention. METHODS: We studied older adults consecutively discharged
      from a general internal medicine service at a large urban teaching hospital to
      determine the prevalence of primary non-adherence and identify characteristics
      associated with primary non-adherence. We reviewed electronic prescriptions,
      electronic discharge summaries and pharmacy dispensing data from April to August 
      2010 for drugs listed on the public formulary. Primary non-adherence was defined 
      as failure to fill one or more new prescriptions after hospital discharge. In
      addition to descriptive analyses, we developed a logistical regression model to
      identify patient characteristics associated with primary non-adherence. RESULTS: 
      There were 493 patients eligible for inclusion in our study, 232 of whom were
      prescribed new medications. In total, 66 (28%) exhibited primary non-adherence at
      7 days after discharge and 55 (24%) at 30 days after discharge. Examples of
      medications to which patients were non-adherent included antibiotics, drugs for
      the management of coronary artery disease (e.g. beta-blockers, statins), heart
      failure (e.g. beta-blockers, angiotensin converting enzyme inhibitors,
      furosemide), stroke (e.g. statins, clopidogrel), diabetes (e.g. insulin), and
      chronic obstructive pulmonary disease (e.g. long-acting bronchodilators,
      prednisone). Discharge to a nursing home was associated with an increased risk of
      primary non-adherence (OR 2.25, 95% CI 1.01-4.95). CONCLUSIONS: Primary
      non-adherence after medications are newly prescribed during a hospitalization is 
      common, and was more likely to occur in patients discharged to a nursing home.
AD  - Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
FAU - Fallis, Brooks A
AU  - Fallis BA
FAU - Dhalla, Irfan A
AU  - Dhalla IA
FAU - Klemensberg, Jason
AU  - Klemensberg J
FAU - Bell, Chaim M
AU  - Bell CM
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3642181
OID - NLM: PMC3642181
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/03 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/05/02 [epublish]
AID - 10.1371/journal.pone.0061735 [doi]
AID - PONE-D-12-34139 [pii]
PST - epublish
SO  - PLoS One. 2013 May 2;8(5):e61735. doi: 10.1371/journal.pone.0061735. Print 2013.

PMID- 23658570
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1729-0503 (Electronic)
IS  - 1680-6905 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Mar
TI  - Factors associated with depression and suicide among patients with diabetes
      mellitus and essential hypertension in a Nigerian teaching hospital.
PG  - 68-77
LID - 10.4314/ahs.v13i1.10 [doi]
AB  - BACKGROUND: Diabetes mellitus (DM) and essential hypertension are chronic medical
      conditions that place a lot of burden on patients. The presence of depression and
      suicidal behaviour may worsen the prognosis. OBJECTIVE: To assess the prevalence 
      of depression and suicidal behaviour in subjects with diabetes mellitus and
      essential hypertension and also determine the socio-demographic correlates.
      METHODS: Major depressive episode and suicidality modules of Mini-International
      Neuropsychiatric Interview were used to assess depression and suicidal behaviour 
      respectively. RESULTS: The prevalence of depression for the subjects with DM was 
      27.8% and 26.7% for essential hypertension. The subjects with DM had prevalence
      of 6.3% for suicidal behaviour while essential hypertension had 7.8%. Depression 
      was higher in subjects with DM if they were not married or had no education while
      the subjects with essential hypertension were more likely to have depression if
      they were not married, had no education or not employed. Suicidal behaviour was
      higher in subjects with DM if they had no education while in essential
      hypertension suicidal behaviour was higher in females, those not married and
      those not educated. CONCLUSION: Depression and suicidal behaviour occur with DM
      and essential hypertension.
AD  - Department of Psychological Medicine, Federal Teaching Hospital Abakaliki, Ebonyi
      State Nigeria.
FAU - Igwe, Mn
AU  - Igwe M
FAU - Uwakwe, R
AU  - Uwakwe R
FAU - Ahanotu, Ca
AU  - Ahanotu C
FAU - Onyeama, Gm
AU  - Onyeama G
FAU - Bakare, Mo
AU  - Bakare M
FAU - Ndukuba, Ac
AU  - Ndukuba A
LA  - eng
PT  - Journal Article
PL  - Uganda
TA  - Afr Health Sci
JT  - African health sciences
JID - 101149451
SB  - IM
PMC - PMC3645089
OID - NLM: PMC3645089
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.4314/ahs.v13i1.10 [doi]
AID - jAFHS.v13.i1.pg68 [pii]
PST - ppublish
SO  - Afr Health Sci. 2013 Mar;13(1):68-77. doi: 10.4314/ahs.v13i1.10.

PMID- 23658569
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1729-0503 (Electronic)
IS  - 1680-6905 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Mar
TI  - Non communicable disease and risky behaviour in an urban university community
      Nigeria.
PG  - 62-7
LID - 10.4314/ahs.v13i1.9 [doi]
AB  - BACKGROUND: Most developing countries have only limited information on the burden
      of Non Communicable Diseases (NCDs) even though rapid transitions in these NCDs
      have been predicted. OBJECTIVES: To describe the burden of selected NCDs and
      associated risk behaviours in an urban university community in Nigeria. METHODS: 
      A cross-sectional survey of 525 representative staff of a University in a large
      city in Nigeria was conducted. RESULTS: In all, 27.6% were already diagnosed with
      at least one NCD (hypertension-21.5%, diabetes-11%, cancer 2.9%) while 67.4%
      reported at least one risk behaviour (unhealthy diet- 96%, sedentary living-
      27.4% excessive alcohol use-5.1% and smoking- 1.9%). Multiple risk behaviours
      were observed in 29.9% with no significant variation by sex or age. Those 40
      years and above had significantly higher prevalence of NCD, particularly for
      hypertension (p<0.05). Only 7%, considered themselves to be at risk of NCDs.
      Those whose parents had NCDs OR: 5.9 (2.4-14.5) and those who currently had NCDs 
      OR: 3.9(1.8-8.1) perceived themselves at risk of one or more NCDs, but not those 
      with multiple risk behaviours. CONCLUSION: The high burden of NCDs and risk
      behaviours in the face of limited self-perceived risk has been demonstrated and
      calls for urgent intervention.
AD  - Department of Community Medicine, University College Hospital, Ibadan, Nigeria.
FAU - Ige, Ok
AU  - Ige O
FAU - Owoaje, Et
AU  - Owoaje E
FAU - Adebiyi, Oa
AU  - Adebiyi O
LA  - eng
PT  - Journal Article
PL  - Uganda
TA  - Afr Health Sci
JT  - African health sciences
JID - 101149451
SB  - IM
PMC - PMC3645087
OID - NLM: PMC3645087
OTO - NOTNLM
OT  - Nigeria
OT  - Non communicable disease
OT  - risk behaviour
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.4314/ahs.v13i1.9 [doi]
AID - jAFHS.v13.i1.pg62 [pii]
PST - ppublish
SO  - Afr Health Sci. 2013 Mar;13(1):62-7. doi: 10.4314/ahs.v13i1.9.

PMID- 23658553
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130509
DCOM- 20130510
LR  - 20130513
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 4
DP  - 2013
TI  - Alterations in polyadenylation and its implications for endocrine disease.
PG  - 53
LID - 10.3389/fendo.2013.00053 [doi]
AB  - Introduction: Polyadenylation is the process in which the pre-mRNA is cleaved at 
      the poly(A) site and a poly(A) tail is added - a process necessary for normal
      mRNA formation. Genes with multiple poly(A) sites can undergo alternative
      polyadenylation (APA), producing distinct mRNA isoforms with different 3'
      untranslated regions (3' UTRs) and in some cases different coding regions. Two
      thirds of all human genes undergo APA. The efficiency of the polyadenylation
      process regulates gene expression and APA plays an important part in
      post-transcriptional regulation, as the 3' UTR contains various cis-elements
      associated with post-transcriptional regulation, such as target sites for
      micro-RNAs and RNA-binding proteins. Implications of alterations in
      polyadenylation for endocrine disease: Alterations in polyadenylation have been
      found to be causative of neonatal diabetes and IPEX (immune dysfunction,
      polyendocrinopathy, enteropathy, X-linked) and to be associated with type I and
      II diabetes, pre-eclampsia, fragile X-associated premature ovarian insufficiency,
      ectopic Cushing syndrome, and many cancer diseases, including several types of
      endocrine tumor diseases. Perspectives: Recent developments in high-throughput
      sequencing have made it possible to characterize polyadenylation genome-wide.
      Antisense elements inhibiting or enhancing specific poly(A) site usage can induce
      desired alterations in polyadenylation, and thus hold the promise of new
      therapeutic approaches. Summary: This review gives a detailed description of
      alterations in polyadenylation in endocrine disease, an overview of the current
      literature on polyadenylation and summarizes the clinical implications of the
      current state of research in this field.
AD  - Genomic Medicine, Rigshospitalet, Copenhagen University Hospital Copenhagen,
      Denmark.
FAU - Rehfeld, Anders
AU  - Rehfeld A
FAU - Plass, Mireya
AU  - Plass M
FAU - Krogh, Anders
AU  - Krogh A
FAU - Friis-Hansen, Lennart
AU  - Friis-Hansen L
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC3647115
OID - NLM: PMC3647115
OTO - NOTNLM
OT  - IGF-1
OT  - RET
OT  - antisense elements
OT  - diabetes
OT  - gene expression regulation
OT  - polyadenylation
OT  - pre-eclampsia
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:01
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/10 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/08 [epublish]
AID - 10.3389/fendo.2013.00053 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2013 May 8;4:53. doi: 10.3389/fendo.2013.00053.
      Print 2013.

PMID- 23658497
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130509
DCOM- 20130510
LR  - 20130513
IS  - 1179-1349 (Electronic)
IS  - 1179-1349 (Linking)
VI  - 5
DP  - 2013
TI  - The NordiNet(R) International Outcome Study and NovoNet(R) ANSWER Program(R):
      rationale, design, and methodology of two international pharmacoepidemiological
      registry-based studies monitoring long-term clinical and safety outcomes of
      growth hormone therapy (Norditropin(R)).
PG  - 119-27
LID - 10.2147/CLEP.S42602 [doi]
AB  - OBJECTIVE: Randomized controlled trials have shown that growth hormone (GH)
      therapy has effects on growth, metabolism, and body composition. GH therapy is
      prescribed for children with growth failure and adults with GH deficiency.
      Carefully conducted observational study of GH treatment affords the opportunity
      to assess long-term treatment outcomes and the clinical factors and variables
      affecting those outcomes, in patients receiving GH therapy in routine clinical
      practice. DESIGN: The NordiNet(R) International Outcome Study (IOS) and the
      American Norditropin(R) Studies: Web Enabled Research (ANSWER Program(R)) are two
      complementary, non-interventional, observational studies that adhere to current
      guidelines for pharmacoepidemiological data. PATIENTS: The studies include
      pediatric and adult patients receiving Norditropin(R), as prescribed by their
      physicians. MEASUREMENTS: The studies gather long-term data on the safety and
      effectiveness of reallife treatment with the recombinant human GH,
      Norditropin(R). We describe the origins, aims, objectives, and design methodology
      of the studies, as well as their governance and validity, strengths, and
      limitations. CONCLUSION: The NordiNet(R) IOS and ANSWER Program(R) studies will
      provide valid insights into the effectiveness and safety of GH treatment across a
      diverse and large patient population treated in accordance with real-world
      clinical practice and following the Good Pharmacoepidemiological Practice and
      STrengthening the Reporting of OBservational studies in Epidemiology (STROBE)
      guidelines.
AD  - Department of Molecular Medicine and Surgery, Karolinska Institute and Department
      of Endocrinology, Metabolism and Diabetes, Stockholm, Sweden.
FAU - Hoybye, Charlotte
AU  - Hoybye C
FAU - Savendahl, Lars
AU  - Savendahl L
FAU - Christesen, Henrik Thybo
AU  - Christesen HT
FAU - Lee, Peter
AU  - Lee P
FAU - Pedersen, Birgitte Tonnes
AU  - Pedersen BT
FAU - Schlumpf, Michael
AU  - Schlumpf M
FAU - Germak, John
AU  - Germak J
FAU - Ross, Judith
AU  - Ross J
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - New Zealand
TA  - Clin Epidemiol
JT  - Clinical epidemiology
JID - 101531700
PMC - PMC3641810
OID - NLM: PMC3641810
OTO - NOTNLM
OT  - growth hormone replacement therapy
OT  - pharmacoepidemiology
OT  - survey
OT  - treatment outcome
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:01
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/26 [epublish]
AID - 10.2147/CLEP.S42602 [doi]
AID - clep-5-119 [pii]
PST - epublish
SO  - Clin Epidemiol. 2013 Apr 26;5:119-27. doi: 10.2147/CLEP.S42602. Print 2013.

PMID- 23658482
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1178-2013 (Electronic)
IS  - 1176-9114 (Linking)
VI  - 8
DP  - 2013
TI  - Preparation, characterization, and in vitro and in vivo investigation of
      chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal
      delivery of exendin-4.
PG  - 1141-54
LID - 10.2147/IJN.S41457 [doi]
AB  - BACKGROUND: Exendin-4 is an incretin mimetic agent approved for type 2 diabetes
      treatment. However, the required frequent injections restrict its clinical
      application. Here, the potential use of chitosan-coated poly
      (d,l-lactide-co-glycolide) (CS-PLGA) nanoparticles was investigated for
      intestinal delivery of exendin-4. METHODS AND RESULTS: Nanoparticles were
      prepared using a modified water-oil-water (w/o/w) emulsion solvent-evaporation
      method, followed by coating with chitosan. The physical properties, particle
      size, and cell toxicity of the nanoparticles were examined. The cellular uptake
      mechanism and transmembrane permeability were performed in Madin-Darby canine
      kidney-cell monolayers. Furthermore, in vivo intraduodenal administration of
      exendin-4-loaded nanoparticles was carried out in rats. The PLGA nanoparticle
      coating with chitosan led to a significant change in zeta potential, from
      negative to positive, accompanied by an increase in particle size of ~30 nm.
      Increases in both the molecular weight and degree of deacetylation of chitosan
      resulted in an observable increase in zeta potential but no apparent change in
      the particle size of ~300 nm. Both unmodified PLGA and chitosan-coated
      nanoparticles showed only slight cytotoxicity. Use of different temperatures and 
      energy depletion suggested that the cellular uptake of both types of
      nanoparticles was energy-dependent. Further investigation revealed that the
      uptake of PLGA nanoparticles occurred via caveolin-mediated endocytosis and that 
      of CS-PLGA nanoparticles involved both macropinocytosis and clathrin-mediated
      endocytosis, as evidenced by using endocytic inhibitors. However, under all
      conditions, CS-PLGA nanoparticles showed a greater potential to be transported
      into cells, as shown by flow cytometry and confocal microscopy. Transmembrane
      permeability analysis showed that unmodified and modified PLGA nanoparticles
      could improve the transport of exendin-4 by up to 8.9- and 16.5-fold,
      respectively, consistent with the evaluation in rats. CONCLUSION: The
      chitosan-coated nanoparticles have a higher transport potential over both free
      drug and unmodified particles, providing support for their potential development 
      as a candidate oral delivery agent for exendin-4.
AD  - National Engineering Laboratory for AIDS Vaccine, College of Life Science, Jilin 
      University, Changchun, People's Republic of China.
FAU - Wang, Mengshu
AU  - Wang M
FAU - Zhang, Yong
AU  - Zhang Y
FAU - Feng, Jiao
AU  - Feng J
FAU - Gu, Tiejun
AU  - Gu T
FAU - Dong, Qingguang
AU  - Dong Q
FAU - Yang, Xu
AU  - Yang X
FAU - Sun, Yanan
AU  - Sun Y
FAU - Wu, Yongge
AU  - Wu Y
FAU - Chen, Yan
AU  - Chen Y
FAU - Kong, Wei
AU  - Kong W
LA  - eng
PT  - Journal Article
DEP - 20130315
PL  - New Zealand
TA  - Int J Nanomedicine
JT  - International journal of nanomedicine
JID - 101263847
SB  - IM
PMC - PMC3607418
OID - NLM: PMC3607418
OTO - NOTNLM
OT  - PLGA
OT  - chitosan
OT  - intestinal absorption
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/15 [epublish]
AID - 10.2147/IJN.S41457 [doi]
AID - ijn-8-1141 [pii]
PST - ppublish
SO  - Int J Nanomedicine. 2013;8:1141-54. doi: 10.2147/IJN.S41457. Epub 2013 Mar 15.

PMID- 23658425
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1541-6100 (Electronic)
IS  - 0022-3166 (Linking)
DP  - 2013 May 8
TI  - A Whey Protein Hydrolysate Promotes Insulinotropic Activity in a Clonal
      Pancreatic beta-Cell Line and Enhances Glycemic Function in ob/ob Mice.
AB  - Whey protein hydrolysates (WPHs) represent novel antidiabetic agents that affect 
      glycemia in animals and humans, but little is known about their insulinotropic
      effects. The effects of a WPH were analyzed in vitro on acute glucose-induced
      insulin secretion in pancreatic BRIN-BD11 beta cells. WPH permeability across
      Caco-2 cell monolayers was determined in a 2-tiered intestinal model. WPH effects
      on insulin resistance were studied in vivo following an 8-wk oral ingestion (100 
      mg/kg body weight) by ob/ob (OB-WPH) and wild-type mice (WT-WPH) compared with
      vehicle control (OB and WT groups) using a 2 x 2 factorial design, genotype x
      treatment. BRIN-BD11 cells showed a robust and reproducible dose-dependent
      insulinotropic effect of WPH (from 0.01 to 5.00 g/L). WPH bioactive constituents 
      were permeable across Caco-2 cell monolayers. In the OB-WPH and WT-WPH groups,
      WPH administration improved glucose clearance after a glucose challenge (2 g/kg
      body weight), as indicated by differences in the area under curves (AUCs) (P </= 
      0.05). The basal plasma glucose concentration was not affected by WPH treatment
      in either genotype. The plasma insulin concentration was lower in the OB-WPH than
      in the OB group (P </= 0.005) but was similar between the WT and WT-WPH groups;
      the interaction genotype x treatment was significant (P </= 0.005). Insulin
      release from pancreatic islets isolated from the OB-WPH group was greater (P </= 
      0.005) than that from the OB group but did not differ between the WT-WPH and WT
      groups; the interaction genotype x treatment was not significant. In conclusion, 
      an 8-wk oral administration of WPH improved blood glucose clearance, reduced
      hyperinsulinemia, and restored the pancreatic islet capacity to secrete insulin
      in response to glucose in ob/ob mice. Hence, it may be useful in diabetes
      management.
AD  - School of Biomolecular and Biomedical Sciences, Health Sciences Centre, and.
FAU - Gaudel, Celine
AU  - Gaudel C
FAU - Nongonierma, Alice B
AU  - Nongonierma AB
FAU - Maher, Samuel
AU  - Maher S
FAU - Flynn, Sarah
AU  - Flynn S
FAU - Krause, Mauricio
AU  - Krause M
FAU - Murray, Brian A
AU  - Murray BA
FAU - Kelly, Phillip M
AU  - Kelly PM
FAU - Baird, Alan W
AU  - Baird AW
FAU - Fitzgerald, Richard J
AU  - Fitzgerald RJ
FAU - Newsholme, Philip
AU  - Newsholme P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Nutr
JT  - The Journal of nutrition
JID - 0404243
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - jn.113.174912 [pii]
AID - 10.3945/jn.113.174912 [doi]
PST - aheadofprint
SO  - J Nutr. 2013 May 8.

PMID- 23658423
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1541-6100 (Electronic)
IS  - 0022-3166 (Linking)
DP  - 2013 May 8
TI  - Adiponectin Gene Variant Interacts with Fish Oil Supplementation to Influence
      Serum Adiponectin in Older Individuals.
AB  - Marine n3 polyunsaturated fatty acids (PUFAs) activate the transcription factor
      peroxisome proliferator-activated receptor (PPARgamma), which modulates the
      expression of adiponectin. We investigated the interaction of dietary n3 PUFAs
      with adiponectin gene (ADIPOQ) single nucleotide polymorphism (SNP) genotypes as 
      a determinant of serum adiponectin concentration. The Modulation of
      Atherosclerosis Risk by Increasing Doses of n3 Fatty Acids study is a parallel
      design, double-blind, controlled trial. Serum adiponectin was measured in 142
      healthy men and 225 women aged 45-70 y randomized to treatment with doses of
      0.45, 0.9, and 1.8 g/d 20:5n3 and 22:6n3 (1.51:1), or placebo for 12 mo. The 310 
      participants who completed the study were genotyped for 5 SNPs at the ADIPOQ
      locus: -11391 G/A (rs17300539), -11377 C/G (rs266729), -10066 G/A (rs182052), +45
      T/G (rs2241766), and +276 G/T (rs1501299). The -11391 A-allele was associated
      with a higher serum adiponectin concentration at baseline (n = 290; P < 0.001).
      The interaction between treatment and age as a determinant of adiponectin was
      significant in participants aged >58 y after the highest dose (n = 92; P =
      0.020). The interaction between +45 T/G and treatment and age was a nominally
      significant determinant of serum adiponectin after adjustment for BMI, gender,
      and ethnicity (P = 0.029). Individuals homozygous for the +45 T-allele aged >58 y
      had a 22% increase in serum adiponectin concentration compared with baseline
      after the highest dose (P-treatment effect = 0.008). If substantiated in a larger
      sample, a diet high in n3 PUFAs may be recommended for older individuals,
      especially those of the +45 TT genotype who have reported increased risk of
      hypoadiponectinemia, type 2 diabetes, and obesity.
AD  - King's College London, School of Medicine, Diabetes and Nutritional Sciences
      Division, London SE1 9NH, UK.
FAU - Alsaleh, Aseel
AU  - Alsaleh A
FAU - Crepostnaia, Daria
AU  - Crepostnaia D
FAU - Maniou, Zoitsa
AU  - Maniou Z
FAU - Lewis, Fiona J
AU  - Lewis FJ
FAU - Hall, Wendy L
AU  - Hall WL
FAU - Sanders, Thomas A B
AU  - Sanders TA
FAU - O'Dell, Sandra D
AU  - O'Dell SD
CN  - on behalf of the MARINA study team
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Nutr
JT  - The Journal of nutrition
JID - 0404243
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - jn.112.172585 [pii]
AID - 10.3945/jn.112.172585 [doi]
PST - aheadofprint
SO  - J Nutr. 2013 May 8.

PMID- 23658380
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 80
IP  - 23
DP  - 2013 Jun 4
TI  - Mild cognitive impairment: Incidence and vascular risk factors in a
      population-based cohort.
PG  - 2112-20
LID - 10.1212/WNL.0b013e318295d776 [doi]
AB  - OBJECTIVE: We examined the incidence of mild cognitive impairment (MCI) and its
      potential vascular risk factors in a prospective population-based study. METHODS:
      An age-stratified random population-based cohort (baseline n = 1,982), followed
      for up to 4 years, was annually assessed for cognitive and everyday functioning. 
      Incidence rates were calculated for both cognitive (neuropsychological [NP]-MCI) 
      and functional (Clinical Dementia Rating [CDR] = 0.5) definitions of MCI. Several
      measures of vascular, metabolic, and inflammatory risk were assessed at baseline.
      Risk factor analyses used interval censoring survival models, followed by joint
      modeling of both MCI and attrition due to mortality and illness. RESULTS:
      Incidence rates for NP-MCI and CDR = 0.5 were 95 and 55 per 1,000 person-years.
      In individual joint models, risk factors for NP-MCI were diabetes and adiposity
      (waist: hip ratio), while APOE epsilon4 genotype and heart failure increased risk
      of attrition. Adiposity, stroke, heart failure, and diabetes were risk factors
      for nonamnestic MCI. For CDR = 0.5, risk factors were stroke and heart failure;
      heart failure and adiposity increased risk of attrition. In multivariable joint
      models combining all risk factors, adiposity increased risk of NP-MCI, while
      stroke and heart failure increased risk for CDR = 0.5. Current alcohol use
      appeared protective against all subtypes. CONCLUSION: Incidence of MCI increased 
      with age regardless of definition and did not vary by sex or education. Several
      vascular risk factors elevated the risk of incident MCI, whether defined
      cognitively or functionally, but most were associated with nonamnestic MCI and
      CDR = 0.5. Controlling vascular risk may potentially reduce risk of MCI.
AD  - From the Departments of Psychiatry (M.G., B.F., T.F.H.), Neurology (M.G.,
      B.E.S.), and Medicine (C.-C.H.C.), School of Medicine, and Departments of
      Epidemiology (M.G.) and Biostatistics (B.F., C.-C.H.C.), Graduate School of
      Public Health, University of Pittsburgh, Pittsburgh, PA.
FAU - Ganguli, Mary
AU  - Ganguli M
FAU - Fu, Bo
AU  - Fu B
FAU - Snitz, Beth E
AU  - Snitz BE
FAU - Hughes, Tiffany F
AU  - Hughes TF
FAU - Chang, Chung-Chou H
AU  - Chang CC
LA  - eng
GR  - K23 AG038479/AG/NIA NIH HHS/United States
GR  - R01 AG023651/AG/NIA NIH HHS/United States
PT  - Journal Article
DEP - 20130508
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - AIM
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/05/08 [aheadofprint]
AID - WNL.0b013e318295d776 [pii]
AID - 10.1212/WNL.0b013e318295d776 [doi]
PST - ppublish
SO  - Neurology. 2013 Jun 4;80(23):2112-20. doi: 10.1212/WNL.0b013e318295d776. Epub
      2013 May 8.

PMID- 23658371
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1477-9137 (Electronic)
IS  - 0021-9533 (Linking)
VI  - 126
IP  - Pt 7
DP  - 2013 Apr 1
TI  - A comparative perspective on lipid storage in animals.
PG  - 1541-52
LID - 10.1242/jcs.104992 [doi]
AB  - Lipid storage is an evolutionary conserved process that exists in all organisms
      from simple prokaryotes to humans. In Metazoa, long-term lipid accumulation is
      restricted to specialized cell types, while a dedicated tissue for lipid storage 
      (adipose tissue) exists only in vertebrates. Excessive lipid accumulation is
      associated with serious health complications including insulin resistance, type 2
      diabetes, cardiovascular diseases and cancer. Thus, significant advances have
      been made over the last decades to dissect out the molecular and cellular
      mechanisms involved in adipose tissue formation and maintenance. Our current
      understanding of adipose tissue development comes from in vitro cell culture and 
      mouse models, as well as recent approaches to study lipid storage in genetically 
      tractable lower organisms. This Commentary gives a comparative insight into lipid
      storage in uni- and multi-cellular organisms with a particular emphasis on
      vertebrate adipose tissue. We also highlight the molecular mechanisms and
      nutritional signals that regulate the formation of mammalian adipose tissue.
AD  - Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA
      02142, USA.
FAU - Birsoy, Kivanc
AU  - Birsoy K
FAU - Festuccia, William T
AU  - Festuccia WT
FAU - Laplante, Mathieu
AU  - Laplante M
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Cell Sci
JT  - Journal of cell science
JID - 0052457
SB  - IM
OTO - NOTNLM
OT  - Adipocyte stem cell
OT  - Adipose tissue
OT  - Invertebrate fat
OT  - Lipid storage
OT  - Nutrients
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 126/7/1541 [pii]
AID - 10.1242/jcs.104992 [doi]
PST - ppublish
SO  - J Cell Sci. 2013 Apr 1;126(Pt 7):1541-52. doi: 10.1242/jcs.104992.

PMID- 23658196
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 2047-2927 (Electronic)
DP  - 2013 May 8
TI  - Vascular regenerative therapies for the treatment of erectile dysfunction:
      current approaches.
LID - 10.1111/j.2047-2927.2013.00087.x [doi]
AB  - The pharmacological treatment of erectile dysfunction (ED) is mainly represented 
      by the administration of inhibitors of phosphodiesterase-5 (PDE5). However, in
      the clinical practice many patients do not benefit from such a treatment, hence
      the scientific interest extends to other therapeutic strategies; in particular,
      to the vascular regenerative therapy. This review describes the main acquisitions
      related to this approach represented by the mesenchymal stem cell or adipose
      tissue stem cell transplantation and endothelial nitric oxide synthase or
      vascular endothelial growth factor gene therapy. Moreover, there are other two
      aspects of wide interest represented by the potential vascular regenerative
      effects exerted by the PDE5 inhibitors and the therapeutic strategies for a
      category of patients who more frequently do not respond to the conventional
      treatment for ED, the patients with diabetes mellitus.
CI  - (c) 2013 American Society of Andrology and European Academy of Andrology.
AD  - Section of Endocrinology, Andrology and Internal Medicine, Department of Medical 
      and Pediatric Sciences, University of Catania, Catania, Italy.
FAU - Condorelli, R A
AU  - Condorelli RA
FAU - Calogero, A E
AU  - Calogero AE
FAU - Vicari, E
AU  - Vicari E
FAU - Favilla, V
AU  - Favilla V
FAU - Morgia, G
AU  - Morgia G
FAU - Cimino, S
AU  - Cimino S
FAU - La Vignera, S
AU  - La Vignera S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Andrology
JT  - Andrology
JID - 101585129
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/01/01 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/03/09 [accepted]
AID - 10.1111/j.2047-2927.2013.00087.x [doi]
PST - aheadofprint
SO  - Andrology. 2013 May 8. doi: 10.1111/j.2047-2927.2013.00087.x.

PMID- 23658158
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Linking)
VI  - 33
IP  - 19
DP  - 2013 May 8
TI  - The nNOS-p38MAPK Pathway Is Mediated by NOS1AP during Neuronal Death.
PG  - 8185-8201
AB  - Neuronal nitric oxide synthase (nNOS) and p38MAPK are strongly implicated in
      excitotoxicity, a mechanism common to many neurodegenerative conditions, but the 
      intermediary mechanism is unclear. NOS1AP is encoded by a gene recently
      associated with sudden cardiac death, diabetes-associated complications, and
      schizophrenia (Arking et al., 2006; Becker et al., 2008; Brzustowicz, 2008;
      Lehtinen et al., 2008). Here we find it interacts with p38MAPK-activating kinase 
      MKK3. Excitotoxic stimulus induces recruitment of NOS1AP to nNOS in rat cortical 
      neuron culture. Excitotoxic activation of p38MAPK and subsequent neuronal death
      are reduced by competing with the nNOS:NOS1AP interaction and by knockdown with
      NOS1AP-targeting siRNAs. We designed a cell-permeable peptide that competes for
      the unique PDZ domain of nNOS that interacts with NOS1AP. This peptide inhibits
      NMDA-induced recruitment of NOS1AP to nNOS and in vivo in rat, doubles surviving 
      tissue in a severe model of neonatal hypoxia-ischemia, a major cause of neonatal 
      death and pediatric disability. The highly unusual sequence specificity of the
      nNOS:NOS1AP interaction and involvement in excitotoxic signaling may provide
      future opportunities for generation of neuroprotectants with high specificity.
AD  - Molecular Signalling Laboratory, Department of Neurobiology, A.I. Virtanen
      Institute, University of Eastern Finland, FI-70211 Kuopio, Finland, Division of
      Neonatology, Department of Paediatrics and Paediatric Surgery and University
      Hospital Centre and University of Lausanne, CH-1015 Lausanne, Switzerland,
      Department of Fundamental Neurosciences, University of Lausanne, CH-1015
      Lausanne, Switzerland, Turku Centre for Biotechnology, BioCity, University of
      Turku and Abo Akademi University, FI-20521 Turku, Finland, and Xigen SA, 1003
      Lausanne, Switzerland.
FAU - Li, Li-Li
AU  - Li LL
FAU - Ginet, Vanessa
AU  - Ginet V
FAU - Liu, Xiaonan
AU  - Liu X
FAU - Vergun, Olga
AU  - Vergun O
FAU - Tuittila, Minna
AU  - Tuittila M
FAU - Mathieu, Marc
AU  - Mathieu M
FAU - Bonny, Christophe
AU  - Bonny C
FAU - Puyal, Julien
AU  - Puyal J
FAU - Truttmann, Anita C
AU  - Truttmann AC
FAU - Courtney, Michael J
AU  - Courtney MJ
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for
      Neuroscience
JID - 8102140
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 33/19/8185 [pii]
AID - 10.1523/JNEUROSCI.4578-12.2013 [doi]
PST - ppublish
SO  - J Neurosci. 2013 May 8;33(19):8185-8201.

PMID- 23658150
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1520-6300 (Electronic)
IS  - 1042-0533 (Linking)
DP  - 2013 May 9
TI  - The hidden cost of moving up: Type 2 diabetes and the escape from persistent
      poverty in the American South.
LID - 10.1002/aajhb.22399 [doi]
AB  - OBJECTIVES: The paper tests the thrifty phenotype hypothesis, according to which 
      nonharmonious growth trajectories are costly for adult health. METHODS: The
      American surge in the prevalence of type 2 diabetes is concentrated in the South,
      a region characterized by a long history of poverty followed by rapid economic
      growth beginning in the 1960s. Civil rights legislation further accelerated
      income growth for African-Americans in the region. The paper investigates the
      hypothesis by using per capita income at the state level as a proxy for net
      nutritional conditions. RESULTS: Regressions at the state level explain 56% of
      the variation in the prevalence rate of type 2 diabetes in 2009 using two
      explanatory variables: the ratio of per capita income in 1980 to that in 1950 and
      the share of the population that was African-American. The paper discusses ways
      that rapid economic growth may have translated into weight gain and type 2
      diabetes. CONCLUSIONS: If the thrifty phenotype hypothesis is correct, future
      rates in the prevalence of type 2 diabetes are predictable based on income
      history. The forecast for rapidly developing countries such as India and China
      are ominous. Am. J. Hum. Biol., 2013. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Economics, Anthropology and History Departments, Ohio State University, 1945 N.
      High St., Columbus, Ohio, 43210.
FAU - Steckel, Richard H
AU  - Steckel RH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Am J Hum Biol
JT  - American journal of human biology : the official journal of the Human Biology
      Council
JID - 8915029
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/10/03 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/03/02 [accepted]
AID - 10.1002/aajhb.22399 [doi]
PST - aheadofprint
SO  - Am J Hum Biol. 2013 May 9. doi: 10.1002/aajhb.22399.

PMID- 23658123
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 8
TI  - Vibration perception threshold for sight-threatening retinopathy screening in
      type 2 diabetic outpatients.
LID - 10.1002/dmrr.2423 [doi]
AB  - OBJECTIVE: We investigated the relationship between vibration perception
      threshold (VPT) and diabetic retinopathy (DR), and verified the screening value
      of VPT for severe diabetic retinopathy. METHODS: A total of 955 patients with
      type 2 diabetes were recruited and divided into three groups according to their
      fundus oculi photography results: no diabetic retinopathy (NDR) (n = 654,
      68.48%), non-sight-threatening diabetic retinopathy (NSTDR) (n = 189, 19.79%) and
      sight-threatening diabetic retinopathy (STDR) (n = 112, 11.73%). Their clinical
      and biochemical characteristics, VPT and the DR grades were detected and
      compared. RESULTS: There were significant differences in diabetes duration and
      blood glucose levels among three groups (all p < 0.05). The values of VPT
      increased with the rising severity of retinopathy, and the VPT level of STDR
      group was significantly higher than both NSTDR and NDR groups (both p < 0.01).
      The prevalence of STDR in VPT >25 V group was significantly higher than 16-24 V
      group (p < 0.01). The severity of DR was positively associated with diabetes
      duration, blood glucose indexes and VPT (all p < 0.01). Multiple stepwise
      regression analysis proved that HbA1c (beta = 0.385, p = 0.000), diabetes
      duration (beta = 0.275, p = 0.000) and VPT (beta = 0.180, p = 0.015) were
      independent risk factors for DR. Receiver operating characteristic analysis
      further revealed that VPT higher than 18 V was the optimal cut point for
      reflecting high risk of STDR (OR = 4.20, 95% CI = 2.67-6.59). CONCLUSIONS: There 
      was a close association between VPT and the severity of diabetic retinopathy. VPT
      was a potential screening method for diabetic retinopathy, and its optimal
      cut-off for prompting high risk of sight-threatening retinopathy was 18 V. This
      article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Endocrinology & Metabolism, Shanghai Jiaotong University Affiliated
      Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes
      Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, 200233, China.
FAU - Shen, Jing
AU  - Shen J
FAU - Hu, Yanyun
AU  - Hu Y
FAU - Liu, Fang
AU  - Liu F
FAU - Zeng, Hui
AU  - Zeng H
FAU - Li, Lianxi
AU  - Li L
FAU - Zhao, Jun
AU  - Zhao J
FAU - Zhao, Jungong
AU  - Zhao J
FAU - Zheng, Taishan
AU  - Zheng T
FAU - Lu, Huijuan
AU  - Lu H
FAU - Lu, Fengdi
AU  - Lu F
FAU - Bao, Yuqian
AU  - Bao Y
FAU - Jia, Weiping
AU  - Jia W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1002/dmrr.2423 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 8. doi: 10.1002/dmrr.2423.

PMID- 23658071
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 8
TI  - Diabetes is not an independent risk factor for hepatocellular carcinoma.
LID - 10.1002/dmrr.2422 [doi]
AB  - BACKGROUND: Whether diabetes is a risk factor for hepatocellular carcinoma (HCC) 
      in countries with high prevalence of viral hepatitis like Taiwan is
      controversial. METHODS: From the Taiwanese National Health Insurance, 1,000,000
      insurants were randomly selected for the study. Among them 494,080 men and
      502,841 women without HCC were followed from 2003 until 2005. Relative risks were
      estimated taking into account alcohol-related diagnoses, chronic liver disease,
      potential HCC detection examinations and other covariates. RESULTS: The diabetes 
      patients were more likely to receive examinations of abdominal sonography, HBsAg,
      anti-HCV and alpha-fetoprotein. Multivariable-adjusted relative risk (95%
      confidence interval) was not significant for diabetes as a risk factor for HCC in
      either men or women: 0.932 (0.788-1.101) for men and 1.158 (0.968-1.386) for
      women. While comparing diabetes duration <1, 1-3 and >/=3 years to non-diabetes
      individuals, the respective relative risks were 1.043 (0.751-1.448), 0.945
      (0.738-1.209) and 0.901 (0.744-1.091) for men; and were 0.950 (0.610-1.480),
      1.169 (0.884-1.546), and 1.189 (0.974-1.452) for women. For both sexes, age,
      alcohol-related diagnoses, chronic liver disease and potential detection bias
      were significantly associated with higher risk, but dyslipidemia and stroke a
      lower risk. In addition, chronic obstructive pulmonary disease was associated
      with a lower risk and sulfonylurea a higher risk in men. Models that did not
      consider alcohol-related diagnoses, chronic liver disease and potential detection
      bias would result in spurious association between diabetes and HCC. CONCLUSIONS: 
      Diabetes is not an independent risk factor for HCC after considering the effects 
      of alcohol-related diagnoses, chronic liver disease and potential detection bias.
      This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Internal Medicine, National Taiwan University College of Medicine, 
      Taipei, Taiwan; Division of Endocrinology and Metabolism, Department of Internal 
      Medicine, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Tseng, Chin-Hsiao
AU  - Tseng CH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1002/dmrr.2422 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 8. doi: 10.1002/dmrr.2422.

PMID- 23658055
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 May 8
TI  - Diminished Autophagy Limits Cardiac Injury in Mouse Models of Type 1 Diabetes.
AB  - Cardiac autophagy is inhibited in type 1 diabetes. However, it remains unknown if
      the reduced autophagy contributes to the pathogenesis of diabetic cardiomyopathy.
      We addressed this question using mouse models with gain- and loss-of-autophagy.
      Autophagic flux was inhibited in diabetic hearts when measured at multiple time
      points following diabetes induction by streptozotocin as assessed by protein
      levels of microtubule-associated protein light chain 3 form 2 (LC3-II) or GFP-LC3
      puncta in the absence and presence of the lysosome inhibitor bafilomycin A1.
      Autophagy in diabetic hearts was further reduced in beclin 1 or Atg16 deficient
      mice, but was restored partially or completely by overexpression of beclin 1 to
      different levels. Surprisingly, diabetes-induced cardiac damage was substantially
      attenuated in beclin 1 and Atg16 deficient mice as shown by improved cardiac
      function as well as reduced levels of oxidative stress, interstitial fibrosis and
      myocyte apoptosis. In contrast, diabetic cardiac damage was dose-dependently
      exacerbated by beclin 1 overexpression. The cardioprotective effects of autophagy
      deficiency were reproduced in OVE26 diabetic mice. These effects were associated 
      with partially restored mitophagy and increased expression and mitochondrial
      localization of Rab9, an essential regulator of a non-canonical alternative
      autophagic pathway. Together, these findings demonstrate that the diminished
      autophagy is an adaptive response that limits cardiac dysfunction in type 1
      diabetes, presumably through up-regulation of alternative autophagy and
      mitophagy.
AD  - Sanford Research/USD, United States;
FAU - Xu, Xianmin
AU  - Xu X
FAU - Kobayashi, Satoru
AU  - Kobayashi S
FAU - Chen, Kai
AU  - Chen K
FAU - Timm, Derek
AU  - Timm D
FAU - Volden, Paul
AU  - Volden P
FAU - Huang, Yuan
AU  - Huang Y
FAU - Gulick, James
AU  - Gulick J
FAU - Yue, Zhenyu
AU  - Yue Z
FAU - Robbins, Jeffrey
AU  - Robbins J
FAU - Epstein, Paul N
AU  - Epstein PN
FAU - Liang, Qiangrong
AU  - Liang Q
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Apoptosis
OT  - Autophagy
OT  - Cardiomyopathy
OT  - Diabetes
OT  - Mitochondria
OT  - Oxidative stress
OT  - Rab9
OT  - alternative autophagy
OT  - beclin 1
OT  - mitophagy
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - M113.474650 [pii]
AID - 10.1074/jbc.M113.474650 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 May 8.

PMID- 23658042
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1757-7861 (Electronic)
IS  - 1757-7853 (Linking)
VI  - 5
IP  - 2
DP  - 2013 May
TI  - Charcot neuroarthropathy of the foot and ankle.
PG  - 86-93
LID - 10.1111/os.12032 [doi]
AB  - Charcot neuroarthropathy (CN) is a rare, progressive, deforming disease of bone
      and joints, especially affecting the foot and ankle and leading to considerable
      morbidity. It can also affect other joints such as the wrist, knee, spine and
      shoulder. This disease, described originally in reference to syphilis, is now one
      of the most common associates of diabetes mellitus. As the number of diabetics
      increase, the incidence of CN is bound to rise. Faster initial diagnosis and
      prompt institution of treatment may help to reduce its sequelae. There should be 
      a low threshold for ordering investigations to assist coming to this diagnosis.
      No single investigation is the gold standard. Recent studies on pathogenesis and 
      development of newer investigation modalities have helped to clarify the mystery 
      of its pathogenesis and of its diagnosis in the acute phase. Various
      complementary investigations together allow the correct diagnosis to be made.
      Osteomyelitis continues to be confused with acute CN. Hybrid positron emission
      tomography has shown some promise in differentiating these conditions. A
      multispecialty approach involving diabetologists, orthopaedists and podiatrists
      should be used to tackle this difficult problem. The aim of this article is to
      describe current knowledge about CN with particular reference to the status of
      diagnostic indicators and management options.
CI  - (c) 2013 Chinese Orthopaedic Association and Wiley Publishing Asia Pty Ltd.
AD  - Department of Orthopaedics, Melaka Manipal Medical College, Jalan Batu Hampar,
      Bukit Baru, Melaka, Malaysia.
FAU - Madan, Simerjit Singh
AU  - Madan SS
FAU - Pai, Dinker R
AU  - Pai DR
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Orthop Surg
JT  - Orthopaedic surgery
JID - 101501666
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/11/05 [received]
PHST- 2012/12/20 [accepted]
AID - 10.1111/os.12032 [doi]
PST - ppublish
SO  - Orthop Surg. 2013 May;5(2):86-93. doi: 10.1111/os.12032.

PMID- 23658008
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1521-0111 (Electronic)
IS  - 0026-895X (Linking)
DP  - 2013 May 8
TI  - Low Molecular Weight Fucoidan (LMWF) Improves ER Stress-Reduced Insulin
      Sensitivity through AMPK Activation in L6 Myotubes and Restores Lipid Homeostasis
      in a Mouse Model of Type 2 Diabetes.
AB  - Low molecular weight fucoidan (LMWF) is widely used to treat metabolic disorders,
      but its physiologic effects have not been well determined. In the present study, 
      we investigated the metabolic effects of LMWF in db/db mice and the underlying
      molecular mechanisms involved in endoplasmic reticulum (ER) stress-responsive L6 
      myotubes. The effect of LMWF-mediated AMP-activated protein kinase (AMPK)
      activation on insulin resistance via regulation of the ER stress-dependent
      pathway was examined in vitro and in vivo. In db/db mice, LMWF markedly reduced
      serum glucose, triglyceride, cholesterol, and LDL levels, and gradually reduced
      body weights by reducing lipid parameters. Furthermore, it effectively
      ameliorated glucose homeostasis by elevating glucose tolerance. In addition, the 
      phosphorylation level of AMPK and Akt were markedly reduced by ER stressor, and
      subsequently, glucose uptake and fatty acid oxidation were also reduced. However,
      these adverse effects of ER stress were significantly ameliorated by LMWF.
      Finally, in L6 myotubes, LMWF markedly reduced the ER stress-induced upregulation
      of mammalian target of rapamycin (mTOR)-p70S61 kinase (S6K) network and
      subsequently improved the action of insulin via AMPK stimulation. Our findings
      suggest that AMPK activation by LMWF could prevent metabolic diseases by
      controlling the ER stress-dependent pathway and that this beneficial effect of
      LMWF provides a potential therapeutic strategy for ameliorating ER
      stress-mediated metabolic dysfunctions.
AD  - 1 College of Pharmacy, Yeungnam University;
FAU - Jeong, Yong-Tae
AU  - Jeong YT
FAU - Kim, Yong Deuk
AU  - Kim YD
FAU - Jung, Young-Mi
AU  - Jung YM
FAU - Park, Dong-Chan
AU  - Park DC
FAU - Lee, Dong-Sub
AU  - Lee DS
FAU - Ku, Sae-Kwang
AU  - Ku SK
FAU - Li, Xian
AU  - Li X
FAU - Lu, Yue
AU  - Lu Y
FAU - Chao, Guang Hsuan
AU  - Chao GH
FAU - Kim, Keuk-Jun
AU  - Kim KJ
FAU - Lee, Jai-Youl
AU  - Lee JY
FAU - Baek, Moon-Chang
AU  - Baek MC
FAU - Kang, Wonku
AU  - Kang W
FAU - Hwang, Seung-Lark
AU  - Hwang SL
FAU - Chang, Hyeun Wook
AU  - Chang HW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Mol Pharmacol
JT  - Molecular pharmacology
JID - 0035623
OTO - NOTNLM
OT  - Insulin
OT  - Mammalian target of rapamycin (mTOR)
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - mol.113.085100 [pii]
AID - 10.1124/mol.113.085100 [doi]
PST - aheadofprint
SO  - Mol Pharmacol. 2013 May 8.

PMID- 23657992
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 22
DP  - 2013 May
TI  - [SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes
      mellitus?].
PG  - 1172-7
LID - 10.1055/s-0032-1333023 [doi]
AB  - Since end of 2012 a new therapeutical approach for the treatment of type 2
      diabetes is available in Germany. It relies on the modulation of glucose
      re-absorption in the kidney by inhibition of so called Sodium Glucose Linked
      Transporters (SGLT) thereby leading to therapeutical glucosuria. Putting the
      kidney in the centre of therapeutical approach of glucose regulation is
      unfamiliar for physicians. Therefore, it is helpful to elucidate the underlying
      renal mechanisms and to present the advantages and disadvantages of this new
      therapeutic class.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Abteilung Innere Medizin I und Klinische Chemie, Universitatsklinikum Heidelberg.
FAU - Rudofsky, G
AU  - Rudofsky G
FAU - Russmann, H-J
AU  - Russmann HJ
FAU - Siegmund, T
AU  - Siegmund T
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - SGLT2-Inhibition: Ein wirksames Therapieprinzip des Diabetes mellitus?
DEP - 20130508
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/05/08 [epublish]
PHST- 2013/05/08 [aheadofprint]
AID - 10.1055/s-0032-1333023 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(22):1172-7. doi: 10.1055/s-0032-1333023. Epub 
      2013 May 8.

PMID- 23657989
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
DP  - 2013 May 9
TI  - Physical activity for the prevention and treatment of metabolic disorders.
AB  - Metabolic syndrome and its various features (obesity, hypertension, dyslipidemia,
      diabetes, and nonalcoholic fatty liver disease) are increasing worldwide and
      constitute a severe risk for the sustainability of the present universal Italian 
      health care system. Lifestyle interventions should be the first therapeutic
      strategy to prevent/treat metabolic diseases, far before pharmacologic treatment.
      The role of diet and weight loss has been fully ascertained, whereas the role of 
      physical activity is frequently overlooked both by physicians and by patients.
      Physical activity has favorable effects on all components of the metabolic
      syndrome and on the resulting cardiovascular risk, the cornerstone in the
      development of cardiometabolic diseases. The quantity and the frequency of
      physical activity necessary to produce beneficial effects has not been defined as
      yet, but brisk walking is considered particularly appropriate, as it can be
      practiced by a large number of individuals, without any additional cost, and has 
      a low rate of injury. The effects of exercise and leisure time physical activity 
      extend from prevention to treatment of the various components of the metabolic
      syndrome, as well as to mood and quality of life. Any effort should be done to
      favor adherence to protocols of physical activity in the community.
AD  - Unit of Metabolic Diseases and Clinical Dietetics, "Alma Mater Studiorum"
      University, Bologna, Italy.
FAU - Montesi, Luca
AU  - Montesi L
FAU - Moscatiello, Simona
AU  - Moscatiello S
FAU - Malavolti, Marcella
AU  - Malavolti M
FAU - Marzocchi, Rebecca
AU  - Marzocchi R
FAU - Marchesini, Giulio
AU  - Marchesini G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/01/12 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 10.1007/s11739-013-0953-7 [doi]
PST - aheadofprint
SO  - Intern Emerg Med. 2013 May 9.

PMID- 23657966
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
DP  - 2013 May 9
TI  - Capsule Commentary on Kaplan et al., Reducing Racial/Ethnic Disparities in
      Diabetes: The Coached Care (R2D2C2) Project.
AD  - Division of General Internal Medicine, Zablocki VA Medical Center, Milwaukee, WI,
      53295, USA, jjackson@mcw.edu.
FAU - Jackson, Jeffrey L
AU  - Jackson JL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1007/s11606-013-2485-2 [doi]
PST - aheadofprint
SO  - J Gen Intern Med. 2013 May 9.

PMID- 23657947
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2013 May 9
TI  - The effects of sulfonylureas plus metformin on lipids, blood pressure, and
      adverse events in type 2 diabetes: a meta-analysis of randomized controlled
      trials.
AB  - To compare the effects of sulfonylureas and metformin versus metformin on lipid
      profiles, blood pressure, and adverse events. PubMed, EMbase, Chinese BioMedical 
      Literature on disc, China National Knowledge Infrastructure, VIP database, and
      Wanfang database were searched for randomized controlled trials (RCTs), from
      inception to August 2012. Key outcomes were low-density lipoprotein cholesterol
      (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), total 
      cholesterol (TC), blood pressure (BP), hemoglobin A1c (HbA1c), fasting insulin,
      and adverse events. Twenty RCTs were included in the analysis. Compared to
      metformin, the combination therapy of sulfonylureas and metformin slightly
      reduced HDL-C [-0.03, 95 % CI (-0.06, -0.01)] and HbA1c (-0.79, 95 % CI -0.96 to 
      -0.63). However, it showed little effects on LDL-C, TG, TC, and BP. Glipizide
      plus metformin significantly increased fasting insulin [2.33, 95 % CI (1.94,
      2.73)]. Hypoglycemia and nervous system side events were more frequent among
      patients treated with sulfonylureas plus metformin than metformin alone (RR =
      6.79, 95 % CI 3.79-12.17; RR = 1.27, 95 % CI 1.03-1.57; respectively), but less
      in digestive symptoms (RR = 0.75, 95 % CI 0.67-0.84). Combination therapy with
      sulfonylureas and metformin may be more effective than metformin alone in
      improving HbA1c and reducing gastrointestinal reactions. But it had disadvantage 
      of decreasing HDL-C, increasing the risk of hypoglycemia and nervous system side 
      events.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Tongji
      Medical College, Huazhong University of Science and Technology, 13 Hangkong Road,
      Wuhan, 430030, China.
FAU - Zhang, Fan
AU  - Zhang F
FAU - Xiang, Hao
AU  - Xiang H
FAU - Fan, Yunzhou
AU  - Fan Y
FAU - Ganchuluun, Tsend-Ayush
AU  - Ganchuluun TA
FAU - Kong, Wenhua
AU  - Kong W
FAU - Ouyang, Qian
AU  - Ouyang Q
FAU - Sun, Jingwen
AU  - Sun J
FAU - Cao, Beibei
AU  - Cao B
FAU - Jiang, Hongbo
AU  - Jiang H
FAU - Nie, Shaofa
AU  - Nie S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Endocrine
JT  - Endocrine
JID - 9434444
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/12/28 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 10.1007/s12020-013-9970-6 [doi]
PST - aheadofprint
SO  - Endocrine. 2013 May 9.

PMID- 23657907
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 2047-2927 (Electronic)
DP  - 2013 May 8
TI  - The impact of frequently encountered cardiovascular risk factors on sexual
      dysfunction in rheumatic disorders.
LID - 10.1111/j.2047-2927.2013.00094.x [doi]
AB  - Traditional cardiovascular risk factors have been acknowledged as major
      contributors to sexual dysfunction in the general population. The purpose of this
      study was to explore their impact on sexual function in rheumatologic patients. A
      total of 557 consecutive rheumatologic patients, 449 females and 108 males, had
      their sexual function evaluated with the Female Sexual Functioning Index (FSFI)
      and the International Index of Erectile Function (IIEF) questionnaire
      respectively. Personal data regarding presence of cardiovascular risk factors
      were collected and analysed in association with the FSFI and IIEF scores. Mean
      age of the participants was 54.1 +/- 14.1 years, mean body mass index was 27.5
      +/- 5.29 and mean systolic and diastolic blood pressure was 130.5 +/- 19.82 and
      79.5 +/- 10.51 mmHg respectively. Hypertension was present in 39% of the
      participants, diabetes mellitus in 10.2%, dyslipidaemia in 33.6% and history of
      cardiovascular events in 8.6%, whereas smoking was recorded by 28.4% and alcohol 
      consumption by 7.4%. Sexual dysfunction affected 68.6% of our study population
      (73.5% of females and 48.1% of males, p < 0.001). Logistic regression analysis
      revealed that age was the only factor associated with a significantly higher
      prevalence of sexual dysfunction (p < 0.001 for both genders, p = 0.013 in males 
      and p < 0.001 in females). Increased age was identified as the only independent
      predictor of sexual dysfunction in our population. Apart from age, traditional
      cardiovascular risk factors failed to explain the increased prevalence of sexual 
      dysfunction in these patients. Other contributing factors (physical and/or
      psychological) might account for the increased occurrence of sexual dysfunction
      in rheumatic disorders.
CI  - (c) 2013 American Society of Andrology and European Academy of Andrology.
AD  - 2nd Prop. Department of Internal Medicine, Aristotle University, Thessaloniki,
      Greece.
FAU - Anyfanti, P
AU  - Anyfanti P
FAU - Pyrpasopoulou, A
AU  - Pyrpasopoulou A
FAU - Triantafyllou, A
AU  - Triantafyllou A
FAU - Doumas, M
AU  - Doumas M
FAU - Gavriilaki, E
AU  - Gavriilaki E
FAU - Triantafyllou, G
AU  - Triantafyllou G
FAU - Gkaliagkousi, E
AU  - Gkaliagkousi E
FAU - Chatzimichailidou, S
AU  - Chatzimichailidou S
FAU - Petidis, K
AU  - Petidis K
FAU - Avagianou, P-A
AU  - Avagianou PA
FAU - Zamboulis, C
AU  - Zamboulis C
FAU - Aslanidis, S
AU  - Aslanidis S
FAU - Douma, S
AU  - Douma S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Andrology
JT  - Andrology
JID - 101585129
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/10/04 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/04/02 [accepted]
AID - 10.1111/j.2047-2927.2013.00094.x [doi]
PST - aheadofprint
SO  - Andrology. 2013 May 8. doi: 10.1111/j.2047-2927.2013.00094.x.

PMID- 23657857
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1522-1466 (Electronic)
IS  - 1522-1466 (Linking)
DP  - 2013 May 8
TI  - NITRIC OXIDE - ANGIOTENSIN II INTERACTIONS AND RENAL HEMODYNAMIC FUNCTION IN
      PATIENTS WITH UNCOMPLICATED TYPE-1 DIABETES.
AB  - Objective: To elucidate the effect of nitric oxide (NO)-renin-angiotensin system 
      (RAS) interactions on renal hemodynamic function in uncomplicated, type 1
      diabetes mellitus (DM). Methods: In 14 salt-replete, male healthy volunteers (C) 
      and 9 male DM patients on euglycemia, Glomerular Filtration Rate (GFR), Renal
      Blood Flow (RBF), Filtration Fraction (FF) and sodium excretion (UNaV) were
      measured at baseline and during 90-minute infusion of 3.0 mug.kg.min-1
      NG-nitro-L-arginine-methyl-ester (L-NAME) after 3-days pre-treatment with either 
      placebo (PL) or 50-mg losartan (LOS). Results: Baseline GFR, RBF and FF were
      higher in DM (p<0.005). In the C group, PL+L-NAME caused declines in GFR (101+/-3
      to 90+/-3 ml.min-1.1.73 m2), RBF (931+/-22 to 754+/-31 ml.min-1.1.73 m2), and
      UNaV (158+/-12 to 82+/-18 mumol.min-1) and an increase in FF (0.19+/-0.02 to
      0.21+/-02) (p<0.001), which were not influenced by LOS pre-treatment (p>0.05 for 
      LOS+L-NAME-C versus PL+L-NAME-C). In DM, PL+L-NAME resulted in exaggerated renal 
      effects, with changes in GFR (128+/-3 to 104+/-3 ml.min-1.1.73 m2), RBF
      (1019+/-27 to 699+/-34 ml.min-1.1.73 m2), UNaV (150+/-13 to 39+/-14 mumol.min-1),
      and FF (0.22+/-0.03 to 0.26+/-0.02) that were significantly greater versus
      PL+L-NAME-C (p<0.005). LOS pre-treatment blunted GFR, RBF, FF and UNaV responses 
      to L-NAME in DM (p<0.005 versus PL+L-NAME-DM), resulting in a response profile
      that was similar to PL+L-NAME and LOS+L-NAME in C (p>0.05). Conclusions: Renal
      responses to L-NAME in uncomplicated, type 1 DM are exaggerated versus C,
      consistent with an up-regulation of NO bioactivity. LOS, without effects in C,
      prevents the accentuated actions of L-NAME in DM, thus indicating an augmented
      role for NO-RAS interactions in renal hemodynamic function in DM.
AD  - 1Parma University Medical School.
FAU - Montanari, Alberto
AU  - Montanari A
FAU - Pela, Giovanna
AU  - Pela G
FAU - Musiari, Luisa
AU  - Musiari L
FAU - Crocamo, Antonio
AU  - Crocamo A
FAU - Boeti, Luisella
AU  - Boeti L
FAU - Cabassi, Aderville
AU  - Cabassi A
FAU - Biggi, Almerina
AU  - Biggi A
FAU - Cherney, David Z
AU  - Cherney DZ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Am J Physiol Renal Physiol
JT  - American journal of physiology. Renal physiology
JID - 100901990
OTO - NOTNLM
OT  - L-NAME
OT  - nitric oxide
OT  - renal hemodynamic function
OT  - renin-angiotensin system
OT  - type-1 diabetes mellitus
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - ajprenal.00109.2013 [pii]
AID - 10.1152/ajprenal.00109.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Renal Physiol. 2013 May 8.

PMID- 23657847
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1573-9104 (Electronic)
IS  - 0921-9668 (Linking)
VI  - 68
IP  - 2
DP  - 2013 Jun
TI  - Influence of coffee brew in metabolic syndrome and type 2 diabetes.
PG  - 184-9
LID - 10.1007/s11130-013-0355-z [doi]
AB  - This study aimed to evaluate the effect of coffee drinking on clinical markers of
      diabetes and metabolic syndrome in Zucker rats. Diabetic Zucker rats with
      metabolic syndrome and control Zucker rats were used for in vivo tests. The
      animals received daily doses of coffee drink by gavage for 30 days. After the
      treatment, the levels of glucose, triglycerides, total cholesterol and fractions,
      creatinine, uric acid, activity of aspartate aminotransferase and alanine
      aminotransferase were evaluated. Urea and creatinine levels were also analyzed in
      urine. By collaborating in the modulation of the metabolic syndrome and diabetes 
      mellitus type 2, coffee drink helped in reducing serum glucose, total cholesterol
      and triglycerides. The results demonstrate that treatment with roasted coffee
      drink, because of its hypoglycemic and hypolipidemic effect, is efficient in the 
      protection of animals with metabolic syndrome and diabetes mellitus type 2.
AD  - Fluminense Federal Institute, Av. Dario Vieira Borges, 235, 28360-000, Bom Jesus 
      do Itabapoana, RJ, Brazil, sheilanutri@yahoo.com.br.
FAU - Abrahao, Sheila Andrade
AU  - Abrahao SA
FAU - Pereira, Rosemary Gualberto Fonseca Alvarenga
AU  - Pereira RG
FAU - de Sousa, Raimundo Vicente
AU  - de Sousa RV
FAU - Lima, Adriene Ribeiro
AU  - Lima AR
FAU - Crema, Gabriela Previatti
AU  - Crema GP
FAU - Barros, Bianca Sacramento
AU  - Barros BS
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Plant Foods Hum Nutr
JT  - Plant foods for human nutrition (Dordrecht, Netherlands)
JID - 8803554
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1007/s11130-013-0355-z [doi]
PST - ppublish
SO  - Plant Foods Hum Nutr. 2013 Jun;68(2):184-9. doi: 10.1007/s11130-013-0355-z.

PMID- 23657830
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 0070-217X (Print)
IS  - 0070-217X (Linking)
DP  - 2013 May 10
TI  - Central Tolerance Induction.
AB  - A critical function of the thymus is to help enforce tolerance to self. The
      importance of central tolerance in preventing autoimmunity has been enlightened
      by a deeper understanding of the interactions of developing T cells with a
      diverse population of thymic antigen presenting cell populations. Furthermore,
      there has been rapid progress in our understanding of how autoreactive T cell
      specificities are diverted into the T regulatory lineage. Here we review and
      highlight the recent progress in how tolerance is imposed on the developing
      thymocyte repertoire.
AD  - Diabetes Center, University of California-San Francisco, Box 0540, San Francisco,
      CA, 94143, USA.
FAU - Mouchess, Maria L
AU  - Mouchess ML
FAU - Anderson, Mark
AU  - Anderson M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Curr Top Microbiol Immunol
JT  - Current topics in microbiology and immunology
JID - 0110513
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1007/82_2013_321 [doi]
PST - aheadofprint
SO  - Curr Top Microbiol Immunol. 2013 May 10.

PMID- 23657801
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1742-2051 (Electronic)
IS  - 1742-2051 (Linking)
DP  - 2013 May 8
TI  - Development of a novel non-radioactive cell-based method for the screening of
      SGLT1 and SGLT2 inhibitors using 1-NBDG.
AB  - Sodium-coupled glucose co-transporters SGLT1 and SGLT2 play important roles in
      intestinal absorption and renal reabsorption of glucose, respectively. Blocking
      SGLT2 is a novel mechanism for lowering the blood glucose level by inhibiting
      renal glucose reabsorption and selective SGLT2 inhibitors are under development
      for treatment of type 2 diabetes. Furthermore, it has been reported that
      perturbation of SGLT1 is associated with cardiomyopathy and cancer. Therefore,
      both SGLT1 and SGLT2 are potential therapeutic targets. Here we report the
      development of a non-radioactive cell-based method for the screening of SGLT
      inhibitors using COS-7 cells transiently expressing human SGLT1 (hSGLT1), CHO-K1 
      cells stably expressing human SGLT2 (hSGLT2), and a novel fluorescent d-glucose
      analogue 1-NBDG as a substrate. Our data indicate that 1-NBDG can be a good
      replacement for the currently used isotope-labeled SGLT substrate, 14C-AMG. The
      Michaelis constant of 1-NBDG transport (0.55 mM) is similar to that of d-glucose 
      (0.51 mM) and AMG (0.40 mM) transport through hSGLT1. The IC50 values of a SGLT
      inhibitor phlorizin for hSGLT1 obtained using 1-NBDG and 14C-AMG were identical
      (0.11 muM) in our cell-based system. The IC50 values of dapagliflozin, a
      well-known selective SGLT2 inhibitor, for hSGLT2 and hSGLT1 determined using
      1-NBDG were 1.86 nM and 880 nM, respectively, which are comparable to the
      published results obtained using 14C-AMG. Compared to 14C-AMG, the use of 1-NBDG 
      is cost-effective, convenient and potentially more sensitive. Taken together, a
      non-radioactive system using 1-NBDG has been validated as a rapid and reliable
      method for the screening of SGLT1 and SGLT2 inhibitors.
AD  - School of Pharmacy, National Taiwan University, 12F, No. 1, Section 1, Jen-Ai
      Road, Taipei 10051, Taiwan. lhsu@ntu.edu.tw.
FAU - Chang, Hung-Chi
AU  - Chang HC
FAU - Yang, Su-Fu
AU  - Yang SF
FAU - Huang, Ching-Chun
AU  - Huang CC
FAU - Lin, Tzung-Sheng
AU  - Lin TS
FAU - Liang, Pi-Hui
AU  - Liang PH
FAU - Lin, Chun-Jung
AU  - Lin CJ
FAU - Hsu, Lih-Ching
AU  - Hsu LC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Mol Biosyst
JT  - Molecular bioSystems
JID - 101251620
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1039/c3mb70060g [doi]
PST - aheadofprint
SO  - Mol Biosyst. 2013 May 8.

PMID- 23657800
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 10
TI  - The prenatal environment and type 1 diabetes.
AB  - There is ample evidence that environmental factors are involved in the aetiology 
      of type 1 diabetes, but the nature and timing of the interactions are poorly
      understood. The intrauterine environment is known to play a role in the later
      development of type 2 diabetes, and this review considers a possible role in type
      1 diabetes. Autoimmune type 1 diabetes is rare in those diagnosed before 6 months
      of age, but endogenous autoantibodies predictive of future type 1 diabetes may be
      detectable by 6-12 months of age, suggesting that environmental factors may
      operate before this age in some cases. Indirect evidence of a protective effect
      for the intrauterine environment comes from the observation that mothers with
      type 1 diabetes are less likely than affected fathers to transmit diabetes to
      their offspring, although the precise role (if any) is unclear. The risk of
      childhood-onset type 1 diabetes increases with maternal age at delivery, and with
      high birthweight, but these associations are weak and heterogeneous, and these
      factors are unlikely to be directly causally related to type 1 diabetes. No firm 
      conclusion can be drawn from studies of maternal enteroviral infection or from
      various nutritional exposures. The birth process itself may play a role, as
      suggested by the slightly increased risk in children born by Caesarean section;
      lack of contact with maternal bacteria is one suggested mechanism. In sum, there 
      is circumstantial evidence, but no proof of principle, that maternal or
      intrauterine conditions may modulate genetic risk of type 1 diabetes. The disease
      process culminating in type 1 diabetes typically begins in early life, but it is 
      not clear whether the trail begins before or after birth.
AD  - Division of Epidemiology, Norwegian Institute of Public Health, P.O. Box 4404
      Nydalen, NO-0403, Oslo, Norway, lars.christian.stene@fhi.no.
FAU - Stene, L C
AU  - Stene LC
FAU - Gale, E A M
AU  - Gale EA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/11/14 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/05/10 [aheadofprint]
AID - 10.1007/s00125-013-2929-6 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 10.

PMID- 23657799
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 9
TI  - Next-generation sequencing for viruses in children with rapid-onset type 1
      diabetes.
AB  - AIMS/HYPOTHESIS: Viruses are candidate causative agents in the pathogenesis of
      autoimmune (type 1) diabetes. We hypothesised that children with a rapid onset of
      type 1 diabetes may have been exposed to such agents shortly before the
      initiation of islet autoimmunity, possibly at high dose, and thus study of these 
      children could help identify viruses involved in the development of autoimmune
      diabetes. METHODS: We used next-generation sequencing to search for viruses in
      plasma samples and examined the history of infection and fever in children
      enrolled in The Environmental Determinants of Diabetes in the Young (TEDDY) study
      who progressed to type 1 diabetes within 6 months from the appearance of islet
      autoimmunity, and in matched islet-autoantibody-negative controls. RESULTS:
      Viruses were not detected more frequently in plasma from rapid-onset patients
      than in controls during the period surrounding seroconversion. In addition,
      infection histories were found to be similar between children with rapid-onset
      diabetes and control children, although episodes of fever were reported less
      frequently in children with rapid-onset diabetes. CONCLUSIONS/INTERPRETATION:
      These findings do not support the presence of viraemia around the time of
      seroconversion in young children with rapid-onset type 1 diabetes.
AD  - Pediatrics Epidemiology Center, Department of Pediatrics, University of South
      Florida, Tampa, FL, USA.
FAU - Lee, H-S
AU  - Lee HS
FAU - Briese, T
AU  - Briese T
FAU - Winkler, C
AU  - Winkler C
FAU - Rewers, M
AU  - Rewers M
FAU - Bonifacio, E
AU  - Bonifacio E
FAU - Hyoty, H
AU  - Hyoty H
FAU - Pflueger, M
AU  - Pflueger M
FAU - Simell, O
AU  - Simell O
FAU - She, J X
AU  - She JX
FAU - Hagopian, W
AU  - Hagopian W
FAU - Lernmark, A
AU  - Lernmark A
FAU - Akolkar, B
AU  - Akolkar B
FAU - Krischer, J P
AU  - Krischer JP
FAU - Ziegler, A G
AU  - Ziegler AG
CN  - the TEDDY study group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/02/06 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 10.1007/s00125-013-2924-y [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 9.

PMID- 23657766
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1439-6327 (Electronic)
IS  - 1439-6319 (Linking)
DP  - 2013 May 9
TI  - Whole body vibration training improves leg blood flow and adiposity in patients
      with type 2 diabetes mellitus.
AB  - This study aimed at examined the effect of a 12-week whole body vibration (WBV)
      training program on leg blood flow and body composition in people with type 2
      diabetes mellitus (T2DM). Forty participants were randomly assigned to either a
      WBV training group (WBV; n = 20) or usual-care control group (CON; n = 20). Body 
      composition [waist circumference, waist to hip ratio (WHR), weight, height,
      percentage of body fat and fat-free mass], heart rate, and blood flow [femoral
      artery diameter, maximum systolic velocity, maximum diastolic velocity (DV), time
      averaged mean, pulsatility index and resistance index (RI), mean velocity (V
      med), and peak blood velocities (PBV)] were assessed at baseline and after 12
      weeks. There were significant increases in the blood flow (p = 0.046), V med (p =
      0.050), and DV (p = 0.037) after WBV compared with CON. Within-group analysis
      showed significant differences in V med, PBV, and DV in the WBV group.
      Significant decreases after the intervention in weight (p < 0.001), waist
      circumference (p < 0.001), WHR (p < 0.05), and body fat (p < 0.05) were also
      found, with significant between-groups decreases in all these outcomes in the WBV
      group. Significant correlations existed between changes in percent body fat and
      blood flow [blood flow (-0.761), V med (-0.607), PBV (-0.677), and RI (0.0510)]. 
      WBV training can be considered an effective means to increase leg blood flow and 
      to reduce adiposity in patients with T2DM.
AD  - Physical Education and Sports Department, University of Seville, Pirotecnia s/n, 
      41012, Seville, Spain, bsancor@us.es.
FAU - Sanudo, Borja
AU  - Sanudo B
FAU - Alfonso-Rosa, Rosa
AU  - Alfonso-Rosa R
FAU - Del Pozo-Cruz, Borja
AU  - Del Pozo-Cruz B
FAU - Del Pozo-Cruz, Jesus
AU  - Del Pozo-Cruz J
FAU - Galiano, Delfin
AU  - Galiano D
FAU - Figueroa, Arturo
AU  - Figueroa A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Eur J Appl Physiol
JT  - European journal of applied physiology
JID - 100954790
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/02/19 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 10.1007/s00421-013-2654-3 [doi]
PST - aheadofprint
SO  - Eur J Appl Physiol. 2013 May 9.

PMID- 23657764
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 10
TI  - Current State of Care for Diabetic Retinopathy in India.
AB  - In this article we review the current state of care of diabetic retinopathy in
      India. We discuss the magnitude of the problem; diabetes, and diabetic
      retinopathy in India. We highlight the causes of vision loss in diabetic
      retinopathy. The current level of awareness among general population and
      physicians is a concern. Current screening strategies practiced in India and the 
      situational analysis of ophthalmologists in India are also reviewed. We review
      the current management of diabetic macular edema and proliferative diabetic
      retinopathy. To know the current practice pattern among retinal surgeons in
      India, a survey was done and the results of the survey are presented. There are
      few studies in the Indian population which have found some genetic risk and
      protective factors and a summary of these studies are also presented in this
      article.
AD  - Retina & Vitreous Services, Aravind Eye Care System, No.1 Anna Nagar, Madurai,
      Tamilnadu, India, 625 020, kim@aravind.org.
FAU - Ramasamy, Kim
AU  - Ramasamy K
FAU - Raman, Rajiv
AU  - Raman R
FAU - Tandon, Manish
AU  - Tandon M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1007/s11892-013-0388-6 [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 10.

PMID- 23657763
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 10
TI  - Novel Biomarkers for the Progression of Diabetic Nephropathy: Soluble TNF
      Receptors.
AB  - Despite 2 decades of advances in therapy of diabetic patients, the prevalence of 
      diabetic nephropathy among patients with diabetes has not decreased. However,
      large-scale multicenter studies have achieved great success in terms of the
      reduction of albuminuria, suggesting that albuminuria might not be an accurate
      surrogate marker for slowing the rate of renal function decline. It is important 
      to be able to identify individuals at high risk for renal function decline, or
      ultimately, end-stage kidney disease (ESKD) and its associated cardiovascular
      disease (CVD). More sensitive early biomarkers, other than albuminuria and the
      estimated glomerular filtration rate (eGFR), should be required. Recently, serum 
      concentrations of soluble tumor necrosis factor (TNF), receptor 1 (TNFR1), and
      TNFR2 have predicted future GFR loss and ESKD in patients of a wide variety of
      stages and both types of diabetes. Longitudinal interventional studies are needed
      to validate these biomarkers in a broad range of populations prior to
      implementation in routine diabetes management.
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University,
      Faculty of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo, 113-8421, Japan.
FAU - Gohda, Tomohito
AU  - Gohda T
FAU - Tomino, Yasuhiko
AU  - Tomino Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130510
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1007/s11892-013-0385-9 [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 10.

PMID- 23657617
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1432-1289 (Electronic)
IS  - 0020-9554 (Linking)
DP  - 2013 May 10
TI  - [Vertebral osteomyelitis.]
AB  - Infections of the vertebra and neighboring disc create the characteristic lesions
      of vertebral osteomyelitis. The incidence has been estimated to range from 0.3 to
      6.5 cases/100,000 persons. The hematogenous route of infection is predominant
      while direct inoculation through iatrogenic procedures and contiguous spread from
      adjacent tissue are rare. Most patients with hematogenous vertebral osteomyelitis
      exhibit predisposing factors, such as advanced age and diabetes mellitus.
      Diagnosis is often delayed due to the nonspecific nature of back pain, the main
      symptom. Furthermore, fever is frequently absent. Staphylococcus aureus is the
      most prevalent pathogen of pyogenic vertebral osteomyelitis in Europe. Magnetic
      resonance imaging (MRI) is the method of choice for the radiological diagnosis
      and blood cultures belong to the standard procedures. In cases of negative blood 
      cultures a biopsy is generally warranted for microbiological diagnosis, either by
      computed tomography (CT)-guided needle biopsy or open surgery. Randomized trials 
      that have addressed different antibiotic regimens are lacking. The recommended
      duration of treatment ranges from 6 weeks to 3 months. Patients with abscesses
      and implant devices in particular should be treated for 3 months.
AD  - Klinik 1 fur Innere Medizin, Uniklinik Koln, Kerpener Str. 62, 50935, Koln,
      Deutschland, norma.jung@uk-koeln.de.
FAU - Jung, N
AU  - Jung N
FAU - Seifert, H
AU  - Seifert H
FAU - Siewe, J
AU  - Siewe J
FAU - Fatkenheuer, G
AU  - Fatkenheuer G
LA  - GER
PT  - JOURNAL ARTICLE
TT  - Spondylodiszitis.
DEP - 20130510
TA  - Internist (Berl)
JT  - Der Internist
JID - 0264620
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1007/s00108-012-3142-2 [doi]
PST - aheadofprint
SO  - Internist (Berl). 2013 May 10.

PMID- 23657602
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
DP  - 2013 May 9
TI  - Transcriptome meta-analysis of peripheral lymphomononuclear cells indicates that 
      gestational diabetes is closer to type 1 diabetes than to type 2 diabetes
      mellitus.
AB  - We performed a meta-analysis of the transcription profiles of type 1, type 2 and 
      gestational diabetes to evaluate similarities and dissimilarities among these
      diabetes types. cRNA samples obtained from peripheral blood lymphomononuclear
      cells (PBMC) of 56 diabetes mellitus patients (type 1 = 19; type 2 = 20;
      gestational = 17) were hybridized to the same whole human genome oligomicroarray 
      platform, encompassing 44,000 transcripts. The GeneSpring software was used to
      perform analysis and hierarchical clustering, and the DAVID database was used for
      gene ontology. The gene expression profiles showed more similarity between
      gestational and type 1 diabetes rather than between type 2 and gestational
      diabetes, a finding that was not influenced by patient gender and age. The
      meta-analysis of the three types of diabetes disclosed 3,747 differentially and
      significantly expressed genes. A total of 486 genes were characteristic of
      gestational diabetes, 202 genes of type 1, and 651 genes of type 2 diabetes. 19
      known genes were shared by type 1, type 2 and gestational diabetes, highlighting 
      EGF, FAM46C, HBEGF, ID1, SH3BGRL2, VEPH1, and TMEM158 genes. The meta-analysis of
      PBMC transcription profiles characterized each type of diabetes revealing that
      gestational and type 1 diabetes were transcriptionally related.
AD  - Division of Clinical Immunology, Department of Medicine, Faculty of Medicine of
      Ribeirao Preto, University of Sao Paulo, Avenida Bandeirantes 3900, Monte Alegre,
      Ribeirao Preto, SP, 14049-900, Brazil.
FAU - Collares, C V A
AU  - Collares CV
FAU - Evangelista, A F
AU  - Evangelista AF
FAU - Xavier, D J
AU  - Xavier DJ
FAU - Takahashi, P
AU  - Takahashi P
FAU - Almeida, R
AU  - Almeida R
FAU - Macedo, C
AU  - Macedo C
FAU - Manoel-Caetano, F
AU  - Manoel-Caetano F
FAU - Foss, M C
AU  - Foss MC
FAU - Foss-Freitas, M C
AU  - Foss-Freitas MC
FAU - Rassi, D M
AU  - Rassi DM
FAU - Sakamoto-Hojo, E T
AU  - Sakamoto-Hojo ET
FAU - Passos, G A
AU  - Passos GA
FAU - Donadi, E A
AU  - Donadi EA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/09/21 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 10.1007/s11033-013-2635-y [doi]
PST - aheadofprint
SO  - Mol Biol Rep. 2013 May 9.

PMID- 23657598
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
DP  - 2013 May 9
TI  - High glucose induces mitochondrial p53 phosphorylation by p38 MAPK in pancreatic 
      RINm5F cells.
AB  - Pancreatic beta-cell death in type 2 diabetes has been related to p53 subcellular
      localisation and phosphorylation. However, the mechanisms by which p53 is
      phosphorylated and its activation in response to oxidative stress remain poorly
      understood. Therefore, the aim of this study was to investigate mitochondrial p53
      phosphorylation, its subcellular localisation and its relationship with apoptotic
      induction in RINm5F cells cultured under high glucose conditions. Our results
      show that p53 phosphorylation in the mitochondrial fraction was greater at ser392
      than at ser15. This increased phosphorylation correlated with an increase in
      reactive oxygen species, a decrease in the Bcl-2/Bax ratio, a release of
      cytochrome c and an increase in the rate of apoptosis. We also observed a decline
      in ERK 1/2 phosphorylation over time, which is an indicator of cell
      proliferation. To identify the kinase responsible for phosphorylating p53, p38
      mitogen-activated protein kinase (MAPK) activation was analysed. We found that
      high glucose induced an increase in p38 MAPK phosphorylation in the mitochondria 
      after 24-72 h. Moreover, the phosphorylation of p53 (ser392) by p38 MAPK in
      mitochondria was confirmed by colocalisation studies with confocal microscopy.
      The addition of a specific p38 MAPK inhibitor (SB203580) to the culture medium
      during high glucose treatment blocked p53 mobilisation to the mitochondria and
      phosphorylation; thus, the release of cytochrome c and the apoptosis rate in
      RINm5F cells decreased. These results suggest that mitochondrial p53
      phosphorylation by p38 MAPK plays an important role in RINm5F cell death under
      high glucose conditions.
AD  - Unidad de Investigacion Medica en Bioquimica, HE, Centro Medico Nacional Siglo
      XXI. IMSS., Av. Cuauhtemoc 330, Col Doctores, Del. Cuauhtemoc, Mexico, DF,
      Mexico.
FAU - Flores-Lopez, Luis A
AU  - Flores-Lopez LA
FAU - Diaz-Flores, Margarita
AU  - Diaz-Flores M
FAU - Garcia-Macedo, Rebeca
AU  - Garcia-Macedo R
FAU - Avalos-Rodriguez, Alejandro
AU  - Avalos-Rodriguez A
FAU - Vergara-Onofre, Marcela
AU  - Vergara-Onofre M
FAU - Cruz, Miguel
AU  - Cruz M
FAU - Contreras-Ramos, Alejandra
AU  - Contreras-Ramos A
FAU - Konigsberg, Mina
AU  - Konigsberg M
FAU - Ortega-Camarillo, Clara
AU  - Ortega-Camarillo C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/08/29 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 10.1007/s11033-013-2595-2 [doi]
PST - aheadofprint
SO  - Mol Biol Rep. 2013 May 9.

PMID- 23657563
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
DP  - 2013 May 9
TI  - Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in
      Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation.
AB  - PURPOSE: The increase in endothelin-1 (ET-1) and the decrease in endothelial
      nitric oxide synthase (eNOS) both induce vasoconstriction and lead to molecular
      changes associated with diabetes mellitus and atherosclerosis. Glucagon-like
      peptide-1 (GLP-1) activation stimulates insulin secretion and may prevent
      atherosclerosis by increasing eNOS synthesis. However, there is paucity of
      information on the effect of GLP-1 activation on ET-1 expression. This study was 
      conducted to address this issue. METHODS AND RESULTS: Human umbilical vein
      endothelial cells (HUVECs) were incubated with different concentrations of
      liraglutide, a GLP-1 agonist, and the expression of ET-1 and eNOS and activity of
      NF-kappaB were measured. Liraglutide, in a concentration-dependent manner, was
      observed to promote eNOS expression and to inhibit ET-1 expression both at mRNA
      and protein levels. Liraglutide also inhibited NF-kappaB phosphorylation and its 
      translocation from cytoplasm to the nucleus. To ascertain the role of NF-kappaB
      activation in the altered expression of ET-1 and eNOS, we treated HUVECs with
      phorbol 12-myristate 13-acetate (PMA). PMA activated NF-kappaB and reversed the
      effects of liraglutide on eNOS and ET-1 expression. The effects of PMA on eNOS
      and ET-1 expression were reproduced in experiments wherein cells were treated
      with TNF-alpha. Further, we measured the generation of IL-6, apowerful
      pro-inflammatory molecule released by endothelial cells, as a measure of cellular
      function. PMA increased IL-6 generation, and this effect was blocked by
      liraglutide. CONCLUSIONS: Our observations suggest liraglutide suppresses ET-1
      expression by inhibiting the phosphorylation of NF-kappaB. This mechanism may
      underlie the potential anti-atherosclerotic effects of GLP-1 agonists. Of note,
      these effects of liraglutide were seen in an in vitro setting wherein cellular
      glucose concentrations were elevated.
AD  - Department of Endocrinology, The First Affiliated Hospital of Anhui Medical
      University, Hefei, Anhui, People's Republic of China.
FAU - Dai, Yao
AU  - Dai Y
FAU - Mehta, Jawahar L
AU  - Mehta JL
FAU - Chen, Mingwei
AU  - Chen M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy / sponsored by the International Society of
      Cardiovascular Pharmacotherapy
JID - 8712220
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1007/s10557-013-6463-z [doi]
PST - aheadofprint
SO  - Cardiovasc Drugs Ther. 2013 May 9.

PMID- 23657549
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
DP  - 2013 May 8
TI  - Survival in patients with acute kidney injury requiring dialysis after coronary
      artery bypass grafting.
AB  - OBJECTIVES: The aim was a nationwide analysis of need for dialysis and survival
      in all patients who had coronary artery bypass grafting (CABG) in Sweden during
      2002 up to 2008. METHODS: Primary isolated CABG was performed in 28 220 patients 
      without preoperative need for dialysis. Survival was analysed in patients
      suffering postoperative acute kidney injury requiring dialysis. RESULTS:
      Postoperative dialysis was needed in 162 patients (0.6%). Old age, female gender,
      reduced glomerular filtration rate (GFR), diabetes mellitus, peripheral vascular 
      disease, chronic obstructive pulmonary disease, prior myocardial infarction,
      prior stroke and reduced left ventricular function were associated with need for 
      dialysis. Only 0.3% of the patients with GFR >60 ml/min/1.73 m2 needed
      postoperative dialysis compared with 9.5% if GFR was <30 ml/min/1.73 m2. Sixteen 
      of 54 patients (27%) with GFR <30 l/min/1.73 m2 and a >/=50% increase in
      postoperative serum creatinine needed dialysis. There were 42 deaths (26%) within
      30 days in patients who needed dialysis and 1% if dialysis was not required.
      Early mortality was markedly higher in patients who required dialysis than in
      those without dialysis after multivariable adjustment for age, sex, diabetes
      mellitus, left ventricular function and GFR (odds ratio 19, 95% confidence
      interval 13-29). The corresponding risk of late death was 2-fold higher in
      patients who survived for 90 days and had required dialysis compared with those
      who did not (hazard ratio 2.4, 95% confidence interval 1.7-3.3). Five-year
      survival was 43 and 89%, respectively. The risk of death increased with age.
      Five-year survival after dialysis was 66% in patients younger than 65 years, but 
      32% in those aged over 70 years. Fifty-one per cent (14 of 27) of patients 80
      years of age or older who required dialysis died early compared with 3% (68 of
      2426) of those who did not (P < 0.001). Nine survivors who needed dialysis
      developed end-stage renal disease. CONCLUSIONS: Need for dialysis after
      non-emergency was an uncommon serious complication associated with high early
      mortality and an increased risk of late death. Old age and impaired preoperative 
      renal function were strong predictors of need for dialysis after CABG.
      Postoperative dialysis after CABG was a marker of poor outcome but could, in some
      patients, be life-saving.
AD  - Department of Cardiothoracic Surgery and Anaesthesiology, Karolinska University
      Hospital, Stockholm, Sweden.
FAU - Ivert, Torbjorn
AU  - Ivert T
FAU - Holzmann, Martin J
AU  - Holzmann MJ
FAU - Sartipy, Ulrik
AU  - Sartipy U
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European
      Association for Cardio-thoracic Surgery
JID - 8804069
OTO - NOTNLM
OT  - Coronary artery bypass grafting
OT  - Dialysis
OT  - Survival
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - ezt247 [pii]
AID - 10.1093/ejcts/ezt247 [doi]
PST - aheadofprint
SO  - Eur J Cardiothorac Surg. 2013 May 8.

PMID- 23657502
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1523-1747 (Electronic)
IS  - 0022-202X (Linking)
DP  - 2013 May 8
TI  - Risk of rosacea in patients with diabetes using insulin or oral antidiabetic
      drugs.
LID - 10.1038/jid.2013.225 [doi]
AD  - 1] Basel Pharmacoepidemiology Unit, Division ofClinical Pharmacy and
      Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, 
      Switzerland [2] Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
FAU - Spoendlin, J
AU  - Spoendlin J
FAU - Voegel, J J
AU  - Voegel JJ
FAU - Jick, S S
AU  - Jick SS
FAU - Meier, Ch R
AU  - Meier CR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/05/08 [aheadofprint]
AID - jid2013225 [pii]
AID - 10.1038/jid.2013.225 [doi]
PST - aheadofprint
SO  - J Invest Dermatol. 2013 May 8. doi: 10.1038/jid.2013.225.

PMID- 23657467
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130509
DCOM- 20130510
LR  - 20130515
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 5
DP  - 2013
TI  - Does contact with a podiatrist prevent the occurrence of a lower extremity
      amputation in people with diabetes? A systematic review and meta-analysis.
LID - 10.1136/bmjopen-2012-002331 [doi]
LID - e002331 [pii]
AB  - OBJECTIVE: To determine the effect of contact with a podiatrist on the occurrence
      of Lower Extremity Amputation (LEA) in people with diabetes. DESIGN AND DATA
      SOURCES: We conducted a systematic review of available literature on the effect
      of contact with a podiatrist on the risk of LEA in people with diabetes. Eligible
      studies, published in English, were identified through searches of PubMed,
      CINAHL, EMBASE and Cochrane databases. The key terms, 'podiatry', 'amputation'
      and 'diabetes', were searched as Medical Subject Heading terms. Reference lists
      of selected papers were hand-searched for additional articles. No date
      restrictions were imposed. STUDY SELECTION: Published randomised and analytical
      observational studies of the effect of contact with a podiatrist on the risk of
      LEA in people with diabetes were included. Cross-sectional studies, review
      articles, chart reviews and case series were excluded. Two reviewers
      independently assessed titles, abstracts and full articles to identify eligible
      studies and extracted data related to the study design, characteristics of
      participants, interventions, outcomes, control for confounding factors and risk
      estimates. ANALYSIS: Meta-analysis was performed separately for randomised and
      non-randomised studies. Relative risks (RRs) with 95% CIs were estimated with
      fixed and random effects models as appropriate. RESULTS: Six studies met the
      inclusion criteria and five provided data included in meta-analysis. The
      identified studies were heterogenous in design and included people with diabetes 
      at both low and high risk of amputation. Contact with a podiatrist did not
      significantly affect the RR of LEA in a meta-analysis of available data from
      randomised controlled trials (RCTs); (1.41, 95% CI 0.20 to 9.78, 2 RCTs) or from 
      cohort studies; (0.73, 95% CI 0.39 to 1.33, 3 Cohort studies with four substudies
      in one cohort). CONCLUSIONS: There are very limited data available on the effect 
      of contact with a podiatrist on the risk of LEA in people with diabetes.
AD  - Department of General Practice, University College Cork, Cork, Ireland.
FAU - Buckley, C M
AU  - Buckley CM
FAU - Perry, I J
AU  - Perry IJ
FAU - Bradley, C P
AU  - Bradley CP
FAU - Kearney, P M
AU  - Kearney PM
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3651976
OID - NLM: PMC3651976
OTO - NOTNLM
OT  - Vascular surgery
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:01
CRDT- 2013/05/10 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2012-002331 [pii]
AID - 10.1136/bmjopen-2012-002331 [doi]
PST - epublish
SO  - BMJ Open. 2013 May 8;3(5). pii: e002331. doi: 10.1136/bmjopen-2012-002331. Print 
      2013.

PMID- 23657268
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Linking)
DP  - 2013 May 14
TI  - Acute coronary syndrome behavior: results of a Brazilian registry.
LID - S0066-782X2013005000034 [pii]
AB  - BACKGROUND: Brazil lacks published multicenter registries of acute coronary
      syndrome. OBJECTIVE: The Brazilian Registry of Acute Coronary Syndrome is a
      multicenter national study aiming at providing data on clinical aspects,
      management and hospital outcomes of acute coronary syndrome in our country.
      METHODS: A total of 23 hospitals from 14 cities, participated in this study.
      Eligible patients were those who came to the emergency wards with suspected acute
      coronary syndrome within the first 24 hours of symptom onset, associated with
      compatible electrocardiographic alterations and/or altered necrosis biomarkers.
      Follow-up lasted until hospital discharge or death, whichever occurred first.
      RESULTS: Between 2003 and 2008, 2,693 ACS patients were enrolled, of which 864
      (32.1%) were females. T he final diagnosis was unstable angina in 1,141 patients,
      (42.4%), with a mortality rate of 3.06%, non-ST elevation acute myocardial
      infarction (AMI) in 529 (19.6%), with mortality of 6.8%, ST-elevation AMI 950
      (35.3%), with mortality of 8.1% and non-confirmed diagnosis 73 (2.7%), with
      mortality of 1.36%. The overall mortality was 5.53%. The multiple logistic
      regression model identified the following as risk factors for death regarding
      demographic factors and interventions: female gender (OR=1.45), diabetes mellitus
      (OR=1.59), body mass index (OR=1.27) and percutaneous coronary intervention
      (OR=0.70). A second model for death due to major complications identified:
      cardiogenic shock/acute pulmonary edema (OR=4.57), reinfarction (OR=3.48), stroke
      (OR=21.56), major bleeding (OR=3.33), cardiopulmonary arrest (OR=40.27) and
      Killip functional class (OR=3.37). CONCLUSION: The Brazilian Registry of Acute
      Coronary Syndrome data do not differ from other data collected abroad. The
      understanding of their findings may help promote better planning and management
      of acute coronary syndrome care in public and private health services.
AD  - Instituto Dante Pazzanese de Cardiologia, Sao Paulo, SP.
FAU - Piegas, Leopoldo Soares
AU  - Piegas LS
FAU - Avezum, Alvaro
AU  - Avezum A
FAU - Guimaraes, Helio Penna
AU  - Guimaraes HP
FAU - Muniz, Antonio Jose
AU  - Muniz AJ
FAU - Reis, Helder J L
AU  - Reis HJ
FAU - Santos, Elizabete Silva Dos
AU  - Santos ES
FAU - Knobel, Marcos
AU  - Knobel M
FAU - Souza, Roberta de
AU  - Souza RD
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
TT  - Comportamento da sindrome coronariana aguda: resultados de um registro
      brasileiro.
DEP - 20130514
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/04/09 [received]
PHST- 2012/11/19 [accepted]
AID - S0066-782X2013005000034 [pii]
PST - aheadofprint
SO  - Arq Bras Cardiol. 2013 May 14. pii: S0066-782X2013005000034.

PMID- 23657252
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Linking)
DP  - 2013 May 9
TI  - beta-Adrenoceptor-mediated regulation of glucose uptake in skeletal
      muscle-ligand-directed signalling or a reflection of system complexity?
AB  - The capacity of G protein-coupled receptors (GPCRs) to activate multiple G
      protein isoforms and additional effectors such as beta-arrestins has become a
      well-established paradigm and provides the basis for developing drugs that
      preferentially activate beneficial signalling pathways. There are many published 
      examples of ligand-directed signalling, and recent studies have provided direct
      evidence that different agonists stabilise distinct GPCR conformations. This
      field is rapidly evolving, but a key question is whether signalling bias observed
      in heterologous cell expression systems can be translated to physiological
      systems of therapeutic relevance. The paper by Ngala et al. in this issue of the 
      journal addresses the capacity of agonists acting at the beta2-adrenoceptor to
      engender signalling bias in relation to glucose uptake in isolated skeletal
      muscle, an area of considerable potential interest in targeting
      insulin-independent pathways for the treatment of type 2 diabetes. The authors
      show that clenbuterol and BRL37344 have opposite effects on glucose uptake,
      despite both having agonist actions at beta2-adrenoceptors. This study underlines
      some of the obstacles associated with studies in a complex physiological system
      but nonetheless highlights the need to consider signalling bias in the relevant
      target tissue when developing novel drugs.
AD  - Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 399 Royal
      Parade, Parkville, Melbourne, VIC, 3052, Australia.
FAU - Evans, Bronwyn A
AU  - Evans BA
FAU - Hutchinson, Dana S
AU  - Hutchinson DS
FAU - Summers, Roger J
AU  - Summers RJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/04/21 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 10.1007/s00210-013-0879-7 [doi]
PST - aheadofprint
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2013 May 9.

PMID- 23657174
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
DP  - 2013 May 8
TI  - Admission Hyperglycemia Predicts Inhospital Mortality and Major Adverse Cardiac
      Events After Primary Percutaneous Coronary Intervention in Patients Without
      Diabetes mellitus.
AB  - Admission hyperglycemia is associated with high inhospital and long-term adverse 
      events in patients that undergo primary percutaneous coronary intervention (PCI).
      We aimed to evaluate whether hyperglycemia predicts inhospital mortality. We
      prospectively analyzed 503 consecutive patients. The patients were divided into
      tertiles according to the admission glucose levels. Tertile I: glucose <118 mg/dL
      (n = 166), tertile II: glucose 118 to 145 mg/dL (n = 168), and tertile III:
      glucose >145 mg/dL (n = 169). Inhospital mortality was 0 in tertile I, 2 in
      tertile II, and 9 in tertile III (P < .02). Cardiogenic shock occurred more
      frequently in tertile III compared to tertiles I and II (10% vs 4.1% and 0.6%,
      respectively, P = .01). Multivariate logistic regression analysis revealed that
      patients in tertile III had significantly higher risk of inhospital major adverse
      cardiac events compared to patients in tertile I (odds ratio: 9.55, P < .02).
      Admission hyperglycemia predicts inhospital adverse cardiac events in mortality
      and acute ST-segment elevation myocardial infarction in patients that underwent
      primary PCI.
AD  - 1Clinic of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery
      Center Training and Research Hospital, Istanbul, Turkey.
FAU - Ekmekci, Ahmet
AU  - Ekmekci A
FAU - Cicek, Gokhan
AU  - Cicek G
FAU - Uluganyan, Mahmut
AU  - Uluganyan M
FAU - Gungor, Baris
AU  - Gungor B
FAU - Osman, Faizel
AU  - Osman F
FAU - Ozcan, Kazim Serhan
AU  - Ozcan KS
FAU - Bozbay, Mehmet
AU  - Bozbay M
FAU - Ertas, Gokhan
AU  - Ertas G
FAU - Zencirci, Aycan
AU  - Zencirci A
FAU - Sayar, Nurten
AU  - Sayar N
FAU - Eren, Mehmet
AU  - Eren M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Angiology
JT  - Angiology
JID - 0203706
OTO - NOTNLM
OT  - ST-segment elevation myocardial infarction
OT  - hyperglycemia
OT  - major adverse cardiac events
OT  - mortality
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 0003319713488930 [pii]
AID - 10.1177/0003319713488930 [doi]
PST - aheadofprint
SO  - Angiology. 2013 May 8.

PMID- 23657152
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1473-6519 (Electronic)
IS  - 1363-1950 (Linking)
VI  - 16
IP  - 4
DP  - 2013 Jul
TI  - High-sugar diets, type 2 diabetes and Alzheimer's disease.
PG  - 440-5
LID - 10.1097/MCO.0b013e328361c7d1 [doi]
AB  - PURPOSE OF REVIEW: Recent findings suggest that high-sugar diets can lead to
      cognitive impairment predisposing to neurodegenerative disorders such as
      Alzheimer's disease. This article discusses metabolic derangements induced by
      high-fructose/sucrose diets and presents evidence for the involvement of insulin 
      resistance in sporadic Alzheimer's disease pathogenesis. RECENT FINDINGS: There
      has been much concern regarding the role of dietary sugars (fructose/sucrose) in 
      the development of type 2 diabetes (T2D). Accumulating evidence has also
      demonstrated a connection between T2D and Alzheimer's disease. The risk for
      developing T2D and Alzheimer's disease increases exponentially with age and
      having T2D increases the risk of developing Alzheimer's disease. SUMMARY: The
      incidence of T2D increased dramatically over the last decades mainly due to
      Western lifestyle factors such as lack of exercise and high calorie diets. In
      fact, high-sugar diets are thought to promote weight gain and insulin resistance 
      predisposing to T2D. To aggravate this scenario, it has been consistently shown
      that T2D is a risk factor for Alzheimer's disease and both disorders share
      similar demographic profiles, risk factors, and clinical and biochemical features
      (e.g. insulin resistance). Therefore, dietary changes can significantly reduce
      the risk of T2D and Alzheimer's disease and thereby increase the quality of life 
      and improve longevity.
AD  - aLaboratory of Physiology, Faculty of Medicine, University of Coimbra bCenter for
      Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
FAU - Moreira, Paula I
AU  - Moreira PI
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Clin Nutr Metab Care
JT  - Current opinion in clinical nutrition and metabolic care
JID - 9804399
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1097/MCO.0b013e328361c7d1 [doi]
PST - ppublish
SO  - Curr Opin Clin Nutr Metab Care. 2013 Jul;16(4):440-5. doi:
      10.1097/MCO.0b013e328361c7d1.

PMID- 23657074
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1536-5948 (Electronic)
IS  - 1076-2752 (Linking)
VI  - 55
IP  - 5
DP  - 2013 May
TI  - Advancing Workplace Health Protection and Promotion for an Aging Workforce.
PG  - 500-506
AB  - OBJECTIVE:: To explore issues related to the aging workforce, including barriers 
      to integrating health protection and promotion programs, and provide
      recommendations for best practices to maximize contributions by aging workers.
      METHODS:: Workgroups reviewed literature and case studies to develop consensus
      statements and recommendations for a national approach to issues related to older
      workers. RESULTS:: Consensus statements and actions steps were identified for
      each of the Summit goals and call-to-action statements were developed.
      CONCLUSIONS:: A national dialogue to build awareness of integrated health
      protection and promotion for the aging workforce is needed. Workers will benefit 
      from improved health and performance; employers will realize a more engaged and
      productive workforce; and the nation will gain a vital, competitive workforce.
AD  - From US Preventive Medicine (Dr Loeppke), Brentwood, Tenn; National Institute for
      Occupational Safety and Health (Dr Schill), Washington, DC; Total Worker Health
      (Dr Chosewood), National Institute for Occupational Safety and Health, Centers
      for Disease Control and Prevention, Atlanta, Ga; National Institute for
      Occupational Safety and Health (Dr Grosch), Centers for Disease Control and
      Prevention, Cincinnati, Ohio; Division of Diabetes Translation (Dr Allweiss),
      Centers for Disease Control and Prevention, Atlanta, Ga; American
      Express-Wellness Center (Dr Burton), New York, NY; Department of Psychology (Dr
      Barnes-Farrell), University of Connecticut, Storrs; Institute for Health and
      Productivity Studies (Dr Goetzel), Rollins School of Public Health, Emory
      University, Washington, DC; Consulting and Applied Research (Dr Goetzel),
      Analytic Consulting and Research Services, Truven Health Analytics, Bethesda, Md;
      Institute on Innovation in Workforce Well-being (Ms Heinen) and Institute on
      Health, Productivity and Human Capital (Ms Heinen), National Business Group on
      Health, Washington, DC; Occupational Health Facility (Dr Hudson), University of
      California, Los Angeles, Medical Center, Los Angeles; Walt Disney Parks and
      Resorts (Dr Hymel), Burbank, Calif; Department of Preventive Medicine and
      Environmental Health (Dr Merchant), University of Iowa, Iowa City; Health
      Management Research Center (Dr Edington), University of Michigan, Ann Arbor; KDK 
      Solutions, Ltd (Ms Konicki), Chicago, Ill; and Paul Larson Communications (Mr
      Larson), Evanston, Ill.
FAU - Loeppke, Ronald R
AU  - Loeppke RR
FAU - Schill, Anita L
AU  - Schill AL
FAU - Chosewood, L Casey
AU  - Chosewood LC
FAU - Grosch, James W
AU  - Grosch JW
FAU - Allweiss, Pamela
AU  - Allweiss P
FAU - Burton, Wayne N
AU  - Burton WN
FAU - Barnes-Farrell, Janet L
AU  - Barnes-Farrell JL
FAU - Goetzel, Ron Z
AU  - Goetzel RZ
FAU - Heinen, Luann
AU  - Heinen L
FAU - Hudson, T Warner
AU  - Hudson TW
FAU - Hymel, Pamela
AU  - Hymel P
FAU - Merchant, James
AU  - Merchant J
FAU - Edington, Dee W
AU  - Edington DW
FAU - Konicki, Doris L
AU  - Konicki DL
FAU - Larson, Paul W
AU  - Larson PW
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - J Occup Environ Med
JT  - Journal of occupational and environmental medicine / American College of
      Occupational and Environmental Medicine
JID - 9504688
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1097/JOM.0b013e31829613a4 [doi]
AID - 00043764-201305000-00006 [pii]
PST - ppublish
SO  - J Occup Environ Med. 2013 May;55(5):500-506.

PMID- 23657039
OWN - NLM
STAT- In-Process
DA  - 20130509
IS  - 2169-981X (Electronic)
VI  - 29
IP  - 2
DP  - 2013 Mar-Apr
TI  - Inpatient insulin pump therapy: assessing the effectiveness of an educational
      program.
PG  - 84-9
LID - 10.1097/NND.0b013e318286c5da [doi]
AB  - Technological advances in diabetes management include continuous subcutaneous
      insulin infusion. This article describes a pilot project using an educational
      intervention by a diabetes nurse educator aimed at familiarizing nurses with
      insulin pump therapy at a large teaching hospital. Teaching points included
      appropriate patient selection, principles of insulin therapy, and safe insulin
      pump operation. An embedded mixed-method design was employed to assess
      educational effectiveness. Results of the pretest and posttest analysis indicated
      that the program significantly increased knowledge and confidence among nurses
      for managing pump therapy.
AD  - Loma Linda University Medical Center, Loma Linda, California 92354, USA.
      tjsweeney23@gmail.com
FAU - Sweeney, Thomas J
AU  - Sweeney TJ
FAU - Kenny, Deborah J
AU  - Kenny DJ
FAU - Schubert, Christiane C
AU  - Schubert CC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Nurses Prof Dev
JT  - Journal for nurses in professional development
JID - 101603887
SB  - N
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1097/NND.0b013e318286c5da [doi]
AID - 01709760-201303000-00008 [pii]
PST - ppublish
SO  - J Nurses Prof Dev. 2013 Mar-Apr;29(2):84-9. doi: 10.1097/NND.0b013e318286c5da.

PMID- 23657005
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 13
DP  - 2013
TI  - Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus 
      patients: a randomized double-blind, placebo-controlled study.
PG  - 81
LID - 10.1186/1471-230X-13-81 [doi]
AB  - BACKGROUND: Recently, the relationship between gut microbiota and obesity has
      been highlighted. The present randomized, double-blind, placebo-controlled study 
      aimed to evaluate the efficacy of transglucosidase (TGD) in modulating blood
      glucose levels and body weight gain in patients with type 2 diabetes mellitus
      (T2DM) and to clarify the underlying mechanism by analyzing the gut microbiota of
      T2DM patients. METHODS: This study included 60 patients who received placebo or
      TGD orally (300 or 900 mg/day) for 12 weeks, and blood and fecal samples were
      collected before and after 12 weeks. Comparisons of fecal bacterial communities
      were performed before and after the TGD treatment and were performed between T2DM
      patients and 10 healthy individuals, using the terminal-restriction fragment
      length polymorphism analysis. RESULTS: The Clostridium cluster IV and subcluster 
      XIVa components were significantly decreased, whereas the Lactobacillales and
      Bifidobacterium populations significantly increased in the T2DM patients compared
      with the healthy individuals. By dendrogram analysis, most of the healthy
      individuals (6/10) and T2DM patients (45/60) were classified into cluster I,
      indicating no significant difference in fecal bacterial communities between the
      healthy individuals and the T2DM patients. In the placebo and TGD groups, the
      bacterial communities were generally similar before and after the treatment.
      However, after 12 weeks of TGD therapy, the Bacteroidetes-to-Firmicutes ratio in 
      the TGD groups significantly increased and was significantly higher compared with
      that in the placebo group, indicating that TGD improved the growth of the fecal
      bacterial communities in the T2DM patients. CONCLUSIONS: Therefore, TGD treatment
      decreased blood glucose levels and prevented body weight gain in the T2DM
      patients by inducing the production of oligosaccharides in the alimentary tract
      and modulating gut microbiota composition. TRIAL REGISTRATION: UMIN-CTR
      UMIN000010318.
AD  - Department of Gastroenterology, Aichi Medical University School of Medicine, 1-1 
      Yazakokarimata, Nagakute, Aichi 480-1195, Japan. msasaki@aichi-med-u.ac.jp.
FAU - Sasaki, Makoto
AU  - Sasaki M
FAU - Ogasawara, Naotaka
AU  - Ogasawara N
FAU - Funaki, Yasushi
AU  - Funaki Y
FAU - Mizuno, Mari
AU  - Mizuno M
FAU - Iida, Akihito
AU  - Iida A
FAU - Goto, Chiho
AU  - Goto C
FAU - Koikeda, Satoshi
AU  - Koikeda S
FAU - Kasugai, Kunio
AU  - Kasugai K
FAU - Joh, Takashi
AU  - Joh T
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
SB  - IM
PMC - PMC3658914
OID - NLM: PMC3658914
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/12/11 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 1471-230X-13-81 [pii]
AID - 10.1186/1471-230X-13-81 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2013 May 8;13:81. doi: 10.1186/1471-230X-13-81.

PMID- 23657002
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1460-2377 (Electronic)
IS  - 0953-8178 (Linking)
DP  - 2013 May 8
TI  - Linking the microbiota and metabolic disease with lymphotoxin.
AB  - The field of lymphotoxin biology has seen many advances in the past decade.
      Notably, a role for lymphotoxin as a key effector cytokine has emerged to add to 
      its foundational contribution to lymphoid organogenesis. It is now clear that
      lymphotoxin contributes to host defense for a wide variety of pathogens, and the 
      lymphotoxin receptor is a defining feature of and regulatory mechanism in both
      innate and adaptive immunities. Specifically, lymphotoxin contributes to Th
      education, licensing of IL-22 production from type 3 innate lymphoid cells, and
      even maintains innate myeloid populations within the fully developed lymph node. 
      Most recently, lymphotoxin has been implicated in regulation of the microbiota
      and metabolic disease. Early studies revealed that lymphotoxin might influence
      composition of the commensal microbiota through its regulation of immunological
      compartmentalization in the gut. Additionally, several epidemiological studies
      have linked polymorphisms in lymphotoxin to metabolic disease. Studies exploring 
      the role of lymphotoxin in metabolic disease have demonstrated that lymphotoxin
      may influence metabolism both directly in the liver and indirectly through
      regulation of gut immune responses. It now appears that lymphotoxin may bridge
      the gap between altered composition of the commensal microbiota and metabolism.
AD  - Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
FAU - Upadhyay, Vaibhav
AU  - Upadhyay V
FAU - Fu, Yang-Xin
AU  - Fu YX
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Int Immunol
JT  - International immunology
JID - 8916182
OTO - NOTNLM
OT  - SFB
OT  - diabetes
OT  - lymphotoxin
OT  - metabolism
OT  - microbiota
OT  - obesity
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - dxt018 [pii]
AID - 10.1093/intimm/dxt018 [doi]
PST - aheadofprint
SO  - Int Immunol. 2013 May 8.

PMID- 23657001
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1460-2377 (Electronic)
IS  - 0953-8178 (Linking)
DP  - 2013 May 8
TI  - Killer Treg cells ameliorate inflammatory insulitis in non-obese diabetic mice
      through local and systemic immunomodulation.
AB  - Treg cells endowed with enhanced killing activity through decoration with
      Fas-ligand (FasL) protein (killer Treg) have been effective in delay of
      hyperglycemia in prediabetic non-obese diabetic (NOD) mice. In this study, we
      assessed the therapeutic efficacy of these cells, harvested from age-matched
      euglycemic NOD donors, on the course of disease in new-onset diabetics. One dose 
      of 4 x 106 killer Treg cells stabilized blood glucose associated with increased
      insulin levels in 5 of 9 mice and partially reversed the severity of islet
      inflammation, whereas naive Treg cells did not modulate the course of disease
      significantly. Killer Treg cells were shown to operate through induction of cell 
      apoptosis within the pancreatic lymph nodes, resulting in reduced efficiency of
      adoptive disease transfer to NOD/SCID recipients. A second mechanism of action
      consisted of increased fractions of CD4+CD25-FoxP3+ T cells in the pancreas and
      all lymphoid organs. Immunomodulation with FasL rather than Treg cells enhanced
      the expression of CD25 and FoxP3 in the thymus, suggesting a possible
      contribution of thymic output to prolonged stabilization of the glucose levels.
      Autologous Treg cells evolve as excellent vehicles for targeted delivery of FasL 
      as an immunomodulatory protein, which delete pathogenic cells at the site of
      inflammation and induce systemic dominance of suppressor subsets.
AD  - Frankel Laboratory, Center for Stem Cell Research, Schneider Children's Medical
      Center of Israel, Petach Tikva 49202, Israel.
FAU - Kaminitz, Ayelet
AU  - Kaminitz A
FAU - Yolcu, Esma S
AU  - Yolcu ES
FAU - Mizrahi, Keren
AU  - Mizrahi K
FAU - Shirwan, Haval
AU  - Shirwan H
FAU - Askenasy, Nadir
AU  - Askenasy N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Int Immunol
JT  - International immunology
JID - 8916182
OTO - NOTNLM
OT  - Fas-ligand
OT  - NOD mice
OT  - destructive insulitis
OT  - killer Treg
OT  - new-onset diabetes
OT  - regulatory T cell
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - dxt016 [pii]
AID - 10.1093/intimm/dxt016 [doi]
PST - aheadofprint
SO  - Int Immunol. 2013 May 8.

PMID- 23656997
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
DP  - 2013 May 7
TI  - Single-Nucleotide Polymorphisms in Adiponectin, AdipoR1, and AdipoR2 Genes:
      Insulin Resistance and Type 2 Diabetes Mellitus Candidate Genes.
AB  - It has already been a decade and a half since the discovery of adiponectin and
      its role as an insulin sensitizer and only 7 years since its receptors, AdipoR1
      and AdipoR2, were described. A single-nucleotide polymorphism (SNP) is a DNA
      sequence variation that affects only one nucleotide; it may vary from one
      population to another with different predisposing factors to diseases and other
      ailments. Once some of the effects of adiponectin and its receptors were known,
      it was not long until an effort was made to find the associations between
      specific SNPs of the genes of this hormone and its receptors as genetic risk
      factors for insulin resistance, type 2 diabetes mellitus, and metabolic syndrome,
      although these genes were investigated as possible candidates related to the
      development of these metabolic disorders. All of these possible associations were
      studied in different populations from France, Finland, the United Kingdom, North 
      America, and Japan, showing hardly concluding results, and because of that it is 
      highly controversial to directly associate one of the genes mentioned above to
      insulin resistance, type 2 diabetes mellitus, and metabolic syndrome. All of
      these inconsistencies lead to a review that summarizes the SNPs of the genes of
      adiponectin, AdipoR1, and AdipoR2 that are mostly related to insulin resistance
      syndrome, type 2 diabetes mellitus, and metabolic syndrome, although presenting
      the possible factors that should be taken into account to homogenize the results 
      obtained until now.
AD  - 1Biochemistry Department, Endocrine and Metabolic Diseases Research Center,
      School of Medicine, University of Zulia, Maracaibo, Venezuela 2Clinical
      Pharmacologic Unit, Vargas Medical School, Central University of Venezuela,
      Caracas, Venezuela.
FAU - Bermudez, Valmore J
AU  - Bermudez VJ
FAU - Rojas, Edward
AU  - Rojas E
FAU - Toledo, Alexandra
AU  - Toledo A
FAU - Rodriguez-Molina, Daloha
AU  - Rodriguez-Molina D
FAU - Vega, Keren
AU  - Vega K
FAU - Suarez, Luis
AU  - Suarez L
FAU - Pacheco, Maikol
AU  - Pacheco M
FAU - Canelon, Roger
AU  - Canelon R
FAU - Arraiz, Nailet
AU  - Arraiz N
FAU - Rojas, Joselyn
AU  - Rojas J
FAU - Velasco, Manuel
AU  - Velasco M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1097/MJT.0b013e318235f206 [doi]
PST - aheadofprint
SO  - Am J Ther. 2013 May 7.

PMID- 23656982
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 8
TI  - Estimating the Population Prevalence of Diagnosed and Undiagnosed Diabetes.
AB  - OBJECTIVEHealth administrative data are frequently used for diabetes
      surveillance, but validation studies are limited, and undiagnosed diabetes has
      not been considered in previous studies. We compared the test properties of an
      administrative definition with self-reported diabetes and estimated prevalence of
      undiagnosed diabetes by measuring glucose levels in mailed-in capillary blood
      samples.RESEARCH DESIGN AND METHODSA stratified random sample of 6,247
      individuals (Quebec province) was surveyed by telephone and asked to mail in
      fasting blood samples on filter paper to a central laboratory. An administrative 
      definition was applied (two physician claims or one hospitalization for diabetes 
      within a 2-year period) and compared with self-reported diabetes alone and with
      self-reported diabetes or elevated blood glucose level (>/=7 mmol/L).
      Population-level prevalence was estimated with the use of the administrative
      definition corrected for its sensitivity and specificity.RESULTSCompared with
      self-reported diabetes, sensitivity and specificity were 84.3% (95% CI
      79.3-88.5%) and 97.9% (97.4-98.4%), respectively. Compared with diabetes by
      self-report and/or glucose testing, sensitivity was lower at 58.2% (52.2-64.6%), 
      whereas specificity was similar at 98.7% (98.0-99.3%). Adjusted for sampling
      weights, population-level prevalence of physician-diagnosed diabetes was 7.2%
      (6.3-8.0%). Prevalence of total diabetes (physician-diagnosed and undiagnosed)
      was 13.4% (11.7-15.0%), indicating that approximately 40% of diabetes cases are
      undiagnosed.CONCLUSIONSA substantial proportion of diabetes cases are missed by
      surveillance methods that use health administrative databases. This finding is
      concerning because individuals with undiagnosed diabetes are likely to have a
      delay in treatment and, thus, a higher risk for diabetes-related complications.
AD  - Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
FAU - Leong, Aaron
AU  - Leong A
FAU - Dasgupta, Kaberi
AU  - Dasgupta K
FAU - Chiasson, Jean-Louis
AU  - Chiasson JL
FAU - Rahme, Elham
AU  - Rahme E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - dc12-2543 [pii]
AID - 10.2337/dc12-2543 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 8.

PMID- 23656981
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 8
TI  - Fat Distribution and Glucose Intolerance Among Greenland Inuit.
AB  - OBJECTIVEA high amount of subcutaneous fat is suggested to explain the
      observation of lower obesity-associated metabolic risk among Inuit than among
      Europeans. We examined the association between measures of obesity (visceral
      adipose tissue [VAT], subcutaneous adipose tissue [SAT], BMI, waist circumference
      [WC], and percentage of body fat) and the indices of glucose metabolism (fasting 
      and 2-h glucose levels, insulin resistance per homeostasis model assessment
      [HOMA-IR], and the insulin sensitivity index [ISI0,120]) among Greenland
      Inuit.RESEARCH DESIGN AND METHODSA total of 3,108 adult Inuit participated in a
      population-based study. The examination included a 75-g oral glucose tolerance
      test and anthropometric measurements. VAT and SAT were measured by ultrasound
      according to a validated protocol. Information on sociodemographic
      characteristics and health behaviors was obtained by interview.RESULTSMean SATs
      were 1.8 and 3.5 cm in men and women, respectively. Mean VATs were 7.0 and 6.3 cm
      in men and women, respectively. The total prevalence of type 2 diabetes was 9%.
      Percentage of body fat generally was most strongly associated with all outcomes. 
      Both SAT and VAT were significantly associated with glucose intolerance, fasting 
      and 2-h P-glucose levels, HOMA-IR, and ISI0,120. VAT was more strongly associated
      with all outcomes than was SAT. After further adjustment for BMI or WC, VAT was
      associated with glucose intolerance and insulin resistance, whereas there was a
      trend toward a negative or no association with SAT.CONCLUSIONSHigh mean values of
      SAT may to a large extent explain the high WC in Inuit populations, and this is
      suggested to contribute to the lower observed metabolic risk for a given level of
      obesity.
AD  - Steno Diabetes Center, Gentofte, Denmark.
FAU - Jorgensen, Marit Eika
AU  - Jorgensen ME
FAU - Borch-Johnsen, Knut
AU  - Borch-Johnsen K
FAU - Stolk, Ronald
AU  - Stolk R
FAU - Bjerregaard, Peter
AU  - Bjerregaard P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - dc12-2703 [pii]
AID - 10.2337/dc12-2703 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 8.

PMID- 23656980
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 8
TI  - Characteristics Associated With Maintenance of Mean A1C <6.5% in People With
      Dysglycemia in the ORIGIN Trial.
AB  - OBJECTIVETo assess the success and baseline predictors of maintaining glycemic
      control for up to 5 years of therapy using basal insulin glargine or standard
      glycemic care in people with dysglycemia treated with zero or one oral
      glucose-lowering agentsRESEARCH DESIGN AND METHODSData from 12,537 participants
      in the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial
      were examined by baseline glycemic status (with or without type 2 diabetes) and
      by therapeutic approach (titrated insulin glargine or standard therapy) using an 
      intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and
      A1C and percentages with A1C <6.5% (48 mmol/mol) during randomized treatment were
      calculated. Factors independently associated with maintaining updated mean A1C
      <6.5% were analyzed with linear regression models.RESULTSMedian A1C in the whole 
      population was 6.4% at baseline; at 5 years, it was 6.2% with glargine treatment 
      and 6.5% with standard care. Of those with diabetes at baseline, 60% using
      glargine and 45% using standard care had A1C <6.5% at 5 years. Lack of diabetes
      and lower baseline A1C were independently associated with 5-year mean A1C <6.5%. 
      Maintaining mean A1C <6.5% was more likely with glargine (odds ratio [OR] 2.98
      [95% CI 2.67-3.32], P < 0.001) than standard care after adjustment for other
      independent predictors.CONCLUSIONSSystematic intervention with basal insulin
      glargine or standard care early in the natural history of dysglycemia can
      maintain glycemic control near baseline levels for at least 5 years, whether
      diabetes is present at baseline or not. Keeping mean A1C <6.5% is more likely in 
      people with lower baseline A1C and with the glargine-based regimen.
CN  - The ORIGIN Trial Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - dc12-2238 [pii]
AID - 10.2337/dc12-2238 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 8.

PMID- 23656979
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 8
TI  - Glucose Metabolism After Renal Transplantation.
AB  - OBJECTIVEWe determined prevalence, risk factors, phenotype, and
      pathophysiological mechanism of new-onset diabetes after transplantation (NODAT) 
      to generate strategies for optimal pharmacological management of hyperglycemia in
      NODAT patients.RESEARCH DESIGN AND METHODSRetrospective cohort study comparing
      demographics, laboratory data, and oral glucose tolerance test (OGTT)-derived
      metabolic parameters from kidney transplant recipients versus subjects not
      receiving transplants.RESULTSAmong 1,064 stable kidney transplant recipients
      (>/=6 months posttransplantation), 113 (11%) had a history of NODAT and 132 (12%)
      had pretransplant diabetes. In the remaining patients, randomly assigned OGTTs
      showed a high prevalence of abnormal glucose metabolism (11% diabetes; 32%
      impaired fasting glucose, impaired glucose tolerance, or both), predominantly in 
      older patients who received tacrolimus as the primary immunosuppressant. Compared
      with 1,357 nontransplant subjects, stable kidney transplant recipients had lower 
      basal glucose, higher glycated hemoglobin, lower insulin secretion, and greater
      insulin sensitivity in each of the three subgroups, defined by OGTT 2-h glucose
      (<140, 140-199, >/=200 mg/dL). These findings were reinforced in linear spline
      interpolation models of insulin secretion and sensitivity (all P < 0.001) and in 
      another regression model in which the estimated oral glucose insulin sensitivity 
      index was substantially higher (by 79-112 mL/min m2) for transplant versus
      nontransplant subjects despite adjustments for age, sex, and BMI (all P <
      0.001).CONCLUSIONSGlucose metabolism differs substantially between kidney
      transplant recipients and nontransplant controls. Because impaired insulin
      secretion appears to be the predominant pathophysiological feature after renal
      transplantation, early therapeutic interventions that preserve, maintain, or
      improve beta-cell function are potentially beneficial in this population.
AD  - Department of Nephrology, Medical University of Vienna, Vienna, Austria.
FAU - Hecking, Manfred
AU  - Hecking M
FAU - Kainz, Alexander
AU  - Kainz A
FAU - Werzowa, Johannes
AU  - Werzowa J
FAU - Haidinger, Michael
AU  - Haidinger M
FAU - Doller, Dominik
AU  - Doller D
FAU - Tura, Andrea
AU  - Tura A
FAU - Karaboyas, Angelo
AU  - Karaboyas A
FAU - Horl, Walter H
AU  - Horl WH
FAU - Wolzt, Michael
AU  - Wolzt M
FAU - Sharif, Adnan
AU  - Sharif A
FAU - Roden, Michael
AU  - Roden M
FAU - Moro, Ermanno
AU  - Moro E
FAU - Pacini, Giovanni
AU  - Pacini G
FAU - Port, Friedrich K
AU  - Port FK
FAU - Saemann, Marcus D
AU  - Saemann MD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - dc12-2441 [pii]
AID - 10.2337/dc12-2441 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 8.

PMID- 23656967
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 20
IP  - 3
DP  - 2013 May-Jun
TI  - A review of the etiology, asssociated comorbidities, and treatment of orthostatic
      hypotension.
PG  - 279-91
LID - 10.1097/MJT.0b013e31828bfb7f [doi]
AB  - The magnitude of increase in systolic blood pressure in response to the shift
      from supine to upright posture is considered to reflect the adequacy of
      orthostatic regulation. Orthostatic integrity is largely maintained by the
      interaction between the skeletal muscle pump, neurovascular compensation,
      neurohumoral effects, and cerebral blood flow regulation. Various physiological
      states and disease conditions may disrupt these mechanisms as seen in vasovagal
      syncope, dysautonomic orthostatic intolerance, and postural orthostatic
      tachycardia syndrome. Orthostatic hypotension (OH) and decreased cerebral blood
      flow are strongly related. Even subclinical OH has been associated to different
      degrees with impaired cognitive function, decreased effort, reduced motivation,
      increased hopelessness, and signs of attention-deficit hyperactivity disorder and
      dementia, diabetes mellitus, and Parkinson disease. Furthermore, subclinical
      levels of inadequate blood pressure regulation in response to orthostasis have
      been linked to increased depression and anxiety and intergenerational behavioral 
      sequelae between mother and child. Identifying causes of subclinical and clinical
      OH is critical in improving quality of life for both children and older adults. A
      better understanding of the underlying causes responsible for the etiology of OH 
      could lead to a rational design of novel effective therapeutic regimens for the
      treatment of this condition and associated comorbidities.
AD  - 1Department of Psychology, Rosalind Franklin University of Medicine and Science, 
      North Chicago, IL; 2Chicago Medical School, Rosalind Franklin University of
      Medicine and Science, North Chicago, IL; and 3Department of Cellular and
      Molecular Pharmacology, Chicago Medical School, Rosalind Franklin University of
      Medicine and Science, North Chicago, IL.
FAU - Perlmuter, Lawrence C
AU  - Perlmuter LC
FAU - Sarda, Garima
AU  - Sarda G
FAU - Casavant, Vanessa
AU  - Casavant V
FAU - Mosnaim, Aron D
AU  - Mosnaim AD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1097/MJT.0b013e31828bfb7f [doi]
AID - 00045391-201305000-00010 [pii]
PST - ppublish
SO  - Am J Ther. 2013 May-Jun;20(3):279-91. doi: 10.1097/MJT.0b013e31828bfb7f.

PMID- 23656889
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 8
TI  - Blockade of KCa3.1 Ameliorates Renal Fibrosis Through the TGF-beta1/Smad Pathway 
      in Diabetic Mice.
AB  - The Ca2+-activated K+ channel KCa3.1 mediates cellular signaling processes
      associated with dysfunction of vasculature. However, the role of KCa3.1 in
      diabetic nephropathy is unknown. We sought to assess whether KCa3.1 mediates the 
      development of renal fibrosis in two animal models of diabetic nephropathy.
      Wild-type and KCa3.1-/- mice, and secondly eNOS-/- mice, were induced to diabetes
      with streptozotocin and then treated with/without a selective inhibitor of KCa3.1
      (TRAM34). Our results have shown that the albumin-to-creatinine ratio
      significantly decreased in diabetic KCa3.1-/- mice compared with diabetic
      wild-type mice and in diabetic eNOS-/- mice treated with TRAM34 compared with
      diabetic mice. The expression of monocyte chemoattractant protein-1 (MCP-1),
      intercellular adhesion molecule 1 (ICAM-1), F4/80, plasminogen activator
      inhibitor type 1 (PAI-1), and type III and IV collagen significantly decreased (P
      < 0.01) in kidneys of diabetic KCa3.1-/- mice compared with diabetic wild-type
      mice. Similarly, TRAM34 reduced the expression of inflammatory and fibrotic
      markers described above in diabetic eNOS-/- mice. Furthermore, blocking the
      KCa3.1 channel in both animal models led to a reduction of transforming growth
      factor-beta1 (TGF-beta1), TGF-beta1 type II receptor (TbetaRII), and
      phosphorylation of Smad2/3. Our results provide evidence that KCa3.1 mediates
      renal fibrosis in diabetic nephropathy through the TGF-beta1/Smad signaling
      pathway. Blockade of KCa3.1 may be a novel target for therapeutic intervention in
      patients with diabetic nephropathy.
AD  - Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney Medical
      School, and University of Sydney, St Leonards, Sydney, New South Wales,
      Australia.
FAU - Huang, Chunling
AU  - Huang C
FAU - Shen, Sylvie
AU  - Shen S
FAU - Ma, Qing
AU  - Ma Q
FAU - Chen, Jason
AU  - Chen J
FAU - Gill, Anthony
AU  - Gill A
FAU - Pollock, Carol A
AU  - Pollock CA
FAU - Chen, Xin-Ming
AU  - Chen XM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - db13-0135 [pii]
AID - 10.2337/db13-0135 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 8.

PMID- 23656888
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 8
TI  - Leptin administration enhances islet transplant performance in diabetic mice.
AB  - Islet transplantation is an effective method to obtain long-term glycemic control
      for patients with type 1 diabetes, yet its widespread use is limited by an
      inadequate supply of donor islets. The hormone leptin has profound
      glucose-lowering and insulin-sensitizing action in type 1 diabetic rodent models.
      We hypothesized that leptin administration could reduce the dose of transplanted 
      islets required to achieve metabolic control in a mouse model of type 1 diabetes.
      We first performed a leptin dose response study in C57Bl/6 mice with
      streptozotocin (STZ)-induced diabetes to determine a leptin dose insufficient to 
      reverse hyperglycemia. Subsequently, we compared the ability of suboptimal islet 
      transplants of 50 or 125 syngeneic islets to achieve glycemic control in
      STZ-diabetic C57Bl/6 mice treated with or without this dose of leptin. The dose
      response study revealed that leptin reverses STZ-diabetes in a dose-dependent
      manner. Supraphysiological leptin levels were necessary to restore euglycemia,
      but simultaneously increased risk of hypoglycemia, and also lost efficacy after
      12 days of administration. In contrast, 1 microg/day leptin only modestly reduced
      blood glucose, but maintained efficacy throughout the study duration. We then
      administered 1 microg/day leptin to diabetic mice transplanted with 50 or 125
      islets. While these islet doses were insufficient to ameliorate hyperglycemia
      alone, co-administration of leptin with islet transplantation robustly improved
      control of glucose and lipid metabolism, without increasing circulating insulin
      levels. This study reveals that low-dose leptin administration can reduce the
      number of transplanted islets required to achieve metabolic control in
      STZ-diabetic mice.
AD  - Department of Cellular and Physiological Sciences, Life Sciences Institute,
      University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Denroche, Heather C
AU  - Denroche HC
FAU - Quong, Whitney L
AU  - Quong WL
FAU - Bruin, Jennifer E
AU  - Bruin JE
FAU - Tuduri, Eva
AU  - Tuduri E
FAU - Asadi, Ali
AU  - Asadi A
FAU - Glavas, Maria M
AU  - Glavas MM
FAU - Fox, Jessica K
AU  - Fox JK
FAU - Kieffer, Timothy J
AU  - Kieffer TJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - db12-1684 [pii]
AID - 10.2337/db12-1684 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 8.

PMID- 23656887
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 8
TI  - Npas4 Is a Novel Activity-Regulated Cytoprotective Factor in Pancreatic
      beta-Cells.
AB  - Cellular homeostasis requires intrinsic sensing mechanisms to temper function in 
      the face of prolonged activity. In the pancreatic beta-cell, glucose is likely a 
      physiological trigger that activates an adaptive response to stimulation, thereby
      maintaining cellular homeostasis. Immediate early genes (IEGs) are activated as a
      first line of defense in cellular homeostasis and are largely responsible for
      transmitting an environmental cue to a cellular response. Here we examine the
      regulation and function of the novel beta-cell IEG, neuronal PAS domain protein 4
      (Npas4). Using MIN6 cells, mouse and human islets, as well as in vivo infusions, 
      we demonstrate that Npas4 is expressed within pancreatic islets and is
      upregulated by beta-cell depolarizing agents. Npas4 tempers beta-cell function
      through a direct inhibitory interaction with the insulin promoter and by blocking
      the potentiating effects of GLP-1 without significantly reducing
      glucose-stimulated secretion. Finally, Npas4 expression is induced by classical
      endoplasmic reticulum (ER) stressors and can prevent thapsigargin- and
      palmitate-induced dysfunction and cell death. These results suggest that Npas4 is
      a key activity-dependent regulator that improves beta-cell efficiency in the face
      of stress. We posit that Npas4 could be a novel therapeutic target in type 2
      diabetes that could both reduce ER stress and cell death and maintain basal cell 
      function.
AD  - Diabetes Research Group, Child and Family Research Institute, Vancouver, British 
      Columbia, Canada.
FAU - Sabatini, Paul V
AU  - Sabatini PV
FAU - Krentz, Nicole A J
AU  - Krentz NA
FAU - Zarrouki, Bader
AU  - Zarrouki B
FAU - Westwell-Roper, Clara Y
AU  - Westwell-Roper CY
FAU - Nian, Cuilan
AU  - Nian C
FAU - Uy, Ryan A
AU  - Uy RA
FAU - Shapiro, A M James
AU  - Shapiro AM
FAU - Poitout, Vincent
AU  - Poitout V
FAU - Lynn, Francis C
AU  - Lynn FC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - db12-1527 [pii]
AID - 10.2337/db12-1527 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 8.

PMID- 23656883
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Adapting the SLIM diabetes prevention intervention to a Dutch real-life setting: 
      joint decision making by science and practice.
PG  - 457
LID - 10.1186/1471-2458-13-457 [doi]
AB  - BACKGROUND: Although many evidence-based diabetes prevention interventions exist,
      they are not easily applicable in real-life settings. Moreover, there is a lack
      of examples which describe the adaptation process of these interventions to
      practice. In this paper we present an example of such an adaptation. We adapted
      the SLIM (Study on Lifestyle intervention and Impaired glucose tolerance
      Maastricht) diabetes prevention intervention to a Dutch real-life setting, in a
      joint decision making process of intervention developers and local health care
      professionals. METHODS: We used 3 adaptation steps in accordance with current
      adaptation frameworks. In the first step, the elements of the SLIM intervention
      were identified. In the second step, these elements were judged for their
      applicability in a real-life setting. In the third step, adaptations were
      proposed and discussed for those elements which were deemed not applicable.
      Participants invited for this process included intervention developers and local 
      health care professionals (n=19). RESULTS: In the first adaptation step, a total 
      of 22 intervention elements were identified. In the second step, 12 of these 22
      intervention elements were judged as inapplicable. In the third step, a consensus
      was achieved for the adaptations of all 12 elements. The adapted elements were in
      the following categories: target population, techniques, intensity, delivery
      mode, materials, organisational structure, and political and financial
      conditions. The adaptations either lay in changing the SLIM protocol (6 elements)
      or the real-life working procedures (1 element), or a combination of both (4
      elements). CONCLUSIONS: The positive result of this study is that a consensus was
      achieved within a relatively short time period (nine months) between the
      developers of the SLIM intervention and local health care professionals on the
      adaptations needed to make SLIM applicable in a Dutch real-life setting. Our
      example shows that it is possible to combine the perspectives of scientists and
      practitioners, and to find a balance between evidence-base and applicability
      concerns.
AD  - Community Health Service GGD Gelre-IJssel; Academic Collaborative Centre AGORA,
      GGD Gelre-IJssel, PO Box 51, 7300, AB, Apeldoorn, The Netherlands.
      s.jansen@ggdgelre-ijssel.nl.
FAU - Jansen, Sophia C
AU  - Jansen SC
FAU - Haveman-Nies, Annemien
AU  - Haveman-Nies A
FAU - Duijzer, Geerke
AU  - Duijzer G
FAU - Ter Beek, Josien
AU  - Ter Beek J
FAU - Hiddink, Gerrit J
AU  - Hiddink GJ
FAU - Feskens, Edith Jm
AU  - Feskens EJ
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3658924
OID - NLM: PMC3658924
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/07/11 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 1471-2458-13-457 [pii]
AID - 10.1186/1471-2458-13-457 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 8;13:457. doi: 10.1186/1471-2458-13-457.

PMID- 23656854
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1555-2101 (Electronic)
IS  - 0160-6689 (Linking)
VI  - 74
IP  - 4
DP  - 2013 Apr
TI  - The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with
      schizophrenia in a Han Chinese population.
PG  - e287-92
LID - 10.4088/JCP.12m07846 [doi]
AB  - BACKGROUND: Patients with schizophrenia have an increased prevalence of type 2
      diabetes mellitus, and type 2 diabetes mellitus has shown an association with the
      rs4402960 gene polymorphism in the insulin-like growth factor II messenger RNA
      (mRNA)-binding protein 2 gene (IGF2BP2). We tested this polymorphism and mRNA
      expression levels of IGF2BP2 for an association in Han Chinese patients with
      schizophrenia compared to healthy controls. METHOD: The rs4402960 polymorphism
      was genotyped in 790 chronic schizophrenic patients (diagnosed according to
      DSM-IV) and 1,083 unrelated healthy controls in a case-control design. The
      IGF2BP2 gene expression levels were assayed in 34 patients with chronic
      schizophrenia and 30 healthy controls by using real-time polymerase chain
      reaction (PCR). The study was conducted between 2005 and 2007. RESULTS: We found 
      significant differences in the rs4402960 genotype (chi22 = 7.316, P = .026) and
      allele (chi21 = 7.056, P = .008) distributions between the patient and control
      groups. The rs4402960 T allelic frequency was significantly higher in male
      schizophrenic patients than male controls (28.9% vs 23.5%; P = .004) but not in
      female patients compared to female controls (27.1% vs 25.5%; P = .498). When
      real-time PCR was used, the IGF2BP2 gene's isoform B expression levels were
      significantly greater in schizophrenia than controls (P = .0008). CONCLUSIONS:
      These results suggest that the IGF2BP2 gene may play a role in susceptibility to 
      schizophrenia, supporting the hypothesis that the co-occurrence of type 2
      diabetes mellitus and schizophrenia may be explained by shared genetic risk
      variants. However, this finding remains preliminary since this association has
      yet to be replicated.
CI  - (c) Copyright 2013 Physicians Postgraduate Press, Inc.
AD  - Jilin University, 18 Ziqiang St, Changchun 130041, China xyzhang@bcm.edu.
FAU - Zhang, Xuan
AU  - Zhang X
FAU - Hui, Li
AU  - Hui L
FAU - Liu, Yang
AU  - Liu Y
FAU - Wang, Zhen-Qi
AU  - Wang ZQ
FAU - You, Yang
AU  - You Y
FAU - Miao, Li-Ning
AU  - Miao LN
FAU - Sun, Shi-Long
AU  - Sun SL
FAU - Guan, Song-Lei
AU  - Guan SL
FAU - Xiang, Yutao
AU  - Xiang Y
FAU - Kosten, Thomas R
AU  - Kosten TR
FAU - Zhang, Xiang Yang
AU  - Zhang XY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Psychiatry
JT  - The Journal of clinical psychiatry
JID - 7801243
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/04/11 [received]
PHST- 2012/10/25 [accepted]
AID - 10.4088/JCP.12m07846 [doi]
PST - ppublish
SO  - J Clin Psychiatry. 2013 Apr;74(4):e287-92. doi: 10.4088/JCP.12m07846.

PMID- 23656829
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1477-7525 (Electronic)
IS  - 1477-7525 (Linking)
VI  - 11
IP  - 1
DP  - 2013 May 8
TI  - The development and validation of the major life changing decision profile
      (MLCDP).
PG  - 78
AB  - BACKGROUND: Chronic diseases may influence patients taking major life changing
      decisions (MLCDs) concerning for example education, career, relationships, having
      children and retirement. A validated measure is needed to evaluate the impact of 
      chronic diseases on MLCDs, improving assessment of their life-long burden. The
      aims of this study were to develop a validated questionnaire, the "Major Life
      Changing Decision Profile" (MLCDP) and to evaluate its psychometric properties.
      METHODS: 50 interviews and two focus group meetings with dermatology patients and
      258 questionnaires, completed by cardiology, rheumatology, nephrology, diabetes
      and respiratory disorder patients, were analysed for qualitative data using
      Nvivo8 software. Content validation was carried out by a panel of experts. The
      first version of the MLCDP was completed by 210 patients and an iterative process
      of multiple Exploratory Factor Analyses and item prevalence was used to guide
      item reduction. Face validity and practicability was assessed by patients.
      RESULTS: 48 MLCDs were selected from analysis of the transcripts and
      questionnaires for the first version of the MLCDP, and reduced to 45 by
      combination of similar themes. There was a high intraclass correlation
      coefficient (0.7) between the 13 members of the content validation panel. Four
      more items were deleted leaving a 41-item MLCDP that was completed by 210
      patients. The most frequently recorded MLCDs were decisions to change eating
      habits (71.4%), to change smoking/drinking alcohol habits (58.5%) and not to
      travel or go for holidays abroad (50.9%).Factor analysis suggested item number
      reduction from 41 to 34, to 29, then 23 items. However after taking into account 
      item prevalence data as well as factor analysis results, 32 items were retained. 
      The 32-item MLCDP has five domains education (3 items), job/career (9),
      family/relationships (5), social (10) and physical (5). The MLCDP score is
      expressed as the absolute number of decisions that have been affected.
      CONCLUSIONS: The 32-item (5 domains) MLCDP has been developed as an easy to
      complete generic tool for use in clinical practice and for quality of life and
      epidemiological research. Further validation is required.
FAU - Bhatti, Zaheer U
AU  - Bhatti ZU
FAU - Salek, Sam S
AU  - Salek SS
FAU - Bolton, Charlotte E
AU  - Bolton CE
FAU - George, Lindsay
AU  - George L
FAU - Halcox, Julian P
AU  - Halcox JP
FAU - Jones, Sharon M
AU  - Jones SM
FAU - Ketchell, Ian R
AU  - Ketchell IR
FAU - Moore, Richard H
AU  - Moore RH
FAU - Sabit, Ramsey
AU  - Sabit R
FAU - Piguet, Vincent
AU  - Piguet V
FAU - Finlay, Andrew Y
AU  - Finlay AY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Health Qual Life Outcomes
JT  - Health and quality of life outcomes
JID - 101153626
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/10/03 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 1477-7525-11-78 [pii]
AID - 10.1186/1477-7525-11-78 [doi]
PST - aheadofprint
SO  - Health Qual Life Outcomes. 2013 May 8;11(1):78.

PMID- 23656801
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1554-6179 (Electronic)
IS  - 1539-4182 (Linking)
DP  - 2013 May 8
TI  - A Novel Case of Diabetic Muscle Necrosis in a Patient with Cystic
      Fibrosis-Related Diabetes.
AB  - Cystic fibrosis (CF) is a recessive autosomal disease caused by mutations in the 
      cystic fibrosis transmembrane conductance regulator gene. Cystic fibrosis-related
      diabetes (CFRD) is a common comorbidity of cystic fibrosis. Diabetic myonecrosis 
      is a rare self-limited complication of poorly controlled diabetes mellitus that
      commonly presents with acute, intense pain and swelling of lower extremities and 
      responds well to conservative management. We report the first case of diabetic
      myonecrosis in a patient with CFRD.
AD  - *Department of Internal/Hospital Medicine, Marshfield Clinic, Marshfield,
      Wisconsin, USA.
FAU - Chalasani, Sreelatha
AU  - Chalasani S
FAU - Bettadahalli, Shankar S
AU  - Bettadahalli SS
FAU - Bhupathi, Satya V
AU  - Bhupathi SV
FAU - Aswani, Vijay H
AU  - Aswani VH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Clin Med Res
JT  - Clinical medicine & research
JID - 101175887
OTO - NOTNLM
OT  - Cystic Fibrosis/complications
OT  - Cystic Fibrosis/physiopathology
OT  - Diabetic myonecrosis
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - cmr.2013.1124 [pii]
AID - 10.3121/cmr.2013.1124 [doi]
PST - aheadofprint
SO  - Clin Med Res. 2013 May 8.

PMID- 23656798
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1554-6179 (Electronic)
IS  - 1539-4182 (Linking)
DP  - 2013 May 8
TI  - Prostate Cancer Risk in Pre-Diabetic Men: A Matched Cohort Study.
AB  - BackgroundDiagnosis and duration of type 2 diabetes mellitus (DM) appears to be
      associated with decreased prostate cancer risk. Limitations of previous studies
      include methods of subject selection and accurate definition of DM diagnosis. We 
      examined the temporal relationship between DM and prostate cancer risk exploring 
      the period of greatest risk starting from the prediabetic to the post-diabetic
      period using clinical and administrative data to accurately define the date of DM
      diagnosis.MethodsWe identified 5,813 men who developed DM between January 1, 1995
      and December 31, 2009 (reference date, date of DM onset or matched date for
      non-diabetic cohort) and 28,019 non-diabetic men matched by age, smoking history,
      residence, and reference date. Prostate cancer incidence before and after the
      reference date was assessed using Cox regression modeling adjusted for matching
      variables, body mass index, insurance status, and comorbidities. Primary outcomes
      included hazard ratio (HR) and number needed to be exposed to DM for one
      additional person to be harmed (NNEH) or benefit (NNEB) with respect to prostate 
      cancer risk.ResultsAfter full adjustment, the HR for prostate cancer before DM
      diagnosis was 0.96 (95% CI 0.85 1.08; P=0.4752), and the NNEB was 974 at DM
      diagnosis. After the reference date, the fully-adjusted HR for prostate cancer in
      diabetic men was 0.84 (95% CI 0.72 0.97, P=0.0167), and the NNEB 3 years after DM
      onset was 425. The NNEB continued to decrease over time, reaching 63 at 15 years 
      after DM onset, suggesting an increasing protective effect of DM on prostate
      cancer risk over time. No significant difference between the diabetic and
      non-diabetic cohort was found prior to reference date.ConclusionProstate cancer
      risk is not reduced in pre-diabetic men but decreases after DM diagnosis and the 
      protective effect of DM onset on prostate cancer risk increases with DM duration.
AD  - *Department of Hematology/Oncology, Marshfield Clinic Weston Center, Weston,
      Wisconsin, USA.
FAU - Onitilo, Adedayo A
AU  - Onitilo AA
FAU - Berg, Richard L
AU  - Berg RL
FAU - Engel, Jessica M
AU  - Engel JM
FAU - Stankowski, Rachel V
AU  - Stankowski RV
FAU - Glurich, Ingrid
AU  - Glurich I
FAU - Williams, Gail M
AU  - Williams GM
FAU - Doi, Suhail A
AU  - Doi SA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Clin Med Res
JT  - Clinical medicine & research
JID - 101175887
OTO - NOTNLM
OT  - NNEH/NNEB
OT  - Prostatic neoplasms/epidemiology
OT  - Risk factors
OT  - Type 2 diabetes mellitus
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - cmr.2013.1160 [pii]
AID - 10.3121/cmr.2013.1160 [doi]
PST - aheadofprint
SO  - Clin Med Res. 2013 May 8.

PMID- 23656751
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 47
IP  - 6
DP  - 2013 Jun
TI  - Pharmacist-physician collaboration for diabetes care: the diabetes initiative
      program.
PG  - 781-9
LID - 10.1345/aph.1S079 [doi]
AB  - BACKGROUND: Multiple complications can arise secondary to poor control of
      glucose, blood pressure, and cholesterol in a patient with diabetes. OBJECTIVE:
      To evaluate the effect of a pharmacist-physician collaboration on attainment of
      diabetes-related measures of control. METHODS: This was a prospective,
      multicenter, cohort study. Patients were enrolled from 7 practice sites
      throughout Tennessee if they had been diagnosed with type 2 diabetes, were aged
      18 years or older with a life expectancy greater than 1 year, and were English
      speaking. Pregnant women were excluded. Patients were followed for 12 months
      following enrollment by informed consent. The pharmacist-physician collaboration 
      method was established prior to study initiation. Primary outcomes included
      hemoglobin A1c (A1C), number of patients with A1C less than 7%, and percentage of
      patients with A1C greater than 9%. RESULTS: Of the 206 patients enrolled, the
      mean age was 59.73 years, and most were male (59.71%) and white (66.02%). The A1C
      was reduced by an average of 1.16% (p < 0.0001). The proportion of patients with 
      A1C less than 7% increased from 12.75% at baseline to 36.76% at study conclusion 
      (p = 0.0002). The proportion of patients with A1C greater than 9% decreased from 
      34.15% to 16.50%, (p < 0.0001). CONCLUSIONS: Pharmacist-physician collaborative
      management at multiple practice loca tions and types of setting (eg, private,
      academic, Veterans Affairs medical center) has a positive impact on glycemic
      control and diabetes-related health maintenance. This was accomplished without
      increasing the total number of antihyperglycemic agents prescribed and without an
      increase in patient-reported episodes of hypoglycemia.
AD  - College of Pharmacy, Health Science Center, University of Tennessee, Knoxville
      Campus.
FAU - Farland, Michelle Zingone
AU  - Farland MZ
FAU - Byrd, Debbie C
AU  - Byrd DC
FAU - McFarland, M Shawn
AU  - McFarland MS
FAU - Thomas, Jeremy
AU  - Thomas J
FAU - Franks, Andrea S
AU  - Franks AS
FAU - George, Christa M
AU  - George CM
FAU - Gross, Benjamin N
AU  - Gross BN
FAU - Guirguis, Alexander B
AU  - Guirguis AB
FAU - Suda, Katie J
AU  - Suda KJ
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/05/08 [aheadofprint]
AID - aph.1S079 [pii]
AID - 10.1345/aph.1S079 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2013 Jun;47(6):781-9. doi: 10.1345/aph.1S079. Epub 2013 May 8.

PMID- 23656714
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1531-6963 (Electronic)
IS  - 1040-8711 (Linking)
VI  - 25
IP  - 4
DP  - 2013 Jul
TI  - Study design considerations for a large simple trial of bisphosphonates.
PG  - 517-23
LID - 10.1097/BOR.0b013e328362062b [doi]
AB  - PURPOSE OF REVIEW: To evaluate design considerations for an osteoporosis large
      simple trial (LST). RECENT FINDINGS: There is a growing need for more comparative
      effectiveness studies in osteoporosis. However, the design of such studies is
      challenged by issues surrounding study design, choosing comparator therapies,
      participant and outcome selection, data acquisition and data analysis. SUMMARY:
      LSTs are real-world studies that can have high levels of generalizability, if
      designed properly. We propose novel approaches to LSTs focusing on some of the
      challenges associated with comparative effectiveness research in osteoporosis. In
      this review, we discuss these considerations in the context of bisphosphonate
      active comparator initiation and discontinuation trials, while presenting
      advantages and disadvantages of the various design aspects for such studies.
AD  - aDepartment of Epidemiology bDivision of Endocrinology, Diabetes & Metabolism
      cDivision of Clinical Immunology & Rheumatology, University of Alabama at
      Birmingham, Birmingham, Alabama, USA.
FAU - Wright, Nicole C
AU  - Wright NC
FAU - Warriner, Amy H
AU  - Warriner AH
FAU - Saag, Kenneth G
AU  - Saag KG
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1097/BOR.0b013e328362062b [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2013 Jul;25(4):517-23. doi: 10.1097/BOR.0b013e328362062b.

PMID- 23656648
OWN - NLM
STAT- MEDLINE
DA  - 20130509
DCOM- 20130521
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 368
IP  - 19
DP  - 2013 May 9
TI  - Images in clinical medicine. A ticking time bomb.
PG  - 1826
LID - 10.1056/NEJMicm1214469 [doi]
AD  - Wayne State University, Detroit, MI, USA. george.sharon15@gmail.com
FAU - George, Sharon
AU  - George S
FAU - Sandal, Shaifali
AU  - Sandal S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
SB  - AIM
SB  - IM
MH  - Aged, 80 and over
MH  - Anaplasma phagocytophilum/*isolation & purification
MH  - Animals
MH  - Diabetic Ketoacidosis/etiology
MH  - Ehrlichiosis/complications/*diagnosis
MH  - Humans
MH  - Ixodes/*microbiology
MH  - Male
MH  - Polymerase Chain Reaction
EDAT- 2013/05/10 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/10 06:00
AID - 10.1056/NEJMicm1214469 [doi]
PST - ppublish
SO  - N Engl J Med. 2013 May 9;368(19):1826. doi: 10.1056/NEJMicm1214469.

PMID- 23656508
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1535-4970 (Electronic)
IS  - 1073-449X (Linking)
DP  - 2013 May 8
TI  - Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases.
AB  - Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the
      breakdown of cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine
      monophosphate (GMP) to their inactive form. PDE4 is the main selective
      cAMP-metabolizing enzyme in inflammatory and immune cells. Because PDE4 is highly
      expressed in leukocytes and other inflammatory cells involved in the pathogenesis
      of inflammatory lung diseases, such as asthma and chronic obstructive pulmonary
      disease (COPD), inhibition of PDE4 has been predicted to have an
      anti-inflammatory effect and thus therapeutic efficacy. The limited and
      inconsistent efficacy and side effects of the early compounds made their further 
      development less desirable in asthma, given the excellent efficacy/tolerability
      ratio of inhaled steroids. The lack of effective anti-inflammatory drug treatment
      for COPD has thus shifted the interest in development toward COPD. Roflumilast,
      the only PDE4 inhibitor that has reached the market because of the good
      efficacy/tolerability ratio, is recommended for COPD patients with severe airflow
      limitation, symptoms of chronic bronchitis, and a history of exacerbations whose 
      disease is not adequately controlled by long-acting bronchodilators. Albeit safe,
      it maintains significant side effects (diarrhea, nausea, weight loss) that make
      it intolerable in some patients. Future developments of PDE4 inhibitors include
      ?extended indications of roflumilast (i) in patients with COPD and (ii) in other 
      respiratory (e.g., asthma) and non-respiratory chronic inflammatory/metabolic
      conditions (eg diabetes) ?as well as (iii) the development of new molecules with 
      PDE4 inhibitory properties with an improved efficacy/tolerability profile.
AD  - University of Modena and Reggio Emilia, Section of Respiratory Diseases, Modena, 
      Italy ; bianca.beghe@unimore.it.
FAU - Beghe, Bianca
AU  - Beghe B
FAU - Rabe, Klaus F
AU  - Rabe KF
FAU - Fabbri, Leonardo M
AU  - Fabbri LM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1164/rccm.201301-0021PP [doi]
PST - aheadofprint
SO  - Am J Respir Crit Care Med. 2013 May 8.

PMID- 23656502
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1520-6882 (Electronic)
IS  - 0003-2700 (Linking)
VI  - 85
IP  - 11
DP  - 2013 Jun 4
TI  - Enzymatic Product-Mediated Stabilization of CdS Quantum Dots Produced In Situ:
      Application for Detection of Reduced Glutathione, NADPH, and Glutathione
      Reductase Activity.
PG  - 5542-6
LID - 10.1021/ac4007705 [doi]
AB  - Glutathione is the most abundant nonprotein molecule in the cell and plays an
      important role in many biological processes, including the maintenance of
      intracellular redox states, detoxification, and metabolism. Furthermore,
      glutathione levels have been linked to several human diseases, such as AIDS,
      Alzheimer disease, alcoholic liver disease, cardiovascular disease, diabetes
      mellitus, and cancer. A novel concept in bioanalysis is introduced and applied to
      the highly sensitive and inexpensive detection of reduced glutathione (GSH), over
      its oxidized form (GSSG), and glutathione reductase (GR) in human serum. This new
      fluorogenic bioanalytical system is based on the GSH-mediated stabilization of
      growing CdS nanoparticles. The sensitivity of this new assay is 5 pM of GR, which
      is 3 orders of magnitude better than other fluorogenic methods previously
      reported.
AD  - CICbiomaGUNE, Parque Tecnologico de San Sebastian, Paseo Miramon 182, 20009,
      Donostia-San Sebastian, Spain.
FAU - Garai-Ibabe, Gaizka
AU  - Garai-Ibabe G
FAU - Saa, Laura
AU  - Saa L
FAU - Pavlov, Valeri
AU  - Pavlov V
LA  - eng
PT  - Journal Article
DEP - 20130522
PL  - United States
TA  - Anal Chem
JT  - Analytical chemistry
JID - 0370536
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/05/22 [aheadofprint]
AID - 10.1021/ac4007705 [doi]
PST - ppublish
SO  - Anal Chem. 2013 Jun 4;85(11):5542-6. doi: 10.1021/ac4007705. Epub 2013 May 22.

PMID- 23656394
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1473-0766 (Electronic)
IS  - 0951-3590 (Linking)
VI  - 29
IP  - 6
DP  - 2013 Jun
TI  - Birth weight and childhood growth in daughters of women with irregular menstrual 
      cycles.
PG  - 615-8
LID - 10.3109/09513590.2013.788638 [doi]
AB  - Abstract Menstrual irregularity has been associated with insulin resistance, type
      2 diabetes mellitus and markers of metabolic dysfunction. This study aimed to
      determine whether irregular menstrual cycles (MCs) in reproductive-age women are 
      associated with the weight of their daughters at birth and growth up to age five.
      We studied 4863 pregnant women with menstrual history data in a prospective
      cohort, recruited from the Kaiser Health Plan (1959-1966). Serial measures of
      their daughters' weight and height were abstracted from medical records. We used 
      analysis of covariance, stratified by maternal body mass index, to explore the
      association between maternal MC and infant birth weight (BW). We included 4774
      daughters in a repeated measures analysis to compare the effect of maternal MC on
      childhood weight through age five. Daughters of non-obese women with irregular MC
      had a statistically significant lower BW compared to daughters of women with
      regular MC; this difference was notably amplified among obese women. The
      daughters' weights were not statistically different when growth was assessed from
      birth to five years. We conclude that daughters of obese women with irregular MC,
      in particular, had significantly lower BW compared to daughters of women with
      regular MC, which did not persist over five years of follow-up.
AD  - Cedars Sinai Medical Center , Los Angeles, CA , USA .
FAU - Wang, Erica T
AU  - Wang ET
FAU - Cirillo, Piera M
AU  - Cirillo PM
FAU - Kao, Chia-Ning
AU  - Kao CN
FAU - Cohn, Barbara A
AU  - Cohn BA
FAU - Cedars, Marcelle I
AU  - Cedars MI
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gynecol Endocrinol
JT  - Gynecological endocrinology : the official journal of the International Society
      of Gynecological Endocrinology
JID - 8807913
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.3109/09513590.2013.788638 [doi]
PST - ppublish
SO  - Gynecol Endocrinol. 2013 Jun;29(6):615-8. doi: 10.3109/09513590.2013.788638.

PMID- 23656335
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 6
IP  - 3
DP  - 2013 May
TI  - New medicines for Type 2 diabetes in adolescents: many products, few patients.
PG  - 227-9
LID - 10.1586/ecp.13.9 [doi]
AD  - European Medicines Agency, 7 Westferry Circus, London E14 4HB, UK.
      janina.karres@ema.europa.eu.
FAU - Karres, Janina
AU  - Karres J
FAU - Tomasi, Paolo
AU  - Tomasi P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1586/ecp.13.9 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2013 May;6(3):227-9. doi: 10.1586/ecp.13.9.

PMID- 23656250
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1532-4230 (Electronic)
IS  - 1532-1819 (Linking)
VI  - 34
IP  - 3
DP  - 2013 Jul
TI  - Comparison of in-house developed ELISA with HPLC for measurement of hba1c.
PG  - 305-12
LID - 10.1080/15321819.2012.731462 [doi]
AB  - In-house developed ELISA for HbA1c was evaluated in comparison with Bio-Rad D-10 
      Dual Program (HPLC). % HbA1c was estimated using said methods in 40 blood
      samples. Intra and inter assay coefficient of variation (CV) were in acceptable
      range i.e., <3%. HbA1c results obtained by two methods showed good correlation,
      (y = 0.8942x + 0.7229 R2 = 0.877). Sensitivity, specificity, positive, and
      negative predictive value for in-house ELISA classifying patients as controlled
      and uncontrolled diabetes against HPLC were recorded as 87%, 94.1%, 95.0%, and
      93.8%, respectively, while accuracy of the test was 90.0%. In-house ELISA for
      HbA1c is not only accurate, cost effective and simple but also precise comparable
      to HPLC in deciding glycemic status of patients.
AD  - a PMRC Research Centre, Shaikh Zayed Medical Complex, Lahore , Pakistan.
FAU - Mohsin, Saima Naz
AU  - Mohsin SN
FAU - Ghafoor, Farkhanda
AU  - Ghafoor F
FAU - Aasim, Muhammad
AU  - Aasim M
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Immunoassay Immunochem
JT  - Journal of immunoassay & immunochemistry
JID - 100963688
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1080/15321819.2012.731462 [doi]
PST - ppublish
SO  - J Immunoassay Immunochem. 2013 Jul;34(3):305-12. doi:
      10.1080/15321819.2012.731462.

PMID- 23656217
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 0304-4920 (Print)
IS  - 0304-4920 (Linking)
VI  - 56
IP  - 3
DP  - 2013 Jun 30
TI  - Role of KCa3.1 Channels in Proliferation and Migration of Vascular Smooth Muscle 
      Cells by Diabetic Rat Serum.
LID - CJP.2013.BAB104 [pii]
LID - 10.4077/CJP.2013.BAB104 [doi]
AB  - Proliferation and migration of vascular smooth muscle cells (VSMCs) are important
      events in the development of diabetic atherosclerosis. Previous studies have
      suggested that KCa3.1 channels participate in atherosclerosis and coronary artery
      restenosis. In the present study, we attempted to clarify the roles of KCa3.1
      channels in the proliferation and migration of VSMCs using experimental type-2
      diabetes rat serum and aortic smooth muscle cells (SMC) prepared from
      non-diabetic rats. mRNA and protein levels and current density of KCa3.1 channels
      were greatly enhanced in cultured VSMCs treated with diabetic serum. In addition,
      diabetic serum promoted cell proliferation and migration in cultured VSMCs, and
      the effects were fully reversed in the cells treated with the KCa3.1 channels
      blocker TRAM-34. In conclusion, serum from diabetic rats increases the expression
      of KCa3.1 channels and promotes proliferation and migration of VSMCs to possibly 
      participate in vascular remodeling in diabetes.
AD  - Department of Pathophysiology, Xi'an Medical University, 1 Xinwang Road, Xi'an,
      Shaanxi 710021, The People's Republic of China.
FAU - Su, Xing-Li
AU  - Su XL
FAU - Zhang, Hong
AU  - Zhang H
FAU - Yu, Wei
AU  - Yu W
FAU - Wang, Shuang
AU  - Wang S
FAU - Zhu, Wei-Jun
AU  - Zhu WJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130630
TA  - Chin J Physiol
JT  - The Chinese journal of physiology
JID - 7804502
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - CJP.2013.BAB104 [pii]
AID - 10.4077/CJP.2013.BAB104 [doi]
PST - aheadofprint
SO  - Chin J Physiol. 2013 Jun 30;56(3). pii: CJP.2013.BAB104. doi:
      10.4077/CJP.2013.BAB104.

PMID- 23656177
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
DP  - 2013 Apr 19
TI  - Non-alcoholic fatty liver disease independently predicts prediabetes during a
      7-year prospective follow-up.
LID - 10.1111/liv.12200 [doi]
AB  - BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is suspected to
      confer an increased risk for developing type 2 diabetes (DM). However, only a few
      prospective studies evaluated NAFLD as a predictor for DM, most did not adjust
      for the full range of potential cofounders and none used an objectively
      quantified degree of steatosis. Our aim was to evaluate the independent role of
      NAFLD in predicting the development of pre-DM in a 7-year prospective follow-up
      of healthy volunteers. METHODS: A prospective cohort of a subsample of the
      Israeli National Health Survey evaluated at baseline and after 7 years by
      identical protocols. Metabolic parameters and ultrasonographic evidence of NAFLD 
      were evaluated in 213 subjects, without known liver disease or history of alcohol
      abuse. Exclusion criteria were pre-DM at the baseline survey. Steatosis was
      quantified by ultrasound with the hepato-renal ultrasound index (HRI). RESULTS:
      The study included 141 volunteers (mean age 48.78 +/- 9.68, 24.82% with NAFLD)
      without pre-DM/DM at baseline. Both NAFLD on regular US (OR=2.93, 1.02-8.41
      95%CI) and HRI (OR=7.87, 1.83-33.82) were independent predictors for the
      development of pre-DM, adjusting for age, gender, BMI, family history of DM,
      baseline insulin, adiponectin and glucose. Further adjustment for physical
      activity and dietary intake did not weaken the association. Furthermore, NAFLD
      was a stronger predictor for pre-DM than the metabolic syndrome. Subjects with
      both NAFLD and glucose >/=89 had 93.3% incidence rate of pre-DM. CONCLUSION:
      Non-alcoholic fatty liver disease is a strong and independent risk factor for
      pre-DM in the general adult population; thus, NAFLD patients should be classified
      as a population at risk.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Department of Gastroenterology, Tel Aviv Sourasky Medical Center, Tel Aviv,
      Israel; School of Public Health, Haifa University, Haifa, Israel.
FAU - Zelber-Sagi, Shira
AU  - Zelber-Sagi S
FAU - Lotan, Roni
AU  - Lotan R
FAU - Shibolet, Oren
AU  - Shibolet O
FAU - Webb, Muriel
AU  - Webb M
FAU - Buch, Assaf
AU  - Buch A
FAU - Nitzan-Kaluski, Dorit
AU  - Nitzan-Kaluski D
FAU - Halpern, Zamir
AU  - Halpern Z
FAU - Santo, Erwin
AU  - Santo E
FAU - Oren, Ran
AU  - Oren R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the
      Study of the Liver
JID - 101160857
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2012/10/09 [received]
PHST- 2013/04/14 [accepted]
AID - 10.1111/liv.12200 [doi]
PST - aheadofprint
SO  - Liver Int. 2013 Apr 19. doi: 10.1111/liv.12200.

PMID- 23656171
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 91
IP  - 5
DP  - 2013 May
TI  - Beneficial effect of flax seeds in streptozotocin (STZ) induced diabetic mice:
      isolation of active fraction having islet regenerative and glucosidase inhibitory
      properties.
PG  - 325-31
LID - 10.1139/cjpp-2011-0428 [doi]
AB  - Diabetes mellitus is a metabolic disorder that affects millions of people
      worldwide. Present study highlights the antidiabetogenic property of Linum
      usitassimum active fraction (LU6) in streptozotocin (STZ) induced diabetic Swiss 
      mice. Treatment with LU6 fraction showed improved glucose utilization with
      increase in liver glucose-6-phosphate dehydrogenase enzyme activity and normal
      glycogenesis in hepatic and muscle tissues. Reduction in pancreatic and
      intestinal glucosidase inhibitory activity was observed with LU6 treatment,
      indicating beneficial effects in reducing postprandial hyperglycemia (PPHG).
      Normalization of plasma insulin and C-peptide levels were observed in diabetic
      mice, indicating endogenous insulin secretion after the treatment with LU6. The
      histochemical and immunohistochemical analysis on pancreatic islets suggests the 
      role of LU6 fraction in islet regeneration and insulin secretion as evident in
      increase functional pancreatic islets producing insulin. Furthermore, significant
      insulin producing islet formation was also observed in in vitro PANC-1 cells
      after LU6 treatment, indicating the cellular aggregates to be newly formed
      islets. This suggests the potential of LU6 fraction in the formation of new
      islets in vitro, as well as in vivo. Thus, LU6 can be used as a
      neutraceutical-based first-line treatment for diabetes.
AD  - Biometry and Nutrition Division, Agharkar Research Institute, G.G. Agharkar Road,
      Pune 411 004, India.
FAU - Dusane, Menakshi Bhat
AU  - Dusane MB
FAU - Joshi, Bimba N
AU  - Joshi BN
LA  - eng
PT  - Journal Article
DEP - 20130116
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PHST- 2013/01/16 [aheadofprint]
AID - 10.1139/cjpp-2011-0428 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2013 May;91(5):325-31. doi: 10.1139/cjpp-2011-0428. Epub
      2013 Jan 16.

PMID- 23656117
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1089-7690 (Electronic)
IS  - 0021-9606 (Linking)
VI  - 138
IP  - 17
DP  - 2013 May 7
TI  - A simplified representation of anisotropic charge distributions within proteins.
PG  - 174110
LID - 10.1063/1.4803099 [doi]
AB  - Effective coarse-grained representations of protein-protein interaction
      potentials are vital in the modeling of large scale systems. We develop a method 
      to fit an arbitrary number of effective charges to approximate the electrostatic 
      potential of a protein at a given pH in an ionic solution. We find that the
      effective charges can reproduce an input potential calculated from a high
      resolution Poisson-Boltzmann calculation. Since the effective charges used in
      this model are not constrained to the locations of the original charged groups,
      the extra degrees of freedom allows us to reproduce the field anisotropy with
      fewer charges. The fitting procedure uses a number of approximations in the
      charge magnitudes, initial conditions, and multipoles to speed convergence. The
      most significant gains are found by fitting the multipole moments of the
      effective charge potential to the moments of the original field. We show that the
      Yukawa potential is not only sufficient as a pairwise summation in reproducing
      the potential, but comes naturally from the linearized expansion of the
      Poisson-Boltzmann equation. We compute interaction energies and find excellent
      agreement to the original potential. From the effective charge model we compute
      the electrostatic contribution to the second virial coefficient.
AD  - National Institutes of Health, National Institute of Diabetes and Digestive and
      Kidney Diseases, Bethesda, Maryland 20892, USA.
FAU - Hoppe, Travis
AU  - Hoppe T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Chem Phys
JT  - The Journal of chemical physics
JID - 0375360
SB  - IM
PMC - PMC3656951
OID - NLM: PMC3656951 [Available on 05/07/14]
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PMCR- 2014/05/07 00:00
AID - 10.1063/1.4803099 [doi]
PST - ppublish
SO  - J Chem Phys. 2013 May 7;138(17):174110. doi: 10.1063/1.4803099.

PMID- 23655733
OWN - NLM
STAT- In-Process
DA  - 20130509
IS  - 1520-8524 (Electronic)
IS  - 0001-4966 (Linking)
VI  - 133
IP  - 5
DP  - 2013 May
TI  - Radial shear strain elastography imaging of carotid atherosclerotic plaques in a 
      porcine model.
PG  - 3540
LID - 10.1121/1.4806400 [doi]
AB  - The objective is to show the feasibility of shear strain elastography (SSE) in
      vivo with intravascular ultrasound (IVUS) radio-frequency data acquired at 20 MHz
      in carotid arteries of pigs. We previously proposed the Lagrangian Speckle Model 
      Estimator (LSME) to estimate the strain tensor including the shear strain that
      could be involved in atherosclerotic plaque hemorrhage, inflammation, and rupture
      mechanisms. However, the LSME performance to compute SSE had never been
      validated. Atherosclerotic pigs with significant plaques on carotids were
      studied. To induce atherosclerosis, pigs were put on an atherogenic diet and
      partial ligations of common carotid arteries were performed. Diabetes was induced
      by selective intra-arterial injection of streptozotocin. IVUS acquisitions were
      performed before sacrifice and histologic analysis were realized on fixed
      dissected carotids. SSE maps at end diastole were estimated with a new
      implementation of the LSME and matching with histology sections was realized. SSE
      clearly identified all plaques; reported figures show SSE mapping characterized
      by cohabitation of high positive and high negative shear values in the specific
      region of the plaque. This study demonstrates the performance of the LSME
      implementation to estimate accurately the shear strain distribution, and the
      feasibility of SSE to highlight atherosclerotic plaque vulnerability
      characteristics.
AD  - Lab. of Biorheology and Med. Ultrason., Univ. of Montreal Hospital, 2099
      Alexandre de Seve, Montreal, QC H2L 2W5, Canadaguy.cloutier@umontreal.ca.
FAU - Cloutier, Guy
AU  - Cloutier G
FAU - Majdouline, Younes
AU  - Majdouline Y
FAU - Garcia, Damien
AU  - Garcia D
FAU - Allard, Louise
AU  - Allard L
FAU - Lerouge, Sophie
AU  - Lerouge S
FAU - Ohayon, Jacques
AU  - Ohayon J
FAU - Soulez, Gilles
AU  - Soulez G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Acoust Soc Am
JT  - The Journal of the Acoustical Society of America
JID - 7503051
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
AID - 10.1121/1.4806400 [doi]
PST - ppublish
SO  - J Acoust Soc Am. 2013 May;133(5):3540. doi: 10.1121/1.4806400.

PMID- 23654136
OWN - NLM
STAT- In-Process
DA  - 20130509
IS  - 1438-3276 (Print)
IS  - 1438-3276 (Linking)
VI  - 155
IP  - 5
DP  - 2013 Mar 21
TI  - [Diabetes and sleep. What remains unrecognized by the patient].
PG  - 63-5
AD  - Innere Medizin, Endokrinologie, Thuringen Kliniken Georgius Agricola,
      Saalfeld/Saale. iharsch@thueringen-kliniken.de
FAU - Harsch, I A
AU  - Harsch IA
LA  - ger
PT  - Journal Article
TT  - Womit sich Zuckerkranke nachts herumqualen.
PL  - Germany
TA  - MMW Fortschr Med
JT  - MMW Fortschritte der Medizin
JID - 100893959
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PST - ppublish
SO  - MMW Fortschr Med. 2013 Mar 21;155(5):63-5.

PMID- 23654096
OWN - NLM
STAT- In-Process
DA  - 20130509
IS  - 1000-8020 (Print)
IS  - 1000-8020 (Linking)
VI  - 42
IP  - 2
DP  - 2013 Mar
TI  - [Influence of magnesium supplementation on insulin receptor affinity in
      erythrocytes of type 2 diabetes rats].
PG  - 217-20
AB  - OBJECTIVE: To observe the influence of oral magnesium supplementation on insulin 
      receptor affinity in erythrocytes of type 2 diabetes rats. METHOD: diabetes rats 
      were induced by high-fat-diet and intraperitoneal injection of streptozocin, and 
      divided into 4 groups. Magnesium was supplemented in high-fat-diet at the dose of
      2000, 1000, 200 and 0 mg/kg,respectively. Normal control rats were fed with
      ordinary diet. Rats were killed after four weeks. Erythrocytes insulin receptor
      number, combination constants, combined capacity, fasting insulin level and
      fasting glucose levels were measured, and insulin resistance index and insulin
      sensitivity index were calculated. RESULTS: High affinity insulin receptor
      combination constant, combined capacity and receptor number in high dosage group 
      were (1.24 +/- 0.47) x 10(9) L/mol, (1.26 +/- 0.53) x 10(14)/L and 80.23 +/- 0.47
      respectively, significantly higher than diabetes control group. Insulin
      resistance index decreased and insulin sensitivity index increased in high dosage
      group than diabetes control. CONCLUSION: Magnesium supplementation could improve 
      erythrocyte insulin receptor affinity and improve insulin resistance in type 2
      diabetic rats.
AD  - Chinese PLA General Hospital, Beijing 100853, China. chinazhongww@yahoo.com.cn
FAU - Zhong, Wenwen
AU  - Zhong W
FAU - Fang, Fusheng
AU  - Fang F
FAU - Cheng, Xiaoling
AU  - Cheng X
FAU - Li, Chunlin
AU  - Li C
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Wei Sheng Yan Jiu
JT  - Wei sheng yan jiu = Journal of hygiene research
JID - 9426367
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PST - ppublish
SO  - Wei Sheng Yan Jiu. 2013 Mar;42(2):217-20.

PMID- 23654089
OWN - NLM
STAT- In-Process
DA  - 20130509
IS  - 1000-8020 (Print)
IS  - 1000-8020 (Linking)
VI  - 42
IP  - 2
DP  - 2013 Mar
TI  - [Plasma proteomic research on obesity subtype and non-obesity subtype of T2DM].
PG  - 173-8
AB  - OBJECTIVE: With the increasingly serious epidemic situation of diabetes, plasma
      proteomic method and OFFGEL electrophoresis have been applied for screening
      different proteins between obese and non-obese T2DM patients, which may be used
      to further explain the mechanism of T2DM. METHODS: Twenty male T2DM volunteers
      (Obesity Subtype: 10; Non-obesity Subtype: 10) with the age of 18-44 years have
      been selected. The control group has been matched considering the factors of age,
      gender, etc. Albumin and IgG were removed from the plasma samples with highly
      specific immune-affinity method. Then the peptide-mixed samples were separated by
      pI with OFFGEL electrophoresis after solution digestion. Further separation and
      identification were performed by Nano HPLC-Chip-MS/MS system. Comparing the three
      groups, the differences were obtained and annotated on functions and its
      mechanism. RESULTS: 391, 415 and 371 proteins have been identified in the
      experimental groups and control group, respectively. The different proteins in
      groups and their annotations showed that adiponectin was down-regulated in
      obesity subtype of T2DM group, while STIM1 (stromal interaction molecule 1) was
      up-regulated. There were six protein kinases high expression in non-obesity DM
      patients, such as Serine-protein kinase ATM, Serine/threonine-protein kinase
      WNK1. CONCLUSION: Adiponectin, STIM1 and protein kinases may act in different
      roles on the pathogenesis of obesity subtype and non-obesity subtype of T2DM.
AD  - Shenzhen Center for Chronic Disease Control, Shenzhen 518020, China.
      junwangwh96@gmail.com
FAU - Wang, Jun
AU  - Wang J
FAU - Yu, Wei
AU  - Yu W
FAU - Xu, Jian
AU  - Xu J
FAU - Feng, Liru
AU  - Feng L
FAU - Yang, Hui
AU  - Yang H
FAU - Liu, Xiaoli
AU  - Liu X
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Wei Sheng Yan Jiu
JT  - Wei sheng yan jiu = Journal of hygiene research
JID - 9426367
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PST - ppublish
SO  - Wei Sheng Yan Jiu. 2013 Mar;42(2):173-8.

PMID- 23653988
OWN - NLM
STAT- In-Process
DA  - 20130509
IS  - 0025-8105 (Print)
IS  - 0025-8105 (Linking)
VI  - 66
IP  - 3-4
DP  - 2013 Mar-Apr
TI  - Quadriceps tendon injuries.
PG  - 121-5
AB  - INTRODUCTION: The aim of study was to analyze risk factors, mechanisms of injury,
      symptoms and time that elapsed from injury until operation of complete quadriceps
      tendon ruptures. MATERIAL AND METHODS: This retrospective multicenter study
      included 30 patients operated for this injury, of whom 28 (93.3%) were men. The
      average age was 53.7 years (18-73). Twenty-six patients had reconstruction of
      unilateral rupture and four of bilateral one. RESULTS: Eighty percent of them had
      some risk factors for rupture of the tendon with degenerative changes. Eight
      patients had diabetes, seven patients were on renal dialysis, two patients had
      secondary hyperparathyroidism, five patients were obese and two patients had
      former knee operations. These injuries occurred in 80% following minor trauma
      caused by falls on stairs, on flat surfaces and squatting. The most frequent
      symptoms were: pain, swelling, lack of extension of knee and defect above
      patella, and three cases were initially misdiagnosed. During the first 10 days
      after injury, acute and chronic ruptures were reconstructed in 22 (73.3%) and 8
      patients, respectively. CONCLUSION: Quadriceps tendon injuries most often happen 
      to male patients with predisposing conditions in their fifth and sixth decade of 
      life due to trivial trauma. Patients on renal dialysis are the most vulnerable
      population group.
AD  - General Hospital Subotica, Department of Orthopedics and Traumatology, Clinical
      Centre of Vojvodina, Novi Sad. ristic@tippnet.rs
FAU - Ristic, Vladimir
AU  - Ristic V
FAU - Maljanovic, Mirsad
AU  - Maljanovic M
FAU - Popov, Iva
AU  - Popov I
FAU - Harhaji, Vladimir
AU  - Harhaji V
FAU - Milankov, Vukadin
AU  - Milankov V
LA  - eng
PT  - Journal Article
PL  - Serbia
TA  - Med Pregl
JT  - Medicinski pregled
JID - 2985249R
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/10 06:00
PST - ppublish
SO  - Med Pregl. 2013 Mar-Apr;66(3-4):121-5.

PMID- 23647720
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Clinical experience with BIAsp 30: Results from the Indonesian cohort of the
      international A1chieve study.
PG  - S54-9
LID - 10.1016/S0168-8227(13)70011-1 [doi]
LID - S0168-8227(13)70011-1 [pii]
AB  - AIM: To evaluate the safety and effectiveness of biphasic insulin aspart 30
      (BIAsp 30) in Indonesian patients with type 2 diabetes (T2D) as part of the
      24-week, international, prospective, non-interventional A1chieve study. METHODS: 
      Indonesian patients who started BIAsp 30 were included. Safety and efficacy was
      measured as part of routine clinical practice at baseline, Week 12 and Week 24.
      Results: Overall, 1324 patients having a mean+/-SD age, duration of diabetes and 
      body mass index of 55.2+/-9.9 yrs, 6.8+/-5.2 yrs and 24.1+/-3.6kg/m(2),
      respectively, were enrolled. 67% of patients were insulin-naive and 33% were
      prior insulin users. Glycaemic control was poor at baseline. After 24 weeks,
      significant reductions from baseline were observed in the mean glycated
      haemoglobin A1c (HbA1c) (-2.6%), fasting plasma glucose (-93.8 mg/dL) and
      postprandial plasma glucose (-134.8 mg/dL) levels in the entire cohort (p <
      0.001). Significant reductions were also seen in insulin-naive patients and prior
      insulin users. At Week 24, 29.9% of patients in the entire cohort achieved target
      HbA1c level of <7.0%, while 26.7% and 39.2% achieved this target among
      insulin-naive patients and prior insulin users, respectively. The proportion of
      patients reporting overall hypoglycaemia significantly decreased in the entire
      cohort after 24 weeks of BIAsp 30 therapy. A small significant increase in body
      weight was noted in the entire cohort, insulin-naive patients and prior insulin
      users. CONCLUSION: The current study suggests that BIAsp 30 can be considered as 
      a safe and effective option for initiating as well as intensifying insulin
      therapy in Indonesian patients with T2D.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia.
      Electronic address: soewondops@yahoo.com.
FAU - Soewondo, Pradana
AU  - Soewondo P
FAU - Pramono, R Bowo
AU  - Pramono RB
FAU - Langi, Yuanita Asri
AU  - Langi YA
FAU - Soetedjo, Nanny N M
AU  - Soetedjo NN
FAU - Kshanti, Ida Ayu
AU  - Kshanti IA
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70011-1 [pii]
AID - 10.1016/S0168-8227(13)70011-1 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S54-9. doi:
      10.1016/S0168-8227(13)70011-1.

PMID- 23647719
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Clinical experience with insulin detemir: Results from the Indonesian cohort of
      the international A1chieve study.
PG  - S47-53
LID - 10.1016/S0168-8227(13)70010-X [doi]
LID - S0168-8227(13)70010-X [pii]
AB  - AIM: To determine the safety and efficacy of insulin detemir in Indonesian
      patients with type 2 diabetes (T2D) as a sub-analysis of the 24-week,
      prospective, multinational, non-interventional A1chieve study. METHODS: This
      study included 477 Indonesian T2D patients starting insulin detemir at the
      discretion of their physicians. Safety and efficacy was measured in routine
      clinical practice at baseline, interim (around 12 weeks from baseline) and final 
      (around 24 weeks from baseline) visit. RESULTS: At baseline the mean age,
      duration of diabetes and mean BMI were 55.3+/-8.5 years, 5.9+/-4.0 years and
      24+/-3.6kg/m(2), respectively. Of these patients, 78% were insulin-naive and 22% 
      were prior insulin users. Glycaemic control was poor at baseline. After 24 weeks,
      significant reductions were observed in mean HbA1c (2.2%, p < 0.001), fasting
      plasma glucose (90.0 mg/dL, p < 0.001) and postprandial plasma glucose (115.4
      mg/dL, p < 0.001) levels, in the entire cohort. Similar significant reductions
      were also seen in insulin-naive patients and prior insulin users. In the entire
      cohort, 32.5% patients achieved HbA1c levels <7.0% while 32.0% insulin-naive
      patients and 33.9% prior insulin users achieved this target after 24 weeks. No
      hypoglycaemic events were reported in the entire cohort. Modest increase in body 
      weight was noted in the insulin-naive group, while mean body weight decreased in 
      prior insulin users after 24 weeks of insulin detemir therapy. CONCLUSION: This
      sub-analysis suggests that insulin detemir can be a safe and effective option for
      initiating insulin therapy in people with T2D in Indonesia.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia.
      Electronic address: soewondops@yahoo.com.
FAU - Soewondo, Pradana
AU  - Soewondo P
FAU - Kshanti, Ida Ayu
AU  - Kshanti IA
FAU - Pramono, R Bowo
AU  - Pramono RB
FAU - Langi, Yuanita Asri
AU  - Langi YA
FAU - Dalem-Pemayun, Tjokorda Gde
AU  - Dalem-Pemayun TG
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70010-X [pii]
AID - 10.1016/S0168-8227(13)70010-X [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S47-53. doi:
      10.1016/S0168-8227(13)70010-X.

PMID- 23647718
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2
      diabetes patients switched from biphasic human insulin 30: Results from the
      Indonesian cohort of the A1chieve study.
PG  - S41-6
LID - 10.1016/S0168-8227(13)70009-3 [doi]
LID - S0168-8227(13)70009-3 [pii]
AB  - AIM: To evaluate the safety and effectiveness of biphasic insulin aspart 30
      (BIAsp 30) in Indonesian type 2 diabetes patients switched from biphasic human
      insulin 30 (BHI 30) as a sub-analysis of the A1chieve study. METHODS: Clinical
      safety and effectiveness over 24 weeks was evaluated in Indonesian patients who
      switched from BHI 30 to BIAsp 30 at the discretion of their physician. RESULTS: A
      total of 244 patients with mean age +/- SD 55.6+/-9.5 years, BMI
      24.6+/-3.8kg/m(2), and mean diabetes duration 7.8+/-5.7 years were included. The 
      mean pre-study BHI 30 dose was 0.56+/-0.25 IU/kg and the baseline BIAsp 30 dose
      was 0.60+/-0.26U/kg titrated up to 0.65+/-0.25 U/kg by Week 24. No serious
      adverse drug reactions were reported throughout the study. Overall hypoglycaemia 
      decreased from 2.18 to 0.06 events/patient-year with a significant decrease in
      the proportion of patients affected (p < 0.0001). No nocturnal or major
      hypoglycaemia was reported at Week 24. HbA1c improved from 8.8+/-1.2% at baseline
      to 7.3+/-0.8% at Week 24. A total of 45 patients achieved HbA1c <7.0% as compared
      to 5 patients with HbA1c <7.0% at baseline. FPG and PPPG improved significantly
      after 24 weeks (p < 0.001). Quality of life was positively impacted (change in
      visual analogue scores, 3.0+/-11.6 points, p < 0.001). CONCLUSION: Switching from
      BHI 30 to BIAsp 30 in this Indonesian cohort was well-tolerated and improved
      glycaemic control with a decreased risk of hypoglycaemia.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia.
      Electronic address: soewondops@yahoo.com.
FAU - Soewondo, Pradana
AU  - Soewondo P
FAU - Lindarto, Dharma
AU  - Lindarto D
FAU - Wibisono, Sony
AU  - Wibisono S
FAU - Renaldi, Olly
AU  - Renaldi O
FAU - Dalem-Pemayun, Tjokorda Gde
AU  - Dalem-Pemayun TG
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70009-3 [pii]
AID - 10.1016/S0168-8227(13)70009-3 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S41-6. doi:
      10.1016/S0168-8227(13)70009-3.

PMID- 23647717
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes
      patients switched from biphasic human insulin 30: Results from the Filipino
      cohort of the A1chieve study.
PG  - S35-40
LID - 10.1016/S0168-8227(13)70008-1 [doi]
LID - S0168-8227(13)70008-1 [pii]
AB  - AIM: To evaluate the safety and effectiveness of biphasic insulin aspart 30
      (BIAsp 30) in Filipino patients with type 2 diabetes previously treated with
      biphasic human insulin 30 (BHI 30). Methods: Safety and effectiveness outcomes
      were measured in all patients switching from BHI 30 to BIAsp 30 in the Filipino
      cohort of the 24-week, multinational, prospective, non-interventional A1chieve
      study. RESULTS: A total of 111 Filipino patients (mean age +/- SD, 57.4+/-12.8
      years; BMI, 25.8+/-5.6kg/m(2)) with mean diabetes duration of 9.9+/-7.1 years
      switched therapy from BHI 30 to BIAsp 30. The mean pre-study BHI 30 dose was
      0.65+/-0.28 IU/kg and the baseline BIAsp 30 dose was 0.65+/-0.26 U/kg titrated up
      to 0.70+/-0.26 U/kg by Week 24. No serious adverse drug reactions were reported. 
      Overall hypoglycaemia was reduced from 5.62 to 1.98 events/patient-year. Minor
      and nocturnal hypoglycaemia decreased and no major hypoglycaemia was reported at 
      Week 24. Glucose control improved from baseline to Week 24 (HbA1c, -2.2+/-2.1%
      [24+/-23 mmol/mol]; FPG, -72.0+/-71.8 mg/dL; PPPG, -145.5+/-125.4 mg/dL). A total
      of 24 patients achieved HbA1c levels <7.0% at Week 24 compared to 6 patients
      reporting this target at baseline. Quality of life was positively impacted at
      Week 24 (change in visual analogue scores, 15.3+/-16.9 points). CONCLUSION:
      Switching from BHI 30 to BIAsp 30 improved glycaemic control without increasing
      the risk of hypoglycaemia.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - University of the Philippines College of Medicine, Manila, Philippines.
      Electronic address: docmalim@gmail.com.
FAU - Lim-Abrahan, Mary Anne
AU  - Lim-Abrahan MA
FAU - Yu-Gan, Susan
AU  - Yu-Gan S
FAU - Jain, Anand B
AU  - Jain AB
FAU - Sobrepena, Leorino M
AU  - Sobrepena LM
FAU - Racho, Veronica A
AU  - Racho VA
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70008-1 [pii]
AID - 10.1016/S0168-8227(13)70008-1 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S35-40. doi:
      10.1016/S0168-8227(13)70008-1.

PMID- 23647716
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup 
      of type 2 diabetic patients switched from biphasic human insulin 30: A
      sub-analysis of the A1chieve study.
PG  - S30-4
LID - 10.1016/S0168-8227(13)70007-X [doi]
LID - S0168-8227(13)70007-X [pii]
AB  - AIM: To determine the safety and effectiveness of biphasic insulin aspart 30
      (BIAsp 30) therapy in Bangladeshi type 2 diabetes (T2D) patients switched from
      biphasic human insulin (BHI) as a sub-analysis of the A1chieve study. METHODS:
      Bangladeshi patients switched from BHI to BIAsp 30 at the discretion of their
      physicians were included. The primary outcome was the incidence of serious
      adverse drug reactions (SADRs), including major hypoglycaemia. Secondary outcomes
      comprised changes from baseline to Week 24 in the number of hypoglycaemic events,
      glycated haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), postprandial
      plasma glucose (PPPG), systolic blood pressure and body weight. Quality of life
      (QoL) was evaluated at baseline and Week 24 using the EQ-5D questionnaire.
      RESULTS: A total of 82 patients (mean age +/- SD: 52.3+/-12.2 years; body mass
      index: 25.6+/-3.3kg/m(2)) with a mean diabetes duration of 9.5+/-5.5 years and
      mean duration on insulin of 2.5+/-2.4 years were included. The mean BIAsp 30 dose
      was 0.49+/-0.20 U/kg at baseline and 0.47+/-0.17 U/kg at Week 24. No SADRs were
      reported. No events of hypoglycaemia (overall, major, minor or nocturnal) were
      reported at Week 24. Mean HbA1c, FPG and PPPG levels improved by -2.5+/-1.3%,
      -65.0+/-31.8 mg/dL and -119.3+/-48.7 mg/dL, respectively, over 24 weeks. QoL also
      improved (mean change from baseline: +28.5+/-12.9 points). CONCLUSION: Switching 
      from BHI to BIAsp 30 therapy improved blood glucose control and was
      well-tolerated in this Bangladeshi subgroup.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - BIRDEM Hospital, Dhaka, Bangladesh.
FAU - Latif, Zafar Ahmed
AU  - Latif ZA
FAU - Pathan, Md Faruque
AU  - Pathan MF
FAU - Siddiqui, Md Nazrul Islam
AU  - Siddiqui MN
FAU - Sobhan, Md Javed
AU  - Sobhan MJ
FAU - Rahman, Md Mahfuzur
AU  - Rahman MM
FAU - Ashrafuzzaman, S M
AU  - Ashrafuzzaman SM
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70007-X [pii]
AID - 10.1016/S0168-8227(13)70007-X [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S30-4. doi:
      10.1016/S0168-8227(13)70007-X.

PMID- 23647715
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes:
      Results from the ASEAN cohort of the A1chieve study.
PG  - S3-9
LID - 10.1016/S0168-8227(13)70003-2 [doi]
LID - S0168-8227(13)70003-2 [pii]
AB  - AIM: To determine the safety and effectiveness of biphasic insulin aspart 30
      (BIAsp 30) in the ASEAN cohort of the A1chieve study. METHODS: Type 2 diabetes
      patients from Indonesia, Malaysia, Philippines and Singapore prescribed BIAsp 30 
      therapy were included. The primary outcome was evaluation of serious adverse drug
      reactions including major hypoglycaemia over 24 weeks. Secondary outcomes were
      changes in hypoglycaemic events, serious adverse events (SAEs) and effectiveness 
      parameters. RESULTS: This sub-analysis included 2798 patients (insulin-naive,
      1903; insulin-experienced, 895) with mean age +/- SD, 55.3+/-10.8 years, BMI,
      24.9+/-4.6kg/m(2) and diabetes duration, 7.5+/-5.9 years. Baseline HbA1c in the
      entire cohort was poor (9.9%, 85 mmol/mol). A total of 15 SAEs were reported in 7
      insulin-experienced patients (1 moderate event was related to BIAsp 30). Overall 
      hypoglycaemia at Week 24 was 0.88 events/patient-year compared to 1.71
      events/patient-year reported at baseline (change in proportion of patients
      affected, p < 0.0001). No major hypoglycaemia was reported at Week 24. BIAsp 30
      significantly improved glucose control (HbA1c, fasting plasma glucose and
      postprandial plasma glucose, p < 0.001) at Week 24. The proportion of patients
      achieving HbA1c <7.0% at Week 24 was 35.3% compared to 3.5% at baseline. The
      lipid profile and systolic blood pressure also improved significantly (p <
      0.001). Quality of life was positively impacted (mean change in visual analogue
      scores from EQ-5D = 10.6+/-13.8 points, p < 0.001). CONCLUSION: BIAsp 30 was
      well-tolerated and improved glucose control while decreasing the risk of
      hypoglycaemia.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - University of the Philippines College of Medicine, Manila, Philippines.
      Electronic address: docmalim@gmail.com.
FAU - Lim-Abrahan, Mary Anne
AU  - Lim-Abrahan MA
FAU - Jain, Anand B
AU  - Jain AB
FAU - Bebakar, Wan Mohamad Wan
AU  - Bebakar WM
FAU - Seah, Darren
AU  - Seah D
FAU - Soewondo, Pradana
AU  - Soewondo P
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70003-2 [pii]
AID - 10.1016/S0168-8227(13)70003-2 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S3-9. doi:
      10.1016/S0168-8227(13)70003-2.

PMID- 23647714
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2
      diabetes: Results from the ASEAN subgroup of the A1chieve study.
PG  - S24-9
LID - 10.1016/S0168-8227(13)70006-8 [doi]
LID - S0168-8227(13)70006-8 [pii]
AB  - AIM: To evaluate the safety and effectiveness of biphasic insulin aspart 30
      (BIAsp 30) in ASEAN type 2 diabetes (T2D) patients switched from biphasic human
      insulin (BHI) in the non-interventional 24-week A1chieve study. METHODS:
      Indonesian, Malaysian, Filipino and Singaporean patients switched from BHI to
      BIAsp 30 at their physicians' discretion were included. The incidence of serious 
      adverse drug reactions (SADRs), including major hypoglycaemia was the primary
      endpoint. Changes in hypoglycaemia, glycated haemoglobin A1c (HbA1c), fasting
      plasma glucose (FPG), postprandial plasma glucose (PPPG), lipids, body weight and
      systolic blood pressure were also evaluated. Quality of life (QoL) was measured
      using the EQ-5D questionnaire. RESULTS: For the 465 patients included (mean+/-SD 
      age: 56+/-10.3 years, diabetes duration: 9.7+/-7.1 years, baseline HbA1c:
      9.4+/-1.8%), the mean pre-study BHI dose was 0.62+/-0.28 IU/kg and 63.4% were
      dosing BHI twice daily (bid). The mean baseline BIAsp 30 dose was
      0.65+/-0.27U/kg, titrated up to 0.71+/-0.28U/kg over 24 weeks, and most patients 
      continued bid dosing. No SADRs or major hypoglycaemic episodes were reported. The
      proportion of patients reporting overall hypoglycaemia decreased significantly
      from 10.8% at baseline to 3.4% at Week 24 (p < 0.0001). Significant improvements 
      in glycaemic control were noted (HbA1c: -1.4+/-1.7%, FPG: -56.7+/-72.5 mg/dL,
      post-breakfast PPPG: -84.8+/-82.8 mg/dL, p < 0.001). Mean QoL improved by
      +6.6+/-14.6 points (p < 0.001). CONCLUSION: BIAsp 30 was well-tolerated and
      significantly increased glycaemic control in this ASEAN subgroup poorly
      controlled on BHI.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Hospital Putrajaya, Putrajaya, Malaysia. Electronic address:
      zanariahh@hotmail.com.
FAU - Hussein, Zanariah
AU  - Hussein Z
FAU - Lim-Abrahan, Mary Anne
AU  - Lim-Abrahan MA
FAU - Jain, Anand B
AU  - Jain AB
FAU - Goh, Su Yen
AU  - Goh SY
FAU - Soewondo, Pradana
AU  - Soewondo P
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70006-8 [pii]
AID - 10.1016/S0168-8227(13)70006-8 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S24-9. doi:
      10.1016/S0168-8227(13)70006-8.

PMID- 23647713
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Safety and effectiveness of insulin aspart in type 2 diabetic patients: Results
      from the ASEAN cohort of the A1chieve study.
PG  - S17-23
LID - 10.1016/S0168-8227(13)70005-6 [doi]
LID - S0168-8227(13)70005-6 [pii]
AB  - AIM: To examine the clinical safety and effectiveness of insulin aspart (IAsp)
      therapy in type 2 diabetes (T2D) patients from the ASEAN cohort of the
      international, 24-week, non-interventional A1chieve study. METHODS: T2D patients 
      from Indonesia, Malaysia, Philippines and Singapore, who started IAsp therapy
      with or without oral glucose-lowering drugs, were included. The primary endpoint 
      was the incidence of serious adverse drug reactions (SADRs), including major
      hypoglycaemic events. Secondary endpoints included hypoglycaemia, glycated
      haemoglobin A1c [HbA1c], fasting plasma glucose [FPG], postprandial plasma
      glucose [PPPG], systolic blood pressure [SBP], body weight and lipids. Quality of
      life (QoL) was assessed using the EQ-5D questionnaire. Results: Overall, 312 T2D 
      patients (222 insulin-naive and 90 insulin-experienced) with a mean+/-SD age of
      56.6+/-11.2 years, BMI of 24.2+/-3.9 kg/m(2) and diabetes duration of 7.0+/-5.7
      years were included. The mean daily IAsp dose was 0.51+/-0.31U/kg at baseline
      titrated up to 0.60+/-0.29U/kg at Week 24. No SADRs or major hypoglycaemic events
      were reported in the entire subgroup. The proportion of patients who reported
      overall hypoglycaemia decreased from baseline to Week 24 (7.1% vs. 0.3%, p <
      0.0001). The mean HbA1c improved from 9.5+/-1.6% at baseline to 7.6+/-1.3% after 
      24 weeks (p < 0.001). The mean FPG, post-breakfast PPPG and SBP also improved (p 
      < 0.001). Health-related QoL scores increased in the entire subgroup (mean
      increase: 9.8+/-14.6 points, p < 0.001). CONCLUSIONS: Starting IAsp therapy was
      well-tolerated and was associated with significantly improved overall glycaemic
      control in the ASEAN cohort.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Universiti Sains Malaysia, 16150 Kubang Kerian, Kota Bharu, Kelantan, Malaysia.
      Electronic address: wanmohd@kb.usm.my.
FAU - Bebakar, Wan Mohamad Wan
AU  - Bebakar WM
FAU - Lim-Abrahan, Mary Anne
AU  - Lim-Abrahan MA
FAU - Jain, Anana B
AU  - Jain AB
FAU - Seah, Darren
AU  - Seah D
FAU - Soewondo, Pradana
AU  - Soewondo P
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70005-6 [pii]
AID - 10.1016/S0168-8227(13)70005-6 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S17-23. doi:
      10.1016/S0168-8227(13)70005-6.

PMID- 23647712
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Safety and effectiveness of insulin detemir in type 2 diabetes: Results from the 
      ASEAN cohort of the A1chieve study.
PG  - S10-6
LID - 10.1016/S0168-8227(13)70004-4 [doi]
LID - S0168-8227(13)70004-4 [pii]
AB  - AIM: To determine the safety and effectiveness of insulin detemir (IDet) in type 
      2 diabetes patients from the ASEAN cohort of the A1chieve study. METHODS:
      Patients from Indonesia, Malaysia, Philippines and Singapore prescribed IDet at
      the discretion of their physicians were included. The primary outcome was the
      incidence of serious adverse drug reactions including major hypoglycaemia over 24
      weeks. Secondary endpoints included changes in the frequency of hypoglycaemia,
      serious adverse events and effectiveness assessments. RESULTS: This sub-analysis 
      included 1540 patients (insulin-naive, 1239; insulin-experienced, 301) with mean 
      age +/- SD 56.4+/-10.9 years, BMI 25.4+/-4.6kg/m(2) and diabetes duration
      6.9+/-5.3 years. Insulin-naive patients received a baseline IDet dose of
      0.24+/-0.11U/kg titrated up to 0.37+/-0.21 U/kg by Week 24. The pre-study insulin
      dose in insulin-experienced patients was 0.41+/-0.25 U/kg and baseline IDet dose 
      was 0.31+/-0.24U/kg titrated up to 0.40+/-0.20 U/kg by Week 24. Overall
      hypoglycaemia decreased from 1.73 to 0.46 events/patient-year from baseline to
      Week 24 (change in proportion of patients affected, p < 0.0001). At Week 24, 1
      major hypoglycaemic event was reported in 1 insulin-experienced patient. IDet
      significantly improved glucose control (p < 0.001) at Week 24. The lipid profile 
      and systolic blood pressure improved (p < 0.001) and body weight did not change
      significantly. Quality of life was positively impacted (p < 0.001). CONCLUSION:
      IDet was well-tolerated and improved glycaemic control without increasing the
      risk of hypoglycaemia or weight gain.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia.
      Electronic address: soewondops@yahoo.com.
FAU - Soewondo, Pradana
AU  - Soewondo P
FAU - Mohamed, Mafauzy
AU  - Mohamed M
FAU - Jain, Anand B
AU  - Jain AB
FAU - Sy, Rosa Allyn G
AU  - Sy RA
FAU - Khoo, Chin Meng
AU  - Khoo CM
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)70004-4 [pii]
AID - 10.1016/S0168-8227(13)70004-4 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S10-6. doi:
      10.1016/S0168-8227(13)70004-4.

PMID- 23647711
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100 Suppl 1
DP  - 2013 Apr
TI  - Observational research: an integral part of enhancing diabetes management in
      south-east Asia.
PG  - S1-2
LID - 10.1016/S0168-8227(13)00159-9 [doi]
LID - S0168-8227(13)00159-9 [pii]
AD  - Institute of Cellular Medicine - Diabetes, Newcastle University, Newcastle upon
      Tyne, UK. Electronic address: philip.home@newcastle.ac.uk.
FAU - Home, Philip
AU  - Home P
LA  - eng
PT  - Editorial
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/10 06:00
MHDA- 2013/05/10 06:00
CRDT- 2013/05/08 06:00
AID - S0168-8227(13)00159-9 [pii]
AID - 10.1016/S0168-8227(13)00159-9 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S1-2. doi:
      10.1016/S0168-8227(13)00159-9.

PMID- 23653894
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 2314-6141 (Electronic)
VI  - 2013
DP  - 2013
TI  - Current aspects in the pathophysiology and treatment of chronic wounds in
      diabetes mellitus.
PG  - 385641
LID - 10.1155/2013/385641 [doi]
AB  - Impaired wound healing is a frequent and very severe problem in patients with
      diabetes mellitus, yet little is known about the underlying pathomechanisms. In
      this paper we review the biology of wound healing with particular attention to
      the pathophysiology of chronic wounds in diabetic patients. The standard
      treatment of diabetic ulcers includes measures to optimize glycemic control as
      well as extensive debridement, infection elimination by antibiotic therapy based 
      on wound pathogen cultures, the use of moisture dressings, and offloading high
      pressure from the wound bed. In this paper we discuss novel adjuvant therapies
      with particular reference to the use of autologous skin transplants for the
      treatment of diabetic foot ulcers which do not respond to standard care.
AD  - Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine
      III, Technical University Medical Center, 01307 Dresden, Germany.
FAU - Tsourdi, Elena
AU  - Tsourdi E
FAU - Barthel, Andreas
AU  - Barthel A
FAU - Rietzsch, Hannes
AU  - Rietzsch H
FAU - Reichel, Andreas
AU  - Reichel A
FAU - Bornstein, Stefan R
AU  - Bornstein SR
LA  - eng
PT  - Journal Article
DEP - 20130407
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
PMC - PMC3638655
OID - NLM: PMC3638655
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/10/28 [received]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/07 [epublish]
AID - 10.1155/2013/385641 [doi]
PST - ppublish
SO  - Biomed Res Int. 2013;2013:385641. doi: 10.1155/2013/385641. Epub 2013 Apr 7.

PMID- 23653873
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130508
DCOM- 20130509
LR  - 20130510
IS  - 2090-6668 (Print)
IS  - 2090-6676 (Linking)
VI  - 2013
DP  - 2013
TI  - Not just another cause of dyspnea: common complaint leads to a rare diagnosis.
PG  - 974085
LID - 10.1155/2013/974085 [doi]
AB  - A 62-year-old man with past medical history of type 2 diabetes mellitus (DM-2)
      and hypertension presented with progressive shortness of breath since three
      months. He was diagnosed with diabetic polyradiculopathy with diaphragmatic
      involvement and was started on intravenous immunoglobulin (IVIg) therapy. Rapid
      improvement was seen as evidenced by increased vital capacity and other pulmonary
      function parameters. Considering the patient's positive response to intravenous
      immunoglobulins (IVIg), this case strengthens the fact that diaphragmatic
      involvement in Type 2 Diabetes Mellitus can be a part of focal or polyneuropathy 
      and that the pathogenesis is immune mediated.
AD  - Department of Internal Medicine, Mercer University School of Medicine, 707 Pine
      Street, Macon, GA 31201, USA.
FAU - Goyal, Hemant
AU  - Goyal H
FAU - Arora, Shitij
AU  - Arora S
FAU - Duffoo, Frantz
AU  - Duffoo F
FAU - Bhat, Utpal
AU  - Bhat U
FAU - Bhandari, Rekha
AU  - Bhandari R
FAU - Rajupet, Sritha
AU  - Rajupet S
FAU - Lwin, Kyaw Kyaw
AU  - Lwin KK
FAU - Patel, Jigar
AU  - Patel J
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - United States
TA  - Case Rep Neurol Med
JT  - Case reports in neurological medicine
JID - 101576451
PMC - PMC3638553
OID - NLM: PMC3638553
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:01
CRDT- 2013/05/09 06:00
PHST- 2013/01/25 [received]
PHST- 2013/03/03 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1155/2013/974085 [doi]
PST - ppublish
SO  - Case Rep Neurol Med. 2013;2013:974085. doi: 10.1155/2013/974085. Epub 2013 Apr 8.

PMID- 23653857
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 2090-0716 (Electronic)
IS  - 2090-0708 (Linking)
VI  - 2013
DP  - 2013
TI  - Adipose tissue dysfunction in nascent metabolic syndrome.
PG  - 393192
LID - 10.1155/2013/393192 [doi]
AB  - The metabolic syndrome (MetS) confers an increased risk for both type 2 diabetes 
      mellitus (T2DM) and cardiovascular disease (CVD). Moreover, studies on adipose
      tissue biology in nascent MetS uncomplicated by T2DM and/or CVD are scanty.
      Recently, we demonstrated that adipose tissue dysregulation and aberrant
      adipokine secretion contribute towards the syndrome's low-grade chronic
      proinflammatory state and insulin resistance. Specifically, we have made the
      novel observation that subcutaneous adipose tissue (SAT) in subjects with nascent
      MetS has increased macrophage recruitment with cardinal crown-like structures. We
      have also shown that subjects with nascent MetS have increased the levels of
      SAT-secreted adipokines (IL-1, IL-6, IL-8, leptin, RBP-4, CRP, SAA, PAI-1, MCP-1,
      and chemerin) and plasma adipokines (IL-1, IL-6, leptin, RBP-4, CRP, SAA, and
      chemerin), as well as decreased levels of plasma adiponectin and both plasma and 
      SAT omentin-1. The majority of these abnormalities persisted following correction
      for increased adiposity. Our data, as well as data from other investigators,
      thus, highlight the importance of subcutaneous adipose tissue dysfunction in
      subjects with MetS and its contribution to the proinflammatory state and insulin 
      resistance. This adipokine profile may contribute to increased insulin resistance
      and low-grade inflammation, promoting the increased risk of T2DM and CVD.
AD  - Department of Pediatrics, Vanderbilt University, Nashville, TN 37232-9170, USA.
FAU - Bremer, Andrew A
AU  - Bremer AA
FAU - Jialal, Ishwarlal
AU  - Jialal I
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - United States
TA  - J Obes
JT  - Journal of obesity
JID - 101526295
SB  - IM
PMC - PMC3638696
OID - NLM: PMC3638696
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/01/26 [received]
PHST- 2013/02/14 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1155/2013/393192 [doi]
PST - ppublish
SO  - J Obes. 2013;2013:393192. doi: 10.1155/2013/393192. Epub 2013 Apr 4.

PMID- 23653856
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130508
DCOM- 20130509
LR  - 20130510
IS  - 2090-0384 (Print)
VI  - 2013
DP  - 2013
TI  - Hypertension and diabetes: entry points for prevention and control of the global 
      cardiovascular epidemic.
PG  - 878460
LID - 10.1155/2013/878460 [doi]
AD  - Management of Noncommunicable Diseases, World Health Organization, Geneva 1211,
      Switzerland.
FAU - Mendis, Shanthi
AU  - Mendis S
FAU - O'Brien, Eoin
AU  - O'Brien E
FAU - Seedat, Yackoob Kassim
AU  - Seedat YK
FAU - Yusuf, Salim
AU  - Yusuf S
LA  - eng
PT  - Journal Article
DEP - 20130407
PL  - United States
TA  - Int J Hypertens
JT  - International journal of hypertension
JID - 101538881
PMC - PMC3638673
OID - NLM: PMC3638673
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:01
CRDT- 2013/05/09 06:00
PHST- 2013/02/10 [received]
PHST- 2013/02/10 [accepted]
PHST- 2013/04/07 [epublish]
AID - 10.1155/2013/878460 [doi]
PST - ppublish
SO  - Int J Hypertens. 2013;2013:878460. doi: 10.1155/2013/878460. Epub 2013 Apr 7.

PMID- 23653855
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130508
DCOM- 20130509
LR  - 20130510
IS  - 2090-0384 (Print)
VI  - 2013
DP  - 2013
TI  - Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 
      25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective
      Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial.
PG  - 749830
LID - 10.1155/2013/749830 [doi]
AB  - Objective. Report of prespecified and post hoc subgroup analyses of a randomized,
      controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) 
      combination therapy with T80 monotherapy, according to the presence of
      cardiovascular disease (CVD) risk factors. Methods. Hypertensive patients were
      randomized (2 : 1) to receive T80/H25 or T80 for 6 weeks, following a 1-week,
      low-dose, and run-in period. Systolic blood pressure (SBP) and diastolic BP
      reductions and BP goal achievement were evaluated in patients with CVD risk
      factors: presence of diabetes mellitus (DM), renal impairment, increased body
      mass index (BMI), and 10-year estimated risk for coronary heart disease (CHD).
      Results. In total, 888 patients received treatment. Overall, T80/H25 therapy
      significantly reduced SBP more than T80 monotherapy, irrespective of patient
      subgroup. In patients with DM, renal impairment, high BMI, and high CHD risk, BP 
      goal achievement rates (<140/90 mm Hg) at Week 7, among those treated with
      T80/H25, were 52.8%, 52.8%, 50.6%, and 38.5%, respectively. More patients with DM
      reached a guideline-based BP goal (<130/80 mm Hg) at 7 weeks with T80/H25 than
      with T80 monotherapy (16.7% versus 8.8%). Rates of treatment-related adverse
      events were low and comparable across patient subgroups. Conclusions.
      Antihypertensive treatment with T80/H25 single-pill combination is effective and 
      generally well tolerated, irrespective of the presence of CVD risk factors.
AD  - Louisville Metabolic and Atherosclerosis Research Center Inc. (L-MARC), 3288
      Illinois Avenue, Louisville, KY 40213, USA.
FAU - Bays, Harold
AU  - Bays H
FAU - Gao, Pingjin
AU  - Gao P
FAU - Volker, Birgit
AU  - Volker B
FAU - Mattheus, Michaela
AU  - Mattheus M
FAU - Ruilope, Luis M
AU  - Ruilope LM
FAU - Zhu, Dingliang
AU  - Zhu D
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - United States
TA  - Int J Hypertens
JT  - International journal of hypertension
JID - 101538881
PMC - PMC3638649
OID - NLM: PMC3638649
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:01
CRDT- 2013/05/09 06:00
PHST- 2012/11/26 [received]
PHST- 2013/02/21 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1155/2013/749830 [doi]
PST - ppublish
SO  - Int J Hypertens. 2013;2013:749830. doi: 10.1155/2013/749830. Epub 2013 Apr 4.

PMID- 23653644
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130508
DCOM- 20130509
LR  - 20130510
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Glucose lowering therapeutic strategies for type 2 diabetic patients with chronic
      kidney disease in primary care setting in france: a cross-sectional study.
PG  - 640632
LID - 10.1155/2013/640632 [doi]
AB  - Aim. To understand glucose lowering therapeutic strategies of French general
      practitioners (GPs) in the management of type 2 diabetes mellitus (T2DM) patients
      with chronic kidney disease (CKD). Methods. A multicenter cross-sectional study
      was conducted from March to June 2011 among a sample of French GPs who contribute
      to the IMS Lifelink Disease Analyzer database. Eligible patients were those with 
      T2DM and moderate-to-severe CKD who visited their GPs at least once during the
      study period. Data were collected through electronic medical records and an
      additional questionnaire. Results. 116 GPs included 297 patients: 86 with stage
      3a (Group 1, GFR = 45-60 mL/min/1.73 m(2)) and 211 with stages 3b, 4, or 5 (Group
      2, GFR < 45 mL/min/1.73 m(2)). Patients' mean age was approximately 75 years.
      Insulin was used in 19% of patients, and was predominant in those with severe
      CKD. More than two-thirds of patients were treated with glucose lowering agents
      which were either contraindicated or not recommended for CKD. Conclusion
      Physicians most commonly considered the severity of diabetes and not CKD in their
      therapeutic decision making, exposing patients to potential iatrogenic risks. The
      recent patient oriented approach and individualization of glycemic objectives
      according to patient profile rather than standard HbA1c would improve this
      situation.
AD  - IMS Health France, 5-7 Place de la Pyramide, 92088 Paris La Defense, France.
FAU - Grandfils, N
AU  - Grandfils N
FAU - Detournay, B
AU  - Detournay B
FAU - Attali, C
AU  - Attali C
FAU - Joly, D
AU  - Joly D
FAU - Simon, D
AU  - Simon D
FAU - Verges, B
AU  - Verges B
FAU - Toussi, M
AU  - Toussi M
FAU - Briand, Y
AU  - Briand Y
FAU - Delaitre, O
AU  - Delaitre O
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3638677
OID - NLM: PMC3638677
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:01
CRDT- 2013/05/09 06:00
PHST- 2013/01/04 [received]
PHST- 2013/02/20 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1155/2013/640632 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:640632. doi: 10.1155/2013/640632. Epub 2013 Apr 4.

PMID- 23653642
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130508
DCOM- 20130509
LR  - 20130510
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease:
      newer data.
PG  - 450639
LID - 10.1155/2013/450639 [doi]
AB  - Nonalcoholic fatty liver disease (NAFLD) is the most common, chronic liver
      disease worldwide. Within this spectrum, steatosis alone is apparently benign,
      while nonalcoholic steatohepatitis may progress to cirrhosis and hepatocellular
      carcinoma. NAFLD is strongly associated with obesity, dyslipidemia, type 2
      diabetes mellitus, and cardiovascular disease. The pathogenesis of hepatic
      steatosis is not clearly known, but its main characteristics are considered
      insulin resistance, mitochondrial dysfunction, increased free fatty acids reflux 
      from adipose tissue to the liver, hepatocyte lipotoxicity, stimulation of chronic
      necroinflammation, and fibrogenic response. With recent advances in technology,
      advanced imaging techniques provide important information for diagnosis. There is
      a significant research effort in developing noninvasive monitoring of disease
      progression to fibrosis and response to therapy with potential novel biomarkers, 
      in order to facilitate diagnosis for the detection of advanced cirrhosis and to
      minimize the need of liver biopsy. The identification of NAFLD should be sought
      as part of the routine assessment of type 2 diabetics, as sought the
      microvascular complications and cardiovascular disease, because it is essential
      for the early diagnosis and proper intervention. Diet, exercise training, and
      weight loss provide significant clinical benefits and must be considered of first
      line for treating NAFLD.
AD  - 2nd Medical Department and Diabetes Center, NIMTS Hospital, 12 Monis Petraki,
      11521 Athens, Greece.
FAU - Mavrogiannaki, A N
AU  - Mavrogiannaki AN
FAU - Migdalis, I N
AU  - Migdalis IN
LA  - eng
PT  - Journal Article
DEP - 20130403
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3638654
OID - NLM: PMC3638654
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:01
CRDT- 2013/05/09 06:00
PHST- 2013/03/09 [received]
PHST- 2013/03/12 [accepted]
PHST- 2013/04/03 [epublish]
AID - 10.1155/2013/450639 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:450639. doi: 10.1155/2013/450639. Epub 2013 Apr 3.

PMID- 23653641
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130508
DCOM- 20130509
LR  - 20130510
IS  - 1687-8337 (Print)
IS  - 1687-8337 (Linking)
VI  - 2013
DP  - 2013
TI  - Association between Osteocalcin, Metabolic Syndrome, and Cardiovascular Risk
      Factors: Role of Total and Undercarboxylated Osteocalcin in Patients with Type 2 
      Diabetes.
PG  - 197519
LID - 10.1155/2013/197519 [doi]
AB  - Studies have demonstrated that total osteocalcin (TOC) is associated with
      metabolic syndrome (MetS) and therefore might influence the risk of
      cardiovascular disease in humans. Undercarboxylated osteocalcin (uOC) regulates
      insulin secretion and sensitivity in mice, but its relation to MetS in humans is 
      unclear. We aimed to determine whether uOC is related to MetS and/or its
      individual components and other cardiovascular risk factors in patients with type
      2 diabetes mellitus (T2DM), and whether TOC and uOC have utility in predicting
      the cardiovascular risk. We studied 203 T2DM patients with and without MetS. MetS
      was defined based on the NCEP-ATP III criteria. A correlation analysis was
      performed between the three outcome variables: (i) TOC, (ii) uOC, and (iii)
      carboxylated osteocalcin (cOC) and MetS components and other cardiovascular risk 
      factors. Both TOC and uOC were significantly lower in patients with MetS compared
      to those without MetS, independent of body mass index. In patients with MetS, uOC
      was significantly and positively correlated with HDL cholesterol, while TOC was
      significantly and negatively correlated with serum triglycerides. We report for
      the first time that uOC is related to lipid indices in patients with T2DM.
      Further studies are necessary to determine whether uOC can be utilized for
      cardiovascular risk assessments in these patients.
AD  - Obesity Research Center, College of Medicine, King Saud University, P.O. Box 2925
      (98), Riyadh 11461, Saudi Arabia ; Department of Medicine, College of Medicine,
      King Saud University, P.O. Box 2925 (38), Riyadh 11461, Saudi Arabia.
FAU - Alfadda, Assim A
AU  - Alfadda AA
FAU - Masood, Afshan
AU  - Masood A
FAU - Shaik, Shaffi Ahamed
AU  - Shaik SA
FAU - Dekhil, Hafedh
AU  - Dekhil H
FAU - Goran, Michael
AU  - Goran M
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - Egypt
TA  - Int J Endocrinol
JT  - International journal of endocrinology
JID - 101516376
PMC - PMC3638647
OID - NLM: PMC3638647
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:01
CRDT- 2013/05/09 06:00
PHST- 2012/12/05 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1155/2013/197519 [doi]
PST - ppublish
SO  - Int J Endocrinol. 2013;2013:197519. doi: 10.1155/2013/197519. Epub 2013 Apr 9.

PMID- 23653585
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130508
DCOM- 20130509
LR  - 20130510
IS  - 1661-8769 (Print)
IS  - 1661-8769 (Linking)
VI  - 4
IP  - 3
DP  - 2013 Mar
TI  - Report on a patient with a 12q24.31 microdeletion inherited from an
      insulin-dependent diabetes mellitus father.
PG  - 136-42
LID - 10.1159/000346473 [doi]
AB  - We report a 2.3-year-old female patient with global developmental delay,
      infantile spasms, hypotonia, microcephaly, flat face, full cheeks, macroglossia, 
      highly arched palate, retro-gnathia, narrow ear orifices, and cafe-au-lait spots.
      Molecular karyotyping revealed approximately a 1-Mb interstitial deletion of the 
      long arm of one chromosome 12, del(12)(q24.31). The same deletion was identified 
      in her father who presents insulin-dependent diabetes mellitus (IDDM) diagnosed
      at 14 years. Only one other patient with a similar de novo deletion has been
      reported previously [Mol Syndromol 2010;1:42-45]. A phenotype-genotype
      correlation is discussed, and the description of a novel rare microdeletion
      entity is raised.
AD  - Unite de Genetique Medicale et Laboratoire Associe INSERM a l'Unite UMR_S 910,
      Pole Technologie Sante, Universite Saint-Joseph, Beirut, Lebanon.
FAU - Chouery, E
AU  - Chouery E
FAU - Choucair, N
AU  - Choucair N
FAU - Abou Ghoch, J
AU  - Abou Ghoch J
FAU - El Sabbagh, S
AU  - El Sabbagh S
FAU - Corbani, S
AU  - Corbani S
FAU - Megarbane, A
AU  - Megarbane A
LA  - eng
PT  - Journal Article
DEP - 20130115
PL  - Switzerland
TA  - Mol Syndromol
JT  - Molecular syndromology
JID - 101525192
PMC - PMC3638924
OID - NLM: PMC3638924
OTO - NOTNLM
OT  - Chromosome 12q
OT  - Developmental delay
OT  - HNF1A
OT  - Haploinsufficient
OT  - Microdeletion 12q24.31
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:01
CRDT- 2013/05/09 06:00
PHST- 2012/12/04 [accepted]
PHST- 2013/01/15 [epublish]
AID - 10.1159/000346473 [doi]
AID - msy-0004-0136 [pii]
PST - ppublish
SO  - Mol Syndromol. 2013 Mar;4(3):136-42. doi: 10.1159/000346473. Epub 2013 Jan 15.

PMID- 23653460
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 May 7
TI  - Dipeptidylpeptidase Inhibition is Associated with Improvement in Blood Pressure
      and Diastolic Function in Insulin Resistant Male Zucker Obese Rats.
AB  - Diastolic dysfunction is a prognosticator for future cardiovascular events that
      demonstrates a strong correlation with obesity. Pharmacological inhibition of
      dipeptidylpeptidase-4 (DPP-4) to increase the bioavailability of glucagon like
      peptide-1 (GLP-1) is an emerging therapy for control of glycemia in type 2
      diabetes patients. Accumulating evidence suggests GLP-1 has insulin-independent
      actions in cardiovascular tissue; however it is not known whether DPP-4
      inhibition improves obesity-related diastolic dysfunction. Eight week old Zucker 
      Obese (ZO) and Zucker Lean (ZL) rats were fed normal chow diet or diet containing
      the DPP-4 inhibitor, linagliptin (LGT), for 8 weeks. Plasma DPP-4 activity was
      3.3-fold higher in ZO compared to ZL rats and was reduced by 95% with LGT
      treatment. LGT improved echocardiographic and pressure volume-derived indices of 
      diastolic function that were impaired in ZO control rats, without altering food
      intake or body wt gain during the study period. LGT also blunted elevated blood
      pressure progression in ZO rats involving improved skeletal muscle arteriolar
      function, without reducing left ventricular hypertrophy (LVH), fibrosis, or
      oxidative stress in ZO hearts. Expression of phosphorylated-eNOSser1177, total
      eNOS and SERCA2a protein was elevated in the LGT-treated ZO heart suggesting
      improved Ca2+ handling. The ZO myocardium had an abnormal mitochondrial
      sarcomeric arrangement and cristae structure that were normalized by LGT. These
      studies suggest that LGT reduces blood pressure and improves intracellular Cai2+ 
      mishandling and cardiomyocyte ultrastructure which collectively result in
      improvements in diastolic function in the absence of reductions in LVH, fibrosis,
      or oxidative stress in insulin resistant ZO rats.
AD  - 1University of Missouri School of Medicine, Departments of Internal Medicine and.
FAU - Aroor, Annayya R
AU  - Aroor AR
FAU - Sowers, James R
AU  - Sowers JR
FAU - Bender, Shawn B
AU  - Bender SB
FAU - Nistala, Ravi
AU  - Nistala R
FAU - Garro, Mona
AU  - Garro M
FAU - Mugerfeld, Irina
AU  - Mugerfeld I
FAU - Hayden, Melvin R
AU  - Hayden MR
FAU - Johnson, Megan S
AU  - Johnson MS
FAU - Salam, Muhammad
AU  - Salam M
FAU - Whaley-Connell, Adam
AU  - Whaley-Connell A
FAU - Demarco, Vincent G
AU  - Demarco VG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - en.2013-1096 [pii]
AID - 10.1210/en.2013-1096 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 May 7.

PMID- 23653455
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
DP  - 2013 May 7
TI  - Mechanisms in Endocrinology: Non-alcoholic fatty liver disease in common
      endocrine disorders.
AB  - Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease spanning from 
      simple benign steatosis through to steatohepatitis with fibrosis and scarring
      that can eventually lead to cirrhosis. Its prevalence is rising rapidly and is
      developing into the leading indication for liver transplantation world-wide.
      Abnormalities in endocrine axes have been associated with NALFD, including
      hypogonadism, hypothyroidism, growth hormone deficiency and hypercortisolaemia.
      In some instances, correction of the endocrine defects has been shown to have a
      beneficial impact. Whilst in patients with type 2 diabetes the association with
      NAFLD is well established and recognised, there is a more limited appreciation of
      the condition amongst common endocrine diseases presenting with hormonal excess
      or deficiency. In this review, we examine the published data that have suggested 
      a mechanistic link between endocrine abnormalities and NAFLD and summarize the
      clinical data endorsing these observations.
AD  - J Hazlehurst, Centre for Diabetes, Endocrinology and Metabolism, University of
      Birmingham, Birmingham, United Kingdom.
FAU - Hazlehurst, Jonathan M
AU  - Hazlehurst JM
FAU - Tomlinson, Jeremy W
AU  - Tomlinson JW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - EJE-13-0296 [pii]
AID - 10.1530/EJE-13-0296 [doi]
PST - aheadofprint
SO  - Eur J Endocrinol. 2013 May 7.

PMID- 23653454
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
DP  - 2013 May 7
TI  - Ketoacidosis as the initial clinical condition in nine patients with acromegaly: 
      A review of 860 cases at a single institute.
AB  - OBJECTIVE: Excess growth hormone (GH) causes insulin resistance and impaired
      glucose metabolism. The objective of this study was to clarify the prevalence of 
      ketoacidosis as the initial presenting symptom of acromegaly. DESIGN AND METHODS:
      Data were collected from 860 patients with acromegaly who received pituitary
      surgery at Toranomon Hospital over the last 32 years, between 1980 and 2011.
      RESULTS: Nine cases had ketoacidosis before being diagnosed with acromegaly,
      including seven males and two females with a mean +/- SD age of 38.8 +/- 14.2
      years old. Serum GH and IGF-1 levels were 155 +/- 203 ng/ml and 9.86 +/- 0.68
      SDS, respectively, before pituitary surgery and 3.6 +/- 1.7 ng/ml and 3.72 +/-
      3.40 SDS after surgery, respectively. The maximum tumor diameter was 28.2 +/-
      11.6 mm (ranging from 15 mm to 47 mm, n=8). None of the patients were diagnosed
      with diabetes mellitus (DM), nor were they positive for antibodies related to
      type 1 DM. A possible precipitating factor for ketoacidosis in six cases was
      excessive ingestion of sugar-containing soft drinks. All of the cases had
      invasive pituitary adenomas. After pituitary surgery, plasma glucose levels were 
      under control without requiring insulin in all cases. Furthermore, six patients
      did not need oral hypoglycemic agents. CONCLUSIONS: Approximately 1% of patients 
      with acromegaly presented with diabetic ketoacidosis as their first clinical
      condition. (219 words).
AD  - N Yoshida, Endocrine Center, Toranomon Hospital, Tokyo, Japan.
FAU - Yoshida, Naohiro
AU  - Yoshida N
FAU - Goto, Hiromasa
AU  - Goto H
FAU - Suzuki, Hisanori
AU  - Suzuki H
FAU - Nagasawa, Kaoru
AU  - Nagasawa K
FAU - Takeshita, Akira
AU  - Takeshita A
FAU - Okubo, Minoru
AU  - Okubo M
FAU - Megumi, Miyakawa
AU  - Megumi M
FAU - Mori, Yasumichi
AU  - Mori Y
FAU - Fukuhara, Noriaki
AU  - Fukuhara N
FAU - Nishioka, Hiroshi
AU  - Nishioka H
FAU - Yamada, Shozo
AU  - Yamada S
FAU - Takeuchi, Yasuhiro
AU  - Takeuchi Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - EJE-13-0060 [pii]
AID - 10.1530/EJE-13-0060 [doi]
PST - aheadofprint
SO  - Eur J Endocrinol. 2013 May 7.

PMID- 23653431
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 7
TI  - Consumption of yogurts fortified in vitamin D and calcium reduces serum
      parathyroid hormone and markers of bone resorption: a double-blind randomized
      controlled trial in institutionalized elderly women.
AB  - Context:Nutritional prevention of bone deterioration with fortified foods seems
      particularly suitable in institutionalized elderly women at risk of vitamin D
      deficiency, secondary hyperparathyroidism, increased bone resorption and
      osteoporotic fracture.Objective:To evaluate whether fortification of yogurts with
      vitamin D and calcium exerts an additional lowering effect on serum parathyroid
      hormone (PTH) and bone resorption markers (BRM) as compared to iso-caloric and
      iso-protein dairy products in elderly women.Design:A randomized double-blind
      controlled trial, 56-d intervention was conducted in institutionalized women
      (mean age 85.5 yr) consuming two 125 g servings of either vitamin D and
      calcium-fortified yogurts (FY) at supplemental levels of 10 mug vitamin D3/d and 
      calcium 800 mg/d, or non fortified control yogurts (CY) providing 280 mg/d of
      calcium.Main Outcomes:The endpoints were serum changes from baseline (D0) to D28 
      and D56 in 25-hydroxyvitamin-D (25OHD), PTH and in BRM:
      Tartrate-resistant-acid-phosphatase-isoform-5b (TRAP5b), the primary outcome, and
      carboxy-terminal-cross-linked-telopeptide of type-I-collagen (CTX).Results:At
      D56, serum 25OHD increased (mean+/-SEM) by 25.3+/-1.8 vs. 5.2+/-2.5 nmol/L in FY 
      (n=29) and CY (n=27), respectively (P<0.0001). The corresponding changes in PTH
      were -28.6+/-7.2 vs. -8.0+/-4.3% (P=0.0003), TRAP5b -21.9+/-4.3 vs. 3.0+/-3.2%
      (P<0.0001), CTX -11.0+/-9.7 vs. -3.0+/-4.1% (P=0.0146), in FY and CY,
      respectively. At D28, these differences were less pronounced, but already
      significant for 25OHD, PTH and TRAP5b.Conclusions:This study in institutionalized
      elderly at high risk for osteoporotic fracture suggests that fortification of
      dairy products with vitamin D3 and calcium provides a greater prevention of
      accelerated bone resorption as compared to non-fortified equivalent foods.
AD  - Division of Bone Disease, University Hospitals and Faculty of Medicine, Geneva,
      Switzerland (JPB), Groupe de Recherche Nutritionnelle, Yoplait, 150 rue Gallieni,
      92641 Boulogne, France (VB and FP).; Division of Endocrinology, Diabetes, and
      Metabolism, University Hospital Basel, Switzerland (MK).
FAU - Bonjour, Jean-Philippe
AU  - Bonjour JP
FAU - Benoit, Valerie
AU  - Benoit V
FAU - Payen, Flore
AU  - Payen F
FAU - Kraenzlin, Marius
AU  - Kraenzlin M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - jc.2013-1274 [pii]
AID - 10.1210/jc.2013-1274 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 7.

PMID- 23653391
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1933-7205 (Electronic)
IS  - 1933-7191 (Linking)
DP  - 2013 May 7
TI  - Metformin, at Concentrations Corresponding to the Treatment of Diabetes,
      Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer
      Cells.
AB  - The use of the type 2 diabetics drug metformin has been correlated with enhanced 
      progression-free survival in ovarian cancer. The literature has speculated that
      this enhancement is due to the high concentration of metformin directly causing
      cancer cell death. However, this explanation does not fit with clinical data
      reporting that the women exposed to constant micromolar concentrations of
      metformin, as present in the treatment of diabetes, respond better to
      chemotherapy. Herein, our aim was to examine whether micromolar concentrations of
      metformin alone could bring about cancer cell death and whether micromolar
      metformin could increase the cytotoxic effect of commonly used chemotherapies in 
      A2780 and SKOV3 cell lines and primary cultured cancer cells isolated from the
      peritoneal fluid of patients with advanced ovarian cancer. Our results in cell
      lines demonstrate that no significant loss of viability or change in cell cycle
      was observed with micromolar metformin alone; however, we observed cytotoxicity
      with micromolar metformin in combination with chemotherapy at concentrations
      where the chemotherapy alone produced no loss in viability. We demonstrate that
      previous exposure and maintenance of metformin in conjunction with carboplatin
      produces a synergistic enhancement in cytotoxicity of A2780 and SKOV3 cells (55% 
      and 43%, respectively). Furthermore, in 5 (44%) of the 11 ovarian cancer primary 
      cultures, micromolar metformin improved the cytotoxic response to carboplatin but
      not paclitaxel or doxorubicin. In conclusion, we present data that support the
      need for a clinical study to evaluate the adjuvant maintenance or prescription of
      currently approved doses of metformin during the chemotherapeutic treatment of
      ovarian cancer.
AD  - 1Departamento de Fisiologia, Facultad de Ciencias Biologicas, Pontificia
      Universidad Catolica de Chile, Santiago, Chile.
FAU - Erices, Rafaela
AU  - Erices R
FAU - Bravo, Maria Loreto
AU  - Bravo ML
FAU - Gonzalez, Pamela
AU  - Gonzalez P
FAU - Oliva, Barbara
AU  - Oliva B
FAU - Racordon, Dusan
AU  - Racordon D
FAU - Garrido, Marcelo
AU  - Garrido M
FAU - Ibanez, Carolina
AU  - Ibanez C
FAU - Kato, Sumie
AU  - Kato S
FAU - Branes, Jorge
AU  - Branes J
FAU - Pizarro, Javier
AU  - Pizarro J
FAU - Barriga, Maria Isabel
AU  - Barriga MI
FAU - Barra, Alejandro
AU  - Barra A
FAU - Bravo, Erasmo
AU  - Bravo E
FAU - Alonso, Catalina
AU  - Alonso C
FAU - Bustamente, Eva
AU  - Bustamente E
FAU - Cuello, Mauricio A
AU  - Cuello MA
FAU - Owen, Gareth I
AU  - Owen GI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Reprod Sci
JT  - Reproductive sciences (Thousand Oaks, Calif.)
JID - 101291249
OTO - NOTNLM
OT  - chemotherapy
OT  - doxorubicin
OT  - paclitaxel
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 1933719113488441 [pii]
AID - 10.1177/1933719113488441 [doi]
PST - aheadofprint
SO  - Reprod Sci. 2013 May 7.

PMID- 23653387
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1933-7205 (Electronic)
IS  - 1933-7191 (Linking)
DP  - 2013 May 7
TI  - L-Methionine Placental Uptake: Characterization and Modulation in Gestational
      Diabetes Mellitus.
AB  - Our aim was to investigate the influence of gestational diabetes mellitus (GDM)
      and GDM-associated conditions upon the placental uptake of 14C-l-methionine
      (14C-l-Met). The 14C-l-Met uptake by human trophoblasts (TBs) obtained from
      normal pregnancies (normal trophoblast [NTB] cells) is mainly system l-type amino
      acid transporter 1 (LAT1 [L])-mediated, although a small contribution of system
      y+LAT2 is also present. Comparison of 14C-l-Met uptake by NTB and by human TBs
      obtained from GDM pregnancies (diabetic trophoblast [DTB] cells) reveals similar 
      kinetics, but a contribution of systems A, LAT2, and b0+ and a greater
      contribution of system y+LAT1 appears to exist in DTB cells. Short-term exposure 
      to insulin and long-term exposure to high glucose, tumor necrosis factor-alpha,
      and leptin decrease 14C-l-Met uptake in a human TB (Bewo) cell line. The effect
      of leptin was dependent upon phosphoinositide 3-kinase,
      extracellular-signal-regulated kinase 1/2 (ERK/MEK 1/2), and p38
      mitogen-activated protein kinase. In conclusion, GDM does not quantitatively
      alter 14C-l-Met placental uptake, although it changes the nature of transporters 
      involved in that process.
AD  - 1Department of Biochemistry (U38-FCT), Faculty of Medicine, University of Porto, 
      Porto, Portugal.
FAU - Araujo, Joao R
AU  - Araujo JR
FAU - Correia-Branco, Ana
AU  - Correia-Branco A
FAU - Ramalho, Carla
AU  - Ramalho C
FAU - Goncalves, Pedro
AU  - Goncalves P
FAU - Pinho, Maria J
AU  - Pinho MJ
FAU - Keating, Elisa
AU  - Keating E
FAU - Martel, Fatima
AU  - Martel F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Reprod Sci
JT  - Reproductive sciences (Thousand Oaks, Calif.)
JID - 101291249
OTO - NOTNLM
OT  - gestational diabetes
OT  - l-methionine
OT  - placenta
OT  - transport
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 1933719113488442 [pii]
AID - 10.1177/1933719113488442 [doi]
PST - aheadofprint
SO  - Reprod Sci. 2013 May 7.

PMID- 23653377
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 7
TI  - Circulating secreted frizzled-related protein 5 and wingless-type MMTV
      integration site family member 5a levels in patients with type 2 diabetes
      mellitus.
LID - 10.1002/dmrr.2426 [doi]
AB  - BACKGROUND: Secreted frizzled-related protein 5 (Sfrp5), an endogenous inhibitor 
      of wingless-type MMTV integration site family (Wnt) signaling, is an
      anti-inflammatory adipokine whose expression is perturbed in models of obesity
      and type 2 diabetes mellitus (T2DM). Wnt member 5a (Wnt5a) is a representative
      ligand and recent reports suggest that Wnt5a is involved in inflammatory diseases
      and metabolic disorders. The aim of this study was to investigate whether plasma 
      Wnt5a and Sfrp5 levels are altered in patients with T2DM. METHODS: Plasma Sfrp5
      as well as Wnt5a concentrations were measured through ELISA in type 2 diabetic
      and nondiabetic subjects. RESULTS: A total of 82 patients with T2DM and 42
      non-diabetic subjects were studied. Plasma Sfrp5 levels were found to be elevated
      in patients with T2DM (9.4 +/- 9.0 vs. 7.4 +/- 10.9 ng/mL, P = 0.006). In
      contrast, Wnt5a levels were decreased (6.8 +/- 12.6 vs. 9.1 +/- 4.0 ng/dL, P <
      0.001). Increasing concentrations of Sfrp5 were independently and significantly
      associated with T2DM. Multiple logistic regression analysis revealed Sfrp5 as an 
      independent association factor for T2DM, even after full adjustment of known
      biomarkers. In a multiple linear regression analysis, only the fasting glucose
      level was positively associated with the plasma Sfrp5 level. CONCLUSIONS: Our
      results indicate that Sfrp5 may play a role in the pathogenesis of T2DM. This
      article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Division of Endocrinologic, E-Da Hospital, I-Shou University, Kaohsiung, 82445,
      Taiwan; Department of Medical Nutrition, Institute of Biotechnology and Chemical 
      Engineering and I-Shou University, Kaohsiung, 82445, Taiwan.
FAU - Lu, Yung-Chuan
AU  - Lu YC
FAU - Wang, Chao-Ping
AU  - Wang CP
FAU - Hsu, Chia-Chang
AU  - Hsu CC
FAU - Chiu, Cheng-An
AU  - Chiu CA
FAU - Yu, Teng-Hung
AU  - Yu TH
FAU - Hung, Wei-Chin
AU  - Hung WC
FAU - Lu, Li-Fen
AU  - Lu LF
FAU - Chung, Fu-Mei
AU  - Chung FM
FAU - Tsai, I-Ting
AU  - Tsai IT
FAU - Lin, Hsien-Chang
AU  - Lin HC
FAU - Lee, Yau-Jiunn
AU  - Lee YJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1002/dmrr.2426 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 7. doi: 10.1002/dmrr.2426.

PMID- 23653368
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 7
TI  - Deep wound cultures and bone biopsy in diabetic foot osteomyelitis.
LID - 10.1002/dmrr.2425 [doi]
AB  - BACKGROUND: Osteomyelitis is a major complication in patients with diabetic foot 
      ulceration. Accurate pathogenic identification of organisms can aid the clinician
      to a specific antibiotic therapy thereby preventing the need for amputation.
      METHODS: All diabetic patients with bone biopsy- confirmed osteomyelitis were
      included into the study: biopsies were performed either during surgical removal
      of infected bone, or percutaneously under guided fluoroscopy through non-infected
      tissue. The depth and extent of the ulcer was assessed using a sterile blunt
      metal probe. Deep wound cultures were taken from the wound base after sharp
      debridement. RESULTS: Of 66 cases of suspected Osteomyelitis in 102 joints, 34
      patients had both bone biopsies and deep wound cultures over the study period.
      Thirty two of 34 (94%), had a history of preceding foot ulceration, and in 25 of 
      the cases a positive probe to bone test was recorded. In a high proportion of
      patients, at least one similar organism was isolated from both the deep wound
      culture and bone biopsy procedures (n = 25, 73.5% of cases; p < 0.001). When
      organisms were isolated from both wound cultures and bone biopsies, the identical
      strain was identified in both procedures in a significant proportion of cases (n 
      = 14, 56% of cases; p < 0.001. CONCLUSIONS: Deep wound cultures correlate well
      with osseous cultures and provide a sensitive method in assessing and targeting
      likely pathogens that cause osseous infections. This will help aid the clinician 
      in guiding antibiotic therapy in centers where bone biopsies may not be readily
      available. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Podiatry Department, Liverpool Hospital, South Western Sydney Local Health
      District, Sydney, NSW, Australia; Department of Surgery, Podiatric Surgery Unit, 
      National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, Kingdom of
      Saudi Arabia.
FAU - Malone, M
AU  - Malone M
FAU - Bowling, F L
AU  - Bowling FL
FAU - Gannass, A
AU  - Gannass A
FAU - Jude, E B
AU  - Jude EB
FAU - Boulton, A J M
AU  - Boulton AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1002/dmrr.2425 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 7. doi: 10.1002/dmrr.2425.

PMID- 23653365
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Linking)
VI  - 41
IP  - 3
DP  - 2013 Jun
TI  - Impact of type 1 diabetes mellitus on academic performance.
PG  - 855-8
LID - 10.1177/0300060513483417 [doi]
AB  - OBJECTIVE: To examine the effect of type 1 diabetes on academic performance.
      METHODS: Ethnically Saudi students with type 1 diabetes, and age, sex, ethnicity 
      and socio-economic status-matched nondiabetic control students were recruited
      from eight schools. Overall academic grades were recorded, based on the scores
      obtained in written examinations in English, mathematics, physics, chemistry,
      biology and humanities. RESULTS: Students with type 1 diabetes (n = 36) obtained 
      significantly lower academic grades compared with their nondiabetic control
      classmates (n = 36) (86.58 +/- 1.48 vs 90.62 +/- 1.36). CONCLUSIONS: Overall
      academic performance is significantly lower in students with type 1 diabetes
      compared with their nondiabetic classmates. This decline in academic performance 
      may be explained by an association between diabetes and cognitive function.
AD  - Department of Physiology, College of Medicine, King Khalid University Hospital,
      King Saud University, Riyadh, Saudi Arabia.
FAU - Meo, Sultan Ayoub
AU  - Meo SA
FAU - Alkahlan, Mohammad Abdulaziz
AU  - Alkahlan MA
FAU - Al-Mubarak, Mohammed Abdulrahman
AU  - Al-Mubarak MA
FAU - Al-Obayli, Mohammed Saad
AU  - Al-Obayli MS
FAU - Melaibary, Bader Abdullah
AU  - Melaibary BA
FAU - Dous, Abdullah Nasser Bin
AU  - Dous AN
FAU - Alhassoun, Asim Ibrahim
AU  - Alhassoun AI
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
SB  - IM
OTO - NOTNLM
OT  - Type 1 diabetes mellitus
OT  - academic grades
OT  - cognitive function
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/07 [aheadofprint]
AID - 0300060513483417 [pii]
AID - 10.1177/0300060513483417 [doi]
PST - ppublish
SO  - J Int Med Res. 2013 Jun;41(3):855-8. doi: 10.1177/0300060513483417. Epub 2013 May
      7.

PMID- 23653335
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 7
TI  - AdipoQ polymorphisms are associated with type 2 diabetes mellitus: a
      meta-analysis study.
LID - 10.1002/dmrr.2424 [doi]
AB  - OBJECTIVE: Adiponectin (AdipoQ) plays an important role in the pathogenesis of
      diabetes mellitus and is considered as an important candidate gene for type 2
      diabetes mellitus (T2DM). So far, there have been many studies to investigate the
      association between the AdipoQ polymorphisms and T2DM risk. However, the results 
      are conflicting. To derive a more precise estimation, we performed a
      meta-analysis to assess the association between five AdipoQ polymorphisms
      [-11426A > G (rs16861194), -11391G > A (rs17300539), -11377C > G (rs266729), +45 
      T > G (rs2241766) and +276G > T (rs1501299)] and T2DM risk. METHODS: The fixed
      and random-effects model should be used to assess the summary odd ratios (ORs) of
      each study. ORs with 95% confidence intervals (CIs) were used to evaluate the
      strength of association. Based on the included criteria, we selected 39 papers,
      among which eight for -11426A > G, 14 for -11391G > A, 21 for -11377C > G, 28 for
      +45 T > G, and 24 for +276G > T. Sensitivity analyses were conducted to assess
      the stability of the results. Both Begg's funnel plots and Egger's test are
      commonly used to evaluate publication bias. RESULTS: Overall, we found that
      individuals with the -11426G allele had a 0.15-fold significantly increased T2DM 
      risk (additive model: 1.15, 1.04-1.27, 0.222). In the stratified analyses, we
      found that the -11426A > G, -11391G > A, and -11377 C > G polymorphisms could
      increase T2DM risk in European populations in the additive model. For Asian
      populations, we found that the -11377C > G polymorphism also could elevate T2DM
      risk. CONCLUSIONS: Our results suggested that the AdipoQ -11426A > G polymorphism
      could contribute to the T2DM risk. This article is protected by copyright. All
      rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing
      Medical University, Nanjing, China; Department of Environmental Genomics, Jiangsu
      Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing
      Medical University, Nanjing, China; Department of Genetic Toxicology, the Key
      Laboratory of Modern Toxicology of Ministry of Education, School of Public
      Health, Nanjing Medical University, Nanjing, China.
FAU - Chu, Haiyan
AU  - Chu H
FAU - Wang, Meilin
AU  - Wang M
FAU - Zhong, Dongyan
AU  - Zhong D
FAU - Shi, Danni
AU  - Shi D
FAU - Ma, Lan
AU  - Ma L
FAU - Tong, Na
AU  - Tong N
FAU - Zhang, Zhengdong
AU  - Zhang Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1002/dmrr.2424 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 7. doi: 10.1002/dmrr.2424.

PMID- 23653323
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 May 7
TI  - Clinical characteristics and insulin-independency of new-onset Korean type 2
      diabetics presenting with diabetic ketoacidosis.
LID - 10.1002/dmrr.2421 [doi]
AB  - BACKGROUND: We evaluated the incidence, characteristics, and insulin-independency
      of newly diagnosed Korean type 2 diabetes (T2D) initially presenting with
      diabetic ketoacidosis (DKA). METHODS: We analyzed clinical and biochemical data
      from diabetic patients presenting with DKA. They were classified into
      ketosis-prone diabetes (KPD)-T1A (A + beta-), KPD-T1B (A - beta-), KPD-T2A (A +
      beta+) or KPD-T2B (A - beta+) according to the presence or absence of
      autoantibody and beta-cell reserve. Changes in therapy after insulin
      discontinuation were evaluated for up to 4 years. We also compared clinical and
      biochemical characteristics between newly diagnosed T2D presenting with DKA and
      previously-diagnosed T2D presenting with DKA. RESULTS: Among 60 newly diagnosed
      KPD patients, 18, 21, and 21 patients were classified as KPD-T1A, KPD-T1B, and
      KPD-T2B, respectively. In the KPD-T2B group, both fasting and stimulated
      C-peptide recovered over 6 months. After 4 years of DKA development, 75% of
      KPD-T2B subjects no longer required insulin. Compared to previously diagnosed T2D
      patients presenting with DKA, newly diagnosed KPD-T2B patients tended to be
      younger, more obese, and showed better insulin secretory function after recovery 
      from DKA. CONCLUSIONS: New-onset T2D presenting with DKA was not uncommon among
      the Korean population. In contrast to previously-diagnosed T2D patients
      presenting with DKA who showed a progressive decrease in insulin secretory
      function, new-onset KPD-T2B patients recovered insulin secretory function over
      time, and insulin independence could be expected. This article is protected by
      copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei
      University College of Medicine, Seoul, Korea.
FAU - Seok, H
AU  - Seok H
FAU - Jung, C H
AU  - Jung CH
FAU - Kim, S W
AU  - Kim SW
FAU - Lee, M J
AU  - Lee MJ
FAU - Lee, W J
AU  - Lee WJ
FAU - Kim, J H
AU  - Kim JH
FAU - Lee, B W
AU  - Lee BW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1002/dmrr.2421 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 May 7. doi: 10.1002/dmrr.2421.

PMID- 23653288
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1097-4547 (Electronic)
IS  - 0360-4012 (Linking)
VI  - 91
IP  - 7
DP  - 2013 Jul
TI  - Blocking central galanin receptors attenuates insulin sensitivity in myocytes of 
      diabetic trained rats.
PG  - 971-7
LID - 10.1002/jnr.23228 [doi]
AB  - Galanin (Gal), a bioactive neuropeptide, is widely distributed throughout the
      central nervous system and has diverse modulatory effects. To understand the
      central effect of this training-stimulatory peptide on insulin sensitivity, its
      antagonist M35 was injected into the cerebral ventricle in type 2 diabetic rats. 
      A treadmill running of the rats was used to stimulate circulating Gal secretion
      and central Gal mRNA expression. The results showed that M35 significantly
      decreased glucose infusion rates in euglycemic-hyperinsulinemic clamp tests as
      well as 2-deoxy-[(3) H]D-glucose uptake and peroxisome proliferator-activated
      receptor-alpha expression levels in skeletal muscles. M35 also attenuated glucose
      transporter 4 (GLUT4) concentration in plasma membranes and total cell membranes 
      of myocytes, and the ratios of the GLUT4 contents in the former to the latter in 
      M35 groups were lower than those of each diabetic control. These results imply
      that endogenous Gal, acting through its central receptor, may facilitate GLUT4
      translocation from cytoplasm vesicles to cellular surface of myocytes to
      accelerate glucose uptake and to enhance insulin sensitivity in healthy and type 
      2 diabetic rats. Gal and its relative agents are potential targets for treatment 
      of type 2 diabetes mellitus and its complications. (c) 2013 Wiley Periodicals,
      Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Endocrinology, Shanghai 10th People's Hospital, Tongji University
      School of Medicine, Shanghai, China.
FAU - Bu, Le
AU  - Bu L
FAU - Liu, Zhimin
AU  - Liu Z
FAU - Zou, Junjie
AU  - Zou J
FAU - Gao, Xiang
AU  - Gao X
FAU - Bao, Yi
AU  - Bao Y
FAU - Qu, Shen
AU  - Qu S
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - J Neurosci Res
JT  - Journal of neuroscience research
JID - 7600111
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/11/27 [received]
PHST- 2013/02/23 [revised]
PHST- 2013/03/05 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 10.1002/jnr.23228 [doi]
PST - ppublish
SO  - J Neurosci Res. 2013 Jul;91(7):971-7. doi: 10.1002/jnr.23228. Epub 2013 May 7.

PMID- 23653255
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1573-7365 (Electronic)
IS  - 0885-7490 (Linking)
DP  - 2013 May 8
TI  - Neurodegenerative disease and obesity: what is the role of weight loss and
      bariatric interventions?
AB  - Neurodegenerative diseases are amongst the leading causes of worldwide
      disability, morbidity and decreased quality of life. They are increasingly
      associated with the concomitant worldwide epidemic of obesity. Although the
      prevalence of both AD and PD continue to rise, the available treatment strategies
      to combat these conditions remain ineffective against an increase in global
      neurodegenerative risk factors. There is now epidemiological and mechanistic
      evidence associating obesity and its related disorders of impaired glucose
      homeostasis, type 2 diabetes mellitus and metabolic syndrome with both AD and PD.
      Here we describe the clinical and molecular relationship between obesity and
      neurodegenerative disease. Secondly we outline the protective role of weight
      loss, metabolic and caloric modifying interventions in the context of AD and PD. 
      We conclude that the application of caloric restriction through dietary changes, 
      bariatric (metabolic) surgery and gut hormone therapy may offer novel therapeutic
      strategies against neurodegenerative disorders. Investigating the protective
      mechanisms of weight loss, metabolic and caloric modifying interventions can
      increase our understanding of these major public health diseases and their
      management.
AD  - The Department of Surgery and Cancer, Imperial College London, Imperial College
      London at St Mary's Hospital Campus, 10th Floor, Queen Elizabeth the Queen Mother
      (QEQM) Building, Praed Street, London, W2 1NY, UK, h.ashrafian@imperial.ac.uk.
FAU - Ashrafian, Hutan
AU  - Ashrafian H
FAU - Harling, Leanne
AU  - Harling L
FAU - Darzi, Ara
AU  - Darzi A
FAU - Athanasiou, Thanos
AU  - Athanasiou T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Metab Brain Dis
JT  - Metabolic brain disease
JID - 8610370
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/01/11 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 10.1007/s11011-013-9412-4 [doi]
PST - aheadofprint
SO  - Metab Brain Dis. 2013 May 8.

PMID- 23653087
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1530-9932 (Electronic)
IS  - 1530-9932 (Linking)
VI  - 14
IP  - 2
DP  - 2013 Jun
TI  - 25-Hydroxyvitamin D3-Loaded PLA Microspheres: In Vitro Characterization and
      Application in Diabetic Periodontitis Models.
PG  - 880-9
LID - 10.1208/s12249-013-9978-5 [doi]
AB  - This study aimed at the preparation of a sustained-release 25-hydroxyvitamin D3
      (25OHD) treatment for diabetic periodontitis, a known complication of diabetes.
      25OHD-loaded polylactic acid (PLA) microspheres were prepared using oil-in-water 
      emulsion-solvent evaporation method. The prepared microspheres exhibited intact
      surfaces, with average sizes ranging from 42.3 to 119.4 mum. The encapsulation
      efficiency ranged from 79.2% (w/w) to 88.5% (w/w), and the drug content was
      between 15.8% (w/w) and 17.8% (w/w). Drug release from the produced microspheres 
      followed a near-to-zero-order release pattern and lasted over 10 weeks. In an in 
      vitro model of diabetic periodontitis, the abnormal morphological changes and the
      decrease in the cell viability of bone marrow stromal cells could be effectively 
      attenuated after the 25OHD-loaded microsphere application. Additionally, in a rat
      model of diabetic periodontitis, alveolar bone loss was inhibited and osteoid
      formation in the periodontium was promoted upon 25OHD-loaded microsphere
      treatment. In conclusion, 25OHD-loaded PLA microspheres may provide an effective 
      approach for the treatment of this disease.
AD  - State Key Laboratory of Oral Diseases, West China Hospital of Stomatology,
      Sichuan University, 14 3rd Section S Renmin Road, Chengdu, 610041, China.
FAU - Li, Hao
AU  - Li H
FAU - Wang, Qi
AU  - Wang Q
FAU - Xiao, Yu
AU  - Xiao Y
FAU - Bao, Chongyun
AU  - Bao C
FAU - Li, Wei
AU  - Li W
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - United States
TA  - AAPS PharmSciTech
JT  - AAPS PharmSciTech
JID - 100960111
SB  - IM
PMC - PMC3666022
OID - NLM: PMC3666022 [Available on 05/08/14]
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PMCR- 2014/05/08 00:00
PHST- 2013/01/03 [received]
PHST- 2013/04/28 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 10.1208/s12249-013-9978-5 [doi]
PST - ppublish
SO  - AAPS PharmSciTech. 2013 Jun;14(2):880-9. doi: 10.1208/s12249-013-9978-5. Epub
      2013 May 8.

PMID- 23653085
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 0026-1270 (Print)
IS  - 0026-1270 (Linking)
VI  - 52
IP  - 3
DP  - 2013 May 7
TI  - More than four decades of medical informatics education for medical students in
      Germany. New recommendations published.
PG  - 181-3
AB  - The publication of German competencybased learning objectives "Medical
      Informatics" for undergraduate medical education gives reason to report on more
      publications of the German journal GMS Medical Informatics, Biometry and
      Epidemiology ( MIBE ) in Methods. The publications in focus deal with support of 
      medical education by health and biomedical informatics, hospital information
      systems and their relation to medical devices, transinstitutional health
      information systems and the need of national eHealth strategies, epidemiological 
      research on predicting high consumption of resources, and with the interaction of
      epidemiologists and medical statisticians in examining mortality risks in
      diabetes, in genome wide association studies and in dealing with limits and
      thresholds. This report is the beginning of an annual series intending to support
      better international cooperation to achieve good information as a basis for good 
      medicine and good healthcare.
AD  - Prof. Dr. Alfred Winter, Leipzig University, Institute for Medical Informatics,
      Statistics and Epidemiology, Haertelstr. 16 -18, 04107 Leipzig, Germany, E-Mail: 
      alfred.winter@imise.uni-leipzig.de.
FAU - Winter, A
AU  - Winter A
FAU - Hilgers, R-D
AU  - Hilgers RD
FAU - Hofestadt, R
AU  - Hofestadt R
FAU - Knaup-Gregori, P
AU  - Knaup-Gregori P
FAU - Ose, C
AU  - Ose C
FAU - Trimmer, A
AU  - Trimmer A
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Methods Inf Med
JT  - Methods of information in medicine
JID - 0210453
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 13030181 [pii]
PST - ppublish
SO  - Methods Inf Med. 2013 May 7;52(3):181-3.

PMID- 23653011
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 8
TI  - Combination Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin
      Receptor Blockers in Diabetic Kidney Disease.
AB  - Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor
      blockers (ARB) have played a major role in slowing the progression of diabetic
      kidney disease, since they lower urine protein levels, lower blood pressure, and 
      slow progression. Studies have suggested that the combination of ACE-I and ARB
      offered greater benefits for patients with diabetic kidney disease. In 2008, the 
      large ONTARGET study reported no benefit with combination therapy, as compared
      with monotherapy. This study has changed practice patterns, but few patients in
      this study had diabetic kidney disease. In this review, the data in favor of the 
      combination use of these agents in patients with diabetic kidney disease and data
      against the combination are reviewed. At this time, there is little support for
      using the combination in diabetic patients with no kidney disease or early stage 
      diabetic kidney disease. But there are patients who may benefit from combination 
      use.
AD  - Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Harvard Medical
      School, Boston, MA, USA, Robert.Stanton@joslin.harvard.edu.
FAU - Stanton, Robert C
AU  - Stanton RC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1007/s11892-013-0391-y [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 8.

PMID- 23652994
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
DP  - 2013 May 8
TI  - Hexokinase cellular trafficking in ischemia-reperfusion and ischemic
      preconditioning is altered in type I diabetic heart.
AB  - Diabetes mellitus (DM) has been reported to alter the cardiac response to
      ischemia-reperfusion (IR). In addition, cardioprotection induced by ischemic
      preconditioning (IPC) is often impaired in diabetes. We have previously shown
      that the subcellular localisation of the glycolytic enzyme hexokinase (HK) is
      causally related to IR injury and IPC protective potential. Especially the
      binding of HK to mitochondria and prevention of HK solubilisation (HK detachment 
      from mitochondria) during ischemia confers cardioprotection. It is unknown
      whether diabetes affects HK localisation during IR and IPC as compared to
      non-diabetes. In this study we hypothesize that DM alters cellular trafficking of
      hexokinase in response to IR and IPC, possibly explaining the altered response to
      IR and IPC in diabetic heart. Control (CON) and type I diabetic (DM) rat hearts
      (65 mg/kg streptozotocin, 4 weeks) were isolated and perfused in Langendorff-mode
      and subjected to 35 min I and 30 min R with or without IPC (3 times 5 min I).
      Cytosolic and mitochondrial fractions were obtained at (1) baseline, i.e. after
      IPC but before I, (2) 35 min I, (3) 5 min R and (4) 30 min R. DM improved
      rate-pressure product recovery (RPP; 71 +/- 10 % baseline (DM) versus 9 +/- 1 %
      baseline (CON) and decreased contracture (end-diastolic pressure: 24 +/- 8 mmHg
      (DM) vs 77 +/- 4 mmHg (CON)) after IR as compared to control, and was associated 
      with prevention of HK solubilisation at 35 min I. IPC improved cardiac function
      in CON but not in DM hearts. IPC in CON prevented HK solubilisation at 35 min I
      and at 5 min R, with a trend for increased mitochondrial HK. In contrast, the
      non-effective IPC in DM was associated with solubilisation of HK and decreased
      mitochondrial HK at early reperfusion and a reciprocal behaviour at late
      reperfusion. We conclude that type I DM significantly altered cellular HK
      translocation patterns in the heart in response to IR and IPC, possibly
      explaining altered response to IR and IPC in diabetes.
AD  - Department of Biology, Faculty of Science, Istanbul University, Istanbul, Turkey.
FAU - Gurel, Ebru
AU  - Gurel E
FAU - Ustunova, Savas
AU  - Ustunova S
FAU - Kapucu, Aysegul
AU  - Kapucu A
FAU - Yilmazer, Nadim
AU  - Yilmazer N
FAU - Eerbeek, Otto
AU  - Eerbeek O
FAU - Nederlof, Rianne
AU  - Nederlof R
FAU - Hollmann, Markus W
AU  - Hollmann MW
FAU - Demirci-Tansel, Cihan
AU  - Demirci-Tansel C
FAU - Zuurbier, Coert J
AU  - Zuurbier CJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 10.1007/s11033-013-2495-5 [doi]
PST - aheadofprint
SO  - Mol Biol Rep. 2013 May 8.

PMID- 23652936
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1432-1076 (Electronic)
IS  - 0340-6199 (Linking)
DP  - 2013 May 8
TI  - Effects of birth size, post-natal growth and current size on insulin resistance
      in 9-year-old children: a prospective cohort study.
AB  - The influence of pre-natal conditions on later type 2 diabetes risk factors such 
      as insulin resistance (IR) may be mediated by post-natal growth trajectory. We
      aimed to investigate the association of body size at birth and 9 years with IR at
      9 years. Using data from a prospective Australian cohort study, we examined the
      influence of body size from birth to 9 years [z-score for weight or body mass
      index (BMI)] on IR at 9 years (estimated by homeostasis model assessment). At age
      9 years, 151 children provided a fasting blood sample. z-BMI at age 9 was
      positively associated with IR. Birth z-BMI was inversely associated with IR only 
      after adjustment for z-BMI at age 9 years. This may be interpreted as an effect
      of accelerated growth between birth and 9 years on IR. There was a statistically 
      significant interaction between birth and 9-year z-BMI. Results from regression
      models including z-BMI at all available time points (birth, 6 and 12 months, and 
      2, 3.5 and 9 years) indicate a possible inverse association between body size at 
      3.5 years and HOMA-IR at 9 years. Results were similar when the analyses were
      repeated with z-weight substituted for z-BMI. These results add to the body of
      evidence concerning the importance of growth in early life for later IR, and
      highlight a possible interaction between pre- and post-natal growth. The
      potential influence of growth at around 3.5 years for HOMA-IR at 9 years warrants
      further investigation.
AD  - Discipline of Obstetrics & Gynaecology, School of Paediatrics & Reproductive
      Health, The University of Adelaide, Mail Drop 327, Adelaide, SA, 5005, Australia,
      melissa.whitrow@adelaide.edu.au.
FAU - Whitrow, Melissa J
AU  - Whitrow MJ
FAU - Davies, Michael J
AU  - Davies MJ
FAU - Giles, Lynne C
AU  - Giles LC
FAU - De Stavola, Bianca L
AU  - De Stavola BL
FAU - Owens, Julie A
AU  - Owens JA
FAU - Maftei, Oana
AU  - Maftei O
FAU - Moore, Vivienne M
AU  - Moore VM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/12/03 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/04/18 [revised]
PHST- 2013/05/08 [aheadofprint]
AID - 10.1007/s00431-013-2017-4 [doi]
PST - aheadofprint
SO  - Eur J Pediatr. 2013 May 8.

PMID- 23652883
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 11
IP  - 5
DP  - 2013
TI  - A Shark Liver Gene-Derived Active Peptide Expressed in the Silkworm, Bombyx mori:
      Preliminary Studies for Oral Administration of the Recombinant Protein.
PG  - 1492-505
LID - 10.3390/md11051492 [doi]
AB  - Active peptide from shark liver (APSL) is a cytokine from Chiloscyllium plagiosum
      that can stimulate liver regeneration and protects the pancreas. To study the
      effect of orally administered recombinant APSL (rAPSL) on an animal model of type
      2 diabetes mellitus, the APSL gene was cloned, and APSL was expressed in Bombyx
      mori N cells (BmN cells), silkworm larvae and silkworm pupae using the silkworm
      baculovirus expression vector system (BEVS). It was demonstrated that rAPSL was
      able to significantly reduce the blood glucose level in mice with type 2 diabetes
      induced by streptozotocin. The analysis of paraffin sections of mouse pancreatic 
      tissues revealed that rAPSL could effectively protect mouse islets from
      streptozotocin-induced lesions. Compared with the powder prepared from normal
      silkworm pupae, the powder prepared from pupae expressing rAPSL exhibited greater
      protective effects, and these results suggest that rAPSL has potential uses as an
      oral drug for the treatment of diabetes mellitus in the future.
AD  - Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine,
      Institute of Biochemistry, Zhejiang Sci-Tech University, Hangzhou 310018, China. 
      zhengbingl@zstu.edu.cn.
FAU - Liu, Yunlong
AU  - Liu Y
FAU - Chen, Ying
AU  - Chen Y
FAU - Chen, Jianqing
AU  - Chen J
FAU - Zhang, Wenping
AU  - Zhang W
FAU - Sheng, Qing
AU  - Sheng Q
FAU - Chen, Jian
AU  - Chen J
FAU - Yu, Wei
AU  - Yu W
FAU - Nie, Zuoming
AU  - Nie Z
FAU - Zhang, Yaozhou
AU  - Zhang Y
FAU - Wu, Wutong
AU  - Wu W
FAU - Wang, Lisha
AU  - Wang L
FAU - Indran, Inthrani Raja
AU  - Indran IR
FAU - Li, Jun
AU  - Li J
FAU - Qian, Lian
AU  - Qian L
FAU - Lv, Zhengbing
AU  - Lv Z
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/02/12 [received]
PHST- 2013/04/26 [revised]
PHST- 2013/04/28 [accepted]
AID - md11051492 [pii]
AID - 10.3390/md11051492 [doi]
PST - epublish
SO  - Mar Drugs. 2013 May 7;11(5):1492-505. doi: 10.3390/md11051492.

PMID- 23652868
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
DP  - 2013 May 3
TI  - The Ability of Lumbar Spine DXA and Phalanx QUS to Detect Previous Fractures in
      Young Thalassemic Patients With Hypogonadism, Hypothyroidism, Diabetes, and
      Hepatitis-B: A 2-Year Subgroup Analysis From the Taranto Area of Apulia Region.
AB  - BACKGROUND:: Osteoporosis is a leading cause of morbidity in patients affected by
      beta-thalassemia major or intermediate; we aimed to assess the association
      between demineralization observed in young thalassemic patients. METHODS:: A
      total of 88 patients with beta-thalassemia were recruited at Microcitemia Center 
      of Taranto Hospital under the Prevention Osteoporosis and Fractures research
      project from 2008 to 2010. All the patients were screened with both dual energy
      x-ray absorptiometry (DXA) and quantitative ultrasound (QUS). T score and Z score
      values were obtained for each subject. RESULTS:: The overall prevalence of
      demineralization was 84% with DXA and 70% with QUS, whereas normality was found
      in 16% of patients screened with DXA and in 30% of cases with QUS. Hypogonadism, 
      hypothyroidism, diabetes mellitus, hepatitis-B, and the presence of previous
      fragility fractures were significantly associated with the demineralization
      status (lower T scores values) both with DXA and QUS. CONCLUSION:: Our data
      confirm that DXA and QUS examinations are both useful for detecting bone
      demineralization in thalassemic patients.
AD  - *Euro Mediterranean Biomedical Scientific Institute (ISBEM), Brindisi
      daggerDepartment of Pharmacology, University of Pisa, Pisa double
      daggerDepartment of Biological and Enviromental Science and Technology,
      University of Salento, Lecce section signLocal Health Authority, ASL Taranto,
      Taranto parallelDepartment of Public Health and Infectious Diseases, La Sapienza 
      University of Rome, Rome paragraph signDepartment of Internal Medicine,
      University of Florence, Florence, Italy.
FAU - Argentiero, Alberto
AU  - Argentiero A
FAU - Neglia, Cosimo
AU  - Neglia C
FAU - Peluso, Angelo
AU  - Peluso A
FAU - di Rosa, Salvatore
AU  - di Rosa S
FAU - Ferrarese, Antonio
AU  - Ferrarese A
FAU - Di Tanna, Gianluca
AU  - Di Tanna G
FAU - Caiaffa, Vincenzo
AU  - Caiaffa V
FAU - Benvenuto, Marco
AU  - Benvenuto M
FAU - Cozma, Alexandru
AU  - Cozma A
FAU - Chitano, Giovanna
AU  - Chitano G
FAU - Agnello, Nadia
AU  - Agnello N
FAU - Paladini, Daniele
AU  - Paladini D
FAU - Baldi, Nicola
AU  - Baldi N
FAU - Distante, Alessandro
AU  - Distante A
FAU - Piscitelli, Prisco
AU  - Piscitelli P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1097/MPH.0b013e31828e6cab [doi]
PST - aheadofprint
SO  - J Pediatr Hematol Oncol. 2013 May 3.

PMID- 23652855
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 3
DP  - 2013 May 8
TI  - Destruction of tissue, cells and organelles in type 1 diabetic rats presented at 
      macromolecular resolution.
PG  - 1804
LID - 10.1038/srep01804 [doi]
AB  - Finding alternatives for insulin therapy and making advances in etiology of type 
      1 diabetes benefits from a full structural and functional insight into Islets of 
      Langerhans. Electron microscopy (EM) can visualize Islet morphology at the
      highest possible resolution, however, conventional EM only provides biased
      snapshots and lacks context. We developed and employed large scale EM and
      compiled a resource of complete cross sections of rat Islets during
      immuno-destruction to provide unbiased structural insight of thousands of cells
      at macromolecular resolution. The resource includes six datasets, totalling
      25.000 micrographs, annotated for cellular and ultrastructural changes during
      autoimmune diabetes. Granulocytes are attracted to the endocrine tissue, followed
      by extravasation of a pleiotrophy of leukocytes. Subcellullar changes in beta
      cells include endoplasmic reticulum stress, insulin degranulation and glycogen
      accumulation. Rare findings include erythrocyte extravasation and nuclear
      actin-like fibers. While we focus on a rat model of autoimmune diabetes, our
      approach is general applicable.
AD  - Dept. Molecular Cell Biology, Leiden University Medical Center, P. O. Box 9600,
      2300 RC, Leiden, The Netherlands.
FAU - Ravelli, Raimond B G
AU  - Ravelli RB
FAU - Kalicharan, Ruby D
AU  - Kalicharan RD
FAU - Avramut, M Cristina
AU  - Avramut MC
FAU - Sjollema, Klaas A
AU  - Sjollema KA
FAU - Pronk, Joachim W
AU  - Pronk JW
FAU - Dijk, Freark
AU  - Dijk F
FAU - Koster, Abraham J
AU  - Koster AJ
FAU - Visser, Jeroen T J
AU  - Visser JT
FAU - Faas, Frank G A
AU  - Faas FG
FAU - Giepmans, Ben N G
AU  - Giepmans BN
LA  - eng
PT  - Journal Article
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
PMC - PMC3647201
OID - NLM: PMC3647201
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/02/21 [received]
PHST- 2013/04/19 [accepted]
AID - srep01804 [pii]
AID - 10.1038/srep01804 [doi]
PST - ppublish
SO  - Sci Rep. 2013 May 8;3:1804. doi: 10.1038/srep01804.

PMID- 23652775
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 32
IP  - 1
DP  - 2013 Jul
TI  - Chrysanthemum zawadskii extract protects osteoblastic cells from highly reducing 
      sugar-induced oxidative damage.
PG  - 241-50
LID - 10.3892/ijmm.2013.1371 [doi]
AB  - In this study, Chrysanthemum zawadskii extract (CZE) was investigated to
      determine its effects on 2-deoxy-D-ribose (dRib)-induced oxidative damage and
      cellular dysfunction in the MC3T3-E1 mouse osteoblastic cell line. Osteoblastic
      cells were treated with the highly reducing sugar, dRib, in the presence or
      absence of CZE. Cell viability, apoptosis and reactive oxygen species (ROS)
      production were subsequently examined. It was observed that dRib reduced cell
      survival, while it markedly increased the intracellular levels of ROS and
      apoptosis. However, pre-treatment of the cells with CZE attenuated all the
      dRib-induced effects. The antioxidant, N-acetyl-L-cysteine (NAC), also prevented 
      dRib-induced oxidative cell damage. In addition, treatment with CZE resulted in a
      significant increase in alkaline phosphatase (ALP) activity and collagen content,
      as well as in the expression of genes associated with osteoblast differentiation 
      [ALP, collagen, osteopontin (OPN), osteoprotegerin (OPG), bone sialoprotein
      (BSP), osteocalcin (OC) and bone morphogenetic protein (BMP)2, BMP4 and BMP7]. In
      mechanistic studies of the antioxidative potential of CZE, we found that CZE
      reversed the dRib-induced decrease in the expression of phosphatidylinositol
      3-kinase (PI3K) and protein kinase B (AKT)1 and AKT2 genes, which are master
      regulators of survival-related signaling pathways. CZE also upregulated the gene 
      expression of the antioxidant enzymes, superoxide dismutase (SOD)2, SOD3 and
      glutathione peroxidase 4 (GPx4), which was inhibited by dRib. Taken together,
      these results suggest that CZE attenuates dRib-induced cell damage in
      osteoblastic cells and may be useful for the treatment of diabetes-associated
      bone disease.
AD  - Research Institute of Endocrinology, Kyung Hee University Hospital,
      Dongdaemun-gu, Seoul 130-702, Republic of Korea.
FAU - Suh, Kwang Sik
AU  - Suh KS
FAU - Rhee, Sang Youl
AU  - Rhee SY
FAU - Jung, Woon Won
AU  - Jung WW
FAU - Kim, Nam Jae
AU  - Kim NJ
FAU - Jang, Young Pyo
AU  - Jang YP
FAU - Kim, Hye Jin
AU  - Kim HJ
FAU - Kim, Min Kyoung
AU  - Kim MK
FAU - Choi, Young Kil
AU  - Choi YK
FAU - Kim, Young Seol
AU  - Kim YS
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/02/26 [received]
PHST- 2013/05/01 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 10.3892/ijmm.2013.1371 [doi]
PST - ppublish
SO  - Int J Mol Med. 2013 Jul;32(1):241-50. doi: 10.3892/ijmm.2013.1371. Epub 2013 May 
      8.

PMID- 23652685
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1531-698X (Electronic)
IS  - 1040-8703 (Linking)
VI  - 25
IP  - 3
DP  - 2013 Jun
TI  - Congenital hyperinsulinism.
PG  - 357-61
LID - 10.1097/MOP.0b013e3283600ebb [doi]
AB  - PURPOSE OF REVIEW: Congenital hyperinsulinism (CHI) is a multifaceted disease and
      continues to be the most common cause of persistent hypoglycemia in infants. The 
      purpose of the review is to highlight important recent developments regarding
      CHI. RECENT FINDINGS: Several recent studies have highlighted the advances in
      medical genetics, imaging techniques, histological variety, and surgical decision
      making regarding CHI. The advancements have resulted in the ability to often
      distinguish between diffuse and focal disease, thus allowing a more focused
      medical and surgical approach to the patient. When genetic information is
      combined with advanced imaging and intraoperative histological analysis, surgical
      results have improved. Despite medical and surgical advancements, recent studies 
      also reveal the need for better medical options for patients and that aggressive 
      surgery may lead to the onset of diabetes. SUMMARY: Current advances have
      improved the overall care of the patient with CHI, although there are still
      improvements to be achieved. The ability to apply these advancements is best
      accomplished with an experienced team consisting of geneticists, radiologists,
      endocrinologists, pathologists, and surgeons. Utilizing a team approach results
      in a complete evaluation and allows a customized care plan for each patient.
AD  - Division of Pediatric Surgery, Department of Surgery, Washington University
      School of Medicine, St Louis, Missouri, USA.
FAU - Dillon, Patrick A
AU  - Dillon PA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Opin Pediatr
JT  - Current opinion in pediatrics
JID - 9000850
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1097/MOP.0b013e3283600ebb [doi]
AID - 00008480-201306000-00013 [pii]
PST - ppublish
SO  - Curr Opin Pediatr. 2013 Jun;25(3):357-61. doi: 10.1097/MOP.0b013e3283600ebb.

PMID- 23652675
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-3762 (Electronic)
IS  - 0301-3073 (Linking)
VI  - 41
DP  - 2013
TI  - Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid
      cancer.
PG  - 141-8
LID - 10.1159/000345674 [doi]
AB  - Nonmedullary thyroid cancer (NMTC) is one of the most inheritable forms of all
      cancers with an 8- to 10-fold risk of a first-degree relative developing disease.
      Familial nonmedullary thyroid cancer (FNMTC) describes this familial aggregation 
      and is comprised of two distinct subgroups; syndromic and nonsyndromic. Greater
      than 85% of thyroid tumors in nonsyndromic FNMTC are papillary thyroid cancer,
      followed by FTC ( approximately 10%), poorly differentiated, and anaplastic
      thyroid cancer ( approximately 5%). Compared to sporadic NMTC, FNMTC presents at 
      a younger age and is associated with a higher incidence of multifocal disease and
      metastasis. The transmission pattern most frequently follows an autosomal
      dominant mode of inheritance. While there has been extensive investigation to
      find a high-penetrant, single locus as the causative genetic factor, more recent 
      data suggest that FNMTC is a polygenic disorder with variable penetrance likely
      associated with a low-to-moderate number of low-penetrant alleles. A number of
      case-controlled, familial and population-based studies using genomewide
      association single-nucleotide polymorphism arrays have begun to unravel the
      complex genetic environment of FNMTC. These studies highlight the significant
      challenges in identifying markers predictive of disease onset and progression.
      Continued efforts will hopefully lead to identification of a panel of genetic
      markers used to identify family members at risk. Until this time, clinical
      factors appear to be the most efficient and accurate method for surveillance and 
      diagnosis.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Thyroid Center, Division of Endocrinology and Diabetes, Children's Hospital of
      Philadelphia, Philadelphia, Pa., USA.
FAU - Bauer, Andrew J
AU  - Bauer AJ
LA  - eng
PT  - Journal Article
DEP - 20130319
PL  - Switzerland
TA  - Front Horm Res
JT  - Frontiers of hormone research
JID - 0320246
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/03/19 [aheadofprint]
AID - 000345674 [pii]
AID - 10.1159/000345674 [doi]
PST - ppublish
SO  - Front Horm Res. 2013;41:141-8. doi: 10.1159/000345674. Epub 2013 Mar 19.

PMID- 23652628
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1663-2826 (Electronic)
VI  - 79
IP  - 4
DP  - 2013
TI  - Detection and Characterization of Two Novel Mutations in the HNF4A Gene in
      Maturity-Onset Diabetes of the Young Type 1 in Two Japanese Families.
PG  - 220-6
LID - 10.1159/000350520 [doi]
AB  - Background: Maturity-onset diabetes of the young (MODY) is a subgroup of
      monogenic diabetes mellitus, of which MODY1, caused by HNF4A mutations, accounts 
      for only 5% or less and has been rarely reported in East Asian countries. Here we
      report two novel HNF4A mutations in two Japanese families with MODY1. Methods:
      Proband 1 is an 8-year-old girl and proband 2 is a 14-year-old girl. Both were
      nonobese, demonstrated elevated HbA1c and negative serum anti-glutamic acid
      decarboxylase antibodies, and had a family history of diabetes. We directly
      sequenced HNF4A and performed functional analysis of the detected missense
      mutation. Results: Proband 1 had a heterozygous missense mutation, c.824A>G
      (p.Asn275Ser). Luciferase assay demonstrated a significant reduction in
      transcriptional activity. A heterozygous frame shift mutation, c.692-695delAGGA
      (p.Lys231ThrfsX5), was detected in proband 2. Affected family members shared the 
      same mutations, showing high penetrance. Both mutations reside in the HNF4alpha
      dimerization domain and the corresponding amino acids are well conserved between 
      species. Conclusions: These two mutations are most likely the cause of MODY1 in
      these families. Considering the effectiveness of sulfonylureas, it is important
      to correctly diagnose MODY1.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Pediatrics, Osaka University Graduate School of Medicine, Suita,
      Japan.
FAU - Fujiwara, Makoto
AU  - Fujiwara M
FAU - Namba, Noriyuki
AU  - Namba N
FAU - Miura, Kohji
AU  - Miura K
FAU - Kitaoka, Taichi
AU  - Kitaoka T
FAU - Hirai, Haruhiko
AU  - Hirai H
FAU - Kondou, Hiroki
AU  - Kondou H
FAU - Shimotsuji, Tsunesuke
AU  - Shimotsuji T
FAU - Numakura, Chikahiko
AU  - Numakura C
FAU - Ozono, Keiichi
AU  - Ozono K
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - Switzerland
TA  - Horm Res Paediatr
JT  - Hormone research in paediatrics
JID - 101525157
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/08/06 [received]
PHST- 2013/03/04 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 000350520 [pii]
AID - 10.1159/000350520 [doi]
PST - ppublish
SO  - Horm Res Paediatr. 2013;79(4):220-6. doi: 10.1159/000350520. Epub 2013 May 1.

PMID- 23652600
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1941-7632 (Electronic)
IS  - 1941-7640 (Linking)
DP  - 2013 May 7
TI  - Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary
      Percutaneous Coronary Intervention: The HORIZONS-AMI ECG Substudy Report.
AB  - BACKGROUND: IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
      UNDERGOING THROMBOLYTIC THERAPY, THE DEGREE OF ST-SEGMENT RESOLUTION (STR)
      CORRELATES WITH LONG-TERM CARDIOVASCULAR MORTALITY. THE LONG-TERM PREDICTIVE
      VALUE OF STR AFTER PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PCI) IS LESS WELL 
      UNDERSTOOD. WE SOUGHT TO DETERMINE THE LONG-TERM PROGNOSTIC VALUE OF STR AFTER
      PRIMARY PCI IN ST-SEGMENTELEVATION MYOCARDIAL INFARCTION.METHODS AND RESULTS: IN 
      A FORMAL SUBSTUDY FROM THE HARMONIZING OUTCOMES WITH REVASCULARIZATION AND STENTS
      IN ACUTE MYOCARDIAL INFARCTION (HORIZONS-AMI) TRIAL, 2484 PATIENTS WITH
      ST-SEGMENTELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY PCI WITH
      INTERPRETABLE BASELINE AND 60-MINUTE POST-PCI ELECTROCARDIOGRAMS HAD AT LEAST 1
      MM OF BASELINE ST-SEGMENT ELEVATION IN 2 CONTIGUOUS LEADS. PATIENTS WERE
      CATEGORIZED BY THE DEGREE OF STR AT 60 MINUTES: (1) COMPLETE (70%); (2) PARTIAL
      (30%70%); AND (3) ABSENT (30%). ABSENT, INCOMPLETE, AND COMPLETE STR WERE
      ACHIEVED IN 514 (20.7%), 712 (28.7%), AND 1258 (50.5%) PATIENTS, RESPECTIVELY.
      STR 30% WAS ASSOCIATED WITH A GREATER LIKELIHOOD OF HYPERTENSION, DIABETES
      MELLITUS, LONGER SYMPTOM ONSET TO BALLOON TIME, LOWER LEFT VENTRICULAR EJECTION
      FRACTION, AND FINAL THROMBOLYSIS IN MYOCARDIAL INFARCTION FLOW 3. AT 3 YEARS,
      PATIENTS WITH STR30% EXPERIENCED A HIGHER RATE OF MAJOR ADVERSE CARDIOVASCULAR
      EVENTS (DEATH, REINFARCTION, ISCHEMIA-DRIVEN TARGET VESSEL REVASCULARIZATION OR
      STROKE; 29.9% VERSUS 20.1% VERSUS 19.6%; P0.0001), ISCHEMIA-DRIVEN TARGET VESSEL 
      REVASCULARIZATION (20.4% VERSUS 14.0% VERSUS 11.7%; P0.001), AND MORTALITY (8.4% 
      VERSUS 5.0% VERSUS 5.6%; P=0.03) THAN THOSE WITH PARTIAL AND COMPLETE STR,
      RESPECTIVELY. BY MULTIVARIABLE ANALYSIS, STR30% WAS AN INDEPENDENT PREDICTOR OF
      3-YEAR MAJOR ADVERSE CARDIOVASCULAR EVENTS (HAZARD RATIO, 1.58; 95% CONFIDENCE
      INTERVAL, 1.242.00; P=0.0002) AND 3-YEAR ISCHEMIA-DRIVEN TARGET VESSEL
      REVASCULARIZATION (HAZARD RATIO, 1.87; 95% CONFIDENCE INTERVAL, 1.412.48;
      P0.0001).CONCLUSIONS: IN THIS LARGE INTERNATIONAL STUDY, ABSENT STR 60 MINUTES
      AFTER PRIMARY PCI WAS PRESENT IN 1 IN 5 PATIENTS WITH ST-SEGMENTELEVATION
      MYOCARDIAL INFARCTION AND WAS A SIGNIFICANT INDEPENDENT PREDICTOR OF MAJOR
      ADVERSE CARDIOVASCULAR EVENTS AND TARGET VESSEL REVASCULARIZATION AT 3
      YEARS.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique
      identifier: NCT00433966.
AD  - Peter Munk Cardias Centre and Heart and Stroke Lewar Centre, Toronto, ON.
FAU - Farkouh, Michael E
AU  - Farkouh ME
FAU - Reiffel, James
AU  - Reiffel J
FAU - Dressler, Ovidiu
AU  - Dressler O
FAU - Nikolsky, Eugenia
AU  - Nikolsky E
FAU - Parise, Helen
AU  - Parise H
FAU - Cristea, Ecatarina
AU  - Cristea E
FAU - Baran, David A
AU  - Baran DA
FAU - Dizon, Jose
AU  - Dizon J
FAU - Merab, Jacques P
AU  - Merab JP
FAU - Lansky, Alexandra J
AU  - Lansky AJ
FAU - Mehran, Roxana
AU  - Mehran R
FAU - Stone, Gregg W
AU  - Stone GW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Circ Cardiovasc Interv
JT  - Circulation. Cardiovascular interventions
JID - 101499602
OTO - NOTNLM
OT  - ECG
OT  - myocardial infarction
OT  - prognosis
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - CIRCINTERVENTIONS.112.000142 [pii]
AID - 10.1161/CIRCINTERVENTIONS.112.000142 [doi]
PST - aheadofprint
SO  - Circ Cardiovasc Interv. 2013 May 7.

PMID- 23652584
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 32
IP  - 1
DP  - 2013 Jul
TI  - Assessment of cardiac inflammation and remodeling during the development of
      streptozotocin-induced diabetic cardiomyopathy in vivo: A time course analysis.
PG  - 158-64
LID - 10.3892/ijmm.2013.1368 [doi]
AB  - In this study, we examined cardiac inflammation, fibrosis and left ventricular
      (LV) function during the development of streptozotocin (STZ)-induced diabetic
      cardiomyopathy using an animal model of diabetes mellitus (DM). Diabetes was
      induced in 22 SpragueDawley rats by an intraperitoneal single injection of STZ
      (70 mg/kg). Non-diabetic animals served as the controls (n=6). LV function was
      documented using the conductance catheter technique 2 and 6 weeks after the
      induction of diabetes. Cardiac tissue was analyzed for cardiac immune cell
      infiltration, oxidative stress and remodeling in rats with STZ-induced diabetes
      at 2 different time points by immunohistochemistry. Cardiac function was
      significantly impaired in the diabetic animals. After 2 weeks, the induction of
      diabetes resulted in impaired cardiac function indexed by a decrease in systolic 
      and diastolic LV function. This impairment of LV performance continued for up to 
      6 weeks after the STZ injection. This was associated with an increase in cardiac 
      CD3+ and CD8a+ immune cell invasion and fibrosis, indexed by an increase in
      collagen content (p<0.05). Furthermore, oxidative stress response and matrix
      remodeling were increased after 2 weeks and this continued for up to 6 weeks
      after the induction of diabetes. In conclusion, cardiac dysfunction is associated
      with cardiac inflammation and adverse remodeling in experimental diabetic
      cardiomyopathy. Our results suggest that the model of STZ-induced diabetic
      cardiomyopathy is a robust model for investigating cardiac immune response and LV
      remodeling processes under diabetic conditions.
AD  - Department of Cardiology and Pneumology, Charite University Hospital Berlin,
      Campus Benjamin Franklin, D-12200 Berlin, Germany.
FAU - Becher, P M
AU  - Becher PM
FAU - Lindner, D
AU  - Lindner D
FAU - Frohlich, M
AU  - Frohlich M
FAU - Savvatis, K
AU  - Savvatis K
FAU - Westermann, D
AU  - Westermann D
FAU - Tschope, C
AU  - Tschope C
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/02/28 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - 10.3892/ijmm.2013.1368 [doi]
PST - ppublish
SO  - Int J Mol Med. 2013 Jul;32(1):158-64. doi: 10.3892/ijmm.2013.1368. Epub 2013 May 
      2.

PMID- 23652487
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
DP  - 2013 May 7
TI  - Racial Differences in Retinal Vessel Geometric Characteristics: A Multi-Ethnic
      Study in Healthy Asians.
LID - iovs.12-11126v1 [pii]
LID - 10.1167/iovs.12-11126 [doi]
AB  - PURPOSE: To investigate potential racial/ethnic differences in retinal vascular
      geometric parameters in a multi-ethnic Asian population (Chinese, Malay and
      Indian) free of clinical diseases. METHODS: A series of retinal vascular
      parameters were measured from retinal photographs using a computer-assisted
      program following a standardized protocol. Healthy participants were defined as
      non- smokers, absence of diabetes mellitus, uncontrolled hypertension, obesity,
      stroke, heart disease, glaucoma and retinopathy. RESULTS: There were significant 
      differences in measurements of retinal vascular caliber, tortuosity and fractal
      dimension among the three ethnic groups. In multivariate liner regression model
      controlling for age, gender, body mass index, systolic blood pressure,
      cholesterol, and glucose levels, Indians had largest arteriolar and venular
      calibers (arterioles [standard error: SE]: 158.94 microm [1.00]; venules: 228.26 
      microm [1.53]), followed by Malays (arterioles: 138.31 microm [0.74]; venules:
      204.26 microm [1.13]), and then Chinese (arterioles: 131.20 microm [0.84];
      venules: 195.09 microm [1.28]). Chinese had largest arteriolar and venular
      tortuosity (arterioles (x105): 7.20 [0.08]; venules (x105): 9.09 [0.10]), and
      venular fractal dimension (1.244 [0.003]). There were no statistically
      significant differences in other retinal vascular parameters after correcting
      multiple comparisons by the method of modified false discovery rate. CONCLUSIONS:
      We found that among ethnic groups comprising of healthy Chinese, Malay and
      Indians, there were statistically significant differences in several retinal
      parameters. There exist racial influence in retinal vascular parameters and other
      yet unknown or unmeasured environmental factor or lifestyle habits and genetic
      variations not related to race that may also contribute to these differences.
AD  - Department of Statistics and Applied Probability, National University of
      Singapore, Singapore.
FAU - Li, Xiang
AU  - Li X
FAU - Wong, Wan Ling
AU  - Wong WL
FAU - Cheung, Carol Yim-Lui
AU  - Cheung CY
FAU - Cheng, Ching-Yu
AU  - Cheng CY
FAU - Ikram, Mohammad Kamran
AU  - Ikram MK
FAU - Li, Jialiang
AU  - Li J
FAU - Chia, Kee Seng
AU  - Chia KS
FAU - Wong, Tien Yin
AU  - Wong TY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - iovs.12-11126 [pii]
AID - 10.1167/iovs.12-11126 [doi]
PST - aheadofprint
SO  - Invest Ophthalmol Vis Sci. 2013 May 7. pii: iovs.12-11126v1. doi:
      10.1167/iovs.12-11126.

PMID- 23652453
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2782 (Electronic)
IS  - 0302-5144 (Linking)
VI  - 179
DP  - 2013
TI  - Stroke feature and management in dialysis patients.
PG  - 100-9
LID - 10.1159/000346728 [doi]
AB  - Strokes remain the major complication among dialysis population as the number of 
      diabetes and elderly is increasing. In chronic hemodialysis patients, prevalence 
      and incidence of stroke is higher than that of the general population. According 
      to the annual registry data of the Japanese Society for Dialysis Therapy,
      prevalence of stroke death has been declining, yet the incidence of nonfatal
      incidence of stroke is not known. Underlying mechanisms of stroke are multiple.
      Among them, control of hypertension is important for the primary prevention;
      however, the ideal target level of blood pressure is not determined. Other than
      hypertension, maintaining good nutritional status is utmost important. Most
      observational studies suggested that the target was 140/90 mm Hg at
      prehemodialysis session. However, blood pressure levels are variable in both at
      office (before and after dialysis session) and at home. It is advisable to
      measure blood pressure multiple occasions and also at home. In case of acute
      cerebral hemorrhage, glycerol is indicated to prevent cerebral edema. Blood
      pressure is recommended to control as systolic <180 mm Hg or mean arterial
      pressure <130 mm Hg, and lower blood pressure gradually to 80% of the baseline
      level. In case of acute cerebral infarction hypertension is not treated unless
      severely hypertensive, systolic >220 mm Hg or diastolic >120 mm Hg and lower
      blood pressure gradually to 85-90% of the baseline level. Use of warfarin is
      controversial in case of acute cerebral infarction. Modification of dialysis
      modality is needed to prevent the increase in intracranial pressure and/or
      recurrence of stroke.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Dialysis Unit, University Hospital of the Ryukyus, Okinawa, Japan.
FAU - Iseki, Kunitoshi
AU  - Iseki K
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - Switzerland
TA  - Contrib Nephrol
JT  - Contributions to nephrology
JID - 7513582
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/03 [aheadofprint]
AID - 000346728 [pii]
AID - 10.1159/000346728 [doi]
PST - ppublish
SO  - Contrib Nephrol. 2013;179:100-9. doi: 10.1159/000346728. Epub 2013 May 3.

PMID- 23652449
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2782 (Electronic)
IS  - 0302-5144 (Linking)
VI  - 179
DP  - 2013
TI  - Risk of stroke in kidney disease.
PG  - 58-66
LID - 10.1159/000346724 [doi]
AB  - Stroke is a leading cause of mortality and morbidity worldwide. Traditional
      cardiovascular risk factors - hypertension, diabetes and dyslipidemia - are
      related to the incidence of stroke. Chronic kidney disease has also been
      recognized to be a major public health problem as a cardiovascular risk factor.
      Growing evidence has suggested that chronic kidney disease is associated with an 
      increased risk of cardiovascular disease including stroke in general populations.
      Those with chronic kidney disease have a greater prevalence of traditional
      cardiovascular risk factors. Several meta-analyses assessing the association
      between chronic kidney disease and stroke have found that the magnitude of the
      risk estimates adjusted for known traditional cardiovascular risk factors were
      reduced as compared with the age-adjusted risk estimates. While these findings on
      the surface seem to downplay the effect of chronic kidney disease on stroke, they
      may actually suggest that an accumulation of traditional cardiovascular risk
      factors in those with chronic kidney disease increases the risk of stroke, and
      that applying appropriate treatments to those with chronic kidney disease is
      important for reducing the risk of stroke. Additionally, other large-scale
      meta-analyses demonstrated that chronic kidney disease was a significant risk
      factor for stroke independent of known cardiovascular risk factors. Chronic
      kidney disease may also be associated with an increase in nontraditional risk
      factors such as hyperhomocysteinemia, inflammation, asymmetric dimethylarginine, 
      oxidative stress, and anemia, and thrombogenic factors such as left ventricular
      hypertrophy, endothelial dysfunction, and arterial stiffness. Herein, we review
      the results of meta-analyses of published cohort studies for a better
      understanding of the precise nature of the relationship between chronic kidney
      disease and stroke, important to both the clinical and public health fields.
      Further studies are warranted to determine whether interventions to prevent the
      progression of kidney impairment are effective at reducing the risk of stroke.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences,
      Kyushu University, Fukuoka, Japan.
FAU - Ninomiya, Toshiharu
AU  - Ninomiya T
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - Switzerland
TA  - Contrib Nephrol
JT  - Contributions to nephrology
JID - 7513582
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/03 [aheadofprint]
AID - 000346724 [pii]
AID - 10.1159/000346724 [doi]
PST - ppublish
SO  - Contrib Nephrol. 2013;179:58-66. doi: 10.1159/000346724. Epub 2013 May 3.

PMID- 23652448
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2782 (Electronic)
IS  - 0302-5144 (Linking)
VI  - 179
DP  - 2013
TI  - Kidney disease and cognitive function.
PG  - 42-57
LID - 10.1159/000346722 [doi]
AB  - We provide a brief review of research on chronic kidney disease and cognitive
      performance, including dementia. We touch briefly on the literature relating
      end-stage-renal disease to cognitive function, but focus on studies of modest and
      moderate forms of chronic kidney disease (CKD) that precede dialysis and
      transplantation. We summarize previous reviews dealing with case control studies 
      of patients but more fully examine community-based studies with large samples and
      necessary controls for demographic risk factors, cardiovascular variables, and
      other confounds such as depression. In addition we suggest potential biological
      and social-psychological mediators between CKD and cognition. Studies follow in
      two categories of design: (1) cross-sectional studies, and (2) longitudinal
      studies. In each, CKD is related to a wide range of deficits in cognitive
      functioning including verbal and visual memory and organization, and components
      of executive functioning and fluid intellect. In general, prior to the need to
      treat with hemodialysis (HD) or kidney transplant (KT), magnitude of effect with 
      relation to CKD and function are small or modest in persons free from acute
      stroke and dementia. However, HD and KT can result in major impairment. We
      discuss needed controls, the greater demand on controls after the start of HD and
      KT, and suggest that mechanisms intervening relations between hypertension, or
      diabetes, and cognitive performance may be similar to those intervening between
      hypertension and cognitive performance and the hypertension and diabetes
      literature on cognition provides a good model for the study of early stage kidney
      disease and cognitive ability. We posit that the mechanisms linking CKD and
      cognition may be similar to those linking hypertension or diabetes to cognition. 
      We identify the need for more studies with multiple cognitive test batteries,
      measures of every-day cognitive abilities relevant to patient understanding of
      the disease and treatments, and more studies with prevalent and incident dementia
      outcomes. Descriptors: kidney disease, chronic kidney disease, cognitive
      function, dementia and cardiovascular risk factors.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Psychology and Graduate School of Biomedical Sciences, The
      University of Maine, Orono, Me., USA.
FAU - Elias, Merrill F
AU  - Elias MF
FAU - Dore, Gregory A
AU  - Dore GA
FAU - Davey, Adam
AU  - Davey A
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - Switzerland
TA  - Contrib Nephrol
JT  - Contributions to nephrology
JID - 7513582
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/03 [aheadofprint]
AID - 000346722 [pii]
AID - 10.1159/000346722 [doi]
PST - ppublish
SO  - Contrib Nephrol. 2013;179:42-57. doi: 10.1159/000346722. Epub 2013 May 3.

PMID- 23652446
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2782 (Electronic)
IS  - 0302-5144 (Linking)
VI  - 179
DP  - 2013
TI  - Subclinical cerebral abnormalities in chronic kidney disease.
PG  - 24-34
LID - 10.1159/000346719 [doi]
AB  - Background and Purpose: Impaired kidney function or chronic kidney disease (CKD),
      as measured by estimated glomerular filtration rate (eGFR), is associated with
      incident stroke risk. However, few studies have examined the relationship between
      CKD and subclinical cerebral abnormalities. Methods: We examined 675 elderly
      subjects (mean age 69.9 years), who were living independently at home without
      apparent dementia, using magnetic resonance imaging. Serum creatinine values,
      measured by the enzymatic method, were used for the Japanese equation of eGFR.
      Results: Subclinical lacunar infarction, deep white matter lesions, and
      periventricular hyperintensities were detected in 88 (13.0%), 240 (35.6%) and 158
      (23.4%) of the 675 participants, respectively. In the forward stepwise method of 
      logistic analysis, age (OR 2.081/10, 95% CI 1.541-2.810), hypertension (OR 3.656,
      95% CI 2.184-6.119), diabetes mellitus (OR 1.961, 95% CI 1.007-3.820), alcohol
      intake (OR 2.130, 95% CI 1.283-3.535), and eGFR <45 ml/min/1.73 m(2) were
      significant factors concerning subclinical lacunar infarction. CKD defined as
      eGFR <60 ml/min/1.73 m(2) was not significantly associated with subclinical
      lacunar infarction. Decreased eGFR was not a significant factor associated with
      white matter lesions (WMLs). Age (OR 2.781/10, 95% CI 2.252-3.435), hypertension 
      (OR 1.746, 95% CI 1.231-2.477), diabetes mellitus (OR 1.854, 95% CI 1.070-3.213),
      but not eGFR were significant factors concerning WMLs. Conclusions: The present
      study showed that community-dwelling elderly subjects with late stage 3 CKD were 
      at high risk for prevalent subclinical lacunar infarction. The identification of 
      CKD-specific modifiable risk factors for SBI and WMLs is of increased importance 
      for prevention of subclinical brain ischemic lesions.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Center for Emotional and Behavioral Disorders, National Hospital Organization
      Hizen Psychiatric Center, Saga, Saitama, Japan.
FAU - Yao, Hiroshi
AU  - Yao H
FAU - Takashima, Yuki
AU  - Takashima Y
FAU - Hashimoto, Manabu
AU  - Hashimoto M
FAU - Uchino, Akira
AU  - Uchino A
FAU - Yuzuriha, Takefumi
AU  - Yuzuriha T
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - Switzerland
TA  - Contrib Nephrol
JT  - Contributions to nephrology
JID - 7513582
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/03 [aheadofprint]
AID - 000346719 [pii]
AID - 10.1159/000346719 [doi]
PST - ppublish
SO  - Contrib Nephrol. 2013;179:24-34. doi: 10.1159/000346719. Epub 2013 May 3.

PMID- 23652401
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2979 (Electronic)
IS  - 1421-7082 (Linking)
VI  - 25
DP  - 2013
TI  - Clinical perspectives for ghrelin-derived therapeutic products.
PG  - 157-66
LID - 10.1159/000346065 [doi]
AB  - Because of its orexigenic, adipogenic and diabetogenic activities, acylated
      ghrelin (AG) has emerged as an attractive target for the treatment of obesity and
      type 2 diabetes. Pharmacological tools have been designed in order to antagonize 
      or block the hormone's activity, or inhibit ghrelin O-acyltransferase (GOAT), the
      enzyme that catalyzes its acylation. AG antagonists, shown to be potent
      inhibitors of growth hormone (GH) secretion, were not able to consistently induce
      the desirable metabolic effects. Some of them, on the contrary, acted as AG
      agonists. Similarly, AG-blocking agents including Spiegelmers, vaccines, and
      monoclonal antibodies, gave mixed results. More encouraging yet very preliminary 
      data were obtained with a novel GOAT inhibitor. However, although significant,
      the observed decrease in circulating AG levels was partial and improvement work
      remains to be done. Unacylated ghrelin (UAG) and analogs were shown to potently
      and rapidly inhibit plasma AG levels, and to improve glucose metabolism in
      addition to displaying beneficial effects on a variety of cells. These data
      support the rationale for further development of this new therapeutic class in
      type 2 diabetes and the Prader-Willi syndrome. A development program is underway 
      with AZP-531, a cyclized UAG(6-13) analog with improved pharmacokinetic
      properties.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Alize Pharma, Ecully, France.
FAU - Allas, Soraya
AU  - Allas S
FAU - Abribat, Thierry
AU  - Abribat T
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Switzerland
TA  - Endocr Dev
JT  - Endocrine development
JID - 101138956
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/25 [aheadofprint]
AID - 000346065 [pii]
AID - 10.1159/000346065 [doi]
PST - ppublish
SO  - Endocr Dev. 2013;25:157-66. doi: 10.1159/000346065. Epub 2013 Apr 25.

PMID- 23652399
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2979 (Electronic)
IS  - 1421-7082 (Linking)
VI  - 25
DP  - 2013
TI  - Ghrelin function in insulin release and glucose metabolism.
PG  - 135-43
LID - 10.1159/000346064 [doi]
AB  - Given its wide spectrum of biological activities such as growth hormone (GH)
      release, feeding stimulation, adiposity and cardiovascular actions, the discovery
      of ghrelin opened many new perspectives within neuroendocrine, metabolic and
      cardiovascular research, thus suggesting its possible clinical application.
      Circulating ghrelin is produced predominantly in the stomach, and its receptor GH
      secretagogue receptor (GHS-R) is expressed in a variety of central and peripheral
      tissues. Ghrelin, GHS-R and ghrelin O-acyltransferase (GOAT), the enzyme that
      promotes the acylation of the third serine residue of ghrelin, are all expressed 
      in pancreatic islets, and this peptide is released into pancreatic
      microcirculations. Ghrelin inhibits insulin release in mice, rats and humans. The
      signal transduction mechanisms of ghrelin receptor in islet beta-cells are very
      unique, being distinct from those utilized for GH release. Pharmacological and
      genetic blockade of islet-derived ghrelin markedly augments glucose-induced
      insulin release in vitro. Ablation of ghrelin, GHS-R or GOAT enhances insulin
      release and prevents impaired glucose tolerance in high-fat, diet-induced and
      leptin-deficient obese models. Thus, manipulation of the insulinostatic function 
      of the ghrelin-GHS-R system, particularly that in islets, could optimize the
      amount of insulin release to meet the systemic demand. Ghrelin antagonism
      provides a novel strategy to treat type 2 diabetes with dysregulated insulin
      release.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Division of Integrative Physiology, Department of Physiology, Jichi Medical
      University School of Medicine, Shimotsuke, Japan.
FAU - Dezaki, Katsuya
AU  - Dezaki K
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Switzerland
TA  - Endocr Dev
JT  - Endocrine development
JID - 101138956
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/25 [aheadofprint]
AID - 000346064 [pii]
AID - 10.1159/000346064 [doi]
PST - ppublish
SO  - Endocr Dev. 2013;25:135-43. doi: 10.1159/000346064. Epub 2013 Apr 25.

PMID- 23652397
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2979 (Electronic)
IS  - 1421-7082 (Linking)
VI  - 25
DP  - 2013
TI  - Des-acyl ghrelin: a metabolically active Peptide.
PG  - 112-21
LID - 10.1159/000346059 [doi]
AB  - Unacylated ghrelin (UAG), or des-acyl ghrelin, is slowly fighting its way up into
      the field of interest that studies preproghrelin gene-encoded peptides. Long
      considered to be an inert degradation product of (acylated) ghrelin (AG), UAG
      nowadays emerges as an important hormone, separate from the other
      proghrelin-derived peptides, AG and obestatin. UAG appears to have its own
      receptor, and it can share this receptor with AG, under experimental conditions
      at least. An increasing number of studies suggest that UAG can act as a potent
      functional inhibitor of ghrelin. It can even strongly suppress ghrelin levels in 
      obese human diabetic subjects. Moreover, UAG can improve postprandial glycemia,
      especially in those subjects in whom preprandial acylated ghrelin levels are
      high, which makes UAG, or UAG analogs strong potential candidates for the
      development of drugs for the treatment of metabolic disorders or other conditions
      in which elevated AG/UAG ratios occur, such as diabetes, obesity and Prader-Willi
      syndrome.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Medicine, Erasmus University MC, Rotterdam, The Netherlands.
FAU - Delhanty, Patric J
AU  - Delhanty PJ
FAU - Neggers, Sebastian J
AU  - Neggers SJ
FAU - van der Lely, Aart J
AU  - van der Lely AJ
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Switzerland
TA  - Endocr Dev
JT  - Endocrine development
JID - 101138956
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/25 [aheadofprint]
AID - 000346059 [pii]
AID - 10.1159/000346059 [doi]
PST - ppublish
SO  - Endocr Dev. 2013;25:112-21. doi: 10.1159/000346059. Epub 2013 Apr 25.

PMID- 23652395
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2979 (Electronic)
IS  - 1421-7082 (Linking)
VI  - 25
DP  - 2013
TI  - Ghrelin - a key pleiotropic hormone-regulating systemic energy metabolism.
PG  - 91-100
LID - 10.1159/000346590 [doi]
AB  - The gastrointestinal peptide hormone ghrelin was discovered in 1999 as the
      endogenous ligand for the growth hormone secretagogue receptor (GHSR-1a). Since
      its discovery tremendous research efforts have been directed at unraveling
      ghrelin's mechanisms of action, revealing that ghrelin is a pleiotropic hormone
      implicated in myriad of molecular signaling mechanisms. Accordingly, ghrelin is
      the only known circulating peripheral hormone with the ability to promote a
      positive energy balance by stimulating food intake while decreasing energy
      expenditure and body fat utilization. Moreover, beyond its ability to promote the
      release of growth hormone from the anterior pituitary, ghrelin stimulates gut
      motility and gastric acid secretion, modulates sleep, taste sensation and
      behavior, and regulates glucose metabolism. Due to ghrelin's ability to promote
      body weight gain and adiposity via centrally mediated signaling mechanisms,
      modulation of the endogenous ghrelin system is considered a promising strategy to
      treat individuals with pathologically reduced body weight, such as patients with 
      anorexia nervosa or cachexia. The aim of this chapter is to summarize the current
      knowledge of how ghrelin affects systemic energy metabolism.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Institute for Diabetes and Obesity, Helmholtz Zentrum Munchen and Department of
      Medicine, Technische Universitat Munchen, Munich, Germany.
FAU - Muller, Timo D
AU  - Muller TD
FAU - Tschop, Matthias H
AU  - Tschop MH
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Switzerland
TA  - Endocr Dev
JT  - Endocrine development
JID - 101138956
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/25 [aheadofprint]
AID - 000346590 [pii]
AID - 10.1159/000346590 [doi]
PST - ppublish
SO  - Endocr Dev. 2013;25:91-100. doi: 10.1159/000346590. Epub 2013 Apr 25.

PMID- 23652388
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1662-2979 (Electronic)
IS  - 1421-7082 (Linking)
VI  - 25
DP  - 2013
TI  - Discovery of ghrelin o-acyltransferase.
PG  - 16-24
LID - 10.1159/000346039 [doi]
AB  - Ghrelin is a gut hormone with potent orexigenic and growth hormone release
      stimulatory effects, and is the first known endogenous ligand of the growth
      hormone secretagogue receptor. A notable feature of ghrelin is that it carries an
      acyl group, in most cases an octanoyl group, in the third serine. While it has
      been shown that the acylation is critical for the majority of ghrelin functions, 
      the mechanisms of acylation of ghrelin remained poorly understood. In 2008, it
      was discovered that ghrelin O-acyltransferase (GOAT) is the enzyme responsible
      for acylating ghrelin. GOAT is highly conserved from zebrafish to humans. It is
      most abundant in the stomach and pancreas. GOAT mRNA expression is regulated by
      energy balance, being upregulated by energy restriction and downregulated by
      energy abundance. GOAT attenuation using synthetic inhibitors enhances insulin
      secretion and reduces body weight. GOAT inhibitors are currently being developed 
      for the treatment of metabolic disorders. In addition to its ghrelin mediated
      effects, GOAT is also known to directly regulate bile acid secretion. The
      discovery of GOAT helped to redefine the ghrelin research field and enabled the
      development of another target molecule for potential therapies aimed to
      prevent/treat diabetes and obesity.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Veterinary Biomedical Sciences, Laboratory of Integrative
      Neuroendocrinology, Western College of Veterinary Medicine, University of
      Saskatchewan, Saskatoon, SAS, Canada.
FAU - Mohan, Haneesha
AU  - Mohan H
FAU - Unniappan, Suraj
AU  - Unniappan S
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Switzerland
TA  - Endocr Dev
JT  - Endocrine development
JID - 101138956
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/25 [aheadofprint]
AID - 000346039 [pii]
AID - 10.1159/000346039 [doi]
PST - ppublish
SO  - Endocr Dev. 2013;25:16-24. doi: 10.1159/000346039. Epub 2013 Apr 25.

PMID- 23652376
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1476-5438 (Electronic)
IS  - 1018-4813 (Linking)
DP  - 2013 May 8
TI  - A novel ALMS1 splice mutation in a non-obese juvenile-onset insulin-dependent
      syndromic diabetic patient.
LID - 10.1038/ejhg.2013.87 [doi]
AB  - Insulin-dependent juvenile-onset diabetes may occur in the context of rare
      syndromic presentations suggesting monogenic inheritance rather than common
      multifactorial autoimmune type 1 diabetes. Here, we report the case of a Lebanese
      patient diagnosed with juvenile-onset insulin-dependent diabetes presenting
      ketoacidosis, early-onset retinopathy with optic atrophy, hearing loss, diabetes 
      insipidus, epilepsy, and normal weight and stature, who later developed insulin
      resistance. Despite similarities with Wolfram syndrome, we excluded the WFS1 gene
      as responsible for this disease. Using combined linkage and candidate gene study,
      we selected ALMS1, responsible for Alstrom syndrome, as a candidate gene. We
      identified a novel splice mutation in intron 18 located 3 bp before the
      intron-exon junction (IVS18-3T>G), resulting in exon 19 skipping and consequent
      frameshift generating a truncated protein (V3958fs3964X). The clinical
      presentation of the patient significantly differed from typical Alstrom syndrome 
      by the absence of truncal obesity and short stature, and by the presence of
      ketoacidotic insulin-dependent diabetes, optic atrophy and diabetes insipidus.
      Our observation broadens the clinical spectrum of Alstrom syndrome and suggests
      that ALMS1 mutations may be considered in patients who initially present with an 
      acute onset of insulin-dependent diabetes.European Journal of Human Genetics
      advance online publication, 8 May 2013; doi:10.1038/ejhg.2013.87.
AD  - 1] Inserm UMR-S958, Medical Faculty Paris 7, site Villemin, Paris, France [2]
      University Paris 7 Denis-Diderot, Paris, France.
FAU - Sanyoura, May
AU  - Sanyoura M
FAU - Woudstra, Cedric
AU  - Woudstra C
FAU - Halaby, George
AU  - Halaby G
FAU - Baz, Patrick
AU  - Baz P
FAU - Senee, Valerie
AU  - Senee V
FAU - Guillausseau, Pierre-Jean
AU  - Guillausseau PJ
FAU - Zalloua, Pierre
AU  - Zalloua P
FAU - Julier, Cecile
AU  - Julier C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Eur J Hum Genet
JT  - European journal of human genetics : EJHG
JID - 9302235
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/08 [aheadofprint]
AID - ejhg201387 [pii]
AID - 10.1038/ejhg.2013.87 [doi]
PST - aheadofprint
SO  - Eur J Hum Genet. 2013 May 8. doi: 10.1038/ejhg.2013.87.

PMID- 23652283
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1423-0291 (Electronic)
IS  - 1015-2008 (Linking)
VI  - 80
IP  - 4
DP  - 2013
TI  - Design of a bioartificial pancreas.
PG  - 194-202
LID - 10.1159/000345873 [doi]
AB  - Islet transplantation has been shown to be a viable treatment option for patients
      afflicted with type 1 diabetes. However, the lack of availablity of human
      pancreases and the need to use risky immunosuppressive drugs to prevent
      transplant rejection remain two major obstacles to the routine use of islet
      transplantation in diabetic patients. Successful development of a bioartificial
      pancreas using the approach of microencapsulation with perm-selective coating of 
      islets in hydrogels for graft immunoisolation holds tremendous promise for
      diabetic patients because it has great potential to overcome these two barriers. 
      In this review article, we will discuss the need for a bioartificial pancreas,
      provide a detailed description of the microencapsulation process, and review the 
      status of the technology in clinical development. We will also critically review 
      the various factors that will need to be taken into consideration in order to
      achieve the ultimate goal of routine clinical application.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Institute for Regenerative Medicine, Wake Forest School of Medicine,
      Winston-Salem, N.C., USA.
FAU - Pareta, Rajesh A
AU  - Pareta RA
FAU - Farney, Alan C
AU  - Farney AC
FAU - Opara, Emmanuel C
AU  - Opara EC
LA  - eng
GR  - R01 DK080897/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130506
PL  - Switzerland
TA  - Pathobiology
JT  - Pathobiology : journal of immunopathology, molecular and cellular biology
JID - 9007504
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/06 [aheadofprint]
AID - 000345873 [pii]
AID - 10.1159/000345873 [doi]
PST - ppublish
SO  - Pathobiology. 2013;80(4):194-202. doi: 10.1159/000345873. Epub 2013 May 6.

PMID- 23652271
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
DP  - 2013 May 7
TI  - Moyamoya Disease in a Primarily White, Midwestern US Population: Increased
      Prevalence of Autoimmune Disease.
AB  - BACKGROUND AND PURPOSE: Moyamoya disease is an uncommon, cerebrovascular
      occlusive disease of unknown pathogenesis. Previously described Moyamoya cohorts 
      include predominantly Asian populations or ethnically diverse North American
      cohorts. To gain further insight into the pathogenesis of moyamoya, we examined
      clinical characteristics of a primarily white, Midwestern US population METHODS: 
      Retrospective analysis of patients with angiographically confirmed moyamoya
      disease evaluated at our institution was performed. Prevalence of comorbidities, 
      cerebrovascular risk factors, and autoimmune diseases were compared with the
      general population. RESULTS: Ninety-four patients with moyamoya were evaluated;
      72.3% were female. Ethnic composition was primarily white (85%). A significantly 
      higher prevalence of autoimmune disease was seen, particularly type 1 diabetes
      mellitus (8.5% versus 0.4% in the general population) and thyroid disease (17.0% 
      versus 8.0% in the institutional general patient population). Hyperlipidemia was 
      also increased (27.7% versus 16.3% in the general population). CONCLUSIONS: This 
      study of a unique, primarily white, Midwestern population of moyamoya patients
      demonstrates a significantly higher prevalence of autoimmune disease than in the 
      general population. This supports a possible autoimmune component to the
      pathogenesis of moyamoya disease.
AD  - From the Departments of Neurosurgery, Endocrinology, and Neurology, Mayo Clinic
      College of Medicine, Rochester, MN.
FAU - Bower, Regina S
AU  - Bower RS
FAU - Mallory, Grant W
AU  - Mallory GW
FAU - Nwojo, Macaulay
AU  - Nwojo M
FAU - Kudva, Yogish C
AU  - Kudva YC
FAU - Flemming, Kelly D
AU  - Flemming KD
FAU - Meyer, Fredric B
AU  - Meyer FB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Stroke
JT  - Stroke; a journal of cerebral circulation
JID - 0235266
OTO - NOTNLM
OT  - immunology
OT  - moyamoya
OT  - pathogenesis
OT  - risk factor
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - STROKEAHA.111.000307 [pii]
AID - 10.1161/STROKEAHA.111.000307 [doi]
PST - aheadofprint
SO  - Stroke. 2013 May 7.

PMID- 23652172
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1827-1596 (Electronic)
IS  - 0375-9393 (Linking)
DP  - 2013 May 6
TI  - Management of the patient with diabetic peripheral neuropathy presenting for
      peripheral regional anaesthesia: a European survey and Review of literature.
AB  - Background: Diabetic peripheral neuropathy (DPN) is a frequent complication of
      longstanding diabetes mellitus. There is no evidence-based consensus whether
      neuropathic patients undergoing peripheral regional anaesthesia are at increased 
      risk of neurologic damage. It is unknown whether these controversial results have
      been incorporated into clinical practice. Objective: We conducted a survey to
      test the hypothesis that the majority of respondents would consider DPN a
      potential risk factor for nerve damage in regional anaesthesia, and would adapt
      their technique when performing regional anaesthesia. In parallel, we sought to
      summarize the current knowledge-base regarding regional anaesthesia and DPN.
      Methods: We therefore performed (1) a literature search to review current
      literature and (2) an online computerbased survey among members of the European
      Society of Regional Anaesthesia and Pain Therapy (ESRA). Results: The overall
      response rate was 19 % (584 responders / 3,107 invitations). We received. About a
      quarter of participants would avoid regional anaesthesia in patients with
      diabetic neuropathy, and 59 % of respondents would counsel patients with diabetic
      neuropathy about increased risk of regional anaesthesia. When techniques were
      modified, most participants would decrease or omit epinephrine, while fewer
      respondents would decrease dose of local anaesthetic or perform other
      adjustments. More than eighty percent agreed with the statement that nerve blocks
      could be performed safely in diabetic neuropathic patients. Conclusions: In
      conclusion, we report the results of the first survey analyzing attitudes and
      standards of care among European anaesthesiologists with regards to Regional
      Anaesthesia in DPN. While literature is divided on the question whether
      pre-existing diabetic neuropathy is a risk factor for new neurological deficit
      after regional anaesthesia, most of the responders of this survey take measures
      to reduce risks, counsel patients on a possible greater risk of neurologic
      complications, but only a minority of responders would avoid peripheral regional 
      anaesthesia altogether.
AD  - Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, 
      The Netherlands (PL,MVH, MFS, MWH) - m.w.hollmann@amc.uva.nl.
FAU - Lirk, P
AU  - Lirk P
FAU - Rutten, M V H
AU  - Rutten MV
FAU - Haller, I
AU  - Haller I
FAU - Stevens, M F
AU  - Stevens MF
FAU - Laudolff-Birmingham, J
AU  - Laudolff-Birmingham J
FAU - Hollmann, M
AU  - Hollmann M
FAU - Birmingham, B
AU  - Birmingham B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Minerva Anestesiol
JT  - Minerva anestesiologica
JID - 0375272
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - R02138577 [pii]
PST - aheadofprint
SO  - Minerva Anestesiol. 2013 May 6.

PMID- 23652116
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 19
IP  - 5
DP  - 2013 May
TI  - PPARgamma signaling and metabolism: the good, the bad and the future.
PG  - 557-66
LID - 10.1038/nm.3159 [doi]
AB  - Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the
      nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARgamma) and
      are highly effective oral medications for type 2 diabetes. However, their unique 
      benefits are shadowed by the risk for fluid retention, weight gain, bone loss and
      congestive heart failure. This raises the question as to whether it is possible
      to build a safer generation of PPARgamma-specific drugs that evoke fewer side
      effects while preserving insulin-sensitizing potential. Recent studies that have 
      supported the continuing physiologic and therapeutic relevance of the PPARgamma
      pathway also provide opportunities to develop newer classes of molecules that
      reduce or eliminate adverse effects. This review highlights key advances in
      understanding PPARgamma signaling in energy homeostasis and metabolic disease and
      also provides new explanations for adverse events linked to TZD-based therapy.
AD  - Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla,
      California, USA.
FAU - Ahmadian, Maryam
AU  - Ahmadian M
FAU - Suh, Jae Myoung
AU  - Suh JM
FAU - Hah, Nasun
AU  - Hah N
FAU - Liddle, Christopher
AU  - Liddle C
FAU - Atkins, Annette R
AU  - Atkins AR
FAU - Downes, Michael
AU  - Downes M
FAU - Evans, Ronald M
AU  - Evans RM
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/10/01 [received]
PHST- 2013/03/06 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - nm.3159 [pii]
AID - 10.1038/nm.3159 [doi]
PST - ppublish
SO  - Nat Med. 2013 May;19(5):557-66. doi: 10.1038/nm.3159. Epub 2013 May 7.

PMID- 23652062
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 126
IP  - 9
DP  - 2013 May
TI  - Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary
      intervention: a meta-analysis.
PG  - 1750-4
AB  - BACKGROUND: The combination of cilostazol, aspirin and clopidogrel (triple
      antiplatelet therapy, TAT) after a percutaneous coronary intervention has been
      used as an alternative therapy. We performed a meta-analysis to evaluate the
      efficacy and safety of TAT for patients after percutaneous coronary intervention 
      (PCI). METHODS: We systematically searched Pubmed, Embase and Web of Science
      databases to identify all randomized controlled trials (RCTs) that compared dual 
      antiplatelet therapy (DAT) with and without cilostazol after PCI. All analyses
      were conducted using Review Manager 5.0. RESULTS: The final analysis consisted of
      4474 patients from ten studies. The combined results suggested that there was a
      lower risk of cardiac death (relative risk (RR) = 0.55, 95% confidence interval
      (CI): 0.31 - 0.98, P < 0.05) and major adverse cardiac events (MACEs) (RR = 0.63,
      95%CI: 0.54 - 0.74, P < 0.05) in patients treated with TAT as compared to those
      with DAT follow-ups after six months to one year; no significant difference was
      observed in bleeding and non-fatal myocardial infarction (MI) (RR = 1.14, 95%CI: 
      0.80 - 1.64, P > 0.05;RR = 0.87, 95%CI: 0.42 - 1.83, P > 0.05). However, the rate
      of adverse drug reaction was higher in patients receiving TAT than in patients
      receiving DAT (RR = 2.21, 95%CI: 1.84 - 2.66, P < 0.05). Moreover, there was a
      lower risk of stent thrombosis in patients treated with TAT as compared to those 
      treated with DAT (RR = 0.44, 95%CI: 0.21 - 0.94, P < 0.05). The TAT group had a
      reduced risk of target lesion revascularization (TLR) (RR = 0.60, 95%CI: 0.43 -
      0.82, P = 0.001) and target vessel revascularization (TVR) than the DAT group (RR
      = 0.56, 95%CI: 0.45 - 0.71, P < 0.05). The number of MACEs was lower for patients
      in the TAT group than in the DAT group with diabetes mellitus sub-analysis (RR = 
      0.41, 95%CI: 0.28 - 0.61, P < 0.05). But no significant difference was observed
      between the two groups regarding MACEs in patients with drug-eluting stent
      implantations (RR = 0.82, 95%CI: 0.65 - 1.03, P > 0.05). CONCLUSION: TAT could
      significantly reduce the rates of MACEs and cardiac death in comparison to DAT,
      but more attention should be paid to adverse side effects of the drugs.
AD  - Department of Geriatrics, First Affiliated Hospital of Anhui Medical University, 
      Hefei, Anhui 230022 China.
FAU - Zhang, Yong
AU  - Zhang Y
FAU - Tang, Hai-Qin
AU  - Tang HQ
FAU - Li, Jin
AU  - Li J
FAU - Fu, Zhao-Xin
AU  - Fu ZX
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PST - ppublish
SO  - Chin Med J (Engl). 2013 May;126(9):1750-4.

PMID- 23652054
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 126
IP  - 9
DP  - 2013 May
TI  - Effect of pomegranate peel polyphenol gel on cutaneous wound healing in
      alloxan-induced diabetic rats.
PG  - 1700-6
AB  - BACKGROUND: Pomegranate (punica granatum) belongs to the family Punicaceae, and
      its peel has been used as a traditional Chinese medicine because of its efficacy 
      in restraining intestine, promoting hemostasis, and killing parasites.
      Pomegranate peel has been reported to possess wound-healing properties which are 
      mainly attributed to its polyphenol extracts. The purpose of this study was to
      investigate the effect of pomegranate peel polyphenols (PPP) gel on cutaneous
      wound healing in diabetic rats. METHODS: Alloxan-induced diabetic rats were given
      incisional wounds on each side of the mid-back and then treated daily with PPP
      gel (polyphenol mass fraction = 30%) post-wounding. Rats were sacrificed on days 
      4, 7, 14, and 21 post-wounding to assess the rates of wound closure, histological
      characteristics; and to detect the contents of hydroxyproline, production of
      nitric oxide (NO), and activities of NO synthase (NOS), as well as the
      expressions of transforming growth factor-beta1 (TGF-beta1), vascular endothelial
      growth factor (VEGF), and epidermal growth factor (EGF) in wound tissue. RESULTS:
      Wound closure was significantly shortened when PPP gel was applied to the wounds 
      of diabetic rats. Histological examination showed the ability of PPP gel to
      increase fibroblast infiltration, collagen regeneration, vascularization, and
      epithelialization in the wound area of diabetic rats. In addition, PPP
      gel-treated diabetic rats showed increased contents of hydroxyproline, production
      of NO, and activities of NOS and increased expressions of TGF-beta1, VEGF, and
      EGF in wound tissues. CONCLUSION: PPP gel may be a beneficial method for treating
      wound disorders associated with diabetes.
AD  - Pharmacy College, Shihezi University, Shihezi, Xinjiang 832002, China; Xinjiang
      Institute of Materia Medica, Urumqi, Xinjiang 830004, China.
FAU - Yan, Huan
AU  - Yan H
FAU - Peng, Ke-Jun
AU  - Peng KJ
FAU - Wang, Qiu-Lin
AU  - Wang QL
FAU - Gu, Zheng-Yi
AU  - Gu ZY
FAU - Lu, Yao-Qin
AU  - Lu YQ
FAU - Zhao, Jun
AU  - Zhao J
FAU - Xu, Fang
AU  - Xu F
FAU - Liu, Yi-Lun
AU  - Liu YL
FAU - Tang, Ying
AU  - Tang Y
FAU - Deng, Feng-Mei
AU  - Deng FM
FAU - Zhou, Peng
AU  - Zhou P
FAU - Jin, Jia-Gui
AU  - Jin JG
FAU - Wang, Xin-Chun
AU  - Wang XC
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PST - ppublish
SO  - Chin Med J (Engl). 2013 May;126(9):1700-6.

PMID- 23652053
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 126
IP  - 9
DP  - 2013 May
TI  - Effect of the regimen of Gaoshan Hongjingtian on the mechanism of poly
      (ADP-ribose) polymerase regulation of nuclear factor kappa B in the experimental 
      diabetic retinopathy.
PG  - 1693-9
AB  - BACKGROUND: Poly(ADP-ribose) polymerase (PARP) plays an important role in the
      death of retinal capillary cells in diabetic retinopathy (DR) partly via its
      regulation of nuclear factor kappa B (NF-kappaB). The current study investigated 
      the effect of the regimen of Gaoshan Hongjingtian (RG) on the mechanism of PARP
      regulation of NF-kappaB, and demonstrated the possible impact of the RG and
      Gaoshan Hongjingtian (Rhodiola sachalinensis, RS) on diabetic retinopathy.
      METHODS: Wistar rats were made diabetic by administering streptozotocin. They
      were then assigned to three groups at random. After 2 months, the three groups of
      these diabetic rats were treated with RS or RG, or untreated. Analyses of
      expression levels of PARP, NF-kappaB, and intercellular adhesion molecule-1
      (ICAM-1) in the retinas of rats in different groups were performed by Western
      blotting and immunohistochemical assays, and mRNA levels of NF-kappaB and ICAM-1 
      were determined by real-time polymerase chain reaction (PCR). In addition, the
      basement membranes of capillaries in the rats' retinas were observed using
      electron microscopy, and diabetes-induced capillary degeneration (ghost pericytes
      and acellular capillaries) were quantitated. RESULTS: From the third month after 
      the injection of streptozotocin, the diabetic rats were given daily RG, RS or tap
      water separately. The diabetic rats failed to gain weight compared with normal
      age-matched rats, whereas their glycated hemoglobin levels were significantly
      increased. After 5 months, the mRNA levels of NF-kappaB and ICAM-1 and the
      protein expression of PARP, NF-kappaB, and ICAM-1 were significantly increased in
      the retinas of diabetic rats in the untreated group compared with the nondiabetic
      controls. After 8 months, the number of degenerated retinal capillaries (ghost
      pericytes and acellular capillaries) was significantly increased in the diabetic 
      rats in the untreated group compared with normal age-matched rats. RG and RS
      inhibited diabetes-induced over-expression of PARP, NF-kappaB, and ICAM-1 in the 
      retinas of diabetic rats at the end of 5-month diabetic duration. Treatment using
      RG and RS significantly inhibited increases in the number of acellular
      capillaries and pericyte ghosts and suppressed the basement membrane thickening
      in the retinas of rats with diabetes for 8 months compared with the control
      diabetic rats. CONCLUSIONS: These results indicate that PARP plays an important
      role in the pathogenesis of diabetic retinopathy. RS and RG may have acted on the
      mechanism of PARP regulation of NF-kappaB, which suppressed the expression of
      NF-kappaB and ICAM-1, and led to the inhibition of retinal capillary
      degeneration.
AD  - Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University;
      Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing, 100730,China.
FAU - Zhao, Hong-Shu
AU  - Zhao HS
FAU - Shi, Xiang-Yu
AU  - Shi XY
FAU - Wei, Wen-Bin
AU  - Wei WB
FAU - Wang, Ning-Li
AU  - Wang NL
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PST - ppublish
SO  - Chin Med J (Engl). 2013 May;126(9):1693-9.

PMID- 23652045
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 126
IP  - 9
DP  - 2013 May
TI  - Effects of triterpenic acid from Prunella vulgaris L. on glycemia and pancreas in
      rat model of streptozotozin diabetes.
PG  - 1647-53
AB  - BACKGROUND: The effects of triterpenic acid from Prunella vulgaris L. (TAP) on
      diabetes and its mechanism are uncertain. The aim of this study was to
      investigate the effects of TAP on antihyperglycemic, antioxidant, and
      pancreas-protective in streptozotozin (STZ)-diabetic rats. METHODS: The diabetic 
      model was produced by injection of 60 mg/kg STZ. Blood was drawn from the tail
      vein of rats after 72 hours. Rats with blood glucose >/= 16.7 mmol/L were
      considered diabetic. Diabetic rats were randomly divided into four groups: (1)
      Diabetes rat (STZ), (2) Diabetic rats treated with 50 mg/kg of triterpenic acid
      from Prunella vulgaris L (STZ + TAP50), (3) Diabetic rats treated with 100 mg/kg 
      TAP (STZ + TAP100), and (4) Diabetic rats treated with 200 mg/kg TAP (STZ +
      TAP200). Normal rats (n = 10) acted as the control group (NC). TAP was
      administered by the intragastric route once each day for six weeks. Body weight
      and the concentration of blood glucose (BG) were measured after three and six
      weeks. Fructosamine (FMN), malondialdehyde (MDA), and nitric oxide (NO), and the 
      activities of nitric oxide synthase (NOS) and superoxide dismutase (SOD) in serum
      were determined after six weeks using commercially available kits following the
      manufacturer's instructions. Pathologic changes in pancreatic beta-cells were
      also investigated by microscopic examination after hematoxylin-eosin (HE)
      staining. The level of SOD mRNA in pancreatic beta-cells was measured by
      polymerase chain reaction (PCR). RESULTS: The levels of BG, FMN, NO, and MDA and 
      the activities of NOS in serum in the four diabetes groups were significantly
      increased compared with the control group (P < 0.01). The activity of SOD in
      serum and the body weight was significantly decreased compared with the control
      group (P < 0.01). After administration of TAP to diabetic rats for six weeks, the
      body weight and the levels of BG, FMN, MDA, NO and the activity of NOS in serum
      decreased significantly compared with the STZ group in a dose-dependent manner.
      The activity of SOD in serum and body weight increased significantly compared
      with the STZ group in a dose-dependent manner. In addition, diabetic rats showed 
      a significant decrease in SOD mRNA expression in pancreatic beta cells. However, 
      these changes were reversed by TAP. Histopathological examination also showed the
      protective effect of TAP on pancreatic beta cells. CONCLUSIONS: Triterpenic acid 
      from Prunella vulgaris L. has an anti-diabetic effect, by controlling blood
      glucose and antioxidants, and has a protective effect on the pancreas.
AD  - Institute of Pediatric Medicine, Soochow University Affiliated Children's
      Hospital, Suzhou, Jiangsu 215003, China; Department of Pediatrics, Suzhou Kowloon
      Hospital Affiliated to Shanghai Jiaotong University, Suzhou, Jiangsu 215021,
      China; Department of Pharmacy, Suzhou Kowloon Hospital Affiliated to Shanghai
      Jiaotong University, Suzhou, Jiangsu 215021, China.
FAU - Zhou, Qiao-Xia
AU  - Zhou QX
FAU - Liu, Feng
AU  - Liu F
FAU - Zhang, Jing-Shuo
AU  - Zhang JS
FAU - Lu, Ji-Guang
AU  - Lu JG
FAU - Gu, Zhen-Lun
AU  - Gu ZL
FAU - Gu, Gui-Xiong
AU  - Gu GX
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PST - ppublish
SO  - Chin Med J (Engl). 2013 May;126(9):1647-53.

PMID- 23651991
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1873-5169 (Electronic)
IS  - 0196-9781 (Linking)
VI  - 45C
DP  - 2013 May 4
TI  - Mechanisms of glucagon degradation at alkaline pH.
PG  - 40-47
LID - S0196-9781(13)00146-0 [pii]
LID - 10.1016/j.peptides.2013.04.005 [doi]
AB  - Glucagon is unstable and undergoes degradation and aggregation in aqueous
      solution. For this reason, its use in portable pumps for closed loop management
      of diabetes is limited to very short periods. In this study, we sought to
      identify the degradation mechanisms and the bioactivity of specific degradation
      products. We studied degradation in the alkaline range, a range at which
      aggregation is minimized. Native glucagon and analogs identical to glucagon
      degradation products were synthesized. To quantify biological activity in
      glucagon and in the degradation peptides, a protein kinase A-based bioassay was
      used. Aged, fresh, and modified peptides were analyzed by liquid chromatography
      with mass spectrometry (LCMS). Oxidation of glucagon at the Met residue was
      common but did not reduce bioactivity. Deamidation and isomerization were also
      common and were more prevalent at pH 10 than 9. The biological effects of
      deamidation and isomerization were unpredictable; deamidation at some sites did
      not reduce bioactivity. Deamidation of Gln 3, isomerization of Asp 9, and
      deamidation with isomerization at Asn 28 all caused marked potency loss. Studies 
      with molecular-weight-cutoff membranes and LCMS revealed much greater
      fibrillation at pH 9 than 10. Further work is necessary to determine formulations
      of glucagon that minimize degradation and fibrillation.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Oregon Health and Science University, United States.
FAU - Caputo, Nicholas
AU  - Caputo N
FAU - Castle, Jessica R
AU  - Castle JR
FAU - Bergstrom, Colin P
AU  - Bergstrom CP
FAU - Carroll, Julie M
AU  - Carroll JM
FAU - Bakhtiani, Parkash A
AU  - Bakhtiani PA
FAU - Jackson, Melanie A
AU  - Jackson MA
FAU - Roberts, Charles T Jr
AU  - Roberts CT Jr
FAU - David, Larry L
AU  - David LL
FAU - Ward, W Kenneth
AU  - Ward WK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Peptides
JT  - Peptides
JID - 8008690
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/03/08 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/04/08 [accepted]
AID - S0196-9781(13)00146-0 [pii]
AID - 10.1016/j.peptides.2013.04.005 [doi]
PST - aheadofprint
SO  - Peptides. 2013 May 4;45C:40-47. doi: 10.1016/j.peptides.2013.04.005.

PMID- 23651956
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Linking)
DP  - 2013 May 4
TI  - Molecular understanding of curcumin in diabetic nephropathy.
LID - S1359-6446(13)00127-X [pii]
LID - 10.1016/j.drudis.2013.04.009 [doi]
AB  - Diabetic nephropathy is characterized by a plethora of signaling abnormalities.
      Recent trials have suggested that intensive glucose-lowering treatment leads to
      hypoglycemic events, which can be dangerous. Curcumin is the active ingredient of
      turmeric, which has been widely used in many countries for centuries to treat
      numerous diseases. The preventive and therapeutic properties of curcumin are
      associated with its antioxidant and anti-inflammatory properties. Here, we
      highlight the renoprotective role of curcumin in diabetes mellitus (DM) with an
      emphasis on the molecular basis of this effect. We also briefly discuss the
      numerous approaches that have been undertaken to improve the pharmacokinetics of 
      curcumin.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata 
      University of Pharmacy and Applied Life Sciences, Niigata City 956-8603, Japan;
      Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta
      10430, Indonesia. Electronic address: vivian_09st@yahoo.com.
FAU - Soetikno, Vivian
AU  - Soetikno V
FAU - Suzuki, Kenji
AU  - Suzuki K
FAU - Veeraveedu, Punniyakoti T
AU  - Veeraveedu PT
FAU - Arumugam, Somasundaram
AU  - Arumugam S
FAU - Lakshmanan, Arun P
AU  - Lakshmanan AP
FAU - Sone, Hirohito
AU  - Sone H
FAU - Watanabe, Kenichi
AU  - Watanabe K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/01/30 [received]
PHST- 2013/03/29 [revised]
PHST- 2013/04/26 [accepted]
AID - S1359-6446(13)00127-X [pii]
AID - 10.1016/j.drudis.2013.04.009 [doi]
PST - aheadofprint
SO  - Drug Discov Today. 2013 May 4. pii: S1359-6446(13)00127-X. doi:
      10.1016/j.drudis.2013.04.009.

PMID- 23651953
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1663-2826 (Electronic)
DP  - 2013 May 7
TI  - Rapid Improvement of Hepatic Steatosis after Initiation of Leptin Substitution in
      a Leptin-Deficient Girl.
AB  - Background: Leptin deficiency is associated with severe obesity and metabolic
      disturbances. Increased liver fat content has been reported in only one case
      beforehand, even though hepatic steatosis is a typical comorbidity of common
      obesity. It is also frequent in patients with lipodystrophy where it resolves
      under leptin therapy. Subject and Methods: In 2010, we reported a
      leptin-deficient patient with a novel homozygous mutation in the leptin gene and 
      severe hepatic steatosis. We have now studied serum changes and changes in liver 
      fat content during the substitution with recombinant methionyl human leptin.
      Results: After 23 weeks of leptin substitution, elevated transaminases, total
      cholesterol and low-density lipoprotein levels normalized. After 62 weeks,
      homeostasis model assessment of insulin resistance improved from 10.7 to 6.0 and 
      body fat mass dropped from 50.2 to 37.8%. Liver fat content was drastically
      reduced from 49.7 to 9.4%. The first changes in liver fat content were detectable
      after 3 days of therapy. Conclusion: Our patient showed a remarkable reduction of
      liver fat content during the treatment with recombinant methionyl human leptin.
      These changes occurred rapidly after initiation of the substitution, which
      implies that leptin has a direct effect on hepatic lipid metabolism in humans as 
      it is seen in rodents.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Division of Pediatric Endocrinology and Diabetes, University Medical Center Ulm, 
      Ulm, Germany.
FAU - von Schnurbein, J
AU  - von Schnurbein J
FAU - Heni, M
AU  - Heni M
FAU - Moss, A
AU  - Moss A
FAU - Nagel, S A
AU  - Nagel SA
FAU - Machann, J
AU  - Machann J
FAU - Muehleder, H
AU  - Muehleder H
FAU - Debatin, K M
AU  - Debatin KM
FAU - Farooqi, S
AU  - Farooqi S
FAU - Wabitsch, M
AU  - Wabitsch M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Horm Res Paediatr
JT  - Hormone research in paediatrics
JID - 101525157
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/10/23 [received]
PHST- 2013/02/01 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 000348541 [pii]
AID - 10.1159/000348541 [doi]
PST - aheadofprint
SO  - Horm Res Paediatr. 2013 May 7.

PMID- 23651930
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - Impact of post-challenge hyperglycemia on clinical outcomes in japanese patients 
      with stable angina undergoing percutaneous coronary intervention.
PG  - 74
LID - 10.1186/1475-2840-12-74 [doi]
AB  - BACKGROUND: Post-challenge hyperglycemia (PH) is well-established as one of risk 
      factors for coronary artery disease. However, it remains unclear whether PH
      affects clinical outcomes in patients with stable angina undergoing percutaneous 
      coronary intervention (PCI). METHODS: A total of 828 patients with stable angina 
      undergoing PCI were retrospectively analyzed. Of these, 452 patients with
      previously diagnosed diabetes mellitus (DM) or fasting plasma glucose (PG) >/=126
      mg/dl and HbA1c >/=6.5% were defined as known DM. The remaining 376 patients were
      divided into the two groups according to 2-h PG: PH (2-h PG >/=140 mg/dl, n=236) 
      and normal glucose tolerance (NGT, 2-h PG <140 mg/dl, n=140). We assessed the
      rate of major adverse cardiovascular events (MACE), defined as a composite of
      cardiovascular death, myocardial infarction, stroke, and clinically-driven
      revascularization. RESULTS: During the median follow-up of 4.3 years, the MACE
      rate was significantly higher in the DM and PH groups than the NGT group (39.3%
      vs. 20.7%, P <0.001; 31.4% vs. 20.7%, P=0.044, respectively). Compared with the
      NGT group, the cumulative incidence of revascularization was significantly higher
      in the DM group (35.1% vs. 18.5%, P <0.001) and tended to be higher in the PH
      group (27.1% vs. 18.5%, P=0.067). In the multivariate analysis, known DM (Hazard 
      ratio [HR]: 2.16, 95% confidence interval (CI): 1.49-3.27, P < 0.001), PH (HR:
      1.62, 95% CI: 1.07-2.53, P = 0.023), LDL-C >100 mg/dl (HR: 1.62, 95% CI: 1.26 to 
      2.10, P < 0.001), and previous stroke (HR: 1.47, 95% CI: 1.03-2.04, P = 0.034)
      were predictors of MACE. CONCLUSION: PH is associated with future cardiovascular 
      events in patients with stable angina undergoing PCI.
AD  - Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-ku,
      Kitakyushu 802-8555, Japan. kuramitsu@circulation.jp.
FAU - Kuramitsu, Shoichi
AU  - Kuramitsu S
FAU - Yokoi, Hiroyoshi
AU  - Yokoi H
FAU - Domei, Takenori
AU  - Domei T
FAU - Nomura, Akihiro
AU  - Nomura A
FAU - Watanabe, Hirotoshi
AU  - Watanabe H
FAU - Yamaji, Kyohei
AU  - Yamaji K
FAU - Soga, Yoshimitsu
AU  - Soga Y
FAU - Arita, Takeshi
AU  - Arita T
FAU - Kondo, Katsuhiro
AU  - Kondo K
FAU - Shirai, Shinichi
AU  - Shirai S
FAU - Ando, Kenji
AU  - Ando K
FAU - Sakai, Koyu
AU  - Sakai K
FAU - Iwabuchi, Masashi
AU  - Iwabuchi M
FAU - Nosaka, Hedeyuki
AU  - Nosaka H
FAU - Nobuyoshi, Masakiyo
AU  - Nobuyoshi M
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3651729
OID - NLM: PMC3651729
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/03/25 [received]
PHST- 2013/05/05 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 1475-2840-12-74 [pii]
AID - 10.1186/1475-2840-12-74 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 May 7;12:74. doi: 10.1186/1475-2840-12-74.

PMID- 23651926
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1873-1449 (Electronic)
IS  - 1538-4721 (Linking)
DP  - 2013 May 4
TI  - Identification of comorbidities that place men at highest risk of death from
      androgen deprivation therapy before brachytherapy for prostate cancer.
LID - S1538-4721(13)00241-9 [pii]
LID - 10.1016/j.brachy.2013.02.005 [doi]
AB  - PURPOSE: To determine which specific comorbidities predispose men to excess
      mortality by androgen deprivation therapy (ADT) given before and during
      brachytherapy for prostate cancer. METHODS AND MATERIALS: We analyzed 5972 men
      with T1c-T3b prostate cancer treated with brachytherapy-based radiation with or
      without neoadjuvant ADT. Cox multivariable analysis with propensity scoring was
      used to determine if ADT was associated with increased all-cause mortality (ACM) 
      in men divided into groups stratified by cardiac comorbidities. Tests for
      interaction between risk group and outcome were performed. RESULTS: ADT was
      associated with increased ACM in men with a history of myocardial infarction or
      congestive heart failure, regardless of whether they underwent revascularization 
      (adjusted hazard ratio [AHR], 2.1 [95% confidence interval {CI}, 1.02-4.17;
      p=0.04]) or not (AHR, 1.8 [95% CI, 1.05-3.20; p = 0.03]), but this effect was not
      seen in men with less severe comorbidity. However, among men with diabetes, there
      was a significant interaction with risk group (p=0.01) such that ADT was
      associated with excess mortality in men with low-risk disease (AHR = 2.21
      [1.04-4.68]; p=0.04) but not in men with intermediate or high-risk disease (AHR, 
      0.64 [0.33-1.22]; p=0.17). CONCLUSIONS: ADT was associated with excess ACM in all
      patients with a history of congestive heart failure or myocardial infarction,
      regardless of whether they were revascularized, and in diabetics with low-risk
      disease. ADT for gland downsizing before brachytherapy should be avoided in these
      men.
CI  - Copyright (c) 2013 American Brachytherapy Society. Published by Elsevier Inc. All
      rights reserved.
AD  - Department of Radiation Oncology, Dana Farber/Brigham and Women's Hospital,
      Harvard Medical School, Boston, MA.
FAU - Parekh, Arti
AU  - Parekh A
FAU - Chen, Ming-Hui
AU  - Chen MH
FAU - D'Amico, Anthony V
AU  - D'Amico AV
FAU - Dosoretz, Daniel E
AU  - Dosoretz DE
FAU - Ross, Rudi
AU  - Ross R
FAU - Salenius, Sharon
AU  - Salenius S
FAU - Graham, Powell L
AU  - Graham PL
FAU - Beckman, Joshua A
AU  - Beckman JA
FAU - Beard, Clair J
AU  - Beard CJ
FAU - Choueiri, Toni K
AU  - Choueiri TK
FAU - Ennis, Ronald D
AU  - Ennis RD
FAU - Hoffman, Karen E
AU  - Hoffman KE
FAU - Hu, Jim C
AU  - Hu JC
FAU - Ma, Jing
AU  - Ma J
FAU - Martin, Neil E
AU  - Martin NE
FAU - Nguyen, Paul L
AU  - Nguyen PL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Brachytherapy
JT  - Brachytherapy
JID - 101137600
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/01/04 [received]
PHST- 2013/02/12 [revised]
PHST- 2013/02/21 [accepted]
AID - S1538-4721(13)00241-9 [pii]
AID - 10.1016/j.brachy.2013.02.005 [doi]
PST - aheadofprint
SO  - Brachytherapy. 2013 May 4. pii: S1538-4721(13)00241-9. doi:
      10.1016/j.brachy.2013.02.005.

PMID- 23651916
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1475-2727 (Electronic)
IS  - 1368-9800 (Linking)
DP  - 2013 May 7
TI  - Sodium and nutrition labelling: a qualitative study exploring New Zealand
      consumers' food purchasing behaviours.
PG  - 1-9
AB  - OBJECTIVE: Dietary sodium reduction is an important public health intervention
      that would reduce blood pressure and chronic disease. An understanding of how New
      Zealand consumers' food purchasing behaviour is influenced by perceptions of
      dietary sodium will inform future sodium-reduction strategies. DESIGN: The
      present qualitative study used in-depth interviews of adult consumers to explore 
      consumer knowledge, understanding of food labels and food purchasing behaviour
      with respect to dietary sodium. SETTING: New Zealand. SUBJECTS: A convenience
      sample of sixteen adult grocery shoppers. RESULTS: A thematic analysis of the
      transcripts showed New Zealand consumers lacked the background knowledge
      necessary to understand and regulate their own salt intake and were unable to
      interpret existing food labels with respect to dietary salt. CONCLUSIONS: The
      findings add further weight to calls for food labels that do not require
      background knowledge or numerical skills and highlight the need for
      population-based public health interventions. Education of New Zealand consumers 
      on the health benefits of sodium reduction and how this may be achieved would
      complement this approach.
AD  - 1 Edgar National Centre for Diabetes & Obesity Research, Dunedin School of
      Medicine, University of Otago, PO Box 913, Dunedin 9054, New Zealand.
FAU - McLean, Rachael
AU  - McLean R
FAU - Hoek, Janet
AU  - Hoek J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Public Health Nutr
JT  - Public health nutrition
JID - 9808463
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - S1368980013001079 [pii]
AID - 10.1017/S1368980013001079 [doi]
PST - aheadofprint
SO  - Public Health Nutr. 2013 May 7:1-9.

PMID- 23651849
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 May 7
TI  - Overexpression of intra-islet ghrelin enhances beta-cell proliferation after
      streptozotocin-induced beta-cell injury in mice.
AB  - Previously, we reported that exogenous administration of ghrelin ameliorates
      glucose metabolism in a neonate streptozotocin (STZ)-induced diabetic rat model
      through enhancement of beta-cell proliferation. However, it was not clear whether
      the observed beta-cell proliferation was a direct or indirect effect (e.g., via
      orexigenic or growth hormone-stimulated pathways) of ghrelin activity. Here, we
      aim to investigate whether ghrelin directly impacts beta-cell proliferation after
      STZ-induced injury in mice. Seven-week-old male rat insulin II promoter-ghrelin
      internal ribosomal sequence ghrelin O-acyltransferase transgenic (RIP-GG Tg)
      mice, which have elevated pancreatic ghrelin levels, but only minor changes in
      plasma ghrelin levels, when fed a medium-chain triglyceride-rich diet, were
      treated with STZ. Then, serum insulin, pancreatic insulin mRNA expression, and
      islet histology were evaluated. We found that the serum insulin levels, but not
      blood glucose levels, of RIP-GG Tg mice were significantly ameliorated 14 days
      post-STZ treatment. Pancreatic insulin mRNA expression was significantly elevated
      in RIP-GG Tg mice, and beta-cell numbers in islets were increased. Furthermore,
      the number of phospho-histone H3+ or Ki67+ proliferating beta cells was
      significantly elevated in RIP-GG Tg mice, while the apoptotic indices within the 
      islets, as determined by the TUNEL assay, were not changed. These results
      indicated that ghrelin can directly stimulate beta-cell proliferation in vivo
      after beta-cell injury even without its orexigenic or GH-stimulating activities, 
      although it did not have enough impacts to normalize the glucose tolerance in
      adult mice.
AD  - 1Kyoto University Hosopital.
FAU - Bando, Mika
AU  - Bando M
FAU - Iwakura, Hiroshi
AU  - Iwakura H
FAU - Ariyasu, Hiroyuki
AU  - Ariyasu H
FAU - Koyama, Hiroyuki
AU  - Koyama H
FAU - Hosoda, Kiminori
AU  - Hosoda K
FAU - Adachi, Souichi
AU  - Adachi S
FAU - Nakao, Kazuwa
AU  - Nakao K
FAU - Kangawa, Kenji
AU  - Kangawa K
FAU - Akamizu, Takashi
AU  - Akamizu T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - beta cell
OT  - diabetes
OT  - ghrelin
OT  - streptozotocin
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - ajpendo.00112.2013 [pii]
AID - 10.1152/ajpendo.00112.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 May 7.

PMID- 23651846
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 May 7
TI  - Nutrient infusion bypassing duodenum - jejunum reverses insulin resistance in
      normotolerant and diabetic obese subjects.
AB  - The mechanisms of type-2 diabetes remission after bariatric surgery is still not 
      fully elucidated. In the present study we tried to simulate the Roux-en-Y
      gastric-bypass with a canonical or longer biliary limb, by infusing a
      liquid-formula-diet into different intestinal sections. Nutrients (Nutrison
      Energy) were infused into mid or proximal jejunum, and duodenum during three
      successive days in 10 diabetic and 10 normal glucose-tolerant subjects. Plasma
      glucose, insulin, C-peptide, glucagon, incretins, and non-esterified fatty-acids 
      (NEFA) were measured before and up to 360 min following. Glucose
      rate-of-appearance (Ra) and insulin sensitivity (SI), secretion rate (ISR) and
      clearance were assessed by mathematical models. SI increased when nutrients were 
      delivered in mid jejunum versus duodenum (SIx104 min-1pM-1: 1.11+/-0.44 vs.
      0.62+/-0.22, P<0.015, in controls and 0.79+/-0.34 vs. 0.40+/-0.20, P<0.05, in
      diabetic subjects), while glucose Ra was not affected. In controls, insulin
      sensitivity of NEFA production was doubled in mid jejunum vs. duodenum
      (2.80+/-1.36 vs. 1.13+/-0.78x106, P<0.005) and insulin-clearance increased in mid
      jejunum vs. duodenum (2.05+/-1.05 vs. 1.09+/-0.38 Lxmin-1, P<0.03). Bypass of
      duodenum and proximal jejunum by nutrients enhances insulin sensitivity, inhibits
      lipolysis, and increases insulin clearance. These results may further our
      knowledge of the effects of bariatric surgery on both insulin resistance and
      diabetes.
AD  - 1Sapienza-University of Rome.
FAU - Salinari, Serenella
AU  - Salinari S
FAU - Carr, Richard D
AU  - Carr RD
FAU - Guidone, Caterina
AU  - Guidone C
FAU - Bertuzzi, Alessandro
AU  - Bertuzzi A
FAU - Cercone, Stefania
AU  - Cercone S
FAU - Riccioni, Maria E
AU  - Riccioni ME
FAU - Manto, Andrea
AU  - Manto A
FAU - Ghirlanda, Giovanni
AU  - Ghirlanda G
FAU - Mingrone, Geltrude
AU  - Mingrone G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
OTO - NOTNLM
OT  - Bariatric Surgery
OT  - Insulin Sensitivity
OT  - intestinal glucose infusion
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - ajpendo.00559.2012 [pii]
AID - 10.1152/ajpendo.00559.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 May 7.

PMID- 23651827
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 May 4
TI  - Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular
      events in patients with non-valvular atrial fibrillation.
LID - S0167-5273(13)00789-4 [pii]
LID - 10.1016/j.ijcard.2013.04.142 [doi]
AB  - BACKGROUND: Non-valvular atrial fibrillation is associated with an increase in
      thromboembolism, i.e. stroke, and atherosclerotic events, i.e. myocardial
      infarction. Vitamin E possesses anti-coagulant as well as anti-atherosclerotic
      properties. Our aim was to assess whether vitamin E is associated with
      cardiovascular events in patients with non-valvular atrial fibrillation. METHODS:
      Serum levels of cholesterol-adjusted vitamin E were measured in 1012 patients
      with non-valvular atrial fibrillation. Patients were followed for a mean time of 
      27.0months, and cardiovascular events, such as cardiovascular death and fatal and
      nonfatal stroke or myocardial infarction, were recorded. RESULTS: During the
      follow-up period, cardiovascular events occurred in 109 (11%) patients (18 fatal 
      and 14 nonfatal myocardial infarction; 13 fatal and 19 nonfatal ischemic strokes;
      45 cardiovascular deaths). Lower vitamin E serum levels were found in patients
      who experienced cardiovascular events compared to those who did not (3.8+/-1.2
      vs. 4.4+/-1.8mumol/mmol cholesterol; p<0.001). Using a Cox proportional hazard
      model, age, diabetes, history of stroke and myocardial infarction and vitamin E
      serum levels (HR 0.77; 95% CI: 0.67-0.89; p=0.001) independently predicted
      cardiovascular events. Patients with vitamin E<4.2mumol/mmol cholesterol (median 
      values) had an increased risk of cardiovascular events (HR 1.87; 95% CI:
      1.25-2.80: p=0.002). CONCLUSIONS: Low vitamin E serum levels are associated with 
      an increased risk of cardiovascular events in patients with non-valvular atrial
      fibrillation.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - I Clinica Medica, Atherothrombosis Center, "Sapienza" University of Rome, Rome,
      Italy.
FAU - Cangemi, Roberto
AU  - Cangemi R
FAU - Pignatelli, Pasquale
AU  - Pignatelli P
FAU - Carnevale, Roberto
AU  - Carnevale R
FAU - Corazza, Gino Roberto
AU  - Corazza GR
FAU - Pastori, Daniele
AU  - Pastori D
FAU - Farcomeni, Alessio
AU  - Farcomeni A
FAU - Basili, Stefania
AU  - Basili S
FAU - Davi, Giovanni
AU  - Davi G
FAU - Ferro, Domenico
AU  - Ferro D
FAU - Hiatt, William R
AU  - Hiatt WR
FAU - Licata, Giuseppe
AU  - Licata G
FAU - Lip, Gregory Y H
AU  - Lip GY
FAU - Loffredo, Lorenzo
AU  - Loffredo L
FAU - Mannucci, Pier Mannuccio
AU  - Mannucci PM
FAU - Vestri, Annarita
AU  - Vestri A
FAU - Violi, Francesco
AU  - Violi F
CN  - in collaboration with the ARA PACIS study group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/10/30 [received]
PHST- 2013/02/12 [revised]
PHST- 2013/04/06 [accepted]
AID - S0167-5273(13)00789-4 [pii]
AID - 10.1016/j.ijcard.2013.04.142 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 May 4. pii: S0167-5273(13)00789-4. doi:
      10.1016/j.ijcard.2013.04.142.

PMID- 23651730
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130510
DCOM- 20130513
LR  - 20130513
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Vitamin B12 deficiency among patients with diabetes mellitus: is routine
      screening and supplementation justified?
PG  - 17
LID - 10.1186/2251-6581-12-17 [doi]
AB  - Vitamin B12 is an essential micronutrient required for optimal hemopoetic,
      neuro-cognitive and cardiovascular function. Biochemical and clinical vitamin B12
      deficiency has been demonstrated to be highly prevalent among patients with type 
      1 and type 2 diabetes mellitus. It presents with diverse clinical manifestations 
      ranging from impaired memory, dementia, delirium, peripheral neuropathy, sub
      acute combined degeneration of the spinal cord, megaloblastic anemia and
      pancytopenia. This review article offers a current perspective on the
      physiological roles of vitamin B12, proposed pathophysiological mechanisms of
      vitamin B12 deficiency, screening for vitamin B12 deficiency and vitamin B12
      supplementation among patients with diabetes mellitus.
AD  - Department of Medicine, St, Raphael of St, Francis hospital Nsambya, P,O,BOX
      7146, Kampala, Uganda. davouirek@yahoo.co.uk.
FAU - Kibirige, Davis
AU  - Kibirige D
FAU - Mwebaze, Raymond
AU  - Mwebaze R
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3649932
OID - NLM: PMC3649932
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:01
CRDT- 2013/05/09 06:00
PHST- 2012/11/04 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 2251-6581-12-17 [pii]
AID - 10.1186/2251-6581-12-17 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 May 7;12(1):17. doi: 10.1186/2251-6581-12-17.

PMID- 23651634
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1552-9924 (Electronic)
IS  - 0091-6765 (Linking)
DP  - 2013 May 7
TI  - Evaluation of the Association between Persistent Organic Pollutants (POPs) and
      Diabetes in Epidemiological Studies: A National Toxicology Program Workshop
      Review.
AB  - BACKGROUND: Diabetes is a major threat to public health in the US and world-wide.
      Understanding the role of environmental chemicals in the development or
      progression of diabetes is an emerging issue in environmental health. OBJECTIVE: 
      The objective of this evaluation is to assess the epidemiologic literature for
      evidence of associations between POPS and type 2 diabetes. METHODS: We identified
      72 epidemiological studies investigating associations of POPs with diabetes from 
      a PubMed search and reference lists of relevant studies or review articles. This 
      literature was evaluated for consistency, strengths and weaknesses of study
      design (including power and statistical methods), clinical diagnosis, exposure
      assessment, and study population characteristics; and to identify data gaps and
      areas for future research. CONCLUSIONS: Heterogeneity of the studies precluded
      conducting a meta-analysis, but the overall evidence is sufficient for a positive
      association of some organochlorine POPs with type 2 diabetes. Collectively, these
      data were not considered sufficient to establish causality. Initial data-mining
      revealed that the strongest positive correlation of diabetes with POPs occurred
      with organochlorine compounds, such as trans-nonachlor, DDE, PCBs, and
      dioxins/dioxin-like chemicals. There is less indication for an association with
      other non-organochlorine POPs, such as perfluoroalkyl acids (PFAAs) and
      brominated compounds. Experimental data are needed to confirm the causality of
      these findings which will shed a new light on the pathogenesis of diabetes with
      consequences for governmental bodies involved in the regulation of environmental 
      contaminants.
AD  - Office of Health Assessment and Translation, Division of the National Toxicology 
      Program, National Institute of Environmental Health Sciences, National Institutes
      of Health, Department of Health and Human Services, Research Triangle Park, North
      Carolina, USA.
FAU - Taylor, Kyla W
AU  - Taylor KW
FAU - Novak, Raymond F
AU  - Novak RF
FAU - Anderson, Henry A
AU  - Anderson HA
FAU - Birnbaum, Linda S
AU  - Birnbaum LS
FAU - Blystone, Chad
AU  - Blystone C
FAU - Devito, Michael
AU  - Devito M
FAU - Jacobs, David Jr
AU  - Jacobs D Jr
FAU - Kohrle, Josef
AU  - Kohrle J
FAU - Lee, Duk-Hee
AU  - Lee DH
FAU - Rylander, Lars
AU  - Rylander L
FAU - Rignell-Hydbom, Anna
AU  - Rignell-Hydbom A
FAU - Tornero-Velez, Rogelio
AU  - Tornero-Velez R
FAU - Turyk, Mary E
AU  - Turyk ME
FAU - Boyles, Abee
AU  - Boyles A
FAU - Thayer, Kristina A
AU  - Thayer KA
FAU - Lind, Lars
AU  - Lind L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Environ Health Perspect
JT  - Environmental health perspectives
JID - 0330411
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/05/21 [received]
PHST- 2012/10/16 [revised]
PHST- 2013/05/01 [accepted]
AID - 10.1289/ehp.1205502 [doi]
PST - aheadofprint
SO  - Environ Health Perspect. 2013 May 7.

PMID- 23651614
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 13
DP  - 2013
TI  - Cost-effectiveness of a stepped-care intervention to prevent major depression in 
      patients with type 2 diabetes mellitus and/or coronary heart disease and
      subthreshold depression: design of a cluster-randomized controlled trial.
PG  - 128
LID - 10.1186/1471-244X-13-128 [doi]
AB  - BACKGROUND: Co-morbid major depression is a significant problem among patients
      with type 2 diabetes mellitus and/or coronary heart disease and this negatively
      impacts quality of life. Subthreshold depression is the most important risk
      factor for the development of major depression. Given the highly significant
      association between depression and adverse health outcomes and the limited
      capacity for depression treatment in primary care, there is an urgent need for
      interventions that successfully prevent the transition from subthreshold
      depression into a major depressive disorder. Nurse led stepped-care is a
      promising way to accomplish this. The aim of this study is to evaluate the
      cost-effectiveness of a nurse-led indicated stepped-care program to prevent major
      depression among patients with type 2 diabetes mellitus and/or coronary heart
      disease in primary care who also have subthreshold depressive symptoms.
      METHODS/DESIGN: An economic evaluation will be conducted alongside a
      cluster-randomized controlled trial in approximately thirty general practices in 
      the Netherlands. Randomization takes place at the level of participating practice
      nurses. We aim to include 236 participants who will either receive a nurse-led
      indicated stepped-care program for depressive symptoms or care as usual. The
      stepped-care program consists of four sequential but flexible treatment steps: 1)
      watchful waiting, 2) guided self-help treatment, 3) problem solving treatment and
      4) referral to the general practitioner. The primary clinical outcome measure is 
      the cumulative incidence of major depressive disorder as measured with the Mini
      International Neuropsychiatric Interview. Secondary outcomes include severity of 
      depressive symptoms, quality of life, anxiety and physical outcomes. Costs will
      be measured from a societal perspective and include health care utilization,
      medication and lost productivity costs. Measurements will be performed at
      baseline and 3, 6, 9 and 12 months. DISCUSSION: The intervention being
      investigated is expected to prevent new cases of depression among people with
      type 2 diabetes mellitus and/or coronary heart disease and subthreshold
      depression, with subsequent beneficial effects on quality of life, clinical
      outcomes and health care costs. When proven cost-effective, the program provides 
      a viable treatment option in the Dutch primary care system. TRIAL REGISTRATION:
      Dutch Trial Register NTR3715.
AD  - Department of Health Sciences and the EMGO institute for Health and Care
      research, Faculty of Earth and Life Sciences, VU University Amsterdam, De
      Boelelaan 1085, Amsterdam, HV, 1081, The Netherlands. s.e.m.van.dijk@vu.nl.
FAU - van Dijk, Susan Em
AU  - van Dijk SE
FAU - Pols, Alide D
AU  - Pols AD
FAU - Adriaanse, Marcel C
AU  - Adriaanse MC
FAU - Bosmans, Judith E
AU  - Bosmans JE
FAU - Elders, Petra Jm
AU  - Elders PJ
FAU - van Marwijk, Harm Wj
AU  - van Marwijk HW
FAU - van Tulder, Maurits W
AU  - van Tulder MW
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - England
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
SB  - IM
PMC - PMC3654943
OID - NLM: PMC3654943
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/10 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 1471-244X-13-128 [pii]
AID - 10.1186/1471-244X-13-128 [doi]
PST - epublish
SO  - BMC Psychiatry. 2013 May 7;13:128. doi: 10.1186/1471-244X-13-128.

PMID- 23651601
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1824-7288 (Electronic)
IS  - 1720-8424 (Linking)
VI  - 39
IP  - 1
DP  - 2013 May 8
TI  - Progress in Pediatrics in 2012: choices in allergy, endocrinology,
      gastroenterology, hematology, infectious diseases, neurology, nutrition and
      respiratory tract illnesses.
PG  - 26
AB  - In this review, we summarize the progresses in allergy, endocrinology,
      gastroenterology, hematology, infectious diseases, neurology, nutrition and
      respiratory tract illnesses that have been published in The Italian Journal of
      Pediatrics in 2012. The induction of Treg activity by probiotics might be
      effective for promoting tolerance towards food allergens. Nasal cytology is
      useful in patients with rhinitis for diagnosing chronic non-allergic
      non-infectious diseases. Atopic eczema is associated both with an aberrant skin
      matrix and impaired systemic immune response. Therefore, isolated topical
      treatment may have suboptimal effect. Diagnostic work-up of exercise-induced
      anaphylaxis, including exercise challenge test, is necessary to reach a
      diagnosis. Studies may support a role for nutrition on prevention of asthma and
      cardiovascular diseases. Clinicians need to early identify adolescent menstrual
      abnormalities to minimize sequelae, and to promote health information. In
      Multiple Endocrine Neoplasia type 2B investigations include acetylcholinesterase 
      study of rectal mucosa followed by the molecular analysis of RET mutation. Low
      adherence to gluten-free diet and osteopenia are common problems in children with
      diabetes mellitus type 1 and celiac disease. In infantile colic, laboratory tests
      are usually unnecessary and the treatment is based on reassurance. Prevalence of 
      obesity and stunting is elucidated by several studies. Evidences are growing that
      dietetic measures are needed to prevent obesity in children with acute leukemia. 
      Treatment studies for infectious diseases show promise for probiotics along with 
      standard triple therapy in children with Helicobacter pilori infection, while
      zinc has no effect on pneumonia. Educational programs about the proper management
      of the febrile child are warranted. A new hour-specific total serum bilirubin
      nomogram has been shown to be able to predict newborns without hyperbilirubinemia
      after 48 to 72 hours of life. Newborns with hypoxic-ischemic encephalopathy
      present ECG and cardiac enzymes alterations leading to reduced neonatal survival.
      Rehabilitation programs including sensory integration therapy and motor
      performance, may improve activities of daily living in children with
      developmental coordination disorder. Aerobic exercise training in addition to
      chest physiotherapy might be useful in children with cystic fibrosis. Studies on 
      effectiveness of leukotriene receptor antagonists, alone or with other drugs in
      preschool wheezing are needed.
FAU - Caffarelli, Carlo
AU  - Caffarelli C
FAU - Santamaria, Francesca
AU  - Santamaria F
FAU - Vottero, Alessandra
AU  - Vottero A
FAU - Bernasconi, Sergio
AU  - Bernasconi S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Ital J Pediatr
JT  - Italian journal of pediatrics
JID - 101510759
PMC - PMC3660281
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/26 [received]
PHST- 2013/05/08 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 1824-7288-39-26 [pii]
AID - 10.1186/1824-7288-39-26 [doi]
PST - aheadofprint
SO  - Ital J Pediatr. 2013 May 8;39(1):26.

PMID- 23651573
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1873-4235 (Electronic)
IS  - 0956-5663 (Linking)
VI  - 48C
DP  - 2013 Apr 11
TI  - Construction of near-infrared photonic crystal glucose-sensing materials for
      ratiometric sensing of glucose in tears.
PG  - 94-99
LID - S0956-5663(13)00263-7 [pii]
LID - 10.1016/j.bios.2013.03.082 [doi]
AB  - Noninvasive monitoring of glucose in tears is highly desirable in tight glucose
      control. The polymerized crystalline colloidal array (PCCA) that can be
      incorporated into contact lens represents one of the most promising materials for
      noninvasive monitoring of glucose in tears. However, low sensitivity and slow
      time response of the PCCA reported in previous arts has limited its clinical
      utility. This paper presents a new PCCA, denoted as NIR-PCCA, comprising a CCA of
      glucose-responsive sub-micrometered
      poly(styrene-co-acrylamide-co-3-acrylamidophenylboronic acid) microgels embedded 
      within a slightly positive charged hydrogel matrix of
      poly(acrylamide-co-2-(dimethylamino)ethyl acrylate). This newly designed NIR-PCCA
      can reflect near-infrared (NIR) light, whose intensity (at 1722nm) would decrease
      evidently with increasing glucose concentration over the physiologically relevant
      range in tears. The lowest glucose concentration reliably detectable was as low
      as ca. 6.1mug/dL. The characteristic response time tausensing was 22.1+/-0.2s
      when adding glucose to 7.5mg/dL, and the higher the glucose concentration is, the
      faster the time response. Such a rationally designed NIR-PCCA is well suited for 
      ratiometric NIR sensing of tear glucose under physiological conditions, thereby
      likely to bring this promising glucose-sensing material to the forefront of
      analytical devices for diabetes.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - State Key Laboratory for Physical Chemistry of Solid Surfaces, The Key Laboratory
      for Chemical Biology of Fujian Province, and Department of Chemistry, College of 
      Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, China.
FAU - Hu, Yumei
AU  - Hu Y
FAU - Jiang, Xiaomei
AU  - Jiang X
FAU - Zhang, Laiying
AU  - Zhang L
FAU - Fan, Jiao
AU  - Fan J
FAU - Wu, Weitai
AU  - Wu W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Biosens Bioelectron
JT  - Biosensors & bioelectronics
JID - 9001289
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/01/29 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/03/26 [accepted]
AID - S0956-5663(13)00263-7 [pii]
AID - 10.1016/j.bios.2013.03.082 [doi]
PST - aheadofprint
SO  - Biosens Bioelectron. 2013 Apr 11;48C:94-99. doi: 10.1016/j.bios.2013.03.082.

PMID- 23651531
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Linking)
DP  - 2013 May 7
TI  - Red meat consumption is associated with the risk of type 2 diabetes in men but
      not in women: a Japan Public Health Center-based Prospective Study.
PG  - 1-9
AB  - The relationship between different types of meat intake and the risk of type 2
      diabetes remains unclear. We prospectively examined the association between total
      meat, total red meat, unprocessed red meat, processed meat and poultry intake and
      the incidence of type 2 diabetes. Subjects were 27 425 men and 36 424 women aged 
      45-75 years who participated in the second survey of the Japan Public Health
      Center-based Prospective Study, and had no history of type 2 diabetes, cancer,
      stroke, IHD, chronic liver disease or kidney disease. Meat intake was estimated
      using a validated 147-item FFQ. OR of self-reported, physician-diagnosed type 2
      diabetes over 5 years were estimated using a multiple logistic regression. A
      total of 1178 newly diagnosed cases of type 2 diabetes were self-reported.
      Intakes of total meat and total red meat were associated with the increased risk 
      of type 2 diabetes in men but not in women. The multivariate-adjusted OR for the 
      highest quartile compared with the lowest quartile of total meat and total red
      meat intake were 1.36 (95 % CI 1.07, 1.73; P for trend = 0.006) and 1.48 (95 % CI
      1.15, 1.90; P for trend = 0.003) for men, respectively, and 0.82 (95 % CI 0.62,
      1.09; P for trend = 0.14) and 0.77 (95 % CI 0.57, 1.02; P for trend = 0.08) for
      women, respectively. Intakes of processed red meat and poultry were not
      associated with the increased risk of diabetes in either men or women. In
      conclusion, elevated intake of red meat is associated with the increased risk of 
      type 2 diabetes in Japanese men but not in women.
AD  - Department of Epidemiology and Prevention, Clinical Research Center, National
      Center for Global Health and Medicine, Tokyo 162-8655, Japan.
FAU - Kurotani, Kayo
AU  - Kurotani K
FAU - Nanri, Akiko
AU  - Nanri A
FAU - Goto, Atsushi
AU  - Goto A
FAU - Mizoue, Tetsuya
AU  - Mizoue T
FAU - Noda, Mitsuhiko
AU  - Noda M
FAU - Oba, Shino
AU  - Oba S
FAU - Kato, Masayuki
AU  - Kato M
FAU - Matsushita, Yumi
AU  - Matsushita Y
FAU - Inoue, Manami
AU  - Inoue M
FAU - Tsugane, Shoichiro
AU  - Tsugane S
CN  - for the Japan Public Health Center-based Prospective Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - S0007114513001128 [pii]
AID - 10.1017/S0007114513001128 [doi]
PST - aheadofprint
SO  - Br J Nutr. 2013 May 7:1-9.

PMID- 23651509
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1464-3391 (Electronic)
IS  - 0968-0896 (Linking)
VI  - 21
IP  - 13
DP  - 2013 Jul 1
TI  - Synthesis and biological evaluation of C-glucosides with azulene rings as
      selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus:
      Discovery of YM543.
PG  - 3934-48
LID - 10.1016/j.bmc.2013.03.067 [doi]
LID - S0968-0896(13)00289-7 [pii]
AB  - Here, a series of C-glucosides with azulene rings in the aglycon moiety was
      synthesized and the inhibitory activities toward hSGLT1 and hSGLT2 were
      evaluated. Starting from the azulene derivative 7 which had relatively good SGLT2
      inhibitory activity, compound 8a which has a 3-[(azulen-2-yl)methyl]phenyl group 
      was identified as a lead compound for further optimization. Introduction of a
      phenolic hydroxyl group onto the central benzene ring afforded a potent and
      selective SGLT2 inhibitor 8e, which reduced blood glucose levels in a
      dose-dependent manner in rodent diabetic models. A mono choline salt of 8e
      (YM543) was selected as a clinical candidate for use in treating type 2 diabetes 
      mellitus.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Drug Discovery Research, Astellas Pharmaceutical Inc., 21 Miyukigaoka, Tsukuba,
      Ibaraki 305-8585, Japan. Electronic address: kazuhiro.ikegai@astellas.com.
FAU - Ikegai, Kazuhiro
AU  - Ikegai K
FAU - Imamura, Masakazu
AU  - Imamura M
FAU - Suzuki, Takayuki
AU  - Suzuki T
FAU - Nakanishi, Keita
AU  - Nakanishi K
FAU - Murakami, Takeshi
AU  - Murakami T
FAU - Kurosaki, Eiji
AU  - Kurosaki E
FAU - Noda, Atsushi
AU  - Noda A
FAU - Kobayashi, Yoshinori
AU  - Kobayashi Y
FAU - Yokota, Masayuki
AU  - Yokota M
FAU - Koide, Tomokazu
AU  - Koide T
FAU - Kosakai, Kazuhiro
AU  - Kosakai K
FAU - Ohkura, Yasufumi
AU  - Ohkura Y
FAU - Takeuchi, Makoto
AU  - Takeuchi M
FAU - Tomiyama, Hiroshi
AU  - Tomiyama H
FAU - Ohta, Mitsuaki
AU  - Ohta M
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - England
TA  - Bioorg Med Chem
JT  - Bioorganic & medicinal chemistry
JID - 9413298
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/03/01 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0968-0896(13)00289-7 [pii]
AID - 10.1016/j.bmc.2013.03.067 [doi]
PST - ppublish
SO  - Bioorg Med Chem. 2013 Jul 1;21(13):3934-48. doi: 10.1016/j.bmc.2013.03.067. Epub 
      2013 Apr 10.

PMID- 23651473
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
DP  - 2013 May 7
TI  - The Higher Diabetogenic Risk of Tacrolimus Depends on Pre-Existing Insulin
      Resistance. A Study in Obese and Lean Zucker Rats.
LID - 10.1111/ajt.12236 [doi]
AB  - Insulin resistance may interact with calcineurin inhibitors, enhancing the
      diabetogenic effect of tacrolimus compared with cyclosporine-A. We studied both
      drugs in insulin-resistant animals: obese Zucker rats (n = 45), and
      insulin-sensitive animals: lean Zucker rats (n = 21). During 11 days, animals
      received saline-buffer, cyclosporine-A (2.5 mg/kg/day) or tacrolimus (0.3
      mg/kg/day). At Days 0 and 12 animals underwent intraperitoneal glucose tolerance 
      test (0-30-60-120 min). Islet morphometry, beta-cell proliferation, apoptosis and
      Ins2 gene expression were analyzed. By Day 12, no lean animal had developed
      diabetes, while all obese animals on tacrolimus and 40% on cyclosporine-A had. In
      obese animals, tacrolimus reduced beta-cell proliferation and Ins2 gene
      expression compared with cyclosporine-A. Five days after treatment
      discontinuation, partial recovery was observed, with only 10% and 60% of the
      animals on cyclosporine and tacrolimus remaining diabetic respectively. Beta-cell
      proliferation increased in animals on tacrolimus while Ins2 gene expression
      remained unaltered. In conclusion, insulin resistance exacerbated the
      diabetogenic effect of tacrolimus compared with cyclosporine-A. This may be
      explained by greater inhibition of Ins2 gene and beta-cell proliferation by
      tacrolimus in the insulin resistant state. Discontinuation of the drugs may allow
      the recovery of the metabolic alterations.
CI  - (c) Copyright 2013 The American Society of Transplantation and the American
      Society of Transplant Surgeons.
AD  - Research Unit, University Hospital of the Canary Islands, Tenerife, Spain.
FAU - Rodriguez-Rodriguez, A E
AU  - Rodriguez-Rodriguez AE
FAU - Trinanes, J
AU  - Trinanes J
FAU - Velazquez-Garcia, S
AU  - Velazquez-Garcia S
FAU - Porrini, E
AU  - Porrini E
FAU - Vega Prieto, M J
AU  - Vega Prieto MJ
FAU - Diez Fuentes, M L
AU  - Diez Fuentes ML
FAU - Arevalo, M
AU  - Arevalo M
FAU - Salido Ruiz, E
AU  - Salido Ruiz E
FAU - Torres, A
AU  - Torres A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/10/31 [received]
PHST- 2013/02/22 [revised]
PHST- 2013/02/28 [accepted]
AID - 10.1111/ajt.12236 [doi]
PST - aheadofprint
SO  - Am J Transplant. 2013 May 7. doi: 10.1111/ajt.12236.

PMID- 23651430
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1520-5118 (Electronic)
IS  - 0021-8561 (Linking)
VI  - 61
IP  - 19
DP  - 2013 May 15
TI  - alpha-Glucosidase Inhibiton and Antiglycation Activity of Laccase-Catalyzed
      Catechin Polymers.
PG  - 4577-84
LID - 10.1021/jf400791r [doi]
AB  - Catechin polymers were produced by laccase (12 U/mL) in a mixture of sodium
      acetate buffer (1% (+)-catechin, 100 mM, pH 5) and methanol (buffer:methanol =
      95:5, v/v). The freeze-dried catechin polymers were recovered from the
      precipitate after dialysis followed by centrifugation. Catechin polymers
      extracted with 20% ethanol had potent inhibitory activity against
      alpha-glucosidase with an IC50 value of 4 mug/mL, and they were present as a
      mixture of dimers, trimers, and tetramers. The antihyperglycemic effect of the
      catechin polymers was confirmed by an oral maltose tolerance test. The catechin
      polymers also had significantly improved antiglycation and superoxide
      dismutase-like activities compared to those of (+)-catechin. Since formation of
      advanced glycation end products and oxidative stress are accelerated in
      hyperglycemic conditions, we suggest that enzymatic production of catechin
      polymers could have a potential protective effect in type 2 diabetes, diabetic
      complications, and other free radical related diseases.
AD  - Department of Foods and Nutrition, Kookmin University , Seoul, Korea.
FAU - Jeon, So-Youn
AU  - Jeon SY
FAU - Oh, Sejong
AU  - Oh S
FAU - Kim, Eungseok
AU  - Kim E
FAU - Imm, Jee-Young
AU  - Imm JY
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - J Agric Food Chem
JT  - Journal of agricultural and food chemistry
JID - 0374755
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/07 [aheadofprint]
AID - 10.1021/jf400791r [doi]
PST - ppublish
SO  - J Agric Food Chem. 2013 May 15;61(19):4577-84. doi: 10.1021/jf400791r. Epub 2013 
      May 7.

PMID- 23651427
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
DP  - 2013 Jun 3
TI  - Ischemia/Reperfusion-Inducible Protein Modulates the Function of Organic Cation
      Transporter 1 and Multidrug and Toxin Extrusion 1.
AB  - The recently identified ischemia/reperfusion-inducible protein (IRIP) has been
      reported to negatively modulate the activities of several transporters in cell
      culture systems. The goal of this study is to determine whether IRIP regulates
      the activities of OCT1 and MATE1, and hence the disposition in vivo of their
      substrate metformin, a therapeutic drug for diabetes and other obesity-related
      syndromes. In the uptake studies in the human embryonic kidney 293 cells
      overexpressing IRIP with and without OCT1 or MATE1, IRIP overexpression was found
      to significantly inhibit the uptake of 1-methyl-4-phenylpyridinium mediated by
      OCT1 or MATE1. In contrast, knockdown of IRIP by small hairpin RNA (shRNA)
      increased the transporter activities in vitro. IRIP overexpression decreased the 
      membrane localization of transporter proteins without any changes in transcript
      levels in cells. By overexpressing IRIP in mouse liver via hydrodynamic tail vein
      injection, we demonstrated that increased IRIP expression could cause a
      significant reduction in hepatic accumulation of metformin (P < 0.01). In
      addition, we observed that the expression of IRIP was approximately half (P <
      0.01) in ob/ob mice when compared to their lean littermates, with significant
      increases in hepatic Oct1 protein expression and metformin accumulation. In
      conclusion, IRIP negatively modulates the function of OCT1 and MATE1 in cells.
      Importantly, we provide in vivo evidence for such modulation that may cause an
      alteration in drug disposition. The regulation by IRIP on transporter activities 
      likely occurs at a post-transcriptional level, and future studies are needed to
      characterize the exact mechanism.
AD  - Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland
      at Baltimore, Baltimore, Maryland, United States.
FAU - Li, Qing
AU  - Li Q
FAU - Yang, Hyekyung
AU  - Yang H
FAU - Peng, Xiujuan
AU  - Peng X
FAU - Guo, Dong
AU  - Guo D
FAU - Dong, Zhongqi
AU  - Dong Z
FAU - Polli, James E
AU  - Polli JE
FAU - Shu, Yan
AU  - Shu Y
LA  - ENG
GR  - R01 GM099742/GM/NIGMS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130603
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1021/mp400013t [doi]
PST - aheadofprint
SO  - Mol Pharm. 2013 Jun 3.

PMID- 23651394
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1535-3907 (Electronic)
IS  - 1535-3893 (Linking)
VI  - 12
IP  - 6
DP  - 2013 Jun 7
TI  - Early diet impacts infant rhesus gut microbiome, immunity, and metabolism.
PG  - 2833-45
LID - 10.1021/pr4001702 [doi]
AB  - Epidemiological research has indicated a relationship between infant formula
      feeding and increased risk of chronic diseases later in life including obesity,
      type-2 diabetes, and cardiovascular disease. The present study used an infant
      rhesus monkey model to compare the comprehensive metabolic implications of
      formula- and breast-feeding practices using NMR spectroscopy to characterize
      metabolite fingerprints from urine and serum, in combination with anthropometric 
      measurements, fecal microbial profiling, and cytokine measurements. Here we show 
      that formula-fed infants are larger than their breast-fed counterparts and have a
      different gut microbiome that includes higher levels of bacteria from the
      Ruminococcus genus and lower levels of bacteria from the Lactobacillus genus. In 
      addition, formula-fed infants have higher serum insulin coupled with higher amino
      acid levels, while amino acid degradation products were higher in breast-fed
      infants. Increases in serum and urine galactose and urine galactitol were
      observed in the second month of life in formula-fed infants, along with higher
      levels of TNFalpha, IFN-gamma, IL-1beta, IL-4, and other cytokines and growth
      factors at week 4. These results demonstrate that metabolic and gut microbiome
      development of formula-fed infants is different from breast-fed infants and that 
      the choice of infant feeding may hold future health consequences.
AD  - Department of Nutrition, section signDepartment of Food Science and Technology,
      One Shields Avenue, University of California, Davis , Davis, California 95616,
      United States.
FAU - O'Sullivan, Aifric
AU  - O'Sullivan A
FAU - He, Xuan
AU  - He X
FAU - McNiven, Elizabeth M S
AU  - McNiven EM
FAU - Haggarty, Neill W
AU  - Haggarty NW
FAU - Lonnerdal, Bo
AU  - Lonnerdal B
FAU - Slupsky, Carolyn M
AU  - Slupsky CM
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - United States
TA  - J Proteome Res
JT  - Journal of proteome research
JID - 101128775
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/23 [aheadofprint]
AID - 10.1021/pr4001702 [doi]
PST - ppublish
SO  - J Proteome Res. 2013 Jun 7;12(6):2833-45. doi: 10.1021/pr4001702. Epub 2013 May
      23.

PMID- 23651392
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
DP  - 2013 May 8
TI  - Impact of vitamin D insufficiency on insulin homeostasis and beta cell function
      in nondiabetic male HIV-infected patients.
LID - 10.1111/hiv.12042 [doi]
AB  - OBJECTIVES: Vitamin D is thought to play a role in glucose homeostasis and beta
      cell function. Our aim was to examine the impact of plasma 25-hydroxyvitamin D
      [25(OH)D] upon in vivo insulin sensitivity and beta cell function in HIV-infected
      male patients without diabetes. METHODS: A cross-sectional study was carried out 
      involving a cohort of HIV-infected patients undergoing regular assessment in a
      tertiary hospital. Eighty-nine patients [mean (+/- standard deviation) age 42 +/-
      8 years] were included in the study: 14 patients were antiretroviral therapy
      (ART)-naive, while 75 were on ART. Vitamin D insufficiency (VDI) was defined as
      25(OH)D < 75 nmol/L; insulin sensitivity was determined using a 2-h continuous
      infusion of glucose model assessment with homeostasis (CIGMA-HOMA), using the
      trapezoidal model to calculate the incremental insulin and glucose areas under
      the curve (AUCins and AUGglu, respectively). Beta cell function was assessed
      using the disposition index (DI). Abdominal visceral adipose tissue (VAT) and
      hepatic triglyceride content (HTGC) were measured by magnetic resonance imaging
      (MRI) and 1-H magnetic resonance spectroscopy. Multivariate linear regression
      analysis was performed. RESULTS: VDI was associated with insulin resistance (IR),
      as indicated by a higher CIGMA-HOMA index (odds ratio 1.1) [1.01-1.2]. This
      association was independent of the main confounders, such as age, Centers for
      Disease Control and Prevention (CDC) stage, ART, lipodystrophy, body mass index, 
      VAT:subcutaneous adipose tissue ratio and HTGC, as confirmed by multivariate
      analysis (B = 12.3; P = 0.01; r2 = 0.7). IR in patients with VDI was compensated 
      by an increase in insulin response. However, beta cell function was lower in the 
      VDI subpopulation (33% decrease in DI). CONCLUSIONS: VDI in nondiabetic
      HIV-positive male patients is associated with impaired insulin sensitivity and a 
      decrease in pancreatic beta cell function.
CI  - (c) 2013 British HIV Association.
AD  - Endocrinology and Nutrition Department, Alicante University General Hospital,
      Alicante, Spain.
FAU - Moreno-Perez, O
AU  - Moreno-Perez O
FAU - Portilla, J
AU  - Portilla J
FAU - Escoin, C
AU  - Escoin C
FAU - Alfayate, R
AU  - Alfayate R
FAU - Reus, S
AU  - Reus S
FAU - Merino, E
AU  - Merino E
FAU - Boix, V
AU  - Boix V
FAU - Bernabeu, A
AU  - Bernabeu A
FAU - Giner, L
AU  - Giner L
FAU - Mauri, M
AU  - Mauri M
FAU - Sanchez-Paya, J
AU  - Sanchez-Paya J
FAU - Pico, A
AU  - Pico A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/03/20 [accepted]
AID - 10.1111/hiv.12042 [doi]
PST - aheadofprint
SO  - HIV Med. 2013 May 8. doi: 10.1111/hiv.12042.

PMID- 23651351
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1945-0257 (Electronic)
DP  - 2013 May 7
TI  - Prolactin Receptor Gene Polymorphisms Are Associated with Gestational Diabetes.
AB  - Aims: Human placental lactogen (hPL) acts via the prolactin receptor (PRLR) on
      maternal beta-cells to mediate increases in beta-cell mass and function during
      normal pregnancy. This interaction between hPL and PRLR is essential to maintain 
      normal glucose homeostasis and to address the increased metabolic demands of
      pregnancy. Given the importance of the PRLR-hPL axis in pancreatic islet cell
      adaptation to pregnancy, we hypothesized that genetic variation in the PRLR gene 
      could influence risk of development of gestational diabetes mellitus (GDM). DNA
      samples from 96 mothers affected by GDM and 96 unaffected cases were genotyped
      for 8 selected single nucleotide polymorphisms (SNPs) in PRLR. Results:
      Significant associations were identified in two SNPs analyzed. The minor alleles 
      of PRLR SNPs rs10068521 and rs9292578 were more frequently observed in GDM cases 
      than controls and were associated with a 2.36-fold increased risk for GDM in
      those carrying the minor allele. Conclusion: SNPs of the PRLR gene 5' UTR and
      promoter region are associated with increased risk for GDM in a population of
      Chilean subjects.
AD  - 1 Department of Pediatrics, Children's Hospital of Richmond at Virginia
      Commonwealth University , Richmond, Virginia.
FAU - Le, Trang N
AU  - Le TN
FAU - Elsea, Sarah H
AU  - Elsea SH
FAU - Romero, Roberto
AU  - Romero R
FAU - Chaiworapongsa, Tinnakorn
AU  - Chaiworapongsa T
FAU - Francis, Gary L
AU  - Francis GL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Genet Test Mol Biomarkers
JT  - Genetic testing and molecular biomarkers
JID - 101494210
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1089/gtmb.2013.0009 [doi]
PST - aheadofprint
SO  - Genet Test Mol Biomarkers. 2013 May 7.

PMID- 23651347
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1743-6109 (Electronic)
IS  - 1743-6095 (Linking)
DP  - 2013 May 7
TI  - Adrenomedullin and Angiopoietin-1 Additively Restore Erectile Function in
      Diabetic Rats: Comparison with the Combination Therapy of Vascular Endothelial
      Growth Factor and Angiopoietin-1.
LID - 10.1111/jsm.12177 [doi]
AB  - INTRODUCTION: Erectile dysfunction (ED) is a major health problem. We have shown 
      that adrenomedullin (AM) restores erectile function in diabetic rats. AIM: The
      aim of this study is to explore a better treatment for ED, we examined whether
      combination of AM and angiopoietin-1 (Ang-1) was more effective to treat ED than 
      treatment with AM alone or Ang-1 alone. We also compared the effect of the
      combination therapy with that of treatment with vascular endothelial growth
      factor-A (VEGF-A). METHODS: Male Wistar rats were injected with streptozotocin
      (STZ) to induce diabetes. Adenoviruses expessing AM (AdAM), Ang-1 (AdAng-1), and 
      VEGF-A (AdVEGF-A) were injected into the penis 6 weeks after STZ administration. 
      Erectile function, penile histology, and protein expression were analyzed 4 weeks
      after the injection of the adenoviruses. MAIN OUTCOME MEASURES: Intracavernous
      pressure and mean arterial pressure were measured to evaluate erectile function. 
      The morphology of the penis was analyzed by Elastica van Gieson stain and
      immunohistochemistry. The expression of alpha-smooth muscle actin (SMA),
      VE-cadherin and type I collagen was assessed by Western blot analysis. RESULTS:
      Infection with AdAM plus AdAng-1 more effectively restored erectile function than
      infection with AdAM alone or AdAng-1 alone. This combination therapy restored
      erectile function to a level similar to that observed in the age-matched Wistar
      rats. Expression of SMA and VE-cadherin increased more significantly in the AdAM 
      plus AdAng-1-treated group than in the AdAM- or AdAng-1-treated group. Although
      AdVEGF-A infection restored erectile function significantly, it also caused
      enlargement of the trabeculae of the cavernous body, aberrant angiogenesis, and
      overproduction of type I collagen. CONCLUSIONS: These results suggested that
      combination therapy with AM and Ang-1 potently restored erectile function and
      normal morphology of the cavernous body compared with VEGF-A administration. This
      combination therapy will be useful to treat ED patients with a severely damaged
      cavernous body. Nishimatsu H, Suzuki E, Nomiya A, Niimi A, Suzuki M, Fujimura T, 
      Fukuhara H, and Homma Y. Adrenomedullin and angiopoietin-1 additively restore
      erectile function in diabetic rats: Comparison with the combination therapy of
      vascular endothelial growth factor and angiopoietin-1. J Sex Med **;**:**-**.
CI  - (c) 2013 International Society for Sexual Medicine.
AD  - The Department of Urology, Faculty of Medicine, University of Tokyo, Tokyo,
      Japan.
FAU - Nishimatsu, Hiroaki
AU  - Nishimatsu H
FAU - Suzuki, Etsu
AU  - Suzuki E
FAU - Nomiya, Akira
AU  - Nomiya A
FAU - Niimi, Aya
AU  - Niimi A
FAU - Suzuki, Motofumi
AU  - Suzuki M
FAU - Fujimura, Tetsuya
AU  - Fujimura T
FAU - Fukuhara, Hiroshi
AU  - Fukuhara H
FAU - Homma, Yukio
AU  - Homma Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1111/jsm.12177 [doi]
PST - aheadofprint
SO  - J Sex Med. 2013 May 7. doi: 10.1111/jsm.12177.

PMID- 23651237
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1557-7465 (Electronic)
IS  - 1079-9907 (Linking)
DP  - 2013 May 7
TI  - Association of Cytokine Gene Polymorphisms with Oral Lichen Planus in
      Malayalam-Speaking Ethnicity from South India (Kerala).
AB  - Oral lichen planus (OLP) is a chronic mucocutaneous condition that affects the
      oral mucous membrane as well as skin. It is a chronic cell-mediated autoimmune
      condition where the T-cell-mediated immune response plays an important part in
      the pathogenesis by causing damage to basal keratinocytes in oral mucosa.
      Cytokine gene polymorphisms have an unquestionable role in the orchestration of
      the immune response, leading to different functional scenarios, which in turn
      influence the outcome of the disease establishment and evolution. The purpose of 
      this study was to understand the role of these cytokine gene polymorphisms in the
      tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and IL-6
      genes with OLP in 101 individuals of Malayalam-speaking ethnicity from South
      India (Kerala). We further investigated the role of these polymorphisms in
      patients suffering from OLP with other comorbid factors. Genotyping was carried
      out by polymerase chain reaction-restriction fragment length polymorphism. The
      results demonstrate that the A allele in the TNF-alpha -308 polymorphism could
      play an important role in the susceptibility to OLP. IL-1beta +3954 in OLP was
      associated with other comorbid factors in both allelic and genotypic
      combinations. However, when patients suffering from OLP were stratified to
      understand the involvement of other comorbid factors, we observed that the T and 
      C alleles were independent risk factors for chronic periodontitits and diabetes
      mellitus. On the other hand, IL-6 -597 did not show any disease association with 
      OLP in the study population. This study indicates that proinflammatory cytokines 
      are an important factor in understanding the disease burden of OLP and their
      comorbid factors.
AD  - 1 Department of Oral Pathology and Microbiology, Himachal Institute of Dental
      Sciences , Paonta Sahib, India .
FAU - Chauhan, Isha
AU  - Chauhan I
FAU - V T, Beena
AU  - V T B
FAU - Srinivas, Lekshmy
AU  - Srinivas L
FAU - Sathyan, Sanish
AU  - Sathyan S
FAU - Banerjee, Moinak
AU  - Banerjee M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the
      International Society for Interferon and Cytokine Research
JID - 9507088
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1089/jir.2012.0115 [doi]
PST - aheadofprint
SO  - J Interferon Cytokine Res. 2013 May 7.

PMID- 23651179
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1460-2709 (Electronic)
IS  - 1369-3786 (Linking)
DP  - 2013 May 8
TI  - Candida cerebral abscesses: a case report and review of the literature.
AB  - Cerebral abscess caused by Candida spp. is a rare disease, with a nonspecific
      presentation, little data on treatment, and generally poor outcomes. We present a
      case of this type of Candida infection in a 57-year-old man with a history of
      uncontrolled diabetes mellitus and intravenous drug abuse, and review the
      literature on this disease. Our patient had a good treatment outcome with
      liposomal amphotericin B and flucytosine, followed by oral fluconazole.
      Comorbidities include prior antibiotic use (52%), prior surgery (28%), malignancy
      (28%), stem cell or solid organ transplant (20%), prior corticosteroid use (16%),
      central venous catheter (CVC) insertion (10%), and burns (7%). Diagnosis requires
      a high index of suspicion, as clinical presentations and laboratory data can be
      nonspecific and difficult to differentiate from bacterial cerebral abscesses. In 
      reviewed cases, 55% of blood cultures and 23% of cerebrospinal fluid (CSF)
      cultures were positive for Candida spp. and outcomes were poor, as the mortality 
      rate of the non-autopsy cases reviewed was 69%.
AD  - * Department of Internal Medicine.
FAU - Fennelly, Andrea M
AU  - Fennelly AM
FAU - Slenker, Amy K
AU  - Slenker AK
FAU - Murphy, Lara C
AU  - Murphy LC
FAU - Moussouttas, Michael
AU  - Moussouttas M
FAU - Desimone, Joseph A
AU  - Desimone JA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Med Mycol
JT  - Medical mycology : official publication of the International Society for Human
      and Animal Mycology
JID - 9815835
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.3109/13693786.2013.789566 [doi]
PST - aheadofprint
SO  - Med Mycol. 2013 May 8.

PMID- 23651176
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
DP  - 2013 May 8
TI  - Renal diseases in haemophilic patients: pathogenesis and clinical management.
LID - 10.1111/ejh.12134 [doi]
AB  - Haemophilia A and B are genetic X-linked bleeding disorders, caused by mutations 
      in genes encoding factor VIII and IX, respectively. Clinical manifestations of
      haemophilia are spontaneous haemorrhage or acute bleeding caused by minor trauma,
      resulting in severe functional consequences that can culminate in a debilitating 
      arthropathy. Life expectancy and quality of life of haemophilic patients have
      dramatically improved over the last years, mainly for new therapeutic options and
      the awareness to the risk of HCV and HIV infections. Different clinical problems 
      arise from this important change in history of haemophilic patients. In
      particular, aging-related diseases, such as diabetes, hypertension, cancer and
      chronic viral infections, are emerging as new challenges in this patient
      population. Among the different types of chronic illnesses, renal diseases are of
      special interest since they involve some difficult management issues. In fact,
      decisions regarding adequate preventive strategies and viral infection treatment,
      the choice of the dialytic modality, placement of vascular access and
      prescription of dialytic treatments are particularly complicated, also because
      only few data are available. In this review, we discuss the pathogenesis of renal
      damage in haemophilic patients, especially in those with blood transmitted viral 
      infections, and the major issues about the management of renal diseases,
      including problems related to dialytic treatment and kidney transplantation,
      providing practical algorithms to guide the clinical decision-making process.
      This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico
      S.Matteo and University of Pavia, Italy.
FAU - Esposito, Pasquale
AU  - Esposito P
FAU - Rampino, Teresa
AU  - Rampino T
FAU - Gregorini, Marilena
AU  - Gregorini M
FAU - Fasoli, Gianluca
AU  - Fasoli G
FAU - Gamba, Gabriella
AU  - Gamba G
FAU - Canton, Antonio Dal
AU  - Canton AD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/03 [accepted]
AID - 10.1111/ejh.12134 [doi]
PST - aheadofprint
SO  - Eur J Haematol. 2013 May 8. doi: 10.1111/ejh.12134.

PMID- 23651165
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1873-5592 (Electronic)
IS  - 1389-4501 (Linking)
DP  - 2013 May 6
TI  - Ppar-Gamma in Ulcerative Colitis: A Novel Target for Intervention.
AB  - Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear
      receptor, originally described in adipose tissue, that controls the expression of
      a large number of regulatory genes in lipid metabolism and insulin sensitization.
      Well known by endocrinologists, thiazolidinediones (TZDs) are classical PPARgamma
      synthetic agonists which were currently used as insulin-sensitizing agents in the
      treatment of type 2 diabetes. While the clinical benefits of TZDs in treating
      metabolic disorders have been clearly demonstrated, new studies performed in
      animal models of colitis and in patients with ulcerative colitis have also
      revealed the key roles of PPARgamma activation in the regulation of inflammation 
      and immune response, notably in the colon through epithelial cells. During
      inflammation, PPAR acts directly to negatively regulate gene expression of
      proinflammatory genes in a ligand-dependent manner by antagonizing the activities
      of other transcription factors such as members of the NF-kappaB and AP-1
      families. A major mechanism that underlies the ability of PPARs to interfere with
      the activities of these transcription factors has been termed transrepression.
      PPARgamma acts by inhibiting signal-dependent transcription factors that mediate 
      inflammatory programs of gene activation. However, due to safety issues
      concerning particularly the greater risk of myocardial infarction, use of TZDs
      has been severely limited for the treatment of type 2 diabetes and/or
      inflammatory diseases, justifying the development of a new family of PPARgamma
      agonists with major transrepressive effects and without toxicity. By the
      demonstration that the anti-inflammatory effects of 5-aminosalicylic acid (5-ASA)
      in patients with ulcerative colitis were mediated by PPARgamma activation,
      several molecules having 5-ASA similarities have been developed and screened
      leading to the selection of a aminophenyl-alpha-methoxy-propionic acids named
      GED-0507-34-Levo (GED). This compound activating PPARgamma has 100-to 150-fold
      higher anti-inflammatory activity than 5-ASA. This new PPAR modulator is giving
      promising results both in vitro and in vivo, without toxicity and is currently
      evaluated in a phase 2 clinical trial. The aim of this review is to present and
      discuss the evidence suggesting that PPARgamma targeting is of therapeutic
      interest in the treatment of UC.
AD  - Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New
      York, USA. jean-frederic.colombel@mssm.edu.
FAU - Bertin, Benjamin
AU  - Bertin B
FAU - Dubuquoy, Laurent
AU  - Dubuquoy L
FAU - Colombel, Jean-Frederic
AU  - Colombel JF
FAU - Desreumaux, Pierre
AU  - Desreumaux P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Curr Drug Targets
JT  - Current drug targets
JID - 100960531
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/06 [received]
PHST- 2013/05/05 [accepted]
AID - CDT-EPUB-20130506-3 [pii]
PST - aheadofprint
SO  - Curr Drug Targets. 2013 May 6.

PMID- 23651102
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1521-0464 (Electronic)
IS  - 1071-7544 (Linking)
DP  - 2013 May 8
TI  - Formulation and evaluation of metformin hydrochloride-loaded niosomes as
      controlled release drug delivery system.
AB  - Abstract Lactic acidosis is a serious, metabolic complication that may occur due 
      to metformin hydrochloride (MH) accumulation during the treatment of diabetes
      mellitus. The aim of this study is to enhance the bioavailability of MH by oral
      route. Span 40 and cholesterol were used for the preparation of MH-loaded
      niosomes by the reverse phase evaporation technique. Dicetyl phosphate (DCP) and 
      1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) were used to
      obtain negatively and positively charged vesicles, respectively. The mean
      particle size ranged from 223.5 to 384.6 nm and the MH-loaded niosomes' surface
      was negatively charged in the absence of charge inducing agents (-16.6 +/- 1.4
      mV) and also with DCP (-26.9 +/- 1.0 mV), while it was positively charged (+8.7
      +/- 1.2 mV) with DOTAP. High entrapment efficiency was observed in all the
      formulations. MH-loaded niosomes were found to effectively sustain the release of
      drug, particularly with positively charged niosomes. The bioavailability of
      MH-loaded niosomes was assessed by measuring the serum values of glucose and
      metformin in the different studied Wistar rats groups. The pharmacokinetic data
      of MH-loaded niosomal preparation showed a significant prolongation and increased
      intensity of hypoglycemic effect more than that observed for free MH solution.
      Area above the blood glucose levels-time curve (AAC), maximum hypoglycemic
      response and time of maximum response (Tmax) were significantly higher (p <
      0.001) when MH was administered in niosomal form compared to free drug solution. 
      It could be concluded that MH-loaded niosome is promising extended-release
      preparation with better hypoglycemic efficiency.
AD  - Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal 
      University , Al-Ahsa, Hufof , Saudi Arabia .
FAU - Hasan, Azza A
AU  - Hasan AA
FAU - Madkor, Hafez
AU  - Madkor H
FAU - Wageh, Sherief
AU  - Wageh S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.3109/10717544.2013.779332 [doi]
PST - aheadofprint
SO  - Drug Deliv. 2013 May 8.

PMID- 23651064
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Linking)
VI  - 45
IP  - 4
DP  - 2013 Jun
TI  - Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in
      subjects with chest pain.
PG  - 322-7
LID - 10.3109/07853890.2013.783996 [doi]
AB  - Abstract Background. Early diagnosis of acute coronary syndrome (ACS) is
      frequently a challenging task. Aims. To assess the role of novel biomarkers to
      identify ACS. Methods. Concentrations of lipids, lipoproteins, oxidized LDL
      (oxLDL), high-sensitivity C-reactive protein (hsCRP), paraoxonase-1 (PON1),
      secretory phospholipase A2 (sPLA2), and myeloperoxidase (MPO) were measured in
      703 patients (mean age 65.5 +/- 11.2 years; 422 men, 281 women) without diabetes 
      mellitus assigned to coronary angiogram. The subjects were divided into three
      groups: ACS (n = 242), stable angina pectoris (SAP) (n = 242), and normal
      coronary artery (NCA) (n = 219). Results. HDL-cholesterol (HDL-C) (P < 0.001) and
      apolipoproteinA-I concentrations (P < 0.0001) were lowest in subjects with ACS.
      LDL-C (P = 0.008) and non-HDL (P < 0.0001) were higher in the ACS group than in
      the SAP group. Leukocyte count (P < 0.0001), oxLDL (P < 0.05), hsCRP (P < 0.001),
      sPLA2 (P < 0.05), and MPO (P < 0.0001) were highest in the ACS group. In
      multivariate models, comprising all biomarkers, elevated level of MPO had the
      best discriminatory power to identify patients with ACS. Receiver-operating
      characteristic curve with and without MPO comparison differed significantly (P = 
      0.03 for both ACS versus NCA and ACS versus SAP). Conclusion. Our study shows
      that ACS associates with low HDL-C and biomarkers of oxidative stress and
      inflammation. The addition of MPO in biomarker panels might improve diagnostic
      accuracy for ACS.
AD  - Heart and Lung Center, Division of Cardiology, Helsinki University Central
      Hospital , Helsinki , Finland.
FAU - Graner, Marit
AU  - Graner M
FAU - Tikkanen, Emmi
AU  - Tikkanen E
FAU - Rimpila, Olga
AU  - Rimpila O
FAU - Tikkanen, Helena
AU  - Tikkanen H
FAU - Ripatti, Samuli
AU  - Ripatti S
FAU - Lokki, Marja-Liisa
AU  - Lokki ML
FAU - Nieminen, Markku S
AU  - Nieminen MS
FAU - Taskinen, Marja-Riitta
AU  - Taskinen MR
FAU - Sinisalo, Juha
AU  - Sinisalo J
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/05/08 [aheadofprint]
AID - 10.3109/07853890.2013.783996 [doi]
PST - ppublish
SO  - Ann Med. 2013 Jun;45(4):322-7. doi: 10.3109/07853890.2013.783996. Epub 2013 May
      8.

PMID- 23651029
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 14
IP  - 7
DP  - 2013 May
TI  - SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
PG  - 825-33
LID - 10.2217/pgs.13.61 [doi]
AB  - The kidney has attracted the attention of diabetologists as an organ involved in 
      the regulation of glucose homeostasis not only by gluconeogenesis, but also by
      renal glucose excretion. Sodium-glucose cotransporters (SGLTs), particularly
      SGLT2, are responsible for reabsorption of up to 99% of the filtered glucose.
      SGLT2 is coded by the SLC5A2 gene, which maps on chromosome 16. Pharmacological
      reduction of tubular glucose reabsorption results in improved glycemic control in
      Type 2 diabetic patients. Since the SGLTs reabsorb most of the filtered glucose
      (90%), it is not surprising that mutations in SLC5A2 cause familial renal
      glucosuria. A recent study pointed out a possible role of common genetic
      variation in SLC5A2 in the control of glucose homeostasis. SLC5A2 polymorphisms
      might therefore represent potential candidates for pharmacogenomic studies
      targeting the impact of these variants on the efficacy of antidiabetic treatment 
      that is based on inhibition of SGLT2 activity.
AD  - University of Leipzig, Medical Department, Liebigstrasse 21, 04103 Leipzig,
      Germany.
FAU - Tonjes, Anke
AU  - Tonjes A
FAU - Kovacs, Peter
AU  - Kovacs P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.2217/pgs.13.61 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2013 May;14(7):825-33. doi: 10.2217/pgs.13.61.

PMID- 23650988
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1365-277X (Electronic)
IS  - 0952-3871 (Linking)
DP  - 2013 May 7
TI  - Do clinical and behavioural correlates of obese patients seeking bariatric
      surgery differ from those of individuals involved in conservative weight loss
      programme?
LID - 10.1111/jhn.12080 [doi]
AB  - BACKGROUND: Clinical practice has suggested that, in severely obese patients
      seeking bariatric surgery, clinical conditions, behavioural characteristics and
      psychological status might all differ from those of their counterparts starting
      conventional conservative therapy. METHODS: Two groups of obese patients with
      closely similar body mass values were considered. The first group included
      individuals voluntarily and spontaneously seeking biliopancreatic diversion and
      the second group comprised patients at the beginning of a weight loss programme. 
      After anthropometric and metabolic evaluation, the patients underwent an
      alimentary interview; eating behaviour and psychological status were assessed by 
      Three Factor Eating Questionnaire and by Toronto Alexithymia Scale (TAS).
      RESULTS: Among bariatric candidates, a greater number of individuals with type 2 
      diabetes and dyslipidaemia and high tendency to disinhibition and susceptibility 
      to hunger scores was observed, whereas the other aspects of eating pattern were
      essentially similar. In the two groups, no difference in TAS score and or number 
      of patients with alexithymic traits was observed. Finally, a logistic regression 
      model showed that only age and metabolic derangement predicted the bariatric
      option, whereas eating behaviour or psychological status did not influence
      individual therapeutic choice. CONCLUSIONS: Independently of the degree of
      obesity, bariatric surgery was requested by the more metabolically deranged
      patients, whereas, in the surgical candidates, the eating pattern and
      psychological conditions were very similar to those of obese persons at the
      beginning of a conservative weight loss programme. These results suggest a highly
      realistic and practical attitude in severely obese patients towards obesity and
      bariatric surgery.
CI  - (c) 2013 The Authors Journal of Human Nutrition and Dietetics (c) 2013 The
      British Dietetic Association Ltd.
AD  - Department of Clinical Nutrition, Ospedale San Martino and University of Genova, 
      Genova, Italy.
FAU - Gradaschi, R
AU  - Gradaschi R
FAU - Noli, G
AU  - Noli G
FAU - Cornicelli, M
AU  - Cornicelli M
FAU - Camerini, G
AU  - Camerini G
FAU - Scopinaro, N
AU  - Scopinaro N
FAU - Adami, G F
AU  - Adami GF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - J Hum Nutr Diet
JT  - Journal of human nutrition and dietetics : the official journal of the British
      Dietetic Association
JID - 8904840
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1111/jhn.12080 [doi]
PST - aheadofprint
SO  - J Hum Nutr Diet. 2013 May 7. doi: 10.1111/jhn.12080.

PMID- 23650983
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 May 8
TI  - Heart failure in hospitalized patients with diabetic foot ulcers: clinical
      characteristics and its relationship to prognosis.
LID - 10.1111/1753-0407.12062 [doi]
AB  - BACKGROUND: In the present study, we evaluated the incidence of heart failure
      (HF) in diabetic foot ulcer (DFU) patients, investigated clinical characteristics
      and its relationship to prognosis in such a population. METHODS: Clinical
      characteristics of 330 consecutive Chinese subjects (137 males and 193 females)
      hospitalized for diabetic foot ulcers were collected. Clinical characteristics
      were assessed to determine the effects about the presence of HF on DFU. All the
      subjects were followed up for 3 months. Rates of healing, new ulcers, amputations
      and mortality were calculated at the end of the follow-up to analyze the effect
      of heart failure on the prognosis of diabetic foot ulcer. RESULTS: HF accounted
      for 64.3% of the patients with ulcers, and the rate would increase from Wagner 1 
      to Wagner 5 ( 42.4% vs.59.1%vs. 64.7% vs. 73.3% vs. 87.0%), higher than 33.6% for
      diabetes(Wagner 0). Factors associated with high risk for HF were plasma albumin 
      level, creatine clearance rate, NYHA grade, and neutrophil count. And HF
      conferred a greater increase in relative risk of worse prognosis when compared
      with non-HF. The 3-month healing rates of diabetic foot ulcer were 60.3% vs.
      75.7% between HF and non-HF patients. More frequent recurrences and amputations
      were detected in HF when compared with non-HF counterparts (13.2% vs. 7.5%, 28.6%
      vs. 20.0%, respectively, P<0.05). All-cause mortality occurred in 14 of 126 HF
      subjects compared with 3 of 70 non-HF subjects (11.1% vs. 4.3%, P<0.05).
      CONCLUSIONS: The prevalence of HF was high in Chinese inpatient with DFU, and the
      presence of HF indicated a worse prognosis.
CI  - This article is protected by copyright. All rights reserved.
AD  - Diabetic Foot Disease Center, Shanghai Yuanyang Hospital, Shanghai, China.
FAU - Xu, Lei
AU  - Xu L
FAU - Qian, Hongjie
AU  - Qian H
FAU - Gu, Junyi
AU  - Gu J
FAU - Shi, Jianyuan
AU  - Shi J
FAU - Gu, Xueming
AU  - Gu X
FAU - Tang, Zhengyi
AU  - Tang Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130508
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/04/30 [accepted]
AID - 10.1111/1753-0407.12062 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 May 8. doi: 10.1111/1753-0407.12062.

PMID- 23650970
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 7
TI  - Heart rate variability in pubertal girls with type 1 diabetes: its relationship
      with glycaemic control, insulin resistance and hyperandrogenism.
LID - 10.1111/cen.12238 [doi]
AB  - OBJECTIVE: To examine the association between glycaemic control, insulin
      resistance and hyperandrogenism on cardiac autonomic function in peripubertal
      girls with type 1 diabetes. DESIGN: Prospective, clinic-based study of 125 girls 
      with diabetes and 46 age-matched nondiabetic girls. MEASUREMENTS: Heart rate
      variability (HRV) parameters derived from a 10-min ECG recording using LabChart
      Pro were as follows: standard deviation of mean NN intervals (SDNN), where NN =
      adjacent QRS complexes; root mean squared difference of successive NN intervals
      (RMSSD) - estimates of overall HRV; and low-/high-frequency (LF:HF) ratio - an
      estimate of the sympathovagal balance. Androgens and sex hormone binding globulin
      (SHBG) were measured in girls with diabetes, and free androgen index (FAI)
      calculated. HRV and anthropometry were measured in nondiabetic controls. RESULTS:
      Adolescents with diabetes (median age 15.1 years [13.3-16.0], diabetes duration
      7.0 years [4.6-10.0] and median HbA1c 8.4% [7.5-9.3]) had higher HR and lower HRV
      compared with controls. Using multivariate models in the diabetes group, higher
      HR was associated with higher HbA1c, total daily dose insulin/kg body weight and 
      systolic BP standard deviation scores (SDS), whilst reduced HRV was associated
      with higher HbA1c (SDNN, RMSSD and LF:HF ratio), lower SHBG (SDNN and RMSSD) and 
      higher weight SDS (LF:HF ratio). Higher FAI was associated with higher HR and
      reduced HRV measures in the univariate analyses only. CONCLUSIONS: In adolescent 
      girls with diabetes, reduced HRV parameters are associated with worse glycaemic
      control, lower SHBG and higher weight SDS. SHBG should be considered in the
      cardiac risk models for this population.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead,
      Sydney, NSW, Australia; Discipline of Paediatrics and Child Health & Department
      of Ophthalmology, University of Sydney, Sydney, NSW, Australia.
FAU - Cho, Yoon Hi
AU  - Cho YH
FAU - Craig, Maria E
AU  - Craig ME
FAU - Srinivasan, Shubha
AU  - Srinivasan S
FAU - Benitez-Aguirre, Paul
AU  - Benitez-Aguirre P
FAU - Mitchell, Paul
AU  - Mitchell P
FAU - Jopling, Tracey
AU  - Jopling T
FAU - Donaghue, Kim C
AU  - Donaghue KC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/12/31 [received]
PHST- 2013/02/01 [revised]
PHST- 2013/03/28 [revised]
PHST- 2013/05/03 [accepted]
AID - 10.1111/cen.12238 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 7. doi: 10.1111/cen.12238.

PMID- 23650948
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 11
IP  - 3
DP  - 2013 May 1
TI  - Pleiotropic Effects of PPARgamma Agonist on Hemostatic Activation in Type 2
      Diabetes Mellitus.
PG  - 338-51
AB  - Thiazolidinediones (TZDs) represent a class of peroxisome proliferator-activated 
      receptor (PPAR)gamma agonists widely used as insulin-sensitizers in the treatment
      of type 2 diabetes mellitus (T2DM). The beneficial effects of hypoglycemic drugs,
      including TZDs, on the hemostatic abnormalities associated to T2DM have been
      formerly related to improved metabolic control, rather than to direct effects.
      However, in recent years the pleiotropic effects of PPARgamma agonists on
      hemostatic function have become evident. In particular, the role of platelets as 
      a pivotal player in diabetes complications by stimulating and sustaining
      inflammation has been lately acknowledged. Upon activation platelets synthesize
      and release many bioactive substances such as thromboxane A2 (TXA2) or
      pro-inflammatory mediators including CD40 ligand (CD40L) that exert autocrine and
      paracrine activation processes in vascular inflammation leading to cardiovascular
      disease (CVD). Although PPARgamma is a nuclear hormone receptor, anucleate
      platelets also highly express this receptor and treatment with synthetic
      PPARgamma ligands dampens the release of soluble(s)CD40L and TXA2 in
      thrombin-activated platelets. Moreover, PPARgamma through Sirtuin1 pathway has
      been implicated in modulating inflammatory and atherosclerotic processes in
      patients with T2DM. Therefore, in T2DM, where platelet activation contributes to 
      the pathogenesis of CVD, TZDs may have an enhanced therapeutic role, despite some
      potentially serious adverse side effects. This review will discuss the
      pleiotropic effects of PPARgamma treatment on the hemostatic abnormalities
      associated with T2DM, with particular focus on platelet activation.
AD  - Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San
      Raffaele Pisana, Via della Pisana, 235, 00163 Rome, Italy.
      patrizia.ferroni@sanraffaele.it.
FAU - Ferroni, Patrizia
AU  - Ferroni P
FAU - Della-Morte, David
AU  - Della-Morte D
FAU - Pileggi, Antonello
AU  - Pileggi A
FAU - Riondino, Silvia
AU  - Riondino S
FAU - Rundek, Tatjana
AU  - Rundek T
FAU - Ricordi, Camillo
AU  - Ricordi C
FAU - Guadagni, Fiorella
AU  - Guadagni F
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
SB  - IM
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/06/15 [received]
PHST- 2012/07/03 [revised]
PHST- 2012/07/20 [accepted]
AID - CVP-EPUB-11-03-338 [pii]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2013 May 1;11(3):338-51.

PMID- 23650946
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 7
TI  - Pituitary Dysfunction after Traumatic Brain Injury in Children: Is there a Need
      for Ongoing Endocrine Assessment?
LID - 10.1111/cen.12237 [doi]
AB  - Hypopituitarism has been widely described in adults after traumatic brain injury 
      (TBI); however, the available data in pediatric populations are scarce. Here, we 
      report the results of a prospective, long-term study in children, adolescents and
      young adults. STUDY GROUP: Thirty-seven children (age, 2 mo to 19.9 yr) out of 51
      eligible patients were followed for 1 yr. Clinical and baseline endocrine
      variables were assessed in all 3 and 12 mo after TBI; children >/= 6 y underwent 
      two stimulation tests (glucagon stimulation and megatest). RESULTS: In the group 
      >/= 6 y, 11/23 patients (47.8%) had a subnormal GH peak 3 mo after TBI that
      persisted in 8/23 patients (34%) after one year. The GH response showed no
      correlation with injury severity (GCS, Marshall classification). Growth velocity 
      was normal in all patients, except for one. Body mass index (BMI) SDS increased
      significantly in the group with low GH response. A suboptimal cortisol was
      observed in 10/23 subjects, which normalized in all but three, one year
      thereafter. All patients but one showed a pubertal response to GnRH testing. No
      clinical or hormonal abnormalities were detectable in children < 6 yr.
      CONCLUSION: Our results recommend to prospectively follow children after TBI;
      firstly because the impairment of pituitary function can not be predicted, and
      secondly, to avoid the potential consequences of pituitary dysfunction.
      Prospective clinical trials are needed before recommending a systematic screening
      after TBI, and/or GH therapy either in postpubertal children or in prepubertal
      children who grow normally. This article is protected by copyright. All rights
      reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Pediatric Endocrinology Unit, Hospital Sant Joan de Deu, University of Barcelona,
      08950 Esplugues, Barcelona. Endocrinology, Hospital Sant Joan de Deu and CIBER de
      Diabetes y Enfermedades Metabolicas Asociadas (CIBERDEM), Barcelona, Spain.
FAU - Casano-Sancho, Paula
AU  - Casano-Sancho P
FAU - Suarez, Larisa
AU  - Suarez L
FAU - Ibanez, Lourdes
AU  - Ibanez L
FAU - Garcia-Fructuoso, Gemma
AU  - Garcia-Fructuoso G
FAU - Medina, Julita
AU  - Medina J
FAU - Febrer, Anna
AU  - Febrer A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2013/01/03 [received]
PHST- 2013/01/14 [revised]
PHST- 2013/04/24 [revised]
PHST- 2013/05/02 [accepted]
AID - 10.1111/cen.12237 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 7. doi: 10.1111/cen.12237.

PMID- 23650944
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1365-2702 (Electronic)
IS  - 0962-1067 (Linking)
VI  - 22
IP  - 13-14
DP  - 2013 Jul
TI  - Factors associated with numbers of remaining teeth among type 2 diabetes: a
      cross-sectional study.
PG  - 1926-32
LID - 10.1111/jocn.12225 [doi]
AB  - AIMS AND OBJECTIVES: To explore the factors associated with the numbers of
      remaining teeth among type 2 diabetes community residents. BACKGROUND: Promoting 
      oral health is an important nursing role for patients with diabetes, especially
      in disadvantaged areas. However, limited research has been carried out on the
      relationship between numbers of remaining teeth, diabetes-related biomarkers and 
      personal oral hygiene among diabetic rural residents. DESIGN: A cross-sectional, 
      descriptive design with a simple random sample was used. METHODS: This study was 
      part of a longitudinal cohort study of health promotion for preventing diabetic
      foot among rural community diabetic residents. It was carried out in 18 western
      coastal and inland districts of Chiayi County in central Taiwan. In total, 703
      participants were enrolled in this study. RESULTS: The findings indicated that a 
      high percentage of the participants (26%) had no remaining natural teeth. Nearly 
      three quarters (74%) had fewer than 20 natural teeth. After controlling for the
      potential confounding factors, multivariate analysis demonstrated that the
      factors determining numbers of remaining teeth were age (p < 0.001), education (p
      < 0.001), using dental floss (p = 0.003), ankle brachial pressure index (p =
      0.028), waist circumference (p = 0.024) and HbA1C (p = 0.033). CONCLUSIONS:
      Except for some unmodifiable factors, the factors most significantly associated
      with numbers of remaining teeth were less tooth-brushing with dental floss,
      abnormal ankle brachial pressure and poor glycemic control. RELEVANCE TO CLINICAL
      PRACTICE: This study highlights the importance of nursing intervention in oral
      hygiene for patients with type 2 diabetes. It is necessary to initiate oral
      health promotion activities when diabetes is first diagnosed, especially for
      older diabetic residents of rural or coastal areas who are poorly educated.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital, Chiayi,
      Taiwan.
FAU - Huang, Jui-Chu
AU  - Huang JC
FAU - Peng, Yun-Shing
AU  - Peng YS
FAU - Fan, Jun-Yu
AU  - Fan JY
FAU - Jane, Sui-Whi
AU  - Jane SW
FAU - Tu, Liang-Tse
AU  - Tu LT
FAU - Chang, Chang-Cheng
AU  - Chang CC
FAU - Chen, Mei-Yen
AU  - Chen MY
LA  - eng
PT  - Journal Article
DEP - 20130508
PL  - England
TA  - J Clin Nurs
JT  - Journal of clinical nursing
JID - 9207302
SB  - N
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
PHST- 2012/12/09 [accepted]
PHST- 2013/05/08 [aheadofprint]
AID - 10.1111/jocn.12225 [doi]
PST - ppublish
SO  - J Clin Nurs. 2013 Jul;22(13-14):1926-32. doi: 10.1111/jocn.12225. Epub 2013 May
      8.

PMID- 23650924
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1741-2358 (Electronic)
IS  - 0734-0664 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Jun
TI  - Clinical aspects of the use of dental adhesive materials in patients with chronic
      xerostomia.
PG  - 162-6
LID - 10.1111/j.1741-2358.2012.00659.x [doi]
AB  - doi: 10.1111/j.1741-2358.2012.00659.x Clinical aspects of the use of dental
      adhesive materials in patients with chronic xerostomia Adhesives are commonly
      used by denture wearers to increase the retention and stability of the complete
      denture, to improve the chewing and masticatory abilities and to psychologically 
      support the patient to make the complete denture more acceptable. Denture
      fixatives can be especially recommended for use and to aid retention for patients
      with dryness of the mouth, poor secretion of saliva and xerostomia (e.g. diabetes
      mellitus). Dental adhesives may be contaminated with bacteria, yeast and fungi
      during the manufacturing process, and they have been shown to initiate and
      promote microbial growth. Some products have been shown to release formaldehyde, 
      which is cytotoxic to cell culture and fibroblasts and is a potent allergen.
      Patients with chronic xerostomia may use denture adhesives during the course of
      the treatment and disease. These patients are often immunocompromised, and
      microorganisms they are exposed to must be considered potential pathogens.
CI  - (c) 2013 John Wiley & Sons A/S and The Gerodontology Society. Published by John
      Wiley & Sons Ltd.
AD  - Department of Prosthetic Dentistry, Wroclaw Medical University, Wroclaw, Poland.
FAU - Bogucki, Zdzislaw Artur
AU  - Bogucki ZA
LA  - eng
PT  - Journal Article
PL  - England
TA  - Gerodontology
JT  - Gerodontology
JID - 8215850
SB  - D
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1111/j.1741-2358.2012.00659.x [doi]
PST - ppublish
SO  - Gerodontology. 2013 Jun;30(2):162-6. doi: 10.1111/j.1741-2358.2012.00659.x.

PMID- 23650901
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 May 7
TI  - Patch Pump Versus Conventional Pump: Postprandial Glycemic Excursions and the
      Influence of Wear Time.
AB  - Abstract Background and Aims: The aim of this study was to compare blood glucose 
      and plasma insulin profiles after bolus insulin infusion by a patch pump (PP)
      versus a conventional pump (CP), directly after placement and after Day 3 of use.
      Patients and Methods: Twenty patients with type 1 diabetes came in for two blocks
      of visits: one block of two visits while wearing the OmniPod(R) (Insulet Corp.,
      Bedford, MA) insulin pump (PP) and one block of two visits while wearing the
      Medtronic Diabetes (Northridge, CA) Paradigm(R) pump (CP). Patients administered 
      an identical mealtime insulin bolus of at least 6 IU. Results: For PP, maximum
      glucose levels were 28.7% lower on Day 3 (P=0.020), when maximum insulin levels
      were 30.3% higher (P=0.002). For CP, maximum glucose levels were 26.5% lower on
      Day 3 (P=0.015), when maximum insulin levels were 46.4% higher (P=0.003). Glucose
      levels (mean [interquartile range]) were significantly lower on Day 3 for PP
      (168.2 [145.8] mg/dL vs. 139.4 [77.8] mg/dL; P=0.013), but not significantly so
      for CP (159.0 [66.1] mg/dL vs. 139.5 [57.9] mg/dL; P=0.084). Mean insulin levels 
      were significantly higher on Day 3 for CP (195 [120] pmol/L vs. 230 [90] pmol/L; 
      P=0.01), but not significantly so for PP (178 [106] pmol/L vs. 194 [120] pmol/L; 
      P=0.099). There were no significant differences between the two catheter lengths.
      Conclusions: Postprandial glycemic excursions were lower on Day 3 of catheter
      wear time, but there were no differences between PPs and CPs. These findings
      support the proposal that catheter wear time plays an important role in insulin
      absorption.
AD  - 1 Internal Medicine, Academic Medical Centre , Amsterdam, The Netherlands .
FAU - Luijf, Yoeri M
AU  - Luijf YM
FAU - Arnolds, Sabine
AU  - Arnolds S
FAU - Avogaro, Angelo
AU  - Avogaro A
FAU - Benesch, Carsten
AU  - Benesch C
FAU - Bruttomesso, Daniela
AU  - Bruttomesso D
FAU - Farret, Anne
AU  - Farret A
FAU - Heinemann, Lutz
AU  - Heinemann L
FAU - Place, Jerome
AU  - Place J
FAU - Renard, Eric
AU  - Renard E
FAU - Scotton, Rachele
AU  - Scotton R
FAU - Devries On Behalf Of The Ap Home Consortium, J Hans
AU  - Devries On Behalf Of The Ap Home Consortium JH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1089/dia.2013.0016 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 May 7.

PMID- 23650900
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 May 7
TI  - Accuracy and Reliability of Continuous Glucose Monitoring Systems: A Head-to-Head
      Comparison.
AB  - Abstract Objective: This study assessed the accuracy and reliability of three
      continuous glucose monitoring (CGM) systems. Research Design and Methods: We
      studied the Animas(R) (West Chester, PA) Vibe with Dexcom(R) (San Diego, CA) G4
      version A sensor (G4A), the Abbott Diabetes Care (Alameda, CA) Freestyle(R)
      Navigator I (NAV), and the Medtronic (Northridge, CA) Paradigm(R) with Enlite
      sensor (ENL) in 20 patients with type 1 diabetes mellitus. All systems were
      investigated both in a clinical research center (CRC) and at home. In the CRC,
      patients received a meal with a delayed and increased insulin dose to induce a
      postprandial glucose peak and nadir. Hereafter, randomization determined which
      two of the three systems would be worn at home until the end of functioning,
      attempting use beyond manufacturer-specified lifetime. Patients performed at
      least five reference finger sticks per day. An analysis of variance was performed
      on all data points >/=15 min apart. Results: Overall average mean absolute
      relative difference (MARD) (SD) measured at the CRC was 16.5% (14.3%) for NAV and
      16.4% (15.6%) for ENL, outperforming G4A at 20.5% (18.2%) (P<0.001). Overall MARD
      when assessed at home was 14.5% (16.7%) for NAV and 16.5 (18.8%) for G4A,
      outperforming ENL at 18.9% (23.6%) (P=0.006). Median time until end of
      functioning was similar: 10.0 (1.0) days for G4A, 8.0 (3.5) days for NAV, and 8.0
      (1.5) days for ENL (P=0.119). Conclusions: In the CRC, G4A was less accurate than
      NAV and ENL sensors, which seemed comparable. However, at home, ENL was less
      accurate than NAV and G4A. Moreover, CGM systems often show sufficient accuracy
      to be used beyond manufacturer-specified lifetime.
AD  - 1 Internal Medicine, Academic Medical Center , Amsterdam, The Netherlands .
FAU - Luijf, Yoeri M
AU  - Luijf YM
FAU - Mader, Julia K
AU  - Mader JK
FAU - Doll, Werner
AU  - Doll W
FAU - Pieber, Thomas
AU  - Pieber T
FAU - Farret, Anne
AU  - Farret A
FAU - Place, Jerome
AU  - Place J
FAU - Renard, Eric
AU  - Renard E
FAU - Bruttomesso, Daniela
AU  - Bruttomesso D
FAU - Filippi, Alessio
AU  - Filippi A
FAU - Avogaro, Angelo
AU  - Avogaro A
FAU - Arnolds, Sabine
AU  - Arnolds S
FAU - Benesch, Carsten
AU  - Benesch C
FAU - Heinemann, Lutz
AU  - Heinemann L
FAU - Devries On Behalf Of The Ap Home Consortium, J Hans
AU  - Devries On Behalf Of The Ap Home Consortium JH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/05/09 06:00
MHDA- 2013/05/09 06:00
CRDT- 2013/05/09 06:00
AID - 10.1089/dia.2013.0049 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 May 7.

PMID- 23650649
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1071-1007 (Print)
IS  - 1071-1007 (Linking)
DP  - 2013 May 6
TI  - Tibiotalocalcaneal Arthrodesis With Bulk Femoral Head Allograft for Salvage of
      Large Defects in the Ankle.
AB  - BACKGROUND: Tibiotalocalcaneal arthrodesis in patients with large segmental bony 
      defects presents a substantial challenge to successful reconstruction. These
      defects typically occur following failed total ankle replacement, avascular
      necrosis of the talus, trauma, osteomyelitis, Charcot, or failed reconstructive
      surgery. This study examined the outcomes of tibiotalocalcaneal (TTC) arthrodesis
      using bulk femoral head allograft to fill this defect. METHODS: Thirty-two
      patients underwent TTC arthrodesis with bulk femoral head allograft. Patients who
      demonstrated radiographic union were contacted for SF-12 clinical scoring and
      repeat radiographs. Patients with asymptomatic nonunions were also contacted for 
      SF-12 scoring alone. Preoperative, intraoperative, and postoperative factors were
      analyzed to determine positive predictors for successful fusion. RESULTS: Sixteen
      patients healed their fusion (50% fusion rate). Diabetes mellitus was found to be
      the only predictive factor of outcome; all 9 patients with diabetes developed a
      nonunion. In this series, 19% of the patients went on to require a below-knee
      amputation. CONCLUSIONS: Although the radiographic fusion rate was low, when the 
      7 patients who had an asymptomatic nonunion were combined with the radiographic
      union group, the overall rate of functional limb salvage rose to 71%. TTC
      arthrodesis using femoral head allograft should be considered a salvage procedure
      that is technically difficult and carries a high risk for complications. Patients
      with diabetes mellitus are at an especially high risk for nonunion. LEVEL OF
      EVIDENCE: Therapeutic level IV.
AD  - Institute for Foot and Ankle Reconstruction, Mercy Medical Center, Baltimore, MD,
      USA.
FAU - Jeng, Clifford L
AU  - Jeng CL
FAU - Campbell, John T
AU  - Campbell JT
FAU - Tang, Edward Y
AU  - Tang EY
FAU - Cerrato, Rebecca A
AU  - Cerrato RA
FAU - Myerson, Mark S
AU  - Myerson MS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Foot Ankle Int
JT  - Foot & ankle international. / American Orthopaedic Foot and Ankle Society [and]
      Swiss Foot and Ankle Society
JID - 9433869
OTO - NOTNLM
OT  - allograft
OT  - ankle
OT  - arthritis
OT  - arthrodesis
OT  - diabetes
OT  - tibiotalocalcaneal fusion
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 1071100713488765 [pii]
AID - 10.1177/1071100713488765 [doi]
PST - aheadofprint
SO  - Foot Ankle Int. 2013 May 6.

PMID- 23650645
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
DP  - 2013 May 6
TI  - Acute Insulin Resistance Assessed by the Homeostatic Model Assessment in Acute
      Coronary Syndromes Without Previously Known Diabetes.
AB  - We assessed the incidence and the prognostic role for early death of acute
      insulin resistance (by means of homeostatic model assessment [HOMA] index) in
      1350 patients with acute coronary syndrome (ACS) consecutively admitted to our
      intensive cardiac care unit (ICCU). The incidence of HOMA positivity was 5% (68
      of 1350), with the highest percentage of HOMA positivity among ST-segment
      elevation myocardial infarction (STEMI). Patients with HOMA positivity showed a
      higher body mass index (P = .003), lower values of admission and discharge
      left-ventricular ejection fraction (LVEF; P < .001 and P = .003, respectively),
      and higher levels of peak troponin I (Tn I; P < .001). The HOMA index was an
      independent predictor of early death (odds ratio 1.724, 95% confidence interval
      1.252-2.375, P = .001). In patients with ACS and without previously known
      diabetes, acute insulin resistance (HOMA index) is associated with a larger
      myocardial damage (ie, higher values of peak Tn I and lower LVEF) and a greater
      inflammatory activation (indicated by correlation with leukocyte count). The HOMA
      positivity was an independent predictor of in-ICCU mortality.
AD  - 1Intensive Cardiac Coronary Unit, Heart and Vessel Department, Azienda
      Ospedaliero-Universitaria Careggi, Florence, Italy.
FAU - Lazzeri, Chiara
AU  - Lazzeri C
FAU - Valente, Serafina
AU  - Valente S
FAU - Chiostri, Marco
AU  - Chiostri M
FAU - Attana, Paola
AU  - Attana P
FAU - Mattesini, Alessio
AU  - Mattesini A
FAU - Gensini, Gian Franco
AU  - Gensini GF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Angiology
JT  - Angiology
JID - 0203706
OTO - NOTNLM
OT  - acute coronary syndrome
OT  - acute insulin resistance
OT  - early death
OT  - without previously known diabetes
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 0003319713489018 [pii]
AID - 10.1177/0003319713489018 [doi]
PST - aheadofprint
SO  - Angiology. 2013 May 6.

PMID- 23650507
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 5
DP  - 2013
TI  - Novel Insulin Sensitizer Modulates Nutrient Sensing Pathways and Maintains
      beta-Cell Phenotype in Human Islets.
PG  - e62012
LID - 10.1371/journal.pone.0062012 [doi]
AB  - Major bottlenecks in the expansion of human beta-cell mass are limited
      proliferation, loss of beta-cell phenotype, and increased apoptosis. In our
      previous studies, activation of Wnt and mTOR signaling significantly enhanced
      human beta-cell proliferation. However, isolated human islets displayed insulin
      signaling pathway resistance, due in part to chronic activation of mTOR/S6K1
      signaling that results in negative feedback of the insulin signaling pathway and 
      a loss of Akt phosphorylation and insulin content. We evaluated the effects of a 
      new generation insulin sensitizer, MSDC-0160, on restoring insulin/IGF-1
      sensitivity and insulin content in human beta-cells. This novel TZD has low
      affinity for binding and activation of PPARgamma and has insulin-sensitizing
      effects in mouse models of diabetes and ability to lower glucose in Phase 2
      clinical trials. MSDC-0160 treatment of human islets increased AMPK activity and 
      reduced mTOR activity. This was associated with the restoration of IGF-1-induced 
      phosphorylation of Akt, GSK-3, and increased protein expression of Pdx1.
      Furthermore, MSDC-0160 in combination with IGF-1 and 8 mM glucose increased
      beta-cell specific gene expression of insulin, pdx1, nkx6.1, and nkx2.2, and
      maintained insulin content without altering glucose-stimulated insulin secretion.
      Human islets were unable to simultaneously promote DNA synthesis and maintain the
      beta-cell phenotype. Lithium-induced GSK-3 inhibition that promotes DNA synthesis
      blocked the ability of MSDC-0160 to maintain the beta-cell phenotype. Conversely,
      MSDC-0160 prevented an increase in DNA synthesis by blocking beta-catenin nuclear
      translocation. Due to the counteracting pathways involved in these processes, we 
      employed a sequential ex vivo strategy to first induce human islet DNA synthesis,
      followed by MSDC-0160 to promote the beta-cell phenotype and insulin content.
      This new generation PPARgamma sparing insulin sensitizer may provide an initial
      tool for relieving inherent human islet insulin signaling pathway resistance that
      is necessary to preserve the beta-cell phenotype during beta-cell expansion for
      the treatment of diabetes.
AD  - Department of Pathology and Immunology, Washington University in St. Louis, St.
      Louis, Missouri, United States of America.
FAU - Rohatgi, Nidhi
AU  - Rohatgi N
FAU - Aly, Haytham
AU  - Aly H
FAU - Marshall, Connie A
AU  - Marshall CA
FAU - McDonald, William G
AU  - McDonald WG
FAU - Kletzien, Rolf F
AU  - Kletzien RF
FAU - Colca, Jerry R
AU  - Colca JR
FAU - McDaniel, Michael L
AU  - McDaniel ML
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3641131
OID - NLM: PMC3641131
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/15 [received]
PHST- 2013/03/17 [accepted]
PHST- 2013/05/01 [epublish]
AID - 10.1371/journal.pone.0062012 [doi]
AID - PONE-D-12-35733 [pii]
PST - epublish
SO  - PLoS One. 2013 May 1;8(5):e62012. doi: 10.1371/journal.pone.0062012. Print 2013.

PMID- 23650450
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130507
DCOM- 20130508
LR  - 20130509
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 6
DP  - 2013
TI  - Managing diabetic patients with moderate or severe renal impairment using DPP-4
      inhibitors: focus on vildagliptin.
PG  - 161-70
LID - 10.2147/DMSO.S28951 [doi]
AB  - BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified oral
      anti-diabetic drugs for the treatment of type 2 diabetes mellitus (T2DM) that
      provide important reduction in glycated hemoglobin, with a low risk for
      hypoglycemia and no weight gain. In T2DM patients with reduced renal function,
      adequate glycemic control is essential to delay the progress of kidney
      dysfunction, but they are at a greater risk of experiencing hypoglycemic events, 
      especially with longer-acting sulfonylureas and meglitinides. OBJECTIVE: To
      evaluate vildagliptin as an option to achieve glycemic control in T2DM patients
      with moderate or severe chronic kidney disease (CKD). METHODS: A comprehensive
      search in the literature was performed using the term "vildagliptin." Original
      articles and reviews exploring our topic were carefully selected. RESULTS:
      Vildagliptin provides effective glycemic control in patients with T2DM and CKD.
      Dose reductions are required for vildagliptin and other DPP-4 inhibitors, except 
      linagliptin, in T2DM patients with moderate-to-severe CKD. Dose of vildagliptin
      had to be reduced by half (to 50 mg/day) both for moderate (estimated glomerular 
      filtration rate [eGFR] >/=30 to </=50 mL/min) and severe CKD (eGFR < 30 mL/min). 
      Available results support a favorable efficacy, safety, and tolerability profile 
      for vildagliptin in T2DM with moderate or severe renal failure. Preliminary data 
      may suggest additional benefits beyond improvement of glycemic control.
      CONCLUSION: Vildagliptin can be safely used in T2DM patients with varying degrees
      of renal impairment. Dose adjustments for renal impairment are required.
      Potential long-term renal benefit of vildagliptin needs to be further explored.
AD  - Department of Clinical and Experimental Medicine, Section of Diabetes and
      Metabolic Disease, Azienda Ospedaliero Universitaria di Pisa, and University of
      Pisa, Pisa, Italy.
FAU - Russo, Eleonora
AU  - Russo E
FAU - Penno, Giuseppe
AU  - Penno G
FAU - Del Prato, Stefano
AU  - Del Prato S
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3639752
OID - NLM: PMC3639752
OTO - NOTNLM
OT  - chronic kidney disease
OT  - renal function
OT  - type 2 diabetes mellitus
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:01
CRDT- 2013/05/08 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/24 [epublish]
AID - 10.2147/DMSO.S28951 [doi]
AID - dmso-6-161 [pii]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2013 Apr 24;6:161-70. doi: 10.2147/DMSO.S28951. Print 
      2013.

PMID- 23650440
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1540-9538 (Electronic)
IS  - 0022-1007 (Linking)
VI  - 210
IP  - 6
DP  - 2013 Jun 3
TI  - Regulatory T cells control NK cells in an insulitic lesion by depriving them of
      IL-2.
PG  - 1153-65
LID - 10.1084/jem.20122248 [doi]
AB  - Regulatory T (T reg) cells control progression to autoimmune diabetes in the
      BDC2.5/NOD mouse model by reining in natural killer (NK) cells that infiltrate
      the pancreatic islets, inhibiting both their proliferation and production of
      diabetogenic interferon-gamma. In this study, we have explored the molecular
      mechanisms underlying this NK-T reg cell axis, following leads from a kinetic
      exploration of gene expression changes early after punctual perturbation of T reg
      cells in BDC2.5/NOD mice. Results from gene signature analyses, quantification of
      STAT5 phosphorylation levels, cytokine neutralization experiments, cytokine
      supplementation studies, and evaluations of intracellular cytokine levels
      collectively argue for a scenario in which T reg cells regulate NK cell functions
      by controlling the bioavailability of limiting amounts of IL-2 in the islets,
      generated mainly by infiltrating CD4(+) T cells. This scenario represents a
      previously unappreciated intertwining of the innate and adaptive immune systems: 
      CD4(+) T cells priming NK cells to provoke a destructive T effector cell
      response. Our findings highlight the need to consider potential effects on NK
      cells when designing therapeutic strategies based on manipulation of IL-2 levels 
      or targets.
AD  - Division of Immunology, Department of Microbiology and Immunobiology, Harvard
      Medical School, Boston, MA 02115.
FAU - Sitrin, Jonathan
AU  - Sitrin J
FAU - Ring, Aaron
AU  - Ring A
FAU - Garcia, K Christopher
AU  - Garcia KC
FAU - Benoist, Christophe
AU  - Benoist C
FAU - Mathis, Diane
AU  - Mathis D
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - United States
TA  - J Exp Med
JT  - The Journal of experimental medicine
JID - 2985109R
SB  - IM
PMC - PMC3674700
OID - NLM: PMC3674700 [Available on 12/03/13]
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PMCR- 2013/12/03 00:00
PHST- 2013/05/06 [aheadofprint]
AID - jem.20122248 [pii]
AID - 10.1084/jem.20122248 [doi]
PST - ppublish
SO  - J Exp Med. 2013 Jun 3;210(6):1153-65. doi: 10.1084/jem.20122248. Epub 2013 May 6.

PMID- 23650218
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1552-485X (Electronic)
IS  - 1552-4841 (Linking)
VI  - 162
IP  - 4
DP  - 2013 Jun
TI  - Association of aggression with a novel microRNA binding site polymorphism in the 
      wolframin gene.
PG  - 404-12
LID - 10.1002/ajmg.b.32157 [doi]
AB  - Rare mutations in the WFS1 gene lead to Wolfram syndrome, a severe multisystem
      disorder with progressive neurodegeneration and diabetes mellitus causing
      life-threatening complications and premature death. Only a few association
      studies using small clinical samples tested the possible effects of common WFS1
      gene variants on mood disorders and suicide, the non-clinical spectrum has not
      been studied yet. Self-report data on Aggression, Impulsiveness, Anxiety, and
      Depression were collected from a large (N = 801) non-psychiatric sample. Single
      nucleotide polymorphisms (SNPs) were selected to provide an adequate coverage of 
      the entire WFS1 gene, as well as to include putative microRNA binding site
      polymorphisms. Molecular analysis of the assumed microRNA binding site variant
      was performed by an in vitro reporter-gene assay of the cloned 3' untranslated
      region with coexpression of miR-668. Among the 17 WFS1 SNPs, only the rs1046322, 
      a putative microRNA (miR-668) binding site polymorphism showed significant
      association with psychological dimensions after correction for multiple testing: 
      those with the homozygous form of the minor allele reported higher aggression on 
      the Buss-Perry Aggression Questionnaire (P = 0.0005). Functional effect of the
      same SNP was also demonstrated in a luciferase reporter system: the minor A
      allele showed lower repression compared to the major G allele, if co-expressed
      with miR-668. To our knowledge, this is the first report describing a microRNA
      binding site polymorphism of the WFS1 gene and its association with human
      aggression based on a large, non-clinical sample. (c) 2013 Wiley Periodicals,
      Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry,
      Semmelweis University, Budapest, Hungary.
FAU - Kovacs-Nagy, Reka
AU  - Kovacs-Nagy R
FAU - Elek, Zsuzsanna
AU  - Elek Z
FAU - Szekely, Anna
AU  - Szekely A
FAU - Nanasi, Tibor
AU  - Nanasi T
FAU - Sasvari-Szekely, Maria
AU  - Sasvari-Szekely M
FAU - Ronai, Zsolt
AU  - Ronai Z
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - United States
TA  - Am J Med Genet B Neuropsychiatr Genet
JT  - American journal of medical genetics. Part B, Neuropsychiatric genetics : the
      official publication of the International Society of Psychiatric Genetics
JID - 101235742
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/10/29 [received]
PHST- 2013/03/13 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - 10.1002/ajmg.b.32157 [doi]
PST - ppublish
SO  - Am J Med Genet B Neuropsychiatr Genet. 2013 Jun;162(4):404-12. doi:
      10.1002/ajmg.b.32157. Epub 2013 May 3.

PMID- 23650169
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
DP  - 2013 May 6
TI  - THE FETAL SAFETY OF MACROLIDES.
AB  - Introduction:Macrolide antibiotics are largely used in pregnancy for different
      bacterial infections. Their fetal safety has been studied by several groups,
      yielding opposing results. In particular, there have been studies claiming
      association between macrolides and cardiovascular malformations. Exposure in
      early infancy has been associated with pyloric stenosis and intussusception. This
      has led to avoidance of macrolides in several Scandinavian countries. The
      Objectives of the present study was to investigate the fetal safety of this class
      of drug by linking large administrative database of drug dispensing and pregnancy
      outcome in Southern Israel.Methods:A computerized database of medications
      dispensed from 1999 to 2009 to all women registered in the "Clalit" health
      maintenance organization in Southern Israel, was linked with two computerized
      databases containing maternal and infant hospitalization records. Also, medical
      pregnancy terminations data were analyzed. The following confounders were
      controlled for: maternal age, ethnicity, maternal pre gestational diabetes,
      parity and year of birth or medical pregnancy termination. First and third
      trimester exposures to macrolide antibiotics as a group, and to individual drugs 
      was analyzed.Results:During the study period there were 105,492 pregnancies among
      Clalit women that met the inclusion criteria. 104,380 of them ended up in live or
      dead fetus and 1,112 by abortion due to medical reasons. In the first trimester
      of pregnancy 1,033 women were exposed to macrolides. There was no association
      between macrolides and either major malformations [OR 1.08 (95% CI 0.84-1.38)],
      or specific malformations, after accounting for maternal age, parity, ethnicity, 
      pre pregnancy diabetes and year of exposure. During the third trimester of
      pregnancy 959 women were exposed to macrolides. There was no association between 
      such exposure and perinatal mortality, low birth weight, low Apgar score or
      preterm delivery. Similarly, no associations were demonstrated with pyloric
      stenosis or intussusception.Conclusions:Use of macrolides in the first trimester 
      of pregnancy is not associated with an increased risk of major malformations.
      Exposure in the third trimester is not likely to increase neonatal risks for
      pyloric stenosis or intussusception in a clinically meaningful manner.
AD  - Departments of Public Health.
FAU - Dinur, Anat B
AU  - Dinur AB
FAU - Koren, Gideon
AU  - Koren G
FAU - Matok, Ilan
AU  - Matok I
FAU - Wiznitzer, Arnon
AU  - Wiznitzer A
FAU - Uziel, Elya
AU  - Uziel E
FAU - Gorodischer, Rafael
AU  - Gorodischer R
FAU - Levy, Amalia
AU  - Levy A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - AAC.01691-12 [pii]
AID - 10.1128/AAC.01691-12 [doi]
PST - aheadofprint
SO  - Antimicrob Agents Chemother. 2013 May 6.

PMID- 23650131
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
DP  - 2013 May 5
TI  - Galectin-3 in heart failure with preserved ejection fraction.
AB  - In the last decades it has been appreciated that many patients with heart failure
      (HF) suffer from HF with preserved ejection fraction (HFpEF). The diagnosis and
      treatment of HFpEF is difficult, as we lack specific markers of the disease and
      no specific treatments have been identified. Galectin-3 has a strong relationship
      to several aspects of the pathophysiology of HF, especially myocardial fibrosis, 
      the transition from compensated to decompensated HF, and co-morbidities such as
      renal disease and diabetes. Many of these traits are very commonly observed in
      patients with HFpEF, and this suggests that galectin-3 may be particularly
      important and useful in the study of HFpEF. This review summarizes our knowledge 
      of the role of galectin-3 in fibrosis, specifically in experimental models of HF 
      and HFpEF. Galectin-3 may be a marker and also a causal factor, and experimental 
      studies suggested that galectin-3 may be a target for therapy in HFpEF. The
      detrimental effects of aldosterone may, in part, be conferred via galectin-3, and
      there are data to suggest that aldosterone blockers are of more benefit in
      patients with high levels of galectin-3. Furthermore, the relationship of
      galectin-3 to clinical correlates of developing HFpEF in human subjects is
      discussed, and the association between increased levels of galectin-3 and
      new-onset HF and mortality in the general population is highlighted.
      Additionally, the usefulness of galectin-3 in patients with established HFpEF is 
      described. We conclude that galectin-3 may be useful for early detection,
      phenotyping, risk stratification, and therapeutic targeting of individuals with
      early or established HFpEF in which fibrosis is a major contributor to the
      disease. Finally, we propose areas of further research that should validate the
      role of galectin-3 in HFpEF.
AD  - University Medical Center Groningen, Department of Cardiology, University of
      Groningen, Hanzeplein 1, 9700RB, Groningen.
FAU - de Boer, Rudolf A
AU  - de Boer RA
FAU - Edelmann, Frank
AU  - Edelmann F
FAU - Cohen-Solal, Alain
AU  - Cohen-Solal A
FAU - Mamas, Mamas A
AU  - Mamas MA
FAU - Maisel, Alan
AU  - Maisel A
FAU - Pieske, Burkert
AU  - Pieske B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130505
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
OTO - NOTNLM
OT  - Biomarker
OT  - Fibrosis
OT  - Galectin-3
OT  - Heart failure
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - hft077 [pii]
AID - 10.1093/eurjhf/hft077 [doi]
PST - aheadofprint
SO  - Eur J Heart Fail. 2013 May 5.

PMID- 23650093
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1098-1128 (Electronic)
IS  - 0198-6325 (Linking)
DP  - 2013 May 3
TI  - Perspectives and Potential Applications of Mitochondria-Targeted Antioxidants in 
      Cardiometabolic Diseases and Type 2 Diabetes.
LID - 10.1002/med.21285 [doi]
AB  - There is abundant evidence to suggest that mitochondrial dysfunction is a main
      cause of insulin resistance and related cardiometabolic comorbidities. On the
      other hand, insulin resistance is one of the main characteristics of type 2
      diabetes, obesity, and metabolic syndrome. Lipid and glucose metabolism require
      mitochondria to generate energy, and when O2 consumption is low due to
      inefficient nutrient oxidation, there is an increase in reactive oxygen species, 
      which can impair different types of molecules, including DNA, lipids, proteins,
      and carbohydrates, thereby inducing proinflammatory processes. Factors which
      contribute to mitochondrial dysfunction, such as mitochondrial biogenesis and
      genetics, can also lead to insulin resistance in different insulin-target
      tissues, and its association with mitochondrial dysfunction can culminate in the 
      development of cardiovascular diseases. In this context, therapies that improve
      mitochondrial function may also improve insulin resistance. This review explains 
      mechanisms of mitochondrial function related to the pathological effects of
      insulin resistance in different tissues. The pathogenesis of cardiometabolic
      diseases will be explained from a mitochondrial perspective and the potential
      beneficial effects of mitochondria-targeted antioxidants as a therapy for
      modulating mitochondrial function in cardiometabolic diseases, especially
      diabetes, will also be considered.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Fundacion para la Investigacion Sanitaria y Biomedica de la Comunidad Valenciana 
      FISABIO, Valencia, Spain; University Hospital Doctor Peset, Endocrinology
      Service, Valencia, Spain; INCLIVA Foundation, Valencia, Spain.
FAU - Rocha, Milagros
AU  - Rocha M
FAU - Apostolova, Nadezda
AU  - Apostolova N
FAU - Herance, Jose Raul
AU  - Herance JR
FAU - Rovira-Llopis, Susana
AU  - Rovira-Llopis S
FAU - Hernandez-Mijares, Antonio
AU  - Hernandez-Mijares A
FAU - Victor, Victor M
AU  - Victor VM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Med Res Rev
JT  - Medicinal research reviews
JID - 8103150
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1002/med.21285 [doi]
PST - aheadofprint
SO  - Med Res Rev. 2013 May 3. doi: 10.1002/med.21285.

PMID- 23650085
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 29
IP  - 4
DP  - 2013 May
TI  - Issue information.
PG  - i
LID - 10.1002/dmrr.2330 [doi]
LA  - eng
PT  - Journal Article
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1002/dmrr.2330 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2013 May;29(4):i. doi: 10.1002/dmrr.2330.

PMID- 23650004
OWN - NLM
STAT- In-Process
DA  - 20130507
IS  - 0028-3843 (Print)
IS  - 0028-3843 (Linking)
VI  - 47
IP  - 2
DP  - 2013 Mar-Apr
TI  - The beta-fibrinogen -455G/A gene polymorphism and the risk of ischaemic stroke in
      a Polish population.
PG  - 152-6
AB  - BACKGROUND AND PURPOSE: Ischaemic stroke is considered to be multifactorial and
      interactions between environmental and genetic factors play an important role.
      Although vascular risk factors are well known, the genetic ones are still
      undiscovered. In the present study, we assessed the significance of the
      beta-fibrinogen -455G/A gene polymorphism and the risk of ischaemic stroke in a
      Polish population. MATERIAL AND METHODS: 426 ischaemic stroke patients classified
      according to stroke aetiologies (small vessel disease, large vessel disease or
      cardioembolic stroke) and 234 controls were included in the study. The
      association of the beta-fibrinogen genotypes with ischaemic stroke was tested
      using logistic regression analysis under dominant, recessive or additive models
      of inheritance. RESULTS: The allele and genotype distributions of the
      beta-fibrinogen -455G/A gene polymorphism did not differ significantly between
      patients and controls (patients: G - 75%, GG - 56.6%, GA - 36.8%, AA - 6.6%;
      controls: G - 73.7%, GG - 57.3%, GA - 32.9%, AA - 9.8%; p > 0.05, chi2). In
      addition, logistic regression analysis adjusted for the known risk factors, i.e. 
      hypertension, ischaemic heart disease, myocardial infarction,
      hypercholesterolaemia, diabetes mellitus and smoking, did not show a role of the 
      studied polymorphism in ischaemic stroke. CONCLUSIONS: The beta-fibrinogen
      -455G/A gene polymorphism is not a risk factor for ischaemic stroke in a Polish
      population.
AD  - Department of Neurology, Jagiellonian University Medical College, ul. Botaniczna 
      3, 31-503 Krakow, Poland. agolenia@gmail.com
FAU - Golenia, Aleksandra
AU  - Golenia A
FAU - Chrzanowska-Wasko, Joanna
AU  - Chrzanowska-Wasko J
FAU - Jagiella, Jeremiasz
AU  - Jagiella J
FAU - Wnuk, Marcin
AU  - Wnuk M
FAU - Ferens, Antoni
AU  - Ferens A
FAU - Klimkowicz-Mrowiec, Aleksandra
AU  - Klimkowicz-Mrowiec A
FAU - Adamski, Mateusz
AU  - Adamski M
FAU - Ciecko-Michalska, Irena
AU  - Ciecko-Michalska I
FAU - Slowik, Agnieszka
AU  - Slowik A
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Neurol Neurochir Pol
JT  - Neurologia i neurochirurgia polska
JID - 0101265
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 20593 [pii]
PST - ppublish
SO  - Neurol Neurochir Pol. 2013 Mar-Apr;47(2):152-6.

PMID- 23649954
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
DP  - 2013 May 4
TI  - Diabetes mellitus and corticotherapy as risk factors for alendronate-related
      osteonecrosis of the jaws: A study in Wistar rats.
LID - 10.1002/hed.23260 [doi]
AB  - BACKGROUND: The purpose of this study was to investigate the influence of
      diabetes and corticotherapy on the development of osteonecrosis of the jaws
      associated with sodium alendronate. METHODS: Rats were allocated into 4 groups of
      11 animals each, representing different treatments: (1) alendronate; (2)
      alendronate and corticotherapy; (3) alendronate and diabetes; and (4) control.
      Tooth extractions were performed in all animals, and histological analysis was
      performed by hematoxylin and eosin staining and immunohistochemistry using
      anti-bone morphogenetic protein (BMP)-4 and anti-matrix metalloproteinase
      (MMP)-13 antibodies. RESULTS: On hematoxylin and eosin analysis, proportions of
      inflammatory infiltrate, microbial colonies, and osteonecrosis were significantly
      greater in the diabetes group. BMP-4 expression in connective tissue was higher
      in the corticosteroid group than the alendronate group. There were no significant
      differences between the other groups. MMP-13 expression did not differ between
      the groups analyzed. CONCLUSION: Diabetes but not corticotherapy is associated
      with jaw osteonecrosis in rats undergoing alendronate therapy and subjected to
      tooth extractions. (c) 2013 Wiley Periodicals, Inc. Head Neck, 2013.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Dental College, Pontifical Catholic University of Rio Grande do Sul, Hospital Sao
      Lucas, Porto Alegre, RS, Brazil.
FAU - Berti-Couto, Soraya A
AU  - Berti-Couto SA
FAU - Vasconcelos, Ana Carolina U
AU  - Vasconcelos AC
FAU - Iglesias, Julia E
AU  - Iglesias JE
FAU - Figueiredo, Maria Antonia Z
AU  - Figueiredo MA
FAU - Salum, Fernanda G
AU  - Salum FG
FAU - Cherubini, Karen
AU  - Cherubini K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Head Neck
JT  - Head & neck
JID - 8902541
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/01/22 [accepted]
AID - 10.1002/hed.23260 [doi]
PST - aheadofprint
SO  - Head Neck. 2013 May 4. doi: 10.1002/hed.23260.

PMID- 23649947
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 7
TI  - Antioxidants and Diabetic Retinopathy.
AB  - The biochemical perturbations in diabetes mellitus (DM) create the conditions for
      the production of free radicals, the consequence of which is increased oxidative 
      stress. Evidence has accrued over the past 2 decades that suggests that oxidative
      stress is an important pathogenetic factor in the development of diabetic
      retinopathy (DR). Experimental data show that the use of strategies that
      ameliorate oxidative stress can prevent and retard the development of DR in the
      animal model. Clinical observations also suggest that reducing oxidative stress
      may help to reverse pathological manifestations of DR. The present article
      constitutes an examination of the role of antioxidants in the management of DR
      and the current state of clinically relevant knowledge.
AD  - Medical Ophthalmology, Department of Ophthalmology, Royal Victoria Hospital,
      Belfast Health and Social Care Trust, Belfast, BT12 6BA, Northern Ireland, UK.
FAU - Williams, Michael
AU  - Williams M
FAU - Hogg, Ruth E
AU  - Hogg RE
FAU - Chakravarthy, Usha
AU  - Chakravarthy U
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1007/s11892-013-0384-x [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 7.

PMID- 23649945
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 7
TI  - Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing
      Early Renal Function Loss (PERL) Allopurinol Study.
AB  - Diabetic kidney disease causes significant morbidity and mortality among people
      with type 1 diabetes (T1D). Intensive glucose and blood pressure control have
      thus far failed to adequately curb this problem and therefore a major need for
      novel treatment approaches exists. Multiple observations link serum uric acid
      levels to kidney disease development and progression in diabetes and strongly
      argue that uric acid lowering should be tested as one such novel intervention. A 
      pilot of such a trial, using allopurinol, is currently being conducted by the
      Preventing Early Renal Function Loss (PERL) Consortium. Although the PERL trial
      targets T1D individuals at highest risk of kidney function decline, the use of
      allopurinol as a renoprotective agent may also be relevant to a larger segment of
      the population with diabetes. As allopurinol is inexpensive and safe, it could be
      cost-effective even for relatively low-risk patients, pending the completion of
      appropriate trials at earlier stages.
AD  - Barbara Davis Center for Childhood Diabetes, University of Colorado Denver,
      Aurora, CO, USA.
FAU - Maahs, David M
AU  - Maahs DM
FAU - Caramori, Luiza
AU  - Caramori L
FAU - Cherney, David Z I
AU  - Cherney DZ
FAU - Galecki, Andrzej T
AU  - Galecki AT
FAU - Gao, Chuanyun
AU  - Gao C
FAU - Jalal, Diana
AU  - Jalal D
FAU - Perkins, Bruce A
AU  - Perkins BA
FAU - Pop-Busui, Rodica
AU  - Pop-Busui R
FAU - Rossing, Peter
AU  - Rossing P
FAU - Mauer, Michael
AU  - Mauer M
FAU - Doria, Alessandro
AU  - Doria A
CN  - on behalf of the PERL Consortium
LA  - ENG
GR  - K23 DK088833/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1007/s11892-013-0381-0 [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 7.

PMID- 23649823
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1754-8411 (Electronic)
IS  - 1754-8403 (Linking)
DP  - 2013 May 2
TI  - Evidence for transgenerational metabolic programming in Drosophila.
AB  - Worldwide epidemiologic studies have repeatedly demonstrated an association
      between pre-natal nutritional environment, birth weight and susceptibility to
      adult diseases including obesity, cardiovascular disease and type 2 diabetes.
      Despite advances in mammalian model systems, the molecular mechanisms underlying 
      this phenomenon are unclear, but may involve programming mechanisms such as
      epigenetics. Here we describe a new system for evaluating metabolic programming
      mechanisms using a simple, genetically tractable Drosophila model. We examined
      the effect of maternal caloric excess on offspring and found that a high sugar
      maternal diet alters body composition of larval offspring for at least two
      generations, augments an obese-like phenotype under suboptimal, high calorie,
      feeding conditions in adult offspring, and modifies expression of metabolic
      genes. Our data indicate that nutritional programming mechanisms may be highly
      conserved and support the use of Drosophila as a model for evaluating the
      underlying genetic and epigenetic contributions to this phenomenon.
AD  - Washington University School of Medicine, St. Louis, MO, USA.
FAU - Buescher, Jessica L
AU  - Buescher JL
FAU - Musselman, Laura P
AU  - Musselman LP
FAU - Wilson, Christina A
AU  - Wilson CA
FAU - Lang, Tieming
AU  - Lang T
FAU - Keleher, Madeline
AU  - Keleher M
FAU - Baranski, Thomas J
AU  - Baranski TJ
FAU - Duncan, Jennifer G
AU  - Duncan JG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Dis Model Mech
JT  - Disease models & mechanisms
JID - 101483332
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - dmm.011924 [pii]
AID - 10.1242/dmm.011924 [doi]
PST - aheadofprint
SO  - Dis Model Mech. 2013 May 2.

PMID- 23649812
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1875-9114 (Electronic)
IS  - 0277-0008 (Linking)
VI  - 33
IP  - 5
DP  - 2013 May
TI  - Targeting Potassium Channels Kv1.3 and KC a 3.1: Routes to Selective
      Immunomodulators in Autoimmune Disorder Treatment?
PG  - 515-28
LID - 10.1002/phar.1236 [doi]
AB  - The Kv1.3 and KC a 3.1 potassium channels are promising targets for the treatment
      of autoimmune disorders. Many Kv1.3 and KC a 3.1 blockers have a more favorable
      adverse event profiles than existing immunosuppressants, suggesting the
      selectivity of Kv1.3 and KC a 3.1 blockade. The Kv1.3 and KC a 3.1 blockers exert
      differential effects in different autoimmune diseases. The Kv1.3 inhibitors or
      gene deletion have been shown to have benefits in multiple sclerosis, type 1
      diabetes, rheumatoid arthritis, psoriasis, and rapidly progressive
      glomerulonephritis. The KC a 3.1 blockers have demonstrated efficacy in human
      primary biliary cirrhosis and showed protective effects in animal models of
      severe colitis, allergic encephalomyelitis, inflammatory bowel disease, and
      multiple sclerosis. The KC a 3.1 blockers are not considered candidates for
      treatment of multiple sclerosis. The selective immunosuppressive effects of the
      Kv1.3 and KC a 3.1 blockers are due to the differences in their distribution on
      autoimmune-related immune cells and tissues and beta1 integrin (very late
      activating antigen)-Kv1.3 channel cross-talk.
CI  - (c) 2013 Pharmacotherapy Publications, Inc.
AD  - Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China; Department of Pharmacology,
      College of Medicine, Wuhan University of Science and Technology, Wuhan, China.
FAU - Wang, Jun
AU  - Wang J
FAU - Xiang, Ming
AU  - Xiang M
LA  - eng
PT  - Journal Article
DEP - 20130405
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/04/05 [aheadofprint]
AID - 10.1002/phar.1236 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2013 May;33(5):515-28. doi: 10.1002/phar.1236. Epub 2013 Apr 5.

PMID- 23649801
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1433-2965 (Electronic)
IS  - 0937-941X (Linking)
DP  - 2013 May 7
TI  - Successful treatment of nonunion with teriparatide after failed ankle arthrodesis
      for Charcot arthropathy.
AB  - We describe a case of successful treatment to nonunion after multiple arthrodesis
      operations for Charcot arthropathy with teriparatide. We describe the case of a
      25-year-old woman with severe Type I diabetes mellitus that resulted in nonunion 
      after multiple arthrodesis operations for Charcot arthropathy. The woman
      sustained a femoral shaft fracture for which she underwent surgery with
      intramedullary nail fixation. Immediately after surgery, an empiric course of
      teriparatide was initiated. Femoral shaft fracture healing was observed after 2
      weeks, and the woman was able to walk 12 weeks after the surgery, at which point 
      plain film and computed tomography images revealed complete union of the ankle.
AD  - Osaka City General Hospital, 2-13-22, Miyakojima hondori, Miyakojimaku, Osaka,
      Japan, tamaik1983_s58_04_22@yahoo.co.jp.
FAU - Tamai, K
AU  - Tamai K
FAU - Takamatsu, K
AU  - Takamatsu K
FAU - Kazuki, K
AU  - Kazuki K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Osteoporos Int
JT  - Osteoporosis international : a journal established as result of cooperation
      between the European Foundation for Osteoporosis and the National Osteoporosis
      Foundation of the USA
JID - 9100105
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/03/19 [received]
PHST- 2013/04/02 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 10.1007/s00198-013-2367-9 [doi]
PST - aheadofprint
SO  - Osteoporos Int. 2013 May 7.

PMID- 23649735
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1439-7641 (Electronic)
IS  - 1439-4235 (Linking)
DP  - 2013 May 6
TI  - Continuous Glucose Monitoring: 40 Years, What We've Learned and What's Next.
LID - 10.1002/cphc.201300172 [doi]
AB  - After 40 years of research and development, today continuous glucose monitoring
      (CGM) is demonstrating the benefit it provides for millions with diabetes. To
      provide in vivo accuracy, new permselective membranes and mediated systems have
      been developed to prevent enzyme saturation and to minimize interference signals.
      Early in vivo implanted sensor research clearly showed that the foreign body
      response was a more difficult issue to overcome. Understanding the biological
      interface and circumventing the inflammatory response continue to drive
      development of a CGM sensor with accuracy and reliability performance suitable in
      a closed-loop artificial pancreas. Along with biocompatible polymer development, 
      other complimentary algorithm and data analysis techniques have improved the
      performance of commercial systems significantly. For example, the mean average
      relative difference of Dexcom's CGM system improved from 26 to 14 % and its
      use-life was extended from 3 to 7 d. Significant gains in usability, including
      size, flexibility, insertion, calibration, and data interface, have been
      incorporated into new generations of commercial CGM systems. Besides Medtronic,
      Dexcom, and Abbott, other major players are also investing in CGM. Becton
      Dickinson is conducting clinical trials with an optical galactose glucose binding
      system. Development of fully implanted sensor systems fulfills the desire for a
      discreet, reliable CGM system. Research continues to find innovative ways to help
      make living with diabetes easier and more normal, and new segments are being
      pursued (intensive care unit, surgery, behavior modification) in which CGM is
      being utilized.
CI  - Copyright (c) 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
AD  - Life Science, Acreo Swedish ICT AB, Box 787 SE-601 17 Norrkoping (Sweden).
      raeann.gifford@acreo.se.
FAU - Gifford, Raeann
AU  - Gifford R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Chemphyschem
JT  - Chemphyschem : a European journal of chemical physics and physical chemistry
JID - 100954211
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/02/18 [received]
AID - 10.1002/cphc.201300172 [doi]
PST - aheadofprint
SO  - Chemphyschem. 2013 May 6. doi: 10.1002/cphc.201300172.

PMID- 23649733
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
DP  - 2013 May 7
TI  - Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces
      colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced
      rats.
LID - 10.1002/ijc.28260 [doi]
AB  - Type 2 diabetes mellitus (T2DM) and insulin resistance (IR) increase colon cancer
      risk. Antidiabetic drugs stabilizing incretin hormones, such as inhibitors of
      dipeptidyl peptidase-4 activity (DPP4i), may affect colon carcinogenesis;
      however, the data remain controversial. Therefore, the authors studied whether
      long-term administration of the DPP4i Sitagliptin (SITA) affects
      1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis. Male F344 rats fed a
      high-fat (HF) diet promoting colon carcinogenesis and IR, were induced with DMH
      (100 mg/kg x 2 times). One week later, the animals were allocated to two groups: 
      one continuing with HF diet (controls; n = 8) and one receiving SITA (n = 8)
      mixed in the diet (260 ppm). Body weight, food consumption and glycemia were not 
      affected by SITA. Fifteen weeks after DMH, the number of the precancerous lesions
      mucin-depleted foci (MDF) was significantly lower in rats treated with SITA
      [MDF/colon: 9.5 +/- 0.9 and 6.4 +/- 0.9 in controls (n = 8) and SITA groups (n = 
      8), respectively; means +/- SE, p < 0.05]. Reactive oxygen species in the blood
      were also significantly lower in the SITA group [6.75 +/- 0.69 and 5.63 +/- 0.75 
      (H2 O2 in mM) in controls (n = 5) and SITA (n = 6), respectively; means +/- SE, p
      < 0.05]. Rats treated with SITA had a lower DPP4 activity in the intestine but
      not in the plasma. Intestine growth morphometric parameters and colon
      proliferation, as proliferating cell nuclear antigen expression, were not
      affected by SITA. In conclusion, the results suggest a protective effect of DPP4i
      against colon carcinogenesis that could be exploited in chemoprevention trials.
CI  - Copyright (c) 2013 UICC.
AD  - Section of Pharmacology and Toxicology, NEUROFARBA Department, University of
      Florence, Florence, Italy.
FAU - Femia, Angelo Pietro
AU  - Femia AP
FAU - Raimondi, Laura
AU  - Raimondi L
FAU - Maglieri, Giulia
AU  - Maglieri G
FAU - Lodovici, Maura
AU  - Lodovici M
FAU - Mannucci, Edoardo
AU  - Mannucci E
FAU - Caderni, Giovanna
AU  - Caderni G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Int J Cancer
JT  - International journal of cancer. Journal international du cancer
JID - 0042124
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/02/18 [received]
PHST- 2013/04/26 [accepted]
AID - 10.1002/ijc.28260 [doi]
PST - aheadofprint
SO  - Int J Cancer. 2013 May 7. doi: 10.1002/ijc.28260.

PMID- 23649727
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 May 6
TI  - The Future of Diabetes Education: Expanded Opportunities and Roles for Diabetes
      Educators.
AB  - PurposeThe purpose of the article is to explore challenges and opportunities
      associated with the state of practice for diabetes education and diabetes
      educators.MethodsObservations, assumptions, predictions, and recommendations
      based on a literature review and the 2011 workforce study and workforce summit
      held by the American Association of Diabetes Educators (AADE) are
      presented.ResultsDemand for diabetes educators is projected to increase. The
      employer base will broaden beyond traditional outpatient venues and extend into
      industry, retail pharmacy clinics, and community-based organizations. Increasing 
      roles in management, quality assurance, and technology interface design are
      possible for diabetes educators. Challenges limiting diabetes education such as
      poor understanding of what diabetes educators do and underutilization of diabetes
      education continue to need redress.ConclusionsIncreasing utilization of diabetes 
      education and insight about health care trends can allow diabetes educators to
      thrive in the workplace of the future. Diabetes educators are urged to promote
      the evidence concerning the benefits of diabetes education, to work to increase
      physician referrals, and to acquire needed competencies for the workplace of the 
      future.
AD  - Lenzi Martin Communications, Inc, Chicago, Illinois (Ms Martin).
FAU - Martin, Annette Lenzi
AU  - Martin AL
FAU - Lipman, Ruth D
AU  - Lipman RD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 0145721713486526 [pii]
AID - 10.1177/0145721713486526 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 May 6.

PMID- 23649678
OWN - NLM
STAT- In-Process
DA  - 20130507
IS  - 0888-5109 (Print)
IS  - 0888-5109 (Linking)
VI  - 28
IP  - 5
DP  - 2013 May
TI  - Evaluation of type 2 diabetes mellitus medication management and control in older
      adults.
PG  - 296-306
LID - 10.4140/TCP.n.2013.296 [doi]
AB  - Objectives: The primary aims of this study were to characterize glycemic control 
      and pharmacologic management in older patients and to compare glycemic control
      and pharmacological management in patients 65 to 79 years of age ("young-old")
      with those 80 to 89 years of age ("old-old"). We hypothesized that patients 80 to
      89 years of age would be prescribed fewer medications and would have higher A1c
      values compared with younger patients. Design: Retrospective medical record
      review. Setting: This study was conducted in outpatient clinics within a
      university hospital setting. Patients, Participants: This study included 400
      adults 65 to 89 years of age with a diagnosis of type 2 diabetes mellitus and at 
      least one A1c measurement over 12 months. Main Outcome Measures: A1c measurements
      and diabetes mellitus medications were assessed in these patients. Results: The
      overall mean A1c was similar in the young-old compared with the old-old (7.1 +/- 
      1.1% vs. 7.0 +/- 1.1%; P = NS). There was no difference between groups for any of
      the A1c ranges studied. Fewer diabetes medications were prescribed in the old-old
      compared with the young-old (P = 0.003). In the young-old compared with the
      old-old, metformin (51.0% vs. 33.0%; P < 0.01), glucagon-like peptide-1 agonists 
      (6.7% vs. 0%; P < 0.01), insulin glargine/detemir (24.7% vs. 13.0%; P < 0.05),
      and short-acting insulin (15.0% vs. 7.0%; P < 0.05) were more frequently
      prescribed. Conclusion: Our results indicate that glycemic control was similar
      between the young-old and old-old. However, the old-old required fewer diabetic
      medications for this same level of glycemic control.
AD  - Department of Clinical Pharmacy, University of Colorado, Aurora, CO, USA.
FAU - Thompson, Angela
AU  - Thompson A
FAU - Vande Griend, Joseph P
AU  - Vande Griend JP
FAU - Linnebur, Sunny A
AU  - Linnebur SA
FAU - Saseen, Joseph J
AU  - Saseen JJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Consult Pharm
JT  - The Consultant pharmacist : the journal of the American Society of Consultant
      Pharmacists
JID - 9013983
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - LM77V21267V1J160 [pii]
AID - 10.4140/TCP.n.2013.296 [doi]
PST - ppublish
SO  - Consult Pharm. 2013 May;28(5):296-306. doi: 10.4140/TCP.n.2013.296.

PMID- 23649646
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1574-4647 (Electronic)
DP  - 2013 May 7
TI  - Late-life alcohol consumption and cognitive function in elderly men.
AB  - Moderate alcohol consumption (one to two drinks per day) has been associated with
      better cognitive function and lower risk of developing dementia in the elderly.
      In light of alcohol's well-known neurotoxic properties, more evidence from
      well-controlled population-based studies is required. The objective of this study
      was to examine whether self-reported alcohol intake at age 70 is linked to
      cognitive function (assessed by trail making tests (TMTs) A and B, which are
      measures of attention, mental speed, and flexibility) in a population-based
      cohort consisting of 652 cognitively healthy elderly men. Linear regression
      models were used to assess both cross-sectional (i.e., age 70) and prospective
      (i.e., age 77) associations between alcohol intake and cognitive function. The
      analyses were adjusted for education, body mass index, energy intake,
      self-reported physical activity, smoking, a history of hypertension or diabetes, 
      apolipoprotein E epsilon4 status, and cholesterol levels at the age of 70.
      Baseline data were obtained from 1990 to 1996. Self-reported alcohol intake (mean
      6.9 +/- 7.1 g/day) was associated with better performance on TMT-B at ages 70 and
      77 (beta = -0.87, p < 0.001). In contrast, alcohol intake was not predictive of
      the difference in performance on these tests between ages 70 and 77. Despite
      cross-sectional associations with performance in a test of executive functioning,
      moderate intake of alcohol was not linked to differences in cognitive performance
      between ages 70 and 77 in the present study. Thus, our findings do not support
      the view that daily moderate alcohol consumption is a recommendable strategy to
      slow cognitive aging in elderly populations.
AD  - Department of Neuroscience, Uppsala University, Box 593, 751 24, Uppsala, Sweden,
      pleunie.hogenkamp@neuro.uu.se.
FAU - Hogenkamp, Pleunie S
AU  - Hogenkamp PS
FAU - Benedict, Christian
AU  - Benedict C
FAU - Sjogren, Per
AU  - Sjogren P
FAU - Kilander, Lena
AU  - Kilander L
FAU - Lind, Lars
AU  - Lind L
FAU - Schioth, Helgi B
AU  - Schioth HB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Age (Dordr)
JT  - Age (Dordrecht, Netherlands)
JID - 101250497
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/02/12 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 10.1007/s11357-013-9538-7 [doi]
PST - aheadofprint
SO  - Age (Dordr). 2013 May 7.

PMID- 23649617
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 6
TI  - A Novel Use of Structural Equation Models to Examine Factors Associated With
      Prediabetes Among Adults Aged 50 Years and Older: National Health and Nutrition
      Examination Survey 2001-2006.
AB  - OBJECTIVETo use structural modeling to test a hypothesized model of causal
      pathways related with prediabetes among older adults in the U.S.RESEARCH DESIGN
      AND METHODSCross-sectional study of 2,230 older adults (>/=50 years) without
      diabetes included in the morning fasting sample of the 2001-2006 National Health 
      and Nutrition Examination Surveys. Demographic data included age, income, marital
      status, race/ethnicity, and education. Behavioral data included physical activity
      (metabolic equivalent hours per week for vigorous, moderate,
      muscle-strengthening, walking/biking, and house/yard work), and poor diet
      (refined grains, red meat, added sugars, solid fats, and high-fat dairy).
      Structural-equation modeling was performed to examine the interrelationships
      among these variables with family history of diabetes, high blood pressure, BMI, 
      large waist (waist circumference: women, >/=35 inches; men, >/=40 inches),
      triglycerides >/=200 mg/dL, and total- and HDL (>/=60 mg/dL)
      cholesterol.RESULTSAfter dropping BMI and total cholesterol, our best-fit model
      included three single factors: socioeconomic position (SEP), physical activity,
      and poor diet. Large waist had the strongest direct effect on prediabetes
      (0.279), followed by male sex (0.270), SEP (-0.157), high blood pressure (0.122),
      family history of diabetes (0.070), and age (0.033). Physical activity had direct
      effects on HDL (0.137), triglycerides (-0.136), high blood pressure (-0.132), and
      large waist (-0.067); poor diet had direct effects on large waist (0.146) and
      triglycerides (0.148).CONCLUSIONSOur results confirmed that, while including
      factors known to be associated with high risk of developing prediabetes, large
      waist circumference had the strongest direct effect. The direct effect of SEP on 
      prediabetes suggests mediation by some unmeasured factor(s).
AD  - Division of Diabetes Translation, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta,
      Georgia.
FAU - Bardenheier, Barbara H
AU  - Bardenheier BH
FAU - Bullard, Kai McKeever
AU  - Bullard KM
FAU - Caspersen, Carl J
AU  - Caspersen CJ
FAU - Cheng, Yiling J
AU  - Cheng YJ
FAU - Gregg, Edward W
AU  - Gregg EW
FAU - Geiss, Linda S
AU  - Geiss LS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - dc12-2608 [pii]
AID - 10.2337/dc12-2608 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 6.

PMID- 23649600
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1614-7499 (Electronic)
IS  - 0944-1344 (Linking)
DP  - 2013 May 7
TI  - Prolonged environmental exposure of arsenic through drinking water on the risk of
      hypertension and type 2 diabetes.
AB  - Prolonged exposure to inorganic arsenic has been a severe environmental public
      health issue worldwide in the recent decades. Increasing evidence has suggested a
      possible role of prolonged arsenic exposure through drinking water in the
      development of arsenic-induced chronic noncancer diseases, among which
      hypertension and type 2 diabetes (T2D) are the focus of concern. Although
      exposure to high levels of arsenic has been reported to be associated with excess
      risk of hypertension or T2D in a dose-dependent manner, the association has yet
      to be established, especially low-level exposure. This cross-sectional study was 
      designed to evaluate the potential association between prolonged environmental
      arsenic exposure through drinking water and the prevalence of hypertension and
      T2D in Inner Mongolia, China, with emphasis on the assessment of low-level
      exposure. In this study (a total of 669 men and women), we found that the blood
      pressure levels were significantly correlated with cumulative arsenic exposure
      and that the systolic blood pressure of the subjects with arsenic exposure >50
      mug/L was significantly higher than those of the subjects with <10 and 10-50
      mug/L exposure. Significant prevalence of hypertension was found in the subjects 
      of the >50 mug/L group both before and after adjustment for confounders. In
      addition, a significant negative relationship was found between urinary arsenic
      percentage of dimethylated arsenic (DMA%) and the prevalence of hypertension in
      the >50 mug/L group. However, low-level arsenic exposure (10-50 mug/L) was not
      statistically associated with hypertension. No significant difference of blood
      glucose was found among the groups with different arsenic exposure levels. No
      statistical association was found between arsenic exposure and T2D. Our findings 
      suggested that prolonged arsenic exposure might play a role in the development of
      hypertension; however, only high-level arsenic was associated with the risk of
      hypertension. Our findings also indicated that lower DMA% might be related with
      the increased susceptibility of arsenic-induced hypertension.
AD  - Department of Environmental and Occupational Health, School of Public Health,
      China Medical University, No. 92 Bei Er Road, Heping District, Shenyang, Liaoning
      Province, 110001, China.
FAU - Li, Xin
AU  - Li X
FAU - Li, Bing
AU  - Li B
FAU - Xi, Shuhua
AU  - Xi S
FAU - Zheng, Quanmei
AU  - Zheng Q
FAU - Lv, Xiuqiang
AU  - Lv X
FAU - Sun, Guifan
AU  - Sun G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Environ Sci Pollut Res Int
JT  - Environmental science and pollution research international
JID - 9441769
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/12/21 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 10.1007/s11356-013-1768-9 [doi]
PST - aheadofprint
SO  - Environ Sci Pollut Res Int. 2013 May 7.

PMID- 23649542
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1469-896X (Electronic)
IS  - 0961-8368 (Linking)
DP  - 2013 May 4
TI  - A Common landscape for membrane-active peptides.
LID - 10.1002/pro.2274 [doi]
AB  - Three families of membrane-active peptides are commonly found in nature, and are 
      classified according to their initial apparent activity. Antimicrobial peptides
      are ancient components of the innate immune system and typically act by
      disruption of microbial membranes leading to cell death. Amyloid peptides
      contribute to the pathology of diverse diseases from Alzheimer's to type II
      diabetes. Pre-amyloid states of these peptides can act as toxins by binding to
      and permeabilizing cellular membranes. Cell-penetrating peptides are natural or
      engineered short sequences that can spontaneously translocate across a membrane. 
      Despite these differences in classification, many similarities in sequence,
      structure, and activity suggest that peptides from all three classes act through 
      a small, common set of physical principles. Namely, these peptides alter the
      Brownian properties of phospholipid bilayers, enhancing the sampling of intrinsic
      fluctuations that include membrane defects. A complete energy landscape for such 
      systems can be described by the innate membrane properties, differential
      partition, and the associated kinetics of peptides dividing between surface and
      defect regions of the bilayer. The goal of this review is to argue that the
      activities of these membrane-active families of peptides simply represent
      different facets of what is a shared energy landscape.
CI  - Copyright (c) 2013 The Protein Society.
AD  - Department of Molecular Biophysics and Biochemistry, Yale University, 260 Whitney
      Avenue, New Haven, Connecticut, 06520-8114.
FAU - Last, Nicholas B
AU  - Last NB
FAU - Schlamadinger, Diana E
AU  - Schlamadinger DE
FAU - Miranker, Andrew D
AU  - Miranker AD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Protein Sci
JT  - Protein science : a publication of the Protein Society
JID - 9211750
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/04/10 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/04/24 [accepted]
AID - 10.1002/pro.2274 [doi]
PST - aheadofprint
SO  - Protein Sci. 2013 May 4. doi: 10.1002/pro.2274.

PMID- 23649520
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 6
TI  - The exaggerated glucagon-like peptide-1 response is important for the improved
      beta-cell function and glucose tolerance after Roux-en-Y gastric bypass in
      patients with type 2 diabetes.
AB  - beta-cell function is improved in patients with type 2 diabetes in response to an
      oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery. This has
      been linked to an exaggerated glucagon-like peptide 1 (GLP-1) secretion, but
      causality has not been established. The aim of this study was to investigate the 
      role of GLP-1 in improving beta-cell function and glucose tolerance and in
      regulating glucagon release after RYGB, using the GLP-1 receptor
      (GLP-1R)-specific antagonist, Exendin(9-39) (Ex-9). Nine patients with type 2
      diabetes, were examined before, 1 week and 3 months after surgery. Each visit
      consisted of two experimental days, allowing a meal test with infusion of saline 
      or Ex-9 in random order. After RYGB, glucose tolerance improved, beta-cell
      glucose sensitivity (beta-GS) doubled, the GLP-1 response greatly increased and
      glucagon secretion was augmented. GLP-1R blockade did not affect beta-cell
      function and meal-induced glucagon release before the operation, but did impair
      glucose tolerance. After RYGB, beta-GS decreased to preoperative levels, glucagon
      secretion increased and glucose tolerance was impaired by Ex-9 infusion. Thus,
      the exaggerated effect of GLP-1 after RYGB is of major importance for the
      improvement in beta-cell function, and the controlof glucagon release and glucose
      tolerance in patients with type 2 diabetes. ClinicalTrials.gov (NCT01579981).
AD  - Dept. of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark.
FAU - Jorgensen, Nils B
AU  - Jorgensen NB
FAU - Dirksen, Carsten
AU  - Dirksen C
FAU - Bojsen-Moller, Kirstine N
AU  - Bojsen-Moller KN
FAU - Jacobsen, Siv H
AU  - Jacobsen SH
FAU - Worm, Dorte
AU  - Worm D
FAU - Hansen, Dorte L
AU  - Hansen DL
FAU - Kristiansen, Viggo B
AU  - Kristiansen VB
FAU - Naver, Lars
AU  - Naver L
FAU - Madsbad, Sten
AU  - Madsbad S
FAU - Holst, Jens J
AU  - Holst JJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - db13-0022 [pii]
AID - 10.2337/db13-0022 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 6.

PMID- 23649519
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 6
TI  - Tetrahydrobiopterin has a glucose-lowering effect by suppressing hepatic
      gluconeogenesis in an endothelial nitric oxide synthase-dependent manner in
      diabetic mice.
AB  - Endothelial nitric oxide synthase (eNOS) dysfunction induces insulin resistance
      and glucose intolerance. Tetrahydrobiopterin (BH4) is an essential co-factor of
      eNOS that regulates eNOS activity. In the diabetic state, BH4 is oxidized to 7,
      8-dihydrobiopterin, which leads to eNOS dysfunction due to eNOS uncoupling. The
      present study investigates the effects of BH4 on glucose metabolism and insulin
      sensitivity in diabetic mice. Single administration of BH4 lowered fasting blood 
      glucose levels in streptozotocin (STZ)-induced diabetic wild-type mice, and
      alleviated eNOS dysfunction by increasing eNOS dimerization in the liver of these
      mice. Liver has a critical role in glucose-lowering effects of BH4 through
      suppression of hepatic gluconeogenesis. BH4 activated AMP kinase (AMPK) and the
      suppressing effect of BH4 on gluconeogenesis was AMPK-dependent. In addition, the
      glucose-lowering effect and activation of AMPK by BH4 did not appear in
      STZ-induced diabetic mice lacking eNOS. Consecutive administration of BH4 in
      ob/ob mice ameliorated glucose intolerance and insulin resistance. Taken
      together, BH4 suppresses hepatic gluconeogenesis in an eNOS-dependent manner, and
      BH4 has a glucose-lowering effect as well as an insulin sensitizing effect in
      diabetic mice. BH4 has a potential in the treatment of type 2 diabetes.
AD  - Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto
      University, Kyoto, Japan.
FAU - Abudukadier, Abulizi
AU  - Abudukadier A
FAU - Fujita, Yoshihito
AU  - Fujita Y
FAU - Obara, Akio
AU  - Obara A
FAU - Ohashi, Akiko
AU  - Ohashi A
FAU - Fukushima, Toru
AU  - Fukushima T
FAU - Sato, Yuichi
AU  - Sato Y
FAU - Ogura, Masahito
AU  - Ogura M
FAU - Nakamura, Yasuhiko
AU  - Nakamura Y
FAU - Fujimoto, Shimpei
AU  - Fujimoto S
FAU - Hosokawa, Masaya
AU  - Hosokawa M
FAU - Hasegawa, Hiroyuki
AU  - Hasegawa H
FAU - Inagaki, Nobuya
AU  - Inagaki N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - db12-1242 [pii]
AID - 10.2337/db12-1242 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 6.

PMID- 23649518
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 May 6
TI  - Transforming Growth Factor-beta induced cross talk between p53 and a microRNA in 
      the pathogenesis of Diabetic Nephropathy.
AB  - Elevated p53 expression is associated with several kidney diseases including
      diabetic nephropathy (DN). However the mechanisms are unclear. We report that
      expression levels of transforming growth factor-beta1 (TGF-beta), p53 and
      microRNA-192 (miR-192), are increased in the renal cortex of diabetic mice, and
      this is associated with enhanced glomerular expansion and fibrosis relative to
      non-diabetic mice. Targeting miR-192 with locked-nucleic-acid modified inhibitors
      (LNA-192) in vivo decreases expression of p53 in the renal cortex of control and 
      streptozotocin injected diabetic mice. Furthermore, mice with genetic deletion of
      miR-192 in vivo display attenuated renal cortical TGF-beta and p53 expression
      when made diabetic, and reduced renal fibrosis, hypertrophy, proteinuria and
      albuminuria relative to diabetic wild-type mice. In vitro promoter regulation
      studies show that TGF-beta induces reciprocal activation of miR-192 and p53, via 
      the miR-192 target Zeb2, leading to augmentation of downstream events related to 
      DN. Inverse correlation between miR-192 and Zeb2 was observed in glomeruli of
      human subjects with early DN consistent with the mechanism seen in mice. Our
      results demonstrate for the first time a TGF-beta-induced feedback amplification 
      circuit between p53 and miR-192 related to the pathogenesis of DN, and that
      miR-192-knockout mice are protected from key features of DN.
AD  - Irell & Manella Graduate School of Biological Sciences.
FAU - Deshpande, Supriya D
AU  - Deshpande SD
FAU - Putta, Sumanth
AU  - Putta S
FAU - Wang, Mei
AU  - Wang M
FAU - Lai, Jennifer Y
AU  - Lai JY
FAU - Bitzer, Markus
AU  - Bitzer M
FAU - Nelson, Robert G
AU  - Nelson RG
FAU - Lanting, Linda L
AU  - Lanting LL
FAU - Kato, Mitsuo
AU  - Kato M
FAU - Natarajan, Rama
AU  - Natarajan R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - db13-0305 [pii]
AID - 10.2337/db13-0305 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 May 6.

PMID- 23649484
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
DP  - 2013 May 7
TI  - Overview of vasculitis and vasculopathy in rheumatoid arthritis-something to
      think about.
AB  - The vasculature plays a crucial role in inflammation and atherosclerosis
      associated with the pathogenesis of rheumatoid arthritis. Vasculitis in
      rheumatoid arthritis is associated with longstanding disease, has an important
      impact on a patient's quality of life and influences patient life expectancy.
      Seropositivity, specific human leukocyte antigen variations, antibodies to cyclic
      citrullinated peptides, and cigarette smoking are among the genetic and
      environmental predictors of rheumatoid vasculitis. Atherosclerosis is an early
      and common finding in rheumatoid arthritis and it correlates with disease
      duration, activity, and severity. Apart from conventional risk factors such as
      cigarette smoking, physical inactivity, obesity, arterial hypertension,
      dyslipidemia and diabetes mellitus, rheumatoid arthritis-related risk factors
      including disease duration, severity and activity, rheumatoid factor and
      antibodies to cyclic citrullinated peptides status, functional impairment,
      C-reactive protein, radiographic changes, presence of the shared epitope, and
      treatment modalities are all implicated in the development of accelerated
      atherosclerosis. Atherosclerosis is also considered an inflammatory disease;
      thus, it may share common pathogenic mechanisms with rheumatic diseases such as
      rheumatoid arthritis. Advances in treatment of rheumatoid arthritis with
      disease-modifying biologic and nonbiologic agents will probably continue to
      reduce the incidence of vasculitis. Since the goal of treatment for rheumatoid
      arthritis is to decrease inflammatory burden, successful treatment may
      theoretically reduce the risk of accelerated atherosclerosis.
AD  - Division of Rheumatology and Clinical Immunology, University of Split School of
      Medicine, University Hospital Centre Split, Sizgoriceva 20/II, 21 000, Split,
      Croatia, mislavradic@gmail.com.
FAU - Radic, Mislav
AU  - Radic M
FAU - Kaliterna, Dusanka Martinovic
AU  - Kaliterna DM
FAU - Radic, Josipa
AU  - Radic J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/03/19 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 10.1007/s10067-013-2273-8 [doi]
PST - aheadofprint
SO  - Clin Rheumatol. 2013 May 7.

PMID- 23649482
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
DP  - 2013 May 7
TI  - Treatment of rheumatoid arthritis with methotrexate in Congolese patients.
AB  - Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis
      (RA) but data concerning the effectiveness of treatment with this compound are
      lacking in the Congolese population. In the present study, the evolution of RA in
      Congolese patients on MTX treatment is reported from before disease-modifying
      antirheumatic drug (DMARD) initiation till 20 months later. All consecutive
      DMARD-naive RA patients (ACR 1987 criteria) attending the rheumatology unit of
      the University Hospital of Kinshasa from January 2008 to September 2010 were
      included. All were treated with MTX (started at 7.5 mg/week) and bridging
      steroids (started at 30mg/day). Treatment adaptations of MTX and concomitant
      drugs are reported as well as evolution of disease activity (DAS28-ESR),
      functionality (Health Assessment Questionnaire), radiological damage, and safety 
      over 20 months. Of 98 patients recruited, more than one third were lost at
      follow-up. A follow-up visit at 20 months was available for 51 patients. These 48
      women and 3 men had a mean age of 51.2 +/- 13 years and a mean delay from symptom
      onset till their first visit of 3.2 years. At 20 months, the average MTX dose was
      9.7 mg weekly. A second DMARD was added in three patients. The average dose of
      prednisone at 20 months was 7.5 mg daily. A significant improvement of DAS28 and 
      functional disability was observed and 35.3 % of patients entered remission
      (DAS28 <2.6). A progression of X-ray damage was observed in one third of
      patients. Two patients had to stop MTX because of severe side effects and two
      patients developed diabetes. Methotrexate and bridging steroids therapy is
      effective also in sub-Saharan Africa but the average weekly MTX dose remains low.
      Implementation of a regular follow-up is a major issue.
AD  - Unit of Rheumatology, Department of Internal Medicine, University Hospital of
      Kinshasa, Kinshasa, Democratic Republic of the Congo.
FAU - Malemba, J J
AU  - Malemba JJ
FAU - Mbuyi Muamba, J M
AU  - Mbuyi Muamba JM
FAU - Mukaya, J
AU  - Mukaya J
FAU - Bossuyt, X
AU  - Bossuyt X
FAU - Verschueren, P
AU  - Verschueren P
FAU - Westhovens, R
AU  - Westhovens R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/11/13 [received]
PHST- 2013/04/18 [accepted]
PHST- 2013/03/27 [revised]
PHST- 2013/05/07 [aheadofprint]
AID - 10.1007/s10067-013-2269-4 [doi]
PST - aheadofprint
SO  - Clin Rheumatol. 2013 May 7.

PMID- 23649472
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 May 7
TI  - The melanocortin system and insulin resistance in humans: insights from a patient
      with complete POMC deficiency and type 1 diabetes mellitus.
LID - 10.1038/ijo.2013.53 [doi]
AB  - The central melanocortin system is essential for the regulation of long-term
      energy homeostasis in humans. Rodent experiments suggest that this system also
      affects glucose metabolism, in particular by modulating peripheral insulin
      sensitivity independently of its effect on adiposity. Rare patients with complete
      genetic defects in the central melanocortin system can provide insight into the
      role of this system in glucose homeostasis in humans. We here describe the eighth
      individual with complete proopiomelanocortin (POMC) deficiency and the first with
      coincidental concomitant type 1 diabetes, which provides a unique opportunity to 
      determine the role of melanocortins in glucose homeostasis in human. Direct
      sequencing of the POMC gene in this severely obese patient with isolated
      adrenocorticotropic hormone deficiency identified a homozygous 5' untranslated
      region mutation -11C>A, which we find to abolish normal POMC protein synthesis,
      as assessed in vitro. The patient's insulin requirements were as expected for his
      age and pubertal development. This unique patient suggests that in humans the
      central melanocortin system does not seem to affect peripheral insulin
      sensitivity, independently of its effect on adiposity.International Journal of
      Obesity advance online publication, 7 May 2013; doi:10.1038/ijo.2013.53.
AD  - Children's Hospital Oakland & Research Center Institute, San Francisco, CA, USA.
FAU - Aslan, I R
AU  - Aslan IR
FAU - Ranadive, S A
AU  - Ranadive SA
FAU - Valle, I
AU  - Valle I
FAU - Kollipara, S
AU  - Kollipara S
FAU - Noble, J A
AU  - Noble JA
FAU - Vaisse, C
AU  - Vaisse C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/07 [aheadofprint]
AID - ijo201353 [pii]
AID - 10.1038/ijo.2013.53 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 May 7. doi: 10.1038/ijo.2013.53.

PMID- 23649413
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1488-2329 (Electronic)
IS  - 0820-3946 (Linking)
VI  - 185
IP  - 9
DP  - 2013 Jun 11
TI  - Prevalence estimates of chronic kidney disease in Canada: results of a nationally
      representative survey.
PG  - E417-23
LID - 10.1503/cmaj.120833 [doi]
AB  - BACKGROUND: Chronic kidney disease is an important risk factor for death and
      cardiovascular-related morbidity, but estimates to date of its prevalence in
      Canada have generally been extrapolated from the prevalence of end-stage renal
      disease. We used direct measures of kidney function collected from a nationally
      representative survey population to estimate the prevalence of chronic kidney
      disease among Canadian adults. METHODS: We examined data for 3689 adult
      participants of cycle 1 of the Canadian Health Measures Survey (2007-2009) for
      the presence of chronic kidney disease. We also calculated the age-standardized
      prevalence of cardiovascular risk factors by chronic kidney disease group. We
      cross-tabulated the estimated glomerular filtration rate (eGFR) with albuminuria 
      status. RESULTS: The prevalence of chronic kidney disease during the period
      2007-2009 was 12.5%, representing about 3 million Canadian adults. The estimated 
      prevalence of stage 3-5 disease was 3.1% (0.73 million adults) and albuminuria
      10.3% (2.4 million adults). The prevalence of diabetes, hypertension and
      hypertriglyceridemia were all significantly higher among adults with chronic
      kidney disease than among those without it. The prevalence of albuminuria was
      high, even among those whose eGFR was 90 mL/min per 1.73 m(2) or greater (10.1%) 
      and those without diabetes or hypertension (9.3%). Awareness of kidney
      dysfunction among adults with stage 3-5 chronic kidney disease was low (12.0%).
      INTERPRETATION: The prevalence of kidney dysfunction was substantial in the
      survey population, including individuals without hypertension or diabetes,
      conditions most likely to prompt screening for kidney dysfunction. These findings
      highlight the potential for missed opportunities for early intervention and
      secondary prevention of chronic kidney disease.
FAU - Arora, Paul
AU  - Arora P
FAU - Vasa, Priya
AU  - Vasa P
FAU - Brenner, Darren
AU  - Brenner D
FAU - Iglar, Karl
AU  - Iglar K
FAU - McFarlane, Phil
AU  - McFarlane P
FAU - Morrison, Howard
AU  - Morrison H
FAU - Badawi, Alaa
AU  - Badawi A
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - Canada
TA  - CMAJ
JT  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale
      canadienne
JID - 9711805
SB  - AIM
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/06 [aheadofprint]
AID - cmaj.120833 [pii]
AID - 10.1503/cmaj.120833 [doi]
PST - ppublish
SO  - CMAJ. 2013 Jun 11;185(9):E417-23. doi: 10.1503/cmaj.120833. Epub 2013 May 6.

PMID- 23649376
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 58
IP  - 5
DP  - 2013 May
TI  - Trying to prevent the clogged drain: optimizing the yield and function of portal 
      vein-infused islets.
PG  - 1170-2
LID - 10.1007/s10620-013-2682-1 [doi]
AD  - Department of Surgery, Schulze Diabetes Institute, University of Minnesota,
      Minneapolis, MN, USA.
FAU - Balamurugan, A N
AU  - Balamurugan AN
FAU - Pruett, Timothy L
AU  - Pruett TL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
SB  - AIM
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1007/s10620-013-2682-1 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2013 May;58(5):1170-2. doi: 10.1007/s10620-013-2682-1.

PMID- 23649262
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1347-6947 (Electronic)
IS  - 0916-8451 (Linking)
VI  - 77
IP  - 5
DP  - 2013 May 23
TI  - Studies Targeting alpha-Glucosidase Inhibition, Antiangiogenic Effects, and Lipid
      Modification Regulation: Background, Evaluation, and Challenges in the
      Development of Food Ingredients for Therapeutic Purposes.
PG  - 900-8
AB  - Since the discovery of alpha-glucosidase inhibitors and their inhibitory effects 
      on the digestion of carbohydrates, promising results have been obtained as to the
      antidiabetic effects of this family of compounds. Antiangiogenic compounds have
      been identified that suppress tumor growth via a unique mechanism, confirming
      that such compounds can act as clinically applicable anticancer agents. Lipid
      peroxidation and lipid glycation have been suggested to play roles in food
      deterioration and in the pathophysiology of human diseases such as atherogenesis 
      and diabetes, and antioxidative and antiglycative compounds can potentially be
      used in the prevention of food deterioration as well as to treat disease. On this
      basis, this review describes studies of alpha-glucosidase inhibition by mulberry 
      1-deoxynojirimycin, antiangiogenic effects of rice bran tocotrienol, and membrane
      lipid peroxidation/glycation and its inhibitors. These studies are ongoing in our
      work, with an emphasis on analytical techniques.
AD  - Food and Biodynamic Chemistry Laboratory, Graduate School of Agricultural
      Science, Tohoku University.
FAU - Nakagawa, Kiyotaka
AU  - Nakagawa K
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - Japan
TA  - Biosci Biotechnol Biochem
JT  - Bioscience, biotechnology, and biochemistry
JID - 9205717
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/07 [aheadofprint]
AID - DN/JST.JSTAGE/bbb/120908 [pii]
PST - ppublish
SO  - Biosci Biotechnol Biochem. 2013 May 23;77(5):900-8. Epub 2013 May 7.

PMID- 23649224
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1528-1132 (Electronic)
IS  - 0009-921X (Linking)
DP  - 2013 May 7
TI  - Veterans With Diabetes Receive Arthroplasty More Frequently and at a Younger Age.
AB  - BACKGROUND: A future increase in total joint arthroplasties in patients with
      diabetes seems likely considering the prevalence of osteoarthritis and diabetes
      mellitus are increasing. However, the rates of arthroplasty in the population of 
      patients with diabetes are unclear. QUESTIONS/PURPOSES: We sought to determine
      whether lower extremity arthroplasties in a veteran population with diabetes is
      different from a similar population without diabetes. The following specific
      questions were asked: (1) Is the rate of TKA in veterans with diabetes higher
      than in those without diabetes? (2) Is the rate of THA in veterans with diabetes 
      higher than in those without diabetes? (3) Are arthroplasty revision rates
      greater in veterans with diabetes than in veterans without diabetes? METHODS: The
      US Department of Veterans Affairs Health administrative data from fiscal year
      2000 was used to identify persons with primary or secondary TKA or THA. The rate 
      of surgeries among a diabetic population was compared with that among a
      nondiabetic population. RESULTS: The diabetic cohort received total joint
      arthroplasties at a higher rate than the nondiabetic cohort at all ages younger
      than 66 years, with a range of odd ratios from 1.3 to 3.4. In answer to our
      specific questions, (1) the rate of TKA (95% CI, 2.1-3.7), (2) the rate of THA
      (95% CI, 1.0-2.6), and (3) the rates of arthroplasty revision (95% CI, 0.9-5.8
      TKA and 0.7-6.8 THA) were higher in veterans with diabetes. Furthermore, those
      with diabetes in the youngest age group studied received total joint
      arthroplasties and revision surgeries at approximately double the rates of those 
      without diabetes. CONCLUSIONS: If these findings hold true for the population as 
      a whole, they imply that clinicians in the United States may see a sharp increase
      in younger diabetic candidates for joint arthroplasty. LEVEL OF EVIDENCE: Level
      III, prognostic study. See Guidelines for Authors for a complete description of
      levels of evidence.
AD  - Department of Orthopaedics, University of Colorado Denver, 12800 E 19th Avenue,
      RC1 North, Room 2103, Aurora, CO, 80045, USA, karen.king@ucdenver.edu.
FAU - King, Karen B
AU  - King KB
FAU - Findley, Thomas W
AU  - Findley TW
FAU - Williams, Allison E
AU  - Williams AE
FAU - Bucknell, Allan L
AU  - Bucknell AL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Clin Orthop Relat Res
JT  - Clinical orthopaedics and related research
JID - 0075674
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/12/20 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 10.1007/s11999-013-3026-3 [doi]
PST - aheadofprint
SO  - Clin Orthop Relat Res. 2013 May 7.

PMID- 23649017
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-507X (Electronic)
IS  - 1759-5061 (Linking)
DP  - 2013 May 7
TI  - Diabetes: Pre-eclampsia: association with increased risk of diabetes.
LID - 10.1038/nrneph.2013.96 [doi]
FAU - Allison, Susan J
AU  - Allison SJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Nat Rev Nephrol
JT  - Nature reviews. Nephrology
JID - 101500081
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/07 [aheadofprint]
AID - nrneph.2013.96 [pii]
AID - 10.1038/nrneph.2013.96 [doi]
PST - aheadofprint
SO  - Nat Rev Nephrol. 2013 May 7. doi: 10.1038/nrneph.2013.96.

PMID- 23648893
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1938-2022 (Electronic)
VI  - 5
IP  - 2
DP  - 2013 Mar 1
TI  - Antigen-based vs. systemic immunomodulation in type 1 diabetes: The pros and
      cons.
AB  - In type 1 diabetic patients insulin-producing pancreatic beta-cells are destroyed
      by an orchestrated immune process involving self-reactive auto-antigen-specific
      CD4 (+) and CD8 (+) T cells. Efforts to reverse or prevent this destructive
      immunological cascade have led to promising results in animal models, however,
      the transition to the clinic has yet been unsuccessful. In addition, current
      clinical studies lack reliable biomarkers to circumscribe end-point parameters
      and define therapeutic success. Here, we give a current overview of both
      antigen-specific and non-specific systemic immunomodulatory approaches with a
      focus on the therapies verified or under evaluation in a clinical setting. While 
      both approaches have their advantages and disadvantages, rationally designed
      combination therapies may yield the highest therapeutic efficacy. In order for
      future strategies to be effective, new well-defined biomarkers need to be
      developed and the extrapolation process of dose, timing and frequency from in
      vivo models to patients needs to be carefully reconsidered.
AD  - Clinical and Experimental Endocrinology; Katholieke Universiteit Leuven; Campus
      Gasthuisberg; Leuven, Belgium.
FAU - Robert, Sofie
AU  - Robert S
FAU - Korf, Hannelie
AU  - Korf H
FAU - Gysemans, Conny
AU  - Gysemans C
FAU - Mathieu, Chantal
AU  - Mathieu C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130301
TA  - Islets
JT  - Islets
JID - 101495366
OTO - NOTNLM
OT  - Ag-specific
OT  - clinical trial
OT  - combination therapy
OT  - patient
OT  - systemic
OT  - therapy
OT  - type 1 diabetes
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 24785 [pii]
PST - aheadofprint
SO  - Islets. 2013 Mar 1;5(2).

PMID- 23648871
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 May 7
TI  - Diabetes: Betatrophin-inducing beta-cell expansion to treat diabetes mellitus?
LID - 10.1038/nrendo.2013.98 [doi]
FAU - Kugelberg, Elisabeth
AU  - Kugelberg E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/07 [aheadofprint]
AID - nrendo.2013.98 [pii]
AID - 10.1038/nrendo.2013.98 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 May 7. doi: 10.1038/nrendo.2013.98.

PMID- 23648804
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Linking)
DP  - 2013 May 5
TI  - Regional and Neighborhood Disparities in the Odds of Type 2 Diabetes: Results
      From 5 Population-Based Studies in Germany (DIAB-CORE Consortium).
AB  - The objective of this study was to investigate the association between
      residential environment and type 2 diabetes. We pooled cross-sectional data from 
      5 population-based German studies (1997-2006): the Cardiovascular Disease, Living
      and Ageing in Halle Study, the Dortmund Health Study, the Heinz Nixdorf Recall
      Study, the Cooperative Health Research in the Region of Augsburg Study, and the
      Study of Health in Pomerania. The outcome of interest was the presence of
      self-reported type 2 diabetes. We conducted mixed logistic regression models in a
      hierarchical data set with 8,879 individuals aged 45-74 years on level 1; 226
      neighborhoods on level 2; and 5 study regions on level 3. The analyses were
      adjusted for age, sex, social class, and employment status. The odds ratio for
      type 2 diabetes was highest in eastern Germany (odds ratio = 1.98, 95% confidence
      interval: 1.81, 2.14) and northeastern Germany (odds ratio = 1.58, 95% confidence
      interval: 1.40, 1.77) and lowest in southern Germany (reference) after adjustment
      for individual variables. Neighborhood unemployment rates explained a large
      proportion of regional differences. Individuals residing in neighborhoods with
      high unemployment rates had elevated odds of type 2 diabetes (odds ratio = 1.62, 
      95% confidence interval: 1.25, 2.09). The diverging levels of unemployment in
      neighborhoods and regions are an independent source of disparities in type 2
      diabetes.
FAU - Muller, Grit
AU  - Muller G
FAU - Kluttig, Alexander
AU  - Kluttig A
FAU - Greiser, Karin Halina
AU  - Greiser KH
FAU - Moebus, Susanne
AU  - Moebus S
FAU - Slomiany, Uta
AU  - Slomiany U
FAU - Schipf, Sabine
AU  - Schipf S
FAU - Volzke, Henry
AU  - Volzke H
FAU - Maier, Werner
AU  - Maier W
FAU - Meisinger, Christa
AU  - Meisinger C
FAU - Tamayo, Teresa
AU  - Tamayo T
FAU - Rathmann, Wolfgang
AU  - Rathmann W
FAU - Berger, Klaus
AU  - Berger K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130505
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
OTO - NOTNLM
OT  - diabetes mellitus
OT  - lifestyle
OT  - multilevel analysis
OT  - residence characteristics
OT  - socioeconomic factors
OT  - type 2 diabetes
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - kws466 [pii]
AID - 10.1093/aje/kws466 [doi]
PST - aheadofprint
SO  - Am J Epidemiol. 2013 May 5.

PMID- 23648800
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1897-9483 (Electronic)
IS  - 0032-3772 (Linking)
DP  - 2013 Apr 12
TI  - Advanced glycation end products and cathepsin cysteine protease in type 2
      diabetic patients.
LID - AOP_13_017 [pii]
AB  - INTRODUCTION In type 2 diabetes (T2D) chronic hyperglycemia induces multi-faceted
      disturbances and development of diabetic late complications (DLC). Nonenzymatic
      glycation, leading to advanced glycation end products (AGEs) formation, is one of
      the most important consequence of hyperglycemia. Disturbances in action of some
      proteolytic enzymes are also observed. OBJECTIVES The aim of the study was to
      evaluate and check reciprocal dependence of plasma levels of different forms of
      AGEs and cathepsin B (CB) cysteine protease activity in plasma and neutrophils
      derived from patients with T2D as well as estimate of their relation with DLC.
      PATIENTS AND METHODS In the 102 patients with T2D and 55 healthy adults, plasma
      levels of total, low and high molecular weight AGEs (T-AGEs, LMW-AGEs and
      HMW-AGEs, respectively) and CB activity in plasma and neutrophils were measured
      (by fluorescence methods), simultaneously in the same subjects. RESULTS T2D
      patients had significantly higher levels and activities of all examined
      parameters than control group. In diabetic patients HMW-AGEs correlated
      negatively with plasma CB and LMW-AGEs with neutrophil CB. In quartiles of
      increasing levels of HMW-AGEs and LMW-AGEs, successive decrease of plasma and
      neutrophils CB, respectively were observed. In groups with different DLC only
      plasma level of LMW-AGEs was significantly differ. CONCLUSIONS Our study, showing
      significant increase of all forms of AGEs connected with corresponding changes of
      CB activity, both in plasma and neutrophils, as well as their significant
      reciprocal relationship and ambiguous changes in groups with DLC, indicates on
      the quite complicated nature of their reciprocal influence in T2D patients.
FAU - Grzebyk, Ewa
AU  - Grzebyk E
FAU - Knapik-Kordecka, Maria
AU  - Knapik-Kordecka M
FAU - Piwowar, Agnieszka
AU  - Piwowar A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Pol Arch Med Wewn
JT  - Polskie Archiwum Medycyny Wewnetrznej
JID - 0401225
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/04/12 [aheadofprint]
AID - AOP_13_017 [pii]
PST - aheadofprint
SO  - Pol Arch Med Wewn. 2013 Apr 12. pii: AOP_13_017.

PMID- 23648791
OWN - NLM
STAT- Publisher
DA  - 20130509
IS  - 1536-4801 (Electronic)
IS  - 0277-2116 (Linking)
DP  - 2013 May 5
TI  - Diabetes in Microvillus Inclusion Disease.
AD  - *Division of Pediatric Endocrinology and Diabetes, Phoenix Children's Hospital,
      Phoenix, AZ daggerDivision of Pediatric Gastroenterology, Hepatology and
      Nutrition, Phoenix Children's Hospital, Phoenix, AZ.
FAU - Oatman, Oliver
AU  - Oatman O
FAU - Djedjos, Constantine
AU  - Djedjos C
FAU - Olson, Micah
AU  - Olson M
FAU - Shub, Mitchell
AU  - Shub M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130505
TA  - J Pediatr Gastroenterol Nutr
JT  - Journal of pediatric gastroenterology and nutrition
JID - 8211545
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1097/MPG.0b013e3182999b4f [doi]
PST - aheadofprint
SO  - J Pediatr Gastroenterol Nutr. 2013 May 5.

PMID- 23648743
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1095-6840 (Electronic)
IS  - 0016-6480 (Linking)
DP  - 2013 May 4
TI  - Monitoring for potential residual disease activity by serum insulin-like growth
      factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: 
      Is there an impact of the genomic deletion of exon 3 in the growth hormone
      receptor (d3-GHR) gene on "safe" GH cut-off values?
LID - S0016-6480(13)00200-1 [pii]
LID - 10.1016/j.ygcen.2013.04.024 [doi]
AB  - BACKGROUND: Acromegaly is an illness usually defined by excessively high growth
      hormone (GH) and insulin like growth factor 1 (IGF-1) levels, the latter mainly
      reflecting GH action on the liver. IGF-1, also known as somatomedin C, mediates
      several actions of GH. The diagnosis and management of acromegaly is relatively
      straight forward, but long-term follow-up of patients can be difficult, as
      elevated IGF-1 levels can occur in the presence of apparently normalised GH
      levels and late recurrence of acromegaly may arise despite previous suppression
      on oral glucose tolerance testing. Data suggest this applies especially to
      patients in whom the GH receptor lacks exon 3. In such patients, GH may not
      always be a useful marker of disease, and traditional GH cut-offs may be
      misleading. Recent data suggest that soluble Klotho (sKlotho), besides and in
      addition to IGF-1, may help monitor the activity of GH-producing adenomas
      (presumably reflecting GH action on the kidneys) and may be a useful
      supplementary tool. METHODS: GHR genotyping was performed in 112 patients with
      acromegaly. IGF-1 and sKlotho levels were measured in the sera of patients before
      and after transsphenoidal surgery, with emphasis on patients judged
      inconclusively cured by surgery or with small residual tumour masses shortly
      after surgery. Patients were assessed for recurrence of acromegaly with GH levels
      (random or nadir during an oGTT). RESULTS: Of the 48 patients who underwent
      surgery between 2000 and 2009 and who had well-documented longer term follow-up
      at our institution, 29 had no biochemical evidence of residual disease activity
      after transsphenoidal surgery (marked reduction in IGF-1 and sKlotho levels, GH
      suppressible to <1ng/ml) and were classified as in remission. 2 of these patients
      developed recurrent symptoms of acromegaly during follow-up with increasing
      levels of IGF-1 and sKlotho, and both patients were carriers of the d3-GHR
      genotype. CONCLUSIONS: Acromegalic patients with the d3-GHR polymorphism might be
      - for a given low postsurgical GH level - at higher risk for recurrence and may
      require a lower GH nadir during oGTT to be classified as in remission. Soluble
      Klotho could be useful in the follow-up of acromegalic patients. The question
      arises whether sKlotho not only reflects the activity of GH-secreting pituitary
      adenomas but whether Klotho (ectodomain clipping?) could also mediate selected
      actions of GH.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
AD  - Department of Internal Medicine, Division of Endocrinology and Diabetes,
      University Hospital Zurich, Ramistrasse 100, CH-8091 Zurich, Switzerland.
FAU - Kohler, S
AU  - Kohler S
FAU - Tschopp, O
AU  - Tschopp O
FAU - Sze, L
AU  - Sze L
FAU - Neidert, M
AU  - Neidert M
FAU - Bernays, R-L
AU  - Bernays RL
FAU - Spanaus, K-S
AU  - Spanaus KS
FAU - Wiesli, P
AU  - Wiesli P
FAU - Schmid, C
AU  - Schmid C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Gen Comp Endocrinol
JT  - General and comparative endocrinology
JID - 0370735
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/01/03 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/19 [accepted]
AID - S0016-6480(13)00200-1 [pii]
AID - 10.1016/j.ygcen.2013.04.024 [doi]
PST - aheadofprint
SO  - Gen Comp Endocrinol. 2013 May 4. pii: S0016-6480(13)00200-1. doi:
      10.1016/j.ygcen.2013.04.024.

PMID- 23648699
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
DP  - 2013 May 6
TI  - Determinants of Progression of Aortic Stiffness in Hemodialysis Patients: A
      Prospective Longitudinal Study.
AB  - Aortic stiffness is associated with increased cardiovascular mortality in
      patients with chronic kidney disease. However, the rate of progression of
      arterial stiffness and the role of cardiovascular risk factors in the progression
      of arterial stiffness has never been established in a longitudinal study. In a
      prospective, longitudinal, observational study, carotid-femoral pulse wave
      velocity and carotid-radial pulse wave velocity were assessed in 109 hemodialysis
      patients at baseline and after a mean follow-up of 1.2 years. We examined the
      impact of age, atherosclerotic cardiovascular disease, diabetes mellitus,
      dialysis vintage, and pentosidine (a well-characterized, advanced glycation end
      products) on the rate of progression of aortic stiffness. The annual rate of
      changes in carotid-femoral pulse wave velocity and carotid-radial pulse wave
      velocity were 0.84 m/s per year (95% confidence interval, 0.50-1.12 m/s per year)
      and -0.66 m/s per year (95% confidence interval, -0.85 to -0.47 m/s per year),
      respectively. Older subjects, and patients with diabetes mellitus or
      atherosclerotic cardiovascular disease had higher aortic stiffness at baseline,
      however, the rate of progression of aortic stiffness was only determined by
      plasma pentosidine levels (P=0.001). The degree of baseline aortic stiffness was 
      a significant determinant of the regression of brachial stiffness (P<0.001)
      suggesting that the regression of brachial stiffness occurs in response to
      central aortic stiffness. These findings suggest that traditional cardiovascular 
      risk factors may play some role in the progression of aortic stiffness before
      development of advanced chronic kidney disease, and that the enhanced rate of
      progression of aortic stiffness in chronic kidney disease patients on dialysis
      are probably determined by more specific chronic kidney disease-related risk
      factors such as advanced-glycation end products.
AD  - CHU de Quebec Research Center, L'Hotel Dieu de Quebec Hospital Quebec, Quebec,
      Canada.
FAU - Utescu, Mihai S
AU  - Utescu MS
FAU - Couture, Veronique
AU  - Couture V
FAU - Mac-Way, Fabrice
AU  - Mac-Way F
FAU - De Serres, Sacha A
AU  - De Serres SA
FAU - Marquis, Karine
AU  - Marquis K
FAU - Lariviere, Richard
AU  - Lariviere R
FAU - Desmeules, Simon
AU  - Desmeules S
FAU - Lebel, Marcel
AU  - Lebel M
FAU - Boutouyrie, Pierre
AU  - Boutouyrie P
FAU - Agharazii, Mohsen
AU  - Agharazii M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Hypertension
JT  - Hypertension
JID - 7906255
OTO - NOTNLM
OT  - advanced-glycation end products
OT  - aortic stiffness
OT  - brachial stiffness
OT  - chronic kidney disease
OT  - hemodialysis
OT  - pulse wave velocity
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - HYPERTENSIONAHA.113.01200 [pii]
AID - 10.1161/HYPERTENSIONAHA.113.01200 [doi]
PST - aheadofprint
SO  - Hypertension. 2013 May 6.

PMID- 23648648
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 4
IP  - 6
DP  - 2013 Jun 28
TI  - Microencapsulation of tannic acid for oral administration to inhibit carbohydrate
      digestion in the gastrointestinal tract.
PG  - 899-905
LID - 10.1039/c3fo30374h [doi]
AB  - The prevalence of diabetes mellitus and obesity is rapidly rising worldwide.
      Recently, there is increasing evidence that phytochemicals such as polyphenols in
      our diet could directly inhibit the activities of key digestive enzymes,
      representing a novel method of controlling and preventing diabetes mellitus and
      obesity. More research is required to determine how to effectively utilize
      phytochemicals within the gastrointestinal (GI) tract to obtain maximum
      inhibition of digestive enzymes. This study investigated the inhibition effciency
      of tannic acid (TA) on alpha-amylase as compared with other potential inhibitors 
      using an in vitro method. The inhibition mode and kinetics were studied. The
      results showed that tannic acid (TA) is more effective in inhibiting
      alpha-amylase than a commercial starch blocker (Phase 2 Starch Blocker), and some
      selected flavonoids and polyphenols including quercetin, rutin, and polyphenon
      from green tea. It is also found that inhibition of alpha-amylase by TA in the GI
      tract is difficult if administered orally due to the non-specific and reversible 
      noncompetitive interaction between tannic acid and alpha-amylase or other
      proteins. Accordingly, a pH-sensitive delivery system using calcium-alginate
      microspheres encapsulating tannic acid was successfully developed for oral
      administration to inhibit carbohydrate digestion in the GI tract. The
      encapsulated TA in calcium-alginate microspheres could be protected from the
      proteins in the stomach, and sustain release and inhibit alpha-amylase activity
      in the small intestine.
AD  - Department of Food Science & Technology, University of Georgia, 100 Cedar Street,
      Athens, GA 30602-2610, USA. fkong@uga.edu.
FAU - Zhao, Wei
AU  - Zhao W
FAU - Iyer, Vidya
AU  - Iyer V
FAU - Flores, Floirendo P
AU  - Flores FP
FAU - Donhowe, Erik
AU  - Donhowe E
FAU - Kong, Fanbin
AU  - Kong F
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/05/07 [aheadofprint]
PHST- 2013/05/28 [epublish]
AID - 10.1039/c3fo30374h [doi]
PST - ppublish
SO  - Food Funct. 2013 Jun 28;4(6):899-905. doi: 10.1039/c3fo30374h. Epub 2013 May 7.

PMID- 23648633
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1434-6621 (Electronic)
IS  - 1434-6621 (Linking)
DP  - 2013 May 7
TI  - A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and
      FN3K-related protein activity in human erythrocytes.
PG  - 1-9
LID - 10.1515/cclm-2012-0853 [doi]
LID - /j/cclm.ahead-of-print/cclm-2012-0853/cclm-2012-0853.xml [pii]
AB  - Abstract Background: An impact on glycation, and possibly on diabetic
      complications, is attributed to fructosamine-3-kinase (FN3K) and its related
      protein (FN3K-RP) because they degrade Amadori compounds in vivo. Little is known
      about individual differences in FN3K-RP activity, which might contribute to an
      individual risk for diabetic complications. Methods: An HPLC-based activity assay
      for FN3K-RP in erythrocytes with the substrate
      N-alpha-hippuryl-N-epsilon-psicosyllysine was developed. The activities of FN3K
      and FN3K-RP were also analysed in erythrocytes of 103 consecutive participants of
      a health-care survey amongst a high-risk group for diabetes. The potential
      associations of these activities with the subjects' health background
      (anthropometric data, glucose tolerance and HbA1c, blood lipids, history of
      metabolic diseases in the subjects and their families, and medication) were
      examined. Results: The interindividual variability of FN3K-RP is less pronounced 
      than that of FN3K [60-135 vs. 2.8-12.5 mU/g haemoglobin (Hb)]. No correlations
      with age, sex, body weight, blood cholesterol, or plasma glucose in an oral
      glucose tolerance test were observed. Subjects with kidney disease had higher
      activity of mainly FN3K-RP [111+/-15 vs. 98+/-18 mU/g Hb, mean+/-standard
      deviations (SDs), n=16 vs. 87, p=0.009], whereas subjects whose parents or
      siblings had a stroke showed lower FN3K activity (6.2+/-1.6 vs. 7.1+/-1.8 mU/g
      Hb, mean+/-SD, n=24 vs. 66, p=0.040). Conclusions: There is a likely impact of
      FN3K and FN3K-RP on the glycation cascade in vivo with potential positive and
      negative effects. The new screening method enables further studies to elucidate
      the function and importance of FN3K-RP.
FAU - Hellwig, Anne
AU  - Hellwig A
FAU - Scherber, Anja
AU  - Scherber A
FAU - Koehler, Carsta
AU  - Koehler C
FAU - Hanefeld, Markolf
AU  - Hanefeld M
FAU - Henle, Thomas
AU  - Henle T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine : CCLM / FESCC
JID - 9806306
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/12/07 [received]
PHST- 2013/04/01 [accepted]
AID - 10.1515/cclm-2012-0853 [doi]
AID - /j/cclm.ahead-of-print/cclm-2012-0853/cclm-2012-0853.xml [pii]
PST - aheadofprint
SO  - Clin Chem Lab Med. 2013 May 7:1-9. doi: 10.1515/cclm-2012-0853.

PMID- 23648584
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1873-6815 (Electronic)
IS  - 0531-5565 (Linking)
DP  - 2013 May 4
TI  - When aging-onset diabetes is coming across with Alzheimer disease: Comparable
      pathogenesis and therapy.
LID - S0531-5565(13)00120-4 [pii]
LID - 10.1016/j.exger.2013.04.013 [doi]
AB  - Diabetes mellitus is a metabolic disorder that is characterized by high blood
      glucose because of the insulin-resistance and insulin-deficiency in Type 2, while
      the insulin deficiency due to destruction of islet cells in the pancreas in Type 
      1. The development of Type 2 diabetes is caused by a combination of lifestyle and
      genetic factors. Aging patients with diabetes are at increased risk of developing
      cognitive and memory dysfunctions, which is one of the significant symptoms of
      Alzheimer disease (AD). Also, over 2/3 of AD patients were clinically indentified
      with impairment of glucose. Cognitive dysfunction would be associated with poor
      self-care ability in diabetes patients. This review will briefly summarize the
      current knowledge of the pathogenesis of these two diseases and highlight
      similarities in their pathophysiologies. Furthermore, we will shortly discuss
      recent progress in the insulin-targeted strategy, aiming to explore the inner
      linkage between these two diseases in aging populations.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Laboratory Medicine & Pathology, Kogod Center on Aging, Mayo
      Clinic,200 First Street SW, Rochester, MN 55905,USA.
FAU - Tang, Jun
AU  - Tang J
FAU - Pei, Yijin
AU  - Pei Y
FAU - Zhou, Guangji
AU  - Zhou G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Exp Gerontol
JT  - Experimental gerontology
JID - 0047061
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/11/14 [received]
PHST- 2013/04/12 [revised]
PHST- 2013/04/27 [accepted]
AID - S0531-5565(13)00120-4 [pii]
AID - 10.1016/j.exger.2013.04.013 [doi]
PST - aheadofprint
SO  - Exp Gerontol. 2013 May 4. pii: S0531-5565(13)00120-4. doi:
      10.1016/j.exger.2013.04.013.

PMID- 23648429
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1880-3873 (Electronic)
IS  - 1340-3478 (Linking)
DP  - 2013 May 2
TI  - Arterial Wall Elasticity Measured Using the Phased Tracking Method and
      Atherosclerotic Risk Factors in Patients with Type 2 Diabetes.
AB  - Aim: The aim of this study was to investigate the relationship between
      atherosclerotic manifestations and brachial and radial arterial wall elasticity
      (AWE) measured using the phased tracking method in patients with type 2 diabetes 
      mellitus (T2DM).Methods: This study included T2DM patients (n= 220, mean age 59
      years) without a history of stroke or coronary artery disease. The brachial AWE, 
      radial AWE, carotid mean intima-media thickness (IMT), max-IMT and flow-mediated 
      vasodilation (FMD) were measured. The patients were classified according to the
      number of atherosclerotic risk factors, including obesity, dyslipidemia and
      hypertension. Group 1 included T2DM patients only, group 2 included patients with
      two risk factors, group 3 included patients with three risk factors and group 4
      included patients with four risk factors. The patients were also divided into two
      groups according to microangiopathic complications, including retinopathy and
      nephropathy. The between-group differences were analyzed.Results: The brachial
      AWE (548, 697, 755 and 771 kPa for groups 1, 2, 3 and 4, respectively) and radial
      AWE (532, 637, 717 and 782 kPa for groups 1, 2, 3 and 4, respectively)
      significantly increased in association with an increasing number of risk factors.
      The brachial AWE and radial AWE were significantly higher in the patients with
      microangiopathic complications than in those without microangiopathic
      complications (brachial AWE 797 and 694 kPa and radial AWE 780 and 660 kPa,
      respectively). Receiver operating characteristic curve analyses revealed that,
      for brachial AWE and radial AWE, the area under the curve was equal to the
      max-IMT and higher than the mean-IMT and FMD.Conclusions: Upper limb AWE
      measurement can reflect the degree of atherosclerosis risk overload and may be
      useful for evaluating vascular complications in T2DM patients.
AD  - Department of Clinical Laboratory Medicine, Jichi Medical University.
FAU - Miyamoto, Michiaki
AU  - Miyamoto M
FAU - Kotani, Kazuhiko
AU  - Kotani K
FAU - Okada, Kenta
AU  - Okada K
FAU - Ando, Akihiko
AU  - Ando A
FAU - Hasegawa, Hideyuki
AU  - Hasegawa H
FAU - Kanai, Hiroshi
AU  - Kanai H
FAU - Ishibashi, Shun
AU  - Ishibashi S
FAU - Yamada, Toshiyuki
AU  - Yamada T
FAU - Taniguchi, Nobuyuki
AU  - Taniguchi N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - J Atheroscler Thromb
JT  - Journal of atherosclerosis and thrombosis
JID - 9506298
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - DN/JST.JSTAGE/jat/16220 [pii]
PST - aheadofprint
SO  - J Atheroscler Thromb. 2013 May 2.

PMID- 23648338
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
DP  - 2013 May 3
TI  - Elevation of miR-221 and -222 in the internal mammary arteries of diabetic
      subjects and normalization with metformin.
LID - S0303-7207(13)00171-8 [pii]
LID - 10.1016/j.mce.2013.04.019 [doi]
AB  - Diabetes is a major risk factor for cardiovascular disease and is associated with
      increased intimal thickening and accelerated vascular smooth muscle cell (VSMC)
      proliferation. We measured the expression of two microRNAs that promote intimal
      thickening, miR-221/222, and mRNA encoding a downstream target, p27Kip1, in
      internal mammary artery (IMA) segments collected from 37 subjects undergoing
      coronary artery bypass grafting. The segments were stratified into three groups: 
      non-diabetic subjects (ND), diabetic subjects not on metformin (DMMet-), and
      diabetic subjects on metformin (DMMet+). The DMMet- group exhibited a significant
      increase in miR-221/222 and decrease in p27Kip1 mRNA compared to both the ND and 
      DMMet+ groups. miR-221/222 levels inversely correlated with metformin dose. VSMCs
      isolated from the IMAs of the DMMet- group proliferate at a faster rate than
      those of the ND and DMMet+ groups. Further studies into the importance of
      miR-221/222 in the increased intimal thickening observed in diabetic subjects is 
      warranted.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - Laboratory of Molecular Cardiology, Ochsner Clinic Foundation, New Orleans, LA,
      United States; Department of Pharmacology, Tulane University Health Sciences
      Center - New Orleans, New Orleans, LA, United States.
FAU - Coleman, Chasity B
AU  - Coleman CB
FAU - Lightell, Daniel J Jr
AU  - Lightell DJ Jr
FAU - Moss, Stephanie C
AU  - Moss SC
FAU - Bates, Michael
AU  - Bates M
FAU - Eugene Parrino, P
AU  - Eugene Parrino P
FAU - Cooper Woods, T
AU  - Cooper Woods T
LA  - ENG
GR  - P20 RR017659/RR/NCRR NIH HHS/United States
GR  - P20 RR018766/RR/NCRR NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/11/06 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/04/24 [accepted]
AID - S0303-7207(13)00171-8 [pii]
AID - 10.1016/j.mce.2013.04.019 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 May 3. pii: S0303-7207(13)00171-8. doi:
      10.1016/j.mce.2013.04.019.

PMID- 23648321
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 0027-5107 (Print)
IS  - 0027-5107 (Linking)
DP  - 2013 May 3
TI  - Telmisartan ameliorates germ cell toxicity in the STZ-induced diabetic rat:
      Studies on possible molecular mechanisms.
LID - S1383-5718(13)00115-0 [pii]
LID - 10.1016/j.mrgentox.2013.04.013 [doi]
AB  - Testicular damage is a common clinical problem in diabetic individuals that
      severely affects the quality of life. The present study investigates the possible
      protective mechanisms of telmisartan, an angiotensin II-receptor antagonist in
      the germ cell of diabetic rat. Male SD rats were used and randomized into six
      groups: control, telmisartan control, diabetic control and diabetic group treated
      with telmisartan at the doses of 3, 6 and 12mg/kg/day, per oral for 4 weeks.
      Diabetes was induced by injecting a single dose of streptozotocin (STZ),
      (55mg/kg) dissolved in ice-cold 10mM citrate buffer; pH 4.4 and administered i.p.
      immediately after preparation to the SD rats. At the end of the study, rats were 
      sacrificed and the levels of nitrite, superoxide, malondialdehyde (MDA),
      glutathione (reduced and peroxidase) and superoxide dismutase (SOD) were
      measured. Germ cell toxicity was evaluated by using sperm count, sperm comet
      assay, histology of testes and terminal deoxynucleotidyl transferase-mediated
      dUTP nick end labeling (TUNEL) assay. Further to confirm the oxidative and
      nitrosative damage, immunohistological quantification of 8-oxo-dG
      (8-oxo-7,8-dihydro-2'-deoxyguanosine) and 3-nitrotyrosine were evaluated
      respectively. Results showed that telmisartan significantly restored the levels
      of nitrite, superoxide, malondialdehyde, and glutathione and superoxide dismutase
      in diabetic testes. Further, telmisartan significantly increased the sperm
      counts, reduced apoptotic cell death, sperm DNA damage, oxidative and nitrosative
      damage in diabetic rat. Western blot analysis showed that telmisartan reduced the
      testicular inflammation and cell death by down-regulating the expression of
      NF-kappaB, IL-6, TNF-alpha, p-ERK1/2, iNOS, caspase-3 and increasing the
      PPAR-gamma expression. Results clearly indicate that telmisartan significantly
      reduced the both oxidative and nitrosative stress, inflammation and cell death in
      diabetic testes. The present results confirmed that telmisartan exhibited
      beneficial role in the germ cell of diabetic rat.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Facility for Risk Assessment & Intervention Studies, Department of Pharmacology
      and Toxicology, National Institute of Pharmaceutical Education and Research,
      Sector-67, S.A.S. Nagar, Punjab 160062, India. Electronic address:
      sapna.pharm@gmail.com.
FAU - Kushwaha, S
AU  - Kushwaha S
FAU - Jena, G B
AU  - Jena GB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Mutat Res
JT  - Mutation research
JID - 0400763
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/12/25 [received]
PHST- 2013/03/27 [revised]
PHST- 2013/04/21 [accepted]
AID - S1383-5718(13)00115-0 [pii]
AID - 10.1016/j.mrgentox.2013.04.013 [doi]
PST - aheadofprint
SO  - Mutat Res. 2013 May 3. pii: S1383-5718(13)00115-0. doi:
      10.1016/j.mrgentox.2013.04.013.

PMID- 23648312
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1095-9319 (Electronic)
IS  - 0026-2862 (Linking)
VI  - 88
DP  - 2013 Jul
TI  - Telmisartan inhibits AGE-induced podocyte damage and detachment.
PG  - 79-83
LID - 10.1016/j.mvr.2013.04.006 [doi]
LID - S0026-2862(13)00066-6 [pii]
AB  - Advanced glycation end products (AGE) formed at an accelerated rate under
      diabetes, could cause podocyte apoptosis, thereby being involved in the
      development and progression of diabetic nephropathy. Renin-angiotensin system
      (RAS) plays a role in diabetic nephropathy as well. However, it remains unknown
      whether there exists a pathophysiological crosstalk between the RAS and AGE in
      podocyte damage in diabetic nephropathy. Therefore, this study investigated the
      effects of telmisartan, an angiotensin II (Ang II) type 1 receptor (AT1R) blocker
      on AGE or Ang II-induced podocyte damage in vitro. We further examined here the
      effects of AGE on AT1R expression levels in podocytes. AGE or Ang II not only
      increased DNA damage of podocytes which was evaluated by comet assay, but also
      induced cell detachment, both of which were significantly blocked by the
      treatment with telmisartan. AGE significantly increased AT1R levels in podocytes,
      whereas podocyte Ang II production was modestly stimulated by AGE. Telmisartan
      alone did not affect the release of lactate dehydrogenase from podocytes. Our
      present study suggests that AGE could induce podocyte DNA damage and detachment
      partly via stimulation of the Ang II-AT1R axis, thus providing a novel beneficial
      aspect of telmisartan in diabetic nephropathy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Nephrology, Department of Medicine, Kurume University School of
      Medicine, Fukuoka, Japan.
FAU - Fukami, Kei
AU  - Fukami K
FAU - Yamagishi, Sho-Ichi
AU  - Yamagishi S
FAU - Kaifu, Kumiko
AU  - Kaifu K
FAU - Matsui, Takanori
AU  - Matsui T
FAU - Kaida, Yusuke
AU  - Kaida Y
FAU - Ueda, Seiji
AU  - Ueda S
FAU - Takeuchi, Masayoshi
AU  - Takeuchi M
FAU - Asanuma, Katsuhiko
AU  - Asanuma K
FAU - Okuda, Seiya
AU  - Okuda S
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - United States
TA  - Microvasc Res
JT  - Microvascular research
JID - 0165035
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/01/29 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/28 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - S0026-2862(13)00066-6 [pii]
AID - 10.1016/j.mvr.2013.04.006 [doi]
PST - ppublish
SO  - Microvasc Res. 2013 Jul;88:79-83. doi: 10.1016/j.mvr.2013.04.006. Epub 2013 May
      3.

PMID- 23648189
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 11
DP  - 2013
TI  - Stromal cell derived factor-1alpha protects stem cell derived insulin-producing
      cells from glucotoxicity under high glucose conditions in-vitro and ameliorates
      drug induced diabetes in rats.
PG  - 115
LID - 10.1186/1479-5876-11-115 [doi]
AB  - BACKGROUND: Diabetes mellitus is affecting more than 300 million people
      worldwide. Current treatment strategies cannot prevent secondary complications.
      Stem cells due to their regenerative power have long been the attractive target
      for the cell-based therapies. Mesenchymal stem cells (MSCs) possess the ability
      to differentiate into several cell types and to escape immune recognition in
      vitro. MSCs can be differentiated into insulin-producing cells (IPCs) and could
      be an exciting therapy for diabetes but problems like poor engraftment and
      survivability need to be confronted. It was hypothesized that stromal cell
      derived factor- 1alpha (SDF-1alpha) will enhance therapeutic potential of stem
      cell derived IPCs by increasing their survival and proliferation rate. METHODS:
      Novel culture conditions were developed to differentiate bone marrow derived
      mesenchymal stem cells (BMSCs) into IPCs by using endocrine differentiation
      inducers and growth factors via a three stage protocol. In order to enhance their
      therapeutic potential, we preconditioned IPCs with SDF-1alpha. RESULTS: Our
      results showed that SDF-1alpha increases survival and proliferation of IPCs and
      protects them from glucotoxicity under high glucose conditions in vitro.
      SDF-1alpha also enhances the glucose responsive insulin secretion in IPCs in
      vitro. SDF-1alpha preconditioning reverses hyperglycemia and increase serum
      insulin in drug induced diabetic rats. CONCLUSIONS: The differentiation of BMSCs 
      into IPCs and enhancement of their therapeutic potential by SDF-1alpha
      preconditioning may contribute to cell based therapies for diabetes.
AD  - National Centre of Excellence in Molecular Biology, University of the Punjab,
      Lahore, Pakistan. m_awan_tariq@hotmail.com.
FAU - Tariq, Muhammad
AU  - Tariq M
FAU - Masoud, Muhammad Sharif
AU  - Masoud MS
FAU - Mehmood, Azra
AU  - Mehmood A
FAU - Khan, Shaheen N
AU  - Khan SN
FAU - Riazuddin, Sheikh
AU  - Riazuddin S
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
SB  - IM
PMC - PMC3660237
OID - NLM: PMC3660237
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/01/17 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/05/06 [aheadofprint]
AID - 1479-5876-11-115 [pii]
AID - 10.1186/1479-5876-11-115 [doi]
PST - epublish
SO  - J Transl Med. 2013 May 6;11:115. doi: 10.1186/1479-5876-11-115.

PMID- 23648145
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1365-3156 (Electronic)
IS  - 1360-2276 (Linking)
DP  - 2013 May 6
TI  - Diabetes is a strong predictor of mortality during tuberculosis treatment: a
      prospective cohort study among tuberculosis patients from Mwanza, Tanzania.
LID - 10.1111/tmi.12120 [doi]
AB  - OBJECTIVE: Strong evidence suggests diabetes may be associated with tuberculosis 
      (TB) and could influence TB treatment outcomes. We assessed the role of diabetes 
      on sputum culture conversion and mortality among patients undergoing TB
      treatment. METHODS: A total of 1250 Tanzanian TB patients were followed
      prospectively during TB treatment with sputum culture after 2 and 5 months.
      Survival status was assessed at least 1 year after initiation of treatment. At
      baseline, all participants underwent testing for diabetes and HIV, and the serum 
      concentration of the acute phase reactant alpha-1 glycoprotein (AGP) was
      determined. RESULTS: There were no differences between participants with and
      without diabetes regarding the proportion of positive cultures at 2 (3.8% vs.
      5.8%) and 5 (1.3% vs. 0.9%) months (P > 0.46). However, among patients with a
      positive TB culture, relatively more patients with diabetes died before the
      5-month follow-up. Within the initial 100 days of TB treatment, diabetes was
      associated with a fivefold increased risk of mortality (RR 5.09, 95% CI 2.36;
      11.02, P < 0.001) among HIV uninfected, and a twofold increase among HIV
      co-infected patient (RR 2.33 95% CI 1.20; 4.53, P = 0.012), while diabetes was
      not associated with long-term mortality. Further adjustment with AGP did not
      change the estimates. CONCLUSION: Diabetes considerably increases risk of early
      mortality during TB treatment. The effect may not be explained by increased
      severity of TB, but could be due to impaired TB treatment response. Research is
      needed to clarify the mechanism and to assess whether glycaemic control improves 
      survival.
CI  - (c) 2013 Blackwell Publishing Ltd.
AD  - Department of Nutrition, Exercise and Sports, University of Copenhagen,
      Frederiksberg, Denmark.
FAU - Faurholt-Jepsen, Daniel
AU  - Faurholt-Jepsen D
FAU - Range, Nyagosya
AU  - Range N
FAU - Praygod, George
AU  - Praygod G
FAU - Jeremiah, Kidola
AU  - Jeremiah K
FAU - Faurholt-Jepsen, Maria
AU  - Faurholt-Jepsen M
FAU - Aabye, Martine G
AU  - Aabye MG
FAU - Changalucha, John
AU  - Changalucha J
FAU - Christensen, Dirk L
AU  - Christensen DL
FAU - Grewal, Harleen M S
AU  - Grewal HM
FAU - Martinussen, Torben
AU  - Martinussen T
FAU - Krarup, Henrik
AU  - Krarup H
FAU - Witte, Daniel R
AU  - Witte DR
FAU - Andersen, Aase B
AU  - Andersen AB
FAU - Friis, Henrik
AU  - Friis H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Trop Med Int Health
JT  - Tropical medicine & international health : TM & IH
JID - 9610576
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1111/tmi.12120 [doi]
PST - aheadofprint
SO  - Trop Med Int Health. 2013 May 6. doi: 10.1111/tmi.12120.

PMID- 23648096
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1447-0594 (Electronic)
IS  - 1447-0594 (Linking)
DP  - 2013 May 6
TI  - Migraine and vascular risk factors in the elderly.
LID - 10.1111/ggi.12061 [doi]
AB  - AIM: The association between migraine and cerebrovascular disease is well
      documented in younger migraine patients, especially those with aura. Prevalence
      estimates of vascular risk factors among elderly migraine sufferers are lacking. 
      The present study was designed to estimate the prevalence of vascular risk
      factors in the elderly population with late onset of migraine without aura.
      METHODS: The medical records of 163 patients aged 50 years and older suffering
      from migraine without aura were assessed for vascular risk factors, including
      hypertension, elevated serum lipid levels, diabetes mellitus and cardiovascular
      disease. Prevalence was estimated and compared with age- and sex-matched vascular
      risk factor estimates for the general population extracted from the 2003-2004
      Israeli National Health Interview Survey, and to a group of patients matched by
      age suffering from migraine with aura. RESULTS: Among women with migraine without
      aura, hypertension, hyperlipidemia and diabetes mellitus were significantly less 
      prevalent than among women without migraine without aura. Prevalence estimates
      for vascular risk factors did not differ by migraine among males. The group of
      older patients suffering from migraine with aura showed a higher incidence of
      vascular risk factors in respect to the group of migraine patients without aura. 
      CONCLUSIONS: The findings of the present study might have an important clinical
      relevance, suggesting another pathophysiological process in respect to patients
      suffering from migraine with aura, and this evidence might have different
      therapeutic implications. Geriatr Gerontol Int 2013; : -.
CI  - (c) 2013 Japan Geriatrics Society.
AD  - Department of Neurology, Wolfson Medical Center, Holon.
FAU - Gilad, Ronit
AU  - Gilad R
FAU - Boaz, Mona
AU  - Boaz M
FAU - Dabby, Ron
AU  - Dabby R
FAU - Finkelstein, Vitali
AU  - Finkelstein V
FAU - Rapoport, Abraham
AU  - Rapoport A
FAU - Lampl, Yair
AU  - Lampl Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Geriatr Gerontol Int
JT  - Geriatrics & gerontology international
JID - 101135738
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/02/18 [accepted]
AID - 10.1111/ggi.12061 [doi]
PST - aheadofprint
SO  - Geriatr Gerontol Int. 2013 May 6. doi: 10.1111/ggi.12061.

PMID- 23648089
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1474-9726 (Electronic)
IS  - 1474-9718 (Linking)
DP  - 2013 May 4
TI  - Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose
      intolerant but insulin sensitive.
LID - 10.1111/acel.12097 [doi]
AB  - Rapamycin, an inhibitor of the mechanistic target of rapamycin (mTOR) signaling
      pathway, extends the life span of yeast, worms, flies, and mice. Interventions
      that promote longevity are often correlated with increased insulin sensitivity,
      and it therefore is surprising that chronic rapamycin treatment of mice, rats,
      and humans is associated with insulin resistance (J Am Soc Nephrol., 19, 2008,
      1411; Diabetes, 00, 2010, 00; Science, 335, 2012, 1638). We examined the effect
      of dietary rapamycin treatment on glucose homeostasis and insulin resistance in
      the genetically heterogeneous HET3 mouse strain, a strain in which dietary
      rapamycin robustly extends mean and maximum life span. We find that rapamycin
      treatment leads to glucose intolerance in both young and old HET3 mice, but in
      contrast to the previously reported effect of injected rapamycin in C57BL/6 mice,
      HET3 mice treated with dietary rapamycin responded normally in an insulin
      tolerance test. To gauge the overall consequences of rapamycin treatment on
      average blood glucose levels, we measured HBA1c. Dietary rapamycin increased
      HBA1c over the first 3 weeks of treatment in young animals, but the effect was
      lost by 3 months, and no effect was detected in older animals. Our results
      demonstrate that the extended life span of HET3 mice on a rapamycin diet occurs
      in the absence of major changes in insulin sensitivity and highlight the
      importance of strain background and delivery method in testing effects of
      longevity interventions.
CI  - (c) 2013 John Wiley & Sons Ltd and The Anatomical Society.
AD  - Whitehead Institute for Biomedical Research, Cambridge, MA, 02142, USA;
      Department of Biology, MIT, Cambridge, MA, 02139, USA; Howard Hughes Medical
      Institute, MIT, Cambridge, MA, 02139, USA; Broad Institute of Harvard and MIT,
      Seven Cambridge Center, Cambridge, MA, 02142, USA; The David H. Koch Institute
      for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
FAU - Lamming, Dudley W
AU  - Lamming DW
FAU - Ye, Lan
AU  - Ye L
FAU - Astle, Clinton M
AU  - Astle CM
FAU - Baur, Joseph A
AU  - Baur JA
FAU - Sabatini, David M
AU  - Sabatini DM
FAU - Harrison, David E
AU  - Harrison DE
LA  - ENG
GR  - K99 AG041765/AG/NIA NIH HHS/United States
GR  - P30 DK019525/DK/NIDDK NIH HHS/United States
GR  - R01 AG038560/AG/NIA NIH HHS/United States
GR  - R01 CA129105/CA/NCI NIH HHS/United States
GR  - U01 AG022308/AG/NIA NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Aging Cell
JT  - Aging cell
JID - 101130839
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/04/24 [accepted]
AID - 10.1111/acel.12097 [doi]
PST - aheadofprint
SO  - Aging Cell. 2013 May 4. doi: 10.1111/acel.12097.

PMID- 23648009
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1532-8449 (Electronic)
IS  - 0882-5963 (Linking)
DP  - 2013 May 4
TI  - Diabetic Peripheral Neuropathy in Youth.
LID - S0882-5963(13)00145-0 [pii]
LID - 10.1016/j.pedn.2013.04.001 [doi]
AD  - Division of Endocrinology/Diabetes, University of Pennsylvania, Perelman School
      of Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA.
      Electronic address: moserj@email.chop.edu.
FAU - Moser, Joanne T
AU  - Moser JT
FAU - Langdon, David R
AU  - Langdon DR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - J Pediatr Nurs
JT  - Journal of pediatric nursing
JID - 8607529
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - S0882-5963(13)00145-0 [pii]
AID - 10.1016/j.pedn.2013.04.001 [doi]
PST - aheadofprint
SO  - J Pediatr Nurs. 2013 May 4. pii: S0882-5963(13)00145-0. doi:
      10.1016/j.pedn.2013.04.001.

PMID- 23647943
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 3
TI  - Added value of novel circulating and genetic biomarkers in type 2 diabetes
      prediction: A systematic review.
LID - S0168-8227(13)00104-6 [pii]
LID - 10.1016/j.diabres.2013.03.023 [doi]
AB  - AIMS: To provide a systematic overview of the added value of novel circulating
      and genetic biomarkers in predicting type 2 diabetes (T2DM). METHODS: We searched
      MEDLINE and EMBASE (January 2000 to September 2012) for studies that reported a
      measure of improvement in the performance of T2DM risk prediction models
      subsequent to adding novel biomarkers to traditional risk factors. We extracted
      data on study methods and metrics of incremental predictive value of novel
      biomarkers. RESULTS: We included 34 publications from 30 studies. All studies
      reported a change in the area under the receiver-operating characteristic curve, 
      which was modest, ranging from -0.004 to 0.1, with claims of statistically
      significant improvements in eleven studies. The net reclassification index was
      evaluated in 11 studies, and ranged from -2.2% to 10.2% after inclusion of
      genetic markers in six studies (statistically significant in two cases), and from
      -0.5% to 27.5% after inclusion of non-genetic markers in five studies
      (non-significant in two studies). The integrated discrimination index (0-2.04)
      was reported in eight studies, being statistically significant in five of these. 
      CONCLUSIONS: Currently known novel circulating and genetic biomarkers do not
      substantially improve T2DM risk prediction above and beyond the ability of
      traditional risk factors.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Hubert Department of Global Health, Rollins School of Public Health, Emory
      University, 1518 Clifton Road, Northeast Atlanta, GA 30322, USA. Electronic
      address: jechouf@emory.edu.
FAU - Echouffo-Tcheugui, Justin B
AU  - Echouffo-Tcheugui JB
FAU - Dieffenbach, Sara D
AU  - Dieffenbach SD
FAU - Kengne, Andre P
AU  - Kengne AP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/07/19 [received]
PHST- 2012/10/13 [revised]
PHST- 2013/03/15 [accepted]
AID - S0168-8227(13)00104-6 [pii]
AID - 10.1016/j.diabres.2013.03.023 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 3. pii: S0168-8227(13)00104-6. doi:
      10.1016/j.diabres.2013.03.023.

PMID- 23647942
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 4
TI  - Stability of stored samples for assays of glycated albumin.
LID - S0168-8227(13)00106-X [pii]
LID - 10.1016/j.diabres.2013.03.025 [doi]
AD  - Department of Clinical Laboratory, Jichi Medical University, Saitama Medical
      Center, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama 330-8503, Japan.
FAU - Watano, Tatsuro
AU  - Watano T
FAU - Sasaki, Katsuichi
AU  - Sasaki K
FAU - Omoto, Kiyoka
AU  - Omoto K
FAU - Kawano, Mikihiko
AU  - Kawano M
LA  - ENG
PT  - LETTER
DEP - 20130504
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/03/08 [received]
PHST- 2013/03/21 [accepted]
AID - S0168-8227(13)00106-X [pii]
AID - 10.1016/j.diabres.2013.03.025 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 4. pii: S0168-8227(13)00106-X. doi:
      10.1016/j.diabres.2013.03.025.

PMID- 23647939
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
DP  - 2013 May 3
TI  - Prevention of Obesity and Diabetes in Childbearing Women.
LID - 10.1111/jmwh.12051 [doi]
AB  - Obesity and diabetes have become pandemic in the United States, with more than
      one-third of the US population obese and 8.3% of the population affected by
      diabetes. Efforts to prevent type 2 diabetes focus primarily on healthy eating
      and physical activity. In particular, women from at-risk racial and ethnic groups
      and those who have experienced gestational diabetes are at high risk for
      developing type 2 diabetes. Achieving a healthy weight prior to conception,
      staying within weight gain guidelines during pregnancy, and losing accumulated
      pregnancy weight postpartum are key prevention factors. Maintaining a healthy
      weight in the long-term is a challenge. Behavioral psychology and coaching
      techniques are presented in this article that can be useful in sustaining
      behaviors that promote a healthy weight.
CI  - (c) 2013 by the American College of Nurse-Midwives.
FAU - Trout, Kimberly K
AU  - Trout KK
FAU - Ellis, Kathryn K
AU  - Ellis KK
FAU - Bratschie, Alexandra
AU  - Bratschie A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1111/jmwh.12051 [doi]
PST - aheadofprint
SO  - J Midwifery Womens Health. 2013 May 3. doi: 10.1111/jmwh.12051.

PMID- 23647931
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1879-3061 (Electronic)
IS  - 1043-2760 (Linking)
DP  - 2013 May 3
TI  - The pancreatic beta cell and type 1 diabetes: innocent bystander or active
      participant?
LID - S1043-2760(13)00063-5 [pii]
LID - 10.1016/j.tem.2013.03.005 [doi]
AB  - Type 1 diabetes mellitus (T1DM) is a chronic disease resulting from destruction
      of insulin-producing pancreatic beta cells. Genetic and environmental factors
      contribute to T1DM onset. Use of high-throughput DNA sequencing has allowed
      geneticists to perform genome-wide association studies (GWAS) to identify novel
      gene loci associated with T1DM. Interestingly, >50% of these genes encode
      products that are expressed in beta cells. These studies, coupled with emerging
      molecular evidence that beta cells are impaired by gain-of-function or
      loss-of-function of these loci, suggest an active role for the beta cell in
      eliciting its own demise. Although immune dysregulation plays a vital role in
      T1DM pathogenesis, understanding the mechanisms contributing to beta cell failure
      may lead to new strategies to preserve or improve beta cell function in patients 
      with T1DM.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Institute for Diabetes, Obesity, and Metabolism, and the Division of
      Endocrinology, Diabetes, and Metabolism, Department of Medicine, Perelman School 
      of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
FAU - Soleimanpour, Scott A
AU  - Soleimanpour SA
FAU - Stoffers, Doris A
AU  - Stoffers DA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Trends Endocrinol Metab
JT  - Trends in endocrinology and metabolism: TEM
JID - 9001516
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/12/07 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/31 [accepted]
AID - S1043-2760(13)00063-5 [pii]
AID - 10.1016/j.tem.2013.03.005 [doi]
PST - aheadofprint
SO  - Trends Endocrinol Metab. 2013 May 3. pii: S1043-2760(13)00063-5. doi:
      10.1016/j.tem.2013.03.005.

PMID- 23647930
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1879-3061 (Electronic)
IS  - 1043-2760 (Linking)
VI  - 24
IP  - 6
DP  - 2013 Jun
TI  - Cracking the O-GlcNAc code in metabolism.
PG  - 301-9
LID - 10.1016/j.tem.2013.02.002 [doi]
LID - S1043-2760(13)00033-7 [pii]
AB  - Nuclear, cytoplasmic, and mitochondrial proteins are extensively modified by
      O-linked beta-N-acetylglucosamine (O-GlcNAc) moieties. This sugar modification
      regulates fundamental cellular processes in response to diverse nutritional and
      hormonal cues. The enzymes O-GlcNAc transferase (OGT) and O-linked
      beta-N-acetylglucosaminase (O-GlcNAcase) mediate the addition and removal of
      O-GlcNAc, respectively. Aberrant O-GlcNAcylation has been implicated in a
      plethora of human diseases, including diabetes, cancer, aging, cardiovascular
      disease, and neurodegenerative disease. Because metabolic dysregulation is a
      vital component of these diseases, unraveling the roles of O-GlcNAc in metabolism
      is of emerging importance. Here, we review the current understanding of the
      functions of O-GlcNAc in cell signaling and gene transcription involved in
      metabolism, and focus on its relevance to diabetes, cancer, circadian rhythm, and
      mitochondrial function.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Program in Integrative Cell Signaling and Neurobiology of Metabolism, Yale
      University School of Medicine, 333 Cedar Street, New Haven, CT 06519, USA;
      Section of Comparative Medicine, Yale University School of Medicine, 333 Cedar
      Street, New Haven, CT 06519, USA.
FAU - Ruan, Hai-Bin
AU  - Ruan HB
FAU - Singh, Jay Prakash
AU  - Singh JP
FAU - Li, Min-Dian
AU  - Li MD
FAU - Wu, Jing
AU  - Wu J
FAU - Yang, Xiaoyong
AU  - Yang X
LA  - eng
GR  - P30 DK034989/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130504
PL  - United States
TA  - Trends Endocrinol Metab
JT  - Trends in endocrinology and metabolism: TEM
JID - 9001516
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/01/04 [received]
PHST- 2013/02/16 [revised]
PHST- 2013/02/17 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - S1043-2760(13)00033-7 [pii]
AID - 10.1016/j.tem.2013.02.002 [doi]
PST - ppublish
SO  - Trends Endocrinol Metab. 2013 Jun;24(6):301-9. doi: 10.1016/j.tem.2013.02.002.
      Epub 2013 May 4.

PMID- 23647908
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
DP  - 2013 May 3
TI  - The lactase persistence genotype is associated with body mass index and dairy
      consumption in the D.E.S.I.R. study.
LID - S0026-0495(13)00103-0 [pii]
LID - 10.1016/j.metabol.2013.04.006 [doi]
AB  - OBJECTIVE: The T allele of a functional polymorphism (rs4988235: LCT-13910 C>T), 
      close to the lactase gene, correlates with lactase persistence (LP) in adults.
      The LP genotype (TT+TC) has been associated with a higher BMI in European
      populations in cross-sectional studies. In the French D.E.S.I.R. cohort, a high
      consumption of dairy products was associated with a lower body weight gain over
      9-years, and with a lower incidence of high plasma glucose levels and/or the
      metabolic syndrome. Our aim was to test in this study, the association of
      rs4988235 with BMI and related metabolic diseases, in interaction with dairy
      product consumption. METHODS: Among 5212 subjects from D.E.S.I.R., 3575
      Caucasians born in mainland France were genotyped and followed over 9years.
      RESULTS: Those with the LP genotype (frequency: 78.5%) had a higher dairy product
      consumption, at inclusion and at year-9 (P<0.001). They also had a higher BMI at 
      both time points (difference=0.3kg/m2, P=0.05), but this effect was restricted to
      medium/high dairy product consumers (difference=0.5kg/m2, P=0.006). This genotype
      was also associated with the metabolic syndrome (IDF definition), but this
      association disappeared after adjustment for BMI. In the whole population, the C 
      allele was associated with a higher prevalence of impaired fasting glycemia
      and/or type 2 diabetes. CONCLUSIONS: The lactase persistence genotype was shown
      to be associated with a higher BMI in a longitudinal study, mainly in those
      consuming high amounts of dairy products. The association of the C allele,
      responsible for lactase non-persistence, with the risk of hyperglycemia needs to 
      be replicated.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - INSERM, U695, Genetic Determinants of Type 2 Diabetes and Its Vascular
      Complications, Paris, France; Univ Paris Diderot, Sorbonne Paris Cite, UMRS 695, 
      UFR de Medecine Site Bichat, Paris, France.
FAU - Lamri, Amel
AU  - Lamri A
FAU - Poli, Antoine
AU  - Poli A
FAU - Emery, Nathalie
AU  - Emery N
FAU - Bellili, Naima
AU  - Bellili N
FAU - Velho, Gilberto
AU  - Velho G
FAU - Lantieri, Olivier
AU  - Lantieri O
FAU - Balkau, Beverley
AU  - Balkau B
FAU - Marre, Michel
AU  - Marre M
FAU - Fumeron, Frederic
AU  - Fumeron F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/11/20 [received]
PHST- 2013/03/05 [revised]
PHST- 2013/04/03 [accepted]
AID - S0026-0495(13)00103-0 [pii]
AID - 10.1016/j.metabol.2013.04.006 [doi]
PST - aheadofprint
SO  - Metabolism. 2013 May 3. pii: S0026-0495(13)00103-0. doi:
      10.1016/j.metabol.2013.04.006.

PMID- 23647889
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 0019-4832 (Print)
IS  - 0019-4832 (Linking)
VI  - 65
IP  - 2
DP  - 2013 Mar-Apr
TI  - Effects of a yoga intervention on lipid profiles of diabetes patients with
      dyslipidemia.
PG  - 127-31
LID - 10.1016/j.ihj.2013.02.010 [doi]
LID - S0019-4832(13)00036-9 [pii]
AB  - OBJECTIVE: The present study was conducted to assess the effectiveness of yoga in
      the management of dyslipidemia in patients of type 2 diabetes mellitus. METHODS: 
      This randomized parallel study was carried out in Medical College Trivandrum,
      Kerala, India. Hundred type 2 diabetics with dyslipidemia were randomized into
      control and yoga groups. The control group was prescribed oral hypoglycemic
      drugs. The yoga group practiced yoga daily for 1 h duration along with oral
      hypoglycemic drugs for 3 months. The lipid profiles of both the groups were
      compared at the start and at the end of 3 months. RESULTS: After intervention
      with yoga for a period of 3 months the study group showed a decrease in total
      cholesterol, triglycerides and LDL, with an improvement in HDL. CONCLUSION: Yoga,
      being a lifestyle incorporating exercise and stress management training, targets 
      the elevated lipid levels in patients with diabetes through integrated
      approaches.
CI  - Copyright (c) 2013 Cardiological Society of India. Published by Elsevier B.V. All
      rights reserved.
AD  - Department of Physiology, Gulf Medical University, Ajman, P.O. Box 4184, UAE.
      Electronic address: nisha@gmu.ac.ae.
FAU - Shantakumari, Nisha
AU  - Shantakumari N
FAU - Sequeira, Shiefa
AU  - Sequeira S
FAU - El Deeb, Rasha
AU  - El Deeb R
LA  - eng
PT  - Journal Article
DEP - 20130228
PL  - India
TA  - Indian Heart J
JT  - Indian heart journal
JID - 0374675
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/06/18 [received]
PHST- 2012/12/01 [revised]
PHST- 2013/02/14 [accepted]
PHST- 2013/02/28 [aheadofprint]
AID - S0019-4832(13)00036-9 [pii]
AID - 10.1016/j.ihj.2013.02.010 [doi]
PST - ppublish
SO  - Indian Heart J. 2013 Mar-Apr;65(2):127-31. doi: 10.1016/j.ihj.2013.02.010. Epub
      2013 Feb 28.

PMID- 23647841
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1879-0828 (Electronic)
IS  - 0953-6205 (Linking)
DP  - 2013 May 3
TI  - Elevated fasting glucose levels within normal range are associated with an
      increased risk of metabolic syndrome in older women.
LID - S0953-6205(13)00097-6 [pii]
LID - 10.1016/j.ejim.2013.03.013 [doi]
AB  - OBJECTIVE: The prevalence of cardiovascular disease (CVD) and metabolic syndrome 
      (MetS) increases with increasing fasting plasma glucose (FPG) levels in an
      elderly population with pre-diabetes or diabetes. However, it remains unknown
      whether the relationship between elevated FPG and increased risks of MetS exists 
      in older women with normoglycemia (FPG<100mg/dL). Therefore, the present study
      was conducted to fill the lack of information in that area. MATERIALS AND
      METHODS: We included 6505 apparently healthy women, aged 65years and older, with 
      normoglycemia who participated in routine health checkups at health screening
      centers in Taiwan. Components of MetS (FPG, waist circumference (WC),
      high-density lipoprotein cholesterol (HDL-C), triglycerides, and
      systolic/diastolic blood pressure), body mass index (BMI), low-density
      lipoprotein cholesterol (LDL-C), total cholesterol, and percentage body fat (PBF)
      were examined in all subjects. RESULTS: Subjects were sub-grouped by FPG levels
      (<90mg/dL, 91-95mg/dL and >95mg/dL for group 1, group 2 and group 3,
      respectively). Subjects in group 2 and group 3 were 1.22-fold (P=0.017) and
      1.25-fold (P=0.007) more likely to have MetS compared with those in group 1. Age,
      WC, BMI, PBF, systolic and diastolic blood pressure, total cholesterol,
      triglycerides, and HDL-C were significantly correlated with FPG, whereas HDL-C
      was negatively correlated with FPG. In a multivariate stepwise regression
      analysis, PBF, LDL-C, triglycerides, and age were significantly and independently
      associated with FPG. CONCLUSION: Among older women, the risk of MetS was
      significantly associated with elevated FPG even for subjects with normal FPG.
      Lifestyle interventions for reducing PBF and controlling dyslipidemia could help 
      reduce the risk of MetS in this population.
CI  - Copyright (c) 2013 European Federation of Internal Medicine. Published by
      Elsevier B.V. All rights reserved.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan;
      Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical
      University, Taipei, Taiwan.
FAU - Hsiao, Fone-Ching
AU  - Hsiao FC
FAU - Hsieh, Chang-Hsun
AU  - Hsieh CH
FAU - Wu, Chung-Ze
AU  - Wu CZ
FAU - Hsu, Chun-Hsien
AU  - Hsu CH
FAU - Lin, Jiunn-Diann
AU  - Lin JD
FAU - Lee, Ting-I
AU  - Lee TI
FAU - Pei, Dee
AU  - Pei D
FAU - Chen, Yen-Lin
AU  - Chen YL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Eur J Intern Med
JT  - European journal of internal medicine
JID - 9003220
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/12/23 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/03/21 [accepted]
AID - S0953-6205(13)00097-6 [pii]
AID - 10.1016/j.ejim.2013.03.013 [doi]
PST - aheadofprint
SO  - Eur J Intern Med. 2013 May 3. pii: S0953-6205(13)00097-6. doi:
      10.1016/j.ejim.2013.03.013.

PMID- 23647812
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1471-0528 (Electronic)
IS  - 1470-0328 (Linking)
DP  - 2013 May 7
TI  - Association between gestational diabetes mellitus and subsequent overactive
      bladder among premenopausal female twins.
LID - 10.1111/1471-0528.12253 [doi]
AB  - OBJECTIVE: To investigate the association between a history of gestational
      diabetes mellitus (GDM) and overactive bladder (OAB) in women of premenopausal
      age. DESIGN: Population-based study. SETTING: The Swedish Twin Register.
      POPULATION: In 2005, a total of 14 094 female twins born between 1959 and 1985 in
      the Swedish Twin Registry participated in a comprehensive survey on common
      exposures and complex diseases. Structured questions provided information on GDM 
      and OAB. The present study was designed as a cross-sectional analysis including
      all women in the cohort having given birth before 2005 (n = 7855). METHODS: A
      logistic regression model based on generalised estimating equations was used to
      derive odds ratios (ORs). MAIN OUTCOME MEASURE: The association between a history
      of GDM and OAB was estimated using ORs with 95% confidence intervals (CIs).
      RESULTS: The prevalence of OAB in women with a history of GDM was 19.1% compared 
      with 10.7% in women without GDM. This corresponded to a two-fold increased odds
      of OAB in women with a history of gestational diabetes (OR 2.13, 95% CI
      1.48-3.05). After adjusting the analysis for age, body mass index, parity,
      smoking, and diabetes mellitus, having had GDM was associated with doubled odds
      of OAB (OR 1.88, 95% CI 1.26-2.80). CONCLUSIONS: A history of GDM was positively 
      associated with OAB among women of premenopausal age. The association does not
      seem to be mediated by body mass index or type-I or type-II diabetes mellitus.
CI  - (c) 2013 The Authors BJOG An International Journal of Obstetrics and Gynaecology 
      (c) 2013 RCOG.
AD  - Division of Obstetrics and Gynaecology, Department of Medical Epidemiology and
      Biostatistics, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.
FAU - Tettamanti, G
AU  - Tettamanti G
FAU - Iliadou, An
AU  - Iliadou A
FAU - Pedersen, Nl
AU  - Pedersen N
FAU - Bellocco, R
AU  - Bellocco R
FAU - Altman, D
AU  - Altman D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - BJOG
JT  - BJOG : an international journal of obstetrics and gynaecology
JID - 100935741
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/03/08 [accepted]
AID - 10.1111/1471-0528.12253 [doi]
PST - aheadofprint
SO  - BJOG. 2013 May 7. doi: 10.1111/1471-0528.12253.

PMID- 23647771
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
VI  - 49
IP  - 5
DP  - 2013 May
TI  - Reactive pituitary hyperplasia associated with paediatric primary hypothyroidism.
PG  - 421-2
LID - 10.1111/jpc.12201 [doi]
AD  - Department of Endocrinology and Diabetes, The Royal Children's Hospital,
      Melbourne, Victoria, Australia.
FAU - Mills, Nicholas Jw
AU  - Mills NJ
FAU - Wong, Sze Choong
AU  - Wong SC
FAU - Sabin, Matthew A
AU  - Sabin MA
FAU - Hewitt, Jacqueline K
AU  - Hewitt JK
LA  - eng
PT  - Letter
PL  - Australia
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1111/jpc.12201 [doi]
PST - ppublish
SO  - J Paediatr Child Health. 2013 May;49(5):421-2. doi: 10.1111/jpc.12201.

PMID- 23647754
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1879-0887 (Electronic)
IS  - 0167-8140 (Linking)
DP  - 2013 May 3
TI  - Risk of endocrine pancreatic insufficiency in patients receiving adjuvant
      chemoradiation for resected gastric cancer.
LID - S0167-8140(13)00188-6 [pii]
LID - 10.1016/j.radonc.2013.04.013 [doi]
AB  - BACKGROUND: Adjuvant radiotherapy combined with 5-fluorouracil based chemotherapy
      has become the new standard after curative resection in high risk gastric cancer.
      Beside many complications due to surgery, the addition of chemotherapy and
      radiotherapy as adjuvant treatment may lead to both acute and late toxicities.
      Pancreatic tissue irradiation during this adjuvant treatment because of
      incidental and unavoidable inclusion of the organ within the radiation field may 
      affect exocrine and endocrine functions of the organ. MATERIALS AND METHODS:
      Fifty-three patients with gastric adenocarcinoma were evaluated for adjuvant
      chemoradiotherapy after surgery. While 37 out of 53 patients were treated
      postoperatively due to either serosal or adjacent organ or lymph node
      involvement, 16 patients without these risk factors were followed up regularly
      without any additional treatment and they served as the control group. Fasting
      blood glucose (FBG), hemoglobin A1c (HBA1c), insulin and C-peptide levels were
      measured in the control and study groups after the surgery and 6months and 1year 
      later. RESULTS: At the baseline there was no difference in FBG, HbA1c, C-peptide 
      and insulin levels between the control and the study groups. At the end of the
      study there was a statistically significant decline in insulin and C-peptide
      levels in the study group, (7.5+/-6.0 vs 4.5+/-4.4IU/L, p: 0.002 and 2.3+/-0.9 vs
      1.56+/-0.9ng/ml, p: 0.001) respectively. CONCLUSIONS: Adjuvant radiotherapy in
      gastric cancer leads to a decrease in beta cell function and insulin secretion
      capacity of the pancreas with possible diabetes risk. Radiation-induced
      pancreatic injury and late effects of radiation on normal pancreatic tissue are
      unknown, but pancreas is more sensitive to radiation than known. This organ
      should be studied extensively in order to determine the tolerance doses and it
      should be contoured during abdominal radiotherapy planning as an organ at risk.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, 
      Turkey. Electronic address: cegemici@yahoo.com.
FAU - Gemici, Cengiz
AU  - Gemici C
FAU - Sargin, Mehmet
AU  - Sargin M
FAU - Uygur-Bayramicli, Oya
AU  - Uygur-Bayramicli O
FAU - Mayadagli, Alpaslan
AU  - Mayadagli A
FAU - Yaprak, Gokhan
AU  - Yaprak G
FAU - Dabak, Resat
AU  - Dabak R
FAU - Kocak, Mihriban
AU  - Kocak M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic
      Radiology and Oncology
JID - 8407192
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/06/07 [received]
PHST- 2013/02/10 [revised]
PHST- 2013/04/10 [accepted]
AID - S0167-8140(13)00188-6 [pii]
AID - 10.1016/j.radonc.2013.04.013 [doi]
PST - aheadofprint
SO  - Radiother Oncol. 2013 May 3. pii: S0167-8140(13)00188-6. doi:
      10.1016/j.radonc.2013.04.013.

PMID- 23647658
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - The over time development of chronic illness self-management patterns: a
      longitudinal qualitative study.
PG  - 452
LID - 10.1186/1471-2458-13-452 [doi]
AB  - BACKGROUND: There currently exists a vast amount of literature concerning chronic
      illness self-management, however the developmental patterns and sustainability of
      self-management over time remain largely unknown. This paper aims to describe the
      patterns by which different chronic illness self-management behaviors develop and
      are maintained over time. METHOD: Twenty-one individuals newly diagnosed with
      chronic illnesses (e.g., diabetes, rheumatism, ischemic heart disease, multiple
      sclerosis, chronic renal disease, inflammatory bowel disease) were repeatedly
      interviewed over two-and-a-half years. The interviews were conducted in Sweden
      from 2006 to 2008. A total of 81 narrative interviews were analyzed with an
      interpretive description approach. RESULTS: The participants' self-management
      behaviors could be described in four different developmental patterns:
      consistent, episodic, on demand, and transitional. The developmental patterns
      were related to specific self-management behaviors. Most participants took
      long-term medications in a consistent pattern, whereas exercise was often
      performed according to an episodic pattern. Participants managed health crises
      (e.g., angina, pain episodes) according to an on demand pattern and everyday
      changes due to illness (e.g., adaptation of work and household activities)
      according to a transitional pattern. All of the participants used more than one
      self-management pattern. CONCLUSION: The findings show that self-management does 
      not develop as one uniform pattern. Instead different self-management behaviors
      are enacted in different patterns. Therefore, it is likely that self-management
      activities require support strategies tailored to each behavior's developmental
      pattern.
AD  - Department of Health Sciences, Mid Sweden University, SE-851 70, Sundsvall,
      Sweden. asa.audulv@miun.se.
FAU - Audulv, Asa
AU  - Audulv A
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3649883
OID - NLM: PMC3649883
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/05/08 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 1471-2458-13-452 [pii]
AID - 10.1186/1471-2458-13-452 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 7;13:452. doi: 10.1186/1471-2458-13-452.

PMID- 23647654
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 2046-4053 (Electronic)
IS  - 2046-4053 (Linking)
VI  - 2
DP  - 2013
TI  - Improving quality of care for persons with diabetes: an overview of systematic
      reviews - what does the evidence tell us?
PG  - 26
LID - 10.1186/2046-4053-2-26 [doi]
AB  - BACKGROUND: Ensuring high quality care for persons with diabetes remains a
      challenge for healthcare systems globally with consistent evidence of suboptimal 
      care and outcomes. There is increasing interest in quality improvement strategies
      to improve diabetes management as reflected by a growing number of systematic
      reviews. These reviews are of varying quality and dispersed across many sources. 
      In this paper, we present an overview of systematic reviews evaluating the impact
      of interventions to improve the quality of diabetes care. METHODS: We searched
      for systematic reviews evaluating the effectiveness of any intervention intended 
      to improve intermediate patient outcomes and process of care measures for
      patients with any type of diabetes. Two reviewers independently screened search
      results, appraised each systematic review using AMSTAR and extracted data from
      high quality reviews (AMSTAR score >/= 5). Within reviews, we used vote counting 
      by direction of effect to report the number of studies favouring an intervention 
      for each outcome. We produced summaries of results for each intervention
      category. RESULTS: We identified 125 reviews of varying methodological quality
      and summarised key findings from 50 high quality reviews. We categorised reviews 
      by quality improvement intervention. Eight reviews were broad based (involving a 
      variety of strategies). Other reviews considered: patient education and support
      (n = 21), telemedicine (n = 10), provider role changes (n = 7), and
      organisational changes (n = 4). Reviews reported intermediate patient outcomes
      (e.g. glycaemic control) (n = 49) and process of care outcomes (n = 9). There was
      evidence of considerable overlap of included studies between reviews.
      CONCLUSIONS: There is consistent evidence from high quality systematic reviews
      that patient education and support, provider role changes, and telemedicine are
      associated with improvements in glycaemic and vascular risk factor control in
      patients. There is less evidence about the impact of quality improvement
      interventions on other key process measures such as screening patients for
      diabetic complications. This paper provides decision makers with a comprehensive 
      overview of evidence from high quality systematic reviews about the effects of
      quality improvement interventions on improving diabetes care.
AD  - Cochrane Effective Practice and Organisation of Care Group, Centre for
      Practice-Changing Research, Ottawa Hospital Research Institute, The Ottawa
      Hospital - General Campus, 501 Smyth Road, Box 711, Ottawa, Ontario K1H 8M5,
      Canada. jgrimshaw@ohri.ca.
FAU - Worswick, Julia
AU  - Worswick J
FAU - Wayne, S Carolyn
AU  - Wayne SC
FAU - Bennett, Rachel
AU  - Bennett R
FAU - Fiander, Michelle
AU  - Fiander M
FAU - Mayhew, Alain
AU  - Mayhew A
FAU - Weir, Michelle C
AU  - Weir MC
FAU - Sullivan, Katrina J
AU  - Sullivan KJ
FAU - Grimshaw, Jeremy M
AU  - Grimshaw JM
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - England
TA  - Syst Rev
JT  - Systematic reviews
JID - 101580575
SB  - IM
PMC - PMC3667096
OID - NLM: PMC3667096
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/09/24 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 2046-4053-2-26 [pii]
AID - 10.1186/2046-4053-2-26 [doi]
PST - epublish
SO  - Syst Rev. 2013 May 7;2:26. doi: 10.1186/2046-4053-2-26.

PMID- 23647644
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1365-2516 (Electronic)
IS  - 1351-8216 (Linking)
DP  - 2013 May 7
TI  - Results of the WIRK prospective, non-interventional observational study of
      recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia
      with inhibitors and other bleeding disorders.
LID - 10.1111/hae.12156 [doi]
AB  - Recombinant activated factor VII (rFVIIa) has been available for the treatment of
      acute bleeding and for prevention of bleeding during surgery and invasive
      procedures in patients with congenital haemophilia with inhibitors (CHwI) and
      acquired haemophilia since 1996. The study objective was to assess the efficacy
      and safety of rFVIIa in patients with CHwI, acquired haemophilia, congenital FVII
      deficiency and Glanzmann's thrombasthenia, in a real-life clinical setting. There
      were no specific inclusion or exclusion criteria; participation was offered to
      all German haemophilia centres known to use rFVIIa to treat patients with the
      above indications. Data on rFVIIa use and efficacy for the treatment of acute
      bleeding episodes and invasive procedures were recorded. Adverse drug reactions
      and recurrent bleeding episodes were also monitored. In total, 64 patients (50.0%
      women) received rFVIIa treatment. Patients experienced 281 evaluable bleeding
      episodes and underwent 44 invasive procedures. In 252 of 281 (89.7%) bleeding
      episodes, a stop (66.5%) or a significant reduction (23.1%) in bleeding was
      observed. No bleeding complications were reported for 42 of 44 (95.5%) invasive
      procedures covered with rFVIIa. A clear positive association was observed between
      early initiation of rFVIIa treatment for acute bleeding and efficacy. The total
      cumulative dose and number of injections were 468.3 +/- 545.8 mug kg-1 and 3.6
      +/- 4.6 respectively. No drug-related adverse events were reported. rFVIIa use in
      Germany provided effective haemostatic cover without associated adverse events in
      the management of acute bleeds and invasive procedures across a range of bleeding
      disorders.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center,
      Ruhr University Bochum, Bad Oeynhausen, Germany.
FAU - Birschmann, I
AU  - Birschmann I
FAU - Klamroth, R
AU  - Klamroth R
FAU - Eichler, H
AU  - Eichler H
FAU - Schenk, J
AU  - Schenk J
FAU - Kirchmaier, C M
AU  - Kirchmaier CM
FAU - Halimeh, S
AU  - Halimeh S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Haemophilia
JT  - Haemophilia : the official journal of the World Federation of Hemophilia
JID - 9442916
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/04/02 [accepted]
AID - 10.1111/hae.12156 [doi]
PST - aheadofprint
SO  - Haemophilia. 2013 May 7. doi: 10.1111/hae.12156.

PMID- 23647640
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1531-6564 (Electronic)
IS  - 0363-5023 (Linking)
VI  - 38
IP  - 6
DP  - 2013 Jun
TI  - Epidemiology of adult acute hand infections at an urban medical center.
PG  - 1189-93
LID - 10.1016/j.jhsa.2013.03.013 [doi]
LID - S0363-5023(13)00376-6 [pii]
AB  - PURPOSE: To define the current epidemiology of adult acute hand infections in an 
      urban setting, with the aim of helping to improve empiric treatment, as hand
      infections represent a major source of morbidity and can result in stiffness and,
      possibly, amputation. METHODS: We performed an electronic medical record search
      to identify all patients admitted to our urban academic medical center with
      diagnoses related to open wounds and infections in the hand and fingers over a
      6-year period (2005-2010). We recorded demographic data, location of infection,
      medical comorbidities, and culture data. RESULTS: Of the 2,287 patients admitted 
      with diagnoses related to open wounds and infections in the hand and fingers,
      1,507 incision and drainage procedures were performed, which resulted in 458
      patients (30%) with culture-positive infections. Wound cultures identified 39
      different species of bacteria. Most of these were methicillin-resistant
      Staphylococcus aureus, which compromised 53% of positive cultures, followed by
      methicillin-sensitive S aureus in 23% of positive cultures. The cultures were
      polymicrobial in 19%. History of intravenous drug use or diabetes mellitus was a 
      strong predictor of polymicrobial infection. CONCLUSIONS: Methicillin-resistant
      Staphylococcus aureus was the most common bacteria cultured from these
      infections. Empiric antibiotic coverage should routinely cover
      methicillin-resistant S aureus. We noted a higher incidence of polymicrobial
      infections than previously reported, particularly with intravenous drug use,
      diabetes, and human bites. Volar hand infections had the highest percentage of
      positive cultures, whereas paronychia had the lowest percentage. TYPE OF
      STUDY/LEVEL OF EVIDENCE: Prognostic IV.
CI  - Copyright (c) 2013 American Society for Surgery of the Hand. Published by
      Elsevier Inc. All rights reserved.
AD  - Department of Orthopaedics, University of Pittsburgh, Pittsburgh, PA; and the
      Rothman Institute; Philadelphia, PA. Electronic address: johnfowler10@gmail.com.
FAU - Fowler, John R
AU  - Fowler JR
FAU - Ilyas, Asif M
AU  - Ilyas AM
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - United States
TA  - J Hand Surg Am
JT  - The Journal of hand surgery
JID - 7609631
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/11/05 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/03/01 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - S0363-5023(13)00376-6 [pii]
AID - 10.1016/j.jhsa.2013.03.013 [doi]
PST - ppublish
SO  - J Hand Surg Am. 2013 Jun;38(6):1189-93. doi: 10.1016/j.jhsa.2013.03.013. Epub
      2013 May 3.

PMID- 23647616
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Determinants of lifestyle behavior in type 2 diabetes: results of the 2011
      cross-sectional survey on living with chronic diseases in Canada.
PG  - 451
LID - 10.1186/1471-2458-13-451 [doi]
AB  - BACKGROUND: Lifestyle behavior modification is an essential component of
      self-management of type 2 diabetes. We evaluated the prevalence of engagement in 
      lifestyle behaviors for management of the disease, as well as the impact of
      healthcare professional support on these behaviors. METHODS: Self-reported data
      were available from 2682 adult respondents, age 20 years or older, to the 2011
      Survey on Living with Chronic Diseases in Canada's diabetes component.
      Associations with never engaging in and not sustaining self-management behaviors 
      (of dietary change, weight control, exercise, and smoking cessation) were
      evaluated using binomial regression models. RESULTS: The prevalence of reported
      dietary change, weight control/loss, increased exercise and smoking cessation
      (among those who smoked since being diagnosed) were 89.7%, 72.1%, 69.5%, and
      30.6%, respectively. Those who reported not receiving health professional advice 
      in the previous 12 months were more likely to report never engaging in dietary
      change (RR = 2.7, 95% CI 1.8 - 4.2), exercise (RR = 1.7, 95% CI 1.3 - 2.1), or
      weight control/loss (RR = 2.2, 95% CI 1.3 - 3.6), but not smoking cessation (RR =
      1.0; 95% CI: 0.7 - 1.5). Also, living with diabetes for more than six years was
      associated with not sustaining dietary change, weight loss and smoking cessation.
      CONCLUSION: Health professional advice for lifestyle behaviors for type 2
      diabetes self-management may support individual actions. Patients living with the
      disease for more than 6 years may require additional support in sustaining
      recommended behaviors.
AD  - Department of Public Health Sciences, 2-040 Li Ka Shing Center for Health
      Research and Innovation, University of Alberta, Edmonton, AB T6G 2E1, Canada.
      jeff.johnson@ualberta.ca.
FAU - Agborsangaya, Calypse B
AU  - Agborsangaya CB
FAU - Gee, Marianne E
AU  - Gee ME
FAU - Johnson, Steven T
AU  - Johnson ST
FAU - Dunbar, Peggy
AU  - Dunbar P
FAU - Langlois, Marie-France
AU  - Langlois MF
FAU - Leiter, Lawrence A
AU  - Leiter LA
FAU - Pelletier, Catherine
AU  - Pelletier C
FAU - Johnson, Jeffrey A
AU  - Johnson JA
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3651408
OID - NLM: PMC3651408
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2012/09/27 [received]
PHST- 2013/05/03 [accepted]
PHST- 2013/05/07 [aheadofprint]
AID - 1471-2458-13-451 [pii]
AID - 10.1186/1471-2458-13-451 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 7;13:451. doi: 10.1186/1471-2458-13-451.

PMID- 23647541
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
VI  - 13
IP  - 10
DP  - 2013 May 1
TI  - Recent progresses in identifying nuclear receptors and their families.
PG  - 1192-200
AB  - Nuclear receptors (NRs) are members of a large superfamily of evolutionarily
      related DNA-binding transcription factors. They regulate diverse functions, such 
      as homeostasis, reproduction, development and metabolism. As nuclear receptors
      bind small molecules that can easily be modified by drug design, and control
      functions associated with major diseases (e.g. cancer, osteoporosis and
      diabetes), they are promising pharmacological targets. According to their
      different action mechanisms or functions, NR superfamily has been classified into
      seven families: NR1 (thyroid hormone like), NR2 (HNF4-like), NR3 (estrogen like),
      NR4 (nerve growth factor IB-like), NR5 (fushi tarazu-F1 like), NR6 (germ cell
      nuclear factor like), and NR0 (knirps or DAX like). With the avalanche of protein
      sequences generated in the postgenomic age, Scientists are facing the following
      challenging problems. Given an uncharacterized protein sequence, how can we
      identify whether it is a nuclear receptor? If it is, what family even subfamily
      it belongs to? To address these problems, many cheminformatics tools have been
      developed for nuclear receptor prediction. The current review is mainly focused
      on this field, including the functions, computational methods and limitations of 
      these tools.
AD  - Computer Department, Jing- De-Zhen Ceramic Institute, China. jdzxiaoxuan@163.com;
      xxiao@gordonlifescience.org.
FAU - Xiao, Xuan
AU  - Xiao X
FAU - Wang, Pu
AU  - Wang P
FAU - Chou, Kuo-Chen
AU  - Chou KC
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/02/26 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/04/08 [accepted]
AID - CTMC-EPUB-20130503-6 [pii]
PST - ppublish
SO  - Curr Top Med Chem. 2013 May 1;13(10):1192-200.

PMID- 23647503
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 May 6
TI  - Oestradiol concentrations are not elevated in obesity-associated
      hypogonadotrophic hypogonadism.
LID - 10.1111/cen.12236 [doi]
AD  - Division of Endocrinology, Diabetes and Metabolism, State University of New York 
      at Buffalo and Kaleida Health, Buffalo, NY, USA.
FAU - Dhindsa, Sandeep
AU  - Dhindsa S
FAU - Batra, Manav
AU  - Batra M
FAU - Kuhadiya, Nitesh
AU  - Kuhadiya N
FAU - Dandona, Paresh
AU  - Dandona P
LA  - ENG
PT  - LETTER
DEP - 20130506
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1111/cen.12236 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 May 6. doi: 10.1111/cen.12236.

PMID- 23647398
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 29
IP  - 7
DP  - 2013 Jul
TI  - Achieving recommended low density lipoprotein cholesterol goals and the factors
      associated with target achievement of hypercholesterolemia patients with
      rosuvastatin in primary care.
PG  - 751-60
LID - 10.1185/03007995.2013.802683 [doi]
AB  - Abstract Objective: Hypercholesterolemia is a major risk factor for
      cardiovascular disease and requires continuous management. The role of primary
      physicians in this regard is important, yet the factors associated with
      successful lipid lowering treatments in primary clinics have not been clearly
      identified. We aimed to evaluate the rate of successful hypercholesterolemia
      treatment in Korean primary care, and to identify the factors associated with
      achieving low density lipoprotein cholesterol (LDL-C) targets. Methods: We
      prospectively recruited and retrospectively assessed 1851 Korean patients with
      hypercholesterolemia who visited family physicians and were prescribed
      rosuvastatin for the first time. LDL-C lowering targets, defined according to
      NCEP ATP III guidelines, were evaluated at 6 months after the first prescription.
      The factors associated with achieving these targets were also assessed. Results: 
      Overall, 87.6% of our participants attained their LDL-C goals. In multiple
      logistic regression analysis, good adherence to medication was strongly
      associated with the achievement of target LDL-C levels, whereas higher
      cardiovascular risk factors including diabetes (in both sexes), low high density 
      lipoprotein, and current smoking status (in males), and hypertension (in females)
      were related to LDL-C target level failures. Conclusion: Our observations of the 
      short period for hypercholesterolemia in Korean primary care has revealed that
      the rate of achieving target LDL-C levels was high in these patients, whereas
      patients at higher risk for cardiovascular disease tended to have lower LDL-C
      achievement outcomes. Primary care physicians should pay more attention to
      patients showing higher cardiovascular risk and stress the need for good
      adherence and management regimens in these individuals.
AD  - Department of Family Medicine, University of Ulsan College of Medicine , Seoul , 
      Korea.
FAU - Lee, Jung Ah
AU  - Lee JA
FAU - Sunwoo, Sung
AU  - Sunwoo S
FAU - Kim, Young Sik
AU  - Kim YS
FAU - Oh, Han Jin
AU  - Oh HJ
FAU - Kang, Hee-Cheol
AU  - Kang HC
FAU - Park, Kyung-Chae
AU  - Park KC
FAU - Sin, Dong Hyuk
AU  - Sin DH
FAU - Lee, Sang Yeoup
AU  - Lee SY
FAU - Yang, Yun Jun
AU  - Yang YJ
FAU - Yu, Byung Yeon
AU  - Yu BY
FAU - Kim, Chul-Min
AU  - Kim CM
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
SB  - IM
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1185/03007995.2013.802683 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2013 Jul;29(7):751-60. doi: 10.1185/03007995.2013.802683.

PMID- 23647314
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
DP  - 2013 May 6
TI  - Optimal Blood Pressure for Cognitive Function: Findings from an Elderly
      African-American Cohort Study.
LID - 10.1111/jgs.12259 [doi]
AB  - OBJECTIVES: To report the results from a prospective cohort study on the
      association between blood pressure (BP) and cognitive function in elderly African
      Americans. DESIGN: Prospective cohort study conducted from 1997 to 2009. SETTING:
      Community-based study in Indianapolis. PARTICIPANTS: African Americans aged 65
      years or older (N = 3,145). MEASUREMENTS: At each assessment, participant
      cognitive function was measured using the Community Screening Interview for
      Dementia. Other measurements included BP, height, weight, education level,
      antihypertensive medication use, alcohol use, smoking, and history of chronic
      medical conditions. RESULTS: Longitudinal assessments (n = 5,995) contributed by 
      2,721 participants with complete independent variables were analyzed using a
      semiparametric mixed-effects model. Systolic BP (SBP) of approximately 135 mmHg
      and diastolic BP (DBP) of approximately 80 mmHg were associated with optimal
      cognitive function after adjusting for other variables (P = .02). Weight loss
      with body mass index < 30.0 kg/m2 was significantly related to poorer cognitive
      performance (P < .001). Older age at first assessment, lower education level;
      smoking; and history of depression, stroke, and diabetes mellitus were related to
      worse cognitive function; taking antihypertensive medication and drinking alcohol
      were associated with better cognitive function. CONCLUSION: High and low BP were 
      associated with poorer cognitive performance. A joint optimal region of SBP and
      DBP for cognitive function has been identified, which may provide useful clinical
      information on optimal BP control in cognitive health and lead to better quality 
      of life for elderly adults.
CI  - (c) 2013, Copyright the Authors Journal compilation (c) 2013, The American
      Geriatrics Society.
AD  - Department of Biostatistics, Indiana University, Indianapolis, Indiana.
FAU - Liu, Hai
AU  - Liu H
FAU - Gao, Sujuan
AU  - Gao S
FAU - Hall, Kathleen S
AU  - Hall KS
FAU - Unverzagt, Frederick W
AU  - Unverzagt FW
FAU - Lane, Kathleen A
AU  - Lane KA
FAU - Callahan, Christopher M
AU  - Callahan CM
FAU - Hendrie, Hugh C
AU  - Hendrie HC
LA  - ENG
GR  - P30 AG010133/AG/NIA NIH HHS/United States
GR  - R01 AG019181/AG/NIA NIH HHS/United States
GR  - R24 MH080827/MH/NIMH NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
AID - 10.1111/jgs.12259 [doi]
PST - aheadofprint
SO  - J Am Geriatr Soc. 2013 May 6. doi: 10.1111/jgs.12259.

PMID- 23647015
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Linking)
DP  - 2013 May 3
TI  - Quercetin and Allopurinol Reduce Liver Thioredoxin-Interacting Protein to Improve
      Inflammation and Lipid Accumulation in Diabetic Rats.
LID - 10.1111/bph.12226 [doi]
AB  - BACKGROUND AND PURPOSE: Thioredoxin-interacting protein (TXNIP), a regulator of
      cellular oxidative stress, is related to the NOD-like receptor 3 (NLRP3)
      inflammasome activation, inflammation and lipid metabolism, suggesting its role
      in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) in diabetes. This
      study investigated whether TXNIP was involved in type 1 diabetes-associated
      NAFLD, and anti-oxidants quercetin and allopurinol targeting TXNIP improved these
      disorders. EXPERIMENTAL APPROACH: Diabetes was induced in male SD rats by a
      single intraperitoneal injection of 55 mg/kg streptozotocin (STZ). Quercetin and 
      allopurinol were orally given to diabetic rats for 7 weeks. Hepatic function,
      oxidative stress, inflammation and lipid level were determined. Rat BRL-3A and
      human HepG2 cells were exposed to high glucose (30 mM) in the presence or absence
      of anti-oxidants, or TXNIP siRNA transfection or caspase-1 inhibitor Ac-YVAD-CMK.
      KEY RESULTS: Quercetin and allopurinol significantly inhibited TXNIP
      over-expression and NLRP3 inflammasome activation, up-regulated peroxisome
      proliferator-activated receptor alpha (PPARalpha) and down-regulated sterol
      regulatory element binding protein 1c (SREBP-1c), SREBP-2, fatty acid synthase
      (FAS) and liver X receptor alpha (LXR alpha), accompanying with reactive oxygen
      species (ROS) and interleukin-1beta reduction in diabetic rat liver. These
      effects were confirmed in hepatocyte cell models, showing that TXNIP
      down-regulation contributed to suppression of the NLRP3 inflammasome activation, 
      inflammation, PPARalpha/SREBPs dysexpression. CONCLUSIONS AND IMPLICATIONS: These
      results demonstrate that hepatic TXNIP inhibition by quercetin and allopurinol
      contributes to the improvement of liver inflammation and lipid accumulation under
      hyperglycemia condition. Therefore, quercetin and allopurinol targeting hepatic
      TXNIP may have therapeutic application to prevent type 1 diabetes-associated
      NAFLD.
CI  - This article is protected by copyright. All rights reserved.
AD  - State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences,
      Nanjing University, Nanjing, 210093, P. R., China.
FAU - Wang, Wei
AU  - Wang W
FAU - Wang, Chuang
AU  - Wang C
FAU - Ding, Xiao-Qin
AU  - Ding XQ
FAU - Pan, Ying
AU  - Pan Y
FAU - Gu, Ting-Ting
AU  - Gu TT
FAU - Wang, Ming-Xing
AU  - Wang MX
FAU - Liu, Yang-Liu
AU  - Liu YL
FAU - Wang, Fu-Meng
AU  - Wang FM
FAU - Wang, Shui-Juan
AU  - Wang SJ
FAU - Kong, Ling-Dong
AU  - Kong LD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/04/11 [accepted]
AID - 10.1111/bph.12226 [doi]
PST - aheadofprint
SO  - Br J Pharmacol. 2013 May 3. doi: 10.1111/bph.12226.

PMID- 23646921
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1439-0272 (Electronic)
IS  - 0303-4569 (Linking)
DP  - 2013 May 6
TI  - Transplantation KCNMA1 modified bone marrow-mesenchymal stem cell therapy for
      diabetes mellitus-induced erectile dysfunction.
LID - 10.1111/and.12104 [doi]
AB  - This study assessed the effect of KCNMA1 transfected bone marrow-mesenchymal stem
      cells (BM-MSCs) on the improvement of erectile function in diabetic rats. Sixty
      male Sprague-Dawley rats were injected with streptozotocin (STZ) and screened
      with apomorphine (APO) to establish diabetes mellitus-induced erectile
      dysfunction (DMED). DMED rats were randomly divided into four groups: rats in
      each group underwent intracavernous injection with either phosphate buffer
      solution (DMED+PBS), nontransfected MSCs (DMED+MSCs), empty vector transfected
      MSCs (DMED+null-MSCs) or KCNMA1 transfected MSCs (DMED+KCNMA1-MSCs). Before
      injection, high levels of KCNMA1 expression were confirmed in KCNMA1-MSCs using
      RT-PCR and Western blotting. The lentivirus transfected MSCs maintained their
      potential for multidirectional differentiation. Four weeks after injection,
      erectile function was ascertained by measuring intracavernous pressure (ICP).
      Penile tissues were collected for immunohistochemical analysis. The expression of
      KCNMA1 in the corpus cavernosum was increased, and the DMED+KCNMA1-MSCs group
      displayed a significant improvement of erectile function. We concluded that
      KCNMA1 was able to enhance the positive effect of MSCs in the treatment of
      diabetes-associated erectile dysfunction.
CI  - (c) 2013 Blackwell Verlag GmbH.
AD  - Department of Urology, the First Affiliated Hospital, Chongqing Medical
      University, Chongqing, China; Chongqing Key Laboratory of Neurology, the First
      Affiliated Hospital, Chongqing Medical University, Chongqing, China; Department
      of Urology, Suining Central Hospital, Sichuan, China.
FAU - He, Y
AU  - He Y
FAU - He, W
AU  - He W
FAU - Qin, G
AU  - Qin G
FAU - Luo, J
AU  - Luo J
FAU - Xiao, M
AU  - Xiao M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Andrologia
JT  - Andrologia
JID - 0423506
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PHST- 2013/03/04 [accepted]
AID - 10.1111/and.12104 [doi]
PST - aheadofprint
SO  - Andrologia. 2013 May 6. doi: 10.1111/and.12104.

PMID- 23646411
OWN - NLM
STAT- In-Process
DA  - 20130507
IS  - 1472-0795 (Print)
IS  - 1472-0795 (Linking)
VI  - 25
IP  - 3
DP  - 2013 Apr
TI  - Age discrimination lies behind poor diabetes care.
PG  - 5
FAU - Berry, Lisa
AU  - Berry L
LA  - eng
PT  - News
PL  - England
TA  - Nurs Older People
JT  - Nursing older people
JID - 101084156
SB  - N
EDAT- 2013/05/08 06:00
MHDA- 2013/05/08 06:00
CRDT- 2013/05/08 06:00
PST - ppublish
SO  - Nurs Older People. 2013 Apr;25(3):5.

PMID- 23646298
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 2221-1691 (Print)
IS  - 2221-1691 (Linking)
VI  - 3
IP  - 5
DP  - 2013 May
TI  - Hypoglycemic and anti-hyperglycemic study of Gynura procumbens leaf extracts.
PG  - 358-66
LID - 10.1016/S2221-1691(13)60077-5 [doi]
AB  - OBJECTIVE: To study the antidiabetic activity of Gynura procumbens (G.
      procumbens) used in the traditional management of diabetes in Southern Asia.
      METHODS: G. procumbens leaves were extracted sequentially with graded percentage 
      of ethanol in water (95%, 75%, 50%, 25% and 0%), and the extracts were tested for
      antidiabetic activity using acute (7 h), subcutaneous glucose tolerance test and 
      sub-chronic (14 d) test in non-diabetic and streptozotocin-induced diabetic rats.
      The extracts were further subjected to phytochemical studies. RESULTS: In acute
      dose (1 g/kg), the extracts significantly lowered fasting blood glucose (FBG) in 
      streptozotocin-induced diabetic rats (P<0.05). However, the FBG-lowering effect
      of the 25% extract compared to the other extracts, was rapid (47% after 2 h) and 
      the highest: 53%, 53% and 60% in the 3rd, 5th, and 7th h, respectively (P<0.05), 
      comparable only to the effect of metformin. Furthermore, the extracts suppressed 
      peak FBG in subcutaneous glucose tolerance test, but only the 0% and 25%
      extracts, and metformin sustained the decrease until the 90th min (P<0.05).
      Moreover, in the 14 days study, the 25% extract exerted the highest FBG-lowering 
      effect, namely 49.38% and 65.43% on days 7 and 14, respectively (P<0.05), similar
      to the effect of metformin (46.26% and 65.42%). Total flavanoid and phenolic
      contents in the extracts were found to decrease with increase in polarity of
      extraction solvents. The composition of reference compounds (chlorogenic acid,
      rutin, astragalin and kaempferol-3-O-rutinoside) followed a similar trend.
      CONCLUSIONS: G. procumbens contains antidiabetic principles, most extracted in
      25% ethanol. Interaction among active components appears to determine the
      antidiabetic efficacy, achieved likely by a metformin-like mechanism.
AD  - School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang,
      Malaysia.
FAU - Algariri, Khalid
AU  - Algariri K
FAU - Meng, Kuong Y
AU  - Meng KY
FAU - Atangwho, Item J
AU  - Atangwho IJ
FAU - Asmawi, Mohd Z
AU  - Asmawi MZ
FAU - Sadikun, Amirin
AU  - Sadikun A
FAU - Murugaiyah, Vikneswaran
AU  - Murugaiyah V
FAU - Ismail, Norhyati
AU  - Ismail N
FAU - Eteng, Mbeh Ubana
AU  - Eteng MU
LA  - eng
PT  - Journal Article
PL  - China
TA  - Asian Pac J Trop Biomed
JT  - Asian Pacific journal of tropical biomedicine
JID - 101557706
PMC - PMC3642444
OID - NLM: PMC3642444
OTO - NOTNLM
OT  - Antidiabetic
OT  - Fasting blood glucose
OT  - Flavanoids
OT  - Gynura procumbens
OT  - Phenolics
OT  - Streptozotocin-induced diabetes
OT  - Subcutaneous glucose tolerance test
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/19 [received]
PHST- 2013/04/16 [accepted]
AID - 10.1016/S2221-1691(13)60077-5 [doi]
AID - apjtb-03-05-358 [pii]
PST - ppublish
SO  - Asian Pac J Trop Biomed. 2013 May;3(5):358-66. doi:
      10.1016/S2221-1691(13)60077-5.

PMID- 23646198
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Ablation of C/EBP Homologous Protein Does Not Protect T17M RHO Mice from Retinal 
      Degeneration.
PG  - e63205
LID - 10.1371/journal.pone.0063205 [doi]
AB  - Despite the proposed link between ablation of the CHOP protein and delay of the
      onset of ER stress-mediated disorders including diabetes, Alzheimer Disease, and 
      cardiac hypertrophy, the role of CHOP protein in photoreceptor cell death
      associated with Autosomal Dominant Retinitis Pigmentosa (ADRP) has not been
      investigated. T17M RHO transgenic mice carry a mutated human rhodopsin transgene,
      the expression of which in retina leads to protein misfolding, activation of UPR 
      and progressive retinal degeneration. The purpose of this study is to investigate
      the role of CHOP protein in T17M RHO retina. Wild-type, CHOP-/-, T17M RHO and
      T17M RHO CHOP-/-mice were used in the study. Evaluation of the impact of CHOP
      ablation was performed using electroretinography (ERG), spectral-domain optical
      coherence tomography (SD-OCT), quantitative Real-Time PCR (qRT-PCR) and western
      blot analysis. Dark-adapted ERG analysis demonstrated that by 1 month, the T17M
      RHO CHOP-/- mice had a 70% reduction of the a-wave amplitude compared to the T17M
      RHO mice. The loss of function in T17M RHO CHOP-/- photoreceptors was associated 
      with a 22-24% decline in the thickness of the outer nuclear layer. These mice had
      significant reduction in the expression of transcription factors, Crx and Nrl,
      and also in mouse Rho, and human RHO. The reduction was associated with an 8-fold
      elevation of the UPR marker, p-eIf2alpha protein and 30% down-regulation of sXbp1
      protein. In addition, the histone deacetylase 1 (Hdac1) protein was 2-fold
      elevated in the T17M RHO CHOP-/- retina. The ablation of CHOP led to a reduction 
      in the expression of photoreceptor-specific transcriptional factors, and both
      endogenous and exogenous RHO mRNA. Thus, despite its role in promoting apoptosis,
      CHOP protects rod photoreceptors carrying an ADRP mutation.
AD  - Department of Cell Biology and Anatomy, University of North Texas Health Science 
      Center, Fort Worth, Texas, United States of America.
FAU - Nashine, Sonali
AU  - Nashine S
FAU - Bhootada, Yogesh
AU  - Bhootada Y
FAU - Lewin, Alfred S
AU  - Lewin AS
FAU - Gorbatyuk, Marina
AU  - Gorbatyuk M
LA  - eng
GR  - R01 EY020905/EY/NEI NIH HHS/United States
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3640035
OID - NLM: PMC3640035
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013 [ppublish]
PHST- 2012/08/17 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.1371/journal.pone.0063205 [doi]
AID - PONE-D-12-25750 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 30;8(4):e63205. doi: 10.1371/journal.pone.0063205. Print 2013.

PMID- 23646149
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Rosiglitazone Treatment of Type 2 Diabetic db/db Mice Attenuates Urinary Albumin 
      and Angiotensin Converting Enzyme 2 Excretion.
PG  - e62833
LID - 10.1371/journal.pone.0062833 [doi]
AB  - Alterations within the renal renin angiotensin system play a pivotal role in the 
      development and progression of cardiovascular and renal disease. Angiotensin
      converting enzyme 2 (ACE2) is highly expressed in renal tubules and has been
      shown to be renoprotective in diabetes. The protease, a disintegrin and
      metalloprotease (ADAM) 17, is involved in the ectodomain shedding of several
      transmembrane proteins including ACE2. Renal ACE2 and ADAM17 were significantly
      increased in db/db mice compared to controls. We investigated the effect of the
      insulin sensitizer, rosiglitazone, on albuminuria, renal ADAM17 protein
      expression and ACE2 shedding in db/db diabetic mice. Rosiglitazone treatment of
      db/db mice normalized hyperglycemia, attenuated renal injury and decreased
      urinary ACE2 and renal ADAM17 protein expression. Urinary excreted ACE2 is
      enzymatically active. Western blot analysis of urinary ACE2 demonstrated two
      prominent immunoreactive bands at approximately 70 & 90 kDa. The predominant
      immunoreactive band is approximately 20 kDa shorter than the one demonstrated for
      kidney lysate, indicating possible ectodomain shedding of active renal ACE2 in
      the urine. Therefore, it is tempting to speculate that renoprotection of
      rosiglitazone could be partially mediated via downregulation of renal ADAM17 and 
      ACE2 shedding. In addition, there was a positive correlation between blood
      glucose, urinary albumin, plasma glucagon, and triglyceride levels with urinary
      ACE2 excretion. In conclusion, urinary ACE2 could be used as a sensitive
      biomarker of diabetic nephropathy and for monitoring the effectiveness of
      renoprotective medication.
AD  - Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright
      State University, Dayton, Ohio, United States of America.
FAU - Chodavarapu, Harshita
AU  - Chodavarapu H
FAU - Grobe, Nadja
AU  - Grobe N
FAU - Somineni, Hari K
AU  - Somineni HK
FAU - Salem, Esam S B
AU  - Salem ES
FAU - Madhu, Malav
AU  - Madhu M
FAU - Elased, Khalid M
AU  - Elased KM
LA  - eng
GR  - F32 DK093226/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3639987
OID - NLM: PMC3639987
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/07 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.1371/journal.pone.0062833 [doi]
AID - PONE-D-13-05794 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 30;8(4):e62833. doi: 10.1371/journal.pone.0062833. Print 2013.

PMID- 23646121
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - The Clinical Significance and Risk Factors of Anti-Platelet Factor 4/heparin
      Antibody on Maintenance Hemodialysis Patients: A Two-Year Prospective Follow-up.
PG  - e62239
LID - 10.1371/journal.pone.0062239 [doi]
AB  - BACKGROUND: Heparin-induced thrombocytopenia is an immune response mediated by
      anti-PF4/heparin antibody, which is clinically characterized by thrombocytopenia 
      and thromboembolic events. In this study, a prospective and multi-center clinical
      investigation [Formula: see text] determined the positive rate of
      anti-PF4/heparin antibody in maintenance hemodialysis patients in China,
      [Formula: see text] identified the related risk factors, and [Formula: see text] 
      further explored the effect of the anti-PF4/heparin antibody on bleeding,
      thromboembolic events, and risk of death in the patients. METHODS: The serum
      anti-PF4/heparin antibody was measured in 661 patients from nine hemodialysis
      centers, detected by IgG-specific ELISA and followed by confirmation with excess 
      heparin. Risk factors of these patients were analyzed. Based on a two-year
      follow-up, the association between the anti-PF4/heparin antibody and bleeding,
      thromboembolic events, and risk of death in the patients was investigated.
      RESULTS: [Formula: see text] The positivity rate of the anti-PF4/heparin antibody
      in maintenance hemodialysis patients was 5.6%. With diabetes as an independent
      risk factor, the positivity rate of the anti-PF4/heparin antibody decreased in
      the patients undergoing weekly dialyses >/=3 times. [Formula: see text] The
      positivity rate of the anti-PF4/heparin antibody was not related to the
      occurrence of clinical thromboembolic events and was not a risk factor for death 
      within two years in maintenance hemodialysis patients. [Formula: see text]
      Negativity for the anti-PF4/heparin antibody combined with a reduction of the
      platelet count or combined with the administration of antiplatelet drugs yielded 
      a significant increase in bleeding events. However, the composite determination
      of the anti-PF4/heparin antibody and thrombocytopenia, as well as the
      administration of antiplatelet drugs, was not predictive for the risk of
      thromboembolic events in the maintenance hemodialysis patients. CONCLUSIONS: A
      single detection of the anti-PF4/heparin antibody did not predict the occurrence 
      of clinical bleeding, thromboembolic events, or risk of death in the maintenance 
      hemodialysis patients.
AD  - Department of Nephrology, Chinese PLA General Hospital, State Key Laboratory of
      Kidney Disease (2011DAV00088), Beijing, China.
FAU - Zhao, Delong
AU  - Zhao D
FAU - Sun, Xuefeng
AU  - Sun X
FAU - Yao, Li
AU  - Yao L
FAU - Lin, Hongli
AU  - Lin H
FAU - Li, Jijun
AU  - Li J
FAU - Zhao, Jiuyang
AU  - Zhao J
FAU - Zhang, Zhimin
AU  - Zhang Z
FAU - Lun, Lide
AU  - Lun L
FAU - Zhang, Jianrong
AU  - Zhang J
FAU - Li, Mingxu
AU  - Li M
FAU - Huang, Qi
AU  - Huang Q
FAU - Yang, Yang
AU  - Yang Y
FAU - Jiang, Shimin
AU  - Jiang S
FAU - Wang, Yong
AU  - Wang Y
FAU - Zhu, Hanyu
AU  - Zhu H
FAU - Chen, Xiangmei
AU  - Chen X
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3639940
OID - NLM: PMC3639940
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/15 [received]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.1371/journal.pone.0062239 [doi]
AID - PONE-D-13-02341 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 30;8(4):e62239. doi: 10.1371/journal.pone.0062239. Print 2013.

PMID- 23645990
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
LR  - 20130508
IS  - 1179-5476 (Electronic)
IS  - 1179-5476 (Linking)
VI  - 6
DP  - 2013
TI  - Graves' thyrotoxicosis-induced reversible cardiomyopathy: a case report.
PG  - 47-50
LID - 10.4137/CCRep.S10534 [doi]
AB  - The objective of this report is to present a case of Graves'
      thyrotoxicosis-induced cardiomyopathy. This is a case of a 26 year old woman that
      presented with severe symptomatic congestive heart failure and was subsequently
      diagnosed with dilated cardiomyopathy secondary to Graves' disease. Despite an
      initial left ventricular systolic ejection fraction of 20% on echocardiography,
      treatment with anti-thyroid agents led to rapid improvement of her clinical
      status and normalization of her ejection fraction. The proposed mechanisms
      underlying the development of systolic dysfunction in thyrotoxicosis are
      discussed and the literature on similar cases previously reported is highlighted.
      Cardiomyopathy should be considered even in young patients with Graves'
      thyrotoxicosis.
AD  - Specialized Diabetes and Endocrine Center, King Fahad Medical City, Riyadh, Saudi
      Arabia.
FAU - Al-Ghamdi, Ahmad S
AU  - Al-Ghamdi AS
FAU - Aljohani, Naji
AU  - Aljohani N
LA  - eng
PT  - Journal Article
DEP - 20130327
PL  - New Zealand
TA  - Clin Med Insights Case Rep
JT  - Clinical medicine insights. Case reports
JID - 101531893
PMC - PMC3623610
OID - NLM: PMC3623610
OTO - NOTNLM
OT  - Graves’ disease
OT  - cardiomyopathy
OT  - congestive heart failure
OT  - thyrotoxicosis
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:01
CRDT- 2013/05/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/27 [epublish]
AID - 10.4137/CCRep.S10534 [doi]
AID - ccrep-6-2013-047 [pii]
PST - epublish
SO  - Clin Med Insights Case Rep. 2013 Mar 27;6:47-50. doi: 10.4137/CCRep.S10534. Print
      2013.

PMID- 23645989
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
LR  - 20130508
IS  - 1179-5468 (Electronic)
VI  - 7
DP  - 2013
TI  - Unique and Varied Contributions of Traditional CVD Risk Factors: A Systematic
      Literature Review of CAD Risk Factors in China.
PG  - 59-86
LID - 10.4137/CMC.S10225 [doi]
AB  - This study is the first systematic review of risk factors for stroke in China and
      supports the importance of current public health initiatives to manage the risk
      factors appropriately to reduce risk of stroke in high risk patients.
      Additionally, this study has been co-authored by prominent Chinese and US
      physicians and researchers with expertise in cardiovascular disease, neurologic
      disorders, epidemiology, and real world data. While there have been several
      systematic reviews of real world associations of risk factors for coronary artery
      disease, none focus specifically on the population of China, where there is
      growing evidence that such risk factors are poorly treated or uncontrolled,
      especially in rural areas. BACKGROUND: To better understand the impact of
      traditional cardiovascular risk factors on risk of coronary artery disease (CAD) 
      in China, a systematic review of all Chinese observational studies published in
      either English or Chinese in MEDLINE and EMBASE over the last 5 years was
      performed and the association between any of 5 traditional risk factors (ie,
      hypertension, diabetes, elevated lipid levels, obesity, and smoking) and the risk
      of CAD was studied. METHODS AND RESULTS: The study found a consistent
      relationship between lipid levels and CAD. Higher low-density lipoprotein
      cholesterol values were associated with greater risk of CAD, with an odds ratio
      as high as 3.31. Other factors found to be significant contributors to the risk
      of CAD included hypertension (crude odds ratio range of 1.40-5.11), diabetes
      (1.50-5.97), and smoking (1.37-5.19). An association between obesity and CAD in
      China was observed, but the evidence supporting this was considered weak due to
      the paucity of studies found as part of this review. CONCLUSIONS: This review
      provides a systematic summary of CAD risk factors in China and demonstrates the
      important differences that exist in CAD risk factors between countries and
      regions. Approaches to reduce CAD globally must take into account the unique risk
      factors that drive CAD in each country and region as is demonstrated by these
      findings.
AD  - Cardiovascular Wellness Program, Brigham and Women's Hospital, Boston, MA, USA.
FAU - Foody, Joanne
AU  - Foody J
FAU - Huo, Yong
AU  - Huo Y
FAU - Ji, Linong
AU  - Ji L
FAU - Zhao, Dong
AU  - Zhao D
FAU - Boyd, Dylan
AU  - Boyd D
FAU - Meng, Hai Jin
AU  - Meng HJ
FAU - Shiff, Susan
AU  - Shiff S
FAU - Hu, Dayi
AU  - Hu D
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - New Zealand
TA  - Clin Med Insights Cardiol
JT  - Clinical Medicine Insights. Cardiology
JID - 101525768
PMC - PMC3623600
OID - NLM: PMC3623600
OTO - NOTNLM
OT  - coronary disease
OT  - diabetes
OT  - dyslipidemia
OT  - hypertension
OT  - risk factors
OT  - smoking
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:01
CRDT- 2013/05/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/04 [epublish]
AID - 10.4137/CMC.S10225 [doi]
AID - cmc-7-2013-059 [pii]
PST - epublish
SO  - Clin Med Insights Cardiol. 2013 Apr 4;7:59-86. doi: 10.4137/CMC.S10225. Print
      2013.

PMID- 23645988
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
LR  - 20130508
IS  - 1179-5441 (Electronic)
IS  - 1179-5441 (Linking)
VI  - 6
DP  - 2013
TI  - Comorbidity profile among patients with rheumatoid arthritis and the impact on
      prescriptions trend.
PG  - 11-8
LID - 10.4137/CMAMD.S11481 [doi]
AB  - Comorbid conditions play a pivotal role in rheumatoid arthritis management and
      outcomes. We estimated the percentage of comorbid illness among rheumatoid
      arthritis patients and explored the relationship between this comorbidity and
      different prescriptions. A cross-sectional study of patients with rheumatoid
      arthritis in three centers in Saudi Arabia was carried out. Comorbidity and
      antirheumatoid medication regimens prescribed were recorded on a specially
      designed Performa. The association between comorbidity and different drugs was
      analyzed. A total of 340 patients were included. The most comorbidities were
      hypertension 122 (35.9%), diabetes 105 (30.9%), osteoporosis 88 (25.8%), and
      dyslipidemia in 66 (19.4). The most common drug prescribed was prednisolone in
      275 (80.8%) patients followed by methotrexate in 253 (74.4%) and biological
      therapy in 142 (41.5%) patients. Glucocorticoids were prescribed considerably
      more frequently in hypertensive and diabetic patients as well as in patients with
      osteoporosis and dyslipidemia. Most patients with rheumatoid arthritis suffered
      from comorbid diseases.
AD  - Department of internal Medicine, Taif University, Taif, PO Box 11153, Saudi
      Arabia.
FAU - Al-Bishri, J
AU  - Al-Bishri J
FAU - Attar, Sm
AU  - Attar S
FAU - Bassuni, Nawal
AU  - Bassuni N
FAU - Al-Nofaiey, Yasser
AU  - Al-Nofaiey Y
FAU - Qutbuddeen, Hamed
AU  - Qutbuddeen H
FAU - Al-Harthi, Salma
AU  - Al-Harthi S
FAU - Subahi, Sarah
AU  - Subahi S
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - New Zealand
TA  - Clin Med Insights Arthritis Musculoskelet Disord
JT  - Clinical medicine insights. Arthritis and musculoskeletal disorders
JID - 101542737
PMC - PMC3623601
OID - NLM: PMC3623601
OTO - NOTNLM
OT  - NSAIDs
OT  - RA
OT  - comorbidity
OT  - diabetes
OT  - glucocorticoids
OT  - hypertension
OT  - rheumatoid arthritis
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:01
CRDT- 2013/05/07 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/04 [epublish]
AID - 10.4137/CMAMD.S11481 [doi]
AID - cmamd-6-2013-011 [pii]
PST - epublish
SO  - Clin Med Insights Arthritis Musculoskelet Disord. 2013 Apr 4;6:11-8. doi:
      10.4137/CMAMD.S11481. Print 2013.

PMID- 23645958
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
LR  - 20130508
IS  - 0253-0716 (Print)
IS  - 0253-0716 (Linking)
VI  - 38
IP  - 1
DP  - 2013 Mar
TI  - Determination of blood glucose concentration by using wavelet transform and
      neural networks.
PG  - 51-6
AB  - Background: Early and non-invasive determination of blood glucose level is of
      great importance. We aimed to present a new technique to accurately infer the
      blood glucose concentration in peripheral blood flow using non-invasive optical
      monitoring system. Methods: The data for the research were obtained from 900
      individuals. Of them, 750 people had diabetes mellitus (DM). The system was
      designed using a helium neon laser source of 632.8 nm wavelength with 5mW power, 
      photo detectors and digital storage oscilloscope. The laser beam was directed
      through a single optical fiber to the index finger and the scattered beams were
      collected by the photo detectors placed circumferentially to the transmitting
      fiber. The received signals were filtered using band pass filter and finally sent
      to a digital storage oscilloscope. These signals were then decomposed into
      approximation and detail coefficients using modified Haar Wavelet Transform. Back
      propagation neural and radial basis functions were employed for the prediction of
      blood glucose concentration. Results: The data of 450 patients were randomly used
      for training, 225 for testing and the rest for validation. The data showed that
      outputs from radial basis function were nearer to the clinical value. Significant
      variations could be seen from signals obtained from patients with DM and those
      without DM. Conclusion: The proposed non-invasive optical glucose monitoring
      system is able to predict the glucose concentration by proving that there is a
      definite variation in hematological distribution between patients with DM and
      those without DM.
AD  - Electronics and Communication Engineering, Nandha College of Technology, Erode,
      India;
FAU - Ashok, Vajravelu
AU  - Ashok V
FAU - Kumar, Nirmal
AU  - Kumar N
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Med Sci
JT  - Iranian journal of medical sciences
JID - 8104374
PMC - PMC3642945
OID - NLM: PMC3642945
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Neural networks
OT  - Noninvasive
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:01
CRDT- 2013/05/07 06:00
PHST- 2011/12/13 [received]
PHST- 2011/02/06 [revised]
PHST- 2012/04/08 [accepted]
PST - ppublish
SO  - Iran J Med Sci. 2013 Mar;38(1):51-6.

PMID- 23645956
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
LR  - 20130508
IS  - 0253-0716 (Print)
IS  - 0253-0716 (Linking)
VI  - 38
IP  - 1
DP  - 2013 Mar
TI  - Effect of probiotics on lipid profile, glycemic control, insulin action,
      oxidative stress, and inflammatory markers in patients with type 2 diabetes: a
      clinical trial.
PG  - 38-43
AB  - Background: The dramatic increase in the incidence of diabetes and its associated
      complications require a natural and safe solution to control and delay such
      complications. The present study tested the hypothesis that probiotics may affect
      biochemical indices of diabetic patients Methods: Thirty four types 2 diabetic
      patients aged between 25 to 65 years, and diagnosed with diabetes for less than
      15 years were selected for this single- blinded clinical trial. Using balanced
      block random sampling, the patients were divided into two groups of intervention 
      (probiotics) and placebo. Blood samples tested for baseline glucose, insulin, TG,
      total cholesterol, LDL-C, HDL-C, malondialdehyde, high sensitive CRP (hs-CRP) and
      IL-6. After six weeks of experiment, fasting blood samples were re-tested and the
      data obtained were analyzed using SPSS software. Results: There were no
      significant differences between anthropometric data including body mass index and
      waist to hip ratio in placebo and treatment groups. There was no significant
      difference in FBS, Serum TG concentration total cholesterol and LDL-C levels
      between placebo and treatment groups. HDL-C levels were slightly elevated after
      probiotic treatment, which were not statistically significant. Insulin, MDA and
      IL-6 levels were reduced and high sensitive CRP hs.CRP levels were elevated,
      although, not statistically significant. Conclusion: The result of this study
      indicates a non- significant declining trend in the level of TG, MDA and IL-6 and
      insulin resistance after consumption of probiotics.
AD  - Department of Nutrition, School of Health and Nutrition, Shiraz University of
      Medical Sciences, Shiraz, Iran;
FAU - Mazloom, Zohreh
AU  - Mazloom Z
FAU - Yousefinejad, Abbas
AU  - Yousefinejad A
FAU - Dabbaghmanesh, Mohammad Hossein
AU  - Dabbaghmanesh MH
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Iran J Med Sci
JT  - Iranian journal of medical sciences
JID - 8104374
PMC - PMC3642943
OID - NLM: PMC3642943
OTO - NOTNLM
OT  - CRP
OT  - Diabetes
OT  - Insulin resistance
OT  - Probiotic
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:01
CRDT- 2013/05/07 06:00
PHST- 2011/09/03 [received]
PHST- 2011/11/12 [revised]
PHST- 2011/12/11 [accepted]
PST - ppublish
SO  - Iran J Med Sci. 2013 Mar;38(1):38-43.

PMID- 23645912
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
LR  - 20130508
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 5
DP  - 2013
TI  - Job strain and supervisor support in primary care health centres and glycaemic
      control among patients with type 2 diabetes: a cross-sectional study.
LID - 10.1136/bmjopen-2012-002297 [doi]
LID - e002297 [pii]
AB  - OBJECTIVES: This study investigates associations between healthcare personnel's
      perceived job strain, supervisor support and the outcome of care in terms of
      glycaemic control among patients with type 2 diabetes. DESIGN: A cross-sectional 
      study from 2006. SETTING: 18 primary care health centres (HCs) from five
      municipalities in Finland. PARTICIPANTS: Aggregated survey data on perceived job 
      strain and supervisor support from healthcare personnel (doctors, n=122, mean age
      45.5 years, nurses, n=300, mean age 47.1 years) were combined with registered
      data (Electronic Medical Records) from 8975 patients (51% men, mean age 67 years)
      with type 2 diabetes. OUTCOME MEASURE: Poor glycaemic control (glycated
      haemoglobin (HbA1c) >/=7%). RESULTS: The mean HbA1c level among patients with
      type 2 diabetes was 7.1 (SD 1.2, range 4.5-19.1), and 43% had poor glycaemic
      control (HbA1c >/=7%). Multilevel logistic regression analyses, adjusted for
      patient's age and sex, and HC and HC service area-level characteristics, showed
      that patients' HbA1c-levels were less optimal in high-strain HCs than in
      low-strain HCs (OR 1.44, 95% CI 1.12 to 1.86). Supervisor support in HCs was not 
      associated with the outcome of care. CONCLUSIONS: The level of job strain among
      healthcare personnel may play a role in achieving good glycaemic control among
      patients with type 2 diabetes.
AD  - Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki,
      Finland.
FAU - Koponen, Anne
AU  - Koponen A
FAU - Vahtera, Jussi
AU  - Vahtera J
FAU - Pitkaniemi, Janne
AU  - Pitkaniemi J
FAU - Virtanen, Marianna
AU  - Virtanen M
FAU - Pentti, Jaana
AU  - Pentti J
FAU - Simonsen-Rehn, Nina
AU  - Simonsen-Rehn N
FAU - Kivimaki, Mika
AU  - Kivimaki M
FAU - Suominen, Sakari
AU  - Suominen S
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3646170
OID - NLM: PMC3646170
OTO - NOTNLM
OT  - Primary Care
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:01
CRDT- 2013/05/07 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2012-002297 [pii]
AID - 10.1136/bmjopen-2012-002297 [doi]
PST - epublish
SO  - BMJ Open. 2013 May 2;3(5). pii: e002297. doi: 10.1136/bmjopen-2012-002297. Print 
      2013.

PMID- 23645908
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
LR  - 20130508
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 5
DP  - 2013
TI  - Body mass index and perioperative complications after oesophagectomy for
      adenocarcinoma: a systematic database review.
LID - 10.1136/bmjopen-2012-001336 [doi]
LID - e001336 [pii]
AB  - OBJECTIVE: Given the increasing rate of obesity, the effects of excessive body
      weight on surgical outcomes constitute a relevant quality of care concern. Our
      aim was to determine the relationship between preoperative body mass index (BMI) 
      on perioperative complications after oesophagectomy for adenocarcinoma of the
      oesophagus. DESIGN: Retrospective database review. SETTING: Single institution
      high volume oncological tertiary care referral centre. PARTICIPANTS: From our
      comprehensive oesophageal cancer database consisting of 709 patients, we
      stratified patients according to BMI: 155 normal-weight (BMI 20-24), 198
      overweight (BMI 25-29) and 187 obese (BMI >/=30) patients. INTERVENTIONS: All
      patients underwent oesophagectomy for cancer. PRIMARY AND SECONDARY OUTCOME
      MEASURES: Incidences of preoperative risk factors and perioperative complications
      in each group were analysed. RESULTS: The patient cohort consisted of 474 men and
      66 women with a mean age of 64.3 years (28-86). They were similar in terms of
      demographics and comorbidities, with the exception of a younger age (65.2 vs 65.4
      vs 62.5 years, p=0.0094), and a higher incidence of diabetes (9.1% vs 13.2% vs
      22.7%, p=0.001), hiatal hernia (16.8% vs 17.8% vs 28.8%, p=0.009) and Barrett
      oesophagus (24.7% vs 25.4% vs 36.2%, p=0.025) for obese patients. The type of
      surgery performed, overall blood loss, extent of lymphadenectomy, R0 resections
      and complications were not influenced by BMI on univariate and multivariate
      analysis. CONCLUSIONS: In our experience, patients with an elevated BMI and
      oesophageal adenocarcinoma do not experience an increase in morbidity and
      mortality after oesophagectomy as stated in previous reports, when performed at a
      high volume centre. Additionally, BMI did not affect the quality of oncological
      resection as determined by number of harvested lymph-nodes and rates of R0
      resections. TRIAL REGISTRATION: MCC 15030, IRB 105286.
AD  - Department of Surgery, New York University Medical School, New York, New York,
      USA.
FAU - Melis, Marcovalerio
AU  - Melis M
FAU - Weber, Jill
AU  - Weber J
FAU - Shridhar, Ravi
AU  - Shridhar R
FAU - Hoffe, Sarah
AU  - Hoffe S
FAU - Almhanna, Khaldoun
AU  - Almhanna K
FAU - Karl, Richard C
AU  - Karl RC
FAU - Meredith, Kenneth L
AU  - Meredith KL
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3646172
OID - NLM: PMC3646172
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:01
CRDT- 2013/05/07 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2012-001336 [pii]
AID - 10.1136/bmjopen-2012-001336 [doi]
PST - epublish
SO  - BMJ Open. 2013 May 2;3(5). pii: e001336. doi: 10.1136/bmjopen-2012-001336. Print 
      2013.

PMID- 23645889
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1473-6810 (Electronic)
IS  - 1356-5524 (Linking)
DP  - 2013 May 3
TI  - Coronary revascularisation in patients with diabetes: a chance to be better.
AD  - Department of Cardiology, Bern University Hospital, , Bern, Switzerland.
FAU - Windecker, Stephan
AU  - Windecker S
FAU - Stefanini, Giulio G
AU  - Stefanini GG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Evid Based Med
JT  - Evidence-based medicine
JID - 9608386
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - eb-2013-101259 [pii]
AID - 10.1136/eb-2013-101259 [doi]
PST - aheadofprint
SO  - Evid Based Med. 2013 May 3.

PMID- 23645888
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1473-6810 (Electronic)
IS  - 1356-5524 (Linking)
DP  - 2013 May 3
TI  - Meta-analysis shows limited benefit of lowering blood pressure below 130/80 mm Hg
      in patients with type 2 diabetes.
AD  - VA Connecticut Healthcare System and Yale University School of Medicine, , West
      Haven, Connecticut, USA.
FAU - Koraishy, Farrukh M
AU  - Koraishy FM
FAU - Peixoto, Aldo J
AU  - Peixoto AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Evid Based Med
JT  - Evidence-based medicine
JID - 9608386
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - eb-2013-101302 [pii]
AID - 10.1136/eb-2013-101302 [doi]
PST - aheadofprint
SO  - Evid Based Med. 2013 May 3.

PMID- 23645886
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 3
TI  - Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650
      Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes.
AB  - OBJECTIVESEvaluate ITCA 650, a continuous subcutaneous miniature osmotic pump
      delivery system of exenatide versus twice-daily exenatide injections (Ex-BID) in 
      subjects with type 2 diabetes.RESEARCH DESIGN AND METHODSRandomized, two-stage,
      24-week, open-label, phase 2 study in type 2 diabetes inadequately controlled
      with metformin. Stage I: 155 subjects were randomized to 20 or 40 mug/day of ITCA
      650 or Ex-BID 5-->10 mug. Stage II: 131 subjects were rerandomized to 20, 40, 60,
      or 80 mug/day of ITCA 650. Change from baseline for HbA1c, weight, and fasting
      plasma glucose were evaluated at weeks 12 and 24.RESULTSHbA1c was significantly
      lower in all groups after 12 and 24 weeks. Stage I: mean change in HbA1c from a
      mean baseline of 7.9-8.0% was -0.98, -0.95, and -0.72% for the 20 and 40 mug/day 
      ITCA 650 and Ex-BID groups, respectively, with 63, 65, and 50% of subjects
      achieving HbA1c levels </=7% (P < 0.05). Stage II: significant (P < 0.05)
      reductions in HbA1c ( approximately 1.4% from baseline) were achieved with 60 and
      80 mug/day ITCA 650, and 86 and 78% of subjects achieved HbA1c </=7% at 24 weeks;
      respectively. Weight was reduced by 2.8-3.7 kg (P < 0.05) at 24 weeks in all
      except the 20-->20 mug/day group. ITCA 650 was well-tolerated; nausea was lower
      and transient with 20 mug/day relative to Ex-BID; and 60 mug/day had the best
      profile of tolerability and HbA1c lowering.CONCLUSIONITCA 650 significantly
      reduced HbA1c and weight and was well-tolerated. The 20-->60 mug/day regimen was 
      considered the best dose for further examination in phase 3.
AD  - University of California, San Diego, La Jolla, California.
FAU - Henry, Robert R
AU  - Henry RR
FAU - Rosenstock, Julio
AU  - Rosenstock J
FAU - Logan, Douglas K
AU  - Logan DK
FAU - Alessi, Thomas R
AU  - Alessi TR
FAU - Luskey, Kenneth
AU  - Luskey K
FAU - Baron, Michelle A
AU  - Baron MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - dc12-2410 [pii]
AID - 10.2337/dc12-2410 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 3.

PMID- 23645885
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 6
TI  - A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the
      GLP-1 therapies safe?
AB  - There is no question that incretin-based glucose-lowering medications have proven
      to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor
      agonists demonstrate an efficacy comparable to insulin treatment and appear to do
      so with significant effects to promote weight loss with minimal hypoglycemia. In 
      addition, there is significant data with dipeptidyl peptidase 4 (DPP-4)
      inhibitors showing efficacy comparable to sulfonylureas but with weight neutral
      effects and reduced risk for hypoglycemia. However, over the recent past there
      have been concerns reported regarding the long-term consequences of using such
      therapies, and the issues raised are in regard to the potential of both classes
      to promote acute pancreatitis, to initiate histological changes suggesting
      chronic pancreatitis including associated preneoplastic lesions, and potentially,
      in the long run, pancreatic cancer. Other issues relate to a potential risk for
      the increase in thyroid cancer. There is clearly conflicting data that has been
      presented in preclinical studies and in epidemiologic studies. To provide an
      understanding of both sides of the argument, we provide a discussion of this
      topic as part of this two-part point-counterpoint narrative. In the point
      narrative below, Dr. Butler and colleagues provide their opinion and review of
      the data to date and that we need to reconsider the use of incretin-based
      therapies because of the growing concern of potential risk and based on a clearer
      understanding of the mechanism of action. In the counterpoint narrative following
      the contribution by Dr. Butler and colleagues, Dr. Nauck provides a defense of
      incretin-based therapies and that the benefits clearly outweigh any concern of
      risk.-WILLIAM T. CEFALU, MDEDITOR IN CHIEF, DIABETES CARE.
AD  - From the Larry L. Hillblom Islet Research Center, University of California Los
      Angeles, David Geffen School of Medicine, Los Angeles, California; the.
FAU - Butler, Peter C
AU  - Butler PC
FAU - Elashoff, Michael
AU  - Elashoff M
FAU - Elashoff, Robert
AU  - Elashoff R
FAU - Gale, Edwin A M
AU  - Gale EA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/05/03 [aheadofprint]
AID - dc12-2713 [pii]
AID - 10.2337/dc12-2713 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 6.

PMID- 23645884
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 6
TI  - A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits
      by far outweigh the potential risks.
AB  - There is no question that incretin-based glucose-lowering medications have proven
      to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor
      agonists demonstrate an efficacy comparable to insulin treatment and appear to do
      so with significant effects to promote weight loss with minimal hypoglycemia. In 
      addition, there is significant data with dipeptidyl peptidase 4 (DPP-4)
      inhibitors showing efficacy comparable to sulfonylureas but with weight neutral
      effects and reduced risk for hypoglycemia. However, over the recent past there
      have been concerns regarding the long-term consequences of using such therapies, 
      and the issues raised are in regard to the potential of both classes to promote
      acute pancreatitis, to initiate histological changes suggesting chronic
      pancreatitis including associated preneoplastic lesions, and potentially, in the 
      long run, pancreatic cancer. Other issues relate to an increase in thyroid
      cancer. There is clearly conflicting data that has been presented in preclinical 
      studies and in epidemiologic studies. To provide an understanding of both sides
      of the argument, we provide a discussion of this topic as part of this two-part
      point-counterpoint narrative. In the point narrative preceding the counterpoint
      narrative below, Dr. Butler and colleagues provide their opinion and review of
      the data to date and that we need to reconsider use of incretin-based therapies
      because of the growing concern of potential risk and based on a clearer
      understanding of the mechanism of action. In the counterpoint narrative provided 
      below, Dr. Nauck provides a defense of incretin-based therapies and that benefits
      clearly outweigh any concern of risk.-WILLIAM T. CEFALU, MDEDITOR IN CHIEF,
      DIABETES CARE.
AD  - From the Diabetes Center, Bad Lauterberg, Bad Lauterberg im Harz, Germany.
FAU - Nauck, Michael A
AU  - Nauck MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/05/03 [aheadofprint]
AID - dc12-2504 [pii]
AID - 10.2337/dc12-2504 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 6.

PMID- 23645699
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Pituitary granulomatosis with polyangiitis.
LID - 10.1136/bcr-2013-008656 [doi]
LID - bcr2013008656 [pii]
AB  - Granulomatosis with polyangiitis (GPA) is a small vessel vasculitis that can
      affect several organs, most commonly the respiratory tract and kidneys. Pituitary
      involvement is exceptionally rare. Most case reports of GPA of the pituitary
      gland have been described in middle-aged women who have concomitant ears, nose
      and throat involvement. The most frequent manifestation is diabetes insipidus due
      to a preponderance of posterior pituitary infiltration. The majority of cases
      sustain permanent damage to the pituitary gland even with remission of the
      underlying granulomatous disease. Here, the authors describe a case of pituitary 
      GPA involving both the anterior and posterior pituitary glands with permanent
      residual pituitary insufficiency.
AD  - Division of Endocrinology, Department of Medicine, University of Alberta,
      Edmonton, Alberta, Canada.
FAU - Slabu, Hannah
AU  - Slabu H
FAU - Arnason, Terra
AU  - Arnason T
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - bcr-2013-008656 [pii]
AID - 10.1136/bcr-2013-008656 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 3;2013. pii: bcr2013008656. doi: 10.1136/bcr-2013-008656.

PMID- 23645676
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 May 3
TI  - A Self-Defeating Anabolic Program Leads to beta cell apoptosis in ER
      Stress-Induced Diabetes via Regulation of Amino Acid Flux.
AB  - ER stress-induced responses are associated with the loss of insulin producing
      beta-cells in Type 2 Diabetes Mellitus. beta-cell survival during ER stress is
      believed to depend on decreased protein synthesis rates that are mediated via
      phosphorylation of the translation initiation factor eIF2alpha. It is reported
      here that chronic ER stress correlated with increased islet protein synthesis and
      apoptosis in beta-cells in vivo. Paradoxically, chronic ER stress in beta-cells
      induced an anabolic transcription program to overcome translational repression by
      eIF2alpha phosphorylation. This program included expression of amino acid
      transporter and aminoacyl-tRNA synthetase genes downstream of the stress-induced 
      ATF4-mediated transcription program. The anabolic response was associated with
      increased amino acid flux and charging of tRNAs for branched-chain and aromatic
      amino acids (e.g leucine and tryptophan), the levels of which are early serum
      indicators of diabetes. We conclude that regulation of amino acid transport in
      beta-cells during ER stress involves responses leading to increased protein
      synthesis, which can be protective during acute stress but can lead to apoptosis 
      during chronic stress. These studies suggest that the increased expression of
      amino acid transporters in islets can serve as early diagnostic biomarkers for
      the development of diabetes.
AD  - Case Western Reserve University, United States;
FAU - Krokowski, Dawid
AU  - Krokowski D
FAU - Han, Jaeseok
AU  - Han J
FAU - Saikia, Mridusmita
AU  - Saikia M
FAU - Majumder, Mithu
AU  - Majumder M
FAU - Yuan, Celvie L
AU  - Yuan CL
FAU - Guan, Bo-Jhih
AU  - Guan BJ
FAU - Bevilacqua, Elena
AU  - Bevilacqua E
FAU - Bussolati, Ovidio
AU  - Bussolati O
FAU - Broer, Stefan
AU  - Broer S
FAU - Arvan, Peter
AU  - Arvan P
FAU - Tchorzewski, Marek
AU  - Tchorzewski M
FAU - Snider, Martin D
AU  - Snider MD
FAU - Puchowicz, Michelle
AU  - Puchowicz M
FAU - Croniger, Colleen M
AU  - Croniger CM
FAU - Kimball, Scot R
AU  - Kimball SR
FAU - Pan, Tao
AU  - Pan T
FAU - Koromilas, Antonis E
AU  - Koromilas AE
FAU - Kaufman, Randal J
AU  - Kaufman RJ
FAU - Hatzoglou, Maria
AU  - Hatzoglou M
LA  - ENG
GR  - R01 DK015658/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Amino acids transport
OT  - Aminoacyl tRNA synthetase
OT  - Beta cell
OT  - Diabetes
OT  - ER stress
OT  - Glutamine
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - M113.466920 [pii]
AID - 10.1074/jbc.M113.466920 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 May 3.

PMID- 23645657
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia
      (CLL) in end-stage renal disease (ESRD).
LID - 10.1136/bcr-2013-009637 [doi]
LID - bcr2013009637 [pii]
AB  - A patient with a history of type 2 diabetes mellitus and chronic lymphocytic
      leukaemia has renal failure with large kidneys. The patient refused kidney biopsy
      to determine the aetiology of her renal failure. She uses peritoneal dialysis to 
      treat renal failure. She received rituximab and bendamustine to treat chronic
      lymphocytic leukaemia. Adenopathy resolves with treatment and she does not
      experience any electrolyte disturbances or decrease in urine output as a result
      of chemotherapy in the setting of renal failure. Renal function did not recover
      with chemotherapy.
AD  - Department of Medicine, George Washington University, Washington, DC, USA.
FAU - Shoji, Jun
AU  - Shoji J
FAU - Lew, Susie Q
AU  - Lew SQ
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - bcr-2013-009637 [pii]
AID - 10.1136/bcr-2013-009637 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 2;2013. pii: bcr2013009637. doi: 10.1136/bcr-2013-009637.

PMID- 23645655
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Mucormycosis: an atrocious mate of patients with diabetes.
LID - 10.1136/bcr-2013-009600 [doi]
LID - bcr2013009600 [pii]
AB  - Mucormycosis also called zygomycosis is a rare infection caused by saprophytic
      aerobic fungus that belongs to a group of fungi called Mucoromycotina in the
      order Mucorales. Earlier these fungi were called Zygomycota but this scientific
      name has recently been changed. Mucormycosis can result in an acute, rapidly
      advancing and occasionally fatal disease caused by different fungi typically
      found in the soil and in association with decaying organic matter such as leaves,
      compost piles or rotten wood. These fungal infections are relatively infrequent; 
      however, they occur in individuals who are debilitated in some major way and
      occasionally in groups of people with multiple penetrating injuries that are
      contaminated with soil and water from the environment. Mucormycosis is not
      contagious and does not spread from person to person.
AD  - Department of Oral Pathology, St Joseph Dental College, Eluru, Andhra Pradesh,
      India.
FAU - Ananthaneni, Anu Radha
AU  - Ananthaneni AR
FAU - Undavalli, Suresh Babu
AU  - Undavalli SB
FAU - Velagapudi, Ram Prasad
AU  - Velagapudi RP
FAU - Guduru, Vijay Srinivas
AU  - Guduru VS
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - bcr-2013-009600 [pii]
AID - 10.1136/bcr-2013-009600 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 May 2;2013. pii: bcr2013009600. doi: 10.1136/bcr-2013-009600.

PMID- 23645620
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1468-3288 (Electronic)
IS  - 0017-5749 (Linking)
DP  - 2013 May 3
TI  - Nr5a2 maintains acinar cell differentiation and constrains oncogenic
      Kras-mediated pancreatic neoplastic initiation.
AB  - OBJECTIVES: Emerging evidence from mouse models suggests that mutant Kras can
      drive the development of pancreatic ductal adenocarcinoma (PDA) precursors from
      acinar cells by enforcing ductal de-differentiation at the expense of acinar
      identity. Recently, human genome-wide association studies have identified NR5A2, 
      a key regulator of acinar function, as a susceptibility locus for human PDA. We
      investigated the role of Nr5a2 in exocrine maintenance, regeneration and Kras
      driven neoplasia. DESIGN: To investigate the function of Nr5a2 in the pancreas,
      we generated mice with conditional pancreatic Nr5a2 deletion (PdxCrelate;
      Nr5a2c/c). Using this model, we evaluated acinar differentiation, regeneration
      after caerulein pancreatitis and Kras driven pancreatic neoplasia in the setting 
      of Nr5a2 deletion. RESULTS: We show that Nr5a2 is not required for the
      development of the pancreatic acinar lineage but is important for maintenance of 
      acinar identity. Nr5a2 deletion leads to destabilisation of the mature acinar
      differentiation state, acinar to ductal metaplasia and loss of regenerative
      capacity following acute caerulein pancreatitis. Loss of Nr5a2 also dramatically 
      accelerates the development of oncogenic Kras driven acinar to ductal metaplasia 
      and PDA precursor lesions. CONCLUSIONS: Nr5a2 is a key regulator of acinar
      plasticity. It is required for maintenance of acinar identity and re-establishing
      acinar fate during regeneration. Nr5a2 also constrains pancreatic neoplasia
      driven by oncogenic Kras, providing functional evidence supporting a potential
      role as a susceptibility gene for human PDA.
AD  - Diabetes Center, University of California-San Francisco, , San Francisco,
      California, USA.
FAU - von Figura, Guido
AU  - von Figura G
FAU - Morris, John P 4th
AU  - Morris JP 4th
FAU - Wright, Christopher V E
AU  - Wright CV
FAU - Hebrok, Matthias
AU  - Hebrok M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Gut
JT  - Gut
JID - 2985108R
OTO - NOTNLM
OT  - PANCREATIC CANCER
OT  - PANCREATIC DAMAGE
OT  - PANCREATITIS
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - gutjnl-2012-304287 [pii]
AID - 10.1136/gutjnl-2012-304287 [doi]
PST - aheadofprint
SO  - Gut. 2013 May 3.

PMID- 23645580
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1724-6040 (Electronic)
IS  - 0391-3988 (Linking)
DP  - 2013 May 6
TI  - Cardiac autonomic dysfunction in the early phase after left ventricular assist
      device implant: Implications for surgery and follow-up.
PG  - 0
LID - 073AE643-0A0F-4366-BC49-7C95B668D622 [pii]
LID - 10.5301/ijao.5000210 [doi]
AB  - Purpose: In congestive heart failure (CHF) patients, a profound cardiac autonomic
      derangement, clinically expressed by reduced heart rate variability (HRV), is
      present and is related to the degree of ventricular dysfunction. Implantation of 
      a left ventricular assist device (LVAD) can progressively improve HRV, associated
      with an increased circulatory output. Data from patients studied at different
      times after LVAD implantation are controversial. The aims of this study were to
      assess cardiac autonomic function in the early phases after axial-flow LVAD
      implantation, and to estimate the potential relevance of recent major surgical
      stress on the autonomic balance.Methods: HRV (time-domain; 24-h Holter) was
      evaluated in 14 patients, 44.8 +/- 25.8 days after beginning of Jarvik-2000 LVAD 
      support; 47 advanced stage CHF, 24 cardiac surgery (CS) patients and 30 healthy
      subjects served as control groups. Inclusion criteria: sinus rhythm, stable
      clinical conditions, no diabetes or other known causes of HRV alteration.Results:
      HRV was considerably reduced in LVAD patients in the early phases after device
      implantation in comparison to all control groups. A downgrading of HRV parameters
      was also present in CS controls. Circadian oscillations were highly depressed in 
      LVAD and CHF patients, and slightly reduced in CS patients.Conclusions: In CHF
      patients supported by a continuous-flow LVAD, a profound cardiac dysautonomia is 
      still evident in the first two months from the beginning of circulatory support; 
      the degree of cardiac autonomic imbalance is even greater in comparison to
      advanced CHF patients. The recent surgical stress could be partly linked to these
      abnormalities.
AD  - Preventive Cardiology and Rehabilitation, Codivilla-Putti Institute, Cortina
      d'Ampezzo, Belluno - Italy.
FAU - Compostella, Leonida
AU  - Compostella L
FAU - Russo, Nicola
AU  - Russo N
FAU - Setzu, Tiziana
AU  - Setzu T
FAU - Tursi, Vincenzo
AU  - Tursi V
FAU - Bottio, Tomaso
AU  - Bottio T
FAU - Tarzia, Vincenzo
AU  - Tarzia V
FAU - Compostella, Caterina
AU  - Compostella C
FAU - Covolo, Elisa
AU  - Covolo E
FAU - Livi, Ugolino
AU  - Livi U
FAU - Gerosa, Gino
AU  - Gerosa G
FAU - Sani, Guido
AU  - Sani G
FAU - Bellotto, Fabio
AU  - Bellotto F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Int J Artif Organs
JT  - The International journal of artificial organs
JID - 7802649
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/05/06 [aheadofprint]
PHST- 2013/01/27 [accepted]
AID - 073AE643-0A0F-4366-BC49-7C95B668D622 [pii]
AID - 10.5301/ijao.5000210 [doi]
PST - aheadofprint
SO  - Int J Artif Organs. 2013 May 6:0. doi: 10.5301/ijao.5000210.

PMID- 23645578
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1724-6040 (Electronic)
IS  - 0391-3988 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May 17
TI  - The relationship between depressive symptoms and erythropoietin resistance in
      stable hemodialysis patients with adequate iron stores.
PG  - 314-9
LID - 10.5301/ijao.5000184 [doi]
AB  - Introduction: Resistance to erythropoietin (EPO) treatment has been associated
      with inflammation and malnutrition in hemodialysis (HD) patients. Depression has 
      also been associated with both inflammation and malnutrition; however, the
      specific relationship between depressive symptoms and EPO resistance is not
      known. In the current study, the relationship between depressive symptoms and EPO
      resistance as evaluated by erythropoiesis stimulating agent (ESA)
      hyporesponsiveness index (EHRI) was analyzed. Methods: Study participants had
      their medical history taken and underwent physical examination; dialysis adequacy
      calculation, biochemical analysis and evaluation of depressive symptoms by Beck
      Depression Inventory (BDI) were performed. EHRI was calculated as the weekly dose
      of EPO divided by per kilogram of body weight divided by the hemoglobin
      level.Results: The mean BDI score of the patients was 10.99 +/- 3.94. Pearson
      correlation analysis revealed that the logarithmically converted EHRI score was
      correlated with albumin (r = -0.270, p = 0.011), hs-CRP (r = 0.383, P<0.0001),
      hemoglobin (r = -0.617, p<0.0001), intact PTH (r = 0.215, p = 0.043) and
      logarithmically converted BDI (r = 0.299, p = 0.004). The stepwise linear
      regression analysis revealed that being female (p = 0.012), presence of diabetes 
      mellitus (p = 0.119), hs-CRP (p = 0.009) and BDI score (p = 0.037) were
      independently related with logarithmically converted EHRI (as a dependent
      variable). Conclusion: Depressive symptoms were independently related with EHRI
      in HD patients. Studies are needed to highlight underlying mechanisms between
      depression and EHRI.
AD  - Department of Medicine, Division of Nephrology, Konya Numune State Hospital,
      Konya - Turkey.
FAU - Afsar, Baris
AU  - Afsar B
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - Italy
TA  - Int J Artif Organs
JT  - The International journal of artificial organs
JID - 7802649
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/05/17 [ppublish]
PHST- 2013/05/06 [aheadofprint]
PHST- 2012/11/07 [accepted]
AID - 7425629A-E0BB-4320-A712-4631DEA09D80 [pii]
AID - 10.5301/ijao.5000184 [doi]
PST - ppublish
SO  - Int J Artif Organs. 2013 May 17;36(5):314-9. doi: 10.5301/ijao.5000184. Epub 2013
      May 6.

PMID- 23645577
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1879-5447 (Electronic)
IS  - 0158-9938 (Linking)
DP  - 2013 May 5
TI  - Measurement of subcutaneous adipose tissue thickness by near-infrared.
AB  - Obesity is strongly associated with the risks of diabetes and cardiovascular
      disease, and there is a need to measure the subcutaneous adipose tissue (SAT)
      layer thickness and to understand the distribution of body fat. A device was
      designed to illuminate the body parts by near-infrared (NIR), measure the
      backscattered light, and predict the SAT layer thickness. The device was
      controlled by a single-chip microcontroller (SCM), and the thickness value was
      presented on a liquid crystal display (LCD). There were 30 subjects in this
      study, and the measurements were performed on 14 body parts for each subject. The
      paper investigated the impacts of pressure and skin colour on the measurement.
      Combining with principal component analysis (PCA) and support vector regression
      (SVR), the measurement accuracy of SAT layer thickness was 89.1 % with a
      mechanical caliper as reference. The measuring range was 5-11 mm. The study
      provides a non-invasive and low-cost technique to detect subcutaneous fat
      thickness, which is more accessible and affordable compared to other conventional
      techniques. The designed device can be used at home and in community.
AD  - College of Life Science and Bioengineering, Beijing University of Technology,
      Beijing, 100124, China.
FAU - Wang, Yu
AU  - Wang Y
FAU - Yang, Zeqiang
AU  - Yang Z
FAU - Hao, Dongmei
AU  - Hao D
FAU - Zhang, Song
AU  - Zhang S
FAU - Yang, Yimin
AU  - Yang Y
FAU - Zeng, Yanjun
AU  - Zeng Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130505
TA  - Australas Phys Eng Sci Med
JT  - Australasian physical & engineering sciences in medicine / supported by the
      Australasian College of Physical Scientists in Medicine and the Australasian
      Association of Physical Sciences in Medicine
JID - 8208130
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/09/30 [received]
PHST- 2013/04/25 [accepted]
PHST- 2013/05/05 [aheadofprint]
AID - 10.1007/s13246-013-0196-y [doi]
PST - aheadofprint
SO  - Australas Phys Eng Sci Med. 2013 May 5.

PMID- 23645508
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1970-9366 (Electronic)
IS  - 1828-0447 (Linking)
DP  - 2013 May 5
TI  - COPD patients with and without metabolic syndrome: clinical and functional
      differences.
AB  - Chronic obstructive pulmonary disease (COPD) and the metabolic syndrome (MetS)
      are considered public health challenges of the 21st century. The coexistence of
      MetS in COPD patients and any clinical differences between COPD patients with and
      without MetS have not been extensively studied. We aimed to describe the clinical
      characteristics of patients with MetS and COPD. An observational, multicenter
      study of 375 patients hospitalized for a COPD exacerbation with spirometric
      confirmation was performed. We measured the components of the MetS and collected 
      comorbidity information using the Charlson index and other conditions. Dyspnea,
      use of steroids, exacerbations, and hospitalizations were also investigated. The 
      overall prevalence of MetS in COPD patients was 42.9 %, was more frequent in
      women (59.5 %) than men (40.8 %), p = 0.02, but with no differences in age and
      smoking history. COPD patients with MetS had greater % predicted FEV1, more
      dyspnea, and more comorbidity and used more inhaled steroids (all p < 0.05).
      Diabetes, osteoporosis, coronary artery disease, and heart failure were more
      frequent in patients with MetS. They had been hospitalized more frequently for
      any cause but not for COPD. In multivariate analysis, the presence of MetS was
      independently associated with greater FEV1, inhaled steroids use, osteoporosis,
      diabetes, and heart failure. MetS is a frequent condition in COPD patients, and
      it is associated with greater FEV1, more dyspnea, and more comorbidities.
AD  - Internal Medicine Service, Hospital Royo Villanova, Avda San Gregorio no 30,
      50015, Saragossa, Spain, jdiez@aragon.es.
FAU - Diez-Manglano, Jesus
AU  - Diez-Manglano J
FAU - Barquero-Romero, Jose
AU  - Barquero-Romero J
FAU - Almagro, Pedro
AU  - Almagro P
FAU - Cabrera, Francisco Javier
AU  - Cabrera FJ
FAU - Lopez Garcia, Francisco
AU  - Lopez Garcia F
FAU - Montero, Lorena
AU  - Montero L
FAU - Soriano, Joan Baptiste
AU  - Soriano JB
CN  - Working Group on COPD; Spanish Society of Internal Medicine
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130505
TA  - Intern Emerg Med
JT  - Internal and emergency medicine
JID - 101263418
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/02/11 [received]
PHST- 2013/04/20 [accepted]
PHST- 2013/05/05 [aheadofprint]
AID - 10.1007/s11739-013-0945-7 [doi]
PST - aheadofprint
SO  - Intern Emerg Med. 2013 May 5.

PMID- 23645452
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
DP  - 2013 May 4
TI  - Reducing Racial/Ethnic Disparities in Diabetes: The Coached Care (R2D2C2)
      Project.
AB  - BACKGROUND: Despite numerous efforts to change healthcare delivery, the profile
      of disparities in diabetes care and outcomes has not changed substantially over
      the past decade. OBJECTIVE: To understand potential contributors to disparities
      in diabetes care and glycemic control. DESIGN: Cross sectional analysis.
      SSETTING: Seven outpatient clinics affiliated with an academic medical center.
      PATIENTS: Adult patients with type 2 diabetes who were Mexican American,
      Vietnamese American or non-Hispanic white (n = 1,484). MEASUREMENTS: Glycemic
      control was measured as hemoglobin A1c (HbA1c) level. Patient, provider and
      system characteristics included demographic characteristics; access to care;
      quality of process of care including clinical inertia; quality of interpersonal
      care; illness burden; mastery (diabetes management confidence, passivity); and
      adherence to treatment. RESULTS: Unadjusted HbA1c values were significantly
      higher for Mexican American patients (n = 782) (mean = 8.3 % [SD:2.1]) compared
      with non-Hispanic whites (n = 389) (mean = 7.1 % [SD:1.4]). There were no
      significant differences in HbA1c values between Vietnamese American and
      non-Hispanic white patients. There were no statistically significant group
      differences in glycemic control after adjustment for multiple measures of access,
      and quality of process and interpersonal care. Disease management mastery and
      adherence to treatment were related to glycemic control for all patients,
      independent of race/ethnicity. LIMITATIONS: Generalizability to other minorities 
      or to patients with poorer access to care may be limited. CONCLUSIONS: The
      complex interplay among patient, physician and system characteristics contributed
      to disparities in HbA1c between Mexican American and non-Hispanic white patients.
      In contrast, Vietnamese American patients achieved HbA1c levels comparable to
      non-Hispanic whites and adjustment for numerous characteristics failed to
      identify confounders that could have masked disparities in this subgroup. Disease
      management mastery appeared to be an important contributor to glycemic control
      for all patient subgroups.
AD  - Health Policy Research Institute and Department of Medicine, School of Medicine, 
      University of California, Irvine, 100 Theory Suite 110, Irvine, CA, 92697, USA,
      skaplan@uci.edu.
FAU - Kaplan, Sherrie H
AU  - Kaplan SH
FAU - Billimek, John
AU  - Billimek J
FAU - Sorkin, Dara H
AU  - Sorkin DH
FAU - Ngo-Metzger, Quyen
AU  - Ngo-Metzger Q
FAU - Greenfield, Sheldon
AU  - Greenfield S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.1007/s11606-013-2452-y [doi]
PST - aheadofprint
SO  - J Gen Intern Med. 2013 May 4.

PMID- 23645412
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1563-258X (Electronic)
IS  - 0043-5341 (Linking)
VI  - 163
IP  - 7-8
DP  - 2013 Apr
TI  - [Conservative lymphedema therapy-Lymphological rehabilitation treatment].
PG  - 169-76
LID - 10.1007/s10354-013-0205-5 [doi]
AB  - The most important column in the conservative lymphedema therapy still represents
      the complex decongestive physical therapy/KPE.This is a multimodal therapy, which
      consists of four components. (1) skin restoration and/or skin care, (2) manual
      lymphatic drainage, (3) compression therapy and (4) decongestive exercises. The
      KPE is also divided into two phases. Phase 1-the decongestion-serves primarily
      the mobilization and transporting away the banked protein-rich oedema fluid and
      seamless transition into the Phase 2-the maintenance phase, which serves to
      preserve the achieved treatment success. The implementation of the KPE should be 
      stage-adjusted, but depends also on the location (genital, head, face), and on
      co-existing comorbidities (congestive heart failure, diabetes mellitus, obesity, 
      muscular-skeletal disorders, mental illness, etc.). It should be modified for
      children, elderly persons and for patients with malignant lymphedema.
AD  - FA f. physikalische Medizin und allgemeine Rehabilitation, LKH Wolfsberg, Zentrum
      fur Lymphologie - Physikalische Medizin und allgemeine Rehabilitation, Paul
      Hackhoferstrasse 9, 9400, Wolfsberg, Osterreich, gert.apich@lkh-wo.at.
FAU - Apich, Gert
AU  - Apich G
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Konservative Therapie des Lymphodems - Lymphologische Rehabilitationsbehandlung.
DEP - 20130504
PL  - Austria
TA  - Wien Med Wochenschr
JT  - Wiener medizinische Wochenschrift (1946)
JID - 8708475
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/14 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 10.1007/s10354-013-0205-5 [doi]
PST - ppublish
SO  - Wien Med Wochenschr. 2013 Apr;163(7-8):169-76. doi: 10.1007/s10354-013-0205-5.
      Epub 2013 May 4.

PMID- 23645327
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 92
IP  - 3
DP  - 2013 May
TI  - Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1: A 
      Prospective Study: Comparison of 106 MEN1/Zollinger-Ellison Syndrome Patients
      With 1613 Literature MEN1 Patients With or Without Pancreatic Endocrine Tumors.
PG  - 135-81
LID - 10.1097/MD.0b013e3182954af1 [doi]
AB  - Multiple endocrine neoplasia type 1 (MEN1) is classically characterized by the
      development of functional or nonfunctional hyperplasia or tumors in endocrine
      tissues (parathyroid, pancreas, pituitary, adrenal). Because effective treatments
      have been developed for the hormone excess state, which was a major cause of
      death in these patients in the past, coupled with the recognition that
      nonendocrine tumors increasingly develop late in the disease course, the natural 
      history of the disease has changed. An understanding of the current causes of
      death is important to tailor treatment for these patients and to help identify
      prognostic factors; however, it is generally lacking.To add to our understanding,
      we conducted a detailed analysis of the causes of death and prognostic factors
      from a prospective long-term National Institutes of Health (NIH) study of 106
      MEN1 patients with pancreatic endocrine tumors with Zollinger-Ellison syndrome
      (MEN1/ZES patients) and compared our results to those from the pooled literature 
      data of 227 patients with MEN1 with pancreatic endocrine tumors (MEN1/PET
      patients) reported in case reports or small series, and to 1386 patients reported
      in large MEN1 literature series. In the NIH series over a mean follow-up of 24.5 
      years, 24 (23%) patients died (14 MEN1-related and 10 non-MEN1-related deaths).
      Comparing the causes of death with the results from the 227 patients in the
      pooled literature series, we found that no patients died of acute complications
      due to acid hypersecretion, and 8%-14% died of other hormone excess causes, which
      is similar to the results in 10 large MEN1 literature series published since
      1995. In the 2 series (the NIH and pooled literature series), two-thirds of
      patients died from an MEN1-related cause and one-third from a non-MEN1-related
      cause, which agrees with the mean values reported in 10 large MEN1 series in the 
      literature, although in the literature the causes of death varied widely. In the 
      NIH and pooled literature series, the main causes of MEN1-related deaths were due
      to the malignant nature of the PETs, followed by the malignant nature of thymic
      carcinoid tumors. These results differ from the results of a number of the
      literature series, especially those reported before the 1990s. The causes of
      non-MEN1-related death for the 2 series, in decreasing frequency, were
      cardiovascular disease, other nonendocrine tumors > lung diseases,
      cerebrovascular diseases. The most frequent non-MEN1-related tumor deaths were
      colorectal, renal > lung > breast, oropharyngeal. Although both overall and
      disease-related survival are better than in the past (30-yr survival of NIH
      series: 82% overall, 88% disease-related), the mean age at death was 55 years,
      which is younger than expected for the general population.Detailed analysis of
      causes of death correlated with clinical, laboratory, and tumor characteristics
      of patients in the 2 series allowed identification of a number of prognostic
      factors. Poor prognostic factors included higher fasting gastrin levels, presence
      of other functional hormonal syndromes, need for >3 parathyroidectomies, presence
      of liver metastases or distant metastases, aggressive PET growth, large PETs, or 
      the development of new lesions.The results of this study have helped define the
      causes of death of MEN1 patients at present, and have enabled us to identify a
      number of prognostic factors that should be helpful in tailoring treatment for
      these patients for both short- and long-term management, as well as in directing 
      research efforts to better define the natural history of the disease and the most
      important factors determining long-term survival at present.
AD  - From the Department of Medicine and Bioregulatory Science (TI, HI), Graduate
      School of Medical Sciences, Kyushu University, Fukuoka, Japan; Digestive Diseases
      Branch (TI, HI, HU, MJB, RTJ), National Institute of Diabetes and Digestive and
      Kidney Diseases, National Institutes of Health, Bethesda, Maryland; and Hopital
      Kirchberg (MJB), Luxembourg, Luxembourg.
FAU - Ito, Tetsuhide
AU  - Ito T
FAU - Igarashi, Hisato
AU  - Igarashi H
FAU - Uehara, Hirotsugu
AU  - Uehara H
FAU - Berna, Marc J
AU  - Berna MJ
FAU - Jensen, Robert T
AU  - Jensen RT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - AIM
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.1097/MD.0b013e3182954af1 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2013 May;92(3):135-81. doi: 10.1097/MD.0b013e3182954af1.

PMID- 23645293
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1573-7403 (Electronic)
IS  - 1386-341X (Linking)
DP  - 2013 May 5
TI  - Pituitary carcinoma with endolymphatic sac metastasis.
AB  - Pituitary carcinoma is characterized by the presence of a metastatic lesion(s) in
      a location non-contiguous with the original pituitary tumor. The mechanism(s) of 
      malignant transformation are not known. A 15 year-old male was diagnosed in 1982 
      with a pituitary macroadenoma and acromegaly (random GH 67 ng/ml and no
      suppression by oral glucose). His prolactin was normal between 18 and 23 ng/ml.
      Transcranial resection in July 1983 was followed by radiation therapy. The tumor 
      was immunopositive for GH and prolactin. The proliferation MIB-1 index was 0-1 %.
      With aqueous Octreotide 100 mcg 4x daily both GH and IGF-1 became normal. The
      patient was lost to follow-up and was treated by his local physician. In 2001,
      his IGF-1 level was 1271 ng/ml, and his random GH was 1.8-2.4 ng/ml by ILMA
      despite progressive increase in the dose of Sandostatin LAR to 140 mg/month in
      divided doses. Prolactin remained normal or minimally increased between 15 and 25
      ng/ml. In 2009 he was diagnosed with the tumor in the location of left
      endolymphatic sac. Histological examination showed low grade pituitary carcinoma 
      strongly immunopositive for prolactin but negative for GH. MIB-1 antibody labeled
      0-5 % cells. In 2012 endoscopic resection of the pituitary tumor remnant was
      attempted. Immunohistochemical stains were strongly immunopositive for both
      prolactin and GH, similar to his original pituitary tumor. The MIB-1
      proliferation index was low from 0 to 1 %. To our knowledge this is the first
      case of pituitary carcinoma in the endolymphatic sac region. The dichotomy
      between the cell population of the pituitary lesion (GH/prolactin producing) and 
      the metastasis (purely prolactin-producing) may suggest that the metastatic
      pituitary lesion derived from a clone distinct from the original one.
AD  - Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann
      Arbor, MI, USA.
FAU - Balili, Irida
AU  - Balili I
FAU - Sullivan, Steven
AU  - Sullivan S
FAU - McKeever, Paul
AU  - McKeever P
FAU - Barkan, Ariel
AU  - Barkan A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130505
TA  - Pituitary
JT  - Pituitary
JID - 9814578
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.1007/s11102-013-0489-x [doi]
PST - aheadofprint
SO  - Pituitary. 2013 May 5.

PMID- 23645286
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1869-6953 (Print)
DP  - 2013 May 4
TI  - Comparison of National/Regional Diabetes Guidelines for the Management of Blood
      Glucose Control in non-Western Countries.
AB  - INTRODUCTION: Development of higher standards for diabetes care is a core element
      of coping with the global diabetes epidemic. Diabetes guidelines are part of the 
      approach to raising standards. The epidemic is greatest in countries with recent 
      rises in income from a low base. The objective of the current study was to
      investigate the availability and nature of locally produced diabetes guidelines
      in such countries. METHODS: Searches were conducted using Medline, Google, and
      health ministry and diabetes association websites. RESULTS: Guidelines were
      identified in 33 of 75 countries outside North America, western Europe, and
      Australasia. In 25 of these 33 countries, management strategies for type 1
      diabetes were included. National guidelines relied heavily on pre-existing
      national and international guidelines, with reference to American Diabetes
      Association standards of medical care and/or other consensus statements by 55%,
      International Diabetes Federation by 36%, European Association for the Study of
      Diabetes by 12%, and American Association of Clinical Endocrinologists by 9%. The
      identified guidelines were generally evidence-based, though there was some use of
      secondary evidence reviews, including other guidelines, rather than original
      literature reviews and evidence synthesis. In type 1 diabetes guidelines, the
      option of different insulin regimens (mostly meal-time + basal or premix
      regimens) was recommended depending on patient need. Type 2 diabetes guidelines
      either recommended a glycosylated hemoglobin target of <7.0% (<53 mmol/mol) (70% 
      of guidelines) or <6.5% (<47 mmol/mol) (30% of guidelines) as the ideal glycemic 
      target. Most guidelines recommended a target fasting plasma glucose that fell
      within the range of 3.8-7.2 mmol/L. Most guidelines also set a 2-h post-prandial 
      glucose target value within the range of 4.0-8.3 mmol/L. CONCLUSION: While only a
      first step in achieving a high quality of disease management, national guidelines
      of quality and with fair consistency of recommendations are becoming prevalent
      globally. A further challenge is implementation of guidelines, by integration
      into local care processes.
AD  - Institute of Cellular Medicine, The Medical School, Newcastle University,
      Framlington Place, Newcastle upon Tyne, NE2 4HH, UK, philip.home@ncl.ac.uk.
FAU - Home, Philip
AU  - Home P
FAU - Haddad, Jihad
AU  - Haddad J
FAU - Latif, Zafar Ahmed
AU  - Latif ZA
FAU - Soewondo, Pradana
AU  - Soewondo P
FAU - Benabbas, Youcef
AU  - Benabbas Y
FAU - Litwak, Leon
AU  - Litwak L
FAU - Guler, Serdar
AU  - Guler S
FAU - Chen, Jian-Wen
AU  - Chen JW
FAU - Zilov, Alexey
AU  - Zilov A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/31 [received]
PHST- 2013/05/04 [aheadofprint]
AID - 10.1007/s13300-013-0022-2 [doi]
PST - aheadofprint
SO  - Diabetes Ther. 2013 May 4.

PMID- 23645245
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1672-7347 (Print)
IS  - 1672-7347 (Linking)
VI  - 38
IP  - 4
DP  - 2013 Apr
TI  - [Correlation between self-management behaviors and blood glucose control in
      patients with type 2 diabetes mellitus in community].
PG  - 425-31
LID - 10.3969/j.issn.1672-7347.2013.04.015 [doi]
AB  - Objective: To investigate the self-management behaviors of patients with type 2
      diabetes mellitus (DM) in a community and to explore the relationship between
      self-management behaviors and the glycemic control. Methods: A total of 211 type 
      2 DM patients in a community were selected by stratified random sampling.
      Patients were grouped according to the scores of self-management behaviors. The
      fasting plasma glucose (FPG), 2 h postprandial plasma glucose (2hPG) and glycated
      hemoglobin (HbA1C) level were tested. The differences between groups and
      relationship between self-management behaviors and glycemic control were
      analyzed. Results: Self-management behaviors of most patients were not effective,
      and 2hPG and HbA1C were affected by different levels of the self-management
      behaviors (P<0.05). The self-management behaviors were negatively related to FPG 
      (r=-0.277, P=0.015), 2hPG (r=-0.453, P=0.001), and HbA1C (r=-0.435, P=0.001).
      Glycemic control of the patients whose course of disease was over 5 years was
      significantly different due to different self-management behaviors. FPG level of 
      the patients was positively related to alimentary control. The 2hPG level of the 
      patients was positively related to alimentary control, medication persistence,
      and blood glucose self-monitoring. The HbA1C level of the patients was positively
      related to alimentary control and medication persistence. The times the patients 
      received DM education, the way to use insulin, and the disease course of the
      patients were important factors to affect self-management behaviors of type 2 DM 
      in the community. Conclusion: Self-management behaviors of type 2 DM patients in 
      the community are not effective. Satisfactory self-management behaviors,
      specially the control of 2hPG and HbA1C are beneficial to glycemic control. We
      can improve the self-management behaviors in type 2 DM patients by paying
      attention to the disease course, the treatment method, and the contents and
      effect of DM education.
AD  - Department of Geriatrics, Xiangya Hospital, Central South University, Changsha
      410008, China.
FAU - Yu, Pingping
AU  - Yu P
FAU - Xiao, Xiangcheng
AU  - Xiao X
FAU - Wang, Linyun
AU  - Wang L
FAU - Wang, Lei
AU  - Wang L
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhong Nan Da Xue Xue Bao Yi Xue Ban
JT  - Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University.
      Medical sciences
JID - 101230586
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.3969/j.issn.1672-7347.2013.04.015 [doi]
PST - ppublish
SO  - Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Apr;38(4):425-31. doi:
      10.3969/j.issn.1672-7347.2013.04.015.

PMID- 23645229
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
DP  - 2013 May 7
TI  - The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular
      Protection: Current Position and Perspectives.
AB  - Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of oral
      anti-hyperglycemic agents that prolong the bioavailability of the endogenously
      secreted incretin hormone glucagon-like peptide-1 (GLP-1) and the
      glucose-dependent insulinotropic polypeptide (GIP), are effective in the
      treatment of diabetes. Accumulating data have indicated that DPP-4 inhibitors
      play important protective roles in the cardiovascular system. DPP-4 inhibitors
      act to decrease myocardial infarct size, stabilize the cardiac
      electrophysiological state during myocardial ischemia, reduce
      ischemia/reperfusion injury, and prevent left ventricular remodeling after
      myocardial infarction. Moreover, DPP-4 inhibitors can mobilize stem/progenitor
      cells to move to sites of cardiovascular injury, thus further promoting tissue
      repair. In addition, DPP-4 inhibitors not only improve myocardial metabolism but 
      also regulate cardioactive peptides. DPP-4 inhibitors can also protect the
      vasculature through their anti-inflammatory and anti-atherosclerotic effects and 
      through the ability of the inhibitors to promote vascular relaxation. Finally,
      the potential effects of DPP-4 inhibitors on blood pressure and lipid metabolism 
      have also been investigated. However, some reports on the cardioprotective
      activities of DPP-4 inhibitors are controversial. Herein, we summarize the
      available data on cardiovascular protection by DPP-4 inhibitors that have emerged
      in recent years and discuss current position and future perspectives concerning
      the use of DPP-4 inhibitors in cardiovascular medicine.
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai
      Hospital, National Centre for Cardiovascular Diseases, Chinese Academy of Medical
      Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District,
      Beijing, 100037, People's Republic of China.
FAU - Wang, Xi-Mei
AU  - Wang XM
FAU - Yang, Yue-Jin
AU  - Yang YJ
FAU - Wu, Yong-Jian
AU  - Wu YJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130507
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy / sponsored by the International Society of
      Cardiovascular Pharmacotherapy
JID - 8712220
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.1007/s10557-013-6459-8 [doi]
PST - aheadofprint
SO  - Cardiovasc Drugs Ther. 2013 May 7.

PMID- 23645186
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1573-3572 (Electronic)
IS  - 1068-9583 (Linking)
DP  - 2013 May 4
TI  - Assessment of Identity and Quality of Life in Diabetic and Renal Transplant
      Adolescents in Comparison to Healthy Adolescents.
AB  - Identity development represents a central task of adolescence. Identity
      achievement is characterized by a coherent sense of who one is following a period
      of exploration and can help navigate the challenges of adulthood. This study
      examined identity within a quality of life (QOL) context in 85 adolescents with a
      renal transplant or with Type 1 diabetes in comparison to 90 healthy controls.
      Results revealed significant differences in ideological identity, with patients
      showing higher levels of diffusion and controls showing higher levels of
      foreclosure. No differences with respect to interpersonal identity, QOL,
      perceived control over the QOL domains, and perceived opportunities for growth
      and development were found. Future research should assess identity and QOL over a
      longer period of time to determine whether differences between chronically ill
      and healthy young adults can be detected.
AD  - Department of Psychology, Universite de Montreal, C.P. 6128 Succ. Centre-Ville,
      Montreal, QC, H3C 3J7, Canada, tziona.lugasi@umontreal.ca.
FAU - Lugasi, Tziona
AU  - Lugasi T
FAU - Achille, Marie
AU  - Achille M
FAU - Blydt-Hansen, Tom
AU  - Blydt-Hansen T
FAU - Clermont, Marie-Jose
AU  - Clermont MJ
FAU - Geoffroy, Louis
AU  - Geoffroy L
FAU - Legault, Laurent
AU  - Legault L
FAU - Phan, Veronique
AU  - Phan V
FAU - Bell, Lorraine E
AU  - Bell LE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - J Clin Psychol Med Settings
JT  - Journal of clinical psychology in medical settings
JID - 9435680
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.1007/s10880-012-9344-x [doi]
PST - aheadofprint
SO  - J Clin Psychol Med Settings. 2013 May 4.

PMID- 23645185
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1437-7780 (Electronic)
IS  - 1341-321X (Linking)
DP  - 2013 May 4
TI  - Assessment of antimicrobial prophylaxis to prevent perioperative infection in
      patients undergoing prostate brachytherapy: multicenter cohort study.
AB  - To propose an appropriate prophylactic antimicrobial therapy for patients
      undergoing brachytherapy, we evaluated the relationships between various
      antimicrobial prophylaxis (AMP) protocols and the incidence of postimplant
      infections in a multicenter cohort study conducted in Japan. The records of 826
      patients with localized prostate cancer who underwent a transperineal 125I
      brachytherapy procedure between January 2009 and December 2010 were
      retrospectively reviewed. Perioperative infections, including surgical site and
      remote infections, were recorded up to postoperative day 30. A total of 6 (0.73
      %) patients had a perioperative infection following seed implantation, of whom
      all received AMP for 1 or more days. None of the patients who received a
      single-dose protocol of AMP using fluoroquinolone p.o. or penicillin with a
      beta-lactamase inhibitor i.v. developed a perioperative infection. Statistical
      analysis showed that a single-dose protocol was more significantly related to a
      lower risk of perioperative infection as compared to the other AMP protocols
      examined (p = 0.045). Furthermore, our results indicated that bacteriuria and
      preoperative hair removal were risk factors of perioperative infection with
      statistical significance (p = 0.007, p = 0.004). Analysis of patient clinical
      parameters, including age, American Society of Anesthesiologists score, diabetes 
      mellitus, prostate volume, numbers of implanted seeds and needle punctures,
      operation time, and indwelling duration time of the Foley catheter, did not
      reveal significant differences in terms of perioperative infection. Our results
      indicated that a single-dose AMP protocol is sufficient to prevent perioperative 
      infections following seed implantation. On the other hand, AMP is only one of
      several measures to prevent perioperative infectious complications. It is
      necessary to know that the patient must have no bacteriuria and that preoperative
      hair removal should be avoided.
AD  - Department of Urology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 
      Hyogo, 663-8501, Japan, rikiya0910@yahoo.co.jp.
FAU - Taoka, Rikiya
AU  - Taoka R
FAU - Togo, Yoshikazu
AU  - Togo Y
FAU - Kubo, Tatsuhiko
AU  - Kubo T
FAU - Kido, Masahito
AU  - Kido M
FAU - Miki, Kenta
AU  - Miki K
FAU - Kiyota, Hiroshi
AU  - Kiyota H
FAU - Egawa, Shin
AU  - Egawa S
FAU - Sugawara, Takashi
AU  - Sugawara T
FAU - Yasuda, Mitsuru
AU  - Yasuda M
FAU - Nakano, Masahiro
AU  - Nakano M
FAU - Deguchi, Takashi
AU  - Deguchi T
FAU - Nishino, Masashi
AU  - Nishino M
FAU - Ishikawa, Kiyohito
AU  - Ishikawa K
FAU - Shiroki, Ryoichi
AU  - Shiroki R
FAU - Matsumoto, Minori
AU  - Matsumoto M
FAU - Shigemura, Katsumi
AU  - Shigemura K
FAU - Tanaka, Kazushi
AU  - Tanaka K
FAU - Arakawa, Soichi
AU  - Arakawa S
FAU - Fujisawa, Masato
AU  - Fujisawa M
FAU - Wada, Koichiro
AU  - Wada K
FAU - Watanabe, Toyohiko
AU  - Watanabe T
FAU - Kumon, Hiromi
AU  - Kumon H
FAU - Kobayashi, Kanao
AU  - Kobayashi K
FAU - Matsubara, Akio
AU  - Matsubara A
FAU - Sho, Takehiko
AU  - Sho T
FAU - Hamasuna, Ryoichi
AU  - Hamasuna R
FAU - Matsumoto, Tetsuro
AU  - Matsumoto T
FAU - Hayami, Hiroshi
AU  - Hayami H
FAU - Nakagawa, Masayuki
AU  - Nakagawa M
FAU - Yamamoto, Shingo
AU  - Yamamoto S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/22 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 10.1007/s10156-013-0610-0 [doi]
PST - aheadofprint
SO  - J Infect Chemother. 2013 May 4.

PMID- 23645137
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1557-1904 (Electronic)
IS  - 1557-1890 (Linking)
DP  - 2013 May 5
TI  - Evidence for a Dysregulated Immune System in the Etiology of Psychiatric
      Disorders.
AB  - There is extensive bi-directional communication between the brain and the immune 
      system in both health and disease. In recent years, the role of an altered immune
      system in the etiology of major psychiatric disorders has become more apparent.
      Studies have demonstrated that some patients with major psychiatric disorders
      exhibit characteristic signs of immune dysregulation and that this may be a
      common pathophysiological mechanism that underlies the development and
      progression of these disorders. Furthermore, many psychiatric disorders are also 
      often accompanied by chronic medical conditions related to immune dysfunction
      such as autoimmune diseases, diabetes and atherosclerosis. One of the major
      psychiatric disorders that has been associated with an altered immune system is
      schizophrenia, with approximately one third of patients with this disorder
      showing immunological abnormalities such as an altered cytokine profile in serum 
      and cerebrospinal fluid. An altered cytokine profile is also found in a
      proportion of patients with major depressive disorder and is thought to be
      potentially related to the pathophysiology of this disorder. Emerging evidence
      suggests that altered immune parameters may also be implicated in the
      neurobiological etiology of autism spectrum disorders. Further support for a role
      of immune dysregulation in the pathophysiology of these psychiatric disorders
      comes from studies showing the immunomodulating effects of antipsychotics and
      antidepressants, and the mood altering effects of anti-inflammatory therapies.
      This review will not attempt to discuss all of the psychiatric disorders that
      have been associated with an augmented immune system, but will instead focus on
      several key disorders where dysregulation of this system has been implicated in
      their pathophysiology including depression, schizophrenia and autism spectrum
      disorder.
AD  - Department of Immunology, Na1101, Erasmus MC, Dr. Molewaterplein 50, Erasmus MC, 
      3015 GE, Rotterdam, The Netherlands, s.gibney@erasmusmc.nl.
FAU - Gibney, Sinead M
AU  - Gibney SM
FAU - Drexhage, Hemmo A
AU  - Drexhage HA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130505
TA  - J Neuroimmune Pharmacol
JT  - Journal of neuroimmune pharmacology : the official journal of the Society on
      NeuroImmune Pharmacology
JID - 101256586
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/16 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/05/05 [aheadofprint]
AID - 10.1007/s11481-013-9462-8 [doi]
PST - aheadofprint
SO  - J Neuroimmune Pharmacol. 2013 May 5.

PMID- 23645136
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Linking)
VI  - 15
IP  - 3
DP  - 2013 Jun
TI  - Heart rate and the cardiometabolic risk.
PG  - 253-9
LID - 10.1007/s11906-013-0342-7 [doi]
AB  - Resting heart rate is a well recognized marker of autonomic nervous system tone, 
      and in many population studies has been found to be a significant correlate of
      blood pressure, increased body mass index, and metabolic disturbances. This
      association is particularly striking in patients with hypertension or diabetes,
      and cardiovascular morbidity related to high heart rate in these conditions seems
      to depend mainly on the clustering of these risk factors. The prospective
      relationship between tachycardia and metabolic abnormalities found in
      longitudinal studies indicates that the adrenergic overdrive is the cause rather 
      than the consequence of the insulin resistance state. Findings from observational
      studies and clinical trials have shown that heart rate measured during the
      follow-up provides prognostic information over and above heart rate measured at
      baseline, whereas the predictive value of heart rate measured out of the office
      is still debated. Antihypertensive drugs that decrease blood pressure and heart
      rate through a reduction of the sympathetic outflow may be more beneficial in
      clinical situations characterized by heightened sympathetic activity associated
      to insulin resistance.
AD  - Dipartimento di Medicina, University of Padova, via Giustiniani, 2, 35128,
      Padova, Italy, palatini@ux1.unipd.it.
FAU - Palatini, Paolo
AU  - Palatini P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.1007/s11906-013-0342-7 [doi]
PST - ppublish
SO  - Curr Hypertens Rep. 2013 Jun;15(3):253-9. doi: 10.1007/s11906-013-0342-7.

PMID- 23645121
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 May 4
TI  - The influence of exposure to maternal diabetes in utero on the rate of decline in
      beta-cell function among youth with diabetes.
PG  - 1-7
LID - 10.1515/jpem-2012-0385 [doi]
LID - /j/jpem.ahead-of-print/jpem-2012-0385/jpem-2012-0385.xml [pii]
AB  - Abstract We explored the influence of exposure to maternal diabetes in utero on
      beta cell decline measured by fasting C-peptide (FCP) among 1079 youth <20 years 
      with diabetes, including 941 with type 1 and 138 with type 2 diabetes. Youths
      exposed to maternal diabetes had FCP levels that were 17% lower among youth with 
      type 2 diabetes [95% confidence interval (CI): -34%, +6%] and 15% higher among
      youth with type 1 diabetes (95%CI: -14%, +55%) than their unexposed counterparts,
      although differences were not statistically significant (p=0.13 and p=0.35,
      respectively). Exposure to maternal diabetes was not associated with FCP decline 
      in youth with type 2 (p=0.16) or type 1 diabetes (p=0.90); nor was the effect of 
      in utero exposure on FCP modified by diabetes type. Findings suggest that
      exposure to maternal diabetes in utero may not be an important determinant of
      short-term beta-cell function decline in youth with type 1 or type 2 diabetes.
FAU - Crume, Tessa L
AU  - Crume TL
FAU - Andrews, Jeanette S
AU  - Andrews JS
FAU - D'Agostino, Ralph B
AU  - D'Agostino RB
FAU - Pettitt, David J
AU  - Pettitt DJ
FAU - Mayer-Davis, Elizabeth J
AU  - Mayer-Davis EJ
FAU - Law, Jennifer R
AU  - Law JR
FAU - Dolan, Lawrence
AU  - Dolan L
FAU - Lawrence, Jean M
AU  - Lawrence JM
FAU - Saydah, Sharon
AU  - Saydah S
FAU - Greenbaum, Carla
AU  - Greenbaum C
FAU - Rodriguez, Beatriz L
AU  - Rodriguez BL
FAU - Dabelea, Dana
AU  - Dabelea D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/12/03 [received]
PHST- 2013/03/24 [accepted]
AID - 10.1515/jpem-2012-0385 [doi]
AID - /j/jpem.ahead-of-print/jpem-2012-0385/jpem-2012-0385.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 May 4:1-7. doi: 10.1515/jpem-2012-0385.

PMID- 23645056
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1557-2501 (Electronic)
IS  - 1042-3931 (Linking)
VI  - 25
IP  - 5
DP  - 2013 May
TI  - Carotid artery thrombosis treated with catheter intervention using proximal
      occlusion and flow reversal.
PG  - E106-9
AB  - We present a case of symptomatic carotid artery thrombosis treated with catheter 
      intervention under proximal occlusion and flow reversal embolic protection.
      Although catheter intervention is contraindicated in carotid artery thrombosis
      due to the risk of distal embolization, the introduction of proximal occlusion
      embolic protection devices allow interventionalists to use catheter intervention 
      where it was previously deemed too high a risk. A Gore Flow Reversal device was
      used in a 57-year-old male with obesity, uncontrolled type I diabetes mellitus,
      hypertension, hyperlipidemia, and prior stroke who had previously undergone left 
      internal carotid artery revascularization with carotid artery endarterectomy and 
      patch angioplasty. Since balloon disruption and manual aspiration through the
      balloon sheath of the flow reversal device was unable to remove the thrombosis,
      an AngioJet 4 Fr RX catheter was used to mechanically remove material via
      mechanical thrombectomy. As there was still residual stenosis, a stent was placed
      in the area to decrease the remaining blockage. Follow-up carotid artery duplex
      scanning showed that the procedure eliminated the carotid occlusion. The embolic 
      protection device and the procedural technical aspects are described herein, as
      are reports of both clinical and anatomical follow-up. We show that by using a
      Gore Flow Reversal protection device, we were able to use catheter therapy to
      treat a carotid thrombosis, which was previously contraindicated for this
      condition.
AD  - Appleton Heart Institute, Cardiology Department, Appleton, WI USA.
      kalaswad@gmail.com.
FAU - Alaswad, Khaldoon
AU  - Alaswad K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PST - ppublish
SO  - J Invasive Cardiol. 2013 May;25(5):E106-9.

PMID- 23644927
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1573-7365 (Electronic)
IS  - 0885-7490 (Linking)
DP  - 2013 May 4
TI  - Association between the characteristics of metabolic syndrome and Alzheimer's
      disease.
AB  - Various epidemiological studies have shown that type 2 diabetes and metabolic
      syndrome are highly correlated with Alzheimer's disease (AD). Here, we sought to 
      assess the impact of metabolic syndrome characteristics on the progression of AD.
      Five-week-old male, spontaneously hypertensive (n = 32) and Wistar Kyoto
      (abbreviated WKY; n = 8) rats were divided into 5 groups (each n = 8): WKY,
      hypertension (HTN), streptozotocin-induced diabetes (STZ), high-fat diet (HFD),
      and STZ + high-fat diet-induced diabetes mellitus (DM). All animals were
      sacrificed and samples of the blood, liver, and brain were collected for further 
      biological analysis. During the 15-week period of induction, the STZ and DM
      groups (animals injected with low-dose STZ) had significantly higher fasting
      glucose levels; the HFD group had elevated insulin levels, but normal blood
      glucose levels. The HFD and DM groups had hypercholesterolemia and higher hepatic
      levels of triglycerides and cholesterol. Additionally, correlations between HFD
      and elevated brain amyloid-beta 42 (Abeta-42), hyperglycemia and down-regulation 
      of brain insulin receptor, and serum Abeta-42 and hepatic triglyceride
      concentrations (r2 = 0.41, p < 0.05) were observed. Serum C-reactive protein and 
      malondialdehyde did not appear to have a significant influence on the association
      with biomarkers of AD. Thus, our study demonstrated that rats with
      characteristics of metabolic syndrome had a large number of biomarkers predicting
      AD; however, no relationship between traditional inflammatory and oxidative
      markers and AD was found. Further studies are necessary to prove that these
      findings in rats are relevant to AD processes in humans.
AD  - Department of Nutrition, China Medical University, No.91 Hsueh-Shih Road,
      Taichung, Taiwan, 40402, Republic of China.
FAU - Yang, Hui-Ting
AU  - Yang HT
FAU - Sheen, Yi-Jing
AU  - Sheen YJ
FAU - Kao, Chuen-Der
AU  - Kao CD
FAU - Chang, Chin-An
AU  - Chang CA
FAU - Hu, Ya-Chun
AU  - Hu YC
FAU - Lin, Jiann-Liang
AU  - Lin JL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Metab Brain Dis
JT  - Metabolic brain disease
JID - 8610370
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/02/28 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 10.1007/s11011-013-9406-2 [doi]
PST - aheadofprint
SO  - Metab Brain Dis. 2013 May 4.

PMID- 23644877
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1433-2965 (Electronic)
IS  - 0937-941X (Linking)
DP  - 2013 May 4
TI  - The anti-diabetic drug metformin does not affect bone mass in vivo or fracture
      healing.
AB  - The present study shows no adverse effects of the anti-diabetic drug metformin on
      bone mass and fracture healing in rodents but demonstrates that metformin is not 
      osteogenic in vivo, as previously proposed. INTRODUCTION: In view of the
      increased incidence of fractures in patients with type 2 diabetes mellitus
      (T2DM), we investigated the effects of metformin, a widely used T2DM therapy, on 
      bone mass and fracture healing in vivo using two different rodent models and
      modes of metformin administration. METHODS: We first subjected 12-week-old female
      C57BL/6 mice to ovariectomy (OVX). Four weeks after OVX, mice received either
      saline or metformin administered by gavage (100 mg/kg/daily). After 4 weeks of
      treatment, bone micro-architecture and cellular activity were determined in tibia
      by micro-CT and bone histomorphometry. In another experiment, female Wistar rats 
      aged 3 months were given only water or metformin for 8 weeks via the drinking
      water (2 mg/ml). After 4 weeks of treatment, a mid-diaphyseal osteotomy was
      performed in the left femur. Rats were sacrificed 4 weeks after osteotomy and
      bone architecture analysed by micro-CT in the right tibia while fracture healing 
      and callus volume were determined in the left femur by X-ray analysis and
      micro-CT, respectively. RESULTS: In both models, our results show no significant 
      differences in cortical and trabecular bone architecture in metformin-treated
      rodents compared to saline. Metformin had no effect on bone resorption but
      reduced bone formation rate in trabecular bone. Mean X-ray scores assessed on
      control and metformin fractures showed no significant differences of healing
      between the groups. Fracture callus volume and mineral content after 4 weeks were
      similar in both groups. CONCLUSIONS: Our results indicate that metformin has no
      effect on bone mass in vivo or fracture healing in rodents.
AD  - Department of Comparative and Biomedical Sciences, Royal Veterinary College,
      Royal College Street, London, NW1 0TU, UK.
FAU - Jeyabalan, J
AU  - Jeyabalan J
FAU - Viollet, B
AU  - Viollet B
FAU - Smitham, P
AU  - Smitham P
FAU - Ellis, S A
AU  - Ellis SA
FAU - Zaman, G
AU  - Zaman G
FAU - Bardin, C
AU  - Bardin C
FAU - Goodship, A
AU  - Goodship A
FAU - Roux, J P
AU  - Roux JP
FAU - Pierre, M
AU  - Pierre M
FAU - Chenu, C
AU  - Chenu C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Osteoporos Int
JT  - Osteoporosis international : a journal established as result of cooperation
      between the European Foundation for Osteoporosis and the National Osteoporosis
      Foundation of the USA
JID - 9100105
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/15 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 10.1007/s00198-013-2371-0 [doi]
PST - aheadofprint
SO  - Osteoporos Int. 2013 May 4.

PMID- 23644838
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1432-2218 (Electronic)
IS  - 0930-2794 (Linking)
DP  - 2013 May 4
TI  - Risk factors for complications and mortality of percutaneous endoscopic
      gastrostomy: a multicenter, retrospective study.
AB  - BACKGROUND: Percutaneous endoscopic gastrostomy (PEG) is performed to provide
      nutrition to patients with swallowing difficulties. A multicenter study was
      conducted to evaluate the predictors of complications and mortality after PEG
      placement. METHODS: This study retrospectively analyzed patients who underwent
      initial PEG placement between January 2004 and December 2011 at seven tertiary
      hospitals in the Republic of Korea. RESULTS: All 1,625 patients underwent PEG
      placement by the pull-string method. The median age of the patients was 66 years,
      and 1,108 of the patients were men. The median follow-up period was 254 days. The
      common indications were stroke (31.6 %) and malignancy (18.9 %). The complication
      rate was 13.2 %. The prophylactic use of antibiotics (odds ratio [OR], 0.58; 95 %
      confidence interval [CI], 0.38-0.88; p = 0.010) reduced the PEG-related infection
      rate, but the actual usage rate was 81.1 %. The use of anticoagulants (OR, 7.26; 
      95 % CI, 2.23-23.68; p = 0.001) and the presence of diabetes mellitus (OR, 4.02; 
      95 % CI, 1.49-10.87; p = 0.006) increased the risk of bleeding, but antiplatelet 
      therapy did not. The procedural, 30-day, and overall mortality rates were 0.2,
      2.4 and 14.0 %, respectively. Serum albumin levels lower than 31.5 g/L (OR, 8.55;
      95 % CI, 3.11-23.45; p < 0.001) and C-reactive protein levels higher than 21.5
      mg/L (OR, 3.01; 95 % CI, 1.27-7.16; p = 0.012) increased the risk of 30-day
      mortality, and the patients who had both risk factors had a significantly shorter
      median survival time than those who did not (1,740 vs 3,181 days) (p < 0.001,
      log-rank). CONCLUSIONS: The findings showed PEG to be a safe and feasible
      procedure, but the patient's nutritional and inflammatory status should be
      considered in predicting the outcomes of PEG placement.
AD  - Department of Internal Medicine and Healthcare Research Institute, Healthcare
      System Gangnam Center, Seoul National University Hospital, Seoul, Republic of
      Korea, mdchlee@gmail.com.
FAU - Lee, Changhyun
AU  - Lee C
FAU - Im, Jong Pil
AU  - Im JP
FAU - Kim, Ji Won
AU  - Kim JW
FAU - Kim, Seong-Eun
AU  - Kim SE
FAU - Ryu, Dong Yup
AU  - Ryu DY
FAU - Cha, Jae Myung
AU  - Cha JM
FAU - Kim, Eun Young
AU  - Kim EY
FAU - Kim, Eun Ran
AU  - Kim ER
FAU - Chang, Dong Kyung
AU  - Chang DK
CN  - Small Intestine Research Group of the Korean Association for the Study of
      Intestinal Disease (KASID)
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - Surg Endosc
JT  - Surgical endoscopy
JID - 8806653
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/21 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 10.1007/s00464-013-2979-3 [doi]
PST - aheadofprint
SO  - Surg Endosc. 2013 May 4.

PMID- 23644712
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
DP  - 2013 May 3
TI  - Recurrence of mediastinal node cancer after lobe-specific systematic nodal
      dissection for non-small-cell lung cancer.
AB  - OBJECTIVES: The standard surgical treatment for patients with non-small-cell lung
      cancer (NSCLC) is lobectomy with systematic nodal dissection (SND). Lobe-specific
      patterns of nodal metastases have been recognized, and lobe-specific SND (L-SND) 
      has been reported. We performed L-SND depending on patient-related factors, such 
      as age or the presence of diabetes or respiratory dysfunction, or in the context 
      of specific tumour-related factors, such as the presence of a tumour with a wide 
      area of ground-glass opacity. METHODS: Between September 2002 and December 2008, 
      335 consecutive patients with clinical and intraoperative N0 NSCLC underwent
      curative lobectomies at Shizuoka Cancer Center Hospital. Among these 335
      patients, 206 underwent SND (Group A) and 129 underwent L-SND. Of the 129
      patients undergoing L-SND, 98 underwent L-SND due to patient-related factors
      (Group B) and 31 underwent L-SND due to tumour-related factors (Group C).
      RESULTS: There were no significant differences in morbidity or blood loss between
      patients undergoing SND or L-SND, but there was a significant difference in the
      mean operative times. The 5-year disease-free survival (5-DFS) and 5-year overall
      survival (5-OS) of patients in Group C were 100%. Although the patients in Group 
      B showed no significant difference in 5-DFS and 5-OS compared with Group A,
      patients in Group B had significantly more initial recurrence of mediastinal node
      cancer than did the Group A patients (P = 0.0050). CONCLUSIONS: The recurrence of
      mediastinal node cancer in patients undergoing L-SND was significantly greater
      than that in those undergoing SND.
AD  - Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
FAU - Maniwa, Tomohiro
AU  - Maniwa T
FAU - Okumura, Takehiro
AU  - Okumura T
FAU - Isaka, Mitsuhiro
AU  - Isaka M
FAU - Nakagawa, Kazuo
AU  - Nakagawa K
FAU - Ohde, Yasuhisa
AU  - Ohde Y
FAU - Kondo, Haruhiko
AU  - Kondo H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European
      Association for Cardio-thoracic Surgery
JID - 8804069
OTO - NOTNLM
OT  - Lobectomy
OT  - Lung cancer
OT  - Lymph node dissection
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - ezt195 [pii]
AID - 10.1093/ejcts/ezt195 [doi]
PST - aheadofprint
SO  - Eur J Cardiothorac Surg. 2013 May 3.

PMID- 23644647
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1432-1076 (Electronic)
IS  - 0340-6199 (Linking)
DP  - 2013 May 5
TI  - Short stature in child with early-onset diabetes.
AB  - We present a girl who initially presented at 12 weeks of age with antibody
      negative diabetes. Genetic screening for common mutations of monogenic diabetes
      was negative. She was noted to have short stature at 8 years of age (height <0.4 
      centile), as well as overlapping toes and distal abnormalities of her fingers. On
      reevaluation, further investigation revealed an EIF2AK3 mutation, and a diagnosis
      of Wolcott Rallison syndrome was made. This case highlights the importance of
      close follow up of patients with neonatal diabetes for the development of
      syndromic features that may lead to a unifying diagnosis.
AD  - Department of Paediatric Endocrinology, Children's University Hospital, Temple
      Street, Dublin, Ireland.
FAU - Hawkes, C P
AU  - Hawkes CP
FAU - McGlacken-Byrne, S M
AU  - McGlacken-Byrne SM
FAU - Murphy, N P
AU  - Murphy NP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130505
TA  - Eur J Pediatr
JT  - European journal of pediatrics
JID - 7603873
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/05/05 [aheadofprint]
AID - 10.1007/s00431-013-2007-6 [doi]
PST - aheadofprint
SO  - Eur J Pediatr. 2013 May 5.

PMID- 23644594
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1559-2308 (Electronic)
IS  - 1559-2294 (Linking)
VI  - 8
IP  - 5
DP  - 2013 Apr 17
TI  - A genome-wide methylation study on obesity: Differential variability and
      differential methylation.
AB  - Besides differential methylation, DNA methylation variation has recently been
      proposed and demonstrated to be a potential contributing factor to cancer risk.
      Here we aim to examine whether differential variability in methylation is also an
      important feature of obesity, a typical non-malignant common complex disease. We 
      analyzed genome-wide methylation profiles of over 470,000 CpGs in peripheral
      blood samples from 48 obese and 48 lean African-American youth aged 14-20 y old. 
      A substantial number of differentially variable CpG sites (DVCs), using
      statistics based on variances, as well as a substantial number of differentially 
      methylated CpG sites (DMCs), using statistics based on means, were identified.
      Similar to the findings in cancers, DVCs generally exhibited an outlier structure
      and were more variable in cases than in controls. By randomly splitting the
      current sample into a discovery and validation set, we observed that both the
      DVCs and DMCs identified from the first set could independently predict obesity
      status in the second set. Furthermore, both the genes harboring DMCs and the
      genes harboring DVCs showed significant enrichment of genes identified by
      genome-wide association studies on obesity and related diseases, such as
      hypertension, dyslipidemia, type 2 diabetes and certain types of cancers,
      supporting their roles in the etiology and pathogenesis of obesity. We
      generalized the recent finding on methylation variability in cancer research to
      obesity and demonstrated that differential variability is also an important
      feature of obesity-related methylation changes. Future studies on the epigenetics
      of obesity will benefit from both statistics based on means and statistics based 
      on variances.
AD  - Georgia Prevention Institute; Department of Pediatrics; Georgia Regents
      University; Augusta, GA USA.
FAU - Xu, Xiaojing
AU  - Xu X
FAU - Su, Shaoyong
AU  - Su S
FAU - Barnes, Vernon A
AU  - Barnes VA
FAU - De Miguel, Carmen
AU  - De Miguel C
FAU - Pollock, Jennifer
AU  - Pollock J
FAU - Ownby, Dennis
AU  - Ownby D
FAU - Shi, Hidong
AU  - Shi H
FAU - Zhu, Haidong
AU  - Zhu H
FAU - Snieder, Harold
AU  - Snieder H
FAU - Wang, Xiaoling
AU  - Wang X
LA  - ENG
GR  - R01 HL105689/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Epigenetics
JT  - Epigenetics : official journal of the DNA Methylation Society
JID - 101265293
OTO - NOTNLM
OT  - blacks
OT  - epigenome-wide association study (EWAS)
OT  - genome-wide association study (GWAS)
OT  - methylation variation
OT  - obesity
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 24506 [pii]
PST - aheadofprint
SO  - Epigenetics. 2013 Apr 17;8(5).

PMID- 23644451
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 148
IP  - 1
DP  - 2013 Jul
TI  - Low C-peptide levels and decreased expression of TNF and CD45 in children with
      high risk of type 1 diabetes.
PG  - 4-15
LID - 10.1016/j.clim.2013.03.011 [doi]
LID - S1521-6616(13)00084-3 [pii]
AB  - Type 1 diabetes (T1D) patients have numeral and functional defects in peripheral 
      immune cells, but the pre-diabetic period is fairly uncharacterized. Our aim was 
      to analyze expression of immunological markers in T1D high risk children and
      relate it to clinical/immunological parameters. Children from ABIS (All Babies in
      Southeast Sweden) with >/=2 diabetes related autoantibodies were considered at
      high risk. Age-matched controls and new-onset T1D patients were included.
      Expression of genes related to immune cell function and different arms of the
      immune system was assessed in peripheral blood mononuclear cells using PCR array.
      Risk children had lower TNF and CD45, and although there were few differences
      between the groups, expression of many genes differed when comparing children
      with regard to residual insulin secretion. Hence, expression of immune related
      genes seemed related not only to the autoimmune process but rather to residual
      beta-cell function, which was decreased already during the pre-diabetic phase.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Pediatrics, Department of Clinical and Experimental Medicine, Faculty
      of Health Sciences, Linkoping University, Linkoping, Sweden. Electronic address: 
      linda.akerman@liu.se.
FAU - Akerman, Linda
AU  - Akerman L
FAU - Ludvigsson, Johnny
AU  - Ludvigsson J
FAU - Casas, Rosaura
AU  - Casas R
LA  - eng
PT  - Journal Article
DEP - 20130329
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/16 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/03/18 [accepted]
PHST- 2013/03/29 [aheadofprint]
AID - S1521-6616(13)00084-3 [pii]
AID - 10.1016/j.clim.2013.03.011 [doi]
PST - ppublish
SO  - Clin Immunol. 2013 Jul;148(1):4-15. doi: 10.1016/j.clim.2013.03.011. Epub 2013
      Mar 29.

PMID- 23644407
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
DP  - 2013 May 2
TI  - New and Emerging Risk Factors for Coronary Heart Disease.
AB  - : Coronary heart disease (CHD) is one of the leading causes of death in the
      United States. Traditional risk factors such as family history, hypertension,
      hypercholesterolemia, diabetes mellitus and smoking cannot account for the entire
      risk for incident coronary events. Several other potential risk factors have been
      identified in an effort to improve risk assessment for CHD. This article reviews 
      the current evidence on new and emerging risk factors for CHD and their current
      utility in screening, specifically focusing on coronary artery calcium score,
      C-reactive protein, lipoprotein (a), carotid intima-media thickness,
      homocysteine, lipoprotein-associated phospholipase A2, as well as high-density
      lipoprotein functionality.
AD  - Department of Internal Medicine (EA, JT), Mount Sinai School of Medicine, New
      York, New York; Department of Medicine (J-WC, SL), Emory University School of
      Medicine, Atlanta, Georgia; and St. Francis Hospital-The Heart Center (TJV),
      Division of Cardiology, Center of Advanced Cardiac Therapeutics, Roslyn, New
      York; Department of Internal Medicine (GC), Winthrop University Hospital,
      Mineola, New York; Cardiovascular Consultants of Long Island, PC (KMG), New Hyde 
      Park, New York; and Zena and Michael A. Wiener Cardiovascular Institute (CEK),
      Mount Sinai School of Medicine, New York, New York.
FAU - Akhabue, Ehimare
AU  - Akhabue E
FAU - Thiboutot, Jeffrey
AU  - Thiboutot J
FAU - Cheng, Jeh-Wei
AU  - Cheng JW
FAU - Vittorio, Timothy J
AU  - Vittorio TJ
FAU - Christodoulidis, Georgios
AU  - Christodoulidis G
FAU - Grady, Kathleen M
AU  - Grady KM
FAU - Lerakis, Stamatios
AU  - Lerakis S
FAU - Kosmas, Constantine E
AU  - Kosmas CE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.1097/MAJ.0b013e31828aab45 [doi]
PST - aheadofprint
SO  - Am J Med Sci. 2013 May 2.

PMID- 23644310
OWN - NLM
STAT- In-Process
DA  - 20130506
IS  - 0028-3886 (Print)
IS  - 0028-3886 (Linking)
VI  - 61
IP  - 2
DP  - 2013 Mar-Apr
TI  - Surgical management of selected pituitary macroadenomas using extended endoscopic
      endonasal transsphenoidal approach: early experience.
PG  - 122-30
LID - 10.4103/0028-3886.111114 [doi]
AB  - BACKGROUND AND OBJECTIVES: The endoscopic transsphenoidal approach is commonly
      used surgical approach for pituitary adenomas. However, adenomas with dumbbell
      configuration, pure suprasellar location, and fibrous consistency are difficult
      to remove by this approach. Recently, the extended endoscopic endonasal approach 
      (EEEA) has been utilized to excise this subgroup of pituitary adenomas
      successfully. MATERIALS AND METHODS: Between January 2009 and December 2011, 13
      patients with pituitary macroadenomas were treated with EEEA. The tumor subgroups
      included: Dumbbell tumor configuration (4), pure suprasellar tumor location (2), 
      and large suprasellar tumors with subfrontal extension (2). Five patients had
      fibrous/recurrent tumors and required addition of transtubercular-transplanum
      extension to the standard endoscopic endonasal exposure for radical resection.
      RESULTS: The tumor removal was gross total in 8 (61.5%) patients, subtotal in 4
      (30.7%), and partial in 1 (7.7%) patient. Clinical improvement was observed in
      almost all patients, immediate relief in headaches in 88% and normalization of
      vision in 90% of patients with pre-operative visual disturbances. Three patients 
      with secreting adenomas, two with growth hormone-secreting adenomas and one with 
      prolactin-secreting adenoma, had normalization of hormonal status. Three patients
      developed temporary diabetes insipidus two patients suffered transient ischemic
      attacks and one patient with a recurrent giant pituitary adenoma experienced a
      serious injury to the perforating artery. Four patients (30.7%) developed
      post-operative cerebrospinal rhinorrhea and two patients required surgical
      repair. CONCLUSIONS: Our early experience suggests that the EEEA offers a
      potentially viable treatment option in certain pituitary tumors which are
      difficult to remove by the standard endoscopic approaches. However, longer
      follow-up and larger series are needed to establish the efficacy of this
      approach.
AD  - Department of Neurosurgery, Dr. Balabhai Nanavati Hospital and Saifee Hospital,
      Mumbai, Maharashtra, India. sankhlasuresh@gmail.com
FAU - Sankhla, Suresh K
AU  - Sankhla SK
FAU - Jayashankar, Narayan
AU  - Jayashankar N
FAU - Khan, Ghulam M
AU  - Khan GM
LA  - eng
PT  - Journal Article
PL  - India
TA  - Neurol India
JT  - Neurology India
JID - 0042005
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - ni_2013_61_2_122_111114 [pii]
AID - 10.4103/0028-3886.111114 [doi]
PST - ppublish
SO  - Neurol India. 2013 Mar-Apr;61(2):122-30. doi: 10.4103/0028-3886.111114.

PMID- 23644258
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
DP  - 2013 May 3
TI  - Differences in Cardiovascular Risk Factors Between Patients With Acute Limb
      Ischemia and Intermittent Claudication.
AB  - In this retrospective study, cardiovascular risk factors of patients with acute
      limb ischemia (ALI) were compared with those of intermittent claudication (IC).
      Furthermore, the association of ALI with environmental temperature and/or
      hematocrit level was tested. A total of 436 patients treated for ALI and 832
      patients with IC were included in the analysis. Diabetes (P = .0001), smoking (P 
      < .0001), and hypertension (P < .0001) were significantly less prevalent in the
      patients with ALI. Patients with IC had a higher rate of coronary artery disease 
      (P = .003), and patients with ALI had a higher rate of cerebrovascular disease (P
      < .0001). There was no association between the outside temperature or hematocrit 
      level and the occurrence of ALI. The hypothesis of seasonal incidence of ALI
      could not be confirmed, and there was no association of ALI with the hematocrit
      level.
AD  - 1Clinic for Angiology, University Hospital Zurich, Switzerland.
FAU - Johner, Fabian
AU  - Johner F
FAU - Thalhammer, Christoph
AU  - Thalhammer C
FAU - Jacomella, Vincenzo
AU  - Jacomella V
FAU - Husmann, Marc
AU  - Husmann M
FAU - Amann-Vesti, Beatrice
AU  - Amann-Vesti B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Angiology
JT  - Angiology
JID - 0203706
OTO - NOTNLM
OT  - acute limb ischemia
OT  - claudication
OT  - peripheral artery disease
OT  - risk factors
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 0003319713487428 [pii]
AID - 10.1177/0003319713487428 [doi]
PST - aheadofprint
SO  - Angiology. 2013 May 3.

PMID- 23644181
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
DP  - 2013 May 3
TI  - Prognostic value of myocardial circumferential strain for incident heart failure 
      and cardiovascular events in asymptomatic individuals: the Multi-Ethnic Study of 
      Atherosclerosis.
AB  - AIMS: Left ventricular (LV) circumferential strain (Ecc) is a sensitive index of 
      regional myocardial function. Currently, no studies have assessed its prognostic 
      value in general population. We sought to investigate whether Ecc has a
      prognostic value for predicting incident heart failure (HF) and other major
      cardiovascular events in asymptomatic individuals without a history of previous
      cardiovascular diseases. METHODS AND RESULTS: We, prospectively, assessed
      incident HF and atherosclerotic events during a 5.5 +/- 1.3-year period in 1768
      asymptomatic individuals aged 45-84 (mean age 65 years; 47% female) who underwent
      tagged magnetic resonance imaging for strain determination. During the follow-up 
      period, 39 (2.2%) participants experienced incident HF and 108 (6.1%)
      participants had atherosclerotic cardiovascular events. Average of peak Ecc of
      12-LV segments (Ecc-global) and mid-slice (Ecc-mid) was -17.0 +/- 2.4 and -17.5
      +/- 2.7%, respectively. Participants with average absolute Ecc-mid lower than
      -16.9% had a higher cumulative hazard of incident HF (log-rank test, P = 0.001). 
      In cox regression analysis, Ecc-mid predicted incident HF independent of age,
      diabetes status, hypertension, interim myocardial infarction, LV mass index, and 
      LV ejection fraction (hazard ratio 1.15 per 1%, 95% CI: 1.01-1.31, P = 0.03).
      This relationship remained significant after adjustment for LV-end-systolic wall 
      stress into covariates. In addition, by adding Ecc-mid to risk factors, LV
      ejection fraction, and the LV mass index, both the global chi2 value (76.6 vs.
      82.4, P = 0.04) and category-less net-reclassification index (P = 0.01, SE =
      0.18, z = 2.53) were augmented for predicting HF. Circumferential strain was also
      significantly related to the composite atherosclerotic cardiovascular events, but
      its relationship was attenuated after introducing the LV mass index. CONCLUSION: 
      Circumferential shortening provides robust, independent, and incremental
      predictive value for incident HF in asymptomatic subjects without any history of 
      previous clinical cardiovascular disease. CLINICAL TRIAL REGISTRATION::
      http://www.clinicaltrials.gov. Unique identifier: NCT00005487.
AD  - Johns Hopkins University, Baltimore, MD, USA.
FAU - Choi, Eui-Young
AU  - Choi EY
FAU - Rosen, Boaz D
AU  - Rosen BD
FAU - Fernandes, Veronica R S
AU  - Fernandes VR
FAU - Yan, Raymond T
AU  - Yan RT
FAU - Yoneyama, Kihei
AU  - Yoneyama K
FAU - Donekal, Sirisha
AU  - Donekal S
FAU - Opdahl, Anders
AU  - Opdahl A
FAU - Almeida, Andre L C
AU  - Almeida AL
FAU - Wu, Colin O
AU  - Wu CO
FAU - Gomes, Antoinette S
AU  - Gomes AS
FAU - Bluemke, David A
AU  - Bluemke DA
FAU - Lima, Joao A C
AU  - Lima JA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
OTO - NOTNLM
OT  - Cardiovascular events
OT  - Heart failure
OT  - Myocardial function
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - eht133 [pii]
AID - 10.1093/eurheartj/eht133 [doi]
PST - aheadofprint
SO  - Eur Heart J. 2013 May 3.

PMID- 23644179
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
DP  - 2013 May 3
TI  - Factors underlying regression of coronary atheroma with potent statin therapy.
AB  - AIMS: Statins can inhibit the progression of coronary atherosclerosis. We aimed
      to characterize clinical factors that associate with differing measures of
      coronary atheroma volume following potent statin therapy. METHODS AND RESULTS:
      SATURN employed serial intravascular ultrasound (IVUS) to monitor changes in
      measures of coronary atheroma burden [total atheroma volume (TAV) and per cent
      atheroma volume (PAV)] in 1039 patients with coronary artery disease, treated
      with rosuvastatin (40 mg) or atorvastatin (80 mg) daily for 24 months.
      Rosuvastatin-treated patients demonstrated greater reductions in low-density
      lipoprotein cholesterol (LDL-C, 47 vs. 40%, P < 0.001) and greater increases in
      high-density lipoprotein cholesterol (HDL-C, 13 vs. 10%, P = 0.02). These
      alterations in the lipid profile associated with greater TAV (-6.4 vs. -4.4 mm3, 
      P = 0.01), but not PAV (-1.22 vs. -0.99%, P = 0.17) regression. Greater TAV
      reductions with rosuvastatin vs. atorvastatin occurred in patients with diabetes 
      (P = 0.01, treatment by diabetic status interaction P-value 0.05). Greater PAV
      reductions with rosuvastatin were evident in females (P = 0.01, treatment by sex 
      interaction P-value 0.03) and in those with greater than or equal to median
      baseline LDL-C (P = 0.02, treatment by LDL-C group interaction P-value 0.03) or
      HDL-C levels (P = 0.02, treatment by HDL-C group interaction P-value 0.04). On
      multivariable analysis assessing change in TAV and PAV, both higher baseline TAV 
      and PAV independently associated with TAV and PAV regression, respectively
      (standardized estimates: TAV -0.25, P < 0.001; PAV -0.23, P < 0.001). CONCLUSION:
      Higher-risk patients, particularly those with greater baseline coronary atheroma 
      volume, are more likely to experience less disease progression with potent statin
      therapy.
AD  - Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
FAU - Puri, Rishi
AU  - Puri R
FAU - Nissen, Steven E
AU  - Nissen SE
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
FAU - Barter, Phillip J
AU  - Barter PJ
FAU - Chapman, M John
AU  - Chapman MJ
FAU - Erbel, Raimund
AU  - Erbel R
FAU - Libby, Peter
AU  - Libby P
FAU - Raichlen, Joel S
AU  - Raichlen JS
FAU - St John, Julie
AU  - St John J
FAU - Wolski, Kathy
AU  - Wolski K
FAU - Uno, Kiyoko
AU  - Uno K
FAU - Kataoka, Yu
AU  - Kataoka Y
FAU - Nicholls, Stephen J
AU  - Nicholls SJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
OTO - NOTNLM
OT  - Atherosclerosis
OT  - IVUS
OT  - Risk factors
OT  - Statins
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - eht084 [pii]
AID - 10.1093/eurheartj/eht084 [doi]
PST - aheadofprint
SO  - Eur Heart J. 2013 May 3.

PMID- 23644134
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1673-4254 (Print)
IS  - 1673-4254 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Apr 20
TI  - [Diagnosis and treatment of glucagonoma: report of one case].
PG  - 618-insidebackcover
AB  - OBJECTIVE: lucagonoma is a rare islet alpha-cell tumor. We report a case of
      glucagonoma in a 55-year-old male patient with such clinical findings of
      necrolytic migratory erythema, diabetes mellitus, body weight loss, and anemia.
      CT examination found a space-occupying lesion in the pancreas, and an elevated
      serum glucagon level indicate the diagnosis of glucagonoma, which was confirmed
      postoperatively by pathological examination of the tumor tissue. A definite
      diagnosis of glucagonoma relies on pathological report, and so far no standard
      treatment strategy has been available for this tumor. Surgical resection is an
      effective means for treatment of glucagonoma.
AD  - Department of General Surgery, First Affiliated Hospital of Chongqing Medical
      University, Chongqing 400016, China. E-mail: eschenghong@126.com.
FAU - Cheng, Hong
AU  - Cheng H
FAU - Chen, Mao-Shan
AU  - Chen MS
FAU - Yang, Guang-Lun
AU  - Yang GL
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2013 Apr 20;33(4):618-insidebackcover.

PMID- 23644116
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1673-4254 (Print)
IS  - 1673-4254 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Apr 20
TI  - [Correlation of aldehyde dehydrogenase-2 gene polymorphism with hypertension in
      patients with coronary heart disease complicated by diabetes mellitus].
PG  - 542-5
AB  - OBJECTIVE: To investigate the correlation of G487A polymorphism of aldehyde
      dehydrogenase-2 (ALDH2) gene with hypertension in patients with coronary heart
      disease complicated by type 2 diabetes. METHODS: This study was conducted among
      167 patients with coronary heart disease complicated by diabetes mellitus. The
      polymorphisms of gene G487A ALDH2 were determined using polymerase chain
      reaction-restricted fragments length polymorphism technique (PCR-RFLP). According
      to the genotypes, the patients were divided into GG group (n=105) and GA/AA group
      (n=62), and the incidence of hypertension, risk factors of hypertension, systolic
      and diastolic pressures, and pulse pressure indexes were compared between the two
      groups. Multivariate logistic regression analysis was performed to adjust the
      effects of the confounding factors. RESULTS: The incidence of hypertension in
      GA/AA group was significantly higher than that in GG group (P<0.05), and the
      former group showed a significantly greater differences between systolic and
      pulse pressure; the diastolic pressure was comparable between the two groups.
      Multivariate logistic regression analysis showed that GA/AA was associated with
      an increased risk of hypertension in synergy with high insulin level and insulin 
      resistance. CONCLUSION: ALDH2 gene G487A polymorphism may be associated with
      hypertension in patients with coronary heart disease complicated by type 2
      diabetes, and the patients with an A allele have a greater risk of developing
      hypertension.
AD  - Department of Cardiology, First Affiliated Hospital of Bengbu Medical College,
      Bengbu 233004, China; Bengbu Medical College, Bengbu 233030, China. E-mail:
      docwhj1101@163.com.
FAU - Wang, Hong-Ju
AU  - Wang HJ
FAU - Pan, Qiang-Qiang
AU  - Pan QQ
FAU - Gao, Qin
AU  - Gao Q
FAU - Kang, Pinfang
AU  - Kang P
FAU - Li, Miao-Nan
AU  - Li MN
FAU - He, Pei-Bao
AU  - He PB
FAU - Tang, Yang
AU  - Tang Y
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2013 Apr 20;33(4):542-5.

PMID- 23644087
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 May 1
TI  - Are post-operative arrhythmias in patients with metabolic syndrome a sign of
      dysfunctional mitochondria?
LID - S0735-1097(13)01724-5 [pii]
LID - 10.1016/j.jacc.2013.03.057 [doi]
AD  - Department of Physiology and the East Carolina Diabetes Institute, Brody School
      of Medicine, East Carolina University, Greenville NC, USA. Electronic address:
      brownda@ecu.edu.
FAU - Brown, David A
AU  - Brown DA
FAU - Moukdar, Fatiha
AU  - Moukdar F
LA  - ENG
PT  - EDITORIAL
DEP - 20130501
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/12 [received]
PHST- 2013/03/19 [accepted]
AID - S0735-1097(13)01724-5 [pii]
AID - 10.1016/j.jacc.2013.03.057 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 May 1. pii: S0735-1097(13)01724-5. doi:
      10.1016/j.jacc.2013.03.057.

PMID- 23644033
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-2747 (Electronic)
IS  - 0361-9230 (Linking)
VI  - 96C
DP  - 2013 Apr 30
TI  - Pronociceptive changes in the activity of rostroventromedial medulla (RVM) pain
      modulatory cells in the streptozotocin-diabetic rat.
PG  - 39-44
LID - S0361-9230(13)00074-9 [pii]
LID - 10.1016/j.brainresbull.2013.04.008 [doi]
AB  - Neuropathic pain is one of the most frequent complications of diabetes. The
      increased neuronal activity of primary afferents and spinal cord neurons in
      streptozotocin (STZ)-diabetic rats increases the recruitment of the nociceptive
      ascending pathways, which may affect the activity of pain control circuits in the
      brain. This study aimed to characterize the electrophysiological responses of
      neurons of the rostroventromedial medulla (RVM), a key brainstem area involved in
      descending modulation of nociceptive neurotransmission at the spinal cord, in
      STZ-diabetic rats. Spontaneous and noxious-evoked activity of ON-like cells (pain
      facilitatory cells) and OFF-like cells (pain inhibitory cells) in the RVM were
      analyzed by single cell extracellular electrophysiological recordings in
      STZ-diabetic rats with behavioral signs of diabetic neuropathic pain 4 weeks
      after diabetes induction and in age-matched non-diabetic controls (CTRL). The
      electrophysiological analysis revealed an increase in the spontaneous activity of
      RVM pronociceptive ON-like cells in STZ-diabetic rats when compared to CTRL. On
      the contrary, the number of active antinociceptive OFF-like cells was
      significantly lower in the STZ-diabetic rats and their spontaneous activity was
      decreased when compared with CTRL. Overall, the changes in the activity of RVM
      pain modulatory cells in STZ-diabetic rats point to enhancement of descending
      pain facilitation. Based on similar results obtained at the RVM in traumatic
      neuropathic pain models, the changes in the electrophysiological responses of RVM
      in STZ-diabetic rats may account for exacerbated pain-like behaviors in diabetic 
      neuropathy.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Experimental Biology, Faculty of Medicine of Porto and IBMC,
      University of Porto, Rua Dr Placido Costa, 4200-450 Porto, Portugal. Electronic
      address: martalvesilva@gmail.com.
FAU - Silva, M
AU  - Silva M
FAU - Amorim, D
AU  - Amorim D
FAU - Almeida, A
AU  - Almeida A
FAU - Tavares, I
AU  - Tavares I
FAU - Pinto-Ribeiro, F
AU  - Pinto-Ribeiro F
FAU - Morgado, C
AU  - Morgado C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Brain Res Bull
JT  - Brain research bulletin
JID - 7605818
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/04/19 [accepted]
AID - S0361-9230(13)00074-9 [pii]
AID - 10.1016/j.brainresbull.2013.04.008 [doi]
PST - aheadofprint
SO  - Brain Res Bull. 2013 Apr 30;96C:39-44. doi: 10.1016/j.brainresbull.2013.04.008.

PMID- 23644012
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1873-1244 (Electronic)
IS  - 0899-9007 (Linking)
DP  - 2013 May 2
TI  - Effects of a meal rich in medium-chain saturated fat on postprandial lipemia in
      relatives of type 2 diabetics.
LID - S0899-9007(13)00086-5 [pii]
LID - 10.1016/j.nut.2013.01.018 [doi]
AB  - OBJECTIVE: Patients with type 2 diabetes and their relatives (REL) have increased
      risk for cardiovascular disease (CVD). Postprandial triglyceridemia (PPL), which 
      is influenced by diet, is an independent risk factor for CVD. Little is known
      about the effects of medium-chain saturated fatty acids (medium-chain SFA) on PPL
      and gene expression in REL. The objective of this study was to test the
      hypothesis that medium-chain SFA cause larger PPL response in REL compared with
      controls (CON) and have a differential effect on circulating incretins and
      ghrelin and gene expression in muscle and adipose tissue in REL and CON. METHODS:
      Seventeen REL and 17 CON received a fat-rich meal (79 energy percent from fat)
      based on medium-chain SFA (coconut oil). Plasma concentrations of triglycerides
      (TG), free-fatty acids, insulin, glucose, glucagon-like peptide-1,
      glucose-dependent insulintropic peptide, and ghrelin were measured before and
      during 240 min postprandially. Muscle and adipose tissue biopsies were taken at
      baseline and after the test meal. RESULTS: After the test meal, REL had a higher 
      plasma TG response (P = 0.002) and a tendency toward higher insulin response (P =
      0.100). A number of genes were upregulated in response to the meal rich in
      medium-chain SFA in CON, but not in REL. CONCLUSION: A meal high in medium-chain 
      SFA resulted in larger PPL response in REL than in CON. It remains to be
      clarified whether this can be reproduced by a pure medium-chain fat (MCT) load.
      The meal exerted a differential effect on gene expression in muscle, but not
      adipose tissue, of REL compared with CON.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Endocrinology and Metabolism MEA, Aarhus University Hospital,
      Aarhus, Denmark. Electronic address: annapiet@rm.dk.
FAU - Pietraszek, Anna
AU  - Pietraszek A
FAU - Hermansen, Kjeld
AU  - Hermansen K
FAU - Pedersen, Steen B
AU  - Pedersen SB
FAU - Langdahl, Bente L
AU  - Langdahl BL
FAU - Holst, Jens J
AU  - Holst JJ
FAU - Gregersen, Soren
AU  - Gregersen S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Nutrition
JT  - Nutrition (Burbank, Los Angeles County, Calif.)
JID - 8802712
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/08/20 [received]
PHST- 2013/01/28 [revised]
PHST- 2013/01/29 [accepted]
AID - S0899-9007(13)00086-5 [pii]
AID - 10.1016/j.nut.2013.01.018 [doi]
PST - aheadofprint
SO  - Nutrition. 2013 May 2. pii: S0899-9007(13)00086-5. doi:
      10.1016/j.nut.2013.01.018.

PMID- 23643895
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
DP  - 2013 May 2
TI  - Cholesterol affects gene expression of the Jun family in colon carcinoma cells
      using different signaling pathways.
LID - S0303-7207(13)00156-1 [pii]
LID - 10.1016/j.mce.2013.04.011 [doi]
AB  - Hyperlipidemia and hypercholesterolemia have been found to be important factors
      in cancer development and metastasis. However, the metabolic mechanism and
      downstream cellular processes following cholesterol stimulation are still
      unknown. Here we tested the effect of cholesterol on MC-38 colon cancer cells.
      Using Illumina gene array technology we found a number of genes that were
      differentially expressed following short term (20-40min) and longer term (between
      2 and 5h) cholesterol stimulation. Three genes were consistently increased at
      these time points; c-Jun, Jun-B and the chemokine CXCL-1. We have previously
      shown that cholesterol stimulation leads to PI3K/Akt phosphorylation, and now
      demonstrated that cholesterol inhibits ERK1/2 phosphorylation; both effects
      reversed when cholesterol is depleted from lipid rafts using
      methyl-beta-cyclodextrin (MBCD). In addition, vanadate, an inhibitor of
      phosphatases, reversed the cholesterol inhibition of ERK1/2 phosphorylation.
      Specific inhibition of p-Akt by wortmannin did not affect cholesterol's
      stimulation of the expression of c-Jun and Jun-B, however the vanadate effect of 
      increasing p-ERK1/2, inhibited c-Jun expression, specifically, and the MBCD
      effect of increasing p-Erk and inhibiting p-Akt reduced c-Jun expression. In
      contrast MBCD and vanadate both enhanced Jun-B gene expression in the presence of
      cholesterol and elevation of Erk phosphorylation. Thus there is apparently, a
      differential signaling pathway whereby cholesterol enhances gene expression of
      the Jun family members.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Diabetes and Metabolism Clinical Research Center of Excellence, Clinical Research
      Institute at Rambam (CRIR) and the Faculty of Medicine, Technion, Haifa, Israel.
FAU - Scheinman, Eyal J
AU  - Scheinman EJ
FAU - Rostoker, Ran
AU  - Rostoker R
FAU - Leroith, Derek
AU  - Leroith D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/29 [received]
PHST- 2013/04/17 [revised]
PHST- 2013/04/18 [accepted]
AID - S0303-7207(13)00156-1 [pii]
AID - 10.1016/j.mce.2013.04.011 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 May 2. pii: S0303-7207(13)00156-1. doi:
      10.1016/j.mce.2013.04.011.

PMID- 23643839
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Linking)
DP  - 2013 May 2
TI  - Activator or inhibitor? GSK-3 as a new drug target.
LID - S0006-2952(13)00282-7 [pii]
LID - 10.1016/j.bcp.2013.04.022 [doi]
AB  - Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein
      kinase that phosphorylates and inhibits glycogen synthase, thereby inhibiting
      glycogen synthesis from glucose. However, this serine/threonine kinase is now
      known to regulate numerous cellular processes through a number of signaling
      pathways important for cell proliferation, stem cell renewal, apoptosis and
      development. Because of these diverse roles, malfunction of this kinase is also
      known to be involved in the pathogenesis of human diseases, such as nervous
      system disorders, diabetes, bone formation, inflammation, cancer and heart
      failure. Therefore, GSK-3 is recognized as an attractive target for the
      development of new drugs. The present review summarizes the roles of GSK-3 in the
      insulin, Wnt/beta-catenin and hedgehog signaling pathways including the
      regulation of their activities. The roles of GSK-3 in the development of human
      diseases within the context of its participation in various signaling pathways
      are also summarized. Finally, the possibility of new drug development targeting
      this kinase is discussed with recent information about inhibitors and activators 
      of GSK-3.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu
      University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan; Global Medical
      Science Education Unit, Faculty of Medical Sciences, Kyushu University, 3-1-1
      Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Electronic address:
      yanaga@med.kyushu-u.ac.jp.
FAU - Takahashi-Yanaga, Fumi
AU  - Takahashi-Yanaga F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/14 [received]
PHST- 2013/04/25 [revised]
PHST- 2013/04/25 [accepted]
AID - S0006-2952(13)00282-7 [pii]
AID - 10.1016/j.bcp.2013.04.022 [doi]
PST - aheadofprint
SO  - Biochem Pharmacol. 2013 May 2. pii: S0006-2952(13)00282-7. doi:
      10.1016/j.bcp.2013.04.022.

PMID- 23643719
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1578-1283 (Electronic)
IS  - 0213-9111 (Linking)
DP  - 2013 May 2
TI  - Socioeconomic inequalities in the incidence and prevalence of type 2 diabetes
      mellitus in Europe.
LID - S0213-9111(13)00051-4 [pii]
LID - 10.1016/j.gaceta.2013.03.002 [doi]
AB  - OBJECTIVE: The aim of this study was to analyze socioeconomic position (SEP)
      inequalities in the prevalence and incidence of type 2 diabetes mellitus (T2DM)
      in people aged 50 years and over in Europe and to describe the contribution of
      body mass index (BMI) and other possible mediators. METHODS: This was a
      cross-sectional and longitudinal study including men and women >/=50 years old in
      11 European countries in 2004 and 2006 (n=21,323). The prevalence and cumulative 
      incidence of T2DM were calculated with self-reported T2DM or when the individual 
      took drugs for diabetes. Prevalence ratio (PR) and relative risk (RR) of
      prevalent and incident T2DM were calculated according to educational level and
      adjusted by BMI and other possible mediators. RESULTS: The age-adjusted and
      country-adjusted prevalence of T2DM in 2004 was 10.2% in men and 8.5% in women.
      Compared to those with higher education, men and women with lower education had a
      PR [95% CI] of T2DM of 1.29 [1.12-1.50] and 1.61 [1.39-1.86], respectively.
      SEP-related inequalities in incidence (RR [95%CI]) were 1.88 [1.35-2.62] in women
      and 1.04 [0.78-1.40] in men. Adjusting for potential mediators reduced
      inequalities in the prevalence and incidence of T2DM among women by 26.2% and
      21.6%, respectively, and inequalities in prevalence among men by 44.8%.
      CONCLUSIONS: We observed significant inequalities in the prevalence and incidence
      (women only) of T2DM as a function of socioeconomic position. These inequalities 
      were mediated by BMI.
CI  - Copyright (c) 2012 SESPAS. Published by Elsevier Espana. All rights reserved.
AD  - Agencia de Salut Publica de Barcelona, Barcelona, Spain; CIBER de Epidemiologia y
      Salud Publica (CIBERESP), Spain; Institut d'Investigacio Biomedica Sant Pau (IIB 
      Sant Pau), Barcelona, Spain; Departament de Psicobiologia i Metodologia de les
      Ciencies de la Salut, Universitat Autonoma de Barcelona, Bellaterra (Barcelona), 
      Spain. Electronic address: aespelt@aspb.cat.
FAU - Espelt, Albert
AU  - Espelt A
FAU - Borrell, Carme
AU  - Borrell C
FAU - Palencia, Laia
AU  - Palencia L
FAU - Goday, Alberto
AU  - Goday A
FAU - Spadea, Teresa
AU  - Spadea T
FAU - Gnavi, Roberto
AU  - Gnavi R
FAU - Font-Ribera, Laia
AU  - Font-Ribera L
FAU - Kunst, Anton E
AU  - Kunst AE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Gac Sanit
JT  - Gaceta sanitaria / S.E.S.P.A.S
JID - 8901623
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/12/10 [received]
PHST- 2013/03/16 [revised]
PHST- 2013/03/18 [accepted]
AID - S0213-9111(13)00051-4 [pii]
AID - 10.1016/j.gaceta.2013.03.002 [doi]
PST - aheadofprint
SO  - Gac Sanit. 2013 May 2. pii: S0213-9111(13)00051-4. doi:
      10.1016/j.gaceta.2013.03.002.

PMID- 23643668
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1542-2224 (Electronic)
IS  - 1067-2516 (Linking)
DP  - 2013 May 2
TI  - Ewing Sarcoma in a Diabetic Male with History of Foot Ulceration.
LID - S1067-2516(13)00144-0 [pii]
LID - 10.1053/j.jfas.2013.03.029 [doi]
AB  - Ewing sarcoma is a rare diagnosis, with as few as 225 new cases diagnosed in
      North America annually, and only 3% occurring in the foot. They generally present
      in the second decade of life and are very infrequently found in patients older
      than 40 years. The diagnosis of Ewing sarcoma can be difficult, especially in
      older patients with diabetes and a history of ulceration, because it can have an 
      appearance on radiography similar to that of osteomyelitis. We present a case of 
      Ewing sarcoma of the foot in a patient with type 2 diabetes in his sixth decade
      of life.
CI  - Copyright (c) 2013 American College of Foot and Ankle Surgeons. Published by
      Elsevier Inc. All rights reserved.
AD  - Postgraduate Year 2 Resident, Southern Arizona Veterans Affairs Medical Center,
      Tucson, AZ.
FAU - Peotter, Jill
AU  - Peotter J
FAU - Neiderer, Katherine M
AU  - Neiderer KM
FAU - Walters, Jodi L
AU  - Walters JL
FAU - Dancho, James F
AU  - Dancho JF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - J Foot Ankle Surg
JT  - The Journal of foot and ankle surgery : official publication of the American
      College of Foot and Ankle Surgeons
JID - 9308427
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/07/23 [received]
AID - S1067-2516(13)00144-0 [pii]
AID - 10.1053/j.jfas.2013.03.029 [doi]
PST - aheadofprint
SO  - J Foot Ankle Surg. 2013 May 2. pii: S1067-2516(13)00144-0. doi:
      10.1053/j.jfas.2013.03.029.

PMID- 23643613
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 42
IP  - 5
DP  - 2013 May
TI  - [Management of type 2 diabetes: New or previous agents, how to choose?].
PG  - 861-70
LID - 10.1016/j.lpm.2013.04.002 [doi]
LID - S0755-4982(13)00542-3 [pii]
AB  - Once lifestyle measures implemented, if hyperglycemia persists, above individual 
      HbA1c targets, a medication should be started in type 2 diabetic patients (T2DM).
      First, unless exception, an oral antidiabetic drug. Except in case of
      intolerance, the initial monotherapy, metformin remains the strengthening
      treatment. Latter, combination of two oral drugs, now offers several options,
      mainly the choice to associate a "conventional insulin-secretor", sulfonylureas, 
      glinide, or a "new one" belonging the class of "incretin", more readily a
      gliptine (DPP-4 inhibitors) rather than injectable GLP-1 analogue which can also 
      be sometimes chosen at this stage. These options are mostly new and have the
      advantage a neutral or favourable (for GLP-1) effect on body weight in obese type
      2 DM patient and the absence of any hypoglycaemic risk in both classes of
      incretins. But this risk varies depending on the patient profile, much higher if 
      the target HbA1c is low (6 to 6.5 or 7%), or in the elderly, fragile and/or in
      case of renal insufficiency. These two different situations with a high risk of
      hypoglycaemia, define best indications of this new class. If dual oral therapy
      does not achieve the goals we are faced with three options: triple oral therapy: 
      metformin-sulfonylurea-gliptine or one of two approaches with injections, insulin
      or GLP-1 analogues. The use of GLP-1 analogues is often delayed today and put
      wrongly in balance with the transition to insulin, a use already delayed in
      France and insufficient. The use of incretins is new and needs to be validated by
      studies of sustainability on glycemic control, prevention of microvascular and
      macrovascular complications and after years on the market security of use,
      primarily on the exocrine pancreas. In short, individualization of strategies and
      HbA1c targets are required, the new molecules can help us in this process. This
      individualization can easily be done through the handy guide proposed by the
      experts ADA EASD statement, endorsed by the SFD, abandoning the complex algorithm
      recently again proposed by HAS and ANSM in 2013. A recommendation that
      prioritizes the costs of the strategies. An absolutely critical issue, while
      admitting not to have the tools to measure them in all their dimensions. Finally,
      we must reconsider every treatment after a maximum of 6months of use, if the
      results are deemed inadequate substitute rather than adding drugs.
CI  - Copyright (c) 2013. Published by Elsevier Masson SAS.
AD  - CHU de Grenoble, pole digestif-DUNE, service de diabetologie endocrinologie
      nutrition, 38043 Grenoble cedex, France; Universite Joseph-Fourier Grenoble,
      38041 Saint-Martin-d'Heres, France. Electronic address: shalimi@chu-grenoble.fr.
FAU - Halimi, Serge
AU  - Halimi S
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Prise en charge du diabete de type 2 : anciens ou nouveaux medicaments, comment
      choisir ?
DEP - 20130502
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/01/09 [received]
PHST- 2013/04/09 [revised]
PHST- 2013/04/09 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - S0755-4982(13)00542-3 [pii]
AID - 10.1016/j.lpm.2013.04.002 [doi]
PST - ppublish
SO  - Presse Med. 2013 May;42(5):861-70. doi: 10.1016/j.lpm.2013.04.002. Epub 2013 May 
      2.

PMID- 23643611
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 42
IP  - 5
DP  - 2013 May
TI  - [Management of type 2 diabetes: New drugs, new recommendations].
PG  - 828-9
LID - 10.1016/j.lpm.2013.04.003 [doi]
LID - S0755-4982(13)00543-5 [pii]
AD  - CHRU, hopital Claude-Huriez, clinique endocrinologique Marc-Linquette, 59037
      Lille cedex, France. Electronic address: jl-wemeau@chru-lille.fr.
FAU - Wemeau, Jean-Louis
AU  - Wemeau JL
FAU - Gautier, Jean-Francois
AU  - Gautier JF
LA  - fre
PT  - Editorial
TT  - Diabete de type 2 : nouveaux medicaments, nouvelles recommandations.
DEP - 20130502
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/04/09 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - S0755-4982(13)00543-5 [pii]
AID - 10.1016/j.lpm.2013.04.003 [doi]
PST - ppublish
SO  - Presse Med. 2013 May;42(5):828-9. doi: 10.1016/j.lpm.2013.04.003. Epub 2013 May
      2.

PMID- 23643522
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1873-4847 (Electronic)
IS  - 0955-2863 (Linking)
DP  - 2013 May 2
TI  - Inflammation markers predict zinc transporter gene expression in women with type 
      2 diabetes mellitus.
LID - S0955-2863(13)00044-2 [pii]
LID - 10.1016/j.jnutbio.2013.02.006 [doi]
AB  - The pathology of type 2 diabetes mellitus (DM) often is associated with
      underlying states of conditioned zinc deficiency and chronic inflammation. Zinc
      and omega-3 polyunsaturated fatty acids each exhibit anti-inflammatory effects
      and may be of therapeutic benefit in the disease. The present randomized,
      double-blind, placebo-controlled, 12-week trial was designed to investigate the
      effects of zinc (40 mg/day) and alpha-linolenic acid (ALA; 2 g/day flaxseed oil) 
      supplementation on markers of inflammation [interleukin (IL)-1beta, IL-6, tumor
      necrosis factor (TNF)-alpha, C-reactive protein (CRP)] and zinc transporter and
      metallothionein gene expression in 48 postmenopausal women with type 2 DM. No
      significant effects of zinc or ALA supplementation were observed on inflammatory 
      marker concentrations or fold change in zinc transporter and metallothionein gene
      expression. Significant increases in plasma zinc concentrations were observed
      over time in the groups supplemented with zinc alone or combined with ALA (P=.007
      and P=.009, respectively). An impact of zinc treatment on zinc transporter gene
      expression was found; ZnT5 was positively correlated with Zip3 mRNA (P<.001) only
      in participants receiving zinc, while zinc supplementation abolished the
      relationship between ZnT5 and Zip10. IL-6 predicted the expression levels and CRP
      predicted the fold change of the ZnT5, ZnT7, Zip1, Zip7 and Zip10 mRNA cluster
      (P<.001 and P=.031, respectively). Fold change in the expression of
      metallothionein mRNA was predicted by TNF-alpha (P=.022). Associations among
      inflammatory cytokines and zinc transporter and metallothionein gene expression
      support an interrelationship between zinc homeostasis and inflammation in type 2 
      DM.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Discipline of Nutrition and Metabolism, School of Molecular Bioscience,
      University of Sydney NSW 2006, Australia.
FAU - Foster, Meika
AU  - Foster M
FAU - Petocz, Peter
AU  - Petocz P
FAU - Samman, Samir
AU  - Samman S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - J Nutr Biochem
JT  - The Journal of nutritional biochemistry
JID - 9010081
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/07/23 [received]
PHST- 2013/01/30 [revised]
PHST- 2013/02/10 [accepted]
AID - S0955-2863(13)00044-2 [pii]
AID - 10.1016/j.jnutbio.2013.02.006 [doi]
PST - aheadofprint
SO  - J Nutr Biochem. 2013 May 2. pii: S0955-2863(13)00044-2. doi:
      10.1016/j.jnutbio.2013.02.006.

PMID- 23643513
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1556-3871 (Electronic)
IS  - 1547-5271 (Linking)
DP  - 2013 May 2
TI  - Cardiac magnetic resonance T1 mapping of left atrial myocardium.
LID - S1547-5271(13)00511-0 [pii]
LID - 10.1016/j.hrthm.2013.05.003 [doi]
AB  - BACKGROUND: Cardiac magnetic resonance (CMR) T1 mapping is an emerging tool for
      objective quantification of myocardial fibrosis. OBJECTIVES: To (a) establish the
      feasibility of left atrial (LA) T1 measurements, (b) determine the range of LA T1
      values in patients with atrial fibrillation (AF) vs healthy volunteers, and (c)
      validate T1 mapping vs LA intracardiac electrogram voltage amplitude measures.
      METHODS: CMR imaging at 1.5 T was performed in 51 consecutive patients before AF 
      ablation and in 16 healthy volunteers. T1 measurements were obtained from the
      posterior LA myocardium by using the modified Look-Locker inversion-recovery
      sequence. Given the established association of reduced electrogram amplitude with
      fibrosis, intracardiac point-by-point bipolar LA voltage measures were recorded
      for the validation of T1 measurements. RESULTS: The median LA T1 relaxation time 
      was shorter in patients with AF (387 [interquartile range 364-428] ms) compared
      to healthy volunteers (459 [interquartile range 418-532] ms; P < .001) and was
      shorter in patients with AF with prior ablation compared to patients without
      prior ablation (P = .035). In a generalized estimating equations model, adjusting
      for data clusters per participant, age, rhythm during CMR, prior ablation, AF
      type, hypertension, and diabetes, each 100-ms increase in T1 relaxation time was 
      associated with 0.1 mV increase in intracardiac bipolar LA voltage (P = .025).
      CONCLUSIONS: Measurement of the LA myocardium T1 relaxation time is feasible and 
      strongly associated with invasive voltage measures. This methodology may improve 
      the quantification of fibrotic changes in thin-walled myocardial tissues.
CI  - Copyright (c) 2013 Heart Rhythm Society. All rights reserved.
AD  - Division of Cardiology, Johns Hopkins University, Baltimore, Maryland. Electronic
      address: rbeiner1@jhmi.edu.
FAU - Beinart, Roy
AU  - Beinart R
FAU - Khurram, Irfan M
AU  - Khurram IM
FAU - Liu, Songtao
AU  - Liu S
FAU - Yarmohammadi, Hirad
AU  - Yarmohammadi H
FAU - Halperin, Henry R
AU  - Halperin HR
FAU - Bluemke, David A
AU  - Bluemke DA
FAU - Gai, Neville
AU  - Gai N
FAU - van der Geest, Rob J
AU  - van der Geest RJ
FAU - Lima, Joao A C
AU  - Lima JA
FAU - Calkins, Hugh
AU  - Calkins H
FAU - Zimmerman, Stefan L
AU  - Zimmerman SL
FAU - Nazarian, Saman
AU  - Nazarian S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Heart Rhythm
JT  - Heart rhythm : the official journal of the Heart Rhythm Society
JID - 101200317
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/08 [received]
AID - S1547-5271(13)00511-0 [pii]
AID - 10.1016/j.hrthm.2013.05.003 [doi]
PST - aheadofprint
SO  - Heart Rhythm. 2013 May 2. pii: S1547-5271(13)00511-0. doi:
      10.1016/j.hrthm.2013.05.003.

PMID- 23643483
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1879-3169 (Electronic)
IS  - 0378-4274 (Linking)
VI  - 220
IP  - 2
DP  - 2013 Apr 30
TI  - Interactive effects of smoking and glutathione S-transferase polymorphisms on the
      development of non-alcoholic fatty liver disease.
PG  - 143-149
LID - S0378-4274(13)00174-4 [pii]
LID - 10.1016/j.toxlet.2013.04.019 [doi]
AB  - Glutathione S-transferases (GSTs) protect cells against exogenous and endogenous 
      oxidative stress. GST polymorphisms are associated with the development of
      cardiovascular disease (CVD) and diabetes mellitus (DM), especially in
      current-smokers. Non-alcoholic fatty liver disease (NAFLD) is a predictor of
      future CVD or DM, because oxidative stress contributes to their pathogenesis.
      This study investigated whether the combination of smoking status and GST
      genotypes could affect the risk for NAFLD. A cross-sectional analysis was
      conducted among 713 Japanese participants (458 males and 255 females) during a
      health screening program. The GSTM1 null, GSTT1 null, GSTP1 *A/*B or *B/*B and
      GSTA1 *A/*B or *B/*B genotypes were determined and deemed to be high-risk
      genotypes. The prevalence of NAFLD was 18.7%. Among never-smokers, carriers of
      one, and those of two or more high-risk GSTM1, GSTP1 or GSTA1 genotypes were at a
      higher risk for NAFLD than those who were not carriers [odds ratio (95%
      confidence interval): 2.6 (1.1-5.9) and 3.3 (1.3-8.1), respectively], and the
      risk was further increased among current-smokers [4.6 (1.6-13.0) and 5.4
      (1.2-23.7), respectively]. This is the first report to show that the combination 
      of current-smoking and harboring high-risk GSTM1, GSTP1 and/or GSTA1 genotypes is
      interactively associated with the risk of NAFLD.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical
      Sciences, Kumamoto University, Kumamoto, Japan.
FAU - Oniki, Kentaro
AU  - Oniki K
FAU - Hori, Masaharu
AU  - Hori M
FAU - Saruwatari, Junji
AU  - Saruwatari J
FAU - Morita, Kazunori
AU  - Morita K
FAU - Kajiwara, Ayami
AU  - Kajiwara A
FAU - Sakata, Misaki
AU  - Sakata M
FAU - Mihara, Shuichi
AU  - Mihara S
FAU - Ogata, Yasuhiro
AU  - Ogata Y
FAU - Nakagawa, Kazuko
AU  - Nakagawa K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Toxicol Lett
JT  - Toxicology letters
JID - 7709027
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/14 [received]
PHST- 2013/04/21 [revised]
PHST- 2013/04/23 [accepted]
AID - S0378-4274(13)00174-4 [pii]
AID - 10.1016/j.toxlet.2013.04.019 [doi]
PST - aheadofprint
SO  - Toxicol Lett. 2013 Apr 30;220(2):143-149. doi: 10.1016/j.toxlet.2013.04.019.

PMID- 23643441
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 May 1
TI  - The effectiveness of footwear as an intervention to prevent or to reduce
      biomechanical risk factors associated with diabetic foot ulceration: A systematic
      review.
LID - S1056-8727(13)00056-1 [pii]
LID - 10.1016/j.jdiacomp.2013.03.001 [doi]
AB  - AIM: Footwear interventions are used within clinical practice in an effort to
      reduce ulcerations however the effectiveness of these interventions is unclear.
      The aim of this paper was to conduct a systematic review which examined the
      effectiveness of footwear as an intervention for prevention of diabetic foot
      ulcers or the reduction of biomechanical risk factors for ulceration and to
      discuss the quality and interpret the findings of research to date. METHODS: The 
      CINAHL, Medline and Cochrane Register of Controlled Trials databases were
      searched with 12 articles identified for review. RESULTS: The majority of these
      studies were cross sectional and examined the effect of different footwear
      conditions on plantar pressure measurements. Factors which influenced study
      findings such as participant selection, measurement and analysis techniques,
      footwear design and compliance are discussed and recommendations for future
      studies are provided. CONCLUSIONS: No research to date has examined the
      effectiveness of footwear in preventing ulceration. Conflicting findings are
      reported on the effective of footwear interventions to prevent reulceration.
      While the use of rocker sole footwear and custom orthoses in plantar pressure
      reduction are supported in cross sectional studies, longitudinal studies are
      required to confirm their benefit.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - CSHER, Faculty of Health Sciences, Staffordshire University, Stoke on Trent, ST4 
      2DF, United Kingdom. Electronic address: a.healy@staffs.ac.uk.
FAU - Healy, Aoife
AU  - Healy A
FAU - Naemi, Roozbeh
AU  - Naemi R
FAU - Chockalingam, Nachiappan
AU  - Chockalingam N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/25 [received]
PHST- 2013/03/04 [accepted]
AID - S1056-8727(13)00056-1 [pii]
AID - 10.1016/j.jdiacomp.2013.03.001 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 May 1. pii: S1056-8727(13)00056-1. doi:
      10.1016/j.jdiacomp.2013.03.001.

PMID- 23643404
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
DP  - 2013 May 2
TI  - Liver enzymes and vitamin D levels in metabolically healthy but obese
      individuals: Korean National Health and Nutrition Examination Survey.
LID - S0026-0495(13)00099-1 [pii]
LID - 10.1016/j.metabol.2013.04.002 [doi]
AB  - OBJECTIVE: Increased liver enzymes and decreased vitamin D levels are associated 
      with insulin resistance and type 2 diabetes. We examined liver enzymes and
      vitamin D levels in metabolically healthy but obese (MHO) individuals and
      compared the values with those of other body size phenotypes in the Korean
      population. MATERIALS/METHODS: A total of 16,190 people over the age of 18years
      were analyzed using data from the Fourth Korean National Health and Nutrition
      Examination Survey, which is a nationally representative survey. Body size
      phenotypes were classified into four groups by body mass index (BMI) and number
      of metabolic syndrome components. RESULTS: The prevalence of MHO was 14.9% in the
      entire population and 47.7% in the obese population. In a correlation analysis
      adjusted for age, sex, and BMI, AST and ALT levels were positively correlated
      with insulin resistance and cardiometabolic risk factors of the metabolic
      syndrome, whereas vitamin D level was negatively correlated with these variables.
      MHO individuals had significantly lower concentrations of AST and ALT compared to
      metabolically abnormal obese (MAO) subjects, although vitamin D levels were not
      significantly different. Furthermore, a multiple logistic regression analysis
      revealed that MHO individuals had lower risk of liver enzyme abnormality compared
      to MAO after adjusting for potential confounding factors. However, the risk of
      vitamin D deficiency was not significantly different among groups with different 
      body size phenotypes. CONCLUSIONS: Although both liver enzymes and vitamin D
      levels are related to insulin resistance and metabolic syndrome, only liver
      enzymes were independently associated with MHO phenotype.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      College of Medicine, Korea University, Seoul, Korea.
FAU - Hong, Ho Cheol
AU  - Hong HC
FAU - Lee, Ji-Sung
AU  - Lee JS
FAU - Choi, Hae Yoon
AU  - Choi HY
FAU - Yang, Sae Jeong
AU  - Yang SJ
FAU - Yoo, Hye Jin
AU  - Yoo HJ
FAU - Seo, Ji A
AU  - Seo JA
FAU - Kim, Sin Gon
AU  - Kim SG
FAU - Kim, Nan Hee
AU  - Kim NH
FAU - Baik, Sei Hyun
AU  - Baik SH
FAU - Choi, Dong Seop
AU  - Choi DS
FAU - Choi, Kyung Mook
AU  - Choi KM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/27 [received]
PHST- 2013/03/22 [revised]
PHST- 2013/04/02 [accepted]
AID - S0026-0495(13)00099-1 [pii]
AID - 10.1016/j.metabol.2013.04.002 [doi]
PST - aheadofprint
SO  - Metabolism. 2013 May 2. pii: S0026-0495(13)00099-1. doi:
      10.1016/j.metabol.2013.04.002.

PMID- 23643380
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1537-6605 (Electronic)
IS  - 0002-9297 (Linking)
VI  - 92
IP  - 5
DP  - 2013 May 2
TI  - Sherlock: Detecting Gene-Disease Associations by Matching Patterns of Expression 
      QTL and GWAS.
PG  - 667-80
LID - 10.1016/j.ajhg.2013.03.022 [doi]
LID - S0002-9297(13)00159-6 [pii]
AB  - Genetic mapping of complex diseases to date depends on variations inside or close
      to the genes that perturb their activities. A strong body of evidence suggests
      that changes in gene expression play a key role in complex diseases and that
      numerous loci perturb gene expression in trans. The information in trans
      variants, however, has largely been ignored in the current analysis paradigm.
      Here we present a statistical framework for genetic mapping by utilizing
      collective information in both cis and trans variants. We reason that for a
      disease-associated gene, any genetic variation that perturbs its expression is
      also likely to influence the disease risk. Thus, the expression quantitative
      trait loci (eQTL) of the gene, which constitute a unique "genetic signature,"
      should overlap significantly with the set of loci associated with the disease. We
      translate this idea into a computational algorithm (named Sherlock) to search for
      gene-disease associations from GWASs, taking advantage of independent eQTL data. 
      Application of this strategy to Crohn disease and type 2 diabetes predicts a
      number of genes with possible disease roles, including several predictions
      supported by solid experimental evidence. Importantly, predicted genes are often 
      implicated by multiple trans eQTL with moderate associations. These genes are far
      from any GWAS association signals and thus cannot be identified from the GWAS
      alone. Our approach allows analysis of association data from a new perspective
      and is applicable to any complex phenotype. It is readily generalizable to
      molecular traits other than gene expression, such as metabolites, noncoding RNAs,
      and epigenetic modifications.
CI  - Copyright (c) 2013 The American Society of Human Genetics. Published by Elsevier 
      Inc. All rights reserved.
AD  - Department of Biochemistry and Biophysics, University of California at San
      Francisco, San Francisco, CA 94143, USA; Lane Center of Computational Biology,
      Carnegie Mellon University, Pittsburgh, PA 15213, USA.
FAU - He, Xin
AU  - He X
FAU - Fuller, Chris K
AU  - Fuller CK
FAU - Song, Yi
AU  - Song Y
FAU - Meng, Qingying
AU  - Meng Q
FAU - Zhang, Bin
AU  - Zhang B
FAU - Yang, Xia
AU  - Yang X
FAU - Li, Hao
AU  - Li H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Hum Genet
JT  - American journal of human genetics
JID - 0370475
SB  - IM
PMC - PMC3644637
OID - NLM: PMC3644637 [Available on 11/02/13]
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PMCR- 2013/11/02 00:00
PHST- 2012/10/10 [received]
PHST- 2013/03/07 [revised]
PHST- 2013/03/25 [accepted]
AID - S0002-9297(13)00159-6 [pii]
AID - 10.1016/j.ajhg.2013.03.022 [doi]
PST - ppublish
SO  - Am J Hum Genet. 2013 May 2;92(5):667-80. doi: 10.1016/j.ajhg.2013.03.022.

PMID- 23643354
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
DP  - 2013 Apr 17
TI  - GLP-1 agonists in type 1 diabetes.
LID - S1521-6616(13)00097-1 [pii]
LID - 10.1016/j.clim.2013.04.006 [doi]
AB  - Despite years of research in the field of type 1 diabetes, patients with the
      disease remain without a therapeutic agent that can alter the underlying immune
      response in a clinically beneficial way. Glucagon-like peptide 1 agonist
      therapies have shown some promising effects in terms of positively affecting
      overall beta cell health and increasing beta cell mass, primarily in mouse
      models. The three agents of this class currently available for patients with type
      2 diabetes have shown beneficial clinical effects on glucose control in this
      patient population. The purpose of this article is to review the preclinical and 
      clinical data of these agents to date with a focus on the potential immunological
      and clinical benefits these drugs may have on patients with type 1 diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - University of California San Diego, San Diego, CA, USA; Veterans Affairs
      Hospital, La Jolla, CA, USA. Electronic address: Jpettus@ucsd.edu.
FAU - Pettus, Jeremy
AU  - Pettus J
FAU - Hirsch, Irl
AU  - Hirsch I
FAU - Edelman, Steven
AU  - Edelman S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/02/25 [received]
PHST- 2013/03/30 [revised]
PHST- 2013/04/01 [accepted]
AID - S1521-6616(13)00097-1 [pii]
AID - 10.1016/j.clim.2013.04.006 [doi]
PST - aheadofprint
SO  - Clin Immunol. 2013 Apr 17. pii: S1521-6616(13)00097-1. doi:
      10.1016/j.clim.2013.04.006.

PMID- 23643353
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 May 2
TI  - Glycogen storage disease type 1 and diabetes: Learning by comparing and
      contrasting the two disorders.
LID - S1262-3636(13)00044-X [pii]
LID - 10.1016/j.diabet.2013.03.002 [doi]
AB  - Glycogen storage disease type 1 (GSD1) and diabetes may look at first like
      totally opposite disorders, as diabetes is characterized by uncontrolled
      hyperglycaemia, whereas GSD1 is characterized by severe fasting hypoglycaemia.
      Diabetes is due to a failure to suppress endogenous glucose production (EGP) in
      the postprandial state because of either a lack of insulin or insulin resistance.
      In contrast, GSD1 is characterized by a lack of EGP. However, both diseases share
      remarkably similar patterns in terms of pathophysiology such as the long-term
      progression of renal dysfunction and hepatic steatosis leading to renal failure
      and the development of hepatic tumours, respectively. Thus, much may be learned
      from considering the similarities between GSD1 and diabetes, especially in the
      metabolic pathways underlying nephropathy and fatty liver, and perhaps even more 
      from their differences. In this review, the differences between diabetes and GSD1
      are first highlighted, as both are characterized by alterations in EGP. The
      molecular pathways involved in liver pathologies, including steatosis,
      hepatomegaly (glycogenic hepatopathy) and the development of liver tumours are
      also compared. These pathologies are mainly due to the accumulation of lipids
      and/or glycogen in hepatocytes. Finally, the similar pathways leading to
      nephropathy in both diabetic and GSD1 patients are described. In conclusion,
      comparisons of these pathologies should lead to a better understanding of the
      crucial role of EGP in the control of glucose and energy homoeostasis. Moreover, 
      it may highlight similar therapeutic targets for the two disorders. Thus, this
      review suggests that the treatment of adult patients with either GSD1 or diabetes
      could be carried out by the same specialists-diabetologists.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - U855, Institut national de la sante et de la recherche medicale, 69008 Lyon,
      France; Universite de Lyon, 69008 Lyon, France; Universite Lyon 1, 69622
      Villeurbanne, France. Electronic address: fabienne.rajas@univ-lyon1.fr.
FAU - Rajas, F
AU  - Rajas F
FAU - Labrune, P
AU  - Labrune P
FAU - Mithieux, G
AU  - Mithieux G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/02/06 [received]
PHST- 2013/02/25 [revised]
PHST- 2013/03/11 [accepted]
AID - S1262-3636(13)00044-X [pii]
AID - 10.1016/j.diabet.2013.03.002 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 May 2. pii: S1262-3636(13)00044-X. doi:
      10.1016/j.diabet.2013.03.002.

PMID- 23643352
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 May 2
TI  - Relationship between blood pressure, cognitive function and education level in
      elderly patients with diabetes: A preliminary study.
LID - S1262-3636(13)00045-1 [pii]
LID - 10.1016/j.diabet.2013.02.008 [doi]
AB  - AIMS: This study aimed to assess the relationship between blood pressure and
      cognitive function in elderly patients with diabetes mellitus (DM). METHODS: A
      total of 32 patients with DM aged>/=65 years (seven women and 25 men; mean+/-SD
      age: 74.3+/-6.4 years) were included in this cross-sectional study. Relationships
      between blood pressure and neuropsychological tests were determined using
      Spearman's rank correlations (rho) and multivariable linear regression models.
      RESULTS: Lower diastolic blood pressure was associated with lower scores on the
      Frontal Assessment Battery (rho=0.32, P=0.02), longer times to complete the Trail
      Making Test Part B (rho=0.51, P=0.003), lower scores for the Finger Tapping Test 
      (rho=0.36, P=0.046) and less verbal fluency (rho=0.36, P=0.047). In multivariable
      models, these relationships were attenuated after adjusting for levels of
      education. CONCLUSION: There was an association between lower diastolic blood
      pressure and poorer executive function in this cohort of elderly DM patients.
      These results underline the importance of systematic cognitive evaluation in
      elderly patients with DM, and suggest that a too-low diastolic blood pressure may
      have deleterious effects on mental function. Larger studies in the future are
      required to confirm these preliminary results.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Service of Internal Medicine B, AP-HP, Hopital Lariboisiere, University Paris 7
      Denis-Diderot, Paris, France.
FAU - Talfournier, J
AU  - Talfournier J
FAU - Bitu, J
AU  - Bitu J
FAU - Paquet, C
AU  - Paquet C
FAU - Gobron, C
AU  - Gobron C
FAU - Guillausseau, P J
AU  - Guillausseau PJ
FAU - Hugon, J
AU  - Hugon J
FAU - Dumurgier, J
AU  - Dumurgier J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/22 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/02/27 [accepted]
AID - S1262-3636(13)00045-1 [pii]
AID - 10.1016/j.diabet.2013.02.008 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 May 2. pii: S1262-3636(13)00045-1. doi:
      10.1016/j.diabet.2013.02.008.

PMID- 23643351
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May
TI  - Physical activity and type 2 diabetes. Recommandations of the SFD (Francophone
      Diabetes Society) diabetes and physical activity working group.
PG  - 205-16
LID - 10.1016/j.diabet.2013.03.005 [doi]
LID - S1262-3636(13)00053-0 [pii]
AB  - Although regular physical activity is an integral part of T2D management, few
      diabetic patients have a sufficient level of physical activity. However over the 
      past decade or so, the beneficial effects of regular physical activity have been 
      well demonstrated, both in T2D prevention (50% reduction in the incidence of T2D 
      in subjects with high metabolic risk) as well as T2D management for the
      improvement of glycaemic control (mean 0.7% improvement of HbA1c) and the
      reduction of T2D-related comorbidities (improvement in blood pressure values and 
      lipid profile, decrease in insulin resistance). Physical activity has both acute 
      effects (effects of one exercise session) and more prolonged effects of exercise 
      when it is repeated on a regular basis (training effect). In addition, the
      physical activity recommendations have been extended to a wide range of physical 
      activities (by combining both endurance and muscle strengthening exercises), thus
      varying the physical activity practiced according to the patient's available
      time, practice sites, preferences and interests. Following a pathophysiology
      review, the effects of physical activity will be discussed and presented in terms
      of evidence-based medicine. The recommendations will be defined and practical
      prescribing information will be suggested, while taking into account that
      clinicians are concerned with answering questions regarding how, where and with
      whom: how can patients be motivated to practice a physical activity over the
      long-term? And how can qualified exercise trainers and appropriate practice
      settings be found?
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Service de medecine du sport et des explorations fonctionnelles, CHU de
      Clermont-Ferrand, Clermont-Ferrand, France; INRA, UMR 1019, UNH, centre de
      recherche en nutrition humaine d'Auvergne, Clermont universite, universite
      d'Auvergne, unite de nutrition humaine, Clermont-Ferrand, France. Electronic
      address: mduclos@chu-clermontferrand.fr.
FAU - Duclos, M
AU  - Duclos M
FAU - Oppert, J-M
AU  - Oppert JM
FAU - Verges, B
AU  - Verges B
FAU - Coliche, V
AU  - Coliche V
FAU - Gautier, J-F
AU  - Gautier JF
FAU - Guezennec, Y
AU  - Guezennec Y
FAU - Reach, G
AU  - Reach G
FAU - Strauch, G
AU  - Strauch G
CN  - SFD diabetes and physical activity working group
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/17 [received]
PHST- 2013/03/17 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - S1262-3636(13)00053-0 [pii]
AID - 10.1016/j.diabet.2013.03.005 [doi]
PST - ppublish
SO  - Diabetes Metab. 2013 May;39(3):205-16. doi: 10.1016/j.diabet.2013.03.005. Epub
      2013 May 2.

PMID- 23643350
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 May 2
TI  - Impaired endothelial function is not associated with arterial stiffness in adults
      with type 1 diabetes.
LID - S1262-3636(13)00054-2 [pii]
LID - 10.1016/j.diabet.2013.03.006 [doi]
AB  - AIM: This study investigated the relationship between endothelial dysfunction
      (ED) and arterial stiffness (AS) in adults with type 1 diabetes and no clinical
      cardiovascular (CV) disease. METHODS: A total of 68 patients with type 1 diabetes
      and 68 age- and gender-matched healthy (non-diabetic) subjects were evaluated. ED
      was assessed by reactive hyperaemia peripheral arterial tonometry (RH-PAT) and by
      serum concentrations of soluble intercellular adhesion molecule-1 (sICAM-1),
      soluble vascular cell adhesion molecule-1 (sVCAM-1) and E-selectin. AS was
      assessed by aortic pulse wave velocity (aPWV). All statistical analyses were
      stratified by gender. RESULTS: Adults with type 1 diabetes had RH-PAT index
      scores similar to those of their matching controls [men: 1.55 (1.38-1.98)% versus
      1.61 (1.40-2.17)%, P=0.556; women: 2.07 (1.55-2.31)% versus 2.08 (1.79-2.49)%;
      P=0.215]. However, after adjusting for potential confounders, type 1 diabetes
      emerged as the main determinant of the RH-PAT index in women. Also, differences
      between genders in both the controls and type 1 diabetes patients disappeared.
      Men with diabetes had higher serum concentrations of E-selectin, and women had
      higher serum concentrations of sICAM-1, sVCAM-1 and E-selectin than their
      respective controls. However, after adjusting for potential confounders, only the
      differences in sICAM-1 (women) and E-selectin (both genders) remained
      significant. No association was found between aPWV and the RH-PAT index and ED
      markers after adjusting for CV risk factors. CONCLUSION: ED was increased in
      adults with type 1 diabetes compared with age-matched non-diabetic subjects.
      Also, gender differences in ED were lost in type 1 diabetes. However, ED was not 
      associated with AS after adjusting for potential confounders. These findings
      suggest that ED occurs earlier than AS in type 1 diabetes.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Department of Diabetes, Endocrinology and Nutrition, Hospital of Sabadell,
      Corporacio Sanitaria i Universitaria Parc Tauli (Universitat Autonoma de
      Barcelona), 08208 Sabadell, Spain.
FAU - Llaurado, G
AU  - Llaurado G
FAU - Ceperuelo-Mallafre, V
AU  - Ceperuelo-Mallafre V
FAU - Vilardell, C
AU  - Vilardell C
FAU - Simo, R
AU  - Simo R
FAU - Albert, L
AU  - Albert L
FAU - Berlanga, E
AU  - Berlanga E
FAU - Vendrell, J
AU  - Vendrell J
FAU - Gonzalez-Clemente, J M
AU  - Gonzalez-Clemente JM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/05/07 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/12 [accepted]
AID - S1262-3636(13)00054-2 [pii]
AID - 10.1016/j.diabet.2013.03.006 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 May 2. pii: S1262-3636(13)00054-2. doi:
      10.1016/j.diabet.2013.03.006.

PMID- 23643349
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May
TI  - Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives.
PG  - 195-201
LID - 10.1016/j.diabet.2013.03.001 [doi]
LID - S1262-3636(13)00043-8 [pii]
AB  - The incretin effect refers to the augmentation of insulin secretion after oral
      administration of glucose compared with intravenous glucose administration at
      matched glucose levels. The incretin effect is largely due to the release and
      action on beta-cells of the gut hormones glucose-dependent insulinotropic
      polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This system has in recent 
      years had considerable interest due to the success of incretin therapy as a
      glucose-lowering strategy in type 2 diabetes. In non-diabetic subjects, the
      incretin effect is responsible for 50-70% of insulin release during oral glucose 
      administration. In type 2 diabetes patients, the incretin effect is impaired and 
      contributes to only 20-35% of the insulin response to oral glucose. The reason
      for the defective incretin effect in type 2 diabetes has been the subject of many
      studies. Although the reports in the literature are mixed, most studies of GIP
      and GLP-1 secretory responses to oral glucose or a mixed meal have shown fairly
      normal results in type 2 diabetes. In contrast, the insulinotropic effects of
      both GIP and GLP-1 are impaired in type 2 diabetes with greater suppression of
      insulin secretion augmentation with GIP than with GLP-1. The suggested causes of 
      these defects are a defective beta-cell receptor expression or post-receptor
      defects secondary to the diabetes milieu, defective beta-cell function in general
      resulting in defective incretin effect and genetic factors initiating incretin
      hormone resistance. Identifying the mechanisms in greater detail would be
      important for understanding the strengths, weaknesses and efficacy of incretin
      therapy in individual patients to more specifically target this glucose-lowering 
      therapy.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Department of Clinical Sciences Lund, Lund University, Solvegatan 19, SE 221 84
      Lund, Sweden. Electronic address: bo.ahren@med.lu.se.
FAU - Ahren, B
AU  - Ahren B
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/02/04 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/11 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - S1262-3636(13)00043-8 [pii]
AID - 10.1016/j.diabet.2013.03.001 [doi]
PST - ppublish
SO  - Diabetes Metab. 2013 May;39(3):195-201. doi: 10.1016/j.diabet.2013.03.001. Epub
      2013 May 2.

PMID- 23643348
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 May 2
TI  - Prediction of macrosomia by serial sonographic measurements of fetal soft-tissues
      and the liver in women with pregestational diabetes.
LID - S1262-3636(13)00052-9 [pii]
LID - 10.1016/j.diabet.2013.03.004 [doi]
AB  - OBJECTIVES: This study aimed to determine whether antenatal ultrasound
      measurements of fetal soft-tissues and liver can predict macrosomia in women with
      pregestational diabetes. METHODS: Fetal biometry, soft-tissue thickness (anterior
      abdominal wall [STAW], thigh [STT], upper arm [STA], scapular [STS]) and liver
      size were measured sonographically at 23, 28, 31 and 34 weeks of gestation. Large
      for gestational age (LGA) was defined as a birth weight greater than 90th
      percentile for gestational age on standard curves adjusted for maternal height
      and weight, parity and fetal gender. The area (+/-standard error) under receiver 
      operating characteristic (AUROC) curves were also calculated. RESULTS: A total of
      29 pregnant women with pregestational diabetes were included, and a total of 663 
      measurements taken. Fifteen neonates were LGA. There was no significant
      difference in fetal soft-tissue thickness at 23, 28 and 31 weeks between the LGA 
      and non-LGA neonates. In contrast, at 34 weeks, fetal soft-tissues were
      significantly thicker in LGA neonates (P<0.05), but with no difference in liver
      surface area between the two groups. The specificity and sensitivity of 34-week
      ultrasonography to detect macrosomia was 78.6% and 66.7%, respectively, for
      abdominal circumference (AC), 71.4% and 93.3% for STT, 85.7% and 80.0% for STA,
      and 71.4% and 86.7% for STAW. No parameter was more powerful than the others. The
      best AUROC curves were found for AC (0.807), STT (0.821), STA (0.855) and STAW
      (0.821). CONCLUSION: Third-trimester sonographic measurements of fetal
      soft-tissue may help to detect macrosomia in pregnancies complicated by
      pregestational diabetes.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Pole d'obstetrique, maternite Jeanne-de-Flandre, CHRU de Lille, avenue
      Eugene-Avinee, 59037 Lille, France. Electronic address:
      charles.garabedian@gmail.com.
FAU - Garabedian, C
AU  - Garabedian C
FAU - Vambergue, A
AU  - Vambergue A
FAU - Salleron, J
AU  - Salleron J
FAU - Deruelle, P
AU  - Deruelle P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/22 [received]
PHST- 2013/03/03 [revised]
PHST- 2013/03/12 [accepted]
AID - S1262-3636(13)00052-9 [pii]
AID - 10.1016/j.diabet.2013.03.004 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 May 2. pii: S1262-3636(13)00052-9. doi:
      10.1016/j.diabet.2013.03.004.

PMID- 23643347
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 May 2
TI  - Skin autofluorescence is associated with past glycaemic control and complications
      in type 1 diabetes mellitus.
LID - S1262-3636(13)00051-7 [pii]
LID - 10.1016/j.diabet.2013.03.003 [doi]
AB  - As skin autofluorescence (AF) can assess subcutaneous accumulation of fluorescent
      advanced glycation end-products (AGEs), this study aimed to investigate whether
      it was linked to glycaemic control and complications in patients with type 1
      diabetes mellitus (T1DM). Using the AGE Reader, AF was measured in T1DM patients 
      referred to Haut-Leveque Hospital (Bordeaux, France); data on their HbA1c levels 
      measured every 6months as far back as the last 5years were also collected. The
      association of AF with the patients' past glucose control, based on their latest 
      HbA1c values, and the means of the last five and 10 HbA1c values, and with
      diabetic complications was also examined by linear regression analysis. The
      sample included 300 patients: 58% were male; the mean age was 49 (SD 17) years
      and the mean diabetes duration was 21 (SD 13) years. The median skin AF
      measurement was 2.0 [25th-75th percentiles: 1.7-2.4] arbitrary units (AU), and
      this was associated with age (beta=0.15 per 10years, P<0.001) and diabetes
      duration (beta=0.17 per 10years, P<0.001). After adjusting for age and estimated 
      glomerular filtration rate (eGFR), the skin AF measurement was also related to
      the means of the last five and 10 HbA1c values (beta=0.10 per 1% of HbA1c,
      P=0.005, and beta=0.13 per 1% of HbA1c, P=0.001, respectively). In addition, the 
      skin AF was associated with retinopathy (P<0.001), albuminuria (P<0.001) and
      decreased eGFR (P<0.001). In conclusion, the skin AF is related to the long-term 
      glucose control and diabetic complications.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Nutrition-Diabetologie, Bordeaux hospital, 33600 Pessac, France; Universite
      Bordeaux Segalen, 33000 Bordeaux, France.
FAU - Genevieve, M
AU  - Genevieve M
FAU - Vivot, A
AU  - Vivot A
FAU - Gonzalez, C
AU  - Gonzalez C
FAU - Raffaitin, C
AU  - Raffaitin C
FAU - Barberger-Gateau, P
AU  - Barberger-Gateau P
FAU - Gin, H
AU  - Gin H
FAU - Rigalleau, V
AU  - Rigalleau V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/09/21 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/03/12 [accepted]
AID - S1262-3636(13)00051-7 [pii]
AID - 10.1016/j.diabet.2013.03.003 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 May 2. pii: S1262-3636(13)00051-7. doi:
      10.1016/j.diabet.2013.03.003.

PMID- 23643207
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1478-5242 (Electronic)
IS  - 0960-1643 (Linking)
VI  - 63
IP  - 610
DP  - 2013 May
TI  - Diabetes is on the rise, so why are we not bothered?
PG  - 236
LID - 10.3399/bjgp13X667051 [doi]
AD  - The Royal Docks Medical Practice, Newham, UK. asadnaqvi01@hotmail.co.uk.
FAU - Naqvi, Asadullah
AU  - Naqvi A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of
      General Practitioners
JID - 9005323
SB  - IM
PMC - PMC3635552
OID - NLM: PMC3635552 [Available on 05/01/14]
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PMCR- 2014/05/01 00:00
AID - 10.3399/bjgp13X667051 [doi]
PST - ppublish
SO  - Br J Gen Pract. 2013 May;63(610):236. doi: 10.3399/bjgp13X667051.

PMID- 23643206
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1478-5242 (Electronic)
IS  - 0960-1643 (Linking)
VI  - 63
IP  - 610
DP  - 2013 May
TI  - Diagnosing type 2 diabetes and identifying high-risk individuals using the new
      glycated haemoglobin (HbA1c) criteria.
PG  - 235
LID - 10.3399/bjgp13X665503 [doi]
AD  - 28 Kings Road, Harrogate, HG1 5JP, UK. Mick.Leach@gp-b82013.nhs.uk.
FAU - Leach, Mick
AU  - Leach M
FAU - Evans, Philip H
AU  - Evans PH
FAU - Pereira Gray, Denis J
AU  - Pereira Gray DJ
FAU - Wright, Christine
AU  - Wright C
FAU - Langley, Peter
AU  - Langley P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Gen Pract
JT  - The British journal of general practice : the journal of the Royal College of
      General Practitioners
JID - 9005323
SB  - IM
PMC - PMC3635550
OID - NLM: PMC3635550 [Available on 05/01/14]
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PMCR- 2014/05/01 00:00
AID - 10.3399/bjgp13X665503 [doi]
PST - ppublish
SO  - Br J Gen Pract. 2013 May;63(610):235. doi: 10.3399/bjgp13X665503.

PMID- 23643053
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 17
TI  - Egg consumption and risk of cardiovascular diseases and diabetes: A
      meta-analysis.
LID - S0021-9150(13)00243-8 [pii]
LID - 10.1016/j.atherosclerosis.2013.04.003 [doi]
AB  - OBJECTIVES: To assess the dose-response relationship between egg consumption and 
      the risk of cardiovascular diseases (CVD) and diabetes. METHODS: We
      systematically searched MEDLINE database through December 2012. Fixed- or
      random-effects model was used to pool the relative risks (RRs) and their 95%
      confidence intervals (CIs). Subgroup analyses was performed to explore the
      potential sources of heterogeneity. Weighted linear regression model was used to 
      estimate the dose-response relationship. RESULTS: Fourteen studies involving
      320,778 subjects were included. The pooled RRs of the risk of CVD, CVD for
      separated diabetes patients, and diabetes for the highest vs lowest egg intake
      were 1.19 (95% CI 1.02-1.38), 1.83 (95% CI 1.42-2.37), 1.68 (95% CI 1.41-2.00),
      respectively. For each 4/week increment in egg intake, the RRs of the risk for
      CVD, CVD for separated diabetes patients, diabetes was 1.06 (95% CI 1.03-1.10),
      1.40 (95% CI 1.25-1.57), 1.29 (95% CI 1.21-1.37), respectively. Subgroup analyses
      showed that population in other western countries have increased CVD than ones in
      USA (RR 2.00, 95% CI 1.14 to 3.51 vs 1.13, 95% CI 0.98 to 1.30, P = 0.02 for
      subgroup difference). CONCLUSIONS: Our study suggests that there is a
      dose-response positive association between egg consumption and the risk of CVD
      and diabetes.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - State Key Laboratory of Cardiovascular Medicine, Fuwai Hospital, National Center 
      for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing 100037, China; Department of Hypertension, Fuwai
      Hospital, National Center for Cardiovascular Disease, Beijing 100037, China; Key 
      Laboratory for Clinical Cardiovascular Genetics and Sino-German Laboratory for
      Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease,
      Beijing 100037, China.
FAU - Li, Yuehua
AU  - Li Y
FAU - Zhou, Chenghui
AU  - Zhou C
FAU - Zhou, Xianliang
AU  - Zhou X
FAU - Li, Lihuan
AU  - Li L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/02/08 [received]
PHST- 2013/03/09 [revised]
PHST- 2013/04/02 [accepted]
AID - S0021-9150(13)00243-8 [pii]
AID - 10.1016/j.atherosclerosis.2013.04.003 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 17. pii: S0021-9150(13)00243-8. doi:
      10.1016/j.atherosclerosis.2013.04.003.

PMID- 23643052
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 18
TI  - Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of
      endogenous stem cells in diabetes and beyond.
LID - S0021-9150(13)00247-5 [pii]
LID - 10.1016/j.atherosclerosis.2013.04.007 [doi]
AB  - Endothelial integrity is maintained by local neighboring cells, but studies in
      the field of regenerative medicine have highlighted that circulating bone
      marrow-derived endothelial progenitor cells (EPCs) contribute to endothelial
      homeostasis in health and disease. In addition, bone-marrow derived smooth muscle
      precursors may be recruited to the diseased vasculature. Therefore, modulation of
      vascular stem/progenitor cells holds promises to tackle the development and
      progression of vascular disease. The dipeptidyl peptidase-4 (DPP-4) ectopeptidase
      cleaves several proteins, including the incretin hormones that regulate
      meal-induced insulin release. Another attractive DPP-4 natural substrate is the
      highly-conserved chemokine SDF-1alpha, a major regulator of stem/progenitor cell 
      trafficking in the bone marrow and tissues. DPP-4 might also broadly affect bone 
      marrow function, by acting on hematopoietic growth factors. Emerging data
      indicate that diabetes is associated with impaired bone marrow structure and
      function, which translates into pauperization of vascular regenerative cells and 
      contributes to vascular disease. DPP-4 inhibition has potentials to tackle these 
      alteration and promote vascular repair. Currently, millions of diabetic patients 
      around the world are being treated with DPP-4 inhibitors and the study of
      ancillary effects is gaining an increasing interest for the possible
      cardiovascular benefit of these drugs beyond glucose control. As DPP-4 inhibitors
      show favorable safety profiles and do not cause hypoglycemia, they are attractive
      drugs also for non-diabetic patients and may become part of a vascular
      regenerative pharmacotherapy.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Medicine, University of Padova, Via Giustiniani, 2, 35100 Padova,
      Italy. Electronic address: gianpaolofadini@hotmail.com.
FAU - Fadini, Gian Paolo
AU  - Fadini GP
FAU - Avogaro, Angelo
AU  - Avogaro A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/22 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/04/08 [accepted]
AID - S0021-9150(13)00247-5 [pii]
AID - 10.1016/j.atherosclerosis.2013.04.007 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 18. pii: S0021-9150(13)00247-5. doi:
      10.1016/j.atherosclerosis.2013.04.007.

PMID- 23643015
OWN - NLM
STAT- In-Process
DA  - 20130506
IS  - 1000-503X (Print)
IS  - 1000-503X (Linking)
VI  - 35
IP  - 2
DP  - 2013 Apr
TI  - [Research progress of mechanisms through which dipeptidyl peptidase-4 inhibitors 
      regulate glycemia].
PG  - 229-33
LID - 10.3881/j.issn.1000-503X.2013.02.019 [doi]
AB  - Dipeptidyl peptidase-4 (DPP-4) inhibitors are promising new antidiabetic drugs.
      It had been proposed that DPP-4 inhibitors exert their antidiabetic effect by
      inhibiting the degradation of glucagon-like peptide 1(GLP-1) . However, new
      evidence has shown that the increase of GLP-1 is not notable after the use of
      these drugs in patients with type 2 diabetes. Therefore, the specific mechanisms 
      via which DPP-4 inhibitors in controlling blood glucose has became questionable. 
      In recent years, studies have revealed many possible mechanisms through which
      DPP-4 inhibitors regulate glycemia: DPP-4 inhibitors may selectively reduce DPP-4
      activity in the intestine, causing the increase of portal plasma GLP-1 level and 
      thus promoting the release of insulin via nerve reflex;also, they may decrease
      the cleavage product of GLP-1 and reduce the degradation of other bioactive
      peptides.
AD  - Department of Cadre Health Care, Tongde Hospital of Zhejiang Province, Hangzhou, 
      China. wwjjss2000@163.com
FAU - Wang, Ji-sheng
AU  - Wang JS
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao
JT  - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
JID - 8006230
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.3881/j.issn.1000-503X.2013.02.019 [doi]
PST - ppublish
SO  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013 Apr;35(2):229-33. doi:
      10.3881/j.issn.1000-503X.2013.02.019.

PMID- 23643004
OWN - NLM
STAT- In-Process
DA  - 20130506
IS  - 1000-503X (Print)
IS  - 1000-503X (Linking)
VI  - 35
IP  - 2
DP  - 2013 Apr
TI  - [Diagnosis and treatment of adipsic diabetes insipidus accompanied with
      intracranial calcification].
PG  - 161-5
LID - 10.3881/j.issn.1000-503X.2013.02.007 [doi]
AB  - OBJECTIVE: To summarize our experience in the management of adipsic central
      diabetes insipidus(ADI) accompanied with intracranial calcification. METHOD: The 
      clinical data of one ADI patient accompanied with intracranial calcification who 
      was treated in our hospital since December 2011 were retrospectively summarized. 
      RESULTS: The 24-hour urine volume was 800 ml. She didn't feel thirsty even with
      increased plasma sodium concentration(153 mmol/L) and blood osmotic pressure(333 
      mmol/L) . Combined water deprivation and vasopressin test revealed the diagnosis 
      of central diabetes insipidus. The high intensity signal(on T1-weighted magnetic 
      resonance imaging) in the posterior lobe of pituitary gland was found. Computed
      tomography showed calcifications in the bilateral basal ganglia.Serum
      cytomegalovirus IgG was positive. She was treated with desmopressin and asked for
      regular water intake regardless of the adipsia. The plasma sodium concentration
      was still below 150 mmol/L during the 4-month follow-up. CONCLUSIONS: Routine
      adipsia evaluation and combined water deprivation and vasopressin test are
      critical for the diagnosis and treatment of ADI. Past insidious intracranial
      cytomegalovirus infection may explain the cause of ADI and calcification.
AD  - Department of Endocrinology, PUMC Hospital, CAMS and PUMC, Beijing, China.
FAU - Hu, Ming-ming
AU  - Hu MM
FAU - Liu, Min
AU  - Liu M
FAU - Liu, Wei
AU  - Liu W
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao
JT  - Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
JID - 8006230
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.3881/j.issn.1000-503X.2013.02.007 [doi]
PST - ppublish
SO  - Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013 Apr;35(2):161-5. doi:
      10.3881/j.issn.1000-503X.2013.02.007.

PMID- 23642969
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 1
TI  - Diabetes in the Middle East and North Africa.
LID - S0168-8227(13)00088-0 [pii]
LID - 10.1016/j.diabres.2013.03.010 [doi]
AB  - AIMS: Even though the Middle East and North Africa (MENA) region had the highest 
      comparative prevalence of diabetes in 2012, little is known about the nuances of 
      diabetes risk and capacity to address the burdens. To provide a comprehensive
      overview, we reviewed the literature on diabetes in the MENA region. METHODS: We 
      conducted a systematic search in PubMed between January 1990 and January 2012 for
      studies on diabetes in the MENA region without language restriction. RESULTS:
      There was a paucity of country-specific epidemiology data in the region. Diabetes
      prevalence varied widely across studies, from 2.5% in 1982 to 31.6% in 2011.
      Older age and higher body mass index were the most strongly associated risk
      factors for diabetes. Among people with diabetes, over half did not meet
      recommended care targets. In addition, macrovascular and microvascular
      complications were observed in 9-12% and 15-54% of diabetes population,
      respectively. CONCLUSIONS: This review suggests a need for more representative
      surveillance data in this noteworthy focal point of the global diabetes epidemic.
      Such actions will not only help to understand the actual burden of diabetes but
      also motivate actions on design and implementation of diabetes prevention and
      control programs.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Hubert Department of Global Health, Rollins School of Public Health, Emory
      University, Atlanta, GA, United States. Electronic address: azabeti@emory.edu.
FAU - Zabetian, Azadeh
AU  - Zabetian A
FAU - Keli, Heval Mohamed
AU  - Keli HM
FAU - Echouffo-Tcheugui, Justin B
AU  - Echouffo-Tcheugui JB
FAU - Narayan, K M Venkat
AU  - Narayan KM
FAU - Ali, Mohammed K
AU  - Ali MK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/14 [received]
PHST- 2013/03/04 [accepted]
AID - S0168-8227(13)00088-0 [pii]
AID - 10.1016/j.diabres.2013.03.010 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 1. pii: S0168-8227(13)00088-0. doi:
      10.1016/j.diabres.2013.03.010.

PMID- 23642968
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Gestational diabetes mellitus: Including serum pregnancy-associated plasma
      protein-A testing in the clinical management of primiparous women? A case-control
      study.
PG  - 340-7
LID - 10.1016/j.diabres.2013.04.002 [doi]
LID - S0168-8227(13)00157-5 [pii]
AB  - AIMS: To assess pregnancy-associated plasma protein A (PAPP-A) correlation with
      GDM and its usefulness in predicting GDM in primiparous women. METHODS: First
      trimester data related to 307 pregnant women affected by GDM and 366 control
      pregnant women were retrieved from a computer data base and integrated with ad
      hoc data. Clinical data were recorded at delivery. A logistic model was used to
      analyze the association between first trimester data and subsequent clinical
      outcomes. We derived a risk score using both classical risk factors for GDM and
      PAPP-A. RESULTS: Diabetic and control women were significantly different in terms
      of age (p<0.001), BMI (p<0.001), weight (p<0.001), family history of diabetes
      (p<0.001), PAPP-A concentration and PAPP-A corrected multiple of the median (MoM)
      (p<0.001). The ROC-AUC of the clinical risk score was 0.60 (95%CI 0.56-0.64), the
      adjusted score including PAPP-A MoM was 0.70 (95%CI 0.66-0.74). CONCLUSIONS: Low 
      PAPP-A was strongly associated with GDM and lower values were found in diabetic
      women needing insulin therapy. Adding PAPP-A to first trimester screening could
      improve the prediction of women at high risk who will develop GDM. Further
      studies are needed to validate the applicability of our findings in different
      populations and settings.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - First Department of Medicine, IRCCS Fondazione Policlinico San Matteo, University
      of Pavia, Pavia, Italy. Electronic address: e.lovati@smatteo.pv.it.
FAU - Lovati, Elisabetta
AU  - Lovati E
FAU - Beneventi, Fausta
AU  - Beneventi F
FAU - Simonetta, Margherita
AU  - Simonetta M
FAU - Laneri, Marco
AU  - Laneri M
FAU - Quarleri, Lara
AU  - Quarleri L
FAU - Scudeller, Luigia
AU  - Scudeller L
FAU - Albonico, Giulia
AU  - Albonico G
FAU - Locatelli, Elena
AU  - Locatelli E
FAU - Cavagnoli, Chiara
AU  - Cavagnoli C
FAU - Tinelli, Carmine
AU  - Tinelli C
FAU - Spinillo, Arsenio
AU  - Spinillo A
FAU - Corazza, Gino R
AU  - Corazza GR
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/12/11 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/04/08 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - S0168-8227(13)00157-5 [pii]
AID - 10.1016/j.diabres.2013.04.002 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):340-7. doi:
      10.1016/j.diabres.2013.04.002. Epub 2013 May 1.

PMID- 23642967
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 May 1
TI  - Racial disparities in screening for diabetic retinopathy in youth with type 1
      diabetes.
LID - S0168-8227(13)00087-9 [pii]
LID - 10.1016/j.diabres.2013.03.009 [doi]
AB  - Of 1112 children with type 1 diabetes, dilated eye exams were performed in 717
      (64%). Children were less likely to be screened for diabetic retinopathy (DR) if 
      they were black (OR=1.6; p=0.005) or had poorer diabetes control (p=0.002). Those
      at greatest risk for DR were least likely to be screened.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, 
      Philadelphia, PA, United States. Electronic address: dumser@email.chop.edu.
FAU - Dumser, Susan M
AU  - Dumser SM
FAU - Ratcliffe, Sarah J
AU  - Ratcliffe SJ
FAU - Langdon, David R
AU  - Langdon DR
FAU - Murphy, Kathryn M
AU  - Murphy KM
FAU - Lipman, Terri H
AU  - Lipman TH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/07/16 [received]
PHST- 2013/01/02 [revised]
PHST- 2013/03/04 [accepted]
AID - S0168-8227(13)00087-9 [pii]
AID - 10.1016/j.diabres.2013.03.009 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 May 1. pii: S0168-8227(13)00087-9. doi:
      10.1016/j.diabres.2013.03.009.

PMID- 23642956
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1873-6963 (Electronic)
IS  - 0965-2299 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Jun
TI  - Syzygium cumini (L.) Skeels., a novel therapeutic agent for diabetes: Folk
      medicinal and pharmacological evidences.
PG  - 232-43
LID - 10.1016/j.ctim.2013.03.004 [doi]
LID - S0965-2299(13)00059-9 [pii]
AB  - OBJECTIVES: During the past few decades numerous folk medicinal and scientific
      investigations on the antidiabetic effects of jambolan (Syzygium cumini (L.)
      Skeels) have been reported. However no comprehensive evidence-based review is
      available. Hence this review was aimed to summarize the antidiabetic effects of
      different parts and active principles of jambolan. METHODS: The review is based
      on the available electronic literature indexed in the PubMed. The search terms
      were: Syzygium cumini, Eugenia jambolana, jambolan, jamun, and java plum with and
      without antidiabetic effect. RESULTS: Based on experimental studies and folk
      medicinal evidences, we summarized an up to date and comprehensive report on the 
      antidiabetic activity of jambolan. The mode of action of some of the parts and
      active principles is also included. Preclinical and clinical studies suggest
      that, different parts of this plant especially fruits, seeds and stem bark were
      reported for promising activity against diabetes. CONCLUSIONS: Till date no
      review is available for the evidence based preclinical/clinical study of jambolan
      with its antidiabetic effect. There is an immediate attention need for detailed
      analysis to identify its active principles. It could be used to produce safer
      drugs to treat diabetes.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Post Graduate and Research Department of Botany, Pachaiyappa's College, Chennai
      600 030, Tamil Nadu, India. Electronic address: asmayyanar@yahoo.com.
FAU - Ayyanar, Muniappan
AU  - Ayyanar M
FAU - Subash-Babu, Pandurangan
AU  - Subash-Babu P
FAU - Ignacimuthu, Savarimuthu
AU  - Ignacimuthu S
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Scotland
TA  - Complement Ther Med
JT  - Complementary therapies in medicine
JID - 9308777
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2011/01/28 [received]
PHST- 2013/03/07 [revised]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - S0965-2299(13)00059-9 [pii]
AID - 10.1016/j.ctim.2013.03.004 [doi]
PST - ppublish
SO  - Complement Ther Med. 2013 Jun;21(3):232-43. doi: 10.1016/j.ctim.2013.03.004. Epub
      2013 Apr 25.

PMID- 23642929
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
DP  - 2013 Apr 30
TI  - Methylglyoxal chronic administration promotes diabetes-like cardiac ischaemia
      disease in Wistar normal rats.
LID - S0939-4753(13)00008-2 [pii]
LID - 10.1016/j.numecd.2013.01.005 [doi]
AB  - BACKGROUND AND AIMS: The influence of lifestyle is well documented, especially
      the diet regime, in the development of type 2 diabetes (T2D) and associated
      cardiovascular diseases. Diabetic patients have increased risk of suffering
      cardiac ischemia and impaired response to such accidents. Methylglyoxal (MG)
      circulates at high concentration in diabetics' blood and is linked to the
      development of diabetes chronic complications. We propose that besides promoting 
      the cardiovascular disease, MG may also negatively regulate the endogenous
      cardioprotection pathways after ischemia. METHODS AND RESULTS: We performed a
      comparative study between three animal groups: normal Wistar (W), type 2 diabetic
      non-obese Goto-Kakizaki (GK) and normal rats submitted to MG chronic
      administration (3months) with gradually enhanced concentration, up to 75 mg/Kg
      (WMG). Hearts were submitted to different experimental conditions: control,
      ischemia and ischemia-reperfusion. Levels of oxidative stress markers, advanced
      glycation end-products (AGEs) and their receptors (RAGEs) were evaluated. The
      serine/threonine protein kinase Akt (Akt), crucial for cardiomyocytes recovery
      after ischemia, and apoptosis markers were also assessed. Levels of MG, systemic 
      and cardiac oxidative stress markers, AGEs and RAGEs were similar in GK and WMG
      groups. Akt protein was negatively regulated by MG, leading to impaired apoptotic
      markers. CONCLUSION: Chronic MG administration to normal rodents mimicked most
      diabetic alterations, being associated with the development of cardiovascular
      disease and the impairment of survival pathways. Our results demonstrate the
      negative effect of MG rich diet in healthy animals and suggest the potential of
      methylglyoxal as a therapeutic target in diabetes.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Laboratory of Physiology, Institute of Biomedical Research in Light and Image
      (IBILI), Faculty of Medicine of University of Coimbra (FMUC), Coimbra, Portugal. 
      Electronic address: joanacrisostomo@hotmail.com.
FAU - Crisostomo, J
AU  - Crisostomo J
FAU - Matafome, P
AU  - Matafome P
FAU - Santos-Silva, D
AU  - Santos-Silva D
FAU - Rodrigues, L
AU  - Rodrigues L
FAU - Sena, C M
AU  - Sena CM
FAU - Pereira, P
AU  - Pereira P
FAU - Seica, R
AU  - Seica R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/07/31 [received]
PHST- 2013/01/08 [revised]
PHST- 2013/01/09 [accepted]
AID - S0939-4753(13)00008-2 [pii]
AID - 10.1016/j.numecd.2013.01.005 [doi]
PST - aheadofprint
SO  - Nutr Metab Cardiovasc Dis. 2013 Apr 30. pii: S0939-4753(13)00008-2. doi:
      10.1016/j.numecd.2013.01.005.

PMID- 23642926
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
DP  - 2013 May 1
TI  - Modifiable risk factor burden and the prevalence of peripheral artery disease in 
      different vascular territories.
LID - S0741-5214(13)00327-3 [pii]
LID - 10.1016/j.jvs.2013.01.053 [doi]
AB  - BACKGROUND: The precise relationship between risk factor burden and prevalence of
      peripheral artery disease (PAD) in different vascular territories (PAD, carotid
      artery stenosis [CAS], and abdominal aortic aneurysms [AAAs]) is unclear.
      METHODS: We investigated the association of modifiable risk factors
      (hypertension, hypercholesterolemia, smoking, diabetes, and sedentary lifestyle) 
      with any and type-specific peripheral vascular disease (PVD) among 3.3 million
      patients in the U.S., aged 40 to 99, who underwent screening bilateral ankle
      brachial indices, carotid duplex ultrasound, and abdominal aortic ultrasound in
      the Life Line Screening program between 2004 and 2008. Multivariate logistic
      regression analysis was used to estimate the odds of disease in different risk
      factor categories. Population-attributable risk was calculated to estimate the
      proportion of disease that could be potentially ascribed to modifiable risk
      factors. RESULTS: Among 3,319,993 participants, prevalence of any PVD was 7.51%
      (95% confidence interval [CI], 7.50%-7.53%). PAD was present in 3.56% (95% CI,
      3.54%-3.58%), CAS in 3.94% (95% CI, 3.92%-3.96%), and AAAs in 0.88% (95% CI,
      0.86%-0.89%). The multivariate-adjusted prevalence with the presence of 0, 1, 2, 
      3, 4, and 5 modifiable risk factors was 2.76, 4.63, 7.12, 10.73, 16.00, and 22.08
      (P < .0001 for trend) for any PVD; 1.18, 2.09, 3.28, 5.14, 8.32, and 12.43 (P <
      .0001 for trend) for PAD; 1.41, 2.36, 3.72, 5.73, 8.48, and 11.58 (P < .0001 for 
      trend) for CAS; and 0.31, 0.54, 0.85, 1.28, 1.82, and 2.39 (P < .0001 for trend) 
      for AAAs, respectively. These associations were similar for men and women. For
      every additional modifiable risk factor that was present, the
      multivariate-adjusted odds of having vascular disease increased significantly
      (any PVD [odds ratio (OR), 1.58; 95% CI, 1.58-1.59]; PAD [OR, 1.62; 95% CI,
      1.62-1.63]; CAS [OR, 1.57; 95% CI, 1.56-1.57]; and AAA [OR, 1.51; 95% CI,
      1.50-1.53]). CONCLUSION: This very large contemporary database demonstrates that 
      risk factor burden is associated with an increased prevalence of PVD, and there
      is a graded association between the number of risk factors present and the
      prevalence of PAD, CAS, and AAAs.
CI  - Copyright (c) 2013 Society for Vascular Surgery. Published by Mosby, Inc. All
      rights reserved.
AD  - Department of Medicine, Division of Cardiology, New York University Langone
      Medical Center, New York University School of Medicine, New York, NY; Department 
      of Surgery, Division of Vascular Surgery, New York University Langone Medical
      Center, New York University School of Medicine, New York, NY. Electronic address:
      Jeffrey.berger@nyumc.org.
FAU - Berger, Jeffrey S
AU  - Berger JS
FAU - Hochman, Judith
AU  - Hochman J
FAU - Lobach, Iryna
AU  - Lobach I
FAU - Adelman, Mark A
AU  - Adelman MA
FAU - Riles, Thomas S
AU  - Riles TS
FAU - Rockman, Caron B
AU  - Rockman CB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/20 [received]
PHST- 2013/01/28 [revised]
PHST- 2013/01/29 [accepted]
AID - S0741-5214(13)00327-3 [pii]
AID - 10.1016/j.jvs.2013.01.053 [doi]
PST - aheadofprint
SO  - J Vasc Surg. 2013 May 1. pii: S0741-5214(13)00327-3. doi:
      10.1016/j.jvs.2013.01.053.

PMID- 23642924
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
DP  - 2013 May 1
TI  - The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the 
      Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex
      NitInol STent SYstem II (DURABILITY II).
LID - S0741-5214(13)00115-8 [pii]
LID - 10.1016/j.jvs.2012.12.066 [doi]
AB  - OBJECTIVE: Angioplasty and stenting are options for revascularization of
      symptomatic femoral popliteal disease. Although angioplasty alone is effective in
      short lesions, longer lesions are often treated with stents. Multiple overlapping
      stents are expensive and may be associated with stent fracture. This trial
      evaluated the safety and efficacy of a single self-expanding stent up to 20 cm in
      length in patients with atherosclerotic disease of the superficial femoral artery
      (SFA) and proximal popliteal artery. METHODS: Patients with lesions >4 cm and <18
      cm were enrolled in this nonrandomized, prospective, multicenter trial that
      evaluated the Protege EverFlex Self-Expanding Peripheral Stent System (Covidien, 
      Plymouth, Minn). The study's primary end points were the 30-day major adverse
      event rate and duplex ultrasound-assessed patency at 1 year. These were compared 
      with published performance goals. A preplanned analysis was conducted for the
      primary effectiveness end points at 1 year. Follow-up, including history,
      ankle-brachial index, patient-reported outcomes, duplex ultrasound assessment,
      and radiographs, is planned through 3 years. There was core laboratory review of 
      angiograms, ultrasound scans, and plain radiographs. A subgroup of patients was
      studied with graded treadmill testing. RESULTS: The study enrolled 287 patients
      (66% male; mean age, 68 years) with stenotic, restenotic, or occluded lesions of 
      the SFA at 44 investigational sites in the United States and Europe. Systemic
      comorbidities included hypertension (88%), hyperlipidemia (86%), diabetes (43%), 
      and prior SFA intervention (41%). The mean lesion length measured by the core
      laboratory was 89 mm. The mean normal-to-normal lesion length measured by sites
      was 110 mm. A total of 303 stents were implanted, and 95% of patients received a 
      single stent. No major adverse events occurred at 30 days. At 1 year, primary
      outcome of duplex ultrasound stent patency was 67.7% in evaluable patients, and
      among 1-year secondary outcomes, the mean ankle-brachial index increased by 0.25.
      Walking Improvement Questionnaire scores improved in pain by 33.7, distance by
      37.1, speed by 18.6, and stair climbing by 24.7. The Kaplan-Meier estimate of
      primary patency was 77.2%, primary assisted patency was 86.9%, and secondary
      patency was 87.3%. Rutherford clinical category improved in 83.5% of patients.
      Stent fracture rate was 0.4%. Matched absolute claudication distance was 412 feet
      greater and was not statistically different in this subgroup of 29 individuals.
      CONCLUSIONS: The results of DURABILITY II (StuDy for EvalUating EndovasculaR
      TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By
      usIng the Protege EverfLex NitInol Stent SYstem II) suggest that a new single
      stent strategy is safe and effective for the treatment of long lesions of the SFA
      and proximal popliteal arteries at 1 year.
CI  - Copyright (c) 2013 Society for Vascular Surgery. Published by Mosby, Inc. All
      rights reserved.
AD  - University of Wisconsin School of Medicine and Public Health, Madison, Wisc.
      Electronic address: ellis@surgery.wisc.edu.
FAU - Matsumura, Jon S
AU  - Matsumura JS
FAU - Yamanouchi, Dai
AU  - Yamanouchi D
FAU - Goldstein, Jeffrey A
AU  - Goldstein JA
FAU - Pollock, Christopher W
AU  - Pollock CW
FAU - Bosiers, Marc
AU  - Bosiers M
FAU - Schultz, Greg A
AU  - Schultz GA
FAU - Scheinert, Dierk
AU  - Scheinert D
FAU - Rocha-Singh, Krishna J
AU  - Rocha-Singh KJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/07/25 [received]
PHST- 2012/12/12 [revised]
PHST- 2012/12/20 [accepted]
AID - S0741-5214(13)00115-8 [pii]
AID - 10.1016/j.jvs.2012.12.066 [doi]
PST - aheadofprint
SO  - J Vasc Surg. 2013 May 1. pii: S0741-5214(13)00115-8. doi:
      10.1016/j.jvs.2012.12.066.

PMID- 23642916
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
DP  - 2013 May 1
TI  - Open repair of intact thoracoabdominal aortic aneurysms in the American College
      of Surgeons National Surgical Quality Improvement Program.
LID - S0741-5214(13)00651-4 [pii]
LID - 10.1016/j.jvs.2013.03.037 [doi]
AB  - OBJECTIVE: Open surgical repair of thoracoabdominal aortic aneurysms (TAAAs) is
      uncommon. Mortality rates of 20% are reported in studies using national data and 
      are 5% to 8% in single-institution studies. Clinical trials are currently
      evaluating branched and fenestrated endografts. The purpose of this study is to
      establish a benchmark for future comparisons with endovascular trials using open 
      repair of TAAAs in the National Surgical Quality Improvement Program (NSQIP)
      database. METHODS: We identified all patients undergoing open elective and
      emergency surgical repair of intact TAAAs in NSQIP (2005 to 2010) using Current
      Procedural Terminology (American Medical Association, Chicago, Ill) and
      International Classification of Diseases, 9th Edition codes. We analyzed
      demographics, comorbidities, 30-day mortality, postoperative complications, and
      length of stay. Multivariable logistic regression was used to identify predictors
      of mortality. RESULTS: We identified 450 patients who underwent open surgical
      repair (418 elective, 32 emergent) of an intact TAAA. Mean age was 69.4 years,
      60.7% were male, and 85.6% were white. Comorbidities included hypertension
      (87.1%), chronic obstructive pulmonary disease (27.3%), prior stroke or transient
      ischemic attack (16.7%), diabetes (11.6%), and peripheral vascular disease
      (9.6%). Thirty-day mortality was 10.0%. Pulmonary complications were the most
      common: failure to wean from ventilator (39.1%), pneumonia (23.1%), and
      reintubation (13.8%). Acute renal failure requiring dialysis occurred in 10.7% of
      patients. Multivariable analysis (odds ratio [95% confidence interval]) showed
      predictors of mortality were emergent repair (3.3 [1.03-10.83]; P = .04), age >70
      years (3.5 [1.03-7.56], P = .001), preoperative dialysis (8.4 [1.90-37.29], P =
      .005), cardiac complication (2.9 [1.05-8.21], P = .04), and renal complications
      (8.4 [3.41-20.56], P < .001). CONCLUSIONS: In this study of NSQIP hospitals, the 
      first to analyze open surgical repair of TAAAs, the 30-day mortality rate of
      10.0% is similar to single-institution reports. However, morbidity and mortality 
      after open TAAA repair remain high, confirming the need for less invasive
      procedures.
CI  - Copyright (c) 2013 Society for Vascular Surgery. Published by Mosby, Inc. All
      rights reserved.
AD  - Department of Surgery, Division of Vascular and Endovascular Surgery, Beth Israel
      Deaconess Medical Center and Harvard Medical School.
FAU - Bensley, Rodney P
AU  - Bensley RP
FAU - Curran, Thomas
AU  - Curran T
FAU - Hurks, Rob
AU  - Hurks R
FAU - Lo, Ruby C
AU  - Lo RC
FAU - Wyers, Mark C
AU  - Wyers MC
FAU - Hamdan, Allen D
AU  - Hamdan AD
FAU - Chaikof, Elliot L
AU  - Chaikof EL
FAU - Schermerhorn, Marc L
AU  - Schermerhorn ML
LA  - ENG
GR  - T32 HL007734/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/12 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/03/19 [accepted]
AID - S0741-5214(13)00651-4 [pii]
AID - 10.1016/j.jvs.2013.03.037 [doi]
PST - aheadofprint
SO  - J Vasc Surg. 2013 May 1. pii: S0741-5214(13)00651-4. doi:
      10.1016/j.jvs.2013.03.037.

PMID- 23642913
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 17
TI  - The effect of HIV infection on atherosclerosis and lipoprotein metabolism: A one 
      year prospective study.
LID - S0021-9150(13)00250-5 [pii]
LID - 10.1016/j.atherosclerosis.2013.04.010 [doi]
AB  - OBJECTIVES: HIV infection is associated with dyslipidaemia and increased risk of 
      cardiovascular disease. The effects of HIV infection and antiretroviral treatment
      on surrogate markers of atherosclerosis, and lipoprotein metabolism were
      evaluated in a 12 month prospective study. METHODS AND RESULTS: Treatment-naive
      HIV patients were recruited into one of three groups: untreated HIV infection not
      likely to require initiation of antiretroviral therapy (ART) for at least 12
      months; initiating treatment with non nucleoside reverse transcriptase
      inhibitor-containing ART regimen and initiating treatment with protease
      inhibitor-containing ART regimen. The patients underwent assessment of carotid
      intima-media thickness (cIMT), pulse wave velocity (PWV), brachial flow-mediated 
      dilation (FMD) and variables of plasma lipoprotein metabolism at baseline and 12 
      months. The findings were compared with published values for age and sex matched 
      HIV-negative healthy subjects in a cross-sectional fashion. cIMT and FMD were
      lower while PWV was higher in HIV-patients compared with HIV-negative
      individuals; none of the markers changed significantly during 12 months follow
      up. HIV patients had hypoalphalipoproteinemia and elevated plasma levels of
      lecithin:cholesterol acyltransferase (LCAT) and cholesteryl ester transfer
      protein. The only significant changes in lipid-related variables were elevation
      of total cholesterol and triglycerides in patients treated with PI-containing
      regimen and elevation of plasma LCAT levels in patients treated with
      NNRTI-containing regimen. The ability of whole and apoB-depleted plasma to effect
      cholesterol efflux was not impaired in all three groups. CONCLUSIONS: This study 
      did not find evidence for rapid progression of subclinical atherosclerosis and
      deterioration of dyslipidaemia in HIV patients within 1 year.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Baker Heart and Diabetes Institute, Melbourne, Australia.
FAU - Rose, Honor
AU  - Rose H
FAU - Low, Hann
AU  - Low H
FAU - Dewar, Elizabeth
AU  - Dewar E
FAU - Bukrinsky, Michael
AU  - Bukrinsky M
FAU - Hoy, Jennifer
AU  - Hoy J
FAU - Dart, Anthony
AU  - Dart A
FAU - Sviridov, Dmitri
AU  - Sviridov D
LA  - ENG
GR  - R01 HL101274/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/29 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/02 [accepted]
AID - S0021-9150(13)00250-5 [pii]
AID - 10.1016/j.atherosclerosis.2013.04.010 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 17. pii: S0021-9150(13)00250-5. doi:
      10.1016/j.atherosclerosis.2013.04.010.

PMID- 23642850
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
DP  - 2013 May 1
TI  - Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic
      Syndrome and Androgenetic Alopecia in a Latin American Population.
LID - S0090-4295(13)00303-8 [pii]
LID - 10.1016/j.urology.2013.03.001 [doi]
AB  - OBJECTIVE: To evaluate the association of male lower urinary tract symptoms
      (LUTS) with metabolic syndrome (MetS) and androgenetic alopecia in a Latin
      American population. METHODS: We enrolled 907 patients for prospective evaluation
      at a single institution. LUTS were evaluated with the International Prostate
      Symptom Score (IPSS). Subjects were evaluated with respect to hypertension,
      diabetes, dyslipidemia, previous cardiovascular events, body mass index (BMI),
      waist and hip circumference, and a laboratorial investigation including
      prostate-specific antigen (PSA), C-reactive protein (CRP), and gonadal steroids. 
      Alopecia was classified according to the Norwood-Hamilton scale. RESULTS: Mean
      patient age was 61.0 years; 57.5% of subjects had moderate/severe LUTS; MetS was 
      present in 17.2% of subjects and 53.9% were classified as bald. Age,
      hypertension, diabetes, dyslipidemia, alopecia, previous cardiovascular event,
      and elevated waist-to-hip ratio (WHR) were associated with moderate/severe LUTS
      and with storage symptoms (P <.05). On multivariable analysis, age (odds ratio
      [OR] 2.30, 95% confidence interval [CI] 1.63-3.25), cardiovascular events (OR
      1.73, 95% CI 1.07-2.78), and WHR (OR 1.65, 95% CI 1.13-2.40) were independent
      predictors for LUTS. For storage symptoms, age (OR 1.80, 95% CI 1.28-2.54),
      cardiovascular event (OR 2.07, 95% CI 1.27-3.39), WHR (OR 1.54, 95% CI
      1.06-2.25), and MetS (OR 1.70, 95% CI 1.01-2.86) were independent risk factors.
      Age and cardiovascular event were the only independent predictors for voiding
      symptoms. CONCLUSION: Components of the MetS were strongly associated with
      moderate and severe LUTS. WHR and cardiovascular events were independent
      predictors of voiding and storage symptoms, and MetS was an independent predictor
      of storage symptoms. Alopecia was not an independent predictor of LUTS.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Urology, University of Sao Paulo Medical School, Sao Paulo, Brazil.
      Electronic address: jbrunhara@gmail.com.
FAU - Barbosa, Joao Arthur B A
AU  - Barbosa JA
FAU - Muracca, Eduardo
AU  - Muracca E
FAU - Nakano, Elcio
AU  - Nakano E
FAU - Paranhos, Mario
AU  - Paranhos M
FAU - Natalino, Renato
AU  - Natalino R
FAU - Cordeiro, Paulo
AU  - Cordeiro P
FAU - Srougi, Miguel
AU  - Srougi M
FAU - Antunes, Alberto Azoubel
AU  - Antunes AA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Urology
JT  - Urology
JID - 0366151
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/26 [received]
PHST- 2013/02/21 [revised]
PHST- 2013/03/01 [accepted]
AID - S0090-4295(13)00303-8 [pii]
AID - 10.1016/j.urology.2013.03.001 [doi]
PST - aheadofprint
SO  - Urology. 2013 May 1. pii: S0090-4295(13)00303-8. doi:
      10.1016/j.urology.2013.03.001.

PMID- 23642801
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1873-5894 (Electronic)
IS  - 0730-725X (Linking)
DP  - 2013 May 1
TI  - Feasibility of coronary artery wall thickening assessment in asymptomatic
      coronary artery disease using phase-sensitive dual-inversion recovery MRI at 3T.
LID - S0730-725X(13)00097-0 [pii]
LID - 10.1016/j.mri.2013.03.011 [doi]
AB  - OBJECTIVES: The purpose of this study was to (a) investigate the image quality of
      phase-sensitive dual-inversion recovery (PS-DIR) coronary wall imaging in healthy
      subjects and in subjects with known coronary artery disease (CAD) and to (b)
      investigate the utilization of PS-DIR at 3T in the assessment of coronary artery 
      thickening in subjects with asymptomatic but variable degrees of CAD. MATERIALS
      AND METHODS: A total of 37 subjects participated in this institutional review
      board-approved and HIPAA-compliant study. These included 21 subjects with known
      CAD as identified on multidetector computed tomography angiography (MDCT).
      Sixteen healthy subjects without known history of CAD were included. All subjects
      were scanned using free-breathing PS-DIR magnetic resonance imaging (MRI) for the
      assessment of coronary wall thickness at 3T. Lumen-tissue contrast-to-noise ratio
      (CNR), signal-to-noise ratio (SNR) and quantitative vessel parameters including
      lumen area and wall thickness were measured. Statistical analyses were performed.
      RESULTS: PS-DIR was successfully completed in 76% of patients and in 88% of the
      healthy subjects. Phase-sensitive signed-magnitude reconstruction, compared to
      modulus-magnitude images, significantly improved lumen-tissue CNR in healthy
      subjects (26.73+/-11.95 vs. 14.65+/-9.57, P<.001) and in patients (21.45+/-7.61
      vs. 16.65+/-5.85, P<.001). There was no difference in image CNR and SNR between
      groups. In arterial segments free of plaques, coronary wall was thicker in
      patients in comparison to healthy subjects (1.74+/-0.27mm vs. 1.17+/-0.14mm,
      P<.001), without a change in lumen area (4.51+/-2.42mm2 vs. 5.71+/-3.11mm2,
      P=.25). CONCLUSIONS: This is the first study to demonstrate the feasibility of
      successfully obtaining vessel wall images at 3T using PS-DIR in asymptomatic
      patients with known variable degrees of CAD as detected by MDCT. This was
      achieved with a fixed subject-invariant planning of blood signal nulling. With
      that limitation alleviated, PS-DIR coronary wall MRI is capable of detecting
      arterial thickening and positive arterial remodeling at 3T in asymptomatic CAD.
CI  - Published by Elsevier Inc.
AD  - Biomedical and Metabolic Imaging Branch, The National Institute of Diabetes and
      Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
FAU - Gharib, Ahmed M
AU  - Gharib AM
FAU - Zahiri, Homeira
AU  - Zahiri H
FAU - Matta, Jatin
AU  - Matta J
FAU - Pettigrew, Roderic I
AU  - Pettigrew RI
FAU - Abd-Elmoniem, Khaled Z
AU  - Abd-Elmoniem KZ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Magn Reson Imaging
JT  - Magnetic resonance imaging
JID - 8214883
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/13 [received]
PHST- 2013/02/26 [revised]
PHST- 2013/03/09 [accepted]
AID - S0730-725X(13)00097-0 [pii]
AID - 10.1016/j.mri.2013.03.011 [doi]
PST - aheadofprint
SO  - Magn Reson Imaging. 2013 May 1. pii: S0730-725X(13)00097-0. doi:
      10.1016/j.mri.2013.03.011.

PMID- 23642732
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 19
TI  - Association of SNPs in the UGT1A gene cluster with total bilirubin and mortality 
      in the Diabetes Heart Study.
LID - S0021-9150(13)00248-7 [pii]
LID - 10.1016/j.atherosclerosis.2013.04.008 [doi]
AB  - OBJECTIVE: A negative relationship between total bilirubin concentration (TBili) 
      and CVD risk has been documented in a series of epidemiological studies. In
      addition, TBili is thought to be under strong genetic regulation via the UGT1A
      gene family, suggesting it may be a heritable CVD risk factor. However, few
      studies directly relate TBili-associated UGT1A variants to CVD severity or
      outcome. This study replicated the genetic association for TBili in the Diabetes 
      Heart Study (DHS), and examined the relationships of TBili-associated SNPs with
      measures of subclinical CVD and mortality. METHODS: This investigation included
      1220 self-described European American (EA) individuals from the DHS, a
      family-based study examining risk for macrovascular complications in type 2
      diabetes (T2D). Genetic associations with TBili were examined using the
      Affymetrix Genome-wide Human SNP Array 5.0 and the Illumina Infinium Human Exome 
      beadchip v1.0. Subsequent analyses assessed the relationships of the top
      TBili-associated SNPs with measures of vascular calcified plaque and mortality.
      RESULTS: A genome-wide association study detected 18 SNPs within the UGT1A gene
      family associated with TBili at p < 5 x 10-8. The top hit was rs887829 (p = 8.67 
      x 10-20). There was no compelling evidence of association between the top
      TBili-associated SNPs and vascular calcified plaque (p = 0.05-0.88). There was,
      however, evidence of association with all-cause mortality (p = 0.0004-0.06), the 
      top hit being rs2741034. CONCLUSION: These findings support a potential role for 
      UGT1A genetic variants in risk for mortality in T2D. Further quantification of
      the extent of CVD risk conferred by UGT1A gene family variants in a high risk
      cohort with T2D is still required.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Center for Genomics and Personalized Medicine Research, Wake Forest School of
      Medicine, Winston-Salem, NC, USA; Center for Diabetes Research, Wake Forest
      School of Medicine, Winston-Salem, NC, USA; Department of Biochemistry, Wake
      Forest School of Medicine, Winston-Salem, NC, USA. Electronic address:
      dbowden@wakehealth.edu.
FAU - Cox, Amanda J
AU  - Cox AJ
FAU - Ng, Maggie C-Y
AU  - Ng MC
FAU - Xu, Jianzhao
AU  - Xu J
FAU - Langefeld, Carl D
AU  - Langefeld CD
FAU - Koch, Kenneth L
AU  - Koch KL
FAU - Dawson, Paul A
AU  - Dawson PA
FAU - Carr, J Jeffrey
AU  - Carr JJ
FAU - Freedman, Barry I
AU  - Freedman BI
FAU - Hsu, Fang-Chi
AU  - Hsu FC
FAU - Bowden, Donald W
AU  - Bowden DW
LA  - ENG
GR  - R01 HL092301/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/01 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/04/08 [accepted]
AID - S0021-9150(13)00248-7 [pii]
AID - 10.1016/j.atherosclerosis.2013.04.008 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 19. pii: S0021-9150(13)00248-7. doi:
      10.1016/j.atherosclerosis.2013.04.008.

PMID- 23642731
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 17
TI  - Food sources of sodium, saturated fat and added sugar in the Spanish hypertensive
      and diabetic population.
LID - S0021-9150(13)00241-4 [pii]
LID - 10.1016/j.atherosclerosis.2013.04.001 [doi]
AB  - OBJECTIVES: Previous research has shown that the diet of hypertensive and
      diabetic patients has a low accordance with the main nutritional recommendations,
      mostly due to the high intake of sodium, saturated fat and added sugars. This is 
      the first study to identify the main food sources of these nutrients in these
      patients. METHODS: Cross-sectional study conducted in 2008-2010 in a
      representative sample of the Spanish adult population, including 2323 patients
      with hypertension and 635 with diabetes. The habitual diet was assessed using a
      validated diet history. The intake of sodium, saturated fat and added sugars was 
      estimated with Spanish food composition tables. RESULTS: The hypertensive and
      diabetic population showed, respectively, an intake of 2.9 and 3.1 g/day of
      sodium, 26 and 26 g/day of saturated fat, and 33 and 24 g/day of added sugar. In 
      hypertensive and diabetic patients, respectively, most sodium intake came from
      bread (35%, 34%), raw-cured sausages (15%, 15%), cooked sausages (6%, 7%), and
      soup (5%, 6%). The main sources of saturated fat were cured cheese (13%, 13%),
      bakery products (12%, 11%), red meat (10%, 11%), raw-cured sausages (8%, 9%) and 
      whole milk (4%, 4%). The food groups that most contributed to added sugar intake 
      were sugar directly added to coffee and other beverages (27%, 19%), bakery
      products (15%, 19%), sugary soft drinks (10%, 13%), and whole yogurt (9%, 12%).
      The main food sources of nutrients were similar in all sex and age groups.
      CONCLUSIONS: In patients with hypertension and diabetes, the intake of sodium,
      saturated fat and added sugar can be substantially reduced by prioritizing
      low-salt varieties of bread, reducing the consumption of bakery products and
      sausages, replacing cured cheese and other whole dairy products by low-fat
      products, using non-sugary sweeteners, and substituting sugar-free soft drinks,
      or plain water, for sugary sodas.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Departamento Medicina Preventiva y Salud Publica, Universidad Autonoma de
      Madrid/IdiPaz, CIBERESP, Madrid, Spain. Electronic address:
      mpilar.guallar@uam.es.
FAU - Guallar-Castillon, Pilar
AU  - Guallar-Castillon P
FAU - Munoz-Pareja, Maritza
AU  - Munoz-Pareja M
FAU - Aguilera, Ma Teresa
AU  - Aguilera MT
FAU - Leon-Munoz, Luz Maria
AU  - Leon-Munoz LM
FAU - Rodriguez-Artalejo, Fernando
AU  - Rodriguez-Artalejo F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/29 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/04/01 [accepted]
AID - S0021-9150(13)00241-4 [pii]
AID - 10.1016/j.atherosclerosis.2013.04.001 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 17. pii: S0021-9150(13)00241-4. doi:
      10.1016/j.atherosclerosis.2013.04.001.

PMID- 23642717
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1557-9875 (Electronic)
IS  - 0733-8619 (Linking)
VI  - 31
IP  - 2
DP  - 2013 May
TI  - Diabetic neuropathy part 1: overview and symmetric phenotypes.
PG  - 425-45
LID - 10.1016/j.ncl.2013.02.004 [doi]
LID - S0733-8619(13)00014-5 [pii]
AB  - Diabetes is the most common cause of neuropathy in United States and neuropathies
      are the most common complication of diabetes mellitus, affecting up to 50% of
      patients with type 1 and type 2 diabetes mellitus. Symptoms usually include
      numbness, tingling, pain, and weakness. Dizziness with postural changes can be
      seen with autonomic neuropathy. Metabolic, vascular, and immune theories have
      been proposed for the pathogenesis of diabetic neuropathy. Axonal damage and
      segmental demyelination can be seen with diabetic neuropathies. Management of
      diabetic neuropathy should begin at the initial diagnosis of diabetes and mainly 
      requires tight and stable glycemic control.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Neurology, University of Kansas Medical Center, Kansas City, KS,
      USA. Electronic address: mpasnoor@kumc.edu.
FAU - Pasnoor, Mamatha
AU  - Pasnoor M
FAU - Dimachkie, Mazen M
AU  - Dimachkie MM
FAU - Kluding, Patricia
AU  - Kluding P
FAU - Barohn, Richard J
AU  - Barohn RJ
LA  - eng
PT  - Journal Article
DEP - 20130315
PL  - United States
TA  - Neurol Clin
JT  - Neurologic clinics
JID - 8219232
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/15 [aheadofprint]
AID - S0733-8619(13)00014-5 [pii]
AID - 10.1016/j.ncl.2013.02.004 [doi]
PST - ppublish
SO  - Neurol Clin. 2013 May;31(2):425-45. doi: 10.1016/j.ncl.2013.02.004. Epub 2013 Mar
      15.

PMID- 23642643
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 Apr 30
TI  - Prevalence of treatment for diabetes during 1997-2007, and trends in
      cardiovascular risk factors between 2001 and 2007 according to diabetic
      treatment, in the IPC (Investigations Preventives et Cliniques; Preventive and
      Clinical Investigations) cohort.
LID - S1262-3636(13)00020-7 [pii]
LID - 10.1016/j.diabet.2013.01.003 [doi]
AB  - AIM: This study aimed to evaluate changes in the prevalence of glucose-lowering
      agents in a large, unselected general French population from 1997 to 2007, with
      specific focus on changes in other cardiovascular risk factors in relation to
      diabetic status during 2001-2002 and 2006-2007. METHODS: The prevalence of
      treated diabetes was assessed in a large population who had a health check-up at 
      the "Investigations Preventives et Cliniques" Center between 1997-2007. Baseline 
      characteristics and risk profiles of individuals with and without treatment for
      diabetes were assessed and compared with data for 2001-2002 and 2006-2007.
      RESULTS: From 1997 to 2007, the prevalence of treatment for diabetes increased
      from 0.75% to 1.73% in men and from 0.7% to 2.28% in women. In 2006-2007 compared
      with 2001-2002, the odds ratios for receiving glucose-lowering agents, adjusted
      for age, body mass index (BMI) and educational level, were 1.54 (95% CI:
      1.28-1.86) in men and 1.59 (95% CI: 1.26-2.03) in women. In those treated for
      diabetes compared with untreated subjects, greater decreases in blood pressure,
      cholesterol and glycaemia were found, stress and depression scores improved, and 
      a greater increase in BMI was found. Smoking decreased in both treated and
      untreated individuals. Physical activity decreased in treated individuals, but
      remained unchanged in the general population. CONCLUSION: The prevalence of
      people treated with diabetes increased in the Paris area. Although most
      concomitant risk factors decreased more in treated individuals than in the
      general population, physical activity and BMI worsened, thus, emphasizing the
      need for improving patient education.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Centre d'Investigations Preventives et Cliniques (IPC), 6, rue La Perouse, 75116 
      Paris, France. Electronic address: thomas@ipc.asso.fr.
FAU - Thomas, F
AU  - Thomas F
FAU - Eschwege, E
AU  - Eschwege E
FAU - Bean, K
AU  - Bean K
FAU - Pannier, B
AU  - Pannier B
FAU - Danchin, N
AU  - Danchin N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/16 [received]
PHST- 2013/01/08 [revised]
PHST- 2013/01/11 [accepted]
AID - S1262-3636(13)00020-7 [pii]
AID - 10.1016/j.diabet.2013.01.003 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 Apr 30. pii: S1262-3636(13)00020-7. doi:
      10.1016/j.diabet.2013.01.003.

PMID- 23642642
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 Apr 30
TI  - Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: A review of 
      the current evidence from clinical studies.
LID - S1262-3636(13)00002-5 [pii]
LID - 10.1016/j.diabet.2012.12.003 [doi]
AB  - AIM: Low-dose intravenous infusions of regular insulin, usually initiated in the 
      emergency department and continued in the intensive care unit (ICU), are the
      standard care for patients with diabetic ketoacidosis (DKA) to ensure rapid
      resolution of hyperglycaemia and ketoacidosis. Several studies have evaluated
      whether subcutaneous injections of the rapid-acting analogue insulin lispro may
      be an alternative to intravenous insulin infusion for avoiding ICU admissions of 
      uncomplicated DKA cases. METHODS: This review summarizes the current clinical
      evidence for the effectiveness and safety of subcutaneous insulin lispro
      injections in non-severe DKA patients. Relevant studies were identified by a
      systematic literature search through the PubMed database. RESULTS: To date, four 
      small randomized studies (156 patients overall; three studies in adults and one
      in paediatric patients with diabetes) have directly compared subcutaneous insulin
      lispro injections every 1-2h vs continuous intravenous infusions of regular
      insulin. Patients with severe complications were excluded. In all studies, the
      mean time to resolution of DKA was similar in both treatment groups [range (three
      studies): lispro 10-14.8h; regular insulin 11-13.2h]. The mean time to resolution
      of hyperglycaemia, total insulin doses required, number of hospitalization days
      and number of hypoglycaemic episodes were similar in both treatment groups; no
      severe complications or DKA recurrences were reported, and one study showed a 39%
      cost reduction for the insulin lispro group. CONCLUSION: In patients with
      mild-to-moderate DKA, subcutaneous injections of insulin lispro every 1-2h offer 
      a feasible alternative to continuous intravenous infusions of regular insulin,
      and should now be evaluated in larger, more appropriately powered studies.
CI  - Copyright (c) 2013. Published by Elsevier Masson SAS.
AD  - Medical - Diabetes, Lilly France, Suresnes, France.
FAU - Vincent, M
AU  - Vincent M
FAU - Nobecourt, E
AU  - Nobecourt E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/04 [received]
PHST- 2012/12/05 [revised]
PHST- 2012/12/10 [accepted]
AID - S1262-3636(13)00002-5 [pii]
AID - 10.1016/j.diabet.2012.12.003 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 Apr 30. pii: S1262-3636(13)00002-5. doi:
      10.1016/j.diabet.2012.12.003.

PMID- 23642641
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 Apr 30
TI  - Effects of tactile massage on metabolic biomarkers in patients with type 2
      diabetes.
LID - S1262-3636(13)00036-0 [pii]
LID - 10.1016/j.diabet.2013.02.002 [doi]
AB  - AIM: Tactile massage (TM) is a gentle and superficial form of massage. A pilot
      study of patients with type 2 diabetes in primary care reported a reduction of
      0.8% in glycosylated haemoglobin (HbA1c), whereas a randomized study comparing
      the effects of 10weeks of TM once per week with relaxation exercises performed
      once per week as per instructions on a CD found no effects of TM on HbA1c in an
      intention-to-treat analysis. However, a significant reduction in waist
      circumference (WC) was found between the groups. METHODS: This was a secondary
      per-protocol analysis of the effect of TM (n=21) compared with relaxation (n=25) 
      on other metabolic biomarkers. Anthropometrics (BMI and WC) and metabolic factors
      (B HbA1c, S IGF, fS insulin, S adiponectin, S leptin and fP ghrelin) were
      assessed, insulin resistance (IR) was determined by modified homoeostasis model
      assessment (HOMA2-IR) using fP glucose and fS insulin, and ratios of
      adiponectin-to-leptin, adiponectin-to-HOMA-IR, adiponectin-to-WC and
      adiponectin-to-HbA1c were calculated at baseline, and at 10weeks and 6months
      after the intervention. RESULTS: Significant results adjusted for age, gender and
      changes in lifestyle and medical factors were shown for WC in women (-6.2cm [95% 
      CI: -10.4, -1.9]), but not in men. In addition, improvements in the TM group were
      found for adiponectin and ratios of adiponectin-to-leptin and
      adiponectin-to-HbA1c levels. CONCLUSION: Our data indicate that TM therapy may
      affect metabolic markers in type 2 diabetes despite the lack of significant
      effects on HbA1c. The clinical implications of our findings need to be evaluated 
      in further studies.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Centre for Family Medicine, Karolinska Institute, Alfred Nobels alle 12, S-141 83
      Huddinge, Sweden. Electronic address: per.wandell@ki.se.
FAU - Wandell, P E
AU  - Wandell PE
FAU - Arnlov, J
AU  - Arnlov J
FAU - Nixon Andreasson, A
AU  - Nixon Andreasson A
FAU - Andersson, K
AU  - Andersson K
FAU - Tornkvist, L
AU  - Tornkvist L
FAU - Carlsson, A C
AU  - Carlsson AC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/08 [received]
PHST- 2013/02/05 [revised]
PHST- 2013/02/05 [accepted]
AID - S1262-3636(13)00036-0 [pii]
AID - 10.1016/j.diabet.2013.02.002 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 Apr 30. pii: S1262-3636(13)00036-0. doi:
      10.1016/j.diabet.2013.02.002.

PMID- 23642614
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 Apr 30
TI  - Serum neuregulin-1beta levels are positively correlated with VEGF and
      Angiopoietin-1 levels in patients with diabetes and unstable angina pectoris.
LID - S0167-5273(13)00672-4 [pii]
LID - 10.1016/j.ijcard.2013.04.088 [doi]
AD  - Department of Cardiology, The First Affiliated Hospital, Guangxi Medical
      University, Nanning, Guangxi, People's Republic of China.
FAU - Zeng, Zhiyu
AU  - Zeng Z
FAU - Gui, Chun
AU  - Gui C
FAU - Nong, Qinling
AU  - Nong Q
FAU - Du, Fang
AU  - Du F
FAU - Zhu, Liguang
AU  - Zhu L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/24 [received]
PHST- 2013/04/06 [accepted]
AID - S0167-5273(13)00672-4 [pii]
AID - 10.1016/j.ijcard.2013.04.088 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 Apr 30. pii: S0167-5273(13)00672-4. doi:
      10.1016/j.ijcard.2013.04.088.

PMID- 23642538
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 34
IP  - 23
DP  - 2013 Jul
TI  - The generation of pancreatic beta-cell spheroids in a simulated microgravity
      culture system.
PG  - 5785-91
LID - 10.1016/j.biomaterials.2013.04.003 [doi]
LID - S0142-9612(13)00447-X [pii]
AB  - Islet transplantation can induce a substantial improvement in the treatment of
      type 1 diabetes mellitus. However, the clinical application of islet
      transplantation is severely limited by the shortage of donor organs. It is thus
      essential to improve the engraftment rate to achieve the expected outcome in the 
      treatment of diabetes mellitus using a limited amount of donor islets. In this
      manuscript, we describe the generation of beta-cell spheroids using mouse
      insulinoma cells (MIN6) as a model of beta-cells. We established a 3D culture
      system that simulates microgravity using a 3D clinostat. Using this method, we
      were able to produce 100 spheroids per mL of culture media. The optimization of
      the culture conditions in the clinostat produced spheroids with a size of
      approximately 250 mum, which is a size that is known to induce good graft
      survival after islet transplantation. The spheroids produced in the clinostat
      expressed several beta-cell signature genes at higher levels than the levels that
      were found in MIN6 cells that were cultured in a standard 2D culture dish
      (MIN6-2D). The transplantation of the spheroids into the portal vein of
      streptozotocin-induced diabetic mice ameliorates hyperglycemia, whereas the
      transplantation of the equivalent number of 2D-cultured cells failed to cure
      diabetes. These results indicate that the clinostat culture provides a new method
      for the reconstitution of a large number of functional beta-cell spheroids for
      diabetes treatment.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Regenerative Medicine, Graduate School of Medicine, Yokohama City
      University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
FAU - Tanaka, Hiroyasu
AU  - Tanaka H
FAU - Tanaka, Shin
AU  - Tanaka S
FAU - Sekine, Keisuke
AU  - Sekine K
FAU - Kita, Sayaka
AU  - Kita S
FAU - Okamura, Ai
AU  - Okamura A
FAU - Takebe, Takanori
AU  - Takebe T
FAU - Zheng, Yun-Wen
AU  - Zheng YW
FAU - Ueno, Yasuharu
AU  - Ueno Y
FAU - Tanaka, Junzo
AU  - Tanaka J
FAU - Taniguchi, Hideki
AU  - Taniguchi H
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/02/20 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - S0142-9612(13)00447-X [pii]
AID - 10.1016/j.biomaterials.2013.04.003 [doi]
PST - ppublish
SO  - Biomaterials. 2013 Jul;34(23):5785-91. doi: 10.1016/j.biomaterials.2013.04.003.
      Epub 2013 May 2.

PMID- 23642536
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 34
IP  - 23
DP  - 2013 Jul
TI  - The role of exendin-4-conjugated superparamagnetic iron oxide nanoparticles in
      beta-cell-targeted MRI.
PG  - 5843-52
LID - 10.1016/j.biomaterials.2013.04.021 [doi]
LID - S0142-9612(13)00465-1 [pii]
AB  - Noninvasive targeted visualization of pancreatic beta cells or islets is becoming
      the focus of molecular imaging application in diabetes and islet transplantation 
      studies, but it is currently unsuccessful due to the lack of specific beta cell
      biomarkers. Glucagon-like peptide 1 receptor (GLP-1R) is highly expressed in beta
      cells and considered as a promising target. We here developed a targeted
      superparamagnetic iron oxide (SPIO) nanoparticle using GLP-1 analog-exendin-4
      which is conjugated to polyethylene glycol coated SPIO (PEG-SPIO). The results
      demonstrated that exendin-4 functionalized SPIO was able to specifically bind to 
      and internalized by GLP-1R-expressing INS-1 cells, with the higher labeling
      efficiency than non-targeted nanoparticles. Notably, SPIO-exendin4 could
      differentially label islets in pancreatic slices or beta cell grafts in vitro.
      Systemic delivery of SPIO-exendin4 into nude mice bearing s.c. insulinomas
      (derived from INS-1 cells) leads to the accumulation of the nanoparticles in
      tumors, generating a strong magnetic resonance imaging contrast detectable by a
      clinical MRI scanner at field strength of 3.0 T, and the iron deposition in
      tumors was further confirmed by Prussian blue staining. Furthermore, preliminary 
      biodistribution study indicated that SPIO-exendin4 had a tendency to accumulate
      in pancreas. Toxicity assessments demonstrated good biocompatibility in vivo.
      These results suggest that SPIO-exendin4 has potential as molecularly targeted
      imaging agents for in vivo imaging of insulinoma, and possibly for future beta
      cell imaging.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Surgery, 2nd Affiliated Hospital, School of Medicine, Zhejiang
      University, 88 Jiefang Road, Zhejiang Province, Hangzhou 310009, PR China.
FAU - Zhang, Bo
AU  - Zhang B
FAU - Yang, Bin
AU  - Yang B
FAU - Zhai, Chuanxin
AU  - Zhai C
FAU - Jiang, Biao
AU  - Jiang B
FAU - Wu, Yulian
AU  - Wu Y
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/27 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - S0142-9612(13)00465-1 [pii]
AID - 10.1016/j.biomaterials.2013.04.021 [doi]
PST - ppublish
SO  - Biomaterials. 2013 Jul;34(23):5843-52. doi: 10.1016/j.biomaterials.2013.04.021.
      Epub 2013 May 2.

PMID- 23642511
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Apr 30
TI  - Left Ventricular Function by Echocardiography, Tissue Doppler Imaging, and
      Carotid Intima-Media Thickness in Obese Adolescents With Nonalcoholic Fatty Liver
      Disease.
LID - S0002-9149(13)00917-X [pii]
LID - 10.1016/j.amjcard.2013.03.056 [doi]
AB  - The aims of this study were to evaluate left ventricular (LV) systolic and
      diastolic function in obese adolescents with nonalcoholic fatty liver disease
      (NAFLD) using conventional echocardiography and pulsed-wave tissue Doppler
      imaging and to investigate the relations between LV function and carotid
      intima-media thickness (CIMT). LV remodeling, tissue Doppler-derived LV
      velocities, and cardiovascular risk profiles in obese adolescents with NAFLD were
      also studied. One hundred eighty obese adolescents and 68 healthy controls were
      enrolled in the study. LV end-diastolic and end-systolic and left atrial
      diameters and LV mass were higher in the 2 obese groups compared with controls.
      By pulsed-wave Doppler echocardiography and pulsed-wave tissue Doppler imaging,
      the NAFLD group had normal LV systolic function, impaired diastolic function, and
      altered global systolic and diastolic myocardial performance. In patients with
      NAFLD, LV mass was positively correlated with homeostasis model assessment of
      insulin resistance and serum alanine aminotransferase. CIMT was positively
      correlated with homeostasis model assessment of insulin resistance, alanine
      aminotransferase, and LV mass. By multiple stepwise regression analysis, alanine 
      aminotransferase (beta = 0.124, p = 0.026), homeostasis model assessment of
      insulin resistance (beta = 0.243, p = 0.0001), LV mass (beta = 0.874, p = 0.0001)
      were independent parameters associated with increased CIMT. In conclusion,
      insulin resistance has a significant independent impact on CIMT and LV remodeling
      in the absence of diabetes in patients with NAFLD. Pulsed-wave tissue Doppler
      imaging is suggested to detect LV dysfunction at an earlier stage in obese
      adolescents with NAFLD for careful monitoring of cardiovascular risk.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Pediatric Cardiology, Konya Training and Research Hospital, Konya, 
      Turkey. Electronic address: ahmetsert2@hotmail.com.
FAU - Sert, Ahmet
AU  - Sert A
FAU - Aypar, Ebru
AU  - Aypar E
FAU - Pirgon, Ozgur
AU  - Pirgon O
FAU - Yilmaz, Hakan
AU  - Yilmaz H
FAU - Odabas, Dursun
AU  - Odabas D
FAU - Tolu, Ismet
AU  - Tolu I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/12 [received]
PHST- 2013/03/24 [revised]
PHST- 2013/03/24 [accepted]
AID - S0002-9149(13)00917-X [pii]
AID - 10.1016/j.amjcard.2013.03.056 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Apr 30. pii: S0002-9149(13)00917-X. doi:
      10.1016/j.amjcard.2013.03.056.

PMID- 23642501
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
DP  - 2013 Apr 30
TI  - Sex differentiation with regard to coronary artery disease.
LID - S0914-5087(13)00091-9 [pii]
LID - 10.1016/j.jjcc.2013.03.001 [doi]
AB  - Coronary artery disease was considered a male disease for many years. However,
      nowadays, coronary artery disease constitutes the leading cause of death in
      women, although there are a lot of gender-related differences regarding the
      presentation of acute myocardial infarction, its diagnosis, its treatment, short-
      and long-term mortality rates, and post-acute myocardial infarction
      complications. Generally, women have smaller and stiffer hearts and cardiac
      vessels, suffering a greater extent of atherosclerosis and endothelial and smooth
      muscle dysfunction. They are usually older than men and they have more
      comorbidities such as hypertension, renal impairment, and diabetes mellitus.
      Moreover, female coronary artery disease, the diagnosis of which is more
      complicated due to more false negative results of some diagnostic methods in
      women, is more often presented with atypical symptoms and women's symptoms of
      typical or atypical angina are more severe. Furthermore, women delay
      significantly more in seeking care and they are more frequently undertreated.
      Finally, women are associated with generally poorer in-hospital and long-term
      prognosis having almost two-fold higher early mortality and they are more prone
      to complications such as bleeding complications, shock, and heart failure, as
      well as to post-myocardial infarction depression and poorer physical function and
      mental health. In this review, we discuss these sex-related differences according
      to current literature.
CI  - Copyright (c) 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All
      rights reserved.
AD  - General Surgery Department, University Hospital of Ioannina, School of Medicine, 
      45500 Ioannina, Greece. Electronic address: nikppk@yahoo.gr.
FAU - Papakonstantinou, Nikolaos A
AU  - Papakonstantinou NA
FAU - Stamou, Maria I
AU  - Stamou MI
FAU - Baikoussis, Nikolaos G
AU  - Baikoussis NG
FAU - Goudevenos, John
AU  - Goudevenos J
FAU - Apostolakis, Efstratios
AU  - Apostolakis E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/17 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/03/04 [accepted]
AID - S0914-5087(13)00091-9 [pii]
AID - 10.1016/j.jjcc.2013.03.001 [doi]
PST - aheadofprint
SO  - J Cardiol. 2013 Apr 30. pii: S0914-5087(13)00091-9. doi:
      10.1016/j.jjcc.2013.03.001.

PMID- 23642403
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1475-2727 (Electronic)
IS  - 1368-9800 (Linking)
DP  - 2013 May 3
TI  - Alarming predictions for obesity and non-communicable diseases in the Middle
      East.
PG  - 1-9
AB  - OBJECTIVE: The present study aimed to model obesity trends and future
      obesity-related disease for nine countries in the Middle East; in addition, to
      explore how hypothetical reductions in population obesity levels could ameliorate
      anticipated disease burdens. DESIGN: A regression analysis of cross-sectional
      data v. BMI showed age- and sex-specific BMI trends, which fed into a micro
      simulation with a million Monte Carlo trials for each country. We also examined
      two alternative scenarios where population BMI was reduced by 1 % and 5 %.
      SETTING: Statistical modelling of obesity trends was carried out in nine Middle
      East countries (Bahrain, Egypt, Iran, Jordan, Kuwait, Lebanon, Oman, Saudi Arabia
      and Turkey). SUBJECTS: BMI data along with disease incidence, mortality and
      survival data from national and sub-national data sets were used for the
      modelling process. RESULTS: High rates of overweight and obesity increased in
      both men and women in most countries. The burden of incident type 2 diabetes, CHD
      and stroke would be moderated with even small reductions in obesity levels.
      CONCLUSIONS: Obesity is a growing problem in the Middle East which requires
      government action on the primary prevention of obesity. The present results are
      important for policy makers to know the effectiveness of obesity interventions on
      future disease burden.
AD  - 1 National Heart Forum, 7th Floor Victoria House, London WC1B 4AD, UK.
FAU - Kilpi, Fanny
AU  - Kilpi F
FAU - Webber, Laura
AU  - Webber L
FAU - Musaigner, Abdulrahman
AU  - Musaigner A
FAU - Aitsi-Selmi, Amina
AU  - Aitsi-Selmi A
FAU - Marsh, Tim
AU  - Marsh T
FAU - Rtveladze, Ketevan
AU  - Rtveladze K
FAU - McPherson, Klim
AU  - McPherson K
FAU - Brown, Martin
AU  - Brown M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Public Health Nutr
JT  - Public health nutrition
JID - 9808463
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - S1368980013000840 [pii]
AID - 10.1017/S1368980013000840 [doi]
PST - aheadofprint
SO  - Public Health Nutr. 2013 May 3:1-9.

PMID- 23642393
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
DP  - 2013 Apr 6
TI  - Carbohydrate intake in relation to BMI, HbA1c and lipid profile in children and
      adolescents with type 1 diabetes.
LID - S0261-5614(13)00095-2 [pii]
LID - 10.1016/j.clnu.2013.03.017 [doi]
AB  - BACKGROUND & AIMS: To compare reported and recommended carbohydrate intake in
      children and adolescents with type 1 diabetes (T1D) and to explore associations
      with BMI, HbA1c and lipid profile. METHODS: A cross-sectional observational study
      of reported carbohydrate intake in 46,010 patients with T1D aged 1-18 years from 
      332 diabetes centres in Germany and Austria in comparison to age-matched healthy 
      children and adolescents. RESULTS: The median reported carbohydrate intake in T1D
      patients was markedly lower than in healthy children. It varied between 56% and
      90% of recommended amounts across the paediatric age range with younger patients 
      showing levels closer to recommend. Lower carbohydrate intake was associated with
      higher BMI-SDS (p < 0.001), particularly during adolescence, higher total
      cholesterol (p < 0.001), higher LDL-cholesterol (p = 0.005) and lower HbA1c (p < 
      0.001). CONCLUSIONS: The methodologically simple measure of reported carbohydrate
      intake may be a valuable addition to the information gathered on paediatric
      patients with T1D in an outpatient setting. Children and adolescents with T1D
      appear to restrict their consumption of carbohydrates, which may have adverse
      effects on BMI and the lipid profile, particularly if there is a compensatory
      increased fat intake. Health care providers should therefore advise patients and 
      parents of the recommended age-dependent levels of carbohydrate intake.
CI  - Copyright (c) 2013 Elsevier Ltd and European Society for Clinical Nutrition and
      Metabolism. All rights reserved.
AD  - Department of General Paediatrics, Neonatology and Paediatric Cardiology,
      University Children's Hospital Dusseldorf, Moorenstr. 5, 40225 Duesseldorf,
      Germany. Electronic address: thomas.meissner@med.uni-duesseldorf.de.
FAU - Meissner, Thomas
AU  - Meissner T
FAU - Wolf, Johannes
AU  - Wolf J
FAU - Kersting, Mathilde
AU  - Kersting M
FAU - Frohlich-Reiterer, Elke
AU  - Frohlich-Reiterer E
FAU - Flechtner-Mors, Marion
AU  - Flechtner-Mors M
FAU - Salgin, Burak
AU  - Salgin B
FAU - Stahl-Pehe, Anna
AU  - Stahl-Pehe A
FAU - Holl, Reinhard W
AU  - Holl RW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130406
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/30 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/24 [accepted]
AID - S0261-5614(13)00095-2 [pii]
AID - 10.1016/j.clnu.2013.03.017 [doi]
PST - aheadofprint
SO  - Clin Nutr. 2013 Apr 6. pii: S0261-5614(13)00095-2. doi:
      10.1016/j.clnu.2013.03.017.

PMID- 23642381
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 May 1
TI  - Comparison by Meta-Analysis of Mortality After Isolated Coronary Artery Bypass
      Grafting in Women Versus Men.
LID - S0002-9149(13)00895-3 [pii]
LID - 10.1016/j.amjcard.2013.03.034 [doi]
AB  - Short- and long-term mortality in women who undergo coronary artery bypass
      grafting (CABG) has been evaluated in multiple studies with conflicting results. 
      The investigators conducted a meta-analysis of all existing studies to evaluate
      the impact of female gender on mortality in patients who undergo isolated CABG. A
      comprehensive search of studies published through May 31, 2012 identified 20
      studies comparing men and women who underwent isolated CABG. All-cause mortality 
      was evaluated at short-term (postoperative period and/or at 30 days), midterm
      (1-year), and long-term (5-year) follow-up. Odds ratios (ORs) and 95% confidence 
      interval (CIs) were calculated using a random-effects model. A total of 966,492
      patients (688,709 men [71%], 277,783 women [29%]) were included in this
      meta-analysis. Women were more likely to be older; had significantly greater
      co-morbidities, including hypertension, diabetes mellitus, hyperlipidemia,
      unstable angina, congestive heart failure, and peripheral vascular disease; and
      were more likely to undergo urgent CABG (51% vs 44%, p <0.01). Short-term
      mortality (OR 1.77, 95% CI 1.67 to 1.88) was significantly higher in women. At
      midterm and long-term follow-up, mortality remained high in women compared with
      men. Women remained at increased risk for short-term mortality in 2 subgroup
      analyses including prospective studies (n = 41,500, OR 1.83, 95% CI 1.59 to 2.12)
      and propensity score-matched studies (n = 11,522, OR 1.36, 95% CI 1.04 to 1.78). 
      In conclusion, women who underwent isolated CABG experienced higher mortality at 
      short-term, midterm, and long-term follow-up compared with men. Mortality
      remained independently associated with female gender despite propensity
      score-matched analysis of outcomes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Section of Cardiology, Baylor College of Medicine, Houston, Texas; Department of 
      Medicine, Baylor College of Medicine, Houston, Texas. Electronic address:
      malam@bcm.tmc.edu.
FAU - Alam, Mahboob
AU  - Alam M
FAU - Bandeali, Salman J
AU  - Bandeali SJ
FAU - Kayani, Waleed T
AU  - Kayani WT
FAU - Ahmad, Waqas
AU  - Ahmad W
FAU - Shahzad, Saima A
AU  - Shahzad SA
FAU - Jneid, Hani
AU  - Jneid H
FAU - Birnbaum, Yochai
AU  - Birnbaum Y
FAU - Kleiman, Neal S
AU  - Kleiman NS
FAU - Coselli, Joseph S
AU  - Coselli JS
FAU - Ballantyne, Christie M
AU  - Ballantyne CM
FAU - Lakkis, Nasser
AU  - Lakkis N
FAU - Virani, Salim S
AU  - Virani SS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/02 [received]
PHST- 2013/03/16 [revised]
PHST- 2013/03/16 [accepted]
AID - S0002-9149(13)00895-3 [pii]
AID - 10.1016/j.amjcard.2013.03.034 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 May 1. pii: S0002-9149(13)00895-3. doi:
      10.1016/j.amjcard.2013.03.034.

PMID- 23642349
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1532-2955 (Electronic)
IS  - 1087-0792 (Linking)
DP  - 2013 Apr 30
TI  - Untreated obstructive sleep apnea and the risk for serious long-term adverse
      outcomes: A systematic review.
LID - S1087-0792(13)00007-5 [pii]
LID - 10.1016/j.smrv.2013.01.003 [doi]
AB  - BACKGROUND: Reports on the association between obstructive sleep apnea (OSA) and 
      risk of death, cardiovascular (CV) events, diabetes and depression have been
      inconsistent. METHODS: We conducted a systematic review of the prognostic value
      of clinical and polysomnographic (PSG) characteristics of OSA for adverse
      long-term outcomes of untreated OSA in adult patients. A comprehensive search
      strategy for prognosis studies, OSA, CV events, mortality, depression and
      diabetes was developed in collaboration with a medical information specialist.
      All English language studies, from Jan 1999 to Dec 2011, with longitudinal design
      in adults with OSA diagnosed by PSG recording, found through Medline, Embase and 
      bibliographies of identified articles, were considered eligible. Quality was
      assessed using published guidelines. RESULTS: Among 26 articles, ten evaluated
      the association of OSA with mortality, 9 with a composite CV outcome, 4 with
      stroke, 2 with diabetes and 1 with depression. Significant relationships between 
      the apnea-hypopnea index (AHI) and outcomes of interest were reported in 18
      studies: seven for all-cause mortality, six for composite CV events, three for
      stroke, one for diabetes and one for depression. The effect of AHI was attenuated
      by female gender, older age, absence of daytime sleepiness and higher body mass
      index. Due to clinical heterogeneity between studies, meta-analyses were not
      performed. CONCLUSION: Evidence exists in men for a relationship between OSA and 
      all-cause mortality and a composite CV outcome. Associations between OSA and
      other outcomes remain uncertain. Among OSA-specific markers, only AHI was a
      consistent predictor. Other consistent predictors were traditional CV risk
      factors. Research is required to identify effect modifiers and the predictive
      ability of various AHI threshold values and hypopnea definitions. An enhanced set
      of OSA-specific predictors will allow better risk stratification to guide OSA
      treatment.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Institute of Health Policy, Management and Evaluation, Faculty of Medicine,
      University of Toronto, 155 College Street, Suite 425, Toronto, ON, Canada M5T
      3M6. Electronic address: tetyana.kendzerska@mail.utoronto.ca.
FAU - Kendzerska, Tetyana
AU  - Kendzerska T
FAU - Mollayeva, Tatyana
AU  - Mollayeva T
FAU - Gershon, Andrea S
AU  - Gershon AS
FAU - Leung, Richard S
AU  - Leung RS
FAU - Hawker, Gillian
AU  - Hawker G
FAU - Tomlinson, George
AU  - Tomlinson G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Sleep Med Rev
JT  - Sleep medicine reviews
JID - 9804678
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/17 [received]
PHST- 2013/01/09 [revised]
PHST- 2013/01/10 [accepted]
AID - S1087-0792(13)00007-5 [pii]
AID - 10.1016/j.smrv.2013.01.003 [doi]
PST - aheadofprint
SO  - Sleep Med Rev. 2013 Apr 30. pii: S1087-0792(13)00007-5. doi:
      10.1016/j.smrv.2013.01.003.

PMID- 23642290
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
DP  - 2013 May 1
TI  - Retrospective Real-World Adherence in Patients With Type 2 Diabetes Initiating
      Once-Daily Liraglutide 1.8 mg or Twice-Daily Exenatide 10 mug.
LID - S0149-2918(13)00169-0 [pii]
LID - 10.1016/j.clinthera.2013.03.021 [doi]
AB  - BACKGROUND: The effectiveness of a drug is significantly influenced by a
      patient's adherence to the required regimen. OBJECTIVE: The goal of this
      retrospective database analysis was to determine the factors affecting adherence 
      over a 12-month follow-up period in adults with type 2 diabetes mellitus (DM)
      initiating once-daily liraglutide (1.8 mg) or twice-daily exenatide (10 mug).
      METHODS: A patient-centric claims database was used, covering the period January 
      2009 to December 2011. Patients were included if they had >/=1 claim of
      once-daily liraglutide 1.8 mg or twice-daily exenatide 10 mug from January to
      December 2010 (index date [ID]), >/=2 diagnoses of type 2 DM before ID,
      continuous enrollment for 12 months before and after ID, and age >/=18 years at
      ID. Patients were required to be glucagon-like peptide-1 receptor agonist
      treatment-naive in the 12 months preceding ID and have a second prescription for 
      once-daily liraglutide 1.8 mg or twice-daily exenatide 10 mug during the 12
      months after ID. The medication possession ratio (MPR) was used as a continuous
      variable and to categorize patients as high-adherent (MPR >/=80%) or low-adherent
      (MPR <80%). Regression analyses were conducted to determine the predictors for
      nonadherence in the type 2 DM population, with bivariate testing of the MPR
      categories conducted initially to determine the predictors to be included in the 
      final regression model. RESULTS: A total of 3623 patients (once-daily liraglutide
      1.8 mg, n = 2036; twice-daily exenatide 10 mug, n = 1587) were identified.
      Variables found to reduce adherence were younger age, female sex, Southern
      geographic region, twice-daily exenatide treatment, and higher percentage of
      copayment from the claimant. After adjusting for confounding factors, patients
      receiving once-daily liraglutide 1.8 mg were approximately 11% more adherent than
      patients receiving twice-daily exenatide 10 mug (95% CI, 7-14; P < 0.0001). The
      odds ratio for "poor" adherence (MPR <80%) with twice-daily exenatide 10 mug
      therapy compared with liraglutide 1.8 mg once-daily was 1.33 (95% CI, 1.16-1.53; 
      P < 0.0001). CONCLUSIONS: This study found that adherence to once-daily
      liraglutide 1.8 mg treatment was superior to twice-daily exenatide 10 mug over a 
      12-month follow-up period. Nonadherence has important implications to the health 
      care system, both in terms of clinical effectiveness and economic burden (eg,
      hospitalization, productivity losses). Using strategies to increase adherence is 
      vital to reduce the future clinical and economic burden of diabetes.
CI  - Copyright (c) 2013 Elsevier HS Journals, Inc. All rights reserved.
AD  - HERON Evidence Development, Stockholm, Sweden. Electronic address:
      maria.malmenas@heronhealth.com.
FAU - Malmenas, Maria
AU  - Malmenas M
FAU - Bouchard, Jonathan R
AU  - Bouchard JR
FAU - Langer, Jakob
AU  - Langer J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/12/28 [received]
PHST- 2013/03/04 [revised]
PHST- 2013/03/28 [accepted]
AID - S0149-2918(13)00169-0 [pii]
AID - 10.1016/j.clinthera.2013.03.021 [doi]
PST - aheadofprint
SO  - Clin Ther. 2013 May 1. pii: S0149-2918(13)00169-0. doi:
      10.1016/j.clinthera.2013.03.021.

PMID- 23642288
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly
      diagnosed type 2 diabetic patients: a preliminary report.
PG  - 73
LID - 10.1186/1475-2840-12-73 [doi]
AB  - BACKGROUND: Treatment with the alpha-glucosidase inhibitor (AGI) acarbose is
      associated with a significant reduction the risk of cardiovascular events.
      However, the underlying mechanisms of this effect are unclear. AGIs were recently
      suggested to participate in stimulating glucagon-like peptide 1 (GLP-1)
      secretion. We therefore examined the effects of a 24-week treatment of acarbose
      on endogenous GLP-1, nitric oxide (NO) levels, nitric oxide synthase (NOS)
      activity, and carotid intima-media thickness (CIMT) in newly diagnosed patients
      with type 2 diabetes (T2D). METHODS: Blood was drawn from 24 subjects (14 male,
      10 female, age: 50.7 +/- 7.36 years, BMI: 26.64 +/- 3.38 kg/m2, GHbA1c: 7.00 +/- 
      0.74%) with drug-naive T2D at 0 and 120 min following a standard mixed meal for
      the measurements of active GLP-1, NO and NOS. The CIMT was measured prior to and 
      following 24 weeks of acarbose monotherapy (mean dose: 268 mg daily). RESULTS:
      Following 24 weeks of acarbose treatment, both fasting and postprandial plasma
      GLP-1 levels were increased. In patients with increased postprandial GLP-1
      levels, serum NO levels and NOS activities were also significantly increased and 
      were positively related to GLP-1 levels. Although the CIMT was not significantly 
      altered following treatment with acarbose, a decreased CIMT was negatively
      correlated with increased GLP-1 levels. CONCLUSIONS: Twenty-four weeks of
      acarbose monotherapy in newly diagnosed patients with T2D is associated with
      significantly increased levels of both fasting and postprandial GLP-1 as well as 
      significantly increased NO levels and NOS activity for those patients in whom
      postprandial GLP-1 levels were increased. Therefore, the benefits of acarbose on 
      cardiovascular risk may be related to its stimulation of GLP-1 secretion.
AD  - Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease
      Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University,
      Tianjin 300070, China. changbc1970@126.com.
FAU - Zheng, Miao-Yan
AU  - Zheng MY
FAU - Yang, Ju-Hong
AU  - Yang JH
FAU - Shan, Chun-Yan
AU  - Shan CY
FAU - Zhou, Hong-Tao
AU  - Zhou HT
FAU - Xu, Yan-Guang
AU  - Xu YG
FAU - Wang, Ying
AU  - Wang Y
FAU - Ren, Hui-Zhu
AU  - Ren HZ
FAU - Chang, Bao-Cheng
AU  - Chang BC
FAU - Chen, Li-Ming
AU  - Chen LM
LA  - eng
PT  - Journal Article
DEP - 20130504
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3653752
OID - NLM: PMC3653752
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/03/22 [received]
PHST- 2013/05/01 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 1475-2840-12-73 [pii]
AID - 10.1186/1475-2840-12-73 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 May 4;12:73. doi: 10.1186/1475-2840-12-73.

PMID- 23642261
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients.
PG  - 72
LID - 10.1186/1475-2840-12-72 [doi]
AB  - BACKGROUND: Circulating adipocyte fatty acid-binding protein (FABP4) levels are
      considered to be a link between obesity, insulin resistance, diabetes, and
      cardiovascular (CV) diseases. In vitro, FABP4 has exhibited cardiodepressant
      activity by suppressing cardiomyocyte contraction. We have explored the
      relationship between FABP4 and the N-terminal fragment of pro-B-type natriuretic 
      peptide (NT-proBNP) as a clinical parameter of heart failure (HF). METHODS: We
      included 179 stable HF patients who were referred to a specialized HF unit, 108
      of whom were prospectively followed for up to 6 months. A group of 163 non-HF
      patients attending a CV risk unit was used as the non-HF control group for the
      FABP4 comparisons. RESULTS: In the HF patients, FABP4 and NT-proBNP were assayed,
      along with a clinical and functional assessment of the heart at baseline and
      after 6 months of specialized monitoring. The FABP4 levels were higher in the
      patients with HF than in the non-HF high CV risk control group (p<0.001). The
      FABP4 levels were associated with the NT-proBNP levels in patients with HF
      (r=0.601, p<0.001), and this association was stronger in the diabetic patients.
      FABP4 was also associated with heart rate and the results of the 6-minute walk
      test. After the follow-up period, FABP4 decreased in parallel to NT-proBNP and to
      the clinical parameters of HF. CONCLUSIONS: FABP4 is associated with the clinical
      manifestations and biomarkers of HF. It exhibits a parallel evolution with the
      circulating levels of NT-proBNP in HF patients.
AD  - Unitat de Recerca en Lipids i Arteriosclerosi, Hospital Universitari Sant Joan,
      CIBERDEM, Reus, Spain. luismasana@urv.cat.
FAU - Cabre, Anna
AU  - Cabre A
FAU - Valdovinos, Pilar
AU  - Valdovinos P
FAU - Lazaro, Iolanda
AU  - Lazaro I
FAU - Bonet, Gil
AU  - Bonet G
FAU - Bardaji, Alfredo
AU  - Bardaji A
FAU - Masana, Lluis
AU  - Masana L
LA  - eng
PT  - Journal Article
DEP - 20130504
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3653725
OID - NLM: PMC3653725
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/25 [received]
PHST- 2013/04/28 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 1475-2840-12-72 [pii]
AID - 10.1186/1475-2840-12-72 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 May 4;12:72. doi: 10.1186/1475-2840-12-72.

PMID- 23642238
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 13
DP  - 2013
TI  - The delivery of preventive care to clients of community health services.
PG  - 167
LID - 10.1186/1472-6963-13-167 [doi]
AB  - BACKGROUND: Smoking, poor nutrition, risky alcohol use, and physical inactivity
      are the primary behavioral risks for common causes of mortality and morbidity.
      Evidence and guidelines support routine clinician delivery of preventive care.
      Limited evidence describes the level delivered in community health settings. The 
      objective was to determine the: prevalence of preventive care provided by
      community health clinicians; association between client and service
      characteristics and receipt of care; and acceptability of care. This will assist 
      in informing interventions that facilitate adoption of opportunistic preventive
      care delivery to all clients. METHODS: In 2009 and 2010 a telephone survey was
      undertaken of 1284 clients across a network of 56 public community health
      facilities in one health district in New South Wales, Australia. The survey
      assessed receipt of preventive care (assessment, brief advice, and
      referral/follow-up) regarding smoking, inadequate fruit and vegetable
      consumption, alcohol overconsumption, and physical inactivity; and acceptability 
      of care. RESULTS: Care was most frequently reported for smoking (assessment:
      59.9%, brief advice: 61.7%, and offer of referral to a telephone service: 4.5%)
      and least frequently for inadequate fruit or vegetable consumption (27.0%, 20.0% 
      and 0.9% respectively). Sixteen percent reported assessment for all risks, 16.2% 
      received brief advice for all risks, and 0.6% were offered a specific referral
      for all risks. The following were associated with increased care: diabetes
      services, number of appointments, being male, Aboriginal, unemployed, and
      socio-economically disadvantaged. Acceptability of preventive care was high
      (76.0%-95.3%). CONCLUSIONS: Despite strong client support, preventive care was
      not provided opportunistically to all, and was preferentially provided to select 
      groups. This suggests a need for practice change strategies to enhance preventive
      care provision to achieve adherence to clinical guidelines.
AD  - Population Health, Hunter New England Local Health District, Booth Building,
      Wallsend Health Services, Longworth Avenue, Wallsend, NSW 2287, Australia.
      Kathleen.McElwaine@hnehealth.nsw.gov.au.
FAU - McElwaine, Kathleen M
AU  - McElwaine KM
FAU - Freund, Megan
AU  - Freund M
FAU - Campbell, Elizabeth M
AU  - Campbell EM
FAU - Knight, Jenny
AU  - Knight J
FAU - Bowman, Jennifer A
AU  - Bowman JA
FAU - Doherty, Emma L
AU  - Doherty EL
FAU - Wye, Paula M
AU  - Wye PM
FAU - Wolfenden, Luke
AU  - Wolfenden L
FAU - Lecathelinais, Christophe
AU  - Lecathelinais C
FAU - McLachlan, Scott
AU  - McLachlan S
FAU - Wiggers, John H
AU  - Wiggers JH
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
SB  - IM
PMC - PMC3656789
OID - NLM: PMC3656789
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/19 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/06 [aheadofprint]
AID - 1472-6963-13-167 [pii]
AID - 10.1186/1472-6963-13-167 [doi]
PST - epublish
SO  - BMC Health Serv Res. 2013 May 6;13:167. doi: 10.1186/1472-6963-13-167.

PMID- 23642227
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
DP  - 2013 May 3
TI  - Perturbations in skeletal muscle sarcomere structure of heart failure and type 2 
      diabetes patients: Restorative effects of (-)-epicatechin-rich cocoa.
AB  - Heart failure and type 2 diabetes mellitus associate with detrimental alterations
      in skeletal muscle structure/function. We have demonstrated that (-)-epicatechin 
      rich cocoa (ERC) improves skeletal muscle mitochondrial structure (Taub et al,
      2012. Clin Trans Sci. 5, 43). We hypothesized that improved mitochondrial
      structure may facilitate the reversal of detrimental alterations in sarcomeric
      microstructure. In a pilot study, five patients with heart failure and type 2
      diabetes consumed ERC for three months; treadmill testing (VO2 max) and skeletal 
      muscle biopsies were performed. Westerns, immunohistochemistry and electron
      microscopy were used. We report severe perturbations in components of the
      dystrophin-associated protein complex (DAPC) as well as sarcomeric microstructure
      at baseline. ERC induced recovery/enhancement of DAPC protein levels, sarcomeric 
      microstructure and in a coordinated fashion alterations in markers of skeletal
      muscle growth/differentiation consistent with myofiber regeneration. VO2 max
      increased (~24%) but did not reach statistical significance. These initial
      results warrant further rigorous investigation, since the use of ERC (or pure
      epicatechin) may represent a safe and novel means of improving muscle function.
FAU - Taub, Pam R
AU  - Taub PR
FAU - Ramirez-Sanchez, Israel
AU  - Ramirez-Sanchez I
FAU - Ciaraldi, Theodore P
AU  - Ciaraldi TP
FAU - Gonzalez-Basurto, Silvia
AU  - Gonzalez-Basurto S
FAU - Coral-Vazquez, Ramon
AU  - Coral-Vazquez R
FAU - Perkins, Guy
AU  - Perkins G
FAU - Hogan, Michael
AU  - Hogan M
FAU - Maisel, Alan S
AU  - Maisel AS
FAU - Henry, Robert R
AU  - Henry RR
FAU - Ceballos, Guillermo
AU  - Ceballos G
FAU - Villarreal, Francisco
AU  - Villarreal F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/01/11 [received]
PHST- 2013/04/30 [revised]
PHST- 2013/05/03 [accepted]
AID - CS20130023 [pii]
AID - 10.1042/CS20130023 [doi]
PST - aheadofprint
SO  - Clin Sci (Lond). 2013 May 3.

PMID- 23642195
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1545-4312 (Electronic)
IS  - 0199-9885 (Linking)
DP  - 2013 Apr 29
TI  - O-GlcNAc Cycling: A Link Between Metabolism and Chronic Disease.
AB  - To maintain homeostasis under variable nutrient conditions, cells rapidly and
      robustly respond to fluctuations through adaptable signaling networks. Evidence
      suggests that the O-linked N-acetylglucosamine (O-GlcNAc) posttranslational
      modification of serine and threonine residues functions as a critical regulator
      of intracellular signaling cascades in response to nutrient changes. O-GlcNAc is 
      a highly regulated, reversible modification poised to integrate metabolic signals
      and acts to influence many cellular processes, including cellular signaling,
      protein stability, and transcription. This review describes the role O-GlcNAc
      plays in governing both integrated cellular processes and the activity of
      individual proteins in response to nutrient levels. Moreover, we discuss the ways
      in which cellular changes in O-GlcNAc status may be linked to chronic diseases
      such as type 2 diabetes, neurodegeneration, and cancers, providing a unique
      window through which to identify and treat disease conditions. Expected final
      online publication date for the Annual Review of Nutrition Volume 33 is July 17, 
      2013. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised
      estimates.
AD  - National Institute of Diabetes Digestive and Kidney Diseases, National Institutes
      of Health, Bethesda, MD 20892; email: bondmr@mail.nih.gov.
FAU - Bond, Michelle R
AU  - Bond MR
FAU - Hanover, John A
AU  - Hanover JA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Annu Rev Nutr
JT  - Annual review of nutrition
JID - 8209988
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
AID - 10.1146/annurev-nutr-071812-161240 [doi]
PST - aheadofprint
SO  - Annu Rev Nutr. 2013 Apr 29.

PMID- 23642086
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 12
DP  - 2013
TI  - Relationship between serum levels of triglycerides and vascular inflammation,
      measured as COX-2, in arteries from diabetic patients: a translational study.
PG  - 62
LID - 10.1186/1476-511X-12-62 [doi]
AB  - BACKGROUND: Inflammation is a common feature in the majority of cardiovascular
      disease, including Diabetes Mellitus (DM). Levels of pro-inflammatory markers
      have been found in increasing levels in serum from diabetic patients (DP).
      Moreover, levels of Cyclooxygenase-2 (COX-2) are increased in coronary arteries
      from DP. METHODS: Through a cross-sectional design, patients who underwent CABG
      were recruited. Vascular smooth muscle cells (VSMC) were cultured and COX-2 was
      measured by western blot. Biochemical and clinical data were collected from the
      medical record and by blood testing. COX-2 expression was analyzed in internal
      mammary artery cross-sections by confocal microscopy. Eventually, PGI2 and PGE2
      were assessed from VSMC conditioned media by ELISA. RESULTS: Only a high glucose 
      concentration, but a physiological concentration of triglycerides exposure of
      cultured human VSMC derived from non-diabetic patients increased COX-2 expression
      .Diabetic patients showed increasing serum levels of glucose, Hb1ac and
      triglycerides. The bivariate analysis of the variables showed that triglycerides 
      was positively correlated with the expression of COX-2 in internal mammary
      arteries from patients (r2 = 0.214, P < 0.04). CONCLUSIONS: We conclude that is
      not the glucose blood levels but the triglicerydes leves what increases the
      expression of COX-2 in arteries from DP.
AD  - Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, 
      Spain. santiredondo@hotmail.com.
FAU - Gordillo-Moscoso, Antonio
AU  - Gordillo-Moscoso A
FAU - Ruiz, Emilio
AU  - Ruiz E
FAU - Carnero, Manuel
AU  - Carnero M
FAU - Reguillo, Fernando
AU  - Reguillo F
FAU - Rodriguez, Enrique
AU  - Rodriguez E
FAU - Tejerina, Teresa
AU  - Tejerina T
FAU - Redondo, Santiago
AU  - Redondo S
LA  - eng
PT  - Journal Article
DEP - 20130503
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
SB  - IM
PMC - PMC3667010
OID - NLM: PMC3667010
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/02/01 [received]
PHST- 2013/04/18 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - 1476-511X-12-62 [pii]
AID - 10.1186/1476-511X-12-62 [doi]
PST - epublish
SO  - Lipids Health Dis. 2013 May 3;12:62. doi: 10.1186/1476-511X-12-62.

PMID- 23641969
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130515
DCOM- 20130516
LR  - 20130521
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Pilot educational program to enhance empowering patient education of school-age
      children with diabetes.
PG  - 16
LID - 10.1186/2251-6581-12-16 [doi]
AB  - BACKGROUND: Nurses have a crucial role in patient education of children with type
      1 diabetes, but they often exhibit lack of knowledge of the patient education
      process. This study aimed to describe an educational program to enhance
      empowering patient education process for the blood glucose monitoring education
      of school-age children and nurses' perceptions of using empowering techniques.
      METHODS: An empowering patient education process for the diabetes education of
      school-age children was developed. The researcher collected nurse's perceptions
      of managing the educational program by semi-structured interviews. Ten nurses
      carried out the diabetes education, and 8 of them participated in the interview. 
      Three nurses implemented the diabetes education twice and were interviewed twice.
      The data consisted of 11 descriptions of the blood glucose monitoring education. 
      The interviewer analyzed the data deductively and inductively by content
      analysis. RESULTS: Nurses described successful managing of the empowering patient
      education process. The need assessment consisted of using multiple methods and
      clarifying the capabilities and challenges of children and their parents.
      Planning manifested itself in adequate preparation and multiple objectives stated
      together with the family. Implementation comprised the relevant content, and the 
      use of suitable teaching materials and methods. Evaluation was performed with
      various methods and documented accurately. Nurses also faced some challenges
      related to management and leadership, ambivalence with traditional and empowering
      patient education, and families' overall situation. CONCLUSION: An example of
      developing evidence-based patient education program is presented, but besides
      education other factors supporting changes in work practices should be considered
      in further development.
AD  - Institute of Behavioural Sciences, University of Helsinki, Siltavuorenpenger 5 A,
      P,O, Box 9, Helsinki, 00140, Finland. marjatta.kelo@metropolia.fi.
FAU - Kelo, Marjatta
AU  - Kelo M
FAU - Eriksson, Elina
AU  - Eriksson E
FAU - Eriksson, Ilse
AU  - Eriksson I
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3654888
OID - NLM: PMC3654888
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:01
CRDT- 2013/05/07 06:00
PHST- 2012/08/17 [received]
PHST- 2013/05/02 [accepted]
PHST- 2013/05/06 [aheadofprint]
AID - 2251-6581-12-16 [pii]
AID - 10.1186/2251-6581-12-16 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 May 6;12(1):16. doi: 10.1186/2251-6581-12-16.

PMID- 23641947
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 4
TI  - Evaluation of the inhibition of carbohydrate hydrolysing enzymes, antioxidant
      activity and polyphenolic content of extracts of ten African Ficus species
      (Moraceae) used traditionally to treat diabetes.
PG  - 94
AB  - BACKGROUND: Some Ficus species have been used in traditional African medicine in 
      the treatment ofdiabetes. The antidiabetic potential of certain species has been 
      confirmed in vivo but themechanism of activity remains uncertain. The aim of this
      study was to determine the activityand to investigate the mechanism of
      antidiabetic activity of ten selected Ficus species throughinhibition of
      a-amylase and a-glucosidase activity, and the possible relationship betweenthese 
      activities, the total polyphenolic content and the antioxidant activity. METHODS:
      Dried acetone leaf extracts were reconstituted with appropriate solvents and used
      todetermine total polyphenolic content antioxidant activity, a-amylase and
      a-glucosidaseinhibitory activity. RESULTS: The crude acetone extract of F. lutea 
      had the highest polyphenolic content (56.85 +/- 1.82 mgGAE/g of dry material) and
      the strongest antioxidant activity with a TEAC value of 4.80 +/- 0.90. The
      antioxidant activity of the acetone extracts of the Ficus species may not be
      ascribedto total polyphenolic content alone. The crude extract at a concentration
      of 0.5 mg/ml of F.lutea (64.3 +/- 3.6%) had the best a-glucosidase (sucrase)
      inhibitory activity. The EC50 of F.lutea (290 +/- 111 ug/ml) was not
      significantly different from that of F. sycomorus (217 +/- 69 ug/ml). The
      a-amylase inhibitory activity of F. lutea (95.4 +/- 1.2%) at a concentration of
      1mg/ml was the highest among the Ficus species screened. The EC50 for F. lutea
      (9.42 +/- 2.01 ug/ml), though the highest, was not significantly different
      (p?0.05) from that of F.craterostoma and F. natalensis. It was apparent that the 
      crude acetone extract of F. lutea is apartially un-competitive inhibitor of
      a-amylase and a-glucosidase. Based on correlationcoefficients polyphenolics may
      be responsible for a-glucosidase activity but probably not fora-amylase activity.
      CONCLUSION: Antidiabetic activity potential via inhibition of a-amylase and
      a-glucosidase was discoveredin Ficus lutea which has not been previously
      reported. The acetone extract of the leaves washigh in total polyphenolic content
      and antioxidant activity, and was a potent inhibitor of a-amylase activity.
      Research is underway to isolate the active compound(s) responsible for
      theantidiabetic activity and to confirm the in vitro antidiabetic activity and to
      investigate in vitrotoxicity.
FAU - Olaokun, Oyinlola O
AU  - Olaokun OO
FAU - McGaw, Lyndy J
AU  - McGaw LJ
FAU - Eloff, Jacobus N
AU  - Eloff JN
FAU - Naidoo, Vinny
AU  - Naidoo V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130504
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
PMC - PMC3665600
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/10/30 [received]
PHST- 2013/05/04 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 1472-6882-13-94 [pii]
AID - 10.1186/1472-6882-13-94 [doi]
PST - aheadofprint
SO  - BMC Complement Altern Med. 2013 May 4;13(1):94.

PMID- 23641944
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1471-2156 (Electronic)
IS  - 1471-2156 (Linking)
VI  - 14
DP  - 2013
TI  - Genetic background (DDD/Sgn versus C57BL/6J) strongly influences postnatal growth
      of male mice carrying the Ay allele at the agouti locus: identification of
      quantitative trait loci associated with diabetes and body weight loss.
PG  - 35
LID - 10.1186/1471-2156-14-35 [doi]
AB  - BACKGROUND: Mice carrying the Ay allele at the agouti locus become obese and are 
      heavier than their non-Ay littermates. However, this does not hold true for the
      genetic background of the DDD mouse strain. At 22 weeks of age, DDD.Cg-Ay females
      are heavier than DDD females, whereas DDD.Cg-Ay males are lighter than DDD males.
      This study aimed to determine the possible cause and identify the genes
      responsible for the lower body weight of DDD.Cg-Ay males. RESULTS: Growth curves 
      of DDD.Cg-Ay mice were analyzed and compared with those of B6.Cg-Ay mice from 5
      to 25 weeks. In DDD.Cg-Ay males, body weight gain stopped between 16 and 17 weeks
      and the body weight gradually decreased; thus, the lower body weight was a
      consequence of body weight loss. Quantitative trait locus (QTL) mapping was
      performed in backcrossed (BC) males of DDD x (B6 x DDD.Cg-Ay) F1-Ay mice. For the
      body weight at 25 weeks, significant QTLs were identified on chromosomes 1 and 4.
      The DDD allele was associated with a lower body weight at both loci. In
      particular, the QTL on chromosome 4 interacted with the Ay allele. Furthermore,
      suggestive QTLs for plasma glucose and high molecular weight adiponectin levels
      were coincidentally mapped to chromosome 4. The DDD allele was associated with
      increased glucose and decreased adiponectin levels. When the body weight at 25
      weeks and plasma glucose levels were considered as dependent and independent
      variables, respectively, BC Ay males were classified into two groups according to
      statistical analysis using the partition method. Mice of one group had
      significantly higher glucose and lower adiponectin levels than those of the other
      group and exhibited body weight loss as observed with DDD-Ay males. CONCLUSIONS: 
      The lower body weight of DDD.Cg-Ay male mice was a consequence of body weight
      loss. Diabetes mellitus has been suggested to be a possible contributory factor
      causing body weight loss. The QTL on distal chromosome 4 contained the major
      responsible genes. This QTL interacted with the Ay allele, implying the reason
      why body weight loss occurs in DDD.Cg-Ay but not in DDD males.
AD  - Agrogenomics Research Center, National Institute of Agrobiological Sciences,
      Tsukuba, Ibaraki 305-8634, Japan. jsuto@affrc.go.jp.
FAU - Suto, Jun-Ichi
AU  - Suto J
FAU - Satou, Kunio
AU  - Satou K
LA  - eng
PT  - Journal Article
DEP - 20130504
PL  - England
TA  - BMC Genet
JT  - BMC genetics
JID - 100966978
SB  - IM
PMC - PMC3669036
OID - NLM: PMC3669036
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2012/11/16 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/04 [aheadofprint]
AID - 1471-2156-14-35 [pii]
AID - 10.1186/1471-2156-14-35 [doi]
PST - epublish
SO  - BMC Genet. 2013 May 4;14:35. doi: 10.1186/1471-2156-14-35.

PMID- 23641928
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 14
IP  - 9
DP  - 2013 Jun
TI  - Percutaneous coronary intervention with drug-eluting stents or coronary artery
      bypass surgery in subjects with type 2 diabetes.
PG  - 1269-73
LID - 10.1517/14656566.2013.796932 [doi]
AB  - There is a debate as to whether percutaneous coronary intervention (PCI) with
      drug-eluting stents or coronary artery bypass surgery (CABG) is the best
      procedure for subjects with type 2 diabetes and coronary artery disease requiring
      revascularization. There is some evidence that by following these procedures,
      there is less further revascularization with CABG than PCI in subjects with
      diabetes. Two recent studies, namely, the FREEDOM (Future Revascularization
      Evaluation in patients with Diabetes mellitus: Optimal Management of Multivessel 
      Disease) trial and a trial using a real-world diabetic population from a Registry
      have shown that the benefits of CABG over PCI in subjects with type 2 diabetes
      extend to lower rates of death and myocardial infarction, in addition to lower
      rates of revascularization. However, the rates of stroke may be higher with CABG 
      than PCI with drug-eluting stents in this population. Thus, if CABG is going to
      be preferred to PCI in subjects with type 2 diabetes and multivessel coronary
      disease, consideration should be given as to how to reduce the rates of stroke
      with CABG.
AD  - Queensland University of Technology, School of Biomedical Sciences, Faculty of
      Health , GPO 2434, QLD 4001, Brisbane , Australia +61 73 138 2015 ; +61 7 3138
      1534 ; sheila.doggrell@qut.edu.au.
FAU - Doggrell, Sheila A
AU  - Doggrell SA
LA  - eng
PT  - Journal Article
DEP - 20130506
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
SB  - IM
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PHST- 2013/05/06 [aheadofprint]
AID - 10.1517/14656566.2013.796932 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2013 Jun;14(9):1269-73. doi:
      10.1517/14656566.2013.796932. Epub 2013 May 6.

PMID- 23641567
OWN - NLM
STAT- In-Process
DA  - 20130506
IS  - 0038-0814 (Print)
IS  - 0038-0814 (Linking)
IP  - 773
DP  - 2013 Mar
TI  - [Diab'a'table, a therapeutic education programme dedicated to eating behaviour].
PG  - 19-21
AB  - A long-lasting change in eating behaviour, essential when treating patients
      suffering from type 2 diabetes, can be difficult to put in practice. In order to 
      achieve this objective, a therapeutic education programme was used with volunteer
      patients. Its encouraging results show the benefits it can offer for obese
      patients suffering from type 2 diabetes.
AD  - Unite mobile d'education therapeutique diabete de Haute Cote-d'Or, Dijon, France.
      gabrielle.invernizzi@numericable.fr
FAU - Invernizzi, Gabrielle
AU  - Invernizzi G
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Diab'a'Table, un programme d'education therapeutique centre sur le comportement
      alimentaire.
PL  - France
TA  - Soins
JT  - Soins; la revue de reference infirmiere
JID - 20910580R
SB  - N
EDAT- 2013/05/07 06:00
MHDA- 2013/05/07 06:00
CRDT- 2013/05/07 06:00
PST - ppublish
SO  - Soins. 2013 Mar;(773):19-21.

PMID- 23641453
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 0363-7913 (Print)
IS  - 0363-7913 (Linking)
VI  - 96
IP  - 4
DP  - 2013
TI  - Gestational diabetes in rhode island.
PG  - 45-8
AD  - Master's degree candidate in the Warren Alpert Medical School of Brown
      University, Program in Public Health.
FAU - Giang, Lena
AU  - Giang L
FAU - Gjelsvik, Annie
AU  - Gjelsvik A
FAU - Cain, Rachel
AU  - Cain R
FAU - Paine, Virginia
AU  - Paine V
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - United States
TA  - R I Med J (2013)
JT  - Rhode Island medical journal (2013)
JID - 101605827
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PST - epublish
SO  - R I Med J (2013). 2013 Apr 1;96(4):45-8.

PMID- 23641405
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130506
LR  - 20130506
IS  - 2251-6085 (Print)
IS  - 2251-6085 (Linking)
VI  - 42
IP  - 3
DP  - 2013
TI  - The effect of sociostructural and collaborative decision-making on diabetes
      self-management.
PG  - 280-92
AB  - BACKGROUND: Diabetic self-management is important for controlling the diabetes
      complications and promoting health-related quality of life in these patients. The
      objective of this study was to examine a hypothetical model regarding influences 
      of sociostructural determinants, collaborative decision-making and patient's
      beliefs system on diabetes self-management. METHODS: In a cross-sectional
      descriptive study from Dec 2010 to Mar 2010, 500 patients of Iranian adult
      patients with type II diabetes attended the outpatient diabetic clinics of the
      Shariati Hospital in Tehran were selected by convenience sampling. Data were
      collected by The Demographical Information, Social- Economical Status and
      Diabetic History Questionnaire and eleven self-reported scales of this research. 
      Structural equation modeling (SEM) with LIZREL software applied for data
      analysis. RESULTS: The modified model had a desirable fitness to the observed
      data. Patient's beliefs system directly influenced the diabetes self-management. 
      Sociostructural determinants influenced diabetes self-management indirectly via
      collaborative decision-making and Patient's beliefs system. In addition,
      collaborative decision-making significantly influenced patient's beliefs system
      that thereby impacted diabetes self-management. CONCLUSIONS: Sociostructural
      determinants, collaborative decision-making and patient's beliefs system are
      integrated and cooperatively affect on diabetes self-management. Comprehensive
      intervention schedules required to improve these agents for encouragement the
      type II diabetes self-management.
AD  - Dept. of Clinical Psychology, Faculty of Psychology and Educational Sciences,
      Semnan University, Semnan, Iran.
FAU - Rahimian Boogar, Isaac
AU  - Rahimian Boogar I
FAU - Mohajeri-Tehrani, Mohammad Reza
AU  - Mohajeri-Tehrani MR
FAU - Besharat, Mohammad Ali
AU  - Besharat MA
FAU - Talepasand, Seyavash
AU  - Talepasand S
LA  - eng
PT  - Journal Article
DEP - 20130301
PL  - Iran
TA  - Iran J Public Health
JT  - Iranian journal of public health
JID - 7505531
PMC - PMC3633798
OID - NLM: PMC3633798
OTO - NOTNLM
OT  - Beliefs
OT  - Decision-making
OT  - Diabetes
OT  - Motivation
OT  - Self-management
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/15 [received]
PHST- 2013/02/11 [accepted]
PHST- 2013/03/01 [epublish]
PST - epublish
SO  - Iran J Public Health. 2013 Mar 1;42(3):280-92. Print 2013.

PMID- 23641399
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130506
LR  - 20130506
IS  - 2251-6085 (Print)
IS  - 2251-6085 (Linking)
VI  - 42
IP  - 3
DP  - 2013
TI  - Prevalence and risk factors of type 2 diabetes in the adults in haikou city,
      hainan island, china.
PG  - 222-30
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) occurs around the world with high
      prevalence and causes serious physical harm and economic burden to the afflicted.
      Haikou City is China's southernmost tropical island city, which has not been
      previously studied for its T2DM prevalence. The objective of the study in
      employing a cross-sectional survey is to discuss the epidemiologic status of T2DM
      in Haikou City and to analyze the possible determinants. METHODS: A total of
      12,000 community residents over 18 years old from four districts in Haikou City
      were stratified-randomly sampled. A questionnaire survey and physical examination
      were conducted. Data entry and statistical analysis were performed using SPSS17.0
      software. RESULTS: The prevalence of T2DM in Haikou City was 5.3% (5.15% for
      males and 5.46% for females). According to the multivariate analysis, the
      positive factors mainly associated with T2DM in the city included family history,
      Waist-to-Hip Ratio (WHR), triglycerides, low high-density lipoproteins (HDL), and
      blood pressure. For both men and women, family history was the highest
      independent risk factor associated with T2DM (OR= 47.128). The T2DM risk
      increased with increasing metabolic aggregate. CONCLUSION: The prevalence of T2DM
      for the community population of Haikou City was low. The possible risk factors
      included age, occupation, BMI, waist circumference, WHR, overweight, systemic
      obesity, central obesity, systolic blood pressure, diastolic blood pressure,
      total cholesterol, triglycerides, low-density lipoproteins, family history, and
      HDL.
AD  - School of Public Health, Central South University, Changsha, Hunan, China ;
      School of Public Health, Hainan Medical College, Haikou, Hainan, China.
FAU - Xia, Zhenfang
AU  - Xia Z
FAU - Wang, Zhuansuo
AU  - Wang Z
FAU - Cai, Qunfang
AU  - Cai Q
FAU - Yang, Jianjun
AU  - Yang J
FAU - Zhang, Xuan
AU  - Zhang X
FAU - Yang, Tubao
AU  - Yang T
LA  - eng
PT  - Journal Article
DEP - 20130301
PL  - Iran
TA  - Iran J Public Health
JT  - Iranian journal of public health
JID - 7505531
PMC - PMC3633792
OID - NLM: PMC3633792
OTO - NOTNLM
OT  - Diabetes type 2
OT  - Epidemiology
OT  - Haikou
OT  - Prevalence
OT  - Risk factors
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/21 [received]
PHST- 2013/02/12 [accepted]
PHST- 2013/03/01 [epublish]
PST - epublish
SO  - Iran J Public Health. 2013 Mar 1;42(3):222-30. Print 2013.

PMID- 23641358
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Response: increasing prevalence of type 2 diabetes in a rural bangladeshi
      population: a population based study for 10 years (diabetes metab j
      2013;37:46-53).
PG  - 153-4
LID - 10.4093/dmj.2013.37.2.153 [doi]
AD  - Department of Community Medicine, Institute of Health and Society, University of 
      Oslo Faculty of Medicine, Oslo, Norway.
FAU - Bhowmik, Bishwajit
AU  - Bhowmik B
FAU - Afsana, Faria
AU  - Afsana F
FAU - My Diep, Lien
AU  - My Diep L
FAU - Binte Munir, Sanjida
AU  - Binte Munir S
FAU - Wright, Erica
AU  - Wright E
FAU - Mahmood, Sharif
AU  - Mahmood S
FAU - Khan, A K Azad
AU  - Khan AK
FAU - Hussain, Akhtar
AU  - Hussain A
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638228
OID - NLM: PMC3638228
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
AID - 10.4093/dmj.2013.37.2.153 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):153-4. doi: 10.4093/dmj.2013.37.2.153.

PMID- 23641357
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Letter: increasing prevalence of type 2 diabetes in a rural bangladeshi
      population: a population based study for 10 years (diabetes metab j
      2013;37:46-53).
PG  - 152
LID - 10.4093/dmj.2013.37.2.152 [doi]
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea 
      University College of Medicine, Seoul, Korea.
FAU - Kim, Nan Hee
AU  - Kim NH
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638227
OID - NLM: PMC3638227
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
AID - 10.4093/dmj.2013.37.2.152 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):152. doi: 10.4093/dmj.2013.37.2.152.

PMID- 23641356
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Is the indicator magnifying window for insulin pens helpful for elderly diabetic 
      patients?
PG  - 149-51
LID - 10.4093/dmj.2013.37.2.149 [doi]
AB  - Patients with type 2 diabetes who require insulin therapy are commonly elderly
      and have poor visual acuity. In this study, we examined the clinical usefulness
      of the indicator magnifying window (IMW) for elderly patients with type 2
      diabetes. We recruited 50 patients with type 2 diabetes over the age of 60 who
      had used insulin pens for glucose control. They were asked to set the insulin pen
      at randomly selected doses with or without an IMW. We assessed dosing accuracy,
      convenience, self-confidence, need for eyeglasses, preference, and willingness to
      recommend the IMW to other patients. Although the IMW did not improve the dosing 
      accuracy or convenience, it significantly decreased the need for eyeglasses.
      Overall, the clinical usefulness of the IMW is quite limited in elderly patients 
      with type 2 diabetes.
AD  - Department of Internal Medicine, Chungnam National University School of Medicine,
      Daejeon, Korea.
FAU - Lee, Ju Hee
AU  - Lee JH
FAU - Hong, Eun Shil
AU  - Hong ES
FAU - Ohn, Jung Hun
AU  - Ohn JH
FAU - Cho, Young Min
AU  - Cho YM
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638226
OID - NLM: PMC3638226
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Insulin
OT  - Insulin pen
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2012/11/15 [received]
PHST- 2013/01/02 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.4093/dmj.2013.37.2.149 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):149-51. doi: 10.4093/dmj.2013.37.2.149. Epub
      2013 Apr 16.

PMID- 23641355
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Effects of high performance inulin supplementation on glycemic control and
      antioxidant status in women with type 2 diabetes.
PG  - 140-8
LID - 10.4093/dmj.2013.37.2.140 [doi]
AB  - BACKGROUND: The purpose of this study was to evaluate the effects of high
      performance inulin supplementation on blood glycemic control and antioxidant
      status in women with type 2 diabetes. METHODS: In a randomized, triple-blind
      controlled trial, 49 females (fiber intake <30 g/day, 25<body mass index <35
      kg/m(2)) with type 2 diabetes were recruited from the Iran Diabetes Society and
      from endocrinology and metabolism clinics associated with the Tabriz University
      of Medical Science. The participants were divided into one of two groups in which
      the participants either received 10 g/day of inulin (intervention, n=24) or
      maltodextrin (control, n=25) for 2 months. Fasting blood samples were obtained
      and both glycemic control and antioxidant status were determined at baseline and 
      at the end of the study. RESULTS: At the end of the study period, there were
      significant decreases in fasting plasma glucose (8.47%), glycosylated hemoglobin 
      (10.43%), and malondialdehyde (37.21%) levels and significant increases in total 
      antioxidant capacity (18.82%) and superoxide dismutase activity (4.36%) in the
      inulin group when compared to the maltodextrin group (P<0.05). Changes in fasting
      insulin, homeostasis model assessment of insulin resistance, and catalase
      activity were not significant in the inulin group when compared with the
      maltodextrin group. Glutathione peroxidase activity remained unchanged in both
      groups. CONCLUSION: Inulin supplementation may improve some glycemic and
      antioxidant indices and decrease malondialdehyde levels in women with type 2
      diabetes. Further investigations are needed in order to confirm the positive
      effects that inulin may have on the glycemic and antioxidant indices of patients 
      with type 2 diabetes.
AD  - Department of Biochemistry and Diet Therapy, Nutrition Research Center, Tabriz
      University of Medical Sciences, Tabriz, Iran.
FAU - Pourghassem Gargari, Bahram
AU  - Pourghassem Gargari B
FAU - Dehghan, Parvin
AU  - Dehghan P
FAU - Aliasgharzadeh, Akbar
AU  - Aliasgharzadeh A
FAU - Asghari Jafar-Abadi, Mohammad
AU  - Asghari Jafar-Abadi M
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638225
OID - NLM: PMC3638225
OTO - NOTNLM
OT  - Antioxidants
OT  - Diabetes mellitus, type 2
OT  - Insulin resistance
OT  - Inulin
OT  - Malondialdehyde
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2012/09/19 [received]
PHST- 2013/01/03 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.4093/dmj.2013.37.2.140 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):140-8. doi: 10.4093/dmj.2013.37.2.140. Epub 2013
      Apr 16.

PMID- 23641354
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Low levels of physical activity are associated with increased metabolic syndrome 
      risk factors in korean adults.
PG  - 132-9
LID - 10.4093/dmj.2013.37.2.132 [doi]
AB  - BACKGROUND: Low levels of physical activity (PA) are strongly associated with the
      development of metabolic syndrome (MetS) and chronic diseases. However, few
      studies have examined this association in Koreans. The primary purpose of this
      study was to examine the associations between PA and MetS risks in Korean adults.
      METHODS: A total of 1,016 Korean adults (494 males and 522 females) participated 
      in this study. PA levels were assessed using the International PA Questionnaire. 
      MetS risk factors were determined using clinically established diagnostic
      criteria. RESULTS: Compared with the highest PA group, the group with the lowest 
      level of PA was at greater risk of high triglyceride (TG) in males (odds ratio
      [OR], 1.87; 95% confidence interval [CI], 1.07 to 3.24) and of hemoglobin A1c
      >/=5.5% in females (OR, 1.75; 95% CI, 1.00 to 3.04) after adjusting for age and
      body mass index. Compared with subjects who met the PA guidelines, those who did 
      not meet the guidelines were more likely to have low high density lipoprotein
      cholesterol in both males (OR, 1.69; 95% CI, 1.11 to 2.58), and females (OR,
      1.82; 95% CI, 1.20 to 2.77). Furthermore, those who did not meet the PA
      guidelines were at increased risk of high TG levels in males (OR, 1.69; 95% CI,
      1.23 to 2.86) and abnormal fasting glucose (OR, 1.93; 95% CI, 1.17 to 3.20) and
      MetS (OR, 2.10; 95% CI, 1.15 to 3.84) in females. CONCLUSION: Increased levels of
      PA are significantly associated with a decreased risk of abnormal MetS
      components.
AD  - Department of Sport and Leisure Studies, Yonsei University College of Sciences in
      Education, Seoul, Korea.
FAU - Lee, Dong Hoon
AU  - Lee DH
FAU - Kim, Yoon Myung
AU  - Kim YM
FAU - Jekal, Yoonsuk
AU  - Jekal Y
FAU - Park, Sukyung
AU  - Park S
FAU - Kim, Kyong-Chol
AU  - Kim KC
FAU - Naruse, Masayo
AU  - Naruse M
FAU - Kim, Sun Hyun
AU  - Kim SH
FAU - Kim, Sang-Hwan
AU  - Kim SH
FAU - Park, Ji-Hye
AU  - Park JH
FAU - Lee, Mi Kyung
AU  - Lee MK
FAU - Chu, Sang Hui
AU  - Chu SH
FAU - Jeon, Justin Y
AU  - Jeon JY
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638224
OID - NLM: PMC3638224
OTO - NOTNLM
OT  - Hemoglobin A, glycosylated
OT  - International physical activity guestionnaire
OT  - Metabolic syndrome
OT  - Physical activity
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2012/06/08 [received]
PHST- 2012/11/20 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.4093/dmj.2013.37.2.132 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):132-9. doi: 10.4093/dmj.2013.37.2.132. Epub 2013
      Apr 16.

PMID- 23641353
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - The Relationship between Metformin and Cancer in Patients with Type 2 Diabetes.
PG  - 125-31
LID - 10.4093/dmj.2013.37.2.125 [doi]
AB  - BACKGROUND: Recently, several studies reported that the cancer incidence in type 
      2 diabetes patients is higher than in the general population. Although a number
      of risks are shared between cancer and diabetes patients, there have been few
      studies of its correlation. We evaluated the influences of several factors
      including low density lipoprotein cholesterol (LDL-C), albuminuria and use of
      metformin on the risk of cancer in patients with type 2 diabetes. METHODS: We
      enrolled 1,320 patients with at least 5 years of follow-up and 73 patients were
      diagnosed with cancer during this period. The associations of the risk factors
      with cancer incidence were evaluated by multiple regression analysis. The
      subjects were placed into two subgroups based on metformin dosage (<1,000 mg/day,
      >/=1,000 mg/day) and we compared cancer incidence using analysis of covariance.
      RESULTS: LDL-C and albuminuria were not significantly correlated with cancer
      risk. In contrast, metformin showed a reverse correlation with cancer risk
      (P=0.006; relative risk, 0.574). In the metformin nonadministration group,
      smoking, male gender, and high triglyceride levels tended to be contributing
      factors without statistical significance. Cancer occurence was lower in the low
      dose metformin group (less than 1,000 mg/day) (P=0.00). CONCLUSION: These results
      suggest that the administration of low dose metformin in patients with type 2
      diabetes may be associated with a reduced risk of cancer.
AD  - Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, 
      Korea.
FAU - Chung, Hyun Hee
AU  - Chung HH
FAU - Moon, Jun Sung
AU  - Moon JS
FAU - Yoon, Ji Sung
AU  - Yoon JS
FAU - Lee, Hyoung Woo
AU  - Lee HW
FAU - Won, Kyu Chang
AU  - Won KC
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638223
OID - NLM: PMC3638223
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Metformin
OT  - Neoplasms
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2012/09/10 [received]
PHST- 2012/12/06 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.4093/dmj.2013.37.2.125 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):125-31. doi: 10.4093/dmj.2013.37.2.125. Epub
      2013 Apr 16.

PMID- 23641352
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Efficacy and safety of biphasic insulin aspart 30/70 in type 2 diabetes
      suboptimally controlled on oral antidiabetic therapy in Korea: a multicenter,
      open-label, single-arm study.
PG  - 117-24
LID - 10.4093/dmj.2013.37.2.117 [doi]
AB  - BACKGROUND: The purpose of this study was to evaluate change in glycosylated
      hemoglobin (HbA1c), side effects, and quality of life (QOL) after a 16-week
      treatment period with Biphasic insulin aspart 30/70 (BIasp30) in patients with
      type 2 diabetes mellitus (T2DM) who had been suboptimally controlled with oral
      antidiabetic drugs (OADs). METHODS: The study consisted of a 4-week titration
      period when concurrent OAD(s) were replaced with BIasp30 and followed by a
      12-week maintenance period. All patients completed the Diabetes Treatment
      Satisfaction Questionnaire at the beginning and the end of the trial.
      Hypoglycemic episodes were recorded by the patient throughout the trial. RESULTS:
      Sixty patients were included, of whom 55 patients (92%) completed the full
      16-week treatment period. Seven-point blood glucose was significantly improved as
      compared with the baseline, except for the postlunch blood glucose level. HbA1c
      at the end of period was significantly improved from 9.2% to 8.2% (P<0.001).
      Eleven percent (n=6) of patients achieved HbA1c values </=6.5% and 22% (n=12) of 
      patients achieved <7.0%. There were 3.4 episodes/patients-year of minor
      hypoglycemia and 0.05 episodes/patients-year of major hypoglycemia. QOL showed
      significant changes only in the acceptability of high blood glucose category
      (P=0.003). CONCLUSION: Treatment with once or twice daily BIasp30 may be an
      option for the patients with T2DM suboptimally controlled with OADs in Korea.
      However, considering the low number of patients achieving the HbA1c target and
      the high postlunch blood glucose levels, additional management with another
      modality may be required for optimal control.
AD  - Department of Internal Medicine, Konkuk University School of Medicine, Seoul,
      Korea.
FAU - Song, Kee-Ho
AU  - Song KH
FAU - Kim, Jung Min
AU  - Kim JM
FAU - Noh, Jung-Hyun
AU  - Noh JH
FAU - Park, Yongsoo
AU  - Park Y
FAU - Son, Hyun-Shik
AU  - Son HS
FAU - Min, Kyong Wan
AU  - Min KW
FAU - Ko, Kyung Soo
AU  - Ko KS
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638222
OID - NLM: PMC3638222
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Glycemic control
OT  - Insulin aspart, insulin aspart protamine drug combination 30:70
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2012/08/20 [received]
PHST- 2012/11/20 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.4093/dmj.2013.37.2.117 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):117-24. doi: 10.4093/dmj.2013.37.2.117. Epub
      2013 Apr 16.

PMID- 23641351
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Metformin and cancer in type 2 diabetes.
PG  - 113-6
LID - 10.4093/dmj.2013.37.2.113 [doi]
AD  - Department of Internal Medicine, Soonchunhyang University College of Medicine,
      Seoul, Korea.
FAU - Park, Hyeong Kyu
AU  - Park HK
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638221
OID - NLM: PMC3638221
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
AID - 10.4093/dmj.2013.37.2.113 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):113-6. doi: 10.4093/dmj.2013.37.2.113.

PMID- 23641350
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - A systematic review of oxidative stress and safety of antioxidants in diabetes:
      focus on islets and their defense.
PG  - 106-12
LID - 10.4093/dmj.2013.37.2.106 [doi]
AB  - A growing body of evidence suggests that hyperglycemia-induced oxidative stress
      plays an important role in diabetic complications, especially beta-cell
      dysfunction and failure. Under physiological conditions, reactive oxygen species 
      serve as second messengers that facilitate signal transduction and gene
      expression in pancreatic beta-cells. However, under pathological conditions, an
      imbalance in redox homeostasis leads to aberrant tissue damage and beta-cell
      death due to a lack of antioxidant defense systems. Taking into account the
      vulnerability of islets to oxidative damage, induction of endogenous antioxidant 
      enzymes or exogenous antioxidant administration has been proposed as a way to
      protect beta-cells against diabetic insults. Here, we consider recent insights
      into how the redox response becomes deregulated under diabetic conditions, as
      well as the therapeutic benefits of antioxidants, which may provide clues for
      developing strategies aimed at the treatment or prevention of diabetes associated
      with beta-cell failure.
AD  - Departments of Internal Medicine, Biochemistry and Cell Biology, Research
      Institute of Aging and Metabolism and World Class University Program, Kyungpook
      National University School of Medicine, Daegu, Korea.
FAU - Karunakaran, Udayakumar
AU  - Karunakaran U
FAU - Park, Keun-Gyu
AU  - Park KG
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638220
OID - NLM: PMC3638220
OTO - NOTNLM
OT  - Glucose stimulated insulin secretion
OT  - Nitric oxide
OT  - Reactive nitrogen species
OT  - Reactive oxygen species
OT  - Superoxide dismutase
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
AID - 10.4093/dmj.2013.37.2.106 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):106-12. doi: 10.4093/dmj.2013.37.2.106.

PMID- 23641349
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - Cell therapy for diabetic neuropathy using adult stem or progenitor cells.
PG  - 91-105
LID - 10.4093/dmj.2013.37.2.91 [doi]
AB  - Diabetic neuropathy (DN) is the most common and disabling complication of
      diabetes that may lead to foot ulcers and limb amputations. Despite widespread
      awareness of DN, the only effective treatments are glucose control and pain
      management. A growing body of evidence suggests that DN is characterized by
      reduction of vascularity in peripheral nerves and deficiency in neurotrophic and 
      angiogenic factors. Previous studies have tried to introduce neurotrophic or
      angiogenic factors in the form of protein or gene for therapy, but the effect was
      not significant. Recent studies have shown that bone marrow (BM)-derived stem or 
      progenitor cells have favorable effects on the repair of cardiovascular diseases.
      Since these BM-derived stem or progenitor cells contain various angiogenic and
      neurotrophic factors, these cells have been attempted for treating experimental
      DN, and turned out to be effective for reversing various manifestations of
      experimental DN. These evidences suggest that cell therapy, affecting both
      vascular and neural components, can represent a novel therapeutic option for
      treatment of clinical DN.
AD  - Division of Cardiology, Department of Medicine, Emory University School of
      Medicine, Atlanta, GA, USA.
FAU - Han, Ji Woong
AU  - Han JW
FAU - Sin, Min Young
AU  - Sin MY
FAU - Yoon, Young-Sup
AU  - Yoon YS
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638231
OID - NLM: PMC3638231
OTO - NOTNLM
OT  - Diabetic neuropathies
OT  - Stem cells
OT  - Tissue therapy
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
AID - 10.4093/dmj.2013.37.2.91 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):91-105. doi: 10.4093/dmj.2013.37.2.91.

PMID- 23641348
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130508
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 37
IP  - 2
DP  - 2013 Apr
TI  - The mechanism of white and brown adipocyte differentiation.
PG  - 85-90
LID - 10.4093/dmj.2013.37.2.85 [doi]
AB  - Obesity gives vent to many diseases such as type 2 diabetes, hypertension, and
      hyperlipidemia, being considered as the main causes of mortality and morbidity
      worldwide. The pathogenesis and pathophysiology of metabolic syndrome can well be
      understood by studying the molecular mechanisms that control the development and 
      function of adipose tissue. In human body, exist two types of adipose tissue, the
      white and the brown one, which are reported to play various roles in energy
      homeostasis. The major and most efficient storage of energy occurs in the form of
      triglycerides in white adipose tissue while brown adipose tissue actively
      participates in both basal and inducible energy consumption in the form of
      thermogenesis. Recent years have observed a rapid and greater interest towards
      developmental plasticity and therapeutic potential of stromal cells those
      isolated from adipose tissue. The adipocyte differentiation involves a couple of 
      regulators in the white or brown adipogenesis. Peroxisome proliferators-activated
      receptor-gamma actively participates in regulating carbohydrate and lipid
      metabolism, and also acts as main regulator of both white and brown adipogenesis.
      This review based on our recent research, seeks to highlight the adipocyte
      differentiation.
AD  - Division of Vascular Medicine and Epigenetics, Osaka University United Graduate
      School of Child Development, Osaka, Japan.
FAU - Nakagami, Hironori
AU  - Nakagami H
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
PMC - PMC3638230
OID - NLM: PMC3638230
OTO - NOTNLM
OT  - Adipogenesis
OT  - Adipose tissue, brown
OT  - Genes, homeobox
OT  - Obesity
OT  - miR-196a
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
AID - 10.4093/dmj.2013.37.2.85 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2013 Apr;37(2):85-90. doi: 10.4093/dmj.2013.37.2.85.

PMID- 23641341
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130506
LR  - 20130506
IS  - 0036-8709 (Print)
IS  - 0036-8709 (Linking)
VI  - 81
IP  - 1
DP  - 2013 Mar
TI  - Inhibition of key digestive enzymes related to diabetes and hyperlipidemia and
      protection of liver-kidney functions by trigonelline in diabetic rats.
PG  - 233-46
LID - 10.3797/scipharm.1211-14 [doi]
AB  - Diabetes is a serious health problem and a source of risk for numerous severe
      complications such as obesity and hypertension. Treatment of diabetes and its
      related diseases can be achieved by inhibiting key digestive enzymes related to
      starch and lipid digestion. The findings revealed that the administration of
      trigonelline to surviving diabetic rats helped to protect the pancreas beta-cells
      from death and damage. Additionally, the supplement of trigonelline to surviving 
      diabetic rats significantly decreased intestinal alpha-amylase and maltase by 36 
      and 52%, respectively, which led to a significant decrease in the blood glucose
      rate by 46%. Moreover, the administration of trigonelline to surviving diabetic
      rats potentially inhibited key enzymes of lipid metabolism and absorption such as
      lipase activity in the small intestine by 56%, which led to a notable decrease in
      serum triglyceride (TG) and total cholesterol (TC) rates and an increase in the
      HDL cholesterol level. This treatment also improved glucose, maltase, starch, and
      lipid oral tolerance. Trigonelline was also observed to protect the liver-kidney 
      functions efficiently, which was evidenced by the significant decrease in the
      serum aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl
      transpeptidase (GGT), and lactate dehydrogenase (LDH) activities and creatinine, 
      albumin, and urea rates. The histological analysis of the pancreas, liver, and
      kidney tissues further established the positive effect of trigonelline. Overall, 
      the findings presented in this study demonstrate that the administration of
      trigonelline to diabetic rats can make it a potentially strong candidate for
      industrial application as a pharmacological agent for the treatment of
      hyperglycemia, hyperlipidemia, and liver-kidney dysfunctions.
AD  - Biotechnology High School of Sfax (ISBS),University of Sfax, Soukra Km 45; PO Box
      261, Sfax 3038, Tunisia.
FAU - Hamden, Khaled
AU  - Hamden K
FAU - Mnafgui, Kais
AU  - Mnafgui K
FAU - Amri, Zahra
AU  - Amri Z
FAU - Aloulou, Ahmed
AU  - Aloulou A
FAU - Elfeki, Abdelfattah
AU  - Elfeki A
LA  - eng
PT  - Journal Article
DEP - 20121220
PL  - Austria
TA  - Sci Pharm
JT  - Scientia pharmaceutica
JID - 0026251
PMC - PMC3617660
OID - NLM: PMC3617660
OTO - NOTNLM
OT  - Diabetes
OT  - Digestive enzymes
OT  - Lipase
OT  - Pancreas
OT  - Trigonelline
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2013/03 [ppublish]
PHST- 2012/11/19 [received]
PHST- 2012/12/20 [accepted]
PHST- 2012/12/20 [epublish]
AID - 10.3797/scipharm.1211-14 [doi]
AID - scipharm-2013-81-233 [pii]
PST - ppublish
SO  - Sci Pharm. 2013 Mar;81(1):233-46. doi: 10.3797/scipharm.1211-14. Epub 2012 Dec
      20.

PMID- 23641235
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130506
LR  - 20130506
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 4
DP  - 2013
TI  - Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A
      Timely Challenge Illustrated with GLP-1R and GPER.
PG  - 50
LID - 10.3389/fendo.2013.00050 [doi]
AB  - G protein-coupled receptors (GPCRs) constitute a large family of receptors that
      sense molecules outside the cell and activate inside signal transduction pathways
      and cellular responses. GPCR are involved in a wide variety of physiological
      processes, including in the neuroendocrine system. GPCR are also involved in many
      diseases and are the target of 30% of marketed medicinal drugs. Whereas the
      majority of the GPCR-targeting drugs have proved their therapeutic benefit, some 
      of them were associated with undesired effects. We develop two examples of used
      drugs whose therapeutic benefits are tarnished by carcinogenesis risks. The
      chronic administration of glucagon-like peptide-1 (GLP-1) analogs widely used to 
      treat type-2 diabetes was associated with an increased risk of pancreatic or
      thyroid cancers. The long-term treatment with the estrogen antagonist tamoxifen, 
      developed to target breast cancer overexpressing estrogen receptors ER, presents 
      agonist activity on the G protein-coupled estrogen receptor which is associated
      with an increased incidence of endometrial cancer and breast cancer resistance to
      hormonotherapy. We point out and discuss the need of pharmacological studies to
      understand and overcome the undesired effects associated with the chronic
      administration of GPCR ligands. In fact, biological effects triggered by GPCR
      often result from the activation of multiple intracellular signaling pathways.
      Deciphering which signaling networks are engaged following GPCR activation
      appears to be primordial to unveil their contribution in the physiological and
      physiopathological processes. The development of biased agonists to elucidate the
      role of the different signaling mechanisms mediated by GPCR activation will allow
      the generation of new therapeutic agents with improved efficacy and reduced side 
      effects. In this regard, the identification of GLP-1R biased ligands promoting
      insulin secretion without inducing pro-tumoral effects would offer therapeutic
      benefit.
AD  - Universite de Toulouse, Universite Paul Sabatier Toulouse, France.
FAU - Gigoux, Veronique
AU  - Gigoux V
FAU - Fourmy, Daniel
AU  - Fourmy D
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC3638125
OID - NLM: PMC3638125
OTO - NOTNLM
OT  - G protein
OT  - GLP-1
OT  - adverse effects
OT  - arrestin
OT  - biased ligands
OT  - cancer
OT  - estrogen
OT  - receptor
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/11 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/04/29 [epublish]
AID - 10.3389/fendo.2013.00050 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2013 Apr 29;4:50. doi: 10.3389/fendo.2013.00050.
      Print 2013.

PMID- 23641149
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130503
DCOM- 20130506
LR  - 20130506
IS  - 1177-5467 (Print)
IS  - 1177-5467 (Linking)
VI  - 7
DP  - 2013
TI  - Retinal vascular tortuosity in obstructive sleep apnea.
PG  - 787-92
LID - 10.2147/OPTH.S41795 [doi]
AB  - PURPOSE: Endothelial dysfunction and vascular disease are common in obstructive
      sleep apnea (OSA). We sought to examine the retinal vascular manifestations of
      OSA. METHODS: Nine consecutive patients with OSA underwent ophthalmic examination
      regardless of any ocular complaints. Seven patients without OSA matched for
      demographics were used as controls. Fundus photographs from both eyes were used
      to quantitate retinal vascular tortuosity of the temporal arterial and venous
      arcades using ImageJ digital analysis software. The tortuosity of each vessel
      from the optic disc rim to the crossing point of a 5 disc diameter (5DD) circle
      and 10 disc diameter (10DD) circle centered on the optic disc were quantitated.
      RESULTS: The mean age of patients with OSA in the study was 52 years +/- SD of 10
      years and 67 years +/- SD of 10 years in the control group. The apnea-hypopnea
      index in patients with OSA ranged from 12 to 102 events/hr of sleep. The nadir
      saturation during sleep in patients with OSA ranged from 60% to 87%. There was no
      significant difference in the frequency of diabetes or hypertension between the
      groups. Total tortuosity was increased at the 5DD (P = 0.011) and 10DD (P =
      0.004) marks. Arterial tortuosity was significantly increased at the 10DD mark (P
      = 0.016). Venular tortuosity was increased at both the 5DD (P = 0.001) and 10DD
      (P = 0.028) marks. CONCLUSION: Patients with OSA have increased retinal vascular 
      tortuosity as compared to matched controls. Increased tortuosity of the retinal
      vasculature may be a novel association with OSA. A larger prospective study will 
      be necessary to further explore this relationship and its clinical significance.
AD  - epartment of Ophthalmology and Visual Science, Yale University School of
      Medicine, New Haven, Connecticut, USA.
FAU - Mohsenin, Amir
AU  - Mohsenin A
FAU - Mohsenin, Vahid
AU  - Mohsenin V
FAU - Adelman, Ron A
AU  - Adelman RA
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC3639720
OID - NLM: PMC3639720
OTO - NOTNLM
OT  - retinal vascular tortuosity
OT  - retinal vasculature
OT  - retinal vessel tortuosity
OT  - sleep apnea
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:01
CRDT- 2013/05/04 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/26 [epublish]
AID - 10.2147/OPTH.S41795 [doi]
AID - opth-7-787 [pii]
PST - ppublish
SO  - Clin Ophthalmol. 2013;7:787-92. doi: 10.2147/OPTH.S41795. Epub 2013 Apr 26.

PMID- 23641048
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Diabetes control in older people.
PG  - f2836
LID - 10.1136/bmj.f2836 [doi]
LID - bmj.f2836 [pii]
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PST - epublish
SO  - BMJ. 2013 May 2;346:f2836. doi: 10.1136/bmj.f2836.

PMID- 23641033
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Derivation and validation of QStroke score for predicting risk of ischaemic
      stroke in primary care and comparison with other risk scores: a prospective open 
      cohort study.
PG  - f2573
LID - 10.1136/bmj.f2573 [doi]
LID - bmj.f2573 [pii]
AB  - OBJECTIVE: To develop and validate a risk algorithm (QStroke) to estimate risk of
      stroke or transient ischaemic attack in patients without prior stroke or
      transient ischaemic attack at baseline; to compare (a) QStroke with CHADS2 and
      CHA2DS2VASc scores in patients with atrial fibrillation and (b) the performance
      of QStroke with the Framingham stroke score in the full population free of stroke
      or transient ischaemic attack. DESIGN: Prospective open cohort study using
      routinely collected data from general practice during the study period 1 January 
      1998 to 1 August 2012. SETTING: 451 general practices in England and Wales
      contributing to the national QResearch database to develop the algorithm and 225 
      different QResearch practices to validate the algorithm. PARTICIPANTS: 3.5
      million patients aged 25-84 years with 24.8 million person years in the
      derivation cohort who experienced 77 578 stroke events. For the validation
      cohort, we identified 1.9 million patients aged 25-84 years with 12.7 million
      person years who experienced 38 404 stroke events. We excluded patients with a
      prior diagnosis of stroke or transient ischaemic attack and those prescribed oral
      anticoagulants at study entry. MAIN OUTCOME MEASURES: Incident diagnosis of
      stroke or transient ischaemic attack recorded in general practice records or
      linked death certificates during follow-up. RISK FACTORS: Self assigned
      ethnicity, age, sex, smoking status, systolic blood pressure, ratio of total
      serum cholesterol to high density lipoprotein cholesterol concentrations, body
      mass index, family history of coronary heart disease in first degree relative
      under 60 years, Townsend deprivation score, treated hypertension, type 1
      diabetes, type 2 diabetes, renal disease, rheumatoid arthritis, coronary heart
      disease, congestive cardiac failure, valvular heart disease, and atrial
      fibrillation RESULTS: The QStroke algorithm explained 57% of the variation in
      women and 55% in men without a prior stroke. The D statistic for QStroke was 2.4 
      in women and 2.3 in men. QStroke had improved performance on all measures of
      discrimination and calibration compared with the Framingham score in patients
      without a prior stroke. Among patients with atrial fibrillation, levels of
      discrimination were lower, but QStroke had some improved performance on all
      measures of discrimination compared with CHADS2 and CHA2DS2VASc. CONCLUSION:
      QStroke provides a valid measure of absolute stroke risk in the general
      population of patients free of stroke or transient ischaemic attack as shown by
      its performance in a separate validation cohort. QStroke also shows some
      improvement on current risk scoring methods, CHADS2 and CHA2DS2VASc, for the
      subset of patients with atrial fibrillation for whom anticoagulation may be
      required. Further research is needed to evaluate the cost effectiveness of using 
      these algorithms in primary care.
AD  - Division of Primary Care, University Park, Nottingham NG2 7RD, UK.
FAU - Hippisley-Cox, Julia
AU  - Hippisley-Cox J
FAU - Coupland, Carol
AU  - Coupland C
FAU - Brindle, Peter
AU  - Brindle P
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
PMC - PMC3641809
OID - NLM: PMC3641809
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PST - epublish
SO  - BMJ. 2013 May 2;346:f2573. doi: 10.1136/bmj.f2573.

PMID- 23641007
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
DP  - 2013 May 13
TI  - Diabetes and vascular disease: pathophysiology, clinical consequences, and
      medical therapy: part I.
AB  - Hyperglycemia and insulin resistance are key players in the development of
      atherosclerosis and its complications. A large body of evidence suggest that
      metabolic abnormalities cause overproduction of reactive oxygen species (ROS). In
      turn, ROS, via endothelial dysfunction and inflammation, play a major role in
      precipitating diabetic vascular disease. A better understanding of ROS-generating
      pathways may provide the basis to develop novel therapeutic strategies against
      vascular complications in this setting. Part I of this review will focus on the
      most current advances in the pathophysiological mechanisms of vascular disease:
      (i) emerging role of endothelium in obesity-induced insulin resistance; (ii)
      hyperglycemia-dependent microRNAs deregulation and impairment of vascular repair 
      capacities; (iii) alterations of coagulation, platelet reactivity, and
      microparticle release; (iv) epigenetic-driven transcription of ROS-generating and
      proinflammatory genes. Taken together these novel insights point to the
      development of mechanism-based therapeutic strategies as a promising option to
      prevent cardiovascular complications in diabetes.
AD  - Cardiology and Cardiovascular Research, University of Zurich, Zurich,
      Switzerland.
FAU - Paneni, Francesco
AU  - Paneni F
FAU - Beckman, Joshua A
AU  - Beckman JA
FAU - Creager, Mark A
AU  - Creager MA
FAU - Cosentino, Francesco
AU  - Cosentino F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130513
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
OTO - NOTNLM
OT  - Diabetes
OT  - Pathophysiology
OT  - Vascular disease
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/02 [aheadofprint]
AID - eht149 [pii]
AID - 10.1093/eurheartj/eht149 [doi]
PST - aheadofprint
SO  - Eur Heart J. 2013 May 13.

PMID- 23640969
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 2
TI  - Genetic Variation in NR1H4 Encoding the Bile Acid Receptor FXR Determines Fasting
      Glucose and Free Fatty Acid Levels in Humans.
AB  - Context:Bile acid signaling via farnesoid X receptor (FXR) regulates glucose and 
      lipid levels, fat mass, and hepatic steatosis in animal models.Objective:To
      understand the role of FXR in human metabolism, we investigated associations of
      common single-nucleotide polymorphisms (SNPs) in the FXR-encoding gene NR1H4 with
      glucose and lipid metabolism, body fat mass, and liver fat content.Design:We
      genotyped 2166 healthy German subjects for 7 tagging SNPs within NR1H4 (rs35735, 
      rs1030454, rs11110415, rs11610264, rs17030285, rs4764980, and rs11110390)
      covering 100% of a common genetic variation (minor allele frequency >
      10%).Outcome Measures:Subjects were metabolically characterized by an oral
      glucose tolerance test. In subgroups, hyperinsulinemic-euglycemic clamp and liver
      fat quantification by 1H-magnetic resonance spectroscopy were
      performed.Results:SNP rs4764980 was significantly associated with fasting
      glycemia (P = .0043) and nominally associated with fasting and postglucose load
      free fatty acid (FFA) levels (P = .01). Upon interrogation of publicly available 
      Meta-Analyses of Glucose and Insulin-related traits Consortium data, the
      association of rs4764980 with fasting glycemia was replicated (Meta-Analyses of
      Glucose and Insulin-related traits Consortium, P = .005). Additionally, SNP
      rs11110390 showed significant associations with fasting (P = .0054) and postload 
      (P = .0051) FFA levels. For none of the investigated SNPs, the associations with 
      insulin secretion or sensitivity, body fat mass, or liver fat content were
      detected.Conclusions:We conclude that FXR contributes to fasting glucose and FFA 
      levels in humans independent of unhealthy body fat accumulation. The receptor
      represents an interesting target to influence lipid and glucose metabolism.
AD  - Department of Internal Medicine (M.H., R.W., C.K., A.B., K.L., A.M.H., N.S.,
      H.-U.H., A.F., H.S.), Division of Endocrinology, Diabetology, Angiology,
      Nephrology, and Clinical Chemistry, and Section on Experimental Radiology (J.M., 
      F.S.), Department of Diagnostic and Interventional Radiology, University
      Hospital, Eberhard Karls University Tubingen, D-72016 Tubingen, Germany; German
      Center for Diabetes Research (M.H., R.W., C.K., A.B., K.L., F.M., J.M., F.S.,
      A.M.H., N.S., H.-U.H., A.F., H.S.), D-85764 Neuherberg, Germany; and Institute
      for Diabetes Research and Metabolic Diseases (C.K., A.B., K.L., F.M., J.M., F.S.,
      A.M.H., N.S., H.-U.H., A.F., H.S.), Helmholtz Center Munich at the University of 
      Tubingen, Tubingen, Germany; 4) Eberhard Karls University Tubingen, D-72074
      Tubingen, Germany.
FAU - Heni, Martin
AU  - Heni M
FAU - Wagner, Robert
AU  - Wagner R
FAU - Ketterer, Caroline
AU  - Ketterer C
FAU - Buhm, Anja
AU  - Buhm A
FAU - Linder, Katarzyna
AU  - Linder K
FAU - Machicao, Fausto
AU  - Machicao F
FAU - Machann, Jurgen
AU  - Machann J
FAU - Schick, Fritz
AU  - Schick F
FAU - Hennige, Anita M
AU  - Hennige AM
FAU - Stefan, Norbert
AU  - Stefan N
FAU - Haring, Hans-Ulrich
AU  - Haring HU
FAU - Fritsche, Andreas
AU  - Fritsche A
FAU - Staiger, Harald
AU  - Staiger H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - jc.2013-1177 [pii]
AID - 10.1210/jc.2013-1177 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 2.

PMID- 23640967
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 May 2
TI  - Two Novel Functional Single Nucleotide Polymorphisms of ADRB3 Are Associated With
      Type 2 Diabetes in the Chinese Population.
AB  - Aims:The purpose of this study was to investigate the association of two novel
      beta3-adrenergic receptor (ADRB3) gene polymorphisms (Ser165Pro and Ser257Pro)
      with type 2 diabetes (T2DM) in the Chinese population. Methods:A total of 650
      patients with T2DM and 1337 health volunteers were enrolled to conduct the
      association study. Two candidate polymorphisms were recreated by site-directed
      mutagenesis and tested for their effect on ADRB3 expression and function in
      stable transfected human embryonic kidney 293 and Chinese hamster ovary-K1 cells.
      Real-time PCR, Western blot, confocal microscopy, and cAMP assay were used to
      determine mRNA, protein expression, trafficking, and ADRB3 function,
      respectively. Results:We found that both polymorphisms were significantly
      associated with T2DM (odds ratio = 2.060 and 95% confidence interval =
      1.303-3.258 for Ser165Pro and odds ratio = 7.588, 95% confidence interval =
      1.639-35.138 for Ser257Pro). Patients with T2DM with the Ser165Pro C allele had
      higher hemoglobin A1c, fasting plasma glucose and postprandial plasma glucose
      values than those in TT genotypes. We also found that patients with T2DM with the
      Ser257Pro C allele had lower fasting serum insulin, postprandial serum insulin,
      and homeostasis model assessment for insulin resistance levels than TT genotype
      carriers. Further in vitro study indicated that cell lines stably expressing
      Ser165Pro and Ser257Pro mutants of the ADRB3 gene showed impaired cAMP
      accumulation activity. However, both polymorphisms had no effect on ADRB3
      expression and trafficking. Conclusions:Ser165Pro and Ser257Pro polymorphisms
      affected ADRB3 function and were significantly associated with susceptibility to 
      and development of T2DM.
AD  - Institute of Clinical Pharmacology (Q.H., Y.-S.Z., X.-P.C., J.C., H.-H.Z.,
      J.-Y.Y., Z.-Q.L.), Hunan Key Laboratory of Pharmacogenetics, Xiangya School of
      Medicine, Central South University, Changsha, Hunan 410078, People's Republic of 
      China; Institute of Clinical Pharmacology (Q.H., W.W.), Key Laboratory of
      Antiinflammatory and Immune Medicine, Ministry of Education, Anhui Medical
      University, Hefei, Anhui 230032, People's Republic of China; Institutes of
      Hypertension (T.-L.Y.) and Integrated Traditional Chinese and Western Medicine
      (X.H.) and Departments of Neurology (B.-S.T.) and Dermatology (X.C.), Xiangya
      Hospital, Central South University, Changsha, Hunan 410008, People's Republic of 
      China; Institute of Endocrinology and Metabolism (X.-H.L.), The Second Xiangya
      Hospital of Central South University, Changsha, Hunan 410011, People's Republic
      of China; and Department of Epidemiology and Biostatistics (P.-C.H.), School of
      Public Health, Xiangya School of Medicine, Central South University, Changsha,
      Hunan 410078, People's Republic of China.
FAU - Huang, Qiong
AU  - Huang Q
FAU - Yang, Tian-Lun
AU  - Yang TL
FAU - Tang, Bei-Sha
AU  - Tang BS
FAU - Chen, Xiang
AU  - Chen X
FAU - Huang, Xi
AU  - Huang X
FAU - Luo, Xiang-Hang
AU  - Luo XH
FAU - Zhu, Yuan-Shan
AU  - Zhu YS
FAU - Chen, Xiao-Ping
AU  - Chen XP
FAU - Hu, Ping-Cheng
AU  - Hu PC
FAU - Chen, Juan
AU  - Chen J
FAU - Wei, Wei
AU  - Wei W
FAU - Zhou, Hong-Hao
AU  - Zhou HH
FAU - Yin, Ji-Ye
AU  - Yin JY
FAU - Liu, Zhao-Qian
AU  - Liu ZQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - jc.2013-1137 [pii]
AID - 10.1210/jc.2013-1137 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 May 2.

PMID- 23640951
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1898-4002 (Electronic)
IS  - 1896-1126 (Linking)
DP  - 2013 May 1
TI  - Plasma vascular endothelial growth factor and angiogenin are positively related
      to erythropoietin dose in hemodialysis patients.
PG  - 64-70
LID - 10.2478/v10039-012-0071-1 [doi]
LID - /j/ams.ahead-of-print/v10039-012-0071-1/v10039-012-0071-1.xml [pii]
AB  - ABSTRACT Purpose: Experimental data confirmed that erythropoietin (EPO)
      administration alters the course of various pathological situations such as heart
      failure and tumor growth by inducing vascular endothelial growth factor-A
      (VEGF-A) expression. The effect of EPO dose on plasma VEGF-A level in
      hemodialysis (HD) patients was evaluated. The effect of EPO dose on plasma
      angiogenin level in HD patients was also evaluated, since angiogenin is necessary
      for angiogenesis induced by VEGF-A. Methods: Thirty two HD patients (10
      diabetics) enrolled into the study. Patients were iron replete and did not suffer
      from infections, autoimmune diseases or malignancies. Plasma VEGF-A and
      angiogenin, as well as serum interleukin-6 and tumor necrosis factor-alpha were
      measured by means of ELISA. Results: Weekly EPO dose per kg of dry body weight
      was positively related to both VEGF-A and angiogenin, whereas no relation was
      detected among VEGF-A or angiogenin and hemoglobin, inflammation or presence of
      diabetes mellitus. These relations among EPO dose and VEGF-A or angiogenin
      remained after adjustment for hemoglobin concentration or inflammation or
      presence of diabetes mellitus. Conclusions: EPO dose may affect plasma VEGF-A and
      angiogenin concentrations in HD patients.
FAU - Eleftheriadis, Theodoros
AU  - Eleftheriadis T
FAU - Antoniadi, G
AU  - Antoniadi G
FAU - Liakopoulos, V
AU  - Liakopoulos V
FAU - Pissas, G
AU  - Pissas G
FAU - Galaktidou, G
AU  - Galaktidou G
FAU - Stefanidis, I
AU  - Stefanidis I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Adv Med Sci
JT  - Advances in medical sciences
JID - 101276222
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.2478/v10039-012-0071-1 [doi]
AID - /j/ams.ahead-of-print/v10039-012-0071-1/v10039-012-0071-1.xml [pii]
PST - aheadofprint
SO  - Adv Med Sci. 2013 May 1:64-70. doi: 10.2478/v10039-012-0071-1.

PMID- 23640946
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1898-4002 (Electronic)
IS  - 1896-1126 (Linking)
DP  - 2013 May 1
TI  - Comparative efficacy of exenatide versus insulin glargine on glycemic control in 
      type 2 diabetes mellitus patients inadequately treated with metformin
      monotherapy.
PG  - 30-35
LID - 10.2478/v10039-012-0078-7 [doi]
LID - /j/ams.ahead-of-print/v10039-012-0078-7/v10039-012-0078-7.xml [pii]
AB  - Abstract Purpose: Comparative efficacy of exenatide versus insulin glargine
      primarily on glucemic control, and secondarily on body mass index (BMI), lipid
      profile and blood pressure, in type 2 diabetes mellitus (T2DM) patients
      suboptimally treated with metformin monotherapy. Material/Methods: Forty-seven
      inadequately treated T2DM patients on metformin assigned to exenatide (n=18) or
      insulin glargine (n=29) for 26 weeks. Glycosylated hemoglobin (HbA1c), serum
      lipids, BMI, systolic and diastolic blood pressure, and adverse events, including
      episodes of hypoglycemia and gastrointestinal symptoms, were recorded. Results:
      Either treatment had a similar favorable mean reduction in HbA1c. However, more
      patients in exenatide group achieved HbA1c </= 7% at the 26th week compared with 
      insulin glargine group (p=0.036). Insulin glargine group had significantly more
      episodes of hypoglycemia compared with exenatide group (p=0.039).
      Gastrointestinal adverse events were non-significantly higher in the exenatide
      group. A significantly greater BMI reduction was observed in exenatide group,
      whereas BetaMuIota was not altered in insulin glargine group. Total and LDL
      cholesterol (p=0.012), and triglycerides (p=0.016) significantly decreased,
      whereas HDL cholesterol increased (p=0.021) in the exenatide group, whereas only 
      total cholesterol decreased in insulin glargine group. Changes in systolic and
      diastolic blood pressure were insignificant in both groups. Conclusions:
      Exenatide provided similar reduction in HbA1c, but fewer episodes of
      hypoglycemia, compared with insulin glargine. Exenatide had also a favorable
      effect on weight loss, although more gastrointestinal adverse events. Exenatide
      may provide a justified alternative in second line treatment of T2DM, but more
      trials are required to elucidate its long-term safety and cost-effectiveness.
FAU - Karagianni, Panagiota
AU  - Karagianni P
FAU - Polyzos, S A
AU  - Polyzos SA
FAU - Kartali, N
AU  - Kartali N
FAU - Zografou, J
AU  - Zografou J
FAU - Sambanis, Ch
AU  - Sambanis C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Adv Med Sci
JT  - Advances in medical sciences
JID - 101276222
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.2478/v10039-012-0078-7 [doi]
AID - /j/ams.ahead-of-print/v10039-012-0078-7/v10039-012-0078-7.xml [pii]
PST - aheadofprint
SO  - Adv Med Sci. 2013 May 1:30-35. doi: 10.2478/v10039-012-0078-7.

PMID- 23640926
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 0032-373X (Print)
IS  - 0032-373X (Linking)
VI  - 85
IP  - 4
DP  - 2013 Apr 1
TI  - Treatment possibilities of reverse-flow sural flap in covering the defects of
      lower extremities.
PG  - 192-7
LID - 10.2478/pjs-2013-0029 [doi]
LID - /j/pjs.2013.85.issue-4/pjs-2013-0029/pjs-2013-0029.xml [pii]
AB  - Soft tissue defects of the lower extremity pose an important surgical challenge, 
      often because of inviability of primary covering. Therapeutic modalities of
      choice comprise of local perforator flaps, as well as of free flaps created with 
      the use of microsurgical skills. However, these methods cannot be applied in
      patients with important comorbidities, and it is in such cases where the reverse 
      sural flap proves to be the best solution. The aim of the study was to present
      the results of treating lower extremity defects with various modifications of the
      reverse sural flap. Material and methods. Sixteen patients, males aged 17-56
      years, were operated on from 2007 to 2013. Diabetes with multiple complications, 
      disseminated atheromatosis, and extensive soft tissue trauma involving the
      arteries crucial for microsurgica anastomoses were the most common reason
      disqualifying from the free and perforator-based flap techniques. Results. All of
      the patients achieved very good results; in two cases distal and marginal flap
      necrosis was observed which, once exiced, covered with granulation, and was
      successfully covered with a partialthickness skin graft. Conclusions. The reverse
      sural flap, technically easy, offers a viable, low-risk alternative to free and
      perforator-based flaps.
FAU - Elsaftawy, Ahmed
AU  - Elsaftawy A
FAU - Jablecki, Jerzy
AU  - Jablecki J
FAU - Domanasiewicz, Adam
AU  - Domanasiewicz A
FAU - Paruzel, Maciej
AU  - Paruzel M
FAU - Kaczmarzyk, Janusz
AU  - Kaczmarzyk J
FAU - Kaczmarzyk, Leszek
AU  - Kaczmarzyk L
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Pol Przegl Chir
JT  - Polski przeglad chirurgiczny
JID - 0376426
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.2478/pjs-2013-0029 [doi]
AID - /j/pjs.2013.85.issue-4/pjs-2013-0029/pjs-2013-0029.xml [pii]
PST - ppublish
SO  - Pol Przegl Chir. 2013 Apr 1;85(4):192-7. doi: 10.2478/pjs-2013-0029.

PMID- 23640887
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 May 2
TI  - Activation of Asparaginyl Endopeptidase Leads to Tau Hyperphosphorylation in
      Alzheimer's Disease.
AB  - Neurofibrillary pathology of abnormally hyperphosphorylated tau is a key lesion
      of Alzheimer's disease and other tauopathies and its density in the brain
      directly correlates with dementia. The phosphorylation of tau is regulated by
      protein phosphatase -2A, which in turn is regulated by inhibitor-2, I2PP2A. In
      acidic conditions such as generated by brain ischemia and hypoxia, especially in 
      association with hyperglycemia as in diabetes, I2PP2A is cleaved by asparaginyl
      endopeptidase at N175 into N-terminal fragment (I2NTF) and C-terminal fragment
      (I2CTF). Both I2NTF and I2CTF are known to bind to the catalytic subunit of
      protein phosphatase-2A and inhibit its activity. Here we show that the level of
      activated asparaginyl endopeptidase is significantly increased, and this enzyme
      and I2PP2A translocate, respectively, from neuronal lysosomes and nucleus to the 
      cytoplasm where they interact and are associated with hyperphosphorylated tau in 
      Alzheimer's disease brain. Asparaginyl endopeptidase from Alzheimer's disease
      brain could cleave GST-I2PP2A except when I2PP2A was mutated at the cleavage site
      N 175 to Q. Finally, an induction of acidosis by treatment with kainic acid or pH
      6.0 medium activated asparaginyl endopeptidase and consequently produced the
      cleavage of I2PP2A, inhibition of protein phosphatase-2A, and
      hyperphosphorylation of tau, and the knockdown of asparaginyl endopeptidase with 
      siRNA abolished this pathway in SH-SY5Y cells. These findings suggest the
      involvement of brain acidosis in the etiopathogenesis of Alzheimer's disease, and
      asparaginyl endopeptidase-I2PP2A-protein phosphatase-2A-tau hyperphosphorylation 
      pathway as a therapeutic target.
AD  - New York State Institute for Basic Research in Developmental Disabilities, United
      States.
FAU - Basurto-Islas, Gustavo
AU  - Basurto-Islas G
FAU - Grundke-Iqbal, Inge
AU  - Grundke-Iqbal I
FAU - Tung, Yunn Chyn
AU  - Tung YC
FAU - Liu, Fei
AU  - Liu F
FAU - Iqbal, Khalid
AU  - Iqbal K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Acidosis
OT  - Alzheimers disease
OT  - I2PP2A
OT  - Lysosomes
OT  - PP2A
OT  - SET
OT  - Tau
OT  - legumain
OT  - tau hyperphosphorylation
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - M112.446070 [pii]
AID - 10.1074/jbc.M112.446070 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 May 2.

PMID- 23640882
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 May 2
TI  - Protein-Tyrosine Phosphatase 1B Regulates Pyruvate Kinase M2 Tyrosine
      Phosphorylation.
AB  - Protein-tyrosine phosphatase 1B (PTP1B) is a physiological regulator of glucose
      homeostasis and adiposity and is a drug target for the treatment of obesity and
      diabetes. Herein, we identify pyruvate kinase M2 (PKM2) as a novel PTP1B
      substrate in adipocytes. PTP1B deficiency leads to increased PKM2 total tyrosine 
      and Tyr105 phosphorylation in cultured adipocytes and in vivo. Substrate-trapping
      and mutagenesis studies identify PKM2 Tyr105 and Tyr148 as key sites that mediate
      PTP1B-PKM2 interaction. In addition, in vitro analyses illustrate a direct effect
      of Tyr105 phosphorylation on PKM2 activity in adipocytes. Importantly, PTP1B
      pharmacological inhibition increased PKM2 Tyr105 phosphorylation and decreased
      PKM2 activity. Moreover, PKM2 Tyr105 phosphorylation is nutritionally regulated, 
      decreasing in adipose tissue depots after high fat feeding. Further, decreased
      PKM2 Tyr105 phosphorylation correlates with the development of glucose
      intolerance and insulin resistance in rodents, non-human primates and humans.
      Together, these findings identify PKM2 as a novel substrate of PTP1B, and provide
      new insights into the regulation of adipose PKM2 activity.
AD  - University of California Davis, United States;
FAU - Bettaieb, Ahmed
AU  - Bettaieb A
FAU - Bakke, Jesse
AU  - Bakke J
FAU - Nagata, Naoto
AU  - Nagata N
FAU - Matsuo, Kosuke
AU  - Matsuo K
FAU - Xi, Yannan
AU  - Xi Y
FAU - Liu, Siming
AU  - Liu S
FAU - Aboubechara, Daniel
AU  - Aboubechara D
FAU - Melhem, Ramzi
AU  - Melhem R
FAU - Stanhope, Kimber
AU  - Stanhope K
FAU - Cummings, Bethany
AU  - Cummings B
FAU - Graham, James
AU  - Graham J
FAU - Bremer, Andrew
AU  - Bremer A
FAU - Zhang, Sheng
AU  - Zhang S
FAU - Lyssiotis, Costas A
AU  - Lyssiotis CA
FAU - Zhang, Zhong-Yin
AU  - Zhang ZY
FAU - Cantley, Lewis C
AU  - Cantley LC
FAU - Havel, Peter J
AU  - Havel PJ
FAU - Haj, Fawaz G
AU  - Haj FG
LA  - ENG
GR  - R01 DK090492/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
OTO - NOTNLM
OT  - Adipocyte
OT  - Diabetes
OT  - Metabolism
OT  - Pyruvate kinase
OT  - Signal transduction
OT  - Tyrosine protein phosphatase (Tyrosine phosphatase)
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - M112.441469 [pii]
AID - 10.1074/jbc.M112.441469 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 May 2.

PMID- 23640826
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 44
IP  - 6
DP  - 2013 Jun
TI  - Cardiovascular risk profile and cognitive function in young, middle-aged, and
      elderly subjects.
PG  - 1543-9
LID - 10.1161/STROKEAHA.111.000496 [doi]
AB  - BACKGROUND AND PURPOSE: Cognitive decline occurs earlier than previously realized
      and is already evident at the age of 45. Because cardiovascular risk factors are 
      established risk factors for cognitive decline in old age, we investigated
      whether cardiovascular risk factors are also associated with cognitive decline in
      young and middle-aged groups. METHODS: The cross-sectional study included 3778
      participants aged 35 to 82 years (mean age, 54 years) and free of cardiovascular 
      disease and stroke. Cognitive function was measured with the Ruff Figural Fluency
      Test (RFFT; worst score, 0; best score, 175 points) and the Visual Association
      Test (VAT; worst score, 0; best score, 12 points). Overall cardiovascular risk
      was assessed with the Framingham Risk Score (FRS) for general cardiovascular
      disease (best score, -5; worst score, 33 points). RESULTS: Mean RFFT score (SD)
      was 70 (26) points, median VAT score (interquartile range) was 10 (9-11) points, 
      and mean FRS (SD) was 10 (6) points. Using linear regression analysis adjusting
      for educational level, RFFT was negatively associated with FRS. RFFT score
      decreased by 1.54 points (95% confidence interval, -1.66 to -1.44; P<0.001) per
      point increase in FRS. This negative association was not only limited to older
      age groups, but also found in the young (35-44 years). The main influencing
      components of the FRS were age (P<0.001), diabetes mellitus (P=0.001), and
      smoking (P<0.001). Similar results were found for VAT score as outcome measure.
      CONCLUSIONS: In this large population-based cohort, a worse overall
      cardiovascular risk profile was associated with poorer cognitive function. This
      association was already present in young adults aged 35 to 44 years.
AD  - University Medical Center Groningen, University of Groningen, P.O. Box 30.001,
      9700 RB, The Netherlands. j.m.h.joosten@umcg.nl.
FAU - Joosten, Hanneke
AU  - Joosten H
FAU - van Eersel, Marlise E A
AU  - van Eersel ME
FAU - Gansevoort, Ron T
AU  - Gansevoort RT
FAU - Bilo, Henk J G
AU  - Bilo HJ
FAU - Slaets, Joris P J
AU  - Slaets JP
FAU - Izaks, Gerbrand J
AU  - Izaks GJ
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - Stroke
JT  - Stroke; a journal of cerebral circulation
JID - 0235266
SB  - IM
OTO - NOTNLM
OT  - amnesia
OT  - cardiovascular disease
OT  - cross-sectional analysis
OT  - executive function
OT  - risk assessment
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/02 [aheadofprint]
AID - STROKEAHA.111.000496 [pii]
AID - 10.1161/STROKEAHA.111.000496 [doi]
PST - ppublish
SO  - Stroke. 2013 Jun;44(6):1543-9. doi: 10.1161/STROKEAHA.111.000496. Epub 2013 May
      2.

PMID- 23640805
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1862-8354 (Electronic)
IS  - 1862-8346 (Linking)
DP  - 2013 May 3
TI  - O-GlcNAcomics - Revealing Roles of O-GlcNAcylation in Disease Mechanisms and
      Development of Potential Diagnostics.
LID - 10.1002/prca.201300001 [doi]
AB  - O-linked-beta-N-acetylglucosamine (O-GlcNAc) is a dynamic post-translational
      modification of the 3'-hydroxyl groups of serine or threonine residues of
      nuclear, cytoplasmic, and mitochondrial proteins. The cycling of this
      modification is regulated in response to nutrients, stress, and other
      extracellular stimuli by the catalytic activities of O-GlcNAc transferase and
      O-GlcNAcase. O-GlcNAc is functionally similar to phosphorylation and has been
      demonstrated to play critical roles in numerous biological processes, including
      cell signaling, transcription, and disease etiology. Since its discovery nearly
      thirty years ago, studies have demonstrated that the O-GlcNAc is highly abundant 
      and widespread, like phosphorylation however, the development of methodologies to
      study O-GlcNAc at the site level has been challenging. Recently, a number of
      studies have overcome these challenges and describe new tagging, enrichment, and 
      mass spectrometric-based approaches to study O-GlcNAc in terms of its site
      identification, stoichiometry, and dynamics on proteins. The development of these
      methods are key for elucidation of O-GlcNAc's functional crosstalk with
      phosphorylation and other PTMs, and will serve to provide the necessary
      information for the development of site-specific antibodies, which will aid in
      the determination of a particular protein's site specific function. In this
      review, we describe these methods and summarize results obtained from them
      demonstrating the roles of O-GlcNAc in diabetes, cancer, Alzheimer's, and in
      learning and memory, while also describing how these new strategies have
      implicated O-GlcNAc as a potential diagnostic for the screening of patients for
      prediabetes. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Biological Chemistry, The Johns Hopkins University, School of
      Medicine, 725 North Wolfe Street, Baltimore, MD, 21205-2185.
FAU - Copeland, Ronald J
AU  - Copeland RJ
FAU - Han, Guanghui
AU  - Han G
FAU - Hart, Gerald W
AU  - Hart GW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Proteomics Clin Appl
JT  - Proteomics. Clinical applications
JID - 101298608
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/01/02 [received]
PHST- 2013/01/02 [revised]
PHST- 2013/01/17 [accepted]
AID - 10.1002/prca.201300001 [doi]
PST - aheadofprint
SO  - Proteomics Clin Appl. 2013 May 3. doi: 10.1002/prca.201300001.

PMID- 23640796
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1096-9861 (Electronic)
IS  - 0021-9967 (Linking)
DP  - 2013 May 3
TI  - Distinct glutamatergic and GABAergic subsets of hypothalamic proopiomelanocortin 
      neurons revealed by in situ hybridization in male rats and mice.
LID - 10.1002/cne.23350 [doi]
AB  - Proopiomelanocortin (POMC) and agouti-related protein (AGRP) neurons in the
      hypothalamus regulate various aspects of energy homeostasis and metabolism. POMC 
      and AGRP neurons, respectively, agonize and antagonize melanocortin receptors on 
      their common downstream neurons. However, it is unknown whether they also
      reciprocally stimulate and inhibit the same neurons by amino acid transmitters.
      While AGRP neurons are mostly GABAergic, surprisingly, only a small population of
      POMC neurons has been found to be glutamatergic, and a significantly larger
      subpopulation to be GABAergic. To further examine amino acid phenotypes of POMC
      neurons, we studied mRNA expression for the glutamatergic marker, type 2
      vesicular glutamate transporter (VGLUT2), and the GABA synthetic enzyme, GAD67,
      in POMC neurons of both rats and mice using in situ hybridization techniques. In 
      rats, approximately 58% of POMC neurons were labeled for VGLUT2 and 37% for GAD67
      mRNA. In mice, approximately 43% of POMC neurons contained VGLUT2, and 54%
      contained GAD67 mRNA. In both species, a prominent medio-lateral distribution
      pattern was observed at rostral and mid levels of the POMC cell group with
      VGLUT2-POMC neurons dominating in lateral portions and GAD67-POMC neurons in
      medial portions. These data demonstrate that both glutamatergic and GABAergic
      cells are present in comparably significant numbers among POMC neurons. Their
      glutamatergic or GABAergic phenotype may represent a major functional division
      within the POMC cell group. J. Comp. Neurol., 2013. (c) 2013 Wiley Periodicals,
      Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc., A Wiley Company.
AD  - Department of Medicine, Division of Endocrinology, Diabetes and Metabolism,
      Tupper Research Institute, Tufts Medical Center, Boston, MA 02111, USA.
FAU - Wittmann, Gabor
AU  - Wittmann G
FAU - Hrabovszky, Erik
AU  - Hrabovszky E
FAU - Lechan, Ronald M
AU  - Lechan RM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - J Comp Neurol
JT  - The Journal of comparative neurology
JID - 0406041
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/11/23 [received]
PHST- 2013/04/07 [revised]
PHST- 2013/04/25 [accepted]
AID - 10.1002/cne.23350 [doi]
PST - aheadofprint
SO  - J Comp Neurol. 2013 May 3. doi: 10.1002/cne.23350.

PMID- 23640708
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 Apr 30
TI  - Ang(1-7) treatment attenuates beta-cell dysfunction by improving pancreatic
      microcirculation in a rat model of type 2 diabetes.
AB  - Aims: Pancreatic microcirculation plays a pivotal role in the physiological
      function and survival of beta cells. Ang(1-7) is a novel component of the RAS
      that has beneficial effects on microcirculation. In the present study, we
      investigated the effects of systemic Ang(1-7) administration (with or without its
      receptor Mas antagonist A-779) on pancreatic microcirculation and beta-cell
      function. Methods: These effects were studied in vivo using a rat model of type 2
      diabetes. Pancreatic microcirculation and islet microvessel density were
      measured; and beta-cell function, insulin content and the apoptosis of islet
      cells were assessed, respectively. Additionally, we evaluated endothelial nitric 
      oxide synthase (eNOS) expression and nitric oxide (NO) concentration in islets.
      Results: After Ang(1-7) intervention, pancreatic microcirculation and intra-islet
      microvessel density were significantly improved (P<0.05), and more importantly,
      first-phase insulin secretion of beta cells as well as relative insulin content
      in islets were increased, and the amount of apoptotic islet cells was decreased
      (P<0.05). And eNOS expression and NO release were up-regulated in pancreatic
      islets by Ang(1-7) administration (P<0.05). These positive effects of Ang(1-7)
      were prevented by the addition of A-779 (P<0.05). Conclusions: Our findings
      suggest that systemic Ang(1-7) treatment could attenuate beta-cell dysfunction
      and ameliorate islet cell apoptosis in type 2 diabetic rats by improving
      pancreatic microcirculation, which perhaps through the mechanism of endothelial
      vasodilation.
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College of HuaZhong
      Science & Technology University, 1277 Jiefang Road, Wuhan430022, China.
FAU - Yuan, Li
AU  - Yuan L
FAU - Li, Yang
AU  - Li Y
FAU - Li, Guangli
AU  - Li G
FAU - Song, Yonghua
AU  - Song Y
FAU - Gong, Xun
AU  - Gong X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 8951 [pii]
AID - 10.3275/8951 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 Apr 30.

PMID- 23640692
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1573-6881 (Electronic)
IS  - 0145-479X (Linking)
DP  - 2013 May 3
TI  - Long-term administration of rosuvastatin prevents contractile and electrical
      remodelling of diabetic rat heart.
AB  - In recent years, many findings have been presented about the potential benefit of
      statin therapy on diabetes-induced cardiovascular complications. Cardioprotective
      effects of statins were suggested to be mediated at least in part through
      inhibition of small GTPases, particularly those of the Rho family. The present
      study was designed to examine whether rosuvastatin can improve electrical
      remodeling and contractile dysfunction in type 1 diabetic rat heart via
      modulation of RhoA pathway. Type 1 diabetes was induced by single dose injection 
      of STZ (50 mg/kg). One week after injection rosuvastatin (10 mg/kg/day) and sham 
      treatment was given for 5 weeks in the diabetic rats, as well as in control
      groups. Shortening and Ca2+ transients were recorded in myocytes loaded with
      Fura2-AM. Membrane currents and Ca2+ transients were measured synchronously via
      whole-cell patch clamping. In untreated diabetic rats, relaxation of shortening
      and decay of the matched Ca2+ transients were prolonged. Fractional shortening
      and Ca2+ transients were also decreased. Rosuvastatin treatment reversed those
      changes. ICaL density did not change in either group but rosuvastatin recovered
      the loss of sarcoplasmic reticulum Ca2+ and Na+/Ca2+ exchange as evidenced from
      amplitude and decay of caffeine-induced Ca2+ transients, peak INCX and calculated
      sarcoplasmic reticulum Ca2+ content. Diabetes-induced attenuation of Ito and Isus
      was also reversed, whilst IK1 was unchanged in diabetes and unaffected by
      treatment. Rosuvastatin prevented the diabetes-induced increase in RhoA
      expression. Plasma cholesterol and triglyceride levels were higher in diabetic
      rats, but rosuvastatin reduced only the latter. In conclusion, HMG-CoA reductase 
      inhibitor rosuvastatin can prevent diabetes-induced electrical and functional
      remodeling of heart due to inhibition of RhoA signalling rather than reduction of
      cholesterol level.
AD  - Department of Biophysics, Akdeniz University Faculty of Medicine, Antalya,
      Turkey.
FAU - Ozturk, Nihal
AU  - Ozturk N
FAU - Yaras, Nazmi
AU  - Yaras N
FAU - Ozmen, Asli
AU  - Ozmen A
FAU - Ozdemir, Semir
AU  - Ozdemir S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - J Bioenerg Biomembr
JT  - Journal of bioenergetics and biomembranes
JID - 7701859
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/01/29 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - 10.1007/s10863-013-9514-z [doi]
PST - aheadofprint
SO  - J Bioenerg Biomembr. 2013 May 3.

PMID- 23640687
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 73
IP  - 8
DP  - 2013 Jun
TI  - Drug-induced macular edema.
PG  - 789-802
LID - 10.1007/s40265-013-0055-x [doi]
AB  - Macular edema constitutes a serious pathologic entity of ophthalmology resulting 
      in vision loss with a remarkable impact on the quality of life of patients. It is
      the final common pathway of various systemic diseases and underlying intraocular 
      conditions, with diabetes mellitus being the most frequent cause. Other causes
      include venous occlusive disease, intraocular surgery, and inflammatory
      conditions of the posterior segment of the eye. Macular edema is a recognized
      side effect of various systemic and local medications and requires special
      consideration among ophthalmologists and other clinicians. Recently, antidiabetic
      thiazolidinediones have been implicated in the development of macular edema, and 
      a review of the English literature revealed that other systemically administered 
      drugs like fingolimod, recently approved for relapsing forms of multiple
      sclerosis, the anticancer agents tamoxifen and the taxanes, as well as niacin and
      interferons have been reported to cause macular edema. Ophthalmologic
      pharmaceutical agents, like prostaglandin analogs, epinephrine, timolol, and
      ophthalmic preparation preservatives have also been reported to cause macular
      edema as an adverse event. The purpose of this article is to provide a short,
      balanced overview of the available evidence in this regard. The available data
      and the possible pathophysiologic mechanisms leading to the development of
      macular edema are discussed. Possible therapeutic strategies for drug-induced
      macular edema are also proposed.
AD  - Department of Ophthalmology, Medical School, University of Patras, Rio, 26504,
      Patras, Greece.
FAU - Makri, Olga E
AU  - Makri OE
FAU - Georgalas, Ilias
AU  - Georgalas I
FAU - Georgakopoulos, Constantine D
AU  - Georgakopoulos CD
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.1007/s40265-013-0055-x [doi]
PST - ppublish
SO  - Drugs. 2013 Jun;73(8):789-802. doi: 10.1007/s40265-013-0055-x.

PMID- 23640666
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 100
IP  - 7
DP  - 2013 Jun
TI  - Lymphangiogenesis in abdominal aortic aneurysm.
PG  - 895-903
LID - 10.1002/bjs.9128 [doi]
AB  - BACKGROUND: Ongoing angiogenesis is implicated in the inflammatory environment
      that characterizes abdominal aortic aneurysm (AAA). Although lymphangiogenesis
      has been associated with chronic inflammatory conditions, it has yet to be
      demonstrated in AAA. The aim was to determine the presence of lymphangiogenesis
      and to delineate the relationship between inflammation and neovascularization in 
      AAA tissue. METHODS: AAA samples and preoperative computed tomography images were
      obtained from patients undergoing elective AAA repair. Control samples were
      age-matched abdominal aortic tissue. Specific immunostains for blood vessels
      (CD31, CD105), lymphatic vessels (D2-40), vascular endothelial growth factor
      (VEGF) A and VEGF receptor (VEGFR) 3 allowed characterization and quantitation of
      vasculature. RESULTS: The AAA wall contained high levels of inflammatory
      infiltrate; microvascular densities of blood (P < 0.001) and lymphatic (P =
      0.003) vessels were significantly increased in AAA samples compared with
      controls. Maximal AAA vascularity was observed in inflammatory areas, with
      vessels that stained positively for CD31 (rho = 0.625, P = 0.017), CD105 (rho =
      0.692, P = 0.009) and D2-40 (rho = 0.675, P = 0.008) correlating positively with 
      the extent of inflammation. Increased VEGFR-3 and VEGF-A expression was also
      evident within inflammatory AAA areas. CONCLUSION: These findings demonstrated
      lymphatic vessel involvement in end-stage AAA disease, which was associated with 
      the degree of inflammation, and confirmed the involvement of neovascularization.
CI  - (c) 2013 British Journal of Surgery Society Ltd. Published by John Wiley & Sons
      Ltd.
AD  - Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics,
      Health and Therapeutics, and Multidisciplinary Cardiovascular Research Centre,
      University of Leeds, Leeds, UK.
FAU - Scott, D J A
AU  - Scott DJ
FAU - Allen, C J
AU  - Allen CJ
FAU - Honstvet, C A
AU  - Honstvet CA
FAU - Hanby, A M
AU  - Hanby AM
FAU - Hammond, C
AU  - Hammond C
FAU - Johnson, A B
AU  - Johnson AB
FAU - Perry, S L
AU  - Perry SL
FAU - Jones, P F
AU  - Jones PF
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - AIM
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/02/14 [accepted]
AID - 10.1002/bjs.9128 [doi]
PST - ppublish
SO  - Br J Surg. 2013 Jun;100(7):895-903. doi: 10.1002/bjs.9128.

PMID- 23640647
OWN - NLM
STAT- In-Process
DA  - 20130503
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 24
IP  - 3
DP  - 2013 May
TI  - Fate of patients during the first year of dialysis.
PG  - 605-9
AB  - Care in dialysis is often associated with significant morbidity and mortality
      during the first year. Knowledge of its magnitude and causes could improve the
      prognosis of these patients. The aim of this study was to evaluate the survival
      and morbidity during the first year of dialysis for patients who initiated their 
      dialysis between January 1, 2009 and December 31, 2009 and to study their
      possible correlation with baseline status at the beginning of treatment. A
      multi-center retrospective study was conducted in 11 dialysis centers. Clinical
      data at the beginning of dialysis and during the following year were collected.
      Mortality and morbidity risk factors were assessed by comparing different groups.
      Statistical analysis was performed with SPSS version 11. This study involved 134 
      patients, 79 men and 55 women, of whom 132 were on hemodialysis and two patients 
      were on peritoneal dialysis. The mean age at initiation of treatment was 54.37
      +/- 18.09 years. Initial causes of nephropathy were dominated by diabetes
      (44.02%) and hypertension (11.19%). Among these patients, 39.55% had never
      received prior nephrological follow-up and 64.92% had started renal replacement
      therapy on an emergency basis. The initial clinical state was dominated by the
      presence of hypertension (50.74%), diabetes (44.02%), coronary insufficiency
      (13.43%) and heart failure (7.46%). Only 26.86% of the incident patients showed
      no comorbidity. During the first year of follow-up, 37.31% of the patients
      experienced at least one episode of comorbidity. Hospitalization was necessary in
      about half of these cases (17.91% of all patients). The overall mortality rate
      was 14.17%. One patient received a kidney transplant. The mortality rate in the
      first year of dialysis was lower in our study than in other series. Regular
      nephrological follow-up of these patients before they reach end-stage could have 
      a significant influence on survival in dialysis.
AD  - Department of Nephrology, Ibn Rochd University Hospital Center, Casablanca,
      Morocco.
FAU - El Khayat, Selma Siham
AU  - El Khayat SS
FAU - Hallal, Karima
AU  - Hallal K
FAU - Gharbi, Mohamed Benghanem
AU  - Gharbi MB
FAU - Ramdani, Benyounes
AU  - Ramdani B
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - SaudiJKidneyDisTranspl_2013_24_3_605_111085 [pii]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2013 May;24(3):605-9.

PMID- 23640644
OWN - NLM
STAT- In-Process
DA  - 20130503
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 24
IP  - 3
DP  - 2013 May
TI  - Another face of type-1 diabetes.
PG  - 598-9
FAU - Gude, Dilip
AU  - Gude D
FAU - Chennemsetty, Sashidhar
AU  - Chennemsetty S
FAU - Narayan, Girish
AU  - Narayan G
FAU - Jha, Ratan
AU  - Jha R
LA  - eng
PT  - Comment
PT  - Letter
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
SB  - IM
CON - Saudi J Kidney Dis Transpl. 2010 May;21(3):526-30. PMID: 20427883
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - SaudiJKidneyDisTranspl_2013_24_3_598_111081 [pii]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2013 May;24(3):598-9.

PMID- 23640638
OWN - NLM
STAT- In-Process
DA  - 20130503
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 24
IP  - 3
DP  - 2013 May
TI  - Morbidity and mortality in Tunisian patients with post-transplant diabetes
      mellitus.
PG  - 583-6
FAU - Ali, Insaf Hadj
AU  - Ali IH
FAU - Abderrahim, Ezzeddine
AU  - Abderrahim E
FAU - Barbouch, Samia
AU  - Barbouch S
FAU - Abdelghani, Khaoula Ben
AU  - Abdelghani KB
FAU - Khiari, Karima
AU  - Khiari K
FAU - M'chirgui, Nadia
AU  - M'chirgui N
FAU - Romdhane, Nahla
AU  - Romdhane N
FAU - Abdallah, Nejib Ben
AU  - Abdallah NB
FAU - Abdallah, Taieb Ben
AU  - Abdallah TB
FAU - Kheder, Adel
AU  - Kheder A
LA  - eng
PT  - Letter
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - SaudiJKidneyDisTranspl_2013_24_3_583_111073 [pii]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2013 May;24(3):583-6.

PMID- 23640625
OWN - NLM
STAT- In-Process
DA  - 20130503
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 24
IP  - 3
DP  - 2013 May
TI  - Dialysis for acute kidney injury associated with influenza a (H1N1) infection.
PG  - 527-33
AB  - In June 2009, the World Health Organization declared a novel influenza A, S-OIV
      (H1N1), pandemic. We observed 44 consecutive patients during the "first wave" of 
      the pandemic. 70.5% of them showed co-morbidities (hypertension, obesity, chronic
      respiratory diseases, chronic renal disease, diabetes, pregnancy). Serious cases 
      were admitted to the intensive care unit (ICU), particularly those with severe
      acute respiratory failure. Some of them developed acute kidney injury (AKI) and
      required renal replacement therapy (RRT). The average time between admission to
      the ICU and initiation of RRT was 3.16 +/- 2.6 days. At initiation of RRT, most
      patients required mechanical ventilation. No relationship was found with
      creatinine-kinase levels. Seventy-five percent of the cases were observed during 
      a 3-week period and mortality, related to respiratory failure, doubling of
      alanine amino transferase and use of inotropics was 81.8%. In conclusion, the
      H1N1-infected patients who developed RRT-requiring AKI, in the context of
      multi-organ failure, showed a high mortality rate. Thus, it is mandatory that
      elaborate strategies aimed at anticipating potential renal complications
      associated to future pandemics are implemented.
AD  - Nephrology and Kidney Transplant Unit, Argerich Hospital, Junin City, Buenos
      Aires Province, Argentina. acvallejos@gmail.com
FAU - Vallejos, Augusto
AU  - Vallejos A
FAU - Arias, Marcelo
AU  - Arias M
FAU - Cusumano, Ana
AU  - Cusumano A
FAU - Coste, Eduardo
AU  - Coste E
FAU - Simon, Miguel
AU  - Simon M
FAU - Martinez, Ricardo
AU  - Martinez R
FAU - Mendez, Sandra
AU  - Mendez S
FAU - Rano, Miguel
AU  - Rano M
FAU - Sintado, Luis
AU  - Sintado L
FAU - Lococo, Bruno
AU  - Lococo B
FAU - Blanco, Carlos
AU  - Blanco C
FAU - Cestari, Jorge
AU  - Cestari J
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - SaudiJKidneyDisTranspl_2013_24_3_527_111045 [pii]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2013 May;24(3):527-33.

PMID- 23640623
OWN - NLM
STAT- In-Process
DA  - 20130503
IS  - 1319-2442 (Print)
IS  - 1319-2442 (Linking)
VI  - 24
IP  - 3
DP  - 2013 May
TI  - Quality of life and sleep in hemodialysis patients.
PG  - 514-8
AB  - The purpose of this study was to determine the quality of life and sleep of
      chronic hemodialysis (HD) patients. Quality of sleep was measured using the
      Pittsburgh Sleep Quality Index (PSQI) and quality of life (QoL) was measured
      using the Medical Outcomes Study 36-item Short Form (SF-36) in 115 HD patients.
      One hundred (87%) patients were "poor sleepers" (global PSQI >/=5). The SF-36
      mental component summary and physical component summary (PCS) scores were higher 
      than 50 only in 43% and 32% of the subjects, respectively. No significant
      differences were found in QoL and sleep according to the patient's gender,
      presence of diabetes and time on HD. Correlation between total SF-36 score and
      global PSQI was statistically significant (r = -0.227, P <0.05). Poor sleep is
      common in dialysis patients and is associated with lower QoL, especially with
      mental health component of life quality.
AD  - Department of Internal Medicine, Arak Medical Sciences University, Arak, Iran.
      mahedalat@arakmu.ac.ir
FAU - Edalat-Nejad, Mahnaz
AU  - Edalat-Nejad M
FAU - Qlich-Khani, Mehdi
AU  - Qlich-Khani M
LA  - eng
PT  - Journal Article
PL  - Saudi Arabia
TA  - Saudi J Kidney Dis Transpl
JT  - Saudi journal of kidney diseases and transplantation : an official publication of
      the Saudi Center for Organ Transplantation, Saudi Arabia
JID - 9436968
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - SaudiJKidneyDisTranspl_2013_24_3_514_111031 [pii]
PST - ppublish
SO  - Saudi J Kidney Dis Transpl. 2013 May;24(3):514-8.

PMID- 23640562
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 0971-5916 (Print)
IS  - 0971-5916 (Linking)
VI  - 137
IP  - 3
DP  - 2013 Mar
TI  - Ellagic acid & gallic acid from Lagerstroemia speciosa L. inhibit HIV-1 infection
      through inhibition of HIV-1 protease & reverse transcriptase activity.
PG  - 540-8
AB  - Background & objectives: Banaba (Lagerstroemia speciosa L.) extracts have been
      used as traditional medicines and are effective in controlling diabetes and
      obesity. The aim of this study was to evaluate the anti-HIV property of the
      extracts prepared from the leaves and stems of banaba, and further purification
      and characterization of the active components. Methods: Aqueous and 50 per cent
      ethanolic extracts were prepared from leaves and stems of banaba and were
      evaluated for cytotoxicity and anti-HIV activity using in vitro reporter gene
      based assays. Further, three compounds were isolated from the 50 per cent
      ethanolic extract of banaba leaves using silica gel column chromatography and
      characterization done by HPLC, NMR and MS analysis. To delineate the mode of
      action of the active compounds, reverse transcriptase assay and protease assay
      were performed using commercially available kits. Results: All the extracts
      showed a dose dependent inhibition of HIV-1-infection in TZM-bl and CEM-GFP cell 
      lines with a maximum from the 50 per cent ethanolic extract from leaves (IC 50 = 
      1 to 25 mug/ml). This observation was confirmed by the virus load (p24)
      estimation in infected CEM-GFP cells when treated with the extracts. Gallic acid 
      showed an inhibition in reverse transcriptase whereas ellagic acid inhibited the 
      HIV-1 protease activity. Interpretation & conclusions: The present study shows a 
      novel anti-HIV activity of banaba. The active components responsible for anti-HIV
      activity were gallic acid and ellagic acid, through inhibition of reverse
      transcriptase and HIV protease, respectively and hence could be regarded as
      promising candidates for the development of topical anti-HIV-1 agents.
AD  - Reproductive Cell Biology Laboratory, National Institute of Immunology, New
      Delhi, India.
CN  - Nutan
FAU - Modi, Manoj
AU  - Modi M
FAU - Goel, Tanvi
AU  - Goel T
FAU - Das, Tiyasa
AU  - Das T
FAU - Malik, Shweta
AU  - Malik S
FAU - Suri, Samiksha
AU  - Suri S
FAU - Rawat, Ajay Kumar Singh
AU  - Rawat AK
FAU - Srivastava, Sharad Kumar
AU  - Srivastava SK
FAU - Tuli, Rakesh
AU  - Tuli R
FAU - Malhotra, Swadesh
AU  - Malhotra S
FAU - Gupta, Satish Kumar
AU  - Gupta SK
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - IndianJMedRes_2013_137_3_540_111020 [pii]
PST - ppublish
SO  - Indian J Med Res. 2013 Mar;137(3):540-8.

PMID- 23640486
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
DP  - 2013 May 2
TI  - Impaired Lipoprotein Processing in HIV Patients on Antiretroviral Therapy:
      Aberrant High-Density Lipoprotein Lipids, Stability, and Function.
AB  - OBJECTIVE: HIV patients on antiretroviral therapy (HIV/ART) exhibit a unique
      atherogenic dyslipidemic profile with hypertriglyceridemia (HTG) and low plasma
      concentrations of high-density lipoprotein (HDL) cholesterol. In the Heart
      Positive Study of HIV/ART patients, a hypolipidemic therapy of fenofibrate,
      niacin, diet, and exercise reduced HTG and plasma non-HDL cholesterol
      concentrations and raised plasma HDL cholesterol and adiponectin concentrations. 
      We tested the hypothesis that HIV/ART HDL have abnormal structures and properties
      and are dysfunctional. APPROACH AND RESULTS: Hypolipidemic therapy reduced the TG
      contents of low-density lipoprotein and HDL. At baseline, HIV/ART low-density
      lipoproteins were more triglyceride (TG)-rich and HDL were more TG- and
      cholesteryl ester-rich than the corresponding lipoproteins from normolipidemic
      (NL) subjects. Very-low-density lipoproteins, low-density lipoprotein, and HDL
      were larger than the corresponding lipoproteins from NL subjects; HIV/ART HDL
      were less stable than NL HDL. HDL-[3H]cholesteryl ester uptake by Huh7
      hepatocytes was used to assess HDL functionality. HIV/ART plasma were found to
      contain significantly less competitive inhibition activity for hepatocyte
      HDL-cholesteryl ester uptake than NL plasma were found to contain (P<0.001).
      CONCLUSIONS: Compared with NL subjects, lipoproteins from HIV/ART patients are
      larger and more neutral lipid-rich, and their HDL are less stable and less
      receptor-competent. On the basis of this work and previous studies of lipase
      activity in HIV, we present a model in which plasma lipolytic activities or
      hepatic cholesteryl ester uptake are impaired in HIV/ART patients. These findings
      provide a rationale to determine whether the distinctive lipoprotein structure,
      properties, and function of HIV/ART HDL predict atherosclerosis as assessed by
      carotid artery intimal medial thickness.
AD  - From the Section of Atherosclerosis and Vascular Medicine (B.K.G., J.L.R.,
      H.J.P.) and Diabetes Research Center, Division of Diabetes, Endocrinology, and
      Metabolism, Department of Medicine (R.R.-E., D.I., I.C., A.B.), Baylor College of
      Medicine, Houston, TX; and Atherosclerosis & Lipoprotein Research, The Methodist 
      Hospital Research Institute, Houston, TX (B.K.G., H.J.P.).
FAU - Gillard, Baiba K
AU  - Gillard BK
FAU - Raya, Joe L
AU  - Raya JL
FAU - Ruiz-Esponda, Raul
AU  - Ruiz-Esponda R
FAU - Iyer, Dinakar
AU  - Iyer D
FAU - Coraza, Ivonne
AU  - Coraza I
FAU - Balasubramanyam, Ashok
AU  - Balasubramanyam A
FAU - Pownall, Henry J
AU  - Pownall HJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
OTO - NOTNLM
OT  - HIV dyslipidemia
OT  - hepatocyte cholesteryl ester uptake
OT  - high-density lipoprotein function
OT  - lipoprotein composition
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - ATVBAHA.113.301538 [pii]
AID - 10.1161/ATVBAHA.113.301538 [doi]
PST - aheadofprint
SO  - Arterioscler Thromb Vasc Biol. 2013 May 2.

PMID- 23640454
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 2041-4889 (Electronic)
VI  - 4
DP  - 2013
TI  - Exenatide promotes cognitive enhancement and positive brain metabolic changes in 
      PS1-KI mice but has no effects in 3xTg-AD animals.
PG  - e612
LID - 10.1038/cddis.2013.139 [doi]
AB  - Recent studies have shown that type 2 diabetes mellitus (T2DM) is a risk factor
      for cognitive dysfunction or dementia. Insulin resistance is often associated
      with T2DM and can induce defective insulin signaling in the central nervous
      system as well as increase the risk of cognitive impairment in the elderly.
      Glucagone like peptide-1 (GLP-1) is an incretin hormone and, like GLP-1 analogs, 
      stimulates insulin secretion and has been employed in the treatment of T2DM.
      GLP-1 and GLP-1 analogs also enhance synaptic plasticity and counteract cognitive
      deficits in mouse models of neuronal dysfunction and/or degeneration. In this
      study, we investigated the potential neuroprotective effects of long-term
      treatment with exenatide, a GLP-1 analog, in two animal models of neuronal
      dysfunction: the PS1-KI and 3xTg-AD mice. We found that exenatide promoted
      beneficial effects on short- and long-term memory performances in PS1-KI but not 
      in 3xTg-AD animals. In PS1-KI mice, the drug increased brain lactate
      dehydrogenase activity leading to a net increase in lactate levels, while no
      effects were observed on mitochondrial respiration. On the contrary, exenatide
      had no effects on brain metabolism of 3xTg-AD mice. In summary, our data indicate
      that exenatide improves cognition in PS1-KI mice, an effect likely driven by
      increasing the brain anaerobic glycolysis rate.
AD  - 1] Molecular Neurology Unit, Center of Excellence on Aging (CeSI), University Gd 
      Annunzio Chieti-Pescara, Chieti, Italy [2] Department of Neuroscience and
      Imaging, University Gd Annunzio, Chieti, Italy.
FAU - Bomba, M
AU  - Bomba M
FAU - Ciavardelli, D
AU  - Ciavardelli D
FAU - Silvestri, E
AU  - Silvestri E
FAU - Canzoniero, L Mt
AU  - Canzoniero LM
FAU - Lattanzio, R
AU  - Lattanzio R
FAU - Chiappini, P
AU  - Chiappini P
FAU - Piantelli, M
AU  - Piantelli M
FAU - Di Ilio, C
AU  - Di Ilio C
FAU - Consoli, A
AU  - Consoli A
FAU - Sensi, S L
AU  - Sensi SL
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - Cell Death Dis
JT  - Cell death & disease
JID - 101524092
SB  - IM
PMC - PMC3674348
OID - NLM: PMC3674348
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - cddis2013139 [pii]
AID - 10.1038/cddis.2013.139 [doi]
PST - epublish
SO  - Cell Death Dis. 2013 May 2;4:e612. doi: 10.1038/cddis.2013.139.

PMID- 23640434
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1128-3602 (Print)
IS  - 1128-3602 (Linking)
VI  - 17
IP  - 7
DP  - 2013 Apr
TI  - Uncontrolled hypertension among black Africans in the city of Brussels: a
      case-control study.
PG  - 886-94
LID - 3672 [pii]
AB  - AIM: The aim of this study is to identify determinants that are associated with
      uncontrolled hypertension among black Africans in the city of Brussels. DESIGN: A
      not-matched case-control study. METHODS: Seventy-five black Africans were
      assigned to a case group with uncontrolled hypertension and a control group with 
      controlled hypertension. Demographic characteristics, lifestyle and compliance
      were recorded as well as their blood pressure. Compliance in patients was
      evaluated by means of the Morisky Medication Adherence Scale-4 (MMAS-4). RESULTS:
      The mean age of the case group was 52 years (SD 7.8) and for the control group 49
      years (SD 6.2). Almost 60% were women. Uncontrolled hypertension was associated
      with obesity (p = 0.01) and sedentary lifestyle (p = 0.034). About 50% of women
      were obese and 70% of these had uncontrolled hypertension. Patients with type 2
      diabetes had a 4.5 times higher risk for uncontrolled hypertension and lower
      compliance to the medication regimen compared to non-diabetics. Patients were
      often treated with diuretics (29%), renin-angiotensin inhibitors (25%), and
      calcium-channel inhibitors (23%). According to the MMAS4-score uncontrolled
      patients had an intermediate compliance and the controlled patients had a high
      compliance. CONCLUSIONS: Black obese women and diabetics had the highest risk for
      uncontrolled hypertension. Compliance was significantly lower among uncontrolled 
      patients.
AD  - Department of Family Medicine, Vrije Universiteit Brussel, Belgium.
      dirk.devroey@vub.ac.be.
FAU - Decoste, M
AU  - Decoste M
FAU - Vanobberghen, R
AU  - Vanobberghen R
FAU - Borgermans, L
AU  - Borgermans L
FAU - Devroey, D
AU  - Devroey D
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2013 Apr;17(7):886-94.

PMID- 23640372
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
DP  - 2013 May 3
TI  - Metabolic syndrome and endometrial cancer: a meta-analysis.
AB  - We performed a systematic review and meta-analysis on the association of
      metabolic syndrome with endometrial cancer. A systematic literature search of
      electronic databases (Medline, ISI Web of Knowledge and Scopus) was conducted and
      complemented by cross-referencing to identify studies published before 31 January
      2013. Core items of identified studies were independently extracted by two
      reviewers, and results were summarized by random effects meta-analysis. We
      identified six studies, which reported on 3,132 cancer cases. Metabolic syndrome 
      was associated with an increased risk of endometrial cancer (RR: 1.89, 95 % CI
      1.34-2.67, P < 0.001), with significant heterogeneity among studies (I 2 = 92 %, 
      P < 0.001), but no indication for publication bias in the Egger's test (P =
      0.240). A sensitivity analysis omitting two studies produced no heterogeneity (I 
      2 = 0 %) and attenuated the association (RR: 1.39, 1.31-1.48, P < 0.001). The
      risk estimates for any single factor of the syndrome were 2.21 (P < 0.001) for
      higher values of body mass index and/or waist, 1.81 (P = 0.044) for
      hyperglycemia, 1.81 (P = 0.024) for higher blood pressure values, and 1.17 (P <
      0.001) for high triglyceride levels; there was no significant association with
      low HDL-cholesterol. Metabolic syndrome is associated with an increased risk of
      endometrial cancer; among the components of the syndrome, obesity/high waist is
      that more strongly associated with endometrial cancer.
AD  - Division of Endocrinology, Diabetes, and Metabolic Diseases, Department of
      Clinical and Experimental Medicine and Surgery, Second University of Naples,
      Piazza L. Miraglia 2, 80138, Naples, Italy, katherine.esposito@unina2.it.
FAU - Esposito, Katherine
AU  - Esposito K
FAU - Chiodini, Paolo
AU  - Chiodini P
FAU - Capuano, Annalisa
AU  - Capuano A
FAU - Bellastella, Giuseppe
AU  - Bellastella G
FAU - Maiorino, Maria Ida
AU  - Maiorino MI
FAU - Giugliano, Dario
AU  - Giugliano D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Endocrine
JT  - Endocrine
JID - 9434444
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/03/15 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - 10.1007/s12020-013-9973-3 [doi]
PST - aheadofprint
SO  - Endocrine. 2013 May 3.

PMID- 23640349
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 70
IP  - 10
DP  - 2013 May 15
TI  - Enhancing diabetes care by adding a pharmacist to the primary care team.
PG  - 877-886
AB  - PURPOSE: The impact of pharmacist interventions on short-term clinical markers
      and long-term cardiovascular risk in patients with type 2 diabetes is
      investigated. METHODS: Selected health outcomes were retrospectively analyzed in 
      147 adults with type 2 diabetes whose care was managed by a team of providers
      including a pharmacist (the enhanced care group) and a matched sample of patients
      (n = 147) managed by a primary care physician only (the control group). All
      patients received services through the same health maintenance organization
      (HMO). The primary study endpoints were (1) the changes from baseline to 12-month
      follow-up in glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol
      (LDL-C), and blood pressure (BP) values, (2) rates of attainment of HbA1c, LDL-C 
      and BP goals, and (3) changes from baseline in predicted 10-year risks of
      coronary heart disease (CHD) and stroke. RESULTS: During the 12-month study
      period, the mean HbA1c value was decreased from 9.5% to 6.9% in the enhanced care
      group and from 9.3% to 8.4% in the control group (p < 0.001); patients in the
      enhanced care group were significantly more likely to attain goals for HbA1c
      (odds ratio [OR], 3.9), LDL-C (OR, 2.0), and BP reduction (OR, 2.0) and three
      times more likely to attain all three goals (OR, 3.2). The estimated 10-year risk
      of CHD was decreased from 16.4% to 9.3% with enhanced care versus a reduction
      from 17.4% to 14.8% with usual care (p < 0.001). CONCLUSION: The addition of a
      pharmacist to an HMO primary care team improved short-term surrogate markers as
      well as long-term cardiovascular risk in adult patients with type 2 diabetes.
AD  - Eric J. Ip, Pharm.D., BCPS, CSCS, CDE, is Associate Professor, Department of
      Pharmacy Practice, College of Pharmacy, Touro University California, Vallejo, and
      Diabetes Specialist and Clinical Pharmacist, Department of Internal Medicine,
      Kaiser Permanente Mountain View Medical Offices, Mountain View, CA. Bijal M.
      Shah, B.Pharm., Ph.D., is Associate Professor; and Junhua Yu, Ph.D., is Assistant
      Professor, Department of Social, Behavioral, and Administrative Sciences, College
      of Pharmacy, Touro University California. James Chan, Pharm.D., Ph.D., is
      Pharmacy Quality and Outcomes Coordinator, Pharmacy Outcomes Research Group,
      Kaiser Permanente Medical Care Program, Oakland, CA. Lynda T. Nguyen, Pharm.D.,
      is Postgraduate Year 1 Resident, College of Pharmacy, Touro University
      California. Deempal C. Bhatt, Pharm.D., BCPS, is Inpatient Clinical Pharmacist,
      Sutter Tracy Medical Center, Tracy, CA.
FAU - Ip, Eric J
AU  - Ip EJ
FAU - Shah, Bijal M
AU  - Shah BM
FAU - Yu, Junhua
AU  - Yu J
FAU - Chan, James
AU  - Chan J
FAU - Nguyen, Lynda T
AU  - Nguyen LT
FAU - Bhatt, Deempal C
AU  - Bhatt DC
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the
      American Society of Health-System Pharmacists
JID - 9503023
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 70/10/877 [pii]
AID - 10.2146/ajhp120238 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2013 May 15;70(10):877-886.

PMID- 23640337
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 70
IP  - 10
DP  - 2013 May 15
TI  - Canagliflozin approved for type 2 diabetes.
PG  - 834
LID - 10.2146/news130035 [doi]
FAU - Traynor, Kate
AU  - Traynor K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the
      American Society of Health-System Pharmacists
JID - 9503023
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 70/10/834 [pii]
AID - 10.2146/news130035 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2013 May 15;70(10):834. doi: 10.2146/news130035.

PMID- 23640309
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 2168-6173 (Electronic)
IS  - 2168-6165 (Linking)
DP  - 2013 May 2
TI  - Incidence and Associated Endocrine and Neurologic Abnormalities of Optic Nerve
      Hypoplasia.
PG  - 1-5
LID - 10.1001/jamaophthalmol.2013.65 [doi]
AB  - IMPORTANCE Optic nerve hypoplasia (ONH) is an increasingly recognized cause of
      congenital blindness in children; however, there is significant discord regarding
      its incidence and the rate of associated conditions. OBJECTIVE To determine the
      incidence of ONH and the rate of associated endocrine, neurologic, and
      developmental abnormalities among a population-based cohort of pediatric
      patients. DESIGN Retrospective, population-based study. SETTING Olmsted County,
      Minnesota (95.7% white in 1990). PARTICIPANTS All pediatric residents (aged
      &lt;19 years) of Olmstead County, diagnosed as having ONH from January 1, 1984,
      through December 31, 2008. MAIN OUTCOMES AND MEASURES Incidence of ONH and the
      rate of associated endocrine, neurologic, and developmental abnormalities.
      RESULTS Optic nerve hypoplasia was diagnosed in 19 pediatric patients during the 
      25-year study period, for an annual incidence of 2.4 (95% CI, 1.2-3.5) per 100
      000 residents younger than 19 years or 1 in 2287 live births. The mean age at
      diagnosis was 2.1 years, and 10 (53%) patients were male. Commonly associated
      perinatal conditions included primiparity in 8 patients (42%), premature birth in
      6 (32%), and maternal diabetes mellitus in 3 (16%). Of the 19 study patients, 16 
      (84%) had bilateral involvement at initial examination, 9 (47%) had decreased
      visual acuity, 8 (42%) had strabismus, and 5 (26%) had nystagmus. Systemic
      conditions included developmental delay in 12 (63%), neurologic deficits in 10
      (53%), and endocrine dysfunction in 5 (26%). CONCLUSIONS AND RELEVANCE This
      population-based study demonstrated an incidence of ONH of 1 in 2287 live births.
      More than half of the patients had developmental and neurologic deficits, and
      one-fourth had a diagnosis of endocrine dysfunction.
FAU - Mohney, Brian G
AU  - Mohney BG
FAU - Young, Ryan C
AU  - Young RC
FAU - Diehl, Nancy
AU  - Diehl N
LA  - ENG
GR  - R01 AG034676/AG/NIA NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - JAMA Ophthalmol
JT  - JAMA ophthalmology
JID - 101589539
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 1682372 [pii]
AID - 10.1001/jamaophthalmol.2013.65 [doi]
PST - aheadofprint
SO  - JAMA Ophthalmol. 2013 May 2:1-5. doi: 10.1001/jamaophthalmol.2013.65.

PMID- 23640303
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 May 2
TI  - Impact of Reinforcement of Diabetes Self-Care on Poorly Controlled Diabetes: A
      Randomized Controlled Trial.
AB  - PurposeThe purpose of the study was to assess the value of reinforcing diabetes
      self-management for improving glycemia and self-care among adults with type 2
      diabetes who had at least 3 hours of prior diabetes education.MethodsIn this
      randomized controlled trial, 134 participants (75% white, 51% female, 59 +/- 9
      years old, 13 +/- 8 years with diabetes, A1C = 8.4% +/- 1.2%) were randomized to 
      either a group map-based program (intervention) or group education on cholesterol
      and blood pressure (control). Participants were assessed for A1C levels, diabetes
      self-care behaviors (3-day pedometer readings, 6-minute walk test, blood glucose 
      checks, frequency of self-care), and psychosocial factors (distress, frustration,
      quality of life) at baseline, 3, 6, and 12 months post intervention and health
      literacy at baseline.ResultsGroups did not differ on baseline characteristics
      including A1C levels, health literacy, or self-care; however, the intervention
      group had more years of education than controls. Intervention arm participants
      modestly improved A1C levels at 3 months post intervention but did not maintain
      that improvement at 6 and 12 months while control patients did not improve A1C
      levels at any time during follow-up. Importantly, frequency of self-reported
      self-care, diabetes quality of life, diabetes-related distress, and frustration
      with diabetes self-care improved in both groups over time.ConclusionsReinforcing 
      self-care with diabetes education for patients who have not met glycemic targets 
      helps improve A1C and could be considered a necessary component of ongoing
      diabetes care. The best method to accomplish reinforcement needs to be
      established.
AD  - Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Boston,
      Massachusetts (Dr Beverly, Mr Fitzgerald, Ms Brooks, Ms Hultgren, Dr Ganda, Dr
      Munshi, Dr Weinger).
FAU - Beverly, Elizabeth A
AU  - Beverly EA
FAU - Fitzgerald, Shane M
AU  - Fitzgerald SM
FAU - Brooks, Kelly M
AU  - Brooks KM
FAU - Hultgren, Brittney A
AU  - Hultgren BA
FAU - Ganda, Om P
AU  - Ganda OP
FAU - Munshi, Medha
AU  - Munshi M
FAU - Weinger, Katie
AU  - Weinger K
LA  - ENG
GR  - P30 DK036836/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 0145721713486837 [pii]
AID - 10.1177/0145721713486837 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 May 2.

PMID- 23640302
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 May 2
TI  - The Impact of Diabetes Counseling and Education: Clinical and Cost Outcomes From 
      a Large Population of US Managed Care Patients With Type 2 Diabetes.
AB  - PurposeThe purpose of this study is to examine outcomes in adult patients with
      type 2 diabetes mellitus who received diabetes counseling and education (C/E)
      services compared with those who did not.MethodsA matched, retrospective cohort
      study of 17 483 C/E recipients and 17 470 non-C/E controls was followed for up to
      12 months. Outcomes included glycemic control (glycosylated hemoglobin A1C levels
      <7.0%), hypoglycemic events, and health care utilization and
      costs.ResultsCompared with the non-C/E group, patients in the C/E group had
      significantly lower A1C (7.7% vs 7.2%) and were more likely to achieve glycemic
      control at 6 months' follow-up; they were also more likely to have a hypoglycemic
      event. During the 1-year period following the index date, C/E recipients had more
      inpatient visits (0.21 vs 0.20 visits per patient) and ambulatory visits (21.5 vs
      18.6 visits per patient) compared with non-C/E controls. The increased use of
      health care services in the C/E groups was associated with $2388 higher annual
      overall costs and $827 higher diabetes-related costs.ConclusionsDiabetes C/E is
      associated with improved glycemic control, albeit with a slight increase in the
      risk of hypoglycemia. C/E was associated with higher health care costs across 12 
      months. Further analyses are needed to evaluate long-term cost-effectiveness of
      diabetes counseling and education.
AD  - University of Washington, Seattle, Washington (Dr Sullivan).
FAU - Sullivan, Sean D
AU  - Sullivan SD
FAU - Dalal, Mehul R
AU  - Dalal MR
FAU - Burke, James P
AU  - Burke JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 0145721713486525 [pii]
AID - 10.1177/0145721713486525 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 May 2.

PMID- 23640301
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 May 2
TI  - Perceptions of Barriers in Managing Diabetes: Perspectives of Hispanic Immigrant 
      Patients and Family Members.
AB  - PurposeHispanics show poorer self-management of type 2 diabetes than non-Hispanic
      whites. Although previous studies have reported socioeconomic and cultural
      barriers to diabetes self-management by Hispanics, little is known about
      perceived barriers to diabetes self-management from the perspectives of both
      Hispanics and their family members. The purpose of the study was to explore
      perceived barriers among Hispanic immigrants with diabetes and their family
      members.MethodsA qualitative study using 5 focus groups was conducted. A total of
      73 Hispanic immigrants with type 2 diabetes (n = 36) and family members (n = 37) 
      were recruited in the southeastern United States for a family-based intervention 
      study of diabetes-self management. Participants were asked to describe their
      perceptions of barriers to self-management. The 5 sessions were audiotaped and
      transcribed, translated from Spanish into English, and analyzed using standard
      content analysis. Demographics, hemoglobin A1C levels, blood pressure, and body
      mass index (BMI) were obtained both for participants with diabetes and for their 
      family members.ResultsBarriers to diabetes self-management identified by
      participants with diabetes were in 3 major themes categorized as: suffering from 
      diabetes, difficulties in managing the disease, and lack of resources/support.
      Two key themes emerged pertaining to family members: we can provide support and
      we lack knowledge.ConclusionsPerceived barriers to diabetes self-management
      described by Hispanic immigrants with diabetes and family members indicate a lack
      of intervention strategies to meet their needs. Interventions should include
      culturally relevant resources, family support, and diabetes self- management
      skills education.
AD  - University of North Carolina at Greensboro, School of Nursing, Greensboro, North 
      Carolina (Drs Hu, Amirehsani, Wallace, Letvak).
FAU - Hu, Jie
AU  - Hu J
FAU - Amirehsani, Karen
AU  - Amirehsani K
FAU - Wallace, Debra C
AU  - Wallace DC
FAU - Letvak, Susan
AU  - Letvak S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 0145721713486200 [pii]
AID - 10.1177/0145721713486200 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 May 2.

PMID- 23640300
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
DP  - 2013 May 2
TI  - Characteristics of American Young Adults With Increased Risk for Type 2 Diabetes:
      A Pilot Study.
AB  - PurposeThe purpose of the study was to examine the characteristics of American
      young adults with increased risk for type 2 diabetes (T2D).MethodsParticipants
      ages 18 to 29, overweight/obese, and sedentary were recruited from the metro
      Atlanta area in the United States. Variables included demographics,
      anthropometric and clinical variables, and physical activity. Of 107
      participants, 3 participants had undiagnosed diabetes and 1 participant did not
      complete the modifiable activity questionnaire. Thus, 103 young adults remained
      for the final data analysis.ResultsMost participants were females and African
      Americans. About 30% of participants had prediabetes, either impaired fasting
      glucose, an A1C of 5.7% to 6.4%, or both. Overall, prediabetes young adults were 
      heavier and did less physical activity than Diabetes Prevention Program (DPP)
      trial participants. In addition, these young adults had a higher prevalence of
      parental T2D history and lower level of physical activity compared to young
      adults with normoglycemia.ConclusionsPhysical activity and parent T2D history are
      key risk factors for identifying young adults with prediabetes. Multilevel
      strategies are necessary to raise awareness of diabetes risk and to prevent T2D
      in young adults.
AD  - Emory University, Atlanta, Georgia (Drs Cha, Umpierrez, Dunbar, Ms Bello).
FAU - Cha, Eunseok
AU  - Cha E
FAU - Umpierrez, Guillermo
AU  - Umpierrez G
FAU - Kim, Kevin H
AU  - Kim KH
FAU - Bello, Morenike K
AU  - Bello MK
FAU - Dunbar, Sandra B
AU  - Dunbar SB
LA  - ENG
GR  - K01 NR012779/NR/NINR NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 0145721713486199 [pii]
AID - 10.1177/0145721713486199 [doi]
PST - aheadofprint
SO  - Diabetes Educ. 2013 May 2.

PMID- 23640247
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
DP  - 2013 May 3
TI  - Synergetic Insulin Sensitizing Effect of Rimonabant and BGP-15 in Zucker-Obes
      Rats.
AB  - Abdominal obesity is referred for as a common pathogenic root of multiple risk
      factors, which include insulin resistance, dyslipidemia, hypertension, and a
      pro-atherogenic and pro-inflammatory state. Irrespective of its psychiatric side 
      effects, rimonabant through blocking cannabinoid-1 receptor (CB1R) induces an
      increase in whole body insulin sensitivity. The aim of this work was to study the
      effect of selected doses of another insulin sensitizer compound BGP-15, and
      rimonabant on insulin resistance in Zucker obese rats with a promise of inducing 
      insulin sensitization together at lower doses than would have been expected by
      rimonabant alone. We found that BGP-15 potentiates the insulin sensitizing effect
      of rimonabant. The combination at doses, which do not induce insulin
      sensitization by themselves, improved insulin signaling. Furthermore our results 
      suggest that capsaicin-induced signal may play a role in insulin sensitizing
      effect of both molecules. Our data might indicate that a lower dose of rimonabant
      in the treatment of insulin resistance and type 2 diabetes is sufficient to
      administer, thus a lower incidence of the unfavorable psychiatric side effects of
      rimonabant are to be expected.
AD  - Department of Medical Chemistry, Molecular Biology and Pathobiochemistry,
      Semmelweis University, Budapest, Hungary.
FAU - Literati-Nagy, Zsuzsanna
AU  - Literati-Nagy Z
FAU - Tory, Kalman
AU  - Tory K
FAU - Literati-Nagy, Botond
AU  - Literati-Nagy B
FAU - Bajza, Agnes
AU  - Bajza A
FAU - Vigh, Laszlo Jr
AU  - Vigh L Jr
FAU - Vigh, Laszlo
AU  - Vigh L
FAU - Mandl, Jozsef
AU  - Mandl J
FAU - Szilvassy, Zoltan
AU  - Szilvassy Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/12/28 [received]
PHST- 2013/02/22 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - 10.1007/s12253-013-9620-6 [doi]
PST - aheadofprint
SO  - Pathol Oncol Res. 2013 May 3.

PMID- 23640095
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1989-2284 (Electronic)
IS  - 0211-6995 (Linking)
VI  - 33
IP  - 3
DP  - 2013 May 17
TI  - Magnesium its role in CKD.
PG  - 389-399
LID - 10.3265/Nefrologia.pre2013.Feb.11840 [doi]
AB  - Magnesium containing compounds present promising oral phosphate binders for the
      treatment of hyperphosphataemia in patients with chronic kidney disease (CKD).
      However, the impact of magnesium in CKD patients still remains unclear in
      clinical routine practice. Therefore, this publication provides a practicable
      overview of knowledge about the physiological role of magnesium in general and in
      particular in CKD patients. Prevalence of hypomagnesaemia is high in the general 
      population and especially in intensive care unit patients, but often not being
      detected. Magnesium deficiency increases the risk for several diseases, like
      diabetes mellitus type 2, hypertension and atherosclerosis. Moderate
      hypermagnesaemia, however, seems to have beneficial effects on vascular
      calcification and mortality rates in CKD patients. On the other hand, higher
      serum magnesium levels are reported to be linked to lower PTH levels and results 
      on the effects on bone are controversial. In addition, low magnesium levels are
      associated with low bone mass, osteoporosis and vascular calcification. In
      dialysis patients serum magnesium levels are dependent mainly on the dialysate
      magnesium concentration. To confirm the potential delay of arterial calcification
      and improved survival outcomes by long-term intervention with magnesium powered
      randomized studies are required in dialysis patients. Since a recent trial
      revealed that a phosphate binder containing a combination of magnesium carbonate 
      and calcium acetate was as effective as the polymer-based agent sevelamer
      hydrochloride and had an equally good tolerability profile, it is time for a
      re-examination of the role of magnesium in CKD patients.
FAU - M de Francisco, Angel L
AU  - M de Francisco AL
FAU - Rodriguez, Mariano
AU  - Rodriguez M
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Magnesio y enfermedad renal cronica.
DEP - 20130502
TA  - Nefrologia
JT  - Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
JID - 8301215
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/02/05 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - 10.3265/Nefrologia.pre2013.Feb.11840 [doi]
PST - ppublish
SO  - Nefrologia. 2013 May 17;33(3):389-399. doi: 10.3265/Nefrologia.pre2013.Feb.11840.
      Epub 2013 May 2.

PMID- 23640038
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 54
IP  - 6
DP  - 2013
TI  - Retinal Neurodegeneration in Type II Diabetic Otsuka Long-Evans Tokushima Fatty
      Rats.
PG  - 3844-51
LID - 10.1167/iovs.12-11309 [doi]
AB  - PURPOSE: We evaluated whether diabetes causes longitudinal thinning of retinal
      layers as a sign of retinal neurodegeneration in a type II diabetic animal model,
      the Otuska Long-Evans Tokushima fatty rats (OLETF), using spectral domain-optical
      coherence tomography (SD-OCT) and investigated the corresponding histology.
      METHODS: Retinal thickness in OLETF and Long-Evans Tokushima Otsuka rats (LETO)
      was measured at 1300 mum from the center of the optic nerve head (ONH) at 12, 20,
      28, and 36 weeks using SD-OCT. Total retinal thickness (TRT) was measured
      automatically by built-in software. The retinal nerve fiber layer (RNFL) and
      other layers' thicknesses were measured manually. At 36 weeks, eyes were
      processed for morphometric analysis and detection of apoptosis based on active
      caspase-3(+) and TUNEL(+) analysis. RESULTS: TRT was significantly thinner in
      OLETF at 28 and 36 weeks (236.26 +/- 5.64 and 235.98 +/- 5.42 mum, respectively) 
      than in LETO (243.82 +/- 7.36 and 239.58 +/- 6.99 mum, respectively; P = 0.042
      and P = 0.01). At 28 weeks, RNFL thickness was significantly lower in OLETF
      (21.52 +/- 1.91 mum) than in LETO (24.75 +/- 2.10 mum, P = 0.042). The change of 
      TRT correlated significantly with change of RNFL thickness. At 36 weeks, OLETF
      (24.0 +/- 3.1/cross-section) had significantly fewer ganglion cells than LETO
      (28.4 +/- 6.7/cross-section, P = 0.028). Active caspase-3(+) and TUNEL(+) cells
      in RNFL were observed significantly more frequently in OLETF (6.8 +/-
      5.2/cross-section and 3.75 +/- 0.96/cross-section, respectively) than in LETO
      (1.5 +/- 2.3/cross-section, P = 0.008 and 1.0 +/- 0.8/cross-section, P = 0.029,
      respectively). CONCLUSIONS: OLETF exhibited a significantly reduced TRT,
      especially RNFL thickness, based on SD-OCT. Further, histology revealed increased
      apoptosis and a decrease in the number of ganglion cells. These results suggest
      that retinal neurodegeneration occurs in type II diabetic OLETF.
AD  - Department of Ophthalmology, Kyung Hee University Hospital, Kyung Hee University,
      Seoul, Korea.
FAU - Yang, Ji Ho
AU  - Yang JH
FAU - Kwak, Hyung Woo
AU  - Kwak HW
FAU - Kim, Tae Gi
AU  - Kim TG
FAU - Han, Jisang
AU  - Han J
FAU - Moon, Sang Woong
AU  - Moon SW
FAU - Yu, Seung Young
AU  - Yu SY
LA  - eng
PT  - Journal Article
DEP - 20130603
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
SB  - IM
OTO - NOTNLM
OT  - OLETF
OT  - diabetic retinopathy
OT  - neurodegeneration
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - iovs.12-11309 [pii]
AID - 10.1167/iovs.12-11309 [doi]
PST - epublish
SO  - Invest Ophthalmol Vis Sci. 2013 Jun 3;54(6):3844-51. doi: 10.1167/iovs.12-11309.

PMID- 23640034
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1432-0738 (Electronic)
IS  - 0340-5761 (Linking)
DP  - 2013 May 3
TI  - Mechanism of BDE209-induced impaired glucose homeostasis based on gene microarray
      analysis of adult rat liver.
AB  - Several persistent organic pollutants are reported to be potentially associated
      with the risk of human diabetes that has become rapidly epidemic in China
      currently. 2,2',3,3',4,4',5,5',6,6'-decabromodiphenyl ether (BDE209) is
      commercially most important both in the production and in the use of
      polybrominated diphenyl ethers (PBDEs). It might bioaccumulate in wildlife and
      human and is the only PBDEs mixture still used today. In the present study, male 
      adult rats treated with BDE209 (0, 0.05, 1, and 20 mg/kg) for 8 weeks were used
      to explore the effects of BDE209 on glucose homeostasis and possible mechanisms; 
      0.05 mg/kg of BDE209 induced dose-related hyperglycemia. Then, we performed the
      full-genome gene expression microarrays, gene ontology analysis, and pathway
      analysis in this group and control. BDE209 induced 1,257 liver gene transcript
      changes, and 18 canonical pathways were significantly enriched. Four of them were
      involved in immune diseases, including autoimmune thyroid disease,
      graft-versus-host disease, allograft rejection, and type I diabetes mellitus
      (T1MD), which was confirmed by the decrease in serum insulin. Subsequently, gene 
      act network and gene co-expression network found that some MHC molecules and
      TNF-alpha were involved in T1DM pathway, which was then confirmed by the increase
      in serum TNF-alpha. Additionally, reduced glutathione and superoxide dismutase in
      plasma indicated that oxidative damage might partly contribute to BDE209-induced 
      hyperglycemia. The results of this study provide some new experimental evidence
      that the exposure to high levels of BDE209 may contribute to the onset of
      diabetes in human populations. Further work needs to be done to confirm this
      link.
AD  - Key Lab of Modern Toxicology of Ministry of Education, School of Public Health,
      Nanjing Medical University, 818 East Tiangyuan Rd., Nanjing, 211166, China.
FAU - Zhang, Zhan
AU  - Zhang Z
FAU - Sun, Zhen-Zhen
AU  - Sun ZZ
FAU - Xiao, Xue
AU  - Xiao X
FAU - Zhou, Shixin
AU  - Zhou S
FAU - Wang, Xi-Chen
AU  - Wang XC
FAU - Gu, Jun
AU  - Gu J
FAU - Qiu, Liang-Lin
AU  - Qiu LL
FAU - Zhang, Xu-Hui
AU  - Zhang XH
FAU - Xu, Qiujin
AU  - Xu Q
FAU - Zhen, Binghui
AU  - Zhen B
FAU - Wang, Xinru
AU  - Wang X
FAU - Wang, Shou-Lin
AU  - Wang SL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Arch Toxicol
JT  - Archives of toxicology
JID - 0417615
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/11/23 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - 10.1007/s00204-013-1059-8 [doi]
PST - aheadofprint
SO  - Arch Toxicol. 2013 May 3.

PMID- 23640014
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1573-7365 (Electronic)
IS  - 0885-7490 (Linking)
DP  - 2013 May 3
TI  - Berberine chloride improved synaptic plasticity in STZ induced diabetic rats.
AB  - Previous studies indicated that diabetes affects synaptic transmission in the
      hippocampus, leading to impairments of synaptic plasticity and defects in
      learning and memory. Although berberine treatment ameliorates memory impairment
      and improves synaptic plasticity in streptozotocin (STZ) induced diabetic rats,
      it is not clear if the effects are pre- or post-synaptic or both. The aim of this
      study was to evaluate the effects of berberine chloride on short-term plasticity 
      in inhibitory interneurons in the dentate gyrus of STZ-induced diabetic rats.
      Experimental groups included: The control, control berberine treated (100 mg/kg),
      diabetic and diabetic berberine treated (50,100 mg/kg/day for 12 weeks) groups.
      The paired pulse paradigm was used to stimulate the perforant pathway and field
      excitatory post-synaptic potentials (fEPSP) were recorded in dentate gyrus (DG). 
      In comparison with control, paired pulse facilitation in the diabetic group was
      significantly increased (P < 0.01) and this effect prevented by chronic berberine
      treatment (50,100 mg/kg). However, there were no differences between responses of
      the control berberine 100 mg/kg treated and diabetes berberine treated (50 and
      100 mg/kg) groups as compared to the control group. The present results suggest
      that the pre-synaptic component of synaptic plasticity in the dentate gyrus is
      affected under diabetic conditions and that berberine prevents this effect.
AD  - Department of Physiology, School of Medicine, Shahroud University of Medical
      Sciences, Shahroud, Iran, h.kalalian@gmail.com.
FAU - Moghaddam, Hamid Kalalian
AU  - Moghaddam HK
FAU - Baluchnejadmojarad, Tourandokht
AU  - Baluchnejadmojarad T
FAU - Roghani, Mehrdad
AU  - Roghani M
FAU - Goshadrou, Fatemeh
AU  - Goshadrou F
FAU - Ronaghi, Abdolaziz
AU  - Ronaghi A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Metab Brain Dis
JT  - Metabolic brain disease
JID - 8610370
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/08/13 [received]
PHST- 2013/03/10 [accepted]
PHST- 2013/05/03 [aheadofprint]
AID - 10.1007/s11011-013-9411-5 [doi]
PST - aheadofprint
SO  - Metab Brain Dis. 2013 May 3.

PMID- 23639991
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
DP  - 2013 May 3
TI  - Glycemic Memories and the Epigenetic Component of Diabetic Nephropathy.
AB  - A strong case for the deregulation of epigenetic chromatin modifications in the
      development and progression of various chronic complications of diabetes has
      emerged from recent experimental observations. Clinical trials of type 1 and type
      2 diabetes patients highlight the importance of early and intensive treatment and
      the prolonged damage of hyperglycemia on organs such as the kidney. The
      functional relationship between the regulation of chromatin architecture and
      persistent gene expression changes conferred by prior hyperglycemia represents an
      important avenue of investigation for explaining diabetic nephropathy. While
      several studies implicate epigenetic changes at the chromatin template in the
      deregulated gene expression associated with diabetic nephropathy, the molecular
      determinants of metabolic memory in renal cells remain poorly understood. There
      is now strong evidence from experimental animals and cell culture of persistent
      glucose-driven changes in vascular endothelial gene expression that may also have
      relevance for the microvasculature of the kidney. Exploration of epigenetic
      mechanisms underlying the hyperglycemic cue mediating persistent transcriptional 
      changes in renal cells holds novel therapeutic potential for diabetic
      nephropathy.
AD  - Epigenetics in Human Health and Disease Laboratory, Baker IDI Heart and Diabetes 
      Institute, The Alfred Medical Research and Education Precinct, Melbourne,
      Victoria, 3004, Australia.
FAU - Keating, Samuel T
AU  - Keating ST
FAU - El-Osta, Assam
AU  - El-Osta A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.1007/s11892-013-0383-y [doi]
PST - aheadofprint
SO  - Curr Diab Rep. 2013 May 3.

PMID- 23639961
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 524
IP  - 2
DP  - 2013 Jul 25
TI  - Uncoupling protein 2 -866G/A and uncoupling protein 3 -55C/T polymorphisms in
      young South African Indian coronary artery disease patients.
PG  - 79-83
LID - 10.1016/j.gene.2013.04.048 [doi]
LID - S0378-1119(13)00515-5 [pii]
AB  - BACKGROUND: Uncoupling proteins (UCPs) 2 and 3 play an important role in the
      regulation of oxidative stress which contributes to chronic inflammation.
      Promoter polymorphisms of these genes have been linked to chronic diseases
      including heart disease and type II diabetes mellitus in several populations.
      This is the first investigation of the UCP2 -866G/A rs659366 and UCP3 -55C/T
      rs1800849 polymorphisms in young South African (SA) Indians with coronary artery 
      disease (CAD). METHODS: A total of 300 subjects were recruited into this study of
      which 100 were SA Indian males with CAD, 100 age- (range 24-45years), gender- and
      race-matched controls and 100 age-matched black SA males. The frequency of the
      UCP2 -866G/A and UPC3 -55C/T genotypes was assessed by polymerase chain reaction 
      restriction fragment length polymorphism (PCR-RFLP). RESULTS: The heterozygous
      UCP2 -866G/A and homozygous UCP3 -55C/C genotypes occurred at highest frequency
      in CAD patients (60% and 64%, respectively) compared to SA Indian controls (52%
      and 63%) and SA Black controls (50% and 58%). The UCP2 -886G/A (OR=1.110; 95%
      CI=0.7438-1.655; p=0.6835) and UCP3 -55C/T (OR=0.788; 95% CI=0.482-1.289;
      p=0.382) polymorphisms did not influence the risk of CAD. The rare homozygous
      UCP3 -55T/T genotype was associated with highest fasting glucose
      (11.87+/-3.7mmol/L vs. C/C:6.11+/-0.27mmol/L and C/T:6.48+/-0.57mmol/L,
      p=0.0025), HbA1c (10.05+/-2.57% vs. C/C:6.44+/-0.21% and C/T:6.76+/-0.35%,
      p=0.0006) and triglycerides (6.47+/-1.7mmol/L vs. C/C:2.33+/-0.17mmol/L and
      C/T:2.06+/-0.25mmol/L, p<0.0001) in CAD patients. CONCLUSION: The frequency of
      the UCP2 -866G/A and UCP3 -55C/T polymorphisms was similar in our SA Indian and
      SA Black groups. The presence of the UCP2 -866G/A and UCP3 -55C/T polymorphisms
      does not influence the risk of CAD in young South African Indian CAD patients.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Discipline of Medical Biochemistry, Nelson R Mandela School of Medicine,
      University of KwaZulu-Natal, Private Bag 7, Congella, 4013 Durban, South Africa.
FAU - Phulukdaree, Alisa
AU  - Phulukdaree A
FAU - Moodley, Devapregasan
AU  - Moodley D
FAU - Khan, Sajidah
AU  - Khan S
FAU - Chuturgoon, Anil A
AU  - Chuturgoon AA
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/01/25 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/04 [accepted]
PHST- 2013/04/29 [aheadofprint]
AID - S0378-1119(13)00515-5 [pii]
AID - 10.1016/j.gene.2013.04.048 [doi]
PST - ppublish
SO  - Gene. 2013 Jul 25;524(2):79-83. doi: 10.1016/j.gene.2013.04.048. Epub 2013 Apr
      29.

PMID- 23639858
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
DP  - 2013 Apr 10
TI  - Paraoxonase1 (PON1) reduces insulin resistance in mice fed a high-fat diet, and
      promotes GLUT4 overexpression in myocytes, via the IRS-1/Akt pathway.
LID - S0021-9150(13)00204-9 [pii]
LID - 10.1016/j.atherosclerosis.2013.03.028 [doi]
AB  - OBJECTIVE: To analyze Paraoxonase1 (PON1) impact on GLUT4 expression, glucose
      metabolism, and the insulin signaling pathway in skeletal muscle cells. METHODS
      AND RESULTS: We analyzed the effect of PON1 in high-fat-diet-induced insulin
      resistance in C57BL/6J and in PON1KO mice. Mice were fed normal diet (ND) or high
      Fat Diet (HFD) for 8 weeks. PON1 deficiency caused enhanced insulin resistance in
      both ND and HFD mice. PON1 deficiency was associated with increased oxidative
      stress (OS), increased p38MAPK activity and attenuated insulin-mediated tyrosine 
      phosphorylation of muscle insulin receptor substrate-1 (IRS-1), with a
      corresponding increase in serine phosphorylation. These effects resulted in
      decreased glucose uptake in whole-body level, as reflected by glucose tolerance
      test (GTT), by insulin tolerance test (ITT) and by cellular glycogen accumulation
      in the liver and in the muscles. PON1 addition to cultured C2 muscle cells
      enhanced GLUT4 mRNA expression, in a time and concentration dependent manner,
      increased GLUT4 protein and cellular glycogen accumulation. These effects were
      mediated via inhibition of p38MAPK activity, resulting in reduced IRS-1 serine
      phosphorylation and in enhanced IRS-1 tyrosine phosphorylation. The ability of
      PON1 to increase myocytes GLUT4 expression was partially inhibited upon blocking 
      PON1 SH group, and completely abolished upon PON1 mutation in HIS115 of its
      catalytic site. CONCLUSION: PON1 plays a beneficial role in glucose regulation
      and metabolism and may serve as an important tool in diabetes control.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family
      Institute for Research in the Medical Sciences, and Rambam Medical Center, Haifa,
      Israel.
FAU - Koren-Gluzer, Marie
AU  - Koren-Gluzer M
FAU - Aviram, Michael
AU  - Aviram M
FAU - Hayek, Tony
AU  - Hayek T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130410
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/01/13 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/03/22 [accepted]
AID - S0021-9150(13)00204-9 [pii]
AID - 10.1016/j.atherosclerosis.2013.03.028 [doi]
PST - aheadofprint
SO  - Atherosclerosis. 2013 Apr 10. pii: S0021-9150(13)00204-9. doi:
      10.1016/j.atherosclerosis.2013.03.028.

PMID- 23639840
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1836
IP  - 1
DP  - 2013 Aug
TI  - A molecular rheostat at the interface of cancer and diabetes.
PG  - 166-76
LID - 10.1016/j.bbcan.2013.04.005 [doi]
LID - S0304-419X(13)00025-5 [pii]
AB  - Epidemiology studies revealed the connection between several types of cancer and 
      type 2 diabetes (T2D) and suggested that T2D is both a symptom and a risk factor 
      of pancreatic cancer. High level of circulating insulin (hyperinsulinemia) in
      obesity has been implicated in promoting aggressive types of cancers. Insulin
      resistance, a symptom of T2D, pressures pancreatic beta-cells to increase insulin
      secretion, leading to hyperinsulinemia, which in turn leads to a gradual loss of 
      functional beta-cell mass, thus indicating a fine balance and interplay between
      beta-cell function and mass. While the mechanisms of these connections are
      unclear, the mTORC1-Akt signaling pathway has been implicated in controlling
      beta-cell function and mass, and in mediating the link of cancer and T2D.
      However, incomplete understating of how the pathway is regulated and how it
      integrates body metabolism has hindered its efficacy as a clinical target. The IQ
      motif containing GTPase activating protein 1 (IQGAP1)-Exocyst axis is a growth
      factor- and nutrient-sensor that couples cell growth and division. Here we
      discuss how IQGAP1-Exocyst, through differential interactions with Rho-type of
      small guanosine triphosphatases (GTPases), acts as a rheostat that modulates the 
      mTORC1-Akt and MAPK signals, and integrates beta-cell function and mass with
      insulin signaling, thus providing a molecular mechanism for cancer initiation in 
      diabetes. Delineating this regulatory pathway may have the potential of
      contributing to optimizing the efficacy and selectivity of future therapies for
      cancer and diabetes.
CI  - Published by Elsevier B.V.
AD  - Warren Alpert Medical School, Division of Biology and Medicine, Molecular
      Pharmacology, Physiology and Biotechnology, Brown University; Providence, RI
      02912, USA. Electronic address: Mahasin_Osman@Brown.edu.
FAU - Osman, Mahasin A
AU  - Osman MA
FAU - Sarkar, Fazlul H
AU  - Sarkar FH
FAU - Rodriguez-Boulan, Enrique
AU  - Rodriguez-Boulan E
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
SB  - IM
PMC - PMC3667713
MID - NIHMS473942
OID - NLM: NIHMS473942 [Available on 08/01/14]
OID - NLM: PMC3667713 [Available on 08/01/14]
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PMCR- 2014/08/01 00:00
PHST- 2013/03/25 [received]
PHST- 2013/04/23 [accepted]
PHST- 2013/04/29 [aheadofprint]
AID - S0304-419X(13)00025-5 [pii]
AID - 10.1016/j.bbcan.2013.04.005 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2013 Aug;1836(1):166-76. doi: 10.1016/j.bbcan.2013.04.005. 
      Epub 2013 Apr 29.

PMID- 23639765
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1545-1151 (Electronic)
VI  - 10
DP  - 2013
TI  - Local health department use of twitter to disseminate diabetes information,
      United States.
PG  - E70
LID - 10.5888/pcd10.120215 [doi]
AB  - INTRODUCTION: Diabetes may affect one-third of US adults by 2050. Adopting a
      healthful diet and increasing physical activity are effective in preventing type 
      2 diabetes and decreasing the severity of diabetes-related complications.
      Educating and informing the public about health problems is a service provided by
      local health departments (LHDs). The objective of this study was to examine how
      LHDs are using social media to educate and inform the public about diabetes.
      METHODS: In June 2012 we used NVivo 10 to collect all tweets ever posted from
      every LHD with a Twitter account and identified tweets about diabetes. We used a 
      2010 National Association of County and City Health Officials survey to compare
      characteristics of LHDs that tweeted about diabetes with those that did not.
      Content analysis was used to classify each tweet topic. RESULTS: Of 217 LHDs with
      Twitter accounts, 126 had ever tweeted about diabetes, with 3 diabetes tweets
      being the median since adopting Twitter. LHDs tweeting about diabetes were in
      jurisdictions with larger populations and had more staff and higher spending than
      LHDs not tweeting about diabetes. They were significantly more likely to employ a
      public information specialist and provide programs in diabetes-related areas.
      There was also a weak positive association between jurisdiction diabetes rate and
      the percentage of all tweets that were about diabetes (r = .16; P = .049).
      CONCLUSION: LHDs are beginning to use social media to educate and inform their
      constituents about diabetes. An understanding of the reach and effectiveness of
      social media could enable public health practitioners to use them more
      effectively.
AD  - Brown School, Washington University in St. Louis, One Brookings Dr, St. Louis, MO
      63130. E-mail: harrisj@wustl.edu.
FAU - Harris, Jenine K
AU  - Harris JK
FAU - Mueller, Nancy L
AU  - Mueller NL
FAU - Snider, Doneisha
AU  - Snider D
FAU - Haire-Joshu, Debra
AU  - Haire-Joshu D
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - Prev Chronic Dis
JT  - Preventing chronic disease
JID - 101205018
SB  - IM
PMC - PMC3652718
OID - NLM: PMC3652718
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.5888/pcd10.120215 [doi]
AID - E70 [pii]
PST - epublish
SO  - Prev Chronic Dis. 2013 May 2;10:E70. doi: 10.5888/pcd10.120215.

PMID- 23639680
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1549-9642 (Electronic)
IS  - 1549-9634 (Linking)
DP  - 2013 Apr 29
TI  - Getting nano tattoos right-A checklist of legal and ethical hurdles for an
      emerging nanomedical technology.
LID - S1549-9634(13)00178-0 [pii]
LID - 10.1016/j.nano.2013.04.006 [doi]
AB  - The nano tattoo represents a nascent technology designed to be implanted in the
      skin to provide continuous and reliable glucose detection for diabetics. Its
      potential benefits are compelling not only for its ability to prevent diabetic
      complications and decrease related social costs, but also for its ease of use and
      relative patient-user comfort. This Note aims to articulate a checklist of
      fundamental intellectual property, bioethical and system design issues that are
      appropriately considered in the pre-clinical, pre-commercialization phase of nano
      tattoo development. Early and regular consideration of these factors can increase
      the odds of a societally beneficial dissemination of this device by engaging
      relevant researcher, medical, patient-user and patient-advocate communities
      concerned with its appropriate application, as well as policymaking communities
      focused on effectively managing diabetes-related healthcare costs. The checklist 
      of factors includes fundamental issues and is generally applicable to nanomedical
      inventions.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Northeastern University School of Law, Boston, MA 02115, USA. Electronic address:
      m.bennett@neu.edu.
FAU - Bennett, Michael G
AU  - Bennett MG
FAU - Naranja, R John Jr
AU  - Naranja RJ Jr
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Nanomedicine
JT  - Nanomedicine : nanotechnology, biology, and medicine
JID - 101233142
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/11/01 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/04/18 [accepted]
AID - S1549-9634(13)00178-0 [pii]
AID - 10.1016/j.nano.2013.04.006 [doi]
PST - aheadofprint
SO  - Nanomedicine. 2013 Apr 29. pii: S1549-9634(13)00178-0. doi:
      10.1016/j.nano.2013.04.006.

PMID- 23639610
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 Apr 29
TI  - Assessment of awareness of diabetic retinopathy and utilization of eye care
      services among Turkish diabetic patients.
LID - S1751-9918(13)00043-0 [pii]
LID - 10.1016/j.pcd.2013.04.002 [doi]
AB  - AIMS: Raising awareness of diabetic retinopathy (DR) was shown to be a key
      element for early diagnosis and treatment of this blinding disease. There is very
      limited data about the knowledge level, attitude, and behavior of diabetic
      patients regarding DR in Turkey. This study was planned to assess the awareness
      of DR and the utilization of eye care services among Turkish diabetic patients.
      METHODS: Diabetic patients who were under the care of ophthalmologists,
      endocrinologists, and/or primary care physicians were administered a
      questionnaire in order to assess their awareness of diabetes and its ocular
      complications. RESULTS: A total of 437 patients (51.8% female and 48.2% male)
      with a mean age of 55.2+/-11.9 were included in the study. Of the 437 patients,
      31.8% had not been educated about diabetes, 88.1% were aware that diabetes can
      affect the eyes, and 39.8% thought that diabetics with good glycaemic control
      might suffer from DR. While 86.7% thought that early diagnosis was possible in
      DR, 77.3% previously had eye examinations, and 41.9% stated that annual eye
      examinations were necessary for diabetics. An educational level of middle school 
      or higher, duration of DM longer than 5years, previous DM education, and
      recruitment from the university (ophthalmology department and endocrinology
      department) were associated with better awareness of DR. The independent factors 
      associated with visiting an ophthalmologist on a regular basis were DM education,
      DM duration, and site of recruitment. CONCLUSION: Although most of the patients
      know that DM affects the eye, there is a lack of appropriate knowledge and
      behavior about the management of DR. The importance of better control of DM and
      regular eye examination in the prevention of DR should be emphasized.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Department of Ophthalmology, Faculty of Medicine, Pamukkale University, Denizli, 
      Turkey. Electronic address: cetin.ebru@gmail.com.
FAU - Cetin, Ebru N
AU  - Cetin EN
FAU - Zencir, Mehmet
AU  - Zencir M
FAU - Fenkci, Semin
AU  - Fenkci S
FAU - Akin, Fulya
AU  - Akin F
FAU - Yildirim, Cem
AU  - Yildirim C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/12/11 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/04/01 [accepted]
AID - S1751-9918(13)00043-0 [pii]
AID - 10.1016/j.pcd.2013.04.002 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 Apr 29. pii: S1751-9918(13)00043-0. doi:
      10.1016/j.pcd.2013.04.002.

PMID- 23639609
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 Apr 29
TI  - Risk factors for foot ulcers-A cross sectional survey from a primary care setting
      in Brazil.
LID - S1751-9918(13)00044-2 [pii]
LID - 10.1016/j.pcd.2013.04.003 [doi]
AB  - AIMS: To identify the prevalence of higher risk of foot ulceration and associated
      factors among patients with diabetes mellitus (DM) at primary health care
      services. METHODS: Individuals with DM, registered at primary health care
      services in a municipality in southern Brazil, were interviewed and underwent
      foot examinations. Their risk of ulceration was classified in accordance with the
      recommendations of the International Working Group on the Diabetic Foot. Poisson 
      bivariate and multivariate analyses were performed and adjusted prevalence ratios
      (PR) and 95% confidence intervals (CI) were calculated. RESULTS: The prevalence
      of higher risk of foot ulceration among the 337 interviewees was 27.9% (95% CI
      23.1-32.9). The following factors were associated with this risk: having been
      diagnosed with DM for more than 10 years (Adjusted-PR 1.669; 95% CI 1.175-2.373; 
      p=0.004); having had previous diagnoses of acute myocardial infarction
      (Adjusted-PR 1.873; 95% CI 1.330-2.638; p<0.001) and stroke (Adjusted-PR 1.684;
      95% CI 1.089-2.604; p=0.019); presenting interdigital mycosis (Adjusted-PR 1.539;
      95% CI 1.030-2.300; p=0.035) and calluses (Adjusted-PR 1.654; 95% CI 1.117-2.451;
      p=0.012). CONCLUSIONS: The prevalence of higher risk of ulceration was high,
      which reinforces the importance of continued education for health care
      professionals in order to prevent complications in the feet of these patients.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Department of Public Health, Postgraduate Program of Public Health, State
      University of Londrina, Brazil. Electronic address: mairabortoletto@hotmail.com.
FAU - Bortoletto, Maira Sayuri Sakay
AU  - Bortoletto MS
FAU - Andrade, Selma Maffei de
AU  - Andrade SM
FAU - Matsuo, Tiemi
AU  - Matsuo T
FAU - Haddad, Maria do Carmo Lourenco
AU  - Haddad MD
FAU - Gonzalez, Alberto Duran
AU  - Gonzalez AD
FAU - Silva, Ana Maria Rigo
AU  - Silva AM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/09/16 [received]
PHST- 2013/03/16 [revised]
PHST- 2013/04/01 [accepted]
AID - S1751-9918(13)00044-2 [pii]
AID - 10.1016/j.pcd.2013.04.003 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 Apr 29. pii: S1751-9918(13)00044-2. doi:
      10.1016/j.pcd.2013.04.003.

PMID- 23639608
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 Apr 29
TI  - Impaired glucose metabolism and health related quality of life.
LID - S1751-9918(13)00039-9 [pii]
LID - 10.1016/j.pcd.2013.03.001 [doi]
AB  - AIMS: We aimed at investigating whether different categories of glucose tolerance
      have any effect on a person's HRQoL. METHODS: Population-based cross-sectional
      study conducted as a community sample of apparently healthy middle-aged
      individuals living in Western Finland. The subjects of the study, 1383
      individuals, aged 45-70 years, had at least one cardiovascular risk factor but no
      previous diagnoses of either diabetes or cardiovascular disease. They completed
      health related quality of life (HRQoL) questionnaire before the oral glucose
      tolerance test (OGTT) was performed to diagnose the gategories of glucose
      tolerance. RESULTS: Persons with newly diagnosed type 2 diabetes (NDM) had lower 
      scores for physical functioning, general health and emotional role than subjects 
      with normal glucose tolerance. CONCLUSION: The results of the HRQoL questionnaire
      demonstrated that NDM is negatively associated with HRQoL, but prediabetes - IFG 
      or IGT - does not.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Pori Health Center, Saarentie 81, 28300 Pori, Finland. Electronic address:
      tellervo.seppala@pori.fi.
FAU - Seppala, Tellervo
AU  - Seppala T
FAU - Saxen, Ulla
AU  - Saxen U
FAU - Kautiainen, Hannu
AU  - Kautiainen H
FAU - Jarvenpaa, Salme
AU  - Jarvenpaa S
FAU - Korhonen, Paivi E
AU  - Korhonen PE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/01/03 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/03/24 [accepted]
AID - S1751-9918(13)00039-9 [pii]
AID - 10.1016/j.pcd.2013.03.001 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 Apr 29. pii: S1751-9918(13)00039-9. doi:
      10.1016/j.pcd.2013.03.001.

PMID- 23639598
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
DP  - 2013 Apr 29
TI  - The Ghrelin Agonist RM-131 Accelerates Gastric Emptying of Solids and Reduces
      Symptoms in Patients with Type 1 Diabetes Mellitus.
LID - S1542-3565(13)00578-8 [pii]
LID - 10.1016/j.cgh.2013.04.019 [doi]
AB  - BACKGROUND & AIMS: RM-131, a synthetic ghrelin agonist, greatly accelerates
      gastric emptying of solids in patients with type 2 diabetes and delayed gastric
      emptying (DGE). We investigated the safety and effects of a single dose of RM-131
      on gastric emptying and upper gastrointestinal (GI) symptoms in patients with
      type 1 diabetes and previously documented DGE. METHODS: In a double-blind
      crossover study, 10 patients with type 1 diabetes (age 45.7+/-4.4 y; body mass
      index 24.1+/-1.1 kg/m2) and previously documented DGE were assigned in random
      order to receive a single dose of RM-131 (100 mug, subcutaneously) or placebo.
      Thirty min later, they ate a radiolabeled solid-liquid meal containing
      Eggbeaters(R), and then underwent 4 h gastric emptying and 6 h colonic filling
      analyses by scintigraphy. Upper GI symptoms were assessed using daily diaries, to
      determine gastroparesis cardinal symptom index (total GCSI-DD) and nausea,
      vomiting, fullness, and pain (NVFP) scores (scales of 0-5). RESULTS: At
      screening, participants' mean level of hemoglobin A1c was 9.1%+/-0.5%; their
      total GCSI-DD score was 1.66+/-0.38 (median 1.71) and total NVFP score was
      1.73+/-0.39 (median 1.9). The t1/2 of solid gastric emptying was 84.9+/-31.6 min 
      when subjects were given RM-131 and 118.7+/-26.7 when they were given placebo.
      The median reduction in t1/2 following administration of RM-131 was 33.9 min
      (interquartile range [IQR], 12 to 49), or 54.7% (IQR, 21%-110%). RM-131 decreased
      gastric retention of solids at 1 h (P=.005) and 2 h (P=.019). Numerical
      differences in t1/2 for gastric emptying of liquids, solid gastric emptying lag
      time, and colonic filling at 6 h were not significant. Total GCSI-DD scores were 
      0.79 on placebo (IQR, 0.75-2.08) and 0.17 on RM-131 (IQR, 0.00-0.67; P=.026);
      NVFP scores were lower on RM-131 (P=.041). There were no significant adverse
      effects. CONCLUSIONS: RM-131 significantly reduces the t1/2 of gastric emptying
      of solids and upper GI symptoms in patients with type 1 diabetes and documented
      DGE. CLINICALTRIALS.GOV: NCT01394055.
CI  - Copyright (c) 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
AD  - Clinical Enteric Neuroscience Translational and Epidemiological Research
      (CENTER).
FAU - Shin, Andrea
AU  - Shin A
FAU - Camilleri, Michael
AU  - Camilleri M
FAU - Busciglio, Irene
AU  - Busciglio I
FAU - Burton, Duane
AU  - Burton D
FAU - Smith, Steven A
AU  - Smith SA
FAU - Vella, Adrian
AU  - Vella A
FAU - Ryks, Michael
AU  - Ryks M
FAU - Rhoten, Deborah
AU  - Rhoten D
FAU - Zinsmeister, Alan R
AU  - Zinsmeister AR
LA  - ENG
GR  - M01 RR000585/RR/NCRR NIH HHS/United States
GR  - R01 DK067071/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal
      of the American Gastroenterological Association
JID - 101160775
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/02/21 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/02 [accepted]
AID - S1542-3565(13)00578-8 [pii]
AID - 10.1016/j.cgh.2013.04.019 [doi]
PST - aheadofprint
SO  - Clin Gastroenterol Hepatol. 2013 Apr 29. pii: S1542-3565(13)00578-8. doi:
      10.1016/j.cgh.2013.04.019.

PMID- 23639570
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 Apr 29
TI  - The association of type 2 diabetes and insulin resistance/secretion with
      persistent organic pollutants in two First Nations communities in northern
      Ontario.
LID - S1262-3636(13)00033-5 [pii]
LID - 10.1016/j.diabet.2013.01.006 [doi]
AB  - AIMS: Recent evidence suggests an association between persistent organic
      pollutants (POPs) and type 2 diabetes. In two First Nations communities where
      wild food is consumed by a large portion of the population, we compared
      pollutants in plasma between diabetic and non-diabetic individuals, and
      investigated the strength of association between pollutants and insulin
      resistance/secretion in non-diabetic individuals. METHODS: The study population
      consisted of 72 participants. Oral Glucose Tolerance Tests were used to assess
      diabetes status. Plasma was used to determine POP concentrations and mercury
      concentrations were determined from hair samples. RESULTS: Age-adjusted plasma
      concentrations of some pollutants were significantly higher in diabetic than in
      non-diabetic individuals. When taking into account age, adiposity levels, and
      smoking status, POP levels were not associated with insulin resistance nor with
      insulin secretion in non-diabetic individuals. CONCLUSIONS: These findings
      confirm that POP concentrations in plasma may be higher in diabetic than in
      non-diabetic individuals. No association was however seen between POP
      concentrations and markers of insulin resistance/secretion in non-diabetic
      individuals.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Department of Biology, University of Ottawa, 30, Marie Curie, K1N 6N5 Ottawa,
      Ontario, Canada.
FAU - Pal, S
AU  - Pal S
FAU - Blais, J M
AU  - Blais JM
FAU - Robidoux, M A
AU  - Robidoux MA
FAU - Haman, F
AU  - Haman F
FAU - Krummel, E
AU  - Krummel E
FAU - Seabert, T A
AU  - Seabert TA
FAU - Imbeault, P
AU  - Imbeault P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/08/20 [received]
PHST- 2013/01/11 [revised]
PHST- 2013/01/11 [accepted]
AID - S1262-3636(13)00033-5 [pii]
AID - 10.1016/j.diabet.2013.01.006 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 Apr 29. pii: S1262-3636(13)00033-5. doi:
      10.1016/j.diabet.2013.01.006.

PMID- 23639569
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 Apr 29
TI  - Interference of the most frequent haemoglobin variants on quantification of HbA: 
      Comparison between the LC-MS (IFCC reference method) and three routinely used
      methods.
LID - S1262-3636(13)00021-9 [pii]
LID - 10.1016/j.diabet.2013.01.004 [doi]
AB  - AIM: Assaying HbA1c in patients with haemoglobin variants has long been a
      technical challenge, despite methodological advances that have progressively
      limited the problem. The purpose of this study was to evaluate the impact of the 
      most frequent haemoglobin variants on three routine separation methods compared
      with the IFCC reference method. PATIENTS: Blood samples from heterozygous
      patients (AS, AC, AD, AE) were analyzed using the IFCC reference method (LC-MS), 
      and the results compared with those obtained by capillary electrophoresis
      (CAPILLARYS 2 Flex Piercing, Sebia) and two HPLC methods using cation-exchange
      (Variant II, Bio-Rad) and affinity chromatography (Ultra2, Primus). RESULTS:
      HbA1c values obtained by the IFCC reference method were comparable to those
      obtained by the three tested methods whatever the haemoglobin variant. Mean
      relative biases did not exceed the threshold of 7% (above which differences are
      generally considered clinically significant), although some individual values
      were above this limit with Variant II in samples with HbS and for all three
      methods in samples with HbE. CONCLUSION: This comparative study of the LC-MS
      reference method and three field methods has demonstrated that these assays are
      not clinically influenced by the presence of the most common haemoglobin
      variants. The present results also confirm that the interpretation of HbA1c
      values in patients with Hb variants remains complex and depends on the assays
      used and should, in some cases, take into account parameters other than
      analytical ones (such as differences in glycation rates and half-lives of
      haemoglobin variants).
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Laboratory of Paediatric Biology and Research, American Memorial Hospital,
      University Hospital of Reims, 47, rue Cognacq-Jay, 51092 Reims cedex, France;
      Laboratory of Medical Biochemistry and Molecular Biology, FRE CNRS/URCA n(o)
      3481, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France. 
      Electronic address: sjaisson@chu-reims.fr.
FAU - Jaisson, S
AU  - Jaisson S
FAU - Leroy, N
AU  - Leroy N
FAU - Desroches, C
AU  - Desroches C
FAU - Tonye-Libyh, M
AU  - Tonye-Libyh M
FAU - Guillard, E
AU  - Guillard E
FAU - Gillery, P
AU  - Gillery P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/12/07 [received]
PHST- 2013/01/18 [revised]
PHST- 2013/01/21 [accepted]
AID - S1262-3636(13)00021-9 [pii]
AID - 10.1016/j.diabet.2013.01.004 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 Apr 29. pii: S1262-3636(13)00021-9. doi:
      10.1016/j.diabet.2013.01.004.

PMID- 23639568
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
DP  - 2013 Apr 29
TI  - A novel GATA6 mutation leading to congenital heart defects and permanent neonatal
      diabetes: A case report.
LID - S1262-3636(13)00032-3 [pii]
LID - 10.1016/j.diabet.2013.01.005 [doi]
AB  - Permanent neonatal diabetes mellitus is a rare condition mostly due to
      heterozygous mutations in the KCNJ11, ABCC8 and INS genes. Neonatal diabetes due 
      to pancreatic agenesis is extremely rare. Mutations in PDX1, PTF1A, HNF1B,
      EIF2AK3, RFX6 and GATA6 genes have been shown to result in pancreatic agenesis or
      hypoplasia. This report describes a 40-day-old male infant diagnosed with
      permanent neonatal diabetes associated with atrial septal defect, pulmonary
      stenosis, patent ductus arteriosus and a novel de novo heterozygous missense
      mutation (p.N466S) in the GATA6 gene with no evidence of exocrine pancreas
      insufficiency. In addition to permanent neonatal diabetes, the patient had
      transient idiopathic neonatal cholestasis and hypoglycaemic episodes unrelated to
      insulin treatment, features that are rarely described in children with permanent 
      neonatal diabetes.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Department of Pediatric Endocrinology, Dokuz Eylul University, Faculty of
      Medicine, Balcova, 35340 Izmir, Turkey.
FAU - Catli, G
AU  - Catli G
FAU - Abaci, A
AU  - Abaci A
FAU - Flanagan, S E
AU  - Flanagan SE
FAU - De Franco, E
AU  - De Franco E
FAU - Ellard, S
AU  - Ellard S
FAU - Hattersley, A
AU  - Hattersley A
FAU - Guleryuz, H
AU  - Guleryuz H
FAU - Bober, E
AU  - Bober E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/12/17 [received]
PHST- 2013/01/30 [revised]
PHST- 2013/01/30 [accepted]
AID - S1262-3636(13)00032-3 [pii]
AID - 10.1016/j.diabet.2013.01.005 [doi]
PST - aheadofprint
SO  - Diabetes Metab. 2013 Apr 29. pii: S1262-3636(13)00032-3. doi:
      10.1016/j.diabet.2013.01.005.

PMID- 23639547
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1532-821X (Electronic)
IS  - 0003-9993 (Linking)
DP  - 2013 Apr 29
TI  - Rehabilitation Outcomes of Stroke Patients With and Without Diabetes.
LID - S0003-9993(13)00320-1 [pii]
LID - 10.1016/j.apmr.2013.04.014 [doi]
AB  - OBJECTIVE: To investigate the relation of diabetes comorbidity and the
      rehabilitation outcomes of patients with stroke. DESIGN: Secondary data analysis.
      SETTING: Inpatient rehabilitation facilities. PARTICIPANTS: Patients with stroke 
      (N=35,243) who received inpatient rehabilitation in 2004 through 2008.
      INTERVENTIONS: None. MAIN OUTCOME MEASURES: FIM, length of stay, and discharge
      destination. RESULTS: Mean age +/- SD of the sample was 71.0+/-13.2 years. The
      percent of the sample of Medicare beneficiaries was 53.8%, whereas 46.2% had
      other sources of funding. Of the patients in the sample, 34.5% had a comorbidity 
      of diabetes, with 17.2% classified as tier-eligible and 82.8% as nontier
      eligible. Findings included that patients in this sample with diabetes were
      admitted for rehabilitation services at a younger age than those without diabetes
      and support previous studies in which tier-eligible diabetes comorbidities
      moderated by patient age were found to be significant predictors of stroke
      rehabilitation outcomes. Furthermore, similar findings remained regardless of
      payer source. CONCLUSIONS: This study provides additional evidence that diabetes 
      as a comorbidity is significantly related to stroke rehabilitation outcome, but
      the relation is moderated by patient age.
CI  - Copyright (c) 2013 American Congress of Rehabilitation Medicine. Published by
      Elsevier Inc. All rights reserved.
AD  - Department of Occupational Therapy, UT Health Science Center at San Antonio, San 
      Antonio, TX. Electronic address: piernikyoder@uthscsa.edu.
FAU - Piernik-Yoder, Bridgett
AU  - Piernik-Yoder B
FAU - Ketchum, Norma
AU  - Ketchum N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Arch Phys Med Rehabil
JT  - Archives of physical medicine and rehabilitation
JID - 2985158R
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/01/02 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/04/22 [accepted]
AID - S0003-9993(13)00320-1 [pii]
AID - 10.1016/j.apmr.2013.04.014 [doi]
PST - aheadofprint
SO  - Arch Phys Med Rehabil. 2013 Apr 29. pii: S0003-9993(13)00320-1. doi:
      10.1016/j.apmr.2013.04.014.

PMID- 23639538
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 23
IP  - 11
DP  - 2013 Jun 1
TI  - A dihydrochalcone and several homoisoflavonoids from Polygonatum odoratum are
      activators of adenosine monophosphate-activated protein kinase.
PG  - 3137-9
LID - 10.1016/j.bmcl.2013.04.027 [doi]
LID - S0960-894X(13)00496-4 [pii]
AB  - Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a major cellular
      energy sensor and master regulator of metabolic homeostasis; thus, AMPK plays a
      central role in studies on diabetes and related metabolic diseases. From the
      rhizomes of Polygonatum odoratum (Mill.) Druce, six homoisoflavonoids (1-6) and
      one dihydrochalcone (7) were isolated, and the structures of polygonatones A-D
      (4-7) were elucidated by various spectroscopic analyses. Compounds 1-7 were
      evaluated for their effect on AMPK activation. The amount of active
      phosphorylated AMPK and acetyl-CoA carboxylase in rat liver epithelial IAR-20
      cells increased when the cells were incubated with the aforementioned compounds. 
      Specifically,
      (3R)-5,7-dihydroxyl-6-methyl-8-methoxyl-3-(4'-hydroxylbenzyl)-chroman-4-one (1), 
      (3R)-5,7-dihydroxyl-6,8-dimethyl-3-(4'-hydroxylbenzyl)-chroman-4-one (2),
      (3R)-5,7-dihydroxyl-6-methyl-3-(4'-hydroxylbenzyl)-chroman-4-one (3), and
      polygonatone D (7) exhibited significant activation effects.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Institute of Materia Medica, Shandong Academy of Medical Sciences, Jinan,
      Shandong 250062, PR China; School of Medicine and Life Sciences, University of
      Jinan, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, PR China.
FAU - Guo, Huanjie
AU  - Guo H
FAU - Zhao, Huanxin
AU  - Zhao H
FAU - Kanno, Yuichiro
AU  - Kanno Y
FAU - Li, Wei
AU  - Li W
FAU - Mu, Yanling
AU  - Mu Y
FAU - Kuang, Xinzhu
AU  - Kuang X
FAU - Inouye, Yoshio
AU  - Inouye Y
FAU - Koike, Kazuo
AU  - Koike K
FAU - Jiang, Haipeng
AU  - Jiang H
FAU - Bai, Hong
AU  - Bai H
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/02/12 [received]
PHST- 2013/04/03 [revised]
PHST- 2013/04/10 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - S0960-894X(13)00496-4 [pii]
AID - 10.1016/j.bmcl.2013.04.027 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2013 Jun 1;23(11):3137-9. doi: 10.1016/j.bmcl.2013.04.027. 
      Epub 2013 Apr 17.

PMID- 23639525
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1769-714X (Electronic)
IS  - 1286-4579 (Linking)
DP  - 2013 Apr 30
TI  - Influence of a high-glucose diet on the sensitivity of Caenorhabditis elegans
      towards Escherichia coli and Staphylococcus aureus strains.
LID - S1286-4579(13)00087-7 [pii]
LID - 10.1016/j.micinf.2013.04.006 [doi]
AB  - It was recently observed that a glucose-enriched diet activates the insulin-like 
      pathway in Caenorhabditis elegans, resulting in an inhibition of the FOXO
      transcription factor DAF-16. Because this signalling pathway is highly conserved 
      from invertebrates to mammals and DAF-16 is a key player in innate immunity, we
      wondered whether a high-glucose diet, resembling the hyperglycaemic conditions in
      diabetic patients, would affect the susceptibility of C. elegans to bacterial
      pathogens isolated from different clinical situations (urinary tract or diabetic 
      foot infections). We confirmed previous reports showing that such a diet
      decreases the lifespan of C. elegans fed with an avirulent Escherichia coli
      strain. However, glucose-fed nematodes appeared to be more resistant to most
      clinical isolates tested, showing that this invertebrate model does not mimic
      infections encountered in human diabetes, where patients show increased
      susceptibility to bacterial infections. This study also suggests that modulation 
      of innate immunity in C. elegans, upon activation of the IGF1/insulin-like
      pathway by glucose, is not exclusively mediated by DAF-16, but also involves an
      additional factor that requires DAF-16 activity.
CI  - Copyright (c) 2013 Institut Pasteur. Published by Elsevier Masson SAS. All rights
      reserved.
AD  - Inserm U1047, UFR Medecine, 186 Chemin de Carreau de Lanes, 30908 Nimes Cedex 2, 
      France; Universite Montpellier 1, UFR Medecine, 186 Chemin de Carreau de Lanes,
      30908 Nimes Cedex 2, France; Laboratoire de Bacteriologie, CHU Caremeau, place du
      Professeur Robert Debre, 30029 Nimes Cedex 09, France.
FAU - Lavigne, Jean-Philippe
AU  - Lavigne JP
FAU - Audibert, Sylvain
AU  - Audibert S
FAU - Molinari, Nicolas
AU  - Molinari N
FAU - O'Callaghan, David
AU  - O'Callaghan D
FAU - Keriel, Anne
AU  - Keriel A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Microbes Infect
JT  - Microbes and infection / Institut Pasteur
JID - 100883508
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/17 [revised]
PHST- 2013/04/18 [accepted]
AID - S1286-4579(13)00087-7 [pii]
AID - 10.1016/j.micinf.2013.04.006 [doi]
PST - aheadofprint
SO  - Microbes Infect. 2013 Apr 30. pii: S1286-4579(13)00087-7. doi:
      10.1016/j.micinf.2013.04.006.

PMID- 23639273
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 0210-5705 (Electronic)
IS  - 0210-5705 (Linking)
DP  - 2013 Apr 29
TI  - [Recommendations of the Spanish Pancreatic Club on the diagnosis and treatment of
      chronic pancreatitis: Part 2 (treatment).]
LID - S0210-5705(13)00060-5 [pii]
LID - 10.1016/j.gastrohep.2012.12.003 [doi]
AB  - Chronic pancreatitis (CP) is a complex disease with a wide spectrum of clinical
      manifestations ranging from asymptomatic disease to disabling forms or serious
      complications. The management of CP frequently differs among geographical areas
      and even among centers. These differences are due to the scarcity of high-quality
      studies and clinical practice guidelines that focus on the diagnosis and
      treatment of this disease. The aim of the Spanish Pancreatic Club was to create
      evidence-based recommendations for the management of CP. Two coordinators chose a
      multidisciplinary panel of 24 experts in this disease. These experts were
      selected on the basis of their clinical and research experience in CP. A list of 
      questions was drawn up and each question was then reviewed by two panelists.
      These questions were then used to produce a draft, which was discussed in a
      face-to-face meeting with all the participants. Levels of evidence were based on 
      the classification of the Oxford Centre for Evidence-Based Medicine. In the
      second part of the consensus process, recommendations were established for the
      management of pain, pseudocysts, biliary and duodenal stenosis, pancreatic
      fistula and ascites, left portal hypertension, diabetes mellitus, exocrine
      pancreatic insufficiency, and nutritional support in CP.
CI  - Copyright (c) 2012 Elsevier Espana, S.L. y AEEH y AEG. All rights reserved.
AD  - Unidad Pancreatica, Hospital General Universitario de Alicante, Alicante, Espana.
      Electronic address: madaria@hotmail.com.
FAU - de-Madaria, Enrique
AU  - de-Madaria E
FAU - Abad-Gonzalez, Angel
AU  - Abad-Gonzalez A
FAU - Aparicio, Jose Ramon
AU  - Aparicio JR
FAU - Aparisi, Luis
AU  - Aparisi L
FAU - Boadas, Jaume
AU  - Boadas J
FAU - Boix, Evangelina
AU  - Boix E
FAU - de Las Heras, Gonzalo
AU  - de Las Heras G
FAU - Dominguez-Munoz, Enrique
AU  - Dominguez-Munoz E
FAU - Farre, Antonio
AU  - Farre A
FAU - Fernandez-Cruz, Laureano
AU  - Fernandez-Cruz L
FAU - Gomez, Luis
AU  - Gomez L
FAU - Iglesias-Garcia, Julio
AU  - Iglesias-Garcia J
FAU - Garcia-Malpartida, Katherine
AU  - Garcia-Malpartida K
FAU - Guarner, Luisa
AU  - Guarner L
FAU - Larino-Noia, Jose
AU  - Larino-Noia J
FAU - Lluis, Felix
AU  - Lluis F
FAU - Lopez, Antonio
AU  - Lopez A
FAU - Molero, Xavier
AU  - Molero X
FAU - Moreno-Perez, Oscar
AU  - Moreno-Perez O
FAU - Navarro, Salvador
AU  - Navarro S
FAU - Palazon, Jose Maria
AU  - Palazon JM
FAU - Perez-Mateo, Miguel
AU  - Perez-Mateo M
FAU - Sabater, Luis
AU  - Sabater L
FAU - Sastre, Yolanda
AU  - Sastre Y
FAU - Vaquero, Eva C
AU  - Vaquero EC
FAU - Martinez, Juan
AU  - Martinez J
CN  - en representacion del Club Espanol Pancreatico
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Recomendaciones del Club Espanol Pancreatico para el diagnostico y tratamiento de
      la pancreatitis cronica: parte 2 (tratamiento).
DEP - 20130429
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/06/18 [received]
PHST- 2012/12/20 [revised]
PHST- 2012/12/27 [accepted]
AID - S0210-5705(13)00060-5 [pii]
AID - 10.1016/j.gastrohep.2012.12.003 [doi]
PST - aheadofprint
SO  - Gastroenterol Hepatol. 2013 Apr 29. pii: S0210-5705(13)00060-5. doi:
      10.1016/j.gastrohep.2012.12.003.

PMID- 23639222
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1879-1409 (Electronic)
IS  - 0305-4179 (Linking)
DP  - 2013 Apr 29
TI  - Fire disaster following LPG tanker explosion at Chala in Kannur (Kerala, India): 
      August 27, 2012.
LID - S0305-4179(13)00106-X [pii]
LID - 10.1016/j.burns.2013.04.004 [doi]
AB  - A fire disaster following LPG tanker explosion occurred at Chala bypass, Kannur, 
      Kerala, India on August 27, 2012. The three chambered tanker with total 16tonnes 
      (162.57 quintal) LPG collided with a road divider and exploded thrice. A total of
      41 people became victims during first blast; out of which 20 died in various
      hospitals. Five people remained inside the house after first blast and escaped
      unhurt from the zone of accident before second blast. All the victims were
      transferred to various hospitals; of these, six were transferred to the burns
      unit of the Kasturba Hospital, Manipal (320km from Chala). Five (5/6) were
      transferred within 1-5 days at our burns unit suffered 31-72% total body surface 
      area (TBSA) burn, none had external injuries. One (1/6) was transferred on 20th
      day as a follow up case of 15% TBSA burn with 4% residual raw area and diabetes
      mellitus. Except one, all were managed conservatively using Limited access
      dressings (LAD; Negative Pressure Wound Therapy). One of the patient wound bed
      prepared under LAD and on 41 post burn day underwent split skin grafting under
      LAD. Out of the six patients admitted at the burns unit, two (2/6) admitted
      patients expired (one due to inhalation injury and another due to sepsis with
      multiple organ failure). One survivor (1/4) developed sepsis related liver
      dysfunction with hepatomegaly but recovered well. The total hospital stay of
      survivors at the burns unit varied from 8 to 60 days (mean hospital stay 36.5
      days). All the victims who developed psychological symptoms were treated by
      psychiatrists and counselled before discharge. Three of survivors developed
      psychological symptoms. Two of them (2/3) developed mixed anxiety-depression
      disorder (ICD 10 code F41.8) and one of these two showed grief reaction too (ICD 
      10 code F43.23). One victim (1/3) developed non-organic insomnia (ICD 10 code
      F51.0) and responded to counselling. The article describes the incident,
      mechanism of the incident, injuries sustained, author, explanations on pattern of
      burn and suggestions in relation to future safety measures.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Burns and Plastic Surgery, Kasturba Medical College, Manipal 576 104, Karnataka, 
      India. Electronic address: pkumar86@hotmail.com.
FAU - Kumar, Pramod
AU  - Kumar P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Burns
JT  - Burns : journal of the International Society for Burn Injuries
JID - 8913178
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2012/12/10 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/04/02 [accepted]
AID - S0305-4179(13)00106-X [pii]
AID - 10.1016/j.burns.2013.04.004 [doi]
PST - aheadofprint
SO  - Burns. 2013 Apr 29. pii: S0305-4179(13)00106-X. doi: 10.1016/j.burns.2013.04.004.

PMID- 23639187
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
DP  - 2013 Apr 29
TI  - Amelioration of palmitate-induced insulin resistance in C2C12 muscle cells by
      rooibos (Aspalathus linearis).
LID - S0944-7113(13)00127-X [pii]
LID - 10.1016/j.phymed.2013.03.018 [doi]
AB  - Increased levels of free fatty acids (FFAs), specifically saturated free fatty
      acids such as palmitate are associated with insulin resistance of muscle, fat and
      liver. Skeletal muscle, responsible for up to 80% of the glucose disposal from
      the peripheral circulation, is particularly vulnerable to increased levels of
      saturated FFAs. Rooibos (Aspalathus linearis) and its unique dihydrochalcone
      C-glucoside, aspalathin, shown to reduce hyperglycemia in diabetic rats, could
      play a role in preventing or ameliorating the development of insulin resistance. 
      This study aims to establish whether rooibos can ameliorate
      experimentally-induced insulin-resistance in C2C12 skeletal muscle cells.
      Palmitate-induced insulin resistant C2C12 cells were treated with an
      aspalathin-enriched green (unfermented) rooibos extract (GRE), previously shown
      for its blood glucose lowering effect in vitro and in vivo or an aqueous extract 
      of fermented rooibos (FRE). Glucose uptake and mitochondrial activity were
      measured using 2-deoxy-[3H]-d-glucose, MTT and ATP assays, respectively.
      Expression of proteins relevant to glucose metabolism was analysed by Western
      blot. GRE contained higher levels of all compounds, except the enolic
      phenylpyruvic acid-2-O-glucoside and luteolin-7-O-glucoside. Both rooibos
      extracts increased glucose uptake, mitochondrial activity and ATP production.
      Compared to FRE, GRE was more effective at increasing glucose uptake and ATP
      production. At a mechanistic level both extracts down-regulated PKC theta
      activation, which is associated with palmitate-induced insulin resistance.
      Furthermore, the extracts increased activation of key regulatory proteins (AKT
      and AMPK) involved in insulin-dependent and non-insulin regulated signalling
      pathways. Protein levels of the glucose transporter (GLUT4) involved in glucose
      transport via these two pathways were also increased. This in vitro study
      therefore confirms that rooibos can ameliorate palmitate-induced insulin
      resistance in C2C12 skeletal muscle cells. Inhibition of PKC theta activation and
      increased activation of AMPK and AKT offer a plausible mechanistic explanation
      for this ameliorative effect.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
AD  - Diabetes Discovery Platform, South African Medical Research Council, P.O. Box
      19070, Tygerberg 7505, South Africa; Department of Biochemistry and Microbiology,
      University of Zululand, Private Bag X1001, Kwa-Dlangezwa 3886, South Africa.
      Electronic address: Sithandiwe.mazibuko@mrc.ac.za.
FAU - Mazibuko, S E
AU  - Mazibuko SE
FAU - Muller, C J F
AU  - Muller CJ
FAU - Joubert, E
AU  - Joubert E
FAU - de Beer, D
AU  - de Beer D
FAU - Johnson, R
AU  - Johnson R
FAU - Opoku, A R
AU  - Opoku AR
FAU - Louw, J
AU  - Louw J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/02/18 [received]
PHST- 2013/03/27 [accepted]
AID - S0944-7113(13)00127-X [pii]
AID - 10.1016/j.phymed.2013.03.018 [doi]
PST - aheadofprint
SO  - Phytomedicine. 2013 Apr 29. pii: S0944-7113(13)00127-X. doi:
      10.1016/j.phymed.2013.03.018.

PMID- 23639094
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 7
IP  - 4
DP  - 2013 May
TI  - Cardiovascular risk, atherosclerosis and metabolic syndrome after liver
      transplantation: a mini review.
PG  - 361-4
LID - 10.1586/egh.13.19 [doi]
AB  - Liver transplantation is the standard of care for acute and chronic end-stage
      liver disease. Advances in medical therapy and surgical techniques have
      transformed the long-term survival of liver-transplant (LT) recipients. The
      prevalence of post-transplant cardiovascular complications has been rising with
      increased life expectancy after liver transplantation. Currently, deaths related 
      to cardiovascular complications are one of the main causes of long-term mortality
      in LT recipients, as cardiovascular disease is the reason of 19-42% of
      non-liver-related mortality after transplant. On the other hand, metabolic
      syndrome is common among LT recipients before and after transplantation. In fact,
      their components (abdominal obesity, diabetes mellitus, hypertension and
      dyslipidemia) are often exacerbated by transplant-specific factors, such as
      immunosuppression, inappropriate diet, smoking and a sedentary lifestyle, and add
      a significant risk of developing atherosclerosis. These aspects are discussed in 
      this article.
AD  - Department of Gastroenterology, Clinical Division, University of Sao Paulo,
      School of Medicine, Hepatology Branch (LIM-07), Sao Paulo, Brazil.
FAU - Oliveira, Claudia Pinto Marques Souza de
AU  - Oliveira CP
FAU - Stefano, Jose Tadeu
AU  - Stefano JT
FAU - Alvares-da-Silva, Mario Reis
AU  - Alvares-da-Silva MR
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.1586/egh.13.19 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2013 May;7(4):361-4. doi: 10.1586/egh.13.19.

PMID- 23639086
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 7
IP  - 4
DP  - 2013 May
TI  - Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or
      consequence?
PG  - 295-7
LID - 10.1586/egh.13.13 [doi]
AD  - Department of Health Sciences, University Magna Graecia, Viale Europa, Germaneto,
      88100, Catanzaro, Italy. l.abenavoli@unicz.it.
FAU - Abenavoli, Ludovico
AU  - Abenavoli L
FAU - Rouabhia, Samir
AU  - Rouabhia S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.1586/egh.13.13 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2013 May;7(4):295-7. doi: 10.1586/egh.13.13.

PMID- 23638994
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1557-9077 (Electronic)
IS  - 1050-7256 (Linking)
DP  - 2013 May 2
TI  - Low Normal Free Thyroxine Confers Decreased Serum Bilirubin in Type 2 Diabetes
      Mellitus.
AB  - Background: Bilirubin may confer cardiovascular protection due to its strong
      anti-oxidative properties. Both thyroid dysfunction and the diabetic state affect
      bilirubin metabolism. Here we tested whether low-normal thyroid function affects 
      serum bilirubin among euthyroid subjects with and without Type 2 diabetes
      mellitus (T2DM). Methods: Serum total bilirubin, thyroid-stimulating hormone
      (TSH) and free thyroxine (free T4), transaminases, insulin sensitivity
      (homeostasis model assessment) and lipids were measured in 74 T2DM and 82
      non-diabetic subjects with TSH and free T4 levels within the euthyroid range.
      Results: Bilirubin was positively related to free T4 in T2DM subjects (r=0.370,
      p<0.001), but not in non-diabetic subjects (r=0.047, p=0.68). In age- and sex
      adjusted multiple linear regression analysis, free T4 was found to interact
      positively with the presence of T2DM on serum bilirubin (interaction term:
      ss=0.251, p=0.024). This interaction remained present after additional adjustment
      for alcohol intake, aspartate aminotransferase and insulin sensitivity
      (interaction term: ss=0.222, p=0.043), or alternatively for cholesterol and
      triglycerides (interaction term: ss=0.203, p=0.057). Conclusions: Lower free T4
      levels within the euthyroid range confer decreased bilirubin in T2DM. Low normal 
      thyroid function could enhance atherosclerosis susceptibility in T2DM by
      decreasing serum bilirubin.
AD  - University Medical Center Groningen, Department of Medicine, Groningen,
      Netherlands ; p.e.deetman@umcg.nl.
FAU - Deetman, Petronella E
AU  - Deetman PE
FAU - Kwakernaak, Arjan J
AU  - Kwakernaak AJ
FAU - Bakker, Stephan J L
AU  - Bakker SJ
FAU - Dullaart, Robin P F
AU  - Dullaart RP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Thyroid
JT  - Thyroid : official journal of the American Thyroid Association
JID - 9104317
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.1089/thy.2013.0156 [doi]
PST - aheadofprint
SO  - Thyroid. 2013 May 2.

PMID- 23638917
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1744-5094 (Electronic)
IS  - 1381-6810 (Linking)
DP  - 2013 May 2
TI  - Leber's Congenital Amaurosis as the Retinal Degenerative Phenotype in Thiamine
      Responsive Megaloblastic Anemia: A Case Report.
AB  - Abstract Background: Thiamine responsive megaloblastic anemia syndrome (TRMA), an
      autosomal recessive disorder is caused by mutations in the SLC19A2 gene which
      encodes for thiamine transporter 1 (THTR1) protein. TRMA presents with a triad of
      clinical features that includes diabetes mellitus, megaloblastic anemia and
      sensorineural hearing loss. Apart from the triad, reported ophthalmic features
      include cone rod dystrophy, optic atropy and retinitis pigmentosa. Materials and 
      Methods: A female child presented with Leber's congenital amaurosis at 10 months 
      of age, later diagnosed with hearing impairment at 1 year, diabetes mellitus and 
      megaloblastic anemia at 3 and a half years of age and hence as a case of thiamine
      responsive megaloblastic anemia. Six exons of the candidate gene SLC19A2 were
      screened by PCR and direct sequencing. SIFT and PolyPhen analysis was done to
      predict the probable effect of the mutation. Results: Sequence analysis of the
      SLC19A2 coding region revealed a novel missense mutation in exon 2; c.314 G > A
      (p.G105E). Segregation analysis revealed parents heterozygous for the mutation
      and unaffected sib homozygous for wild type. SIFT and PolyPhen analyses predicted
      the mutation to be "damaging" (score-0.02) and "probably damaging" (score-0.994),
      respectively. Conclusions: SLC19A2, the high-affinity thiamine transporter, is
      the only gene known to be associated with TRMA. Here we describe for the first
      time Leber's congenital amaurosis as the retinal phenotype and also report a
      novel point mutation in the SLC19A2 gene that co-segregated with the disease in a
      TRMA patient.
AD  - SNONGC Department of Genetics and Molecular Biology, Vision Research Foundation ,
      Chennai, Tamil Nadu , India and.
FAU - Srikrupa, Natarajan N
AU  - Srikrupa NN
FAU - Meenakshi, Swaminathan
AU  - Meenakshi S
FAU - Arokiasamy, Tharigopala
AU  - Arokiasamy T
FAU - Murali, Kaushik
AU  - Murali K
FAU - Soumittra, Nagasamy
AU  - Soumittra N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Ophthalmic Genet
JT  - Ophthalmic genetics
JID - 9436057
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.3109/13816810.2013.793363 [doi]
PST - aheadofprint
SO  - Ophthalmic Genet. 2013 May 2.

PMID- 23638904
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1740-8709 (Electronic)
IS  - 1740-8695 (Linking)
DP  - 2013 May 3
TI  - Effect of a low glycaemic index diet in gestational diabetes mellitus on
      post-natal outcomes after 3 months of birth: a pilot follow-up study.
LID - 10.1111/mcn.12039 [doi]
AB  - A low glycaemic index (LGI) diet during pregnancy complicated by gestational
      diabetes mellitus (GDM) may offer benefits to the mother and infant pair beyond
      those during pregnancy. We aimed to investigate the effect of an LGI diet during 
      pregnancy complicated with GDM on early post-natal outcomes. Fifty-eight women
      (age: 23-41 years; mean +/- SD pre-pregnancy body mass index: 24.5 +/- 5.6 kg m-2
      ) who had GDM and followed either an LGI diet (n = 33) or a conventional
      high-fibre diet (HF; n = 25) during pregnancy had a 75-g oral glucose tolerance
      test and blood lipid tests at 3 months post-partum. Anthropometric assessments
      were conducted for 55 mother-infant pairs. The glycaemic index of the antenatal
      diets differed modestly (mean +/- SD: 46.8 +/- 5.4 vs. 52.4 +/- 4.4; P < 0.001), 
      but there were no significant differences in any of the post-natal outcomes. In
      conclusion, an LGI diet during pregnancy complicated by GDM has outcomes similar 
      to those of a conventional healthy diet. Adequately powered studies should
      explore the potential beneficial effects of LGI diet on risk factors for chronic 
      disease.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - School of Molecular Bioscience and Boden Institute of Obesity, Nutrition,
      Exercise and Eating Disorders, University of Sydney, Sydney, New South Wales,
      Australia; School of Health Sciences, Faculty of Health and Behavioral Sciences, 
      The University of Wollongong, Wollongong, New South Wales, Australia.
FAU - Louie, Jimmy Chun Yu
AU  - Louie JC
FAU - Markovic, Tania P
AU  - Markovic TP
FAU - Ross, Glynis P
AU  - Ross GP
FAU - Foote, Deborah
AU  - Foote D
FAU - Brand-Miller, Jennie C
AU  - Brand-Miller JC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Matern Child Nutr
JT  - Maternal & child nutrition
JID - 101201025
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.1111/mcn.12039 [doi]
PST - aheadofprint
SO  - Matern Child Nutr. 2013 May 3. doi: 10.1111/mcn.12039.

PMID- 23638864
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Issue information.
PG  - i
LID - 10.1111/dom.1684 [doi]
LA  - eng
PT  - Journal Article
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.1111/dom.1684 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2013 Jun;15(6):i. doi: 10.1111/dom.1684.

PMID- 23638862
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1744-4160 (Electronic)
IS  - 1381-3455 (Linking)
VI  - 119
IP  - 2
DP  - 2013 May
TI  - Inhibitory activities of Ulva lactuca polysaccharides on digestive enzymes
      related to diabetes and obesity.
PG  - 81-7
LID - 10.3109/13813455.2013.775159 [doi]
AB  - Abstract The aim of this study was to evaluate the effect of alga Ulva lactuca
      polysaccharides (ULPS) on key enzymes related to diabetes and obesity. This
      marine natural product, ULPS, exerted potential inhibition on key enzymes related
      to starch digestion and absorption in both plasma and small intestine mainly
      alpha-amylase by 53% and 34% and maltase by 97 and 164% respectively, leading to 
      a significant decrease in blood glucose rate by 297%. Moreover, ULPS potentially 
      inhibited key enzymes of lipid metabolism and absorption as lipase activity in
      both plasma and small intestine by 235 and 287% respectively, which led to a
      notable decrease of blood LDL-cholesterol and triglycerides levels, and in the
      counterpart an increase in HDL-cholesterol level in surviving diabetic rats.
      Additively, ULPS significantly protected the liver-kidney functions, by
      decreasing of aspartate transaminase (AST), alanine transaminase (ALT) and
      gamma-glytamyl transpeptidase (GGT) activities and creatinine, urea and albumin
      rates in plasma.
AD  - Laboratory of Animal Ecophysiology, University of Sfax, Faculty of Sciences of
      Sfax , PO Box 95, Sfax , Tunisia and.
FAU - Belhadj, Sahla
AU  - Belhadj S
FAU - Hentati, Olfa
AU  - Hentati O
FAU - Elfeki, Abdelfattah
AU  - Elfeki A
FAU - Hamden, Khaled
AU  - Hamden K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Arch Physiol Biochem
JT  - Archives of physiology and biochemistry
JID - 9510153
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.3109/13813455.2013.775159 [doi]
PST - ppublish
SO  - Arch Physiol Biochem. 2013 May;119(2):81-7. doi: 10.3109/13813455.2013.775159.

PMID- 23638810
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1502-3850 (Electronic)
IS  - 0001-6357 (Linking)
DP  - 2013 May 3
TI  - Detection of sulphate-reducing bacteria in human saliva.
AB  - Abstract Objective. The aim of the current study was to investigate the presence 
      of sulphate-reducing bacteria (SRB) in human saliva and correlate with oral and
      systemic conditions. Methods. Saliva samples were collected from 118 patients and
      inoculated in 2 ml of modified Postgate's E medium culture. After 28 days of
      incubation at 30 degrees C the presence of SRB was identified by the production
      of sulphide. Results. Of 118 saliva samples collected, 35 were positive for the
      presence of SRB. Three positive samples were randomly chosen to identify the
      species of SRB by PCR and sequenced. The three selected samples were identified
      as Desulfovibrio fairfieldensis, Desulfovibrio desulfuricans and Raoultella
      ornithinolytica. Gastritis (14.4%) was the most prevalent systemic disease,
      followed by diabetes (3.4%), while periodontitis (11%) and traumatic fibroma
      (4.2%) were the oral manifestations most frequently found. A bivariate analysis
      was performed to examine for the presence of SRB and the most prevalent systemic 
      and oral manifestations. Only periodontitis showed a statistically significant
      association (p = 0.0003). Conclusions. The results showed SRB can be found in
      oral microbiota of healthy patients. Regarding the several conditions studied,
      there was a higher prevalence of SRB in patients with gastritis and patients with
      periodontal disease, with a possible correlation between the presence of SRB in
      the oral microbiota and periodontal disease.
AD  - Fluminense Federal University , Rio de Janeiro , Brazil.
FAU - Heggendorn, Fabiano Luiz
AU  - Heggendorn FL
FAU - Souza Goncalves, Lucio
AU  - Souza Goncalves L
FAU - Dias, Eliane Pedra
AU  - Dias EP
FAU - Silva Junior, Arley
AU  - Silva Junior A
FAU - Galvao, Mariana Machado
AU  - Galvao MM
FAU - Lutterbach, Marcia T S
AU  - Lutterbach MT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130503
TA  - Acta Odontol Scand
JT  - Acta odontologica Scandinavica
JID - 0370344
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.3109/00016357.2013.770163 [doi]
PST - aheadofprint
SO  - Acta Odontol Scand. 2013 May 3.

PMID- 23638642
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1936-086X (Electronic)
IS  - 1936-0851 (Linking)
VI  - 7
IP  - 5
DP  - 2013 May 28
TI  - Injectable nano-network for glucose-mediated insulin delivery.
PG  - 4194-201
LID - 10.1021/nn400630x [doi]
AB  - Diabetes mellitus, a disorder of glucose regulation, is a global burden affecting
      366 million people across the world. An artificial "closed-loop" system able to
      mimic pancreas activity and release insulin in response to glucose level changes 
      has the potential to improve patient compliance and health. Herein we develop a
      glucose-mediated release strategy for the self-regulated delivery of insulin
      using an injectable and acid-degradable polymeric network. Formed by
      electrostatic interaction between oppositely charged dextran nanoparticles loaded
      with insulin and glucose-specific enzymes, the nanocomposite-based porous
      architecture can be dissociated and subsequently release insulin in a
      hyperglycemic state through the catalytic conversion of glucose into gluconic
      acid. In vitro insulin release can be modulated in a pulsatile profile in
      response to glucose concentrations. In vivo studies validated that these
      formulations provided improved glucose control in type 1 diabetic mice
      subcutaneously administered with a degradable nano-network. A single injection of
      the developed nano-network facilitated stabilization of the blood glucose levels 
      in the normoglycemic state (<200 mg/dL) for up to 10 days.
AD  - Department of Chemical Engineering and double daggerDavid H. Koch Institute for
      Integrative Cancer Research, Massachusetts Institute of Technology , 77
      Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
FAU - Gu, Zhen
AU  - Gu Z
FAU - Aimetti, Alex A
AU  - Aimetti AA
FAU - Wang, Qun
AU  - Wang Q
FAU - Dang, Tram T
AU  - Dang TT
FAU - Zhang, Yunlong
AU  - Zhang Y
FAU - Veiseh, Omid
AU  - Veiseh O
FAU - Cheng, Hao
AU  - Cheng H
FAU - Langer, Robert S
AU  - Langer RS
FAU - Anderson, Daniel G
AU  - Anderson DG
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - ACS Nano
JT  - ACS nano
JID - 101313589
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PHST- 2013/05/02 [aheadofprint]
AID - 10.1021/nn400630x [doi]
PST - ppublish
SO  - ACS Nano. 2013 May 28;7(5):4194-201. doi: 10.1021/nn400630x. Epub 2013 May 2.

PMID- 23638620
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1473-0766 (Electronic)
IS  - 0951-3590 (Linking)
DP  - 2013 May 2
TI  - Role of A1c in the postpartum screening of women with gestational diabetes.
AB  - Abstract Objective: This study aimed to determine whether A1c detects a different
      prediabetes prevalence in women with a history of gestational diabetes mellitus
      (GDM) compared to those diagnosed with oral glucose tolerance test (OGTT) and the
      influence of haemoglobin concentrations on A1c levels. Design and patients: We
      evaluated carbohydrate metabolism status by performing OGTT and A1c tests in 141 
      postpartum women with prior GDM in the first year post-delivery. Results: The
      overall prevalence of prediabetes was 41.8%. Prevalence of isolated A1c 5.7-6.4%,
      impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) was 10.6%,
      7.1%, and 9.2%, respectively. Isolated A1c 5.7-6.4% was associated with Caucasian
      origin (66.7% versus 32.6%, p = 0.02) and with higher LDL cholesterol
      concentrations (123 +/- 28.4 mg/dl versus 101.6 +/- 19.2 mg/dl, p = 0.037)
      compared with patients diagnosed by OGTT (IFG or IGT). Women with postpartum
      anaemia had similar A1c levels to those with normal haemoglobin concentrations
      (5.5% +/- 0.6% versus 5.4% +/- 0.4%, p = 0.237). Conclusions: Use of A1c in
      postpartum screening of women with GDM detected an additional 10.6% of patients
      with prediabetes and a more adverse lipid profile. Haemoglobin concentrations did
      not influence A1c values.
AD  - Department of Endocrinology and Nutrition, Hospital del Mar. , Barcelona , Spain 
      and.
FAU - Benaiges, D
AU  - Benaiges D
FAU - Chillaron, J J
AU  - Chillaron JJ
FAU - Pedro-Botet, J
AU  - Pedro-Botet J
FAU - Mas, A
AU  - Mas A
FAU - Puig de Dou, J
AU  - Puig de Dou J
FAU - Sagarra, E
AU  - Sagarra E
FAU - Carrera, M J
AU  - Carrera MJ
FAU - Goday, A
AU  - Goday A
FAU - Flores-Le Roux, J A
AU  - Flores-Le Roux JA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Gynecol Endocrinol
JT  - Gynecological endocrinology : the official journal of the International Society
      of Gynecological Endocrinology
JID - 8807913
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
AID - 10.3109/09513590.2013.788639 [doi]
PST - aheadofprint
SO  - Gynecol Endocrinol. 2013 May 2.

PMID- 23638608
OWN - NLM
STAT- In-Process
DA  - 20130503
IS  - 0047-2166 (Print)
IS  - 0047-2166 (Linking)
IP  - 1
DP  - 2013 Mar
TI  - [Recommendations for the management of diabetes during Ramadan].
PG  - 18-9
AD  - Unite Soins Pharmaceutiques, Faculte des Sciences Pharmaceutiques, Universite de 
      Gand, Harelbekestraat 72, B-9000 Gand, Belgique.
FAU - Peeters, B
AU  - Peeters B
FAU - Mehuys, E
AU  - Mehuys E
FAU - Boussery, K
AU  - Boussery K
LA  - fre
PT  - Journal Article
TT  - Diabete et ramadan: contexte et recommandations pratiques.
PL  - Belgium
TA  - J Pharm Belg
JT  - Journal de pharmacie de Belgique
JID - 0375351
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PST - ppublish
SO  - J Pharm Belg. 2013 Mar;(1):18-9.

PMID- 23638607
OWN - NLM
STAT- In-Process
DA  - 20130503
IS  - 0047-2166 (Print)
IS  - 0047-2166 (Linking)
IP  - 1
DP  - 2013 Mar
TI  - [Diabetes and fasting during Ramadan. A observational study among Turkish
      immigrants in Belgium].
PG  - 12-6
AB  - AIMS: To investigate (i) Ramadan participation, (ii) provision of Ramadan related
      advice by healthcare providers (iii) medication use during Ramadan fasting among 
      Turkish migrants with diabetes in Belgium. METHODS: This pilot observational
      study was conducted among a convenience sample of 52 Turkish migrants with
      diabetes in Belgium. Two questionnaires collected information on
      socio-demographic characteristics, diabetes related characteristics, current
      hypoglycaemic medication with dosing regimen, participation in the past Ramadan, 
      reasons for (non)participation, use of hypoglycaemic medication during the past
      Ramadan, advice from their healthcare providers about fasting during Ramadan and 
      follow up of this advice. RESULTS: Sixteen patients (31%) had fasted during the
      past Ramadan. Main reason for Ramadan participation was reinforcement of faith
      (12/15), while the main reason for non participation was having diabetes (34/36).
      About 56% of the study population had received recommendations from their
      healthcare provider(s) about fasting and diabetes during Ramadan. The most
      commonly provided advice was not to participate in Ramadan, followed by
      modification of drug therapy. Only 3 patients ignored the advice of their
      healthcare professionals. In addition, only 60% of those who actually fasted
      received recommendations about intake of diabetes medication during the ramadan. 
      Most fasters continued their medication dose unchanged (87% of OHA users and 80% 
      of the insulin users). CONCLUSIONS: This pilot study found a low prevalence of
      Ramadan fasting among Turkish migrants with diabetes in Belgium. We also found
      that provision of advice by healthcare providers could be improved. Larger scale 
      studies are warranted to confirm these findings.
AD  - Unite Soins Pharmaceutiques, Faculte des Sciences Pharmaceutiques. Universite de 
      Gand, Harelbekestraat 72, B-9000 Gand, Belgique. b.peeters@ugent.be
FAU - Peeters, B
AU  - Peeters B
FAU - Mehuys, E
AU  - Mehuys E
FAU - Van Tongelen, I
AU  - Van Tongelen I
FAU - Van Bever, E
AU  - Van Bever E
FAU - Bultereys, L
AU  - Bultereys L
FAU - Avonts, D
AU  - Avonts D
FAU - Yildiz, G
AU  - Yildiz G
FAU - Remon, J P
AU  - Remon JP
FAU - Boussery, K
AU  - Boussery K
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Diabete et jeune pendant le ramadan. Etude observationnelle parmi les migrants
      d'origine turque en Belgique.
PL  - Belgium
TA  - J Pharm Belg
JT  - Journal de pharmacie de Belgique
JID - 0375351
SB  - IM
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PST - ppublish
SO  - J Pharm Belg. 2013 Mar;(1):12-6.

PMID- 23638530
OWN - NLM
STAT- In-Process
DA  - 20130503
IS  - 0896-1263 (Print)
IS  - 0896-1263 (Linking)
VI  - 27
IP  - 5
DP  - 2013 Apr
TI  - Advances in the treatment of diabetic nephropathy.
PG  - 18, 33
AB  - While renal and cardiovascular outcomes trials are required, several new
      therapies for patients with diabetes are promising. The diabetic nephropathy
      research community will hopefully continue to learn from recent experiences,
      through the step-wise design of clinical trials, including proof-of-principle and
      mechanistic studies, followed by investment in adequately powered clinical trials
      that will capture important renal and cardiovascular long-term outcomes.
AD  - Division of Nephrology at Toronto General Hospital.
FAU - Cherney, David Z I
AU  - Cherney DZ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nephrol News Issues
JT  - Nephrology news & issues
JID - 8709753
SB  - N
EDAT- 2013/05/04 06:00
MHDA- 2013/05/04 06:00
CRDT- 2013/05/04 06:00
PST - ppublish
SO  - Nephrol News Issues. 2013 Apr;27(5):18, 33.

PMID- 23638485
STAT- Publisher
DA  - 20130503
PB  - Agency for Healthcare Research and Quality (US)
CTI - AHRQ Comparative Effectiveness Reviews
DP  - 2013 Mar
BTI - Strategies to Prevent Weight Gain Among Adults
AB  - Adults tend to gain weight progressively through middle age. Although the average
      weight gain is 0.5 to 1 kg per year, this modest accumulation of weight can lead 
      to obesity over time. We aimed to compare the effectiveness, safety, and impact
      on quality of life of strategies to prevent weight gain among adults.
      Self-management, dietary, physical activity, orlistat and combinations of these
      strategies were considered. We searched MEDLINE(R), Embase(R), the Cochrane
      Central Register of Controlled Trials, CINAHL(R), and PsycINFO(R) through June
      2012 for published articles that were potentially eligible for this review. Two
      reviewers independently reviewed titles, abstracts, and articles, and included
      English-language articles that reported on maintenance of weight or prevention of
      weight gain among adults. Studies targeting a combination of weight loss with
      weight maintenance or weight loss exclusively were considered to be outside of
      the scope of this review. Trials of interventions and observational studies of
      approaches with at least 1 year of followup with a weight outcome were included. 
      Data were abstracted on measures of weight, adherence, obesity-related outcomes, 
      safety, and quality of life. The timepoints of interest for weight outcomes were:
      1 year, 2 years, 5 years, and the last reported timepoint after 5 years. For the 
      other outcomes, we abstracted data only from the last reported timepoint on or
      after 1 year. We selected a meaningful difference threshold in addition to a
      statistically significant threshold (p<0.05) for the outcomes. A meaningful
      between group difference was defined as 0.5 kg of weight, 0.2 units of BMI (based
      on a 0.5-kg change for an individual with a BMI of 27), or 1 cm of waist
      circumference per year of followup. We considered an intervention or approach
      effective if the difference between groups met the meaningful between group
      difference threshold and was statistically significant. We qualitatively
      synthesized the studies by population, intervention, and outcome. We included 58 
      publications (describing 51 studies) involving 555,783 patients. Two
      interventions may be effective compared with no intervention at preventing weight
      gain with moderate strengths of evidence: workplace interventions having
      individual and environmental components and exercise performed at home by women
      with cancer. Potentially effective interventions with low strength of evidence
      include a clinic-based program to teach heart rate monitoring, a combination
      intervention for mothers of young children, small group sessions to educate
      college women, and physical activity among individuals at risk of cardiovascular 
      disease and diabetes. Potentially effective approaches described in observational
      studies having low strength of evidence include eating meals prepared at home
      among college graduates and less television viewing among individuals with
      colorectal cancer. When reported, adherence to interventions tended to be below
      80 percent. There were no adverse events among the few trials that reported on
      adverse events. Trial study quality tended to be poor due to knowledge of the
      intervention by the study personnel who measured the weight of the participants
      or lack of reporting on this item. This lack of blinding of the outcome assessor 
      along with inclusion of studies that were not designed to prevent weight gain
      resulted in a low strength of evidence for the majority of comparisons. The
      literature provides some, although limited, evidence about interventions and
      approaches that may prevent weight gain. Although there is not strong evidence to
      promote a particular weight gain prevention strategy, there is no evidence that
      not adopting a strategy to prevent weight gain is preferable.
FAU - Hutfless, Susan
AU  - Hutfless S
FAU - Maruthur, Nisa M
AU  - Maruthur NM
FAU - Wilson, Renee F
AU  - Wilson RF
FAU - Gudzune, Kimberly A
AU  - Gudzune KA
FAU - Brown, Rochelle
AU  - Brown R
FAU - Lau, Brandyn
AU  - Lau B
FAU - Fawole, Oluwakemi A
AU  - Fawole OA
FAU - Chaudhry, Zoobia W
AU  - Chaudhry ZW
FAU - Anderson, Cheryl AM
AU  - Anderson CAM
FAU - Segal, Jodi B
AU  - Segal JB
LA  - eng
PT  - Book
PL  - Rockville (MD)
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CDAT- 2013/05/03 06:00
AID - NBK133218 [bookaccession]

PMID- 23638475
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Decoding the food label: how to decide what products are best for you.
PG  - 58-62
FAU - Neithercott, Tracey
AU  - Neithercott T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):58-62.

PMID- 23638474
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Fresh pleasures.
PG  - 54-7
FAU - Webb, Robyn
AU  - Webb R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):54-7.

PMID- 23638473
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Mapping fat: where your flab is stored matters, spurring scientists to develop
      new ways to assess your health.
PG  - 46-9
FAU - Gebel, Erika
AU  - Gebel E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):46-9.

PMID- 23638472
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Diabetes basics: true or false? These up-to-date diabetes management practices
      may surprise you.
PG  - 40-3
FAU - Neithercott, Tracey
AU  - Neithercott T
FAU - Gebel, Erika
AU  - Gebel E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):40-3.

PMID- 23638471
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Straight up: climber Steve Richert's year of testing himself.
PG  - 35-9
FAU - Neithercott, Tracey
AU  - Neithercott T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):35-9.

PMID- 23638470
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Finding the nerve: diabetic neuropathy often goes undercover, but doctors have
      ways to unmask it.
PG  - 30-2
FAU - Gebel, Erika
AU  - Gebel E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):30-2.

PMID- 23638469
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Look on the bright side: progress in defining and treating depression and
      diabetes.
PG  - 26-8
FAU - Gebel, Erika
AU  - Gebel E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):26-8.

PMID- 23638466
OWN - NLM
STAT- In-Process
DA  - 20130501
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 67
IP  - 4
DP  - 2013 Apr
TI  - Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes
      mellitus inadequately controlled on metformin alone: long-term (52-week)
      extension of a 52-week randomised controlled trial.
PG  - 307-16
AB  - AIM: To compare the long-term safety, tolerability and efficacy of saxagliptin
      vs. glipizide as add-on therapy to metformin. Methods: Adults with glycated
      haemoglobin (HbA1c) > 6.5-10% (on stable metformin >/= 1500 mg/day) were
      randomised to saxagliptin 5 mg/day (n = 428) or glipizide titrated from 5 to 20
      mg/day (mean dose 15 mg/day; n = 430) for 52 weeks with a 52-week extension
      (NCT00575588). Assessment of the long-term safety, tolerability and efficacy of
      add-on saxagliptin vs. glipizide after 104 weeks was a tertiary objective of the 
      initial 52-week study. RESULTS: Saxagliptin was well tolerated during the
      104-week period; 67.1% of patients receiving saxagliptin vs. 72.6% receiving
      glipizide had >/= 1 adverse event (AE), and few patients (4.9% vs. 5.6%)
      discontinued owing to AEs. Fewer patients treated with saxagliptin experienced
      hypoglycaemia (3.5% vs. 38.4% with glipizide; difference, -34.9%, 95% CI, -39.8
      to -30.0) or confirmed hypoglycaemia (0 vs. 9.1% with glipizide). Weight loss was
      observed with saxagliptin (-1.5 kg) vs. weight gain with glipizide (+1.3 kg;
      between-group difference, -2.8 kg, 95% CI, -3.32 kg to -2.20 kg). Change from
      baseline in HbA1c was -0.41 +/- 0.04% with saxagliptin and -0.35 +/- 0.04% with
      glipizide (between-group difference, -0.05%, 95% CI, -0.17 to 0.06%). A post hoc 
      analysis showed that the proportion of patients with baseline HbA1c >/= 7% who
      achieved HbA1c < 7% (observed data) at week 104 was 23.1% for saxagliptin +
      metformin and 22.7% for glipizide + metformin. DISCUSSION AND CONCLUSION: A lower
      risk of hypoglycaemia and reduced body weight were observed with saxagliptin vs. 
      glipizide. No other clinically significant differences were observed between
      groups in safety profile. No significant between-group differences were observed 
      for reductions in glycaemic parameters. After week 24, a smaller weekly rise in
      HbA1c was observed with saxagliptin vs. glipizide as add-on therapy to metformin.
AD  - Ludwig Maximilian University of Munich, Department of Internal Medicine, Munich, 
      Germany.
FAU - Goke, Burkhard
AU  - Goke B
FAU - Gallwitz, Baptist
AU  - Gallwitz B
FAU - Eriksson, Johan G
AU  - Eriksson JG
FAU - Hellqvist, Asa
AU  - Hellqvist A
FAU - Gause-Nilsson, Ingrid
AU  - Gause-Nilsson I
LA  - eng
SI  - ClinicalTrials.gov/NCT00575588
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Int J Clin Pract. 2013 Apr;67(4):307-16.

PMID- 23638431
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130502
DCOM- 20130503
LR  - 20130506
IS  - 2222-3959 (Print)
IS  - 2222-3959 (Linking)
VI  - 6
IP  - 2
DP  - 2013
TI  - Iris microhaemangioma: a management strategy.
PG  - 246-50
LID - 10.3980/j.issn.2222-3959.2013.02.26 [doi]
AB  - AIM: To analyse previous literature and to formulate a management strategy for
      iris microhaemangiomas (IMH). METHODS: A review of the literature in English
      language articles on IMH. RESULTS: Thirty five English language articles
      fulfilled the criteria for inclusion to the study and based on the contents on
      these articles a management strategy was formulated. Age at presentation ranged
      from 42 to 80 years with no sex or racial predisposition. Most patients with IMH 
      have no systemic disease but a higher incidence had been reported in patients
      with diabetes mellitus, myotonic dystrophy, chronic obstructive pulmonary disease
      (COPD) and several other systemic and ophthalmic co-morbidities. Most patients
      remained asymptomatic until they experienced a sudden blurring of vision due to a
      hyphaema. Some patients only develop a self-limiting single episode of hyphaema
      and therefore the laser or surgical photocoagulation of iris should be reserved
      for the cases complicated with recurrent hyphaema. In some patients, several
      laser photocoagulation sessions may be needed and the recurrent iris vascular
      tufts may require more aggressive treatment. Iris fluorescein angiography (IFA)
      is useful in identifying the true extent of the disease and helps to improve the 
      precision of the laser treatment. Surgical excision (iridectomy) should only be
      considered in patients who fail to respond to repeated laser treatment. In some
      cases IMHs has been initially misdiagnosed as amaurosis fugax, iritis and
      Posner-Schlossman syndrome. CONCLUSION: Owing to its scarcity, there is no good
      quality scientific evidence to support the management of IMH. The authors discuss
      the various treatment options and present a management strategy based on the
      previous literature for the management for this rare condition and its
      complications.
AD  - Department of Ophthalmology, Royal Bolton Hospital Foundation Trust, Bolton, BL4 
      0JR, United Kingdom.
FAU - Dharmasena, Aruna
AU  - Dharmasena A
FAU - Wallis, Simon
AU  - Wallis S
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC3633769
OID - NLM: PMC3633769
OTO - NOTNLM
OT  - Argon laser photocoagulation
OT  - Cobb's tufts
OT  - capillary haemangioma of iris
OT  - iris microhaemangioma
OT  - iris vascular tufts
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/27 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.3980/j.issn.2222-3959.2013.02.26 [doi]
AID - ijo-06-02-246 [pii]
PST - epublish
SO  - Int J Ophthalmol. 2013 Apr 18;6(2):246-50. doi:
      10.3980/j.issn.2222-3959.2013.02.26. Print 2013.

PMID- 23638428
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130502
DCOM- 20130503
LR  - 20130506
IS  - 2222-3959 (Print)
IS  - 2222-3959 (Linking)
VI  - 6
IP  - 2
DP  - 2013
TI  - Potential therapeutic effects of pigment epithelium-derived factor for treatment 
      of diabetic retinopathy.
PG  - 221-7
LID - 10.3980/J.ISSN.2222-3959.2013.02.22 [doi]
AB  - Diabetic retinopathy (DR), a major micro-vascular complication of diabetes, has
      emerged as a leading cause of visual impairment and blindness among working
      adults in the worldwide. The pathobiology of DR involves multiple molecular
      pathways and is characterized chronic neurovascular degeneration. Current
      approaches to prevent or to treat DR are still far from satisfactory. Therefore, 
      it is important to develop new therapeutic strategies for the prevention and
      treatment to DR. Pigment epithelium-derived factor (PEDF), a 50-kDa secreted
      glycoprotein, has been described as a multi-functional protein. Some emerging
      evidences indicate that PEDF are able to target multiple pathways exerting
      neurotropic, neuroprotective, anti-angiogenic, antivasopermeability,
      anti-inflammation, anti-thrombogenic and anti-oxidative effects in DR. In this
      review, we addressed the functions of PEDF in different pathways, which could
      lead to potential therapeutics on the treatment to DR.
AD  - Department of Ophthalmology, Institution of Ophthalmic Center, The Second Xiangya
      Hospital, Central South University, No.139 Middle Renmin Road, Changsha 410011,
      Hunan Province, China.
FAU - Liu, Xiao
AU  - Liu X
FAU - Chen, Hui-Hui
AU  - Chen HH
FAU - Zhang, Li-Wei
AU  - Zhang LW
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC3633765
OID - NLM: PMC3633765
OTO - NOTNLM
OT  - diabetic retinopathy
OT  - molecular therapeutics
OT  - pigment epithelium derived factor
OT  - pleiotropic functions
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/08 [received]
PHST- 2013/03/10 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.3980/J.ISSN.2222-3959.2013.02.22 [doi]
AID - ijo-06-02-221 [pii]
PST - epublish
SO  - Int J Ophthalmol. 2013 Apr 18;6(2):221-7. doi:
      10.3980/J.ISSN.2222-3959.2013.02.22. Print 2013.

PMID- 23638412
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130502
DCOM- 20130503
LR  - 20130506
IS  - 2222-3959 (Print)
IS  - 2222-3959 (Linking)
VI  - 6
IP  - 2
DP  - 2013
TI  - Effects of intensive control of blood glucose and blood pressure on microvascular
      complications in patients with type II diabetes mellitus.
PG  - 141-5
LID - 10.3980/j.issn.2222-3959.2013.02.06 [doi]
AB  - AIM: To evaluate the effects of intensive control of blood glucose and blood
      pressure on microvascular complications in patients with type II diabetes by
      comparing the therapeutic effects of intensive and standard treatment in patients
      with type II diabetes. METHODS: A total of 107 patients with type II diabetes
      were randomly assigned into intensive and standard treatment groups. Patients in 
      the intensive treatment group received preterax (perindopril/ indapamide) to
      control blood pressure, and gliclazide (diamicron) MR to control blood glucose.
      Patients in the standard treatment group received routine medications or placebo.
      Urinary microalbumin (UMA), urinary creatinine (UCR), the UMA/UCR ratio, and
      visual acuity were monitored according to the study design of the ADVANCE trial. 
      Direct ophthalmoscopy and seven-field stereoscopic retinal photography were used 
      to examine the fundi at baseline, and repeated after 5 years of treatment.
      RESULTS: The characteristics of patients in both groups were well balanced at
      baseline. After 5 years of treatment, visual acuity was found to be decreased in 
      the standard group (P=0.04), but remained stable in the intensive group. The
      severity of diabetic retinopathy had not progressed in patients in the intensive 
      group, but had deteriorated in the standard group (P=0.0006). The UMA/UCR ratio
      was not obviously changed in patients in the intensive group, whereas it was
      significantly increased in the standard group (P=0.00). CONCLUSION: Intensive
      control of blood glucose and blood pressure can decrease the incidence or slow
      the progression of microvascular complications in patients with type II diabetes,
      and maintain stable vision.
AD  - Department of Ophthalmology, Ruijin Hospital, School of Medicine, Shanghai
      Jiaotong University, Shanghai 200025, China.
FAU - Zhu, Cai-Hong
AU  - Zhu CH
FAU - Zhang, Shi-Sheng
AU  - Zhang SS
FAU - Kong, Yan
AU  - Kong Y
FAU - Bi, Yu-Fang
AU  - Bi YF
FAU - Wang, Ling
AU  - Wang L
FAU - Zhang, Qiong
AU  - Zhang Q
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - China
TA  - Int J Ophthalmol
JT  - International journal of ophthalmology
JID - 101553860
PMC - PMC3633749
OID - NLM: PMC3633749
OTO - NOTNLM
OT  - diabetes mellitus
OT  - diabetic retinopathy
OT  - intensive therapy
OT  - microvascular complications
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/07/05 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.3980/j.issn.2222-3959.2013.02.06 [doi]
AID - ijo-06-02-141 [pii]
PST - epublish
SO  - Int J Ophthalmol. 2013 Apr 18;6(2):141-5. doi:
      10.3980/j.issn.2222-3959.2013.02.06. Print 2013.

PMID- 23638390
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130502
DCOM- 20130503
LR  - 20130508
IS  - 2167-8359 (Electronic)
VI  - 1
DP  - 2013
TI  - Hypothyroidism and diabetes mellitus - a risky dual gestational endocrinopathy.
PG  - e52
LID - 10.7717/peerj.52 [doi]
AB  - Objectives. Diabetes mellitus (DM) and hypothyroidism are each associated with
      increased rate of pregnancy complications. However, their combined morbidity
      during gestation is poorly studied. Therefore, the aims of this study were to
      determine the prevalence of the combined morbidity of DM & hypothyroidism and
      whether it is associated with adverse maternal and neonatal outcome. Study
      design. This population based retrospective cohort study included 87,213 women
      who had 232,293 deliveries. All deliveries were divided into the following
      groups: (1) hypothyroidism & DM (n = 171); (2) hypothyroidism (n = 1502); (3) DM 
      (n = 13,324); and (4) deliveries of women with neither endocrinopathy, who served
      as a control group (n = 217, 296). Results. The prevalence of DM & hypothyroidism
      in our population was 0.17%. In comparisons to the other study groups, women with
      DM & hypothyroidism had higher rates of infertility (p < 0.001), preeclampsia (p 
      < 0.001), chronic hypertension (p < 0.001), preterm birth (p < 0.001), and
      cesarean deliveries (p < 0.001). In Generalized Estimating Equations (GEE) model,
      hypothyroidism & DM was an independent risk factor for cesarean section (OR 3.46;
      95% CI 2.53-4.75) and for preeclampsia (OR 1.82; 95%CI 1.16-2.84). Conclusion.
      The combination of DM & hypothyroidism is rare, yet it is associated with higher 
      rate of infertility, cesarean sections, preterm deliveries, and hypertensive
      disorders of pregnancy than the rest of the population. This dual
      endocrinological combination is an independent risk factor for preeclampsia and
      cesarean section. These findings suggest that these patients are at risk for
      perinatal complications and should be followed and delivered as high risk
      pregnancies.
AD  - Department of Obstetrics & Gynecology, Soroka University Medical Center , Beer
      Sheva , Israel.
FAU - Tirosh, Dan
AU  - Tirosh D
FAU - Benshalom-Tirosh, Neta
AU  - Benshalom-Tirosh N
FAU - Novack, Lena
AU  - Novack L
FAU - Press, Fernanda
AU  - Press F
FAU - Beer-Weisel, Ruthy
AU  - Beer-Weisel R
FAU - Wiznitzer, Arnon
AU  - Wiznitzer A
FAU - Mazor, Moshe
AU  - Mazor M
FAU - Erez, Offer
AU  - Erez O
LA  - eng
PT  - Journal Article
DEP - 20130319
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
PMC - PMC3628609
OID - NLM: PMC3628609
OTO - NOTNLM
OT  - Cesarean section
OT  - Preeclampsia
OT  - Pregnancy
OT  - Preterm delivery
OT  - Preterm labor
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/02 [received]
PHST- 2013/02/28 [accepted]
PHST- 2013/03/19 [epublish]
AID - 10.7717/peerj.52 [doi]
AID - 52 [pii]
PST - epublish
SO  - PeerJ. 2013 Mar 19;1:e52. doi: 10.7717/peerj.52. Print 2013.

PMID- 23638232
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 6
IP  - 5
DP  - 2013
TI  - Cutaneous pseudolymphoma: a case report with an immunohistochemical study.
PG  - 966-72
AB  - Cutaneous pseudolymphoma (C-PSL) is defined as reactive polyclonal benign
      lymphoproliferative process predominantly composed of either B-cells or T-cells, 
      localized or disseminated. It heals spontaneously after cessation of the
      causative factor (e.g. drugs) or after non-aggressive treatment. The author
      herein presents a case of C-PSL with an immunohistochemical study. A 78-year-old 
      man consulted our hospital because of slightly itching skin swelling on the arm. 
      He denied insect bite and traumatic injury. His usual intake drugs were drugs of 
      hypertension, hyperlipidemia, diabetes mellitus, and emotional disorders.
      Physical examination showed mildly erosive swelling of the am. The lesion
      measured 1 x 1 x 0.2 cm. Biopsy of the lesion was taken, and it revealed
      excessive proliferation of small lymphoid cells. The lymphoid cells lacked
      apparent atypical features and appeared matures. Lymphoblastic cells with
      nucleoli were scattered. Nodular structures were also seen in the lower dermis.
      Immunohistochemically, the lymphoid cells were positive for vimentin, CD3, CD4,
      CD5, CD8, CD10, CD15, CD20, CD23, CD30, CD43, CD38, CD138, CD45RO, CD79alpha,
      bcl-2, bcl-6, kappa-chain, lambda-chain, and Ki-67 (labeling index=7%). No light 
      chain restriction is seen. The lymphoblastic cells were positively labeled for
      CD15 and CD30. Plasma cells positive for CD38, CK79alpha and CD138 were seen in a
      significant amounts. They were negative for cytokeratin (CK) CAM5.2, CKAE1/3,
      CK34BE12, CK5/6, CK7, CK8, CK18, CK19, CK20, EMA, CEA, CD56, CD57, p53, KIT,
      PDGFRA, and cyclin D1. Because the constituent cells were both B-cells including 
      plasm cells and T-cells, no light-chain restriction was seen, and no histological
      atypia was seen, a diagnosis of cutaneous pseudolymphoma was made. The low Ki-67 
      labeling and negative p53 also suggested the diagnosis. The lesion slightly
      reduced in size (from 1 cm to 0.7 cm), the causative agent was still unknown 11
      months after the biopsy.
AD  - Departments of Pathology, Shizuoka City Shimizu Hospital Shizuoka, Japan.
FAU - Terada, Tadashi
AU  - Terada T
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
SB  - IM
PMC - PMC3638111
OID - NLM: PMC3638111
OTO - NOTNLM
OT  - CD
OT  - Cutaneous pseudolymphoma
OT  - immunohistochemistry
OT  - low grade lymphoid neoplasm
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/21 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/15 [epublish]
PST - epublish
SO  - Int J Clin Exp Pathol. 2013 Apr 15;6(5):966-72. Print 2013.

PMID- 23638164
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - The impact and desirability of news of risk for schizophrenia.
PG  - e62904
LID - 10.1371/journal.pone.0062904 [doi]
AB  - In studies of schizotypy, investigators seldom inform participants that they are 
      engaged in research designed to shed light on risk for schizophrenia. Such
      nondisclosure is justified in part by the argument that disclosure of risk status
      may be harmful. However, there is little evidence that this is the case. Harm
      arising from disclosure of risk status was examined in two experiments. In the
      first, participants (n = 114 psychology undergraduates) were asked to anticipate 
      their reactions to news of risk for schizophrenia, depression, cancer, and
      diabetes, and also to indicate whether they would want to know their
      schizophrenia risk status. Participants anticipated schizophrenia risk would have
      a negative impact that was significantly greater than depression or diabetes risk
      but similar to cancer risk. The anticipated impact of schizophrenia risk was
      predicted by expectations of stigmatization as well as confidence in the accuracy
      of biological screening. Although 81% indicated a preference for knowing their
      risk status, just 11% were prepared to undergo an assessment to find out. In the 
      second, a between-subjects deception paradigm was used to inform participants (n 
      = 144 psychology undergraduates) they had an enzyme deficiency that placed them
      at increased risk for schizophrenia, cancer, or depression. Impact was assessed
      using prospective self-report and salivary cortisol and retrospective
      self-report. Impact was modeled using measures of stigmatization and health locus
      of control. Retrospectively, schizophrenia, cancer, and depression risk had
      strong negative impacts relative to a control group, but there was no effect on
      prospective measures. Together, the findings suggest that news of risk for
      schizophrenia has the potential to engender distress, although participants'
      anticipations and reflections of responses are not corroborated in prospectively 
      measured outcomes.
AD  - Department of Psychology, University of Otago, Dunedin, New Zealand.
FAU - Alder, Roni G
AU  - Alder RG
FAU - Young, Jennifer L
AU  - Young JL
FAU - Russell, Elizabeth I
AU  - Russell EI
FAU - McHardy, Danielle R
AU  - McHardy DR
FAU - Linscott, Richard J
AU  - Linscott RJ
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3639267
OID - NLM: PMC3639267
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/07 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/29 [epublish]
AID - 10.1371/journal.pone.0062904 [doi]
AID - PONE-D-13-01603 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 29;8(4):e62904. doi: 10.1371/journal.pone.0062904. Print 2013.

PMID- 23638123
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Socio-Demographic and Clinical Differences in Subjects with Tuberculosis with and
      without Diabetes Mellitus in Brazil - A Multivariate Analysis.
PG  - e62604
LID - 10.1371/journal.pone.0062604 [doi]
AB  - BACKGROUND: Several studies have evaluated the relationship between diabetes
      mellitus (DM) and tuberculosis (TB), but the nature of this relationship is not
      fully understood. TB incidence may be influenced by immunosuppression from DM,
      but this association may be confounded by other clinical and socioeconomic
      factors. We aimed to assess socio-demographic and clinical differences in TB
      patients with and without DM. METHODS: Using the Brazilian national surveillance 
      system (SINAN), we compared 1,797 subjects with TB and DM with 29,275 subjects
      diagnosed with TB only in 2009. We performed multivariate analysis to identify
      factors associated with the presence of DM among TB patients. RESULTS: Subjects
      with TB - DM were older; have initial positive sputum smear test (OR = 1.42, 95% 
      CI 1.26-1.60), and were more likely to die from TB (OR = 1.44, 95% CI 1.03-2.01).
      They were less likely to have been institutionalized [in prison, shelter,
      orphanage, psychiatric hospital (OR = 0.74, 95% CI 0.60-0.93)]; developed extra
      pulmonary TB (OR = 0.62, 95% CI 0.51-0.75) and to return to TB treatment after
      abandonment (OR = 0.66, 95% CI 0.51-0.86). CONCLUSIONS: Prevalence of NCD
      continues to rise in developing countries, especially with the rise of elderly
      population, the prevention and treatment of infectious diseases will be urgent.
      DM and TB represent a critical intersection between communicable and
      non-communicable diseases in these countries and the effect of DM on TB incidence
      and outcomes provide numerous opportunities for collaboration and management of
      these complex diseases in the national public health programs.
AD  - Lab-Epi UFES - Laboratory of Epidemiology, Universidade Federal do Espirito
      Santo, Vitoria, Espirito Santo, Brazil.
FAU - Reis-Santos, Barbara
AU  - Reis-Santos B
FAU - Locatelli, Rodrigo
AU  - Locatelli R
FAU - Horta, Bernardo L
AU  - Horta BL
FAU - Faerstein, Eduardo
AU  - Faerstein E
FAU - Sanchez, Mauro N
AU  - Sanchez MN
FAU - Riley, Lee W
AU  - Riley LW
FAU - Maciel, Ethel Leonor
AU  - Maciel EL
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3634755
OID - NLM: PMC3634755
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/18 [received]
PHST- 2013/03/23 [accepted]
PHST- 2013/04/24 [epublish]
AID - 10.1371/journal.pone.0062604 [doi]
AID - PONE-D-12-39622 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 24;8(4):e62604. doi: 10.1371/journal.pone.0062604. Print 2013.

PMID- 23638101
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Differential Susceptibility and Response of Primary Human Myeloid BDCA1(+)
      Dendritic Cells to Infection with Different Enteroviruses.
PG  - e62502
LID - 10.1371/journal.pone.0062502 [doi]
AB  - Coxsackie B viruses (CVBs) and echoviruses (EVs) form the Human Enterovirus-B
      (HEV-B) species within the family Picornaviridae. HEV-B infections are widespread
      and generally cause mild disease; however, severe infections occur and HEV-B are 
      associated with various chronic diseases such as cardiomyopathy and type 1
      diabetes. Dendritic cells (DCs) are the professional antigen-presenting cells of 
      our immune system and initiate and control immune responses to invading
      pathogens, yet also maintain tolerance to self-antigens. We previously reported
      that EVs, but not CVBs, can productively infect in vitro generated
      monocyte-derived DCs. The interactions between HEV-B and human myeloid DCs (mDCs)
      freshly isolated from blood, however, remain unknown. Here, we studied the
      susceptibility and responses of BDCA1(+) mDC to HEV-B species and found that
      these mDC are susceptible to EV, but not CVB infection. Productive EV7 infection 
      resulted in massive, rapid cell death without DC activation. Contrary, EV1
      infection, which resulted in lower virus input at the same MOI, resulted in DC
      activation as observed by production of type I interferon-stimulated genes
      (ISGs), upregulation of co-stimulatory and co-inhibitory molecules (CD80, CD86,
      PDL1) and production of IL-6 and TNF-alpha, with a relative moderate decrease in 
      cell viability. EV1-induced ISG expression depended on virus replication. CVB
      infection did not affect DC viability and resulted in poor induction of ISGs and 
      CD80 induction in part of the donors. These data show for the first time the
      interaction between HEV-B species and BDCA1(+) mDCs isolated freshly from blood. 
      Our data indicate that different HEV-B species can influence DC homeostasis in
      various ways, possibly contributing to HEV-B associated pathology.
AD  - Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences &
      Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
FAU - Schulte, Barbara M
AU  - Schulte BM
FAU - Kers-Rebel, Esther D
AU  - Kers-Rebel ED
FAU - Prosser, Amy C
AU  - Prosser AC
FAU - Galama, Jochem M D
AU  - Galama JM
FAU - van Kuppeveld, Frank J M
AU  - van Kuppeveld FJ
FAU - Adema, Gosse J
AU  - Adema GJ
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3634769
OID - NLM: PMC3634769
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/14 [received]
PHST- 2013/03/22 [accepted]
PHST- 2013/04/24 [epublish]
AID - 10.1371/journal.pone.0062502 [doi]
AID - PONE-D-12-39561 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 24;8(4):e62502. doi: 10.1371/journal.pone.0062502. Print 2013.

PMID- 23638076
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Natural killer cell function, an important target for infection and tumor
      protection, is impaired in type 2 diabetes.
PG  - e62418
LID - 10.1371/journal.pone.0062418 [doi]
AB  - Patients with Type 2 diabetes (T2D) are highly susceptible to infection and have 
      an increased incidence of some tumors, possibly due to immune system dysfunction.
      In the innate cellular immune system, Natural Killer (NK) lymphocytes are
      important effectors responsible for controlling infections and combating tumor
      development. We analyzed NK cell subsets in 51 patients with long-standing T2D.
      Compared with healthy blood donors, diabetic patients showed a profound decrease 
      in both NKG2D-positive NK cells (44% vs. 55.5%, P<0.01) and NKp46-positive cells 
      (26% vs. 50%, P<0.01). Decreased expression of these receptors was associated
      with functional defects, such as reduced NK degranulation capacity when
      challenged with the tumor target cell line K562 (10.3 vs. 15.8%, P<0.05). This
      defect could be restored in vitro by stimulating NK cells from T2D patients with 
      IL-15 (P<0.05). NKG2D expression was found to be negatively correlated with HBA1c
      level (r = -0.50; P = 0.009), suggesting that sustained hyperglycemia could
      directly influence NK cell defects. We demonstrated that endoplasmic reticulum
      (ER) stress, an important mediator in diabetes-associated complications, was
      inducible in vitro in normal NK cells and that tunicamycin treatment resulted in 
      a significant decrease in NKG2D expression (P<0.05). Furthermore, markers of the 
      Unfolded Protein Response (UPR) BiP, PDI and sXBP1 mRNAs were significantly
      increased in NK cells from T2D patients (P<0.05, P<0.01, P<0.05, respectively),
      indicating that ER stress is activated in vivo through both PERK and IRE1
      sensors. These results demonstate for the first time defects in NK
      cell-activating receptors NKG2D and NKp46 in T2D patients, and implicate the UPR 
      pathway as a potential mechanism. These defects may contribute to susceptibility 
      to infections and malignancies and could be targetted therapeutically.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM), UMR 940,
      Paris, France ; Assistance Publique-Hopitaux de Paris (AP-HP), Hopital
      Saint-Louis Centre d'Investigations Biomedicales "H-O-G", Paris, France.
FAU - Berrou, Jeannig
AU  - Berrou J
FAU - Fougeray, Sophie
AU  - Fougeray S
FAU - Venot, Marion
AU  - Venot M
FAU - Chardiny, Victor
AU  - Chardiny V
FAU - Gautier, Jean-Francois
AU  - Gautier JF
FAU - Dulphy, Nicolas
AU  - Dulphy N
FAU - Toubert, Antoine
AU  - Toubert A
FAU - Peraldi, Marie-Noelle
AU  - Peraldi MN
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3636194
OID - NLM: PMC3636194
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/08/13 [received]
PHST- 2013/03/24 [accepted]
PHST- 2013/04/25 [epublish]
AID - 10.1371/journal.pone.0062418 [doi]
AID - PONE-D-12-24067 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 25;8(4):e62418. doi: 10.1371/journal.pone.0062418. Print 2013.

PMID- 23638033
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Activation of AMPK by Bitter Melon Triterpenoids Involves CaMKKbeta.
PG  - e62309
LID - 10.1371/journal.pone.0062309 [doi]
AB  - We recently showed that bitter melon-derived triterpenoids (BMTs) activate AMPK
      and increase GLUT4 translocation to the plasma membrane in vitro, and improve
      glucose disposal in insulin resistant models in vivo. Here we interrogated the
      mechanism by which these novel compounds activate AMPK, a leading anti-diabetic
      drug target. BMTs did not activate AMPK directly in an allosteric manner as AMP
      or the Abbott compound (A-769662) does, nor did they activate AMPK by inhibiting 
      cellular respiration like many commonly used anti-diabetic medications. BMTs
      increased AMPK activity in both L6 myotubes and LKB1-deficient HeLa cells by
      20-35%. Incubation with the CaMKKbeta inhibitor, STO-609, completely attenuated
      this effect suggesting a key role for CaMKKbeta in this activation. Incubation of
      L6 myotubes with the calcium chelator EGTA-AM did not alter this activation
      suggesting that the BMT-dependent activation was Ca(2+)-independent. We therefore
      propose that CaMKKbeta is a key upstream kinase for BMT-induced activation of
      AMPK.
AD  - Diabetes and Obesity Research Program, Garvan Institute of Medical Research,
      Sydney, Australia.
FAU - Iseli, Tristan J
AU  - Iseli TJ
FAU - Turner, Nigel
AU  - Turner N
FAU - Zeng, Xiao-Yi
AU  - Zeng XY
FAU - Cooney, Gregory J
AU  - Cooney GJ
FAU - Kraegen, Edward W
AU  - Kraegen EW
FAU - Yao, Sheng
AU  - Yao S
FAU - Ye, Yang
AU  - Ye Y
FAU - James, David E
AU  - James DE
FAU - Ye, Ji-Ming
AU  - Ye JM
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3636144
OID - NLM: PMC3636144
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/14 [received]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/25 [epublish]
AID - 10.1371/journal.pone.0062309 [doi]
AID - PONE-D-12-35811 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 25;8(4):e62309. doi: 10.1371/journal.pone.0062309. Print 2013.

PMID- 23637966
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Celastrol, an NF-kappaB Inhibitor, Improves Insulin Resistance and Attenuates
      Renal Injury in db/db Mice.
PG  - e62068
LID - 10.1371/journal.pone.0062068 [doi]
AB  - The NF-kappaB pathway plays an important role in chronic inflammatory and
      autoimmune diseases. Recently, NF-kappaB has also been suggested as an important 
      mechanism linking obesity, inflammation, and metabolic disorders. However, there 
      is no current evidence regarding the mechanism of action of NF-kappaB inhibition 
      in insulin resistance and diabetic nephropathy in type 2 diabetic animal models. 
      We investigated the effects of the NF-kappaB inhibitor celastrol in db/db mice.
      The treatment with celastrol for 2 months significantly lowered fasting plasma
      glucose (FPG), HbA1C and homeostasis model assessment index (HOMA-IR) levels.
      Celastrol also exhibited significant decreases in body weight, kidney/body weight
      and adiposity. Celastrol reduced insulin resistance and lipid abnormalities and
      led to higher plasma adiponectin levels. Celastrol treatment also significantly
      mitigated lipid accumulation and oxidative stress in organs including the kidney,
      liver and adipose tissue. The treated group also exhibited significantly lower
      creatinine levels and urinary albumin excretion was markedly reduced. Celastrol
      treatment significantly lowered mesangial expansion and suppressed type IV
      collagen, PAI-1 and TGFbeta1 expressions in renal tissues. Celastrol also
      improved abnormal lipid metabolism, oxidative stress and proinflammatory cytokine
      activity in the kidney. In cultured podocytes, celastrol treatment abolished
      saturated fatty acid-induced proinflammatory cytokine synthesis. Taken together, 
      celastrol treatment not only improved insulin resistance, glycemic control and
      oxidative stress, but also improved renal functional and structural changes
      through both metabolic and anti-inflammatory effects in the kidney. These results
      suggest that targeted therapy for NF-kappaB may be a useful new therapeutic
      approach for the management of type II diabetes and diabetic nephropathy.
AD  - Department of Internal Medicine, Division of Nephrology, Korea University, Ansan 
      City, Kyungki-Do, Korea.
FAU - Kim, Jung Eun
AU  - Kim JE
FAU - Lee, Mi Hwa
AU  - Lee MH
FAU - Nam, Deok Hwa
AU  - Nam DH
FAU - Song, Hye Kyoung
AU  - Song HK
FAU - Kang, Young Sun
AU  - Kang YS
FAU - Lee, Ji Eun
AU  - Lee JE
FAU - Kim, Hyun Wook
AU  - Kim HW
FAU - Cha, Jin Joo
AU  - Cha JJ
FAU - Hyun, Young Youl
AU  - Hyun YY
FAU - Han, Sang Youb
AU  - Han SY
FAU - Han, Kum Hyun
AU  - Han KH
FAU - Han, Jee Young
AU  - Han JY
FAU - Cha, Dae Ryong
AU  - Cha DR
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3637455
OID - NLM: PMC3637455
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/30 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/26 [epublish]
AID - 10.1371/journal.pone.0062068 [doi]
AID - PONE-D-12-33658 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 26;8(4):e62068. doi: 10.1371/journal.pone.0062068. Print 2013.

PMID- 23637948
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Identification and validation of novel contraction-regulated myokines released
      from primary human skeletal muscle cells.
PG  - e62008
LID - 10.1371/journal.pone.0062008 [doi]
AB  - Proteins secreted by skeletal muscle, so called myokines, have been shown to
      affect muscle physiology and additionally exert systemic effects on other tissues
      and organs. Although recent profiling studies have identified numerous myokines, 
      the amount of overlap from these studies indicates that the secretome of skeletal
      muscle is still incompletely characterized. One limitation of the models used is 
      the lack of contraction, a central characteristic of muscle cells. Here we aimed 
      to characterize the secretome of primary human myotubes by cytokine antibody
      arrays and to identify myokines regulated by contraction, which was induced by
      electrical pulse stimulation (EPS). In this study, we validated the regulation
      and release of two selected myokines, namely pigment epithelium derived factor
      (PEDF) and dipeptidyl peptidase 4 (DPP4), which were recently described as
      adipokines. This study reveals that both factors, DPP4 and PEDF, are secreted by 
      primary human myotubes. PEDF is a contraction-regulated myokine, although PEDF
      serum levels from healthy young men decrease after 60 min cycling at VO2max of
      70%. Most interestingly, we identified 52 novel myokines which have not been
      described before to be secreted by skeletal muscle cells. For 48 myokines we show
      that their release is regulated by contractile activity. This profiling study of 
      the human skeletal muscle secretome expands the number of myokines, identifies
      novel contraction-regulated myokines and underlines the overlap between proteins 
      which are adipokines as well as myokines.
AD  - Paul-Langerhans-Group of Integrative Physiology, German Diabetes Center,
      Dusseldorf, Germany.
FAU - Raschke, Silja
AU  - Raschke S
FAU - Eckardt, Kristin
AU  - Eckardt K
FAU - Bjorklund Holven, Kirsten
AU  - Bjorklund Holven K
FAU - Jensen, Jorgen
AU  - Jensen J
FAU - Eckel, Jurgen
AU  - Eckel J
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3634789
OID - NLM: PMC3634789
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/10 [received]
PHST- 2013/03/17 [accepted]
PHST- 2013/04/24 [epublish]
AID - 10.1371/journal.pone.0062008 [doi]
AID - PONE-D-12-39146 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 24;8(4):e62008. doi: 10.1371/journal.pone.0062008. Print 2013.

PMID- 23637927
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Common Genetic Variation in the Human FNDC5 Locus, Encoding the Novel
      Muscle-Derived 'Browning' Factor Irisin, Determines Insulin Sensitivity.
PG  - e61903
LID - 10.1371/journal.pone.0061903 [doi]
AB  - AIMSHYPOTHESIS: Recently, the novel myokine irisin was described to drive adipose
      tissue 'browning', to increase energy expenditure, and to improve obesity and
      insulin resistance in high fat-fed mice. Here, we assessed whether common single 
      nucleotide polymorphisms (SNPs) in the FNDC5 locus, encoding the irisin
      precursor, contribute to human prediabetic phenotypes (overweight, glucose
      intolerance, insulin resistance, impaired insulin release). METHODS: A population
      of 1,976 individuals was characterized by oral glucose tolerance tests and
      genotyped for FNDC5 tagging SNPs. Subgroups underwent
      hyperinsulinaemic-euglycaemic clamps, magnetic resonance imaging/spectroscopy,
      and intravenous glucose tolerance tests. From 37 young and 14 elderly
      participants recruited in two different centres, muscle biopsies were obtained
      for the preparation of human myotube cultures. RESULTS: After appropriate
      adjustment and Bonferroni correction for the number of tested variants, SNPs
      rs16835198 and rs726344 were associated with in vivo measures of insulin
      sensitivity. Via interrogation of publicly available data from the Meta-Analyses 
      of Glucose and Insulin-related traits Consortium, rs726344's effect on insulin
      sensitivity was replicated. Moreover, novel data from human myotubes revealed a
      negative association between FNDC5 expression and appropriately adjusted in vivo 
      measures of insulin sensitivity in young donors. This finding was replicated in
      myotubes from elderly men. CONCLUSIONSINTERPRETATION: This study provides
      evidence that the FNDC5 gene, encoding the novel myokine irisin, determines
      insulin sensitivity in humans. Our gene expression data point to an unexpected
      insulin-desensitizing effect of irisin.
AD  - Department of Internal Medicine, Division of Endocrinology, Diabetology,
      Angiology, Nephrology and Clinical Chemistry, Eberhard Karls University Tubingen,
      Tubingen, Germany ; Institute for Diabetes Research and Metabolic Diseases of the
      Helmholtz Centre Munich at the University of Tubingen, Tubingen, Germany ; German
      Centre for Diabetes Research (DZD), Neuherberg, Germany.
FAU - Staiger, Harald
AU  - Staiger H
FAU - Bohm, Anja
AU  - Bohm A
FAU - Scheler, Mika
AU  - Scheler M
FAU - Berti, Lucia
AU  - Berti L
FAU - Machann, Jurgen
AU  - Machann J
FAU - Schick, Fritz
AU  - Schick F
FAU - Machicao, Fausto
AU  - Machicao F
FAU - Fritsche, Andreas
AU  - Fritsche A
FAU - Stefan, Norbert
AU  - Stefan N
FAU - Weigert, Cora
AU  - Weigert C
FAU - Krook, Anna
AU  - Krook A
FAU - Haring, Hans-Ulrich
AU  - Haring HU
FAU - de Angelis, Martin Hrabe
AU  - de Angelis MH
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3636229
OID - NLM: PMC3636229
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/23 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/25 [epublish]
AID - 10.1371/journal.pone.0061903 [doi]
AID - PONE-D-12-36864 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 25;8(4):e61903. doi: 10.1371/journal.pone.0061903. Print 2013.

PMID- 23637918
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - The Association between Pulse Wave Velocity and Cognitive Function: The Sydney
      Memory and Ageing Study.
PG  - e61855
LID - 10.1371/journal.pone.0061855 [doi]
AB  - OBJECTIVES: Pulse wave velocity (PWV) is a measure of arterial stiffness and its 
      increase with ageing has been associated with damage to cerebral microvessels and
      cognitive impairment. This study examined the relationship between
      carotid-femoral PWV and specific domains of cognitive function in a non-demented 
      elderly sample. METHOD: Data were drawn from the Sydney Memory and Ageing Study, 
      a cohort study of non-demented community-dwelling individuals aged 70-90 years,
      assessed in successive waves two years apart. In Wave 2, PWV and cognitive
      function were measured in 319 participants. Linear regression was used to analyse
      the cross-sectional relationship between arterial stiffness and cognitive
      function in the whole sample, and separately for men and women. Analysis of
      covariance was used to assess potential differences in cognition between subjects
      with PWV measurements in the top and bottom tertiles of the cohort. Covariates
      were age, education, body mass index, pulse rate, systolic blood pressure,
      cholesterol, depression, alcohol, smoking, hormone replacement therapy,
      apolipoprotein E epsilon4 genotype, use of anti-hypertensive medications, history
      of stroke, transient ischemic attack, myocardial infarction, angina, diabetes,
      and also sex for the whole sample analyses. RESULTS: There was no association
      between PWV and cognition after Bonferroni correction for multiple testing. When 
      examining this association for males and females separately, an association was
      found in males, with higher PWV being associated with lower global cognition and 
      memory, however, a significant difference between PWV and cognition between males
      and females was not found. CONCLUSION: A higher level of PWV was not associated
      with lower cognitive function in the whole sample.
AD  - Brain and Aging Research Program, School of Psychiatry, University of New South
      Wales, Sydney, Australia ; Department of Developmental Disability
      Neuropsychiatry, School of Psychiatry, University of New South Wales, Sydney,
      Australia.
FAU - Singer, Joel
AU  - Singer J
FAU - Trollor, Julian N
AU  - Trollor JN
FAU - Crawford, John
AU  - Crawford J
FAU - O'Rourke, Michael F
AU  - O'Rourke MF
FAU - Baune, Bernhard T
AU  - Baune BT
FAU - Brodaty, Henry
AU  - Brodaty H
FAU - Samaras, Katherine
AU  - Samaras K
FAU - Kochan, Nicole A
AU  - Kochan NA
FAU - Campbell, Lesley
AU  - Campbell L
FAU - Sachdev, Perminder S
AU  - Sachdev PS
FAU - Smith, Evelyn
AU  - Smith E
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3640074
OID - NLM: PMC3640074
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/24 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/30 [epublish]
AID - 10.1371/journal.pone.0061855 [doi]
AID - PONE-D-12-37099 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 30;8(4):e61855. doi: 10.1371/journal.pone.0061855. Print 2013.

PMID- 23637851
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Achievement of Cardiometabolic Goals among Diabetic Patients in Spain. A
      Nationwide Population-Based Study.
PG  - e61549
LID - 10.1371/journal.pone.0061549 [doi]
AB  - BACKGROUND: No previous study has reported a comprehensive assessment of the
      attainment of cardiometabolic goals in the diabetic population of a European
      country. We examined the achievement of cardiometabolic goals among diabetics in 
      Spain. METHODS AND FINDINGS: A cross-sectional survey was performed in 2008-2010 
      among 12,077 individuals representative of the Spanish population aged >/=18
      years. Information on cardiometabolic characteristics was collected at the
      participants' homes through structured questionnaires, physical examination, and 
      fasting blood samples. Attainment of cardiometabolic goals was evaluated
      according to the most well-known guidelines. A total of 834 individuals had
      diabetes (fasting serum glucose >/=126 mg/dl, or glycosylated hemoglobin
      >/=6.5%,) or were being treated with oral antidiabetic drugs or insulin). Among
      diabetic patients, 661 (79.2%) were aware of their condition. Among the aware
      diabetic patients, only 11.4% had neither general (body mass index <25 kg/m(2))
      nor abdominal obesity (waist circumference </=102 cm in men and </=88 cm in
      women), 8.6% consumed <7% of calories daily from saturated fats, and 41.1%
      achieved the recommendation on weekly physical activity. About 71% had
      glycosylated hemoglobin <7%, 22% had blood pressure <130/80 mmHg, and 36% reached
      the LDL-cholesterol goal of <100 mg/dl. Although a large proportion of aware
      diabetic individuals received lifestyle medical advice, only 38% of overweight
      individuals and 20% of daily smokers were offered a specific strategy for weight 
      loss or quitting smoking, respectively. CONCLUSIONS: In a European country with
      universal healthcare coverage, achievement of many cardiometabolic goals, in
      particular lifestyle, among aware diabetic individuals is poor. This suggests a
      need for improvement in both clinical guidelines' implementation and patients'
      adherence.
AD  - Department of Preventive Medicine and Public Health, Universidad Autonoma de
      Madrid/IdiPAZ; CIBERESP, Madrid, Spain.
FAU - Navarro-Vidal, Beatriz
AU  - Navarro-Vidal B
FAU - Banegas, Jose R
AU  - Banegas JR
FAU - Leon-Munoz, Luz M
AU  - Leon-Munoz LM
FAU - Rodriguez-Artalejo, Fernando
AU  - Rodriguez-Artalejo F
FAU - Graciani, Auxiliadora
AU  - Graciani A
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3630125
OID - NLM: PMC3630125
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/04 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.1371/journal.pone.0061549 [doi]
AID - PONE-D-12-38524 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 18;8(4):e61549. doi: 10.1371/journal.pone.0061549. Print 2013.

PMID- 23637830
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Therapeutic effects of 15 Hz pulsed electromagnetic field on diabetic peripheral 
      neuropathy in streptozotocin-treated rats.
PG  - e61414
LID - 10.1371/journal.pone.0061414 [doi]
AB  - Although numerous clinical studies have reported that pulsed electromagnetic
      fields (PEMF) have a neuroprotective role in patients with diabetic peripheral
      neuropathy (DPN), the application of PEMF for clinic is still controversial. The 
      present study was designed to investigate whether PEMF has therapeutic potential 
      in relieving peripheral neuropathic symptoms in streptozotocin (STZ)-induced
      diabetic rats. Adult male Sprague-Dawley rats were randomly divided into three
      weight-matched groups (eight in each group): the non-diabetic control group
      (Control), diabetes mellitus with 15 Hz PEMF exposure group (DM+PEMF) which were 
      subjected to daily 8-h PEMF exposure for 7 weeks and diabetes mellitus with sham 
      PEMF exposure group (DM). Signs and symptoms of DPN in STZ-treated rats were
      investigated by using behavioral assays. Meanwhile, ultrastructural examination
      and immunohistochemical study for vascular endothelial growth factor (VEGF) of
      sciatic nerve were also performed. During a 7-week experimental observation, we
      found that PEMF stimulation did not alter hyperglycemia and weight loss in
      STZ-treated rats with DPN. However, PEMF stimulation attenuated the development
      of the abnormalities observed in STZ-treated rats with DPN, which were
      demonstrated by increased hind paw withdrawal threshold to mechanical and thermal
      stimuli, slighter demyelination and axon enlargement and less VEGF immunostaining
      of sciatic nerve compared to those of the DM group. The current study
      demonstrates that treatment with PEMF might prevent the development of
      abnormalities observed in animal models for DPN. It is suggested that PEMF might 
      have direct corrective effects on injured nerves and would be a potentially
      promising non-invasive therapeutic tool for the treatment of DPN.
AD  - School of Biomedical Engineering, Fourth Military Medical University, Xi'an,
      China.
FAU - Lei, Tao
AU  - Lei T
FAU - Jing, Da
AU  - Jing D
FAU - Xie, Kangning
AU  - Xie K
FAU - Jiang, Maogang
AU  - Jiang M
FAU - Li, Feijiang
AU  - Li F
FAU - Cai, Jing
AU  - Cai J
FAU - Wu, Xiaoming
AU  - Wu X
FAU - Tang, Chi
AU  - Tang C
FAU - Xu, Qiaoling
AU  - Xu Q
FAU - Liu, Juan
AU  - Liu J
FAU - Guo, Wei
AU  - Guo W
FAU - Shen, Guanghao
AU  - Shen G
FAU - Luo, Erping
AU  - Luo E
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3630223
OID - NLM: PMC3630223
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/11 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.1371/journal.pone.0061414 [doi]
AID - PONE-D-12-39054 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 18;8(4):e61414. doi: 10.1371/journal.pone.0061414. Print 2013.

PMID- 23637817
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Salivary biomarkers for detection of systemic diseases.
PG  - e61356
LID - 10.1371/journal.pone.0061356 [doi]
AB  - BACKGROUND AND OBJECTIVE: Analysis of inflammatory biomarkers in saliva could
      offer an attractive opportunity for the diagnosis of different systemic
      conditions specifically in epidemiological surveys. The aim of this study was to 
      investigate if certain salivary biomarkers could be used for detection of common 
      systemic diseases. MATERIALS AND METHODS: A randomly selected sample of 1000
      adults living in Skane, a county in the southern part of Sweden, was invited to
      participate in a clinical study of oral health. 451 individuals were enrolled in 
      this investigation, 51% women. All participants were asked to fill out a
      questionnaire, history was taken, a clinical examination was made and stimulated 
      saliva samples were collected. Salivary concentrations of IL-1beta, -6, -8,
      TNF-alpha, lysozyme, MMP-8 and TIMP-1 were determined using ELISA, IFMA or
      Luminex assays. RESULTS: Salivary IL-8 concentration was found to be twice as
      high in subjects who had experience of tumour diseases. In addition, IL-8 levels 
      were also elevated in patients with bowel disease. MMP-8 levels were elevated in 
      saliva from patients after cardiac surgery or suffering from diabetes, and muscle
      and joint diseases. The levels of IL-1beta, IL-8 and MMP-8, as well as the
      MMP-8/TIMP-1 ratio were higher in subjects with muscle and joint diseases.
      CONCLUSION: Biomarkers in saliva have the potential to be used for screening
      purposes in epidemiological studies. The relatively unspecific inflammatory
      markers used in this study can not be used for diagnosis of specific diseases but
      can be seen as markers for increased systemic inflammation.
AD  - Karolinska Institutet, Department of Dental Medicine, Division of Periodontology,
      Stockholm, Sweden.
FAU - Rathnayake, Nilminie
AU  - Rathnayake N
FAU - Akerman, Sigvard
AU  - Akerman S
FAU - Klinge, Bjorn
AU  - Klinge B
FAU - Lundegren, Nina
AU  - Lundegren N
FAU - Jansson, Henrik
AU  - Jansson H
FAU - Tryselius, Ylva
AU  - Tryselius Y
FAU - Sorsa, Timo
AU  - Sorsa T
FAU - Gustafsson, Anders
AU  - Gustafsson A
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3634781
OID - NLM: PMC3634781
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/22 [received]
PHST- 2013/03/07 [accepted]
PHST- 2013/04/24 [epublish]
AID - 10.1371/journal.pone.0061356 [doi]
AID - PONE-D-12-37078 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 24;8(4):e61356. doi: 10.1371/journal.pone.0061356. Print 2013.

PMID- 23637777
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Relative Metabolic Stability, but Disrupted Circadian Cortisol Secretion during
      the Fasting Month of Ramadan.
PG  - e60917
LID - 10.1371/journal.pone.0060917 [doi]
AB  - BACKGROUND: Chronic feeding and sleep schedule disturbances are stressors that
      exert damaging effects on the organism. Practicing Muslims in Saudi Arabia go
      through strict Ramadan fasting from dawn till sunset for one month yearly. Modern
      era Ramadan practices in Saudi Arabia are associated with disturbed feeding and
      sleep patterns, namely abstaining from food and water and increasing daytime
      sleep, and staying awake and receiving food and water till dawn. HYPOTHESIS:
      Strict Ramadan practices in Saudi Arabia may influence metabolism, sleep and
      circadian cortisol secretion. PROTOCOL: Young, male Ramadan practitioners were
      evaluated before and two weeks into the Ramadan. Blood samples were collected at 
      9.00 am and 9.00 pm for measurements of metabolic parameters and cortisol. Saliva
      was collected serially during the day for cortisol determinations. RESULTS:
      Ramadan practitioners had relative metabolic stability or changes expected by the
      pattern of feeding. However, the cortisol circadian rhythm was abolished and
      circulating insulin levels and HOMA index were increased during this period.
      DISCUSSION: The flattening of the cortisol rhythm is typical of conditions
      associated with chronic stress or endogenous hypercortisolism and associated with
      insulin resistance. CONCLUSIONS: Modern Ramadan practices in Saudi Arabia are
      associated with evening hypercortisolism and increased insulin resistance. These 
      changes might contribute to the high prevalence of chronic stress-related
      conditions, such as central obesity, hypertension, metabolic syndrome and
      diabetes mellitus type 2, and their cardiovascular sequelae observed in the
      Kingdom.
AD  - Department of ClinicalBiochemistry-Faculty of Medicine, King Abdulaziz
      University, Jeddah, Saudi Arabia ; Saudi Diabetes Study Research Group, King Fahd
      Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
FAU - Bahijri, Suhad
AU  - Bahijri S
FAU - Borai, Anwar
AU  - Borai A
FAU - Ajabnoor, Ghada
AU  - Ajabnoor G
FAU - Abdul Khaliq, Altaf
AU  - Abdul Khaliq A
FAU - Alqassas, Ibrahim
AU  - Alqassas I
FAU - Al-Shehri, Dhafer
AU  - Al-Shehri D
FAU - Chrousos, George
AU  - Chrousos G
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3630175
OID - NLM: PMC3630175
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/06 [received]
PHST- 2013/03/04 [accepted]
PHST- 2013/04/18 [epublish]
AID - 10.1371/journal.pone.0060917 [doi]
AID - PONE-D-12-39047 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 18;8(4):e60917. doi: 10.1371/journal.pone.0060917. Print 2013.

PMID- 23637743
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Lifestyles and Risk Factors Associated with Adherence to the Mediterranean Diet: 
      A Baseline Assessment of the PREDIMED Trial.
PG  - e60166
LID - 10.1371/journal.pone.0060166 [doi]
AB  - BACKGROUND: The traditional Mediterranean dietary pattern (MedDiet) is associated
      with longevity and low rates of cardiovascular disease (CVD). However, there is
      little information on who is more likely to follow this food pattern. AIM: To
      evaluate how different factors are associated with lower MedDiet adherence in
      older Spanish subjects. METHODS: We included 7305 participants (men aged 55-80 y,
      women 60-80 y) at high-risk of CVD recruited into the PREDIMED trial
      (ISRCTN35739639). Socioeconomic, anthropometric, lifestyle characteristics and
      CVD risk factors were recorded. A validated 14-item questionnaire was used to
      evaluate MedDiet adherence at baseline. Multivariate models were used to estimate
      odds ratios (OR) and 95% confidence intervals for lower adherence to the MedDiet 
      (<9 points out of 14) and ascertain factors independently associated with it.
      RESULTS: Former smoking (OR = 0.87; 95% CI, 0.78-0.98), physical activity (OR for
      the 3(rd) vs. the 1(st)tertile: 0.69; 0.62-0.78), and higher educational level
      (OR for university vs. less than primary school: 0.54; 0.38-0.77) were associated
      with higher MedDiet adherence. Conversely, having a larger waist-to-height ratio 
      (OR for 0.1 units, 1.35; 1.22-1.49), being diabetic (OR = 1.13; 1.03-1.24), being
      single (OR = 1.27; 1.01-1.61) or divorced or separated (OR = 1.44; 1.09-1.89),
      and current smoking (OR = 1.28; 1.11-1.47) were associated with lower adherence. 
      CONCLUSIONS: Participants with little education, a larger waist-to-height ratio, 
      or diabetes and those who were less physically active, single, divorced or
      separated, or smokers were less likely to adhere to the MedDiet, an ideal model
      for food choices. Stronger efforts of health promotion are needed in these groups
      to foster adoption of the MedDiet.
AD  - Department of Nutrition, Harvard School of Public Health, Harvard University,
      Boston, Massachusetts, United States of America.
FAU - Hu, Emily A
AU  - Hu EA
FAU - Toledo, Estefania
AU  - Toledo E
FAU - Diez-Espino, Javier
AU  - Diez-Espino J
FAU - Estruch, Ramon
AU  - Estruch R
FAU - Corella, Dolores
AU  - Corella D
FAU - Salas-Salvado, Jordi
AU  - Salas-Salvado J
FAU - Vinyoles, Ernest
AU  - Vinyoles E
FAU - Gomez-Gracia, Enrique
AU  - Gomez-Gracia E
FAU - Aros, Fernando
AU  - Aros F
FAU - Fiol, Miquel
AU  - Fiol M
FAU - Lapetra, Jose
AU  - Lapetra J
FAU - Serra-Majem, Lluis
AU  - Serra-Majem L
FAU - Pinto, Xavier
AU  - Pinto X
FAU - Portillo, Maria Puy
AU  - Portillo MP
FAU - Lamuela-Raventos, Rosa M
AU  - Lamuela-Raventos RM
FAU - Ros, Emilio
AU  - Ros E
FAU - Sorli, Jose V
AU  - Sorli JV
FAU - Martinez-Gonzalez, Miguel A
AU  - Martinez-Gonzalez MA
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3639284
OID - NLM: PMC3639284
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2012/09/18 [received]
PHST- 2013/02/22 [accepted]
PHST- 2013/04/29 [epublish]
AID - 10.1371/journal.pone.0060166 [doi]
AID - PONE-D-12-29808 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 29;8(4):e60166. doi: 10.1371/journal.pone.0060166. Print 2013.

PMID- 23637559
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130502
DCOM- 20130503
LR  - 20130506
IS  - 1179-1365 (Electronic)
IS  - 1179-1365 (Linking)
VI  - 5
DP  - 2013
TI  - Pharmacovigilance as a tool for safety and monitoring: a review of general issues
      and the specific challenges with end-stage renal failure patients.
PG  - 105-12
LID - 10.2147/DHPS.S43104 [doi]
AB  - Pharmacovigilance is instrumental in helping to ensure patient safety for both
      newly released drugs and those that are well established in the market. However, 
      while pharmacovigilance procedures are strictly regulated in the clinical trial
      setting, post-marketing adverse event reporting is not well implemented or
      enforced. As such, the underreporting of adverse events, in relation to drugs
      that are on the market, is estimated to be in the region of 90%. The
      identification of drug safety issues in patients with complex diseases and
      extensive comorbidities is therefore particularly challenging. Dialysis patients 
      - those with end-stage renal disease and often other comorbidities such as
      diabetes, hypertension, and cardiovascular disease - are a population with
      significant treatment challenges. Patients receive dialysis using complex medical
      devices (eg, a peritoneal dialysis home cycler) and also receive a range of
      pharmaceutical agents as part of dialysis itself (eg, peritoneal dialysis
      solutions). Many of the pharmaceutical agents used to treat these patients have
      been developed in populations without these complications and, therefore, an
      extensive knowledge of potential problems and contraindications in the dialysis
      population is lacking. It is important that the nephrology community understands 
      the concept of pharmacovigilance - the pharmacologic science relating to the
      detection, assessment, understanding, and prevention of adverse effects,
      particularly long-term and short-term side effects, of medicines. Health care
      professionals (HCPs) and providers, pharmaceutical companies, global regulatory
      agencies, and the patients themselves all play unique and critical roles in this 
      process. This review defines the science of pharmacovigilance and the process of 
      adverse event reporting, highlights the new directions that pharmacovigilance has
      taken, and provides insight for HCPs managing dialysis patients into the
      important role that they play in helping to shape the understanding of a drug's
      safety profile in order to continually enhance patient safety.
AD  - Baxter Healthcare Corporation, Deerfield, IL, USA.
FAU - Jacob, Dalia
AU  - Jacob D
FAU - Marron, Belen
AU  - Marron B
FAU - Ehrlich, Jay
AU  - Ehrlich J
FAU - Rutherford, Peter A
AU  - Rutherford PA
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - New Zealand
TA  - Drug Healthc Patient Saf
JT  - Drug, healthcare and patient safety
JID - 101544775
PMC - PMC3636760
OID - NLM: PMC3636760
OTO - NOTNLM
OT  - adverse events
OT  - comorbidities
OT  - dialysis
OT  - drug safety
OT  - end-stage renal disease
OT  - peritoneal fluids
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/15 [epublish]
AID - 10.2147/DHPS.S43104 [doi]
AID - dhps-5-105 [pii]
PST - epublish
SO  - Drug Healthc Patient Saf. 2013 Apr 15;5:105-12. doi: 10.2147/DHPS.S43104. Print
      2013.

PMID- 23637557
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130502
DCOM- 20130503
LR  - 20130506
IS  - 1178-7104 (Electronic)
IS  - 1178-7104 (Linking)
VI  - 6
DP  - 2013
TI  - Current Perspectives on rosuvastatin.
PG  - 15-25
LID - 10.2147/IBPC.S34814 [doi]
AB  - Rosuvastatin is one of the most potent statins available for reducing circulating
      low-density lipoprotein cholesterol (LDL-C) levels, which enables more high-risk 
      patients to achieve their lipid goals. Its favorable balance of effects on
      atherogenic and protective lipoproteins and its pleiotropic effects, including
      anti-inflammatory and antioxidant effects and improvement in endothelial
      dysfunction, are associated with slowing of progression of atherosclerosis within
      the artery wall and have been translated into clinical benefits for
      cardiovascular outcomes. This review provides an update on the safety and the
      efficacy of rosuvastatin in recent large clinical trials. It appears that
      rosuvastatin has a beneficial effect on the progression of atherosclerosis across
      the clinical dosage range of 2.5-40 mg. It reduced cardiovascular events in
      relatively low-risk subjects with elevated high-sensitivity C-reactive protein
      and normal low-density lipoprotein cholesterol. As with other statins,
      rosuvastatin did not show overall benefit in terms of survival in patients with
      heart failure, but certain clinical or biochemical markers reflecting underlying 
      disease characteristics may help to identify subgroups of patients that benefit
      from statin therapy. In patients with end-stage renal disease undergoing chronic 
      hemodialysis, rosuvastatin had no effect on reducing cardiovascular events.
      Although there is a slightly increased risk of incident diabetes with this class 
      of agents, the absolute benefits of statin therapy on cardiovascular events
      overweigh the risk in patients with moderate or high cardiovascular risk or with 
      documented cardiovascular disease. As with other statins, rosuvastatin is an
      appropriate therapy in addition to antihypertensive treatment to reduce
      cardiovascular risk in hypertensive patients.
AD  - Department of Medicine and Therapeutics, Chinese University of Hong Kong, Shatin,
      Hong Kong.
FAU - Hu, Miao
AU  - Hu M
FAU - Tomlinson, Brian
AU  - Tomlinson B
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - New Zealand
TA  - Integr Blood Press Control
JT  - Integrated blood pressure control
JID - 101562709
PMC - PMC3636766
OID - NLM: PMC3636766
OTO - NOTNLM
OT  - atherosclerosis
OT  - cardiovascular disease
OT  - lipids
OT  - rosuvastatin
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/18 [epublish]
AID - 10.2147/IBPC.S34814 [doi]
AID - ibpc-6-015 [pii]
PST - epublish
SO  - Integr Blood Press Control. 2013 Apr 18;6:15-25. doi: 10.2147/IBPC.S34814. Print 
      2013.

PMID- 23637538
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2
      diabetes.
PG  - 155-63
LID - 10.2147/VHRM.S33934 [doi]
AB  - Type 2 diabetes carries a risk for hypoglycemia, particularly in patients on an
      intensive glucose control plan as a glucose-lowering strategy, where hypoglycemia
      may be a limitation for the therapy and also a factor underlying clinical
      inertia. Glucose-lowering medications that increase circulating insulin in a
      glucose-independent manner, such as insulin and sulfonylurea therapy, are the
      most common cause of hypoglycemia. However, other factors such as a delayed or
      missed meal, physical exercise, or drug or alcohol consumption may also
      contribute. Specific risk factors for development of hypoglycemia are old age,
      long duration of diabetes, some concomitant medication, renal dysfunction,
      hypoglycemia unawareness, and cognitive dysfunction. Hypoglycemia is associated
      with acute short-term symptoms related to either counterregulation, such as
      tachycardia and sweating, or to neuroglycopenia, such as irritability, confusion,
      and in severe cases stupor, coma, and even death. However, there are also
      long-term consequences of hypoglycemia such as reduced working capacity, weight
      gain, loss of self-confidence with reduced quality of life, and increased risk
      for cardiovascular diseases. For both the patients, the health care system, and
      the society at large, hypoglycemia carries a high cost. Strategies to mitigate
      the risk of hypoglycemia include awareness of the condition; education of
      patients, relatives, and health care providers; and selecting appropriate
      glucose-lowering medication that also judges the risk for hypoglycemia to prevent
      this complication. This article summarizes the current knowledge of hypoglycemia 
      and its consequences with a special emphasis on its consequences for the choice
      of glucose-lowering therapy.
AD  - Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University,
      Lund, Sweden.
FAU - Ahren, Bo
AU  - Ahren B
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
SB  - IM
PMC - PMC3639216
OID - NLM: PMC3639216
OTO - NOTNLM
OT  - hypoglycemia
OT  - incretin therapy
OT  - insulin
OT  - sulfonylurea
OT  - treatment
OT  - type 2 diabetes
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/24 [epublish]
AID - 10.2147/VHRM.S33934 [doi]
AID - vhrm-9-155 [pii]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:155-63. doi: 10.2147/VHRM.S33934. Epub 2013 Apr
      24.

PMID- 23637411
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1098-5514 (Electronic)
IS  - 0022-538X (Linking)
VI  - 87
IP  - 13
DP  - 2013 Jul
TI  - Induction of an Antiviral State and Attenuated Coxsackievirus Replication in Type
      III Interferon-Treated Primary Human Pancreatic Islets.
PG  - 7646-54
LID - 10.1128/JVI.03431-12 [doi]
AB  - Type III interferons (IFNs), also called lambda interferons (IFN-lambda),
      comprise three isoforms, IFN-lambda1 (interleukin-29 [IL-29]), IFN-lambda2
      (IL-28A), and IFN-lambda3 (IL-28B). Only limited information is available on
      their expression and biological functions in humans. Type I and type II IFNs
      protect human pancreatic islets against coxsackievirus infection, and this is
      important since such viruses have been proposed to play a role in the development
      of human type 1 diabetes. Here we investigated whether type III IFN is expressed 
      during infection of human islet cells with coxsackievirus and if type III IFN
      regulates permissiveness to such infections. We show that human islets respond to
      a coxsackievirus serotype B3 (CVB3) infection by inducing the expression of type 
      III IFNs. We also demonstrate that islet endocrine cells from nondiabetic
      individuals express the type III IFN receptor subunits IFN-lambdaR1 and IL-10R2. 
      Pancreatic alpha cells express both receptor subunits, while pancreatic beta
      cells express only IL-10R2. Type III IFN stimulation elicited a biological
      response in human islets as indicated by the upregulated expression of antiviral 
      genes as well as pattern recognition receptors. We also show that type III IFN
      significantly reduces CVB3 replication. Our studies reveal that type III IFNs are
      expressed during CVB3 infection and that the expression of the type III IFN
      receptor by the human pancreatic islet allows this group of IFNs to regulate the 
      islets' permissiveness to infection. Our novel observations suggest that type III
      IFNs may regulate viral replication and thereby contribute to reduced tissue
      damage and promote islet cell survival during coxsackievirus infection.
AD  - Department of Medicine HS, The Center for Infectious Medicine, Karolinska
      Institutet, Karolinska University Hospital, Stockholm, Sweden.
FAU - Lind, Katharina
AU  - Lind K
FAU - Richardson, Sarah J
AU  - Richardson SJ
FAU - Leete, Pia
AU  - Leete P
FAU - Morgan, Noel G
AU  - Morgan NG
FAU - Korsgren, Olle
AU  - Korsgren O
FAU - Flodstrom-Tullberg, Malin
AU  - Flodstrom-Tullberg M
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - J Virol
JT  - Journal of virology
JID - 0113724
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/05/01 [aheadofprint]
AID - JVI.03431-12 [pii]
AID - 10.1128/JVI.03431-12 [doi]
PST - ppublish
SO  - J Virol. 2013 Jul;87(13):7646-54. doi: 10.1128/JVI.03431-12. Epub 2013 May 1.

PMID- 23637357
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Chronotype Is Independently Associated With Glycemic Control in Type 2 Diabetes.
AB  - OBJECTIVETo examine whether chronotype and daily caloric distribution are
      associated with glycemic control in patients with type 2 diabetes independently
      of sleep disturbances.RESEARCH DESIGN AND METHODSPatients with type 2 diabetes
      had a structured interview and completed questionnaires to collect information on
      diabetes history and habitual sleep duration, quality, and timing. Shift workers 
      were excluded. A recently validated construct derived from mid-sleep time on
      weekends was used as an indicator of chronotype. One-day food recall was used to 
      compute the temporal distribution of caloric intake. Hierarchical linear
      regression analyses controlling for demographic and sleep variables were computed
      to determine whether chronotype was associated with HbA1c values and whether this
      association was mediated by a higher proportion of caloric intake at
      dinner.RESULTSWe analyzed 194 completed questionnaires. Multiple regression
      analyses adjusting for age, sex, race, BMI, insulin use, depressed mood, diabetes
      complications, and perceived sleep debt found that chronotype was significantly
      associated with glycemic control (P = 0.001). This association was partially
      mediated by a greater percentage of total daily calories consumed at
      dinner.CONCLUSIONSLater chronotype and larger dinner were associated with poorer 
      glycemic control in patients with type 2 diabetes independently of sleep
      disturbances. These results suggest that chronotype may be predictive of disease 
      outcomes and lend further support to the role of the circadian system in
      metabolic regulation.
AD  - Section of Endocrinology, Department of Medicine, Rush University Medical Center,
      Chicago, Illinois.
FAU - Reutrakul, Sirimon
AU  - Reutrakul S
FAU - Hood, Megan M
AU  - Hood MM
FAU - Crowley, Stephanie J
AU  - Crowley SJ
FAU - Morgan, Mary K
AU  - Morgan MK
FAU - Teodori, Marsha
AU  - Teodori M
FAU - Knutson, Kristen L
AU  - Knutson KL
FAU - Van Cauter, Eve
AU  - Van Cauter E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-2697 [pii]
AID - 10.2337/dc12-2697 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637356
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Work Stress, Sense of Coherence, and Risk of Type 2 Diabetes in a Prospective
      Study of Middle-Aged Swedish Men and Women.
AB  - OBJECTIVETo investigate the prospective influence of work stress on type 2
      diabetes (T2D).RESEARCH DESIGN AND METHODSThis population-based cohort included
      3,205 women and 2,227 men, aged 35-56 years, with baseline normal glucose
      tolerance measured with oral glucose tolerance test. At follow-up 8-10 years
      later, T2D was diagnosed in 60 women and 111 men. Work stress factors evaluated
      by questionnaire (i.e., demands, decision latitude, job strain, shift work,
      overtime work, and also sense of coherence) were studied in association with T2D.
      Odds ratios (ORs) and 95% CIs adjusted for age, education, BMI, physical
      activity, smoking, family history of diabetes, and psychological distress were
      calculated.RESULTSIn women, low decision latitude was associated with T2D on its 
      own (OR 2.4 [95% CI 1.1-5.2]) and combined with high demands: job strain (OR 4.2 
      [2.0-8.7]), adjusted for all available potential confounders. Also, shift work
      increased the risk of T2D in women (OR 2.2 [1.0-4.7]) when adjusted for age,
      education, and psychological distress, although this risk was diluted after
      multifactor adjustment (OR 1.9 [0.8-4.4]). In men, high work demands and high
      strain decreased the risk of T2D (OR 0.5 [0.3-0.9]) for both measures, as did an 
      active job (high demands and high decision latitude, OR 0.4
      [0.2-0.9]).CONCLUSIONSWork stress and shift work may contribute to the
      development of T2D in women. In men, the risk was decreased by high work demands,
      high strain, and an active job.
AD  - Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet,
      Stockholm, Sweden.
FAU - Eriksson, Anna-Karin
AU  - Eriksson AK
FAU - van den Donk, Maureen
AU  - van den Donk M
FAU - Hilding, Agneta
AU  - Hilding A
FAU - Ostenson, Claes-Goran
AU  - Ostenson CG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-1738 [pii]
AID - 10.2337/dc12-1738 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637355
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Obesity and the Food Environment: Income and Ethnicity Differences Among People
      With Diabetes: The Diabetes Study of Northern California (DISTANCE).
AB  - OBJECTIVESIt is unknown whether any association between neighborhood food
      environment and obesity varies according to individual income and/or
      race/ethnicity. The objectives of this study were to test whether there was an
      association between food environments and obesity among adults with diabetes and 
      whether this relationship differed according to individual income or
      race/ethnicity.RESEARCH DESIGN AND METHODSSubjects (n = 16,057) were participants
      in the Diabetes Study of Northern California survey. Kernel density estimation
      was used to create a food environment score for each individual's residence
      address that reflected the mix of healthful and unhealthful food vendors nearby. 
      Logistic regression models estimated the association between the modeled food
      environment and obesity, controlling for confounders, and testing for
      interactions between food environment and race/ethnicity and income.RESULTSThe
      authors found that more healthful food environments were associated with lower
      obesity in the highest income groups (incomes 301-600% and >600% of U.S. poverty 
      line) among whites, Latinos, and Asians. The association was negative, but
      smaller and not statistically significant, among high-income blacks. On the
      contrary, a more healthful food environment was associated with higher obesity
      among participants in the lowest-income group (<100% poverty threshold), which
      was statistically significant for black participants in this income
      category.CONCLUSIONSThese findings suggest that the availability of healthful
      food environments may have different health implications when financial resources
      are severely constrained.
AD  - Center for Health and Community, University of California, San Francisco, San
      Francisco, California.
FAU - Jones-Smith, Jessica C
AU  - Jones-Smith JC
FAU - Karter, Andrew J
AU  - Karter AJ
FAU - Warton, E Margaret
AU  - Warton EM
FAU - Kelly, Maggi
AU  - Kelly M
FAU - Kersten, Ellen
AU  - Kersten E
FAU - Moffet, Howard H
AU  - Moffet HH
FAU - Adler, Nancy
AU  - Adler N
FAU - Schillinger, Dean
AU  - Schillinger D
FAU - Laraia, Barbara A
AU  - Laraia BA
LA  - ENG
GR  - K01 HD047122/HD/NICHD NIH HHS/United States
GR  - R01 DK080744/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-2190 [pii]
AID - 10.2337/dc12-2190 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637354
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Secular Changes in the Age-Specific Prevalence of Diabetes Among U.S. Adults:
      1988-2010.
AB  - OBJECTIVETo examine the age-specific changes of prevalence of diabetes among U.S.
      adults during the past 2 decades.RESEARCH DESIGN AND METHODSThis study included
      22,586 adults sampled in three periods of the National Health and Nutrition
      Examination Survey (1988-1994, 1999-2004, and 2005-2010). Diabetes was defined as
      having self-reported diagnosed diabetes or having a fasting plasma glucose level 
      >/=126 mg/dL or HbA1c >/=6.5% (48 mmol/mol).RESULTSThe number of adults with
      diabetes increased by 75% from 1988-1994 to 2005-2010. After adjusting for sex,
      race/ethnicity, and education level, the prevalence of diabetes increased over
      the two decades across all age-groups. Younger adults (20-34 years of age) had
      the lowest absolute increase in diabetes prevalence of 1.0%, followed by
      middle-aged adults (35-64) at 2.7% and older adults (>/=65) at 10.0% (all P <
      0.001). Comparing 2005-2010 with 1988-1994, the adjusted prevalence ratios (PRs) 
      by age-group were 2.3, 1.3, and 1.5 for younger, middle-aged, and older adults,
      respectively (all P < 0.05). After additional adjustment for body mass index
      (BMI), waist-to-height ratio (WHtR), or waist circumference (WC), the adjusted PR
      remained statistically significant only for adults >/=65 years of
      age.CONCLUSIONDuring the past two decades, the prevalence of diabetes increased
      across all age-groups, but adults >/=65 years of age experienced the largest
      increase in absolute change. Obesity, as measured by BMI, WHtR, or WC, was
      strongly associated with the increase in diabetes prevalence, especially in
      adults <65.
AD  - Division of Diabetes Translation, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta,
      Georgia.
FAU - Cheng, Yiling J
AU  - Cheng YJ
FAU - Imperatore, Giuseppina
AU  - Imperatore G
FAU - Geiss, Linda S
AU  - Geiss LS
FAU - Wang, Jing
AU  - Wang J
FAU - Saydah, Sharon H
AU  - Saydah SH
FAU - Cowie, Catherine C
AU  - Cowie CC
FAU - Gregg, Edward W
AU  - Gregg EW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-2074 [pii]
AID - 10.2337/dc12-2074 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637353
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Diabetes Prevention and Treatment Strategies: Are we doing enough?
AB  - OBJECTIVEEffective interventions to prevent, delay, or remit diabetes are
      currently available. However, their impact on the prevalence of diabetes at the
      population level is unknown. This study aimed to estimate the impact of a range
      of diabetes interventions on the population prevalence of diabetes for Australian
      adults between 2010 and 2025.RESEARCH DESIGN AND METHODSWe used the Australian
      Diabetes Projection Model to estimate the impact of a population-wide strategy,
      high-risk prevention, surgical diabetes treatment, and a combination strategy on 
      the future population prevalence of diabetes and to estimate the number of
      diabetes cases that could be potentially prevented in the year 2025.RESULTSWe
      estimate that a population-wide strategy would reduce the number of diabetes
      cases by 60,000-85,000 in 2025 from an estimated 2 million cases under the status
      quo scenario. A high-risk prevention strategy would result in 106,000 to 150,000 
      fewer cases of diabetes in 2025, and surgically induced weight loss would result 
      in 3,000-6,000 fewer cases. No single intervention, or combination of
      interventions, reversed the increasing trend in diabetes prevalence over the next
      15 years.CONCLUSIONSTo reverse upward trends in diabetes prevalence in future
      years, it is essential that current approaches to diabetes prevention and
      treatment are optimized and implemented and that alternative approaches to reduce
      the prevalence of diabetes at a population level are developed.
AD  - Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
FAU - Backholer, Kathryn
AU  - Backholer K
FAU - Peeters, Anna
AU  - Peeters A
FAU - Herman, William H
AU  - Herman WH
FAU - Shaw, Jonathan E
AU  - Shaw JE
FAU - Liew, Danny
AU  - Liew D
FAU - Ademi, Zanfina
AU  - Ademi Z
FAU - Magliano, Dianna J
AU  - Magliano DJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - DC12-2501 [pii]
AID - 10.2337/DC12-2501 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637352
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Metabolically healthy obesity and risk of mortality: Does the definition of
      metabolic health matter?
AB  - OBJECTIVETo assess the association of a "metabolically healthy obese" phenotype
      with mortality using five definitions of metabolic health.RESEARCH DESIGN AND
      METHODSAdults (n = 5,269; 71.7% men) aged 39-62 years in 1991 through 1993
      provided data on BMI and metabolic health, defined using data from the Adult
      Treatment Panel-III (ATP-III); criteria from two studies; and the Matsuda and
      homeostasis model assessment (HOMA) indices. Cross-classification of BMI
      categories and metabolic status (healthy/unhealthy) created six groups. Cox
      proportional hazards regression models were used to analyze associations with
      all-cause and cardiovascular disease (CVD) mortality during a median follow-up of
      17.7 years.RESULTSA total of 638 individuals (12.1% of the cohort) were obese, of
      whom 9-41% were metabolically healthy, depending on the definition. Regardless of
      the definition, compared with metabolically healthy, normal-weight individuals,
      both the metabolically healthy obese (hazard ratios [HR] ranged from 1.81 [95% CI
      1.16-2.84] for ATP-III to 2.30 [1.13-4.70] for the Matsuda index) and the
      metabolically abnormal obese (HRs ranged from 1.57 [1.08-2.28] for the Matsuda
      index to 2.05 [1.44-2.92] for criteria defined in a separate study) had an
      increased risk of mortality. The only exception was the lack of excess risk using
      the HOMA criterion for the metabolically healthy obese (1.08; 0.67-1.74). Among
      the obese, the risk of mortality did not vary as a function of metabolic health
      apart from when using the HOMA criterion (1.93; 1.15-3.22). Similar results were 
      obtained for cardiovascular mortality.CONCLUSIONSFor most definitions of
      metabolic health, both metabolically healthy and unhealthy obese patients carry
      an elevated risk of mortality.
AD  - INSERM, Centre for Research in Epidemiology and Population Health, Hopital Paul
      Brousse, Villejuif Cedex, France.
FAU - Hinnouho, Guy-Marino
AU  - Hinnouho GM
FAU - Czernichow, Sebastien
AU  - Czernichow S
FAU - Dugravot, Aline
AU  - Dugravot A
FAU - Batty, G David
AU  - Batty GD
FAU - Kivimaki, Mika
AU  - Kivimaki M
FAU - Singh-Manoux, Archana
AU  - Singh-Manoux A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-1654 [pii]
AID - 10.2337/dc12-1654 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637351
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - The Expression of Inflammatory Genes Is Upregulated in Peripheral Blood of
      Patients with Type 1 Diabetes.
AB  - OBJECTIVEOur previous gene expression microarray studies identified a number of
      genes differentially expressed in patients with type 1 diabetes (T1D) and islet
      autoantibody-positive subjects. This study was designed to validate these gene
      expression changes in T1D patients and to identify gene expression changes in
      diabetes complications.RESEARCH DESIGH AND METHODSWe performed high-throughput
      real-time RT-PCR to validate gene expression changes in peripheral blood
      mononuclear cells (PBMCs) from a large sample set of 928 T1D patients and 922
      control subjects.RESULTSOf the 18 genes analyzed here, eight genes (S100A8,
      S100A9, MNDA, SELL, TGFB1, PSMB3, CD74, and IL12A) had higher expression and
      three genes (GNLY, PSMA4, and SMAD7) had lower expression in T1D patients
      compared with control subjects, indicating that genes involved in inflammation,
      immune regulation, and antigen processing and presentation are significantly
      altered in PBMCs from T1D patients. Furthermore, one adhesion molecule (SELL) and
      three inflammatory genes mainly expressed by myeloid cells (S100A8, S100A9, and
      MNDA) were significantly higher in T1D patients with complications (odds ratio
      [OR] 1.3-2.6, adjusted P value = 0.005-10-8), especially those patients with
      neuropathy (OR 4.8-7.9, adjusted P value <0.005).CONCLUSIONSThese findings
      suggest that inflammatory mediators secreted mainly by myeloid cells are
      implicated in T1D and its complications.
AD  - Center for Biotechnology and Genomic Medicine, Medical College of Georgia,
      Georgia Regents University, Augusta, Georgia.
FAU - Jin, Yulan
AU  - Jin Y
FAU - Sharma, Ashok
AU  - Sharma A
FAU - Carey, Colleen
AU  - Carey C
FAU - Hopkins, Diane
AU  - Hopkins D
FAU - Wang, Xiaoxiao
AU  - Wang X
FAU - Robertson, David G
AU  - Robertson DG
FAU - Bode, Bruce
AU  - Bode B
FAU - Anderson, Stephen W
AU  - Anderson SW
FAU - Reed, John Chip
AU  - Reed JC
FAU - Steed, R Dennis
AU  - Steed RD
FAU - Steed, Leigh
AU  - Steed L
FAU - She, Jin-Xiong
AU  - She JX
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-1986 [pii]
AID - 10.2337/dc12-1986 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637350
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Cardiovascular Complications and Mortality After Diabetes Diagnosis for South
      Asian and Chinese Patients: A population-based cohort study.
AB  - OBJECTIVEMany non-European ethnic groups have an increased risk for diabetes;
      however, the published literature demonstrates considerable uncertainty about the
      rates of diabetes complications among minority populations. The objective of this
      study was to determine the risks of cardiovascular complications and of mortality
      after diabetes diagnosis for South Asian and Chinese patients, compared with
      European patients.RESEARCH DESIGN AND METHODSA population-based cohort study
      identified all 491,243 adults with newly diagnosed diabetes in Ontario, Canada,
      between April 2002 and March 2009. Subjects were followed until March 2011 for
      the first occurrence of any cardiovascular complication of diabetes (coronary
      artery disease, stroke, or lower-extremity amputation) and for all-cause
      mortality. Median follow-up was 4.7 years.RESULTSThe crude incidence of
      cardiovascular complications after diabetes diagnosis was 17.9 per 1,000
      patient-years among European patients, 12.0 among South Asian patients, and 7.7
      among Chinese patients. After adjusting for baseline characteristics, the
      cause-specific hazard ratios (HRs) for cardiovascular complications relative to
      European patients were 0.95 (95% CI 0.90-1.00; P = 0.056) and 0.50 (0.46-0.53; P 
      < 0.001) for South Asian and Chinese patients, respectively. Mortality was lower 
      for both minority groups (adjusted HR for South Asian patients 0.56 [95% CI
      0.52-0.60]; P < 0.001; for Chinese patients 0.58 [0.55-0.62]; P <
      0.001).CONCLUSIONSChinese patients were at substantially lower risk than European
      patients for cardiovascular complications after diabetes diagnosis, whereas South
      Asian patients were at comparable risk. Mortality after diabetes diagnosis was
      markedly lower for both minority populations.
AD  - Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
FAU - Shah, Baiju R
AU  - Shah BR
FAU - Victor, J Charles
AU  - Victor JC
FAU - Chiu, Maria
AU  - Chiu M
FAU - Tu, Jack V
AU  - Tu JV
FAU - Anand, Sonia S
AU  - Anand SS
FAU - Austin, Peter C
AU  - Austin PC
FAU - Manuel, Douglas G
AU  - Manuel DG
FAU - Hux, Janet E
AU  - Hux JE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-2105 [pii]
AID - 10.2337/dc12-2105 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637349
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Awareness, Treatment, and Control of LDL Cholesterol Are Lower Among United
      States Adults With Undiagnosed Diabetes Versus Diagnosed Diabetes.
AB  - OBJECTIVEDiabetes is often undiagnosed, resulting in incorrect risk
      stratification for lipid-lowering therapy. We conducted a cross-sectional
      analysis of National Health and Nutrition Examination Survey (NHANES) 2005-2010
      to determine the prevalence, awareness, treatment, and control of elevated LDL
      cholesterol (LDL-C) among United States adults with undiagnosed diabetes.RESEARCH
      DESIGN AND METHODSFasting NHANES participants 20 years of age or older who had
      10-year Framingham coronary heart disease (CHD) risk scores <20% and were free of
      CHD or other CHD risk equivalents (n = 5,528) were categorized as having normal
      glucose, impaired fasting glucose, undiagnosed diabetes, or diagnosed diabetes.
      High LDL-C was defined by the 2004 Adult Treatment Panel (ATP) III
      guidelines.RESULTSThe prevalence of diagnosed and of undiagnosed diabetes were 8 
      and 4%, respectively. Mean LDL-C was 102 +/- 2 mg/dL among those with diagnosed
      diabetes and 117 +/- 3 mg/dL for those with undiagnosed diabetes (P < 0.001). The
      prevalence of high LDL-C was similar among people with undiagnosed (81%) and
      diagnosed (77%) diabetes. Among people with undiagnosed diabetes and high LDL-C, 
      38% were aware, 27% were treated, and 16% met the ATP III LDL-C goal for
      diabetes. In contrast, among people with diagnosed diabetes and high LDL-C, 70%
      were aware, 61% were treated, and 36% met the ATP III goal. People with
      undiagnosed diabetes remained less likely to have controlled LDL-C after
      multivariable adjustment (prevalence ratio, 0.42; 95% CI,
      0.23-0.80).CONCLUSIONSImproved screening for diabetes and reducing the prevalence
      of undiagnosed diabetes may identify individuals requiring more intensive LDL-C
      reduction.
AD  - Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
FAU - Brown, Todd M
AU  - Brown TM
FAU - Tanner, Rikki M
AU  - Tanner RM
FAU - Carson, April P
AU  - Carson AP
FAU - Yun, Huifeng
AU  - Yun H
FAU - Rosenson, Robert S
AU  - Rosenson RS
FAU - Farkouh, Michael E
AU  - Farkouh ME
FAU - Woolley, J Michael
AU  - Woolley JM
FAU - Thacker, Evan L
AU  - Thacker EL
FAU - Glasser, Stephen P
AU  - Glasser SP
FAU - Safford, Monika M
AU  - Safford MM
FAU - Muntner, Paul
AU  - Muntner P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-2318 [pii]
AID - 10.2337/dc12-2318 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637348
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - Development and Validation of a Predicting Model of All-Cause Mortality in
      Patients With Type 2 Diabetes Mellitus.
AB  - OBJECTIVETo develop and validate a parsimonious model for predicting short-term
      all-cause mortality in patients with type 2 diabetes mellitus (T2DM).RESEARCH
      DESIGN AND METHODSTwo cohorts of patients with T2DM were investigated. The
      Gargano Mortality Study (GMS, n = 679 patients) was the training set and the
      Foggia Mortality Study (FMS, n = 936 patients) represented the validation sample.
      GMS and FMS cohorts were prospectively followed-up for 7.40 +/- 2.15 and 4.51 +/-
      1.69 years, respectively, and all-cause mortality was registered. A new forward
      variable selection within a multivariate Cox regression was implemented. Starting
      from the empty model, each step selected the predictor that, once included into
      the multivariate Cox model, yielded the maximum continuous net reclassification
      improvement (cNRI). The selection procedure stopped when no further statistically
      significant cNRI increase was detected.RESULTSNine variables (age, BMI, diastolic
      blood pressure, LDL cholesterol, triglycerides, HDL cholesterol, urine
      albumin-to-creatinine ratio, and antihypertensive and insulin therapy) were
      included in the final predictive model with a C statistic of 0.88 (95% CI
      0.82-0.94) in the GMS and 0.82 (0.76-0.87) in the FMS. Finally, we used a
      recursive partition and amalgamation algorithm to identify patients at
      intermediate and high mortality risk (hazard ratio 7.0 and 24.4, respectively, as
      compared with those at low risk). A web-based risk calculator was also
      developed.CONCLUSIONSWe developed and validated a parsimonious all-cause
      mortality equation in T2DM, providing also a user-friendly web-based risk
      calculator. Our model may help prioritize the use of available resources for
      targeting aggressive preventive and treatment strategies in a subset of very
      high-risk individuals.
AD  - Unit of Endocrinology, IRCCS Casa Sollievo della Sofferenza, San Giovanni
      Rotondo, Italy.
FAU - De Cosmo, Salvatore
AU  - De Cosmo S
FAU - Copetti, Massimiliano
AU  - Copetti M
FAU - Lamacchia, Olga
AU  - Lamacchia O
FAU - Fontana, Andrea
AU  - Fontana A
FAU - Massa, Michela
AU  - Massa M
FAU - Morini, Eleonora
AU  - Morini E
FAU - Pacilli, Antonio
AU  - Pacilli A
FAU - Fariello, Stefania
AU  - Fariello S
FAU - Palena, Antonio
AU  - Palena A
FAU - Rauseo, Anna
AU  - Rauseo A
FAU - Viti, Rafaella
AU  - Viti R
FAU - Di Paola, Rosa
AU  - Di Paola R
FAU - Menzaghi, Claudia
AU  - Menzaghi C
FAU - Cignarelli, Mauro
AU  - Cignarelli M
FAU - Pellegrini, Fabio
AU  - Pellegrini F
FAU - Trischitta, Vincenzo
AU  - Trischitta V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-1906 [pii]
AID - 10.2337/dc12-1906 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637347
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 1
TI  - The Atrial Natriuretic Peptide Genetic Variant Rs5068 Is Associated With a
      Favorable Cardiometabolic Phenotype in a Mediterranean Population.
AB  - OBJECTIVEWe hypothesized that the minor allele of the atrial natriuretic peptide 
      (ANP) genetic variant rs5068 is associated with a favorable cardiometabolic
      phenotype in a general Mediterranean population.RESEARCH DESIGN AND METHODSWe
      genotyped a random sample of the residents of Ventimiglia di Sicilia, Sicily, for
      rs5068.RESULTSGenotype frequencies of rs5068 are AA, 93.5%; AG, 6.4%; and GG,
      0.1%. All subsequent analyses are AA versus AG+GG. After adjusting for age and
      sex, the minor G allele is associated with lower BMI (estimate [SE]: -1.7 kg/m2
      [0.8], P = 0.04). In the AG+GG group, males with HDL cholesterol levels <40 mg/dL
      are less frequent (P = 0.05) and obesity tends to be less prevalent (P = 0.07).
      Importantly, the G allele is associated with a lower prevalence of metabolic
      syndrome (P = 0.02). After adjusting for BMI, the above associations were
      attenuated. Independently of age, sex, and BMI, the minor allele is also
      associated with lower systolic blood pressure (-6.0 mmHg [2.5], P = 0.02) and
      lower prevalence of hypertension (odds ratio 0.41 [95% CI 0.20-0.83], P =
      0.01).CONCLUSIONSThe association between the minor allele of rs5068 and a
      favorable cardiometabolic phenotype that we previously reported in a U.S.
      population is now replicated in a Mediterranean population in which the G allele 
      of rs5068 is associated with lower blood pressure, BMI, and prevalence of
      hypertension and metabolic syndrome. These findings may lead to a diagnostic
      strategy to assess cardiometabolic risk and lay the foundation for the future
      development of an ANP or ANP-like therapy for metabolic syndrome.
AD  - Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo
      Clinic, Rochester, Minnesota.
FAU - Cannone, Valentina
AU  - Cannone V
FAU - Cefalu', Angelo Baldassare
AU  - Cefalu' AB
FAU - Noto, Davide
AU  - Noto D
FAU - Scott, Christopher G
AU  - Scott CG
FAU - Bailey, Kent R
AU  - Bailey KR
FAU - Cavera, Giovanni
AU  - Cavera G
FAU - Pagano, Michele
AU  - Pagano M
FAU - Sapienza, Michelangelo
AU  - Sapienza M
FAU - Averna, Maurizio R
AU  - Averna MR
FAU - Burnett, John C Jr
AU  - Burnett JC Jr
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - dc12-2337 [pii]
AID - 10.2337/dc12-2337 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 1.

PMID- 23637276
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Linking)
VI  - 41
IP  - 3
DP  - 2013 Jun
TI  - Efficacy of shellac, a natural product, for the prevention of wet gangrene.
PG  - 795-803
LID - 10.1177/0300060513483391 [doi]
AB  - OBJECTIVE: To determine the effects of applying a natural polymer solution
      (shellac) to dry gangrene, and thereby prevent infection and progression to wet
      gangrene, in diabetic patients. METHODS: This randomized, controlled, pilot study
      included patients with type 2 diabetes mellitus who had unreconstructable
      peripheral vascular disease and were awaiting autoamputation. Eligible patients
      were contraindicated for surgery, had a limited life expectancy and/or had
      refused surgical amputations. All patients received the best possible medical
      treatment and were randomized to receive either topical shellac or antiseptic
      application of 10% povidone-iodine (PVP-I) solution to gangrenous areas. RESULTS:
      A total of 26 diabetic patients were eligible for inclusion, of whom 23 completed
      the study: 13 were treated with shellac and 10 with PVP-I. The amputation rate
      was higher in the conventional treatment group versus the shellac group (60.0%
      versus 46.2%, respectively), although this difference was not statistically
      significant. CONCLUSIONS: Shellac is a natural solution that may be used to
      embalm gangrenous tissue in selected diabetic patients. More studies are needed
      to assess the long-term outcomes of this technique.
AD  - Mohammed Hussein Al-Amoudi Chair for Diabetic Foot Research, King Abdulaziz
      University, Jeddah, Saudi Arabia.
FAU - Alzahrani, Hasan
AU  - Alzahrani H
FAU - Bedir, Yhya
AU  - Bedir Y
FAU - Al-Hayani, Abdulmonaim
AU  - Al-Hayani A
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
SB  - IM
OTO - NOTNLM
OT  - Shellac
OT  - amputation
OT  - diabetes mellitus
OT  - gangrene
OT  - ischaemia
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/05/01 [aheadofprint]
AID - 0300060513483391 [pii]
AID - 10.1177/0300060513483391 [doi]
PST - ppublish
SO  - J Int Med Res. 2013 Jun;41(3):795-803. doi: 10.1177/0300060513483391. Epub 2013
      May 1.

PMID- 23637249
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1526-3347 (Electronic)
IS  - 0191-9601 (Linking)
VI  - 34
IP  - 5
DP  - 2013 May
TI  - Type 1 diabetes mellitus.
PG  - 203-15
LID - 10.1542/pir.34-5-203 [doi]
AD  - Pediatric Endocrinology Clinical Fellow, Ian Burr Division of Pediatric
      Endocrinology and Diabetes, Vanderbilt University School of Medicine, Nashville, 
      TN.
FAU - Gregory, Justin M
AU  - Gregory JM
FAU - Moore, Daniel J
AU  - Moore DJ
FAU - Simmons, Jill H
AU  - Simmons JH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Rev
JT  - Pediatrics in review / American Academy of Pediatrics
JID - 8103046
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 34/5/203 [pii]
AID - 10.1542/pir.34-5-203 [doi]
PST - ppublish
SO  - Pediatr Rev. 2013 May;34(5):203-15. doi: 10.1542/pir.34-5-203.

PMID- 23637136
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1522-1490 (Electronic)
IS  - 0363-6119 (Linking)
DP  - 2013 May 1
TI  - Role of collecting duct renin in blood pressure regulation.
AB  - Numerous studies indicate that renin is synthesized and secreted by the
      collecting duct. Collecting duct-derived renin may act directly upon intercalated
      and/or principal cells through direct interaction with prorenin receptors and/or 
      through cleavage of proximal tubule-derived angiotensinogen to ultimately produce
      angiotensin II and activate AT1 receptors. Preliminary studies suggest that the
      net effect of CD renin would be to increase distal nephron salt reabsorption and 
      increase blood pressure. Collecting duct renin production is markedly increased
      in diabetes and angiotensin-II induced hypertension, suggesting that this system 
      may exert pathophysiological effects. In this brief review, we summarize the
      current literature on synthesis and regulation of CD renin and consider potential
      mechanisms by which it regulates blood pressure.
AD  - 1University of Utah.
FAU - Ramkumar, Nirupama
AU  - Ramkumar N
FAU - Kohan, Donald E
AU  - Kohan DE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Am J Physiol Regul Integr Comp Physiol
JT  - American journal of physiology. Regulatory, integrative and comparative
      physiology
JID - 100901230
OTO - NOTNLM
OT  - Collecting duct
OT  - blood pressure
OT  - renin
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - ajpregu.00191.2013 [pii]
AID - 10.1152/ajpregu.00191.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Regul Integr Comp Physiol. 2013 May 1.

PMID- 23637135
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1522-1490 (Electronic)
IS  - 0363-6119 (Linking)
DP  - 2013 May 1
TI  - Association of Rev-erbalpha in Adipose Tissues with Type 2 Diabetes Mellitus
      Amelioration after Gastric Bypass Surgery in Goto-Kakizaki Rats.
AB  - We estimated the key molecules related to type 2 diabetes mellitus (T2DM) in
      adipose, liver, and muscle tissues, from non-obese diabetic Goto-Kakizaki (GK)
      rats and their Wistar controls, by computationally analyzing the expression
      profiles in open source data. With the aid of information from previous reports, 
      Rev-erbalpha in adipose tissue emerged as one of the most plausible candidates.
      Here, in animal models, including GK rats surgically-treated to ameliorate T2DM, 
      we examined the association of Rev-erbalpha in adipose tissue with T2DM
      progression. After analyses of the Rev-erbalpha mRNA expression in the adipose
      tissue of our animal models, we compared the Rev-erbalpha protein expression
      levels in the adipose, liver, and muscle tissues of GK and Wistar controls at the
      ages of 1 month (M), 3M and 6M. The Rev-erbalpha protein levels in adipose tissue
      showed a distinctive pattern, with the negative correlation of an increasing
      trend in GK rats and a decreasing trend in Wistar rats during aging, from those
      in liver and muscle tissues. Moreover, dysregulation of the circadian
      Rev-erbalpha expression in the adipose tissue of 6M old GK rats was also
      observed. In particular, we ameliorated T2DM in GK rats by gastric bypass
      surgery, and revealed that T2DM amelioration in diabetic GK rats was associated
      with improved circadian Rev-erbalpha expression, in a comparison between the
      surgically-treated and untreated GK rats. The roles of Rev-erbalpha in adipose
      tissue were further investigated by observations of Rev-erbalpha-related
      molecules, with reference to previous reports.
AD  - 1Clinical Medical Collage of Yangzhou University, Yangzhou.
FAU - Zhang, Rui
AU  - Zhang R
FAU - Yan, Caifeng
AU  - Yan C
FAU - Zhou, Xinrong
AU  - Zhou X
FAU - Qian, Bangguo
AU  - Qian B
FAU - Li, Fuqiang
AU  - Li F
FAU - Sun, Yidan
AU  - Sun Y
FAU - Shi, Chen
AU  - Shi C
FAU - Li, Bing
AU  - Li B
FAU - Saito, Shigeru
AU  - Saito S
FAU - Horimoto, Katsuhisa
AU  - Horimoto K
FAU - Zhou, Huarong
AU  - Zhou H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Am J Physiol Regul Integr Comp Physiol
JT  - American journal of physiology. Regulatory, integrative and comparative
      physiology
JID - 100901230
OTO - NOTNLM
OT  - Rev-erb
OT  - adipose tissue
OT  - gastric bypass surgery
OT  - network analysis
OT  - type 2 diabetes mellitus
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - ajpregu.00520.2012 [pii]
AID - 10.1152/ajpregu.00520.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Regul Integr Comp Physiol. 2013 May 1.

PMID- 23637029
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
DP  - 2013 May 2
TI  - LAP-BAND for lower BMI: 2 year results from the multicenter pivotal study.
LID - 10.1002/oby.20477 [doi]
AB  - Objective: The goal of this study was to examine the safety and effectiveness of 
      the LAP-BAND(R) System for patients with 3039.9 BMI and associated comorbidities.
      Design and Methods: In this prospective, multicenter, interventional cohort
      study, subjects with a BMI between 30 and 39.9 who had failed prior weight loss
      attempts were recruited from 7 surgical centers. The primary effectiveness
      endpoint required that >40% of subjects achieve >/=30% excess weight loss (EWL)
      at 1 year. Secondary endpoints included assessment of comorbidities and
      quality-of-life. Results: Of 149 subjects, 90.6% were female, with mean BMI of
      35.3kg/m2 . At 1 year, 84.6% of subjects achieved >/=30% EWL (p<0.0001), with
      65.0% mean EWL; 66.4% of subjects were no longer obese (BMI<30). Baseline
      comorbidities improved at 1 year for 64.4% with dyslipidemia, 59.6% with
      hypertension, and 85.7% with diabetes. Quality-of-life (IWQOL-Lite) also improved
      (p<0.0001). The Year 1 results were maintained or improved at 2 years. Regression
      analysis indicates that each additional 10% weight loss at Year 2 was associated 
      with an increase in IWQOL-Lite by 7.1points and a decrease in triglycerides by
      13.7mg/dL, fasting glucose by 3.5mg/dL, and systolic blood pressure by 3.3mmHg.
      Most adverse events were mild to moderate and resolved without sequelae within 1 
      month. Five subjects (3.4%) had explantations. Conclusion: LAGB is safe and
      effective for people with 30-39.9 BMI, with weight loss and comorbidity
      improvement through at least 2 years.
CI  - Copyright (c) 2013 The Obesity Society.
AD  - Northwest Weight Loss Surgery, Everett, Washington.
FAU - Michaelson, Robert
AU  - Michaelson R
FAU - Murphy, Diane K
AU  - Murphy DK
FAU - Gross, Todd M
AU  - Gross TM
FAU - Whitcup, Scott M
AU  - Whitcup SM
CN  - LAP-BAND(R) Lower BMI Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/05/17 [received]
PHST- 2013/03/05 [revised]
PHST- 2013/03/11 [accepted]
AID - 10.1002/oby.20477 [doi]
PST - aheadofprint
SO  - Obesity (Silver Spring). 2013 May 2. doi: 10.1002/oby.20477.

PMID- 23637016
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1552-4833 (Electronic)
IS  - 1552-4825 (Linking)
VI  - 161
IP  - 6
DP  - 2013 Jun
TI  - De novo 19p13.2 microdeletion encompassing the insulin receptor and resistin
      genes in a patient with obesity and learning disability.
PG  - 1480-6
LID - 10.1002/ajmg.a.35927 [doi]
AB  - Genetic studies have provided novel insights of appetite regulation and
      pathophysiology of obesity. The adipose tissue is an active endocrine organ
      secreting several hormones contributing to insulin resistance and the development
      of the comorbidities of obesity, such as type 2 diabetes and cardiovascular
      disease. Herein, we report on a patient with severe obesity and mild learning
      disability with a 750 kb de novo deletion of chromosome 19. The deletion
      encompasses several genes, including resistin and the first part of the insulin
      receptor, genes that are relevant for obesity. This novel deletion may therefore 
      represent a region for obesity research. Plasma analyses and gene expression
      demonstrated that the deletion resulted in haploinsufficiency for resistin and
      insulin receptor in the patient compared to controls. We then studied the
      biochemical and adipocytokine profile in these subjects. We observed no
      differences in glucose and lipid parameters between the patient and the controls.
      Thus, haploinsufficiency of insulin receptor and resistin does not appear to
      influence glucose and lipid metabolism. However, the patient had considerably
      higher values of adiponectin and TNFalpha than controls. In conclusion, we
      identified a 19p13.2 microdeletion encompassing the insulin receptor and resistin
      genes resulting in haploinsufficiency in an obese, but otherwise healthy patient.
      No firm conclusions could be drawn regarding the potential effect of the
      microdeletion on adipokine profile. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
FAU - Wangensteen, Teresia
AU  - Wangensteen T
FAU - Retterstol, Lars
AU  - Retterstol L
FAU - Rodningen, Olaug K
AU  - Rodningen OK
FAU - Hjelmesaeth, Joran
AU  - Hjelmesaeth J
FAU - Aukrust, Pal
AU  - Aukrust P
FAU - Halvorsen, Bente
AU  - Halvorsen B
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - Am J Med Genet A
JT  - American journal of medical genetics. Part A
JID - 101235741
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/04/15 [received]
PHST- 2013/02/02 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 10.1002/ajmg.a.35927 [doi]
PST - ppublish
SO  - Am J Med Genet A. 2013 Jun;161(6):1480-6. doi: 10.1002/ajmg.a.35927. Epub 2013
      May 1.

PMID- 23636999
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 May 1
TI  - Moderate Physical Activity as Predictor of Weight Loss After Bariatric Surgery.
AB  - BACKGROUND: The prevalence of obesity is 33 % and is expected to reach 50 % based
      on current US trends. Bariatric surgery is effective in producing long-term
      weight loss, yet it requires adherence to the recommended diet and physical
      activity. This study assessed whether the short-form International Physical
      Activity Questionnaire (IPAQ-SF) data at 1 year postbariatric surgery would
      correlate with success (defined as more than 50 % excess weight loss (EWL)) after
      surgery. METHODS: The IPAQ-SF questionnaire provided assessment of subjects'
      activity level over the last 7 days, in four separate activity domains: vigorous,
      moderate, walking, and sitting. RESULTS: Questionnaires were completed and
      collected at the 1-year postbariatric surgery group visit. Then, 118 subjects who
      completed the IPAQ-SF were subdivided based on loss of greater than or less than 
      50 % of their excess weight, which in turn was based on ideal body weight. In
      subjects with >/=50% EWL (n = 49), we noted 67.1 +/- 8.8 % EWL versus 33.2 +/-
      9.4 % in those with <50 % EWL (n = 69) (p < 0.001). The >/=50 % EWL group
      performed 420 (216-960) min of total activity per week versus 300 (172-718) min
      for the <50 % group. The >/=50 % EWL group engaged in 120 (8-180) min of vigorous
      activity, 150 (28-330) min of moderate activity, and 233 (109-512) min of walking
      versus 40 (0-255), 68 (0-204), and 188 (83-341) min, respectively, for the <50 % 
      EWL group. CONCLUSIONS: Physical activity does correlate with success after
      bariatric surgery, as measured by excess weight loss (>/=50 % EWL).
AD  - Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, 200 
      1st Street SW, Rochester, MN, 55905, USA, mundi.manpreet@mayo.edu.
FAU - Mundi, Manpreet S
AU  - Mundi MS
FAU - Lorentz, Paul A
AU  - Lorentz PA
FAU - Swain, James
AU  - Swain J
FAU - Grothe, Karen
AU  - Grothe K
FAU - Collazo-Clavell, Maria
AU  - Collazo-Clavell M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1007/s11695-013-0979-y [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 May 1.

PMID- 23636998
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 May 1
TI  - Duodenal-Jejunal Bypass Improves Glucose Metabolism and Adipokine Expression
      Independently of Weight Loss in a Diabetic Rat Model.
AB  - BACKGROUND: There is accumulating evidence that adipokines lead to a
      proinflammatory state, which plays crucial roles in insulin resistance and
      development of type 2 diabetes mellitus (T2DM). Previous studies demonstrated
      that weight loss after bariatric surgery is accompanied by a suppression of the
      proinflammatory state. However, the effect of bariatric surgery on adipokine
      expression beyond weight loss is still elusive. The aim of this study was to
      investigate the effect of duodenal-jejunal bypass (DJB) on glucose homeostasis
      and adipokine expression independently of weight loss. METHODS: A T2DM rat model 
      was developed by a high-fat diet and low dose of streptozotocin. Twenty-one
      diabetic rats and 10 age-matched SD rats were randomly assigned to the DJB group,
      sham-DJB (S-DJB) group, and control group. For 12 weeks after surgery, their body
      weight, food intake, glucose homeostasis, lipid parameters, serum adipokine
      levels, and adipokine gene expression in the mesocolon adipose tissue were
      measured. RESULTS: Compared to the S-DJB group, DJB induced significant and
      sustained glycemic control with improved insulin sensitivity and glucose
      tolerance independently of weight loss. DJB improved the lipid metabolism by
      decreasing fasting free fatty acids and triglycerides. Serum leptin and IL-6
      significantly decreased 12 weeks after DJB, whereas adiponectin increased and
      TNF-alpha remained unchanged. The mRNA expression levels of leptin, TNF-alpha,
      and IL-6 decreased, whereas adiponectin increased in the mesocolon adipose
      tissue. CONCLUSION: DJB reduced the proinflammatory adipokines and increased the 
      anti-inflammatory adipokines independently of weight loss, which may contribute
      to the improvement of insulin sensitivity.
AD  - Department of General Surgery, Qilu Hospital of Shandong University, 107#, Wenhua
      Xi Road, Jinan, 250012, Shandong, People's Republic of China.
FAU - Hu, Chunxiao
AU  - Hu C
FAU - Zhang, Guangyong
AU  - Zhang G
FAU - Sun, Dong
AU  - Sun D
FAU - Han, Haifeng
AU  - Han H
FAU - Hu, Sanyuan
AU  - Hu S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1007/s11695-013-0976-1 [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 May 1.

PMID- 23636992
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 May 1
TI  - The Authors Respond: A Multisite Study of Long-Term Remission and Relapse of Type
      2 Diabetes Mellitus Following Gastric Bypass.
AD  - Group Health Research Institute, Seattle, WA, USA, arterburn.d@ghc.org.
FAU - Arterburn, David E
AU  - Arterburn DE
FAU - Campos, Guilherme M
AU  - Campos GM
FAU - Haneuse, Sebastien
AU  - Haneuse S
FAU - Sherwood, Nancy E
AU  - Sherwood NE
FAU - Bogart, Andy
AU  - Bogart A
FAU - Sidney, Stephen
AU  - Sidney S
FAU - Coleman, Karen J
AU  - Coleman KJ
FAU - Theis, Mary Kay
AU  - Theis MK
FAU - O'Connor, Patrick
AU  - O'Connor P
FAU - Fisher, David
AU  - Fisher D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1007/s11695-013-0960-9 [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 May 1.

PMID- 23636991
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 May 1
TI  - Letter to the Editor: A Multisite Study of Long-Term Remission and Relapse of
      Type 2 Diabetes Mellitus Following Gastric Bypass.
AD  - Princess Royal University Hospital, Orpington, UK, azahrahussain@yahoo.com.
FAU - Hussain, A
AU  - Hussain A
FAU - El-Hasani, S
AU  - El-Hasani S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1007/s11695-013-0959-2 [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 May 1.

PMID- 23636924
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1939-2869 (Electronic)
IS  - 0891-1150 (Linking)
VI  - 80
IP  - 5
DP  - 2013 May
TI  - Aspirin: Its risks, benefits, and optimal use in preventing cardiovascular
      events.
PG  - 318-26
LID - 10.3949/ccjm.80a.12146 [doi]
AB  - Aspirin has a well-established role in preventing adverse events in patients with
      known cardiovascular disease. However, its benefit in patients without a history 
      of cardiovascular disease is not as clear, particularly in people with diabetes, 
      in women, and in the elderly. Recent studies have provided insight into the risks
      of aspirin use, particularly bleeding, compared with its benefits in these
      subgroups.
AD  - Division of Cardiovascular Medicine, University of Florida, 1600 SW Archer Road, 
      Box 100277, Gainesville, FL 32610; bavryaa@medicine.ufl.edu.
FAU - Park, Ki
AU  - Park K
FAU - Bavry, Anthony A
AU  - Bavry AA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cleve Clin J Med
JT  - Cleveland Clinic journal of medicine
JID - 8703441
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 80/5/318 [pii]
AID - 10.3949/ccjm.80a.12146 [doi]
PST - ppublish
SO  - Cleve Clin J Med. 2013 May;80(5):318-26. doi: 10.3949/ccjm.80a.12146.

PMID- 23636813
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1529-7268 (Electronic)
IS  - 0006-3363 (Linking)
DP  - 2013 May 1
TI  - Analysis of Maternal and Fetal Cardiovascular Systems During Hyperglycemic
      Pregnancy in the Non-Obese Diabetic Mouse.
AB  - Preconception or gestationally-induced diabetes increases morbidities and
      elevates long-term cardiovascular disease risks in women and their children.
      Spontaneously hyperglycemic (d)-NOD/ShiLtJ females, a type 1 diabetes model,
      develop bradycardia and hypotension after midpregnancy compared with
      normoglycemic, age and gestation day (gd)-matched controls (c-NOD). We
      hypothesized that onset of the placental circulation at gd9-10 and rapid fetal
      growth from gd14 correlate with aberrant hemodynamic outcomes in d-NOD females.
      To develop further gestational time course correlations between maternal cardiac 
      and renal parameters, high-frequency ultrasonography was applied to virgin and
      gd8-16 d- and c-NODs. Cardiac output and left ventricular (LV) mass increased in 
      c- but not d-NODs. Ultrasound and postmortem histopathology showed overall
      greater LV dilation in d- than c-NOD mice in mid-late gestation. These changes
      suggest blunted remodeling and altered functional adaptation of d-NOD hearts.
      Umbilical cord ultrasounds revealed lower fetal heart rates from gd12 and lower
      umbilical flow velocities at gd14 and 16 in d- versus c-NOD pregnancies. From
      gd14-16, d-NOD fetal losses exceeded those of c-NOD. Similar aberrant responses
      in human diabetic pregnancies may elevate postpartum maternal and child
      cardiovascular risk, particularly if mothers lack adequate prenatal care or have 
      poor glycemic control over gestation.
FAU - Aasa, Kristiina L
AU  - Aasa KL
FAU - Kwong, Kenneth K
AU  - Kwong KK
FAU - Adams, Michael A
AU  - Adams MA
FAU - Croy, B Anne
AU  - Croy BA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Biol Reprod
JT  - Biology of reproduction
JID - 0207224
OTO - NOTNLM
OT  - Cardiovascular
OT  - Developmental origins of health and disease
OT  - Diabetes
OT  - Pregnancy
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - biolreprod.112.105759 [pii]
AID - 10.1095/biolreprod.112.105759 [doi]
PST - aheadofprint
SO  - Biol Reprod. 2013 May 1.

PMID- 23636657
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1937-6995 (Electronic)
IS  - 1556-9039 (Linking)
DP  - 2013 May 2
TI  - L-Carnitine for the Treatment of a Calcium Channel Blocker and Metformin
      Poisoning.
AB  - INTRODUCTION: The object of the current communication is to discuss the theory
      and the evidence for the use of L-carnitine in calcium channel blocker and
      metformin poisonings. CASE REPORT: A 68-year-old male known for hypertension and 
      type II diabetes was admitted to the critical care unit of a community hospital
      following an overdose of amlodipine and metformin. The patient was intubated,
      ventilated, and hemodynamically supported with vasopressors. Despite calcium,
      glucagon, high-dose insulin (HDI), and lipid emulsion for calcium channel blocker
      and bicarbonate for metabolic acidosis, the patient remained hemodynamically
      unstable. The patient was considered too unstable to initiate continuous renal
      replacement therapy; and without access to extracorporeal life support, the
      administration of L-carnitine was administered as a last resort. One hour after
      L-carnitine, the norepinephrine requirements started to decrease, the patient
      began to improve and was subsequently extubated successfully without apparent
      sequelae in less than 4 days. DISCUSSION: L-Carnitine combined with HDI may have 
      helped with the calcium channel blocker (CCB) poisoning by decreasing insulin
      resistance, promoting intracellular glucose transport, facilitating the
      metabolism of free fatty acids, and increasing calcium channel sensitivity. It
      may have also stimulated oxidative utilization of glucose instead of converting
      pyruvate into lactate and contributed to decrease lactate production with
      metformin poisoning.
AD  - Clinical Pharmacology/Toxicology, University of Toronto, 50 Stephanie Street
      Suite 1507, Toronto, ON, M5T1B3, Canada, egnomie@hotmail.com.
FAU - St-Onge, Maude
AU  - St-Onge M
FAU - Ajmo, Ian
AU  - Ajmo I
FAU - Poirier, Diane
AU  - Poirier D
FAU - Laliberte, Martin
AU  - Laliberte M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - J Med Toxicol
JT  - Journal of medical toxicology : official journal of the American College of
      Medical Toxicology
JID - 101284598
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1007/s13181-013-0301-3 [doi]
PST - aheadofprint
SO  - J Med Toxicol. 2013 May 2.

PMID- 23636640
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 May 2
TI  - Enhanced beta cell function and anti-inflammatory effect after chronic treatment 
      with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged
      diet-induced obesity mouse model.
AB  - AIMS/HYPOTHESIS: Studies have shown that dipeptidyl peptidase-4 (DPP4) inhibitors
      stimulate insulin secretion and increase beta cell mass in rodents. However, in
      these models hyperglycaemia has been induced early on in life and the treatment
      periods have been short. To explore the long-term effects of DPP4 inhibition on
      insulin secretion and beta cell mass, we have generated a high-fat diet
      (HFD)-induced-obesity model in mice of advanced age (10 months old). METHODS:
      After 1 month of HFD alone, the mice were given the DPP4 inhibitor vildagliptin
      for a further 11 months. At multiple time points throughout the study, OGTTs were
      performed and beta cell area and long-term survival were evaluated. RESULTS: Beta
      cell function and glucose tolerance were significantly improved by vildagliptin
      with both diets. In contrast, in spite of the long treatment period, beta cell
      area was not significantly different between vildagliptin-treated mice and
      controls. Mice of advanced age chronically fed an HFD displayed clear and
      extensive pancreatic inflammation and peri-insulitis, mainly formed by
      CD3-positive T cells, which were completely prevented by vildagliptin treatment. 
      Chronic vildagliptin treatment also improved survival rates for HFD-fed mice.
      CONCLUSIONS/INTERPRETATION: In a unique advanced-aged HFD-induced-obesity mouse
      model, insulin secretion was improved and the extensive peri-insulitis prevented 
      by chronic DPP4 inhibition. The improved survival rates for obese mice
      chronically treated with vildagliptin suggest that chronic DPP4 inhibition
      potentially results in additional quality-adjusted life-years for individuals
      with type 2 diabetes, which is the primary goal of any diabetes therapy.
AD  - Department of Clinical Sciences, Biomedical Center, C11, Lund University, SE221
      84, Lund, Sweden, bilal.omar@med.lu.se.
FAU - Omar, B A
AU  - Omar BA
FAU - Vikman, J
AU  - Vikman J
FAU - Winzell, M S
AU  - Winzell MS
FAU - Voss, U
AU  - Voss U
FAU - Ekblad, E
AU  - Ekblad E
FAU - Foley, J E
AU  - Foley JE
FAU - Ahren, B
AU  - Ahren B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130502
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/12/23 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - 10.1007/s00125-013-2927-8 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 May 2.

PMID- 23636639
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Islet encapsulation: advances and obstacles.
PG  - 1458-61
LID - 10.1007/s00125-013-2921-1 [doi]
AB  - It has been known for decades that encapsulation can protect transplanted islets 
      from immune destruction in rodents, but it has proved difficult to extend this
      success to large animals and humans. A new study in this issue by
      Jacobs-Tulleneers-Thevissen et al (doi: 10.1007/s00125-013-2906-0 ) advances the 
      field by showing that human islets contained in alginate capsules can function
      very well, not only in the peritoneal cavity of mice, but also in a human with
      type 1 diabetes. Many obstacles must still be overcome, but this technology has
      the potential to safely protect transplanted beta cells from autoimmunity and
      allorejection.
AD  - Section on Islet Cell Biology and Regenerative Medicine, Joslin Diabetes Center, 
      One Joslin Place, Boston, MA, 02215, USA, gordon.weir@joslin.harvard.edu.
FAU - Weir, G C
AU  - Weir GC
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/04/03 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1007/s00125-013-2921-1 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1458-61. doi: 10.1007/s00125-013-2921-1. Epub 2013
      Apr 30.

PMID- 23636509
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1432-1440 (Electronic)
IS  - 0946-2716 (Linking)
DP  - 2013 May 1
TI  - Protective role for netrin-1 during diabetic nephropathy.
AB  - Recent studies implicate neuronal guidance molecules in the orchestration of
      inflammatory events. For example, previous studies demonstrate a functional role 
      for netrin-1 in attenuating acute kidney injury. Here, we hypothesized a
      kidney-protective role for netrin-1 during chronic kidney disease, such as occurs
      during diabetic nephropathy. To study the role of netrin-1 during diabetic
      nephropathy, we induced diabetes in mice at the age of 8 weeks by streptocotozin 
      (STZ) treatment. Sixteen weeks after STZ treatment, we examined the kidneys.
      Initial studies in wild-type mice demonstrated robust induction of renal,
      urinary, and plasma netrin-1 protein levels during diabetic nephropathy.
      Subsequent genetic studies in mice with partial netrin-1 deficiency (Ntrn1 +/-
      mice) revealed a more severe degree of diabetic nephropathy, including more
      severe loss of kidney function (albuminuria, glomerular filtration rate,
      histology). We subsequently performed pharmacologic studies with recombinant
      netrin-1 treatment given continuously via osmotic pump. Indeed, netrin-1
      treatment was associated with attenuated albuminuria and improved histologic
      scores for diabetic nephropathy compared to controls. Consistent with previous
      studies implicating purinergic signaling in netrin-1-elicited tissue protection, 
      mice deficient in the Adora2b adenosine receptor were not protected. Taken
      together, these studies demonstrate a functional role for endogenous netrin-1 in 
      attenuating diabetic kidney disease.
AD  - Department of Anesthesiology, University of Colorado Denver, Anschutz Medical
      Campus, 12700 E 19th Avenue, Mailstop B112, Research Complex 2, Room 7121,
      Aurora, CO, 80045, USA.
FAU - Tak, Eunyoung
AU  - Tak E
FAU - Ridyard, Douglas
AU  - Ridyard D
FAU - Badulak, Alexander
AU  - Badulak A
FAU - Giebler, Antasia
AU  - Giebler A
FAU - Shabeka, Uladzimir
AU  - Shabeka U
FAU - Werner, Tilmann
AU  - Werner T
FAU - Clambey, Eric
AU  - Clambey E
FAU - Moldovan, Radu
AU  - Moldovan R
FAU - Zimmerman, Michael A
AU  - Zimmerman MA
FAU - Eltzschig, Holger K
AU  - Eltzschig HK
FAU - Grenz, Almut
AU  - Grenz A
LA  - ENG
GR  - R01 DK083385/DK/NIDDK NIH HHS/United States
GR  - R01 DK097075/DK/NIDDK NIH HHS/United States
GR  - R01 HL092188/HL/NHLBI NIH HHS/United States
GR  - R01 HL098294/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Mol Med (Berl)
JT  - Journal of molecular medicine (Berlin, Germany)
JID - 9504370
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/12/13 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/04/03 [revised]
PHST- 2013/05/01 [aheadofprint]
AID - 10.1007/s00109-013-1041-1 [doi]
PST - aheadofprint
SO  - J Mol Med (Berl). 2013 May 1.

PMID- 23636469
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1438-2199 (Electronic)
IS  - 0939-4451 (Linking)
DP  - 2013 May 1
TI  - Suppression of native defense mechanisms, SIRT1 and PPARgamma, by dietary
      glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered 
      chronic diseases.
AB  - SIRT1 and PPARgamma, host defenses regulating inflammation and metabolic
      functions, are suppressed under chronic high oxidant stress and inflammation
      (OS/Infl) conditions. In diabetes, dietary advanced glycation end products
      (dAGEs) cause OS/Infl and suppress SIRT1. Herein, we ask whether dAGEs also
      suppress host defense in adults without diabetes. The relationships between dAGEs
      and basal SIRT1 mRNA, PPARgamma protein levels in mononuclear cells (MNC) and
      circulating inflammatory/metabolic markers were examined in 67 healthy adults
      aged >60 years and in 18 subjects, before and after random assignment to either a
      standard diet (regular >15 AGE Eq/day) or an isocaloric AGE-restricted diet (<10 
      AGE Eq/day) for 4 months. Also, the interactions of AGEs and anti-AGE receptor-1 
      (AGER1) with SIRT1 and PPARgamma were assessed in wild type (WT) and
      AGER1-transduced (AGER1+) MNC-like THP-1 cells. We found that dAGE, but not
      caloric intake, correlated negatively with MNC SIRT1 mRNA levels and positively
      with circulating AGEs (sAGEs), OS/infl, MNC TNFalpha and RAGE. Basal MNC
      PPARgamma protein was also lower in consumers of regular vs. AGE-restricted diet.
      AGE restriction restored MNC SIRT1 and PPARgamma, and significantly decreased
      sAGEs, 8-isoprostanes, VCAM-1, MNC TNFalpha and RAGE. Model AGEs suppressed SIRT1
      protein and activity, and PPARgamma protein in WT, but not in AGER1+ cells in
      vitro. In conclusion, chronic consumption of high-AGE diets depletes defenses
      such as SIRT1 and PPARgamma, independent of calories, predisposing to OS/Infl and
      chronic metabolic disease. Restricted entry of oral AGEs may offer a
      disease-prevention alternative for healthy adults.
AD  - Department of Medicine, The Mount Sinai School of Medicine, One Gustave Levy
      Place, New York, NY, 10029, USA, jaime.uribarri@mssm.edu.
FAU - Uribarri, Jaime
AU  - Uribarri J
FAU - Cai, Weijing
AU  - Cai W
FAU - Pyzik, Renata
AU  - Pyzik R
FAU - Goodman, Susan
AU  - Goodman S
FAU - Chen, Xue
AU  - Chen X
FAU - Zhu, Li
AU  - Zhu L
FAU - Ramdas, Maya
AU  - Ramdas M
FAU - Striker, Gary E
AU  - Striker GE
FAU - Vlassara, Helen
AU  - Vlassara H
LA  - ENG
GR  - R01 DK091231/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Amino Acids
JT  - Amino acids
JID - 9200312
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/10/06 [received]
PHST- 2013/04/13 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 10.1007/s00726-013-1502-4 [doi]
PST - aheadofprint
SO  - Amino Acids. 2013 May 1.

PMID- 23636465
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1557-1920 (Electronic)
IS  - 1557-1912 (Linking)
DP  - 2013 May 1
TI  - Type 2 Diabetes is Associated with Vertebral Fractures in a Sample of Clinic- and
      Hospital-Based Latinos.
AB  - Latinos are the fastest growing ethnic population in the United States and type 2
      diabetes is a major health burden in this population, but little effort has been 
      made to study the prevalence of diabetic vertebral fragility in Latinos. We
      performed a cross-sectional study to determine vertebral fracture prevalence in a
      hospital-based population of South Texas residents (N = 296). We defined
      fractures in X-rays as a >20 % reduction in vertebral body height. Numerous
      variables were recorded, including age, body mass index, indicators of diabetes
      management and others. 71 % of the sample (N = 296) was Latino. The prevalence of
      vertebral fracture was increased in diabetic subjects relative to non-diabetic
      subjects (diabetic 27.9 %, non-diabetic 13.8 %) and, regardless of sex and
      diabetics status, decreased in Latinos relative to non-Latinos (Latino 16.7 %,
      non-Latino 26.4 %). These data suggest that vertebral fractures may be a growing 
      concern for diabetic Latinos as well as diabetics of any racial/ethnic
      background.
AD  - Department of Orthopaedics MSC-7774, University of Texas Health Science Center at
      San Antonio, 7703 Floyd Curl Dr., San Antonio, TX, 78229, USA.
FAU - Kilpadi, K L
AU  - Kilpadi KL
FAU - Eldabaje, R
AU  - Eldabaje R
FAU - Schmitz, J E
AU  - Schmitz JE
FAU - Ehler, B
AU  - Ehler B
FAU - Thames, T A
AU  - Thames TA
FAU - Joshi, A P
AU  - Joshi AP
FAU - Simmons Iii, J W
AU  - Simmons Iii JW
FAU - Michalek, J E
AU  - Michalek JE
FAU - Fajardo, R J
AU  - Fajardo RJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Immigr Minor Health
JT  - Journal of immigrant and minority health / Center for Minority Public Health
JID - 101256527
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1007/s10903-013-9833-5 [doi]
PST - aheadofprint
SO  - J Immigr Minor Health. 2013 May 1.

PMID- 23636445
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 169
IP  - 1
DP  - 2013 Jul
TI  - Gestational diabetes mellitus among Norwegian women with polycystic ovary
      syndrome: prevalence and risk factors according to the WHO and the modified
      IADPSG criteria.
PG  - 65-72
LID - 10.1530/EJE-12-1107 [doi]
AB  - OBJECTIVE: The consequences of the recently proposed International Association of
      Diabetes in Pregnancy Study Group (IADPSG) criteria for gestational diabetes
      mellitus (GDM) in women with polycystic ovary syndrome (PCOS) are not known. We
      compared the prevalence rates and risk factors for GDM in PCOS women according to
      both the WHO and the modified IADPSG criteria. DESIGN: Post hoc analyses from a
      randomized, multicenter study were used. METHODS: Fasting and 2-h plasma glucose 
      levels were measured using a 75 g oral glucose tolerance test. GDM was diagnosed 
      according to both the WHO and the modified IADPSG criteria. RESULTS: The
      prevalence rates of GDM according to the WHO and the modified IADPSG criteria
      were 9.2 and 15.0% at week 12, 18.7 and 18.7% at week 19, and 25.6 and 24.2% at
      week 32. Shorter stature and increased insulin levels were correlated with
      WHO-GDM, but not with modified IADPSG-GDM at weeks 12 and 19. Less weight gain in
      pregnancy predicted GDM according to both sets of criteria. GDM diagnosis was
      correlated with less maternal weight loss the first year post-partum.
      CONCLUSIONS: No difference was found in the prevalence of GDM between the two
      sets of criteria used. Less weight gain in pregnancy was associated with GDM,
      independent of the diagnostic criteria used. Reduced weight loss the first year
      post-partum in women with GDM raises the question of whether GDM diagnosis per se
      or the fact that these women lose less weight after pregnancy predicts later
      diabetes mellitus.
AD  - Department of Medicine, Drammen Hospital, Vestre Viken, Norway.
FAU - Helseth, R
AU  - Helseth R
FAU - Vanky, E
AU  - Vanky E
FAU - Salvesen, O
AU  - Salvesen O
FAU - Carlsen, S M
AU  - Carlsen SM
LA  - eng
PT  - Journal Article
DEP - 20130607
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology / European Federation of Endocrine Societies
JID - 9423848
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013 [ppublish]
AID - EJE-12-1107 [pii]
AID - 10.1530/EJE-12-1107 [doi]
PST - epublish
SO  - Eur J Endocrinol. 2013 Jun 7;169(1):65-72. doi: 10.1530/EJE-12-1107. Print 2013
      Jul.

PMID- 23636434
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1718-4304 (Electronic)
IS  - 0896-8608 (Linking)
DP  - 2013 May 1
TI  - LIFETIME COSTS FOR PERITONEAL DIALYSIS AND HEMODIALYSIS IN PATIENTS IN TAIWAN.
AB  - BACKGROUND: This study compared the lifetime costs for peritoneal dialysis (PD)
      and hemodialysis (HD) patients in Taiwan. METHODS: Using the National Health
      Insurance (NHI) database of all end-stage renal disease patients on maintenance
      dialysis registered from July 1997 to December 2005, we matched eligible PD
      patients with eligible HD patients on age, sex, and diabetes status. The matched 
      patients were followed until 31 December 2006. Patients were excluded if they
      were less than 18 years of age, had been diagnosed with cancer before dialysis,
      or had been dialyzed at centers or clinics other than hospitals.
      Outcomes-including life expectancy, total lifetime costs, and costs per life-year
      paid by the NHI-were estimated and compared. RESULTS: The 3136 pairs of matched
      PD and HD patients had a mean age of 53.2 +/- 15.4 years. The total lifetime cost
      for PD patients (US$139 360 +/- US$8 336) was significantly lower than that for
      HD patients (US$185 235 +/- US$9 623, p < 0.001). Except for patients with
      diabetes (who had a short life expectancy), the total lifetime cost was
      significantly lower for PD patients than for HD patients regardless of sex and
      age (p < 0.01). CONCLUSION: In Taiwan, the total lifetime costs paid by the NHI
      were lower for PD than for HD patients.
AD  - Department of Internal Medicine, National Taiwan University Hospital and National
      Taiwan University College of Medicine, Taipei, Taiwan.
FAU - Kao, Tze-Wah
AU  - Kao TW
FAU - Chang, Yu-Ying
AU  - Chang YY
FAU - Chen, Pau-Chung
AU  - Chen PC
FAU - Hsu, Chih-Cheng
AU  - Hsu CC
FAU - Chang, Yu-Kang
AU  - Chang YK
FAU - Chang, Yu-Hung
AU  - Chang YH
FAU - Lee, Lukas Jyuhn-Hsiarn
AU  - Lee LJ
FAU - Wu, Kwan-Dun
AU  - Wu KD
FAU - Tsai, Tun-Jun
AU  - Tsai TJ
FAU - Wang, Jung-Der
AU  - Wang JD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Perit Dial Int
JT  - Peritoneal dialysis international : journal of the International Society for
      Peritoneal Dialysis
JID - 8904033
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - pdi.2012.00081 [pii]
AID - 10.3747/pdi.2012.00081 [doi]
PST - aheadofprint
SO  - Perit Dial Int. 2013 May 1.

PMID- 23636301
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1875-8312 (Electronic)
IS  - 1569-5794 (Linking)
DP  - 2013 May 1
TI  - Coronary computed tomography angiography-adapted Leaman score as a tool to
      noninvasively quantify total coronary atherosclerotic burden.
AB  - To describe a coronary computed tomography angiography (CCTA)-adapted Leaman
      score (CT-LeSc) as a tool to quantify total coronary atherosclerotic burden with 
      information regarding localization, type of plaque and degree of stenosis and to 
      identify clinical predictors of a high coronary atherosclerotic burden as
      assessed by the CT-LeSc. Single center prospective registry including a total of 
      772 consecutive patients undergoing CCTA (Dual-source CT) from April 2011 to
      March 2012. For the purpose of this study, 581 stable patients referred for
      suspected coronary artery disease (CAD) without previous myocardial infarction or
      revascularization procedures were included. Pre-test CAD probability was
      determined using both the Diamond-Forrester extended CAD consortium method
      (DF-CAD consortium model) and the Morise score. Cardiovascular risk was assessed 
      with the HeartScore. The cut-off for the 3rd tercile (CT-LeSc >/=8.3) was used to
      define a population with a high coronary atherosclerotic burden. The median
      CT-LeSc in this population (n = 581, 8,136 coronary segments evaluated; mean age 
      57.6 +/- 11.1; 55.8 % males; 14.6 % with diabetes) was 2.2 (IQR 0-6.8). In
      patients with CAD (n = 341), the median CT-LeSc was 5.8 (IQR 3.2-9.6). Among
      patients with nonobstructive CAD, most were classified in the lowest terciles
      (T1, 43.0 %; T2, 36.1 %), but 20.9 % were in the highest tercile (T3). The
      majority of the patients with obstructive CAD were classified in T3 (78.2 %), but
      21.8 % had a CT-LeSc in lower terciles (T1 or T2). The independent predictors of 
      a high CT-LeSc were: Male sex (OR 1.73; 95 % CI 1.04-2.90) diabetes (OR 2.91; 95 
      % CI 1.61-5.23), hypertension (OR 2.54; 95 % CI 1.40-4.63), Morise score >/=16
      (OR 1.97; 95 % CI 1.06-3.67) and HeartScore >/=5 (OR 2.42; 95 % CI 1.41-4.14). We
      described a cardiac CT adapted Leaman score as a tool to quantify total
      (obstructive and nonobstructive) coronary atherosclerotic burden, reflecting the 
      comprehensive information about localization, degree of stenosis and type of
      plaque provided by CCTA. Male sex, hypertension, diabetes, a HeartScore >/=5 %
      and a Morise score >/=16 were associated with a high coronary atherosclerotic
      burden, as assessed by the CT-LeSc. About one fifth of the patients with
      nonobstructive CAD had a CT-LeSc in the highest tercile, and this could
      potentially lead to a reclassification of the risk profile of this subset of
      patients identified by CCTA, once the prognostic value of the CT-LeSc is
      validated.
AD  - Cardiology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal,
      paraujogoncalves@yahoo.co.uk.
FAU - de Araujo Goncalves, Pedro
AU  - de Araujo Goncalves P
FAU - Garcia-Garcia, Hector M
AU  - Garcia-Garcia HM
FAU - Dores, Helder
AU  - Dores H
FAU - Carvalho, Maria Salome
AU  - Carvalho MS
FAU - Jeronimo Sousa, Pedro
AU  - Jeronimo Sousa P
FAU - Marques, Hugo
AU  - Marques H
FAU - Ferreira, Antonio
AU  - Ferreira A
FAU - Cardim, Nuno
AU  - Cardim N
FAU - Campante Teles, Rui
AU  - Campante Teles R
FAU - Raposo, Luis
AU  - Raposo L
FAU - Mesquita Gabriel, Henrique
AU  - Mesquita Gabriel H
FAU - Sousa Almeida, Manuel
AU  - Sousa Almeida M
FAU - Aleixo, Ana
AU  - Aleixo A
FAU - Mota Carmo, Miguel
AU  - Mota Carmo M
FAU - Pereira Machado, Francisco
AU  - Pereira Machado F
FAU - Mendes, Miguel
AU  - Mendes M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Int J Cardiovasc Imaging
JT  - The international journal of cardiovascular imaging
JID - 100969716
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/04/19 [received]
PHST- 2013/04/24 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 10.1007/s10554-013-0232-8 [doi]
PST - aheadofprint
SO  - Int J Cardiovasc Imaging. 2013 May 1.

PMID- 23636268
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 May 1
TI  - Expression of tissue inhibitor of metalloprotease 3 is reduced in ischemic but
      not neuropathic ulcers from patients with type 2 diabetes mellitus.
AB  - Diabetic foot ulceration remains one of the most common and most serious
      consequences of diabetes. Persistently high levels of matrix metalloproteases
      (MMPs) contribute to wound chronicity. Our aim was to assess the concentrations
      of MMPs and tissue inhibitors of metalloproteinases (TIMPs) in neuropathic and
      ischemic diabetic foot ulcers by analyzing biopsy samples. In this study,
      biopsies were taken from 35 diabetic foot ulcers of type 2 diabetes mellitus
      patients and distinguished in neuropathic (n = 14) or ischemic (n = 21).
      Zymography assay was utilized for the analysis of MMP-2 and MMP-9 activity. TACE 
      activity was evaluated by a specific fluorimetric assay. mRNA levels of MMPs as
      well as TIMPs were detected using quantitative real-time polymerase chain
      reaction. The activity of MMP9 and A Disintegrin and A MetalloProtease Domain
      17/TNF-Alpha Converting Enzyme (ADAM17/TACE) was significantly increased in
      ischemic compared to neuropathic biopsies. No differences were detected between
      both groups for the mRNA levels of MMPs as well as of ADAMs. However, TIMP3 mRNA 
      expression was decreased in ischemic samples. The combination of increased
      activity of MMP9 and ADAM17/TACE with decreased concentrations of TIMP-3 mRNA
      expression in ischemic diabetic foot ulcers compared to neuropathic samples
      suggests that the increased proteolytic environment may represent a causative
      factor in the ulcer progression. New treatment strategies for healing diabetic
      foot ulcers could be directed toward increasing levels of TIMP3.
AD  - Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier
      1, 00133, Rome, Italy.
FAU - Menghini, R
AU  - Menghini R
FAU - Uccioli, L
AU  - Uccioli L
FAU - Vainieri, E
AU  - Vainieri E
FAU - Pecchioli, C
AU  - Pecchioli C
FAU - Casagrande, V
AU  - Casagrande V
FAU - Stoehr, R
AU  - Stoehr R
FAU - Cardellini, M
AU  - Cardellini M
FAU - Porzio, O
AU  - Porzio O
FAU - Rizza, S
AU  - Rizza S
FAU - Federici, M
AU  - Federici M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/04/17 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 10.1007/s00592-013-0478-6 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 May 1.

PMID- 23636267
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 May 1
TI  - Relationship between urinary bisphenol A levels and prediabetes among subjects
      free of diabetes.
AB  - Bisphenol A (BPA) is a high volume production chemical used in the manufacture of
      polycarbonate plastics and epoxy resins. Recent experimental studies have
      suggested that BPA affects glucose metabolism through diverse mechanisms
      including insulin resistance, pancreatic beta-cell dysfunction, adipogenesis,
      inflammation and oxidative stress. Prediabetes is a stage earlier in the
      hyperglycemia continuum associated with increased future risk of developing
      diabetes. Therefore, we examined the association between BPA exposure and
      prediabetes among subjects free of diabetes. We examined the association between 
      urinary BPA levels and prediabetes in 3,516 subjects from the National Health and
      Nutritional Examination Survey 2003-2008. Urinary BPA levels were examined in
      tertiles. Prediabetes was defined as fasting glucose concentration 100-125 mg/dL 
      or 2-h glucose concentration of 140-199 mg/dL or an A1C value of 5.7-6.4 %.
      Overall, we observed a positive association between higher levels of urinary BPA 
      and prediabetes, independent of potential confounders including body mass index, 
      alcohol intake, blood pressure and serum cholesterol levels. Compared to tertile 
      1 (referent), the multivariate-adjusted odds ratio (95 % confidence interval) of 
      prediabetes associated with tertile 3 of BPA was 1.34 (1.03-1.73), p-trend =
      0.02. In subgroup analysis, this association was stronger among women and obese
      subjects. Higher urinary BPA levels are found to be associated with prediabetes
      independent of traditional diabetes risk factors. Future prospective studies are 
      needed to confirm or disprove this finding.
AD  - Department of Community Medicine, West Virginia University School of Medicine,
      P.O. Box 9190, Morgantown, WV, 26506-9190, USA,
      charumathi.sabanayagam@seri.com.sg.
FAU - Sabanayagam, Charumathi
AU  - Sabanayagam C
FAU - Teppala, Srinivas
AU  - Teppala S
FAU - Shankar, Anoop
AU  - Shankar A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2011/08/24 [received]
PHST- 2011/12/08 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 10.1007/s00592-013-0472-z [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 May 1.

PMID- 23636253
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 1435-1803 (Electronic)
IS  - 0300-8428 (Linking)
VI  - 108
IP  - 3
DP  - 2013 May
TI  - Dickkopf-1 (DKK1) phosphatase and tensin homolog on chromosome 10 (PTEN)
      crosstalk via microRNA interference in the diabetic heart.
PG  - 352
LID - 10.1007/s00395-013-0352-2 [doi]
AB  - Competitive endogenous RNAs (ceRNAs) regulate mRNA transcripts containing common 
      microRNA (miRNA) recognition elements (MREs) through sequestration of shared
      miRNAs. Interactions of ceRNA have been demonstrated in cancerous cells. However,
      a paucity of information is available relative to the interactions of ceRNAs
      interaction in diabetes mellitus and the myocardium. The purpose of this study is
      to assess the potential role of DKK1 and PTEN in ceRNA regulation utilizing their
      common miRNAs in diabetic cardiomyocytes. The interactions' regulation between
      PTEN and DKK1 were determined in two diabetic models in vivo
      (streptozotocin-induced type-1 DM mice and db/db mice) and in vitro (human
      cardiomyocytes cells exposed to hyperglycemia). The levels of DKK1 and PTEN (mRNA
      and protein) were upregulated in parallel in all three diabetic models. DKK1
      modulates PTEN protein levels in a miRNA and 3'UTR-dependent manner.
      RNAi-mediated DKK1 gene silencing resulted in a decreased PTEN expression and
      vice versa. The effect was blocked when Dicer was inhibited. Silencing either
      PTEN or DKK1 resulted in an increase of the availabilities of shared miRNAs. The 
      silencing of either PTEN or DKKI resulted in a suppression end of the
      luciferase-PTEN 3'UTR activity. However, the over expression of DKK1 3'UTR or
      PTEN 3'UTR resulted in an increase in the activity. The attenuation of DKK1
      increased AKT phosphorylation, improved glucose uptake and decreased apoptosis in
      HCMs exposed to hyperglycemia. The effects were blocked by PI3K inhibition. DKK1 
      and PTEN transcripts are co-upregulated in DM and hyperglycemia. DKK1 and PTEN
      serve as ceRNA, affecting the expression of each other via competition for miRNAs
      binding.
AD  - School of Life Science and Technology, Harbin Institute of Technology, Harbin,
      Heilongjiang, China.
FAU - Ling, Shukuan
AU  - Ling S
FAU - Birnbaum, Yochai
AU  - Birnbaum Y
FAU - Nanhwan, Manjyot K
AU  - Nanhwan MK
FAU - Thomas, Bejoy
AU  - Thomas B
FAU - Bajaj, Mandeep
AU  - Bajaj M
FAU - Li, Yu
AU  - Li Y
FAU - Li, Yinghui
AU  - Li Y
FAU - Ye, Yumei
AU  - Ye Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130501
PL  - Germany
TA  - Basic Res Cardiol
JT  - Basic research in cardiology
JID - 0360342
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/01/25 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/03/12 [revised]
PHST- 2013/05/01 [aheadofprint]
AID - 10.1007/s00395-013-0352-2 [doi]
PST - ppublish
SO  - Basic Res Cardiol. 2013 May;108(3):352. doi: 10.1007/s00395-013-0352-2. Epub 2013
      May 1.

PMID- 23636187
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1535-1386 (Electronic)
VI  - 95
IP  - 9
DP  - 2013 May 1
TI  - Elevated Postoperative Blood Glucose and Preoperative Hemoglobin A1C Are
      Associated with Increased Wound Complications Following Total Joint Arthroplasty.
PG  - 808-14
LID - 10.2106/JBJS.L.00494 [doi]
AB  - BACKGROUND: Diabetes is an established risk factor for complications following
      total joint arthroplasty. However, the correlation between postoperative blood
      glucose and preoperative hemoglobin A1C levels with complications following total
      joint arthroplasty is not well described. METHODS: All patients undergoing
      elective primary total joint arthroplasty at our institution from 2004 through
      2011 with both postoperative blood glucose and preoperative hemoglobin A1C levels
      were identified in a retrospective review. From among 1702 patients, those with
      wound complications within thirty days after the index arthroplasty were
      identified. A control group matched for exact age, sex, procedure, tourniquet
      use, surgical approach, and use of antibiotic cement was also created. Thirty
      patients met the study group inclusion criteria. The mean patient age was
      seventy-two years (range, fifty-three to eighty-nine years); the majority (53%)
      of patients were female. RESULTS: The odds ratio for developing a wound
      complication was 3.75 (95% confidence interval, 1.25 to 11.22; p = 0.02) in
      patients with a mean postoperative glucose of &gt;200 mg/dL, 3.0 (95% confidence 
      interval, 0.97 to 9.30; p = 0.08) in patients with a maximum postoperative blood 
      glucose of &gt;260 mg/dL, and 9.0 (95% confidence interval, 1.14 to 71.20; p =
      0.03) in patients with a preoperative hemoglobin A1C value of &gt;6.7%.
      CONCLUSIONS: Patients with a mean postoperative blood glucose of &gt;200 mg/dL or
      a preoperative hemoglobin A1C level of &gt;6.7% are at increased risk for wound
      complications following elective primary total joint arthroplasty. These results 
      show that poor preoperative and postoperative glucose control is independently
      associated with wound complications. LEVEL OF EVIDENCE: Prognostic Level III. See
      Instructions for Authors for a complete description of levels of evidence.
AD  - Departments of Orthopedic Surgery (L.S.S., M.P.A., M.E.M., M.M.M., and B.F.M.)
      and Anesthesiology (D.J.K.), Mayo Clinic, 200 First Street SW, Rochester, MN
      55905. E-mail address for B.F. Morrey: morrey.bernard@mayo.edu.
FAU - Stryker, Louis S
AU  - Stryker LS
FAU - Abdel, Matthew P
AU  - Abdel MP
FAU - Morrey, Mark E
AU  - Morrey ME
FAU - Morrow, Melissa M
AU  - Morrow MM
FAU - Kor, Daryl J
AU  - Kor DJ
FAU - Morrey, Bernard F
AU  - Morrey BF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
SB  - AIM
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 1679103 [pii]
AID - 10.2106/JBJS.L.00494 [doi]
PST - ppublish
SO  - J Bone Joint Surg Am. 2013 May 1;95(9):808-14. doi: 10.2106/JBJS.L.00494.

PMID- 23636183
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1535-1386 (Electronic)
VI  - 95
IP  - 9
DP  - 2013 May 1
TI  - Risk factors associated with deep surgical site infections after primary total
      knee arthroplasty: an analysis of 56,216 knees.
PG  - 775-82
LID - 10.2106/JBJS.L.00211 [doi]
AB  - BACKGROUND: Deep surgical site infection following total knee arthroplasty is a
      devastating complication. Patient and surgical risk factors for this complication
      have not been thoroughly examined. The purpose of this study was to evaluate risk
      factors associated with deep surgical site infection following total knee
      arthroplasty in a large U.S. integrated health-care system. METHODS: A
      retrospective review of a prospectively followed cohort of primary total knee
      arthroplasties recorded in a total joint replacement registry from 2001 to 2009
      was conducted. Records were screened for deep surgical site infection with use of
      a validated algorithm, and the results were adjudicated by chart review. Patient 
      factors, surgical factors, and surgeon and hospital characteristics were
      identified with use of the total joint replacement registry. Cox regression
      models were used to assess risk factors associated with deep surgical site
      infection. RESULTS: A total of 56,216 total knee arthroplasties were identified; 
      63.0% were done in women, the average age of the patients was 67.4 years
      (standard deviation [SD] = 9.6), and the average body mass index (BMI) was 32
      kg/m2 (SD = 6). The incidence of deep surgical site infection was 0.72%
      (404/56,216). In a fully adjusted model, patient factors associated with deep
      surgical site infection included a BMI of >/=35 (hazard ratio [HR] = 1.47),
      diabetes mellitus (HR = 1.28), male sex (HR = 1.89), an American Society of
      Anesthesiologists (ASA) score of >/=3 (HR = 1.65), a diagnosis of osteonecrosis
      (HR = 3.65), and a diagnosis of posttraumatic arthritis (HR = 3.23). Hispanic
      race was protective (HR = 0.69). Protective surgical factors included use of
      antibiotic irrigation (HR = 0.67), a bilateral procedure (HR = 0.51), and a lower
      annual hospital volume (HR = 0.33). Surgical risk factors included
      quadriceps-release exposure (HR = 4.76) and the use of antibiotic-laden cement
      (HR = 1.53). In a subanalysis, operative time was a risk factor, with a 9%
      increased risk per fifteen-minute increment. CONCLUSIONS: Use of a comprehensive 
      infection surveillance system, combined with a total joint replacement registry, 
      identified patient and surgical factors associated with infection following total
      knee arthroplasty in a large sample. High-risk patients should be counseled, and 
      modifiable clinical conditions should be optimized. Use of antibiotic irrigation 
      should be encouraged, but antibiotic-laden cement may not be useful. LEVEL OF
      EVIDENCE: Prognostic Level II. See Instructions for Authors for a complete
      description of levels of evidence.
AD  - Department of Orthopedic Surgery, Kaiser Permanente Orange County, Southern
      California Permanente Medical Group, 6670 Alton Parkway, Irvine, CA 92618.
FAU - Namba, Robert S
AU  - Namba RS
FAU - Inacio, Maria C S
AU  - Inacio MC
FAU - Paxton, Elizabeth W
AU  - Paxton EW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Bone Joint Surg Am
JT  - The Journal of bone and joint surgery. American volume
JID - 0014030
SB  - AIM
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 1679099 [pii]
AID - 10.2106/JBJS.L.00211 [doi]
PST - ppublish
SO  - J Bone Joint Surg Am. 2013 May 1;95(9):775-82. doi: 10.2106/JBJS.L.00211.

PMID- 23636118
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1536-3708 (Electronic)
IS  - 0148-7043 (Linking)
DP  - 2013 Apr 30
TI  - Autologous Transplantation of Adipose-Derived Stem Cells Enhances Skin Graft
      Survival and Wound Healing in Diabetic Rats.
AB  - BACKGROUND: Diabetes can lead to impaired wound healing and skin grafts used
      surgically for diabetic wounds are often complicated with necrosis, although
      different therapies have been proposed. Adipose-derived stem cells (ASCs)
      participate in tissue repair processes and may have a role during impaired wound 
      healing. In this study, autologous transplantation of ASCs was used to determine 
      if it increases angiogenesis and skin graft survival and enhances wound healing
      in diabetic rats. METHODS: Adipose-derived stem cells were successfully isolated 
      and cultured. A full-thickness skin graft model was used to determine the effects
      of locally administered ASCs in 10 rats rendered diabetic (group 1), whereas 10
      others served as controls (group 2). Histological examination of skin grafts
      followed after 1 week. Additionally, immunohistochemical staining intensity of
      vascular endothelial growth factor (VEGF) and transforming growth factor beta3
      (TGF-beta3) was assessed in all grafts. RESULTS: The gross and histological
      results showed significantly increased survival, angiogenesis, and
      epithelialization. Mean area of graft necrosis was significantly less in group 1 
      than in group 2 (7.49% vs 39.67%, P < 0.001). Statistically significant increase 
      of capillary density, collagen intensity, VEGF, and TGF-beta3 expression was
      noted in group 1 compared with group 2. CONCLUSIONS: These findings suggest that 
      autologous ASC transplantation can enhance skin graft survival in diabetic rats
      through differentiation, vasculogenesis, and secretion of growth factors such as 
      VEGF and TGF-beta3. This might represent a novel therapeutic approach in skin
      graft surgery for diabetic wounds.
AD  - From the *Laboratory of Experimental Surgery and Research, daggerSurgical
      Department, and double daggerPathology Department, University of Athens School of
      Medicine; and section signHellenic Cord Blood Bank, Biomedical Research
      Foundation, Academy of Athens, Athens, Greece.
FAU - Zografou, Aggeliki
AU  - Zografou A
FAU - Papadopoulos, Othon
AU  - Papadopoulos O
FAU - Tsigris, Christos
AU  - Tsigris C
FAU - Kavantzas, Nikolaos
AU  - Kavantzas N
FAU - Michalopoulos, Efstathios
AU  - Michalopoulos E
FAU - Chatzistamatiou, Theofanis
AU  - Chatzistamatiou T
FAU - Papassavas, Andreas
AU  - Papassavas A
FAU - Stavropoulou-Gioka, Catherine
AU  - Stavropoulou-Gioka C
FAU - Dontas, Ismini
AU  - Dontas I
FAU - Perrea, Despoina
AU  - Perrea D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Ann Plast Surg
JT  - Annals of plastic surgery
JID - 7805336
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1097/SAP.0b013e31826af01a [doi]
PST - aheadofprint
SO  - Ann Plast Surg. 2013 Apr 30.

PMID- 23636086
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1537-7385 (Electronic)
IS  - 0894-9115 (Linking)
DP  - 2013 Apr 29
TI  - Is Kyphosis Related to Mobility, Balance, and Disability?
AB  - OBJECTIVE: The aim of this study was to determine the association of increased
      kyphosis with declines in mobility, balance, and disability among
      community-living older adults. DESIGN: The 18-mo follow-up visit data from 2006
      to 2009 for 620 participants from the population-based Maintenance of Balance,
      Independent Living, Intellect, and Zest in the Elderly Boston Study of older
      adults was used. Cross-sectional multivariable regression analyses were performed
      to assess the relationship between kyphosis (measured using the kyphosis index)
      and measures of mobility performance (Short Physical Performance Battery),
      balance (Berg Balance Scale score), and disability (self-reported difficulty
      walking a quarter of a mile or climbing a flight of stairs). The authors then
      evaluated the men and the women separately. Adjustment variables included
      demographic factors (age, sex, race, and education), body mass index, self-rated 
      health, comorbidities (heart disease, diabetes, stroke, and depressive symptoms),
      back pain, knee pain, and falls self-efficacy. RESULTS: After full adjustment,
      greater kyphosis index was associated with lower Short Physical Performance
      Battery scores (adjusted beta = -0.08, P = 0.01) but not with lower Berg Balance 
      Scale (adjusted beta = -0.09, P = 0.23) or self-reported disability (adjusted
      beta = 1.00; 95% confidence interval, 0.93-1.06) scores. In sex-specific
      analyses, kyphosis index was associated with only the Short Physical Performance 
      Battery in the women. CONCLUSIONS: Greater kyphosis is associated with poorer
      mobility performance but not with poorer balance or self-reported disability.
      This association with the Short Physical Performance Battery was observed only
      among the women. Mechanisms by which increased kyphosis influences physical
      performance should be explored prospectively.
AD  - From the Pioneer Spine and Sports Physicians, West Springfield, Massachusetts
      (RE); University of Massachusetts Boston (SGL); Hebrew Senior Life, Roslindale,
      Massachusetts (DKK, DPK, EJS); Harvard Medical School, Boston, Massachusetts
      (DPK, JFB); and Spaulding Rehabilitation Hospital, Boston, Massachusetts (JFB).
FAU - Eum, Regina
AU  - Eum R
FAU - Leveille, Suzanne G
AU  - Leveille SG
FAU - Kiely, Dan K
AU  - Kiely DK
FAU - Kiel, Douglas P
AU  - Kiel DP
FAU - Samelson, Elizabeth J
AU  - Samelson EJ
FAU - Bean, Jonathan F
AU  - Bean JF
LA  - ENG
GR  - K24 HD070966/HD/NICHD NIH HHS/United States
GR  - P01 AG004390/AG/NIA NIH HHS/United States
GR  - R01 AG041525/AG/NIA NIH HHS/United States
GR  - R01 AG041658/AG/NIA NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Am J Phys Med Rehabil
JT  - American journal of physical medicine & rehabilitation / Association of Academic 
      Physiatrists
JID - 8803677
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1097/PHM.0b013e31829233ee [doi]
PST - aheadofprint
SO  - Am J Phys Med Rehabil. 2013 Apr 29.

PMID- 23636037
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1532-2971 (Electronic)
IS  - 1090-0233 (Linking)
DP  - 2013 Apr 29
TI  - Differential expression of circulating microRNAs in diabetic and healthy lean
      cats.
LID - S1090-0233(13)00145-7 [pii]
LID - 10.1016/j.tvjl.2013.03.027 [doi]
AB  - MicroRNAs (miRNAs) regulate gene expression and play a role in the pathogenesis
      of human type 2 diabetes mellitus. This study investigated whether miRNA
      expression profiles differ between healthy and diabetic cats. Total RNA was
      extracted from sera of healthy lean cats, newly diagnosed diabetic cats and cats 
      in diabetic remission. Microarrays representing 1079 mouse miRNA targets were
      used to measure miRNA expression in serum samples from eight healthy lean and
      seven newly diagnosed diabetic cats; 227 distinct miRNAs could be detected.
      Nineteen miRNAs were differentially expressed in newly diagnosed diabetic cats
      compared to healthy lean cats, with a false discovery rate of 10%. Hierarchical
      cluster analysis of these 19 miRNAs grouped healthy lean and newly diagnosed
      diabetic cats into separate clusters. After correction for multiple testing, only
      miR-122 and miR-193b reached statistical significance (P<0.05), with a false
      discovery rate of 1%. Specific quantitative real-time PCR assays for three target
      miRNAs (miR-122, miR-193b and miR-483*) were applied to four samples from each of
      the three groups. miR-122 expression was >40-fold higher in newly diagnosed
      diabetic cats compared to healthy lean cats and cats in diabetic remission,
      whereas miR-193b showed >14-fold higher expression. MiR-483* was expressed
      sixfold higher in newly diagnosed diabetic cats compared to both other groups.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Centre for Clinical Veterinary Medicine, Clinic of Small Animal Medicine, Ludwig 
      Maximilian University Munich, Veterinaerstrasse 13, 80539 Munich, Germany.
FAU - Fleischhacker, Stefanie N
AU  - Fleischhacker SN
FAU - Bauersachs, Stefan
AU  - Bauersachs S
FAU - Wehner, Astrid
AU  - Wehner A
FAU - Hartmann, Katrin
AU  - Hartmann K
FAU - Weber, Karin
AU  - Weber K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Vet J
JT  - Veterinary journal (London, England : 1997)
JID - 9706281
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/09/05 [received]
PHST- 2013/03/22 [revised]
PHST- 2013/03/25 [accepted]
AID - S1090-0233(13)00145-7 [pii]
AID - 10.1016/j.tvjl.2013.03.027 [doi]
PST - aheadofprint
SO  - Vet J. 2013 Apr 29. pii: S1090-0233(13)00145-7. doi: 10.1016/j.tvjl.2013.03.027.

PMID- 23636015
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 31
IP  - 6
DP  - 2013 Jun
TI  - Protein intake in type 1 diabetes: putting controversies into perspectives.
PG  - 1086-90
LID - 10.1097/HJH.0b013e32836163c0 [doi]
AD  - aSection of Cardiology, ASL 1 Umbria, Perugia bDepartment of Internal Medicine,
      University of Perugia, Perugia cDepartment of Internal Medicine, Hospital of
      Assisi, Assisi, Italy.
FAU - Angeli, Fabio
AU  - Angeli F
FAU - Reboldi, Gianpaolo
AU  - Reboldi G
FAU - Verdecchia, Paolo
AU  - Verdecchia P
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1097/HJH.0b013e32836163c0 [doi]
AID - 00004872-201306000-00005 [pii]
PST - ppublish
SO  - J Hypertens. 2013 Jun;31(6):1086-90. doi: 10.1097/HJH.0b013e32836163c0.

PMID- 23635963
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 80
IP  - 22
DP  - 2013 May 28
TI  - Phenotypic heterogeneity of the 8344A>G mtDNA "MERRF" mutation.
PG  - 2049-2054
AB  - OBJECTIVES: Myoclonic epilepsy with ragged-red fibers (MERRF) is a rare
      mitochondrial syndrome, mostly caused by the 8344A>G mitochondrial DNA mutation. 
      Most of the previous studies have been based on single case/family reports or
      series with few patients. The primary aim of this study was the characterization 
      of a large cohort of patients with the 8344A>G mutation. The secondary aim was
      revision of the previously published data. METHODS: Retrospective, database-based
      study (Nation-wide Italian Collaborative Network of Mitochondrial Diseases) and
      systematic revision. RESULTS: Forty-two patients carrying the mutation were
      identified. The great majority did not have full-blown MERRF syndrome. Myoclonus 
      was present in 1 of 5 patients, whereas myopathic signs and symptoms, generalized
      seizures, hearing loss, eyelid ptosis, and multiple lipomatosis represented the
      most common clinical features. Some asymptomatic mutation carriers have also been
      observed. Myoclonus was more strictly associated with ataxia than generalized
      seizures in adult 8344A>G subjects. Considering all of the 321 patients so far
      available, including our dataset and previously published cases, at the mean age 
      of approximately 35 years, the clinical picture was characterized by the
      following signs/symptoms, in descending order: myoclonus, muscle weakness, ataxia
      (35%-45% of patients); generalized seizures, hearing loss (25%-34.9%); cognitive 
      impairment, multiple lipomatosis, neuropathy, exercise intolerance (15%-24.9%);
      and increased creatine kinase levels, ptosis/ophthalmoparesis, optic atrophy,
      cardiomyopathy, muscle wasting, respiratory impairment, diabetes, muscle pain,
      tremor, migraine (5%-14.9%). CONCLUSIONS: Our results showed higher clinical
      heterogeneity than commonly thought. Moreover, MERRF could be better defined as a
      myoclonic ataxia rather than a myoclonic epilepsy.
AD  - From the Neurological Clinic (M. Mancuso, D.O., E.C.I., G.S.), University of
      Pisa; Neurological Clinic (C.A., E.P., M. Spinazzi), University of Padova, and
      IRCCS S. Camillo, Venice; Bambino Gesu Hospital (E.B., D.M.), Rome; IRCCS
      Istituto di Scienze Neurologiche and Department of Biomedical and Neuromotor
      Sciences (V.C., M.L.V.), University of Bologna; Dino Ferrari Centre (G.P.C.,
      D.R.), Neuroscience Section, Department of Pathophysiology and Transplantation
      (DEPT), University of Milan, Neurology Unit, IRCCS Foundation Ca' Granda Ospedale
      Maggiore Policlinico, Milan; Neuropediatric and Muscle Disorders Unit (C.M.,
      C.B.), University of Genoa and G. Gaslini Institute, Genoa; Neuromuscular Unit,
      Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (M. Moggio, M.
      Sciacco), Milano, Dino Ferrari Centre University of Milan; Department of
      Neuroscience (T.M., L.V.), University of Turin; Institute of Neurology (S.S.,
      D.S.), Catholic University, Rome; Neurological Clinic (P.T., M. Scarpelli),
      University of Verona; Department of Neurosciences (A.T., O.M.), University of
      Messina; Child Neurology Unit (G.U., I.M.) and Unit of Molecular Neurogenetics
      (C.L., M.Z.), The Foundation "Carlo Besta" Institute of Neurology-IRCCS, Milan;
      University Hospital Spedali Civili (M.F.), Neurological Clinic, Brescia; and
      IRCCS Stella Maris (F.M.S.), Pisa, Italy.
FAU - Mancuso, Michelangelo
AU  - Mancuso M
FAU - Orsucci, Daniele
AU  - Orsucci D
FAU - Angelini, Corrado
AU  - Angelini C
FAU - Bertini, Enrico
AU  - Bertini E
FAU - Carelli, Valerio
AU  - Carelli V
FAU - Comi, Giacomo Pietro
AU  - Comi GP
FAU - Minetti, Carlo
AU  - Minetti C
FAU - Moggio, Maurizio
AU  - Moggio M
FAU - Mongini, Tiziana
AU  - Mongini T
FAU - Servidei, Serenella
AU  - Servidei S
FAU - Tonin, Paola
AU  - Tonin P
FAU - Toscano, Antonio
AU  - Toscano A
FAU - Uziel, Graziella
AU  - Uziel G
FAU - Bruno, Claudio
AU  - Bruno C
FAU - Caldarazzo Ienco, Elena
AU  - Caldarazzo Ienco E
FAU - Filosto, Massimiliano
AU  - Filosto M
FAU - Lamperti, Costanza
AU  - Lamperti C
FAU - Martinelli, Diego
AU  - Martinelli D
FAU - Moroni, Isabella
AU  - Moroni I
FAU - Musumeci, Olimpia
AU  - Musumeci O
FAU - Pegoraro, Elena
AU  - Pegoraro E
FAU - Ronchi, Dario
AU  - Ronchi D
FAU - Santorelli, Filippo Maria
AU  - Santorelli FM
FAU - Sauchelli, Donato
AU  - Sauchelli D
FAU - Scarpelli, Mauro
AU  - Scarpelli M
FAU - Sciacco, Monica
AU  - Sciacco M
FAU - Spinazzi, Marco
AU  - Spinazzi M
FAU - Valentino, Maria Lucia
AU  - Valentino ML
FAU - Vercelli, Liliana
AU  - Vercelli L
FAU - Zeviani, Massimo
AU  - Zeviani M
FAU - Siciliano, Gabriele
AU  - Siciliano G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Neurology
JT  - Neurology
JID - 0401060
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/05/01 [aheadofprint]
AID - WNL.0b013e318294b44c [pii]
AID - 10.1212/WNL.0b013e318294b44c [doi]
PST - ppublish
SO  - Neurology. 2013 May 28;80(22):2049-2054. Epub 2013 May 1.

PMID- 23635905
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 35
IP  - 4
DP  - 2013
TI  - Aspirin resistance in patients with hemodynamic cerebral ischemia undergoing
      extracranial-intracranial bypass surgery.
PG  - 355-62
LID - 10.1159/000348649 [doi]
AB  - Background: Aspirin (acetylsalicylic acid, ASA) is the treatment of choice for
      prevention of vascular events in symptomatic steno-occlusive cerebrovascular
      disease (CVD). Cerebral revascularization using standard
      extracranial-intracranial (EC-IC) bypass surgery may be used to revert
      hemodynamic compromise. Aspirin is prescribed as standard medication in order to 
      avoid bypass failure. Accumulating evidence of an increased risk of major adverse
      clinical events led to this study, in which we aimed to assess the prevalence of 
      aspirin resistance and prothrombotic disorders among patients scheduled for EC-IC
      bypass surgery, and the effectiveness of aspirin dose escalation. Methods: We
      prospectively screened patients with circumscribed high-grade stenosis or
      occlusion of brain-supplying vessels fulfilling the hemodynamic criteria for
      EC-IC bypass surgery for aspirin resistance using a platelet function analyzer
      (PFA-100(R)) test. We also determined their smoking habits and screened for
      prothrombotic disorders and comorbidities. The patients were divided into 2 major
      groups: group A had atherosclerotic steno-occlusive CVD and group B consisted of 
      patients with nonatherosclerotic steno-occlusive CVD (moyamoya disease) and a
      subgroup of pediatric moyamoya patients (pediatric subgroup). Bypass patency was 
      documented via digital subtraction angiography. Standard initial ASA dose applied
      was 100 mg/day. In cases of aspirin resistance, doses were increased and the
      PFA-100 test was repeated. Results: A total of 56 patients were included over a
      time period of 6 months. In group A (n = 25), we found a ratio of 40% of patients
      with primary resistance to aspirin 100 mg/day. In contrast, in group B (n = 25), 
      only 20% of the patients were resistant to aspirin 100 mg/day; in the pediatric
      population (n = 6), there was no primary aspirin resistance. After a dose
      escalation to 300 mg/day, the ratio of aspirin resistance was reduced to 20% in
      group A and to 0% in group B. Altogether 5 patients with atherosclerotic
      steno-occlusive CVD remained aspirin-resistant despite the dose escalation; 2 of 
      them suffered an early bypass failure. Smoking habits and diabetes mellitus were 
      positively correlated with aspirin resistance. Moreover, 25% of all patients had 
      laboratory signs of a prothrombotic disorder, but this had no influence on
      aspirin response or bypass patency. Conclusions: Aspirin resistance is common in 
      the population of patients with hemodynamic cerebral ischemia scheduled for
      cerebral revascularization. It may have an adverse impact on the outcome of
      surgery. Screening and treatment via dose escalation of aspirin is a
      straightforward and sensible routine for patients undergoing EC-IC bypass
      surgery.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Neurosurgery, Charite University Medicine Berlin, Berlin, Germany.
FAU - Jussen, Daniel
AU  - Jussen D
FAU - Horn, Peter
AU  - Horn P
FAU - Vajkoczy, Peter
AU  - Vajkoczy P
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/11/05 [received]
PHST- 2012/01/23 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 000348649 [pii]
AID - 10.1159/000348649 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2013;35(4):355-62. doi: 10.1159/000348649. Epub 2013 Apr 30.

PMID- 23635809
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1550-5049 (Electronic)
IS  - 0889-4655 (Linking)
DP  - 2013 Apr 30
TI  - Cost-effectiveness of Nurse Practitioner/Community Health Worker Care to Reduce
      Cardiovascular Health Disparities.
AB  - BACKGROUND:: Although evidence-based guidelines on the management of
      cardiovascular disease (CVD) and type 2 diabetes have been widely published,
      implementation of recommended therapies is suboptimal. OBJECTIVE:: The aim of
      this study was to evaluate the cost-effectiveness of a comprehensive program of
      CVD risk reduction delivered by nurse practitioner/community health worker
      (NP/CHW) teams versus enhanced usual care to improve lipids, blood pressure (BP),
      and hemoglobin (Hb) A1c levels in patients in urban community health centers.
      METHODS:: A total of 525 patients with documented CVD, type 2 diabetes,
      hypercholesterolemia, or hypertension and levels of low-density lipoprotein
      cholesterol, BP, or Hb A1c that exceeded goals established by national guidelines
      were randomized to NP/CHW (n = 261) or enhanced usual care (n = 264) groups.
      Cost-effectiveness ratios were calculated, determining costs per percent and unit
      change in the primary outcomes. RESULTS:: The mean incremental total cost per
      patient (NP/CHW and physician) was only $627 (confidence interval, 248-1015). The
      cost-effectiveness of the 1-year intervention was $157 for every 1% drop in
      systolic BP and $190 for every 1% drop in diastolic BP, $149 per 1% drop in Hb
      A1c, and $40 per 1% drop in low-density lipoprotein cholesterol. CONCLUSIONS::
      The findings suggest that management by an NP/CHW team is a cost-effective
      approach for community health centers to consider in improving the care of
      patients with existing CVD or at high risk for the development of CVD.
AD  - Jerilyn K. Allen, RN, ScD, FAAN M Adelaide Nutting Professor of Nursing, Public
      Health and Medicine and Associate Dean for Research, School of Nursing, Johns
      Hopkins University, Baltimore, Maryland. Cheryl R. Dennison Himmelfarb, RN, ANP, 
      PhD, FAAN Associate Professor, School of Nursing and Medicine, Johns Hopkins
      University, Baltimore, Maryland. Sarah L. Szanton, PhD, CRNP Associate Professor,
      School of Nursing, Johns Hopkins University, Baltimore, Maryland. Kevin D. Frick,
      PhD, MA Professor, Bloomberg School of Public Health and School of Nursing, Johns
      Hopkins University, Baltimore, Maryland.
FAU - Allen, Jerilyn K
AU  - Allen JK
FAU - Dennison Himmelfarb, Cheryl R
AU  - Dennison Himmelfarb CR
FAU - Szanton, Sarah L
AU  - Szanton SL
FAU - Frick, Kevin D
AU  - Frick KD
LA  - ENG
GR  - R01 HL082638/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Cardiovasc Nurs
JT  - The Journal of cardiovascular nursing
JID - 8703516
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1097/JCN.0b013e3182945243 [doi]
PST - aheadofprint
SO  - J Cardiovasc Nurs. 2013 Apr 30.

PMID- 23635802
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1873-1244 (Electronic)
IS  - 0899-9007 (Linking)
DP  - 2013 Apr 28
TI  - Light and shadows of dietary protein restriction in elderly with Chronic Kidney
      Disease.
LID - S0899-9007(13)00091-9 [pii]
LID - 10.1016/j.nut.2013.01.023 [doi]
AB  - Approximately 45% of the elderly population suffers from chronic kidney disease
      (CKD). The onset and the course of CKD can be ameliorated to a significant degree
      by several interventions, such as lowering blood pressure and serum lipid levels 
      and achieving optimal glucose control in diabetes. In elderly patients with more 
      advanced CKD, additional treatment may be needed. In these patients, a
      low-protein diet (LPD) regimen may delay the need for dialysis therapy. However, 
      in the elderly, feasibility and compliance to LPD could be difficult and its
      effects are uncertain. In this contribution, we discuss the usefulness and the
      barriers of LPD regimen in the elderly.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Gerontology, Geriatrics and Metabolic Diseases, Second University
      of Naples, Italy. Electronic address: mauro.giordano@unina2.it.
FAU - Giordano, Mauro
AU  - Giordano M
FAU - Ciarambino, Tiziana
AU  - Ciarambino T
FAU - Castellino, Pietro
AU  - Castellino P
FAU - Paolisso, Giuseppe
AU  - Paolisso G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Nutrition
JT  - Nutrition (Burbank, Los Angeles County, Calif.)
JID - 8802712
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/12/10 [received]
PHST- 2013/01/21 [revised]
PHST- 2013/01/30 [accepted]
AID - S0899-9007(13)00091-9 [pii]
AID - 10.1016/j.nut.2013.01.023 [doi]
PST - aheadofprint
SO  - Nutrition. 2013 Apr 28. pii: S0899-9007(13)00091-9. doi:
      10.1016/j.nut.2013.01.023.

PMID- 23635793
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 123
IP  - 5
DP  - 2013 May 1
TI  - Diabetes increases mortality after myocardial infarction by oxidizing CaMKII.
PG  - 2333
LID - 10.1172/JCI70180 [doi]
LID - 70180 [pii]
FAU - Luo, Min
AU  - Luo M
FAU - Guan, Xiaoqun
AU  - Guan X
FAU - Luczak, Elizabeth D
AU  - Luczak ED
FAU - Lang, Di
AU  - Lang D
FAU - Kutschke, William
AU  - Kutschke W
FAU - Gao, Zhan
AU  - Gao Z
FAU - Yang, Jinying
AU  - Yang J
FAU - Glynn, Patric
AU  - Glynn P
FAU - Sossalla, Samuel
AU  - Sossalla S
FAU - Swaminathan, Paari D
AU  - Swaminathan PD
FAU - Weiss, Robert M
AU  - Weiss RM
FAU - Yang, Baoli
AU  - Yang B
FAU - Rokita, Adam G
AU  - Rokita AG
FAU - Maier, Lars S
AU  - Maier LS
FAU - Efimov, Igor R
AU  - Efimov IR
FAU - Hund, Thomas J
AU  - Hund TJ
FAU - Anderson, Mark E
AU  - Anderson ME
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
SB  - AIM
SB  - IM
PMC - PMC3635753
OID - NLM: PMC3635753
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/05/01 [aheadofprint]
PHST- 2013/05/01 [epublish]
AID - 70180 [pii]
AID - 10.1172/JCI70180 [doi]
PST - ppublish
SO  - J Clin Invest. 2013 May 1;123(5):2333. doi: 10.1172/JCI70180. Epub 2013 May 1.

PMID- 23635737
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 121
IP  - 5
DP  - 2013 May
TI  - Patient satisfaction after midurethral sling surgery for stress urinary
      incontinence.
PG  - 1009-16
LID - 10.1097/AOG.0b013e31828ca49e [doi]
AB  - OBJECTIVE: : To identify factors that may contribute to patient satisfaction with
      outcome in women who received retropubic and transobturator midurethral slings.
      METHODS: : Satisfaction was assessed 12 months postsurgery as a planned analysis 
      in 597 participants from a multicenter randomized trial comparing retropubic with
      transobturator midurethral slings using the Incontinence Surgery Satisfaction
      Questionnaire. Significantly related variables associated with satisfaction in
      univariable analyses were entered into multivariable logistic regression models
      to test their independent association with satisfaction. RESULTS: : One year
      after surgery, 264 (88.6%) in the retropubic group and 263 (88.0%) in the
      transobturator group completed satisfaction questionnaires. Both treatment groups
      demonstrated a high level of satisfaction with respect to urine leakage
      (retropubic 85.9% compared with transobturator 90.0%; P=.52), urgency to urinate,
      frequency of urination, capability of physical activity, social activity, ability
      to engage in sexual activity, and from an emotional standpoint. Baseline
      characteristics associated with reduced satisfaction were higher Medical,
      Epidemiologic, and Social Aspects of Aging Questionnaire urgency subscale scores,
      detrusor overactivity, and diabetes mellitus. The severity of both objective
      (frequency of incontinence episodes, pad test weight) and subjective
      (Incontinence Impact Questionnaire and Urogenital Distress Inventory score)
      measures of incontinence at baseline and the patients' perceptions of
      preoperative severity of incontinence and expectations of achieving postoperative
      cure or improvement were not statistically different between satisfied and
      unsatisfied patients. In the final multivariable model, satisfaction was
      associated with overall treatment success (odds ratio [OR] 2.57, 95% confidence
      interval [CI] 1.29-5.13], greater reduction in Urogenital Distress Inventory (OR 
      0.97, 95% CI 0.96-0.98) and Incontinence Impact Questionnaire scores (OR 0.99,
      95% CI 0.98-0.99), and fewer complications (OR 0.55, 95% CI 0.30-0.99).
      CONCLUSION: : The high level of satisfaction seen after midurethral sling
      procedures is associated with greater objective and patient-perceived improvement
      of stress incontinence and fewer complications. CLINICAL TRIAL REGISTRATION: :
      ClinicalTrials.gov, www.clinicaltrials.gov, NCT00325039. LEVEL OF EVIDENCE: : II.
AD  - University of Texas Southwestern, Dallas, Texas; the New England Research
      Institutes, Watertown, Massachusetts; the University of Pittsburgh, Pittsburgh,
      Pennsylvania; Department of Veterans Affairs and The University of Alabama at
      Birmingham, Birmingham, Alabama; Loyola University Stritch School of Medicine,
      Chicago, Illinois; the University of Maryland, Baltimore, Maryland; and the
      University of California, San Diego, California.
FAU - Wai, Clifford Y
AU  - Wai CY
FAU - Curto, Teresa M
AU  - Curto TM
FAU - Zyczynski, Halina M
AU  - Zyczynski HM
FAU - Stoddard, Anne M
AU  - Stoddard AM
FAU - Burgio, Kathryn L
AU  - Burgio KL
FAU - Brubaker, Linda
AU  - Brubaker L
FAU - Rickey, Leslie M
AU  - Rickey LM
FAU - Menefee, Shawn A
AU  - Menefee SA
CN  - Urinary Incontinence Treatment Network
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - AIM
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1097/AOG.0b013e31828ca49e [doi]
AID - 00006250-201305000-00015 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2013 May;121(5):1009-16. doi: 10.1097/AOG.0b013e31828ca49e.

PMID- 23635734
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 121
IP  - 5
DP  - 2013 May
TI  - Factors associated with urgent cesarean delivery in women with type 1 diabetes
      mellitus.
PG  - 983-9
LID - 10.1097/AOG.0b013e31828b6d97 [doi]
AB  - OBJECTIVE: : Type 1 diabetes mellitus (DM) is associated with a threefold to
      fivefold increased risk for stillbirth during pregnancy. The objective of the
      present study was to identify factors associated with prelabor urgent cesarean
      delivery for fetal compromise in women with type 1 DM. METHODS: : We performed a 
      nested case-control study within a prospective cohort of single pregnancies in
      women with type 1 DM managed with standardized protocols regarding treatment of
      diabetes and prenatal care. Twice-weekly home antenatal surveillance including
      nonstress test was initiated at 32 weeks of gestation and continued until planned
      delivery at 38-39 weeks of gestation. We identified factors associated with
      urgent cesarean delivery for an abnormal nonstress test. The calculated total
      sample size was 416 pregnancies. Independent factors and adjusted odds ratio (OR)
      were identified by logistic regression. RESULTS: : Among 479 pregnancies, the
      rate of urgent cesarean delivery for an abnormal nonstress test was 4%. A
      hemoglobin A1C (Hb A1C) level at delivery of 6.4% or higher occurred in 34% of
      the pregnancies and was independently associated with urgent cesarean delivery
      (2% compared with 8%, P=.003, OR 4.16, 95% confidence interval 1.40-12.32). In
      the multivariable analysis, lack of preconception care and occurrence of
      gestational hypertension or preeclampsia were not associated with urgent cesarean
      delivery. The rate of stillbirth was 2 per 1,000. CONCLUSION: : In women with
      type 1 DM, an Hb A1C level at delivery of 6.4% or higher was associated with
      prelabor urgent cesarean delivery. This suggests that tight glycemic control
      throughout pregnancy might reduce the risk of late fetal compromise. LEVEL OF
      EVIDENCE: : III.
AD  - Department of Obstetrics and Gynecology of Port Royal, Department of Diabetology,
      Cochin Hospital, Assistance Publique-Hopitaux de Paris, France; Paris Descartes
      University, Sorbonne Paris Cite, and INSERM Unit 953, Epidemiological Research
      Unit on Perinatal Health and Women's Health, Paris, France.
FAU - Miailhe, Gregoire
AU  - Miailhe G
FAU - Le Ray, Camille
AU  - Le Ray C
FAU - Timsit, Jose
AU  - Timsit J
FAU - Lepercq, Jacques
AU  - Lepercq J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - AIM
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1097/AOG.0b013e31828b6d97 [doi]
AID - 00006250-201305000-00012 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2013 May;121(5):983-9. doi: 10.1097/AOG.0b013e31828b6d97.

PMID- 23635733
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 121
IP  - 5
DP  - 2013 May
TI  - Risk of childhood obesity in the toddler offspring of mothers with gestational
      diabetes.
PG  - 976-82
LID - 10.1097/AOG.0b013e31828bf70d [doi]
AB  - OBJECTIVE: : To estimate whether children aged 2-4 years of mothers with
      gestational diabetes are at increased risk for childhood obesity. Secondary
      objectives included examining the associations between maternal body mass index
      (BMI), gestational weight gain, large-for-gestational-age (LGA) newborns, and
      race or ethnicity with childhood obesity. METHODS: : Retrospective cohort study
      of women with and without gestational diabetes mellitus (GDM), and their term
      offspring, who delivered at a single institution between 2004 and 2007. RESULTS: 
      : We identified 255 woman and toddler pairs with GDM and 1,838 woman and toddler 
      pairs without GDM. Mean BMI percentiles of toddlers of women with and without GDM
      did not differ (mean 51.8 percentile compared with 55.3 percentile; P=.12).
      Adjusted logistic regression models demonstrated increased risk of toddler
      obesity with higher prepregnancy BMI compared with normal-weight mothers
      (adjusted odds ratio [OR] 2.56, 95% confidence interval [CI] 1.92-3.42).
      Additionally, LGA increased the odds of toddler overweight and obesity (adjusted 
      OR 1.8, 95% CI 1.4-2.3). CONCLUSION: : Childhood obesity was not associated with 
      GDM but was associated with higher prepregnancy maternal BMI and LGA. LEVEL OF
      EVIDENCE: : II.
AD  - Departments of Obstetrics and Gynecology, Kaiser Permanente Northern California
      at Fremont, Fremont, California, Kaiser Permanente Northern California at Santa
      Clara, Santa Clara, California, and Oregon Health & Science University, Portland,
      Oregon.
FAU - Pham, Michelle T
AU  - Pham MT
FAU - Brubaker, Katherine
AU  - Brubaker K
FAU - Pruett, Kimberly
AU  - Pruett K
FAU - Caughey, Aaron B
AU  - Caughey AB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - AIM
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1097/AOG.0b013e31828bf70d [doi]
AID - 00006250-201305000-00011 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2013 May;121(5):976-82. doi: 10.1097/AOG.0b013e31828bf70d.

PMID- 23635714
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1421-9670 (Electronic)
IS  - 0250-8095 (Linking)
VI  - 37
IP  - 5
DP  - 2013
TI  - The Association of Prevalent Kidney Stone Disease with Mortality in US Adults:
      The National Health and Nutrition Examination Survey III, 1988-1994.
PG  - 501-6
LID - 10.1159/000350691 [doi]
AB  - Background: Kidney stone disease is associated with hypertension, diabetes,
      metabolic syndrome, kidney function decline, and increased cardiovascular (CV)
      events. However, its association with all-cause and CV mortality is unclear.
      Methods: We used the Third National Health and Nutrition Examination Survey, a
      large US population-based study with mortality data through 2006 determined via
      linkage to the National Death Index to examine kidney stone disease in relation
      to all-cause and CV mortality risks. Results: Among 14,879 men and women over 18 
      years of age who were eligible for analysis, 683 participants reported a history 
      of kidney stones. There was a total of 3,590 all-cause and 1,608 CV deaths during
      a median follow-up of 14.9 years. Stone formers had a significantly higher risk
      for all-cause mortality [hazard ratio (HR): 1.95, 95% CI: 1.64-2.33, p < 0.0001) 
      and CV mortality (HR: 2.05, 95% CI: 1.60-2.62, p < 0.0001) in unadjusted
      analyses. However, after multivariate adjustment for age, gender, race, and
      poverty, stone formers no longer had increased risk for all-cause mortality (HR: 
      1.08, 95% CI: 0.93-1.26, p = 0.3) and CV mortality (HR: 1.07, 95% CI: 0.84-1.36, 
      p = 0.6). Results remain unchanged after further adjustment for other clinical
      variables including history of hypertension, diabetes, and CV disease.
      Conclusion: The increased risk of all-cause and CV mortality in kidney stone
      formers is likely a reflection of unique demographics and associated
      comorbidities. There is no independent association of prevalent kidney stone
      disease with all-cause and CV mortality.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Division of Renal Disease and Hypertension, University of Colorado School of
      Medicine, Aurora, Colo., USA.
FAU - Tang, Jie
AU  - Tang J
FAU - Mettler, Pam
AU  - Mettler P
FAU - McFann, Kim
AU  - McFann K
FAU - Chonchol, Michel
AU  - Chonchol M
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/02/14 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 000350691 [pii]
AID - 10.1159/000350691 [doi]
PST - ppublish
SO  - Am J Nephrol. 2013;37(5):501-6. doi: 10.1159/000350691. Epub 2013 May 1.

PMID- 23635674
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 121
IP  - 4
DP  - 2013 Apr
TI  - Influence of food intake on the predictive value of the gestational diabetes
      mellitus screening test.
PG  - 750-8
LID - 10.1097/AOG.0b013e31828784d3 [doi]
AB  - OBJECTIVE: : To investigate the influence of prior food ingestion on the
      predictive value of a screening test for gestational diabetes mellitus. METHODS: 
      : This prospective, nonrandomized study enrolled 1,387 pregnant women who
      underwent the 50-g glucose challenge test. Gestational diabetes mellitus was
      diagnosed according to the National Diabetes Data Group criteria. A nutritional
      survey of dietary information before the glucose challenge test was conducted.
      The patients were stratified into three groups based on the time of last food
      ingestion (fasting interval): 1 hour or less, 1-2 hours, and more than 2 hours.
      The more than 2-hours fasting interval group was defined as the "fasting" group, 
      and the combined 1 hour or less and 1-2 hours fasting interval groups were
      defined as the "fed" group. We calculated the positivity rate and the positive
      predictive value to detect the predictive value. RESULTS: : Among women who
      fasted 1 hour or less, 1-2 hours, and more than 2 hours before a glucose
      challenge test, 2.5%, 3.1%, and 6.9% were diagnosed with gestational diabetes
      mellitus, respectively. The positive predictive value of the glucose challenge
      test was greater in the fasting group than in the fed group (27.1% compared with 
      13.7%, P=.003). A multinomial logistic analysis showed that gestational diabetes 
      mellitus was more prevalent in the fasting group than in the fed group (adjusted 
      odds ratio 2.86, 95% confidence interval 1.65-4.95). CONCLUSION: : Our findings
      suggest that food intake influences the predictive value of the gestational
      diabetes screening test. LEVEL OF EVIDENCE: : II.
AD  - Departments of Obstetrics and Gynecology, Medical Research, Nutrition, and
      Community Health, Ditmanson Medical Foundation, Chia-Yi Christian Hospital,
      Chia-Yi City, Taiwan.
FAU - Wang, Panchalli
AU  - Wang P
FAU - Lu, Mei-Chun
AU  - Lu MC
FAU - Yu, Cheng-Wei
AU  - Yu CW
FAU - Wang, Li-Chu
AU  - Wang LC
FAU - Yan, Yuan-Horng
AU  - Yan YH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - AIM
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1097/AOG.0b013e31828784d3 [doi]
AID - 00006250-201304000-00009 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2013 Apr;121(4):750-8. doi: 10.1097/AOG.0b013e31828784d3.

PMID- 23635650
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1663-2826 (Electronic)
DP  - 2013 Apr 26
TI  - Study of Primary IGF-1 Deficiency in Egyptian Children with Idiopathic Short
      Stature.
AB  - Background/Aims: Primary insulin-like growth factor-1 (IGF-1) deficiency (IGFD)
      is defined by low levels of IGF-1 without growth hormone (GH) deficiency and
      absence of secondary causes. The aim of this study was to evaluate IGF-1 in
      Egyptian children with idiopathic short stature (ISS) and describe patients with 
      IGFD. Methods: This cross-sectional study included 50 children with ISS following
      up at the Diabetes Endocrine and Metabolism Pediatric Unit at Cairo University
      Pediatric Hospital. Children were included based on the following criteria: (1)
      short stature with current height standard deviation score (SDS) </=-2.5; (2) age
      between 2 and 9 years in boys and 2 and 8 years in girls, and (3) prepubertal
      status. Exclusion criteria were: (1) identified cause of short stature and (2)
      pubertal children. IGF-1-deficient children were defined as children without GH
      deficiency and with IGF-1 levels below the 2.5th percentile. Results: Among 50
      children with ISS, 14 (28%) patients had low IGF-1 levels, consistent with the
      diagnosis of primary IGFD. When compared with non-IGFD children, IGFD children
      had lower birth weight SDS (-1.8 vs. -0.7 SDS, p < 0.0001) and lower height SDS
      (-4.2 vs. -3.1 SDS, p < 0.05) and more delayed bone age (2.6 vs. 1.6 years, p =
      0.001). Conclusion: Primary IGF-1 deficiency is found in 28% of children with
      ISS.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Pediatrics, Cairo University, Cairo, Egypt.
FAU - Anwar, Ghada M
AU  - Anwar GM
FAU - Kandeel, Wafaa A
AU  - Kandeel WA
FAU - Mandour, Iman A
AU  - Mandour IA
FAU - Kamal, Ayat N
AU  - Kamal AN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Horm Res Paediatr
JT  - Hormone research in paediatrics
JID - 101525157
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/08/20 [received]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 000350824 [pii]
AID - 10.1159/000350824 [doi]
PST - aheadofprint
SO  - Horm Res Paediatr. 2013 Apr 26.

PMID- 23635648
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Seeing double: the low carb diet.
PG  - f2563
LID - 10.1136/bmj.f2563 [doi]
LID - bmj.f2563 [pii]
AD  - Department of Diabetes and Endocrinology, Glasgow Royal Infirmary, Glasgow G4
      0SF, UK. louise.mckenna@glasgow.ac.uk
FAU - McKenna, Louise A
AU  - McKenna LA
FAU - Drummond, Russell S
AU  - Drummond RS
FAU - Drummond, Suzannah
AU  - Drummond S
FAU - Talwar, Dinesh
AU  - Talwar D
FAU - Lean, Michael E J
AU  - Lean ME
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - epublish
SO  - BMJ. 2013 May 1;346:f2563. doi: 10.1136/bmj.f2563.

PMID- 23635550
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1663-2826 (Electronic)
VI  - 79
IP  - 4
DP  - 2013
TI  - Two Novel GATA6 Mutations Cause Childhood-Onset Diabetes Mellitus, Pancreas
      Malformation and Congenital Heart Disease.
PG  - 250-6
LID - 10.1159/000348844 [doi]
AB  - Background: GATA6 mutations are the most frequent cause of pancreatic agenesis
      and diabetes in human sporadic cases. In families, dominantly inherited mutations
      show a variable phenotype also in terms of endocrine and exocrine pancreatic
      disease. We report two novel GATA6 mutations in an independent cohort of 8
      children with pancreas aplasia or hypoplasia and diabetes. Methods: We sequenced 
      GATA6 in 8 children with diabetes and inborn pancreas abnormalities, i.e.
      hypoplasia or aplasia in which other known candidate genes causing monogenic
      diabetes and pancreatic defects had been excluded. Results: We found two novel
      heterozygous GATA6 mutations (c.951_954dup and c.754_904del) in 2 patients with
      sporadic pancreas hypoplasia, diabetes and severe cardiac defects (common truncus
      arteriosus and tetralogy of Fallot), but not in the remaining 6 patients. GATA6
      mutations in carriers exhibited hypoplastic pancreas with absent head in 1
      patient and with increased echogenicity and decreasing exocrine function in the
      other patient. Additionally, hepatobiliary malformations and brain atrophy were
      found in 1 patient. Conclusion: Our 2 cases with novel GATA6 mutations add more
      phenotype characteristics of GATA6 haploinsufficiency. In agreement with an
      increasing number of published cases, the wide phenotypic spectrum of GATA6
      diabetes syndrome should draw the attention of both pediatric endocrinologists
      and geneticists.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Max Delbruck Center for Molecular Medicine, Charite, Berlin, Germany.
FAU - Gong, Maolian
AU  - Gong M
FAU - Simaite, Deimante
AU  - Simaite D
FAU - Kuhnen, Peter
AU  - Kuhnen P
FAU - Heldmann, Michael
AU  - Heldmann M
FAU - Spagnoli, Francesca
AU  - Spagnoli F
FAU - Blankenstein, Oliver
AU  - Blankenstein O
FAU - Hubner, Norbert
AU  - Hubner N
FAU - Hussain, Khalid
AU  - Hussain K
FAU - Raile, Klemens
AU  - Raile K
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - Switzerland
TA  - Horm Res Paediatr
JT  - Hormone research in paediatrics
JID - 101525157
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/10/26 [received]
PHST- 2013/02/11 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 000348844 [pii]
AID - 10.1159/000348844 [doi]
PST - ppublish
SO  - Horm Res Paediatr. 2013;79(4):250-6. doi: 10.1159/000348844. Epub 2013 Apr 26.

PMID- 23635439
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 60
IP  - 123
DP  - 2013 May 1
TI  - The Prevalence and Risk Factors of Gallstones in Korean Patients with Liver
      Cirrhosis.
LID - 10.5754/hge11950 [doi]
AB  - :Background/Aims: The aims of this study were to evaluate the frequency of
      gallstones and the related risk factors in patients with liver cirrhosis.
      Methodology: Patients (n=1,333) with liver cirrhosis who were diagnosed at
      Yeungnam University Hospital between January 2006 and December 2008 were analyzed
      retrospectively. Healthy people (n=16,922) who underwent an examination at the
      health promotion center were enrolled as a control group. We analyzed the
      clinical and laboratory findings between the cirrhotic patients with and without 
      gallstones. Results: Liver cirrhosis was an independent risk factor for gallstone
      formation (OR: 2.017; p=0.00). Diabetes and hypertriglyceridemia increased the
      risk for gallstones by 2.2-fold and 1.9-fold in cirrhotic patents, respectively. 
      The severity of the liver cirrhosis according to the Child-Pugh class carried a
      significantly greater risk of gallstone formation. Multiple logistic regression
      analysis showed that diabetes, hypertriglyceridemia, and Child-Pugh class C were 
      significantly related to the risk of gallstone formation in patients with liver
      cirrhosis. Conclusions: The prevalence of gallstones is significantly higher in
      patients with liver cirrhosis, and the related risk factors are diabetes,
      hypertriglyceridemia and severity of liver cirrhosis.
FAU - Park, Jae Hyun
AU  - Park JH
FAU - Kim, Tae Nyeun
AU  - Kim TN
FAU - Lee, Si Hyung
AU  - Lee SH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.5754/hge11950 [doi]
PST - aheadofprint
SO  - Hepatogastroenterology. 2013 May 1;60(123). doi: 10.5754/hge11950.

PMID- 23635430
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1555-3892 (Electronic)
IS  - 0963-6897 (Linking)
DP  - 2013 Apr 29
TI  - Enhancement of In Vitro and In Vivo Function of Agarose Encapsulated Porcine
      Islets by Changes in the Islet Microenvironment.
AB  - The transplantation of porcine islets of Langerhans to treat Type 1 diabetes may 
      provide asolution to the demand for insulin-producing cells. Porcine islets
      encapsulated in agaroseagarosemacrobeads have been shown to function in
      non-immunosuppressed xenogeneicmodels of both streptozotocin-induced and
      autoimmune Type 1 diabetes. One advantage ofagarose encapsulation is the ability 
      to culture macrobeads for extended periods, permittingmicrobiological and
      functional assessment. Herein we describe optimization of the agarosematrix that 
      results in improved islet function. Porcine islets (500 IEQ) from retired
      breedingsows were encapsulated in 1.5% SeaKem Gold (SG), 0.8% SG, or 0.8% Litex
      (Li) agarose,followed by an outer capsule of 5% SG agarose. Insulin production by
      the encapsulated isletsexhibited an agarose-specific effect with 20% (0.8% SG) to
      50% (0.8% Li) higher initialinsulin production relative to 1.5% SG macrobeads.
      Insulin production was further increasedby 40-50% from week 2 to week 12 in both 
      agarose types at the 0.8% concentration whileislets encapsulated in 1.5% SG
      agarose increased insulin production by approximately 20%.Correspondingly, fewer 
      macrobeads were required to restore normoglycemia instreptozotocin-induced
      diabetic female CD(SD) rats that received 0.8% Li (15 macrobeads) or0.8% SG (17
      macrobeads) as compared to 1.5% SG (19 macrobeads). Islet-cell proliferationwas
      also observed during the first 2 months post-encapsulation, peaking at 4 weeks
      whereapproximately 50% of islets contained proliferative cells, including beta
      cells, regardless ofagarose type. These results illustrate the importance of
      optimizing the microenvironment ofencapsulated islets to improve islet
      performance and advance the potential of isletxenotransplantation for the
      treatment of Type 1 diabetes.
FAU - Holdcraft, Robert W
AU  - Holdcraft RW
FAU - Gazda, Lawrence S
AU  - Gazda LS
FAU - Circle, Lisa
AU  - Circle L
FAU - Adkins, Hollie
AU  - Adkins H
FAU - Harbeck, Steven G
AU  - Harbeck SG
FAU - Meyer, Eric B
AU  - Meyer EB
FAU - Bautista, Melissa A
AU  - Bautista MA
FAU - Martis, Prithy C
AU  - Martis PC
FAU - Laramore, Melissa A
AU  - Laramore MA
FAU - Vinerean, Horatiu V
AU  - Vinerean HV
FAU - Hall, Richard D
AU  - Hall RD
FAU - Smith, Barry H
AU  - Smith BH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - ct0865holdcraft [pii]
AID - 10.3727/096368913X667033 [doi]
PST - aheadofprint
SO  - Cell Transplant. 2013 Apr 29.

PMID- 23635424
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1756-994X (Print)
VI  - 5
IP  - 4
DP  - 2013 Apr 30
TI  - Protein-protein interaction networks: probing disease mechanisms using model
      systems.
PG  - 37
AB  - Protein-protein interactions (PPIs) and multi-protein complexes perform central
      roles in the cellular systems of all living organisms. In humans, disruptions of 
      the normal patterns of PPIs and protein complexes can be causative or indicative 
      of a disease state. Recent developments in the biological applications of mass
      spectrometry (MS)-based proteomics have expanded the horizon for the application 
      of systematic large-scale mapping of physical interactions to probe disease
      mechanisms. In this review, we examine the application of MS-based approaches for
      the experimental analysis of PPI networks and protein complexes, focusing on the 
      different model systems (including human cells) used to study the molecular basis
      of common diseases such as cancer, cardiomyopathies, diabetes, microbial
      infections, and genetic and neurodegenerative disorders.
AD  - Banting and Best Department of Medical Research and Donnelly Centre for Cellular 
      and Biomolecular Research, University of Toronto, 160 College Street, Toronto,
      Ontario M5S 3E1, Canada. andrew.emili@utoronto.ca.
FAU - Kuzmanov, Uros
AU  - Kuzmanov U
FAU - Emili, Andrew
AU  - Emili A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Genome Med
JT  - Genome medicine
JID - 101475844
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/04/30 [aheadofprint]
AID - gm441 [pii]
AID - 10.1186/gm441 [doi]
PST - aheadofprint
SO  - Genome Med. 2013 Apr 30;5(4):37.

PMID- 23635406
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1875-8908 (Electronic)
IS  - 1387-2877 (Linking)
DP  - 2013 May 1
TI  - LDL Phenotype in Subjects with Mild Cognitive Impairment and Alzheimer's Disease.
AB  - Background: Centenarians with normal cognitive function have a "longevity
      phenotype" characterized by large low-density lipoproteins (LDL) and high-density
      lipoproteins (HDL) and low incidence of metabolic syndrome, hypertension, and
      cognitive impairment. Alzheimer's disease (AD) is associated with a number of
      cardiovascular risk factors, but it is not known if they have or lack the
      "longevity phenotype". Objective: The study was designed to determine LDL size
      and body fat content and distribution in subjects with mild cognitive impairment 
      (MCI) and AD. Results: Fifty-eight persons with MCI or AD (cases) and 42 control 
      subjects of similar age had measurement of LDL size and lipoprotein lipids after 
      a 12 h fast and analysis of body composition by dual x-ray absorptiometry. Cases 
      had small LDL size more often than controls (73% versus 66%) associated with
      significantly higher triglycerides, lower HDL cholesterol, and higher
      triglyceride/HDL cholesterol ratio (p </= 0.02). Cases with large LDL had a
      better lipoprotein profile than those with small LDL. Cases and controls had
      similar percent body fat, fat index, and lean mass index. Forty-seven percent of 
      cases and 39% of controls were obese. Conclusion: The prevalence of small LDL
      phenotype in MCI and AD cases contrasts with the "longevity phenotype" reported
      for centenarians with preserved cognitive function. The small LDL phenotype is an
      atherogenic lipoprotein profile found in metabolic syndrome, type 2 diabetes, and
      insulin resistance. It is now also reported in persons with MCI and AD.
AD  - Center for Human Nutrition and Departments of Clinical Nutrition, TX, USA.
FAU - Vikarunnessa, Sheikh
AU  - Vikarunnessa S
FAU - Weiner, Myron F
AU  - Weiner MF
FAU - Vega, Gloria Lena
AU  - Vega GL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Alzheimers Dis
JT  - Journal of Alzheimer's disease : JAD
JID - 9814863
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - X26140867WU5J2W0 [pii]
AID - 10.3233/JAD-130443 [doi]
PST - aheadofprint
SO  - J Alzheimers Dis. 2013 May 1.

PMID- 23635395
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1555-3892 (Electronic)
IS  - 0963-6897 (Linking)
DP  - 2013 Apr 29
TI  - Automated Digital Image Analysis of islet cell mass using Nikon's inverted
      Eclipse Ti microscope and software to improve engraftment may help to advance the
      therapeutic efficacy and accessibility of islet transplantation across centers.
LID - 10.3727/096368913X667493 [doi]
AB  - Reliable assessment of islet viability, mass and purity must be met prior to
      transplanting an islet preparation into patients with type 1 diabetes. The
      standard method for quantifying human islet preparations is by direct microscopic
      analysis of dithizone-stained islet samples,but this technique may be susceptible
      to inter / intra observer variability, which may induce false positive / negative
      islet counts. Here we describe a simple, reliable, automated digitalimage
      analysis (ADIA) technique, for accurately quantifying islets into total islet
      number,islet equivalent number (IEQ), and islet purity before islet
      transplantation.Islets were isolated and purified from n=42 human pancreata
      according to the automated method of Ricordi et al. For each preparation, three
      islet samples were stained with dithizone,and expressed as IEQ number. Islets
      were analyzed manually by microscopy, or automaticallyquantified using Nikon's
      inverted Eclipse Ti microscope, with built in NIS-ElementsAdvanced Research (AR) 
      software.The AIDA method significantly enhanced the number of islet preparations 
      eligible forengraftment compared to the standard manual method (P<0.001).
      Comparisons of individual methods showed good correlations between mean values of
      IEQ number (r(sup)2(/sup)</=0.91), and total islet number (r(sup)2(/sup)=0.88),
      and thus, increased to (r(sup)2(/sup)=0.93) when islet surface area was estimated
      comparatively with IEQ number. The ADIA method showed very high intra-observer
      reproducibility compared to the standard manual method (P<0.001). However, islet 
      purity was routinely estimated as significantly higher with the manual method vs.
      the ADIA method(p<0.001). The ADIA method also detected small islets between
      10-50 mum in size.Automated digital image analysis utilizing the Nikon
      Instruments (Nikon) software is anunbiased, simple, and reliable teaching tool to
      comprehensively assess the individual size ofeach islet cell preparation prior to
      transplantation. Implementation of this technology toimprove engraftment may help
      to advance the therapeutic efficacy and accessibility of islet transplantation
      across centers.
AD  - European Genomic Institute for Diabetes, FR 3508, FR 3508 F-59000 Lille, France.
FAU - Gmyr, Valery
AU  - Gmyr V
FAU - Bonner, Caroline
AU  - Bonner C
FAU - Lukowiak, Bruno
AU  - Lukowiak B
FAU - Pawlowski, Valerie
AU  - Pawlowski V
FAU - Dellaleau, Nathalie
AU  - Dellaleau N
FAU - Belaich, Sandrine
AU  - Belaich S
FAU - Aluka, Isanga
AU  - Aluka I
FAU - Moermann, Ericka
AU  - Moermann E
FAU - Thevenet, Julien
AU  - Thevenet J
FAU - Ezzouaoui, Rimed
AU  - Ezzouaoui R
FAU - Queniat, Gurvan
AU  - Queniat G
FAU - Pattou, Francois
AU  - Pattou F
FAU - Kerr-Conte, Julie
AU  - Kerr-Conte J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/04/29 [aheadofprint]
AID - ct0845gmyr [pii]
AID - 10.3727/096368913X663514 [doi]
PST - aheadofprint
SO  - Cell Transplant. 2013 Apr 29. doi: 10.3727/096368913X667493.

PMID- 23635331
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - The effectiveness of text messages support for diabetes self-management: protocol
      of the TEXT4DSM study in the democratic Republic of Congo, Cambodia and the
      Philippines.
PG  - 423
LID - 10.1186/1471-2458-13-423 [doi]
AB  - BACKGROUND: People with diabetes find it difficult to sustain adequate
      self-management behaviour. Self-Management Support strategies, including the use 
      of mobile technology, have shown potential benefit. This study evaluates the
      effectiveness of a mobile phone support intervention on top of an existing
      strategy in three countries, DR Congo, Cambodia and the Philippines to improve
      health outcomes, access to care and enablement of people with diabetes, with 480 
      people with diabetes in each country who are randomised to either standard
      support or to the intervention. DESIGN/METHODS: The study consists of three
      sub-studies with a similar design in three countries to be independently
      implemented and analysed. The design is a two-arm Randomised Controlled Trial, in
      which a total of 480 adults with diabetes participating in an existing DSME
      programme will be randomly allocated to either usual care in the existing
      programme or to usual care plus a mobile phone self-management support
      intervention. Participants in both arms complete assessments at baseline, one
      year and two years after inclusion.Glycosylated haemoglobin blood pressure,
      height, weight, waist circumference will be measured. Individual interviews will 
      be conducted to determine the patients' assessment of chronic illness care,
      degree of self-enablement, and access to care before implementation of the
      intervention, at intermediate moments and at the end of the study.Analyses of
      quantitative data including assessment of differences in changes in outcomes
      between the intervention and usual care group will be done. A probability of
      <0.05 is considered statistically significant. Outcome indicators will be plotted
      over time. All data are analysed for confounding and interaction in multivariate 
      regression analyses taking potential clustering effects into account.Differences 
      in outcome measures will be analysed per country and realistic evaluation to
      assess processes and context factors that influence implementation in order to
      understand why it works, for whom, under which circumstances. A costing study
      will be performed. DISCUSSION: The intervention addresses the problem that the
      greater part of diabetes management takes place without external support and that
      many challenges, unforeseen problems and questions occur at moments in between
      scheduled contacts with the support system, by exploiting communication
      technology. TRIAL REGISTRATION: ISRCTN86247213.
AD  - Department of Public Health, Institute of Tropical Medicine, Brussels, Antwerp,
      Belgium. jvanolmen@itg.be.
FAU - van Olmen, Josefien
AU  - van Olmen J
FAU - Ku, Grace Marie
AU  - Ku GM
FAU - van Pelt, Maurits
AU  - van Pelt M
FAU - Kalobu, Jean Clovis
AU  - Kalobu JC
FAU - Hen, Heang
AU  - Hen H
FAU - Darras, Christian
AU  - Darras C
FAU - Van Acker, Kristien
AU  - Van Acker K
FAU - Villaraza, Balthazar
AU  - Villaraza B
FAU - Schellevis, Francois
AU  - Schellevis F
FAU - Kegels, Guy
AU  - Kegels G
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3658970
OID - NLM: PMC3658970
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/02/21 [received]
PHST- 2013/03/19 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 1471-2458-13-423 [pii]
AID - 10.1186/1471-2458-13-423 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 1;13:423. doi: 10.1186/1471-2458-13-423.

PMID- 23635096
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - Effects of co-administration of candesartan with pioglitazone on inflammatory
      parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary 
      report.
PG  - 71
LID - 10.1186/1475-2840-12-71 [doi]
AB  - BACKGROUND: Angiotensin receptor blockers (ARBs) are reported to provide direct
      protection to many organs by controlling inflammation and decreasing oxidant
      stress. Pioglitazone, an anti-diabetic agent that improves insulin resistance,
      was also reported to decrease inflammation and protect against atherosclerosis.
      This study aimed to evaluate the utility of combination therapy with both
      medicines from the viewpoint of anti-inflammatory effects. METHODS: We
      administered candesartan (12 mg daily) and pioglitazone (15 mg daily)
      simultaneously for 6 months to hypertensive patients with type 2 diabetes
      mellitus (T2DM) and evaluated whether there were improvements in the serum
      inflammatory parameters of high-molecular-weight adiponectin (HMW-ADN),
      plasminogen activator inhibitor-1 (PAI-1), highly sensitive C-reactive protein
      (Hs-CRP), vascular cell adhesion molecule-1 (VCAM-1), and
      urinary-8-hydroxydeoxyguanosine (U-8-OHdG). We then analyzed the relationship
      between the degree of reductions in blood pressure and HbA1c values and
      improvements in inflammatory factors. Furthermore, we analyzed the relationship
      between pulse pressure and the degree of lowering of HbA1c and improvements in
      inflammatory factors. Finally, we examined predictive factors in patients who
      received benefits from the co-administration of candesartan with pioglitazone
      from the viewpoint of inflammatory factors. RESULTS: After 6 months of treatment,
      in all patients significant improvements from baseline values were observed in
      HMW-ADN and PAI-1 but not in VCAM-1, Hs-CRP, and U-8-OHdG. Changes in HbA1c were 
      significantly correlated with changes in HMW-ADN and PAI-1 in all patients, but
      changes in blood pressure were not correlated with any of the parameters
      examined. Correlation and multilinear regression analyses were performed to
      determine which factors could best predict changes in HbA1c. Interestingly, we
      found a significant positive correlation of pulse pressure values at baseline
      with changes in HbA1c. CONCLUSIONS: Our data suggest that the pulse pressure
      value at baseline is a key predictive factor of changes in HbA1c.
      Co-administration of candesartan with pioglitazone, which have anti-inflammatory 
      (changes in HMW-ADN and PAI-1) effects and protective effects on organs, could be
      an effective therapeutic strategy for treating hypertensive patients with type 2 
      diabetes mellitus. TRIAL REGISTRATION: UMIN-CTR: UMIN000010142.
AD  - Department of Internal Medicine, Division of Diabetes, Metabolism and
      Endocrinology, Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi,
      Minato-ku, Tokyo 105-8461, Japan. m-sakamoto@umin.ac.jp.
FAU - Suzuki, Hirofumi
AU  - Suzuki H
FAU - Sakamoto, Masaya
AU  - Sakamoto M
FAU - Hayashi, Takeshi
AU  - Hayashi T
FAU - Iuchi, Hiroyuki
AU  - Iuchi H
FAU - Ohashi, Kennosuke
AU  - Ohashi K
FAU - Isaka, Tsuyoshi
AU  - Isaka T
FAU - Sakamoto, Noriko
AU  - Sakamoto N
FAU - Kayama, Yosuke
AU  - Kayama Y
FAU - Tojo, Katsuyoshi
AU  - Tojo K
FAU - Yoshimura, Michihiro
AU  - Yoshimura M
FAU - Utsunomiya, Kazunori
AU  - Utsunomiya K
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3663745
OID - NLM: PMC3663745
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/03/21 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - 1475-2840-12-71 [pii]
AID - 10.1186/1475-2840-12-71 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 May 2;12:71. doi: 10.1186/1475-2840-12-71.

PMID- 23635075
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1744-8603 (Electronic)
IS  - 1744-8603 (Linking)
VI  - 9
DP  - 2013
TI  - Costs, outcomes and challenges for diabetes care in Spain.
PG  - 17
LID - 10.1186/1744-8603-9-17 [doi]
AB  - BACKGROUND: Diabetes is becoming of increasing concern in Spain due to rising
      incidence and prevalence, although little information is known with regards to
      costs and outcomes. The information on cost of diabetes in Spain is fragmented
      and outdated. Our objective is to update diabetes costs, and to identify outcomes
      and quality of care of diabetes in Spain. METHODS: We performed systematic
      searches from secondary sources, including scientific literature and government
      data and reports. RESULTS: Diabetes Type II prevalence is estimated at 7.8%, and 
      an additional 6% of the population is estimated to be undiagnosed. Four Spanish
      diabetes cost studies were analyzed to create a projection of direct costs in the
      NHS and productivity losses, estimating euro5.1 billion for direct costs along
      with euro1.5 billion for diabetes-related complications (2009) and labour
      productivity losses represented euro2.8 billion. Glycemic control (glycolysated
      hemoglobin) is considered acceptable in 59% of adult Type II cases, in addition
      to 85% with HDL cholesterol >/=40mg/dl and 65% with blood pressure <140/90 mmHg, 
      pointing to good intermediate outcomes. However, annual figures indicate that
      over half of the Type II diabetics are obese (BMI >30), 15% have diabetic
      retinopathy, 16% with microalbuminuria, and 15% with cardiovascular disease.
      CONCLUSIONS: The direct health care costs (8% of the total National Health System
      expenditure) and the loss of labour productivity are high. The importance of a
      multi-sectoral approach in prevention and improvements in management of diabetes 
      are discussed, along with policy considerations to help modify the disease
      course.
AD  - University Castilla La Mancha, Avda Real Fabrica de Seda s/n, Talavera de la
      Reina, Toledo 45600, Spain. julio.lopezbastida@uclm.es.
FAU - Lopez-Bastida, Julio
AU  - Lopez-Bastida J
FAU - Boronat, Mauro
AU  - Boronat M
FAU - Moreno, Juan Oliva
AU  - Moreno JO
FAU - Schurer, Willemien
AU  - Schurer W
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - England
TA  - Global Health
JT  - Globalization and health
JID - 101245734
SB  - IM
PMC - PMC3658938
OID - NLM: PMC3658938
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/10/13 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 1744-8603-9-17 [pii]
AID - 10.1186/1744-8603-9-17 [doi]
PST - epublish
SO  - Global Health. 2013 May 1;9:17. doi: 10.1186/1744-8603-9-17.

PMID- 23635051
OWN - NLM
STAT- MEDLINE
DA  - 20130502
DCOM- 20130521
LR  - 20130529
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 368
IP  - 18
DP  - 2013 May 2
TI  - The Oregon experiment--effects of Medicaid on clinical outcomes.
PG  - 1713-22
LID - 10.1056/NEJMsa1212321 [doi]
AB  - BACKGROUND: Despite the imminent expansion of Medicaid coverage for low-income
      adults, the effects of expanding coverage are unclear. The 2008 Medicaid
      expansion in Oregon based on lottery drawings from a waiting list provided an
      opportunity to evaluate these effects. METHODS: Approximately 2 years after the
      lottery, we obtained data from 6387 adults who were randomly selected to be able 
      to apply for Medicaid coverage and 5842 adults who were not selected. Measures
      included blood-pressure, cholesterol, and glycated hemoglobin levels; screening
      for depression; medication inventories; and self-reported diagnoses, health
      status, health care utilization, and out-of-pocket spending for such services. We
      used the random assignment in the lottery to calculate the effect of Medicaid
      coverage. RESULTS: We found no significant effect of Medicaid coverage on the
      prevalence or diagnosis of hypertension or high cholesterol levels or on the use 
      of medication for these conditions. Medicaid coverage significantly increased the
      probability of a diagnosis of diabetes and the use of diabetes medication, but we
      observed no significant effect on average glycated hemoglobin levels or on the
      percentage of participants with levels of 6.5% or higher. Medicaid coverage
      decreased the probability of a positive screening for depression (-9.15
      percentage points; 95% confidence interval, -16.70 to -1.60; P=0.02), increased
      the use of many preventive services, and nearly eliminated catastrophic
      out-of-pocket medical expenditures. CONCLUSIONS: This randomized, controlled
      study showed that Medicaid coverage generated no significant improvements in
      measured physical health outcomes in the first 2 years, but it did increase use
      of health care services, raise rates of diabetes detection and management, lower 
      rates of depression, and reduce financial strain.
AD  - Department of Health Policy and Management, Harvard School of Public Health,
      Boston, MA 02115, USA. kbaicker@hsph.harvard.edu
FAU - Baicker, Katherine
AU  - Baicker K
FAU - Taubman, Sarah L
AU  - Taubman SL
FAU - Allen, Heidi L
AU  - Allen HL
FAU - Bernstein, Mira
AU  - Bernstein M
FAU - Gruber, Jonathan H
AU  - Gruber JH
FAU - Newhouse, Joseph P
AU  - Newhouse JP
FAU - Schneider, Eric C
AU  - Schneider EC
FAU - Wright, Bill J
AU  - Wright BJ
FAU - Zaslavsky, Alan M
AU  - Zaslavsky AM
FAU - Finkelstein, Amy N
AU  - Finkelstein AN
CN  - Oregon Health Study Group
FAU - Carlson, Matt
AU  - Carlson M
FAU - Edlund, Tina
AU  - Edlund T
FAU - Gallia, Charles
AU  - Gallia C
FAU - Smith, Jeanene
AU  - Smith J
LA  - eng
GR  - P30 AG012810/AG/NIA NIH HHS/United States
GR  - P30AG012810/AG/NIA NIH HHS/United States
GR  - R01AG0345151/AG/NIA NIH HHS/United States
GR  - RC2AGO36631/RC/CCR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Hemoglobin A, Glycosylated)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2013 May 2;368(18):1744-5. PMID: 23635055
MH  - Adult
MH  - Depressive Disorder/epidemiology/therapy
MH  - Diabetes Mellitus/diagnosis/therapy
MH  - *Health Care Costs
MH  - Health Services/utilization
MH  - *Health Status
MH  - Hemoglobin A, Glycosylated/analysis
MH  - Humans
MH  - Hypercholesterolemia/drug therapy/epidemiology
MH  - Hypertension/drug therapy/epidemiology
MH  - *Insurance Coverage/economics
MH  - *Medicaid/economics
MH  - Middle Aged
MH  - Oregon/epidemiology
MH  - Prevalence
MH  - United States
MH  - Young Adult
EDAT- 2013/05/03 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/05/03 06:00
AID - 10.1056/NEJMsa1212321 [doi]
PST - ppublish
SO  - N Engl J Med. 2013 May 2;368(18):1713-22. doi: 10.1056/NEJMsa1212321.

PMID- 23634960
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1557-8577 (Electronic)
IS  - 1549-1684 (Linking)
DP  - 2013 May 1
TI  - Maillard reactions in Hyperthermophilic Archaea: implications for understanding
      controls of non-enzymatic glycation in biology.
AB  - Maillard reactions are an unavoidable feature of life that appear to be damaging 
      to cell and organisms. Consequently, all living systems must have ways to protect
      themselves against this process. As of 2012, several such defense mechanisms have
      been identified. They are all enzymatic and were found in mesophilic organisms.
      To date, no systematic study of Maillard reactions and the relevant defense
      mechanisms has been conducted in thermophiles (50oC - 80oC) or hyperthermophiles 
      (80oC - 120oC). This is surprisingly, because Maillard reactions become
      significantly faster and more potent with increasing temperatures. This review
      was undertaken to examine this neglected issue in two well-defined sets of
      hyperthermophiles. My analysis suggests that hyperthermophiles cope with
      glycation stress by several mechanisms: * Headgroups of hyperthermophilic
      phospholipids do not contain any glycation-prone groups such as ethanolamines. * 
      Reactive carbohydrates and labile metabolic intermediates are protected by
      substrate channeling. * Excess reactive sugars such as glucose are converted to
      non-reactive storage compounds including trehalose, di-myo-inositol-phosphate and
      mannosylglycerate. * Methylglyoxal and other ketoaldehydes are converted to inert
      products by a variety of reductases and dehydrogenases. * Remaining carbonyls are
      scavenged by nucleophilic amines, including a variety of novel polyamines. The
      most unique, and possibly the most important, among these mechanisms appears to
      be the polyamine-based scavenging system. Undertaking research of the Maillard
      process in hyperthermophiles is important because, beyond its intrinsic value, it
      is likely to provide new insights for the control of these reactions in man,
      especially in diseases such as diabetes mellitus.
AD  - Deglycation Research, 26 Pleasant Street, West Lebanon, NH 03784, West Lebanon,
      New Hampshire, United States, 03784, 603-359-9280 ; szwerg115@gmail.com.
FAU - Szwergold, Benjamin S
AU  - Szwergold BS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Rejuvenation Res
JT  - Rejuvenation research
JID - 101213381
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1089/rej.2012.1401 [doi]
PST - aheadofprint
SO  - Rejuvenation Res. 2013 May 1.

PMID- 23634949
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
IS  - 1758-5996 (Electronic)
VI  - 5
IP  - 1
DP  - 2013
TI  - Historical facts of screening and diagnosing diabetes in pregnancy.
PG  - 22
LID - 10.1186/1758-5996-5-22 [doi]
AB  - Diabetes is the most common metabolic disorder affecting pregnancy. Its
      prevalence seems to be growing in parallel with the epidemics of overweight and
      obesity. Recognizing and treating diabetes or any degree of glucose intolerance
      in pregnancy results in lowering maternal and fetal complications. These patients
      present higher risk for excessive weight gain, preeclampsia, cesarean sections, a
      high risk of developing type 2 diabetes and cardiovascular disease in the future.
      Infants born to these mothers are at higher risk for macrosomia and birth trauma,
      and after delivery, these infants have a higher risk of developing hypoglycemia, 
      hypocalcemia, hyperbilirubinemia, respiratory distress syndrome, polycythemia and
      subsequent obesity and type 2 diabetes. Despite several international workshops
      and a lot of research there is still no unique approach to diagnose and treat
      diabetes in pregnancy. Who, when and how to screen and diagnose diabetes in
      pregnancy has been debated in the literature for so many decades and this debate 
      seems to be endless. We present the evolution that screening and diagnosing
      diabetes in pregnancy has had over time. Besides many evidence of the benefits
      these procedures bring, health care providers still often prefer to use alternate
      criteria for this purpose. The myriad of maternal and fetal complications that
      could be avoided with an appropriate and simple screening procedure are ignored. 
      Robust clinical trials such as the Hyperglycemia and Adverse Pregnancy Outcomes
      (HAPO) study have shown how harmful can even slightly altered blood glucose
      levels be, but it has been found a resistance in the adoption of the new criteria
      proposed after this and other trials by many diabetes organizations. These
      organizations state that these new criteria would increase the incidence of
      diabetes in pregnancy, would imply in longer term follow-up of these patients and
      would pose an economic problem; they also state that alerting too many people in 
      order to benefit a relatively few potential diabetics would arise psychologic
      ill-effects. We think that health care providers should look for an uniformity in
      the screening and diagnosing diabetes in pregnancy based on evidence based
      medicine and not on specialists consensus.
AD  - Bauru's Diabetics Association, Department of Internal Medicine, Bauru, Sao Paulo,
      17012-433, Brazil. carlosnegrato@uol.com.br.
FAU - Negrato, Carlos Antonio
AU  - Negrato CA
FAU - Gomes, Marilia Brito
AU  - Gomes MB
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC3644500
OID - NLM: PMC3644500
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:01
CRDT- 2013/05/03 06:00
PHST- 2013/02/24 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 1758-5996-5-22 [pii]
AID - 10.1186/1758-5996-5-22 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2013 May 1;5(1):22. doi: 10.1186/1758-5996-5-22.

PMID- 23634936
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
VI  - 125
IP  - 4
DP  - 2013 Aug 1
TI  - The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?
PG  - 167-82
LID - 10.1042/CS20120413 [doi]
AB  - The rising epidemic of T2DM (Type 2 diabetes mellitus) worldwide is of
      significant concern. The inherently silent nature of the disease in its early
      stages precludes early detection; hence cardiovascular disease is often
      established by the time diabetes is diagnosed. This increased cardiovascular risk
      leads to significant morbidity and mortality in these individuals. Progressive
      development of complications as a result of previous exposure to metabolic
      disturbances appears to leave a long-lasting impression on cells of the
      vasculature that is not easily reversed and is termed 'metabolic memory'. SMCs
      (smooth muscle cells) of blood vessel walls, through their inherent ability to
      switch between a contractile quiescent phenotype and an active secretory state,
      maintain vascular homoeostasis in health and development. This plasticity also
      confers SMCs with the essential capacity to adapt and remodel in pathological
      states. Emerging clinical and experimental studies propose that SMCs in diabetes 
      may be functionally impaired and thus contribute to the increased incidence of
      macrovascular complications. Although this idea has general support, the
      underlying molecular mechanisms are currently unknown and hence are the subject
      of intense research. The aim of the present review is to explore and evaluate the
      current literature relating to the problem of vascular disease in T2DM and to
      discuss the critical role of SMCs in vascular remodelling. Possibilities for
      therapeutic strategies specifically at the level of T2DM SMCs, including recent
      novel advances in the areas of microRNAs and epigenetics, will be evaluated.
      Since restoring glucose control in diabetic patients has limited effect in
      ameliorating their cardiovascular risk, discovering alternative strategies that
      restrict or reverse disease progression is vital. Current research in this area
      will be discussed.
FAU - Porter, Karen E
AU  - Porter KE
FAU - Riches, Kirsten
AU  - Riches K
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - CS20120413 [pii]
AID - 10.1042/CS20120413 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 2013 Aug 1;125(4):167-82. doi: 10.1042/CS20120413.

PMID- 23634804
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1432-2277 (Electronic)
IS  - 0934-0874 (Linking)
DP  - 2013 Apr 15
TI  - Diagnosis, management and treatment of glucometabolic disorders emerging after
      kidney transplantation: A position statement from the Nordic Transplantation
      Societies.
LID - 10.1111/tri.12112 [doi]
AB  - After successful solid organ transplantation, new-onset diabetes (NODAT) is
      reported to develop in about 15-40% of the patients. The variation in incidence
      may partly depend on differences in the populations that have been studied and
      partly depend on the different definitions of NODAT that have been used. The
      diagnosis was often based on 'the use of insulin postoperatively', 'oral agents
      used', random glucose monitoring and a fasting glucose value between 7 and 13
      mmol/l (126-234 mg/dl). Only few have used a 2-h glucose tolerance test performed
      before transplantation. There is a huge variation in the literature regarding
      risk factors for developing NODAT. They can be divided into factors related to
      glucose metabolism or to patient demographics and the latter into modifiable and 
      nonmodifiable. Screening for risk factors should start early and be re-evaluated 
      while being on the waitlist. Patients on the waiting list for renal
      transplantation and transplanted patients share many characteristics in having
      hyperglycaemia, disturbed insulin secretion and increased insulin resistance. We 
      present guidelines for early risk factor assessment and a screening/treatment
      strategy for disturbed glucose metabolism, both before and after transplantation.
      The aim was to avoid the increased cardiovascular disease and mortality rates
      associated with NODAT.
CI  - (c) 2013 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
AD  - Department of Nephrology, Copenhagen University Hospital Rigshospitalet,
      Copenhagen, Denmark.
FAU - Hornum, Mads
AU  - Hornum M
FAU - Lindahl, Jorn P
AU  - Lindahl JP
FAU - von Zur-Muhlen, Bengt
AU  - von Zur-Muhlen B
FAU - Jenssen, Trond
AU  - Jenssen T
FAU - Feldt-Rasmussen, Bo
AU  - Feldt-Rasmussen B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Transpl Int
JT  - Transplant international : official journal of the European Society for Organ
      Transplantation
JID - 8908516
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/01/21 [received]
PHST- 2013/02/11 [revised]
PHST- 2013/04/06 [accepted]
AID - 10.1111/tri.12112 [doi]
PST - aheadofprint
SO  - Transpl Int. 2013 Apr 15. doi: 10.1111/tri.12112.

PMID- 23634802
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 13
IP  - 1
DP  - 2013 May 1
TI  - Rates of obstetric intervention during birth and selected maternal and neonatal
      outcomes for low risk women born in Australia compared to those born overseas.
PG  - 100
AB  - BACKGROUND: There are mixed reports in the literature about obstetric
      intervention and maternal and neonatal outcomes for migrant women born in
      resource rich countries. The aim of this study was to compare the risk profile,
      rates of obstetric intervention and selected maternal and neonatal outcomes for
      low risk women born in Australia compared to those born overseas. METHOD: A
      population-based descriptive study was undertaken in NSW of all singleton births 
      recorded in the NSW Midwives Data Collection between 2000--2008 (n=691,738). Risk
      profile, obstetric intervention rates and selected maternal and neonatal outcomes
      were examined. RESULTS: Women born in Australia were slightly younger (30 vs 31
      years), less likely to be primiparous (41% vs 43%), three times more likely to
      smoke (18% vs 6%) and more likely to give birth in a private hospital (26% vs
      18%) compared to women not born in Australia. Among the seven most common migrant
      groups to Australia, women born in Lebanon were the youngest, least likely to be 
      primiparous and least likely to give birth in a private hospital. Hypertension
      was lowest amongst Vietnamese women (3%) and gestational diabetes highest amongst
      women born in China (14%). The highest caesarean section (31%), instrumental
      birth rates (16%) and episiotomy rates (32%) were seen in Indian women, along
      with the highest rates of babies <10th centile (22%) and <3rd centile (8%).
      Lebanese women had the highest rates of stillbirth (7.2/1000). Similar trends
      were found in the different migrant groups when only low risk women were
      included. CONCLUSION: The results suggest there are significant differences in
      risk profiles, obstetric intervention rates and maternal and neonatal outcomes
      between Australian-born and women born overseas and these differences are seen
      overall and in low risk populations. The finding that Indian women (the leading
      migrant group to Australia) have the lowest normal birth rate and high rates of
      low birth weight babies is concerning, and attention needs to be focused on why
      there are disparities in outcomes and on effective models of care that might
      improve outcomes for this population.
FAU - Dahlen, Hannah G
AU  - Dahlen HG
FAU - Schmied, Virginia
AU  - Schmied V
FAU - Dennis, Cindy-Lee
AU  - Dennis CL
FAU - Thornton, Charlene
AU  - Thornton C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
PMC - PMC3651396
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/11/19 [received]
PHST- 2013/05/01 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 1471-2393-13-100 [pii]
AID - 10.1186/1471-2393-13-100 [doi]
PST - aheadofprint
SO  - BMC Pregnancy Childbirth. 2013 May 1;13(1):100.

PMID- 23634778
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 2047-783X (Electronic)
IS  - 0949-2321 (Linking)
VI  - 18
IP  - 1
DP  - 2013
TI  - Leptin, resistin and visfatin: the missing link between endocrine metabolic
      disorders and immunity.
PG  - 12
LID - 10.1186/2047-783X-18-12 [doi]
AB  - Adipose tissue is still regarded as a principle site for lipid storage and
      mobilizing tissue with an important role in the control of energy homeostasis.
      Additionally, adipose tissue-secreted hormones such as leptin, visfatin,
      resistin, apelin, omentin, sex steroids, and various growth factors are now
      regarded as a functional part of the endocrine system. These hormones also play
      an important role in the immune system. Several in vitro and in vivo studies have
      suggested the complex role of adipocyte-derived hormones in immune system and
      inflammation. Adipokines mediate beneficial and detrimental effects in immunity
      and inflammation. Many of these adipocytokines have a physiological role in
      metabolism. The uncontrolled secretions of several adipocytokines were associated
      with the stimulation of inflammatory processes leading to metabolic disorders
      including obesity, atherosclerosis, insulin resistance and type 2 diabetes.
      Obesity leads to the dysfunction of adipocytes andcorrelated with the imbalance
      of adipokines levels. In obese and diabetic conditions, leptin deficiency
      inhibited the Jak/Stat3/PI3K and insulin pathways. In this review, ample evidence
      exists to support the recognition of the adipocyte's role in various tissues and 
      pathologies. New integral insights may add dimensions to translate any potential 
      agents into the future clinical armamentarium of chronic endocrine metabolic and 
      inflammatory diseases. Functional balance of both adipocytes and immune cells is 
      important to exert their effects on endocrine metabolic disorders; furthermore,
      adipose tissue should be renamed not only as a functional part of the endocrine
      system but also as a new part of the immune system.
AD  - Department of Biology, Sciences College, University of Dammam, Dammam, Saudi
      Arabia. Ealsuhaimi@ud.edu.sa.
FAU - Al-Suhaimi, Ebtesam A
AU  - Al-Suhaimi EA
FAU - Shehzad, Adeeb
AU  - Shehzad A
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
SB  - IM
PMC - PMC3655867
OID - NLM: PMC3655867
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/01/05 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 2047-783X-18-12 [pii]
AID - 10.1186/2047-783X-18-12 [doi]
PST - epublish
SO  - Eur J Med Res. 2013 May 1;18(1):12. doi: 10.1186/2047-783X-18-12.

PMID- 23634672
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 5
DP  - 2013 May
TI  - Standardization versus customization of glucose reporting.
PG  - 439-43
LID - 10.1089/dia.2013.0116 [doi]
AB  - Abstract Bergenstal et al. (Diabetes Technol Ther 2013;15:198-211) described an
      important approach toward standardization of reporting and analysis of continuous
      glucose monitoring and self-monitoring of blood glucose (SMBG) data. The
      ambulatory glucose profile (AGP), a composite display of glucose by time of day
      that superimposes data from multiple days, is perhaps the most informative and
      useful of the many graphical approaches to display glucose data. However, the AGP
      has limitations; some variations are desirable and useful. Synchronization with
      respect to meals, traditionally used in glucose profiles for SMBG data, can
      improve characterization of postprandial glucose excursions. Several other types 
      of graphical display are available, and recently developed ones can augment the
      information provided by the AGP. There is a need to standardize the parameters
      describing glycemic variability and cross-validate the available computer
      programs that calculate glycemic variability. Clinical decision support software 
      can identify and prioritize clinical problems, make recommendations for
      modifications of therapy, and explain its justification for those
      recommendations. The goal of standardization is challenging in view of the
      diversity of clinical situations and of computing and display platforms and
      software. Standardization is desirable but must be done in a manner that permits 
      flexibility and fosters innovation.
AD  - Biomedical Informatics Consultants LLC , Potomac, Maryland.
FAU - Rodbard, David
AU  - Rodbard D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1089/dia.2013.0116 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 May;15(5):439-43. doi: 10.1089/dia.2013.0116.

PMID- 23634671
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 5
DP  - 2013 May
TI  - Comparison of glycemic variability in patients with type 2 diabetes given
      sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
PG  - 378-85
LID - 10.1089/dia.2012.0262 [doi]
AB  - Abstract Objective: This study compared glycemic variability in patients with
      type 2 diabetes given sitagliptin or voglibose. Patients and Methods: Seventeen
      type 2 diabetes patients were given sitagliptin 50 mg/day or voglibose 0.9 mg/day
      for 2 months and were hospitalized for a 4-day evaluation by continuous glucose
      monitoring (CGM). On discharge, they were crossed over to the other regimen for 2
      months of treatment/4 days of evaluation. The CGM data were used to compare each 
      parameter for glycemic variability. Results: The average glucose levels with
      sitagliptin and voglibose were significantly different at 138.6 and 152.6 mg/dL
      for 24 h (P=0.014) and 147.2 and 160.9 mg/dL for during daytime (P=0.050),
      respectively. The patients' glucose levels with sitagliptin and voglibose were
      significantly different at 125.3 and 139.7 mg/dL before breakfast (P=0.015) and
      112.7 and 131.4 mg/dL before lunch (P=0.049), respectively. The time from before 
      meal to postprandial peak glucose levels was significantly longer after dinner
      with voglibose than with sitagliptin (91.5 and 122.3 min, respectively; P=0.012).
      All of the slopes of glucose elevation were significantly lower with voglibose
      after each meal, with that after breakfast, lunch, and dinner being 1.16 and 0.86
      mg/dL/min (P=0.031), 0.70 and 0.45 mg/dL/min (P=0.048), and 1.06 and 0.73
      mg/dL/min (P=0.028), respectively. Conclusions: This CGM-based pilot study
      revealed that sitagliptin significantly lowered 24-h and daytime mean glucose
      levels and glucose levels before breakfast and lunch compared with voglibose,
      whereas the time from before dinner to peak postprandial glucose levels was
      significantly longer, and the slope of postprandial elevation of glucose level
      was significantly lower after each meal, with voglibose compared with
      sitagliptin.
AD  - Division of Diabetes, Metabolism and Endocrinology Department, Department of
      Internal Medicine, The Jikei University School of Medicine , Tokyo, Japan .
FAU - Seo, Chiaki
AU  - Seo C
FAU - Sakamoto, Masaya
AU  - Sakamoto M
FAU - Nishimura, Rimei
AU  - Nishimura R
FAU - Tsujino, Daisuke
AU  - Tsujino D
FAU - Ando, Kiyotaka
AU  - Ando K
FAU - Morimoto, Aya
AU  - Morimoto A
FAU - Utsunomiya, Kazunori
AU  - Utsunomiya K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1089/dia.2012.0262 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 May;15(5):378-85. doi: 10.1089/dia.2012.0262.

PMID- 23634670
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 5
DP  - 2013 May
TI  - Obesity and diabetes: newer concepts in imaging.
PG  - 351-61
LID - 10.1089/dia.2013.0039 [doi]
AB  - Abstract Quantifying body fat is currently an area of active research. Recent
      studies have shown that the quantity and location of fat in different
      compartments have varying clinical significance. This information can now be
      obtained from computed tomography (CT) or magnetic resonance (MR), and it can
      inform clinical decision making for patient management. Diabetes patients with
      insulin resistance and hyperinsulinemia have nonalcoholic fatty liver disease
      (NAFLD) ranging from steatosis to nonalcoholic steatohepatitis (NASH) and
      cirrhosis, typically diagnosed by liver biopsy or serum markers. There is now an 
      emerging role of noninvasive imaging tests such as MR imaging or MR spectroscopy 
      or elastography, which can provide quantitative information and have potential to
      avoid biopsy. Obese patients with diabetes are also at risk for cardiovascular
      disease and cancer. There is an emerging role for imaging in early detection of
      not only structural but also functional abnormalities of myocardium at a
      subclinical stage. Screening for cancer is currently recommended only for breast,
      colon, prostate, and cervix. Given wider availability and advances in imaging
      techniques such as positron emission tomography/CT (faster scans with higher
      resolution and less ionizing radiation) and better understanding of molecular
      biology and risk-stratification, more and more cancers are being detected in
      early stages with better clinical outcomes. Concerns related to cost,
      overdiagnosis, and unnecessary interventions must be addressed before
      population-based screening for other cancers is recommended. Based on ongoing
      imaging research, it is expected that it will be possible to provide more precise
      measurement of body fat and detect cardiovascular disease and cancers earlier in 
      their course.
AD  - Department of Radiology, University of Colorado Denver School of Medicine ,
      Aurora, Colorado.
FAU - Garg, Kavita
AU  - Garg K
FAU - Chang, Samuel
AU  - Chang S
FAU - Scherzinger, Ann
AU  - Scherzinger A
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2013/04/15 [aheadofprint]
AID - 10.1089/dia.2013.0039 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 May;15(5):351-61. doi: 10.1089/dia.2013.0039. Epub
      2013 Apr 15.

PMID- 23634669
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 5
DP  - 2013 May
TI  - Has the time come for routine imaging studies in diabetes?
PG  - 349-50
LID - 10.1089/dia.2013.0087 [doi]
AD  - Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialities Centre 
      , WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control, 
      IDF Centre for Education, Gopalapuram, Chennai, India .
FAU - Mohan, Viswanathan
AU  - Mohan V
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1089/dia.2013.0087 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 May;15(5):349-50. doi: 10.1089/dia.2013.0087.

PMID- 23634655
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1540-8167 (Electronic)
IS  - 1045-3873 (Linking)
DP  - 2013 Apr 8
TI  - Periesophageal Vagal Nerve Injury Post-AF Ablation: The Esophagus a Vulnerable
      Neighbor?
LID - 10.1111/jce.12165 [doi]
AD  - Alfred Heart Centre, Alfred Hospital, Baker IDI Heart and Diabetes Research
      Institute, the Department of Medicine, University of Melbourne, Melbourne,
      Victoria, Australia.
FAU - McLellan, Alex J A
AU  - McLellan AJ
FAU - Kistler, Peter M
AU  - Kistler PM
LA  - ENG
PT  - EDITORIAL
DEP - 20130408
TA  - J Cardiovasc Electrophysiol
JT  - Journal of cardiovascular electrophysiology
JID - 9010756
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
AID - 10.1111/jce.12165 [doi]
PST - aheadofprint
SO  - J Cardiovasc Electrophysiol. 2013 Apr 8. doi: 10.1111/jce.12165.

PMID- 23634648
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 43
IP  - 7
DP  - 2013 Jul
TI  - Diagnostic accuracy of HbA1c in diabetes between Eastern and Western.
PG  - 716-26
LID - 10.1111/eci.12098 [doi]
AB  - BACKGROUND: In 2010, the American Diabetes Association recommended the use of
      HbA1c as a diagnostic criterion for diabetes. However, HbA1c is not an accepted
      diagnostic tool for diabetes in Eastern Asia, because genetic differences
      compromise the standardization of the diagnostic cut-off point. OBJECTIVES: This 
      study evaluated differences in the use of HbA1c for diagnosing diabetes in
      Eastern and Western populations and investigated whether HbA1c cut-off point of
      >/= 6.5% is diagnostic of diabetes in patients from Eastern Asia. METHODS:
      Literature was obtained from MEDLINE, EMBASE and Cochrane databases. The pooled
      sensitivity and specificity of each HbA1c cut-off point were extracted and
      compared between Western and Eastern populations. Differences in the cut-off
      point for diagnosing diabetes in each region were compared by examining
      differences in the area under summary receiver operating characteristic (SROC)
      curves. RESULTS: Twelve publications from Eastern countries (n = 59 735) and 13
      from Western countries (n = 22 954) were included in the analysis. Areas under
      SROC curves in the Eastern and Western groups were 0.9331 and 0.9120,
      respectively (P = 0.98). The cut-off point of the highest Youden index was 6.0%. 
      At the HbA1c cut-off point of 6.5%, the pooled sensitivity and specificity were
      58.7% and 98.4% for Eastern countries and 65.5% and 98.1% for Western countries, 
      respectively. CONCLUSIONS: HbA1c exhibits the same diagnostic value for diabetes 
      in Eastern and Western populations. In both populations, HbA1c levels > 6.0%
      identify the population at high risk of diabetes, and HbA1c > 6.5% is diagnostic 
      of clinically established diabetes.
CI  - (c) 2013 Stichting European Society for Clinical Investigation Journal
      Foundation. Published by John Wiley & Sons Ltd.
AD  - Department of Endocrinology and Metabolism Disease, The 4th Affiliated Hospital
      of Harbin Medical University, Harbin, Heilongjiang, China.
FAU - Yan, Shuang
AU  - Yan S
FAU - Liu, Siying
AU  - Liu S
FAU - Zhao, Yashuang
AU  - Zhao Y
FAU - Zhang, Wencui
AU  - Zhang W
FAU - Sun, Xiaohui
AU  - Sun X
FAU - Li, Jianing
AU  - Li J
FAU - Jiang, Fuli
AU  - Jiang F
FAU - Ju, Jiaming
AU  - Ju J
FAU - Lang, Ning
AU  - Lang N
FAU - Zhang, Yingqi
AU  - Zhang Y
FAU - Zhou, Weiyu
AU  - Zhou W
FAU - Li, Qiang
AU  - Li Q
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PHST- 2012/11/13 [received]
PHST- 2013/03/22 [accepted]
PHST- 2013/05/02 [aheadofprint]
AID - 10.1111/eci.12098 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2013 Jul;43(7):716-26. doi: 10.1111/eci.12098. Epub 2013 May
      2.

PMID- 23634489
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Biggest winner: Channelle Washington took a crash course to make herself
      healthier.
PG  - 50-3
FAU - Wahowiak, Lindsey
AU  - Wahowiak L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):50-3.

PMID- 23634488
OWN - NLM
STAT- In-Process
DA  - 20130502
IS  - 0095-8301 (Print)
IS  - 0095-8301 (Linking)
VI  - 66
IP  - 4
DP  - 2013 Apr
TI  - Wise friends: after nearly 300 years of diabetes experience, these women are
      still going strong.
PG  - 44-5
FAU - Wahowiak, Lindsey
AU  - Wahowiak L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Forecast
JT  - Diabetes forecast
JID - 7504241
SB  - K
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/03 06:00
PST - ppublish
SO  - Diabetes Forecast. 2013 Apr;66(4):44-5.

PMID- 23631580
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1943-3670 (Electronic)
IS  - 0022-3492 (Linking)
VI  - 84
IP  - 4 Suppl
DP  - 2013 Apr
TI  - Periodontitis and systemic diseases: a record of discussions of working group 4
      of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases.
PG  - S20-3
LID - 10.1902/jop.2013.1340020 [doi]
AB  - Abstract Background: There has been an explosion in research into possible
      associations between periodontitis and various systemic diseases and conditions. 
      Aim: To review the evidence for associations between periodontitis and various
      systemic diseases and conditions, including chronic obstructive pulmonary disease
      (COPD), pneumonia, chronic kidney disease, rheumatoid arthritis, cognitive
      impairment, obesity, metabolic syndrome and cancer, and to document headline
      discussions of the state of each field. Periodontal associations with diabetes,
      cardiovascular disease and adverse pregnancy outcomes were not discussed by
      working group 4. Results: Working group 4 recognized that the studies performed
      to date were largely cross-sectional or case-control with few prospective cohort 
      studies and no randomized clinical trials. The best current evidence suggests
      that periodontitis is characterized by both infection and pro-inflammatory
      events, which variously manifest within the systemic diseases and disorders
      discussed. Diseases with at least minimal evidence of an association with
      periodontitis include COPD, pneumonia, chronic kidney disease, rheumatoid
      arthritis, cognitive impairment, obesity, metabolic syndrome and cancer. The
      working group agreed that there is insufficient evidence to date to infer causal 
      relationships with the exception that organisms originating in the oral
      microbiome can cause lung infections. Conclusions: The group was unanimous in
      their opinion that the reported associations do not imply causality, and
      establishment of causality will require new studies that fulfil the Bradford Hill
      or equivalent criteria. Precise and community-agreed case definitions of
      periodontal disease states must be implemented systematically to enable
      consistent and clearer interpretations of studies of the relationship to systemic
      diseases. The members of the working group were unanimous in their opinion that
      to develop data that best inform clinicians, investigators and the public,
      studies should focus on robust disease outcomes and avoid surrogate endpoints. It
      was concluded that because of the relative immaturity of the body of evidence for
      each of the purported relationships, the field is wide open and the gaps in
      knowledge are large.
AD  - Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, 
      Queen's University Belfast, Belfast, Northern Ireland, UK.
FAU - Linden, Gerry J
AU  - Linden GJ
FAU - Herzberg, Mark C
AU  - Herzberg MC
CN  - working group 4 of the joint EFP/AAP workshop*
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/02 06:00
AID - 10.1902/jop.2013.1340020 [doi]
PST - ppublish
SO  - J Periodontol. 2013 Apr;84(4 Suppl):S20-3. doi: 10.1902/jop.2013.1340020.

PMID- 23631575
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1943-3670 (Electronic)
IS  - 0022-3492 (Linking)
VI  - 84
IP  - 4 Suppl
DP  - 2013 Apr
TI  - Evidence that periodontal treatment improves diabetes outcomes: a systematic
      review and meta-analysis.
PG  - S153-69
LID - 10.1902/jop.2013.1340017 [doi]
AB  - Abstract Context: The effect of periodontal therapy on diabetes outcomes has not 
      been established. Objective: This update examines the effect of periodontal
      treatment on diabetes outcomes. Data sources: Literature since October 2009 using
      MEDLINE. Study eligibility criteria: Published RCTs including periodontal therapy
      for diabetic subjects, a metabolic outcome, an untreated control group, and
      follow-up of 3 months. Data extraction: Pre-defined data fields, including study 
      quality indicators were used. Data synthesis: A search revealed 56 publications
      of which 9 met inclusion criteria. Mean change of HbA1c from baseline was
      compared across treatment groups. Pooled analysis was based on random effects
      models. Results: A meta-analysis indicated a mean treatment effect of _0.36%
      HbA1c (CI _0.54, _0.19) compared to no treatment after periodontal therapy (p <
      0.0001). Heterogeneity tests revealed only minimal evidence of publication bias
      (I2 = 9%). Limitations: Small sample size and high risk of bias remain
      problematic for studies of this type. Periodontal therapy varied considerably.
      Conclusion: The modest reduction in HbA1c observed as a result of periodontal
      therapy in subjects with type 2 diabetes is consistent with previous systematic
      reviews. Despite this finding, there is limited confidence in the conclusion due 
      to a lack of multi-centre trials of sufficient sample size are lacking.
AD  - Department of Periodontology and Implant Dentistry, New York University, New
      York, NY, USA;
FAU - Engebretson, Steven
AU  - Engebretson S
FAU - Kocher, Thomas
AU  - Kocher T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/02 06:00
AID - 10.1902/jop.2013.1340017 [doi]
PST - ppublish
SO  - J Periodontol. 2013 Apr;84(4 Suppl):S153-69. doi: 10.1902/jop.2013.1340017.

PMID- 23631574
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1943-3670 (Electronic)
IS  - 0022-3492 (Linking)
VI  - 84
IP  - 4 Suppl
DP  - 2013 Apr
TI  - Effect of periodontal disease on diabetes: systematic review of epidemiologic
      observational evidence.
PG  - S135-52
LID - 10.1902/jop.2013.1340013 [doi]
AB  - Abstract Background: Periodontal disease and diabetes mellitus are common,
      chronic diseases worldwide. Epidemiologic and biologic evidence suggest
      periodontal disease may affect diabetes. Objective: To systematically review
      non-experimental, epidemiologic evidence for effects of periodontal disease on
      diabetes control, complications and incidence. Data sources: Electronic
      bibliographic databases, supplemented by hand searches of recent and future
      issues of relevant journals. Study eligibility criteria and participants:
      Longitudinal and cross-sectional epidemiologic, non-interventional studies that
      permit determination of directionality of observed effects were included. Study
      appraisal and synthesis methods: Four reviewers evaluated pair-wise each study.
      Review findings regarding study results and quality were summarized in tables by 
      topic, using the PRISMA Statement for reporting and the Newcastle-Ottawa System
      for quality assessment, respectively. From 2246 citations identified and
      available abstracts screened, 114 full-text reports were assessed and 17 included
      in the review. Results: A small body of evidence supports significant, adverse
      effects of periodontal disease on glycaemic control, diabetes complications, and 
      development of type 2 (and possibly gestational) diabetes. Limitations: There
      were only a limited number of eligible studies, several of which included small
      sample sizes. Exposure and outcome parameters varied, and the generalizability of
      their results was limited. Conclusions and implications of key findings: Current 
      evidence suggests that periodontal disease adversely affects diabetes outcomes,
      and that further longitudinal studies are warranted.
AD  - University of Michigan School of Dentistry, Ann Arbor, MI, USA.
FAU - Borgnakke, Wenche S
AU  - Borgnakke WS
FAU - Yl Ostalo, Pekka V
AU  - Yl Ostalo PV
FAU - Taylor, George W
AU  - Taylor GW
FAU - Genco, Robert J
AU  - Genco RJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/02 06:00
AID - 10.1902/jop.2013.1340013 [doi]
PST - ppublish
SO  - J Periodontol. 2013 Apr;84(4 Suppl):S135-52. doi: 10.1902/jop.2013.1340013.

PMID- 23631573
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1943-3670 (Electronic)
IS  - 0022-3492 (Linking)
VI  - 84
IP  - 4 Suppl
DP  - 2013 Apr
TI  - A review of the evidence for pathogenic mechanisms that may link periodontitis
      and diabetes.
PG  - S113-34
LID - 10.1902/jop.2013.134005 [doi]
AB  - Aims: To review the evidence for the molecular and cellular processes that may
      potentially link periodontal disease and diabetes. The pathogenic roles of
      cytokines and metabolic molecules (e.g. glucose, lipids) are explored and the
      role of periodontal bacteria is also addressed. Paradigms for bidirectional
      relationships between periodontitis and diabetes are discussed and opportunities 
      for elaborating these models are considered. Methods: Database searches were
      performed using MeSH terms, keywords, and title words. Studies were evaluated and
      summarized in a narrative review. Results: Periodontal microbiota appears
      unaltered by diabetes and there is little evidence that it may influence
      glycaemic control. Small-scale clinical studies and experiments in animal models 
      suggest that IL-1b, TNF-a, IL-6, OPG and RANKL may mediate periodontitis in
      diabetes. The AGE-RAGE axis is likely an important pathway of tissue destruction 
      and impaired repair in diabetesassociated periodontitis. A role for locally
      activated pro-inflammatory factors in the periodontium, which subsequently impact
      on diabetes, remains speculative. Conclusion: There is substantial information on
      potential mechanistic pathways which support a close association between diabetes
      and periodontitis, but there is a real need for longitudinal clinical studies
      using larger patient groups, integrated with studies of animal models and
      cells/tissues in vitro.
AD  - Centre for Oral Health Research and Institute of Cellular Medicine, Newcastle
      University, Newcastle upon Tyne, UK;
FAU - Taylor, John J
AU  - Taylor JJ
FAU - Preshaw, Philip M
AU  - Preshaw PM
FAU - Lalla, Evanthia
AU  - Lalla E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/02 06:00
AID - 10.1902/jop.2013.134005 [doi]
PST - ppublish
SO  - J Periodontol. 2013 Apr;84(4 Suppl):S113-34. doi: 10.1902/jop.2013.134005.

PMID- 23631572
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1943-3670 (Electronic)
IS  - 0022-3492 (Linking)
VI  - 84
IP  - 4 Suppl
DP  - 2013 Apr
TI  - Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop
      on Periodontitis and Systemic Diseases.
PG  - S106-12
LID - 10.1902/jop.2013.1340011 [doi]
AB  - Abstract Background: Diabetes and periodontitis are complex chronic diseases with
      an established bidirectional relationship. There is long-established evidence
      that hyperglycaemia in diabetes is associated with adverse periodontal outcomes. 
      However, given the ubiquity of periodontal diseases and the emerging global
      diabetes epidemic, the complications of which contribute to significant morbidity
      and premature mortality, it is timely to review the role of periodontitis in
      diabetes. Aims: To report the epidemiological evidence from cross-sectional,
      prospective and intervention studies for the impact of periodontal disease on
      diabetes incidence, control and complications and to identify potential
      underpinning mechanisms. Epidemiology: Over the last 20 years, consistent and
      robust evidence has emerged that severe periodontitis adversely affects glycaemic
      control in diabetes and glycaemia in non-diabetes subjects. In diabetes patients,
      there is a direct and dose-dependent relationship between periodontitis severity 
      and diabetes complications. Emerging evidence supports an increased risk for
      diabetes onset in patients with severe periodontitis. Biological mechanisms: Type
      2 diabetes is preceded by systemic inflammation, leading to reduced pancreatic
      b-cell function, apoptosis and insulin resistance.Increasing evidence supports
      elevated systemic inflammation (acute-phase and oxidative stress biomarkers)
      resulting from the entry of periodontal organisms and their virulence factors
      into the circulation, providing biological plausibility for the effects of
      periodontitis on diabetes. AGE (Advanced Glycation Endproducts)-RAGE (Receptor
      for AGEs) interactions and oxidative-stress-mediated pathways provide plausible
      mechanistic links in the diabetes to periodontitis direction. Interventions:
      Randomized controlled trials (RCTs) consistently demonstrate that mechanical
      periodontal therapy associates with approximately a 0.4% reduction in HbA1C at 3 
      months, a clinical impact equivalent to adding a second drug to a pharmacological
      regime for diabetes. RCTs are needed with larger numbers of subjects and longer
      term follow-up, and if results are substantiated, adjunctive periodontal
      therapies subsequently need to be evaluated. There is no current evidence to
      support adjunctive use of antimicrobials for periodontal management of diabetes
      patients. Guidelines: Given the current evidence, it is timely to provide
      guidelines for periodontal care in diabetes patients for medical and dental
      professionals and recommendations for patients/the public.
AD  - Periodontal Research Group & MRC Centre for Immune Regulation, University of
      Birmingham School of Dentistry, Birmingham, UK.
FAU - Chapple, Iain L C
AU  - Chapple IL
FAU - Genco, Robert
AU  - Genco R
CN  - working group 2 of the joint EFP/AAP workshop*
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Periodontol
JT  - Journal of periodontology
JID - 8000345
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/02 06:00
AID - 10.1902/jop.2013.1340011 [doi]
PST - ppublish
SO  - J Periodontol. 2013 Apr;84(4 Suppl):S106-12. doi: 10.1902/jop.2013.1340011.

PMID- 23627330
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1600-051X (Electronic)
IS  - 0303-6979 (Linking)
VI  - 40 Suppl 14
DP  - 2013 Apr
TI  - Periodontitis and systemic diseases: a record of discussions of working group 4
      of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases.
PG  - S20-3
LID - 10.1111/jcpe.12091 [doi]
AB  - BACKGROUND: There has been an explosion in research into possible associations
      between periodontitis and various systemic diseases and conditions. AIM: To
      review the evidence for associations between periodontitis and various systemic
      diseases and conditions, including chronic obstructive pulmonary disease (COPD), 
      pneumonia, chronic kidney disease, rheumatoid arthritis, cognitive impairment,
      obesity, metabolic syndrome and cancer, and to document headline discussions of
      the state of each field. Periodontal associations with diabetes, cardiovascular
      disease and adverse pregnancy outcomes were not discussed by working group 4.
      RESULTS: Working group 4 recognized that the studies performed to date were
      largely cross-sectional or case-control with few prospective cohort studies and
      no randomized clinical trials. The best current evidence suggests that
      periodontitis is characterized by both infection and pro-inflammatory events,
      which variously manifest within the systemic diseases and disorders discussed.
      Diseases with at least minimal evidence of an association with periodontitis
      include COPD, pneumonia, chronic kidney disease, rheumatoid arthritis, cognitive 
      impairment, obesity, metabolic syndrome and cancer. The working group agreed that
      there is insufficient evidence to date to infer causal relationships with the
      exception that organisms originating in the oral microbiome can cause lung
      infections. CONCLUSIONS: The group was unanimous in their opinion that the
      reported associations do not imply causality, and establishment of causality will
      require new studies that fulfil the Bradford Hill or equivalent criteria. Precise
      and community-agreed case definitions of periodontal disease states must be
      implemented systematically to enable consistent and clearer interpretations of
      studies of the relationship to systemic diseases. The members of the working
      group were unanimous in their opinion that to develop data that best inform
      clinicians, investigators and the public, studies should focus on robust disease 
      outcomes and avoid surrogate endpoints. It was concluded that because of the
      relative immaturity of the body of evidence for each of the purported
      relationships, the field is wide open and the gaps in knowledge are large.
CI  - (c) 2013 European Federation of Periodontology and American Academy of
      Periodontology.
AD  - Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, 
      Queen's University Belfast, Belfast, Northern Ireland, UK.
FAU - Linden, Gerry J
AU  - Linden GJ
FAU - Herzberg, Mark C
AU  - Herzberg MC
CN  - working group 4 of the joint EFP/AAP workshop
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Periodontol
JT  - Journal of clinical periodontology
JID - 0425123
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/14 [accepted]
AID - 10.1111/jcpe.12091 [doi]
PST - ppublish
SO  - J Clin Periodontol. 2013 Apr;40 Suppl 14:S20-3. doi: 10.1111/jcpe.12091.

PMID- 23627325
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1600-051X (Electronic)
IS  - 0303-6979 (Linking)
VI  - 40 Suppl 14
DP  - 2013 Apr
TI  - Evidence that periodontal treatment improves diabetes outcomes: a systematic
      review and meta-analysis.
PG  - S153-63
LID - 10.1111/jcpe.12084 [doi]
AB  - CONTEXT: The effect of periodontal therapy on diabetes outcomes has not been
      established. OBJECTIVE: This update examines the effect of periodontal treatment 
      on diabetes outcomes. DATA SOURCES: Literature since October 2009 using MEDLINE. 
      STUDY ELIGIBILITY CRITERIA: Published RCTs including periodontal therapy for
      diabetic subjects, a metabolic outcome, an untreated control group, and follow-up
      of 3 months. DATA EXTRACTION: Pre-defined data fields, including study quality
      indicators were used. DATA SYNTHESIS: A search revealed 56 publications of which 
      9 met inclusion criteria. Mean change of HbA1c from baseline was compared across 
      treatment groups. Pooled analysis was based on random effects models. RESULTS: A 
      meta-analysis indicated a mean treatment effect of -0.36% HbA1c (CI -0.54, -0.19)
      compared to no treatment after periodontal therapy (p < 0.0001). Heterogeneity
      tests revealed only minimal evidence of publication bias (I(2 ) = 9%).
      LIMITATIONS: Small sample size and high risk of bias remain problematic for
      studies of this type. Periodontal therapy varied considerably. CONCLUSION: The
      modest reduction in HbA1c observed as a result of periodontal therapy in subjects
      with type 2 diabetes is consistent with previous systematic reviews. Despite this
      finding, there is limited confidence in the conclusion due to a lack of
      multi-centre trials of sufficient sample size are lacking.
CI  - (c) 2013 European Federation of Periodontology and American Academy of
      Periodontology.
AD  - Department of Periodontology and Implant Dentistry, New York University, New
      York, NY, USA.
FAU - Engebretson, Steven
AU  - Engebretson S
FAU - Kocher, Thomas
AU  - Kocher T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Periodontol
JT  - Journal of clinical periodontology
JID - 0425123
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/14 [accepted]
AID - 10.1111/jcpe.12084 [doi]
PST - ppublish
SO  - J Clin Periodontol. 2013 Apr;40 Suppl 14:S153-63. doi: 10.1111/jcpe.12084.

PMID- 23627324
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1600-051X (Electronic)
IS  - 0303-6979 (Linking)
VI  - 40 Suppl 14
DP  - 2013 Apr
TI  - Effect of periodontal disease on diabetes: systematic review of epidemiologic
      observational evidence.
PG  - S135-52
LID - 10.1111/jcpe.12080 [doi]
AB  - BACKGROUND: Periodontal disease and diabetes mellitus are common, chronic
      diseases worldwide. Epidemiologic and biologic evidence suggest periodontal
      disease may affect diabetes. OBJECTIVE: To systematically review
      non-experimental, epidemiologic evidence for effects of periodontal disease on
      diabetes control, complications and incidence. DATA SOURCES: Electronic
      bibliographic databases, supplemented by hand searches of recent and future
      issues of relevant journals. STUDY ELIGIBILITY CRITERIA AND PARTICIPANTS:
      Longitudinal and cross-sectional epidemiologic, non-interventional studies that
      permit determination of directionality of observed effects were included. STUDY
      APPRAISAL AND SYNTHESIS METHODS: Four reviewers evaluated pair-wise each study.
      Review findings regarding study results and quality were summarized in tables by 
      topic, using the PRISMA Statement for reporting and the Newcastle-Ottawa System
      for quality assessment, respectively. From 2246 citations identified and
      available abstracts screened, 114 full-text reports were assessed and 17 included
      in the review. RESULTS: A small body of evidence supports significant, adverse
      effects of periodontal disease on glycaemic control, diabetes complications, and 
      development of type 2 (and possibly gestational) diabetes. LIMITATIONS: There
      were only a limited number of eligible studies, several of which included small
      sample sizes. Exposure and outcome parameters varied, and the generalizability of
      their results was limited. CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: Current 
      evidence suggests that periodontal disease adversely affects diabetes outcomes,
      and that further longitudinal studies are warranted.
CI  - (c) 2013 European Federation of Periodontology and American Academy of
      Periodontology.
AD  - University of Michigan School of Dentistry, Ann Arbor, MI, USA.
FAU - Borgnakke, Wenche S
AU  - Borgnakke WS
FAU - Ylostalo, Pekka V
AU  - Ylostalo PV
FAU - Taylor, George W
AU  - Taylor GW
FAU - Genco, Robert J
AU  - Genco RJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Periodontol
JT  - Journal of clinical periodontology
JID - 0425123
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/14 [accepted]
AID - 10.1111/jcpe.12080 [doi]
PST - ppublish
SO  - J Clin Periodontol. 2013 Apr;40 Suppl 14:S135-52. doi: 10.1111/jcpe.12080.

PMID- 23627323
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1600-051X (Electronic)
IS  - 0303-6979 (Linking)
VI  - 40 Suppl 14
DP  - 2013 Apr
TI  - A review of the evidence for pathogenic mechanisms that may link periodontitis
      and diabetes.
PG  - S113-34
LID - 10.1111/jcpe.12059 [doi]
AB  - AIMS: To review the evidence for the molecular and cellular processes that may
      potentially link periodontal disease and diabetes. The pathogenic roles of
      cytokines and metabolic molecules (e.g. glucose, lipids) are explored and the
      role of periodontal bacteria is also addressed. Paradigms for bidirectional
      relationships between periodontitis and diabetes are discussed and opportunities 
      for elaborating these models are considered. METHODS: Database searches were
      performed using MeSH terms, keywords, and title words. Studies were evaluated and
      summarized in a narrative review. RESULTS: Periodontal microbiota appears
      unaltered by diabetes and there is little evidence that it may influence
      glycaemic control. Small-scale clinical studies and experiments in animal models 
      suggest that IL-1beta, TNF-alpha, IL-6, OPG and RANKL may mediate periodontitis
      in diabetes. The AGE-RAGE axis is likely an important pathway of tissue
      destruction and impaired repair in diabetes-associated periodontitis. A role for 
      locally activated pro-inflammatory factors in the periodontium, which
      subsequently impact on diabetes, remains speculative. CONCLUSION: There is
      substantial information on potential mechanistic pathways which support a close
      association between diabetes and periodontitis, but there is a real need for
      longitudinal clinical studies using larger patient groups, integrated with
      studies of animal models and cells/tissues in vitro.
CI  - (c) 2013 European Federation of Periodontology and American Academy of
      Periodontology.
AD  - Centre for Oral Health Research and Institute of Cellular Medicine, Newcastle
      University, Newcastle upon Tyne, UK.
FAU - Taylor, John J
AU  - Taylor JJ
FAU - Preshaw, Philip M
AU  - Preshaw PM
FAU - Lalla, Evanthia
AU  - Lalla E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Periodontol
JT  - Journal of clinical periodontology
JID - 0425123
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/14 [accepted]
AID - 10.1111/jcpe.12059 [doi]
PST - ppublish
SO  - J Clin Periodontol. 2013 Apr;40 Suppl 14:S113-34. doi: 10.1111/jcpe.12059.

PMID- 23627322
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1600-051X (Electronic)
IS  - 0303-6979 (Linking)
VI  - 40 Suppl 14
DP  - 2013 Apr
TI  - Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop
      on Periodontitis and Systemic Diseases.
PG  - S106-12
LID - 10.1111/jcpe.12077 [doi]
AB  - BACKGROUND: Diabetes and periodontitis are complex chronic diseases with an
      established bidirectional relationship. There is long-established evidence that
      hyperglycaemia in diabetes is associated with adverse periodontal outcomes.
      However, given the ubiquity of periodontal diseases and the emerging global
      diabetes epidemic, the complications of which contribute to significant morbidity
      and premature mortality, it is timely to review the role of periodontitis in
      diabetes. AIMS: To report the epidemiological evidence from cross-sectional,
      prospective and intervention studies for the impact of periodontal disease on
      diabetes incidence, control and complications and to identify potential
      underpinning mechanisms. EPIDEMIOLOGY: Over the last 20 years, consistent and
      robust evidence has emerged that severe periodontitis adversely affects glycaemic
      control in diabetes and glycaemia in non-diabetes subjects. In diabetes patients,
      there is a direct and dose-dependent relationship between periodontitis severity 
      and diabetes complications. Emerging evidence supports an increased risk for
      diabetes onset in patients with severe periodontitis. BIOLOGICAL MECHANISMS: Type
      2 diabetes is preceded by systemic inflammation, leading to reduced pancreatic
      beta-cell function, apoptosis and insulin resistance. Increasing evidence
      supports elevated systemic inflammation (acute-phase and oxidative stress
      biomarkers) resulting from the entry of periodontal organisms and their virulence
      factors into the circulation, providing biological plausibility for the effects
      of periodontitis on diabetes. AGE (Advanced Glycation Endproducts)-RAGE (Receptor
      for AGEs) interactions and oxidative-stress-mediated pathways provide plausible
      mechanistic links in the diabetes to periodontitis direction. INTERVENTIONS:
      Randomized controlled trials (RCTs) consistently demonstrate that mechanical
      periodontal therapy associates with approximately a 0.4% reduction in HbA1C at 3 
      months, a clinical impact equivalent to adding a second drug to a pharmacological
      regime for diabetes. RCTs are needed with larger numbers of subjects and longer
      term follow-up, and if results are substantiated, adjunctive periodontal
      therapies subsequently need to be evaluated. There is no current evidence to
      support adjunctive use of antimicrobials for periodontal management of diabetes
      patients. GUIDELINES: Given the current evidence, it is timely to provide
      guidelines for periodontal care in diabetes patients for medical and dental
      professionals and recommendations for patients/the public.
CI  - (c) 2013 European Federation of Periodontology and American Academy of
      Periodontology.
AD  - Periodontal Research Group & MRC Centre for Immune Regulation, University of
      Birmingham School of Dentistry, Birmingham, UK.
FAU - Chapple, Iain L C
AU  - Chapple IL
FAU - Genco, Robert
AU  - Genco R
CN  - working group 2 of the joint EFP/AAP workshop
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Periodontol
JT  - Journal of clinical periodontology
JID - 0425123
SB  - D
SB  - IM
EDAT- 2013/05/03 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/12/21 [received]
PHST- 2013/01/05 [revised]
PHST- 2012/11/14 [accepted]
AID - 10.1111/jcpe.12077 [doi]
PST - ppublish
SO  - J Clin Periodontol. 2013 Apr;40 Suppl 14:S106-12. doi: 10.1111/jcpe.12077.

PMID- 23634392
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130501
DCOM- 20130502
LR  - 20130503
IS  - 2249-782X (Print)
IS  - 0973-709X (Linking)
VI  - 7
IP  - 3
DP  - 2013 Mar
TI  - The bacteriology of diabetic foot ulcers, with a special reference to multidrug
      resistant strains.
PG  - 441-5
LID - 10.7860/JCDR/2013/5091.2794 [doi]
AB  - Introduction: A diabetic foot infection is one of the most feared complications
      of Diabetes mellitus. Many studies have reported on the bacteriology of Diabetic 
      Foot Infections (DFIs) over the past 25 years, but the results have been varied
      and often contradictory. Aims and Objectives: This study was carried out to
      determine the bacterial profiles of infected ulcers and the antibiotic resistance
      pattern of the isolates. Materials and Methods: Samples were collected from 50
      patients with diabetic foot ulcers by using sterile swabs and they were
      processed. Results: A total of 75 bacterial isolates were obtained from 50
      patients with diabetic foot ulcers. The age group of these patients ranged from
      35 to 80 years and the maximum number of patients was in the age group of 60 to
      65 years. Gram negative bacilli were more prevalent (65.1%) than gram positive
      cocci (34.9%). The commonest isolate was Pseudomonas spp (16%), followed by
      Escherichia coli (14.6%) and Staphylococcus aureus (13.3%).The antibiotic
      sensivity profiles of the bacteria were also studied. 37.5% of the gram negative 
      bacilli were ESBL producers and 31% were carbapenemase producers. Conclusion:
      This study showed a preponderance of gram negative bacilli among the isolates
      from the diabetic foot ulcers. Knowledge on the antibiotic sensitivity pattern of
      the isolates will be helpful in determining the drugs for the empirical treatment
      of diabetic ulcers.
AD  - Associate Professor, Microbiology, Chettinad Hospital and Research Institute ,
      Rajiv Gandhi Salai, Kelambakkam, Kanchipuram Dist - 603103, India .
FAU - Shanmugam, Priyadarshini
AU  - Shanmugam P
FAU - M, Jeya
AU  - M J
FAU - Susan S, Linda
AU  - Susan S L
LA  - eng
PT  - Journal Article
DEP - 20130301
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC3616552
OID - NLM: PMC3616552
OTO - NOTNLM
OT  - Antibiotic sensitivity
OT  - Bacterial profile
OT  - Diabetic foot ulcer
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:01
CRDT- 2013/05/02 06:00
PHST- 2012/09/15 [received]
PHST- 2012/12/04 [accepted]
PHST- 2013/03/01 [epublish]
AID - 10.7860/JCDR/2013/5091.2794 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2013 Mar;7(3):441-5. doi: 10.7860/JCDR/2013/5091.2794. Epub
      2013 Mar 1.

PMID- 23634245
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130501
DCOM- 20130502
LR  - 20130503
IS  - 1943-8141 (Electronic)
VI  - 5
IP  - 3
DP  - 2013
TI  - Novel insight into the distribution of L-cells in the rat intestinal tract.
PG  - 347-58
AB  - BACKGROUND: Gut secreted incretin hormones and gastric bypass surgery currently
      provides some of the most successful treatments for diabetes and obesity
      respectively. However, despite the evident importance of the gut endocrine system
      no information exists on the total number and distribution of different types of 
      endocrine cells in the gut. Here we have used the established preclinical Zucker 
      Diabetic Fatty (ZDF) rat model which displays elevated levels of GLP-1 to assess 
      L-cell distribution and L-cell dynamics in the full rostro-caudal extension of
      the rat intestinal tract. METHODS: Using mathematically unbiased stereology we
      provide total and regional estimates of gut volume, gut surface area and the
      total number of L-cells throughout the intestinal tract in obese ZDF rats and
      lean controls. RESULTS: The total number of L-cells in the lean and obese ZDF gut
      is estimated to 4.8 and 10.9 million, respectively, coupled with a corresponding 
      near doubling in total gut volume and total surface area. L-cell numbers were
      found to be distributed rather evenly throughout the jejunum, ileum and colon.
      CONCLUSION: The present study provides the first stereological report of total
      L-cell number and L-cell distribution throughout the rat intestinal tract. In
      contrast to the currently held view, the majority of L-cells are actually located
      proximal to the traditionally defined ileum and colon.
AD  - Gubra Aps Agern Alle 1, 2970 Horsholm ; Department of Human Nutrition, University
      of Copenhagen Frederiksberg,Denmark.
FAU - Hansen, Carl Frederik
AU  - Hansen CF
FAU - Vrang, Niels
AU  - Vrang N
FAU - Sangild, Per Torp
AU  - Sangild PT
FAU - Jelsing, Jacob
AU  - Jelsing J
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC3633977
OID - NLM: PMC3633977
OTO - NOTNLM
OT  - GLP-1
OT  - L-cell
OT  - ZDF
OT  - diabetes
OT  - stereology
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:01
CRDT- 2013/05/02 06:00
PHST- 2013 [ppublish]
PHST- 2013/03/01 [received]
PHST- 2013/03/30 [accepted]
PHST- 2013/04/19 [epublish]
PST - epublish
SO  - Am J Transl Res. 2013 Apr 19;5(3):347-58. Print 2013.

PMID- 23634223
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Role of the Human Endogenous Retrovirus HERV-K18 in Autoimmune Disease
      Susceptibility: Study in the Spanish Population and Meta-Analysis.
PG  - e62090
LID - 10.1371/journal.pone.0062090 [doi]
AB  - BACKGROUND: Human endogenous retroviruses (HERVs) are genomic sequences that
      resulted from ancestral germ-line infections by exogenous retroviruses and
      therefore are transmitted in a Mendelian fashion. Increased HERV expression and
      antibodies to HERV antigens have been found in various autoimmune diseases.
      HERV-K18 in chromosome 1 was previously associated with type one diabetes and
      multiple sclerosis (MS). The etiology of these complex conditions has not been
      completely elucidated even after the powerful genome wide association studies
      (GWAS) performed. Nonetheless, this approach does not scrutinize the repetitive
      sequences within the genome, and part of the missing heritability could lie
      behind these sequences. We aimed at evaluating the role of HERV-K18 in chromosome
      1 on autoimmune disease susceptibility. METHODS: Two HERV-K18 SNPs (97Y/C and
      154W/Stop substitutions) conforming three haplotypes were genotyped in Spanish
      cohorts of multiple sclerosis (n = 942), rheumatoid arthritis (n = 462) and
      ethnically matched controls (n = 601). Our findings were pooled in a
      meta-analysis including 5312 autoimmune patients and 4032 controls. RESULTS:
      Significant associations of both HERV-K18 polymorphisms in chromosome 1 with MS
      patients stratified by HLA-DRB1*15ratio01 were observed [97Y/C p = 0.02; OR (95% 
      CI) = 1.5 (1.04-2.17) and 154W/Stop: p = 0.001; OR (95% CI) = 1.6 (1.19-2.16)].
      Combined meta-analysis of the previously published association studies of
      HERV-K18 with different autoimmune diseases, together with data derived from
      Spanish cohorts, yielded a significant association of the HERV-K18.3 haplotype
      [97Y-154W: pM-H = 0.0008; ORM-H (95% CI) = 1.22 (1.09-1.38)]. CONCLUSION:
      Association of the HERV-K18.3 haplotype in chromosome 1 with autoimmune-disease
      susceptibility was confirmed through meta-analysis.
AD  - Immunology Department, Hospital Clinico San Carlos, Instituto de Investigacion
      Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain.
FAU - de la Hera, Belen
AU  - de la Hera B
FAU - Varade, Jezabel
AU  - Varade J
FAU - Garcia-Montojo, Marta
AU  - Garcia-Montojo M
FAU - Lamas, Jose Ramon
AU  - Lamas JR
FAU - de la Encarnacion, Ana
AU  - de la Encarnacion A
FAU - Arroyo, Rafael
AU  - Arroyo R
FAU - Fernandez-Gutierrez, Benjamin
AU  - Fernandez-Gutierrez B
FAU - Alvarez-Lafuente, Roberto
AU  - Alvarez-Lafuente R
FAU - Urcelay, Elena
AU  - Urcelay E
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3636236
OID - NLM: PMC3636236
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/25 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/25 [epublish]
AID - 10.1371/journal.pone.0062090 [doi]
AID - PONE-D-13-04330 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 25;8(4):e62090. doi: 10.1371/journal.pone.0062090. Print 2013.

PMID- 23633759
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1550-9109 (Electronic)
IS  - 0161-8105 (Linking)
VI  - 36
IP  - 5
DP  - 2013
TI  - Vascular inflammation and sleep disordered breathing in a community-based cohort.
PG  - 763-8
LID - 10.5665/sleep.2644 [doi]
AB  - STUDY OBJECTIVES: Sleep disordered breathing is associated with cardiovascular
      disease. The pathophysiologic mechanisms remain unclear, but enhanced vascular
      inflammation is implicated. We sought to evaluate the association of sleep
      disordered breathing with biomarkers of inflammation. DESIGN: Cross-sectional,
      observational. SETTING: Community-based. PARTICIPANTS: There were 900
      participants from the Framingham Heart Study site of the Sleep Heart Health Study
      (52% females, mean age 60 y, 23% ethnic minorities). INTERVENTIONS: None.
      MEASUREMENTS: We assessed circulating levels of nine inflammatory biomarkers in
      relation to polysomnographically-derived apnea-hypopnea index and hypoxemia index
      (% sleep time with oxyhemoglobin saturation < 90%). Multivariable models were
      adjusted for demographics, smoking, cardiovascular diseases, diabetes, and other 
      potential confounders, without and with adjustment for body mass index. RESULTS: 
      With multivariable adjustment not including body mass index, the apnea-hypopnea
      index was associated with C-reactive protein, inter-leukin-6, fibrinogen,
      intercellular adhesion molecule-1, and P-selectin levels and hypoxemia index was 
      associated with C-reactive protein, interleukin-6, and fibrinogen levels. After
      adjustment for body mass index, only the association of interleukin-6 with sleep 
      disordered breathing remained significant: the adjusted mean serum interleukin-6 
      level was 2.93, 3.14, 3.34, and 4.62 pg/mL, respectively, in participants with
      apnea-hypopnea index < 5, 5-14.9, 15-29.9, and >/= 30 events/h (P = 0.01 for
      trend) and 2.97, 3.01, 3.35, and 4.85 pg/mL, respectively, in participants with
      hypoxemia index < 0.5, 0.5-4.9, 5-9.9, and >/= 10% of sleep time (P = 0.02 for
      trend). CONCLUSIONS: In a community-based sample, sleep disordered breathing is
      associated with higher levels of interleukin-6, a marker of myocardial infarction
      risk and mortality. Adiposity may mediate the increased levels of C-reactive
      protein, fibrinogen, intercellular adhesion molecule-1, and P-selectin observed
      in sleep disordered breathing. CITATION: Chami HA; Fontes JD; Vasan RS; Keaney
      JF; O'Connor GT; Larson MG; Benjamin EJ; Gottlieb DJ. Vascular Inflammation and
      sleep disordered breathing in a community-based cohort. SLEEP 2013;36(5):763-768.
AD  - Department of Medicine, American University of Beirut, Beirut, Lebanon ;
      Department of Medicine, Boston University School of Medicine, Boston, MA.
FAU - Chami, Hassan A
AU  - Chami HA
FAU - Fontes, Joao D
AU  - Fontes JD
FAU - Vasan, Ramachandran S
AU  - Vasan RS
FAU - Keaney, John F Jr
AU  - Keaney JF Jr
FAU - O'Connor, George T
AU  - O'Connor GT
FAU - Larson, Martin G
AU  - Larson MG
FAU - Benjamin, Emelia J
AU  - Benjamin EJ
FAU - Gottlieb, Daniel J
AU  - Gottlieb DJ
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
SB  - IM
PMC - PMC3622647
OID - NLM: PMC3622647 [Available on 11/01/13]
OTO - NOTNLM
OT  - Epidemiology
OT  - inflammation
OT  - sleep apnea syndromes
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PMCR- 2013/11/01 00:00
AID - 10.5665/sleep.2644 [doi]
PST - epublish
SO  - Sleep. 2013 May 1;36(5):763-8. doi: 10.5665/sleep.2644.

PMID- 23633746
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1550-9109 (Electronic)
IS  - 0161-8105 (Linking)
VI  - 36
IP  - 5
DP  - 2013
TI  - Long-term effect of weight loss on obstructive sleep apnea severity in obese
      patients with type 2 diabetes.
PG  - 641-9
LID - 10.5665/sleep.2618 [doi]
AB  - STUDY OBJECTIVES: To examine whether the initial benefit of weight loss on
      obstructive sleep apnea (OSA) severity at 1 year is maintained at 4 years.
      DESIGN: Randomized controlled trial with follow-up at 1, 2, and 4 years. SETTING:
      4 Look AHEAD clinical centers. PARTICIPANTS: Two hundred sixty-four obese adults 
      with type 2 diabetes and OSA. INTERVENTIONS: Intensive lifestyle intervention
      with a behavioral weight loss program or diabetes support and education.
      MEASUREMENTS: Change in apnea-hypopnea index on polysomnogram. RESULTS: The
      intensive lifestyle intervention group's mean weight loss was 10.7 +/- 0.7
      (standard error), 7.4 +/- 0.7, and 5.2 +/- 0.7 kg at 1, 2, and 4 years
      respectively, compared to a less than 1-kg weight loss for the control group at
      each time (P < 0.001). Apnea-hypopnea index difference between groups was 9.7 +/-
      2.0, 8.0 +/- 2.0, and 7.7 +/- 2.3 events/h at 1, 2 and 4 years respectively (P < 
      0.001). Change in apnea-hypopnea index over time was related to the amount of
      weight loss (P < 0.0001) and intervention, independent of weight loss (P =
      0.001). Remission of OSA at 4 years was 5 times more common with intensive
      lifestyle intervention (20.7%) than diabetes support and education (3.6%).
      CONCLUSIONS: Among obese adults with type 2 diabetes and OSA, intensive lifestyle
      intervention produced greater reductions in weight and apnea-hypopnea index over 
      a 4 year period than did diabetes support and education. Beneficial effects of
      intensive lifestyle intervention on apneahypopnea index at 1 year persisted at 4 
      years, despite an almost 50% weight regain. Effect of intensive lifestyle
      intervention on apnea-hypopnea index was largely, but not entirely, due to weight
      loss. CITATION: Kuna ST; Reboussin DM; Borradaile KE; Sanders MH; Millman RP;
      Zammit G; Newman AB; Wadden TA; Jakicic JM; Wing RR; Pi-Sunyer FX; Foster GD;
      Sleep AHEAD Research Group. Long-term effect of weight loss on obstructive sleep 
      apnea severity in obese patients with type 2 diabetes. SLEEP 2013;36(5):641-649.
AD  - University of Pennsylvania, Philadelphia, PA ; Philadelphia Veterans Affairs
      Medical Center, Philadelphia, PA.
FAU - Kuna, Samuel T
AU  - Kuna ST
FAU - Reboussin, David M
AU  - Reboussin DM
FAU - Borradaile, Kelley E
AU  - Borradaile KE
FAU - Sanders, Mark H
AU  - Sanders MH
FAU - Millman, Richard P
AU  - Millman RP
FAU - Zammit, Gary
AU  - Zammit G
FAU - Newman, Anne B
AU  - Newman AB
FAU - Wadden, Thomas A
AU  - Wadden TA
FAU - Jakicic, John M
AU  - Jakicic JM
FAU - Wing, Rena R
AU  - Wing RR
FAU - Pi-Sunyer, F Xavier
AU  - Pi-Sunyer FX
FAU - Foster, Gary D
AU  - Foster GD
CN  - Sleep AHEAD Research Group of the Look AHEAD Research Group
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
SB  - IM
PMC - PMC3624818
OID - NLM: PMC3624818 [Available on 11/01/13]
OTO - NOTNLM
OT  - Apnea-hypopnea index
OT  - polysomnogram
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PMCR- 2013/11/01 00:00
AID - 10.5665/sleep.2618 [doi]
PST - epublish
SO  - Sleep. 2013 May 1;36(5):641-9. doi: 10.5665/sleep.2618.

PMID- 23633736
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1468-2877 (Electronic)
IS  - 0033-3549 (Linking)
VI  - 128
IP  - 3
DP  - 2013 May
TI  - Using GIS and Secondary Data to Target Diabetes-Related Public Health Efforts.
PG  - 212-20
AB  - OBJECTIVES: To efficiently help communities prevent and manage diabetes, health
      departments need to be able to target populations with high risk but low
      resources. To aid in this process, we mapped county-level diabetes-related rates 
      and resources/use using publicly available secondary data to identify Michigan
      counties with high diabetes prevalence and low or no medical and/or community
      resources. METHODS: We collected county-level diabetes-related rates and
      resources from Web-based sources and mapped them using geographic information
      systems (GIS) software. Data included age-adjusted county diabetes rates,
      diabetes-related medical resource and resource use (i.e., the number of
      endocrinologists and percentage of Medicare patients with diabetes who received
      hemoglobin A1c testing in the past year), community resources (i.e., the number
      of certified diabetes self-management education and diabetes support groups), as 
      well as population estimates and demographics (e.g., rural residence, education, 
      poverty, and race/ethnicity). We created GIS maps highlighting areas that had
      higher-than-median rates of disease and lower-than-median resources. We also
      conducted linear, logistic, and Poisson regression analyses to confirm GIS
      findings. RESULTS: There were clear regional trends in resource distribution
      across Michigan. The 15 counties in the Upper Peninsula were lacking in medical
      resources but higher in community resources compared with the 68 counties in the 
      Lower Peninsula. There was little apparent association between need (diabetes
      prevalence) and diabetes-related resources/use. Specific counties with high
      diabetes prevalence and low resources were easily identified using GIS mapping.
      CONCLUSION: Using public data and mapping tools identified diabetes
      health-service shortage areas for targeted public health programming.
AD  - Western Michigan University, College of Health & Human Services,
      Interdisciplinary Health Sciences, Kalamazoo, MI.
FAU - Curtis, Amy B
AU  - Curtis AB
FAU - Kothari, Catherine
AU  - Kothari C
FAU - Paul, Rajib
AU  - Paul R
FAU - Connors, Elyse
AU  - Connors E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Public Health Rep
JT  - Public health reports (Washington, D.C. : 1974)
JID - 9716844
SB  - AIM
SB  - IM
PMC - PMC3610073
OID - NLM: PMC3610073 [Available on 05/01/14]
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PMCR- 2014/05/01 00:00
PST - ppublish
SO  - Public Health Rep. 2013 May;128(3):212-20.

PMID- 23633695
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1943-4723 (Electronic)
IS  - 0002-8177 (Linking)
VI  - 144
IP  - 5
DP  - 2013 May
TI  - Diabetes and tooth loss: An analysis of data from the National Health and
      Nutrition Examination Survey, 2003-2004.
PG  - 478-85
AB  - BACKGROUND: The authors conducted an analysis of data from the National Health
      and Nutrition Examination Survey (NHANES) to understand the association between
      diabetes and tooth loss in the United States. METHODS: The authors analyzed the
      oral examination and self-reported diabetes data obtained from the NHANES
      2003-2004 cycle and included 2,508 participants representing a civilian,
      noninstitutionalized U.S. population 50 years and older. The authors calculated
      the prevalence of edentulism and the number of missing teeth among dentate
      people, and they used multiple regression analyses to assess the association
      between diabetes and tooth loss. RESULTS: The prevalence of edentulism was 28
      percent and 14 percent among people with and without diabetes, respectively. The 
      multiple logistic regression analysis revealed that people with diabetes were
      more likely to be edentulous than were those without diabetes (adjusted odds
      ratio = 2.25; 95 percent confidence interval, 1.19-4.21). Among dentate adults,
      those with diabetes had a higher number of missing teeth than did adults without 
      diabetes (mean [standard error {SE}] = 9.8 [0.67]), mean [SE] = 6.7 [0.29]); P < 
      .01). CONCLUSIONS: These study results revealed that adults with diabetes are at 
      higher risk of experiencing tooth loss and edentulism than are adults without
      diabetes. One of every five cases of edentulism in the United States is linked to
      diabetes. Practical Implications. Although the association between diabetes and
      periodontal disease is well established, health care professionals also need to
      recognize the risk of tooth loss and its effect on quality of life among people
      with diabetes.
AD  - When this article was written, Dr. Patel was a public health resident at the
      Bureau of Dental Health, New York State Department of Health, Albany. He now is
      enrolled in the Program for Advanced Standing Students, School of Dental
      Medicine, University at Buffalo, The State University of New York.
FAU - Patel, Manthan H
AU  - Patel MH
FAU - Kumar, Jayanth V
AU  - Kumar JV
FAU - Moss, Mark E
AU  - Moss ME
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Am Dent Assoc
JT  - Journal of the American Dental Association (1939)
JID - 7503060
SB  - D
SB  - IM
OTO - NOTNLM
OT  - Diabetes
OT  - National Health and Nutrition Examination Survey (NHANES)
OT  - edentulism
OT  - tooth loss
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 144/5/478 [pii]
PST - ppublish
SO  - J Am Dent Assoc. 2013 May;144(5):478-85.

PMID- 23633679
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
DP  - 2013 Apr 29
TI  - A Randomized, Placebo-Controlled Trial of Selenium Supplementation in Patients
      With Type 2 Diabetes: Effects on Glucose Homeostasis, Oxidative Stress, and Lipid
      Profile.
AB  - Selenium is an antioxidant trace element. Patients with diabetes are shown to
      have increased oxidative stress together with decreased selenium concentrations. 
      Whether raising serum selenium will improve blood glucose management in diabetes 
      is largely unknown. In this randomized, double-blind placebo-controlled trial, we
      assessed the effects of selenium on blood glucose, lipid profile, and oxidative
      stress in 60 patients with type 2 diabetes. Selenium 200 microg/d or placebo was 
      administered orally for 3 months. Serum concentrations of fasting plasma glucose,
      glycosylated hemoglobin A1c (HbA1c), insulin, and lipid profile, as well as
      ferric-reducing ability of plasma and thiobarbituric acid-reactive substances
      were determined in the fasting state at baseline and after 3 months. Mean (SD)
      serum selenium at baseline was 42.69 (29.47) microg/L and 47.11 (42.86) microg/L 
      in selenium and placebo groups, respectively. At endpoint, selenium concentration
      reached to 71.98 (45.08) microg/L in selenium recipients compared with 45.38
      (46.45) microg/L in placebo recipients (P < 0.01). Between-group comparison
      showed that fasting plasma glucose, glycosylated hemoglobin A1c, and high-density
      lipoprotein cholesterol were statistically significantly higher in the selenium
      recipient arm. Other endpoints changes during the course of trial were not
      statistically different across the 2 treatment arms. This study suggests that
      selenium supplementation in patients with type 2 diabetes may be associated with 
      adverse effects on blood glucose homeostasis, even when plasma selenium
      concentration is raised from deficient status to the optimal concentration of
      antioxidant activity. Until results of further studies become available,
      indiscriminate use of selenium supplements in patients with type 2 diabetes
      warrants caution.
AD  - 1Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of
      Medical Sciences, Tehran, Iran; 2Children's Medical Center, Tehran University of 
      Medical Sciences, Tehran, Iran; 3Endocrinology and Metabolism Research Center,
      Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran;
      4Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of
      Medical Sciences, Tehran, Iran; 5Department of Public Health, Alborz University
      of Medical Sciences, Karaj, Iran; 6Department of Epidemiology, Iran University of
      Medical Sciences, Tehran, Iran; and 7Department of Toxicology and Pharmacology,
      Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Faghihi, Toktam
AU  - Faghihi T
FAU - Radfar, Mania
AU  - Radfar M
FAU - Barmal, Maedeh
AU  - Barmal M
FAU - Amini, Peyvand
AU  - Amini P
FAU - Qorbani, Mostafa
AU  - Qorbani M
FAU - Abdollahi, Mohammad
AU  - Abdollahi M
FAU - Larijani, Bagher
AU  - Larijani B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1097/MJT.0b013e318269175f [doi]
PST - aheadofprint
SO  - Am J Ther. 2013 Apr 29.

PMID- 23633659
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 54
IP  - 6
DP  - 2013
TI  - Transcription factor nrf2-mediated antioxidant defense system in the development 
      of diabetic retinopathy.
PG  - 3941-8
LID - 10.1167/iovs.13-11598 [doi]
AB  - PURPOSE: Increase in reactive oxygen species (ROS) is one of the major retinal
      metabolic abnormalities associated with the development of diabetic retinopathy. 
      NF-E2-related factor 2 (Nrf2), a redox sensitive factor, provides cellular
      defenses against the cytotoxic ROS. In stress conditions, Nrf2 dissociates from
      its cytosolic inhibitor, Kelch like-ECH-associated protein 1 (Keap1), and moves
      to the nucleus to regulate the transcription of antioxidant genes including the
      catalytic subunit of glutamylcysteine ligase (GCLC), a rate-limiting reduced
      glutathione (GSH) biosynthesis enzyme. Our aim is to understand the role of
      Nrf2-Keap1-GCLC in the development of diabetic retinopathy. METHODS: Effect of
      diabetes on Nrf2-Keap1-GCLC pathway, and subcellular localization of Nrf2 and its
      binding with Keap1 was investigated in the retina of streptozotocin-induced
      diabetic rats. The binding of Nrf2 at GCLC was quantified by chromatin
      immunoprecipitation technique. The results were confirmed in isolated retinal
      endothelial cells, and also in the retina from human donors with diabetic
      retinopathy. RESULTS: Diabetes increased retinal Nrf2 and its binding with Keap1,
      but decreased DNA-binding activity of Nrf2 and also its binding at the promoter
      region of GCLC. Similar impairments in Nrf2-Keap1-GCLC were observed in the
      endothelial cells exposed to high glucose and in the retina from donors with
      diabetic retinopathy. In retinal endothelial cells, glucose-induced impairments
      in Nrf2-GCLC were prevented by Nrf2 inducer tBHQ and also by Keap1-siRNA.
      CONCLUSIONS: Due to increased binding of Nrf2 with Keap1, its translocation to
      the nucleus is compromised contributing to the decreased GSH levels. Thus,
      regulation of Nrf2-Keap1 by pharmacological or molecular means could serve as a
      potential adjunct therapy to combat oxidative stress and inhibit the development 
      of diabetic retinopathy.
AD  - Kresge Eye Institute, Wayne State University, Detroit, Michigan.
FAU - Zhong, Qing
AU  - Zhong Q
FAU - Mishra, Manish
AU  - Mishra M
FAU - Kowluru, Renu A
AU  - Kowluru RA
LA  - eng
PT  - Journal Article
DEP - 20130606
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
SB  - IM
PMC - PMC3676188
OID - NLM: PMC3676188 [Available on 12/01/13]
OTO - NOTNLM
OT  - Nrf2
OT  - antioxidant defense
OT  - diabetic retinopathy
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PMCR- 2013/12/01 00:00
AID - iovs.13-11598 [pii]
AID - 10.1167/iovs.13-11598 [doi]
PST - epublish
SO  - Invest Ophthalmol Vis Sci. 2013 Jun 6;54(6):3941-8. doi: 10.1167/iovs.13-11598.

PMID- 23633651
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 Apr 30
TI  - Prevalence of MAGI in patients with type 2 diabetes mellitus.
AB  - Background. MAGI is an acronym that identifies the "male accessory gland
      inflammations/infections", a potential cause of male infertility. Type 2 diabetes
      mellitus (DM2) prevalence is going to increase among men of reproductive age. Due
      to the high prevalence of these two conditions, we could suppose that they might 
      appear together in the same patient. Aim. To evaluate MAGI prevalence in patients
      with DM2 in fertile age. Subjects and Methods. A cross-sectional study carried
      out on patients with DM2 of fertile age. All patients underwent andrological
      evaluation for the identification of conventional MAGI diagnostic criteria.
      Results. DM2 patients showed a frequency of MAGI about 43%, significantly lower
      (p<0.05) than in infertile patients of the same age without diabetes, which
      showed a MAGI overall frequency of 61%. Among examined diabetic patients the
      prevalence of MAGI did not significantly differ between patients attending for
      diabetes care problems (glycemic control) and patients with andrological
      disorders. Finally, no significant difference in seminal inflammatory signs
      frequency was detected between patients with DM2 and infertile patients without
      diabetes. Finally, the correlation analysis showed a significant direct
      correlation between duration of diabetes and glycemic control with the prevalence
      of MAGI. Conclusion. MAGI prevalence in DM2 is lower than the one detected in age
      matched infertile non-diabetic patients, however, as in infertile patients, there
      is a high frequency of seminal inflammatory signs. Moreover, the observed
      prevalence among diabetic patients with diabetes care problems and diabetic
      patients with andrological problems is not statistically different.
AD  - Section of Endocrinology, Andrology and Internal Medicine, Department of Medical 
      and Pediatric Sciences, University of Catania, Italy.
FAU - Condorelli, Rosita A
AU  - Condorelli RA
FAU - Calogero, Aldo E
AU  - Calogero AE
FAU - Vicari, Enzo
AU  - Vicari E
FAU - Duca, Ylenia
AU  - Duca Y
FAU - Favilla, Vincenzo
AU  - Favilla V
FAU - Morgia, Giuseppe
AU  - Morgia G
FAU - Cimino, Sebastiano
AU  - Cimino S
FAU - Di Mauro, Maurizio
AU  - Di Mauro M
FAU - La Vignera, Sandro
AU  - La Vignera S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 8950 [pii]
AID - 10.3275/8950 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 Apr 30.

PMID- 23633532
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
DP  - 2013 Apr 30
TI  - Regulation of Lipid Metabolism by Glucocorticoids and 11beta-HSD1 in Skeletal
      Muscle.
AB  - The prevalence of insulin resistance and type 2 diabetes mellitus are rising
      dramatically and as a consequence there is an urgent need to understand the
      pathogenesis underpinning these conditions to develop new and more efficacious
      treatments.We have tested the hypothesis that glucocorticoid-mediated changes in 
      insulin sensitivity may be associated with changes in lipid flux. Furthermore,
      pre-receptor modulation of glucocorticoid availability by 11beta-hydroxysteroid
      dehydrogenase type 1 (11beta-HSD1) may represent a critical regulatory
      step.Dexamethasone decreased lipogenesis in both murine C2C12 and human LHC-NM2
      myotubes. Inactivating p-Ser-79/218 of acetyl-CoA carboxylase 1/2 (ACC1/2) and
      activating p-Thr-172 of AMP-activated protein kinase (AMPK) were both increased
      following dexamethasone treatment in C2C12 myotubes. By contrast, dexamethasone
      increased beta-oxidation. Selective 11beta-HSD1 inhibition blocked the
      11-dehydrocorticosterone (11DHC)-mediated decrease in lipogenic, and increase in 
      lipolytic gene expression. Lipogenic gene expression was decreased, whilst
      lipolytic and beta-oxidative genes expression increased in corticosterone (CORT) 
      and 11DHC treated wild-type mice, and CORT (but not 11DHC) treated 11beta-HSD1-/-
      mice. Furthermore, CORT and 11DHC treated wild-type mice, and CORT (but not
      11DHC) treated 11beta-HSD1-/- mice had increased p-Ser-79/218 ACC1/2, p-Thr-172
      AMPK and intramyocellular diacylglyderide content.In summary, we have shown that 
      glucocorticoids have potent actions upon intramyocellular lipid homeostasis by
      decreasing lipid storage, increasing lipid mobilisation and utilisation and
      increasing diacylglyderide content. It is plausible that dysregulated
      intramyocellular lipid metabolism may underpin GC-induced insulin resistance of
      skeletal muscle.
AD  - 1Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and
      Experimental Medicine, Institute of Biomedical Research, University of
      Birmingham, Birmingham, UK, B15 2TT.
FAU - Morgan, Stuart A
AU  - Morgan SA
FAU - Gathercole, Laura L
AU  - Gathercole LL
FAU - Simonet, Claire
AU  - Simonet C
FAU - Hassan-Smith, Zaki K
AU  - Hassan-Smith ZK
FAU - Bujalska, Iwona
AU  - Bujalska I
FAU - Guest, Phil
AU  - Guest P
FAU - Abrahams, Lianne
AU  - Abrahams L
FAU - Smith, Dave M
AU  - Smith DM
FAU - Stewart, Paul M
AU  - Stewart PM
FAU - Lavery, Gareth G
AU  - Lavery GG
FAU - Tomlinson, Jeremy W
AU  - Tomlinson JW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - en.2012-2214 [pii]
AID - 10.1210/en.2012-2214 [doi]
PST - aheadofprint
SO  - Endocrinology. 2013 Apr 30.

PMID- 23633525
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 30
TI  - Association Between Metformin Therapy and Mortality After Breast Cancer: A
      Population-Based Study.
AB  - OBJECTIVEMetformin has been associated with a reduction in breast cancer risk and
      may improve survival after cancer through direct and indirect tumor-suppressing
      mechanisms. The purpose of this study was to evaluate the effect of metformin
      therapy on survival in women with breast cancer using methods that accounted for 
      the duration of treatment with glucose-lowering therapies.RESEARCH DESIGN AND
      METHODSThis population-based study, using Ontario health care databases,
      recruited women aged 66 years or older diagnosed with diabetes and breast cancer 
      between 1 April 1997 and 31 March 2008. Using Cox regression analyses, we
      explored the association between cumulative duration of past metformin use and
      all-cause and breast cancer-specific mortality. We modeled cumulative duration of
      past metformin use as a time-varying exposure.RESULTSOf 2,361 breast cancer
      patients identified, mean (+/- SD) age at cancer diagnosis was 77.4 +/- 6.3
      years, and mean follow-up was 4.5 +/- 3.0 years. There were 1,101 deaths(46.6%), 
      among which 386 (16.3%) were breast cancer-specific deaths. No significant
      association was found between cumulative duration of past metformin use and
      all-cause mortality (adjusted hazard ratio 0.97 [95% CI 0.92-1.02]) or breast
      cancer-specific mortality (0.91 [0.81-1.03]) per additional year of cumulative
      use.CONCLUSIONSOur findings failed to show an association between improved
      survival and increased cumulative metformin duration in older breast cancer
      patients who had recent-onset diabetes. Further research is needed to clarify
      this association, accounting for effects of cancer stage and BMI in younger
      populations or those with differing stages of diabetes as well as in nondiabetic 
      populations.
AD  - Women's College Research Institute, Women's College Hospital, Toronto, Ontario,
      Canada.
FAU - Lega, Iliana C
AU  - Lega IC
FAU - Austin, Peter C
AU  - Austin PC
FAU - Gruneir, Andrea
AU  - Gruneir A
FAU - Goodwin, Pamela J
AU  - Goodwin PJ
FAU - Rochon, Paula A
AU  - Rochon PA
FAU - Lipscombe, Lorraine L
AU  - Lipscombe LL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - dc12-2535 [pii]
AID - 10.2337/dc12-2535 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 30.

PMID- 23633524
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 30
TI  - Sucralose Affects Glycemic and Hormonal Responses to an Oral Glucose Load.
AB  - OBJECTIVENonnutritive sweeteners (NNS), such as sucralose, have been reported to 
      have metabolic effects in animal models. However, the relevance of these findings
      to human subjects is not clear. We evaluated the acute effects of sucralose
      ingestion on the metabolic response to an oral glucose load in obese
      subjects.RESEARCH DESIGN AND METHODSSeventeen obese subjects (BMI 42.3 +/- 1.6
      kg/m2) who did not use NNS and were insulin sensitive (based on a homeostasis
      model assessment of insulin resistance score </=2.6) underwent a 5-h modified
      oral glucose tolerance test on two separate occasions preceded by consuming
      either sucralose (experimental condition) or water (control condition) 10 min
      before the glucose load in a randomized crossover design. Indices of beta-cell
      function, insulin sensitivity (SI), and insulin clearance rates were estimated by
      using minimal models of glucose, insulin, and C-peptide kinetics.RESULTSCompared 
      with the control condition, sucralose ingestion caused 1) a greater incremental
      increase in peak plasma glucose concentrations (4.2 +/- 0.2 vs. 4.8 +/- 0.3
      mmol/L; P = 0.03), 2) a 20 +/- 8% greater incremental increase in insulin area
      under the curve (AUC) (P < 0.03), 3) a 22 +/- 7% greater peak insulin secretion
      rate (P < 0.02), 4) a 7 +/- 4% decrease in insulin clearance (P = 0.04), and 5) a
      23 +/- 20% decrease in SI (P = 0.01). There were no significant differences
      between conditions in active glucagon-like peptide 1, glucose-dependent
      insulinotropic polypeptide, glucagon incremental AUC, or indices of the
      sensitivity of the beta-cell response to glucose.CONCLUSIONSThese data
      demonstrate that sucralose affects the glycemic and insulin responses to an oral 
      glucose load in obese people who do not normally consume NNS.
AD  - Center for Human Nutrition, Washington University School of Medicine, St. Louis, 
      Missouri.
FAU - Pepino, M Yanina
AU  - Pepino MY
FAU - Tiemann, Courtney D
AU  - Tiemann CD
FAU - Patterson, Bruce W
AU  - Patterson BW
FAU - Wice, Burton M
AU  - Wice BM
FAU - Klein, Samuel
AU  - Klein S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - dc12-2221 [pii]
AID - 10.2337/dc12-2221 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 30.

PMID- 23633523
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 30
TI  - The Relationship Between Diabetic Retinopathy and Cognitive Impairment.
AB  - OBJECTIVERecent studies have shown an increased risk for cognitive impairment and
      dementia in patients with diabetes. An association between diabetic retinopathy
      (DR) and retinal microvasculature disease and cognitive impairment has been
      reported as potential evidence for a microvascular component to the cognitive
      impairment. It was hypothesized that severity of DR would be associated with
      cognitive impairment in individuals with type 2 diabetes.RESEARCH DESIGN AND
      METHODSThree hundred eighty patients with type 2 diabetes were recruited from a
      population-based eye screening program and grouped by severity of DR as follows: 
      no/mild DR (n = 252) and proliferative diabetic retinopathy (PDR) (n = 128). Each
      participant underwent psychosocial assessment; depression screening; ophthalmic
      and physical examination, including blood assays; and cognitive assessment with
      the Addenbrooke's Cognitive Examination-Revised (ACE-R), Mini-Mental State
      Examination (MMSE), and the Mini-Cog. General linear modeling was used to examine
      severity of DR and cognitive impairment, adjusting for
      confounders.RESULTSSeverity of DR demonstrated an inverse relationship with
      cognitive impairment (fully adjusted R2 = 0.415, P < 0.001). Ethnicity
      contributed most to the variance observed (16%) followed by education (7.3%) and 
      retinopathy status (6.8%). The no/mild DR group had lower cognitive impairment
      scores on ACE-R (adjusted mean +/- SE 77.0 +/- 1.9) compared with the PDR group
      (82.5 +/- 2.2, P < 0.001). The MMSE cutoff scores showed that 12% of the no/mild 
      DR group (n = 31) had positive screening results for dementia or significant
      cognitive impairment compared with 5% in the PDR group (n =
      6).CONCLUSIONSPatients with minimal DR demonstrated more cognitive impairment
      than those with advanced DR. Therefore, the increased prevalence of cognitive
      impairment in diabetes may be associated with factors other than evident retinal 
      microvascular disease.
AD  - Florence Nightingale School of Nursing and Midwifery, King's College London,
      London, U.K.
FAU - Crosby-Nwaobi, Roxanne R
AU  - Crosby-Nwaobi RR
FAU - Sivaprasad, Sobha
AU  - Sivaprasad S
FAU - Amiel, Stephanie
AU  - Amiel S
FAU - Forbes, Angus
AU  - Forbes A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - dc12-2141 [pii]
AID - 10.2337/dc12-2141 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 30.

PMID- 23633521
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 30
TI  - Loss of Kruppel-like Factor 3 (KLF3/BKLF) leads to upregulation of the
      insulin-sensitizing factor adipolin (FAM132A/CTRP12/C1qdc2).
AB  - Kruppel-like Factor 3 (KLF3) is a transcriptional regulator that we have shown to
      be involved in the regulation of adipogenesis in vitro. Here we report that KLF3 
      null mice are lean and protected from diet-induced obesity and glucose
      intolerance. On a chow diet, plasma levels of leptin are decreased, and
      adiponectin is increased. Despite significant reductions in body weight and
      adiposity, wildtype and knockout animals show equivalent energy intake,
      expenditure and excretion. To investigate the molecular events underlying these
      observations, we used microarray analysis to compare gene expression in Klf3+/+
      and Klf3-/- tissues. We found that mRNA expression of Fam132a, which encodes a
      newly identified insulin-sensitizing adipokine, adipolin, is significantly
      upregulated in the absence of KLF3. We confirmed that KLF3 binds the Fam132a
      promoter in vitro and in vivo and that this leads to repression of promoter
      activity. Further, plasma adipolin levels were significantly increased in Klf3-/-
      mice compared to wild-type littermates. Boosting levels of adipolin via targeting
      of KLF3 offers a novel potential therapeutic strategy for the treatment of
      insulin resistance.
AD  - School of Molecular Bioscience, University of Sydney, Sydney, NSW 2006,
      Australia.
FAU - Bell-Anderson, Kim S
AU  - Bell-Anderson KS
FAU - Funnell, Alister P
AU  - Funnell AP
FAU - Williams, Helen
AU  - Williams H
FAU - Jusoh, Hanapi Mat
AU  - Jusoh HM
FAU - Scully, Tiffany
AU  - Scully T
FAU - Lim, Wooi F
AU  - Lim WF
FAU - Burdach, Jon G
AU  - Burdach JG
FAU - Mak, Ka Sin
AU  - Mak KS
FAU - Knights, Alexander J
AU  - Knights AJ
FAU - Hoy, Andrew J
AU  - Hoy AJ
FAU - Nicholas, Hannah R
AU  - Nicholas HR
FAU - Sainsbury, Amanda
AU  - Sainsbury A
FAU - Turner, Nigel
AU  - Turner N
FAU - Pearson, Richard C
AU  - Pearson RC
FAU - Crossley, Merlin
AU  - Crossley M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - db12-1745 [pii]
AID - 10.2337/db12-1745 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 30.

PMID- 23633462
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
DP  - 2013 May 1
TI  - A polymorphism in an autophagy-related gene, ATG16L1, influences time to delivery
      in women with an unfavorable cervix who require labor induction.
PG  - 1-4
LID - 10.1515/jpm-2012-0278 [doi]
LID - /j/jpme.ahead-of-print/jpm-2012-0278/jpm-2012-0278.xml [pii]
AB  - Abstract Autophagy is an intracellular process that maintains homeostasis by the 
      removal of damaged organelles and proteins. A single nucleotide polymorphism
      (SNP) in the autophagy-related 16-like 1 (ATG16L1) gene results in decreased
      autophagy. We evaluated whether the ATG16L1 polymorphism influenced the time to
      delivery during labor induction in pregnant women with an unfavorable cervix. DNA
      from 69 women with an unfavorable cervix who required labor induction due to
      post-term (>294 days) (n=26), oligohydramnios (n=17), hypertension or
      pre-eclampsia (n=10), abnormal fetal heart rate (n=8), diabetes (n=3) or other
      reasons (n=5) was tested by gene amplification and endonuclease digestion for a
      SNP in ATG16L1 (rs2241880). The mean hours (SD) from induction to delivery was
      20.8 (9.7) for women who were A,A homozygotes, 19.2 (8.8) for A,G heterozygotes
      and 14.3 (6.6) for homozygote carriers of the G,G variant (P=0.03 A,A vs. G,G,
      P=0.04 A,A/A,G vs. G,G). The G,G prevalence was 24.4% and 4.2% for those who
      delivered in <24 and >24 h, respectively (P=0.04). There was no difference in
      genotype distribution by indication for induction. A decreased genetic capacity
      for autophagy may be beneficial in women with an unfavorable cervix whose labor
      has to be induced.
FAU - Doulaveris, Georgios
AU  - Doulaveris G
FAU - Orfanelli, Theofano
AU  - Orfanelli T
FAU - Benn, Kiesha
AU  - Benn K
FAU - Zervoudakis, Ioannis
AU  - Zervoudakis I
FAU - Skupski, Daniel
AU  - Skupski D
FAU - Witkin, Steven S
AU  - Witkin SS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/11/29 [received]
PHST- 2013/01/04 [accepted]
AID - 10.1515/jpm-2012-0278 [doi]
AID - /j/jpme.ahead-of-print/jpm-2012-0278/jpm-2012-0278.xml [pii]
PST - aheadofprint
SO  - J Perinat Med. 2013 May 1:1-4. doi: 10.1515/jpm-2012-0278.

PMID- 23633415
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130501
DCOM- 20130502
LR  - 20130507
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 4
DP  - 2013
TI  - Real-world outcomes of US employees with type 2 diabetes mellitus treated with
      insulin glargine or neutral protamine Hagedorn insulin: a comparative
      retrospective database study.
LID - 10.1136/bmjopen-2012-002348 [doi]
LID - e002348 [pii]
AB  - OBJECTIVES: To compare real-world outcomes of initiating insulin glargine (GLA)
      versus neutral protamine Hagedorn (NPH) insulin among employees with type 2
      diabetes mellitus (T2DM) who had both employer-sponsored health insurance and
      short-tem-disability coverages. DESIGN: Retrospective cohort study. SETTING:
      MarketScan Commercial Claims and Encounters/Health and Productivity Management
      Databases 2003-2009. PARTICIPANTS: Adult employees with T2DM who were previously 
      treated with oral antidiabetic drugs and/or glucagon-like-peptide 1 receptor
      agonists and initiated GLA or NPH were included if they were continuously
      enrolled in healthcare and short-term-disability coverages for 3 months before
      (baseline) and 1 year after (follow-up) initiation. Treatment selection bias was 
      addressed by 2:1 propensity score matching. Sensitivity analyses were conducted
      using different matching ratios. PRIMARY AND SECONDARY OUTCOME MEASURES: Outcomes
      during 1-year follow-up were measured and compared: insulin treatment persistence
      and adherence; hypoglycaemia rates and daily average consumption of insulin;
      total and diabetes-specific healthcare resource utilisation and costs and loss in
      productivity, as measured by short-term disability, and the associated costs.
      RESULTS: A total of 534 patients were matched and analysed (GLA: 356; NPH 178)
      with no significant differences in baseline characteristics. GLA patients were
      more persistent and adherent (both p<0.05), had lower rates of hospitalisation
      (23% vs 31.4%; p=0.036) and endocrinologist visits (19.1% vs 26.9%; p=0.038),
      similar hypoglycaemia rates (both 4.4%; p=1.0), higher diabetes drug costs ($2031
      vs $1522; p<0.001), but similar total healthcare costs ($14 550 vs $16 093;
      p=0.448) and total diabetes-related healthcare costs ($4686 vs $5604; p=0.416).
      Short-term disability days and costs were numerically lower in the GLA cohort
      (16.0 vs 24.5 days; p=0.086 and $2824 vs $4363; p=0.081, respectively).
      Sensitivity analyses yielded similar findings. CONCLUSIONS: Insulin GLA results
      in better persistence and adherence, compared with NPH insulin, with no overall
      cost disadvantages. Better persistence and adherence may lead to long-term health
      benefits for employees with T2DM.
AD  - STATinMED Research, Ann Arbor, Michigan, USA.
FAU - Wang, Li
AU  - Wang L
FAU - Wei, Wenhui
AU  - Wei W
FAU - Miao, Raymond
AU  - Miao R
FAU - Xie, Lin
AU  - Xie L
FAU - Baser, Onur
AU  - Baser O
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3641450
OID - NLM: PMC3641450
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:01
CRDT- 2013/05/02 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2012-002348 [pii]
AID - 10.1136/bmjopen-2012-002348 [doi]
PST - epublish
SO  - BMJ Open. 2013 Apr 30;3(4). pii: e002348. doi: 10.1136/bmjopen-2012-002348. Print
      2013.

PMID- 23633368
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 4
DP  - 2013
TI  - Workplace pedometer interventions for increasing physical activity.
PG  - CD009209
LID - 10.1002/14651858.CD009209.pub2 [doi]
AB  - BACKGROUND: The World Health Organization and the World Economic Forum have
      recommended further research to strengthen current knowledge of workplace health 
      programmes, particularly on effectiveness and using simple instruments. A
      pedometer is one such simple instrument that can be incorporated in workplace
      interventions. OBJECTIVES: To assess the effectiveness of pedometer interventions
      in the workplace for increasing physical activity and improving subsequent health
      outcomes. SEARCH METHODS: Electronic searches of the Cochrane Central Register of
      Controlled Trials (671 potential papers), MEDLINE (1001), Embase (965), CINAHL
      (1262), OSH UPDATE databases (75) and Web of Science (1154) from the earliest
      record to between 30th January and 6th February 2012 yielded 3248 unique records.
      Reference lists of articles yielded an additional 34 papers. Contact with
      individuals and organisations did not produce any further records. SELECTION
      CRITERIA: We included individual and cluster-randomised controlled trials of
      workplace health promotion interventions with a pedometer component in employed
      adults. The primary outcome was physical activity and was part of the eligibility
      criteria. We considered subsequent health outcomes, including adverse effects, as
      secondary outcomes. DATA COLLECTION AND ANALYSIS: Two review authors undertook
      the screening of titles and abstracts and the full-text papers independently. Two
      review authors (RFP and MC) independently completed data extraction and risk of
      bias assessment. We contacted authors to obtain additional data and
      clarification. MAIN RESULTS: We found four relevant studies providing data for
      1809 employees, 60% of whom were allocated to the intervention group. All studies
      assessed outcomes immediately after the intervention had finished and the
      intervention duration varied between three to six months. All studies had usual
      treatment control conditions; however one study's usual treatment was an
      alternative physical activity programme while the other three had minimally
      active controls. In general, there was high risk of bias mainly due to lack of
      blinding, self reported outcome measurement, incomplete outcome data due to
      attrition, and most of the studies had not published protocols, which increases
      the likelihood of selective reporting.Three studies compared the pedometer
      programme to a minimally active control group, but the results for physical
      activity could not be combined because each study used a different measure of
      activity. One study observed an increase in physical activity under a pedometer
      programme, but the other two did not find a significant difference. For secondary
      outcomes we found improvements in body mass index, waist circumference, fasting
      plasma glucose, the quality of life mental component and worksite injury
      associated with the pedometer programmes, but these results were based on limited
      data from one or two small studies. There were no differences between the
      pedometer programme and the control group for blood pressure, a number of
      biochemical outcomes and the quality of life physical component. Sedentary
      behaviour and disease risk scores were not measured by any of the included
      studies.One study compared a pedometer programme and an alternative physical
      activity programme, but baseline imbalances made it difficult to distinguish the 
      true improvements associated with either programme.Overall, there was
      insufficient evidence to assess the effectiveness of pedometer interventions in
      the workplace.There is a need for more high quality randomised controlled trials 
      to assess the effectiveness of pedometer interventions in the workplace for
      increasing physical activity and improving subsequent health outcomes. To improve
      the quality of the evidence available, future studies should be registered in an 
      online trials register, publish a protocol, allocate time and financial support
      to reducing attrition, and try to blind personnel (especially those who undertake
      measurement). To better identify the effects of pedometer interventions, future
      studies should report a core set of outcomes (total physical activity in METs,
      total time sitting in hours and minutes, objectively measured cardiovascular
      disease and type II diabetes risk factors, quality of life and injury), assess
      outcomes in the long term and undertake subgroup analyses based upon demographic 
      subgroups (e.g. age, gender, educational status). Future studies should also
      compare different types of active intervention to test specific intervention
      components (eligibility, duration, step goal, step diary, settings), and settings
      (occupation, intervention provider). AUTHORS' CONCLUSIONS: There was limited and 
      low quality data providing insufficient evidence to assess the effectiveness of
      pedometer interventions in the workplace for increasing physical activity and
      improving subsequent health outcomes.
AD  - Department of Epidemiology and Preventive Medicine, School of Public Health and
      Preventive Medicine, Monash University, Alfred Hospital, Commercial Road,
      Melbourne, Victoria, Australia, 3004.
FAU - Freak-Poli, Rosanne L A
AU  - Freak-Poli RL
FAU - Cumpston, Miranda
AU  - Cumpston M
FAU - Peeters, Anna
AU  - Peeters A
FAU - Clemes, Stacy A
AU  - Clemes SA
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - England
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1002/14651858.CD009209.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2013 Apr 30;4:CD009209. doi:
      10.1002/14651858.CD009209.pub2.

PMID- 23633364
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 4
DP  - 2013
TI  - Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
PG  - CD009008
LID - 10.1002/14651858.CD009008.pub2 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a growing health problem
      worldwide. Whether sulphonylureas show better, equal or worse therapeutic effects
      in comparison with other antidiabetic interventions for patients with T2DM
      remains controversial. OBJECTIVES: To assess the effects of sulphonylurea
      monotherapy versus placebo, no intervention or other antidiabetic interventions
      for patients with T2DM. SEARCH METHODS: We searched publications in The Cochrane 
      Library, MEDLINE, EMBASE, Science Citation Index Expanded, LILACS and CINAHL (all
      until August 2011) to obtain trials fulfilling the inclusion criteria for our
      review. SELECTION CRITERIA: We included clinical trials that randomised patients 
      18 years old or more with T2DM to sulphonylurea monotherapy with a duration of 24
      weeks or more. DATA COLLECTION AND ANALYSIS: Two authors independently assessed
      the risk of bias. The primary outcomes were all-cause and cardiovascular
      mortality. Secondary outcomes were other patient-important outcomes and metabolic
      variables. Where possible, we used risk ratios (RR) with 95% confidence intervals
      (95% CI) to analyse the treatment effect of dichotomous outcomes. We used mean
      differences with 95% CI to analyse the treatment effect of continuous outcomes.
      We evaluated the risk of bias. We conducted trial sequential analyses to assess
      whether firm evidence could be established for a 10% relative risk reduction
      (RRR) between intervention groups. MAIN RESULTS: We included 72 randomised
      controlled trials (RCTs) with 22,589 participants; 9707 participants randomised
      to sulphonylureas versus 12,805 participants randomised to control interventions.
      The duration of the interventions varied from 24 weeks to 10.7 years. We judged
      none of the included trials as low risk of bias for all bias domains.
      Patient-important outcomes were seldom reported.First-generation sulphonylureas
      (FGS) versus placebo or insulin did not show statistical significance for
      all-cause mortality (versus placebo: RR 1.46, 95% CI 0.87 to 2.45; P = 0.15; 2
      trials; 553 participants; high risk of bias (HRB); versus insulin: RR 1.18, 95%
      CI 0.88 to 1.59; P = 0.26; 2 trials; 1944 participants; HRB). FGS versus placebo 
      showed statistical significance for cardiovascular mortality in favour of placebo
      (RR 2.63, 95% CI 1.32 to 5.22; P = 0.006; 2 trials; 553 participants; HRB). FGS
      versus insulin did not show statistical significance for cardiovascular mortality
      (RR 1.36, 95% CI 0.68 to 2.71; P = 0.39; 2 trials; 1944 participants; HRB). FGS
      versus alpha-glucosidase inhibitors showed statistical significance in favour of 
      FGS for adverse events (RR 0.63, 95% CI 0.52 to 0.76; P = 0.01; 2 trials; 246
      participants; HRB) and for drop-outs due to adverse events (RR 0.28, 95% CI 0.12 
      to 0.67; P = 0.004; 2 trials; 246 participants; HRB).Second-generation
      sulphonylureas (SGS) versus metformin (RR 0.98, 95% CI 0.61 to 1.58; P = 0.68; 6 
      trials; 3528 participants; HRB), thiazolidinediones (RR 0.92, 95% CI 0.60 to
      1.41; P = 0.70; 7 trials; 4955 participants; HRB), insulin (RR 0.96, 95% CI 0.79 
      to 1.18; P = 0.72; 4 trials; 1642 participants; HRB), meglitinides (RR 1.44, 95% 
      CI 0.47 to 4.42; P = 0.52; 7 trials; 2038 participants; HRB), or incretin-based
      interventions (RR 1.39, 95% CI 0.52 to 3.68; P = 0.51; 2 trials; 1503
      participants; HRB) showed no statistically significant effects regarding
      all-cause mortality in a random-effects model. SGS versus metformin (RR 1.47; 95%
      CI 0.54 to 4.01; P = 0.45; 6 trials; 3528 participants; HRB), thiazolidinediones 
      (RR 1.30, 95% CI 0.55 to 3.07; P = 0.55; 7 trials; 4955 participants; HRB),
      insulin (RR 0.96, 95% CI 0.73 to 1.28; P = 0.80; 4 trials; 1642 participants;
      HRB) or meglitinide (RR 0.97, 95% CI 0.27 to 3.53; P = 0.97; 7 trials, 2038
      participants, HRB) showed no statistically significant effects regarding
      cardiovascular mortality. Mortality data for the SGS versus placebo were sparse. 
      SGS versus thiazolidinediones and meglitinides did not show statistically
      significant differences for a composite of non-fatal macrovascular outcomes. SGS 
      versus metformin showed statistical significance in favour of SGS for a composite
      of non-fatal macrovascular outcomes (RR 0.67, 95% CI 0.48 to 0.93; P = 0.02; 3018
      participants; 3 trials; HRB). The definition of non-fatal macrovascular outcomes 
      varied among the trials. SGS versus metformin, thiazolidinediones and
      meglitinides showed no statistical significance for non-fatal myocardial
      infarction. No meta-analyses could be performed for microvascular outcomes. SGS
      versus placebo, metformin, thiazolidinediones, alpha-glucosidase inhibitors or
      meglitinides showed no statistical significance for adverse events. SGS versus
      alpha-glucosidase inhibitors showed statistical significance in favour of SGS for
      drop-outs due to adverse events (RR 0.48, 95% CI 0.24 to 0.96; P = 0.04; 9
      trials; 870 participants; HRB). SGS versus meglitinides showed no statistical
      significance for the risk of severe hypoglycaemia. SGS versus metformin and
      thiazolidinediones showed statistical significance in favour of metformin (RR
      5.64, 95% CI 1.22 to 26.00; P = 0.03; 4 trials; 3637 participants; HRB) and
      thiazolidinediones (RR 6.11, 95% CI 1.57 to 23.79; P = 0.009; 6 trials; 5660
      participants; HRB) for severe hypoglycaemia.Third-generation sulphonylureas (TGS)
      could not be included in any meta-analysis of all-cause mortality, cardiovascular
      mortality or non-fatal macro- or microvascular outcomes. TGS versus
      thiazolidinediones showed statistical significance regarding adverse events in
      favour of TGS (RR 0.88, 95% CI 0.78 to 0.99; P = 0.03; 3 trials; 510
      participants; HRB). TGS versus thiazolidinediones did not show any statistical
      significance for drop-outs due to adverse events. TGS versus other comparators
      could not be performed due to lack of data.For the comparison of SGS versus FGS
      no meta-analyses of all-cause mortality, cardiovascular mortality, non-fatal
      macro- or microvascular outcomes, or adverse events could be
      performed.Health-related quality of life and costs of intervention could not be
      meta-analysed due to lack of data.In trial sequential analysis, none of the
      analyses of mortality outcomes, vascular outcomes or severe hypoglycaemia met the
      criteria for firm evidence of a RRR of 10% between interventions. AUTHORS'
      CONCLUSIONS: There is insufficient evidence from RCTs to support the decision as 
      to whether to initiate sulphonylurea monotherapy. Data on patient-important
      outcomes are lacking. Therefore, large-scale and long-term randomised clinical
      trials with low risk of bias, focusing on patient-important outcomes are
      required.
AD  - Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department
      7812, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, 
      Denmark, DK-2100.
FAU - Hemmingsen, Bianca
AU  - Hemmingsen B
FAU - Schroll, Jeppe B
AU  - Schroll JB
FAU - Lund, Soren S
AU  - Lund SS
FAU - Wetterslev, Jorn
AU  - Wetterslev J
FAU - Gluud, Christian
AU  - Gluud C
FAU - Vaag, Allan
AU  - Vaag A
FAU - Sonne, David Peick
AU  - Sonne DP
FAU - Lundstrom, Lars H
AU  - Lundstrom LH
FAU - Almdal, Thomas
AU  - Almdal T
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - England
TA  - Cochrane Database Syst Rev
JT  - Cochrane database of systematic reviews (Online)
JID - 100909747
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1002/14651858.CD009008.pub2 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2013 Apr 30;4:CD009008. doi:
      10.1002/14651858.CD009008.pub2.

PMID- 23633267
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1559-0291 (Electronic)
IS  - 0273-2289 (Linking)
VI  - 170
IP  - 4
DP  - 2013 Jun
TI  - Extrinsic factors promoting in vitro differentiation of insulin-secreting cells
      from human adipose tissue-derived mesenchymal stem cells.
PG  - 962-71
LID - 10.1007/s12010-013-0250-y [doi]
AB  - Understanding of beta cell regeneration is needed to develop new treatment
      modalities in diabetes mellitus. We present our experience of glucose-sensitive
      insulin-secreting mesenchymal stem cells (IS-MSC) generated and differentiated
      from human adipose tissue (h-AD) with application of specific differentiation
      media, sans xenogenic material. h-AD from donor abdominal wall was collected in
      proliferation medium composed of alpha-Minimum Essential Media, albumin,
      fibroblast-growth factor and antibiotics, minced, incubated in collagenase I at
      37 degrees C with shaker and centrifuged. Supernatant and pellets were separately
      cultured in proliferation medium on cell + plates at 37 degrees C with 5 % CO2
      for 10 days. Cells were harvested, checked for viability, sterility,
      quantification, flow-cytometry (CD45(-)/90(+)/73(+)), and differentiated into
      insulin-expressing cells using medium composed of Dulbecco's modified eagle's
      medium, gene expressing upregulators and antibiotics for 3 days. They were
      studied for transcriptional factors paired box genes-6(Pax-6), islet 1
      transcriptional factor (Isl-1), pancreatic and duodenal homobox-1(Pdx-1).
      C-peptide and insulin were measured by chemiluminescence. IS-MSC showed presence 
      of all three transcriptional factors and showed rise in insulin and c-peptide
      level in presence of glucose stimuli. It can be concluded that the specific
      extrinsic factors used in the defined differentiation media effectively and
      safely promote differentiation of glucose-sensitive insulin-secreting cells from 
      human adipose tissue, without any genetic modulation.
AD  - Department of Pathology, Laboratory Medicine, Transfusion Services and
      Immunohematology, G. R. Doshi and K. M. Mehta Institute Of Kidney Diseases &
      Research Centre (IKDRC)- Dr. H.L. Trivedi Institute of Transplantation Sciences
      (ITS), Civil Hospital Campus, Asarwa, Ahmedabad, 380016, Gujarat, India,
      shrutiddave@yahoo.com.
FAU - Dave, S D
AU  - Dave SD
FAU - Vanikar, A V
AU  - Vanikar AV
FAU - Trivedi, H L
AU  - Trivedi HL
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - Appl Biochem Biotechnol
JT  - Applied biochemistry and biotechnology
JID - 8208561
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/01/25 [received]
PHST- 2013/04/21 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1007/s12010-013-0250-y [doi]
PST - ppublish
SO  - Appl Biochem Biotechnol. 2013 Jun;170(4):962-71. doi: 10.1007/s12010-013-0250-y. 
      Epub 2013 Apr 30.

PMID- 23633238
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1523-4681 (Electronic)
IS  - 0884-0431 (Linking)
DP  - 2013 Apr 30
TI  - Muscle size, strength and physical performance and their associations with bone
      structure in the Hertfordshire Cohort Study.
LID - 10.1002/jbmr.1972 [doi]
AB  - Sarcopenia is associated with a greater fracture risk; this relationship was
      originally thought to be explained by an increased risk of falls in sarcopenic
      individuals. However, in addition, there is growing evidence of a functional
      muscle-bone unit in which bone health may be directly influenced by muscle
      function. Since a definition of sarcopenia encompasses muscle size, strength and 
      physical performance, we investigated relationships for each of these with bone
      size, bone density and bone strength to interrogate these hypotheses further in
      participants from the Hertfordshire Cohort Study. 313 men and 318 women underwent
      baseline assessment of health and detailed anthropometric measurements. Muscle
      strength was measured by grip strength and physical performance was determined by
      gait speed. Peripheral quantitative computed tomography (pQCT) examination of the
      calf and forearm was performed to assess muscle cross-sectional area (mCSA) at
      the 66% level, and bone structure (radius and tibia, 4% and 66% levels). Muscle
      size was positively associated with bone size (distal radius total bone area beta
      = 17.5mm2 /SD [12.0, 22.9]) and strength (strength strain index (beta = 23.3mm3
      /SD [18.2, 28.4]) amongst women (p < 0.001). These associations were also seen in
      men and were maintained after adjustment for age, height,
      weight-adjusted-for-height, limb length-adjusted-for-height, social class,
      smoking status, alcohol consumption, calcium intake, physical activity, diabetes 
      mellitus, and in women, years since menopause and estrogen replacement therapy.
      While grip strength showed similar associations with bone size and strength in
      both sexes, these were substantially attenuated after similar adjustment.
      Consistent relationships between gait speed and bone structure were not seen. We 
      conclude that while muscle size and grip strength are associated with bone size
      and strength, relationships between gait speed and bone structure and strength
      were not apparent in this cohort, supporting a role for the muscle-bone unit.
CI  - Copyright (c) 2013 American Society for Bone and Mineral Research.
AD  - MRC Lifecourse Epidemiology Unit, University of Southampton, University Hospital 
      Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK.
FAU - Edwards, Mh
AU  - Edwards M
FAU - Gregson, Cl
AU  - Gregson C
FAU - Patel, Hp
AU  - Patel H
FAU - Jameson, Ka
AU  - Jameson K
FAU - Harvey, Nc
AU  - Harvey N
FAU - Sayer, A Aihie
AU  - Sayer AA
FAU - Dennison, Em
AU  - Dennison E
FAU - Cooper, C
AU  - Cooper C
LA  - ENG
GR  - MC_UP_A620_1015/Medical Research Council/United Kingdom
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Bone Miner Res
JT  - Journal of bone and mineral research : the official journal of the American
      Society for Bone and Mineral Research
JID - 8610640
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/01/29 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/17 [accepted]
AID - 10.1002/jbmr.1972 [doi]
PST - aheadofprint
SO  - J Bone Miner Res. 2013 Apr 30. doi: 10.1002/jbmr.1972.

PMID- 23633210
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 6
DP  - 2013 Jun
TI  - Metabolic Signature Shift in Type 2 Diabetes Mellitus Revealed by Mass
      Spectrometry-based Metabolomics.
PG  - E1060-5
LID - 10.1210/jc.2012-4132 [doi]
AB  - Objective: Metabolic profiling of small molecules offers a snapshot of
      physiological processes. To identify metabolic signatures associated with type 2 
      diabetes and impaired fasting glucose (IFG) beyond differences in glucose, we
      used mass spectrometry-based metabolic profiling. Research Design and Methods:
      Individuals attending an institutional health screen were enrolled. IFG (n = 24) 
      was defined as fasting glucose (FG) of 6.1 to 6.9 mmol/L and 2-hour post glucose 
      load <11.1 mmol/L or glycosylated hemoglobin <6.5%, type 2 diabetes (n = 27), FG 
      >/=7.0 mmol/L, or 2-hour post glucose load >/=11.1 mmol/L, or glycosylated
      hemoglobin >/=6.5%, and healthy controls (n = 60), FG <6.1 mmol/L. Fasting serum 
      metabolomes were profiled and compared using gas chromatography/mass spectrometry
      and liquid chromatography/mass spectrometry. Results: Compared to healthy
      controls, those with IFG and type 2 diabetes had significantly raised fructose,
      alpha-hydroxybutyrate, alanine, proline, phenylalanine, glutamine, branched-chain
      amino acids (leucine, isoleucine, and valine), low carbon number lipids
      (myristic, palmitic, and stearic acid), and significantly reduced pyroglutamic
      acid, glycerophospohlipids, and sphingomyelins, even after adjusting for age,
      gender, and body mass index. Conclusions: Using 2 highly sensitive metabolomic
      techniques, we report distinct serum profile change of a wide range of
      metabolites from healthy persons to type 2 diabetes mellitus. Apart from glucose,
      IFG and diabetes mellitus are characterized by abnormalities in amino acid, fatty
      acids, glycerophospholipids, and sphingomyelin metabolism. These early
      broad-spectrum metabolic changes emphasize the complex abnormalities present in a
      disease defined mainly by elevated blood glucose levels.
AD  - School of Public Health, National University of Singapore, 16 Medical Drive MD3, 
      Singapore 117597. ephocn@nus.edu.sg.
FAU - Xu, Fengguo
AU  - Xu F
FAU - Tavintharan, Subramaniam
AU  - Tavintharan S
FAU - Sum, Chee Fang
AU  - Sum CF
FAU - Woon, Kaing
AU  - Woon K
FAU - Lim, Su Chi
AU  - Lim SC
FAU - Ong, Choon Nam
AU  - Ong CN
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [aheadofprint]
AID - jc.2012-4132 [pii]
AID - 10.1210/jc.2012-4132 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Jun;98(6):E1060-5. doi: 10.1210/jc.2012-4132. Epub 
      2013 Apr 30.

PMID- 23633202
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Apr 30
TI  - Relation Between Circulating Levels of 25(OH) Vitamin D and Parathyroid Hormone
      in Chronic Kidney Disease: Quest for a Threshold.
AB  - Context:Vitamin D deficiency is common in patients with chronic kidney disease
      (CKD). Current guidelines recommend treatment strategies in these patients
      similar to those for the general population, but the vitamin D nutritional status
      sufficient to prevent PTH levels from increasing in CKD is unknown.Objective,
      Main Outcome Measure:To study the relation between circulating PTH and 25(OH)D
      levels and to search for a 25(OH)D threshold associated with a significant PTH
      increase.Design, Setting, and Patients:In the hospital-referred NephroTest cohort
      study, we measured 25(OH)D, PTH, and glomerular filtration rate (mGFR) by
      51Cr-EDTA renal clearance in 929 adult patients with nondialysis CKD stages 1 to 
      5 and no vitamin D supplementation. Patients' mean age was 60.1 +/- 14.7 years;
      71% were men, and 9% were black. Their mean mGFR was 37.8 mL/min/1.73
      m2.Results:We found a 25(OH)D threshold of 8 ng/mL with an upper limit of 20
      ng/mL (95% confidence interval) by linear piecewise regression modeling of
      log-PTH for 25(OH)D adjusted for mGFR, age, race, and ionized calcium level. The 
      smoothed curve confirmed that PTH concentration rose steeply when circulating
      25(OH)D levels fell to less than 20 ng/mL.Conclusions:Spontaneous 25(OH)D levels 
      greater than 20 ng/mL seem sufficient to control serum PTH in CKD patients. This 
      result reinforces guidelines to supplement vitamin D only if less than 30 ng/mL.
AD  - Institut National de la Sante et de la Recherche Medicale (INSERM) (M.M., C.G.,
      M.Fr., B.S.), CESP Centre for Research in Epidemiology and Population Health,
      U1018, Diabetes, Obesity, and Chronic Kidney Disease Epidemiology Team, 94807
      Villejuif, France; Universite Paris Sud 11 (M.M., C.G., B.S.), Unite Mixte de
      Recherche (UMR) S 1018, F-94807, Villejuif, France; Departments of Physiology and
      Nephrology (C.G., P.H., E.T.), Hopital Europeen G Pompidou, Assistance
      Publique-Hopitaux de Paris, France; Universite Paris Descartes (P.H., E.T.,
      M.Fr., P.U.-T.), Sorbonne Paris Cite, France; INSERM UMR S 872 (P.H.), Paris,
      France; Departments of Physiology (J.P.H., J.-J.B.) and Nephrology, Hopital
      Tenon, Assistance Publique-Hopitaux de Paris, Paris, France; Universite Pierre et
      Marie Curie (J.P.H., J.-J.B.), Paris, France; INSERM UMR S 702 (J.P.H., J.-J.B.),
      Paris, France; Departments of Physiology (M.Fl., F.V.) and Nephrology, Hopital
      Bichat, Assistance Publique-Hopitaux de Paris, Paris, France; Universite Paris
      Diderot (M.Fl., F.V.), Paris, France; INSERM UMR S 699 (M.Fl., F.V.), Paris,
      France; INSERM UMR S 775 (M.Fr.), Paris, France; and Nephology Dialysis
      (P.U.-T.), Clinique du Landy, St Ouen, France.
FAU - Metzger, Marie
AU  - Metzger M
FAU - Houillier, Pascal
AU  - Houillier P
FAU - Gauci, Cedric
AU  - Gauci C
FAU - Haymann, Jean Philippe
AU  - Haymann JP
FAU - Flamant, Martin
AU  - Flamant M
FAU - Thervet, Eric
AU  - Thervet E
FAU - Boffa, Jean-Jacques
AU  - Boffa JJ
FAU - Vrtovsnik, Francois
AU  - Vrtovsnik F
FAU - Froissart, Marc
AU  - Froissart M
FAU - Stengel, Benedicte
AU  - Stengel B
FAU - Urena-Torres, Pablo
AU  - Urena-Torres P
CN  - on behalf of the NephroTest Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - jc.2013-1294 [pii]
AID - 10.1210/jc.2013-1294 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Apr 30.

PMID- 23633201
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 5
DP  - 2013 May
TI  - Effects of ingestion routes on hormonal and metabolic profiles in
      gastric-bypassed humans.
PG  - E856-61
LID - 10.1210/jc.2012-3996 [doi]
AB  - Context: Gastric bypass surgery (GBP) results in the rapid resolution of type 2
      diabetes. Most studies aiming to explain the underlying mechanisms are limited to
      data obtained after a postsurgical recovery period, making assessment of
      confounding influences from, for example, weight loss and altered nutrient intake
      difficult. Objective: To examine the impact of GBP on hormonal and metabolite
      profiles under conditions of identical nutrient intake independent of weight
      loss, we studied GBP patients fitted with a gastrostomy tube to enable the
      administration of nutrients to bypassed segments of the gut. Thus, this model
      allowed us to simulate partially the preoperative condition and compare this with
      the postoperative situation in the same patient. Design: Patients (n = 4) were
      first given a mixed meal test (MMT) orally and then via the gastrostomy tube,
      preceded by overnight and 2-hour fasting, respectively. Blood samples were
      assessed for hormones and metabolites. Results: The oral MMT yielded 4.6-fold
      increase in plasma insulin (P < .05), 2-fold in glucagon-like peptide-1 (P <
      .05), and 2.5-fold in glucose-dependent insulinotropic peptide (P < .05) plasma
      levels, compared with the gastrostomy MMT. The changes in hormone levels were
      accompanied by elevated branched-chain amino acid levels (1.4-2-fold, P < .05)
      and suppressed fatty acid levels ( approximately 50%, P < .05). Conclusions:
      These data, comparing identical nutrient delivery, demonstrate markedly higher
      incretin and insulin responses after oral MMT than after gastric MMT, thereby
      providing a potential explanation for the rapid remission of type 2 diabetes
      observed after GBP. The simultaneous increase in branched-chain amino acid
      questions its role as a marker for insulin resistance.
AD  - PhD, Neuroendocrine Cell Biology, Department of Clinical Sciences in Malmo, Lund 
      University Diabetes Centre, Scania University Hospital, Clinical Research Centre,
      Jan Waldenstroms gata 35, SE-205 02 Malmo, Sweden. nils.wierup@med.lu.se.
FAU - Lindqvist, Andreas
AU  - Lindqvist A
FAU - Spegel, Peter
AU  - Spegel P
FAU - Ekelund, Mikael
AU  - Ekelund M
FAU - Mulder, Hindrik
AU  - Mulder H
FAU - Groop, Leif
AU  - Groop L
FAU - Hedenbro, Jan
AU  - Hedenbro J
FAU - Wierup, Nils
AU  - Wierup N
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [aheadofprint]
AID - jc.2012-3996 [pii]
AID - 10.1210/jc.2012-3996 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 May;98(5):E856-61. doi: 10.1210/jc.2012-3996. Epub 
      2013 Apr 30.

PMID- 23633196
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 6
DP  - 2013 Jun
TI  - Joint effect of insulin signaling genes on insulin secretion and glucose
      homeostasis.
PG  - E1143-7
LID - 10.1210/jc.2012-4282 [doi]
AB  - Context: Reduced insulin signaling in insulin secreting beta-cells causes
      defective insulin secretion and hyperglycemia in mice. Objective: We investigated
      whether functional polymorphisms affecting insulin signaling (ie, ENPP1 K121Q,
      rs1044498; IRS1 G972R, rs1801278; and TRIB3 Q84R, rs2295490) exert a joint effect
      on insulin secretion and abnormal glucose homeostasis (AGH). Design: Insulin
      secretion was evaluated by 1) the disposition index (DI) from an oral glucose
      tolerance test (OGTT) in 829 individuals; 2) insulin secretion stimulation index 
      (SI) in islets from nondiabetic donors after glucose (n = 92) or glibenclamide (n
      = 89) stimulation. AGH (including impaired fasting glucose and/or impaired
      glucose tolerance or type 2 diabetes; T2D) was evaluated in case-control studies 
      from the GENetics of Type 2 Diabetes in Italy and the United States (GENIUS T2D) 
      Consortium (n = 6607). Results: Genotype risk score, obtained by totaling
      individual weighted risk allele effects, was associated with the following: 1) DI
      (P = .005); 2) glucose and glibenclamide SI (P = .046 and P = .009); or 3) AGH
      (odds ratio 1.08, 95% confidence interval 1.03-1.13; P = .001). We observed an
      inverse relationship between genetic effect and age at AGH onset, as indicated by
      a linear correlation between AGH-genotype risk score odds ratios and
      age-at-diagnosis cutoffs (R(2) = 0.80, P < .001). Conclusions: Functional
      polymorphisms affecting insulin signaling exert a joint effect on both in vivo
      and in vitro insulin secretion as well as on early-onset AGH. Our data provide
      further evidence that abnormal insulin signaling reduces beta-cell function and
      impairs glucose homeostasis.
AD  - PhD, CSS-Mendel Institute, Viale Regina Margherita 261, 00198 Rome, Italy.
      s.prudente@css-mendel.it.
FAU - Prudente, Sabrina
AU  - Prudente S
FAU - Morini, Eleonora
AU  - Morini E
FAU - Marselli, Lorella
AU  - Marselli L
FAU - Baratta, Roberto
AU  - Baratta R
FAU - Copetti, Massimiliano
AU  - Copetti M
FAU - Mendonca, Christine
AU  - Mendonca C
FAU - Andreozzi, Francesco
AU  - Andreozzi F
FAU - Chandalia, Manisha
AU  - Chandalia M
FAU - Pellegrini, Fabio
AU  - Pellegrini F
FAU - Bailetti, Diego
AU  - Bailetti D
FAU - Alberico, Federica
AU  - Alberico F
FAU - Shah, Hetal
AU  - Shah H
FAU - Abate, Nicola
AU  - Abate N
FAU - Sesti, Giorgio
AU  - Sesti G
FAU - Frittitta, Lucia
AU  - Frittitta L
FAU - Marchetti, Piero
AU  - Marchetti P
FAU - Doria, Alessandro
AU  - Doria A
FAU - Trischitta, Vincenzo
AU  - Trischitta V
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [aheadofprint]
AID - jc.2012-4282 [pii]
AID - 10.1210/jc.2012-4282 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Jun;98(6):E1143-7. doi: 10.1210/jc.2012-4282. Epub 
      2013 Apr 30.

PMID- 23633194
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Apr 30
TI  - The DPP-4 inhibitor linagliptin restores beta-cell function & survival in human
      isolated islets through GLP-1 stabilization.
AB  - Context.Inhibition of Dipeptidyl peptidase-4 (DPP-4) is a potent strategy to
      increase GIP and GLP-1 induced insulin secretion in diabetes. It is important to 
      know if new drugs approved for the treatment of type 2 diabetes have direct
      effects on the beta-cell.Objective.Herein, we investigated the effect of
      linagliptin, a novel DPP-4 inhibitor, on beta-cell function and
      survival.Design.Human islets were exposed to a diabetic milieu (11.1-33.3 mM
      glucose, 0.5 mM palmitic acid, the mixture of 2 ng/ml IL-1beta+1,000 U/ml
      IFN-gamma or 50 muM H2O2) with or without 500 ng/ml Interleukin-1Receptor
      Antagonist (IL-1Ra) or 30-50 nM linagliptin.Results.Linagliptin restored
      beta-cell function and turnover, which was impaired when islets were exposed to
      elevated glucose, palmitate, cytokines or H2O2. Pre-treatment with IL-1Ra was
      similarly effective, except against H2O2 treatment. Nitrotyrosine concentrations 
      in islet lysates, an indicator of oxidative stress, were highly elevated under
      diabetic conditions, but not in islets treated with linagliptin or IL-1Ra.
      Linagliptin also reduced cytokine secretion and stabilized GLP-1 in islet
      supernatants.Conclusions.We show that the novel DPP-4 inhibitor linagliptin
      protected from gluco-, lipo- and cytokine-toxicity and stabilized active GLP-1
      secreted from human islets. This provides a direct GLP-1 mediated protective
      effect of linagliptin on beta-cell function and survival.
AD  - 1Centre for Biomolecular Interactions Bremen, University of Bremen, Germany.
FAU - Shah, Payal
AU  - Shah P
FAU - Ardestani, Amin
AU  - Ardestani A
FAU - Dharmadhikari, Gitanjali
AU  - Dharmadhikari G
FAU - Laue, Svenja
AU  - Laue S
FAU - Schumann, Desiree M
AU  - Schumann DM
FAU - Kerr-Conte, Julie
AU  - Kerr-Conte J
FAU - Pattout, Francois
AU  - Pattout F
FAU - Klein, Thomas
AU  - Klein T
FAU - Maedler, Kathrin
AU  - Maedler K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - jc.2013-1029 [pii]
AID - 10.1210/jc.2013-1029 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Apr 30.

PMID- 23633155
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
DP  - 2013 Apr 30
TI  - Disrupted Circadian Rhythmicity of the Intestinal Glucose Transporter SGLT1 in
      Zucker Diabetic Fatty Rats.
AB  - BACKGROUND: Intestinal absorptive capacity shows a circadian rhythm synchronized 
      with eating patterns. Disrupting these coordinated rhythms, e.g., with shift
      work, may contribute to metabolic disease. Circadian expression of nutrient
      transporters has not been studied in metabolic disease. We studied the circadian 
      rhythm of intestinal transporter sodium glucose co-transporter type 1 (SGLT1) in 
      an obese diabetic rat. METHODS: We compared obese Zucker diabetic fatty (ZDF)
      rats to lean ZDF littermates. Temporal feeding patterns were assessed, then rats 
      were harvested at Zeitgeber (ZT, ZT0 = 7:00 a.m.) 3, 9, or 15 to measure insulin 
      resistance, SGLT1 expression and intestinal glucose absorption capacity.
      Regulators of SGLT1 (sweet taste receptor T1R2/3; clock genes) were measured to
      elucidate underlying mechanisms. RESULTS: Both groups exhibited altered circadian
      food intake. Obese ZDF rats lost circadian rhythmicity of SGLT1 mRNA expression
      and functional activity. Lean ZDF rats maintained rhythmicity of SGLT1 mRNA
      expression but that of functional glucose absorption was blunted. Circadian
      rhythms of intestinal clock genes were maintained in both groups. Neither group
      had discernible rhythms of intestinal GLUT2 (glucose transporter) or T1R2 (sweet 
      taste receptor component) mRNA expression. In summary, lean and obese ZDF rats
      exhibited similar disruptions in circadian feeding. Glucose intolerance was
      evident in lean rats, but only obese rats further developed diabetes and
      exhibited disrupted circadian rhythmicity of both SGLT1 mRNA expression and
      function. CONCLUSIONS: Our findings suggest that disrupted circadian feeding
      rhythms contribute to glucose intolerance, but additional factors (genetics,
      changes in nutrient sensing/transport) are needed to lead to full diabetes.
AD  - Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 75
      Francis Street, Boston, MA, 02115, USA, hbhutta@partners.org.
FAU - Bhutta, Hina Y
AU  - Bhutta HY
FAU - Deelman, Tara E
AU  - Deelman TE
FAU - Ashley, Stanley W
AU  - Ashley SW
FAU - Rhoads, David B
AU  - Rhoads DB
FAU - Tavakkoli, Ali
AU  - Tavakkoli A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/11/25 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1007/s10620-013-2669-y [doi]
PST - aheadofprint
SO  - Dig Dis Sci. 2013 Apr 30.

PMID- 23633127
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1433-8726 (Electronic)
IS  - 0724-4983 (Linking)
DP  - 2013 Apr 30
TI  - Lichen sclerosus in men is associated with elevated body mass index, diabetes
      mellitus, coronary artery disease and smoking.
AB  - PURPOSE: To elucidate disease associations and possible etiology of lichen
      sclerosus (LS), we identified comorbidities present in men with LS. LS is a
      chronic inflammatory disease of unknown etiology affecting genitals and urethra
      of men commonly resulting in strictures. METHODS: Men with LS of the urethra,
      penis, prepuce and scrotum were identified. A control population was generated
      from men seen in the Department of Urology matched by age and race in a 5:1
      ratio. A case-control study was performed and comorbidities identified by ICD9,
      CPT codes and medication use via systematic electronic medical record review.
      Subgroup analysis of men with urethral strictures was performed based on their LS
      status. RESULTS: Men with LS had a significantly higher mean body mass index
      [31.0 (range 18.9-52.6)] compared to controls [28.1 (16.8-64.1), p = 0.001],
      significantly increased rate of coronary artery disease (CAD) (15.3 vs. 8.9 %, p 
      = 0.05) as well as a twofold higher rate of diabetes mellitus (15.5 vs. 8.3 %, p 
      = 0.02). Of men with LS and stricture disease, 11/19 (58 %) were current or
      former smokers, compared to 28 % of men with strictures without LS (p = 0.006).
      No association of LS with other morbidities like hyperlipidemia, hypertension,
      cerebrovascular disease, peripheral vascular disease or dermatologic disorders
      was found. CONCLUSIONS: Men suffering from LS have an increased BMI and a higher 
      prevalence of concomitant CAD, diabetes mellitus and tobacco use. Development and
      chronicity of LS may not be a purely dermatologic condition, but be associated or
      confounded by systemic or vascular compromise from disorders of CAD, DM and
      smoking.
AD  - Department of Urology, Feinberg School of Medicine, Northwestern University, 675 
      North St. Clair Street, Galter 20-150, Chicago, IL, 60611, USA.
FAU - Hofer, Matthias D
AU  - Hofer MD
FAU - Meeks, Joshua J
AU  - Meeks JJ
FAU - Mehdiratta, Nitin
AU  - Mehdiratta N
FAU - Granieri, Michael A
AU  - Granieri MA
FAU - Cashy, John
AU  - Cashy J
FAU - Gonzalez, Chris M
AU  - Gonzalez CM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - World J Urol
JT  - World journal of urology
JID - 8307716
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/02/21 [received]
PHST- 2013/04/20 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1007/s00345-013-1090-7 [doi]
PST - aheadofprint
SO  - World J Urol. 2013 Apr 30.

PMID- 23633003
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
DP  - 2013 Apr 30
TI  - Impact of diabetes on overall and cancer-specific mortality in colorectal cancer 
      patients.
AB  - PURPOSE: Diabetes is associated with increased risk of developing colorectal
      cancer (CRC), but its effect on overall and cancer-specific mortality in CRC
      patients has been little investigated. The aim of this study was to assess the
      influence of diabetes on overall and cancer-specific mortality in Italian CRC
      patients. METHODS: Cases of adult (>/=15 years) CRC, diagnosed in 2003-2005, most
      followed-up to the end of 2008, were randomly selected from the Italian Cancer
      Registries database. Diabetic status, sex, age, tumor stage, subsite, treatment, 
      morphology, and grade were obtained by consultation of patient clinical records. 
      Poisson multivariable regression models, adjusted for potential confounding
      variables, were used to estimate hazard ratios (HRs) for all-cause and
      CRC-specific mortality, according to diabetic status. RESULTS: A total of 1,039
      CRC cases with known fasting glucose or diabetic status, archived in 7 cancer
      registries, was analyzed. Compared to non-diabetics, diabetics (specific
      diagnosis or glucose >/=126 mg/dl) were older and less likely to receive adjuvant
      therapy. Diabetics were at higher risk of all-cause death [HR 1.41; 95 %
      confidence interval (CI) 1.18-1.70] and CRC death (HR 1.36; 95 % CI 1.11-1.67),
      with no differences by sex or subsite. CONCLUSIONS: Diabetes was significantly
      associated with increased overall and CRC-specific mortality. Our findings
      indicate that diabetes is a negative prognostic factor for CRC and suggest that
      in patients with CRC, diabetes prevention and treatments that stabilize the
      condition and control its complications might reduce mortality. Further studies
      are required to ascertain the mechanisms linking diabetes to greater mortality in
      CRC patients.
AD  - Analytical Epidemiology and Health Impact Unit, Department of Preventive and
      Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian
      1, 20133, Milan, Italy, francesca.bella@istitutotumori.mi.it.
FAU - Bella, Francesca
AU  - Bella F
FAU - Minicozzi, Pamela
AU  - Minicozzi P
FAU - Giacomin, Adriano
AU  - Giacomin A
FAU - Crocetti, Emanuele
AU  - Crocetti E
FAU - Federico, Massimo
AU  - Federico M
FAU - Ponz de Leon, Maurizio
AU  - Ponz de Leon M
FAU - Fusco, Mario
AU  - Fusco M
FAU - Tumino, Rosario
AU  - Tumino R
FAU - Mangone, Lucia
AU  - Mangone L
FAU - Giuliani, Orietta
AU  - Giuliani O
FAU - Budroni, Mario
AU  - Budroni M
FAU - Sant, Milena
AU  - Sant M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/03/12 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1007/s00432-013-1439-8 [doi]
PST - aheadofprint
SO  - J Cancer Res Clin Oncol. 2013 Apr 30.

PMID- 23632974
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 44
IP  - 6
DP  - 2013 Jun
TI  - Factors associated with length of hospitalization in patients admitted with
      transient ischemic attack in United States.
PG  - 1601-5
LID - 10.1161/STROKEAHA.111.000590 [doi]
AB  - BACKGROUND AND PURPOSE: Approximately 70% of all patients presenting with
      transient ischemic attack are admitted to the hospital in United States. The
      duration and cost of hospitalization and associated factors are poorly
      understood. This article seeks to identify the proportion and determinants of
      prolonged hospitalization and to determine the impact on hospital charges using
      nationally representative data. METHODS: We determined the national estimates of 
      length of stay, mortality, and charges incurred in patients admitted with
      transient ischemic attack (diagnosis-related code 524 or 069) using Nationwide
      Inpatient Sample data from 2002 to 2010. Nationwide Inpatient Sample is the
      largest all-payer inpatient care database in the United States and contains data 
      from approximately 1000 hospitals, which is a 20% stratified sample of US
      community hospitals. All the variables pertaining to hospitalization were
      compared in 3 groups on the basis of length of hospital stay (</=1, 2-6, and >/=7
      days). RESULTS: A total of 949 558 patients were admitted with the diagnosis of
      transient ischemic attack during the study period. The length of hospitalization 
      was </=1, 2 to 6, and >/=7 days in 232 732 (24.4%), 662 909 (70%), and 53 917
      (5.6%) patients, respectively. The mean hospitalization charges were $10 876, $17
      187, and $38 200 for patients hospitalized for </=1, 2 to 6, and >/=7 days,
      respectively. The use of thrombolytics (0.03%, 0.09%, and 0.1%; P<0.0001) for
      ischemic stroke was very low among the 3 strata defined by length of
      hospitalization. In the multivariate analysis, the following factors were
      associated with length of hospitalization of >/=2 days: age >65 years (odds ratio
      [OR], 1.5), women (OR, 1.2), admission to teaching hospitals (OR, 1.1), renal
      failure (OR, 1.7), hypertension (OR, 1.1), diabetes mellitus (OR, 1.2), chronic
      lung disease (OR, 1.4), congestive heart failure (OR, 1.4), atrial fibrillation
      (OR, 1.5), ischemic stroke occurrence (OR, 1.4), Medicare/Medicaid insurance (OR,
      1.3), and hospital location in Northeast US region (OR, 1.5; all P values
      <0.025). CONCLUSIONS: Approximately 75% of patients admitted with transient
      ischemic attack stay in the hospital for >/=2 days, with the most important
      determinants being pre-existing medical comorbidities. Longer duration of
      hospital stay is associated with 2- to 5-fold greater hospitalization charges.
AD  - Zeenat Qureshi Stroke Research Center, University of Minnesota, 420 Delaware St
      SE, MMC 295, Minneapolis, MN 55455. aiqureshi@hotmail.com.
FAU - Qureshi, Adnan I
AU  - Qureshi AI
FAU - Adil, Malik M
AU  - Adil MM
FAU - Zacharatos, Haralabos
AU  - Zacharatos H
FAU - Suri, M Fareed K
AU  - Suri MF
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - Stroke
JT  - Stroke; a journal of cerebral circulation
JID - 0235266
SB  - IM
OTO - NOTNLM
OT  - Nationwide Inpatient Sample
OT  - hospital charges
OT  - hospital days
OT  - national estimate
OT  - thrombolytics
OT  - transient ischemic attack
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [aheadofprint]
AID - STROKEAHA.111.000590 [pii]
AID - 10.1161/STROKEAHA.111.000590 [doi]
PST - ppublish
SO  - Stroke. 2013 Jun;44(6):1601-5. doi: 10.1161/STROKEAHA.111.000590. Epub 2013 Apr
      30.

PMID- 23632905
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
DP  - 2013 Apr 30
TI  - Clock Gene Expression in the Liver of Streptozotocin-induced and Spontaneous Type
      1 Diabetic Rats.
AB  - Several investigations have shown a relation between diabetes and alterations of 
      the liver circadian clock. We investigated the diurnal expression of clock genes 
      and clock-controlled genes (CCGs) in 3-hour intervals for a 24-h period in the
      livers of male streptozotocin (STZ)-treated rats, male spontaneous type 1
      diabetic LEW.1AR1-iddm (Iddm) rats, and Iddm rats treated for 10 days with
      insulin. Hepatic mRNA was extracted, and the relative expression of clock genes
      (Per1, Per2, Bmal1, Clock, Cry1), as well as CCGs (Dbp, E4bp4, RevErbalpha,
      Roralpha, Ppargamma), was analyzed by reverse transcription followed by real-time
      polymerase chain reaction. Diabetic STZ and Iddm rats, as well as
      insulin-substituted Iddm rats, exhibited a significant diurnal expression pattern
      of clock genes as determined by Cosinor analysis; however, the MESOR (midline
      estimating statistic of rhythm) of Bmal1, Per2, and Clock transcript expression
      was altered in Iddm and insulin-substituted Iddm rats. The hepatic expression of 
      the CCGs Dbp and RevErbalpha revealed a diurnal rhythm in all investigated
      groups. Insulin administration to Iddm rats normalized the enhanced MESOR in the 
      expression of Dbp, RevErbalpha, and E4bp4 to the levels of normoglycemic
      controls. Cosinor analysis indicated no diurnal rhythm of Ppargamma expression in
      the livers of diabetic STZ or Iddm rats or in those of insulin-substituted Iddm
      rats. Also, insulin substitution could not reverse the decreased MESOR of
      Ppargamma expression in Iddm rats. In consequence of the diabetic disease,
      changes in the expression of clock genes and CCGs suggest alterations in the
      hepatic peripheral clock mechanism.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Department of Anatomy and Cell Biology, Faculty of Medicine, Martin Luther
      University Halle (Saale), Germany.
FAU - Hofmann, K
AU  - Hofmann K
FAU - Schonerstedt, U
AU  - Schonerstedt U
FAU - Muhlbauer, E
AU  - Muhlbauer E
FAU - Wedekind, D
AU  - Wedekind D
FAU - Peschke, E
AU  - Peschke E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [epublish]
AID - 10.1055/s-0033-1343462 [doi]
PST - aheadofprint
SO  - Horm Metab Res. 2013 Apr 30.

PMID- 23632817
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
DP  - 2013 Apr 30
TI  - Meat-Related Mutagens and Pancreatic Cancer: null results from a clinic-based
      case-control study.
AB  - Background: Pancreatic cancer is a devastating disease for which the role of
      dietary factors remains inconclusive. The study objective was to evaluate risk of
      pancreatic cancer associated with meat preparation methods and meat-related
      mutagen consumption using a clinic-based case-control design. Methods: There were
      384 cases and 983 controls; subjects provided demographic information and
      completed a 144-item food frequency questionnaire, which was used to estimate
      meat mutagen intake using the National Cancer Institute's CHARRED database.
      Logistic regression was used to calculate odds ratios (OR) and 95% confidence
      intervals (95% CI), adjusted for factors including age, sex, cigarette smoking,
      body mass index, and diabetes mellitus. Results: Overall, the findings were null 
      with respect to meat mutagen intake and pancreatic cancer. Conclusion: The
      results do not support an association between well-done meat or meat-related
      mutagen intake and pancreatic cancer and contrast with generally increased risks 
      reported in previous studies. Impact: These data contribute to evidence regarding
      pancreatic cancer and potentially carcinogenic compounds in meat.
AD  - Health Sciences Research, Mayo Clinic.
FAU - Jansen, Rick J
AU  - Jansen RJ
FAU - Robinson, Dennis P
AU  - Robinson DP
FAU - Frank, Ryan D
AU  - Frank RD
FAU - Stolzenberg-Solomon, Rachael Z
AU  - Stolzenberg-Solomon RZ
FAU - Bamlet, William R
AU  - Bamlet WR
FAU - Oberg, Ann L
AU  - Oberg AL
FAU - Rabe, Kari G
AU  - Rabe KG
FAU - Olson, Janet E
AU  - Olson JE
FAU - Petersen, Gloria M
AU  - Petersen GM
FAU - Sinha, Rashmi
AU  - Sinha R
FAU - Anderson, Kristin E
AU  - Anderson KE
LA  - ENG
GR  - P50 CA102701/CA/NCI NIH HHS/United States
GR  - R25 CA092049/CA/NCI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American
      Association for Cancer Research, cosponsored by the American Society of
      Preventive Oncology
JID - 9200608
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 1055-9965.EPI-13-0343 [pii]
AID - 10.1158/1055-9965.EPI-13-0343 [doi]
PST - aheadofprint
SO  - Cancer Epidemiol Biomarkers Prev. 2013 Apr 30.

PMID- 23632749
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1476-5640 (Electronic)
IS  - 0954-3007 (Linking)
DP  - 2013 May 1
TI  - Metabolic and hormonal consequences of two different meals after a moderate
      intensity exercise bout in obese prepubertal children.
LID - 10.1038/ejcn.2013.86 [doi]
AB  - Background/objectives:To investigate the relationship between postprandial
      nutrient balance, satiety and hormone changes induced by two different meals
      taken after a moderate intensity exercise bout.Subjects/Methods:Ten prepubertal
      obese children participated in the study. The experiment was designed as a
      cross-over study for repeated measures. Each test period lasted five consecutive 
      hours during which the children were under medical supervision. The effects of
      two isocaloric meals were compared after a moderate intensity exercise (4
      multiples of resting metabolic rate, 30 min, cycling): a
      low-fat/high-carbohydrate meal (meal A) and a high-fat/low-carbohydrate meal
      (meal B). Pre and postprandial (3 h) substrate oxidation, biochemical parameters,
      gastrointestinal hormone concentrations and appetite were measured.Results:The
      main results were: (i) higher fat balance (5.1+/-5.0 vs -5.0+/-6.6 g, P=0.001)
      and lower carbohydrate balance after meal B than A (-9.7+/-13.3 vs 11.3+/-18.3 g,
      P<0.01); (ii) higher energy balance after meal B than after meal A (5.9+/-21.5 vs
      -13.9+/-20.2 kcal, P<0.05); (iii) higher plasma triglyceride concentrations (area
      under the curve) after meal B than after meal A (2962.5+/-2095.8 mg*180 min/dl vs
      -169.5+/-1633.7 mg*180 min/dl, P<0.01); (iv) higher serum glucagon-like peptide-1
      concentrations after meal B than after meal A (1101.5+/-873.0 pmol*180 min/l vs
      478.8+/-638.3 pmol*180 min/l, P<0.05).Conclusions:After a bout of moderate
      intensity exercise, a meal with a high-fat/low-carbohydrate ratio had a less
      favorable metabolic impact than an isoenergetic, isoproteic
      low-fat/high-carbohydrate meal.European Journal of Clinical Nutrition advance
      online publication, 1 May 2013; doi:10.1038/ejcn.2013.86.
AD  - Unit of Pediatric Diabetes, Clinical Nutrition and Obesity, Department of Life
      and Reproduction Sciences, University of Verona, Verona, Italy.
FAU - Maffeis, C
AU  - Maffeis C
FAU - Bonadonna, R
AU  - Bonadonna R
FAU - Maschio, M
AU  - Maschio M
FAU - Aiello, G
AU  - Aiello G
FAU - Tommasi, M
AU  - Tommasi M
FAU - Marigliano, M
AU  - Marigliano M
FAU - Fornari, E
AU  - Fornari E
FAU - Morandi, A
AU  - Morandi A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Eur J Clin Nutr
JT  - European journal of clinical nutrition
JID - 8804070
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/05/01 [aheadofprint]
AID - ejcn201386 [pii]
AID - 10.1038/ejcn.2013.86 [doi]
PST - aheadofprint
SO  - Eur J Clin Nutr. 2013 May 1. doi: 10.1038/ejcn.2013.86.

PMID- 23632431
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1537-1921 (Electronic)
IS  - 0898-4921 (Linking)
DP  - 2013 Apr 29
TI  - A Retrospective Analysis of Stridor After Vestibular Schwannoma Surgery.
AB  - BACKGROUND:: Transient lower cranial nerve deficits may occur after surgery in
      the posterior cranial fossa. Stridor has been reported after cerebellopontine
      angle epidermoid resection. The aim of this retrospective study is to find out
      whether any preoperative, intraoperative, and postoperative factors lead to
      stridor after resection of vestibular schwannoma. METHODS:: Data of patients who 
      underwent vestibular schwannoma resection from 2006 to 2011 were collected. We
      collected the following factors-age, sex, weight, diabetes, hypertension,
      preoperative cranial nerve deficits, tumor characteristics, intraoperative use of
      nitrous oxide, difficult endotracheal intubation, duration of surgery,
      postoperative cough and swallowing difficulty, limb weakness, and facial edema.
      Data of patients who developed stridor were compared with those who did not
      develop stridor. Odds ratio (OR) was used to assess the risk of developing
      stridor with each factor. RESULTS:: Thirteen patients (4.65%) developed stridor
      in immediate postextubation period. The risk of stridor was significantly high in
      patients who had difficult intubation (OR=9.56), longer duration of surgery
      (P=0.034) and in patients who developed facial edema (OR=13.33), upperlimb
      weakness (OR=32.88), poor cough (OR=7.72), and swallowing difficulty (OR=24.97)
      in the postoperative period. CONCLUSIONS:: The identification of the exact
      etiology of stridor often is difficult. Our results suggest that stridor may be
      more likely in patients who were difficult to intubate, had longer duration of
      surgery, who develop facial and neck edema and upperlimb weakness, poor cough,
      and swallowing after surgery. Establishing airway patency with intubation of the 
      trachea may be required if patients develop oxygen desaturation due to stridor.
AD  - *Departments of Anesthesiology daggerNeurosurgery, Sree Chitra Tirunal Institute 
      for Medical Sciences & Technology, Trivandrum, India.
FAU - Arulvelan, Appavoo
AU  - Arulvelan A
FAU - Gayatri, Parthasarathi
AU  - Gayatri P
FAU - Smita, Vimalakumari
AU  - Smita V
FAU - Nair, Suresh N
AU  - Nair SN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - J Neurosurg Anesthesiol
JT  - Journal of neurosurgical anesthesiology
JID - 8910749
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1097/ANA.0b013e3182945267 [doi]
PST - aheadofprint
SO  - J Neurosurg Anesthesiol. 2013 Apr 29.

PMID- 23632402
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1536-481X (Electronic)
IS  - 1057-0829 (Linking)
DP  - 2013 Apr 29
TI  - Evaluation of the Effect of Pan Retinal Photocoagulation on Optic Nerve Head
      Parameters Using HRT3.
AB  - PURPOSE:: To evaluate the optic disc topography after pan retinal
      photocoagulation (PRP) in diabetic retinopathy patients using confocal scanning
      laser ophthalmoscopy (HRT3). METHODS:: Thirty eyes of 30 diabetic patients
      (non-insulin-dependent diabetes mellitus) underwent PRP for proliferative
      diabetic retinopathy. Subjects with glaucoma or family history of glaucoma, any
      coexisting neuroophthalmic disease, uveitis, retinal artery or vein occlusion,
      corneal opacity or lasered previously were excluded from the study. Optic nerve
      head (ONH) of these patients were evaluated by confocal scanning laser
      ophthalmoscopy (HRT3) at baseline, 3, and 6 months after completion of PRP.
      RESULTS:: There were 23 males and 7 females with a mean age of 51.8 years (36 to 
      67 y). The mean intraocular pressure was 13.1+/-2.57 mm Hg at baseline,
      13.4+/-2.6 mm Hg at 3 months, and 13.3+/-2.2 mm Hg at 6 months (P=0.6). The
      global values of ONH parameters showed no significant change from baseline at 3
      months. At 6 months, there was a significant increase in vertical cup:disc ratio 
      (P=0.021), cup volume (P=0.036), mean cup depth (P=0.042), and maximum cup depth 
      (P=0.05) as compared with baseline values. CONCLUSIONS:: PRP induces significant 
      changes in the ONH in patients with diabetic retinopathy as measured with HRT3.
      This is an important consideration in the diagnosis and evaluation of progression
      in glaucoma patients with diabetic retinopathy who have undergone PRP.
AD  - Glaucoma Facility, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India
      Institute of Medical Sciences, New Delhi, India.
FAU - Singh, Harshinder
AU  - Singh H
FAU - Garg, Satpal
AU  - Garg S
FAU - Sharma, Reetika
AU  - Sharma R
FAU - Venkatesh, Pradeep
AU  - Venkatesh P
FAU - Saxena, Rohit
AU  - Saxena R
FAU - Dada, Tanuj
AU  - Dada T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - J Glaucoma
JT  - Journal of glaucoma
JID - 9300903
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1097/IJG.0b013e3182946536 [doi]
PST - aheadofprint
SO  - J Glaucoma. 2013 Apr 29.

PMID- 23632400
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1536-481X (Electronic)
IS  - 1057-0829 (Linking)
DP  - 2013 Apr 29
TI  - Oral Fluoroquinolones and Risk of Glaucoma.
AB  - OBJECTIVE:: To evaluate the risk of developing glaucoma in patients taking
      systemic fluoroquinolones. METHODS:: A case-control study was carried out among a
      cohort of subjects who had visited an ophthalmologist in the Province of British 
      Columbia, Canada from 2000 to 2007. Cases were identified as those newly
      diagnosed with glaucoma (ICD-9 360). For each case, 5 controls were selected and 
      matched to the cases by age and calendar time. Crude and adjusted rate ratios
      (RRs) for current, recent, past, and distant use of fluoroquinolones were
      calculated. RESULTS:: From the cohort of 989,591 subjects, 178,264 subjects were 
      diagnosed with glaucoma and 891,320 were corresponding controls. The 2 groups had
      same average age of 65 and comparable systemic comorbidities including
      hypertension, coronary artery disease, and diabetes. There was no statistically
      significant association between the use of systemic fluoroquinolones and the
      development of glaucoma for current use [RR=1.01 (95% confidence interval (CI),
      0.95-1.07)], recent use [RR=1.00 (95% CI, 0.92-1.08)], or past use [RR=0.94 (95% 
      CI, 0.90-1.00)]. Distant use of systemic fluoroquinolones had a small
      statistically significant increased risk of developing glaucoma [RR=1.12 (95% CI,
      1.09-1.14)]. CONCLUSIONS:: There was no detected increased association of the
      development of glaucoma with current, recent, or past use of systemic
      fluoroquinolone but a minimal statistically significant increased risk was
      associated with distant use. Future studies should further examine a potential
      delayed response with fluoroquinolones and glaucoma.
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, BC, Canada.
FAU - Yang, Louis
AU  - Yang L
FAU - Etminan, Mahyar
AU  - Etminan M
FAU - Mikelberg, Frederick S
AU  - Mikelberg FS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - J Glaucoma
JT  - Journal of glaucoma
JID - 9300903
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1097/IJG.0b013e31829463c1 [doi]
PST - aheadofprint
SO  - J Glaucoma. 2013 Apr 29.

PMID- 23632295
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
DP  - 2013 Apr 27
TI  - Peripheral baroreflex and chemoreflex function after eversion carotid
      endarterectomy.
LID - S0741-5214(13)00008-6 [pii]
LID - 10.1016/j.jvs.2012.11.130 [doi]
AB  - OBJECTIVE: This study assessed the long-term effect of the eversion technique for
      carotid endarterectomy (e-CEA) on arterial baroreflex and peripheral chemoreflex 
      function. METHODS: The study included 13 patients who underwent, between 2001 and
      2006, bilateral e-CEA and 16 who underwent bilateral standard CEA (s-CEA) to
      eliminate the complicating effects of intact contralateral carotid sinus
      function. Exclusion criteria were age >70 years, diabetes mellitus, chronic
      pulmonary disease, ischemic cardiac disease or medical therapy with
      beta-blockers, cardiac arrhythmia, neurologic deficits, carotid restenosis, and
      previous neck or chest surgery or irradiation. Young and aged-matched healthy
      individuals were recruited as controls. All patients underwent standard
      cardiovascular reflex tests, including lying-to-standing, orthostatic
      hypotension, deep breathing, and Valsalva maneuver. Autonomic cardiovascular
      modulation was indirectly evaluated by spectral analysis of heart rate
      variability and systolic arterial pressure variability. The chemoreflex
      sensitivity to hypoxia was obtained during classic rebreathing tests from the
      slopes of the linear regression of minute ventilation (VE) vs arterial oxygen
      saturation measured by pulse oximetry (SpO2%) and partial pressure of end-tidal
      oxygen (PetO2). RESULTS: Patients (16 men; age, 62.4 +/- 8.0 years) were enrolled
      after a mean interval of 24 +/- 17 months from the last CEA. All were
      asymptomatic, and results of standard tests were negative. Residual baroreflex
      performance was documented in both patient groups, although reduced, compared
      with young controls. Notably, baroreflex sensitivity (msec/mm Hg) was better
      maintained after e-CEA than after s-CEA at rest (young controls, 19.93 +/- 9.50; 
      age-matched controls, 7.75 +/- 5.68; e-CEA, 13.85 +/- 14.54; and s-CEA, 3.83 +/- 
      1.15; analysis of variance [ANOVA], P = .001); and at standing (young controls,
      7.83 +/- 2.55; age-matched controls, 3.71 +/- 1.59; e-CEA, 7.04 +/- 5.62; and
      s-CEA 3.57 +/- 3.80; ANOVA, P = .001). Similarly, chemoreflex sensitivity to
      hypoxia was maintained in both patient groups, which did not differ from each
      other, and was reduced compared with controls (controls vs patient groups
      DeltaVE/DeltaSpO2: -1.37 +/- 0.33 vs -0.33 +/- 0.08 and SpO2% -0.29 +/- 0.13
      L/min; P = .002; DeltaVE/DeltaPetO2: -0.20 +/- 0.1 vs -0.01 +/- 0.0 and -0.07 +/-
      0.02 L/min/mm Hg; P = .04, ANOVA with least significant difference correction for
      multiple comparisons). CONCLUSIONS: Our data show that e-CEA, even when performed
      on both sides, preserves baroreflexes and chemoreflexes and, therefore, does not 
      confer permanent carotid sinus denervation. Also, e-CEA does not increase
      long-term arterial pressure variability, and this suggests that perioperative
      hemodynamic derangements can be attributed to the temporary effects of surgical
      trauma.
CI  - Copyright (c) 2013 Society for Vascular Surgery. Published by Mosby, Inc. All
      rights reserved.
AD  - Vascular Surgery, San Raffaele Scientific Institute, Milan, Italy. Electronic
      address: max_marrocco@yahoo.com.
FAU - Marrocco-Trischitta, Massimiliano M
AU  - Marrocco-Trischitta MM
FAU - Cremona, George
AU  - Cremona G
FAU - Lucini, Daniela
AU  - Lucini D
FAU - Natali-Sora, Maria Grazia
AU  - Natali-Sora MG
FAU - Cursi, Marco
AU  - Cursi M
FAU - Cianflone, Domenico
AU  - Cianflone D
FAU - Pagani, Massimo
AU  - Pagani M
FAU - Chiesa, Roberto
AU  - Chiesa R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/03/22 [received]
PHST- 2012/08/20 [revised]
PHST- 2012/11/25 [accepted]
AID - S0741-5214(13)00008-6 [pii]
AID - 10.1016/j.jvs.2012.11.130 [doi]
PST - aheadofprint
SO  - J Vasc Surg. 2013 Apr 27. pii: S0741-5214(13)00008-6. doi:
      10.1016/j.jvs.2012.11.130.

PMID- 23632280
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 47
IP  - 6
DP  - 2013 Jun
TI  - Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes
      mellitus.
PG  - 877-85
LID - 10.1345/aph.1R754 [doi]
AB  - OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of 
      the thiazolidinedione rivoglitazone, a peroxisome proliferator-activated
      receptor-gamma (PPAR-gamma) agonist, to determine its potential role in the
      treatment of type 2 diabetes mellitus. DATA SOURCES: A MEDLINE search
      (1966-February 2013) was conducted for English-language studies in humans, using 
      the terms rivoglitazone and CS011. Abstracts presented at the American Diabetes
      Association and European Association for the Study of Diabetes annual meetings
      from 2007 to 2012 were also evaluated for relevant data. STUDY SELECTION AND DATA
      EXTRACTION: Articles pertinent to the pharmacology, pharmacokinetics, efficacy,
      and safety of rivoglitazone were reviewed. DATA SYNTHESIS: Rivoglitazone has been
      shown, through small clinical studies, to decrease hemoglobin A1c (A1C) by
      0.11-1.1% when compared with placebo and may provide greater A1C reduction than
      pioglitazone. Rivoglitazone reduces hyperglycemia, hyperinsulinemia, and
      hypertriglyceridemia by acting as an agonist of PPAR-gamma. Rivoglitazone is the 
      most potent PPAR-gamma agonist; the initial recommended dose is 1 mg daily, with 
      adjustment as needed to a maximum dose of 2 mg daily. Additionally, rivoglitazone
      has a longer half-life than other PPAR-gamma agonists. Similar to those of the
      other PPAR-gamma agonists, rivoglitazone's adverse effects include peripheral
      edema and weight gain. CONCLUSIONS: Rivoglitazone is the fourth agent in the
      thiazolidinedione class of antidiabetes drugs. Although rivoglitazone appears to 
      be more potent in its ability to lower A1C levels compared with other
      thiazolidinediones, further studies of longer duration are needed to fully assess
      the risks associated with this drug. Until these can be completed, we cannot
      recommend rivoglitazone over currently approved drugs in this class.
AD  - Harrison School of Pharmacy, Auburn University, Auburn, AL.
FAU - Koffarnus, Robin L
AU  - Koffarnus RL
FAU - Wargo, Kurt A
AU  - Wargo KA
FAU - Phillippe, Haley M
AU  - Phillippe HM
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [aheadofprint]
AID - aph.1R754 [pii]
AID - 10.1345/aph.1R754 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2013 Jun;47(6):877-85. doi: 10.1345/aph.1R754. Epub 2013 Apr
      30.

PMID- 23632200
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1532-2661 (Electronic)
IS  - 0034-5288 (Linking)
DP  - 2013 Apr 27
TI  - Characterization of the use of liraglutide for glycemic control in healthy and
      Type 1 diabetes mellitus suffering dogs.
LID - S0034-5288(13)00129-X [pii]
LID - 10.1016/j.rvsc.2013.04.003 [doi]
AB  - Glucagon-like peptide 1 (GLP-1) is a glucose-lowering, intestinal-derived factor 
      with multiple physiological effects, making it attractive for diabetes therapy.
      However, the therapeutic potential of endogenous GLP-1 is limited, because of
      rapid inactivation by dipeptidyl peptidase-4. Recently, enhanced incretin
      preparations, such as liraglutide, have emerged, which are more resistant to
      degradation and longer lasting. Liraglutide is a long-acting acylated human GLP-1
      receptor agonist, with a 97% amino acid sequence identity to endogenous human
      GLP-1, and 100% amino acid sequence homology with canine GLP-1. Since liraglutide
      has yet to be examined for use in dogs, and the incretin effect has been reported
      to exist in dogs, we sought to initially characterize liraglutide's ability for
      glycemic control in healthy dogs, under an oral glucose tolerance test (OGTT)
      environment initially. This was followed up a more realistic scenario involving
      food with insulin injection +/- liraglutide injection resulting in a glucose
      curve based study involving dogs suffering from Type 1 diabetes mellitus (T1DM). 
      Overall, liraglutide had a stabilizing effect on glucose levels, maintaining
      circulating levels between 77.0 and 137.0mg/ml throughout the OGTT test period,
      resulting in a significant reduction of 13.8% in glucose AUC0-120min (total area 
      under the curve for 0-120min) as compared to baseline control in healthy dogs
      (n=5). Interestingly, the liraglutide associated reduction in circulating glucose
      was not accompanied by any significant increase in insulin. Moreover, T1DM dogs
      (n=4) responded favorably to liraglutide treatment, which lead to a significant
      reduction of 46.0% in glucose AUC0-12h (total area under the curve for 0-12h),
      and a significant reduction of 66.5% in serum glucose as compared to baseline
      controls (insulin treatment only). Therefore, liraglutide's prandial glucagon
      suppressive ability appears to play a key role in its glucose-lowering
      capability, and offers great potential for use with dogs suffering from T1DM.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Veterinary Nursing & Technology, School of Veterinary Science
      Nippon Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo 
      180-8602, Japan.
FAU - Oda, H
AU  - Oda H
FAU - Mori, A
AU  - Mori A
FAU - Lee, P
AU  - Lee P
FAU - Saeki, K
AU  - Saeki K
FAU - Ishioka, K
AU  - Ishioka K
FAU - Arai, T
AU  - Arai T
FAU - Sako, T
AU  - Sako T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Res Vet Sci
JT  - Research in veterinary science
JID - 0401300
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/07/18 [received]
PHST- 2013/02/20 [revised]
PHST- 2013/04/02 [accepted]
AID - S0034-5288(13)00129-X [pii]
AID - 10.1016/j.rvsc.2013.04.003 [doi]
PST - aheadofprint
SO  - Res Vet Sci. 2013 Apr 27. pii: S0034-5288(13)00129-X. doi:
      10.1016/j.rvsc.2013.04.003.

PMID- 23632184
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Emphysematous cystitis: a tympanic bladder.
LID - 10.1136/bcr-2013-009050 [doi]
LID - bcr2013009050 [pii]
AB  - An 86-year-old woman with type 2 diabetes was admitted with increasing lethargy
      and hyperglycaemia. On examination she was noted to have a tender and tympanic
      bladder. CT revealed a distended bladder with gas locules in the bladder wall.
      She was diagnosed with hyperglycaemic hyperosmolar non-ketosis precipitated by
      emphysematous cystitis. After systemic antibiotics and bladder drainage via a
      urethral catheter, her symptoms readily improved. Radiographic appearances of the
      bladder were normal one week after instigating treatment. Emphysematous cystitis 
      is characterized by gas within the bladder wall. Although rare it is increasingly
      more recognized with the advent of modern imaging. The mainstay of treatment is
      antibiotics and bladder drainage. Rarely surgical debridement and even cystectomy
      is required.
AD  - Charing Cross Hospital, London, UK.
FAU - Dixon, Luke
AU  - Dixon L
FAU - Winkler, Mathias
AU  - Winkler M
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - bcr-2013-009050 [pii]
AID - 10.1136/bcr-2013-009050 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 29;2013. pii: bcr2013009050. doi: 10.1136/bcr-2013-009050.

PMID- 23632173
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Poorly controlled type 2 diabetes complicated by an episode of severe
      hypertriglyceridaemia-induced pancreatitis.
LID - 10.1136/bcr-2012-008455 [doi]
LID - bcr2012008455 [pii]
AB  - A 23-year-old woman with a history of type 2 diabetes and non-compliance
      presented to the emergency department with abdominal epigastric pain and nausea. 
      Laboratory examination revealed a mild ketoacidosis while an abdominal CT scan
      performed the following day demonstrated a severe acute pancreatitis of the body 
      and tail (Balthazar grade E) despite normal amylase serum levels on admission.
      The presence of a lactescent serum was the clue to an extremely high triglyceride
      level (>10 000 mg/dl) causing the pancreatitis. The hypertriglyceridaemia itself 
      was attributed mainly to the diabetic ketoacidosis. There was no family history
      of hypertriglyceridaemia. The triad consisting of diabetic ketoacidosis,
      hypertriglyceridaemia and acute pancreatitis is an unusual presentation of poorly
      controlled diabetes which can occur in type 1 as well as type 2 diabetic adults
      and children. Treatment with intravenous insulin and hydration successfully
      resolved the ketoacidosis and hypertriglyceridaemia and reversed the episode of
      acute pancreatitis.
AD  - Department of Endocrinology-Diabetes, UZ Brussel, Brussels, Belgium.
FAU - Denecker, Nathalie
AU  - Denecker N
FAU - Decochez, Katelijn
AU  - Decochez K
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - bcr-2012-008455 [pii]
AID - 10.1136/bcr-2012-008455 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 29;2013. pii: bcr2012008455. doi: 10.1136/bcr-2012-008455.

PMID- 23632148
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1558-3171 (Electronic)
IS  - 0039-6109 (Linking)
VI  - 93
IP  - 3
DP  - 2013 Jun
TI  - Type 2 diabetes mellitus and pancreatic cancer.
PG  - 619-27
LID - 10.1016/j.suc.2013.02.003 [doi]
LID - S0039-6109(13)00023-6 [pii]
AB  - Tumorigenesis of pancreatic cancer (PC) and the pathophysiology of type 2
      diabetes mellitus (DM2) are emerging as intertwined pathways. As the operative
      morbidity and mortality of pancreatectomy has improved, incidence has increased
      and survival has remained mostly unchanged. The diagnosis of DM2 suggests
      pancreatic dysfunction and possible early carcinogenesis. DM2 is a significant
      comorbidity predicting worse outcomes in patients undergoing pancreatic resection
      as part of the treatment of PC. This article examines this phenomena and suggests
      possible approaches to screening and diagnosis.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, The Kirklin Clinic, UAB Medical Center, 1802 6th Avenue
      South, Birmingham, AL 35294, USA.
FAU - McAuliffe, John C
AU  - McAuliffe JC
FAU - Christein, John D
AU  - Christein JD
LA  - eng
PT  - Journal Article
DEP - 20130403
PL  - United States
TA  - Surg Clin North Am
JT  - The Surgical clinics of North America
JID - 0074243
SB  - AIM
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/03 [aheadofprint]
AID - S0039-6109(13)00023-6 [pii]
AID - 10.1016/j.suc.2013.02.003 [doi]
PST - ppublish
SO  - Surg Clin North Am. 2013 Jun;93(3):619-27. doi: 10.1016/j.suc.2013.02.003. Epub
      2013 Apr 3.

PMID- 23632126
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1552-9924 (Electronic)
IS  - 0091-6765 (Linking)
DP  - 2013 Apr 26
TI  - Risk of Incident Diabetes in Relation to Long-term Exposure to Fine Particulate
      Matter in Ontario, Canada.
AB  - BACKGROUND: Laboratory studies suggest that fine particulate matter (2.5microm in
      diameter or less; PM2.5) can activate pathophysiological responses which may
      induce insulin resistance and type-2 diabetes. However, epidemiological evidence 
      relating PM2.5 and diabetes is sparse, particularly for incident diabetes.
      OBJECTIVES: We conducted a population-based cohort study to determine whether
      long-term exposure to ambient PM2.5 is associated with incident diabetes.
      METHODS: We assembled a cohort of 62,012 nondiabetic adults who lived in Ontario,
      Canada and completed one of five population-based health surveys between 1996 and
      2005. Follow-up extended until December 31, 2010. Incident diabetes diagnosed
      between 1996 and 2010 was ascertained using the Ontario Diabetes Database, a
      validated registry of persons diagnosed with diabetes (sensitivity=86%,
      specificity=97%). Six-year average concentrations of PM2.5 at the postal codes of
      baseline residences were derived from satellite observations. We used Cox
      proportional hazards models to estimate the associations, adjusting for various
      individual-level risk factors and contextual covariates such as smoking, body
      mass index, physical activity, and neighbourhood-level household income. We also 
      conducted multiple sensitivity analyses. In addition, we examined effect
      modification for selected comorbidities and sociodemographic characteristics.
      RESULTS: There were 6,310 incident cases of diabetes over 484,644 total
      person-years of follow up. The adjusted hazard ratio for a 10-microg/m3 increase 
      in PM2.5 was 1.11 (95% CI: 1.02, 1.21). Estimated associations were comparable
      among all sensitivity analyses. We did not find strong evidence of effect
      modification by comorbidities or sociodemographic covariates. CONCLUSIONS: This
      study suggests that long-term exposure to PM2.5 may contribute to the development
      of diabetes.
AD  - Public Health Ontario, and Dalla Lana School of Public Health, University of
      Toronto, Toronto, Ontario, Canada.
FAU - Chen, Hong
AU  - Chen H
FAU - Burnett, Richard T
AU  - Burnett RT
FAU - Kwong, Jeffrey C
AU  - Kwong JC
FAU - Villeneuve, Paul J
AU  - Villeneuve PJ
FAU - Goldberg, Mark S
AU  - Goldberg MS
FAU - Brook, Robert D
AU  - Brook RD
FAU - van Donkelaar, Aaron
AU  - van Donkelaar A
FAU - Jerrett, Michael
AU  - Jerrett M
FAU - Martin, Randall V
AU  - Martin RV
FAU - Brook, Jeffrey R
AU  - Brook JR
FAU - Copes, Ray
AU  - Copes R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Environ Health Perspect
JT  - Environmental health perspectives
JID - 0330411
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/09/01 [received]
PHST- 2012/12/01 [revised]
PHST- 2013/04/24 [accepted]
AID - 10.1289/ehp.1205958 [doi]
PST - aheadofprint
SO  - Environ Health Perspect. 2013 Apr 26.

PMID- 23632068
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1542-2224 (Electronic)
IS  - 1067-2516 (Linking)
DP  - 2013 Apr 27
TI  - Low-profile Titanium Plate Construct for Early Weightbearing with First
      Metatarsophalangeal Joint Arthrodesis.
LID - S1067-2516(13)00109-9 [pii]
LID - 10.1053/j.jfas.2013.03.008 [doi]
AB  - First metatarsophalangeal joint arthrodesis is a useful procedure for various
      first ray pathologic entities. Multiple constructs for fixation have provided
      successful fusion. A retrospective study of 21 feet (18 patients) was performed
      after first metatarsophalangeal joint fusion using crossed Kirschner wires or
      compression fixation with cannulated screws followed by the application of a
      2-hole low-profile partially locking titanium plate. The median age was 59 (range
      41 to 76) years, and we had 4 smokers and 3 patients with diabetes in our series.
      Postoperatively, a compression dressing with a posterior splint was applied. The 
      patients then transitioned to a controlled ankle motion walker, and all patients 
      reported full weightbearing by 2 weeks postoperatively. The mean follow-up
      duration was 11.43 (range 6 to 27) months. The overall primary fusion rate was
      95.24% (20 of 21). Two nonunions occurred; one was asymptomatic and successfully 
      consolidated at 12 months. The second nonunion required revisional surgery with
      an autogenous bone graft to heal successfully. This patient was noncompliant with
      the postoperative regimen and had a 48-pack year history of tobacco usage. Our
      results have shown early weightbearing after first metatarsophalangeal joint
      arthrodesis can be successfully initiated with splintage or lag screw fixation
      and a 2-hole, low-profile, partially locking titanium plate.
CI  - Copyright (c) 2013 American College of Foot and Ankle Surgeons. Published by
      Elsevier Inc. All rights reserved.
AD  - Resident, Dekalb Medical, Decatur, GA. Electronic address: mannjj0618@gmail.com.
FAU - Mann, Joshua J
AU  - Mann JJ
FAU - Moon, Jared L
AU  - Moon JL
FAU - Brosky, Thomas A 2nd
AU  - Brosky TA 2nd
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - J Foot Ankle Surg
JT  - The Journal of foot and ankle surgery : official publication of the American
      College of Foot and Ankle Surgeons
JID - 9308427
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/07/22 [received]
AID - S1067-2516(13)00109-9 [pii]
AID - 10.1053/j.jfas.2013.03.008 [doi]
PST - aheadofprint
SO  - J Foot Ankle Surg. 2013 Apr 27. pii: S1067-2516(13)00109-9. doi:
      10.1053/j.jfas.2013.03.008.

PMID- 23631910
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1532-1681 (Electronic)
IS  - 0268-960X (Linking)
VI  - 27
IP  - 3
DP  - 2013 May
TI  - The role of tissue factor pathway inhibitor in atherosclerosis and arterial
      thrombosis.
PG  - 119-32
LID - 10.1016/j.blre.2013.03.001 [doi]
LID - S0268-960X(13)00016-7 [pii]
AB  - Tissue factor pathway inhibitor (TFPI) is the main inhibitor of tissue factor
      (TF)-mediated coagulation. In atherosclerotic plaques TFPI co-localizes with TF, 
      where it is believed to play an important role in attenuating TF activity.
      Findings in animal models such as TFPI knockout models and gene transfer models
      are consistent on the role of TFPI in arterial thrombosis as they reveal an
      active role for TFPI in attenuating arterial thrombus formation. In addition,
      ample experimental evidence exists indicating that TFPI has inhibitory effects on
      both smooth muscle cell migration and proliferation, both which are recognized as
      important pathological features in atherosclerosis development. Nonetheless, the 
      clinical relevance of these antithrombotic and atheroprotective effects remains
      unclear. Paradoxically, the majority of clinical studies find increased instead
      of decreased TFPI antigen and activity levels in atherothrombotic disease,
      particularly in atherosclerosis and coronary artery disease (CAD). Increased TFPI
      levels in cardiovascular disease might result from complex interactions with
      established cardiovascular risk factors, such as hypercholesterolemia, diabetes
      and smoking. Moreover, it is postulated that increased TFPI levels reflect either
      the amount of endothelial perturbation and platelet activation, or a compensatory
      mechanism for the increased procoagulant state observed in cardiovascular
      disease. In all, the prognostic value of plasma TFPI in cardiovascular disease
      remains to be established. The current review focuses on TFPI in clinical studies
      of asymptomatic and symptomatic atherosclerosis, coronary artery disease and
      ischemic stroke, and discusses potential atheroprotective actions of TFPI.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Biochemistry, Cardiovascular Research Institute Maastricht, MUMC,
      Maastricht, The Netherlands; Department of Internal Medicine, Cardiovascular
      Research Institute Maastricht, MUMC, Maastricht, The Netherlands.
FAU - Winckers, Kristien
AU  - Winckers K
FAU - Ten Cate, Hugo
AU  - Ten Cate H
FAU - Hackeng, Tilman M
AU  - Hackeng TM
LA  - eng
PT  - Journal Article
DEP - 20130428
PL  - England
TA  - Blood Rev
JT  - Blood reviews
JID - 8708558
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/28 [aheadofprint]
AID - S0268-960X(13)00016-7 [pii]
AID - 10.1016/j.blre.2013.03.001 [doi]
PST - ppublish
SO  - Blood Rev. 2013 May;27(3):119-32. doi: 10.1016/j.blre.2013.03.001. Epub 2013 Apr 
      28.

PMID- 23631889
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1532-8503 (Electronic)
IS  - 1051-2276 (Linking)
DP  - 2013 Apr 27
TI  - Influence of Psychosocial Factors on the Energy and Protein Intake of Older
      People on Dialysis.
LID - S1051-2276(13)00076-9 [pii]
LID - 10.1053/j.jrn.2013.02.009 [doi]
AB  - OBJECTIVE: To explore the relationship between nutritional parameters and
      psychosocial factors in older people on dialysis. DESIGN: A cross-sectional
      observational study in prevalent older people on hemodialysis (HD) and peritoneal
      dialysis (PD). SETTING: A secondary analysis from a quality of life study in
      older people (Broadening Options for Long-term Dialysis in the Elderly).
      SUBJECTS: One-hundred and six patients 65 years of age or older and on dialysis
      for at least 90 days were purposively recruited (HD patients matched to PD
      patients by age, sex, dialysis vintage, ethnicity and Index of Deprivation). Half
      were on HD, the mean age was 72.7 years, 72% were male, 92% were from a White
      ethnic background, and 26% had diabetes. INTERVENTION: The patients attended one 
      visit at which they completed nutritional assessments (3-day food diary,
      subjective global assessment, handgrip strength, and body mass index) and
      questionnaires: Short Form-12 (SF-12), the Hospital Anxiety and Depression Scale 
      (HADS), the Mini Mental State Exam, and social networks. MAIN OUTCOME MEASURES:
      The differences in nutritional parameters between patients on PD and HD were
      determined by univariate analyses, and the relationships between nutritional
      intake and demographic, clinical, and psychosocial variables were determined by
      multivariate analyses. RESULTS: There was no difference in the energy and protein
      intake and nutritional status between older people on HD and PD. For the whole
      sample, multivariate analyses found that lower energy intake was related to fewer
      social networks (P = .002) and lower SF-12 Physical Component Scale (PCS) scores 
      (P = .021). A lower protein intake was related to worsening Index of Deprivation 
      scores (P = .028) and an interaction between SF-12 PCS and presence of possible
      depression (P = .015). CONCLUSION: Energy and protein intake in older people
      (regardless of modality) appears to be independently associated with psychosocial
      variables.
CI  - Copyright (c) 2013 National Kidney Foundation, Inc. Published by Elsevier Inc.
      All rights reserved.
AD  - Imperial College Healthcare National Health Service Trust, Imperial Renal and
      Transplant Centre, Hammersmith Hospital, London, United Kingdom. Electronic
      address: l.johansson@imperial.ac.uk.
FAU - Johansson, Lina
AU  - Johansson L
FAU - Hickson, Mary
AU  - Hickson M
FAU - Brown, Edwina A
AU  - Brown EA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - J Ren Nutr
JT  - Journal of renal nutrition : the official journal of the Council on Renal
      Nutrition of the National Kidney Foundation
JID - 9112938
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/10/04 [received]
PHST- 2013/02/24 [revised]
PHST- 2013/02/24 [accepted]
AID - S1051-2276(13)00076-9 [pii]
AID - 10.1053/j.jrn.2013.02.009 [doi]
PST - aheadofprint
SO  - J Ren Nutr. 2013 Apr 27. pii: S1051-2276(13)00076-9. doi:
      10.1053/j.jrn.2013.02.009.

PMID- 23631876
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1873-3778 (Electronic)
IS  - 0021-9673 (Linking)
VI  - 1292
DP  - 2013 May 31
TI  - Liquid chromatography-mass spectrometry in metabolomics research: Mass analyzers 
      in ultra high pressure liquid chromatography coupling.
PG  - 51-65
LID - 10.1016/j.chroma.2013.04.017 [doi]
LID - S0021-9673(13)00595-5 [pii]
AB  - The present review gives an introduction into the concept of metabolomics and
      provides an overview of the analytical tools applied in non-targeted metabolomics
      with a focus on liquid chromatography (LC). LC is a powerful analytical tool in
      the study of complex sample matrices. A further development and configuration
      employing Ultra-High Pressure Liquid Chromatography (UHPLC) is optimized to
      provide the largest known liquid chromatographic resolution and peak capacity.
      Reasonably UHPLC plays an important role in separation and consequent metabolite 
      identification of complex molecular mixtures such as bio-fluids. The most
      sensitive detectors for these purposes are mass spectrometers. Almost any mass
      analyzer can be optimized to identify and quantify small pre-defined sets of
      targets; however, the number of analytes in metabolomics is far greater.
      Optimized protocols for quantification of large sets of targets may be rendered
      inapplicable. Results on small target set analyses on different sample matrices
      are easily comparable with each other. In non-targeted metabolomics there is
      almost no analytical method which is applicable to all different matrices due to 
      limitations pertaining to mass analyzers and chromatographic tools. The
      specifications of the most important interfaces and mass analyzers are discussed.
      We additionally provide an exemplary application in order to demonstrate the
      level of complexity which remains intractable up to date. The potential of
      coupling a high field Fourier Transform Ion Cyclotron Resonance Mass Spectrometer
      (ICR-FT/MS), the mass analyzer with the largest known mass resolving power, to
      UHPLC is given with an example of one human pre-treated plasma sample. This
      experimental example illustrates one way of overcoming the necessity of faster
      scanning rates in the coupling with UHPLC. The experiment enabled the extraction 
      of thousands of features (analytical signals). A small subset of this
      compositional space could be mapped into a mass difference network whose topology
      shows specificity toward putative metabolite classes and retention time.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Research Unit Analytical BioGeoChemistry, Helmholtz Zentrum Munchen, German
      Research Center for Environment Health, D-85764 Neuherberg, Germany; German
      Center for Diabetes Research (DZD), Germany. Electronic address:
      sara.forcisi@helmholtz-muenchen.de.
FAU - Forcisi, Sara
AU  - Forcisi S
FAU - Moritz, Franco
AU  - Moritz F
FAU - Kanawati, Basem
AU  - Kanawati B
FAU - Tziotis, Dimitrios
AU  - Tziotis D
FAU - Lehmann, Rainer
AU  - Lehmann R
FAU - Schmitt-Kopplin, Philippe
AU  - Schmitt-Kopplin P
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - Netherlands
TA  - J Chromatogr A
JT  - Journal of chromatography. A
JID - 9318488
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/08/08 [received]
PHST- 2013/03/29 [revised]
PHST- 2013/04/10 [accepted]
PHST- 2013/04/11 [aheadofprint]
AID - S0021-9673(13)00595-5 [pii]
AID - 10.1016/j.chroma.2013.04.017 [doi]
PST - ppublish
SO  - J Chromatogr A. 2013 May 31;1292:51-65. doi: 10.1016/j.chroma.2013.04.017. Epub
      2013 Apr 11.

PMID- 23631862
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 2047-4881 (Electronic)
IS  - 2047-4873 (Linking)
DP  - 2013 Apr 30
TI  - Smoking ban in public areas is associated with a reduced incidence of hospital
      admissions due to ST-elevation myocardial infarctions in non-smokers. Results
      from the BREMEN STEMI REGISTRY.
AB  - INTRODUCTION: Laws banning tobacco smoking from public areas have been passed in 
      several countries, including the region of Bremen, Germany at the end of 2007.
      The present study analyses the incidence of hospital admissions due to
      ST-elevation myocardial infarctions (STEMIs) before and after such a smoking ban 
      was implemented, focusing on differences between smokers and non-smokers. In this
      respect, data of the Bremen STEMI Registry (BSR) give a complete epidemiological 
      overview of a region in northwest Germany with approximately 800,000 inhabitants 
      since all STEMIs are admitted to one central heart centre. METHODS AND RESULTS:
      Between January 2006 and December 2010, data from the BSR was analysed focusing
      on date of admission, age, gender, and prior nicotine consumption. A total of
      3545 patients with STEMI were admitted in the Bremen Heart Centre during this
      time period. Comparing 2006-2007 vs. 2008-2010, hence before and after the
      smoking ban, a 16% decrease of the number of STEMIs was observed: from a mean of 
      65 STEMI/month in 2006-2007 to 55/month in 2008-2010 (p < 0.01). The group of
      smokers showed a constant number of STEMIs: 25/month in 2006-2007 to 26/month in 
      2008-2010 (+4%, p = 0.8). However, in non-smokers, a significant reduction of
      STEMIs over time was found: 39/month in 2006-2007 to 29/month in 2008-2010 (-26%,
      p < 0.01). The decline of STEMIs in non-smokers was consistently observed in all 
      age groups and both sexes. Adjusting for potentially confounding factors like
      hypertension, obesity, and diabetes mellitus did not explain the observed
      decline. CONCLUSIONS: In the BSR, a significant decline of hospital admissions
      due to STEMIs in non-smokers was observed after the smoking ban in public areas
      came into force. No reduction of STEMI-related admissions was found in smokers.
      These results may be explained by the protection of non-smokers from passive
      smoking and the absence of such an effect in smokers by the dominant effect of
      active smoking.
AD  - The Institut fur Herz- und Kreislaufforschung am Klinikum Links der Weser,
      Bremen, Germany.
FAU - Schmucker, J
AU  - Schmucker J
FAU - Wienbergen, H
AU  - Wienbergen H
FAU - Seide, S
AU  - Seide S
FAU - Fiehn, E
AU  - Fiehn E
FAU - Fach, A
AU  - Fach A
FAU - Wurmann-Busch, B
AU  - Wurmann-Busch B
FAU - Gohlke, H
AU  - Gohlke H
FAU - Gunther, K
AU  - Gunther K
FAU - Ahrens, W
AU  - Ahrens W
FAU - Hambrecht, R
AU  - Hambrecht R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Eur J Prev Cardiol
JT  - European journal of preventive cardiology
JID - 101564430
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 2047487313483610 [pii]
AID - 10.1177/2047487313483610 [doi]
PST - aheadofprint
SO  - Eur J Prev Cardiol. 2013 Apr 30.

PMID- 23631851
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1879-3061 (Electronic)
IS  - 1043-2760 (Linking)
DP  - 2013 Apr 27
TI  - The fatty acid receptor FFA1/GPR40 a decade later: how much do we know?
LID - S1043-2760(13)00050-7 [pii]
LID - 10.1016/j.tem.2013.03.003 [doi]
AB  - Glucose homeostasis requires the highly coordinated regulation of insulin
      secretion by pancreatic beta cells. This is primarily mediated by glucose itself,
      but other nutrients, including free fatty acids (FFAs), potentiate the
      insulinotropic capacity of glucose. A decade ago, the seven-transmembrane domain 
      receptor (7TMR) GPR40 was demonstrated to be predominantly expressed in beta
      cells and activated by long-chain FFAs. This discovery added a new dimension to
      our understanding of FFA-mediated control of glucose homeostasis. Furthermore,
      GPR40 has drawn considerable interest as a novel therapeutic target to enhance
      insulin secretion in type 2 diabetes. However, our understanding of the biology
      of GPR40 remains incomplete and its physiological role controversial. Here we
      summarize the current state of knowledge and emerging concepts regarding the role
      of GPR40 in regulating glucose homeostasis.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Montreal Diabetes Research Center, Centre de Recherche du Centre Hospitalier de
      l'Universite de Montreal (CRCHUM), and Department of Medicine, Universite de
      Montreal, Montreal, QC, Canada.
FAU - Mancini, Arturo D
AU  - Mancini AD
FAU - Poitout, Vincent
AU  - Poitout V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Trends Endocrinol Metab
JT  - Trends in endocrinology and metabolism: TEM
JID - 9001516
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/01/21 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/03/21 [accepted]
AID - S1043-2760(13)00050-7 [pii]
AID - 10.1016/j.tem.2013.03.003 [doi]
PST - aheadofprint
SO  - Trends Endocrinol Metab. 2013 Apr 27. pii: S1043-2760(13)00050-7. doi:
      10.1016/j.tem.2013.03.003.

PMID- 23631844
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
DP  - 2013 Apr 8
TI  - Prevalence of and factors associated with sarcopenia in elderly patients with
      end-stage renal disease.
LID - S0261-5614(13)00102-7 [pii]
LID - 10.1016/j.clnu.2013.04.002 [doi]
AB  - BACKGROUND & AIMS: We investigated the prevalence of sarcopenia in elderly
      patients with end-stage renal disease (ESRD) and its relationship with various
      markers of nutrition, cognitive function, depressive symptoms, inflammation and
      beta2-microglobulin. METHODS: A cross-sectional study was conducted with 95
      patients having ESRD aged over 50 years. Sarcopenia was defined as a decline in
      both muscle mass and strength. RESULTS: The mean age was 63.9 +/- 10.0 years;
      56.8% were men and 52.6% had diabetes. Sarcopenia was highly prevalent in elderly
      patients with ESRD (37.0% in men and 29.3% in women). Subjective Global
      Assessment (SGA), inflammatory markers and beta2-microglobulin levels were
      significantly associated with sarcopenia, even after adjustment for age, gender, 
      diabetes, and body mass index. Additionally, patients with depressive symptoms
      showed a higher risk of sarcopenia relative to those without depressive symptoms 
      (odds ratio, OR = 6.87, 95% confidence interval, CI = 2.06-22.96) and sarcopenia 
      was more likely to be present in patients with mild cognitive dysfunction (OR =
      6.35, 95% CI = 1.62-34.96). CONCLUSIONS: Sarcopenia is highly prevalent in
      elderly patients with ESRD and is closely associated with SGA, inflammatory
      markers, beta2-microglobulin, depression and cognitive dysfunction.
CI  - Copyright (c) 2013 Elsevier Ltd and European Society for Clinical Nutrition and
      Metabolism. All rights reserved.
AD  - Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang,
      Republic of Korea; Kidney Research Institute, Hallym University College of
      Medicine, Republic of Korea.
FAU - Kim, Jwa-Kyung
AU  - Kim JK
FAU - Choi, Sun Ryoung
AU  - Choi SR
FAU - Choi, Myung Jin
AU  - Choi MJ
FAU - Kim, Sung Gyun
AU  - Kim SG
FAU - Lee, Young Ki
AU  - Lee YK
FAU - Noh, Jung Woo
AU  - Noh JW
FAU - Kim, Hyung Jik
AU  - Kim HJ
FAU - Song, Young Rim
AU  - Song YR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130408
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/09/17 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/04/02 [accepted]
AID - S0261-5614(13)00102-7 [pii]
AID - 10.1016/j.clnu.2013.04.002 [doi]
PST - aheadofprint
SO  - Clin Nutr. 2013 Apr 8. pii: S0261-5614(13)00102-7. doi:
      10.1016/j.clnu.2013.04.002.

PMID- 23631804
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Study protocol: the effect of vitamin D supplements on cardiometabolic risk
      factors among urban premenopausal women in a tropical country - a randomized
      controlled trial.
PG  - 416
LID - 10.1186/1471-2458-13-416 [doi]
AB  - BACKGROUND: Besides its classical role in musculoskeletal diseases, vitamin D
      deficiency has recently been found to be associated with cardiometabolic risks
      such as hypertension, diabetes mellitus and hypercholesterolemia. Although
      Malaysia is a sunshine-abundant country, recent studies found that vitamin D
      deficiency prevalence was significantly high. However, few published studies that
      measured its effect on cardiometabolic risk factors were found in Malaysia. There
      are also limited clinical trials carried out globally that tried to establish the
      causality of vitamin D and cardiometabolic risks. Therefore, a double blind,
      parallel, randomized controlled trial on vitamin D and cardiometabolic risks is
      planned to be carried out.The objective of this study is to investigate whether
      vitamin D supplements can reduce the cardiometabolic risk and improve the quality
      of life in urban premenopausal women with vitamin D deficiency. METHODS/DESIGN:
      Three hundred and twenty premenopausal women working in a public university in
      Kuala Lumpur, Malaysia will be randomized to receive either vitamin D supplement 
      (50,000 IU weekly for 8 weeks and 50,000 IU monthly for 10 months) or placebo for
      12 months. At baseline, all participants are vitamin D deficient (</= 20 ng/ml or
      50 nmol/l). Both participants and researchers will be blinded. The serum vitamin 
      D levels of all participants collected at various time points will only be
      analysed at the end of the trial. Outcome measures such as 25(OH) D3, HOMA-IR,
      blood pressure, full lipid profiles will be taken at baseline, 6 months and 12
      months. Health related quality of life will be measured at baseline and 12
      months. The placebo group will be given delayed treatment for six months after
      the trial. DISCUSSION: This trial will be the first study investigating the
      effect of vitamin D supplements on both the cardiometabolic risk and quality of
      life among urban premenopausal women in Malaysia. Our findings will contribute to
      the growing body of knowledge in the role of vitamin D supplements in the primary
      prevention for cardiometabolic disease. TRIAL REGISTRATION: ACTRN12612000452897.
AD  - Department of Social and Preventive Medicine, Faculty of Medicine, University of 
      Malaya, Kuala Lumpur, 50603, Malaysia. drmazliza@wp.moh.gov.my.
FAU - Ramly, Mazliza
AU  - Ramly M
FAU - Moy, Foong Ming
AU  - Moy FM
FAU - Pendek, Rokiah
AU  - Pendek R
FAU - Suboh, Suhaili
AU  - Suboh S
FAU - Tan Tong Boon, Alexander
AU  - Tan Tong Boon A
LA  - eng
PT  - Journal Article
DEP - 20130501
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3664076
OID - NLM: PMC3664076
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/10/25 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/05/01 [aheadofprint]
AID - 1471-2458-13-416 [pii]
AID - 10.1186/1471-2458-13-416 [doi]
PST - epublish
SO  - BMC Public Health. 2013 May 1;13:416. doi: 10.1186/1471-2458-13-416.

PMID- 23631744
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1366-5928 (Electronic)
IS  - 0049-8254 (Linking)
DP  - 2013 Apr 30
TI  - Elucidation of the biochemical basis for a clinical drug-drug interaction between
      atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic 
      acid (CP-778 875), a subtype selective agonist of the peroxisome
      proliferator-activated receptor alpha.
AB  - Abstract 1. 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid 
      (CP-778 875), an agonist of the peroxisome proliferator-activated receptor alpha,
      has been evaluated in the clinic to treat dyslipidemia and type 2 diabetes
      mellitus. Herein, we investigate the effect of CP-778 875 on the pharmacokinetics
      of atorvastatin acid and its metabolites in humans. 2. The study incorporated a
      fixed-sequence design conducted in two groups. Group A was designed to estimate
      the effects of multiple doses of CP-778 875 on the single dose pharmacokinetics
      of atorvastatin. Subjects in group A (n = 26) received atorvastatin (40 mg) on
      days 1 and 9 and CP-778 875 (1.0 mg QD) on days 5-12. Group B was designed to
      examine the effects of multiple doses of atorvastatin on the single dose
      pharmacokinetics of CP-778 875. Subjects in group B (n = 29) received CP-778 875 
      (0.3 mg) on days 1 and 9 and atorvastatin (40 mg QD) on days 5-12. 3. Mean
      maximum serum concentration (Cmax) and area under the curve of atorvastatin were 
      increased by 45% and 20%, respectively, upon co-administration with CP-778 875.
      Statistically significant increases in the systemic exposure of ortho- and
      para-hydroxyatorvastatin were also observed upon concomitant dosing with CP-778
      875. CP-778 875 pharmacokinetics, however, were not impacted upon concomitant
      dosing with atorvastatin. 4. Inhibition of organic anion transporting polypeptide
      1B1 by CP-778 875 (IC50 = 2.14 +/-0.40 muM) could be the dominant cause of the
      pharmacokinetic interaction as CP-778 875 did not exhibit significant inhibition 
      of cytochrome P450 3A4/3A5, multidrug resistant protein 1 or breast cancer
      resistant protein, which are also involved in the hepatobiliary disposition of
      atorvastatin.
AD  - Pharmacokinetics, Dynamics and Metabolism Department , Pfizer Inc., Cambridge, MA
      , USA .
FAU - Kalgutkar, Amit S
AU  - Kalgutkar AS
FAU - Chen, Danny
AU  - Chen D
FAU - Varma, Manthena V
AU  - Varma MV
FAU - Feng, Bo
AU  - Feng B
FAU - Terra, Steven G
AU  - Terra SG
FAU - Scialis, Renato J
AU  - Scialis RJ
FAU - Rotter, Charles J
AU  - Rotter CJ
FAU - Frederick, Kosea S
AU  - Frederick KS
FAU - West, Mark A
AU  - West MA
FAU - Goosen, Theunis C
AU  - Goosen TC
FAU - Gosset, James R
AU  - Gosset JR
FAU - Walsky, Robert L
AU  - Walsky RL
FAU - Francone, Omar L
AU  - Francone OL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Xenobiotica
JT  - Xenobiotica; the fate of foreign compounds in biological systems
JID - 1306665
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.3109/00498254.2013.791004 [doi]
PST - aheadofprint
SO  - Xenobiotica. 2013 Apr 30.

PMID- 23631624
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1532-7027 (Electronic)
IS  - 1041-0236 (Linking)
DP  - 2013 Apr 30
TI  - Depression Is to Diabetes as Antidepressants Are to Insulin: The Unraveling of an
      Analogy?
AB  - The common comparison of depression to diabetes enables the construction of
      depression as a nonstigmatizing chronic illness that requires medication. We
      explore, through the use of discourse analysis, how both long-term users of
      antidepressants and family physicians invoked this analogy in research
      interviews. Specifically, we show how these participants explicitly or implicitly
      challenged the aptness of the depression-diabetes analogy as framed either within
      a generic (and presumably type 1) conception of diabetes or within the model of
      type 2 diabetes. These challenges include demonstrating how the elements or
      inferences of the analogy do not correspond, and how the analogy does not have
      its intended effects. We consider the implications of the unraveling of this
      analogy for the construction of depression as a chronic medical condition, for
      the supposed ease of prescribing and taking antidepressants, and for the
      reduction of stigma.
AD  - a Department of Psychology , University of Saskatchewan.
FAU - McMullen, Linda M
AU  - McMullen LM
FAU - Sigurdson, Kristjan J
AU  - Sigurdson KJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Health Commun
JT  - Health communication
JID - 8908762
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1080/10410236.2012.753660 [doi]
PST - aheadofprint
SO  - Health Commun. 2013 Apr 30.

PMID- 23631608
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 30
TI  - Real-Time Hypoglycemia Detection from Continuous Glucose Monitoring Data of
      Subjects with Type 1 Diabetes.
AB  - Abstract Background: Hypoglycemia is a potentially fatal condition. Continuous
      glucose monitoring (CGM) has the potential to detect hypoglycemia in real time
      and thereby reduce time in hypoglycemia and avoid any further decline in blood
      glucose level. However, CGM is inaccurate and shows a substantial number of cases
      in which the hypoglycemic event is not detected by the CGM. The aim of this study
      was to develop a pattern classification model to optimize real-time hypoglycemia 
      detection. Materials and Methods: Features such as time since last insulin
      injection and linear regression, kurtosis, and skewness of the CGM signal in
      different time intervals were extracted from data of 10 male subjects
      experiencing 17 insulin-induced hypoglycemic events in an experimental setting.
      Nondiscriminative features were eliminated with SEPCOR and forward selection. The
      feature combinations were used in a Support Vector Machine model and the
      performance assessed by sample-based sensitivity and specificity and event-based 
      sensitivity and number of false-positives. Results: The best model was composed
      by using seven features and was able to detect 17 of 17 hypoglycemic events with 
      one false-positive compared with 12 of 17 hypoglycemic events with zero
      false-positives for the CGM alone. Lead-time was 14 min and 0 min for the model
      and the CGM alone, respectively. Conclusions: This optimized real-time
      hypoglycemia detection provides a unique approach for the diabetes patient to
      reduce time in hypoglycemia and learn about patterns in glucose excursions.
      Although these results are promising, the model needs to be validated on CGM data
      from patients with spontaneous hypoglycemic events.
AD  - 1 Department of Health Science and Technology, Aalborg University , Aalborg
      Denmark .
FAU - Jensen, Morten Hasselstrom
AU  - Jensen MH
FAU - Christensen, Toke Folke
AU  - Christensen TF
FAU - Tarnow, Lise
AU  - Tarnow L
FAU - Seto, Edmund
AU  - Seto E
FAU - Dencker Johansen, Mette
AU  - Dencker Johansen M
FAU - Hejlesen, Ole Kristian
AU  - Hejlesen OK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1089/dia.2013.0069 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 30.

PMID- 23631607
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Nateglinide and acarbose are comparably effective reducers of postprandial
      glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2
      diabetes.
PG  - 481-8
LID - 10.1089/dia.2013.0046 [doi]
AB  - Abstract Background: Recent studies have identified postprandial glycemic
      excursions as risk factors for diabetes complications. This study aimed to
      compare the effects of nateglinide and acarbose treatments on postprandial
      glycemic excursions in Chinese subjects with type 2 diabetes. Subjects and
      Methods: This was a multicenter, open-label, randomized, active-controlled,
      parallel-group study. One hundred three antihyperglycemic agent-naive subjects
      with type 2 diabetes (hemoglobin A1c range, 6.5-9.0%) were prospectively
      recruited from four hospitals in China. The intervention was nateglinide (120 mg 
      three times a day) or acarbose (50 mg three times a day) therapy for 2 weeks. A
      continuous glucose monitoring system was used to calculate the incremental area
      under the curve of postprandial blood glucose (AUCpp), the incremental glucose
      peak (IGP), mean amplitude of glycemic excursions, SD of blood glucose, the mean 
      of daily differences, and 24-h mean blood glucose (MBG). Subjects' serum glycated
      albumin and the plasma insulin levels were also analyzed. Results: Both agents
      caused significant reductions on AUCpp and IGP. Similarly, both treatment groups 
      showed significant improvements in the intra- and interday glycemic excursions,
      as well as the 24-h MBG and serum glycated albumin compared with baseline
      (P<0.001). However, neither of the agents produced a significantly better effect 
      (P>0.05). Moreover, the nateglinide-treated group had significantly increased
      insulin levels at 30 min and at 120 min after a standard meal compared with
      baseline, whereas the acarbose-treated group decreased. No serious adverse events
      occurred in either group. The rates of hypoglycemic episodes were comparable in
      the two groups, and no severe hypoglycemic episode occurred in either group.
      Conclusions: Nateglinide and acarbose were comparably effective in reducing
      postprandial glycemic excursions in antihyperglycemic agent-naive Chinese
      patients with type 2 diabetes, possibly through different pathophysiological
      mechanisms.
AD  - 1 Department of Endocrinology and Metabolism, Shanghai Jiao Tong University
      Affiliated Sixth People's Hospital , Shanghai Clinical Center for Diabetes,
      Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Diabetes Institute,
      Shanghai, China .
FAU - Zhou, Jian
AU  - Zhou J
FAU - Li, Hong
AU  - Li H
FAU - Zhang, Xiuzhen
AU  - Zhang X
FAU - Peng, Yongde
AU  - Peng Y
FAU - Mo, Yifei
AU  - Mo Y
FAU - Bao, Yuqian
AU  - Bao Y
FAU - Jia, Weiping
AU  - Jia W
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [aheadofprint]
AID - 10.1089/dia.2013.0046 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 Jun;15(6):481-8. doi: 10.1089/dia.2013.0046. Epub
      2013 Apr 30.

PMID- 23631606
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Abnormal Glycemic Profiles by CGMS in Obese First-Degree Relatives of Type 2
      Diabetes Mellitus Patients.
PG  - 461-5
LID - 10.1089/dia.2012.0333 [doi]
AB  - Abstract Introduction: The conventionally used oral glucose tolerance test (OGTT)
      has been the mainstay for diagnosis of diabetes and prediabetes. However, recent 
      studies have indicated that a continuous glucose monitoring system (CGMS) could
      detect impaired glycemia much earlier than OGTT, especially in certain groups. We
      aimed to study the 24-h glucose profile of high-risk obese first-degree relatives
      of type 2 diabetes patients by CGMS and ascertain if it was better than OGTT for 
      early detection of type 2 diabetes. Subjects and Methods: CGMS data of 20
      subjects each in normal glucose tolerance (NGT), impaired fasting glucose (IFG), 
      impaired glucose tolerance (IGT), and newly detected diabetes mellitus (NDDM)
      groups were obtained. We considered minimum, maximum, mean, and range of glucose 
      levels as well as number, duration, and area under the curve (AUC) for
      excursions. Results: We found three (15%) NGT, seven (35%) IFG, and eight (40%)
      IGT subjects showed excursions in the diabetes range, whereas 18 (90%) NGT and 17
      (85%) pure IFG subjects showed excursions in the IGT range. The maximum glucose
      values for NGT and IFG subjects were 176.0+/-41.4 mg/dL and 186.5+/-39.3 mg/dL,
      respectively, which is much above the present 2-h OGTT cutoff limit of 140 mg/dL.
      However, the average number of excursions and AUC of excursions did not differ
      significantly among the NGT, IFG, and IGT groups. The differences in the duration
      of excursion between NGT subjects with IFG values and NGT subjects with IGT
      values were statistically significant for an excursion limit of 140 mg/dL.
      However, this did not differ significantly between the IFG and IGT groups.
      Conclusions: CGMS indicated the presence of significant dysglycemia in
      first-degree relatives of diabetes patients without diabetes who were centrally
      obese. Hence it could be useful for early identification of individuals at
      greater risk of diabetes. A deranged glycemic profile may precede onset of overt 
      diabetes by a long time, which may partly explain why some patients with
      new-onset type 2 diabetes or even prediabetes present with vascular complications
      at the outset.
AD  - Department of Medicine, University College of Medical Sciences , Delhi, India .
FAU - Madhu, Sri Venkata
AU  - Madhu SV
FAU - Muduli, Subrat Kumar
AU  - Muduli SK
FAU - Avasthi, Rajnish
AU  - Avasthi R
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [aheadofprint]
AID - 10.1089/dia.2012.0333 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 Jun;15(6):461-5. doi: 10.1089/dia.2012.0333. Epub
      2013 Apr 30.

PMID- 23631605
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 30
TI  - Advanced Glycation End Products Assessed by Skin Autofluorescence-A New Marker of
      Diabetic Foot Ulceration.
AB  - Abstract Background: Accumulation of advanced glycation end products (AGEs) may
      contribute to diabetic foot ulceration (DFU). Our goal was to determine whether
      AGEs measurement by skin autofluorescence (SAF) would be an additional marker for
      DFU management. Patients and Methods: We performed SAF analysis in 66 patients
      with a history of DFU prospectively included and compared the results with those 
      of 84 control patients with diabetic peripheral neuropathy without DFU. We then
      assessed the prognostic value of SAF levels on the healing rate in the DFU group.
      Results: Mean SAF value was significantly higher in the DFU group in comparison
      with the control group, even after adjustment for other diabetes complications
      (3.2+/-0.6 arbitrary units vs. 2.9+/-0.6 arbitrary units; P=0.001). In the DFU
      group, 58 (88%) patients had an active wound at inclusion. The mean DFU duration 
      was 14+/-13 weeks. The healing rate was 47% after 2 months of appropriate foot
      care. A trend for a correlation between SAF levels and healing time in DFU
      subjects was observed but was not statistically significant (P=0.06).
      Conclusions: Increased SAF levels are associated with neuropathic foot
      complications in diabetes. Use of SAF measurement to assess foot vulnerability
      and to predict DFU events in high-risk patients appears to be promising.
AD  - 1 Department of Endocrinology and Diabetes, Hospices Civils de Lyon, Hospital
      Center of Lyon-Sud , Pierre Benite, France .
FAU - Vouillarmet, Julien
AU  - Vouillarmet J
FAU - Maucort-Boulch, Delphine
AU  - Maucort-Boulch D
FAU - Michon, Paul
AU  - Michon P
FAU - Thivolet, Charles
AU  - Thivolet C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1089/dia.2013.0009 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 30.

PMID- 23631604
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 30
TI  - Real-Time Continuous Glucose Monitoring or Continuous Subcutaneous Insulin
      Infusion, What Goes First?: Results of a Pilot Study.
AB  - Abstract Background: Dual devices allow both continuous subcutaneous insulin
      infusion (CSII) and real-time (RT) continuous glucose monitoring (CGM). Patients 
      usually start with CSII, adding RT-CGM later (CGM post-CSII). Lack of use of
      RT-CGM is the main limiting factor of dual device results. Initiating RT-CGM
      before CSII (CGM pre-CSII) could increase RT-CGM frequency use and further
      improve glycemic control. Subjects and Methods: In this 26-week pilot study, we
      randomly assigned, via sealed envelopes, 16 CSII and RT-CGM to naive patients 14 
      years of age or older with type 1 diabetes mellitus (T1DM) to CGM post-CSII or
      CGM pre-CSII. The Paradigm(R) Veo (Medtronic Inc., Northridge, CA) was the dual
      device used in all patients. The primary end point was frequency of use of RT-CGM
      between both groups at week 26. Results: We detected a significant higher RT-CGM 
      frequency use in the CGM pre-CSII group at week 26 (78.4+/-10.9% vs.
      56.0+/-40.8%; P=0.01), although we did not detect hemoglobin A1c level
      differences. In addition, CGM pre-CSII patients presented less time in
      hypoglycemia (average daily area under curve <70 mg/dL per 24 h, 0.87+/-1.02
      mg/dL/day vs. 3.32+/-2.19 mg/dL/day; P=0.021), and no severe hypoglycemia events 
      were detected during 26 weeks in this group. Conclusions: CGM pre-CSII is
      effective in increasing RT-CGM frequency use in T1DM patients. This is
      accompanied by a significant reduction in time in hypoglycemia.
AD  - 1 Service of Endocrinology, Ciudad Real University Hospital , Ciudad Real, Spain 
      .
FAU - Moreno-Fernandez, Jesus
AU  - Moreno-Fernandez J
FAU - Gomez, Francisco Javier
AU  - Gomez FJ
FAU - Gazquez, Montserrat
AU  - Gazquez M
FAU - Pedroche, Marta
AU  - Pedroche M
FAU - Garcia-Manzanares, Alvaro
AU  - Garcia-Manzanares A
FAU - Tenias, Jose Maria
AU  - Tenias JM
FAU - Benito, Pedro
AU  - Benito P
FAU - Gomez, Ines Rosa
AU  - Gomez IR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1089/dia.2013.0033 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 30.

PMID- 23631563
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 13
DP  - 2013
TI  - Risk factors for pulmonary tuberculosis in patients with chronic obstructive
      airway disease in Taiwan: a nationwide cohort study.
PG  - 194
LID - 10.1186/1471-2334-13-194 [doi]
AB  - BACKGROUND: An association between chronic obstructive pulmonary disease (COPD)
      and tuberculosis (TB) has been described, mainly due to smoking and
      corticosteroid use. Whether inhaled corticosteroid (ICS) therapy is associated
      with an increased risk of TB remains unclear. METHODS: We selected COPD cases by 
      using six diagnostic scenarios and control subjects from a nationwide health
      insurance database, and applied time-dependent Cox regression analysis to
      identify the risk factors for TB. RESULTS: Among 1,000,000 beneficiaries, 23,594 
      COPD cases and 47,188 non-COPD control subjects were selected. Cox regression
      analysis revealed that age, male gender, diabetes mellitus, end-stage renal
      disease, and cirrhosis, as well as COPD (hazard ratio = 2.468 [2.205-2.762]) were
      independent risk factors for TB. Among the COPD cases, those who developed TB
      received more oral corticosteroids and oral beta-agonists. Time-dependent Cox
      regression analysis revealed that age, male gender, diabetes mellitus, low
      income, oral corticosteroid dose, and oral beta-agonist dose, but not ICS dose,
      were independent risk factors for TB. The identified risk factors and their
      hazard ratios were similar among the COPD cases selected using different
      scenarios. CONCLUSION: Keeping a high suspicion and regularly monitoring for the 
      development of pulmonary TB in COPD patients are necessary, especially for those 
      receiving higher doses of oral corticosteroids and other COPD medications.
      Although ICS therapy has been shown to predispose COPD patients to pneumonia in
      large randomized clinical trials, it does not increase the risk of TB in real
      world practice.
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei,
      Taiwan. jywang@ntu.edu.tw.
FAU - Lee, Chih-Hsin
AU  - Lee CH
FAU - Lee, Ming-Chia
AU  - Lee MC
FAU - Shu, Chin-Chung
AU  - Shu CC
FAU - Lim, Chor-Shen
AU  - Lim CS
FAU - Wang, Jann-Yuan
AU  - Wang JY
FAU - Lee, Li-Na
AU  - Lee LN
FAU - Chao, Kun-Mao
AU  - Chao KM
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
SB  - IM
PMC - PMC3652752
OID - NLM: PMC3652752
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/11/30 [received]
PHST- 2013/04/25 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 1471-2334-13-194 [pii]
AID - 10.1186/1471-2334-13-194 [doi]
PST - epublish
SO  - BMC Infect Dis. 2013 Apr 30;13:194. doi: 10.1186/1471-2334-13-194.

PMID- 23631497
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1557-7600 (Electronic)
IS  - 1096-620X (Linking)
VI  - 16
IP  - 5
DP  - 2013 May
TI  - Potential efficacy of broccoli sprouts as a unique supplement for management of
      type 2 diabetes and its complications.
PG  - 375-82
LID - 10.1089/jmf.2012.2559 [doi]
AB  - Abstract Functional foods and their nutraceutical components are now considered
      as supplementary treatments in type 2 diabetes and prevention of its long-term
      complications. Young broccoli sprouts as a functional food contain many bioactive
      compounds specially sulforaphane. In hyperglycemic and oxidative conditions,
      sulforaphane has the potential to activate the NF-E2-related factor-2
      (Nrf2)-dependent antioxidant response-signaling pathway, induces phase 2 enzymes,
      attenuates oxidative stress, and inactivates nuclear factor kappa-B (NF-kappaB), 
      a key modulator of inflammatory pathways. Interestingly, sulforaphane induces
      some peroxisome proliferator-activated receptors, which contribute to lipid
      metabolism and glucose homeostasis. In animal and in vitro models, sulforaphane
      also shows antihypertensive, anticancer, cardioprotective, and
      hypocholesterolemic capacity, and has bactericidal properties against
      Helicobacter pylori. Supplementation of type 2 diabetics with high sulforaphane
      content broccoli sprouts resulted in increased total antioxidant capacity of
      plasma and in decreased oxidative stress index, lipid peroxidation, serum
      triglycerides, oxidized low-density lipoprotein (LDL)/LDL-cholesterol ratio,
      serum insulin, insulin resistance, and serum high-sensitive C-reactive protein.
      Sulforaphane could prevent nephropathy, diabetes-induced fibrosis, and vascular
      complications. Potential efficacy of sulforaphane and probably other bioactive
      components of young broccoli sprouts makes it as an excellent choice for
      supplementary treatment in type 2 diabetes.
AD  - 1 Obesity, Shahid Beheshti University of Medical Sciences , Tehran, Iran .
FAU - Bahadoran, Zahra
AU  - Bahadoran Z
FAU - Mirmiran, Parvin
AU  - Mirmiran P
FAU - Azizi, Fereidoun
AU  - Azizi F
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - J Med Food
JT  - Journal of medicinal food
JID - 9812512
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2013/04/30 [aheadofprint]
AID - 10.1089/jmf.2012.2559 [doi]
PST - ppublish
SO  - J Med Food. 2013 May;16(5):375-82. doi: 10.1089/jmf.2012.2559. Epub 2013 Apr 30.

PMID- 23631462
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1542-2011 (Electronic)
IS  - 1526-9523 (Linking)
DP  - 2013 Apr 30
TI  - Interconception Care for Women With Prior Gestational Diabetes Mellitus.
LID - 10.1111/jmwh.12019 [doi]
AB  - The diagnosis of gestational diabetes mellitus (GDM) signals greater pregnancy
      risk but also increased lifelong risk of developing diabetes and cardiovascular
      disease. In women with GDM, insulin resistance exceeds that observed in normal
      pregnancy and to varying degrees may persist or worsen after birth. Therefore,
      during postpartum and interconception periods, women with a history of GDM must
      be monitored for manifestations of increasing insulin resistance, hyperglycemia, 
      dyslipidemia, hypertension, and increased adiposity. Care of women with prior GDM
      in the postpartum and interconception periods affords clinicians a unique
      opportunity for targeted screening and health promotion. The objective of this
      review was to synthesize evidence related to interconception care for women
      following a pregnancy complicated by GDM and to suggest principles of care: 1)
      case finding and multiple patient/clinician reminders for women with prior GDM
      are necessary so that screening occurs in the postpartum through interconception 
      periods; 2) monitoring of metabolic (glucose) and cardiovascular risk (lipids,
      blood pressure, adiposity) should occur at regular intervals and more often in
      women with additional risk factors such as insulin use during pregnancy, early
      diagnosis of GDM, obesity, prediabetes, and dyslipidemia; 3) breastfeeding and
      use of long-term contraception should be encouraged; and 4) lifestyle
      modifications that are effective in preventing and delaying disease should be
      encouraged.
CI  - (c) 2013 by the American College of Nurse-Midwives.
FAU - Mielke, Ruth T
AU  - Mielke RT
FAU - Kaiser, Deborah
AU  - Kaiser D
FAU - Centuolo, Rhonda
AU  - Centuolo R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Midwifery Womens Health
JT  - Journal of midwifery & women's health
JID - 100909407
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
AID - 10.1111/jmwh.12019 [doi]
PST - aheadofprint
SO  - J Midwifery Womens Health. 2013 Apr 30. doi: 10.1111/jmwh.12019.

PMID- 23631443
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 2050-6511 (Electronic)
IS  - 2050-6511 (Linking)
VI  - 14
IP  - 1
DP  - 2013 Apr 30
TI  - Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel
      SGLT2 inhibitor, and metformin when co-administered in subjects with type 2
      diabetes mellitus.
PG  - 25
AB  - BACKGROUND: The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in
      absorptive epithelia of the renal tubules. Remogliflozin etabonate (RE) is the
      prodrug of remogliflozin, the active entity that inhibits SGLT2. An inhibitor of 
      this pathway would enhance urinary glucose excretion (UGE), and potentially
      improve plasma glucose concentrations in diabetic patients. RE is intended for
      use for the treatment of type 2 diabetes mellitus (T2DM) as monotherapy and in
      combination with existing therapies. Metformin, a dimethylbiguanide, is an
      effective oral antihyperglycemic agent widely used for the treatment of T2DM.
      METHODS: This was a randomized, open-label, repeat-dose, two-sequence, cross-over
      study in 13 subjects with T2DM. Subjects were randomized to one of two treatment 
      sequences in which they received either metformin alone, RE alone, or both over
      three, 3-day treatment periods separated by two non-treatment intervals of
      variable duration. On the evening before each treatment period, subjects were
      admitted and confined to the clinical site for the duration of the 3-day
      treatment period. Pharmacokinetic, pharmacodynamic (urine glucose and fasting
      plasma glucose), and safety (adverse events, vital signs, ECG, clinical
      laboratory parameters including lactic acid) assessments were performed at
      check-in and throughout the treatment periods. Pharmacokinetic sampling occurred 
      on Day 3 of each treatment period. RESULTS: This study demonstrated the lack of
      effect of RE on steady state metformin pharmacokinetics. Metformin did not affect
      the AUC of RE, remogliflozin, or its active metabolite, GSK279782, although Cmax 
      values were slightly lower for remogliflozin and its metabolite after
      co-administration with metformin compared with administration of RE alone.
      Metformin did not alter the pharmacodynamic effects (UGE) of RE. Concomitant
      administration of metformin and RE was well tolerated with minimal hypoglycemia, 
      no serious adverse events, and no increase in lactic acid. CONCLUSIONS:
      Coadministration of metformin and RE was well tolerated in this study. The
      results support continued development of RE as a treatment for T2DM.Trial
      registration: ClinicalTrials.gov: NCT00376038.
FAU - Hussey, Elizabeth K
AU  - Hussey EK
FAU - Kapur, Anita
AU  - Kapur A
FAU - O Connor-Semmes, Robin
AU  - O Connor-Semmes R
FAU - Tao, Wenli
AU  - Tao W
FAU - Rafferty, Bryan
AU  - Rafferty B
FAU - Polli, Joseph W
AU  - Polli JW
FAU - James, Charles D Jr
AU  - James CD Jr
FAU - Dobbins, Robert L
AU  - Dobbins RL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - BMC Pharmacol Toxicol
JT  - BMC pharmacology & toxicology
JID - 101590449
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PHST- 2012/02/17 [received]
PHST- 2013/04/30 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 2050-6511-14-25 [pii]
AID - 10.1186/2050-6511-14-25 [doi]
PST - aheadofprint
SO  - BMC Pharmacol Toxicol. 2013 Apr 30;14(1):25.

PMID- 23631326
OWN - NLM
STAT- In-Process
DA  - 20130501
IS  - 0035-8665 (Print)
IS  - 0035-8665 (Linking)
VI  - 159 Suppl 1
DP  - 2013 Mar
TI  - Managing endocrine dysfunction following blast injury to the male external
      genitalia.
PG  - i45-8
AB  - Blast injury to the external genitalia is associated with considerable morbidity,
      including the risk of primary hypogonadism due to insufficient testosterone. It
      is of the utmost importance that, prior to any testosterone replacement being
      commenced, serious consideration is given to sperm retrieval. The clinical and
      biochemical picture of hypogonadism allows a relatively straightforward diagnosis
      in most cases although it is important to be alert to the possibility of
      hypogonadism in the context of partial testicular tissue preservation. It is also
      prudent to consider the possibility of secondary hypogonadism especially in
      patients with chronic pain or those on opiate medication. Therapeutic options for
      testosterone replacement are diverse but relatively simple. This article aims to 
      give guidance to the non-specialist in the consideration, diagnosis, and
      treatment of hypogonadism, with particular reference to blast injury of the
      external genitalia.
AD  - Department of Endocrinology and Diabetes, Northumbria and Newcastle NHS Trusts,
      University of Newcastle, Newcastle upon Tyne, UK. DoctorDRWoods@aol.com
FAU - Woods, David R
AU  - Woods DR
FAU - Phillip, R
AU  - Phillip R
FAU - Quinton, R
AU  - Quinton R
LA  - eng
PT  - Journal Article
PL  - England
TA  - J R Army Med Corps
JT  - Journal of the Royal Army Medical Corps
JID - 7505627
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PST - ppublish
SO  - J R Army Med Corps. 2013 Mar;159 Suppl 1:i45-8.

PMID- 23631255
OWN - NLM
STAT- In-Process
DA  - 20130501
IS  - 0029-0203 (Print)
IS  - 0029-0203 (Linking)
VI  - 117
IP  - 3
DP  - 2013 Mar
TI  - [Noninvasive analysis of retinal microstructure and function: challenges and a
      promising future].
PG  - 212-44; discussion 245
AB  - Challenges in the evaluation of the retinal microstructure. To facilitate
      evaluation of the retinal microstructure we participated in the development of a 
      scanning laser ophthalmoscope (SLO) for 32 years. The 'retro-mode' is the latest 
      developed lateral aperture SLO made in Japan. This instrument enables us to
      observe the cystoid spaces and retinal microfolds underlying the epiretinal
      membrane. We investigated the pathogenesis and the mechanism of early development
      of idiopathic macular holes (MHs) and the vitreomacular interface in idiopathic
      full-thickness MHs using spectral-domain optical coherence tomography (SD-OCT).
      We studied the anatomic morphology of stage 1-A impending MHs, characterized by a
      foveolar yellow spot, using SD-OCT in the fellow eyes of patients diagnosed with 
      a full-thickness MH. SD-OCT showed the reflectivity of the perifoveal posterior
      vitreous detachment (PVD) with vitreofoveal adhesion in the eyes with a yellow
      spot; the foveal microstructure had a triangular foveolar detachment of the cone 
      outer segment tip line. The foveolar detachment of the cone outer segment tip
      line might be responsible for the yellow spot seen in stage 1-A MHs. Using
      SD-OCT, we also analyzed the vitreomacular interface in idiopathic full-thickness
      MHs and identified four configurations of the vitreomacular interface in MHs
      without a complete PVD. The majority, i.e., 92%, of eyes with a MH without a
      complete PVD are likely due to the anteroposterior vitreofoveal traction exerted 
      by a perifoveal PVD. About 55% of cases with an open roof in the eyes without a
      complete PVD might be at risk of progression to operculum formation (loss of
      retinal tissue). 2. Challenges in the evaluation of retinal function SLO
      microperimetry is used to evaluate the retinal function during observation of the
      retinal microstructure. We evaluated the retinal sensitivity and the focal visual
      acuity using our original microperimetry program and clarified the
      characteristics of the preferred retinal locus (PRL) in macular diseases and the 
      importance of the PRL evaluation. Further refinement of the SLO as an all-in-one 
      instrument with the addition of a treatment feature is planned. We evaluated the 
      retinal blood flow (RBF) using a laser Doppler velocimetry instrument that we
      developed. In clinical studies, we found that the RBF decreased in patients with 
      type 2 diabetes mellitus with no or mild retinopathy compared with healthy
      subjects. In in vivo animal studies performed in anesthetized cats, we elucidated
      the mechanism of RBF regulation in response to physiologic stimuli, i.e.,
      systemic hypoxia, hypercapnia, hyperoxia, hyperglycemia and hypertension. We
      showed that the retinal vascular endothelium plays an important role in
      regulating the RBF. In in vitro studies, we examined the effects of laminar shear
      stress on gene expression in human retinal microvascular endothelial cells
      (HRMECs) and found that long-term exposure to physiologic shear stress in the
      retinal arterioles upregulated eNOS and thrombomodulin mRNA expression and
      down-regulated ET-1 mRNA expression in the HRMECs. In ex vivo studies, we found
      that simvastatin, pioglitazone, resveratrol and fenofibrate dilated isolated
      porcine retinal arterioles, suggesting that systemic administration of these
      drugs may have the therapeutic potential to improve the impaired RBF in patients 
      with type 2 diabetes mellitus. 3. Challenges to the development of a telemedicine
      support system We established a real-time telemedicine system that can transmit
      precise retinal images of patients between Asahikawa Medical University Hospital 
      and our branch hospitals. We also developed a method of 3-dimensional
      high-definition transmission and stereoscopic display for ophthalmology.
      Moreover, we established a system to share medical information using Peer to Peer
      technology and network control technology that can transmit urgent information
      during a disaster. In response to a request from the Chinese Government, which
      has limited medical facilities in rural areas, we donated our system to four
      hospitals in Beijing, Shanghai, Sichuan and Shaanxi Provinces. As a result of the
      development of our unique telemedicine home medical care system, patients can be 
      followed at home even after discharge from a hospital. 4. Conclusions. We believe
      that ophthalmologists can obtain important information about not only ocular but 
      also systemic diseases by analyzing the retinal microstructure and functions
      simultaneously and can share this information worldwide via the telemedicine
      technology that we established, which can be a promising advance in patient care.
AD  - Department of Ophthalmology, Asahikawa Medical University, Hokkaido, Japan.
      pyoshida@asahikawa-med.ac.jp
FAU - Yoshida, Akitoshi
AU  - Yoshida A
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Ganka Gakkai Zasshi
JT  - Nippon Ganka Gakkai zasshi
JID - 7505716
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PST - ppublish
SO  - Nihon Ganka Gakkai Zasshi. 2013 Mar;117(3):212-44; discussion 245.

PMID- 23631252
OWN - NLM
STAT- In-Process
DA  - 20130501
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 71
IP  - 3
DP  - 2013 Mar
TI  - [Significance of combination therapy with an insulin sensitizer and a
      DPP-4(dipeptidyl peptidase-4) inhibitor].
PG  - 555-62
AB  - Type 2 diabetes mellitus is characterized by insulin resistance in peripheral
      tissues and relative impairment in insulin secretion from pancreatic beta cell.
      Insulin sensitizers such as metformin and pioglitazone reduce peripheral insulin 
      resistance, whereas dipeptidyl peptidase-4(DPP-4) inhibitors augment postprandial
      insulin secretion and inhibit glucagon secretion. Combination therapy with an
      insulin sensitizer and a DPP-4 inhibitor provides substantial and additive
      glycemic improvement because of the complementary mechanisms of action of these
      agents. In addition, combination therapy with these agents is an attractive from 
      the perspective of low incidence of hypoglycemia, beta cell preservation,
      augmentation of the incretin effect, and anti-atherogenic action.
AD  - Department of Metabolic Medicine, Osaka University Graduate School of Medicine.
FAU - Yasuda, Tetsuyuki
AU  - Yasuda T
FAU - Shimomura, Iichiro
AU  - Shimomura I
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PST - ppublish
SO  - Nihon Rinsho. 2013 Mar;71(3):555-62.

PMID- 23631232
OWN - NLM
STAT- In-Process
DA  - 20130501
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 71
IP  - 3
DP  - 2013 Mar
TI  - [Effect of smoking on diabetes mellitus and dyslipidemia (effect of smoking on
      glucose and lipid metabolism)].
PG  - 443-8
AB  - Smoking is one of the important risk factors of cardiovascular disease. Its
      effects on arteriosclerotic diseases act not only directly but indirectly, by
      worsening control of blood pressure, lipid metabolism and glucose metabolism. And
      in patients with diabetes, it affects both macroangiopathy and diabetic
      microangiopathy(especially diabetic nephronpathy) adversely. Unfortunately, all
      effects and mechanisms of smoking on metabolic diseases are not yet unclear. But 
      smoking cessation improves lipid metabolism and may improve glucose metabolism
      and may decrease risk of impaired glucose tolerance, type 2 diabetes, and
      diabetic microangiopathy. All patients with metabolic diseases must quit smoking 
      for control of diseases and prevention of arteriosclerotic disease as soon as
      possible.
AD  - Center for Medical Sciences, Ibaraki Prefectural University of Health Sciences.
FAU - Saito, Kazumi
AU  - Saito K
FAU - Sone, Hirohito
AU  - Sone H
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
SB  - IM
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:00
CRDT- 2013/05/02 06:00
PST - ppublish
SO  - Nihon Rinsho. 2013 Mar;71(3):443-8.

PMID- 23630949
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
DP  - 2013 Apr 29
TI  - Prevalence and Risk Factors for Hypertension in Hemophilia.
AB  - Hypertension (HTN) is a major risk factor for intracranial hemorrhage. We,
      therefore, investigated the prevalence, treatment, and control of HTN in adult
      patients with hemophilia (PWH). PWH>/=18 years (n=458) from 3 geographically
      different cohorts in the United States were evaluated retrospectively for HTN and
      risk factors. Results were compared with the nationally representative sample
      provided by the contemporary National Health and Nutrition Examination Survey
      (NHANES). PWH had a significantly higher prevalence of HTN compared with NHANES. 
      Overall, the prevalence of HTN was 49.1% in PWH compared with 31.7% in NHANES. At
      ages 18 to 44, 45 to 64, 65 to 74, and >/=75 years, the prevalence of HTN for PWH
      was 31.8%, 72.6%, 89.7%, and 100.0% compared with 12.5%, 41.2%, 64.1%, and 71.7% 
      in NHANES, respectively. Of treated hypertensive PWH, only 27.1% were controlled,
      compared with 47.7% in NHANES (all P<0.05). Age, body mass index, diabetes
      mellitus, and renal function were independently associated with HTN. Among
      patients with moderate or severe hemophilia there was a trend ( approximately
      1.5-fold) for higher odds of having HTN compared with patients with mild
      hemophilia. On the basis of these results, new care models for adult PWH and
      further studies for the causes of HTN in hemophilia are recommended.
AD  - Division of Hematology/Oncology, Department of Medicine, University of
      California, San Diego, CA.
FAU - von Drygalski, Annette
AU  - von Drygalski A
FAU - Kolaitis, Nicholas A
AU  - Kolaitis NA
FAU - Bettencourt, Ricki
AU  - Bettencourt R
FAU - Bergstrom, Jaclyn
AU  - Bergstrom J
FAU - Kruse-Jarres, R
AU  - Kruse-Jarres R
FAU - Quon, Doris V
AU  - Quon DV
FAU - Wassel, Christina
AU  - Wassel C
FAU - Li, Ming C
AU  - Li MC
FAU - Waalen, Jill
AU  - Waalen J
FAU - Elias, Darlene J
AU  - Elias DJ
FAU - Mosnier, Laurent O
AU  - Mosnier LO
FAU - Allison, Matthew
AU  - Allison M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Hypertension
JT  - Hypertension
JID - 7906255
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - HYPERTENSIONAHA.113.01174 [pii]
AID - 10.1161/HYPERTENSIONAHA.113.01174 [doi]
PST - aheadofprint
SO  - Hypertension. 2013 Apr 29.

PMID- 23630616
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Ablation of Ghrelin O-Acyltransferase Does Not Improve Glucose Intolerance or
      Body Adiposity in Mice on a Leptin-Deficient ob/ob Background.
PG  - e61822
LID - 10.1371/journal.pone.0061822 [doi]
AB  - Type 2 Diabetes is a global health burden and based on current estimates will
      become an even larger problem in the future. Developing new strategies to prevent
      and treat diabetes is a scientific challenge of high priority. The stomach
      hormone ghrelin has been associated with playing a role in the regulation of
      glucose homeostasis. However, its precise mechanism and impact on whole glucose
      metabolism remains to be elucidated. This study aims to clarify the role of the
      two ghrelin isoforms acyl- and desacyl ghrelin in regulating glucose homeostasis.
      Therefore ghrelin activating enzyme Ghrelin-O-acyltransferase (GOAT) was ablated 
      in leptin-deficient ob/ob mice to study whether specific acyl ghrelin deficiency 
      or desacyl ghrelin abundance modifies glucose tolerance on a massively obese
      background. As targeted deletion of acyl ghrelin does not improve glucose
      homeostasis in our GOAT-ob/ob mouse model we conclude that neither acyl ghrelin
      nor the increased ratio of desacyl/acyl ghrelin is crucial for controlling
      glucose homeostasis in the here presented model of massive obesity induced by
      leptin deficiency.
AD  - Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm,
      Sweden.
FAU - Kirchner, Henriette
AU  - Kirchner H
FAU - Heppner, Kristy M
AU  - Heppner KM
FAU - Holland, Jenna
AU  - Holland J
FAU - Kabra, Dhiraj
AU  - Kabra D
FAU - Tschop, Matthias H
AU  - Tschop MH
FAU - Pfluger, Paul T
AU  - Pfluger PT
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3632576
OID - NLM: PMC3632576
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/29 [received]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/22 [epublish]
AID - 10.1371/journal.pone.0061822 [doi]
AID - PONE-D-12-33810 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 22;8(4):e61822. doi: 10.1371/journal.pone.0061822. Print 2013.

PMID- 23630613
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - The risk of type 2 diabetes in men is synergistically affected by parental
      history of diabetes and overweight.
PG  - e61763
LID - 10.1371/journal.pone.0061763 [doi]
AB  - Interactions between genetic- and lifestyle factors may be of specific importance
      for the development of type 2 diabetes. Only a few earlier studies have evaluated
      interaction effects for the combination of family history of diabetes and
      presence of risk factors related to lifestyle. We explored whether 60-year-old
      men and women from Stockholm with a parental history of diabetes are more
      susceptible than their counterparts without a parental history of diabetes to the
      negative influence from physical inactivity, overweight or smoking regarding risk
      of developing type 2 diabetes. The study comprised 4232 participants of which 205
      men and 113 women had diabetes (the vast majority type 2 diabetes considering the
      age of study participants) and 224 men and 115 women had prediabetes (fasting
      glucose 6.1-6.9 mmol/l). Prevalence odds ratios (OR) with 95% confidence
      intervals (95% CI) were calculated using logistic regression. Biologic
      interaction was analyzed using a Synergy index (S) score. The crude OR for type 2
      diabetes associated with a parental history of diabetes was 2.4 (95% CI 1.7-3.5) 
      in men and 1.4 (95% CI 0.9-2.3) in women. Adjustments for overweight, physical
      inactivity and current smoking had minimal effects on the association observed in
      men whereas in women it attenuated results. In men, but not in women, a
      significant interaction effect that synergistically increases the risk of
      developing type 2 diabetes was observed for the combination of BMI>30 and a
      parental history of diabetes, S 2.4 (95% CI 1.1-5.1). No signs of interactions
      were noted for a parental history of diabetes combined with physical inactivity
      and smoking, respectively. In conclusion, obesity in combination with presence of
      a parental history of diabetes may be particularly hazardous in men as these two 
      factors were observed to synergistically increase the risk of developing type 2
      diabetes in men.
AD  - Division of Cardiovascular Epidemiology, Institute of Environmental Medicine,
      Karolinska Institutet, Stockholm, Sweden.
FAU - Wikner, Cecilia
AU  - Wikner C
FAU - Gigante, Bruna
AU  - Gigante B
FAU - Hellenius, Mai-Lis
AU  - Hellenius ML
FAU - de Faire, Ulf
AU  - de Faire U
FAU - Leander, Karin
AU  - Leander K
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3632519
OID - NLM: PMC3632519
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/26 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/22 [epublish]
AID - 10.1371/journal.pone.0061763 [doi]
AID - PONE-D-12-33728 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 22;8(4):e61763. doi: 10.1371/journal.pone.0061763. Print 2013.

PMID- 23630589
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - FGF21 Can Be Mimicked In Vitro and In Vivo by a Novel Anti-FGFR1c/beta-Klotho
      Bispecific Protein.
PG  - e61432
LID - 10.1371/journal.pone.0061432 [doi]
AB  - The endocrine hormone FGF21 has attracted considerable interest as a potential
      therapeutic for treating diabetes and obesity. As an alternative to the native
      cytokine, we generated bispecific Avimer polypeptides that bind with high
      affinity and specificity to one of the receptor and coreceptor pairs used by
      FGF21, FGFR1c and beta-Klotho. These Avimers exhibit FGF21-like activity in in
      vitro assays with potency greater than FGF21. In a study conducted in obese male 
      cynomolgus monkeys, animals treated with an FGFR1c/beta-Klotho bispecific Avimer 
      showed improved metabolic parameters and reduced body weight comparable to the
      effects seen with FGF21. These results not only demonstrate the essential roles
      of FGFR1c and beta-Klotho in mediating the metabolic effects of FGF21, they also 
      describe a first bispecific activator of this unique receptor complex and provide
      validation for a novel therapeutic approach to target this potentially important 
      pathway for treating diabetes and obesity.
AD  - Therapeutic Discovery, Amgen Inc., South San Francisco, California, United States
      of America.
FAU - Smith, Richard
AU  - Smith R
FAU - Duguay, Amy
AU  - Duguay A
FAU - Bakker, Alice
AU  - Bakker A
FAU - Li, Peng
AU  - Li P
FAU - Weiszmann, Jennifer
AU  - Weiszmann J
FAU - Thomas, Melissa R
AU  - Thomas MR
FAU - Alba, Benjamin M
AU  - Alba BM
FAU - Wu, Xinle
AU  - Wu X
FAU - Gupte, Jamila
AU  - Gupte J
FAU - Yang, Li
AU  - Yang L
FAU - Stevens, Jennitte
AU  - Stevens J
FAU - Hamburger, Agnes
AU  - Hamburger A
FAU - Smith, Stephen
AU  - Smith S
FAU - Chen, Jiyun
AU  - Chen J
FAU - Komorowski, Renee
AU  - Komorowski R
FAU - Moore, Kevin W
AU  - Moore KW
FAU - Veniant, Murielle M
AU  - Veniant MM
FAU - Li, Yang
AU  - Li Y
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3632592
OID - NLM: PMC3632592
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/08 [received]
PHST- 2013/03/09 [accepted]
PHST- 2013/04/22 [epublish]
AID - 10.1371/journal.pone.0061432 [doi]
AID - PONE-D-13-06661 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 22;8(4):e61432. doi: 10.1371/journal.pone.0061432. Print 2013.

PMID- 23630563
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Correction: Smoking Cessation Increases Short-Term Risk of Type 2 Diabetes
      Irrespective of Weight Gain: The Japan Public Health Center-Based Prospective
      Study.
LID - 10.1371/annotation/23aa7c42-9a4d-42a7-8f50-9d0ac4b85396 [doi]
AB  - [This corrects the article on p. e17061 in vol. 7.].
FAU - Oba, Shino
AU  - Oba S
FAU - Noda, Mitsuhiko
AU  - Noda M
FAU - Waki, Kayo
AU  - Waki K
FAU - Nanri, Akiko
AU  - Nanri A
FAU - Kato, Masayuki
AU  - Kato M
FAU - Takahashi, Yoshihiko
AU  - Takahashi Y
FAU - Poudel-Tandukar, Kalpana
AU  - Poudel-Tandukar K
FAU - Matsushita, Yumi
AU  - Matsushita Y
FAU - Inoue, Manami
AU  - Inoue M
FAU - Mizoue, Tetsuya
AU  - Mizoue T
FAU - Tsugane, Shoichiro
AU  - Tsugane S
CN  - for the Japan Public Health Center-based Prospective Study Group
LA  - ENG
PT  - PUBLISHED ERRATUM
DEP - 20130415
TA  - PLoS One
JT  - PloS one
JID - 101285081
PMC - PMC3632408
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/15 [epublish]
AID - 10.1371/annotation/23aa7c42-9a4d-42a7-8f50-9d0ac4b85396 [doi]
PST - epublish
SO  - PLoS One. 2013 Apr 15;8(4). doi:
      10.1371/annotation/23aa7c42-9a4d-42a7-8f50-9d0ac4b85396. Print 2013.

PMID- 23630502
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130430
DCOM- 20130501
LR  - 20130502
IS  - 1664-042X (Electronic)
IS  - 1664-042X (Linking)
VI  - 4
DP  - 2013
TI  - Novel insights into obesity and diabetes through genome-scale metabolic modeling.
PG  - 92
LID - 10.3389/fphys.2013.00092 [doi]
AB  - The growing prevalence of metabolic diseases, such as obesity and diabetes, are
      putting a high strain on global healthcare systems as well as increasing the
      demand for efficient treatment strategies. More than 360 million people worldwide
      are suffering from type 2 diabetes (T2D) and, with the current trends, the
      projection is that 10% of the global adult population will be affected by 2030.
      In light of the systemic properties of metabolic diseases as well as the
      interconnected nature of metabolism, it is necessary to begin taking a holistic
      approach to study these diseases. Human genome-scale metabolic models (GEMs) are 
      topological and mathematical representations of cell metabolism and have proven
      to be valuable tools in the area of systems biology. Successful applications of
      GEMs include the process of gaining further biological and mechanistic
      understanding of diseases, finding potential biomarkers, and identifying new drug
      targets. This review will focus on the modeling of human metabolism in the field 
      of obesity and diabetes, showing its vast range of applications of clinical
      importance as well as point out future challenges.
AD  - Systems and Synthetic Biology, Department of Chemical and Biological Engineering,
      Chalmers University of Technology Gothenburg, Sweden.
FAU - Varemo, Leif
AU  - Varemo L
FAU - Nookaew, Intawat
AU  - Nookaew I
FAU - Nielsen, Jens
AU  - Nielsen J
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC3635026
OID - NLM: PMC3635026
OTO - NOTNLM
OT  - constraint-based modeling
OT  - diabetes
OT  - genome-scale metabolic models
OT  - metabolic networks
OT  - metabolism
OT  - obesity
OT  - systems biology
OT  - topology
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:01
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/13 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/04/25 [epublish]
AID - 10.3389/fphys.2013.00092 [doi]
PST - epublish
SO  - Front Physiol. 2013 Apr 25;4:92. doi: 10.3389/fphys.2013.00092. Print 2013.

PMID- 23630454
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1545-7885 (Electronic)
IS  - 1544-9173 (Linking)
VI  - 11
IP  - 4
DP  - 2013 Apr
TI  - PICK1 Deficiency Impairs Secretory Vesicle Biogenesis and Leads to Growth
      Retardation and Decreased Glucose Tolerance.
PG  - e1001542
LID - 10.1371/journal.pbio.1001542 [doi]
AB  - Secretory vesicles in endocrine cells store hormones such as growth hormone (GH) 
      and insulin before their release into the bloodstream. The molecular mechanisms
      governing budding of immature secretory vesicles from the trans-Golgi network
      (TGN) and their subsequent maturation remain unclear. Here, we identify the lipid
      binding BAR (Bin/amphiphysin/Rvs) domain protein PICK1 (protein interacting with 
      C kinase 1) as a key component early in the biogenesis of secretory vesicles in
      GH-producing cells. Both PICK1-deficient Drosophila and mice displayed somatic
      growth retardation. Growth retardation was rescued in flies by reintroducing
      PICK1 in neurosecretory cells producing somatotropic peptides. PICK1-deficient
      mice were characterized by decreased body weight and length, increased fat
      accumulation, impaired GH secretion, and decreased storage of GH in the
      pituitary. Decreased GH storage was supported by electron microscopy showing
      prominent reduction in secretory vesicle number. Evidence was also obtained for
      impaired insulin secretion associated with decreased glucose tolerance. PICK1
      localized in cells to immature secretory vesicles, and the PICK1 BAR domain was
      shown by live imaging to associate with vesicles budding from the TGN and to
      possess membrane-sculpting properties in vitro. In mouse pituitary, PICK1
      co-localized with the BAR domain protein ICA69, and PICK1 deficiency abolished
      ICA69 protein expression. In the Drosophila brain, PICK1 and ICA69
      co-immunoprecipitated and showed mutually dependent expression. Finally, both in 
      a Drosophila model of type 2 diabetes and in high-fat-diet-induced obese mice, we
      observed up-regulation of PICK1 mRNA expression. Our findings suggest that PICK1,
      together with ICA69, is critical during budding of immature secretory vesicles
      from the TGN and thus for vesicular storage of GH and possibly other hormones.
      The data link two BAR domain proteins to membrane remodeling processes in the
      secretory pathway of peptidergic endocrine cells and support an important role of
      PICK1/ICA69 in maintenance of metabolic homeostasis.
AD  - Laboratory for Molecular Pharmacology, Novo Nordisk Foundation Center for Basic
      Metabolic Research, The Faculty of Health Sciences, Panum Institute, University
      of Copenhagen, Copenhagen, Denmark ; Department of Neuroscience and Pharmacology,
      The Faculty of Health Sciences, Panum Institute, University of Copenhagen,
      Copenhagen, Denmark.
FAU - Holst, Birgitte
AU  - Holst B
FAU - Madsen, Kenneth L
AU  - Madsen KL
FAU - Jansen, Anna M
AU  - Jansen AM
FAU - Jin, Chunyu
AU  - Jin C
FAU - Rickhag, Mattias
AU  - Rickhag M
FAU - Lund, Viktor K
AU  - Lund VK
FAU - Jensen, Morten
AU  - Jensen M
FAU - Bhatia, Vikram
AU  - Bhatia V
FAU - Sorensen, Gunnar
AU  - Sorensen G
FAU - Madsen, Andreas N
AU  - Madsen AN
FAU - Xue, Zhichao
AU  - Xue Z
FAU - Moller, Siri K
AU  - Moller SK
FAU - Woldbye, David
AU  - Woldbye D
FAU - Qvortrup, Klaus
AU  - Qvortrup K
FAU - Huganir, Richard
AU  - Huganir R
FAU - Stamou, Dimitrios
AU  - Stamou D
FAU - Kjaerulff, Ole
AU  - Kjaerulff O
FAU - Gether, Ulrik
AU  - Gether U
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - PLoS Biol
JT  - PLoS biology
JID - 101183755
SB  - IM
PMC - PMC3635866
OID - NLM: PMC3635866
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04 [ppublish]
PHST- 2012/10/31 [received]
PHST- 2013/03/12 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.1371/journal.pbio.1001542 [doi]
AID - PBIOLOGY-D-12-04348 [pii]
PST - ppublish
SO  - PLoS Biol. 2013 Apr;11(4):e1001542. doi: 10.1371/journal.pbio.1001542. Epub 2013 
      Apr 23.

PMID- 23630453
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1545-7885 (Electronic)
IS  - 1544-9173 (Linking)
VI  - 11
IP  - 4
DP  - 2013 Apr
TI  - PICK1 and ICA69 Control Insulin Granule Trafficking and Their Deficiencies Lead
      to Impaired Glucose Tolerance.
PG  - e1001541
LID - 10.1371/journal.pbio.1001541 [doi]
AB  - Diabetes is a metabolic disorder characterized by hyperglycemia. Insulin, which
      is secreted by pancreatic beta cells, is recognized as the critical regulator of 
      blood glucose, but the molecular machinery responsible for insulin trafficking
      remains poorly defined. In particular, the roles of cytosolic factors that govern
      the formation and maturation of insulin granules are unclear. Here we report that
      PICK1 and ICA69, two cytosolic lipid-binding proteins, formed heteromeric
      BAR-domain complexes that associated with insulin granules at different stages of
      their maturation. PICK1-ICA69 heteromeric complexes associated with immature
      secretory granules near the trans-Golgi network (TGN). A brief treatment of
      Brefeldin A, which blocks vesicle budding from the Golgi, increased the amount of
      PICK1 and ICA69 at TGN. On the other hand, mature secretory granules were
      associated with PICK1 only, not ICA69. PICK1 deficiency in mice caused the
      complete loss of ICA69 and led to increased food and water intake but lower body 
      weight. Glucose tolerance tests demonstrated that these mutant mice had high
      blood glucose, a consequence of insufficient insulin. Importantly, while the
      total insulin level was reduced in PICK1-deficient beta cells, proinsulin was
      increased. Lastly, ICA69 knockout mice also displayed similar phenotype as the
      mice deficient in PICK1. Together, our results indicate that PICK1 and ICA69 are 
      key regulators of the formation and maturation of insulin granules. AUTHOR
      SUMMARY: Insulin is a key regulator of blood glucose and insufficient insulin
      leads to diabetes. Insulin is synthesized as proinsulin, processed in endoplasmic
      reticulum and Golgi, and eventually packaged into insulin granules, a type of
      dense core vesicles. Despite its importance, the molecular mechanisms governing
      the biogenesis and maturation of insulin granules are not fully understood. In
      this study, we identified two cytosolic proteins, PICK1 and ICA69, as important
      regulators of insulin granule biogenesis and maturation. Both PICK1 and ICA69
      have the banana-shaped BAR domain that can bend the lipid membrane and help the
      formation of dense core vesicles. We show that without PICK1 or ICA69, insulin
      granules cannot be properly formed and, as a result, proinsulin cannot be
      effectively processed into mature insulin. Mice lacking functional PICK1 or ICA69
      genes have reduced insulin but increased proinsulin. Consequently, these mice
      have high levels of glucose, a prominent feature found in diabetes patients.
      These results add to previous findings that PICK1 is important for the generation
      of proacrosomal granules found in cells of the testis, and thereby support a
      wider role for PICK1 and ICA69 in regulating dense core vesicle biogenesis and
      maturation.
AD  - Division of Life Science, Division of Biomedical Engineering and State Key
      Laboratory of Molecular Neuroscience, The Hong Kong University of Science and
      Technology, Hong Kong, China.
FAU - Cao, Mian
AU  - Cao M
FAU - Mao, Zhuo
AU  - Mao Z
FAU - Kam, Chuen
AU  - Kam C
FAU - Xiao, Nan
AU  - Xiao N
FAU - Cao, Xiaoxing
AU  - Cao X
FAU - Shen, Chong
AU  - Shen C
FAU - Cheng, Kenneth K Y
AU  - Cheng KK
FAU - Xu, Aimin
AU  - Xu A
FAU - Lee, Kwong-Man
AU  - Lee KM
FAU - Jiang, Liwen
AU  - Jiang L
FAU - Xia, Jun
AU  - Xia J
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - PLoS Biol
JT  - PLoS biology
JID - 101183755
SB  - IM
PMC - PMC3635858
OID - NLM: PMC3635858
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04 [ppublish]
PHST- 2012/05/16 [received]
PHST- 2013/03/12 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.1371/journal.pbio.1001541 [doi]
AID - PBIOLOGY-D-12-01903 [pii]
PST - ppublish
SO  - PLoS Biol. 2013 Apr;11(4):e1001541. doi: 10.1371/journal.pbio.1001541. Epub 2013 
      Apr 23.

PMID- 23630429
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130430
DCOM- 20130501
LR  - 20130502
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 6
DP  - 2013
TI  - An observational study of acarbose treatment in patients with type 2 diabetes
      from the Middle East and Morocco.
PG  - 141-50
LID - 10.2147/DMSO.S36012 [doi]
AB  - BACKGROUND: The prevalence of type 2 diabetes is increasing dramatically in the
      Middle East and North Africa region. However, there are few trials that have
      determined the effect of antidiabetic treatment in an observational setting in
      these countries. METHODS: This was a noninterventional study performed in Morocco
      in 2006-2007 and in the Middle East in 2005-2006 to observe the efficacy and
      safety of acarbose in patients with pretreated or untreated type 2 diabetes.
      Glycemic parameters (fasting blood glucose, one-hour postprandial blood glucose, 
      and HbA1c) were recorded within a 3-month period. The observation period included
      an initial visit at the start of acarbose therapy and up to three follow-ups.
      RESULTS: Acarbose was effective in reducing glycemic parameters in patients from 
      Morocco (n = 1082) and the Middle East (n = 1737). The mean one-hour postprandial
      blood glucose decreased by 35.5% to 165.4 +/- 47.9 mg/dL in the Middle East and
      by 35.5% to 179.0 +/- 49.9 mg/dL in Morocco. Mean fasting blood glucose decreased
      by 30.8% to 126.6 +/- 34.2 mg/dL (Middle East) and by 34.5% to 150.6 +/- 47.1
      mg/dL (Morocco). The absolute reduction in HbA1c was 1.3% in the Middle East
      (final value 7.4%) and 1.0% in Morocco (final value 7.5%). Overall, 107 patients 
      (Middle East) and 26 patients (Morocco) experienced minor drug-related adverse
      events, which were mainly gastrointestinal. The tolerability of acarbose was
      rated as very good/good by 80.8% in the Middle East and by 68.6% in Morocco.
      CONCLUSION: This study illustrates the efficacy and safety of acarbose in the
      treatment of type 2 diabetic patients in an observational setting.
AD  - Al Ain Centre, Dubai, United Arab Emirates.
FAU - Shihabi, Abdul R
AU  - Shihabi AR
FAU - Moussa, Essam M
AU  - Moussa EM
FAU - Sobierajska, Hania
AU  - Sobierajska H
FAU - Schmidt, Birgit
AU  - Schmidt B
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3626400
OID - NLM: PMC3626400
OTO - NOTNLM
OT  - Glucobay®
OT  - Glucor®
OT  - acarbose
OT  - noninterventional
OT  - observational
OT  - type 2 diabetes
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:01
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/09 [epublish]
AID - 10.2147/DMSO.S36012 [doi]
AID - dmso-6-141 [pii]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2013 Apr 9;6:141-50. doi: 10.2147/DMSO.S36012. Print
      2013.

PMID- 23630428
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130430
DCOM- 20130501
LR  - 20130502
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 6
DP  - 2013
TI  - Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment
      of obesity.
PG  - 131-9
LID - 10.2147/DMSO.S43403 [doi]
AB  - Qsymia (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and
      delayed-release topiramate, has been available in the US since September 2012 for
      the treatment of obesity. Phentermine is an anorexigenic agent, which is approved
      for the short-term treatment of obesity, while topiramate is approved for
      nonweight loss indications - seizure disorders and migraine prophylaxis. The
      amount of weight loss achieved with combination therapy is of a greater magnitude
      than what could be achieved with either agent alone. Adverse events that occur
      with the combination therapy are in line with the known side effect profiles of
      the constituent drugs; teratogenicity, a slight increase in heart rate,
      psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.
AD  - Department of Community and Family Medicine, Duke University Medical Center,
      Durham, NC, USA.
FAU - Shin, Jin Hee
AU  - Shin JH
FAU - Gadde, Kishore M
AU  - Gadde KM
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3626409
OID - NLM: PMC3626409
OTO - NOTNLM
OT  - Qsymia
OT  - antiobesity drugs
OT  - combination drug
OT  - obesity
OT  - phentermine
OT  - topiramate
OT  - weight loss
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:01
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/08 [epublish]
AID - 10.2147/DMSO.S43403 [doi]
AID - dmso-6-131 [pii]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2013 Apr 8;6:131-9. doi: 10.2147/DMSO.S43403. Print
      2013.

PMID- 23630427
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130430
DCOM- 20130501
LR  - 20130502
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 6
DP  - 2013
TI  - Gender difference in response predictors after 1-year exenatide therapy twice
      daily in type 2 diabetic patients: a real world experience.
PG  - 123-9
LID - 10.2147/DMSO.S42729 [doi]
AB  - PURPOSE: To investigate whether gender affects therapeutic response by exenatide 
      twice a day (BID) in type 2 diabetes by using a database concerning patients
      monitored by five outpatient clinics in Tuscany, Italy. PATIENTS AND METHODS: We 
      considered a cohort of 315 (154 male/161 female) patients experiencing
      therapeutic failure while on oral therapy (metformin, or combination therapy
      metformin + sulphonylureas), who were given exenatide (10 mug/BID) and who fully 
      completed 4 months, 8 months, and 12 months of follow-ups. RESULTS: Among
      patients stratified by gender and well matched for age, body mass index, and
      hemoglobin A1c (HbA1c), it was found that the length of disease was longer in
      females than in males (12 +/- 8 years versus 10 +/- 7 years; P = 0.037), and the 
      ratio of patients on metformin to those on combination therapy was higher in men 
      (P = 0.018). Target glycemic response (1-year HbA1c </= 7%) was achieved in a
      significantly higher proportion of males than females (38% versus 27%; chi(2) =
      4.66; P = 0.03). Target weight loss expressed as 1-year weight percent fall from 
      baseline >/= 75th percentile (8.5%) was significantly higher in females at 8 and 
      12 months (P < 0.05; for both). One-year glycemic target response was inversely
      related to baseline HbA1c levels and diabetes duration among males, while
      metformin therapy (compared to oral combination therapy) was a significant
      predictor of better glycemic targets among females. Homeostasis model
      assessment-B, measured in 117 patients, predicted hypoglycemic response only in
      women (P = 0.009). Target 1-year weight loss was predicted by longer diabetes
      duration among males and by lower baseline HbA1c among females. Finally, no
      significant difference between genders was noted as to gastrointestinal side
      effects after exenatide therapy. CONCLUSION: According to this "real world"
      experience, predictors of glycemic control and body weight loss after 12 months
      of exenatide BID therapy are different between genders in type 2 diabetes.
AD  - Diabetes Unit, Spedali Riuniti, Pistoia, Italy.
FAU - Anichini, Roberto
AU  - Anichini R
FAU - Cosimi, Sabrina
AU  - Cosimi S
FAU - Di Carlo, Alberto
AU  - Di Carlo A
FAU - Orsini, Paola
AU  - Orsini P
FAU - De Bellis, Alessandra
AU  - De Bellis A
FAU - Seghieri, Giuseppe
AU  - Seghieri G
FAU - Franconi, Flavia
AU  - Franconi F
FAU - Baccetti, Fabio
AU  - Baccetti F
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3626369
OID - NLM: PMC3626369
OTO - NOTNLM
OT  - GLP-1 agonist therapy
OT  - exenatide BID
OT  - real world setting
OT  - type 2 diabetes
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:01
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/08 [epublish]
AID - 10.2147/DMSO.S42729 [doi]
AID - dmso-6-123 [pii]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2013 Apr 8;6:123-9. doi: 10.2147/DMSO.S42729. Print
      2013.

PMID- 23630416
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130430
DCOM- 20130501
LR  - 20130502
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 7
DP  - 2013
TI  - Evaluation of preference for a novel durable insulin pen with memory function
      among patients with diabetes and health care professionals.
PG  - 285-92
LID - 10.2147/PPA.S41929 [doi]
AB  - BACKGROUND: Improving adherence to insulin treatment for better glycemic control 
      remains a challenge in the management of diabetes. New technological aids are
      required to help support adherence. This study evaluated preference for the
      NovoPen((R)) 5 (NP5), a durable insulin pen with memory function, compared with
      the HumaPen Luxura((R)) (HPL) among patients with diabetes and health care
      professionals. METHODS: This crossover, multicenter usability study included
      insulin pen-experienced patients with diabetes and health care professionals
      treating patients with diabetes in Canada, China, and Germany. Participants
      evaluated NP5 and HPL in a randomized order by performing handling tasks in a
      usability test related to everyday use during a face-to-face interview. Tasks,
      pens, and preferences were assessed by completing a questionnaire comprised of
      rating and open-ended questions relating to confidence in everyday diabetes
      management. RESULTS: Overall, 300 patients with diabetes and 150 health care
      professionals participated in the study. Significantly more participants
      preferred NP5 (81%) to HPL (18%) (P < 0.001). Also, 82% of patients with diabetes
      had more confidence in NP5 for managing their daily injections versus 11% with
      HPL (P < 0.001), and 7% had no preference. Memory function was most helpful in
      giving patients with diabetes confidence about when they last injected (63%), how
      much insulin they last injected (62%) and improving diabetes management (55%).
      Participants gave higher ratings to NP5 than to HPL on all parameters relating to
      performing an injection (ease of handling, satisfaction when using the pen,
      convenience of using the pen day-to-day, quality of the pen, and the extent to
      which the pen meets their needs; P < 0.05 for all comparisons). CONCLUSION: NP5
      was preferred to HPL by most participants. Significantly more patients with
      diabetes had more confidence for managing daily insulin injections when using
      NP5, the pen with a memory function.
AD  - Internal Medicine Diabetology Practice, Aschaffenburg, Germany.
FAU - Klausmann, Gerhard
AU  - Klausmann G
FAU - Hramiak, Irene
AU  - Hramiak I
FAU - Qvist, Marianne
AU  - Qvist M
FAU - Mikkelsen, Kristian Handberg
AU  - Mikkelsen KH
FAU - Guo, Xiaohui
AU  - Guo X
LA  - eng
PT  - Journal Article
DEP - 20130405
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC3623548
OID - NLM: PMC3623548
OTO - NOTNLM
OT  - confidence
OT  - diabetes
OT  - durable insulin pen
OT  - memory function
OT  - patient preference
OT  - usability
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:01
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/05 [epublish]
AID - 10.2147/PPA.S41929 [doi]
AID - ppa-7-285 [pii]
PST - epublish
SO  - Patient Prefer Adherence. 2013 Apr 5;7:285-92. doi: 10.2147/PPA.S41929. Print
      2013.

PMID- 23630415
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 7
DP  - 2013
TI  - Effects of vildagliptin (Galvus(R)) therapy in patients with type 2 diabetes
      mellitus after heart transplantation.
PG  - 297-303
LID - 10.2147/DDDT.S43092 [doi]
AB  - BACKGROUND: Type 2 Diabetes mellitus (T2DM) is a common comorbidity in patients
      after heart transplantation (HTx) and is associated with adverse long-term
      outcomes. METHODS: The retrospective study reported here analyzed the effects of 
      vildagliptin therapy in stable patients post-HTx with T2DM and compared these
      with control patients for matched-pairs analysis. A total of 30 stable patients
      post-HTx with T2DM were included in the study. Fifteen patients (mean age 58.6
      +/- 6.0 years, mean time post-HTx 4.9 +/- 5.3 years, twelve male and three
      female) were included in the vildagliptin group (VG) and 15 patients were
      included in the control group (CG) (mean age 61.2 +/- 8.3 years, mean time
      post-HTx 7.2 +/- 6.6 years, all male). RESULTS: Mean glycated hemoglobin (HbA1c) 
      in the VG was 7.4% +/- 0.7% before versus 6.8% +/- 0.8% after 8 months of
      vildagliptin therapy (P = 0.002 vs baseline). In the CG, HbA1c was 7.0% +/- 0.7% 
      versus 7.3% +/- 1.2% at follow-up (P = 0.21). Additionally, there was a
      significant reduction in mean blood glucose in the VG, from 165.0 +/- 18.8 mg/dL 
      to 147.9 +/- 22.7 mg/dL (P = 0.002 vs baseline), whereas mean blood glucose
      increased slightly in the CG from 154.7 +/- 19.7 mg/dL to 162.6 +/- 35.0 mg/dL (P
      = 0.21). No statistically significant changes in body weight (from 83.3 +/- 10.8 
      kg to 82.0 +/- 10.9 kg, P = 0.20), total cholesterol (1.5%, P = 0.68), or
      triglyceride levels (8.0%, P = 0.65) were seen in the VG. No significant changes 
      in immunosuppressive drug levels or dosages were observed in either group.
      CONCLUSION: Vildagliptin therapy significantly reduced HbA1c and mean blood
      glucose levels in post-HTx patients in this study with T2DM and did not have any 
      negative effects on lipid profile or body weight. Thus, vildagliptin therapy
      presented an interesting therapeutic approach for this selected patient cohort.
AD  - Department of Cardiology, University of Heidelberg, Heidelberg.
FAU - Gueler, Ibrahim
AU  - Gueler I
FAU - Mueller, Susanne
AU  - Mueller S
FAU - Helmschrott, Matthias
AU  - Helmschrott M
FAU - Oeing, Christian U
AU  - Oeing CU
FAU - Erbel, Christian
AU  - Erbel C
FAU - Frankenstein, Lutz
AU  - Frankenstein L
FAU - Gleissner, Christian
AU  - Gleissner C
FAU - Ruhparwar, Arjang
AU  - Ruhparwar A
FAU - Ehlermann, Philipp
AU  - Ehlermann P
FAU - Dengler, Thomas J
AU  - Dengler TJ
FAU - Katus, Hugo A
AU  - Katus HA
FAU - Doesch, Andreas O
AU  - Doesch AO
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
SB  - IM
PMC - PMC3623547
OID - NLM: PMC3623547
OTO - NOTNLM
OT  - glycated hemoglobin
OT  - immunosuppression
OT  - mean blood glucose
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/08 [epublish]
AID - 10.2147/DDDT.S43092 [doi]
AID - dddt-7-297 [pii]
PST - epublish
SO  - Drug Des Devel Ther. 2013 Apr 8;7:297-303. doi: 10.2147/DDDT.S43092. Print 2013.

PMID- 23630413
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 7
DP  - 2013
TI  - Find novel dual-agonist drugs for treating type 2 diabetes by means of
      cheminformatics.
PG  - 279-88
LID - 10.2147/DDDT.S42113 [doi]
AB  - The high prevalence of type 2 diabetes mellitus in the world as well as the
      increasing reports about the adverse side effects of the existing diabetes
      treatment drugs have made developing new and effective drugs against the disease 
      a very high priority. In this study, we report ten novel compounds found by
      targeting peroxisome proliferator-activated receptors (PPARs) using virtual
      screening and core hopping approaches. PPARs have drawn increasing attention for 
      developing novel drugs to treat diabetes due to their unique functions in
      regulating glucose, lipid, and cholesterol metabolism. The reported compounds are
      featured with dual functions, and hence belong to the category of dual agonists. 
      Compared with the single PPAR agonists, the dual PPAR agonists, formed by
      combining the lipid benefit of PPARalpha agonists (such as fibrates) and the
      glycemic advantages of the PPARgamma agonists (such as thiazolidinediones), are
      much more powerful in treating diabetes because they can enhance metabolic
      effects while minimizing the side effects. This was observed in the studies on
      molecular dynamics simulations, as well as on absorption, distribution,
      metabolism, and excretion, that these novel dual agonists not only possessed the 
      same function as ragaglitazar (an investigational drug developed by Novo Nordisk 
      for treating type 2 diabetes) did in activating PPARalpha and PPARgamma, but they
      also had more favorable conformation for binding to the two receptors. Moreover, 
      the residues involved in forming the binding pockets of PPARalpha and PPARgamma
      among the top ten compounds are explicitly presented, and this will be very
      useful for the in-depth conduction of mutagenesis experiments. It is anticipated 
      that the ten compounds may become potential drug candidates, or at the very
      least, the findings reported here may stimulate new strategies or provide useful 
      insights for designing new and more powerful dual-agonist drugs for treating type
      2 diabetes.
AD  - PET/CT Center, General Hospital of Tianjin Medical University, Tianjin, People's 
      Republic of China.
FAU - Liu, Lei
AU  - Liu L
FAU - Ma, Ying
AU  - Ma Y
FAU - Wang, Run-Ling
AU  - Wang RL
FAU - Xu, Wei-Ren
AU  - Xu WR
FAU - Wang, Shu-Qing
AU  - Wang SQ
FAU - Chou, Kuo-Chen
AU  - Chou KC
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
SB  - IM
PMC - PMC3623550
OID - NLM: PMC3623550
OTO - NOTNLM
OT  - ADME
OT  - PPAR-alpha
OT  - PPAR-gamma
OT  - binding pocket
OT  - core hopping
OT  - diabetes
OT  - dual-agonist drug
OT  - molecular docking
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/08 [epublish]
AID - 10.2147/DDDT.S42113 [doi]
AID - dddt-7-279 [pii]
PST - epublish
SO  - Drug Des Devel Ther. 2013 Apr 8;7:279-88. doi: 10.2147/DDDT.S42113. Print 2013.

PMID- 23630352
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 190
IP  - 11
DP  - 2013 Jun 1
TI  - OX40L/Jagged1 Cosignaling by GM-CSF-Induced Bone Marrow-Derived Dendritic Cells
      Is Required for the Expansion of Functional Regulatory T Cells.
PG  - 5516-25
LID - 10.4049/jimmunol.1202298 [doi]
AB  - Earlier, we had demonstrated that treatment with low dose of GM-CSF can prevent
      the development of experimental autoimmune thyroiditis (EAT), experimental
      autoimmune myasthenia gravis, and type 1 diabetes, and could also reverse ongoing
      EAT and experimental autoimmune myasthenia gravis. The protective effect was
      mediated through the induction of tolerogenic CD11C(+)CD8alpha(-) dendritic cells
      (DCs) and consequent expansion of Foxp3(+) regulatory T cells (Tregs).
      Subsequently, we showed that GM-CSF acted specifically on bone marrow precursors 
      and facilitated their differentiation into tolerogenic dendritic cells (DCs;
      GM-CSF-induced bone marrow-derived DCs [GM-BMDCs]), which directed Treg expansion
      in a contact-dependent manner. This novel mechanism of Treg expansion was
      independent of TCR-mediated signaling but required exogenous IL-2 and cosignaling
      from DC-bound OX40L. In this study, we observed that OX40L-mediated signaling by 
      GM-BMDCs, although necessary, was not sufficient for Treg expansion and required 
      signaling by Jagged1. Concurrent signaling induced by OX40L and Jagged1 via OX40 
      and Notch3 receptors expressed on Tregs was essential for the Treg expansion with
      sustained FoxP3 expression. Adoptive transfer of only OX40L(+)Jagged1(+) BMDCs
      led to Treg expansion, increased production of IL-4 and IL-10, and suppression of
      EAT in the recipient mice. These results showed a critical role for OX40L- and
      Jagged1-induced cosignaling in GM-BMDC-induced Treg expansion.
AD  - Department of Microbiology and Immunology, University of Illinois at Chicago,
      Chicago, IL 60612;
FAU - Gopisetty, Anupama
AU  - Gopisetty A
FAU - Bhattacharya, Palash
AU  - Bhattacharya P
FAU - Haddad, Christine
AU  - Haddad C
FAU - Bruno, Joseph C Jr
AU  - Bruno JC Jr
FAU - Vasu, Chenthamarakshan
AU  - Vasu C
FAU - Miele, Lucio
AU  - Miele L
FAU - Prabhakar, Bellur S
AU  - Prabhakar BS
LA  - eng
GR  - R01 AI058190/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
SB  - AIM
SB  - IM
PMC - PMC3660466
MID - NIHMS459992
OID - NLM: NIHMS459992 [Available on 06/01/14]
OID - NLM: PMC3660466 [Available on 06/01/14]
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PMCR- 2014/06/01 00:00
PHST- 2013/04/29 [aheadofprint]
AID - jimmunol.1202298 [pii]
AID - 10.4049/jimmunol.1202298 [doi]
PST - ppublish
SO  - J Immunol. 2013 Jun 1;190(11):5516-25. doi: 10.4049/jimmunol.1202298. Epub 2013
      Apr 29.

PMID- 23630351
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 190
IP  - 11
DP  - 2013 Jun 1
TI  - Yersinia enterocolitica Provides the Link between Thyroid-Stimulating Antibodies 
      and Their Germline Counterparts in Graves' Disease.
PG  - 5373-81
LID - 10.4049/jimmunol.1203412 [doi]
AB  - Graves' disease results from thyroid-stimulating Abs (TSAbs) activating the
      thyrotropin receptor (TSHR). How TSAbs arise from early precursor B cells has not
      been established. Genetic and environmental factors may contribute to
      pathogenesis, including the bacterium Yersinia enterocolitica. We developed two
      pathogenic monoclonal TSAbs from a single experimental mouse undergoing Graves'
      disease, which shared the same H and L chain germline gene rearrangements and
      then diversified by numerous somatic hypermutations. To address the Ag
      specificity of the shared germline precursor of the monoclonal TSAbs, we prepared
      rFab germline, which showed negligible binding to TSHR, indicating importance of 
      somatic hypermutation in acquiring TSAb activity. Using rFab chimeras, we
      demonstrate the dominant role of the H chain V region in TSHR recognition. The
      role of microbial Ags was tested with Y. enterocolitica proteins. The monoclonal 
      TSAbs recognize 37-kDa envelope proteins, also recognized by rFab germline.
      MALDI-TOF identified the proteins as outer membrane porin (Omp) A and OmpC. Using
      recombinant OmpA, OmpC, and related OmpF, we demonstrate cross-reactivity of
      monoclonal TSAbs with the heterogeneous porins. Importantly, rFab germline binds 
      recombinant OmpA, OmpC, and OmpF confirming reactivity with Y. enterocolitica. A 
      human monoclonal TSAb, M22 with similar properties to murine TSAbs, also binds
      recombinant porins, showing cross-reactivity of a spontaneously arising
      pathogenic Ab with Y. enterocolitica. The data provide a mechanistic framework
      for molecular mimicry in Graves' disease, where early precursor B cells are
      expanded by Y. enterocolitica porins to undergo somatic hypermutation to acquire 
      a cross-reactive pathogenic response to TSHR.
AD  - Division of Diabetes and Nutritional Sciences, King's College London School of
      Medicine, London SE5 9NU, United Kingdom;
FAU - Hargreaves, Chantal E
AU  - Hargreaves CE
FAU - Grasso, Marco
AU  - Grasso M
FAU - Hampe, Christiane S
AU  - Hampe CS
FAU - Stenkova, Anna
AU  - Stenkova A
FAU - Atkinson, Steve
AU  - Atkinson S
FAU - Joshua, George W P
AU  - Joshua GW
FAU - Wren, Brendan W
AU  - Wren BW
FAU - Buckle, Ashley M
AU  - Buckle AM
FAU - Dunn-Walters, Deborah
AU  - Dunn-Walters D
FAU - Banga, J Paul
AU  - Banga JP
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
SB  - AIM
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/29 [aheadofprint]
AID - jimmunol.1203412 [pii]
AID - 10.4049/jimmunol.1203412 [doi]
PST - ppublish
SO  - J Immunol. 2013 Jun 1;190(11):5373-81. doi: 10.4049/jimmunol.1203412. Epub 2013
      Apr 29.

PMID- 23630305
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 29
TI  - Cord Serum Lipidome in Prediction of Islet Autoimmunity and Type 1 Diabetes.
AB  - Earlier studies show that children who later progress to type 1 diabetes (T1D)
      have decreased pre-autoimmune concentrations of multiple phospholipids as
      compared to non-progressors. It is still unclear whether these changes associate 
      with development of beta-cell autoimmunity or specifically with clinical T1D.
      Here we studied umbilical cord serum lipidome in newborn infants who later
      developed T1D (N=33), infants who developed three or four (N=31), two (N=31), or 
      one (N=48) islet autoantibody during the follow-up, and controls (N=143) matched 
      for gender, HLA-DQB1 genotype, city and period of birth. The analyses of serum
      molecular lipids were performed using the established lipidomics platform based
      on Ultra Performance Liquid ChromatographyTM coupled to mass spectrometry
      (UPLC-MS). We found that T1D progressors are characterized by a distinct cord
      blood lipidomic profile which includes reduced major choline-containing
      phospholipids including sphingomyelins and phosphatidylcholines. A molecular
      signature was developed comprising seven lipids which predicted high risk for
      progression to T1D, with an odds ratio of 5.94 (95% CI, 1.07 - 17.50). Reduction 
      in choline-containing phospholipids in cord blood is therefore specifically
      associated with progression to T1D but not with development of beta-cell
      autoimmunity in general.
AD  - VTT Technical Research Centre of Finland, Espoo, Finland.
FAU - Oresic, Matej
AU  - Oresic M
FAU - Gopalacharyulu, Peddinti
AU  - Gopalacharyulu P
FAU - Mykkanen, Juha
AU  - Mykkanen J
FAU - Lietzen, Niina
AU  - Lietzen N
FAU - Makinen, Marjaana
AU  - Makinen M
FAU - Nygren, Heli
AU  - Nygren H
FAU - Simell, Satu
AU  - Simell S
FAU - Simell, Ville
AU  - Simell V
FAU - Hyoty, Heikki
AU  - Hyoty H
FAU - Veijola, Riitta
AU  - Veijola R
FAU - Ilonen, Jorma
AU  - Ilonen J
FAU - Sysi-Aho, Marko
AU  - Sysi-Aho M
FAU - Knip, Mikael
AU  - Knip M
FAU - Hyotylainen, Tuulia
AU  - Hyotylainen T
FAU - Simell, Olli
AU  - Simell O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - db13-0159 [pii]
AID - 10.2337/db13-0159 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 29.

PMID- 23630304
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 29
TI  - DNA aptamer raised against AGEs blocks the progression of experimental diabetic
      nephropathy.
AB  - Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in
      diabetic nephropathy. We screened DNA aptamer directed against AGEs
      (AGEs-aptamer) in vitro, and examined its effects on renal injury in KKAy/Ta
      mice, an animal model of type 2 diabetes. Eight week-old male KKAy/Ta or C57BL/6J
      mice received continuous intraperitoneal infusion of AGEs- or control-aptamer for
      8 weeks. AGEs-aptamer was detected and its level was increased in the kidney for 
      at least 7 days. The elimination half-lives of AGEs-aptamer in the kidney were
      about 7 days. Compared with C57BL/6J mice, glomerular AGEs levels were
      significantly increased in KKAy/Ta mice, which were blocked by AGEs-aptamer.
      Urinary albumin and 8-hydroxy-2'-deoxy-guanosine levels were increased, and
      glomerular hypertrophy and enhanced extracellular matrix accumulation were
      observed in KKAy/Ta mice, all of which were prevented by AGEs-aptamer. Moreover, 
      AGEs-aptamer significantly reduced gene expression of RAGE, monocyte
      chemoattractant protein-1, connective tissue growth factor or type-IV collagen
      both in the kidney of KKAy/Ta mice and in AGEs-exposed human cultured mesangial
      cells. Our present data suggest that continuous administration of AGEs-aptamer
      could protect against experimental diabetic nephropathy by blocking the AGEs-RAGE
      axis and may be a feasible and promising therapeutic strategy for the treatment
      of diabetic nephropathy.
AD  - Division of Nephrology, Department of Medicine.
FAU - Kaida, Yusuke
AU  - Kaida Y
FAU - Fukami, Kei
AU  - Fukami K
FAU - Matsui, Takanori
AU  - Matsui T
FAU - Higashimoto, Yuichiro
AU  - Higashimoto Y
FAU - Nishino, Yuri
AU  - Nishino Y
FAU - Obara, Nana
AU  - Obara N
FAU - Nakayama, Yosuke
AU  - Nakayama Y
FAU - Ando, Ryotaro
AU  - Ando R
FAU - Toyonaga, Maki
AU  - Toyonaga M
FAU - Ueda, Seiji
AU  - Ueda S
FAU - Takeuchi, Masayoshi
AU  - Takeuchi M
FAU - Inoue, Hiroyoshi
AU  - Inoue H
FAU - Okuda, Seiya
AU  - Okuda S
FAU - Yamagishi, Sho-Ichi
AU  - Yamagishi SI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - db12-1608 [pii]
AID - 10.2337/db12-1608 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 29.

PMID- 23630303
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 29
TI  - Development of the human pancreas from foregut to endocrine commitment.
AB  - Knowledge of human pancreas development underpins our interpretation and
      exploitation of human pluripotent stem cell (PSC) differentiation towards a
      beta-cell fate. However, almost no information exists on the early events of
      human pancreatic specification in the distal foregut, bud formation and early
      development. Here, we have studied the expression profiles of key
      lineage-specific markers to understand differentiation and morphogenetic events
      during human pancreas development. The notochord was adjacent to the dorsal
      foregut endoderm during the fourth week of development prior to PDX1 detection.
      In contrast to the published data from mouse embryos, during human pancreas
      development we detected only a single phase of NEUROG3 expression and endocrine
      differentiation from approximately 8 weeks, prior to which NKX2.2 was not
      observed in the pancreatic progenitor cell population. In addition to revealing a
      number of disparities in timing between human and mouse development, these data, 
      directly assembled from human tissue, allow combinations of transcription factors
      to define sequential stages and differentiating pancreatic cell-types. The data
      are anticipated to provide a useful reference point for stem cell researchers
      looking to differentiate human PSCs in vitro towards the pancreatic beta-cell so 
      as to model human development, or enable drug discovery and potential cell
      therapy.
AD  - Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of
      Medical & Human Sciences, Manchester Academic Health Sciences Centre, University 
      of Manchester, Oxford Rd, Manchester M13 9PT, UK.
FAU - Jennings, Rachel E
AU  - Jennings RE
FAU - Berry, Andrew A
AU  - Berry AA
FAU - Kirkwood-Wilson, Rebecca
AU  - Kirkwood-Wilson R
FAU - Roberts, Neil A
AU  - Roberts NA
FAU - Hearn, Thomas
AU  - Hearn T
FAU - Salisbury, Rachel J
AU  - Salisbury RJ
FAU - Blaylock, Jennifer
AU  - Blaylock J
FAU - Hanley, Karen Piper
AU  - Hanley KP
FAU - Hanley, Neil A
AU  - Hanley NA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - db12-1479 [pii]
AID - 10.2337/db12-1479 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 29.

PMID- 23630302
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 29
TI  - Pancreatic Islet Vasculature Adapts to Insulin Resistance through Dilation and
      Not Angiogenesis.
AB  - Pancreatic islets adapt to insulin resistance through a complex set of changes,
      including beta cell hyperplasia and hypertrophy. To determine if islet
      vascularization changes in response to insulin resistance, we investigated three 
      independent models of insulin resistance: ob/ob, GLUT4+/-, and mice with high-fat
      diet-induced obesity (HFD). Intravital blood vessel labeling and
      immunocytochemistry revealed a vascular plasticity in which islet vessel area was
      significantly increased but intra-islet vessel density was decreased as the
      result of insulin resistance. These vascular changes were independent of islet
      size and were only observed within the beta cell core but not in the islet
      periphery. Intra-islet endothelial cell (EC) fenestration, proliferation, and
      islet angiogenic factor/receptor expression were unchanged in insulin-resistant
      compared to control mice, indicating that islet capillary expansion is mediated
      by dilation of pre-existing vessels and not by angiogenesis. Based on these data,
      we propose that the islet capillary dilation is modulated by eNOS via
      complementary signals derived from beta cells, parasympathetic nerves, and
      increased islet blood flow. These compensatory changes in islet vascularization
      may influence whether beta cells can adequately respond to insulin resistance and
      prevent the development of diabetes.
AD  - Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine.
FAU - Dai, Chunhua
AU  - Dai C
FAU - Brissova, Marcela
AU  - Brissova M
FAU - Reinert, Rachel B
AU  - Reinert RB
FAU - Nyman, Lara
AU  - Nyman L
FAU - Liu, Eric H
AU  - Liu EH
FAU - Thompson, Courtney
AU  - Thompson C
FAU - Shostak, Alena
AU  - Shostak A
FAU - Shiota, Masakazu
AU  - Shiota M
FAU - Takahashi, Takamune
AU  - Takahashi T
FAU - Powers, Alvin C
AU  - Powers AC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - db12-1657 [pii]
AID - 10.2337/db12-1657 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 29.

PMID- 23630301
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 29
TI  - Strong Parent-of-Origin Effects in the Association of KCNQ1 Variants with Type 2 
      Diabetes Mellitus in American Indians.
AB  - Parent-of-origin effects were observed in an Icelandic population for several
      genetic variants associated with type 2 diabetes, including those in KLF14
      (rs4731702), MOB2 (rs2334499) and KCNQ1 (rs2237892, rs231362). We analyzed
      parent-of-origin effects for these variants, along with two others in KCNQ1
      identified in previous genome-wide association studies (rs2237895, rs2299620), in
      7351 Pima Indians from 4549 nuclear families; 34% of participants had diabetes.
      In a subset of 287 normoglycemic individuals, acute insulin secretion was
      measured by an intravenous glucose tolerance test. Statistically significant
      (P<0.05) parent-of-origin effects were seen for association with type 2 diabetes 
      for all variants. The strongest effect was seen at rs2299620 in KCNQ1: the C
      allele was associated with increased diabetes when maternally-derived (odds
      ratio=1.92, P=4.1x10-12), but not when paternally-derived (odds ratio=0.93,
      P=0.47; P=9.9x10-6 for difference in maternal and paternal effects). A
      maternally-derived C allele was also associated with a 28% decrease in insulin
      secretion (P=0.002). This study confirms parent-of-origin effects in the
      association with type 2 diabetes for variants in KLF14, MOB2 and KCNQ1. In Pima
      Indians the effect of maternally-derived KCNQ1 variants appears to be mediated
      through decreased insulin secretion, and is particularly strong, accounting for
      4% of the variance in liability to diabetes.
AD  - Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes 
      and Digestive and Kidney Diseases 1550 East Indian School Road Phoenix, AZ,
      85014.
FAU - Hanson, Robert L
AU  - Hanson RL
FAU - Guo, Tingwei
AU  - Guo T
FAU - Muller, Yunhua Li
AU  - Muller YL
FAU - Fleming, Jamie
AU  - Fleming J
FAU - Knowler, William C
AU  - Knowler WC
FAU - Kobes, Sayuko
AU  - Kobes S
FAU - Bogardus, Clifton
AU  - Bogardus C
FAU - Baier, Leslie J
AU  - Baier LJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - db12-1767 [pii]
AID - 10.2337/db12-1767 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 29.

PMID- 23630300
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 29
TI  - Improvement in beta-Cell Secretory Capacity Following Human Islet Transplantation
      According to the CIT07 Protocol.
AB  - The Clinical Islet Transplantation 07 (CIT07) protocol utilizes anti-thymocyte
      globulin and etanercept induction, islet culture, heparinization and intensive
      insulin therapy, with the same low-dose tacrolimus and sirolimus maintenance
      immunosuppression as in the Edmonton protocol. To determine whether CIT07
      improves engrafted islet beta-cell mass, our center measured beta-cell secretory 
      capacity from glucose-potentiated arginine tests at days 75 and 365
      post-transplant, and compared the results to those previously achieved by our
      group with the Edmonton protocol, and to normal. All subjects were insulin-free
      with CIT07 subjects receiving fewer islet equivalents from a median 1 vs. 2
      donors in Edmonton subjects. The acute insulin response to glucose-potentiated
      arginine (AIRpot) was greater in CIT07 than Edmonton and less in both cohorts
      than normal, with similar findings for C-peptide. The CIT07 subjects who
      completed reassessment at day 365 exhibited increasing AIRpot by trend relative
      to day 75. These data indicate that engrafted islet beta-cell mass is markedly
      improved with the CIT07 protocol, especially given more frequent use of single
      islet donors. While several peri-transplant differences may have each contributed
      to this improvement, the lack of deterioration in beta-cell secretory capacity
      over time in CIT07 suggests that low-dose tacrolimus and sirolimus are not toxic 
      to islets.
AD  - Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, the.
FAU - Rickels, Michael R
AU  - Rickels MR
FAU - Liu, Chengyang
AU  - Liu C
FAU - Shlansky-Goldberg, Richard D
AU  - Shlansky-Goldberg RD
FAU - Soleimanpour, Scott A
AU  - Soleimanpour SA
FAU - Vivek, Kumar
AU  - Vivek K
FAU - Kamoun, Malek
AU  - Kamoun M
FAU - Min, Zaw
AU  - Min Z
FAU - Markmann, Eileen
AU  - Markmann E
FAU - Palangian, Maral
AU  - Palangian M
FAU - Dalton-Bakes, Cornelia
AU  - Dalton-Bakes C
FAU - Fuller, Carissa
AU  - Fuller C
FAU - Chiou, Allen J
AU  - Chiou AJ
FAU - Barker, Clyde F
AU  - Barker CF
FAU - Luning Prak, Eline T
AU  - Luning Prak ET
FAU - Naji, Ali
AU  - Naji A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - db12-1802 [pii]
AID - 10.2337/db12-1802 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 29.

PMID- 23630299
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 29
TI  - Somatostatin Receptor Type 2 Antagonism Improves Glucagon Counter-regulation In
      BioBreeding Diabetic Rats.
AB  - Impaired counterregulation during hypoglycemia in type-1 diabetes (T1D) is in
      part due to inadequate glucagon secretion. Intra-islet somatostatin suppression
      of hypoglycemia-stimulated alpha-cell glucagon release plays an important role.
      We hypothesized that hypoglycemia can be prevented in autoimmune T1D by
      somatostatin receptor type-2 (SSTR2) antagonism of alpha-cells, which relieve
      SSTR2 inhibition, thereby increasing glucagon secretion. Diabetic (D) Biobreeding
      diabetes-prone (BBDP) rats mimic insulin-dependent human autoimmune T1D, whereas 
      non-diabetic (N) BBDP rats mimic prediabetes. D and N rats underwent a 3-h
      infusion of vehicle vs SSTR2 antagonist (SSTR2a) during insulin-induced
      hypoglycemia clamped at 3+/-0.5 mmol/L. D, treated with SSTR2a, needed little or 
      no glucose infusion compared to untreated rats. We attribute this effect to
      SSTR2a restoration of the attenuated glucagon response. Direct effects of SSTR2a 
      on alpha-cells was assessed by resecting the pancreas, cut into fine slices and
      subjected to perifusion to monitor glucagon release. SSTR2a treatment enhanced
      low glucose-stimulated glucagon and corticosterone secretion to normal in D.
      SSTR2a had similar effects in vivo on N, and promoted glucagon secretion from N
      and human pancreas slices. We conclude that somatostatin contributes to impaired 
      glucagon responsiveness to hypoglycemia in autoimmune T1D. SSTR2a treatment can
      fully restore hypoglycemia-stimulated glucagon release sufficient to attain
      normoglycemia in both diabetic and prediabetic stages.
AD  - Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
FAU - Karimian, Negar
AU  - Karimian N
FAU - Qin, Tairan
AU  - Qin T
FAU - Liang, Tao
AU  - Liang T
FAU - Osundiji, Mayowa
AU  - Osundiji M
FAU - Huang, Yachi
AU  - Huang Y
FAU - Teich, Trevor
AU  - Teich T
FAU - Riddell, Michael C
AU  - Riddell MC
FAU - Cattral, Mark S
AU  - Cattral MS
FAU - Coy, David H
AU  - Coy DH
FAU - Vranic, Mladen
AU  - Vranic M
FAU - Gaisano, Herbert Y
AU  - Gaisano HY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - db13-0164 [pii]
AID - 10.2337/db13-0164 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 29.

PMID- 23630298
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 29
TI  - Systemic regulation of the age-related decline of pancreatic beta-cell
      replication.
AB  - The frequency of pancreatic beta-cell replication declines dramatically with age,
      potentially contributing to the increased risk of type 2 diabetes in old age.
      Previous studies have shown the involvement of cell-autonomous factors in this
      phenomenon, in particular the decline of Polycomb genes and accumulation of
      p16/INK4. Here we demonstrate that a systemic factor found in the young
      circulation is able to increase the proliferation rate of old pancreatic
      beta-cells. Old mice parabiosed to young mice have increased beta-cell
      replication compared with unjoined old mice or old mice parabiosed to old mice.
      In addition, we demonstrate that old beta-cells transplanted into young
      recipients have increased replication rate compared with cells transplanted into 
      old recipients ; conversely, young beta-cells transplanted into old mice decrease
      their replication rate compared with young cells transplanted into young
      recipients. The expression of p16/Ink4A mRNA did not change in heterochronic
      parabiosis, suggesting the involvement of other pathways. We conclude that
      systemic factors contribute to the replicative decline of old pancreatic
      beta-cells.
AD  - Department of Developmental Biology and Cancer Research and Molecular Biology,
      The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah 
      Medical School, Jerusalem 91120, Israel.
FAU - Salpeter, Seth J
AU  - Salpeter SJ
FAU - Khalaileh, Abed
AU  - Khalaileh A
FAU - Weinberg-Corem, Noa
AU  - Weinberg-Corem N
FAU - Ziv, Oren
AU  - Ziv O
FAU - Glaser, Ben
AU  - Glaser B
FAU - Dor, Yuval
AU  - Dor Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - db13-0160 [pii]
AID - 10.2337/db13-0160 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 29.

PMID- 23630254
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 110
IP  - 20
DP  - 2013 May 14
TI  - Gene silencing in adipose tissue macrophages regulates whole-body metabolism in
      obese mice.
PG  - 8278-83
LID - 10.1073/pnas.1300492110 [doi]
AB  - Adipose tissue (AT) inflammation and infiltration by macrophages is associated
      with insulin resistance and type 2 diabetes in obese humans, offering a potential
      target for therapeutics. However, whether AT macrophages (ATMs) directly
      contribute to systemic glucose intolerance has not been determined. The reason is
      the lack of methods to ablate inflammatory genes expressed in macrophages
      specifically localized within AT depots, leaving macrophages in other tissues
      unaffected. Here we report that i.p. administration of siRNA encapsulated by
      glucan shells in obese mice selectively silences genes in epididymal ATMs,
      whereas macrophages within lung, spleen, kidney, heart, skeletal muscle,
      subcutaneous (SubQ) adipose, and liver are not targeted. Such administration of
      GeRPs to silence the inflammatory cytokines TNF-alpha or osteopontin in
      epididymal ATMs of obese mice caused significant improvement in glucose
      tolerance. These data are consistent with the hypothesis that cytokines produced 
      by ATMs can exacerbate whole-body glucose intolerance.
AD  - Program in Molecular Medicine, University of Massachusetts Medical School,
      Worcester, MA 01605.
FAU - Aouadi, Myriam
AU  - Aouadi M
FAU - Tencerova, Michaela
AU  - Tencerova M
FAU - Vangala, Pranitha
AU  - Vangala P
FAU - Yawe, Joseph C
AU  - Yawe JC
FAU - Nicoloro, Sarah M
AU  - Nicoloro SM
FAU - Amano, Shinya U
AU  - Amano SU
FAU - Cohen, Jessica L
AU  - Cohen JL
FAU - Czech, Michael P
AU  - Czech MP
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
SB  - IM
PMC - PMC3657808
OID - NLM: PMC3657808 [Available on 11/14/13]
OTO - NOTNLM
OT  - RNAi
OT  - immune cells
OT  - obesity
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PMCR- 2013/11/14 00:00
PHST- 2013/04/29 [aheadofprint]
AID - 1300492110 [pii]
AID - 10.1073/pnas.1300492110 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 2013 May 14;110(20):8278-83. doi:
      10.1073/pnas.1300492110. Epub 2013 Apr 29.

PMID- 23630208
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 31
IP  - 17
DP  - 2013 Jun 10
TI  - Treatment of Orbital Metastases From a Primary Midgut Neuroendocrine Tumor With
      Peptide-Receptor Radiolabeled Therapy Using 177Lutetium-DOTATATE.
PG  - e272-5
LID - 10.1200/JCO.2012.45.8612 [doi]
AD  - MBChB Hons, MRCP (UK), University Hospital Aintree, Department of Diabetes &
      Endocrinology, Clinical Sciences Centre, 3rd floor, Lower Lane, Liverpool L9 7AL,
      United Kingdom; rebecca.dobson@liverpool.ac.uk.
FAU - Dobson, Rebecca
AU  - Dobson R
FAU - Vinjamuri, Sobhan
AU  - Vinjamuri S
FAU - Hsuan, James
AU  - Hsuan J
FAU - Banks, Melissa
AU  - Banks M
FAU - Terlizzo, Monica
AU  - Terlizzo M
FAU - Wieshmann, Hulya
AU  - Wieshmann H
FAU - Daousi, Christina
AU  - Daousi C
FAU - Poston, Graeme P
AU  - Poston GP
FAU - Cuthbertson, Daniel J
AU  - Cuthbertson DJ
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/29 [aheadofprint]
AID - JCO.2012.45.8612 [pii]
AID - 10.1200/JCO.2012.45.8612 [doi]
PST - ppublish
SO  - J Clin Oncol. 2013 Jun 10;31(17):e272-5. doi: 10.1200/JCO.2012.45.8612. Epub 2013
      Apr 29.

PMID- 23630144
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1332-8166 (Electronic)
IS  - 0353-9504 (Linking)
VI  - 54
IP  - 2
DP  - 2013 Apr 15
TI  - Taurine attenuates oxidative stress and alleviates cardiac failure in type I
      diabetic rats.
PG  - 171-9
AB  - Aim. To investigate cardioprotective effect of taurine in diabetic rats. Methods.
      Male Sprague-Dawley rats were assigned randomly into four groups of 15 rats:
      control group, control+taurine group, streptozotocin (STZ) group, and STZ +
      taurine group. Rats in STZ and STZ+ taurine groups were treated by a single
      injection of STZ (70 mg kg-1, intraperitoneally) dissolved in 0.01 M citrate
      buffer (pH 4.5) for induction of diabetes, and rats in control and
      control+taurine groups were treated with the same volume citrate buffer. Taurine 
      was orally administered to rats in control+taurine and STZ + taurine groups daily
      for 8 weeks. Rats were examined for diabetic cardiomyopathy by left ventricular
      (LV) hemodynamic analysis. Myocardial oxidative stress was assessed by measuring 
      the activity of superoxide dismutase (SOD) and the level of malondialdehyde
      (MDA). Myocardial protein kinase B (Akt/PKB) phosphorylation and heme oxygenase-1
      (HO-1) protein levels were measured by Western blot in all rats at the end of the
      study. Results. In untreated diabetic rats, LV systolic pressure, rate of
      pressure rise, and rate of pressure fall were decreased, while LV end-diastolic
      pressure was increased, indicating reduced LV contractility and slowing of LV
      relaxation. The levels of Akt/PKB phosphorylation and SOD activity were decreased
      and HO-1 protein expression and MDA content increased. Taurine treatment
      significantly improved LV systolic and diastolic function, and there were
      persistent increases in activities of Akt/PKB and SOD, and the level of HO-1
      protein. Conclusion. Taurine treatment ameliorates myocardial function and heart 
      oxidant status, while increasing myocardial Akt/PKB phosphorylation, and HO-1
      levels have beneficial effects on diabetic cardiomyopathy.
AD  - Guo-guang Wang, Department of Pathophysiology, Wannan Medical College, 22 West of
      Wenchang Road, Wuhu, China, guoguangw1226@sina.com.
FAU - Wang, Guo-Guang
AU  - Wang GG
FAU - Li, Wei
AU  - Li W
FAU - Lu, Xiao-Hua
AU  - Lu XH
FAU - Zhao, Xue
AU  - Zhao X
FAU - Xu, Lei
AU  - Xu L
LA  - eng
PT  - Journal Article
PL  - Croatia
TA  - Croat Med J
JT  - Croatian medical journal
JID - 9424324
SB  - IM
PMC - PMC3641874
OID - NLM: PMC3641874
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PST - ppublish
SO  - Croat Med J. 2013 Apr 15;54(2):171-9.

PMID- 23630132
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1460-2245 (Electronic)
IS  - 0957-4824 (Linking)
DP  - 2013 Apr 28
TI  - A risky occupation? (Un)healthy lifestyle behaviors among Danish seafarers.
AB  - Sedentary working conditions, smoking, unhealthy eating habits and lack of
      exercise are some of the lifestyle risk factors that form a potentially growing
      problem for seafarers within certain parts of the maritime sector creating a
      heightened risk for chronic diseases such as diabetes and cardiovascular disease.
      Health promotion initiatives to combat this negative development requires as a
      first step identifying the magnitude of the different risk factors. A survey was 
      conducted in 2007-08 with two Danish shipping companies on seafarers' health,
      wellbeing, diet, smoking and physical activity. In addition, a health profile was
      offered to the respondents, consisting of physiological measurements, such as
      fitness rating, body mass index (BMI), cholesterol measurement and blood
      pressure. The response rate in the questionnaire study was 57% (n = 360) of which
      76% (n = 272) of the respondents received a health profile. Results (males)
      showed 44% daily smokers compared with 32% in the general Danish adult male
      population. Twenty-five percent of the seafarers were obese with a BMI > 30
      compared with 12% of the Danish adult male population. Fifty-one percent of the
      respondents were defined as having metabolic syndrome, compared with 20% of the
      Danish adult male population. Seafaring is a risky occupation when looking at the
      seafarers' health and wellbeing. The results of this survey confirm the need for 
      health promotion interventions such as smoking cessation courses, healthy cooking
      courses and physical exercise programs, etc. that can enable healthier lifestyle.
      The challenge will be to take into account the special seafaring conditions when 
      implementing the interventions.
AD  - 1Centre of Maritime Health and Society, Institute of Public Health, University of
      Southern Denmark, Niels Bohrs Vej 9, 6700 Esbjerg, Denmark.
FAU - Hjarnoe, Lulu
AU  - Hjarnoe L
FAU - Leppin, Anja
AU  - Leppin A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Health Promot Int
JT  - Health promotion international
JID - 9008939
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - dat024 [pii]
AID - 10.1093/heapro/dat024 [doi]
PST - aheadofprint
SO  - Health Promot Int. 2013 Apr 28.

PMID- 23630102
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1469-0705 (Electronic)
IS  - 0960-7692 (Linking)
DP  - 2013 Apr 30
TI  - Maternal age and adverse pregnancy outcomes: a cohort study.
LID - 10.1002/uog.12494 [doi]
AB  - OBJECTIVE: The aim of this study was to examine the association between maternal 
      age and a wide range of adverse pregnancy outcomes after adjustment for
      confounding factors in obstetric history and maternal characteristics. METHODS:
      This was a retrospective study in women with singleton pregnancies attending the 
      first routine hospital visit at 11+0 -13+6 weeks of gestation. Data on maternal
      characteristics, medical and obstetric history were collected and pregnancy
      outcomes ascertained. Maternal age was studied, both as a continuous and as a
      categorical variable. Regression analysis was performed to examine the
      association between maternal age and adverse pregnancy outcomes including
      preeclampsia (PE), gestational hypertension (GH), gestational diabetes mellitus
      (GDM), preterm delivery (PTD), small for gestational age (SGA), large for
      gestational age (LGA), miscarriage, stillbirth, elective and emergency cesarean
      section (CS). RESULTS: The study population included 76,158 singleton pregnancies
      with a live fetus at 11+0 -13+6 weeks. After adjusting for maternal and pregnancy
      potential confounding variables, advanced maternal age (defined as >/=40 years)
      was associated with increased risk of miscarriage [OR (95% CI): 2.32 (1.83-2.93),
      p < 0.001], PE [1.49 (1.22-1.82), p < 0.001], GDM [1.88 (1.55-2.29) p < 0.001],
      SGA [1.46 (1.27-1.69) p < 0.001] and CS [1.95 (1.77-2.14) p < 0.001], but not for
      stillbirth, GH, spontaneous PTD or LGA. CONCLUSION: Maternal age should be
      combined with other maternal characteristics and obstetric history when
      calculating an individualised adjusted risk for adverse pregnancy complications. 
      Advanced maternal age is a risk factor for miscarriage, PE, SGA, GDM and CS, but 
      not for stillbirth, GH, spontaneous PTD or LGA.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Fetal Medicine, Institute for Women's Health, University College
      London Hospitals, London, UK.
FAU - Khalil, Asma
AU  - Khalil A
FAU - Syngelaki, Argyro
AU  - Syngelaki A
FAU - Maiz, Nerea
AU  - Maiz N
FAU - Zinevich, Yana
AU  - Zinevich Y
FAU - Nicolaides, Kypros H
AU  - Nicolaides KH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Ultrasound Obstet Gynecol
JT  - Ultrasound in obstetrics & gynecology : the official journal of the International
      Society of Ultrasound in Obstetrics and Gynecology
JID - 9108340
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/02/05 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/03/28 [accepted]
AID - 10.1002/uog.12494 [doi]
PST - aheadofprint
SO  - Ultrasound Obstet Gynecol. 2013 Apr 30. doi: 10.1002/uog.12494.

PMID- 23630073
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1549-5477 (Electronic)
IS  - 0890-9369 (Linking)
VI  - 27
IP  - 8
DP  - 2013 Apr 15
TI  - Emerging roles of the corepressors NCoR1 and SMRT in homeostasis.
PG  - 819-35
LID - 10.1101/gad.214023.113 [doi]
AB  - Epigenetic regulation of gene expression is strongly influenced by the
      accessibility of nucleosomal DNA or the state of chromatin compaction. In this
      context, coregulators, including both coactivators and corepressors, are pivotal 
      intermediates that bridge chromatin-modifying enzymes and transcription factors. 
      NCoR1 (nuclear receptor corepressor) and SMRT (silencing mediator of retinoic
      acid and thyroid hormone receptor) are among the best-characterized corepressors 
      from a molecular point of view. These coregulators have conserved orthologs in
      lower organisms, which underscores their functional importance. Here we summarize
      the results from recent in vivo studies that reveal the wide-ranging roles of
      NCoR1 and SMRT in developmental as well as homeostatic processes, including
      metabolism, inflammation, and circadian rhythms. We also discuss the potential
      implications of NCoR1 and SMRT regulation of pathways ranging from genomic
      stability and carcinogenesis to metabolic diseases such as type 2 diabetes.
AD  - Laboratory for Integrative and Systems Physiology, Ecole Polytechnique Federale
      de Lausanne, Lausanne CH-1015, Switzerland.
FAU - Mottis, Adrienne
AU  - Mottis A
FAU - Mouchiroud, Laurent
AU  - Mouchiroud L
FAU - Auwerx, Johan
AU  - Auwerx J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Genes Dev
JT  - Genes & development
JID - 8711660
SB  - IM
PMC - PMC3650221
OID - NLM: PMC3650221
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - 27/8/819 [pii]
AID - 10.1101/gad.214023.113 [doi]
PST - ppublish
SO  - Genes Dev. 2013 Apr 15;27(8):819-35. doi: 10.1101/gad.214023.113.

PMID- 23630060
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 2047-6310 (Electronic)
IS  - 2047-6302 (Linking)
DP  - 2013 Apr 29
TI  - Does consumption of high-fructose corn syrup beverages cause obesity in children?
LID - 10.1111/j.2047-6310.2013.00173.x [doi]
AB  - WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: High Fructose Corn Syrup (HFCS)
      consumption in the form of beverages has increased among U.S. school-aged
      children. HFCS is a common sweetener found in the U.S. food supply including
      fruit juices, soft drinks, and sport drinks. Obesity exposes school-aged children
      to preventative health risks. WHAT THIS STUDY ADDS: There is inconclusive
      scientific evidence to definitively link HFCS beverage consumption in school-aged
      children to obesity. Consumption of HFCS beverages in children may displace
      consumption of milk. Many entities contribute to childhood yet limitation of
      sweetened beverages may decrease obesity in children. The consumption of
      high-fructose corn syrup (HFCS) beverages has increased since the 1970s. At the
      same time, childhood obesity is on the rise, causing children to be at risk of
      heart disease, diabetes and other diseases. Healthcare providers have attributed 
      childhood obesity to the consumption of HFCS in the form of beverages. This
      article will look at the available research and determine if there is scientific 
      evidence underlying the idea that sweetened soft drinks, especially those
      containing HFCS, could cause or contribute to childhood obesity. A thorough
      literature search was performed using the ISI Web of Sciences, PubMed and Scopus 
      databases within the years 2006-2012. The search generated 19 results. The
      articles were screened, and six were deemed eligible: four systematic reviews and
      two meta-analyses. Two systematic reviews found that there is no relationship
      between consumption of HFCS beverages and obesity in children. The other two
      systematic reviews found possible links between HFCS and childhood obesity. The
      meta-analysis articles found that consumption of HFCS beverages can contribute to
      childhood obesity, and limitation of sweetened beverages may help decrease
      obesity in children. Available research studies demonstrate inconclusive
      scientific evidence definitively linking HFCS to obesity in children.
CI  - (c) 2013 The Author. Pediatric Obesity (c) 2013 International Association for the
      Study of Obesity.
AD  - School of Nursing, University of Pennsylvania, Philadelphia, PA, USA.
FAU - Morgan, R E
AU  - Morgan RE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Pediatr Obes
JT  - Pediatric obesity
JID - 101572033
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/08/01 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/26 [accepted]
AID - 10.1111/j.2047-6310.2013.00173.x [doi]
PST - aheadofprint
SO  - Pediatr Obes. 2013 Apr 29. doi: 10.1111/j.2047-6310.2013.00173.x.

PMID- 23630033
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
DP  - 2013 Apr 29
TI  - Study Design and Rationale of a Dose-Ranging Trial of LX4211, a Dual Inhibitor of
      SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin
      Monotherapy.
LID - 10.1002/clc.22125 [doi]
AB  - Sodium-glucose cotransporters 1 (SGLT1) and 2 (SGLT2) are the major cellular
      transporters responsible for gastrointestinal (GI) glucose absorption and renal
      glucose reabsorption, respectively. LX4211, a dual inhibitor of SGLT1 and SGLT2, 
      reduces glucose absorption from the GI tract and enhances urinary glucose
      excretion. Although several SGLT2-selective inhibitors have been tested in large 
      phase 2 studies, dual inhibition of SGLT1 and SGLT2 is novel at this stage of
      drug development, and it has implications for clinical-trial design. In this
      article, we describe the design and rationale of a phase 2, multicenter,
      randomized, double-blind, placebo-controlled, parallel group study to evaluate
      the safety and efficacy of LX4211 in subjects with type 2 diabetes mellitus who
      have inadequate glycemic control on metformin monotherapy. The primary endpoint
      is the change in glycated hemoglobin A1c from baseline to week 12. Secondary
      endpoints include the proportion of subjects achieving a glycated hemoglobin A1c 
      value of <7%, change from baseline in fasting plasma glucose and postprandial
      glucose (as part of an oral glucose tolerance test), body weight, and blood
      pressure. Safety is evaluated with particular focus on hypoglycemia, GI symptoms,
      and incidence of genitourinary tract infections.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Clinical Development.
FAU - Lapuerta, Pablo
AU  - Lapuerta P
FAU - Rosenstock, Julio
AU  - Rosenstock J
FAU - Zambrowicz, Brian
AU  - Zambrowicz B
FAU - Powell, David R
AU  - Powell DR
FAU - Ogbaa, Ike
AU  - Ogbaa I
FAU - Freiman, Joel
AU  - Freiman J
FAU - Cefalu, William T
AU  - Cefalu WT
FAU - Banks, Phillip
AU  - Banks P
FAU - Frazier, Kenny
AU  - Frazier K
FAU - Kelly, Mike
AU  - Kelly M
FAU - Sands, Arthur
AU  - Sands A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/01/02 [received]
PHST- 2013/03/15 [revised]
AID - 10.1002/clc.22125 [doi]
PST - aheadofprint
SO  - Clin Cardiol. 2013 Apr 29. doi: 10.1002/clc.22125.

PMID- 23629957
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1757-4684 (Electronic)
IS  - 1757-4676 (Linking)
VI  - 5
IP  - 6
DP  - 2013 Jun
TI  - Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin
      sensitivity to tumours.
PG  - 935-48
LID - 10.1002/emmm.201202006 [doi]
AB  - Endotrophin is a cleavage product of collagenVIalpha3 (COL6A3). Here, we explore 
      the relationship between thiazolidinediones (TZDs), endotrophin and cisplatin
      resistance in the context of a mammary tumour model. COL6A3 levels are increased 
      in response to cisplatin exposure in tumours. Endotrophin, in turn, causes
      cisplatin resistance. The effects of endotrophin can be bypassed, either through 
      use of COL6 null (COL6(-/-) ) mice or by administering TZDs in wild-type mice
      (leading to a downregulation of endotrophin). Both approaches sensitize tumours
      to cisplatin through the suppression of endotrophin-induced
      epithelial-mesenchymal transition. The beneficial effects of TZDs on cisplatin
      sensitivity are diminished in COL6(-/-) mice, whereas endotrophin(+) tumours are 
      sensitive to the TZD/cisplatin combination. Therefore, the chemosensitization
      obtained with TZDs is achieved through a downregulation of endotrophin. Treatment
      with an endotrophin neutralizing antibody in combination with cisplatin
      completely inhibits tumour growth of tumour allografts. Combined, our data
      suggest that endotrophin levels are a strong prognostic marker for the
      effectiveness of the combination therapy of TZDs with cisplatin, and
      neutralization of endotrophin activity dramatically improves the therapeutic
      response to combination therapy.
CI  - Copyright (c) 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf
      of EMBO.
AD  - Departments of Internal Medicine, Touchstone Diabetes Center, The University of
      Texas Southwestern Medical Center, Dallas, TX, USA.
FAU - Park, Jiyoung
AU  - Park J
FAU - Morley, Thomas S
AU  - Morley TS
FAU - Scherer, Philipp E
AU  - Scherer PE
LA  - eng
GR  - P30 CA142543/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20130430
PL  - England
TA  - EMBO Mol Med
JT  - EMBO molecular medicine
JID - 101487380
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/09/09 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1002/emmm.201202006 [doi]
PST - ppublish
SO  - EMBO Mol Med. 2013 Jun;5(6):935-48. doi: 10.1002/emmm.201202006. Epub 2013 Apr
      30.

PMID- 23629871
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 228
IP  - 9
DP  - 2013 Sep
TI  - Functional and morphological impact of ER stress on mitochondria.
PG  - 1802-18
LID - 10.1002/jcp.24360 [doi]
AB  - Over the past years, knowledge and evidence about the existence of crosstalks
      between cellular organelles and their potential effects on survival or cell death
      have been constantly growing. More recently, evidence accumulated showing an
      intimate relationship between endoplasmic reticulum (ER) and mitochondria. These 
      close contacts not only establish extensive physical links allowing exchange of
      lipids and calcium but they can also coordinate pathways involved in cell life
      and death. It is now obvious that ER dysfunction/stress and unfolded protein
      response (UPR) as well as mitochondria play major roles in apoptosis. However,
      while the effects of major ER stress on cell death have been largely studied and 
      reviewed, it becomes more and more evident that cells might regularly deal with
      sublethal ER stress, a condition that does not necessarily lead to cell death but
      might affect the function/activity of other organelles such as mitochondria. In
      this review, we will particularly focus on these new, interesting and intriguing 
      metabolic and morphological events that occur during the early adaptative phase
      of the ER stress, before the onset of cell death, and that remain largely
      unknown. Relevance and implication of these mitochondrial changes in response to 
      ER stress conditions for human diseases such as type II diabetes and Alzheimer's 
      disease will also be considered. J. Cell. Physiol. 9999: XX-XX, 2013. (c) 2013
      Wiley Periodicals, Inc. J. Cell. Physiol. 228: 1802-1818, 2013. (c) 2013 Wiley
      Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Laboratory of Biochemistry and Cellular Biology, URBC-NARILIS (NAmur Research
      Institute for LIfe Sciences), University of Namur (FUNDP), Namur, Belgium.
FAU - Vannuvel, Kayleen
AU  - Vannuvel K
FAU - Renard, Patricia
AU  - Renard P
FAU - Raes, Martine
AU  - Raes M
FAU - Arnould, Thierry
AU  - Arnould T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/02/21 [received]
PHST- 2013/03/04 [accepted]
AID - 10.1002/jcp.24360 [doi]
PST - ppublish
SO  - J Cell Physiol. 2013 Sep;228(9):1802-18. doi: 10.1002/jcp.24360.

PMID- 23629823
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
DP  - 2013 Apr 29
TI  - Prothrombotic Changes in Diabetes Mellitus.
AB  - Although our understanding of vascular pathology has greatly improved in recent
      years, the cellular and molecular mechanisms underlying the enhanced thrombotic
      propensity in type 2 diabetes mellitus (T2DM) remain incompletely characterized. 
      Detrimental interactions between activated vascular cells (i.e., platelets,
      leukocytes, endothelial cells) and the vulnerable atheromatous plaque are a major
      determinant of the increased atherothrombotic burden in T2DM patients.
      Endothelial damage and accelerated senescence, impairment of the endothelial
      progenitor cell repair system, plaque neovascularization and inflammation,
      decreased clearance of detrimental molecules within the plaque, and increased
      expression of matrix metalloproteinases may collectively contribute to
      intraplaque hemorrhage and subsequent rupture. Notably, recent data demonstrates 
      the central importance of the tissue factor-microparticle-mediated pathway in
      diabetic thrombophilia and cardiovascular complications. Acting as detrimental
      amplifiers of various biological responses (including thrombogenicity and plaque 
      remodeling), microparticles have also emerged as a key marker of global vascular 
      damage in T2DM patients. Available evidence suggests that targeting the tissue
      factor-microparticle pathway may be a promising approach for reducing the burden 
      of the atherosclerotic complications of diabetes.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
AD  - Unite de recherche EA 7293 Stress vasculaire et tissulaire en Transplantation,
      Faculte de Medecine, Universite de Strasbourg, Strasbourg, France.
FAU - Morel, Olivier
AU  - Morel O
FAU - Jesel, Laurence
AU  - Jesel L
FAU - Abbas, Malak
AU  - Abbas M
FAU - Morel, Nicolas
AU  - Morel N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/29 [epublish]
AID - 10.1055/s-0033-1343888 [doi]
PST - aheadofprint
SO  - Semin Thromb Hemost. 2013 Apr 29.

PMID- 23629748
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1576-6578 (Electronic)
IS  - 0210-0010 (Linking)
VI  - 56
IP  - 9
DP  - 2013 May 1
TI  - [Detection of vascular risk factors and unknown atrial fibrillation in patients
      hospitalised in the stroke unit].
PG  - 464-70
AB  - INTRODUCTION. Certain modifiable cerebrovascular risk factors, such as arterial
      hypertension, diabetes mellitus, dyslipidaemia and atrial fibrillation, must be
      recognised and controlled if a decrease in the appearance of cerebrovascular
      diseases is to be achieved. On some occasions the presenting symptom of these
      risk factors may be a stroke. PATIENTS AND METHODS. A prospective
      observation-based study was conducted with a sample of patients who were admitted
      to the stroke unit of our hospital due to an acute cerebrovascular disease,
      namely transient ischaemic attack and ischaemic stroke, in order to determine the
      percentage of patients with previously undiagnosed arterial hypertension,
      diabetes mellitus, dyslipidaemia and atrial fibrillation. RESULTS. A total of 186
      patients were selected for the study. Of the total number of patients, 24
      presented unknown arterial hypertension (12.9%); 11 had unknown diabetes mellitus
      (5.9%); 49 had unknown hypercholesterolemia (26.3%); 15 had unknown
      hypertriglyceridemia (8.1%); and 22 had unknown atrial fibrillation (11.8%).
      Altogether 96 of them (51.6%) had at least one of these cerebrovascular risk
      factors. The existence of a previously undiagnosed risk factor was higher in the 
      rural setting, in subjects who had not died at six months and in transient
      ischaemic attacks than in cases of ischaemic strokes. CONCLUSIONS. Over half the 
      subjects who suffer a cerebrovascular event have a risk factor that has not
      previously been diagnosed. Campaigns should be carried out to implement detection
      of these factors, and increased efforts must be made to lower the appearance and 
      recurrence of vascular pathologies.
AD  - Hospital San Pedro de Alcantara, 10003 Caceres, Espana.
FAU - Jimenez-Caballero, P E
AU  - Jimenez-Caballero PE
FAU - Lopez-Espuela, F
AU  - Lopez-Espuela F
FAU - Portilla-Cuenca, J C
AU  - Portilla-Cuenca JC
FAU - Jimenez-Gracia, M A
AU  - Jimenez-Gracia MA
FAU - Casado-Naranjo, I
AU  - Casado-Naranjo I
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Deteccion de factores de riesgo vascular y fibrilacion auricular no conocida en
      pacientes ingresados en la unidad de ictus.
PL  - Spain
TA  - Rev Neurol
JT  - Revista de neurologia
JID - 7706841
SB  - IM
OAB - Publisher: Abstract available from the publisher.
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - rn2012636 [pii]
PST - ppublish
SO  - Rev Neurol. 2013 May 1;56(9):464-70.

PMID- 23629625
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1098-5549 (Electronic)
IS  - 0270-7306 (Linking)
VI  - 33
IP  - 13
DP  - 2013 Jul
TI  - SAD-A Potentiates Glucose-Stimulated Insulin Secretion as a Mediator of
      Glucagon-Like Peptide 1 Response in Pancreatic beta Cells.
PG  - 2527-34
LID - 10.1128/MCB.00285-13 [doi]
AB  - Type 2 diabetes is characterized by defective glucose-stimulated insulin
      secretion (GSIS) from pancreatic beta cells, which can be restored by
      glucagon-like peptide 1 (GLP-1), an incretin hormone commonly used for the
      treatment of type 2 diabetes. However, molecular mechanisms by which GLP-1
      affects glucose responsiveness in islet beta cells remain poorly understood. Here
      we investigated a role of SAD-A, an AMP-activated protein kinase (AMPK)-related
      kinase, in regulating GSIS in mice with conditional SAD-A deletion. We show that 
      selective deletion of SAD-A in pancreas impaired incretin's effect on GSIS,
      leading to glucose intolerance. Conversely, overexpression of SAD-A significantly
      enhanced GSIS and further potentiated GLP-1's effect on GSIS from isolated mouse 
      islets. In support of SAD-A as a mediator of incretin response, SAD-A is
      expressed exclusively in pancreas and brain, the primary targeting tissues of
      GLP-1 action. Additionally, SAD-A kinase is activated in response to stimulation 
      by GLP-1 through cyclic AMP (cAMP)/Ca(2+)-dependent signaling pathways in islet
      beta cells. Furthermore, we identified Thr443 as a key autoinhibitory
      phosphorylation site which mediates SAD-A's effect on incretin response in islet 
      beta cells. Consequently, ablation of Thr443 significantly enhanced GLP-1's
      effect on GSIS from isolated mouse islets. Together, these findings identified
      SAD-A kinase as a pancreas-specific mediator of incretin response in islet beta
      cells.
AD  - Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical 
      University, Nanjing, China.
FAU - Nie, Jia
AU  - Nie J
FAU - Lilley, Brendan N
AU  - Lilley BN
FAU - Pan, Y Albert
AU  - Pan YA
FAU - Faruque, Omar
AU  - Faruque O
FAU - Liu, Xiaolei
AU  - Liu X
FAU - Zhang, Weiping
AU  - Zhang W
FAU - Sanes, Joshua R
AU  - Sanes JR
FAU - Han, Xiao
AU  - Han X
FAU - Shi, Yuguang
AU  - Shi Y
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - Mol Cell Biol
JT  - Molecular and cellular biology
JID - 8109087
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/29 [aheadofprint]
AID - MCB.00285-13 [pii]
AID - 10.1128/MCB.00285-13 [doi]
PST - ppublish
SO  - Mol Cell Biol. 2013 Jul;33(13):2527-34. doi: 10.1128/MCB.00285-13. Epub 2013 Apr 
      29.

PMID- 23629573
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 0300-5283 (Print)
IS  - 0300-5283 (Linking)
VI  - 68
IP  - 2
DP  - 2013 Apr
TI  - Melioidosis and peritoneal dialysis related peritonitis.
PG  - 179-80
AB  - We report a case of melioidosis presenting as peritonitis in a patient on
      continuous ambulatory peritoneal dialysis (CAPD). A 47-year-old man, a lorry
      driver, with end-stage renal disease due to diabetes mellitus on CAPD presented
      in PD-related peritonitis. He was started on intraperitoneal cloxacillin and
      ceftazidime, and changed to intraperitoneal vancomycin and meropenam after day 5 
      due to nonresponse. Burkholderia pseudomallei was identified from the dialysate
      culture. He was treated with intraperitoneal meropenam for two weeks, and IV
      ceftazidime for 4 weeks. He responded, and the Tenckhoff catheter was not
      removed. He was discharged well and continued on oral
      sulfamethoxazole/trimethoprim for six months. This patient had done his PD
      exchanges in a lorry.
AD  - Hospital Queen Elizabeth, Medical, Karung Berkunci 2029, Kota Kinabalu, Sabah
      88586, Malaysia. drwongkohwei@gmail.com.
FAU - Wong, K W
AU  - Wong KW
LA  - eng
PT  - Journal Article
PL  - Malaysia
TA  - Med J Malaysia
JT  - The Medical journal of Malaysia
JID - 0361547
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PST - ppublish
SO  - Med J Malaysia. 2013 Apr;68(2):179-80.

PMID- 23629558
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 0300-5283 (Print)
IS  - 0300-5283 (Linking)
VI  - 68
IP  - 2
DP  - 2013 Apr
TI  - Community-based cardiovascular Risk Factors Intervention Strategies (CORFIS) in
      managing hypertension: A pragmatic non-randomised controlled trial.
PG  - 129-35
AB  - BACKGROUND: Hypertension is the number one cardiovascular risk factor in
      Malaysia. This study aimed to evaluate the effectiveness of a Community-Based
      Cardiovascular Risk Factors Intervention Strategies (CORFIS) in the management of
      hypertension in primary care. METHODS: This is a pragmatic, non-randomized
      controlled trial. Seventy general practitioners (GPs) were selected to provide
      either CORFIS (44 GPs) or conventional care (26 GPs) for 6 months. A total of 486
      hypertensive patients were recruited; 309 were in the intervention and 177 in the
      control groups. Primary outcome was the proportion of hypertensive patients who
      achieved target blood pressure (BP) of <140/90mmHg (for those without diabetes
      mellitus) and <130/80mmHg (with diabetes mellitus). Secondary outcomes include
      change in the mean/median BP at 6-month as compared to baseline. RESULTS: The
      proportion of hypertensive patients who achieved target BP at 6-month was
      significantly higher in the CORFIS arm (69.6%) as compared to the control arm
      (57.6%), P=0.008. Amongst those who had uncontrolled BP at baseline, the
      proportion who achieved target BP at 6-month was also significantly higher in the
      CORFIS arm (56.6%) as compared to the control arm (34.1%), p<0.001. There was no 
      difference in the patients who had already achieved BP control at baseline. There
      were significant reductions in SBP in the CORFIS arm (median -9.0mmHg; -60 to 50)
      versus control (median -2mmHg; -50 to 48), p=0.003; as well as in DBP (CORFIS
      arm: median -6.0mmHg; ranged from -53 to 30 versus control arm: median 0.0mmHg;
      ranged from -42 to 30), p<0.001. CONCLUSIONS: Patients who received CORFIS care
      demonstrated significant improvements in achieving target BP.
AD  - Clinical Research Center, Clinical Epidemiology Unit, 1st Floor MMA House, 124,
      Jalan Pahang, Kuala Lumpur 53000 Malaysia. wymenseet@gmail.com.
FAU - Low, W H H
AU  - Low WH
FAU - Seet, W
AU  - Seet W
FAU - A S, Ramli
AU  - A S R
FAU - Ng, K K
AU  - Ng KK
FAU - H, Jamaiyah
AU  - H J
FAU - Dan, S P
AU  - Dan SP
FAU - Teng, C L
AU  - Teng CL
FAU - Lee, V K M
AU  - Lee VK
FAU - Chua, S S
AU  - Chua SS
FAU - M Y, Faridah Aryani
AU  - M Y FA
FAU - T, Karupaiah
AU  - T K
FAU - Chee, W S S
AU  - Chee WS
FAU - Goh, P P
AU  - Goh PP
FAU - M, Zaki
AU  - M Z
FAU - Lim, T O
AU  - Lim TO
LA  - eng
PT  - Journal Article
PL  - Malaysia
TA  - Med J Malaysia
JT  - The Medical journal of Malaysia
JID - 0361547
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PST - ppublish
SO  - Med J Malaysia. 2013 Apr;68(2):129-35.

PMID- 23629540
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Apr 30
TI  - Circulating microRNAs as novel biomarkers for diabetes mellitus.
LID - 10.1038/nrendo.2013.86 [doi]
AB  - Diabetes mellitus is characterized by insulin secretion from pancreatic beta
      cells that is insufficient to maintain blood glucose homeostasis. Autoimmune
      destruction of beta cells results in type 1 diabetes mellitus, whereas conditions
      that reduce insulin sensitivity and negatively affect beta-cell activities result
      in type 2 diabetes mellitus. Without proper management, patients with diabetes
      mellitus develop serious complications that reduce their quality of life and life
      expectancy. Biomarkers for early detection of the disease and identification of
      individuals at risk of developing complications would greatly improve the care of
      these patients. Small non-coding RNAs called microRNAs (miRNAs) control gene
      expression and participate in many physiopathological processes. Hundreds of
      miRNAs are actively or passively released in the circulation and can be used to
      evaluate health status and disease progression. Both type 1 diabetes mellitus and
      type 2 diabetes mellitus are associated with distinct modifications in the
      profile of miRNAs in the blood, which are sometimes detectable several years
      before the disease manifests. Moreover, circulating levels of certain miRNAs seem
      to be predictive of long-term complications. Technical and scientific obstacles
      still exist that need to be overcome, but circulating miRNAs might soon become
      part of the diagnostic arsenal to identify individuals at risk of developing
      diabetes mellitus and its devastating complications.
AD  - University of Lausanne, Department of Fundamental Neurosciences, Rue du Bugnon 9,
      1005 Lausanne, Switzerland.
FAU - Guay, Claudiane
AU  - Guay C
FAU - Regazzi, Romano
AU  - Regazzi R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/30 [aheadofprint]
AID - nrendo.2013.86 [pii]
AID - 10.1038/nrendo.2013.86 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Apr 30. doi: 10.1038/nrendo.2013.86.

PMID- 23629539
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - Diagnosis and treatment of growth hormone deficiency in adults.
PG  - 335-45
LID - 10.1038/nrendo.2013.77 [doi]
AB  - The availability of synthetic recombinant human growth hormone (GH) in
      potentially unlimited quantities since the 1980s has improved understanding of
      the many nonstatural effects of GH on metabolism, body composition, physical and 
      psychological function, as well as the consequences of GH deficiency in adult
      life. Adult GH deficiency is now recognized as a distinct if nonspecific syndrome
      with considerable adverse health consequences. GH replacement therapy in lower
      doses than those used in children can reverse many of these abnormalities and
      restore functional capacities toward or even to normal; if dosed appropriately,
      GH therapy has few adverse effects. Although some doubts remain about possible
      long-term risks of childhood GH therapy, most registries of adult GH replacement 
      therapy, albeit limited in study size and duration, have not shown an increased
      incidence of cancers or of cardiovascular morbidity or mortality.
AD  - Division of Endocrinology, Diabetes, and Metabolism, University of Miami Miller
      School of Medicine, 1400 North West 10th Avenue, Suite 807, Miami, FL 33136, USA.
FAU - Kargi, Atil Y
AU  - Kargi AY
FAU - Merriam, George R
AU  - Merriam GR
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/30 [aheadofprint]
AID - nrendo.2013.77 [pii]
AID - 10.1038/nrendo.2013.77 [doi]
PST - ppublish
SO  - Nat Rev Endocrinol. 2013 Jun;9(6):335-45. doi: 10.1038/nrendo.2013.77. Epub 2013 
      Apr 30.

PMID- 23629434
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1940-087X (Electronic)
IS  - 1940-087X (Linking)
IP  - 74
DP  - 2013
TI  - Generation of High Quality Chromatin Immunoprecipitation DNA Template for
      High-throughput Sequencing (ChIP-seq).
LID - 10.3791/50286 [doi]
AB  - ChIP-sequencing (ChIP-seq) methods directly offer whole-genome coverage, where
      combining chromatin immunoprecipitation (ChIP) and massively parallel sequencing 
      can be utilized to identify the repertoire of mammalian DNA sequences bound by
      transcription factors in vivo. "Next-generation" genome sequencing technologies
      provide 1-2 orders of magnitude increase in the amount of sequence that can be
      cost-effectively generated over older technologies thus allowing for ChIP-seq
      methods to directly provide whole-genome coverage for effective profiling of
      mammalian protein-DNA interactions. For successful ChIP-seq approaches, one must 
      generate high quality ChIP DNA template to obtain the best sequencing outcomes.
      The description is based around experience with the protein product of the gene
      most strongly implicated in the pathogenesis of type 2 diabetes, namely the
      transcription factor transcription factor 7-like 2 (TCF7L2). This factor has also
      been implicated in various cancers. Outlined is how to generate high quality ChIP
      DNA template derived from the colorectal carcinoma cell line, HCT116, in order to
      build a high-resolution map through sequencing to determine the genes bound by
      TCF7L2, giving further insight in to its key role in the pathogenesis of complex 
      traits.
AD  - Division of Human Genetics, Children's Hospital of Philadelphia Research
      Institute.
FAU - Deliard, Sandra
AU  - Deliard S
FAU - Zhao, Jianhua
AU  - Zhao J
FAU - Xia, Qianghua
AU  - Xia Q
FAU - Grant, Struan F A
AU  - Grant SF
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - J Vis Exp
JT  - Journal of visualized experiments : JoVE
JID - 101313252
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - 10.3791/50286 [doi]
PST - epublish
SO  - J Vis Exp. 2013 Apr 19;(74). doi: 10.3791/50286.

PMID- 23629025
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1478-3975 (Electronic)
IS  - 1478-3967 (Linking)
VI  - 10
IP  - 3
DP  - 2013 Jun
TI  - The fractal spatial distribution of pancreatic islets in three dimensions: a
      self-avoiding growth model.
PG  - 036009
LID - 10.1088/1478-3975/10/3/036009 [doi]
AB  - The islets of Langerhans, responsible for controlling blood glucose levels, are
      dispersed within the pancreas. A universal power law governing the fractal
      spatial distribution of islets in two-dimensional pancreatic sections has been
      reported. However, the fractal geometry in the actual three-dimensional pancreas 
      volume, and the developmental process that gives rise to such a self-similar
      structure, has not been investigated. Here, we examined the three-dimensional
      spatial distribution of islets in intact mouse pancreata using optical projection
      tomography and found a power law with a fractal dimension of 2.1. Furthermore,
      based on two-dimensional pancreatic sections of human autopsies, we found that
      the distribution of human islets also follows a universal power law with a
      fractal dimension of 1.5 in adult pancreata, which agrees with the value
      previously reported in smaller mammalian pancreas sections. Finally, we developed
      a self-avoiding growth model for the development of the islet distribution and
      found that the fractal nature of the spatial islet distribution may be associated
      with the self-avoidance in the branching process of vascularization in the
      pancreas.
AD  - Laboratory of Biological Modeling, National Institute of Diabetes and Digestive
      and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
FAU - Jo, Junghyo
AU  - Jo J
FAU - Hornblad, Andreas
AU  - Hornblad A
FAU - Kilimnik, German
AU  - Kilimnik G
FAU - Hara, Manami
AU  - Hara M
FAU - Ahlgren, Ulf
AU  - Ahlgren U
FAU - Periwal, Vipul
AU  - Periwal V
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - England
TA  - Phys Biol
JT  - Physical biology
JID - 101197454
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/29 [aheadofprint]
AID - 10.1088/1478-3975/10/3/036009 [doi]
PST - ppublish
SO  - Phys Biol. 2013 Jun;10(3):036009. doi: 10.1088/1478-3975/10/3/036009. Epub 2013
      Apr 29.

PMID- 23628994
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130430
DCOM- 20130430
LR  - 20130507
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 4
DP  - 2013
TI  - Obesity in young men, and individual and combined risks of type 2 diabetes,
      cardiovascular morbidity and death before 55 years of age: a Danish 33-year
      follow-up study.
LID - 10.1136/bmjopen-2013-002698 [doi]
LID - e002698 [pii]
AB  - OBJECTIVES: To examine the association between body mass index (BMI) in young
      adulthood and cardiovascular risks, including venous thromboembolism, before 55
      years of age. DESIGN: Cohort study using population-based medical databases.
      SETTING: Outcomes registered from all hospitals in Denmark from 1977 onwards.
      PARTICIPANTS: 6502 men born in 1955 and eligible for conscription in Northern
      Denmark. MAIN OUTCOME MEASURES: Follow-up began at participants' 22nd birthday
      and continued until death, emigration or 55 years of age, whichever came first.
      Using regression analyses, we calculated the risks and HRs, adjusting for
      cognitive test score and years of education. RESULTS: 48% of all obese young men 
      (BMI >/=30 kg/m(2)) were either diagnosed with type 2 diabetes, hypertension,
      myocardial infarction, stroke or venous thromboembolism or died before reaching
      55 years of age. Comparing obese men with normal weight men (BMI 18.5 to <25.0
      kg/m(2)), the risk difference for any outcome was 28% (95% CI 19% to 38%) and the
      HR was 3.0 (95% CI 2.3 to 4.0). Compared with normal weight, obesity was
      associated with an event rate that was increased more than eightfold for type 2
      diabetes, fourfold for venous thromboembolism and twofold for hypertension,
      myocardial infarction and death. CONCLUSIONS: In this cohort of young men,
      obesity was strongly associated with adverse cardiometabolic events before 55
      years of age, including venous thromboembolism. Compared with those of normal
      weight, young obese men had an absolute risk increase for type 2 diabetes,
      cardiovascular morbidity or premature death of almost 30%.
AD  - Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N,
      Denmark.
FAU - Schmidt, Morten
AU  - Schmidt M
FAU - Johannesdottir, Sigrun A
AU  - Johannesdottir SA
FAU - Lemeshow, Stanley
AU  - Lemeshow S
FAU - Lash, Timothy L
AU  - Lash TL
FAU - Ulrichsen, Sinna P
AU  - Ulrichsen SP
FAU - Botker, Hans Erik
AU  - Botker HE
FAU - Toft Sorensen, Henrik
AU  - Toft Sorensen H
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3641453
OID - NLM: PMC3641453
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:01
CRDT- 2013/05/01 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2013-002698 [pii]
AID - 10.1136/bmjopen-2013-002698 [doi]
PST - epublish
SO  - BMJ Open. 2013 Apr 29;3(4). pii: e002698. doi: 10.1136/bmjopen-2013-002698. Print
      2013.

PMID- 23628963
OWN - NLM
STAT- In-Process
DA  - 20130430
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
VI  - 25
IP  - 6
DP  - 2013 Jun
TI  - Multidisciplinary strategies to improve treatment outcomes in hepatocellular
      carcinoma: a European perspective.
PG  - 639-51
LID - 10.1097/MEG.0b013e32835e33bb [doi]
AB  - Hepatocellular carcinoma (HCC) is a complex disease with a poor prognosis.
      Incidence and mortality rates are increasing in many geographical regions,
      indicating a need for better management strategies. Among several risk factors
      for HCC, the most common are cirrhosis because of chronic hepatitis B virus or
      hepatitis C virus infection and alcohol consumption, obesity, and diabetes. In
      some patients, combined risk factors present additional challenges to the
      prevention and treatment of HCC. Screening and surveillance of high-risk
      populations varies widely by geographic regions, and access to optimal
      surveillance is critical for early diagnosis. The treatment choice for HCC
      depends on the cancer stage, patient performance status, and liver function and
      requires a multidisciplinary approach and close cooperation among specialists for
      the best patient outcomes. Despite advances in surgical treatments and
      locoregional therapies, recurrence and liver failure remain significant
      challenges. The pathogenesis of HCC is a multistep and complex process, wherein
      angiogenesis plays an important role. The multikinase inhibitor sorafenib is the 
      only approved targeted agent for advanced HCC, although promising results have
      been obtained with other targeted agents and combinations, and the results of
      ongoing trials are eagerly awaited. Clinical trials with rigorous study designs, 
      including molecular classification and validation of new molecular biomarkers,
      are required to improve the personalized treatment of HCC. This article provides 
      an overview of HCC and was developed through a review of relevant literature,
      clinical trial data, and updated clinical guidelines.
AD  - 1st Division of Gastroenterology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore
      Policlinico, University of Milan, Milan, Italy. massimo.colombo@unimi.it
FAU - Colombo, Massimo
AU  - Colombo M
FAU - Raoul, Jean-Luc
AU  - Raoul JL
FAU - Lencioni, Riccardo
AU  - Lencioni R
FAU - Galle, Peter R
AU  - Galle PR
FAU - Zucman-Rossi, Jessica
AU  - Zucman-Rossi J
FAU - Banares, Rafael
AU  - Banares R
FAU - Seehofer, Daniel
AU  - Seehofer D
FAU - Neuhaus, Peter
AU  - Neuhaus P
FAU - Johnson, Philip
AU  - Johnson P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - 10.1097/MEG.0b013e32835e33bb [doi]
AID - 00042737-201306000-00001 [pii]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2013 Jun;25(6):639-51. doi:
      10.1097/MEG.0b013e32835e33bb.

PMID- 23628951
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1873-734X (Electronic)
IS  - 1010-7940 (Linking)
DP  - 2013 Apr 28
TI  - Coronary artery bypass grafting vs percutaneous coronary intervention in a
      'real-world' setting: a comparative effectiveness study based on propensity
      score-matched cohorts.
AB  - OBJECTIVES: Most studies comparing coronary artery bypass grafting (CABG) and
      percutaneous coronary interventions (PCI) showed that fewer patients who had
      undergone CABG required repeat revascularizations , but no difference in
      survival, with the exception of some subgroups of patients. However, long-term
      real-world evidence on patients in whom both procedures are technically feasible 
      is yet not available. The aim of this study was to compare 5-year rates of death,
      myocardial infarction (MI), target vessel revascularization (TVR) and stroke in a
      large cohort of patients with left main coronary artery (LMCA) or multivessel
      disease, treated with CABG or PCI (with or without DES) or PCI with DES only.
      METHODS: Two propensity score (PS)-matched cohorts of patients undergoing
      revascularization procedures at the regional public and private centres of
      Emilia-Romagna over the period July 2002-December 2008 were used to compare
      long-term outcomes of PCI (6246 patients) and CABG (5504 patients). RESULTS: PCI 
      was associated with higher risk of death (HR = 1.6; 95% CI 1.4-1.8, P < 0.0001), 
      MI (HR = 3.3; 95% CI 2.7-4.0, P < 0.0001) and TVR (HR = 4.5; 95% CI 3.8-5.2, P < 
      0.0001) at 5 years. No significant difference was shown for stroke (HR = 1.1; 95%
      CI 0.9-1.4, P = 0.43). CABG benefit was more evident in the risk of death in
      patients with two-vessel disease plus LMCA and in those with three-vessel
      disease, LVEF <35%, congestive heart failure and diabetes. Adjusted comparison
      with PS between PCI with DES only and CABG confirmed significant differences in
      favour of CABG for mortality, MI and TVR rates. Competing risk analysis showed
      that the difference in the mortality rate was due to higher rate of MI in PCI.
      CONCLUSIONS: In the 'real-world' setting of this study, CABG was associated with 
      significantly lower rates of death, MI and TVR in patients with LMCA or
      multivessel disease, so it remains the standard of care, particularly for
      patients with more extensive coronary disease and diabetes.
AD  - Regional Agency for Health and Social Care of Emilia-Romagna, Bologna, Italy.
FAU - Fortuna, Daniela
AU  - Fortuna D
FAU - Nicolini, Francesco
AU  - Nicolini F
FAU - Guastaroba, Paolo
AU  - Guastaroba P
FAU - De Palma, Rossana
AU  - De Palma R
FAU - Di Bartolomeo, Stefano
AU  - Di Bartolomeo S
FAU - Saia, Francesco
AU  - Saia F
FAU - Pacini, Davide
AU  - Pacini D
FAU - Grilli, Roberto
AU  - Grilli R
CN  - on behalf of RERIC (Regional Registry of Cardiac Surgery)
CN  - REAL (Regional Registry of Coronary Angioplasties) Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Eur J Cardiothorac Surg
JT  - European journal of cardio-thoracic surgery : official journal of the European
      Association for Cardio-thoracic Surgery
JID - 8804069
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - ezt197 [pii]
AID - 10.1093/ejcts/ezt197 [doi]
PST - aheadofprint
SO  - Eur J Cardiothorac Surg. 2013 Apr 28.

PMID- 23628929
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 80
IP  - 18
DP  - 2013 Apr 30
TI  - Adherence to a Mediterranean diet and risk of incident cognitive impairment.
PG  - 1684-1692
AB  - OBJECTIVE: We sought to determine the relationship of greater adherence to
      Mediterranean diet (MeD) and likelihood of incident cognitive impairment (ICI)
      and evaluate the interaction of race and vascular risk factors. METHODS: A
      prospective, population-based, cohort of individuals enrolled in the Reasons for 
      Geographic and Racial Differences in Stroke (REGARDS) Study 2003-2007, excluding 
      participants with history of stroke, impaired cognitive status at baseline, and
      missing data on Food Frequency Questionnaires (FFQ), was evaluated. Adherence to 
      a MeD (scored as 0-9) was computed from FFQ. Cognitive status was evaluated at
      baseline and annually during a mean follow-up period of 4.0 +/- 1.5 years using
      Six-item-Screener. RESULTS: ICI was identified in 1,248 (7%) out of 17,478
      individuals fulfilling the inclusion criteria. Higher adherence to MeD was
      associated with lower likelihood of ICI before (odds ratio [lsqb]OR[rsqb] 0.89;
      95% confidence interval [lsqb]CI[rsqb] 0.79-1.00) and after adjustment for
      potential confounders (OR 0.87; 95% CI 0.76-1.00) including demographic
      characteristics, environmental factors, vascular risk factors, depressive
      symptoms, and self-reported health status. There was no interaction between race 
      (p = 0.2928) and association of adherence to MeD with cognitive status. However, 
      we identified a strong interaction of diabetes mellitus (p = 0.0134) on the
      relationship of adherence to MeD with ICI; high adherence to MeD was associated
      with a lower likelihood of ICI in nondiabetic participants (OR 0.81; 95% CI
      0.70-0.94; p = 0.0066) but not in diabetic individuals (OR 1.27; 95% CI
      0.95-1.71; p = 0.1063). CONCLUSIONS: Higher adherence to MeD was associated with 
      a lower likelihood of ICI independent of potential confounders. This association 
      was moderated by presence of diabetes mellitus.
AD  - From the Second Department of Neurology, School of Medicine, Attikon Hospital,
      University of Athens, Greece; Comprehensive Stroke Center (G.T., A.V.A.), the
      Departments of Biostatistics (S.J., A.J.L., G.H.) and Epidemiology (V.J.H.),
      School of Public Health, and the Department of Medicine (V.G.W.), University of
      Alabama at Birmingham, Birmingham; International Clinical Research Center (G.T.),
      St. Anne's University Hospital Brno, Brno, Czech Republic; the Department of
      Neurology (F.N.), Emory University, Atlanta, GA; the Department of Psychiatry
      (F.W.U.), Indiana University School of Medicine, Indianapolis; National Institute
      of Neurological Disorders and Stroke (C.M.), National Institutes of Health,
      Bethesda, MD; and the Department of Neurology (B.K.), University of Cincinnati,
      Cincinnati, OH. Coinvestigators are listed on the Neurology(R) Web site at
      www.neurology.org.
FAU - Tsivgoulis, Georgios
AU  - Tsivgoulis G
FAU - Judd, Suzanne
AU  - Judd S
FAU - Letter, Abraham J
AU  - Letter AJ
FAU - Alexandrov, Andrei V
AU  - Alexandrov AV
FAU - Howard, George
AU  - Howard G
FAU - Nahab, Fadi
AU  - Nahab F
FAU - Unverzagt, Frederick W
AU  - Unverzagt FW
FAU - Moy, Claudia
AU  - Moy C
FAU - Howard, Virginia J
AU  - Howard VJ
FAU - Kissela, Brett
AU  - Kissela B
FAU - Wadley, Virginia G
AU  - Wadley VG
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - Neurology
JT  - Neurology
JID - 0401060
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - 80/18/1684 [pii]
AID - 10.1212/WNL.0b013e3182904f69 [doi]
PST - ppublish
SO  - Neurology. 2013 Apr 30;80(18):1684-1692.

PMID- 23628877
OWN - NLM
STAT- In-Process
DA  - 20130430
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Bad medicine: the way we manage diabetes.
PG  - f2695
LID - 10.1136/bmj.f2695 [doi]
LID - bmj.f2695 [pii]
AD  - destwo@yahoo.co.uk
FAU - Spence, Des
AU  - Spence D
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PST - epublish
SO  - BMJ. 2013 Apr 29;346:f2695. doi: 10.1136/bmj.f2695.

PMID- 23628854
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 Apr 3
TI  - FTO predicts weight regain in the Look AHEAD clinical trial.
LID - 10.1038/ijo.2013.54 [doi]
AB  - Background:Genome-wide association studies have provided new insights into the
      genetic factors that contribute to the development of obesity. We hypothesized
      that these genetic markers would also predict magnitude of weight loss and weight
      regain after initial weight loss.Methods:Established obesity risk alleles
      available on the Illumina CARe iSelect (IBC) chip were characterized in 3899
      overweight or obese participants with type 2 diabetes from the Look AHEAD (Action
      for Health in Diabetes), a randomized trial to determine the effects of intensive
      lifestyle intervention (ILI) and diabetes support and education (DSE) on
      cardiovascular morbidity and mortality. Primary analyses examined the interaction
      between 13 obesity risk polymorphisms in eight genes and randomized treatment arm
      in predicting weight change at year 1, and weight regain at year 4 among
      individuals who lost 3% or more of their baseline weight by year 1.Results:No
      single-nucleotide polymorphisms (SNPs) were significantly associated with
      magnitude of weight loss or interacted with treatment arm at year 1. However, fat
      mass and obesity associated gene (FTO) rs3751812 predicted weight regain within
      DSE (1.56 kg per risk allele, P=0.005), but not ILI (P=0.761), resulting in SNP x
      treatment arm interaction (P=0.009). In a partial replication of prior research, 
      the obesity risk (G) allele at BDNF rs6265 was associated with greater weight
      regain across treatment arms (0.773 kg per risk allele), although results were of
      borderline statistical significance (P=0.051).Conclusions:Variations in the FTO
      and BDNF loci may contribute risk of weight regain after weight
      loss.International Journal of Obesity advance online publication, 30 April 2013; 
      doi:10.1038/ijo.2013.54.
AD  - Weight Control and Diabetes Research Center, Department of Psychiatry and Human
      Behavior, The Miriam Hospital and Brown Medical School, Providence, RI, USA.
FAU - McCaffery, J M
AU  - McCaffery JM
FAU - Papandonatos, G D
AU  - Papandonatos GD
FAU - Huggins, G S
AU  - Huggins GS
FAU - Peter, I
AU  - Peter I
FAU - Kahn, S E
AU  - Kahn SE
FAU - Knowler, W C
AU  - Knowler WC
FAU - Hudnall, G E
AU  - Hudnall GE
FAU - Lipkin, E W
AU  - Lipkin EW
FAU - Kitabchi, A E
AU  - Kitabchi AE
FAU - Wagenknecht, L E
AU  - Wagenknecht LE
FAU - Wing, R R
AU  - Wing RR
LA  - ENG
GR  - R01 DK090043/DK/NIDDK NIH HHS/United States
GR  - U01 DK056992/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130403
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/03 [aheadofprint]
PHST- 2013/04/30 [aheadofprint]
AID - ijo201354 [pii]
AID - 10.1038/ijo.2013.54 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 Apr 3. doi: 10.1038/ijo.2013.54.

PMID- 23628730
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 154
IP  - 18
DP  - 2013 May 1
TI  - [Cognitive functions in type 1 and type 2 diabetes. Metaanalysis].
PG  - 694-9
LID - 10.1556/OH.2013.29602 [doi]
AB  - Introduction: Diabetes has been repeatedly associated with a wide variety of
      cognitive impairments. Aim: To clarify the differences in cognitive dysfunctions 
      between the two types of diabetes. Method: Metaanalysis was performed using
      databases of Medline, PubMed and ScienceDirect (3 studies with type 1 and 6 with 
      type 2 diabetes). Results: Adults with type 1 diabetes showed lower performance
      than control subjects in all fields. The effect size had the highest value in
      psychomotor activity (D = -0.69). The effect size was small for delayed verbal
      memory (D = -0.48), attention (D = -0.47), language (D = -0.44), visual
      processing (D = -0.35), immediate verbal memory (D = -0.30), working memory (D = 
      -0.27) and executive functions (D = -0.26). Adults with type 2 diabetes showed
      lower performance than control subjects in all cognitive domains, except for
      working memory (D = +0.03). The effect size had the highest value in immediate
      verbal memory (D = -1.12), psychomotor activity (D = -0.82) and delayed verbal
      memory (D = -0.81). The effect size was moderate for general intellectual
      abilities (D = -0.68) and small for general memory (D = -0.37), attention (D =
      -0.35), language (D = -0.35), visual processing (D = -0.33) and executive
      functions (D = -0.33). Conclusion: Both types of diabetes are associated with
      reduced performance in numerous cognitive domains. Orv. Hetil., 2013, 154,
      694-699.
AD  - Babes-Bolyai Tudomanyegyetem, Pszichologia es Nevelestudomanyi Kar Alkalmazott
      Pszichologia Tanszek Kolozsvar.
FAU - Kalcza-Janosi, Kinga
AU  - Kalcza-Janosi K
FAU - Lukacs, Andrea
AU  - Lukacs A
FAU - Barkai, Laszlo
AU  - Barkai L
FAU - Szamoskozi, Istvan
AU  - Szamoskozi I
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - Kognitiv funkciok az 1-es es 2-es tipusu cukorbetegsegben. Metaanalizis.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
SB  - IM
OAB - Publisher: Abstract available from the publisher.
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - Q6R050VU8J792808 [pii]
AID - 10.1556/OH.2013.29602 [doi]
PST - ppublish
SO  - Orv Hetil. 2013 May 1;154(18):694-9. doi: 10.1556/OH.2013.29602.

PMID- 23628652
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1569-9285 (Electronic)
IS  - 1569-9285 (Linking)
DP  - 2013 Apr 28
TI  - A multicentre Spanish study for multivariate prediction of perioperative
      in-hospital cerebrovascular accident after coronary bypass surgery: the PACK2
      score.
AB  - OBJECTIVETo develop a multivariate predictive risk score of perioperative
      in-hospital stroke after coronary artery bypass grafting (CABG) surgery.METHODA
      total of 26 347 patients were enrolled from 21 Spanish hospital databases.
      Logistic regression analysis was used to predict the risk of perioperative stroke
      (ictus or transient ischaemic attack). The predictive scale was developed from a 
      training set of data and validated by an independent test set, both selected
      randomly. The assessment of the accuracy of prediction was related to the area
      under the ROC curve. The variables considered were: preoperative (age, gender,
      diabetes mellitus, arterial hypertension, previous stroke, cardiac failure and/or
      left ventricular ejection fraction <40%, non-elective priority of surgery,
      extracardiac arteriopathy, chronic kidney failure and/or creatininemia >/=2 mg/dl
      and atrial fibrillation) and intraoperative (on/off-pump).RESULTSGlobal
      perioperative stroke incidence was 1.38%. Non-elective priority of surgery
      (priority; OR = 2.32), vascular disease (arteriopathy; OR = 1.37), cardiac
      failure (cardiac; OR = 3.64) and chronic kidney failure (kidney; OR = 6.78) were 
      found to be independent risk factors for perioperative stroke in uni- and
      multivariate models in the training set of data; P < 0.0001; AUC = 0.77, 95% CI
      0.73-0.82. The PACK2 stroke CABG score was established with 1 point for each
      item, except for chronic kidney failure with 2 points (range 0-5 points); AUC =
      0.76, 95% CI 0.72-0.80. In patients with PACK2 score >/=2 points, off-pump
      reduced perioperative stoke incidence by 2.3% when compared with on-pump
      CABG.CONCLUSIONSPACK2 risk scale shows good predictive accuracy in the data
      analysed and could be useful in clinical practice for decision making and patient
      selection.
AD  - Servicio de Cirugia Cardiaca, Instituto Cardiovascular, Hospital General
      Universitario, Valencia, Spain.
FAU - Hornero, Fernando
AU  - Hornero F
FAU - Martin, Elio
AU  - Martin E
FAU - Rodriguez, Rafael
AU  - Rodriguez R
FAU - Castella, Manel
AU  - Castella M
FAU - Porras, Carlos
AU  - Porras C
FAU - Romero, Bernat
AU  - Romero B
FAU - Maroto, Luis
AU  - Maroto L
FAU - Perez De La Sota, Enrique
AU  - Perez De La Sota E
CN  - on behalf of the Working Group on Arrhythmia Surgery and Cardiac Pacing of the
      Spanish Society for Cardiovascular and Thoracic Surgery (SECTCV)
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Interact Cardiovasc Thorac Surg
JT  - Interactive cardiovascular and thoracic surgery
JID - 101158399
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - ivt102 [pii]
AID - 10.1093/icvts/ivt102 [doi]
PST - aheadofprint
SO  - Interact Cardiovasc Thorac Surg. 2013 Apr 28.

PMID- 23628649
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1569-9285 (Electronic)
IS  - 1569-9285 (Linking)
DP  - 2013 Apr 28
TI  - A modified technique for implantation of the HeartWare left ventricular assist
      device when using bivalirudin anticoagulation in patients with acute
      heparin-induced thrombocytopenia.
AB  - In patients with acute heparin-induced thrombocytopenia (HIT) needing urgent
      cardiac surgery, bivalirudin is recommended as a first-line strategy for
      intraoperative anticoagulation. However, due to the unique elimination process of
      bivalirudin, careful adjustment of the perfusion and surgical strategy is
      mandatory as blood stasis in the circuit or prolonged interruption of areas or
      compartments containing blood from the systemic circulation may result in
      thrombus formation. We report here a modified surgical strategy for the
      implantation of the HeartWare left ventricular assist device, which avoids
      prolonged disconnection of the blood-filled device from the systemic blood flow, 
      so that bivalirudin can be safely used as anticoagulant.
AD  - Clinic for Heart, Thoracic and Cardiovascular Surgery, Heart and Diabetes Centre 
      NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.
FAU - Morshuis, Michiel
AU  - Morshuis M
FAU - Boergermann, Jochen
AU  - Boergermann J
FAU - Gummert, Jan
AU  - Gummert J
FAU - Koster, Andreas
AU  - Koster A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Interact Cardiovasc Thorac Surg
JT  - Interactive cardiovascular and thoracic surgery
JID - 101158399
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - ivt187 [pii]
AID - 10.1093/icvts/ivt187 [doi]
PST - aheadofprint
SO  - Interact Cardiovasc Thorac Surg. 2013 Apr 28.

PMID- 23628621
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 29
TI  - Quality of Care of People With Type 2 Diabetes in Eight European Countries:
      Findings from the Guideline Adherence to Enhance Care (GUIDANCE) study.
AB  - OBJECTIVESWe sought to determine levels of adherence in eight European countries 
      to recommendations for the management of type 2 diabetes and to investigate
      factors associated with key intermediate outcomes.RESEARCH DESIGN AND
      METHODSGUIDANCE was a cross-sectional study including retrospective data
      extraction from the medical records of people with type 2 diabetes recruited,
      using a shared protocol, from primary and specialist care sites in the following 
      eight European countries: Belgium, France, Germany, Italy, Ireland, Sweden, the
      Netherlands, and the United Kingdom. The dataset for analysis comprised 7,597
      cases. Proportions meeting process and outcome criteria were determined,
      including between-country variations. Logistic regression was used to investigate
      potential predictors of meeting targets for HbA1c, blood pressure, and LDL
      cholesterol.RESULTSIn the total sample, adherence to process recommendations was 
      high for some measures, for example, HbA1c recorded in past 12 months in 97.6% of
      cases. Target achievement for intermediate outcome measures was lower, with only 
      53.6% having HbA1c <7%. Considerable between-country variation was identified for
      both processes and outcomes. The following characteristics were associated with
      an increased likelihood of meeting targets for all three measures considered
      (HbA1c, blood pressure, LDL cholesterol): shorter diagnosis of diabetes; having
      one or more macrovascular complications; lower BMI; being prescribed
      lipid-lowering medication; and no current antihypertensive
      prescribing.CONCLUSIONSCompared with earlier reports, we have suggested some
      encouraging positive trends in Europe in relation to meeting targets for the
      management of people with type 2 diabetes, but there is still scope for further
      improvement and greater between-country consistency.
AD  - University of Leicester, Leicester, United Kingdom.
FAU - Stone, Margaret A
AU  - Stone MA
FAU - Charpentier, Guillaume
AU  - Charpentier G
FAU - Doggen, Kris
AU  - Doggen K
FAU - Kuss, Oliver
AU  - Kuss O
FAU - Lindblad, Ulf
AU  - Lindblad U
FAU - Kellner, Christiane
AU  - Kellner C
FAU - Nolan, John
AU  - Nolan J
FAU - Pazderska, Agnieszka
AU  - Pazderska A
FAU - Rutten, Guy
AU  - Rutten G
FAU - Trento, Marina
AU  - Trento M
FAU - Khunti, Kamlesh
AU  - Khunti K
CN  - On behalf of the GUIDANCE Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - dc12-1759 [pii]
AID - 10.2337/dc12-1759 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 29.

PMID- 23628620
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 29
TI  - Receiver Operating Characteristic Analysis of HLA, CTLA4, and Insulin Genotypes
      for Type 1 Diabetes.
AB  - OBJECTIVEThis study assessed the ability to distinguish between type 1
      diabetes-affected individuals and their unaffected relatives using HLA and single
      nucleotide polymorphism (SNP) genotypes.RESEARCH DESIGN AND METHODSEight models, 
      ranging from only the high-risk DR3/DR4 genotype to all significantly associated 
      HLA genotypes and two SNPs mapping to the cytotoxic T-cell-associated antigen-4
      gene (CTLA4) and insulin (INS) genes, were fitted to high-resolution class I and 
      class II HLA genotyping data for patients from the Type 1 Diabetes Genetics
      Consortium collection. Pairs of affected individuals and their unaffected
      siblings were divided into a "discovery" (n = 1,015 pairs) and a "validation" set
      (n = 318 pairs). The discriminating performance of various combinations of
      genetic information was estimated using receiver operating characteristic (ROC)
      curve analysis.RESULTSThe use of only the presence or absence of the high-risk
      DR3/DR4 genotype achieved very modest discriminating ability, yielding an area
      under the curve (AUC) of 0.62 in the discovery set and 0.59 in the validation
      set. The full model, which included HLA information from the class II loci DPB1, 
      DRB1, DQB1, selected alleles from HLA class I loci A and B, and SNPs from the
      CTLA4 and INS genes, increased the AUC to 0.74 in the discovery set and to 0.71
      in the validation set. A cost-effective alternative is proposed, using genotype
      information equivalent to typing four SNPs (DR3, DR4-DQB1*03:02, CTLA-4, and
      INS), which achieved an AUC of 0.72 in the discovery set and 0.69 in the
      validation set.CONCLUSIONSGenotyping data sufficient to tag DR3, DR4-DQB1*03:02, 
      CTLA4, and INS was shown to distinguish between subjects with type 1 diabetes and
      their unaffected siblings adequately to achieve clinically utility to identify
      children in multiplex families to be considered for early intervention.
AD  - Academic Rheumatology, University of Nottingham, Nottingham, U.K.
FAU - Valdes, Ana M
AU  - Valdes AM
FAU - Varney, Michael D
AU  - Varney MD
FAU - Erlich, Henry A
AU  - Erlich HA
FAU - Noble, Janelle A
AU  - Noble JA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - dc12-2284 [pii]
AID - 10.2337/dc12-2284 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 29.

PMID- 23628619
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 29
TI  - Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With
      Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose
      Levels.
AB  - OBJECTIVEFibroblast growth factor 19 (FGF19), a hormone secreted from the small
      intestine, has recently been shown to stimulate glycogen synthesis and inhibit
      gluconeogenesis through insulin-independent pathways. This study investigated the
      change of FGF19 in prediabetes and newly diagnosed type 2 diabetes mellitus
      (T2DM), and explored the association of serum FGF19 levels with parameters of
      glucose metabolism in Chinese subjects.RESEARCH DESIGN AND METHODSFasting serum
      FGF19 levels were determined by ELISA in 81 normal glucose tolerance (NGT), 91
      impaired fasting glucose (IFG), 93 impaired glucose tolerance (IGT), and 104
      newly diagnosed T2DM subjects, and their association with parameters of glucose
      metabolism was studied. An ordinal logistic regression analysis was performed in 
      subjects with NGT, IFG, and T2DM. Serum FGF19 levels at 2 h after a 75-g oral
      glucose tolerance test in the different glucose tolerance categories were studied
      in a subgroup.RESULTSFasting serum FGF19 levels in subjects with IFG (210 pg/mL
      [142-327]) (median [interquartile range]) and T2DM (196 pg/mL [137-280]) were
      significantly lower than those in NGT subjects (289 pg/mL [224-393]) (both P <
      0.001). However, no significant difference in fasting FGF19 levels was observed
      between IGT (246 pg/mL [138-379]) and NGT subjects. Fasting serum FGF19 levels
      were negatively associated with fasting plasma glucose and independently
      associated with the deterioration of glucometabolic status from NGT to IFG and
      T2DM.CONCLUSIONSFasting serum FGF19 levels were decreased in Chinese subjects
      with IFG and inversely associated with fasting glucose levels.
AD  - Department of Endocrinology and Metabolism, Shanghai Jiao Tong University
      Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Key
      Laboratory of Diabeties Mellitus, Shanghai Clinical Center of Diabetes, Shanghai,
      China.
FAU - Fang, Qichen
AU  - Fang Q
FAU - Li, Huating
AU  - Li H
FAU - Song, Qianqian
AU  - Song Q
FAU - Yang, Wenjing
AU  - Yang W
FAU - Hou, Xuhong
AU  - Hou X
FAU - Ma, Xiaojing
AU  - Ma X
FAU - Lu, Junxi
AU  - Lu J
FAU - Xu, Aimin
AU  - Xu A
FAU - Jia, Weiping
AU  - Jia W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - dc12-1766 [pii]
AID - 10.2337/dc12-1766 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 29.

PMID- 23628618
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 29
TI  - Glycemic Control Associated With Secure Patient-Provider Messaging Within a
      Shared Electronic Medical Record: A Longitudinal Analysis.
AB  - OBJECTIVETo study differences in glycemic control and HbA1c testing associated
      with use of secure electronic patient-provider messaging. We hypothesized that
      messaging use would be associated with better glycemic control and a higher rate 
      of adherence to HbA1c testing recommendations.RESEARCH DESIGN AND
      METHODSRetrospective observational study of secure messaging at Group Health, a
      large nonprofit health care system. Our analysis included adults with diabetes
      who had registered for access to a shared electronic medical record (SMR) between
      2003 and 2006. We fit log-linear regression models, using generalized estimating 
      equations, to estimate the adjusted rate ratio of meeting three indicators of
      glycemic control (HbA1c <7%, HbA1c <8%, and HbA1c >9%) and HbA1c testing
      adherence by level of previous messaging use. Multiple imputation and inverse
      probability weights were used to account for missing data.RESULTSDuring the study
      period, 6,301 adults with diabetes registered for access to the SMR. Of these
      individuals, 74% used messaging at least once during that time. Frequent use of
      messaging during the previous calendar quarter was associated with a higher rate 
      of good glycemic control (HbA1c <7%: rate ratio, 1.26; 95% CI, 1.15-1.37) and a
      higher rate testing adherence (1.20 [1.15-1.25]).CONCLUSIONSAmong SMR users,
      recent and frequent messaging use was associated with better glycemic control and
      a higher rate of HbA1c testing adherence. These results suggest that secure
      messaging may facilitate important processes of care and help some patients to
      achieve or maintain adequate glycemic control.
AD  - Department of Health Services, University of Washington School of Public Health, 
      Seattle, Washington.
FAU - Harris, Lynne T
AU  - Harris LT
FAU - Koepsell, Thomas D
AU  - Koepsell TD
FAU - Haneuse, Sebastien J
AU  - Haneuse SJ
FAU - Martin, Diane P
AU  - Martin DP
FAU - Ralston, James D
AU  - Ralston JD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - dc12-2003 [pii]
AID - 10.2337/dc12-2003 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 29.

PMID- 23628617
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 May 6
TI  - Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by
      Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison
      (GetGoal-L).
AB  - OBJECTIVETo examine the efficacy and safety of adding the once-daily
      glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide to established
      basal insulin therapy alone or together with metformin, in people with type 2
      diabetes and elevated glycated hemoglobin (HbA1c).RESEARCH DESIGN AND METHODSA
      double-blind, parallel-group, placebo-controlled trial. Patients (n = 495) with
      established basal insulin therapy but inadequate glycemic control were randomized
      to add lixisenatide 20 mug or placebo for 24 weeks. Basal insulin dosage was
      unchanged except to limit hypoglycemia. HbA1c reduction from baseline was the
      primary end point.RESULTSMean duration of diabetes was 12.5 years, duration of
      insulin use was 3.1 years, insulin dosage was 55 units/day, and baseline HbA1c
      was 8.4%. With lixisenatide, the placebo-corrected change of HbA1c from baseline 
      was -0.4% (95% CI -0.6 to -0.2; P = 0.0002), and mean HbA1c at end point was
      7.8%. HbA1c <7.0% (53 mmol/mol) was attained by more lixisenatide (28%) than
      placebo (12%; P < 0.0001) participants. Lixisenatide reduced plasma glucose
      levels after a standardized breakfast (placebo-corrected reduction, -3.8 mmol/L; 
      P < 0.0001); seven-point glucose profiles showed a reduction persisting through
      the day. Reductions in body weight (placebo corrected, -1.3 kg; P < 0.0001) and
      insulin dosage (-3.7 units/day; P = 0.012) were greater with lixisenatide. Main
      adverse events (AEs) with lixisenatide were gastrointestinal. Symptomatic
      hypoglycemia was 28% for lixisenatide and 22% for placebo; 4 of 328 subjects
      (1.2%) had severe hypoglycemia with lixisenatide vs. 0 of 167 with
      placebo.CONCLUSIONSBy improving HbA1c and postprandial hyperglycemia without
      weight gain in type 2 diabetes with inadequate glycemic control despite stable
      basal insulin, lixisenatide may provide an alternative to rapid-acting insulin or
      other treatment options.
AD  - Oregon Health and Science University, Portland, Oregon.
FAU - Riddle, Matthew C
AU  - Riddle MC
FAU - Aronson, Ronnie
AU  - Aronson R
FAU - Home, Philip
AU  - Home P
FAU - Marre, Michel
AU  - Marre M
FAU - Niemoeller, Elisabeth
AU  - Niemoeller E
FAU - Miossec, Patrick
AU  - Miossec P
FAU - Ping, Lin
AU  - Ping L
FAU - Ye, Jenny
AU  - Ye J
FAU - Rosenstock, Julio
AU  - Rosenstock J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130506
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/29 [aheadofprint]
AID - dc12-2454 [pii]
AID - 10.2337/dc12-2454 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 May 6.

PMID- 23628550
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May
TI  - High prevalence of undiagnosed diabetes and high risk for diabetes using HbA1c
      criteria in middle-aged patients undergoing cataract surgery.
PG  - 271-5
LID - 10.1016/j.diabet.2012.10.009 [doi]
LID - S1262-3636(12)00227-3 [pii]
AB  - AIM: This study assessed the prevalence of undiagnosed diabetes and a high risk
      for diabetes using glycated haemoglobin (HbA1c) values in middle-aged patients
      undergoing cataract surgery. METHODS: The study comprised 137 consecutive
      patients, aged 40 to 65 years, with no known diabetes undergoing cataract surgery
      at a French national eye centre. Fasting glucose, obesity parameters, and
      vascular and ocular cataract risk factors were recorded. HbA1c was measured on
      the day of cataract surgery. Prevalence of undiagnosed diabetes (HbA1c>/=6.5%)
      and a high risk of diabetes (>/=6.0% but<6.5%) in the study population was
      compared with recently published estimates from general French, Dutch and US
      populations. RESULTS: In the study population, undiagnosed diabetes was found in 
      12 patients (9%; 95% CI: 4-14%) and a high risk for diabetes in 47 (34%; 95% CI: 
      26-42%). These prevalences were four to 11 times higher than the corresponding
      population-based estimates, whereas obesity parameters recorded in the general
      populations and in our study population were similar according to HbA1c
      subcategories. Of the 125 patients with HbA1c less than 6.5%, values were higher 
      in patients without ocular cataract risk factors (n=73; 58%) than in those with
      cataract risk factors (n=52; 42%) at 5.92+/-0.30% and 5.57+/-0.29%, respectively 
      (P<0.001), thereby suggesting a significant role for blood glucose levels in
      cataractogenesis. CONCLUSION: Middle-aged patients undergoing cataract surgery
      showed a high prevalence of diabetes and a high risk for diabetes not recognized 
      before surgery, suggesting that this patient population should be targeted for
      diabetes screening and prevention.
CI  - Copyright (c) 2012 Elsevier Masson SAS. All rights reserved.
AD  - Service de medecine interne, CHNO des Quinze-Vingts, 28, rue de Charenton, 75571 
      Paris cedex 12, France. Electronic address: s.feldman@quinze-vingts.fr.
FAU - Feldman-Billard, S
AU  - Feldman-Billard S
FAU - Sedira, N
AU  - Sedira N
FAU - Boelle, P-Y
AU  - Boelle PY
FAU - Poisson, F
AU  - Poisson F
FAU - Heron, E
AU  - Heron E
LA  - eng
PT  - Journal Article
DEP - 20130428
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/10/28 [received]
PHST- 2012/10/29 [accepted]
PHST- 2013/04/28 [aheadofprint]
AID - S1262-3636(12)00227-3 [pii]
AID - 10.1016/j.diabet.2012.10.009 [doi]
PST - ppublish
SO  - Diabetes Metab. 2013 May;39(3):271-5. doi: 10.1016/j.diabet.2012.10.009. Epub
      2013 Apr 28.

PMID- 23628503
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1578-147X (Electronic)
IS  - 0009-739X (Linking)
DP  - 2013 Apr 27
TI  - Is the morbid obesity surgery profitable in times of crisis? A cost-benefit
      analysis of bariatric surgery.
LID - S0009-739X(13)00097-3 [pii]
LID - 10.1016/j.ciresp.2013.02.004 [doi]
AB  - Morbid obesity is a serious health problem whose prevalence is increasing.
      Expensive co-morbidities are associated to these patients, as well as a reduction
      in the survival. Bariatric surgery resolves the co-morbidities (type 2 diabetes
      mellitus, 86.6%; cardiovascular risk, 79.0%; obstructive sleep apnea syndrome,
      83.6%; hypertension, 61.7%), reduces the mortality rate (among 31-40%), and
      increases the morbid obese patients survival over a 10-years period. It provides 
      significant savings for the National Health System. The obese patients consume a 
      20% plus of health resources and 68% plus of drugs than general population.
      Bariatric surgery requires an initial investment (diagnosis-related group cost:
      7,468 euro), but it is recovered in a cost-effectiveness ratio of 2.5 years.
      Significant savings are obtained from the third year. To the direct economic
      benefits associated with reduced health expenditures it should be added an
      increase in tax collection (sick leave and unemployment reduction is estimated in
      18%, with a productivity increase of 57% for self-employed people). Bariatric
      surgery is one of the most cost-effective procedures in the healthcare system.
CI  - Copyright (c) 2012 AEC. Published by Elsevier Espana. All rights reserved.
AD  - Complejo Hospitalario de Pontevedra, Espana. Electronic address:
      raquelsanchezsantos@gmail.com.
FAU - Sanchez-Santos, Raquel
AU  - Sanchez-Santos R
FAU - Sabench Pereferrer, Fatima
AU  - Sabench Pereferrer F
FAU - Estevez Fernandez, Sergio
AU  - Estevez Fernandez S
FAU - Del Castillo Dejardin, Daniel
AU  - Del Castillo Dejardin D
FAU - Vilarrasa, Nuria
AU  - Vilarrasa N
FAU - Frutos Bernal, Dolores
AU  - Frutos Bernal D
FAU - Ruiz de Adana, Juan Carlos
AU  - Ruiz de Adana JC
FAU - Masdevall Noguera, Carlos
AU  - Masdevall Noguera C
FAU - Torres Garcia, Antonio
AU  - Torres Garcia A
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - inverted question markEs rentable operar a los obesos morbidos en tiempos de
      crisis? Analisis coste-beneficio de la cirugia bariatrica.
DEP - 20130427
TA  - Cir Esp
JT  - Cirugia espanola
JID - 1254104
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/12/03 [received]
PHST- 2013/02/03 [revised]
PHST- 2013/02/05 [accepted]
AID - S0009-739X(13)00097-3 [pii]
AID - 10.1016/j.ciresp.2013.02.004 [doi]
PST - aheadofprint
SO  - Cir Esp. 2013 Apr 27. pii: S0009-739X(13)00097-3. doi:
      10.1016/j.ciresp.2013.02.004.

PMID- 23628425
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 6
IP  - 1
DP  - 2013 Apr 29
TI  - Clinical course and visual outcome in patients with diabetes mellitus and
      uveitis.
PG  - 167
AB  - Purpose: We report the clinical course and visual outcome of patients with
      diabetes mellitus (DM) who subsequently developed uveitis from any cause.
      METHODS: Longitudinal, retrospective case note review. RESULTS: A total of 36
      patients (M/F: 18/18, 58 eyes) were included, Of the 36 patients, 35 had Type 2
      DM and one had Type 1 DM. Mean age of onset of DM was 49 years and uveitis 55
      years. The uveitis was bilateral in 22 (61%) patients. There were 19 patients
      with anterior uveitis, 12 with panuveitis and 5 with intermediate uveitis. Mean
      follow up was 4.4 years (range 1-18). Mean number of uveitis recurrences was 3
      (range 1-7). Causes of vision of 6/18 or worse appeared related to the uveitis in
      9 eyes and diabetes in 4 eyes. Cataract occurred in 22 eyes, glaucoma in 17 eyes,
      and cystoid macular oedema in 10 eyes. Diabetic retinopathy was detected in 38
      (65.5%) eyes (29 non-proliferative including 6 with clinically significant
      macular oedema, and 9 proliferative). Progression of diabetic retinopathy to
      proliferative stage occurred in 7 eyes of 4 patients over a mean duration of 4.4 
      years. In 10 patients with active uveitis the mean HbA1c was 80 mmol/mol [9.5%], 
      (range 49-137 [6.6-14.7]), and 67 mmol/mol [8.3%] (range 46-105 [6.4-11.8]) when 
      the uveitis was quiescent, p = 0.01. Better glycaemic control was required in 10 
      patients during episodes of uveitis. CONCLUSIONS: Patients with DM who develop
      uveitis may have a high complication rate, reduced vision and poor glycaemic
      control. Checking blood glucose during episodes of uveitis is important.
FAU - Oswal, Kadambari S
AU  - Oswal KS
FAU - Sivaraj, Ramesh R
AU  - Sivaraj RR
FAU - Murray, Philip I
AU  - Murray PI
FAU - Stavrou, Panagiota
AU  - Stavrou P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
PMC - PMC3651352
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/03/31 [received]
PHST- 2013/04/29 [accepted]
PHST- 2013/04/29 [aheadofprint]
AID - 1756-0500-6-167 [pii]
AID - 10.1186/1756-0500-6-167 [doi]
PST - aheadofprint
SO  - BMC Res Notes. 2013 Apr 29;6(1):167.

PMID- 23628421
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - 2013 update on the worldwide standardization of the hemoglobin A1c measurement.
PG  - e64-5
LID - 10.1016/j.diabres.2013.03.035 [doi]
LID - S0168-8227(13)00134-4 [pii]
AD  - Department of Pediatrics, NU Hospital Group, Uddevalla, Sweden; The Sahlgrenska
      Academy, University of Gothenburg, Gothenburg, Sweden. Electronic address:
      ragnar.hanas@vgregion.se.
FAU - Hanas, Ragnar
AU  - Hanas R
FAU - John, W Garry
AU  - John WG
LA  - eng
PT  - Letter
DEP - 20130428
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/28 [aheadofprint]
AID - S0168-8227(13)00134-4 [pii]
AID - 10.1016/j.diabres.2013.03.035 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):e64-5. doi:
      10.1016/j.diabres.2013.03.035. Epub 2013 Apr 28.

PMID- 23628400
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
DP  - 2013 Apr 27
TI  - Meta-analysis reveals an association of STAT4 polymorphisms with systemic
      autoimmune disorders and anti-dsDNA antibody.
LID - S0198-8859(13)00120-1 [pii]
LID - 10.1016/j.humimm.2013.04.034 [doi]
AB  - Signal transducer and activator of transcription 4 (STAT4) has been recently
      identified as a susceptibility gene for multiple autoimmune diseases. Here we
      performed a comprehensive analysis of the association between STAT4 and several
      different autoimmune disorders to identify potential common inflammatory
      principles behind this association. Our meta-analysis revealed that the STAT4
      rs7574865 polymorphism is associated with four autoimmune diseases with systemic 
      pathology, including systemic lupus erythematosus (OR=1.52; 95% CI=1.48-1.56,
      P<1.0x10-16), rheumatoid arthritis (OR=1.27; 95% CI=1.21-1.33, P<1.00x10-16),
      systemic sclerosis (OR=1.38; 95% CI=1.27-1.50, P<1.44x10-14), and primary
      Sjogren's syndrome (OR=1.32; 95% CI=1.01-1.73, P=4.40x10-2), while no association
      was found with type I diabetes, juvenile idiopathic arthritis, ulcerative colitis
      and Crohn's disease. Furthermore, the stratified meta-analysis also demonstrate
      that the STAT4 rs7574865 polymorphism is associated with the presence of
      autoantibodies with systemic reactivity (anti-ds-DNA antibodies) in SLE patients 
      (OR=1.37; 95% CI=1.21-1.56, P=1.12x10-6). However, no such specific association
      was seen in RA with regard to the presence of non-systemically reacting
      antibodies, including rheumatoid factor and anti-cyclic citrullinated peptide
      antibodies. Taken together, these results suggest that STAT4 polymorphisms are
      associated with autoimmune diseases which are characterized by a systemic
      pathology and anti-dsDNA antibody.
CI  - Copyright (c) 2013 American Society for Histocompatibility and Immunogenetics.
      Published by Elsevier Inc. All rights reserved.
AD  - Laboratory of Autoimmunity, The Medical College of Xiamen University, Xiamen
      University, 361005 Xiamen, China.
FAU - Zheng, Junfeng
AU  - Zheng J
FAU - Yin, Junping
AU  - Yin J
FAU - Huang, Renliang
AU  - Huang R
FAU - Petersen, Frank
AU  - Petersen F
FAU - Yu, Xinhua
AU  - Yu X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/01/17 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/04/12 [accepted]
AID - S0198-8859(13)00120-1 [pii]
AID - 10.1016/j.humimm.2013.04.034 [doi]
PST - aheadofprint
SO  - Hum Immunol. 2013 Apr 27. pii: S0198-8859(13)00120-1. doi:
      10.1016/j.humimm.2013.04.034.

PMID- 23628393
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
DP  - 2013 Apr 27
TI  - Characterization and specification of microsatellite markers in the HLA-DRB1 gene
      region: A revision to major histocompatibility complex database.
LID - S0198-8859(13)00118-3 [pii]
LID - 10.1016/j.humimm.2013.04.032 [doi]
AB  - Association between HLA-DRB1 and a large number of diseases such as multiple
      sclerosis, type I diabetes and rheumatoid arthritis has been demonstrated. In the
      present study, we attempted to identify and characterize potential
      microsatellites in the HLA-DRB1 gene region to find specific markers for
      genotyping and linkage analysis of this gene. The microsatellites including
      M2_3_22, M2_2_36, D6S2878, D6S2805, D6S2879 and D6S2880 were selected from
      microsatellite resource in the Major Histocompatibility Complex database (dbMHC).
      In silico analysis showed that only M2_3_22 was specific for HLA-DRB1. Moreover, 
      our findings revealed some more accurate characteristics of the other
      investigated microsatellites. M2_3_22 existed as a single copy in all the MHC
      haplotype sequences and was located next to HLA-DRB1. Therefore, a new set of
      primers compatible with all the last published MHC haplotype sequences were
      designed and used to amplify M2_3_22 in 164 DNA samples obtained from unrelated
      Iranian individuals. M2_3_22 was successfully amplified in all DNA samples and
      three different alleles were identified. This locus was found in the
      Hardy-Weinberg equilibrium (P>0.05) in the studied population. Together, the
      findings suggested that M2_3_22 could be introduced as a specific locus in the
      HLA-DRB1 gene region for linkage analysis and disease association studies.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Division of Genetics, Department of Biology, Faculty of Science, University of
      Isfahan, Isfahan, Iran. Electronic address: persicarose@yahoo.com.
FAU - Shaykholeslam Esfahani, Maryam
AU  - Shaykholeslam Esfahani M
FAU - Vallian, Sadeq
AU  - Vallian S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/06 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/04/10 [accepted]
AID - S0198-8859(13)00118-3 [pii]
AID - 10.1016/j.humimm.2013.04.032 [doi]
PST - aheadofprint
SO  - Hum Immunol. 2013 Apr 27. pii: S0198-8859(13)00118-3. doi:
      10.1016/j.humimm.2013.04.032.

PMID- 23628332
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 23
IP  - 11
DP  - 2013 Jun 1
TI  - Anti-adipogenic activity of compounds isolated from Idesia polycarpa on 3T3-L1
      cells.
PG  - 3170-4
LID - 10.1016/j.bmcl.2013.04.011 [doi]
LID - S0960-894X(13)00480-0 [pii]
AB  - Recently, obesity is a complex multifactorial chronic disease increasing the risk
      for type 2 diabetes, coronary heart disease and hypertension, and has become a
      major worldwide health problem. In the course of screening natural products
      employing 3T3-L1 cells as an in vitro system, the methanol extract of Idesia
      polycarpa Maxim. Fruits (Flacourtiaceae) significantly inhibited adipocyte
      differentiation by measuring lipid contents using oil red O staining. One new
      compound,
      6-(oxymethyl)-2-hydroxyphenyl-O-beta-d-glucopyranosyl-(1-->6)-beta-d-glucopyranos
      ide (8), was isolated along with nine known compounds (1-7 and 9-10) from CHCl3
      and n-BuOH fractions of the methanol extract of I. polycarpa fruits. Among them, 
      idescarpin (1) with 1-hydroxy-6-oxo-2-cyclohexenecarboxylate moiety showed the
      most potent inhibitory activity on adipocyte differentiation with IC50 values of 
      23.2muM. Idescarpin (1) dramatically suppressed the induction of C/EBPalpha
      expression, whereas it significantly increased the induction of PPARgamma
      expression, supported by quantitative real time PCR and Western blot analysis.
      The down-regulation in mRNA levels of SREBP1c, SCD-1, and FAS by idescarpin (1)
      during adipocyte differentiation revealed that the inhibition of adipocyte
      differentiation was mediated by the regulation of lipogenesis. Taken together, we
      suggest that idescarpin (1) shows a great potential against obesity and diabetes 
      though the anti-adipogenic activity and the up-regulation of PPARgamma.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - College of Pharmacy and Research Institute of Pharmaceutical Science, Seoul
      National University, Daehak-Dong, San 56-1, Sillim-Dong, Gwanak-Gu, Seoul
      151-742, Republic of Korea.
FAU - Lee, Mina
AU  - Lee M
FAU - Lee, Hyang Hwa
AU  - Lee HH
FAU - Lee, Jin-Ku
AU  - Lee JK
FAU - Ye, Sang-Kyu
AU  - Ye SK
FAU - Kim, Seung Hyun
AU  - Kim SH
FAU - Sung, Sang Hyun
AU  - Sung SH
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/09 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0960-894X(13)00480-0 [pii]
AID - 10.1016/j.bmcl.2013.04.011 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2013 Jun 1;23(11):3170-4. doi: 10.1016/j.bmcl.2013.04.011. 
      Epub 2013 Apr 10.

PMID- 23628306
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Apr 26
TI  - Comparative Analysis of Cardiovascular Disease Risk Factors Influencing Nonfatal 
      Acute Coronary Syndrome and Ischemic Stroke.
LID - S0002-9149(13)00900-4 [pii]
LID - 10.1016/j.amjcard.2013.03.039 [doi]
AB  - The aim of the present work was to compare the influence of classic
      cardiovascular disease (CVD) risk factors on the development of acute coronary
      syndrome (ACS) and ischemic stroke. During 2009-2010, 1,000 participants were
      enrolled: 250 were consecutive patients with a first ACS, 250 were consecutive
      patients with a first ischemic stroke, and 500 were population-based, control
      subjects, 1-for-1 matched to the patients by age and gender. The following CVD
      risk factors were evaluated: smoking/passive smoking, family history of CVD,
      physical inactivity, hypertension, hypercholesterolemia, diabetes mellitus,
      presence of overweight and obesity, trait anxiety (assessed with the Spielberger 
      State-Trait Anxiety Inventory form Y-2), and adherence to the Mediterranean diet 
      (assessed by the MedDietScore). Furthermore, participants graded the perceived
      significance of the aforementioned factors, using a scale from 1 (not important) 
      to 9 (very important). The risk factors with the highest effect size for ACS, as 
      determined by the Wald criterion, were smoking and hypercholesterolemia;
      regarding stroke, they were anxiety and family history of CVD (all p <0.01). When
      the odds ratios of each factor for ACS and stroke were compared, insignificant
      differences were observed, except for smoking. On the basis of the participants' 
      health beliefs, smoking and stress emerged as the most important risk factors,
      whereas all subjects graded passive smoking as a least important factor. In
      conclusion, similarities of the risk factors regarding ACS and ischemic stroke
      facilitate simultaneous primary prevention measures.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - School of Medicine, University of Ioannina, Ioannina, Greece; Department of
      Nutrition and Dietetics, Harokopio University, Athens, Greece.
FAU - Kastorini, Christina-Maria
AU  - Kastorini CM
FAU - Georgousopoulou, Ekavi
AU  - Georgousopoulou E
FAU - Vemmos, Konstantinos N
AU  - Vemmos KN
FAU - Nikolaou, Vassilios
AU  - Nikolaou V
FAU - Kantas, Dimitrios
AU  - Kantas D
FAU - Milionis, Haralampos J
AU  - Milionis HJ
FAU - Goudevenos, John A
AU  - Goudevenos JA
FAU - Panagiotakos, Demosthenes B
AU  - Panagiotakos DB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/01/26 [received]
PHST- 2013/03/16 [revised]
PHST- 2013/03/16 [accepted]
AID - S0002-9149(13)00900-4 [pii]
AID - 10.1016/j.amjcard.2013.03.039 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Apr 26. pii: S0002-9149(13)00900-4. doi:
      10.1016/j.amjcard.2013.03.039.

PMID- 23628280
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
DP  - 2013 Apr 26
TI  - Diabetes and bone health.
LID - S0378-5122(13)00109-6 [pii]
LID - 10.1016/j.maturitas.2013.04.004 [doi]
AB  - The increasing prevalence of diabetes especially type 2 diabetes worldwide is
      indisputable. Diabetics suffer increased morbidity and mortality, compared to
      their non-diabetic counterparts, not only because of vascular complications, but 
      also because of an increased fracture incidence. Both types 1 and 2 diabetes and 
      some medications used to treat it are associated with osteoporotic fractures. The
      responsible mechanisms remain incompletely elucidated. In this review, we
      evaluate the role of glycemic control in bone health, and the effect of
      anti-diabetic medications such as thiazolidinediones, sulfonylureas, DPP-4
      inhibitors, and GLP-1 agonists. In addition, we examine the possible role of
      insulin and metformin as anabolic agents for bone. Lastly, we identify the
      current and future screening tools that help evaluate bone health in diabetics
      and their limitations. In this way we can offer individualized treatment, to the 
      at-risk diabetic population.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - SUNY Downstate Medical Center, United States.
FAU - Antonopoulou, Marianna
AU  - Antonopoulou M
FAU - Bahtiyar, Gul
AU  - Bahtiyar G
FAU - Banerji, Mary Ann
AU  - Banerji MA
FAU - Sacerdote, Alan S
AU  - Sacerdote AS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Maturitas
JT  - Maturitas
JID - 7807333
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/03 [received]
PHST- 2013/04/08 [accepted]
AID - S0378-5122(13)00109-6 [pii]
AID - 10.1016/j.maturitas.2013.04.004 [doi]
PST - aheadofprint
SO  - Maturitas. 2013 Apr 26. pii: S0378-5122(13)00109-6. doi:
      10.1016/j.maturitas.2013.04.004.

PMID- 23628170
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 0210-5705 (Electronic)
IS  - 0210-5705 (Linking)
DP  - 2013 Apr 26
TI  - [Diabetes in liver cirrhosis.]
LID - S0210-5705(13)00077-0 [pii]
LID - 10.1016/j.gastrohep.2013.01.012 [doi]
AB  - The prevalence of overt diabetes mellitus (DM) in liver cirrhosis is about 30%.
      However, DM or impaired glucose tolerance can be observed in 90% after an oral
      glucose tolerance test in patients with normal fasting plasma glucose. Type 2 DM 
      may produce cirrhosis, whereas DM may be a complication of cirrhosis. The latter 
      is known as <<hepatogenous diabetes>>. Overt and subclinical DM is associated
      with liver complications and death in cirrhotic patients. Treating diabetes is
      difficult in cirrhotic patients because of the metabolic impairments due to liver
      disease and because the most appropriate pharmacologic treatment has not been
      defined. It is also unknown if glycemic control with hypoglycemic agents has any 
      impact on the course of the liver disease.
CI  - Copyright (c) 2013 Elsevier Espana, S.L. y AEEH y AEG. All rights reserved.
AD  - Servicio de Gastroenterologia y Departamento de Medicina Interna, Hospital
      Universitario Dr. Jose E. Gonzalez, Facultad de Medicina, Universidad Autonoma de
      Nuevo Leon, Monterrey, Mexico. Electronic address:
      digarciacompean@prodigy.net.mx.
FAU - Garcia-Compean, Diego
AU  - Garcia-Compean D
FAU - Jaquez-Quintana, Joel O
AU  - Jaquez-Quintana JO
FAU - Gonzalez-Gonzalez, Jose A
AU  - Gonzalez-Gonzalez JA
FAU - Lavalle-Gonzalez, Fernando J
AU  - Lavalle-Gonzalez FJ
FAU - Villarreal-Perez, Jesus Z
AU  - Villarreal-Perez JZ
FAU - Maldonado-Garza, Hector J
AU  - Maldonado-Garza HJ
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - La diabetes en la cirrosis hepatica.
DEP - 20130426
TA  - Gastroenterol Hepatol
JT  - Gastroenterologia y hepatologia
JID - 8406671
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/01/25 [received]
PHST- 2013/01/31 [accepted]
AID - S0210-5705(13)00077-0 [pii]
AID - 10.1016/j.gastrohep.2013.01.012 [doi]
PST - aheadofprint
SO  - Gastroenterol Hepatol. 2013 Apr 26. pii: S0210-5705(13)00077-0. doi:
      10.1016/j.gastrohep.2013.01.012.

PMID- 23627982
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
DP  - 2013 Apr 25
TI  - Characteristics Other Than the Diagnostic Criteria Associated with Metabolic
      Syndrome: an Overview.
AB  - Metabolic syndrome (MetS), a cluster of dyslipidaemia, central obesity,
      hypertension and/or insulin resistance, is associated with increased
      cardiovascular disease (CVD) type 2 diabetes risk. Different diagnostic criteria 
      for MetS have been proposed but in 2009 a joint statement by several scientific
      societies was released. Apart from the diagnostic criteria, MetS has also been
      associated with other risk factors including waist to hip ratio, high density
      lipoprotein dysfunction, small dense low density lipoprotein, postprandial
      hypertriglyceridaemia, lipoprotein (a), uric acid, liver function tests,
      prothrombotic factors, cytokines, adipokines, vitamin D, arterial stiffness,
      renal dysfunction, nephrolithiasis, polycystic ovary syndrome, obstructive sleep 
      apnea. We discuss the extensive list of MetS-associated factors that may
      influence vascular risk. Furthermore, we discuss the impact of frequently
      prescribed drugs (e.g. hypolipidaemic agents) on these variables. These effects
      may need to be taken into consideration when treating MetS patients.
AD  - Second Propedeutic Department of Internal Medicine, Medical School, Aristotle
      University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece. 44,
      Tsimiski street, Thessaloniki, 54623, Greece. athyros@med.auth.gr.
FAU - Katsiki, Niki
AU  - Katsiki N
FAU - Athyros, Vasilios G
AU  - Athyros VG
FAU - Karagiannis, Asterios
AU  - Karagiannis A
FAU - Mikhailidis, Dimitri P
AU  - Mikhailidis DP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/10/18 [received]
PHST- 2012/11/16 [revised]
PHST- 2012/11/16 [accepted]
AID - CVP-EPUB-20130425-9 [pii]
PST - aheadofprint
SO  - Curr Vasc Pharmacol. 2013 Apr 25.

PMID- 23627981
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
DP  - 2013 Apr 25
TI  - Insulin Resistance in Brain and Possible Therapeutic Approaches.
AB  - Although the brain has long been considered an insulin-independent organ, recent 
      research has shown that insulin has significant effects on the brain, where it
      plays a role in maintaining glucose and energy homeostasis. To avoid peripheral
      insulin resistance, the brain may act via hypoinsulinemic responses, maintaining 
      glucose metabolism and insulin sensitivity within its own confines; however,
      brain insulin resistance may develop due to environmental factors. Insulin has
      two important functions in the brain: controlling food intake and regulating
      cognitive functions, particularly memory. Notably, defects in insulin signaling
      in the brain may contribute to neurodegenerative disorders. Insulin resistance
      may damage the cognitive system and lead to dementia states. Furthermore,
      inflammatory processes in the hypothalamus, where insulin receptors are expressed
      at high density, impair local signaling systems and cause glucose and energy
      metabolism disorders. Excessive caloric intake and high-fat diets initiate
      insulin and leptin resistance by inducing mitochondrial dysfunction and
      endoplasmic reticulum stress in the hypothalamus. This may lead to obesity and
      diabetes mellitus (DM). Exercise can enhance brain and hypothalamic insulin
      sensitivity, but it is the option least preferred and/or continuously practiced
      by the general population. Pharmacological treatments that increase brain and
      hypothalamic insulin sensitivity may provide new insights into the prevention of 
      dementia disorders, obesity, and type 2 DM in the future.
AD  - Department of Endocrinology and Metabolic Diseases Ege University Medical School 
      35100 Bornova-IZMIR- TURKEY. scetinkalp@hotmail.com.
FAU - Cetinkalp, Sevki
AU  - Cetinkalp S
FAU - Simsir, Ilgin Yildirim
AU  - Simsir IY
FAU - Ertek, Sibel
AU  - Ertek S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/14 [received]
PHST- 2012/12/10 [revised]
PHST- 2012/12/12 [accepted]
AID - CVP-EPUB-20130425-8 [pii]
PST - aheadofprint
SO  - Curr Vasc Pharmacol. 2013 Apr 25.

PMID- 23627978
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
DP  - 2013 Apr 25
TI  - Prediabetes, Prehypertension- Do We Need Pre-ckd?
AB  - Screening is the systematic use of a test for a health problem or risk factor
      when no recognized signs or symptoms would indicate the presence of that problem 
      or risk factor. Abnormal glucose metabolism can be documented years before the
      onset of overt diabetes. Nowadays, prediabetes can be subdivided into impaired
      fasting glucose or impaired glucose tolerance. Substantial number of subjects
      with either will progress to overt diabetes within years. Prediabetes bears also 
      the increased risk of cardiovascular complications. Prehypertension is much newer
      term introduced by the seventh report of the Joint National Committee (JNC 7)
      published in 2003 as systolic blood pressure from 120 to 139 mmHg or diastolic
      blood pressure from 80 to 89 mmHg in adults (not receiving blood
      pressure-lowering treatment). Similarly prehypertension also increased the risk
      of cardiovascular complications and progression to hypertension. Chronic kidney
      disease is also highly prevalent mainly in the elderly. It is associated with
      important adverse outcomes such as cardiovascular mortality and morbidity.
      Factors associated with higher risk of chronic kidney disease include mainly
      hypertension, diabetes, obesity and older age. Early detection and diagnosis of
      chronic kidney disease may prevent the full blown disease and its end-stage
      requiring renal replacement therapy. The review focus on the problem of high risk
      population for development of diabetes, hypertension and whether time has come to
      focus also on the conditions predisposing to the development of chronic kidney
      disease.
AD  - Jolanta Malyszko, FASN Department of Nephrology and Transplantology, Medical
      University, 15-540 Bialystok, Zurawia 14, Poland. jolmal@poczta.onet.pl.
FAU - Malyszko, Jolanta
AU  - Malyszko J
FAU - Banach, Maciej
AU  - Banach M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/10/27 [received]
PHST- 2012/11/03 [revised]
PHST- 2012/11/07 [revised]
AID - CVP-EPUB-20130425-5 [pii]
PST - aheadofprint
SO  - Curr Vasc Pharmacol. 2013 Apr 25.

PMID- 23627976
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
DP  - 2013 Apr 25
TI  - Is There U Turn From Insulin Back to Pills in Diabetes?
AB  - Type 2 diabetes is characterized by insulin resistance together with progressive 
      loss of beta-cell function. After recognition of gluco- and lipo-toxicity,
      attention was focused on the preservation and/or restoration of beta cell
      function, especially at the early stages of the diabetes, with better beta-cell
      reserve and in the absence of complications. Early treatment of glucotoxicity
      with insulin was searched by early insulin treatment studies, and these studies
      have some promising results, pointing the possibility of ''remission'' of
      diabetes in some patients. According to the results of these studies, patients
      with early diagnosis of diabetes, the ones with better beta cell reserve,
      patients with low tendency for ''insulin-abuse'' could make ''U' -turn from
      insulin to pills or even drug-free life. Criteria to turn back to pills could be 
      listed as disappearance of diabetic symptoms, daily insulin need < 0.25 unit/kg, 
      euglycemia in both fasting and postprandial state, and better beta cell function.
      The main problems in early insulin treatment are the ''insulin resistance'' of
      both patients and doctors, hypoglycemia, weight gain and increased appetite.
      Meanwhile, hyperinsulinemia desensitizes receptors and causes worsening of
      situation in a vicious cycle of insulin resistance and hyperglycemia. Therefore, 
      patients should be selected properly and U-turn could be performed in relevant
      conditions explained in the text. It could be possible to see early insulin
      treatment and U-turn strategies in future guidelines for type 2 diabetes.
AD  - Turkish Ministry of Health, Sanliurfa Education and Research Hospital, Department
      of Endocrinology and Metabolic Diseases, 63100 Esentepe, Sanliurfa- Turkey.
      sibelertek@yahoo.it.
FAU - Ertek, S
AU  - Ertek S
FAU - Cetinkalp, S
AU  - Cetinkalp S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/09 [received]
PHST- 2012/11/27 [revised]
PHST- 2012/12/29 [accepted]
AID - CVP-EPUB-20130425-3 [pii]
PST - aheadofprint
SO  - Curr Vasc Pharmacol. 2013 Apr 25.

PMID- 23627975
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
DP  - 2013 Apr 25
TI  - Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease.
AB  - There is a global epidemic of obesity, metabolic syndrome, and diabetes mellitus.
      Insulin resistance (IR) is etiologic for both metabolic syndrome and diabetes
      mellitus. IR induces a broad range of toxic systemic effects, including
      dyslipidemia, hypertension, hyperglycemia, increased production of advanced
      glycosylation end products, increased inflammatory tone, as well as a
      prothrombotic and pro-oxidative state. Patients with IR are highly vulnerable to 
      the development of accelerated atherosclerosis as well its clinical sequelae,
      including coronary artery disease and myocardial infarction, carotid artery
      disease and ischemic stroke, peripheral arterial disease and claudication/lower
      extremity amputation, and coronary mortality. Among the most important risk
      factors patients afflicted with IR develop is the so-called atherogenic lipid
      triad: large numbers of small, dense low-density lipoprotein (sdLDL) particles,
      hypertriglyceridemia, and low serum concentrations of high-density lipoprotein
      cholesterol. Though controversial, much recent evidence suggests that the
      formation of sdLDL particles in the setting of IR is an important metabolic
      transition. Some studies suggest that these smaller particles are more
      atherogenic than their larger, more buoyant counterparts. At least part of the
      explanation for the apparent augmented atherogenicity of small LDL particles is
      their reduced systemic clearance by the LDL receptor, increased vulnerability to 
      oxidation rendering them more apt for scavenging by macrophages, and possible
      increased flux into the subendothelial space of arterial walls. Numerous small
      studies suggest that sdLDL is highly correlated with cardiovascular events.
      Cardiovascular medicine is in need of a large prospective, randomized study that 
      would more definitively investigate the impact of small, dense LDL (sdLDL) on
      risk for cardiovascular disease and whether therapeutic interventions designed to
      specifically reduce the burden of sdLDL are associated with reductions in
      cardiovascular events over and above that seen with LDL-C reduction per se.
AD  - CGH Medical Center 101, East Miller Road Sterling, Illinois University of
      Illinois, School of Medicine Peoria, Illinois Michigan State University College
      of Osteopathic Medicine East Lansing, Michigan USA. peter.toth@cghmc.com.
FAU - Toth, Peter P
AU  - Toth PP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/11/19 [received]
PHST- 2012/11/24 [revised]
PHST- 2012/12/02 [accepted]
AID - CVP-EPUB-20130425-2 [pii]
PST - aheadofprint
SO  - Curr Vasc Pharmacol. 2013 Apr 25.

PMID- 23627940
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 20
IP  - 21
DP  - 2013 Jul 1
TI  - Pharmacological Inhibition of Protein Tyrosine Phosphatase 1B: A Promising
      Strategy for the Treatment of Obesity and Type 2 Diabetes Mellitus.
PG  - 2609-25
AB  - Obesity and metabolic syndrome represent major public health problems, and are
      the biggest preventable causes of death worldwide. Obesity is the leading risk
      factor for type 2 diabetes mellitus (T2DM), cardiovascular diseases and
      non-alcoholic fatty liver disease. Obesity-associated insulin resistance, which
      is characterized by reduced uptake and utilization of glucose in muscle, adipose 
      and liver tissues, is a key predictor of metabolic syndrome and T2DM. With
      increasing prevalence of obesity in adults and children, the need to identify and
      characterize potential targets for treating metabolic syndrome is imminent.
      Emerging evidence from animal models, clinical studies and cell lines studies
      suggest that protein tyrosine phosphatase 1B (PTP1B), an enzyme that negatively
      regulates insulin signaling, is likely to be involved in the pathways leading to 
      insulin resistance. PTP1B is tethered to the cytosolic surface of endoplasmic
      reticulum (ER), an organelle that is responsible for folding, modification, and
      trafficking of proteins. Recent evidence links the disruption of ER homeostasis, 
      referred to as ER stress, to the pathogenesis of obesity and T2DM. PTP1B has been
      recognized as an important player linking ER stress and insulin resistance in
      obese subjects. This review highlights recent advances in the research related to
      the role of PTP1B in signal transduction processes implicated in pathophysiology 
      of obesity and type 2 diabetes, and focuses on the potential therapeutic
      exploitation of PTP1B inhibitors for the management of these conditions.
AD  - Center for Cardiovascular Research and Alternative Medicine, University of
      Wyoming College of Health Sciences, Laramie, WY 82071, USA. sreejay@uwyo.edu.
FAU - Panzhinskiy, E
AU  - Panzhinskiy E
FAU - Ren, J
AU  - Ren J
FAU - Nair, S
AU  - Nair S
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/12/31 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/04/08 [accepted]
AID - CMC-EPUB-20130418-7 [pii]
PST - ppublish
SO  - Curr Med Chem. 2013 Jul 1;20(21):2609-25.

PMID- 23627924
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1365-277X (Electronic)
IS  - 0952-3871 (Linking)
DP  - 2013 Apr 30
TI  - A high-fibre bean-rich diet versus a low-carbohydrate diet for obesity.
LID - 10.1111/jhn.12118 [doi]
AB  - BACKGROUND: High-fibre and low-carbohydrate diets may enhance satiety and promote
      weight loss. We compared a diet rich in beans aiming to increase dietary fibre
      and promote weight loss with a low-carbohydrate diet in a randomised controlled
      trial to assess effect and tolerability of the high-fibre bean-rich diet. METHODS
      AND RESULTS: One hundred and seventy-three women and men, with a mean body mass
      index of approximately 36 kg m-2 (one-fifth with diabetes type 2) were randomised
      to a high-fibre bean-rich diet that achieved mean (SD) fibre intakes of 35.5
      (18.6) g day-1 for women and 42.5 (30.3) g day-1 for men, or a low-carbohydrate
      diet. Both diets were induced gradually over 4 weeks and included a 3-day feeding
      phase. Among 123 (71.1%) completers at 16 weeks, mean (SD) weight loss was 4.1
      (4.0) kg in the high-fibre versus 5.2 (4.5) kg in the low-carbohydrate group
      [difference, 1.1 kg, 95% confidence interval (CI) = -2.6 to -0.5; P = 0.2], with 
      results similar to the intent-to-treat population. Low-density lipoprotein
      (LDL)-cholesterol levels decreased with the high-fibre diet (difference in
      LDL-cholesterol versus low-carbohydrate diet, 0.2 mmol L-1 , 95% CI = 0.01-0.44
      mmol L-1 ; P = 0.045), as did total cholesterol (P = 0.038), whereas changes in
      other lipids and glucose did not differ. After 52 weeks, the low-carbohydrate (n 
      = 24) group tended to retain weight loss better than the high-fibre group (P =
      0.06), although total cholesterol remained lower with the bean-rich diet (P =
      0.049). CONCLUSIONS: A high-fibre bean-rich diet was as effective as a
      low-carbohydrate diet for weight loss, although only the bean-rich diet lowered
      atherogenic lipids.
CI  - (c) 2013 The Authors Journal of Human Nutrition and Dietetics (c) 2013 The
      British Dietetic Association Ltd.
AD  - School of Public Health, Loma Linda University, Loma Linda, CA, USA.
FAU - Tonstad, S
AU  - Tonstad S
FAU - Malik, N
AU  - Malik N
FAU - Haddad, E
AU  - Haddad E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Hum Nutr Diet
JT  - Journal of human nutrition and dietetics : the official journal of the British
      Dietetic Association
JID - 8904840
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - 10.1111/jhn.12118 [doi]
PST - aheadofprint
SO  - J Hum Nutr Diet. 2013 Apr 30. doi: 10.1111/jhn.12118.

PMID- 23627914
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1744-7674 (Electronic)
IS  - 1354-3776 (Linking)
DP  - 2013 Apr 30
TI  - Glycogen phosphorylase inhibitors: a patent review (2008 - 2012).
AB  - Introduction: Glycogen phosphorylase (GP) is the enzyme responsible for the
      synthesis of glucose-1-phosphate, the source of energy for muscles and the rest
      of the body. The binding of different ligands in catalytic or allosteric sites
      assures activation and deactivation of the enzyme. A description of the
      regulation mechanism and the implications in glycogen metabolism are given. Areas
      covered: Deregulation of GP has been observed in diseases such as diabetes
      mellitus or cancers. Therefore, it appears as an attractive therapeutic target
      for the treatment of such pathologies. Numbers of inhibitors have been published 
      in academic literature or patented in the last two decades. This review presents 
      the main patent claims published between 2008 and 2012. Expert opinion: Good
      inhibitors with interesting IC50 and in vivo results are presented. However, such
      therapeutic strategy raises questions and some answers are proposed to bring new 
      insights in the field.
AD  - University of Athens, Department of Pharmacy and Natural Products Chemistry ,
      Panepistimiopolis Zografou, GR-15771 Athens , Greece skaltsounis@pharm.uoa.gr.
FAU - Gaboriaud-Kolar, Nicolas
AU  - Gaboriaud-Kolar N
FAU - Skaltsounis, Alexios-Leandros
AU  - Skaltsounis AL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Expert Opin Ther Pat
JT  - Expert opinion on therapeutic patents
JID - 9516419
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - 10.1517/13543776.2013.794790 [doi]
PST - aheadofprint
SO  - Expert Opin Ther Pat. 2013 Apr 30.

PMID- 23627912
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
VI  - 14
IP  - 4
DP  - 2013 Jun
TI  - Autonomic neuropathy in young people with type 1 diabetes: a systematic review.
PG  - 239-48
LID - 10.1111/pedi.12039 [doi]
AD  - School of Women's and Children's Health, University of New South Wales,
      Kensington, NSW, 2052, Australia; Institute of Endocrinology and Diabetes, The
      Children's Hospital at Westmead, Westmead, NSW, 2145, Australia.
FAU - Tang, Melissa
AU  - Tang M
FAU - Donaghue, Kim C
AU  - Donaghue KC
FAU - Cho, Yoon Hi
AU  - Cho YH
FAU - Craig, Maria E
AU  - Craig ME
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Denmark
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/12/24 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/03/20 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1111/pedi.12039 [doi]
PST - ppublish
SO  - Pediatr Diabetes. 2013 Jun;14(4):239-48. doi: 10.1111/pedi.12039. Epub 2013 Apr
      30.

PMID- 23627895
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 Apr 30
TI  - Lessons from the Hvidoere International Study Group on childhood diabetes: be
      dogmatic about outcome and flexible in approach.
LID - 10.1111/pedi.12036 [doi]
AD  - Department of Endocrinology and Diabetes, Royal Children's Hospital, Murdoch
      Children's Research Institute, University of Melbourne, Melbourne, Australia.
FAU - Cameron, Fj
AU  - Cameron F
FAU - de Beaufort, C
AU  - de Beaufort C
FAU - Aanstoot, H-J
AU  - Aanstoot HJ
FAU - Hoey, H
AU  - Hoey H
FAU - Lange, K
AU  - Lange K
FAU - Castano, L
AU  - Castano L
FAU - Mortensen, Hb
AU  - Mortensen H
CN  - the Hvidoere International Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/12/09 [received]
PHST- 2013/02/03 [revised]
PHST- 2013/03/07 [accepted]
AID - 10.1111/pedi.12036 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 Apr 30. doi: 10.1111/pedi.12036.

PMID- 23627878
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
VI  - 14
IP  - 4
DP  - 2013 Jun
TI  - The promise and peril of mobile health applications for diabetes and
      endocrinology.
PG  - 231-8
LID - 10.1111/pedi.12034 [doi]
AB  - We are in the midst of what some have called a "mobile health revolution".
      Medical applications ("apps") for mobile phones are proliferating in the
      marketplace and clinicians are likely encountering patients with questions about 
      the medical value of these apps. We conducted a review of medical apps focused on
      endocrine disease. We found a higher percentage of relevant apps in our searches 
      of the iPhone app store compared with the Android marketplace. For our diabetes
      search in the iPhone store, the majority of apps (33%) focused on health tracking
      (blood sugars, insulin doses, carbohydrates), requiring manual entry of health
      data. Only two apps directly inputted blood sugars from glucometers attached to
      the mobile phone. The remainder of diabetes apps were teaching/training apps
      (22%), food reference databases (8%), social blogs/forums (5%), and physician
      directed apps (8%). We found a number of insulin dose calculator apps which
      technically meet criteria for being a medically regulated mobile application, but
      did not find evidence for FDA-approval despite their availability to consumers.
      Far fewer apps were focused on other endocrine disease and included medical
      reference for the field of endocrinology, access to endocrine journals, height
      predictors, medication trackers, and fertility apps. Although mobile health apps 
      have great potential for improving chronic disease care, they face a number of
      challenges including lack of evidence of clinical effectiveness, lack of
      integration with the health care delivery system, the need for formal evaluation 
      and review and organized searching for health apps, and potential threats to
      safety and privacy.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Division of Pediatric Endocrinology, University of Michigan, Ann Arbor, MI, USA.
FAU - Eng, Donna S
AU  - Eng DS
FAU - Lee, Joyce M
AU  - Lee JM
LA  - eng
GR  - K08 DK082386/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130430
PL  - Denmark
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/02/12 [received]
PHST- 2013/02/28 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1111/pedi.12034 [doi]
PST - ppublish
SO  - Pediatr Diabetes. 2013 Jun;14(4):231-8. doi: 10.1111/pedi.12034. Epub 2013 Apr
      30.

PMID- 23627860
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 Apr 30
TI  - Clinical application of regulatory T cells in type 1 diabetes.
LID - 10.1111/pedi.12029 [doi]
AB  - Regulatory T cells (Tregs) are responsible for the maintenance of peripheral
      tolerance. Animal studies have shown that administration of Tregs can prevent
      type 1 diabetes (DM1). Several clinical trials attempted to induce Tregs with
      various agents, and thus provide long-term tolerance of beta cells in DM1.
      Nevertheless, most of these studies have focused on clinical parameters (e.g.
      C-peptide) and not Treg numbers nor their function after treatment. Therefore, it
      is not possible to conclude if the majority of these therapies failed because the
      drugs did not induce Tregs, or if they failed despite Treg expansion. The current
      knowledge regarding Tregs, along with our experience in Treg therapy of patients 
      with graft versus host disease, prompted us to use ex vivo expanded Tregs in 10
      children with recent-onset DM1. No adverse effects in the treated individuals
      were observed. There was a significant increase in Treg number in peripheral
      blood immediately after the treatment administration, while the first clinical
      differences between treated and control patients were observed 4 months after
      Treg injection. Treated individuals had higher C-peptide levels and lower insulin
      requirements than non-treated children. Eleven months after diagnosis of DM1,
      there are still 2 individuals who are independent of exogenous insulin. These
      results indicate that autologous Tregs are a safe and well-tolerated therapy in
      children with DM1, which can inhibit or delay the destruction of pancreatic beta 
      cells. Additionally, Tregs can be a useful tool for local protection of
      transplanted pancreatic islets. Isolation and expansion of antigen-specific Tregs
      is one of the directions for future studies on cellular therapy of DM1.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Department of Family Medicine, Medical University of Gdansk, Gdansk, Poland.
FAU - Marek-Trzonkowska, Natalia
AU  - Marek-Trzonkowska N
FAU - Mysliwec, Malgorzata
AU  - Mysliwec M
FAU - Siebert, Janusz
AU  - Siebert J
FAU - Trzonkowski, Piotr
AU  - Trzonkowski P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/01/01 [received]
PHST- 2013/01/28 [revised]
PHST- 2013/01/31 [accepted]
AID - 10.1111/pedi.12029 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 Apr 30. doi: 10.1111/pedi.12029.

PMID- 23627824
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1746-076X (Electronic)
IS  - 1746-0751 (Linking)
VI  - 8
IP  - 3
DP  - 2013 May
TI  - Transient overexpression of Ppargamma2 and C/ebpalpha in mesenchymal stem cells
      induces brown adipose tissue formation.
PG  - 295-308
LID - 10.2217/rme.13.25 [doi]
AB  - Background: Brown adipose tissue plays a pivotal role in mammal metabolism and
      thermogenesis. It has a great therapeutic potential in several metabolic
      disorders such as obesity and diabetes. Mesenchymal stem cells (MSCs) are
      suitable candidates for brown adipose tissue formation de novo. Ppargamma2 and
      C/ebpalpha are nucleic receptors known to mediate adipogenic differentiation. We 
      hypothesized that overexpression of the Ppargamma2 and C/ebpalpha genes in MSCs
      would lead to the formation of adipose tissue. Materials & methods: MSCs bearing 
      the Luc reporter gene were transfected to overexpress Ppargamma2 and C/ebpalpha. 
      Differentiation of nucleofected cells was evaluated in vitro and in vivo
      following ectopic implantation of the cells in C3H/HeN mice. Results: After
      implantation, the engineered cells survived for 5 weeks and brown adipose-like
      tissue was observed in histological samples. Immunostaining and bioluminescent
      imaging showed new adipocytes expressing Luc and the brown adipose tissue marker,
      UCP1, in vitro and in vivo. Conclusion: We show that gene delivery of
      transcription factors into MSCs generates brown adipose tissue in vitro and in
      vivo.
AD  - Skeletal Biotech Laboratory, Hebrew University-Hadassah, Faculty of Dental
      Medicine, Jerusalem, Israel.
FAU - Sheyn, Dmitriy
AU  - Sheyn D
FAU - Pelled, Gadi
AU  - Pelled G
FAU - Tawackoli, Wafa
AU  - Tawackoli W
FAU - Su, Susan
AU  - Su S
FAU - Ben-David, Shiran
AU  - Ben-David S
FAU - Gazit, Dan
AU  - Gazit D
FAU - Gazit, Zulma
AU  - Gazit Z
LA  - eng
PT  - Journal Article
PL  - England
TA  - Regen Med
JT  - Regenerative medicine
JID - 101278116
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - 10.2217/rme.13.25 [doi]
PST - ppublish
SO  - Regen Med. 2013 May;8(3):295-308. doi: 10.2217/rme.13.25.

PMID- 23627775
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 Apr 30
TI  - Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes 
      insufficiently controlled on pioglitazone (GetGoal-P).
LID - 10.1111/dom.12121 [doi]
AB  - AIMS: To compare the efficacy and safety of once-daily prandial lixisenatide with
      placebo in type 2 diabetes mellitus (T2DM) insufficiently controlled by
      pioglitazone +/- metformin. METHODS: This randomized, double-blind study included
      a 24-week main treatment period and a >/=52-week variable extension period.
      Patients were randomized 2 : 1 to receive lixisenatide 20 microg once daily or
      placebo. The primary endpoint was change in glycated haemoglobin (HbA1c) at week 
      24. RESULTS: In total, 484 patients were randomized: 323 to lixisenatide; 161 to 
      placebo. After 24 weeks, lixisenatide once daily significantly improved HbA1c
      (-0.56% vs. placebo; p < 0.0001) and increased the proportion of patients
      achieving HbA1c <7% compared with placebo (52.3% vs. 26.4%, respectively; p <
      0.0001) and significantly improved fasting plasma glucose (-0.84 mmol/l vs.
      placebo; p < 0.0001). There was a small decrease in body weight with lixisenatide
      once daily and a small increase with placebo, with no statistically significant
      difference between the two groups. Overall, lixisenatide once daily was well
      tolerated, with a similar proportion of treatment-emergent adverse events (TEAEs)
      and serious TEAEs between groups (lixisenatide: 72.4% and 2.5%; placebo: 72.7%
      and 1.9%). Symptomatic hypoglycaemia rates were also relatively low in both
      groups (lixisenatide 3.4% and placebo 1.2%), with no severe episodes.
      Lixisenatide continued to be efficacious and well tolerated during the variable
      extension period. CONCLUSIONS: Lixisenatide once daily significantly improved
      glycaemic control with a low risk of hypoglycaemia, and was well tolerated over
      24 weeks and during the long-term, double-blind extension period in patients with
      T2DM insufficiently controlled on pioglitazone +/- metformin.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Endocrinology and Diabetes, HUS, Strasbourg, France.
FAU - Pinget, M
AU  - Pinget M
FAU - Goldenberg, R
AU  - Goldenberg R
FAU - Niemoeller, E
AU  - Niemoeller E
FAU - Muehlen-Bartmer, I
AU  - Muehlen-Bartmer I
FAU - Guo, H
AU  - Guo H
FAU - Aronson, R
AU  - Aronson R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/03/05 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/23 [accepted]
AID - 10.1111/dom.12121 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 Apr 30. doi: 10.1111/dom.12121.

PMID- 23627768
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1365-2788 (Electronic)
IS  - 0964-2633 (Linking)
DP  - 2013 Apr 30
TI  - Associations of symptoms of anxiety and depression with diabetes and
      cardiovascular risk factors in older people with intellectual disability.
LID - 10.1111/jir.12049 [doi]
AB  - BACKGROUND: Depression, anxiety, diabetes and cardiovascular risk factors are
      frequent health problems among older people with intellectual disability (ID).
      These conditions may be bidirectionally related. Depression and anxiety may have 
      biological effects causing glucose intolerance, fat accumulation and also
      lifestyle changes causing metabolic syndrome. But also the effects of diabetes,
      metabolic syndrome and subsequent cardiovascular disease may affect mood and
      anxiety. This study investigated the association between depression, anxiety and 
      diabetes and cardiovascular risk factors in older people with ID. METHODS: The
      healthy ageing in intellectual disability-study (HA-ID study) is a
      cross-sectional study among people aged 50 years and over with ID, receiving
      formal ID care. Screening instruments for symptoms of anxiety and depression were
      completed and physical examination and vena-puncture were performed to establish 
      components of the metabolic syndrome, peripheral arterial disease and c-reactive 
      protein. RESULTS: Of the 990 people who participated, 17% had symptoms of
      depression and 16% had symptoms of anxiety. Type I diabetes was present in 1%,
      type II diabetes in 13% of the study population. Metabolic syndrome, central
      obesity, hypercholesterolemia and hypertension were present in 45%, 48%, 23% and 
      53% respectively. In a multivariate logistic regression analysis a significant
      association was found between increased anxiety symptoms and diabetes only (OR
      2.4, 95%CI 1.2-4.9). CONCLUSIONS: Increased anxiety symptoms and diabetes are
      related in older people with ID. This association may be bidirectional. No other 
      associations of depression and anxiety symptoms with cardiovascular risk factors 
      could be proven to be significant. Therefore, more research is needed to unravel 
      the mechanisms of stress, mood disorders and cardiovascular disease in older
      people with ID. To provide comprehensive care for older people with ID, screening
      for diabetes and components of the metabolic syndrome in people with anxiety or
      mood disorders, and screening for symptoms of anxiety or depression in people
      with diabetes is warranted.
CI  - (c) 2013 The Authors. Journal of Intellectual Disability Research (c) 2013
      Blackwell Publishing Ltd.
AD  - Intellectual Disability Medicine, Erasmus Medical Center Rotterdam, Department of
      General Practice, Rotterdam, The Netherlands; Reinaerde, Den Dolder, The
      Netherlands.
FAU - de Winter, C F
AU  - de Winter CF
FAU - Hermans, H
AU  - Hermans H
FAU - Evenhuis, H M
AU  - Evenhuis HM
FAU - Echteld, M A
AU  - Echteld MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - J Intellect Disabil Res
JT  - Journal of intellectual disability research : JIDR
JID - 9206090
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/04 [accepted]
AID - 10.1111/jir.12049 [doi]
PST - aheadofprint
SO  - J Intellect Disabil Res. 2013 Apr 30. doi: 10.1111/jir.12049.

PMID- 23627758
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1875-5828 (Electronic)
IS  - 1567-2050 (Linking)
DP  - 2013 Apr 29
TI  - Alzheimer Disease and Diabetes Mellitus: Do They Have Anything In Common?
AB  - The prevalence of diabetes mellitus (DM) continues to increase because of
      sedentary life style and inappropriate diet. DM is one of the most common
      metabolic diseases, affecting more than 240 million people worldwide. It is
      projected that the number of people with DM will continue to increase in the next
      decade. Alzheimer disease (AD) is the most common cause of dementia, and affects 
      over 24 million people globally, mostly senior citizens. The worldwide prevalence
      of AD is estimated to double in the next 20 years. How are these two chronic and 
      debilitating diseases similar? Do they have common denominators? AD is similar to
      DM in many ways, in that both are associated with defective insulin release
      and/or signalling, impaired glucose uptake, amyloidosis, increased oxidative
      stress, stimulation of the apoptotic pathway, angiopathy, abnormal lipid
      peroxidation, ageing (in type 2 DM), brain atrophy, increased formation of
      advanced glycation end products and tau phosphorylation, impaired lipid
      metabolism and mitochondrial pathology. The pathogenesis of both AD and DM has
      genetic as well as environmental components. Both can also cause impaired
      cognition and dementia. All of these common denominators indicate that AD and DM 
      share a lot of factors in terms of pathophysiology, histopathology and clinical
      outcome. These similarities can be used in the search for and design of effective
      pharmacotherapy for AD, since potent therapeutic agents such as insulin,
      incretins, oral hypoglycaemic agents and antioxidants used in the management of
      DM may play a key role in the treatment of patients with AD.
AD  - Department of Anatomy, Faculty of Medicine & Health Sciences, United Arab
      Emirates University P.O. Box 17666, Al Ain, United Arab Emirates.
      eadeghate@uaeu.ac.ae.
FAU - Adeghate, E
AU  - Adeghate E
FAU - Donath, T
AU  - Donath T
FAU - Adem, A
AU  - Adem A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Curr Alzheimer Res
JT  - Current Alzheimer research
JID - 101208441
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/04/03 [received]
PHST- 2013/04/24 [accepted]
AID - CAR-EPUB-20130429-9 [pii]
PST - aheadofprint
SO  - Curr Alzheimer Res. 2013 Apr 29.

PMID- 23627757
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1875-5828 (Electronic)
IS  - 1567-2050 (Linking)
DP  - 2013 Apr 29
TI  - Vascular Risk Factors and Neurodegeneration in Ageing related Dementias:
      Alzheimer's Disease and Vascular Dementia.
AB  - Age is the strongest risk factor for brain degeneration whether it results from
      vascular or neurodegenerative mechanisms or both. To evaluate the current views
      on the impact of vascular disease on the most common causes of dementia. Most
      relevant articles to the selected subject headings were reviewed until October
      2011 from the popularly used databases including Pubmed, Cochrane Database and
      Biological Abstracts. Within the past decade, there has been four-fold increased 
      interest in the vascular basis of neurodegeneration and dementia. Vascular ageing
      involving arterial stiffness, endothelial changes and blood-brain barrier
      dysfunction affects neuronal survival by impairing several intracellular
      protective mechanisms leading to chronic hypoperfusion. Modifiable risk factors
      such as hypertension, diabetes, dyslipidaemia and adiposity linked to Alzheimer's
      disease and vascular dementia promote the degeneration and reduce the
      regenerative capacity of the vascular system. These in tandem with accumulation
      of abnormal proteins such as amyloid beta likely disrupt cerebral autoregulation,
      neurovascular coupling and perfusion of the deeper structures to variable degrees
      to produce white matter changes and selective brain atrophy. Brain pathological
      changes may be further modified by genetic factors such as the apoliopoprotein E 
      epsilon4 allele. Lifestyle measures that maintain or improve vascular health
      including consumption of healthy diets, moderate use of alcohol and implementing 
      regular physical exercise in general appear effective for reducing dementia risk.
      Interventions that improve vascular function are important to sustain cognitive
      status even during ageing whereas preventative measures that reduce risk of
      vascular disease are predicted to lessen the burden of dementia in the long-term.
AD  - Institute for Ageing and Health, Wolfson Research Centre (Neuropathology), Campus
      for Ageing & Vitality Newcastle upon Tyne, NE4 5PL, United Kingdom .
      raj.kalaria@ncl.ac.uk.
FAU - Akinyemi, R
AU  - Akinyemi R
FAU - Mukaetova-Ladinska, E
AU  - Mukaetova-Ladinska E
FAU - Attems, J
AU  - Attems J
FAU - Attems, J
AU  - Attems J
FAU - Ihara, M
AU  - Ihara M
FAU - Kalaria, R N
AU  - Kalaria RN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Curr Alzheimer Res
JT  - Current Alzheimer research
JID - 101208441
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/01/22 [received]
PHST- 2013/04/24 [accepted]
AID - CAR-EPUB-20130429-8 [pii]
PST - aheadofprint
SO  - Curr Alzheimer Res. 2013 Apr 29.

PMID- 23627755
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1875-5828 (Electronic)
IS  - 1567-2050 (Linking)
DP  - 2013 Apr 29
TI  - Type 2 Diabetes Is Associated With Increased Alzheimer's Disease Neuropathology
      in ApoE epsilon4 Carriers.
AB  - Background Past studies of Alzheimer's disease (AD) pathology association with
      diabetes mellitus type 2 (DM2) have provided conflicting results. While several
      studies indicate that subjects with comorbid AD and DM2 have less AD pathology,
      others have found no significant differences in AD pathology between the two
      groups. Other studies have indicated that individuals with AD and DM2 have
      significantly greater neuropathology than AD individuals who do not have DM2.
      Additional research has demonstrated that ApoE epsilon4 carriers with AD and DM2 
      have significantly greater pathology than ApoE epsilon4 non-carriers. Methods
      Data on clinically and pathologically diagnosed Alzheimer's disease (NINDS-ADRDA 
      clinically and NIA Reagan intermediate or high pathologically) with DM2 (n= 40)
      and those without DM2 (n= 322) from the Banner Sun Health Research Institute
      Brain and Body Donation Program were obtained for this study. Plaque and tangle
      scores from the frontal, parietal, temporal, entorhinal and hippocampal regions
      were compared between the DM2+ and DM2 - groups. In addition, total plaque count,
      total tangle count, and Braak scores were also compared between groups. Similar
      analyses were carried out to discern differences between ApoE epsilon4 carriers
      and non-carriers with AD and DM2. Results There were no significant differences
      in plaque and tangle pathology between DM2+ and DM2 - groups. Logistic regression
      analyses, which accounted for the effects of ApoE epsilon4 carrier status and age
      at death, found no association between total plaque [OR 1.05 (0.87, 1.27), p =
      .60] or total tangle [OR 0.97 (0.89, 1.07) p = .58] counts and DM2 status.
      Chi-square analysis found no significant association between ApoE epsilon4
      carrier status and DM2 status [chi2 = 0.30 (df = 1), p = .58]. Within the DM2+
      group, ApoE epsilon4 carriers had significantly greater plaque and tangle
      pathology when compared to DM2+ ApoE epsilon4 non-carriers. Conclusion Overall,
      the presence of DM2 does not affect plaque and tangle burden in a sample of
      clinically and pathologically confirmed AD cases. Among AD individuals with DM2, 
      those who are ApoE epsilon4 carriers had significantly greater neuropathology
      than ApoE epsilon4 non-carriers. The presence of ApoE epsilon4 appears to
      exacerbate AD neuropathology in the presence of DM2.
AD  - Banner Sun Health Research Institute, 10515 W. Santa Fe Dr Sun City, AZ 85351,
      USA. marwan.sabbagh@bannerhealth.com.
FAU - Malek-Ahmadi, M
AU  - Malek-Ahmadi M
FAU - Beach, T
AU  - Beach T
FAU - Obradov, A
AU  - Obradov A
FAU - Obradov, A
AU  - Obradov A
FAU - Sue, L
AU  - Sue L
FAU - Belden, C
AU  - Belden C
FAU - Davis, K
AU  - Davis K
FAU - Walker, D G
AU  - Walker DG
FAU - Lue, L
AU  - Lue L
FAU - Adem, A
AU  - Adem A
FAU - Sabbagh, M N
AU  - Sabbagh MN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Curr Alzheimer Res
JT  - Current Alzheimer research
JID - 101208441
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/03/31 [received]
PHST- 2013/04/24 [accepted]
AID - CAR-EPUB-20130429-6 [pii]
PST - aheadofprint
SO  - Curr Alzheimer Res. 2013 Apr 29.

PMID- 23627695
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1520-5126 (Electronic)
IS  - 0002-7863 (Linking)
VI  - 135
IP  - 18
DP  - 2013 May 8
TI  - Polymorph-Specific Kinetics and Thermodynamics of beta-Amyloid Fibril Growth.
PG  - 6860-71
LID - 10.1021/ja311963f [doi]
AB  - Amyloid fibrils formed by the 40-residue beta-amyloid peptide (Abeta1-40) are
      highly polymorphic, with molecular structures that depend on the details of
      growth conditions. Underlying differences in physical properties are not well
      understood. Here, we investigate differences in growth kinetics and thermodynamic
      stabilities of two Abeta1-40 fibril polymorphs for which detailed structural
      models are available from solid-state nuclear magnetic resonance (NMR) studies.
      Rates of seeded fibril elongation in the presence of excess soluble Abeta1-40 and
      shrinkage in the absence of soluble Abeta1-40 are determined with atomic force
      microscopy (AFM). From these rates, we derive polymorph-specific values for the
      soluble Abeta1-40 concentration at quasi-equilibrium, from which relative
      stabilities can be derived. The AFM results are supported by direct measurements 
      by ultraviolet absorbance, using a novel dialysis system to establish
      quasi-equilibrium. At 24 degrees C, the two polymorphs have significantly
      different elongation and shrinkage kinetics but similar thermodynamic
      stabilities. At 37 degrees C, differences in kinetics are reduced, and
      thermodynamic stabilities are increased significantly. Fibril length
      distributions in AFM images provide support for an intermittent growth model, in 
      which fibrils switch randomly between an "on" state (capable of elongation) and
      an "off" state (incapable of elongation). We also monitor interconversion between
      polymorphs at 24 degrees C by solid-state NMR, showing that the two-fold
      symmetric "agitated" ([Formula: see text]) polymorph is more stable than the
      three-fold symmetric "quiescent" ([Formula: see text]) polymorph. Finally, we
      show that the two polymorphs have significantly different rates of fragmentation 
      in the presence of shear forces, a difference that helps explain the observed
      predominance of the [Formula: see text] structure when fibrils are grown in
      agitated solutions.
AD  - Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and 
      Kidney Diseases, National Institutes of Health , Bethesda, Maryland 20892-0520,
      United States.
FAU - Qiang, Wei
AU  - Qiang W
FAU - Kelley, Kevin
AU  - Kelley K
FAU - Tycko, Robert
AU  - Tycko R
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - United States
TA  - J Am Chem Soc
JT  - Journal of the American Chemical Society
JID - 7503056
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/04/29 [aheadofprint]
AID - 10.1021/ja311963f [doi]
PST - ppublish
SO  - J Am Chem Soc. 2013 May 8;135(18):6860-71. doi: 10.1021/ja311963f. Epub 2013 Apr 
      29.

PMID- 23627689
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1524-475X (Electronic)
IS  - 1067-1927 (Linking)
DP  - 2013 Apr 29
TI  - Diabetes impairs adipose tissue-derived stem cell function and efficiency in
      promoting wound healing.
LID - 10.1111/wrr.12051 [doi]
AB  - Adipose tissue-derived stem cells (ASCs) are gaining increasing consideration in 
      tissue repair therapeutic application. Recent evidence indicates that ASCs
      enhance skin repair in animal models of impaired wound healing. To assess the
      therapeutic activity of autologous vs. allogeneic ASCs in the treatment of
      diabetic ulcers, we functionally characterized diabetic ASCs and investigated
      their potential to promote wound healing with respect to nondiabetic ones.
      Adipose tissue-derived cells from streptozotocin-induced type 1 diabetic mice
      were analyzed either freshly isolated as stromal vascular fraction (SVF), or
      following a single passage of culture (ASCs). Diabetic ASCs showed decreased
      proliferative potential and migration. Expression of surface markers was altered 
      in diabetic SVF and cultured ASCs, with a reduction in stem cell marker-positive 
      cells. ASCs from diabetic mice released lower amounts of hepatocyte growth
      factor, vascular endothelial growth factor (VEGF)-A, and insulin-like growth
      factor-1, growth factors playing important roles in skin repair. Accordingly, the
      supernatant of diabetic ASCs manifested reduced capability to promote
      keratinocyte and fibroblast proliferation and migration. Therapeutic potential of
      diabetic SVF administered to wounds of diabetic mice was blunted as compared with
      cells isolated from nondiabetic mice. Our data indicate that diabetes alters ASC 
      intrinsic properties and impairs their function, thus affecting therapeutic
      potential in the autologous treatment for diabetic ulcers.
CI  - (c) 2013 by the Wound Healing Society.
AD  - Laboratory of Molecular and Cell Biology, Istituto Dermopatico
      dell'Immacolata-IRCCS, Rome, Italy.
FAU - Cianfarani, Francesca
AU  - Cianfarani F
FAU - Toietta, Gabriele
AU  - Toietta G
FAU - Di Rocco, Giuliana
AU  - Di Rocco G
FAU - Cesareo, Eleonora
AU  - Cesareo E
FAU - Zambruno, Giovanna
AU  - Zambruno G
FAU - Odorisio, Teresa
AU  - Odorisio T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Wound Repair Regen
JT  - Wound repair and regeneration : official publication of the Wound Healing Society
      [and] the European Tissue Repair Society
JID - 9310939
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/07/06 [received]
PHST- 2013/02/25 [accepted]
AID - 10.1111/wrr.12051 [doi]
PST - aheadofprint
SO  - Wound Repair Regen. 2013 Apr 29. doi: 10.1111/wrr.12051.

PMID- 23627599
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1520-5118 (Electronic)
IS  - 0021-8561 (Linking)
VI  - 61
IP  - 20
DP  - 2013 May 22
TI  - Chemical Composition and Hypoglycemic and Pancreas-Protective Effect of Leaf
      Essential Oil from Indigenous Cinnamon ( Cinnamomum osmophloeum Kanehira).
PG  - 4905-13
LID - 10.1021/jf401039z [doi]
AB  - The antidiabetic effect of cinnamon has generated broad interest during the past 
      decade. We investigated the hypoglycemic activity and pancreas-protective effect 
      of leaf essential oil from indigenous cinnamon (CO) in diabetic rats induced with
      streptozotocin (STZ, iv, 65 mg/(kg bw)) and found linalool to be the major
      component representing 40.24% of the CO composition. In diabetics, all tested
      doses of CO significantly lowered fasting blood glucose and fructosamine and are 
      concomitant with elevated plasma and pancreatic insulin levels under a fasting
      condition. However, during the oral glucose tolerance test (OGTT) period the
      effect of 25 and 50 mg/(kg bw) of CO was shown to be less effective than that of 
      12.5 mg/(kg bw) in ameliorating the accumulation of plasma insulin. In addition, 
      at 12.5 mg/(kg bw), CO significantly ameliorated pancreatic values of
      thiobarbituric acid reactive substances and activities of superoxide dismutase
      and glutathione reductase in diabetics to an extent greater than that of higher
      CO doses. At doses 12.5 and 25 but not 50 mg/(kg bw), CO significantly
      ameliorated pancreatic levels of interleukin-1beta and nitric oxide. In
      conclusion, appropriate doses of CO of the linalool chemotype exhibited
      therapeutic potential in glycemic control in diabetes that was at least partially
      resulted from improved insulin secretion. The ameliorated oxidative stress and
      proinflammatory environment in the pancreas by CO may provide a protective effect
      on pancreatic beta cells and warrant further investigation.
AD  - Department of BioIndustry Technology, Da-Yeh University , Changhua 51591, Taiwan,
      Republic of China.
FAU - Lee, Shih-Chieh
AU  - Lee SC
FAU - Xu, Wen-Xin
AU  - Xu WX
FAU - Lin, Li-Yun
AU  - Lin LY
FAU - Yang, Jia-Jung
AU  - Yang JJ
FAU - Liu, Cheng-Tzu
AU  - Liu CT
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - United States
TA  - J Agric Food Chem
JT  - Journal of agricultural and food chemistry
JID - 0374755
SB  - IM
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/05/13 [aheadofprint]
AID - 10.1021/jf401039z [doi]
PST - ppublish
SO  - J Agric Food Chem. 2013 May 22;61(20):4905-13. doi: 10.1021/jf401039z. Epub 2013 
      May 13.

PMID- 23627464
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Linking)
DP  - 2013 Apr 29
TI  - The extract of Cinnamomum cassia twigs inhibits adipocyte differentiation via
      activation of the insulin signaling pathway in 3T3-L1 preadipocytes.
AB  - Abstract Context: Obesity is associated with a number of diseases with metabolic 
      abnormalities such as type 2 diabetes (T2D). Medicinal plants have been widely
      used for the treatment of obesity and related complications. Objective: In this
      study, we investigated the antidiabetic properties of the extract of twigs of
      Cinnamomum cassia Blume (Lauraceae) (Cinnamomi Ramulus; CR) in 3T3-L1 murine
      preadipocytes. Materials and methods: 3T3-L1 cells were differentiated into
      adipocytes for 3 d in insulin-conditioned medium and then treated with CR extract
      at concentrations of 100 and 500 mug/mL for 6 d. Adipocyte differentiation was
      measured by Oil Red O staining, and the expression of master transcription
      factors, peroxisome proliferator-activated receptor-gamma (PPARgamma),
      CCAAT/enhancer binding protein-alpha (C/EBPalpha), and sterol regulatory element 
      binding protein-1c (SREBP-1c), and lipid metabolism factors were investigated by 
      reverse transcription-polymerase chain reaction (RT-PCR). The activation of the
      AMP-activated protein kinase (AMPK)/insulin signaling pathway was assessed by
      western blot analysis. Results: CR extract significantly reduced lipid
      accumulation and down-regulated the expression of PPARgamma, C/EBPalpha, and
      SREBP-1c in 3T3-L1 adipocytes. CR extract also suppressed the expression of fatty
      acid synthase (FAS), acyl-CoA synthase, and perilipin. Moreover, CR extract
      markedly up-regulated the phosphorylation of AMPK and acetyl-CoA carboxylase
      (ACC). In addition, CR extract effectively increased the expression levels of
      glucose transporter-4 (GLUT-4), phosphatidylinositol 3-kinase (PI3K), and insulin
      receptor substrate-1 (IRS-1) in 3T3-L1 adipocytes. Discussion and conclusion:
      These results suggest that CR extract may have therapeutic potential as a natural
      agent for the improvement of T2D via regulation of the insulin-dependent
      signaling pathway.
AD  - Oriental Medicine R&D Center, Dongguk University , Gyeongju , Republic of Korea .
FAU - Han, Yunkyung
AU  - Han Y
FAU - Jung, Hyo Won
AU  - Jung HW
FAU - Bae, Hyo Sang
AU  - Bae HS
FAU - Kang, Jong-Seong
AU  - Kang JS
FAU - Park, Yong-Ki
AU  - Park YK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
AID - 10.3109/13880209.2013.772211 [doi]
PST - aheadofprint
SO  - Pharm Biol. 2013 Apr 29.

PMID- 23627403
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130515
DCOM- 20130516
LR  - 20130516
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 13
IP  - 1
DP  - 2013
TI  - Impact of therapy escalation on ambulatory care costs among patients with type 2 
      diabetes in France.
PG  - 15
LID - 10.1186/1472-6823-13-15 [doi]
AB  - BACKGROUND: This study compares annual ambulatory care expenditures per patient
      with type 2 diabetes mellitus (T2DM) in France according to treatment phase and
      renal function status. METHODS: Records from patients with T2DM were extracted
      from a health insurance database. Patients were classified in subgroups, by
      treatment phase: oral/GLP1 monotherapy, double therapy, triple therapy or insulin
      therapy, and according to renal function status (identified using pharmacy, lab
      and consultation claims). Annual ambulatory expenditures were estimated from the 
      national insurance perspective by year (from 2005 to 2010) and subgroup. RESULTS:
      The number of patients ranged from 9,682 to 11,772 between 2005 and 2010. The
      average annual expenditure per individual in 2010 ranged from euro3,017 (standard
      deviation: euro3,829) for monotherapy to euro3,609 +/- euro3,801 for triple
      therapy, and euro7,398 +/- euro5,487 with insulin (adjusted ratio insulin
      therapy/monotherapy: 2.36, p < 0.001). Similar differences between treatement
      stages were found in previous years. Additional costs for insulin were mainly
      related to nursing care (multiplied by 18.42, p < 0.001), medical devices and
      pharmacy costs. DM-attributable drug costs were mainly related to antidiabetic
      drugs (28% for monotherapy to 71% for triple therapy), but also to cardiovascular
      system drugs (21% for monotherapy to 51% with insulin) and nervous system drugs
      (up to 8% with insulin). Declining renal function was associated with an increase
      in expenses by 12% to 53% according to treatment stage. CONCLUSIONS: Overall,
      ambulatory care expenditures increase with treatment escalation and declining
      renal function amongst patients with T2DM. Insulin therapy is associated with
      substantially increased costs, related to pharmacy, nursing care and medical
      device costs.
AD  - EPHE Sorbonne, Systemes integres, environnement et biodiversite, (SIEB), Paris,
      France. fgu@creativ-ceutical.com.
FAU - Guelfucci, Florent
AU  - Guelfucci F
FAU - Clay, Emilie
AU  - Clay E
FAU - Aballea, Samuel
AU  - Aballea S
FAU - Lassalle, Regis
AU  - Lassalle R
FAU - Moore, Nicholas
AU  - Moore N
FAU - Toumi, Mondher
AU  - Toumi M
LA  - eng
PT  - Journal Article
DEP - 20130429
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
PMC - PMC3653727
OID - NLM: PMC3653727
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:01
CRDT- 2013/05/01 06:00
PHST- 2012/10/03 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/04/29 [aheadofprint]
AID - 1472-6823-13-15 [pii]
AID - 10.1186/1472-6823-13-15 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2013 Apr 29;13(1):15. doi: 10.1186/1472-6823-13-15.

PMID- 23627341
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 Apr 30
TI  - HLA-typing, clinical, and immunological characterization of youth with type 2
      diabetes mellitus phenotype from the German/Austrian DPV database.
LID - 10.1111/pedi.12043 [doi]
AB  - AIM: To characterize the clinical and immunological features of HLA-typed youth
      with pediatric onset of type 2 diabetes mellitus (T2DM). METHOD: One hundred and 
      seven patients with clinically diagnosed T2DM (aged </=20 yr at diagnosis) were
      examined. DNA and serum, obtained after a median diabetes duration of 2.2 (Q1-Q3:
      0.8-4.6) yr, were used for centralized HLA-typing and autoantibody (GADA, IA-2A, 
      ZnT8A) measurements. RESULTS: 64.6% of patients were female and median age at
      diagnosis was 13.8 (Q1-Q3: 11.6-15.4) yr. Patients were obese [median body mass
      index-standard deviation score (BMI-SDS): 2.6 (2.0-3.1)], 88.0% had a family
      history of diabetes and 40.2% a migration background. Islet autoantibodies were
      detected in 16 (15.0%), among which 7 (6.5%) had multiple islet autoantibodies.
      Autoantibody positive patients had poorer metabolic control than autoantibody
      negative patients [glycosylated hemoglobin A1c (HbA1c): 8.1 (6.9-10.1) % vs. 6.6 
      (5.9-8.0) %; p = 0.033], while patients with HLA-DR genetic risk had higher
      BMI-SDS than those with HLA-DRXX [2.6 (2.4-3.7) vs. 2.4 (1.7-2.9); p = 0.007].
      Metabolic syndrome (61.7%), microalbuminuria (13.4%), and retinopathy (3.9%) were
      diagnosed. Therapies used were lifestyle only (35.5%), oral anti-diabetics (OAD) 
      only (43.3 %), insulin + OAD (15.9%) and insulin only (5.6%). Patients with
      beta-cell autoimmunity or HLA-DR genetic risk more frequently used insulin than
      confirmed T2DM patients (50.0 vs. 22.0%; p = 0.037) and less often had diabetic
      relatives (61.1 vs. 86.0%; p = 0.030). CONCLUSION: T2DM was confirmed in about
      90% of patients while about 10% with beta-cell autoimmunity or HLA-DR genetic
      risk likely had either T1.5DM or 'double diabetes' or an unknown diabetes type.
CI  - (c) 2013 John Wiley & Sons A/S.
AD  - Faculty of Medicine, Institute of Epidemiology and Medical Biometry, University
      of Ulm, Ulm, 89081, Germany.
FAU - Awa, Wendy L
AU  - Awa WL
FAU - Boehm, Bernard O
AU  - Boehm BO
FAU - Rosinger, Silke
AU  - Rosinger S
FAU - Achenbach, Peter
AU  - Achenbach P
FAU - Ziegler, Anette G
AU  - Ziegler AG
FAU - Krause, Stephanie
AU  - Krause S
FAU - Meissner, Thomas
AU  - Meissner T
FAU - Wiegand, Susanne
AU  - Wiegand S
FAU - Reinehr, Thomas
AU  - Reinehr T
FAU - Kapellen, Thomas
AU  - Kapellen T
FAU - Karges, Beate
AU  - Karges B
FAU - Eiermann, Thomas
AU  - Eiermann T
FAU - Schober, Edith
AU  - Schober E
FAU - Holl, Reinhard W
AU  - Holl RW
CN  - on behalf of the DPV Initiative and the German BMBF Competence Networks Diabetes 
      Mellitus and Obesity
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/09/24 [received]
PHST- 2013/01/30 [revised]
PHST- 2013/03/26 [accepted]
AID - 10.1111/pedi.12043 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 Apr 30. doi: 10.1111/pedi.12043.

PMID- 23627262
OWN - NLM
STAT- Publisher
DA  - 20130430
IS  - 1399-5448 (Electronic)
IS  - 1399-543X (Linking)
DP  - 2013 Apr 30
TI  - Are metabolic syndrome antecedents in prepubertal children associated with being 
      born idiopathic large for gestational age?
LID - 10.1111/pedi.12041 [doi]
AB  - INTRODUCTION: Being born large for gestational age (LGA) is a risk factor for
      development of metabolic syndrome (MS) in adolescents and adults. OBJECTIVE: To
      evaluate prepubertal children born idiopathic LGA to non-obese mothers without
      gestational diabetes or glucosuria with respect to the presence of MS
      antecedents. PATIENTS AND METHODS: We conducted a cross-sectional study to
      compare 40 (19 F) LGA-born prepubertal children of a mean age of 6.1 +/- 2.5 yr
      and 49 (25 F) appropriate for gestational age (AGA)-born body mass index
      (BMI)-matched peers of a mean age of 5.4 +/- 1.8 yr with respect to their
      anthropometric data, blood pressure measurements, fasting serum glucose and
      insulin levels, homeostasis model assessment-insulin resistance (HOMA-IR), and
      lipids and atherogenic index (AI) [triglyceride (TG)/high-density lipoprotein
      cholesterol (HDL-C)]. HOMA-IR > 2.5 was used to define IR. HDL-C </= 40 mg/dL and
      TG >/= 110 mg/dL were used to define dyslipidemia. Both groups were further
      divided into subgroups as obese and non-obese according to their BMI percentiles 
      and the analyses were repeated. RESULTS: Non-obese LGA children had higher waist 
      circumference (WC) standard deviation scores (SDSs) than BMI-matched AGA-born
      peers (p = 0.024). There were no significant differences between pooled, obese
      and non-obese subgroups of LGA-born children and their AGA counterparts with
      respect to dyslipidemia and IR. AI was higher in non-obese LGA children than in
      AGA counterparts (p = 0.028). CONCLUSIONS: Non-obese idiopathic LGA-born children
      have higher AIs than AGA-born counterparts in the absence of IR. WC seems to be a
      good clinical screening tool in identifying at risk of non-obese LGA children.
      Further studies are needed to evaluate MS antecedents in idiopathic LGA-born
      children.
CI  - (c) 2013 John Wiley & Sons A/S.
AD  - Paediatric Endocrinology and Diabetes Unit, Istanbul Faculty of Medicine,
      Istanbul University, Istanbul, Turkey.
FAU - Cetin, Ceren
AU  - Cetin C
FAU - Ucar, Ahmet
AU  - Ucar A
FAU - Bas, Firdevs
AU  - Bas F
FAU - Poyrazoglu, Sukran
AU  - Poyrazoglu S
FAU - Bundak, Ruveyde
AU  - Bundak R
FAU - Saka, Nurcin
AU  - Saka N
FAU - Ozden, Tulin
AU  - Ozden T
FAU - Darendeliler, Feyza
AU  - Darendeliler F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Pediatr Diabetes
JT  - Pediatric diabetes
JID - 100939345
EDAT- 2013/05/01 06:00
MHDA- 2013/05/01 06:00
CRDT- 2013/05/01 06:00
PHST- 2013/01/31 [received]
PHST- 2013/03/07 [revised]
PHST- 2013/03/26 [accepted]
AID - 10.1111/pedi.12041 [doi]
PST - aheadofprint
SO  - Pediatr Diabetes. 2013 Apr 30. doi: 10.1111/pedi.12041.

PMID- 23626961
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2250-1541 (Print)
IS  - 1947-2714 (Linking)
VI  - 5
IP  - 3
DP  - 2013 Mar
TI  - Carotid Intima Media Thickness as a Reflection of Generalized Atherosclerosis is 
      Related to Body Mass Index in Ischemic Stroke Patients.
PG  - 228-34
LID - 10.4103/1947-2714.109200 [doi]
AB  - BACKGROUND: Carotid artery intima media thickness reflects the ongoing process of
      atherosclerosis in the body. The pathologic process occurring in the obese
      patients in the vascular system is atherosclerosis which is an important cause of
      ischemic stroke. Body mass index is an indirect measure of obesity in general
      population. AIM: The study was to assess the role of carotid artery intima media 
      thickness as a marker of atherosclerosis and its relation with body mass index in
      ischemic stroke patients. MATERIALS AND METHODS: Body mass index of the all
      stroke patients was calculated by using formula body mass in kilograms divided by
      the square of height in meters. The patients were classified in four groups of
      body mass index according to Indian standards. Carotid sonography was done to
      assess the common carotid artery intima media thickness in millimeters by using
      high resolution 7.5 MHz sonography technique. RESULTS: The average Carotid intima
      media thickness in this study was 9.23mm. There was a significant association
      found between increasing carotid artery intima media thickness and groups of body
      mass index (P- <0.05) in ischemic stroke patients. CONCLUSIONS: Body mass index
      as an indicator of obesity and carotid intima media thickness both are very
      important risk factors for ischemic stroke and are associated with each other.
AD  - Department of Medicine, King George Medical University, Lucknow, Uttar Pradesh,
      India.
FAU - Singh, Amit Shankar
AU  - Singh AS
FAU - Atam, Virendra
AU  - Atam V
FAU - Patel, Munna Lal
AU  - Patel ML
FAU - Chaudhary, Shyam Chand
AU  - Chaudhary SC
FAU - Sawlani, Kamal Kumar
AU  - Sawlani KK
FAU - Das, Liza
AU  - Das L
LA  - eng
PT  - Journal Article
PL  - India
TA  - N Am J Med Sci
JT  - North American journal of medical sciences
JID - 101521411
PMC - PMC3632029
OID - NLM: PMC3632029
OTO - NOTNLM
OT  - Body mass index
OT  - Carotid intima media thickness
OT  - Cerebrovascular diseases
OT  - Diabetes mellitus
OT  - Lipoproteins
OT  - Obesity
OT  - Sonography
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
AID - 10.4103/1947-2714.109200 [doi]
AID - NAJMS-5-228 [pii]
PST - ppublish
SO  - N Am J Med Sci. 2013 Mar;5(3):228-34. doi: 10.4103/1947-2714.109200.

PMID- 23626958
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2250-1541 (Print)
IS  - 1947-2714 (Linking)
VI  - 5
IP  - 3
DP  - 2013 Mar
TI  - Antioxidant Enzymes and Lipid Peroxidation in Type 2 Diabetes Mellitus Patients
      with and without Nephropathy.
PG  - 213-9
LID - 10.4103/1947-2714.109193 [doi]
AB  - BACKGROUND: Oxidative stress has been considered to be a pathogenic factor of
      diabetic complications including nephropathy. There are many controversies and
      limited studies regarding the antioxidant enzymes in diabetic nephropathy. AIM:
      This study was to evaluate the levels of antioxidant enzymes and lipid
      peroxidation in Type-2 Diabetes Mellitus (DM) patients with and without
      nephropathy. MATERIALS AND METHODS: The study included 90 age and sex matched
      subjects. Blood samples of all subjects were analyzed for all biochemical and
      oxidative stress parameters. RESULTS: The malondialdehyde (MDA) levels and
      catalase (CAT) activity were significantly increased and reduced glutathione
      (GSH) levels and activities of glutathione peroxidase (GPx) and glutathione
      reductase (GR) were significantly decreased in Type-2 DM with and without
      nephropathy as compared to controls and also in Type-2 DM with nephropathy as
      compared to Type-2 DM without nephropathy. There were an excellent positive
      correlation of glycohemoglobin (HbA1c) with MDA and a good negative correlation
      of GPx with GSH in controls. There were positive correlations of GR, CAT, and
      superoxide dismutase (SOD) with MDA in Type-2 diabetes patients with nephropathy.
      CONCLUSIONS: Intensity of oxidative stress in Type-2 diabetic patients with
      nephropathy is greater when compared with Type-2 diabetic patients without
      nephropathy as compared to the controls.
AD  - Department of Biochemistry, Pandit Bhagwat Dayal Sharma University of Health
      Sciences, Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
FAU - Kumawat, Manjulata
AU  - Kumawat M
FAU - Sharma, Tarun Kumar
AU  - Sharma TK
FAU - Singh, Ishwar
AU  - Singh I
FAU - Singh, Neelima
AU  - Singh N
FAU - Ghalaut, Veena Singh
AU  - Ghalaut VS
FAU - Vardey, Satish Kumar
AU  - Vardey SK
FAU - Shankar, Vijay
AU  - Shankar V
LA  - eng
PT  - Journal Article
PL  - India
TA  - N Am J Med Sci
JT  - North American journal of medical sciences
JID - 101521411
PMC - PMC3632026
OID - NLM: PMC3632026
OTO - NOTNLM
OT  - Antioxidant enzymes
OT  - Glycosylated hemoglobin and diabetic nephropathy
OT  - Lipid profile
OT  - Malondialdehyde
OT  - Non-insulin dependent diabetes mellitus
OT  - Reduced glutathione
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
AID - 10.4103/1947-2714.109193 [doi]
AID - NAJMS-5-213 [pii]
PST - ppublish
SO  - N Am J Med Sci. 2013 Mar;5(3):213-9. doi: 10.4103/1947-2714.109193.

PMID- 23626954
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2250-1541 (Print)
IS  - 1947-2714 (Linking)
VI  - 5
IP  - 3
DP  - 2013 Mar
TI  - New guidelines for diagnosis of gestational diabetes: pathology-based impact
      assessment.
PG  - 191-4
LID - 10.4103/1947-2714.109184 [doi]
AB  - BACKGROUND: A recent study indicated an average of 19.5% abnormal oral glucose
      tolerance in antenatal clients per year. AIM: The purpose of this study was to
      determine the impact on gestational diabetes cases due to new guidelines for
      diagnosis and classification of hyperglycaemia in pregnancy. MATERIALS AND
      METHODS: This study reviewed the archived clinical pathology data on oral glucose
      tolerance tests performed between January 1999 and December 2008 on antenatal
      clients (N = 615). The cases were reviewed to determine changes if any in
      percentage of gestational diabetes due to new guidelines. RESULTS: Over the 10
      years period, a yearly average of additional 10.8% antenatal cases suggestive of 
      gestational diabetes was observed due to the new recommended thresholds. Further,
      the average yearly incidence would have increased from 8.8 cases to 16.2 cases,
      which translates to almost 46% increase in the prospective numbers of gestational
      diabetes. CONCLUSIONS: This report presents the extent of how the new recommended
      guidelines for diagnosis and classification of hyperglycaemia in pregnancy could 
      increase the prevalence of gestational diabetes. It also provides pathology-based
      evidence for the epidemiology of gestational diabetes mellitus and allows for
      planning the costs that would be attendant to the full implementation of the new 
      guidelines.
AD  - Charles Darwin University, NT Australia ; NSW Health Pathology, NSW Australia.
FAU - Nwose, Ezekiel Uba
AU  - Nwose EU
FAU - Richards, Ross Stuart
AU  - Richards RS
FAU - Bwititi, Phillip Taderera
AU  - Bwititi PT
FAU - Butkowski, Eugene George
AU  - Butkowski EG
LA  - eng
PT  - Journal Article
PL  - India
TA  - N Am J Med Sci
JT  - North American journal of medical sciences
JID - 101521411
PMC - PMC3632022
OID - NLM: PMC3632022
OTO - NOTNLM
OT  - Gestational diabetes
OT  - Impact evaluation
OT  - New guidelines
OT  - Oral glucose tolerance test
OT  - Pathology-based evidence
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
AID - 10.4103/1947-2714.109184 [doi]
AID - NAJMS-5-191 [pii]
PST - ppublish
SO  - N Am J Med Sci. 2013 Mar;5(3):191-4. doi: 10.4103/1947-2714.109184.

PMID- 23626914
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2093-3681 (Print)
IS  - 2093-3681 (Linking)
VI  - 19
IP  - 1
DP  - 2013 Mar
TI  - Comparison of machine learning algorithms for classification of the sentences in 
      three clinical practice guidelines.
PG  - 16-24
LID - 10.4258/hir.2013.19.1.16 [doi]
AB  - OBJECTIVES: Clinical Practice Guidelines (CPGs) are an effective tool for
      minimizing the gap between a physician's clinical decision and medical evidence
      and for modeling the systematic and standardized pathway used to provide better
      medical treatment to patients. METHODS: In this study, sentences within the
      clinical guidelines are categorized according to a classification system. We used
      three clinical guidelines that incorporated knowledge from medical experts in the
      field of family medicine. These were the seventh report of the Joint National
      Committee (JNC7) on Prevention, Detection, Evaluation, and Treatment of High
      Blood Pressure from the National Heart, Lung, and Blood Institute; the third
      report of the National Cholesterol Education Program (NCEP) Expert Panel on
      Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults from the
      same institution; and the Standards of Medical Care in Diabetes 2010 report from 
      the American Diabetes Association. Three annotators each tagged 346 sentences
      hand-chosen from these three clinical guidelines. The three annotators then
      carried out cross-validations of the tagged corpus. We also used various machine 
      learning-based classifiers for sentence classification. RESULTS: We conducted
      experiments using real-valued features and token units, as well as a Boolean
      feature. The results showed that the combination of maximum entropy-based
      learning and information gain-based feature extraction gave the best
      classification performance (over 98% f-measure) in four sentence categories.
      CONCLUSIONS: This result confirmed the contribution of the feature reduction
      algorithm and optimal technique for very sparse feature spaces, such as the
      sentence classification problem in the clinical guideline document.
AD  - Information and Communication Science, Semyung University, Jecheon, Korea.
FAU - Song, Mi Hwa
AU  - Song MH
FAU - Lee, Young Ho
AU  - Lee YH
FAU - Kang, Un Gu
AU  - Kang UG
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Korea (South)
TA  - Healthc Inform Res
JT  - Healthcare informatics research
JID - 101534553
PMC - PMC3633167
OID - NLM: PMC3633167
OTO - NOTNLM
OT  - Data Mining
OT  - Information Storage and Retrieval
OT  - Knowledge Bases
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
PHST- 2012/10/15 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/03/21 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.4258/hir.2013.19.1.16 [doi]
PST - ppublish
SO  - Healthc Inform Res. 2013 Mar;19(1):16-24. doi: 10.4258/hir.2013.19.1.16. Epub
      2013 Mar 31.

PMID- 23626913
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2093-3681 (Print)
IS  - 2093-3681 (Linking)
VI  - 19
IP  - 1
DP  - 2013 Mar
TI  - Informatics as tool for quality improvement: rapid implementation of guidance for
      the management of chronic kidney disease in England as an exemplar.
PG  - 9-15
LID - 10.4258/hir.2013.19.1.9 [doi]
AB  - OBJECTIVES: Chronic kidney disease (CKD) is an important cause of excess
      cardiovascular mortality and morbidity; as well as being associated with
      progression to end stage renal disease. This condition was largely unheard of in 
      English primary care prior to the introduction of pay-for-performance targets for
      management in 2006. A realist review of how informatics has been a mechanism for 
      national implementation of guidance for the improved management of CKD. METHODS: 
      Realist review of context, the English National Health Service with a drive to
      implement explicit national quality standards; mechanism, the informatics
      infrastructure and its alignment with policy objectives; and outcomes are
      describe at the micro-data and messaging, meso-patient care and quality
      improvement initiatives, and marco-national policy levels. RESULTS: At the
      micro-level computerised medical records can be used to reliably identify people 
      with CKD; though differences in creatinine assays, fluctuation in renal function,
      and errors in diabetes coding were less well understood. At the meso-level more
      aggressive management of blood pressure (BP) in individual patients appears to
      slow or reverse decline in renal function; technology can support case finding
      and quality improvement at the general practice level. At the macro-level
      informaticians can help ensure that leverage from informatics is incorporated in 
      policy, and ecological investigations inform if there is any association with
      improved health outcomes. CONCLUSIONS: In the right policy context informatics
      appears to be an enabler of rapid quality improvement. However, a causal
      relationship or generalisability of these findings has not been demonstrated.
AD  - Department of Health Care Management and Policy, University of Surrey, Guildford,
      UK.
FAU - de Lusignan, Simon
AU  - de Lusignan S
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Korea (South)
TA  - Healthc Inform Res
JT  - Healthcare informatics research
JID - 101534553
PMC - PMC3633175
OID - NLM: PMC3633175
OTO - NOTNLM
OT  - Computerized Medical Records Systems
OT  - Diabetes Mellitus
OT  - Health Policy
OT  - Kidney Function Tests
OT  - Medical Informatics
OT  - Quality of Health Care
OT  - Renal Insufficiency
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
PHST- 2013/03/12 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.4258/hir.2013.19.1.9 [doi]
PST - ppublish
SO  - Healthc Inform Res. 2013 Mar;19(1):9-15. doi: 10.4258/hir.2013.19.1.9. Epub 2013 
      Mar 31.

PMID- 23626903
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2042-0188 (Print)
IS  - 2042-0188 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr
TI  - Optimal treatment of diabetic retinopathy.
PG  - 61-71
LID - 10.1177/2042018813477886 [doi]
AB  - Diabetic retinopathy (DRP) is a common complication caused by multiple
      biochemical abnormalities of the underlying metabolic disease. While the
      incidence of DRP appears to decline due to evidence-based changes in diabetes
      management, the predicted increase in patients affected in particular by type 2
      diabetes may outweigh the positive trend. The diagnosis is based on the
      alterations of the vessels, usually indicating abnormalities of the blood-retinal
      barrier and increased vasoregression, but the neuroglial elements appear equally 
      vulnerable to the diabetic condition. Control of blood glucose, blood pressure
      and timely identification of coincident nephropathy are important to prevent
      progression to vision-threatening stages. Guidelines give specific indications
      for laser photocoagulation, in particular when euglycemia is no longer effective 
      in preventing progression to advanced stages. Intravitreal administration of
      antibodies directed against the single best characterized propagator of
      clinically significant macular edema, vascular endothelial growth factor (VEGF), 
      has become popular despite uncertainty about the patient subgroups which benefit 
      best and the optimum administration schedule. Multifactorial intervention beyond 
      glycemic control includes antihypertensive, lipid-lowering and antiaggregatory
      and is effective in type 2 diabetic patients with high-risk profiles, in
      particular coincident nephropathy.
AD  - 5th Medical Department, Universitatsmedizin Mannheim, Theodor-Kutzer-Ufer 1-3,
      68167 Mannheim, Germany.
FAU - Hammes, Hans-Peter
AU  - Hammes HP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ther Adv Endocrinol Metab
JT  - Therapeutic advances in endocrinology and metabolism
JID - 101532143
PMC - PMC3632004
OID - NLM: PMC3632004
OTO - NOTNLM
OT  - biomarkers
OT  - cardiovascular risk
OT  - diabetic retinopathy
OT  - treatment
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
AID - 10.1177/2042018813477886 [doi]
AID - 10.1177_2042018813477886 [pii]
PST - ppublish
SO  - Ther Adv Endocrinol Metab. 2013 Apr;4(2):61-71. doi: 10.1177/2042018813477886.

PMID- 23626902
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2042-0188 (Print)
IS  - 2042-0188 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr
TI  - The importance of local criteria in the diagnosis of metabolic syndrome in Saudi 
      Arabia.
PG  - 51-9
LID - 10.1177/2042018813483165 [doi]
AB  - The clustering of risk factors predisposing an individual to cardiovascular
      morbidity and mortality are usually referred to as the 'metabolic syndrome' (MS).
      Several definitions exist, causing confusion to practicing clinicians. A
      consensus definition was reached by several major organizations stating that the 
      presence of any three of five risk factors (abdominal obesity, elevated
      triglyceride, reduced high-density lipoprotein cholesterol, elevated blood
      pressure, and elevated fasting glucose) constitutes a diagnosis. Cutoff points
      for each of the risk factors were defined, taking into account ethnicity in case 
      of abdominal obesity. The prevalence of MS has been reported to be on the rise
      globally, and was mainly attributed to changes in diet and lifestyle, in addition
      to genetic factors and metabolic susceptibility. The risk of cardiovascular
      disease (CVD) has almost doubled and the risk of developing type 2 diabetes
      mellitus (T2DM) has increased fivefold in individuals diagnosed with MS. The
      prevalence T2DM in Saudi Arabia is increasing, making it an epidemic health
      hazard. Intervention programs to decrease the risk of progression from MS to full
      T2DM, and later CVD have been successful in many countries. Therefore, diagnosing
      MS is important to address risk factors and to prevent progression to the more
      serious chronic conditions. The prevalence of MS in Saudi adults varies from 16% 
      to 40% depending on the definition used and the study location. Use of the
      consensus definition might decrease the number of missed cases. However, in the
      absence of local cutoff points for various risk factors for MS, the use of ratios
      such as waist/hip ratio and low-density lipoprotein cholesterol/high-density
      lipoprotein cholesterol ratio, and family history of diabetes and CVD might aid
      diagnosis. Priority should be given to establishing national normal ranges,
      screening programs for hyperglycemia and hypertension, and community-directed
      programs to combat obesity and inactivity.
AD  - Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz
      University, PO Box 80205, Jeddah 21589, Jeddah, Saudi Arabia.
FAU - Bahijri, Suhad M
AU  - Bahijri SM
FAU - Al Raddadi, Rajaa M
AU  - Al Raddadi RM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ther Adv Endocrinol Metab
JT  - Therapeutic advances in endocrinology and metabolism
JID - 101532143
PMC - PMC3632005
OID - NLM: PMC3632005
OTO - NOTNLM
OT  - Saudis
OT  - criteria
OT  - definition
OT  - metabolic syndrome
OT  - prevalence
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
AID - 10.1177/2042018813483165 [doi]
AID - 10.1177_2042018813483165 [pii]
PST - ppublish
SO  - Ther Adv Endocrinol Metab. 2013 Apr;4(2):51-9. doi: 10.1177/2042018813483165.

PMID- 23626890
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2008-7802 (Print)
IS  - 2008-7802 (Linking)
VI  - 4
IP  - 3
DP  - 2013 Mar
TI  - Comparison of newborn outcomes in women with gestational diabetes mellitus
      treated with metformin or insulin: a randomised blinded trial.
PG  - 327-33
AB  - BACKGROUND: Few studies have been done on the use of metformin in pregnancy and
      their results were not similar, therefore this research is performed to compare
      neonatal outcomes of metformin and insulin in the treatment of gestational
      diabetes. METHODS: In this prospective randomized trial, 200 pregnant women
      within their 24(th) to 34(th) weeks of gestation with gestational diabetes,
      single fetus pregnancy, and in need of hyperglycemia treatment were entered and
      grouped as either metformin or insulin. Data related to maternal and neonatal
      outcomes were recorded and analyzed. RESULTS: Considering data recorded of HbA1c 
      at the beginning of pregnancy, pregnancy induced hypertension, preeclampsia,
      birth weight, dystocia, first and 5(th) min APGAR, neonatal sepsis, rout of
      delivery, liver function tests of neonate, hypoglycemia, anomaly, and still
      birth, there were no significant statistical differences between groups. The end 
      pregnancy HbA1c, maternal weight gain during pregnancy, preterm labor, neonatal
      jaundice, respiratory distress and hospitalization of infants were higher in
      insulin group. CONCLUSIONS: Considering data from this study, metformin is
      efficient to control hyperglycemia in pregnancy. It is suggested performing more 
      studies to evaluate long term side effects of metformin in pregnancy with higher 
      sample size and longer follow-up of newborns.
AD  - Department of Obstetrics and Gynecology, Kashan University of Medical Sciences,
      Kashan, Iran.
FAU - Mesdaghinia, Elahe
AU  - Mesdaghinia E
FAU - Samimi, Mansoureh
AU  - Samimi M
FAU - Homaei, Zhila
AU  - Homaei Z
FAU - Saberi, Farzaneh
AU  - Saberi F
FAU - Moosavi, Seyyed Gholam Abbas
AU  - Moosavi SG
FAU - Yaribakht, Mohammad
AU  - Yaribakht M
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Int J Prev Med
JT  - International journal of preventive medicine
JID - 101535380
PMC - PMC3634172
OID - NLM: PMC3634172
OTO - NOTNLM
OT  - Hemoglobin A1c
OT  - glucose tolerance test
OT  - hyperglycemia
OT  - pregnancy
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
PHST- 2012/05/25 [received]
PHST- 2012/09/03 [accepted]
PST - ppublish
SO  - Int J Prev Med. 2013 Mar;4(3):327-33.

PMID- 23626883
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130502
IS  - 2008-7802 (Print)
IS  - 2008-7802 (Linking)
VI  - 4
IP  - 3
DP  - 2013 Mar
TI  - Tooth brushing and cardiometabolic risk factors in adolescents: Is there an
      association? The CASPIAN-III study.
PG  - 271-8
AB  - BACKGROUND: A growing body of evidence supports an association between oral
      health and cardiovascular diseases and diabetes in adults. This study aimed to
      investigate the relationship between tooth brushing frequency and cardiometabolic
      risk factors in adolescents. METHODS: This nationwide population-based study was 
      conducted among 5258 Iranian students, aged 10-18 years, living in urban and
      rural areas of 27 provinces in Iran. The association of tooth brushing frequency 
      was assessed with anthropometric indexes and cardiometabolic risk factors after
      adjustment for potential confounders. RESULTS: Higher frequency of tooth brushing
      was associated with lower mean levels of low-density lipoprotein cholesterol
      (LDL-C) in both genders (P < 0.0001) and lower frequency of elevated LDL-C in
      girls (P = 0.03). The frequency of elevated blood pressure decreased with higher 
      tooth brushing frequency in boys (P = 0.03). After adjustment for many potential 
      cofounders such as age, gender, anthropometric indexes, screen time,
      socioeconomic status, and family history of non-communicable diseases,
      participants who washed their teeth at least once a day had lower risk of high
      LDL-C and low high-density lipoprotein cholesterol (HDL-C) levels in comparison
      to those who reported lower frequency of tooth brushing; some different
      associations were observed among girls and boys. CONCLUSIONS: Our findings
      suggest an independent and protective role of teeth brushing frequency for some
      cardiometabolic risk factors in adolescents. Increasing both the general health
      awareness and improving oral health should be considered in primordial and
      primary prevention of non-communicable diseases.
AD  - Department of Pediatrics, Child Growth and Development Research Center, Isfahan
      University of Medical Sciences, Isfahan, Iran.
FAU - Kelishadi, Roya
AU  - Kelishadi R
FAU - Mirmoghtadaee, Parisa
AU  - Mirmoghtadaee P
FAU - Qorbani, Mostafa
AU  - Qorbani M
FAU - Motlagh, Mohammad Esmaeil
AU  - Motlagh ME
FAU - Heshmat, Ramin
AU  - Heshmat R
FAU - Taslimi, Mahnaz
AU  - Taslimi M
FAU - Mahmoudarabi, Minoosadat
AU  - Mahmoudarabi M
FAU - Ardalan, Gelayol
AU  - Ardalan G
FAU - Larijani, Bagher
AU  - Larijani B
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - Int J Prev Med
JT  - International journal of preventive medicine
JID - 101535380
PMC - PMC3634165
OID - NLM: PMC3634165
OTO - NOTNLM
OT  - Blood pressure
OT  - cardiometabolic risk factors
OT  - lipid profile
OT  - obesity
OT  - prevention
OT  - tooth brushing
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
PHST- 2012/09/20 [received]
PHST- 2012/12/07 [accepted]
PST - ppublish
SO  - Int J Prev Med. 2013 Mar;4(3):271-8.

PMID- 23626843
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Gain-of-function mutations in the K(ATP) channel (KCNJ11) impair coordinated
      hand-eye tracking.
PG  - e62646
LID - 10.1371/journal.pone.0062646 [doi]
AB  - BACKGROUND: Gain-of-function mutations in the ATP-sensitive potassium channel can
      cause permanent neonatal diabetes mellitus (PNDM) or neonatal diabetes
      accompanied by a constellation of neurological symptoms (iDEND syndrome). Studies
      of a mouse model of iDEND syndrome revealed that cerebellar Purkinje cell
      electrical activity was impaired and that the mice exhibited poor motor
      coordination. In this study, we probed the hand-eye coordination of PNDM and
      iDEND patients using visual tracking tasks to see if poor motor coordination is
      also a feature of the human disease. METHODS: Control participants (n = 14),
      patients with iDEND syndrome (n = 6 or 7), and patients with PNDM (n = 7)
      completed three computer-based tasks in which a moving target was tracked with a 
      joystick-controlled cursor. Patients with PNDM and iDEND were being treated with 
      sulphonylurea drugs at the time of testing. RESULTS: No differences were seen
      between PNDM patients and controls. Patients with iDEND syndrome were
      significantly less accurate than controls in two of the three tasks. The greatest
      differences were seen when iDEND patients tracked blanked targets, i.e. when
      predictive tracking was required. In this task, iDEND patients incurred more
      discrepancy errors (p = 0.009) and more velocity errors (p= 0.009) than controls.
      CONCLUSIONS: These results identify impaired hand-eye coordination as a new
      clinical feature of iDEND. The aetiology of this feature is likely to involve
      cerebellar dysfunction. The data further suggest that sulphonylurea doses that
      control the diabetes of these patients may be insufficient to fully correct their
      neurological symptoms.
AD  - Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford,
      Oxfordshire, United Kingdom.
FAU - McTaggart, James S
AU  - McTaggart JS
FAU - Jenkinson, Ned
AU  - Jenkinson N
FAU - Brittain, John-Stuart
AU  - Brittain JS
FAU - Greeley, Siri A W
AU  - Greeley SA
FAU - Hattersley, Andrew T
AU  - Hattersley AT
FAU - Ashcroft, Frances M
AU  - Ashcroft FM
LA  - eng
GR  - P60 DK020595/DK/NIDDK NIH HHS/United States
GR  - UL1RR024999/RR/NCRR NIH HHS/United States
GR  - Medical Research Council/United Kingdom
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130423
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3633835
OID - NLM: PMC3633835
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/08 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.1371/journal.pone.0062646 [doi]
AID - PONE-D-12-39200 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 23;8(4):e62646. doi: 10.1371/journal.pone.0062646. Print 2013.

PMID- 23626772
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Parents of adolescents with type 1 diabetes--their views on information and
      communication needs and internet use. A qualitative study.
PG  - e62096
LID - 10.1371/journal.pone.0062096 [doi]
AB  - BACKGROUND: Little is known about parents' views on the use of online resources
      for information, education and support regarding childhood type 1 diabetes
      (T1DM). Considering the rapidly evolving new communication practices, parents'
      perspectives need to be explored. The main purpose of this paper was to explore
      parents' perceptions of their information-seeking, Internet use, and social
      networking online. This applied to their everyday life, including the contexts of
      T1DM and contact with peers. A second aim was to identify implications for future
      development of Internet use in this respect. METHODOLOGY/PRINCIPAL FINDINGS:
      Twenty-seven parents of 24 young persons aged 10-17 with T1DM participated in
      eight focus group interviews during their regular visits to a county hospital.
      Focus group discussions were video/audio-taped, transcribed and analysed using
      inductive qualitative content analysis. Self-reported demographic and medical
      information was also collected. A main theme was Finding things out, including
      two sub-themes, Trust and Suitability. The latter were key factors affecting
      parents' perceptions of online resources. Parents' choice of information source
      was related to the situation, previous experiences and knowledge about sources
      and, most importantly, the level of trust in the source. A constantly present
      background theme was Life situation, including two sub-themes, Roles and
      functions and Emotions and needs. Parents' information-seeking regarding T1DM
      varied greatly, and was closely associated with their life situation, the
      adolescents development phases and the disease trajectory.
      CONCLUSIONS/SIGNIFICANCE: Health practitioners and system developers need to
      focus on creating trust and suitability for users' needs. They should understand 
      the children's diverse needs, which depend on their life situation, on the
      children's development, and on the disease trajectory. To enhance trust in online
      health information and support services, the participation of local practitioners
      is crucial.
AD  - Division of Child and Adolescent Psychiatry, Department of Clinical and
      Experimental Medicine, Linkoping University, Linkoping, Sweden.
      sam.nordfeldt@liu.se
FAU - Nordfeldt, Sam
AU  - Nordfeldt S
FAU - Angarne-Lindberg, Teresia
AU  - Angarne-Lindberg T
FAU - Nordwall, Maria
AU  - Nordwall M
FAU - Krevers, Barbro
AU  - Krevers B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130423
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3633913
OID - NLM: PMC3633913
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/05 [received]
PHST- 2013/03/17 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.1371/journal.pone.0062096 [doi]
AID - PONE-D-13-07457 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 23;8(4):e62096. doi: 10.1371/journal.pone.0062096. Print 2013.

PMID- 23626757
OWN - NLM
STAT- In-Data-Review
DA  - 20130429
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Development of GMDR-GPU for Gene-Gene Interaction Analysis and Its Application to
      WTCCC GWAS Data for Type 2 Diabetes.
PG  - e61943
LID - 10.1371/journal.pone.0061943 [doi]
AB  - Although genome-wide association studies (GWAS) have identified a significant
      number of single-nucleotide polymorphisms (SNPs) associated with many complex
      human traits, the susceptibility loci identified so far can explain only a small 
      fraction of the genetic risk. Among other possible explanations, the lack of a
      comprehensive examination of gene-gene interaction (GxG) is often considered a
      source of the missing heritability. Previously, we reported a model-free
      Generalized Multifactor Dimensionality Reduction (GMDR) approach for detecting
      GxG in both dichotomous and quantitative phenotypes. However, the computational
      burden and less efficient implementation of the original programs make them
      impossible to use for GWAS. In this study, we developed a graphics processing
      unit (GPU)-based GMDR program (named GWAS-GPU), which is able not only to analyze
      GWAS data but also to run much faster than the earlier version of the GMDR
      program. As a demonstration of the program, we used the GMDR-GPU software to
      analyze a publicly available GWAS dataset on type 2 diabetes (T2D) from the
      Wellcome Trust Case Control Consortium. Through an exhaustive search of pair-wise
      interactions and a selected search of three- to five-way interactions conditioned
      on significant pair-wise results, we identified 24 core SNPs in six genes (FTO:
      rs9939973, rs9940128, rs9922047, rs1121980, rs9939609, rs9930506; TSPAN8:
      rs1495377; TCF7L2: rs4074720, rs7901695, rs4506565, rs4132670, rs10787472,
      rs11196205, rs10885409, rs11196208; L3MBTL3: rs10485400, rs4897366; CELF4:
      rs2852373, rs608489; RUNX1: rs445984, rs1040328, rs990074, rs2223046, rs2834970) 
      that appear to be important for T2D. Of these core SNPs, 11 in FTO, TSPAN8, and
      TCF7L2 have been reported to be associated with T2D, obesity, or both, providing 
      an independent replication of previously reported SNPs. Importantly, we
      identified three new susceptibility genes; i.e., L3MBTL3, CELF4, and RUNX1, for
      T2D, a finding that warrants further investigation with independent samples.
AD  - Institute of Bioinformatics, Zhejiang University, Hangzhou, China ; State Key
      Laboratory for Diagnosis and Treatment of Infection Diseases, First Affiliated
      Hospital, Zhejiang University School of Medicine, Hangzhou, China.
FAU - Zhu, Zhixiang
AU  - Zhu Z
FAU - Tong, Xiaoran
AU  - Tong X
FAU - Zhu, Zhihong
AU  - Zhu Z
FAU - Liang, Meimei
AU  - Liang M
FAU - Cui, Wenyan
AU  - Cui W
FAU - Su, Kunkai
AU  - Su K
FAU - Li, Ming D
AU  - Li MD
FAU - Zhu, Jun
AU  - Zhu J
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3633958
OID - NLM: PMC3633958
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/21 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.1371/journal.pone.0061943 [doi]
AID - PONE-D-12-36724 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 23;8(4):e61943. doi: 10.1371/journal.pone.0061943. Print 2013.

PMID- 23626740
OWN - NLM
STAT- In-Data-Review
DA  - 20130429
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Lifestyle behaviors of african american breast cancer survivors: a sisters
      network, inc. Study.
PG  - e61854
LID - 10.1371/journal.pone.0061854 [doi]
AB  - INTRODUCTION: African American breast cancer survivors experience poor cancer
      outcomes that may, in part, be remedied by healthy lifestyle choices. Few studies
      have evaluated the health and lifestyle behaviors of this population. The purpose
      of this study was to characterize the health and lifestyle habits of African
      American breast cancer survivors and evaluate the socio-demographic and medical
      correlates of these behaviors. METHODS: A total of 470 African American breast
      cancer survivors (mean age = 54 years) participated in an online survey. All
      participants completed measures assessing medical and demographic
      characteristics, physical activity, and sedentary behavior. Chi-square tests for 
      association, nonparametric tests, and logistic regression models were used to
      assess associations. All statistical tests were two sided. RESULTS: Almost half
      (47%) of the women met the current guidelines for physical activity, almost half 
      (47%) were obese, and many reported having high blood pressure (53%) or diabetes 
      (21%). The prevalence of high blood pressure, diabetes, and high cholesterol
      increased by age (P<0.001), and obese women had a higher prevalence of high blood
      pressure (63% vs. 44%) and diabetes (21% vs. 12%) than did non-obese women (all
      P<0.05). Obese women participated in significantly fewer total minutes of
      physical activity per week (100 minutes/week) than did non-obese women (150
      minutes/week; P<0.05). The number of comorbid conditions was associated with
      increased odds for physical inactivity (odds ratio = 1.40) and obesity (odds
      ratio = 2.22). CONCLUSION: Many African American breast cancer survivors had
      chronic conditions that may be exacerbated by poor lifestyle choices. Our results
      also provide evidence that healthy lifestyle interventions among obese African
      American breast cancer survivors are urgently needed.
AD  - Dorothy I. Height Center for Health Equity & Evaluation Research at the
      University of Houston/The University of Texas MD Anderson Cancer Center, Houston,
      Texas, United States of America.
FAU - Paxton, Raheem J
AU  - Paxton RJ
FAU - Taylor, Wendell C
AU  - Taylor WC
FAU - Chang, Shine
AU  - Chang S
FAU - Courneya, Kerry S
AU  - Courneya KS
FAU - Jones, Lovell A
AU  - Jones LA
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3633932
OID - NLM: PMC3633932
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/29 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/23 [epublish]
AID - 10.1371/journal.pone.0061854 [doi]
AID - PONE-D-12-37930 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 23;8(4):e61854. doi: 10.1371/journal.pone.0061854. Print 2013.

PMID- 23626461
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1178-1998 (Electronic)
IS  - 1176-9092 (Linking)
VI  - 8
DP  - 2013
TI  - Tolerability and efficacy of glycemic control with saxagliptin in older patients 
      (aged >/= 65 years) with inadequately controlled type 2 diabetes mellitus.
PG  - 419-30
LID - 10.2147/CIA.S41246 [doi]
AB  - PURPOSE: To assess safety and efficacy of saxagliptin in older patients with type
      2 diabetes mellitus (T2DM). PATIENTS AND METHODS: This was a post hoc analysis of
      pooled data from older patients (>/=65 years of age) from five 24-week phase III 
      trials: three studies of saxagliptin versus placebo as an add-on therapy to
      metformin, glyburide, or a thiazolidinedione; and two studies of saxagliptin
      versus placebo as monotherapy in drug-naive patients. Separate analyses were
      conducted on one study of initial combination therapy with saxagliptin plus
      metformin versus metformin monotherapy in drug-naive patients. The safety
      analysis population for the five-study pool included 428 patients >/= 65 years of
      age with baseline glycated hemoglobin (HbA(1c)) 7.0% to 10.5% who received
      saxagliptin 2.5 or 5 mg or placebo, and for the study of initial combination
      therapy included 69 patients >/= 65 years of age with baseline HbA(1c) 8.0% to
      12.0% who received saxagliptin 5 mg in combination with metformin or metformin
      monotherapy. The primary efficacy endpoint was change from baseline HbA(1c).
      RESULTS: In the five-study pool, the differences in the adjusted mean change from
      baseline HbA(1c) among older patients receiving saxagliptin versus placebo were
      -0.60% (95% confidence interval [CI], -0.99% to -0.21%) for saxagliptin 2.5 mg
      and -0.55% (-0.97% to -0.14%) for saxagliptin 5 mg; in the initial combination
      study, the difference was -1.22% (-2.27% to -0.17%) among older patients
      receiving saxagliptin 5 mg plus metformin versus metformin monotherapy. The
      results were generally similar in older and younger patients. Saxagliptin was
      well tolerated; the incidence and types of adverse events were similar for
      saxagliptin and comparators. Hypoglycemia was reported in 3.0% to 9.4% of
      patients receiving saxagliptin (0%-8.0% for comparators) and was confirmed
      (finger stick glucose </= 50 mg/dL, with associated symptoms) in 0% to 0.7%
      (0%-0.7% for comparators); hypoglycemic episodes did not vary by age category and
      did not require medical intervention. CONCLUSION: Saxagliptin was effective and
      well tolerated, with a low risk of hypoglycemia, when used as monotherapy, add-on
      therapy, or initial combination therapy with metformin in older patients with
      T2DM.
AD  - Bristol-Myers Squibb, Princeton, NJ, USA. chetan.karyekar@bms.com
FAU - Karyekar, Chetan S
AU  - Karyekar CS
FAU - Ravichandran, Shoba
AU  - Ravichandran S
FAU - Allen, Elsie
AU  - Allen E
FAU - Fleming, Douglas
AU  - Fleming D
FAU - Frederich, Robert
AU  - Frederich R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130416
PL  - New Zealand
TA  - Clin Interv Aging
JT  - Clinical interventions in aging
JID - 101273480
SB  - IM
PMC - PMC3632630
OID - NLM: PMC3632630
OTO - NOTNLM
OT  - DPP-4 inhibitor
OT  - clinical trial
OT  - dipeptidyl peptidase-4
OT  - hypoglycemia
OT  - metformin
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/16 [epublish]
AID - 10.2147/CIA.S41246 [doi]
AID - cia-8-419 [pii]
PST - ppublish
SO  - Clin Interv Aging. 2013;8:419-30. doi: 10.2147/CIA.S41246. Epub 2013 Apr 16.

PMID- 23626013
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1550-6606 (Electronic)
IS  - 0022-1767 (Linking)
VI  - 190
IP  - 11
DP  - 2013 Jun 1
TI  - gammadelta T Cells Are Essential Effectors of Type 1 Diabetes in the Nonobese
      Diabetic Mouse Model.
PG  - 5392-401
LID - 10.4049/jimmunol.1203502 [doi]
AB  - gammadelta T cells, a lineage of innate-like lymphocytes, are distinguished from 
      conventional alphabeta T cells in their Ag recognition, cell activation
      requirements, and effector functions. gammadelta T cells have been implicated in 
      the pathology of several human autoimmune and inflammatory diseases and their
      corresponding mouse models, but their specific roles in these diseases have not
      been elucidated. We report that gammadelta TCR(+) cells, including both the
      CD27(-)CD44(hi) and CD27(+)CD44(lo) subsets, infiltrate islets of prediabetic NOD
      mice. Moreover, NOD CD27(-)CD44(hi) and CD27(+)CD44(lo) gammadelta T cells were
      preprogrammed to secrete IL-17, or IFN-gamma upon activation. Adoptive transfer
      of type 1 diabetes (T1D) to T and B lymphocyte-deficient NOD recipients was
      greatly potentiated when gammadelta T cells, and specifically the CD27(-)
      gammadelta T cell subset, were included compared with transfer of alphabeta T
      cells alone. Ab-mediated blockade of IL-17 prevented T1D transfer in this
      setting. Moreover, introgression of genetic Tcrd deficiency onto the NOD
      background provided robust T1D protection, supporting a nonredundant, pathogenic 
      role of gammadelta T cells in this model. The potent contributions of CD27(-)
      gammadelta T cells and IL-17 to islet inflammation and diabetes reported in this 
      study suggest that these mechanisms may also underlie human T1D.
AD  - Programme in Genetics and Genome Biology, The Hospital for Sick Children,
      Toronto, Ontario MG5 1L7, Canada;
FAU - Markle, Janet G M
AU  - Markle JG
FAU - Mortin-Toth, Steve
AU  - Mortin-Toth S
FAU - Wong, Andrea S L
AU  - Wong AS
FAU - Geng, Liping
AU  - Geng L
FAU - Hayday, Adrian
AU  - Hayday A
FAU - Danska, Jayne S
AU  - Danska JS
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
SB  - AIM
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/04/26 [aheadofprint]
AID - jimmunol.1203502 [pii]
AID - 10.4049/jimmunol.1203502 [doi]
PST - ppublish
SO  - J Immunol. 2013 Jun 1;190(11):5392-401. doi: 10.4049/jimmunol.1203502. Epub 2013 
      Apr 26.

PMID- 23625864
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
DP  - 2013 Apr 29
TI  - Brand name or generic? What are the health professionals prescribed for treating 
      diabetes? A longitudinal analysis of the National Health Insurance reimbursement 
      database.
LID - 10.1002/pds.3445 [doi]
AB  - OBJECTIVE: This study aimed to explore whether physicians prescribe more
      brand-name oral hypoglycemic agents (OHA) for diabetic patients with medical
      training background (MP) than for general patients (GP). RESEARCH DESIGN AND
      METHODS: A longitudinal analysis of 1 000 000 National Health Insurance cohorts
      of 1998-2008 was conducted. Univariate and multivariate models were performed to 
      assess the associations of the outcome (the ratio of brand-name/generic odds in
      the MP group to that in the GP group) and the covariates, including patient
      medical training background, characteristics of patient, prescriber, and medical 
      settings, and market competition. A generalized estimating equation method was
      used to control the dependency of longitudinal data. RESULTS: A total of 46 850
      diabetic patients were prescribed with 2 703 149 OHA prescriptions during the
      study period. Compared with GP, MP had 1.37 times greater odds of being
      prescribed with brand-name instead of generic OHA, among whom pharmacists and
      physicians had the highest odds ratios of 2.78 (95%CI, 1.05-7.36) and 1.68
      (95%CI, 0.99-2.85), respectively. Patients' diabetes severity, prescribers' level
      of experience, medical settings that were publicly owned, had a higher
      accreditation level, and were located in a higher urbanized area, lower market
      competition, and earlier dates of prescription were positively associated with
      brand-name prescription. Among all medical sub-specialties, cardiologists were
      more likely to prescribe brand-name OHA. CONCLUSIONS: This study is the first to 
      demonstrate how a patients' medical training background, in addition to the
      characteristics of patients, prescribers, and medical settings, and market
      competition might influence physicians' prescribing choice of brand-name or
      generic OHA. Copyright (c) 2013 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
AD  - Department of Pharmacy, Taichung Veterans General Hospital, Taichung, Taiwan;
      College of Pharmacy, China Medical University, Taichung, Taiwan.
FAU - Liou, Wen-Shyong
AU  - Liou WS
FAU - Hsieh, Shu-Ching
AU  - Hsieh SC
FAU - Chang, Wai-Yuan
AU  - Chang WY
FAU - Wu, Grace Hui-Min
AU  - Wu GH
FAU - Huang, Hsu-Shan
AU  - Huang HS
FAU - Lee, Chuanfang
AU  - Lee C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/06/06 [received]
PHST- 2013/01/13 [revised]
PHST- 2013/03/06 [accepted]
AID - 10.1002/pds.3445 [doi]
PST - aheadofprint
SO  - Pharmacoepidemiol Drug Saf. 2013 Apr 29. doi: 10.1002/pds.3445.

PMID- 23625843
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1098-5530 (Electronic)
IS  - 0021-9193 (Linking)
VI  - 195
IP  - 13
DP  - 2013 Jul
TI  - Mutations in the Escherichia coli Ribosomal Protein L22 Selectively Suppress the 
      Expression of a Secreted Bacterial Virulence Factor.
PG  - 2991-9
LID - 10.1128/JB.00211-13 [doi]
AB  - Mutations in the ribosomal protein L22 that impair peptide-mediated translation
      arrest in Escherichia coli have been shown to reduce the expression of several
      genes, including secA, which encodes an ATPase that drives protein export via the
      Sec pathway. Here, we used a comparative proteomic approach to obtain insight
      into the global effects of the L22(Delta82-84) mutation on gene expression and
      protein synthesis. While the mutation did not affect or modestly affected the
      level of most soluble proteins, it dramatically reduced the level of antigen 43
      (Ag43), a secreted virulence factor that promotes autoaggregation. The reduced
      protein concentration correlated with a sharp decrease in the abundance and
      stability of Ag43 mRNA. We found that the overexpression of secA or the
      inactivation of genes that encode presecretory and membrane proteins restored
      Ag43 production in the L22 mutant strain. Furthermore, impairment of the Sec
      pathway in a wild-type strain reduced Ag43 production but did not significantly
      affect the synthesis of other presecretory proteins. Taken together, these
      results indicate that Ag43 gene expression is exquisitely sensitive to the status
      of the Sec machinery and strongly suggest that the L22 mutation decreases the
      Ag43 concentration indirectly by reducing secA expression. Our results imply the 
      existence of a novel regulatory mechanism in which the efficiency of protein
      export is coupled to gene expression and help to explain the modulation of SecA
      synthesis that has been observed in response to secretion stress.
AD  - Genetics and Biochemistry Branch, National Institute of Diabetes and Digestive
      and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
FAU - Yap, Mee-Ngan F
AU  - Yap MN
FAU - Bernstein, Harris D
AU  - Bernstein HD
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - United States
TA  - J Bacteriol
JT  - Journal of bacteriology
JID - 2985120R
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/04/26 [aheadofprint]
AID - JB.00211-13 [pii]
AID - 10.1128/JB.00211-13 [doi]
PST - ppublish
SO  - J Bacteriol. 2013 Jul;195(13):2991-9. doi: 10.1128/JB.00211-13. Epub 2013 Apr 26.

PMID- 23625798
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 2047-6310 (Electronic)
IS  - 2047-6302 (Linking)
DP  - 2013 Apr 29
TI  - Calorie-sweetened beverages and fructose: what have we learned 10 years later.
LID - 10.1111/j.2047-6310.2013.00171.x [doi]
AB  - WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Consumption of high-fructose corn syrup
      (HFCS) beverages may play a role in the epidemic of obesity. Fructose from sugar 
      (sucrose) is just as bad as from HFCS. Soft Drink consumption related to risk of 
      obesity, diabetes, and CVD in adults and children. WHAT THIS STUDY ADDS:
      Non-alcoholic fatty liver increased by consuming fructose in containing
      beverages. Consumption of sugar sweetened beverages, fruit drinks and probably
      fruit juice may mimic metabolic syndrome. Reducing intake of calorically
      sweetened beverages slows weight gain. BACKGROUND: Sugar-sweetened drinks and the
      fructose they provide are associated with several health problems. METHODS: Data 
      from the Nielsen Homescan and product content were analysed for sweetener type
      using the Gladson Nutrition Database. Meta-analyses and randomized clinical
      trials were used to evaluate outcomes of beverage and fructose intake. RESULTS:
      Over 70% of all foods contain some amounts of added sugar, and consumption of
      soft drinks has increased fivefold since 1950. Meta-analyses suggest that
      consumption of sugar-sweetened beverages is related to the risk of diabetes, the 
      metabolic syndrome and cardiovascular disease in adults and in children. Drinking
      two sugar-sweetened beverages per day for 6 months induced features of the
      metabolic syndrome and fatty liver. Randomized, controlled trials in children and
      adults lasting from 6 months to 2 years have shown that lowering the intake of
      soft drinks reduced weight gain. Genetic factors influence the weight gain when
      drinking soft drinks. CONCLUSION: Consumption of calorie-sweetened beverages and 
      the fructose they contain has continued to increase and may play a role in the
      epidemic of obesity, the metabolic syndrome and fatty liver disease. Reducing
      intake of soft drinks is associated with less weight gain and metabolic
      improvement as well.
CI  - (c) 2013 The Authors. Pediatric Obesity (c) 2013 International Association for
      the Study of Obesity.
AD  - Pennington Biomedical Research Center, Louisiana State University, Baton Rouge,
      LA, USA.
FAU - Bray, G A
AU  - Bray GA
FAU - Popkin, B M
AU  - Popkin BM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Pediatr Obes
JT  - Pediatric obesity
JID - 101572033
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/02/25 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/25 [accepted]
AID - 10.1111/j.2047-6310.2013.00171.x [doi]
PST - aheadofprint
SO  - Pediatr Obes. 2013 Apr 29. doi: 10.1111/j.2047-6310.2013.00171.x.

PMID- 23625788
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1439-0973 (Electronic)
IS  - 0300-8126 (Linking)
DP  - 2013 Apr 28
TI  - Aspergillus vertebral osteomyelitis in immunocompetent subjects: case report and 
      review of the literature.
AB  - Aspergillus spondylodiscitis (AS) is rare in immunocompetent (IC) patients. A
      65-year-old diabetic IC male subject presented with cervical AS 18 months after
      otomycosis. Two serological tests, mastoidectomy and biopsy of the sphenoid bone,
      were negative. A prevertebral biopsy identified A. flavus. The patient was
      successfully treated with voriconazole. Forty-three cases of AS in IC patients
      have been published. A predisposition was found in 84 % of cases. Fever was
      reported in 20 % of cases, whereas neurological defects were present in 41 %.
      Serology was inconsistently positive (5/7) and diagnosis was confirmed by biopsy 
      or surgery. A. fumigatus was the most frequently isolated species (74 %). All
      episodes were medically treated, associated with surgery in 57 % of cases, and 73
      % of patients fully recovered. AS must be discussed in IC patients presenting
      with risk factors, including diabetes mellitus. Biopsy is necessary to confirm
      diagnosis, since serology offers low sensitivity. Nevertheless, the prognosis is 
      good.
AD  - Infectious Diseases Unit, University Hospital of Caen, 14000, Caen, France.
FAU - Nicolle, A
AU  - Nicolle A
FAU - de la Blanchardiere, A
AU  - de la Blanchardiere A
FAU - Bonhomme, J
AU  - Bonhomme J
FAU - Hamon, M
AU  - Hamon M
FAU - Leclercq, R
AU  - Leclercq R
FAU - Hitier, M
AU  - Hitier M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Infection
JT  - Infection
JID - 0365307
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/06 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/04/28 [aheadofprint]
AID - 10.1007/s15010-013-0463-6 [doi]
PST - aheadofprint
SO  - Infection. 2013 Apr 28.

PMID- 23625696
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1559-0720 (Electronic)
IS  - 0163-4984 (Linking)
VI  - 153
IP  - 1-3
DP  - 2013 Jun
TI  - Antidiabetic and Pancreas-Protective Effects of Zinc Threoninate Chelate in
      Diabetic Rats may be Associated with its Antioxidative Stress Ability.
PG  - 291-8
LID - 10.1007/s12011-013-9675-y [doi]
AB  - Zinc exerts a wide range of important biological roles. The present study was
      carried out to investigate the effects of zinc threoninate chelate in blood
      glucose levels, lipid peroxidation, activities of antioxidant defense systems and
      nitrite concentration, and histology of the pancreas in diabetic rats. Wistar
      rats were intravenously injected with a single dose of streptozotocin to induce
      diabetes. Then, diabetic rats were administrated orally with zinc threoninate
      chelate (3, 6, and 9 mg/kg body weight) once daily for 7 weeks. Fasting blood
      glucose was monitored weekly. At the end of the experimental period, the diabetic
      rats were killed, and levels of serum insulin, malondialdehyde, and nitric oxide,
      activities of glutathione peroxidase, total superoxide dismutase,
      copper/zinc-superoxide dismutase, and nitric oxide synthase were determined;
      pancreas was examined histopathologically as well. Zinc threoninate chelate
      significantly reduced the blood glucose levels and significantly increased the
      serum insulin levels in diabetic rats. In addition, zinc threoninate chelate
      caused a significant increase in activities of antioxidant enzymes and
      significant decrease in nitrite concentration and malondialdehyde formation in
      the pancreas and serum of diabetic rats. These biochemical observations were
      supplemented by histopathological examination of the pancreas. These results
      suggested that the antidiabetic effect of zinc threoninate chelate may be related
      to its antioxidative stress ability in diabetic rats.
AD  - State Key Laboratory of Food Science and Technology, Nanchang University, 235
      Nanjing East Road, Nanchang, 330047, China.
FAU - Zhu, Kexue
AU  - Zhu K
FAU - Nie, Shaoping
AU  - Nie S
FAU - Li, Chuan
AU  - Li C
FAU - Huang, Jianqin
AU  - Huang J
FAU - Hu, Xiaobo
AU  - Hu X
FAU - Li, Wenjuan
AU  - Li W
FAU - Gong, Deming
AU  - Gong D
FAU - Xie, Mingyong
AU  - Xie M
LA  - eng
PT  - Journal Article
DEP - 20130427
PL  - United States
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/02/21 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/27 [aheadofprint]
AID - 10.1007/s12011-013-9675-y [doi]
PST - ppublish
SO  - Biol Trace Elem Res. 2013 Jun;153(1-3):291-8. doi: 10.1007/s12011-013-9675-y.
      Epub 2013 Apr 27.

PMID- 23625677
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - A rare cause of epigastric pain in a middle-aged man.
LID - 10.1136/bcr-2013-009605 [doi]
LID - bcr2013009605 [pii]
AB  - A 50-year-old man presents to the emergency department with epigastric pain and
      is found to have severe hypertension on clinical examination. After admission to 
      hospital, further investigation with CT imaging reveals the patient has an
      uncomplicated splenic artery dissection. Conservative management is chosen as
      advised by a vascular surgery team and the patient was subsequently discharged
      from hospital with warfarin anticoagulation and antihypertensive medicines. This 
      case report aims to build a profile of a patient who may present with splenic
      artery dissection and details our recommended management plan.
AD  - Department of Diabetes and Endocrinology, Maidstone Hopsital, Maidstone and
      Tunbridge Wells NHS Trust, Kent, UK. rannienahas@doctors.org.uk
FAU - Nahas, Rannie
AU  - Nahas R
FAU - Pain, Thomas
AU  - Pain T
FAU - Goulden, Peter
AU  - Goulden P
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - bcr-2013-009605 [pii]
AID - 10.1136/bcr-2013-009605 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 25;2013. pii: bcr2013009605. doi: 10.1136/bcr-2013-009605.

PMID- 23625528
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1460-2393 (Electronic)
IS  - 1460-2393 (Linking)
DP  - 2013 Apr 25
TI  - The novel use of commonly captured data to assess a district's diabetes service
      that encompasses both primary and secondary care.
AB  - AIM: To identify commonly captured data in the UK to look at the performance of a
      district's diabetes care that encompasses both primary and secondary care.
      METHODS: Primary care quality outcomes framework (QOF) measures for diabetes,
      referral rates for first appointment for specialist secondary care and emergency 
      admission rates for diabetes (Dr Foster/HES) were used to produce a performance
      index scoring system. Illustrative measures from QOF were total diabetes points, 
      DM23 attainment of HbA1c <7% (53 mmol/mol) and its exemption rate (number of
      patients excluded from analysis).The performance index was used to study the
      effectiveness of the Medway district diabetes service and this was compared to
      another district (Guildford) within the same Strategic Health Authority and
      nationally. RESULTS: Medway has the highest prevalence of Diabetes (6.1%) of the 
      8 Primary Care Trusts examined, the lowest achievement of diabetes QOF points
      (96.1%) and the lowest achievement of an HbA1c level <7% (53 mmol/mol) (54.3%).
      Exemption reporting was the 3rd highest. SAR for first diabetes out-patient
      appointment to the hospital was low at 281 (predicted 576) 48% of expected. The
      emergency admission rate was high at 225 (predicted 168) 133% of expected. Thus
      primary care diabetes needs to raise performance and implement a lower threshold 
      for OPD referral to prevent emergency admissions. CONCLUSION: It is possible to
      produce an assessment of diabetes care that transcends primary/secondary care
      that gives a true reflection of a district's performance which will be useful to 
      plan future health service provision.
AD  - From the King's College London, Academic Centre, First Floor, Henriette Raphael
      House, Guy's Campus, London SE1 1UL, Medway Maritime Hospital, Windmill Road,
      Gillingham, Kent, ME7 5NY and St Mary's Island Surgery, Edgeway, St Mary's
      Island, Chatham, Kent, ME4 3EP, UK.
FAU - Russell-Jones, E C
AU  - Russell-Jones EC
FAU - Gough, A
AU  - Gough A
FAU - Lawrence, S
AU  - Lawrence S
FAU - Scobie, I N
AU  - Scobie IN
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - hct097 [pii]
AID - 10.1093/qjmed/hct097 [doi]
PST - aheadofprint
SO  - QJM. 2013 Apr 25.

PMID- 23625527
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1460-2393 (Electronic)
IS  - 1460-2393 (Linking)
DP  - 2013 Apr 25
TI  - An unusual case of pituitary apoplexy.
AD  - From the Diabetes and Endocrinology Department, Prince Charles Hospital, Cwm Taf 
      Health Board, Merthyr Tydfil, Mid Glamorgan CF47 9DT, UK and Radiology
      Department, Prince Charles Hospital, Cwm Taf Health Board, Merthyr Tydfil, Mid
      Glamorgan CF47 9DT, UK.
FAU - Witczak, J K
AU  - Witczak JK
FAU - Davies, R
AU  - Davies R
FAU - Okosieme, O E
AU  - Okosieme OE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - hct094 [pii]
AID - 10.1093/qjmed/hct094 [doi]
PST - aheadofprint
SO  - QJM. 2013 Apr 25.

PMID- 23625435
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1011-601X (Print)
IS  - 1011-601X (Linking)
VI  - 26
IP  - 3
DP  - 2013 May
TI  - Relationship between serum nitric oxide and sialic acid in coexisted diabetes,
      hypertension and nephropathy.
PG  - 593-7
AB  - This study was designed to study the relationship between serum nitric oxide and 
      sialic acid in patients of diabetic nephropathy. Total 210 diabetic patients
      including 115 males and 95 females, suffering from diabetes and nephropathy (DN) 
      were selected followed by informed consent and approval from institutional
      ethical committee. Equal number of age and sex matched normal healthy subjects
      were selected without any known history of hyperglycemia, hypertension and renal 
      insufficiency as controls. Fasting blood samples from patients and controls were 
      collected and analyzed for serum nitric oxide, sialic acid, fasting blood glucose
      (FBG), serum urea, creatinine, HbA1c and golmerular filtration rate (GFR). The
      raised levels (p<0.05) of systolic and diastolic blood pressures, BMI, FBG,
      HbA1c, serum urea, creatinine and sialic acid were noted in DN patients as
      compared to controls. Significantly lower levels of GFR and serum nitric oxide
      (p<0.05) were observed in DN patients as compared to controls. Strong negative
      correlation was found between serum sialic acid and nitric oxide levels in
      patients diabetic nephropathy (p<0.05). The relationship between the levels of
      serum nitric oxide and sialic acid may be considered as a strong biochemical
      indicator for micro and macro vascular complications of diabetes such as
      hypertension and nephropathy. These parameters should be taken into account
      during screening procedures regarding identifications of the diabetic patients to
      get them rid of progressive renal impairment to ESRD.
AD  - The Karachi Institute of Biotechnology & Genetic Engineering, University of
      Karachi, Pakistan. smshahid@uok.edu.pk
FAU - Shahid, Syed Muhammad
AU  - Shahid SM
FAU - Jawed, Muhammad
AU  - Jawed M
FAU - Mahboob, Tabassum
AU  - Mahboob T
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Pharm Sci
JT  - Pakistan journal of pharmaceutical sciences
JID - 9426356
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PST - ppublish
SO  - Pak J Pharm Sci. 2013 May;26(3):593-7.

PMID- 23625299
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1615-6692 (Electronic)
IS  - 0340-9937 (Linking)
VI  - 38
IP  - 4
DP  - 2013 Jun
TI  - Impact of ischemia and scar on therapeutic benefit of myocardial
      revascularization.
PG  - 344-349
AB  - The question of how to optimally manage coronary artery disease (CAD) has been a 
      challenge for the cardiology community. The results of early, large randomized
      clinical trials (RCTs) comparing strategies of medical therapy alone versus
      revascularization plus medical therapy in patients with stable CAD suggested a
      survival advantage for a revascularization strategy in the setting of more
      advanced, higher-risk CAD (left main, three-vessel CAD), but a superiority of
      medical therapy in patients with more limited, relatively lower-risk CAD (one
      vessel, limited two-vessel CAD). The results of the Clinical Outcomes Utilizing
      Revascularization and Aggressive Drug Evaluation (COURAGE) and Bypass Angioplasty
      Revascularization Investigation 2 Diabetes (BARI 2D) trials redefined the
      management of CAD, supporting the concept that the impact of aggressively applied
      modern "medical therapy" on patient survival and patient-reported outcomes is not
      further improved by the addition of percutaneous intervention. On the other hand,
      RCTs incorporating fractional flow reserve have shown that this physiologic
      metric can help identify which patients will benefit from a revascularization
      strategy. This paradigm has been extended to the use of myocardial perfusion
      imaging-identified ischemia to determine which patients may have enhanced
      survival with early revascularization versus medical therapy. Although data from 
      a series of observational studies suggest that inducible ischemia on myocardial
      perfusion scintigraphy can identify revascularization candidates, several
      studies, including substudies from major RCTs, do not support this idea. Until
      RCTs comparing revascularization with medical therapy strategies are performed,
      many questions remain open. The correct thresholds for treatment, the metric to
      guide treatment, and how revascularization should be performed are as yet
      undefined.
AD  - Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart
      and Vascular Institute, Cleveland Clinic, Euclid Avenue, 44195, Cleveland, Ohio, 
      USA, hachamr@ccf.org.
FAU - Hachamovitch, R
AU  - Hachamovitch R
LA  - ENG
PT  - JOURNAL ARTICLE
TT  - Einfluss von Ischamien und Narben auf den therapeutischen Nutzen der
      Myokardrevaskularisierung.
TA  - Herz
JT  - Herz
JID - 7801231
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1007/s00059-013-3804-4 [doi]
PST - ppublish
SO  - Herz. 2013 Jun;38(4):344-349.

PMID- 23625296
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
DP  - 2013 Apr 28
TI  - The effect of diabetes mellitus and end-stage renal disease on the number of
      CD34+ cells in the blood.
AB  - The aim of this study was to investigate the effect of end-stage renal disease
      (ESRD) and diabetes mellitus (DM) on the number of stem cells in the peripheral
      blood. Sixty-two patients diagnosed with ESRD who had not received dialysis
      previously, 25 patients with a diagnosis of DM without nephropathy, and 21
      healthy volunteers were included in the study. The group diagnosed with ESRD was 
      divided into two groups. The first group (DM-CRD) consisted of 28 patients with
      DM who had developed chronic renal disease (CRD). The second group (NON-DM-CRD)
      consisted of 34 patients without DM who had CRD by etiology. The routine complete
      blood count, renal function, and number of CD34+ cells were determined for all of
      those involved in the study. The microalbumin/creatinine levels were measured,
      and glomerular filtration rates were calculated in all patients. The number of
      CD34+ cells was found to be significantly lower in the DM control group and
      DM-CRD group compared with the healthy group. No statistically significant
      difference was found between the NON-DM-CRD and the healthy control group. There 
      was a moderate negative correlation between the ratio of microalbumin/creatinine 
      and the number of CD34+ cells. A significant reduction in the number of CD34+
      cells was shown in subjects with DM and ESRD caused by diabetic nephropathy.
AD  - Department of Hematology, Erciyes Stem Cell Transplantation Hospital, Faculty of 
      Medicine, Erciyes University, 38039, Kayseri, Turkey, drcigdempala@gmail.com.
FAU - Pala, Cigdem
AU  - Pala C
FAU - Altun, Ilker
AU  - Altun I
FAU - Koker, Yavuz
AU  - Koker Y
FAU - Kurnaz, Fatih
AU  - Kurnaz F
FAU - Sivgin, Serdar
AU  - Sivgin S
FAU - Kocyigit, Ismail
AU  - Kocyigit I
FAU - Tanriverdi, Fatih
AU  - Tanriverdi F
FAU - Kaynar, Leylagul
AU  - Kaynar L
FAU - Elmali, Ferhan
AU  - Elmali F
FAU - Cetin, Mustafa
AU  - Cetin M
FAU - Eser, Bulent
AU  - Eser B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/02/04 [received]
PHST- 2013/04/07 [accepted]
PHST- 2013/04/28 [aheadofprint]
AID - 10.1007/s00277-013-1760-y [doi]
PST - aheadofprint
SO  - Ann Hematol. 2013 Apr 28.

PMID- 23625211
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
DP  - 2013 Apr 26
TI  - Diabetes and vascular disease: pathophysiology, clinical consequences, and
      medical therapy: part II.
AB  - In part II of this review, we describe the epidemiology and clinical consequences
      of vascular disease in patients with diabetes, and discuss the efficacy of risk
      factor modification and antiplatelet treatment. Specifically, evidence-based
      cardiovascular therapies are discussed through novel clinical insights on
      management of hyperglycaemia, hypertension, dyslipidaemia as well as platelet
      dysfunction. Recent trends in the incidence and outcomes of vascular disease in
      diabetes suggest that timely and effective implementation of therapies is making 
      a favourable impact.
AD  - Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School,
      75 Francis Street, Boston, MA 02115, USA.
FAU - Beckman, Joshua A
AU  - Beckman JA
FAU - Paneni, Francesco
AU  - Paneni F
FAU - Cosentino, Francesco
AU  - Cosentino F
FAU - Creager, Mark A
AU  - Creager MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - eht142 [pii]
AID - 10.1093/eurheartj/eht142 [doi]
PST - aheadofprint
SO  - Eur Heart J. 2013 Apr 26.

PMID- 23625197
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1539-0829 (Electronic)
IS  - 1534-4827 (Linking)
VI  - 13
IP  - 3
DP  - 2013 Jun
TI  - The future of thiazolidinedione therapy in the management of type 2 diabetes
      mellitus.
PG  - 329-41
LID - 10.1007/s11892-013-0378-8 [doi]
AB  - Since their approval, thiazolidinediones (TZDs) have been used extensively as
      insulin-sensitizers for the management of type 2 diabetes mellitus (T2DM).
      Activation of peroxisomal proliferator-activated receptor gamma (PPARgamma)
      nuclear receptors by TZDs leads to a vast spectrum of metabolic and
      antiinflammatory effects. In the past decade, clinicians and scientists across
      the fields of metabolism, diabetes, liver disease (NAFLD), atherosclerosis,
      inflammation, infertility, and even cancer have had high hopes about the
      potential for TZDs to treat many of these diseases. However, an increasing
      awareness about undesirable "off-target" effects of TZDs have made us rethink
      their role and be more cautious about the long-term benefits and risks related to
      their use. This review examines the most relevant work on the benefits and risks 
      associated with TZD treatment, with a focus on the only PPARgamma agonist
      currently available (pioglitazone), aiming to offer the reader a balanced
      overview about the current and future role of TZDs in the management of
      insulin-resistant states and T2DM.
AD  - Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The
      University of Florida North Florida/South Georgia Veterans Health System,
      Gainesville, Florida, USA.
FAU - Yau, Hanford
AU  - Yau H
FAU - Rivera, Kathya
AU  - Rivera K
FAU - Lomonaco, Romina
AU  - Lomonaco R
FAU - Cusi, Kenneth
AU  - Cusi K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Diab Rep
JT  - Current diabetes reports
JID - 101093791
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1007/s11892-013-0378-8 [doi]
PST - ppublish
SO  - Curr Diab Rep. 2013 Jun;13(3):329-41. doi: 10.1007/s11892-013-0378-8.

PMID- 23625196
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Linking)
DP  - 2013 Apr 27
TI  - The Q192R polymorphism of the paraoxonase 1 gene is a risk factor for coronary
      artery disease in Saudi subjects.
AB  - Paraoxonase-1 (PON1) is a HDL-bound antioxidant enzyme that protects LDL from
      oxidative modification. Discovery of the antioxidant properties of PON1 led to
      extensive research on its role in the initiation and progression of
      atherosclerosis. The Q192R (rs662; A/G) polymorphism, which results in the
      glutamine to arginine substitution at position 192, of the PON1 gene has been
      linked to increased atherosclerosis risk in several but not all population
      studies. Besides genetic factors, environmental variables and ethnicity have been
      implicated as factors responsible for the ambiguity in relating the PON1 gene
      with atherosclerotic risk. Here, we tested the association of the Q192R
      polymorphism with coronary artery disease (CAD) in Saudi ethnic subjects taking
      environmental factors into consideration. The genomic DNA samples from 121
      angiographically confirmed CAD cases and 108 normal healthy control subjects were
      genotyped by PCR-RFLP analysis. The distribution of QQ, QR, and RR genotypes was 
      significantly different between cases and controls (p < 0.005). The RR genotype
      was associated with CAD risk independently of several established risk factors
      including age, gender, smoking, obesity, and diabetes (OR 2.2, 1.4-7.4, p <
      0.01). Genotype-based stratification of demographic and biochemical data revealed
      that the RR genotype has proatherogenic properties. This study, thus, identifies 
      the Q192R polymorphism as an additional risk factor for CAD in the Saudi
      population and suggests that it may have prognostic value. The negative effect of
      this genetic variant is presumably due to the diminished ability of the RR
      variant genotype of PON1 to blunt LDL oxidation.
AD  - Department of Biochemistry College of Science, King Saud University, Riyadh,
      Saudi Arabia.
FAU - Hassan, Mohammed A
AU  - Hassan MA
FAU - Al-Attas, Omar S
AU  - Al-Attas OS
FAU - Hussain, Tajamul
AU  - Hussain T
FAU - Al-Daghri, Nasser M
AU  - Al-Daghri NM
FAU - Alokail, Majed S
AU  - Alokail MS
FAU - Mohammed, Abdul K
AU  - Mohammed AK
FAU - Vinodson, Benjamin
AU  - Vinodson B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/02/28 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/04/27 [aheadofprint]
AID - 10.1007/s11010-013-1665-z [doi]
PST - aheadofprint
SO  - Mol Cell Biochem. 2013 Apr 27.

PMID- 23625112
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 Apr 25
TI  - Blood pressure levels and risk of cardiovascular events and mortality in type-2
      diabetes: cohort study of 34 009 primary care patients.
AB  - OBJECTIVE:: The optimal blood pressure (BP) in persons with type-2 diabetes is
      debated. We investigated shapes of the associations of SBP and DBP levels with
      risk of cardiovascular events and mortality in a large primary care-based sample 
      of diabetic patients. METHODS:: We investigated all 34 009 consecutive
      cardiovascular disease-free type-2 diabetes patients aged 35 years or older (mean
      age 64 years) at 84 primary care centers in central Sweden between 1999 and 2008.
      We followed this cohort until the end of 2009 in national registries for the
      incidence of major cardiovascular events (a composite endpoint of myocardial
      infarction, stroke, heart failure, or cardiovascular mortality) or total
      mortality. RESULTS:: During up to 11 years of follow-up, 6344 patients (18.7%)
      had a first cardiovascular event, and 6235 died (18.3%). The associations of
      annually updated SBP and DBP with risk of major cardiovascular events were
      U-shaped. The lowest risk of cardiovascular events was observed at a SBP of
      135-139 mmHg and a DBP of 74-76 mmHg, and the lowest mortality risk at a SBP of
      142-150 mmHg and a DBP of 78-79 mmHg, in both antihypertensive drug-untreated and
      drug-treated persons. CONCLUSION:: In a large primary care-based sample of
      patients with type-2 diabetes, associations of SBP and DBP with risk of major
      cardiovascular events and mortality were U-shaped. This may have implications for
      risk stratification of persons with diabetes.
AD  - aDepartment of Medical Sciences, Uppsala University bUppsala Clinical Research
      Center cDepartment of Medical and Health Sciences, Linkoping University,
      Linkoping dAstraZeneca Nordic, Sodertalje eDepartment of Clinical Sciences; Lund 
      University, Malmo University Hospital, Malmo fDepartment of Public Health and
      Caring Sciences, Uppsala University, Uppsala, Sweden.
FAU - Sundstrom, Johan
AU  - Sundstrom J
FAU - Sheikhi, Reza
AU  - Sheikhi R
FAU - Ostgren, Carl J
AU  - Ostgren CJ
FAU - Svennblad, Bodil
AU  - Svennblad B
FAU - Bodegard, Johan
AU  - Bodegard J
FAU - Nilsson, Peter M
AU  - Nilsson PM
FAU - Johansson, Gunnar
AU  - Johansson G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1097/HJH.0b013e32836123aa [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 Apr 25.

PMID- 23625068
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 0303-4240 (Print)
IS  - 0303-4240 (Linking)
DP  - 2013 Apr 30
TI  - Free Fatty Acid Receptors and Their Role in Regulation of Energy Metabolism.
AB  - The free fatty acid receptor (FFAR) is a G protein-coupled receptor (GPCR)
      activated by free fatty acids (FFAs), which play important roles not only as
      essential nutritional components but also as signaling molecules in numerous
      physiological processes. In the last decade, FFARs have been identified by the
      GPCR deorphanization strategy derived from the human genome database. To date,
      several FFARs have been identified and characterized as critical components in
      various physiological processes. FFARs are categorized according to the chain
      length of FFA ligands that activate each FFAR; FFA2 and FFA3 are activated by
      short chain FFAs, GPR84 is activated by medium-chain FFAs, whereas FFA1 and
      GPR120 are activated by medium- or long-chain FFAs. FFARs appear to act as
      physiological sensors for food-derived FFAs and digestion products in the
      gastrointestinal tract. Moreover, they are considered to be involved in the
      regulation of energy metabolism mediated by the secretion of insulin and incretin
      hormones and by the regulation of the sympathetic nerve systems, taste
      preferences, and inflammatory responses related to insulin resistance. Therefore,
      because FFARs can be considered to play important roles in physiological
      processes and various pathophysiological processes, FFARs have been targeted in
      therapeutic strategies for the treatment of metabolic disorders including type 2 
      diabetes and metabolic syndrome. In this review, we present a summary of recent
      progress regarding the understanding of their physiological roles in the
      regulation of energy metabolism and their potential as therapeutic targets.
AD  - World-Leading Drug Discovery Research Center, Graduate School of Pharmaceutical
      Sciences, Kyoto University, 46-29 Yoshida-Shimoadachi-cho, Sakyo-ku, Kyoto,
      606-8501, Japan, t-hara@pharm.kyoto-u.ac.jp.
FAU - Hara, Takafumi
AU  - Hara T
FAU - Kimura, Ikuo
AU  - Kimura I
FAU - Inoue, Daisuke
AU  - Inoue D
FAU - Ichimura, Atsuhiko
AU  - Ichimura A
FAU - Hirasawa, Akira
AU  - Hirasawa A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130430
TA  - Rev Physiol Biochem Pharmacol
JT  - Reviews of physiology, biochemistry and pharmacology
JID - 0434624
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1007/112_2013_13 [doi]
PST - aheadofprint
SO  - Rev Physiol Biochem Pharmacol. 2013 Apr 30.

PMID- 23624993
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
LR  - 20130520
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 4
DP  - 2013
TI  - Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage
      renal disease: protocol for an investigator-initiated prospective, randomised,
      placebo-controlled, double-blinded, parallel intervention study.
LID - 10.1136/bmjopen-2013-002764 [doi]
LID - e002764 [pii]
AB  - INTRODUCTION: Diabetes is the leading cause of end-stage renal disease (ESRD).
      Owing to renal clearance, several antidiabetic agents cannot be used in patients 
      with ESRD. The present protocol describes an investigator-initiated trial aiming 
      to test safety and efficacy of treatment with the glucagon-like peptide-1
      receptor agonist liraglutide in patients with type 2 diabetes and
      dialysis-dependent ESRD. METHODS AND ANALYSIS: Twenty patients with type 2
      diabetes and ESRD will be compared with 20 matched patients with type 2 diabetes 
      and normal kidney function in a randomised, parallel, placebo-controlled (1 : 1),
      double-blinded setting. All participants will receive 12 weeks of daily treatment
      with liraglutide/placebo in an individually titrated dose of 0.6, 1.2 or 1.8 mg. 
      Over nine visits, plasma liraglutide, glycaemic control, beta-cell response,
      cardiovascular parameters, various biomarkers and adverse events will be
      assessed. The primary endpoint will be evaluated from dose-corrected plasma
      trough liraglutide concentration at the final trial visit to determine potential 
      accumulation in the ESRD group. ETHICS AND DISSEMINATION: The study has been
      approved by the Danish Medicines Agency, the Scientific-Ethical Committee of the 
      Capital Region of Denmark and the Danish Data Protection Agency. An external
      monitoring committee (The Good Clinical Practice Unit at Copenhagen University
      Hospitals) will oversee the study. The results of the study will be presented at 
      national and international scientific meetings, and publications will be
      submitted to peer-reviewed journals. TRIAL REGISTRATION: ClinicalTrials.gov
      Identifier: NCT01394341.
AD  - Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen,
      Denmark.
FAU - Idorn, Thomas
AU  - Idorn T
FAU - Knop, Filip K
AU  - Knop FK
FAU - Jorgensen, Morten
AU  - Jorgensen M
FAU - Jensen, Tonny
AU  - Jensen T
FAU - Resuli, Marsela
AU  - Resuli M
FAU - Hansen, Pernille M
AU  - Hansen PM
FAU - Christensen, Karl B
AU  - Christensen KB
FAU - Holst, Jens J
AU  - Holst JJ
FAU - Hornum, Mads
AU  - Hornum M
FAU - Feldt-Rasmussen, Bo
AU  - Feldt-Rasmussen B
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3641449
OID - NLM: PMC3641449
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2013-002764 [pii]
AID - 10.1136/bmjopen-2013-002764 [doi]
PST - epublish
SO  - BMJ Open. 2013 Apr 26;3(4). pii: e002764. doi: 10.1136/bmjopen-2013-002764. Print
      2013.

PMID- 23624964
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1533-9866 (Electronic)
IS  - 0029-7828 (Linking)
VI  - 68
IP  - 5
DP  - 2013 May
TI  - Obesity in pregnancy: a big problem and getting bigger.
PG  - 389-99
LID - 10.1097/OGX.0b013e31828738ce [doi]
AB  - Obesity has increased dramatically in the United States over the last several
      decades, with approximately 40% of women now considered overweight or obese.
      Obesity has been shown to be associated with poor pregnancy outcomes, including
      increased rates of cesarean delivery, preeclampsia, gestational diabetes, fetal
      macrosomia, stillbirth, and postterm pregnancy. In this review, we discuss the
      association of obesity with maternal, fetal, and pregnancy outcomes as well as
      the recommendations for care of the obese gravida. TARGET AUDIENCE: Obstetricians
      and gynecologists and family physicians. LEARNING OBJECTIVES: After completing
      the CME activity, physicians should be better able to describe the maternal,
      neonatal, and intrapartum complications associated with obesity in pregnancy and 
      implement additional changes to prenatal care appropriate for the obese gravida.
AD  - Department of Obstetrics and Gynecology, Oregon Health and Science University,
      Portland, OR 97239, USA. mission@ohsu.edu
FAU - Mission, John F
AU  - Mission JF
FAU - Marshall, Nicole E
AU  - Marshall NE
FAU - Caughey, Aaron B
AU  - Caughey AB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol Surv
JT  - Obstetrical & gynecological survey
JID - 0401007
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1097/OGX.0b013e31828738ce [doi]
PST - ppublish
SO  - Obstet Gynecol Surv. 2013 May;68(5):389-99. doi: 10.1097/OGX.0b013e31828738ce.

PMID- 23624822
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 32
IP  - 1
DP  - 2013 Jul
TI  - Crude extract of Ceriporia lacerata has a protective effect on
      dexamethasone-induced cytotoxicity in INS-1 cells via the modulation of PI3K/PKB 
      activity.
PG  - 179-86
LID - 10.3892/ijmm.2013.1364 [doi]
AB  - Excessive and/or long-term glucocorticoid therapy reduces beta-cell mass and
      induces hyperglycemia, which contribute to the development of steroidinduced
      diabetes. Ceriporia (C.) lacerata is one of the whiterot fungi and has been used 
      in bioremediations, such as lignocellulose degradation, in nature. The
      pharmacologic effect of C. lacerata on steroid-induced beta-cell toxicity is not 
      known. In this study, we evaluated the effect of a crude extract from a submerged
      cultivation of C. lacerata on the survival and apoptosis of INS-1 rat
      insulin-secreting cells exposed to dexamethasone (Dex), a synthetic diabetogenic 
      glucocorticoid. Treatment with the C. lacerata crude extract (CLCE) largely
      blocked the Dex-induced reduction in survival and apoptosis of INS-1 cells.
      Moreover, CLCE treatment inhibited Dex-induced protein kinase B (PKB)
      dephosphorylation without affecting Dex-induced extracellular signal-regulated
      protein kinase-1/2 dephosphorylation and MKP-1 upregulation. Importantly, the
      protective effect of CLCE on Dex-induced cytotoxicity in INS-1 cells was
      attenuated by LY294002, an inhibitor of PI3K/PKB. CLCE treatment, however, did
      not protect the INS-1 cells from the cytotoxic effects triggered by other
      insults, such as interleukin-1beta (an inflammatory cytokine), streptozotocin (a 
      diabetogenic drug), thapsigargin (a calcium mobilizing agent), and tunicamycin
      (an ER stress inducer). Collectively, these findings demonstrate for the first
      time the ability of CLCE to specifically protect INS-1 cells from Dex-induced
      cytotoxicity through the modulation of the PI3K/PKB pathway. It is suggested that
      CLCE may be applied for the prevention and/or treatment of steroid diabetes in
      which reduction of beta-cell survival and induction of beta-cell apoptosis play
      pathogenic roles.
AD  - Department of Medical Genetic Engineering, Keimyung University School of
      Medicine, Dalseo-gu, Daegu 704-701, Republic of Korea.
FAU - Kim, Ji-Hye
AU  - Kim JH
FAU - Park, Yu-Kyoung
AU  - Park YK
FAU - Kim, Ji-Eun
AU  - Kim JE
FAU - Lee, Sam-Pin
AU  - Lee SP
FAU - Kim, Byoung-Cheon
AU  - Kim BC
FAU - Jang, Byeong-Churl
AU  - Jang BC
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/10/18 [received]
PHST- 2012/12/14 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.3892/ijmm.2013.1364 [doi]
PST - ppublish
SO  - Int J Mol Med. 2013 Jul;32(1):179-86. doi: 10.3892/ijmm.2013.1364. Epub 2013 Apr 
      26.

PMID- 23624817
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 139
IP  - 2
DP  - 2013 Jun
TI  - Adiponectin pathway polymorphisms and risk of breast cancer in African Americans 
      and Hispanics in the Women's Health Initiative.
PG  - 461-8
LID - 10.1007/s10549-013-2546-6 [doi]
AB  - Adiponectin, a protein secreted by the adipose tissue, is an endogenous insulin
      sensitizer with circulating levels that are decreased in obese and diabetic
      subjects. Recently, circulating levels of adiponectin have been correlated with
      breast cancer risk. Our previous work showed that polymorphisms of the
      adiponectin pathway are associated with breast cancer risk. We conducted the
      first study of adiponectin pathways in African Americans and Hispanics in the
      Women's Health Initiative SNP Health Association Resource cohort of 3,642
      self-identified Hispanic women and 8,515 self-identified African American women
      who provided consent for DNA analysis. Single nucleotide polymorphisms (SNPs)
      from three genes were included in this analysis: ADIPOQ, ADIPOR1, and ADIPOR2.
      The genome-wide human SNP array 6.0 (909,622 SNPs) ( www.affymetrix.com ) was
      used. We found that rs1501299, a functional SNP of ADIPOQ that we previously
      reported was associated with breast cancer risk in a mostly Caucasian population,
      was also significantly associated with breast cancer incidence (HR for the GG/TG 
      genotype: 1.23; 95 % CI 1.059-1.43) in African American women. We did not find
      any other SNPs in these genes to be associated with breast cancer incidence. This
      is the first study assessing the role of adiponectin pathway SNPs in breast
      cancer risk in African Americans and Hispanics. RS1501299 is significantly
      associated with breast cancer risk in African American women. As the rates of
      obesity and diabetes increase in African Americans and Hispanics, adiponectin and
      its functional SNPs may aid in breast cancer risk assessment.
AD  - Division Hematology/Oncology, Department of Medicine, Northwestern University,
      676 North St. Clair Street, Suite 850, Chicago, IL, 60611, USA,
      v-kaklamani@northwestern.edu.
FAU - Kaklamani, Virginia G
AU  - Kaklamani VG
FAU - Hoffmann, Thomas J
AU  - Hoffmann TJ
FAU - Thornton, Timothy A
AU  - Thornton TA
FAU - Hayes, Geoffrey
AU  - Hayes G
FAU - Chlebowski, Rowan
AU  - Chlebowski R
FAU - Van Horn, Linda
AU  - Van Horn L
FAU - Mantzoros, Christos
AU  - Mantzoros C
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/04/19 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/04/30 [aheadofprint]
AID - 10.1007/s10549-013-2546-6 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2013 Jun;139(2):461-8. doi: 10.1007/s10549-013-2546-6.
      Epub 2013 Apr 30.

PMID- 23624762
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 Apr 26
TI  - Prevalence and predictors of diabetes and cardiometabolic risk among construction
      workers in Ireland: The Construction Workers Health Trust screening study.
AB  - Construction workers (CW) are at increased risk for a range of chronic diseases. 
      We screened 983 CW for diabetes and cardiometabolic risk. The age range was 18-64
      years, with mean age of 36.3 years. Self-reported questionnaires, Finnish
      diabetes risk score and fasting blood tests were collected at the workplace. The 
      unadjusted prevalence of pre-diabetes and type 2 diabetes mellitus were 3.6% and 
      1.2%, respectively; 21% of CW had the metabolic syndrome (MetS). The majority
      were either overweight (48.3%) or obese (21.8%). In a regression model, age
      remained the strongest predictor of fasting glucose (p < 0.001). Pre-diabetes and
      diabetes mellitus were significantly associated with presence of the MetS [odds
      ratio (OR) 5.6; 95% confidence interval (CI): 2.8-11.5, p < 0.001 and OR 5.5; 95%
      CI: 1.6-18.7, p = 0.006, respectively]. Subjects engaged in greater physical
      activity outside of work had lower body mass index (26.9 vs. 28.8 kg/m2, p =
      0.03), waist circumference (95.8 vs. 98.1 cm, p = 0.03) and fasting serum
      triglycerides (1.1 vs. 1.4 mmol/L, p = 0.03) compared to those who were
      sedentary. Despite their youth and a physically demanding occupation, CW are at
      risk of cardiometabolic diseases. This risk increases with age and the MetS.
      Screening tools may be useful to identify those who are at risk.
AD  - Metabolic Research Unit, St James Hospital, Dublin, Ireland.
FAU - Thabit, Hood
AU  - Thabit H
FAU - Burns, Nicole
AU  - Burns N
FAU - Shah, Shabahat
AU  - Shah S
FAU - Brema, Imad
AU  - Brema I
FAU - Crowley, Vivion
AU  - Crowley V
FAU - Finnegan, Fran
AU  - Finnegan F
FAU - Daly, Brian
AU  - Daly B
FAU - Nolan, John J
AU  - Nolan JJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 1479164113479808 [pii]
AID - 10.1177/1479164113479808 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 Apr 26.

PMID- 23624761
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
DP  - 2013 Apr 26
TI  - Comparison of the abilities of the plasma triglyceride/high-density lipoprotein
      cholesterol ratio and the metabolic syndrome to identify insulin resistance.
AB  - This study compares the ability of an elevated triglyceride/high-density
      lipoprotein cholesterol (TG/HDL-C) ratio, using sex-specific cut-points, to
      identify insulin-resistant individuals within a population without known cardiac 
      disease or diabetes with that obtained using the diagnostic criteria of the
      metabolic syndrome (MetS). Measurements were made of waist circumference (WC),
      systolic and diastolic blood pressure, fasting plasma glucose, fasting plasma
      insulin (FPI), plasma TG and plasma HDL-C concentrations in 1102 women and 464
      men. These data were used to classify subjects as being insulin resistant (FPI
      concentration in the upper quartile) and having the MetS or an elevated TG/HDL-C 
      ratio (>2.5 and >3.5 for women and men, respectively). The sensitivity and
      specificity with which the two indices identified insulin-resistant subjects were
      similar (43% and 81% for TG/HDL-C ratio and 45% and 82% for MetS), as the number 
      of individuals was found with either an elevated TG/HDL-C ratio (n = 386) or the 
      MetS (n = 384). Eighty-one per cent of the individuals were identified
      concordantly. Cardio-metabolic risk profiles in 'low-risk' individuals identified
      by a low TG/HDL-C ratio were comparable to those who did not have the MetS, and
      this was also the case when comparing 'high-risk' groups identified by having the
      MetS or an elevated TG/HDL-C ratio. These findings suggest that TG/HDL-C
      concentration ratio is as adequate as MetS diagnosis to identify
      insulin-resistant subjects.
AD  - Hospital Universitario General San Martin, La Plata, Argentina.
FAU - Salazar, Martin R
AU  - Salazar MR
FAU - Carbajal, Horacio A
AU  - Carbajal HA
FAU - Espeche, Walter G
AU  - Espeche WG
FAU - Leiva Sisnieguez, Carlos E
AU  - Leiva Sisnieguez CE
FAU - March, Carlos E
AU  - March CE
FAU - Balbin, Eduardo
AU  - Balbin E
FAU - Dulbecco, Carlos A
AU  - Dulbecco CA
FAU - Aizpurua, Marcelo
AU  - Aizpurua M
FAU - Marillet, Alberto G
AU  - Marillet AG
FAU - Reaven, Gerald M
AU  - Reaven GM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research : official journal of the International
      Society of Diabetes and Vascular Disease
JID - 101234011
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 1479164113479809 [pii]
AID - 10.1177/1479164113479809 [doi]
PST - aheadofprint
SO  - Diab Vasc Dis Res. 2013 Apr 26.

PMID- 23624746
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1365-2346 (Electronic)
IS  - 0265-0215 (Linking)
VI  - 30
IP  - 7
DP  - 2013 Jul
TI  - Increased electrical nerve stimulation threshold of the sciatic nerve in patients
      with diabetic foot gangrene: A prospective parallel cohort study.
PG  - 435-40
LID - 10.1097/EJA.0b013e328360bd85 [doi]
AB  - CONTEXT: Peripheral neuropathy may affect nerve conduction in patients with
      diabetes mellitus. OBJECTIVE: This study was designed to test the hypothesis that
      the electrical stimulation threshold for a motor response of the sciatic nerve is
      increased in patients suffering from diabetic foot gangrene compared to
      non-diabetic patients. DESIGN: Prospective non-randomised trial with two parallel
      groups. SETTING: Two university-affiliated hospitals. PARTICIPANTS: Patients
      scheduled for surgical treatment of diabetic foot gangrene (n = 30) and
      non-diabetic patients (n = 30) displaying no risk factors for neuropathy
      undergoing orthopaedic foot or ankle surgery. MAIN OUTCOME MEASURE: The minimum
      current intensity required to elicit a typical motor response (dorsiflexion or
      eversion of the foot) at a pulse width of 0.1 ms and a stimulation frequency of 1
      Hz when the needle tip was positioned under ultrasound control directly adjacent 
      to the peroneal component of the sciatic nerve. RESULTS: The non-diabetic
      patients were younger [64 (SD 12) vs. 74 (SD 7) years] and predominantly female
      (23 vs. 8). The geometric mean of the motor stimulation threshold was 0.26 [95%
      confidence interval (95% CI) 0.24 to 0.28] mA in non-diabetic and 1.9 (95% CI 1.6
      to 2.2) mA in diabetic patients. The geometric mean of the electrical stimulation
      threshold was significantly (P < 0.001) increased by a factor of 7.2 (95% CI 6.1 
      to 8.4) in diabetic compared to non-diabetic patients. CONCLUSION: The electrical
      stimulation threshold for a motor response of the sciatic nerve is increased by a
      factor of 7.2 in patients with diabetic foot gangrene, which might hamper nerve
      identification.
AD  - From the Department of Anaesthesiology, Heart Centre Freiburg University, Bad
      Krozingen (CK, TH, GA) and the Department of Anaesthesiology, Marienhospital
      Gelsenkirchen, Gelsenkirchen (AS, CW), Germany.
FAU - Keyl, Cornelius
AU  - Keyl C
FAU - Held, Tanja
AU  - Held T
FAU - Albiez, Georg
AU  - Albiez G
FAU - Schmack, Astrid
AU  - Schmack A
FAU - Wiesenack, Christoph
AU  - Wiesenack C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Anaesthesiol
JT  - European journal of anaesthesiology
JID - 8411711
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1097/EJA.0b013e328360bd85 [doi]
PST - ppublish
SO  - Eur J Anaesthesiol. 2013 Jul;30(7):435-40. doi: 10.1097/EJA.0b013e328360bd85.

PMID- 23624652
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1473-6519 (Electronic)
IS  - 1363-1950 (Linking)
VI  - 16
IP  - 4
DP  - 2013 Jul
TI  - Sugar-sweetened beverages and cardio-metabolic disease risks.
PG  - 478-84
LID - 10.1097/MCO.0b013e328361c53e [doi]
AB  - PURPOSE OF REVIEW: Sucrose-sweetened beverages (SSB) have for decades been
      implicated in cardiometabolic diseases. The purpose of this review is to
      summarize recent epidemiological but particularly recent human intervention
      studies on the metabolic effects associated/induced by SSB. RECENT FINDINGS:
      Recent epidemiological studies support the positive association between SSB
      intake and enhanced risk for metabolic syndrome, type 2 diabetes, coronary heart 
      diseases, and stroke. From the human intervention studies rather similar results 
      are obtained with enhanced accumulation of fat in the liver, muscle, and in the
      visceral fat depot induced by SSB. Moreover, SSB induces enhanced levels of
      circulating triglycerides and enhanced de-novo lipogenesis in the liver. The
      specific effect of SSB on body weigh/obesity is still not completely elucidated
      but SSB enhances body weight/fat mass even though not to a significant degree in 
      all studies. Concerning the mechanisms for SSB to induce these metabolic
      aberrations most of the studies are in agreement with the fact that it is mainly 
      fructose (free or as part of the sucrose molecule) that is the main driver of
      these metabolic aberrations presumably primarily by inducing lipid synthesis in
      and release from the liver. SUMMARY: There are now convincing evidences for
      enhanced cardiometabolic risk after higher intake of SSB where both
      epidemiological studies and human intervention studies are pointing in the same
      direction. A so-called 'well tolerated' intake of SSB is not determined.
      Accordingly, intake of SSB should generally be reduced as much as possible to
      improve the health of the population.
AD  - Department of Internal Medicine and Endocrinology, Aarhus University Hospital,
      Aarhus, Denmark.
FAU - Richelsen, Bjorn
AU  - Richelsen B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Clin Nutr Metab Care
JT  - Current opinion in clinical nutrition and metabolic care
JID - 9804399
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1097/MCO.0b013e328361c53e [doi]
PST - ppublish
SO  - Curr Opin Clin Nutr Metab Care. 2013 Jul;16(4):478-84. doi:
      10.1097/MCO.0b013e328361c53e.

PMID- 23624627
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1522-1539 (Electronic)
IS  - 0363-6135 (Linking)
DP  - 2013 Apr 26
TI  - Adenylyl Cyclase Type 5 in Cardiac Disease, Metabolism and Aging.
AB  - G-protein coupled receptor/adenylyl cyclase (AC)/cAMP signaling is crucial for
      all cellular responses to physiological and pathophysiological stimuli. There are
      9 isoforms of membrane-bound AC, with type 5 being one of the two major isoforms 
      in the heart. Since the role of AC in the heart in regulating cAMP and acute
      changes in inotropic and chronotropic state are well known, this review will
      address our current understanding of the distinct regulatory role of the AC5
      isoform in response to chronic stress. Transgenic overexpression of AC5 in
      cardiomyocytes of the heart (AC5-Tg) improves baseline cardiac function, but
      impairs the ability of the heart to withstand stress. For example, chronic
      catecholamine stimulation induces cardiomyopathy, which is more severe in AC5-Tg 
      mice, mediated through the AC5/SIRT1/FoxO3a pathway. Conversely, disrupting AC5, 
      i.e., AC5 knockout (KO) protects the heart from chronic catecholamine
      cardiomyopathy as well as the cardiomyopathies resulting from chronic pressure
      overload or aging. Moreover, AC5-KO results in a 30% increase in healthy
      lifespan, resembling the most widely studied model of longevity, i.e., calorie
      restriction. These two models of longevity share similar gene regulation in the
      heart, muscle, liver and brain that are both protected against diabetes and
      obesity. A pharmacological inhibitor of AC5 also provides protection against
      cardiac stress, diabetes and obesity. Thus, AC5 inhibition has novel, potential
      therapeutic applicability to several diseases, not only in the heart, but also in
      aging, diabetes and obesity.
AD  - 1UMDNJ - New Jersey Medical School.
FAU - Vatner, Stephen F
AU  - Vatner SF
FAU - Park, Misun
AU  - Park M
FAU - Yan, Lin
AU  - Yan L
FAU - Lee, Grace Jung Ah
AU  - Lee GJ
FAU - Lai, Lo
AU  - Lai L
FAU - Iwatsubo, Kousaku
AU  - Iwatsubo K
FAU - Ishikawa, Yoshihiro
AU  - Ishikawa Y
FAU - Pessin, Jeffrey E
AU  - Pessin JE
FAU - Vatner, Dorothy E
AU  - Vatner DE
LA  - ENG
GR  - R01 HL093481/HL/NHLBI NIH HHS/United States
GR  - R01 HL106511/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - ajpheart.00080.2013 [pii]
AID - 10.1152/ajpheart.00080.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Heart Circ Physiol. 2013 Apr 26.

PMID- 23624551
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 Apr 27
TI  - Gene expression analysis of human islets in a subject at onset of type 1
      diabetes.
AB  - Swollen islet cells have been repeatedly described at onset of type 1 diabetes,
      but the underlying mechanism of this observation, termed hydropic degeneration,
      awaits characterization. In this study, laser capture microdissection was applied
      to extract the islets from an organ donor that died at onset of type 1 diabetes
      and from an organ donor without pancreatic disease. Morphologic analysis revealed
      extensive hydropic degeneration in 73 % of the islets from the donor with type 1 
      diabetes. Expression levels of genes involved in apoptosis, ER stress, beta cell 
      function, and inflammation were analyzed in isolated and laser-captured islets by
      qPCR. The chemokine MCP-1 was expressed in islets from the donor with type 1
      diabetes while undetectable in the control donor. No other signs of inflammation 
      were detected. There were no signs of apoptosis on the gene expression level,
      which was also confirmed by negative immunostaining for cleaved caspase-8. There 
      was an increased expression of the transcription factor ATF4, involved in
      transcription of ER stress genes, in the diabetic islets, but no further signs of
      ER stress were identified. In summary, on the transcription level, islets at
      onset of type 1 diabetes in which many beta cells display hydropic degeneration
      show no obvious signs of apoptosis, ER stress, or inflammation, supporting the
      notion that these cells are responding normally to high glucose and eventually
      succumbing to beta cell exhaustion. Also, this study validates the feasibility of
      performing qPCR analysis of RNA extracted from islets from subjects with recent
      onset of T1D and healthy controls by laser capture microdissection.
AD  - IGP, Rudbeck Laboratory C11, Department of Immunology, Genetics and Pathology,
      Uppsala University, 751 85, Uppsala, Sweden.
FAU - Hopfgarten, Johan
AU  - Hopfgarten J
FAU - Stenwall, Per-Anton
AU  - Stenwall PA
FAU - Wiberg, Anna
AU  - Wiberg A
FAU - Anagandula, Mahesh
AU  - Anagandula M
FAU - Ingvast, Sofie
AU  - Ingvast S
FAU - Rosenling, Therese
AU  - Rosenling T
FAU - Korsgren, Olle
AU  - Korsgren O
FAU - Skog, Oskar
AU  - Skog O
LA  - ENG
GR  - U01 AI065192/AI/NIAID NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/03/11 [received]
PHST- 2013/04/21 [accepted]
PHST- 2013/04/27 [aheadofprint]
AID - 10.1007/s00592-013-0479-5 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 Apr 27.

PMID- 23624546
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Apr 28
TI  - Copeptin, a surrogate marker for arginine vasopressin, is associated with
      declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).
AB  - AIM/HYPOTHESIS: Arginine vasopressin (AVP), the hormone important for maintaining
      fluid balance, has been shown to cause kidney damage in rodent models of
      diabetes. We investigated the potential role of AVP in the natural course of
      kidney function decline in diabetes in an epidemiological study. METHODS: Plasma 
      copeptin, a surrogate for AVP, was measured in baseline samples from patients
      with type 2 diabetes treated in primary care and included in the Zwolle
      Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort. RESULTS: 
      Samples from 1,328 patients were available; 349 were analysed separately because 
      they used renin-angiotensin-aldosterone system inhibition (RAASi), which
      influences albumin/creatinine ratio (ACR) and estimated (e)GFR. In the other 979 
      patients (46% men, age 68 years [58-75], ACR 1.8 mg/mmol [0.9-5.7], eGFR 67 +/-
      14 ml min-1 1.73 m-2) baseline copeptin (5.3 pmol/l [3.2-9.5]) was significantly 
      associated with log e [ACR] and eGFR, even after adjustment for sex, age and risk
      factors for kidney function decline (standardised [std] beta 0.13, p < 0.001, std
      beta -0.20, p < 0.001 respectively). Follow-up data were available for 756
      patients (6.5 years [4.1-9.6]). Baseline copeptin was associated with increase in
      ACR (std beta 0.09, p = 0.02), but lost significance after adjustment (std beta
      0.07, p = 0.08). Copeptin was associated with a decrease in eGFR after adjustment
      (std beta -0.09, p = 0.03). The strength of the association of copeptin with
      change in eGFR was stronger than that of established risk factors for kidney
      function decline (e.g. BMI, HbA1c). In patients who used RAASi there was a
      significant association between baseline copeptin and ACR and eGFR, but not with 
      change in ACR and eGFR. CONCLUSIONS/INTERPRETATION: In patients with diabetes not
      using RAASi a higher baseline copeptin concentration is significantly associated 
      with higher baseline ACR and lower eGFR values and with a decline in eGFR during 
      follow-up. This last association is independent of, and stronger than, most
      traditional risk factors for kidney function decline.
AD  - Department of Nephrology, University of Groningen, University Medical Center
      Groningen, PO Box 30.001, 9700 RB, Groningen, the Netherlands,
      w.e.boertien@umcg.nl.
FAU - Boertien, W E
AU  - Boertien WE
FAU - Riphagen, I J
AU  - Riphagen IJ
FAU - Drion, I
AU  - Drion I
FAU - Alkhalaf, A
AU  - Alkhalaf A
FAU - Bakker, S J L
AU  - Bakker SJ
FAU - Groenier, K H
AU  - Groenier KH
FAU - Struck, J
AU  - Struck J
FAU - de Jong, P E
AU  - de Jong PE
FAU - Bilo, H J G
AU  - Bilo HJ
FAU - Kleefstra, N
AU  - Kleefstra N
FAU - Gansevoort, R T
AU  - Gansevoort RT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/11/16 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/28 [aheadofprint]
AID - 10.1007/s00125-013-2922-0 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Apr 28.

PMID- 23624545
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
DP  - 2013 Apr 25
TI  - Chronic Infection With Pseudomonas aeruginosa in Cystic Fibrosis: A Risk Factor
      for Nasal Polyposis After Lung Transplantation.
AB  - BACKGROUND: Nasal polyposis (NP) is common in cystic fibrosis (CF) patients. The 
      prevalence of the CF phenotype with NP after lung transplantation (LTx) is
      unknown. Risk factors for the development of NP after LTx are not well described.
      METHODS: CF patients with LTx at our center between November 1992 and December
      2009 were included. They were regularly investigated with nasal endoscopy and
      aspiration of sinus secretions with microbiological evaluation. Patients with and
      without development of NP were compared along the following parameters: gender,
      age, dF508, diabetes, acute rejection, NP at LTx, and microbiology of the sinuses
      before and after LTx. A multivariate Cox regression analysis was performed.
      RESULTS: The study included 94 patients; 21 were excluded because of incomplete
      data. Thirty-five (48%) of the remaining 73 patients developed NP. Mean time to
      diagnosis of NP was 4.2 (2.9-5.6) years after LTx. Prevalence of NP was 11% after
      the first year and 18%, 33%, and 44% after the first 2, 5, and 10 years,
      respectively. Patients with posttransplantation NP were younger, had NP before
      LTx, and were chronically infected with Pseudomonas aeruginosa (PA) in the nose. 
      Multivariate analysis demonstrated that chronic infection with PA was the only
      significant risk factor for the development of nasal polyps after LTx (hazards
      ratio, 7.2; 95% confidence interval, 2.1-24.2; P=0.001). CONCLUSIONS: In contrast
      to pretransplantation patients, NP is more common after LTx. Development of NP
      occurs throughout the whole observation time. Chronic sinonasal PA infection
      seems to be the only significant risk factor for NP after LTx.
AD  - 1 Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital
      of Zurich, Zurich, Switzerland. 2 Department of Pulmonary Medicine, University
      Hospital of Zurich, Zurich, Switzerland. 3 Address correspondence to: Markus
      Hofer, M.D., Department of Pulmonary Medicine, University Hospital of Zurich,
      Raemistrasse 100, 8091 Zurich, Switzerland.
FAU - Vital, Domenic
AU  - Vital D
FAU - Holzmann, David
AU  - Holzmann D
FAU - Boehler, Annette
AU  - Boehler A
FAU - Hofer, Markus
AU  - Hofer M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Transplantation
JT  - Transplantation
JID - 0132144
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1097/TP.0b013e31829282cd [doi]
PST - aheadofprint
SO  - Transplantation. 2013 Apr 25.

PMID- 23624531
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Cause-specific mortality in Scottish patients with colorectal cancer with and
      without type 2 diabetes (2000-2007).
PG  - 1531-41
LID - 10.1007/s00125-013-2917-x [doi]
AB  - AIMS/HYPOTHESIS: The objective of this study was to use Scottish national data to
      assess the influence of type 2 diabetes on (1) survival (overall and
      cause-specific) in multiple time intervals after diagnosis of colorectal cancer
      and (2) cause of death. METHODS: Data from the Scottish Cancer Registry were
      linked to data from a population-based national diabetes register. All people in 
      Scotland diagnosed with non-metastatic cancer of the colon or rectum in 2000-2007
      were included. The effect of pre-existing type 2 diabetes on survival over four
      discrete time intervals (<1, 1-2, 3-5 and >5 years) after cancer diagnosis was
      assessed by Cox regression. Cumulative incidence functions were calculated
      representing the respective probabilities of death from the competing causes of
      colorectal cancer, cardiovascular disease, other cancers and any other cause.
      RESULTS: Data were available for 19,505 people with colon or rectal cancer (1,957
      with pre-existing diabetes). Cause-specific mortality analyses identified a
      stronger association between diabetes and cardiovascular disease mortality than
      that between diabetes and cancer mortality. Beyond 5 years after colon cancer
      diagnosis, diabetes was associated with a detrimental effect on all-cause
      mortality after adjustment for age, socioeconomic status and cancer stage (HR
      [95% CI]: 1.57 [1.19, 2.06] in men; 1.84 [1.36, 2.50] in women). For patients
      with rectal cancer, diabetes was not associated with differential survival in any
      time interval. CONCLUSIONS/INTERPRETATION: Poorer survival observed for colon
      cancer associated with type 2 diabetes in Scotland may be explained by higher
      mortality from causes other than cancer.
AD  - Centre for Population Health Sciences, The University of Edinburgh, Teviot Place,
      Edinburgh, EH8 9AG, Scotland, UK, jeremy.walker@ed.ac.uk.
FAU - Walker, J J
AU  - Walker JJ
FAU - Brewster, D H
AU  - Brewster DH
FAU - Colhoun, H M
AU  - Colhoun HM
FAU - Fischbacher, C M
AU  - Fischbacher CM
FAU - Lindsay, R S
AU  - Lindsay RS
FAU - Wild, S H
AU  - Wild SH
CN  - Scottish Diabetes Research Network (SDRN) Epidemiology Group
LA  - eng
PT  - Journal Article
DEP - 20130427
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/11/26 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/04/27 [aheadofprint]
AID - 10.1007/s00125-013-2917-x [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1531-41. doi: 10.1007/s00125-013-2917-x. Epub 2013
      Apr 27.

PMID- 23624530
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Prevalence of monogenic diabetes in the population-based Norwegian Childhood
      Diabetes Registry.
PG  - 1512-9
LID - 10.1007/s00125-013-2916-y [doi]
AB  - AIMS/HYPOTHESIS: Monogenic diabetes (MD) might be misdiagnosed as type 1
      diabetes. The prevalence of MD among children with apparent type 1 diabetes has
      not been established. Our aim was to estimate the prevalence of common forms of
      MD in childhood diabetes. METHODS: We investigated 2,756 children aged 0-14 years
      with newly diagnosed diabetes who had been recruited to the nationwide
      population-based Norwegian Childhood Diabetes Registry (NCDR), from July 2002 to 
      March 2012. Completeness of ascertainment was 91%. Children diagnosed with
      diabetes who were under12 months of age were screened for mutations in KCNJ11,
      ABCC8 and INS. Children without GAD and protein tyrosine phosphatase-like protein
      antibodies were screened in two ways. Those who had a parent with diabetes were
      screened for mutations in HNF1A, HNF4A, INS and MT-TL1. Children with HbA1c <7.5%
      (<58 mmol/mol) and no insulin requirement were screened for mutations in GCK.
      Finally, we searched the Norwegian MODY Registry for children with genetically
      verified MD. RESULTS: We identified 15 children harbouring a mutation in HNF1A,
      nine with one in GCK, four with one in KCNJ11, one child with a mutation in INS
      and none with a mutation in MT-TL1. The minimum prevalence of MD in the NCDR was 
      therefore 1.1%. By searching the Norwegian MODY Registry, we found 24 children
      with glucokinase-MODY, 15 of whom were not present in the NCDR. We estimated the 
      minimum prevalence of MD among Norwegian children to be 3.1/100,000.
      CONCLUSIONS/INTERPRETATION: This is the first prevalence study of the common
      forms of MD in a nationwide, population-based registry of childhood diabetes. We 
      found that 1.1% of patients in the Norwegian Childhood Diabetes Registry had MD.
AD  - KG Jebsen Center for Diabetes Research, Department of Clinical Science,
      University of Bergen, Bergen, Norway.
FAU - Irgens, H U
AU  - Irgens HU
FAU - Molnes, J
AU  - Molnes J
FAU - Johansson, B B
AU  - Johansson BB
FAU - Ringdal, M
AU  - Ringdal M
FAU - Skrivarhaug, T
AU  - Skrivarhaug T
FAU - Undlien, D E
AU  - Undlien DE
FAU - Sovik, O
AU  - Sovik O
FAU - Joner, G
AU  - Joner G
FAU - Molven, A
AU  - Molven A
FAU - Njolstad, P R
AU  - Njolstad PR
LA  - eng
PT  - Journal Article
DEP - 20130427
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/17 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/27 [aheadofprint]
AID - 10.1007/s00125-013-2916-y [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1512-9. doi: 10.1007/s00125-013-2916-y. Epub 2013
      Apr 27.

PMID- 23624504
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 434
IP  - 4
DP  - 2013 May 17
TI  - Where do health benefits of flavonoids come from? Insights from flavonoid targets
      and their evolutionary history.
PG  - 701-4
LID - 10.1016/j.bbrc.2013.04.035 [doi]
LID - S0006-291X(13)00661-X [pii]
AB  - Flavonoid intake is negatively correlated with the incidence of some chronic
      diseases including cardiovascular diseases, type II diabetes, neurodegenerative
      diseases, and cancers. Thus, the molecular mechanisms underlying this correlation
      are of great interest. Although ample attention has been given to the free
      radical-scavenging potential of flavonoids, the poor bioavailability of exogenous
      flavonoids suggests that the direct antioxidant activity is unlikely responsible 
      for their favorable effects. This study comprehensively analyzed flavonoid
      targets. The results show that the main functions of these targets are associated
      with cancers and cardiovascular and metabolic diseases. Moreover, evolutionary
      analysis of these targets showed that approximately 1000 of the targets have
      homologues in human gut bacterial metagenomes. Clusters of orthologous groups of 
      proteins (COG) analysis indicated that most of these bacterial targets are
      associated with bacterial metabolism. Given that the metabolism of gut microbiota
      is coupled with the metabolism of the host, this finding implies that flavonoids 
      exert their benefits by regulating gut microbes. Therefore, the health benefits
      of flavonoids are well explained by their targets rather than their direct
      antioxidant potential.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - School of Life Sciences, Shandong Normal University, Jinan 250014, PR China;
      School of Life Sciences, Shandong University of Technology, Zibo 255049, PR
      China.
FAU - Lu, Ming-Feng
AU  - Lu MF
FAU - Xiao, Zheng-Tao
AU  - Xiao ZT
FAU - Zhang, Hong-Yu
AU  - Zhang HY
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/04/01 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/23 [aheadofprint]
AID - S0006-291X(13)00661-X [pii]
AID - 10.1016/j.bbrc.2013.04.035 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2013 May 17;434(4):701-4. doi:
      10.1016/j.bbrc.2013.04.035. Epub 2013 Apr 23.

PMID- 23624351
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1878-5867 (Electronic)
IS  - 0039-128X (Linking)
DP  - 2013 Apr 26
TI  - Cardiovascular disease risk in women with PCOS.
LID - S0039-128X(13)00091-3 [pii]
LID - 10.1016/j.steroids.2013.04.009 [doi]
AB  - Cardiac disease is the number one killer in women. Adolescents and reproductive
      age women with PCOS have an increased prevalence of cardiovascular risk factors. 
      These include obesity, impaired glucose tolerance, diabetes, hypertension, mood
      disorders and metabolic syndrome. There is sufficient evidence to confirm the
      presence of subclinical atherosclerosis in women with PCOS compared to age
      matched controls. There are, however, few prospective studies examining non-fatal
      and fatal cardiac events in women with well-defined PCOS. Future directions of
      research should include longitudinal studies in peri- and post-menopausal women
      with prospectively defined PCOS to better estimate the risk of cardiac morbidity 
      and mortality in this high-risk population. In the meantime, regular screening
      for risk factors and timely early interventions are critical to reduce the
      overall risk burden.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Obstetrics and Gynecology, University of Pennsylvania, 3701 Market St, Suite 800,
      Philadelphia, PA 19104, USA. Electronic address: ADokras@obgyn.upenn.edu.
FAU - Dokras, Anuja
AU  - Dokras A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Steroids
JT  - Steroids
JID - 0404536
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/03/26 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/03/28 [accepted]
AID - S0039-128X(13)00091-3 [pii]
AID - 10.1016/j.steroids.2013.04.009 [doi]
PST - aheadofprint
SO  - Steroids. 2013 Apr 26. pii: S0039-128X(13)00091-3. doi:
      10.1016/j.steroids.2013.04.009.

PMID- 23624335
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
DP  - 2013 Apr 23
TI  - Clinical, pathophysiological and structure/function consequences of modification 
      of albumin by Amadori-glucose adducts.
LID - S0304-4165(13)00162-1 [pii]
LID - 10.1016/j.bbagen.2013.04.024 [doi]
AB  - BACKGROUND: The nonenzymatic condensation of glucose with albumin results in the 
      formation of albumin modified by Amadori glucose adducts, the principal form in
      which glycated albumin exists in vivo. SCOPE OF REVIEW: This review focuses on
      (a) the utility of measurement of Amadori-modified glycated albumin (AGA) as a
      biomarker in diabetes, where elevated levels attend the hyperglycemic state; (b) 
      the role of AGA as a causal factor in the pathogenesis of complications of
      diabetes; (c) effects on transport properties; and (d) structural and functional 
      consequences of the modification of albumin by Amadori glucose adducts. It does
      not discuss counterparts with respect to Advanced Glycation Endproducts (AGE),
      which may be found in other publications. MAJOR CONCLUSIONS: Nonenzymatic
      glycation of albumin, which is increased in diabetes, has clinical relevance and 
      pathophysiologic importance, with ramifications for the management of this
      disease, the development of its complications, and the transport of endogenous
      and exogenous ligands. GENERAL SIGNIFICANCE: Appreciation of the manifold
      consequences of AGA has afforded new avenues for assessing clinical management of
      diabetes, awareness of the impact of nonenzymatic glycation on albumin biology,
      insights into the pathogenesis of vascular complications of diabetes, and avenues
      of investigation of and intervention strategies for these complications. This
      article is part of a Special Issue on albumin. This article is part of a Special 
      Issue entitled Serum Albumin.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Glycadia, Inc., 1880 JFK Boulevard, Suite 200, Philadelphia, PA 19103, United
      States. Electronic address: drmpcohen@aol.com.
FAU - Cohen, Margo P
AU  - Cohen MP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/03/13 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/17 [accepted]
AID - S0304-4165(13)00162-1 [pii]
AID - 10.1016/j.bbagen.2013.04.024 [doi]
PST - aheadofprint
SO  - Biochim Biophys Acta. 2013 Apr 23. pii: S0304-4165(13)00162-1. doi:
      10.1016/j.bbagen.2013.04.024.

PMID- 23624294
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1095-8304 (Electronic)
IS  - 0195-6663 (Linking)
DP  - 2013 Apr 25
TI  - Roles for central leptin receptors in the control of meal size.
LID - S0195-6663(13)00154-2 [pii]
LID - 10.1016/j.appet.2013.04.017 [doi]
AB  - The adiposity hormone leptin has been implicated in the regulation of behavioral 
      and metabolic controls of body weight. Leptin receptors are found in multiple
      peripheral and central tissues, particularly within hypothalamic and brainstem
      neuronal populations. Central leptinergic signaling acts as an indirect control
      to modulate the feeding inhibitory potency of the direct controls of meal size.
      Mouse models of neuronal leptin loss and gain of function have helped to identify
      and characterize how central leptin contributes to the central control of food
      intake.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Departments of Medicine & Neuroscience, Albert Einstein College of Medicine,
      Diabetes Research and Training Center, New York Obesity Research Center, USA.
FAU - Schwartz, Gary J
AU  - Schwartz GJ
FAU - Azzara, Anthony V
AU  - Azzara AV
FAU - Heaner, Martica K
AU  - Heaner MK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Appetite
JT  - Appetite
JID - 8006808
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/07 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/04/18 [accepted]
AID - S0195-6663(13)00154-2 [pii]
AID - 10.1016/j.appet.2013.04.017 [doi]
PST - aheadofprint
SO  - Appetite. 2013 Apr 25. pii: S0195-6663(13)00154-2. doi:
      10.1016/j.appet.2013.04.017.

PMID- 23624165
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 58
DP  - 2013 Jul
TI  - Antioxidant effect of nondigestible levan and its impact on cardiovascular
      disease and atherosclerosis.
PG  - 281-6
LID - 10.1016/j.ijbiomac.2013.04.058 [doi]
LID - S0141-8130(13)00241-9 [pii]
AB  - Levan polysaccharide, a type of fructan, has been shown to favorably affect
      diabetes type 2 and hypercholesterolemia. Recent reports have indicated that
      excessive oxidative stress contributes to the development of atherosclerosis
      linked metabolic syndrome. The objective of this current study was to investigate
      the possible protection against oxidative stress linked atherosclerosis. A group 
      of twenty four male rats was divided into four subgroups; a normal diet group
      (Control), normal rats received levan (L), a high-cholesterol diet group (Chol)
      and a high-cholesterol diet with 5% (w/w) levan group. After the treatment
      period, the plasma antioxidant enzymes and lipid profiles were determined. Our
      results show that treatment with levan positively changed plasma antioxidant
      enzyme activities by increasing superoxide dismutase (SOD) and catalase (CAT) by 
      40% and 28%, respectively, in heart. Similarly, the treatment of Chol fed groups 
      with levan positively changed lipid profiles by decreasing total cholesterol,
      triglycerides and LDL-cholesterol by 50%, 38.33% and 64%, respectively. Thus may 
      have potential antioxidant effects and could protect against oxidative stress
      linked atherosclerosis.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Biochemistry Laboratory, Faculty of Sciences of Sfax, PB 802, 3018 Sfax, Tunisia.
      Electronic address: imenbiologie@yahoo.fr.
FAU - Dahech, Imen
AU  - Dahech I
FAU - Harrabi, Bahira
AU  - Harrabi B
FAU - Hamden, Khaled
AU  - Hamden K
FAU - Feki, Abdelfattah
AU  - Feki A
FAU - Mejdoub, Hafedh
AU  - Mejdoub H
FAU - Belghith, Hafedh
AU  - Belghith H
FAU - Belghith, Karima Srih
AU  - Belghith KS
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/03/13 [received]
PHST- 2013/04/14 [revised]
PHST- 2013/04/17 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - S0141-8130(13)00241-9 [pii]
AID - 10.1016/j.ijbiomac.2013.04.058 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2013 Jul;58:281-6. doi: 10.1016/j.ijbiomac.2013.04.058. Epub
      2013 Apr 24.

PMID- 23624164
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1879-0003 (Electronic)
IS  - 0141-8130 (Linking)
VI  - 59
DP  - 2013 Aug
TI  - alpha-d-Glucosidase inhibitory activity of polysaccharide isolated from Acacia
      tortilis gum exudate.
PG  - 214-20
LID - 10.1016/j.ijbiomac.2013.04.057 [doi]
LID - S0141-8130(13)00240-7 [pii]
AB  - The study aims to explore the antihyperglycemic activity of Acacia tortilis
      polysaccharide isolated from the gum exudate. alpha-d-Glucosidase from
      Saccharomyces cerevisiae and rat small intestine was used as in vitro model to
      assess alpha-d-glucosidase inhibitory activity of the polysaccharide against
      yeast and mammalian enzyme. The reduction in postprandial blood glucose level
      after carbohydrate rich diet fed to Albino Wistar rats was employed as in vivo
      model of alpha-d-glucosidase inhibition. The study revealed alpha-d-glucosidase
      inhibitory activity of the polysaccharide in both in vitro as well as in vivo
      models. Therefore, polysaccharide isolated from A. tortilis plant gum exudate may
      be a potential drug for diabetes mellitus and its complications.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Chemistry Division, Forest Research Institute, Dehradun 248006, India; Department
      of Pharmacology, Pharmaceutical Division, S.G.R.R.I.T.S., Dehradun 248001, India.
FAU - Bisht, Swati
AU  - Bisht S
FAU - Kant, Ravi
AU  - Kant R
FAU - Kumar, Vineet
AU  - Kumar V
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Netherlands
TA  - Int J Biol Macromol
JT  - International journal of biological macromolecules
JID - 7909578
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/01/28 [received]
PHST- 2013/04/16 [revised]
PHST- 2013/04/17 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - S0141-8130(13)00240-7 [pii]
AID - 10.1016/j.ijbiomac.2013.04.057 [doi]
PST - ppublish
SO  - Int J Biol Macromol. 2013 Aug;59:214-20. doi: 10.1016/j.ijbiomac.2013.04.057.
      Epub 2013 Apr 24.

PMID- 23624121
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1095-6840 (Electronic)
IS  - 0016-6480 (Linking)
VI  - 189C
DP  - 2013 Apr 25
TI  - Mechanism of insulin production in canine bone marrow derived mesenchymal stem
      cells.
PG  - 1-6
LID - S0016-6480(13)00185-8 [pii]
LID - 10.1016/j.ygcen.2013.04.009 [doi]
AB  - Insulin is a critical hormone in the regulation of blood glucose levels and is
      produced exclusively by pancreatic islet beta-cells. Insulin deficiency due to
      reduced pancreatic islet beta-cell number underlies the progression of diabetes
      mellitus, prompting efforts to develop beta-cell replacement therapies. However, 
      precise information on beta-cell replacement and differentiation in canines is
      limited. In this study, we established insulin-producing cells from bone marrow
      derived mesenchymal stem cells transiently expressing canine pancreatic and
      duodenal homeobox 1 (Pdx1), beta cell transactivator 2 (Beta2) and V-maf avian
      musculoaponeurotic fibrosarcoma oncogene homolog A (Mafa) using a gene transfer
      technique. Real-time PCR analysis revealed an increase in insulin mRNA expression
      of transfected cells. And ELISA revealed that insulin protein expressed was
      detected in cytoplasmic fraction. Insulin immunostaining analysis was performed
      and observed in cytoplasmic fraction. These results suggest that co-transfection 
      of Pdx1, Beta2 and Mafa induce insulin production in canine BMSCs. Our findings
      provide a clue to basic research into the mechanisms underlying insulin
      production in the canines.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Veterinary Science, School of Veterinary Medicine, Nippon
      Veterinary and Life Science University, 1-7-1 Kyonancho, Musashino, Tokyo
      180-8602, Japan.
FAU - Takemitsu, Hiroshi
AU  - Takemitsu H
FAU - Zhao, Dongwei
AU  - Zhao D
FAU - Ishikawa, Shingo
AU  - Ishikawa S
FAU - Michishita, Masaki
AU  - Michishita M
FAU - Arai, Toshiro
AU  - Arai T
FAU - Yamamoto, Ichiro
AU  - Yamamoto I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Gen Comp Endocrinol
JT  - General and comparative endocrinology
JID - 0370735
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/18 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/04/11 [accepted]
AID - S0016-6480(13)00185-8 [pii]
AID - 10.1016/j.ygcen.2013.04.009 [doi]
PST - aheadofprint
SO  - Gen Comp Endocrinol. 2013 Apr 25;189C:1-6. doi: 10.1016/j.ygcen.2013.04.009.

PMID- 23624033
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1878-5867 (Electronic)
IS  - 0039-128X (Linking)
DP  - 2013 Apr 24
TI  - Interventions for the metabolic dysfunction in polycystic ovary syndrome.
LID - S0039-128X(13)00090-1 [pii]
LID - 10.1016/j.steroids.2013.04.008 [doi]
AB  - Polycystic ovary syndrome (PCOS) is associated with metabolic disturbances
      including obesity, insulin resistance, diabetes and dyslipidemia. Cardiometabolic
      risk should be assessed at regular intervals starting from diagnosis. A
      comprehensive clinical evaluation includes determination of body mass index,
      waist circumference, blood pressure and measurement of serum lipid and glucose
      levels in all women with PCOS. A standard 2-h 75g oral glucose tolerance test is 
      required for women with a body mass index over 25kg/m2 and with other risk
      factors for glucose intolerance. No long-term data are available for the risk or 
      benefit of any medical intervention for metabolic dysfunction of PCOS. For the
      initial management of metabolic dysfunction in PCOS, available guidelines
      recommend lifestyle intervention which improves androgen excess and insulin
      resistance without significant effect on glucose intolerance or dyslipidemia.
      Pharmacological interventions include insulin sensitizing agents and statins.
      Metformin is the most commonly prescribed insulin sensitizer in PCOS. Available
      randomized controlled trials suggest that metformin improves insulin resistance
      without any effect on body mass index, fasting glucose or lipid levels. Short
      term use of statins alone or in combination with metformin decreases total
      cholesterol, low-density lipoprotein-cholesterol and triglycerides in PCOS
      patients with dyslipidemia. Low dose oral contraception in PCOS appears not to be
      associated with clinically significant metabolic dysfunction.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Obstetrics and Gynecology, Hacettepe University School of Medicine,
      Ankara, Turkey.
FAU - Bozdag, Gurkan
AU  - Bozdag G
FAU - Yildiz, Bulent O
AU  - Yildiz BO
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Steroids
JT  - Steroids
JID - 0404536
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/04/04 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/05 [accepted]
AID - S0039-128X(13)00090-1 [pii]
AID - 10.1016/j.steroids.2013.04.008 [doi]
PST - aheadofprint
SO  - Steroids. 2013 Apr 24. pii: S0039-128X(13)00090-1. doi:
      10.1016/j.steroids.2013.04.008.

PMID- 23624031
OWN - NLM
STAT- Publisher
DA  - 20130527
IS  - 1878-5867 (Electronic)
IS  - 0039-128X (Linking)
DP  - 2013 Apr 25
TI  - Changes in the PCOS phenotype with age.
LID - S0039-128X(13)00087-1 [pii]
LID - 10.1016/j.steroids.2013.04.005 [doi]
AB  - Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder of
      reproductive-age women. The diagnosis of PCOS is mainly based on the following
      three components: (1) hyperandrogenism, (2) oligo-amenorrhea, and (3) the
      observation of polycystic ovaries on a sonogram. The comorbidities may include
      insulin resistance, type II diabetes mellitus, hypertension and cardiovascular
      disease. Importantly, the diagnostic criteria and complications related to PCOS
      are age-dependent. Androgen production in women may decrease because of ovarian
      aging or decreased production by the adrenal glands over time. The prevalence of 
      hirsutism and acne decreases with age. Ovarian volume and follicle number also
      decrease with age, with the age-related decrease in follicle number seemingly
      greater than that of ovarian volume. Aging may also be associated with increased 
      risk of insulin resistance and metabolic disturbances. Therefore, these
      age-related changes may affect the observed incidence and complications of PCOS. 
      In adolescent patients, the criteria described above pose particular diagnostic
      problems because the characteristics of normal puberty often overlap with the
      signs and symptoms of PCOS. Hyperandrogenism and chronic anovulation are the
      primary disturbances in younger women with PCOS; whereas, obesity, insulin
      resistance, and metabolic disturbances are predominant in older women with PCOS. 
      The deterioration of insulin resistance during the reproductive life of women
      with PCOS appears to be mainly attributable to the increase in obesity.
      Therefore, if body weight could be controlled properly, younger hyperandrogenic
      PCOS women might reduce their risk of insulin resistance and metabolic
      disturbances later in life.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical
      University, No.111, Sec. 3, Xinglong Road, Taipei 11696, Taiwan. Electronic
      address: hsumingi@yahoo.com.tw.
FAU - Hsu, Ming-I
AU  - Hsu MI
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Steroids
JT  - Steroids
JID - 0404536
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/03/21 [received]
PHST- 2013/03/23 [revised]
PHST- 2013/03/23 [accepted]
AID - S0039-128X(13)00087-1 [pii]
AID - 10.1016/j.steroids.2013.04.005 [doi]
PST - aheadofprint
SO  - Steroids. 2013 Apr 25. pii: S0039-128X(13)00087-1. doi:
      10.1016/j.steroids.2013.04.005.

PMID- 23624030
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1878-5867 (Electronic)
IS  - 0039-128X (Linking)
DP  - 2013 Apr 25
TI  - Ethnic differences in the phenotypic expression of polycystic ovary syndrome.
LID - S0039-128X(13)00088-3 [pii]
LID - 10.1016/j.steroids.2013.04.006 [doi]
AB  - Polycystic ovary syndrome (PCOS) is the most common endocrine problem affecting
      women of reproductive age and is investigated from many regions of the world.
      Some reports have indicated ethnic difference in its manifestation. This review
      addressed the evidences for ethnic variation in the expression of PCOS phenotypes
      and explored the potential ethnic-specific diagnosis of this syndrome. To
      determine ethnic variation, community prevalence and clinical and metabolic
      problems, including hyperandrogenism, oligomenorrhoea/amenorrhoea, polycystic
      ovaries, obesity, insulin resistance and the metabolic syndrome, had been
      compared from differing backgrounds and populations. Moreover, a link between
      ethnicity and variation in the metabolic phenotype of PCOS had also been
      identified. East Asian women with PCOS have a lower BMI and a milder
      hyperandrogenic phenotype, but with the highest prevalence of metabolic syndrome.
      South Asians in particular have a high prevalence of insulin resistance and
      metabolic syndrome, and are at risk for type 2 diabetes, with central obesity
      more than BMI reflecting their metabolic risk. African American and Hispanic
      women are more obese and more prone to metabolic problems. Besides, there is a
      higher prevalence of hirsutism among women of Middle Eastern and Mediterranean
      origin. Ethnically appropriate guidelines are needed for identifying
      anthropometric thresholds for better screening and diagnosis in high-risk ethnic 
      groups.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Reproductive Medical Center, Department of Obstetrics and Gynecology, Peking
      University Third Hospital, Beijing, China; Key Laboratory of Assisted
      Reproduction, Ministry of Education, Beijing, China; Beijing Key Laboratory of
      Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, China.
FAU - Zhao, Yue
AU  - Zhao Y
FAU - Qiao, Jie
AU  - Qiao J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Steroids
JT  - Steroids
JID - 0404536
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/02/27 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/03/17 [accepted]
AID - S0039-128X(13)00088-3 [pii]
AID - 10.1016/j.steroids.2013.04.006 [doi]
PST - aheadofprint
SO  - Steroids. 2013 Apr 25. pii: S0039-128X(13)00088-3. doi:
      10.1016/j.steroids.2013.04.006.

PMID- 23623967
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1528-0012 (Electronic)
IS  - 0016-5085 (Linking)
VI  - 144
IP  - 7
DP  - 2013 Jun
TI  - Drug-induced liver injury: icelandic lessons.
PG  - 1335-6
LID - 10.1053/j.gastro.2013.04.026 [doi]
LID - S0016-5085(13)00606-9 [pii]
AD  - Liver Disease Research Branch, Division of Digestive Diseases and Nutrition,
      National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
      National Institutes of Health, Bethesda, Maryland. Electronic address:
      HoofnagleJ@extra.niddk.nih.gov.
FAU - Hoofnagle, Jay H
AU  - Hoofnagle JH
FAU - Navarro, Victor J
AU  - Navarro VJ
LA  - eng
PT  - Editorial
DEP - 20130424
PL  - United States
TA  - Gastroenterology
JT  - Gastroenterology
JID - 0374630
SB  - AIM
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/04/24 [aheadofprint]
AID - S0016-5085(13)00606-9 [pii]
AID - 10.1053/j.gastro.2013.04.026 [doi]
PST - ppublish
SO  - Gastroenterology. 2013 Jun;144(7):1335-6. doi: 10.1053/j.gastro.2013.04.026. Epub
      2013 Apr 24.

PMID- 23623913
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 Apr 23
TI  - Risk Stratification of Resistant Hypertension in Chronic Kidney Disease.
LID - S0735-1097(13)01585-4 [pii]
LID - 10.1016/j.jacc.2013.03.048 [doi]
AD  - Joslin Diabetes Center, Boston, Massachusetts and; Cardiovascular Division,
      Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:
      lweinrauch@hms.harvard.edu.
FAU - Weinrauch, Larry A
AU  - Weinrauch LA
FAU - Desai, Akshay S
AU  - Desai AS
FAU - Skali, Hicham
AU  - Skali H
FAU - D'Elia, John A
AU  - D'Elia JA
LA  - ENG
PT  - EDITORIAL
DEP - 20130423
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/01/14 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/03/04 [accepted]
AID - S0735-1097(13)01585-4 [pii]
AID - 10.1016/j.jacc.2013.03.048 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 Apr 23. pii: S0735-1097(13)01585-4. doi:
      10.1016/j.jacc.2013.03.048.

PMID- 23623908
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
DP  - 2013 Apr 23
TI  - Prevalence and Prognostic Role of Resistant Hypertension in Chronic Kidney
      Disease Patients.
LID - S0735-1097(13)01583-0 [pii]
LID - 10.1016/j.jacc.2012.12.061 [doi]
AB  - OBJECTIVES: To evaluate in CKD prevalence and prognosis of true resistant
      hypertension (RH), that is, confirmed by ambulatory blood pressure (ABP)
      monitoring. BACKGROUND: In CKD, uncontrolled hypertension is a major risk factor 
      but no study has properly investigated the role of RH. METHODS: We prospectively 
      studied 436 hypertensive CKD patients under nephrology care. Four groups were
      constituted by combining 24h-ABP with diagnosis of RH (office BP >/=130/80 mmHg
      despite adherence to >/=3 full-dose antihypertensive drugs including a diuretic
      or >/=4 drugs): control (ABP<125/75 without RH), pseudoresistance (ABP<125/75
      with RH), sustained hypertension (ABP>/=125/75 without RH), true resistance
      (ABP>/=125/75 with RH). Endpoints of survival analysis were renal (end-stage
      renal disease or death), and cardiovascular events (fatal and non-fatal
      cardiovascular event). RESULTS: Age was 65+/-14 years, males 58%, diabetes 36%,
      cardiovascular disease 30%, median proteinuria 0.24 (interquartile range
      0.09-0.83) g/day, eGFR 43+/-20 mL/min/1.73m2, office BP 146+/-19/82+/-12 mmHg,
      24h-ABP 129+/-17/72+/-10 mmHg. True resistant patients were 22.9% and
      pseudoresistant 7.1%, while patients with sustained hypertension were 42.9% and
      controls 27.1%. Over 57 months of follow up, 109 cardiovascular events and 165
      renal events occurred. Compared to controls, cardiovascular risk [Hazard Ratio,
      (95% Confidence Interval)] was 1.24 (0.55-2.78) in pseudoresistance, 1.11
      (0.67-1.84) in sustained hypertension and 1.98 (1.14-3.43) in true resistance.
      Corresponding hazards for renal events were 1.18 (0.45-3.13), 2.14 (1.35-3.40)
      and 2.66 (1.62-4.37). CONCLUSIONS: In CKD, pseudoresistance is not associated
      with an increased cardio-renal risk and sustained hypertension predicts only
      renal outcome. True resistance is prevalent and identifies patients carrying the 
      highest cardiovascular risk.
CI  - Copyright (c) 2013 American College of Cardiology Foundation. Published by
      Elsevier Inc. All rights reserved.
AD  - Nephrology, Second University of Naples, Italy.
FAU - De Nicola, Luca
AU  - De Nicola L
FAU - Gabbai, Francis B
AU  - Gabbai FB
FAU - Agarwal, Rajiv
AU  - Agarwal R
FAU - Chiodini, Paolo
AU  - Chiodini P
FAU - Borrelli, Silvio
AU  - Borrelli S
FAU - Bellizzi, Vincenzo
AU  - Bellizzi V
FAU - Nappi, Felice
AU  - Nappi F
FAU - Conte, Giuseppe
AU  - Conte G
FAU - Minutolo, Roberto
AU  - Minutolo R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/10/11 [received]
PHST- 2012/11/26 [revised]
PHST- 2012/12/12 [accepted]
AID - S0735-1097(13)01583-0 [pii]
AID - 10.1016/j.jacc.2012.12.061 [doi]
PST - aheadofprint
SO  - J Am Coll Cardiol. 2013 Apr 23. pii: S0735-1097(13)01583-0. doi:
      10.1016/j.jacc.2012.12.061.

PMID- 23623902
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1090-2163 (Electronic)
IS  - 0008-8749 (Linking)
VI  - 282
IP  - 1
DP  - 2013 Mar
TI  - B7-H4.Ig inhibits the development of Type 1 diabetes by regulating Th17 cells in 
      NOD mice.
PG  - 1-8
LID - 10.1016/j.cellimm.2013.03.005 [doi]
LID - S0008-8749(13)00041-5 [pii]
AB  - Type 1 diabetes (T1D) is an autoimmune disease characterized by immunological
      destruction of insulin-producing pancreatic beta-cells and subsequent
      hyperglycemia. The non-obese diabetic (NOD) mouse strain spontaneously develops a
      disease similar to human T1D and is commonly used as an animal model for studying
      this disease. We have previously shown that the administration of
      B7-H4-immunoglobulin fusion protein (B7-H4.Ig), a newly identified T-cell
      co-inhibitory signaling molecule, blocks the onset of diabetes in NOD mice.
      However, the mechanism(s) by which B7-H4 protects NOD mice from T1D is not fully 
      understood. IL-17 is a pro-inflammatory cytokine, produced by Th17 cells, that
      activates T cells and other immune cells to produce a variety of cytokines and
      chemokines. Increasing evidence has shown that therapeutic agents targeting the
      IL-17 molecule or directly inhibiting IL-17-producing cells regulate autoimmune
      diabetes in NOD mice, suggesting that IL-17 is involved in the pathogenesis of
      this disease. In this study, we investigate whether B7-H4.Ig treatment inhibits
      the generation of Th17 cells which subsequently decreases IL-17 production and
      prevents the onset of T1D in NOD mice. Pre-diabetic female NOD mice were injected
      intraperitoneally with control mouse IgG or B7-H4.Ig starting at 4weeks of age
      for 12weeks. Our data showed that the frequency of Th17 cells in B7-H4.Ig-treated
      mice was significantly decreased. In addition, our data showed that
      B7-H4.Ig-treated mice had decreased levels of pro-inflammatory cytokines and
      Th17-associated cytokines, and an increased level of the potent Th17 inhibitor
      IFN-gamma. To further investigate the effect of B7-H4.Ig on differentiation of
      Th17 cells, we co-cultured splenocytes with Th17-polarizing cytokines in the
      absence or presence of B7-H4.Ig. Our results indicated that splenocytes, under
      the Th17 driving conditions in the presence of B7-H4.Ig, had significantly
      decreased the numbers of Th17 cells compared to cells co-cultured in the absence 
      of B7-H4.Ig. Together, this study suggests that blocking the generation of Th17
      cells with the administration of B7-H4.Ig effectively inhibits the development of
      T1D in NOD mice.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Surgery, University of British Columbia, Vancouver, BC, Canada.
FAU - Lee, I-Fang
AU  - Lee IF
FAU - Wang, Xiaojie
AU  - Wang X
FAU - Hao, Jianqiang
AU  - Hao J
FAU - Akhoundsadegh, Noushin
AU  - Akhoundsadegh N
FAU - Chen, Lieping
AU  - Chen L
FAU - Liu, Linda
AU  - Liu L
FAU - Langermann, Sol
AU  - Langermann S
FAU - Ou, Dawei
AU  - Ou D
FAU - Warnock, Garth L
AU  - Warnock GL
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - United States
TA  - Cell Immunol
JT  - Cellular immunology
JID - 1246405
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/08/14 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/04 [aheadofprint]
AID - S0008-8749(13)00041-5 [pii]
AID - 10.1016/j.cellimm.2013.03.005 [doi]
PST - ppublish
SO  - Cell Immunol. 2013 Mar;282(1):1-8. doi: 10.1016/j.cellimm.2013.03.005. Epub 2013 
      Apr 4.

PMID- 23623817
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
DP  - 2013 Apr 25
TI  - Correlation between inflammation state and successful medical cardioversion using
      bepridil for refractory atrial fibrillation.
LID - S0914-5087(13)00105-6 [pii]
LID - 10.1016/j.jjcc.2013.03.003 [doi]
AB  - BACKGROUND: It has been reported that inflammation is associated with long-term
      maintenance of sinus rhythm after electrical cardioversion for non-valvular
      atrial fibrillation (AF). However, the relation between high-sensitive C-reactive
      protein (hs-CRP) and the recurrence of AF after medical cardioversion is unknown.
      On the other hand, bepridil is very effective in restoring sinus rhythm for
      patients with refractory AF. METHODS AND RESULTS: In 119 patients with
      non-valvular AF lasting >6 months who failed to maintain sinus rhythm after
      medical cardioversion without bepridil or electrical cardioversion, we prescribed
      bepridil. We divided our patients into success group who maintained sinus rhythm 
      for at least 6 months using bepridil and failure group, and compared the
      following parameters, which were measured just before prescription of bepridil,
      between the two groups: hs-CRP as a marker of inflammation, left ventricular
      end-diastolic dimension, ejection fraction, and left atrial dimension as
      echocardiographic markers, and the incidence of dyslipidemia, hypertension, and
      diabetes mellitus. After the treatment with bepridil, 57 patients converted to
      sinus rhythm; however, 12 patients among these 57 patients could not maintain
      sinus rhythm. Therefore, the success group consisted of 45 patients (38%).
      Univariate analysis revealed that left atrial dimension and the value of hs-CRP
      were significantly lower and ejection fraction was significantly higher in the
      success group than the failure group. Multivariate analysis showed that hs-CRP
      and left atrial dimension were independent factors for AF recurrence.
      CONCLUSIONS: Bepridil is effective in restoring sinus rhythm for refractory AF
      patients. Inflammation, in addition to left atrial dimension, may be associated
      with successful cardioversion using bepridil.
CI  - Copyright (c) 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All
      rights reserved.
AD  - Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan. Electronic address:
      mnishino@orh.go.jp.
FAU - Nishino, Masami
AU  - Nishino M
FAU - Mori, Naoki
AU  - Mori N
FAU - Nakamura, Daisuke
AU  - Nakamura D
FAU - Lee, Yasuharu
AU  - Lee Y
FAU - Yoshimura, Takahiro
AU  - Yoshimura T
FAU - Taniike, Masayuki
AU  - Taniike M
FAU - Makino, Nobuhiko
AU  - Makino N
FAU - Kato, Hiroyasu
AU  - Kato H
FAU - Egami, Yasuyuki
AU  - Egami Y
FAU - Shutta, Ryu
AU  - Shutta R
FAU - Tanouchi, Jun
AU  - Tanouchi J
FAU - Yamada, Yoshio
AU  - Yamada Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/11 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/03/06 [accepted]
AID - S0914-5087(13)00105-6 [pii]
AID - 10.1016/j.jjcc.2013.03.003 [doi]
PST - aheadofprint
SO  - J Cardiol. 2013 Apr 25. pii: S0914-5087(13)00105-6. doi:
      10.1016/j.jjcc.2013.03.003.

PMID- 23623717
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1095-9157 (Electronic)
IS  - 0896-8411 (Linking)
VI  - 43
DP  - 2013 Jun
TI  - The Idd13 congenic interval defines the number of merocytic dendritic cells, a
      novel trait associated with autoimmune diabetes susceptibility.
PG  - 70-7
LID - 10.1016/j.jaut.2013.04.004 [doi]
LID - S0896-8411(13)00051-6 [pii]
AB  - When antigens derived from apoptotic cells are presented by conventional
      dendritic cells (cDC), T cell tolerance is induced. Surprisingly, the
      presentation of apoptotic cell antigens by an unconventional DC subset, termed
      merocytic dendritic cells (mcDC), can reverse T cell anergy. The potency of mcDC 
      at breaking T cell tolerance has been demonstrated in the context of tumors and
      autoimmunity, suggesting that modulating the number of mcDC in vivo may be of
      clinical interest. To identify the genetic determinants that define the number of
      mcDC, we performed a linkage analysis between NOD and C57BL/6 mouse strains,
      where autoimmune-prone NOD mice show an increased proportion of mcDC relative to 
      the non-autoimmune-prone C57BL/6 mice. We identified a locus on chromosome 2
      significantly linked to both the proportion and the absolute number of mcDC in
      the spleen. Interestingly, the dominant interval on chromosome 2 overlaps with a 
      locus previously associated with diabetes protection, namely Idd13. Using
      NOD.Idd13 congenic mice, we validate the impact of the Idd13 congenic interval in
      defining the proportion and number of mcDC in the spleen. These results show that
      the decreased number of mcDC is conferred by C57BL/6 alleles at the Idd13 locus, 
      which is linked to diabetes resistance.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Immunology-Oncology, Maisonneuve-Rosemont Hospital, Montreal,
      Quebec H1T 2M4, Canada; Department of Microbiology and Immunology, University of 
      Montreal, Montreal, Quebec H3C 3J7, Canada. Electronic address:
      adam.nicolas.pelletier@umontreal.ca.
FAU - Pelletier, Adam-Nicolas
AU  - Pelletier AN
FAU - Lesage, Sylvie
AU  - Lesage S
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - England
TA  - J Autoimmun
JT  - Journal of autoimmunity
JID - 8812164
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/03/26 [received]
PHST- 2013/04/01 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - S0896-8411(13)00051-6 [pii]
AID - 10.1016/j.jaut.2013.04.004 [doi]
PST - ppublish
SO  - J Autoimmun. 2013 Jun;43:70-7. doi: 10.1016/j.jaut.2013.04.004. Epub 2013 Apr 26.

PMID- 23623710
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1768-3122 (Electronic)
IS  - 0248-8663 (Linking)
DP  - 2013 Apr 25
TI  - [Unexplained, subclinical chronically elevated transaminases.]
LID - S0248-8663(13)00089-1 [pii]
LID - 10.1016/j.revmed.2013.02.043 [doi]
AB  - Unexplained, subclinical chronically elevated transaminases is mainly a marker of
      non-alcoholic fatty liver disease, metabolic syndrome, alcoholism and diabetes,
      which are very common situations but viral hepatitis and iatrogenic origin must
      also be considered. Before looking for hepatic or genetic rare diseases, it is
      worth considering hypertransaminasemia as a clue for muscular disease,
      particularly in paediatric settings, and creatine phosphokinase is a specific
      marker. Then, patient history, examination and appropriate biologic requests can 
      permit the identification of less frequent disorders where isolated
      hypertransaminasemia is possibly the unique marker of the disease for a long
      while: hemochromatosis, celiac disease, autoimmune hepatitis, Wilson's disease,
      alpha1-anti-trypsine deficiency, thyroid dysfunctions, Addison's disease. Liver
      biopsy should be performed only in patients with aspartate aminotransferases
      upper the normal range or alanine aminotransferases higher than twice the normal 
      range after 6 months delay with dietetic corrections.
CI  - Copyright (c) 2013 Societe nationale francaise de medecine interne (SNFMI).
      Published by Elsevier SAS. All rights reserved.
AD  - Service de medecine interne, centre hospitalier Lyon-Sud, universite de Lyon,
      69495 Pierre Benite cedex, France. Electronic address:
      denis.vital-durand@chu-lyon.fr.
FAU - Vital Durand, D
AU  - Vital Durand D
FAU - Lega, J-C
AU  - Lega JC
FAU - Fassier, T
AU  - Fassier T
FAU - Zenone, T
AU  - Zenone T
FAU - Durieu, I
AU  - Durieu I
LA  - FRE
PT  - JOURNAL ARTICLE
TT  - Elevation moderee, persistante et inexpliquee des transaminases.
DEP - 20130425
TA  - Rev Med Interne
JT  - La Revue de medecine interne / fondee ... par la Societe nationale francaise de
      medecine interne
JID - 8101383
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/09/24 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/02/28 [accepted]
AID - S0248-8663(13)00089-1 [pii]
AID - 10.1016/j.revmed.2013.02.043 [doi]
PST - aheadofprint
SO  - Rev Med Interne. 2013 Apr 25. pii: S0248-8663(13)00089-1. doi:
      10.1016/j.revmed.2013.02.043.

PMID- 23623699
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May
TI  - SLC29A3 mutation in a patient with syndromic diabetes with features of pigmented 
      hypertrichotic dermatosis with insulin-dependent diabetes, H syndrome and
      Faisalabad histiocytosis.
PG  - 281-5
LID - 10.1016/j.diabet.2013.03.007 [doi]
LID - S1262-3636(13)00078-5 [pii]
AB  - AIMS: Atypical forms of diabetes may be caused by monogenic mutations in key
      genes controlling beta-cell development, survival and function. This report
      describes an insulin-dependent diabetes patient with a syndromic presentation in 
      whom a homozygous SLC29A3 mutation was identified. METHODS: SLC29A3 was selected 
      as the candidate gene based on the patient's clinical manifestations, and all
      exons and flanking regions in the patient's genomic DNA were sequenced. RESULTS: 
      A homozygous splice mutation (c.300+1G>C) resulting in a frameshift and truncated
      protein (p.N101LfsX34) was identified. The patient had insulin-dependent
      diabetes, congenital deafness, short stature, hyperpigmented patches on the skin,
      dysmorphic features, cardiomegaly, arthrogryposis, hepatosplenomegaly, anaemia
      with erythroblastopenia, and an inflammatory syndrome with fever and arthritis;
      she also presented with a fibrotic mediastinal mass. These clinical features
      overlapped with pigmented hypertrichosis with insulin-dependent diabetes (PHID), 
      H syndrome, Faisalabad histiocytosis and sinus histiocytosis with massive
      lymphadenopathy (SHML), all of which are also caused by SLC29A3 mutations.
      CONCLUSION: This is the most severe case reported of SLC29A3 mutations with
      cumulative features of all these syndromes. This extreme severity coincides with 
      the most N-terminal location of the truncation mutation, thereby affecting all
      alternative transcripts of the gene. This case report extends the clinical
      variability of homozygous SLC29A3 mutations that result in a spectrum of
      multisystemic manifestations.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Inserm UMR-S958, Medical Faculty Paris 7, site Villemin, Paris, France;
      University Paris 7 Denis-Diderot, Paris, France.
FAU - de Jesus, J
AU  - de Jesus J
FAU - Imane, Z
AU  - Imane Z
FAU - Senee, V
AU  - Senee V
FAU - Romero, S
AU  - Romero S
FAU - Guillausseau, P-J
AU  - Guillausseau PJ
FAU - Balafrej, A
AU  - Balafrej A
FAU - Julier, C
AU  - Julier C
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/01/07 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/23 [aheadofprint]
AID - S1262-3636(13)00078-5 [pii]
AID - 10.1016/j.diabet.2013.03.007 [doi]
PST - ppublish
SO  - Diabetes Metab. 2013 May;39(3):281-5. doi: 10.1016/j.diabet.2013.03.007. Epub
      2013 Apr 23.

PMID- 23623640
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1532-8384 (Electronic)
IS  - 0010-440X (Linking)
DP  - 2013 Apr 24
TI  - Orgasmic dysfunction among Malay diabetic women in Malaysia.
LID - S0010-440X(13)00061-8 [pii]
LID - 10.1016/j.comppsych.2013.03.009 [doi]
AB  - OBJECTIVES: The present study aimed to determine the prevalence and associated
      factors of orgasmic dysfunction among Malay women with type 2 diabetes mellitus
      in Malaysia. METHODS: This cross-sectional study involved 347 women (174 non
      diabetic and 173 diabetic subjects) who attended the diabetic clinic in a
      university hospital. Orgasmic dysfunction was assessed using the orgasmic
      subscale of Malay Version of the Female Sexual Function Index (MVFSFI).
      Sociodemographic information of the subjects was collected with a pre-designed
      questionnaire. RESULTS: Prevalence of orgasmic dysfunction among Malay women was 
      13.3% and 10.3% in type 2 diabetes mellitus and control group, respectively.
      However, the difference was not statistically significant. Multivariate logistic 
      regression analysis showed that unemployment (Adjusted Odds Ratio, AOR=2.69, 95% 
      CI=1.22, 5.97) and lower academic status (AOR=0.35, 95% CI=0.17, 0.72) were
      significantly associated with sexual orgasmic dysfunction in diabetic women.
      CONCLUSION: Orgasmic dysfunction was highly prevalent among the Malay women
      regardless of the diabetic state. It is recommended that orgasmic dysfunction in 
      women with diabetes should be assessed during routine clinical health visit to
      the hospital for early treatment.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Family Medicine, Faculty of Medicine & Health Sciences, Universiti 
      Putra Malaysia, Serdang, Selangor 43400, Malaysia.
FAU - Ismail, Adibah Hanim
AU  - Ismail AH
FAU - Baw, Rawa
AU  - Baw R
FAU - Sidi, Hatta
AU  - Sidi H
FAU - Guan, Ng Chong
AU  - Guan NC
FAU - Midin, Marhani
AU  - Midin M
FAU - Jaafar, Nik Ruzyanei Nik
AU  - Jaafar NR
FAU - Das, Srijit
AU  - Das S
FAU - Manaf, Mohd Rizal Abdul
AU  - Manaf MR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Compr Psychiatry
JT  - Comprehensive psychiatry
JID - 0372612
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/10/22 [received]
PHST- 2013/02/04 [revised]
PHST- 2013/03/04 [accepted]
AID - S0010-440X(13)00061-8 [pii]
AID - 10.1016/j.comppsych.2013.03.009 [doi]
PST - aheadofprint
SO  - Compr Psychiatry. 2013 Apr 24. pii: S0010-440X(13)00061-8. doi:
      10.1016/j.comppsych.2013.03.009.

PMID- 23623608
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 Apr 25
TI  - Clinical outcomes and costs for patients with type 2 diabetes mellitus initiating
      insulin therapy in Greece: Two-year experience from the INSTIGATE study.
LID - S1751-9918(13)00042-9 [pii]
LID - 10.1016/j.pcd.2013.04.001 [doi]
AB  - AIMS: To evaluate the quality of metabolic control, clinical outcomes, resource
      costs, and quality of life among patients with type 2 diabetes mellitus (T2DM),
      who initiated insulin for the first time as part of routine clinical practice.
      METHODS: The INSTIGATE study is a prospective, multicentric, observational study 
      of patients initiating insulin treatment. This sub-cohort analysis focuses on
      Hellenic outcomes. RESULTS: At baseline, 263 Greek patients were enrolled just
      before initiating insulin for the first time. At the 6-month visit, 237 patients 
      (90.1%) remained and consented to an additional 18-month observation period. In
      these 237 extension patients, over the 24-month post-initiation period, HbA1c
      (mean(SD)) decreased from 9.7%(1.6%) to 7.1%(0.9%) and body weight and BMI
      increased (+3(6)kg and +1.1(2.2)kg/m2, respectively). At each post-baseline visit
      approximately one in five patients reported >/=1 episodes of hypoglycaemia in the
      preceding 3-6 months. Median total costs fluctuated from 438euro at baseline to
      538euro up to 6 months and 451euro at 24 months; mean costs were 496(383)euro,
      573(276)euro and 485(247)euro, respectively. CONCLUSIONS: In this cohort, insulin
      treatment seems to be effective with little long-term impact on cost. Findings
      should be interpreted in the context of an observational study.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - European Medical Research Institute by Pharmaserve-Lilly, Athens, Greece.
      Electronic address: aloumanisk@hotmail.com.
FAU - Aloumanis, Kyriakos
AU  - Aloumanis K
FAU - Benroubi, Marianna
AU  - Benroubi M
FAU - Sourmeli, Sotiria
AU  - Sourmeli S
FAU - Drossinos, Vangelis
AU  - Drossinos V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/10/10 [received]
PHST- 2013/02/25 [revised]
PHST- 2013/04/01 [accepted]
AID - S1751-9918(13)00042-9 [pii]
AID - 10.1016/j.pcd.2013.04.001 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 Apr 25. pii: S1751-9918(13)00042-9. doi:
      10.1016/j.pcd.2013.04.001.

PMID- 23623574
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
DP  - 2013 Apr 23
TI  - Serum 25-Hydroxyvitamin D Deficiency and the 5-Year Incidence of CKD.
LID - S0272-6386(13)00666-5 [pii]
LID - 10.1053/j.ajkd.2013.03.010 [doi]
AB  - BACKGROUND: Low serum 25-hydroxyvitamin D (25[OH]D) levels have been associated
      with chronic kidney disease in cross-sectional studies. However, this association
      has not been studied prospectively in a large general population-based cohort.
      STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 6,180 adults 25
      years or older participating in the baseline and 5-year follow-up phases of the
      Australian Diabetes, Obesity and Lifestyle (AusDiab) Study. PREDICTOR: Serum
      25(OH)D levels <15 ng/mL were considered deficient. OUTCOMES & MEASUREMENTS:
      Incident chronic kidney disease was defined as being negative at baseline but
      positive after 5 years for (1) reduced estimated glomerular filtration rate
      (eGFR; <60 mL/min/1.72 m2) or (2) albuminuria (spot urine albumin-creatinine
      ratio >/=2.5 mg/mmol [>/=22.1 mg/g] for men and >/=3.5 mg/mmol [>/=30.9 mg/g] for
      women). RESULTS: 623 (10.9%) participants were vitamin D deficient, 161 developed
      incident reduced eGFR, and 222 developed incident albuminuria. In participants
      with and without vitamin D deficiency, annual age-standardized incidences were
      0.92% (95% CI, 0.56%-1.30%) and 0.59% (95% CI, 0.51%-0.68%), respectively, for
      eGFR <60 mL/min/1.72 m2 and 1.50% (95% CI, 1.06%-1.95%) and 0.66% (95% CI,
      0.56%-0.76%), respectively, for albuminuria. In multivariate regression models,
      vitamin D deficiency was associated significantly with the 5-year incidence of
      albuminuria (OR, 1.71; 95% CI, 1.12-2.61; P = 0.01), but not reduced eGFR (OR,
      0.93; 95% CI, 0.53-1.66; P = 0.8). LIMITATIONS: The observational nature of the
      study does not account for unmeasured confounders. Only baseline 25(OH)D level
      was measured and therefore may not accurately reflect lifetime levels.
      Differences in baseline characteristics of participants who were included
      compared with those excluded due to missing data or follow-up may limit the
      applicability of results to the original AusDiab cohort. CONCLUSIONS: Our
      prospective cohort study shows that vitamin D deficiency is associated with a
      higher annual incidence of albuminuria and reduced eGFR and independently
      predicts the 5-year incidence of albuminuria. These associations warrant further 
      exploration in long-term prospective clinical trials.
CI  - Copyright (c) 2013 National Kidney Foundation, Inc. Published by Elsevier Inc.
      All rights reserved.
AD  - Department of Nephrology, Monash Medical Centre, Melbourne, Australia; Department
      of Medicine, Monash University, Melbourne, Australia. Electronic address:
      matthew.damasiewicz@monash.edu.
FAU - Damasiewicz, Matthew J
AU  - Damasiewicz MJ
FAU - Magliano, Dianna J
AU  - Magliano DJ
FAU - Daly, Robin M
AU  - Daly RM
FAU - Gagnon, Claudia
AU  - Gagnon C
FAU - Lu, Zhong X
AU  - Lu ZX
FAU - Sikaris, Ken A
AU  - Sikaris KA
FAU - Ebeling, Peter R
AU  - Ebeling PR
FAU - Chadban, Steven J
AU  - Chadban SJ
FAU - Atkins, Robert C
AU  - Atkins RC
FAU - Kerr, Peter G
AU  - Kerr PG
FAU - Shaw, Jonathan E
AU  - Shaw JE
FAU - Polkinghorne, Kevan R
AU  - Polkinghorne KR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/07/16 [received]
PHST- 2013/03/06 [accepted]
AID - S0272-6386(13)00666-5 [pii]
AID - 10.1053/j.ajkd.2013.03.010 [doi]
PST - aheadofprint
SO  - Am J Kidney Dis. 2013 Apr 23. pii: S0272-6386(13)00666-5. doi:
      10.1053/j.ajkd.2013.03.010.

PMID- 23623572
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1528-8447 (Electronic)
IS  - 1526-5900 (Linking)
DP  - 2013 Apr 23
TI  - Reduced Number, G Protein Coupling, and Antinociceptive Efficacy of Spinal
      Mu-Opioid Receptors in Diabetic Rats Are Reversed by Nerve Growth Factor.
LID - S1526-5900(13)00836-5 [pii]
LID - 10.1016/j.jpain.2013.01.776 [doi]
AB  - This study investigated putative mechanisms of impaired spinal opioid
      antinociception such as a downregulation of mu-opioid receptor (MOR) number,
      coupling, and efficacy in rats with advanced (12 weeks) streptozotocin
      (STZ)-induced diabetes. Intravenous injection of STZ (45 mg/kg) in Wistar rats
      led to selective degeneration of insulin-producing pancreatic ss-cells, elevated 
      blood glucose, and mechanical hyperalgesia. In these animals, dose-dependent and 
      naloxone-reversible intrathecal fentanyl antinociception was significantly
      impaired and associated with a loss in MOR immunoreactivity of calcitonin
      gene-related peptide-immunoreactive (CGRP-IR) sensory nerve terminals,
      membrane-bound MOR binding sites, and MOR-stimulated G protein coupling within
      the dorsal horn of the spinal cord. Intrathecal delivery of nerve growth factor
      (NGF) in diabetic animals normalized spinal MOR number and G protein coupling and
      rescued spinal fentanyl-induced antinociception. These findings identify for the 
      first time a loss in functional MOR on central terminals of sensory neurons as a 
      contributing factor for the impaired spinal opioid responsiveness during advanced
      STZ-induced diabetes that can be reversed by NGF. Moreover, they support growing 
      evidence of a distinct regulation of opioid responsiveness during various painful
      states of disease (eg, arthritis, cancer, neuropathy) and may give novel
      therapeutic incentives. PERSPECTIVE: In diabetic neuropathy a loss in sensory
      neuron mu-opioid receptor number and coupling contributes to impaired spinal
      opioid antinociception that can be reversed by NGF. These findings support
      growing evidence of a distinct regulation of opioid responsiveness during various
      painful diseases and may give novel therapeutic incentives.
CI  - Copyright (c) 2013 American Pain Society. Published by Elsevier Inc. All rights
      reserved.
AD  - Department of Anaesthesiology and Intensive Care Medicine, Charite University
      Berlin, Campus Virchow Klinikum and Campus Charite Mitte, Berlin, Germany.
FAU - Shaqura, Mohammed
AU  - Shaqura M
FAU - Khalefa, Baled I
AU  - Khalefa BI
FAU - Shakibaei, Mehdi
AU  - Shakibaei M
FAU - Winkler, Jens
AU  - Winkler J
FAU - Al-Khrasani, Mahmoud
AU  - Al-Khrasani M
FAU - Furst, Susanna
AU  - Furst S
FAU - Mousa, Shaaban A
AU  - Mousa SA
FAU - Schafer, Michael
AU  - Schafer M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - J Pain
JT  - The journal of pain : official journal of the American Pain Society
JID - 100898657
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/11/06 [received]
PHST- 2013/01/16 [revised]
PHST- 2013/01/31 [accepted]
AID - S1526-5900(13)00836-5 [pii]
AID - 10.1016/j.jpain.2013.01.776 [doi]
PST - aheadofprint
SO  - J Pain. 2013 Apr 23. pii: S1526-5900(13)00836-5. doi:
      10.1016/j.jpain.2013.01.776.

PMID- 23623517
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1097-6833 (Electronic)
IS  - 0022-3476 (Linking)
DP  - 2013 Apr 25
TI  - Thyroid Function from Birth to Adolescence in Prader-Willi Syndrome.
LID - S0022-3476(13)00377-6 [pii]
LID - 10.1016/j.jpeds.2013.03.058 [doi]
AB  - OBJECTIVES: To describe the response of thyroid-stimulating hormone (TSH) to
      thyroid-releasing hormone in children and adolescents with Prader-Willi syndrome 
      (PWS), and to compare TSH and total thyroxine (TT4) concentrations measured on
      neonatal screening for congenital hypothyroidism in children with PWS and
      controls. STUDY DESIGN: All participants had genetically confirmed PWS. The TSH
      responses to thyroid-releasing hormone, free thyroxine (fT4), and free
      triiodothyronine (fT3) were measured in 21 subjects (14 females and 7 males; mean
      age, 6.4 years). Capillary TT4 was measured on neonatal screening samples from 23
      subjects with PWS (14 females and 9 males), each of whom was matched for birth
      weight and sex with 4 anonymized controls. RESULTS: One subject with PWS had
      tertiary hypothyroidism. TSH level increased from 1.37 mU/L at baseline to 39.6
      mU/L at 20 minutes, 47.2 mU/L at 40 minutes, 44.5 mU/L at 60 minutes, and 47.2
      mU/L at 120 minutes. fT4 concentration was 6.3 pmol/L, and fT3 concentration was 
      4.6 pmol/L. In the other 20 subjects, mean TSH level was 1.9 mU/L (range, 0.8-4.2
      mU/L) at baseline and 21.8 mU/L (range, 10.0-46.7 mU/L) at 20 minutes (peak).
      Mean fT4 concentration (10.4 pmol/L; range, 8.2-13.5 pmol/L) was in the lower
      one-third of the normal range in 18 subjects, and mean fT3 concentration (6.1
      pmol/L; range, 4.8-8.4 pmol/L) was above the median in 13 subjects. In neonates, 
      mean TSH level was 3.1 mU/L (range, 0.4-10.0 mU/L) in subjects with PWS versus
      3.3 mU/L (range, 0.0-7.0 mU/L) in controls, and mean TT4 in subjects with PWS was
      111% (range, 17%-203%) that of controls (P = not significant). CONCLUSION:
      Thyroid function was normal in our newborn subjects. In older children, frank
      hypothyroidism was found in only 1 of our 21 subjects. Thus, levothyroxine
      treatment should not be routinely prescribed to youth with PWS.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Endocrinology and Diabetes Unit, British Columbia's Children's Hospital,
      University of British Columbia, Vancouver, British Columbia, Canada.
FAU - Sharkia, Mohamad
AU  - Sharkia M
FAU - Michaud, Stephanie
AU  - Michaud S
FAU - Berthier, Marie-Therese
AU  - Berthier MT
FAU - Giguere, Yves
AU  - Giguere Y
FAU - Stewart, Laura
AU  - Stewart L
FAU - Deladoey, Johnny
AU  - Deladoey J
FAU - Deal, Cheri
AU  - Deal C
FAU - Van Vliet, Guy
AU  - Van Vliet G
FAU - Chanoine, Jean-Pierre
AU  - Chanoine JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/11/07 [received]
PHST- 2013/02/20 [revised]
PHST- 2013/03/20 [accepted]
AID - S0022-3476(13)00377-6 [pii]
AID - 10.1016/j.jpeds.2013.03.058 [doi]
PST - aheadofprint
SO  - J Pediatr. 2013 Apr 25. pii: S0022-3476(13)00377-6. doi:
      10.1016/j.jpeds.2013.03.058.

PMID- 23623476
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1916-7075 (Electronic)
IS  - 0828-282X (Linking)
DP  - 2013 Apr 23
TI  - Survey of Diabetes Care in Patients Presenting With Acute Coronary Syndromes in
      Canada.
LID - S0828-282X(13)00033-0 [pii]
LID - 10.1016/j.cjca.2013.01.012 [doi]
AB  - Diabetes (DM) adversely affects prognosis in acute coronary syndromes (ACS).
      Guidelines promote optimal glycemic management. Cardiac care often occurs in
      subspecialty units where DM care might not be a primary focus. A questionnaire
      was circulated to 1183 cardiologists (CARDs), endocrinologists (ENDOs), and
      internists between February and May 2012 to determine current practices of DM
      management in patients presenting with ACS. The response rate was 14%. ENDOs
      differed in perception of DM frequency compared with CARDs and the availability
      of ENDO consultation within 24 hours and on routinely-ordered tests. Disparity
      also existed in who was believed to be primarily responsible for in-hospital DM
      care in ACS: ENDOs perceived they managed glycemia more often than CARDs believed
      they did. CARDs indicated they most often managed DM after discharge and ENDOs
      said this occurred much less. However, CARDs reported ENDOs were the best health 
      care professional to follow patients after discharge. ENDOs had higher comfort
      initiating and titrating oral hypoglycemic agents or various insulin regimens.
      There was also no difference in these specialists' perceptions that optimizing
      glucose levels during the acute phase and in the long-term improves
      cardiovascular outcomes. Significant differences exist in the perception of the
      magnitude of the problem, acute and longer-term process of care, and comfort
      initiating new therapies. Nevertheless, all practitioners agree that optimal DM
      care affects short- and long-term outcomes of patients. Better systems of care
      are required to optimally manage ACS patients with DM during admission and after 
      discharge from cardiology services.
CI  - Copyright (c) 2013 Canadian Cardiovascular Society. Published by Elsevier Inc.
      All rights reserved.
AD  - University of Alberta, Edmonton, Alberta, Canada. Electronic address:
      Blair.oneill@albertahealthservices.ca.
FAU - O'Neill, Blair J
AU  - O'Neill BJ
FAU - Mann, Ursula M
AU  - Mann UM
FAU - Gupta, Milan
AU  - Gupta M
FAU - Verma, Subodh
AU  - Verma S
FAU - Leiter, Lawrence A
AU  - Leiter LA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Can J Cardiol
JT  - The Canadian journal of cardiology
JID - 8510280
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/19 [received]
PHST- 2013/01/24 [revised]
PHST- 2013/01/24 [accepted]
AID - S0828-282X(13)00033-0 [pii]
AID - 10.1016/j.cjca.2013.01.012 [doi]
PST - aheadofprint
SO  - Can J Cardiol. 2013 Apr 23. pii: S0828-282X(13)00033-0. doi:
      10.1016/j.cjca.2013.01.012.

PMID- 23623422
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1578-6749 (Electronic)
IS  - 0210-5691 (Linking)
DP  - 2013 Apr 25
TI  - Markers for early detection of alterations in carbohydrate metabolism after acute
      myocardial infarction.
LID - S0210-5691(13)00022-3 [pii]
LID - 10.1016/j.medin.2013.02.004 [doi]
AB  - OBJECTIVES: Undiagnosed abnormal glucose metabolism is often seen in patients
      admitted with acute myocardial infarction, although there is no consensus on
      which patients should be studied with a view to establishing an early diagnosis. 
      The present study examines the potential of certain variables obtained upon
      admission to diagnose abnormal glucose metabolism. DESIGN: A prospective cohort
      study was carried out. SETTING: The Intensive Care Unit of Arrixaca University
      Hospital (Murcia), Spain. PATIENTS: A total of 138 patients admitted to the
      Intensive Care Unit with acute myocardial infarction and without known or de novo
      diabetes mellitus. After one year, oral glucose tolerance testing was performed. 
      MAIN OUTCOMES: Clinical and laboratory test parameters were recorded upon
      admission and one year after discharge. Additionally, after one year, oral
      glucose tolerance tests were made, and a study was made of the capacity of the
      variables obtained at admission to diagnose diabetes, based on the ROC curves and
      multivariate analysis. RESULTS: Of the 138 patients, 112 (72.5%) had glucose
      metabolic alteration, including 16.7% with diabetes. HbA1c was independently
      associated with a diagnosis of diabetes (RR: 7.28, 95%CI 1.65 to 32.05, P =
      .009), and showed the largest area under the ROC curve for diabetes (0.81, 95%CI 
      0.69 to 0.92, P = .001). CONCLUSIONS: In patients with acute myocardial
      infarction, HbA1c helps identify those individuals with abnormal glucose
      metabolism after one year. Thus, its determination in this group of patients
      could be used to identify those subjects requiring a more exhaustive study in
      order to establish an early diagnosis.
CI  - Copyright (c) 2012 Elsevier Espana, S.L. y SEMICYUC. All rights reserved.
AD  - Unidad de Cuidados Intensivos, Hospital Universitario Virgen de la Arrixaca,
      Murcia, Espana. Electronic address: josehdegea@hotmail.com.
FAU - de Gea-Garcia, J H
AU  - de Gea-Garcia JH
FAU - Benali, L
AU  - Benali L
FAU - Galcera-Tomas, J
AU  - Galcera-Tomas J
FAU - Padilla-Serrano, A
AU  - Padilla-Serrano A
FAU - Andreu-Soler, E
AU  - Andreu-Soler E
FAU - Melgarejo-Moreno, A
AU  - Melgarejo-Moreno A
FAU - Alonso-Fernandez, N
AU  - Alonso-Fernandez N
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Marcadores para la deteccion precoz de las alteraciones del metabolismo
      hidrocarbonado tras un infarto agudo de miocardio.
DEP - 20130425
TA  - Med Intensiva
JT  - Medicina intensiva / Sociedad Espanola de Medicina Intensiva y Unidades
      Coronarias
JID - 9207689
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/09/01 [received]
PHST- 2013/01/10 [revised]
PHST- 2013/02/03 [accepted]
AID - S0210-5691(13)00022-3 [pii]
AID - 10.1016/j.medin.2013.02.004 [doi]
PST - aheadofprint
SO  - Med Intensiva. 2013 Apr 25. pii: S0210-5691(13)00022-3. doi:
      10.1016/j.medin.2013.02.004.

PMID- 23623393
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1878-3279 (Electronic)
IS  - 0171-2985 (Linking)
VI  - 218
IP  - 8
DP  - 2013 Aug
TI  - Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes
      patients is associated with a reduction of IL-17 levels.
PG  - 1113-8
LID - 10.1016/j.imbio.2013.03.002 [doi]
LID - S0171-2985(13)00042-9 [pii]
AB  - We explored the effect of therapeutic glucoregulation on the blood levels of
      proinflammatory T helper (Th)17 cytokines interleukin (IL)-17 and IL-23, and Th1 
      cytokines interferon (IFN)-gamma and IL-12 in newly diagnosed type 2 diabetes
      patients. The investigated group consisted of 23 subjects (17 men and 6 women,
      age 26-64). The cytokine serum levels, glycated hemoglobin (HbA1c) as a marker of
      glucoregulation, homeostasis model assessment index as a measure of insulin
      resistance (HOMA-IR), and body mass index (BMI) were determined before and after 
      12 weeks of therapy consisting of standard lifestyle modification and metformin
      (1000mg b.i.d.). The levels of Th17 and Th1 cytokines before treatment did not
      correlate with age, BMI or HOMA-IR. The patients with poor glucoregulation
      (HbA1c>7%, n=12), compared to those with good glucoregulation (HbA1c</=7%, n=11),
      had higher serum levels of Th17 and Th1 cytokines, but only the differences in
      IL-17 (median 21.2pg/ml vs. 4.8pg/ml) and IFN-gamma 5 (0.6pg/ml vs. 27.7pg/ml)
      reached statistical significance (p=0.003 and p=0.012, respectively). The
      reduction of HbA1c values (from 8.6 to 5.9%, p=0.000) observed upon treatment in 
      patients with poor glucoregulation was associated with a significant decrease in 
      the concentration of IL-17 (from 21.2 to 12.9pg/ml, p=0.020), but not IFN-gamma
      (50.6 vs. 52.3, p=0.349). These data indicate that therapeutic improvement of
      glucoregulation might contribute to a reduction of IL-17 levels in newly
      diagnosed type 2 diabetes patients.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
AD  - Clinic for Endocrinology, Diabetes and Diseases of Metabolism, School of
      Medicine, University of Belgrade, Dr Subotica 13, Belgrade 11000, Serbia.
FAU - Sumarac-Dumanovic, Mirjana
AU  - Sumarac-Dumanovic M
FAU - Jeremic, Danka
AU  - Jeremic D
FAU - Pantovic, Aleksandar
AU  - Pantovic A
FAU - Janjetovic, Kristina
AU  - Janjetovic K
FAU - Stamenkovic-Pejkovic, Danica
AU  - Stamenkovic-Pejkovic D
FAU - Cvijovic, Goran
AU  - Cvijovic G
FAU - Stevanovic, Darko
AU  - Stevanovic D
FAU - Micic, Dragan
AU  - Micic D
FAU - Trajkovic, Vladimir
AU  - Trajkovic V
LA  - eng
PT  - Journal Article
DEP - 20130316
PL  - Netherlands
TA  - Immunobiology
JT  - Immunobiology
JID - 8002742
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/08/31 [received]
PHST- 2013/02/07 [revised]
PHST- 2013/03/11 [accepted]
PHST- 2013/03/16 [aheadofprint]
AID - S0171-2985(13)00042-9 [pii]
AID - 10.1016/j.imbio.2013.03.002 [doi]
PST - ppublish
SO  - Immunobiology. 2013 Aug;218(8):1113-8. doi: 10.1016/j.imbio.2013.03.002. Epub
      2013 Mar 16.

PMID- 23623385
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1879-0070 (Electronic)
IS  - 0732-8893 (Linking)
DP  - 2013 Apr 24
TI  - Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other
      antimicrobial agents against aerobic and anaerobic bacteria cultured from
      infected diabetic foot wounds.
LID - S0732-8893(13)00188-0 [pii]
LID - 10.1016/j.diagmicrobio.2013.03.019 [doi]
AB  - Foot infections are the most common infectious complication of diabetes. Moderate
      to severe diabetic foot infections (DFI) are typically polymicrobial with both
      aerobic and anaerobic organisms. The role of MRSA in these wounds has become an
      increasing concern. To determine if the addition of avibactam, a novel
      non-beta-lactam beta-lactamase inhibitor, to ceftaroline would be more active
      than ceftaroline alone, we tested 316 aerobic pathogens and 154 anaerobic
      recovered from patients with moderate to severe DFI, and compared ceftaroline
      with and without avibactam to other agents. Testing on aerobes was done by broth 
      microdilution and by agar dilution for anaerobes, according to CLSI M11-A8, and
      M7-A8 standards. Ceftaroline-avibactam MIC90 for all Staphylococcus spp.
      including MRSA was 0.5 mug/mL, and for enterococci was 1 mug/mL. The MIC90s for
      enteric Gram-negative rods was 0.125 mug/mL. The addition of avibactam to
      ceftaroline reduced the ceftaroline MICs for 2 strains of resistant Enterobacter 
      spp. and for 1 strain of Morganella. Against anaerobic Gram-positive cocci
      ceftaroline-avibactam had an MIC90 0.125 mug/mL and for clostridia 1 mug/mL.
      Avibactam improved ceftaroline's MIC90s for Bacteroides fragilis from >32 to 2
      mug/mL and for Prevotella spp. from >32 to 1 mug/mL. Ceftaroline alone
      demonstrates excellent in vitro activity against most of the aerobes found in
      moderate to severe DFI. The addition of avibactam provides an increased spectrum 
      of activity including the beta-lactamase producing Prevotella, Bacteroides
      fragilis and ceftaroline resistant gram-negative enteric organisms.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - R. M. Alden Research Laboratory, Culver City, CA 90230; David Geffen School of
      Medicine, University of California at Los Angeles, Los Angeles, CA 90095.
      Electronic address: ejcgmd@aol.com.
FAU - Goldstein, Ellie J C
AU  - Goldstein EJ
FAU - Citron, Diane M
AU  - Citron DM
FAU - Merriam, C Vreni
AU  - Merriam CV
FAU - Tyrrell, Kerin L
AU  - Tyrrell KL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Diagn Microbiol Infect Dis
JT  - Diagnostic microbiology and infectious disease
JID - 8305899
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/02/07 [received]
PHST- 2013/03/10 [revised]
PHST- 2013/03/18 [accepted]
AID - S0732-8893(13)00188-0 [pii]
AID - 10.1016/j.diagmicrobio.2013.03.019 [doi]
PST - aheadofprint
SO  - Diagn Microbiol Infect Dis. 2013 Apr 24. pii: S0732-8893(13)00188-0. doi:
      10.1016/j.diagmicrobio.2013.03.019.

PMID- 23623334
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
DP  - 2013 Mar 26
TI  - Wogonin ameliorates hyperglycemia and dyslipidemia via PPARalpha activation in
      db/db mice.
LID - S0261-5614(13)00091-5 [pii]
LID - 10.1016/j.clnu.2013.03.013 [doi]
AB  - BACKGROUND & AIMS: Wogonin is a flavonoid extracted from the root of Scutellaria 
      baicalensis Gerogi. We evaluated the therapeutic effects of wogonin using db/db
      mice. METHODS: Mice received wogonin or vehicle by oral gavage for 2 weeks. Blood
      glucose, insulin, and cholesterol levels were measured, and liver morphology was 
      observed with histopathological analysis. The mRNA expression levels of
      PPARalpha, PPARgamma, and adiponectin in the liver and white adipose tissue (WAT)
      were determined by real-time PCR. Immunoblotting for AMPK and PPARgamma, and
      adipocyte differentiation were investigated in vitro using 3T3-L1 cells. A
      luciferase assay was used to measure PPARalpha and PPARgamma binding activity.
      RESULTS: The wogonin group showed decreased weight gain without a change in food 
      intake and improved glucose tolerance. Serum insulin and cholesterol levels in
      the wogonin group were significantly decreased compared to those in the control
      group. The wogonin group also showed less accumulation of lipid droplets and
      glycogen in the liver. PPARalpha and PPARgamma expression levels in the liver and
      WAT and adiponectin expression level in WAT in the wogonin group were higher than
      those in the control group. In 3T3-L1 cells, wogonin was shown to stimulate AMPK 
      activation in a dose-dependent manner. The presence of wogonin did not affect
      adipocyte differentiation or PPARgamma protein level during adipogenesis.
      Notably, wogonin enhanced PPARalpha but not PPARgamma transactivation.
      CONCLUSIONS: These indicate that wogonin may have beneficial effects on glucose
      and lipid metabolism related to enhanced PPARalpha and adiponectin expression via
      AMPK activation. Importantly, wogonin did not cause deleterious effects, such as 
      weight gain and fatty liver. Wogonin might be a useful therapeutic agent to treat
      type 2 diabetes.
CI  - Copyright (c) 2013 Elsevier Ltd and European Society for Clinical Nutrition and
      Metabolism. All rights reserved.
AD  - Oral Cancer Research Institute, Yonsei University College of Dentistry, Seoul,
      Republic of Korea.
FAU - Bak, Eun-Jung
AU  - Bak EJ
FAU - Kim, Jinmoon
AU  - Kim J
FAU - Choi, Yun Hui
AU  - Choi YH
FAU - Kim, Ji-Hye
AU  - Kim JH
FAU - Lee, Dong-Eun
AU  - Lee DE
FAU - Woo, Gye-Hyeong
AU  - Woo GH
FAU - Cha, Jeong-Heon
AU  - Cha JH
FAU - Yoo, Yun-Jung
AU  - Yoo YJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130326
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/09/04 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/18 [accepted]
AID - S0261-5614(13)00091-5 [pii]
AID - 10.1016/j.clnu.2013.03.013 [doi]
PST - aheadofprint
SO  - Clin Nutr. 2013 Mar 26. pii: S0261-5614(13)00091-5. doi:
      10.1016/j.clnu.2013.03.013.

PMID- 23623209
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 Apr 25
TI  - On the importance of global cardiovascular risk assessment in people with type 2 
      diabetes.
LID - S1751-9918(13)00040-5 [pii]
LID - 10.1016/j.pcd.2013.03.002 [doi]
AB  - This narrative review examines the concept of diabetes as a cardiovascular
      disease (CVD) risk equivalent, the rationale and approaches to absolute CVD risk 
      estimation in type 2 diabetes. In people with diabetes, CVD risk follows a
      gradient. Reliably capturing this gradient depends on the combination of several 
      risk factors. Existing CVD risk tools applicable to people with diabetes have
      shown a modest-to-acceptable performance. Future improvements may include
      updating existing models or constructing new ones with improved predictive
      accuracy. Ultimately, developed models should be tested in independent
      populations, and the impact of their uptake on clinical decision making and the
      outcome of care assessed.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - Hubert Department of Global Health, Rollins School of Public Health, Emory
      University, Atlanta, GA, USA.
FAU - Echouffo-Tcheugui, Justin B
AU  - Echouffo-Tcheugui JB
FAU - Kengne, Andre P
AU  - Kengne AP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/10/08 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/24 [accepted]
AID - S1751-9918(13)00040-5 [pii]
AID - 10.1016/j.pcd.2013.03.002 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 Apr 25. pii: S1751-9918(13)00040-5. doi:
      10.1016/j.pcd.2013.03.002.

PMID- 23623194
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1873-5126 (Electronic)
IS  - 1353-8020 (Linking)
VI  - 19
IP  - 7
DP  - 2013 Jul
TI  - Cerebral white matter hyperintensity in Parkinson's disease: A major risk factor 
      for mild cognitive impairment.
PG  - 680-3
LID - 10.1016/j.parkreldis.2013.03.008 [doi]
LID - S1353-8020(13)00124-7 [pii]
AB  - BACKGROUND: Mild cognitive impairment (MCI) and dementia contribute to a poor
      quality of life among patients with PD. The influence of cerebral ischemia as a
      risk factor for MCI in PD has not been adequately investigated. To address this
      issue, we examined the influence of the volume and distribution of white matter
      hyperintensity (WMH) as a risk factor for MCI in early PD. METHODS: Prospective
      study of patients with early idiopathic PD. All patients had baseline MRI-FLAIR, 
      clinical assessment and detailed neuropsychological evaluation. Data on
      demographics, vascular risk factors, cognitive performance and WMH volumes were
      analyzed. RESULTS: 91 patients; mean age 64.9 years, mean education of 10.5
      years. 24 patients fulfilled the Movement Disorder Society criteria for MCI and
      were classified as PD-MCI while the rest were classified as PD with no cognitive 
      impairment (PD-NCI). Patients with PD-MCI and PD-NCI did not differ in Hoehn &
      Yahr staging. PD-MCI patients had a higher prevalence of diabetes mellitus,
      hypertension and hyperlipidemia. PD-MCI patients had significantly greater volume
      of periventricular (6.04 ml vs. 2.66 ml, p = 0.001) and deep subcortical WMH
      (2.16 vs.1.44, p = 0.002). Regional WMH was significantly greater among PD-MCI in
      the frontal, parietal and occipital regions. Logistic regression analyses
      demonstrated WMH to be associated with PD-MCI independent of age, education, and 
      vascular risk factors. Increasing WMH volume was associated with lower
      performance on executive function, memory and language. CONCLUSIONS: WMH is an
      important risk factor for PD-MCI independent of vascular risk factors. PD
      patients with WMH should be regularly screened for MCI.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Neurology, National Neuroscience Institute, Singapore; Duke-NUS
      Graduate Medical School, Singapore. Electronic address:
      Nagaendran_Kandiah@nni.com.sg.
FAU - Kandiah, Nagaendran
AU  - Kandiah N
FAU - Mak, Elijah
AU  - Mak E
FAU - Ng, Amanda
AU  - Ng A
FAU - Huang, Shan
AU  - Huang S
FAU - Au, Wing Lok
AU  - Au WL
FAU - Sitoh, Yih Yian
AU  - Sitoh YY
FAU - Tan, Louis C S
AU  - Tan LC
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - England
TA  - Parkinsonism Relat Disord
JT  - Parkinsonism & related disorders
JID - 9513583
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/26 [received]
PHST- 2013/02/25 [revised]
PHST- 2013/03/20 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - S1353-8020(13)00124-7 [pii]
AID - 10.1016/j.parkreldis.2013.03.008 [doi]
PST - ppublish
SO  - Parkinsonism Relat Disord. 2013 Jul;19(7):680-3. doi:
      10.1016/j.parkreldis.2013.03.008. Epub 2013 Apr 24.

PMID- 23622911
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 165
IP  - 5
DP  - 2013 May
TI  - Impact of catalytic iron on mortality in patients with acute coronary syndrome
      exposed to iodinated radiocontrast-The Iscom Study.
PG  - 744-51
LID - 10.1016/j.ahj.2013.02.016 [doi]
LID - S0002-8703(13)00143-9 [pii]
AB  - BACKGROUND: Catalytic iron (CI) mediates vascular injury by generating reactive
      oxygen species. We evaluated role of CI in predicting mortality in patients with 
      acute coronary syndrome (ACS) and studied association of contrast nephropathy
      with CI levels. METHODS: We investigated 806 patients with ACS undergoing
      contrast exposure for a cardiac procedure who were followed up for 30 days.
      RESULTS: Overall mortality was 1.6% at 30 days. Catalytic iron at baseline
      predicted mortality with CI levels significantly higher in those who died, 0.45
      mumol/L (0.37, 0.68) compared with survivors 0.31 mumol/L (0.21, 0.40); P = .004.
      Catalytic iron was associated with increased risk of death in the highest
      quartile compared with lower 3 quartiles (hazard ratio 7.88, P = .001) after
      adjustment for age, diabetes, ST deviation, Killip class, ejection fraction,
      baseline creatinine, hemoglobin level, and troponin. Fifty-five patients (6.8%)
      developed contrast nephropathy. Patients with contrast nephropathy had a 27%
      increase in median CI levels from baseline up to 48 hours compared with a
      marginal 2.9% increase in those without contrast nephropathy (0.37, 0.14 mumol/L 
      to 0.47, 0.20 mumol/L versus 0.35, 0.12 mumol/L to 0.36, 0.14 mumol/L, P <
      .0001). Patients with contrast nephropathy had significantly higher mortality
      compared with those without contrast nephropathy (9.1% vs 1.1%, P = .001).
      CONCLUSION: High baseline CI levels predicted mortality in patients with ACS.
      Occurrence of contrast nephropathy was associated with rise in CI levels and
      higher mortality. Therapeutic options to buffer or chelate CI may have beneficial
      effects on mortality in this setting.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Cardiology, Bhailal Amin General Hospital, Baroda, Gujarat, India. 
      lelesuhas@yahoo.com
FAU - Lele, Suhas S
AU  - Lele SS
FAU - Mukhopadhyay, Banibrata N
AU  - Mukhopadhyay BN
FAU - Mardikar, Mohan M
AU  - Mardikar MM
FAU - Patel, Tejas A
AU  - Patel TA
FAU - Vasavada, Apoorva K
AU  - Vasavada AK
FAU - Banker, Darshan N
AU  - Banker DN
FAU - Kapasi, Ketan D
AU  - Kapasi KD
FAU - Chauhan, Virendra C
AU  - Chauhan VC
FAU - Chawla, Kamaldeep C
AU  - Chawla KC
FAU - Raju, Soma R
AU  - Raju SR
FAU - Hiremath, Shirish S
AU  - Hiremath SS
FAU - Chinchole, Sashi S
AU  - Chinchole SS
FAU - Rajapurkar, Mohan M
AU  - Rajapurkar MM
LA  - eng
PT  - Journal Article
DEP - 20130326
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
SB  - AIM
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/09/10 [received]
PHST- 2013/02/18 [accepted]
PHST- 2013/03/26 [aheadofprint]
AID - S0002-8703(13)00143-9 [pii]
AID - 10.1016/j.ahj.2013.02.016 [doi]
PST - ppublish
SO  - Am Heart J. 2013 May;165(5):744-51. doi: 10.1016/j.ahj.2013.02.016. Epub 2013 Mar
      26.

PMID- 23622897
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 0025-7753 (Electronic)
IS  - 0025-7753 (Linking)
DP  - 2013 Apr 23
TI  - [INERTIA study: Clinical inertia in non-insulinized patients on oral hypoglycemic
      treatment. A study in Spanish primary and specialty care settings.]
LID - S0025-7753(13)00218-2 [pii]
LID - 10.1016/j.medcli.2013.02.032 [doi]
AB  - BACKGROUND AND OBJECTIVE: To study clinical inertia in the management of oral
      hypoglycemic agents (OHA) in non-insulin treated patients with type 2 diabetes
      mellitus (T2DM) in Spain. PATIENTS AND METHOD: Epidemiological, cross-sectional, 
      retrospective (2 years), multicenter study. Clinical inertia was measured as the 
      total number of patients without OHA treatment intensification divided by the
      total number of patients with inadequate HbA1c values (>/=7%), multiplied by 100.
      Total clinical inertia (TCI) was the absence of OHA treatment intensification in 
      all visits with a HbA1c>/=7% values in the previous 2 years; partial clinical
      inertia (PCI) occurred when this absence only occurred in some of these visits.
      We assessed OHA treatment compliance with the Morisky-Green test. RESULTS: We
      included 2,971 patients, 1,416 adequately controlled (HbA1c<7%) and 1,555
      inadequately controlled (HbA1c>/=7%). PCI prevalence was 52.5%(95% confidence
      interval [95% CI] 52.4-52.6%) while TCI prevalence was 12.8% (95% CI 12.2-13.8%).
      PCI was lower in patients adequately controlled as compared with those
      inadequately controlled (31.4% vs. 71.8%; P<.001). PCI was associated with
      sedentary lifestyle, hypertension and higher prevalence of micro and
      macrovascular complications. Only 38.0% of patients were compliant with the OHA
      treatment, being this percentage even lower in subjects with ICP. Two variables
      were independently associated with ICP: female sex (odds ratio [OR] 1.43; 95% CI 
      1.09-1.86%) and a shorter duration of DM2 (OR 0.98; 95% CI 0.95-0.99).
      CONCLUSIONS: One out of 2 patients with T2DM and treated with OHA without insulin
      suffer from PCI. Only 4 out of 10 patients are compliant with OHA treatment.
      Female sex and a shorter duration of T2DM are independently associated with PCI.
CI  - Copyright (c) 2012 Elsevier Espana, S.L. All rights reserved.
AD  - Servicio de Diabetes, Endocrinologia y Nutricion, Hospital de Sabadell,
      Corporacion Sanitaria Parc Tauli, Instituto Universitario Parc Tauli, Universitat
      Autonoma de Barcelona, Sabadell, Barcelona, Espana. Electronic address:
      jmgonzalez@tauli.cat.
FAU - Gonzalez-Clemente, Jose Miguel
AU  - Gonzalez-Clemente JM
FAU - Font, Beatriu
AU  - Font B
FAU - Lahoz, Raquel
AU  - Lahoz R
FAU - Llaurado, Gemma
AU  - Llaurado G
FAU - Gambus, Gemma
AU  - Gambus G
CN  - en nombre del Grupo de investigadores del Estudio INERCIA
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Estudio INERCIA: inercia clinica en pacientes con diabetes mellitus tipo 2 no
      insulinizados en tratamiento con hipoglucemiantes orales. Un estudio en Espana,
      en atencion primaria y especializada.
DEP - 20130423
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/06/08 [received]
PHST- 2013/02/19 [revised]
PHST- 2013/02/21 [accepted]
AID - S0025-7753(13)00218-2 [pii]
AID - 10.1016/j.medcli.2013.02.032 [doi]
PST - aheadofprint
SO  - Med Clin (Barc). 2013 Apr 23. pii: S0025-7753(13)00218-2. doi:
      10.1016/j.medcli.2013.02.032.

PMID- 23622883
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1097-6795 (Electronic)
IS  - 0894-7317 (Linking)
DP  - 2013 Apr 24
TI  - Frequent Periodic Leg Movement during Sleep Is Associated with Left Ventricular
      Hypertrophy and Adverse Cardiovascular Outcomes.
LID - S0894-7317(13)00216-2 [pii]
LID - 10.1016/j.echo.2013.03.018 [doi]
AB  - BACKGROUND: Sleep disturbance caused by obstructive sleep apnea is recognized as 
      a contributing factor to adverse cardiovascular outcomes. However, the effect of 
      restless legs syndrome, another common cause of fragmented sleep, on cardiac
      structure, function, and long-term outcomes is not known. The aim of this study
      was to assess the effect of frequent leg movement during sleep on cardiac
      structure and outcomes in patients with restless legs syndrome. METHODS: In our
      retrospective study, patients with restless legs syndrome referred for
      polysomnography were divided into those with frequent (periodic movement index > 
      35/hour) and infrequent (</=35/hour) leg movement during sleep. Long-term
      outcomes were determined using Kaplan-Meier and logistic regression models.
      RESULTS: Of 584 patients, 47% had a periodic movement index > 35/hour. Despite
      similarly preserved left ventricular ejection fraction, the group with periodic
      movement index > 35/hour had significantly higher left ventricular mass and mass 
      index, reflective of left ventricular hypertrophy (LVH). There were no
      significant baseline differences in the proportion of patients with hypertension,
      diabetes, hyperlipidemia, prior myocardial infarction, stroke or heart failure,
      or the use of antihypertensive medications between the groups. Patients with
      frequent periodic movement index were older, predominantly male, and had more
      prevalent coronary artery disease and atrial fibrillation. However, on
      multivariate analysis, periodic movement index > 35/hour remained the strongest
      predictor of LVH (odds ratio, 2.45; 95% confidence interval, 1.67-3.59; P <
      .001). Advanced age, female sex, and apnea-hypopnea index were other predictors
      of LVH. Patients with periodic movement index > 35/hour had significantly higher 
      rates of heart failure and mortality over median 33-month follow-up. CONCLUSIONS:
      Frequent periodic leg movement during sleep is an independent predictor of severe
      LVH and is associated with increased cardiovascular morbidity and mortality.
CI  - Copyright (c) 2013 American Society of Echocardiography. Published by Mosby, Inc.
      All rights reserved.
AD  - Center for Integrative Research on Cardiovascular Aging, Aurora University of
      Wisconsin Medical Group, Milwaukee, Wisconsin; Division of Cardiovascular
      Diseases, Mayo Clinic, Scottsdale, Arizona.
FAU - Mirza, Mahek
AU  - Mirza M
FAU - Shen, Win-Kuang
AU  - Shen WK
FAU - Sofi, Aamir
AU  - Sofi A
FAU - Jahangir, Ahad
AU  - Jahangir A
FAU - Mori, Naoyo
AU  - Mori N
FAU - Tajik, A Jamil
AU  - Tajik AJ
FAU - Jahangir, Arshad
AU  - Jahangir A
LA  - ENG
GR  - R01 HL089542/HL/NHLBI NIH HHS/United States
GR  - R01 HL101240/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - J Am Soc Echocardiogr
JT  - Journal of the American Society of Echocardiography : official publication of the
      American Society of Echocardiography
JID - 8801388
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/06/29 [received]
AID - S0894-7317(13)00216-2 [pii]
AID - 10.1016/j.echo.2013.03.018 [doi]
PST - aheadofprint
SO  - J Am Soc Echocardiogr. 2013 Apr 24. pii: S0894-7317(13)00216-2. doi:
      10.1016/j.echo.2013.03.018.

PMID- 23622877
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1549-4713 (Electronic)
IS  - 0161-6420 (Linking)
DP  - 2013 Apr 25
TI  - Pseudoexfoliation: Normative Data and Associations: The Beijing Eye Study 2011.
LID - S0161-6420(13)00035-3 [pii]
LID - 10.1016/j.ophtha.2013.01.020 [doi]
AB  - OBJECTIVE: To assess the prevalence of pseudoexfoliation syndrome (PEX) and its
      associations in a population-based setting. DESIGN: Population-based,
      cross-sectional cohort study. PARTICIPANTS: Of 4403 eligible subjects with an age
      of >/=50 years, 3468 individuals (78.8%) participated in the Beijing Eye Study
      2011 (mean age, 64.6+/-9.8 years; range, 50-93 years). METHODS: All study
      participants underwent a detailed ophthalmologic examination. After medical pupil
      dilation, PEX was assessed by an experienced ophthalmologist using
      slit-lamp-based biomicroscopy. MAIN OUTCOME MEASURES: Prevalence and associations
      of PEX. RESULTS: Slit-lamp examination results were available for 3022 study
      participants (87.1%). Definite pseudoexfoliation was observed in 72 of the 3022
      subjects, with a prevalence of 2.38% (95% confidence interval [CI], 1.84-2.93).
      Suspected PEX was detected in 104 of the subjects (3.44%; 95% CI, 2.8-4.1). The
      overall prevalence of PEX (definite and suspected) was 176 of 3022 or 5.82% (95% 
      CI, 4.99-6.66). In 80 subjects (45.5%), PEX was detected in both eyes, whereas it
      was detected only in the right eye in 42 subjects (23.9%) and only in the left
      eye in 54 (30.7%). The prevalence of PEX increased from 1.1% in among those 50 to
      54 years old, to 3.5%, 5.7%, and 11.8% among those 60 to 64 years, 70 to 74
      years, and >/=80 years, respectively. In multivariate analysis, presence of PEX
      was significantly associated with older age (P<0.001; odds ratio [OR], 1.08; 95% 
      CI, 1.04-1.10), shorter axial length (P = 0.03; OR, 0.82; 95% CI, 0.68,0.98), and
      shallower anterior chamber (P = 0.03; OR, 0.59; 95% CI, 0.36-0.95). We found that
      PEX was not associated (all P>0.05) with sex, diabetes mellitus, blood pressure, 
      psychological depression, smoking, dyslipidemia, body mass index, central corneal
      thickness, corneal diameter, optic nerve head measurements, choroidal thickness, 
      retinal vessel diameters, early age-related macular degeneration, or retinal vein
      occlusion. CONCLUSIONS: In a North Chinese population aged >/=50 years, the
      prevalence of definite PEX was 2.38% (95% CI, 1.84-2.93), suspect PEX was 3.4%
      (95% CI, 2.8-4.1) and overall PEX was 5.82% (95% CI, 4.99-6.66). We found PEX to 
      be associated with older age, shorter axial length, and shallower anterior
      chamber. The relationship between PEX and glaucomatous optic neuropathy remained 
      inconclusive among our population. FINANCIAL DISCLOSURE(S): The authors have no
      proprietary or commercial interest in any materials discussed in this article.
CI  - Copyright (c) 2013 American Academy of Ophthalmology. Published by Elsevier Inc. 
      All rights reserved.
AD  - Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University 
      of Medical Science, Beijing, China.
FAU - You, Qi Sheng
AU  - You QS
FAU - Xu, Liang
AU  - Xu L
FAU - Wang, Ya Xing
AU  - Wang YX
FAU - Yang, Hua
AU  - Yang H
FAU - Ma, Ke
AU  - Ma K
FAU - Li, Jian Jun
AU  - Li JJ
FAU - Zhang, Li
AU  - Zhang L
FAU - Jonas, Jost B
AU  - Jonas JB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/09/13 [received]
PHST- 2013/01/06 [revised]
PHST- 2013/01/11 [accepted]
AID - S0161-6420(13)00035-3 [pii]
AID - 10.1016/j.ophtha.2013.01.020 [doi]
PST - aheadofprint
SO  - Ophthalmology. 2013 Apr 25. pii: S0161-6420(13)00035-3. doi:
      10.1016/j.ophtha.2013.01.020.

PMID- 23622869
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1879-1409 (Electronic)
IS  - 0305-4179 (Linking)
DP  - 2013 Apr 24
TI  - Does the type of skin replacement surgery influence the rate of infection in
      acute burn injured patients?
LID - S0305-4179(13)00089-2 [pii]
LID - 10.1016/j.burns.2013.03.015 [doi]
AB  - INTRODUCTION: Infection is a major cause of morbidity and mortality following
      burn. Early debridement and wound closure minimize the risk of infection. This
      study aimed to examine the association of surgical modalities with burn wound
      infection (BWI) rate, graft loss and length of stay (LOS) outcome. METHOD: This
      study is a retrospective analysis of all patients undergoing surgical
      intervention at the Royal Perth Hospital between 2004 and 2011. Multivariable
      regression analyses were used to predict the impact of burn and patient factors
      on the outcomes. RESULTS: Seven hundred seventy patients were eligible for
      inclusion with 74.8% males and a mean total body surface area (TBSA) burnt of
      7.9% (range 1.0-75). Sixty-seven patients (8.7%) had positive post-operative
      swabs indicating potential wound infection. Age and TBSA significantly increased 
      the risk of BWI (confirmed by quantitative swab). Positive microbiology was not
      associated with surgery type. Age, TBSA, diabetes and surgical modalities had
      significant influence on LOS in hospital. Only TBSA was an independent predictor 
      of graft loss. CONCLUSION: Age, TBSA and diabetes were associated with poorer
      outcomes after burn. Surgery type was not associated independently with the risk 
      of infection.
CI  - Copyright (c) 2013 Elsevier Ltd and ISBI. All rights reserved.
AD  - Burns Service of Western Australia, Royal Perth Hospital, Fiona Wood Foundation
      of Western, Australia; School of Medicine, University of Notre Dame, Fremantle,
      Australia.
FAU - Park, Jae H
AU  - Park JH
FAU - Heggie, Katrina M
AU  - Heggie KM
FAU - Edgar, Dale W
AU  - Edgar DW
FAU - Bulsara, Max K
AU  - Bulsara MK
FAU - Wood, Fiona M
AU  - Wood FM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Burns
JT  - Burns : journal of the International Society for Burn Injuries
JID - 8913178
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/11/14 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/03/22 [accepted]
AID - S0305-4179(13)00089-2 [pii]
AID - 10.1016/j.burns.2013.03.015 [doi]
PST - aheadofprint
SO  - Burns. 2013 Apr 24. pii: S0305-4179(13)00089-2. doi: 10.1016/j.burns.2013.03.015.

PMID- 23622819
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1545-004X (Electronic)
IS  - 0894-1130 (Linking)
DP  - 2013 Apr 24
TI  - Hand impairment and activity limitations in four chronic diseases.
LID - S0894-1130(13)00026-4 [pii]
LID - 10.1016/j.jht.2013.03.002 [doi]
AB  - STUDY DESIGN: Retrospective cohort. INTRODUCTION: Hand involvement in
      osteoarthritis (OA) and rheumatoid arthritis (RA) are well known to occupational 
      and physical therapists; however, it is not known whether the impairments and
      activity limitations with diabetes (DMII) and systemic sclerosis (SSc) are as
      severe as those observed with OA and RA. PURPOSE: To compare the hand impairments
      and activity limitations in the 4 diseases. METHODS: A convenience sample of 156 
      participants received evaluations of hand impairments: strength, joint motion,
      and dexterity and completed a hand activity limitations questionnaire. RESULTS:
      The SSc and RA participants had weaker pinch, decreased joint motion and more
      activity limitations than the DMII and OA groups. There were no significant
      differences between the groups for right hand grip strength and pegboard
      dexterity, and applied dexterity. CONCLUSIONS: OA and DMII groups had
      significantly less impairments and activity limitations than the SSc and RA
      groups. LEVEL OF EVIDENCE: 2C.
CI  - Copyright (c) 2013 Hanley & Belfus. Published by Elsevier Inc. All rights
      reserved.
AD  - Occupational Therapy Graduate Program MSC09 5240, University of New Mexico,
      Albuquerque, NM 87131-0001, USA. Electronic address: jpoole@salud.unm.edu.
FAU - Poole, Janet L
AU  - Poole JL
FAU - Santhanam, Deepa D
AU  - Santhanam DD
FAU - Latham, Autumn L
AU  - Latham AL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - J Hand Ther
JT  - Journal of hand therapy : official journal of the American Society of Hand
      Therapists
JID - 8806591
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/12/21 [received]
PHST- 2013/03/17 [revised]
PHST- 2013/03/22 [accepted]
AID - S0894-1130(13)00026-4 [pii]
AID - 10.1016/j.jht.2013.03.002 [doi]
PST - aheadofprint
SO  - J Hand Ther. 2013 Apr 24. pii: S0894-1130(13)00026-4. doi:
      10.1016/j.jht.2013.03.002.

PMID- 23622812
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1872-7484 (Electronic)
IS  - 1566-0702 (Linking)
DP  - 2013 Apr 23
TI  - Cardiovascular autonomic dysfunction in non-obese diabetic mice.
LID - S1566-0702(13)00071-4 [pii]
LID - 10.1016/j.autneu.2013.03.011 [doi]
AB  - It is known that diabetes is associated with autonomic dysfunction; however, data
      about autonomic function in non-obese diabetic mice (NOD) remain scarce. We
      evaluated the autonomic profile of NOD mice. Female mice, 24-28week old, were
      divided in two groups: NOD (n=6) and control (n=6, Swiss mice). NOD mice with
      glycemia >/=300mg/dl were used. Heart rate variability (HRV) and arterial
      pressure variability (APV) in time and frequency domains, symbolic analysis of
      heart rate (HR) and baroreflex sensitivity were evaluated. HR and arterial
      pressure (AP) were similar between the groups; however, HRV (total variance of RR
      interval: NOD=21.07+/-3.75 vs. C=42.02+/-6.54ms2) and the vagal modulation index 
      RMSSD were lower in NOD group (4.01+/-0.32 vs. 8.28+/-0.97ms). Moreover, the
      absolute and normalized low-frequency (LF) components were also enhanced in NOD
      (normalized=61.0+/-4.0%) as compared to control mice (normalized=20.0+/-4.0%).
      Both the absolute and normalized high-frequency (HF) components were lower in NOD
      (normalized=39.0+/-4.0%) when compared to the control group
      (normalized=80.0+/-4.0). In the symbolic analysis the 0V pattern, an indication
      of sympathetic activity, was higher in NOD and 2LV pattern, an indication of
      parasympathetic activity, was lower in the NOD than in the control group. Both
      bradycardic and tachycardic responses were decreased in NOD (3.01+/-0.72 vs.
      4.54+/-0.36bpm/mmHg and 2.49+/-0.31 vs. C=3.43+/-0.33bpm/mmHg) when compared to
      the control group. Correlation analysis showed negative correlations between
      vagal indexes (RMSSD, %HF and 2LV) and glycemic levels. In conclusion, NOD mice
      develop severe diabetes correlated with autonomic dysfunction.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Hypertension Unit, Heart Institute (InCor), School of Medicine, University of Sao
      Paulo (FMUSP), 44 Dr Eneas de Carvalho Aguiar Avenue, 05403-000 Sao Paulo/SP,
      Brazil; Nove de Julho University, Sao Paulo/SP, Brazil. Electronic address:
      oscaralbuquerque@yahoo.com.br.
FAU - Moraes, Oscar A
AU  - Moraes OA
FAU - Colucci, Juliana A
AU  - Colucci JA
FAU - Souza, Leandro E
AU  - Souza LE
FAU - Scapini, Katia B
AU  - Scapini KB
FAU - Moraes-Silva, Ivana C
AU  - Moraes-Silva IC
FAU - Mostarda, Cristiano
AU  - Mostarda C
FAU - De Angelis, Katia
AU  - De Angelis K
FAU - Casarini, Dulce E
AU  - Casarini DE
FAU - Irigoyen, Maria Claudia
AU  - Irigoyen MC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Auton Neurosci
JT  - Autonomic neuroscience : basic & clinical
JID - 100909359
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/01/21 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/03/27 [accepted]
AID - S1566-0702(13)00071-4 [pii]
AID - 10.1016/j.autneu.2013.03.011 [doi]
PST - aheadofprint
SO  - Auton Neurosci. 2013 Apr 23. pii: S1566-0702(13)00071-4. doi:
      10.1016/j.autneu.2013.03.011.

PMID- 23622804
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 2090-2387 (Electronic)
IS  - 1687-1979 (Linking)
VI  - 14
IP  - 1
DP  - 2013 Mar
TI  - Hepatitis C virus genotype distribution in Egyptian diabetic patients: a
      preliminary study.
PG  - 14-9
LID - 10.1016/j.ajg.2013.01.005 [doi]
LID - S1687-1979(13)00022-1 [pii]
AB  - BACKGROUND AND STUDY AIMS: There is controversy regarding whether a specific
      hepatitis C virus (HCV) genotype is associated with diabetes mellitus. This study
      aimed to investigate HCV genotype distribution in diabetics and its relation to
      some clinical and laboratory variables in HCV-positive diabetic versus
      non-diabetic Egyptians in East Delta. PATIENTS AND METHODS: The study included
      100 HCV-positive patients of which 66 were diabetic in addition to 35 healthy
      adults as a control group. Clinical assessment, laboratory measurements of plasma
      glucose, insulin, C-peptide, C-reactive protein (CRP), tumour necrosis
      factor-alpha (TNF-alpha) and liver functions (alanine aminotransferase (ALT),
      aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT)) as well as 
      HCV genotype determination were done, and AST/platelet ratio index (APRI) and
      Homoeostasis Model of Assessment-Insulin Resistance (HOMA-IR) were calculated.
      RESULTS: The main results were the presence of HCV genotype 3, in 31.8% of the
      diabetic group and in 26.5% of the non-diabetic group, while the remainder of
      cases had genotype 4, the predominant genotype in Egypt. This is the first report
      of the presence of HCV genotype 3 in about 30% of an Egyptian cohort. However,
      there was no significant difference in genotype distribution between both groups.
      Further, there were significantly higher values of HOMA-IR, insulin and C-peptide
      in HCV-positive groups in comparison to the control group, while TNF-alpha was
      significantly higher in the HCV-positive diabetic group. However, there were no
      significant differences between both genotypes regarding these parameters.
      CONCLUSION: Although this study reveals for the first time the presence of HCV
      genotype 3 in a significant percentage of a group of Egyptian patients, where the
      majority were diabetic, the association between diabetes and certain HCV
      genotypes could not be confirmed on the basis of our findings. Hence, taking into
      consideration the impact of such a finding on the treatment decisions of those
      patients, further studies are warranted to explore these findings to a greater
      extent.
CI  - Copyright (c) 2013 Arab Journal of Gastroenterology. Published by Elsevier Ltd.
      All rights reserved.
AD  - Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura 
      City, Egypt. omasaleh@gmail.com
FAU - Saleh, Omayma
AU  - Saleh O
FAU - Baiomy, Azza A
AU  - Baiomy AA
FAU - El-desouky, Ayman
AU  - El-desouky A
FAU - Zaghloul, Hosam
AU  - Zaghloul H
FAU - El-Arman, Mohammad
AU  - El-Arman M
FAU - Dahab, Gamal M
AU  - Dahab GM
FAU - Abdel-Rahman, Mohamed S
AU  - Abdel-Rahman MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130307
PL  - Egypt
TA  - Arab J Gastroenterol
JT  - Arab journal of gastroenterology : the official publication of the Pan-Arab
      Association of Gastroenterology
JID - 101298363
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2011/11/12 [received]
PHST- 2012/09/04 [revised]
PHST- 2012/12/29 [accepted]
PHST- 2013/03/07 [aheadofprint]
AID - S1687-1979(13)00022-1 [pii]
AID - 10.1016/j.ajg.2013.01.005 [doi]
PST - ppublish
SO  - Arab J Gastroenterol. 2013 Mar;14(1):14-9. doi: 10.1016/j.ajg.2013.01.005. Epub
      2013 Mar 7.

PMID- 23622655
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 3
DP  - 2013 Apr
TI  - Long-term renal function deteriorates at a similar rate among liver transplant
      patients with preserved renal function at 1 year and in the general population:
      is chronic calcineurin inhibitor nephrotoxicity overrated?
PG  - 1182-7
LID - 10.1016/j.transproceed.2012.10.015 [doi]
LID - S0041-1345(12)01191-8 [pii]
AB  - BACKGROUND: Chronic calcineurin inhibitor (CNI) nephrotoxicity is associated with
      histologic kidney lesions, but the contribution of maintenance-dose CNI use to
      the decline over time in glomerular filtration rate (GFR) post liver
      transplantation (OLT) remains unclear. METHODS: We studied annual changes in
      estimated GFR >1 year posttransplant among 105 CNI-treated adult OLT patients
      with a GFR of 60-100 mL/min at 1 year during a mean follow-up of 7 years (20
      years in 20 patients). RESULTS: The annual GFR decline >1 year posttransplant was
      0.2 mL/min per year (SD 3.8). This decline rate was unaffected by the decade of
      OLT, follow-up period, or GFR at 1 year, and showed no correlation with CNI blood
      levels. Of the 13 (12%) patients with a GFR deterioration >3 mL/min per year, 77%
      presented with hypertension, diabetes, and/or dyslipidemia. The decline in GFR >1
      year post-OLT did not exceed the decline of 0.5-0.8 mL/min per year reported in
      the general population. Declines faster than 3 mL/min per year, which occurred no
      more frequently among patients than in the general population, seemed
      attributable to coexistent vascular risk factors. CONCLUSIONS: Among OLT patients
      with preserved renal function at 1 year posttransplant, our findings challenge
      the clinical impact of chronic progressive CNI nephrotoxicity and highlight the
      importance of a tight control of blood pressures, glucose and lipid levels, and
      other modifiable risk factors in order to preserve long-term renal function.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki,
      Finland. Fredrik.Aberg@helsinki.fi
FAU - Aberg, F
AU  - Aberg F
FAU - Makisalo, H
AU  - Makisalo H
FAU - Nordin, A
AU  - Nordin A
FAU - Isoniemi, H
AU  - Isoniemi H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - S0041-1345(12)01191-8 [pii]
AID - 10.1016/j.transproceed.2012.10.015 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Apr;45(3):1182-7. doi: 10.1016/j.transproceed.2012.10.015.

PMID- 23622647
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 3
DP  - 2013 Apr
TI  - Effects of cyclosporine and sirolimus on insulin-stimulated glucose transport and
      glucose tolerance in a rat model.
PG  - 1142-8
LID - 10.1016/j.transproceed.2013.02.009 [doi]
LID - S0041-1345(13)00158-9 [pii]
AB  - Cyclosporine (CsA) and sirolimus (SRL) have been associated with undesirable side
      effects, including posttransplantation diabetes and hyperlipidemia, but the
      molecular mechanisms underlying these effects remain to be elucidated. Animal
      studies focusing on clinically relevant doses are advised. This study sought to
      compare the metabolic effects on isolated rat adipocytes treated with either CsA 
      or SRL ex vivo and after long-term in vivo treatment in Wistar rats. We assessed 
      the ex vivo effects of CsA (0.5-30 mumol/L) and SRL (1-250 mumol/L) on
      insulin-stimulated (14)C-glucose uptake in epididymal adipocytes (n = 6-9). In
      parallel, rats (n = 12) were treated with either vehicle, CsA (5 mg/kg/d) or SRL 
      (1 mg/kg/d) for either 3 or 9 weeks. At the end of the treatment, glucose
      tolerance test (GTT) and insulin-stimulated (14)C-glucose uptake as well as
      biochemical parameters were analyzed. A significant reduction in the
      insulin-stimulated glucose uptake over basal was observed among isolated
      adipocytes, whether exposed ex vivo or in vivo to CsA or SRL treatment.
      Furthermore, the SRL group showed significantly lighter fat pads and smaller
      adipocytes at 3 weeks with a smaller gain in body weight throughout the study
      compared with either the vehicle or CsA cohorts. Glucose intolerance was observed
      after a GTT, at the end of the treatment with either drug. Additionally, at 9
      weeks serum triglycerides were increased by CsA compared with vehicle or SRL
      treatment. Interestingly, although SRL-treated animals presented higher fed and
      fasted insulin levels compared with either group, suggesting insulin resistance, 
      the CsA group presented lower fed and fasted insulin values, suggesting a defect 
      in insulin secretion at 9 weeks. These results suggested that either ex vivo
      treatment of fat cells or in vivo treatment of rats with CsA or SRL impaired
      insulin-stimulated glucose uptake by adipocytes. Both drugs caused glucose
      intolerance, which altogether could be responsible for the development of
      posttransplantation diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra,
      Portugal.
FAU - Lopes, P
AU  - Lopes P
FAU - Fuhrmann, A
AU  - Fuhrmann A
FAU - Sereno, J
AU  - Sereno J
FAU - Pereira, M J
AU  - Pereira MJ
FAU - Nunes, P
AU  - Nunes P
FAU - Pedro, J
AU  - Pedro J
FAU - Melao, A
AU  - Melao A
FAU - Reis, F
AU  - Reis F
FAU - Carvalho, E
AU  - Carvalho E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - S0041-1345(13)00158-9 [pii]
AID - 10.1016/j.transproceed.2013.02.009 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Apr;45(3):1142-8. doi: 10.1016/j.transproceed.2013.02.009.

PMID- 23622633
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 3
DP  - 2013 Apr
TI  - Pregnancy after kidney transplantation: graft, mother, and newborn complications.
PG  - 1088-91
LID - 10.1016/j.transproceed.2013.02.006 [doi]
LID - S0041-1345(13)00155-3 [pii]
AB  - An important benefit associated with kidney transplantation (KT) in women of
      childbearing age is increased fertility. We retrospectively evaluated the
      complications associated with 24 pregnancies among our KT over 28 years. In
      particular, we examined the evolution of serum creatinine as well as maternal and
      fetal complications. To assess the impact on graft survival, our control group
      included women without pregnancy who were matched for age at KT, year of KT, and 
      follow-up time. Most women (79.2%) were primiparous. All were prescribed a
      calcineurin inhibitor, which in 75% of the cases was cyclosporine. Overall, 45.8%
      had prior hypertension, only one of whom remained on the previous
      antihypertensive regimen. The drugs most often used were nifedipine and
      methyldopa. The median age at time of KT was 24.16 (interquartile range [IQR]
      21.33 to 29.72) years and at delivery, 28.39 (IQR 25.59 to 33.88) years. The
      average interval between KT and delivery was 4.5 +/- 2.7 years (range, 1 to 10
      years). Maternal complications were anemia (n = 16), graft pyelonephritis (n =
      6), preeclampsia (n = 6), de novo proteinuria > 1 g/d (n = 3), or gestational
      diabetes mellitus (n = 2). There was no acute rejection episode or opportunistic 
      infection. The fetal complications included delayed intrauterine growth (n = 8), 
      preterm deliveries (n = 13), or congenital enzymatic deficit (n = 1). One case
      was a twin pregnancy. The average gestational age was 35.2 +/- 3 weeks, and the
      mean birth weight 2318.2 +/- 597.1 grams. In 16 pregnancies, deliveries were
      performed by caesarean section. The median serum creatinine at 1 month before
      conception was 1.20 (IQR 0.97 to 1.37) mg/dL and at 1 year after delivery it had 
      tended to increase to 1 to 20 (IQR 1.03 to 1.50) mg/dL. Death-censored graft
      survival did not differ from the control group. In conclusion, pregnancy after KT
      may be associated with serious maternal and fetal complications. We did not
      observe an increased risk of graft loss.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Nephrology, Centro Hospitalar do Porto, Porto, Portugal.
      acrisbraga@gmail.com
FAU - Rocha, A
AU  - Rocha A
FAU - Cardoso, A
AU  - Cardoso A
FAU - Malheiro, J
AU  - Malheiro J
FAU - Martins, L S
AU  - Martins LS
FAU - Fonseca, I
AU  - Fonseca I
FAU - Braga, J
AU  - Braga J
FAU - Henriques, A C
AU  - Henriques AC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - S0041-1345(13)00155-3 [pii]
AID - 10.1016/j.transproceed.2013.02.006 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Apr;45(3):1088-91. doi: 10.1016/j.transproceed.2013.02.006.

PMID- 23622631
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 3
DP  - 2013 Apr
TI  - New-onset diabetes after transplantation: assessment of risk factors and clinical
      outcomes.
PG  - 1079-83
LID - 10.1016/j.transproceed.2013.03.009 [doi]
LID - S0041-1345(13)00312-6 [pii]
AB  - BACKGROUND: New-onset diabetes after transplantation (NODAT) is a serious
      complicatin of kidney transplantation (KT) with adverse impacts on graft and
      patient survivals. This study aims assess potential risk factors for development 
      of NODAT and compare clinical outcomes of KT recipients with versus without
      NODAT. METHODS: We retrospectively evaluated 648 patients who underwent KT
      between 2005 and 2009. From the 83 (12.8%) subjects who developed NODAT, we
      selected 47 for comparison with controls free of diabetes. RESULTS: The diagnosis
      of NODAT was made at 4.3 +/- 8.5 months after transplantation in 47 patients,
      including 76.6% males, with an overall mean age of 54.5 +/- 10.8 years. Patients 
      with NODAT presented higher pretransplantation fasting plasma glucose levels (P <
      .001) as well as cyclosporine and tacrolimus trough levels (P = .003 and P <
      .001, respectively). On multivariate analysis, higher pretransplantation fasting 
      plasma glucose and higher tacrolimus, but not cyclosporine concentrations were
      independent predictors of NODAT. No differences were found for other potential
      risk factors. Upon follow-up at 6, 12, 24, 36, 48, and 60 months, renal function 
      (estimated Glomerular Filtration Rate using Modification of Diet in Renal
      Disease), 24 hour proteinuria and proportions of patients with hypertension were 
      similar between groups. Patients with NODAT showed comparable numbers of
      hospitalizations and infections, as well as acute rejection episodes and acute
      cardiovascular events as their counterparts. Event-free survival (loss of graft
      function/death with functioning graft) was similar between the groups (P = .418; 
      K-M). DISCUSSION: In our population, higher pretransplantation fasting plasma
      glucose levels and higher tacrolimus concentrations were independent predictors
      of NODAT. During a mean follow-up of 3 years, NODAT was not associated with worse
      clinical outcomes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Nephrology, Centro Hospitalar e Universitario de Coimbra, Coimbra, 
      Portugal. patriciacotovio@gmail.com
FAU - Cotovio, P
AU  - Cotovio P
FAU - Neves, M
AU  - Neves M
FAU - Rodrigues, L
AU  - Rodrigues L
FAU - Alves, R
AU  - Alves R
FAU - Bastos, M
AU  - Bastos M
FAU - Baptista, C
AU  - Baptista C
FAU - Macario, F
AU  - Macario F
FAU - Mota, A
AU  - Mota A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - S0041-1345(13)00312-6 [pii]
AID - 10.1016/j.transproceed.2013.03.009 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Apr;45(3):1079-83. doi: 10.1016/j.transproceed.2013.03.009.

PMID- 23622627
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 3
DP  - 2013 Apr
TI  - Living versus cadaveric-donor renal transplant recipients: a comparison on sexual
      function.
PG  - 1066-9
LID - 10.1016/j.transproceed.2013.03.011 [doi]
LID - S0041-1345(13)00314-X [pii]
AB  - Erectile dysfunction is experienced by 50% of men with end-stage renal disease
      (ESRD) and uremia. The origin of this dysfunction is multifactorial. The aim of
      this study was to compare living donor versus cadaveric donor transplant
      recipients regarding male sexual function. Seventy-seven sexually active male
      kidney transplant recipients (44 from living donors; 33 from cadaveric donors)
      were randomly selected from our single-center prospective database of 2016 renal 
      transplants. Epidemiological and clinical data were collected between June 2010
      and June 2011. Male sexual function was evaluated with the International Index of
      Erectile Function questionnaire (IIEF-15). We assessed the prevalence of male
      sexual dysfunction according to established cutoff points for each of the IIEF-15
      domains. Mann-Whitney and Pearson's chi- square statistical tests were used to
      compare continuous and categorical variables, respectively. The median age at the
      time of completion of the questionnaires was 43 and 51 years (P = .003) with
      median times from transplantation was of 36 and 42 months for living donor and
      cadaveric donor recipients, respectively (P = .31). Median durations of ESRD
      before surgery were 17.5 and 57 months for living donor and cadaveric donor
      recipients, respectively (P < .001). Living donor and cadaveric donor recipients 
      had median creatinine clearance values of 55 and 57 mL/min, respectively (P =
      .44). Median time after renal transplantation for first sexual intercourse was 1 
      and 2 months for living donor and cadaveric donor recipients, respectively (P =
      .35). Median body mass indices for living donor and cadaveric donor recipients
      were 24.8 and 24, respectively (P = .31). Regarding sexual function domains,
      there were significant differences only for intercourse satisfaction. In our
      cohort, living donor recipients tended to be younger, have shorter time of ESRD, 
      and less incidence of hypertension or diabetes mellitus but with greater tobacco 
      use. In conclusion, living donor transplantation exerted a favorable impact on
      sexual function.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Urology, Centro Hospitalar Porto, Porto, Portugal.
      fredbl@hotmail.com
FAU - Branco, F
AU  - Branco F
FAU - Cavadas, V
AU  - Cavadas V
FAU - Rocha, A
AU  - Rocha A
FAU - Vidinha, J
AU  - Vidinha J
FAU - Osorio, L
AU  - Osorio L
FAU - Martins, L
AU  - Martins L
FAU - Braga, I
AU  - Braga I
FAU - Cabral, J
AU  - Cabral J
FAU - Dias, L
AU  - Dias L
FAU - Henriques, C
AU  - Henriques C
FAU - Louro, N
AU  - Louro N
FAU - Silva-Ramos, M
AU  - Silva-Ramos M
FAU - Carvalho, L
AU  - Carvalho L
FAU - Fraga, A
AU  - Fraga A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - S0041-1345(13)00314-X [pii]
AID - 10.1016/j.transproceed.2013.03.011 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Apr;45(3):1066-9. doi: 10.1016/j.transproceed.2013.03.011.

PMID- 23622626
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 3
DP  - 2013 Apr
TI  - Cardiovascular risk factors and events in pancreas-kidney transplants.
PG  - 1063-5
LID - 10.1016/j.transproceed.2013.02.087 [doi]
LID - S0041-1345(13)00276-5 [pii]
AB  - Cardiovascular and cerebrovascular disease (CCVD) are major causes of morbidity
      and mortality among patients with diabetes. Strict control of treatable risk
      factors that contribute to atherosclerosis is important to reduce the risk of
      stroke, myocardial infarction, and peripheral arterial disease. Simultaneous
      pancreas-kidney transplantation (SPKT) may significantly improve these risk
      factors in patients with type 1 diabetes. We studied 103 SPKT from our center
      with both organs functioning for metabolic and hypertensive control; body mass
      index (BMI); immunosuppression; and CCVD events. The 53 females/50 males showed a
      mean age of 35 +/- 6 years, diabetes for 24 +/- 6 years, and on dialysis for 31
      +/- 23 months. The follow-up ranged from 6-142 months. Mean value of last
      creatinine clearance was 76 +/- 24 mL/min, all 103 SPKT were insulin-independent 
      with mean glycemia = 81 +/- 10 mg/dL and hemoglobin A1c (HbA1c) = 5.3% +/- 0.4%. 
      All of them were under tacrolimus treatment; 9.7% also with sirolimus but 67%
      steroid-free. According to the National Cholesterol Education Program Adult
      Treatment Panel 3 criteria, 4 patients showed a fasting glucose > 100 mg/dL; only
      one, HbA1c > 5.6%. Hypertension was recorded in 38.5%; low high-density
      lipoprotein cholesterol in 19.4%; hypertriglyceridemia in 7.8%; BMI > 30% in only
      2 patients; 21.4% were prescribed statins. We registered cardiovascular events in
      7 patients (6.8%). Patients with steroid treatment showed higher triglycerides
      (122 +/- 53 vs 90 +/- 36 mg/dL; P = .001) and more often tended to be
      hypertensive (41.2% vs 37.7%, P = .073) compared with those free of these drugs. 
      Hypertension was associated with an higher BMI (24.1 +/- 2.8 vs 22.3 +/- 2.9
      kg/m(2), P = .002). BMI > 25% was associated with higher total cholesterol (195
      +/- 47 vs 169 +/- 28 mg/dL, P = .015) and low-density lipoprotein cholesterol
      (116 +/- 40 vs 96 +/- 27 mg/dL, P = .003). Among our SPKT the prevalences of CCVD
      and metabolic syndrome were low. Hypertension was the most frequent single
      factor. Obesity was rare. In patients on steroids, hypertriglyceridemia was more 
      prevalent and hypertension tended to be more frequent. Hypertensive patients
      showed a higher BMI, which correlated with a worse lipid profile. Steroid
      withdrawal, whenever possible, may be important to achieve metabolic goals and
      minimize cardiovascular risk.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Nephrology Department, Hospital Santo Antonio, Porto, Portugal; Transplantation
      Department, Hospital Santo Antonio, Porto, Portugal. lasalet@gmail.com
FAU - Martins, L
AU  - Martins L
FAU - Fonseca, I
AU  - Fonseca I
FAU - Dias, L
AU  - Dias L
FAU - Malheiro, J
AU  - Malheiro J
FAU - Rocha, A
AU  - Rocha A
FAU - Azevedo, P
AU  - Azevedo P
FAU - Silva, H
AU  - Silva H
FAU - Almeida, R
AU  - Almeida R
FAU - Henriques, A C
AU  - Henriques AC
FAU - Davide, J
AU  - Davide J
FAU - Cabrita, A
AU  - Cabrita A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - S0041-1345(13)00276-5 [pii]
AID - 10.1016/j.transproceed.2013.02.087 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Apr;45(3):1063-5. doi: 10.1016/j.transproceed.2013.02.087.

PMID- 23622607
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 3
DP  - 2013 Apr
TI  - Acinetobacter infection in a liver transplantation intensive care unit.
PG  - 998-1000
LID - 10.1016/j.transproceed.2013.02.077 [doi]
LID - S0041-1345(13)00266-2 [pii]
AB  - OBJECTIVE: Despite the advances in surgical technique and postoperative care,
      infectious complications are associated with high mortality rates. Acinetobacter 
      species are emerging as a leading worldwide nosocomial pathogen in intensive care
      unit (ICU) patients. This study was designed to evaluate the results of the
      patients who developed Acinetobacter infection in the ICU after liver
      transplantation. METHODS: We retrospectively analyzed 220 patients who had
      undergone liver transplantation between August 2011 and August 2012. Among the 55
      positive culture results with clinical signs of infection, Acinetobacter was the 
      single infectious agent for 10 of them, who were included in the study. RESULTS: 
      The mean age of the patients was 43.1 +/- 11.79 years with a male dominance (70%,
      n = 7). Eighty percent of the patients underwent living donor liver
      transplantations (n = 8). Mean Model for End-stage Liver Disease score was 28.5
      +/- 14.99. Graft dysfunction was present in 50% (n = 5), all of whom had a
      history of preoperative hospitalization (100%, n = 10). Forty percent (n = 4) of 
      patients had a history of diabetes mellitus and 60% were subject to extended
      mechanical ventilation. Mean platelet count was 20.32 +/- 8.1 x 10(9)/mL. The
      majority of the patients had multiple culture-positive sites (90%, n = 9).
      Positive culture results for Acinetobacter species included bloodstream (n = 8), 
      drain fluid (n = 5), sputum (n = 3), paracenthesis material (n = 3), and catheter
      (n = 1). The mean period of postoperative positive culture results was 12.7 +/-
      9.5 days. Mortality was 90% (n = 9). CONCLUSION: Acinetobacter infections in the 
      ICU after liver transplantation were asociated with a high mortality presenting
      with thrombocytopenia.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Inonu University School of Medicine and Institute of Liver Transplantation,
      Malatya, Turkey. otanemrah@yahoo.de
FAU - Otan, E
AU  - Otan E
FAU - Aydin, C
AU  - Aydin C
FAU - Usta, S
AU  - Usta S
FAU - Kutluturk, K
AU  - Kutluturk K
FAU - Kayaalp, C
AU  - Kayaalp C
FAU - Yilmaz, S
AU  - Yilmaz S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - S0041-1345(13)00266-2 [pii]
AID - 10.1016/j.transproceed.2013.02.077 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Apr;45(3):998-1000. doi:
      10.1016/j.transproceed.2013.02.077.

PMID- 23622583
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 45
IP  - 3
DP  - 2013 Apr
TI  - Kidney transplant recipients with functioning grafts for more than 15 years.
PG  - 904-7
LID - 10.1016/j.transproceed.2013.02.051 [doi]
LID - S0041-1345(13)00240-6 [pii]
AB  - BACKGROUND: Renal transplantation is the best renal replacement therapy because
      it significantly improves patient survival. The developments in transplantation
      and increasing number of patients with end-stage renal disease (ESRD) have
      unmasked long-term complications secondary to immunosuppressive drugs and chronic
      renal failure. METHODS AND RESULTS: Eighty-six renal transplant recipients with
      grafts that have functioned more than 15 years were included in the study. This
      cross-sectional retrospective analysis of demographic, clinical, and laboratory
      findings was conducted in 3 Turkish transplantation centers. The mean age was
      30.4 +/- 10.2 years at the time of the transplantation. The mean time between the
      transplantation and the study was 19.1 +/- 3.6 years. At the time of the study,
      mean creatinine level was 1.52 +/- 0.60 mg/dL, 70.09% of the patients displayed
      glomerular filtration rates <60 mL/min/1.73 m(2). Urinary protein excretion was
      0.57 +/- 0.65 g/d. Hypertension and hyperlipidemia were the most common comorbid 
      diseases. Twelve patients had diabetes and 9 cardiovascular disease. Seventeen
      patients had been diagnosed with skin and 5 with non-skin cancer. CONCLUSIONS: As
      the number of recipients with long-term functioning grafts increases, long-term
      complications become evident, particularly chronic renal failure. Survivors
      should be evaluated regularly and treated early for risk factors and
      complications to improve long-term graft and patient survival.
CI  - Crown Copyright (c) 2013. Published by Elsevier Inc. All rights reserved.
AD  - Division of Nephrology, Department of Internal Medicine, School of Medicine, Ege 
      University, Izmir, Turkey. aygul.celtik@ege.edu.tr
FAU - Celtik, A
AU  - Celtik A
FAU - Alpay, N
AU  - Alpay N
FAU - Celik, A
AU  - Celik A
FAU - Sezer, T O
AU  - Sezer TO
FAU - Turkmen, A
AU  - Turkmen A
FAU - Camsari, T
AU  - Camsari T
FAU - Toz, H
AU  - Toz H
FAU - Sever, M S
AU  - Sever MS
FAU - Hoscoskun, C
AU  - Hoscoskun C
CN  - Turkish Society of Nephrology Kidney Transplantation Working Group
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - S0041-1345(13)00240-6 [pii]
AID - 10.1016/j.transproceed.2013.02.051 [doi]
PST - ppublish
SO  - Transplant Proc. 2013 Apr;45(3):904-7. doi: 10.1016/j.transproceed.2013.02.051.

PMID- 23622263
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1476-4245 (Electronic)
IS  - 1475-4916 (Linking)
VI  - 102
IP  - 2
DP  - 2013 Apr
TI  - A prospective multi-centric open clinical trial of homeopathy in diabetic distal 
      symmetric polyneuropathy.
PG  - 130-8
LID - 10.1016/j.homp.2013.02.004 [doi]
LID - S1475-4916(13)00009-X [pii]
AB  - OBJECTIVES: To evaluate homeopathic treatment in the management of diabetic
      distal symmetric polyneuropathy. METHODS: A prospective multi-centric clinical
      observational study was carried out from October 2005 to September 2009 by
      Central Council for Research in Homeopathy (CCRH) (India) at its five
      institutes/units. Patients suffering from diabetes mellitus (DM) and presenting
      with symptoms of diabetic polyneuropathy (DPN) were screened, investigated and
      were enrolled in the study after fulfilling the inclusion and exclusion criteria.
      Patients were evaluated by the diabetic distal symmetric polyneuropathy symptom
      score (DDSPSS) developed by the Council. A total of 15 homeopathic medicines were
      identified after repertorizing the nosological symptoms and signs of the disease.
      The appropriate constitutional medicine was selected and prescribed in 30, 200
      and 1 M potency on an individualized basis. Patients were followed up regularly
      for 12 months. RESULTS: Out of 336 patients (167 males and 169 females) enrolled 
      in the study, 247 patients (123 males and 124 females) were analyzed. All
      patients who attended at least three follow-up appointments and baseline curve
      conduction studies were included in the analysis.). A statistically significant
      improvement in DDSPSS total score (p = 0.0001) was found at 12 months from
      baseline. Most objective measures did not show significant improvement.
      Lycopodium clavatum (n = 132), Phosphorus (n = 27) and Sulphur (n = 26) were the 
      medicines most frequently prescribed. Adverse event of hypoglycaemia was observed
      in one patient only. CONCLUSION: This study suggests homeopathic medicines may be
      effective in managing the symptoms of DPN patients. Further studies should be
      controlled and include the quality of life (QOL) assessment.
CI  - Copyright (c) 2013 The Faculty of Homeopathy. Published by Elsevier Ltd. All
      rights reserved.
AD  - Central Council for Research in Homoeopathy, New Delhi, India.
FAU - Nayak, Chaturbhuja
AU  - Nayak C
FAU - Oberai, Praveen
AU  - Oberai P
FAU - Varanasi, Roja
AU  - Varanasi R
FAU - Baig, Hafeezullah
AU  - Baig H
FAU - Ch, Raveender
AU  - Ch R
FAU - Reddy, G R C
AU  - Reddy GR
FAU - Devi, Pratima
AU  - Devi P
FAU - S, Bhubaneshwari
AU  - S B
FAU - Singh, Vikram
AU  - Singh V
FAU - Singh, V P
AU  - Singh VP
FAU - Singh, Hari
AU  - Singh H
FAU - Shitanshu, Shashi Shekhar
AU  - Shitanshu SS
LA  - eng
PT  - Journal Article
PL  - Scotland
TA  - Homeopathy
JT  - Homeopathy : the journal of the Faculty of Homeopathy
JID - 101140517
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2010/09/28 [received]
PHST- 2013/01/24 [revised]
PHST- 2013/02/05 [accepted]
AID - S1475-4916(13)00009-X [pii]
AID - 10.1016/j.homp.2013.02.004 [doi]
PST - ppublish
SO  - Homeopathy. 2013 Apr;102(2):130-8. doi: 10.1016/j.homp.2013.02.004.

PMID- 23622115
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 17
IP  - 2
DP  - 2013 Apr 28
TI  - Inhaled aerosolized insulin ameliorates hyperglycemia-induced inflammatory
      responses in the lungs in experimental model of acute lung injury.
PG  - R83
AB  - INTRODUCTION: Previous studies have shown that patients with diabetes mellitus
      appear to have a lower prevalence of acute lung injury. We assumed that insulin
      prescribed to patients with diabetes has an anti-inflammatory property and
      pulmonary administration of insulin might exert beneficial effects much more than
      intravenous administration. METHODS: Twenty eight mechanically ventilated rabbits
      underwent lung injury by saline lavage, and then animals were allocated into
      normoglycemia group (NG), hyperglycemia group (HG), HG treated with intravenous
      insulin (HG-VI) group or HG treated with aerosolized insulin (HG-AI) group with
      continuous infusion of different fluid solutions and treatments: normal saline,
      50% glucose, 50% glucose with intravenous insulin, or 50% glucose with inhaled
      aerosolized insulin, respectively. After 4 hours of treatment and the lungs and
      heart were excised en bloc, and then high-mobility group B1 concentration in
      bronchoalveolar lavage fluid, interleukin-8 and toll-like receptor 4 mRNA
      expression in bronchoalveolar lavage fluid cells, and lung myeloperoxidase
      activity were measured. RESULTS: Treatment with both aerosolized insulin and
      intravenous insulin attenuated toll-like receptor 4 mRNA expressions in the
      bronchoalveolar lavage fluid cells. Interleukin-8 and toll-like receptor 4 mRNA
      expression was significantly lower in the HG-AI group than in the HG-IV group.
      The lung myeloperoxidase activity in the normal healthy group showed
      significantly lower levels compared to the NG group but not different compared to
      those of the HG, HG-VI, and HG-AI groups. CONCLUSIONS: The results suggest that
      insulin attenuates inflammatory responses in the lungs augmented by hyperglycemia
      in acute lung injury and its efficacy may be better when administered by aerosol.
FAU - Fan, Wei
AU  - Fan W
FAU - Nakazawa, Koichi
AU  - Nakazawa K
FAU - Abe, Shinya
AU  - Abe S
FAU - Inoue, Miori
AU  - Inoue M
FAU - Kitagawa, Masanobu
AU  - Kitagawa M
FAU - Nagahara, Noriyuki
AU  - Nagahara N
FAU - Makita, Koshi
AU  - Makita K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130428
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/01/16 [received]
PHST- 2013/04/28 [accepted]
PHST- 2013/04/28 [aheadofprint]
AID - cc12697 [pii]
AID - 10.1186/cc12697 [doi]
PST - aheadofprint
SO  - Crit Care. 2013 Apr 28;17(2):R83.

PMID- 23622036
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 24
IP  - 5
DP  - 2013 May
TI  - Catheter-based radiofrequency renal sympathetic denervation for resistant
      hypertension.
PG  - 632-9
LID - 10.1016/j.jvir.2013.01.491 [doi]
LID - S1051-0443(13)00532-0 [pii]
AB  - PURPOSE: To evaluate the feasibility, efficacy, and safety of catheter-based
      radiofrequency renal sympathetic denervation for treatment of resistant
      hypertension. MATERIALS AND METHODS: Twenty-four patients with essential
      hypertension unresponsive to at least three antihypertensive agents underwent
      renal denervation (RDN). Three patients had variant renal anatomy. Comorbidities 
      included diabetes (n = 11), renal failure (n = 4), and obstructive sleep apnea (n
      = 2). The effect on 24-hour ambulatory blood pressure (BP) was assessed at 6
      months. Patients with a decrease in systolic BP of at least 10mm Hg were
      considered responders. RESULTS: RDN was bilateral in 19 patients and single-sided
      in five. The 19 patients with bilateral RDN showed mean reductions in 24-hour
      ambulatory BP of 20.7/8.7mm Hg+/-18.1/9.9 (systolic/diastolic; P = .0001/P =
      .0012). Sixteen bilaterally treated patients (84.2%) showed a systolic BP
      reduction of at least 10mm Hg and were considered responders, whereas only one of
      the five patients with single-sided RDN showed a response. Two responders with
      sleep apnea showed improvement in polysomnography indices, and one with left
      concentric ventricular hypertrophy showed complete cardiac remodeling 11 months
      after the RDN procedure. Renal function remained unchanged in all patients,
      including those with renal failure. Optical coherence tomography of the renal
      arteries in one patient showed sporadic endothelial scarring. Renal angiograms at
      9 months (one patient) and 12 months (two patients) had normal findings.
      CONCLUSIONS: Catheter-based RDN was carried out safely, even in patients with
      comorbidities, abnormal renal arteries, or anatomic variants. The response rate
      for bilateral RDN (84.2%) was comparable to previous reports.
CI  - Copyright (c) 2013 SIR. Published by Elsevier Inc. All rights reserved.
AD  - Department of Interventional Radiology, EMO GVM Centro Cuore Columbus, Milan,
      Italy. bruno.damascelli@fastwebnet.it
FAU - Damascelli, Bruno
AU  - Damascelli B
FAU - Patelli, Gianluigi
AU  - Patelli G
FAU - Ticha, Vladimira
AU  - Ticha V
FAU - Della Rocca, Federica
AU  - Della Rocca F
FAU - Lattuada, Salvatore
AU  - Lattuada S
FAU - Sala, Chiara
AU  - Sala C
FAU - Albertoni, Alberto
AU  - Albertoni A
FAU - D'Alessio, Andrea
AU  - D'Alessio A
FAU - Funaro, Alfonso
AU  - Funaro A
FAU - Scotti, Lorenza
AU  - Scotti L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/10/30 [received]
PHST- 2013/01/15 [revised]
PHST- 2013/01/18 [accepted]
AID - S1051-0443(13)00532-0 [pii]
AID - 10.1016/j.jvir.2013.01.491 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2013 May;24(5):632-9. doi: 10.1016/j.jvir.2013.01.491.

PMID- 23621997
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1471-2474 (Electronic)
IS  - 1471-2474 (Linking)
VI  - 14
DP  - 2013
TI  - Metabolic syndrome in rheumatoid arthritis: case control study.
PG  - 147
LID - 10.1186/1471-2474-14-147 [doi]
AB  - BACKGROUND: Metabolic syndrome, a cluster of classical cardiovascular risk
      factors, including hypertension, obesity, glucose intolerance, and dyslipidemia
      is highly prevalent in patients with rheumatoid arthritis (RA). The aim of the
      study was to assess the frequency of metabolic syndrome (MS) in RA patients, and 
      to evaluate the relationships between metabolic syndrome and RA. METHODS: The
      study was conducted on 120 RA patients according to the 1987 revised American
      College of Rheumatology classification criteria, and 100 age and sex matched
      apparently healthy controls. The frequency of metabolic syndrome was assessed
      using six Metabolic Syndrome definitions (Joint Consensus 2009, National
      Cholesterol Education Programme 2004 and 2001, International Diabetes Federation,
      World Health Organisation and European Group for Study of Insulin Resistance).
      Logistic regression was used to identify independent predictors of metabolic
      Syndrome. RESULTS: The frequency of metabolic syndrome varied from 18 to 48.6% in
      RA according to the definition used and was significantly higher than controls
      (for all definitions p<0.05). In multivariate analysis, higher ESR was
      independently associated with the presence of Met S (OR =1.36; CI: 1.18-2.12; p =
      0.03). Glucocorticoid use, but not other disease modifying anti-rheumatic drugs
      (DMARDs), values remained significant independent predictors of the presence of
      metabolic syndrome in RA patients (OR = 1.45; CI: 1.12-2.14; p = 0.04).
      CONCLUSIONS: In summary, the frequency of metabolic syndrome in RA varies
      according to the definition used and was significantly higher compared to
      controls (for all definitions p<0.05). Higher systemic inflammatory marker, and
      glucocorticoids use were independent predictors associated with the presence of
      metabolic syndrome in patients with RA. These findings suggest that physicians
      should screen for metabolic syndrome in patients with RA to control its
      components and therefore reduce the risk of cardiovascular disease in these
      patients.
AD  - Department of Rheumatology, University Mohammed V Souissi, Faculty of Medicine
      and Pharmacy, El Ayachi hospital, University Hospital of Rabat-Sale, PO Box:
      10000, Sale, Morocco. rostomsamira2003@yahoo.fr.
FAU - Rostom, Samira
AU  - Rostom S
FAU - Mengat, Mariam
AU  - Mengat M
FAU - Lahlou, Racha
AU  - Lahlou R
FAU - Hari, Asmaa
AU  - Hari A
FAU - Bahiri, Rachid
AU  - Bahiri R
FAU - Hajjaj-Hassouni, Najia
AU  - Hajjaj-Hassouni N
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - England
TA  - BMC Musculoskelet Disord
JT  - BMC musculoskeletal disorders
JID - 100968565
SB  - IM
PMC - PMC3639853
OID - NLM: PMC3639853
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/09/20 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 1471-2474-14-147 [pii]
AID - 10.1186/1471-2474-14-147 [doi]
PST - epublish
SO  - BMC Musculoskelet Disord. 2013 Apr 26;14:147. doi: 10.1186/1471-2474-14-147.

PMID- 23621991
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2585 (Electronic)
IS  - 1047-2797 (Linking)
VI  - 23
IP  - 5
DP  - 2013 May
TI  - Inverse association between body mass index and chronic kidney disease in older
      diabetic adults.
PG  - 255-9
LID - 10.1016/j.annepidem.2013.03.005 [doi]
LID - S1047-2797(13)00059-8 [pii]
AB  - PURPOSE: To identify associations among body mass index (BMI), diabetes, and
      chronic kidney disease (CKD) in older adults in Taiwan. METHODS: This study
      enrolled 3334 participants aged 65 years and above who underwent an annual health
      screening at a medical center from January 2006 to December 2010. CKD was defined
      as an estimated glomerular filtration rate less than 60 mL/min/1.73 m(2). A
      multiple logistic regression analysis was used to determine associations among
      BMI, diabetes, and CKD. RESULTS: The prevalence rate of CKD was 19.7% and 10.5%
      in diabetic and nondiabetic subjects, respectively. A multivariate model
      indicated that age, diabetes, hypertriglyceridemia, low levels of high-density
      lipoprotein cholesterol, and hyperuricemia were associated with an increased risk
      of CKD. Furthermore, there was an inverse association between BMI and CKD in
      older diabetic patients, with odds ratios of 3.71, 2.32, 2.12, and 1.31 in
      underweight, normal, overweight, and obese subjects, respectively, compared with 
      nondiabetic subjects of normal weight. CONCLUSIONS: There was an inverse
      association between BMI and CKD in older diabetic patients but no such
      association was found in nondiabetic older adults. More attention should be given
      to older underweight diabetic patients because they have a higher risk of CKD.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Family Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei,
      Taiwan.
FAU - Kao, Yu-Man
AU  - Kao YM
FAU - Chen, Jong-Dar
AU  - Chen JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Epidemiol
JT  - Annals of epidemiology
JID - 9100013
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2012/10/17 [received]
PHST- 2013/02/24 [revised]
PHST- 2013/03/08 [accepted]
AID - S1047-2797(13)00059-8 [pii]
AID - 10.1016/j.annepidem.2013.03.005 [doi]
PST - ppublish
SO  - Ann Epidemiol. 2013 May;23(5):255-9. doi: 10.1016/j.annepidem.2013.03.005.

PMID- 23621944
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130513
DCOM- 20130514
LR  - 20130514
IS  - 2191-1991 (Electronic)
VI  - 3
IP  - 1
DP  - 2013
TI  - Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in
      Argentina.
PG  - 11
LID - 10.1186/2191-1991-3-11 [doi]
AB  - BACKGROUND: The increasing prevalence of diabetes and its inadequate management
      results in a heavy burden of the disease for the patients, the health and the
      productive system and the overall community. Consequently, it is necessary to
      have new effective drugs to treat people with diabetes to decrease such burden.
      DPP-4 inhibitors can help to cope with this demand, but its usage is challenged
      by its apparent high cost. The aim of the current study was to compare a
      simulated cost-effectiveness ratio of metformin (MET) plus one drug of the DPP-4 
      inhibitors family, saxagliptin (SAXA) or sulfonylurea (SU) treatment during a
      20-year period, from the perspective of the social security system, in a cohort
      of people with Type 2 diabetes (T2DM) who did not attain glycosylated hemoglobin 
      treatment target values only with MET. METHODS: A discrete event simulation model
      (Cardiff diabetes model) based on UKPDS 68 was used to simulate disease
      progression and to estimate the economic and health treatment consequences in
      people with T2DM. The clinical efficacy parameters for SAXA administration were
      obtained from the literature; local standard costs were considered for drug
      acquisition, adverse events (AEs), and micro/macrovascular complications. Costs
      were expressed in US dollars (2009) with an annual 3.5% discount and a 20-year
      time horizon. RESULTS: The SAXA + MET treated group had a lower number of
      non-fatal events than the SU + MET treated group. The model also predicted a
      lower number of fatal macrovascular events for the SAXA + MET group (149.6 vs.
      152.8). The total cost of the SAXA + MET cohort was 15% higher than that of the
      SU + MET cohort. Treatment with SAXA + MET resulted in a higher number of
      quality-adjusted life years (QALYs) (9.54 vs. 9.32) and life-years gained (LYGs) 
      (20.84 vs. 20.76) compared to those treated with SU + MET. The incremental cost
      per QALY and LYG gained was $7,374 and $20,490, respectively. CONCLUSIONS:
      According to the criteria proposed by the Commission on Macroeconomics and
      Health, the use of the combination SAXA + MET is highly cost-effective in
      Argentina.
AD  - CENEXA - Center of Experimental and Applied Endocrinology (UNLP-CONICET La
      Plata), PAHO/WHO Collaborating Center for Diabetes, La Plata, Argentina.
      jelgart@cenexa.org.
FAU - Elgart, Jorge F
AU  - Elgart JF
FAU - Caporale, Joaquin E
AU  - Caporale JE
FAU - Gonzalez, Lorena
AU  - Gonzalez L
FAU - Aiello, Eleonora
AU  - Aiello E
FAU - Waschbusch, Maximiliano
AU  - Waschbusch M
FAU - Gagliardino, Juan J
AU  - Gagliardino JJ
LA  - eng
PT  - Journal Article
DEP - 20130427
PL  - Germany
TA  - Health Econ Rev
JT  - Health economics review
JID - 101583209
PMC - PMC3651339
OID - NLM: PMC3651339
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:01
CRDT- 2013/04/30 06:00
PHST- 2012/08/09 [received]
PHST- 2013/04/19 [accepted]
PHST- 2013/04/27 [aheadofprint]
AID - 2191-1991-3-11 [pii]
AID - 10.1186/2191-1991-3-11 [doi]
PST - epublish
SO  - Health Econ Rev. 2013 Apr 27;3(1):11. doi: 10.1186/2191-1991-3-11.

PMID- 23621926
OWN - NLM
STAT- In-Data-Review
DA  - 20130429
IS  - 0767-0974 (Print)
IS  - 0767-0974 (Linking)
VI  - 29
IP  - 4
DP  - 2013 Apr
TI  - [Superkines: cytokines displaying better targeted functions].
PG  - 345-9
LID - 10.1051/medsci/2013294004 [doi]
AD  - Department of Medicine, Columbia center for translational immunology and Naomi
      Berrie Diabetes Center, 630 West 168th Street, Mail Box 127, New York, NY 10032, 
      Etats-Unis.
FAU - Creusot, Remi J
AU  - Creusot RJ
FAU - Moraga, Ignacio
AU  - Moraga I
LA  - fre
PT  - Journal Article
TT  - Superkines, des cytokines aux fonctions mieux ciblees.
DEP - 20130426
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/04/26 [epublish]
AID - 10.1051/medsci/2013294004 [doi]
AID - medsci2013294p345 [pii]
PST - ppublish
SO  - Med Sci (Paris). 2013 Apr;29(4):345-9. doi: 10.1051/medsci/2013294004. Epub 2013 
      Apr 26.

PMID- 23621920
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Unravelling the impact of ethnicity on health in Europe: the HELIUS study.
PG  - 402
LID - 10.1186/1471-2458-13-402 [doi]
AB  - BACKGROUND: Populations in Europe are becoming increasingly ethnically diverse,
      and health risks differ between ethnic groups. The aim of the HELIUS (HEalthy
      LIfe in an Urban Setting) study is to unravel the mechanisms underlying the
      impact of ethnicity on communicable and non-communicable diseases.
      METHODS/DESIGN: HELIUS is a large-scale prospective cohort study being carried
      out in Amsterdam, the Netherlands. The sample is made up of Amsterdam residents
      of Surinamese (with Afro-Caribbean Surinamese and South Asian-Surinamese as the
      main ethnic groups), Turkish, Moroccan, Ghanaian, and ethnic Dutch origin. HELIUS
      focuses on three disease categories: cardiovascular disease (including diabetes),
      mental health (depressive disorders and substance use disorders), and infectious 
      diseases. The explanatory mechanisms being studied include genetic profile,
      culture, migration history, ethnic identity, socio-economic factors and
      discrimination. These might affect disease risks through specific risk factors
      including health-related behaviour and living and working conditions. Every five 
      years, participants complete a standardized questionnaire and undergo a medical
      examination. Biological samples are obtained for diagnostic tests and storage.
      Participants' data are linked to morbidity and mortality registries. The aim is
      to recruit a minimum of 5,000 respondents per ethnic group, to a total of 30,000 
      participants. DISCUSSION: This paper describes the rationale, conceptual
      framework, and design and methods of the HELIUS study. HELIUS will contribute to 
      an understanding of inequalities in health between ethnic groups and the
      mechanisms that link ethnicity to health in Europe.
AD  - Department of Public Health, Academic Medical Center, University of Amsterdam,
      Amsterdam, The Netherlands. k.stronks@amc.uva.nl.
FAU - Stronks, Karien
AU  - Stronks K
FAU - Snijder, Marieke B
AU  - Snijder MB
FAU - Peters, Ron Jg
AU  - Peters RJ
FAU - Prins, Maria
AU  - Prins M
FAU - Schene, Aart H
AU  - Schene AH
FAU - Zwinderman, Aeilko H
AU  - Zwinderman AH
LA  - eng
PT  - Journal Article
DEP - 20130427
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3646682
OID - NLM: PMC3646682
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/02/19 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/04/27 [aheadofprint]
AID - 1471-2458-13-402 [pii]
AID - 10.1186/1471-2458-13-402 [doi]
PST - epublish
SO  - BMC Public Health. 2013 Apr 27;13:402. doi: 10.1186/1471-2458-13-402.

PMID- 23621823
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 27
TI  - Evaluation of a Diabetes Education Video Among the Tz'utujil Maya in Guatemala.
AD  - 1 School of Medicine, University of California , San Francisco, San Francisco,
      California.
FAU - Nagata, Jason M
AU  - Nagata JM
FAU - Cassidy, L Charles
AU  - Cassidy LC
FAU - Hickey, Matthew D
AU  - Hickey MD
FAU - Chuc, Juan Manuel
AU  - Chuc JM
FAU - Bream, Kent D W
AU  - Bream KD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1089/dia.2013.0058 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 27.

PMID- 23621793
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 26
TI  - Comparison Between Shorter Straight and Thinner Microtapered Insulin Injection
      Needles.
AB  - Abstract Background: Many diabetes patients who require insulin perform multiple 
      subcutaneous injections every day that often cause pain, discomfort, and anxiety.
      We compared efficacy (glycemic control) and patient preference for two types of
      needle: a shorter straight needle (32 gaugex4 mm, straight wall; Nippon Becton
      Dickinson Co., Ltd., Tokyo, Japan; hereafter referred to as BD32S4) and a thinner
      microtapered needle (33-gauge tip and 28-gauge basex5 mm, double-tapered wall;
      Terumo Corp., Tokyo, Japan; hereafter referred to as TR33T5) in a single-center
      study. Patients and Methods: Eighty-four patients with diabetes were enrolled in 
      a randomized, open-label crossover trial. The patients injected their usual
      insulin dosage with one type of needle for 4 weeks and then switched to the other
      type for the next 4 weeks. The serum glycated albumin level was measured before
      and after each 4-week period. Each patient assessed pain during injection on a
      150-mm visual analog scale (VAS). Needle preference, perceptions of handling, and
      acceptance were assessed by the patients, who completed a questionnaire after
      using each type of needle for 4 weeks. Results: In total, 79 patients completed
      the study. There was no difference of glycemic control between the two needles.
      The mean VAS score was -14.5 mm (95% confidence interval, -20.9, -8.0 mm),
      indicating that the patients perceived less pain with the BD32S4 needle. In the
      overall evaluation, a significantly higher percentage of patients selected the
      BD32S4 as the better needle compared with the TR33T5 (60.3% vs. 19.2%; P<0.0001).
      Conclusions: The BD32S4 needle was more highly evaluated and was preferred by the
      patients with respect to pain during injection, usability, and visual impression,
      without having a negative impact on glycemic control. The overall preference of
      patients for the shorter needle in this study suggests that needle length may be 
      one of the major contributing factors for patients' comfort in insulin injection,
      although the other relevant factors of needles still need to be considered.
AD  - Department of Internal Medicine, Division of Metabolism and Endocrinology, St.
      Marianna University School of Medicine , Kawasaki, Japan .
FAU - Nagai, Yoshio
AU  - Nagai Y
FAU - Ohshige, Toshihiko
AU  - Ohshige T
FAU - Arai, Kaori
AU  - Arai K
FAU - Kobayashi, Hidetoshi
AU  - Kobayashi H
FAU - Sada, Yukiyoshi
AU  - Sada Y
FAU - Ohmori, Shintaro
AU  - Ohmori S
FAU - Furukawa, Kentaro
AU  - Furukawa K
FAU - Kato, Hiroyuki
AU  - Kato H
FAU - Kawata, Takehiro
AU  - Kawata T
FAU - Ohta, Akio
AU  - Ohta A
FAU - Tanaka, Yasushi
AU  - Tanaka Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1089/dia.2012.0334 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 26.

PMID- 23621722
OWN - NLM
STAT- In-Data-Review
DA  - 20130429
IS  - 0374-9096 (Print)
IS  - 0374-9096 (Linking)
VI  - 47
IP  - 2
DP  - 2013 Apr
TI  - [Risk factors for gastrointestinal colonization by ESBL-producing Klebsiella
      pneumoniae and Escherichia coli in anaesthesiology and reanimation intensive care
      unit].
PG  - 223-9
AB  - In this study it was aimed to investigate the risk factors for gastrointestinal
      colonization by extended-spectrum beta-lactamase (ESBL)-producing Klebsiella
      pneumoniae and Escherichia coli in intensive care unit (ICU) of anaesthesiology
      and reanimation, Ege University Faculty of Medicine, Izmir, Turkey. This study
      was performed prospectively on adult patients hospitalized in ICU of
      anaesthesiology and reanimation and rectal swab cultures were performed in all
      patients in the first 48 hours of hospitalization and every one week until
      discharge or death. Samples were transported to the laboratory in Stuart
      transport medium and were cultured on two EMB agar plates (one including 4 mg/L
      ceftazidime) and incubated for 48 hours. E.coli and K.pneumoniae isolates were
      identified by conventional methods. Antibiotic susceptibility tests were
      performed by disc diffusion method on Mueller Hinton agar and interpreted
      according to CLSI guidelines. ESBL was confirmed by double disc synergy test. A
      total of 140 patients (49 female 91 male; age range: 18-83 years, mean age: 56.3 
      years) were evaluated, and 41 (29.3%) of the patients were found to be colonized 
      with ESBL positive E.coli (n= 39) or K.pneumoniae (n= 2). The mean time for
      colonization was 11.15 +/- 10.91 (range between 2-39) days. Age and gender of the
      patients and antibiotic consumption before or during the stay in ICU of
      anaesthesiology and reanimation were not found to be associated with colonization
      (p> 0.05). However length of ICU of anaesthesiology and reanimation stay in
      colonized patients was longer than non-colonized patients (27.59 +/- 22.52 vs.
      17.78 +/- 11.74 days; p< 0.05). Infectious episodes developed in 22% (9/41) of
      the colonized cases and three of the nine strains were isolated from the blood
      cultures, five from the urine cultures and one from both blood and
      bronchoalveolar lavage cultures. ESBL-positive E.coli or K.pneumoniae
      colonization was found as an independent risk factor for the development of
      infection (9/41 vs. 4/99 cases; p= 0.002). Forward logistic regression analysis
      revealed that diabetes mellitus, immunosuppresive drug use and length of
      intubation were associated with ESBL-positive E.coli or K.pneumoniae colonization
      (p< 0.05). The results of this study indicated that the risk of development of
      infection was significantly high in intensive care patients colonized by ESBL
      positive E.coli and K.pneumoniae and the identification of the related risk
      factors was critically important for the establishment of effective control
      measures.
AD  - Ege University Faculty of Medicine, Department of Infectious Diseases and
      Clinical Microbiology, Izmir, Turkey. draytacerdem@hotmail.com.
FAU - Oguz Mizrakci, Serpil
AU  - Oguz Mizrakci S
FAU - Arda, Bilgin
AU  - Arda B
FAU - Erdem, Huseyin Aytac
AU  - Erdem HA
FAU - Uyar, Mehmet
AU  - Uyar M
FAU - Tunger, Alper
AU  - Tunger A
FAU - Sipahi, Oguz Resat
AU  - Sipahi OR
FAU - Ulusoy, Sercan
AU  - Ulusoy S
LA  - tur
PT  - English Abstract
PT  - Journal Article
TT  - Anesteziyoloji ve reanimasyon yogun bakim unitesinde GSBL ureten Klebsiella
      pneumoniae ve Escherichia coli kolonizasyonu icin risk faktorleri.
PL  - Turkey
TA  - Mikrobiyol Bul
JT  - Mikrobiyoloji bulteni
JID - 7503830
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PST - ppublish
SO  - Mikrobiyol Bul. 2013 Apr;47(2):223-9.

PMID- 23621629
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 27
IP  - 3
DP  - 2013 May
TI  - Completely steroid-free immunosuppression in liver transplantation: a randomized 
      study.
PG  - 463-71
LID - 10.1111/ctr.12119 [doi]
AB  - INTRODUCTION: Corticosteroids (CS) have been standard immunosuppression to
      prevent and treat rejection. However, CS are associated with increased risk of
      infection, obesity, hypertension, hyperlipidemia, diabetes, and accelerated
      hepatitis C virus (HCV) recurrence post-orthotopic liver transplantation (OLT).
      This study assesses the safety and efficacy of CS-free immunosuppressive regimen 
      in adult OLT. METHODS: A two-yr, prospective, randomized study of CS with delayed
      withdrawal (CS) or CS-free regimen with basiliximab, tacrolimus, and
      enteric-coated mycophenolate sodium (EC-MPS) was performed in 39 patients (CS=20;
      CS-free=19). CS group received intra-operative methylprednisolone weaned by six
      months. HCV patients had HCV PCR pre-OLT and 0.5, one, three, and six months
      post-OLT. Protocol liver biopsies were performed at OLT, 2 and 24 wk post-OLT or 
      when indicated. RESULTS: Rejection occurred in two patients. Patient survival at 
      one yr (100% vs. 95%), three yr (85% vs. 63%), and five yr (80% vs. 63%) post-OLT
      were similar between CS and CS-free group, respectively. Death-censored graft
      survival at one yr (100% vs. 95%), three yr (85% vs. 63%), and five yr (75% vs.
      63%) were also similar. The risk of new-onset DM, hypertension,
      hypercholesterolemia, and weight gain was similar between groups. CONCLUSION: CS 
      avoidance with basiliximab, calcineurin inhibitor, and EC-MPS is safe and
      effective as CS- containing immunosuppression in adult OLT.
CI  - (c) 2013 John Wiley & Sons A/S.
AD  - Division of Transplantation, Department of Surgery, Thomas Jefferson University, 
      Philadelphia, PA, USA.
FAU - Ramirez, Carlo B
AU  - Ramirez CB
FAU - Doria, Cataldo
AU  - Doria C
FAU - Frank, Adam M
AU  - Frank AM
FAU - Armenti, Stephen T
AU  - Armenti ST
FAU - Marino, Ignazio R
AU  - Marino IR
LA  - eng
PT  - Journal Article
DEP - 20130428
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/02/12 [accepted]
PHST- 2013/04/28 [aheadofprint]
AID - 10.1111/ctr.12119 [doi]
PST - ppublish
SO  - Clin Transplant. 2013 May;27(3):463-71. doi: 10.1111/ctr.12119. Epub 2013 Apr 28.

PMID- 23621621
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1549-960X (Electronic)
IS  - 1549-9596 (Linking)
VI  - 53
IP  - 5
DP  - 2013 May 24
TI  - Unraveling the Allosteric Inhibition Mechanism of PTP1B by Free Energy
      Calculation Based on Umbrella Sampling.
PG  - 1157-67
LID - 10.1021/ci300526u [doi]
AB  - Protein tyrosine phosphatase 1B (PTP1B) is a promising target for the treatment
      of obesity and type II diabetes. Allosteric inhibitors can stabilize an active
      conformation of PTP1B by hindering the conformational transition of the WPD loop 
      of PTP1B from the open to the closed state. Here, the umbrella sampling molecular
      dynamics (MD) simulations were employed to compute the reaction path of the
      conformational transition of PTP1B, and the snapshots extracted from the MD
      trajectory were clustered into 58 conformational groups based on the key
      conformational parameter. Then, the impact of the conformational change of the
      WPD loop on the interactions between the allosteric site of PTP1B and an
      allosteric inhibitor BB3 was explored by using the MM/GBSA binding free energy
      calculations and free energy decomposition analysis. The simulation results show 
      that the binding free energy of BB3 increases gradually from the open to the
      closed conformation of the WPD loop, providing the molecular mechanism of
      allosteric inhibition. Correlation analysis of the different energy terms
      indicates that the allosteric inhibitor with more negative van der Waals
      contribution cannot only exhibit stronger binding affinity but also hinder the
      swing of the WPD loop more effectively. Besides, it is found that the energy
      contribution of Lys292 in the alpha7 helix undergoes significant change, which
      reveals that Lys292 is not only the key residue for ligand binding but also plays
      an important role in hindering the conformational change of the WPD loop.
AD  - School of Chemistry and Chemical Engineering, University of Chinese Academy of
      Sciences , Beijing 100049, China.
FAU - Cui, Wei
AU  - Cui W
FAU - Cheng, Yuan-Hua
AU  - Cheng YH
FAU - Geng, Ling-Ling
AU  - Geng LL
FAU - Liang, Den-Sheng
AU  - Liang DS
FAU - Hou, Ting-Jun
AU  - Hou TJ
FAU - Ji, Ming-Juan
AU  - Ji MJ
LA  - eng
PT  - Journal Article
DEP - 20130513
PL  - United States
TA  - J Chem Inf Model
JT  - Journal of chemical information and modeling
JID - 101230060
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/05/13 [aheadofprint]
AID - 10.1021/ci300526u [doi]
PST - ppublish
SO  - J Chem Inf Model. 2013 May 24;53(5):1157-67. doi: 10.1021/ci300526u. Epub 2013
      May 13.

PMID- 23621569
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1563-5279 (Electronic)
IS  - 0020-7454 (Linking)
DP  - 2013 Apr 29
TI  - Effects of uncoupling protein 2 -866G/A polymorphism on platelet reactivity and
      prognosis in Chinese patients with type 2 diabetes and ischemic stroke.
AB  - ABSTRACT The purpose of this study was to assess the effects of -866G>A
      polymorphism of mitochondrial uncoupling protein 2 (UCP-2) on platelet reactivity
      and prognosis in patients with type 2 diabetes and ischemic stroke (IS). A total 
      of 405 Chinese patients with type 2 diabetes and stroke were assessed in a 4-year
      follow-up case-control study. Patient response to antiplatelet therapy was
      measured with the Platelet Function Analyzer-100 by means of collagen/adenosine
      diphosphate (CADP) and collagen/epinephrine (CEPI) cartridges. The primary end
      point was a composite of stroke and TIA (transient ischemic attack), the
      secondary end point was death. The -866G>A polymorphism in UCP-2 was genotyped by
      TaqMan MGB probe method. The -866G>A SNP in UCP-2 was not significantly
      associated with recurrence of diabetic ischemical stroke (P = 0.57). A
      significant trend toward non-full response to antiplatelet therapy was seen in
      patients carrying A allel in comparison with those carrying GG genotype, as shown
      by the CADP and CEPI tests (P<0.0001). Our 4-year follow-up study shows no
      association between -866G>A variant of UCP-2 in type 2 diabetes and the risk of
      developing stroke. But in conclusion, the A allel is associated with clopidogrel 
      resistance.
AD  - 1State Key Laboratory of Pharmaceutical Biotechnology, Department of Anatomy
      Histology and Pharmacology, Laboratory of Neuropharmacology, School of Life
      Sciences , Nanjing University, Nanjing 210093 , China.
FAU - Chai, Yi
AU  - Chai Y
FAU - Gu, Bing
AU  - Gu B
FAU - Qiu, Jin-Rong
AU  - Qiu JR
FAU - Yi, Hong-Gang
AU  - Yi HG
FAU - Zhu, Qian
AU  - Zhu Q
FAU - Zhang, Lu
AU  - Zhang L
FAU - Hu, Gang
AU  - Hu G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - Int J Neurosci
JT  - The International journal of neuroscience
JID - 0270707
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.3109/00207454.2013.798733 [doi]
PST - aheadofprint
SO  - Int J Neurosci. 2013 Apr 29.

PMID- 23621515
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 29
IP  - 7
DP  - 2013 Jul
TI  - Time to initiation of oral antihyperglycemic and statin therapy in previously
      untreated patients with type 2 diabetes in the United States.
PG  - 801-6
LID - 10.1185/03007995.2013.800473 [doi]
AB  - Abstract Objective: To assess the time from the first observed diagnosis of type 
      2 diabetes (T2DM) to initiation of an oral antihyperglycemic agent (OAHA) and
      statin. Methods: In a retrospective US cohort study using the GE electronic
      medical record database, patients >/=18 years were included if they had a T2DM
      diagnosis between January 1, 2004 and December 31, 2005 (index period), had a
      last pre-index HbA1c value >/=7%, and had not received antihyperglycemic agents
      within one year prior to diagnosis (index date). Patients were eligible for
      statin therapy but not on a statin within one year before the index date.
      Patients had medical records for one year prior to (baseline) and two years after
      (follow up) diagnosis. Results: Of the 2254 eligible patients, 58% were male,
      mean age was 58 years, mean HbA1c was 8.5%, and mean LDL cholesterol was 115
      mg/dL (2.97 mmol/L) at baseline. Additionally, 21% of patients had pre-existing
      overt cardiovascular disease, 40% had dyslipidemia, 37% were obese, and 11% were 
      smokers. During follow-up, 66.1% and 41.9% of patients initiated an OAHA and a
      statin, respectively. Among the treated patients, median time from the first
      observed diabetes diagnosis to therapy initiation was 3 months (interquartile
      range: 1, 9) for OAHAs and 6 months (2, 13) for statins. Limitations: Treatment
      initiation with injectable antihyperglycemic agents and/or non-statin
      lipid-modifying therapies as well as contraindications to OAHAs or statins were
      not assessed, therefore their impact on our study results cannot be determined.
      Laboratory measurements were not available for every patient and thus many
      patients were excluded from the analysis. Conclusion: Treatment initiation with
      OAHAs and/or statins was suboptimal in patients with T2DM who were treatment
      eligible and previously untreated with OAHAs and statins. Of those treated,
      patients initiated treatment with an OAHA more often and earlier than with a
      statin.
AD  - Kailo Research Group , Fishers, IN , USA.
FAU - Sun, Peter
AU  - Sun P
FAU - Tunceli, Kaan
AU  - Tunceli K
FAU - Zhang, Qiaoyi
AU  - Zhang Q
FAU - Seck, Thomas
AU  - Seck T
FAU - Iglay, Kristy
AU  - Iglay K
FAU - Davies, Michael J
AU  - Davies MJ
FAU - Ambegaonkar, Baishali
AU  - Ambegaonkar B
FAU - Radican, Larry
AU  - Radican L
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/05/10 [aheadofprint]
AID - 10.1185/03007995.2013.800473 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2013 Jul;29(7):801-6. doi: 10.1185/03007995.2013.800473. Epub 
      2013 May 10.

PMID- 23621506
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
DP  - 2013 May 15
TI  - Is dabigatran considered a cost-effective alternative to warfarin treatment: a
      review of current economic evaluations worldwide.
AB  - Abstract Objective: Dabigatran was the first of a new generation of
      anticoagulation drugs for the indication of non-valvular atrial fibrillation (AF)
      to be approved. Evidence show that dabigatran 150 mg twice daily significantly
      reduces the risk of stroke and systemic embolism (RR = 0.65; p < 0.001) and shows
      a comparable rate of major bleedings (RR = 0.93; p = 0.32), whereas dabigatran
      110 mg twice daily was associated with a comparable rate of stroke and systemic
      embolism (RR = 0.90; p = 0.30) and a significantly lower rate of major bleedings 
      compared to warfarin treatment (RR = 0.80; p = 0.003). The purpose is to review
      current economic evaluations of these alternatives for healthcare professionals
      to include these findings in their decision-making. Methods: A systematic
      literature search identified 43 economic evaluations, of which 10 were included
      and evaluated according to the Consensus Health Economic Criteria list
      (CHEC-list) and the Oxford model. Results: Six economic evaluations concluded
      that dabigatran was a cost-effective alternative to warfarin. One evaluation
      concluded the same except when quality in warfarin treatment was excellent, with 
      a mean time in therapeutic range (TTR) > 73%. Three evaluations concluded that
      dabigatran was a cost-effective alternative to warfarin in patient sub-groups;
      TTR </= 64%, congestive heart failure, hypertension, age >/= 75, diabetes
      mellitus, prior stroke or transient ischemic attack (CHADS2 score) >/=3, or a
      CHADS2 score = 2 unless international normalized ratio (INR) control was
      excellent, and with high risk of stroke or in a low-quality warfarin treatment.
      Dabigatran 110 mg twice daily was in general dominated by dabigatran 150 mg twice
      daily. Limitations: The evaluations were not fully homogeneous, as some did not
      include loss of productivity, costs of dyspepsia, and annual costs of dabigatran 
      patient management. Conclusions: In the majority of the economic evaluations,
      dabigatran is a cost-effective alternative to warfarin treatment. In some
      evaluations dabigatran is only cost-effective in sub-groups, such as patients
      with a low TTR-value in warfarin treatment and a CHADS2 score >/=2.
AD  - Danish Center for Healthcare Improvements, Faculty of Social Sciences and Faculty
      of Health Sciences, Aalborg University , Denmark.
FAU - Hesselbjerg, Louise Justesen
AU  - Hesselbjerg LJ
FAU - Pedersen, Heidi Sjoelund
AU  - Pedersen HS
FAU - Asmussen, Mikael Bergholdt
AU  - Asmussen MB
FAU - Petersen, Karin Dam
AU  - Petersen KD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130515
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.3111/13696998.2013.800523 [doi]
PST - aheadofprint
SO  - J Med Econ. 2013 May 15.

PMID- 23621504
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
DP  - 2013 May 23
TI  - Hospitalization with acute exacerbation of chronic obstructive pulmonary disease 
      and associated health resource utilization: A population-based Danish cohort
      study.
AB  - Abstract Objective: Health resource utilization (HRU) and outcomes associated
      with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) are not
      well described. Therefore, a population-based cohort study was conducted to
      characterize patients hospitalized with AECOPD with regard to HRU, mortality,
      recurrence, and predictors of readmission with AECOPD. Methods: Using Danish
      healthcare databases, this study identified COPD patients with at least one
      AECOPD hospitalization between 2005-2009 in Northern Denmark. Hospitalized AECOPD
      patients' HRU, in-hospital mortality, 30-day, 60-day, 90-day, and 180-day
      post-discharge mortality and recurrence risk, and predictors of readmission with 
      AECOPD in the year following study inclusion were characterized. Results: This
      study observed 6612 AECOPD hospitalizations among 3176 prevalent COPD patients.
      Among all AECOPD hospitalizations, median length of stay was 6 days
      (interquartile range [IQR] 3-9 days); 5 days (IQR 3-9) among those without ICU
      stay and 11 days (IQR 7-20) among the 8.6% admitted to the ICU. Mechanical
      ventilation was provided to 193 (2.9%) and non-invasive ventilation to 479 (7.2%)
      admitted patients. In-hospital mortality was 5.6%. Post-discharge mortality was
      4.2%, 7.8%, 10.5%, and 17.4% at 30, 60, 90, and 180 days, respectively. Mortality
      and readmission risk increased with each AECOPD hospitalization experienced in
      the first year of follow-up. Readmission at least twice in the first year of
      follow-up was observed among 286 (9.0%) COPD patients and was related to
      increasing age, male gender, obesity, asthma, osteoporosis, depression,
      myocardial infarction, diabetes I and II, any malignancy, and hospitalization
      with AECOPD or COPD in the prior year. Limitations: The study included only
      hospitalized AECOPD patients among prevalent COPD patients. Furthermore,
      information was lacking on clinical variables. Conclusion: These findings
      indicate that AECOPD hospitalizations are associated with substantial mortality
      and risk of recurrence.
AD  - Department of Clinical Epidemiology, Aarhus University Hospital , Aarhus N ,
      Denmark.
FAU - Johannesdottir, Sigrun A
AU  - Johannesdottir SA
FAU - Christiansen, Christian F
AU  - Christiansen CF
FAU - Johansen, Martin B
AU  - Johansen MB
FAU - Olsen, Morten
AU  - Olsen M
FAU - Xu, Xiao
AU  - Xu X
FAU - Parker, Joseph M
AU  - Parker JM
FAU - Molfino, Nestor A
AU  - Molfino NA
FAU - Lash, Timothy L
AU  - Lash TL
FAU - Fryzek, Jon P
AU  - Fryzek JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130523
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.3111/13696998.2013.800525 [doi]
PST - aheadofprint
SO  - J Med Econ. 2013 May 23.

PMID- 23621447
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 2212-4055 (Electronic)
IS  - 1871-5281 (Linking)
DP  - 2013 Apr 25
TI  - Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic
      Nephropathy.
AB  - Diabetes is one of the risk factors to human health, which progressively leads to
      renal complications known as diabetic nephropathy. Many previous studies
      illustrated biochemical and morphological abnormalities in various animal models 
      of diabetic nephropathy, which may be attributed to altered action of adenosine, 
      an endogenous purine nucleoside released from various tissues and organs.
      Adenosine is a potent autocrine anti-inflammatory and immunosuppressive molecule 
      that is released from cells into the extracellular space at sites of inflammation
      and tissue injury. This review will give a general overview of the adenosine
      receptors and focuses on their role in diabetes nephropathy. The insight into the
      signaling pathway through adenosine receptors could be helpful in developing
      novel therapeutic tools to regulate the pathophysiological conditions that arise 
      progressively in diabetes.
AD  - Faculty of Pharmacy, University of Mansoura, Mansoura 35516, Egypt.
      mhgayyar@yahoo.com.
FAU - Elsherbiny, N M
AU  - Elsherbiny NM
FAU - Al-Gayyar, M M
AU  - Al-Gayyar MM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Inflamm Allergy Drug Targets
JT  - Inflammation & allergy drug targets
JID - 101266886
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/03/06 [received]
PHST- 2013/04/23 [revised]
PHST- 2013/04/24 [accepted]
AID - CDTIA-EPUB-20130425-2 [pii]
PST - aheadofprint
SO  - Inflamm Allergy Drug Targets. 2013 Apr 25.

PMID- 23621406
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1365-2648 (Electronic)
IS  - 0309-2402 (Linking)
DP  - 2013 Apr 29
TI  - Exploring risk, prevention and educational approaches for the non-diabetic
      offspring of patients with type 2 diabetes - a qualitative study.
LID - 10.1111/jan.12162 [doi]
AB  - AIM: To understand the knowledge and perceptions of type 2 diabetes and to
      explore preferable educational strategies in the non-diabetic offspring of
      patients with the disease. BACKGROUND: Type 2 diabetes is an increasingly
      prevalent disease with significant long-term consequences. Offspring of patients 
      with type 2 diabetes have an increased risk of developing the disease compared
      with the general population. Previous studies have shown that offspring have a
      poor perception of their own risk. DESIGN: A qualitative study was carried out
      using semi-structured one-to-one interviews. Analysis was completed using a
      structured framework approach. METHODS: Research was carried out during
      January-March 2011 in the north east of UK. Six offspring of patients diagnosed
      with the disease were interviewed. RESULTS: Participants balanced positive and
      negative aspects of their lifestyle behaviours to estimate their own risk. They
      had adequate knowledge of healthy lifestyle behaviours, but were uncertain about 
      the long-term effects and seriousness of the disease and the role of inheritance.
      Behavioural changes at an individual level would only be motivated by an event,
      which would impact on their own health. Participants believed that 'fear'-based
      strategies to health promotion would be most effective to encourage behaviour
      change. CONCLUSION: Knowledge of individual risk and why diabetes was serious was
      limited and variable. The health behaviours of this at-risk group were complex.
      Nurses engaged in the care of at-risk individuals must take this complexity into 
      account when developing and implementing multi-faceted strategies to improve
      awareness.
CI  - (c) 2013 Blackwell Publishing Ltd.
AD  - Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
FAU - Gordon, Charlotte
AU  - Gordon C
FAU - Walker, Mark
AU  - Walker M
FAU - Carrick-Sen, Debbie
AU  - Carrick-Sen D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130429
TA  - J Adv Nurs
JT  - Journal of advanced nursing
JID - 7609811
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
PHST- 2013/03/30 [accepted]
AID - 10.1111/jan.12162 [doi]
PST - aheadofprint
SO  - J Adv Nurs. 2013 Apr 29. doi: 10.1111/jan.12162.

PMID- 23621381
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
DP  - 2013 Apr 27
TI  - Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
AB  - Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) play an
      increasing role in the management of type 2 diabetes. Such incretin-based
      therapies offer some advantages over other glucose-lowering agents, but might be 
      associated with an increased risk of acute pancreatitis. Areas covered: An
      extensive literature search was performed to analyze clinical cases of acute
      pancreatitis reported in the literature or to the Food and Drug Administration
      (FDA), in randomized clinical trials, and in observational studies with five
      DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and
      linagliptin. Expert opinion: An increased risk of pancreatitis has been reported 
      in diabetic versus nondiabetic patients. Several anecdotal clinical cases of
      pancreatitis have been reported with sitagliptin and vildagliptin and an
      increased relative risk reported to the FDA with sitagliptin versus other
      comparators, but reporting bias cannot be excluded. In rather short-term clinical
      trials with well-selected diabetic patients, no increased risk of acute
      pancreatitis has been observed with any of the five commercialized DPP-4
      inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin. 
      Similarly, real-life cohort studies showed no increased incidence of pancreatitis
      with gliptins compared with other glucose-lowering agents, a finding recently
      challenged by a case- control study. These results must be confirmed in
      postmarketing surveillance programs and in ongoing large prospective trials with 
      cardiovascular outcomes.
AD  - Chu Sart Tilman , Liege , Belgium andre.scheen@chu.ulg.ac.be.
FAU - Scheen, Andre
AU  - Scheen A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1517/14740338.2013.793671 [doi]
PST - aheadofprint
SO  - Expert Opin Drug Saf. 2013 Apr 27.

PMID- 23621137
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1744-8344 (Electronic)
IS  - 1477-9072 (Linking)
VI  - 11
IP  - 5
DP  - 2013 May
TI  - Percutaneous coronary intervention in diabetic patients: should choice of stents 
      be influenced?
PG  - 541-53
LID - 10.1586/erc.13.38 [doi]
AB  - Patients with diabetes mellitus are prone to a diffuse and rapidly progressive
      form of coronary artery disease. As a result, diabetic patients undergoing
      coronary revascularization are at higher risk of cardiovascular events compared
      with nondiabetic patients. Due to marked advances of stent device technology and 
      adjunctive pharmacology, percutaneous coronary intervention has been regarded as 
      an efficient revascularization strategy in diabetic patients. Numerous randomized
      trials and large observational registries have compared the efficacy and safety
      of bare-metal stents and drug-eluting stents, as well as several DE platforms.
      This article systematically reviews the cumulative evidence from key clinical
      studies and tries to help guide the physician in making informed decisions on the
      optimal stent type for patients with diabetes mellitus.
AD  - Academic Medical Center, University of Amsterdam, The Netherlands.
FAU - Harskamp, Ralf E
AU  - Harskamp RE
FAU - Park, Duk-Woo
AU  - Park DW
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
SB  - IM
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1586/erc.13.38 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2013 May;11(5):541-53. doi: 10.1586/erc.13.38.

PMID- 23621113
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1557-8518 (Electronic)
IS  - 1540-4196 (Linking)
DP  - 2013 Apr 27
TI  - Influence of Vitamin D Treatment on Transcriptional Regulation of
      Insulin-Sensitive Genes.
AB  - Abstract Background: Obesity is a risk factor for diabetes and metabolic
      syndrome, which are characterized by insulin resistance. Inflammation is a
      co-morbid condition associated with obesity. Vitamin D, besides being a
      transcriptional regulator, is an inflammation suppressor. However, the role of
      vitamin D in alleviating obesity-induced insulin resistance is still not well
      understood. Methods: The influence of vitamin D treatment on the transcriptional 
      level of insulin receptor (IR), insulin receptor substrate (IRS-1), glucose
      transporter type 4 (GLUT-4), and vitamin D receptor (VDR) in insulin target
      tissues of liver, adipose, and muscle of mice fed on a high-fat diet (HFD) or
      low-fat diet (LFD) was studied by quantitative RT-PCR. Results: A gradual weight 
      reduction was observed in HFD-fed mice treated with vitamin D compared to a
      steady weight increase in control animals (P<0.01). In HFD mice, vitamin D
      decreased VDR expression to 0.5-fold in muscle (P=0.002), and increased it to
      3.6-fold in the liver (P<0.001); however, VDR transcription was unaltered in
      adipose tissue. Similarly, vitamin D did not influence tissue expression of IR in
      either LFD- or HFD-fed mice. Muscle IRS-1 transcription level was upregulated to 
      2.4-fold (P=0.005) in HFD mice, whereas it was reduced to 0.15-fold in liver
      tissue (P<0.001). Vitamin D treatment had no effect on GLUT-4 transcript levels
      in any of the tissues under HFD conditions. Conclusion: Vitamin D treatment
      influenced the expression of insulin-sensitive genes in a tissue-specific
      fashion. On the basis of the present findings, vitamin D does not aid glucose
      transport across cells of liver and adipose tissues, the major insulin-sensitive 
      tissues, in HFD-fed mice; however, it appears to enhance the intracellular
      mechanisms of insulin action mediated by IRS-1 and VDR in muscle tissue.
AD  - 1 Department of Clinical Pharmacy, College of Pharmacy, King Saud University ,
      Riyadh, Saudi Arabia .
FAU - Alkharfy, Khalid M
AU  - Alkharfy KM
FAU - Al-Daghri, Nasser M
AU  - Al-Daghri NM
FAU - Yakout, Sobhy M
AU  - Yakout SM
FAU - Hussain, Tajamul
AU  - Hussain T
FAU - Mohammed, Abdul Khader
AU  - Mohammed AK
FAU - Krishnaswamy, Soundararajan
AU  - Krishnaswamy S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Metab Syndr Relat Disord
JT  - Metabolic syndrome and related disorders
JID - 101150318
EDAT- 2013/04/30 06:00
MHDA- 2013/04/30 06:00
CRDT- 2013/04/30 06:00
AID - 10.1089/met.2012.0068 [doi]
PST - aheadofprint
SO  - Metab Syndr Relat Disord. 2013 Apr 27.

PMID- 23620761
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Metformin downregulates the insulin/IGF-I signaling pathway and inhibits
      different uterine serous carcinoma (USC) cells proliferation and migration in
      p53-dependent or -independent manners.
PG  - e61537
LID - 10.1371/journal.pone.0061537 [doi]
AB  - Accumulating epidemiological evidence shows that obesity is associated with an
      increased risk of several types of adult cancers, including endometrial cancer.
      Chronic hyperinsulinemia, a typical hallmark of diabetes, is one of the leading
      factors responsible for the obesity-cancer connection. Numerous cellular and
      circulating factors are involved in the biochemical chain of events leading from 
      hyperinsulinemia and insulin resistance to increased cancer risk and, eventually,
      tumor development. Metformin is an oral anti-diabetic drug of the biguanide
      family used for treatment of type 2 diabetes. Recently, metformin was shown to
      exhibit anti-proliferative effects in ovarian and Type I endometrial cancer,
      although the mechanisms responsible for this non-classical metformin action
      remain unclear. The insulin-like growth factors (IGFs) play a prominent role in
      cancer biology and their mechanisms of action are tightly interconnected with the
      insulin signaling pathways. Given the cross-talk between the insulin and IGF
      signaling pathways, the aim of this study was to examine the hypothesis that the 
      anti-proliferative actions of metformin in uterine serous carcinoma (USC) are
      potentially mediated via suppression of the IGF-I receptor (IGF-IR) pathway. Our 
      results show that metformin interacts with the IGF pathway, and induces apoptosis
      and inhibition of proliferation and migration of USC cell lines with both wild
      type and mutant p53. Taken together, our results suggest that metformin therapy
      could be a novel and attractive therapeutic approach for human USC, a highly
      aggressive variant of endometrial cancer.
AD  - Department of Human Molecular Genetics and Biochemistry, Sackler School of
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Sarfstein, Rive
AU  - Sarfstein R
FAU - Friedman, Yael
AU  - Friedman Y
FAU - Attias-Geva, Zohar
AU  - Attias-Geva Z
FAU - Fishman, Ami
AU  - Fishman A
FAU - Bruchim, Ilan
AU  - Bruchim I
FAU - Werner, Haim
AU  - Werner H
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3631250
OID - NLM: PMC3631250
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/20 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/19 [epublish]
AID - 10.1371/journal.pone.0061537 [doi]
AID - PONE-D-13-00017 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 19;8(4):e61537. doi: 10.1371/journal.pone.0061537. Print 2013.

PMID- 23620712
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1534-8644 (Print)
IS  - 1534-8644 (Linking)
VI  - 11
IP  - 1
DP  - 2013 Mar 1
TI  - The role of vitamin D in the metabolic homeostasis of diabetic bone.
PG  - 28-37
AB  - Most studies across a variety of geographic locations suggest that vitamin D
      insufficiency is more common in individuals with type 1 diabetes (T1D) compared
      to the general population. In type 2 diabetes (T2D), while obesity is commonplace
      and lower vitamin D levels are present in obese adolescents and adults, the
      association between vitamin D insufficiency and T2D is less clear. Studies
      suggest that the relationship between T2D and vitamin D may be concurrently
      influenced by ethnicity, geography, BMI and age. None-the-less, diabetic
      osteopathy is a significant co-morbidity of both forms of diabetes, and is
      characterized by micro-architectural changes that decrease bone quality leading
      to an increased risk for bone fracture in both disorders. The question remains,
      however, to what degree vitamin D homeostasis contributes to or exacerbates
      skeletal pathology in diabetes. Proposed mechanisms for vitamin D deficiency in
      diabetes include: 1) genetic predisposition (T1D); 2) increased BMI (T2D); 3)
      concurrent albuminuria (T1D or T2D); or 4) exaggerated renal excretion of vitamin
      D metabolites or vitamin D binding protein (T1D, T2D, animal models). The
      specific effects of vitamin D treatment on diabetic osteoporosis have been
      examined in rodents, and demonstrate skeletal improvements even in the face of
      untreated diabetes. However, human clinical trial data examining whether vitamin 
      D status can be directly related to or is predictive of bone quality and fracture
      risk in those with diabetes is still needed. Herein, we provide a review of the
      literature linking vitamin D, diabetes and skeletal health.
AD  - Department of Pediatrics, University of Arkansas for Medical Sciences, Little
      Rock, AR.
FAU - Thrailkill, Kathryn M
AU  - Thrailkill KM
FAU - Fowlkes, John L
AU  - Fowlkes JL
LA  - ENG
GR  - R01 DK055653-10/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
TA  - Clin Rev Bone Miner Metab
JT  - Clinical reviews in bone and mineral metabolism
JID - 101130733
PMC - PMC3632098
MID - NIHMS350641
OTO - NOTNLM
OT  - diabetic fracture
OT  - diabetic osteoporosis
OT  - type 1 diabetes
OT  - type 2 diabetes
OT  - vitamin D binding protein
OT  - vitamin D receptor
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PMCR- 2014/03/01 00:00
AID - 10.1007/s12018-012-9127-9 [doi]
PST - ppublish
SO  - Clin Rev Bone Miner Metab. 2013 Mar 1;11(1):28-37.

PMID- 23620579
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1758-1060 (Electronic)
IS  - 1355-8196 (Linking)
DP  - 2013 Apr 25
TI  - Developing parent expertise: A framework to guide parental care following
      diagnosis of Type 1 Diabetes in a young child.
AB  - OBJECTIVES: This article examines how health professionals guide parental
      acquisition of knowledge and development of expertise following diagnosis of Type
      1 diabetes in a young child. METHODS: Fifty-five consultations from two
      outpatient paediatric diabetes clinics, one in the UK and one in the US, were
      audio recorded, transcribed and analysed; eight exemplar extracts are presented
      here. Participants were parents, whose child younger than 6 years of age had been
      diagnosed with diabetes within the previous 14 months, and health professionals, 
      who were experienced doctors, nurses, dieticians and social workers. RESULTS:
      Over the first year following diagnosis, experienced health professionals use
      four strategies to enable parental self-management of their child's diabetes.
      Clinicians begin by setting expectations to define the shared responsibilities
      for the management of the child's disease. Next, they introduce two concepts,
      trial and error, to help parents respond to variations in blood glucose values
      and pattern recognition, to help parents refine therapy. As parents gain
      confidence, clinicians encourage independent pro-active management. Together,
      these four strategies form a framework to enable development of parental
      expertise. CONCLUSIONS: This framework addresses the needs of parents and guides 
      their socialization as they assume the role of an expert health care provider for
      their child. If incorporated into clinical guidelines and health professional
      training programmes, the framework could facilitate improved self-management of
      diabetes and perhaps of other chronic diseases.
AD  - Research Fellow, European Centre on Health of Societies in Transition, London
      School of Hygiene and Tropical Medicine, UK.
FAU - Niedel, Selaine
AU  - Niedel S
FAU - Traynor, Michael
AU  - Traynor M
FAU - Tamborlane, William
AU  - Tamborlane W
FAU - Acerini, Carlo
AU  - Acerini C
FAU - McKee, Martin
AU  - McKee M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - J Health Serv Res Policy
JT  - Journal of health services research & policy
JID - 9604936
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 1355819613475602 [pii]
AID - 10.1177/1355819613475602 [doi]
PST - aheadofprint
SO  - J Health Serv Res Policy. 2013 Apr 25.

PMID- 23620537
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1460-2393 (Electronic)
IS  - 1460-2393 (Linking)
DP  - 2013 Apr 24
TI  - Relative and attributable diabetes risk associated with hyperuricemia in US
      veterans with gout.
AB  - BACKGROUND: Hyperuricemia is known to be a risk factor for incident type 2
      diabetes mellitus, but the absolute magnitude of the association is not known. We
      aimed to evaluate the strength of association between hyperuricemia and the risk 
      of developing diabetes among the US veterans with gout.Methods: Patients (age >/=
      18 years) with >/=2 clinical encounters with gout diagnoses, no history of
      inflammatory diseases or diabetes and two serum urate (sUA) measurements between 
      1 January 2002 and 1 January 2011 were selected. Diabetes was identified using
      International Classification of Disease-9-Clinical Modification codes, use of
      anti-diabetic medications or HbA1c >/=6.5%. sUA levels were assessed at 6-month
      cycles (hyperuricemia: sUA >7 mg/dl). Accumulated hazard curves for time to first
      diabetes diagnosis were derived from Kaplan-Meier (KM) analysis. Risk of diabetes
      associated with hyperuricemia was estimated using a Cox proportional hazards
      model. Population attributable fraction (AF) of new-onset diabetes within 1 year 
      was estimated using logistic regression.Results: Among 1923 patients, average age
      was 62.9 years, body mass index was 30.6 kg/m2, and follow-up time was 80 months.
      Diabetes rates from KM were 19% for sUA </= 7 mg/dl, 23% for 7 mg/dl < sUA </= 9 
      mg/dl and 27% for sUA > 9 mg/dl at the end of follow-up period (P < 0.001).
      Hyperuricemia was associated with a significantly higher risk of developing
      diabetes, after adjusting for confounding factors (hazard ratio: 1.19, 95%
      confidence interval: [1.01-1.41]). Approximately, 8.7% of all new cases of
      diabetes were statistically attributed to hyperuricemia.Conclusions: Among
      veterans, hyperuricemia was associated with excess risk for developing diabetes. 
      Approximately, 1 in 11 new cases of diabetes were statistically attributed to
      hyperuricemia.
AD  - From the Department of Medicine, Stanford University, 300 Pasteur Drive,
      Stanford, CA 94305, USA, Takeda Pharmaceuticals International Inc. One Takeda
      Parkway, Deerfield, IL 60015, USA, Analysis Group, Inc. 111 Huntington Ave.,
      Boston, MA 02199, USA and Tulane University, 1440 Canal Street, New Orleans, LA
      70112, USA.
FAU - Krishnan, E
AU  - Krishnan E
FAU - Akhras, K S
AU  - Akhras KS
FAU - Sharma, H
AU  - Sharma H
FAU - Marynchenko, M
AU  - Marynchenko M
FAU - Wu, E Q
AU  - Wu EQ
FAU - Tawk, R
AU  - Tawk R
FAU - Liu, J
AU  - Liu J
FAU - Shi, L
AU  - Shi L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - QJM
JT  - QJM : monthly journal of the Association of Physicians
JID - 9438285
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - hct093 [pii]
AID - 10.1093/qjmed/hct093 [doi]
PST - aheadofprint
SO  - QJM. 2013 Apr 24.

PMID- 23620478
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 25
TI  - Diabetic Retinopathy and Microalbuminuria Can Predict Macroalbuminuria and Renal 
      Function Decline in Japanese Type 2 Diabetic Patients: Japan Diabetes
      Complications Study.
AB  - OBJECTIVETo examine the interactive relationship between diabetic retinopathy
      (DR) and diabetic nephropathy (DN) in type 2 diabetic patients, and to elucidate 
      the role of DR and microalbuminuria on the onset of macroalbuminuria and renal
      function decline.RESEARCH DESIGN AND METHODSWe explored the effects of DR and
      microalbuminuria on the progression of DN from normoalbuminuria and low
      microalbuminuria (<150 mg/gCr) to macroalbuminuria or renal function decline in
      the Japan Diabetes Complications Study (JDCS), which is a nationwide randomized
      controlled study of type 2 diabetic patients focusing on lifestyle modification. 
      Patients were divided into four groups according to presence or absence of DR and
      MA: normoalbuminuria without DR [NA(DR-)] (n = 773), normoalbuminuria with DR
      [NA(DR+)] (n = 279), microalbuminuria without DR [MA(DR-)] (n = 277), and
      microalbuminuria with DR [MA(DR+)] (n = 146). Basal urinary albumin-to-creatinine
      ratio and DR status were determined at baseline and followed for a median of 8.0 
      years.RESULTSAnnual incidence rates of macroalbuminuria were 1.6/1,000
      person-years (9 incidences), 3.9/1,000 person-years (8 incidences), 18.4/1,000
      person-years (34 incidences), and 22.1/1,000 person-years (22 incidences) in the 
      four groups, respectively. Multivariate-adjusted hazard ratios of the progression
      to macroalbuminuria were 2.48 (95% CI 0.94-6.50; P = 0.07), 10.40 (4.91-22.03; P 
      < 0.01), and 11.55 (5.24-25.45; P < 0.01) in NA(DR+), MA(DR-), and MA(DR+),
      respectively, in comparison with NA(DR-). Decline in estimated glomerular
      filtration rate (GFR) per year was two to three times faster in MA(DR+) (-1.92
      mL/min/1.73 m2/year) than in the other groups.CONCLUSIONSIn normo- and low
      microalbuminuric Japanese type 2 diabetic patients, presence of microalbuminuria 
      at baseline was associated with higher risk of macroalbuminuria in 8 years.
      Patients with microalbuminuria and DR showed the fastest GFR decline. Albuminuria
      and DR should be considered as risk factors of renal prognosis in type 2 diabetic
      patients. An open sharing of information will benefit both ophthalmologists and
      diabetologists.
AD  - Health Care Center, Kitasato University, Kanagawa, Japan.
FAU - Moriya, Tatsumi
AU  - Moriya T
FAU - Tanaka, Shiro
AU  - Tanaka S
FAU - Kawasaki, Ryo
AU  - Kawasaki R
FAU - Ohashi, Yasuo
AU  - Ohashi Y
FAU - Akanuma, Yasuo
AU  - Akanuma Y
FAU - Yamada, Nobuhiro
AU  - Yamada N
FAU - Sone, Hirohito
AU  - Sone H
FAU - Yamashita, Hidetoshi
AU  - Yamashita H
FAU - Katayama, Shigehiro
AU  - Katayama S
CN  - for the Japan Diabetes Complication Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - dc12-2327 [pii]
AID - 10.2337/dc12-2327 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 25.

PMID- 23620477
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 25
TI  - Overexpression of Hemopexin in the Diabetic Eye: A new pathogenic candidate for
      diabetic macular edema.
AB  - OBJECTIVEHemopexin is a well-recognized permeability factor in the kidney, but
      its potential role in blood-retinal barrier (BRB) breakdown has not been
      explored. The main aims of this study were as follows: 1) to determine hemopexin 
      expression in the retina and its content in the vitreous fluid from diabetic
      patients with diabetic macular edema (DME) and nondiabetic patients, 2) to
      evaluate the effect of hemopexin on BRB permeability, and 3) to determine whether
      dexamethasone prevents an eventual hemopexin-induced hyperpermeability.RESEARCH
      DESIGN AND METHODSBiological material included 1) retinas from 10 diabetic donors
      with nonproliferative retinopathy and from 10 nondiabetic donors and 2) vitreous 
      fluid from 14 patients with DME and 14 nondiabetic patients. Hemopexin and
      hemopexin receptor mRNA levels were measured by quantitative RT-PCR and hemopexin
      concentrations by ELISA. The effect of hemopexin on permeability in culture was
      evaluated in human retinal pigment epithelial (ARPE)-19 cells and bovine retinal 
      endothelial cells. The experiments were repeated in the presence of
      hemopexin-neutralizing antibodies and dexamethasone.RESULTSA higher expression of
      hemopexin was detected in the retinal pigment epithelium (RPE) from diabetic
      patients in comparison with nondiabetic control subjects. Intravitreal hemopexin 
      concentration was higher in patients with DME than in nondiabetic subjects.
      Hemopexin significantly increased permeability in ARPE-19 cells, which was
      prevented by both hemopexin-neutralizing antibodies and
      dexamethasone.CONCLUSIONSHemopexin is overexpressed in the RPE of diabetic
      patients with DME and induces the breakdown of RPE cells in vitro. Dexamethasone 
      was able to prevent hemopexin-induced hyperpermeability. Our results suggest that
      hemopexin can be considered a new pathogenic candidate for DME.
AD  - Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute,
      Universitat Autonoma de Barcelona, Spain.
FAU - Hernandez, Cristina
AU  - Hernandez C
FAU - Garcia-Ramirez, Marta
AU  - Garcia-Ramirez M
FAU - Simo, Rafael
AU  - Simo R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - dc12-2634 [pii]
AID - 10.2337/dc12-2634 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 25.

PMID- 23620476
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 25
TI  - Changes in Detection of Retinopathy in Type 2 Diabetes in the First 4 Years of a 
      Population-Based Diabetes Eye Screening Program: Retrospective cohort study.
AB  - OBJECTIVEAnnual diabetes eye screening has been implemented in England since
      2008. This study aimed to estimate changes in the detection of retinopathy in the
      first 4 years of the program.RESEARCH DESIGN AND METHODSParticipants included
      32,340 patients with type 2 diabetes resident in three London boroughs with one
      or more screening records between 2008 and 2011. Data for 87,570 digital images
      from 2008 to 2011 were analyzed. Frequency of sight-threatening diabetic
      retinopathy (STDR) was estimated by year of screen for first screens and for
      subsequent screens according to retinopathy status at first screen.RESULTSAmong
      16,621 first-ever screens, the frequency of STDR was 7.1% in 2008, declining to
      6.4% in 2011 (P = 0.087). The proportion with a duration of diabetes of <1 year
      at first screen increased from 18.7% in 2008 to 48.6% in 2011. Second or later
      screens were received by 26,308 participants. In participants with mild
      nonproliferative retinopathy at first screen, the proportion with STDR at second 
      or later screen declined from 21.6% in 2008 to 8.4% in 2011 (annual change -2.2% 
      [95% CI -3.3 to -1.0], P < 0.001). In participants with no retinopathy at first
      screen, STDR declined from 9.2% in 2008 to 3.2% in 2011 (annual change -1.8%
      [-2.0 to -1.7], P < 0.001). Declining trends were similar in sociodemographic
      subgroups.CONCLUSIONSAfter the inception of population-based diabetes eye
      screening, patients at lower risk of STDR contribute an increasing proportion to 
      the eligible population, and the proportion detected with STDR at second or
      subsequent screening rounds declines rapidly.
AD  - Department of Primary Care and Public Health Sciences, King's College London,
      London, U.K.
FAU - Forster, Alice S
AU  - Forster AS
FAU - Forbes, Angus
AU  - Forbes A
FAU - Dodhia, Hiten
AU  - Dodhia H
FAU - Connor, Clare
AU  - Connor C
FAU - Du Chemin, Alain
AU  - Du Chemin A
FAU - Sivaprasad, Sobha
AU  - Sivaprasad S
FAU - Mann, Samantha
AU  - Mann S
FAU - Gulliford, Martin C
AU  - Gulliford MC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - dc13-0130 [pii]
AID - 10.2337/dc13-0130 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 25.

PMID- 23620444
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1555-905X (Electronic)
IS  - 1555-9041 (Linking)
DP  - 2013 Apr 25
TI  - Type 2 Translational Research for CKD.
AB  - Strategies to effectively treat people with CKD have been identified by
      conventional clinical research. Despite this evidence, awareness, screening,
      detection, diagnosis, risk factor control, treatment, and outcomes remain
      substandard. Translating clinical evidence into actionable measures that reduce
      the burden of CKD is a pressing need. Expansion from a "bench-to-bedside"
      paradigm (conventional type 1 translation) to research that encompasses "clinic
      and community" is the core concept of type 2 translation. Specifically, this is
      the discipline of identifying factors and using strategies that lead to adoption,
      maintenance, and sustainability of science-based interventions in practice. This 
      review identifies key elements of type 2 translational research and highlights
      the current scope of this type of research for CKD. For type 2 translation to
      achieve the goals of providing high-quality care and better health outcomes, key 
      facilitators (e.g., theory-based frameworks, adaptable interventions, and
      inclusion of sustainability and evaluation metrics) and essential elements (e.g.,
      multidisciplinary team care, health information technology, and stakeholder
      engagement) must be integrated. The National Institute of Diabetes and Digestive 
      and Kidney Diseases recently funded five proposals that aim to improve outcomes
      for people with CKD, focusing on diverse components of the healthcare continuum: 
      patient safety and transitions; delivery of high-quality, evidence-based CKD
      care; and elimination of disparities. The need for type 2 translational research 
      in CKD is urgent because of preventable human suffering and unsustainable costs
      of providing care. Focus on the theory, framework, and approaches we have
      suggested may help us meet that challenge.
AD  - Providence Medical Research Center, Providence Sacred Heart Medical Center and
      Children's Hospital, Spokane, Washington;, daggerNephrology Division, Department 
      of Medicine, University of Washington School of Medicine, Seattle, Washington;,
      double daggerDivision of Nephrology and, paragraph signDepartment of Medicine,
      University of California San Francisco, San Francisco, California, section
      signCollege of Nursing and, ||College of Pharmacy, Washington State University,
      Spokane, Washington.
FAU - Tuttle, Katherine R
AU  - Tuttle KR
FAU - Tuot, Delphine S
AU  - Tuot DS
FAU - Corbett, Cynthia L
AU  - Corbett CL
FAU - Setter, Stephen M
AU  - Setter SM
FAU - Powe, Neil R
AU  - Powe NR
LA  - ENG
GR  - K23 DK094850/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Clin J Am Soc Nephrol
JT  - Clinical journal of the American Society of Nephrology : CJASN
JID - 101271570
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - CJN.00130113 [pii]
AID - 10.2215/CJN.00130113 [doi]
PST - aheadofprint
SO  - Clin J Am Soc Nephrol. 2013 Apr 25.

PMID- 23620415
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1530-8561 (Electronic)
IS  - 0009-9147 (Linking)
DP  - 2013 Apr 25
TI  - Fasting Serum Lipid and Dehydroepiandrosterone Sulfate as Important Metabolites
      for Detecting Isolated Postchallenge Diabetes: Serum Metabolomics via
      Ultra-High-Performance Liquid Chromatography/Mass Spectrometry.
AB  - BACKGROUND: Isolated postchallenge diabetes (IPD), a subtype of type 2 diabetes
      mellitus (T2DM) defined as 2-h postprandial plasma glucose >/=200 mg/dL (>/=11.1 
      mmol/L) and fasting plasma glucose (FPG) <108 mg/dL (<6.0 mmol/L), is often
      overlooked during screening for diabetes on the basis of FPG concentrations. A
      key challenge is early identification of IPD by the use of fasting serum, which
      is critical for large-scale diabetes screening.METHODS: We applied a nontargeted 
      metabolomic approach using ultra-high-performance liquid
      chromatography/quadrupole TOF/mass spectrometry (UPLC-QTOF-MS) to analyze serum
      samples from 51 patients with IPD, 52 with newly diagnosed T2DM, and 49 healthy
      individuals. We processed metabolite profiles by multivariate analysis to
      identify potential metabolites, which were further confirmed by tandem mass
      spectrometry. We also used GC-MS and ELISA methods to detect potentially
      important metabolites. A number of independent samples were selected to validate 
      the identified candidates.RESULTS: We selected 15 metabolites with a view to
      distinguishing patients with IPD, whereas 11 were identified with an authentic
      standard. The selected metabolites included linoleic acid, oleic acid,
      phospholipids, and dehydroepiandrosterone sulfate (DHEA-S). In IPD samples,
      significantly higher linoleic and oleic acid (P < 0.001) and lower DHEA-S (P <
      0.001) concentrations were observed, compared with controls. The area under the
      curve from a combination of linoleic acid, oleic acid, and DHEA-S in the
      validation study was 0.849 for the IPD group.CONCLUSIONS: The current study
      provides useful information to bridge the gaps in our understanding of the
      metabolic alterations associated with IPD and might facilitate the
      characterization of patients with IPD by the use of fasting serum.
AD  - Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical
      University, Harbin, P. R. China.
FAU - Liu, Liyan
AU  - Liu L
FAU - Wang, Maoqing
AU  - Wang M
FAU - Yang, Xue
AU  - Yang X
FAU - Bin, Mingxin
AU  - Bin M
FAU - Na, Lixin
AU  - Na L
FAU - Niu, Yucun
AU  - Niu Y
FAU - Li, Ying
AU  - Li Y
FAU - Sun, Changhao
AU  - Sun C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - clinchem.2012.200527 [pii]
AID - 10.1373/clinchem.2012.200527 [doi]
PST - aheadofprint
SO  - Clin Chem. 2013 Apr 25.

PMID- 23620396
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1533-3450 (Electronic)
IS  - 1046-6673 (Linking)
VI  - 24
IP  - 6
DP  - 2013 May
TI  - The impact of membrane permeability and dialysate purity on cardiovascular
      outcomes.
PG  - 1014-23
LID - 10.1681/ASN.2012090908 [doi]
AB  - The effects of high-flux dialysis and ultrapure dialysate on survival of
      hemodialysis patients are incompletely understood. We conducted a randomized
      controlled trial to investigate the effects of both membrane permeability and
      dialysate purity on cardiovascular outcomes. We randomly assigned 704 patients on
      three times per week hemodialysis to either high- or low-flux dialyzers and
      either ultrapure or standard dialysate using a two-by-two factorial design. The
      primary outcome was a composite of fatal and nonfatal cardiovascular events
      during a minimum 3 years follow-up. We did not detect statistically significant
      differences in the primary outcome between high- and low-flux (HR=0.73, 95%
      CI=0.49 to 1.08, P=0.12) and between ultrapure and standard dialysate (HR=0.90,
      95% CI=0.61 to 1.32, P=0.60). Posthoc analyses suggested that cardiovascular
      event-free survival was significantly better in the high-flux group compared with
      the low-flux group for the subgroup with arteriovenous fistulas, which
      constituted 82% of the study population (adjusted HR=0.61, 95% CI=0.38 to 0.97,
      P=0.03). Furthermore, high-flux dialysis associated with a lower risk for
      cardiovascular events among diabetic subjects (adjusted HR=0.49, 95% CI=0.25 to
      0.94, P=0.03), and ultrapure dialysate associated with a lower risk for
      cardiovascular events among subjects with more than 3 years of dialysis (adjusted
      HR=0.55, 95% CI=0.31 to 0.97, P=0.04). In conclusion, this trial did not detect a
      difference in cardiovascular event-free survival between flux and dialysate
      groups. Posthoc analyses suggest that high-flux hemodialysis may benefit patients
      with an arteriovenous fistula and patients with diabetes and that ultrapure
      dialysate may benefit patients with longer dialysis vintage.
AD  - Division of Nephrology and.
FAU - Asci, Gulay
AU  - Asci G
FAU - Tz, Huseyin
AU  - Tz H
FAU - Ozkahya, Mehmet
AU  - Ozkahya M
FAU - Duman, Soner
AU  - Duman S
FAU - Demirci, Meltem Sezis
AU  - Demirci MS
FAU - Cirit, Mustafa
AU  - Cirit M
FAU - Sipahi, Savas
AU  - Sipahi S
FAU - Dheir, Hamad
AU  - Dheir H
FAU - Bozkurt, Devrim
AU  - Bozkurt D
FAU - Kircelli, Fatih
AU  - Kircelli F
FAU - Ok, Ebru Sevinc
AU  - Ok ES
FAU - Erten, Sinan
AU  - Erten S
FAU - Ertilav, Muhittin
AU  - Ertilav M
FAU - Kose, Timur
AU  - Kose T
FAU - Basci, Ali
AU  - Basci A
FAU - Raimann, Jochen G
AU  - Raimann JG
FAU - Levin, Nathan W
AU  - Levin NW
FAU - Ok, Ercan
AU  - Ok E
CN  - EGE Study Group
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - J Am Soc Nephrol
JT  - Journal of the American Society of Nephrology : JASN
JID - 9013836
SB  - IM
PMC - PMC3665396
OID - NLM: PMC3665396 [Available on 05/31/14]
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PMCR- 2014/05/31 00:00
PHST- 2013/04/25 [aheadofprint]
AID - ASN.2012090908 [pii]
AID - 10.1681/ASN.2012090908 [doi]
PST - ppublish
SO  - J Am Soc Nephrol. 2013 May;24(6):1014-23. doi: 10.1681/ASN.2012090908. Epub 2013 
      Apr 25.

PMID- 23620395
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1533-3450 (Electronic)
IS  - 1046-6673 (Linking)
DP  - 2013 Apr 25
TI  - Maintenance of Endothelial Guanosine Triphosphate Cyclohydrolase I Ameliorates
      Diabetic Nephropathy.
AB  - In diabetes, endothelial nitric oxide synthase (eNOS) produces superoxide anion
      rather than nitric oxide, referred to as "eNOS uncoupling," which may contribute 
      to endothelial dysfunction, albuminuria, and diabetic nephropathy. Reduced levels
      of endothelium-derived tetrahydrobiopterin (BH4), an essential cofactor for eNOS,
      promote eNOS uncoupling. Accelerated degradation of guanosine triphosphate
      cyclohydrolase I (GTPCH I), the rate-limiting enzyme in BH4 biosynthesis, also
      occurs in diabetes, suggesting that GTPCH I may have a role in diabetic
      microvascular disease. Here, we crossed endothelium-dominant GTPCH I transgenic
      mice with Ins2+/Akita diabetic mice and found that endothelial overexpression of 
      GTPCH I led to higher levels of intrarenal BH4 and lower levels of urinary
      albumin and reactive oxygen species compared with diabetic control mice.
      Furthermore, GTPCH I overexpression attenuated the hyperpermeability of
      macromolecules observed in diabetic control mice. In addition, we treated
      Ins2+/Akita mice with metformin, which activates AMP-activated protein kinase
      (AMPK) and thereby slows the degradation of GTPCH I; despite blood glucose levels
      that were similar to untreated mice, those treated with metformin had
      significantly less albuminuria. Similarly, in vitro, treating human glomerular
      endothelial cells with AMPK activators attenuated glucose-induced reductions in
      phospho-AMPK, GTPCH I, and coupled eNOS. Taken together, these data suggest that 
      maintenance of endothelial GTPCH I expression and the resulting improvement in
      BH4 biosynthesis ameliorate diabetic nephropathy.
AD  - Departments of *Nephrology and Hypertension and.
FAU - Kidokoro, Kengo
AU  - Kidokoro K
FAU - Satoh, Minoru
AU  - Satoh M
FAU - Channon, Keith M
AU  - Channon KM
FAU - Yada, Toyotaka
AU  - Yada T
FAU - Sasaki, Tamaki
AU  - Sasaki T
FAU - Kashihara, Naoki
AU  - Kashihara N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - J Am Soc Nephrol
JT  - Journal of the American Society of Nephrology : JASN
JID - 9013836
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - ASN.2012080783 [pii]
AID - 10.1681/ASN.2012080783 [doi]
PST - aheadofprint
SO  - J Am Soc Nephrol. 2013 Apr 25.

PMID- 23620354
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1477-8602 (Electronic)
IS  - 1477-8599 (Linking)
DP  - 2013 Apr 24
TI  - Bifurcation analysis of an existing mathematical model reveals novel treatment
      strategies and suggests potential cure for type 1 diabetes.
AB  - Type 1 diabetes is a disease with serious personal and socioeconomic consequences
      that has attracted the attention of modellers recently. But as models of this
      disease tend to be complicated, there has been only limited mathematical analysis
      to date. Here we address this problem by providing a bifurcation analysis of a
      previously published mathematical model for the early stages of type 1 diabetes
      in diabetes-prone NOD mice, which is based on the data available in the
      literature. We also show positivity and the existence of a family of attracting
      trapping regions in the positive 5D cone, converging towards a smaller trapping
      region, which is the intersection over the family. All these trapping regions are
      compact sets, and thus, practical weak persistence is guaranteed. We conclude our
      analysis by proposing 4 novel treatment strategies: increasing the phagocytic
      ability of resting macrophages or activated macrophages, increasing the
      phagocytic ability of resting and activated macrophages simultaneously and
      lastly, adding additional macrophages to the site of inflammation. The latter
      seems counter-intuitive at first glance, but nevertheless it appears to be the
      most promising, as evidenced by recent results.
AD  - Department of Science, Systems, and Models, Roskilde University, Universitetsvej 
      1, Building 27, 4000 Roskilde, Denmark.
FAU - Nielsen, Kenneth H M
AU  - Nielsen KH
FAU - Pociot, Flemming M
AU  - Pociot FM
FAU - Ottesen, Johnny T
AU  - Ottesen JT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Math Med Biol
JT  - Mathematical medicine and biology : a journal of the IMA
JID - 101182345
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - dqt006 [pii]
AID - 10.1093/imammb/dqt006 [doi]
PST - aheadofprint
SO  - Math Med Biol. 2013 Apr 24.

PMID- 23620341
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Linking)
DP  - 2013 Apr 26
TI  - Effects of exercise training on excitation-contraction coupling and related mRNA 
      expression in hearts of Goto-Kakizaki type 2 diabetic rats.
AB  - Although, several novel forms of intervention aiming at newly identified
      therapeutic targets are currently being developed for diabetes mellitus (DM), it 
      is well established that physical exercise continues to be one of the most
      valuable forms of non-pharmacological therapy. The aim of the study was to
      investigate the effects of exercise training on excitation-contraction coupling
      and related gene expression in the Goto-Kakizaki (GK) type 2 diabetic rat heart
      and whether exercise is able to reverse diabetes-induced changes in
      excitation-contraction coupling and gene expression. Experiments were performed
      in GK and control rats aged 10-11 months following 2-3 months of treadmill
      exercise training. Shortening, [Ca2+]i and L-type Ca2+ current were measured in
      ventricular myocytes with video edge detection, fluorescence photometry and whole
      cell patch clamp techniques, respectively. Expression of mRNA was assessed in
      ventricular muscle with real-time RT-PCR. Amplitude of shortening, Ca2+
      transients and L-type Ca2+ current were not significantly altered in ventricular 
      myocytes from GK sedentary compared to control sedentary rats or by exercise
      training. Expression of mRNA encoding Tpm2, Gja4, Atp1b1, Cacna1g, Cacnb2, Hcn2, 
      Kcna3 and Kcne1 were up-regulated and Gja1, Kcnj2 and Kcnk3 were down-regulated
      in hearts of sedentary GK rats compared to sedentary controls. Gja1, Cav3 and
      Kcnk3 were up-regulated and Hcn2 was down-regulated in hearts of exercise trained
      GK compared to sedentary GK controls. Ventricular myocyte shortening and Ca2+
      transport were generally well preserved despite alterations in the profile of
      expression of mRNA encoding a variety of cardiac muscle proteins in the adult
      exercise trained GK diabetic rat heart.
AD  - Department of Pharmacology, College of Medicine & Health Sciences, United Arab
      Emirates University, Al Ain, UAE.
FAU - Salem, K A
AU  - Salem KA
FAU - Qureshi, M A
AU  - Qureshi MA
FAU - Sydorenko, V
AU  - Sydorenko V
FAU - Parekh, K
AU  - Parekh K
FAU - Jayaprakash, P
AU  - Jayaprakash P
FAU - Iqbal, T
AU  - Iqbal T
FAU - Singh, J
AU  - Singh J
FAU - Oz, M
AU  - Oz M
FAU - Adrian, T E
AU  - Adrian TE
FAU - Howarth, F C
AU  - Howarth FC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/02/25 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s11010-013-1662-2 [doi]
PST - aheadofprint
SO  - Mol Cell Biochem. 2013 Apr 26.

PMID- 23620340
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Linking)
DP  - 2013 Apr 26
TI  - Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and
      pancreas in streptozotocin-induced diabetes.
AB  - We have investigated how diabetes affects the expression of adropin (ADR) in rat 
      brain, cerebellum, kidneys, heart, liver, and pancreas tissues. The rats in the
      diabetic group were administered an intraperitoneal (i.p.) injection of a single 
      dose of 60 mg/kg streptozotocin (STZ) dissolved in a 0.1 M phosphate-citrate
      buffer (pH 4.5). The rats were maintained in standard laboratory conditions in a 
      temperature between 21 and 23 degrees C and a relative humidity of 70 %, under a 
      12-h light/dark cycle. The animals were fed a standard commercial pellet diet.
      After 10 weeks, the animals were sacrified. ADR concentrations in the serum and
      tissue supernatants were measured by ELISA, and immunohistochemical staining was 
      used to follow the expression of the hormones in the brain, cerebellum, kidneys, 
      heart, liver, and pancreas tissues. The quantities were then compared. Increased 
      ADR immunoreaction was seen in the brain, cerebellum, kidneys, heart, liver, and 
      pancreas in the diabetes-induced rats compared to control subjects. ADR was
      detected in the brain (vascular area, pia mater, neuroglial cell, and neurons),
      cerebellum (neuroglial cells, Purkinje cells, vascular areas, and granular
      layer), kidneys (glomerulus, peritubular interstitial cells, and peritubular
      capillary endothelial cells), heart (endocardium, myocardium, and epicardium),
      liver (sinusoidal cells), and pancreas (serous acini). Its concentrations (based 
      on mg/wet weight tissues) in these tissues were measured by using ELISA showed
      that the levels of ADR were higher in the diabetic rats compared to the control
      rats. Tissue ADR levels based on mg/wet weight tissues were as follows: Pancreas 
      > liver > kidney > heart > brain > cerebellar tissues. Evidence is presented that
      shows ADR is expressed in various tissues in the rats and its levels increased in
      STZ-induced diabetes; however, this effect on the pathophysiology of the disorder
      remains to be understood.
AD  - Department of Medical Biochemistry (Firat Hormone Research Groups), School of
      Medicine, Firat University, Elazig, 23119, Turkey, saydin1@hotmail.com.
FAU - Aydin, Suleyman
AU  - Aydin S
FAU - Kuloglu, Tuncay
AU  - Kuloglu T
FAU - Aydin, Suna
AU  - Aydin S
FAU - Eren, Mehmet Nesimi
AU  - Eren MN
FAU - Yilmaz, Musa
AU  - Yilmaz M
FAU - Kalayci, Mehmet
AU  - Kalayci M
FAU - Sahin, Ibrahim
AU  - Sahin I
FAU - Kocaman, Nevin
AU  - Kocaman N
FAU - Citil, Cihan
AU  - Citil C
FAU - Kendir, Yalcin
AU  - Kendir Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/03/15 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s11010-013-1660-4 [doi]
PST - aheadofprint
SO  - Mol Cell Biochem. 2013 Apr 26.

PMID- 23620335
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Linking)
DP  - 2013 Apr 27
TI  - Green tea extract with polyethylene glycol-3350 reduces body weight and improves 
      glucose tolerance in db/db and high-fat diet mice.
AB  - Green tea extract (GTE) is regarded to be effective against obesity and type 2
      diabetes, but definitive evidences have not been proven. Based on the assumption 
      that the gallated catechins (GCs) in GTE attenuate intestinal glucose and lipid
      absorption, while enhancing insulin resistance when GCs are present in the
      circulation through inhibiting cellular glucose uptake in various tissues, this
      study attempted to block the intestinal absorption of GCs and prolong their
      residence time in the lumen. We then observed whether GTE containing the
      nonabsorbable GCs could ameliorate body weight (BW) gain and glucose intolerance 
      in db/db and high-fat diet mice. Inhibition of the intestinal absorption of GCs
      was accomplished by co-administering the nontoxic polymer polyethylene
      glycol-3350 (PEG). C57BLKS/J db/db and high-fat diet C57BL/6 mice were treated
      for 4 weeks with drugs as follows: GTE, PEG, GTE + PEG, voglibose, or
      pioglitazone. GTE mixed with meals did not have any ameliorating effects on BW
      gain and glucose intolerance. However, the administration of GTE plus PEG
      significantly reduced BW gain, insulin resistance, and glucose intolerance,
      without affecting food intake and appetite. The effect was comparable to the
      effects of an alpha-glucosidase inhibitor and a peroxisome proliferator-activated
      receptor-gamma/alpha agonist. These results indicate that prolonging the action
      of GCs of GTE in the intestinal lumen and blocking their entry into the
      circulation may allow GTE to be used as a prevention and treatment for both
      obesity and obesity-induced type 2 diabetes.
AD  - Department of Physiology and Endocrinology, Keimyung University School of
      Medicine, 1095 Dalgubeoldae-Ro, Dalseo-Gu, Daegu, 704-701, South Korea.
FAU - Park, Jae-Hyung
AU  - Park JH
FAU - Choi, Yoon Jung
AU  - Choi YJ
FAU - Kim, Yong Woon
AU  - Kim YW
FAU - Kim, Sang Pyo
AU  - Kim SP
FAU - Cho, Ho-Chan
AU  - Cho HC
FAU - Ahn, Shinbyoung
AU  - Ahn S
FAU - Bae, Ki-Cheor
AU  - Bae KC
FAU - Im, Seung-Soon
AU  - Im SS
FAU - Bae, Jae-Hoon
AU  - Bae JH
FAU - Song, Dae-Kyu
AU  - Song DK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130427
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/12/29 [received]
PHST- 2013/04/02 [accepted]
PHST- 2013/04/27 [aheadofprint]
AID - 10.1007/s00210-013-0869-9 [doi]
PST - aheadofprint
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr 27.

PMID- 23620308
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
DP  - 2013 Apr 25
TI  - Neutrophil-to-Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients 
      Undergoing Primary Percutaneous Coronary Intervention.
AB  - We investigated the relationship between baseline neutrophil-to-lymphocyte ratio 
      (NLR) and contrast-induced nephropathy (CIN) in patients with ST-segment
      elevation myocardial infarction (STEMI). Consecutive patients diagnosed with
      STEMI (n = 691) who underwent primary percutaneous coronary intervention (p-PCI) 
      were included in the study. The CIN was defined as an increase in serum
      creatinine concentration >/=25% over baseline at 48 hours. Both NLR and
      C-reactive protein levels were significantly higher in the CIN group. There was a
      stronger correlation in patients with a known history of chronic kidney disease
      and in patients with a history of diabetes mellitus (DM). Advanced age, DM, low
      baseline glomerular filtration rate, reduced postprocedural ST resolution, high
      amount of contrast media, high NLR, and low left ventricular ejection fraction
      were independent predictors of CIN. The NLR may be used as a simple and reliable 
      indicator of CIN in patients with STEMI who underwent p-PCI.
AD  - 1Department of Cardiology, Ordu University Medical School, Ordu, Turkey.
FAU - Kaya, Ahmet
AU  - Kaya A
FAU - Kaya, Yasemin
AU  - Kaya Y
FAU - Topcu, Selim
AU  - Topcu S
FAU - Gunaydin, Zeki Yuksel
AU  - Gunaydin ZY
FAU - Kurt, Mustafa
AU  - Kurt M
FAU - Tanboga, Ibrahim Halil
AU  - Tanboga IH
FAU - Kalkan, Kamuran
AU  - Kalkan K
FAU - Aksakal, Enbiya
AU  - Aksakal E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Angiology
JT  - Angiology
JID - 0203706
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 0003319713484789 [pii]
AID - 10.1177/0003319713484789 [doi]
PST - aheadofprint
SO  - Angiology. 2013 Apr 25.

PMID- 23620256
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1473-0189 (Electronic)
IS  - 1473-0189 (Linking)
DP  - 2013 Apr 26
TI  - Study of endothelial cell apoptosis using fluorescence resonance energy transfer 
      (FRET) biosensor cell line with hemodynamic microfluidic chip system.
AB  - To better understand how hyperglycemia induces endothelial cell dysfunction under
      the diabetic conditions, a hemodynamic microfluidic chip system was developed.
      The system combines a caspase-3-based fluorescence resonance energy transfer
      (FRET) biosensor cell line which can detect endothelial cell apoptosis in
      real-time, post-treatment effect and with a limited cell sample, by using a
      microfluidic chip which can mimic the physiological pulsatile flow profile in the
      blood vessel. The caspase-3-based FRET biosensor endothelial cell line (HUVEC-C3)
      can produce a FRET-based sensor protein capable of probing caspase-3 activation. 
      When the endothelial cells undergo apoptosis, the color of the sensor cells
      changes from green to blue, thus sensing apoptosis. A double-labeling fluorescent
      technique (yo pro-1 and propidium iodide) was used to validate the findings
      revealed by the FRET-based caspase sensor. The results show high rates of
      apoptosis and necrosis of endothelial cells when high glucose concentration was
      applied in our hemodynamic microfluidic chip combined with an exhaustive
      pulsatile flow profile. The two apoptosis detection techniques (fluorescent
      method and FRET biosensor) are comparable; but FRET biosensor offers more
      advantages such as real-time observation and a convenient operating process to
      generate more accurate and reliable data. Furthermore, the activation of the FRET
      biosensor also confirms the endothelial cell apoptosis induced by the abnormal
      pulsatile shear stress and high glucose concentration is through caspase-3
      pathway. A 12% apoptotic rate (nearly a 4-fold increase compared to the static
      condition) was observed when the endothelial cells were exposed to a high glucose
      concentration of 20 mM under 2 h exhaustive pulsatile shear stress of 30 dyne
      cm-2 and followed with another 10 h normal pulsatile shear stress of 15 dyne
      cm-2. Therefore, the most important finding of this study is to develop a novel
      endothelial cell apoptosis detection method, which combines the microfluidic chip
      system and FRET biosensor. This finding may provide new insight into how glucose 
      causes endothelial cell dysfunction, which is the major cause of diabetes-derived
      complications.
AD  - School of Electrical and Electronic Engineering, Nanyang Technological
      University, 50 Nanyang Avenue, Singapore 639798. kluo@ntu.edu.sg.
FAU - Yu, J Q
AU  - Yu JQ
FAU - Liu, X F
AU  - Liu XF
FAU - Chin, L K
AU  - Chin LK
FAU - Liu, A Q
AU  - Liu AQ
FAU - Luo, K Q
AU  - Luo KQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Lab Chip
JT  - Lab on a chip
JID - 101128948
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1039/c3lc50105a [doi]
PST - aheadofprint
SO  - Lab Chip. 2013 Apr 26.

PMID- 23620237
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1524-4571 (Electronic)
IS  - 0009-7330 (Linking)
VI  - 112
IP  - 9
DP  - 2013 Apr 26
TI  - Cell therapy of peripheral arterial disease: from experimental findings to
      clinical trials.
PG  - 1288-302
LID - 10.1161/CIRCRESAHA.113.300565 [doi]
AB  - The age-adjusted prevalence of peripheral arterial disease in the US population
      was estimated to approach 12% in 1985, and as the population ages, the overall
      population having peripheral arterial disease is predicted to rise. The clinical 
      consequences of occlusive peripheral arterial disease include intermittent
      claudication, that is, pain with walking, and critical limb ischemia (CLI), which
      includes pain at rest and loss of tissue integrity in the distal limbs, which may
      ultimately lead to amputation of a portion of the lower extremity. The risk
      factors for CLI are similar to those linked to coronary artery disease and
      include advanced age, smoking, diabetes mellitus, hyperlipidemia, and
      hypertension. The worldwide incidence of CLI was estimated to be 500 to 1000
      cases per million people per year in 1991. The prognosis is poor for CLI subjects
      with advanced limb disease. One study of >400 such subjects in the United Kingdom
      found that 25% required amputation and 20% (including some subjects who had
      required amputation) died within 1 year. In the United States, approximately 280 
      lower-limb amputations for ischemic disease are performed per million people each
      year. The first objective in treating CLI is to increase blood circulation to the
      affected limb. Theoretically, increased blood flow could be achieved by
      increasing the number of vessels that supply the ischemic tissue with blood. The 
      use of pharmacological agents to induce new blood vessel growth for the treatment
      or prevention of pathological clinical conditions has been called therapeutic
      angiogenesis. Since the identification of the endothelial progenitor cell in 1997
      by Asahara and Isner, the field of cell-based therapies for peripheral arterial
      disease has been in a state of continuous evolution. Here, we review the current 
      state of that field.
AD  - Department of Medicine, Division of Cardiology, Northwestern University Feinberg 
      School of Medicine, Chicago, IL 60611, USA.
FAU - Raval, Zankhana
AU  - Raval Z
FAU - Losordo, Douglas W
AU  - Losordo DW
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Circ Res
JT  - Circulation research
JID - 0047103
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 112/9/1288 [pii]
AID - 10.1161/CIRCRESAHA.113.300565 [doi]
PST - ppublish
SO  - Circ Res. 2013 Apr 26;112(9):1288-302. doi: 10.1161/CIRCRESAHA.113.300565.

PMID- 23620212
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1179-2027 (Electronic)
IS  - 1170-7690 (Linking)
VI  - 31
IP  - 6
DP  - 2013 Jun
TI  - Transferability of indirect cost of chronic disease: a systematic review and
      meta-analysis.
PG  - 501-8
LID - 10.1007/s40273-013-0053-6 [doi]
AB  - BACKGROUND: Indirect cost is an important component in economic evaluations. The 
      variation in the magnitude of indirect costs across studies and countries is
      substantial and affects the transferability of results across jurisdictions.
      OBJECTIVE: This study explored the factors involved in the variation of reported 
      indirect cost and investigated the feasibility of transferring indirect costs
      across settings. METHODS: A systematic literature review was conducted to
      identify studies estimating indirect costs for four selected chronic diseases,
      namely, asthma (AS), diabetes (DI), rheumatoid arthritis (RA) and schizophrenia
      (SC). A multiple linear regression analysis was run to identify the factors that 
      potentially explain the variation in reported indirect costs. Parametric (fixed- 
      and random-effect models) and non-parametric (bootstrapping method) meta-analyses
      were applied to local gross domestic product (GDP)/capita-adjusted indirect costs
      for each disease. Results from the three different analytical methods were
      compared to ascertain the robustness of estimation. RESULTS: The systematic
      literature review identified 77 articles that reported indirect costs of AS (n = 
      18), DI (n = 20), RA (n = 25) and SC (n = 14) for literature synthesis.
      Substantial inter- and intra-disease variations among the indirect cost studies
      were observed with respect to geographic distribution, methodology and magnitude 
      of cost estimation. Regression analysis showed that disease categories and local 
      GDP/capita significantly (p < 0.001) contributed to the variance of indirect
      cost. The range of intra-disease variation in indirect costs was substantially
      reduced after adjusting by and expressing values as local GDP/capita. The
      GDP-adjusted indirect cost in terms of percentage of local GDP/capita of AS was
      the lowest and that of SC was the highest. Bootstrapping estimation was
      relatively conservative, with slightly wider confidence intervals (CIs) than the 
      parametric method, with a mean (95 % CI) of 2.12 % (1.4089-2.9332) for AS, 10.65 
      % (7.215-14.7438) for DI, 21.98 % (17.4360-27.0631) for RA, and 79.19 %
      (52.4243-117.833) for SC. CONCLUSION: It would be convenient and feasible to
      construct a universal reference range of indirect cost for a specific disease
      based on existing data and present this as a percentage of local GDP to assist
      local decision making in jurisdictions where indirect cost data are not
      available.
AD  - School of Biomedical Sciences and Pharmacy, University of Newcastle, R108, MS
      building, University of Newcastle, Callaghan, NSW, 2308, Australia.
FAU - Zhao, Fei-Li
AU  - Zhao FL
FAU - Xie, Feng
AU  - Xie F
FAU - Hu, Hao
AU  - Hu H
FAU - Li, Shu-Chuen
AU  - Li SC
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
SB  - T
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1007/s40273-013-0053-6 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2013 Jun;31(6):501-8. doi: 10.1007/s40273-013-0053-6.

PMID- 23620200
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 73
IP  - 6
DP  - 2013 May
TI  - Insulin degludec and insulin degludec/insulin aspart: a review of their use in
      the management of diabetes mellitus.
PG  - 575-93
LID - 10.1007/s40265-013-0051-1 [doi]
AB  - Insulin degludec (Tresiba((R))) is an ultra-long-acting insulin analogue that is 
      also available as a coformulation with rapid-acting insulin aspart (insulin
      degludec/insulin aspart) [Ryzodeg((R))]. Insulin degludec has a flat, stable
      glucose-lowering profile with a duration of action of >42 h, and less
      within-patient day-to-day variability in glucose-lowering effect than the
      long-acting insulin analogue insulin glargine. In clinical trials, insulin
      degludec achieved similar glycaemic control to that seen with insulin glargine in
      patients with type 1 or 2 diabetes, but with a lower risk of nocturnal
      hypoglycaemia. In addition, trials examining a flexible dosing regimen of insulin
      degludec in patients with type 1 or 2 diabetes show the potential for adjusting
      the injection time, without compromising glycaemic control or safety. A 200 U/mL 
      formulation of insulin degludec is also available for use in patients who require
      large volumes of basal insulin. Insulin degludec/insulin aspart was noninferior
      to the long-acting insulin analogue insulin detemir in patients with type 1
      diabetes and has the potential to reduce the number of daily injections. Trial
      results also indicate that insulin degludec/insulin aspart may be an appropriate 
      option for initiating insulin therapy in patients with type 2 diabetes
      inadequately controlled with oral antidiabetic drugs. Subcutaneous insulin
      degludec was generally well tolerated in patients with type 1 or 2 diabetes. In
      conclusion, insulin degludec and insulin degludec/insulin aspart represent a
      useful advance in the treatment of type 1 or 2 diabetes.
AD  - Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754,
      Auckland, New Zealand, demail@springer.com.
FAU - Keating, Gillian M
AU  - Keating GM
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1007/s40265-013-0051-1 [doi]
PST - ppublish
SO  - Drugs. 2013 May;73(6):575-93. doi: 10.1007/s40265-013-0051-1.

PMID- 23620139
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 7
IP  - 6
DP  - 2013 Jun
TI  - Treadmill exercise ameliorates apoptotic cell death in the retinas of diabetic
      rats.
PG  - 1745-50
LID - 10.3892/mmr.2013.1439 [doi]
AB  - Apoptotic neuronal cell death in the retina is a hallmark of diabetic
      retinopathy. Exercise has been recommended for the alleviation of symptoms in
      patients with diabetes. In the present study, the effect of treadmill exercise on
      apoptosis in the retinas of diabetic rats was investigated. Diabetes was induced 
      by intraperitoneal injection of streptozotocin. The rats in the exercise groups
      ran on a treadmill for 30 min/day, 5 times a week, over the course of 6 weeks. In
      this study, the terminal deoxynucleotidyl transferasemediated dUTP nickend
      labeling (TUNEL) assay, immunohistochemistry staining of caspase3 and western
      blot analysis for Bax, Bcl2 and phosphorylated protein kinase B (pAkt) in the
      retinas of diabetic rats were performed. The results demonstrated that the number
      of TUNEL and caspase3positive cells was increased in the retinas of diabetic
      rats, whereas treadmill exercise decreased these numbers. In addition, the
      expression of the proapoptotic protein Bax and the antiapoptotic protein Bcl2 was
      enhanced in the retinas of diabetic rats. Treadmill exercise suppressed Bax and
      enhanced Bcl2 levels. The expression of the cell survival factor, pAkt, was
      decreased in the retinas of diabetic rats and treadmill exercise increased the
      expression of pAkt. The results of the present study demonstrated that treadmill 
      exercise ameliorated diabetesinduced apoptosis in retinal cells by enhancing pAkt
      levels in the retina. Treadmill exercise represents an effective strategy to
      delay or prevent the onset of ocular complications in diabetic patients.
AD  - Department of Protection Science, Kyungwoon University, Kumi 730739, Republic of 
      Korea.
FAU - Kim, Dae-Young
AU  - Kim DY
FAU - Jung, Sun-Young
AU  - Jung SY
FAU - Kim, Chang-Ju
AU  - Kim CJ
FAU - Sung, Yun-Hee
AU  - Sung YH
FAU - Kim, Jae-Deung
AU  - Kim JD
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/12/30 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 10.3892/mmr.2013.1439 [doi]
PST - ppublish
SO  - Mol Med Rep. 2013 Jun;7(6):1745-50. doi: 10.3892/mmr.2013.1439. Epub 2013 Apr 25.

PMID- 23620135
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1477-4054 (Electronic)
IS  - 1467-5463 (Linking)
DP  - 2013 Apr 25
TI  - Detecting tissue-specific early warning signals for complex diseases based on
      dynamical network biomarkers: study of type 2 diabetes by cross-tissue analysis.
AB  - Identifying early warning signals of critical transitions during disease
      progression is a key to achieving early diagnosis of complex diseases. By
      exploiting rich information of high-throughput data, a novel model-free method
      has been developed to detect early warning signals of diseases. Its theoretical
      foundation is based on dynamical network biomarker (DNB), which is also called as
      the driver (or leading) network of the disease because components or molecules in
      DNB actually drive the whole system from one state (e.g. normal state) to another
      (e.g. disease state). In this article, we first reviewed the concept and main
      results of DNB theory, and then applied the new method to the analysis of type 2 
      diabetes mellitus (T2DM). Specifically, based on the temporal-spatial gene
      expression data of T2DM, we identified tissue-specific DNBs corresponding to the 
      critical transitions occurring in liver, adipose and muscle during T2DM
      development and progression. Actually, we found that there are two different
      critical states during T2DM development characterized as responses to insulin
      resistance and serious inflammation, respectively. Interestingly, a new
      T2DM-associated function, i.e. steroid hormone biosynthesis, was discovered, and 
      those related genes were significantly dysregulated in liver and adipose at the
      first critical transition during T2DM deterioration. Moreover, the dysfunction of
      genes related to responding hormone was also detected in muscle at the similar
      period. Based on the functional and network analysis on pathogenic molecular
      mechanism of T2DM, we showed that most of DNB genes, in particular the core ones,
      tended to be located at the upstream of biological pathways, which implied that
      DNB genes act as the causal factors rather than the consequence to drive the
      downstream molecules to change their transcriptional activities. This also
      validated our theoretical prediction of DNB as the driver network. As shown in
      this study, DNB can not only signal the emergence of the critical transitions for
      early diagnosis of diseases, but can also provide the causal network of the
      transitions for revealing molecular mechanisms of disease initiation and
      progression at a network level.
FAU - Li, Meiyi
AU  - Li M
FAU - Zeng, Tao
AU  - Zeng T
FAU - Liu, Rui
AU  - Liu R
FAU - Chen, Luonan
AU  - Chen L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Brief Bioinform
JT  - Briefings in bioinformatics
JID - 100912837
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - bbt027 [pii]
AID - 10.1093/bib/bbt027 [doi]
PST - aheadofprint
SO  - Brief Bioinform. 2013 Apr 25.

PMID- 23620079
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1942-7611 (Electronic)
DP  - 2013 Apr 25
TI  - Detection of diabetic metabolism disorders post-mortem - forensic case reports on
      cause of death hyperglycaemia.
LID - 10.1002/dta.1479 [doi]
AB  - Diabetic coma is the most severe form of hyperglycaemic metabolic disorders. The 
      post-mortem diagnosis of this disorder of glucose metabolism can be difficult and
      vague due to a lack of characteristic morphological findings. Six death cases
      caused by diabetic coma are described with special focus on biochemical (and
      histological) findings. The possible glycaemia markers glucose, lactate, HbA1c,
      fructosamine, anhydroglucitol, and ketone bodies were measured and the usefulness
      of these parameters is evaluated and discussed. Estimations of glucose
      concentrations in vitreous humour or cerebrospinal fluid and of ketone bodies in 
      blood or other matrices are obligatory while measurements of HbA1c, fructosamine,
      or anhydroglucitol can only provide additional information on the long-term
      adjustment of diabetes in the deceased. Lactate concentrations (addition of
      glucose and lactate levels to form the sum formula of Traub) do not give more
      information than the glucose concentration itself and can be therefore omitted.
      Copyright (c) 2013 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
AD  - Institute of Forensic Medicine, University of Bonn, Stiftsplatz 12, 53111, Bonn, 
      Germany.
FAU - Hess, C
AU  - Hess C
FAU - Wollner, K
AU  - Wollner K
FAU - Musshoff, F
AU  - Musshoff F
FAU - Madea, B
AU  - Madea B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Drug Test Anal
JT  - Drug testing and analysis
JID - 101483449
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/02/06 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/06 [accepted]
AID - 10.1002/dta.1479 [doi]
PST - aheadofprint
SO  - Drug Test Anal. 2013 Apr 25. doi: 10.1002/dta.1479.

PMID- 23620061
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Apr 26
TI  - The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of
      individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is
      associated with sVCAM-1.
AB  - AIMS/HYPOTHESIS: Methylglyoxal (MGO) is a major precursor for advanced glycation 
      end-products (AGEs), which are thought to play a role in vascular complications
      in diabetes. Known MGO-arginine-derived AGEs are 5-hydro-5-methylimidazolone
      (MG-H1), argpyrimidine and tetrahydropyrimidine (THP). We studied THP in relation
      to type 1 diabetes, endothelial dysfunction, low-grade inflammation, vascular
      complications and atherosclerosis. METHODS: We raised and characterised a
      monoclonal antibody against MGO-derived THP. We measured plasma THP with a
      competitive ELISA in two cohort studies: study A (198 individuals with type 1
      diabetes and 197 controls); study B (individuals with type 1 diabetes, 175 with
      normoalbuminuria and 198 with macroalbuminuria [>300 mg/24 h]). We measured
      plasma markers of endothelial dysfunction and low-grade inflammation, and
      evaluated the presence of THP and N epsilon-(carboxymethyl)lysine (CML) in
      atherosclerotic arteries. RESULTS: THP was higher in individuals with type 1
      diabetes than in those without (median [interquartile range] 115.5 U/mul
      [102.4-133.2] and 109.8 U/mul [91.8-122.3], respectively; p = 0.03). THP was
      associated with plasma soluble vascular cell adhesion molecule 1 in both study A 
      (standardised beta = 0.48 [95% CI 0.38, 0.58]; p < 0.001) and study B
      (standardised beta = 0.31 [95% CI 0.23, 0.40]; p < 0.001), and with secreted
      phospholipase A2 (standardised beta = 0.26 [95% CI 0.17, 0.36]; p < 0.001) in
      study B. We found no association of THP with micro- or macro-vascular
      complications. Both THP and CML were detected in atherosclerotic arteries.
      CONCLUSIONS/INTERPRETATION: Our results suggest that MGO-derived THP may reflect 
      endothelial dysfunction among individuals with and without type 1 diabetes, and
      therefore may potentially play a role in the development of atherosclerosis and
      vascular disease.
AD  - Department of Internal Medicine, Maastricht University Medical Centre,
      Universiteitssingel 50, 6200 MD, Maastricht, the Netherlands.
FAU - van Eupen, M G A
AU  - van Eupen MG
FAU - Schram, M T
AU  - Schram MT
FAU - Colhoun, H M
AU  - Colhoun HM
FAU - Hanssen, N M J
AU  - Hanssen NM
FAU - Niessen, H W M
AU  - Niessen HW
FAU - Tarnow, L
AU  - Tarnow L
FAU - Parving, H H
AU  - Parving HH
FAU - Rossing, P
AU  - Rossing P
FAU - Stehouwer, C D A
AU  - Stehouwer CD
FAU - Schalkwijk, C G
AU  - Schalkwijk CG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/17 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s00125-013-2919-8 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Apr 26.

PMID- 23620060
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Distinct patterns of tissue-specific lipid accumulation during the induction of
      insulin resistance in mice by high-fat feeding.
PG  - 1638-48
LID - 10.1007/s00125-013-2913-1 [doi]
AB  - AIMS/HYPOTHESIS: While it is well known that diet-induced obesity causes insulin 
      resistance, the precise mechanisms underpinning the initiation of insulin
      resistance are unclear. To determine factors that may cause insulin resistance,
      we have performed a detailed time-course study in mice fed a high-fat diet (HFD).
      METHODS: C57Bl/6 mice were fed chow or an HFD from 3 days to 16 weeks and glucose
      tolerance and tissue-specific insulin action were determined. Tissue lipid
      profiles were analysed by mass spectrometry and inflammatory markers were
      measured in adipose tissue, liver and skeletal muscle. RESULTS: Glucose
      intolerance developed within 3 days of the HFD and did not deteriorate further in
      the period to 12 weeks. Whole-body insulin resistance, measured by
      hyperinsulinaemic-euglycaemic clamp, was detected after 1 week of HFD and was due
      to hepatic insulin resistance. Adipose tissue was insulin resistant after 1 week,
      while skeletal muscle displayed insulin resistance at 3 weeks, coinciding with a 
      defect in glucose disposal. Interestingly, no further deterioration in insulin
      sensitivity was observed in any tissue after this initial defect. Diacylglycerol 
      content was increased in liver and muscle when insulin resistance first
      developed, while the onset of insulin resistance in adipose tissue was associated
      with increases in ceramide and sphingomyelin. Adipose tissue inflammation was
      only detected at 16 weeks of HFD and did not correlate with the induction of
      insulin resistance. CONCLUSIONS/INTERPRETATION: HFD-induced whole-body insulin
      resistance is initiated by impaired hepatic insulin action and exacerbated by
      skeletal muscle insulin resistance and is associated with the accumulation of
      specific bioactive lipid species.
AD  - Diabetes & Obesity Research Program, Garvan Institute of Medical Research,
      Darlinghurst, Sydney, NSW, Australia.
FAU - Turner, N
AU  - Turner N
FAU - Kowalski, G M
AU  - Kowalski GM
FAU - Leslie, S J
AU  - Leslie SJ
FAU - Risis, S
AU  - Risis S
FAU - Yang, C
AU  - Yang C
FAU - Lee-Young, R S
AU  - Lee-Young RS
FAU - Babb, J R
AU  - Babb JR
FAU - Meikle, P J
AU  - Meikle PJ
FAU - Lancaster, G I
AU  - Lancaster GI
FAU - Henstridge, D C
AU  - Henstridge DC
FAU - White, P J
AU  - White PJ
FAU - Kraegen, E W
AU  - Kraegen EW
FAU - Marette, A
AU  - Marette A
FAU - Cooney, G J
AU  - Cooney GJ
FAU - Febbraio, M A
AU  - Febbraio MA
FAU - Bruce, C R
AU  - Bruce CR
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/07 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s00125-013-2913-1 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1638-48. doi: 10.1007/s00125-013-2913-1. Epub 2013
      Apr 26.

PMID- 23620059
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - A novel mechanism regulating insulin secretion involving Herpud1 in mice.
PG  - 1569-76
LID - 10.1007/s00125-013-2908-y [doi]
AB  - AIMS/HYPOTHESIS: Type 2 diabetes results from beta cell dysfunction after
      prolonged physiological stress, which causes oversecretion of insulin. We
      recently found that insulin hypersecretion is mediated by at least two genes.
      Among mouse models of type 2 diabetes, the DBA/2 mouse strain is more susceptible
      to diabetes than is the C57BL/6J (B6J) strain. One distinctive feature of the
      DBA/2 mouse is that it hypersecretes insulin, independent of changes in insulin
      sensitivity; we identified Nnt as a gene responsible for this trait. METHODS: To 
      identify the other gene(s) affecting insulin hypersecretion, we tested a panel of
      recombinant inbred BXD strains, which have different combinations of B6 and DBA/2
      alleles. RESULTS: We found that 25% of the BXD strains hypersecreted insulin in
      response to glucose. Microarray profiling of islets from high- and low-secretor
      strains showed that at least four genes were differentially expressed. One gene
      was consistently underexpressed in islets from both DBA/2 and the high-secretor
      BXD strains. This gene (Herpud1 or Herp) encodes the 54 kDa endoplasmic reticulum
      stress-inducible protein (HERP) that resides in the integral endoplasmic
      reticulum membrane. To test directly whether Herpud1 can interact with Nnt,
      Herpud1 was either knocked down or overexpressed in MIN6 cells. These results
      showed that when Herpud1 was suppressed, Nnt expression was reduced, while
      overexpression of Herpud1 led to increased Nnt expression. Furthermore, Herpud1
      suppression resulted in significantly decreased glucose-stimulated insulin
      secretion in the DBA/2 islets but not B6J islets. CONCLUSIONS/INTERPRETATION: We 
      conclude that Herpud1 regulates insulin secretion via control of Nnt expression.
AD  - Department of Medicine (Austin Health), Austin Hospital, University of Melbourne,
      Heidelberg Heights, Melbourne, Victoria, 3084, Australia, wongn@unimelb.edu.au.
FAU - Wong, N
AU  - Wong N
FAU - Morahan, G
AU  - Morahan G
FAU - Stathopoulos, M
AU  - Stathopoulos M
FAU - Proietto, J
AU  - Proietto J
FAU - Andrikopoulos, S
AU  - Andrikopoulos S
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/10/26 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s00125-013-2908-y [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1569-76. doi: 10.1007/s00125-013-2908-y. Epub 2013
      Apr 26.

PMID- 23620058
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Sustained function of alginate-encapsulated human islet cell implants in the
      peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient.
PG  - 1605-14
LID - 10.1007/s00125-013-2906-0 [doi]
AB  - AIMS/HYPOTHESIS: Alginate-encapsulated human islet cell grafts have not been able
      to correct diabetes in humans, whereas free grafts have. This study examined in
      immunodeficient mice whether alginate-encapsulated graft function was inferior to
      that of free grafts of the same size and composition. METHODS: Cultured human
      islet cells were equally distributed over free and alginate-encapsulated grafts
      before implantation in, respectively, the kidney capsule and the peritoneal
      cavity of non-obese diabetic mice with severe combined immunodeficiency and
      alloxan-induced diabetes. Implants were followed for in vivo function and
      retrieved for analysis of cellular composition (all) and insulin secretory
      responsiveness (capsules). RESULTS: Free implants with low beta cell purity (19
      +/- 1%) were non-functional and underwent 90% beta cell loss. At medium purity
      (50 +/- 1%), they were functional at post-transplant week 1, evolving to
      normoglycaemia (4/8) or to C-peptide negativity (4/8) depending on the degree of 
      beta cell-specific losses. Encapsulated implants immediately and sustainably
      corrected diabetes, irrespective of beta cell purity (16/16). Most capsules were 
      retrievable as single units, enriched in endocrine cells that exhibited rapid
      secretory responses to glucose and glucagon. Single capsules with similar
      properties were also retrieved from a type 1 diabetic recipient at
      post-transplant month 3. However, the vast majority were clustered and contained 
      debris, explaining the poor rise in plasma C-peptide. CONCLUSIONS/INTERPRETATION:
      In immunodeficient mice, i.p. implanted alginate-encapsulated human islet cells
      exhibited a better outcome than free implants under the kidney capsule. They did 
      not show primary non-function at low beta cell purity and avoided beta
      cell-specific losses by rapidly establishing normoglycaemia. Retrieved capsules
      presented secretory responses to glucose, which was also observed in a type 1
      diabetic recipient. Trial registration: ClinicalTrials.gov NCT01379729 Funding:
      This study was supported by grants from the JDRF (centre grant 4-2005-1327), the 
      Research Foundation Flanders (G.0801.10), the 6th and 7th Framework Program of
      the European Commission (numbers 512145 and 241883), and the Agency for
      Innovation by Science and Technology in Flanders (IWT-TBM7 090884).
AD  - Diabetes Research Center, Brussels Free University, Laarbeeklaan 103, 1090,
      Brussels, Belgium.
FAU - Jacobs-Tulleneers-Thevissen, D
AU  - Jacobs-Tulleneers-Thevissen D
FAU - Chintinne, M
AU  - Chintinne M
FAU - Ling, Z
AU  - Ling Z
FAU - Gillard, P
AU  - Gillard P
FAU - Schoonjans, L
AU  - Schoonjans L
FAU - Delvaux, G
AU  - Delvaux G
FAU - Strand, B L
AU  - Strand BL
FAU - Gorus, F
AU  - Gorus F
FAU - Keymeulen, B
AU  - Keymeulen B
FAU - Pipeleers, D
AU  - Pipeleers D
CN  - Beta Cell Therapy Consortium EU-FP7
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/08 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s00125-013-2906-0 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1605-14. doi: 10.1007/s00125-013-2906-0. Epub 2013
      Apr 26.

PMID- 23620057
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Consumption of sweet beverages and type 2 diabetes incidence in European adults: 
      results from EPIC-InterAct.
PG  - 1520-30
LID - 10.1007/s00125-013-2899-8 [doi]
AB  - AIMS/HYPOTHESIS: Consumption of sugar-sweetened beverages has been shown, largely
      in American populations, to increase type 2 diabetes incidence. We aimed to
      evaluate the association of consumption of sweet beverages (juices and nectars,
      sugar-sweetened soft drinks and artificially sweetened soft drinks) with type 2
      diabetes incidence in European adults. METHODS: We established a case-cohort
      study including 12,403 incident type 2 diabetes cases and a stratified subcohort 
      of 16,154 participants selected from eight European cohorts participating in the 
      European Prospective Investigation into Cancer and Nutrition (EPIC) study. After 
      exclusions, the final sample size included 11,684 incident cases and a subcohort 
      of 15,374 participants. Cox proportional hazards regression models (modified for 
      the case-cohort design) and random-effects meta-analyses were used to estimate
      the association between sweet beverage consumption (obtained from validated
      dietary questionnaires) and type 2 diabetes incidence. RESULTS: In adjusted
      models, one 336 g (12 oz) daily increment in sugar-sweetened and artificially
      sweetened soft drink consumption was associated with HRs for type 2 diabetes of
      1.22 (95% CI 1.09, 1.38) and 1.52 (95% CI 1.26, 1.83), respectively. After
      further adjustment for energy intake and BMI, the association of sugar-sweetened 
      soft drinks with type 2 diabetes persisted (HR 1.18, 95% CI 1.06, 1.32), but the 
      association of artificially sweetened soft drinks became statistically not
      significant (HR 1.11, 95% CI 0.95, 1.31). Juice and nectar consumption was not
      associated with type 2 diabetes incidence. CONCLUSIONS/INTERPRETATION: This study
      corroborates the association between increased incidence of type 2 diabetes and
      high consumption of sugar-sweetened soft drinks in European adults.
CN  - InterAct consortium
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/12/21 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s00125-013-2899-8 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1520-30. doi: 10.1007/s00125-013-2899-8. Epub 2013
      Apr 26.

PMID- 23620017
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1941-6636 (Electronic)
VI  - 44
IP  - 2
DP  - 2013 Jun
TI  - Nutrients from fruit and vegetable consumption reduce the risk of pancreatic
      cancer.
PG  - 152-61
LID - 10.1007/s12029-012-9441-y [doi]
AB  - PURPOSE: Pancreatic cancer is a devastating disease for which the role of dietary
      factors remains inconclusive. Our objective was to evaluate the risk of
      pancreatic cancer associated with nutrients found in fruits and vegetables and
      nutrient supplementation using a clinic-based case-control design. METHODS: Our
      study included 384 rapidly ascertained cases and 983 controls frequency-matched
      on age at time of recruitment (in 5-year increments), race, sex, and region of
      residence. All subjects provided demographic information and completed a 144-item
      food frequency questionnaire in which they reported no change to their diet
      within 5 years prior to entering the study. Logistic regression was used to
      calculate odds ratios and 95 % confidence intervals, adjusted for age, sex,
      smoking, body mass index, energy intake, and alcohol consumption. RESULTS:
      Results show a significant (trend p value < 0.05) inverse association between
      pancreatic cancer and nutrient/supplement groupings in a dose-dependent manner
      including magnesium, potassium, selenium, alpha-carotene, beta-carotene,
      beta-cryptoxanthin, lutein and zeaxanthin, niacin, total alpha-tocopherol, total 
      vitamin A activity, vitamin B6, and vitamin C. Adjusting for diabetes or total
      sugar intake did not result in significant changes. CONCLUSION: We conclude that 
      most nutrients obtained through consumption of fruits and vegetables may reduce
      the risk of developing pancreatic cancer.
AD  - Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic,
      200 First Street SW, Rochester, MN 55905, USA. jansen.rick@mayo.edu
FAU - Jansen, Rick J
AU  - Jansen RJ
FAU - Robinson, Dennis P
AU  - Robinson DP
FAU - Stolzenberg-Solomon, Rachael Z
AU  - Stolzenberg-Solomon RZ
FAU - Bamlet, William R
AU  - Bamlet WR
FAU - de Andrade, Mariza
AU  - de Andrade M
FAU - Oberg, Ann L
AU  - Oberg AL
FAU - Rabe, Kari G
AU  - Rabe KG
FAU - Anderson, Kristin E
AU  - Anderson KE
FAU - Olson, Janet E
AU  - Olson JE
FAU - Sinha, Rashmi
AU  - Sinha R
FAU - Petersen, Gloria M
AU  - Petersen GM
LA  - eng
GR  - P20 CA102701/CA/NCI NIH HHS/United States
GR  - P50CA102701/CA/NCI NIH HHS/United States
GR  - R25 CA092049/CA/NCI NIH HHS/United States
GR  - R25TCA92049/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Gastrointest Cancer
JT  - Journal of gastrointestinal cancer
JID - 101479627
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1007/s12029-012-9441-y [doi]
PST - ppublish
SO  - J Gastrointest Cancer. 2013 Jun;44(2):152-61. doi: 10.1007/s12029-012-9441-y.

PMID- 23619915
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
DP  - 2013 Apr 26
TI  - Association between baseline body mass index and overall survival among patients 
      over age 60 with acute myeloid leukemia.
LID - 10.1002/ajh.23462 [doi]
AB  - Acute myeloid leukemia (AML) is more common and more lethal among patients over
      the age of 60. Increased body mass index (BMI) has been associated with a higher 
      incidence of various malignancies, including AML. We sought to determine whether 
      patient BMI at the time of AML diagnosis is related to overall survival (OS)
      among elderly patients. We identified 97 patients with AML diagnosed after the
      age of 60 and treated with cytarabine-based induction chemotherapy. The median
      age was 68 years (range 60-87); 52% of patients were male, and our study
      population was predominantly white (89% of patients). The median OS for all
      patients was 316 days (95% CI 246-459). The hazard ratio for mortality was
      increased among patients with a BMI < 25 compared to BMI >/= 30 (HR 2.14, P =
      0.009, 95% CI 1.21-3.77), as well as with older age (HR 1.76, P = 0.015, 95% CI
      1.12-2.79) and with secondary versus de novo disease (HR 1.95, P = 0.006, 95% CI 
      1.21-3.14). After multivariable analysis, we did not find a significant
      association between OS and other potential confounders such as coronary artery
      disease or diabetes among these patients. We conclude that increased BMI was
      independently associated with improved OS among older AML patients at our
      institution. Am. J. Hematol. 00:000-000, 2013. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Hematology and Oncology, Massachusetts General Hospital/Harvard
      Medical School, Boston, Massachusetts.
FAU - Brunner, Andrew M
AU  - Brunner AM
FAU - Sadrzadeh, Hossein
AU  - Sadrzadeh H
FAU - Feng, Yang
AU  - Feng Y
FAU - Drapkin, Benjamin J
AU  - Drapkin BJ
FAU - Ballen, Karen K
AU  - Ballen KK
FAU - Attar, Eyal C
AU  - Attar EC
FAU - Amrein, Philip C
AU  - Amrein PC
FAU - McAfee, Steven L
AU  - McAfee SL
FAU - Chen, Yi-Bin
AU  - Chen YB
FAU - Neuberg, Donna S
AU  - Neuberg DS
FAU - Fathi, Amir T
AU  - Fathi AT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/02/14 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/04/16 [accepted]
AID - 10.1002/ajh.23462 [doi]
PST - aheadofprint
SO  - Am J Hematol. 2013 Apr 26. doi: 10.1002/ajh.23462.

PMID- 23619894
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 Apr 26
TI  - High-sensitivity C-reactive protein and white blood cell count equally predict
      development of the metabolic syndrome in a Japanese health screening population.
AB  - To compare high-sensitivity C-reactive protein (hs-CRP) and white blood cell
      count (WBC) as a predictor of metabolic syndrome (MetS). Hazard ratios (HRs)
      adjusted for age, smoking, and other confounding covariates and areas under
      receiver operating characteristic curve (AUCs) of hs-CRP and WBC for developing
      MetS were calculated in 1,463 men and 920 women from a Japanese health screening 
      population who were free from MetS, diabetes, histories of coronary heart
      disease, and stroke at baseline and followed through 3 years. The adjusted HRs
      (95% confidence interval-CI; p value) of MetS for each 1 SD increases in log
      hs-CRP, and log WBC were 1.345 (1.166-1.553; <0.001) and 1.406 (1.188-1.664;
      <0.001), respectively, in men and 1.388 (1.110-1.736; 0.004) and 1.358
      (1.072-1.721; 0.011), respectively, in women. However, the HRs became
      nonsignificant after further adjusted for the components of MetS. The AUCs (95%
      CI; p value) of hs-CRP and WBC for predicting MetS were 0.616 (0.573-0.660;
      <0.001) and 0.613 (0.566-0.659; <0.001), respectively, in men and 0.636
      (0.573-0.698; <0.001) and 0.606 (0.538-0.673; 0.003), respectively, in women.
      Hs-CRP and WBC equally predict development of MetS, but both are poor predictors 
      of MetS in a Japanese health screening population where obesity is not
      prevailing.
AD  - Medical Check-up Center, Tachikawa Medical Center, Nagachou 2-2-16, Nagaoka,
      Niigata, 940-0053, Japan, ijie@venus.sannet.ne.jp.
FAU - Oda, Eiji
AU  - Oda E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/03/06 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s00592-013-0477-7 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 Apr 26.

PMID- 23619831
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1432-1971 (Electronic)
IS  - 0172-0643 (Linking)
DP  - 2013 Apr 26
TI  - Hemoglobin A1c in Pregestational Diabetic Gravidas and the Risk of Congenital
      Heart Disease in the Fetus.
AB  - This study aimed to determine whether poor glycemic control in early pregnancy is
      associated with an increased risk of congenital heart disease (CHD) for infants
      of women with preexisting diabetes. A retrospective review examined two tertiary 
      care centers of diabetic pregnancies that recorded early hemoglobin A1c (HbA1c)
      values (<20 weeks). The incidence of prenatally diagnosed CHD was calculated and 
      stratified by HbA1c level. Poor glycemic control was defined as an HbA1c level of
      8.5 % or higher. Fetal echocardiography was used to identify fetuses that
      resulted in infants with suspected CHD. Neonatal echocardiograms and pathology
      reports were reviewed for confirmation of the diagnosis. Of 535 patients, 30 (5.6
      %) delivered an infant with confirmed CHD. Among the patients with poor glycemic 
      control, 8.3 % (n = 17) delivered an infant with CHD, whereas 3.9 % (n = 13) of
      those with an HbA1c level lower than 8.5 % delivered an infant with CHD (p =
      0.03). Poor glycemic control in early pregnancy is associated with an increased
      risk of CHD in offspring. The incidence of CHD in patients with adequate glycemic
      control still is sufficiently high to justify routine fetal echocardiography for 
      all gravidas with preexisting diabetes regardless of HbA1c level.
AD  - Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology,
      Women & Infants Hospital of RI and The Warren Alpert Medical School of Brown
      University, Providence, RI, USA, roman.s.starikov@medstar.net.
FAU - Starikov, Roman
AU  - Starikov R
FAU - Bohrer, Justin
AU  - Bohrer J
FAU - Goh, William
AU  - Goh W
FAU - Kuwahara, Melissa
AU  - Kuwahara M
FAU - Chien, Edward K
AU  - Chien EK
FAU - Lopes, Vrishali
AU  - Lopes V
FAU - Coustan, Donald
AU  - Coustan D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Pediatr Cardiol
JT  - Pediatric cardiology
JID - 8003849
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/02/11 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s00246-013-0704-6 [doi]
PST - aheadofprint
SO  - Pediatr Cardiol. 2013 Apr 26.

PMID- 23619778
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 19
DP  - 2013
TI  - Novel drugs and their targets in the potential treatment of diabetic retinopathy.
PG  - 300-8
LID - 10.12659/MSM.883895 [doi]
AB  - Diabetic retinopathy (DR) is the most common complication of diabetes. It causes 
      vision loss, and the incidence is increasing with the growth of the diabetes
      epidemic worldwide. Over the past few decades a number of clinical trials have
      confirmed that careful control of glycemia and blood pressure can reduce the risk
      of developing DR and control its progression. In recent years, many treatment
      options have been developed for clinical management of the complications of DR
      (e.g., proliferative DR and macular edema) using laser-based therapies,
      intravitreal corticosteroids and anti-vascular endothelial growth factors, and
      vitrectomy to remove scarring and hemorrhage, but all these have limited
      benefits. In this review, we highlight and discuss potential molecular targets
      and new approaches that have shown great promise for the treatment of DR. New
      drugs and strategies are based on targeting a number of hyperglycemia-induced
      metabolic stress pathways, oxidative stress and inflammatory pathways, the
      renin-angiotensin system, and neurodegeneration, in addition to the use of stem
      cells and ribonucleic acid interference (RNAi) technologies. At present, clinical
      trials of some of these newer drugs in humans are yet to begin or are in early
      stages. Together, the new therapeutic drugs and approaches discussed may control 
      the incidence and progression of DR with greater efficacy and safety.
AD  - Department of Ophthalmology, College of Medicine, King Saud University, Riyadh,
      Saudi Arabia.
FAU - Nawaz, Mohd Imtiaz
AU  - Nawaz MI
FAU - Abouammoh, Marwan
AU  - Abouammoh M
FAU - Khan, Haseeb A
AU  - Khan HA
FAU - Alhomida, Abdullah S
AU  - Alhomida AS
FAU - Alfaran, Mubarak F
AU  - Alfaran MF
FAU - Ola, Mohammad Shamsul
AU  - Ola MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130426
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and
      clinical research
JID - 9609063
SB  - IM
PMC - PMC3659065
OID - NLM: PMC3659065
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 883895 [pii]
AID - 10.12659/MSM.883895 [doi]
PST - epublish
SO  - Med Sci Monit. 2013 Apr 26;19:300-8. doi: 10.12659/MSM.883895.

PMID- 23619735
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
DP  - 2013 Apr 24
TI  - New-Onset Diabetes After Transplantation (NODAT): An Evaluation of Definitions in
      Clinical Trials.
AB  - BACKGROUND: New-onset diabetes after transplantation (NODAT) occurs commonly.
      Prior NODAT definitions have been inconsistent. Based on the American Diabetic
      Association criteria, we propose a new approach to defining NODAT. METHODS:
      Analysis of 1416 at-risk transplant recipients was performed. Data from three de 
      novo Astellas registration transplant studies (two kidney and one liver)
      evaluated NODAT in 634 at-risk patients receiving tacrolimus, 630 at-risk
      patients receiving tacrolimus extended release, and 152 at-risk patients
      receiving cyclosporine. NODAT was defined as a composite endpoint consisting of
      first occurrence of one of four parameters: (i) two fasting plasma glucose levels
      >/=126 mg/dL (>/=7.0 mmol/L) >/=30 days apart, (ii) oral hypoglycemic agent use
      for >/=30 consecutive days, (iii) insulin therapy for >/=30 consecutive days, and
      (iv) hemoglobin A1c >/=6.5%. We evaluated each of the above parameters, as well
      as the composite endpoint, in an attempt to establish an appropriate clinical
      approach to the diagnosis of NODAT. RESULTS: The composite definition results in 
      a 1-year NODAT incidence of 30% to 37% in kidney and 44% to 45% in liver
      transplant recipients treated with tacrolimus. NODAT incidence was significantly 
      higher with tacrolimus than cyclosporine; there was no difference between the two
      tacrolimus formulations. CONCLUSIONS: Based on these analyses, the proposed
      composite definition for NODAT, incorporating broader criteria, is recommended
      for clinical trials. Appropriate definitions of NODAT allow for a better
      understanding of the incidence of this complication and may result in earlier
      initiation of therapy with improved long-term outcomes.
AD  - Astellas Pharma Global Development, Northbrook, IL.
FAU - First, M Roy
AU  - First MR
FAU - Dhadda, Shobha
AU  - Dhadda S
FAU - Croy, Richard
AU  - Croy R
FAU - Holman, John
AU  - Holman J
FAU - Fitzsimmons, William E
AU  - Fitzsimmons WE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Transplantation
JT  - Transplantation
JID - 0132144
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1097/TP.0b013e318293fcf8 [doi]
PST - aheadofprint
SO  - Transplantation. 2013 Apr 24.

PMID- 23619436
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 0973-3922 (Electronic)
IS  - 0378-6323 (Linking)
VI  - 79
IP  - 3
DP  - 2013 May-Jun
TI  - Polycystic ovarian syndrome.
PG  - 310-21
LID - 10.4103/0378-6323.110759 [doi]
AB  - Polycystic ovarian syndrome (PCOS) is a "multispeciality" disorder suspected in
      patients with irregular menses and clinical signs of hyperandrogenism such as
      acne, seborrhoea, hirsutism, irregular menses, infertility, and alopecia.
      Recently, PCOS has been associated with the metabolic syndrome. Patients may
      develop obesity, insulin resistance, acanthosis nigricans, Type 2 diabetes,
      dyslipidemias, hypertension, non-alcoholic liver disease, and obstructive sleep
      apnoea. Good clinical examination with hematological and radiological
      investigations is required for clinical evaluation. Management is a combined
      effort involving a dermatologist, endocrinologist, gynecologist, and
      nutritionist. Morbidity in addition includes a low "self image" and poor quality 
      of life. Long term medications and lifestyle changes are essential for a
      successful outcome. This article focuses on understanding the normal and abnormal
      endocrine functions involved in the pathogenesis of PCOS. Proper diagnosis and
      management of the patient is discussed.
AD  - Department of Dermatology, P D Hinduja National Hospital, Mahim, Mumbai, India.
FAU - Madnani, Nina
AU  - Madnani N
FAU - Khan, Kaleem
AU  - Khan K
FAU - Chauhan, Phulrenu
AU  - Chauhan P
FAU - Parmar, Girish
AU  - Parmar G
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Dermatol Venereol Leprol
JT  - Indian journal of dermatology, venereology and leprology
JID - 7701852
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - ijdvl_2013_79_3_310_110759 [pii]
AID - 10.4103/0378-6323.110759 [doi]
PST - ppublish
SO  - Indian J Dermatol Venereol Leprol. 2013 May-Jun;79(3):310-21. doi:
      10.4103/0378-6323.110759.

PMID- 23619366
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 123
IP  - 5
DP  - 2013 May 1
TI  - A disease-associated PTPN22 variant promotes systemic autoimmunity in murine
      models.
PG  - 2024-36
LID - 10.1172/JCI66963 [doi]
LID - 66963 [pii]
AB  - Multiple autoimmune diseases, including type 1 diabetes, rheumatoid arthritis,
      Graves disease, and systemic lupus erythematosus, are associated with an allelic 
      variant of protein tyrosine phosphatase nonreceptor 22 (PTPN22), which encodes
      the protein LYP. To model the human disease-linked variant LYP-R620W, we
      generated knockin mice expressing the analogous mutation, R619W, in the murine
      ortholog PEST domain phosphatase (PEP). In contrast with a previous report, we
      found that this variant exhibits normal protein stability, but significantly
      alters lymphocyte function. Aged knockin mice exhibited effector T cell expansion
      and transitional, germinal center, and age-related B cell expansion as well as
      the development of autoantibodies and systemic autoimmunity. Further, PEP-R619W
      affected B cell selection and B lineage-restricted variant expression and was
      sufficient to promote autoimmunity. Consistent with these features, PEP-R619W
      lymphocytes were hyperresponsive to antigen-receptor engagement with a distinct
      profile of tyrosine-phosphorylated substrates. Thus, PEP-R619W uniquely modulates
      T and B cell homeostasis, leading to a loss in tolerance and autoimmunity.
FAU - Dai, Xuezhi
AU  - Dai X
FAU - James, Richard G
AU  - James RG
FAU - Habib, Tania
AU  - Habib T
FAU - Singh, Swati
AU  - Singh S
FAU - Jackson, Shaun
AU  - Jackson S
FAU - Khim, Socheath
AU  - Khim S
FAU - Moon, Randall T
AU  - Moon RT
FAU - Liggitt, Denny
AU  - Liggitt D
FAU - Wolf-Yadlin, Alejandro
AU  - Wolf-Yadlin A
FAU - Buckner, Jane H
AU  - Buckner JH
FAU - Rawlings, David J
AU  - Rawlings DJ
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
SB  - AIM
SB  - IM
PMC - PMC3638909
OID - NLM: PMC3638909
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/09/20 [received]
PHST- 2013/02/07 [accepted]
PHST- 2013/04/24 [aheadofprint]
PHST- 2013/04/24 [epublish]
AID - 66963 [pii]
AID - 10.1172/JCI66963 [doi]
PST - ppublish
SO  - J Clin Invest. 2013 May 1;123(5):2024-36. doi: 10.1172/JCI66963. Epub 2013 Apr
      24.

PMID- 23619356
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1558-8238 (Electronic)
IS  - 0021-9738 (Linking)
VI  - 123
IP  - 5
DP  - 2013 May 1
TI  - Anonymous sources: where do adult beta cells come from?
PG  - 1936-8
LID - 10.1172/JCI69297 [doi]
LID - 69297 [pii]
AB  - Evidence that the pool of insulin-producing beta cells in the pancreas is reduced
      in both major forms of diabetes mellitus has led to efforts to understand beta
      cell turnover in the adult pancreas. Unfortunately, previous studies have reached
      opposing conclusions regarding the source of new beta cells during regeneration
      in the adult pancreas. In this issue of the JCI, Xiao et al. use a novel mouse
      model for detecting new beta cells derived from non-beta cells to demonstrate the
      absence of beta cell neogenesis from non-beta cells during normal postnatal
      growth and in models of beta cell regeneration. This work adds to mounting
      evidence that in most physiological and pathological conditions, beta cell
      neogenesis may not make large contributions to the postnatal beta cell pool - at 
      least not in rodents.
FAU - German, Michael S
AU  - German MS
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
SB  - AIM
SB  - IM
PMC - PMC3635747
OID - NLM: PMC3635747 [Available on 01/01/14]
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PMCR- 2014/01/01 00:00
PHST- 2013/04/24 [aheadofprint]
PHST- 2013/04/24 [epublish]
AID - 69297 [pii]
AID - 10.1172/JCI69297 [doi]
PST - ppublish
SO  - J Clin Invest. 2013 May 1;123(5):1936-8. doi: 10.1172/JCI69297. Epub 2013 Apr 24.

PMID- 23619334
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1743-9159 (Electronic)
IS  - 1743-9159 (Linking)
VI  - 11
IP  - 6
DP  - 2013
TI  - Atmospheric pressure and infra-renal abdominal aortic aneurysm rupture: A single 
      observational study and a comprehensive review of literature.
PG  - 458-62
LID - 10.1016/j.ijsu.2013.04.008 [doi]
LID - S1743-9191(13)00103-9 [pii]
AB  - INTRODUCTION: There have been various suggestions that abdominal aortic aneurysm 
      rupture (rAAA) might have a seasonal variation depending on atmospheric pressure 
      (AP) alteration. Despite above suggestions no study has yet examined the effect
      of fluctuation in AP on daily, seasonal, monthly, AAA size and co-morbidities to 
      reach a conclusive outcome. METHODS: A total of fifty (n = 50) ruptured AAA over 
      a 5-year period were retrospectively studied. Local meteorological data on AP
      were obtained from UK Meteorological Office. The data was subjected to
      statistical analysis using Student's t-test, linear regression (Pearson
      correlation Coefficient) and Coefficient of determination to establish any casual
      link between AP and incidences of rAAA on daily, seasonal and monthly basis. The 
      casual link was also assessed between AP, AAA size and co-morbidities. The
      outcome is presented in a format of comprehensive review of literature that
      detected only 6 papers in MEDLINE and EMBASE from 1951 to 2012 in UK. CONCLUSION:
      There appears to be a significant correlation between mean monthly pressures and 
      mean monthly rupture incidence (Pearson)(n = 12; r = -0.61; p < 0.034; rsq =
      0.37). The periods of low AP are associated with higher incidence of rupture
      (rAAA n = 29 at mean atmospheric pressure 1012 mB Vs rAAA n = 12 at mean
      atmospheric pressure 1016 mB Vs rAAA n = 9 at mean atmospheric pressure of 1020
      mB) in our study and all reviewed literature. In addition, no casual link between
      AP to co-morbidities (diabetes mellitus, hypertension ischaemic heart disease,
      chronic obstructive pulmonary disease) and AAA size could be established or found
      in the literature.
CI  - Copyright (c) 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights
      reserved.
AD  - Mid Essex Hospitals Services NHS Trust, Department of Vascular Surgery,
      Broomfield Hospital, Essex CM1 7ET, UK. Electronic address:
      Alikordzadeh@gmail.com.
FAU - Kordzadeh, Ali
AU  - Kordzadeh A
FAU - Askari, Alan
AU  - Askari A
FAU - Panayiotopoulos, Yiannis
AU  - Panayiotopoulos Y
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - England
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/12/01 [received]
PHST- 2013/04/13 [revised]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - S1743-9191(13)00103-9 [pii]
AID - 10.1016/j.ijsu.2013.04.008 [doi]
PST - ppublish
SO  - Int J Surg. 2013;11(6):458-62. doi: 10.1016/j.ijsu.2013.04.008. Epub 2013 Apr 22.

PMID- 23619295
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1095-8584 (Electronic)
IS  - 0022-2828 (Linking)
VI  - 60
DP  - 2013 Jul
TI  - Increased susceptibility of HIF-1alpha heterozygous-null mice to cardiovascular
      malformations associated with maternal diabetes.
PG  - 129-41
LID - 10.1016/j.yjmcc.2013.04.015 [doi]
LID - S0022-2828(13)00146-6 [pii]
AB  - Cardiovascular malformations are the most common manifestation of diabetic
      embryopathy. The molecular mechanisms underlying the teratogenic effect of
      maternal diabetes have not been fully elucidated. Using genome-wide expression
      profiling, we previously demonstrated that exposure to maternal diabetes resulted
      in dysregulation of the hypoxia-inducible factor 1 (HIF-1) pathway in the
      developing embryo. We thus considered a possible link between HIF-1-regulated
      pathways and the development of congenital malformations. HIF-1alpha
      heterozygous-null (Hif1a(+/-)) and wild type (Wt) littermate embryos were exposed
      to the intrauterine environment of a diabetic mother to analyze the frequency and
      morphology of congenital defects, and assess gene expression changes in Wt and
      Hif1a(+/-) embryos. We observed a decreased number of embryos per litter and an
      increased incidence of heart malformations, including atrioventricular septal
      defects and reduced myocardial mass, in diabetes-exposed Hif1a(+/-) embryos as
      compared to Wt embryos. We also detected significant differences in the
      expression of key cardiac transcription factors, including Nkx2.5, Tbx5, and
      Mef2C, in diabetes-exposed Hif1a(+/-) embryonic hearts compared to Wt
      littermates. Thus, partial global HIF-1alpha deficiency alters gene expression in
      the developing heart and increases susceptibility to congenital defects in a
      mouse model of diabetic pregnancy.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Institute of Biotechnology AS CR, Prague, Czech Republic.
FAU - Bohuslavova, Romana
AU  - Bohuslavova R
FAU - Skvorova, Lada
AU  - Skvorova L
FAU - Sedmera, David
AU  - Sedmera D
FAU - Semenza, Gregg L
AU  - Semenza GL
FAU - Pavlinkova, Gabriela
AU  - Pavlinkova G
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - England
TA  - J Mol Cell Cardiol
JT  - Journal of molecular and cellular cardiology
JID - 0262322
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/09/01 [received]
PHST- 2013/04/13 [revised]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - S0022-2828(13)00146-6 [pii]
AID - 10.1016/j.yjmcc.2013.04.015 [doi]
PST - ppublish
SO  - J Mol Cell Cardiol. 2013 Jul;60:129-41. doi: 10.1016/j.yjmcc.2013.04.015. Epub
      2013 Apr 22.

PMID- 23619232
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1732-2693 (Electronic)
IS  - 0032-5449 (Linking)
VI  - 67
DP  - 2013
TI  - [Lymphocele--urological complication after renal transplantation].
PG  - 326-30
AB  - Renal transplantation is the best renal replacement treatment. It provides longer
      survival and a better quality of life. The outcome of renal transplantation is
      influenced by the occurrence of various complications, including urological. One 
      of the most frequently occurring complications is lymphocele. Most cases of
      lymphocele develop during a period of several weeks after the procedure of
      transplantation. However, there are some literature reports concerning lymphocele
      diagnosis in the later period, even after several years. Most cases of lymphocele
      are asymptomatic and are diagnosed accidentally. Nevertheless, a large lymphocele
      may press the kidney, ureter, urinary bladder or neighbouring blood vessels,
      causing deterioration of renal function, leg oedema and thrombosis of iliac
      vessels. Among other complications there are infections. The cause of lymphocele 
      is collection of the lymph drained from damaged lymph vessels surrounding iliac
      blood vessels and/or lymph vessels of the graft. Important factors predisposing
      to lymphocele are immunosuppressive treatment, including mTOR inhibitors,
      mycophenolic acid derivatives and high doses of glucosteroids. Factors favouring 
      occurrence of lymphocele comprise obesity, diabetes, elderly age of recipient,
      long time of warm ischaemia, acute rejection episodes and delayed graft function.
      The authors describe presently available treatment methods including aspiration
      and percutaneous drainage, with or without sclerotisation, drainage using the
      Tenckhoff catheter and laparoscopic or open fenestration. At present,
      laparoscopic fenestration is considered to be the most efficient and the safest
      method. However, there are clinical cases where open surgical treatment is
      necessary.
AD  - Katedra i Klinika Urologii i Onkologii Urologicznej Uniwersytetu Medycznego,
      50-556 Wroclaw, Poland. wk@softstar.pl
FAU - Krajewski, Wojciech
AU  - Krajewski W
FAU - Piszczek, Radoslaw
AU  - Piszczek R
FAU - Weyde, Waclaw
AU  - Weyde W
FAU - Rybak, Zbigniew
AU  - Rybak Z
FAU - Dembowski, Janusz
AU  - Dembowski J
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Limfocele--powiklanie urologiczne po przeszczepie nerki.
DEP - 20130423
PL  - Poland
TA  - Postepy Hig Med Dosw (Online)
JT  - Postepy higieny i medycyny doswiadczalnej (Online)
JID - 101206517
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 1046281 [pii]
PST - epublish
SO  - Postepy Hig Med Dosw (Online). 2013 Apr 23;67:326-30.

PMID- 23619230
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1732-2693 (Electronic)
IS  - 0032-5449 (Linking)
VI  - 67
DP  - 2013
TI  - Salivary exoglycosidases in gestational diabetes .
PG  - 315-20
AB  - INTRODUCTION: As exoglycosidases have been described as potential markers of
      salivary gland pathology, we decided to check the possibility of the use of these
      enzymes in the detection of salivary gland involvement in gestational diabetes.
      MATERIALS AND METHODS: For this purpose diabetic pregnant women were compared to 
      pregnant and non-pregnant healthy women. The activities of total HEX as well as
      GLU in the saliva were determined in duplicate according to Marciniak et al. The 
      activities of GAL, FUC, and MAN in the saliva were determined in duplicate
      according to Zwierz et al. RESULTS: It was found that the specific activities of 
      exoglycosidases in the saliva of diabetic pregnant women significantly increased 
      in comparison to healthy pregnant and non-pregnant women. CONCLUSION: Increased
      specific activity of exoglycosidases suggests that gestational diabetes provokes 
      structural/functional alterations in salivary glands and changes in the salivary 
      glycoconjugates metabolism.
AD  - Department of Pedodontics, Medical University of Bialystok, 15-274 Bialystok,
      Poland. annazalewska74@yahoo.com
FAU - Zalewska, Anna
AU  - Zalewska A
FAU - Knas, Malgorzata
AU  - Knas M
FAU - Gumiezny, Grzegorz
AU  - Gumiezny G
FAU - Niczyporuk, Marek
AU  - Niczyporuk M
FAU - Waszkiel, Danuta
AU  - Waszkiel D
FAU - Przystupa, Adrian Wojciech
AU  - Przystupa AW
FAU - Zarzycki, Wieslaw
AU  - Zarzycki W
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - Poland
TA  - Postepy Hig Med Dosw (Online)
JT  - Postepy higieny i medycyny doswiadczalnej (Online)
JID - 101206517
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 1046007 [pii]
PST - epublish
SO  - Postepy Hig Med Dosw (Online). 2013 Apr 19;67:315-20.

PMID- 23619228
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1732-2693 (Electronic)
IS  - 0032-5449 (Linking)
VI  - 67
DP  - 2013
TI  - [The role of gut microbiota in the pathogenesis of obesity and diabetes].
PG  - 288-303
AB  - The rapidly increasing number of people with obesity and type 2 diabetes is one
      of the most serious problems of the contemporary world. Until recently, it was
      thought that the main cause of this phenomenon is the change of lifestyle and
      dietary habits. According to recent reports, the gut microbiota may also play an 
      important role in the "epidemic" of obesity and diabetes. Changes in its
      composition have been observed in people suffering from these diseases. In
      addition, the fact that the intestinal microbiota may affect body weight, insulin
      sensitivity or sugar and lipid metabolism has led to the hypothesis that these
      changes may contribute to the pathogenesis of obesity and diabetes. Scientists,
      using antibacterial drugs, pro- and prebiotics, are trying to modify the
      intestinal flora and thus affect its interaction with the host. The results are
      very promising, lead to further analysis and indicate gut microbiota as a
      potential therapeutic target for obesity and diabetes treatment.
AD  - Zaklad Regulacji Metabolizmu, Instytut Biochemii, Wydzial Biologii, Uniwersytet
      Warszawski, Warsaw, Poland.
FAU - Stachowicz, Nina
AU  - Stachowicz N
FAU - Kiersztan, Anna
AU  - Kiersztan A
LA  - pol
PT  - English Abstract
PT  - Journal Article
TT  - Rola mikroflory jelitowej w patogenezie otylosci i cukrzycy.
DEP - 20130415
PL  - Poland
TA  - Postepy Hig Med Dosw (Online)
JT  - Postepy higieny i medycyny doswiadczalnej (Online)
JID - 101206517
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 1044746 [pii]
PST - epublish
SO  - Postepy Hig Med Dosw (Online). 2013 Apr 15;67:288-303.

PMID- 23619195
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 Apr 22
TI  - Lower circulating irisin is associated with type 2 diabetes mellitus.
LID - S1056-8727(13)00057-3 [pii]
LID - 10.1016/j.jdiacomp.2013.03.002 [doi]
AB  - AIMS: Irisin is a novel myokine secreted in response to PPAR-gamma
      co-activator-1alpha (PGC-1alpha) activation. Earlier studies suggested that
      PGC-1alpha expression and activity were lower in myocytes in type 2 diabetes
      mellitus (T2DM). Therefore, we hypothesize that circulating irisin levels are
      lower in T2DM patients. METHODS: In this observational study, we recruited 96
      T2DM subjects and 60 non-diabetic control subjects. Among T2DM subjects, 38% were
      on insulin treatment, 78% were taking statins and 72% were taking
      renin-angiotensin system antagonists. Circulating irisin was quantified by ELISA 
      and its association with markers of metabolic phenotype was analyzed by Pearson
      bivariate correlation and multiple linear regression. RESULTS: Circulating irisin
      was significantly lower in individuals with T2DM compared with non-diabetic
      controls (T2DM 204+/-72ng/ml vs. non-diabetic control 257+/-24ng/ml, p<0.0001).
      In non-diabetic subjects, circulating irisin was correlated with age (r=0.398,
      p<0.01), BMI (r=0.387, p<0.01), total cholesterol (r=0.341, p<0.01), total
      triglycerides (r=0.299, p<0.05), fasting blood glucose (r=0.430, p<0.01) and
      diastolic blood pressure (r=0.306, p<0.05). Multiple linear regression model
      revealed that BMI (beta=0.407, p=0.012) and FBG (beta=0.315, p=0.034) were
      associated with irisin in non-diabetic subjects after adjusting for multiple
      co-variates. However, similar analysis in T2DM subjects didn't reveal significant
      association between circulating irisin and major markers of metabolic phenotype. 
      CONCLUSIONS: Circulating irisin is lower in T2DM compared with non-diabetic
      controls. Plasma irisin levels appear to be associated with important metabolic
      factors in non-diabetic subjects but not in individuals with type 2 diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Clinical Research Unit, Khoo Teck Puat Hospital, Republic of Singapore.
FAU - Liu, Jian-Jun
AU  - Liu JJ
FAU - Wong, Melvin D S
AU  - Wong MD
FAU - Toy, Wan Ching
AU  - Toy WC
FAU - Tan, Clara S H
AU  - Tan CS
FAU - Liu, Sylvia
AU  - Liu S
FAU - Ng, Xiao Wei
AU  - Ng XW
FAU - Tavintharan, Subramaniam
AU  - Tavintharan S
FAU - Sum, Chee Fang
AU  - Sum CF
FAU - Lim, Su Chi
AU  - Lim SC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/09 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/03/19 [accepted]
AID - S1056-8727(13)00057-3 [pii]
AID - 10.1016/j.jdiacomp.2013.03.002 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 Apr 22. pii: S1056-8727(13)00057-3. doi:
      10.1016/j.jdiacomp.2013.03.002.

PMID- 23619194
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 Apr 22
TI  - Diabetic nephropathy: protective factors and a new therapeutic paradigm.
LID - S1056-8727(13)00058-5 [pii]
LID - 10.1016/j.jdiacomp.2013.03.003 [doi]
AB  - Diabetic nephropathy (DN) is the most common cause of chronic kidney disease
      (CKD) and its number has been increasing. CKD is a worldwide threat to health but
      the precise mechanism of this problem is not fully appreciated. It is believed
      that hyperglycemia is one of the most important metabolic factors in the
      development of DN. Multiple molecular mechanisms have been proposed to mediate
      hyperglycemia's adverse effects on kidney. To identify targets for therapeutic
      intervention, most studies have focused on understanding how abnormal levels of
      such metabolities cause DN. However, there have been few reports regarding
      endogenous renal protective factors. Thus, recognition of the importance of this 
      could be providing a new perspective for understanding the development of DN and 
      a new therapeutic paradigm to combat DN.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Nephrology, Graduate School of Medicine, Institute of Health
      Biosciences, University of Tokushima, Tokushima, Japan. Electronic address:
      akiramima@clin.med.tokushima-u.ac.jp.
FAU - Mima, Akira
AU  - Mima A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/04 [received]
PHST- 2013/02/25 [revised]
PHST- 2013/03/19 [accepted]
AID - S1056-8727(13)00058-5 [pii]
AID - 10.1016/j.jdiacomp.2013.03.003 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 Apr 22. pii: S1056-8727(13)00058-5. doi:
      10.1016/j.jdiacomp.2013.03.003.

PMID- 23619142
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1877-783X (Electronic)
IS  - 1877-7821 (Linking)
VI  - 37
IP  - 4
DP  - 2013 Aug
TI  - Rosiglitazone is not associated with an increased risk of bladder cancer.
PG  - 385-9
LID - 10.1016/j.canep.2013.03.013 [doi]
LID - S1877-7821(13)00046-5 [pii]
AB  - BACKGROUND: Whether rosiglitazone may increase bladder cancer risk has not been
      extensively investigated. METHODS: The reimbursement databases of all Taiwanese
      diabetic patients under oral anti-diabetic agents or insulin from 1996 to 2009
      were retrieved from the National Health Insurance. An entry date was set at 1
      January 2006 and a total of 885,236 patients with type 2 diabetes were followed
      up for bladder cancer incidence till end of 2009. Incidences for ever-users,
      never-users and subgroups of rosiglitazone exposure (using tertile cutoffs of
      time since starting rosiglitazone, duration of therapy and cumulative dose) were 
      calculated and hazard ratios estimated by Cox regression. RESULTS: There were
      102,926 ever-users and 782,310 never-users, respective numbers of incident
      bladder cancer 356 (0.35%) and 2753 (0.35%), and respective incidence 98.3 and
      101.6 per 100,000 person-years. The overall hazard ratios (95% confidence
      intervals) did not show significant association in unadjusted model [0.969
      (0.867, 1.082)] and models adjusted for age and sex [0.983 (0.880, 1.098)] or all
      covariates [0.980 (0.870, 1.104)]. Neither the P values for the hazard ratios for
      the different categories of the dose-responsive parameters, nor their P-trends
      were significant. CONCLUSIONS: Rosiglitazone does not increase the risk of
      bladder cancer.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Internal Medicine, National Taiwan University College of Medicine, 
      Taipei, Taiwan; Division of Endocrinology and Metabolism, Department of Internal 
      Medicine, National Taiwan University Hospital, Taipei, Taiwan; Division of
      Environmental Health and Occupational Medicine of the National Health Research
      Institutes, Taipei, Taiwan. Electronic address: ccktsh@ms6.hinet.net.
FAU - Tseng, Chin-Hsiao
AU  - Tseng CH
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - Netherlands
TA  - Cancer Epidemiol
JT  - Cancer epidemiology
JID - 101508793
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/02/06 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/03/31 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - S1877-7821(13)00046-5 [pii]
AID - 10.1016/j.canep.2013.03.013 [doi]
PST - ppublish
SO  - Cancer Epidemiol. 2013 Aug;37(4):385-9. doi: 10.1016/j.canep.2013.03.013. Epub
      2013 Apr 22.

PMID- 23619130
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1524-4628 (Electronic)
IS  - 0039-2499 (Linking)
VI  - 44
IP  - 6
DP  - 2013 Jun
TI  - Diabetes mellitus: a risk factor for ischemic stroke in a large biracial
      population.
PG  - 1500-4
LID - 10.1161/STROKEAHA.113.001318 [doi]
AB  - BACKGROUND AND PURPOSE: We previously reported increased incidence of ischemic
      stroke among both blacks and whites with diabetes mellitus, especially in those
      aged <55 years. With rising prevalence of diabetes mellitus in the past decade,
      we revisit the impact of diabetes mellitus on stroke incidence in the same
      population ( approximately 1.3 million) 5 and 10 years later. METHODS: This is a 
      population-based study. First ischemic strokes among black and white residents of
      the 5-county Greater Cincinnati/Northern Kentucky region, aged >/=20 years, for
      periods 7/1993 to 6/1994, 1999, and 2005, were included in this analysis.
      Incidence rates were adjusted for sex, race, and age, as appropriate, to the 2000
      US population. RESULTS: History of diabetes mellitus among first ischemic strokes
      was reported for 493/1709 (28%) in 1993/1994, 522/1778 (29%) in 1999, and
      544/1680 (33%) in 2005. Risk ratios (95% confidence interval) for rates of stroke
      in those with versus without diabetes mellitus for blacks reduced significantly
      from 5.6 in 1993/1994 to 3.2 in 2005; for whites the risk ratio remained stable
      at 3.8 in 1993/1994 and 2005. However, risk ratios varied with age, with an
      overall 5- to 14-fold increased risk observed in those aged 20 to 65 years.
      CONCLUSIONS: Those with diabetes mellitus remain at greatly increased risk for
      stroke at all ages, especially <65 years, regardless of race. The rates and risk 
      ratios for 1999 and 2005, although similar to those previously reported for the
      mid-1990s, take on increased significance, given the epidemic of diabetes
      mellitus and metabolic syndrome throughout the US and the world.
AD  - Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital
      Medical Center, 3333 Burnett Av, MLC 5041, Cincinnati, OH 45229.
      jane.khoury@cchmc.org.
FAU - Khoury, Jane C
AU  - Khoury JC
FAU - Kleindorfer, Dawn
AU  - Kleindorfer D
FAU - Alwell, Kathleen
AU  - Alwell K
FAU - Moomaw, Charles J
AU  - Moomaw CJ
FAU - Woo, Daniel
AU  - Woo D
FAU - Adeoye, Opeolu
AU  - Adeoye O
FAU - Flaherty, Matthew L
AU  - Flaherty ML
FAU - Khatri, Pooja
AU  - Khatri P
FAU - Ferioli, Simona
AU  - Ferioli S
FAU - Broderick, Joseph P
AU  - Broderick JP
FAU - Kissela, Brett M
AU  - Kissela BM
LA  - eng
GR  - R01 NS030678/NS/NINDS NIH HHS/United States
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - Stroke
JT  - Stroke; a journal of cerebral circulation
JID - 0235266
SB  - IM
OTO - NOTNLM
OT  - black
OT  - diabetes mellitus
OT  - incidence
OT  - ischemic stroke
OT  - population based
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/04/25 [aheadofprint]
AID - STROKEAHA.113.001318 [pii]
AID - 10.1161/STROKEAHA.113.001318 [doi]
PST - ppublish
SO  - Stroke. 2013 Jun;44(6):1500-4. doi: 10.1161/STROKEAHA.113.001318. Epub 2013 Apr
      25.

PMID- 23619125
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1523-6838 (Electronic)
IS  - 0272-6386 (Linking)
DP  - 2013 Apr 22
TI  - Trends in the Prevalence of Reduced GFR in the United States: A Comparison of
      Creatinine- and Cystatin C-Based Estimates.
LID - S0272-6386(13)00669-0 [pii]
LID - 10.1053/j.ajkd.2013.03.013 [doi]
AB  - BACKGROUND: The US prevalence of reduced estimated glomerular filtration rate
      (eGFR) based on serum creatinine level increased during the decade ending in
      2002. National Health and Nutrition Examination Survey (NHANES) cystatin C
      measurements recently were calibrated to the international standard, allowing for
      an independent test of the trend in prevalence of reduced eGFR using cystatin C
      level. STUDY DESIGN: Cross-sectional surveys performed during 2 periods. SETTING 
      & PARTICIPANTS: Nationally representative subsamples of adult participants from
      NHANES III (1988-1994) and the NHANES 1999-2002 surveys. PREDICTOR: Survey
      period. OUTCOMES: Prevalence of reduced GFR, defined as eGFR <60 mL/min/1.73 m2
      based on levels of serum creatinine, cystatin C, or both (eGFRcr, eGFRcys, and
      eGFRcr-cys), using estimating equations developed by the Chronic Kidney Disease
      Epidemiology Collaboration (CKD-EPI). MEASUREMENTS: Serum cystatin C level,
      measured from stored samples in 2006, calibrated to the international standard in
      2012. RESULTS: Between 1988-1994 and 1999-2002, the prevalence of reduced eGFRcr,
      eGFRcys, and eGFRcr-cys increased from 4.7% (95% CI, 4.1%-5.3%) to 6.5% (95% CI, 
      5.9%-7.1%) (P < 0.001), from 5.5% (95% CI, 4.6%-6.5%) to 8.7% (95% CI,
      7.5%-10.0%) (P < 0.001), and from 4.4% (95% CI, 3.7%-5.2%) to 7.1% (95% CI,
      6.2%-8.0%) (P < 0.001), respectively. The higher prevalence of reduced GFR in the
      later period was observed in all subgroups of age, race, sex, and GFR categories.
      After adjusting for changes in the US population by age, sex, race, diabetes,
      hypertension, and body mass index, prevalence ratios of reduced GFR in the later 
      versus earlier survey were 1.24 (95% CI, 1.09-1.45), 1.34 (95% CI, 1.15-1.67),
      and 1.33 (95% CI, 1.17-1.65) using eGFRcr, eGFRcys, and eGFRcr-cys, respectively.
      LIMITATIONS: Likely underascertainment of persons with GFR <15 mL/min/1.73 m2;
      GFR was estimated and not measured; comparability of laboratory assays based on a
      calibration subsample. CONCLUSIONS: The prevalence of reduced eGFRcys in the US
      civilian noninstitutionalized population increased between 1988-1994 and
      1999-2002, confirming the increase observed in the prevalence of reduced eGFRcr.
CI  - Copyright (c) 2013 National Kidney Foundation, Inc. Published by Elsevier Inc.
      All rights reserved.
AD  - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
      Baltimore, MD; Division of Nephrology, Department of Medicine, Johns Hopkins
      University, Baltimore, MD. Electronic address: mgrams2@jhmi.edu.
FAU - Grams, Morgan E
AU  - Grams ME
FAU - Juraschek, Stephen P
AU  - Juraschek SP
FAU - Selvin, Elizabeth
AU  - Selvin E
FAU - Foster, Meredith C
AU  - Foster MC
FAU - Inker, Lesley A
AU  - Inker LA
FAU - Eckfeldt, John H
AU  - Eckfeldt JH
FAU - Levey, Andrew S
AU  - Levey AS
FAU - Coresh, Josef
AU  - Coresh J
LA  - ENG
GR  - K08 DK092287/DK/NIDDK NIH HHS/United States
GR  - L30 DK089648/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Am J Kidney Dis
JT  - American journal of kidney diseases : the official journal of the National Kidney
      Foundation
JID - 8110075
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/10/29 [received]
PHST- 2013/03/15 [accepted]
AID - S0272-6386(13)00669-0 [pii]
AID - 10.1053/j.ajkd.2013.03.013 [doi]
PST - aheadofprint
SO  - Am J Kidney Dis. 2013 Apr 22. pii: S0272-6386(13)00669-0. doi:
      10.1053/j.ajkd.2013.03.013.

PMID- 23619107
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
DP  - 2013 Apr 24
TI  - Cyclosporine-associated Thrombotic Microangiopathy and
      Thrombocytopenia-associated Multiple Organ Failure: A Case Successfully Treated
      With Therapeutic Plasma Exchange.
AB  - INTRODUCTION:: Thrombotic microangiopathy (TMA) is characterized by microvascular
      thrombosis, thrombocytopenia, and microangiopathic hemolytic anemia. Previous
      studies have shown that cyclosporine (CsA) is associated with TMA but the number 
      of reported cases is very limited. We describe a 13-year-old girl with
      CsA-associated TMA and thrombocytopenia-associated multiple organ failure
      (TAMOF). CASE REPORT:: The patient was diagnosed with polyglandular deficiency
      syndrome and had a history of celiac disease, autoimmune thyroiditis, and
      diabetes mellitus type I. CsA was started 7 months before her admission to our
      pediatric intensive care unit for persistent diarrhea associated with celiac
      disease. At the time of her admission to our pediatric intensive care unit, she
      was thrombocytopenic and anemic with multiple organ failure. Laboratory and
      clinical findings were consistent with TMA and TAMOF. CsA was discontinued and
      therapeutic plasma exchange was performed daily for 5 days. The patient improved 
      clinically, laboratory findings normalized, and TMA and multiple organ failure
      dissolved. CONCLUSION:: This case report indicates that therapeutic plasma
      exchange may be effective in the treatment of CsA-associated TMA and TAMOF,
      especially in the presence of systemic findings.
AD  - Divisions of *Pediatric Critical Care daggerPediatric Hematology double
      daggerPediatric Gastroenterology, Faculty of Medicine, Ankara University, Ankara,
      Turkey.
FAU - Odek, Caglar
AU  - Odek C
FAU - Kendirli, Tanil
AU  - Kendirli T
FAU - Yaman, Ayhan
AU  - Yaman A
FAU - Ileri, Talia
AU  - Ileri T
FAU - Kuloglu, Zarife
AU  - Kuloglu Z
FAU - Ince, Erdal
AU  - Ince E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1097/MPH.0b013e31828e505b [doi]
PST - aheadofprint
SO  - J Pediatr Hematol Oncol. 2013 Apr 24.

PMID- 23618969
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 450
IP  - 1-2
DP  - 2013 Jun 25
TI  - Colonic delivery of docosahexaenoic acid improves impaired glucose tolerance via 
      GLP-1 secretion and suppresses pancreatic islet hyperplasia in diabetic KK-A(y)
      mice.
PG  - 63-9
LID - 10.1016/j.ijpharm.2013.04.029 [doi]
LID - S0378-5173(13)00330-X [pii]
AB  - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates the insulin
      secretion depending on blood glucose level. Recent studies show that the
      unsaturated fatty acids can promote GLP-1 secretion from intestinal L-cells. We
      have shown previously that docosahexaenoic acid (DHA) and eicosapentaenoic acid
      (EPA) administered into a mouse closed intestinal loop, especially into the
      colonic segment, stimulate GLP-1 and insulin secretion and have a hypoglycemic
      effect, suggesting that DHA and EPA have potential as antidiabetic agents. The
      present study examined the antidiabetic effect of DHA following long-term in vivo
      delivery to the colon using normal ddY and diabetic KK-A(y) mice. The plasma
      GLP-1 concentration of KK-A(y) mice increased after long-term DHA administration,
      and this had a significant hypoglycemic effect. In contrast, although GLP-1
      secretion in ddY mice tended to increase after DHA administration, blood glucose 
      concentration did not differ between vehicle- and DHA-treated ddY mice.
      Immunostaining of the pancreas after long-term DHA administration showed that
      continuous DHA treatment stimulated beta-cell apoptosis and accordingly
      suppressed islet cell growth in KK-A(y) mice. Colon targeting of DHA may provide 
      a new strategy for improving impaired glucose tolerance in type 2 diabetes
      mellitus by stimulating GLP-1 secretion, which may subsequently suppress the
      compensatory hyperplasia of pancreatic islets.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Ono Pharmaceutical Co., Ltd., 1-8-2 Kyutaro-machi, Chuo-ku, Osaka-shi, Osaka
      541-8564, Japan.
FAU - Shida, Takayuki
AU  - Shida T
FAU - Kamei, Noriyasu
AU  - Kamei N
FAU - Takeda-Morishita, Mariko
AU  - Takeda-Morishita M
FAU - Isowa, Koichi
AU  - Isowa K
FAU - Takayama, Kozo
AU  - Takayama K
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/08 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - S0378-5173(13)00330-X [pii]
AID - 10.1016/j.ijpharm.2013.04.029 [doi]
PST - ppublish
SO  - Int J Pharm. 2013 Jun 25;450(1-2):63-9. doi: 10.1016/j.ijpharm.2013.04.029. Epub 
      2013 Apr 22.

PMID- 23618884
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1536-5948 (Electronic)
IS  - 1076-2752 (Linking)
VI  - 55
IP  - 5
DP  - 2013 May
TI  - Relationship between physical inactivity and health characteristics among
      participants in an employee-wellness program.
PG  - 514-9
LID - 10.1097/JOM.0b013e31827f37d7 [doi]
AB  - OBJECTIVE: : To characterize factors associated with physical inactivity among
      employees with access to workplace wellness program. METHODS: : We examined data 
      on physical inactivity, defined as exercise less than once a week, from the 2010 
      health risk assessment completed by employees at a major academic institution (N 
      = 16,976). RESULTS: : Among employees, 18% of individuals reported physical
      activity less than once a week. Individuals who were physically inactive as
      compared with physically active reported higher prevalence of cardiovascular
      diseases (adjusted odds ratio [AOR], 1.36 [1.23 to 1.51]), fair or poor health
      status (AOR, 3.52 [2.97 to 4.17]), and absenteeism from work (AOR, 1.59 [1.41 to 
      1.79]). Overall, physically inactive employees as compared with physically active
      employees reported more interest in health education programs. CONCLUSION: :
      Future research is needed to address barriers to physical inactivity to improve
      employee wellness and potentially lower health utility costs.
AD  - From the Division of General Internal Medicine and Pediatrics (Drs Birdee,
      Rothman, Rolando, and Yarbrough), Department of Medicine; Vanderbilt Center for
      Integrative Health (Dr Birdee); Health and Wellness, Human Resources (Mr Byrne,
      Ms McGown, Ms Holmes, and Drs Rolando and Yarbrough); Department of Biostatistics
      (Mr Byrne); Diabetes Research and Training Center (Dr Rothman), Department of
      Medicine, Vanderbilt University Medical Center, Nashville, Tenn.
FAU - Birdee, Gurjeet S
AU  - Birdee GS
FAU - Byrne, Daniel W
AU  - Byrne DW
FAU - McGown, Paula W
AU  - McGown PW
FAU - Rothman, Russell L
AU  - Rothman RL
FAU - Rolando, Lori A
AU  - Rolando LA
FAU - Holmes, Marilyn C
AU  - Holmes MC
FAU - Yarbrough, Mary I
AU  - Yarbrough MI
LA  - eng
GR  - K23 AT006965/AT/NCCAM NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - J Occup Environ Med
JT  - Journal of occupational and environmental medicine / American College of
      Occupational and Environmental Medicine
JID - 9504688
SB  - IM
PMC - PMC3651750
MID - NIHMS431270
OID - NLM: NIHMS431270 [Available on 05/01/14]
OID - NLM: PMC3651750 [Available on 05/01/14]
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PMCR- 2014/05/01 00:00
AID - 10.1097/JOM.0b013e31827f37d7 [doi]
PST - ppublish
SO  - J Occup Environ Med. 2013 May;55(5):514-9. doi: 10.1097/JOM.0b013e31827f37d7.

PMID- 23618879
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1536-5948 (Electronic)
IS  - 1076-2752 (Linking)
VI  - 55
IP  - 5
DP  - 2013 May
TI  - Improving patient-centered care: agenda-setting in occupational medicine.
PG  - 479-82
LID - 10.1097/JOM.0b013e31828dc90a [doi]
AB  - OBJECTIVE: : To improve patient satisfaction with care at an occupational
      medicine clinic by promoting agenda-setting before the visit. METHODS: : We
      distributed agenda-setting form to 77 randomly selected patients attending an
      occupational health clinic and used another randomly selected sample of 36
      patients as control group. Patients completed a survey regarding the
      acceptability of this procedure and whether they felt clinicians addressed their 
      important concerns. RESULTS: : Most patients found the form helpful (73%) and
      wanted it offered in future visits (74%). There was no statistically significant 
      difference in terms of the proportion of patients expressing greatest
      satisfaction by answering, "strongly agree" (intervention [86%], control [97%];
      odds ratio, 0.17; 95% confidence interval, 0.02 to 1.38; P = 0.06). CONCLUSION: :
      Agenda-setting can improve patient experience before occupational visits but does
      not improve postvisit satisfaction.
AD  - From the Divisions of Preventive, Occupational, and Aerospace Medicine (Drs
      Kuhle, Truitt, Steffen, and Murad) and Endocrinology, Diabetes, Metabolism, and
      Nutrition (Dr Montori), and Knowledge and Evaluation Research Unit (Drs
      Undavalli, Wang, Montori, and Murad), Mayo Clinic, Rochester, Minn.
FAU - Kuhle, Carol S
AU  - Kuhle CS
FAU - Truitt, Frances
AU  - Truitt F
FAU - Steffen, Mark
AU  - Steffen M
FAU - Undavalli, Chaitanya
AU  - Undavalli C
FAU - Wang, Zhen
AU  - Wang Z
FAU - Montori, Victor M
AU  - Montori VM
FAU - Murad, Mohammad Hassan
AU  - Murad MH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Occup Environ Med
JT  - Journal of occupational and environmental medicine / American College of
      Occupational and Environmental Medicine
JID - 9504688
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1097/JOM.0b013e31828dc90a [doi]
PST - ppublish
SO  - J Occup Environ Med. 2013 May;55(5):479-82. doi: 10.1097/JOM.0b013e31828dc90a.

PMID- 23618722
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Comparative safety and effectiveness of sitagliptin in patients with type 2
      diabetes: retrospective population based cohort study.
PG  - f2267
LID - 10.1136/bmj.f2267 [doi]
LID - bmj.f2267 [pii]
AB  - OBJECTIVE: To determine if the use of sitagliptin in newly treated patients with 
      type 2 diabetes is associated with any changes in clinical outcomes. DESIGN:
      Retrospective population based cohort study. SETTING: Large national commercially
      insured US claims and integrated laboratory database. PARTICIPANTS: Inception
      cohort of new users of oral antidiabetic drugs between 2004 and 2009 followed
      until death, termination of medical insurance, or December 31 2010. MAIN OUTCOME 
      MEASURE: Composite endpoint of all cause hospital admission and all cause
      mortality, assessed with time varying Cox proportional hazards regression after
      adjustment for demographics, clinical and laboratory data, pharmacy claims data, 
      healthcare use, and time varying propensity scores. RESULTS: The cohort included 
      72,738 new users of oral antidiabetic drugs (8032 (11%) used sitagliptin; 7293
      (91%) were taking it in combination with other agents) followed for a total of
      182,409 patient years. The mean age was 52 (SD 9) years, 54% (39,573) were men,
      11% (8111) had ischemic heart disease, and 9% (6378) had diabetes related
      complications at the time their first antidiabetic drug was prescribed. 14,215
      (20%) patients met the combined endpoint. Sitagliptin users showed similar rates 
      of all cause hospital admission or mortality to patients not using sitagliptin
      (adjusted hazard ratio 0.98, 95% confidence interval 0.91 to 1.06), including
      patients with a history of ischemic heart disease (adjusted hazard ratio 1.10,
      0.94 to 1.28) and those with estimated glomerular filtration rate below 60 mL/min
      (1.11, 0.88 to 1.41). CONCLUSIONS: Sitagliptin use was not associated with an
      excess risk of all cause hospital admission or death compared with other glucose 
      lowering agents among newly treated patients with type 2 diabetes. Most patients 
      prescribed sitagliptin in this cohort were concordant with clinical practice
      guidelines, in that it was used as add-on treatment.
AD  - Department of Public Health Sciences, School of Public Health, University of
      Alberta, Edmonton, AB, Canada T6G 2G3. deurich@ualberta.ca
FAU - Eurich, D T
AU  - Eurich DT
FAU - Simpson, S
AU  - Simpson S
FAU - Senthilselvan, A
AU  - Senthilselvan A
FAU - Asche, C V
AU  - Asche CV
FAU - Sandhu-Minhas, J K
AU  - Sandhu-Minhas JK
FAU - McAlister, F A
AU  - McAlister FA
LA  - eng
GR  - MOP-126093/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130425
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
PMC - PMC3635468
OID - NLM: PMC3635468
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PST - epublish
SO  - BMJ. 2013 Apr 25;346:f2267. doi: 10.1136/bmj.f2267.

PMID- 23618684
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1049-7323 (Print)
IS  - 1049-7323 (Linking)
VI  - 23
IP  - 7
DP  - 2013 Jul
TI  - Is consulting patients about their health service preferences a useful exercise?
PG  - 876-86
LID - 10.1177/1049732313485161 [doi]
AB  - As part of the shift toward patient-centered care, patients are increasingly
      being consulted about their preferences for health services and interventions,
      including those explored during randomized controlled trials (RCTs), to ensure
      that service recommendations are aligned to their own circumstances and needs.
      Hence, we interviewed patients (N = 40) who participated in a randomized control 
      trial comparing diabetes education courses delivered using two different formats 
      to establish whether, and why, they preferred one format to the other, to inform 
      recommendations for future course delivery. Not only did patients report changing
      their preferences, and the reasons underlying these preferences, over time, but
      all patients also claimed to prefer the particular course they had attended. We
      use our findings and experiences to problematize the notion of a patient
      preference and to raise questions about what we can really learn from consulting 
      patients about the care they receive within the context of an RCT.
AD  - 1University of Edinburgh, Edinburgh, United Kingdom.
FAU - Lawton, Julia
AU  - Lawton J
FAU - Rankin, David
AU  - Rankin D
FAU - Elliott, Jackie
AU  - Elliott J
CN  - United Kingdom National Institute for Health Research Dose Adjustment for Normal 
      Eating (DAFNE) Study Group
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - Qual Health Res
JT  - Qualitative health research
JID - 9202144
SB  - T
OTO - NOTNLM
OT  - diabetes
OT  - health care, user’s experiences
OT  - interviews
OT  - program evaluation
OT  - research design
OT  - research participation
OT  - research, qualitative
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/04/25 [aheadofprint]
AID - 1049732313485161 [pii]
AID - 10.1177/1049732313485161 [doi]
PST - ppublish
SO  - Qual Health Res. 2013 Jul;23(7):876-86. doi: 10.1177/1049732313485161. Epub 2013 
      Apr 25.

PMID- 23618583
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1221-9118 (Print)
IS  - 1221-9118 (Linking)
VI  - 108
IP  - 2
DP  - 2013 Mar-Apr
TI  - Thigh emphysema as a first sign of abdominal disease.
PG  - 277-9
LID - 23 [pii]
AB  - Thigh infection is a rare complication of intra-abdominal sepsis that can present
      with emphysema. We report a case of infection in the thigh resulting from colonic
      perforation. A 61-year-old woman with cirrhosis, grade Child B6 and diabetes
      treated with oral hypoglycemic drugs was referred to the emergency department
      because of a persistent pain in her left thigh and also for some abdominal
      discomforts during the preceding few days. Ultrasonography identified the
      presence of gas and fluid in the thigh. The patient received fluids and
      antibiotics but on the day after she reported an increase in pain. For this
      reason the patient was submitted to a CT scan that showed a thigh emphysema due
      to intestinal perforation. The patient was submitted to laparotomy. A Hartmann's 
      procedure was performed, with resection of about 15 cm of affected sigmoid colon.
      The left thigh wound did not require any treatment.
CI  - Celsius.
AD  - Department of Surgical Sciences, Organ Transplantation, and Advanced
      Technologies, Cannizzaro Hospital, University of Catania, Italy.
FAU - Toro, A
AU  - Toro A
FAU - Mannino, M
AU  - Mannino M
FAU - Di Carlo, I
AU  - Di Carlo I
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Chirurgia (Bucur)
JT  - Chirurgia (Bucharest, Romania : 1990)
JID - 9213031
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/04/01 [accepted]
AID - 23 [pii]
PST - ppublish
SO  - Chirurgia (Bucur). 2013 Mar-Apr;108(2):277-9.

PMID- 23618565
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1221-9118 (Print)
IS  - 1221-9118 (Linking)
VI  - 108
IP  - 2
DP  - 2013 Mar-Apr
TI  - Post-surgery Morbidity and Mortality in Colo-Rectal Cancer in Elderly Subjects.
PG  - 177-9
LID - 5 [pii]
AB  - AIM: Surgical procedures with curative or palliative intention in colo-rectal
      neoplasm in subjects aged over 80 represent a surgical challenge due to the issue
      they raise: benefits versus increased morbidity. In Romania, according to
      demographic predictions, the population over the age of 65 will double in the
      next half century. This, correlated with the increased incidence of colo-rectal
      cancer in subjects pertaining to the 60- 69 age period and higher, determined us 
      to identify the factors that can influence the occurrence of complications and
      post-surgery deaths in subjects over 80 years of age that were operated on for
      colo-rectal cancer. METHODS: This paper includes a retrospective analysis of
      patients aged over 80, diagnosed and treated for colo-rectal cancer in the 4th
      Surgery Department of the University Emergency Hospital in Bucharest, in the
      period 2000 - 2011, following the type of surgery, morbidity and postoperative
      mortality. Out of a total of 297 cases of patients operated on for colo-rectal
      cancer, 36 were identified with the age over 80, age average being 83 years
      (80-91). RESULTS: Out of the total 36 patients aged over 80 years, 22 were
      subject to surgical procedures with curative intention (in 16 of these subjects a
      right hemicolectomy was performed and in 6 a left hemicolectomy), the remaining
      14 subjects receiving palliative surgical treatment. The factors that negatively 
      influenced post-surgery evolution were diabetes, pre-existing cardiac pathology, 
      evolutionary stage of cancer and the urgency character. In the group with
      resections, we found a 27.2% (6 cases) morbidity rate and a 18.2% (4 cases)
      mortality rate. In patients undergoing palliative surgery, the morbidity rate was
      28.5% (4 cases) with a mortality rate of 14.3% (2 cases). CONCLUSIONS: Between
      the 2 groups of patients postoperative morbidity and mortality appeared to be
      equal. Most often, they were caused by pre-existing cardio-pulmonary pathology
      and by the urgency character of the surgery, that did not allow a proper
      rebalancing, and in a lesser extent by the type of surgery. During those 12
      years, the percentage of patients aged over 80 years diagnosed annually with
      colorectal cancer remained constant. Despite advanced age and associated
      comorbidities, we consider the postoperative evolution to be satisfactory,
      although postoperative morbidity and mortality were higher than in the general
      population, according to the literature. Preoperative compensation of associated 
      comorbidities, a surgical procedure performed by experienced teams, together with
      the ensuring of adequate intensive therapies are required to reduce postoperative
      risks.
CI  - Celsius.
AD  - University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
FAU - Savlovschi, C
AU  - Savlovschi C
FAU - Serban, D
AU  - Serban D
FAU - Trotea, T
AU  - Trotea T
FAU - Borcan, R
AU  - Borcan R
FAU - Dumitrescu, D
AU  - Dumitrescu D
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - Chirurgia (Bucur)
JT  - Chirurgia (Bucharest, Romania : 1990)
JID - 9213031
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/04/01 [accepted]
AID - 5 [pii]
PST - ppublish
SO  - Chirurgia (Bucur). 2013 Mar-Apr;108(2):177-9.

PMID- 23618553
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl
      peptidase-4 inhibitor in patients with type 2 diabetes.
PG  - e66-9
LID - 10.1016/j.diabres.2013.03.034 [doi]
LID - S0168-8227(13)00133-2 [pii]
AB  - A potential adverse effect of dipeptidyl peptidase-4 inhibitors (DPP-4i) on the
      pancreas remains controversial. We evaluated the DPP-4i effects on pancreatic
      amylase and lipase activity in patients with type 2 diabetes. These enzymes were 
      slightly but significantly increased, suggesting DPP-4i cause a low-grade
      inflammatory change in the exocrine pancreas.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Clinical Cell Biology and Medicine, Chiba University Graduate
      School of Medicine, Chiba, Japan; Department of Diabetes and Metabolism, National
      Hospital Organization Chiba Medical Center, Chiba, Japan. Electronic address:
      hiroppy_hiroppy@yahoo.co.jp.
FAU - Tokuyama, Hirotake
AU  - Tokuyama H
FAU - Kawamura, Harukiyo
AU  - Kawamura H
FAU - Fujimoto, Masaki
AU  - Fujimoto M
FAU - Kobayashi, Kazuki
AU  - Kobayashi K
FAU - Nieda, Mie
AU  - Nieda M
FAU - Okazawa, Tetsuya
AU  - Okazawa T
FAU - Takemoto, Minoru
AU  - Takemoto M
FAU - Shimada, Fumio
AU  - Shimada F
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/07/10 [received]
PHST- 2013/02/17 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - S0168-8227(13)00133-2 [pii]
AID - 10.1016/j.diabres.2013.03.034 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):e66-9. doi:
      10.1016/j.diabres.2013.03.034. Epub 2013 Apr 22.

PMID- 23618552
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - PGC-1alpha prevents apoptosis in adipose-derived stem cells by reducing reactive 
      oxygen species production in a diabetic microenvironment.
PG  - 368-75
LID - 10.1016/j.diabres.2013.03.036 [doi]
LID - S0168-8227(13)00137-X [pii]
AB  - AIMS: To examine whether overexpression of peroxisome proliferator activated
      receptor-gamma coactivator-1 alpha (PGC-1alpha) can prevent apoptosis in
      adipose-derived stem cells (ASCs) by reducing reactive oxygen species (ROS)
      production and enhancing mitochondrial function in a diabetic environment.
      METHODS: After the isolation, expansion and characterisation of rat ASCs, we
      overexpressed PGC-1alpha in ASCs using an adenoviral vector encoding green
      fluorescent protein (GFP) or PGC-1alpha and tested the apoptotic effect under
      conditions of high glucose, hypoxia and serum deprivation. The production of
      intracellular ROS and mitochondrial ROS was evaluated using dihydroethidium and
      CM-H2XRos fluorescent probes. RESULTS: Under conditions of high glucose, hypoxia 
      and serum deprivation, the overexpression of PGC-1alpha in ASCs decreased
      apoptosis and led to an increased survival rate. The ASCs modified with
      PGC-1alpha produced lower intracellular and mitochondrial ROS. The mitochondrial 
      morphology and structure in the PGC-1alpha-ASC group remained relatively complete
      compared with the control group. CONCLUSIONS: These results reveal a crucial
      protective role for PGC-1alpha in the treatment of diabetes mellitus and its
      complications using stem cells therapy.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Endocrinology, Southwest Hospital, Third Military Medical
      University, Chongqing 400038, China.
FAU - Jiang, Xiao-Yan
AU  - Jiang XY
FAU - Lu, De-Bin
AU  - Lu DB
FAU - Jiang, You-Zhao
AU  - Jiang YZ
FAU - Zhou, Li-Na
AU  - Zhou LN
FAU - Cheng, Li-Qing
AU  - Cheng LQ
FAU - Chen, Bing
AU  - Chen B
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/29 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/28 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - S0168-8227(13)00137-X [pii]
AID - 10.1016/j.diabres.2013.03.036 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):368-75. doi:
      10.1016/j.diabres.2013.03.036. Epub 2013 Apr 22.

PMID- 23618551
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Country of birth-specific and gender differences in prevalence of diabetes in
      Sweden.
PG  - 404-8
LID - 10.1016/j.diabres.2013.03.014 [doi]
LID - S0168-8227(13)00092-2 [pii]
AB  - OBJECTIVE: The aim was to investigate country or region of birth-specific
      prevalence and gender differences of diabetes in residents in Sweden, using
      Swedish-born men and women as referent. METHODS: The Apolipoprotein MOrtality
      RISk (AMORIS) cohort was used (184,000 men and 151,453 women) aged between 20 and
      80 years, with data from the CALAB laboratory, Stockholm, 1985-1996. Diabetes was
      defined as fasting glucose >/=7.0mmol/L or a hospital diagnosis of diabetes.
      Country of birth was obtained by linkage to Swedish Censuses 1970-1990.
      Standardized prevalence rate ratios (SPRR) with 95% confidence intervals (95% CI)
      were estimated. RESULTS: Five groups of women and one group of men had a
      significantly higher prevalence than Swedish-born (based on SPRR): women born in 
      Iraq (6.0 (95% CI 1.3-28.9)), North Africa (6.9 (95% CI 3.1-15.3)), South Asia
      (3.1 (95% CI 1.0-10.0)), Syria (5.3 (95% CI 1.8-16.0)), Turkey (3.7 (95% CI
      1.2-10.9)) and men born in other Middle Eastern countries (2.3 (95% CI 1.0-5.5)).
      Swedish-born men had a higher age-standardized prevalence of diabetes (3.9%) than
      Swedish born women (2.5%). A higher prevalence among men was also seen in other
      Western countries. In contrast, a higher age-standardized prevalence among women 
      was observed in immigrants from Turkey (8.9% vs. 3.1%, p<0.001), Syria (13.1% vs.
      4.0%, p=0.002), and North Africa (16.8% vs. 6.6%, p<0.001). CONCLUSION: Female
      immigrants to Sweden from Iraq, North Africa, South Asia, Syria, and Turkey have 
      an increased prevalence of diabetes of substantial public health concern.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Centre for Family Medicine, Department of Neurobiology, Care Sciences and
      Society, Karolinska Institutet, Huddinge, Sweden; Department of Public Health and
      Caring Sciences/ Section of Geriatrics Uppsala University, Uppsala, Sweden.
      Electronic address: axelcefam@hotmail.com.
FAU - Carlsson, Axel C
AU  - Carlsson AC
FAU - Wandell, Per E
AU  - Wandell PE
FAU - Hedlund, Ebba
AU  - Hedlund E
FAU - Walldius, Goran
AU  - Walldius G
FAU - Nordqvist, Tobias
AU  - Nordqvist T
FAU - Jungner, Ingmar
AU  - Jungner I
FAU - Hammar, Niklas
AU  - Hammar N
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/08/29 [received]
PHST- 2013/01/22 [revised]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - S0168-8227(13)00092-2 [pii]
AID - 10.1016/j.diabres.2013.03.014 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):404-8. doi:
      10.1016/j.diabres.2013.03.014. Epub 2013 Apr 22.

PMID- 23618545
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1545-1151 (Electronic)
VI  - 10
DP  - 2013
TI  - Prevalence of multiple chronic conditions among US adults: estimates from the
      National Health Interview Survey, 2010.
PG  - E65
LID - 10.5888/pcd10.120203 [doi]
AB  - Preventing and ameliorating chronic conditions has long been a priority in the
      United States; however, the increasing recognition that people often have
      multiple chronic conditions (MCC) has added a layer of complexity with which to
      contend. The objective of this study was to present the prevalence of MCC and the
      most common MCC dyads/triads by selected demographic characteristics. We used
      respondent-reported data from the 2010 National Health Interview Survey (NHIS) to
      study the US adult civilian noninstitutionalized population aged 18 years or
      older (n = 27,157). We categorized adults as having 0 to 1, 2 to 3, or 4 or more 
      of the following chronic conditions: hypertension, coronary heart disease,
      stroke, diabetes, cancer, arthritis, hepatitis, weak or failing kidneys, chronic 
      obstructive pulmonary disease, or current asthma. We then generated descriptive
      estimates and tested for significant differences. Twenty-six percent of adults
      have MCC; the prevalence of MCC has increased from 21.8% in 2001 to 26.0% in
      2010. The prevalence of MCC significantly increased with age, was significantly
      higher among women than men and among non-Hispanic white and non-Hispanic black
      adults than Hispanic adults. The most common dyad identified was arthritis and
      hypertension, and the combination of arthritis, hypertension, and diabetes was
      the most common triad. The findings of this study contribute information to the
      field of MCC research. The NHIS can be used to identify population subgroups most
      likely to have MCC and potentially lead to clinical guidelines for people with
      more common MCC combinations.
AD  - Division of Health Interview Statistics, National Center for Health Statistics,
      Centers for Disease Control and Prevention, 3311 Toledo Rd, Room 2330,
      Hyattsville, MD 20782, USA. bwward@cdc.gov
FAU - Ward, Brian W
AU  - Ward BW
FAU - Schiller, Jeannine S
AU  - Schiller JS
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - Prev Chronic Dis
JT  - Preventing chronic disease
JID - 101205018
SB  - IM
PMC - PMC3652717
OID - NLM: PMC3652717
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.5888/pcd10.120203 [doi]
AID - E65 [pii]
PST - epublish
SO  - Prev Chronic Dis. 2013 Apr 25;10:E65. doi: 10.5888/pcd10.120203.

PMID- 23618544
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1545-1151 (Electronic)
VI  - 10
DP  - 2013
TI  - Multiple chronic conditions among US adults who visited physician offices: data
      from the National Ambulatory Medical Care Survey, 2009.
PG  - E64
LID - 10.5888/pcd10.120308 [doi]
AB  - Most research on adults with chronic conditions focuses on a single disease or
      condition, such as hypertension or diabetes, rather than on multiple chronic
      conditions (MCC). Our study's objective was to compare physician office visits by
      adults with MCC with visits by adults without MCC, by selected patient
      demographic characteristics. We also identified the most prevalent dyads and
      triads of chronic conditions among these patients. We used the National
      Ambulatory Medical Care Survey, a nationally representative survey of office
      visits to nonfederal physicians and used 13 of the 20 conditions defined by the
      National Strategic Framework on Multiple Chronic Conditions. Descriptive
      estimates were generated and significant differences were tested. In 2009, an
      estimated 326 million physician office visits, were made by adults aged 18 years 
      or older with MCC representing 37.6% of all medical office visits by adults.
      Hypertension was the most prevalent chronic condition that appeared in the top 5 
      MCC dyads and triads, by sex and age groups. The number of visits by patients
      with MCC increased with age and was greater for men than for women and for adults
      with public rather than private insurance. Physicians were more likely to
      prescribe medications at office visits made by patients with MCC. Physician
      office visits by adults with MCC were not evenly distributed by demographic
      characteristics.
AD  - Division of Health Care Statistics, National Center for Health Statistics,
      Centers for Disease Control and Prevention, 3311 Toledo Rd, Room 3229,
      Hyattsville, MD 20782, USA. JAshman@cdc.gov
FAU - Ashman, Jill Jacobsen
AU  - Ashman JJ
FAU - Beresovsky, Vladislav
AU  - Beresovsky V
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - Prev Chronic Dis
JT  - Preventing chronic disease
JID - 101205018
SB  - IM
PMC - PMC3652719
OID - NLM: PMC3652719
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.5888/pcd10.120308 [doi]
AID - E64 [pii]
PST - epublish
SO  - Prev Chronic Dis. 2013 Apr 25;10:E64. doi: 10.5888/pcd10.120308.

PMID- 23618543
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1545-1151 (Electronic)
VI  - 10
DP  - 2013
TI  - Health care expenditures for adults with multiple treated chronic conditions:
      estimates from the Medical Expenditure Panel Survey, 2009.
PG  - E63
LID - 10.5888/pcd10.120172 [doi]
AB  - The objective of this article is to illustrate the usefulness of Medical
      Expenditure Panel Survey (MEPS) data for examining variations in medical
      expenditures for people with multiple chronic conditions (MCC). We analyzed 2009 
      MEPS data to produce estimates of treated prevalence for MCC and associated
      medical expenditures for adults in the US civilian noninstitutionalized
      population (sample = 24,870). We also identified the most common dyad and triad
      combinations of treated conditions. Approximately one-quarter of civilian US
      adults were treated for MCCs in 2009; 18.3% were treated for 2 to 3 conditions
      and 7% were treated for 4 or more conditions. The proportion of adults treated
      for MCC increased with age. White non-Hispanic adults were most likely and
      Hispanic and Asian adults were least likely to be treated for MCC. Health care
      expenditures increased as the number of chronic conditions treated increased.
      Regardless of age or sex, hypertension and hyperlipidemia was the most common
      dyad among adults treated for MCC; diabetes in conjunction with these 2
      conditions was a common triad. MEPS has the capacity to produce national
      estimates of health care expenditures associated with MCC. MEPS data in
      conjunction with data from other US Department of Health and Human Services
      sources provide information that can inform policies addressing the complex issue
      of MCC.
AD  - Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and
      Quality, Rockville, Maryland, USA.
FAU - Machlin, Steven R
AU  - Machlin SR
FAU - Soni, Anita
AU  - Soni A
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - Prev Chronic Dis
JT  - Preventing chronic disease
JID - 101205018
SB  - IM
PMC - PMC3652712
OID - NLM: PMC3652712
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.5888/pcd10.120172 [doi]
AID - E63 [pii]
PST - epublish
SO  - Prev Chronic Dis. 2013 Apr 25;10:E63. doi: 10.5888/pcd10.120172.

PMID- 23618540
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1545-1151 (Electronic)
VI  - 10
DP  - 2013
TI  - Co-occurrence of leading lifestyle-related chronic conditions among adults in the
      United States, 2002-2009.
PG  - E60
LID - 10.5888/pcd10.120316 [doi]
AB  - INTRODUCTION: Public health and clinical strategies for meeting the emerging
      challenges of multiple chronic conditions must address the high prevalence of
      lifestyle-related causes. Our objective was to assess prevalence and trends in
      the chronic conditions that are leading causes of disease and death among adults 
      in the United States that are amenable to preventive lifestyle interventions.
      METHODS: We used self-reported data from 196,240 adults aged 25 years or older
      who participated in the National Health Interview Surveys from 2002 to 2009. We
      included data on cardiovascular disease (coronary heart disease, angina pectoris,
      heart attack, and stroke), cancer, chronic obstructive pulmonary disease
      (emphysema and chronic bronchitis), diabetes, and arthritis. RESULTS: In 2002, an
      unadjusted 63.6% of participants did not have any of the 5 chronic conditions we 
      assessed; 23.9% had 1, 9.0% had 2, 2.9% had 3, and 0.7% had 4 or 5. By 2009, the 
      distribution of co-occurrence of the 5 chronic conditions had shifted subtly but 
      significantly. From 2002 to 2009, the age-adjusted percentage with 2 or more
      chronic conditions increased from 12.7% to 14.7% (P < .001), and the number of
      adults with 2 or more conditions increased from approximately 23.4 million to
      30.9 million. CONCLUSION: The prevalence of having 1 or more or 2 or more of the 
      leading lifestyle-related chronic conditions increased steadily from 2002 to
      2009. If these increases continue, particularly among younger adults, managing
      patients with multiple chronic conditions in the aging population will continue
      to challenge public health and clinical practice.
AD  - Centers for Disease Control and Prevention, 4770 Buford Hwy, MS K67, Atlanta, GA 
      30341, USA. eford@cdc.gov
FAU - Ford, Earl S
AU  - Ford ES
FAU - Croft, Janet B
AU  - Croft JB
FAU - Posner, Samuel F
AU  - Posner SF
FAU - Goodman, Richard A
AU  - Goodman RA
FAU - Giles, Wayne H
AU  - Giles WH
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - Prev Chronic Dis
JT  - Preventing chronic disease
JID - 101205018
SB  - IM
PMC - PMC3652715
OID - NLM: PMC3652715
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.5888/pcd10.120316 [doi]
AID - E60 [pii]
PST - epublish
SO  - Prev Chronic Dis. 2013 Apr 25;10:E60. doi: 10.5888/pcd10.120316.

PMID- 23618501
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1879-0887 (Electronic)
IS  - 0167-8140 (Linking)
DP  - 2013 Apr 22
TI  - A predictive model for dysphagia following IMRT for head and neck cancer:
      Introduction of the EMLasso technique.
LID - S0167-8140(13)00150-3 [pii]
LID - 10.1016/j.radonc.2013.03.021 [doi]
AB  - BACKGROUND AND PURPOSE: Design a model for prediction of acute dysphagia
      following intensity-modulated radiotherapy (IMRT) for head and neck cancer.
      Illustrate the use of the EMLasso technique for model selection. MATERIAL AND
      METHODS: Radiation-induced dysphagia was scored using CTCAE v.3.0 in 189 head and
      neck cancer patients. Clinical data (gender, age, nicotine and alcohol use,
      diabetes, tumor location), treatment parameters (chemotherapy, surgery involving 
      the primary tumor, lymph node dissection, overall treatment time), dosimetric
      parameters (doses delivered to pharyngeal constrictor (PC) muscles and esophagus)
      and 19 genetic polymorphisms were used in model building. The predicting model
      was achieved by EMLasso, i.e. an EM algorithm to account for missing values,
      applied to penalized logistic regression, which allows for variable selection by 
      tuning the penalization parameter through crossvalidation on AUC, thus avoiding
      overfitting. RESULTS: Fifty-three patients (28%) developed acutegrade 3
      dysphagia. The final model has an AUC of 0.71 and contains concurrent
      chemotherapy, D2 to the superior PC and the rs3213245 (XRCC1) polymorphism. The
      model's false negative rate and false positive rate in the optimal operation
      point on the ROC curve are 21% and 49%, respectively. CONCLUSIONS: This study
      demonstrated the utility of the EMLasso technique for model selection in
      predictive radiogenetics.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Basic Medical Sciences, Ghent University, Belgium. Electronic
      address: kim.deruyck@UGent.be.
FAU - Kim, De Ruyck
AU  - Kim DR
FAU - Duprez, Frederic
AU  - Duprez F
FAU - Werbrouck, Joke
AU  - Werbrouck J
FAU - Sabbe, Nick
AU  - Sabbe N
FAU - Sofie, De Langhe
AU  - Sofie DL
FAU - Boterberg, Tom
AU  - Boterberg T
FAU - Madani, Indira
AU  - Madani I
FAU - Thas, Olivier
AU  - Thas O
FAU - Wilfried, De Neve
AU  - Wilfried DN
FAU - Thierens, Hubert
AU  - Thierens H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic
      Radiology and Oncology
JID - 8407192
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/02/23 [received]
PHST- 2013/02/22 [revised]
PHST- 2013/03/29 [accepted]
AID - S0167-8140(13)00150-3 [pii]
AID - 10.1016/j.radonc.2013.03.021 [doi]
PST - aheadofprint
SO  - Radiother Oncol. 2013 Apr 22. pii: S0167-8140(13)00150-3. doi:
      10.1016/j.radonc.2013.03.021.

PMID- 23618488
OWN - NLM
STAT- In-Data-Review
DA  - 20130426
IS  - 1916-9736 (Print)
IS  - 1916-9736 (Linking)
VI  - 5
IP  - 3
DP  - 2013 May
TI  - Association of dietary vitamin C and e intake and antioxidant enzymes in type 2
      diabetes mellitus patients.
PG  - 183-7
LID - 10.5539/gjhs.v5n3p183 [doi]
AB  - BACKGROUND: Diabetes mellitus consist of a various metabolic diseases such as
      hyperglycemia, increase glycosylated hemoglobin (HbA1c) and disorder in
      antioxidant enzymes activity, hence supplementing with antioxidant nutrients,
      mainly vitamin C and E seems to reduce oxidative injure in patients with type 2
      diabetes mellitus (T2DM). AIM: To evaluate outcome of vitamin C and E
      supplementation on type 2 DM patients. SETTING AND DESIGN: The study was
      completed in 170 T2DM on consumption of vitamin C, E, combination of C & E and
      placebo. MATERIALS AND METHODS: The cases groups of this study consist of two
      major groups, which were named supplementation and placebo group. The group of
      supplementation consisted of 3 sub-groups, which received three capsules per day 
      for a phase of three months. The parameters such as HbA1c, glucose, superoxide
      dismutase (SOD) and glutathione peroxides (GSH) were evaluated in baseline and
      after three months with supplementation. STATISTICAL ANALYSES: The statistical
      analyses were evaluated with the use of mean +/- SD, ANOVA-test and paired-sample
      t-test. RESULTS: Mean age of 170 patients, 84 male and 86 female were
      53.82+/-5.26 in the range of 30-60 years. The blood pressure results showed
      significant differences between the all supplement groups in baseline as compared
      to after receiving supplements (p<0.05). Use of vitamin C, E, and E & C showed
      significant differences in concentration of plasma FBS and HbA1c (p<0.05 &
      <0.001), but there was no significant differences in placebo groups. SOD and GSH 
      enzymes levels showed a significant increased after consumption of vitamins in
      supplementation groups (p<0.001). CONCLUSION: This research confirmed that
      subjects with T2DM after three months supplementation of vitamins demonstrated
      significantly low level of hypertension, decrease levels of blood glucose, and
      increase SOD and GSH enzyme activity that can probably reduce insulin resistance 
      by enhanced lowering oxidative stress parameters.
AD  - Mazandaran University of Medical Science. shahinarab1@gmail.com.
FAU - Rafighi, Zahra
AU  - Rafighi Z
FAU - Shiva, Atena
AU  - Shiva A
FAU - Arab, Shahin
AU  - Arab S
FAU - Mohd Yousof, Rokia
AU  - Mohd Yousof R
LA  - eng
PT  - Journal Article
DEP - 20130320
PL  - Canada
TA  - Glob J Health Sci
JT  - Global journal of health science
JID - 101519495
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/16 [received]
PHST- 2013/02/03 [accepted]
PST - epublish
SO  - Glob J Health Sci. 2013 Mar 20;5(3):183-7. doi: 10.5539/gjhs.v5n3p183.

PMID- 23618446
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1878-7452 (Electronic)
IS  - 1878-7452 (Linking)
VI  - 70
IP  - 3
DP  - 2013 May-Jun
TI  - Seasonal variations in outcomes after kidney transplantation: UNOS review of
      336,330 transplants.
PG  - 357-67
LID - 10.1016/j.jsurg.2012.12.002 [doi]
LID - S1931-7204(12)00331-5 [pii]
AB  - INTRODUCTION: The "July effect" is a widely discussed phenomenon of worse patient
      outcomes at teaching hospitals in July due to inexperienced house staff. METHODS:
      We conducted a retrospective review of Organ Procurement and Transplantation
      Network data from Oct 1, 1987 to June 30, 2011, including longitudinal censored
      data of 360,330 transplantations. Demographic and comorbid variables for donors
      and recipients were collected. Primary outcomes were graft loss, patient death,
      and delayed graft function. Secondary outcomes were surgical complications,
      length of stay, and graft rejection. We compared survival indicators (1-month,
      1-, 3-, and 5-year survival and median survival times) for both grafts and
      patients. We also analyzed death-censored graft survival. RESULTS: There were
      fewer July donors with diabetes (p = 0.003), hypertension (p = 0.000), and
      extended criteria (p<0.0001). Graft survival (p = 0.000), death-censored graft
      survival (p = 0.001), and patient survival (p = 0.002) were statistically higher 
      in July. After adjusting the Cox model for extended criteria donors, there was no
      difference in outcomes (p>0.05 for graft, death-censored graft survival, and
      patient survival). CONCLUSION: We conclude that there is no July effect.
      Initially identified, superior outcomes in July may be attributed to more
      conservative allografts selection in the beginning of the academic year.
CI  - Copyright (c) 2013 Association of Program Directors in Surgery. Published by
      Elsevier Inc. All rights reserved.
AD  - Department of Surgery, Division of Transplant Surgery, Albert Einstein Medical
      Center, Philadelphia, Pennsylvania 19141, USA.
FAU - Pang, John H
AU  - Pang JH
FAU - Karipineni, Farah
AU  - Karipineni F
FAU - Panchal, Heena
AU  - Panchal H
FAU - Campos, Stalin
AU  - Campos S
FAU - Ortiz, Jorge
AU  - Ortiz J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Surg Educ
JT  - Journal of surgical education
JID - 101303204
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/10/01 [received]
PHST- 2012/11/15 [revised]
PHST- 2012/12/10 [accepted]
AID - S1931-7204(12)00331-5 [pii]
AID - 10.1016/j.jsurg.2012.12.002 [doi]
PST - ppublish
SO  - J Surg Educ. 2013 May-Jun;70(3):357-67. doi: 10.1016/j.jsurg.2012.12.002.

PMID- 23618430
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 Apr 22
TI  - SHBG and endothelial function in older subjects.
LID - S0167-5273(13)00514-7 [pii]
LID - 10.1016/j.ijcard.2013.03.083 [doi]
AB  - BACKGROUND: Endothelial dysfunction is predictor of cardiovascular diseases that 
      have different prevalence in men and women before menopause. Sex hormones and sex
      hormone binding globulin (SHBG), novel risk factors for diabetes and
      cardiovascular diseases even in older individuals, might explain this difference.
      However, the relationship between these hormones and endothelial function has
      never been addressed in the elderly. METHODS AND RESULTS: 430 men and,424 women
      70years older of Prospective Study of the Vasculature in Uppsala Seniors study,
      with complete data on SHBG, testosterone(T), estradiol(E2),
      endothelium-independent vasodilation (EIDV), endothelium-dependent
      vasodilation(EDV), flow-mediated vasodilation (FMD) and the pulse wave analysis
      (reflection index, RI) were evaluated. Multivariate regression analysis adjusted 
      for confounders was used to assess the relationship between T, E2, SHBG and
      endothelial function. In men we found a positive relationship between SHBG and
      EDV (beta+/-SE 3.60+/-0.83, p<0.0001), EIDV (2.42+/-0.58, p<0.0001) but not with 
      FMD. The relationship between SHBG and EDV and EIDV was maintained after
      adjustment for sex (1.64+/-0.47, p<0.001 and 1.79+/-0.35, p<0.0006,
      respectively). After adjustment for confounders, the relationship between SHBG
      and EDV and EIDV was still statistically significant (2.63+/-0.90 and
      1.86+/-0.63, p=0.004 for both). In women SHBG and EIDV were positively associated
      (1.58+/-0.46; p=0.0007), and this relationship was independent of sex
      (1.79+/-0.35; p<0.001). No significant interaction SHBG *SEX was found for EIDV
      (p=0.72). In a combined analysis in two sexes, SHBG and EIDV were positively
      associated (1.13+/-0.45; p=0.01). SHBG was not associated with EDV, FMD and RI.
      No significant relationship was found between T or E2 and EDV, EIDV, FMD or RI in
      both sexes. CONCLUSIONS: In older men SHBG, but not T and E2, is positively and
      independently associated with EDV in resistance arteries. In both sexes, SHBG was
      positively and independently associated with EIDV.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - Department of Clinical and Experimental Medicine, Section of Geriatrics,
      Andrology, Osteometabolic, Endocrinology Unit, University of Parma, Italy;
      Geriatric Clinic Unit, Geriatric-Rehabilitation Department, University-Hospital
      of Parma, Parma, Italy. Electronic address: marcellomaggio2001@yahoo.it.
FAU - Maggio, Marcello
AU  - Maggio M
FAU - Cattabiani, Chiara
AU  - Cattabiani C
FAU - Lauretani, Fulvio
AU  - Lauretani F
FAU - Mantovani, Marco
AU  - Mantovani M
FAU - Butto, Valeria
AU  - Butto V
FAU - De Vita, Francesca
AU  - De Vita F
FAU - Volpi, Riccardo
AU  - Volpi R
FAU - Artoni, Andrea
AU  - Artoni A
FAU - Giallauria, Francesco
AU  - Giallauria F
FAU - Zuliani, Giovanni
AU  - Zuliani G
FAU - Aloe, Rosalia
AU  - Aloe R
FAU - Lippi, Giuseppe
AU  - Lippi G
FAU - Ceresini, Graziano
AU  - Ceresini G
FAU - Cederholm, Tommy
AU  - Cederholm T
FAU - Ceda, Gian Paolo
AU  - Ceda GP
FAU - Lind, Lars
AU  - Lind L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/02 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/28 [accepted]
AID - S0167-5273(13)00514-7 [pii]
AID - 10.1016/j.ijcard.2013.03.083 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 Apr 22. pii: S0167-5273(13)00514-7. doi:
      10.1016/j.ijcard.2013.03.083.

PMID- 23618325
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130506
DCOM- 20130507
LR  - 20130513
IS  - 2251-6581 (Electronic)
IS  - 2251-6581 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Alteration of pulmonary function in diabetic nephropathy.
PG  - 15
LID - 10.1186/2251-6581-12-15 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus is increasing worldwide with an alarming
      rate. It is associated with the development of various chronic complications. The
      aim of this study was to explore the alteration of pulmonary function, and its
      association with renal complications in people with type 2 diabetes mellitus.
      METHODS: This cross-sectional study was conducted on three groups; 40 diabetic
      subjects without nephropathy (urinary albumin<30 mg/day), 40 subjects with
      nephropathy (urinary albumin>/=30 mg/day), and 40 healthy subjects as the control
      group. The subjects with nephropathy were divided into those with
      microalbuminuria (urinary albumin=30-300 mg/day) and those with macroalbuminuria 
      (urinary albumin>300 mg/day) .Diabetic subjects were matched to the control group
      in terms of age, sex, and BMI. Pulmonary function tests were performed and the
      results were compared between groups. RESULTS: Forced vital capacity (FVC; %
      predicted), forced expiratory volume in 1 second (FEV1; % predicted), and peak
      expiratory flow (PEF; % predicted) were significantly lower in subjects with
      diabetic nephropathy compared to the healthy controls (P<0.05). Meanwhile, in
      diabetic subjects, FVC and FEV1 were lower in those with diabetic nephropathy
      compared to those with normal albumin excretion (P<0.05). On the other hand,
      FEV1/FVC was significantly higher in diabetic people with
      nephropathy.Furthermore, a significant difference was observed between FVC and
      FEV1 in diabetic people with microalbuminuria compared to those with
      macroalbuminuria. CONCLUSIONS: This study showed that the pulmonary function was 
      impaired in people with Diabetes. The progression of diabetic nephropathy to more
      advanced stages was also associated with more impairment of pulmonary function.
AD  - Endocrine Research Center (Firouzgar), Institute of Endocrinology and Metabolism,
      Tehran University of Medical Sciences, Karimkhan St, Tehran 1593748711, Iran.
      malekmoj@tums.ac.ir.
FAU - Shafiee, Gita
AU  - Shafiee G
FAU - Khamseh, Mohammad E
AU  - Khamseh ME
FAU - Rezaei, Nader
AU  - Rezaei N
FAU - Aghili, Rokhsareh
AU  - Aghili R
FAU - Malek, Mojtaba
AU  - Malek M
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - England
TA  - J Diabetes Metab Disord
JT  - Journal of diabetes and metabolic disorders
JID - 101590741
PMC - PMC3644225
OID - NLM: PMC3644225
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:01
CRDT- 2013/04/27 06:00
PHST- 2013/04/06 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 2251-6581-12-15 [pii]
AID - 10.1186/2251-6581-12-15 [doi]
PST - epublish
SO  - J Diabetes Metab Disord. 2013 Apr 24;12(1):15. doi: 10.1186/2251-6581-12-15.

PMID- 23618250
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1879-1344 (Electronic)
IS  - 0144-8617 (Linking)
VI  - 95
IP  - 1
DP  - 2013 Jun 5
TI  - Hypoglycemic property of acidic polysaccharide extracted from Saccharina japonica
      and its potential mechanism.
PG  - 143-7
LID - 10.1016/j.carbpol.2013.02.076 [doi]
LID - S0144-8617(13)00216-6 [pii]
AB  - In the present study, a sulfated polysaccharide fucoidan extracted from
      Saccharina japonica was administered to normal and alloxan-diabetic rats/mice,
      and its effects on glycemia, insulin and serum lipid levels were evaluated.
      Fucoidan administered at 200 or 1200 mg/kg body weight/day could significantly
      reduce the blood glucose level by 22% and 34%, respectively, in alloxan-induced
      diabetic rats. Serum insulin levels in diabetic mice were increased by the
      administration of fucoidan (P<0.05). The results of an oral glucose tolerance
      test (OGTT) revealed that fucoidan treatment had some effect on glucose disposal 
      after 15 days of treatment. Furthermore, fucoidan altered plasma lipid levels by 
      lowering cholesterol, triglyceride and plasma low-density lipoprotein
      concentrations, while elevating plasma high-density lipoprotein cholesterol at
      100 or 300 mg/kg body weight/day. The results suggested that fucoidan exhibited a
      considerable hypoglycemic effect, possibly by stimulating pancreatic release of
      insulin and/or by reducing insulin metabolism. Our results indicated that
      fucoidan could be developed as a potential oral hypoglycemic agents or functional
      food for the management of diabetes.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Nantong Branch, Institute of Oceanology, Chinese Academy of Sciences, Nantong,
      Jiangsu 226006, PR China. jingwang@qdio.ac.cn
FAU - Wang, Jing
AU  - Wang J
FAU - Jin, Weihua
AU  - Jin W
FAU - Zhang, Wenjing
AU  - Zhang W
FAU - Hou, Yun
AU  - Hou Y
FAU - Zhang, Hong
AU  - Zhang H
FAU - Zhang, Quanbin
AU  - Zhang Q
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130307
PL  - England
TA  - Carbohydr Polym
JT  - Carbohydrate polymers
JID - 8307156
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/11 [received]
PHST- 2013/02/14 [revised]
PHST- 2013/02/28 [accepted]
PHST- 2013/03/07 [aheadofprint]
AID - S0144-8617(13)00216-6 [pii]
AID - 10.1016/j.carbpol.2013.02.076 [doi]
PST - ppublish
SO  - Carbohydr Polym. 2013 Jun 5;95(1):143-7. doi: 10.1016/j.carbpol.2013.02.076. Epub
      2013 Mar 7.

PMID- 23618167
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 110
DP  - 2013 Jun 15
TI  - Exploring the relationship between 5'AMP-activated protein kinase and markers
      related to type 2 diabetes mellitus.
PG  - 1-7
LID - 10.1016/j.talanta.2013.03.039 [doi]
LID - S0039-9140(13)00188-4 [pii]
AB  - The importance of 5'AMP-activated protein kinase (AMPK) in regulating glucose and
      fatty acid metabolism is increasing. Thus, it is regarded as a new
      pharmacological target for treatment of obesity, insulin resistance and type 2
      diabetes mellitus (T2DM). In order to explore the relationships between AMPK and 
      diabetes mellitus, urines samples from four groups of C57 mice, i.e., the normal 
      male and female C57 mice, female C57-AMPK gene knocked-out mice, and male
      C57-AMPK gene knocked-out mice, were studied by coupling GC/MS with a powerful
      machine learning method, random forest. The experimentation has been designed as 
      two steps: firstly, the normal male and female mice were compared with male and
      female C57-AMPK gene knocked-out mice, respectively; then the differences between
      male C57-AMPK gene knocked-out mice and female C57-AMPK gene knocked-out mice
      were further detected. Finally, not only the differences between the normal C57
      mice and C57-AMPK gene knocked-out mice were observed, but also the
      gender-related metabolites differences of the C57-AMPK gene knocked-out mice were
      obviously visualized. The results obtained with this research demonstrate that
      combining GC/MS profiling with random forest is a useful approach to analyze
      metabolites and to screen the potential biomarkers for exploring the
      relationships between AMPK and diabetes mellitus.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Research Center of Modernization of Traditional Chinese Medicines, Central South 
      University, Changsha 410083, PR China.
FAU - Huang, Jian-Hua
AU  - Huang JH
FAU - He, Rui-Hua
AU  - He RH
FAU - Yi, Lun-Zhao
AU  - Yi LZ
FAU - Xie, Hua-Lin
AU  - Xie HL
FAU - Cao, Dong-sheng
AU  - Cao DS
FAU - Liang, Yi-Zeng
AU  - Liang YZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130322
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/12/15 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/14 [accepted]
PHST- 2013/03/22 [aheadofprint]
AID - S0039-9140(13)00188-4 [pii]
AID - 10.1016/j.talanta.2013.03.039 [doi]
PST - ppublish
SO  - Talanta. 2013 Jun 15;110:1-7. doi: 10.1016/j.talanta.2013.03.039. Epub 2013 Mar
      22.

PMID- 23617887
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1473-0804 (Electronic)
IS  - 1369-7137 (Linking)
DP  - 2013 Jun 6
TI  - Type II diabetes mellitus and menopause: a multinational study.
AB  - Background Type II diabetes mellitus causes metabolic changes that may lead to
      early menopause and worsen climacteric symptoms. Objectives To determine the risk
      factors for type II diabetes mellitus and assess the impact of this disease on
      the age of menopause and on climacteric symptoms. Methods A total of 6079 women
      aged between 40 and 59 years from 11 Latin American countries were requested to
      answer the Menopause Rating Scale and Goldberg Anxiety-Depression Scale. Results 
      The prevalence of diabetes was 6.7%. Diabetes mellitus was associated with
      arterial hypertension (odds ratio (OR) 4.49; 95% confidence interval (CI)
      3.47-5.31), the use of psychotropic drugs (OR 1.54; 95% CI 1.22-1.94), hormonal
      therapy (OR 1.46; 95% CI 1.11-1.92), >/= 50 years of age (OR 1.48; 95% CI
      1.17-1.86), overweight or obese (OR 1.47; 95% CI 1.15-1.89), and waist
      circumference >/= 88 cm (OR 1.32; 95% CI 1.06-1.65). Factors associated with
      lower risk of diabetes were the use of hormonal contraceptives (OR 0.55; 95% CI
      0.35-0.87), alcohol (OR 0.73; 95% CI 0.54-0.98) and living in cities > 2500
      meters above sea level (OR 0.70; 95% CI 0.53-0.91) or with high temperatures (OR 
      0.67; 95% CI 0.51-0.88). In turn, diabetes tripled the risk of menopause in women
      under 45 years of age. Diabetes did not increase the risk of deterioration of
      quality of life due to climacteric symptoms. Conclusion Menopause does not
      increase the risk of type II diabetes mellitus. Diabetes is associated with early
      menopause in women under 45 years of age.
AD  - Universidad de Cartagena , Cartagena , Colombia.
FAU - Monterrosa-Castro, A
AU  - Monterrosa-Castro A
FAU - Blumel, J E
AU  - Blumel JE
FAU - Portela-Buelvas, K
AU  - Portela-Buelvas K
FAU - Mezones-Holguin, E
AU  - Mezones-Holguin E
FAU - Baron, G
AU  - Baron G
FAU - Bencosme, A
AU  - Bencosme A
FAU - Benitez, Z
AU  - Benitez Z
FAU - Bravo, L M
AU  - Bravo LM
FAU - Calle, A
AU  - Calle A
FAU - Chedraui, P
AU  - Chedraui P
FAU - Flores, D
AU  - Flores D
FAU - Espinoza, M T
AU  - Espinoza MT
FAU - Gomez, G
AU  - Gomez G
FAU - Hernandez-Bueno, J A
AU  - Hernandez-Bueno JA
FAU - Laribezcoa, F
AU  - Laribezcoa F
FAU - Lima, S
AU  - Lima S
FAU - Martino, M
AU  - Martino M
FAU - Mostajo, D
AU  - Mostajo D
FAU - Ojeda, E
AU  - Ojeda E
FAU - Onatra, W
AU  - Onatra W
FAU - Sanchez, H
AU  - Sanchez H
FAU - Navarro, D
AU  - Navarro D
FAU - Tserotas, K
AU  - Tserotas K
FAU - Vallejo, M S
AU  - Vallejo MS
FAU - Witis, S
AU  - Witis S
FAU - Zuniga, M C
AU  - Zuniga MC
CN  - for the Collaborative Group for Research of the Climacteric in Latin America
      (REDLINC)
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130606
TA  - Climacteric
JT  - Climacteric : the journal of the International Menopause Society
JID - 9810959
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.3109/13697137.2013.798272 [doi]
PST - aheadofprint
SO  - Climacteric. 2013 Jun 6.

PMID- 23617822
OWN - NLM
STAT- Publisher
DA  - 20130522
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 Apr 25
TI  - Hyperglycaemia promotes cerebral barrier dysfunction through activation of
      protein kinase C-beta
LID - 10.1111/dom.12120 [doi]
AB  - AIM: To examine whether protein kinase C (PKC) and associated downstream
      mechanisms are involved in hyperglycaemia (HG)-evoked blood-brain barrier (BBB)
      damage. METHODS: The activities of total PKC (Peptag assay), NADPH oxidase
      (lucigenin assay) and matrix metalloproteinase-2 (MMP-2; gelatin zymography) were
      measured in human brain microvascular endothelial cells (HBMEC) exposed to
      normoglycaemia (5.5 mM) or HG (25 mM) using the specific assays indicated in
      parentheses. The integrity and function of the in vitro models of human BBB were 
      assessed by measurements of transendothelial electrical resistance and
      paracellular flux of permeability markers, respectively. Occludin protein
      expression was studied by immunoblotting. RESULTS: HG significantly compromised
      the BBB integrity and enhanced total PKC activity to which increases in PKC-beta 
      and PKC-betaII isoforms contributed the most. Elevations in NADPH oxidase and
      MMP-2 activities and decreases in occludin levels contributed to barrier
      dysfunction. Selective inhibition of PKC-beta isoform prevented the changes
      observed in occludin expression and the aforementioned enzyme activities and thus
      effectively preserved barrier integrity. Similarly, apocynin, a specific NADPH
      oxidase inhibitor, also effectively neutralized the effects of HG on barrier
      integrity, MMP-2 activity, occludin expression and PKC-beta activity. CONCLUSION:
      HG promotes cerebral-barrier dysfunction through activation of PKC-beta and
      consequent stimulations of oxidative stress and tight junction dissolution.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Division of Stroke Medicine, School of Clinical Sciences, The University of
      Nottingham, Nottingham, UK.
FAU - Shao, B
AU  - Shao B
FAU - Bayraktutan, U
AU  - Bayraktutan U
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/12/03 [received]
PHST- 2012/12/28 [revised]
PHST- 2013/04/19 [accepted]
AID - 10.1111/dom.12120 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 Apr 25. doi: 10.1111/dom.12120.

PMID- 23617798
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 Apr 25
TI  - The role of glucagon-like peptide-1 impairment in obesity and potential
      therapeutic implications.
LID - 10.1111/dom.12119 [doi]
AB  - The hormone glucagon-like peptide-1 (GLP-1) is released from the gut in response 
      to food intake. It acts as a satiety signal, leading to reduced food intake, and 
      also as a regulator of gastric emptying. Furthermore, GLP-1 functions as an
      incretin hormone, stimulating insulin release and inhibiting glucagon secretion
      from the pancreas in response to food ingestion. Evidence suggests that the
      action or effect of GLP-1 may be impaired in obese subjects, even in those with
      normal glucose tolerance. GLP-1 impairment may help explain the increased gastric
      emptying and decreased satiety signalling seen in obesity. Incretin impairment,
      probably associated with reduced insulinotropic potency of GLP-1, is also
      characteristic of type 2 diabetes (T2D). Therefore, it is possible that incretin 
      impairment may contribute to the pathophysiological bridge between obesity and
      T2D. This review summarises current knowledge about the pathophysiology and
      consequences of GLP-1 and incretin impairment in obesity, and examines the
      evidence for an incretin-related link between obesity and T2D. It also considers 
      the current literature surrounding the novel use of GLP-1 receptor agonists as a 
      treatment for obesity in patients with normoglycaemia, prediabetes and T2D.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Department of Endocrinology, Hvidovre University Hospital, Hvidovre, Denmark.
FAU - Madsbad, S
AU  - Madsbad S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/01/07 [received]
PHST- 2013/02/19 [revised]
PHST- 2013/04/19 [accepted]
AID - 10.1111/dom.12119 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 Apr 25. doi: 10.1111/dom.12119.

PMID- 23617762
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Prevalence and complications of diabetes mellitus in Northern Africa, a
      systematic review.
PG  - 387
LID - 10.1186/1471-2458-13-387 [doi]
AB  - BACKGROUND: Diabetes is increasingly becoming a major chronic disease burden all 
      over the world. This requires a shift in healthcare priorities and up-to-date
      data on the epidemiology and impact of diabetes in all regions of the world to
      help plan and prioritize health programs. We systematically reviewed the
      literature on diabetes prevalence and its complications in the UN sub region of
      Northern Africa including Morocco, Algeria, Tunisia, Libya, Egypt, Sudan, South
      Sudan and Western Sahara. METHODS: A systematic literature review of papers
      published on diabetes prevalence and complications in North Africa from January
      1990 to July 2012. Literature searches were conducted using electronic databases.
      RESULTS: Diabetes prevalence ranged from 2.6% in rural Sudan to 20.0% in urban
      Egypt. Diabetes prevalence was significantly higher in urban areas than in rural 
      areas. Undiagnosed diabetes is common in Northern Africa with a prevalence
      ranging from 18% to 75%. The prevalence of chronic diabetes complications ranged 
      from 8.1% to 41.5% for retinopathy, 21% to 22% for albuminuria, 6.7% to 46.3% for
      nephropathy and 21.9% to 60% for neuropathy. CONCLUSIONS: Diabetes is an
      important and common health problem in Northern Africa. Variations in prevalence 
      of diabetes between individual countries are observed. Chronic complications of
      diabetes are common. Urgent measures are needed to prevent diabetes and its
      related complications in Northern Africa.
AD  - Academic Medical Centre, University of Amsterdam, PO Box 22660, Amsterdam, The
      Netherlands. c.o.agyemang@amc.uva.nl.
FAU - Bos, Manouk
AU  - Bos M
FAU - Agyemang, Charles
AU  - Agyemang C
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3646695
OID - NLM: PMC3646695
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/02/01 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 1471-2458-13-387 [pii]
AID - 10.1186/1471-2458-13-387 [doi]
PST - epublish
SO  - BMC Public Health. 2013 Apr 25;13:387. doi: 10.1186/1471-2458-13-387.

PMID- 23617748
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
DP  - 2013 Apr 26
TI  - Type 1 drug hypersensitivity following first dose of pegvisomant.
LID - 10.1111/cen.12230 [doi]
AB  - The growth hormone receptor antagonist, pegvisomant (Somavert ), is a generally
      well-tolerated medical treatment for acromegaly. Initial reports documenting
      safety and efficacy of pegvisomant suggested an adverse event profile similar to 
      placebo.1 The drug was approved for use in Europe in 2004 and over 1200 patients 
      with acromegaly treated with pegvisomant have been enrolled in the ACROSTUDY to
      assess both safety and treatment outcomes. Major adverse events noted in the
      study related to elevated liver enzymes (2.5%) and injection site reactions
      (2.2%). This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Aberdeen Royal Infirmary, Department of Diabetes and Endocrinology, Ward 27/28,
      Aberdeen, AB25 2ZN, United Kingdom.
FAU - Jacob, Jubbin
AU  - Jacob J
FAU - Bevan, John
AU  - Bevan J
LA  - ENG
PT  - LETTER
DEP - 20130426
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/03/18 [received]
PHST- 2013/04/19 [revised]
PHST- 2013/04/21 [accepted]
AID - 10.1111/cen.12230 [doi]
PST - aheadofprint
SO  - Clin Endocrinol (Oxf). 2013 Apr 26. doi: 10.1111/cen.12230.

PMID- 23617727
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Diabetes in the workplace - diabetic's perceptions and experiences of managing
      their disease at work: a qualitative study.
PG  - 386
LID - 10.1186/1471-2458-13-386 [doi]
AB  - BACKGROUND: Diabetes represents one of the biggest public health challenges
      facing the UK. It is also associated with increasing costs to the economy due to 
      working days lost as people with diabetes have a sickness absence rate 2-3 times 
      greater than the general population. Workplaces have the potential to support or 
      hinder self- management of diabetes but little research has been undertaken to
      examine the relationship between work and diabetes in the UK. This paper seeks to
      go some way to addressing this gap by exploring the perceptions and experiences
      of employees with diabetes. METHODS: Forty three people with diabetes were
      purposively recruited to ascertain ways in which they managed their disease in
      the workplace. Semi-structured, interviews were undertaken, tape recorded and
      transcribed. Analysis was conducted using a constant comparative approach.
      RESULTS: Although respondents had informed managers of their diabetic status they
      felt that their managers had little concept of the effects of the work
      environment on their ability to manage their disease. They did not expect support
      from their managers and were concerned about being stigmatised or treated
      inappropriately. Work requirements took priority. They had to adapt their disease
      management to fit their job and reported running their blood glucose levels at
      higher than optimal levels, thereby putting themselves at higher risk of long
      term complications. CONCLUSIONS: Little research has examined the way in which
      employees with diabetes manage their disease in the workplace. This research
      shows there is a need to increase the awareness of managers of the short and long
      term economic benefit of supporting employees with diabetes to manage their
      disease effectively whist at work. Employees may need individually assessed and
      tailored support on the job in order to manage their disease effectively.
AD  - Centre for Health and Social Care Research, Faculty of Health and Social Care,
      Canterbury Christ Church University, Medway Campus, Cathedral Court, 30 Pembroke 
      Court, Chatham Maritime, Kent, ME4 4UF, UK. annmarie.ruston@canterbury.ac.uk.
FAU - Ruston, Annmarie
AU  - Ruston A
FAU - Smith, Alison
AU  - Smith A
FAU - Fernando, Bernard
AU  - Fernando B
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3649948
OID - NLM: PMC3649948
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/04/27 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 1471-2458-13-386 [pii]
AID - 10.1186/1471-2458-13-386 [doi]
PST - epublish
SO  - BMC Public Health. 2013 Apr 25;13:386. doi: 10.1186/1471-2458-13-386.

PMID- 23617682
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
DP  - 2013 May 30
TI  - The performance of the screening test for gestational diabetes in twin versus
      singleton pregnancies.
AB  - Abstract Objective: To compare the performance of the 50 g glucose challenge test
      (GCT) and the 100 g oral glucose tolerance test (OGTT) in twin versus singleton
      pregnancies. Methods: A retrospective study of all women who underwent a GCT
      (24-28 weeks) and delivered in a single tertiary medical center (2001-2012). The 
      performance of the GCT and the OGTT tests were compared between twin and
      singleton pregnancies. Results: The results of the GCT were available for 14 797 
      women, of whom 14 268 were singleton and 529 were twin pregnancies. Women in the 
      twins group were characterized by a higher mean GCT result (104.7 +/- 28 versus
      98.5 +/- 25, p < 0.001), a higher rate of GCT > 130 mg/dl (20.2% versus 11.8%, p 
      < 0.001) or GCT >140 mg/dl (13.8% versus 9.6%, p = 0.001). The positive
      prediction value (PPV) for a GCT >140 mg/dl was significantly lower in the twins 
      group for the prediction of either >/=1 abnormal values (21.1% versus 33.8%, p = 
      0.03) or >/=2 abnormal values (12.7% versus 23.0%, p = 0.04) in the OGTT. Twin
      pregnancy was independently associated with an increased risk for a GCT result
      >130 mg/dl [odds ratio (OR) = 2.2, 95% confidence interval (CI) 1.7-2.7] or >140 
      mg/dl (OR = 1.9, 95% CI 1.5-2.5) even after adjustment for maternal age, parity
      and fetal sex. Conclusion: The 50 g GCT appears to be associated with a higher
      false positive rate and a lower positive predictive value in twin compared with
      singleton pregnancies.
AD  - Department of Obstetrics and Gynecology, Helen Schneider Hospital for Women,
      Rabin Medical Center, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv
      University , Tel Aviv , Israel.
FAU - Yogev, Yariv
AU  - Yogev Y
FAU - Eisner, Michal
AU  - Eisner M
FAU - Hiersch, Liran
AU  - Hiersch L
FAU - Hod, Moshe
AU  - Hod M
FAU - Wiznitzer, Arnon
AU  - Wiznitzer A
FAU - Melamed, Nir
AU  - Melamed N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the
      European Association of Perinatal Medicine, the Federation of Asia and Oceania
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.3109/14767058.2013.799660 [doi]
PST - aheadofprint
SO  - J Matern Fetal Neonatal Med. 2013 May 30.

PMID- 23617586
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1471-2156 (Electronic)
IS  - 1471-2156 (Linking)
VI  - 14
DP  - 2013
TI  - Carriers of a novel frame-shift insertion in WNT16a possess elevated pancreatic
      expression of TCF7L2.
PG  - 28
LID - 10.1186/1471-2156-14-28 [doi]
AB  - BACKGROUND: The discovery of TCF7L2 as a global type 2 diabetes (T2D) gene has
      sparked investigations to explore the clinical utility of its variants for
      guiding the development of new diagnostic and therapeutic strategies. However,
      interpreting the resulting associations into function still remains unclear.
      Canonical Wnt signaling regulates beta-catenin and its binding with TCF7L2, which
      in turn is critical for the production of glucagon-like peptide-1 (GLP-1). This
      study examines the role of a novel frame-shift insertion discovered in a
      conserved region of WNT16a, and it is proposed that this mutation affects T2D
      susceptibility in conjunction with gene variants in TCF7L2. RESULTS: Our results 
      predicted that the insertion would convert the upstream open reading frame in the
      Wnt16a mRNA to an alternative, in-frame translation initiation site, resulting in
      the prevention of nonsense-mediated decay, leading to a consequent stabilization 
      of the mutated WNT16a message. To examine the role of Wnt16a in the Wnt signaling
      pathway, DNA and serum samples from 2,034 individuals (48% with T2D) from the
      Sikh Diabetes Study were used in this investigation. Prevalence of Wnt16a
      insertion did not differ among T2D cases (33%) and controls (32%). However, there
      was a 3.2 fold increase in Wnt16a mRNA levels in pancreatic tissues from the
      insertion carriers and a significant increase (70%, p < 0.0001) in luciferase
      activity in the constructs carrying the insertion. The expression of TCF7L2 mRNA 
      in pancreas was also elevated (~23-fold) among the insertion carriers (p=0.003). 
      CONCLUSIONS: Our results suggest synergistic effects of WNT16a insertion and the 
      at-risk 'T' allele of TCF7L2 (rs7903146) for elevating the expression of TCF7L2
      in human pancreas which may affect the regulation of downstream target genes
      involved in the development of T2D through Wnt/beta-catenin/TCF7L2 signaling
      pathway. However, further studies would be needed to mechanistically link the two
      definitively.
AD  - Department of Pediatrics, College of Medicine, University of Oklahoma Health
      Sciences Center, 940 Stanton L, Young Blvd,, Rm 317 BMSB, Oklahoma City, OK,
      73104, USA. Dharambir-Sanghera@ouhsc.edu.
FAU - Howard, Eric W
AU  - Howard EW
FAU - Been, Latonya F
AU  - Been LF
FAU - Lerner, Megan
AU  - Lerner M
FAU - Brackett, Daniel
AU  - Brackett D
FAU - Lightfoot, Stan
AU  - Lightfoot S
FAU - Bullen, Elizabeth C
AU  - Bullen EC
FAU - Sanghera, Dharambir K
AU  - Sanghera DK
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - England
TA  - BMC Genet
JT  - BMC genetics
JID - 100966978
SB  - IM
PMC - PMC3675375
OID - NLM: PMC3675375
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/09/21 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/04/23 [aheadofprint]
AID - 1471-2156-14-28 [pii]
AID - 10.1186/1471-2156-14-28 [doi]
PST - epublish
SO  - BMC Genet. 2013 Apr 23;14:28. doi: 10.1186/1471-2156-14-28.

PMID- 23617584
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 61
IP  - 5
DP  - 2013 May
TI  - Quadriceps strength, quadriceps power, and gait speed in older u.s. Adults with
      diabetes mellitus: results from the national health and nutrition examination
      survey, 1999-2002.
PG  - 769-75
LID - 10.1111/jgs.12204 [doi]
AB  - OBJECTIVES: To examine the independent association between diabetes mellitus (and
      its duration and severity) and quadriceps strength, quadriceps power, and gait
      speed in a national population of older adults. DESIGN: Cross-sectional
      nationally representative survey. SETTING: United States. PARTICIPANTS: Two
      thousand five hundred seventy-three adults aged 50 and older in the National
      Health and Nutrition Examination Survey 1999-2002 who had assessment of
      quadriceps strength. METHODS: Diabetes mellitus was ascertained according to
      questionnaire. Measurement of isokinetic knee extensor (quadriceps) strength was 
      performed at 60 masculine/s. Gait speed was assessed using a 20-foot walk test.
      Multiple linear regression analyses were used to assess the association between
      diabetes mellitus status and outcomes, adjusting for potential confounders or
      mediators. RESULTS: Older U.S. adults with diabetes mellitus had significantly
      slower gait speed (0.96 +/- 0.02 m/s) than those without (1.08 +/- 0.01 m/s; P < 
      .001). After adjusting for demographic characteristics, weight, and height,
      diabetes mellitus was also associated with significantly lower quadriceps
      strength (-4.6 +/- 1.9 Nm; P = .02) and power (-4.9 +/- 2.0 W; P = .02) and
      slower gait speed (-0.05 +/- 0.02 m/s; P = .002). Associations remained
      significant after adjusting for physical activity and C-reactive protein. After
      accounting for comorbidities (cardiovascular disease, peripheral neuropathy,
      amputation, cancer, arthritis, fracture, chronic obstructive pulmonary disease), 
      diabetes mellitus was independently associated only with gait speed (-0.04 +/-
      0.02 m/s; P = .02). Diabetes mellitus duration in men and women was negatively
      associated with age-adjusted quadriceps strength (-5.7 and -3.5 Nm/decade of
      diabetes mellitus, respectively) and power (-6.1 and -3.8 W/decade of diabetes
      mellitus, respectively) (all P </= .001, no significant interactions according to
      sex). Glycosylated hemoglobin was not associated with outcomes after accounting
      for body weight. CONCLUSION: Older U.S. adults with diabetes mellitus have lower 
      quadriceps strength and quadriceps power that is related to the presence of
      comorbidities and walk slower than those without diabetes mellitus. Future
      studies should investigate the relationship between hyperglycemia and subsequent 
      declines in leg muscle function.
CI  - (c) 2013, Copyright the Authors Journal compilation (c) 2013, The American
      Geriatrics Society.
AD  - Division of Endocrinology and Metabolism, The Johns Hopkins University,
      Baltimore, Maryland.
FAU - Kalyani, Rita Rastogi
AU  - Kalyani RR
FAU - Tra, Yolande
AU  - Tra Y
FAU - Yeh, Hsin-Chieh
AU  - Yeh HC
FAU - Egan, Josephine M
AU  - Egan JM
FAU - Ferrucci, Luigi
AU  - Ferrucci L
FAU - Brancati, Frederick L
AU  - Brancati FL
LA  - eng
GR  - K23 DK093583/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/04/25 [aheadofprint]
AID - 10.1111/jgs.12204 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2013 May;61(5):769-75. doi: 10.1111/jgs.12204. Epub 2013 Apr
      25.

PMID- 23617557
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
DP  - 2013 May 30
TI  - To evaluate the prevalence and clinical outcomes using a one-step method versus a
      two-step method to screen gestational diabetes mellitus.
AB  - Abstract Objective: The goal of this study is to compare the prevalence and
      clinical outcomes of a one-step with a two-step screening method, both of which
      are commonly used for the diagnosis of gestational diabetes mellitus (GDM).
      Methods: Women who presented for GDM screening and who consented to participate
      in this study were randomized into two groups. The women in Group 1 (n = 386)
      were screened using a one-step method (2-h, 75 g oral glucose tolerance test
      (OGTT)) and in Group 2 (n = 400) by a two-step method (the 50 g glucose challenge
      test (GCT) followed by the 100 g OGTT). The pregnancies were then classified into
      three subgroups as follows: women who had negative 2-h 75 g OGTT results
      according to IADPSG criteria (IADPSG-negative), women with negative 50 g GCT
      results (GCT-negative) and women with positive 50 g GCT results but negative 3-h 
      100 g OGTT results according to C&C criteria (C&C-negative). Results: The
      prevalence of GDM using the one-step and two-step methods was 14.5% and 6%,
      respectively. In adjusted multivariable regression models, women in the
      GCT-negative and the C&C-negative groups had greater risk of polyhydramnios than 
      women in the IADPSG-negative group [adjusted prevalence risk ratios (aPR), 1.40; 
      95% confidence intervals (CI), 1.03-1.91; aPR, 2.76; 95% CI, 1.27-6.02,
      respectively]. Women in the C&C-negative group had greater risk of pre-eclampsia 
      than women in the IADPSG-negative group (aPR, 3.30; 95% CI, 1.57-6.91).
      Conclusions: Women who were defined as having normal glucose tolerance by IADPSG 
      had better perinatal outcomes than women who were defined as having normal
      glucose tolerance by GCT and women who were GCT-positive with a negative OGTT.
AD  - Department of Obstetrics and Gynecology and.
FAU - Sevket, Osman
AU  - Sevket O
FAU - Ates, Seda
AU  - Ates S
FAU - Uysal, Omer
AU  - Uysal O
FAU - Molla, Taner
AU  - Molla T
FAU - Dansuk, Ramazan
AU  - Dansuk R
FAU - Kelekci, Sefa
AU  - Kelekci S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the
      European Association of Perinatal Medicine, the Federation of Asia and Oceania
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.3109/14767058.2013.799656 [doi]
PST - aheadofprint
SO  - J Matern Fetal Neonatal Med. 2013 May 30.

PMID- 23617533
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Linking)
DP  - 2013 Apr 25
TI  - Not-in-trial simulation I: bridging cardiovascular risk from clinical trials to
      real life conditions.
LID - 10.1111/bcp.12151 [doi]
AB  - AIM: he assessment of QTc interval prolongation relies on the evidence of drug
      effects in healthy subjects. This study demonstrates the relevance of
      pharmacokinetic-pharmacodynamic (PKPD) relationships to characterise drug-induced
      QTc-interval prolongation and explore the discrepancies between clinical trials
      and real-life conditions. METHODS: d,l-sotalol data from healthy subjects and
      from the Rotterdam Study cohort were used to assess treatment response in a phase
      I setting and in real life situation, respectively. Using modelling and
      simulation, drug effects at therapeutic doses were predicted in both populations.
      RESULTS: Inclusion criteria were shown to restrict the representativeness of the 
      trial population, as compared to real-life conditions. A significant part of the 
      typical patient population was excluded from trials based on weight and baseline 
      QT-interval measurements. Relative risk was significantly different between
      sotalol users with and without heart failure, hypertension, diabetes, and
      myocardial infarction. Although drug effects do cause an increase in relative
      risk of QT interval prolongation, the presence of diabetes represented an
      increase in relative risk from 4.0 (2.7 - 5.8) to 6.5 (1.6 - 27.1), whilst for
      myocardial infarction it increased from 3.4 (2.3 - 5.13) to 15.5 (4.9 - 49.3)
      (p<0.01). CONCLUSIONS: Our findings show that drug effects on QTc-interval do not
      explain the observed QTc values in the population. The prevalence of high QTc
      values in the real-life population can be assigned to co-morbidities and
      concomitant medications. These findings substantiate the need to account for
      these factors when evaluating cardiovascular risk of medicinal products.
CI  - This article is protected by copyright. All rights reserved.
AD  - Leiden/Amsterdam Centre for Drug Research, Division of Pharmacology, Leiden
      University, P.O. Box 9500, 2300 RA, Leiden, The Netherlands; Department of
      Medical Informatics and Epidemiology, Erasmus Medical Centre, Dr. Molewaterplein 
      50, 3015 GE, Rotterdam, The Netherlands.
FAU - Chain, Asy
AU  - Chain A
FAU - Dieleman, Jp
AU  - Dieleman J
FAU - van Noord, C
AU  - van Noord C
FAU - Hofman, A
AU  - Hofman A
FAU - Stricker, Bhc
AU  - Stricker B
FAU - Danhof, M
AU  - Danhof M
FAU - Sturkenboom, McJm
AU  - Sturkenboom M
FAU - Della Pasqua, O
AU  - Della Pasqua O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/04/04 [accepted]
AID - 10.1111/bcp.12151 [doi]
PST - aheadofprint
SO  - Br J Clin Pharmacol. 2013 Apr 25. doi: 10.1111/bcp.12151.

PMID- 23617411
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Amputations and foot ulcers in patients newly diagnosed with Type 2 diabetes
      mellitus and observed for 19 years. The role of age, gender and co-morbidity.
LID - 10.1111/dme.12196 [doi]
AB  - AIMS: To determine the prevalence of foot ulcers and the incidence of amputations
      in patients with Type 2 diabetes observed for 19 years after diagnosis. We
      investigated the role of gender, age and co-morbidities. METHODS: From the
      Diabetes Care in General Practice study, 1381 patients were included and examined
      at diabetes diagnosis, at 6 years and at 14 years after diagnosis. Register-based
      follow-up was for 19 years. Foot ulcers and amputations were related to gender,
      age and co-morbidities by odds and hazard ratios from logistic and Cox regression
      models, respectively. RESULTS: The incidence of any amputation and major
      amputation was 400 (95% CI 307-512) and 279 (95% CI 203-375) per 100 000
      patient-years, respectively. At the three observation points, the foot ulcer
      prevalences were 2.76% (95% CI 1.89-3.63), 2.93% (95% CI 1.86-4.00) and 4.96%
      (95% CI 3.10-6.82). Multivariate analyses showed associations between foot ulcers
      and peripheral neuropathy, peripheral arterial disease, male gender, retinopathy 
      and myocardial infarction. After multivariate adjustment, significant predictors 
      (hazard ratio; 95% CI) of any amputation were peripheral neuropathy (hazard ratio
      2.09; 95% CI 1.19-3.69), peripheral arterial disease (hazard ratio 3.43; 95% CI
      1.65-7.12), microalbuminuria (hazard ratio 2.11; 95% CI 1.21-3.67), retinopathy
      (hazard ratio 6.42; 95% CI 2.59-15.90), impaired vision (hazard ratio 6.92; 95%
      CI 2.35-20.38) and male gender (hazard ratio 2.40; 95% CI 1.31-4.41). For women, 
      the risk of amputation increased with age, but for men the risk was higher when
      diagnosed with diabetes at a younger age. CONCLUSIONS: Despite improved treatment
      regimens, the incidence of amputations is still high in this population-based
      patient sample. Men diagnosed with diabetes before age 65 years and patients with
      diabetes-related co-morbidities are at particularly high risk of foot ulcers and 
      amputations.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - The Research Unit for General Practice and Section of General Practice,
      Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
FAU - Bruun, C
AU  - Bruun C
FAU - Siersma, V
AU  - Siersma V
FAU - Guassora, A D
AU  - Guassora AD
FAU - Holstein, P
AU  - Holstein P
FAU - de Fine Olivarius, N
AU  - de Fine Olivarius N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2012/10/16 [received]
PHST- 2013/02/08 [revised]
PHST- 2013/03/15 [accepted]
AID - 10.1111/dme.12196 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12196.

PMID- 23617252
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 25
TI  - Long-Term Metabolic Effects of Continuous Subcutaneous Insulin Infusion Therapy
      in Type 1 Diabetes.
AB  - Abstract Background: Continuous subcutaneous insulin infusion (CSII) and
      intensive multiple daily insulin injections (iMDI) program are treatment options 
      in patients with type 1 diabetes not achieving optimal glycemic control. The
      long-term effects of CSII in patients with type 1 diabetes in comparison with
      those educated for iMDI are poorly documented. Research Design and Methods:
      Medical records for patients commenced on CSII or undertaking an iMDI program
      between 2000 and 2011 were extracted. Change in hemoglobin A1c (HbA1c),
      hypoglycemia, and weight were analyzed. Prior to CSII or iMDI commencement, all
      patients were on basal bolus analog insulin. Data from blood glucose meter
      downloads before and 6 months after CSII and iMDI were also analyzed. Results:
      One hundred twenty-six CSII and 121 iMDI patients were studied, with mean (+/-SD)
      follow-up of 39+/-26 and 48+/-26 months, respectively. For CSII, HbA1c was
      significantly lower than baseline at every time period up to 36 months. Peak
      HbA1c reduction was 0.64% at 6 months, following which the HbA1c change declined.
      For iMDI, HbA1c was significantly reduced only at 6 months, by 0.15%. Glucose
      meter data were available for 119 patients. CSII-treated patients had a
      significant decrease in mean glucose and glucose SD with no change hypoglycemia
      at 6 months compared with baseline; no differences were observed for iMDI-treated
      patients. Conclusions: CSII in type 1 diabetes is associated with improved
      glycemic control with no increase in hypoglycemia. HbA1c improvement declined
      over time, suggesting a need for re-education after CSII commencement. The iMDI
      program did not have significant glycemic benefits.
AD  - 1 Baker IDI Heart and Diabetes Institute , Melbourne, Australia .
FAU - Cohen, Neale D
AU  - Cohen ND
FAU - Hong, Eui S
AU  - Hong ES
FAU - Van Drie, Christy
AU  - Van Drie C
FAU - Balkau, Beverley
AU  - Balkau B
FAU - Shaw, Jonathan
AU  - Shaw J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1089/dia.2012.0331 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 25.

PMID- 23617251
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 15
IP  - 6
DP  - 2013 Jun
TI  - Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.
PG  - 455-60
LID - 10.1089/dia.2012.0315 [doi]
AB  - Abstract Aims: It is necessary to evaluate glucose variability and postprandial
      hyperglycemia in patients with well-controlled type 2 diabetes mellitus because
      of the limitations associated with hemoglobin A1c (HbA1c) measurements. We
      evaluated parameters reflecting postprandial hyperglycemia and glycemic
      variability in patients with optimal HbA1c. Patients and Methods: Thirty-nine
      patients with HbA1c levels below 7% were recruited to the study. A continuous
      glucose monitoring system (CGMS) was applied for two 72-h periods.
      1,5-Anhydroglucitol (1,5-AG) and fructosamine (FA) were measured as parameters
      for postprandial hyperglycemia and glucose variability. Using CGMS data, the
      following postprandial hyperglycemia parameters were calculated: mean
      postprandial maximum glucose (MPMG) and area under the curve for glucose above
      180 mg/dL (AUC-180). To measure glycemic variability, we calculated mean
      amplitude of glucose excursion (MAGE) using a classical (MAGEc) and new method
      (MAGE group of sign [MAGEgos]). Results: The baseline HbA1c level was 6.3+/-0.3%.
      The mean MPMG was 10.34+/-1.84 mmol/L, and the mean AUC-180 was 0.17+/-0.23
      mmol/L/day. The mean MAGEgos was 3.27+/-1.29 mmol/L, and MAGEc was 4.30+/-1.43
      mmol/L, indicating glycemic variability in our patients. The mean levels of
      1,5-AG and FA were 16.7+/-7.4 mug/mL and 273.0+/-22.5 mumol/L, respectively. In a
      correlation analysis, FA was significantly correlated with MPMG, AUC-180,
      MAGEgos, and MAGEc. In contrast, 1,5-AG was only correlated with AUC-180.
      Conclusions: This study demonstrated postprandial hyperglycemia and glycemic
      variability in subjects with well-controlled diabetes. FA may reflect
      postprandial hyperglycemia and glycemic variability, but 1,5-AG may be of limited
      value for assessing glucose variability in patients with well-controlled type 2
      diabetes mellitus.
AD  - 1 Department of Endocrinology and Metabolism, Kyung Hee University School of
      Medicine , Seoul, Korea.
FAU - Chon, Suk
AU  - Chon S
FAU - Lee, Yun Jung
AU  - Lee YJ
FAU - Fraterrigo, Gemma
AU  - Fraterrigo G
FAU - Pozzilli, Paolo
AU  - Pozzilli P
FAU - Choi, Moon Chan
AU  - Choi MC
FAU - Kwon, Mi-Kwang
AU  - Kwon MK
FAU - Chin, Sang Ouk
AU  - Chin SO
FAU - Rhee, Sang Youl
AU  - Rhee SY
FAU - Oh, Seungjoon
AU  - Oh S
FAU - Kim, Young-Seol
AU  - Kim YS
FAU - Woo, Jeong-Taek
AU  - Woo JT
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PHST- 2013/04/25 [aheadofprint]
AID - 10.1089/dia.2012.0315 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2013 Jun;15(6):455-60. doi: 10.1089/dia.2012.0315. Epub
      2013 Apr 25.

PMID- 23617250
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 25
TI  - Effect of Vildagliptin on Glucose and Insulin Concentrations During a 24-Hour
      Period in Type 2 Diabetes Patients with Different Ranges of Baseline Hemoglobin
      A1c Levels.
AB  - Abstract Background: Currently, it is still unknown whether differences in
      glycemic control have any effect on glucose and insulin kinetics after
      vildagliptin administration. The aim of this study was to evaluate the effect of 
      vildagliptin on glucose and insulin concentrations during a 24-h period in type 2
      diabetes patients with different ranges of baseline hemoglobin A1c (A1C) levels. 
      Patients and Methods: A randomized, double-blind, crossover, placebo-controlled
      clinical trial was carried out in 12 drug-naive adult volunteers with type 2
      diabetes and overweight or obesity. Subjects had fasting glucose values between
      7.2 and 13.3 mmol/L. Six patients had A1C between 7.0% and 8.4% (Group A), and
      the remaining subjects had A1C between 8.5% and 10.0% (Group B). Patients
      received oral administration of vildagliptin (50 mg twice daily) or placebo in a 
      crossover manner for two consecutive days. Until the second day of the
      interventions, glucose and insulin concentrations were measured every hour during
      a 24-h period, and areas under the curve (AUCs) were calculated. Statistical
      analyses were evaluated with Wilcoxon and Mann-Whitney U tests. Results: There
      were significant decreases in glucose concentrations after vildagliptin
      administration in both groups when comparing placebo in all measurements
      throughout the 24-h period and in the AUC. There were no significant changes in
      insulin concentration in both groups after vildagliptin administration when
      comparing placebo in all measurements throughout the 24-h period and in the AUC. 
      Conclusions: Vildagliptin administration improved glucose control during a 24-h
      period in type 2 diabetes patients, independent of the basal A1C level, without
      changes in insulin levels.
AD  - 1 Research Unit in Clinical Epidemiology, Medical Unit of High Specialty,
      Specialties Hospital, West National Medical Center, Mexican Institute of Social
      Security , Guadalajara, Mexico .
FAU - Gonzalez-Ortiz, Manuel
AU  - Gonzalez-Ortiz M
FAU - Sanchez-Pena, Maria J
AU  - Sanchez-Pena MJ
FAU - Gonzalez-Ortiz, Luis J
AU  - Gonzalez-Ortiz LJ
FAU - Robles-Cervantes, Jose A
AU  - Robles-Cervantes JA
FAU - Garcia-Ortega, Yessica E
AU  - Garcia-Ortega YE
FAU - Gomez-Gaitan, Esteban A
AU  - Gomez-Gaitan EA
FAU - Perez-Rubio, Karina G
AU  - Perez-Rubio KG
FAU - Martinez-Abundis, Esperanza
AU  - Martinez-Abundis E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.1089/dia.2013.0020 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 25.

PMID- 23617228
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
DP  - 2013 Jun 5
TI  - A randomized trial comparing perinatal outcomes using insulin detemir or neutral 
      protamine Hagedorn in type 1 diabetes.
AB  - Abstract Objective: This randomized controlled trial aimed to compare the
      efficacy and safety of insulin detemir (IDet) with neutral protamine Hagedorn
      (NPH), both with insulin aspart, in pregnant women with type 1 diabetes. The
      perinatal and obstetric pregnancy outcomes are presented. Methods: Subjects were 
      randomized to IDet (n = 152) or NPH (n = 158) </=12 months before pregnancy or at
      8-12 gestational weeks. Results: For IDet and NPH, there were 128 and 136 live
      births, 11 and 9 early fetal losses, and two and one perinatal deaths,
      respectively. Gestational age at delivery was greater for children from the IDet 
      arm than the NPH arm (treatment difference: 0.49 weeks [95% CI 0.11;0.88], p =
      0.012, linear regression). Sixteen children had a malformation (IDet: n = 8/142, 
      5.6%; NPH: n = 8/145, 5.5%). The incidence of adverse events was similar between 
      treatments. Conclusion: IDet is as well tolerated as NPH as regards perinatal
      outcomes in pregnant women with type 1 diabetes and no safety issues were
      identified.
AD  - Helen Schneider Women's Hospital, Rabin Medical Center, Sackler Faculty of
      Medicine, Tel Aviv University , Tel Aviv , Israel .
FAU - Hod, Moshe
AU  - Hod M
FAU - Mathiesen, Elisabeth R
AU  - Mathiesen ER
FAU - Jovanovic, Lois
AU  - Jovanovic L
FAU - McCance, David R
AU  - McCance DR
FAU - Ivanisevic, Marina
AU  - Ivanisevic M
FAU - Duran-Garcia, Santiago
AU  - Duran-Garcia S
FAU - Brondsted, Lise
AU  - Brondsted L
FAU - Nazeri, Avideh
AU  - Nazeri A
FAU - Damm, Peter
AU  - Damm P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130605
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the
      European Association of Perinatal Medicine, the Federation of Asia and Oceania
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
AID - 10.3109/14767058.2013.799650 [doi]
PST - aheadofprint
SO  - J Matern Fetal Neonatal Med. 2013 Jun 5.

PMID- 23617205
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1606-0997 (Print)
IS  - 1606-0997 (Linking)
VI  - 31
IP  - 1
DP  - 2013 Mar
TI  - White blood cell count in women: relation to inflammatory biomarkers,
      haematological profiles, visceral adiposity, and other cardiovascular risk
      factors.
PG  - 58-64
AB  - The role of white blood cell (WBC) count in pathogenesis of diabetes,
      cardiovascular disease, and obesity-related disorders has been reported earlier. 
      Recent studies revealed that higher WBC contributes to atherosclerotic
      progression and impaired fasting glucose. However, it is unknown whether
      variations in WBC and haematologic profiles can occur in healthy obese
      individuals. The aim of this study is to further evaluate the influence of
      obesity on WBC count, inflammatory biomarkers, and metabolic risk factors in
      healthy women to establish a relationship among variables analyzed. The sample of
      the present study consisted of 84 healthy women with mean age of 35.56 +/- 6.83
      years. They were categorized into two groups based on their body mass index
      (BMI): obese group with BMI > 30 kg/m2 and non-obese group with BMI < 30 kg/m2.
      We evaluated the relationship between WBC and platelet count (PLT) with serum
      interleukin 6 (IL-6), C-reactive protein (CRP), angiotensin pi (Ang pi), body fat
      percentage (BF %), waist-circumference (WC), and lipid profile. WBC, PLT, CRP,
      and IL-6 in obese subjects were significantly higher than in non-obese subjects
      (p < 0.05). The mean WBC count in obese subjects was 6.4 +/- 0.3 (x10(9)/L)
      compared to 4.4 +/- 0.3 (x10(9)/L) in non-obese subjects (p = 0.035). WBC
      correlated with BF% (r = 0.31, p = 0.004), CRP (r = 0.25, P = 0.03), WC (r =
      0.22, p = 0.04), angiotensin 11 (r = 0.24, p = 0.03), triglyceride (r = 0.24, p =
      0.03), and atherogenic index of plasma (AIP) levels (r = 0.3, p = 0.028) but not 
      with IL-6. Platelet count was also associated with WC and waist-to-hip ratio (p <
      0.05). Haemoglobin and haematocrit were in consistent relationship with
      LDL-cholesterol (p < 0.05). In conclusion, obesity was associated with higher WBC
      count and inflammatory parameters. There was also a positive relationship between
      WBC count and several inflammatory and metabolic risk factors in healthy women.
AD  - Department of Community Nutrition, School of Health and Nutrition, Tabriz
      University of Medical Sciences, Tabriz, Iran.
FAU - Farhangi, Mahdieh Abbasalizad
AU  - Farhangi MA
FAU - Keshavarz, Seyyed-Ali
AU  - Keshavarz SA
FAU - Eshraghian, Mohammadreza
AU  - Eshraghian M
FAU - Ostadrahimi, Alireza
AU  - Ostadrahimi A
FAU - Saboor-Yaraghi, Ali-Akbar
AU  - Saboor-Yaraghi AA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Bangladesh
TA  - J Health Popul Nutr
JT  - Journal of health, population, and nutrition
JID - 100959228
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PST - ppublish
SO  - J Health Popul Nutr. 2013 Mar;31(1):58-64.

PMID- 23617038
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1088-6222 (Print)
IS  - 1088-6222 (Linking)
VI  - 106
IP  - 4
DP  - 2013 Apr
TI  - Glucose monitoring as an impediment to improving glycemic control: a case report.
PG  - 37-8
AB  - Diabetes mellitus is increasing in frequency and is associated with disabling
      acute and chronic complications. There is evidence to indicate that excellent
      glucose control may retard the development and/or progression of these
      complications. In order to optimize diabetic control, patients are encouraged to 
      monitor their glucose frequently. We describe a patient who provided inaccurate
      glucose monitoring results, delaying effective management of hisprogressively
      increasing glycosylated hemoglobin level. The diagnostic due to his erroneous
      glucose monitoring results was the lack of intra-day variation in this patient on
      insulin therapy. Moreover, glucose records within the patient's glucometer
      pointed to a much less frequent glucose monitoring than the written data provided
      by the patient. The glucometer was accurate when used by the patient under direct
      observation. It remains unclear whether this patient deliberately misled his
      providers or if the erroneous data reflected underlying cognitive dysfunction.
      Providers are encouraged to approximate average blood sugars based on
      glycosylated hemoglobin values and compare this to home monitoring results
      provided by the patient. Primary providers should also expect a certain degree of
      variability when reviewing home blood sugar values with their patients (on
      insulin therapy) and consider further investigation should the numbers lack such 
      variation. Clinicians are urged to inspect the actual glucose readings on the
      patient's glucometer as well as inspecting written glucoserecords. Observing the 
      patient's technique and accuracy when using their personal glucometer should also
      be considered.
AD  - Department of Internal Medicine, East Tennessee State University, Johnson City,
      NJ 37614-1708, USA. russellag@etsu.edu
FAU - Russell, Aimee G
AU  - Russell AG
FAU - Chen, Lei
AU  - Chen L
FAU - Jones, Kelli
AU  - Jones K
FAU - Peiris, Alan N
AU  - Peiris AN
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Tenn Med
JT  - Tennessee medicine : journal of the Tennessee Medical Association
JID - 9609310
SB  - IM
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/27 06:00
PST - ppublish
SO  - Tenn Med. 2013 Apr;106(4):37-8.

PMID- 23616676
OWN - NLM
STAT- In-Data-Review
DA  - 20130425
IS  - 0008-4123 (Print)
IS  - 0008-4123 (Linking)
VI  - 66
IP  - 2
DP  - 2013 Mar
TI  - Stability of propranolol in extemporaneously compounded suspensions.
PG  - 118-24
AB  - BACKGROUND: Propranolol is a drug of choice for many diseases occurring in
      neonates and infants, an age group for which oral suspensions are required almost
      exclusively. Many adult and elderly patients for whom propranolol is prescribed
      are also unable to swallow solid dosage forms. In Canada, propranolol is not
      commercially available in a liquid dosage form, and existing recipes for
      extemporaneously compounded suspensions of propranolol (1 mg/mL) are limited by
      concerns regarding diabetes mellitus in certain subpopulations, the need for a
      more concentrated suspension for patients taking larger doses, and the
      tediousness of compounding. OBJECTIVE: To evaluate the stability of propranolol
      suspensions in a sugar-free, commercially available vehicle after storage at room
      temperature and under refrigeration for up to 120 days. METHODS: Suspensions of
      propranolol (2 and 5 mg/mL) were prepared in the sugar-free vehicle (Ora-Blend
      SF), placed in 100-mL amber plastic prescription bottles, and stored at 25
      degrees C and 4 degrees C. Samples were collected from each bottle once weekly
      for 120 days, stored frozen, and analyzed by a validated, stability-indicating
      high-performance liquid chromatography - ultraviolet detection method. A
      suspension was considered stable if it maintained at least 90% of its initial
      concentration of propranolol. Physical compatibility was evaluated in terms of
      colour, taste, precipitation, and pH. RESULTS: Propranolol suspensions 2 mg/mL
      and 5 mg/mL stored at 25 degrees C maintained at least 94.7% of their initial
      concentration for 120 days, and suspensions stored at 4 degrees C maintained at
      least 93.9% of their initial concentration for 120 days. There were no notable
      changes in pH, and all samples remained physically unchanged except for a slight 
      change in colour, around day 70, of suspensions stored at room temperature.
      CONCLUSION: Propranolol suspensions (2 mg/mL and 5 mg/mL) prepared in Ora-Blend
      SF and stored in plastic prescription bottles at either 25 degrees C or 4 degrees
      C are expected to remain stable for 120 days.
AD  - , BS(Pharm), PharmD, FASHP, FCCP, FCSHP, is Professor, Faculty of Pharmaceutical 
      Sciences and Distinguished University Scholar, The University of British
      Columbia, and Clinical Pharmacy Specialist, Department of Pharmacy, Children's
      and Women's Health Centre of British Columbia, Vancouver, British Columbia. She
      is also the Editor of the CJHP .
FAU - Ensom, Mary H H
AU  - Ensom MH
FAU - Kendrick, Jennifer
AU  - Kendrick J
FAU - Rudolph, Susan
AU  - Rudolph S
FAU - Decarie, Diane
AU  - Decarie D
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - Can J Hosp Pharm
JT  - The Canadian journal of hospital pharmacy
JID - 0215645
PMC - PMC3633496
OID - NLM: PMC3633496 [Available on 09/01/13]
OAB - Publisher: Abstract available from the publisher.
OTO - NOTNLM
OT  - propranolol
OT  - stability
OT  - suspension
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PMCR- 2013/09/01 00:00
PST - ppublish
SO  - Can J Hosp Pharm. 2013 Mar;66(2):118-24.

PMID- 23616597
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Linking)
VI  - 56
IP  - 10
DP  - 2013 May
TI  - Photo quiz: fever and progressive swelling of the left thigh in a female heroin
      addict with diabetes mellitus. Klebsiella pneumoniae.
PG  - 1457
LID - 10.1093/cid/cit028 [doi]
FAU - Lee, Meng-Rui
AU  - Lee MR
FAU - Hsueh, Po-Ren
AU  - Hsueh PR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases
      Society of America
JID - 9203213
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - cit028 [pii]
AID - 10.1093/cid/cit028 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2013 May;56(10):1457. doi: 10.1093/cid/cit028.

PMID- 23616560
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1529-2401 (Electronic)
IS  - 0270-6474 (Linking)
VI  - 33
IP  - 17
DP  - 2013 Apr 24
TI  - Gustatory stimuli representing different perceptual qualities elicit distinct
      patterns of neuropeptide secretion from taste buds.
PG  - 7559-64
LID - 10.1523/JNEUROSCI.0372-13.2013 [doi]
AB  - Taste stimuli that evoke different perceptual qualities (e.g., sweet, umami,
      bitter, sour, salty) are detected by dedicated subpopulations of taste bud cells 
      that use distinct combinations of sensory receptors and transduction molecules.
      Here, we report that taste stimuli also elicit unique patterns of neuropeptide
      secretion from taste buds that are correlated with those perceptual qualities. We
      measured tastant-dependent secretion of glucagon-like peptide-1 (GLP-1),
      glucagon, and neuropeptide Y (NPY) from circumvallate papillae of Tas1r3(+/+),
      Tas1r3(+/-) and Tas1r3 (-/-) mice. Isolated tongue epithelia were mounted in
      modified Ussing chambers, permitting apical stimulation of taste buds; secreted
      peptides were collected from the basal side and measured by specific ELISAs.
      Appetitive stimuli (sweet: glucose, sucralose; umami: monosodium glutamate;
      polysaccharide: Polycose) elicited GLP-1 and NPY secretion and inhibited basal
      glucagon secretion. Sweet and umami stimuli were ineffective in Tas1r3(-/-) mice,
      indicating an obligatory role for the T1R3 subunit common to the sweet and umami 
      taste receptors. Polycose responses were unaffected by T1R3 deletion, consistent 
      with the presence of a distinct polysaccharide taste receptor. The effects of
      sweet stimuli on peptide secretion also required the closing of ATP-sensitive
      K(+) (KATP) channels, as the KATP channel activator diazoxide inhibited the
      effects of glucose and sucralose on both GLP-1 and glucagon release. Both sour
      citric acid and salty NaCl increased NPY secretion but had no effects on GLP-1 or
      glucagon. Bitter denatonium showed no effects on these peptides. Together, these 
      results suggest that taste stimuli of different perceptual qualities elicit
      unique patterns of neuropeptide secretion from taste buds.
AD  - Department of Anatomy and Neurobiology, Division of Endocrinology, Diabetes and
      Nutrition, University of Maryland School of Medicine, Baltimore, Maryland 21201, 
      USA.
FAU - Geraedts, Maartje C P
AU  - Geraedts MC
FAU - Munger, Steven D
AU  - Munger SD
LA  - eng
GR  - DC010110/DC/NIDCD NIH HHS/United States
GR  - R01 DC010110/DC/NIDCD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Neurosci
JT  - The Journal of neuroscience : the official journal of the Society for
      Neuroscience
JID - 8102140
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 33/17/7559 [pii]
AID - 10.1523/JNEUROSCI.0372-13.2013 [doi]
PST - ppublish
SO  - J Neurosci. 2013 Apr 24;33(17):7559-64. doi: 10.1523/JNEUROSCI.0372-13.2013.

PMID- 23616464
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1521-3765 (Electronic)
IS  - 0947-6539 (Linking)
VI  - 19
IP  - 25
DP  - 2013 Jun 17
TI  - A QM/MM Investigation of the Catalytic Mechanism of Metal-Ion-Independent Core 2 
      beta1,6-N-Acetylglucosaminyltransferase.
PG  - 8153-62
LID - 10.1002/chem.201300383 [doi]
AB  - beta1,6-GlcNAc-transferase (C2GnT) is an important controlling factor of
      biological functions for many glycoproteins and its activity has been found to be
      altered in breast, colon, and lung cancer cells, in leukemia cells, in the
      lymhomonocytes of multiple sclerosis patients, leukocytes from diabetes patients,
      and in conditions causing an immune deficiency. The result of the action of C2GnT
      is the core 2 structure that is essential for the further elongation of the
      carbohydrate chains of O-glycans. The catalytic mechanism of this
      metal-ion-independent glycosyltransferase is of paramount importance and is
      investigated here by using quantum mechanical (QM) (density functional theory
      (DFT))/molecular modeling (MM) methods with different levels of theory. The
      structural model of the reaction site used in this report is based on the crystal
      structures of C2GnT. The entire enzyme-substrate system was subdivided into two
      different subsystems: the QM subsystem containing 206 atoms and the MM region
      containing 5914 atoms. Three predefined reaction coordinates were employed to
      investigate the catalytic mechanism. The calculated potential energy surfaces
      discovered the existence of a concerted SN 2-like mechanism. In this mechanism, a
      nucleophilic attack by O6 facilitated by proton transfer to the catalytic base
      and the separation of the leaving group all occur almost simultaneously. The
      transition state for the proposed reaction mechanism at the M06-2X/6-31G** (with 
      diffuse functions on the O1', O5', OGlu , and O6 atoms) level was located at
      C1O6=1.74 A and C1O1=2.86 A. The activation energy for this mechanism was
      estimated to be between 20 and 29 kcal mol(-1) , depending on the method used.
      These calculations also identified a low-barrier hydrogen bond between the
      nucleophile O6H and the catalytic base Glu320, and a hydrogen bond between the
      N-acetamino group and the glycosidic oxygen of the donor in the TS. It is
      proposed that these interactions contribute to a stabilization of TS and
      participate in the catalytic mechanism.
CI  - Copyright (c) 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
AD  - Institute of Chemistry, Slovak Academy of Sciences, 845 38 Bratislava (Slovak
      Republic), Fax: (+421) 2-5941-0222; Central European Institute of Technology
      (CEITEC), Masaryk University, 625 00 Brno (Czech Republic). chemitsa@savba.sk.
FAU - Tvaroska, Igor
AU  - Tvaroska I
FAU - Kozmon, Stanislav
AU  - Kozmon S
FAU - Wimmerova, Michaela
AU  - Wimmerova M
FAU - Koca, Jaroslav
AU  - Koca J
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Germany
TA  - Chemistry
JT  - Chemistry (Weinheim an der Bergstrasse, Germany)
JID - 9513783
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/01/31 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1002/chem.201300383 [doi]
PST - ppublish
SO  - Chemistry. 2013 Jun 17;19(25):8153-62. doi: 10.1002/chem.201300383. Epub 2013 Apr
      24.

PMID- 23616419
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1099-0844 (Electronic)
IS  - 0263-6484 (Linking)
DP  - 2013 Apr 25
TI  - Caspase 3 activation and PARP cleavage in lymphocytes from newborn babies of
      diabetic mothers with unbalanced glycaemic control.
LID - 10.1002/cbf.2975 [doi]
AB  - Several epidemiological studies showed that gestational diabetes mellitus is the 
      most frequent metabolic disorder of pregnancy, the pathogenesis of which has yet 
      to be completely clarified. The aim of this study was to investigate the presence
      and processing of caspase 3 (Casp3) and poly(ADP-ribose) polymerase 1 (PARP1) in 
      cord blood lymphocytes as markers of apoptosis in relation to glycaemic control
      during intrauterine life. Our results showed a specific positive correlation
      between the levels of active Casp3 (17-19 kDa) and the inactive form of PARP1 (89
      kDa) in lymphocytes isolated from newborn babies of diabetic women with
      unbalanced glycaemic control, with a direct correlation between the activation of
      casp3 and the inactivation of PARP1, that makes lymphocytes unresponsive towards 
      lipopolysaccharide stimulation, highlighting an altered functional response.
      Besides more studies are required to fully correlate the activation of the
      apoptotic process during the intrauterine life with the foetal health later in
      life, our study indicates that a cord blood lymphocyte, an easily accessible
      source, is informative about the activation of apoptotic stimuli in circulating
      cells of newborn babies in relation to the glycaemic control reached by the
      mother during pregnancy. Copyright (c) 2013 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
AD  - Department of Obstetrics and Gynaecology, University Hospital, Perugia, Italy;
      GeBiSa Research Foundation, Perugia, Italy.
FAU - Tarquini, F
AU  - Tarquini F
FAU - Tiribuzi, R
AU  - Tiribuzi R
FAU - Crispoltoni, L
AU  - Crispoltoni L
FAU - Porcellati, S
AU  - Porcellati S
FAU - Del Pino, A M
AU  - Del Pino AM
FAU - Orlacchio, A
AU  - Orlacchio A
FAU - Coata, G
AU  - Coata G
FAU - Arnone, S
AU  - Arnone S
FAU - Torlone, E
AU  - Torlone E
FAU - Cappuccini, B
AU  - Cappuccini B
FAU - Di Renzo, G C
AU  - Di Renzo GC
FAU - Orlacchio, A
AU  - Orlacchio A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Cell Biochem Funct
JT  - Cell biochemistry and function
JID - 8305874
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/03/10 [received]
PHST- 2013/02/19 [revised]
PHST- 2013/03/18 [accepted]
AID - 10.1002/cbf.2975 [doi]
PST - aheadofprint
SO  - Cell Biochem Funct. 2013 Apr 25. doi: 10.1002/cbf.2975.

PMID- 23616375
OWN - NLM
STAT- MEDLINE
DA  - 20130425
DCOM- 20130611
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - CABG better than PCI for smokers and those with diabetes, PAD, or heart failure.
PG  - f2534
LID - 10.1136/bmj.f2534 [doi]
LID - bmj.f2534 [pii]
LA  - eng
PT  - News
DEP - 20130424
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
MH  - *Coronary Artery Bypass
MH  - Coronary Artery Disease/complications/*surgery
MH  - Decision Making
MH  - *Diabetes Mellitus
MH  - Heart Failure/*complications
MH  - Humans
MH  - *Percutaneous Coronary Intervention
MH  - Peripheral Arterial Disease/*complications
EDAT- 2013/04/26 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/04/26 06:00
PST - epublish
SO  - BMJ. 2013 Apr 24;346:f2534. doi: 10.1136/bmj.f2534.

PMID- 23616363
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 2047-6310 (Electronic)
IS  - 2047-6302 (Linking)
DP  - 2013 Apr 25
TI  - The metabolic inter-relationships between changes in waist circumference,
      triglycerides, insulin sensitivity and small, dense low-density lipoprotein
      particles with acute weight loss in clinically obese children and adolescents.
LID - 10.1111/j.2047-6310.2013.00165.x [doi]
AB  - WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Small, dense LDL is highly atherogenic 
      and the prevalence is higher in obesity. Weight loss lowers the prevalence of
      small, dense LDL. WHAT THIS STUDY ADDS: The important role of TG in lowering LDL 
      peak particle density and the proportion of small, dense LDL particles. Waist or 
      insulin resistance were not predictive of these important changes in LDL
      characteristics. OBJECTIVE: Small, dense low-density lipoprotein (LDL) particles 
      are highly atherogenic and strongly associated with obesity-related dyslipidemia.
      The metabolic inter-relationships between weight loss induced changes in waist
      circumference, triglycerides, insulin sensitivity and small-dense LDL particles
      in clinically obese children and adolescents have not been studied. METHODS:
      Seventy-five clinically obese boys and girls (standardized body mass index 3.07
      +/- 0.59, aged 8-18 years) were recruited. Anthropometric, body composition and
      cardiometabolic risk factors were measured pre- and post-weight loss. RESULTS:
      There were highly significant reductions in anthropometric, body composition and 
      cardiometabolic risk factors. Triglyceride change was positively correlated with 
      LDL peak particle density and percentage LDL pattern B changes (relative
      abundance of small, dense LDL particles). Multiple regression analyses showed
      that changes in triglyceride concentration accounted for between 24 and 18% of
      the variance in LDL peak particle density and percentage LDL pattern B change,
      respectively. Changes in waist circumference and insulin sensitivity did not
      predict these changes in LDL characteristics. CONCLUSION: Acute and highly
      significant weight loss significantly decreased LDL peak particle density and
      percentage LDL pattern B. The change in triglycerides was a strong predictor of
      LDL peak particle density and percentage LDL pattern B change.
CI  - (c) 2013 The Authors. Pediatric Obesity (c) 2013 International Association for
      the Study of Obesity.
AD  - Department of Academic Endocrinology, Diabetes and Metabolism, University of
      Hull, Hull, UK.
FAU - Hobkirk, J P
AU  - Hobkirk JP
FAU - King, R F
AU  - King RF
FAU - Davies, I
AU  - Davies I
FAU - Harman, N
AU  - Harman N
FAU - Gately, P
AU  - Gately P
FAU - Pemberton, P
AU  - Pemberton P
FAU - Smith, A
AU  - Smith A
FAU - Barth, J H
AU  - Barth JH
FAU - Carroll, S
AU  - Carroll S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Pediatr Obes
JT  - Pediatric obesity
JID - 101572033
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/07/02 [received]
PHST- 2013/01/10 [revised]
PHST- 2013/02/11 [accepted]
AID - 10.1111/j.2047-6310.2013.00165.x [doi]
PST - aheadofprint
SO  - Pediatr Obes. 2013 Apr 25. doi: 10.1111/j.2047-6310.2013.00165.x.

PMID- 23616329
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Massive gastric dilation complicating diabetic gastroparesis.
LID - 10.1136/bcr-2013-009420 [doi]
LID - bcr2013009420 [pii]
AB  - A middle-aged man presented at 4:00 with tense distended abdomen, severe pain and
      numb legs. His medical background included poorly controlled insulin-dependent
      diabetes. Abdominal x-ray showed a massively distended, featureless viscus on the
      left side of the abdomen thought to be a sigmoid volvulus. CT scan was delayed
      due to respiratory compromise from diaphragmatic splinting. Nasogastric and
      flatus tube decompression were attempted. Eventually CT was obtained and
      provisionally reported as a sigmoid volvulus. Emergency laparotomy was performed 
      due to the risk of impending perforation. Operative findings were of a hugely
      distended stomach extending into the left iliac fossa almost completely occupying
      the abdominal cavity. Gastrotomy was used to decompress the stomach. No
      mechanical obstruction was identified. Postoperatively he had an episode of
      massive haematemesis thought to be due to sloughing of gastric mucosa. He was
      taken back to theatre and died on table.
AD  - Department of Surgery, University Hospital North Staffordshire, Stoke-on-Trent,
      UK. ballwilliam@doctors.org.uk
FAU - Ball, William Robert
AU  - Ball WR
FAU - Sharples, Alistair James
AU  - Sharples AJ
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - bcr-2013-009420 [pii]
AID - 10.1136/bcr-2013-009420 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 23;2013. pii: bcr2013009420. doi: 10.1136/bcr-2013-009420.

PMID- 23616309
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 2041-2657 (Electronic)
IS  - 2041-2649 (Linking)
DP  - 2013 Apr 24
TI  - Gut microbiota and obesity: lessons from the microbiome.
AB  - The distal gut harbours microbial communities that outnumber our own eukaryotic
      cells. The contribution of the gut microbiota to the development of several
      diseases (e.g. obesity, type 2 diabetes, steatosis, cardiovascular diseases and
      inflammatory bowel diseases) is becoming clear, although the causality remains to
      be proven in humans. Global changes in the gut microbiota have been observed by a
      number of culture-dependent and culture-independent methods, and while the latter
      have mostly included 16S ribosomal RNA gene analyses, more recent studies have
      utilized DNA sequencing of whole-microbial communities. Altogether, these
      high-throughput methods have facilitated the identification of novel candidate
      bacteria and, most importantly, metabolic functions that might be associated with
      obesity and type 2 diabetes. This review discusses the association between
      specific taxa and obesity, together with the techniques that are used to
      characterize the gut microbiota in the context of obesity and type 2 diabetes.
      Recent results are discussed in the framework of the interactions between gut
      microbiota and host metabolism.
FAU - Cani, Patrice D
AU  - Cani PD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Brief Funct Genomics
JT  - Briefings in functional genomics
JID - 101528229
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - elt014 [pii]
AID - 10.1093/bfgp/elt014 [doi]
PST - aheadofprint
SO  - Brief Funct Genomics. 2013 Apr 24.

PMID- 23616239
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Apr 26
TI  - An unbalanced monocyte polarisation in peripheral blood and bone marrow of
      patients with type 2 diabetes has an impact on microangiopathy.
AB  - AIM/HYPOTHESIS: Monocytes/macrophages play important roles in adipose and
      vascular tissues and can be polarised as inflammatory M1 or anti-inflammatory M2.
      We sought to analyse monocyte polarisation status in type 2 diabetes, which is
      characterised by chronic inflammation. METHODS: We enrolled 60 individuals
      without diabetes and 53 patients with type 2 diabetes. We quantified standard
      monocyte subsets defined by cluster of differentiation (CD)14 and CD16. In
      addition, based on the phenotype of polarised macrophages in vitro, we
      characterised and quantified more definite M1 (CD68+CCR2+) and M2
      (CX3CR1+CD206+/CD163+) monocytes. We also analysed bone marrow (BM) samples and
      the effects of granulocyte-colony stimulating factor (G-CSF) stimulation in
      diabetic and control individuals. RESULTS: We found no alterations in standard
      monocyte subsets (classical, intermediate and non-classical) when comparing
      groups. For validation of M1 and M2 phenotypes, we observed that M2 were enriched
      in non-classical monocytes and had lower TNF-alpha content, higher LDL scavenging
      and lower transendothelial migratory capacity than M1. Diabetic patients
      displayed an imbalanced M1/M2 ratio compared with the control group, attributable
      to a reduction in M2. The M1/M2 ratio was directly correlated with waist
      circumference and HbA1c and, among diabetic patients, M2 reduction and M1/M2
      increase were associated with microangiopathy. A decrease in M2 was also found in
      the BM from diabetic patients, with a relative M2 excess compared with the
      bloodstream. BM stimulation with G-CSF mobilised M2 macrophages in diabetic but
      not in healthy individuals. CONCLUSIONS/INTERPRETATION: We show that type 2
      diabetes markedly reduces anti-inflammatory M2 monocytes through a dysregulation 
      in bone-marrow function. This defect may have a negative impact on
      microangiopathy.
AD  - Division of Metabolic Diseases, Department of Medicine, University of Padova, Via
      Giustiniani, 2, 35100, Padova, Italy, gianpaolo.fadini@unipd.it.
FAU - Fadini, G P
AU  - Fadini GP
FAU - de Kreutzenberg, S Vigili
AU  - de Kreutzenberg SV
FAU - Boscaro, E
AU  - Boscaro E
FAU - Albiero, M
AU  - Albiero M
FAU - Cappellari, R
AU  - Cappellari R
FAU - Krankel, N
AU  - Krankel N
FAU - Landmesser, U
AU  - Landmesser U
FAU - Toniolo, A
AU  - Toniolo A
FAU - Bolego, C
AU  - Bolego C
FAU - Cignarella, A
AU  - Cignarella A
FAU - Seeger, F
AU  - Seeger F
FAU - Dimmeler, S
AU  - Dimmeler S
FAU - Zeiher, A
AU  - Zeiher A
FAU - Agostini, C
AU  - Agostini C
FAU - Avogaro, A
AU  - Avogaro A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130426
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/01/02 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/04/26 [aheadofprint]
AID - 10.1007/s00125-013-2918-9 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Apr 26.

PMID- 23616238
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
DP  - 2013 Apr 25
TI  - Common variation in PPARGC1A/B and progression to diabetes or change in metabolic
      traits following preventive interventions: the Diabetes Prevention Program.
AB  - AIMS/HYPOTHESIS: PPARGC1A and PPARGC1B encode transcriptional coactivators that
      regulate numerous type 2 diabetes-related metabolic processes. Common genetic
      variation across PPARGC1A/B was characterised by genotyping tagging variants. We 
      then tested associations of these variants with diabetes incidence or change in
      quantifiable metabolic traits directly or via interactions (with metformin
      treatment or intensive lifestyle modification) in the Diabetes Prevention Program
      (DPP), a randomised controlled trial in persons at high risk of type 2 diabetes. 
      METHODS: We used Tagger software to select 75 PPARGC1A and 94 PPARGC1B tag single
      nucleotide polymorphisms (SNPs) for analysis. These SNPs were tested for
      association with diabetes incidence using Cox proportional hazards regression
      models, and a range of relevant metabolic quantifiable traits, using generalised 
      linear models. RESULTS: Eight PPARGC1A variants were nominally (p < 0.05)
      associated with diabetes incidence, of which one (rs3736265/Thr612Met) was
      associated with diabetes in the DPP (HR 1.31, 95% CI 1.05, 1.63 per copy of the
      612Met allele) and in the DIAGRAM database (OR 1.11, 95% CI 1.01, 1.21).
      Consistent with earlier reports, the Gly482Ser (rs8192678) variant showed
      nominally significant effects on 1 year accumulation of adiposity and worsening
      insulin resistance (both p < 0.05). A third PPARGC1A variant (rs2970852) modified
      the effects of metformin on triacylglycerol levels (p interaction = 0.04; p =
      0.0001 for association of SNP with triacylglycerol concentrations in
      metformin-treated participants). A number of other PPARGC1A/B variants were
      nominally directly associated with diabetes incidence or modified treatment
      effects on diabetes incidence. CONCLUSIONS/INTERPRETATION: These findings provide
      some novel and confirmatory insights into the roles of PPARGC1A/B variation in
      type 2 diabetes and related metabolic traits. TRIAL REGISTRATION:
      ClinicalTrials.gov NCT00004992.
AD  - Department of Clinical Science, Genetic and Molecular Epidemiology Unit, Lund
      University, Malmo, Sweden, paul.franks@med.lu.se.
FAU - Franks, P W
AU  - Franks PW
FAU - Christophi, C A
AU  - Christophi CA
FAU - Jablonski, K A
AU  - Jablonski KA
FAU - Delahanty, L M
AU  - Delahanty LM
FAU - Horton, E S
AU  - Horton ES
FAU - Knowler, W C
AU  - Knowler WC
FAU - Florez, J C
AU  - Florez JC
CN  - on behalf of the Diabetes Prevention Program Research Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/01/03 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 10.1007/s00125-013-2911-3 [doi]
PST - aheadofprint
SO  - Diabetologia. 2013 Apr 25.

PMID- 23616224
OWN - NLM
STAT- MEDLINE
DA  - 20130425
DCOM- 20130611
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Higher risk of diabetes after hypertensive disorders in pregnancy.
PG  - f2533
LID - 10.1136/bmj.f2533 [doi]
LID - bmj.f2533 [pii]
LA  - eng
PT  - News
DEP - 20130424
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
MH  - Diabetes Mellitus/*etiology
MH  - Female
MH  - Humans
MH  - Hypertension, Pregnancy-Induced/*epidemiology
MH  - Incidence
MH  - Pregnancy
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - World Health
EDAT- 2013/04/26 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/04/26 06:00
PST - epublish
SO  - BMJ. 2013 Apr 24;346:f2533. doi: 10.1136/bmj.f2533.

PMID- 23616189
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
DP  - 2013 Apr 24
TI  - Prevalence of Cardiovascular Disease and Risk Factors in the Chinese Population
      with Impaired Glucose Regulation: the 2007-2008 China National Diabetes and
      Metabolic Disorders Study.
AB  - Cardiovascular disease (CVD) is one of the most common chronic diseases in China.
      This aim of this study is to determine the prevalence of CVDs and risk factors in
      Chinese impaired glucose regulation subjects.We used a multistage, stratified
      sampling method to select subjects from the general Chinese population aged 20
      years and older. Subjects underwent an oral glucose tolerance test to identify
      normal glucose tolerance (NGT) and impaired glucose regulation including isolated
      impaired fasting glucose (i-IFG), impaired glucose tolerance (i-IGT), and
      combined IFG/IGT and diabetic mellitus (DM). A logistic regression analysis was
      performed to examine the association between glucose abnormalities and CVD
      events.We identified that 34 293 subjects had NGT, 1 469 i-IFG, 4 571 i-IGT, 957 
      IFG/IGT and 4 949 DM. The age-sex standardized prevalence rate of cardiovascular 
      disease was 1.06% (95% CI 0.87-1.28), 1.79% (95% CI 1.37-2.33) and 3.83% (95% CI 
      2.79-5.24) in NGT, impaired glucose regulation and DM, respectively. Among
      impaired glucose subjects, prevalence of defined CVD risk factors (smoking,
      overweight, obesity, hypertension and dyslipidemia) was 29.52% (95% CI:
      27.8-31.21), 36.25% (95% CI: 34.29-38.26), 10.05% (95% CI: 8.86-11.37), 36.43%
      (95% CI: 34.53-38.36) and 69.96% (95% CI: 67.87-71.98), respectively. Compared to
      1 risk factor, the odds ratios (ORs) of CVDs with 2, 3 or 4 risk factors were
      1.94 (95% CI: 0.74-5.09), 2.76 (95% CI: 1.06-7.21) and 5.84 (95% CI: 1.68-20.26),
      respectively. Additionally, compared to i-IFGs, ORs of CVDs with i-IGT and
      IFG/IGT were 2.88 (95%CI 1.36-6.01) and 2.12 (95% CI 0.83-5.44), respectively.The
      prevalence of cardiovascular risk factors was high in the Chinese impaired
      glucose regulation population. The postprandial hyperglycemia is more associated 
      with CVD than isolated fasting hyperglycemia.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - China-Japan Friendship Hospital, Beijing.
FAU - Yang, Z
AU  - Yang Z
FAU - Xing, X
AU  - Xing X
FAU - Xiao, J
AU  - Xiao J
FAU - Lu, J
AU  - Lu J
FAU - Weng, J
AU  - Weng J
FAU - Jia, W
AU  - Jia W
FAU - Ji, L
AU  - Ji L
FAU - Shan, Z
AU  - Shan Z
FAU - Liu, J
AU  - Liu J
FAU - Tian, H
AU  - Tian H
FAU - Ji, Q
AU  - Ji Q
FAU - Zhu, D
AU  - Zhu D
FAU - Ge, J
AU  - Ge J
FAU - Lin, L
AU  - Lin L
FAU - Chen, L
AU  - Chen L
FAU - Guo, X
AU  - Guo X
FAU - Zhao, Z
AU  - Zhao Z
FAU - Li, Q
AU  - Li Q
FAU - Zhou, Z
AU  - Zhou Z
FAU - Shan, G
AU  - Shan G
FAU - Yang, W
AU  - Yang W
CN  - and the China National Diabetes and Metabolic Disorders Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/24 [epublish]
AID - 10.1055/s-0033-1341520 [doi]
PST - aheadofprint
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr 24.

PMID- 23616188
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
DP  - 2013 Apr 24
TI  - Hyperthyroidism and Thyroid Cancer Risk: A Population-based Cohort Study.
AB  - Thyroid hormones regulate the rate of metabolism and affect the differentiation
      and growth of many tissues in the body. We investigated the association between
      hyperthyroidism and cancer risk in TaiwanA random sample of 1 000 000 individuals
      from Taiwan's National Health Insurance database was enrolled. We found 17 033
      patients to have newly diagnosed hyperthyroidism between 2000 and 2005. These
      patients were recruited along with a match cohort of 34 066 patients without
      hyperthyroidism. Starting from index date, we followed up all patients for 4
      years to identify those who developed cancer.During the 4-year follow-up study,
      cancer was diagnosed in 1.23% of patients with hyperthyroidism and 1.02% of the
      member of the comparison cohort. Regression analysis showed that patients with
      hyperthyroidism were at greater risk of cancer incidence, especially thyroid
      cancer, compared the comparison cohort (HR: 1.213; 95% CI: 1.022-1.440; p<0.05
      and HR: 7.355; 95% CI: 3.885-13.92; p<0.05, respectively). After adjusting for
      age, gender, diabetes mellitus, hypertension, hyperlipidemia, gout, geographic
      region, and income, patients with hyperthyroidism remained at increased risk of
      cancer incidence and thyroid cancer (Adjusted HR: 1.206; 95% CI: 1.015-1.433 and 
      6.803; 95% CI: 3.584-12.91, respectively) (both p<0.05). The longer the duration 
      of hyperthyroidism, the greater the risk of thyroid cancer.This 4-year follow up 
      study suggests that patients with hyperthyroidism are at increased risk of
      cancer, especially thyroid cancer.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chi
      Mei Medical Center, Tainan, Taiwan.
FAU - Yeh, N-C
AU  - Yeh NC
FAU - Chou, C-W
AU  - Chou CW
FAU - Weng, S-F
AU  - Weng SF
FAU - Yang, C-Y
AU  - Yang CY
FAU - Yen, F-C
AU  - Yen FC
FAU - Lee, S-Y
AU  - Lee SY
FAU - Wang, J-J
AU  - Wang JJ
FAU - Tien, K-J
AU  - Tien KJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/24 [epublish]
AID - 10.1055/s-0033-1341474 [doi]
PST - aheadofprint
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr 24.

PMID- 23616187
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
DP  - 2013 Apr 24
TI  - Maturity-Onset Diabetes of the Young and Hepatic Adenomatosis - Characterisation 
      of a New Mutation.
AB  - Hepatocyte nuclear factor 1 alpha (HNF1A) mutations cause maturity-onset diabetes
      of the young (MODY) type 3. Further extending the phenotypic spectrum, HNF1A
      mutations are associated with hepatic adenomatosis. A 20-year old lean, female
      patient with newly diagnosed diabetes mellitus was negative for
      diabetes-associated autoantibodies and had no relevant family history. Hepatic
      adenomatosis was diagnosed. Her HNF1A gene was examined and identified
      alterations further analysed.Sequencing of her HNF1A gene revealed a previously
      uncharacterised Q495X nonsense mutation, along with the known A98V polymorphism, 
      both in the heterozygous state. The patient's father was also a carrier of both
      the mutation and the polymorphism. An oral glucose tolerance test (OGTT) revealed
      impaired glucose tolerance, whereas imaging of his liver was unremarkable. Wild
      type HNF1A and HNF1A carrying the Q495X mutation were co-transfected in reporter 
      gene assays. The mutation causes a dominant-negative HNF1A protein variant which 
      blocks HNF1A wild-type-mediated gene expression.The novel Q495X mutation is the
      likely cause of our patient's diabetes and hepatic adenomatosis. It may also
      cause her father's impaired glucose tolerance. More generally speaking, if
      non-autoimmune diabetes is suspected, examination of the liver may provide
      important diagnostic clues. Furthermore, patients with hepatic adenomatosis
      without known diabetes should be screened by OGTT. Relatives of patients with
      HNF1A mutations should also be screened by OGTT to detect potential early-stage
      diabetes.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Medizinische Klinik I, Universitat zu Lubeck, Lubeck, Germany.
FAU - Iwen, K A
AU  - Iwen KA
FAU - Klein, J
AU  - Klein J
FAU - Hubold, C
AU  - Hubold C
FAU - Lehnert, H
AU  - Lehnert H
FAU - Weitzel, J M
AU  - Weitzel JM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/24 [epublish]
AID - 10.1055/s-0033-1341519 [doi]
PST - aheadofprint
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr 24.

PMID- 23616186
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
DP  - 2013 Apr 24
TI  - Lack of Association between C385A Functional Polymorphism of the Fatty Acid Amide
      Hydrolase Gene and Polycystic Ovary Syndrome.
AB  - The endocannabinoid system contributes to the regulation of appetite, food intake
      and energy balance. Fatty acid amide hydrolase is responsible for degradating
      anandamide, a key messenger of the endocannabinoid system. C385A is a common,
      functionally active genetic polymorphism of the gene encoding fatty acid amide
      hydrolase and has been associated with overweight and obesity. Our aim was to
      establish whether single nucleotide polymorphism C385A has an association with
      polycystic ovary syndrome or its clinical features.A monocentric pilot study was 
      performed on 63 patients with polycystic ovary syndrome and 67 healthy control
      subjects. Anthropometric parameters and laboratory data were acquired from
      subjects. The alleles of the polymorphism were detected using polymerase chain
      reaction and subsequent cleavage by Eco130I (StyI) restriction endonuclease
      verified by direct DNA sequencing.No difference was found in minor allele
      frequency between patient and control groups. Those patients, carrying the C385A 
      polymorphism were associated with higher free thyroxine hormone levels. In the
      control group, carriers of the polymorphism had significantly lower insulin
      levels.Our data indicate that the C385A polymorphism of the fatty acid amide
      hydrolase gene is not a genetic susceptibility factor for the development of
      polycystic ovary syndrome. However, the polymorphism might have a role in
      influencing the synthesis or metabolism of different hormones including thyroxin 
      and insulin.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - 2nd Department of Medicine, Semmelweis University, Budapest, Hungary.
FAU - Grolmusz, V K
AU  - Grolmusz VK
FAU - Stenczer, B
AU  - Stenczer B
FAU - Fekete, T
AU  - Fekete T
FAU - Szendei, G
AU  - Szendei G
FAU - Patocs, A
AU  - Patocs A
FAU - Racz, K
AU  - Racz K
FAU - Reismann, P
AU  - Reismann P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/24 [epublish]
AID - 10.1055/s-0033-1337941 [doi]
PST - aheadofprint
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr 24.

PMID- 23616185
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
DP  - 2013 Apr 24
TI  - Dysregulated miR-155 expression in peripheral blood mononuclear cells from
      patients with type 2 diabetes.
AB  - MicroRNAs (miRNAs) are involved in gene regulation of several physiological
      processes. Alterations in the concentrations of miRNAs may result in cancer and
      autoimmune diseases. In cells of the immune system, miRNA expression is regulated
      by several cytokines and this expression is related to the inflammatory process. 
      In the present work we evaluated miR-155 and miR-146a levels in peripheral blood 
      mononuclear cells (PBMC) from patients with type 2 diabetes (T2D).We analysed the
      expression of miRNAs in PBMC from T2D patients (n=20) and control subjects (n=20)
      using real-time PCR. The quantity of IL-1beta and IL-6 in culture supernatants
      was measured by ELISA.The basal expression of miR-155 and miR-146a in patients
      with T2D was decreased compared to control subjects and associated with age,
      gender and metabolic control but not with the therapeutic treatment used. We
      found significant correlations between the basal expression of miR-155 and
      miR-146a with HbA1c, Glucose and BMI, as well as of miR-155 expression stimulated
      by LPS with the values of TG, HbA1c, Glucose and BMI. Additionally, we detected
      an altered distribution of miR-155 and miR-146a expression related with HbA1c,
      glucose and BMI using the analysis of a three dimensional association of
      variables in the group of T2D patients.Downregulated levels of miR-155 could play
      an important role in the pathogenesis of T2D due to their relationship with
      metabolic control.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Laboratorio de Inmunologia y Biologia Celular y Molecular, Facultad de Ciencias
      Quimicas, UASLP, San Luis Potosi, SLP, Mexico.
FAU - Corral-Fernandez, N E
AU  - Corral-Fernandez NE
FAU - Salgado-Bustamante, M
AU  - Salgado-Bustamante M
FAU - Martinez-Leija, M E
AU  - Martinez-Leija ME
FAU - Cortez-Espinosa, N
AU  - Cortez-Espinosa N
FAU - Garcia-Hernandez, M H
AU  - Garcia-Hernandez MH
FAU - Reynaga-Hernandez, E
AU  - Reynaga-Hernandez E
FAU - Quezada-Calvillo, R
AU  - Quezada-Calvillo R
FAU - Portales-Perez, D P
AU  - Portales-Perez DP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/24 [epublish]
AID - 10.1055/s-0033-1341516 [doi]
PST - aheadofprint
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr 24.

PMID- 23616105
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1522-1490 (Electronic)
IS  - 0363-6119 (Linking)
DP  - 2013 Apr 24
TI  - High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia 
      in rats.
AB  - Overconsumption of high-fat diet promotes weight gain that can result in obesity 
      and associated comorbidities, including type 2 diabetes mellitus. Consumption of 
      high-fat diet also alters gut-brain communication. Glucagon-like peptide 1
      (GLP-1) is an important gastrointestinal signal that modulates both short- and
      long-term energy balance and is integral in maintenance of glucose homeostasis.
      In the current study, we investigated whether high-fat diets (40% or 81% kcal
      from fat) modulated the ability of the GLP-1 receptor (GLP-1r) agonists exendin-4
      (Ex4) and liraglutide to reduce food intake and body weight. We observed that
      rats maintained on high-fat diets had a delayed acute anorexic response to
      peripheral administration of Ex4 or liraglutide compared to low-fat diet-fed rats
      (17% kcal from fat). However, once suppression of food intake in response to Ex4 
      or liraglutide started, the effect persisted for a longer time in the high-fat
      diet-fed rats compared to low-fat diet-fed rats. In contrast, centrally
      administered Ex4 suppressed food intake similarly between high-fat diet-fed and
      low-fat diet-fed rats. Chronic consumption of a high-fat diet did not change the 
      pharmacokinetics of Ex4, but increased intestinal Glp1r expression and decreased 
      hindbrain Glp1r expression. Taken together, these findings demonstrate that
      dietary composition alters the temporal profile of the anorectic response to
      exogenous GLP-1r agonists.
AD  - 1University of Cincinnati.
FAU - Mul, Joram D
AU  - Mul JD
FAU - Begg, Denovan Patrick
AU  - Begg DP
FAU - Barrera, Jason G
AU  - Barrera JG
FAU - Li, Bailing
AU  - Li B
FAU - Matter, Emily K
AU  - Matter EK
FAU - D'Alessio, David A
AU  - D'Alessio DA
FAU - Woods, Stephen C
AU  - Woods SC
FAU - Seeley, Randy J
AU  - Seeley RJ
FAU - Sandoval, Darleen A
AU  - Sandoval DA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Am J Physiol Regul Integr Comp Physiol
JT  - American journal of physiology. Regulatory, integrative and comparative
      physiology
JID - 100901230
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - ajpregu.00588.2012 [pii]
AID - 10.1152/ajpregu.00588.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Regul Integr Comp Physiol. 2013 Apr 24.

PMID- 23616061
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
DP  - 2013 Apr 25
TI  - Clinical factors associated with shock in bacteremic UTI.
AB  - PURPOSE: Urinary tract infection (UTI) often causes bacteremia, resulting in
      shock. The purpose of this study is to investigate urological bacteremia and
      bacteremia shock cases and seek for the clinical factors associated with
      urological bacteremic shock. METHODS: Seventy consecutive cases with bacteremia
      caused by UTI from the Department of Urology, Kobe University Hospital were
      studied. These cases were diagnosed from 2000 to 2010 and had full data available
      for analysis. We investigated the potential clinical factors associated with
      bacteremic shock (systolic blood pressure </=90 mmHg with UTI), including: (1)
      the number of basal general diseases (such as diabetes, malignancy, immune
      diseases, heart diseases, liver diseases, and kidney diseases), (2) causative
      bacteria, (3) antibiotics and therapeutic intervention, (4) gram-negative
      bacteria, (5) resistance to imipenem (which is often used in this infection), and
      (6) serum white blood cell counts and C-reactive protein (CRP) at the time of
      diagnosis of bacteremic UTI. RESULTS: A total of 81 causative bacteria were
      isolated: 42 cases were gram-negative and 39 were gram-positive bacteria. In
      detail, Escherichia coli was the most common, followed by Methicillin-resistant
      Staphylococcus aureus. The comparison data revealed that urological bacteremic
      shock cases had significantly increased CRP (p < 0.001). Our univariate analyses 
      showed indwelling urinary tract catheters (p = 0.02) as a significant clinical
      factor associated with urological bacteremic shock and multivariate analyses
      showed that the presence of indwelling urinary tract catheters before UTI was a
      significant clinical factor associated with urological bacteremic shock (p =
      0.04). CONCLUSIONS: Indwelling urinary catheters before UTI and high CRP were
      clinical factors associated with urological bacteremic shock. This result should 
      be considered during decision-making for UTI treatments in high risk cases or
      urological bacteremia cases.
AD  - Division of Urology, Department of Surgery, Kobe University Graduate School of
      Medicine, 7-5-1Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan,
      yutoshunta@hotmail.co.jp.
FAU - Shigemura, Katsumi
AU  - Shigemura K
FAU - Tanaka, Kazushi
AU  - Tanaka K
FAU - Osawa, Kayo
AU  - Osawa K
FAU - Arakawa, Sochi
AU  - Arakawa S
FAU - Miyake, Hideaki
AU  - Miyake H
FAU - Fujisawa, Masato
AU  - Fujisawa M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/03/07 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 10.1007/s11255-013-0449-4 [doi]
PST - aheadofprint
SO  - Int Urol Nephrol. 2013 Apr 25.

PMID- 23616030
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1365-2168 (Electronic)
IS  - 0007-1323 (Linking)
VI  - 100
IP  - 8
DP  - 2013 Jul
TI  - Effects of pancreatectomy on nutritional state, pancreatic function and quality
      of life.
PG  - 1064-70
LID - 10.1002/bjs.9146 [doi]
AB  - BACKGROUND: There are concerns about the extent of impaired endocrine and
      exocrine pancreatic function and poor quality of life (QoL) after pancreatectomy,
      but there is little information from large prospective follow-up studies.
      METHODS: Consecutive patients undergoing pancreaticoduodenectomy or distal
      pancreatectomy between 2007 and 2011 were included. Relative bodyweight (RBW),
      triceps skinfold thickness (TSFT), serum protein, albumin, transferrin, fasting
      blood glucose, postprandial 2-h glucose (PP2), glycosylated haemoglobin A1c and
      stool elastase measurements, and European Organization for Research and Treatment
      of Cancer QLQ-C30 questionnaires were collected serially for 1 year. RESULTS:
      Some 136 patients undergoing pancreatic resection completed the study. RBW and
      TSFT recovered to over 90 per cent of the preoperative value by 12 months,
      whereas transferrin, albumin and protein had returned to preoperative levels by 3
      months. Diabetes mellitus, impaired fasting glucose or raised PP2 was present in 
      42 of 76 patients at 6 months and 36 of 76 at 12 months. Although steatorrhoea
      and diarrhoea had mainly resolved by 3 months, stool elastase level decreased
      after operation and showed no recovery. Nutritional status, pancreatic endocrine 
      function and QoL returned to preoperative levels in 63 (46.3 per cent), 72 (52.9 
      per cent) and 77 (56.6 per cent) of 136 patients within 6 months of
      pancreatectomy. Multivariable analysis revealed that age 60 years or more,
      operation type, chronic pancreatitis and malignant disease had a significant
      impact on nutritional index, pancreatic function and QoL. CONCLUSION: About half 
      of all patients can expect recovery from pancreatectomy after 6 months, but those
      with risk factors need more careful follow-up and supportive management.
CI  - (c) 2013 British Journal of Surgery Society Ltd. Published by John Wiley & Sons
      Ltd.
AD  - Department of Surgery and Cancer Research Institute, Seoul National University
      College of Medicine, Seoul, South Korea.
FAU - Park, J W
AU  - Park JW
FAU - Jang, J-Y
AU  - Jang JY
FAU - Kim, E-J
AU  - Kim EJ
FAU - Kang, M J
AU  - Kang MJ
FAU - Kwon, W
AU  - Kwon W
FAU - Chang, Y R
AU  - Chang YR
FAU - Han, I W
AU  - Han IW
FAU - Kim, S-W
AU  - Kim SW
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - England
TA  - Br J Surg
JT  - The British journal of surgery
JID - 0372553
SB  - AIM
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/03/07 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1002/bjs.9146 [doi]
PST - ppublish
SO  - Br J Surg. 2013 Jul;100(8):1064-70. doi: 10.1002/bjs.9146. Epub 2013 Apr 24.

PMID- 23615972
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1434-3916 (Electronic)
IS  - 0936-8051 (Linking)
DP  - 2013 Apr 25
TI  - Co-morbidities in elderly patients with hip fracture: recommendations of the
      ISFR-IOF hip fracture outcomes working group.
AB  - INTRODUCTION: Hip fractures are the second leading cause of hospitalization in
      the aged and by 2041, epidemiologists forecast an increase in economic cost to
      $2.4 billion. The hip patient population often presents with comorbidities
      causing these patients to receive less aggressive medical treatment and have a
      low quality of life. We believe that physical function is a patient-important
      outcome for many medical and surgical interventions. The functional co-morbidity 
      index (FCI), unlike prior co-morbidity indices, was developed with physical
      function as an outcome instead of being designed for administrative purposes or
      to predict mortality. Our objective was to evaluate the perceptions of
      practitioners in hip fracture care about the impact of comorbidities on physical 
      function as primary outcome. METHODS: We piloted and then distributed a
      self-administered survey to members of the International Society for Fracture
      Repair hip fracture outcomes working group. For each of the 18 diagnoses included
      in the FCI index, we asked in our survey whether the presence of the co-morbidity
      and whether the severity of the co-morbidity was perceived to impact physical
      function in patients following a hip fracture. RESULTS: Seventeen out of 20
      respondents completed the questionnaire. The presence and severity of arthritis
      was 'strongly' believed to predict physical function in those with hip fracture
      (69 and 85.7 %, respectively). Respondents 'agreed' (range 53-73 %) that 10/18
      diagnoses would predict changes in physical function following hip fracture
      treatment. Whereas, 63 % of the practitioners'strongly disagreed' that diabetes
      types I and II would change physical function scores. Furthermore, dementia was
      listed as an additional diagnosis that would affect physical function.
      CONCLUSION: The FCI may provide a useful instrument to predict functional outcome
      after hip fracture; however, the index may need to be modified for this specific 
      population.
AD  - Institute of Medical Sciences, St. Michael's Hospital, University of Toronto, 30 
      Bond Street (193-6T Yonge Street), Toronto, ON, M5B 1W8, Canada,
      amy.hoang.kim@mail.utoronto.ca.
FAU - Hoang-Kim, Amy
AU  - Hoang-Kim A
FAU - Busse, Jason W
AU  - Busse JW
FAU - Groll, D
AU  - Groll D
FAU - Karanicolas, P J
AU  - Karanicolas PJ
FAU - Schemitsch, E
AU  - Schemitsch E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Arch Orthop Trauma Surg
JT  - Archives of orthopaedic and trauma surgery
JID - 9011043
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/03/21 [received]
PHST- 2013/04/25 [aheadofprint]
AID - 10.1007/s00402-013-1756-z [doi]
PST - aheadofprint
SO  - Arch Orthop Trauma Surg. 2013 Apr 25.

PMID- 23615880
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1438-2199 (Electronic)
IS  - 0939-4451 (Linking)
DP  - 2013 Apr 25
TI  - Glycine metabolism in animals and humans: implications for nutrition and health.
AB  - Glycine is a major amino acid in mammals and other animals. It is synthesized
      from serine, threonine, choline, and hydroxyproline via inter-organ metabolism
      involving primarily the liver and kidneys. Under normal feeding conditions,
      glycine is not adequately synthesized in birds or in other animals, particularly 
      in a diseased state. Glycine degradation occurs through three pathways: the
      glycine cleavage system (GCS), serine hydroxymethyltransferase, and conversion to
      glyoxylate by peroxisomal D-amino acid oxidase. Among these pathways, GCS is the 
      major enzyme to initiate glycine degradation to form ammonia and CO2 in animals. 
      In addition, glycine is utilized for the biosynthesis of glutathione, heme,
      creatine, nucleic acids, and uric acid. Furthermore, glycine is a significant
      component of bile acids secreted into the lumen of the small intestine that is
      necessary for the digestion of dietary fat and the absorption of long-chain fatty
      acids. Glycine plays an important role in metabolic regulation, anti-oxidative
      reactions, and neurological function. Thus, this nutrient has been used to: (1)
      prevent tissue injury; (2) enhance anti-oxidative capacity; (3) promote protein
      synthesis and wound healing; (4) improve immunity; and (5) treat metabolic
      disorders in obesity, diabetes, cardiovascular disease, ischemia-reperfusion
      injuries, cancers, and various inflammatory diseases. These multiple beneficial
      effects of glycine, coupled with its insufficient de novo synthesis, support the 
      notion that it is a conditionally essential and also a functional amino acid for 
      mammals (including pigs and humans).
AD  - State Key Laboratory of Animal Nutrition, China Agricultural University, Beijing,
      100193, China.
FAU - Wang, Weiwei
AU  - Wang W
FAU - Wu, Zhenlong
AU  - Wu Z
FAU - Dai, Zhaolai
AU  - Dai Z
FAU - Yang, Ying
AU  - Yang Y
FAU - Wang, Junjun
AU  - Wang J
FAU - Wu, Guoyao
AU  - Wu G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Amino Acids
JT  - Amino acids
JID - 9200312
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/01 [received]
PHST- 2013/04/02 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 10.1007/s00726-013-1493-1 [doi]
PST - aheadofprint
SO  - Amino Acids. 2013 Apr 25.

PMID- 23615822
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1573-0832 (Electronic)
IS  - 0301-486X (Linking)
DP  - 2013 Apr 25
TI  - Gangrenous Cutaneous Mucormycosis Caused by Rhizopus oryzae: A Case Report and
      Review of Primary Cutaneous Mucormycosis in China Over Past 20 Years.
AB  - Cutaneous mucormycosis is a rare opportunistic infection caused by zygomycetes
      that can be rapidly fatal if unrecognized. We describe the clinical,
      histopathological, fungal and molecular features of a case of gangrenous
      cutaneous mucormycosis. The patient presented with great necrosis on his right
      forearm at the site of detained intravenous cannula needle. He had type II
      diabetes and chronic renal insufficiency. KOH mount of black eschar showed many
      broad, aseptate fungal hyphae with right-angle branching. PAS staining of the
      tissue sample revealed similar broad hyphae in the dermis and cutis. Fungal
      culture and ITS sequence analysis identified this fungus as Rhizopus oryzae. As
      no organ involvement was detected, the patient was diagnosed with primary
      cutaneous mucormycosis. Considering the poor state of the patient, complete
      excision of the infectious tissue was performed without skin graft instead of
      amputation. At the same time, intravenous liposomal amphotericin B was given,
      starting from a small dosage and increased to a total dosage amount of 5.45 g.
      The wound recovered well with granulation. We emphasize that early recognition
      and prompt therapy including the control of the primary diseases were important. 
      In this article, we also reviewed the features of primary cutaneous mucormycosis 
      reported in China over the last 20 years.
AD  - Department of Dermatology, Peking University, People's Hospital, Beijing, 100044,
      People's Republic of China, lhoumin@yahoo.com.cn.
FAU - Li, Houmin
AU  - Li H
FAU - Hwang, Sonia Kay
AU  - Hwang SK
FAU - Zhou, Cheng
AU  - Zhou C
FAU - Du, Juan
AU  - Du J
FAU - Zhang, Jianzhong
AU  - Zhang J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Mycopathologia
JT  - Mycopathologia
JID - 7505689
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/12/19 [received]
PHST- 2013/04/10 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 10.1007/s11046-013-9654-z [doi]
PST - aheadofprint
SO  - Mycopathologia. 2013 Apr 25.

PMID- 23615760
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1460-2385 (Electronic)
IS  - 0931-0509 (Linking)
DP  - 2013 Apr 24
TI  - Long-term vasopressin-V2-receptor stimulation induces regulation of aquaporin 4
      protein in renal inner medulla and cortex of Brattleboro rats.
AB  - BACKGROUND: Desmopressin (dDAVP) induces a decrease in immunolabelling of
      aquaporin (AQP) 4 protein in the terminal inner medulla (IM) of the Brattleboro
      (BB) rat kidney. It is disputed, however, whether the decreased labelling
      reflects real down-regulation of protein abundance, or whether it is a result of 
      epitope shielding in the AQP4 protein, preventing binding of the antibody as
      previously suggested. Furthermore, it is unknown if vasopressin regulates AQP4 in
      the connecting tubule (CNT) and in the cortical collecting duct (CCD). Using BB
      rats, we aimed to determine (i) whether the dDAVP-induced decrease in AQP4
      labelling in the terminal IM reflects down-regulation in protein abundance and
      (ii) whether dDAVP increases the AQP4 protein abundance in the CNT and the CCD.
      METHODS: BB rats received dDAVP or saline (control) via osmotic minipumps pumps
      for 6 days. RESULTS: Immunolight microscopy revealed strong AQP4 labelling in the
      initial inner medullary collecting duct (IMCD1), weak labelling in the middle
      IMCD (IMCD2) and weak/absent labelling in the terminal IMCD (IMCD3) after 6 days 
      of dDAVP administration. AQP3 labelling was similar to that of AQP4. Two-hour
      administration with dDAVP (previously described BB rats) did not change the
      labelling pattern of AQP4, suggesting that potential acute phosphorylation did
      not induce epitope shielding, thereby preventing the binding of the antibody.
      CONCLUSIONS: In BB rats, long-term administration with dDAVP (i) increased the
      AQP4 protein abundance in the IMCD1 and decreased the abundance in the IMCD2 and 
      the IMCD3, and (ii) increased the AQP4 protein abundance in the CNT and the CCD.
AD  - The Water and Salt Research Centre, Department of Biomedicine, Aarhus University,
      Aarhus, Denmark.
FAU - Poulsen, Soren Brandt
AU  - Poulsen SB
FAU - Kim, Young-Hee
AU  - Kim YH
FAU - Frokiaer, Jorgen
AU  - Frokiaer J
FAU - Nielsen, Soren
AU  - Nielsen S
FAU - Christensen, Birgitte Monster
AU  - Christensen BM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
OTO - NOTNLM
OT  - AQP2
OT  - AQP3
OT  - AQP4
OT  - central diabetes insipidus
OT  - vasopressin deficiency
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - gft088 [pii]
AID - 10.1093/ndt/gft088 [doi]
PST - aheadofprint
SO  - Nephrol Dial Transplant. 2013 Apr 24.

PMID- 23615706
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
DP  - 2013 Apr 25
TI  - The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus
      and increases serum level of IL-12p40.
AB  - Besides its well-established oncosuppressor activity, a key function of p53 in
      regulating metabolic pathways has been recently identified. Nevertheless, the
      role of p53 with respect to diabetes mellitus (DM) appears highly controversial. 
      To address this issue, we have used the cis-imidazoline compound Nutlin-3, an
      inhibitor of MDM2/p53 interaction, which represents a potent and selective
      non-genotoxic activator of the p53 pathway both in in vivo and in vitro
      experimental settings. Experimental DM was induced by intraperitoneal injections 
      of low concentrations of streptozotocin (STZ) in C57BL/6N mice (n = 20). A group 
      of control vehicle-injected mice (n = 10) and of STZ-treated mice (n = 10) was
      co-injected with Nutlin-3. Mice co-injected with STZ + Nutlin-3 exhibited
      attenuated features of DM with respect to animals treated with STZ alone. Indeed,
      STZ + Nutlin-3-treated mice were characterized by significantly (p < 0.05) lower 
      levels of hyperglycemia, reduced weight loss, and increased spleen weight. In
      addition, STZ alone promoted a marked decrease in the levels of several
      circulating cytokines, including interleukin-12 (IL-12)p40. On the other hand,
      co-injection of STZ + Nutlin-3 significantly (p < 0.01) counteracted IL-12p40
      down-modulation. In vitro experiments performed on the RAW264.7 macrophagic cell 
      line model, used as cellular source of IL-12p40, demonstrated that Nutlin-3
      treatment increased IL-12p40 release, strongly suggesting a direct effect of
      Nutlin-3 on the immune system. Overall, these data demonstrate that systemic
      administration of Nutlin-3 ameliorates the severity of STZ-induced DM and
      increases the levels of circulating IL-12p40.
AD  - Department of Morphology, Surgery and Experimental Medicine and LTTA Centre,
      University of Ferrara, Ferrara, Italy.
FAU - Secchiero, Paola
AU  - Secchiero P
FAU - Toffoli, Barbara
AU  - Toffoli B
FAU - Melloni, Elisabetta
AU  - Melloni E
FAU - Agnoletto, Chiara
AU  - Agnoletto C
FAU - Monasta, Lorenzo
AU  - Monasta L
FAU - Zauli, Giorgio
AU  - Zauli G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/02/06 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 10.1007/s00592-013-0476-8 [doi]
PST - aheadofprint
SO  - Acta Diabetol. 2013 Apr 25.

PMID- 23615668
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1873-5126 (Electronic)
IS  - 1353-8020 (Linking)
VI  - 19
IP  - 7
DP  - 2013 Jul
TI  - Multicentre analysis of 178,992 type 2 diabetes patients revealed better
      metabolic control despite higher rates of hypertension, stroke, dementia and
      repeated inpatient care in patients with comorbid Parkinson's disease.
PG  - 687-92
LID - 10.1016/j.parkreldis.2013.03.011 [doi]
LID - S1353-8020(13)00127-2 [pii]
AB  - BACKGROUND: Especially in older people, physicians are faced with the coexistence
      of type 2 diabetes mellitus (T2DM) and Parkinson's disease (PD). Therefore, this 
      research aimed to compare diabetes endpoints between T2DM with and without PD.
      METHODS: Based on the standardized, multicenter, prospective DPV database,
      178,992 T2DM patients (>/=40 years) were analyzed. 1579 were diagnosed with PD
      and/or received specific treatment. Hierarchical multivariable regression models 
      were used for group comparisons; adjusted estimates based on observed marginal
      frequencies were calculated. RESULTS: PD patients were significantly older (77.9 
      vs. 70.0 years; p < 0.0001) and had a longer diabetes duration (10.3 vs. 8.4
      years; p < 0.0001). In young PD patients (<50 years), percentage of females was
      significantly higher compared to age-matched T2DM patients without PD or people
      of the German population (66.7 vs. 38.1 vs. 49.0%; p < 0.0001, p < 0.02). After
      demographic adjustment, T2DM patients with PD showed a significantly lower HbA1c 
      (58.0 vs. 60.3 mmol/mol; p < 0.0001), OAD/GLP-1 treatment (41.9 vs. 45.9%; p <
      0.01) and frequency of dyslipidemia (62.0 vs. 64.5%; p < 0.05). In contrast,
      rates of insulin therapy (57.8 vs. 54.8%; p < 0.05), hypertension (73.3 vs.
      68.6%; p < 0.001), antihypertensive medication (60.4 vs. 56.1%; p < 0.01), stroke
      (12.0 vs. 7.3%; p < 0.0001), dementia (9.2 vs. 2.6%; p < 0.0001) and repeated
      inpatient care (15.7 vs. 12.0%; p < 0.0001) were significantly higher and
      duration of hospital stay (6.2 vs. 4.7 days; p < 0.0001) was significantly longer
      in T2DM with PD. CONCLUSION: Clear demographic and clinical differences were
      observed between T2DM with and without PD. In PD patients, metabolic control is
      better, potentially due to more intensive medical care.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - University of Ulm, Institute of Epidemiology and Medical Biometry, ZIBMT,
      Albert-Einstein-Allee 41, 89081 Ulm, Germany. Electronic address:
      nicole.scheuing@uni-ulm.de.
FAU - Scheuing, Nicole
AU  - Scheuing N
FAU - Best, Frank
AU  - Best F
FAU - Dapp, Albrecht
AU  - Dapp A
FAU - Dreyhaupt, Ines
AU  - Dreyhaupt I
FAU - Filz, Hans-Peter
AU  - Filz HP
FAU - Krakow, Dietmar
AU  - Krakow D
FAU - Lang, Wolfgang
AU  - Lang W
FAU - Siegel, Erhard
AU  - Siegel E
FAU - Zeyfang, Andrej
AU  - Zeyfang A
FAU - Holl, Reinhard W
AU  - Holl RW
CN  - DPV initiative and the German BMBF Competence Network Diabetes mellitus
LA  - eng
PT  - Journal Article
DEP - 20130421
PL  - England
TA  - Parkinsonism Relat Disord
JT  - Parkinsonism & related disorders
JID - 9513583
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/12/20 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/21 [aheadofprint]
AID - S1353-8020(13)00127-2 [pii]
AID - 10.1016/j.parkreldis.2013.03.011 [doi]
PST - ppublish
SO  - Parkinsonism Relat Disord. 2013 Jul;19(7):687-92. doi:
      10.1016/j.parkreldis.2013.03.011. Epub 2013 Apr 21.

PMID- 23615646
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Linking)
VI  - 20
IP  - 5
DP  - 2013 May
TI  - Serum osteocalcin levels in relation to metabolic syndrome in Chinese
      postmenopausal women.
PG  - 548-53
LID - 10.1097/GME.0b013e318271b1da [doi]
AB  - OBJECTIVE: It has been revealed that osteocalcin is a regulator of energy
      metabolism. We investigated the relationship between serum osteocalcin levels and
      metabolic syndrome (MetS) in Chinese postmenopausal women. METHODS: A total of
      1,789 postmenopausal women, aged 41 to 78 years, were selected from four
      communities in Shanghai, China. Serum levels of osteocalcin were measured with an
      electrochemiluminescence immunoassay. The diagnostic definition of MetS followed 
      the 2007 Chinese Guidelines on Prevention and Treatment of Dyslipidemia in
      Adults. RESULTS: Serum osteocalcin levels were significantly lower in
      participants with MetS than in non-MetS participants (median [interquartile
      range], 18.51 [15.52-23.46] vs. 21.09 [16.98-26.26] ng/mL, P < 0.01). The
      frequency of MetS and its components decreased with increasing increments of
      serum osteocalcin levels (all P for trend < 0.05), with the exception of the
      frequency of low levels of high-density lipoprotein cholesterol. Serum
      osteocalcin levels significantly decreased with increasing number of metabolic
      disorders (P for trend < 0.01). Furthermore, binary logistic regression analysis 
      revealed that participants with higher serum osteocalcin levels had lower odds
      ratios (ORs) for MetS (OR, 0.123; 95% CI, 0.053-0.283), central obesity (OR,
      0.134; 95% CI, 0.060-0.299), and hyperglycemia (OR, 0.142; 95% CI, 0.066-0.302). 
      CONCLUSIONS: Serum osteocalcin levels are negatively associated with MetS,
      particularly central obesity and hyperglycemia, in Chinese postmenopausal women.
AD  - Department of Endocrinology and Metabolism, Shanghai Jiao Tong University
      Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes,
      Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus,
      Shanghai, China.
FAU - Yang, Rong
AU  - Yang R
FAU - Ma, Xiaojing
AU  - Ma X
FAU - Pan, Xiaoping
AU  - Pan X
FAU - Wang, Feifei
AU  - Wang F
FAU - Luo, Yuqi
AU  - Luo Y
FAU - Gu, Chengchen
AU  - Gu C
FAU - Bao, Yuqian
AU  - Bao Y
FAU - Jia, Weiping
AU  - Jia W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.1097/GME.0b013e318271b1da [doi]
AID - 00042192-201305000-00012 [pii]
PST - ppublish
SO  - Menopause. 2013 May;20(5):548-53. doi: 10.1097/GME.0b013e318271b1da.

PMID- 23615643
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1530-0374 (Electronic)
IS  - 1072-3714 (Linking)
VI  - 20
IP  - 5
DP  - 2013 May
TI  - Association between habitual physical activity and lower cardiovascular risk in
      premenopausal, perimenopausal, and postmenopausal women: a population-based
      study.
PG  - 525-31
LID - 10.1097/GME.0b013e318271b388 [doi]
AB  - OBJECTIVE: Menopause is associated with an increased risk of cardiovascular
      disease. Habitual physical activity, defined as any form of body movement with
      energy expenditure above resting levels, may improve health parameters. We
      assessed the level of habitual physical activity and its effect on anthropometric
      measures and cardiovascular risk factors in a cohort of premenopausal,
      perimenopausal, and postmenopausal women. METHODS: This cross-sectional study is 
      nested on a longitudinal population-based study that was begun in 1995 in the
      city of Passo Fundo, Brazil. For the present analysis, 292 women were included.
      Anthropometric and metabolic profile was evaluated. Habitual physical activity
      was assessed by a digital pedometer for 7 days, and participants were stratified 
      into active and inactive (>/=6,000 and <6,000 steps/day, respectively). RESULTS: 
      The mean (SD) age was 57.1 (5.4) years. The average number of steps per day for
      the total sample was 5,250.7 (3,372.9): 3,472.4 (1,570.2) in the inactive group
      (61.8%) and 9,055.9 (3,033.4) in the active group (31.9%). A negative and
      statistically significant correlation was found between physical activity and
      smoking (P = -0.019), body mass index (P = -0.006), waist circumference (P =
      -0.013), and waist-to-hip ratio of 0.85 or higher (P = -0.043). Inactive women
      presented a higher risk of overweight/obesity (odds ratio [OR], 2.1; 95% CI,
      1.233-3.622; P = 0.006) and waist circumference larger than 88 cm (OR, 1.7; 95%
      CI, 1.054-2.942; P = 0.03), even after adjustment for age, menopause status,
      smoking, and hormone therapy. Inactive women also had a higher risk of diabetes
      mellitus (OR, 2.7; 95% CI, 1.233-6.295; P = 0.014) and metabolic syndrome (OR,
      2.5, 95% CI, 1.443-4.294; P = 0.001). CONCLUSIONS: Habitual physical activity,
      specifically walking 6,000 or more steps daily, was associated with a decreased
      risk of cardiovascular disease and diabetes in middle-aged women, independently
      of menopause status.
AD  - Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clinicas
      de Porto Alegre, Porto Alegre, RS, Brazil.
FAU - Colpani, Veronica
AU  - Colpani V
FAU - Oppermann, Karen
AU  - Oppermann K
FAU - Spritzer, Poli Mara
AU  - Spritzer PM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Menopause
JT  - Menopause (New York, N.Y.)
JID - 9433353
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.1097/GME.0b013e318271b388 [doi]
AID - 00042192-201305000-00009 [pii]
PST - ppublish
SO  - Menopause. 2013 May;20(5):525-31. doi: 10.1097/GME.0b013e318271b388.

PMID- 23615598
OWN - NLM
STAT- MEDLINE
DA  - 20130425
DCOM- 20130611
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Diabetes control in older people.
PG  - f2625
LID - 10.1136/bmj.f2625 [doi]
LID - bmj.f2625 [pii]
FAU - McLaren, Laura A
AU  - McLaren LA
FAU - Quinn, Terence J
AU  - Quinn TJ
FAU - McKay, Gerard A
AU  - McKay GA
LA  - eng
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130424
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Blood Glucose)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Blood Glucose/*analysis
MH  - Diabetes Mellitus/*therapy
MH  - Humans
MH  - *Patient Education as Topic
MH  - Self Care/*methods
MH  - Socioeconomic Factors
EDAT- 2013/04/26 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/04/26 06:00
PST - epublish
SO  - BMJ. 2013 Apr 24;346:f2625. doi: 10.1136/bmj.f2625.

PMID- 23615539
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1421-9786 (Electronic)
IS  - 1015-9770 (Linking)
VI  - 35
IP  - 4
DP  - 2013
TI  - Is isolated aphasia a typical presentation of presumed cardioembolic transient
      ischemic attack or stroke?
PG  - 337-40
LID - 10.1159/000348696 [doi]
AB  - Background: Previous studies have suggested that patients with a transient
      ischemic attack (TIA) or minor ischemic stroke and isolated aphasia should be
      carefully screened for a potential cardiac source of embolism. Most of these
      publications, however, were case reports or small-series. The purpose of this
      study was to assess the relationship between isolated aphasia and atrial
      fibrillation (AF) as the cause of presumed cardioembolic TIA or stroke within the
      setting of 2 large multicenter trials. Methods: The frequency of isolated aphasia
      was compared between patients with a TIA or minor ischemic stroke either with AF 
      [European Atrial Fibrillation Trial (EAFT), n = 1,001] or without AF [Dutch TIA
      Trial (DTT), n = 3,150]. We analyzed data with univariable and multivariable
      logistic regression. Isolated aphasia was defined as aphasia without dysarthria, 
      visual-field defects or motor or sensory deficits of the arm, leg or face.
      Because dysarthria can be difficult to detect in aphasic patients, a second
      analysis was done without excluding dysarthric patients. In a third analysis, we 
      excluded patients with a symptomatic lacunar infarct from the DTT, as these
      patients were overrepresented due to the exclusion of patients with AF. Subgroup 
      analysis was performed for patients presenting with TIA and minor stroke.
      Results: Of 4,151 patients, 210 (5.1%) had isolated aphasia, 109 from the EAFT
      and 101 from the DTT, crude odds ratio (OR) 3.69, 95% confidence interval (CI)
      2.79-4.89. Patients with isolated aphasia were older (mean age 70.3 vs. 66.8
      years, p < 0.01), more often female (OR 1.87, 95% CI 1.41-2.46), and more often
      had diabetes (OR 1.73, 95% CI 1.16-2.59) and hypercholesterolemia (OR 1.83, 95%
      CI 1.11-3.03) than those without aphasia. After simultaneous adjustment for age, 
      sex, diabetes and hypercholesterolemia, patients with isolated aphasia still had 
      AF more often than patients without isolated aphasia (adjusted OR 2.94, 95% CI
      2.16-4.01). Both after inclusion of patients with dysarthria in the group of
      patients with isolated aphasia and after exclusion of patients with a symptomatic
      lacunar infarct, essentially the results remained the same. Patients presenting
      with isolated aphasia due to a TIA tended to have AF more often than patients
      with a minor ischemic stroke. Conclusions: Isolated aphasia is an independent
      sign of AF in patients with a TIA or minor ischemic stroke. Careful cardiac
      screening seems warranted in patients with isolated aphasia, as secondary
      prevention is different in patients with a cardiac source of embolism.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Neurology, Ziekenhuis St. Jansdal, Harderwijk, the Netherlands.
FAU - Fennis, Th F M
AU  - Fennis TF
FAU - Compter, A
AU  - Compter A
FAU - van den Broek, M W C
AU  - van den Broek MW
FAU - Koudstaal, P J
AU  - Koudstaal PJ
FAU - Algra, A
AU  - Algra A
FAU - Koehler, P J
AU  - Koehler PJ
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Switzerland
TA  - Cerebrovasc Dis
JT  - Cerebrovascular diseases (Basel, Switzerland)
JID - 9100851
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/10/12 [received]
PHST- 2013/01/23 [accepted]
PHST- 2013/04/23 [aheadofprint]
AID - 000348696 [pii]
AID - 10.1159/000348696 [doi]
PST - ppublish
SO  - Cerebrovasc Dis. 2013;35(4):337-40. doi: 10.1159/000348696. Epub 2013 Apr 23.

PMID- 23615507
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1523-1755 (Electronic)
IS  - 0085-2538 (Linking)
DP  - 2013 Apr 24
TI  - Rho-kinase inhibition prevents the progression of diabetic nephropathy by
      downregulating hypoxia-inducible factor 1alpha
LID - 10.1038/ki.2013.130 [doi]
AB  - The small GTPase Rho and its effector Rho-kinase are involved in the pathogenesis
      of diabetic nephropathy. Accumulating evidence shows that hypoxia-inducible
      factor-1alpha (HIF-1alpha) is a key regulator of renal sclerosis under diabetic
      conditions. However, the interactions of Rho-kinase and HIF-1alpha in the
      development of renal dysfunction have not been defined. Here, we assessed whether
      Rho-kinase blockade attenuates HIF-1alpha induction and the subsequent fibrotic
      response using type 2 diabetic mice and cultured mesangial cells. Fasudil, a
      Rho-kinase inhibitor, reduced urinary albumin excretion, mesangial matrix
      expansion, and the expression of fibrotic mediators in db/db mice.
      Mechanistically, HIF-1alpha accumulation and the expression of its target genes
      that contribute to diabetic glomerulosclerosis were also prevented by fasudil in 
      the renal cortex. In mesangial cells, Rho/Rho-kinase signaling was activated
      under hypoxic conditions. Further in vitro studies showed that pharmacological
      and genetic inhibition of Rho-kinase promoted proteasomal HIF-1alpha degradation,
      which subsequently suppressed HIF-1-dependent profibrotic gene expression by
      upregulation of prolyl hydroxylase 2. Thus, we found a previously unrecognized
      renoprotective mechanism for the effects of Rho-kinase inhibition and this could 
      be a potential therapeutic target for the treatment of diabetic
      nephropathy.Kidney International advance online publication, 24 April 2013;
      doi:10.1038/ki.2013.130.
AD  - Division of Diabetes, Metabolism and Endocrinology, Department of Internal
      Medicine, Jikei University School of Medicine, Tokyo, Japan.
FAU - Matoba, Keiichiro
AU  - Matoba K
FAU - Kawanami, Daiji
AU  - Kawanami D
FAU - Okada, Rina
AU  - Okada R
FAU - Tsukamoto, Masami
AU  - Tsukamoto M
FAU - Kinoshita, Jun
AU  - Kinoshita J
FAU - Ito, Tomoko
AU  - Ito T
FAU - Ishizawa, Sho
AU  - Ishizawa S
FAU - Kanazawa, Yasushi
AU  - Kanazawa Y
FAU - Yokota, Tamotsu
AU  - Yokota T
FAU - Murai, Noriyuki
AU  - Murai N
FAU - Matsufuji, Senya
AU  - Matsufuji S
FAU - Takahashi-Fujigasaki, Junko
AU  - Takahashi-Fujigasaki J
FAU - Utsunomiya, Kazunori
AU  - Utsunomiya K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/24 [aheadofprint]
AID - ki2013130 [pii]
AID - 10.1038/ki.2013.130 [doi]
PST - aheadofprint
SO  - Kidney Int. 2013 Apr 24. doi: 10.1038/ki.2013.130.

PMID- 23615486
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1464-3685 (Electronic)
IS  - 0300-5771 (Linking)
DP  - 2013 Apr 24
TI  - Cohort Profile: The Health2006 cohort, Research Centre for Prevention and Health.
AD  - Research Centre for Prevention and Health, Copenhagen University Hospital
      Glostrup, The Capital Region of Denmark, Denmark, National Allergy Research
      Centre, Department of Dermato-Allergology, Copenhagen University Hospital
      Gentofte, Denmark, Danish Research Centre for Chemical Sensitivities, Gentofte
      University Hospital, University of Copenhagen, Copenhagen, Denmark, Hagedorn
      Research Institute and Steno Diabetes Centre, Gentofte, Denmark, The Novo Nordisk
      Foundation Centre for Basic Metabolic Research, Faculty of Health Sciences,
      University of Copenhagen, Copenhagen, Denmark, Faculty of Health Sciences,
      University of Southern Denmark, Odense, Denmark and Faculty of Health Sciences,
      University of Aarhus, Aarhus, Denmark.
FAU - Thuesen, Betina H
AU  - Thuesen BH
FAU - Cerqueira, Charlotte
AU  - Cerqueira C
FAU - Aadahl, Mette
AU  - Aadahl M
FAU - Ebstrup, Jeanette Frost
AU  - Ebstrup JF
FAU - Toft, Ulla
AU  - Toft U
FAU - Thyssen, Jacob P
AU  - Thyssen JP
FAU - Fenger, Runa Vavia
AU  - Fenger RV
FAU - Hersoug, Lars-Georg
AU  - Hersoug LG
FAU - Elberling, Jesper
AU  - Elberling J
FAU - Pedersen, Oluf
AU  - Pedersen O
FAU - Hansen, Torben
AU  - Hansen T
FAU - Johansen, Jeanne Duus
AU  - Johansen JD
FAU - Jorgensen, Torben
AU  - Jorgensen T
FAU - Linneberg, Allan
AU  - Linneberg A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Int J Epidemiol
JT  - International journal of epidemiology
JID - 7802871
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - dyt009 [pii]
AID - 10.1093/ije/dyt009 [doi]
PST - aheadofprint
SO  - Int J Epidemiol. 2013 Apr 24.

PMID- 23615341
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1539-2864 (Electronic)
IS  - 0275-004X (Linking)
DP  - 2013 Apr 23
TI  - COMPARISON OF STANDARDIZED CLINICAL CLASSIFICATION WITH FUNDUS PHOTOGRAPH GRADING
      FOR THE ASSESSMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA SEVERITY.
AB  - PURPOSE:: To compare evaluation by clinical examination with image grading at a
      reading center for the classification of diabetic retinopathy and diabetic
      macular edema. METHODS:: Action to Control Cardiovascular Risk in Diabetes
      (ACCORD) and Family Investigations of Nephropathy in Diabetes (FIND) had similar 
      methods of clinical and fundus photograph evaluation. For analysis purposes, the 
      photographic grading scales were condensed to correspond to the clinical scales, 
      and agreement between clinicians and reading center classification were compared.
      RESULTS:: Six thousand nine hundred and two eyes of ACCORD participants and 3,638
      eyes of FIND participants were analyzed for agreement (percent, kappa) on
      diabetic retinopathy on a 5-level scale. Exact agreement between clinicians and
      reading center on diabetic retinopathy severity category was 69% in ACCORD and
      74% in FIND (kappa 0.42 and 0.65). Sensitivities of the clinical grading to
      identify the presence of mild nonproliferative retinopathy or worse were 0.53 in 
      ACCORD and 0.84 in FIND. Specificities were 0.97 and 0.96, respectively. Diabetic
      macular edema agreement in 6,649 eyes of ACCORD participants and 3,366 eyes of
      FIND participants was similar (kappa 0.35 and 0.41). Sensitivities of the
      clinical grading to identify diabetic macular edema were 0.44 and 0.53 and
      specificities were 0.99 and 0.94, respectively. CONCLUSION:: The results support 
      the use of clinical information for defining broad severity categories but not
      for documenting small-to-moderate changes in diabetic retinopathy over time.
AD  - *Fundus Photograph Reading Center, Department of Ophthalmology and Visual
      Sciences, University of Wisconsin-Madison, Madison, Wisconsin; daggerDepartment
      of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest
      University School of Medicine, Winston-Salem, North Carolina; double
      daggerClinical Trials Branch, Division of Epidemiology and Clinical Applications,
      National Eye Institute/National Institutes of Health, Bethesda, Maryland; section
      signDepartment of Ophthalmology, Wake Forest School of Medicine, Winston-Salem,
      North Carolina; paragraph signGreater Baltimore Medical Center and Johns Hopkins 
      University, Baltimore, Maryland; and **Division of Nephrology and Hypertension,
      David Geffen School of Medicine, Los Angeles Biomedical Research Institute at
      Harbor-UCLA Medical Center, Torrance, California. Dr. W. T. Wong now with the
      Unit on Neuron-Glia Interactions, National Eye Institute, Bethesda, Maryland.
FAU - Gangaputra, Sapna
AU  - Gangaputra S
FAU - Lovato, James F
AU  - Lovato JF
FAU - Hubbard, Larry
AU  - Hubbard L
FAU - Davis, Matthew D
AU  - Davis MD
FAU - Esser, Barbara A
AU  - Esser BA
FAU - Ambrosius, Walter T
AU  - Ambrosius WT
FAU - Chew, Emily Y
AU  - Chew EY
FAU - Greven, Craig
AU  - Greven C
FAU - Perdue, Letitia H
AU  - Perdue LH
FAU - Wong, Wai T
AU  - Wong WT
FAU - Condren, Audree
AU  - Condren A
FAU - Wilkinson, Charles P
AU  - Wilkinson CP
FAU - Agron, Elvira
AU  - Agron E
FAU - Adler, Sharon
AU  - Adler S
FAU - Danis, Ronald P
AU  - Danis RP
CN  - for the ACCORD Eye Research Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Retina
JT  - Retina (Philadelphia, Pa.)
JID - 8309919
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.1097/IAE.0b013e318286c952 [doi]
PST - aheadofprint
SO  - Retina. 2013 Apr 23.

PMID- 23615327
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
DP  - 2013 Apr 23
TI  - Circulating biomarkers of collagen metabolism in arterial hypertension: relevance
      of target organ damage.
AB  - OBJECTIVE:: Increasing experimental evidence indicates that alterations in the
      extracellular matrix are implicated in hypertension and its chronic
      complications. Selected markers of extracellular matrix metabolism were
      investigated as potential biomarkers for hypertensive remodelling and correlated 
      with the severity and extent of target organ damage (TOD) in patients with
      essential hypertension. METHODS:: We studied 159 consecutive patients being
      treated for essential hypertension. An exhaustive evaluation of the heart, kidney
      and blood vessel damage was performed, and plasma levels of plasma procollagen
      type I (PICP), matrix metalloproteinase-1 (MMP-1) and its inhibitor (tissue
      inhibitor metalloproteinase-1, TIMP-1) were determined. Patients were categorized
      into four groups: no TOD (33 patients), level 1 TOD (52 patients), level 2 TOD
      (44 patients) and level 3 TOD (30 patients). RESULTS:: The serum levels of MMP-1 
      and TIMP-1 were higher in patients with TOD than in hypertensive patients without
      TOD. Increasing levels of these molecules were progressively associated with an
      increase in the number of organs damaged, with highest levels of markers in
      patients with level 3 TOD (heart, kidney and blood vessels). There were no
      differences in PICP levels between groups. We found a slight but significant
      correlation between TIMP-1 and all hypertensive organ damage. Logistic regression
      analysis showed that age, smoking, diabetes mellitus, abdominal perimeter, MMP-1 
      and TIMP-1 were independently related to the level of TOD. CONCLUSION::
      Circulating concentration of MMP-1 and TIMP-1 is associated with an extended
      hypertensive disease, with more TOD. TIMP-1 may have a role as a biomarker of
      total remodelling burden in hypertensive patients.
AD  - aArterial Hypertension Unit, Department of Cardiology, Hospital Universitario de 
      San Juan bCardiocirculatory Unit, Research Center, Hospital Universitario La Fe, 
      Valencia, Spain.
FAU - Morillas, Pedro
AU  - Morillas P
FAU - Quiles, Juan
AU  - Quiles J
FAU - de Andrade, Helder
AU  - de Andrade H
FAU - Castillo, Jesus
AU  - Castillo J
FAU - Tarazon, Estefania
AU  - Tarazon E
FAU - Rosello, Esther
AU  - Rosello E
FAU - Portoles, Manuel
AU  - Portoles M
FAU - Rivera, Miguel
AU  - Rivera M
FAU - Bertomeu-Martinez, Vicente
AU  - Bertomeu-Martinez V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.1097/HJH.0b013e3283614c1c [doi]
PST - aheadofprint
SO  - J Hypertens. 2013 Apr 23.

PMID- 23615312
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1421-9670 (Electronic)
IS  - 0250-8095 (Linking)
VI  - 37
IP  - 5
DP  - 2013
TI  - Microalbuminuria in HIV Disease.
PG  - 443-51
LID - 10.1159/000350384 [doi]
AB  - Background/Aims: Microalbuminuria is a marker for early kidney disease and
      cardiovascular risk. The purposes of this study were to determine the prevalence 
      of microalbuminuria in an HIV-infected clinic population, to test the predictive 
      value of a single urine albumin/creatinine ratio (ACR) to identify persistent
      microalbuminuria and to examine covariates of microalbuminuria. Methods: We
      conducted a prospective cohort study of HIV-infected subjects (n = 182) without
      proteinuria (urine protein/creatinine ratio >/=0.5 g/g), elevated serum
      creatinine, diabetes, or chronic inflammatory conditions. Subjects completed
      three research visits within 9 months. Microalbuminuria was defined as the
      geometric mean ACR of 25-355 mg/g for females and 17-250 mg/g for males. Results:
      The prevalence of microalbuminuria was 14%. The negative predictive value of a
      single urine ACR determination was 98%, whereas the positive predictive value was
      only 74%. Microalbuminuria was similar among Black (15%) and non-Black (14%)
      subjects (p = 0.8). Subjects with microalbuminuria were more likely to have
      hypertension (p = 0.02) and metabolic syndrome (p = 0.03). While duration of HIV 
      infection and the level of HIV viremia were similar between groups, those with
      microalbuminuria were more likely to have a CD4 count <200 cells/mul (p =
      0.0003). In a multivariate logistic regression analysis, the only significant
      independent predictors of microalbuminuria were low CD4 count (p = 0.018) and
      current ritonavir exposure (p = 0.04). Conclusion: The prevalence of
      microalbuminuria in an HIV-infected clinic population was similar to earlier
      reports, and was associated with hypertension and impaired immune function. A
      single normal ACR determination effectively excludes microalbuminuria, whereas an
      elevated ACR requires confirmation.
AD  - Laboratory of Immunoregulation, National Institute of Allergy and Infectious
      Diseases, National Institutes of Health (NIH), Department of Critical Care
      Medicine, NIH, Bethesda, Md., USA.
FAU - Hadigan, Colleen
AU  - Hadigan C
FAU - Edwards, Elizabeth
AU  - Edwards E
FAU - Rosenberg, Alice
AU  - Rosenberg A
FAU - Purdy, Julia B
AU  - Purdy JB
FAU - Fleischman, Estee
AU  - Fleischman E
FAU - Howard, Lilian
AU  - Howard L
FAU - Mican, Joann M
AU  - Mican JM
FAU - Sampath, Karmini
AU  - Sampath K
FAU - Oyalowo, Akinbowale
AU  - Oyalowo A
FAU - Johnson, Antoinette
AU  - Johnson A
FAU - Adler, Alexandra
AU  - Adler A
FAU - Rehm, Catherine
AU  - Rehm C
FAU - Smith, Margo
AU  - Smith M
FAU - Lai, Leon
AU  - Lai L
FAU - Kopp, Jeffrey B
AU  - Kopp JB
LA  - eng
PT  - Journal Article
DEP - 20130420
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/01/16 [received]
PHST- 2013/03/03 [accepted]
PHST- 2013/04/20 [aheadofprint]
AID - 000350384 [pii]
AID - 10.1159/000350384 [doi]
PST - ppublish
SO  - Am J Nephrol. 2013;37(5):443-51. doi: 10.1159/000350384. Epub 2013 Apr 20.

PMID- 23615267
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1423-0267 (Electronic)
IS  - 0030-3755 (Linking)
VI  - 229
DP  - 2013
TI  - Assessment of the Bag-in-the-Lens Implantation Technique in Diabetic Patients.
PG  - 212-8
LID - 10.1159/000350236 [doi]
AB  - Cataract is a common condition observed in patients with diabetes mellitus
      frequently requiring surgical intervention. The bag-in-the-lens (BIL) intraocular
      implant is an alternative approach to standard lens-in-the-bag cataract surgery. 
      The lens is supported by anterior and posterior capsulorhexes, which confers a
      number of advantages in terms of lens centration, rotational stability and
      prevention of posterior capsular opacity. The purpose of this report is to
      describe the results of BIL cataract surgery in a retrospective cohort of
      diabetic patients. Fifty-four cases of BIL surgery are included with a follow-up 
      period of 1 year. Visual acuity outcomes were comparable to previously published 
      standard lens-in-the-bag procedures. There were no reports of posterior capsular 
      opacification and the grade of diabetic retinopathy remained stable. Three cases 
      of clinically significant macular edema were detected over the follow-up period. 
      We conclude that the BIL implantation technique is an advantageous approach to
      treating cataract in the diabetic population.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Ophthalmology, Antwerp University Hospital, Antwerp, Belgium.
FAU - Lauwers, Noemie
AU  - Lauwers N
FAU - Ni Dhubhghaill, Sorcha
AU  - Ni Dhubhghaill S
FAU - Mathysen, Danny G P
AU  - Mathysen DG
FAU - Tassignon, Marie-Jose
AU  - Tassignon MJ
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Switzerland
TA  - Ophthalmologica
JT  - Ophthalmologica. Journal international d'ophtalmologie. International journal of 
      ophthalmology. Zeitschrift fur Augenheilkunde
JID - 0054655
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/02/22 [received]
PHST- 2013/02/24 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 000350236 [pii]
AID - 10.1159/000350236 [doi]
PST - ppublish
SO  - Ophthalmologica. 2013;229:212-8. doi: 10.1159/000350236. Epub 2013 Apr 24.

PMID- 23615237
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1538-7488 (Electronic)
IS  - 0002-936X (Linking)
VI  - 113
IP  - 5
DP  - 2013 May
TI  - Nurse-community teamwork improves diabetes care.
PG  - 18
LID - 10.1097/01.NAJ.0000430225.14445.13 [doi]
AB  - Results in American Samoa could translate to other medically underserved areas.
FAU - Potera, Carol
AU  - Potera C
LA  - eng
PT  - News
PL  - United States
TA  - Am J Nurs
JT  - The American journal of nursing
JID - 0372646
SB  - AIM
SB  - IM
SB  - N
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.1097/01.NAJ.0000430225.14445.13 [doi]
AID - 00000446-201305000-00012 [pii]
PST - ppublish
SO  - Am J Nurs. 2013 May;113(5):18. doi: 10.1097/01.NAJ.0000430225.14445.13.

PMID- 23615216
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 31
IP  - 3
DP  - 2013 Mar
TI  - Morning and smooth 24-h ambulatory blood pressure control is not achieved in
      general practice: results from the SURGE observational study.
PG  - 616-23; discussion 623
LID - 10.1097/HJH.0b013e32835ca8bf [doi]
AB  - BACKGROUND: The aim of this large-scale, practice-based observational study
      [Survey with HBPM and ABPM Under Real clinical conditions in General practice to 
      Evaluate BP control in the early morning (SURGE)] was to ascertain the degree of 
      morning and 24-h ambulatory blood pressure (ABP) control in hypertensive
      patients. METHODS: Hypertensive patients [with uncontrolled clinic blood pressure
      (BP) >140/90 mmHg at screening] from nine different countries were included.
      Ambulatory BP monitoring was performed over 24 h at 15-min intervals during the
      day and at 20-min intervals during the night. Assessments included morning
      (0600-1159 h) and daytime ABP control (BP < 135/85 mmHg), and 24-h ABP control,
      which was set at levels less than 125/80 mmHg (ESH/ESC guidelines) and less than 
      130/80 mmHg (USA guidelines). RESULTS: A total of 3312 patients were enrolled
      [mean clinic BP: 153 +/- 17/91 +/- 10 mmHg; mean 24-h and morning ABP: 130 +/-
      15/77 +/- 10 mmHg and 134 +/- 16/80 +/- 11 mmHg, respectively; antihypertensive
      use: 72.7% (n = 2409)]. Morning and daytime (period of activity) ABP control was 
      observed in 45.2 and 47.4% of treated patients, respectively; 24-h ABP control
      was only achieved in 34.6% (ESH/ESC guidelines) and 44.7% (USA guidelines) of
      treated patients. There was 'poor agreement' between clinic BP and ABP regarding 
      BP control as shown by a negative (</=0) kappa coefficient in treated patients.
      Clinic BP control (<130/80 mmHg) and morning ABP control (<135/85 mmHg) was
      observed in 2.3 and 45.1% of diabetic patients, and in 2.4 and 43.6% of patients 
      with left ventricular hypertrophy (LVH). Morning ABP control was 42.3% in
      patients with high/very high cardiovascular risk. CONCLUSIONS: Clinic BP, morning
      and 24-h ABP control rates were low in treated hypertensive patients, including
      those with comorbidities, such as diabetes or LVH.
AD  - Department of Health Sciences, University of Milano-Bicocca, St Luca Hospital,
      IRCCS Istituto Auxologico Italiano, Milan, Italy. gianfranco.parati@unimib.it
FAU - Parati, Gianfranco
AU  - Parati G
FAU - Bilo, Grzegorz
AU  - Bilo G
FAU - Redon, Josep
AU  - Redon J
CN  - SURGE Steering Committee
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.1097/HJH.0b013e32835ca8bf [doi]
AID - 00004872-201303000-00026 [pii]
PST - ppublish
SO  - J Hypertens. 2013 Mar;31(3):616-23; discussion 623. doi:
      10.1097/HJH.0b013e32835ca8bf.

PMID- 23615188
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 47
IP  - 8
DP  - 2013 Aug
TI  - Increased advanced glycation end-products (AGEs) assessed by skin
      autofluorescence in schizophrenia.
PG  - 1044-8
LID - 10.1016/j.jpsychires.2013.03.016 [doi]
LID - S0022-3956(13)00099-X [pii]
AB  - BACKGROUND: Oxidative stress has been intensively studied as a key biochemical
      system in the pathophysiology of schizophrenia. However, little is known about
      the implication of oxidative stress in the development of physical illnesses in
      schizophrenia patients, who are characterized by high cardiovascular risk and
      decreased life expectancy. Advanced glycation end-products (AGEs) are considered 
      to be markers of oxidative stress and are linked to the development of
      atherosclerosis. METHODS: We investigated AGE levels determined by a noninvasive 
      skin autofluorescence (skin AF) method (AGE-Reader) in schizophrenia patients.
      Skin AF was assessed in 55 schizophrenia patients without diabetes or renal
      disease and 55 healthy controls matched for age, gender and smoking status.
      Nineteen of the 55 schizophrenia patients had a severe form of the disease
      (Kraepelinian schizophrenia). RESULTS: Skin AF was significantly higher in
      schizophrenia patients compared to controls (2.46 +/- 0.52 and 1.90 +/- 0.21,
      respectively, p < 0.0001). Kraepelinian schizophrenia patients had significantly 
      higher skin AF than non-Kraepelinian schizophrenia patients (p = 0.05).
      CONCLUSIONS: This is the first study to demonstrate high AGE levels assessed by a
      noninvasive method in schizophrenia patients.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - University Department of Endocrinology, CHU d'Amiens, University of Picardie,
      Amiens, France.
FAU - Kouidrat, Youssef
AU  - Kouidrat Y
FAU - Amad, Ali
AU  - Amad A
FAU - Desailloud, Rachel
AU  - Desailloud R
FAU - Diouf, Momar
AU  - Diouf M
FAU - Fertout, Eva
AU  - Fertout E
FAU - Scoury, Daphne
AU  - Scoury D
FAU - Lalau, Jean-Daniel
AU  - Lalau JD
FAU - Loas, Gwenole
AU  - Loas G
LA  - eng
PT  - Journal Article
DEP - 20130421
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/11/21 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/03/22 [accepted]
PHST- 2013/04/21 [aheadofprint]
AID - S0022-3956(13)00099-X [pii]
AID - 10.1016/j.jpsychires.2013.03.016 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2013 Aug;47(8):1044-8. doi: 10.1016/j.jpsychires.2013.03.016.
      Epub 2013 Apr 21.

PMID- 23615017
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1559-7776 (Electronic)
IS  - 1559-7768 (Linking)
VI  - 24
IP  - 2
DP  - 2013 Apr-Jun
TI  - Finding the right fit: implementation of a structured interviewing process for
      clinical nurse specialists.
PG  - 194-202
LID - 10.1097/NCI.0b013e31828a0b1f [doi]
AB  - PURPOSE AND BACKGROUND: The purpose of this article is to describe how clinical
      nurse specialists (CNSs) in one organization developed a structured interviewing 
      process for CNS candidates. The process has evolved in relation to implementation
      of national CNS competencies, growth of the role in the organization, and changes
      to reporting structure. OUTCOMES: The CNS interview process includes panel
      interviews with various organizational leaders, CNSs, and team members. A
      behavioral-based tool relevant to the CNS role is used. Involving CNS peers in
      the interview ensures the successful hiring and retaining of suitable candidates.
      Clinical nurse specialists who were interviewed using the current peer interview 
      procedure have reported satisfaction with the experience. IMPLICATIONS: Peer
      interviews for CNSs provide a forum for meaningful dialogue about the CNS role,
      competencies, and fit with the organization. This process can be used for other
      advanced practice disciplines.
AD  - Julie S. Lampe is Diabetes Clinical Nurse Specialist, Orlando Regional Medical
      Center, 1414 Kuhl Ave, Orlando, FL 32806, USA. julie.lampe@orlandohealth.com
FAU - Lampe, Julie S
AU  - Lampe JS
FAU - Geddie, Patricia I
AU  - Geddie PI
FAU - Aguirre, Lillian
AU  - Aguirre L
FAU - Sole, Mary Lou
AU  - Sole ML
LA  - eng
PT  - Journal Article
PL  - United States
TA  - AACN Adv Crit Care
JT  - AACN advanced critical care
JID - 101269322
SB  - N
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.1097/NCI.0b013e31828a0b1f [doi]
AID - 01256961-201304000-00014 [pii]
PST - ppublish
SO  - AACN Adv Crit Care. 2013 Apr-Jun;24(2):194-202. doi:
      10.1097/NCI.0b013e31828a0b1f.

PMID- 23614970
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1423-0267 (Electronic)
IS  - 0030-3755 (Linking)
VI  - 229
IP  - 4
DP  - 2013
TI  - Macular Thickness Measured by Stratus Optical Coherence Tomography in Patients
      with Diabetes Type 2 and Mild Nonproliferative Retinopathy without Clinical
      Evidence of Macular Edema.
PG  - 181-6
LID - 10.1159/000350593 [doi]
AB  - To evaluate macular thickness in eyes with mild nonproliferative diabetic
      retinopathy (NPDR), patients with diabetes type 2, NPDR level 20 or 35, and
      without evidence of clinical macular edema underwent best-corrected visual acuity
      assessment, color fundus photography and Stratus optical coherence tomography.
      Mean center point thickness (CPT) and mean central subfield (CSF) thickness were 
      compared with those of a healthy control population. 410 eyes/patients aged 61.2 
      +/- 8.3 years, and with glycosylated hemoglobin of 7.9 +/- 1.5% were included.
      Mean CPT and CSF were 186.6 +/- 28.4 and 215.2 +/- 25 microm, respectively,
      significantly increased compared to healthy subjects (p < 0.001). CSF thickness
      was abnormally increased in 17.6% of the patients, with values within the normal 
      range in 79.5%, and abnormally decreased in 2.9%. CPT and CSF thickness were
      significantly thicker in men. No systemic factors showed a significant
      association. A significant increase in the macular thickness was found in
      eyes/patients with mild NPDR without clinical macular edema; however, only 17.6% 
      of the eyes/patients had abnormally increased values and less than 3% abnormally 
      decreased values.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Association for Innovation and Biomedical Research on Light and Image, Coimbra,
      Portugal.
FAU - Pires, Isabel
AU  - Pires I
FAU - Santos, Ana Rita
AU  - Santos AR
FAU - Nunes, Sandrina
AU  - Nunes S
FAU - Lobo, Conceicao
AU  - Lobo C
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Switzerland
TA  - Ophthalmologica
JT  - Ophthalmologica. Journal international d'ophtalmologie. International journal of 
      ophthalmology. Zeitschrift fur Augenheilkunde
JID - 0054655
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/03/08 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 000350593 [pii]
AID - 10.1159/000350593 [doi]
PST - ppublish
SO  - Ophthalmologica. 2013;229(4):181-6. doi: 10.1159/000350593. Epub 2013 Apr 24.

PMID- 23614941
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1421-9921 (Electronic)
IS  - 0014-312X (Linking)
VI  - 50
IP  - 2
DP  - 2013
TI  - Distal pancreatectomy utilizing a flexible stapler closure eliminates the risk of
      pancreas-related factors for postoperative pancreatic fistula.
PG  - 71-9
LID - 10.1159/000349977 [doi]
AB  - Objectives: To identify the risk factors for clinically relevant pancreatic
      fistula after distal pancreatectomy with a flexible cartridge stapler, TL60.
      Methods: Forty consecutive patients who underwent a distal pancreatectomy by the 
      TL60 stapler were retrospectively reviewed in association with postoperative
      complications. Results: The overall morbidity rate was 43% (17 patients), and
      mortality was null. Pancreatic fistula was the most frequent postoperative
      complication, seen in 11 patients (27.5%): grade A in 4 (10%) and grade B in 7
      (17.5%). No grade C pancreatic fistula was observed. Univariate analyses of risk 
      factors demonstrated that pancreas-related factors, including diabetes mellitus, 
      thickness and texture of the pancreatic parenchyma, transection line for the
      pancreas, pancreatic duct ligation, and use of artificial patches had no impact
      on the occurrence of pancreatic fistula. A multivariable logistic regression
      analysis identified operative time (>/=300 min) as the only notable predictor of 
      clinically relevant pancreatic fistula (odds ratio = 3.253, 95% confidence
      interval 1.739-5.752; p = 0.031). Conclusion: Distal pancreatectomy with the use 
      of the TL60 stapler eliminated the risk of pancreas-related factors for the
      occurrence of clinically relevant pancreatic fistula.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Digestive and General Surgery, Shimane University Faculty of
      Medicine, Izumo, Japan.
FAU - Kawabata, Y
AU  - Kawabata Y
FAU - Nishi, T
AU  - Nishi T
FAU - Tanaka, T
AU  - Tanaka T
FAU - Yano, S
AU  - Yano S
FAU - Tajima, Y
AU  - Tajima Y
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Switzerland
TA  - Eur Surg Res
JT  - European surgical research. Europaische chirurgische Forschung. Recherches
      chirurgicales europeennes
JID - 0174752
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/12/10 [received]
PHST- 2013/02/17 [accepted]
PHST- 2013/04/23 [aheadofprint]
AID - 000349977 [pii]
AID - 10.1159/000349977 [doi]
PST - ppublish
SO  - Eur Surg Res. 2013;50(2):71-9. doi: 10.1159/000349977. Epub 2013 Apr 23.

PMID- 23614851
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Linking)
VI  - 15
IP  - 5
DP  - 2013 May
TI  - Contribution of glomerular filtration rate to 10-year cardiovascular and
      mortality risk among hypertensive adults: Tehran lipid and glucose study.
PG  - 350-8
LID - 10.1111/jch.12083 [doi]
AB  - The authors tested the hypotheses that (1) estimated glomerular filtration rate
      (eGFR) predicts cardiovascular disease (CVD) or mortality risk among hypertensive
      patients, (2) associations are curvilinear, and (3) diabetes modifies these
      associations. Data from a 10-year follow-up of 3179 hypertensive patients 18
      years and older were analyzed. Measurements included eGFR and CVD risk factors,
      and outcomes were CVD and mortality. Cox models were developed to estimate the
      hazard ratios (HRs) for different endpoints for a 1-standard deviation (SD)
      increment in eGFR. The nonlinearity in associations was examined by cubic spline 
      method. Mean (SD) age of the participants (59.0% women) was 56.3 (12.3) years.
      During follow-up (10-year), 629 incident cases of CVD (296 women) and 320 deaths 
      (130 women) were documented. The incidence rate of different outcomes decreased
      across increasing eGFR quintiles. Among men, irrespective of their diabetes
      status, eGFR was inversely associated with risk of mortality. Among women,
      irrespective of their diabetes status, eGFR did not predict mortality. Neither
      among men nor among women did eGFR predict CVD or coronary heart disease. No
      evidence was found for nonlinearity in these associations. eGFR was independently
      associated with mortality among hypertensive men with or without diabetes. When
      information on traditional CVD risk factors was available, eGFR provided no
      additional predictive value for CVD.
CI  - (c)2013 Wiley Periodicals, Inc.
AD  - Prevention of Metabolic Disorders Research Center, Research Institute for
      Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Mohebi, Reza
AU  - Mohebi R
FAU - Bozorgmanesh, Mohammadreza
AU  - Bozorgmanesh M
FAU - Sheikholeslami, Farhad
AU  - Sheikholeslami F
FAU - Azizi, Fereidoun
AU  - Azizi F
FAU - Hadaegh, Farzad
AU  - Hadaegh F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130313
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/10/25 [received]
PHST- 2013/01/15 [revised]
PHST- 2013/01/18 [accepted]
PHST- 2013/03/13 [aheadofprint]
AID - 10.1111/jch.12083 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2013 May;15(5):350-8. doi: 10.1111/jch.12083. Epub 
      2013 Mar 13.

PMID- 23614847
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Linking)
VI  - 15
IP  - 5
DP  - 2013 May
TI  - Systolic blood pressure and mortality in chronic hemodialysis patients: results
      of a nationwide italian study.
PG  - 328-32
LID - 10.1111/jch.12074 [doi]
AB  - Studies on the relationship between blood pressure (BP) and mortality among
      hemodialysis patients have yielded conflicting results. Reports have come mostly 
      from North America and have dealt with dialysis patients as a homogenous
      population and differed in methods and time of BP measurement and the optimal BP 
      target. In a prospective nationwide study in 3674 unselected Caucasian patients
      with end-stage renal disease undergoing chronic hemodialysis from 73 dialysis
      units, the authors sought to examine the relationship between the different
      measurements of BP and mortality according to antihypertensive treatment. The
      mean age of patients was 67.2+/-14.1 years and the prevalence of diabetes was
      19.5%. During follow-up (26.5+/-10.5 months), 977 deaths were recorded. In the
      whole cohort, BP was not associated with mortality. After grouping the patients
      according to antihypertensive treatment, the analysis showed that only in
      patients who did not take antihypertensive medications (1613) was there an
      inverse relationship between postdialysis systolic BP and mortality. These
      patients differed from the others in BP, dialysis vintage, prevalence of
      diabetes, and type of dialysis technique. This study suggests that with respect
      to the relationship of BP with mortality, dialysis patients are not a homogenous 
      population. Differences in demographic characteristics and in dialysis technique 
      may therefore explain the reported variability of previous results.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Ospedale Santa Maria Della Misericordia, Perugia, Italy. atlosito@tin.it
FAU - Losito, Attilio
AU  - Losito A
FAU - Del Vecchio, Lucia
AU  - Del Vecchio L
FAU - Lusenti, Tiziano
AU  - Lusenti T
FAU - Del Rosso, Goffredo
AU  - Del Rosso G
FAU - Malandra, Rosella
AU  - Malandra R
FAU - Sturani, Alessandra
AU  - Sturani A
CN  - Gruppo di Studio Dell'Ipertensione Arteriosa Societa Italiana Nefrologia
LA  - eng
PT  - Journal Article
DEP - 20130212
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/11/05 [received]
PHST- 2012/12/11 [revised]
PHST- 2012/12/25 [accepted]
PHST- 2013/02/12 [aheadofprint]
AID - 10.1111/jch.12074 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2013 May;15(5):328-32. doi: 10.1111/jch.12074. Epub
      2013 Feb 12.

PMID- 23614842
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Linking)
VI  - 15
IP  - 5
DP  - 2013 May
TI  - Sweet & low: new treatment for diabetes that may reduce blood pressure.
PG  - 305
LID - 10.1111/jch.12092 [doi]
FAU - Cohen, Debbie L
AU  - Cohen DL
FAU - Townsend, Raymond R
AU  - Townsend RR
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/01 [aheadofprint]
AID - 10.1111/jch.12092 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2013 May;15(5):305. doi: 10.1111/jch.12092. Epub
      2013 Apr 1.

PMID- 23614792
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 30
IP  - 6
DP  - 2013 Jun
TI  - The association between diabetes and an episode of depressive symptoms in the
      2002 World Health Survey: an analysis of 231 797 individuals from 47 countries.
PG  - e208-14
LID - 10.1111/dme.12193 [doi]
AB  - AIMS: Depression is common in people with diabetes and increases the risk of poor
      health outcomes, including premature mortality. We explored the association
      between diabetes and an episode of depressive symptoms in a cross-sectional
      multinational study, which included a large number of low- and middle-income
      non-Western countries. METHODS: Data from 47 countries of the 2002 World Health
      Organization World Health Survey were used, including 231 797 adults (mean age 41
      years, 53% female). Diabetes was assessed by self-report of diagnosis or
      treatment. The presence of an episode of depressive symptoms was assessed by
      self-report using an algorithm based on DSM-IV criteria. Odds ratios and 95%
      confidence intervals were calculated to quantify associations between diabetes
      and episodes of depressive symptoms in the entire sample and for countries
      aggregated into four continents: Africa, South America, Asia and Europe. Odds
      ratios were adjusted for age, sex, education, BMI, smoking and physical activity 
      level. RESULTS: The prevalence of diabetes (mean 3.6%, range 0.2-13%) and
      episodes of depressive symptoms (mean 7.9%, range 0.4-38%) differed widely across
      countries. Globally, individuals with diabetes had increased odds of an episode
      of depressive symptoms compared with those without diabetes (adjusted odds ratio 
      2.36, 95% confidence interval 1.91-2.92). Similar associations were found in
      South America, Asia and Europe (odds ratio > 1.97), but not in Africa (odds ratio
      0.86, 95% confidence interval 0.54-1.37). CONCLUSIONS: Globally, diabetes is
      associated with a twofold increased prevalence of an episode of depressive
      symptoms, except in Africa. Given the worldwide rise in diabetes in the coming
      decades, and the increased risk of poor diabetes outcomes associated with
      co-morbid depression, studies examining mechanisms and interventions are
      necessary.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - CoRPS, Center of Research on Psychology in Somatic diseases, Tilburg University, 
      Tilburg, the Netherlands.
FAU - Mommersteeg, P M C
AU  - Mommersteeg PM
FAU - Herr, R
AU  - Herr R
FAU - Pouwer, F
AU  - Pouwer F
FAU - Holt, R I G
AU  - Holt RI
FAU - Loerbroks, A
AU  - Loerbroks A
LA  - eng
PT  - Journal Article
DEP - 20130425
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/03/14 [accepted]
PHST- 2013/04/25 [aheadofprint]
AID - 10.1111/dme.12193 [doi]
PST - ppublish
SO  - Diabet Med. 2013 Jun;30(6):e208-14. doi: 10.1111/dme.12193. Epub 2013 Apr 25.

PMID- 23614659
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
DP  - 2013 May 24
TI  - The usefulness of plasma asymmetric dimethylarginine (ADMA) levels and tissue
      doppler echocardiography for heart function in term infants born to mothers with 
      gestational diabetes mellitus.
AB  - Abstract Objective: The aim of this study was to examine whether asymmetric
      dimethylarginine (ADMA) concentrations are associated with ventricular function
      in the infants of mothers with gestational diabetes. Method: Twenty-five term
      newborns of mothers with gestational diabetes and term newborns as the control
      group (n = 25) with normal general health status were evaluated at two time
      points, on the 3rd postnatal day, at the 3th months. Echocardiographic
      evaluations of all participants were performed and ADMA level was measured.
      Results: In the first analysis, 10 patients (40%) had a septal thickness of 6 mm 
      or more, indicating septal hypertrophy. In the first and second analysis,
      interventricular septum end-diastolic thickness (IVSTd) and the left ventricular 
      posterior wall end-diastolic thickness (LVPWTd) in the patient group were higher 
      than the control group. ADMA level measurement was not significantly different
      between the groups the first and second analysis. There was no difference in ADMA
      levels of the group with septal thickness >/=6 mm and the group with <6 mm.
      Conclusion: Newborn cardiac wall thickness was increased in pregnancies
      complicated by Gestational diabetes mellitus (GDM), and the increase was
      independent of glycemic control. Diastolic newborn cardiac function was impaired 
      in GDM, and this effect was independent of septal thickness. We found no
      association between ADMA levels and cardiac systolic, diastolic functions or
      septum thickness in the GDM newborn.
AD  - Department of Pediatric Cardiology, Selcuk University Medical Faculty , Konya ,
      Turkey and.
FAU - Arslan, Derya
AU  - Arslan D
FAU - Oran, Bulent
AU  - Oran B
FAU - Vatansev, Husamettin
AU  - Vatansev H
FAU - Cimen, Derya
AU  - Cimen D
FAU - Guvenc, Osman
AU  - Guvenc O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130524
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the
      European Association of Perinatal Medicine, the Federation of Asia and Oceania
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.3109/14767058.2013.798288 [doi]
PST - aheadofprint
SO  - J Matern Fetal Neonatal Med. 2013 May 24.

PMID- 23614630
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 29
IP  - 7
DP  - 2013 Jul
TI  - A practice-based approach to the 2012 position statement of the American Diabetes
      Association and the European Association for the Study of Diabetes.
PG  - 793-9
LID - 10.1185/03007995.2013.798637 [doi]
AB  - Abstract The position statement on the management of hyperglycemia in patients
      with type 2 diabetes mellitus issued in 2012 by the American Diabetes Association
      and the European Association for the Study of Diabetes contains significant
      improvements over the 2009 version, including an emphasis on patient-centered
      care, enhanced strategies for lifestyle modification, a focus on comprehensive
      cardiovascular risk reduction, and increased pharmacotherapy choices. As diabetes
      management evolves over time, further improvements may be made in future
      consensus statements, including a focus on prevention and early treatment and
      improved glycemic control in all patients, including those with comorbidities.
      These goals will be achievable by waning use of therapies known to cause
      hypoglycemia and weight gain and the increased use of therapies that do not carry
      these risks.
AD  - Main Line Health System , Bryn Mawr, PA , USA.
FAU - Schwartz, Stanley S
AU  - Schwartz SS
LA  - eng
PT  - Journal Article
DEP - 20130510
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/05/10 [aheadofprint]
AID - 10.1185/03007995.2013.798637 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2013 Jul;29(7):793-9. doi: 10.1185/03007995.2013.798637. Epub 
      2013 May 10.

PMID- 23614592
OWN - NLM
STAT- MEDLINE
DA  - 20130425
DCOM- 20130502
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 368
IP  - 17
DP  - 2013 Apr 25
TI  - Diabetes report card--time for a winning streak.
PG  - 1650-1
LID - 10.1056/NEJMe1302610 [doi]
FAU - McMahon, Graham T
AU  - McMahon GT
FAU - Dluhy, Robert G
AU  - Dluhy RG
LA  - eng
PT  - Comment
PT  - Editorial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
SB  - AIM
SB  - IM
CON - N Engl J Med. 2013 Apr 25;368(17):1613-24. PMID: 23614587
MH  - Diabetes Mellitus/*therapy
MH  - Female
MH  - *Health Promotion
MH  - Humans
MH  - Male
MH  - Patient Compliance/*statistics & numerical data
EDAT- 2013/04/26 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/04/26 06:00
AID - 10.1056/NEJMe1302610 [doi]
PST - ppublish
SO  - N Engl J Med. 2013 Apr 25;368(17):1650-1. doi: 10.1056/NEJMe1302610.

PMID- 23614587
OWN - NLM
STAT- MEDLINE
DA  - 20130425
DCOM- 20130502
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 368
IP  - 17
DP  - 2013 Apr 25
TI  - Achievement of goals in U.S. diabetes care, 1999-2010.
PG  - 1613-24
LID - 10.1056/NEJMsa1213829 [doi]
AB  - BACKGROUND: Tracking national progress in diabetes care may aid in the evaluation
      of past efforts and identify residual gaps in care. METHODS: We analyzed data for
      adults with self-reported diabetes from the National Health and Nutrition
      Examination Survey and the Behavioral Risk Factor Surveillance System to examine 
      risk-factor control, preventive practices, and risk scores for coronary heart
      disease over the 1999-2010 period. RESULTS: From 1999 through 2010, the weighted 
      proportion of survey participants who met recommended goals for diabetes care
      increased, by 7.9 percentage points (95% confidence interval [CI], 0.8 to 15.0)
      for glycemic control (glycated hemoglobin level <7.0%), 9.4 percentage points
      (95% CI, 3.0 to 15.8) for individualized glycemic targets, 11.7 percentage points
      (95% CI, 5.7 to 17.7) for blood pressure (target, <130/80 mm Hg), and 20.8
      percentage points (95% CI, 11.6 to 30.0) for lipid levels (target level of
      low-density lipoprotein [LDL] cholesterol, <100 mg per deciliter [2.6 mmol per
      liter]). Tobacco use did not change significantly, but the 10-year probability of
      coronary heart disease decreased by 2.8 to 3.7 percentage points. However, 33.4
      to 48.7% of persons with diabetes still did not meet the targets for glycemic
      control, blood pressure, or LDL cholesterol level. Only 14.3% met the targets for
      all three of these measures and for tobacco use. Adherence to the recommendations
      for annual eye and dental examinations was unchanged, but annual lipid-level
      measurement and foot examination increased by 5.5 percentage points (95% CI, 1.6 
      to 9.4) and 6.8 percentage points (95% CI, 4.8 to 8.8), respectively. Annual
      vaccination for influenza and receipt of pneumococcal vaccination for
      participants 65 years of age or older rose by 4.5 percentage points (95% CI, 0.8 
      to 8.2) and 6.9 percentage points (95% CI, 3.4 to 10.4), respectively, and daily 
      glucose monitoring increased by 12.7 percentage points (95% CI, 10.3 to 15.1).
      CONCLUSIONS: Although there were improvements in risk-factor control and
      adherence to preventive practices from 1999 to 2010, tobacco use remained high,
      and almost half of U.S. adults with diabetes did not meet the recommended goals
      for diabetes care.
AD  - Division of Diabetes Translation, National Center for Chronic Disease Prevention 
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
      30341, USA. ise1@cdc.gov
FAU - Ali, Mohammed K
AU  - Ali MK
FAU - Bullard, Kai McKeever
AU  - Bullard KM
FAU - Saaddine, Jinan B
AU  - Saaddine JB
FAU - Cowie, Catherine C
AU  - Cowie CC
FAU - Imperatore, Giuseppina
AU  - Imperatore G
FAU - Gregg, Edward W
AU  - Gregg EW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Hemoglobin A, Glycosylated)
SB  - AIM
SB  - IM
CIN - N Engl J Med. 2013 Apr 25;368(17):1650-1. PMID: 23614592
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Aged
MH  - Body Mass Index
MH  - Diabetes Mellitus/blood/epidemiology/*therapy
MH  - Female
MH  - *Health Promotion
MH  - Hemoglobin A, Glycosylated/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nutrition Surveys
MH  - Outcome Assessment (Health Care)
MH  - Patient Compliance/*statistics & numerical data
MH  - Quality Indicators, Health Care
MH  - Risk Factors
MH  - Sex Distribution
MH  - Socioeconomic Factors
MH  - United States/epidemiology
MH  - Young Adult
EDAT- 2013/04/26 06:00
MHDA- 2013/05/03 06:00
CRDT- 2013/04/26 06:00
AID - 10.1056/NEJMsa1213829 [doi]
PST - ppublish
SO  - N Engl J Med. 2013 Apr 25;368(17):1613-24. doi: 10.1056/NEJMsa1213829.

PMID- 23614503
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1445-6354 (Electronic)
IS  - 1445-6354 (Linking)
VI  - 13
DP  - 2013
TI  - Health ownership in American indigenous communities.
PG  - 2302
AB  - INTRODUCTION: Although the Indian Health Service (IHS) has adequately stifled
      acute infectious diseases that once devastated American Indian and Alaska Native 
      (AIAN) communities, this system of health provision has become obsolete in the
      face of chronically debilitating illnesses. Presently, AIAN communities suffer
      disproportionally from chronic diseases that demand adequate, long-term health
      maintenance such as hepatitis, renal failure, and diabetes to name a few. A
      number of research endeavors have sought to define this problem in the
      literature, but few have proposed adequate mechanisms to alleviate the disparity.
      The objective of this study was to examine the efficacy of both the Indian Health
      Service (IHS) and the relative few tribal healthcare systems (PL 93-638)
      respectively in their sociopolitical contexts, to determine their utility among a
      financially lame IHS. METHODS: Domestic and international indigenous health
      systems were compared through analysis of the current literature on community and
      indigenous health. Informal interviews were carried out with indigenous
      practitioners, community members, and political figures to determine how AIAN
      communities were receiving PL 93-638 programs. RESULTS: Although the IHS has
      adequately stifled the acute infectious diseases that once devastated AIAN
      communities, this system of health provision has become obsolete in the face of
      chronically debilitating illnesses. A number of research endeavors have sought to
      define this problem in the literature, but few have proposed adequate mechanisms 
      to alleviate the disparity. International indigenous health systems are noted to 
      have a greater component of community involvement in the successful
      administration of health services. CONCLUSION: Reinstating notions of ownership
      in multiple paradigms, along with novel approaches to empowerment is requisite to
      creating viable solutions to the unique health circumstances in Native America.
      This article demonstrates the importance and need of more qualitative data to
      better characterize how PL 93-638 healthcare delivery is actually experienced by 
      AIAN patients.
AD  - School of Osteopathic Medicine in Arizona, AT Still University, Mesa, Arizona,
      USA.
FAU - Nelson, M
AU  - Nelson M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20130425
PL  - Australia
TA  - Rural Remote Health
JT  - Rural and remote health
JID - 101174860
SB  - IM
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/25 [epublish]
AID - 2302 [pii]
PST - ppublish
SO  - Rural Remote Health. 2013;13:2302. Epub 2013 Apr 25.

PMID- 23614446
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 1089-7690 (Electronic)
IS  - 0021-9606 (Linking)
VI  - 138
IP  - 15
DP  - 2013 Apr 21
TI  - alpha-helix to beta-hairpin transition of human amylin monomer.
PG  - 155101
LID - 10.1063/1.4798460 [doi]
AB  - The human islet amylin polypeptide is produced along with insulin by pancreatic
      islets. Under some circumstances, amylin can aggregate to form amyloid fibrils,
      whose presence in pancreatic cells is a common pathological feature of Type II
      diabetes. A growing body of evidence indicates that small, early stage aggregates
      of amylin are cytotoxic. A better understanding of the early stages of the amylin
      aggregation process and, in particular, of the nucleation events leading to
      fibril growth could help identify therapeutic strategies. Recent studies have
      shown that, in dilute solution, human amylin can adopt an alpha-helical
      conformation, a beta-hairpin conformation, or an unstructured coil conformation. 
      While such states have comparable free energies, the beta-hairpin state exhibits 
      a large propensity towards aggregation. In this work, we present a detailed
      computational analysis of the folding pathways that arise between the various
      conformational states of human amylin in water. A free energy surface for amylin 
      in explicit water is first constructed by resorting to advanced sampling
      techniques. Extensive transition path sampling simulations are then employed to
      identify the preferred folding mechanisms between distinct minima on that
      surface. Our results reveal that the alpha-helical conformer of amylin undergoes 
      a transformation into the beta-hairpin monomer through one of two mechanisms. In 
      the first, misfolding begins through formation of specific contacts near the turn
      region, and proceeds via a zipping mechanism. In the second, misfolding occurs
      through an unstructured coil intermediate. The transition states for these
      processes are identified. Taken together, the findings presented in this work
      suggest that the inter-conversion of amylin between an alpha-helix and a
      beta-hairpin is an activated process and could constitute the nucleation event
      for fibril growth.
AD  - Department of Chemical and Biological Engineering, University of
      Wisconsin-Madison, Madison, Wisconsin 53706, USA.
FAU - Singh, Sadanand
AU  - Singh S
FAU - Chiu, Chi-cheng
AU  - Chiu CC
FAU - Reddy, Allam S
AU  - Reddy AS
FAU - de Pablo, Juan J
AU  - de Pablo JJ
LA  - eng
GR  - 1R01DK088184/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Chem Phys
JT  - The Journal of chemical physics
JID - 0375360
SB  - IM
PMC - PMC3643982
OID - NLM: PMC3643982 [Available on 04/21/14]
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PMCR- 2014/04/21 00:00
AID - 10.1063/1.4798460 [doi]
PST - ppublish
SO  - J Chem Phys. 2013 Apr 21;138(15):155101. doi: 10.1063/1.4798460.

PMID- 23614373
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1464-5165 (Electronic)
IS  - 0963-8288 (Linking)
DP  - 2013 Apr 25
TI  - Risk of fall for people with diabetes.
AB  - Abstract Purpose: To examine the risk of fall for people with diabetes compared
      with healthy control subjects. Correlation between tactile sensation and postural
      control was examined for subjects with diabetes. Methods: Subjects with type 2
      diabetes were classified into two groups: (i) diabetes without neuropathy (n =
      23) and (ii) diabetic peripheral neuropathy (DPN) (n = 9). Age-matched healthy
      control subjects (n = 32) were recruited. Tactile sensation, equilibrium scores
      (ES), strategy scores and sensory analysis scores from the Sensory Organization
      Test (SOT) were compared among the groups. Results: Subjects with diabetes
      without neuropathy demonstrated impaired postural control upon the disruption of 
      somatosensory inputs. Subjects with DPN lost balance upon being deprived of
      visual inputs. A decrease in tactile sensation was associated with a decrease in 
      the ESs in all subjects with diabetes (r = -0.35 to -0.77; p < 0.05), and they
      tend to use more hip strategy for postural control upon being deprived of visual 
      inputs. Conclusions: Different postural control strategies are adopted by various
      subgroups of subjects with diabetes. Subjects with DPN demonstrated a significant
      shift from ankle to hip strategies for balance tests when vision was deprived.
      Implications for Rehabilitation The severity of diabetic peripheral neuropathy
      (DPN) is associated with the risk of fall. Different compensatory strategies in
      balance control have been adopted by different subgroups of people with diabetes.
      In order to minimize the risk of fall, specific balance training program should
      be offered to different subgroups of people with diabetes. The balance training
      should emphasize on optimizing the competence of their existing compensatory
      postural control strategies.
AD  - Department of Rehabilitation Sciences, The Hong Kong Polytechnic University ,
      Hong Kong SAR .
FAU - Chau, Rosanna M W
AU  - Chau RM
FAU - Ng, Thomas K W
AU  - Ng TK
FAU - Kwan, Rachel L C
AU  - Kwan RL
FAU - Choi, Cheung-Hei
AU  - Choi CH
FAU - Cheing, Gladys L Y
AU  - Cheing GL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130425
TA  - Disabil Rehabil
JT  - Disability and rehabilitation
JID - 9207179
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
AID - 10.3109/09638288.2013.770079 [doi]
PST - aheadofprint
SO  - Disabil Rehabil. 2013 Apr 25.

PMID- 23614367
OWN - NLM
STAT- Publisher
DA  - 20130425
IS  - 1365-2826 (Electronic)
IS  - 0953-8194 (Linking)
DP  - 2013 Apr 24
TI  - Grb10-mediated Negative Regulation of IGF1R-Activated Signalling Pathway Results 
      in Cognitive Disorder in Diabetic Rats.
LID - 10.1111/jne.12040 [doi]
AB  - Growth factor receptor-bound protein 10(Grb10)is a Src homology 2 (SH2)
      domain-containing protein and one of the binding partners for several
      trans-membrane tyrosine-kinase receptors, including insulin receptor (IR) and
      insulin-like growth factor-1 receptor (IGF1-R). The hippocampus, which is
      critical for cognitive functions, is one of the main distribution areas of Grb10 
      in the central nervous system. In recent years, diabetic encephalopathy has been 
      defined as a third type of diabetes and the IGF1-IR pathway has been shown to be 
      critical for the neuropathogenic process of cognitive disorder in diabetes.
      However, the role of endogenous Grb10 in regulating the IGF1-IR pathway and
      neurobehavioral changes is not explicit. The objective of this study was to
      determine the in vivo function of endogenous Grb10 in diabetic encephalopathy and
      the underlying mechanisms. Using stereotaxic surgical techniques and lentiviral
      vectors expressing specific short hairpin RNA (shRNA), we could steadily knock
      down Grb10 expression in the hippocampus. More importantly, we demonstrated that 
      hippocampus-specific modulation of Grb10 protein levels led to a prominent
      remission of cognitive disorder, including improvements in both ultrastructural
      pathology and abnormal neurobehavioural changes. Our findings indicate that
      endogenous overexpression of Grb10 functions as a suppressor of the IGF1-IR
      pathway, which may represent an important mechanism that regulates cognitive
      disorder in diabetes. This article is protected by copyright. All rights
      reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Gerontology, The First Affiliated Hospital of Chongqing Medical
      University, Youyi Road, No.1, Chongqing, 400042, China.
FAU - Ma, Lingli
AU  - Ma L
FAU - Wei, Qianping
AU  - Wei Q
FAU - Deng, Huacong
AU  - Deng H
FAU - Zhang, Qunzhou
AU  - Zhang Q
FAU - Li, Gang
AU  - Li G
FAU - Tang, Ni
AU  - Tang N
FAU - Xie, Jing
AU  - Xie J
FAU - Chen, Yanyu
AU  - Chen Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PHST- 2012/11/04 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/04/20 [accepted]
AID - 10.1111/jne.12040 [doi]
PST - aheadofprint
SO  - J Neuroendocrinol. 2013 Apr 24. doi: 10.1111/jne.12040.

PMID- 23614222
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Unintended consequences. When good management efforts go wrong.
PG  - 50-3
AD  - University of New Mexico School of Medicine, USA.
FAU - Dubois, Wil
AU  - Dubois W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):50-3.

PMID- 23614221
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Supermarket smarts. Energy bars.
PG  - 44, 46-9
FAU - Holzmeister, Lea Ann
AU  - Holzmeister LA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):44, 46-9.

PMID- 23614220
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Recipe makeovers. Homemade granola bars.
PG  - 42-3
FAU - Bjerkness, Sandy
AU  - Bjerkness S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):42-3.

PMID- 23614219
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Living gluten-free.
PG  - 40-1
FAU - Cooper, Alwa
AU  - Cooper A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):40-1.

PMID- 23614218
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Insulin resistance. What it is and why it matters.
PG  - 29-30, 32
AD  - Yavapai Regional Medical Center, Prescott, Arizona, USA.
FAU - Rubin, Rita Carey
AU  - Rubin RC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):29-30, 32.

PMID- 23614217
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Diabetes quiz. How much do you know about irritable bowel syndrome?
PG  - 25-6
AD  - Clinical Education Programs, Joslin Diabetes Center, Boston, Massachusetts, USA.
FAU - Campbell, Amy
AU  - Campbell A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):25-6.

PMID- 23614216
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Cooking 101. Easy lunches.
PG  - 21-4
AD  - Central Baptist Hospital, Lexington, Kentucky, USA.
FAU - Stanley, Kathleen
AU  - Stanley K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):21-4.

PMID- 23614215
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Staying active as a family.
PG  - 16, 18-20
AD  - Amylin Pharmaceuticals, LLC., Lexington Kentucky, USA.
FAU - Hieronymus, Laura
AU  - Hieronymus L
FAU - Hieronymus, Lindsay
AU  - Hieronymus L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):16, 18-20.

PMID- 23614214
OWN - NLM
STAT- In-Process
DA  - 20130425
IS  - 0741-6253 (Print)
IS  - 0741-6253 (Linking)
VI  - 30
IP  - 2
DP  - 2013 Mar-Apr
TI  - Preventing falls.
PG  - 10-2, 14
AD  - University of Texas at El Paso, USA. emilyh@utep.edu
FAU - Haltiwanger, Emily Piven
AU  - Haltiwanger EP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Self Manag
JT  - Diabetes self-management
JID - 9883682
SB  - K
EDAT- 2013/04/26 06:00
MHDA- 2013/04/26 06:00
CRDT- 2013/04/26 06:00
PST - ppublish
SO  - Diabetes Self Manag. 2013 Mar-Apr;30(2):10-2, 14.

PMID- 23600920
OWN - NLM
STAT- MEDLINE
DA  - 20130422
DCOM- 20130426
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 30 Suppl 1
DP  - 2013 Mar
TI  - Abstracts of the Diabetes UK Professional Conference 2013. Manchester, United
      Kingdom. March 13-15, 2013.
PG  - 1-213, E1-10
LID - 10.1111/dme.12090_1 [doi]
LA  - eng
PT  - Congresses
PT  - Overall
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
SB  - IM
MH  - Animals
MH  - *Diabetes Mellitus
MH  - Humans
EDAT- 2013/04/26 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/04/23 06:00
AID - 10.1111/dme.12090_1 [doi]
PST - ppublish
SO  - Diabet Med. 2013 Mar;30 Suppl 1:1-213, E1-10. doi: 10.1111/dme.12090_1.

PMID- 23614095
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130424
DCOM- 20130425
LR  - 20130426
IS  - 2233-601X (Print)
IS  - 2233-601X (Linking)
VI  - 46
IP  - 2
DP  - 2013 Apr
TI  - Long term outcomes of aortic root replacement: 18 years' experience.
PG  - 104-10
LID - 10.5090/kjtcs.2013.46.2.104 [doi]
AB  - BACKGROUND: We reviewed the long-term outcomes of aortic root replacement at Asan
      Medical Center and investigated the predictors affecting mortality. MATERIALS AND
      METHODS: A retrospective analysis was performed on 225 consecutive adult patients
      undergoing aortic root replacement with mechanical conduits (n=169), porcine
      aortic root prosthesis (n=23), or aortic homografts (n=33) from January 1992 to
      September 2009. The median follow-up duration was 6.1 years (range, 0 to 18.0
      years). RESULTS: The porcine root group was older than the other groups
      (freestyle 55.9+/-14.3 years vs. mechanical 46.3+/-14.6 years, homograft
      48.1+/-14.7 years; p=0.02). The mechanical group had the highest incidence of the
      Marfan syndrome (mechanical 22%, freestyle 4%, homograft 3%; p=0.01). Surgery
      performed for infective endocarditis was more frequent in the homograft group
      (mechanical 10%, freestyle 10%, homograft 40%; p<0.001). The overall 30-day
      mortality was 5.3% (12/225). Actuarial survival rates in the mechanical, porcine 
      root, and homograft groups were 79.4%, 81.5%, and 83.5% at 5 years and 67%,
      61.9%, and 61.1% at 10 years, respectively (p=0.73). By multivariate analysis,
      preoperative diabetes mellitus, older age, and longer cardiopulmonary bypass time
      were independent predictors of mortality. Incidence of postoperative
      complications, including infective endocarditis and thromboembolism were
      comparable in all of the groups. CONCLUSION: Aortic root replacement can be
      safely performed with different types of prostheses as the outcome was not
      affected by the choice of prosthesis. Further studies are required to assess the 
      long-term durability of biological prostheses.
AD  - Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
      University of Ulsan College of Medicine, Korea.
FAU - Bang, Ji Hyun
AU  - Bang JH
FAU - Im, Yu-Mi
AU  - Im YM
FAU - Kim, Joon Bum
AU  - Kim JB
FAU - Choo, Suk Jung
AU  - Choo SJ
FAU - Chung, Cheol Hyun
AU  - Chung CH
FAU - Lee, Jae Won
AU  - Lee JW
FAU - Jung, Sung-Ho
AU  - Jung SH
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - Korea (South)
TA  - Korean J Thorac Cardiovasc Surg
JT  - The Korean journal of thoracic and cardiovascular surgery
JID - 101563922
PMC - PMC3631783
OID - NLM: PMC3631783
OTO - NOTNLM
OT  - Aorta, surgery
OT  - Aortic valve, surgery
OT  - Follow-up studies
OT  - Heart valve prosthesis
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:01
CRDT- 2013/04/25 06:00
PHST- 2012/08/07 [received]
PHST- 2012/10/17 [revised]
PHST- 2012/10/18 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.5090/kjtcs.2013.46.2.104 [doi]
PST - ppublish
SO  - Korean J Thorac Cardiovasc Surg. 2013 Apr;46(2):104-10. doi:
      10.5090/kjtcs.2013.46.2.104. Epub 2013 Apr 9.

PMID- 23614016
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Deletion of aldose reductase from mice inhibits diabetes-induced retinal
      capillary degeneration and superoxide generation.
PG  - e62081
LID - 10.1371/journal.pone.0062081 [doi]
AB  - PURPOSE: Pharmacologic inhibition of aldose reductase (AR) previously has been
      studied with respect to diabetic retinopathy with mixed results. Since drugs can 
      have off-target effects, we studied the effects of AR deletion on the development
      and molecular abnormalities that contribute to diabetic retinopathy. Since recent
      data suggests an important role for leukocytes in the development of the
      retinopathy, we determined also if AR in leukocytes contributes to
      leukocyte-mediated death of retinal endothelial cells in diabetes. METHODS:
      Wild-type (WT; C57BL/6J) and AR deficient (AR(-/-)) mice were made diabetic with 
      streptozotocin. Mice were sacrificed at 2 and 10 months of diabetes to evaluate
      retinal vascular histopathology, to quantify retinal superoxide production and
      biochemical and physiological abnormalities in the retina, and to assess the
      number of retinal endothelial cells killed by blood leukocytes in a co-culture
      system. RESULTS: Diabetes in WT mice developed the expected degeneration of
      retinal capillaries, and increased generation of superoxide by the retina.
      Leukocytes from diabetic WT mice also killed more retinal endothelial cells than 
      did leukocytes from nondiabetic animals (p<0.0001). Deletion of AR largely
      (P<0.05) inhibited the diabetes-induced degeneration of retinal capillaries, as
      well as the increase in superoxide production by retina. AR-deficiency
      significantly inhibited the diabetes-induced increase in expression of inducible 
      nitric oxide synthase (iNOS) in retina, but had no significant effect on
      expression of intercellular adhesion molecule-1 (ICAM-1), phosphorylated p38
      MAPK, or killing of retinal endothelial cells by leukocytes. CONCLUSIONS: AR
      contributes to the degeneration of retinal capillaries in diabetic mice. Deletion
      of the enzyme inhibits the diabetes-induced increase in expression of iNOS and of
      superoxide production, but does not correct a variety of other pro-inflammatory
      abnormalities associated with the development of diabetic retinopathy.
AD  - Department of Medicine, Case Western Reserve University, Cleveland, Ohio, United 
      States of America. .
FAU - Tang, Jie
AU  - Tang J
FAU - Du, Yunpeng
AU  - Du Y
FAU - Petrash, J Mark
AU  - Petrash JM
FAU - Sheibani, Nader
AU  - Sheibani N
FAU - Kern, Timothy S
AU  - Kern TS
LA  - eng
GR  - EY00300/EY/NEI NIH HHS/United States
GR  - P30EY11373/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130416
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3628579
OID - NLM: PMC3628579
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/02 [received]
PHST- 2013/03/16 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.1371/journal.pone.0062081 [doi]
AID - PONE-D-13-00963 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 16;8(4):e62081. doi: 10.1371/journal.pone.0062081. Print 2013.

PMID- 23613946
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Co-culture of neural crest stem cells (NCSC) and insulin producing beta-TC6 cells
      results in cadherin junctions and protection against cytokine-induced beta-cell
      death.
PG  - e61828
LID - 10.1371/journal.pone.0061828 [doi]
AB  - PURPOSE: Transplantation of pancreatic islets to Type 1 diabetes patients is
      hampered by inflammatory reactions at the transplantation site leading to
      dysfunction and death of insulin producing beta-cells. Recently we have shown
      that co-transplantation of neural crest stem cells (NCSCs) together with the
      islet cells improves transplantation outcome. The aim of the present
      investigation was to describe in vitro interactions between NCSCs and insulin
      producing beta-TC6 cells that may mediate protection against cytokine-induced
      beta-cell death. PROCEDURES: Beta-TC6 and NCSC cells were cultured either alone
      or together, and either with or without cell culture inserts. The cultures were
      then exposed to the pro-inflammatory cytokines IL-1beta and IFN-gamma for 48
      hours followed by analysis of cell death rates (flow cytometry), nitrite
      production (Griess reagent), protein localization (immunofluorescence) and
      protein phosphorylation (flow cytometry). RESULTS: We observed that beta-TC6
      cells co-cultured with NCSCs were protected against cytokine-induced cell death, 
      but not when separated by cell culture inserts. This occurred in parallel with
      (i) augmented production of nitrite from beta-TC6 cells, indicating that
      increased cell survival allows a sustained production of nitric oxide; (ii)
      NCSC-derived laminin production; (iii) decreased phospho-FAK staining in beta-TC6
      cell focal adhesions, and (iv) decreased beta-TC6 cell phosphorylation of
      ERK(T202/Y204), FAK(Y397) and FAK(Y576). Furthermore, co-culture also resulted in
      cadherin and beta-catenin accumulations at the NCSC/beta-TC6 cell junctions.
      Finally, the gap junction inhibitor carbenoxolone did not affect cytokine-induced
      beta-cell death during co-culture with NCSCs. CONCLUSION: In summary, direct
      contacts, but not soluble factors, promote improved beta-TC6 viability when
      co-cultured with NCSCs. We hypothesize that cadherin junctions between NCSC and
      beta-TC6 cells promote powerful signals that maintain beta-cell survival even
      though ERK and FAK signaling are suppressed. It may be that future strategies to 
      improve islet transplantation outcome may benefit from attempts to increase
      beta-cell cadherin junctions to neighboring cells.
AD  - Department of Neuroscience, Uppsala University, Uppsala, Sweden.
FAU - Ngamjariyawat, Anongnad
AU  - Ngamjariyawat A
FAU - Turpaev, Kyril
AU  - Turpaev K
FAU - Vasylovska, Svitlana
AU  - Vasylovska S
FAU - Kozlova, Elena N
AU  - Kozlova EN
FAU - Welsh, Nils
AU  - Welsh N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130417
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3629122
OID - NLM: PMC3629122
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/18 [received]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/17 [epublish]
AID - 10.1371/journal.pone.0061828 [doi]
AID - PONE-D-12-31771 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 17;8(4):e61828. doi: 10.1371/journal.pone.0061828. Print 2013.

PMID- 23613929
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Is serum zinc level associated with prediabetes and diabetes?: a cross-sectional 
      study from Bangladesh.
PG  - e61776
LID - 10.1371/journal.pone.0061776 [doi]
AB  - AIMS: To determine serum zinc level and other relevant biological markers in
      normal, prediabetic and diabetic individuals and their association with
      Homeostasis Model Assessment (HOMA) parameters. METHODS: This cross-sectional
      study was conducted between March and December 2009. Any patient aged >/= 30
      years attending the medicine outpatient department of a medical university
      hospital in Dhaka, Bangladesh and who had a blood glucose level ordered by a
      physician was eligible to participate. RESULTS: A total of 280 participants were 
      analysed. On fasting blood sugar results, 51% were normal, 13% had prediabetes
      and 36% had diabetes. Mean serum zinc level was lowest in prediabetic compared to
      normal and diabetic participants (mean differences were approximately 65 ppb/L
      and 33 ppb/L, respectively). In multiple linear regression, serum zinc level was 
      found to be significantly lower in prediabetes than in those with normoglycemia. 
      Beta cell function was significantly lower in prediabetes than normal
      participants. Adjusted linear regression for HOMA parameters did not show a
      statistically significant association between serum zinc level, beta cell
      function (P = 0.07) and insulin resistance (P = 0.08). Low serum zinc accentuated
      the increase in insulin resistance seen with increasing BMI. CONCLUSION:
      Participants with prediabetes have lower zinc levels than controls and zinc is
      significantly associated with beta cell function and insulin resistance. Further 
      longitudinal population based studies are warranted and controlled trials would
      be valuable for establishing whether zinc supplementation in prediabetes could be
      a useful strategy in preventing progression to Type 2 diabetes.
AD  - Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public
      Health, The University of Newcastle, New Lambton Heights, New South Wales,
      Australia.
FAU - Islam, Md Rafiqul
AU  - Islam MR
FAU - Arslan, Iqbal
AU  - Arslan I
FAU - Attia, John
AU  - Attia J
FAU - McEvoy, Mark
AU  - McEvoy M
FAU - McElduff, Patrick
AU  - McElduff P
FAU - Basher, Ariful
AU  - Basher A
FAU - Rahman, Waliur
AU  - Rahman W
FAU - Peel, Roseanne
AU  - Peel R
FAU - Akhter, Ayesha
AU  - Akhter A
FAU - Akter, Shahnaz
AU  - Akter S
FAU - Vashum, Khanrin P
AU  - Vashum KP
FAU - Milton, Abul Hasnat
AU  - Milton AH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130417
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3629219
OID - NLM: PMC3629219
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/04 [received]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/17 [epublish]
AID - 10.1371/journal.pone.0061776 [doi]
AID - PONE-D-12-38086 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 17;8(4):e61776. doi: 10.1371/journal.pone.0061776. Print 2013.

PMID- 23613879
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Association between myocardial triglyceride content and cardiac function in
      healthy subjects and endurance athletes.
PG  - e61604
LID - 10.1371/journal.pone.0061604 [doi]
AB  - Ectopic fat accumulation plays important roles in various metabolic disorders and
      cardiovascular diseases. Recent studies reported that myocardial triglyceride
      (TG) content measured by proton magnetic resonance spectroscopy ((1)H-MRS) is
      associated with aging, diabetes mellitus, and cardiac dysfunction. However,
      myocardial TG content in athletes has not yet been investigated. We performed
      (1)H-MRS and cardiac magnetic resonance imaging in 10 male endurance athletes and
      15 healthy male controls. Serum markers and other clinical parameters including
      arterial stiffness were measured. Cardiopulmonary exercise testing was also
      performed. There were no significant differences in clinical characteristics
      including age, anthropometric parameters, blood test results, or arterial
      stiffness between the two groups. Peak oxygen uptakes, end-diastolic volume
      (EDV), end-systolic volume (ESV), left ventricular (LV) mass, peak ejection rates
      and peak filling rates were significantly higher in the athlete group than in the
      control group (all P<0.02). Myocardial TG content was significantly lower in the 
      athlete group than in the control group (0.60 +/- 0.20 vs. 0.89 +/- 0.41%,
      P<0.05). Myocardial TG content was negatively correlated with EDV (r = -0.47),
      ESV (r = -0.64), LV mass (r = -0.44), and epicardial fat volume (r = 0.47) (all
      P<0.05). In conclusion, lower levels of myocardial TG content were observed in
      endurance athletes and were associated with morphological changes related to
      physiological LV alteration in athletes, suggesting that metabolic imaging for
      measurement of myocardial TG content by (1)H-MRS may be a useful technique for
      noninvasively assessing the "athlete's heart".
AD  - Department of Cardiology, Juntendo University Graduate School of Medicine, Tokyo,
      Japan.
FAU - Sai, Eiryu
AU  - Sai E
FAU - Shimada, Kazunori
AU  - Shimada K
FAU - Yokoyama, Takayuki
AU  - Yokoyama T
FAU - Sato, Shuji
AU  - Sato S
FAU - Miyazaki, Tetsuro
AU  - Miyazaki T
FAU - Hiki, Makoto
AU  - Hiki M
FAU - Tamura, Yoshifumi
AU  - Tamura Y
FAU - Aoki, Shigeki
AU  - Aoki S
FAU - Watada, Hirotaka
AU  - Watada H
FAU - Kawamori, Ryuzo
AU  - Kawamori R
FAU - Daida, Hiroyuki
AU  - Daida H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130416
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3628784
OID - NLM: PMC3628784
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/20 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.1371/journal.pone.0061604 [doi]
AID - PONE-D-12-32550 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 16;8(4):e61604. doi: 10.1371/journal.pone.0061604. Print 2013.

PMID- 23613868
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Investigation of the effect of type 2 diabetes mellitus on subgingival plaque
      microbiota by high-throughput 16S rDNA pyrosequencing.
PG  - e61516
LID - 10.1371/journal.pone.0061516 [doi]
AB  - Diabetes mellitus is a major risk factor for chronic periodontitis. We
      investigated the effects of type 2 diabetes on the subgingival plaque bacterial
      composition by applying culture-independent 16S rDNA sequencing to periodontal
      bacteria isolated from four groups of volunteers: non-diabetic subjects without
      periodontitis, non-diabetic subjects with periodontitis, type 2 diabetic patients
      without periodontitis, and type 2 diabetic patients with periodontitis. A total
      of 71,373 high-quality sequences were produced from the V1-V3 region of 16S rDNA 
      genes by 454 pyrosequencing. Those 16S rDNA sequences were classified into 16
      phyla, 27 classes, 48 orders, 85 families, 126 genera, and 1141 species-level
      OTUs. Comparing periodontally healthy samples with periodontitis samples
      identified 20 health-associated and 15 periodontitis-associated OTUs. In the
      subjects with healthy periodontium, the abundances of three genera (Prevotella,
      Pseudomonas, and Tannerella) and nine OTUs were significantly different between
      diabetic patients and their non-diabetic counterparts. In the subjects carrying
      periodontitis, the abundances of three phyla (Actinobacteria, Proteobacteria, and
      Bacteriodetes), two genera (Actinomyces and Aggregatibacter), and six OTUs were
      also significantly different between diabetics and non-diabetics. Our results
      show that type 2 diabetes mellitus could alter the bacterial composition in the
      subgingival plaque.
AD  - State Key Laboratory Breeding Base of Basic Science of Stomatology, Key
      Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of
      Stomatology, Wuhan University, Wuhan, Hubei, China.
FAU - Zhou, Mi
AU  - Zhou M
FAU - Rong, Ruichen
AU  - Rong R
FAU - Munro, Daniel
AU  - Munro D
FAU - Zhu, Chunxia
AU  - Zhu C
FAU - Gao, Xiang
AU  - Gao X
FAU - Zhang, Qi
AU  - Zhang Q
FAU - Dong, Qunfeng
AU  - Dong Q
LA  - eng
GR  - Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130422
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3632544
OID - NLM: PMC3632544
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/17 [received]
PHST- 2013/03/10 [accepted]
PHST- 2013/04/22 [epublish]
AID - 10.1371/journal.pone.0061516 [doi]
AID - PONE-D-12-39844 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 22;8(4):e61516. doi: 10.1371/journal.pone.0061516. Print 2013.

PMID- 23613833
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Temporal trends of HLA, CTLA-4 and PTPN22 genotype frequencies among type 1
      diabetes in Continental Italy.
PG  - e61331
LID - 10.1371/journal.pone.0061331 [doi]
AB  - The incidence of type 1 diabetes has, progressively, increased worldwide over the
      last decades and also in Continental Italian population. Previous studies
      performed in northern European countries, showed, alongside a general increase in
      the disease incidence, a decreasing frequency of the highest risk HLA genotype in
      type 1 diabetes populations, thus emphasizing the role of environmental factors. 
      The aim of the study was to evaluate whether a decreasing trend of high risk HLA,
      CTLA-4 and PTPN22 genotypes would be present in type 1 diabetes subjects of
      Continental Italy, a country considered at low incidence of the disease compared 
      to northern European populations. N = 765 type 1 diabetes patients diagnosed from
      1980 to 2012 in Lazio region were included. For HLA, CTLA4 and PTPN22 temporal
      trend evaluation, subjects were subdivided into groups of years according to age 
      at diagnosis. All subjects were typed for HLA-DRB1 and DQB1 by a reverse line
      blot. The CT60 polymorphism of the CTLA4 and C1858T of the PTPN22 gene were
      genotyped using ABI PRISM 7900HT (n = 419 and n = 364 respectively). HLA
      genotypes were divided in high, moderate and low risk categories. The proportion 
      of the HLA risk categories was not statistically different over the three decades
      in subjects with age of onset <15 years and >/= 15 years. The genotype
      distribution of CT60 polymorphism of CTLA4 gene did not show any change in the
      frequencies during time. The analysis of the PTPN22 C1858T variant revealed,
      instead, that the frequency of CT+TT susceptibility genotypes decreased during
      time (23.9% vs 13.6%, p = 0.017). We can hypothesize that the pressure of the
      diabetogenic environment could be milder and therefore not sufficient to reduce
      the need of a strong genetic background (HLA) "to precipitate" diabetes; the
      increased pressure of the environment could have, instead, some effects on minor 
      susceptibility genes in our population.
AD  - Department of Experimental Medicine, University of Rome Sapienza, Rome, Italy.
FAU - Spoletini, Marialuisa
AU  - Spoletini M
FAU - Zampetti, Simona
AU  - Zampetti S
FAU - Campagna, Giuseppe
AU  - Campagna G
FAU - Marandola, Lidia
AU  - Marandola L
FAU - Capizzi, Marco
AU  - Capizzi M
FAU - Buzzetti, Raffaella
AU  - Buzzetti R
CN  - IMDIAB Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130417
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3629148
OID - NLM: PMC3629148
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/24 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/17 [epublish]
AID - 10.1371/journal.pone.0061331 [doi]
AID - PONE-D-13-03734 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 17;8(4):e61331. doi: 10.1371/journal.pone.0061331. Print 2013.

PMID- 23613832
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Prospecting for novel plant-derived molecules of Rauvolfia serpentina as
      inhibitors of Aldose Reductase, a potent drug target for diabetes and its
      complications.
PG  - e61327
LID - 10.1371/journal.pone.0061327 [doi]
AB  - Aldose Reductase (AR) is implicated in the development of secondary complications
      of diabetes, providing an interesting target for therapeutic intervention.
      Extracts of Rauvolfia serpentina, a medicinal plant endemic to the Himalayan
      mountain range, have been known to be effective in alleviating diabetes and its
      complications. In this study, we aim to prospect for novel plant-derived
      inhibitors from R. serpentina and to understand structural basis of their
      interactions. An extensive library of R. serpentina molecules was compiled and
      computationally screened for inhibitory action against AR. The stability of
      complexes, with docked leads, was verified using molecular dynamics simulations. 
      Two structurally distinct plant-derived leads were identified as inhibitors:
      indobine and indobinine. Further, using these two leads as templates, 16 more
      leads were identified through ligand-based screening of their structural analogs,
      from a small molecules database. Thus, we obtained plant-derived indole
      alkaloids, and their structural analogs, as potential AR inhibitors from a
      manually curated dataset of R. serpentina molecules. Indole alkaloids reported
      herein, as a novel structural class unreported hitherto, may provide better
      insights for designing potential AR inhibitors with improved efficacy and fewer
      side effects.
AD  - Biotechnology Division, Institute of Himalayan Bioresource Technology, Council of
      Scientific and Industrial Research, Palampur, Himachal Pradesh, India.
FAU - Pathania, Shivalika
AU  - Pathania S
FAU - Randhawa, Vinay
AU  - Randhawa V
FAU - Bagler, Ganesh
AU  - Bagler G
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3629236
OID - NLM: PMC3629236
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/21 [received]
PHST- 2013/03/07 [accepted]
PHST- 2013/04/17 [epublish]
AID - 10.1371/journal.pone.0061327 [doi]
AID - PONE-D-12-36607 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 17;8(4):e61327. doi: 10.1371/journal.pone.0061327. Print 2013.

PMID- 23613782
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Determination of peripheral neuropathy prevalence and associated factors in
      Chinese subjects with diabetes and pre-diabetes - ShangHai Diabetic neuRopathy
      Epidemiology and Molecular Genetics Study (SH-DREAMS).
PG  - e61053
LID - 10.1371/journal.pone.0061053 [doi]
AB  - OBJECTIVE: This study determined the prevalence and factors associated with
      peripheral neuropathy (PN) in subjects with diabetes mellitus, impaired glucose
      regulation (IGR), and normal glucose tolerance (NGT) in a community-based Chinese
      population. RESEARCH DESIGN AND METHODS: A total of 2035 subjects in Shanghai
      were classified as having NGT, IGR, or diabetes. All subjects underwent complete 
      foot examination. PN was assessed according to the neuropathy symptom and
      neuropathy disability scores. Binary logistic regression was performed to analyze
      the contributions of factors to PN. RESULTS: The prevalence of PN was 8.4%, 2.8%,
      and 1.5% in diabetes mellitus, IGR, and NGT subjects, respectively (P<0.05 for
      diabetes vs. NGT, and IGR). The subjects with known diabetes had the highest
      frequency of PN (13.1%). Among the subjects without diabetes, those with PN were 
      older, had a higher waist circumference and 2-h postprandial plasma glucose
      levels, and were more likely to be hypertensive. Among the IGR subjects, other
      than age, the 2-h postprandial plasma glucose level was an independent factor
      significantly associated with PN. Meanwhile, among the subjects with diabetes, PN
      was associated with fasting plasma glucose, duration of diabetes, and decreased
      estimated glomerular filtration rate. CONCLUSIONS: The prevalence of PN is
      slightly higher in individuals with IGR than that in individuals with NGT, but
      small fibre damage in IGR as the earliest nerve fibre deficit may be
      underestimated in our study. As an independent risk factor, postprandial plasma
      glucose level may be an important target for strategies to prevent or improve PN 
      in IGR subjects.
AD  - Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Lu, Bin
AU  - Lu B
FAU - Hu, Ji
AU  - Hu J
FAU - Wen, Jian
AU  - Wen J
FAU - Zhang, Zhaoyun
AU  - Zhang Z
FAU - Zhou, Linuo
AU  - Zhou L
FAU - Li, Yiming
AU  - Li Y
FAU - Hu, Renming
AU  - Hu R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130416
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3628856
OID - NLM: PMC3628856
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/18 [received]
PHST- 2013/03/05 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.1371/journal.pone.0061053 [doi]
AID - PONE-D-13-03090 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 16;8(4):e61053. doi: 10.1371/journal.pone.0061053. Print 2013.

PMID- 23613691
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130424
DCOM- 20130425
LR  - 20130426
IS  - 1738-5520 (Print)
IS  - 1738-5520 (Linking)
VI  - 43
IP  - 3
DP  - 2013 Mar
TI  - Prevalence and prognostic implication of non-calcified plaque in asymptomatic
      population with coronary artery calcium score of zero.
PG  - 154-60
LID - 10.4070/kcj.2013.43.3.154 [doi]
AB  - BACKGROUND AND OBJECTIVES: Non-calcified plaque (NCP) identified by coronary CT
      angiography (CCTA) has been reported in up to 10% of individuals with coronary
      artery calcium score (CACS) of zero. However, clinical risk factors and the
      prognostic value of NCP in asymptomatic subjects with CACS of zero are unknown.
      SUBJECTS AND METHODS: The study population consisted of consecutive asymptomatic 
      subjects (48+/-8 years, 57% men) who underwent CCTA from December 2005 to January
      2008 as part of a general health evaluation. RESULTS: Among 4491 of overall
      asymptomatic individuals with CACS of zero, 313 subjects (7%) had NCP: 279
      patients (6%) with non-obstructive and 34 (1%) with obstructive. In multivariable
      analyses, age, male gender, diabetes, hypertension, and dyslipidemia were
      significantly associated with presence of NCP (all p<0.05). During the median
      follow-up duration of 22 months (interquartile percentile: 18 to 28 months) of
      subjects with NCP (n=313) and age, gender, and CCTA date matched individuals
      without NCP (n=313), there was no clinical event including all-cause death nor
      composite outcome of cardiac death, myocardial infarct, unstable angina requiring
      hospitalization, and revascularization after 90 days from index CCTA in both
      groups. CONCLUSION: In the largest series of asymptomatic individuals with CACS
      of zero undergoing CCTA, age, male gender, diabetes, hypertension, and
      dyslipidemia were independently associated with NCP. However, a future risk of
      exclusive NCP in asymptomatic subjects with CACS of zero was negligible.
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital,
      Seongnam, Korea.
FAU - Cho, Iksung
AU  - Cho I
FAU - Suh, Jung-Won
AU  - Suh JW
FAU - Chang, Hyuk-Jae
AU  - Chang HJ
FAU - Kim, Kwang-Il
AU  - Kim KI
FAU - Jeon, Eun Ju
AU  - Jeon EJ
FAU - Choi, Sang Il
AU  - Choi SI
FAU - Cho, Young-Seok
AU  - Cho YS
FAU - Youn, Tae-Jin
AU  - Youn TJ
FAU - Chae, In-Ho
AU  - Chae IH
FAU - Kim, Cheol-Ho
AU  - Kim CH
FAU - Choi, Dong-Ju
AU  - Choi DJ
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Korea (South)
TA  - Korean Circ J
JT  - Korean circulation journal
JID - 101247141
PMC - PMC3629240
OID - NLM: PMC3629240
OTO - NOTNLM
OT  - Atherosclerotic plaque
OT  - Calcium
OT  - Computed tomography
OT  - Coronary
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:01
CRDT- 2013/04/25 06:00
PHST- 2012/06/22 [received]
PHST- 2012/08/24 [revised]
PHST- 2012/11/13 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.4070/kcj.2013.43.3.154 [doi]
PST - ppublish
SO  - Korean Circ J. 2013 Mar;43(3):154-60. doi: 10.4070/kcj.2013.43.3.154. Epub 2013
      Mar 31.

PMID- 23613635
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 15
DP  - 2013 Apr 21
TI  - Increased international normalized ratio level in hepatocellular carcinoma
      patients with diabetes mellitus.
PG  - 2395-403
LID - 10.3748/wjg.v19.i15.2395 [doi]
AB  - AIM: To determine the association of diabetes mellitus (DM) and international
      normalized ratio (INR) level in hepatocellular carcinoma (HCC) patients. METHODS:
      Our present study included 375 HCC patients who were treated at the China-Japan
      Friendship Hospital, Ministry of Health (Beijing, China), in the period from
      January 2003 to April 2012, and with a hospital discharge diagnosis of HCC. The
      demographic, clinical, laboratory, metabolic and instrumental features were
      analyzed. chi(2) test, Student's t test and Mann-Whitney U test were used to
      compare the differences between HCC patients with and without DM. Unconditional
      multivariable logistic regression analysis was used to determine the association 
      of DM and INR level in HCC patients. A sub-group analysis was performed to assess
      the effect of liver cirrhosis or hepatitis B virus (HBV) infection on the
      results. The Pearson correlation test was used to determine the relationship
      between INR level and fasting glucose. In addition, association between diabetes 
      duration, and diabetes treatment and INR level was determined considering the
      potentially different effects. RESULTS: Of the total, 63 (16.8%) patients were
      diabetic (diabetic group) and 312 (83.2%) patients were diagnosed without
      diabetes (non-diabetic group). Their mean age was 56.4 +/- 11.0 years and 312
      (83.2%) patients were male. Compared with patients without DM, the HCC patients
      with diabetes were older (59.5 +/- 10.3 vs 55.8 +/- 11.1, P = 0.015), had a lower
      incidence of HBV infection (79.4% vs 89.1%, P = 0.033), had increased levels of
      systolic blood pressure (SBP) (133 +/- 17 vs 129 +/- 16 mmHg, P = 0.048) and INR 
      (1.31 +/- 0.44 vs 1.18 +/- 0.21, P = 0.001), had lower values of hemoglobin
      (124.4 +/- 23.9 vs 134.2 +/- 23.4, P = 0.003) and had a platelet count
      (median/interquartile-range: 113/64-157 vs 139/89-192, P = 0.020). There was no
      statistically significant difference in the percentages of males, overweight or
      obesity, drinking, smoking, cirrhosis and Child classification. After controlling
      for the confounding effects of age, systolic blood pressure, hemoglobin, platelet
      count and HBV infection by logistic analyses, INR was shown as an independent
      variable [odds ratio (OR) = 3.650; 95%CI: 1.372-9.714, P = 0.010]. Considering
      the effect of liver cirrhosis on results, a sub-group analysis was performed and 
      the study population was restricted to those patients with cirrhosis. Univariate 
      analysis showed that diabetic patients had a higher INR than non-diabetic
      patients (1.43 +/- 0.51 vs 1.25 +/- 0.23, P = 0.041). After controlling for
      confounding effect of age, SBP, hemoglobin, platelet count and HBV infection by
      logistic analyses, INR level remained as the sole independent variable (OR =
      5.161; 95%CI: 1.618-16.455, P = 0.006). No significant difference in the
      relationship between INR level and fasting glucose was shown by Pearson test (r =
      0.070, P = 0.184). Among the 63 diabetic patients, 35 (55.6%) patients had been
      diagnosed with DM for more than 5 years, 23 (36.5%) received oral anti-diabetic
      regimens, 11 (17.5%) received insulin, and 30 (47.6%) reported relying on diet
      alone to control serum glucose levels. No significant differences were found for 
      the association between DM duration/treatment and INR level, except for the age
      at diabetes diagnosis. CONCLUSION: The INR level was increased in HCC patients
      with DM and these patients should be monitored for the coagulation function in
      clinical practice.
AD  - Department of Gastroenterology, China-Japan Friendship Hospital, Ministry of
      Health, Beijing 100029, China.
FAU - Zhang, Hui
AU  - Zhang H
FAU - Gao, Chun
AU  - Gao C
FAU - Fang, Long
AU  - Fang L
FAU - Yao, Shu-Kun
AU  - Yao SK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - World J Gastroenterol
JT  - World journal of gastroenterology : WJG
JID - 100883448
SB  - IM
PMC - PMC3631993
OID - NLM: PMC3631993
OTO - NOTNLM
OT  - Chinese patients
OT  - Coagulation function
OT  - Diabetes mellitus
OT  - Hepatocellular carcinoma
OT  - International normalized ratio
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/12/24 [received]
PHST- 2013/01/11 [revised]
PHST- 2013/02/08 [accepted]
AID - 10.3748/wjg.v19.i15.2395 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 Apr 21;19(15):2395-403. doi:
      10.3748/wjg.v19.i15.2395.

PMID- 23613622
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 15
DP  - 2013 Apr 21
TI  - Dipeptidyl peptidase-4: a key player in chronic liver disease.
PG  - 2298-306
LID - 10.3748/wjg.v19.i15.2298 [doi]
AB  - Dipeptidyl peptidase-4 (DPP-4) is a membrane-associated peptidase, also known as 
      CD26. DPP-4 has widespread organ distribution throughout the body and exerts
      pleiotropic effects via its peptidase activity. A representative target peptide
      is glucagon-like peptide-1, and inactivation of glucagon-like peptide-1 results
      in the development of glucose intolerance/diabetes mellitus and hepatic
      steatosis. In addition to its peptidase activity, DPP-4 is known to be associated
      with immune stimulation, binding to and degradation of extracellular matrix,
      resistance to anti-cancer agents, and lipid accumulation. The liver expresses
      DPP-4 to a high degree, and recent accumulating data suggest that DPP-4 is
      involved in the development of various chronic liver diseases such as hepatitis C
      virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma.
      Furthermore, DPP-4 occurs in hepatic stem cells and plays a crucial role in
      hepatic regeneration. In this review, we described the tissue distribution and
      various biological effects of DPP-4. Then, we discussed the impact of DPP-4 in
      chronic liver disease and the possible therapeutic effects of a DPP-4 inhibitor.
AD  - Division of Gastroenterology, Department of Medicine, Kurume University School of
      Medicine, Kurume 830-0011, Japan.
FAU - Itou, Minoru
AU  - Itou M
FAU - Kawaguchi, Takumi
AU  - Kawaguchi T
FAU - Taniguchi, Eitaro
AU  - Taniguchi E
FAU - Sata, Michio
AU  - Sata M
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Gastroenterol
JT  - World journal of gastroenterology : WJG
JID - 100883448
SB  - IM
PMC - PMC3631980
OID - NLM: PMC3631980
OTO - NOTNLM
OT  - Alogliptin
OT  - Cancer
OT  - Incretin
OT  - Insulin resistance
OT  - Linagliptin
OT  - Sitagliptin
OT  - Steatohepatitis
OT  - Teneligliptin
OT  - Vildagliptin
OT  - Viral hepatitis
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/10/29 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/03/06 [accepted]
AID - 10.3748/wjg.v19.i15.2298 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 Apr 21;19(15):2298-306. doi:
      10.3748/wjg.v19.i15.2298.

PMID- 23613614
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Response to comment on: van Dijk et al. Exercise therapy in type 2 diabetes: is
      daily exercise required to optimize glycemic control? Diabetes Care
      2012;35:948-954.
PG  - e74
LID - 10.2337/dc12-2652 [doi]
FAU - van Dijk, Jan-Willem
AU  - van Dijk JW
FAU - van Loon, Luc J C
AU  - van Loon LJ
LA  - eng
PT  - Comment
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
CON - Diabetes Care. 2012 May;35(5):948-54. PMID: 22399700
CON - Diabetes Care. 2013 May;36(5):e73. PMID: 23613613
PMC - PMC3631841
OID - NLM: PMC3631841 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e74 [pii]
AID - 10.2337/dc12-2652 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e74. doi: 10.2337/dc12-2652.

PMID- 23613613
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Comment on: van Dijk et al. Exercise therapy in type 2 diabetes: is daily
      exercise required to optimize glycemic control? Diabetes Care 2012;35:948-954.
PG  - e73
LID - 10.2337/dc12-0879 [doi]
FAU - Thosar, Saurabh S
AU  - Thosar SS
FAU - Wallace, Janet P
AU  - Wallace JP
LA  - eng
PT  - Comment
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
CON - Diabetes Care. 2012 May;35(5):948-54. PMID: 22399700
CIN - Diabetes Care. 2013 May;36(5):e74. PMID: 23613614
PMC - PMC3631830
OID - NLM: PMC3631830 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e73 [pii]
AID - 10.2337/dc12-0879 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e73. doi: 10.2337/dc12-0879.

PMID- 23613612
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Response to comment on: Davidson et al. High-dose vitamin D supplementation in
      people with prediabetes and hypovitaminosis D. Diabetes Care 2013;36:260-266.
PG  - e72
LID - 10.2337/dc12-2225 [doi]
FAU - Davidson, Mayer B
AU  - Davidson MB
LA  - eng
PT  - Comment
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
CON - Diabetes Care. 2013 Feb;36(2):260-6. PMID: 23033239
CON - Diabetes Care. 2013 May;36(5):e71. PMID: 23613611
PMC - PMC3631822
OID - NLM: PMC3631822 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e72 [pii]
AID - 10.2337/dc12-2225 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e72. doi: 10.2337/dc12-2225.

PMID- 23613611
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Comment on: Davidson et al. High-dose vitamin D supplementation in people with
      prediabetes and hypovitaminosis D. Diabetes Care 2013;36:260-266.
PG  - e71
LID - 10.2337/dc12-2089 [doi]
FAU - Pilz, Stefan
AU  - Pilz S
FAU - Rutters, Femke
AU  - Rutters F
FAU - Dekker, Jacqueline M
AU  - Dekker JM
LA  - eng
PT  - Comment
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
CON - Diabetes Care. 2013 Feb;36(2):260-6. PMID: 23033239
CIN - Diabetes Care. 2013 May;36(5):e72. PMID: 23613612
PMC - PMC3631860
OID - NLM: PMC3631860 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e71 [pii]
AID - 10.2337/dc12-2089 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e71. doi: 10.2337/dc12-2089.

PMID- 23613610
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - The effect of the menstrual cycle on glucose control in women with type 1
      diabetes evaluated using a continuous glucose monitoring system.
PG  - e70
LID - 10.2337/dc12-2248 [doi]
FAU - Barata, Denise S
AU  - Barata DS
FAU - Adan, Luis F
AU  - Adan LF
FAU - Netto, Eduardo M
AU  - Netto EM
FAU - Ramalho, Ana Claudia
AU  - Ramalho AC
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631835
OID - NLM: PMC3631835 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - dc12-2248 [pii]
AID - 10.2337/dc12-2248 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e70. doi: 10.2337/dc12-2248.

PMID- 23613609
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Prevalence and associated factors of diabetic retinopathy in rural central India.
PG  - e69
LID - 10.2337/dc12-2377 [doi]
FAU - Jonas, Jost B
AU  - Jonas JB
FAU - Nangia, Vinay
AU  - Nangia V
FAU - Khare, Anshu
AU  - Khare A
FAU - Matin, Arshia
AU  - Matin A
FAU - Bhojwani, Krishna
AU  - Bhojwani K
FAU - Kulkarni, Maithili
AU  - Kulkarni M
FAU - Sinha, Ajit
AU  - Sinha A
FAU - Lambat, Sarang
AU  - Lambat S
FAU - Gupta, Rajesh
AU  - Gupta R
FAU - Panda-Jonas, Songhomitra
AU  - Panda-Jonas S
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631827
OID - NLM: PMC3631827 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e69 [pii]
AID - 10.2337/dc12-2377 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e69. doi: 10.2337/dc12-2377.

PMID- 23613608
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Fulminant type 1 diabetes in the course of Drug Reaction with Eosinophilia and
      Systemic Symptoms (DRESS) syndrome.
PG  - e68
LID - 10.2337/dc12-2107 [doi]
FAU - Dubois-Laforgue, Daniele
AU  - Dubois-Laforgue D
FAU - Moachon, Laurence
AU  - Moachon L
FAU - Laude, Helene
AU  - Laude H
FAU - Timsit, Jose
AU  - Timsit J
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631874
OID - NLM: PMC3631874 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e68 [pii]
AID - 10.2337/dc12-2107 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e68. doi: 10.2337/dc12-2107.

PMID- 23613607
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Association between fasting blood glucose and carotid intima-media thickness of
      polycystic ovary syndrome patients with normal glucose tolerance.
PG  - e66-7
LID - 10.2337/dc12-1924 [doi]
FAU - Son, Kuk Hui
AU  - Son KH
FAU - Lim, Nam Kyoo
AU  - Lim NK
FAU - Chung, Hye Won
AU  - Chung HW
FAU - Jeong, Kyungah
AU  - Jeong K
FAU - Pyun, Wook Bum
AU  - Pyun WB
FAU - Lee, Ji Young
AU  - Lee JY
FAU - Kim, Min Ju
AU  - Kim MJ
FAU - Park, Hyun-Young
AU  - Park HY
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631832
OID - NLM: PMC3631832 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e66 [pii]
AID - 10.2337/dc12-1924 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e66-7. doi: 10.2337/dc12-1924.

PMID- 23613606
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Case report: insulin edema and acute renal failure.
PG  - e65
LID - 10.2337/dc12-2137 [doi]
FAU - Laroche, Suzanne
AU  - Laroche S
FAU - Wucher, Helene
AU  - Wucher H
FAU - Nguyen, Yen-Lan
AU  - Nguyen YL
FAU - Timsit, Jose
AU  - Timsit J
FAU - Larger, Etienne
AU  - Larger E
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631854
OID - NLM: PMC3631854 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e65 [pii]
AID - 10.2337/dc12-2137 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e65. doi: 10.2337/dc12-2137.

PMID- 23613605
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Testing for gestational diabetes mellitus in Australia.
PG  - e64
LID - 10.2337/dc12-2345 [doi]
FAU - Nankervis, Alison
AU  - Nankervis A
FAU - McIntyre, Harold David
AU  - McIntyre HD
FAU - Moses, Robert G
AU  - Moses RG
FAU - Ross, Glynis P
AU  - Ross GP
FAU - Callaway, Leonie K
AU  - Callaway LK
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631863
OID - NLM: PMC3631863 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e64 [pii]
AID - 10.2337/dc12-2345 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e64. doi: 10.2337/dc12-2345.

PMID- 23613604
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Extended 6-month follow-up of a randomized clinical trial to assess the efficacy 
      and safety of real-time continuous glucose monitoring in the management of type 1
      diabetes in young children aged 4 to <10 years.
PG  - e63
LID - 10.2337/dc12-2021 [doi]
FAU - Tansey, Michael
AU  - Tansey M
FAU - Weinzimer, Stuart
AU  - Weinzimer S
FAU - Beck, Roy
AU  - Beck R
FAU - Ruedy, Katrina
AU  - Ruedy K
FAU - Cheng, Peiyao
AU  - Cheng P
FAU - Tamborlane, William
AU  - Tamborlane W
FAU - Kollman, Craig
AU  - Kollman C
FAU - Mauras, Nelly
AU  - Mauras N
FAU - Fox, Larry
AU  - Fox L
FAU - Coffey, Julie
AU  - Coffey J
FAU - White, Neil H
AU  - White NH
CN  - Diabetes Research in Children Network (DirecNet) Study Group
LA  - eng
PT  - Letter
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631880
OID - NLM: PMC3631880 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/e63 [pii]
AID - 10.2337/dc12-2021 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):e63. doi: 10.2337/dc12-2021.

PMID- 23613602
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis
      of prospective studies.
PG  - 1422-8
LID - 10.2337/dc12-0962 [doi]
AB  - OBJECTIVE: To quantitatively assess the strength and shape of the association
      between blood 25-hydroxy vitamin D [25(OH)D] levels and incident risk of type 2
      diabetes. RESEARCH DESIGN AND METHODS: A systematic search of the MEDLINE and
      Embase databases and a hand search of references from original reports were
      conducted up to 31 October 2012. Prospective observational studies that assessed 
      the association between blood levels of 25(OH)D and risk of incident type 2
      diabetes were included for meta-analysis. DerSimonian and Laird's random-effects 
      model was used. A quadratic spline regression analysis was used to examine the
      shape of the association with a generalized least-squares trend test performed
      for the dose-response relation. RESULTS: A total of 21 prospective studies
      involving 76,220 participants and 4,996 incident type 2 diabetes cases were
      included for meta-analysis. Comparing the highest to the lowest category of
      25(OH)D levels, the summary relative risk for type 2 diabetes was 0.62 (95% CI
      0.54-0.70). A spline regression model showed that higher 25(OH)D levels were
      monotonically associated with a lower diabetes risk. This inverse association did
      not differ by sex, duration of follow-up, study sample size, diabetes diagnostic 
      criteria, or 25(OH)D assay method. A linear trend analysis showed that each 10
      nmol/L increment in 25(OH)D levels was associated with a 4% lower risk of type 2 
      diabetes (95% CI 3-6; P for linear trend < 0.0001). CONCLUSIONS: Our
      meta-analysis showed an inverse and significant association between circulating
      25(OH)D levels and risk of type 2 diabetes across a broad range of blood 25(OH)D 
      levels in diverse populations.
AD  - Department of Medicine, Harvard Medical School, Boston, MA, USA.
      ysong3@rics.bwh.harvard.edu
FAU - Song, Yiqing
AU  - Song Y
FAU - Wang, Lu
AU  - Wang L
FAU - Pittas, Anastassios G
AU  - Pittas AG
FAU - Del Gobbo, Liana C
AU  - Del Gobbo LC
FAU - Zhang, Cuilin
AU  - Zhang C
FAU - Manson, Joann E
AU  - Manson JE
FAU - Hu, Frank B
AU  - Hu FB
LA  - eng
GR  - R01 DK088078/DK/NIDDK NIH HHS/United States
GR  - R01-DK-088078/DK/NIDDK NIH HHS/United States
GR  - R01-DK-58845/DK/NIDDK NIH HHS/United States
GR  - R01-DK-76092/DK/NIDDK NIH HHS/United States
GR  - U34-DK-91958/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631862
OID - NLM: PMC3631862 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/1422 [pii]
AID - 10.2337/dc12-0962 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):1422-8. doi: 10.2337/dc12-0962.

PMID- 23613601
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Gene-environment and gene-treatment interactions in type 2 diabetes: progress,
      pitfalls, and prospects.
PG  - 1413-21
LID - 10.2337/dc12-2211 [doi]
AD  - Department of Clinical Science, Lund University, Malmo, Sweden.
      paul.franks@med.lu.se
FAU - Franks, Paul W
AU  - Franks PW
FAU - Pearson, Ewan
AU  - Pearson E
FAU - Florez, Jose C
AU  - Florez JC
LA  - eng
GR  - R01 DK-072041/DK/NIDDK NIH HHS/United States
GR  - R01 DK-088214.A1/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631878
OID - NLM: PMC3631878 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/1413 [pii]
AID - 10.2337/dc12-2211 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):1413-21. doi: 10.2337/dc12-2211.

PMID- 23613600
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Can new-onset diabetes after kidney transplant be prevented?
PG  - 1406-12
LID - 10.2337/dc12-2067 [doi]
AB  - Because the negative consequences of new-onset diabetes mellitus after
      transplantation (NODAT) diminish the significant gains of kidney transplantation,
      it is imperative to develop clinical interventions to reduce the incidence of
      NODAT. In this review, we discuss whether intensive lifestyle interventions that 
      delay or prevent type 2 diabetes mellitus may decrease the incidence of NODAT. We
      examine the literature pertaining to incidence and timing of onset of NODAT, as
      well as the risk factors and pathophysiology that NODAT shares with type 2
      diabetes mellitus, namely pathways related to increased insulin resistance and
      decreased insulin secretion. Our central hypothesis is that NODAT results from
      the same metabolic risk factors that underlie type 2 diabetes mellitus. These
      risk factors are altered and enhanced by transplantation, "tipping" some
      transplant recipients with seemingly normal glucose homeostasis before transplant
      toward the development of NODAT. We describe the diabetogenic properties of
      transplant immunosuppressive drugs. We describe novel methods of prevention that 
      are being explored, including resting the pancreatic beta-cells by administration
      of basal insulin during the period immediately after transplant. On the basis of 
      the current evidence, we propose that intensive lifestyle modification, adapted
      for individuals with chronic kidney disease or end-stage renal disease, as well
      as resting pancreatic beta-cells during the immediate postoperative period, may
      lower the incidence of NODAT.
AD  - Division of Transplantation, Mayo Clinic, Phoenix, AZ, USA.
      chakkera.harini@mayo.edu
FAU - Chakkera, Harini A
AU  - Chakkera HA
FAU - Weil, E Jennifer
AU  - Weil EJ
FAU - Pham, Phuong-Thu
AU  - Pham PT
FAU - Pomeroy, Jeremy
AU  - Pomeroy J
FAU - Knowler, William C
AU  - Knowler WC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631828
OID - NLM: PMC3631828 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/1406 [pii]
AID - 10.2337/dc12-2067 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):1406-12. doi: 10.2337/dc12-2067.

PMID- 23613599
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Relationships between gastric emptying, postprandial glycemia, and incretin
      hormones.
PG  - 1396-405
LID - 10.2337/dc12-1609 [doi]
AD  - Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital,
      Adelaide, Australia.
FAU - Marathe, Chinmay S
AU  - Marathe CS
FAU - Rayner, Christopher K
AU  - Rayner CK
FAU - Jones, Karen L
AU  - Jones KL
FAU - Horowitz, Michael
AU  - Horowitz M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631884
OID - NLM: PMC3631884 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 36/5/1396 [pii]
AID - 10.2337/dc12-1609 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):1396-405. doi: 10.2337/dc12-1609.

PMID- 23613566
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Glucose variability: where it is important and how to measure it.
PG  - 1405-8
LID - 10.2337/db12-1610 [doi]
AB  - Glucose variability predicts hypoglycemia in both type 1 and type 2 diabetes and 
      has consistently been related to mortality in nondiabetic patients in the
      intensive care unit. SD and mean amplitude of glycemic excursions have
      historically been very popular measures of glucose variability. For reasons
      outlined in this counterpoint, I propose to use coefficient of variation and the 
      mean absolute glucose change as preferred measures of glucose variability.
AD  - Academic Medical Center at the University of Amsterdam, Amsterdam, the
      Netherlands. j.h.devries@amc.uva.nl
FAU - DeVries, J Hans
AU  - DeVries JH
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1398-404. PMID: 23613565
PMC - PMC3636643
OID - NLM: PMC3636643 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1405 [pii]
AID - 10.2337/db12-1610 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1405-8. doi: 10.2337/db12-1610.

PMID- 23613565
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Glucose variability.
PG  - 1398-404
LID - 10.2337/db12-1396 [doi]
AB  - The proposed contribution of glucose variability to the development of the
      complications of diabetes beyond that of glycemic exposure is supported by
      reports that oxidative stress, the putative mediator of such complications, is
      greater for intermittent as opposed to sustained hyperglycemia. Variability of
      glycemia in ambulatory conditions defined as the deviation from steady state is a
      phenomenon of normal physiology. Comprehensive recording of glycemia is required 
      for the generation of any measurement of glucose variability. To avoid distortion
      of variability to that of glycemic exposure, its calculation should be devoid of 
      a time component.
AD  - From the Mayo College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
      service.john@ mayo.edu
FAU - Service, F John
AU  - Service FJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CIN - Diabetes. 2013 May;62(5):1405-8. PMID: 23613566
PMC - PMC3636651
OID - NLM: PMC3636651 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1398 [pii]
AID - 10.2337/db12-1396 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1398-404. doi: 10.2337/db12-1396.

PMID- 23613564
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Gene therapy for type 1 diabetes moves a step closer to reality.
PG  - 1396-7
LID - 10.2337/db13-0348 [doi]
AD  - Regenerative Medicine Institute and Department of Medicine, National Centre for
      Biomedical Engineering Science, National University of Ireland and Galway
      University Hospital, Galway, Ireland. timothy.obrien@nuigalway.ie
FAU - O'Brien, Timothy
AU  - O'Brien T
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1718-29. PMID: 23378612
PMC - PMC3636656
OID - NLM: PMC3636656 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1396 [pii]
AID - 10.2337/db13-0348 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1396-7. doi: 10.2337/db13-0348.

PMID- 23613563
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Targeting purinergic receptors in islet transplantation.
PG  - 1394-5
LID - 10.2337/db13-0211 [doi]
AD  - McGill University Health Centre, Montreal, Quebec, Canada.
      reid.aikin@muhc.mcgill.ca
FAU - Aikin, Reid A
AU  - Aikin RA
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1665-75. PMID: 23315496
PMC - PMC3636627
OID - NLM: PMC3636627 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1394 [pii]
AID - 10.2337/db13-0211 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1394-5. doi: 10.2337/db13-0211.

PMID- 23613562
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Glucose control of glucagon secretion: there is more to it than KATP channels.
PG  - 1391-3
LID - 10.2337/db13-0193 [doi]
AD  - Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
      erik.gylfe@mcb.uu.se
FAU - Gylfe, Erik
AU  - Gylfe E
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1612-22. PMID: 23382449
PMC - PMC3636606
OID - NLM: PMC3636606 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1391 [pii]
AID - 10.2337/db13-0193 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1391-3. doi: 10.2337/db13-0193.

PMID- 23613561
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Achieving "PeaK-A" insulin secretion.
PG  - 1389-90
LID - 10.2337/db13-0196 [doi]
AD  - Department of Medicine, Indiana University School of Medicine, Indianapolis,
      Indiana, USA. rmirmira@iu.edu
FAU - Evans-Molina, Carmella
AU  - Evans-Molina C
FAU - Mirmira, Raghavendra G
AU  - Mirmira RG
LA  - eng
GR  - K08 DK080225/DK/NIDDK NIH HHS/United States
GR  - R01 DK060581/DK/NIDDK NIH HHS/United States
GR  - R01 DK083583/DK/NIDDK NIH HHS/United States
GR  - R01 DK093954/DK/NIDDK NIH HHS/United States
GR  - R03 DK 089147/DK/NIDDK NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1527-36. PMID: 23349500
PMC - PMC3636640
OID - NLM: PMC3636640 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1389 [pii]
AID - 10.2337/db13-0196 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1389-90. doi: 10.2337/db13-0196.

PMID- 23613560
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Changing the way we think about endothelial cell insulin sensitivity, nitric
      oxide, and the pathophysiology of type 2 diabetes: the FoxO is loose.
PG  - 1386-8
LID - 10.2337/db13-0183 [doi]
AD  - Division of Cardiovascular and Diabetes Research, Multidisciplinary
      Cardiovascular Research Centre, University of Leeds, The Light Laboratories,
      Leeds, UK. m.t.kearney@leeds.ac.uk
FAU - Kearney, Mark T
AU  - Kearney MT
LA  - eng
GR  - British Heart Foundation/United Kingdom
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1478-89. PMID: 23349480
PMC - PMC3636642
OID - NLM: PMC3636642 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1386 [pii]
AID - 10.2337/db13-0183 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1386-8. doi: 10.2337/db13-0183.

PMID- 23613559
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - "Prediction is very hard, especially about the future": new biomarkers for type 2
      diabetes?
PG  - 1384-5
LID - 10.2337/db13-0057 [doi]
AD  - Division of Endocrinology, Metabolism, and Molecular Medicine, Department of
      Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois,
      USA. wlowe@northwestern.edu
FAU - Lowe, William L Jr
AU  - Lowe WL Jr
FAU - Bain, James R
AU  - Bain JR
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1730-7. PMID: 23160532
PMC - PMC3636630
OID - NLM: PMC3636630 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1384 [pii]
AID - 10.2337/db13-0057 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1384-5. doi: 10.2337/db13-0057.

PMID- 23613558
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Fetal pancreas as a source for islet transplantation: sweet promise and current
      challenges.
PG  - 1382-3
LID - 10.2337/db13-0018 [doi]
AD  - Department of Neonatology, Hadassah Hospital and Hebrew University, Jerusalem,
      Israel.
FAU - Eventov-Friedman, Smadar
AU  - Eventov-Friedman S
FAU - Reisner, Yair
AU  - Reisner Y
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1646-55. PMID: 23423564
PMC - PMC3636611
OID - NLM: PMC3636611 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1382 [pii]
AID - 10.2337/db13-0018 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1382-3. doi: 10.2337/db13-0018.

PMID- 23613557
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - A role for natriuretic peptides in the central control of energy balance?
PG  - 1379-81
LID - 10.2337/db12-1841 [doi]
AD  - Department of Medicine, Diabetes and Obesity Center of Excellence, University of 
      Washington, Seattle, Washington, USA.
FAU - Berkseth, Kathryn E
AU  - Berkseth KE
FAU - Schur, Ellen
AU  - Schur E
FAU - Schwartz, Michael W
AU  - Schwartz MW
LA  - eng
GR  - DK-052989/DK/NIDDK NIH HHS/United States
GR  - DK-083042/DK/NIDDK NIH HHS/United States
GR  - DK-089036/DK/NIDDK NIH HHS/United States
GR  - DK-090320/DK/NIDDK NIH HHS/United States
GR  - P30-DK-017047/DK/NIDDK NIH HHS/United States
GR  - P30-DK-035816/DK/NIDDK NIH HHS/United States
GR  - T32-DK-007247/DK/NIDDK NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1500-4. PMID: 23274904
PMC - PMC3636633
OID - NLM: PMC3636633 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1379 [pii]
AID - 10.2337/db12-1841 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1379-81. doi: 10.2337/db12-1841.

PMID- 23613556
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Immune antibody monitoring predicts outcome in islet transplantation.
PG  - 1377-8
LID - 10.2337/db13-0019 [doi]
AD  - Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta,
      Canada. amjs@islet.ca.
FAU - Shapiro, A M James
AU  - Shapiro AM
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1656-64. PMID: 23274902
PMC - PMC3636639
OID - NLM: PMC3636639 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1377 [pii]
AID - 10.2337/db13-0019 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1377-8. doi: 10.2337/db13-0019.

PMID- 23613555
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Role of fibroblast growth factor 21 in biology of glucagon.
PG  - 1376
LID - 10.2337/db12-1840 [doi]
AD  - Division of Hypothalamic Research, Department of Internal Medicine, University of
      Texas Southwestern Medical Center, Dallas, Texas, USA.
FAU - Berglund, Eric D
AU  - Berglund ED
FAU - Unger, Roger H
AU  - Unger RH
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1453-63. PMID: 23305646
PMC - PMC3636638
OID - NLM: PMC3636638 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1376 [pii]
AID - 10.2337/db12-1840 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1376. doi: 10.2337/db12-1840.

PMID- 23613554
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - New insights and new conundrums in neonatal hypoglycemia: enigmas wrapped in
      mystery.
PG  - 1373-5
LID - 10.2337/db12-1839 [doi]
AD  - Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine,
      Pittsburgh, Pennsylvania, USA. masp@pitt.edu
FAU - Sperling, Mark A
AU  - Sperling MA
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1689-96. PMID: 23274908
PMC - PMC3636644
OID - NLM: PMC3636644 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1373 [pii]
AID - 10.2337/db12-1839 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1373-5. doi: 10.2337/db12-1839.

PMID- 23613553
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Dietary protein and the blood glucose concentration.
PG  - 1371-2
LID - 10.2337/db12-1829 [doi]
AD  - Endocrinology, Metabolism and Nutrition Section, Minneapolis VA Health Care
      System, Minneapolis, Minnesota, USA. nutta001@umn.edu
FAU - Nuttall, Frank Q
AU  - Nuttall FQ
FAU - Gannon, Mary C
AU  - Gannon MC
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1435-42. PMID: 23274906
PMC - PMC3636610
OID - NLM: PMC3636610 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1371 [pii]
AID - 10.2337/db12-1829 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1371-2. doi: 10.2337/db12-1829.

PMID- 23613552
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Hints of unique genetic effects for type 2 diabetes in India.
PG  - 1369-70
LID - 10.2337/db12-1836 [doi]
AD  - Centre for Clinical Epidemiology and Biostatistics, Hunter Medical Research
      Institute and School of Medicine and Public Health, University of Newcastle,
      Newcastle, Australia. liz.holliday@newcastle.edu.au
FAU - Holliday, Elizabeth G
AU  - Holliday EG
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1746-55. PMID: 23300278
PMC - PMC3636658
OID - NLM: PMC3636658 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1369 [pii]
AID - 10.2337/db12-1836 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1369-70. doi: 10.2337/db12-1836.

PMID- 23613551
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - The brain-liver connection between BDNF and glucose control.
PG  - 1367-8
LID - 10.2337/db12-1824 [doi]
AD  - Division of Endocrinology, Department of Medicine, Albert Einstein College of
      Medicine, Bronx, New York, USA.
FAU - Jo, Young-Hwan
AU  - Jo YH
FAU - Chua, Streamson C Jr
AU  - Chua SC Jr
LA  - eng
GR  - DK026687/DK/NIDDK NIH HHS/United States
GR  - DK092246/DK/NIDDK NIH HHS/United States
GR  - HD058155/HD/NICHD NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1512-8. PMID: 23274899
PMC - PMC3636607
OID - NLM: PMC3636607 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1367 [pii]
AID - 10.2337/db12-1824 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1367-8. doi: 10.2337/db12-1824.

PMID- 23613550
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Does obesity-induced tau phosphorylation tip the scale toward dementia?
PG  - 1365-6
LID - 10.2337/db12-1784 [doi]
AD  - Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.
FAU - Gendron, Tania F
AU  - Gendron TF
FAU - Zhang, Yong-Jie
AU  - Zhang YJ
FAU - Petrucelli, Leonard
AU  - Petrucelli L
LA  - eng
GR  - 1-UO1-NS065102-01A1/NS/NINDS NIH HHS/United States
GR  - ES20395-01/ES/NIEHS NIH HHS/United States
GR  - R01 NS 063964-01/NS/NINDS NIH HHS/United States
GR  - R01 NS077402/NS/NINDS NIH HHS/United States
GR  - R01AG026251/AG/NIA NIH HHS/United States
GR  - R21 NS074121-01/NS/NINDS NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
CON - Diabetes. 2013 May;62(5):1681-8. PMID: 23250356
PMC - PMC3636650
OID - NLM: PMC3636650 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1365 [pii]
AID - 10.2337/db12-1784 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1365-6. doi: 10.2337/db12-1784.

PMID- 23613549
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Toward engineering a novel transplantation site for human pancreatic islets.
PG  - 1357-64
LID - 10.2337/db12-1553 [doi]
AD  - Department of Pathology and Medical Biology, University Medical Center Groningen,
      University of Groningen, Groningen, the Netherlands. a.m.smink@umcg.nl
FAU - Smink, Alexandra M
AU  - Smink AM
FAU - Faas, Marijke M
AU  - Faas MM
FAU - de Vos, Paul
AU  - de Vos P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
SB  - AIM
SB  - IM
PMC - PMC3636655
OID - NLM: PMC3636655 [Available on 05/01/14]
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/01 00:00
AID - 62/5/1357 [pii]
AID - 10.2337/db12-1553 [doi]
PST - ppublish
SO  - Diabetes. 2013 May;62(5):1357-64. doi: 10.2337/db12-1553.

PMID- 23613378
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 18
DP  - 2013 May
TI  - [High-fat diets in diabetes].
PG  - 964-6
LID - 10.1055/s-0032-1333058 [doi]
AD  - Abteilung fur Klinische Ernahrung, Deutsches Institut fur Ernahrungsforschung,
      Potsdam Rehbrucke, Nuthetal. afhp@dife.de
FAU - Pfeiffer, A F H
AU  - Pfeiffer AF
LA  - ger
PT  - Journal Article
TT  - Fettreiche Ernahrung bei Diabetes mellitus.
DEP - 20130423
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [epublish]
AID - 10.1055/s-0032-1333058 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(18):964-6. doi: 10.1055/s-0032-1333058. Epub
      2013 Apr 23.

PMID- 23613376
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 18
DP  - 2013 May
TI  - [Early insulin treatment in type 2 diabetes--no].
PG  - 957
LID - 10.1055/s-0032-1332974 [doi]
AD  - Diabeteszentrum, Bad Lauterberg im Harz. nauck@diabeteszentrum.de
FAU - Nauck, M
AU  - Nauck M
LA  - ger
PT  - Comment
PT  - Journal Article
TT  - Fruhe Insulintherapie bei Typ-2-Diabetes--Contra.
DEP - 20130423
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
CON - Dtsch Med Wochenschr. 2013 May;138(18):956. PMID: 23613375
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [epublish]
AID - 10.1055/s-0032-1332974 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(18):957. doi: 10.1055/s-0032-1332974. Epub
      2013 Apr 23.

PMID- 23613375
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 18
DP  - 2013 May
TI  - [Early insulin treatment in type 2 diabetes--yes].
PG  - 956
LID - 10.1055/s-0032-1332975 [doi]
AD  - Klinik fur Endokrinologie, Diabetologie und Angiologie, Stadtisches Klinikum
      Munchen GmbH, Klinikum Bogenhausen.
      petra-maria.schumm-draeger@klinikum-muenchen.de
FAU - Schumm-Draeger, P M
AU  - Schumm-Draeger PM
LA  - ger
PT  - Journal Article
TT  - Fruhe Insulintherapie bei Typ-2-Diabetes--Pro.
DEP - 20130423
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
CIN - Dtsch Med Wochenschr. 2013 May;138(18):957. PMID: 23613376
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [epublish]
AID - 10.1055/s-0032-1332975 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(18):956. doi: 10.1055/s-0032-1332975. Epub
      2013 Apr 23.

PMID- 23613374
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 18
DP  - 2013 May
TI  - [Diabetes and kidneys].
PG  - 949-55
LID - 10.1055/s-0032-1332992 [doi]
AB  - Diabetic nephropathy is the leading cause of end-stage renal disease all over the
      world. Diagnosis is confirmed by measuring urin albumin excretion and calculated 
      renal function (eGFR). Once the diagnosis is confirmed there should be a search
      for confounding cardiovascular risk factors and even established cardiovascular
      disease because of the associated high cardiovascular risk. In type 1 diabetes
      metabolic control is the main issue. In case of renal impairment and in patients 
      with type 2 diabetes a multifactorial approach is necessary, which consists of
      dietary advise, metabolic control, lowering elevated blood-pressure, cessation of
      smoking, ASS and lipid-lowering drug-therapy. Special drugs for the treatment of 
      diabetes-induced renal disease are not available.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Praxis fur Nierenerkrankungen und Diabetes Bochum.
      dirk.gaeckler@dialyse-bochum.de
FAU - Gackler, D
AU  - Gackler D
FAU - Jakel, S
AU  - Jakel S
FAU - Fricke, L
AU  - Fricke L
FAU - Reinsch, B
AU  - Reinsch B
FAU - Fischer, F
AU  - Fischer F
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Diabetes und Niere.
DEP - 20130423
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [epublish]
AID - 10.1055/s-0032-1332992 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(18):949-55. doi: 10.1055/s-0032-1332992. Epub 
      2013 Apr 23.

PMID- 23613373
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 18
DP  - 2013 May
TI  - [43-year-old woman with diabetes and postoperative circulatory collapse].
PG  - 945-6
LID - 10.1055/s-0032-1332869 [doi]
AD  - Medizinische Klinik I, BG Universitatsklinikum Bergmannsheil GmbH, Bochum.
      johannes.dietrich@ruhr-uni-bochum.de
FAU - Dietrich, J W
AU  - Dietrich JW
FAU - Ehren, M
AU  - Ehren M
FAU - Ruff-Dietrich, S
AU  - Ruff-Dietrich S
FAU - Klein, H H
AU  - Klein HH
LA  - ger
PT  - Journal Article
TT  - 43-jahrige Patientin mit Diabetes mellitus und postoperativem Kreislaufkollaps.
DEP - 20130423
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [epublish]
AID - 10.1055/s-0032-1332869 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(18):945-6. doi: 10.1055/s-0032-1332869. Epub
      2013 Apr 23.

PMID- 23613372
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 18
DP  - 2013 May
TI  - [Woman with type 1 diabetes mellitus and rapidly progressive edema].
PG  - 940-4
LID - 10.1055/s-0033-1343162 [doi]
AB  - HISTORY AND CLINICAL FINDINGS: A 47-year-old woman with type 1 diabetes mellitus 
      was presented for evaluation of progressive oedema, fatigue and weight gain. Her 
      medical history was significant for arterial hypertension and autoimmune
      thyroiditis requiring substitution therapy with levothyroxine. Physical
      examination revealed bilateral malleolar and crural oedema, swelling of the
      eyelids and two-sided pleural effusions. DIAGNOSTIC, TREATMENT AND COURSE: The
      blood level of albumin was very low, urine analysis showed proteinuria of > 8
      g/day. The kidney biopsy revealed only slight changes. This led in combination
      with the blood and urine results to the diagnosis of minimal change
      glomerulopathy. After initiation of high dose prednisolone the patient achieved
      near total remission within four weeks. Prednisolone therapy was tapered over
      several months. CONCLUSION: In patients with diabetes mellitus and suddenly
      occurring nephrotic syndrome other diseases than diabetic nephropathy have to be 
      considered. In most cases a kidney biopsy is mandatory.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Medizinische Klinik I, Berufsgenossenschaftliches Universitatsklinikum
      Bergmannsheil GmbH, Bochum. marianne.ehren@bergmannsheil.de
FAU - Ehren, M
AU  - Ehren M
FAU - Dietrich, J W
AU  - Dietrich JW
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Patientin mit Diabetes mellitus Typ 1 und akut aufgetretenen Odemen.
DEP - 20130423
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [epublish]
AID - 10.1055/s-0033-1343162 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(18):940-4. doi: 10.1055/s-0033-1343162. Epub
      2013 Apr 23.

PMID- 23613371
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 18
DP  - 2013 May
TI  - ["DIabetes Versorgungs-Evaluation" (DIVE)--a national quality assurance
      initiative at physicians providing care for patients with diabetes].
PG  - 934-9
LID - 10.1055/s-0033-1343144 [doi]
AB  - BACKGROUND: Due to the variety of affected organ systems, necessitating a
      multidisciplinary and interconnected approach in deciding on individual
      diagnostic and therapeutic strategies, a structured documentation of data for
      patients suffering from diabetes mellitus is steadily gaining importance. Towards
      this purpose, multiple quality initiatives (e. g. SWEET, QS-DPV, EUBIROD etc.) as
      well as several software systems (e. g. [DPV2] DIAMAX, DPV, EMIL, Qmax etc.) have
      been developed to capture patient-related data. This is further complicated by
      the necessity to exchange data with a large variety of doctor's office
      administration systems. METHODS: To address this complex of issues, DiabetesDE in
      cooperation with several societies, doctor's associations and prospective end
      users launched a national register platform. DIVE (Diabetes Care Evaluation) is
      aimed at establishing a national diabetes register to centrally capture data from
      diabetes patients being treated by diabetology specialists in Germany, thus
      making them available for quality assurance and health services research.
      RESULTS: Since September 2011, 142 so far participating doctors have documented
      data for 84,774 patients. Compared to patients treated by general practitioners, 
      persons under specialist care show a more advanced clinical picture with
      substantial co-morbidity. CONCLUSION: DIVE provides a national platform which
      will address essential fields of activity with regard to the development of a
      national diabetes strategy--epidemiology, diabetes registry, health care
      research, quality assurance--based on usual office administration systems, thus
      contributing to the improvement of care and treatment for patients suffering from
      diabetes.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover. danne@hka.de
FAU - Danne, T
AU  - Danne T
FAU - Kaltheuner, M
AU  - Kaltheuner M
FAU - Koch, A
AU  - Koch A
FAU - Ernst, S
AU  - Ernst S
FAU - Rathmann, W
AU  - Rathmann W
FAU - Russmann, H-J
AU  - Russmann HJ
FAU - Bramlage, P
AU  - Bramlage P
CN  - DIVE Studiengruppe
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - DIabetes Versorgungs-Evaluation (DIVE)--eine nationale Initiative zur
      Qualitatssicherung in der diabetologischen Versorgung.
DEP - 20130423
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
IR  - Danne T
FIR - Danne, Thomas
IR  - Garlichs D
FIR - Garlichs, Dietrich
IR  - Bramlage P
FIR - Bramlage, Peter
IR  - Kaltheuner M
FIR - Kaltheuner, Matthias
IR  - Fleischmann H
FIR - Fleischmann, Holger
IR  - Danne T
FIR - Danne, Thomas
IR  - Haeger T
FIR - Haeger, Thomas
IR  - Jecht M
FIR - Jecht, Michael
IR  - Kipp T
FIR - Kipp, Thomas
IR  - Rathmann W
FIR - Rathmann, Wolfgang
IR  - Reuter HM
FIR - Reuter, Hans-Martin
IR  - Scheper N
FIR - Scheper, Nikolaus
IR  - Siegel EG
FIR - Siegel, Erhard G
IR  - Weber D
FIR - Weber, Dietmar
IR  - Berg C
FIR - Berg, Christian
IR  - Ernst S
FIR - Ernst, Stefanie
IR  - Koch A
FIR - Koch, Armin
IR  - von Stritzky B
FIR - von Stritzky, Berndt
IR  - Volk M
FIR - Volk, Michael
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [epublish]
AID - 10.1055/s-0033-1343144 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 May;138(18):934-9. doi: 10.1055/s-0033-1343144. Epub
      2013 Apr 23.

PMID- 23613366
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 2157-1422 (Electronic)
DP  - 2013 Apr 23
TI  - Iron Deficiency Anemia: A Common and Curable Disease.
LID - cshperspect.a011866v1 [pii]
LID - 10.1101/cshperspect.a011866 [doi]
AB  - Iron deficiency anemia arises when the balance of iron intake, iron stores, and
      the body's loss of iron are insufficient to fully support production of
      erythrocytes. Iron deficiency anemia rarely causes death, but the impact on human
      health is significant. In the developed world, this disease is easily identified 
      and treated, but frequently overlooked by physicians. In contrast, it is a health
      problem that affects major portions of the population in underdeveloped
      countries. Overall, the prevention and successful treatment for iron deficiency
      anemia remains woefully insufficient worldwide, especially among underprivileged 
      women and children. Here, clinical and laboratory features of the disease are
      discussed, and then focus is placed on relevant economic, environmental,
      infectious, and genetic factors that converge among global populations.
AD  - Molecular Medicine Branch, National Institute of Diabetes and Digestive and
      Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.
FAU - Miller, Jeffery L
AU  - Miller JL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Cold Spring Harb Perspect Med
JT  - Cold Spring Harbor perspectives in medicine
JID - 101571139
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - cshperspect.a011866 [pii]
AID - 10.1101/cshperspect.a011866 [doi]
PST - aheadofprint
SO  - Cold Spring Harb Perspect Med. 2013 Apr 23. pii: cshperspect.a011866v1. doi:
      10.1101/cshperspect.a011866.

PMID- 23613304
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1097-0029 (Electronic)
IS  - 1059-910X (Linking)
DP  - 2013 Apr 24
TI  - Cyclosporine improves remyelination in diabetic rats submitted to a gliotoxic
      demyelinating model in the brainstem.
LID - 10.1002/jemt.22222 [doi]
AB  - The use of cyclosporine (CsA) has shown to induce an increase in density of
      oligodendrocytes near remyelinating areas following the injection of ethidium
      bromide (EB), a demyelinating agent, in the rat brainstem. It is also known that 
      diabetes mellitus was capable of delaying remyelination by both oligodendrocytes 
      and Schwann cells in this gliotoxic model. This study was designed to assess
      whether CsA had the capacity to improve remyelination in streptozotocin-induced
      (50 mg/kg, intraperitoneal route) diabetic rats. Diabetic Wistar rats were
      divided in different groups receiving 10 microlitres of 0.1% EB or 0.9% saline
      solution into the cisterna pontis and were treated or not with CsA. During 7 days
      and, thereafter, three times a week, 10 mg/kg/day of CsA were given by
      intraperitoneal route. The rats were euthanized from 7 to 31 days after EB or
      saline injection and brainstem sections were collected and processed for light
      and transmission electron microscopy studies. Results from different groups were 
      compared by using a semi-quantitative method developed for documenting the extent
      and nature of remyelination in semithin sections following gliotoxic lesions.
      Results showed that CsA administration to diabetic rats after EB injection
      stimulate both oligodendroglial and Schwann cell remyelination (mean
      remyelination scores of 3.15 +/- 0.5 for oligodendrocytes and 1.36 +/- 0.58 for
      Schwann cells) compared to untreated animals (2.52 +/- 0.71 for oligodendrocytes 
      and 0.73 +/- 0.47 for Schwann cells, respectively). CsA given to diabetic rats
      was capable of reversing some of the deleterial effects of diabetes on
      remyelination. Microsc. Res. Tech., 2013. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Veterinary Medicine, University Paulista (Sao Paulo, SP, Brazil),
      University Cruzeiro do Sul, (Sao Paulo, SP, Brazil).
FAU - Bondan, Eduardo Fernandes
AU  - Bondan EF
FAU - Monteiro Martins, Maria De Fatima
AU  - Monteiro Martins MD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Microsc Res Tech
JT  - Microscopy research and technique
JID - 9203012
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/02/20 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/04/01 [accepted]
AID - 10.1002/jemt.22222 [doi]
PST - aheadofprint
SO  - Microsc Res Tech. 2013 Apr 24. doi: 10.1002/jemt.22222.

PMID- 23613279
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1479-6813 (Electronic)
IS  - 0952-5041 (Linking)
VI  - 51
IP  - 1
DP  - 2013
TI  - Hyperglycemia downregulates Connexin36 in pancreatic islets via the upregulation 
      of ICER-1/ICER-1gamma.
PG  - 49-58
LID - 10.1530/JME-13-0054 [doi]
AB  - Channels formed by the gap junction protein Connexin36 (CX36) contribute to the
      proper control of insulin secretion. We previously demonstrated that chronic
      exposure to glucose decreases Cx36 levels in insulin-secreting cells in vitro.
      Here, we investigated whether hyperglycemia also regulates Cx36 in vivo. Using a 
      model of continuous glucose infusion in adult rats, we showed that prolonged
      (24-48 h) hyperglycemia reduced the Cx36 gene Gjd2 mRNA levels in pancreatic
      islets. Accordingly, prolonged exposure to high glucose concentrations also
      reduced the expression and function of Cx36 in the rat insulin-producing INS-1E
      cell line. The glucose effect was blocked after inhibition of the cAMP/PKA
      pathway and was associated with an overexpression of the inducible cAMP early
      repressor ICER-1/ICER-1gamma, which binds to a functional cAMP-response element
      in the promoter of the Cx36 gene Gjd2. The involvement of this repressor was
      further demonstrated using an antisense strategy of ICER-1 inhibition, which
      prevented glucose-induced downregulation of Cx36. The data indicate that chronic 
      exposure to glucose alters the in vivo expression of Cx36 by the
      insulin-producing beta-cells through ICER-1/ICER-1gamma overexpression. This
      mechanism may contribute to the reduced glucose sensitivity and altered insulin
      secretion, which contribute to the pathophysiology of diabetes.
AD  - Service of Internal Medicine, Department of Physiology, University Hospital
      Lausanne, Bugnon 7a, 1005 Lausanne, SwitzerlandDivision of Endocrinology and
      Diabetology Department of Cell Physiology and Metabolism, School of Medicine,
      C.M.U. University of Geneva, Geneve, Switzerland.
FAU - Haefliger, Jacques-Antoine
AU  - Haefliger JA
FAU - Rohner-Jeanrenaud, Francoise
AU  - Rohner-Jeanrenaud F
FAU - Caille, Dorothee
AU  - Caille D
FAU - Charollais, Anne
AU  - Charollais A
FAU - Meda, Paolo
AU  - Meda P
FAU - Allagnat, Florent
AU  - Allagnat F
LA  - eng
PT  - Journal Article
DEP - 20130517
PL  - England
TA  - J Mol Endocrinol
JT  - Journal of molecular endocrinology
JID - 8902617
SB  - IM
OTO - NOTNLM
OT  - ICER-1
OT  - connexin36
OT  - gap junctions
OT  - glucose
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013 [ppublish]
AID - JME-13-0054 [pii]
AID - 10.1530/JME-13-0054 [doi]
PST - epublish
SO  - J Mol Endocrinol. 2013 May 17;51(1):49-58. doi: 10.1530/JME-13-0054. Print 2013.

PMID- 23613187
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
DP  - 2013 Apr 24
TI  - Gestational weight loss and perinatal outcomes in overweight and obese women
      subsequent to diagnosis of gestational diabetes mellitus.
LID - 10.1002/oby.20490 [doi]
AB  - OBJECTIVE: To investigate whether gestational weight loss after the diagnosis of 
      gestational diabetes mellitus (GDM) in overweight and obese women is associated
      with improved perinatal outcomes. Obesity and GDM are risk factors for adverse
      perinatal outcomes, but few studies have investigated weight loss during
      pregnancy in women with these comorbidities. METHODS: Retrospective cohort study 
      of 26,205 overweight and obese gestational diabetic women enrolled in the
      California Diabetes and Pregnancy Program. Women with gestational weight loss
      (GWL) during program enrollment were compared to those with weight gain.
      Perinatal outcomes were assessed using chi-square test and multivariable logistic
      regression analysis. RESULTS: 5.2% of women experienced GWL. GWL was associated
      with decreased odds of macrosomia (aOR 0.63, 95% CI 0.52-0.77), NICU admission
      (aOR 0.51, 95% CI 0.27-0.95), and cesarean delivery (aOR 0.81, 95% CI 0.68-0.97).
      Odds of SGA status (aOR 1.69, 95% CI 1.32-2.17) and preterm delivery <34 weeks
      (aOR 1.71, 95% CI 1.23-2.37) were increased. CONCLUSIONS: In overweight and obese
      women with GDM, third trimester weight loss is associated with some improved
      maternal and neonatal outcomes, although this effect is lessened by increased
      odds of SGA status and preterm delivery. We recommend further research on weight 
      loss and interventions to improve adherence to weight guidelines in this
      population.
CI  - Copyright (c) 2013 The Obesity Society.
AD  - Department of Obstetrics and Gynecology, Northwestern University Feinberg School 
      of Medicine.
FAU - Yee, Lynn M
AU  - Yee LM
FAU - Cheng, Yvonne W
AU  - Cheng YW
FAU - Inturrisi, Maribeth
AU  - Inturrisi M
FAU - Caughey, Aaron B
AU  - Caughey AB
LA  - ENG
GR  - K12 HD001262/HD/NICHD NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/11/01 [received]
PHST- 2013/03/24 [revised]
PHST- 2013/03/25 [accepted]
AID - 10.1002/oby.20490 [doi]
PST - aheadofprint
SO  - Obesity (Silver Spring). 2013 Apr 24. doi: 10.1002/oby.20490.

PMID- 23613086
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor
      (suPAR) is associated with incident type 2 diabetes among overweight but not
      obese individuals with impaired glucose regulation: effect modification by
      smoking and body weight status.
PG  - 1542-6
LID - 10.1007/s00125-013-2914-0 [doi]
AB  - AIMS/HYPOTHESIS: Recent evidence links the soluble urokinase plasminogen
      activator receptor (suPAR), a stable biomarker of systemic immune activation, to 
      several chronic diseases, including type 2 diabetes. suPAR is also associated
      with adiposity and smoking. We hypothesised that this biomarker would be linked
      to incident type 2 diabetes in individuals with impaired glucose regulation and
      that this association would be modified by smoking and body weight status.
      METHODS: The study included 1,933 participants with impaired glucose regulation, 
      who were drawn from the Danish arm of the Anglo-Danish-Dutch Study of Intensive
      Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION) and 
      for whom data on suPAR, BMI and smoking were available. Logistic regression
      analysis was used to estimate the odds for incident type 2 diabetes per twofold
      increase in suPAR levels. Interactions between both smoking and body weight
      status and suPAR were tested. RESULTS: During a 3-year follow-up (599 incident
      diabetes cases), there was a 48% overall increase in the odds of developing type 
      2 diabetes per twofold increase in suPAR (p = 0.006). This association was
      modified by body weight status in overweight, but not in obese individuals (OR
      2.36, 95% CI 1.48, 3.76 in overweight group), and by smoking status (OR 2.05, 95%
      CI 1.20, 3.51 in non-smokers). After adjustment for other diabetes risk factors, 
      the association between suPAR and type 2 diabetes was attenuated in the whole
      sample and among non-smokers, but remained robust among overweight participants. 
      CONCLUSIONS/INTERPRETATION: suPAR may be a good novel biomarker for systemic
      sub-clinical inflammation and immune activation linked to incident type 2
      diabetes risk in overweight individuals and non-smokers. The observed
      interactions with adiposity and smoking should be investigated further.
AD  - Steno Diabetes Center, Gentofte, Denmark, alex.heraclides@gmail.com.
FAU - Heraclides, A
AU  - Heraclides A
FAU - Jensen, T M
AU  - Jensen TM
FAU - Rasmussen, S S
AU  - Rasmussen SS
FAU - Eugen-Olsen, J
AU  - Eugen-Olsen J
FAU - Haugaard, S B
AU  - Haugaard SB
FAU - Borch-Johnsen, K
AU  - Borch-Johnsen K
FAU - Sandbaek, A
AU  - Sandbaek A
FAU - Lauritzen, T
AU  - Lauritzen T
FAU - Witte, D R
AU  - Witte DR
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/02/07 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1007/s00125-013-2914-0 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1542-6. doi: 10.1007/s00125-013-2914-0. Epub 2013
      Apr 24.

PMID- 23613085
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the
      risks?
PG  - 1462-70
LID - 10.1007/s00125-013-2904-2 [doi]
AB  - In this review, we explore the concept of 'double diabetes', a combination of
      type 1 diabetes with features of insulin resistance and type 2 diabetes. After
      considering whether double diabetes is a useful concept, we discuss potential
      mechanisms of increased insulin resistance in type 1 diabetes before examining
      the extent to which double diabetes might increase the risk of cardiovascular
      disease (CVD). We then go on to consider the proposal that weight gain from
      intensive insulin regimens may be associated with increased CV risk factors in
      some patients with type 1 diabetes, and explore the complex relationships between
      weight gain, insulin resistance, glycaemic control and CV outcome. Important
      comparisons and contrasts between type 1 diabetes and type 2 diabetes are
      highlighted in terms of hepatic fat, fat partitioning and lipid profile, and how 
      these may differ between type 1 diabetic patients with and without double
      diabetes. In so doing, we hope this work will stimulate much-needed research in
      this area and an improvement in clinical practice.
AD  - Department of Medicine, Royal Hampshire County Hospital, Romsey Road, Winchester,
      SO22 5DG, UK, Steve.Cleland@hhft.nhs.uk.
FAU - Cleland, S J
AU  - Cleland SJ
FAU - Fisher, B M
AU  - Fisher BM
FAU - Colhoun, H M
AU  - Colhoun HM
FAU - Sattar, N
AU  - Sattar N
FAU - Petrie, J R
AU  - Petrie JR
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
PMC - PMC3671104
OID - NLM: PMC3671104
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/12/28 [received]
PHST- 2013/02/25 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1007/s00125-013-2904-2 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1462-70. doi: 10.1007/s00125-013-2904-2. Epub 2013
      Apr 24.

PMID- 23613017
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1248-9204 (Electronic)
IS  - 1248-9204 (Linking)
DP  - 2013 Apr 24
TI  - Effect of patient and hospital characteristics on outcomes of elective ventral
      hernia repair in the United States.
AB  - PURPOSES: Our ability to predict complications of ventral hernia repairs (VHR)
      are inadequate. Although impact of patient comorbidities and hospital
      characteristics on outcomes of several surgical procedures has been reported,
      such analysis on elective herniorrhaphy has not been performed to date. We
      hypothesized that obesity and diabetes as well as socioeconomic factors would
      have deleterious outcomes on elective VHR. METHODS: Analysis of 2004-2008
      Nationwide Inpatient Sample database. Main outcome measures included
      wound/systemic morbidity, length of stay, discharge status, and in-hospital
      mortality. Bivariate and multivariate analyses were performed to assess influence
      of diabetes, obesity, patient socioeconomic factors, and hospital characteristics
      on the outcomes of VHR. RESULTS: A total of 78,348 adults undergoing elective VHR
      were analyzed. Obesity had significant risks for cardiopulmonary complications
      and prolonged hospitalization. Diabetics were more likely to have delayed wound
      healing. Hispanic patients had significantly higher rates of pulmonary
      complications and mortality. As compared to private insurance patients, Medicaid 
      and Medicare patients had significantly higher odds of complications, prolonged
      hospitalization, non-routine discharge, and mortality. CONCLUSION: Obesity and
      diabetes appear to be significant predictors of morbidity in patients undergoing 
      elective VHR. Alarmingly, Medicare/Medicaid patients not only had the highest
      rates of wound/systemic complications but also the highest post-operative
      mortality. For the first time, we demonstrated that in addition to comorbidities,
      both patient socioeconomic factors and hospital characteristics appear to be
      major determinants of post-herniorrhaphy complications and mortalities. Improved 
      health maintenance and reduction in income-related disparities in health care
      delivery may be paramount in improving outcomes of VHR in the United States.
AD  - Case Comprehensive Hernia Center, Department of Surgery, University Hospitals
      Case Medical Center, Case Western Reserve University, 11100 Euclid Avenue,
      Cleveland, OH, 44106, USA, yuri.novitsky@uhhospitals.org.
FAU - Novitsky, Y W
AU  - Novitsky YW
FAU - Orenstein, S B
AU  - Orenstein SB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Hernia
JT  - Hernia : the journal of hernias and abdominal wall surgery
JID - 9715168
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/11/19 [received]
PHST- 2013/03/23 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1007/s10029-013-1088-5 [doi]
PST - aheadofprint
SO  - Hernia. 2013 Apr 24.

PMID- 23613014
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
DP  - 2013 Apr 23
TI  - Decreased Permeability Surface Area for Glucose in Obese Women with Postprandial 
      Hyperglycemia: No Effect of Phosphodiesterase-5 (PDE-5) Inhibition.
AB  - Insulin-mediated microvascular recruitment is recognized as a potential mechanism
      contributing to insulin resistance. In this study, we compared a marker of
      microvascular function, the permeability surface area for glucose (PSglu), and
      forearm glucose uptake after an OGTT in obese women with impaired glucose
      metabolism and healthy lean nondiabetic women, with the aim to characterize
      whether decreased permeability surface area for glucose or decreased glucose
      uptake may contribute to postprandial hyperglycemia in the obese group. In
      addition, we evaluated whether the phosphodiesterase-5 (PDE-5) inhibitor
      tadalafil, in a randomized double blind placebo controlled design, might
      attenuate postprandial glucose levels in obese women. For these purposes,
      intramuscular microdialysis, blood sampling from arterial and venous blood of the
      forearm, and measurements of forearm blood flow were performed. The results
      showed an impaired permeability surface area for glucose (IAUC PSglu 31+/-13 vs. 
      124+/-31; p<0.05) in obese when compared with lean participants, but no
      differences in forearm glucose uptake appeared between the groups. Furthermore, a
      single dose of tadalafil 10 mg showed no improvement of the permeability surface 
      area for glucose, glucose uptake, or circulating glucose levels in obese
      participants. In conclusion, the postprandial PSglu response was impaired in
      obese women showing postprandial hyperglycemia, indicating a compromised
      microcirculation. However, we were unable to demonstrate any acute effect on
      either vascular function or glucose uptake of the phosphodiesterase-5 (PDE-5)
      inhibitor tadalafil.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - The Lundberg Laboratory for Diabetes Research, Sahlgrenska Academy at University 
      of Gothenburg, Gothenburg, Sweden.
FAU - Sandqvist, M
AU  - Sandqvist M
FAU - Strindberg, L
AU  - Strindberg L
FAU - Lonnroth, P
AU  - Lonnroth P
FAU - Jansson, P-A
AU  - Jansson PA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [epublish]
AID - 10.1055/s-0033-1341485 [doi]
PST - aheadofprint
SO  - Horm Metab Res. 2013 Apr 23.

PMID- 23612997
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Apr 23
TI  - Effect of birth weight and 12 weeks of exercise training on exercise-induced AMPK
      signaling in human skeletal muscle.
AB  - Subjects with a low birth weight (LBW) display increased risk of developing type 
      2 diabetes (T2D). We hypothesized that this is associated with defects in muscle 
      adaptations following acute and regular physical activity, evident by impairments
      in the exercise-induced activation of AMPK signaling. We investigated 21 LBW and 
      21 normal birth weight (NBW) subjects during 1 hour of acute exercise performed
      at the same relative workload before and after 12 weeks of exercise training.
      Multiple skeletal muscle biopsies were obtained before and after exercise.
      Protein levels and phosphorylation status were determined by Western blotting.
      AMPK activities were measured using activity assays. Protein levels of AMPK
      isoforms alpha1 and gamma1 were significantly increased while gamma3 levels
      decreased with training independent of group. The LBW group had higher
      exercise-induced AMPK Thr172 phosphorylation before training and higher
      exercise-induced ACC2 Ser221 phosphorylation both before and after training
      compared with NBW. Despite exercise being performed at the same relative
      intensity (65% of VO2peak), the acute exercise response on AMPK Thr172, ACC2
      Ser221, AMPK alpha2beta2gamma1 and alpha2beta2gamma3- activities, GS activity,
      adenine nucleotides as well as Hexokinase II mRNA levels were all reduced after
      exercise training. Increased exercise-induced muscle AMPK activation and ACC2
      Ser221 phosphorylation in LBW subjects may indicate a more sensitive AMPK system 
      in this population. Long term exercise training may reduce the need for AMPK to
      control energy turnover during exercise. Thus, the remaining gamma3-associated
      AMPK activation by acute exercise after exercise training might be sufficient to 
      maintain cellular energy balance.
AD  - 1Steno Diabetes Center A/S.
FAU - Mortensen, Brynjulf
AU  - Mortensen B
FAU - Hingst, Janne R
AU  - Hingst JR
FAU - Frederiksen, Nicklas
AU  - Frederiksen N
FAU - Hansen, Rikke W W
AU  - Hansen RW
FAU - Christiansen, Caroline S
AU  - Christiansen CS
FAU - Iversen, Ninna
AU  - Iversen N
FAU - Friedrichsen, Martin
AU  - Friedrichsen M
FAU - Birk, Jesper B
AU  - Birk JB
FAU - Pilegaard, Henriette
AU  - Pilegaard H
FAU - Hellsten, Ylva
AU  - Hellsten Y
FAU - Vaag, Allan
AU  - Vaag A
FAU - Wojtaszewski, Jorgen F P
AU  - Wojtaszewski JF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - ajpendo.00295.2012 [pii]
AID - 10.1152/ajpendo.00295.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Apr 23.

PMID- 23612996
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Apr 23
TI  - Developmental androgen excess programs sympathetic tone and adipose tissue
      dysfunction and predisposes to a cardiometabolic syndrome in female mice.
AB  - Among women, the polycystic ovarian syndrome (PCOS) is considered a form of
      metabolic syndrome with reproductive abnormalities. Women with PCOS show
      increased sympathetic tone, visceral adiposity with enlarged adipocytes,
      hypoadiponectinemia, insulin resistance, glucose intolerance, increased inactive 
      osteocalcin and hypertension. Excess fetal exposure to androgens has been
      hypothesized to play a role in the pathogenesis of PCOS. Previously, we showed
      that neonatal exposure to the androgen testosterone (NT) programs leptin
      resistance in adult female mice. Here, we studied the impact of NT on lean and
      adipose tissues, sympathetic tone in cardiometabolic tissues and the development 
      of metabolic dysfunction in mice. Neonatally androgenized adult female mice (NTF)
      displayed masculinization of lean tissues with increased cardiac and skeletal
      muscle as well as kidney masses. NTF mice showed increased and dysfunctional
      white adipose tissue with increased sympathetic tone in both visceral and
      subcutaneous fat, as well as increased number of enlarged and insulin resistant
      adipocytes that displayed altered expression of developmental genes and
      hypoadiponectinemia. NTF exhibited dysfunctional brown adipose tissue with
      increased mass and decreased energy expenditure. They also displayed decreased
      undercarboxylated and active osteocalcin and were predisposed to obesity during
      chronic androgen excess. NTF showed increased renal sympathetic tone associated
      with increased blood pressure and they developed glucose intolerance and insulin 
      resistance. Thus, developmental exposure to testosterone in female mice programs 
      features of cardiometabolic dysfunction as can be observed in women with PCOS
      including increased sympathetic tone, visceral adiposity, insulin resistance,
      pre-diabetes and hypertension.
AD  - 1Northwestern University School of Medicine.
FAU - Nohara, Kazunari
AU  - Nohara K
FAU - Waraich, Rizwana S
AU  - Waraich RS
FAU - Liu, Suhuan
AU  - Liu S
FAU - Ferron, Mathieu
AU  - Ferron M
FAU - Waget, Aurelie
AU  - Waget A
FAU - Meyers, Matthew S
AU  - Meyers MS
FAU - Karsenty, Gerard
AU  - Karsenty G
FAU - Burcelin, Remy
AU  - Burcelin R
FAU - Mauvais-Jarvis, Franck
AU  - Mauvais-Jarvis F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - ajpendo.00620.2012 [pii]
AID - 10.1152/ajpendo.00620.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Apr 23.

PMID- 23612968
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 288
IP  - 22
DP  - 2013 May 31
TI  - Recruitment of Nox4 to a Plasma Membrane Scaffold Is Required for Localized
      Reactive Oxygen Species Generation and Sustained Src Activation in Response to
      Insulin-like Growth Factor-I.
PG  - 15641-53
LID - 10.1074/jbc.M113.456046 [doi]
AB  - Nox4-derived ROS is increased in response to hyperglycemia and is required for
      IGF-I-stimulated Src activation. This study was undertaken to determine the
      mechanism by which Nox4 mediates sustained Src activation. IGF-I stimulated
      sustained Src activation, which occurred primarily on the SHPS-1 scaffold
      protein. In vitro oxidation experiments indicated that Nox4-derived ROS was able 
      to oxidize Src when they are in close proximity, and Src oxidation leads to its
      activation. Therefore we hypothesized that Nox4 recruitment to the plasma
      membrane scaffold SHPS-1 allowed localized ROS generation to mediate sustained
      Src oxidation and activation. To determine the mechanism of Nox4 recruitment, we 
      analyzed the role of Grb2, a component of the SHPS-1 signaling complex. We
      determined that Nox4 Tyr-491 was phosphorylated after IGF-I stimulation and was
      responsible for Nox4 binding to the SH2 domain of Grb2. Overexpression of a Nox4 
      mutant, Y491F, prevented Nox4/Grb2 association. Importantly, it also prevented
      Nox4 recruitment to SHPS-1. The role of Grb2 was confirmed using a Pyk2 Y881F
      mutant, which blocked Grb2 recruitment to SHPS-1. Cells expressing this mutant
      had impaired Nox4 recruitment to SHPS-1. IGF-I-stimulated downstream signaling
      and biological actions were also significantly impaired in Nox4
      Y491F-overexpressing cells. Disruption of Nox4 recruitment to SHPS-1 in aorta
      from diabetic mice inhibited IGF-I-stimulated Src oxidation and activation as
      well as cell proliferation. These findings provide insight into the mechanism by 
      which localized Nox4-derived ROS regulates the sustained activity of a tyrosine
      kinase that is critical for mediating signal transduction and biological actions.
AD  - From the Department of Medicine, School of Medicine, University of North
      Carolina, Chapel Hill, North Carolina 27599.
FAU - Xi, Gang
AU  - Xi G
FAU - Shen, Xin-Chun
AU  - Shen XC
FAU - Wai, Christine
AU  - Wai C
FAU - Clemmons, David R
AU  - Clemmons DR
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
SB  - IM
PMC - PMC3668724
OID - NLM: PMC3668724 [Available on 05/31/14]
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Diabetes
OT  - Insulin-like Growth Factor (IGF)
OT  - NADPH Oxidase
OT  - Reactive Oxygen Species (ROS)
OT  - Signal Transduction
OT  - Src
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PMCR- 2014/05/31 00:00
PHST- 2013/04/23 [aheadofprint]
AID - M113.456046 [pii]
AID - 10.1074/jbc.M113.456046 [doi]
PST - ppublish
SO  - J Biol Chem. 2013 May 31;288(22):15641-53. doi: 10.1074/jbc.M113.456046. Epub
      2013 Apr 23.

PMID- 23612952
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1680-0745 (Electronic)
IS  - 1015-9657 (Linking)
VI  - 24
IP  - 2
DP  - 2013 Mar
TI  - Consequences of underlying infection complicate CVD management in Africa.
PG  - 44
AB  - Patients in Africa with a high risk of coronary artery disease (CAD) often have
      elevated levels of C-reactive protein due to inflammation caused by infections.
      Additionally, this underlying inflammation produces significant platelet
      dysfunction in people who have the added complication of diabetes. Each of these 
      complications and their therapeutic consequences were discussed by a
      distinguished faculty at a symposium titled: Unmasking cardiovascular
      complications: what are we missing?
LA  - eng
PT  - Journal Article
PL  - South Africa
TA  - Cardiovasc J Afr
JT  - Cardiovascular journal of Africa
JID - 101313864
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PST - ppublish
SO  - Cardiovasc J Afr. 2013 Mar;24(2):44.

PMID- 23612951
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1680-0745 (Electronic)
IS  - 1015-9657 (Linking)
VI  - 24
IP  - 2
DP  - 2013 Mar
TI  - Epidemiology of ischaemic heart disease in sub-Saharan Africa.
PG  - 34-42
LID - 10.5830/CVJA-2012-071 [doi]
AB  - BACKGROUND: The epidemiology of ischaemic heart disease (IHD) in sub-Saharan
      Africa (SSA) remains largely enigmatic. Major obstacles to our understanding of
      the condition include lack of reliable health statistics, particularly
      cause-specific mortality data, inadequate diagnostic capabilities, shortage of
      physicians and cardiologists, and misguided opinions. METHODS: This review of the
      epidemiology of ischaemic heart disease in sub-Saharan Africa involved a
      systematic bibliographic MEDLINE search of published data on IHD in SSA over the 
      past century. Search words included epidemiology, ischaemic (coronary) heart
      disease, myocardial infarction, cardiovascular risk factors and sub-Saharan
      Africa. Selected data are presented on the prevalence of cardiovascular risk
      factors and mortality from ischaemic heart disease from different countries
      representing the main regions of the continent. RESULTS: Although IHD in SSA
      remains relatively uncommon, its prevalence is predicted to rise in the next two 
      decades due to the rising prevalence of risk factors, especially hypertension,
      diabetes, overweight and obesity, physical inactivity, increased tobacco use and 
      dyslipidaemia. It is estimated that age-standardised mortality rates for IHD will
      rise by 27% in African men and 25% in women by 2015, and by 70 and 74%,
      respectively by 2030. CONCLUSION: Ischaemic heart disease remains relatively
      uncommon in SSA, despite an increasing prevalence of risk factors, but its
      incidence is rising. The pace and direction of economic development, rates of
      urbanisation, and changes in life expectancy resulting from the impact of
      pre-transitional diseases and violence will be major determinants of the IHD
      epidemic in SSA. The best window of opportunity for prevention of the emerging
      epidemic of ischaemic heart disease in sub-Saharan Africa is now.
AD  - Centre for Chronic Diseases, Gaborone, Botswana. onenkede@info.bw
FAU - Onen, Churchill Lukwiya
AU  - Onen CL
LA  - eng
PT  - Journal Article
PL  - South Africa
TA  - Cardiovasc J Afr
JT  - Cardiovascular journal of Africa
JID - 101313864
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/01/23 [received]
PHST- 2012/10/16 [accepted]
AID - 10.5830/CVJA-2012-071 [doi]
PST - ppublish
SO  - Cardiovasc J Afr. 2013 Mar;24(2):34-42. doi: 10.5830/CVJA-2012-071.

PMID- 23612947
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1680-0745 (Electronic)
IS  - 1015-9657 (Linking)
VI  - 24
IP  - 2
DP  - 2013 Mar
TI  - Cardioprotective and anti-hypertensive effects of Prosopis glandulosa in rat
      models of pre-diabetes.
PG  - 10-6
LID - 10.5830/CVJA-2012-069 [doi]
AB  - AIM: Obesity and type 2 diabetes present with two debilitating complications,
      namely, hypertension and heart disease. The dried and ground pods of Prosopis
      glandulosa (commonly known as the Honey mesquite tree) which is part of the
      Fabaceae (or legume) family are currently marketed in South Africa as a food
      supplement with blood glucose-stabilising and anti-hypertensive properties. We
      previously determined its hypoglycaemic effects, and in the current study we
      determined the efficacy of P glandulosa as anti-hypertensive agent and its
      myocardial protective ability. METHODS: Male Wistar rats were rendered either
      pre-diabetic (diet-induced obesity: DIO) or hypertensive (high-fat diet: HFD).
      DIO animals were treated with P glandulosa (100 mg/kg/day for the last eight
      weeks of a 16-week period) and compared to age-matched controls. Hearts were
      perfused ex vivo to determine infarct size. Biometric parameters were determined 
      at the time of sacrifice. Cardiac-specific insulin receptor knock-out (CIRKO)
      mice were similarly treated with P glandulosa and infarct size was determined.
      HFD animals were treated with P glandulosa from the onset of the diet or from
      weeks 12-16, using captopril (50 mg/kg/day) as the positive control. Blood
      pressure was monitored weekly. RESULTS: DIO rats and CIRKO mice: P glandulosa
      ingestion significantly reduced infarct size after ischaemia-reperfusion.
      Proteins of the PI-3-kinase/PKB/Akt survival pathway were affected in a manner
      supporting cardioprotection. HFD model: P glandulosa treatment both prevented and
      corrected the development of hypertension, which was also reflected in
      alleviation of water retention. CONCLUSION: P glandulosa was cardioprotective and
      infarct sparing as well as anti-hypertensive without affecting the body weight or
      the intra-peritoneal fat depots of the animals. Changes in the
      PI-3-kinase/PKB/Akt pathway may be causal to protection. Results indicated water 
      retention, possibly coupled to vasoconstriction in the HFD animals, while
      ingestion of P glandulosa alleviated both. We concluded that treatment of
      pre-diabetes, type 2 diabetes or hypertension with P glandulosa poses possible
      beneficial health effects.
AD  - MRC DDP, Parow, South Africa. bh3@sun.ac.za
FAU - Huisamen, B
AU  - Huisamen B
FAU - George, C
AU  - George C
FAU - Dietrich, D
AU  - Dietrich D
FAU - Genade, S
AU  - Genade S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - South Africa
TA  - Cardiovasc J Afr
JT  - Cardiovascular journal of Africa
JID - 101313864
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/06/07 [received]
PHST- 2012/10/12 [accepted]
AID - 10.5830/CVJA-2012-069 [doi]
PST - ppublish
SO  - Cardiovasc J Afr. 2013 Mar;24(2):10-6. doi: 10.5830/CVJA-2012-069.

PMID- 23612946
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1680-0745 (Electronic)
IS  - 1015-9657 (Linking)
VI  - 24
IP  - 2
DP  - 2013 Mar
TI  - Clinical characteristics and outcomes of atrial fibrillation and flutter at the
      Aga Khan University Hospital, Nairobi.
PG  - 6-9
LID - 10.5830/CVJA-2012-064 [doi]
AB  - INTRODUCTION: Scant data exist on the epidemiology and clinical characteristics
      of atrial fibrillation in Kenya. Traditionally, atrial fibrillation (AF) in
      sub-Saharan Africa is as a result of rheumatic valve disease. However, with the
      economic transition in sub-Saharan Africa, risk factors and associated
      complications of this arrhythmia are likely to change. METHODS: A retrospective
      observational survey was carried out between January 2008 and December 2010.
      Patients with a discharge diagnosis of either atrial fibrillation or flutter were
      included for analysis. The data-collection tool included clinical presentation,
      risk factors and management strategy. Follow-up data were obtained from the
      patients' medical records six months after the index presentation. RESULTS: One
      hundred and sixty-two patients were recruited (mean age 67 +/- 17 years, males
      56%). The distribution was paroxysmal (40%), persistent (20%) and permanent AF
      (40%). Associated co-morbidities included hypertension (68%), heart failure (38%)
      diabetes mellitus (33%) and valvular abnormalities (12%). One-third presented
      with palpitations, dizziness or syncope and 15% with a thromboembolic
      complication as the index AF presentation. Rate-control strategies were
      administered to 78% of the patients, with beta-blockers and digoxin more commonly
      prescribed. Seventy-seven per cent had a CHA(2)DS(2)VASC score >/= 2, but
      one-quarter did not receive any form of oral anticoagulation. At the six-month
      follow up, 6% had died and 12% had been re-admitted at least once. Of the
      high-stroke risk patients on anticoagulation, just over one-half were adequately 
      anticoagulated. CONCLUSION: Hypertension and diabetes mellitus, not rheumatic
      valve disease were the more common co-morbidities. Stroke risk stratification and
      prevention needs to be emphasised and appropriately managed.
AD  - Department of Cardiology, Aga Khan University Hospital, Nairobi, Kenya.
      jay.shavadia@aku.edu
FAU - Shavadia, Jay
AU  - Shavadia J
FAU - Yonga, Gerald
AU  - Yonga G
FAU - Mwanzi, Sitna
AU  - Mwanzi S
FAU - Jinah, Ashna
AU  - Jinah A
FAU - Moriasi, Abednego
AU  - Moriasi A
FAU - Otieno, Harun
AU  - Otieno H
LA  - eng
PT  - Journal Article
PL  - South Africa
TA  - Cardiovasc J Afr
JT  - Cardiovascular journal of Africa
JID - 101313864
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2011/08/01 [received]
PHST- 2012/09/12 [accepted]
AID - 10.5830/CVJA-2012-064 [doi]
PST - ppublish
SO  - Cardiovasc J Afr. 2013 Mar;24(2):6-9. doi: 10.5830/CVJA-2012-064.

PMID- 23612930
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 189
IP  - 6
DP  - 2013 Jun
TI  - [Radiation dose to the pancreas and risk of diabetes mellitus in children
      surviving cancer after abdominal radiotherapy].
PG  - 510-1
LID - 10.1007/s00066-013-0351-0 [doi]
AD  - Medizinische Universitat/AKH Wien, Wahringer Gurtel 18-20, A-1090, Wien,
      Osterreich, Wolfgang.Doerr@meduniwien.ac.at.
FAU - Dorr, W
AU  - Dorr W
LA  - ger
PT  - Journal Article
TT  - Bauchspeicheldruse als Risikoorgan fur die Induktion eines Diabetes mellitus bei 
      Kindern nach Abdominalbestrahlung.
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - 10.1007/s00066-013-0351-0 [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2013 Jun;189(6):510-1. doi: 10.1007/s00066-013-0351-0.

PMID- 23612899
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1432-0932 (Electronic)
IS  - 0940-6719 (Linking)
DP  - 2013 Apr 24
TI  - Predisposing factors for surgical site infection of spinal instrumentation
      surgery for diabetes patients.
AB  - PURPOSE: Diabetes mellitus (DM) is known as an important risk factor for surgical
      site infection (SSI) in spine surgery. It is still unclear however which
      DM-related parameters have stronger influence on SSI. The purpose of this study
      is to determine predisposing factors for SSI following spinal instrumentation
      surgery for patients with DM. METHODS: 110 DM patients (66 males and 44 females) 
      who underwent spinal instrumentation surgery in one institute were enrolled in
      this study. For each patient, various preoperative or intraoperative parameters
      were reviewed from medical records. Patients were divided into two groups (SSI or
      non-SSI) based on the postoperative course. Each parameter between these two
      groups was compared. Univariate and multivariate analyses were performed to
      determine predisposing factor for SSI. RESULTS: The SSI group consisted of 11
      patients (10 %), and the non-SSI group of 99 patients (90 %). Univariate analysis
      revealed that preoperative proteinuria (p = 0.01), operation time (p = 0.04) and 
      estimated blood loss (p = 0.02) were significantly higher in the SSI group
      compared to the non-SSI group. Multivariate logistic regression identified
      preoperative proteinuria as a statistically significant predictor of SSI (OR
      6.28, 95 % CI 1.58-25.0, p = 0.009). CONCLUSIONS: Proteinuria is a significant
      predisposing factor for SSI in spinal instrumentation surgery for DM patients. DM
      patients with proteinuria who are likely to suffer latent nephropathy have a
      potential risk for SSI. For them less invasive surgery is recommended for spinal 
      instrumentation. In this retrospective study, there was no significant difference
      of preoperative condition in glycemic control between the two groups.
AD  - Department of Orthopaedic Surgery, Konan Kosei Hospital, 137 Takayamachi
      Ohmatsubara, Konan, 483-8704, Japan, k-satake@konan.jaaikosei.or.jp.
FAU - Satake, Kotaro
AU  - Satake K
FAU - Kanemura, Tokumi
AU  - Kanemura T
FAU - Matsumoto, Akiyuki
AU  - Matsumoto A
FAU - Yamaguchi, Hidetoshi
AU  - Yamaguchi H
FAU - Ishikawa, Yoshimoto
AU  - Ishikawa Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Eur Spine J
JT  - European spine journal : official publication of the European Spine Society, the 
      European Spinal Deformity Society, and the European Section of the Cervical Spine
      Research Society
JID - 9301980
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/11/06 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/03/08 [revised]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1007/s00586-013-2783-8 [doi]
PST - aheadofprint
SO  - Eur Spine J. 2013 Apr 24.

PMID- 23612842
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Linking)
DP  - 2013 Apr 24
TI  - Cerebroprotective effect of resveratrol through antioxidant and anti-inflammatory
      effects in diabetic rats.
AB  - Oxidative stress and inflammation have been implicated in cerebral
      ischemia/reperfusion injury and complication of diabetes. The present study was
      designed to evaluate whether resveratrol has cerebroprotective action through
      antioxidant and anti-inflammatory actions in diabetic rats. Bilateral common
      carotid artery occlusion (30 min) and reperfusion (4 h) was employed to induce
      cerebral infarction in diabetic Wistar rats. Diabetes was induced by
      streptozocine (50 mg/kg) intraperitoneally at once. Diabetic animals were divided
      into groups as: normal, sham, ischemia-reperfusion, and resveratrol-treated (5,
      10, 20, and 30 mg/kg). These were used for estimation of cerebral infarction.
      Furthermore, 20 mg/kg dose was selected for estimation of oxidative stress
      markers (malondialdehyde, superoxide dismutase, and catalase). Inflammatory
      markers like TNF-alpha, IL-6, IL-10, and myeloperoxidase were estimated and
      histological characters were studied. Resveratrol produced dose-dependent
      reduction in percent cerebral infarction. With resveratrol of 20 mg/kg dose,
      levels of oxidative stress markers and inflammatory markers like malondialdehyde,
      TNF-alpha, IL-6, and myeloperoxidase were reduced and there was a significant
      increase in the levels of antioxidant and anti-inflammatory markers like
      catalase, superoxide dismutase, and IL-10. In the present study, we found that
      mechanism(s) responsible for the cerebroprotective effect of resveratrol in the
      diabetic rat brain involves antioxidant and anti-inflammatory actions.
AD  - Srinivasarao College of Pharmacy, P.M.Palem, Visakhapatnam, Andhra Pradesh,
      India, 530041, orsuprabhakar@yahoo.co.in.
FAU - Prabhakar, Orsu
AU  - Prabhakar O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/01/16 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1007/s00210-013-0871-2 [doi]
PST - aheadofprint
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr 24.

PMID- 23612826
OWN - NLM
STAT- In-Data-Review
DA  - 20130424
IS  - 1726-4642 (Electronic)
IS  - 1726-4634 (Linking)
VI  - 30
IP  - 1
DP  - 2013 Mar
TI  - [Rhabdomyolysis and myopathy as the only manifestations of severe hypothyroidism 
      secondary to Hashimotos thyroiditis].
PG  - 129-32
LID - S1726-46342013000100024 [pii]
AB  - Hashimotos thyroiditis is the most frequent cause of hypothyroidism. In the
      regions with no iodine deficiency, it is more frequent in women and oftentimes
      has a familial association. The symptoms and signs of hypothyroidism are systemic
      and depend on the duration and intensity of the thyroid hormone deficiency.
      Neuromuscular manifestations are seldom the only symptoms and signs present. We
      present the case of a young patient with severe myopathy, where rhabdomyolysis
      was the sole manifestation of severe hypothyroidism secondary to Hashimotos
      thyroiditis.
AD  - Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic,
      Rochester, EE. UU.
FAU - Brito, Juan P
AU  - Brito JP
FAU - Domecq, Juan P
AU  - Domecq JP
FAU - Prutsky, Gabriela
AU  - Prutsky G
FAU - Malaga, German
AU  - Malaga G
FAU - Young, Larry
AU  - Young L
FAU - Kargi, Atil Y
AU  - Kargi AY
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Rabdomiolisis y miopatia como unicas manifestaciones de hipotiroidismo severo
      secundario a tiroiditis de Hashimoto.
PL  - Peru
TA  - Rev Peru Med Exp Salud Publica
JT  - Revista peruana de medicina experimental y salud publica
JID - 101227566
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/11/06 [received]
PHST- 2013/01/23 [accepted]
AID - S1726-46342013000100024 [pii]
PST - ppublish
SO  - Rev Peru Med Exp Salud Publica. 2013 Mar;30(1):129-32.

PMID- 23612816
OWN - NLM
STAT- In-Data-Review
DA  - 20130424
IS  - 1726-4642 (Electronic)
IS  - 1726-4634 (Linking)
VI  - 30
IP  - 1
DP  - 2013 Mar
TI  - [Prevalence of left ventricular hypertrophy in diabetic patients].
PG  - 69-72
LID - S1726-46342013000100014 [pii]
AB  - In order to establish the prevalence of left ventricular hypertrophy (LVH) in
      patients with type 2 diabetes mellitus, (DM) a cross-sectional study was
      conducted in these patients studying their anthropometric characteristics, blood 
      pressure and metabolic control. To evaluate the presence of LVH, a trans-thoracic
      echocardiogram was used. The study included 91 patients, finding a 63.7%
      prevalence of HVI, with women being more affected than men (p=0.001).
      Additionally, 46.2% of patients were found to have diastolic dysfunction of the
      left ventricle. We conclude that there is an important prevalence of LVH in
      diabetic patients without defined causes of hypertrophy. There was no association
      with sex, metabolic control, BMI and time of diagnosis.
AD  - Hospital Basico Jipijapa, Jipijapa, Ecuador.
FAU - Valarezo-Sevilla, Diego
AU  - Valarezo-Sevilla D
FAU - Pazmino-Martinez, Armin
AU  - Pazmino-Martinez A
FAU - Morales-Mora, Nidya
AU  - Morales-Mora N
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Prevalencia de hipertrofia ventricular izquierda en pacientes diabeticos.
PL  - Peru
TA  - Rev Peru Med Exp Salud Publica
JT  - Revista peruana de medicina experimental y salud publica
JID - 101227566
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/11/01 [received]
PHST- 2013/02/20 [accepted]
AID - S1726-46342013000100014 [pii]
PST - ppublish
SO  - Rev Peru Med Exp Salud Publica. 2013 Mar;30(1):69-72.

PMID- 23612744
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1573-7284 (Electronic)
IS  - 0393-2990 (Linking)
VI  - 28
IP  - 5
DP  - 2013 May
TI  - Offspring preterm birth and birth size are related to long-term risk of maternal 
      diabetes.
PG  - 427-32
LID - 10.1007/s10654-013-9805-z [doi]
AB  - The aim of the study is to investigate the association between gestational age,
      birth size, and the long-term risk of maternal diabetes. We conducted a
      nation-wide prospective follow-up study of the cohort of all Danish women with a 
      singleton delivery in 1982/1983 (index delivery) and no history of diabetes (n = 
      100,669). Registries were used to extract information on patients with a hospital
      or outpatient diagnosis of diabetes, subsequent deliveries, and death/emigration 
      in the period from the index delivery until the end of 2006. The association
      between the maternal risk of diabetes and the index gestational age and index
      offspring birth size (birth weight adjusted for gestational age) was investigated
      by using Cox proportional hazards regression models stratified according to young
      (</=33 years) and old age (>33 years). During a median follow-up period of 24
      years, 2,021 women (2.0 %) were diagnosed as having diabetes. The risk of
      maternal diabetes was positively associated with increasing index birth size and 
      negatively associated with increasing duration of index gestation in both age
      strata. Among young women, the highest hazard ratios were found for the exposure 
      category of large index offspring birth size (adjusted HR 9.0, 95 % CI
      6.17-13.12) and a preterm delivery at 32-37 weeks (adjusted HR 2.22, 95 % CI
      1.46-3.40). Offspring preterm birth and large size for gestational age at birth
      are associated with increased risk of maternal diabetes.
AD  - Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen
      University, Kettegaard Alle 30, 2650, Hvidovre, Denmark, kvnaver@gmail.com.
FAU - Naver, Klara Vinsand
AU  - Naver KV
FAU - Secher, Niels Jorgen
AU  - Secher NJ
FAU - Ovesen, Per Glud
AU  - Ovesen PG
FAU - Gorst-Rasmussen, Anders
AU  - Gorst-Rasmussen A
FAU - Lundbye-Christensen, Soren
AU  - Lundbye-Christensen S
FAU - Nilas, Lisbeth
AU  - Nilas L
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - Netherlands
TA  - Eur J Epidemiol
JT  - European journal of epidemiology
JID - 8508062
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/04/26 [received]
PHST- 2013/04/13 [accepted]
PHST- 2013/04/24 [aheadofprint]
AID - 10.1007/s10654-013-9805-z [doi]
PST - ppublish
SO  - Eur J Epidemiol. 2013 May;28(5):427-32. doi: 10.1007/s10654-013-9805-z. Epub 2013
      Apr 24.

PMID- 23612703
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 4
IP  - 6
DP  - 2013 Jun 28
TI  - A review of the gastroprotective effects of ginger (Zingiber officinale Roscoe).
PG  - 845-55
LID - 10.1039/c3fo30337c [doi]
AB  - The rhizomes of Zingiber officinale Roscoe (Zingiberaceae), commonly known as
      ginger is an important kitchen spice and also possess a myriad health benefits.
      The rhizomes have been used since antiquity in the various traditional systems of
      medicine to treat arthritis, rheumatism, sprains, muscular aches, pains, sore
      throats, cramps, hypertension, dementia, fever, infectious diseases, catarrh,
      nervous diseases, gingivitis, toothache, asthma, stroke and diabetes. Ginger is
      also used as home remedy and is of immense value in treating various gastric
      ailments like constipation, dyspepsia, belching, bloating, gastritis, epigastric 
      discomfort, gastric ulcerations, indigestion, nausea and vomiting and scientific 
      studies have validated the ethnomedicinal uses. Ginger is also shown to be
      effective in preventing gastric ulcers induced by nonsteroidal anti-inflammatory 
      drugs [NSAIDs like indomethacin, aspirin], reserpine, ethanol, stress
      (hypothermic and swimming), acetic acid and Helicobacter pylori-induced gastric
      ulcerations in laboratory animals. Various preclinical and clinical studies have 
      also shown ginger to possess anti-emetic effects against different emetogenic
      stimuli. However, conflicting reports especially in the prevention of
      chemotherapy-induced nausea and vomiting and motion sickness prevent us from
      drawing any firm conclusion on its effectiveness as a broad spectrum anti-emetic.
      Ginger has been shown to possess free radical scavenging, antioxidant; inhibition
      of lipid peroxidation and that these properties might have contributed to the
      observed gastroprotective effects. This review summarizes the various
      gastroprotective effects of ginger and also emphasizes on aspects that warranty
      future research to establish its activity and utility as a gastroprotective agent
      in humans.
AD  - Department of Research, Research and Development, Father Muller Medical College, 
      Kankanady, Mangalore, Karnataka, India 575002. msbaliga@gmail.com.
FAU - Haniadka, Raghavendra
AU  - Haniadka R
FAU - Saldanha, Elroy
AU  - Saldanha E
FAU - Sunita, Venkatesh
AU  - Sunita V
FAU - Palatty, Princy L
AU  - Palatty PL
FAU - Fayad, Raja
AU  - Fayad R
FAU - Baliga, Manjeshwar Shrinath
AU  - Baliga MS
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/24 [aheadofprint]
PHST- 2013/05/28 [epublish]
AID - 10.1039/c3fo30337c [doi]
PST - ppublish
SO  - Food Funct. 2013 Jun 28;4(6):845-55. doi: 10.1039/c3fo30337c. Epub 2013 Apr 24.

PMID- 23612696
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 Apr 24
TI  - Plasma ceramides are elevated in female children and adolescents with type 2
      diabetes.
PG  - 1-4
LID - 10.1515/jpem-2012-0407 [doi]
LID - /j/jpem.ahead-of-print/jpem-2012-0407/jpem-2012-0407.xml [pii]
AB  - Abstract Accumulation of ceramides within tissues induces insulin resistance.
      Moreover, adiponectin exerts its beneficial metabolic effects at least partially 
      through ceramide catabolism. We hypothesized that specific plasma ceramide
      subspecies are elevated in obese children and adolescents with type 2 diabetes
      (T2D), and that they inversely correlate with adiponectin and measures of insulin
      sensitivity. This was a cross-sectional study. Participants included 14 obese
      female subjects with T2D, ages 10-17, and 14 lean healthy controls of the same
      age and gender. Fasting plasma ceramide subspecies were measured by quantitative 
      tandem mass spectrometry. Subjects with T2D had higher concentrations of C22:0
      and C20:0 ceramides, with a 2-fold increase in C18:0 ceramide and C24:1
      dihydroceramide (p<0.05). C22:0, C20:0 and C18:0 ceramide correlated with
      decreased adiponectin concentrations, increased HOMA-IR, BMI Z-score,
      triglyceride and fasting blood glucose concentrations (p<0.05). Plasma levels of 
      C18:0, C20:0 and C22:0 ceramide, as well as C24:1 dihydroceramide, were elevated 
      in obese female children and adolescents with T2D. This may be a reflection of
      tissue insulin resistance and could be a result of low adiponectin levels.
FAU - Lopez, Ximena
AU  - Lopez X
FAU - Goldfine, Allison B
AU  - Goldfine AB
FAU - Holland, William L
AU  - Holland WL
FAU - Gordillo, Ruth
AU  - Gordillo R
FAU - Scherer, Philipp E
AU  - Scherer PE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/12/17 [received]
PHST- 2013/02/18 [accepted]
AID - 10.1515/jpem-2012-0407 [doi]
AID - /j/jpem.ahead-of-print/jpem-2012-0407/jpem-2012-0407.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 Apr 24:1-4. doi: 10.1515/jpem-2012-0407.

PMID- 23612669
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1434-6621 (Electronic)
IS  - 1434-6621 (Linking)
DP  - 2013 Apr 11
TI  - Relationship between coffee consumption, oxidant status, and antioxidant
      potential in the Japanese general population.
PG  - 1-9
LID - 10.1515/cclm-2013-0146 [doi]
LID - /j/cclm.ahead-of-print/cclm-2013-0146/cclm-2013-0146.xml [pii]
AB  - Abstract Background: Several previous studies have demonstrated an association
      between habitual coffee intake and reduced risk of diabetes, cardiovascular
      morbidity and total mortality. Although the cause and effect relationship could
      not be determined through epidemiological data, antioxidant properties of coffee 
      ingredients are presumed. Methods: In the current study, by analyzing the data
      from 9877 subjects (mean age 59.2+/-10.4 years) who underwent general health
      screening, we evaluated the extent of in vivo oxidative stress by measuring
      derivatives of reactive oxygen metabolites (d-ROMs) and biological antioxidant
      potential (BAP). Results: The mean levels of d-ROM and BAP were significantly
      lower in women than in men. By univariate analysis (ANOVA), coffee consumption
      showed a graded negative association with d-ROM value in men, but not in women.
      Coffee consumption was unrelated to BAP levels in men and women. Smoking was
      significantly associated with increased d-ROM and decreased BAP values in men.
      Multivariate-adjusted analysis showed that coffee intake of three or more cups
      per day was an independent negative correlate of d-ROM value in men. Sugar use
      was negatively associated with d-ROM and BAP values in women. Conclusions: Among 
      an essentially healthy population, coffee intake was negatively associated with
      d-ROMs in men, but not in women. Whether the favorable effect of coffee, if
      present, is related to lower oxidative stress levels needs further investigation.
FAU - Ishizaka, Yuko
AU  - Ishizaka Y
FAU - Yamakado, Minoru
AU  - Yamakado M
FAU - Toda, Akiko
AU  - Toda A
FAU - Tani, Mizuki
AU  - Tani M
FAU - Ishizaka, Nobukazu
AU  - Ishizaka N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine : CCLM / FESCC
JID - 9806306
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/01/03 [received]
PHST- 2013/03/14 [accepted]
AID - 10.1515/cclm-2013-0146 [doi]
AID - /j/cclm.ahead-of-print/cclm-2013-0146/cclm-2013-0146.xml [pii]
PST - aheadofprint
SO  - Clin Chem Lab Med. 2013 Apr 11:1-9. doi: 10.1515/cclm-2013-0146.

PMID- 23612664
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1434-6621 (Electronic)
IS  - 1434-6621 (Linking)
DP  - 2013 Apr 11
TI  - Chelation therapy for the management of diabetic complications: a hypothesis and 
      a proposal for clinical laboratory assessment of metal ion homeostasis in plasma.
PG  - 1-7
LID - 10.1515/cclm-2012-0881 [doi]
LID - /j/cclm.ahead-of-print/cclm-2012-0881/cclm-2012-0881.xml [pii]
AB  - Abstract In a recent article, we presented the hypothesis that
      decompartmentalized metal ions are a major contributor to the development of
      diabetic complications and supported the use of chelation therapy for the
      treatment of diabetic complications [Nagai R, Murray DB, Metz TO, Baynes JW.
      Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and
      other inhibitors of diabetes complications. Diabetes 2012;61:549-59]. Evidence in
      support of this hypothesis included the observation that many drugs used in the
      treatment of diabetes are chelators, that advanced glycation end product (AGE)
      inhibitors and AGE breakers lack carbonyl-trapping or AGE-breaker activity but
      are potent chelators, and that simple copper chelators inhibit vascular pathology
      in diabetes and aging. In the present article, we extend this hypothesis,
      proposing the interplay between copper and iron in the development of pathology
      in diabetes and other chronic age-related diseases, including atherosclerosis and
      neurodegenerative diseases. We also discuss the need and provide a framework for 
      the development of a clinical laboratory test to assess plasma autoxidative
      catalytic activity and transition metal homeostasis in vivo.
FAU - Frizzell, Norma
AU  - Frizzell N
FAU - Baynes, John W
AU  - Baynes JW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine : CCLM / FESCC
JID - 9806306
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/12/14 [received]
PHST- 2013/03/07 [accepted]
AID - 10.1515/cclm-2012-0881 [doi]
AID - /j/cclm.ahead-of-print/cclm-2012-0881/cclm-2012-0881.xml [pii]
PST - aheadofprint
SO  - Clin Chem Lab Med. 2013 Apr 11:1-7. doi: 10.1515/cclm-2012-0881.

PMID- 23612647
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 Apr 22
TI  - Thyroid-stimulating hormone (TSH) level in nutritionally obese children and
      metabolic co-morbidity.
PG  - 1-6
LID - 10.1515/jpem-2012-0384 [doi]
LID - /j/jpem.ahead-of-print/jpem-2012-0384/jpem-2012-0384.xml [pii]
AB  - Abstract Objective: In recent years, there has been increasing focus on thyroid
      function in pediatric obese patients. Our aims were to investigate whether there 
      is an association between serum thyroid-stimulating hormone (TSH) within the
      normal range and body mass index (BMI), and to determine if TSH levels correlate 
      with metabolic risk factors in children. Methods: A retrospective cross-sectional
      analysis was carried out on 528 euthyroid, age- and sex-matched lean, overweight,
      or obese children. Anthropometric indices, blood pressure, fasting blood glucose,
      hepatic enzymes, lipid profiles, TSH, free triiodothyronine (fT3), and free
      thyroxine (fT4) were assessed from medical records and compared among groups.
      Subjects with known presence of diabetes, using medications altering blood
      pressure and glucose or lipid metabolism, with TSH levels >97.5 or <2.5
      percentile, or with autoimmune thyroid disease were excluded. Results:
      Hypertension, dyslipidemia, and elevated levels of hepatic enzymes were found to 
      be more common in overweight and obese children (p<0.001), and those metabolic
      changes were significantly correlated with the increase in BMI (p<0.05). Serum
      concentrations of TSH and fT3 within the normal range were higher in overweight
      and obese children (p<0.01), and TSH was positively correlated with total
      cholesterol, triglycerides, and systolic blood pressure (p<0.05). Conclusion: Our
      findings suggest that obese children have higher serum TSH and fT3 levels even
      within the normal range, and that an increase in TSH is associated with
      dyslipidemia and higher systolic blood pressure. It remains to be seen whether
      TSH might serve as a potential marker of metabolic risk factors in obese
      pediatric patients.
FAU - Aypak, Cenk
AU  - Aypak C
FAU - Turedi, Ozlem
AU  - Turedi O
FAU - Yuce, Adnan
AU  - Yuce A
FAU - Gorpelioglu, Suleyman
AU  - Gorpelioglu S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/12/03 [received]
PHST- 2013/03/05 [accepted]
AID - 10.1515/jpem-2012-0384 [doi]
AID - /j/jpem.ahead-of-print/jpem-2012-0384/jpem-2012-0384.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 Apr 22:1-6. doi: 10.1515/jpem-2012-0384.

PMID- 23612627
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1619-3997 (Electronic)
IS  - 0300-5577 (Linking)
DP  - 2013 Apr 11
TI  - Subsequent pregnancy after stillbirth: obstetrical and medical risks.
PG  - 1-6
LID - 10.1515/jpm-2013-0013 [doi]
LID - /j/jpme.ahead-of-print/jpm-2013-0013/jpm-2013-0013.xml [pii]
AB  - Abstract Objective: To evaluate obstetric outcome after stillbirth according to
      placental and prothrombotic risk factors. Methods: Obstetric outcomes of women
      with prior stillbirth and subsequent pregnancies were reviewed. Data on the
      immediate subsequent pregnancy included fetal loss, stillbirth, obstetric/medical
      complications, gestational age and birth weight at delivery, mode of delivery,
      thrombophilia, and prescribed medication. Placental stillbirth was defined as
      stillbirth associated with placental abruption, intrauterine growth restriction
      (IUGR), or histological evidence of placental infarcts. Controls were unselected 
      women who gave birth at our center during a single calendar year. Factors
      influencing recurrence risks were estimated. Results: Seventy-three subsequent
      pregnancies were identified. Five out of 73 (6.8%) women had a repeat stillbirth,
      significantly higher than controls (relative risk 22.2, 95% confidence interval
      8.9-55.4). Four out of five repeat stillbirth cases occurred <37 weeks gestation.
      Hypertensive complications, diabetes and abruption were higher, while gestational
      age and birth weight at delivery were significantly lower than controls. Prior
      placental stillbirth was associated with a 10.5 times higher risk of IUGR in the 
      subsequent pregnancy compared with non-placental stillbirth. All five repeat
      stillbirth cases occurred in thrombophilic women. Conclusion: Women with prior
      stillbirth face an increased risk of pregnancy complications and stillbirth
      recurrence, especially with concurrent thrombophilia. Most repeat stillbirth
      cases occur preterm.
FAU - Ofir, Keren
AU  - Ofir K
FAU - Kalter, Anat
AU  - Kalter A
FAU - Moran, Orit
AU  - Moran O
FAU - Sivan, Eyal
AU  - Sivan E
FAU - Schiff, Eyal
AU  - Schiff E
FAU - Simchen, Michal J
AU  - Simchen MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - J Perinat Med
JT  - Journal of perinatal medicine
JID - 0361031
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/01/20 [received]
PHST- 2013/03/15 [accepted]
AID - 10.1515/jpm-2013-0013 [doi]
AID - /j/jpme.ahead-of-print/jpm-2013-0013/jpm-2013-0013.xml [pii]
PST - aheadofprint
SO  - J Perinat Med. 2013 Apr 11:1-6. doi: 10.1515/jpm-2013-0013.

PMID- 23612547
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1434-6621 (Electronic)
IS  - 1434-6621 (Linking)
DP  - 2013 Apr 2
TI  - Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from
      SCORE cardiovascular risk score, and remains so after 3 years.
PG  - 1-7
LID - 10.1515/cclm-2012-0825 [doi]
LID - /j/cclm.ahead-of-print/cclm-2012-0825/cclm-2012-0825.xml [pii]
AB  - Abstract Background: Skin autofluorescence (SAF), as a proxy of AGE accumulation,
      is predictive of cardiovascular (CVD) complications in i.a. type 2 diabetes
      mellitus and renal failure, independently of most conventional CVD risk factors. 
      The present exploratory substudy of the Groningen Overweight and Lifestyle
      (GOAL)-project addresses whether SAF is related to Systematic COronary Risk
      Evaluation (SCORE) risk estimation (% 10-year CVD-mortality risk) in
      overweight/obese persons in primary care, without diabetes/renal disease, and if 
      after 3-year treatment of risk factors (change in, Delta) SAF is related to
      DeltaSCORE. Methods: In a sample of 65 participants from the GOAL study, with a
      body mass index (BMI) >25-40 kg/m2, hypertension and/or dyslipidemia, but without
      diabetes/renal disease, SAF and CVD risk factors were measured at baseline, and
      after 3 years of lifestyle and pharmaceutical treatment. Results: At baseline,
      the mean SCORE risk estimation was 3.1+/-2.6%, mean SAF 2.04+/-0.5AU. In
      multivariate analysis SAF was strongly related to age, but not to other risk
      factors/SCORE. After 3 years DeltaSAF was 0.34+/-0.45 AU (p<0.001). DeltaSAF was 
      negatively related to Deltabodyweight but not to DeltaSCORE%, or its components. 
      At follow-up, SAF was higher in 11 patients with a history of CVD compared to 54 
      persons without CVD (p=0.002). Conclusions: Baseline and 3-year-Delta SAF are not
      related to (Delta)SCORE, or its components, except age, in the studied
      population. DeltaSAF was negatively related to Deltaweight. As 3-year SAF was
      higher in persons with CVD, these results support a larger study on SAF to assess
      its contribution to conventional risk factors/SCORE in predicting CVD in
      overweight persons with low-intermediate cardiovascular risk.
FAU - Tiessen, Ans H
AU  - Tiessen AH
FAU - Jager, Willemein
AU  - Jager W
FAU - Ter Bogt, Nancy C W
AU  - Ter Bogt NC
FAU - Beltman, Frank W
AU  - Beltman FW
FAU - van der Meer, Klaas
AU  - van der Meer K
FAU - Broer, Jan
AU  - Broer J
FAU - Smit, Andries J
AU  - Smit AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130402
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine : CCLM / FESCC
JID - 9806306
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/11/29 [received]
PHST- 2013/03/07 [accepted]
AID - 10.1515/cclm-2012-0825 [doi]
AID - /j/cclm.ahead-of-print/cclm-2012-0825/cclm-2012-0825.xml [pii]
PST - aheadofprint
SO  - Clin Chem Lab Med. 2013 Apr 2:1-7. doi: 10.1515/cclm-2012-0825.

PMID- 23612543
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1434-6621 (Electronic)
IS  - 1434-6621 (Linking)
DP  - 2013 Apr 2
TI  - Citric/citrate buffer: an effective antiglycolytic agent.
PG  - 1-7
LID - 10.1515/cclm-2012-0735 [doi]
LID - /j/cclm.ahead-of-print/cclm-2012-0735/cclm-2012-0735.xml [pii]
AB  - Abstract Background: In order to minimize the influence of glycolysis on diabetes
      mellitus (DM) diagnostic tests, we have compared the behavior of citric/citrate, 
      fluoride additives and gel-serum with plasma-heparin under careful preanalytical 
      conditions. Subsequently, we compared the effectiveness of both fluoride and
      citric additives at different pre-centrifugation times. Finally, the influence of
      citric/citrate collection tube on diagnostic tests results was evaluated.
      Methods: The first study of 80 voluntary patients assessed the glucose bias of
      citric/citrate, fluoride additive tubes and gel-serum tubes versus plasma-heparin
      tubes at several medical decision cut-offs (MDC). The second study performed with
      72 volunteers evaluated additives, simulating transport times to the laboratory
      and centrifugation delay periods. Final evaluation compares the proportion of
      positive tests in total tests carried out in two different periods. Results: When
      citric/citrate (n=79) and fluoride tubes (n=60) were compared with plasma-heparin
      under controlled preanalytical conditions, both met the bias specification for
      plasma glucose (+/-1.8%) at seven MDC. On the contrary, serum samples (n=15) did 
      not meet it at five MDC. In the second study, differences in glucose values at
      distinct pre-centrifugation times were not statistically significant for
      citric/citrate tubes, but significant for fluoride tubes and also for comparison 
      of fluoride and citric/citrate tubes. Hemolysis in fluoride tubes was higher.
      Citric/citrate tube implementation in our laboratory caused an increase in
      positive diagnostic tests that were only statistically significant for
      gestational diabetes mellitus (GDM) screening. Conclusions: Citric/citrate
      additive tube is equivalent to plasma-heparin avoiding glycolysis completely and 
      immediately under careful preanalytical conditions even with a 3-h delay in
      plasma separation. According to used MDC we have not statistically significantly 
      increased the diagnoses of DM cases.
FAU - Del Pino, Isabel Garcia
AU  - Del Pino IG
FAU - Constanso, Ignacio
AU  - Constanso I
FAU - Mourin, Luis Vazquez
AU  - Mourin LV
FAU - Safont, Carmela Barbuzano
AU  - Safont CB
FAU - Vazquez, Pastora Rodriguez
AU  - Vazquez PR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130402
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine : CCLM / FESCC
JID - 9806306
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/10/25 [received]
PHST- 2013/02/25 [accepted]
AID - 10.1515/cclm-2012-0735 [doi]
AID - /j/cclm.ahead-of-print/cclm-2012-0735/cclm-2012-0735.xml [pii]
PST - aheadofprint
SO  - Clin Chem Lab Med. 2013 Apr 2:1-7. doi: 10.1515/cclm-2012-0735.

PMID- 23612541
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1434-6621 (Electronic)
IS  - 1434-6621 (Linking)
DP  - 2013 Apr 2
TI  - Increased circulating advanced glycation endproducts (AGEs) in acute trauma
      patients.
PG  - 1-6
LID - 10.1515/cclm-2012-0834 [doi]
LID - /j/cclm.ahead-of-print/cclm-2012-0834/cclm-2012-0834.xml [pii]
AB  - Abstract Background: Circulating levels of pro-inflammatory advanced glycation
      end products (AGEs) are increased in diabetes and other conditions characterized 
      by chronically elevated oxidant stress (OS). OS also increases after acute trauma
      and is implicated in the development of complications such as multiple organ
      failure. Herein, we assess the effect of acute OS on circulating levels of AGEs
      in a cohort of acute trauma victims. Methods: An observational study was
      performed at a large Level 1 Trauma Center. Blood samples for measurement of two 
      AGEs, carboxymethyllysine (CML) and methylglyoxal (MG), were obtained at
      admission, and serially afterwards in patients admitted to the ICU. Demographics,
      dietary history, markers of injury severity and ICU morbidity and mortality data 
      were collected. Results: One hundred and fifty-six trauma patients (TP) (age:
      39+/-17 years, 83% males, injury severity score: 18+/-14) were included in the
      study. TP had significantly higher serum AGE levels than normal healthy controls 
      (CML, TP 12.4+/-8.2 U/mL vs. controls 8.9+/-5.3 U/mL, p<0.001; MG, TP 2.1+/-1.4
      nmol/mL vs. controls 0.79+/-0.3 nmol/mL, p<0.001). Admission serum AGE levels in 
      49 severe TP admitted to the ICU were lower than those who were not. However,
      among the ICU patients, serum AGEs increased further for about 7 days in patients
      with an uncomplicated course, and remained markedly elevated in those with a
      complicated course. Conclusions: Circulating AGEs are transiently increased after
      acute trauma and persistently elevated AGE levels are associated with greater
      severity of injury.
FAU - Schulman, Carl I
AU  - Schulman CI
FAU - Uribarri, Jaime
AU  - Uribarri J
FAU - Cai, Weijing
AU  - Cai W
FAU - Manning, Ron
AU  - Manning R
FAU - Landy, David C
AU  - Landy DC
FAU - Gallardo, Margaret
AU  - Gallardo M
FAU - Castillo, Angela
AU  - Castillo A
FAU - Namias, Nicholas
AU  - Namias N
FAU - Striker, Gary E
AU  - Striker GE
FAU - Livingstone, Alan
AU  - Livingstone A
FAU - Vlassara, Helen
AU  - Vlassara H
LA  - ENG
GR  - R01 DK091231/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130402
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine : CCLM / FESCC
JID - 9806306
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/11/30 [received]
PHST- 2013/03/07 [accepted]
AID - 10.1515/cclm-2012-0834 [doi]
AID - /j/cclm.ahead-of-print/cclm-2012-0834/cclm-2012-0834.xml [pii]
PST - aheadofprint
SO  - Clin Chem Lab Med. 2013 Apr 2:1-6. doi: 10.1515/cclm-2012-0834.

PMID- 23612534
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 0334-018X (Print)
IS  - 0334-018X (Linking)
DP  - 2013 Apr 2
TI  - The contribution of art therapy in poorly controlled youth with type 1 diabetes
      mellitus.
PG  - 1-5
LID - 10.1515/jpem-2012-0342 [doi]
LID - /j/jpem.ahead-of-print/jpem-2012-0342/jpem-2012-0342.xml [pii]
AB  - Abstract Objective: To evaluate the effect of intensive art therapy in youth with
      poorly controlled type 1 diabetes mellitus (T1DM). Methods: A retrospective
      report of the characteristics and outcomes of all patients who were offered to
      receive individual art therapy sessions because of behavioral difficulties.
      Results: The study population included 29 participants. The main behavioral
      difficulties were needle phobia and lack of compliance with nutritional
      recommendations or with insulin administration. The intervention group included
      16 patients, with a mean age of 9.3+/-2.5 years, average intervention length of
      0.77+/-0.41 years, and long-term data of 2.27+/-1.13 years. The control group
      included 13 patients, with a mean age of 9.3+/-3.4 years. Improvement was
      observed in 56% of the case group and in 23% of the control group. Art therapy
      was associated with a decrease in hemoglobin A1c in the intervention group
      compared with a similar control group (-0.79%, +/-0.24%; r=0.17, p=0.025).
      Conclusions: The addition of intensive art therapy for poorly controlled youth
      with T1DM may improve their glycemic control.
FAU - Harel, Shira
AU  - Harel S
FAU - Yanai, Livia
AU  - Yanai L
FAU - Brooks, Ronit
AU  - Brooks R
FAU - Bar, Yakira
AU  - Bar Y
FAU - Bistritzer, Tzvy
AU  - Bistritzer T
FAU - Ivgi, Shosh
AU  - Ivgi S
FAU - Rachmiel, Marianna
AU  - Rachmiel M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130402
TA  - J Pediatr Endocrinol Metab
JT  - Journal of pediatric endocrinology & metabolism : JPEM
JID - 9508900
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/10/21 [received]
PHST- 2013/02/21 [accepted]
AID - 10.1515/jpem-2012-0342 [doi]
AID - /j/jpem.ahead-of-print/jpem-2012-0342/jpem-2012-0342.xml [pii]
PST - aheadofprint
SO  - J Pediatr Endocrinol Metab. 2013 Apr 2:1-5. doi: 10.1515/jpem-2012-0342.

PMID- 23612512
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1476-5640 (Electronic)
IS  - 0954-3007 (Linking)
DP  - 2013 Apr 24
TI  - Overweight, obesity and related non-communicable diseases in Asian Indian girls
      and women.
LID - 10.1038/ejcn.2013.70 [doi]
AB  - The prevalence of obesity is rising globally and in India. Overweight, obesity
      and related diseases need to be delineated in Asian Indian women. A literature
      search was done using key words like 'obesity', 'Asian Indian women', 'body fat
      distribution', 'type 2 diabetes', 'fertility', 'polycystic ovarian disease',
      metabolic syndrome', 'cardiovascular disease', 'non-alcoholic fatty liver
      disease', 'gender', 'sex' and 'prevalence' up to September 2012 in Pubmed and
      Google Scholar search engines. This review highlights the Asian Indian body
      composition with regards to obesity and provides a collated perspective of
      gender-specific prevalence of the co-morbidities. Recent data show that women
      (range of prevalence of overweight and obesity from different studies 15-61%)
      have higher prevalence of overweight and obesity as compared with men (range of
      prevalence of overweight and obesity from different studies 12-54%) in India and 
      that obesity is increasing in the youth. The prevalence of overweight and obesity
      in both men and women steeply rose in a Punjabi community from Jaipur.
      Importantly, prevalence of abdominal obesity has been consistently higher in
      women than in men. The lowest prevalence (6.0%) of type 2 diabetes mellitus in
      women is reported from South India (rural Andhra Pradesh; 2006) and the highest
      (14.0%) by the National Urban Diabetes Survey (2001). Although the clustering of 
      cardiovascular disease risk factors was generally high, it increased further in
      post-menopausal women. There are a number of factors that predispose Indian women
      to obesity; sedentary behaviour, imbalanced diets, sequential and additive
      postpartum weight gain and further decrease in physical activity during this
      period and cultural issues. In view of these data, preventive measures should be 
      specifically targeted to Indian women.European Journal of Clinical Nutrition
      advance online publication, 24 April 2013; doi:10.1038/ejcn.2013.70.
AD  - 1] National Diabetes Obesity and Cholesterol Foundation (N-DOC), New Delhi, India
      [2] Diabetes Foundation (India), New Delhi, India [3] Center for Nutrition and
      Metabolic Research (CNET), New Delhi, India.
FAU - Chopra, S M
AU  - Chopra SM
FAU - Misra, A
AU  - Misra A
FAU - Gulati, S
AU  - Gulati S
FAU - Gupta, R
AU  - Gupta R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Eur J Clin Nutr
JT  - European journal of clinical nutrition
JID - 8804070
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/24 [aheadofprint]
AID - ejcn201370 [pii]
AID - 10.1038/ejcn.2013.70 [doi]
PST - aheadofprint
SO  - Eur J Clin Nutr. 2013 Apr 24. doi: 10.1038/ejcn.2013.70.

PMID- 23612482
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1752-2978 (Electronic)
IS  - 1752-296X (Linking)
VI  - 20
IP  - 3
DP  - 2013 Jun
TI  - Current world literature. Adrenal cortex and medulla.
PG  - 245-58
LID - 10.1097/MED.0b013e328361cfbd [doi]
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Endocrinol Diabetes Obes
JT  - Current opinion in endocrinology, diabetes, and obesity
JID - 101308636
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - 10.1097/MED.0b013e328361cfbd [doi]
AID - 01266029-201306000-00014 [pii]
PST - ppublish
SO  - Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):245-58. doi:
      10.1097/MED.0b013e328361cfbd.

PMID- 23612372
OWN - NLM
STAT- In-Data-Review
DA  - 20130424
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 11
IP  - 4
DP  - 2013
TI  - PTP1B Inhibitory and Anti-Inflammatory Effects of Secondary Metabolites Isolated 
      from the Marine-Derived Fungus Penicillium sp. JF-55.
PG  - 1409-26
LID - 10.3390/md11041409 [doi]
AB  - Protein tyrosine phosphatase 1B (PTP1B) plays a major role in the negative
      regulation of insulin signaling, and is thus considered as an attractive
      therapeutic target for the treatment of diabetes. Bioassay-guided investigation
      of the methylethylketone extract of marine-derived fungus Penicillium sp. JF-55
      cultures afforded a new PTP1B inhibitory styrylpyrone-type metabolite named
      penstyrylpyrone (1), and two known metabolites, anhydrofulvic acid (2) and
      citromycetin (3). Compounds 1 and 2 inhibited PTP1B activity in a dose-dependent 
      manner, and kinetic analyses of PTP1B inhibition suggested that these compounds
      inhibited PTP1B activity in a competitive manner. In an effort to gain more
      biological potential of the isolated compounds, the anti-inflammatory effects of 
      compounds 1-3 were also evaluated. Among the tested compounds, only compound 1
      inhibited the production of NO and PGE2, due to the inhibition of the expression 
      of iNOS and COX-2. Penstyrylpyrone (1) also reduced TNF-alpha and IL-1beta
      production, and these anti-inflammatory effects were shown to be correlated with 
      the suppression of the phosphorylation and degradation of IkappaB-alpha,
      NF-kappaB nuclear translocation, and NF-kappaB DNA binding activity. In addition,
      using inhibitor tin protoporphyrin (SnPP), an inhibitor of HO-1, it was verified 
      that the inhibitory effects of penstyrylpyrone (1) on the pro-inflammatory
      mediators and NF-kappaB DNA binding activity were associated with the HO-1
      expression. Therefore, these results suggest that penstyrylpyrone (1) suppresses 
      PTP1B activity, as well as the production of pro-inflammatory mediators via
      NF-kappaB pathway, through expression of anti-inflammatory HO-1.
AD  - Hanbang Body-Fluid Research Center, Wonkwang University, Iksan 570-749, Korea.
      yckim@wku.ac.kr.
FAU - Lee, Dong-Sung
AU  - Lee DS
FAU - Jang, Jae-Hyuk
AU  - Jang JH
FAU - Ko, Wonmin
AU  - Ko W
FAU - Kim, Kyoung-Su
AU  - Kim KS
FAU - Sohn, Jae Hak
AU  - Sohn JH
FAU - Kang, Myeong-Suk
AU  - Kang MS
FAU - Ahn, Jong Seog
AU  - Ahn JS
FAU - Kim, Youn-Chul
AU  - Kim YC
FAU - Oh, Hyuncheol
AU  - Oh H
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/01/24 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/04/03 [accepted]
AID - md11041409 [pii]
AID - 10.3390/md11041409 [doi]
PST - epublish
SO  - Mar Drugs. 2013 Apr 23;11(4):1409-26. doi: 10.3390/md11041409.

PMID- 23612272
OWN - NLM
STAT- In-Data-Review
DA  - 20130424
IS  - 0026-4946 (Print)
IS  - 0026-4946 (Linking)
VI  - 65
IP  - 2
DP  - 2013 Apr
TI  - Turner's syndrome with mental retardation, microcephaly and type 1 diabetes in a 
      6 year old child. Case report and literature review.
PG  - 251-2
AD  - Department of Pediatric Stomatology, Institute for Maternal and Child Health,
      IRCCS Burlo Garofolo, Trieste, Italy - michele.callea@libero.it.
FAU - Callea, M
AU  - Callea M
FAU - Radovich, F
AU  - Radovich F
FAU - Cappa, M
AU  - Cappa M
FAU - Clarich, G
AU  - Clarich G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Pediatr
JT  - Minerva pediatrica
JID - 0400740
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - R15133624 [pii]
PST - ppublish
SO  - Minerva Pediatr. 2013 Apr;65(2):251-2.

PMID- 23612267
OWN - NLM
STAT- In-Data-Review
DA  - 20130424
IS  - 0026-4946 (Print)
IS  - 0026-4946 (Linking)
VI  - 65
IP  - 2
DP  - 2013 Apr
TI  - Impact of socioeconomic status on health-related quality of life in children with
      type 1 diabetes mellitus in Bosnia and Herze-govina.
PG  - 207-12
AB  - Aim: This study was to evaluate the impact of the family socioeconomic status
      (SES) on health-related quality of life (HRQOL) in children with type 1 diabetes 
      mellitus (T1DM). Methods: The cross-sectional study included 65 consecutive
      children T1DM between ages 5 and 18 years and their mothers. The control group
      was formed by random selection by matching each patient with one or two healthy
      control subjects. To evaluate generic HRQOL in children with T1DM we used the
      PedsQL 4.0 Generic Core Scales which include both a parent proxy-report and a
      child self-report with age-appropriate versions. To categorize the families' SES,
      the parents' education level and current employment were recorded and analyzed
      using the Hollingshed two-factor index of social position. None of the diabetic
      children in the sample came from families of upper social classes, so we
      categorized our diabetic children into the lower and middle social classes.
      Results: Physical health (P=0.02), social functioning (P=0.04), and school
      activities (P=0.0003) were lower in T1DM children with middle SES families than
      in controls from middle SES families. Parental reports revealed statistically
      significantly poorer HRQOL in children from low SES families in total scale score
      (P=0.005) and in terms of physical (P=0.0126), and psychosocial health (P=0.0246)
      as compared with the control group with lower SES. Also the parental proxy
      reports for middle scores of family SES were statistical significantly lower in
      the total score (P=0.0001), psychosocial health (P=0.0001), emotional functioning
      (P=0.0006), and school functioning (P=0.0001) compared with the middle group of
      the control. Conclusion: The current findings suggest that low and middle SES of 
      families in children with T1DM is associated with lower generic HRQOL as compared
      to control children with similar SES of families.
AD  - Department for Research and Education, University Clinical Centre Tuzla, Academy 
      of Sciences and Arts of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina 
      - husref.tahirovic@untz.ba.
FAU - Tahirovic, H
AU  - Tahirovic H
FAU - Toromanovic, A
AU  - Toromanovic A
FAU - Tahirovic, E
AU  - Tahirovic E
FAU - Begic, H
AU  - Begic H
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Minerva Pediatr
JT  - Minerva pediatrica
JID - 0400740
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - R15133701 [pii]
PST - ppublish
SO  - Minerva Pediatr. 2013 Apr;65(2):207-12.

PMID- 23612225
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1945-7189 (Electronic)
IS  - 0163-769X (Linking)
DP  - 2013 Apr 23
TI  - New Insights Into the Role of Sequestosome 1/p62 Mutant Proteins in the
      Pathogenesis of Paget's Disease of Bone.
AB  - Paget's disease of bone (PDB) is characterized by focal areas of aberrant and
      excessive bone turnover, specifically increased bone resorption and disorganized 
      bone formation. Germline mutations in the sequestosome 1/p62 (SQSTM1/p62) gene
      are common in PDB patients, with most mutations affecting the
      ubiquitin-associated domain of the protein. In vitro, osteoclast precursor cells 
      expressing PDB-mutant SQSTM1/p62 protein are associated with increases in nuclear
      factor kappaB activation, osteoclast differentiation, and bone resorption.
      Although the precise mechanisms by which SQSTM1/p62 mutations contribute to
      disease pathogenesis and progression are not well defined, it is apparent that as
      well as affecting nuclear factor kappaB signaling, SQSTM1/p62 is a master
      regulator of ubiquitinated protein turnover via autophagy and the
      ubiquitin-proteasome system. Additional roles for SQSTM1/p62 in the oxidative
      stress-induced Keap1/Nrf2 pathway and in caspase-mediated apoptosis that were
      recently reported are potentially relevant to the pathogenesis of PDB. Thus,
      SQSTM1/p62 may serve as a molecular link or switch between autophagy, apoptosis, 
      and cell survival signaling. The purpose of this review is to outline recent
      advances in understanding of the multiple pathophysiological roles of SQSTM1/p62 
      protein, with particular emphasis on their relationship to PDB, including
      challenges associated with translating SQSTM1/p62 research into clinical
      diagnosis and treatment.
AD  - Laboratory for Molecular Endocrinology (S.L.R., T.R.), Western Australian
      Institute for Medical Research and University of Western Australia Centre for
      Medical Research, University of Western Australia, Crawley, Western Australia
      6009, Australia; Department of Endocrinology and Diabetes (S.L.R., J.P.W., T.R.),
      Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia;
      School of Medicine and Pharmacology (J.P.W.), University of Western Australia,
      Crawley, Western Australia 6009, Australia; School of Biomedical Sciences (R.L.),
      Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, United
      Kingdom; and School of Pathology and Laboratory Medicine (J.X.), University of
      Western Australia, Crawley, Western Australia 6009, Australia.
FAU - Rea, Sarah L
AU  - Rea SL
FAU - Walsh, John P
AU  - Walsh JP
FAU - Layfield, Robert
AU  - Layfield R
FAU - Ratajczak, Thomas
AU  - Ratajczak T
FAU - Xu, Jiake
AU  - Xu J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Endocr Rev
JT  - Endocrine reviews
JID - 8006258
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - er.2012-1034 [pii]
AID - 10.1210/er.2012-1034 [doi]
PST - aheadofprint
SO  - Endocr Rev. 2013 Apr 23.

PMID- 23612224
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1945-7189 (Electronic)
IS  - 0163-769X (Linking)
DP  - 2013 Apr 23
TI  - 11beta-Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects.
AB  - 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) interconverts the
      inactive glucocorticoid cortisone and its active form cortisol. It is widely
      expressed and, although bidirectional, in vivo it functions predominantly as an
      oxoreductase, generating active glucocorticoid. This allows glucocorticoid
      receptor activation to be regulated at a prereceptor level in a tissue-specific
      manner. In this review, we will discuss the enzymology and molecular biology of
      11beta-HSD1 and the molecular basis of cortisone reductase deficiencies. We will 
      also address how altered 11beta-HSD1 activity has been implicated in a number of 
      disease states, and we will explore its role in the physiology and pathologies of
      different tissues. Finally, we will address the current status of selective
      11beta-HSD1 inhibitors that are in development and being tested in phase II
      trials for patients with the metabolic syndrome. Although the data are
      preliminary, therapeutic inhibition of 11beta-HSD1 is also an exciting prospect
      for the treatment of a variety of other disorders such as osteoporosis, glaucoma,
      intracranial hypertension, and cognitive decline.
AD  - Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and
      Experimental Medicine, University of Birmingham, Birmingham B15 2TT, United
      Kingdom.
FAU - Gathercole, Laura L
AU  - Gathercole LL
FAU - Lavery, Gareth G
AU  - Lavery GG
FAU - Morgan, Stuart A
AU  - Morgan SA
FAU - Cooper, Mark S
AU  - Cooper MS
FAU - Sinclair, Alexandra J
AU  - Sinclair AJ
FAU - Tomlinson, Jeremy W
AU  - Tomlinson JW
FAU - Stewart, Paul M
AU  - Stewart PM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Endocr Rev
JT  - Endocrine reviews
JID - 8006258
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - er.2012-1050 [pii]
AID - 10.1210/er.2012-1050 [doi]
PST - aheadofprint
SO  - Endocr Rev. 2013 Apr 23.

PMID- 23612148
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
VI  - 61
IP  - 5
DP  - 2013 Jun
TI  - Natriuretic peptides' metabolic targets for treatment of cancer.
PG  - 816-22
LID - 10.231/JIM.0b013e318292110a [doi]
AB  - Four cardiac hormones are synthesized by the atrial natriuretic peptide
      prohormone gene. These hormones, namely, long-acting natriuretic peptide, vessel 
      dilator, kaliuretic peptide, and atrial natriuretic peptide, help regulate blood 
      pressure and blood volume by causing vasodilation, diuresis, and sodium
      excretion. These cardiac hormones reduce up to 97% of all cancer cells in vitro. 
      These cardiac hormones eliminate up to 86% of human small-cell lung carcinomas,
      two thirds of human breast cancers, and up to 80% of human pancreatic
      adenocarcinomas growing in athymic mice. Their anticancer mechanisms of action,
      after binding to specific receptors on cancer cells, include targeting the Rat
      sarcoma-bound guanosine diphosphate conversion to RAS guanosine triphosphate (95%
      inhibition)-mitogen-activated protein kinase kinase 1/2 (98%
      inhibition)-extracellular signal-related kinase 1/2 (96% inhibition) cascade in
      cancer cells. They also reduce c-Jun-N-terminal kinase 2 up to 89%. These
      multiple kinase inhibitors are also inhibitors of vascular endothelial growth
      factor (VEGF) and its VEGFR2 receptor (up to 89% inhibition). They reduce
      beta-catenin up to 88%. They inhibit the WNT pathway up to 68%, and secreted
      Frizzled-related protein 3 is decreased up to 84%. AKT, a
      serine/threonine-protein kinase, is reduced up to 64% by the cardiac hormones.
      Signal transducer and activator of transcription 3, a final "switch" that
      activates gene expression that leads to malignancy, is decreased by up to 88% by 
      the cardiac hormones. Of importance, the cross talk between the multiple kinases,
      VEGF, B-catenin, WNT, and STAT pathways is inhibited by the 4 cardiac hormones.
AD  - From the *Division of Endocrinology, Diabetes and Metabolism and
      daggerDepartments of Medicine, Molecular Pharmacology, and Physiology, James A.
      Haley VA Medical Center and University of South Florida Cardiac Hormone Center,
      and University of South Florida Morsani School of Medicine, Tampa, FL.
FAU - Vesely, David L
AU  - Vesely DL
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American
      Federation for Clinical Research
JID - 9501229
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - 10.231/JIM.0b013e318292110a [doi]
PST - ppublish
SO  - J Investig Med. 2013 Jun;61(5):816-22. doi: 10.231/JIM.0b013e318292110a.

PMID- 23611977
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
DP  - 2013 Apr 20
TI  - Autologous Umbilical Cord Blood Infusion Followed by Oral Docosahexaenoic Acid
      and Vitamin D Supplementation for C-Peptide Preservation in Children with Type 1 
      Diabetes.
LID - S1083-8791(13)00165-1 [pii]
LID - 10.1016/j.bbmt.2013.04.011 [doi]
AB  - We sought to determine if autologous umbilical cord blood (UCB) infusion followed
      by 1 year of supplementation with vitamin D and docosahexaenoic acid (DHA) can
      preserve C-peptide in children with type 1 diabetes. We conducted an open-label, 
      2:1 randomized study in which 15 type 1 diabetes subjects with stimulated
      C-peptide > .2 pmol/mL received either (1) autologous UCB infusion, 1 year of
      daily oral vitamin D (2000 IU), and DHA (38 mg/kg) and intensive diabetes
      management or (2) intensive diabetes management alone. Primary analyses were
      performed 1 year after UCB infusion. Treated (N = 10) and control (N = 5)
      subjects had median ages of 7.2 and 6.6 years, respectively. No severe adverse
      events were observed. Although the absolute rate of C-peptide decline was slower 
      in treated versus control subjects, intergroup comparisons failed to reach
      significance (P = .29). Area under the curve C-peptide declined and insulin use
      increased in both groups (P < .01). Vitamin D levels remained stable in treated
      subjects but declined in control subjects (P = .01). DHA levels rose in treated
      subjects versus control subjects (P = .003). CD4/CD8 ratio remained stable in
      treated subjects but declined in control subjects (P = .03). No changes were seen
      in regulatory T cell frequency, total CD4 counts, or autoantibody titers.
      Autologous UCB infusion followed by daily supplementation with vitamin D and DHA 
      was safe but failed to preserve C-peptide. Lack of significance may reflect small
      sample size. Future efforts will require expansion of specific immunoregulatory
      cell subsets, optimization of combined immunoregulatory and anti-inflammatory
      agents, and larger study cohorts.
CI  - Copyright (c) 2013 American Society for Blood and Marrow Transplantation.
      Published by Elsevier Inc. All rights reserved.
AD  - Department of Pediatrics, the University of Florida, Gainesville, Florida.
      Electronic address: hallemj@peds.ufl.edu.
FAU - Haller, Michael J
AU  - Haller MJ
FAU - Wasserfall, Clive H
AU  - Wasserfall CH
FAU - Hulme, Maigan A
AU  - Hulme MA
FAU - Cintron, Miriam
AU  - Cintron M
FAU - Brusko, Todd M
AU  - Brusko TM
FAU - McGrail, Keiran M
AU  - McGrail KM
FAU - Wingard, John R
AU  - Wingard JR
FAU - Theriaque, Douglas W
AU  - Theriaque DW
FAU - Shuster, Jonathan J
AU  - Shuster JJ
FAU - Ferguson, Ronald J
AU  - Ferguson RJ
FAU - Kozuch, Marianne
AU  - Kozuch M
FAU - Clare-Salzler, Michael
AU  - Clare-Salzler M
FAU - Atkinson, Mark A
AU  - Atkinson MA
FAU - Schatz, Desmond A
AU  - Schatz DA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for
      Blood and Marrow Transplantation
JID - 9600628
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/01/21 [received]
PHST- 2013/04/15 [accepted]
AID - S1083-8791(13)00165-1 [pii]
AID - 10.1016/j.bbmt.2013.04.011 [doi]
PST - aheadofprint
SO  - Biol Blood Marrow Transplant. 2013 Apr 20. pii: S1083-8791(13)00165-1. doi:
      10.1016/j.bbmt.2013.04.011.

PMID- 23611937
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 2151-8378 (Print)
IS  - 2151-8378 (Linking)
VI  - 19
IP  - 3
DP  - 2013 May-Jun
TI  - Reoperation after sacral neuromodulation therapy: a single-institution
      experience.
PG  - 175-8
LID - 10.1097/SPV.0b013e31828ab3c9 [doi]
AB  - OBJECTIVES: Sacral neuromodulation has become an accepted treatment for various
      types of lower urinary tract dysfunction. However, despite technologic advances
      in device implantation and a trial stimulation period, sacral neuromodulation
      still has a significant reoperation rate. We report our single-institution
      experience of reoperation rates. METHODS: We performed a retrospective review of 
      our patients who had undergone the implantation of the InterStim device from
      April 1999 to December 2011 for lower urinary tract dysfunction. RESULTS: A total
      of 155 InterStim devices were implanted by 2 surgeons. Of the 142 patients with
      complete follow-up, 55 (38.2%) patients required reoperation, for either revision
      or explantation of the device. Revisions were performed in 30 (21.1%) patients,
      most commonly for mechanical failure of device, battery end-of-service, and pain,
      either at the site of the implanted pulse generator or with stimulation. Of the
      30 patients who underwent revision, 14 had successful results, 6 had persistent
      symptoms, and 10 progressed to eventual explantation.The overall explantation
      rate was 24.6% (35 of 142 patients), and the average time to removal was 44
      months. Most of the explantations were performed for poor symptom control and
      failure to maintain response (74.3%).Reoperation was not associated with age,
      sex, obesity, diabetes, chronic pain, use of the tined lead, or type of lower
      urinary tract dysfunction. CONCLUSIONS: Sacral neuromodulation has a substantial 
      revision and explantation rate, without any clear predictors for these
      complications. Patients should be counseled to these complications before
      surgery.
AD  - Department of Urology, University of Washington, Seattle, WA 98195, USA.
      csshih@uw.edu
FAU - Shih, Cheryl
AU  - Shih C
FAU - Miller, Jane L
AU  - Miller JL
FAU - Fialkow, Michael
AU  - Fialkow M
FAU - Vicars, Brenda G
AU  - Vicars BG
FAU - Yang, Claire C
AU  - Yang CC
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Female Pelvic Med Reconstr Surg
JT  - Female pelvic medicine & reconstructive surgery
JID - 101528690
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - 10.1097/SPV.0b013e31828ab3c9 [doi]
AID - 01436319-201305000-00011 [pii]
PST - ppublish
SO  - Female Pelvic Med Reconstr Surg. 2013 May-Jun;19(3):175-8. doi:
      10.1097/SPV.0b013e31828ab3c9.

PMID- 23611722
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1873-4898 (Electronic)
IS  - 1477-5131 (Linking)
DP  - 2013 Apr 20
TI  - A novel mutation of anti-Mullerian hormone gene in Persistent Mullerian Duct
      Syndrome presented with bilateral cryptorchidism: A case report.
LID - S1477-5131(13)00067-3 [pii]
LID - 10.1016/j.jpurol.2013.03.004 [doi]
AB  - BACKGROUND: We report a novel mutation in a case of Persistent Mullerian Duct
      Syndrome (PMDS). PMDS is characterized by the persistence of female reproductive 
      organs derivatives in a 46,XY subject due to the failure of the Mullerian duct to
      regress in utero. To date, 53 different mutations of the anti-Mullerian hormone
      (AMH) gene, including the present one, have been identified. CLINICAL CASE: A
      2-week-old male presented with bilateral cryptorchidism and normal male external 
      genitalia. His karyotype was 46,XY. hCG stimulation test was normal. At age 1
      year and 4 months, he underwent laparoscopic surgery which revealed a uterus and 
      fallopian tubes. The anti-Mullerian hormone (AMH) level was undetectable (<0.01
      ng/mL). Diagnosis of Persistent Mullerian Duct Syndrome, probably due to an AMH
      mutation, was made. GENETIC STUDIES: A unique homozygous T to G base substitution
      was found at position 2219, near the middle of the exon 5, changing codon CTG to 
      CGG in anti-Mullerian hormone (AMH) gene. This mutation causes leucine to be
      converted to arginine at position 426 belonging to a (L)RA(L)LLLKALQ highly
      conserved sequence in the AMH gene. Both parents are heterozygous for the
      mutation. CONCLUSION: Persistent Mullerian Duct Syndrome (PMDS) is a rare cause
      of bilateral cryptorchidism, when in doubt the existence of Mullerian derivatives
      should be explored by laparoscopy. Assay of serum AMH helps to distinguish
      between mutations of AMH and AMH receptor. If serum AMH is very low or
      undetectable, sequencing of the AMH gene usually confirms the presence of a
      mutation.
CI  - Published by Elsevier Ltd.
AD  - Children's Hospital Los Angeles, Center for Endocrinology, Diabetes and
      Metabolism, Los Angeles, CA 90027, USA.
FAU - Wongprasert, H
AU  - Wongprasert H
FAU - Somanunt, S
AU  - Somanunt S
FAU - De Filippo, R
AU  - De Filippo R
FAU - Picard, J Y
AU  - Picard JY
FAU - Pitukcheewanont, P
AU  - Pitukcheewanont P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - J Pediatr Urol
JT  - Journal of pediatric urology
JID - 101233150
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/09/12 [received]
PHST- 2013/03/07 [accepted]
AID - S1477-5131(13)00067-3 [pii]
AID - 10.1016/j.jpurol.2013.03.004 [doi]
PST - aheadofprint
SO  - J Pediatr Urol. 2013 Apr 20. pii: S1477-5131(13)00067-3. doi:
      10.1016/j.jpurol.2013.03.004.

PMID- 23611639
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1556-3669 (Electronic)
IS  - 1530-5627 (Linking)
VI  - 19
IP  - 6
DP  - 2013 Jun
TI  - Electronic reminders to patients within an interactive patient health record.
PG  - 497-500
LID - 10.1089/tmj.2012.0116 [doi]
AB  - Abstract Keeping patients with complex medical illnesses up to date with their
      preventive care and chronic disease management services, such as lipid testing
      and retinal exam in patients with diabetes, is challenging. Within a commercially
      available electronic health record (EHR) with a secure personal health record
      (PHR), we developed a system that sends up to three weekly reminders to patients 
      who will soon be due for preventive care services. The reminder messages reside
      within the secure PHR, which is linked to the EHR, and are displayed on a screen 
      where patients can also send to the physician's office an electronic message to
      request appointments for the needed services. The reminder messages stop when the
      patient logs on to review the reminders. The system, designed with patient input,
      groups together all services that will be due in the next 3 months to avoid
      repeatedly messaging the patient. After 2 months, the cycle of reminders begins
      again. This system, which is feasible and economical to build, has the potential 
      to improve care and compliance with quality measures.
AD  - 1 Department of Medicine, University of Pittsburgh School of Medicine ,
      Pittsburgh, Pennsylvania.
FAU - Fischer, Gary S
AU  - Fischer GS
FAU - Hess, Rachel
AU  - Hess R
FAU - Landeen, Babette M
AU  - Landeen BM
FAU - Weimer, Melissa
AU  - Weimer M
FAU - Zieth, Caroline R
AU  - Zieth CR
FAU - Dong, Xinxin
AU  - Dong X
FAU - Clark, Sunday
AU  - Clark S
FAU - Roberts, Mark S
AU  - Roberts MS
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - Telemed J E Health
JT  - Telemedicine journal and e-health : the official journal of the American
      Telemedicine Association
JID - 100959949
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [aheadofprint]
AID - 10.1089/tmj.2012.0116 [doi]
PST - ppublish
SO  - Telemed J E Health. 2013 Jun;19(6):497-500. doi: 10.1089/tmj.2012.0116. Epub 2013
      Apr 23.

PMID- 23611540
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
VI  - 125
IP  - 7
DP  - 2013 Oct 1
TI  - Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase
      inhibition in diabetic spontaneously hypertensive rats.
PG  - 349-59
LID - 10.1042/CS20130003 [doi]
AB  - We have shown previously that inhibition of sEH (soluble epoxide hydrolase)
      increased EETs (epoxyeicosatrienoic acids) levels and reduced renal injury in
      diabetic mice and these changes were associated with induction of HO (haem
      oxygenase)-1. The present study determines whether the inhibition of HO negates
      the renoprotective effect of sEH inhibition in diabetic SHR (spontaneously
      hypertensive rats). After 6 weeks of induction of diabetes with streptozotocin,
      SHR were divided into the following groups: untreated, treated with the sEH
      inhibitor t-AUCB {trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic
      acid}, treated with the HO inhibitor SnMP (stannous mesoporphyrin), and treated
      with both inhibitors for 4 more weeks; non-diabetic SHR served as a control
      group. Induction of diabetes significantly increased renal sEH expression and
      decreased the renal EETs/DHETEs (dihydroxyeicosatrienoic acid) ratio without
      affecting HO-1 activity or expression in SHR. Inhibition of sEH with t-AUCB
      increased the renal EETs/DHETEs ratio and HO-1 activity in diabetic SHR; however,
      it did not significantly alter systolic blood pressure. Treatment of diabetic SHR
      with t-AUCB significantly reduced the elevation in urinary albumin and nephrin
      excretion, whereas co-administration of the HO inhibitor SnMP with t-AUCB
      prevented these changes. Immunohistochemical analysis revealed elevations in
      renal fibrosis as indicated by increased renal TGF-beta (transforming growth
      factor beta) levels and fibronectin expression in diabetic SHR and these changes 
      were reduced with sEH inhibition. Co-administration of SnMP with t-AUCB prevented
      its ability to reduce renal fibrosis in diabetic SHR. In addition, SnMP treatment
      also prevented t-AUCB-induced decreases in renal macrophage infiltration, IL-17
      expression and MCP-1 levels in diabetic SHR. These findings suggest that HO-1
      induction is involved in the protective effect of sEH inhibition against diabetic
      renal injury.
AD  - *Department of Oral Biology, Georgia Regents University, Augusta, Georgia, U.S.A.
FAU - Elmarakby, Ahmed A
AU  - Elmarakby AA
FAU - Faulkner, Jessica
AU  - Faulkner J
FAU - Pye, Chelsey
AU  - Pye C
FAU - Rouch, Katelyn
AU  - Rouch K
FAU - Alhashim, Abdulmohsin
AU  - Alhashim A
FAU - Maddipati, Krishna Rao
AU  - Maddipati KR
FAU - Baban, Babak
AU  - Baban B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - CS20130003 [pii]
AID - 10.1042/CS20130003 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 2013 Oct 1;125(7):349-59. doi: 10.1042/CS20130003.

PMID- 23611530
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1879-0828 (Electronic)
IS  - 0953-6205 (Linking)
DP  - 2013 Apr 20
TI  - Genetics of melatonin receptor type 2 is associated with left ventricular
      function in hypertensive patients treated according to guidelines.
LID - S0953-6205(13)00099-X [pii]
LID - 10.1016/j.ejim.2013.03.015 [doi]
AB  - BACKGROUND: Melatonin exerts multiple biological effects with potential impact on
      human diseases. This is underscored by genetic studies that demonstrated
      associations between melatonin receptor type 2 gene (MTNR1B) polymorphisms and
      characteristics of type 2 diabetes. We set out to test the hypothesis whether
      genetic variants at MTNR1B are also relevant for other disease phenotypes within 
      the cardiovascular continuum. We thus investigated single nucleotide
      polymorphisms (SNPs) of MTNR1B in relation to blood pressure (BP) and cardiac
      parameters in hypertensive patients. METHODS: Patients (n=605, mean age
      56.2+/-9.4years, 82.3% male) with arterial hypertension and cardiac ejection
      fraction (EF) >/=40% were studied. Cardiac parameters were assessed by
      echocardiography. RESULTS: The cohort comprised subjects with coronary heart
      disease (73.1%) and myocardial infarction (48.1%) with a mean EF of 63.7+/-8.9%. 
      Analysis of SNPs rs10830962, rs4753426, rs12804291, rs10830963, and rs3781638
      revealed two haplotypes 1 and 2 with frequencies of 0.402 and 0.277,
      respectively. Carriers with haplotype 1 (CTCCC) showed compared to non-carriers a
      higher mean 24-hour systolic BP (difference BP: 2.4mmHg, 95% confidence interval 
      (CI): 0.3 to 4.5mmHg, p=0.023). Haplotype 2 (GCCGA) was significantly related to 
      EF with an absolute increase of 1.8% (CI: 0.45 to 3.14%) in carriers versus
      non-carriers (p=0.009). CONCLUSION: Genetics of MTNR1B point to impact of the
      melatonin signalling pathway for BP and left ventricular function. This may
      support the importance of the melatonin system as a potential therapeutic target.
CI  - Copyright (c) 2013 European Federation of Internal Medicine. Published by
      Elsevier B.V. All rights reserved.
AD  - Institute of Clinical Pharmacology and Toxicology, Charite-Universitatsmedizin
      Berlin, Berlin, Germany. Electronic address: matthias.huber@charite.de.
FAU - Huber, Matthias
AU  - Huber M
FAU - Treszl, Andras
AU  - Treszl A
FAU - Reibis, Rona
AU  - Reibis R
FAU - Teichmann, Christopher
AU  - Teichmann C
FAU - Zergibel, Irina
AU  - Zergibel I
FAU - Bolbrinker, Juliane
AU  - Bolbrinker J
FAU - Scholze, Jurgen
AU  - Scholze J
FAU - Wegscheider, Karl
AU  - Wegscheider K
FAU - Voller, Heinz
AU  - Voller H
FAU - Kreutz, Reinhold
AU  - Kreutz R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Eur J Intern Med
JT  - European journal of internal medicine
JID - 9003220
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/12/05 [received]
PHST- 2013/02/18 [revised]
PHST- 2013/03/24 [accepted]
AID - S0953-6205(13)00099-X [pii]
AID - 10.1016/j.ejim.2013.03.015 [doi]
PST - aheadofprint
SO  - Eur J Intern Med. 2013 Apr 20. pii: S0953-6205(13)00099-X. doi:
      10.1016/j.ejim.2013.03.015.

PMID- 23611507
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1467-789X (Electronic)
IS  - 1467-7881 (Linking)
DP  - 2013 Apr 24
TI  - Links between obesity, diabetes and ethnic disparities in breast cancer among
      Hispanic populations.
LID - 10.1111/obr.12030 [doi]
AB  - Breast cancer is the most prevalent malignancy in women worldwide and is a
      growing concern due to rising incidence and ongoing ethnic disparities in both
      incidence and mortality. A number of factors likely contribute to these trends
      including rising rates of obesity and diabetes across the globe and differences
      in genetic predisposition. Here, we emphasize Hispanic populations and summarize 
      what is currently known about obesity, diabetes and individual genetic
      predisposition as they relate to ethnic disparities in breast cancer incidence
      and mortality. In addition, we discuss potential contributions to breast cancer
      aetiology from molecular mechanisms associated with obesity and diabetes
      including dyslipidemia, hyperglycaemia, hyperinsulinaemia, endocrine dysfunction 
      and inflammation. We propose that unique differences in diet and lifestyle
      coupled with individual genetic predisposition and endocrine/immune dysfunction
      explain most of the ethnic disparities seen in breast cancer incidence and
      mortality.
CI  - (c) 2013 The Authors. obesity reviews (c) 2013 International Association for the 
      Study of Obesity.
AD  - Center of Excellence in Cancer Research, Center of Excellence in Diabetes
      Research, Department of Biomedical Sciences MSB1, Texas Tech University Health
      Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA.
FAU - Lopez, R
AU  - Lopez R
FAU - Agullo, P
AU  - Agullo P
FAU - Lakshmanaswamy, R
AU  - Lakshmanaswamy R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Obes Rev
JT  - Obesity reviews : an official journal of the International Association for the
      Study of Obesity
JID - 100897395
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/12/04 [received]
PHST- 2013/01/25 [revised]
PHST- 2013/02/18 [accepted]
AID - 10.1111/obr.12030 [doi]
PST - aheadofprint
SO  - Obes Rev. 2013 Apr 24. doi: 10.1111/obr.12030.

PMID- 23611485
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1600-0765 (Electronic)
IS  - 0022-3484 (Linking)
DP  - 2013 Apr 24
TI  - Periodontal healing after application of enamel matrix derivative in surgical
      supra/infrabony periodontal defects in rats with streptozotocin-induced diabetes.
LID - 10.1111/jre.12084 [doi]
AB  - BACKGROUND AND OBJECTIVE: Epidemiologic and clinical studies have indicated that 
      diabetes is a risk factor for periodontal disease progression and healing. The
      aim of the present study was to evaluate short-term healing after enamel matrix
      derivative (EMD) application in combined supra/infrabony periodontal defects in
      diabetic rats. MATERIAL AND METHODS: Thirty male Wistar rats were initially
      divided into two groups, one with streptozotocin-induced diabetes and another one
      with healthy (non-diabetic) animals. Bony defects were surgically created on the 
      mesial root of the first maxillary molars. After root surface planing and EDTA
      conditioning, EMD was applied to the roots at one side of the maxillae, while
      those on the contralateral sides were left untreated. Animals were killed 3 wk
      after surgery, and block sections were prepared for histologic and
      histomorphometric analysis. RESULTS: There was statistically significant more
      gingival recession in diabetic animals than in non-diabetic animals. The length
      of the junctional epithelium was significantly shorter in the EMD-treated sites
      in both diabetic and normoglycemic rats. Sulcus depth and length of supracrestal 
      soft connective tissue showed no statistically significant differences between
      groups. In all animals, new bone formation was observed. Although new bone
      occurred more frequently in healthy animals, the extent of new bone was not
      significantly different between groups. In none of the teeth, a layer of new
      cementum was detectable. EMD had no influence on bone or cementum regeneration.
      Adverse reactions such as excessive inflammation due to bacterial root
      colonization, ankylosis and bone fractures were exclusively observed in diabetic 
      animals, irrespective of EMD treatment. CONCLUSION: Within the limits of the
      present study, it can be concluded that periodontal healing was impaired in
      streptozotocin-induced diabetic rats. EMD had no beneficial effects on new bone
      and cementum formation during short-term healing in this defect model and could
      not ameliorate the adverse effects in the systemically compromised animals.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Department of Periodontology, School of Dental Medicine, University of Bern,
      Bern, Switzerland; Department of Periodontology, Kagoshima University Graduate
      School of Medical and Dental Sciences, Kagoshima, Japan.
FAU - Shirakata, Y
AU  - Shirakata Y
FAU - Eliezer, M
AU  - Eliezer M
FAU - Nemcovsky, C E
AU  - Nemcovsky CE
FAU - Weinreb, M
AU  - Weinreb M
FAU - Dard, M
AU  - Dard M
FAU - Sculean, A
AU  - Sculean A
FAU - Bosshardt, D D
AU  - Bosshardt DD
FAU - Moses, O
AU  - Moses O
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - J Periodontal Res
JT  - Journal of periodontal research
JID - 0055107
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/03/09 [accepted]
AID - 10.1111/jre.12084 [doi]
PST - aheadofprint
SO  - J Periodontal Res. 2013 Apr 24. doi: 10.1111/jre.12084.

PMID- 23611470
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Linking)
DP  - 2013 Apr 24
TI  - Lunch energy density and the metabolic syndrome in patients with type 2 diabetes 
      mellitus.
PG  - 1-8
AB  - The aim of the present study was to investigate the possible associations between
      dietary energy density (ED) and the metabolic syndrome (MetS) in patients with
      type 2 diabetes. In the present case-control study, the dietary ED of 125
      patients with type 2 diabetes (seventy-eight with (cases) the MetS and
      forty-seven without (controls) the MetS; mean age 62.0 (sd 9.4) years, mean
      diabetes duration 12.5 (sd 8.4) years and mean glycated Hb 7.2 (sd 1.3) %) was
      assessed by weighed diet records. The MetS was defined according to the 2009
      Joint Interim Statement and ED by the amount of energy (kJ) in a given weight of 
      food. Data are expressed as means (standard deviations) or medians (interquartile
      ranges). Patients with the MetS reported lower intakes of total energy and fibre,
      and a higher total food amount than the controls; the total ED did not differ,
      but the cases had a higher ED at lunch (mean 6.3 (sd 1.3) v. 5.9 (sd 0.8) kJ/g;
      P= 0.017). In this meal, patients with the MetS had lower intakes of beans
      (median 0.7 (interquartile range 0.4-1.1) v. 1.1 (interquartile range 0.6-1.6)
      g/kg; P= 0.020), vegetables (median 1.2 (interquartile range 0.6-1.7) v. 1.4
      (interquartile range 1.0-2.0) g/kg; P= 0.046) and total meat (median 1.3
      (interquartile range 1.0-1.6) v. 1.4 (interquartile range 1.2-1.8) g/kg; P=
      0.034) than patients without the MetS. The associations between lunch ED (kJ/g)
      and food groups (g/kg) were confirmed for vegetables (r - 0.584; P< 0.001),
      fruits (r - 0.233; P= 0.070), beans (r - 0.189; P= 0.037) and oils (r 0.323; P<
      0.001). In a multivariate logistic regression model, a high lunch ED was
      associated with the MetS (OR 6.89, 95 % CI 1.35, 35.15; P =0.020) after adjusting
      for confounders. In conclusion, a high ED at lunch increased the odds of the
      presence of the MetS in patients with type 2 diabetes. Beans and vegetables may
      be the major contributors to this association and their consumption might be
      considered to decrease ED.
AD  - Undergraduate Nutrition Course, School of Medicine, Universidade Federal do Rio
      Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
FAU - Menegotto, Giovana
AU  - Menegotto G
FAU - Moraes Silva, Flavia
AU  - Moraes Silva F
FAU - de Azevedo, Mirela Jobim
AU  - de Azevedo MJ
FAU - de Almeida, Jussara Carnevale
AU  - de Almeida JC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130424
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - S0007114513000846 [pii]
AID - 10.1017/S0007114513000846 [doi]
PST - aheadofprint
SO  - Br J Nutr. 2013 Apr 24:1-8.

PMID- 23611384
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1878-3554 (Electronic)
IS  - 0099-2399 (Linking)
VI  - 39
IP  - 5
DP  - 2013 May
TI  - Periapical lesions decrease insulin signal and cause insulin resistance.
PG  - 648-52
LID - 10.1016/j.joen.2012.12.031 [doi]
LID - S0099-2399(13)00021-6 [pii]
AB  - INTRODUCTION: Inflammatory cytokines are associated with decreased insulin signal
      transduction. Moreover, local oral inflammation, such as that accompanying
      periodontal disease, is associated with insulin resistance and type 2 diabetes
      mellitus. The aim of this study was to evaluate the effect of periapical lesions 
      (PLs) on insulin signaling and insulin sensitivity in rats. We hypothesized that 
      PLs alter systemic insulin signaling and insulin sensitivity via elevated
      plasmatic tumor necrosis factor alpha (TNF-alpha). METHODS: Wistar rats were
      divided into control (CN) and PL groups. PLs were induced by exposing pulpal
      tissue to the oral environment. After 30 days, insulin sensitivity was measured
      using the insulin tolerance test. After euthanization, maxillae were processed
      for histopathology. Plasmatic concentrations of tumor necrosis factor alpha
      (TNF-alpha) were determined via the enzyme-linked immunosorbent assay. Insulin
      signal transduction was evaluated using insulin receptor substrate tyrosine
      phosphorylation status and serine phosphorylation status in periepididymal white 
      adipose tissue via Western blotting. For insulin signaling and insulin tolerance 
      tests, the analyses performed were analysis of variance followed by the Tukey
      post hoc test. For TNF-alpha analysis, the Student's t test was used. In all
      tests, P < .05 was considered significant. RESULTS: The rats with PLs showed
      higher plasmatic TNF-alpha, lower constant rate for glucose disappearance values,
      and reduced pp185 tyrosine phosphorylation status but no change in serine
      phosphorylation status in white adipose tissue after insulin stimulation.
      CONCLUSIONS: PLs can cause alterations to both insulin signaling and insulin
      sensitivity, probably because of elevation of plasmatic TNF-alpha. The results
      from this study emphasize the importance of the prevention of local inflammatory 
      diseases, such as PLs, with regard to the prevention of insulin resistance.
CI  - Copyright (c) 2013 American Association of Endodontists. Published by Elsevier
      Inc. All rights reserved.
AD  - Basic Sciences, Aracatuba Dental School, UNESP-Universidade Estadual Paulista,
      Aracatuba, Sao Paulo, Brazil.
FAU - Astolphi, Rafael Dias
AU  - Astolphi RD
FAU - Curbete, Mariane Machado
AU  - Curbete MM
FAU - Colombo, Natalia Helena
AU  - Colombo NH
FAU - Shirakashi, Daisy Jaqueline
AU  - Shirakashi DJ
FAU - Chiba, Fernando Yamamoto
AU  - Chiba FY
FAU - Prieto, Annelise Katrine Carrara
AU  - Prieto AK
FAU - Cintra, Luciano Tavares Angelo
AU  - Cintra LT
FAU - Bomfim, Suely Regina Mogami
AU  - Bomfim SR
FAU - Ervolino, Edilson
AU  - Ervolino E
FAU - Sumida, Doris Hissako
AU  - Sumida DH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130305
PL  - United States
TA  - J Endod
JT  - Journal of endodontics
JID - 7511484
SB  - D
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/08/30 [received]
PHST- 2012/12/22 [revised]
PHST- 2012/12/30 [accepted]
PHST- 2013/03/05 [aheadofprint]
AID - S0099-2399(13)00021-6 [pii]
AID - 10.1016/j.joen.2012.12.031 [doi]
PST - ppublish
SO  - J Endod. 2013 May;39(5):648-52. doi: 10.1016/j.joen.2012.12.031. Epub 2013 Mar 5.

PMID- 23611383
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1878-3554 (Electronic)
IS  - 0099-2399 (Linking)
VI  - 39
IP  - 5
DP  - 2013 May
TI  - Outcome of periapical lesions in a rat model of type 2 diabetes: refractoriness
      to systemic antioxidant therapy.
PG  - 643-7
LID - 10.1016/j.joen.2012.12.030 [doi]
LID - S0099-2399(13)00020-4 [pii]
AB  - INTRODUCTION: This study evaluated the development of periapical lesions in a rat
      model of type 2 diabetes and assessed the potential actions of the antioxidant
      agent tempol in this model. METHODS: Male Wistar rats were used; they received
      tap water (N = 5) or a 20% glucose solution (N = 15) during a period of 9 weeks. 
      At the sixth week, periapical lesions were induced on the first mandibular
      molars, and the animals were subdivided into 4 groups. The subgroup 1 was
      composed of nondiabetic rats orally receiving saline solution (10 mL/kg).
      Chronically glucose-fed rats were divided into the following subgroups: (2)
      saline-treated animals (10 mL/kg by oral route), and animals treated with tempol 
      by gavage at doses of (3) 50 mg/kg or (4) 100 mg/kg. The body weight was
      monitored thoroughly. After 21 days of apical periodontitis induction, the
      animals were killed, and the mandibles were collected and submitted to
      radiographic and histologic analysis. The livers were collected to determine free
      radicals, and the blood plasma was used to measure insulin levels. RESULTS: Type 
      2 diabetic rats displayed a significant decrease of body weight gain and a slight
      increase of insulin levels, which were allied to reduced levels of the
      antioxidant components catalase and reduced glutathione; these alterations were
      reversed by tempol. Concerning the periapical lesions, neither radiographic nor
      histologic analysis revealed any significant difference between control and type 
      2 diabetic rats. In diabetic rats, the apical periodontitis was refractory to
      tempol treatment. CONCLUSIONS: The extent and cellularity of periapical lesions
      in glucose-fed type 2 diabetic rats were similar to those seen in control rats.
      Despite affecting other parameters related to diabetes, tempol failed to improve 
      the outcome of endodontic lesions in type 2 diabetic animals.
CI  - Copyright (c) 2013 American Association of Endodontists. Published by Elsevier
      Inc. All rights reserved.
AD  - Postgraduate Program of Dental College, Pontificia Universidade Catolica do Rio
      Grande do Sul (PUCRS), Partenon, Porto Alegre, Brazil.
FAU - Wolle, Carlos Frederico B
AU  - Wolle CF
FAU - Zollmann, Luciana A
AU  - Zollmann LA
FAU - Bairros, Patricia O
AU  - Bairros PO
FAU - Etges, Adriana
AU  - Etges A
FAU - Leite, Carlos E
AU  - Leite CE
FAU - Morrone, Fernanda B
AU  - Morrone FB
FAU - Campos, Maria M
AU  - Campos MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130210
PL  - United States
TA  - J Endod
JT  - Journal of endodontics
JID - 7511484
SB  - D
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/08/28 [received]
PHST- 2012/12/13 [revised]
PHST- 2012/12/30 [accepted]
PHST- 2013/02/10 [aheadofprint]
AID - S0099-2399(13)00020-4 [pii]
AID - 10.1016/j.joen.2012.12.030 [doi]
PST - ppublish
SO  - J Endod. 2013 May;39(5):643-7. doi: 10.1016/j.joen.2012.12.030. Epub 2013 Feb 10.

PMID- 23611367
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 29 Suppl 3
DP  - 2013 Apr
TI  - Serum uric acid and metabolic risk.
PG  - 9-15
LID - 10.1185/03007995.2013.790801 [doi]
AB  - OBJECTIVES: This review presents the information available on the role of uric
      acid (UA) on metabolic risk and on the link between hyperuricemia and metabolic
      syndrome. METHODS: Key papers for inclusion were identified by a PubMed search
      and articles were selected according to their relevance for the topic, according 
      to the authors' judgment. RESULTS AND CONCLUSIONS: An elevated UA is both
      strongly associated and predictive of the metabolic syndrome, and increasing
      evidence suggests that UA may have a causal role. The classical viewpoint that UA
      is simply an innocuous marker of metabolic syndrome that should not even be
      measured will likely have to be modified. Lowering UA may be a novel treatment
      target for preventing diabetes and justify prospective clinical trials on the
      possible benefits of the measurement and lowering of serum UA on multiple chronic
      disease end points.
AD  - Universite Paris 7, UFR medicale, Assistance Publique-Hopitaux de Paris, Hopital 
      Lariboisiere, Federation de Rhumatologie, Paris, France.
      pascal.richette@lrb.aphp.fr
FAU - Richette, P
AU  - Richette P
FAU - Perez-Ruiz, F
AU  - Perez-Ruiz F
LA  - eng
PT  - Journal Article
DEP - 20130424
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/24 [aheadofprint]
AID - 10.1185/03007995.2013.790801 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2013 Apr;29 Suppl 3:9-15. doi: 10.1185/03007995.2013.790801.
      Epub 2013 Apr 24.

PMID- 23611362
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1520-5118 (Electronic)
IS  - 0021-8561 (Linking)
VI  - 61
IP  - 20
DP  - 2013 May 22
TI  - Low Molecular Weight Chitosan Accelerates Glucagon-like Peptide-1 Secretion in
      Human Intestinal Endocrine Cells via a p38-Dependent Pathway.
PG  - 4855-61
LID - 10.1021/jf305410k [doi]
AB  - Chitosan is widely employed as a dietary supplement. Several studies have shown
      that chitosan possesses an antidiabetic effect. An important intestinal incretin 
      hormone, glucagon-like peptide-1 (GLP-1), is also known to contribute to the
      amelioration of diabetes. This study investigated whether chitosan possesses an
      ability in GLP-1 synthesis and secretion in human intestinal cells. Low molecular
      weight chitosan (LMWC) significantly increases GLP-1 secretion in human
      intestinal endocrine cells (NCI-H716) in a dose-dependent manner. LMWC could also
      dose-dependently increase the mRNA expression of proglucagon, a GLP-1 precursor, 
      but did not affect prohormone convertase 3 (PC 3) mRNA expression. LMWC
      effectively increased the phosphorylation of mitogen-activated protein kinases
      (MAPK)-p38 and c-Jun N-terminal kinases (JNK), but not
      extracellular-signal-regulated kinases (ERK). An inhibitor of p38, but not JNK
      and ERK, significantly reversed the LMWC-increased proglucagon expression. Taken 
      together, LMWC accelerates proglucagon expression and GLP-1 secretion through a
      p38/MAPK-dependent signaling pathway. These findings suggest that LMWC may
      provide a strategy for diabetes therapy.
AD  - Institute of Toxicology, College of Medicine, National Taiwan University ,
      Taipei, Taiwan.
FAU - Liu, Shing Hwa
AU  - Liu SH
FAU - Huang, Ya Wen
AU  - Huang YW
FAU - Wu, Cheng Tien
AU  - Wu CT
FAU - Chiu, Chen Yuan
AU  - Chiu CY
FAU - Chiang, Meng Tsan
AU  - Chiang MT
LA  - eng
PT  - Journal Article
DEP - 20130507
PL  - United States
TA  - J Agric Food Chem
JT  - Journal of agricultural and food chemistry
JID - 0374755
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/05/07 [aheadofprint]
AID - 10.1021/jf305410k [doi]
PST - ppublish
SO  - J Agric Food Chem. 2013 May 22;61(20):4855-61. doi: 10.1021/jf305410k. Epub 2013 
      May 7.

PMID- 23611340
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1520-510X (Electronic)
IS  - 0020-1669 (Linking)
VI  - 52
IP  - 9
DP  - 2013 May 6
TI  - Heme bound amylin: spectroscopic characterization, reactivity, and relevance to
      type 2 diabetes.
PG  - 5226-35
LID - 10.1021/ic4001413 [doi]
AB  - Deposition of human amylin or islet amyloid polypeptide (hIAPP) within the
      beta-cells of the pancreatic islet of Langerhans is implicated in the etiology of
      type 2 diabetes mellitus (T2Dm). Accumulating evidences suggest that increased
      body iron stores, iron overload, and, in particular, higher heme-iron intake is
      significantly associated with higher risk of Type 2 diabetes mellitus (T2Dm)
      (PloS One2012, 7, e41641). Some key pathological features of T2Dm, like iron
      dyshomeostasis, iron accumulation, mitochondrial dysfunction, and oxidative
      stress are very similar to the cytopathologies of Alzheimer's disease, which have
      been invoked to be due to heme complexation with amyloid beta peptides. The
      similar etiology and pathogenic features in both Alzheimer's disease (AD) and
      T2Dm indicate a common underlying mechanism, with heme playing an important role.
      In this study we show that hIAPP can bind heme. His18 residue of hIAPP binds heme
      under physiological conditions and results in an axial high-spin active site with
      a trans-axial water derived ligand. Arg11 is a key residue that is also essential
      for heme binding. Heme(Fe(2+))-hIAPP complexes are prone to produce partially
      reduced oxygen species (PROS). The His18 residue identified in this study is
      absent in rats which do not show T2Dm, implicating the significance of this
      residue as well as heme in the pathology of T2Dm.
AD  - Department of Inorganic Chemistry, Indian Association for the Cultivation of
      Science , Jadavpur, Kolkata, India 700032.
FAU - Mukherjee, Soumya
AU  - Mukherjee S
FAU - Dey, Somdatta Ghosh
AU  - Dey SG
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - United States
TA  - Inorg Chem
JT  - Inorganic chemistry
JID - 0366543
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/23 [aheadofprint]
AID - 10.1021/ic4001413 [doi]
PST - ppublish
SO  - Inorg Chem. 2013 May 6;52(9):5226-35. doi: 10.1021/ic4001413. Epub 2013 Apr 23.

PMID- 23611290
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Association of automated carotid IMT measurement and HbA1c in Japanese patients
      with coronary artery disease.
PG  - 348-53
LID - 10.1016/j.diabres.2013.03.032 [doi]
LID - S0168-8227(13)00131-9 [pii]
AB  - AIMS: The purpose of this study was to evaluate whether carotid IMT (cIMT)
      identified using automated software is associated with HbA1c in Japanese patients
      with coronary artery disease. METHODS: 370 consecutive patients (males 218;
      median age 69 years+/-11) who underwent carotid-US and first coronary angiography
      were prospectively analyzed. After ultrasonographic examinations were performed, 
      the plaque score (PS) was calculated and automated IMT analysis was obtained with
      a dedicated algorithm. Pearson correlation analysis was performed to calculate
      the association between automated IMT, PS and HbA1c. RESULTS: The mean value of
      cIMT was 1.00+/-0.47mm for the right carotid and 1.04+/-0.49mm for the left
      carotid; the average bilateral value was 1.02+/-0.43mm. No significant difference
      of cIMT was detected between men and women. We found a direct correlation between
      cIMT values and HbA1c (p=0.0007) whereas the plaque score did not correlate with 
      the HbA1c values (p>0.05) CONCLUSION: The results of our study confirm that
      automated cIMT values and levels of HbA1c in Japanese patients with coronary
      artery disease are correlated whereas the plaque score does not show a
      statistically significant correlation.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Imaging Sciences, Azienda Ospedaliero Universitaria (A.O.U.) di
      Cagliari - Polo di Monserrato, Universita di Cagliari, s.s. 554 Monserrato,
      Cagliari 09045, Italy.
FAU - Saba, Luca
AU  - Saba L
FAU - Ikeda, Nobutaka
AU  - Ikeda N
FAU - Deidda, Martino
AU  - Deidda M
FAU - Araki, Tadashi
AU  - Araki T
FAU - Molinari, Filippo
AU  - Molinari F
FAU - Meiburger, Kristen M
AU  - Meiburger KM
FAU - Acharya, U Rajendra
AU  - Acharya UR
FAU - Nagashima, Yoshinori
AU  - Nagashima Y
FAU - Mercuro, Giuseppe
AU  - Mercuro G
FAU - Nakano, Masataka
AU  - Nakano M
FAU - Nicolaides, Andrew
AU  - Nicolaides A
FAU - Suri, Jasjit S
AU  - Suri JS
CN  - Fellow AIMBE
LA  - eng
PT  - Journal Article
DEP - 20130421
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/01/23 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/21 [aheadofprint]
AID - S0168-8227(13)00131-9 [pii]
AID - 10.1016/j.diabres.2013.03.032 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):348-53. doi:
      10.1016/j.diabres.2013.03.032. Epub 2013 Apr 21.

PMID- 23611195
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1520-5711 (Electronic)
IS  - 1054-3406 (Linking)
VI  - 23
IP  - 3
DP  - 2013 May
TI  - Bayesian adaptive D-optimal design with delayed responses.
PG  - 559-68
LID - 10.1080/10543406.2012.755996 [doi]
AB  - In some disease areas such as diabetes and obesity, patients may need to be
      studied for several weeks or months for a drug effect to emerge, where
      longitudinal data are normally collected for each patient. These delayed
      responses provide challenges to current adaptive design methods. Fu and Manner ( 
      2010 ) provided an integrated two-component prediction (ITP) model for delayed
      response adaptive design. In this paper, we extend their ITP model to incorporate
      a dose-response model in it and propose an ITP Emax model. Furthermore, we
      propose a utility function for decision making and this utility function is based
      on D-optimal design theory. We demonstrate our method by a simulation study, and 
      potential sample size reduction is also discussed.
AD  - Department of Statistics, Virginia Tech, Blacksburg, VA, USA. jieli@vt.edu
FAU - Li, Jie
AU  - Li J
FAU - Fu, Haoda
AU  - Fu H
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Biopharm Stat
JT  - Journal of biopharmaceutical statistics
JID - 9200436
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - 10.1080/10543406.2012.755996 [doi]
PST - ppublish
SO  - J Biopharm Stat. 2013 May;23(3):559-68. doi: 10.1080/10543406.2012.755996.

PMID- 23611178
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1469-8978 (Electronic)
IS  - 0033-2917 (Linking)
DP  - 2013 Apr 23
TI  - Sociodemographic, psychiatric and somatic risk factors for suicide: a Swedish
      national cohort study.
PG  - 1-11
AB  - BACKGROUND: More effective prevention of suicide requires a comprehensive
      understanding of sociodemographic, psychiatric and somatic risk factors. Previous
      studies have been limited by incomplete ascertainment of these factors. We
      conducted the first study of this issue using sociodemographic and out-patient
      and in-patient health data for a national population. Method We used data from a 
      national cohort study of 7140589 Swedish adults followed for 8 years for suicide 
      mortality (2001-2008). Sociodemographic factors were identified from national
      census data, and psychiatric and somatic disorders were identified from all
      out-patient and in-patient diagnoses nationwide. RESULTS: There were 8721 (0.12%)
      deaths from suicide during 2001-2008. All psychiatric disorders were strong risk 
      factors for suicide among both women and men. Depression was the strongest risk
      factor, with a greater than 15-fold risk among women or men and even higher risks
      (up to 32-fold) within the first 3 months of diagnosis. Chronic obstructive
      pulmonary disease (COPD), cancer, spine disorders, asthma and stroke were
      significant risk factors among both women and men (1.4-2.1-fold risks) whereas
      diabetes and ischemic heart disease were modest risk factors only among men
      (1.2-1.4-fold risks). Sociodemographic risk factors included male sex, unmarried 
      status or non-employment; and low education or income among men. CONCLUSIONS: All
      psychiatric disorders, COPD, cancer, spine disorders, asthma, stroke, diabetes,
      ischemic heart disease and specific sociodemographic factors were independent
      risk factors for suicide during 8 years of follow-up. Effective prevention of
      suicide requires a multifaceted approach in both psychiatric and primary care
      settings, targeting mental disorders (especially depression), specific somatic
      disorders and indicators of social support.
AD  - Department of Medicine, Stanford University, Stanford, CA, USA.
FAU - Crump, C
AU  - Crump C
FAU - Sundquist, K
AU  - Sundquist K
FAU - Sundquist, J
AU  - Sundquist J
FAU - Winkleby, M A
AU  - Winkleby MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Psychol Med
JT  - Psychological medicine
JID - 1254142
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
AID - S0033291713000810 [pii]
AID - 10.1017/S0033291713000810 [doi]
PST - aheadofprint
SO  - Psychol Med. 2013 Apr 23:1-11.

PMID- 23611168
OWN - NLM
STAT- Publisher
DA  - 20130424
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
DP  - 2013 Apr 20
TI  - An inverse correlation between TNF alpha serum levels and heart rate variability 
      in patients with heart failure.
LID - S0914-5087(13)00090-7 [pii]
LID - 10.1016/j.jjcc.2013.02.013 [doi]
AB  - BACKGROUND: Recent evidence indicates that chronic heart failure (CHF) is
      accompanied by both activation of the immune system and autonomic imbalance.
      There is a growing body of evidence that increased levels of proinflammatory
      cytokines and other inflammatory markers have important roles as mediators of
      disease progression and markers of mortality in patients with CHF. OBJECTIVE: The
      aim of this study was to investigate connection between autonomic imbalance
      [obtained by analysis of heart rate variability (HRV)] and activation of the
      immune system [as measured by serum levels of tumor necrosis factor (TNF)-alpha] 
      in patients with chronic heart failure. MATERIALS AND METHODS: This
      cross-sectional study included 21 patients with CHF and 8 age- and gender-matched
      healthy control subjects. We assessed HRV by 24-hour electrocardiographic Holter 
      monitoring and measured serum levels of TNF-alpha using an enzyme-linked
      immunosorbent assay. Clinical assessment and echocardiography were also
      performed. RESULTS: There was an inverse correlation between serum level of
      TNF-alpha and a time-domain parameter of HRV - SDNN (r=-0.542, p<0.05). A similar
      result was found for HRV triangular index, a geometric measure of HRV (r=-0.556; 
      p<0.05). The correlation was stronger for subjects with a diabetes mellitus,
      females, and TNFA2 allele carriers (an "A" at position -308A). The pNN50,
      indirect marker of cardiac vagal activity, was not significantly associated with 
      serum concentration of TNF-alpha. CONCLUSIONS: In conclusion, the results of the 
      present study indicate that increased serum TNF-alpha level is significantly
      associated with reduced HRV indices, suggesting that activation of the immune
      system in patients with CHF is closely related to autonomic imbalance.
CI  - Copyright (c) 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All
      rights reserved.
AD  - Department of Pharmacology, University of Nis Faculty of Medicine, Nis, Serbia.
      Electronic address: valentina@medfak.ni.ac.rs.
FAU - Nikolic, Valentina N
AU  - Nikolic VN
FAU - Jevtovic-Stoimenov, Tatjana
AU  - Jevtovic-Stoimenov T
FAU - Stokanovic, Dragana
AU  - Stokanovic D
FAU - Milovanovic, Milena
AU  - Milovanovic M
FAU - Velickovic-Radovanovic, Radmila
AU  - Velickovic-Radovanovic R
FAU - Pesic, Srdjan
AU  - Pesic S
FAU - Stoiljkovic, Milan
AU  - Stoiljkovic M
FAU - Pesic, Gordana
AU  - Pesic G
FAU - Ilic, Stevan
AU  - Ilic S
FAU - Deljanin-Ilic, Marina
AU  - Deljanin-Ilic M
FAU - Marinkovic, Dragan
AU  - Marinkovic D
FAU - Stefanovic, Nikola
AU  - Stefanovic N
FAU - Jankovic, Slobodan M
AU  - Jankovic SM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/09/21 [received]
PHST- 2013/01/25 [revised]
PHST- 2013/02/20 [accepted]
AID - S0914-5087(13)00090-7 [pii]
AID - 10.1016/j.jjcc.2013.02.013 [doi]
PST - aheadofprint
SO  - J Cardiol. 2013 Apr 20. pii: S0914-5087(13)00090-7. doi:
      10.1016/j.jjcc.2013.02.013.

PMID- 23611123
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1535-3907 (Electronic)
IS  - 1535-3893 (Linking)
VI  - 12
IP  - 6
DP  - 2013 Jun 7
TI  - Second trimester maternal urine for the diagnosis of trisomy 21 and prediction of
      poor pregnancy outcomes.
PG  - 2946-57
LID - 10.1021/pr4002355 [doi]
AB  - Given the recognized lack of prenatal clinical methods for the early diagnosis of
      preterm delivery, intrauterine growth restriction, preeclampsia and gestational
      diabetes mellitus, and the continuing need for optimized diagnosis methods for
      specific chromosomal disorders (e.g., trisomy 21) and fetal malformations, this
      work sought specific metabolic signatures of these conditions in second trimester
      maternal urine, using (1)H Nuclear Magnetic Resonance ((1)H NMR) metabolomics.
      Several variable importance to the projection (VIP)- and b-coefficient-based
      variable selection methods were tested, both individually and through their
      intersection, and the resulting data sets were analyzed by partial least-squares 
      discriminant analysis (PLS-DA) and submitted to Monte Carlo cross validation
      (MCCV) and permutation tests to evaluate model predictive power. The NMR data
      subsets produced significantly improved PLS-DA models for all conditions except
      for pre-premature rupture of membranes. Specific urinary metabolic signatures
      were unveiled for central nervous system malformations, trisomy 21, preterm
      delivery, gestational diabetes, intrauterine growth restriction and preeclampsia,
      and biochemical interpretations were proposed. This work demonstrated, for the
      first time, the value of maternal urine profiling as a complementary means of
      prenatal diagnostics and early prediction of several poor pregnancy outcomes.
AD  - CICECO-Department of Chemistry, Campus Universitario de Santiago, Universidade de
      Aveiro , 3810-193 Aveiro, Portugal.
FAU - Diaz, Silvia O
AU  - Diaz SO
FAU - Barros, Antonio S
AU  - Barros AS
FAU - Goodfellow, Brian J
AU  - Goodfellow BJ
FAU - Duarte, Iola F
AU  - Duarte IF
FAU - Galhano, Eulalia
AU  - Galhano E
FAU - Pita, Cristina
AU  - Pita C
FAU - Almeida, Maria do Ceu
AU  - Almeida Mdo C
FAU - Carreira, Isabel M
AU  - Carreira IM
FAU - Gil, Ana M
AU  - Gil AM
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - United States
TA  - J Proteome Res
JT  - Journal of proteome research
JID - 101128775
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/05/09 [aheadofprint]
AID - 10.1021/pr4002355 [doi]
PST - ppublish
SO  - J Proteome Res. 2013 Jun 7;12(6):2946-57. doi: 10.1021/pr4002355. Epub 2013 May
      9.

PMID- 23611058
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1097-6795 (Electronic)
IS  - 0894-7317 (Linking)
VI  - 26
IP  - 6
DP  - 2013 Jun
TI  - Comparison of Factors Associated with Carotid Intima-Media Thickness in the
      Multi-Ethnic Study of Atherosclerosis (MESA) and the Heinz Nixdorf Recall Study
      (HNR).
PG  - 667-73
LID - 10.1016/j.echo.2013.03.011 [doi]
LID - S0894-7317(13)00209-5 [pii]
AB  - BACKGROUND: The measurement of carotid intima-media thickness (CIMT) is a valid
      method to quantify levels of atherosclerosis. The present study was conducted to 
      compare the strengths of associations between CIMT and cardiovascular risk
      factors in two different populations. METHODS: The Multi-Ethnic Study of
      Atherosclerosis (MESA) and the Heinz Nixdorf Recall Study (HNR) are two
      population-based prospective cohort studies of subclinical cardiovascular
      disease. All Caucasian subjects aged 45 to 75 years from these cohorts who were
      free of baseline cardiovascular disease (n = 2,820 in HNR, n = 2,270 in MESA)
      were combined. CIMT images were obtained using B-mode sonography at the right and
      left common carotid artery and measured 1 cm starting from the bulb. RESULTS: In 
      both studies, age, male sex, and systolic blood pressure showed the strongest
      association (P < .0001 for each) for a higher CIMT. The mean of mean far wall
      CIMT was slightly higher in MESA participants (0.71 vs 0.67 mm). Almost all
      significant variables were consistent between the two cohorts in both magnitude
      of association with CIMT and statistical significance, including age, sex,
      smoking, diabetes, cholesterol levels, and blood pressure. For example, the
      association with systolic blood pressure was (DeltaSD = 0.011; 95% confidence
      interval, 0.0009 to 0.014) per mm Hg in MESA and (DeltaSD = 0.010; 95% confidence
      interval, 0.005 to 0.021) per mm Hg in HNR. This consistency persisted throughout
      the traditional (Framingham) risk factors. CONCLUSIONS: A comparison of the
      associations between traditional cardiovascular risk factors and CIMT across two 
      culturally diverse populations showed remarkable consistency.
CI  - Copyright (c) 2013 American Society of Echocardiography. Published by Mosby, Inc.
      All rights reserved.
AD  - Department of Cardiology, University of Duisburg-Essen, Essen, Germany.
FAU - Bauer, Marcus
AU  - Bauer M
FAU - Delaney, Joseph A C
AU  - Delaney JA
FAU - Mohlenkamp, Stefan
AU  - Mohlenkamp S
FAU - Jockel, Karl-Heinz
AU  - Jockel KH
FAU - Kronmal, Richard A
AU  - Kronmal RA
FAU - Lehmann, Nils
AU  - Lehmann N
FAU - Mukamal, Kenneth J
AU  - Mukamal KJ
FAU - Moebus, Susanne
AU  - Moebus S
FAU - Polak, Joseph F
AU  - Polak JF
FAU - Dragano, Nico
AU  - Dragano N
FAU - Budoff, Matthew J
AU  - Budoff MJ
FAU - Erbel, Raimund
AU  - Erbel R
FAU - McClelland, Robyn L
AU  - McClelland RL
CN  - Multi-Ethnic Study of Atherosclerosis and the Investigator Group of the Heinz
      Nixdorf Recall Study
LA  - eng
GR  - N01 HC095159/HC/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20130420
PL  - United States
TA  - J Am Soc Echocardiogr
JT  - Journal of the American Society of Echocardiography : official publication of the
      American Society of Echocardiography
JID - 8801388
SB  - IM
EDAT- 2013/04/25 06:00
MHDA- 2013/04/25 06:00
CRDT- 2013/04/25 06:00
PHST- 2012/05/05 [received]
PHST- 2013/04/20 [aheadofprint]
AID - S0894-7317(13)00209-5 [pii]
AID - 10.1016/j.echo.2013.03.011 [doi]
PST - ppublish
SO  - J Am Soc Echocardiogr. 2013 Jun;26(6):667-73. doi: 10.1016/j.echo.2013.03.011.
      Epub 2013 Apr 20.

PMID- 23610709
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130423
DCOM- 20130424
LR  - 20130425
IS  - 2093-4777 (Print)
IS  - 2093-4777 (Linking)
VI  - 17
IP  - 1
DP  - 2013 Mar
TI  - The difference of lower urinary tract symptoms between sympathetic hyperactive
      and hypoactive men.
PG  - 30-3
LID - 10.5213/inj.2013.17.1.30 [doi]
AB  - PURPOSE: Heart rate variability (HRV) is a tool used to measure autonomic nervous
      function; however, there is no evidence that it can be used to define sympathetic
      hyperactivity in men with lower urinary tract symptoms (LUTS). We suspected that 
      LUTS would differ between sympathetic hyperactive and hypoactive patients.
      Therefore, we measured HRV and divided the LUTS patients into two groups, a
      sympathetic hyperactive group and a sympathetic hypoactive group according to the
      low frequency/high frequency (LF/HF) ratio and made clinical comparisons between 
      the groups. METHODS: A total of 43 patients with symptomatic LUTS (International 
      Prostate Symptom Score [IPSS] over 8) and 49 healthy volunteers were enrolled. No
      subjects had diseases that could affect the autonomic nervous system, such as
      diabetes or hypertension. Electrocardiographic signals were obtained from
      subjects in the resting state and HRV indexes were calculated with spectral
      analyses. We divided the LUTS patients into two groups by an LF/HF ratio of 1.9, 
      which was the median value in the healthy volunteers, and compared the
      differences in clinical characteristics, IPSS, prostate-specific antigen (PSA),
      and transrectal ultrasound (TRUS) results. The parameters were compared by
      independent sample t-test by use of SPSS ver. 19. RESULTS: There were no
      significant differences in age, serum PSA, or volume of the prostate between the 
      2 LUTS groups. However, analyzing IPSS questionnaires between two groups showed
      that there were significant differences in mean of Q2 score (frequency) and
      storage symptom score ([Q2+Q4+Q7]/3) (P<0.05). CONCLUSIONS: We suggest that an
      imbalance of autonomic nervous system activity may be a factor that evokes
      varieties of symptoms in men with LUTS. LUTS patients with hypoactive sympathetic
      tone may suffer from frequency and storage symptoms.
AD  - Son & Oh Urologic Clinic, Suwon, Korea.
FAU - Oh, Dong Geun
AU  - Oh DG
FAU - Cho, Dae Sung
AU  - Cho DS
FAU - Yun, In Suk
AU  - Yun IS
FAU - Lee, Kuk Bin
AU  - Lee KB
FAU - Choi, Jong Bo
AU  - Choi JB
FAU - Lee, Jung Hwan
AU  - Lee JH
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Korea (South)
TA  - Int Neurourol J
JT  - International neurourology journal
JID - 101534513
PMC - PMC3627996
OID - NLM: PMC3627996
OTO - NOTNLM
OT  - Autonomic nervous system
OT  - Heart rate variability
OT  - Lower urinary tract symptoms
OT  - Prostatic hyperplasia
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:01
CRDT- 2013/04/24 06:00
PHST- 2013/02/27 [received]
PHST- 2013/03/30 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.5213/inj.2013.17.1.30 [doi]
PST - ppublish
SO  - Int Neurourol J. 2013 Mar;17(1):30-3. doi: 10.5213/inj.2013.17.1.30. Epub 2013
      Mar 31.

PMID- 23610602
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130423
DCOM- 20130508
IS  - 1976-1457 (Print)
IS  - 1976-1457 (Linking)
VI  - 7
IP  - 2
DP  - 2013 Apr
TI  - The antidiabetic effects of an herbal formula composed of Alnus hirsuta, Rosa
      davurica, Acanthopanax senticosus and Panax schinseng in the
      streptozotocin-induced diabetic rats.
PG  - 103-8
LID - 10.4162/nrp.2013.7.2.103 [doi]
AB  - A folk prescription consisting of Alnus hirsuta, Rosa davurica, Acanthopanax
      senticosus and Panax schinseng has been used in the treatment of diabetes
      mellitus. The aim of the present investigation was to evaluate the antidiabetic
      effects of the herb formula extract (HFE) composed of Alnus hirsuta, Rosa
      davurica, Acanthopanax senticosus and Panax schinseng in the streptozotocin
      (STZ)-induced diabetic rats. The HFE was mixed in the food supply of the healthy 
      and STZ-induced diabetic male Sprague-Dawley rats, and its effects on the body
      weight, water and food intake, hyperglycemia, hypolipidemic and islet structure
      were studied. The treatment of the rats with STZ for 6 weeks resulted in
      marasmus, polydipsia, polyphagia, hyperglycemia and hypoinsulinemia. In addition,
      the diabetic rats showed an apparent decrease in the insulin immunoreactivity and
      the number of beta-cells in the pancreas. The addition of the HFE to the rats'
      food supply significantly lowered the serum glucose and the serum triglycerides
      level and preserved the normal histological appearance of the pancreatic islets. 
      These results indicate that the HEF have a strong antidiabetic potential along
      with the significant hypoglycemic and hypolipidemic effects, which may be
      applicable in the pharmaceutical industry.
AD  - Department of Medical Biotechnology, College of Biomedical Science, Kangwon
      National University, 192-1 Hyoja-dong, Chuncheon, Gangwon 200-701, Korea.
FAU - Hu, Weicheng
AU  - Hu W
FAU - Yeo, Jin-Hee
AU  - Yeo JH
FAU - Jiang, Yunyao
AU  - Jiang Y
FAU - Heo, Seong-Il
AU  - Heo SI
FAU - Wang, Myeong-Hyeon
AU  - Wang MH
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - Korea (South)
TA  - Nutr Res Pract
JT  - Nutrition research and practice
JID - 101311052
PMC - PMC3627926
OID - NLM: PMC3627926
OTO - NOTNLM
OT  - Antidiabetic
OT  - hyperglycemia
OT  - immunohistochemistry
OT  - multi-herbal formula
OT  - streptozotocin
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:01
CRDT- 2013/04/24 06:00
PHST- 2012/08/09 [received]
PHST- 2012/12/16 [revised]
PHST- 2013/01/04 [accepted]
PHST- 2013/04/01 [epublish]
AID - 10.4162/nrp.2013.7.2.103 [doi]
PST - ppublish
SO  - Nutr Res Pract. 2013 Apr;7(2):103-8. doi: 10.4162/nrp.2013.7.2.103. Epub 2013 Apr
      1.

PMID- 23610569
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130423
DCOM- 20130424
LR  - 20130425
IS  - 1671-5411 (Print)
IS  - 1671-5411 (Linking)
VI  - 10
IP  - 1
DP  - 2013 Mar
TI  - Impact of diabetes on long term follow-up of elderly patients with chronic total 
      occlusion post percutaneous coronary intervention.
PG  - 16-20
LID - 10.3969/j.issn.1671-5411.2013.01.004 [doi]
AB  - BACKGROUND: The prognosis of elderly patients with chronic total occlusion (CTO) 
      and diabetes mellitus (DM) treated with percutaneous coronary intervention (PCI) 
      is not known. OBJECTIVE: To investigate the effect of diabetes on long-term
      follow-up of CTO after PCI in elderly patients. METHODS: A total of 153 elderly
      patients (age > 65 years old) with CTO lesions which were successfully treated
      with PCI were enrolled. Fifty one patients with diabetes and 102 without diabetes
      were compared for long-term outcomes (mean follow up: 36 +/- 12 months). Major
      adverse cardiac events (MACE) which include death, myocardial infarction or
      target lesion revascularization (TLR) were considered as a combined endpoint.
      RESULTS: The combined endpoint occurred in 29.4% of diabetes patients, and 11.3% 
      of the patients without diabetes (P < 0.05). The Cox proportional hazards model
      identified: drug eluting stent (DES) or bare metal stent (BMS) (HR: 0.13, 95%
      confidence interval (95% CI): 0.03-0.62, P = 0.004), DM (HR: 6.69, 95% CI:
      1.62-15.81, P = 0.01) and final minimal lumen diameter (MLD) (HR: 0.37, 95% CI:
      0.13-0.90, P = 0.03 ) as independent predictors of MACE, DM with renal impairment
      (HR: 6.64, 95% CI: 1.32-33.36, P = 0.02), HBA1C on admission (HR: 1.79, 95% CI:
      1.09-2.94, P = 0.02), as independent predictors of MACE at long term follow-up.
      CONCLUSIONS: The study demonstrates that DM is a predictive factor for MACE in
      elderly CTO patients treated with PCI, type of stent, final minimal lumen
      diameter and DM with renal impairment, and HBA1C level on admission are
      predictors of MACE.
AD  - Division of Interventional Cardiology, Cardiovascular Center, Toho University,
      6-11-1, Omori-Nishi, Ota-K, Tokyo 143-8541, Japan ; Department of Cardiology,
      Beijing An Zhen Hospital, Capital Medical University, Chao Yang District, Beijing
      100029, China.
FAU - Liu, Wei
AU  - Liu W
FAU - Wagatsuma, Kenji
AU  - Wagatsuma K
FAU - Nii, Hideo
AU  - Nii H
FAU - Toda, Mikihito
AU  - Toda M
FAU - Amano, Hideo
AU  - Amano H
FAU - Uchida, Yasuto
AU  - Uchida Y
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Geriatr Cardiol
JT  - Journal of geriatric cardiology : JGC
JID - 101237881
PMC - PMC3627706
OID - NLM: PMC3627706
OTO - NOTNLM
OT  - Chronic total occlusion
OT  - Diabetes
OT  - Drug eluting stent
OT  - Elderly patient
OT  - Percutaneous coronary intervention
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:01
CRDT- 2013/04/24 06:00
PHST- 2012/11/09 [received]
PHST- 2012/12/12 [revised]
PHST- 2012/12/18 [accepted]
AID - 10.3969/j.issn.1671-5411.2013.01.004 [doi]
AID - jgc-10-01-016 [pii]
PST - ppublish
SO  - J Geriatr Cardiol. 2013 Mar;10(1):16-20. doi:
      10.3969/j.issn.1671-5411.2013.01.004.

PMID- 23610563
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1549-1676 (Electronic)
IS  - 1549-1277 (Linking)
VI  - 10
IP  - 4
DP  - 2013
TI  - Is it time to screen women with history of hypertensive pregnancy disorders for
      diabetes?
PG  - e1001428
LID - 10.1371/journal.pmed.1001428 [doi]
AB  - Thach Tran discusses a new research article on whether preeclampsia is associated
      with future diabetes, and discusses whether women with a history of hypertensive 
      disorders in pregnancy should be screened for diabetes.
AD  - ARCH: Australian Research Centre for Health of Women and Babies, The Robinson
      Institute, School of Paediatrics and Reproductive Health, The University of
      Adelaide, North Adelaide, Australia. thach.tran@adelaide.edu.au
FAU - Tran, Thach
AU  - Tran T
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - PLoS Med
JT  - PLoS medicine
JID - 101231360
SB  - IM
PMC - PMC3627639
OID - NLM: PMC3627639
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04 [ppublish]
PHST- 2013/04/16 [epublish]
AID - 10.1371/journal.pmed.1001428 [doi]
AID - PMEDICINE-D-13-00699 [pii]
PST - ppublish
SO  - PLoS Med. 2013;10(4):e1001428. doi: 10.1371/journal.pmed.1001428. Epub 2013 Apr
      16.

PMID- 23610561
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1549-1676 (Electronic)
IS  - 1549-1277 (Linking)
VI  - 10
IP  - 4
DP  - 2013
TI  - Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury
      following open heart surgery: a multicenter double-blinded randomized controlled 
      trial.
PG  - e1001426
LID - 10.1371/journal.pmed.1001426 [doi]
AB  - BACKGROUND: Preliminary evidence suggests a nephroprotective effect of urinary
      alkalinization in patients at risk of acute kidney injury. In this study, we
      tested whether prophylactic bicarbonate-based infusion reduces the incidence of
      acute kidney injury and tubular damage in patients undergoing open heart surgery.
      METHODS AND FINDINGS: In a multicenter, double-blinded (patients, clinical and
      research personnel), randomized controlled trial we enrolled 350 adult patients
      undergoing open heart surgery with the use of cardiopulmonary bypass. At
      induction of anesthesia, patients received either 24 hours of intravenous
      infusion of sodium bicarbonate (5.1 mmol/kg) or sodium chloride (5.1 mmol/kg).
      The primary endpoint was the proportion of patients developing acute kidney
      injury. Secondary endpoints included the magnitude of acute tubular damage as
      measured by urinary neutrophil gelatinase-associated lipocalin (NGAL), initiation
      of acute renal replacement therapy, and mortality. The study was stopped early
      under recommendation of the Data Safety and Monitoring Committee because interim 
      analysis suggested likely lack of efficacy and possible harm. Groups were
      non-significantly different at baseline except that a greater proportion of
      patients in the sodium bicarbonate group (66/174 [38%]) presented with
      preoperative chronic kidney disease compared to control (44/176 [25%]; p =
      0.009). Sodium bicarbonate increased urinary pH (from 6.0 to 7.5, p<0.001). More 
      patients receiving bicarbonate (83/174 [47.7%]) developed acute kidney injury
      compared with control patients (64/176 [36.4%], odds ratio [OR] 1.60 [95% CI
      1.04-2.45]; unadjusted p = 0.032). After multivariable adjustment, a
      non-significant unfavorable group difference affecting patients receiving sodium 
      bicarbonate was found for the primary endpoint (OR 1.45 [0.90-2.33], p = 0.120]).
      A greater postoperative increase in urinary NGAL in patients receiving
      bicarbonate infusion was observed compared to control patients (p = 0.011). The
      incidence of postoperative renal replacement therapy was similar but hospital
      mortality was increased in patients receiving sodium bicarbonate compared with
      control (11/174 [6.3%] versus 3/176 [1.7%], OR 3.89 [1.07-14.2], p = 0.031).
      CONCLUSIONS: Urinary alkalinization using sodium bicarbonate infusion was not
      found to reduce the incidence of acute kidney injury or attenuate tubular damage 
      following open heart surgery; however, it was associated with a possible increase
      in mortality. On the basis of these findings we do not recommend the prophylactic
      use of sodium bicarbonate infusion to reduce the risk of acute kidney injury.
      Discontinuation of growing implementation of this therapy in this setting seems
      to be justified. TRIAL REGISTRATION: ClinicalTrials.gov NCT00672334 Please see
      later in the article for the Editors' Summary.
AD  - Department of Nephrology and Hypertension, Diabetes, and Endocrinology,
      Otto-von-Guericke-University Magdeburg, Germany.
FAU - Haase, Michael
AU  - Haase M
FAU - Haase-Fielitz, Anja
AU  - Haase-Fielitz A
FAU - Plass, Michael
AU  - Plass M
FAU - Kuppe, Hermann
AU  - Kuppe H
FAU - Hetzer, Roland
AU  - Hetzer R
FAU - Hannon, Claire
AU  - Hannon C
FAU - Murray, Patrick T
AU  - Murray PT
FAU - Bailey, Michael J
AU  - Bailey MJ
FAU - Bellomo, Rinaldo
AU  - Bellomo R
FAU - Bagshaw, Sean M
AU  - Bagshaw SM
LA  - eng
SI  - ClinicalTrials.gov/NCT00672334
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130416
PL  - United States
TA  - PLoS Med
JT  - PLoS medicine
JID - 101231360
SB  - IM
PMC - PMC3627643
OID - NLM: PMC3627643
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04 [ppublish]
PHST- 2012/11/18 [received]
PHST- 2013/03/07 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.1371/journal.pmed.1001426 [doi]
AID - PMEDICINE-D-12-03441 [pii]
PST - ppublish
SO  - PLoS Med. 2013;10(4):e1001426. doi: 10.1371/journal.pmed.1001426. Epub 2013 Apr
      16.

PMID- 23610560
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1549-1676 (Electronic)
IS  - 1549-1277 (Linking)
VI  - 10
IP  - 4
DP  - 2013
TI  - Preeclampsia as a risk factor for diabetes: a population-based cohort study.
PG  - e1001425
LID - 10.1371/journal.pmed.1001425 [doi]
AB  - BACKGROUND: Women with preeclampsia (PEC) and gestational hypertension (GH)
      exhibit insulin resistance during pregnancy, independent of obesity and glucose
      intolerance. Our aim was to determine whether women with PEC or GH during
      pregnancy have an increased risk of developing diabetes after pregnancy, and
      whether the presence of PEC/GH in addition to gestational diabetes (GDM)
      increases the risk of future (postpartum) diabetes. METHODS AND FINDINGS: We
      performed a population-based, retrospective cohort study for 1,010,068 pregnant
      women who delivered in Ontario, Canada between April 1994 and March 2008. Women
      were categorized as having PEC alone (n = 22,933), GH alone (n = 27,605), GDM
      alone (n = 30,852), GDM+PEC (n = 1,476), GDM+GH (n = 2,100), or none of these
      conditions (n = 925,102). Our main outcome was a new diagnosis of diabetes
      postpartum in the following years, up until March 2011, based on new records in
      the Ontario Diabetes Database. The incidence rate of diabetes per 1,000
      person-years was 6.47 for women with PEC and 5.26 for GH compared with 2.81 in
      women with neither of these conditions. In the multivariable analysis, both PEC
      alone (hazard ratio [HR] = 2.08; 95% CI 1.97-2.19) and GH alone (HR = 1.95; 95%
      CI 1.83-2.07) were risk factors for subsequent diabetes. Women with GDM alone
      were at elevated risk of developing diabetes postpartum (HR = 12.77; 95% CI
      12.44-13.10); however, the co-presence of PEC or GH in addition to GDM further
      elevated this risk (HR = 15.75; 95% CI 14.52-17.07, and HR = 18.49; 95% CI
      17.12-19.96, respectively). Data on obesity were not available. CONCLUSIONS:
      Women with PEC/GH have a 2-fold increased risk of developing diabetes when
      followed up to 16.5 years after pregnancy, even in the absence of GDM. The
      presence of PEC/GH in the setting of GDM also raised the risk of diabetes
      significantly beyond that seen with GDM alone. A history of PEC/GH during
      pregnancy should alert clinicians to the need for preventative counseling and
      more vigilant screening for diabetes. Please see later in the article for the
      Editors' Summary.
AD  - Department of Medicine, University of Toronto, Toronto, Canada.
      d.feig@utoronto.ca
FAU - Feig, Denice S
AU  - Feig DS
FAU - Shah, Baiju R
AU  - Shah BR
FAU - Lipscombe, Lorraine L
AU  - Lipscombe LL
FAU - Wu, C Fangyun
AU  - Wu CF
FAU - Ray, Joel G
AU  - Ray JG
FAU - Lowe, Julia
AU  - Lowe J
FAU - Hwee, Jeremiah
AU  - Hwee J
FAU - Booth, Gillian L
AU  - Booth GL
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130416
PL  - United States
TA  - PLoS Med
JT  - PLoS medicine
JID - 101231360
SB  - IM
PMC - PMC3627640
OID - NLM: PMC3627640
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04 [ppublish]
PHST- 2012/10/14 [received]
PHST- 2013/03/05 [accepted]
PHST- 2013/04/16 [epublish]
AID - 10.1371/journal.pmed.1001425 [doi]
AID - PMEDICINE-D-12-03042 [pii]
PST - ppublish
SO  - PLoS Med. 2013;10(4):e1001425. doi: 10.1371/journal.pmed.1001425. Epub 2013 Apr
      16.

PMID- 23610527
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130423
DCOM- 20130424
LR  - 20130425
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 6
DP  - 2013
TI  - Predictors and prevention of diabetic cardiomyopathy.
PG  - 151-60
LID - 10.2147/DMSO.S30968 [doi]
AB  - Despite our cognizance that diabetes can enhance the chances of heart failure,
      causes multiorgan failure,and contributes to morbidity and mortality, it is
      rapidly increasing menace worldwide. Less attention has been paid to alert
      prediabetics through determining the comprehensive predictors of diabetic
      cardiomyopathy (DCM) and ameliorating DCM using novel approaches. DCM is
      recognized as asymptomatic progressing structural and functional remodeling in
      the heart of diabetics, in the absence of coronary atherosclerosis and
      hypertension. The three major stages of DCM are: (1) early stage, where cellular 
      and metabolic changes occur without obvious systolic dysfunction; (2) middle
      stage, which is characterized by increased apoptosis, a slight increase in left
      ventricular size, and diastolic dysfunction and where ejection fraction (EF) is
      <50%; and (3) late stage, which is characterized by alteration in
      microvasculature compliance, an increase in left ventricular size, and a decrease
      in cardiac performance leading to heart failure. Recent investigations have
      revealed that DCM is multifactorial in nature and cellular, molecular, and
      metabolic perturbations predisposed and contributed to DCM. Differential
      expression of microRNA (miRNA), signaling molecules involved in glucose
      metabolism, hyperlipidemia, advanced glycogen end products, cardiac extracellular
      matrix remodeling, and alteration in survival and differentiation of resident
      cardiac stem cells are manifested in DCM. A sedentary lifestyle and high fat diet
      causes obesity and this leads to type 2 diabetes and DCM. However, exercise
      training improves insulin sensitivity, contractility of cardiomyocytes, and
      cardiac performance in type 2 diabetes. These findings provide new clues to
      diagnose and mitigate DCM. This review embodies developments in the field of DCM 
      with the aim of elucidating the future perspectives of predictors and prevention 
      of DCM.
AD  - Department of Physiology and Biophysics, School of Medicine, University of
      Louisville, Louisville, Kentucky, USA.
FAU - Chavali, Vishalakshi
AU  - Chavali V
FAU - Tyagi, Suresh C
AU  - Tyagi SC
FAU - Mishra, Paras K
AU  - Mishra PK
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC3629872
OID - NLM: PMC3629872
OTO - NOTNLM
OT  - diabetes
OT  - exercise
OT  - heart failure
OT  - miRNA
OT  - obesity
OT  - oxidative stress
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:01
CRDT- 2013/04/24 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/11 [epublish]
AID - 10.2147/DMSO.S30968 [doi]
AID - dmso-6-151 [pii]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2013 Apr 11;6:151-60. doi: 10.2147/DMSO.S30968. Print 
      2013.

PMID- 23610526
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130423
DCOM- 20130424
LR  - 20130425
IS  - 1178-6981 (Electronic)
IS  - 1178-6981 (Linking)
VI  - 5
DP  - 2013
TI  - Improving the economic and humanistic outcomes for diabetic patients: making a
      case for employer-sponsored medication therapy management.
PG  - 153-9
LID - 10.2147/CEOR.S40735 [doi]
AB  - BACKGROUND: The purpose of this study was to determine the cost savings of a
      pharmacist-led, employer-sponsored medication therapy management (MTM) program
      for diabetic patients and to assess for any changes in patient satisfaction and
      self-reported medication adherence for enrollees. METHODS: Participants in this
      study were enrollees of an employer-sponsored MTM program. They were included if 
      their primary medical insurance and prescription coverage was from the City of
      Toledo, they had a diagnosis of type 2 diabetes, and whether or not they had been
      on medication or had been given a new prescription for diabetes treatment. The
      data were analyzed on a prospective, pre-post longitudinal basis, and tracked for
      one year following enrollment. Outcomes included economic costs, patient
      satisfaction, and self-reported patient adherence. Descriptive statistics were
      used to characterize the population, calculate the number of visits, and
      determine the mean costs for each visit. Friedman's test was used to determine
      changes in outcomes due to the nonparametric nature of the data. RESULTS: The
      mean number of visits to a physician's office decreased from 10.22 to 7.07. The
      mean cost of these visits for patients increased from $47.70 to $66.41, but use
      of the emergency room and inpatient visits decreased by at least 50%. Employer
      spending on emergency room visits decreased by $24,214.17 and inpatient visit
      costs decreased by $166,610.84. Office visit spending increased by $11,776.41. A 
      total cost savings of $179,047.80 was realized by the employer at the end of the 
      program. Significant improvements in patient satisfaction and adherence were
      observed. CONCLUSION: Pharmacist interventions provided through the
      employer-sponsored MTM program led to substantial cost savings to the employer
      with improved patient satisfaction and adherence on the part of employees at the 
      conclusion of the program.
AD  - The Pharmaceutical Care and Outcomes Research Laboratory, Department of Pharmacy 
      Practice, College of Pharmacy and Pharmaceutical Sciences, The University of
      Toledo, Toledo, OH.
FAU - Pinto, Sharrel L
AU  - Pinto SL
FAU - Kumar, Jinender
AU  - Kumar J
FAU - Partha, Gautam
AU  - Partha G
FAU - Bechtol, Robert A
AU  - Bechtol RA
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - New Zealand
TA  - Clinicoecon Outcomes Res
JT  - ClinicoEconomics and outcomes research : CEOR
JID - 101560564
PMC - PMC3629878
OID - NLM: PMC3629878
OTO - NOTNLM
OT  - adherence
OT  - costs
OT  - diabetes
OT  - patient satisfaction
OT  - pharmaceutical care
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:01
CRDT- 2013/04/24 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/11 [epublish]
AID - 10.2147/CEOR.S40735 [doi]
AID - ceor-5-153 [pii]
PST - epublish
SO  - Clinicoecon Outcomes Res. 2013 Apr 11;5:153-9. doi: 10.2147/CEOR.S40735. Print
      2013.

PMID- 23610524
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 9
DP  - 2013
TI  - Short-term outcome of patients with preeclampsia.
PG  - 143-8
LID - 10.2147/VHRM.S38970 [doi]
AB  - INTRODUCTION: Preeclampsia constitutes a cause of increased mortality in mothers 
      and fetuses. Screening for promoting factors is essential for adequate prevention
      in the event of any subsequent pregnancy, and for the adequate follow-up of
      concerned patients. The aim of the present study was to evaluate the short-term
      outcome of patients with preeclampsia and to identify possible new factors
      predisposing them to the disease. METHODS: One hundred fifty-five patients having
      experienced preeclampsia between 2005 and 2010 from the Gynecology and Obstetrics
      Department of the Foch Hospital (Suresnes, France) were included in the study.
      All patients had undergone close clinical and standard biological follow-up
      immediately postpartum and then 3 months later with a reference practitioner. In 
      severe cases, further investigation was carried out by full etiological
      examination with an assessment of both autoimmune and thrombophilic status.
      RESULTS: Obesity and gestational diabetes were observed to be major risk factors 
      for preeclampsia, which were found in 46% and 15% of the cases, respectively. The
      etiological assessment showed abnormalities in 11% of the patients. Impaired
      thrombophilia was found in 3% of the patients, impaired autoimmune status in 4%, 
      a combination of both abnormalities in only 1% of the patients, and detection of 
      renal abnormalities in 3% of the patients were observed. In the immediate
      postpartum period, 66% of patients had maintained elevated blood pressure levels,
      and 66% had proteinuria > 0.3 g/24 hours. At the 3-month postpartum assessment,
      persisting arterial hypertension was found in 16% of the patients, requiring
      continuation of antihypertensive therapy, and 22% of the patients had proteinuria
      over the accepted threshold (0.15 g/24 hours). CONCLUSION: Patients with
      preeclampsia have increased cardiovascular risk, necessitating lifestyle measures
      and long-term follow-up. Etiological assessment must be carried out,
      systematically aiming at the detection of promoting underlying diseases and
      adaptation of the management of subsequent pregnancies.
AD  - Department of Gynecology and Obstetrics, Hopital Foch, Suresnes, France.
FAU - Koual, Meriem
AU  - Koual M
FAU - Abbou, Hind
AU  - Abbou H
FAU - Carbonnel, Marie
AU  - Carbonnel M
FAU - Picone, Olivier
AU  - Picone O
FAU - Ayoubi, Jean-Marc
AU  - Ayoubi JM
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
SB  - IM
PMC - PMC3629867
OID - NLM: PMC3629867
OTO - NOTNLM
OT  - gestational hypertensive disorders
OT  - postpartum
OT  - preeclampsia
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013 [ppublish]
PHST- 2013/04/15 [epublish]
AID - 10.2147/VHRM.S38970 [doi]
AID - vhrm-9-143 [pii]
PST - ppublish
SO  - Vasc Health Risk Manag. 2013;9:143-8. doi: 10.2147/VHRM.S38970. Epub 2013 Apr 15.

PMID- 23610474
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1553-6467 (Electronic)
IS  - 0002-9459 (Linking)
VI  - 77
IP  - 3
DP  - 2013 Apr 12
TI  - Diabetes and hypertension screening by pharmacy students in Thai communities.
PG  - 56
LID - 10.5688/ajpe77356 [doi]
AB  - OBJECTIVE. To integrate pharmacy education into a diabetes and hypertension
      screening program to improve pharmacy student disease knowledge and screening
      skills and provide a valuable service to the community. METHODS. One hundred
      eighty third-year PharmD students were trained and subsequently screened people
      aged >/=35 years in 2 Thai communities. Those with high risk factors were
      encouraged to see a pharmacist or nurse for further evaluation and referral to a 
      physician for diagnosis. RESULTS. After training, the third-year students showed 
      significantly higher knowledge scores on diabetes and hypertension than a control
      group of second-year students (p<0.05). More than 80% of the third-year students 
      were rated by pharmacist observers as having good community screening skills.
      More than 95% of community participants were satisfied or very satisfied with the
      screening session. The active screening program improved the screening coverage
      in the targeted communities from 41 people/month under the passive screening
      program to 127 people/month and improved the coverage rate over a 6-month period 
      from 24% to 73%. CONCLUSION. This active screening project by pharmacy students
      enhanced the health knowledge and awareness of members of the targeted
      communities and increased pharmacy students' knowledge of and ability to screen
      for hypertension and diabetes.
AD  - Faculty of Pharmacy, Mahasarakham University, Maha Sarakham, Thailand.
      cntploy@gmail.com
FAU - Ploylearmsang, Chanuttha
AU  - Ploylearmsang C
FAU - Sookaneknun, Phayom
AU  - Sookaneknun P
FAU - Poophalee, Thanapong
AU  - Poophalee T
FAU - Pongruea, Piyatida
AU  - Pongruea P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Pharm Educ
JT  - American journal of pharmaceutical education
JID - 0372650
SB  - IM
PMC - PMC3631731
OID - NLM: PMC3631731
OTO - NOTNLM
OT  - diabetes
OT  - hypertension
OT  - pharmacy education
OT  - screening
OT  - service learning
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/06/02 [received]
PHST- 2012/10/12 [accepted]
AID - 10.5688/ajpe77356 [doi]
AID - ajpe56 [pii]
PST - ppublish
SO  - Am J Pharm Educ. 2013 Apr 12;77(3):56. doi: 10.5688/ajpe77356.

PMID- 23610212
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1758-1001 (Electronic)
IS  - 0004-5632 (Linking)
DP  - 2013 Apr 22
TI  - Influence of age at diagnosis and duration of diabetes on the positivity of
      glutamic acid decarboxylase antibody in South-Brazilian type 1 diabetes mellitus.
AB  - AIM: To evaluate the influence of age of onset and duration of diabetes on the
      positivity of glutamic acid decarboxylase antibody (GADA) in South-Brazilian type
      1 diabetes mellitus (DM) patients. METHODS: GADA was evaluated in 92 patients
      with type 1 diabetes, in 147 gestational DM patients, and in 59 subjects with
      normal glucose tolerance. RESULTS: Type 1 patients with positive GADA (N = 44,
      48%) were older at the onset of diabetes (22 +/- 9 versus 18 +/- 10 y, P = 0.043)
      and had a shorter DM duration (12 +/- 8 versus 19 +/- 9 y, P < 0.001), as
      compared with negative GADA patients. A logistic regression with antibody
      positivity as the dependent variable and diabetes duration as the independent
      variable, showed that the shorter diabetes duration was related to the presence
      of the antibody with an odds ratio (OR) = 5.6; (CI 95% = 2.1-14.6); P < 0.001.
      Another model, with age at diagnosis as the independent variable, did not show
      any association with antibody positivity. However, analysing only men, a shorter 
      DM duration (OR = 6.5; CI = 1.7-24.0; P = 0.006), and also a higher age at
      diagnosis (OR = 5.5; CI = 1.5-21.0; P = 0.01) were significantly related to the
      antibody positivity. The performance of GADA was similar in up to 15 y of
      duration of DM (P = 0.78), but significantly diminished with higher duration (P =
      0.001). CONCLUSION: GADA testing is a helpful tool in the diagnosis of type 1 DM 
      starting in young adults and older individuals. Even though the positivity rate
      declines along the course of disease, it still provides useful information up to 
      15 y after the diabetes diagnosis.
AD  - Programa de Pos-graduacao em Ciencias Medicas: Endocrinologia da Universidade
      Federal do Rio Grande do Sul (UFRGS), Faculdade de Medicina, Rua Ramiro Barcelos,
      2400, 2 andar, 90035-003, Porto Alegre, RS, Brazil.
FAU - Maraschin, Jorge de Faria
AU  - Maraschin JD
FAU - Weinert, Leticia Schwerz
AU  - Weinert LS
FAU - Murussi, Nadia
AU  - Murussi N
FAU - Witter, Vanessa
AU  - Witter V
FAU - Rodrigues, Ticiana da Costa
AU  - Rodrigues TD
FAU - Rossato, Egna Regina
AU  - Rossato ER
FAU - Silveiro, Sandra Pinho
AU  - Silveiro SP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Ann Clin Biochem
JT  - Annals of clinical biochemistry
JID - 0324055
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 0004563212474560 [pii]
AID - 10.1177/0004563212474560 [doi]
PST - aheadofprint
SO  - Ann Clin Biochem. 2013 Apr 22.

PMID- 23610182
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May-Jun
TI  - Synergy to reduce emergency department visits for uncontrolled hyperglycemia.
PG  - 354-64
LID - 10.1177/0145721713484593 [doi]
AB  - Purpose The purpose of this pilot study was to evaluate the safety and
      preliminary efficacy of a treatment algorithm and education intervention for the 
      management of patients with type 2 diabetes and hyperglycemia presenting to the
      emergency department (ED) and stable enough to be discharged home. Methods Urban 
      hospital ED patients (n = 86) with BG >/= 200 mg/dL were enrolled in a 4-week
      prospective, nonrandomized pilot intervention with historic self-controls.
      Follow-up visits occurred at 12 to 72 hours, 2 and 4 weeks, and 6 months. T2DM
      medications were initiated or adjusted at each visit using a guideline-based
      diabetes medication management algorithm. Survival skills diabetes
      self-management education and navigation to outpatient services were provided.
      Results Participants were 51.8% male and 92% black, and 87.3% had private or
      public insurance. The top reasons for presenting to the ED were no provider
      appointment available (41.7%) and no primary care provider (14.6%). No
      hypoglycemia occurred in the first 24 hours following ED T2DM medication
      initiation or titration and overall hypoglycemia rates were low. BG was reduced
      from 356 +/- 110 mg/dL at baseline to 183 +/- 103 mg/dL at 4 weeks (P < .001).
      Conclusion Diabetes medication management and survival skills education for
      uncontrolled diabetes may be safely initiated in the ED, as demonstrated by the
      multidisciplinary STEP-DC intervention, which effectively enabled glycemic
      control in this pilot study.
AD  - Michelle F. Magee, MBBCh, Medstar Diabetes and Research Institutes, Washington
      Hospital Center, 100 Irving St, NW, EB 4114, Washington, DC 20012, USA.
      Michelle.F.Magee@Medstar.net.
FAU - Magee, Michelle F
AU  - Magee MF
FAU - Nassar, Carine M
AU  - Nassar CM
FAU - Copeland, James
AU  - Copeland J
FAU - Fokar, Ali
AU  - Fokar A
FAU - Sharretts, John M
AU  - Sharretts JM
FAU - Dubin, Jeffrey S
AU  - Dubin JS
FAU - Smith, Mark S
AU  - Smith MS
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
SB  - N
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/22 [aheadofprint]
AID - 0145721713484593 [pii]
AID - 10.1177/0145721713484593 [doi]
PST - ppublish
SO  - Diabetes Educ. 2013 May-Jun;39(3):354-64. doi: 10.1177/0145721713484593. Epub
      2013 Apr 22.

PMID- 23610181
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May-Jun
TI  - Feasibility of an internet-based intervention for improving diabetes outcomes
      among low-income patients with a high risk for poor diabetes outcomes followed in
      a community clinic.
PG  - 365-75
LID - 10.1177/0145721713484594 [doi]
AB  - Purpose The purpose of this study was to determine the feasibility of an
      Internet-based intervention, targeting very low-income minority patients with a
      high risk for not engaging in diabetes self-management, to increase diabetes
      self-management and improve diabetes outcomes. Methods Patients with diabetes
      followed in a community clinic were enrolled in the 13-month trial. Participants 
      were requested to test blood sugar and upload glucometer data every day and login
      to the program at least once every second day. Feasibility data included process 
      measures; diabetes outcomes consisted of changes from baseline to follow-up for
      levels of glycosylated hemoglobin (A1C), LDL, HDL, triglyceride and total
      cholesterol, and health-related quality of life using the SF-36. Results Only 22%
      of participants had health insurance. Participants had an average of 4.39
      comorbidities and 7.06 prescriptions. Participants uploaded glucometer data at
      least twice each week and logged into the application at least once each week.
      Participants demonstrated reductions statistically or clinically important
      changes in A1C, LDL cholesterol, total cholesterol, and triglyceride levels.
      Participants engaging in more frequent chat messages and interactive activities
      demonstrated greater reductions in LDL cholesterol levels; however, engaging in
      more frequent chat messages also was associated with increased triglyceride
      levels. Participants rated fewer role limitations from physical health problems
      at follow-up. Conclusions The intervention produced good outcomes; however, an
      alternative platform may be a less expensive approach.
AD  - John G. Ryan, DrPH, Department of Family Medicine and Community Health,
      University of Miami Miller School of Medicine, PO Box 016700 (R-700), Miami, FL
      33101-6700, USA. johngryan@miami.edu.
FAU - Ryan, John G
AU  - Ryan JG
FAU - Schwartz, Robert
AU  - Schwartz R
FAU - Jennings, Terri
AU  - Jennings T
FAU - Fedders, Mark
AU  - Fedders M
FAU - Vittoria, Isabel
AU  - Vittoria I
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
SB  - N
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/22 [aheadofprint]
AID - 0145721713484594 [pii]
AID - 10.1177/0145721713484594 [doi]
PST - ppublish
SO  - Diabetes Educ. 2013 May-Jun;39(3):365-75. doi: 10.1177/0145721713484594. Epub
      2013 Apr 22.

PMID- 23610154
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 80
IP  - 17
DP  - 2013 Apr 23
TI  - Teaching NeuroImages: Comatose patient with bilateral thalamic infarct due to
      internal carotid artery occlusion.
PG  - e185-6
LID - 10.1212/WNL.0b013e31828f1887 [doi]
AB  - An 88-year-old woman with a medical history of diabetes, hypertension, and atrial
      fibrillation presented to the emergency room after being found unresponsive with 
      a NIH Stroke Scale score of 23 and Glasgow Coma Scale score of 3. She was
      unresponsive to painful stimuli. Noncontrast CT demonstrated bilateral thalamic
      infarcts (figure 1A).
AD  - Neuroscience Institute at JFK Medical Center, Edison, NJ, USA.
      Haitham82@gmail.com
FAU - Dababneh, Haitham
AU  - Dababneh H
FAU - Shikhman, Aleksandr
AU  - Shikhman A
FAU - Moussavi, Mohammad
AU  - Moussavi M
FAU - Guerrero, Waldo R
AU  - Guerrero WR
FAU - Panezai, Spozhmy
AU  - Panezai S
FAU - Kirmani, Jawad F
AU  - Kirmani JF
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
SB  - AIM
SB  - IM
PMC - PMC3662329
OID - NLM: PMC3662329 [Available on 04/23/14]
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PMCR- 2014/04/23 00:00
AID - 80/17/e185 [pii]
AID - 10.1212/WNL.0b013e31828f1887 [doi]
PST - ppublish
SO  - Neurology. 2013 Apr 23;80(17):e185-6. doi: 10.1212/WNL.0b013e31828f1887.

PMID- 23610083
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 22
TI  - Two Cases of Diabetic Ketoacidosis in HNF1A-MODY Linked to Severe Dehydration: Is
      It Time to Change the Diagnostic Criteria for MODY?
AB  - OBJECTIVEHepatocyte nuclear factor-1A maturity-onset diabetes of the young
      (HNF1A-MODY) is a monogenic form of diabetes caused by heterozygous mutations in 
      HNF1A. Currently, a history of diabetic ketoacidosis (DKA) is an exclusion
      criterion for genetic testing for MODY.HISTORY AND EXAMINATIONIn this article, we
      describe two unrelated patients aged 17 and 24 years with severe DKA developed
      several years after the diagnosis of HNF1A-MODY.INVESTIGATIONBoth patients were
      treated with insulin, but their metabolic control was poor (HbA1c 15%, 140
      mmol/mol and 13%, 119 mmol/mol, respectively) due to noncompliance and missed
      insulin injections. In both patients, DKA followed a course of recurrent vomiting
      with dehydration and prerenal acute kidney injury. Their glycemia, blood pH, and 
      base excess at admission were 97 mmol/L [1748 mg/dL], 6.80, and -33 mmol/L
      (patient 1), and 34 mmol/L [613 mg/dL], 7.03, and -14 mmol/L (patient
      2).CONCLUSIONSThis anecdotal observation supports the notion that a history of
      DKA does not exclude MODY.
AD  - Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague 
      and University Hospital Motol, Prague, Czech Republic.
FAU - Pruhova, Stepanka
AU  - Pruhova S
FAU - Dusatkova, Petra
AU  - Dusatkova P
FAU - Neumann, David
AU  - Neumann D
FAU - Hollay, Erik
AU  - Hollay E
FAU - Cinek, Ondrej
AU  - Cinek O
FAU - Lebl, Jan
AU  - Lebl J
FAU - Sumnik, Zdenek
AU  - Sumnik Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - dc13-0058 [pii]
AID - 10.2337/dc13-0058 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 22.

PMID- 23610082
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 22
TI  - Factors Associated With Microalbuminuria in 7,549 Children and Adolescents With
      Type 1 Diabetes in the T1D Exchange Clinic Registry.
AB  - OBJECTIVETo examine factors associated with clinical microalbuminuria (MA)
      diagnosis in children and adolescents in the T1D Exchange clinic
      registry.RESEARCH DESIGN AND METHODST1D Exchange participants <20 years of age
      with type 1 diabetes >/=1 year and urinary albumin-to-creatinine ratio (ACR)
      measured within the prior 2 years were included in the analysis. MA diagnosis
      required all of the following: 1) a clinical diagnosis of sustained MA or
      macroalbuminuria, 2) confirmation of MA diagnosis by either the most recent ACR
      being >/=30 mg/g or current treatment with an ACE inhibitor (ACEI) or angiotensin
      receptor blocker (ARB), and 3) no known cause for nephropathy other than
      diabetes. Logistic regression was used to assess factors associated with
      MA.RESULTSMA was present in 329 of 7,549 (4.4%) participants, with a higher
      frequency associated with longer diabetes duration, higher mean glycosylated
      hemoglobin (HbA1c) level, older age, female sex, higher diastolic blood pressure 
      (BP), and lower BMI (P </= 0.01 for each in multivariate analysis). Older age was
      most strongly associated with MA among participants with HbA1c >/=9.5% (>/=80
      mmol/mol). MA was uncommon (<2%) among participants with HbA1c <7.5% (<58
      mmol/mol). Of those with MA, only 36% were receiving ACEI/ARB
      treatment.CONCLUSIONSOur results emphasize the importance of good glycemic and BP
      control, particularly as diabetes duration increases, in order to reduce the risk
      of nephropathy. Since age and diabetes duration are important nonmodifiable
      factors associated with MA, the importance of routine screening is underscored to
      ensure early diagnosis and timely treatment of MA.
AD  - Children's Hospital of Orange County, Orange, California.
FAU - Daniels, Mark
AU  - Daniels M
FAU - Dubose, Stephanie N
AU  - Dubose SN
FAU - Maahs, David M
AU  - Maahs DM
FAU - Beck, Roy W
AU  - Beck RW
FAU - Fox, Larry A
AU  - Fox LA
FAU - Gubitosi-Klug, Rose
AU  - Gubitosi-Klug R
FAU - Laffel, Lori M
AU  - Laffel LM
FAU - Miller, Kellee M
AU  - Miller KM
FAU - Speer, Heather
AU  - Speer H
FAU - Tamborlane, William V
AU  - Tamborlane WV
FAU - Tansey, Michael J
AU  - Tansey MJ
CN  - for the T1D Exchange Clinic Network
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - dc12-2192 [pii]
AID - 10.2337/dc12-2192 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 22.

PMID- 23610081
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 22
TI  - Central Pulse Pressure and Its Hemodynamic Determinants in Middle-Aged Adults
      With Impaired Fasting Glucose and Diabetes: The Asklepios study.
AB  - OBJECTIVEPulse pressure (PP), a strong predictor of cardiovascular events in type
      2 diabetes, is a composite measure affected by several hemodynamic factors.
      Little is known about the hemodynamic determinants of central PP in type 2
      diabetes or whether abnormalities in central pulsatile hemodynamics are already
      present in individuals with impaired fasting glucose (IFG). In a population-based
      study, we aimed to compare central PP and its hemodynamic determinants among
      adults with normal fasting glucose (n = 1654), IFG (n = 240), and type 2 diabetes
      (n = 33).RESEARCH DESIGN AND METHODSWe measured carotid pressure, left
      ventricular outflow, aortic root diameter, carotid artery flow, and distension in
      order to measure various structural and hemodynamic arterial
      parameters.RESULTSIFG was associated with a greater mean arterial pressure (MAP) 
      but was not associated with intrinsic aortic stiffening or abnormal aortic
      pulsatile indices after adjustment for MAP. After adjustment for age, sex, and
      MAP, type 2 diabetes was associated with a higher aortic root characteristic
      impedance (Zc), aortic root elastance-thickness product (Eh), and aortic root
      pulse wave velocity (but not aortic root diameter), a greater carotid-femoral
      pulse wave velocity, and lower total arterial compliance and wave reflection
      magnitude. Carotid size, Zc, distensibility, or Eh did not significantly differ
      between the groups.CONCLUSIONSType 2 diabetes, but not IFG, is associated with
      greater large artery stiffness, without abnormalities in aortic root diameter or 
      carotid stiffness. Subjects with type 2 diabetes demonstrate a decreased
      reflection magnitude, which may indicate an increased penetration of pulsatile
      energy to distal vascular beds.
AD  - University of Pennsylvania School of Medicine/Hospital of the University of
      Pennsylvania. Philadelphia, Pennsylvania.
FAU - Chirinos, Julio A
AU  - Chirinos JA
FAU - Segers, Patrick
AU  - Segers P
FAU - Gillebert, Thierry C
AU  - Gillebert TC
FAU - De Buyzere, Marc L
AU  - De Buyzere ML
FAU - Van Daele, Caroline M
AU  - Van Daele CM
FAU - Khan, Zubair A
AU  - Khan ZA
FAU - Khawar, Umair
AU  - Khawar U
FAU - De Bacquer, Dirk
AU  - De Bacquer D
FAU - Rietzschel, Ernst R
AU  - Rietzschel ER
CN  - on behalf of the Asklepios Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - dc12-1463 [pii]
AID - 10.2337/dc12-1463 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 22.

PMID- 23610061
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 22
TI  - Microphtalmia transcription factor (Mitf) regulates pancreatic beta cell
      function.
AB  - Precise regulation of beta cell function is crucial for maintaining blood glucose
      homeostasis. Pax6 is an essential regulator of beta cell-specific factors like
      insulin and Glut2. Studies in the developing eye suggest that Pax6 interacts with
      Mitf to regulate pigment cell differentiation. Here we show that Mitf, like Pax6,
      is expressed in all pancreatic endocrine cells during mouse postnatal development
      and in the adult islet. A Mitf loss of function mutation results in improved
      glucose tolerance and enhanced insulin secretion, but no increase in beta cell
      mass in adult mice. Mutant beta cells secrete more insulin in response to glucose
      than wild-type cells, suggesting that Mitf is involved in regulating beta cell
      function. In fact, the transcription of genes critical for maintaining glucose
      homeostasis (insulin, Glut2) and beta cell formation and function (Pax4, Pax6) is
      significantly upregulated in Mitf mutant islets. The increased Pax6 expression
      may cause the improved beta cell function observed in Mitf mutant animals as it
      activates insulin and Glut2 transcription. Chromatin immunoprecipitation analysis
      shows that Mitf binds to Pax4 and Pax6 regulatory regions suggesting that Mitf
      represses their transcription in wild-type beta cells. We demonstrate that Mitf
      directly regulates Pax6 transcription and controls beta cell function.
AD  - Stem Cell Center.
FAU - Mazur, Magdalena A
AU  - Mazur MA
FAU - Winkler, Marcus
AU  - Winkler M
FAU - Ganic, Elvira
AU  - Ganic E
FAU - Colberg, Jesper K
AU  - Colberg JK
FAU - Johansson, Jenny
AU  - Johansson J
FAU - Bennet, Hedvig
AU  - Bennet H
FAU - Fex, Malin
AU  - Fex M
FAU - Nuber, Ulrike A
AU  - Nuber UA
FAU - Artner, Isabella
AU  - Artner I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - db12-1464 [pii]
AID - 10.2337/db12-1464 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 22.

PMID- 23610060
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 22
TI  - Very Low Calorie Diet Mimics the Early Beneficial Effect of Roux-en-Y Gastric
      Bypass on Insulin Sensitivity and Beta-Cell Function in Type 2 Diabetic Patients.
AB  - Marked improvement in glycemic control occurs in patients with type 2 diabetes
      (T2DM) shortly after Roux-en-Y gastric bypass surgery (RYGB) and before there is 
      major weight loss. The objective of this study was to determine if the magnitude 
      of this change is primarily due to caloric restriction or is unique to the
      surgical procedure. We studied eleven subjects who underwent RYGB and fourteen
      subjects mean-matched for BMI, HbA1c and diabetes duration who were admitted to
      our inpatient research unit and given a very low calorie diet (VLCD) of 500
      kcal/day with a macronutrient content similar to that consumed by patients after 
      RYGB. Frequently sampled intravenous glucose tolerance tests were performed
      before and after interventions. Both groups lost an equivalent amount of weight
      over a mean study period of 21 days. Insulin sensitivity, acute insulin secretion
      after intravenous glucose administration and beta-cell function as determined by 
      disposition index improved to a similar extent in both groups. Likewise, changes 
      in fasting glucose and fructosamine levels were similar. Based on these data,
      VLCD improves insulin sensitivity and beta-cell function just as well as RYGB in 
      the short term. This study was registered in ClinicalTrials.gov NCT00627484.
AD  - Department of Medicine, Columbia University College of Physicians and Surgeons,
      New York, NY 10032 USA.
FAU - Jackness, Clifton
AU  - Jackness C
FAU - Karmally, Wahida
AU  - Karmally W
FAU - Febres, Gerardo
AU  - Febres G
FAU - Conwell, Irene M
AU  - Conwell IM
FAU - Ahmed, Leaque
AU  - Ahmed L
FAU - Bessler, Marc
AU  - Bessler M
FAU - McMahon, Donald J
AU  - McMahon DJ
FAU - Korner, Judith
AU  - Korner J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - db12-1762 [pii]
AID - 10.2337/db12-1762 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 22.

PMID- 23610059
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 22
TI  - Effect of roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on
      branched-chain amino acid metabolism.
AB  - It has been hypothesized that a greater decline in circulating branched-chain
      amino acids (BCAAs) after weight loss induced by roux-en-Y gastric bypass (RYGB) 
      surgery than after calorie restriction alone has independent effects on glucose
      homeostasis, possibly by decreased signaling through the mammalian target of
      rapamycin (mTOR). We evaluated plasma BCAA and their C3 and C5 acylcarnitine
      metabolites, muscle mTOR phosphorylation, and insulin sensitivity
      (insulin-stimulated glucose rate of disappearance [Rd]) in obese subjects before 
      and after approximately 20% weight loss induced by RYGB (n=10, BMI 45.6+/-6.7
      kg/m2) or laparoscopic adjustable gastric banding (LAGB; n=10, BMI 46.5+/-8.8
      kg/m2). Weight loss increased insulin-stimulated glucose Rd by approximately 55%,
      decreased total plasma BCAA and C3 and C5 acylcarnitine concentrations by 20-35%,
      and did not alter mTOR phosphorylation; no differences were detected between
      surgical groups (all P-values for interaction >0.05). Insulin-stimulated glucose 
      Rd correlated negatively with plasma BCAAs and with C3 and C5 acylcarnitine
      concentrations (r-values: -0.56 to -0.75, P<0.05). These data demonstrate that
      weight loss induced by either LAGB or RYGB causes the same decline in circulating
      BCAAs and their C3 and C5 acylcarnitine metabolites. Plasma BCAA concentration is
      negatively associated with skeletal muscle insulin sensitivity, but the
      mechanism(s) responsible for this relationship is not known.
AD  - Center for Human Nutrition and Atkins Center of Excellence in Obesity Medicine,
      Washington University School of Medicine, St. Louis, MO.
FAU - Magkos, Faidon
AU  - Magkos F
FAU - Bradley, David
AU  - Bradley D
FAU - Schweitzer, George G
AU  - Schweitzer GG
FAU - Finck, Brian N
AU  - Finck BN
FAU - Eagon, J Christopher
AU  - Eagon JC
FAU - Ilkayeva, Olga
AU  - Ilkayeva O
FAU - Newgard, Christopher B
AU  - Newgard CB
FAU - Klein, Samuel
AU  - Klein S
LA  - ENG
GR  - P30 DK056341/DK/NIDDK NIH HHS/United States
GR  - R01 DK037948/DK/NIDDK NIH HHS/United States
GR  - UL1 RR024992/RR/NCRR NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - db13-0185 [pii]
AID - 10.2337/db13-0185 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 22.

PMID- 23610058
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 22
TI  - Suppression of Epithelial to Mesenchymal Transitioning (EMT) Enhances Ex Vivo
      Reprogramming of Human Exocrine Pancreatic Tissue towards Functional Insulin
      Producing beta-Like Cells.
AB  - Due to the lack of tissue available for islet transplantation, new sources of
      beta-cells have been sought for the treatment of type 1 diabetes. The aim of this
      study was to determine whether the human exocrid fraction from the islet
      isolation procedure could be reprogrammed to provide additional islet tissue for 
      transplantation. The exocrine enriched cells rapidly dedifferentiated in culture 
      and grew as a mesenchymal monolayer. Genetic lineage tracing confirmed that these
      mesenchymal cells arose in part through a process of epithelial to mesenchymal
      transitioning (EMT). A protocol was developed whereby transduction of these
      mesenchymal cells with adenoviruses containing Pdx1, Ngn3, MafA and Pax4
      generated a population of cells that were enriched in glucagon-secreting
      alpha-like cells. Transdifferentiation or reprogramming towards insulin secreting
      beta-cells was enhanced, however, when using unpassaged cells in combination with
      inhibition of EMT by inclusion of ROCK and TGF-beta1 inhibitors. Resultant cells 
      were able to secrete insulin in response to glucose and on transplantation, to
      normalise blood glucose levels in streptozotocin diabetic NOD/Scid mice. In
      conclusion, reprogramming of human exocrine enriched tissue can best be achieved 
      using fresh material under conditions whereby EMT is inhibited. .rather than
      allowing the culture to expand as a mesenchymal monolayer.
AD  - School of Medical Sciences, University of Aberdeen, Institute of Medical
      Sciences, Foresterhill, Aberdeen, AB25 2ZD, UK..
FAU - Lima, Maria Joao
AU  - Lima MJ
FAU - Muir, Kenneth R
AU  - Muir KR
FAU - Docherty, Hilary M
AU  - Docherty HM
FAU - Drummond, Robert
AU  - Drummond R
FAU - McGowan, Neil Wa
AU  - McGowan NW
FAU - Forbes, Shareen
AU  - Forbes S
FAU - Heremans, Yves
AU  - Heremans Y
FAU - Houbracken, Isabelle
AU  - Houbracken I
FAU - Ross, James A
AU  - Ross JA
FAU - Forbes, Stuart J
AU  - Forbes SJ
FAU - Ravassard, Philippe
AU  - Ravassard P
FAU - Heimberg, Harry
AU  - Heimberg H
FAU - Casey, John
AU  - Casey J
FAU - Docherty, Kevin
AU  - Docherty K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - db12-1256 [pii]
AID - 10.2337/db12-1256 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 22.

PMID- 23610057
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 22
TI  - Resistance to aerobic exercise training causes metabolic dysfunction and reveals 
      novel exercise-regulated signaling networks.
AB  - Low aerobic exercise capacity is a risk factor for diabetes and strong predictor 
      of mortality; yet some individuals are "exercise resistant", and unable to
      improve exercise capacity through exercise training. To test the hypothesis that 
      resistance to aerobic exercise training underlies metabolic disease-risk, we used
      selective breeding for 15 generation to develop rat models of low- and
      high-aerobic response to training. Before exercise training, rats selected as
      low- and high-responders had similar exercise capacities. However, after 8-wks of
      treadmill training low-responders failed to improve their exercise capacity,
      while high-responders improved by 54%. Remarkably, low-responders to aerobic
      training exhibited pronounced metabolic dysfunction characterized by insulin
      resistance and increased adiposity, demonstrating that the "exercise resistant"
      phenotype segregates with disease risk. Low-responders had impaired
      exercise-induced angiogenes0is in muscle; however, mitochondrial capacity was
      intact and increased normally with exercise training, demonstrating that
      mitochondria are not limiting for aerobic adaptation or responsible for metabolic
      dysfunction in low-responders. Low-responders had increased stress/inflammatory
      signaling and altered TGFbeta signaling, characterized by hyperphosphorylation of
      a novel exercise-regulated phosphorylation site on SMAD2. Using this powerful
      biological model system we have discovered key pathways for low exercise training
      response that may represent novel targets for the treatment of metabolic disease.
AD  - Joslin Diabetes Center, USA.
FAU - Lessard, Sarah J
AU  - Lessard SJ
FAU - Rivas, Donato A
AU  - Rivas DA
FAU - Alves-Wagner, Ana B
AU  - Alves-Wagner AB
FAU - Hirshman, Michael F
AU  - Hirshman MF
FAU - Gallagher, Iain J
AU  - Gallagher IJ
FAU - Constantin-Teodosiu, Dumitru
AU  - Constantin-Teodosiu D
FAU - Atkins, Ryan
AU  - Atkins R
FAU - Greenhaff, Paul
AU  - Greenhaff P
FAU - Qi, Nathan R
AU  - Qi NR
FAU - Gustafsson, Thomas
AU  - Gustafsson T
FAU - Fielding, Roger A
AU  - Fielding RA
FAU - Timmons, James A
AU  - Timmons JA
FAU - Britton, Steven L
AU  - Britton SL
FAU - Koch, Lauren G
AU  - Koch LG
FAU - Goodyear, Laurie J
AU  - Goodyear LJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - db13-0062 [pii]
AID - 10.2337/db13-0062 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 22.

PMID- 23609991
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1532-2149 (Electronic)
IS  - 1090-3801 (Linking)
DP  - 2013 Apr 22
TI  - The effect of spinal cord stimulation frequency in experimental painful diabetic 
      polyneuropathy.
LID - 10.1002/j.1532-2149.2013.00318.x [doi]
AB  - BACKGROUND: Spinal cord stimulation (SCS) has been shown to be an effective
      treatment for painful diabetic polyneuropathy (PDP). An increase of efficacy is
      needed since only 67% of patients benefit from SCS. This study aimed to develop
      an animal model for SCS in PDP and study the effect of various stimulation
      frequencies on the functional outcome. As the pathophysiology of PDP is complex, 
      including vasoconstriction and nerve injury, the frequency of SCS may result in
      different outcomes. METHODS: Diabetes mellitus was induced by an intraperitoneal 
      injection of streptozotocin in 8-week-old female Sprague-Dawley rats (n = 76;
      glucose >15 mmol/L; n = 51). A SCS device was implanted at level Th13 4 weeks
      later. SCS of the dorsal columns was applied for 30 min and the effect on
      mechanical hypersensitivity was evaluated. RESULTS: Mechanical hypersensitivity
      developed in 26 rats, which were included (low-frequency, n = 6; mid-frequency, n
      = 8; high frequency, n = 9; and sham, n = 3). SCS of the dorsal columns was
      applied for 40 min, and the effect on mechanical hypersensitivity was evaluated. 
      In all treatment groups, SCS resulted in reversal of mechanical hypersensitivity 
      and a clinically relevant reduction was achieved in 70% of animals. No
      differences in efficacy were found between the different treatment groups.
      CONCLUSIONS: The pain-relieving effect of SCS in PDP was studied in an
      experimental model. Our study shows that SCS on mechanical hypersensitivity in
      PDP rats is equally effective when applied at low, mid and high frequency.
CI  - (c) 2013 European Federation of International Association for the Study of Pain
      Chapters.
AD  - Pain Management and Research Center, Department of Anesthesiology, Maastricht
      University Hospital, The Netherlands.
FAU - Pluijms, W A
AU  - Pluijms WA
FAU - van Kleef, M
AU  - van Kleef M
FAU - Honig, W M
AU  - Honig WM
FAU - Janssen, S P
AU  - Janssen SP
FAU - Joosten, E A
AU  - Joosten EA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Eur J Pain
JT  - European journal of pain (London, England)
JID - 9801774
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/03/26 [accepted]
AID - 10.1002/j.1532-2149.2013.00318.x [doi]
PST - aheadofprint
SO  - Eur J Pain. 2013 Apr 22. doi: 10.1002/j.1532-2149.2013.00318.x.

PMID- 23609946
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
DP  - 2013 Apr 23
TI  - Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose
      aspirin users: development and validation of risk scores for either medication in
      two large Dutch cohorts.
AB  - BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose
      acetylsalicylic acid (ASA) have several adverse gastrointestinal (GI) effects,
      including upper GI bleeding. We aimed to develop a simple risk score to identify 
      high risk NSAID and ASA users for primary upper GI bleeding. METHODS: Using data 
      from two large anonymized health insurance databases, we defined a development
      and validation cohort with NSAID and ASA users which were followed-up for the
      occurrence of a primary upper GI bleeding. Cox regression analyses identified
      risk factors which were combined into simple risk scores. C-statistics were used 
      to evaluate the discriminative ability of these scores in a validation cohort.
      RESULTS: In total, 421 cases of upper GI bleeding were identified in the initial 
      cohort of 784,263 NSAID users (incidence rate 54.2 per 10,000 person-years),
      while 1,295 cases of upper GI bleeding were identified in 235,531 ASA users
      (incidence rate 37.9 per 10,000 person-years). The risk of upper GI bleeding
      increased with a higher risk score, which for NSAID users included age, male
      gender, anemia and concomitant use of ASA or anticoagulants. For ASA users, age, 
      anemia, diabetes and concomitant use of other antiplatelet drugs or
      anticoagulants were included in the risk score. The C-statistics in the
      validation cohort were 0.68 and 0.63 or NSAID and ASA users, respectively.
      CONCLUSION: Risk factors for primary upper GI bleeding are to a large extent
      similar for NSAID and ASA users. Using a risk score based on these risk factors, 
      patients at the highest risk can be identified with moderate accuracy.
AD  - Department of Gastroenterology and Hepatology, University Medical Center Utrecht,
      P.O. Box 85500, (Internal Code F02.618), 3508 GA, Utrecht, The Netherlands,
      n.l.degroot-3@umcutrecht.nl.
FAU - de Groot, Nicolette L
AU  - de Groot NL
FAU - Hagenaars, Matthijs P
AU  - Hagenaars MP
FAU - Smeets, Hugo M
AU  - Smeets HM
FAU - Steyerberg, Ewout W
AU  - Steyerberg EW
FAU - Siersema, Peter D
AU  - Siersema PD
FAU - van Oijen, Martijn G H
AU  - van Oijen MG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/10/26 [received]
PHST- 2013/03/24 [accepted]
PHST- 2013/04/23 [aheadofprint]
AID - 10.1007/s00535-013-0817-y [doi]
PST - aheadofprint
SO  - J Gastroenterol. 2013 Apr 23.

PMID- 23609936
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 Mar 28
TI  - Insulin and extremity muscle mass in overweight and obese women.
LID - 10.1038/ijo.2013.45 [doi]
AB  - Background:Obesity disproportionately affects women, especially those of African 
      descent, and is associated with increases in both fat and muscle
      masses.Objective:Although increased extremity muscle mass may be compensatory to 
      fat mass load, we propose that elevated insulin levels resulting from diminished 
      insulin sensitivity may additionally contribute to extremity muscle mass in
      overweight or obese women.Methods:The following measurements were performed in
      197 non-diabetic women (57% black, 35% white; age 46+/-11 years (mean+/-s.d.),
      body mass index (BMI) range 25.0-57.7 kg m-2): dual-energy X-ray absorptiometry
      for fat and extremity muscle masses; exercise performance by duration and peak
      oxygen consumption (VO2 peak) during graded treadmill exercise; fasting insulin
      and, in 183 subjects, insulin sensitivity index (SI) calculated from the minimal 
      model.Results:SI (range 0.5-14.1 l mU-1 min-1) was negatively, and fasting
      insulin (range 1.9-35.6 muU ml-1) positively associated with extremity muscle
      mass (both P<0.001), independent of age and height. Sixty-seven percent of women 
      completed 6 months of participation in a weight loss and exercise program: we
      found a significant association between reduction in fasting insulin and a
      decrease in extremity muscle mass (P=0.038), independent of reduction in fat mass
      or improvement in exercise performance by VO2 peak and exercise duration, and
      without association with change in SI or interaction by
      race.Conclusions:Hyperinsulinemia in overweight or obese women is associated with
      increased extremity muscle mass, which is partially reversible with reduction in 
      fasting insulin concentration, consistent with the stimulatory effects of insulin
      on skeletal muscle.International Journal of Obesity advance online publication,
      23 April 2013; doi:10.1038/ijo.2013.45.
AD  - Cardiovascular and Pulmonary Branch, National Institute of Diabetes, Digestive
      Diseases and Kidney Diseases; National Institutes of Health, Bethesda, MD, USA.
FAU - Leon, B
AU  - Leon B
FAU - Jenkins, S
AU  - Jenkins S
FAU - Pepin, K
AU  - Pepin K
FAU - Chaudhry, H
AU  - Chaudhry H
FAU - Smith, K
AU  - Smith K
FAU - Zalos, G
AU  - Zalos G
FAU - Miller, B V 3rd
AU  - Miller BV 3rd
FAU - Chen, K Y
AU  - Chen KY
FAU - Remaley, A T
AU  - Remaley AT
FAU - Waclawiw, M A
AU  - Waclawiw MA
FAU - Sumner, A E
AU  - Sumner AE
FAU - Cannon, R O 3rd
AU  - Cannon RO 3rd
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130328
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/03/28 [aheadofprint]
PHST- 2013/04/23 [aheadofprint]
AID - ijo201345 [pii]
AID - 10.1038/ijo.2013.45 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 Mar 28. doi: 10.1038/ijo.2013.45.

PMID- 23609933
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
DP  - 2013 Mar 28
TI  - Associations between antibiotic exposure during pregnancy, birth weight and
      aberrant methylation at imprinted genes among offspring.
LID - 10.1038/ijo.2013.47 [doi]
AB  - Objectives:Low birth weight (LBW) has been associated with common adult-onset
      chronic diseases, including obesity, cardiovascular disease, type II diabetes and
      some cancers. The etiology of LBW is multi-factorial. However, recent evidence
      suggests exposure to antibiotics may also increase the risk of LBW. The
      mechanisms underlying this association are unknown, although epigenetic
      mechanisms are hypothesized. In this study, we evaluated the association between 
      maternal antibiotic use and LBW and examined the potential role of altered DNA
      methylation that controls growth regulatory imprinted genes in these
      associations.Methods:Between 2009-2011, 397 pregnant women were enrolled and
      followed until delivery. Prenatal antibiotic use was ascertained through maternal
      self-report. Imprinted genes methylation levels were measured at differentially
      methylated regions (DMRs) using bisulfite pyrosequencing. Generalized linear
      models were used to examine associations among antibiotic use, birth weight and
      DMR methylation fractions.Results:After adjusting for infant gender,
      race/ethnicity, maternal body mass index, delivery route, gestational weight
      gain, gestational age at delivery, folic acid intake, physical activity, maternal
      smoking and parity, antibiotic use during pregnancy was associated with 138 g
      lower birth weight compared with non-antibiotic use (beta-coefficient=-132.99,
      s.e.=50.70, P=0.008). These associations were strongest in newborns of women who 
      reported antibiotic use other than penicillins (beta-coefficient=-135.57,
      s.e.=57.38, P=0.02). Methylation at five DMRs, IGF2 (P=0.05), H19 (P=0.15),
      PLAGL1 (P=0.01), MEG3 (P=0.006) and PEG3 (P=0.08), was associated with maternal
      antibiotic use; among these, only methylation at the PLAGL1 DMR was also
      associated with birth weight.Conclusion:We report an inverse association between 
      in utero exposure to antibiotics and lower infant birth weight and provide the
      first empirical evidence supporting imprinted gene plasticity in these
      associations.International Journal of Obesity advance online publication, 23
      April 2013; doi:10.1038/ijo.2013.47.
AD  - 1] Division of Epidemiology, Department of Obstetrics and Gynecology, Duke
      University School of Medicine, Durham, NC, USA [2] Program of Cancer Detection,
      Prevention and Control, Duke University School of Medicine, Durham, NC, USA.
FAU - Vidal, A C
AU  - Vidal AC
FAU - Murphy, S K
AU  - Murphy SK
FAU - Murtha, A P
AU  - Murtha AP
FAU - Schildkraut, J M
AU  - Schildkraut JM
FAU - Soubry, A
AU  - Soubry A
FAU - Huang, Z
AU  - Huang Z
FAU - Neelon, S E B
AU  - Neelon SE
FAU - Fuemmeler, B
AU  - Fuemmeler B
FAU - Iversen, E
AU  - Iversen E
FAU - Wang, F
AU  - Wang F
FAU - Kurtzberg, J
AU  - Kurtzberg J
FAU - Jirtle, R L
AU  - Jirtle RL
FAU - Hoyo, C
AU  - Hoyo C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130328
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/03/28 [aheadofprint]
PHST- 2013/04/23 [aheadofprint]
AID - ijo201347 [pii]
AID - 10.1038/ijo.2013.47 [doi]
PST - aheadofprint
SO  - Int J Obes (Lond). 2013 Mar 28. doi: 10.1038/ijo.2013.47.

PMID- 23609902
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1440-1711 (Electronic)
IS  - 0818-9641 (Linking)
VI  - 91
IP  - 5
DP  - 2013 May
TI  - Designing nanoparticle treatment of autoimmunity with quantitative biology.
PG  - 333-4
LID - 10.1038/icb.2013.20 [doi]
AD  - 1] Department of Molecular & Integrative Physiology, University of Michigan
      Medical School, Ann Arbor, MI, USA [2] Brehm Center for Diabetes Research,
      University of Michigan Medical School, Ann Arbor, MI, USA.
FAU - Schnell, Santiago
AU  - Schnell S
FAU - Pietropaolo, Massimo
AU  - Pietropaolo M
LA  - eng
GR  - R01 DK053456/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130423
PL  - England
TA  - Immunol Cell Biol
JT  - Immunology and cell biology
JID - 8706300
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/23 [aheadofprint]
AID - icb201320 [pii]
AID - 10.1038/icb.2013.20 [doi]
PST - ppublish
SO  - Immunol Cell Biol. 2013 May;91(5):333-4. doi: 10.1038/icb.2013.20. Epub 2013 Apr 
      23.

PMID- 23609875
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1170-229X (Electronic)
IS  - 1170-229X (Linking)
DP  - 2013 Apr 23
TI  - Sulfonylureas and Risk of Falls and Fractures: A Systematic Review.
AB  - BACKGROUND: Sulfonylureas have been linked to increased risk of hypoglycemia.
      Hypoglycemia may lead to falls, and falls may lead to fracture. However, studies 
      quantifying the association between sulfonylureas and fractures are sparse and
      yield inconsistent results. OBJECTIVE: The purpose of this article was to review 
      the literature regarding sulfonylurea use and falls or fall-related fractures
      among older adults with type 2 diabetes mellitus and to delineate areas for
      future research. DATA SOURCES: We searched MEDLINE (1966-March 2012) and CINAHL
      (1937-March 2012) for studies of patients with type 2 diabetes mellitus living in
      the community or nursing homes. STUDY SELECTION: The search algorithms combined
      three domains: (1) diabetic patients, (2) sulfonylurea medications, and (3)
      fractures or falls. We included only publications in English that pertained to
      human subjects. We found 9 randomized trials and 12 non-experimental studies that
      met the inclusion criteria. STUDY APPRAISAL AND SYNTHESIS METHODS: The guidelines
      provided by the Cochrane handbook or Agency for Healthcare Research and Quality
      (AHRQ) Methods Guide are too general to distinguish the quality of included
      non-experimental studies, so we developed several specific domains based on those
      general guidelines. These domains included study design, study population,
      follow-up time, comparison group, exposure definition, outcome definition,
      induction period, confounding adjustment, and attrition or missing data. The data
      were not amenable to a meta-analysis. RESULTS: No clinical trials included
      fracture as a primary endpoint. Most clinical trials excluded older adults. Most 
      studies were not designed to evaluate the risk of sulfonylureas on fractures or
      falls. Studies did not show an increased risk of falls/fractures with
      sulfonylurea. LIMITATIONS: The data available from existing studies suffer from
      methodological limitations including insufficient events, lack of primary
      endpoints, exclusion of older adults, and lack of clarity or inappropriate
      comparison groups. CONCLUSION: Future studies are needed to appropriately
      estimate the effect of sulfonylureas on falls or fall-related fractures in older 
      adults who are at increased risk for hypoglycemia, the hypothesized mechanism for
      fractures related to sulfonylurea therapy.
AD  - Department of Quantitative Health Science, University of Massachusetts Medical
      School, 55 Lake Avenue North, Worcester, MA, 01655, USA,
      kate.lapane@umassmed.edu.
FAU - Lapane, Kate L
AU  - Lapane KL
FAU - Yang, Shibing
AU  - Yang S
FAU - Brown, Monique J
AU  - Brown MJ
FAU - Jawahar, Rachel
AU  - Jawahar R
FAU - Pagliasotti, Caleb
AU  - Pagliasotti C
FAU - Rajpathak, Swapnil
AU  - Rajpathak S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Drugs Aging
JT  - Drugs & aging
JID - 9102074
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1007/s40266-013-0081-0 [doi]
PST - aheadofprint
SO  - Drugs Aging. 2013 Apr 23.

PMID- 23609838
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Apr 22
TI  - Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean
      circulating 25-hydroxyvitamin D: a post-hoc analysis of a randomized controlled
      trial.
AB  - Context:Low serum 25-hydroxyvitamin D is a risk factor for osteoporosis,
      cardiovascular disease, diabetes and cancer. Disruption of non-cholesterol sterol
      absorption due to cholesterol lowering therapies may result in reduced fat
      soluble vitamin absorption.Objective:We have previously reported on the
      cholesterol lowering efficacy and reduced sterol absorption of probiotic bile
      salt hydrolase active L. reuteri NCIMB 30242; however, the effects on fat soluble
      vitamins was previously unknown and the objective of the present study.Design,
      Settings, Patients and Intervention:The study was double-blind,
      placebo-controlled, randomized, parallel-arm, multi-center lasting 13 weeks. 127 
      otherwise healthy hypercholesterolemic adults with LDL-cholesterol >3.4 mmol/l,
      triglycerides <4.0 mmol/l and body mass index of 22-32 kg/m2 were included.
      Subjects were recruited from 6 private practices in Prague, CZ and randomized to 
      consume L. reuteri NCIMB 30242 or placebo capsules over a 9-week intervention
      period.Outcome measures:The primary outcome measure was the change in serum
      LDL-cholesterol over the 9-week intervention. Analysis of fat soluble vitamins at
      Weeks 0 and 9 were performed post-hoc.Results:There were no significant
      differences between L. reuteri NCIMB 30242 and placebo capsule groups in serum
      vitamin A, vitamin E, beta-carotene or dietary intake over the intervention
      period (P>0.05). L. reuteri NCIMB 30242 increased serum 25-hydroxyvitamin D by
      14.9 nmol/l or 25.5% over the intervention period, which was a significant mean
      change relative to placebo of 17.1 nmol/l or 22.4% respectively
      (P=0.003).Conclusions:To our knowledge this is the first report of increased
      circulating 25-hydroxyvitamin D in response to oral probiotic supplementation.
AD  - Biomedical Technology and Cell Therapy Research Laboratory, Department of
      Biomedical Engineering and Physiology, Artificial Cells and Organs Research
      Centre, Faculty of Medicine, McGill University, 3775 University St, Montreal, QC,
      H3A 2B4, Canada.
FAU - Jones, Mitchell L
AU  - Jones ML
FAU - Martoni, Christopher J
AU  - Martoni CJ
FAU - Prakash, Satya
AU  - Prakash S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - jc.2012-4262 [pii]
AID - 10.1210/jc.2012-4262 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Apr 22.

PMID- 23609837
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2013 Apr 22
TI  - Clinical Case Seminar: Nephrogenic diabetes insipidus secondary to syphilis
      infection.
AB  - Context:Nephrogenic diabetes insipidus (NDI) is caused by partial or complete
      renal resistance to the effects of antidiuretic hormone. Acquired NDI can be
      caused by electrolyte imbalances (e.g., hypercalcemia), renal/extra-renal
      diseases (e.g., chronic pyelonephritis) and drugs (e.g., lithium toxicity).
      Syphilis has never been reported to cause NDI.Objective:To report the case of a
      56-year-old man with NDI secondary to syphilis.Case:The 56-year-old patient
      presented with polyuria and polydipsia since more than 40 days. His urine
      specific gravity was 1.002. He had no history of chronic kidney disease or
      contact with toxicants. He had normal blood glucose levels. A water-deprivation
      test and vasopressin administration indicated NDI. His rapid plasma reagin (RPR) 
      titer was 1:128. The serum Treponema pallidum-particle agglutination test was
      positive. He reported engaging in unprotected, extramarital sex 6 months before
      polydipsia onset, and thereafter, developing a skin lesion on the external
      genitalia and arthralgia, both of which resolved spontaneously. Examination of
      renal biopsy specimens showed abundant plasmocytic and lymphocytic infiltration
      of the interstitium and low and flat tubular epithelial cells, indicating renal
      tubular injury. Silver staining revealed T. pallidum-like organisms.
      Immunohistochemical analysis with T. pallidum-specific antibody confirmed the
      presence of treponemes.Intervention:He received 2.4 million units benzathine
      penicillin i.m., once a week for 3 weeks.Results:His urine output gradually
      reduced; he recovered 1 month later. His urine specific gravity was 1.026, and
      syphilis RPR titer was 1:8.Conclusion:Syphilis can cause NDI. The manifestations 
      of syphilis and causes of acquired NDI are diverse.
AD  - 1Department of Endocrinology.
FAU - Zhou, Jiaqiang
AU  - Zhou J
FAU - Hu, Chaohui
AU  - Hu C
FAU - Zheng, Fenping
AU  - Zheng F
FAU - Cheng, Hao
AU  - Cheng H
FAU - Xuan, Junli
AU  - Xuan J
FAU - Li, Hong
AU  - Li H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - jc.2013-1074 [pii]
AID - 10.1210/jc.2013-1074 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2013 Apr 22.

PMID- 23609835
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 6
DP  - 2013 Jun
TI  - Increased Hepatic Insulin Clearance After Roux-en-Y Gastric Bypass.
PG  - E1066-71
LID - 10.1210/jc.2013-1286 [doi]
AB  - Context: Roux-en-Y gastric bypass (RYGB) improves glucose tolerance and
      ameliorates fasting hyperinsulinemia within days after surgery. Improvements in
      hepatic insulin sensitivity and insulin clearance could contribute importantly to
      these effects. Objective: The objective of the investigation was to study changes
      in insulin clearance after RYGB. Design: This was a prospective study of fasting 
      hepatic insulin clearance and, in a subgroup of patients, postprandial insulin
      clearance after a meal test before and 1 week, 3 months, and 1 year after RYGB.
      Setting: The study was conducted at Hvidovre Hospital (Hvidovre, Denmark).
      Patients: Patients included 2 groups of obese RYGB-patients: 1) type 2 diabetes
      (T2D) group: 32 patients with T2D (meal test, n = 13), 2) normal glucose
      tolerance (NGT) group: 32 patients with NGT (meal test, n = 12). Intervention:
      The intervention was RYGB. Main Outcome Measure: Fasting hepatic insulin
      clearance (fasting C-peptide/fasting insulin). Postprandial insulin clearance
      (incremental areas under the curve of insulin secretion rates/incremental areas
      under the curve of insulin). Results: Fasting hepatic insulin clearance increased
      after 1 week (P < .01) and further at 3 months (P < .01), remaining elevated 1
      year postoperatively (P < .01) with no difference between the T2D and NGT groups.
      Postprandial insulin clearance changed only in the T2D group with an increase at 
      1 week (P < .01) that was maintained at 3 months (P = .06) and 1 year (P < .01). 
      Conclusions: RYGB increases insulin clearance within 1 week after surgery,
      highlighting the liver as a key organ involved in the early beneficial effect on 
      glucose metabolism. Postprandial insulin secretion may be underestimated
      postoperatively in patients with type 2 diabetes when evaluated by peripheral
      insulin concentrations instead of insulin secretion rates or C-peptide.
AD  - Department of Endocrinology 541, Hvidovre Hospital, Kettegaard Alle 30, DK-2650
      Hvidovre, Denmark. kirstine.bojsen-moeller@regionh.dk.
FAU - Bojsen-Moller, Kirstine N
AU  - Bojsen-Moller KN
FAU - Dirksen, Carsten
AU  - Dirksen C
FAU - Jorgensen, Nils B
AU  - Jorgensen NB
FAU - Jacobsen, Siv H
AU  - Jacobsen SH
FAU - Hansen, Dorte L
AU  - Hansen DL
FAU - Worm, Dorte
AU  - Worm D
FAU - Naver, Lars
AU  - Naver L
FAU - Kristiansen, Viggo B
AU  - Kristiansen VB
FAU - Holst, Jens J
AU  - Holst JJ
FAU - Madsbad, Sten
AU  - Madsbad S
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/22 [aheadofprint]
AID - jc.2013-1286 [pii]
AID - 10.1210/jc.2013-1286 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Jun;98(6):E1066-71. doi: 10.1210/jc.2013-1286. Epub
      2013 Apr 22.

PMID- 23609765
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1179-1896 (Electronic)
IS  - 1175-5652 (Linking)
VI  - 11
IP  - 3
DP  - 2013 Jun
TI  - Multilevel analysis of the influence of patients' and general practitioners'
      characteristics on patented versus multiple-sourced statin prescribing in france.
PG  - 205-18
LID - 10.1007/s40258-013-0014-4 [doi]
AB  - BACKGROUND: The French National Health Insurance and the Ministry of Health have 
      introduced multiple reforms in recent years to increase prescribing efficiency.
      These include guidelines, academic detailing, financial incentives for the
      prescribing and dispensing of generics drugs as well as a voluntary
      pay-for-performance programme. However, the quality and efficiency of prescribing
      could be enhanced potentially if there was better understanding of the dynamics
      of prescribing behaviour in France. OBJECTIVE: To analyse the patient and general
      practitioner characteristics that influence patented versus multiple-sourced
      statin prescribing in France. METHODOLOGY: Statistical analysis was performed on 
      the statin prescribing habits from 341 general practitioners (GPs) that were
      included in the IMS-Health Permanent Survey on Medical Prescription in France,
      which was conducted between 2009 and 2010 and involved 14,360 patients. Patient
      characteristics included their age and gender as well as five medical profiles
      that were constructed from the diagnoses obtained during consultations. These
      were (1) disorders of lipoprotein metabolism, (2) heart disease, (3) diabetes,
      (4) complex profiles and (5) profiles based on other diagnoses. Physician
      characteristics included their age, gender, solo or group practice, weekly
      workload and payment scheme. RESULTS: Patient age had a statistically significant
      impact on statin prescribing for patients in profile 1 (disorders of lipoprotein 
      metabolism) and profile 3 (complex profiles) with a greater number of patented
      statins being prescribed for the youngest patients. For instance, patients older 
      than 76 years with a complex profile were prescribed fewer patented statins than 
      patients aged 68-76 years old with the same medical profile (coefficient: -0.225;
      p = 0.0008). By contrast, regardless of the patient's age, the medical profile
      did not affect the probability of prescribing a patented statin except in young
      patients with heart diseases who were prescribed a greater number of patented
      statins (coefficient: 0.3992; p = 0.0007). Prescribing was also statistically
      influenced by physician features, e.g., older male physicians were more likely to
      prescribe patented statins (coefficient: 0.245; p = 0.0417) and GPs practicing in
      groups were more likely to prescribe multiple sourced statins (coefficient:
      -0.178; p = 0.0338), which is an important finding of the study. GPs with a lower
      workload prescribed a greater number of patented statins. CONCLUSION: There is
      significant variability in the prescribing of different statins among patient and
      physician profiles as well as between solo and group practices. Consequently,
      there are opportunities to target demand-side measures to enhance the prescribing
      of multiple-sourced statins. Further studies are warranted, in particular in
      other therapeutic classes, to provide a counter-balance to the considerable
      marketing activities of pharmaceutical companies.
AD  - IRDES, 10 rue Vauvenargues, 75018, Paris, France.
FAU - Pichetti, Sylvain
AU  - Pichetti S
FAU - Sermet, Catherine
AU  - Sermet C
FAU - Godman, Brian
AU  - Godman B
FAU - Campbell, Stephen M
AU  - Campbell SM
FAU - Gustafsson, Lars L
AU  - Gustafsson LL
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Appl Health Econ Health Policy
JT  - Applied health economics and health policy
JID - 101150314
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1007/s40258-013-0014-4 [doi]
PST - ppublish
SO  - Appl Health Econ Health Policy. 2013 Jun;11(3):205-18. doi:
      10.1007/s40258-013-0014-4.

PMID- 23609564
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1759-507X (Electronic)
IS  - 1759-5061 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - The effect of vitamin D status on risk factors for cardiovascular disease.
PG  - 337-47
LID - 10.1038/nrneph.2013.74 [doi]
AB  - Vitamin-D-related pathways are implicated in various endocrine, inflammatory and 
      endothelial functions. An estimated 1 billion people in the world have vitamin D 
      deficiency or insufficiency, and undiagnosed vitamin D deficiency is common.
      Vitamin D deficiency is associated with substantial increases in the incidence of
      hypertension, hyperlipidaemia, myocardial infarction and stroke, as well as in
      diseases such as chronic kidney disease and type 2 diabetes. Low vitamin D levels
      also upregulate the renin-angiotensin-aldosterone system, increase inflammation
      and cause endothelial dysfunction. However, the role of vitamin D deficiency in
      cardiovascular morbidity and mortality is an emerging and hotly debated topic.
      Epidemiological studies suggest an association between low vitamin D levels and
      risk factors for cardiovascular disease, but a causal relationship has not been
      established, and clinical trials and meta-analyses have not demonstrated
      convincing evidence that vitamin D therapy improves cardiovascular outcomes. Some
      evidence suggests that vitamin D status is a biomarker of lifestyle, since
      unhealthy and sedentary lifestyles are associated with vitamin D insufficiency or
      deficiency and are also risk factors for cardiovascular complications.
AD  - Division of Pediatric Nephrology, University of California San Diego, 9500 Gilman
      Drive, MC 0634, La Jolla, CA 92093, USA.
FAU - Gunta, Sujana S
AU  - Gunta SS
FAU - Thadhani, Ravi I
AU  - Thadhani RI
FAU - Mak, Robert H
AU  - Mak RH
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - England
TA  - Nat Rev Nephrol
JT  - Nature reviews. Nephrology
JID - 101500081
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/23 [aheadofprint]
AID - nrneph.2013.74 [pii]
AID - 10.1038/nrneph.2013.74 [doi]
PST - ppublish
SO  - Nat Rev Nephrol. 2013 Jun;9(6):337-47. doi: 10.1038/nrneph.2013.74. Epub 2013 Apr
      23.

PMID- 23609494
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130423
DCOM- 20130424
LR  - 20130514
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 14
IP  - 4
DP  - 2013
TI  - MicroRNA Transcriptomes Relate Intermuscular Adipose Tissue to Metabolic Risk.
PG  - 8611-24
LID - 10.3390/ijms14048611 [doi]
AB  - Intermuscular adipose tissue is located between the muscle fiber bundles in
      skeletal muscles, and has similar metabolic features to visceral adipose tissue, 
      which has been found to be related to a number of obesity-related diseases.
      Although various miRNAs are known to play crucial roles in adipose deposition and
      adipogenesis, the microRNA transcriptome of intermuscular adipose tissue has not,
      until now, been studied. Here, we sequenced the miRNA transcriptomes of porcine
      intermuscular adipose tissue by small RNA-sequencing and compared it to a
      representative subcutaneous adipose tissue. We found that the inflammation- and
      diabetes-related miRNAs were significantly enriched in the intermuscular rather
      than in the subcutaneous adipose tissue. A functional enrichment analysis of the 
      genes predicted to be targeted by the enriched miRNAs also indicated that
      intermuscular adipose tissue was associated mainly with immune and inflammation
      responses. Our results suggest that the intermuscular adipose tissue should be
      recognized as a potential metabolic risk factor of obesity.
AD  - Institute of Animal Genetics & Breeding, College of Animal Science & Technology, 
      Sichuan Agricultural University, Ya'an 625014, China. mingzhou.li@163.com.
FAU - Ma, Jideng
AU  - Ma J
FAU - Yu, Shuzhen
AU  - Yu S
FAU - Wang, Fengjiao
AU  - Wang F
FAU - Bai, Lin
AU  - Bai L
FAU - Xiao, Jian
AU  - Xiao J
FAU - Jiang, Yanzhi
AU  - Jiang Y
FAU - Chen, Lei
AU  - Chen L
FAU - Wang, Jinyong
AU  - Wang J
FAU - Jiang, Anan
AU  - Jiang A
FAU - Li, Mingzhou
AU  - Li M
FAU - Li, Xuewei
AU  - Li X
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
PMC - PMC3645765
OID - NLM: PMC3645765
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:01
CRDT- 2013/04/24 06:00
PHST- 2013/03/20 [received]
PHST- 2013/04/15 [revised]
PHST- 2013/04/17 [accepted]
AID - ijms14048611 [pii]
AID - 10.3390/ijms14048611 [doi]
PST - epublish
SO  - Int J Mol Sci. 2013 Apr 22;14(4):8611-24. doi: 10.3390/ijms14048611.

PMID- 23609464
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1708-8267 (Electronic)
IS  - 1081-5589 (Linking)
VI  - 61
IP  - 5
DP  - 2013 Jun
TI  - Serum S100A12 levels are correlated with the presence and severity of coronary
      artery disease in patients with type 2 diabetes mellitus.
PG  - 861-6
LID - 10.231/JIM.0b013e318292fb1e [doi]
AB  - OBJECTIVE: Patients with type 2 diabetes mellitus (T2DM) are at high risk for
      development of atherosclerosis and cardiovascular events. Serum S100A12 levels
      have been reported to be associated with coronary artery disease (CAD) and T2DM. 
      We sought to assess whether serum S100A12 levels are correlated with the presence
      and severity of CAD. METHODS: Type 2 diabetes mellitus levels in 188 consecutive 
      patients with T2DM undergoing coronary angiography for the evaluation of CAD. The
      severity of CAD was assessed by the Coronary Atherosclerosis Index (CAI) scores. 
      RESULTS: Serum S100A12 levels were significantly higher in patients with T2DM
      with CAD than in those without CAD. Multivariate logistic regression analysis
      revealed that serum S100A12 levels were independently associated with the
      presence of CAD. Serum S100A12 levels were positively correlated with the
      Coronary Atherosclerosis Index scores after adjusting for other clinical
      characteristics. CONCLUSION: High S100A12 levels are associated with the presence
      and severity of CAD in patients with T2DM.
AD  - From the *Department of Emergency Medicine, Xijing Hospital, Fourth Military
      Medical University, Xi'an, PR China; and daggerDepartment of Anaesthesiology,
      Wuhan General Hospital of Guangzhou Command, Wuhan, PR China.
FAU - Zhao, Peng
AU  - Zhao P
FAU - Wu, Mingchun
AU  - Wu M
FAU - Yu, Houyou
AU  - Yu H
FAU - Huang, Yang
AU  - Huang Y
FAU - Wang, Yutong
AU  - Wang Y
FAU - Wang, Wei
AU  - Wang W
FAU - Yin, Wen
AU  - Yin W
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Investig Med
JT  - Journal of investigative medicine : the official publication of the American
      Federation for Clinical Research
JID - 9501229
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.231/JIM.0b013e318292fb1e [doi]
PST - ppublish
SO  - J Investig Med. 2013 Jun;61(5):861-6. doi: 10.231/JIM.0b013e318292fb1e.

PMID- 23609390
OWN - NLM
STAT- In-Data-Review
DA  - 20130501
IS  - 1533-712X (Electronic)
IS  - 0271-0749 (Linking)
VI  - 33
IP  - 3
DP  - 2013 Jun
TI  - The effect of 2 different single injections of high dose of vitamin d on
      improving the depression in depressed patients with vitamin d deficiency: a
      randomized clinical trial.
PG  - 378-85
LID - 10.1097/JCP.0b013e31828f619a [doi]
AB  - The correlation between vitamin D deficiency and depression has recently been put
      forward and resulted in controversial findings. The present study was conducted
      to find out the effect of 2 single injections of 150,000 and 300,000 IU of
      vitamin D on improving the depression in depressed patients with vitamin D
      deficiency.This clinical trial study was carried out during 2011-2012 in Yazd,
      Islamic Republic of Iran. A total of 120 patients who had a Beck Depression
      Inventory II score of 17+ and were affected with vitamin D deficiency were
      randomly assigned to 3 groups of 40. They included G300, G150, and NTG. G300 and 
      G150 received an intramuscular single dose of 300,000 and 150,000 IU of vitamin
      D, respectively, and the NTG group received nothing. After 3 months of
      intervention, the depression state, serum vitamin D, calcium, phosphorus, and
      parathormone were measured.The median of serum vitamin D after intervention were 
      60.2, 54.6, and 28.2 nmol/L (P < 0.001) for the G300, G150, and NTG,
      respectively. Percentages of vitamin D deficiency after intervention were 18, 20,
      and 91.2 for the groups, respectively. The serum calcium mean showed a
      statistically significant increase in just the 2 test groups receiving vitamin D.
      There was only significant difference in mean of Beck Depression Inventory II
      test score between G300 and NTG (P = 0.003).The results of the study revealed
      that first, the correction of vitamin D deficiency improved the depression state,
      and second, a single injection dose of 300,000 IU of vitamin D was safe and more 
      effective than a 150,000-IU dose.
AD  - From the *Department of Nutrition, Faculty of Health, daggerDepartment of
      Psychiatry, Faculty of Medicine, and double daggerDepartment of Immunology, Yazd 
      Diabetes Research Center, Shahid Sadoughi University of Medical Sciences; and
      section signDepartment of General Course, Teaching English, Faculty of Medicine, 
      Yazd Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
FAU - Mozaffari-Khosravi, Hassan
AU  - Mozaffari-Khosravi H
FAU - Nabizade, Lale
AU  - Nabizade L
FAU - Yassini-Ardakani, Seyed Mojtaba
AU  - Yassini-Ardakani SM
FAU - Hadinedoushan, Hossein
AU  - Hadinedoushan H
FAU - Barzegar, Kazem
AU  - Barzegar K
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1097/JCP.0b013e31828f619a [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2013 Jun;33(3):378-85. doi: 10.1097/JCP.0b013e31828f619a.

PMID- 23609340
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1532-4796 (Electronic)
IS  - 0883-6612 (Linking)
DP  - 2013 Apr 23
TI  - Six-Month Outcomes from Living Well with Diabetes: A Randomized Trial of a
      Telephone-Delivered Weight Loss and Physical Activity Intervention to Improve
      Glycemic Control.
AB  - BACKGROUND: Intensive lifestyle intervention trials in type 2 diabetes contribute
      evidence on what can be achieved under optimal conditions, but are less
      informative for translation in applied settings. PURPOSE: Living Well with
      Diabetes is a telephone-delivered weight loss intervention designed for
      real-world delivery. METHODS: This study is a randomized controlled trial of
      telephone counseling (n = 151) versus usual care (n = 151); 6-month primary
      outcomes of weight, physical activity, HbA1c; secondary diet outcomes; analysis
      was by adjusted generalized linear models. RESULTS: Relative to usual care,
      telephone counseling participants had small but significantly better weight loss 
      [-1.12 % of initial body weight; 95 % confidence interval (CI) -1.92, -0.33 %];
      physical activity [relative rate (RR) = 1.30; 95 % CI, 1.08, 1.57]; energy intake
      reduction (-0.63 MJ/day; 95 % CI, -1.01, -0.25); and diet quality (3.72 points;
      95 % CI, 1.77, 5.68), with no intervention effect for HbA1c (RR = 0.99; 95 % CI, 
      0.96, 1.01). CONCLUSIONS: Results are discussed in light of challenges to
      intervention delivery.
AD  - The University of Queensland, School of Population Health, Cancer Prevention
      Research Centre, Level 3 Public Health Building, Herston Road, Herston, Brisbane,
      QLD, 4006, Australia, e.eakin@sph.uq.edu.au.
FAU - Eakin, E G
AU  - Eakin EG
FAU - Reeves, M M
AU  - Reeves MM
FAU - Winkler, E
AU  - Winkler E
FAU - Healy, G N
AU  - Healy GN
FAU - Dunstan, D W
AU  - Dunstan DW
FAU - Owen, N
AU  - Owen N
FAU - Marshal, A M
AU  - Marshal AM
FAU - Wilkie, K C
AU  - Wilkie KC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - Ann Behav Med
JT  - Annals of behavioral medicine : a publication of the Society of Behavioral
      Medicine
JID - 8510246
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1007/s12160-013-9498-2 [doi]
PST - aheadofprint
SO  - Ann Behav Med. 2013 Apr 23.

PMID- 23609336
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - Diabetes: Implications of a novel point mutation of SIRT1 in T1DM.
PG  - 323-4
LID - 10.1038/nrendo.2013.87 [doi]
AD  - Department of Neurology and Neurosciences, Cancer Center, F-1222, University of
      Medicine and Dentistry New Jersey, New Jersey Medical School, 205 South Orange
      Avenue, Newark, NJ 07103, USA. zzchong@yahoo.com.
FAU - Chong, Zhao Zhong
AU  - Chong ZZ
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/23 [aheadofprint]
AID - nrendo.2013.87 [pii]
AID - 10.1038/nrendo.2013.87 [doi]
PST - ppublish
SO  - Nat Rev Endocrinol. 2013 Jun;9(6):323-4. doi: 10.1038/nrendo.2013.87. Epub 2013
      Apr 23.

PMID- 23609310
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Heterogeneous nuclear ribonucleoproteins F and K mediate insulin inhibition of
      renal angiotensinogen gene expression and prevention of hypertension and kidney
      injury in diabetic mice.
PG  - 1649-60
LID - 10.1007/s00125-013-2910-4 [doi]
AB  - AIMS/HYPOTHESIS: We investigated whether heterogeneous nuclear ribonucleoproteins
      F and K (hnRNP F, hnRNP K) mediate insulin inhibition of renal Agt expression and
      prevention of hypertension and kidney injury in an Akita mouse model of type 1
      diabetes. METHODS: Adult male Akita mice (12 weeks old) were treated with insulin
      implants and killed at week 16. Untreated non-Akita littermates served as
      controls. The effects of insulin on blood glucose, systolic BP (SBP), renal
      proximal tubular cell (RPTC) gene expression and interstitial fibrosis were
      studied. We also examined immortalised rat RPTCs stably transfected with control 
      plasmid or with plasmid containing rat Agt promoter in vitro. RESULTS: Insulin
      treatment normalised blood glucose levels and SBP, inhibited renal AGT expression
      but enhanced hnRNP F, hnRNP K and angiotensin-converting enzyme-2 expression,
      attenuated renal hypertrophy and glomerular hyperfiltration and decreased urinary
      albumin/creatinine ratio, as well as AGT and angiotensin II levels, in Akita
      mice. In vitro, insulin inhibited Agt but stimulated Hnrnpf and Hnrnpk expression
      in high-glucose media via p44/42 mitogen-activated protein kinase signalling in
      RPTCs. Transfection with Hnrnpf or Hnrnpk small interfering RNAs prevented
      insulin inhibition of Agt expression in RPTCs. CONCLUSIONS/INTERPRETATION: These 
      data indicate that insulin prevents hypertension and attenuates kidney injury, at
      least in part, through suppressing renal Agt transcription via upregulation of
      hnRNP F and hnRNP K expression in diabetic Akita mice. HnRNP F and hnRNP K may be
      potential targets in the treatment of hypertension and kidney injury in diabetes.
AD  - Centre de recherche, Centre hospitalier de l'Universite de Montreal
      (CHUM)-Hotel-Dieu Hospital, Universite de Montreal, Pavillon Masson, 3850 Saint
      Urbain Street, Montreal, Canada, QC, H2W 1T8.
FAU - Abdo, S
AU  - Abdo S
FAU - Lo, C-S
AU  - Lo CS
FAU - Chenier, I
AU  - Chenier I
FAU - Shamsuyarova, A
AU  - Shamsuyarova A
FAU - Filep, J G
AU  - Filep JG
FAU - Ingelfinger, J R
AU  - Ingelfinger JR
FAU - Zhang, S-L
AU  - Zhang SL
FAU - Chan, J S D
AU  - Chan JS
LA  - eng
PT  - Journal Article
DEP - 20130423
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/11/20 [received]
PHST- 2013/03/12 [accepted]
PHST- 2013/04/23 [aheadofprint]
AID - 10.1007/s00125-013-2910-4 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1649-60. doi: 10.1007/s00125-013-2910-4. Epub 2013
      Apr 23.

PMID- 23609178
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1525-1497 (Electronic)
IS  - 0884-8734 (Linking)
DP  - 2013 Apr 23
TI  - Drinking Patterns of Older Adults with Chronic Medical Conditions.
AB  - BACKGROUND: Understanding alcohol consumption patterns of older adults with
      chronic illness is important given the aging baby boomer generation, the increase
      in prevalence of chronic conditions and associated medication use, and the
      potential consequences of excessive drinking in this population. OBJECTIVES: To
      estimate the prevalence of alcohol consumption patterns, including at-risk
      drinking, in older adults with at least one of seven common chronic conditions.
      DESIGN/METHODS: This descriptive study used the nationally representative 2005
      Medicare Current Beneficiary Survey linked with Medicare claims. The sample
      included community-dwelling, fee-for-service beneficiaries 65 years and older
      with one or more of seven chronic conditions (Alzheimer's disease and other
      senile dementia, chronic obstructive pulmonary disease, depression, diabetes,
      heart failure, hypertension, and stroke; n = 7,422). Based on self-reported
      alcohol consumption, individuals were categorized as nondrinkers,
      within-guidelines drinkers, or at-risk drinkers (exceeds guidelines). RESULTS:
      Overall, 30.9 % (CI 28.0-34.1 %) of older adults with at least one of seven
      chronic conditions reported alcohol consumption in a typical month in the past
      year, and 6.9 % (CI 6.0-7.8 %) reported at-risk drinking. Older adults with
      higher chronic disease burdens were less likely to report alcohol consumption and
      at-risk drinking. CONCLUSIONS: Nearly one-third of older adults with selected
      chronic illnesses report drinking alcohol and almost 7 % drink in excess of
      National Institute on Alcohol Abuse and Alcoholism (NIAAA) guidelines. It is
      important for physicians and patients to discuss alcohol consumption as a
      component of chronic illness management. In cases of at-risk drinking, providers 
      have an opportunity to provide brief intervention or to offer referrals if
      needed.
AD  - Heller School for Social Policy and Management, Brandeis University, 415 South
      Street, MS035, Waltham, MA, 02454-9110, USA, mryan@brandeis.edu.
FAU - Ryan, Marian
AU  - Ryan M
FAU - Merrick, Elizabeth L
AU  - Merrick EL
FAU - Hodgkin, Dominic
AU  - Hodgkin D
FAU - Horgan, Constance M
AU  - Horgan CM
FAU - Garnick, Deborah W
AU  - Garnick DW
FAU - Panas, Lee
AU  - Panas L
FAU - Ritter, Grant
AU  - Ritter G
FAU - Blow, Frederic C
AU  - Blow FC
FAU - Saitz, Richard
AU  - Saitz R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - J Gen Intern Med
JT  - Journal of general internal medicine
JID - 8605834
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/06/14 [received]
PHST- 2013/02/27 [accepted]
PHST- 2013/01/10 [revised]
PHST- 2013/04/23 [aheadofprint]
AID - 10.1007/s11606-013-2409-1 [doi]
PST - aheadofprint
SO  - J Gen Intern Med. 2013 Apr 23.

PMID- 23609167
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1941-6636 (Electronic)
DP  - 2013 Apr 23
TI  - Risk Profile of Hepatocellular Carcinoma Reveals Dichotomy among US Veterans.
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) is traditionally associated with
      chronic liver injury resulting from hepatitis B virus (HBV) and hepatitis C virus
      (HCV) infection or excessive consumption of alcohol. In addition, recent evidence
      links HCC to diabetes. AIMS: Since these risk factors are prevalent among US
      veterans, we analyzedcontribution of various etiologies toHCC incidence in this
      population. METHODS: Clinicopathological correlates of 150 male US veterans
      diagnosed with HCC between 2001 and 2010 were analyzed and compared to
      frequency-matched (2:1) non-cancer controls in a single center. RESULTS: HCC was 
      associated with cirrhosis (odds ratio [OR], 250.84; 95 % confidence interval
      [CI], 86.92-723.88; p < 0.0001), chronic hepatitis B (OR, 34.30 95 % CI,
      1.97-598.47; p = 0.015), chronic hepatitis C (OR, 6.84; 95 % CI, 3.89-12.04; p < 
      0.0001), alcohol use (OR, 6.76; 95 % CI, 4.35-10.52; p < 0.0001), and smoking
      (OR, 1.83; 95 % CI, 1.23-2.89; p = 0.009), but surprisingly not with diabetes.
      Only in a subgroup of HCC patients with no "traditional" risk factors did
      diabetes become a strong independent predictor of HCC when compared to HCC
      patients with at least one such risk factor (OR, 10.69; 95 % CI, 1.88-60.63, p = 
      0.007). This subgroup was further distinguished by older age, increased
      prevalence of hypertension, nonsmoking, and a trend to develop noncirrhotic HCC. 
      CONCLUSIONS: While HCC in US veterans is overwhelmingly linked to cirrhosis due
      to "traditional" risk factors, it also occurs with a separate clinical profile
      characterized by diabetes and no evidence of cirrhosis, suggesting distinct
      mechanisms of hepatocarcinogenesis and needs for surveillance.
AD  - Section of Gastroenterology, Department of Medicine, VA Boston Healthcare System,
      150 S Huntington Avenue, Boston, MA, 02130, USA.
FAU - Karagozian, Raffi
AU  - Karagozian R
FAU - Baker, Errol
AU  - Baker E
FAU - Houranieh, Antoun
AU  - Houranieh A
FAU - Leavitt, Daniel
AU  - Leavitt D
FAU - Baffy, Gyorgy
AU  - Baffy G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - J Gastrointest Cancer
JT  - Journal of gastrointestinal cancer
JID - 101479627
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1007/s12029-013-9499-1 [doi]
PST - aheadofprint
SO  - J Gastrointest Cancer. 2013 Apr 23.

PMID- 23609127
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1539-2864 (Electronic)
IS  - 0275-004X (Linking)
DP  - 2013 Apr 19
TI  - TRANSVITREAL FIBRINOID PSEUDOENDOPHTHALMITIS AFTER DIABETIC VITRECTOMY.
AB  - OBJECTIVE:: To describe the presentation and clinical course of noninfectious
      transvitreal fibrinoid response after vitrectomy for diabetic retinopathy.
      METHODS:: Data collected from charts included age, gender, surgical indication,
      preoperative and serial visual acuities, vitrectomy procedures, and postoperative
      clinical characteristics of involved eye. RESULTS:: Patients had a mean age of
      65.6 years (51-82 years) with 5 women and 2 men. Patients had a range of diabetes
      duration from 4 to 27 years and a mean HgbA1C of 9.1 (5.8-14.1). Surgical
      indications included nonclearing vitreous hemorrhage (five), tractional retinal
      detachment (three), and clinically significant macular edema (one). All patients 
      manifested transvitreal bands on postoperative Day 1 without anterior chamber
      reaction. Mean time to resolution of transvitreal bands was 8.75 days (4-15 days)
      on standard postoperative topical medications alone. CONCLUSION:: Transvitreal
      fibrinoid response after diabetic vitrectomy is a remarkable phenomenon that can 
      occur in a wide variety of patients with diabetic retinopathy. It is important to
      differentiate this from infectious endophthalmitis, as this series of cases
      resolved spontaneously on topical medications alone.
AD  - Associated Retinal Consultants, Royal Oak, Michigan.
FAU - Luo, Caesar
AU  - Luo C
FAU - Ruby, Alan
AU  - Ruby A
FAU - Neuwelt, Melissa
AU  - Neuwelt M
FAU - Williams, George A
AU  - Williams GA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Retina
JT  - Retina (Philadelphia, Pa.)
JID - 8309919
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1097/IAE.0b013e31828abe67 [doi]
PST - aheadofprint
SO  - Retina. 2013 Apr 19.

PMID- 23609064
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1539-2864 (Electronic)
IS  - 0275-004X (Linking)
VI  - 33
IP  - 5
DP  - 2013 May
TI  - Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical
      features, diagnosis, and complications. An update of the literature.
PG  - 901-10
LID - 10.1097/IAE.0b013e3182870c15 [doi]
AB  - BACKGROUND/PURPOSE: Retinal vein occlusion is the second most common retinal
      vascular disorder after diabetic retinopathy and is considered to be an important
      cause of visual loss. In this review, the purpose is to make an update of the
      literature about the classification, epidemiology, pathogenesis, risk factors,
      clinical features, and complications of branch retinal vein occlusion (BRVO).
      METHODS: Eligible articles were identified using a comprehensive literature
      search of MEDLINE, using the terms "branch retinal vein occlusion,"
      "pathogenesis," "epidemiology," "risk factors," "clinical features," "diagnosis,"
      and "complications." Additional articles were also selected from reference lists 
      of articles identified by the electronic database search. RESULTS:
      Classification, epidemiology, pathogenesis, risk factors, clinical features, and 
      complications are analyzed. CONCLUSIONS: Branch retinal vein occlusion has an
      incidence of 0.5% to 1.2%. Several risk factors, such as hypertension,
      hyperlipidemia, diabetes mellitus, thrombophilia and hypercoagulation, systemic
      and inflammatory diseases, medications, and ocular conditions, have found to be
      associated with BRVO. The symptoms depended on the site and severity of the
      occlusion. The average reduction in visual acuity for ischemic BRVO is 20/50 and 
      for nonischemic BRVO is 20/60. Acute BRVO can be detected by fundoscopy, where
      flame hemorrhages, dot and blot hemorrhages, cotton wool spots, hard exudates,
      retinal edema, and dilated tortuous veins can be observed. Chronic BRVO would be 
      more subtle and characterized by the appearance of venous collateral formation
      and vascular sheathing, in addition to complications previously mentioned. Areas 
      of ischemia can be evaluated using fluorescein angiography. The extent of macular
      edema and the presence of retinal detachment can be detected by fundoscopic
      examination or fluorescein angiography, although optical coherence tomography is 
      considered to be the best method. As far as complications, the most common is
      macular edema, followed by retinal neovascularization, vitreous hemorrhage, or
      retinal detachment.
AD  - Barts and the London School of Medicine and Dentistry, Queen Mary University of
      London, London E1 2AT, UK.
FAU - Jaulim, Adil
AU  - Jaulim A
FAU - Ahmed, Badia
AU  - Ahmed B
FAU - Khanam, Tina
AU  - Khanam T
FAU - Chatziralli, Irini P
AU  - Chatziralli IP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Retina
JT  - Retina (Philadelphia, Pa.)
JID - 8309919
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1097/IAE.0b013e3182870c15 [doi]
AID - 00006982-201305000-00002 [pii]
PST - ppublish
SO  - Retina. 2013 May;33(5):901-10. doi: 10.1097/IAE.0b013e3182870c15.

PMID- 23609043
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1752-2978 (Electronic)
IS  - 1752-296X (Linking)
VI  - 20
IP  - 3
DP  - 2013 Jun
TI  - Prostate cancer overdiagnosis and overtreatment.
PG  - 204-9
LID - 10.1097/MED.0b013e328360332a [doi]
AB  - PURPOSE OF REVIEW: To summarize the evidence, now extensive, that efforts to
      reduce prostate cancer mortality by screening and early detection result in
      overdiagnosis of disease that is clinically insignificant, and would never have
      been diagnosed in the patient's lifetime in the absence of screening.
      Overdiagnosis may result in overtreatment, which in the case of prostate cancer
      often carries significant, long-term quality-of-life effects. The review also
      addresses the solutions to the problem of overdiagnosis and overtreatment, and
      summarizes the outcomes of these approaches. RECENT FINDINGS: Screening for
      prostate cancer has been demonstrated to reduce mortality, although with a high
      number needed to treat. One approach to this problem is to offer patients with
      favorable risk disease an initial conservative approach, with close monitoring
      and treatment for those patients who are reclassified as higher risk over time.
      Much preclinical data indicates that Gleason 6 prostate cancer does not carry the
      hallmarks of malignancy. However, a number of recent studies have demonstrated
      that in patients diagnosed with favorable risk prostate cancer (Gleason 6 or
      less, prostate-specific antigen <10), about 30% will harbor higher grade cancer
      and benefit from treatment. These patients are identifiable by a combination of
      repeat biopsy, serial prostate-specific antigen, and in borderline cases,
      multiparametric MRI. SUMMARY: Active surveillance is a powerful solution to the
      problem of overdiagnosis and overtreatment associated with screening for prostate
      cancer. For the 40-50% of patients with favorable risk prostate cancer, it offers
      the benefit of personalized medicine, avoiding treatment and related
      quality-of-life effects altogether in the majority, and providing definitive
      management for the minority who are reclassified with higher risk disease over
      time.
AD  - University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Ave MG
      408, Toronto, Ontario, Canada. Laurence.klotz@sunnybrook.ca
FAU - Klotz, Laurence
AU  - Klotz L
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Endocrinol Diabetes Obes
JT  - Current opinion in endocrinology, diabetes, and obesity
JID - 101308636
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1097/MED.0b013e328360332a [doi]
PST - ppublish
SO  - Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):204-9. doi:
      10.1097/MED.0b013e328360332a.

PMID- 23609014
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 158
IP  - 10
DP  - 2013 May 21
TI  - Comparative effectiveness of multivessel coronary bypass surgery and multivessel 
      percutaneous coronary intervention: a cohort study.
PG  - 727-34
LID - 10.7326/0003-4819-158-10-201305210-00639 [doi]
AB  - Chinese translation BACKGROUND: Randomized trials of coronary artery bypass graft
      (CABG) surgery and percutaneous coronary intervention (PCI) suggest that patient 
      characteristics modify the effect of treatment on mortality. OBJECTIVE: To assess
      whether clinical characteristics modify the comparative effectiveness of CABG
      versus PCI in an unselected, general patient population. DESIGN: Observational
      treatment comparison using propensity score matching and Cox proportional hazards
      models. SETTING: United States, 1992 to 2008. PATIENTS: Medicare beneficiaries
      aged 66 years or older. INTERVENTION: Multivessel CABG or multivessel PCI.
      MEASUREMENTS: The CABG-PCI hazard ratio (HR) for all-cause mortality, with
      prespecified treatment-by-covariate interaction tests, and the absolute
      difference in life-years of survival in clinical subgroups after CABG or PCI,
      both over 5 years of follow-up. RESULTS: Among 105 156 propensity score-matched
      patients, CABG was associated with lower mortality than PCI (HR, 0.92 [95% CI,
      0.90 to 0.95]; P &lt; 0.001). Association of CABG with lower mortality was
      significantly greater (interaction P </= 0.002 for each) among patients with
      diabetes (HR, 0.88), a history of tobacco use (HR, 0.82), heart failure (HR,
      0.84), and peripheral arterial disease (HR, 0.85). The overall predicted
      difference in survival between CABG and PCI treatment over 5 years was 0.053
      life-years (range, -0.017 to 0.579 life-years). Patients with diabetes, heart
      failure, peripheral arterial disease, or tobacco use had the largest predicted
      differences in survival after CABG, whereas those with none of these factors had 
      slightly better survival after PCI. LIMITATION: Treatments were chosen by
      patients and physicians rather than being randomly assigned. CONCLUSION:
      Multivessel CABG is associated with lower long-term mortality than multivessel
      PCI in the community setting. This association is substantially modified by
      patient characteristics, with improvement in survival concentrated among patients
      with diabetes, tobacco use, heart failure, or peripheral arterial disease.
      PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.
FAU - Hlatky, Mark A
AU  - Hlatky MA
FAU - Boothroyd, Derek B
AU  - Boothroyd DB
FAU - Baker, Laurence
AU  - Baker L
FAU - Kazi, Dhruv S
AU  - Kazi DS
FAU - Solomon, Matthew D
AU  - Solomon MD
FAU - Chang, Tara I
AU  - Chang TI
FAU - Shilane, David
AU  - Shilane D
FAU - Go, Alan S
AU  - Go AS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
SB  - AIM
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 1679804 [pii]
AID - 10.7326/0003-4819-158-10-201305210-00639 [doi]
PST - ppublish
SO  - Ann Intern Med. 2013 May 21;158(10):727-34. doi:
      10.7326/0003-4819-158-10-201305210-00639.

PMID- 23608868
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Progressive outer retinal necrosis: a missed diagnosis and a blind, young woman.
LID - 10.1136/bcr-2013-009333 [doi]
LID - bcr2013009333 [pii]
AB  - We present a 33-year-old woman with a history significant for HIV/AIDS (CD4 count
      of 17) and diabetes mellitus who was diagnosed as having progressive outer
      retinal necrosis (PORN) after presenting with peripheral vision loss. This case
      provided a diagnostic challenge and demonstrates the devastating effects of a
      misdiagnosis as it pertains to PORN.
AD  - Department of Internal Medicine, Eastern Virginia Medical School, Norfolk,
      Virginia, USA.
FAU - Parekh, Parth
AU  - Parekh P
FAU - Oldfield, Edward C
AU  - Oldfield EC
FAU - Marik, Paul E
AU  - Marik PE
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - bcr-2013-009333 [pii]
AID - 10.1136/bcr-2013-009333 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 22;2013. pii: bcr2013009333. doi: 10.1136/bcr-2013-009333.

PMID- 23608838
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Inferior vena cava thrombosis: a rare complication of fibrocalcific pancreatic
      diabetes.
LID - 10.1136/bcr-2012-008330 [doi]
LID - bcr2012008330 [pii]
AB  - A 42-year-old man presented with a history of recurrent loose motions for the
      previous 7 months. The patient also had a history of diabetes mellitus for the
      last 10 years and was uncontrolled on oral hypoglycaemic agents but responded to 
      insulin. There was no history of any addiction. Examination and investigations
      showed the presence of malabsorption along with a calcified pancreas. The
      presence of a thrombus was also noted in the inferior vena cava. In the absence
      of alcohol intake, a diagnosis of fibrocalcific pancreatic diabetes was made and 
      the patient was investigated for other hypercoagulable states but none was found.
      The patient was put on oral anticoagulants, insulin and pancreatic enzyme
      supplements, and currently, he is under regular follow-up for diabetes.
AD  - Department of Medicine, King Georges Medical University, Lucknow, Uttar Pradesh, 
      India.
FAU - Mishra, R
AU  - Mishra R
FAU - Yathish, B E
AU  - Yathish BE
FAU - Himanshu, D
AU  - Himanshu D
FAU - Usman, K
AU  - Usman K
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - bcr-2012-008330 [pii]
AID - 10.1136/bcr-2012-008330 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 22;2013. pii: bcr2012008330. doi: 10.1136/bcr-2012-008330.

PMID- 23608773
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1435-1803 (Electronic)
IS  - 0300-8428 (Linking)
VI  - 108
IP  - 3
DP  - 2013 May
TI  - Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage
      differentiation, activation and apoptosis.
PG  - 350
LID - 10.1007/s00395-013-0350-4 [doi]
AB  - Atherosclerosis is a chronic inflammatory disorder of the arterial wall leading
      to coronary artery disease, stroke, and peripheral arterial disease. Along with
      the discovery of dipeptidyl peptidase 4 (DPP4) as a therapeutic target in type 2 
      diabetes, a role for DPP4 in atherosclerosis is emerging. However, until now the 
      expression and role of other DPPs such as DPP8 and DPP9 in atherosclerosis is
      completely unknown. In the present study, we first investigated DPP expression in
      human atherosclerotic plaques. DPP4 could only be observed in endothelial cells
      of plaque neovessels in half of the specimens. In contrast, DPP8 and DPP9 were
      abundantly present in macrophage-rich regions of plaques. We then focused on DPP 
      expression and function in macrophage differentiation, activation and apoptosis. 
      DPP8/9 was responsible for most of the DPP activity in macrophages. During
      monocyte to macrophage differentiation, DPP9 was upregulated both in
      pro-inflammatory M1 (3.7 +/- 0.3-fold increase) and anti-inflammatory M2
      macrophages (3.7 +/- 0.4-fold increase) whereas DPP8 expression remained
      unchanged. Inhibition of DPP8/9 activity with compound 1G244 reduced activation
      of M1 macrophages (IL-6 88 +/- 16 vs. 146 +/- 19 pg/ml; TNFalpha 3.8 +/- 1.0 vs. 
      6.6 +/- 1.9 ng/ml in treated vs. untreated cells), but not of M2 macrophages.
      Likewise, DPP9 silencing reduced TNFalpha and IL-6 secretion, pointing to a
      DPP9-mediated effect of the inhibitor. DPP8/9 inhibition also enhanced macrophage
      apoptosis (15 +/- 4 vs. 7 +/- 3 % in untreated cells). Because pro-inflammatory
      macrophages play a key role in atherogenesis, plaque rupture and subsequent
      infarction, DPP9 inhibition might provide interesting therapeutic prospects in
      reducing atherosclerosis and/or in the prevention of plaque rupture.
AD  - Laboratory of Medical Biochemistry, Department of Pharmaceutical Sciences,
      University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium.
FAU - Matheeussen, Veerle
AU  - Matheeussen V
FAU - Waumans, Yannick
AU  - Waumans Y
FAU - Martinet, Wim
AU  - Martinet W
FAU - Van Goethem, Sebastiaan
AU  - Van Goethem S
FAU - Van der Veken, Pieter
AU  - Van der Veken P
FAU - Scharpe, Simon
AU  - Scharpe S
FAU - Augustyns, Koen
AU  - Augustyns K
FAU - De Meyer, Guido R Y
AU  - De Meyer GR
FAU - De Meester, Ingrid
AU  - De Meester I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130423
PL  - Germany
TA  - Basic Res Cardiol
JT  - Basic research in cardiology
JID - 0360342
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/05/15 [received]
PHST- 2013/04/06 [accepted]
PHST- 2013/03/18 [revised]
PHST- 2013/04/23 [aheadofprint]
AID - 10.1007/s00395-013-0350-4 [doi]
PST - ppublish
SO  - Basic Res Cardiol. 2013 May;108(3):350. doi: 10.1007/s00395-013-0350-4. Epub 2013
      Apr 23.

PMID- 23608735
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 Apr 18
TI  - Presentation, diagnostic features and glucose handling in a monocentric series of
      insulinoma.
AB  - Background: new aspects have emerged in the clinical and diagnostic scenarios of 
      insulinoma: current guidelines have lowered the diagnostic insulin threshold to
      3FU/ml in the presence of hypoglycemia (<55 mg/dL); post-prandial hypoglycemia
      has been reported as the only presenting symptom; preexisting diabetes mellitus
      was recognized in some patients. Aim: to evaluate clinical features, diagnostic
      criteria and glucose metabolic profile in a monocentric series of patients
      affected by insulinomas including two subgroups: sporadic and MEN-1. Subjects and
      methods: clinical, pathological and biochemical data regarding 33 patients were
      analyzed. Results: following the current guidelines the 72h-fasting test was
      initially positive in all cases but one. In this case the test, initially
      negative, became positive after a 2-year follow-up. Nadir insulin level was >/=
      3FU/mL but < 6 FU/mL in three patients and >/= 6 FU/mL in the remaining 30 cases.
      At presentation 27 patients (82%) reported only fasting symptoms, 3 (9%) only
      post-prandial and 3 (9%) both. Seven cases (21%) had previously been affected by 
      type 2 diabetes mellitus or impaired glucose metabolism. Conclusions: in our
      series the new cut-off of insulin increased the sensitivity of the 72h-fasting
      test from 87% to 97%. The absence of hypoglycemia during the test cannot
      definitively rule out the diagnosis and the test should be repeated in every
      highly suspicious case. Post-prandial hypoglycaemia can be the only presenting
      symptom. Diabetes mellitus may be associated with the occurrence of insulinoma. A
      possible diagnosis of insulinoma must not be ignored if previous impaired glucose
      handling is evident.
AD  - Department of Internal Medicine D, "G.B. Rossi" University Hospital, Verona,
      Italy.
FAU - Toaiari, M
AU  - Toaiari M
FAU - Davi, M V
AU  - Davi MV
FAU - Dalle Carbonare, L
AU  - Dalle Carbonare L
FAU - Boninsegna, L
AU  - Boninsegna L
FAU - Castellani, C
AU  - Castellani C
FAU - Falconi, M
AU  - Falconi M
FAU - Francia, G
AU  - Francia G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 8942 [pii]
AID - 10.3275/8942 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 Apr 18.

PMID- 23608726
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1872-6968 (Electronic)
IS  - 0303-8467 (Linking)
DP  - 2013 Apr 19
TI  - Two different clinical entities of small vessel occlusion in TOAST
      classification.
LID - S0303-8467(13)00105-4 [pii]
LID - 10.1016/j.clineuro.2013.03.005 [doi]
AB  - BACKGROUND: Small deep infarcts might be classified into 2 types: lacunar and
      branchatheromatous infarcts. However, since their initial description, small deep
      infarcts were still regarded as the same category of the Trial of Org 10172 in
      Acute Stroke Treatment (TOAST) classification, small vessel occlusion (SVO). We
      hypothesized that the 2 types of small deep infarcts would be distinct clinical
      entities. This study was conducted to investigate the clinical characteristics in
      the 2 groups of patients according to lesion pattern and combined atherosclerotic
      diseases. METHODS: We included patients with small deep infarcts in the
      subcortical area. The patients were divided into 2 groups: (1) island lesions and
      (2) linear lesions on coronal diffusion weighted imaging. The status of the
      relevant artery was categorized as no stenosis, non-significant (<50% of luminal 
      narrowing) and significant (>/=50% of luminal narrowing). We compared the
      clinical and imaging characteristics of two lesion types according to various
      arterial status. RESULTS: This study analyzed a total of 248 patients.
      Independent factors for island lesions on coronal DWI were male, severe
      leukoaraiosis, microbleeds, abnormal glycated hemoglobin (HbA1C), and abnormal
      estimated glomerular filtration ratio (eGFR) adjusted by age, sex, and inititial 
      National Institutes of Health Stroke Scale. In addition, in patients without
      significant relevant arterial stenosis, island lesion patterns were more
      frequently associated with severe periventricular white matter hyperintensity,
      diabetes mellitus, abnormal eGFR and abnormal HbA1C than linear lesion patterns. 
      CONCLUSION: This study demonstrated that SVO of TOAST classifications had
      different imaging and clinical characteristics according to the lesion patterns
      of coronal imaging. It suggests that two types of SVO should be regarded as the
      different categories of stroke classification.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Department of Neurology, Cerebrovascular Center, Chonnam National University
      Hospital, Gwangju, Republic of Korea.
FAU - Kim, Dong-Eun
AU  - Kim DE
FAU - Choi, Min-Ji
AU  - Choi MJ
FAU - Kim, Joon-Tae
AU  - Kim JT
FAU - Chang, Jane
AU  - Chang J
FAU - Park, Man-Seok
AU  - Park MS
FAU - Choi, Kang-Ho
AU  - Choi KH
FAU - Oh, Dong-Seok
AU  - Oh DS
FAU - Lee, Seung-Han
AU  - Lee SH
FAU - Cho, Ki-Hyun
AU  - Cho KH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Clin Neurol Neurosurg
JT  - Clinical neurology and neurosurgery
JID - 7502039
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/01/16 [received]
PHST- 2013/02/15 [revised]
PHST- 2013/03/22 [accepted]
AID - S0303-8467(13)00105-4 [pii]
AID - 10.1016/j.clineuro.2013.03.005 [doi]
PST - aheadofprint
SO  - Clin Neurol Neurosurg. 2013 Apr 19. pii: S0303-8467(13)00105-4. doi:
      10.1016/j.clineuro.2013.03.005.

PMID- 23608648
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 61
IP  - 6
DP  - 2013 Jun
TI  - Angiotensin-converting enzyme 2 activation improves endothelial function.
PG  - 1233-8
LID - 10.1161/HYPERTENSIONAHA.111.00627 [doi]
AB  - Diminished release and function of endothelium-derived nitric oxide coupled with 
      increases in reactive oxygen species production is critical in endothelial
      dysfunction. Recent evidences have shown that activation of the protective axis
      of the renin-angiotensin system composed by angiotensin-converting enzyme 2,
      angiotensin-(1-7), and Mas receptor promotes many beneficial vascular effects.
      This has led us to postulate that activation of intrinsic angiotensin-converting 
      enzyme 2 would improve endothelial function by decreasing the reactive oxygen
      species production. In the present study, we tested
      1-[[2-(dimetilamino)etil]amino]-4-(hidroximetil)-7-[[(4-metilfenil)sulfonil]oxi]-
      9H-xantona-9 (XNT), a small molecule angiotensin-converting enzyme 2 activator,
      on endothelial function to validate this hypothesis. In vivo treatment with XNT
      (1 mg/kg per day for 4 weeks) improved the endothelial function of spontaneously 
      hypertensive rats and of streptozotocin-induced diabetic rats when evaluated
      through the vasorelaxant responses to acetylcholine/sodium nitroprusside. Acute
      in vitro incubation with XNT caused endothelial-dependent vasorelaxation in
      aortic rings of rats. This vasorelaxation effect was attenuated by the Mas
      antagonist D-pro7-Ang-(1-7), and it was reduced in Mas knockout mice. These
      effects were associated with reduction in reactive oxygen species production. In 
      addition, Ang II-induced reactive oxygen species production in human aortic
      endothelial cells was attenuated by preincubation with XNT. These results showed 
      that chronic XNT administration improves the endothelial function of hypertensive
      and diabetic rat vessels by attenuation of the oxidative stress. Moreover, XNT
      elicits an endothelial-dependent vasorelaxation response, which was mediated by
      Mas. Thus, this study indicated that angiotensin-converting enzyme 2 activation
      promotes beneficial effects on the endothelial function and it is a potential
      target for treating cardiovascular disease.
AD  - Department of Morphology, Federal University of Minas Gerais, Av. Antonio Carlos,
      6627, 31.270-901 Belo Horizonte, MG, Brazil. anderson@icb.ufmg.br.
FAU - Fraga-Silva, Rodrigo A
AU  - Fraga-Silva RA
FAU - Costa-Fraga, Fabiana P
AU  - Costa-Fraga FP
FAU - Murca, Tatiane M
AU  - Murca TM
FAU - Moraes, Patricia L
AU  - Moraes PL
FAU - Martins Lima, Augusto
AU  - Martins Lima A
FAU - Lautner, Roberto Q
AU  - Lautner RQ
FAU - Castro, Carlos H
AU  - Castro CH
FAU - Soares, Celia Maria A
AU  - Soares CM
FAU - Borges, Clayton L
AU  - Borges CL
FAU - Nadu, Ana Paula
AU  - Nadu AP
FAU - Oliveira, Marilene L
AU  - Oliveira ML
FAU - Shenoy, Vinayak
AU  - Shenoy V
FAU - Katovich, Michael J
AU  - Katovich MJ
FAU - Santos, Robson A S
AU  - Santos RA
FAU - Raizada, Mohan K
AU  - Raizada MK
FAU - Ferreira, Anderson J
AU  - Ferreira AJ
LA  - eng
GR  - R01 HL056921/HL/NHLBI NIH HHS/United States
GR  - R01 HL102033/HL/NHLBI NIH HHS/United States
GR  - RC1 HL099980/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20130422
PL  - United States
TA  - Hypertension
JT  - Hypertension
JID - 7906255
SB  - IM
OTO - NOTNLM
OT  - angiotensin-(1–7)
OT  - diabetes mellitus
OT  - endothelium dysfunction
OT  - oxidative stress
OT  - renin–angiotensin system
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/22 [aheadofprint]
AID - HYPERTENSIONAHA.111.00627 [pii]
AID - 10.1161/HYPERTENSIONAHA.111.00627 [doi]
PST - ppublish
SO  - Hypertension. 2013 Jun;61(6):1233-8. doi: 10.1161/HYPERTENSIONAHA.111.00627. Epub
      2013 Apr 22.

PMID- 23608617
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1095-8673 (Electronic)
IS  - 0022-4804 (Linking)
DP  - 2013 Mar 19
TI  - Nitric oxide differentially affects ERK and Akt in type 1 and type 2 diabetic
      rats.
LID - S0022-4804(13)00195-9 [pii]
LID - 10.1016/j.jss.2013.02.055 [doi]
AB  - BACKGROUND: We have shown that nitric oxide (NO) is more effective at inhibiting 
      neointimal hyperplasia in type 2 diabetic rats than in nondiabetic rats, but is
      not effective in type 1 diabetic rats. Insulin signaling is mediated by the ERK
      and Akt pathways, and thus we hypothesized that NO differentially affects ERK and
      Akt activity in type 1 versus type 2 diabetic rats. MATERIALS AND METHODS: To
      investigate this hypothesis, we induced type 2 diabetes in Zucker diabetic fatty 
      (ZDF) rats by feeding them Purina 5008 chow. To induce type 1 diabetes, lean
      Zucker (LZ) rats were injected with streptozotocin (STZ; 60 mg/kg). The carotid
      artery injury model was performed. Groups included injury and injury + PROLI/NO
      (20 mg/kg) (n = 6/group). RESULTS: Three days following injury, all animal models
      exhibited an increase in pERK levels. Whereas NO reduced pERK levels in LZ and
      STZ rats, NO had no effect on pERK levels in ZDF rats. Following a similar
      pattern, NO reduced pAkt levels in LZ and STZ rats but increased pAkt levels in
      ZDF rats. Fourteen days following injury, NO increased total pERK levels
      throughout the arterial wall in both the STZ and ZDF rats. These changes were
      greatest in the adventitia. Interestingly, whereas NO decreased total pAkt levels
      in LZ and STZ rats, NO increased pAkt levels in ZDF rats. Evaluation of the
      pERK:pAkt ratio revealed that NO increased this ratio in LZ and STZ rats but
      decreased the ratio in ZDF rats. CONCLUSIONS: We report that NO differentially
      affects the expression of pERK and pAkt in type 1 versus type 2 diabetic rats.
      Given that NO is more effective at inhibiting neointimal hyperplasia in type 2
      diabetic animals, the pERK:pAkt ratio may be the best surrogate to predict
      efficacy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Vascular Surgery and Institute for BioNanotechnology in Medicine,
      Northwestern University Feinberg School of Medicine, Chicago, Illinois.
FAU - Rodriguez, Monica P
AU  - Rodriguez MP
FAU - Emond, Zachary M
AU  - Emond ZM
FAU - Varu, Vinit N
AU  - Varu VN
FAU - Ahanchi, Sadaf S
AU  - Ahanchi SS
FAU - Martinez, Janet
AU  - Martinez J
FAU - Kibbe, Melina R
AU  - Kibbe MR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130319
TA  - J Surg Res
JT  - The Journal of surgical research
JID - 0376340
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/02/20 [received]
PHST- 2013/02/20 [revised]
PHST- 2013/02/27 [accepted]
AID - S0022-4804(13)00195-9 [pii]
AID - 10.1016/j.jss.2013.02.055 [doi]
PST - aheadofprint
SO  - J Surg Res. 2013 Mar 19. pii: S0022-4804(13)00195-9. doi:
      10.1016/j.jss.2013.02.055.

PMID- 23608615
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Apr 19
TI  - A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance
      and High Cardiovascular Risk.
LID - S0002-9149(13)00815-1 [pii]
LID - 10.1016/j.amjcard.2013.03.019 [doi]
AB  - We used baseline data from the NAVIGATOR trial to (1) identify risk factors for
      diabetes progression in those with impaired glucose tolerance and high
      cardiovascular risk, (2) create models predicting 5-year incident diabetes, and
      (3) provide risk classification tools to guide clinical interventions.
      Multivariate Cox proportional hazards models estimated 5-year incident diabetes
      risk and simplified models examined the relative importance of measures of
      glycemia in assessing diabetes risk. The C-statistic was used to compare models; 
      reclassification analyses compare the models' ability to identify risk groups
      defined by potential therapies (routine or intensive lifestyle advice or
      pharmacologic therapy). Diabetes developed in 3,254 (35%) participants over 5
      years median follow-up. The full prediction model included fasting and 2-hour
      glucose and hemoglobin A1c (HbA1c) values but demonstrated only moderate
      discrimination for diabetes (C = 0.70). Simplified models with only fasting
      glucose (C = 0.67) or oral glucose tolerance test values (C = 0.68) had higher C 
      statistics than models with HbA1c alone (C = 0.63). The models were unlikely to
      inappropriately reclassify participants to risk groups that might receive
      pharmacologic therapy. Our results confirm that in a population with dysglycemia 
      and high cardiovascular risk, traditional risk factors are appropriate predictors
      and glucose values are better predictors than HbA1c, but discrimination is
      moderate at best, illustrating the challenges of predicting diabetes in a
      high-risk population. In conclusion, our novel risk classification paradigm based
      on potential treatment could be used to guide clinical practice based on cost and
      availability of screening tests.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, 
      University of Oxford, Oxford, United Kingdom; Division of Endocrinology,
      Metabolism, and Nutrition, Department of Medicine, Duke University Medical
      Center, Durham, North Carolina. Electronic address: angelyn.bethel@dtu.ox.ac.uk.
FAU - Bethel, M Angelyn
AU  - Bethel MA
FAU - Chacra, Antonio R
AU  - Chacra AR
FAU - Deedwania, Prakash
AU  - Deedwania P
FAU - Fulcher, Gregory R
AU  - Fulcher GR
FAU - Holman, Rury R
AU  - Holman RR
FAU - Jenssen, Trond
AU  - Jenssen T
FAU - Kahn, Steven E
AU  - Kahn SE
FAU - Levitt, Naomi S
AU  - Levitt NS
FAU - McMurray, John J V
AU  - McMurray JJ
FAU - Califf, Robert M
AU  - Califf RM
FAU - Raptis, Sotirios A
AU  - Raptis SA
FAU - Thomas, Laine
AU  - Thomas L
FAU - Sun, Jie-Lena
AU  - Sun JL
FAU - Haffner, Steven M
AU  - Haffner SM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/11/29 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/08 [accepted]
AID - S0002-9149(13)00815-1 [pii]
AID - 10.1016/j.amjcard.2013.03.019 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Apr 19. pii: S0002-9149(13)00815-1. doi:
      10.1016/j.amjcard.2013.03.019.

PMID- 23608609
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 2047-9980 (Electronic)
IS  - 2047-9980 (Linking)
VI  - 2
IP  - 2
DP  - 2013 Apr
TI  - Cardiovascular risk score, cognitive decline, and dementia in older mexican
      americans: the role of sex and education.
PG  - e004978
LID - 10.1161/JAHA.113.004978 [doi]
AB  - BACKGROUND: The purpose of this study was to examine the associations of
      cardiovascular disease (CVD) risk with cognitive decline and incidence of
      dementia and cognitive impairment but not dementia (CIND) and the role of
      education as a modifier of these effects. METHODS AND RESULTS: One thousand one
      hundred sixteen Mexican American elderly were followed annually in the Sacramento
      Area Latino Study on Aging. Our sex-specific 10-year CVD risk score included
      baseline age, systolic blood pressure, total cholesterol, high-density
      lipoprotein, smoking, body mass index, and diabetes. From adjusted linear mixed
      models, errors on the Modified Mini-Mental State Exam (3MSE) were annually 0.41% 
      lower for women at the 25th percentile of CVD risk, 0.11% higher at the 50th
      percentile, and 0.83% higher at the 75th percentile (P value of CVDriskxtime
      <0.01). In men, 3MSE errors were annually 1.76% lower at the 25th percentile of
      CVD risk, 0.96% lower at the 50th percentile, and 0.12% higher at the 75th
      percentile (P value of CVDriskxtime <0.01). From adjusted linear mixed models,
      the annual decrease in the Spanish and English Verbal Learning Test score was
      0.09 points for women at the 25th percentile of CVD risk, 0.10 points at the 50th
      percentile, and 0.12 points at the 75th percentile (P value of
      CVDriskxtime=0.02). From adjusted Cox models in women, compared with having <6
      years of education, having 12+ years of education was associated with a 76% lower
      hazard of dementia/CIND (95% CI, 0.08 to 0.71) at the 25th percentile of CVD risk
      and with a 45% lower hazard (95% CI, 0.28 to 1.07) at the 75th percentile (P
      value of CVDriskxeducation=0.05). CONCLUSIONS: CVD risk score may provide a
      useful tool for identifying individuals at risk for cognitive decline and
      dementia.
AD  - Department of Epidemiology & Biostatistics, School of Medicine, University of
      California San Francisco, San Francisco, CA 94107, USA.
      Adina.zekialhazzouri@ucsf.edu
FAU - Zeki Al Hazzouri, Adina
AU  - Zeki Al Hazzouri A
FAU - Haan, Mary N
AU  - Haan MN
FAU - Neuhaus, John M
AU  - Neuhaus JM
FAU - Pletcher, Mark
AU  - Pletcher M
FAU - Peralta, Carmen A
AU  - Peralta CA
FAU - Lopez, Lenny
AU  - Lopez L
FAU - Perez Stable, Eliseo J
AU  - Perez Stable EJ
LA  - eng
GR  - AG033751/AG/NIA NIH HHS/United States
GR  - AG12975/AG/NIA NIH HHS/United States
GR  - DK60753/DK/NIDDK NIH HHS/United States
GR  - P30-AG15272/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130422
PL  - England
TA  - J Am Heart Assoc
JT  - Journal of the American Heart Association
JID - 101580524
SB  - IM
PMC - PMC3647277
OID - NLM: PMC3647277
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 2/2/e004978 [pii]
AID - 10.1161/JAHA.113.004978 [doi]
PST - epublish
SO  - J Am Heart Assoc. 2013 Apr 22;2(2):e004978. doi: 10.1161/JAHA.113.004978.

PMID- 23608551
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Continue with long term sulfonylureas in patients with mutations in the KCNJ11
      gene when there is evidence of response even if insulin treatment is still
      required.
PG  - e63
LID - 10.1016/j.diabres.2013.03.029 [doi]
LID - S0168-8227(13)00128-9 [pii]
AD  - Department of Diabetes and Endocrinology, Royal Devon and Exeter NHS Foundation
      Trust, Exeter, UK; NIHR Exeter Clinical Research Facility, University of Exeter
      Medical School, Exeter, UK. Electronic address: T.Babiker@exeter.ac.uk.
FAU - Babiker, T
AU  - Babiker T
FAU - Shepherd, M H
AU  - Shepherd MH
FAU - Hattersley, A T
AU  - Hattersley AT
LA  - eng
PT  - Letter
DEP - 20130419
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/03/19 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - S0168-8227(13)00128-9 [pii]
AID - 10.1016/j.diabres.2013.03.029 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):e63. doi: 10.1016/j.diabres.2013.03.029.
      Epub 2013 Apr 19.

PMID- 23608550
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Clinical outcome and risk factors for mortality in Chinese patients with diabetes
      on peritoneal dialysis: A 5-year clinical cohort study.
PG  - 354-61
LID - 10.1016/j.diabres.2013.03.030 [doi]
LID - S0168-8227(13)00129-0 [pii]
AB  - AIMS: We evaluated clinical outcome and risk factors affecting survival in
      patients with diabetes on continuous ambulatory peritoneal dialysis (CAPD) in
      Southern China. METHODS: This longitudinal cohort study enrolled all incident
      patients who used CAPD as their first renal replacement therapy modality in our
      center from January 2006 to December 2009 and who were followed until December
      2011. Clinical outcomes were compared and risk factors for mortality in patients 
      with diabetes were analyzed. RESULTS: Of 809 incident CAPD patients, 189 (23.4%) 
      had diabetes. Death-censored technique survival showed no significant difference 
      between patients with and without diabetes (p=0.271). The 1-, 2-, 3- and 5-year
      patient survival rates were 90%, 72%, 63% and 36% in patients with diabetes and
      95%, 92%, 87% and 73% in patients without diabetes, respectively (p=0.000).
      Presence of cardiovascular disease (CVD) [hazard ratio (HR) 2.130, 95% confidence
      interval (CI) 1.199-3.786, p=0.010], advanced age (HR 1.042, 95% CI 1.008-1.078, 
      p=0.014), higher glycated hemoglobin (HR 1.309, 95% CI 1.045-1.640, p=0.019),
      lower hemoglobin (HR 0.978, 95% CI 0.964-0.992, p=0.003) and lower serum albumin 
      (HR 0.924, 95% CI 0.876-0.976, p=0.004) at the initiation of CAPD were
      independent risk factors of mortality in CAPD patients with diabetes.
      CONCLUSIONS: Technique survival in CAPD patients with diabetes was similar to
      those without diabetes. Although patients with diabetes had higher risk of
      mortality, the patient survival in our study seems to be improved compared with
      most other reports. Older age, presence of CVD, hyperglycemia, anemia and
      hypoalbuminemia at the commencement of CAPD affected survival in patients with
      diabetes.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou 510080, China.
FAU - Yang, Xiao
AU  - Yang X
FAU - Yi, Chunyan
AU  - Yi C
FAU - Liu, Xinhui
AU  - Liu X
FAU - Guo, Qunying
AU  - Guo Q
FAU - Yang, Rui
AU  - Yang R
FAU - Cao, Peiyi
AU  - Cao P
FAU - Lin, Jiangxiong
AU  - Lin J
FAU - Mao, Haiping
AU  - Mao H
FAU - Yu, Xueqing
AU  - Yu X
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/12/08 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - S0168-8227(13)00129-0 [pii]
AID - 10.1016/j.diabres.2013.03.030 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):354-61. doi:
      10.1016/j.diabres.2013.03.030. Epub 2013 Apr 19.

PMID- 23608549
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
DP  - 2013 Apr 19
TI  - Serum uric acid levels and incidence of impaired fasting glucose and type 2
      diabetes mellitus: A meta-analysis of cohort studies.
LID - S0168-8227(13)00107-1 [pii]
LID - 10.1016/j.diabres.2013.03.026 [doi]
AB  - AIMS: A meta-analysis of cohort studies was conducted to assess the association
      between serum uric acid (SUA) levels and incidence of impaired fasting glucose
      (IFG) and type 2 diabetes mellitus (T2DM). METHODS: A comprehensive search was
      conducted to identify eligible studies. The fixed or random effect pooled measure
      was selected based on between-study heterogeneity. Dose-response relationship was
      assessed by restricted cubic spline model and multivariate random-effect
      meta-regression. RESULTS: Twelve studies with fifteen results were included
      involving 6340 cases and 62,834 participants. The pooled multivariate-adjusted
      relative risk (RR) (95%CI) of IFG and T2DM for the highest vs. lowest level of
      SUA was 1.54 (1.41-1.68), I2=42.2%. The association was consistent and
      significant across subgroup analysis. A nonlinear relationship was found of SUA
      levels with incidence of IFG and T2DM (P<0.01), and the multivariate-adjusted RRs
      (95%CI) of IFG and T2DM were 1.02 (0.95-1.10), 1.04 (0.94-1.15), 1.10
      (0.99-1.22), 1.25 (1.16-1.35), 1.43 (1.31-1.55), 1.50 (1.38-1.63) and 1.49
      (1.34-1.67) for 2.5, 3.5, 4.5, 5.5, 6.5, 7.5 and 8.5mg/dl of SUA. The RR (95%CI) 
      of T2DM for the highest vs. lowest level of SUA was 1.67 (1.51-1.86), and a
      nonlinear relationship was also found between SUA levels and incidence of T2DM.
      CONCLUSIONS: SUA levels are positively associated with incidence of IFG and T2DM,
      and the association might be nonlinear.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Endocrinology, The Affiliated Hospital of Medical College, Qingdao 
      University, Qingdao 266003, China. Electronic address: jiazt1963@163.com.
FAU - Jia, Zhaotong
AU  - Jia Z
FAU - Zhang, Xiaoqian
AU  - Zhang X
FAU - Kang, Shan
AU  - Kang S
FAU - Wu, Yili
AU  - Wu Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/11/09 [received]
PHST- 2013/03/03 [revised]
PHST- 2013/03/21 [accepted]
AID - S0168-8227(13)00107-1 [pii]
AID - 10.1016/j.diabres.2013.03.026 [doi]
PST - aheadofprint
SO  - Diabetes Res Clin Pract. 2013 Apr 19. pii: S0168-8227(13)00107-1. doi:
      10.1016/j.diabres.2013.03.026.

PMID- 23608331
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1995-7645 (Print)
VI  - 6
IP  - 4
DP  - 2013 Apr 13
TI  - Preventive effects of ophiopogon-polysaccharide on apiponectin in gestational
      diabetes mellitus rat.
PG  - 296-9
LID - 10.1016/S1995-7645(13)60059-0 [doi]
LID - S1995-7645(13)60059-0 [pii]
AB  - OBJECTIVE: To investigate the effect of ophiopogon-polysaccharide on adiponectin 
      (APN) in gestational diabetic mellitus rat. METHODS: The model of gestational
      diabeties mellitus rat were established with streptozotocin by intraperitoneal
      injection. Model rats were randomly divided into ophiopogon-polysaccharide 125
      mg/kg group, 250 mg/kg group, 500 mg/kg group, GDM group and normal pregnancy
      group (n=10). Ophiopogon-polysaccharide was given by intragastric administration 
      for 14 days. The fasting blood glucose levels of rats at the 0, 7, 14 day were
      detected respectively. The serum insulin level and APN in fat tissue and placenta
      were detected at the 14 day. RESULTS: The fasting blood glucose level, serum
      insulin level and APN mRNA in fat tissue and placenta were significantly
      decreased in gestational diabetes rats treated by ophiopogon-polysaccharide
      compared with model group (P < 0.05). CONCLUSIONS: Ophiopogon-polysaccharide
      could decrease the fasting blood glucose level and serum insulin level, and
      improve APN mRNA in fat tissue and placenta.
CI  - Copyright (c) 2013 Hainan Medical College. Published by Elsevier B.V. All rights 
      reserved.
AD  - Obstetrical Department, Shandong Provincial Hospital, Shandong Jinan 250021,
      China. xiaofan79@126.com
FAU - Wang, Hong
AU  - Wang H
LA  - eng
PT  - Journal Article
PL  - Singapore
TA  - Asian Pac J Trop Med
JT  - Asian Pacific journal of tropical medicine
JID - 101533720
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/10/10 [received]
PHST- 2012/11/15 [revised]
PHST- 2012/12/15 [accepted]
AID - S1995-7645(13)60059-0 [pii]
AID - 10.1016/S1995-7645(13)60059-0 [doi]
PST - ppublish
SO  - Asian Pac J Trop Med. 2013 Apr 13;6(4):296-9. doi: 10.1016/S1995-7645(13)60059-0.

PMID- 23608311
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 0030-6002 (Print)
IS  - 0030-6002 (Linking)
VI  - 154
IP  - 17
DP  - 2013 Apr 28
TI  - [The cortical collecting duct plays a pivotal role in kidney local
      renin-angiotensin system].
PG  - 643-9
LID - 10.1556/OH.2013.29597 [doi]
AB  - The renin-angiotensin system is one of the most important hormone systems in the 
      body, and the regulations as well as the role in the juxtaglomerular apparatus
      are well known. The present review focuses on renin secretion in a recently
      described localization, the cortical collecting duct. The authors display it in
      parallel of the copying strategy of an adult and a developing kidney.
      Furthermore, based on different animal studies it highlights the local role of
      renin released from the collecting duct. In chronic angiotensin II-infused,
      2-kidney, 1-clip hypertensive model as well as in diabetic rats the major source 
      of (pro)renin is indeed the collecting duct. In this localization this hormone
      can reach both the systemic circulation and the interstitial renin-angiotensin
      system components including the newly described (pro)renin receptor, by which
      (pro)renin is able to locally activate pro-fibrotic intracellular signal
      pathways. Consequently, one can postulate that in the future renin may serve
      either as a new therapeutic target in nephropathy associated with both
      hypertension and diabetes or as an early diagnostic marker in chronic diseases
      leading to nephropathy.
AD  - Semmelweis Egyetem, Altalanos Orvostudomanyi Kar I. Gyermekgyogyaszati Klinika es
      MTA Nefrologiai Kutatolaboratorium Budapest Bokay J. u. 53. 1083.
FAU - Csohany, Rozsa
AU  - Csohany R
FAU - Prokai, Agnes
AU  - Prokai A
FAU - Kosik, Anna
AU  - Kosik A
FAU - Szabo, J Attila
AU  - Szabo JA
LA  - hun
PT  - English Abstract
PT  - Journal Article
TT  - A gyujtocsatorna meghatarozo szerepe a vese lokalis renin-angiotenzin
      rendszereben.
PL  - Hungary
TA  - Orv Hetil
JT  - Orvosi hetilap
JID - 0376412
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 3603625UT835X22T [pii]
AID - 10.1556/OH.2013.29597 [doi]
PST - ppublish
SO  - Orv Hetil. 2013 Apr 28;154(17):643-9. doi: 10.1556/OH.2013.29597.

PMID- 23608304
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1873-2585 (Electronic)
IS  - 1047-2797 (Linking)
VI  - 23
IP  - 6
DP  - 2013 Jun
TI  - The association of whole grain consumption with incident type 2 diabetes: the
      Women's Health Initiative Observational Study.
PG  - 321-7
LID - 10.1016/j.annepidem.2013.03.010 [doi]
LID - S1047-2797(13)00085-9 [pii]
AB  - PURPOSE: Whole grains may offer protection from diabetes by decreasing energy
      intake, preventing weight gain, and direct effects on insulin resistance. This
      study examined associations of whole and refined grains with incident type 2
      diabetes (T2D) ascertained by self-reported medication use in a cohort of
      postmenopausal women. METHODS: We included 72,215 women free of diabetes at
      baseline from the Women's Health Initiative Observational Study. Whole grain
      consumption was categorized as 0, less than 0.5, 0.5 to 1.0, 1.0 to less than
      1.5, 1.5 to less than 2.0, and 2.0 or more servings per day. Proportional hazards
      regression was performed to estimate hazard ratios (HR) and 95% confidence
      intervals adjusting for potential confounders. RESULTS: There were 3465 cases of 
      incident T2D over median follow-up of 7.9 years. Adjusted for age and energy
      intake per day, successively increasing categories of whole grain consumption
      were associated with statistically significant reduced risk of incident T2D (HRs,
      1.00, 0.83, 0.73, 0.69, 0.61, and 0.57; P for trend < 0.0001). Results were
      attenuated after adjustment for confounders and other dietary components. The
      reduction in risk of T2D was greater among nonsmokers and those who maintained
      their weight within 5 pounds with higher consumption of whole grains than smokers
      and women who gained more weight. CONCLUSIONS: This large, prospective study
      found an inverse dose-response relationship between whole grain consumption and
      incident T2D in postmenopausal women.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - HealthPartners Institute for Education and Research, HealthPartners, Bloomington,
      Minnesota. Electronic address: Emily.D.Parker@healthpartners.com.
FAU - Parker, Emily D
AU  - Parker ED
FAU - Liu, Simin
AU  - Liu S
FAU - Van Horn, Linda
AU  - Van Horn L
FAU - Tinker, Leslie F
AU  - Tinker LF
FAU - Shikany, James M
AU  - Shikany JM
FAU - Eaton, Charles B
AU  - Eaton CB
FAU - Margolis, Karen L
AU  - Margolis KL
LA  - eng
GR  - N01 WH022110-024/WH/WHI NIH HHS/United States
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - Ann Epidemiol
JT  - Annals of epidemiology
JID - 9100013
SB  - IM
PMC - PMC3662533
MID - NIHMS470707
OID - NLM: NIHMS470707 [Available on 06/01/14]
OID - NLM: PMC3662533 [Available on 06/01/14]
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PMCR- 2014/06/01 00:00
PHST- 2012/10/17 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/03/22 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - S1047-2797(13)00085-9 [pii]
AID - 10.1016/j.annepidem.2013.03.010 [doi]
PST - ppublish
SO  - Ann Epidemiol. 2013 Jun;23(6):321-7. doi: 10.1016/j.annepidem.2013.03.010. Epub
      2013 Apr 19.

PMID- 23608303
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1873-2585 (Electronic)
IS  - 1047-2797 (Linking)
VI  - 23
IP  - 5
DP  - 2013 May
TI  - A mathematical model for determining age-specific diabetes incidence and
      prevalence using body mass index.
PG  - 248-54
LID - 10.1016/j.annepidem.2013.03.011 [doi]
LID - S1047-2797(13)00086-0 [pii]
AB  - PURPOSE: Few models have been developed specifically for the epidemiology of
      diabetes. Diabetes incidence is critical in predicting diabetes prevalence.
      However, reliable estimates of disease incidence rates are difficult to obtain.
      The aim of this study was to propose a mathematical framework for predicting
      diabetes prevalence using incidence rates estimated within the model using body
      mass index (BMI) data. METHODS: A generic mechanistic model was proposed
      considering birth, death, migration, aging, and diabetes incidence dynamics.
      Diabetes incidence rates were determined within the model using their
      relationships with BMI represented by the Hill equation. The Hill equation
      parameters were estimated by fitting the model to National Health and Nutrition
      Examination Survey (NHANES) 1999-2010 data and used to predict diabetes
      prevalence pertaining to each NHANES survey year. The prevalences were also
      predicted using diabetes incidence rates calculated from the NHANES data
      themselves. The model was used to estimate death rate parameters and to quantify 
      sensitivities of prevalence to each population dynamic. RESULTS: The model using 
      incidence rate estimates from the Hill equations successfully predicted diabetes 
      prevalence of younger, middle-aged, and older adults (prediction error, 20.0%,
      9.64%, and 7.58% respectively). Diabetes prevalence was positively associated
      with diabetes incidence in every age group, but the associations among younger
      adults were stronger. In contrast, diabetes prevalence was more sensitive to
      death rates in older adults than younger adults. Both diabetes incidence and
      prevalence were strongly sensitive to BMI at younger ages, but sensitivity
      gradually declined as age progressed. Younger and middle aged adults diagnosed
      with diabetes had at least a two-fold greater risk of death than their
      nondiabetic counterparts. Nondiabetic older adults were found to be under
      slightly higher death risk (0.079) than those diagnosed with diabetes (0.073).
      CONCLUSIONS: The proposed model predicts diagnosed diabetes incidence and
      prevalence reasonably well using the link between BMI and diabetes development
      risk. Ethnic group and gender-specific model parameter estimates could further
      improve predictions. Model prediction accuracy and applicability need to be
      comprehensively evaluated with independent data sets.
CI  - Published by Elsevier Inc.
AD  - Centre for Nutrition Modelling, University of Guelph, Canada.
      jappuhamy@ucdavis.edu
FAU - Appuhamy, J A D Ranga Niroshan
AU  - Appuhamy JA
FAU - Kebreab, E
AU  - Kebreab E
FAU - France, J
AU  - France J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130419
PL  - United States
TA  - Ann Epidemiol
JT  - Annals of epidemiology
JID - 9100013
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/10/03 [received]
PHST- 2013/02/08 [revised]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - S1047-2797(13)00086-0 [pii]
AID - 10.1016/j.annepidem.2013.03.011 [doi]
PST - ppublish
SO  - Ann Epidemiol. 2013 May;23(5):248-54. doi: 10.1016/j.annepidem.2013.03.011. Epub 
      2013 Apr 19.

PMID- 23608249
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 228
IP  - 2
DP  - 2013 Jun
TI  - Relationship between vitamin D status and incidence of vascular events in the
      Veterans Affairs Diabetes Trial.
PG  - 502-7
LID - 10.1016/j.atherosclerosis.2013.03.024 [doi]
LID - S0021-9150(13)00200-1 [pii]
AB  - OBJECTIVE: Few studies have examined the relationship between vitamin D levels
      and incident cardiovascular events in large well-characterized patient cohorts.
      Therefore, our objective was to determine if low vitamin D levels predicted
      vascular complications of diabetes. METHODS: Prospective analysis of 936 veterans
      with type 2 diabetes (59.7 +/- 8.4 years, 96.9% male) who participated in the
      Veteran Affairs Diabetes Trial (VADT) was conducted. 25(OH)-vitamin D was
      measured a median of two years after entry and participants were subsequently
      followed 3.7 years. Hazard ratios (HRs) were calculated for cardiovascular
      endpoints in relation to 25(OH)-vitamin D quartile. For microvascular endpoints, 
      logistic regression was used to calculate odds ratios. RESULTS: After adjusting
      for age, minority status, treatment arm and history of prior event, individuals
      in the lowest vitamin D quartile (i.e., 1-15.9 ng/ml) were at similar risk of MI 
      [HR = 1.13 (95% CI: 0.53, 2.42)], CHD [HR = 0.87 (95% CI: 0.49, 1.55)],
      congestive heart failure [HR = 1.44 (95% CI: 0.67, 3.06)], and death from any
      cause [HR = 1.04 (95% CI: 0.53, 2.04)] as individuals in the highest vitamin D
      quartile (i.e., 29.9-77.2 ng/ml). Similarly, there were no differences in the
      odds associated with retinopathy or renal disease onset or progression in the
      lowest versus highest vitamin D quartile. CONCLUSIONS: These data indicate that
      vitamin D status had no significant impact on the incidence of vascular events in
      a cohort of high-risk veterans with diabetes in which traditional risk factors
      were managed according to current treatment guidelines.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Medicine, Medical University of South Carolina, Charleston, SC
      29425, USA.
FAU - Alele, Jimmy D
AU  - Alele JD
FAU - Luttrell, Louis M
AU  - Luttrell LM
FAU - Hollis, Bruce W
AU  - Hollis BW
FAU - Luttrell, Deirdre K
AU  - Luttrell DK
FAU - Hunt, Kelly J
AU  - Hunt KJ
CN  - VADT Study Group
LA  - eng
PT  - Journal Article
DEP - 20130404
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/12/21 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/04 [aheadofprint]
AID - S0021-9150(13)00200-1 [pii]
AID - 10.1016/j.atherosclerosis.2013.03.024 [doi]
PST - ppublish
SO  - Atherosclerosis. 2013 Jun;228(2):502-7. doi:
      10.1016/j.atherosclerosis.2013.03.024. Epub 2013 Apr 4.

PMID- 23608222
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1479-6805 (Electronic)
IS  - 0022-0795 (Linking)
VI  - 218
IP  - 1
DP  - 2013
TI  - Cephalic phase insulin secretion is KATP channel independent.
PG  - 25-33
AB  - Glucose-induced insulin secretion from pancreatic beta-cells critically depends
      on the activity of ATP-sensitive K+ channels (KATP channel). We previously
      generated mice lacking Kir6.2, the pore subunit of the beta-cell KATP channel
      (Kir6.2-/-), that show almost no insulin secretion in response to glucose in
      vitro. In this study, we compared insulin secretion by voluntary feeding
      (self-motivated, oral nutrient ingestion) and by forced feeding (intra-gastric
      nutrient injection via gavage) in wild-type (Kir6.2+/+) and Kir6.2-/- mice. Under
      ad libitum feeding or during voluntary feeding of standard chow, blood glucose
      levels and plasma insulin levels were similar in Kir6.2+/+ and Kir6.2-/- mice. By
      voluntary feeding of carbohydrate alone, insulin secretion was induced
      significantly in Kir6.2-/- mice but was markedly attenuated compared with that in
      Kir6.2+/+ mice. On forced feeding of standard chow or carbohydrate alone, the
      insulin secretory response was markedly impaired or completely absent in
      Kir6.2-/- mice. Pretreatment with a muscarine receptor antagonist, atropine
      methyl nitrate, which does not cross the blood-brain barrier, almost completely
      blocked insulin secretion induced by voluntary feeding of standard chow or
      carbohydrate in Kir6.2-/- mice. Substantial glucose-induced insulin secretion was
      induced in the pancreas perfusion study of Kir6.2-/- mice only in the presence of
      carbamylcholine. These results suggest that a KATP channel-independent mechanism 
      mediated by the vagal nerve plays a critical role in insulin secretion in
      response to nutrients in vivo.
AD  - Division of Cellular and Molecular Medicine, Kobe University Graduate School of
      Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan Departments of
      Metabolic Medicine Endocrinology and Diabetes, Nagoya University Graduate School 
      of Medicine, Nagoya 466-8550, Japan Department of Medical Physiology, Graduate
      School of Medicine, Chiba University, Chiba 260-8670, Japan Division of Diabetes 
      and Endocrinology, Department of Internal Medicine, Kobe University Graduate
      School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
FAU - Seino, Yusuke
AU  - Seino Y
FAU - Miki, Takashi
AU  - Miki T
FAU - Fujimoto, Wakako
AU  - Fujimoto W
FAU - Young Lee, Eun
AU  - Young Lee E
FAU - Takahashi, Yoshihisa
AU  - Takahashi Y
FAU - Minami, Kohtaro
AU  - Minami K
FAU - Oiso, Yutaka
AU  - Oiso Y
FAU - Seino, Susumu
AU  - Seino S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130528
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
OTO - NOTNLM
OT  - KATP channel
OT  - acetylcholine
OT  - cephalic phase insulin secretion
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013 [ppublish]
AID - JOE-12-0579 [pii]
AID - 10.1530/JOE-12-0579 [doi]
PST - epublish
SO  - J Endocrinol. 2013 May 28;218(1):25-33. Print 2013.

PMID- 23608219
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1878-0210 (Electronic)
IS  - 1878-0210 (Linking)
DP  - 2013 Apr 19
TI  - Changes in time to insulin initiation in type 2 diabetes patients: A
      retrospective database analysis in Germany and UK (2005-2010).
LID - S1751-9918(13)00041-7 [pii]
LID - 10.1016/j.pcd.2013.03.003 [doi]
AB  - AIMS: To study whether the time to insulin therapy in type 2 diabetic patients in
      primary care in Germany and UK has increased (2005-2010). METHODS: Longitudinal
      data from general practices in Germany and UK (Disease Analyser) from 1995 to
      2010 were analyzed. Patients who started their insulin treatment from 2005 to
      2010 were analyzed regarding the time from the first diabetes diagnosis in the
      practices (index date) and the first insulin prescription, including 6368
      patients (age: 68 (SD: 12) years) in Germany and 1998 patients (age: 64 (12) yrs)
      in UK. RESULTS: Median (interquartile range) time to insulin therapy in the
      practices increased from 943 (214-1994) days in 2005 to 1549 (957-2533) days in
      2010 (p<0.001). In UK, time to onset of insulin treatment increased from 1700
      (649-2521) days in 2005 to 2061 (1309-2686) days in 2010 (p<0.001). The last
      HbA1c values before insulin initiation were high and slightly increased during
      the study period (Germany: 2005: 8.2%, 2010: 8.4%; UK: 2005: 9.5%, 2010: 9.8%;
      both p<0.001). CONCLUSIONS: This real world data shows that the time to insulin
      therapy has increased in type 2 diabetes patients from 2005 to 2010 (Germany,
      UK). The average HbA1c values before insulin therapy also slightly increased
      during this period.
CI  - Copyright (c) 2013 Primary Care Diabetes Europe. Published by Elsevier Ltd. All
      rights reserved.
AD  - IMS HEALTH, Frankfurt, Germany.
FAU - Kostev, Karel
AU  - Kostev K
FAU - Rathmann, Wolfgang
AU  - Rathmann W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Prim Care Diabetes
JT  - Primary care diabetes
JID - 101463825
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/07/25 [received]
PHST- 2013/01/22 [revised]
PHST- 2013/03/26 [accepted]
AID - S1751-9918(13)00041-7 [pii]
AID - 10.1016/j.pcd.2013.03.003 [doi]
PST - aheadofprint
SO  - Prim Care Diabetes. 2013 Apr 19. pii: S1751-9918(13)00041-7. doi:
      10.1016/j.pcd.2013.03.003.

PMID- 23608136
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1873-3360 (Electronic)
IS  - 0306-4530 (Linking)
DP  - 2013 Apr 19
TI  - Perinatal depression-The fourth inflammatory morbidity of pregnancy?: Theory and 
      literature review.
LID - S0306-4530(13)00114-5 [pii]
LID - 10.1016/j.psyneuen.2013.03.019 [doi]
AB  - Perinatal depression is one of the leading causes of maternal morbidity and
      mortality. The biological etiology of this disorder remains in question, despite 
      considerable research into the contributions of hormonal imbalance, the role of
      monoamines, and dysregulation of the HPA axis. Because inflammation is known to
      be associated with major depression in men and non-perinatal women as well as
      with other important morbidities of pregnancy (such as preeclampsia, preterm
      birth, and gestational diabetes), and because these morbidities may correlate
      with perinatal depression, inflammation may be a common physiological pathway
      that can also help explain perinatal depression. In this paper, we review the
      theoretical background of inflammation in perinatal depression and then review
      the literature concerning immune and inflammatory factors in the etiology and
      course of perinatal depression. We close with recommendations for future studies 
      in this still relatively unexplored area. Identification and understanding of a
      common pathophysiology between other pregnancy morbidities and perinatal
      depression would link physical and mental well-being, likely leading to better
      treatment and prevention.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Psychiatry, Columbia University/New York State Psychiatric
      Institute, 1051 Riverside Drive, Box 89, New York, NY 10032, USA. Electronic
      address: lmo17@columbia.edu.
FAU - Osborne, Lauren M
AU  - Osborne LM
FAU - Monk, Catherine
AU  - Monk C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Psychoneuroendocrinology
JT  - Psychoneuroendocrinology
JID - 7612148
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/07/27 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/21 [accepted]
AID - S0306-4530(13)00114-5 [pii]
AID - 10.1016/j.psyneuen.2013.03.019 [doi]
PST - aheadofprint
SO  - Psychoneuroendocrinology. 2013 Apr 19. pii: S0306-4530(13)00114-5. doi:
      10.1016/j.psyneuen.2013.03.019.

PMID- 23608001
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1618-131X (Electronic)
IS  - 1438-4639 (Linking)
DP  - 2013 Mar 30
TI  - Dietary cadmium intake and breast cancer risk in Japanese women: A case-control
      study.
LID - S1438-4639(13)00048-5 [pii]
LID - 10.1016/j.ijheh.2013.03.010 [doi]
AB  - Cadmium, an environmental pollutant, may act like an estrogen and be a potential 
      risk factor for estrogen-dependent diseases such as breast cancer. We examined
      the hypothesis that higher dietary cadmium intake is associated with risk of
      overall and hormone receptor-defined breast cancer in Japanese women, a
      population with a relatively high cadmium intake. The study was conducted under a
      case-control design in 405 eligible matched pairs from May 2001 to September 2005
      at four hospitals in Nagano Prefecture, Japan. Dietary cadmium intake was
      estimated using a food frequency questionnaire. Multivariable-adjusted odds
      ratios (ORs) and 95% confidence intervals (CIs) of breast cancer and its
      hormone-receptor-defined subtypes were calculated by tertile of dietary cadmium
      intake. We found no significant association between dietary cadmium and risk of
      total breast cancer in either crude or multivariable-adjusted analysis. Adjusted 
      ORs for tertiles of cadmium intake were 1.00, 1.19, and 1.23 (95% CI, 0.76-2.00; 
      P for trend=0.39) for whole breast cancer. Further, no significant associations
      were seen across strata of menopausal status, smoking, and diabetes in
      multivariable-adjusted models except for adjusted OR for continuous cadmium
      intake in postmenopausal women. A statistically significant association was found
      for estrogen receptor-positive (ER+) tumors among postmenopausal women (adjusted 
      OR=1.00, 1.16, and 1.94 [95% CI, 1.04-3.63; P for trend=0.032]). Although the
      present study found no overall association between dietary cadmium intake and
      breast cancer risk, higher cadmium intake was associated with increased risk of
      ER+ breast cancer in postmenopausal women, at least at regular intake levels in
      Japanese women in the general population. Further studies are needed to confirm
      this association.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
AD  - Department of Epidemiology and Environmental Health, Juntendo University Faculty 
      of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
FAU - Itoh, Hiroaki
AU  - Itoh H
FAU - Iwasaki, Motoki
AU  - Iwasaki M
FAU - Sawada, Norie
AU  - Sawada N
FAU - Takachi, Ribeka
AU  - Takachi R
FAU - Kasuga, Yoshio
AU  - Kasuga Y
FAU - Yokoyama, Shiro
AU  - Yokoyama S
FAU - Onuma, Hiroshi
AU  - Onuma H
FAU - Nishimura, Hideki
AU  - Nishimura H
FAU - Kusama, Ritsu
AU  - Kusama R
FAU - Yokoyama, Kazuhito
AU  - Yokoyama K
FAU - Tsugane, Shoichiro
AU  - Tsugane S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130330
TA  - Int J Hyg Environ Health
JT  - International journal of hygiene and environmental health
JID - 100898843
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/08/23 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/21 [accepted]
AID - S1438-4639(13)00048-5 [pii]
AID - 10.1016/j.ijheh.2013.03.010 [doi]
PST - aheadofprint
SO  - Int J Hyg Environ Health. 2013 Mar 30. pii: S1438-4639(13)00048-5. doi:
      10.1016/j.ijheh.2013.03.010.

PMID- 23607886
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
DP  - 2013 Apr 8
TI  - CD4 CD45RA FOXP3 Activated Regulatory T-Cells are Functionally Impaired and
      Related with Residual Insulin-secreting Capacity in Patients with Type 1
      Diabetes.
LID - 10.1111/cei.12116 [doi]
AB  - Accumulating lines of evidence have suggested that regulatory T-cells (Tregs)
      play a central role in T-cell mediated immune response and the development of
      type 1A and fulminant type 1 diabetes. CD4+ FOXP3+ T-cells are composed of three 
      phenotypically and functionally distinct subpopulations; CD45RA+ FOXP3low resting
      Tregs (r-Tregs), CD45RA- FOXP3high activated Tregs (a-Tregs) and CD45RA- FOXP3low
      nonsuppressive T-cells (non-Tregs). We aimed to clarify the frequency of these
      three subpopulations in CD4+ FOXP3+ T-cells and the function of a-Tregs with
      reference to subtypes of type 1 diabetes. We examined 20 patients with type 1A
      diabetes, 15 patients with fulminant type 1 diabetes, 20 patients with type 2
      diabetes and 30 healthy control subjects. A flow cytometric analysis in the
      peripheral blood was performed for the frequency analysis. Suppressive function
      of a-Tregs was assessed by their ability to suppress the proliferation of
      responder cells in a 1/2:1 co-culture. A flow cytometric analysis in the
      peripheral blood demonstrated that the frequency of a-Tregs was significantly
      higher in type 1A diabetes, but not in fulminant type 1 diabetes, than the
      controls. Further, the proportion of a-Tregs among CD4+ FOXP3+ T-cells was
      significantly higher in patients with type 1A diabetes with detectable C-peptide 
      but not in patients with type 1A diabetes without it and with fulminant type 1
      diabetes. A proliferation suppression assay showed that a-Tregs were functionally
      impaired both in fulminant type 1 diabetes and in type 1A diabetes. In
      conclusion, a-Tregs were functionally impaired, related with residual
      insulin-secreting capacity and may be associated with the development of type 1
      diabetes.
CI  - (c) 2013 British Society for Immunology.
AD  - Department of Internal Medicine (I), Osaka Medical College.
FAU - Haseda, Fumitaka
AU  - Haseda F
FAU - Imagawa, Akihisa
AU  - Imagawa A
FAU - Murase-Mishiba, Yuko
AU  - Murase-Mishiba Y
FAU - Terasaki, Jungo
AU  - Terasaki J
FAU - Hanafusa, Toshiaki
AU  - Hanafusa T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130408
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/03/29 [accepted]
AID - 10.1111/cei.12116 [doi]
PST - aheadofprint
SO  - Clin Exp Immunol. 2013 Apr 8. doi: 10.1111/cei.12116.

PMID- 23607861
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1365-2796 (Electronic)
IS  - 0954-6820 (Linking)
DP  - 2013 Apr 23
TI  - Alterations in bile acid synthesis in carriers of hepatocyte nuclear factor
      1alpha mutations.
LID - 10.1111/joim.12082 [doi]
AB  - OBJECTIVES: Heterozygous mutations in hepatocyte nuclear factor 1alpha
      (HNF1alpha) cause maturity onset diabetes of the young 3 (MODY3), an autosomal
      dominant form of diabetes. Deficiency of HNF1alpha in mice results in diabetes,
      hypercholesterolaemia and increased bile acid (BA) and cholesterol synthesis.
      Little is known about alterations in lipid metabolism in patients with MODY3. The
      aim of this study was to investigate whether patients with MODY3 have altered
      cholesterol and BA synthesis and intestinal cholesterol absorption. A secondary
      aim was to investigate the effects of HNF1alpha mutations on the transcriptional 
      regulation of BA metabolism. METHODS: Plasma biomarkers of BA and cholesterol
      synthesis and intestinal cholesterol absorption were measured in patients with
      MODY3 (n = 19) and in matched healthy control subjects (n = 15). Cotransfection
      experiments were performed with several promoters involved in BA metabolism along
      with expression vectors carrying the mutations found in these patients. RESULTS: 
      Plasma analysis showed higher levels of BA synthesis in patients with MODY3. No
      differences were observed in cholesterol synthesis or intestinal cholesterol
      absorption. Cotransfection experiments showed that one of the mutations (P379A)
      increased the induction of the cholesterol 7alpha-hydroxylase promoter compared
      with HNF1alpha, without further differences in other studied promoters. By
      contrast, the other four mutations (L107I, T260M, P291fsinsC and R131Q) reduced
      the induction of the farnesoid X receptor (FXR) promoter, which was followed by
      reduced repression of the small heterodimer partner promoter. In addition, these 
      mutations also reduced the induction of the apical sodium-dependent bile salt
      transporter promoter. CONCLUSIONS: BA synthesis is increased in patients with
      MODY3 compared with control subjects. Mutations in HNF1alpha affect promoters
      involved in BA metabolism.
CI  - (c) 2013 The Association for the Publication of the Journal of Internal Medicine.
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Malmo University
      Hospital, Malmo, Sweden.
FAU - Ekholm, E
AU  - Ekholm E
FAU - Nilsson, R
AU  - Nilsson R
FAU - Groop, L
AU  - Groop L
FAU - Pramfalk, C
AU  - Pramfalk C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1111/joim.12082 [doi]
PST - aheadofprint
SO  - J Intern Med. 2013 Apr 23. doi: 10.1111/joim.12082.

PMID- 23607839
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 2325-6621 (Electronic)
VI  - 10
IP  - 2
DP  - 2013 Apr
TI  - Meta-analysis: continuous positive airway pressure improves insulin resistance in
      patients with sleep apnea without diabetes.
PG  - 115-20
LID - 10.1513/AnnalsATS.201209-081OC [doi]
AB  - RATIONALE: Obstructive sleep apnea (OSA) is an independent risk factor for the
      development of insulin resistance (IR). Treatment with continuous positive airway
      pressure (CPAP) for OSA has shown conflicting results on IR. OBJECTIVES: To
      conduct a meta-analysis of randomized controlled trials (RCTs) that have
      evaluated the effect of CPAP on a validated index of IR, the homeostasis model
      assessment of insulin resistance (HOMA-IR). METHODS: PubMed and Embase were
      searched through August 10, 2012. Two independent reviewers screened citations to
      identify trials of the effect of CPAP on HOMA-IR. Data were extracted for
      postintervention HOMA-IR values. MEASUREMENTS AND MAIN RESULTS: A total of five
      studies that enrolled 244 subjects (83% male) met the inclusion criteria. None of
      the subjects in the included studies had diabetes. The pooled estimate of the
      difference in means in HOMA-IR between the CPAP and sham CPAP/control groups was 
      -0.44 (95% confidence interval, -0.82 to -0.06; P = 0.02). The funnel plot does
      not suggest the presence of any publication bias. The I-squared index for the
      data on difference in means in HOMA-IR between the CPAP and sham CPAP/control
      groups was 0.00 (P = 0.61). CONCLUSIONS: The pooled estimate of RCTs shows a
      favorable effect of CPAP on insulin resistance as measured by HOMA-IR in patients
      with OSA without diabetes. The effect size on HOMA-IR is modest, but not
      insignificant, when compared with the effects of thiazolidinedione in nondiabetic
      patients with metabolic syndrome. Further research and RCTs are warranted
      involving a larger number of patients and longer treatment periods to determine
      the beneficial effects of CPAP on IR.
AD  - Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, 
      University of South Carolina, Columbia, SC, USA. Imran.Iftikhar@uscmed.sc.edu
FAU - Iftikhar, Imran H
AU  - Iftikhar IH
FAU - Khan, Meena F
AU  - Khan MF
FAU - Das, Aneesa
AU  - Das A
FAU - Magalang, Ulysses J
AU  - Magalang UJ
LA  - eng
GR  - HL093463/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Am Thorac Soc
JT  - Annals of the American Thoracic Society
JID - 101600811
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1513/AnnalsATS.201209-081OC [doi]
PST - ppublish
SO  - Ann Am Thorac Soc. 2013 Apr;10(2):115-20. doi: 10.1513/AnnalsATS.201209-081OC.

PMID- 23607835
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 2325-6621 (Electronic)
VI  - 10
IP  - 2
DP  - 2013 Apr
TI  - Predictors of mortality in hospitalized adults with acute exacerbation of chronic
      obstructive pulmonary disease.
PG  - 81-9
LID - 10.1513/AnnalsATS.201208-043OC [doi]
AB  - RATIONALE: There is a need to identify clinically meaningful predictors of
      mortality following hospitalized COPD exacerbation. OBJECTIVES: The aim of this
      study was to systematically review the literature to identify clinically
      important factors that predict mortality after hospitalization for acute
      exacerbation of chronic obstructive pulmonary disease (COPD). METHODS: Eligible
      studies considered adults admitted to hospital with COPD exacerbation. Two
      authors independently abstracted data. Odds ratios were then calculated by
      comparing the prevalence of each predictor in survivors versus nonsurvivors. For 
      continuous variables, mean differences were pooled by the inverse of their
      variance, using a random effects model. MEASUREMENTS AND MAIN RESULTS: There were
      37 studies included (189,772 study subjects) with risk of death ranging from 3.6%
      for studies considering short-term mortality, 31.0% for long-term mortality (up
      to 2 yr after hospitalization), and 29.0% for studies that considered solely
      intensive care unit (ICU)-admitted study subjects. Twelve prognostic factors
      (age, male sex, low body mass index, cardiac failure, chronic renal failure,
      confusion, long-term oxygen therapy, lower limb edema, Global Initiative for
      Chronic Lung Disease criteria stage 4, cor pulmonale, acidemia, and elevated
      plasma troponin level) were significantly associated with increased short-term
      mortality. Nine prognostic factors (age, low body mass index, cardiac failure,
      diabetes mellitus, ischemic heart disease, malignancy, FEV1, long-term oxygen
      therapy, and PaO2 on admission) were significantly associated with long-term
      mortality. Three factors (age, low Glasgow Coma Scale score, and pH) were
      significantly associated with increased risk of mortality in ICU-admitted study
      subjects. CONCLUSION: Different factors correlate with mortality from COPD
      exacerbation in the short term, long term, and after ICU admission. These
      parameters may be useful to develop tools for prediction of outcome in clinical
      practice.
AD  - Chest and Allergy Department, St. Mary's Hospital, London, United Kingdom.
      aransinga@gmail.com
FAU - Singanayagam, Aran
AU  - Singanayagam A
FAU - Schembri, Stuart
AU  - Schembri S
FAU - Chalmers, James D
AU  - Chalmers JD
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Am Thorac Soc
JT  - Annals of the American Thoracic Society
JID - 101600811
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1513/AnnalsATS.201208-043OC [doi]
PST - ppublish
SO  - Ann Am Thorac Soc. 2013 Apr;10(2):81-9. doi: 10.1513/AnnalsATS.201208-043OC.

PMID- 23607813
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Apr 22
TI  - Diabetes duration and health-related quality of life in individuals with onset of
      diabetes in the age group 15---34 years -- a Swedish population-based study using
      EQ-5D.
PG  - 377
AB  - BACKGROUND: Diabetes with onset in younger ages affects both length of life and
      health status due to debilitating and life-threatening long-term complications.
      In addition, episodes and fear of hypoglycaemia and of long-term consequences may
      have a substantial impact on health status. This study aims to describe and
      analyse health-related quality of life (HRQoL) in individuals with onset of
      diabetes at the age of 15---34 years and with a disease duration of 1, 8, 15 and 
      24 years compared with control individuals matched for age, sex and county of
      residence. METHODS: Cross-sectional study of 839 individuals with diabetes and
      1564 control individuals. Data on socioeconomic status and HRQoL using EQ-5D were
      collected by a postal questionnaire. Insulin treatment was self-reported by 94%
      of the patients, the majority most likely being type 1. RESULTS: Individuals with
      diabetes reported lower HRQoL, with a significantly lower mean EQ VAS score in
      all cohorts of disease duration compared with control individuals for both men
      and women, and with a significantly lower EQ-5Dindex for women, but not for men, 
      15 years (0.76, p = 0.022) and 24 years (0.77, p = 0.016) after diagnosis
      compared with corresponding control individuals. Newly diagnosed individuals with
      diabetes reported significantly more problems compared with the control
      individuals in the dimension usual activities (women: 13.2% vs. 4.0%, p = 0.048; 
      men: 11.4% vs. 4.1%, p = 0.033). In the other dimensions, differences between
      individuals with diabetes and control individuals were found 15 and 24 years
      after diagnosis: for women in the dimensions mobility, self-care, usual
      activities and pain/discomfort and for men in the dimension mobility.
      Multivariable regression analysis showed that diabetes duration, being a woman,
      having a lower education and not being married or cohabiting had a negative
      impact on HRQoL. CONCLUSIONS: Our study confirms the negative impact of diabetes 
      on HRQoL and that the difference to control individuals increased by disease
      duration for women with diabetes. The small difference one year after diagnosis
      could imply a good management of diabetes care and a relatively quick adaptation.
      Our results also indicate that gender differences still exist in Sweden, despite 
      modern diabetes treatment and management in Sweden.
FAU - Sparring, Vibeke
AU  - Sparring V
FAU - Nystrom, Lennarth
AU  - Nystrom L
FAU - Wahlstrom, Rolf
AU  - Wahlstrom R
FAU - Jonsson, Pia Maria
AU  - Jonsson PM
FAU - Ostman, Jan
AU  - Ostman J
FAU - Burstrom, Kristina
AU  - Burstrom K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
PMC - PMC3640903
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/09/25 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - 1471-2458-13-377 [pii]
AID - 10.1186/1471-2458-13-377 [doi]
PST - aheadofprint
SO  - BMC Public Health. 2013 Apr 22;13(1):377.

PMID- 23607805
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1365-2796 (Electronic)
IS  - 0954-6820 (Linking)
DP  - 2013 Apr 23
TI  - High density lipoprotein cholesterol levels are an independent predictor of the
      progression of chronic kidney disease.
LID - 10.1111/joim.12081 [doi]
AB  - OBJECTIVES: Patients with chronic kidney disease (CKD) often present with reduced
      plasma HDL cholesterol (HDL-C) levels. Whether this reduction in an epiphenomenon
      or is involved in disease progression is unclear. The aim of this study was to
      investigate the relation between HDL-C levels/function and CKD progression in
      patients with different degrees of disease. DESIGN: A total of 176 patients with 
      CKD [glomerular filtration rate (GFR) 50.3 +/- 29.1 mL min-1 ] were recruited and
      followed for up to 84 months. Lipid profile, metabolic status and kidney function
      were evaluated at predetermined times. Age-matched control subjects were selected
      from the PLIC study (n = 453). Scavenger receptor class B member 1 (SR-BI) and
      ATP-binding cassette transporter A1 (ABCA-1)-dependent efflux of cholesterol were
      measured in CKD patients and in age-matched control subjects. RESULTS: Low HDL-C 
      levels, diabetes and hypertension were associated with reduced GFR. At follow-up,
      low HDL-C levels were associated with earlier entry in dialysis or doubling of
      the plasma creatinine level (P = 0.017); HDL-C levels were the only lipid
      parameter that affected the progression of CKD (hazard ratio 0.951, 95%
      confidence interval 0.917-0.986, P = 0.007), independently of the presence of
      diabetes. Only SR-BI-mediated serum cholesterol efflux was significantly reduced 
      in the group of CKD patients with low HDL-C levels compared to the control group.
      CONCLUSIONS: CKD patients with low levels of plasma HDL-C have a poor prognosis. 
      HDL functionality is also impaired in renal dysfunction. These data support the
      relevance of HDL in influencing CKD progression.
CI  - (c) 2013 The Association for the Publication of the Journal of Internal Medicine.
AD  - Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello Balsamo,
      Milan, Italy; Department of Pharmacological and Biomolecular Sciences, Universita
      degli Studi di Milano, Milan, Italy.
FAU - Baragetti, A
AU  - Baragetti A
FAU - Norata, G D
AU  - Norata GD
FAU - Sarcina, C
AU  - Sarcina C
FAU - Rastelli, F
AU  - Rastelli F
FAU - Grigore, L
AU  - Grigore L
FAU - Garlaschelli, K
AU  - Garlaschelli K
FAU - Uboldi, P
AU  - Uboldi P
FAU - Baragetti, I
AU  - Baragetti I
FAU - Pozzi, C
AU  - Pozzi C
FAU - Catapano, A L
AU  - Catapano AL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130423
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
AID - 10.1111/joim.12081 [doi]
PST - aheadofprint
SO  - J Intern Med. 2013 Apr 23. doi: 10.1111/joim.12081.

PMID- 23607762
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1535-3907 (Electronic)
IS  - 1535-3893 (Linking)
VI  - 12
IP  - 6
DP  - 2013 Jun 7
TI  - Quantitative Analytical Method for Determining the Levels of Gastric Inhibitory
      Polypeptides GIP1-42 and GIP3-42 in Human Plasma Using LC-MS/MS/MS.
PG  - 2690-9
LID - 10.1021/pr400069f [doi]
AB  - Gastric inhibitory polypeptide (GIP), an incretin, is an important subject in
      endocrinology. Some LC-MS assays have been proposed; however, their sensitivities
      are insufficient for the study of endogenous human incretin. Here, we describe a 
      nanoflow LC hybrid triple quadrupole/linear ion trap MS assay for the
      simultaneous quantification of GIP1-42 and GIP3-42 from human plasma. We selected
      the surrogate peptide to avoid oxidative modification, and the endoproteinase
      Asp-N was selected for the proteolysis of GIP1-42 and GIP3-42. The phenylalanine 
      residue at position 6 in both GIP1-42 and GIP3-42 was substituted with
      (13)C9,(15)N-labeled phenylalanine, and these substituted GIPs were used as the
      internal standards. This facilitated accurate and precise quantification because 
      large corrections are possible at all steps of sample pretreatment and ionization
      efficiency. The lower limit of quantification was 1 pM for GIP1-42 and 10 pM for 
      GIP3-42 by using 200 muL of plasma. Quantification of GIP1-42 and GIP3-42 in
      plasma from patients with type 2 diabetes was possible using this method, which
      included protein precipitation, Asp-N proteolysis, solid-phase extraction,
      nanoflow LC, and positive-ion multiple reaction monitoring cubed (MRM(3)) for
      GIP1-8, and MRM for GIP3-8 to achieve accurate, precise, and quantitative
      analysis that can be validated to support large clinical trials.
AD  - Laboratory Management Department, Sanwa Kagaku Kenkyusho Co., Ltd. , Mie
      511-0406, Japan.
FAU - Miyachi, Atsushi
AU  - Miyachi A
FAU - Murase, Takayo
AU  - Murase T
FAU - Yamada, Yuichiro
AU  - Yamada Y
FAU - Osonoi, Takeshi
AU  - Osonoi T
FAU - Harada, Ken-Ichi
AU  - Harada K
LA  - eng
PT  - Journal Article
DEP - 20130502
PL  - United States
TA  - J Proteome Res
JT  - Journal of proteome research
JID - 101128775
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/05/02 [aheadofprint]
AID - 10.1021/pr400069f [doi]
PST - ppublish
SO  - J Proteome Res. 2013 Jun 7;12(6):2690-9. doi: 10.1021/pr400069f. Epub 2013 May 2.

PMID- 23607727
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Apr 22
TI  - Time to care? Health of informal older carers and time spent on health related
      activities: an Australian survey.
PG  - 374
AB  - BACKGROUND: Little is known about the time spent on specific health related
      activities by older adult informal carers who assist people with chronic illness.
      Research has not yet addressed the association between carer health status and
      their care demands. Such information could inform policy and health system
      efforts to manage chronic illness. METHODS: We conducted an Australia wide survey
      using recall questionnaires to record time use. The study asked how much time is 
      spent on "most days" for the most common activities like taking medication,
      self-treatment and testing, and how much time in the last month on less common
      activities like attending a physician or shopping associated with health needs.
      The survey was mailed to 5,000 members of National Seniors Australia; 2,500
      registrants on the National Diabetes Services Scheme; and 3,100 members of the
      Australian Lung Foundation. A total of 2519 people responded, including 313
      people who identified as informal carers. Statistical analysis was undertaken
      using Stata 11. Standard errors and confidence intervals were derived using
      bootstrapping techniques within Stata 11. RESULTS: Most carers (96.2%) had
      chronic illness themselves, and those with greater numbers of chronic illnesses
      were those who faced the greatest overall time demands. The top decile of carers 
      devoted between 8.5 and 10 hours a day to personal and caring health related
      activities. Informal carers with chronic illness spent more time managing their
      own health than people with chronic illness who were not informal carers. These
      carers spent more time on caring for others than on caring for their own health. 
      High levels of caring responsibility were associated with poorer reported carer
      health. CONCLUSIONS: Policy and health care services will need to adapt to
      recognise and reduce the time burden on carers who themselves have chronic
      illness. More carefully targeted investment in the social infrastructure of
      formal care would free up carers for other activities (including their own care) 
      and holds the potential to improve the quality of life as well as the health
      outcomes of this population.
FAU - Jowsey, Tanisha
AU  - Jowsey T
FAU - McRae, Ian
AU  - McRae I
FAU - Gillespie, James
AU  - Gillespie J
FAU - Banfield, Michelle
AU  - Banfield M
FAU - Yen, Laurann
AU  - Yen L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
PMC - PMC3641944
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/10/18 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - 1471-2458-13-374 [pii]
AID - 10.1186/1471-2458-13-374 [doi]
PST - aheadofprint
SO  - BMC Public Health. 2013 Apr 22;13(1):374.

PMID- 23607664
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
DP  - 2013 Mar 27
TI  - Induction of autoimmune diabetes in NOD mice requires IL-21-dependent activation 
      autoreactive CD8 T cells.
LID - 10.1111/cei.12108 [doi]
AB  - Non-obese diabetic (NOD) mice lacking IL-21 or IL-21 receptor do not develop
      autoimmune type 1 diabetes (T1D). We have recently shown that IL-21 may promote
      activation of autoreactive CD8+ T cells by increasing their antigen
      responsiveness. To investigate the role of IL-21 in activating diabetogenic CD8+ 
      T cells in the NOD mouse, we generated IL-21 deficient NOD mice expressing the
      highly pathogenic MHC class-I-restricted 8.3 transgenic TCR. IL-21 deficiency
      completely protected 8.3-NOD mice from T1D. CD8+ T cells from the 8.3-NOD.Il21-/-
      mice showed decreased antigen-induced proliferation but displayed robust
      antigen-specific cytolytic activity and production of effector cytokines. IL-21
      deficient 8.3 T cells underwent efficient homeostatic proliferation, and prior
      antigen stimulation enabled these cells to cause diabetes in NOD.scid recipients.
      The 8.3 T cells that developed in IL-21 deficient environment showed impaired
      antigen-specific proliferation in vivo even in IL-21 sufficient mice. These cells
      also showed impaired IL-2 production and Il2 gene transcription following antigen
      stimulation. However, IL-2 addition failed to completely reverse their impaired
      proliferation. These findings indicate that IL-21 is required for efficient
      initial activation of autoreactive CD8+ T cells but is dispensable for the
      activated cells to develop effector functions and cause disease. Hence,
      therapeutic targeting of IL-21 in T1D may inhibit activation of naive
      autoreactive CD8+ T cells, but may have to be combined with other strategies to
      inhibit already activated cells.
CI  - (c) 2013 British Society for Immunology, Clinical and Experimental Immunology.
AD  - Department of Pediatrics, Immunology Division, Faculty of Medicine and Health
      Sciences, Universite de Sherbrooke, Sherbrooke, J1H 5N4, Quebec, Canada.
FAU - Chen, Xi-Lin
AU  - Chen XL
FAU - Bobbala, Diwakar
AU  - Bobbala D
FAU - Rodriguez, Galaxia M
AU  - Rodriguez GM
FAU - Mayhue, Marian
AU  - Mayhue M
FAU - Chen, Yi-Guang
AU  - Chen YG
FAU - Ilangumaran, Subburaj
AU  - Ilangumaran S
FAU - Ramanathan, Sheela
AU  - Ramanathan S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130327
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/03/19 [accepted]
AID - 10.1111/cei.12108 [doi]
PST - aheadofprint
SO  - Clin Exp Immunol. 2013 Mar 27. doi: 10.1111/cei.12108.

PMID- 23607332
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1744-7674 (Electronic)
IS  - 1354-3776 (Linking)
VI  - 23
IP  - 6
DP  - 2013
TI  - Antiobesity carbonic anhydrase inhibitors: a literature and patent review.
PG  - 725-35
LID - 10.1517/13543776.2013.790957 [doi]
AB  - Introduction: Obesity is ranked as one of the top 10 global health problems and
      the major concern deriving from it is the exposure of the population to a vast
      array of chronic pathologies such as cardiovascular and musculoskeletal
      disorders, type 2 diabetes, cancer, such as colon, breast and endometrial cancer,
      together with psychological disorders derived from this condition. The discovery 
      that the clinically used anticonvulsants topiramate (TPM) and zonisamide (ZNS)
      induced weight loss in obese, epileptic patients, afforded the validation of the 
      mitochondrial carbonic anhydrases (CAs, EC 4.2.1.1) VA and VB as targets for the 
      development of antiobesity drugs. Areas covered: This review deals with the
      scientific and patent literature regarding obesity or obesity-related
      pathologies, being particularly focused on the use of carbonic anhydrase
      inhibitors (CAI) such as TPM and ZNS which inhibit the de novo lipogenesis.
      Expert opinion: There is an urgent need of new drugs for the treatment of
      obesity. The identification that the mitochondrial CAs are implicated in the de
      novo lipogenesis allowed to consider selective inhibitors of such enzymes as
      useful for the development of new antiobesity drugs. Actually TPM was approved 1 
      year ago for this therapy, whereas ZNS is also an effective such agent. These
      compounds are the lead molecules in this field and an intense research is on the 
      way in order to develop new compounds based on the selective inhibition of
      mitochondrial CA isoforms.
AD  - Universita degli Studi di Firenze, Laboratorio di Chimica Bioinorganica , Rm.
      188, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Florence) , Italy +39
      0554573005 ; +39 055 4573385 ; fabrizio.carta@unifi.it and +39 0554573005 ; +39
      055 4573385 ; E-mail: claudiu.supuran@unifi.it.
FAU - Scozzafava, Andrea
AU  - Scozzafava A
FAU - Supuran, Claudiu T
AU  - Supuran CT
FAU - Carta, Fabrizio
AU  - Carta F
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - England
TA  - Expert Opin Ther Pat
JT  - Expert opinion on therapeutic patents
JID - 9516419
SB  - IM
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2013/04/22 [aheadofprint]
AID - 10.1517/13543776.2013.790957 [doi]
PST - ppublish
SO  - Expert Opin Ther Pat. 2013;23(6):725-35. doi: 10.1517/13543776.2013.790957. Epub 
      2013 Apr 22.

PMID- 23607267
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1472-6823 (Print)
IS  - 1472-6823 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Apr 22
TI  - Relationship of ethnicity and CD4 Count with glucose metabolism among HIV
      patients on Highly-Active Antiretroviral Therapy (HAART).
PG  - 13
AB  - BACKGROUND: HIV patients on HAART are prone to metabolic abnormalities, including
      insulin resistance, lipodystrophy and diabetes. This study purports to
      investigate the relationship of ethnicity and CD4+ T cell count attained after
      stable highly-active antiretroviral treatment (HAART) with glucose metabolism in 
      hyperrtriglyceridemic HIV patients without a history of diabetes. METHODS:
      Demographic, anthropometric, clinical, endocrinologic, energy expenditure and
      metabolic measures were obtained in 199 multiethnic, healthy but
      hypertriglyceridemic HIV-infected patients [46% Hispanic, 17% African-American,
      37% Non-Hispanic White (NHW)] on stable HAART without a history of diabetes. The 
      relationship of glucose and insulin responses to ethnicity, CD4 strata (low
      (<300/cc) or moderate-to-high (>= 300/cc)), and their interaction was determined.
      RESULTS: African-Americans had significantly greater impairment of glucose
      tolerance (P < 0.05) and HbA1c levels (P < .001) than either Hispanics or NHWs.
      In multivariate models, after adjusting for confounders (age, sex, HIV/HAART
      duration, smoking, obesity, glucose, insulin and lipids), African-Americans and
      Hispanics had significantly higher HbA1c and 2-hour glucose levels than NHW's.
      Demonstrating a significant interaction between ethnicity and CD4 count (P =
      0.023), African Americans with CD4 <300/cc and Hispanics with CD4 >=300/cc had
      the most impaired glucose response following oral glucose challenge. CONCLUSIONS:
      Among hypertriglyceridemic HIV patients on HAART, African-Americans and Hispanics
      are at increased risk of developing diabetes. Ethnicity also interacts with CD4+ 
      T cell count attained on stable HAART to affect post-challenge glycemic response.
FAU - Misra, Ranjita
AU  - Misra R
FAU - Chandra, Prakash
AU  - Chandra P
FAU - Riechman, Steven E
AU  - Riechman SE
FAU - Long, Dustin M
AU  - Long DM
FAU - Shinde, Shivani
AU  - Shinde S
FAU - Pownall, Henry J
AU  - Pownall HJ
FAU - Coraza, Ivonne
AU  - Coraza I
FAU - Lewis, Dorothy E
AU  - Lewis DE
FAU - Sekhar, Rajagopal V
AU  - Sekhar RV
FAU - Balasubramanyam, Ashok
AU  - Balasubramanyam A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
EDAT- 2013/04/24 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/04/24 06:00
PHST- 2012/08/22 [received]
PHST- 2013/04/22 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - 1472-6823-13-13 [pii]
AID - 10.1186/1472-6823-13-13 [doi]
PST - aheadofprint
SO  - BMC Endocr Disord. 2013 Apr 22;13(1):13.

PMID- 23607096
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 2314-6141 (Electronic)
VI  - 2013
DP  - 2013
TI  - Amylin uncovered: a review on the polypeptide responsible for type II diabetes.
PG  - 826706
LID - 10.1155/2013/826706 [doi]
AB  - Amylin is primarily responsible for classifying type II diabetes as an amyloid
      (protein misfolding) disease as it has great potential to aggregate into toxic
      nanoparticles, thereby resulting in loss of pancreatic beta-cells. Although type 
      II diabetes is on the increase each year, possibly due to bad eating habits of
      modern society, research on the culprit for this disease is still in its early
      days. In addition, unlike the culprit for Alzheimer's disease, amyloid
      beta-peptide, amylin has failed to receive attention worthy of being featured in 
      an abundance of review articles. Thus, the aim of this paper is to shine the
      spotlight on amylin in an attempt to put it onto the top of researchers' to-do
      list since the secondary complications of type II diabetes have far-reaching and 
      severe consequences on public health both in developing and fully developed
      countries alike. This paper will cover characteristics of the amylin aggregates, 
      mechanisms of toxicity, and a particular focus on inhibitors of toxicity and
      techniques used to assess these inhibitors.
AD  - Department of Biochemistry, School of Life Sciences, University of KwaZulu Natal,
      Westville Campus, Block F3, University Road, Private Bag X54001, Durban 4000,
      South Africa.
FAU - Pillay, Karen
AU  - Pillay K
FAU - Govender, Patrick
AU  - Govender P
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
PMC - PMC3626316
OID - NLM: PMC3626316
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/12/11 [received]
PHST- 2013/02/21 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.1155/2013/826706 [doi]
PST - ppublish
SO  - Biomed Res Int. 2013;2013:826706. doi: 10.1155/2013/826706. Epub 2013 Mar 31.

PMID- 23607045
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130422
DCOM- 20130423
LR  - 20130424
IS  - 2090-8059 (Print)
IS  - 2042-0064 (Linking)
VI  - 2013
DP  - 2013
TI  - A study of bone mineral density and its determinants in type 1 diabetes mellitus.
PG  - 397814
LID - 10.1155/2013/397814 [doi]
AB  - Type 1 diabetes mellitus (T1DM) has been inconsistently associated with low bone 
      mineral density (BMD) and increased fracture risk. 86 consecutive T1DM cases and 
      140 unrelated age and sex matched healthy nondiabetic controls were included in
      the study. After history and examination, BMD and body composition were assessed 
      by dual energy X-ray absorptiometry (DXA). Serum samples were analyzed for
      calcium, phosphorus, albumin, creatinine, alkaline phosphatase, 25 (OH) vitamin
      D3, intact parathormone (PTH) levels (both cases and controls) and HbA1c,
      antimicrosomal and IgA tissue transglutaminase (IgA TTG) antibodies, cortisol,
      follicle stimulating hormone (FSH), testosterone, sex hormone binding globulin
      (SHBG), tetraiodothyronine (T4), thyroid stimulating hormone (TSH), growth
      hormone (GH), insulin-like growth factor-1 (IGF-1), and insulin-like growth
      factor binding protein 3 (IGFBP3) (cases only). T1DM cases had a lower BMD as
      compared to controls at both total body (TB) and lumbar spine (LS) (P < 0.05).
      Patients with celiac autoimmunity (CA) had significantly, lower BMD as compared
      to age, sex, and body mass index (BMI) matched T1DM controls. Linear regression
      analysis showed that low BMD in T1DM patients was associated with poor glycaemic 
      control, lower IGF-1 levels, less physical activity (in total population as well 
      as in male and female subgroups), and lower body fat percentage (in females) and 
      higher alkaline phosphatase level (in males) (P < 0.05).
AD  - Departmnent of Endocrinology, Topiwala National Medical College & BYL Nair
      Hospital, Mumbai 400008, India.
FAU - Joshi, Ameya
AU  - Joshi A
FAU - Varthakavi, Premlata
AU  - Varthakavi P
FAU - Chadha, Manoj
AU  - Chadha M
FAU - Bhagwat, Nikhil
AU  - Bhagwat N
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - United States
TA  - J Osteoporos
JT  - Journal of osteoporosis
JID - 101538878
PMC - PMC3628496
OID - NLM: PMC3628496
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
CRDT- 2013/04/23 06:00
PHST- 2012/11/09 [received]
PHST- 2013/01/18 [revised]
PHST- 2013/02/21 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.1155/2013/397814 [doi]
PST - ppublish
SO  - J Osteoporos. 2013;2013:397814. doi: 10.1155/2013/397814. Epub 2013 Mar 31.

PMID- 23607043
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130422
DCOM- 20130423
LR  - 20130424
IS  - 2090-8016 (Print)
IS  - 2090-0597 (Linking)
VI  - 2013
DP  - 2013
TI  - Serum uric Acid as a marker of coronary calcification in patients with
      asymptomatic coronary artery disease with preserved left ventricular pump
      function.
PG  - 129369
LID - 10.1155/2013/129369 [doi]
AB  - Objective. To evaluate the interrelation between serum uric acid and artery
      calcification in asymptomatic coronary artery disease subjects. Design and
      Methods. 126 subjects with previously documented asymptomatic coronary artery
      disease were enrolled in the study. Results. Mean value of serum uric acid level 
      was 23.84 mmol/L (95% confidence interval (CI) = 15.75-31.25 mmol/L). In
      multivariate Cox regression analysis, the results showed that serum uric acid
      levels (odds ratio (OR) = 1.42, 95% CI = 1.20-1.82; P < 0.001), osteopontin (OR =
      1.14, 95% CI = 1.12-1.25; P < 0.001), osteoprotegerin (OR = 1.45, 95% CI =
      1.20-1.89; P < 0.001), type 2 diabetes mellitus (OR = 1.41, 95% CI = 1.20-1.72; P
      < 0.001), and total cholesterol (OR = 1.13, 95% CI = 1.10-1.22; P < 0.001) were
      factors that independently associated with coronary artery calcification. The Cox
      models suggested that high quartile of serum uric acid level is very significant 
      in predicting Agatston score index. In conclusion, we suggested that high
      quartile of serum uric acid level (cutoff point equaled 35.9 mmol/L) was a very
      significant predictor of coronary calcification examined by Agatston score index 
      in subjects with asymptomatic coronary artery disease.
AD  - Internal Medicine Department, State Medical University, Zaporozhye 69035,
      Ukraine.
FAU - Berezin, A E
AU  - Berezin AE
FAU - Kremzer, A A
AU  - Kremzer AA
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - United States
TA  - Cardiol Res Pract
JT  - Cardiology research and practice
JID - 101516542
PMC - PMC3626382
OID - NLM: PMC3626382
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
CRDT- 2013/04/23 06:00
PHST- 2013/01/22 [received]
PHST- 2013/02/14 [revised]
PHST- 2013/02/27 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.1155/2013/129369 [doi]
PST - ppublish
SO  - Cardiol Res Pract. 2013;2013:129369. doi: 10.1155/2013/129369. Epub 2013 Mar 31.

PMID- 23606982
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130422
DCOM- 20130423
LR  - 20130424
IS  - 2090-4630 (Print)
IS  - 2090-4630 (Linking)
VI  - 2013
DP  - 2013
TI  - The BB Wistar Rat as a Diabetic Model for Fracture Healing.
PG  - 349604
LID - 10.1155/2013/349604 [doi]
AB  - The advent of improved glucose control with insulin and oral medications has
      allowed for the diabetic population to live longer and healthier lives.
      Unfortunately diabetes remains a worldwide epidemic with multiple health
      implications. Specifically, its affects upon fracture healing have been well
      studied and shown to have negative effects on bone mineral density, biomechanical
      integrity, and fracture healing. Multiple animal models have been used for
      research purposes to gain further insight into the effects and potential
      treatments of this disease process. The diabetic BB Wistar rat is one model that 
      replicates a close homology to human type-1 diabetes and has been used as a
      fracture model to study the effects of diabetes on bone integrity and healing. In
      particular, the effects of tight glucose control, ultrasound therapy,
      platelet-rich plasma (PRP), platelet-derived growth factor (PDGF), bone
      morphogenetic protein 2 (BMP-2), and allograft bone incorporation have been
      studied extensively. We present a review of the literature using the BB Wistar
      rat to elucidate the implications of diabetes on fracture healing.
AD  - Department of Orthopedic Surgery, University of Medicine and Dentistry of New
      Jersey, New Jersey Medical School, Newark, NJ 07103, USA.
FAU - Sood, Amit
AU  - Sood A
FAU - Cunningham, Catie
AU  - Cunningham C
FAU - Lin, Sheldon
AU  - Lin S
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - United States
TA  - ISRN Endocrinol
JT  - ISRN endocrinology
JID - 101568096
PMC - PMC3628493
OID - NLM: PMC3628493
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
CRDT- 2013/04/23 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/03 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/03/31 [epublish]
AID - 10.1155/2013/349604 [doi]
PST - epublish
SO  - ISRN Endocrinol. 2013 Mar 31;2013:349604. doi: 10.1155/2013/349604. Print 2013.

PMID- 23606967
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 2090-2735 (Electronic)
IS  - 2090-2727 (Linking)
VI  - 2013
DP  - 2013
TI  - Risk-based screening for thyroid dysfunction during pregnancy.
PG  - 619718
LID - 10.1155/2013/619718 [doi]
AB  - OBJECTIVE: We conducted the study to see the incidence of thyroid dysfunction in 
      women with obstetrical high-risk factors. METHODS: We retrospectively reviewed
      medical charts of high-risk pregnant women who had examination for thyroid
      function during pregnancy. Women were divided according to clinical presentation,
      symptoms of thyroid disease and those with a personal history of thyroid disease 
      (thyroid disease, n = 32), intrauterine growth restriction (IUGR, n = 115),
      diabetes mellitus (diabetes, n = 115), hypertension (n = 63), intrauterine fetal 
      death (IUFD, n = 52), and placental abruption (abruption, n = 15). The incidence 
      of thyroid dysfunctions including hyperthyroidism or hypothyroidism was compared.
      RESULTS: The overall prevalence of thyroid dysfunction was 24.7%. The incidence
      of thyroid dysfunction in each group was as follows: 31% in thyroid disease, 25% 
      in IUGR, 30% in diabetes, 27% in hypertension, 12% in IUFD, and 7% in abruption. 
      Except IUFD, the incidence was not statistically significant from the group of
      thyroid disease (thyroid disease versus IUFD, P = 0.03 by chi (2) test). Thyroid 
      disease represented for only 10% of all thyroid dysfunctions. CONCLUSION: Testing
      of women with a personal history or current symptoms of thyroid disease during
      pregnancy may be insufficient to detect women with thyroid dysfunction, who will 
      become at high-risk pregnancy.
AD  - Department of Obstetrics & Gynecology, Miyazaki Medical Association Hospital,
      738-1 Shinbepputyo-Funato, Miyazaki, Japan.
FAU - Ohashi, Masanao
AU  - Ohashi M
FAU - Furukawa, Seishi
AU  - Furukawa S
FAU - Michikata, Kaori
AU  - Michikata K
FAU - Kai, Katsuhide
AU  - Kai K
FAU - Sameshima, Hiroshi
AU  - Sameshima H
FAU - Ikenoue, Tsuyomu
AU  - Ikenoue T
LA  - eng
PT  - Journal Article
DEP - 20130327
PL  - Egypt
TA  - J Pregnancy
JT  - Journal of pregnancy
JID - 101553823
SB  - IM
PMC - PMC3625569
OID - NLM: PMC3625569
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/18 [received]
PHST- 2013/02/27 [accepted]
PHST- 2013/03/27 [epublish]
AID - 10.1155/2013/619718 [doi]
PST - ppublish
SO  - J Pregnancy. 2013;2013:619718. doi: 10.1155/2013/619718. Epub 2013 Mar 27.

PMID- 23606957
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130422
DCOM- 20130423
LR  - 20130424
IS  - 2090-1429 (Print)
IS  - 2090-1429 (Linking)
VI  - 2013
DP  - 2013
TI  - From intervention to innovation: applying a formal implementation strategy in
      community primary care.
PG  - 605757
LID - 10.1155/2013/605757 [doi]
AB  - Objective. To describe a comprehensive strategy for implementing an effective
      diabetes self-management support intervention incorporating goal-setting and
      followup support in community health clinics (CHCs) serving vulnerable patients. 
      Methods. The Replicating Effective Programs (REP) framework was applied to
      develop an intervention strategy. In order to create a strategy consistent with
      the REP framework, four CHCs engaged in an iterative process involving
      key-informant interviews with clinic staff, ongoing involvement of clinic staff
      facilitating translational efforts, feedback from national experts, and an
      instructional designer. Results. Moving through the REP process resulted in an
      implementation strategy that aims to facilitate commitment, communication, and
      change at the clinic level, as well as means of providing interactive,
      time-limited education about patient behavior change and support to health care
      providers. Conclusion. The REP offered a useful framework for providing guidance 
      toward the development of a strategy to implement a diabetes self-management
      intervention in CHCs serving medically underserved and underrepresented patient
      populations.
AD  - The University of Iowa College of Nursing, 330 CNB, 50 Newton Road, Iowa City, IA
      52242, USA.
FAU - Wallace, Andrea S
AU  - Wallace AS
FAU - Sussman, Andrew L
AU  - Sussman AL
FAU - Anthoney, Mark
AU  - Anthoney M
FAU - Parker, Edith A
AU  - Parker EA
LA  - eng
PT  - Journal Article
DEP - 20130330
PL  - Egypt
TA  - Nurs Res Pract
JT  - Nursing research and practice
JID - 101561211
PMC - PMC3625572
OID - NLM: PMC3625572
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
CRDT- 2013/04/23 06:00
PHST- 2012/12/28 [received]
PHST- 2013/02/18 [accepted]
PHST- 2013/03/30 [epublish]
AID - 10.1155/2013/605757 [doi]
PST - ppublish
SO  - Nurs Res Pract. 2013;2013:605757. doi: 10.1155/2013/605757. Epub 2013 Mar 30.

PMID- 23606892
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130422
DCOM- 20130423
LR  - 20130424
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Alternanthera sessilis Red Ethyl Acetate Fraction Exhibits Antidiabetic Potential
      on Obese Type 2 Diabetic Rats.
PG  - 845172
LID - 10.1155/2013/845172 [doi]
AB  - The antidiabetic potential of Alternanthera sessilis Red was investigated using
      the obese type 2 diabetic rats induced by high fat diet and streptozotocin. Three
      fractions (hexane, ethyl acetate, and water) were obtained from the crude ethanol
      extract of Alternanthera sessilis Red. Alternanthera sessilis Red ethyl acetate
      fraction (ASEAF) was found to possess the most potent antihyperglycemic effect
      through oral glucose tolerance test. The ASEAF was subsequently given to the
      diabetic rats for two weeks. It was found that two-week administration of ASEAF
      reduces the fasting blood glucose level, triglyceride level, and free fatty acid 
      level of the rats. ASEAF-treated diabetic rats showed higher pancreatic insulin
      content and pancreatic total superoxide dismutase activity compared to the
      untreated diabetic rats. Also, the insulin sensitivity indexes suggested that
      ASEAF ameliorates the insulin resistant state of the diabetic rats. In
      conclusion, ASEAF could be developed into a potential antidiabetic agent for the 
      management of type 2 diabetes.
AD  - Department of Physiology, Faculty of Medicine, University of Malaya, 50603 Kuala 
      Lumpur, Malaysia.
FAU - Tan, Kok Keong
AU  - Tan KK
FAU - Kim, Kah Hwi
AU  - Kim KH
LA  - eng
PT  - Journal Article
DEP - 20130328
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3625611
OID - NLM: PMC3625611
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
CRDT- 2013/04/23 06:00
PHST- 2012/11/14 [received]
PHST- 2013/01/25 [revised]
PHST- 2013/02/28 [accepted]
PHST- 2013/03/28 [epublish]
AID - 10.1155/2013/845172 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:845172. doi: 10.1155/2013/845172.
      Epub 2013 Mar 28.

PMID- 23606883
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130422
DCOM- 20130423
LR  - 20130424
IS  - 1741-427X (Print)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - In Vitro Evaluations of Cytotoxicity of Eight Antidiabetic Medicinal Plants and
      Their Effect on GLUT4 Translocation.
PG  - 549345
LID - 10.1155/2013/549345 [doi]
AB  - Despite the enormous achievements in conventional medicine, herbal-based
      medicines are still a common practice for the treatment of diabetes. Trigonella
      foenum-graecum, Atriplex halimus, Olea europaea, Urtica dioica, Allium sativum,
      Allium cepa, Nigella sativa, and Cinnamomum cassia are strongly recommended in
      the Greco-Arab and Islamic medicine for the treatment and prevention of diabetes.
      Cytotoxicity (MTT and LDH assays) of the plant extracts was assessed using cells 
      from the liver hepatocellular carcinoma cell line (HepG2) and cells from the rat 
      L6 muscle cell line. The effects of the plant extracts (50% ethanol in water) on 
      glucose transporter-4 (GLUT4) translocation to the plasma membrane was tested in 
      an ELISA test on L6-GLUT4myc cells. Results obtained indicate that Cinnamomon
      cassia is cytotoxic at concentrations higher than 100 mu g/mL, whereas all other 
      tested extracts exhibited cytotoxic effects at concentrations higher than 500 mu 
      g/mL. Exposing L6-GLUT4myc muscle cell to extracts from Trigonella
      foenum-graecum, Urtica dioica, Atriplex halimus, and Cinnamomum verum led to a
      significant gain in GLUT4 on their plasma membranes at noncytotoxic
      concentrations as measured with MTT assay and the LDH leakage assay. These
      findings indicate that the observed anti-diabetic properties of these plants are 
      mediated, at least partially, through regulating GLUT4 translocation.
AD  - Qasemi Research Center-Al-Qasemi Academy, P.O. Box 124, 30100 Baqa El-Gharbia,
      Israel ; Casali Institute for Applied Chemistry, Institute of Chemistry, The
      Hebrew University of Jerusalem, Givat Ram, 91904 Jerusalem, Israel.
FAU - Kadan, Sleman
AU  - Kadan S
FAU - Saad, Bashar
AU  - Saad B
FAU - Sasson, Yoel
AU  - Sasson Y
FAU - Zaid, Hilal
AU  - Zaid H
LA  - eng
PT  - Journal Article
DEP - 20130328
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3625546
OID - NLM: PMC3625546
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
CRDT- 2013/04/23 06:00
PHST- 2012/09/25 [received]
PHST- 2013/02/14 [revised]
PHST- 2013/02/22 [accepted]
PHST- 2013/03/28 [epublish]
AID - 10.1155/2013/549345 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:549345. doi: 10.1155/2013/549345.
      Epub 2013 Mar 28.

PMID- 23606858
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130422
DCOM- 20130423
LR  - 20130424
IS  - 1687-9627 (Print)
VI  - 2013
DP  - 2013
TI  - Adult-onset type 1 diabetes and pregnancy: three case reports.
PG  - 920861
LID - 10.1155/2013/920861 [doi]
AB  - From 5% to 10% of diabetic patients have type 1 diabetes. Here we describe three 
      cases of adult-onset type 1 diabetes in pregnancy treated at our clinic between
      2009 and 2012. Two patients came for specialist examination during pregnancy, the
      third after pregnancy. These women had no prior overt diabetes and shared certain
      characteristics, that is, no family diabetes history, age over 35, normal
      prepregnancy BMI, need for insulin therapy as of the early weeks of pregnancy,
      and high-titer anti-GAD antibody positivity. The patients had persistent diabetes
      after delivery, suggesting that they developed adult-onset type 1 diabetes during
      pregnancy. About 10% of GDM patients become pancreatic autoantibody positive and 
      the risk of developing overt diabetes is higher when two or more autoantibodies
      are present (particularly GAD and ICA). GAD-Ab shows the highest sensitivity for 
      type 1 diabetes prediction. We need to bear in mind that older patients might
      conceivably develop an adult-onset type 1 diabetes during or after pregnancy. So 
      we suggest that women with GDM showing the described clinical features shall be
      preferably tested for autoimmunity. Pregnant patients at risk of type 1 diabetes 
      should be identified to avoid the maternal and fetal complications and the acute 
      onset of diabetes afterwards.
AD  - Department of Medicine, Chair of Metabolic Disease, Padova University, via
      Giustiniani 2, 35100 Padova, Italy.
FAU - Bonsembiante, Barbara
AU  - Bonsembiante B
FAU - Dalfra, Maria Grazia
AU  - Dalfra MG
FAU - Masin, Michela
AU  - Masin M
FAU - Gallo, Alessandra
AU  - Gallo A
FAU - Lapolla, Annunziata
AU  - Lapolla A
LA  - eng
PT  - Journal Article
DEP - 20130328
PL  - United States
TA  - Case Rep Med
JT  - Case reports in medicine
JID - 101512910
PMC - PMC3625585
OID - NLM: PMC3625585
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
CRDT- 2013/04/23 06:00
PHST- 2013/01/14 [received]
PHST- 2013/03/13 [accepted]
PHST- 2013/03/28 [epublish]
AID - 10.1155/2013/920861 [doi]
PST - ppublish
SO  - Case Rep Med. 2013;2013:920861. doi: 10.1155/2013/920861. Epub 2013 Mar 28.

PMID- 23606703
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
DP  - 2013 Apr 20
TI  - The risk of atrial fibrillation in patients with rheumatoid arthritis.
AB  - BACKGROUND: Prior research suggests an important role of systemic inflammation in
      pathogenesis of atrial fibrillation (AF). It is well known that rheumatoid
      arthritis (RA), a chronic, systemic inflammatory disorder, increases the risk of 
      cardiovascular disease (CVD), but little evidence exists whether the risk of AF
      is increased in RA. METHODS: Using data from a large US commercial insurance
      plan, we examined the incidence rate (IR) of hospitalisation for AF in patients
      with RA compared with non-RA. RA patients were identified with >/=2 separate
      visits coded for RA and >/=1 disease-modifying antirheumatic drug dispensing. The
      IR of AF in RA patients was also compared with those with osteoarthritis, a
      chronic non-inflammatory condition. RESULTS: There were 20 852 RA and 104 260
      non-RA patients, matched on age, sex and index date. The mean follow-up was 2
      years. The IR per 1000 person-years of AF was 4.0 (95% CI 3.4 to 4.7) in RA and
      2.8 (95% CI 2.6 to 3.0) in non-RA patients. The IR ratio for AF was 1.4 (95% CI
      1.2 to 1.7) in RA compared with non-RA patients. In a multivariable Cox model
      adjusting for a number of risk factors such as diabetes, CVD, medications and
      healthcare utilisation, the risk of AF was no longer increased in RA (HR 1.1, 95%
      CI 0.9 to 1.4) compared with non-RA patients. There was also no difference in the
      AF risk between RA and osteoarthritis patients. CONCLUSIONS: Our results show no 
      increased risk of AF associated with RA, after adjusting for various
      comorbidities, medications and healthcare use.
AD  - Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's
      Hospital, Boston, Massachusetts, USA.
FAU - Kim, Seoyoung C
AU  - Kim SC
FAU - Liu, Jun
AU  - Liu J
FAU - Solomon, Daniel H
AU  - Solomon DH
LA  - ENG
GR  - K23 AR059677/AR/NIAMS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - annrheumdis-2013-203343 [pii]
AID - 10.1136/annrheumdis-2013-203343 [doi]
PST - aheadofprint
SO  - Ann Rheum Dis. 2013 Apr 20.

PMID- 23606586
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1932-7005 (Electronic)
IS  - 1932-6254 (Linking)
DP  - 2013 Apr 18
TI  - Iron dose-dependent differentiation and enucleation of human erythroblasts in
      serum-free medium.
LID - 10.1002/term.1743 [doi]
AB  - Improvements in ex vivo generation of enucleated red blood cells are being sought
      for erythroid biology research, toward the ultimate goal of erythrocyte
      engineering for clinical use. Based upon the high levels of iron-saturated
      transferrin in plasma serum, it was hypothesized that terminal differentiation in
      serum-free media may be highly dependent on the concentration of iron. Here adult
      human CD34+ cells were cultured in a serum-free medium containing dosed levels of
      iron-saturated transferrin (holo-Tf, 0.1-1.0 mg/ml). Iron in the culture medium
      was reduced, but not depleted, with erythroblast differentiation into
      haemoglobinized cells. At the lowest holo-Tf dose (0.1 mg/ml), terminal
      differentiation was significantly reduced and the majority of the cells underwent
      apoptotic death. Cell survival, differentiation and enucleation were enhanced as 
      the holo-Tf dose increased. These data suggest that adequate holo-Tf dosing is
      critical for terminal differentiation and enucleation of human erythroblasts
      generated ex vivo in serum-free culture conditions. Published 2013. This article 
      is a US Government work and is in the public domain in the USA.
CI  - Published 2013. This article is a US Government work and is in the public domain 
      in the USA.
AD  - Molecular Medicine Branch, National Institute of Diabetes and Digestive and
      Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
FAU - Byrnes, Colleen
AU  - Byrnes C
FAU - Lee, Y Terry
AU  - Lee YT
FAU - Meier, Emily R
AU  - Meier ER
FAU - Rabel, Antoinette
AU  - Rabel A
FAU - Sacks, David B
AU  - Sacks DB
FAU - Miller, Jeffery L
AU  - Miller JL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Tissue Eng Regen Med
JT  - Journal of tissue engineering and regenerative medicine
JID - 101308490
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/24 [received]
PHST- 2013/01/11 [revised]
PHST- 2013/02/05 [accepted]
AID - 10.1002/term.1743 [doi]
PST - aheadofprint
SO  - J Tissue Eng Regen Med. 2013 Apr 18. doi: 10.1002/term.1743.

PMID- 23606523
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 53
IP  - 6
DP  - 2013 Jun
TI  - A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose
      Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment.
PG  - 589-600
LID - 10.1002/jcph.86 [doi]
AB  - Predicting late phase outcomes from early-phase findings can help inform
      decisions in drug development. If the measurements in early-phase differ from
      those in late phase, forecasting is more challenging. In this paper, we present a
      model-based approach for predicting glycosylated hemoglobin (HbA1c) in late phase
      using glucose and insulin concentrations from an early-phase study, investigating
      an anti-diabetic treatment. Two previously published models were used; an
      integrated glucose and insulin (IGI) model for meal tolerance tests and an
      integrated glucose-red blood cell-HbA1c (IGRH) model predicting the formation of 
      HbA1c from the average glucose concentration (Cg,av ). Output from the IGI model 
      was used as input to the IGRH model. Parameters of the IGI model and drug effects
      were estimated using data from a phase1 study in 59 diabetic patients receiving
      various doses of a glucokinase activator. Cg,av values were simulated according
      to a Phase 2 study design and used in the IGRH model for predictions of HbA1c.
      The performance of the model-based approach was assessed by comparing the
      predicted to the actual outcome of the Phase 2 study. We have shown that this
      approach well predicts the longitudinal HbA1c response in a 12-week study using
      only information from a 1-week study where glucose and insulin concentrations
      were measured.
CI  - (c) The Author(s) 2013.
AD  - Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
FAU - Kjellsson, Maria C
AU  - Kjellsson MC
FAU - Cosson, Valerie F
AU  - Cosson VF
FAU - Mazer, Norman A
AU  - Mazer NA
FAU - Frey, Nicolas
AU  - Frey N
FAU - Karlsson, Mats O
AU  - Karlsson MO
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/05 [received]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - 10.1002/jcph.86 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2013 Jun;53(6):589-600. doi: 10.1002/jcph.86. Epub 2013 Apr 22.

PMID- 23606485
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 2047-2927 (Electronic)
DP  - 2013 Apr 18
TI  - Retrograde ejaculation and sexual dysfunction in men with diabetes mellitus: a
      prospective, controlled study.
LID - 10.1111/j.2047-2927.2013.00083.x [doi]
AB  - Retrograde ejaculation (RE) and erectile dysfunction may be caused by diabetes
      mellitus (DM), but the prevalence of RE among DM patients is unknown. A
      prospective, blinded case-control study comparing men with DM with matched
      controls according to RE and erectile dysfunction was performed. Twenty-seven men
      with DM matched the inclusion criteria and agreed to participate in the study,
      and of these 26 delivered an ejaculate. We were able to recruit 18 matching
      controls, and of these 16 delivered an ejaculate. Nine of 26 men with DM who
      delivered an ejaculate had RE, whereas none of 16 controls had RE (p < 0.01). The
      mean duration of DM was longer for DM patients with RE (20 years) compared with
      DM patients in whom RE could not be demonstrated (13 years), but the difference
      was not statistically significant. RE could not be associated with BMI, waist
      circumference, blood pressure, Haemoglobin A1c (HgbA1c), high-density lipoprotein
      HDL cholesterol, triglycerides, fasting glucose, or s-testosterone. Diabetics
      suffering from RE more frequently exhibited erectile dysfunction compared with
      non-diabetics and diabetics without RE, and the last-mentioned group again more
      frequently than controls. These findings could not be explained by use of
      antihypertensive drugs. Whereas none of the included control participants showed 
      signs of abnormal ejaculation, every third man with DM exhibited retrograde
      ejaculation. It is important to be aware of this association, and that
      post-ejaculatory urine is routinely analysed from aspermic fertility clinic
      attendants and diabetics with low ejaculate volumes.
CI  - (c) 2013 American Society of Andrology and European Academy of Andrology.
AD  - Laboratory of Reproductive Biology, Scientific Unit, Horsens Hospital, Horsens,
      and Fertility Clinic, Odense University Hospital, Odense, Denmark.
FAU - Fedder, J
AU  - Fedder J
FAU - Kaspersen, M D
AU  - Kaspersen MD
FAU - Brandslund, I
AU  - Brandslund I
FAU - Hojgaard, A
AU  - Hojgaard A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Andrology
JT  - Andrology
JID - 101585129
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/06 [received]
PHST- 2013/02/22 [revised]
PHST- 2013/02/22 [accepted]
AID - 10.1111/j.2047-2927.2013.00083.x [doi]
PST - aheadofprint
SO  - Andrology. 2013 Apr 18. doi: 10.1111/j.2047-2927.2013.00083.x.

PMID- 23606415
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
DP  - 2013 Apr 20
TI  - Concerted expression of the thermogenic and bioenergetic mitochondrial protein
      machinery in brown adipose tissue.
LID - 10.1002/jcb.24577 [doi]
AB  - Brown adipose tissue (BAT) is specialized in non-shivering thermogenesis through 
      the expression of the mitochondrial uncoupling protein-1 (UCP1). In this paper,
      we describe the relationship between UCP1 and proteins involved in ATP synthesis.
      By the use of BATIRKO mice, which have enhanced UCP1 expression in BAT, an
      increase in ATP synthase as well as in ubiquinol cytochrome c reductase levels
      was observed. Alterations in mitochondrial mass or variations in ATP levels were 
      not observed in BAT of these mice. In addition, using a protocol of brown
      adipocyte differentiation, the concerted expression of UCP1 with ATP synthase was
      found. These two scenarios revealed that increases in the uncoupling machinery of
      brown adypocites must be concomitantly followed by an enhancement of proteins
      involved in ATP synthesis. These concerted changes reflect the need to maintain
      ATP production in an essentially uncoupling cell type. J. Cell. Biochem. (c) 2013
      Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy,
      Complutense University of Madrid, Madrid, 28040, Spain; Spanish Biomedical
      Research Centre in Diabetes and Associated Metabolic Disorders, (CIBERDEM),
      Instituto de Salud Carlos III, Spain.
FAU - Guillen, Carlos
AU  - Guillen C
FAU - Bartolome, Alberto
AU  - Bartolome A
FAU - Vila-Bedmar, Rocio
AU  - Vila-Bedmar R
FAU - Garcia-Aguilar, Ana
AU  - Garcia-Aguilar A
FAU - Gomez-Hernandez, Almudena
AU  - Gomez-Hernandez A
FAU - Benito, Manuel
AU  - Benito M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/05 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/04/12 [accepted]
AID - 10.1002/jcb.24577 [doi]
PST - aheadofprint
SO  - J Cell Biochem. 2013 Apr 20. doi: 10.1002/jcb.24577.

PMID- 23606411
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1097-0258 (Electronic)
IS  - 0277-6715 (Linking)
VI  - 32
IP  - 14
DP  - 2013 Jun 30
TI  - Estimating a marginal causal odds ratio in a case-control design: analyzing the
      effect of low birth weight on the risk of type 1 diabetes mellitus.
PG  - 2500-12
LID - 10.1002/sim.5826 [doi]
AB  - Estimation of marginal causal effects from case-control data has two
      complications: (i) confounding due to the fact that the exposure under study is
      not randomized, and (ii) bias from the case-control sampling scheme. In this
      paper, we study estimators of the marginal causal odds ratio, addressing these
      issues for matched and unmatched case-control designs when utilizing the
      knowledge of the known prevalence of being a case. The estimators are implemented
      in simulations where their finite sample properties are studied and
      approximations of their variances are derived with the delta method. Also, we
      illustrate the methods by analyzing the effect of low birth weight on the risk of
      type 1 diabetes mellitus using data from the Swedish Childhood Diabetes Register,
      a nationwide population-based incidence register. Copyright (c) 2013 John Wiley &
      Sons, Ltd.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
AD  - Department of Statistics, USBE, Umea University, SE-90187 Umea, Sweden.
FAU - Persson, Emma
AU  - Persson E
FAU - Waernbaum, Ingeborg
AU  - Waernbaum I
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - England
TA  - Stat Med
JT  - Statistics in medicine
JID - 8215016
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/05/02 [received]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/22 [aheadofprint]
AID - 10.1002/sim.5826 [doi]
PST - ppublish
SO  - Stat Med. 2013 Jun 30;32(14):2500-12. doi: 10.1002/sim.5826. Epub 2013 Apr 22.

PMID- 23606308
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
DP  - 2013 Apr 19
TI  - Pancreatic tissue resident mesenchymal stromal cell (MSC)-like cells as a source 
      of in vitro islet neogenesis.
LID - 10.1002/jcb.24572 [doi]
AB  - Insufficient beta-cell mass is a common denominator for both type1 and type 2
      diabetes. In vitro generation of beta-cells from islet precursor cells, exocrine 
      cells or ductal epithelia provide an alternative source of insulin-producing
      cells. However the presence of multipotent precursor cells within the pancreas is
      also deliberated. In this study we isolated mesenchymal stromal cell (MSC) - like
      cells from adult mouse pancreas by collagenase digestion. We used Knockout DMEM
      for our isolation procedure and the floating islets and acini were removed after 
      48 h. This strategy permitted the adhesion of stromal cells with typical
      mesenchymal morphology. These cells not only expressed MSC-specific markers like 
      Sca-1, CD90.2, CD73 and CD44 but also generated osteocytes, adipocytes and
      neurons when induced with specific growth media. Upon exposure to islet
      differentiation serum-free cocktail a significant upregulation of pancreatic
      markers like Nkx2.2, Nkx6.1, Pdx1, insulin and somatostatin was seen. The
      differentiated islet-like cell aggregates (ICAs) secreted insulin which increased
      over the days in culture in presence of basal glucose levels. Taken together, our
      data strongly indicate that there is a tissue-resident precursor population
      within the pancreas that can be exploited for islet neogenesis in vitro. J. Cell.
      Biochem. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Manipal Institute of Regenerative Medicine (MIRM), Manipal University, Bangalore,
      560065, India.
FAU - Gopurappilly, Renjitha
AU  - Gopurappilly R
FAU - Bhat, Vijay
AU  - Bhat V
FAU - Bhonde, Ramesh
AU  - Bhonde R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/12/05 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/04/11 [accepted]
AID - 10.1002/jcb.24572 [doi]
PST - aheadofprint
SO  - J Cell Biochem. 2013 Apr 19. doi: 10.1002/jcb.24572.

PMID- 23606271
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1098-240X (Electronic)
IS  - 0160-6891 (Linking)
DP  - 2013 Apr 19
TI  - Testing the efficacy of culturally adapted coping skills training for Chinese
      American immigrants with type 2 diabetes using community-based participatory
      research.
LID - 10.1002/nur.21543 [doi]
AB  - Chinese Americans demonstrate greater prevalence of diabetes than non-Hispanic
      whites and find standard diabetes care disregards their cultural health beliefs. 
      Academic researchers and Chinatown agencies collaborated to culturally adapt and 
      test an efficacious cognitive-behavioral intervention using community-based
      participatory research. Using a delayed-treatment repeated-measures design, 145
      adult Chinese immigrants with Type 2 diabetes completed treatment. Immediate
      benefits of treatment were evident in the improvement (p < .05) in diabetes
      self-efficacy, diabetes knowledge, bicultural efficacy, family emotional and
      instrumental support, diabetes quality of life, and diabetes distress. Prolonged 
      benefits were evident in all changed variables 2 months post-intervention. The
      CBPR approach enabled the development of a culturally acceptable, efficacious
      behavioral intervention, and provides a model for working with communities that
      demonstrate health disparities. (c) 2013 Wiley Periodicals, Inc. Res Nurs Health.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Family Health Care Nursing, University of California San Francisco,
      2 Koret Way, Box 0606, San Francisco, CA 94143-0606.
FAU - Chesla, Catherine A
AU  - Chesla CA
FAU - Chun, Kevin M
AU  - Chun KM
FAU - Kwan, Christine M L
AU  - Kwan CM
FAU - Mullan, Joseph T
AU  - Mullan JT
FAU - Kwong, Yulanda
AU  - Kwong Y
FAU - Hsu, Lydia
AU  - Hsu L
FAU - Huang, Peggy
AU  - Huang P
FAU - Strycker, Lisa A
AU  - Strycker LA
FAU - Shum, Tina
AU  - Shum T
FAU - To, Diana
AU  - To D
FAU - Kao, Rudy
AU  - Kao R
FAU - Waters, Catherine M
AU  - Waters CM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Res Nurs Health
JT  - Research in nursing & health
JID - 7806136
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/02/12 [accepted]
AID - 10.1002/nur.21543 [doi]
PST - aheadofprint
SO  - Res Nurs Health. 2013 Apr 19. doi: 10.1002/nur.21543.

PMID- 23606120
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1559-0755 (Electronic)
IS  - 0257-277X (Linking)
DP  - 2013 Apr 19
TI  - Detecting multiple autoantibodies to diagnose autoimmune co-morbidity (multiple
      autoimmune syndromes and overlap syndromes): a challenge for the
      autoimmunologist.
AB  - In the last 15 years, the estimated prevalence of autoimmune diseases increased
      from about 4 to 9.4 %. Autoimmune co-morbidity (i.e., the association between two
      or more autoimmune diseases in the same patient) is present in 0.4-0.5 % of the
      worldwide population, more frequently in patients with multiple sclerosis,
      rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory
      bowel disease and vitiligo. The most common associations between autoimmune
      diseases define two clusters: the multiple autoimmune syndromes and overlap
      syndromes. This review highlights the importance of multiple antibody assays in
      the diagnosis of multiple autoimmune and overlap syndromes and summarizes the
      general conditions of autoantibody detection using the model of the five W's:
      why, who, what, when and where. These conditions represent a new challenge for
      clinical and laboratory autoimmunologists, who, in a multidisciplinary arena,
      cooperate in investigating and treating multiple autoimmune disorders.
AD  - Department of Laboratory Medicine, S. Maria degli Angeli Hospital, Pordenone,
      Italy.
FAU - Tozzoli, Renato
AU  - Tozzoli R
FAU - Sorrentino, Maria Concetta
AU  - Sorrentino MC
FAU - Bizzaro, Nicola
AU  - Bizzaro N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Immunol Res
JT  - Immunologic research
JID - 8611087
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1007/s12026-013-8418-7 [doi]
PST - aheadofprint
SO  - Immunol Res. 2013 Apr 19.

PMID- 23605903
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1179-6901 (Electronic)
IS  - 1174-5886 (Linking)
DP  - 2013 Apr 20
TI  - Efficacy and Safety of a Fixed Combination of Irbesartan/Hydrochlorothiazide in
      Chinese Patients with Moderate to Severe Hypertension.
AB  - BACKGROUND AND OBJECTIVES: In a multi-center, single-arm, prospective study, we
      investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide 
      combination in Chinese patients with moderate to severe hypertension. METHODS:
      Eligible patients were aged 18-75 years, with a blood pressure of 160-199 mmHg
      systolic or 100-119 mmHg diastolic during a 1-week wash-out phase off
      antihypertensive medication. The enrolled patients started antihypertensive
      treatment with irbesartan/hydrochlorothiazide 150 mg/12.5 mg once daily, with the
      possible addition of irbesartan 150 mg once daily and up-titration to
      irbesartan/hydrochlorothiazide 300 mg/25 mg once daily at 4 and 8 weeks of
      follow-up, respectively. The primary efficacy variable was the goal blood
      pressure-attaining rate at 12 weeks of follow-up (<140/90 mmHg, or <130/80 mmHg
      in patients with diabetes mellitus). RESULTS: In the intention-to-treat analysis 
      (n = 501) at 12 weeks of follow-up, the goal blood pressure-attaining rate was
      57.3 %, and the mean change in blood pressure from baseline was 27.8 mmHg [95 %
      confidence interval (CI) 26.4-29.1 mmHg; p < 0.001] systolic and 13.5 mmHg (95 % 
      CI 12.6-14.4 mmHg; p < 0.001) diastolic. Similar findings were observed in the
      per-protocol analysis (n = 449). The prevalence of microalbuminuria and left
      ventricular hypertrophy significantly (p </= 0.01) decreased from 33.4 %
      (150/449) and 50.4 % (215/427) at baseline to 23.4 % (105/447) and 41.3 %
      (176/427) at the end of follow-up, respectively. Four patients (2.0 %) reported a
      serious adverse event. CONCLUSION: The fixed irbesartan/hydrochlorothiazide
      combination may control blood pressure to the target level in about 60 % of
      Chinese patients with moderate to severe hypertension, with an acceptable safety 
      profile.
AD  - The Centre for Epidemiological Studies and Clinical Trials, The Shanghai
      Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School
      of Medicine, Ruijin 2nd Road 197, Shanghai, 200025, China.
FAU - Huang, Qi-Fang
AU  - Huang QF
FAU - Sheng, Chang-Sheng
AU  - Sheng CS
FAU - Li, Yan
AU  - Li Y
FAU - Ma, Gen-Shan
AU  - Ma GS
FAU - Dai, Qiu-Yan
AU  - Dai QY
FAU - Wang, Ji-Guang
AU  - Wang JG
CN  - on behalf of the INCENT Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Drugs R D
JT  - Drugs in R&D
JID - 100883647
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1007/s40268-013-0013-9 [doi]
PST - aheadofprint
SO  - Drugs R D. 2013 Apr 20.

PMID- 23605747
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1573-2649 (Electronic)
IS  - 0962-9343 (Linking)
DP  - 2013 Apr 19
TI  - Psychometric properties of the Norwegian version of the Audit of
      Diabetes-Dependent Quality of Life.
AB  - PURPOSE: To examine the psychometric properties of the Norwegian version of the
      Audit of Diabetes-Dependent Quality of Life version 18 (ADDQoL-18). METHODS: We
      assessed the reliability (Cronbach's alpha and intraclass correlations) and
      construct validity (confirmatory factor analysis and Pearson's correlation
      coefficients) of the instrument in a sample of 292 adults in Norway aged 42.3 (SD
      14.2) years. RESULTS: Internal consistency (Cronbach's alpha 0.88) and 4-week
      test-retest stability (intraclass correlations = 0.87) were satisfactory.
      Confirmatory factor analysis indicated that the one-factor structure of the
      ADDQoL-18 fits moderately (chi 2/df ratio = 3.846, comparative fit index = 0.792,
      root mean square error of approximation = 0.099). Standardized coefficients
      showed that all domains loaded >0.4, except for one item. We found a satisfactory
      correlation between the ADDQoL-18 and the SF-36 Health Survey summary scales
      (physical health and mental health summary scales) and the Hospital Anxiety and
      Depression Scale. The total score was negatively associated with HbA1c (r =
      -0.18; P < 0.002), indicating that lower scores on the ADDQoL-18 were related to 
      poorer glycemic control. Analysis regarding discriminant validity showed that the
      average weighted impact scores were mostly reduced among those reporting
      neuropathy and foot problems. CONCLUSIONS: The Norwegian version of the ADDQoL-18
      showed high internal consistency, good test-retest reliability, and similar
      construct validity as the original instrument. Overall, the results supported the
      ADDQoL-18 being feasible for use in Norway.
AD  - Centre for Evidence-Based Practice, Bergen University College, Postbox 7030,
      5020, Bergen, Norway, miv@hib.no.
FAU - Iversen, Marjolein M
AU  - Iversen MM
FAU - Espehaug, Birgitte
AU  - Espehaug B
FAU - Rokne, Berit
AU  - Rokne B
FAU - Haugstvedt, Anne
AU  - Haugstvedt A
FAU - Graue, Marit
AU  - Graue M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Qual Life Res
JT  - Quality of life research : an international journal of quality of life aspects of
      treatment, care and rehabilitation
JID - 9210257
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/09 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - 10.1007/s11136-013-0413-x [doi]
PST - aheadofprint
SO  - Qual Life Res. 2013 Apr 19.

PMID- 23605674
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1573-9104 (Electronic)
IS  - 0921-9668 (Linking)
VI  - 68
IP  - 2
DP  - 2013 Jun
TI  - Biological Activities of Extracts from Chinese Bayberry (Myrica rubra Sieb. et
      Zucc.): A Review.
PG  - 97-106
LID - 10.1007/s11130-013-0349-x [doi]
AB  - Chinese bayberry (Myrica rubra Sieb. et Zucc.) is a subtropical fruit tree native
      to China and other Asian countries, and culture of this Myricaceae plant has been
      recorded in Chinese history for more than 2000 years. Bayberry fruit is delicious
      with attractive color, flavor, and high economic value. Compared with other
      berries, bayberry fruit is a rich source of cyanidin-3-glucoside (C3G, e.g., 64.8
      mg/100 g fresh weight in 'Biqi' cultivar), which accounts for at least 85 % of
      the anthocyanins in the fruit. Bayberry is also a plant with high medicinal value
      since different organs have been used historically as folk medicines. Research
      efforts suggest bayberry extracts contain antioxidants that exhibit bioactivities
      counteracting inflammation, allergens, diabetes, cancer, bacterial infection,
      diarrhea and other health issues. Bayberry compounds have been isolated and
      characterized to provide a better understanding of the chemical mechanisms
      underlying the biological activities of bayberry extracts and to elaborate the
      structure-activity relationships. As the identification of compounds progresses, 
      studies investigating the in vivo metabolism and bioavailability as well as
      potential toxicity of bayberry extracts in animal models are receiving more
      attention. In addition, breeding and genetic studies of bayberry with high
      accumulation of health-benefiting compounds may provide new insight for the
      bayberry research and industry. This review is focused on the main medicinal
      properties reported and the possible pharmaceutically active compounds identified
      in different bayberry extracts.
AD  - Laboratory of Fruit Quality Biology/The State Agriculture Ministry Laboratory of 
      Horticultural Plant Growth, Development and Quality Improvement, Zhejiang
      University, Zijingang Campus, Hangzhou, 310058, People's Republic of China.
FAU - Sun, Chongde
AU  - Sun C
FAU - Huang, Huizhong
AU  - Huang H
FAU - Xu, Changjie
AU  - Xu C
FAU - Li, Xian
AU  - Li X
FAU - Chen, Kunsong
AU  - Chen K
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Plant Foods Hum Nutr
JT  - Plant foods for human nutrition (Dordrecht, Netherlands)
JID - 8803554
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1007/s11130-013-0349-x [doi]
PST - ppublish
SO  - Plant Foods Hum Nutr. 2013 Jun;68(2):97-106. doi: 10.1007/s11130-013-0349-x.

PMID- 23605606
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 51
IP  - 3
DP  - 2013
TI  - A woman with treated breast cancer, recent neurological symptoms and xanthoderma.
PG  - 195-8
AB  - We describe a 69-year-old-woman with antecedent of breast cancer and recent
      transitory neurological symptoms. Physical examination showed yellow to orange
      skin pigmentation, more conspicuous on her palms and soles, while discoloration
      changes were absent in the eye and oral mucous membranes. Routine laboratory
      findings were not indicative of hemolytic anemia, liver or bile disorders,
      nephrotic syndrome, hypothyroidism or diabetes mellitus. We emphasize the role of
      her excessive ingestion of papaw and tomato. These foods are rich in carotenoids 
      (beta-carotene and lycopene), which are associated with pigmentation disorders.
      The skin discoloration improved in about two months after correction of the
      inadequate diet. Major concerns about differential diagnosis of yellow skin
      pigmentation are also highlighted.
AD  - Catholic University (UCB) AND Armed Forces Hospital (HFA), Brasilia-DF, Brazil.
      vitorinomodesto@gmail.com
FAU - Santos, Vitorino Modesto dos
AU  - Santos VM
FAU - Camilo, Anna Gabriela Oliveira
AU  - Camilo AG
FAU - Souza, Leonardo Aquino de
AU  - Souza LA
FAU - Souza, Diogo Wagner da Silva de
AU  - Souza DW
FAU - Marinho, Christiane Silveira
AU  - Marinho CS
FAU - Monteiro, Lucas Maciel Rodrigues
AU  - Monteiro LM
LA  - eng
PT  - Journal Article
DEP - 20130406
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/08 [received]
PST - epublish
SO  - Acta Med Iran. 2013 Apr 6;51(3):195-8.

PMID- 23605454
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1869-6953 (Print)
DP  - 2013 Apr 19
TI  - Management of Type 2 Diabetes in Older People.
AB  - The prevalence of diabetes is increasing due to aging of the population and
      increasing obesity. In the developed world, there is an epidemiologic shift from 
      diabetes being a disease of middle age to being a disease of older people due to 
      increased life expectancy. In old age, diabetes is associated with high
      comorbidity burden and increased prevalence of geriatric syndromes in addition to
      the traditional vascular complications. Therefore, comprehensive geriatric
      assessment should be performed on initial diagnosis of diabetes. Due to the
      heterogeneous nature of older people with diabetes and variations in their
      functional status, comorbidities, and life expectancy, therapeutic interventions,
      and glycemic targets should be individualized taking into consideration patients'
      preferences and putting quality of life at the heart of their care plans.
AD  - Department of Elderly Medicine, Rotherham General Hospital, Moorgate Road,
      Rotherham, S60 2UD, UK, ahmedhafiz@hotmail.com.
FAU - Abdelhafiz, Ahmed H
AU  - Abdelhafiz AH
FAU - Sinclair, Alan J
AU  - Sinclair AJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/11 [received]
PHST- 2013/04/19 [aheadofprint]
AID - 10.1007/s13300-013-0020-4 [doi]
PST - aheadofprint
SO  - Diabetes Ther. 2013 Apr 19.

PMID- 23605247
OWN - NLM
STAT- In-Process
DA  - 20130603
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 30
IP  - 4
DP  - 2013 Apr
TI  - Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with
      metformin.
PG  - 337-53
AB  - INTRODUCTION: Use of dipeptidyl peptidase-4 (DPP-4) inhibitors is prevalent for
      the treatment of type 2 diabetes since they have fewer adverse effects compared
      with other non-insulin medications currently available; however, as monotherapy, 
      the glycosylated hemoglobin (HbA1c)-lowering power of these agents is moderate.
      The aim of this article is to evaluate the current literature regarding the
      safety and efficacy of DPP-4 inhibitors in combination with metformin. METHODS: A
      literature search was conducted through MEDLINE (from 1950 to October 2012),
      PubMed (from 1966 to October 2012), EMBASE (from 1966 to October 2012), and
      International Pharmaceutical Abstracts (from 1970 to October 2012) using the
      search terms "sitagliptin," "linagliptin," "alogliptin," "vildagliptin,"
      "saxagliptin," and "metformin." Studies that did not evaluate the DPP-4
      inhibitors in combination with metformin and those that were not phase 3, were
      excluded. RESULTS: Many of the studies evaluated DPP-4 inhibitors in combination 
      with metformin versus glucagon-like peptide-1 (GLP-1) agonists, placebo, DPP-4
      inhibitors as monotherapy, thiazolidinediones, and sulfonylureas. The results of 
      these noninferiority trials were that DPP-4 inhibitors as a whole are noninferior
      to either each other or other agents except for GLP-1 agonists. Also, in
      superiority studies, GLP-1 agonists proved to have greater HbA1c lowering.
      CONCLUSION: In summary, DPP-4 inhibitors play a vital role in the treatment of
      diabetes. They have relatively limited adverse effects, especially regarding
      hypoglycemia. DPP-4 inhibitors in combination with metformin are generally well
      tolerated and are available as combination products to reduce pill burden and
      enhance compliance. The limitations to DPP-4 inhibitors are the lack of outcomes 
      data and more limited HbA1c lowering than other medications currently approved
      for the treatment of type 2 diabetes. However, as previously stated,
      thiazolidinediones, glinides, sulfonylureas, pramlinitide, and GLP-1 agonists are
      all quite beneficial in HbA1c lowering but are not without major adverse effects.
      Therefore, DPP-4 inhibitors have a vital role as an oral add-on agent for the
      treatment of type 2 diabetes.
AD  - Department of Pharmacy Practice, Nova Southeastern University, College of
      Pharmacy, 3200 South University Drive, Ft. Lauderdale, FL 33328, USA.
      afass@nova.edu
FAU - Fass, Andrea D
AU  - Fass AD
FAU - Gershman, Jennifer A
AU  - Gershman JA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
SB  - T
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/02/05 [received]
PHST- 2013/04/15 [aheadofprint]
AID - 10.1007/s12325-013-0023-6 [doi]
PST - ppublish
SO  - Adv Ther. 2013 Apr;30(4):337-53.

PMID- 23605179
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 0303-4240 (Print)
IS  - 0303-4240 (Linking)
DP  - 2013 Apr 19
TI  - Spices: The Savory and Beneficial Science of Pungency.
AB  - Spicy food does not only provide an important hedonic input in daily life, but
      has also been anedoctically associated to beneficial effects on our health. In
      this context, the discovery of chemesthetic trigeminal receptors and their spicy 
      ligands has provided the mechanistic basis and the pharmacological means to
      investigate this enticing possibility. This review discusses in molecular terms
      the connection between the neurophysiology of pungent spices and the "systemic"
      effects associated to their trigeminality. It commences with a cultural and
      historical overview on the Western fascination for spices, and, after analysing
      in detail the mechanisms underlying the trigeminality of food, the main dietary
      players from the transient receptor potential (TRP) family of cation channels are
      introduced, also discussing the "alien" distribution of taste receptors outside
      the oro-pharingeal cavity. The modulation of TRPV1 and TRPA1 by spices is next
      described, discussing how spicy sensations can be turned into hedonic pungency,
      and analyzing the mechanistic bases for the health benefits that have been
      associated to the consumption of spices. These include, in addition to a
      beneficial modulation of gastro-intestinal and cardio-vascular function,
      slimming, the optimization of skeletal muscle performance, the reduction of
      chronic inflammation, and the prevention of metabolic syndrome and diabetes. We
      conclude by reviewing the role of electrophilic spice constituents on cancer
      prevention in the light of their action on pro-inflammatory and pro-cancerogenic 
      nuclear factors like NFkappaB, and on their interaction with the electrophile
      sensor protein Keap1 and the ensuing Nrf2-mediated transcriptional activity.
      Spicy compounds have a complex polypharmacology, and just like any other
      bioactive agent, show a balance of beneficial and bad actions. However, at least 
      for moderate consumption, the balance seems definitely in favour of the positive 
      side, suggesting that a spicy diet, a caveman-era technology, could be seriously 
      considered in addition to caloric control and exercise as a measurement to
      prevent and control many chronic diseases associate to malnutrition from a
      Western diet.
AD  - KU Leuven Department of Cellular and Molecular Medicine, Laboratory of Ion
      Channel Research, Leuven, Belgium, bernd.nilius@med.kuleuven.be.
FAU - Nilius, Bernd
AU  - Nilius B
FAU - Appendino, Giovanni
AU  - Appendino G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Rev Physiol Biochem Pharmacol
JT  - Reviews of physiology, biochemistry and pharmacology
JID - 0434624
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1007/112_2013_11 [doi]
PST - aheadofprint
SO  - Rev Physiol Biochem Pharmacol. 2013 Apr 19.

PMID- 23605125
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 2240-2993 (Electronic)
IS  - 0300-9009 (Linking)
DP  - 2013 Apr 20
TI  - Intrasellar cysticercosis: a systematic review.
AB  - The objective of this study was to review patients with intrasellar cysticercosis
      to outline the features of this form of neurocysticercosis. A MEDLINE and manual 
      search of patients with intrasellar cysticercosis were done. Abstracted data
      included clinical manifestations, neuroimaging findings, therapy, and outcome.
      Twenty-three patients were reviewed. Ophthalmological disturbances, including
      diminution of visual acuity and visual field defects following a chiasmatic
      pattern, were recorded in 67 % of cases. Endocrine abnormalities were found in 56
      % of patients (panhypopituitarism, hyperprolactinemia, diabetes insipidus, and
      isolated hypothyroidism). In addition, some patients complained of seizures or
      chronic headaches. Neuroimaging studies showed lesions confined to the sellar
      region in 47 % of cases. The remaining patients also had subarachnoid cysts
      associated or not with hydrocephalus, parenchymal brain cysts, or parenchymal
      brain calcifications. Thirteen patients underwent surgical resection of the
      sellar cyst through a craniotomy in nine cases and by the transsphenoidal
      approach in four. Visual acuity or visual field defects improved in only two of
      these patients. Five patients were treated with cysticidal drugs without
      improvement. Intrasellar cysticercosis is rare and probably under-recognized.
      Clinical manifestations resemble those caused by pituitary tumors, cysts, or
      other granulomatous lesions. Neuroimaging findings are of more value when
      intrasellar cysts are associated with other forms of neurocysticercosis, such as 
      basal subarachnoid cysts or hydrocephalus. Prompt surgical resection is mandatory
      to reduce the risk of permanent loss of visual function. There seems to be no
      role for cysticidal drug therapy in these cases.
AD  - School of Medicine, Universidad Espiritu Santo - Ecuador, Guayaquil, Ecuador,
      oscardelbrutto@hotmail.com.
FAU - Del Brutto, Oscar H
AU  - Del Brutto OH
FAU - Del Brutto, Victor J
AU  - Del Brutto VJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Acta Neurol Belg
JT  - Acta neurologica Belgica
JID - 0247035
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/02 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/04/20 [aheadofprint]
AID - 10.1007/s13760-013-0199-1 [doi]
PST - aheadofprint
SO  - Acta Neurol Belg. 2013 Apr 20.

PMID- 23605082
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 139
IP  - 1
DP  - 2013 May
TI  - Comorbidities and breast cancer survival: a report from the Shanghai Breast
      Cancer Survival Study.
PG  - 227-35
LID - 10.1007/s10549-013-2521-2 [doi]
AB  - We investigated the association of major comorbidities with breast cancer
      outcomes using the Shanghai Breast Cancer Survival Study, a population-based,
      prospective cohort study of Chinese women diagnosed with breast cancer. Analyses 
      included 4,664 women diagnosed with stage I-III incident breast cancer aged 20-75
      years (median age = 51) during 2002-2006. Women were interviewed at 3-11 months
      post-diagnosis (median = 6.4) and followed up by in-person interviews and linkage
      with the vital statistics registry. Multivariable hazard ratios (HRs) and (95 %
      confidence intervals (CIs)) for the associations of comorbidities with breast
      cancer outcomes were estimated using Cox regression models. After a median
      follow-up of 5.3 years (range: 0.64-8.9), 647 women died (516 from breast cancer)
      and 632 recurrence/metastases were documented. The main comorbidities reported
      included: hypertension (22.4 %), chronic gastritis (14.3 %), diabetes mellitus
      (6.2 %), chronic bronchitis/asthma (5.8 %), coronary heart disease (5.0 %), and
      stroke (2.2 %). Diabetes was associated with increased risk of total mortality
      (adjusted HR: 1.40 (1.06-1.85)) and non-breast cancer mortality (adjusted HR:
      2.64 (1.63-4.27)), but not breast cancer-specific mortality (adjusted HR: 0.98
      (0.68-1.41)), adjusting for socio-demographics, clinical characteristics,
      selected lifestyle factors, and other comorbidities. Women with a history of
      stroke had a non-significant increased risk of total mortality (adjusted HR: 1.42
      (0.91-2.22)) and a significant increased risk of non-breast cancer mortality
      (adjusted HR: 2.52 (1.33-4.78)), but not breast cancer-specific mortality
      (adjusted HR: 0.78 (0.38-1.62)). Overall, none of the comorbidities investigated 
      were significantly associated with recurrence. In this large prospective cohort
      of breast cancer survivors, diabetes was significantly associated with increased 
      risk of total and non-breast cancer mortality, and history of stroke was
      associated with increased risk of non-breast cancer mortality.
AD  - Division of Epidemiology, Department of Medicine, Vanderbilt University School of
      Medicine, Nashville, TN, 37203-1738, USA, sarah.nechuta@vanderbilt.edu.
FAU - Nechuta, Sarah
AU  - Nechuta S
FAU - Lu, Wei
AU  - Lu W
FAU - Zheng, Ying
AU  - Zheng Y
FAU - Cai, Hui
AU  - Cai H
FAU - Bao, Ping-Ping
AU  - Bao PP
FAU - Gu, Kai
AU  - Gu K
FAU - Zheng, Wei
AU  - Zheng W
FAU - Shu, Xiao Ou
AU  - Shu XO
LA  - eng
GR  - K12 ES015855/ES/NIEHS NIH HHS/United States
GR  - R01 CA118229/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20130419
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/06 [received]
PHST- 2013/04/01 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - 10.1007/s10549-013-2521-2 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2013 May;139(1):227-35. doi: 10.1007/s10549-013-2521-2. 
      Epub 2013 Apr 19.

PMID- 23605050
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1559-0720 (Electronic)
IS  - 0163-4984 (Linking)
VI  - 153
IP  - 1-3
DP  - 2013 Jun
TI  - Effects of High Iron and Glucose Concentrations over the Relative Expression of
      Bcl2, Bax, and Mfn2 in MIN6 Cells.
PG  - 390-5
LID - 10.1007/s12011-013-9666-z [doi]
AB  - Type 2 diabetes is characterized by hyperglycemia and oxidative stress.
      Hyperglycemia is linked to mitochondrial dysfunction and reduced beta-cell mass
      due to the reduced expression of genes such as Mfn2 as well as the participation 
      of the Bcl2 gene family, responsible for increased apoptosis. The purpose of this
      study was to describe the effect of different iron and/or glucose concentrations 
      over Mfn2, Bax, and Bcl2 expressions in a beta-pancreatic cell line (MIN6 cells).
      MIN6 cells were pre-incubated with different iron and/or glucose concentrations, 
      and the relative mRNA abundance of the Bcl2/Bax ratio and of Mfn2 genes was
      measured by qRT-PCR. Heme oxygenase (HO) activity, iron uptake, superoxide
      dismutase activity, and glutathione content were also determined. The Bcl2/Bax
      ratio increased and Mfn2 expression decreased in MIN6 cells after glucose
      stimulation. These effects were higher when glucose and iron were incubated
      together. Additionally, treatment with glucose/iron showed a higher HO activity. 
      Our study revealed that high glucose/Fe concentrations in MIN6 cells induced an
      increase of the Bcl2/Bax ratio, an indicator of increased cell apoptosis.
AD  - Micronutrient Laboratory, Nutrition Institute and Food Technology, University of 
      Chile, El Libano 5524, Macul, Santiago, Chile.
FAU - Fuentes, Marcela
AU  - Fuentes M
FAU - Andrews, Monica
AU  - Andrews M
FAU - Arredondo-Olguin, Miguel
AU  - Arredondo-Olguin M
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/07 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - 10.1007/s12011-013-9666-z [doi]
PST - ppublish
SO  - Biol Trace Elem Res. 2013 Jun;153(1-3):390-5. doi: 10.1007/s12011-013-9666-z.
      Epub 2013 Apr 19.

PMID- 23604820
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 0253-6269 (Electronic)
IS  - 0253-6269 (Linking)
DP  - 2013 Apr 21
TI  - Kinetics and molecular docking studies of pimarane-type diterpenes as protein
      tyrosine phosphatase (PTP1B) inhibitors from Aralia continentalis roots.
AB  - Since insulin sensitivity to cells is attributed to phosphorylation of the
      insulin receptor (IR), protein tyrosine phosphatase 1B (PTP1B), which
      dephosphorylates the tyrosine residues of IR proteins, is primarily responsible
      for insulin resistance in type 2 diabetes. Therefore, PTP1B inhibitors
      ameliorating the insulin-dependent signaling pathway are potential therapeutic
      candidates for the treatment and prevention of diabetes. As part of our
      continuous search for diterpenes derived from Aralia continentalis as potent
      PTP1B inhibitors, five active diterpenoids, including
      ent-pimara-8(14),15-diene-19-oic acid (1); 7-oxo-ent-pimara-8(14),15-diene-19-oic
      acid (2); 7beta-hydroxy-ent-pimara-8(14),15-diene-19-oic acid (3);
      ent-pimara-8(14),15-diene-19-ol (4); 8alpha-hydroxy-ent-pimara-15-en-19-ol (5);
      and ent-kaur-16-en-19-oic-acid (6) were investigated using the enzyme kinetic
      assay. With the exception of 1 showing mixed inhibition, compounds 2 and 4-6
      exhibited noncompetitive inhibition against PTP1B with K i values ranging
      3.29-12.86 muM. In particular, 2 with an oxo group in the C-7 position showed
      increased PTP1B inhibition compared to nonsubstituted 1. Based on the structure
      and activity relationship, the 3D docking simulations of 1, 2, and 3 were also
      performed. Compounds 1-3 showed negative binding energies of -5.3 to -6.1
      kcal/mol and a high affinity to PTP1B residues (Phe182 and Asp181 in the WPD
      loop; Cys215 in the active sites; Tyr46, Arg47, Asp48, Val49, Ser216, Ala217,
      Gly218, Ile219, Gly220, Arg221, Gln262, and Gln266 in the pocket site),
      indicating that they may stabilize the open form and generate tighter binding to 
      the catalytic sites of PTP1B. The enzymatic kinetics and docking results clearly 
      indicate the promising potential of pimarane-type diterpenes as PTP1B inhibitors.
AD  - Department of Food Science and Human Nutrition, Chonbuk National University,
      Jeonju, 561-756, South Korea.
FAU - Jung, Hyun Ah
AU  - Jung HA
FAU - Cho, Yoon Sook
AU  - Cho YS
FAU - Oh, Sang Ho
AU  - Oh SH
FAU - Lee, Sanghyuk
AU  - Lee S
FAU - Min, Byung-Sun
AU  - Min BS
FAU - Moon, Kyung Ho
AU  - Moon KH
FAU - Choi, Jae Sue
AU  - Choi JS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130421
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/29 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/04/21 [aheadofprint]
AID - 10.1007/s12272-013-0131-5 [doi]
PST - aheadofprint
SO  - Arch Pharm Res. 2013 Apr 21.

PMID- 23604584
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
VI  - 23
IP  - 7
DP  - 2013 Jul
TI  - Comparison Between Laparoscopic Sleeve Gastrectomy and Laparoscopic Adjustable
      Gastric Banding for Morbid Obesity: a Meta-analysis.
PG  - 980-6
LID - 10.1007/s11695-013-0893-3 [doi]
AB  - Bariatric surgery is now widely accepted for treatment of morbid obesity. This
      study compared the effects of laparoscopic sleeve gastrectomy (LSG) and
      laparoscopic adjustable gastric banding (LAGB) on excess weight loss (EWL) and
      type 2 diabetes mellitus (T2DM). PubMed and Embase were searched for publications
      concerning LAGB and LSG from 2000 to 2012, with the last search on August 17,
      2012. EWL and T2DM improvement over 6 and 12 months were pooled and compared by
      meta-analysis. Odds ratios (ORs) and mean differences were calculated with 95 %
      confidence intervals (CIs). Eleven studies involving 1,004 patients met the
      inclusion criteria. Compared with LAGB, LSG achieved greater EWL. The mean
      percentage EWL for LAGB was 33.9 % after 6 months in six studies and 37.8 % after
      12 months in four studies; for LSG, EWL was 50.6 % after 6 months and 51.8 %
      after 12 months in the same studies. LSG was also superior to LAGB in treating
      T2DM. In five studies, T2DM was improved in 42 of 68 (61.8 %) patients after LAGB
      and 66 of 80 (82.5 %) after LSG, representing a pooled OR of 0.34 (95 % CI
      0.16-0.73) and pooled mean differences of -12.55 (95 % CI -15.66 to -9.43) and
      -4.97 (95 % CI -7.58 to -8.36), respectively. LSG is more effective than LAGB in 
      morbid obesity, with higher percentage EWL and greater improvement in T2DM.
AD  - College of Basic Medicine, Nanjing Medical University, Nanjing, 211166, People's 
      Republic of China.
FAU - Wang, Sen
AU  - Wang S
FAU - Li, Ping
AU  - Li P
FAU - Sun, Xiao Fang
AU  - Sun XF
FAU - Ye, Nian Yuan
AU  - Ye NY
FAU - Xu, Ze Kuan
AU  - Xu ZK
FAU - Wang, Daorong
AU  - Wang D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
SB  - IM
PMC - PMC3671102
OID - NLM: PMC3671102
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1007/s11695-013-0893-3 [doi]
PST - ppublish
SO  - Obes Surg. 2013 Jul;23(7):980-6. doi: 10.1007/s11695-013-0893-3.

PMID- 23604551
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Efficacy and safety over 26 weeks of an oral treatment strategy including
      sitagliptin compared with an injectable treatment strategy with liraglutide in
      patients with type 2 diabetes mellitus inadequately controlled on metformin: a
      randomised clinical trial.
PG  - 1503-11
LID - 10.1007/s00125-013-2905-1 [doi]
AB  - AIMS/HYPOTHESIS: The aim of this work was to compare treatment intensification
      strategies based on orally administered vs injectable incretin-based
      antihyperglycaemic agents in patients with type 2 diabetes mellitus on metformin 
      monotherapy. METHODS: In a 26 week, open-label study, 653 patients (baseline
      HbA1c = 8.2% [66 mmol/mol]) were randomised at 111 sites in 21 countries in a 1:1
      ratio to a strategy using oral agents (starting with sitagliptin 100 mg/day) or a
      strategy using the injectable drug liraglutide starting at a dose of 0.6 mg/day, 
      up-titrated to 1.2 mg/day after 1 week. The following patients with type 2
      diabetes mellitus were recruited for the study: those aged 18-79 years, on a
      stable dose of metformin monotherapy >/=1,500 mg/day for >/=12 weeks, with an
      HbA1c >/=7.0% (53 mmol/mol) and </=11.0% (97 mmol/mol) and a fasting fingerstick 
      glucose (FFG) <15 mmol/l (<270 mg/dl) at the randomisation visit, deemed capable 
      by the investigator of using a Victoza pen injection device (containing 6 mg/ml
      liraglutide; Novo Nordisk, Bagsvaerd, Denmark). Women taking part in the study
      agreed to remain abstinent or use an acceptable method of birth control during
      the study. Randomisation was performed via a computer-generated allocation
      schedule using an interactive voice response system. After 12 weeks, patients on 
      sitagliptin with HbA1c >/= 7.0% (53 mmol/mol) and fasting glucose >6.1 mmol/l had
      their treatment intensified with glimepiride; patients on liraglutide with HbA1c 
      >/= 7.0% (53 mmol/mol) had the dose up-titrated to 1.8 mg/day. The primary
      analysis assessed whether the strategy using oral drugs was non-inferior to that 
      using an injectable drug regarding HbA1c change from baseline at week 26 using a 
      per-protocol (PP) population and a non-inferiority margin of 0.4%. RESULTS: In
      the PP population (522 patients included: oral strategy, n = 269; injectable
      strategy, n = 253) antihyperglycaemic therapy was intensified at week 12 in 50.2%
      and 28.5%, respectively. HbA1c decreased over 26 weeks in both treatment strategy
      groups, with a larger initial reduction at week 12 in the injectable strategy
      group. The LS mean change in HbA1c at week 26 was -1.3% (95% CI -1.4, -1.2) in
      the oral strategy group and -1.4% (95% CI -1.5, -1.3) in the injectable strategy 
      group; the study met the non-inferiority criterion. Both treatment regimens were 
      generally well tolerated; hypoglycaemia was reported more often with the oral
      strategy, while nausea, vomiting, diarrhoea and abdominal pain were reported more
      often with the injectable strategy. CONCLUSIONS/INTERPRETATION: An oral,
      incretin-based treatment strategy with sitagliptin and, if needed, glimepiride
      may be a good approach in many patients with type 2 diabetes mellitus for
      managing inadequate glycaemic control on metformin monotherapy, as compared with 
      an injectable treatment strategy with liraglutide. The oral and injectable
      strategies had similar effects on HbA1c and had good overall tolerability. Trial 
      registration ClinicalTrials.gov NCT01296412 Funding The study was sponsored by
      Merck Sharp & Dohme Corp., a subsidiary of Merck and Co., Inc., Whitehouse
      Station, NJ, USA.
AD  - University of Nantes, Nantes, France.
FAU - Charbonnel, B
AU  - Charbonnel B
FAU - Steinberg, H
AU  - Steinberg H
FAU - Eymard, E
AU  - Eymard E
FAU - Xu, L
AU  - Xu L
FAU - Thakkar, P
AU  - Thakkar P
FAU - Prabhu, V
AU  - Prabhu V
FAU - Davies, M J
AU  - Davies MJ
FAU - Engel, S S
AU  - Engel SS
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/12/20 [received]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - 10.1007/s00125-013-2905-1 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1503-11. doi: 10.1007/s00125-013-2905-1. Epub 2013
      Apr 19.

PMID- 23604500
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 0304-4602 (Print)
IS  - 0304-4602 (Linking)
VI  - 42
IP  - 3
DP  - 2013 Mar
TI  - Kidney cancer and diabetes mellitus: a population-based case-control study in
      Taiwan.
PG  - 120-4
AB  - INTRODUCTION: The purpose of this study was to explore whether diabetes mellitus 
      (DM) correlates with the risk of kidney cancer in Taiwan. MATERIALS AND METHODS: 
      We designed a population-based case-control study from the Taiwan National Health
      Insurance Database, which consisted of 116 patients with newly diagnosed kidney
      cancer as cases and 464 subjects without kidney cancer as controls in 2000 to
      2009. Both cases and controls were aged >/=20 years. Baseline comorbidities were 
      compared between kidney cancer cases and controls. RESULTS: Multivariable
      analysis showed no association was detected between DM and kidney cancer (OR
      1.06, 95% CI, 0.58 to 1.94). Hypertension (OR 2.05, 95% CI, 1.23 to 3.42),
      chronic kidney diseases (OR 2.57, 95% CI, 1.23 to 5.37), cystic kidney diseases
      (OR 18.6, 95% CI, 1.84 to 187.6) and kidney stones (OR 4.02, 95% CI, 2.43 to
      6.66) were significant comorbidities associated with increased risk of kidney
      cancer. Use of alpha-glucosidase inhibitor was associated with increased risk of 
      kidney cancer (OR 4.31, 95% CI, 1.07 to 17.3). CONCLUSION: DM does not correlate 
      with the risk of kidney cancer. Hypertension, chronic kidney diseases, cystic
      kidney diseases, kidney stones and use of alpha-glucosidase inhibitors are
      associated with kidney cancer.
AD  - School of Medicine, China Medical University, Taichung, 404, Taiwan.
FAU - Lai, Shih Wei
AU  - Lai SW
FAU - Liao, Kuan Fu
AU  - Liao KF
FAU - Lai, Hsueh Chou
AU  - Lai HC
FAU - Tsai, Pang Yao
AU  - Tsai PY
FAU - Sung, Fung Chang
AU  - Sung FC
FAU - Chen, Pei Chun
AU  - Chen PC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Singapore
TA  - Ann Acad Med Singapore
JT  - Annals of the Academy of Medicine, Singapore
JID - 7503289
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PST - ppublish
SO  - Ann Acad Med Singapore. 2013 Mar;42(3):120-4.

PMID- 23604465
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1438-2199 (Electronic)
IS  - 0939-4451 (Linking)
DP  - 2013 Apr 21
TI  - Faox enzymes inhibited Maillard reaction development during storage both in
      protein glucose model system and low lactose UHT milk.
AB  - Fructosamines, also known as Amadori products, are formed by the condensation of 
      glucose with the amino group of amino acids or proteins. These compounds are
      precursors of advanced glycation end products (AGEs) that can be formed either
      endogenously during aging and diabetes, and exogenously in heat-processed food.
      The negative effects of dietary AGEs on human health as well as their negative
      impact on the quality of dairy products have been widely described, therefore
      specific tools able to prevent the formation of glycation products are needed.
      Two fructosamine oxidase enzymes isolated from Aspergillus sp. namely, Faox I and
      Faox II catalyze the oxidative deglycation of Amadori products representing a
      potential tool for inhibiting the Maillard reaction in dairy products. In this
      paper, the ability of recombinant Faox I and II in limiting the formation of
      carboxy-methyl lysine (CML) and protein-bound hydroxymethyl furfurol (b-HMF) in a
      commercial UHT low lactose milk and a beta-lactoglobulin (beta-LG) glucose model 
      system was investigated. Results show a consistent reduction of CML and b-HMF
      under all conditions. Faox effects were particularly evident on b-HMF formation
      in low lactose commercial milk. Peptide analysis of the beta-LG glucose system
      identified some peptides, derived from cyanogen bromide hydrolysis, as suitable
      candidates to monitor Faox action in milk-based products. All in all data
      suggested that non-enzymatic reactions in dairy products might be strongly
      reduced by implementing Faox enzymes.
AD  - Dipartimento di Scienza degli Alimenti, Universita degli Studi di Napoli Federico
      II Via Salute, Parco Gussone Superiore, Portici (Naples), Italy.
FAU - Troise, Antonio Dario
AU  - Troise AD
FAU - Dathan, Nina A
AU  - Dathan NA
FAU - Fiore, Alberto
AU  - Fiore A
FAU - Roviello, Giovanni
AU  - Roviello G
FAU - Di Fiore, Anna
AU  - Di Fiore A
FAU - Caira, Simonetta
AU  - Caira S
FAU - Cuollo, Marina
AU  - Cuollo M
FAU - De Simone, Giuseppina
AU  - De Simone G
FAU - Fogliano, Vincenzo
AU  - Fogliano V
FAU - Monti, Simona M
AU  - Monti SM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130421
TA  - Amino Acids
JT  - Amino acids
JID - 9200312
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/01 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/04/21 [aheadofprint]
AID - 10.1007/s00726-013-1497-x [doi]
PST - aheadofprint
SO  - Amino Acids. 2013 Apr 21.

PMID- 23604419
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130422
DCOM- 20130423
LR  - 20130507
IS  - 2044-6055 (Electronic)
VI  - 3
IP  - 4
DP  - 2013
TI  - Aspirin treatment and risk of first incident cardiovascular diseases in patients 
      with type 2 diabetes: an observational study from the Swedish National Diabetes
      Register.
LID - 10.1136/bmjopen-2013-002688 [doi]
LID - e002688 [pii]
AB  - OBJECTIVES: To investigate the benefits and risks associated with aspirin
      treatment in patients with type 2 diabetes and no previous cardiovascular disease
      (CVD) in clinical practice. DESIGN: Population-based cohort study between 2005
      and 2009, mean follow-up 3.9 years. SETTING: Hospital outpatient clinics and
      primary care in Sweden. PARTICIPANTS: Men and women with type 2 diabetes, free
      from CVD, including atrial fibrillation and congestive heart failure, at
      baseline, registered in the Swedish National Diabetes Register, with continuous
      low-dose aspirin treatment (n=4608) or no aspirin treatment (n=14 038). MAIN
      OUTCOME MEASURES: Risks of CVD, coronary heart disease (CHD), stroke, mortality
      and bleedings, associated with aspirin compared with no aspirin, were analysed in
      all patients and in subgroups by gender and estimated cardiovascular risk.
      Propensity scores were used to adjust for several baseline risk factors and
      characteristics at Cox regression, and the effect of unknown covariates was
      evaluated in a sensitivity analysis. RESULTS: There was no association between
      aspirin use and beneficial effects on risks of CVD or death. Rather, there was an
      increased risk of non-fatal/fatal CHD associated with aspirin; HR 1.19 (95% CI
      1.01 to 1.41), p=0.04. The increased risk of cardiovascular outcomes associated
      with aspirin was seen when analysing women separately; HR 1.41 (95% CI 1.07 to
      1.87), p=0.02, and HR 1.28 (95% CI 1.01 to 1.61), p=0.04, for CHD and CVD,
      respectively, but not for men separately. There was a trend towards increased
      risk of a composite of bleedings associated with aspirin, n=157; HR 1.41 (95% CI 
      0.99 to 1.99). CONCLUSIONS: The results support the trend towards more
      restrictive use of aspirin in patients with type 2 diabetes and no previous CVD. 
      More research is needed to explore the differences in aspirin's effects in women 
      and men.
AD  - Department of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, 
      Sweden.
FAU - Ekstrom, Nils
AU  - Ekstrom N
FAU - Cederholm, Jan
AU  - Cederholm J
FAU - Zethelius, Bjorn
AU  - Zethelius B
FAU - Eliasson, Bjorn
AU  - Eliasson B
FAU - Fharm, Eva
AU  - Fharm E
FAU - Rolandsson, Olov
AU  - Rolandsson O
FAU - Miftaraj, Mervete
AU  - Miftaraj M
FAU - Svensson, Ann-Marie
AU  - Svensson AM
FAU - Gudbjornsdottir, Soffia
AU  - Gudbjornsdottir S
LA  - eng
PT  - Journal Article
DEP - 20130420
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
PMC - PMC3641436
OID - NLM: PMC3641436
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:01
CRDT- 2013/04/23 06:00
PHST- 2013 [ppublish]
AID - bmjopen-2013-002688 [pii]
AID - 10.1136/bmjopen-2013-002688 [doi]
PST - epublish
SO  - BMJ Open. 2013 Apr 20;3(4). pii: e002688. doi: 10.1136/bmjopen-2013-002688. Print
      2013.

PMID- 23604291
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Linking)
DP  - 2013 Apr 20
TI  - Antiarrhythmic effects and ionic mechanisms of allicin on myocardial injury of
      diabetic rats induced by streptozotocin.
AB  - The aim of this study was to evaluate the antiarrhythmic effect of allicin (AL)
      on streptozotocin (STZ)-induced diabetic rats and explore the possible
      mechanisms. Hyperglycemia was induced in rats by single intraperitoneal injection
      of STZ (40 mg/kg). Three days after STZ treatment, the hyperglycemic rats (plasma
      glucose levels >/=16.7 mM) were administered with AL (4, 8, and 16 mg/kg) by
      intraperitoneal injection daily for 28 days. The fasting blood glucose levels
      were measured on every seventh day during the 28 days of treatment. The body
      weight and blood glucose levels were detected after 28 days. Antiarrhythmic
      effect of AL was observed in the diabetic rats induced by BaCl2. To determine the
      ionic mechanism in rat ventricular myocytes of AL, action potential duration
      (APD), L-type calcium current (ICa-L), and inward rectifier potassium current
      (IK1) were recorded by the whole cell-patch clamp technique. The expressions of
      L-type calcium channel protein alpha1C mRNA and cell potassium channels protein
      Kir2.1 mRNA were studied by RT-PCR. AL normalized the RR interval and QT interval
      in diabetic rats. AL obviously delayed the onset of ventricular arrhythmia and
      reduced the score of arrhythmia induced by BaCl2. Electrophysiological experiment
      revealed that AL could shorten APD through inhibition of ICa-L and enhancement of
      IK1. RT-PCR analysis indicated that long-term treatment with AL could decrease
      the expression of alpha1C mRNA and increase the expression of Kir2.1 mRNA. AL has
      antiarrhythmic effect in STZ-induced diabetic rats. It is tempting for the
      application of AL to be a useful therapeutic approach in diabetes with
      ventricular arrhythmia.
AD  - Department of Pharmacology, Harbin Medical University-Daqing, Daqing,
      Heilongjiang, 163319, China.
FAU - Huang, Wei
AU  - Huang W
FAU - Wang, Ye
AU  - Wang Y
FAU - Cao, Yong-Gang
AU  - Cao YG
FAU - Qi, Han-Ping
AU  - Qi HP
FAU - Li, Lei
AU  - Li L
FAU - Bai, Bing
AU  - Bai B
FAU - Liu, Yang
AU  - Liu Y
FAU - Sun, Hong-Li
AU  - Sun HL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/15 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/20 [aheadofprint]
AID - 10.1007/s00210-013-0872-1 [doi]
PST - aheadofprint
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr 20.

PMID- 23604062
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1349-9092 (Electronic)
IS  - 0917-5040 (Linking)
VI  - 23
IP  - 3
DP  - 2013 May 5
TI  - Classical and novel biomarkers for cardiovascular risk prediction in the United
      States.
PG  - 158-62
AB  - Cardiovascular risk prediction models based on classical risk factors identified 
      in epidemiologic cohort studies are useful in primary prevention of
      cardiovascular disease in individuals. This article briefly reviews aspects of
      cardiovascular risk prediction in the United States and efforts to evaluate novel
      risk factors. Even though many novel risk markers have been found to be
      associated with cardiovascular disease, few appear to improve risk prediction
      beyond the powerful, classical risk factors. A recent US consensus panel
      concluded that clinical measurement of certain novel markers for risk prediction 
      was reasonable, namely, hemoglobin A1c (in all adults), microalbuminuria (in
      patients with hypertension or diabetes), and C-reactive protein,
      lipoprotein-associated phospholipase, coronary calcium, carotid intima-media
      thickness, and ankle/brachial index (in patients deemed to be at intermediate
      cardiovascular risk, based on traditional risk factors).
AD  - Division of Epidemiology and Community Health, School of Public Health,
      University of Minnesota.
FAU - Folsom, Aaron R
AU  - Folsom AR
LA  - eng
PT  - Journal Article
DEP - 20130420
PL  - Japan
TA  - J Epidemiol
JT  - Journal of epidemiology / Japan Epidemiological Association
JID - 9607688
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/20 [aheadofprint]
AID - DN/JST.JSTAGE/jea/JE20120157 [pii]
PST - ppublish
SO  - J Epidemiol. 2013 May 5;23(3):158-62. Epub 2013 Apr 20.

PMID- 23604009
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1476-5365 (Electronic)
IS  - 0268-3369 (Linking)
DP  - 2013 Apr 22
TI  - Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a
      mismatched murine model.
LID - 10.1038/bmt.2013.60 [doi]
AB  - Because of the toxicity associated with myeloablative conditioning,
      nonmyeloablative regimens are increasingly being used in vulnerable patient
      populations. For patients with sickle cell disease, stable mixed chimerism has
      proven sufficient to reverse the phenotype. Because the vast majority of patients
      do not have an HLA-matched sibling, a safe nonmyeloablative regimen that could be
      applied to the haploidentical setting would be ideal. We employed a mismatched
      mouse model using BALB/c donors and C57BL/6 recipients. Recipient mice were
      conditioned with 200 cGy TBI and sirolimus or CSA with or without post transplant
      Cy (PT-Cy). Our data show that when sirolimus or PT-Cy alone is given to C57BL/6 
      recipients, donor cells are not detected. However, when sirolimus is administered
      for 15 or 31 days starting 1 day before or up to 6 days after transplant with
      PT-Cy, all mice maintain stable mixed chimerism. In contrast, conventional
      therapy employing CSA with or without PT-Cy does not result in stable mixed
      chimerism. Lastly, mice with stable mixed chimerism after sirolimus display
      decreased reactivity to donor Ag both in vitro and in vivo. These data identify a
      novel strategy for inducing mixed chimerism for the treatment of nonmalignant
      hematologic diseases.Bone Marrow Transplantation advance online publication, 22
      April 2013; doi:10.1038/bmt.2013.60.
AD  - Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood
      Institute/National Institute of Diabetes and Digestive and Kidney Diseases,
      National Institutes of Health, Bethesda, MD, USA.
FAU - Fitzhugh, C D
AU  - Fitzhugh CD
FAU - Weitzel, R P
AU  - Weitzel RP
FAU - Hsieh, M M
AU  - Hsieh MM
FAU - Phang, O A
AU  - Phang OA
FAU - Madison, C
AU  - Madison C
FAU - Luznik, L
AU  - Luznik L
FAU - Powell, J D
AU  - Powell JD
FAU - Tisdale, J F
AU  - Tisdale JF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/22 [aheadofprint]
AID - bmt201360 [pii]
AID - 10.1038/bmt.2013.60 [doi]
PST - aheadofprint
SO  - Bone Marrow Transplant. 2013 Apr 22. doi: 10.1038/bmt.2013.60.

PMID- 23604004
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 60
IP  - 5
DP  - 2013 May 31
TI  - Recent progress on the role of ChREBP in glucose and lipid metabolism [Review].
PG  - 543-55
AB  - Carbohydrate response element binding protein (ChREBP) is a transcription factor 
      activated by glucose that is highly expressed in liver, pancreatic beta-cells,
      brown and white adipose tissues, and muscle. We reported that hepatic suppression
      of the Chrebp gene improves hepatic steatosis, glucose intolerance, and obesity
      in genetically obese mice. Moreover, we have studied the role of ChREBP with
      special reference to feedforward and feedback looping in liver and pancreatic
      beta-cells. Recently, several groups reported that (1) glucose activates
      ChREBP-alpha transactivity and in turn ChREBP-alpha induces ChREBP-beta on both
      transcriptional and translational levels in adipose tissues, and (2) ChREBP
      regulates glucose transporter type 4 mRNA levels, which may affect glucose uptake
      in adipose tissues. Moreover, in adipose tissues of obese patients, Chrebpb mRNA 
      levels were much lower than those in lean subjects, while the levels were much
      higher in liver of obese patients than those in lean subjects. These findings
      suggest that Chrebpb mRNA levels are different in various tissues and probably in
      the stages of diabetes mellitus. Herein, we review recent progress in the study
      of ChREBP with special references to (1) the mechanisms regulating ChREBP
      transactivity (posttranslational modifications, intramolecular glucose sensing
      module, feedforward mechanism, and the feedback loop between ChREBP and its
      target genes), and (2) the role of ChREBP in liver, pancreatic islets and adipose
      tissues. Understanding the role of ChREBP in each tissue will provide important
      insight into the pathogenesis of metabolic syndrome.
AD  - University Hospital Center for Nutritional Support and Infection Control, Gifu
      University, Gifu 501-1194, Japan.
FAU - Iizuka, Katsumi
AU  - Iizuka K
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/19 [aheadofprint]
AID - DN/JST.JSTAGE/endocrj/EJ13-0121 [pii]
PST - ppublish
SO  - Endocr J. 2013 May 31;60(5):543-55. Epub 2013 Apr 19.

PMID- 23603996
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 5
IP  - 4
DP  - 2013
TI  - Selenium supranutrition: are the potential benefits of chemoprevention outweighed
      by the promotion of diabetes and insulin resistance?
PG  - 1349-65
LID - 10.3390/nu5041349 [doi]
AB  - Selenium was considered a toxin until 1957, when this mineral was shown to be
      essential in the prevention of necrotic liver damage in rats. The hypothesis of
      selenium chemoprevention is principally formulated by the observations that
      cancer incidence is inversely associated with selenium status. However, recent
      clinical and epidemiological studies demonstrate a role for some selenoproteins
      in exacerbating or promoting other disease states, specifically type 2 diabetes, 
      although other data support a role of selenium in stimulating insulin
      sensitivity. Therefore, it is clear that our understanding in the role of
      selenium in glucose metabolism and chemoprevention is inadequate and incomplete. 
      Research exploring the role of selenium in individual healthcare is of upmost
      importance and possibly will help explain how selenium is a double-edged sword in
      the pathologies of chronic diseases.
AD  - Department of Nutrition and Food Science, University of Maryland, College Park,
      MD 20742, USA.
FAU - Rocourt, Caroline R B
AU  - Rocourt CR
FAU - Cheng, Wen-Hsing
AU  - Cheng WH
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/05 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/07 [accepted]
AID - nu5041349 [pii]
AID - 10.3390/nu5041349 [doi]
PST - epublish
SO  - Nutrients. 2013 Apr 19;5(4):1349-65. doi: 10.3390/nu5041349.

PMID- 23603918
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 19
TI  - Secular Changes in U.S. Prediabetes Prevalence Defined by Hemoglobin A1c and
      Fasting Plasma Glucose: National Health and Nutrition Examination Surveys,
      1999-2010.
AB  - OBJECTIVEUsing a nationally representative sample of the civilian
      noninstitutionalized U.S. population, we estimated prediabetes prevalence and its
      changes during 1999-2010.RESEARCH DESIGN AND METHODSData were from 19,182
      nonpregnant individuals aged >/=12 years who participated in the 1999-2010
      National Health and Nutrition Examination Surveys. We defined prediabetes as
      hemoglobin A1c 5.7 to <6.5% (39 to <48 mmol/mol, A1C5.7) or fasting plasma
      glucose (FPG) 100 to <126 mg/dL (impaired fasting glucose [IFG]). We estimated
      the prevalence of prediabetes, A1C5.7, and IFG for 1999-2002, 2003-2006, and
      2007-2010. We calculated estimates age-standardized to the 2000 U.S. census
      population and used logistic regression to compute estimates adjusted for age,
      sex, race/ethnicity, poverty-to-income ratio, and BMI. Participants with
      self-reported diabetes, A1C >/=6.5% (>/=48 mmol/mol), or FPG >/=126 mg/dL were
      included.RESULTSAmong those aged >/=12 years, age-adjusted prediabetes prevalence
      increased from 27.4% (95% CI 25.1-29.7) in 1999-2002 to 34.1% (32.5-35.8) in
      2007-2010. Among adults aged >/=18 years, the prevalence increased from 29.2%
      (26.8-31.8) to 36.2% (34.5-38.0). As single measures among individuals aged >/=12
      years, A1C5.7 prevalence increased from 9.5% (8.4-10.8) to 17.8% (16.6-19.0), a
      relative increase of 87%, whereas IFG remained stable. These prevalence changes
      were similar among the total population, across subgroups, and after controlling 
      for covariates.CONCLUSIONSDuring 1999-2010, U.S. prediabetes prevalence increased
      because of increases in A1C5.7. Continuous monitoring of prediabetes is needed to
      identify, quantify, and characterize the population of high-risk individuals
      targeted for ongoing diabetes primary prevention efforts.
AD  - Division of Diabetes Translation, Centers for Disease Control and Prevention,
      Atlanta, Georgia.
FAU - Bullard, Kai McKeever
AU  - Bullard KM
FAU - Saydah, Sharon H
AU  - Saydah SH
FAU - Imperatore, Giuseppina
AU  - Imperatore G
FAU - Cowie, Catherine C
AU  - Cowie CC
FAU - Gregg, Edward W
AU  - Gregg EW
FAU - Geiss, Linda S
AU  - Geiss LS
FAU - Cheng, Yiling J
AU  - Cheng YJ
FAU - Rolka, Deborah B
AU  - Rolka DB
FAU - Williams, Desmond E
AU  - Williams DE
FAU - Caspersen, Carl J
AU  - Caspersen CJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - dc12-2563 [pii]
AID - 10.2337/dc12-2563 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 19.

PMID- 23603917
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 19
TI  - Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk
      Multi-Ethnic Population: The EpiDREAM Genetic Study.
AB  - OBJECTIVESTo determine if 16 single nucleotide polymorphisms (SNPs) associated
      with type 2 diabetes (T2DM) in Europeans are also associated with T2DM in South
      Asians and Latinos, and if they can add to the prediction of incident T2DM in a
      high-risk population.RESEARCH DESIGN AND METHODSIn the EpiDREAM prospective
      cohort study, physical measures, questionnaires, and blood samples were collected
      from 25,063 individuals at risk for dysglycemia. Sixteen SNPs that have been
      robustly associated with T2DM in Europeans were genotyped. Among 15,466 European,
      South Asian, and Latino subjects, we examined the association of these 16 SNPs
      alone and combined in a gene score with incident cases of T2DM (n = 1,016) that
      developed during 3.3 years of follow-up.RESULTSNine of the 16 SNPs were
      significantly associated with T2DM, and their direction of effect was consistent 
      across the three ethnic groups. The gene score was significantly higher among
      subjects who developed incident T2DM (cases vs. noncases: 16.47 [2.50] vs. 15.99 
      [2.56]; P = 0.00001). The gene score remained an independent predictor of
      incident T2DM with an odds ratio of 1.08 (95% CI, 1.05-1.11) per additional risk 
      allele after adjustment for T2DM risk factors. The gene score in those with no
      family history of T2DM was 16.02, whereas it was 16.19 in those with one parent
      with T2DM and it was 16.32 in those with two parents with T2DM (P trend =
      0.0004). The C statistic of T2DM risk factors was 0.708 (0.691-0.725) and
      increased only marginally to 0.714 (0.698-0.731) with the addition of the gene
      score (P for C statistic change = 0.0052).CONCLUSIONT2DM genetic associations are
      generally consistent across ethnic groups, and a gene score only adds marginal
      information to clinical factors for T2DM prediction.
AD  - Population Health Research Institute, McMaster University and Hamilton Health
      Sciences, Hamilton General Hospital, Hamilton, Ontario, Canada.
FAU - Anand, Sonia S
AU  - Anand SS
FAU - Meyre, David
AU  - Meyre D
FAU - Pare, Guillaume
AU  - Pare G
FAU - Bailey, Swneke D
AU  - Bailey SD
FAU - Xie, Changchun
AU  - Xie C
FAU - Zhang, Xiaohe
AU  - Zhang X
FAU - Montpetit, Alexandre
AU  - Montpetit A
FAU - Desai, Dipika
AU  - Desai D
FAU - Bosch, Jackie
AU  - Bosch J
FAU - Mohan, Viswanathan
AU  - Mohan V
FAU - Diaz, Rafael
AU  - Diaz R
FAU - McQueen, Matthew J
AU  - McQueen MJ
FAU - Cordell, Heather J
AU  - Cordell HJ
FAU - Keavney, Bernard
AU  - Keavney B
FAU - Yusuf, Salim
AU  - Yusuf S
FAU - Gaudet, Daniel
AU  - Gaudet D
FAU - Gerstein, Hertzel
AU  - Gerstein H
FAU - Engert, James C
AU  - Engert JC
CN  - On behalf of the EpiDREAM Genetics Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - dc12-2553 [pii]
AID - 10.2337/dc12-2553 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 19.

PMID- 23603815
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1546-170X (Electronic)
IS  - 1078-8956 (Linking)
VI  - 19
IP  - 5
DP  - 2013 May
TI  - Anatomical localization, gene expression profiling and functional
      characterization of adult human neck brown fat.
PG  - 635-9
LID - 10.1038/nm.3112 [doi]
AB  - The imbalance between energy intake and expenditure is the underlying cause of
      the current obesity and diabetes pandemics. Central to these pathologies is the
      fat depot: white adipose tissue (WAT) stores excess calories, and brown adipose
      tissue (BAT) consumes fuel for thermogenesis using tissue-specific uncoupling
      protein 1 (UCP1). BAT was once thought to have a functional role in rodents and
      human infants only, but it has been recently shown that in response to mild cold 
      exposure, adult human BAT consumes more glucose per gram than any other tissue.
      In addition to this nonshivering thermogenesis, human BAT may also combat weight 
      gain by becoming more active in the setting of increased whole-body energy
      intake. This phenomenon of BAT-mediated diet-induced thermogenesis has been
      observed in rodents and suggests that activation of human BAT could be used as a 
      safe treatment for obesity and metabolic dysregulation. In this study, we
      isolated anatomically defined neck fat from adult human volunteers and compared
      its gene expression, differentiation capacity and basal oxygen consumption to
      different mouse adipose depots. Although the properties of human neck fat vary
      substantially between individuals, some human samples share many similarities
      with classical, also called constitutive, rodent BAT.
AD  - 1] Section of Integrative Physiology and Metabolism, Research Division, Joslin
      Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA. [2].
FAU - Cypess, Aaron M
AU  - Cypess AM
FAU - White, Andrew P
AU  - White AP
FAU - Vernochet, Cecile
AU  - Vernochet C
FAU - Schulz, Tim J
AU  - Schulz TJ
FAU - Xue, Ruidan
AU  - Xue R
FAU - Sass, Christina A
AU  - Sass CA
FAU - Huang, Tian Liang
AU  - Huang TL
FAU - Roberts-Toler, Carla
AU  - Roberts-Toler C
FAU - Weiner, Lauren S
AU  - Weiner LS
FAU - Sze, Cathy
AU  - Sze C
FAU - Chacko, Aron T
AU  - Chacko AT
FAU - Deschamps, Laura N
AU  - Deschamps LN
FAU - Herder, Lindsay M
AU  - Herder LM
FAU - Truchan, Nathan
AU  - Truchan N
FAU - Glasgow, Allison L
AU  - Glasgow AL
FAU - Holman, Ashley R
AU  - Holman AR
FAU - Gavrila, Alina
AU  - Gavrila A
FAU - Hasselgren, Per-Olof
AU  - Hasselgren PO
FAU - Mori, Marcelo A
AU  - Mori MA
FAU - Molla, Michael
AU  - Molla M
FAU - Tseng, Yu-Hua
AU  - Tseng YH
LA  - eng
GR  - K23 DK081604/DK/NIDDK NIH HHS/United States
GR  - KL2 RR025757/RR/NCRR NIH HHS/United States
GR  - P30 DK036836/DK/NIDDK NIH HHS/United States
GR  - R01 DK077097/DK/NIDDK NIH HHS/United States
GR  - RC1 DK087317/DK/NIDDK NIH HHS/United States
GR  - UL1 RR025758/RR/NCRR NIH HHS/United States
PT  - Journal Article
DEP - 20130421
PL  - United States
TA  - Nat Med
JT  - Nature medicine
JID - 9502015
SB  - IM
PMC - PMC3650129
MID - NIHMS440353
OID - NLM: NIHMS440353 [Available on 11/01/13]
OID - NLM: PMC3650129 [Available on 11/01/13]
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PMCR- 2013/11/01 00:00
PHST- 2012/10/01 [received]
PHST- 2013/01/30 [accepted]
PHST- 2013/04/21 [aheadofprint]
AID - nm.3112 [pii]
AID - 10.1038/nm.3112 [doi]
PST - ppublish
SO  - Nat Med. 2013 May;19(5):635-9. doi: 10.1038/nm.3112. Epub 2013 Apr 21.

PMID- 23603786
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Linking)
DP  - 2013 Apr 18
TI  - Liver dysfunction in Turner syndrome and its relationship to exogenous oestrogen.
AB  - Liver dysfunction is commonly seen in women with Turner syndrome and can manifest
      in a variety of pathologies. In this review, we discuss the spectrum of liver
      anomalies associated with this syndrome, and discuss some possible aetiological
      factors and relationships with exogenous oestrogen.
AD  - Department of Diabetes and Endocrinology, University College London Hospitals,
      London, UK.
FAU - Lee, Marilyn C
AU  - Lee MC
FAU - Conway, Gerard S
AU  - Conway GS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1097/MEG.0b013e3283614b75 [doi]
PST - aheadofprint
SO  - Eur J Gastroenterol Hepatol. 2013 Apr 18.

PMID- 23603767
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1540-0514 (Electronic)
IS  - 1073-2322 (Linking)
VI  - 39
IP  - 6
DP  - 2013 Jun
TI  - Ensuring animal welfare while meeting scientific aims using a murine pneumonia
      model of septic shock.
PG  - 488-94
LID - 10.1097/SHK.0b013e3182939831 [doi]
AB  - With animal models, death as an intentional end point is ethically unacceptable. 
      However, in the study of septic shock, death is still considered the only
      relevant end point. We defined eight humane end points into four stages of
      severity (from healthy to moribund) and used to design a clinically relevant
      scoring tool, termed "the mouse clinical assessment score for sepsis" (M-CASS).
      The M-CASS was used to enable a consistent approach to the assessment of disease 
      severity. This allowed an ethical and objective assessment of disease after which
      euthanasia was performed, instead of worsening suffering. The M-CASS displayed a 
      high internal consistency (Cronbach alpha = 0.97) with a high level of agreement 
      and an intraclass correlation coefficient equal to 0.91. The plasma levels of
      cytokines and markers of oxidative stress were all associated with the M-CASS
      score (Kruskal-Wallis test, P < 0.05). The M-CASS allows tracking of disease
      progression and animal welfare requirements.
AD  - *Baker IDI Heart and Diabetes Institute; daggerInfectious Disease Department and 
      double daggerMicrobiology Unit, The Alfred Hospital; and section signANZIC
      Research Centre, Monash University, Melbourne, Victoria, Australia; and
      parallelINSERM, U1018, CESP Centre for research in Epidemiology and Population
      Health, Villejuif, France; and paragraph signUniversity Paris Sud 11, Villejuif, 
      France.
FAU - Huet, Olivier
AU  - Huet O
FAU - Ramsey, Debbie
AU  - Ramsey D
FAU - Miljavec, Sandra
AU  - Miljavec S
FAU - Jenney, Adam
AU  - Jenney A
FAU - Aubron, Cecile
AU  - Aubron C
FAU - Aprico, Andrea
AU  - Aprico A
FAU - Stefanovic, Nada
AU  - Stefanovic N
FAU - Balkau, Beverley
AU  - Balkau B
FAU - Head, Geoff A
AU  - Head GA
FAU - de Haan, Judy B
AU  - de Haan JB
FAU - Chin-Dusting, Jaye P F
AU  - Chin-Dusting JP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Shock
JT  - Shock (Augusta, Ga.)
JID - 9421564
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1097/SHK.0b013e3182939831 [doi]
PST - ppublish
SO  - Shock. 2013 Jun;39(6):488-94. doi: 10.1097/SHK.0b013e3182939831.

PMID- 23603635
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Linking)
DP  - 2013 Apr 18
TI  - Non-peptidyl insulin mimetics as a potential antidiabetic agent.
LID - S1359-6446(13)00099-8 [pii]
LID - 10.1016/j.drudis.2013.04.005 [doi]
AB  - Insulin has an important role in the maintenance of blood sugar. It is the only
      available therapeutic agent for the treatment of type 1 diabetes mellitus and
      there is a dire need for an oral substitute. Different categories of compounds
      including mono and di substituted benzoquinones, vanadium based compounds and
      natural products have been reported to cause insulin-like effects either by
      increasing phosphorylation of insulin receptor (IR) or inhibiting the protein
      tyrosine phosphatases. This review summarizes the development of various insulin 
      mimetics with special emphasis on their structure-activity relationships and
      various biological actions they produce.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Bioengineering and Drug Design Lab, Department of Biotechnology, Indian Institute
      of Technology Madras, Chennai 600036, India.
FAU - Nankar, Rakesh P
AU  - Nankar RP
FAU - Doble, Mukesh
AU  - Doble M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/02 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/04/11 [accepted]
AID - S1359-6446(13)00099-8 [pii]
AID - 10.1016/j.drudis.2013.04.005 [doi]
PST - aheadofprint
SO  - Drug Discov Today. 2013 Apr 18. pii: S1359-6446(13)00099-8. doi:
      10.1016/j.drudis.2013.04.005.

PMID- 23603633
OWN - NLM
STAT- In-Data-Review
DA  - 20130522
IS  - 1741-7899 (Electronic)
IS  - 1470-1626 (Linking)
VI  - 145
IP  - 6
DP  - 2013
TI  - Differences in the transcriptional profiles of human cumulus cells isolated from 
      MI and MII oocytes of patients with polycystic ovary syndrome.
PG  - 597-608
LID - 10.1530/REP-13-0005 [doi]
AB  - Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in 
      women. The abnormalities of endocrine and intra-ovarian paracrine interactions
      may change the microenvironment for oocyte development during the
      folliculogenesis process and reduce the developmental competence of oocytes in
      PCOS patients who are suffering from anovulatory infertility and pregnancy loss. 
      In this microenvironment, the cross talk between an oocyte and the surrounding
      cumulus cells (CCs) is critical for achieving oocyte competence. The aim of our
      study was to investigate the gene expression profiles of CCs obtained from PCOS
      patients undergoing IVF cycles in terms of oocyte maturation by using human
      Genome U133 Plus 2.0 microarrays. A total of 59 genes were differentially
      expressed in two CC groups. Most of these genes were identified to be involved in
      one or more of the following pathways: receptor interactions, calcium signaling, 
      metabolism and biosynthesis, focal adhesion, melanogenesis, leukocyte
      transendothelial migration, Wnt signaling, and type 2 diabetes mellitus.
      According to the different expression levels in the microarrays and their
      putative functions, six differentially expressed genes (LHCGR, ANGPTL1, TNIK,
      GRIN2A, SFRP4, and SOCS3) were selected and analyzed by quantitative RT-PCR
      (qRT-PCR). The qRT-PCR results were consistent with the microarray data.
      Moreover, the molecular signatures (LHCGR, TNIK, and SOCS3) were associated with 
      developmental potential from embryo to blastocyst stage and were proposed as
      biomarkers of embryo viability in PCOS patients. Our results may be clinically
      important as they offer a new potential strategy for competent oocyte/embryo
      selection in PCOS patients.
AD  - Reproductive Medicine Centre, Yuhuangding Hospital of Yantai, Affiliated Hospital
      of Qingdao Medical University, 20 Yuhuangding Road East, Yantai, Shandong,
      264000, People's Republic of China.
FAU - Huang, Xin
AU  - Huang X
FAU - Hao, Cuifang
AU  - Hao C
FAU - Shen, Xiaofang
AU  - Shen X
FAU - Liu, Xiaoyan
AU  - Liu X
FAU - Shan, Yinghua
AU  - Shan Y
FAU - Zhang, Yuhua
AU  - Zhang Y
FAU - Chen, Lili
AU  - Chen L
LA  - eng
PT  - Journal Article
DEP - 20130521
PL  - England
TA  - Reproduction
JT  - Reproduction (Cambridge, England)
JID - 100966036
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013 [ppublish]
AID - REP-13-0005 [pii]
AID - 10.1530/REP-13-0005 [doi]
PST - epublish
SO  - Reproduction. 2013 May 21;145(6):597-608. doi: 10.1530/REP-13-0005. Print 2013.

PMID- 23603521
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1873-7811 (Electronic)
IS  - 0272-7358 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Mar 25
TI  - A systematic review of internet-based self-help therapeutic interventions to
      improve distress and disease-control among adults with chronic health conditions.
PG  - 609-622
LID - S0272-7358(13)00044-5 [pii]
LID - 10.1016/j.cpr.2013.03.004 [doi]
AB  - The evidence base of internet-based self-help interventions has been rapidly
      growing for mental health conditions over the past decade. However, to date a
      systematic review of the application of this technology to chronic health
      conditions has not been reported. The objective of the present review was to
      therefore critically appraise the research on the efficacy of internet self-help 
      interventions for distress and disease outcomes in adults with physical health
      complaints. Electronic searches were conducted in Embase, CINAHL, MEDLINE and
      PsychINFO, and reference lists were examined. Twenty four studies met inclusion
      criteria, covering 8 health conditions. Across health conditions, consistent
      evidence was obtained that online therapeutic interventions were efficacious in
      improving disease-symptoms and control, with the exception of diabetes. Mixed
      evidence was obtained for distress outcomes: 3 health conditions demonstrated
      consistent benefit (irritable bowel syndrome, tinnitus, and one heterogeneous
      chronic illness population); one condition obtained moderate support (chronic
      pain); while results were not promising for diabetes. The limited research
      conducted among epilepsy, cancer, and chronic fatigue precluded conclusions from 
      being drawn. Few studies met all methodological quality criteria. This review
      demonstrates that internet-based self-help interventions hold guarded promise in 
      the amelioration of distress and disease-control, and further research
      implications are discussed.
CI  - Crown Copyright (c) 2013. Published by Elsevier Ltd. All rights reserved.
AD  - School of Psychology, Flinders University, Adelaide, SA 5001, Australia.
      Electronic address: lisa.beatty@flinders.edu.au.
FAU - Beatty, Lisa
AU  - Beatty L
FAU - Lambert, Sylvie
AU  - Lambert S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130325
TA  - Clin Psychol Rev
JT  - Clinical psychology review
JID - 8111117
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/19 [received]
PHST- 2013/02/13 [revised]
PHST- 2013/03/12 [accepted]
AID - S0272-7358(13)00044-5 [pii]
AID - 10.1016/j.cpr.2013.03.004 [doi]
PST - aheadofprint
SO  - Clin Psychol Rev. 2013 Mar 25;33(4):609-622. doi: 10.1016/j.cpr.2013.03.004.

PMID- 23603373
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1469-445X (Electronic)
IS  - 0958-0670 (Linking)
DP  - 2013 May 17
TI  - Inhibitory effect of zinc on glucose-stimulated zinc/insulin secretion in an
      insulin-secreting beta-cell line.
AB  - Diminished or inappropriate secretion of insulin is associated with type II
      diabetes. The cellular/molecular mechanism coupled with the regulation of insulin
      secretion is still under intense investigation. Divalent ion zinc (Zn2+) is
      co-packaged and co-secreted with insulin and is intimately involved in the
      process of insulin biosynthesis and the maturation of insulin secretory granules.
      The study reported here investigated: (1) glucose-stimulated zinc secretion
      (GSZS) and (2) the effect of zinc on glucose-stimulated insulin secretion (GSIS) 
      in the HIT-T15 pancreatic beta-cell line. Zinc secretion was measured using a
      newly developed fluorescent zinc imaging approach, and the insulin secretion was 
      measured using an ELISA assay. There was apparent granular-like zinc staining in 
      beta-cells. The application of glucose induced detectable zinc secretion or GSZS.
      Like GSIS, GSZS was dependent on glucose concentration (5-20 mM) and the presence
      of extracellular calcium. The application of a zinc chelator enhanced GSZS. When 
      brief paired-pulse glucose stimulations, which involve the initial glucose
      stimulation followed by a second round of glucose stimulation, were applied, zinc
      secretion or GSZS that followed the first pulse was inhibited. This inhibition
      was reversed by zinc chelation, suggesting a feedback mechanism on GSZS by zinc
      secreted from beta-cells. Finally, the application of zinc (50 muM) strongly
      inhibited GSIS as measured by ELISA assay. The present study suggests that
      insulin secretion is regulated by co-secreted zinc that may act as an autocrine
      inhibitory modulator.
AD  - Ohio University.
FAU - Slepchenko, Kira G
AU  - Slepchenko KG
FAU - James, Calvin B L
AU  - James CB
FAU - Li, Yang V
AU  - Li YV
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130517
TA  - Exp Physiol
JT  - Experimental physiology
JID - 9002940
OTO - NOTNLM
OT  - B-cell
OT  - Insulin
OT  - Nutrition
OT  - zinc
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/19 [aheadofprint]
PHST- 2013/04/26 [aheadofprint]
AID - expphysiol.2013.072348 [pii]
AID - 10.1113/expphysiol.2013.072348 [doi]
PST - aheadofprint
SO  - Exp Physiol. 2013 May 17.

PMID- 23603335
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1544-0591 (Electronic)
IS  - 0022-0345 (Linking)
VI  - 92
IP  - 6
DP  - 2013 Jun
TI  - Effects of free Fatty acids on human salivary gland epithelial cells.
PG  - 540-6
LID - 10.1177/0022034513487378 [doi]
AB  - Obesity and type 2 diabetes (T2D) are characterized by decreased insulin
      sensitivity and higher concentrations of free fatty acids (FFAs) in plasma. Among
      FFAs, saturated fatty acids (SFAs), such as palmitate, have been proposed to
      promote inflammatory responses. Primary Sjogren's syndrome (SS) is an autoimmune 
      disease characterized by inflammatory mononuclear cell infiltration and
      destruction of epithelial cells in the salivary and lacrimal glands. IL-6
      production and alpha-fodrin degradation are increased in salivary gland
      epithelial cells of patients with primary SS. Although previous studies have
      shown a link between SS and either dyslipidemia or T2D, little is known about the
      clinical significance of FFAs in primary SS. Here we report that SFAs, but not
      unsaturated fatty acids, induced IL-6 production via NF-kappaB and p38 MAPK
      activation in human salivary gland epithelial cells. Moreover, palmitate induced 
      apoptosis and alpha-fodrin degradation by caspase-3 activation. Unlike salivary
      gland epithelial cells, induction of IL-6 production and the degradation of
      alpha-fodrin in response to palmitate were undetectable in squamous carcinoma
      cells and keratinocytes. Taken together, SFAs induced IL-6 production and
      alpha-fodrin degradation in salivary gland epithelial cells, implicating a
      potential link between the pathogenesis of primary SS and SFAs level in plasma.
AD  - Clinical Research Center for Diabetes, Tokushima University Hospital, 2-50-1
      Kuramoto-cho, Tokushima 770-8503, Japan.
FAU - Shikama, Y
AU  - Shikama Y
FAU - Ishimaru, N
AU  - Ishimaru N
FAU - Kudo, Y
AU  - Kudo Y
FAU - Bando, Y
AU  - Bando Y
FAU - Aki, N
AU  - Aki N
FAU - Hayashi, Y
AU  - Hayashi Y
FAU - Funaki, M
AU  - Funaki M
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - United States
TA  - J Dent Res
JT  - Journal of dental research
JID - 0354343
SB  - D
SB  - IM
OTO - NOTNLM
OT  - Sjögren’s syndrome
OT  - alpha-fodrin
OT  - apoptosis
OT  - interleukin-6
OT  - lipids
OT  - palmitate
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/19 [aheadofprint]
AID - 0022034513487378 [pii]
AID - 10.1177/0022034513487378 [doi]
PST - ppublish
SO  - J Dent Res. 2013 Jun;92(6):540-6. doi: 10.1177/0022034513487378. Epub 2013 Apr
      19.

PMID- 23603250
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1532-2742 (Electronic)
IS  - 0163-4453 (Linking)
DP  - 2013 Apr 18
TI  - Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in
      subjects with diabetes mellitus.
LID - S0163-4453(13)00099-6 [pii]
LID - 10.1016/j.jinf.2013.04.010 [doi]
AB  - OBJECTIVE: To evaluate varicella zoster virus-specific cell-mediated immunity and
      humoral immunogenicity against the herpes zoster vaccine, which is licensed as
      the Live Varicella Vaccine (Oka Strain) in Japan, in elderly people with or
      without diabetes mellitus. METHODS: A pilot study was conducted between May 2010 
      and November 2010 at Kitano Hospital, a general hospital in the city of Osaka in 
      Japan. A varicella skin test, interferon-gamma enzyme-linked immunospot assay and
      immunoadherence hemagglutination tests were performed 0, 3, and 6 months after
      vaccination. Vaccine safety was also assessed using questionnaires for 42 days
      and development of zoster during the one-year observational period. We enrolled
      10 healthy volunteers and 10 patients with diabetes mellitus aged 60-70 years.
      RESULTS: The live herpes zoster vaccine boosted virus-specific, cell-mediated and
      humoral immunity between elderly people, with or without diabetes. Moreover, no
      systemic adverse reaction was found. None of the study participants developed
      herpes zoster. CONCLUSION: The live herpes zoster vaccine was used safely. It
      effectively enhanced specific immunity to varicella zoster virus in older people 
      with or without diabetes mellitus.
CI  - Copyright (c) 2013 The British Infection Association. Published by Elsevier Ltd. 
      All rights reserved.
AD  - Department of Infectious Diseases, Kitano Hospital, The Tazuke Kofukai Medical
      Research Institute, 2-4-20 Ohgimachi, Kitaku, Osaka 530-8480, Japan. Electronic
      address: ahata@kitano-hp.or.jp.
FAU - Hata, Atsuko
AU  - Hata A
FAU - Inoue, Fukue
AU  - Inoue F
FAU - Yamasaki, Midori
AU  - Yamasaki M
FAU - Fujikawa, Jun
AU  - Fujikawa J
FAU - Kawasaki, Yukiko
AU  - Kawasaki Y
FAU - Hamamoto, Yoshiyuki
AU  - Hamamoto Y
FAU - Honjo, Sachiko
AU  - Honjo S
FAU - Moriishi, Eiko
AU  - Moriishi E
FAU - Mori, Yasuko
AU  - Mori Y
FAU - Koshiyama, Hiroyuki
AU  - Koshiyama H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Infect
JT  - The Journal of infection
JID - 7908424
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/02 [received]
PHST- 2013/03/27 [revised]
PHST- 2013/04/11 [accepted]
AID - S0163-4453(13)00099-6 [pii]
AID - 10.1016/j.jinf.2013.04.010 [doi]
PST - aheadofprint
SO  - J Infect. 2013 Apr 18. pii: S0163-4453(13)00099-6. doi:
      10.1016/j.jinf.2013.04.010.

PMID- 23603201
OWN - NLM
STAT- Publisher
DA  - 20130426
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
DP  - 2013 Apr 17
TI  - Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin
      induced Alzheimer's disease.
LID - S0028-3908(13)00145-7 [pii]
LID - 10.1016/j.neuropharm.2013.04.008 [doi]
AB  - Type 2 diabetes (T2D) is one of the major risk factors associated with
      Alzheimer's disease (AD). Recent studies have found similarities in molecular
      mechanisms that underlie the respective degenerative developments in the two
      diseases. Pharmacological agents, such as dipeptidyl peptidase-4 (DPP-4)
      inhibitors, which increase the level of glucagon-like peptide-1 (GLP-1) and
      ameliorate T2D, have become valuable candidates as disease modifying agents in
      the treatment of AD. In addition, endogenous GLP-1 levels decrease amyloid beta
      (Abeta) peptide and tau phosphorylation in AD. The present study examines the
      efficacy of Saxagliptin, a DPP-4 inhibitor in a streptozotocin (STZ) induced rat 
      model of AD. Three months following induction of AD by intracerebral
      administration of streptozotocin, animals were orally administered Saxagliptin
      (0.25, 0.5 and 1 mg/kg) for 60 days. The effect of the DPP-4 inhibitor on
      hippocampal GLP-1 levels, Abeta burden, tau phosphorylation, inflammatory markers
      and memory retention were evaluated. The results reveal an attenuation of Abeta, 
      tau phosphorylation and inflammatory markers and an improvement in hippocampal
      GLP-1 and memory retention following treatment. This remarkable therapeutic
      effect of Saxagliptin mediated through DPP-4 inhibition demonstrates a unique
      mechanism for Abeta and tau clearance by increasing GLP-1 levels and reverses the
      behavioural deficits and pathology observed in AD.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Department of Pharmacognosy, JSS College of Pharmacy, Udhagamandalam, Tamilnadu
      643001, India. Electronic address: jayasankar87@hotmail.com.
FAU - Jayasankar, Kosaraju
AU  - Jayasankar K
FAU - Chakravarthi, G Chaitanya
AU  - Chakravarthi GC
FAU - Khatwal, Rizwan Basha
AU  - Khatwal RB
FAU - Dubala, Anil
AU  - Dubala A
FAU - Chinni, Santhivardhan
AU  - Chinni S
FAU - Holsinger, R M Damian
AU  - Holsinger RM
FAU - Subba Rao, M V S S T
AU  - Subba Rao MV
FAU - Satish Kumar, M N
AU  - Satish Kumar MN
FAU - Duraiswamy, Basavan
AU  - Duraiswamy B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/29 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/04/05 [accepted]
AID - S0028-3908(13)00145-7 [pii]
AID - 10.1016/j.neuropharm.2013.04.008 [doi]
PST - aheadofprint
SO  - Neuropharmacology. 2013 Apr 17. pii: S0028-3908(13)00145-7. doi:
      10.1016/j.neuropharm.2013.04.008.

PMID- 23603139
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 92
IP  - 22
DP  - 2013 Jun 13
TI  - Neovascularization in diabetes and its complications. Unraveling the angiogenic
      paradox.
PG  - 1037-45
LID - 10.1016/j.lfs.2013.04.001 [doi]
LID - S0024-3205(13)00216-6 [pii]
AB  - Diabetes mellitus (DM) is a chronic metabolic disease characterized by the
      presence of hyperglycemia, which can lead to many complications over time. These 
      complications, such as nephropathy, retinopathy, neuropathy, impaired wound
      healing and accelerated atherosclerosis, are implicated with a large number of
      cellular and subcellular changes on vessels. In agreement, evidence indicates
      that in retinopathy, nephropathy and atherosclerotic plaque, there is excessive
      angiogenesis, whereas in wound healing and myocardial perfusion, blood vessel
      growth is impaired. Despite the awareness of this angiogenic paradox, many
      questions remain unanswered. This review aims at highlighting the different
      microvascular and macrovascular complications that are often concurrent in
      diabetic patients. A revision of the recent findings published in the literature 
      regarding the angiogenic paradox will be performed. Apparently, endothelial
      dysfunction, as well as molecules such as vascular endothelial growth factor
      (VEGF) and hypoxia-inducible factor (HIF) play a major role in diabetic vascular 
      complications. Specific tissues with impaired angiogenesis exhibit
      microenvironment features, such as increased PAI-1/uPA ratio and decreased blood 
      flow, whereas TGFbeta increases extracellular matrix deposition, preventing the
      vascularization process. In addition, the monocytes/macrophages are important in 
      endothelium activation for arteriogenesis and its arteriogenic response is
      reduced, leading to impaired collateral artery growth. Moreover, molecular
      mechanisms involved will be addressed, including abnormalities in growth factor, 
      cytokines and metabolic derangements.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Biochemistry (U38-FCT), Faculty of Medicine, University of Porto,
      Portugal.
FAU - Costa, Paulo Zoe
AU  - Costa PZ
FAU - Soares, Raquel
AU  - Soares R
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/02/12 [received]
PHST- 2013/03/28 [revised]
PHST- 2013/04/01 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - S0024-3205(13)00216-6 [pii]
AID - 10.1016/j.lfs.2013.04.001 [doi]
PST - ppublish
SO  - Life Sci. 2013 Jun 13;92(22):1037-45. doi: 10.1016/j.lfs.2013.04.001. Epub 2013
      Apr 17.

PMID- 23603037
OWN - NLM
STAT- In-Data-Review
DA  - 20130528
IS  - 1873-4367 (Electronic)
IS  - 0927-7765 (Linking)
VI  - 109
DP  - 2013 Sep 1
TI  - Relative efficacies of insulin and poly (lactic-co-glycolic) acid encapsulated
      nano-insulin in modulating certain significant biomarkers in arsenic intoxicated 
      L6 cells.
PG  - 10-9
LID - 10.1016/j.colsurfb.2013.03.028 [doi]
LID - S0927-7765(13)00215-4 [pii]
AB  - The present study evaluates relative efficacies of insulin and
      PLGA-loaded-nano-insulin (NIn) in combating arsenic-induced impairment of glucose
      uptake, insulin resistance and mitochondrial dysfunction in L6 skeletal muscle
      cells. L6 cells were treated with 0.5mM sodium arsenite for 30min and then the
      cells were further treated with either 100nM insulin (standardized dose) or
      either of the two doses, 50nM and 100nM of nano-insulin. Various biomarkers like 
      pyruvate-kinase and glucokinase, ATP/ADP ratio, mitochondrial membrane potential,
      cytosolic release of mitochondrial cytochrome c, cell membrane potential and
      calcium-ion level were studied and analyzed to ascertain the status of
      mitochondrial functioning in all experimental and control sets of L6 cells. The
      size, morphology and zeta potential of formulated NIn were determined by using
      dynamic light scattering, scanning electronic and atomic-force microscopies.
      Expression of signalling cascades like GLUT4, IRS1, IRS2, UCP2, PI3, and p38 was 
      critically analyzed. Overall results suggested that both insulin and NIn improved
      mitochondrial functioning in arsenite-intoxicated L6 cells, NIn showing better
      effects at a much lower dose (at nearly 10-fold decreased dose) than that
      produced by insulin. Nano-insulin being non-toxic and effective at a much lesser 
      dose, therefore, has potential for therapeutic use in the management of arsenic
      induced diabetes.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Cytogenetics and Molecular Biology Laboratory, Department of Zoology, University 
      of Kalyani, Kalyani 741235, India.
FAU - Samadder, Asmita
AU  - Samadder A
FAU - Das, Sreemanti
AU  - Das S
FAU - Das, Jayeeta
AU  - Das J
FAU - Khuda-Bukhsh, Anisur Rahman
AU  - Khuda-Bukhsh AR
LA  - eng
PT  - Journal Article
DEP - 20130329
PL  - Netherlands
TA  - Colloids Surf B Biointerfaces
JT  - Colloids and surfaces. B, Biointerfaces
JID - 9315133
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/07 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/21 [accepted]
PHST- 2013/03/29 [aheadofprint]
AID - S0927-7765(13)00215-4 [pii]
AID - 10.1016/j.colsurfb.2013.03.028 [doi]
PST - ppublish
SO  - Colloids Surf B Biointerfaces. 2013 Sep 1;109:10-9. doi:
      10.1016/j.colsurfb.2013.03.028. Epub 2013 Mar 29.

PMID- 23603011
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1873-3344 (Electronic)
IS  - 0162-0134 (Linking)
VI  - 124
DP  - 2013 Jul
TI  - Role of liver fatty acid binding protein in hepatocellular injury: Effect of
      CrPic treatment.
PG  - 46-53
LID - 10.1016/j.jinorgbio.2013.03.015 [doi]
LID - S0162-0134(13)00073-1 [pii]
AB  - This study was designed to investigate the molecular mechanisms of chromium
      picolinate (CrPic, Fig. 1) hepatoprotective activity from alloxan-induced hepatic
      injury. Diabetes is induced by alloxan-treatment concurrently with the hepatic
      injury in mice. In this study, we investigate the protective effect of CrPic
      treatment in hepatic injury and the signal role of liver fatty acid binding
      protein in early hepatocellular injury diagnostics. In this study, alanine
      aminotransferase (ALT; EC 2.6.1.2) and aspartate aminotransferase (AST; EC
      2.6.1.1) levels in the alloxan group were higher 71% and 50%, respectively, than 
      those of the control group (ALT: 14.51+/-0.74; AST: 22.60+/-0.69). The AST and
      ALT levels in CrPic group were of minimal difference compared to the control
      groups. Here, CrPic exhibited amelioration alloxan induced oxidative stress in
      mouse livers. A significant increase in liver fatty acid-binding protein (L-FABP)
      was observed, which indicates increased fatty acid utilization in liver tissue
      [1]. In this study, the mRNA levels of L-FABP increased in both the control (1.1 
      fold) and CrPic (0.78 fold) groups compared the alloxan group. These findings
      suggest that hepatic injury may be prevented by CrPic, and is a potential target 
      for use in the treatment of early hepatic injury.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Shandong Key Laboratory of Storage and Transportation Technology of Agricultural 
      Products, National Engineering Research Center for Agricultural Products
      Logistics, Shandong Institute of Commerce and Technology, Jinan 250103, China;
      Key Laboratory for Food Nutrition and Safety of Ministry of Education, Tianjin
      University of Science and Technology, Tianjin, 300457, China.
FAU - Fan, Weijiang
AU  - Fan W
FAU - Chen, Kun
AU  - Chen K
FAU - Zheng, Guoqiang
AU  - Zheng G
FAU - Wang, Wenhang
AU  - Wang W
FAU - Teng, Anguo
AU  - Teng A
FAU - Liu, Anjun
AU  - Liu A
FAU - Ming, Dongfeng
AU  - Ming D
FAU - Yan, Peng
AU  - Yan P
LA  - eng
PT  - Journal Article
DEP - 20130329
PL  - United States
TA  - J Inorg Biochem
JT  - Journal of inorganic biochemistry
JID - 7905788
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/10 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/03/22 [accepted]
PHST- 2013/03/29 [aheadofprint]
AID - S0162-0134(13)00073-1 [pii]
AID - 10.1016/j.jinorgbio.2013.03.015 [doi]
PST - ppublish
SO  - J Inorg Biochem. 2013 Jul;124:46-53. doi: 10.1016/j.jinorgbio.2013.03.015. Epub
      2013 Mar 29.

PMID- 23603006
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-6351 (Electronic)
IS  - 0278-6915 (Linking)
VI  - 58C
DP  - 2013 Apr 18
TI  - Amelioration by chicory seed extract of diabetes- and oleic acid-induced
      non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)
      via modulation of PPARalpha and SREBP-1.
PG  - 198-209
LID - S0278-6915(13)00251-2 [pii]
LID - 10.1016/j.fct.2013.04.018 [doi]
AB  - We evaluated the effect of chicory (Cichorium intybus L.) seed extract (CI) on
      hepatic steatosis caused by early and late stage diabetes in rats (in vivo), and 
      induced in HepG2 cells (in vitro) by BSA-oleic acid complex (OA). Different
      dosages of CI (1.25, 2.5 and 5mg/ml) were applied along with OA (1mM) to HepG2
      cells, simultaneously and non-simultaneously; and without OA to ordinary
      non-steatotic cells. Cellular lipid accumulation and glycerol release, and
      hepatic triglyceride (TG) content were measured. The expression levels of sterol 
      regulatory element-binding protein-1c (SREBP-1c) and peroxisome
      proliferator-activated receptor alpha (PPARalpha) were determined. Liver samples 
      were stained with hematoxylin and eosin (H&E). Significant histological damage
      (steatosis-inflammation-fibrosis) to the cells and tissues and down-regulation of
      SREBP-1c and PPARalpha genes that followed steatosis induction were prevented by 
      CI in simultaneous treatment. In non-simultaneous treatment, CI up-regulated the 
      expression of both genes and restored the normal levels of the corresponding
      proteins; with a greater stimulating effect on PPARalpha, CI acted as a PPARalpha
      agonist. CI released glycerol from HepG2 cells, and targeted the first and the
      second hit phases of hepatic steatosis. A preliminary attempt to characterize CI 
      showed caffeic acid, chlorogenic acid, and chicoric acid, among the constituents.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Biochemistry, School of Medicine, Tehran University of Medical
      Sciences, Tehran, Iran.
FAU - Ziamajidi, Nasrin
AU  - Ziamajidi N
FAU - Khaghani, Shahnaz
AU  - Khaghani S
FAU - Hassanzadeh, Gholamreza
AU  - Hassanzadeh G
FAU - Vardasbi, Safura
AU  - Vardasbi S
FAU - Ahmadian, Shahram
AU  - Ahmadian S
FAU - Nowrouzi, Azin
AU  - Nowrouzi A
FAU - Ghaffari, Seyed Mahmood
AU  - Ghaffari SM
FAU - Abdirad, Afshin
AU  - Abdirad A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Food Chem Toxicol
JT  - Food and chemical toxicology : an international journal published for the British
      Industrial Biological Research Association
JID - 8207483
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/18 [received]
PHST- 2013/03/30 [revised]
PHST- 2013/04/05 [accepted]
AID - S0278-6915(13)00251-2 [pii]
AID - 10.1016/j.fct.2013.04.018 [doi]
PST - aheadofprint
SO  - Food Chem Toxicol. 2013 Apr 18;58C:198-209. doi: 10.1016/j.fct.2013.04.018.

PMID- 23602966
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1872-6240 (Electronic)
IS  - 0006-8993 (Linking)
VI  - 1517
DP  - 2013 Jun 23
TI  - Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes
      mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic,
      normal mice.
PG  - 104-13
LID - 10.1016/j.brainres.2013.04.015 [doi]
LID - S0006-8993(13)00528-3 [pii]
AB  - Effective interventions that provide obvious neuroprotection are currently fairly
      limited. Glucagon-like peptide-1 (GLP-1), an enhancer of insulin production with 
      a trophic effect on beta cells in the islets, has been found to be trophic for
      neuronal cells. Alogliptin benzoate (AGL), a selective inhibitor of
      dipeptidylpeptidase-4 (DPP-4) functioning as a long-acting agonist of GLP-1, is
      in clinical use worldwide for patients with diabetes mellitus type 2. To clarify 
      whether administration of AGL, independent of the insulinotropic effect, protects
      the brain against focal ischemia, we investigated the effect of AGL on the
      development of cerebral infarction in non-diabetic normal mice. Male C57BL/6J
      mice were administered AGL (7.5, 15, or 30mug) once a day for three weeks by
      intragastric gavage. After the induction of temporary focal ischemia, volumes of 
      infarcted lesions and neurological deficits were analyzed at 24h (acute phase)
      and seven days (chronic phase). In the acute phase, significant reductions were
      observed in the volumes of infarcted lesions (p=0.009), and in the severity of
      neurological deficits (p=0.004), in the group treated with 15mug of alogliptin
      benzoate, but not the 7.5 or 30mug-treated groups. This significant reduction in 
      volumes of infarcted lesions persisted into the chronic phase. At the end of the 
      AGL treatment; before the induction of ischemia, the levels of brain-derived
      neurotrophic factor (BDNF), a potent neuroprotectant in the brain, were elevated 
      in the cortex (p=0.008), or in the whole forebrain (p=0.023). AGL could be used
      as a daily neuroprotectant or an enhancer of BDNF production aiming to attenuate 
      cerebral injuries, for the growing number of people who have the risk of ischemic
      stroke.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Laboratory of Neurology and Neurosurgery, National Cerebral and Cardiovascular
      Research Center, Suita 565-8565, Japan; Department of Neurosurgery, National
      Cerebral and Cardiovascular Research Center, Suita 565-8565, Japan; Department of
      Neurosurgery, China-Japan Friendship Hospital, Beijing, PR China.
FAU - Yang, Dong
AU  - Yang D
FAU - Nakajo, Yukako
AU  - Nakajo Y
FAU - Iihara, Koji
AU  - Iihara K
FAU - Kataoka, Hiroharu
AU  - Kataoka H
FAU - Yanamoto, Hiroji
AU  - Yanamoto H
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/02 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - S0006-8993(13)00528-3 [pii]
AID - 10.1016/j.brainres.2013.04.015 [doi]
PST - ppublish
SO  - Brain Res. 2013 Jun 23;1517:104-13. doi: 10.1016/j.brainres.2013.04.015. Epub
      2013 Apr 17.

PMID- 23602926
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1879-3150 (Electronic)
IS  - 0041-0101 (Linking)
VI  - 69
DP  - 2013 Jul
TI  - Connectivity maps for biosimilar drug discovery in venoms: The case of Gila
      Monster Venom and the anti-diabetes drug Byetta((R)).
PG  - 160-7
LID - 10.1016/j.toxicon.2013.03.018 [doi]
LID - S0041-0101(13)00113-X [pii]
AB  - Like most natural product libraries animal venoms have long been recognized as
      potentially rich source of biologically active molecules with the potential to be
      mined for the discovery of drugs, drug leads and/or biosimilars. In this work we 
      demonstrate as a proof of concept a novel approach to explore venoms for
      potential biosimilarity to other drugs based on their ability to alter the
      transcriptomes of test cell lines followed by informatic searches and
      Connectivity Mapping to match the action of the venom on the cell gene expression
      to that of other drugs in the Connectivity Map (C-Map) database. As our test
      animal venom we chose Heloderma suspectum venom (Gila monster) since exendin-4, a
      glucagon-like peptide 1 receptor agonist, isolated from the venom is currently on
      the market to treat type 2 diabetes. The action of Byetta((R)) (exentide,
      synthetic exendin-4), was also used in transcriptome studies. Analysis of
      transcriptomes from cells treated with the venom or the drug showed similarities 
      as well as differences. The former case was primarily attributed to the fact that
      Gila monster venom likely contains a variety of biologically active molecules
      that could alter the MCF7 cell transcriptome compared to that of the single
      perturbant Byetta((R)). Using Ingenuity Pathway Analysis software, insulin-like
      growth factor 1 signaling was identified in the category of "Top Canonical
      Pathways" for both the venom and Byetta((R)). In the category of "Top Molecules" 
      up-regulated, both venom and Byetta((R)) shared IL-8, cyclic AMP-dependent
      transcription factor 3 (ATF-3), neuron-derived orphan receptor 1 (NR4A3),
      dexamethasone-induced Ras-related protein 1 (RASD1) and early growth response
      protein 1, (EGR-1) all with potential relevance in diabetes. Using Connectivity
      Mapping, Gila monster venom showed positive correlation with 1732 instances and
      negative correlation with 793 instances in the Connectivity database whereas
      Byetta((R)) showed positive correlation with 1692 instances and negative
      correlation with 868 instances. Interestingly, the Gila monster venom and
      Byetta((R)) both showed positive correlation with the anti-diabetic drugs
      troglitazone, of the thiazolidinedione class, and metformin, of the biguanide
      class, although Byetta((R)) as a glucagon-like peptide-1 (GLP-1) agonist
      functions in a different manner than either of these two classes of anti-diabetic
      drugs. In summary, despite the fact that Gila monster venom contains a mixture of
      biologically active molecules, similarities in terms of perturbation of gene
      expression profiles on MCF7 cells were observed between the venom and the drug
      Byetta((R)). Furthermore, using Connectivity Mapping the Gila monster venom was
      demonstrated to have nodes of positive correlation to several anti-diabetic drugs
      two of which were the same as observed with Byetta((R)). Therefore, this study
      suggests that by using this approach novel drug activities heretofore
      unconsidered may be discovered in venoms using informatic tools and Connectivity 
      Mapping.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Microbiology, Immunology and Cancer Biology, University of
      Virginia, School of Medicine, PO Box 800734, Charlottesville, VA 22908, USA.
FAU - Aramadhaka, Lavakumar Reddy
AU  - Aramadhaka LR
FAU - Prorock, Alyson
AU  - Prorock A
FAU - Dragulev, Bojan
AU  - Dragulev B
FAU - Bao, Yongde
AU  - Bao Y
FAU - Fox, Jay W
AU  - Fox JW
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - England
TA  - Toxicon
JT  - Toxicon : official journal of the International Society on Toxinology
JID - 1307333
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/22 [received]
PHST- 2013/02/11 [revised]
PHST- 2013/03/22 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - S0041-0101(13)00113-X [pii]
AID - 10.1016/j.toxicon.2013.03.018 [doi]
PST - ppublish
SO  - Toxicon. 2013 Jul;69:160-7. doi: 10.1016/j.toxicon.2013.03.018. Epub 2013 Apr 18.

PMID- 23602874
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 74
IP  - 7
DP  - 2013 Jul
TI  - C1q but not mannose-binding lectin (Mbl-2) gene polymorphisms are associated with
      type 2 diabetes in the genetically homogeneous population of the island of Crete 
      in Greece.
PG  - 878-81
LID - 10.1016/j.humimm.2013.04.003 [doi]
LID - S0198-8859(13)00089-X [pii]
AB  - AIM: To investigate the role of mannose-binding lectin 2 (MBL2) and C1q gene
      polymorphisms on the susceptibility to type 2 diabetes (T2D), that may contribute
      to increased risk of infections in the genetically homogeneous Greek population
      of the island of Crete. METHODS: Ninety five patients with T2D and 333 healthy
      controls, all local Cretans were genotyped for the MBL-2 rs11003125 (C>G) and C1q
      rs292001 (G>A) single-nucleotide polymorphisms (SNPs) by the restriction fragment
      length polymorphism approach. RESULTS: The A/A genotype and the minor allele A of
      C1q SNP (P=0.0001 in both cases) were observed more frequently in T2D than in
      healthy controls. In contrast, the minor allele G of the rs11003125 MBL2 gene did
      not show any statistically significant difference between T2D patients and
      controls. The present study represents the first attempt to implicate the role of
      MBL2 and C1q gene polymorphisms in the susceptibility to T2D. CONCLUSIONS: The
      study has shown that the rs292001 C1q but not the rs11003125 MBL2 SNP are
      associated with increased risk for T2D susceptibility in the Cretan population.
CI  - Copyright (c) 2013 American Society for Histocompatibility and Immunogenetics.
      Published by Elsevier Inc. All rights reserved.
AD  - Laboratory of Molecular Medicine and Human Genetics, Department of Internal
      Medicine, Medical School, University of Crete, Heraklion, Crete, Greece.
FAU - Goulielmos, George N
AU  - Goulielmos GN
FAU - Samonis, George
AU  - Samonis G
FAU - Apergi, Marina
AU  - Apergi M
FAU - Christofaki, Maria
AU  - Christofaki M
FAU - Valachis, Antonis
AU  - Valachis A
FAU - Zervou, Maria I
AU  - Zervou MI
FAU - Kofteridis, Diamantis P
AU  - Kofteridis DP
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/15 [received]
PHST- 2013/02/12 [revised]
PHST- 2013/04/10 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - S0198-8859(13)00089-X [pii]
AID - 10.1016/j.humimm.2013.04.003 [doi]
PST - ppublish
SO  - Hum Immunol. 2013 Jul;74(7):878-81. doi: 10.1016/j.humimm.2013.04.003. Epub 2013 
      Apr 18.

PMID- 23602862
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1532-2165 (Electronic)
IS  - 1078-5884 (Linking)
VI  - 45
IP  - 6
DP  - 2013 Jun
TI  - Is Hypovitaminosis D Associated with Abdominal Aortic Aneurysm, and is There a
      Dose-response Relationship?
PG  - 657-64
LID - 10.1016/j.ejvs.2013.03.015 [doi]
LID - S1078-5884(13)00185-8 [pii]
AB  - OBJECTIVE: This study aims to investigate the association between plasma
      25-hydroxyvitamin D (25(OH)D) concentrations with the presence of abdominal
      aortic aneurysm (AAA) and aortic diameter. DESIGN: An observational study of 4233
      community-dwelling men aged 70-88 years, who participated in a randomised
      controlled trial of screening for AAA. METHODS: Infrarenal aortic diameter
      measured by ultrasound and 25(OH)D by immunoassay. RESULTS: A total of 311 men
      (7.4%) with AAA (defined as aortic diameter >/=30 mm) comprised the study.
      Multivariable models were adjusted for age, smoking, cardiovascular disease,
      hypertension, diabetes, dyslipidaemia, body mass index and serum creatinine
      concentration. Amongst men with the lowest 25(OH)D quartile of values compared
      with the highest quartile, the adjusted odds ratio of having an AAA increased in 
      a graded fashion from 1.23 (95% confidence interval (CI) 0.87-1.73) for AAA >/=30
      mm to 5.42 (95% CI 1.85-15.88) for AAA >/=40 mm. Similarly, there was a
      dose-response relationship between 25(OH)D concentrations and the size of the
      AAA: every 10-nmol l(-1) decrease in 25(OH)D levels was associated with 0.49 mm
      (95% CI 0.11-0.87) increase in mean aortic diameter. CONCLUSIONS: Low vitamin D
      status is associated with the presence of larger AAA in older men, and there is a
      graded inverse relationship between 25(OH)D concentrations and AAA diameter.
      Further research is needed to clarify the mechanisms underlying these
      associations.
CI  - Copyright (c) 2013 European Society for Vascular Surgery. Published by Elsevier
      Ltd. All rights reserved.
AD  - Western Australian Centre for Health and Ageing, Centre for Medical Research,
      Western Australian Institute for Medical Research, Perth, Australia; School of
      Medicine and Pharmacology, University of Western Australia, Perth, Australia;
      Department of Geriatric Medicine, Royal Perth Hospital, Perth, Australia.
      Electronic address: ewong@meddent.uwa.edu.au.
FAU - Wong, Y Y E
AU  - Wong YY
FAU - Flicker, L
AU  - Flicker L
FAU - Yeap, B B
AU  - Yeap BB
FAU - McCaul, K A
AU  - McCaul KA
FAU - Hankey, G J
AU  - Hankey GJ
FAU - Norman, P E
AU  - Norman PE
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - England
TA  - Eur J Vasc Endovasc Surg
JT  - European journal of vascular and endovascular surgery : the official journal of
      the European Society for Vascular Surgery
JID - 9512728
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/12/06 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - S1078-5884(13)00185-8 [pii]
AID - 10.1016/j.ejvs.2013.03.015 [doi]
PST - ppublish
SO  - Eur J Vasc Endovasc Surg. 2013 Jun;45(6):657-64. doi: 10.1016/j.ejvs.2013.03.015.
      Epub 2013 Apr 19.

PMID- 23602822
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
DP  - 2013 Apr 16
TI  - High In-hospital Mortality Following Percutaneous Endoscopic Gastrostomy: Results
      of a Nationwide Population-based Study.
LID - S1542-3565(13)00478-3 [pii]
LID - 10.1016/j.cgh.2013.04.011 [doi]
AB  - BACKGROUND & AIMS: Careful selection of patients who undergo endoscopic
      procedures plays an important role in optimizing healthcare. Percutaneous
      endoscopic gastrostomy (PEG) is a frequently performed invasive endoscopic
      procedure that has been associated with high short-term mortality. We used a
      national database to determine the incidence of, and factors associated with
      in-hospital mortality among patients undergoing PEG. METHODS: We conducted a
      nested, case-control, retrospective study using the US Nationwide Inpatient
      Sample (NIS) to analyze data from all hospitalizations in the year 2006 with an
      ICD-9 procedure code for PEG. Bivariate and multivariate logistic regression
      analysis was performed using demographic and clinical variables to identify
      predictors of in-hospital mortality following the procedure. A separate analysis 
      using propensity score matching technique was conducted to compare mortality to a
      control cohort. Results were validated in an independent analysis of 2007 NIS
      data. RESULTS: In-hospital mortality was 10.8% (95% CI 10.3%-11.3%) among 181,196
      patients who underwent PEG in 2006. Odds of death increased with age (1%/y),
      congestive heart failure, renal failure, chronic pulmonary disease, coagulopathy,
      pulmonary circulation disorders, metastatic cancer and liver disease. Indication 
      for PEG was strongly associated with mortality. Women, and patients with diabetes
      mellitus or paralysis had lower odds of death. PEG was associated with slightly
      higher odds of in-hospital mortality compared to controls. Results were
      qualitatively and quantitatively similar when 2007 NIS data were analyzed.
      CONCLUSIONS: Mortality is almost 11% among hospital in-patients following PEG. We
      have identified factors that increase and decrease the risk of death following
      PEG; these could improve patient selection for those most likely to benefit from 
      this procedure.
CI  - Copyright (c) 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
AD  - Division of Digestive and Liver Diseases, Department of Internal Medicine,
      University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: 
      Gaurav.Arora@UTSouthwestern.edu.
FAU - Arora, Gaurav
AU  - Arora G
FAU - Rockey, Don
AU  - Rockey D
FAU - Gupta, Samir
AU  - Gupta S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal
      of the American Gastroenterological Association
JID - 101160775
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/21 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/02 [accepted]
AID - S1542-3565(13)00478-3 [pii]
AID - 10.1016/j.cgh.2013.04.011 [doi]
PST - aheadofprint
SO  - Clin Gastroenterol Hepatol. 2013 Apr 16. pii: S1542-3565(13)00478-3. doi:
      10.1016/j.cgh.2013.04.011.

PMID- 23602610
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1527-3792 (Electronic)
IS  - 0022-5347 (Linking)
DP  - 2013 Apr 17
TI  - Insights and Interventions in Diabetes Associated Erectile Dysfunction.
LID - S0022-5347(13)04091-3 [pii]
LID - 10.1016/j.juro.2013.04.041 [doi]
AD  - Department of Urology, University of Washington, Seattle, Washington.
FAU - Wessells, Hunter
AU  - Wessells H
LA  - ENG
PT  - EDITORIAL
DEP - 20130417
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/11 [accepted]
AID - S0022-5347(13)04091-3 [pii]
AID - 10.1016/j.juro.2013.04.041 [doi]
PST - aheadofprint
SO  - J Urol. 2013 Apr 17. pii: S0022-5347(13)04091-3. doi: 10.1016/j.juro.2013.04.041.

PMID- 23602596
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 2212-4934 (Electronic)
IS  - 2212-4926 (Linking)
VI  - 53
IP  - 2
DP  - 2013 May
TI  - PtdIns5P and Pin1 in oxidative stress signaling.
PG  - 179-89
LID - 10.1016/j.jbior.2013.02.001 [doi]
LID - S2212-4926(13)00039-0 [pii]
AB  - Oxidative signaling is important in cellular health, involved in aging and
      contributes to the development of several diseases such as cancer,
      neurodegeneration and diabetes. Correct management of reactive oxygen species
      (ROS) prevents oxidative stress within cells and is imperative for cellular
      wellbeing. A key pathway that is regulated by oxidative stress is the activation 
      of proline-directed stress kinases (p38, JNK). Phosphorylation induced by these
      kinases is often translated into cellular outcome through the recruitment of the 
      prolyl-isomerase Pin1. Pin1 binds to phosphorylated substrates using its
      WW-domain and can induce conformational changes in the target protein through its
      prolyl-isomerase activity. We show that exposure of cells to UV irradiation or
      hydrogen peroxide (H2O2), induces the synthesis of the phosphoinositide second
      messenger PtdIns5P in part by inducing the interaction between
      phosphatidylinositol-5-phosphate 4-kinase (PIP4K) enzymes that remove PtdIns5P,
      with Pin1. In response to H2O2 exposure, Murine Embryonic Fibroblasts (MEFs)
      derived from Pin1(-/-) mice showed increased cell viability and an increased
      abundance of PtdIns5P compared to wild-type MEFs. Decreasing the levels of
      PtdIns5P in Pin1(-/-) MEFs decreased both their viability in response to H2O2
      exposure and the expression of genes required for cellular ROS management. The
      decrease in the expression of these genes manifested itself in the increased
      accumulation of cellular ROS. These data strongly argue that PtdIns5P acts as a
      stress-induced second messenger that can calibrate how cells manage ROS.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Inositide Laboratory CRUK, The Paterson Institute for Cancer Research, University
      of Manchester, Manchester M20 4BX, United Kingdom. Electronic address:
      wjkeune@hotmail.com.
FAU - Keune, Willem-Jan
AU  - Keune WJ
FAU - Jones, David R
AU  - Jones DR
FAU - Divecha, Nullin
AU  - Divecha N
LA  - eng
PT  - Journal Article
DEP - 20130313
PL  - England
TA  - Adv Biol Regul
JT  - Advances in biological regulation
JID - 101572336
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/24 [received]
PHST- 2013/02/21 [accepted]
PHST- 2013/03/13 [aheadofprint]
AID - S2212-4926(13)00039-0 [pii]
AID - 10.1016/j.jbior.2013.02.001 [doi]
PST - ppublish
SO  - Adv Biol Regul. 2013 May;53(2):179-89. doi: 10.1016/j.jbior.2013.02.001. Epub
      2013 Mar 13.

PMID- 23602543
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1873-4111 (Electronic)
IS  - 0378-5122 (Linking)
VI  - 75
IP  - 2
DP  - 2013 Jun
TI  - Antihypertensive treatment in diabetic patients. Review of current data.
PG  - 142-7
LID - 10.1016/j.maturitas.2013.03.012 [doi]
LID - S0378-5122(13)00085-6 [pii]
AB  - Thirty to 50% of diabetic patients suffer from hypertension, exhibiting increased
      cardiovascular risk. In the present article we review key studies regarding the
      current knowledge for blood pressure (BP) goals in people with diabetes, the
      treatment used and the possible diabetogenic effects of antihypertensive drugs,
      as well as the beneficial and non-beneficial combinations of antihypertensive
      drugs in diabetic patients. Early placebo controlled trials proved the beneficial
      outcome of BP lowering in diabetic patients with initially high BP levels. More
      recent trials examined the impact of intensive compared to less intensive BP
      goals in diabetic populations. However, initial BP goals had significant
      differences from final achieved BP levels. Accordingly, current data support
      initiation of antihypertensive drug treatment in all patients with diabetes and
      systolic BP >/=140mmHg, with the aim to lower it consistently <140mmHg, although 
      how far below 140mmHg the systolic BP goal should be is not clear. Available
      literature indicates that more than one drug is commonly used to achieve target
      BP. Drugs acting on the renin-angiotensin-aldosterone axis have been shown to act
      protectively on diabetic nephropathy, while beta-blockers and diuretics seem to
      have a diabetogenic effect. Interestingly, recent studies examining the role of
      combined use of available renin-angiotensin-aldosterone axis blockers versus its 
      separate use exhibited an increased incidence of adverse outcome in diabetic
      patients who used combinations of drugs that act against
      renin-angiotensin-aldosterone system. More studies need to be conducted in order 
      to establish the best combination therapy to reduce diabetic complications.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - First Department of Propaedeutic Medicine, Athens University Medical School,
      Laiko General Hospital, Athens, Greece.
FAU - Argyrakopoulou, Georgia
AU  - Argyrakopoulou G
FAU - Tsioufis, Costas
AU  - Tsioufis C
FAU - Sdraka, Eleni
AU  - Sdraka E
FAU - Tsiachris, Dimitris
AU  - Tsiachris D
FAU - Makrilakis, Konstantinos
AU  - Makrilakis K
FAU - Stefanadis, Christodoulos
AU  - Stefanadis C
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - Ireland
TA  - Maturitas
JT  - Maturitas
JID - 7807333
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/02/26 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/03/21 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - S0378-5122(13)00085-6 [pii]
AID - 10.1016/j.maturitas.2013.03.012 [doi]
PST - ppublish
SO  - Maturitas. 2013 Jun;75(2):142-7. doi: 10.1016/j.maturitas.2013.03.012. Epub 2013 
      Apr 17.

PMID- 23602502
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
DP  - 2013 Apr 18
TI  - Comparison of the Hypoglycemic Effect of Acarbose Monotherapy in Patients With
      Type 2 Diabetes Mellitus Consuming an Eastern or Western Diet: A Systematic
      Meta-analysis.
LID - S0149-2918(13)00168-9 [pii]
LID - 10.1016/j.clinthera.2013.03.020 [doi]
AB  - BACKGROUND: Because of its mechanism of action, the starch content of a diet
      might alter the hypoglycemic effect of acarbose. OBJECTIVE: We aimed to determine
      whether differences in this hypoglycemic effect existed between individuals
      consuming Eastern and Western diets with significantly different starch contents,
      a systematic meta-analysis of studies comparing acarbose with placebo or other
      hypoglycemic agents in patients with type 2 diabetes mellitus (T2DM) was
      performed. METHODS: Records were retrieved from the Cochrane clinical controlled 
      trials, MEDLINE, EMBASE, Wanfang, Chinese Technical Periodicals, and ongoing
      trials databases, and full texts and reference lists were screened. Because no
      study has directly compared patients consuming different types of diet, fixed-
      and random-effect models were used to indirectly compare the hypoglycemic effect 
      of acarbose monotherapy with that of placebo and/or comparator drugs in patients 
      with T2DM consuming an Eastern (Eastern Asia) or Western (including Europe and
      North America) diet. RESULTS: A total of 46 studies were included in the
      meta-analysis. The results revealed that, compared with placebo, hemoglobin A1c
      (HbA1c) levels were reduced to a significantly greater extent (1.02%) in the
      Eastern diet (mean [SD], 1.54% [2.00%]) than in the Western diet (mean [SD],
      0.52% [1.20%]) P < 0.00001). The ability of acarbose to reduce HbA1c levels in
      the Eastern (P = 0.20) and Western (P = 0.10) diet groups was similar to that of 
      sulfonylureas, and HbA1c levels were reduced significantly more (0.39%; P <
      0.00001) in the Eastern than in the Western diet group. The ability of acarbose
      to reduce HbA1c levels was similar to those of metformin and
      nateglinide/repaglinide, but a comparison of its efficacy with different diets
      was difficult because of the inclusion of few studies in these categories.
      Analysis of all included studies revealed that acarbose achieved a greater
      absolute reduction of HbA1c levels in the Eastern diet (mean [SD], 1.26% [1.20%])
      than in the Western diet (mean [SD], 0.62% [1.28%]; P < 0.00001) group. However, 
      the poor quality of Eastern diet trials may have affected the outcomes of the
      meta-analysis. CONCLUSION: The hypoglycemic effect of acarbose is superior in
      patients with T2DM consuming an Eastern diet than in those consuming a Western
      diet and is similar to that of sulfonylureas, metformin, and glinide drugs.
CI  - Copyright (c) 2013 Elsevier HS Journals, Inc. All rights reserved.
AD  - Department of Endocrinology and Metabolism, West China Hospital of Sichuan
      University, Chengdu, China.
FAU - Zhu, Qibo
AU  - Zhu Q
FAU - Tong, Yuzhen
AU  - Tong Y
FAU - Wu, Taixiang
AU  - Wu T
FAU - Li, Jieqing
AU  - Li J
FAU - Tong, Nanwei
AU  - Tong N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/26 [received]
PHST- 2013/03/05 [revised]
PHST- 2013/03/28 [accepted]
AID - S0149-2918(13)00168-9 [pii]
AID - 10.1016/j.clinthera.2013.03.020 [doi]
PST - aheadofprint
SO  - Clin Ther. 2013 Apr 18. pii: S0149-2918(13)00168-9. doi:
      10.1016/j.clinthera.2013.03.020.

PMID- 23602466
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1678-4391 (Electronic)
IS  - 1413-8670 (Linking)
VI  - 17
IP  - 3
DP  - 2013 May-Jun
TI  - Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across 
      decades of life.
PG  - 324-31
LID - 10.1016/j.bjid.2012.10.024 [doi]
LID - S1413-8670(13)00064-0 [pii]
AB  - The introduction of highly active antiretroviral therapy during the 1990s was
      crucial to the decline in the rates of morbidity and death related to the
      acquired immunodeficiency syndrome (AIDS) and turned human immunodeficiency virus
      (HIV) infection into a chronic condition. Consequently, the HIV/AIDS population
      is becoming older. The aim of this study was to describe the immunological,
      clinical and comorbidity profile of an urban cohort of patients with HIV/AIDS
      followed up at Instituto de Pesquisa Clinica Evandro Chagas, Oswaldo Cruz
      Foundation in Rio de Janeiro, Brazil. Retrospective data from 2307 patients
      during January 1st, 2008 and December 31st, 2008 were collected. For continuous
      variables, Cuzick's non-parametric test was used. For categorical variables, the 
      Cochran-Armitage non-parametric test for tendency was used. For all tests, the
      threshold for statistical significance was set at 5%. In 2008, 1023 (44.3%), 823 
      (35.7%), 352 (15.3%) and 109 (4.7%) were aged 18-39, 40-49, 50-59 and >/=60
      years-old, respectively. Older and elderly patients (>/=40 years) were more
      likely to have viral suppression than younger patients (18-39 years) (p<0.001).
      No significant difference in the latest CD4(+) T lymphocyte count in the
      different age strata was observed, although elderly patients (>/= 50 years) had
      lower CD4(+) T lymphocyte nadir (p<0.02). The number of comorbidities increased
      with age and the same pattern was observed for the majority of the comorbidities,
      including diabetes mellitus, dyslipidemia, hypertension, cardiovascular diseases,
      erectile dysfunction, HCV, renal dysfunction and also for non-AIDS-related
      cancers (p<0.001). With the survival increase associated to successful
      antiretroviral therapy and with the increasing new infections among elderly
      group, the burden associated to the diagnosis and treatment of the non-AIDS
      related HIV comorbidities will grow. Longitudinal studies on the impact of aging 
      on the HIV/AIDS population are still necessary, especially in resource-limited
      countries.
CI  - Copyright (c) 2013 Elsevier Editora Ltda. All rights reserved.
AD  - Fundacao Oswaldo Cruz, Instituto de Pesquisa Clinica Evandro Chagas, HIV/AIDS
      Clinical Research Center, Rio de Janeiro, RJ, Brazil.
FAU - Torres, Thiago Silva
AU  - Torres TS
FAU - Cardoso, Sandra Wagner
AU  - Cardoso SW
FAU - Velasque, Luciane de Souza
AU  - Velasque Lde S
FAU - Marins, Luana Monteiro Spindola
AU  - Marins LM
FAU - de Oliveira, Marilia Santini
AU  - de Oliveira MS
FAU - Veloso, Valdilea Goncalves
AU  - Veloso VG
FAU - Grinsztejn, Beatriz
AU  - Grinsztejn B
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Brazil
TA  - Braz J Infect Dis
JT  - The Brazilian journal of infectious diseases : an official publication of the
      Brazilian Society of Infectious Diseases
JID - 9812937
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/08/06 [received]
PHST- 2012/10/23 [revised]
PHST- 2012/10/23 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - S1413-8670(13)00064-0 [pii]
AID - 10.1016/j.bjid.2012.10.024 [doi]
PST - ppublish
SO  - Braz J Infect Dis. 2013 May-Jun;17(3):324-31. doi: 10.1016/j.bjid.2012.10.024.
      Epub 2013 Apr 18.

PMID- 23602454
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Association of hyperglycemia mediated increased advanced glycation and
      erythrocyte antioxidant enzyme activity in different stages of diabetic
      retinopathy.
PG  - 376-84
LID - 10.1016/j.diabres.2013.03.031 [doi]
LID - S0168-8227(13)00130-7 [pii]
AB  - AIM: This study aimed to evaluate whether hyperglycemia mediated increased
      formation of advanced glycation end products (AGEs) was associated with
      erythrocyte antioxidant enzyme activity in subjects with different stages of
      diabetic retinopathy (DR). METHODS: Serum level of AGEs was determined by enzyme 
      linked immunosorbent assay. Erythrocyte superoxide dismutase (SOD), glutathione
      reductase (GR) and catalase activity were estimated by enzymatic reaction based
      spectrophotometric assay in patients with type 2 diabetes with proliferative
      diabetic retinopathy (PDR), non-proliferative diabetic retinopathy (NPDR) and no 
      retinopathy (DNR) and also in healthy non-diabetic controls (HC). RESULT:
      Erythrocyte SOD and GR activity was significantly lower among NPDR (p=0.024,
      0.0017, respectively) and PDR (p=0.0003, 0.0001, respectively) subjects compared 
      with DNR individuals. A significant inverse correlation was observed between
      serum AGEs and erythrocyte SOD or GR activity in DNR (p=0.0019; r=-0.3033,
      p=0.0021; r=-0.3015, respectively), NPDR (p=0.0001; r=-0.4602, p=0.0003;
      r=-0.4161, respectively), and PDR (p<0.0001; r=-0.6753, p<0.0001; r=-0.5854,
      respectively) individuals. CONCLUSION: Poor glycemia may be the key factor
      enhancing AGE formation, which may be associated with lower erythrocyte SOD and
      GR activity along with increased catalase activity in DR.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Biochemistry, Dr. B.C. Roy Post Graduate Institute of Basic Medical
      Education and Research (IPGME&R), 244B, AJC Bose Road, Kolkata 700020, India.
FAU - Choudhuri, Subhadip
AU  - Choudhuri S
FAU - Dutta, Deep
AU  - Dutta D
FAU - Chowdhury, Imran H
AU  - Chowdhury IH
FAU - Mitra, Bhaskar
AU  - Mitra B
FAU - Sen, Aditi
AU  - Sen A
FAU - Mandal, Lakshmi K
AU  - Mandal LK
FAU - Mukhopadhyay, Satinath
AU  - Mukhopadhyay S
FAU - Bhattacharya, Basudev
AU  - Bhattacharya B
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/16 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - S0168-8227(13)00130-7 [pii]
AID - 10.1016/j.diabres.2013.03.031 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):376-84. doi:
      10.1016/j.diabres.2013.03.031. Epub 2013 Apr 17.

PMID- 23602378
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1878-1632 (Electronic)
IS  - 1529-9430 (Linking)
DP  - 2013 Apr 17
TI  - Variables affecting postsurgical prognosis of thoracic myelopathy caused by
      ossification of the ligamentum flavum.
LID - S1529-9430(13)00284-2 [pii]
LID - 10.1016/j.spinee.2013.03.001 [doi]
AB  - BACKGROUND CONTEXT: Ossification of the ligamentum flavum (OLF) may result in
      thoracic myelopathy (TM) because of narrowing of the spinal canal. Because
      symptoms vary and are subjective, diagnosis of TM caused by OLF is sometimes
      difficult when based on symptoms and physical examination. Posterior
      decompression is indicated in patients with TM caused by OLF because it is
      believed that surgery is the most effective treatment. However, surgical outcomes
      vary. We are unaware of reports of objective presurgical diagnostic parameters,
      such as neurologic and radiologic findings, relating to the postsurgical
      prognosis in patients with TM caused by OLF. PURPOSE: To determine which
      presurgical and surgical variables were most closely related to postsurgical
      prognosis of TM caused by OLF. STUDY DESIGN: Retrospective review of the records 
      of the cohort of patients who had undergone surgery from 1988 through 2008 at the
      University of Toyama Hospital for TM caused by OLF. PATIENT SAMPLE: Forty-one
      patients who had surgery for TM caused by OLF that was progressive, severe, or
      both and for which the diagnosis was based on clinical, radiologic, and
      pathologic evaluations. OUTCOME MEASURES: Relationship between the highest
      follow-up Japanese Orthopaedic Association (JOA) score for neurologic evaluation 
      and of Hirabayashi's formula to indicate the extent of normalization after
      surgery with respect to the following 10 variables: age at surgery; sex; duration
      of presurgical symptoms; complications of diabetes mellitus; complications of
      hypertension; presence of presurgical hyperreflexia in either or both of the
      patellar tendon reflex and the Achilles tendon reflex; presurgical impairment of 
      joint position sense in the big toes; number of levels affected by OLF;
      concurrent spinal lesions including ossification of the posterior longitudinal
      ligament; and intramedullary change of the spinal cord seen on magnetic resonance
      imaging (MRI). METHODS: Multiple linear analyses were used to evaluate the
      variables related to postsurgical recovery. RESULTS: Presurgical impairment of
      joint position sense in the big toe was the most important predictor of the
      highest postsurgical JOA score and of the highest percentage recovery rate. The
      number of affected OLF levels also predicted the postsurgical highest JOA score, 
      but not statistically significantly so. Age at surgery, sex, and duration of
      symptoms presurgically did not affect postsurgical recovery. Complications of
      diabetes mellitus or of hypertension did not affect percentage recovery rate. The
      difference between recovery rate in patients with or without concurrent spinal
      lesions was not significant. Presurgical hyperreflexia was not correlated with
      recovery. Postsurgical JOA scores and percentage recovery rates of scores in
      patients whose presurgical MRIs had shown intramedullary signal change were not
      statistically significantly different from those whose MRIs had not shown signal 
      change. CONCLUSIONS: An excellent postoperative prognosis is not always possible 
      in patients with TM caused by OLF. It may be important to check for impairment of
      joint position sense in the big toe, the number of levels affected by OLF, and
      presurgical intramedullary signal change on MRI before continuing to surgery.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama,
      2630 Sugitani, Toyama 930-0194, Japan. Electronic address:
      zenji@med.u-toyama.ac.jp.
FAU - Kawaguchi, Yoshiharu
AU  - Kawaguchi Y
FAU - Yasuda, Taketoshi
AU  - Yasuda T
FAU - Seki, Shoji
AU  - Seki S
FAU - Nakano, Masato
AU  - Nakano M
FAU - Kanamori, Masahiko
AU  - Kanamori M
FAU - Sumi, Shigeki
AU  - Sumi S
FAU - Kimura, Tomoatsu
AU  - Kimura T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Spine J
JT  - The spine journal : official journal of the North American Spine Society
JID - 101130732
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2011/03/25 [received]
PHST- 2012/11/19 [revised]
PHST- 2013/03/07 [accepted]
AID - S1529-9430(13)00284-2 [pii]
AID - 10.1016/j.spinee.2013.03.001 [doi]
PST - aheadofprint
SO  - Spine J. 2013 Apr 17. pii: S1529-9430(13)00284-2. doi:
      10.1016/j.spinee.2013.03.001.

PMID- 23602376
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1878-1632 (Electronic)
IS  - 1529-9430 (Linking)
DP  - 2013 Apr 17
TI  - Anterior cervical plating technique to prevent adjacent-level ossification
      development.
LID - S1529-9430(13)00292-1 [pii]
LID - 10.1016/j.spinee.2013.03.009 [doi]
AB  - BACKGROUND CONTEXT: The proximity (<5 mm) of the plate to the adjacent disc space
      is known to be a critical risk factor for adjacent-level ossification development
      (ALOD). As plates provide many advantages including higher fusion rates and
      improved alignment, their use will continue. Instead, it is necessary to modify
      the plating techniques to minimize this complication. PURPOSE: To determine if
      our newer plating technique decreases the incidence of ALOD after anterior
      cervical plating. STUDY DESIGN: Retrospective matched cohort analysis of
      preoperative and postoperative radiographic data. PATIENT SAMPLE: One hundred
      patients were classified into two groups; conventional (C) and new (N) plating
      techniques. The control group (Group C) was matched to the study group (Group N) 
      in a 1:1 fashion using matching criteria of age (within 5 years), gender, number 
      of fusion levels, and comorbidities, including diabetes and tobacco use. OUTCOME 
      MEASURES: The lateral plain X-rays of cervical spine taken at postoperative 6
      months and 2 years were used for analysis. METHODS: In Group N, the cranial and
      caudal screws were started at the anterior end plate corners and angled away from
      the end plates so as to use the shortest possible plate and maximize the distance
      to the adjacent end plates. Group C was the historical control using a longer
      plate with more orthogonal screw angulation. On postoperative 6-week lateral
      films, the distances from the tip of the plate to both cranial and caudal
      adjacent discs (plate-to-disc distances) were measured. Based on the
      postoperative 2-year radiographs, the incidence of ALOD was determined, and the
      severity of ossification was classified on a scale ranging from Grade 0 (no
      ossification) to Grade 3 (complete bridging). RESULTS: Mean plate-to-disc
      distances in Group N were significantly longer at both cranial and caudal
      adjacent levels than those in Group C (p<.001). The incidence of ALOD was
      significantly lower in Group N than in Group C, both at the cranial adjacent disc
      spaces (42% vs. 72%) and caudal adjacent disc spaces (20% vs. 42%) (p<.05).
      Severe ossification (Grade 2 or greater) also developed less frequently in Group 
      N at cranial and caudal levels (6% vs. 20%, respectively; p<.05). CONCLUSIONS:
      The new technique of using a shorter plate with longer angulated screws resulted 
      in significantly reduced incidence and severity of ALOD.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Orthopaedic Surgery, Asan Medical Center, University of Ulsan
      College of Medicine, 388-1, Pungnap2-dong, Songpa-gu, Seoul, 138-736, Korea.
FAU - Lee, Dong-Ho
AU  - Lee DH
FAU - Lee, Jung-Sub
AU  - Lee JS
FAU - Yi, Jin-Seok
AU  - Yi JS
FAU - Cho, Woojin
AU  - Cho W
FAU - Zebala, Lukas P
AU  - Zebala LP
FAU - Riew, K Daniel
AU  - Riew KD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Spine J
JT  - The spine journal : official journal of the North American Spine Society
JID - 101130732
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2011/01/21 [received]
PHST- 2012/11/26 [revised]
PHST- 2013/03/07 [accepted]
AID - S1529-9430(13)00292-1 [pii]
AID - 10.1016/j.spinee.2013.03.009 [doi]
PST - aheadofprint
SO  - Spine J. 2013 Apr 17. pii: S1529-9430(13)00292-1. doi:
      10.1016/j.spinee.2013.03.009.

PMID- 23602322
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Serum Angptl2 levels are independently associated with albuminuria in type 2
      diabetes.
PG  - 385-90
LID - 10.1016/j.diabres.2013.03.028 [doi]
LID - S0168-8227(13)00127-7 [pii]
AB  - BACKGROUND: Elevated serum Angptl2 levels are positively associated with the
      development of type 2 diabetes. We investigated whether serum Angptl2 levels are 
      associated with diabetic nephropathy in patients with type 2 diabetes. METHODS:
      Two hundred and thirty patients with type 2 diabetes and 63 healthy controls
      participated in this cross-sectional study. Subjects with type 2 diabetes were
      divided into three groups using urinary albumin-to-creatinine ratio (ACR): a
      normoalbuminuric group (n=57), a microalbuminuric group (n=130) and a
      macroalbuminuria group (n=43). Serum Angptl2 concentrations were measured by
      enzyme-linked immunosorbent assay. RESULTS: Median serum (interquartile range)
      Angptl2 levels in control subjects and patients with type 2 diabetes with
      normoalbuminuria, microalbuminuria and macroalbuminuria were 24.03 (16.3-33.45), 
      36.14 (27.91-43.07), 44.6 (37.47-49.92), 50.19 (45.95-60.13)ng/ml (p<0.01)
      respectively. Angptl2 levels correlated with urinary ACR in participants with
      type 2 diabetes (r=0.38, p<0.01). Significant intercorrelations of Angptl2 were
      found with age, duration of diabetes, and fasting plasma glucose. After
      adjustment for significant covariates, albuminuria was still significantly
      associated with Angptl2 levels in type 2 diabetes (r=0.31, p<0.01). CONCLUSIONS: 
      Angptl2 levels are elevated in patients with type 2 diabetes with an independent 
      association between increasing Angptl2 levels and increasing levels of
      albuminuria. This suggests a possible role of Angptl2 in progressive nephropathy 
      in patients with type 2 diabetes.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Endocrinology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong
      University School of Medicine, Shanghai 200011, China; Institute of Endocrinology
      and Diabetology at Fudan University, Department of Endocrinology and Metabolism, 
      Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040,
      China.
FAU - Li, Qin
AU  - Li Q
FAU - Gong, Wei
AU  - Gong W
FAU - Yang, Zhihong
AU  - Yang Z
FAU - Lu, Bin
AU  - Lu B
FAU - Yang, Yehong
AU  - Yang Y
FAU - Zhao, Weiwei
AU  - Zhao W
FAU - Hu, Renming
AU  - Hu R
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/24 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/03/22 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - S0168-8227(13)00127-7 [pii]
AID - 10.1016/j.diabres.2013.03.028 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):385-90. doi:
      10.1016/j.diabres.2013.03.028. Epub 2013 Apr 18.

PMID- 23602284
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 Apr 17
TI  - Restoration of blood pressure control with pacemaker implantation in a patient
      with bradycardia and resistant hypertension: A case report.
LID - S0167-5273(13)00511-1 [pii]
LID - 10.1016/j.ijcard.2013.03.080 [doi]
AD  - Heart Centre, Alfred Hospital, Melbourne, Australia; Baker IDI Heart and Diabetes
      Institute, Melbourne, Australia. Electronic address: A.Ellims@alfred.org.au.
FAU - Ellims, Andris H
AU  - Ellims AH
FAU - Mariani, Justin A
AU  - Mariani JA
FAU - Schlaich, Markus P
AU  - Schlaich MP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/19 [received]
PHST- 2013/03/23 [accepted]
AID - S0167-5273(13)00511-1 [pii]
AID - 10.1016/j.ijcard.2013.03.080 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 Apr 17. pii: S0167-5273(13)00511-1. doi:
      10.1016/j.ijcard.2013.03.080.

PMID- 23602242
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1879-0739 (Electronic)
IS  - 0271-5317 (Linking)
VI  - 33
IP  - 4
DP  - 2013 Apr
TI  - Higher glycemic load diet is associated with poorer nutrient intake in women with
      gestational diabetes mellitus.
PG  - 259-65
LID - 10.1016/j.nutres.2013.02.008 [doi]
LID - S0271-5317(13)00036-5 [pii]
AB  - Changes in the quality and quantity of carbohydrate foods may compromise nutrient
      intake in women with gestational diabetes mellitus (GDM). We hypothesized that
      glycemic index, glycemic load (GL), carbohydrate intake, grains, and cereal
      product consumption would be associated with nutrient adequacy. Eighty-two women 
      with GDM (61% of Asian background, 34% whites) completed a 3-day food record
      following their routine group nutrition education session. Nutrient intakes were 
      compared to Nutrient Reference Values (NRV) for Australia and New Zealand.
      Nutrient intake across energy-adjusted tertiles of glycemic index, GL,
      carbohydrate intake, and intake of grains and cereal products were assessed. The 
      majority of women (66%-99%) did not meet the NRV for fiber, folate, vitamin D,
      iodine, and iron, and exceeded NRV for saturated fat and sodium. Higher dietary
      GL was associated with lower intakes of total, monounsaturated, and
      polyunsaturated fat; vitamin E; and potassium (all P < .001). Higher grain intake
      was not significantly associated with intake of any micronutrients. In Australian
      women with GDM, high dietary GL predicts greater risk of poor nutrition.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - School of Molecular Bioscience and Boden Institute of Obesity, Nutrition,
      Exercise and Eating Disorders, University of Sydney, NSW 2006, Australia.
      jlouie@uow.edu.au
FAU - Louie, Jimmy Chun Yu
AU  - Louie JC
FAU - Markovic, Tania P
AU  - Markovic TP
FAU - Ross, Glynis P
AU  - Ross GP
FAU - Foote, Deborah
AU  - Foote D
FAU - Brand-Miller, Jennie C
AU  - Brand-Miller JC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130326
PL  - United States
TA  - Nutr Res
JT  - Nutrition research (New York, N.Y.)
JID - 8303331
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/06/14 [received]
PHST- 2013/02/11 [revised]
PHST- 2013/02/19 [accepted]
PHST- 2013/03/26 [aheadofprint]
AID - S0271-5317(13)00036-5 [pii]
AID - 10.1016/j.nutres.2013.02.008 [doi]
PST - ppublish
SO  - Nutr Res. 2013 Apr;33(4):259-65. doi: 10.1016/j.nutres.2013.02.008. Epub 2013 Mar
      26.

PMID- 23602201
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 62
IP  - 3
DP  - 2013 Jun
TI  - High tumor necrosis factor-alpha/interleukin-10 ratio is associated with
      hepatocellular carcinoma in patients with chronic hepatitis C.
PG  - 421-5
LID - 10.1016/j.cyto.2013.03.024 [doi]
LID - S1043-4666(13)00143-9 [pii]
AB  - Hepatitis C virus (HCV) is the main cause of chronic liver disease, cirrhosis and
      hepatocellular carcinoma (HCC) worldwide. The risk for the development of HCC
      increases with the severity of liver inflammation and fibrosis. The hepatic
      inflammation caused by HCV involves host regulatory immune response, which is
      mediated by cytokines with anti-viral role upon the interaction of viral
      polypeptides with innate and adaptive immunity. Two cytokines; tumor necrosis
      factor-alpha (TNF-alpha) and interleukin-10 (IL-10) play key roles in the
      regulation of cellular immune response in HCV infection. The aim of the present
      study was to determine the levels of IL-10 and TNF-alpha, as well as the ratio of
      TNF-alpha and IL-10 serum levels in patients with HCV and HCC caused by HCV
      (HCC-HCV). The study included 173 patients with chronic HCV. TNF-alpha and IL-10 
      serum levels were measured by ELISA (R&D Systems, Inc.). In the present study, 54
      patients presented liver mild fibrosis, 68 had severe fibrosis and 51 patients
      had HCC. After adjustment in the multivariate regression analysis, the following 
      variables remained significantly associated with HCC-HCV occurrence: diabetes
      (p=0.012 OR 10.44 CI 1.66-65.60), IL-10 lower levels (p<0.0001 OR 0.83 CI
      0.78-0.89) and TNF-alpha higher levels (p<0.0001 OR 1.19 CI 1.11-1.28).
      Individuals with HCC presented higher TNF-alpha/IL-10 ratio than those with
      fibrosis grade F4, F3 or F0+F1+F2 (p=0.0003, p<0.0001, p<0.0001, respectively).
      Patients with HCC were associated to higher index TNF-alpha/IL-10 ratio,
      suggesting that the unbalanced production of these cytokines may represent
      progression to the liver disease severity in HCV infected patients.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Universidade Federal de Pernambuco (UFPE), Recife, Brazil; Universidade de
      Pernambuco (UPE), Recife, Brazil; Instituto do Figado de Pernambuco (IFP),
      Recife, Brazil.
FAU - Aroucha, D C B L
AU  - Aroucha DC
FAU - do Carmo, R F
AU  - do Carmo RF
FAU - Moura, P
AU  - Moura P
FAU - Silva, J L A
AU  - Silva JL
FAU - Vasconcelos, L R S
AU  - Vasconcelos LR
FAU - Cavalcanti, M S M
AU  - Cavalcanti MS
FAU - Muniz, M T C
AU  - Muniz MT
FAU - Aroucha, M L
AU  - Aroucha ML
FAU - Siqueira, E R F
AU  - Siqueira ER
FAU - Cahu, G G O M
AU  - Cahu GG
FAU - Pereira, L M M B
AU  - Pereira LM
FAU - Coelho, M R C D
AU  - Coelho MR
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - Cytokine
JT  - Cytokine
JID - 9005353
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/12/14 [received]
PHST- 2013/03/23 [revised]
PHST- 2013/03/23 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - S1043-4666(13)00143-9 [pii]
AID - 10.1016/j.cyto.2013.03.024 [doi]
PST - ppublish
SO  - Cytokine. 2013 Jun;62(3):421-5. doi: 10.1016/j.cyto.2013.03.024. Epub 2013 Apr
      16.

PMID- 23602197
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 Apr 17
TI  - Combating diabetes complications by 1-Fe, a corrole-based catalytic antioxidant.
LID - S1056-8727(13)00051-2 [pii]
LID - 10.1016/j.jdiacomp.2013.02.005 [doi]
AB  - The potent corrole-based ROS/RNS decomposition catalyst 1-Fe was examined
      regarding its effect on the development of diabetes complications, in parallel
      with studies that addressed safety and toxicity issues that are crucial for
      forwarding the compound towards clinical trials. Cardiotoxicity and mutagenic
      potential were addressed by applying the hERG and AMES tests on 1-Fe, revealing
      that it is safe enough for further development. General toxicity studies in rats 
      disclosed the appearance of mild adverse effect only at a dose of 300mg/kg/day.
      In the streptozotocin-induced rat model of diabetes, 20mg/kg/day 1-Fe prevented
      cataract incidents and reduced its severity, displayed a favorable effect on
      kidney function, and also decreased serum cholesterol and triglyceride levels.
      Comparisons with alpha lipoic acid, a compound with reported benefits in the same
      mouse model, indicate that the benefits of 1-Fe are due to the combination of its
      ability to disarm ROS/RNS and its positive effect on lipid profile.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Technion 
      City, Haifa 32000, Israel.
FAU - Haber, Adi
AU  - Haber A
FAU - Angel, Itzchak
AU  - Angel I
FAU - Mahammed, Atif
AU  - Mahammed A
FAU - Gross, Zeev
AU  - Gross Z
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/12/17 [received]
PHST- 2013/01/28 [revised]
PHST- 2013/02/12 [accepted]
AID - S1056-8727(13)00051-2 [pii]
AID - 10.1016/j.jdiacomp.2013.02.005 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 Apr 17. pii: S1056-8727(13)00051-2. doi:
      10.1016/j.jdiacomp.2013.02.005.

PMID- 23602088
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1873-4588 (Electronic)
IS  - 0892-1997 (Linking)
DP  - 2013 Apr 16
TI  - Prevalence of Laryngopharyngeal Reflux Disease in Patients With Diabetes
      Mellitus.
LID - S0892-1997(12)00111-7 [pii]
LID - 10.1016/j.jvoice.2012.07.010 [doi]
AB  - OBJECTIVE: To study the prevalence of laryngopharyngeal reflux disease (LPRD) in 
      patients with type 2 diabetes mellitus (T2DM) and report the correlation between 
      LPRD and glycemic control, duration of the disease, and presence of neuropathy.
      MATERIALS AND METHODS: This is a cross-sectional study of 100 patients with T2DM 
      and 33 controls matched according to age and gender. The reflux symptom index
      (RSI) was used to assess the presence of LPRD. A score greater than 10 was
      considered diagnostic of LPRD. RESULTS: Twenty-two percent of patients with T2DM 
      had RSI above 10 versus 9.1% of controls. The difference was not statistically
      different (P value of 0.100). The average score of all symptoms of LPRD was
      higher in the diabetic group compared with the control group. There was a
      significant increase in the average score of "throat clearing" and "lump
      sensation in throat," with a borderline significant increase in "annoying cough" 
      in patients with diabetes versus controls (respective P values of 0.03, 0.025,
      and 0.066). There was no correlation between LPRD and any of the demographic
      variables except neuropathy. CONCLUSION: Patients with T2DM are more likely to
      have LPRD compared with controls. However, the prevalence of LPRD is not
      significantly higher in diabetic patients compared with controls. When present,
      LPRD correlates with neuropathy. LEVEL OF EVIDENCE: 2c.
CI  - Copyright (c) 2012 The Voice Foundation. Published by Mosby, Inc. All rights
      reserved.
AD  - Department of Otolaryngology and Head and Neck Surgery, American University of
      Beirut Medical Center, New York, New York.
FAU - Hamdan, Abdul-Latif
AU  - Hamdan AL
FAU - Jabbour, Jad
AU  - Jabbour J
FAU - Barazi, Randa
AU  - Barazi R
FAU - Korban, Zeina
AU  - Korban Z
FAU - Azar, Sami T
AU  - Azar ST
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Voice
JT  - Journal of voice : official journal of the Voice Foundation
JID - 8712262
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/02/24 [received]
PHST- 2012/07/12 [accepted]
AID - S0892-1997(12)00111-7 [pii]
AID - 10.1016/j.jvoice.2012.07.010 [doi]
PST - aheadofprint
SO  - J Voice. 2013 Apr 16. pii: S0892-1997(12)00111-7. doi:
      10.1016/j.jvoice.2012.07.010.

PMID- 23602044
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 Apr 5
TI  - A review of artificial pancreas technologies with an emphasis on bi-hormonal
      therapy.
LID - 10.1111/dom.12107 [doi]
AB  - Since the discovery of insulin, great progress has been made to improve the
      accuracy and safety of automated insulin delivery systems to help patients with
      type 1 diabetes achieve their treatment goals without causing hypoglycaemia. In
      recent years, bioengineering technology has greatly advanced diabetes management,
      with the development of blood glucose meters, continuous glucose monitors,
      insulin pumps and control systems for automatic delivery of one or more hormones.
      New insulin analogues have improved subcutaneous absorption characteristics, but 
      do not completely eliminate the risk of hypoglycaemia. Insulin effect is
      counteracted by glucagon in non-diabetic individuals, while glucagon secretion in
      those with type 1 diabetes is impaired. The use of glucagon in the artificial
      pancreas is therefore a logical and feasible option for preventing and treating
      hypoglycaemia. However, commercially available glucagon is not stable in aqueous 
      solution for long periods, forming potentially cytotoxic fibrils that aggregate
      quickly. Therefore, a more stable formulation of glucagon is needed for long-term
      use and storage in a bi-hormonal pump. In addition, a model of glucagon action in
      type 1 diabetes is lacking, further limiting the inclusion of glucagon into
      systems employing model-assisted control. As a result, although several
      investigators have been working to help develop bi-hormonal systems for patients 
      with type 1 diabetes, most continue to utilize single hormone systems employing
      only insulin. This article seeks to focus on the attributes of glucagon and its
      use in bi-hormonal systems.
CI  - (c) 2013 Blackwell Publishing Ltd.
AD  - Harold Schnitzer Diabetes Center, Oregon Health and Science University, Portland,
      OR, USA.
FAU - Bakhtiani, P A
AU  - Bakhtiani PA
FAU - Zhao, L M
AU  - Zhao LM
FAU - El Youssef, J
AU  - El Youssef J
FAU - Castle, J R
AU  - Castle JR
FAU - Ward, W K
AU  - Ward WK
LA  - ENG
GR  - K23 DK090133/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130405
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/26 [received]
PHST- 2013/01/07 [revised]
PHST- 2013/03/27 [accepted]
AID - 10.1111/dom.12107 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 Apr 5. doi: 10.1111/dom.12107.

PMID- 23602017
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 0929-6646 (Electronic)
IS  - 0929-6646 (Linking)
DP  - 2013 Apr 17
TI  - Ileum and colon perforation following peritoneal dialysis-related peritonitis and
      high-dose calcium polystyrene sulfonate.
LID - S0929-6646(13)00091-0 [pii]
LID - 10.1016/j.jfma.2013.02.006 [doi]
AB  - A rare but severe complication, intestinal necrosis, has been reported after
      sodium polystyrene sulfonate (SPS; Kayexalate) and sorbitol intake. Some case
      reports described bowel perforation following calcium polystyrene sulfonate (CPS;
      Kalimate) administration. We report a case of ileum and colon perforation
      following peritoneal dialysis-related peritonitis and high-dose Kalimate in a
      59-year-old female patient. The patient had a history of hypertension, diabetes
      mellitus, and end-stage renal disease (ESRD). During hospitalization for
      peritoneal dialysis-related peritonitis, she developed hyperkalemia, and Kalimate
      was administered orally. However, severe abdominal distension and pain occurred
      just one day after Kalimate intake. An urgent surgery disclosed several
      perforations in the ileum and sigmoid colon. Pathology of the resected gut showed
      transmural necrosis and perforation with basophilic angulated crystals. The
      patient finally expired during hospitalization due to refractory septic shock.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Division of Nephrology, Department of Internal Medicine, National Taiwan
      University Hospital, National Taiwan University, College of Medicine, Taipei,
      Taiwan; Department of Internal Medicine, Taipei Medical University Hospital,
      Taipei, Taiwan.
FAU - Kao, Chih-Chin
AU  - Kao CC
FAU - Tsai, Yi-Chiun
AU  - Tsai YC
FAU - Chiang, Wen-Chih
AU  - Chiang WC
FAU - Mao, Tsui-Lien
AU  - Mao TL
FAU - Kao, Tze-Wah
AU  - Kao TW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - J Formos Med Assoc
JT  - Journal of the Formosan Medical Association = Taiwan yi zhi
JID - 9214933
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/05/17 [received]
PHST- 2013/02/07 [revised]
PHST- 2013/02/20 [accepted]
AID - S0929-6646(13)00091-0 [pii]
AID - 10.1016/j.jfma.2013.02.006 [doi]
PST - aheadofprint
SO  - J Formos Med Assoc. 2013 Apr 17. pii: S0929-6646(13)00091-0. doi:
      10.1016/j.jfma.2013.02.006.

PMID- 23601803
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1549-4713 (Electronic)
IS  - 0161-6420 (Linking)
DP  - 2013 Apr 16
TI  - Obstructive Sleep Apnea and Increased Risk of Glaucoma: A Population-Based
      Matched-Cohort Study.
LID - S0161-6420(13)00008-0 [pii]
LID - 10.1016/j.ophtha.2013.01.006 [doi]
AB  - PURPOSE: Previous studies had reported an increased prevalence of glaucoma in
      patients with obstructive sleep apnea (OSA). However, the risk of open-angle
      glaucoma (OAG) among patients with OSA remains unclear. Using a nationwide,
      population-based dataset in Taiwan, this study aimed to examine the prevalence
      and risk of OAG among patients with OSA during a 5-year follow-up period after a 
      diagnosis of OSA. DESIGN: A retrospective, matched-cohort study. PARTICIPANTS AND
      CONTROLS: This study used data sourced from the Longitudinal Health Insurance
      Database 2000. We included 1012 subjects with OSA in the study cohort and
      randomly selected 6072 subjects in the comparison group. METHODS: Each subject in
      this study was individually traced for a 5-year period to identify those subjects
      who subsequently received a diagnosis of OAG. Cox proportional hazards regression
      was performed to calculate the 5-year risk of OAG between the study and
      comparison cohorts. MAIN OUTCOME MEASURES: The incidence and risk of OAG between 
      the study and comparison groups. RESULTS: During the 5-year follow-up period, the
      incidence rate per 1000 person-years was 11.26 (95% confidence interval [CI],
      8.61-14.49) and 6.76 (95% CI, 5.80-7.83) for subjects with and without OSA,
      respectively. After adjusting for monthly income, geographic region, diabetes,
      hypertension, coronary heart disease, obesity, hyperlipidemia, renal disease,
      hypothyroidism, and the number of outpatient visits for ophthalmologic care
      during the follow-up period, stratified Cox proportional hazards regression
      revealed that the hazard ratio for OAG within the 5-year period for subjects with
      OSA was 1.67 (95% CI, 1.30-2.17; P<0.001) that of comparison subjects.
      CONCLUSIONS: Our results suggest that OSA is associated with an increased risk of
      subsequent OAG diagnosis during a 5-year follow-up period. FINANCIAL
      DISCLOSURES(S): The authors have no proprietary or commercial interest in any of 
      the materials discussed in this article.
CI  - Copyright (c) 2013 American Academy of Ophthalmology. Published by Elsevier Inc. 
      All rights reserved.
AD  - Graduate Institute of Biomedical Informatics, College of Medical Science and
      Technology, Taipei Medical University, Taipei, Taiwan.
FAU - Lin, Ching-Chun
AU  - Lin CC
FAU - Hu, Chao-Chien
AU  - Hu CC
FAU - Ho, Jau-Der
AU  - Ho JD
FAU - Chiu, Hung-Wen
AU  - Chiu HW
FAU - Lin, Herng-Ching
AU  - Lin HC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/17 [received]
PHST- 2012/12/18 [revised]
PHST- 2013/01/03 [accepted]
AID - S0161-6420(13)00008-0 [pii]
AID - 10.1016/j.ophtha.2013.01.006 [doi]
PST - aheadofprint
SO  - Ophthalmology. 2013 Apr 16. pii: S0161-6420(13)00008-0. doi:
      10.1016/j.ophtha.2013.01.006.

PMID- 23601582
OWN - NLM
STAT- Publisher
DA  - 20130517
IS  - 1758-9193 (Print)
VI  - 5
IP  - 2
DP  - 2013 Apr 19
TI  - Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an
      APP/PS1 mouse model.
PG  - 20
AB  - INTRODUCTION: Type 2 diabetes mellitus has been identified as a risk factor for
      Alzheimer's disease (AD). An impairment of insulin signaling as well as a
      desensitization of its receptor has been found in AD brains. Glucose-dependent
      insulinotropic polypeptide (GIP) normalises insulin signaling by facilitating
      insulin release. GIP directly modulates neurotransmitter release, LTP formation, 
      and protects synapses from the detrimental effects of beta-amyloid fragments on
      LTP formation, and cell proliferation of progenitor cells in the dentate gyrus.
      Here we investigate the potential therapeutic property of the new long lasting
      incretin hormone analogue D-Ala2GIP on key symptoms found in a mouse model of
      Alzheimer' disease (APPswe/PS1detaE9). METHODS: D-Ala2GIP was injected for 21
      days at 25 nmol/kg ip once daily in APP/PS1 male mice and wild type (WT)
      littermates aged 6 or 12 months of age. Amyloid plaque load, inflammation
      biomarkers, synaptic plasticity in the brain (LTP), and memory were measured.
      RESULTS: D-Ala2GIP improved memory in WT mice and rescued the cognitive decline
      of 12 months old APP/PS1 mice in two different memory tasks. Furthermore,
      deterioration of synaptic function in the dentate gyrus and cortex was prevented 
      in 12 months old APP/PS1 mice. D-Ala2GIP facilitated synaptic plasticity in
      APP/PS1 and WT mice and reduced the number of amyloid plaques in the cortex of
      D-Ala2GIP injected APP/PS1 mice. The inflammatory response in microglia was also 
      reduced. CONCLUSION: The results demonstrate that D-Ala2GIP has neuroprotective
      properties on key hallmarks found in AD. This finding shows that novel GIP
      analogues have the potential as a novel therapeutic for AD.
AD  - School of Biomedical Sciences, Ulster University, Cromore road, Coleraine, BT52
      1SA, UK. c.holscher@ulster.ac.uk.
FAU - Faivre, Emilie
AU  - Faivre E
FAU - Holscher, Christian
AU  - Holscher C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Alzheimers Res Ther
JT  - Alzheimer's research & therapy
JID - 101511643
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/12/28 [received]
PHST- 2013/03/09 [revised]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - alzrt174 [pii]
AID - 10.1186/alzrt174 [doi]
PST - aheadofprint
SO  - Alzheimers Res Ther. 2013 Apr 19;5(2):20.

PMID- 23601500
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 228
IP  - 2
DP  - 2013 Jun
TI  - Association of arterial stiffness and diabetes with triglycerides-to-HDL
      cholesterol ratio for Japanese men: The Nagasaki Islands Study.
PG  - 491-5
LID - 10.1016/j.atherosclerosis.2013.03.021 [doi]
LID - S0021-9150(13)00197-4 [pii]
AB  - OBJECTIVE: Although many studies have reported that elevated serum triglycerides 
      to high-density lipoprotein cholesterol (TG-HDL) ratios constitute a risk for
      insulin resistance and increased arterial stiffness, no study has clarified as
      yet the association, in terms of the TG-HDL ratio, between diabetes and increased
      arterial stiffness evaluated by means of carotid intima-media thickness (CIMT)
      and cardio-ankle vascular index (CAVI). To investigate this association, we
      conducted a cross-sectional study of 1344 Japanese men aged 36-79 years
      undergoing a general health check. METHODS: We investigated the associations
      between atherosclerosis/arterial stiffness, evaluated by means of CIMT and CAVI, 
      and diabetes for all subjects, who were divided into tertiles according to TG-HDL
      levels. Diabetes was defined as HbA1c (NGSP) >/=6.5%, and/or initiation of
      glucose-lowering medication or insulin therapy. RESULTS: Of the 130 diabetes
      patients identified in the cohort, 56 patients had high TG-HDL (high TG-HDL
      diabetes) and 43 had low TG-HDL (low TG-HDL diabetes). We found that only
      diabetic patients with high TG-HDL were at a significant risk for atherosclerosis
      (diagnosed as CIMT >/= 1.1 mm) and increased arterial stiffness (diagnosed as
      CAVI >/= 8.0). The multivariable-adjusted odds ratios and 95% confidence
      intervals of atherosclerosis and increased arterial stiffness for diabetes were
      2.67 (95%CI: 1.35-5.28) and 2.36 (95%CI: 1.01-5.50), for total TG-HDL diabetes
      2.57 (95%CI: 1.32-5.02) and 3.56 (95%CI: 1.50-8.46) for high TG-HDL diabetes, and
      1.17 (95%CI: 0.52-2.63) and 0.80 (95%CI: 0.33-1.90) for low TG-HDL diabetes,
      respectively. CONCLUSION: Diabetes, especially high TG-HDL diabetes, constitutes 
      a significant risk for increased arterial stiffness and atherosclerosis.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Community Medicine, Nagasaki University Graduate School of
      Biomedical Sciences, Nagasaki, Japan; Department of Island and Community
      Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki,
      Japan. Electronic address: simizicyuu@yahoo.co.jp.
FAU - Shimizu, Yuji
AU  - Shimizu Y
FAU - Nakazato, Mio
AU  - Nakazato M
FAU - Sekita, Takaharu
AU  - Sekita T
FAU - Kadota, Koichiro
AU  - Kadota K
FAU - Yamasaki, Hironori
AU  - Yamasaki H
FAU - Takamura, Noboru
AU  - Takamura N
FAU - Aoyagi, Kiyoshi
AU  - Aoyagi K
FAU - Maeda, Takahiro
AU  - Maeda T
LA  - eng
PT  - Journal Article
DEP - 20130401
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/05 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/01 [aheadofprint]
AID - S0021-9150(13)00197-4 [pii]
AID - 10.1016/j.atherosclerosis.2013.03.021 [doi]
PST - ppublish
SO  - Atherosclerosis. 2013 Jun;228(2):491-5. doi:
      10.1016/j.atherosclerosis.2013.03.021. Epub 2013 Apr 1.

PMID- 23601475
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - A population-based survey of prevalence of diabetes and correlates in an urban
      slum community in Nairobi, Kenya.
PG  - 371
LID - 10.1186/1471-2458-13-371 [doi]
AB  - BACKGROUND: Urban slum populations in Africa continue to grow faster than
      national populations. Health strategies that focus on non-communicable diseases
      (NCD) in this segment of the population are generally lacking. We determined the 
      prevalence of diabetes and associated cardiovascular disease (CVD) risk factors
      correlates in Kibera, Nairobi's largest slum. METHODS: We conducted a
      population-based household survey utilising cluster sampling with probability
      proportional to size. Households were selected using a random walk method and
      consenting residents aged 18 years and above were recruited. The WHO STEPS
      instrument was administered. A random capillary blood sugar (RCBS) was obtained; 
      known persons with diabetes and subjects with a RCBS >11.1 had an 8 hours fasting
      blood sugar (FBS) drawn. Diabetes was defined as a RCBS of >/= 11.1 mmol/l and a 
      FBS of >/= 7.0 mmol/l, or a prior diagnosis or receiving diabetes drug treatment.
      RESULTS: Out of 2061 enrolled; 50.9% were males, mean age was 33.4 years and 87% 
      had a minimum of primary education. Only 10.6% had ever had a blood sugar
      measurement. Age adjusted prevalence of diabetes was 5.3% (95% CI 4.2-6.4) and
      prevalence increased with age peaking at 10.5% (95% CI 6.8-14.3%) in the 45-54
      year age category. Diabetes mellitus (DM) correlates were: 13.1% smoking, 74.9%
      alcohol consumption, 75.7% high level of physical activity; 16.3% obese and 29%
      overweight with higher rates in women.Among persons with diabetes the odds of
      obesity, elevated waist circumference and hypertension were three, two and three 
      fold respectively compared to those without diabetes. Cardiovascular risk factors
      among subjects with diabetes were high and mirrored that of the entire sample;
      however they had a significantly higher use of tobacco. CONCLUSIONS: This
      previously unstudied urban slum has a high prevalence of DM yet low screening
      rates. Key correlates include cigarette smoking and high alcohol consumption.
      However high levels of physical activity were also reported. Findings have
      important implications for NCD prevention and care. For this rapidly growing
      youthful urban slum population policy makers need to focus their attention on
      strategies that address not just communicable diseases but non communicable
      diseases as well.
AD  - School of Public Health, College of Health Sciences, University of Nairobi, P,O, 
      BOX 19676-00202, KNH, Nairobi, Kenya. richardayah@gmail.com.
FAU - Ayah, Richard
AU  - Ayah R
FAU - Joshi, Mark D
AU  - Joshi MD
FAU - Wanjiru, Rosemary
AU  - Wanjiru R
FAU - Njau, Elijah K
AU  - Njau EK
FAU - Otieno, C Fredrick
AU  - Otieno CF
FAU - Njeru, Erastus K
AU  - Njeru EK
FAU - Mutai, Kenneth K
AU  - Mutai KK
LA  - eng
PT  - Journal Article
DEP - 20130420
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3641964
OID - NLM: PMC3641964
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/14 [received]
PHST- 2013/04/04 [accepted]
PHST- 2013/04/20 [aheadofprint]
AID - 1471-2458-13-371 [pii]
AID - 10.1186/1471-2458-13-371 [doi]
PST - epublish
SO  - BMC Public Health. 2013 Apr 20;13:371. doi: 10.1186/1471-2458-13-371.

PMID- 23601378
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 Apr 22
TI  - Who Needs an Artificial Pancreas?
LID - 10.1111/1753-0407.12052 [doi]
AB  - Ever since the DCCT (1) confirmed that tight glycemic control can prevent long
      term diabetic complications, the goal of diabetes care has been to normalize
      blood sugar without causing hypoglycemia. Unfortunately, achieving this otherwise
      laudable goal requires huge amounts of patient and physician resources. For
      patients, management is onerous since it requires constant attentiveness to the
      volume of carbohydrates consumed, the testing of capillary blood sugar 4 times
      per day, the calculation of insulin doses, and either the injection of 2
      different types of insulin up to 5 times per day or use of a continuously worn
      insulin pump. The current insulin pump, while functioning as a calculator to help
      determine the prandial insulin bolus, still requires vigilance on the part of the
      wearer regarding the appropriateness of the dose which it computes as well as the
      insertion of the pump subcutaneous insulin infusion system every 2-3 days. In
      addition, some patients elect to use a subcutaneous sensor to monitor glucose
      trends which does not, however, obviate the need for glucose testing 4 times per 
      day testing while still requiring the wearing of a second device and subcutaneous
      reinsertion every 7 days. Finally, all of this necessitates the supervision by a 
      physician or certified diabetic educator (CDE), usually with visits at 3 month
      intervals. Given the burden imposed by such a program, it would seem very
      desirable to eliminate the human input and to develop a "closed-loop system"
      wherein a glucose sensing device records the blood sugar level and automatically 
      sends the information to an insulin delivery device. But given the currently
      available technology as well as the biology of blood glucose homeostasis, the
      question is whether the fantasy of this "artificial pancreas" can be transformed 
      into reality in the near future.
CI  - This article is protected by copyright. All rights reserved.
AD  - UCLA David Geffen School of Medicine, Los Angeles, CA, United States.
FAU - Winikoff, Janet
AU  - Winikoff J
FAU - Drexler, Andrew
AU  - Drexler A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/26 [accepted]
AID - 10.1111/1753-0407.12052 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 Apr 22. doi: 10.1111/1753-0407.12052.

PMID- 23601373
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
DP  - 2013 Apr 16
TI  - APOE Genotype Modifies the Relationship between Midlife Vascular Risk Factors and
      Later Cognitive Decline.
LID - S1052-3057(13)00082-7 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2013.03.013 [doi]
AB  - BACKGROUND: Vascular risk factors have been associated with cognitive decline;
      however, it remains unclear whether apolipoprotein E (APOE) genotype modifies
      this relationship. We aimed to further elucidate these relationships and extend
      previous findings by examining data from a more comprehensive cognitive
      assessment than used in prior studies. METHODS: In all, 1436 participants from
      the prospective Framingham Offspring Cohort Study underwent health examination
      from 1991 to 1995, followed by a baseline neuropsychological assessment
      (1999-2003) and a repeat neuropsychological assessment approximately 8 years
      later (2004-2009). Multivariate linear regression analyses were performed to
      examine the relationship among midlife vascular risk factors, presence of the
      APOE epsilon4 allele, and cognitive change. RESULTS: APOE genotype significantly 
      modified the associations between both midlife hypertension and cardiovascular
      disease and decline in language abilities and midlife diabetes and decline in
      verbal memory, attention, and visuospatial abilities. Associations between
      increased midlife vascular risk burden and greater cognitive decline were
      observed among APOE epsilon4 carriers but not noncarriers. CONCLUSIONS: The
      present findings revealed a subgroup at increased risk for cognitive decline
      (APOE epsilon4 carriers with midlife exposure to vascular risk factors) and
      suggest that treatment of vascular risk factors during midlife may reduce the
      risk of cognitive impairment later in life, particularly among APOE epsilon4
      carriers.
CI  - Copyright (c) 2013 National Stroke Association. Published by Elsevier Inc. All
      rights reserved.
AD  - Department of Psychiatry, University of California, San Diego School of Medicine,
      La Jolla, California. Electronic address: kbangen@ucsd.edu.
FAU - Bangen, Katherine J
AU  - Bangen KJ
FAU - Beiser, Alexa
AU  - Beiser A
FAU - Delano-Wood, Lisa
AU  - Delano-Wood L
FAU - Nation, Daniel A
AU  - Nation DA
FAU - Lamar, Melissa
AU  - Lamar M
FAU - Libon, David J
AU  - Libon DJ
FAU - Bondi, Mark W
AU  - Bondi MW
FAU - Seshadri, Sudha
AU  - Seshadri S
FAU - Wolf, Philip A
AU  - Wolf PA
FAU - Au, Rhoda
AU  - Au R
LA  - ENG
GR  - K24 AG026431/AG/NIA NIH HHS/United States
GR  - R01 AG012674/AG/NIA NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National
      Stroke Association
JID - 9111633
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/02/21 [received]
PHST- 2013/03/12 [accepted]
AID - S1052-3057(13)00082-7 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2013.03.013 [doi]
PST - aheadofprint
SO  - J Stroke Cerebrovasc Dis. 2013 Apr 16. pii: S1052-3057(13)00082-7. doi:
      10.1016/j.jstrokecerebrovasdis.2013.03.013.

PMID- 23601344
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1778-7254 (Electronic)
IS  - 1297-319X (Linking)
DP  - 2013 Apr 16
TI  - Lack of association of IL-6 polymorphism with rheumatoid arthritis/type 1
      diabetes: A meta-analysis.
LID - S1297-319X(12)00304-1 [pii]
LID - 10.1016/j.jbspin.2012.11.005 [doi]
AB  - OBJECTIVE: The aim of this study was to determine whether the interleukin (IL)-6 
      -174 single nucleotide polymorphism confers susceptibility to rheumatoid
      arthritis (RA) and type 1 diabetes (T1D) in multiple ethnic populations. METHODS:
      A meta-analysis was conducted on the association between the IL-6 -174
      polymorphism and RA/T1D susceptibility, using fixed and random effects models.
      RESULTS: Thirteen studies were included in the meta-analysis: RA: seven studies, 
      including six European and one Asian population; T1D: six studies, including five
      European and one South American population. There was no significant association 
      both in allele and genotype comparisons between the IL-6 -174 polymorphism and
      RA/T1D in all study subjects. Moreover, meta-analysis stratified by ethnicity
      indicated no significant association between the gene and RA/T1D. CONCLUSIONS:
      This meta-analysis suggests that the IL-6 -174 polymorphism might not confer
      susceptibility to RA/T1D.
CI  - Copyright (c) 2013. Published by Elsevier SAS.
AD  - Department of Epidemiology and Biostatistics, School of Public Health, Anhui
      Medical University, 81, Meishan Road, Hefei, 230032 Anhui, PR China.
FAU - Xu, Wang-Dong
AU  - Xu WD
FAU - Zhou, Mo
AU  - Zhou M
FAU - Peng, Hui
AU  - Peng H
FAU - Pan, Hai-Feng
AU  - Pan HF
FAU - Ye, Dong-Qing
AU  - Ye DQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Joint Bone Spine
JT  - Joint, bone, spine : revue du rhumatisme
JID - 100938016
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/02/26 [received]
PHST- 2012/11/21 [accepted]
AID - S1297-319X(12)00304-1 [pii]
AID - 10.1016/j.jbspin.2012.11.005 [doi]
PST - aheadofprint
SO  - Joint Bone Spine. 2013 Apr 16. pii: S1297-319X(12)00304-1. doi:
      10.1016/j.jbspin.2012.11.005.

PMID- 23601331
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
DP  - 2013 Apr 16
TI  - Insulin sensitivity, and beta-cell function in relation to hemoglobin A1C.
LID - S0939-4753(13)00031-8 [pii]
LID - 10.1016/j.numecd.2013.01.011 [doi]
AB  - BACKGROUND AND AIMS: The A1C diagnostic criterion for identifying individuals at 
      increased risk for diabetes, introduced by the American Diabetes Association in
      2010, was not defined on the basis of the principal pathophysiological
      abnormalities responsible for the development and progression of type 2 diabetes;
      we therefore wished to gain a deeper insight into the metabolic abnormalities
      characterizing the group of at risk individuals with an A1C value of 5.7-6.4%.
      METHODS AND RESULTS: As many as 338 non-diabetic offspring of type 2 diabetic
      patients were consecutively recruited. Insulin secretion was assessed using both 
      indexes derived from oral glucose tolerance test (OGTT), and intravenous glucose 
      tolerance test (IVGTT). Insulin sensitivity was measured by hyperinsulinemic
      euglycemic clamp. As compared with subjects with A1C <5.7%, individuals with A1C 
      of 5.7-6.4% exhibited lower insulin sensitivity after adjusting for age, gender
      and body mass index (BMI). Insulin secretion estimated from the OGTT, did not
      differ between the two groups. By contrast, as compared with subjects with A1C
      <5.7%, the acute insulin response (AIR) during an IVGTT and both IVGTT-derived
      and OGTT-derived disposition indexes were reduced in individuals with A1C of
      5.7-6.4% after adjusting for age, gender and BMI. As A1C increased to >/=5.7%, a 
      sharp decrease in insulin sensitivity and beta-cell function, measured as
      disposition index, was observed. CONCLUSIONS: Caucasian individuals with A1C
      >/=5.7% exhibit both core pathophysiological defects of type 2 diabetes i.e.
      insulin resistance and beta-cell dysfunction.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Systems Medicine, University of Rome-Tor Vergata, Italy.
FAU - Marini, M A
AU  - Marini MA
FAU - Frontoni, S
AU  - Frontoni S
FAU - Succurro, E
AU  - Succurro E
FAU - Arturi, F
AU  - Arturi F
FAU - Sciacqua, A
AU  - Sciacqua A
FAU - Hribal, M L
AU  - Hribal ML
FAU - Perticone, F
AU  - Perticone F
FAU - Sesti, G
AU  - Sesti G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/11/17 [received]
PHST- 2012/12/31 [revised]
PHST- 2013/01/25 [accepted]
AID - S0939-4753(13)00031-8 [pii]
AID - 10.1016/j.numecd.2013.01.011 [doi]
PST - aheadofprint
SO  - Nutr Metab Cardiovasc Dis. 2013 Apr 16. pii: S0939-4753(13)00031-8. doi:
      10.1016/j.numecd.2013.01.011.

PMID- 23601307
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1542-0086 (Electronic)
IS  - 0006-3495 (Linking)
VI  - 104
IP  - 8
DP  - 2013 Apr 16
TI  - Generating accurate contact maps of transient long-range interactions in
      intrinsically disordered proteins by paramagnetic relaxation enhancement.
PG  - 1635-6
LID - 10.1016/j.bpj.2013.01.060 [doi]
LID - S0006-3495(13)00211-7 [pii]
AD  - Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and 
      Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
      mariusc@intra.niddk.nih.gov
FAU - Clore, G Marius
AU  - Clore GM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biophys J
JT  - Biophysical journal
JID - 0370626
SB  - IM
PMC - PMC3628561
OID - NLM: PMC3628561 [Available on 04/16/14]
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PMCR- 2014/04/16 00:00
PHST- 2012/12/11 [received]
PHST- 2013/01/07 [revised]
PHST- 2013/01/08 [accepted]
AID - S0006-3495(13)00211-7 [pii]
AID - 10.1016/j.bpj.2013.01.060 [doi]
PST - ppublish
SO  - Biophys J. 2013 Apr 16;104(8):1635-6. doi: 10.1016/j.bpj.2013.01.060.

PMID- 23601221
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 2212-4411 (Electronic)
VI  - 115
IP  - 5
DP  - 2013 May
TI  - Bisphosphonate related osteonecrosis of the jaws: clinico-pathological
      investigation and histomorphometric analysis.
PG  - 660-6
LID - 10.1016/j.oooo.2013.03.001 [doi]
LID - S2212-4403(13)00107-7 [pii]
AB  - OBJECTIVES: Clinico-pathological evaluation of bisphosphonate (BP)-related
      osteonecrosis of jaws, comparison between oral (PO) and intravenous (IV) BPs and 
      histomorphometric analysis of associated actinomyces. STUDY DESIGN: Retrospective
      clinical and histomorphometric analysis. Data on background, clinical, treatment 
      and follow-up were analyzed. Actinomyces colonies were identified by typical
      filamentous colony morphology, Gram, and PAS stains. Colony density and relative 
      colony surface area were measured. RESULTS: Fifty-two patients were included, 37 
      (71.2%) IV, 15 (28.8%) PO BPs. with a mean duration of 2.33 and, 4.33 years
      respectively. One hundred percent of cases exhibited actinomyces colonization.
      The relative colony surface area was significantly higher in PO treatment (P =
      .024), with no differences in density, healing time or antibiotic treatment
      periods. High frequency of diabetes mellitus (60% PO cases) and corticosteroid
      treatment (25% of cases) were recorded. CONCLUSION: Infection with actinomyces is
      a common denominator in BP-related osteonecrosis of the jaws (BRONJ), regardless 
      of administration route. Diabetes and corticosteroid treatment seem to be
      important contributing factors for BRONJ.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Periodontics, Hebrew University-Hadassah School of Dental Medicine,
      Jerusalem, Israel.
FAU - Anavi-Lev, Karen
AU  - Anavi-Lev K
FAU - Anavi, Yakir
AU  - Anavi Y
FAU - Chaushu, Gavriel
AU  - Chaushu G
FAU - Alon, Dror M
AU  - Alon DM
FAU - Gal, Gavriel
AU  - Gal G
FAU - Kaplan, Ilana
AU  - Kaplan I
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oral Surg Oral Med Oral Pathol Oral Radiol
JT  - Oral surgery, oral medicine, oral pathology and oral radiology
JID - 101576782
SB  - D
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/23 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/03/03 [accepted]
AID - S2212-4403(13)00107-7 [pii]
AID - 10.1016/j.oooo.2013.03.001 [doi]
PST - ppublish
SO  - Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 May;115(5):660-6. doi:
      10.1016/j.oooo.2013.03.001.

PMID- 23601172
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
DP  - 2013 Apr 20
TI  - Blood glucose fluctuation affects skin collagen metabolism in the diabetic mouse 
      by inhibiting the mitogen-activated protein kinase and Smad pathways.
LID - 10.1111/ced.12002 [doi]
AB  - Background. We recently reported that in mice, blood glucose fluctuations (BGF)
      produced more detrimental effects on skin structure and function than did
      diabetes alone. Aim. To determine whether treatment of BGF changes the collagen
      metabolism in the skin of diabetic mice, and to explore its possible molecular
      mechanism further. Methods. The study used diabetic and BGF animal models.
      Immunohistochemistry, western blotting and real-time PCR analysis were used to
      detect the expression of type I collagen, matrix metalloproteinase (MMP)-1, MMP-2
      and MMP-13, tissue inhibitor of metalloproteinase (TIMP)-1, extracellular
      signal-regulated kinase, p38, and Smad2/3. The activities of mitogen-activated
      protein kinase (MAPK) and Smad signal molecules were also detected by western
      blotting, and the skin fibroblast ultrastructure was examined using an electron
      microscope. Results. BGF treatment produced a twofold reduction in type I
      collagen synthesis compared with diabetes-only mice. Expression of MMP-1, MMP-2
      and MMP-13 increased markedly in the BGF-treated mice, but TIMP-1 expression was 
      strongly downregulated by the BGF treatment. There was also evidence of higher
      levels of apoptosis of skin fibroblasts after BGF treatment. Conclusions. BGF
      treatment can affect collagen production in the skin of diabetic BGF mice by
      inhibiting collagen synthesis and increasing collagen degradation. Furthermore,
      both MAPK and Smad signalling pathways seem to play a role in the inhibition of
      collagen production in diabetic mice treated with BGF.
CI  - (c) The Author(s). CED (c) 2013 British Association of Dermatologists.
AD  - Institute of Biomedicine, School of Life Science, East China Normal University,
      Shanghai, China Department of Endocrinology, The Tenth People's Hospital of
      Tongji University, Shanghai, China.
FAU - Ye, X
AU  - Ye X
FAU - Cheng, X
AU  - Cheng X
FAU - Liu, L
AU  - Liu L
FAU - Zhao, D
AU  - Zhao D
FAU - Dang, Y
AU  - Dang Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1111/ced.12002 [doi]
PST - aheadofprint
SO  - Clin Exp Dermatol. 2013 Apr 20. doi: 10.1111/ced.12002.

PMID- 23601171
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1600-6143 (Electronic)
IS  - 1600-6135 (Linking)
VI  - 13
IP  - 6
DP  - 2013 Jun
TI  - Co-transplantation of bone marrow-derived endothelial progenitor cells improves
      revascularization and organization in islet grafts.
PG  - 1429-40
LID - 10.1111/ajt.12222 [doi]
AB  - Bone marrow-derived early endothelial progenitor cells (BM-EPCs) are a clinical
      tool for enhancing revascularization. However, the therapeutic efficacy of
      co-transplantation of BM-EPC with islets has not been investigated. In this
      study, marginal mass islets were co-transplanted with or without BM-EPCs under
      the kidney capsules of syngeneic streptozotocin-induced diabetic mice. Using
      green fluorescent protein transgenic (GFP-Tg) mice as BM-EPC and islet donors or 
      recipients, the role of EPCs in revascularization was assessed for graft
      morphology, vascular density and fate of EPCs by immunohistochemistry. Islet-EPC 
      co-transplantation improved the outcome of islet transplantation as measured by
      glucose tolerance, serum insulin level and diabetes reversal rate, compared with 
      transplantation of islets alone. Between groups, the morphology of islet grafts
      showed significant differences in size and composition of grafted endocrine
      tissues. Significantly more vessel density derived from donors and recipients was
      detected with islet-EPC co-transplantation. Abundant GFP-Tg mice-derived BM-EPCs 
      (GFP-EPCs) were observed in or around islet grafts and incorporated into
      CD31-positive capillaries. Remaining GFP-EPCs expressed VEGF. In conclusion,
      co-transplantation of islets with BM-EPCs could improve the outcome of marginal
      mass islet transplantation by promoting revascularization and preserving islet
      morphology.
CI  - (c) Copyright 2013 The American Society of Transplantation and the American
      Society of Transplant Surgeons.
AD  - Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical
      Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
      Samsung Biomedical Research Institute, Seoul, Republic of Korea.
FAU - Oh, B J
AU  - Oh BJ
FAU - Oh, S H
AU  - Oh SH
FAU - Jin, S M
AU  - Jin SM
FAU - Suh, S
AU  - Suh S
FAU - Bae, J C
AU  - Bae JC
FAU - Park, C-G
AU  - Park CG
FAU - Lee, M-S
AU  - Lee MS
FAU - Lee, M-K
AU  - Lee MK
FAU - Kim, J H
AU  - Kim JH
FAU - Kim, K-W
AU  - Kim KW
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - Am J Transplant
JT  - American journal of transplantation : official journal of the American Society of
      Transplantation and the American Society of Transplant Surgeons
JID - 100968638
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/08/07 [received]
PHST- 2013/02/13 [revised]
PHST- 2013/02/14 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1111/ajt.12222 [doi]
PST - ppublish
SO  - Am J Transplant. 2013 Jun;13(6):1429-40. doi: 10.1111/ajt.12222. Epub 2013 Apr
      18.

PMID- 23601039
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - A practical, clinical approach to the assessment and management of suspected
      insulin allergy.
LID - 10.1111/dme.12194 [doi]
AB  - BACKGROUND: Although allergic reactions to insulin are uncommon, they can be
      difficult to diagnose and management may be very difficult in subjects with Type 
      1 diabetes with severe allergy. Access to allergists and specialist diagnostic
      tests is limited and few diabetes specialists are familiar with desensitization
      as a means of treating allergy. People with diabetes may develop symptoms which
      mimic insulin allergy but are attributable to other conditions. CASE REPORTS:
      Here we describe three cases of insulin allergy. One patient presented with
      severe, albeit localized, urticarial reactions at injection sites. The most
      severe case was a woman with recent-onset Type 1 diabetes who presented with
      grade 2 anaphylaxis. The third patient presented with generalized urticaria and
      angioedema. Insulin allergy was confirmed in all three cases. METHODS: Assessment
      involved measurement of immunoglobulin and anti-insulin antibody levels. Skin
      testing was performed in two cases. Treatments included desensitization in one
      case, alternative insulin preparations, antihistamines and continuous
      subcutaneous insulin infusion. In all three cases of insulin allergy there has
      been successful resolution of symptoms. CONCLUSIONS: The clinical assessment and 
      investigation in cases of suspected insulin allergy is described, along with
      detailed algorithms for skin testing and desensitization. This case series
      demonstrates an approach to challenging cases of suspected insulin allergy which 
      will be helpful for diabetes specialists.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Division of Endocrinology and Metabolism, Department of Medicine, University of
      Alberta, Edmonton, AB, Canada.
FAU - Jacquier, J
AU  - Jacquier J
FAU - Chik, C L
AU  - Chik CL
FAU - Senior, P A
AU  - Senior PA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
AID - 10.1111/dme.12194 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12194.

PMID- 23601034
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1747-0803 (Electronic)
IS  - 1747-079X (Linking)
DP  - 2013 Apr 22
TI  - Interventional Therapy of Supravalvular Pulmonary Stenosis via a Mechanical Valve
      in the Pulmonary Position.
LID - 10.1111/chd.12066 [doi]
AB  - There is an increasing number of patients with congenital heart disease and
      pathology of the right ventricular outflow tract in whom a mechanical pulmonary
      valve replacement is chosen for permanent palliation. Despite corrective surgery,
      some of these patients may have residual or secondary supravalvular pulmonary
      stenosis or peripheral pulmonary stenosis, which necessitate interventional
      therapy after valve replacement. There is a general understanding that
      interventional therapy via a mechanical valve in pulmonary position may induce
      mechanical valve dysfunction and should therefore be avoided. We report our
      experience in three patients with a St. Jude Medical mechanical valve in
      pulmonary position and supravalvular pulmonary stenosis or a peripheral pulmonary
      stenosis where we have safely performed standard interventions (i.e., balloon
      angioplasty and stent implantation) across the mechanical valve without any
      complications. Our specific technique using a long sheath as safety guard, which 
      holds the mechanical valve open during the procedure but allows the positioning
      of all mechanical devices and catheters necessary for the procedures, is
      described. In all patients, the long-term follow-up of the valve function is
      excellent.
CI  - (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Congenital Heart Defects and Pediatric Cardiology, Heart and
      Diabetes Centre NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.
FAU - Habash, Sheeraz
AU  - Habash S
FAU - Haas, Nikolaus A
AU  - Haas NA
FAU - Laser, Kai Thorsten
AU  - Laser KT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130422
TA  - Congenit Heart Dis
JT  - Congenital heart disease
JID - 101256510
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/02/14 [accepted]
AID - 10.1111/chd.12066 [doi]
PST - aheadofprint
SO  - Congenit Heart Dis. 2013 Apr 22. doi: 10.1111/chd.12066.

PMID- 23601012
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Feedback of personal retinal images appears to have a motivational impact in
      people with non-proliferative diabetic retinopathy and suboptimal HbA : findings 
      of a pilot study.
LID - 10.1111/dme.12192 [doi]
AB  - AIM: To conduct a pilot study to explore the potential impact of visual feedback 
      of personal retinal images on diabetes outcomes. METHODS: Twenty-five
      participants with non-proliferative diabetic retinopathy and suboptimal HbA1c (> 
      53 mmol/mol; > 7%) were randomized to receive visual feedback of their own
      retinal images or to a control group. At baseline and 3-month follow-up, HbA1c , 
      standard measures of beliefs, diabetes-related distress and self-care activities 
      were assessed. RESULTS: In unadjusted models, relative to controls, the
      intervention group showed significantly greater improvement in HbA1c at 3-month
      follow-up (-0.6% vs. +0.3%, P < 0.01), as well as enhanced motivation to improve 
      blood glucose management (P < 0.05). CONCLUSIONS: This small pilot study provides
      preliminary evidence that visual feedback of personal retinal images may offer a 
      practical educational strategy for clinicians in eye care services to improve
      diabetes outcomes in non-target compliant patients. A fully powered randomized
      controlled trial is required to confirm these findings and determine the optimal 
      use of feedback to produce sustained effects.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital,
      University of Melbourne, Vic., Australia.
FAU - Rees, G
AU  - Rees G
FAU - Lamoureux, E L
AU  - Lamoureux EL
FAU - Nicolaou, T E
AU  - Nicolaou TE
FAU - Hodgson, L A B
AU  - Hodgson LA
FAU - Weinman, J
AU  - Weinman J
FAU - Speight, J
AU  - Speight J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/14 [accepted]
AID - 10.1111/dme.12192 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12192.

PMID- 23600988
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Exocrine pancreatic function in hepatocyte nuclear factor 1beta-maturity-onset
      diabetes of the young (HNF1B-MODY) is only moderately reduced: compensatory
      hypersecretion from a hypoplastic pancreas.
LID - 10.1111/dme.12190 [doi]
AB  - OBJECTIVES: To examine the exocrine pancreatic function in carriers of the
      hepatocyte nuclear factor 1beta gene (HNF1B) mutation by direct testing. METHODS:
      Patients with HNF1B mutations and control subjects were assessed using rapid
      endoscopic secretin tests and secretin-stimulated magnetic resonance imaging.
      Seven patients and 25 controls underwent endoscopy, while eight patients and 20
      controls had magnetic resonance imaging. Ductal function was assessed according
      to peak bicarbonate concentrations and acinar function was assessed according to 
      peak digestive enzyme activities in secretin-stimulated duodenal juice. The
      association of pancreatic exocrine function and diabetes status with pancreatic
      gland volume was examined. RESULTS: The mean increase in secretin-stimulated
      duodenal fluid was smaller in patients than controls (4.0 vs 6.4 ml/min; P =
      0.003). We found lower ductal function in patients than controls (median peak
      bicarbonate concentration: 73 vs 116 mEq/L; P < 0.001) and lower acinar function 
      (median peak lipase activity: 6.4 vs 33.5 kU/ml; P = 0.01; median peak elastase
      activity: 0.056 vs 0.130 U/ml; P = 0.01). Pancreatic fluid volume outputs
      correlated significantly with pancreatic gland volumes (r2 = 0.71, P = 0.008) in 
      patients. The total fluid output to pancreatic gland volume ratios were higher in
      patients than controls (4.5 vs 1.3 ml/cm3 ; P = 0.03), suggesting compensatory
      hypersecretion in the remaining gland. CONCLUSION: Carriers of the HNF1B mutation
      have lower exocrine pancreatic function involving both ductal and acinar cells.
      Compensatory hypersecretion suggests that the small pancreas of HNF1B mutation
      carriers is attributable to hypoplasia, not atrophy.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - KG Jebsen Center for Diabetes Research, Department of Clinical Science,
      University of Bergen, Bergen, Norway; Department of Pediatrics, Haukeland
      University Hospital, Bergen, Norway.
FAU - Tjora, E
AU  - Tjora E
FAU - Wathle, G
AU  - Wathle G
FAU - Erchinger, F
AU  - Erchinger F
FAU - Engjom, T
AU  - Engjom T
FAU - Molven, A
AU  - Molven A
FAU - Aksnes, L
AU  - Aksnes L
FAU - Haldorsen, I S
AU  - Haldorsen IS
FAU - Dimcevski, G
AU  - Dimcevski G
FAU - Raeder, H
AU  - Raeder H
FAU - Njolstad, P R
AU  - Njolstad PR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/14 [accepted]
AID - 10.1111/dme.12190 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12190.

PMID- 23600924
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1439-0272 (Electronic)
IS  - 0303-4569 (Linking)
DP  - 2013 Apr 20
TI  - Adult circumcision and male sexual health: a retrospective analysis.
LID - 10.1111/and.12101 [doi]
AB  - We aimed to evaluate possible associations of circumcision with several sexual
      dysfunctions and to identify predictors for the development of these outcomes
      post-operatively. Telephone surveys about sexual habits and dysfunctions before
      and after intervention were conducted post-operatively to patients that underwent
      circumcision in Centro Hospitalar Vila Nova de Gaia/Espinho during 2011. McNemar 
      test was used for a matched-pairs analysis of pre- and post-operative data. Odds 
      ratios, adjusted in a multivariate analysis, explored predictors of de novo
      sexual dysfunctions after circumcision. With intervention, there was an increase 
      in frequency of erectile dysfunction (9.7% versus 25.8%, P = 0.002) and delayed
      orgasm (11.3% versus 48.4%, P < 0.001), and a significant symptomatic improvement
      in patients with pain with intercourse (50.0% versus 6.5%, P < 0.001).
      Significant predictors for de novo erectile dysfunction were diabetes mellitus
      (OR 9.81, P = 0.048) and lack of sexual desire (OR 8.76, P = 0.028). Less than
      three sex partners (OR 7.04, P = 0.007) and low sexual desire (OR 7.49, P =
      0.029) were significant predictors for de novo delayed orgasm.
CI  - (c) 2013 Blackwell Verlag GmbH.
AD  - Urology Department, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de
      Gaia, Portugal.
FAU - Dias, J
AU  - Dias J
FAU - Freitas, R
AU  - Freitas R
FAU - Amorim, R
AU  - Amorim R
FAU - Espiridiao, P
AU  - Espiridiao P
FAU - Xambre, L
AU  - Xambre L
FAU - Ferraz, L
AU  - Ferraz L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130420
TA  - Andrologia
JT  - Andrologia
JID - 0423506
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/02/22 [accepted]
AID - 10.1111/and.12101 [doi]
PST - aheadofprint
SO  - Andrologia. 2013 Apr 20. doi: 10.1111/and.12101.

PMID- 23600827
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 172
IP  - 3
DP  - 2013 Jun
TI  - Regulatory T cell phenotype and function 4 years after GAD-alum treatment in
      children with type 1 diabetes.
PG  - 394-402
LID - 10.1111/cei.12078 [doi]
AB  - Glutamic acid decarboxylase (GAD)(65) formulated with aluminium hydroxide
      (GAD-alum) was effective in preserving insulin secretion in a Phase II clinical
      trial in children and adolescents with recent-onset type 1 diabetes. In addition,
      GAD-alum treated patients increased CD4(+) CD25(hi) forkhead box protein 3(+)
      (FoxP3(+)) cell numbers in response to in-vitro GAD(65) stimulation. We have
      carried out a 4-year follow-up study of 59 of the original 70 patients to
      investigate long-term effects on the frequency and function of regulatory T cells
      after GAD-alum treatment. Peripheral blood mononuclear cells were stimulated in
      vitro with GAD65 for 7 days and expression of regulatory T cell markers was
      measured by flow cytometry. Regulatory T cells (CD4(+) CD25(hi) CD127(lo)) and
      effector T cells (CD4(+) CD25(-) CD127(+)) were further sorted, expanded and used
      in suppression assays to assess regulatory T cell function after GAD-alum
      treatment. GAD-alum-treated patients displayed higher frequencies of in-vitro
      GAD(65) -induced CD4(+) CD25(+) CD127(+) as well as CD4(+) CD25(hi) CD127(lo) and
      CD4(+) FoxP3(+) cells compared to placebo. Moreover, GAD(65) stimulation induced 
      a population of CD4(hi) cells consisting mainly of CD25(+) CD127(+) , which was
      specific of GAD-alum-treated patients (16 of 25 versus one of 25 in placebo).
      Assessment of suppressive function in expanded regulatory T cells revealed no
      difference between GAD-alum- and placebo-treated individuals. Regulatory T cell
      frequency did not correlate with C-peptide secretion throughout the study. In
      conclusion, GAD-alum treatment induced both GAD(65) -reactive CD25(+) CD127(+)
      and CD25(hi) CD127(lo) cells, but no difference in regulatory T cell function 4
      years after GAD-alum treatment.
CI  - (c) 2013 British Society for Immunology.
AD  - Division of Pediatrics, Department of Clinical and Experimental Medicine, Faculty
      of Health Sciences, Linkoping University, Linkoping, Sweden.
FAU - Pihl, M
AU  - Pihl M
FAU - Akerman, L
AU  - Akerman L
FAU - Axelsson, S
AU  - Axelsson S
FAU - Cheramy, M
AU  - Cheramy M
FAU - Hjorth, M
AU  - Hjorth M
FAU - Mallone, R
AU  - Mallone R
FAU - Ludvigsson, J
AU  - Ludvigsson J
FAU - Casas, R
AU  - Casas R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
SB  - IM
PMC - PMC3646438
OID - NLM: PMC3646438 [Available on 06/01/14]
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PMCR- 2014/06/01 00:00
PHST- 2013/01/18 [accepted]
AID - 10.1111/cei.12078 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2013 Jun;172(3):394-402. doi: 10.1111/cei.12078.

PMID- 23600826
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 172
IP  - 3
DP  - 2013 Jun
TI  - Fatty acids modulate cytokine and chemokine secretion of stimulated human whole
      blood cultures in diabetes.
PG  - 383-93
LID - 10.1111/cei.12071 [doi]
AB  - Fatty acids, uric acid and glucose are thought to contribute to subclinical
      inflammation associated with diabetes mellitus. We tested whether co-incubation
      of free fatty acids and uric acid or glucose influences the secretion of immune
      mediators from stimulated human whole blood in vitro. Fresh whole blood samples
      from 20 healthy subjects, 20 patients with type 1 diabetes and 23 patients with
      type 2 diabetes were incubated for 24 h with palmitic acid (PAL), linolenic acid 
      (LIN) or eicosapentaenoic acid (EPA) alone or together with elevated
      concentrations of uric acid or glucose. Concentrations of proinflammatory
      cytokines interleukin (IL)-1beta, IL-2, IL-12(p70), IL-18, IFN-gamma, of
      regulatory cytokines IL-4, IL-10, IL-17 and chemokine CCL2 (MCP-1) were measured 
      by multiplex-bead technology from supernatants. Co-incubation of fatty acids with
      uric acid resulted in a significant reduction of IL-10, IL-12(p70), IFN-gamma and
      CCL2 (MCP-1) concentrations in supernatants compared to incubation with uric acid
      alone (P < 0.0001). In contrast, IL-18 was up-regulated upon co-stimulation with 
      fatty acids and uric acid. Similarly, co-incubation of fatty acids with glucose
      diminished secretion of IL-10, IFN-gamma and CCL2 (monocyte chemotactic
      protein-1), while IL-8 was up-regulated (P < 0.001). Samples from healthy and
      diabetic subjects did not differ after adjustment for age, sex, body mass index
      and diabetes type. All three fatty acids similarly influenced whole blood
      cytokine release in vitro and modulated uric acid or glucose-stimulated cytokine 
      secretion. Although the omega-3-fatty acid EPA showed slightly stronger effects, 
      further studies are required to elaborate the differential effects of PAL, LIN
      and EPA on disease risk observed previously in epidemiological studies.
CI  - (c) 2013 British Society for Immunology.
AD  - Institute for Clinical Diabetology, German Diabetes Center, Leibniz-Center for
      Diabetes Research at the Heinrich-Heine-University, Dusseldorf, Germany.
FAU - Simon, M C
AU  - Simon MC
FAU - Bilan, S
AU  - Bilan S
FAU - Nowotny, B
AU  - Nowotny B
FAU - Dickhaus, T
AU  - Dickhaus T
FAU - Burkart, V
AU  - Burkart V
FAU - Schloot, N C
AU  - Schloot NC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
SB  - IM
PMC - PMC3646437
OID - NLM: PMC3646437 [Available on 06/01/14]
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PMCR- 2014/06/01 00:00
PHST- 2013/01/14 [accepted]
AID - 10.1111/cei.12071 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2013 Jun;172(3):383-93. doi: 10.1111/cei.12071.

PMID- 23600825
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 172
IP  - 3
DP  - 2013 Jun
TI  - Effects of combination therapy with dipeptidyl peptidase-IV and histone
      deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
PG  - 375-82
LID - 10.1111/cei.12068 [doi]
AB  - Type 1 diabetes (T1D) results from T helper type 1 (Th1)-mediated autoimmune
      destruction of insulin-producing beta cells. Novel experimental therapies for T1D
      target immunomodulation, beta cell survival and inflammation. We examined
      combination therapy with the dipeptidyl peptidase-IV inhibitor MK-626 and the
      histone deacetylase inhibitor vorinostat in the non-obese diabetic (NOD) mouse
      model of T1D. We hypothesized that combination therapy would ameliorate T1D by
      providing protection from beta cell inflammatory destruction while simultaneously
      shifting the immune response towards immune-tolerizing regulatory T cells
      (T(regs)). Although neither mono- nor combination therapies with MK-626 and
      vorinostat caused disease remission in diabetic NOD mice, the combination of
      MK-626 and vorinostat increased beta cell area and reduced the mean insulitis
      score compared to diabetic control mice. In prediabetic NOD mice, MK-626
      monotherapy resulted in improved glucose tolerance, a reduction in mean insulitis
      score and an increase in pancreatic lymph node T(reg) percentage, and combination
      therapy with MK-626 and vorinostat increased pancreatic lymph node T(reg)
      percentage. We conclude that neither single nor combination therapies using
      MK-626 and vorinostat induce diabetes remission in NOD mice, but combination
      therapy appears to have beneficial effects on beta cell area, insulitis and
      T(reg) populations. Combinations of vorinostat and MK-626 may serve as beneficial
      adjunctive therapy in clinical trials for T1D prevention or remission.
CI  - (c) 2013 British Society for Immunology.
AD  - Department of Pediatrics and the Herman B Wells Center for Pediatric Research,
      Indiana University School of Medicine, Indianapolis, IN, USA.
FAU - Cabrera, S M
AU  - Cabrera SM
FAU - Colvin, S C
AU  - Colvin SC
FAU - Tersey, S A
AU  - Tersey SA
FAU - Maier, B
AU  - Maier B
FAU - Nadler, J L
AU  - Nadler JL
FAU - Mirmira, R G
AU  - Mirmira RG
LA  - eng
GR  - F32 DK094489/DK/NIDDK NIH HHS/United States
GR  - R01 DK083583/DK/NIDDK NIH HHS/United States
GR  - T32 DK065549/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
SB  - IM
PMC - PMC3646436
OID - NLM: PMC3646436 [Available on 06/01/14]
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PMCR- 2014/06/01 00:00
PHST- 2013/01/10 [accepted]
AID - 10.1111/cei.12068 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2013 Jun;172(3):375-82. doi: 10.1111/cei.12068.

PMID- 23600824
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 172
IP  - 3
DP  - 2013 Jun
TI  - Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1
      diabetes.
PG  - 363-74
LID - 10.1111/cei.12064 [doi]
AB  - CD4(+) memory cell development is dependent upon T cell receptor (TCR) signal
      strength, antigen dose and the cytokine milieu, all of which are altered in type 
      1 diabetes (T1D). We hypothesized that CD4(+) T cell turnover would be greater in
      type 1 diabetes subjects compared to controls. In vitro studies of T cell
      function are unable to evaluate dynamic aspects of immune cell homoeostasis.
      Therefore, we used deuterium oxide ((2) H(2)O) to assess in vivo turnover of
      CD4(+) T cell subsets in T1D (n = 10) and control subjects (n = 10). Serial
      samples of naive, memory and regulatory (T(reg)) CD4(+) T cell subsets were
      collected and enrichment of deoxyribose was determined by gas chromatography-mass
      spectrometry (GC-MS). Quantification of T cell turnover was performed using
      mathematical models to estimate fractional enrichment (f, n = 20), turnover rate 
      (k, n = 20), proliferation (p, n = 10) and disappearance (d*, n = 10). Although
      turnover of T(regs) was greater than memory and naive cells in both controls and 
      T1D subjects, no differences were seen between T1D and controls in T(reg) or
      naive kinetics. However, turnover of CD4(+) memory T cells was faster in those
      with T1D compared to control subjects. Measurement and modelling of incorporated 
      deuterium is useful for evaluating the in vivo kinetics of immune cells in T1D
      and could be incorporated into studies of the natural history of disease or
      clinical trials designed to alter the disease course. The enhanced CD4(+) memory 
      T cell turnover in T1D may be important in understanding the pathophysiology and 
      potential treatments of autoimmune diabetes.
CI  - (c) 2013 British Society for Immunology.
AD  - Benaroya Research Institute, Seattle, WA, USA.
FAU - Bollyky, J B
AU  - Bollyky JB
FAU - Long, S A
AU  - Long SA
FAU - Fitch, M
AU  - Fitch M
FAU - Bollyky, P L
AU  - Bollyky PL
FAU - Rieck, M
AU  - Rieck M
FAU - Rogers, R
AU  - Rogers R
FAU - Samuels, P L
AU  - Samuels PL
FAU - Sanda, S
AU  - Sanda S
FAU - Buckner, J H
AU  - Buckner JH
FAU - Hellerstein, M K
AU  - Hellerstein MK
FAU - Greenbaum, C J
AU  - Greenbaum CJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
SB  - IM
PMC - PMC3646435
OID - NLM: PMC3646435 [Available on 06/01/14]
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PMCR- 2014/06/01 00:00
PHST- 2013/01/07 [accepted]
AID - 10.1111/cei.12064 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2013 Jun;172(3):363-74. doi: 10.1111/cei.12064.

PMID- 23600734
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1939-1676 (Electronic)
IS  - 0891-6640 (Linking)
VI  - 27
IP  - 3
DP  - 2013 May
TI  - Prospective evaluation of biweekly streptozotocin in 19 dogs with insulinoma.
PG  - 483-90
LID - 10.1111/jvim.12086 [doi]
AB  - BACKGROUND: Administration of streptozotocin (STZ) at a 21-day interval has been 
      described in dogs with stage II and III insulinoma. Myelosuppression was not
      observed, suggesting the possibility of increasing dose intensity by decreasing
      the interval between doses. OBJECTIVE: To describe the tolerability of a biweekly
      STZ protocol. A secondary objective was to describe the outcome of dogs treated
      with this protocol. ANIMALS: Nineteen dogs with residual local, metastatic, or
      recurrent insulinoma. METHODS: After surgery for insulinoma, or at the time of
      recurrence, dogs were treated with a previously described STZ and saline diuresis
      protocol. Treatments were administered every 14 days. All dogs received
      antiemetic treatment. Adverse events (AEs) were recorded and graded. Outcome
      endpoints assessed were progression-free survival (PFS) and survival. RESULTS:
      None of the dogs experienced neutropenia or thrombocytopenia. Mild to moderate
      gastrointestinal toxicity was the most common AE. Diabetes mellitus was observed 
      in 8 dogs and, in 6, resulted in euthanasia or death. Two dogs developed
      nephrotoxicity manifested as Fanconi syndrome in 1 and nephrogenic diabetes
      insipidus in the other. Six dogs developed increased alanine amino transferase
      activity. Hypoglycemia at the end of the STZ infusion, resulted in collapse in 1 
      dog and a generalized seizure in another. The median overall PFS and survival
      time were 196 and 308 days, respectively. CONCLUSIONS AND CLINICAL IMPORTANCE:
      Streptozotocin can be safely administered to dogs with insulinoma, but serious
      AEs are possible. Additional investigation is required to better define the role 
      of STZ in managing dogs with insulinoma.
CI  - Copyright (c) 2013 by the American College of Veterinary Internal Medicine.
AD  - Department of Small Animal Medicine and Surgery, University of Georgia, College
      of Veterinary Medicine, Athens, GA.
FAU - Northrup, N C
AU  - Northrup NC
FAU - Rassnick, K M
AU  - Rassnick KM
FAU - Gieger, T L
AU  - Gieger TL
FAU - Kosarek, C E
AU  - Kosarek CE
FAU - McFadden, C W
AU  - McFadden CW
FAU - Rosenberg, M P
AU  - Rosenberg MP
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine / American College of Veterinary Internal
      Medicine
JID - 8708660
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/19 [received]
PHST- 2012/12/27 [revised]
PHST- 2013/03/07 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1111/jvim.12086 [doi]
PST - ppublish
SO  - J Vet Intern Med. 2013 May;27(3):483-90. doi: 10.1111/jvim.12086. Epub 2013 Apr
      18.

PMID- 23600679
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1600-0412 (Electronic)
IS  - 0001-6349 (Linking)
DP  - 2013 Apr 19
TI  - Evolution of diagnostic criteria for gestational diabetes mellitus.
LID - 10.1111/aogs.12152 [doi]
AB  - The establishment of universal diagnostic guidelines for gestational diabetes
      mellitus has been a long time coming. The lack of consensus and uniformity in
      procedures for diagnosing this disease has been a problem ever since its
      existence was recognized. The USA, European countries, and Australia have each
      developed their own guidelines through the years, all based either on the
      maternal risk of subsequent diabetes, on arbitrary statistics, or on studies
      conducted on non-pregnant women. None of these guidelines have been based on risk
      for perinatal complications. Recently, the Hyperglycemia and Adverse Pregnancy
      Outcomes study demonstrated that maternal hyperglycemia is associated with
      perinatal risk in a linear way with no obvious threshold. The International
      Association of Diabetes and Pregnancy Study Group has translated these results
      into clinical practice by proposing new diagnostic criteria for gestational
      diabetes mellitus, based for the first time on perinatal outcome.
CI  - (c) 2013 Nordic Federation of Societies of Obstetrics and Gynecology.
AD  - Center for Pregnant Women with Diabetes, Rigshospitalet University Hospital,
      Copenhagen, Denmark; Department of Obstetrics, Rigshospitalet University
      Hospital, Copenhagen, Denmark.
FAU - Houshmand, Azadeh
AU  - Houshmand A
FAU - Jensen, Dorte Moller
AU  - Jensen DM
FAU - Mathiesen, Elisabeth R
AU  - Mathiesen ER
FAU - Damm, Peter
AU  - Damm P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130419
TA  - Acta Obstet Gynecol Scand
JT  - Acta obstetricia et gynecologica Scandinavica
JID - 0370343
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/01/28 [received]
PHST- 2013/04/12 [accepted]
AID - 10.1111/aogs.12152 [doi]
PST - aheadofprint
SO  - Acta Obstet Gynecol Scand. 2013 Apr 19. doi: 10.1111/aogs.12152.

PMID- 23600677
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1600-0501 (Electronic)
IS  - 0905-7161 (Linking)
DP  - 2013 Apr 21
TI  - The effect of local simvastatin application on critical size defects in the
      diabetic rats.
LID - 10.1111/clr.12177 [doi]
AB  - OBJECTIVES: To evaluate bone-healing effects of local simvastatin application to 
      critical size defects (CSDs) in the experimental diabetes mellitus (DM) rat
      model. MATERIALS AND METHODS: A total of 35 male Sprague-Dawley rats with an
      average weight of 350 g and aged 3 months were used in this study. The rats were 
      divided into five groups of seven animals each: passive control (group A), active
      control (group B), 0.5 mg simvastatin (group C), 1.0 mg simvastatin (group D),
      and 1.5 mg simvastatin (group E). Streptozotocin was used to induce Type 1
      diabetes in all rats. Eight mm CSDs were created under anesthesia in each rat
      calvarium. CSDs were left empty in group A. Defects in group B were grafted alone
      with a gelatin sponge mixed with normal saline. Defects in the experimental
      groups (groups A, B, and C) were grafted with gelatin sponge mixed saline
      solutions contain 0.5, 1.0, 1.5 mg simvastatin. Rats were sacrificed after 1
      month, and the defects were prepared for radiologic and histomorphometric
      assessment of regenerated bone. RESULTS: None of the specimens exhibited complete
      closure of new bone across the 8-mm defect. A correlation between computed
      tomography and histomorphometric analysis was not determined. Both amount of
      volume and area of regenerated bone were found higher in the experimental groups 
      than in the control groups. However, these values were not found statistically
      significant degree (P < 0.05) for each groups. The density of regenerated bone in
      the region of interest was higher in the control groups in contrast to in the
      experimental groups. However, statistical significance was just found between
      groups C and A and between groups C and B (P < 0.05). CONCLUSION: The local
      simvastatin application enhanced healing of the bone defects in the diabetic rat 
      model CSDs.
CI  - (c) 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.
AD  - Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Bezmialem
      Vakif University, Istanbul, Turkey.
FAU - Ezirganli, Seref
AU  - Ezirganli S
FAU - Kazancioglu, Hakki O
AU  - Kazancioglu HO
FAU - Mihmanli, Ahmet
AU  - Mihmanli A
FAU - Aydin, Mehmet S
AU  - Aydin MS
FAU - Sharifov, Rasul
AU  - Sharifov R
FAU - Alkan, Alpay
AU  - Alkan A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130421
TA  - Clin Oral Implants Res
JT  - Clinical oral implants research
JID - 9105713
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/19 [accepted]
AID - 10.1111/clr.12177 [doi]
PST - aheadofprint
SO  - Clin Oral Implants Res. 2013 Apr 21. doi: 10.1111/clr.12177.

PMID- 23600614
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Analysis of transfer lesions in patients who underwent surgery for diabetic foot 
      ulcers located on the plantar aspect of the metatarsal heads.
LID - 10.1111/dme.12202 [doi]
AB  - AIMS: To analyse the risk of reulceration caused by the transfer of lesions in
      patients with diabetes, undergoing resection of at least one metatarsal head.
      METHODS: A total of 119 patients with diabetes from the Diabetic Foot Unit
      (Complutense University, Madrid, Spain), who underwent resection of at least one 
      metatarsal head were analysed prospectively from November 2006 to December 2011
      to assess reulceration in the other metatarsal head. RESULTS: Seven patients were
      excluded for being subjected to a pan-metatarsal head resection and 11 patients
      dropped out. During a median follow-up period of 13.1 months (interquartile range
      6.1-22.8 months), 41% of patients suffered from reulcerations. Reulceration
      frequency in patients operated on the 1st, 2nd, 3rd, 4th, 5th and several
      metatarsal heads was 9 (69%), 8 (44%), 12 (52%), 2 (25%), 6 (19%) and 4 (50%)
      events, respectively. The Cox regression model showed hazard ratios that were
      significant for the location of the metatarsal resection. The first metatarsal
      showed the highest risk for reulceration (hazard ratio 3.307; 1.472-7.430) and
      the fifth metatarsal showed the lowest risk (hazard ratio 0.339; 0.138-0.832).
      CONCLUSIONS: Reulceration is a frequent event following resection of a metatarsal
      head and should be regarded as an implicit complication of the intervention. The 
      location of the resection determines the risk of reulceration, which is highest
      for patients operated on the first metatarsal head and lowest for patients
      operated on the fifth metatarsal head.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Unidad de Pie Diabetico, Facultad de Medicina, Universidad Complutense de Madrid,
      Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC),
      Madrid, Spain.
FAU - Molines-Barroso, R J
AU  - Molines-Barroso RJ
FAU - Lazaro-Martinez, J L
AU  - Lazaro-Martinez JL
FAU - Aragon-Sanchez, J
AU  - Aragon-Sanchez J
FAU - Garcia-Morales, E
AU  - Garcia-Morales E
FAU - Beneit-Montesinos, J V
AU  - Beneit-Montesinos JV
FAU - Alvaro-Afonso, F J
AU  - Alvaro-Afonso FJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/03/14 [accepted]
AID - 10.1111/dme.12202 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12202.

PMID- 23600561
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Relative contributions of insulin resistance and beta-cell dysfunction to the
      development of Type 2 diabetes in Koreans.
LID - 10.1111/dme.12201 [doi]
AB  - AIMS: Controversies still exist regarding the relative contributions of insulin
      resistance and beta-cell dysfunction to the pathogenesis of Type 2 diabetes in
      different populations. We examined the associations of baseline insulin
      resistance and beta-cell function indices with the development of Type 2 diabetes
      in Koreans. METHODS: We analysed the clinical and laboratory data of 17 878
      Korean adults (age 20-79 years) who underwent routine medical examinations with a
      median interval of 3.5 years (range 2.5-4.7 years). Using the homeostasis model
      assessment, insulin resistance (HOMA-IR) and beta-cell function (HOMA-%B) indices
      at baseline were assessed. RESULTS: Those who developed diabetes (n = 732, 4.1%) 
      had significantly higher fasting serum insulin level (53.4 +/- 31.2 vs. 41.4 +/- 
      23.4 pmol/l) and HOMA-IR (2.38 +/- 1.45 vs. 1.65 +/- 1.02) and lower HOMA-%B (74 
      +/- 47 vs. 85 +/- 48) at baseline (P < 0.001 for all). Both high HOMA-IR and low 
      HOMA-%B were independently associated with an increased odds ratio of incident
      Type 2 diabetes. Among the participants who developed diabetes, 29% demonstrated 
      predominant beta-cell dysfunction (HOMA-%B < 25th percentile) and 51% had
      predominant insulin resistance (HOMA-IR > 75th percentile). When we divided the
      participants according to the median BMI of the whole population (23.7 kg/m2 ),
      49% of participants in the low BMI group demonstrated predominant beta-cell
      dysfunction and 26% had predominant insulin resistance, whilst 21% in the high
      BMI group demonstrated mainly beta-cell dysfunction and 60% had mainly insulin
      resistance. CONCLUSIONS: In individuals with low BMI, beta-cell dysfunction is
      the predominant defect, whereas insulin resistance is the predominant
      pathogenetic factor in individuals with high BMI in the development of Type 2
      diabetes in Koreans.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      Soonchunhyang University College of Medicine, Bucheon.
FAU - Kim, C-H
AU  - Kim CH
FAU - Kim, H-K
AU  - Kim HK
FAU - Kim, E H
AU  - Kim EH
FAU - Bae, S J
AU  - Bae SJ
FAU - Park, J-Y
AU  - Park JY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/15 [received]
PHST- 2013/01/31 [revised]
PHST- 2013/03/15 [accepted]
AID - 10.1111/dme.12201 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12201.

PMID- 23600518
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Objective measurements of activity patterns in people with newly diagnosed Type 2
      diabetes demonstrate a sedentary lifestyle.
LID - 10.1111/dme.12199 [doi]
AB  - AIMS: To evaluate physical activity in people with newly diagnosed Type 2
      diabetes using objective measures. METHODS: We analysed data from a study aimed
      at assessing carotid femoral pulse wave velocity in which a piezoelectric
      accelerometer was worn by 100 people with newly diagnosed Type 2 diabetes and by 
      100 age- and sex-matched control subjects. Differences in physical activity
      patterns were investigated. RESULTS: Compared with the control group, the people 
      with Type 2 diabetes spent significantly more time engaged in sedentary or lower 
      level activities during the day, with a mean (sd) time of 926 (44) vs 898 (70)
      min, P < 0.001). This difference remained significant after correction for
      differences in BMI between the two groups. CONCLUSIONS: Using objective
      measurements, our findings demonstrate that people with newly diagnosed Type 2
      diabetes have a more sedentary lifestyle compared with well-matched controls.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Department of Endocrinology, Internal Medicine and Medical Research Laboratories,
      Aarhus University Hospital, Denmark.
FAU - Cichosz, S L
AU  - Cichosz SL
FAU - Fleischer, J
AU  - Fleischer J
FAU - Hoeyem, P
AU  - Hoeyem P
FAU - Laugesen, E
AU  - Laugesen E
FAU - Poulsen, P L
AU  - Poulsen PL
FAU - Christiansen, J S
AU  - Christiansen JS
FAU - Ejskjaer, N
AU  - Ejskjaer N
FAU - Hansen, T K
AU  - Hansen TK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/24 [received]
PHST- 2013/01/04 [revised]
PHST- 2013/03/15 [accepted]
AID - 10.1111/dme.12199 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12199.

PMID- 23600479
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Associations between pigment epithelium-derived factor, insulin resistance and
      high density lipoprotein.
LID - 10.1111/dme.12198 [doi]
AB  - AIMS: To measure serum pigment epithelium-derived factor in control subjects with
      normal fasting glucose, and in subjects with impaired fasting glucose and those
      with newly diagnosed Type 2 diabetes, before treatment initiation, and to measure
      pigment epithelium-derived factor prospectively in patients being treated with
      HDL-raising therapy, niacin. METHODS: We enrolled 89 individuals attending an
      institutional health screen. Biochemical indices including lipids, homeostasis
      model assessment-insulin resistance, high-sensitivity C-reactive protein and
      pigment epithelium-derived factor were analysed in fasting blood. To validate the
      association between HDL and pigment epithelium-derived factor, we analysed
      samples from a separate study cohort with low HDL, followed up for 12-weeks while
      on niacin treatment. Secreted pigment epithelium-derived factor from 3T3-L1
      adipocytes, after HDL treatment (24-h), was measured using Western blot analysis.
      RESULTS: Mean (+/- sd) serum pigment epithelium-derived factor was significantly 
      higher in subjects with impaired fasting glucose [13.99 (+/- 3.06) mug/ml] and
      Type 2 diabetes [12.94 (+/- 2.61)] mug/ml, compared with control subjects [11.83 
      (+/- 2.85) mug/ml (P = 0.014)]. In multivariate analyses, serum pigment
      epithelium-derived factor concentration was associated with BMI (beta = 0.32,
      0.007), homeostasis model assessment-insulin resistance (beta = 0.33, P = 0.01)
      and HDL (beta = -0.24, P = 0.05), after adjustment for age, gender and
      high-sensitivity C-reactive protein. In the niacin study, on-treatment HDL was an
      independent determinant of pigment epithelium-derived factor (beta = -0.439, P = 
      0.033), after adjusting for age, homeostasis model assessment-insulin resistance 
      and treatment. Adipocytes treated with HDL were found to have reduced pigment
      epithelium-derived factor secretion [24.8% (50 mug/ml), 28.4% (100 mug/ml) HDL; P
      < 0.05)], compared with the control samples. CONCLUSION: Serum pigment
      epithelium-derived factor is positively associated with homeostasis model
      assessment-insulin resistance and negatively associated with HDL. Further studies
      are needed to understand the mechanism of low HDL and raised pigment
      epithelium-derived factor and to determine if they are causally related to the
      pathobiology of insulin resistance.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Clinical Research Unit, Khoo Teck Puat Hospital, Singapore.
FAU - Pek, S
AU  - Pek S
FAU - Tavintharan, S
AU  - Tavintharan S
FAU - Woon, K
AU  - Woon K
FAU - Niyati, J
AU  - Niyati J
FAU - Lim, S C
AU  - Lim SC
FAU - Sum, C F
AU  - Sum CF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/04 [received]
PHST- 2013/02/01 [revised]
PHST- 2013/03/15 [accepted]
AID - 10.1111/dme.12198 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12198.

PMID- 23600455
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - Progression of chronic kidney disease in a multi-ethnic community cohort of
      patients with diabetes mellitus.
LID - 10.1111/dme.12197 [doi]
AB  - AIMS: Ethnicity is a risk factor for the prevalence of severe chronic kidney
      disease among patients with diabetes. We studied the effect of ethnicity on
      progression of chronic kidney disease in people with diabetes managed in
      community settings. METHODS: A 5-year retrospective, community-based cohort study
      of 3855 people with diabetes mellitus of white, black or South Asian ethnicity
      with an estimated glomerular filtration rate of < 60 ml min-1 1.73 m-2 was
      undertaken. From 135 general practices in east London, all cases with at least 3 
      years clinical data were included. Using repeated-measures analysis, the annual
      decline in estimated glomerular filtration rate was calculated. Comparisons
      between the rate of decline in the three main ethnic groups, with and without
      proteinuria at baseline, were made. RESULTS: The annual adjusted decline in
      estimated glomerular filtration rate for this cohort was 0.85 ml min-1 1.73 m-2 .
      The rate of chronic kidney disease progression was significantly greater in South
      Asian groups (-1.01 ml min-1 1.73 m-2 ) compared with white groups (-0.70 ml
      min-1 1.73 m-2 ) (P = 0.001). For those with proteinuria at baseline, the annual 
      decline was greater at 2.05 ml min-1 1.73 m-2 , with both South Asian and black
      groups having a significantly faster rate of decline than white groups.
      CONCLUSIONS: For patients with diabetes and chronic kidney disease managed in
      primary care, the annual decline of renal function is less than previously
      thought and approximates the age-related annual decline of 1 ml min-1 1.73 m-2 . 
      Patients with proteinuria and those of South Asian and Black ethnicity need
      additional monitoring as they are at greater risk of rapid chronic kidney disease
      progression.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Renal Department, Barts and the London NHS Trust, London, UK.
FAU - Dreyer, G
AU  - Dreyer G
FAU - Hull, S
AU  - Hull S
FAU - Mathur, R
AU  - Mathur R
FAU - Chesser, A
AU  - Chesser A
FAU - Yaqoob, M M
AU  - Yaqoob MM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/09/12 [received]
PHST- 2013/01/21 [revised]
PHST- 2013/03/15 [accepted]
AID - 10.1111/dme.12197 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12197.

PMID- 23600438
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1931-843X (Electronic)
IS  - 1540-9996 (Linking)
VI  - 22
IP  - 5
DP  - 2013 May
TI  - Gender differences in myocardial perfusion defect in asymptomatic postmenopausal 
      women and men with and without diabetes mellitus.
PG  - 439-44
LID - 10.1089/jwh.2012.4055 [doi]
AB  - Abstract Background: To compare the results of myocardial perfusion imaging (MPI)
      of asymptomatic postmenopausal women and age-matched men and to investigate the
      effect of diabetes mellitus (DM) on gender differences and the risk estimation of
      coronary heart disease (CHD). Methods: Sixty-seven postmenopausal women and 27
      men low in Framingham Global Risk Score (FGRS) were recruited from year 2008 to
      2009 in northern Taiwan. Each subject underwent blood tests, a cardiopulmonary
      exercise test, an electrocardiograph (ECG), and MPI. Results: Women had similar
      percentages of predicted oxygen consumption and ECG changes at peak exercise, but
      lower oxygen pulse and rate-pressure product. They also had significantly higher 
      summed stress score (SSS), summed rest score (SRS), and summed difference score
      (SDS) than men, despite showing much lower scores for the FGRS than men. Women
      with DM had a lower 10-year risk of CHD assessed by the United Kingdom
      Prospective Diabetes Study (UKPDS) risk engine, but significantly higher SSS and 
      SDS than men. In the subjects with abnormal MPI, the extent of ischemia was small
      to moderate in men, whereas in 50% of the women, the extent of ischemia was
      large. Conclusion: The results of this preliminary study suggest that
      asymptomatic postmenopausal women had more abnormalities in MPI and those with DM
      had a higher SSS and SDS than age-matched men. The risk of CAD may still be
      underestimated by the UKPDS.
AD  - 1 School and Graduate Institute of Physical Therapy, College of Medicine,
      National Taiwan University , Taipei, Taiwan .
FAU - Wu, Ying-Tai
AU  - Wu YT
FAU - Chien, Chen-Lin
AU  - Chien CL
FAU - Wang, Shan-Ying
AU  - Wang SY
FAU - Yang, Wei-Shiung
AU  - Yang WS
FAU - Wu, Yen-Wen
AU  - Wu YW
LA  - eng
PT  - Journal Article
DEP - 20130421
PL  - United States
TA  - J Womens Health (Larchmt)
JT  - Journal of women's health (2002)
JID - 101159262
SB  - IM
PMC - PMC3653376
OID - NLM: PMC3653376 [Available on 05/01/14]
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PMCR- 2014/05/01 00:00
PHST- 2013/04/21 [aheadofprint]
AID - 10.1089/jwh.2012.4055 [doi]
PST - ppublish
SO  - J Womens Health (Larchmt). 2013 May;22(5):439-44. doi: 10.1089/jwh.2012.4055.
      Epub 2013 Apr 21.

PMID- 23600394
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 65
IP  - 5
DP  - 2013 May
TI  - Antihyperlipidaemic and antioxidant effect of the total flavonoids in Selaginella
      tamariscina (Beauv.) Spring in diabetic mice.
PG  - 757-66
LID - 10.1111/jphp.12035 [doi]
AB  - OBJECTIVES: To investigate the antidiabetic, antihyperlipidaemic and antioxidant 
      activity of total flavonoids in Selaginella tamariscina (Beauv.) Spring (TFST) in
      a mouse model of diabetes. METHODS: Normal mice, mice fed with a high-fat
      emulsion diet and streptozotocin (STZ)-induced diabetic mice were treated with
      TFST for 6 weeks. Serum glucose, insulin and lipid, hepatic steatosis, production
      of the protein visfatin and antioxidant indices were evaluated. KEY FINDINGS:
      TFST significantly decreased the concentration of fasting blood glucose, total
      cholesterol, triglycerides and low-density-lipoprotein cholesterol, while it
      increased the levels of insulin and high-density-lipoprotein cholesterol in
      diabetic mice. TFST also improved the results of the oral glucose tolerance test 
      to a certain degree. Furthermore, both the free fatty acid levels in the liver
      and hepatic steatosis were ameliorated by TFST treatment. These changes may be be
      associated with decreased production of visfatin. Administration of TFST also
      significantly decreased the levels of malondialdehyde, nitric oxide and inducible
      nitric oxide synthase and increased the content of glutathione and the activity
      of superoxide dismutase, catalase, glutathione peroxidase and
      glutathione-S-transferase in the liver. No change in blood glucose levels were
      observed in the normal mice treated with TFST. CONCLUSIONS: TFST showed an
      excellent effect in reducing the high blood glucose level but had no effect on
      normal blood glucose level. The antidiabetic activity of TFST could be explained 
      by its antioxidant and antihyperlipidaemic activity, which finally elevated the
      insulin sensitivity of liver.
CI  - (c) 2013 The Authors. JPP (c) 2013 Royal Pharmaceutical Society.
AD  - Henan University of Traditional Chinese Medicine, Zhengzhou, China.
FAU - Zheng, Xiao-ke
AU  - Zheng XK
FAU - Wang, Wei-wei
AU  - Wang WW
FAU - Zhang, Li
AU  - Zhang L
FAU - Su, Cheng-fu
AU  - Su CF
FAU - Wu, Yong-yong
AU  - Wu YY
FAU - Ke, Ying-ying
AU  - Ke YY
FAU - Hou, Qing-wei
AU  - Hou QW
FAU - Liu, Zhao-yan
AU  - Liu ZY
FAU - Gao, Ai-she
AU  - Gao AS
FAU - Feng, Wei-sheng
AU  - Feng WS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130314
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/10/08 [received]
PHST- 2013/01/06 [accepted]
PHST- 2013/03/14 [aheadofprint]
AID - 10.1111/jphp.12035 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2013 May;65(5):757-66. doi: 10.1111/jphp.12035. Epub 2013 Mar 
      14.

PMID- 23600389
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 65
IP  - 5
DP  - 2013 May
TI  - Rosmarinic acid administration attenuates diabetes-induced vascular dysfunction
      of the rat aorta.
PG  - 713-23
LID - 10.1111/jphp.12037 [doi]
AB  - OBJECTIVES: Oxidative stress as well as inflammation processes are engaged in
      diabetic vascular complications. Rosmarinic acid, a natural phenol antioxidant
      carboxylic acid, was found to have multiple biological activity, including
      anti-inflammatory and antitumour effects, which are a consequence of its
      inhibition of the inflammatory processes and of reactive oxygen species
      scavenging. The aim of this work was to study effects of rosmarinic acid
      administration on vascular impairment induced by experimental diabetes in rats.
      METHODS: Diabetes was induced by streptozocin (3 x 30 mg/kg daily, i.p.) in
      Wistar rats. Rosmarinic acid was administered orally (50 mg/kg daily). Ten weeks 
      after streptozocin administration, the aorta was excised for functional studies, 
      evaluation by electron microscopy and real time PCR analysis. KEY FINDINGS: In
      the aorta of diabetic rats, decreased endothelium-dependent relaxation was
      accompanied by overexpression of interleukin-1beta, tumour necrosis factor-alpha,
      preproendothelin-1 and endothelin converting enzyme-1. Structural alterations in 
      the endothelium, detected by electron microscopy, indicated aortic dysfunction
      caused by diabetes. The diabetes-induced aortic disorders were prevented by
      rosmarinic acid administration. CONCLUSIONS: Rosmarinic acid protected aortic
      endothelial function and ultrastructure against diabetes-induced damage. Both
      antioxidant and anti-inflammatory effects of rosmarinic acid seemed to
      participate in the mechanism of this protection.
CI  - (c) 2013 The Authors. JPP (c) 2013 Royal Pharmaceutical Society.
AD  - Institute of Experimental Pharmacology and Toxicology, Slovak Academy of
      Sciences, Bratislava, Slovak Republic. exfarosa@savba.sk
FAU - Sotnikova, Ruzena
AU  - Sotnikova R
FAU - Okruhlicova, Ludmila
AU  - Okruhlicova L
FAU - Vlkovicova, Jana
AU  - Vlkovicova J
FAU - Navarova, Jana
AU  - Navarova J
FAU - Gajdacova, Beata
AU  - Gajdacova B
FAU - Pivackova, Lenka
AU  - Pivackova L
FAU - Fialova, Silvia
AU  - Fialova S
FAU - Krenek, Peter
AU  - Krenek P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130227
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/08/09 [received]
PHST- 2013/01/06 [accepted]
PHST- 2013/02/27 [aheadofprint]
AID - 10.1111/jphp.12037 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2013 May;65(5):713-23. doi: 10.1111/jphp.12037. Epub 2013 Feb 
      27.

PMID- 23600375
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Mar 21
TI  - A risk-adjusted economic evaluation of alternative models of involvement of
      practice nurses in management of type 2 diabetes.
LID - 10.1111/dme.12195 [doi]
AB  - AIMS: To determine the cost-effectiveness of alternative models of practice nurse
      involvement in the management of type 2 diabetes within the primary care setting.
      METHODS: Linked routinely collected clinical data and resource use (general
      practitioner visits, hospital services and pharmaceuticals) were used to
      undertake a risk-adjusted cost-effectiveness analysis of alternative models of
      care for the management of diabetes patients. These models were based on the
      reported level of involvement of practice nurses in the provision of
      clinical-based activities. Potential confounders were controlled for by using
      propensity score-weighted regression analyses. The impact of alternative models
      of care on outcomes and costs was measured and incremental cost-effectiveness
      estimated. The uncertainty around the estimates of cost-effectiveness was
      illustrated through bootstrapping. RESULTS: Although the difference in total cost
      between two models of care was not statistically significant, the high-level
      model was associated with better outcomes (larger mean reductions in HbA1c ). The
      upper 95% confidence intervals showed that the incremental cost per 1% decrease
      in HbA1c is only $454, and per one additional patient to achieve an HbA1c value
      of less than 53 mmol/mol (7.0%) is $323. Further analyses showed little
      uncertainty surrounding the decision to adopt the high-level model. CONCLUSIONS: 
      The results provide a strong indication that the high-level model is a
      cost-effective way of managing diabetes patients. Our findings highlight the need
      for effective incentives to encourage general practices to better integrate
      practice nurses in the provision of clinical services.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - The University of Adelaide, Adelaide, South Australia.
FAU - Haji Ali Afzali, H
AU  - Haji Ali Afzali H
FAU - Gray, J
AU  - Gray J
FAU - Beilby, J
AU  - Beilby J
FAU - Holton, C
AU  - Holton C
FAU - Banham, D
AU  - Banham D
FAU - Karnon, J
AU  - Karnon J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130321
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2012/08/06 [received]
PHST- 2013/01/17 [revised]
PHST- 2013/03/15 [accepted]
AID - 10.1111/dme.12195 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Mar 21. doi: 10.1111/dme.12195.

PMID- 23600372
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 18
IP  - 5
DP  - 2013 May
TI  - Phenotype variability in nephrogenic diabetes insipidus due to p.D85N mutation in
      the arginine vasopressin receptor 2 gene.
PG  - 390-1
LID - 10.1111/nep.12048 [doi]
FAU - Morimoto, Tetsuji
AU  - Morimoto T
FAU - Nakayama, Makiko
AU  - Nakayama M
FAU - Fujiwara, Ikuma
AU  - Fujiwara I
FAU - Kondo, Yoshiaki
AU  - Kondo Y
FAU - Mugishima, Hideo
AU  - Mugishima H
FAU - Takahashi, Shori
AU  - Takahashi S
LA  - eng
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/02/28 [accepted]
AID - 10.1111/nep.12048 [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2013 May;18(5):390-1. doi: 10.1111/nep.12048.

PMID- 23600363
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 14
IP  - 9
DP  - 2013 Jun
TI  - Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor
      alogliptin in patients with type 2 diabetes showing inadequate response to
      thrice-a-day treatment with alpha-glucosidase inhibitors.
PG  - 1111-8
LID - 10.1517/14656566.2013.790365 [doi]
AB  - Objective: We investigated the effect of addition of alogliptin, while continuing
      the alpha-glucosidase inhibitor (alphaGI) administration at the same or reduced
      dose, or discontinuing the drug, on the glycemic control in type 2 diabetic
      patients showing inadequate response to alphaGI treatment. Research design and
      methods: A prospective, randomized, controlled, multicenter interventional study 
      trial. Subjects were randomly assigned to treatment with alogliptin alone (Intake
      0 group), or alogliptin in addition to an alphaGI administered
      once-/twice-/thrice-daily (Intake 1, 2 and 3 groups). Main outcome measures:
      Changes in glycemic control were measured. Results: The HbA1c and glycoalbumin
      levels at 1 and 3 months were significantly lower than the values at the baseline
      in the Intake 1, 2 and 3 groups, but not the Intake 0 group. The body weight at 3
      months was significantly lower than that at the baseline in the Intake 3 group.
      There were no significant differences in the degree of satisfaction or
      participating volition recorded, before and after the start of the study
      treatments. Conclusions: Addition of alogliptin to once-/twice-daily
      administration of an alphaGI may be effective for obtaining improved glycemic
      control, without lowering the treatment satisfaction level, in type 2 diabetic
      patients.
AD  - Yokohama City University Graduate School of Medicine, Department of Endocrinology
      and Metabolism , Yokohama , Japan.
FAU - Masuda, Kiyomi
AU  - Masuda K
FAU - Aoki, Kazutaka
AU  - Aoki K
FAU - Kamiko, Kazunari
AU  - Kamiko K
FAU - Takihata, Masahiro
AU  - Takihata M
FAU - Ito, Yuzuru
AU  - Ito Y
FAU - Nagakura, Mieko
AU  - Nagakura M
FAU - Kawasaki, Satsuki
AU  - Kawasaki S
FAU - Akema, Noriko
AU  - Akema N
FAU - Hasegawa, Maki
AU  - Hasegawa M
FAU - Nakajima, Shigeru
AU  - Nakajima S
FAU - Shinoda, Kazuaki
AU  - Shinoda K
FAU - Toumura, Shyoken
AU  - Toumura S
FAU - Tsunoda, Seishi
AU  - Tsunoda S
FAU - Enomoto, Hitoshi
AU  - Enomoto H
FAU - Shimotomai, Hidefumi
AU  - Shimotomai H
FAU - Terauchi, Yasuo
AU  - Terauchi Y
LA  - eng
PT  - Journal Article
DEP - 20130422
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PHST- 2013/04/22 [aheadofprint]
AID - 10.1517/14656566.2013.790365 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2013 Jun;14(9):1111-8. doi:
      10.1517/14656566.2013.790365. Epub 2013 Apr 22.

PMID- 23599994
OWN - NLM
STAT- In-Process
DA  - 20130422
VI  - 4
IP  - 4
DP  - 2013 Apr
TI  - Diabetes detour: act now to diagnose prediabetes in at-risk patients.
PG  - 27-8
AD  - Kimbrough Ambulatory Care Center, Fort Meade, MD, USA.
FAU - Ude, Assumpta O
AU  - Ude AO
FAU - Mayhew, Maren S
AU  - Mayhew MS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv NPs PAs
JT  - Advance for NPs & PAs
JID - 101549550
SB  - N
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/23 06:00
PST - ppublish
SO  - Adv NPs PAs. 2013 Apr;4(4):27-8.

PMID- 23582714
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1878-1780 (Electronic)
IS  - 1262-3636 (Linking)
VI  - 39 Suppl 1
DP  - 2013 Mar 26
TI  - [In Process Citation].
PG  - IX
LID - 10.1016/S1262-3636(13)71612-4 [doi]
LID - S1262-3636(13)71612-4 [pii]
AD  - Co-presidents du Comite d'organisation.
FAU - Bringer, Jacques
AU  - Bringer J
FAU - Renard, Eric
AU  - Renard E
LA  - fre
PT  - Editorial
TT  - Editorial.
PL  - France
TA  - Diabetes Metab
JT  - Diabetes & metabolism
JID - 9607599
SB  - IM
EDAT- 2013/04/23 06:00
MHDA- 2013/04/23 06:00
CRDT- 2013/04/16 06:00
AID - S1262-3636(13)71612-4 [pii]
AID - 10.1016/S1262-3636(13)71612-4 [doi]
PST - ppublish
SO  - Diabetes Metab. 2013 Mar 26;39 Suppl 1:IX. doi: 10.1016/S1262-3636(13)71612-4.

PMID- 23599890
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130419
DCOM- 20130422
LR  - 20130422
IS  - 1999-768X (Print)
IS  - 1999-768X (Linking)
VI  - 28
IP  - 2
DP  - 2013 Mar
TI  - Early age at onset of diabetes mellitus may be worse in terms of metabolic side
      effects.
PG  - 151
LID - 10.5001/omj.2013.41 [doi]
AD  - Department of Internal Medicine, Gulhane Medical Faculty, Ankara, Turkey.
FAU - Cakar, Mustafa
AU  - Cakar M
FAU - Sarlak, Hakan
AU  - Sarlak H
FAU - Karaman, Murat
AU  - Karaman M
FAU - Ay, Seyit Ahmet
AU  - Ay SA
FAU - Balta, Sevket
AU  - Balta S
FAU - Demirkol, Sait
AU  - Demirkol S
LA  - eng
PT  - Journal Article
PL  - Oman
TA  - Oman Med J
JT  - Oman medical journal
JID - 101526350
PMC - PMC3628205
OID - NLM: PMC3628205
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:01
CRDT- 2013/04/20 06:00
PHST- 2013/01/10 [received]
PHST- 2013/01/15 [accepted]
AID - 10.5001/omj.2013.41 [doi]
AID - OMJ-D-12-00594 [pii]
PST - ppublish
SO  - Oman Med J. 2013 Mar;28(2):151. doi: 10.5001/omj.2013.41.

PMID- 23599874
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130419
DCOM- 20130422
LR  - 20130422
IS  - 1999-768X (Print)
IS  - 1999-768X (Linking)
VI  - 28
IP  - 2
DP  - 2013 Mar
TI  - Optical coherence tomography: clinical applications in medical practice.
PG  - 86-91
LID - 10.5001/omj.2013.24 [doi]
AB  - Optical Coherence Tomography (OCT) is a success story of scientific and
      technological co-operation between a physicist and a clinician. The concept of
      cross-sectional imaging revolutionalized the applicability of OCT in the medical 
      profession. OCT is a non-contact, topographic, biomicroscopic device that
      provides high resolution, cross-sectional digital images of live biological
      tissues in vivo and in real time. OCT is based on the property of tissues to
      reflect and backscatter light involving low-coherence interferometry. The spatial
      resolution of as little as 3 microns or even less has allowed us to study tissues
      almost at a cellular level. Overall, OCT is an invaluable adjunct in the
      diagnosis and follow up of many diseases of both anterior and posterior segments 
      of the eye, primarily or secondary to systemic diseases. The digitalization and
      advanced software has made it possible to store and retrieve huge patient data
      for patient services, clinical applications and academic research. OCT has
      revolutionized the sensitivity and specificity of diagnosis, follow up and
      response to treatment in almost all fields of clinical practice involving primary
      ocular pathologies and secondary ocular manifestations in systemic diseases like 
      diabetes mellitus, hypertension, vascular and neurological diseases, thus
      benefitting non-ophthalmologists as well. Systemically, OCT is proving to be a
      helpful tool in substantiating early diagnosis in diseases like multiple
      sclerosis and drug induced retinopathies by detecting early changes in morphology
      of the retinal nerve fiber layer.
AD  - Department of Ophthalmology, College of Medicine and Health Sciences, Sultan
      Qaboos University Hospital, Muscat, Sultanate of Oman.
FAU - Al-Mujaini, Abdullah
AU  - Al-Mujaini A
FAU - Wali, Upender K
AU  - Wali UK
FAU - Azeem, Sitara
AU  - Azeem S
LA  - eng
PT  - Journal Article
PL  - Oman
TA  - Oman Med J
JT  - Oman medical journal
JID - 101526350
PMC - PMC3628201
OID - NLM: PMC3628201
OTO - NOTNLM
OT  - Biomicroscopy
OT  - Interferometry
OT  - Optical Coherence Tomography
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:01
CRDT- 2013/04/20 06:00
PHST- 2012/11/12 [received]
PHST- 2013/02/01 [accepted]
AID - 10.5001/omj.2013.24 [doi]
AID - OMJ-D-12-00307 [pii]
PST - ppublish
SO  - Oman Med J. 2013 Mar;28(2):86-91. doi: 10.5001/omj.2013.24.

PMID- 23599872
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130419
DCOM- 20130422
LR  - 20130422
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr 15
TI  - Parental transmission of type 2 diabetes mellitus in a highly endogamous
      population.
PG  - 40-6
LID - 10.4239/wjd.v4.i2.40 [doi]
AB  - AIM: To determine the parental transmission of diabetes mellitus (DM) and
      evaluate its influence on the clinical characteristics. METHODS: This was a cross
      sectional study. The survey was carried out in urban and semi-urban primary
      health care centers. Of the 2400 registered with diagnosed diabetes, 1980 agreed 
      and gave their consent to take part in this study, thus giving a response rate of
      82.5%. Face to face interviews were conducted using a structured questionnaire
      followed by laboratory tests. DM was defined according to the World Health
      Organization expert group. A trained nurse performed physical examinations and
      measurements. RESULTS: Of the study population, 72.9% reported a family history
      of DM. Family history of DM was significantly higher in females (54.2%; P = 0.04)
      and in the age group below 30 years (24%; P < 0.001). The prevalence of diabetes 
      was higher among patients with a diabetic mother (25.4% vs 22.1%) and maternal
      aunts/uncles (31.2% vs 22.2%) compared to patients with a diabetic father and
      paternal aunts/uncles. Family history of DM was higher in patients of
      consanguineous parents (38.5%) than those of non-consanguineous parents (30.2%). 
      The development of type 2 diabetes mellitus (T2DM) complications was higher in
      patients with either a paternal or maternal history of DM than in those without. 
      No significant difference was observed in the metabolic characteristics of
      patients with/without family history of DM except for hypertension. Complications
      were higher in diabetic patients with a family history of DM. CONCLUSION: The
      present study found a significant maternal effect in transmission of T2DM. Family
      history is associated with the increased incidence of diabetes.
AD  - Abdulbari Bener, Mohammad T Yousafzai, Department of Medical Statistics and
      Epidemiology, Hamad Medical Corporation, Doha 3050, Qatar.
FAU - Bener, Abdulbari
AU  - Bener A
FAU - Yousafzai, Mohammad T
AU  - Yousafzai MT
FAU - Al-Hamaq, Abdulla Oaa
AU  - Al-Hamaq AO
FAU - Mohammad, Abdul-Ghani
AU  - Mohammad AG
FAU - Defronzo, Ralph A
AU  - Defronzo RA
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC3629295
OID - NLM: PMC3629295
OTO - NOTNLM
OT  - Consanguinity
OT  - Diabetes mellitus
OT  - Family history
OT  - Genetic disorders
OT  - Maternal transmission
OT  - Parental transmission
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:01
CRDT- 2013/04/20 06:00
PHST- 2012/12/05 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/15 [accepted]
AID - 10.4239/wjd.v4.i2.40 [doi]
PST - ppublish
SO  - World J Diabetes. 2013 Apr 15;4(2):40-6. doi: 10.4239/wjd.v4.i2.40.

PMID- 23599818
OWN - NLM
STAT- In-Process
DA  - 20130419
IS  - 1844-3117 (Electronic)
IS  - 1844-122X (Linking)
VI  - 6
IP  - 1
DP  - 2013 Mar 15
TI  - Metabolic imbalance in affective disorders.
PG  - 45-9
AB  - INTRODUCTION: Depression is the most frequent mental disorder encountered in all 
      medical services. Multiple studies have shown that depression may predict the
      onset of different conditions, such as heart disease, diabetes, stroke and many
      other. The relation between depression and diabetes is still unclear. MATERIALS
      AND METHODS: In this study we evaluated patients with both major depressive
      disorder and type 1 or 2 diabetes, and observed the evolution of depressive and
      diabetes symptoms under adequate treatment. This observational, naturalistic
      study included 43 patients admitted in a psychiatric ward of "Alexandru Obregia" 
      Clinical Hospital, Bucharest, diagnosed with Major Depressive Disorder (MDD) and 
      Diabetes mellitus (DM) type 1 or 2. All patients received antidepressant and
      antidiabetic treatment. RESULTS: The majority of patients were women (60.5%), and
      the mean age was 49.7 years. Average hospitalization period was 23 days, with
      longer period of hospitalization of patients with DM type 1. Patients had severe 
      depression. Mean value of fasting glycemia at admission was of 174 mg / dl, but
      it decreased at discharge, in paralel with the amelioration of depression.
      CONCLUSIONS: The depression associated with DM type 1 is more severe. These
      patients require higher doses of antidepressants and longer hospitalization
      period. Amelioration of depression seems to have a positive impact on the blood
      sugar level of depressed patients with diabetes.
AD  - "Prof. Dr. Alexandru Obregia" Clinical Hospital of Psychiatry, Bucharest.
      marialadea@gmail.com
FAU - Ladea, M
AU  - Ladea M
FAU - Barbu, C M
AU  - Barbu CM
FAU - Rosu, D P
AU  - Rosu DP
LA  - eng
PT  - Journal Article
DEP - 20130325
PL  - Romania
TA  - J Med Life
JT  - Journal of medicine and life
JID - 101477617
SB  - IM
PMC - PMC3624645
OID - NLM: PMC3624645
OTO - NOTNLM
OT  - depression
OT  - diabetes
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/09/24 [received]
PHST- 2013/01/29 [accepted]
PHST- 2013/03/25 [epublish]
PST - ppublish
SO  - J Med Life. 2013 Mar 15;6(1):45-9. Epub 2013 Mar 25.

PMID- 23599736
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 5
IP  - 4
DP  - 2013 Apr
TI  - Self-care practices of Chinese individuals with diabetes.
PG  - 1137-1142
AB  - The aim of this study was to investigate the self-care practices of Chinese
      individuals with diabetes. Data were collected from 163 Chinese individuals with 
      diabetes using a one-to-one interview approach. The Chinese version of the
      Summary of Diabetes Self-Care Activities (SDSCA) was used to assess
      diabetes-related knowledge and self-care practices. The majority of participants 
      were aware of the importance of self-care in managing diabetes. However, only 70 
      participants (43%) scored >50% in the diabetes-related questionnaires. Mean
      fasting blood glucose (FBG) levels were higher (P<0.04) for participants who had 
      extra meals per day (46%). The majority of participants took oral hypoglycemic
      agents (OHAs; 60.1%) and some were also treated with OHA-insulin combination
      therapy (17.8%). Participants with medication adherence (52%) tended to have
      lower FBG levels. Only 13% of participants practiced self-monitoring of blood
      glucose (SMBG). The predictors of a knowledge deficit or poor self-care were a
      low level of education (P<0.01) or old age (older than 53 years old; P=0.002).
      Deficits in diabetes-related knowledge and self-care practices existed among the 
      majority of patients with suboptimal blood glucose control. The understanding of 
      the importance of self-care practices requires improvement in individuals with
      diabetes. The development of effective education strategies to improve the
      awareness of self-care practices by Chinese individuals with diabetes is
      necessary.
AD  - Department of Clinic Nursing, College of Nursing, University of South China,
      Hengyang, Hunan 421001; ; Department of Community Nursing, College of Nursing,
      Central South University, Changsha, Hunan 410083, P.R. China.
FAU - Zhou, Yujuan
AU  - Zhou Y
FAU - Liao, Li
AU  - Liao L
FAU - Sun, Mei
AU  - Sun M
FAU - He, Guoping
AU  - He G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130205
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3628830
OTO - NOTNLM
OT  - diabetes
OT  - diet
OT  - self-care
OT  - self-monitoring of blood glucose
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/12/14 [received]
PHST- 2013/01/28 [accepted]
PHST- 2013/02/05 [epublish]
AID - 10.3892/etm.2013.945 [doi]
AID - etm-05-04-1137 [pii]
PST - ppublish
SO  - Exp Ther Med. 2013 Apr;5(4):1137-1142. Epub 2013 Feb 5.

PMID- 23599638
OWN - NLM
STAT- In-Process
DA  - 20130419
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 13
DP  - 2013 Apr 7
TI  - Alcohol consumption and fatty liver disease.
PG  - 2129-30
LID - 10.3748/wjg.v19.i13.2129 [doi]
AB  - Hamaguchi et al recently reported some interesting observations on alcohol
      consumption and risk of fatty liver disease from a large population. However, we 
      feel that it might be necessary to discuss some concerns in this study. As the
      alcohol consumption categorization was defined by the same criteria in both men
      and women, which might affect their results. As another factor is soft drinks
      consumption. It has been proved that soft drinks, especially fructose,
      contributes to the development of obesity, diabetes, metabolic syndrome, and
      nonalcoholic fatty liver disease. However, this confounding factor was not
      adjusted or discussed in this article. The third is the genetic background, for
      some genetic factors are related with the development of fatty liver disease,
      which was also not considered yet.
FAU - Feng, Ren-Nan
AU  - Feng RN
FAU - Sun, Guo-Dong
AU  - Sun GD
FAU - Zhao, Yan
AU  - Zhao Y
FAU - Guo, Fu-Chuan
AU  - Guo FC
FAU - Sun, Chang-Hao
AU  - Sun CH
LA  - eng
PT  - Comment
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - World J Gastroenterol
JT  - World journal of gastroenterology : WJG
JID - 100883448
SB  - IM
CON - World J Gastroenterol. 2012 Jan 14;18(2):156-67. PMID: 22253522
PMC - PMC3623996
OID - NLM: PMC3623996
OTO - NOTNLM
OT  - Alcohol
OT  - Diabetes
OT  - Fatty liver disease
OT  - Metabolic syndrome
OT  - Obesity
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/08/08 [received]
PHST- 2013/03/02 [revised]
PHST- 2013/03/08 [accepted]
AID - 10.3748/wjg.v19.i13.2129 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 Apr 7;19(13):2129-30. doi: 10.3748/wjg.v19.i13.2129.

PMID- 23599442
OWN - NLM
STAT- In-Data-Review
DA  - 20130516
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Linking)
VI  - 33
IP  - 6
DP  - 2013 Jun
TI  - Insulin sensitivity and carotid intima-media thickness: relationship between
      insulin sensitivity and cardiovascular risk study.
PG  - 1409-17
LID - 10.1161/ATVBAHA.112.300948 [doi]
AB  - OBJECTIVE: Despite a wealth of experimental data in animal models, the
      independent association of insulin resistance with early carotid atherosclerosis 
      in man has not been demonstrated. APPROACH AND RESULTS: We studied a European
      cohort of 525 men and 655 women (mean age, 44+/-8 years) free of conditions known
      to affect carotid wall (diabetes mellitus, hypertension, and dyslipidemia). All
      subjects received an oral glucose tolerance test, a euglycemic hyperinsulinemic
      clamp (M/I as a measure of insulin sensitivity), and B-mode carotid ultrasound.
      In 833 participants (380 men), the carotid ultrasound was repeated after 3 years.
      In men, baseline intima-media thickness in the common carotid artery (CCA-IMT)
      was significantly higher (P<0.05) in the lowest M/I tertile, whereas in women
      CCA-IMT was higher (P<0.0005) in the highest fasting plasma glucose tertile
      (after adjustment for established risk factors). In multiple regression models,
      with CCA-IMT as the dependent variable and with risk factors and univariate
      metabolic correlates as independent variables, circulating free fatty acids and
      the leptin:adiponectin ratio replaced M/I as independent metabolic determinants
      of CCA-IMT in men. The strongest metabolic determinant of CCA-IMT in women was
      fasting plasma glucose. Three-year CCA-IMT changes were not associated with any
      cardio-metabolic risk factor. CONCLUSIONS: In young-to-middle aged apparently
      healthy people, the association of CCA-IMT with insulin sensitivity and its
      metabolic correlates differs between men and women. Lower insulin sensitivity is 
      associated with higher IMT only in men; this association seems to be mediated by 
      circulating free fatty acids and adipocytokines. In women, CCA-IMT is
      independently associated with fasting plasma glucose.
AD  - From the Department of Experimental and Clinical Medicine, University of Pisa,
      Italy (M.K., A.N., E.F.).
FAU - Kozakova, Michaela
AU  - Kozakova M
FAU - Natali, Andrea
AU  - Natali A
FAU - Dekker, Jacqueline
AU  - Dekker J
FAU - Beck-Nielsen, Henning
AU  - Beck-Nielsen H
FAU - Laakso, Markku
AU  - Laakso M
FAU - Nilsson, Peter
AU  - Nilsson P
FAU - Balkau, Beverley
AU  - Balkau B
FAU - Ferrannini, Ele
AU  - Ferrannini E
CN  - RISC Investigators*
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
SB  - IM
OTO - NOTNLM
OT  - adipokine
OT  - atherosclerosis
OT  - carotid intima-media thickness
OT  - fatty acids
OT  - glucose
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/04/18 [aheadofprint]
AID - ATVBAHA.112.300948 [pii]
AID - 10.1161/ATVBAHA.112.300948 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1409-17. doi:
      10.1161/ATVBAHA.112.300948. Epub 2013 Apr 18.

PMID- 23599437
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
DP  - 2013 Apr 18
TI  - VCAM-1 serum levels are associated with arthropathy in hereditary
      haemochromatosis.
AB  - OBJECTIVES: The aim of this study was to assess the role of vascular adhesion
      molecule 1 (VCAM-1) in patients with hereditary haemochromatosis (HH) with or
      without arthropathy. METHODS: Sera from a large cross-sectional cohort of
      unselected HH patients (n=147) were obtained and compared to an age-matched and
      sex-matched control group. Serum levels of VCAM-1 were measured by ELISA and were
      correlated with clinical measures. RESULTS: VCAM-1 serum levels were elevated in 
      HH patients as compared to matched controls (mean 913+/-456 vs 654+/-451 ng/ml,
      p<0.0001). Within the HH patient group, VCAM-1 levels were much higher in
      patients with arthropathy and joint replacement surgery. VCAM-1 levels correlated
      well with radiographic measures of HH arthropathy (r=0.36, p<0.0001).
      Multivariate regression analysis confirmed a highly significant association of
      VCAM-1 serum levels and the presence of HH arthropathy, independent from
      diabetes, body mass index and age. CONCLUSIONS: VCAM-1 serum levels emerge as a
      biomarker for haemochromatosis arthropathy.
AD  - 1st Medical Department, Ludwig Boltzmann Institute of Osteology at the Hanusch
      Hospital of WGKK and AUVA Trauma Centre Meidling, Hanusch Hospital, Vienna,
      Austria.
FAU - Nell-Duxneuner, Valerie
AU  - Nell-Duxneuner V
FAU - Axmann, Roland
AU  - Axmann R
FAU - Husar-Memmer, Emma
AU  - Husar-Memmer E
FAU - Dallos, Tomas
AU  - Dallos T
FAU - Datz, Christian
AU  - Datz C
FAU - Stadlmayr, Andreas
AU  - Stadlmayr A
FAU - Aigner, Elmar
AU  - Aigner E
FAU - Englbrecht, Matthias
AU  - Englbrecht M
FAU - Schett, Georg
AU  - Schett G
FAU - Zwerina, Jochen
AU  - Zwerina J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - annrheumdis-2012-202800 [pii]
AID - 10.1136/annrheumdis-2012-202800 [doi]
PST - aheadofprint
SO  - Ann Rheum Dis. 2013 Apr 18.

PMID- 23599396
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1522-1601 (Electronic)
IS  - 0161-7567 (Linking)
DP  - 2013 Apr 18
TI  - Mild fasting hyperglycemia shifts fuel reliance towards fat during exercise in
      adults with impaired glucose tolerance.
AB  - Impaired glucose tolerance (IGT) is characterized by decreased oxidative capacity
      and reduced carbohydrate utilization during exercise. But, it is unclear if the
      presence of impaired fasting glucose (IFG) affects fuel utilization during
      exercise in adults with IGT. We tested the hypothesis that the presence of IFG in
      adults with IGT decreases reliance on carbohydrate during exercise. Middle-aged, 
      obese, sedentary individuals (n=6,IGT and n=6,IFG+IGT) were compared during
      exercise at 60% VO2peak for 45 minutes on a cycle ergometer. Glucose rates of
      appearance (Ra), disposal (Rd), and muscle glycogen were assessed by stable
      isotope dilution methods, and fat utilization was estimated via indirect
      calorimetry. A 75-gram oral glucose tolerance test (OGTT) was used to determine
      fasting and 2-hour glucose concentrations. A glucose intolerance severity z-score
      was calculated from the OGTT. Glucose flux (i.e. Ra and Rd) was not different
      between groups. However, individuals with IFG+IGT had lower muscle glycogen use
      (p<0.05) and elevated fat oxidation (p<0.01) during exercise compared to those
      with isolated IGT. Plasma non-esterified fatty acids (NEFA) and glucose were
      significantly higher during exercise in subjects with IFG+IGT vs. IGT alone
      (p<0.05). Fat utilization during exercise correlated with fasting glucose
      (r=0.57, p=0.05), glucose intolerance severity z-score (r=0.66, p=0.01), and NEFA
      (trend; r=0.55, p=0.08). The presence of IFG shifts fuel selection towards
      increased fat oxidation and decreased muscle glycogen utilization during exercise
      in adults with IGT. Whether these differences in substrate use contribute to, or 
      are the result of, movement along the continuum from prediabetes to type-2
      diabetes awaits further work.
AD  - 1Cleveland Clinic.
FAU - Malin, Steven K
AU  - Malin SK
FAU - Viskochil, Richard
AU  - Viskochil R
FAU - Oliver, Corianne
AU  - Oliver C
FAU - Braun, Barry
AU  - Braun B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Appl Physiol
JT  - Journal of applied physiology (Bethesda, Md. : 1985)
JID - 8502536
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - japplphysiol.00084.2013 [pii]
AID - 10.1152/japplphysiol.00084.2013 [doi]
PST - aheadofprint
SO  - J Appl Physiol. 2013 Apr 18.

PMID- 23599174
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 2168-6173 (Electronic)
IS  - 2168-6165 (Linking)
DP  - 2013 Apr 18
TI  - Macular Edema After Cataract Surgery in Eyes Without Preoperative
      Central-Involved Diabetic Macular Edema.
PG  - 1-9
LID - 10.1001/jamaophthalmol.2013.2313 [doi]
AB  - IMPORTANCE The incidence of development or worsening of macular edema (ME) is
      variable in eyes without diabetic ME (DME) undergoing cataract surgery. OBJECTIVE
      To estimate the incidence of central-involved ME 16 weeks following cataract
      surgery in eyes with diabetic retinopathy without definite central-involved DME
      preoperatively. DESIGN, SETTING, AND PARTICIPANTS In a multicenter, prospective, 
      observational study, 293 participants with diabetic retinopathy without definite 
      central subfield thickening on optical coherence tomography (OCT) underwent
      cataract surgery. EXPOSURE Cataract extraction surgery performed within 28 days
      of enrollment of eyes without DME in individuals with diabetes mellitus. MAIN
      OUTCOMES AND MEASURES Development of central-involved ME defined as the
      following: (1) OCT central subfield thickness of 250 mum or greater (time-domain 
      OCT) or 310 mum or greater (spectral-domain OCT) with at least a 1-step increase 
      in logOCT central subfield thickness preoperatively to the 16-week visit; (2) at 
      least a 2-step increase in logOCT central subfield thickness preoperatively to
      the 16-week visit; or (3) nontopical treatment for ME received before the 16-week
      visit with either of the OCT criteria met at the time of treatment. RESULTS The
      median participant age was 65 years. The median visual acuity letter score was 69
      letters (Snellen equivalent 20/40). Forty-four percent of eyes had a history of
      treatment for DME. Sixteen weeks postoperatively, central-involved ME was noted
      in 0% (95% CI, 0%-20%) of 17 eyes with no preoperative DME. Of eyes with
      non-central-involved DME, 10% (95% CI, 5%-18%) of 97 eyes without
      central-involved DME and 12% (95% CI, 7%-19%) of 147 eyes with possible
      central-involved DME at baseline progressed to central-involved ME. History of
      DME treatment was significantly associated with central-involved ME development
      (P &lt; .001). CONCLUSIONS AND RELEVANCE In eyes with diabetic retinopathy
      without concurrent central-involved DME, presence of non-central-involved DME
      immediately prior to cataract surgery or history of DME treatment may increase
      the risk of developing central-involved ME 16 weeks after cataract extraction.
CN  - Diabetic Retinopathy Clinical Research Network*
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - JAMA Ophthalmol
JT  - JAMA ophthalmology
JID - 101589539
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - 1679509 [pii]
AID - 10.1001/jamaophthalmol.2013.2313 [doi]
PST - aheadofprint
SO  - JAMA Ophthalmol. 2013 Apr 18:1-9. doi: 10.1001/jamaophthalmol.2013.2313.

PMID- 23599105
OWN - NLM
STAT- In-Process
DA  - 20130419
IS  - 1942-7522 (Electronic)
IS  - 0145-5613 (Linking)
VI  - 92
IP  - 4-5
DP  - 2013 Apr-May
TI  - Airway management in an infant with alobar holoprosencephaly and cebocephaly
      associated with maternal diabetes mellitus.
PG  - 215-8
AB  - We report a case of alobar holoprosencephaly (HPE) and cebocephaly associated
      with uncontrolled maternal type 1 (insulin-dependent) diabetes mellitus. Alobar
      HPE is the most severe form of HPE. Patients with cebocephaly have ocular
      hypotelorism and a proboscis with a single, blind-ended nostril. Shortly after
      our patient was born, we were consulted for airway management, as the parents'
      goal was to bring their child home. A tracheostomy tube was placed, and choanal
      atresia repair was eventually performed. The infant was never decannulated,
      however, and she died at the age of 9 months of acute respiratory distress
      syndrome secondary to an upper respiratory infection. To the best of our
      knowledge, this case represents the longest reported survival of an infant with
      alobar HPE and cebocephaly. Decisions regarding the care of these infants should 
      be made in a collaborative, multidisciplinary fashion, with special attention
      paid to the primary caregivers' goals of care.
AD  - Department of Otolaryngology-Head and Neck Surgery, Virginia Commonwealth
      University, 1200 East Broad St., West Hospital, 12th Floor, South Wing, Suite
      313, PO Box 980146, Richmond, VA 23298-0146, USA. rpetersson@mcvh-vcu.edu
FAU - Petersson, Rajanya S
AU  - Petersson RS
FAU - Carey, William A
AU  - Carey WA
FAU - Thompson, Dana M
AU  - Thompson DM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ear Nose Throat J
JT  - Ear, nose, & throat journal
JID - 7701817
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PST - ppublish
SO  - Ear Nose Throat J. 2013 Apr-May;92(4-5):215-8.

PMID- 23599042
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1522-1547 (Electronic)
IS  - 0193-1857 (Linking)
DP  - 2013 Apr 18
TI  - Glucose Metabolism in the Belgrade rat, a Model of Iron-loading Anemia.
AB  - The iron-diabetes hypothesis proposes an association between iron overload and
      glucose metabolism that is supported by a number of epidemiological studies. The 
      prevalence of type 2 diabetes in patients with hereditary hemochromatosis and
      iron-loading thalassemia support this hypothesis. The Belgrade rat carries a
      mutation in the iron transporter DMT1 resulting in iron-loading anemia. In this
      study, we characterized the glycometabolic status of the Belgrade rat. Belgrade
      rats displayed normal glycemic control. Insulin signaling and secretion were not 
      impaired, and pancreatic tissue did not incur damage despite high levels of
      non-heme iron. These findings suggest that loss of DMT1 protects against
      oxidative damage to the pancreas and helps to maintain insulin sensitivity
      despite iron overload. Belgrade rats had lower body weight but increased food
      consumption compared to heterozygous littermates. The unexpected energy balance
      was associated with increased urinary glucose output. Increased urinary excretion
      of electrolytes, including iron, was also observed. Histopathological evidence
      suggests that altered renal function is secondary to changes in kidney morphology
      including glomerulosclerosis. Thus, loss of DMT1 appears to protect the pancreas 
      from injury but damages the integrity of kidney structure and function.
AD  - 1Harvard School of Public health.
FAU - Jia, Xuming
AU  - Jia X
FAU - Kim, Jonghan
AU  - Kim J
FAU - Veuthey, Tania
AU  - Veuthey T
FAU - Lee, Chih-Hao
AU  - Lee CH
FAU - Wessling-Resnick, Marianne
AU  - Wessling-Resnick M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Am J Physiol Gastrointest Liver Physiol
JT  - American journal of physiology. Gastrointestinal and liver physiology
JID - 100901227
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - ajpgi.00453.2012 [pii]
AID - 10.1152/ajpgi.00453.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Gastrointest Liver Physiol. 2013 Apr 18.

PMID- 23599027
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1460-2083 (Electronic)
IS  - 0964-6906 (Linking)
DP  - 2013 May 1
TI  - Genome-wide association study of age at menarche in African-American women.
AB  - African-American (AA) women have earlier menarche on average than women of
      European ancestry (EA), and earlier menarche is a risk factor for obesity and
      type 2 diabetes among other chronic diseases. Identification of common genetic
      variants associated with age at menarche has a potential value in pointing to the
      genetic pathways underlying chronic disease risk, yet comprehensive genome-wide
      studies of age at menarche are lacking for AA women. In this study, we tested the
      genome-wide association of self-reported age at menarche with common
      single-nucleotide polymorphisms (SNPs) in a total of 18 089 AA women in 15
      studies using an additive genetic linear regression model, adjusting for year of 
      birth and population stratification, followed by inverse-variance weighted
      meta-analysis (Stage 1). Top meta-analysis results were then tested in an
      independent sample of 2850 women (Stage 2). First, while no SNP passed the
      pre-specified P < 5 x 10-8 threshold for significance in Stage 1, suggestive
      associations were found for variants near FLRT2 and PIK3R1, and conditional
      analysis identified two independent SNPs (rs339978 and rs980000) in or near RORA,
      strengthening the support for this suggestive locus identified in EA women.
      Secondly, an investigation of SNPs in 42 previously identified menarche loci in
      EA women demonstrated that 25 (60%) of them contained variants significantly
      associated with menarche in AA women. The findings provide the first evidence of 
      cross-ethnic generalization of menarche loci identified to date, and suggest a
      number of novel biological links to menarche timing in AA women.
AD  - Division of Epidemiology and Community Health, School of Public Health,
      University of Minnesota, Minneapolis, MN, USA.
FAU - Demerath, Ellen W
AU  - Demerath EW
FAU - Liu, Ching-Ti
AU  - Liu CT
FAU - Franceschini, Nora
AU  - Franceschini N
FAU - Chen, Gary
AU  - Chen G
FAU - Palmer, Julie R
AU  - Palmer JR
FAU - Smith, Erin N
AU  - Smith EN
FAU - Chen, Christina T L
AU  - Chen CT
FAU - Ambrosone, Christine B
AU  - Ambrosone CB
FAU - Arnold, Alice M
AU  - Arnold AM
FAU - Bandera, Elisa V
AU  - Bandera EV
FAU - Berenson, Gerald S
AU  - Berenson GS
FAU - Bernstein, Leslie
AU  - Bernstein L
FAU - Britton, Angela
AU  - Britton A
FAU - Cappola, Anne R
AU  - Cappola AR
FAU - Carlson, Christopher S
AU  - Carlson CS
FAU - Chanock, Stephen J
AU  - Chanock SJ
FAU - Chen, Wei
AU  - Chen W
FAU - Chen, Zhao
AU  - Chen Z
FAU - Deming, Sandra L
AU  - Deming SL
FAU - Elks, Cathy E
AU  - Elks CE
FAU - Evans, Michelle K
AU  - Evans MK
FAU - Gajdos, Zofia
AU  - Gajdos Z
FAU - Henderson, Brian E
AU  - Henderson BE
FAU - Hu, Jennifer J
AU  - Hu JJ
FAU - Ingles, Sue
AU  - Ingles S
FAU - John, Esther M
AU  - John EM
FAU - Kerr, Kathleen F
AU  - Kerr KF
FAU - Kolonel, Laurence N
AU  - Kolonel LN
FAU - Le Marchand, Loic
AU  - Le Marchand L
FAU - Lu, Xiaoning
AU  - Lu X
FAU - Millikan, Robert C
AU  - Millikan RC
FAU - Musani, Solomon K
AU  - Musani SK
FAU - Nock, Nora L
AU  - Nock NL
FAU - North, Kari
AU  - North K
FAU - Nyante, Sarah
AU  - Nyante S
FAU - Press, Michael F
AU  - Press MF
FAU - Rodriquez-Gil, Jorge L
AU  - Rodriquez-Gil JL
FAU - Ruiz-Narvaez, Edward A
AU  - Ruiz-Narvaez EA
FAU - Schork, Nicholas J
AU  - Schork NJ
FAU - Srinivasan, Sathanur R
AU  - Srinivasan SR
FAU - Woods, Nancy F
AU  - Woods NF
FAU - Zheng, Wei
AU  - Zheng W
FAU - Ziegler, Regina G
AU  - Ziegler RG
FAU - Zonderman, Alan
AU  - Zonderman A
FAU - Heiss, Gerardo
AU  - Heiss G
FAU - Gwen Windham, B
AU  - Gwen Windham B
FAU - Wellons, Melissa
AU  - Wellons M
FAU - Murray, Sarah S
AU  - Murray SS
FAU - Nalls, Michael
AU  - Nalls M
FAU - Pastinen, Tomi
AU  - Pastinen T
FAU - Rajkovic, Aleksandar
AU  - Rajkovic A
FAU - Hirschhorn, Joel
AU  - Hirschhorn J
FAU - Adrienne Cupples, L
AU  - Adrienne Cupples L
FAU - Kooperberg, Charles
AU  - Kooperberg C
FAU - Murabito, Joanne M
AU  - Murabito JM
FAU - Haiman, Christopher A
AU  - Haiman CA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130501
TA  - Hum Mol Genet
JT  - Human molecular genetics
JID - 9208958
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/04/17 [aheadofprint]
AID - ddt181 [pii]
AID - 10.1093/hmg/ddt181 [doi]
PST - aheadofprint
SO  - Hum Mol Genet. 2013 May 1.

PMID- 23598999
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1362-4962 (Electronic)
IS  - 0305-1048 (Linking)
VI  - 41
IP  - 11
DP  - 2013 Jun 1
TI  - COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA
      methylation analysis.
PG  - e117
AB  - COHCAP (City of Hope CpG Island Analysis Pipeline) is an algorithm to analyze
      single-nucleotide resolution DNA methylation data produced by either an Illumina 
      methylation array or targeted bisulfite sequencing. The goal of the COHCAP
      algorithm is to identify CpG islands that show a consistent pattern of
      methylation among CpG sites. COHCAP is currently the only DNA methylation package
      that provides integration with gene expression data to identify a subset of CpG
      islands that are most likely to regulate downstream gene expression, and it can
      generate lists of differentially methylated CpG islands with approximately 50%
      concordance with gene expression from both cell line data and heterogeneous
      patient data. For example, this article describes known breast cancer biomarkers 
      (such as estrogen receptor) with a negative correlation between DNA methylation
      and gene expression. COHCAP also provides visualization for quality control
      metrics, regions of differential methylation and correlation between methylation 
      and gene expression. This software is freely available at
      https://sourceforge.net/projects/cohcap/.
AD  - Bioinformatics Core, City of Hope National Medical Center, Duarte, CA, 91010,
      USA, Department of Molecular Medicine, City of Hope National Medical Center,
      Duarte, CA, 91010, USA, Cancer Immunotherapeutics and Immunology, City of Hope
      National Medical Center, Duarte, CA, 91010, USA, Department of Biology, City of
      Hope National Medical Center, Duarte, CA, 91010, USA, Department of Diabetes and 
      Metabolic Disease Research, City of Hope National Medical Center, Duarte, CA,
      91010, USA, Functional Genomics Core, City of Hope National Medical Center,
      Duarte, CA, 91010, USA and Department of Molecular & Cellular Biology, City of
      Hope National Medical Center, Duarte, CA, 91010, USA.
FAU - Warden, Charles D
AU  - Warden CD
FAU - Lee, Heehyoung
AU  - Lee H
FAU - Tompkins, Joshua D
AU  - Tompkins JD
FAU - Li, Xiaojin
AU  - Li X
FAU - Wang, Charles
AU  - Wang C
FAU - Riggs, Arthur D
AU  - Riggs AD
FAU - Yu, Hua
AU  - Yu H
FAU - Jove, Richard
AU  - Jove R
FAU - Yuan, Yate-Ching
AU  - Yuan YC
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Nucleic Acids Res
JT  - Nucleic acids research
JID - 0411011
PMC - PMC3675470
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/04/17 [aheadofprint]
AID - gkt242 [pii]
AID - 10.1093/nar/gkt242 [doi]
PST - ppublish
SO  - Nucleic Acids Res. 2013 Jun 1;41(11):e117. Epub 2013 Apr 17.

PMID- 23598952
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1399-3003 (Electronic)
IS  - 0903-1936 (Linking)
DP  - 2013 Apr 18
TI  - Factors associated with FEV1 decline in cystic fibrosis: analysis of the data of 
      the ECFS Patient Registry.
AB  - Pulmonary insufficiency is the main cause of death in cystic fibrosis (CF). The
      European CF Society Patient Registry (ECFSPR) offers a unique database to
      evaluate potential risk factors of CF lung disease in a heterogeneous
      population.We analysed forced expiratory volume in one second (FEV1%) data of
      14732 patients registered in the ECFSPR in year 2007. Linear and logistic
      regressions were used to investigate association between FEV1% and age, age at
      diagnosis, sex, pancreatic status, chronic P. aeruginosa infection, CF-related
      diabetes (CFRD), BMI, and genotype. Estimates were adjusted for country.BMI,
      chronic infection by P. aeruginosa, pancreatic status and CFRD showed a
      statistically significant (all p<0.0001) and clinically relevant effect on FEV1%.
      Age at diagnosis, sex and genotype had a statistically significant (p<0.01), but 
      not clinically relevant effect. We estimate that patients with lower BMI
      experience a 6 fold increased odds (95% CI 5.0;7.3) of having severe lung disease
      (FEV1<40%) compared to patients with normal BMI, and that patients affected by
      CFRD have a 1.8 fold increased odds (1.6;2.2) compared to patients not affected. 
      Being chronically infected with P. aeruginosa increases the odds of severe lung
      disease by 2.4 (2.0;2.7) and pancreatic insufficient patients experience a 2.0
      fold increased odds (1.6;2.5) of severe lung disease compared to pancreatic
      sufficient patients.Nutrition, chronic P. aeruginosa infection, pancreatic status
      and CFRD were found to be potential risk factors of pulmonary function in
      patients with CF regardless of age. Since three of these factors are preventable 
      or treatable, we emphasize the importance of their early identification through
      frequent routine tests, the implementation of infection control measures, and a
      timely initiation of antibiotic therapies. Furthermore, epidemiological and
      clinical studies comparing CF patients from different populations should control 
      for these factors to avoid confounding.
AD  - Hadassah Hebrew University Hospital, Jerusalem, Israel.
FAU - Kerem, Eitan
AU  - Kerem E
FAU - Viviani, Laura
AU  - Viviani L
FAU - Zolin, Anna
AU  - Zolin A
FAU - Macneill, Stephanie
AU  - Macneill S
FAU - Hatziagorou, Elpis
AU  - Hatziagorou E
FAU - Ellemunter, Helmut
AU  - Ellemunter H
FAU - Drevinek, Pavel
AU  - Drevinek P
FAU - Gulmans, Vincent
AU  - Gulmans V
FAU - Krivec, Uros
AU  - Krivec U
FAU - Olesen, Hanne
AU  - Olesen H
CN  - on behalf of the ECFS Patient Registry Steering Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Eur Respir J
JT  - The European respiratory journal : official journal of the European Society for
      Clinical Respiratory Physiology
JID - 8803460
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - 09031936.00166412 [pii]
AID - 10.1183/09031936.00166412 [doi]
PST - aheadofprint
SO  - Eur Respir J. 2013 Apr 18.

PMID- 23598916
OWN - NLM
STAT- MEDLINE
DA  - 20130419
DCOM- 20130611
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 99
IP  - 10
DP  - 2013 May
TI  - Methods of accelerated atherosclerosis in diabetic patients.
PG  - 743-9
LID - 10.1136/heartjnl-2011-301172 [doi]
AD  - Department of Cardiology, Laboratory of Experimental Cardiology, University
      Medical Center Utrecht, Heidelberglaan 100, Room G02-523, Utrecht 3584CX, The
      Netherlands. g.pasterkamp@umcutrecht.nl
FAU - Pasterkamp, Gerard
AU  - Pasterkamp G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
SB  - AIM
SB  - IM
MH  - Atherosclerosis/epidemiology/*etiology
MH  - Diabetic Angiopathies/*complications/epidemiology
MH  - Disease Progression
MH  - Humans
MH  - Incidence
MH  - *Risk Assessment
MH  - Risk Factors
MH  - World Health
EDAT- 2013/04/20 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/04/20 06:00
AID - heartjnl-2011-301172 [pii]
AID - 10.1136/heartjnl-2011-301172 [doi]
PST - ppublish
SO  - Heart. 2013 May;99(10):743-9. doi: 10.1136/heartjnl-2011-301172.

PMID- 23598834
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1936-959X (Electronic)
IS  - 0195-6108 (Linking)
DP  - 2013 Apr 18
TI  - Metabolite Differences in the Lenticular Nucleus in Type 2 Diabetes Mellitus
      Shown by Proton MR Spectroscopy.
AB  - BACKGROUND AND PURPOSE:Previous studies by using proton MR spectroscopy found
      metabolite abnormalities in the cerebral cortex and white matter of patients with
      type 2 diabetes mellitus. The present study was undertaken to detect metabolite
      differences in the lenticular nuclei and thalamus in patients with T2DM.MATERIALS
      AND METHODS:Twenty subjects with T2DM and 22 age-matched control subjects
      underwent single-voxel MR spectroscopy in the left and right lenticular nuclei
      and left and right thalami. NAA/Cr and Cho/Cr ratios were calculated. Brain
      lactic acid, fasting blood glucose, and glycosylated hemoglobin levels were also 
      monitored.RESULTS:The NAA/Cr ratio was lower in the left lenticular nuclei of
      subjects with T2DM (P = .007), whereas the Cho/Cr ratio was increased in both the
      and right lenticular nuclei (P = .001). The NAA/Cr ratio was negatively
      correlated with FBG in the left (r = -0.573, P = .008) and right nuclei (r =
      -0.564, P = .010). It was also negatively correlated to HbA1c in the left (r =
      -0.560, P = .010) and right (r = -0.453, P = .045) nuclei. The Cho/Cr ratio was
      positively correlated with these variables (P < .05). No significant differences 
      in NAA/Cr or Cho/Cr ratios were observed in the thalamus of patients with T2DM.
      Lactic acid was not detected in any of the patients in the study.CONCLUSIONS:The 
      different metabolic statuses of the lenticular nuclei and thalamus suggest
      different effects of T2DM in each of these brain nuclei, with the lenticular
      nuclei being more vulnerable than the thalamus. The abnormal metabolic status was
      observed before lesions had appeared in these brain areas.
AD  - Departments of Neurology and Radiology, Second Affiliated Hospital of Dalian
      Medical University, Dalian, China; Department of Neurology, First Affiliated
      Hospital, Zhejiang University School of Medicine, Hangzhou, China; and Department
      of Physiology, Liaoning Provincial Key Laboratory of Cerebral Diseases, Institute
      for Brain Disorders, Dalian Medical University, Dalian, China.
FAU - Lin, Y
AU  - Lin Y
FAU - Zhou, J
AU  - Zhou J
FAU - Sha, L
AU  - Sha L
FAU - Li, Y
AU  - Li Y
FAU - Qu, X
AU  - Qu X
FAU - Liu, L
AU  - Liu L
FAU - Chen, H
AU  - Chen H
FAU - An, Z
AU  - An Z
FAU - Wang, Y
AU  - Wang Y
FAU - Sun, C
AU  - Sun C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - AJNR Am J Neuroradiol
JT  - AJNR. American journal of neuroradiology
JID - 8003708
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - ajnr.A3492 [pii]
AID - 10.3174/ajnr.A3492 [doi]
PST - aheadofprint
SO  - AJNR Am J Neuroradiol. 2013 Apr 18.

PMID- 23598646
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1414-431X (Electronic)
IS  - 0100-879X (Linking)
VI  - 46
IP  - 4
DP  - 2013 Apr 12
TI  - Exaggerated blood pressure response during the exercise treadmill test as a risk 
      factor for hypertension.
PG  - 368-47
LID - S0100-879X2013005032830 [pii]
AB  - Exaggerated blood pressure response (EBPR) during the exercise treadmill test
      (ETT) has been considered to be a risk factor for hypertension. The relationship 
      of polymorphisms of the renin-angiotensin system gene with hypertension has not
      been established. Our objective was to evaluate whether EBPR during exercise is a
      clinical marker for hypertension. The study concerned a historical cohort of
      normotensive individuals. The exposed individuals were those who presented EBPR. 
      At the end of the observation period (41.7 months = 3.5 years), the development
      of hypertension was analyzed within the two groups. Genetic polymorphisms and
      blood pressure behavior were assessed as independent variables, together with the
      classical risk factors for hypertension. The I/D gene polymorphism of the
      angiotensin-converting enzyme and M235T of angiotensinogen were ruled out as risk
      factors for hypertension. EBPR during ETT is not an independent influence on the 
      chances of developing hypertension. No differences were observed between the
      hypertensive and normotensive individuals regarding gender (P = 0.655), skin
      color (P = 0.636), family history of hypertension (P = 0.225), diabetes mellitus 
      (P = 0.285), or hypertriglyceridemia (P = 0.734). The risk of developing
      hypertension increased with increasing body mass index (BMI) and advancing age.
      The risk factors, which independently influenced the development of hypertension,
      were age and BMI. EBPR did not constitute an independent risk factor for
      hypertension and is probably a preclinical phase in the spectrum of normotension 
      and hypertension.
FAU - Lima, S G
AU  - Lima SG
FAU - Albuquerque, M F P M
AU  - Albuquerque MF
FAU - Oliveira, J R M
AU  - Oliveira JR
FAU - Ayres, C F J
AU  - Ayres CF
FAU - Cunha, J E G
AU  - Cunha JE
FAU - Oliveira, D F
AU  - Oliveira DF
FAU - Lemos, R R
AU  - Lemos RR
FAU - Souza, M B R
AU  - Souza MB
FAU - Silva, O Barbosa E
AU  - Silva OB
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de
      pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.]
JID - 8112917
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/11/26 [received]
PHST- 2013/02/08 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - S0100-879X2013005032830 [pii]
PST - ppublish
SO  - Braz J Med Biol Res. 2013 Apr 12;46(4):368-47. Epub 2013 Apr 19.

PMID- 23598596
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 2047-4881 (Electronic)
IS  - 2047-4873 (Linking)
DP  - 2013 Apr 18
TI  - Effect of intensive glycaemic control on endothelial progenitor cells in patients
      with long-standing uncontrolled type 2 diabetes.
AB  - AIMS: Endothelial progenitor cells (EPCs) have an important role in repair
      following vascular injury. However, in patients with diabetes, EPC number and
      function are markedly reduced. It is unclear whether intensive glycaemic control 
      can modify EPC properties in diabetic patients. We aimed to examine whether
      glycaemic control can improve EPC number and function in patients with
      long-standing uncontrolled type 2 diabetes. METHODS AND RESULTS: Thirty-five
      patients with treated type 2 diabetes and HgA1c >/=8.5% were included. Patients
      were tested at baseline and after 3-4 months of an intensive glycaemic control
      programme, with the aim of achieving HgA1c of 7%. The diabetes group was compared
      to 20 patients without diabetes (control). Circulating EPC levels were assessed
      by flow cytometry for expression of VEGFR2, CD133, and CD34. The capacity of the 
      cells to form colony-forming units (CFUs), and their migration and viability were
      quantified after 1 week of culture. Patients with diabetes (mean age 61.1 +/- 7
      years, 28.6% women, disease duration of 19.2 +/- 8 years) had a baseline HgA1c of
      9.4 +/- 0.8%. After the glycaemic control period, HgA1c decreased to 8 +/- 0.8%. 
      Circulating EPC levels increased significantly after the intensive control period
      and reached a level similar to the control group. The number of EPC CFUs also
      increased significantly after glycaemic control but remained lower than the
      control group. All EPC functional assays improved following the glycaemic
      control. CONCLUSIONS: In patients with uncontrolled long-standing type 2
      diabetes, intensive glycaemic control was associated with an increase in the
      levels of circulating EPCs, and improvement in their functional properties.
AD  - Tel-Aviv University, Tel-Aviv, Israel.
FAU - Lev, Eli I
AU  - Lev EI
FAU - Singer, Joel
AU  - Singer J
FAU - Leshem-Lev, Dorit
AU  - Leshem-Lev D
FAU - Rigler, Merav
AU  - Rigler M
FAU - Dadush, Oshrat
AU  - Dadush O
FAU - Vaduganathan, Muthiah
AU  - Vaduganathan M
FAU - Battler, Alexander
AU  - Battler A
FAU - Kornowski, Ran
AU  - Kornowski R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Eur J Prev Cardiol
JT  - European journal of preventive cardiology
JID - 101564430
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - 2047487313488300 [pii]
AID - 10.1177/2047487313488300 [doi]
PST - aheadofprint
SO  - Eur J Prev Cardiol. 2013 Apr 18.

PMID- 23598595
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 2047-4881 (Electronic)
IS  - 2047-4873 (Linking)
DP  - 2013 Apr 18
TI  - Highly prevalent and poorly controlled cardiovascular risk factors among Chinese 
      elderly people living in the rural community.
AB  - BACKGROUND: The epidemiological scenario of cardiovascular risk factors (CRFs)
      among elderly people in rural China is unclear. We seek to describe the
      distribution, burden and management of major CRFs among older Chinese people
      living in the rural community. METHODS: This cross-sectional study included 1538 
      participants in the Confucius Hometown Aging Project (2010-2011) of people >/=60 
      years of age (mean age 68.6 years; 59.1% women) who lived in a rural community
      nearby Qufu, Shandong, China. Data were collected through a face-to-face
      interview, a clinical examination and laboratory tests. We carried out
      descriptive analysis on the prevalence and management of major CRFs. RESULTS: The
      overall prevalence of current smoking, physical inactivity, hypertension,
      diabetes, high cholesterol and obesity were 13.8%, 83.7%, 76.0%, 26.6%, 42.4% and
      13.1%, respectively: 82.8% and 50.4% of participants had >/=2 and >/=3,
      respectively, of the six CRFs. Prevalence of alcohol consumption was 18.7%. Men
      were more likely to smoke and consume alcohol than women, whereas women were more
      likely to be obese and physically inactive than men (p < 0.001). Prevalence of
      physical inactivity and hypertension increased with age, prevalence of alcohol
      intake and obesity decreased with age, and prevalence of smoking and diabetes was
      stable. Hypertension, diabetes and high cholesterol were treated in 60.6%, 68.1% 
      and 41.1% of those with the disease, respectively, but only 11.3%, 13.7% and
      31.7% achieved good control. CONCLUSIONS: CRFs are highly prevalent and poorly
      controlled among elderly people in rural China, where men and women have
      different CRF profiles. Intervention programs targeting major CRFs may improve
      the health of older people in China.
AD  - School of Public Health, Jining Medical University, China.
FAU - Song, Aiqin
AU  - Song A
FAU - Liang, Yajun
AU  - Liang Y
FAU - Yan, Zhongrui
AU  - Yan Z
FAU - Sun, Binglun
AU  - Sun B
FAU - Cai, Chuanzhu
AU  - Cai C
FAU - Jiang, Hui
AU  - Jiang H
FAU - Qiu, Chengxuan
AU  - Qiu C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Eur J Prev Cardiol
JT  - European journal of preventive cardiology
JID - 101564430
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - 2047487313487621 [pii]
AID - 10.1177/2047487313487621 [doi]
PST - aheadofprint
SO  - Eur J Prev Cardiol. 2013 Apr 18.

PMID- 23598574
OWN - NLM
STAT- In-Process
DA  - 20130419
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Linking)
VI  - 100
IP  - 3
DP  - 2013 Mar
TI  - Evidence-based therapy prescription in high-cardiovascular risk patients: the
      REACT study.
PG  - 212-20
LID - S0066-782X2013000300002 [pii]
AB  - BACKGROUND: Data on outpatient care provided to patients at high cardiovascular
      risk in Brazil are insufficient. OBJECTIVE: To describe the profile and document 
      the clinical practice of outpatient care in patients at high cardiovascular risk 
      in Brazil, regarding the prescription of evidence-based therapies. METHODS:
      Prospective registry that documented the ambulatory clinical practice in
      individuals at high cardiovascular risk, which was defined as the presence of the
      following factors: coronary artery disease, cerebrovascular and peripheral
      vascular diseases, diabetes, or those with at least three of the following
      factors: hypertension, smoking, dyslipidemia, age > 70 years, family history of
      coronary artery disease, chronic kidney disease or asymptomatic carotid artery
      disease. Basal characteristics were assessed and the rate of prescription of
      pharmacological and non-pharmacological interventions was analyzed. RESULTS: A
      total of 2364 consecutive patients were included, of which 52.2% were males, with
      a mean age of 66.0 years (+/- 10.1). Of these, 78.3% used antiplatelet agents,
      77.0% used statins and of patients with a history of myocardial infarction, 58.0%
      received beta-blockers. Concomitant use of these three classes of drugs was 34%; 
      50.9% of hypertensive, 67% of diabetic and 25.7% of dyslipidemic patients did not
      achieve the goals recommended by guidelines. The main predictors of prescription 
      therapies with proven benefit were centers with a cardiologist and history of
      coronary artery disease. CONCLUSION: This national and representative registry
      identified important gaps in the incorporation of therapies with proven benefit, 
      offering a realistic outlook of patients at high cardiovascular risk.
AD  - Hospital do Coracao, Sao Paulo, SP.
FAU - Berwanger, Otavio
AU  - Berwanger O
FAU - Piva e Mattos, Luiz Alberto
AU  - Piva e Mattos LA
FAU - Martin, Jose Fernando Vilela
AU  - Martin JF
FAU - Lopes, Renato Delascio
AU  - Lopes RD
FAU - Figueiredo, Estevao Lanna
AU  - Figueiredo EL
FAU - Magnoni, Daniel
AU  - Magnoni D
FAU - Precoma, Dalton Bertolim
AU  - Precoma DB
FAU - Machado, Carlos Alberto
AU  - Machado CA
FAU - Guimaraes, Jorge Ilha
AU  - Guimaraes JI
FAU - Andrade, Jadelson Pinheiro de
AU  - Andrade JP
LA  - eng
LA  - por
PT  - Journal Article
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/01/11 [received]
PHST- 2013/02/18 [accepted]
AID - S0066-782X2013000300002 [pii]
PST - ppublish
SO  - Arq Bras Cardiol. 2013 Mar;100(3):212-20.

PMID- 23598567
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1546-8364 (Electronic)
IS  - 1059-8405 (Linking)
DP  - 2013 Apr 18
TI  - Observing Anthropometric and Acanthosis Nigrican Changes Among Children Over
      Time.
AB  - This study assessed the anthropometrics and acanthosis nigricans (AN) in a sample
      of 7,337 children at two assessments. Four groups of children were identified
      based on the presence of AN at both time points: those who never had the marker, 
      those who gained the marker, those who lost the marker, and those who maintained 
      the marker. Group differences in height, weight, body composition, and the amount
      of change in these variables over time were explored. Our findings demonstrated
      that children who maintain or gain the AN marker had the greatest height, weight,
      and body composition changes over time. It is apparent that the AN marker does
      disappear in some children and that this is associated with lower weight gain and
      body composition loss. If interventions can be developed targeting children who
      present with the marker, it is likely that their risk of developing type 2
      diabetes could be reduced.
AD  - 1Department of Endocrinology, School of Medicine, University of North Carolina,
      NC, USA.
FAU - Law, Jennifer
AU  - Law J
FAU - Northrup, Karen
AU  - Northrup K
FAU - Wittberg, Richard
AU  - Wittberg R
FAU - Lilly, Christa
AU  - Lilly C
FAU - Cottrell, Lesley
AU  - Cottrell L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Sch Nurs
JT  - The Journal of school nursing : the official publication of the National
      Association of School Nurses
JID - 9206498
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - 1059840513485986 [pii]
AID - 10.1177/1059840513485986 [doi]
PST - aheadofprint
SO  - J Sch Nurs. 2013 Apr 18.

PMID- 23598551
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 2042-650X (Electronic)
IS  - 2042-6496 (Linking)
VI  - 4
IP  - 6
DP  - 2013 Jun 28
TI  - Flavonoids as dietary regulators of nuclear receptor activity.
PG  - 831-44
LID - 10.1039/c3fo60063g [doi]
AB  - Metabolic diseases such as obesity, type II diabetes, and dyslipidemia are a
      rising cause of mortality worldwide. The progression of many metabolic diseases
      is fundamentally regulated on the transcriptional level by a family of
      ligand-activated transcription factors, called nuclear receptors, which detect
      and respond to metabolic changes. Their role in maintaining metabolic homeostasis
      makes nuclear receptors an important pharmaceutical and dietary target. This
      review will present the growing evidence that flavonoids, natural secondary plant
      metabolites, are important regulators of nuclear receptor activity. Structural
      similarities between flavonoids and cholesterol derivatives combined with the
      promiscuous nature of most nuclear receptors provide a wealth of possibilities
      for pharmaceutical and dietary modulation of metabolism. While the challenges of 
      bringing flavonoid-derived therapeutics to the market are significant, we
      consider this rapidly growing field to be an essential aspect of the functional
      food initiative and an important mine for pharmaceutical compounds.
AD  - School of Computer Science and Engineering, Center for Bioengineering, The Hebrew
      University of Jerusalem, Edmond J. Safra Campus (Givat Ram), Silberman 3-512,
      Jerusalem 91904, Israel. ynahmias@cs.huji.ac.il.
FAU - Avior, Yishai
AU  - Avior Y
FAU - Bomze, David
AU  - Bomze D
FAU - Ramon, Ory
AU  - Ramon O
FAU - Nahmias, Yaakov
AU  - Nahmias Y
LA  - eng
GR  - K01 DK080241/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20130419
PL  - England
TA  - Food Funct
JT  - Food & function
JID - 101549033
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/04/19 [aheadofprint]
PHST- 2013/05/28 [epublish]
AID - 10.1039/c3fo60063g [doi]
PST - ppublish
SO  - Food Funct. 2013 Jun 28;4(6):831-44. doi: 10.1039/c3fo60063g. Epub 2013 Apr 19.

PMID- 23598536
OWN - NLM
STAT- In-Process
DA  - 20130419
IS  - 1934-2403 (Electronic)
IS  - 1530-891X (Linking)
VI  - 19
IP  - 2
DP  - 2013 Mar-Apr
TI  - AACE comprehensive diabetes management algorithm 2013.
PG  - 327-36
FAU - Garber, Alan J
AU  - Garber AJ
FAU - Abrahamson, Martin J
AU  - Abrahamson MJ
FAU - Barzilay, Joshua I
AU  - Barzilay JI
FAU - Blonde, Lawrence
AU  - Blonde L
FAU - Bloomgarden, Zachary T
AU  - Bloomgarden ZT
FAU - Bush, Michael A
AU  - Bush MA
FAU - Dagogo-Jack, Samuel
AU  - Dagogo-Jack S
FAU - Davidson, Michael B
AU  - Davidson MB
FAU - Einhorn, Daniel
AU  - Einhorn D
FAU - Garvey, W Timothy
AU  - Garvey WT
FAU - Grunberger, George
AU  - Grunberger G
FAU - Handelsman, Yehuda
AU  - Handelsman Y
FAU - Hirsch, Irl B
AU  - Hirsch IB
FAU - Jellinger, Paul S
AU  - Jellinger PS
FAU - McGill, Janet B
AU  - McGill JB
FAU - Mechanick, Jeffrey I
AU  - Mechanick JI
FAU - Rosenblit, Paul D
AU  - Rosenblit PD
FAU - Umpierrez, Guillermo
AU  - Umpierrez G
FAU - Davidson, Michael H
AU  - Davidson MH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology
      and the American Association of Clinical Endocrinologists
JID - 9607439
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - A38267720403K242 [pii]
PST - ppublish
SO  - Endocr Pract. 2013 Mar-Apr;19(2):327-36.

PMID- 23598534
OWN - NLM
STAT- In-Process
DA  - 20130419
IS  - 1934-2403 (Electronic)
IS  - 1530-891X (Linking)
VI  - 19
IP  - 2
DP  - 2013 Mar-Apr
TI  - Diurnal glucose profiles using continuous glucose monitoring to identify the
      glucose-lowering characteristics of colesevelam HCL (Welchol).
PG  - 275-83
LID - 10.4158/EP12337.OR [doi]
AB  - OBJECTIVES: The study's purpose was to identify the antihyperglycemic affects of 
      colesevelam-HCl (C-HCl) by characterizing the diurnal and postprandial glucose
      patterns in type 2 diabetic subjects treated concomitantly with metformin,
      sulfonylurea, or a combination of metformin/sulfonylurea. A secondary aim was to 
      determine whether C-HCl significantly increased the risk of hypoglycemia.
      METHODS: A prospective, randomized, double-blind, placebo-controlled, crossover
      study employing continuous glucose monitoring (CGM) with ambulatory glucose
      profile (AGP) analysis was undertaken. Fifteen males and 6 females, age 60 +/- 8 
      years, treated with metformin (n = 8), sulfonylurea (n = 2), or combination (n = 
      11) participated. RESULTS: Treatment with C-HCl led to reductions in glycated
      hemoglobin (HbA1c) (7.5 +/- 0.3 to 7.0 +/- 0.4% P<.0001), LDL (90.9 +/- 18.6 to
      68.9 +/- 15.2 mg/dL, P<.0007) and total cholesterol (169.2 +/- 24.4 to 147.8 +/- 
      21.5 mg/dL, P<.001). Significantly lower normalized diurnal (21 mg/dL/hour, P =
      .0006), nocturnal (19 mg/dL/hour, P = .0005), and daytime (22 mg/dL/hour, P =
      .0008) glucose exposure was detected immediately upon C-HCl administration.
      Additionally, there was a significant (P<.004) decline in postprandial glucose
      excursions (averaging 15% or -36 mg/dL/hour) pronounced at dinner following C-HCl
      administration. There was a nonsignificant increase in the incidence of
      hypoglycemia (0.4-1%), with no difference due to antihyperglycemic medications.
      CONCLUSIONS: AGP analysis of CGM visually and quantitatively showed immediate and
      midterm impacts of C-HCl on basal and postprandial glucose patterns. This
      suggests a multifactorial glucose-lowering mechanism for C-HCl affecting both
      meal-related and basal glucose levels.
AD  - International Diabetes Center, and Mayo Clinic, WHO Collaborating Center,
      Minneapolis, MN 55331, USA. rmazze@aol.com
FAU - Mazze, Roger S
AU  - Mazze RS
FAU - Strock, Ellie S
AU  - Strock ES
FAU - Monk, Arlene M
AU  - Monk AM
FAU - Murphy, Matthew M
AU  - Murphy MM
FAU - Xi, Min
AU  - Xi M
FAU - Bergenstal, Richard M
AU  - Bergenstal RM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocr Pract
JT  - Endocrine practice : official journal of the American College of Endocrinology
      and the American Association of Clinical Endocrinologists
JID - 9607439
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - C4657718R6K85T50 [pii]
AID - 10.4158/EP12337.OR [doi]
PST - ppublish
SO  - Endocr Pract. 2013 Mar-Apr;19(2):275-83. doi: 10.4158/EP12337.OR.

PMID- 23598457
OWN - NLM
STAT- Publisher
DA  - 20130606
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Linking)
VI  - 100
IP  - 5
DP  - 2013 May
TI  - Unrecognized diabetes and myocardial necrosis: predictors of hyperglycemia in
      myocardial infarction.
PG  - 404-411
LID - S0066-782X2013005000025 [pii]
AB  - BACKGROUND: Hyperglycemia in the acute phase of myocardial infarction is an
      important prognostic factor. However, its pathophysiology is not fully
      understood. OBJECTIVE: To analyze simultaneously the correlation between
      hyperglycemia and biochemical markers related to stress, glucose and lipid
      metabolism, coagulation, inflammation, and myocardial necrosis. METHODS Eighty
      patients with acute myocardial infarction were prospectively included. The
      following parameters were analyzed: blood glucose; stress hormones (cortisol and 
      norepinephrine); glucose metabolism factors [glycated hemoglobin (HbA1c);
      insulin]; lipoproteins (total cholesterol, LDL, HDL, minimally modified
      electronegative LDL, and adiponectin); glycerides (triglycerides, VLDL and fatty 
      acids); coagulation factors (factor VII, fibrinogen, plasminogen activator
      inhibitor-1); inflammation (high-sensitivity C reactive protein); and myocardial 
      necrosis (CK-MB and troponin). Continuous variables were converted into degrees
      of relevance using fuzzy logic. RESULTS: Significant correlation was observed
      between hyperglycemia and glucose metabolism (p < 0.001), lipoproteins (p =
      0.03), and necrosis factors (p = 0.03). In the multivariate analysis, only
      glucose metabolism (OR = 4.3; CI = 2.1-68.9; and p < 0.001) and myocardial
      necrosis (OR = 22.5; CI = 2-253; and p = 0.012) showed independent and
      significant correlation. For the analysis of the influence of history of diabetes
      mellitus, a regression model including only patients without diabetes mellitus
      was developed, and the results did not change. Finally, in the model adjusted for
      age, gender, and clinical variables (history of diabetes mellitus, hypertension
      and dyslipidemia), three variables maintained a significant and independent
      association with hyperglycemia: glucose metabolism (OR = 24.1; CI = 4.8-122.1;
      and p < 0.001), myocardial necrosis (OR = 21.9; CI = 1.3-360.9; and p = 0.03),
      and history of DM (OR = 27; CI = 3.7-195.7; and p = 0.001). CONCLUSION: Glucose
      metabolism and myocardial necrosis markers were the best predictors of
      hyperglycemia in patients with acute myocardial infarction.
FAU - Ladeira, Renata Teixeira
AU  - Ladeira RT
FAU - Baracioli, Luciano Moreira
AU  - Baracioli LM
FAU - Faulin, Tanize Espirito Santo
AU  - Faulin TE
FAU - Abdalla, Dulcineia Saes Parra
AU  - Abdalla DS
FAU - Seydell, Talita Matttos
AU  - Seydell TM
FAU - Maranhao, Raul Cavalcante
AU  - Maranhao RC
FAU - Mendonca, Berenice Bilharinho
AU  - Mendonca BB
FAU - Strunz, Celia Cassaro
AU  - Strunz CC
FAU - Castro, Isac de
AU  - Castro ID
FAU - Nicolau, Jose Carlos
AU  - Nicolau JC
LA  - ENG
LA  - POR
PT  - JOURNAL ARTICLE
TT  - Diabetes subdiagnosticado e necrose miocardica: preditores de hiperglicemia no
      infarto do miocardio.
DEP - 20130419
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/05/22 [received]
PHST- 2012/12/17 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - S0066-782X2013005000025 [pii]
PST - ppublish
SO  - Arq Bras Cardiol. 2013 May;100(5):404-411. Epub 2013 Apr 19.

PMID- 23598420
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1941-7225 (Electronic)
IS  - 0895-7061 (Linking)
DP  - 2013 Apr 18
TI  - Hypertension, Pulse, and Other Cardiovascular Risk Factors and Vitamin D Status
      in Finnish Men.
AB  - BACKGROUND: Debate exists about the relationship between hypovitaminosis D and
      cardiovascular (CVD) risk. METHODS: This study investigated baseline (n=2,271)
      25-hydroxyvitamin D (25(OH)D) and baseline and 4 year (n=1,957) CVD risk in a
      cohort of Finnish middle-aged male smokers. RESULTS: The prevalences of measured 
      hypertension, high pulse rate, diabetes, and coronary heart disease were 63%,
      16%, 5%, and 10% at baseline and were 64%, 20%, 6%, and 16% at 4 years after
      baseline. The mean 25(OH)D was 41+/-18 nmol/L. At baseline, systolic blood
      pressure (beta = -0.048; P = 0.02), and pulse rate (beta = -0.043; P = 0.04) were
      both associated with lower 25(OH)D levels but not coronary heart disease or
      diabetes prevalence. On remeasuring CVD risk 4 years after baseline, the only
      significant association with baseline 25(OH)D levels was high pulse rate (beta = 
      -0.077; P = 0.001). In addition, a higher 25(OH)D level at baseline was
      associated with a change in pulse rate (beta = -0.055; P = 0.01). These trends
      for hypertension (baseline) and high pulse rate (baseline and 4 years after
      baseline) were also seen on adjusted categorical analysis (Ptrend < 0.05).
      CONCLUSIONS: Vitamin D deficiency at baseline was associated with hypertension in
      Finnish male smokers, but not after 4 years. These results are consistent with
      recent findings in other large cohort studies with measured blood pressure.
      Change in pulse rate over time continued to be significantly associated with
      lower 25(OH)D baseline levels; this new finding should be investigated further.
AD  - Faculty of Health Sciences, University of Sydney, Sydney, Australia.
FAU - Ke, Liang
AU  - Ke L
FAU - Graubard, Barry I
AU  - Graubard BI
FAU - Albanes, Demetrius
AU  - Albanes D
FAU - Fraser, David R
AU  - Fraser DR
FAU - Weinstein, Stephanie J
AU  - Weinstein SJ
FAU - Virtamo, Jarmo
AU  - Virtamo J
FAU - Brock, Kaye E
AU  - Brock KE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Am J Hypertens
JT  - American journal of hypertension
JID - 8803676
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - hpt051 [pii]
AID - 10.1093/ajh/hpt051 [doi]
PST - aheadofprint
SO  - Am J Hypertens. 2013 Apr 18.

PMID- 23598283
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1095-8584 (Electronic)
IS  - 0022-2828 (Linking)
VI  - 60
DP  - 2013 Jul
TI  - Testosterone enhances cardiomyogenesis in stem cells and recruits the androgen
      receptor to the MEF2C and HCN4 genes.
PG  - 164-71
LID - 10.1016/j.yjmcc.2013.04.003 [doi]
LID - S0022-2828(13)00134-X [pii]
AB  - Since a previous study (Goldman-Johnson et al., 2008 [4]) has shown that
      androgens can stimulate increased differentiation of mouse embryonic stem (mES)
      cells into cardiomyocytes using a genomic pathway, the aim of our study is to
      elucidate the molecular mechanisms regulating testosterone-enhanced
      cardiomyogenesis. Testosterone upregulated cardiomyogenic transcription factors, 
      including GATA4, MEF2C, and Nkx2.5, muscle structural proteins, and the pacemaker
      ion channel HCN4 in a dose-dependent manner, in mES cells and P19 embryonal
      carcinoma cells. Knock-down of the androgen receptor (AR) or treatment with
      anti-androgenic compounds inhibited cardiomyogenesis, supporting the requirement 
      of the genomic pathway. Chromatin immunoprecipitation (ChIP) studies showed that 
      testosterone enhanced recruitment of AR to the regulatory regions of MEF2C and
      HCN4 genes, which was associated with increased histone acetylation. In summary, 
      testosterone upregulated cardiomyogenic transcription factor and HCN4 expression 
      in stem cells. Further, testosterone induced cardiomyogenesis, at least in part, 
      by recruiting the AR receptor to the regulatory regions of the MEF2C and HCN4
      genes. These results provide a detailed molecular analysis of the function of
      testosterone in stem cells and may offer molecular insight into the role of
      steroids in the heart.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Biochemistry, Microbiology, and Immunology, University of Ottawa,
      Ottawa, Ontario K1H 8M5, Canada; Pancreatic Islet Biology and Transplantation,
      Dasman Diabetes Institute, P.O. Box 1180, Dasman 15462, Kuwait.
FAU - Al Madhoun, Ashraf Said
AU  - Al Madhoun AS
FAU - Voronova, Anastassia
AU  - Voronova A
FAU - Ryan, Tammy
AU  - Ryan T
FAU - Zakariyah, Abeer
AU  - Zakariyah A
FAU - McIntire, Christian
AU  - McIntire C
FAU - Gibson, Laura
AU  - Gibson L
FAU - Shelton, Michael
AU  - Shelton M
FAU - Ruel, Marc
AU  - Ruel M
FAU - Skerjanc, Ilona S
AU  - Skerjanc IS
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - England
TA  - J Mol Cell Cardiol
JT  - Journal of molecular and cellular cardiology
JID - 0262322
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/07/18 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/04/05 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S0022-2828(13)00134-X [pii]
AID - 10.1016/j.yjmcc.2013.04.003 [doi]
PST - ppublish
SO  - J Mol Cell Cardiol. 2013 Jul;60:164-71. doi: 10.1016/j.yjmcc.2013.04.003. Epub
      2013 Apr 15.

PMID- 23597946
OWN - NLM
STAT- In-Data-Review
DA  - 20130607
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 81
IP  - 1
DP  - 2013 Jul
TI  - Possible use of Trichuris suis ova in autism spectrum disorders therapy.
PG  - 1-4
LID - 10.1016/j.mehy.2013.03.024 [doi]
LID - S0306-9877(13)00143-6 [pii]
AB  - Autism and autism spectrum disorders (ASDs) are heterogeneous, severe
      neurodevelopmental pathologies. The main core symptoms are: dysfunctions in
      social interactions and communication skills, restricted interests, repetitive
      and stereotypic verbal and non-verbal behaviors. Several biochemical processes
      are associated with ASDs: oxidative stress; endoplasmic reticulum stress;
      decreased methylation capacity; limited production of glutathione; mitochondrial 
      dysfunction; intestinal dysbiosis; increased toxic metal burden; immune
      dysregulation. Current available treatments for ASDs can be divided into
      behavioral, nutritional and medical approaches, although no defined standard
      approach exists. Current drugs fail to benefit the ASD core symptoms and can have
      marked adverse effects, are mainly palliative and only sometimes efficacy in
      attenuating specific autistic behaviors. Helminthic therapy shows potential for
      application as anti-inflammatory agent. Several human diseases can be treated by 
      helminths (i.e. inflammatory bowel disease, asthma, multiple sclerosis and
      autoimmune diabetes). Trichuris suis ova (TSO) show strong immunomodulatory
      properties. Authors hypothesize that TSO could be useful in addressing ASD immune
      dysregulations. TSO could be a novel therapeutic option for ASD management.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Experimental Medicine, Second University of Naples, Italy; Centre
      for Autism, La Forza del Silenzio, Caserta, Italy; Cancellautismo - No Profit
      Association for Autism care, Florence, Italy. Electronic address:
      dariosin@uab.edu.
FAU - Siniscalco, Dario
AU  - Siniscalco D
FAU - Antonucci, Nicola
AU  - Antonucci N
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/02/08 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/03/17 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S0306-9877(13)00143-6 [pii]
AID - 10.1016/j.mehy.2013.03.024 [doi]
PST - ppublish
SO  - Med Hypotheses. 2013 Jul;81(1):1-4. doi: 10.1016/j.mehy.2013.03.024. Epub 2013
      Apr 15.

PMID- 23597839
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1879-0267 (Electronic)
IS  - 0020-1383 (Linking)
VI  - 44
IP  - 7
DP  - 2013 Jul
TI  - Open reduction and internal fixation of acute intra-articular displaced calcaneal
      fractures: A retrospective analysis of surgical timing and infection rates.
PG  - 1007-10
LID - 10.1016/j.injury.2013.03.014 [doi]
LID - S0020-1383(13)00135-6 [pii]
AB  - The choice of surgical timing in open reduction for calcaneal fractures has been 
      proposed to be associated with soft-tissue complications and infection. This
      study analysed the correlation between surgical timing and postoperative
      infection rates. We performed a retrospective single-surgeon single-facility
      study (Kaohsiung Medical University Hospital, KMUH) between January 2006 and
      January 2010. Fifty patients with 53 close intra-articular calcaneal fractures
      were included. They received open reduction and internal fixation via the
      extensile lateral L-shaped approach. We assessed the duration between heel trauma
      and operation from the medical records and sorted our patients into early (within
      3 days), intermediate (from 3 to 10 days) and delayed (over 10 days) surgical
      groups. The mean follow-up period was 13 months. Only one of the 50 patients, a
      74-year-old female with diabetes mellitus, developed deep infection requiring
      hardware removal and serial debridement. Overall, we did not find a statistical
      difference in postoperative infection rates in the different timing groups. Our
      conclusion is that in experienced hands, surgical timing may not affect
      postoperative infection rates in calcaneal fracture among strictly selected
      patients who do not have potential risk factors for wound complication.
      Therefore, early operation may be helpful to these patients.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Orthopaedics, Kaohsiung Medical University Hospital, Kaohsiung,
      Taiwan.
FAU - Ho, Cheng-Jung
AU  - Ho CJ
FAU - Huang, Hsuan-Ti
AU  - Huang HT
FAU - Chen, Chung-Hwan
AU  - Chen CH
FAU - Chen, Jian-Chih
AU  - Chen JC
FAU - Cheng, Yuh-Min
AU  - Cheng YM
FAU - Huang, Peng-Ju
AU  - Huang PJ
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - Netherlands
TA  - Injury
JT  - Injury
JID - 0226040
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/08/26 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S0020-1383(13)00135-6 [pii]
AID - 10.1016/j.injury.2013.03.014 [doi]
PST - ppublish
SO  - Injury. 2013 Jul;44(7):1007-10. doi: 10.1016/j.injury.2013.03.014. Epub 2013 Apr 
      15.

PMID- 23597801
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 126
IP  - 6
DP  - 2013 Jun
TI  - Smoking Behavior among US Adults with Diabetes or Impaired Fasting Glucose.
PG  - 541.e15-8
LID - 10.1016/j.amjmed.2012.11.029 [doi]
LID - S0002-9343(13)00102-2 [pii]
AB  - BACKGROUND: Cigarette smoking is a well-known cardiovascular risk factor and its 
      impact on cardiovascular disease is even greater among people with diabetes. The 
      aim of this study is to compare the prevalence and determinants of smoking among 
      US adults with diabetes or impaired fasting glucose, and those without diabetes
      or impaired fasting glucose. METHODS: We analyzed data from the National Health
      and Nutrition Examination Surveys (1999-2008). Age-adjusted prevalence of smoking
      was calculated, and we used logistic regression models to identify the correlates
      of smoking among people with diabetes, impaired fasting glucose, and normal
      glucose metabolism. RESULTS: Among 24,649 participants >/=20 years old,
      age-adjusted smoking prevalence was 25.7% in 3111 individuals with diabetes,
      24.2% in 3557 individuals with impaired fasting glucose, and 24.1% in 17,981
      individuals without diabetes. Smoking prevalence did not differ across groups or 
      change over time (1999-2008) in any group. Younger age, less education, more
      alcohol consumption, less physical activity, and major depression symptoms were
      associated with smoking in people with diabetes, impaired fasting glucose, and
      normal glucose metabolism. CONCLUSIONS: In the US, smoking prevalence among
      people with diabetes and impaired fasting glucose has not changed and is
      comparable with the nondiabetic population. Tobacco control efforts should be
      intensified among this population at high risk for complications and mortality.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Tobacco Research and Treatment Center, Massachusetts General Hospital, Harvard
      Medical School, Boston. Electronic address: carole.willi@gmail.com.
FAU - Clair, Carole
AU  - Clair C
FAU - Meigs, James B
AU  - Meigs JB
FAU - Rigotti, Nancy A
AU  - Rigotti NA
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
SB  - AIM
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/02/07 [received]
PHST- 2012/07/20 [revised]
PHST- 2012/11/15 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S0002-9343(13)00102-2 [pii]
AID - 10.1016/j.amjmed.2012.11.029 [doi]
PST - ppublish
SO  - Am J Med. 2013 Jun;126(6):541.e15-8. doi: 10.1016/j.amjmed.2012.11.029. Epub 2013
      Apr 15.

PMID- 23597799
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1555-7162 (Electronic)
IS  - 0002-9343 (Linking)
VI  - 126
IP  - 6
DP  - 2013 Jun
TI  - Prevalence, extent, and independent predictors of silent myocardial infarction.
PG  - 515-22
LID - 10.1016/j.amjmed.2012.11.028 [doi]
LID - S0002-9343(13)00101-0 [pii]
AB  - BACKGROUND: The phenomenon of silent myocardial infarction is poorly understood. 
      METHODS: We aimed to evaluate the prevalence, extent, and independent predictors 
      of silent myocardial infarction in 2 large independent cohorts of consecutive
      patients without a history of myocardial infarction referred for rest/stress
      myocardial perfusion single photon emission computed tomography. There were 1621 
      patients enrolled in the derivation cohort and 338 patients in the validation
      cohort. Silent myocardial infarction was diagnosed in patients with a myocardial 
      scar >/=5% of the left ventricle. RESULTS: In the derivation cohort, the
      prevalence of silent myocardial infarction was 23.3% (n = 377). The median
      infarct size was 10% (interquartile range [IQR] 5%-15%) of the left ventricle.
      The prevalence of silent myocardial infarction was 28.5% in diabetics and 21.5%
      in nondiabetics (P = .004). Diabetes mellitus was an independent predictor for
      the presence of silent myocardial infarction (odds ratio 1.5; 95% confidence
      interval, 1.1-1.9; P = .004). These findings were confirmed in the independent
      validation cohort. In the validation cohort, the prevalence of silent myocardial 
      infarction was 26.3% (n = 89), while the prevalence was higher in diabetics
      (35.8%) than in nondiabetics (24%; P = .049). The median infarct size was 11.8%
      (IQR 5.9%-17.6%) of the left ventricle. Again, in logistic regression analysis,
      diabetes mellitus was a significant predictor of the presence of silent
      myocardial infarction. CONCLUSION: Silent myocardial infarctions are more common 
      than previously thought. One of 4 patients with suspected coronary artery disease
      had experienced a silent myocardial infarction; the extent in average is 10% of
      the left ventricle, and it is more common in diabetics.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Cardiology, University Hospital Basel, Switzerland.
FAU - Arenja, Nisha
AU  - Arenja N
FAU - Mueller, Christian
AU  - Mueller C
FAU - Ehl, Niklas F
AU  - Ehl NF
FAU - Brinkert, Miriam
AU  - Brinkert M
FAU - Roost, Katharina
AU  - Roost K
FAU - Reichlin, Tobias
AU  - Reichlin T
FAU - Sou, Seoung Mann
AU  - Sou SM
FAU - Hochgruber, Thomas
AU  - Hochgruber T
FAU - Osswald, Stefan
AU  - Osswald S
FAU - Zellweger, Michael J
AU  - Zellweger MJ
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
SB  - AIM
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/10/28 [received]
PHST- 2012/11/12 [revised]
PHST- 2012/11/16 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S0002-9343(13)00101-0 [pii]
AID - 10.1016/j.amjmed.2012.11.028 [doi]
PST - ppublish
SO  - Am J Med. 2013 Jun;126(6):515-22. doi: 10.1016/j.amjmed.2012.11.028. Epub 2013
      Apr 15.

PMID- 23597793
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 23
IP  - 11
DP  - 2013 Jun 1
TI  - Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric
      acid as a potent hypoglycemic agent.
PG  - 3244-7
LID - 10.1016/j.bmcl.2013.03.122 [doi]
LID - S0960-894X(13)00450-2 [pii]
AB  - A tetrazole isosteric analogue of clofibric acid (1) was prepared using a short
      synthetic route and was characterized by elemental analysis, NMR ((1)H, (13)C)
      spectroscopy, and single-crystal X-ray diffraction. The in vitro inhibitory
      activity of 1 against 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1)
      was evaluated, showing a moderate inhibitory enzyme activity (51.17% of
      inhibition at 10muM), being more active than clofibrate and clofibric acid. The
      antidiabetic activity of compound 1 was determined at 50mg/Kg single dose using a
      non insulin dependent diabetes mellitus rat model. The results indicated a
      significant decrease of plasma glucose levels, during the 7h post-administration.
      Additionally, we performed a molecular docking of 1 into the ligand binding
      pocket of one subunit of human 11beta-HSD1. In this model, compound 1 binds into 
      the catalytic site of 11beta-HSD1 in two different orientations. Both of them,
      show important short contacts with the catalytic residues Ser 170, Tyr 183, Asp
      259 and also with the nicotinamide ring of NADP(+).
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Facultad de Farmacia, Universidad Autonoma del Estado de Morelos, Cuernavaca,
      Morelos 62209, Mexico. Electronic address: gabriel_navarrete@uaem.mx.
FAU - Navarrete-Vazquez, Gabriel
AU  - Navarrete-Vazquez G
FAU - Alaniz-Palacios, Alfredo
AU  - Alaniz-Palacios A
FAU - Hidalgo-Figueroa, Sergio
AU  - Hidalgo-Figueroa S
FAU - Gonzalez-Acevedo, Cristina
AU  - Gonzalez-Acevedo C
FAU - Avila-Villarreal, Gabriela
AU  - Avila-Villarreal G
FAU - Estrada-Soto, Samuel
AU  - Estrada-Soto S
FAU - Webster, Scott P
AU  - Webster SP
FAU - Medina-Franco, Jose L
AU  - Medina-Franco JL
FAU - Lopez-Vallejo, Fabian
AU  - Lopez-Vallejo F
FAU - Guerrero-Alvarez, Jorge
AU  - Guerrero-Alvarez J
FAU - Tlahuext, Hugo
AU  - Tlahuext H
LA  - eng
PT  - Journal Article
DEP - 20130405
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/02/13 [received]
PHST- 2013/03/22 [revised]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/05 [aheadofprint]
AID - S0960-894X(13)00450-2 [pii]
AID - 10.1016/j.bmcl.2013.03.122 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2013 Jun 1;23(11):3244-7. doi: 10.1016/j.bmcl.2013.03.122. 
      Epub 2013 Apr 5.

PMID- 23597780
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1096-0279 (Electronic)
IS  - 1046-5928 (Linking)
VI  - 89
IP  - 2
DP  - 2013 Jun
TI  - Expression, purification and preliminary characterization of glucagon receptor
      extracellular domain.
PG  - 232-40
LID - 10.1016/j.pep.2013.04.004 [doi]
LID - S1046-5928(13)00071-5 [pii]
AB  - Glucagon is a pancreatic hormone that plays pivotal roles in regulating glucose
      homeostasis and metabolism. Glucagon exerts its action by binding to its
      receptor, glucagon receptor (GCGR), one of class B G-protein coupled receptors
      (GPCRs). Diabetes is a bihormonal disease in which excessive glucagon secretion
      is a major contributor in the pathogenesis of this disease; elucidation of how
      glucagon binds to GCGR will facilitate the rational design of the GCGR antagonist
      for treating diabetic hyperglycemia. Here we report the successful expression and
      purification of the GCGR extracellular domain (GCGR-ECD) and its fusion protein
      with the glucagon peptide at its C-terminus (GCGR-ECD-Gc). We utilized the
      maltose binding protein (MBP) fusion method and disulfide bond isomerase DsbC
      co-expression approach for the success of the soluble expression of both GCGR-ECD
      and GCGR-ECD-Gc in Escherichia coli. We also obtained a high yield production of 
      secreted GCGR-ECD with the baculovirus expression system by optimizing its
      N-terminal secreting signal. We first utilized isothermal titration calorimetry
      approach to determine the in vitro binding affinities of glucagon to the
      GCGR-ECD. No significant differences were found between the prokaryotic expressed
      GCGR-ECD (7.6muM) and the eukaryotic glycosylated one (6.6muM). The observation
      of the intra ligand-receptor binding within the fusion protein GCGR-ECD-Gc
      suggests it as a good candidate for further structural study.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University,
      Shanghai 200040, China.
FAU - Wu, Lili
AU  - Wu L
FAU - Zhai, Yujia
AU  - Zhai Y
FAU - Lu, Jiuwei
AU  - Lu J
FAU - Wang, Qinghua
AU  - Wang Q
FAU - Sun, Fei
AU  - Sun F
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Protein Expr Purif
JT  - Protein expression and purification
JID - 9101496
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/02/23 [received]
PHST- 2013/04/05 [revised]
PHST- 2013/04/06 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S1046-5928(13)00071-5 [pii]
AID - 10.1016/j.pep.2013.04.004 [doi]
PST - ppublish
SO  - Protein Expr Purif. 2013 Jun;89(2):232-40. doi: 10.1016/j.pep.2013.04.004. Epub
      2013 Apr 15.

PMID- 23597770
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Apr 15
TI  - Aldosterone and Myocardial Extracellular Matrix Expansion in Type 2 Diabetes
      Mellitus.
LID - S0002-9149(13)00715-7 [pii]
LID - 10.1016/j.amjcard.2013.02.060 [doi]
AB  - Myocardial extracellular matrix expansion and reduced coronary flow reserve (CFR)
      occur in patients with type 2 diabetes mellitus without heart failure or coronary
      artery disease. Because aldosterone is implicated in the pathophysiology of
      cardiac fibrosis and vascular injury, the aim of this study was to test the
      hypothesis that aldosterone is associated with extracellular matrix expansion and
      reduced CFR in type 2 diabetes mellitus. Patients with type 2 diabetes mellitus
      without evidence of coronary artery disease were recruited. Blood pressure, lipid
      management, and glycemic control were optimized over 3 months. Cardiac magnetic
      resonance imaging with T1 mapping was used to measure myocardial extracellular
      volume (ECV). Cardiac positron emission tomography was used to assess CFR. On a
      liberal, 250 mEq/day sodium diet, 24-hour urinary aldosterone and change in serum
      aldosterone with angiotensin II stimulation were measured. Fifty-three
      participants with type 2 diabetes (68% men, mean age 53 +/- 7 years, mean body
      mass index 32.2 +/- 4.3 kg/m2, mean glycosylated hemoglobin 6.8 +/- 0.7%, mean
      systolic blood pressure 126 +/- 14 mm Hg) without infarction or ischemia by
      cardiac magnetic resonance and positron emission tomography were studied.
      Subjects had impaired CFR (2.51 +/- 0.83) and elevated ECV (0.36 +/- 0.05),
      despite normal echocardiographic diastolic function and normal left ventricular
      function. Myocardial ECV, but not CFR, was positively associated with 24-hour
      urinary aldosterone excretion (r = 0.37, p = 0.01) and angiotensin II-stimulated 
      aldosterone increase (r = 0.35, p = 0.02). In a best-overall multivariate model
      (including age, gender, body mass index, glycosylated hemoglobin, and blood
      pressure), 24-hour urinary aldosterone was the strongest predictor of myocardial 
      ECV (p = 0.004). In conclusion, in patients with type 2 diabetes mellitus without
      coronary artery disease, aldosterone is associated with myocardial extracellular 
      matrix expansion. These results implicate aldosterone in early myocardial
      remodeling in type 2 diabetes mellitus.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Division of Endocrinology, Diabetes and Hypertension, Department of Medicine,
      Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
FAU - Rao, Ajay D
AU  - Rao AD
FAU - Shah, Ravi V
AU  - Shah RV
FAU - Garg, Rajesh
AU  - Garg R
FAU - Abbasi, Siddique A
AU  - Abbasi SA
FAU - Neilan, Tomas G
AU  - Neilan TG
FAU - Perlstein, Todd S
AU  - Perlstein TS
FAU - Di Carli, Marcelo F
AU  - Di Carli MF
FAU - Jerosch-Herold, Michael
AU  - Jerosch-Herold M
FAU - Kwong, Raymond Y
AU  - Kwong RY
FAU - Adler, Gail K
AU  - Adler GK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/12/09 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/02/28 [accepted]
AID - S0002-9149(13)00715-7 [pii]
AID - 10.1016/j.amjcard.2013.02.060 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Apr 15. pii: S0002-9149(13)00715-7. doi:
      10.1016/j.amjcard.2013.02.060.

PMID- 23597658
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1096-0260 (Electronic)
IS  - 0091-7435 (Linking)
VI  - 57
IP  - 1
DP  - 2013 Jul
TI  - Reducing sitting time in office workers: Short-term efficacy of a multicomponent 
      intervention.
PG  - 43-8
LID - 10.1016/j.ypmed.2013.04.004 [doi]
LID - S0091-7435(13)00113-8 [pii]
AB  - OBJECTIVE: To investigate the short-term efficacy of a multicomponent
      intervention to reduce office workers' sitting time. METHODS: Allocation for this
      non-randomized controlled trial (n=43 participants; 56% women; 26-62years;
      Melbourne, Australia) was by office floor, with data collected during
      July-September 2011. The 4-week intervention emphasized three key messages:
      "Stand Up, Sit Less, Move More" and comprised organizational, environmental, and 
      individual elements. Changes in minutes/day at the workplace spent sitting
      (primary outcome), in prolonged sitting (sitting time accumulated in bouts
      >/=30min), standing, and moving were objectively measured (activPAL3). RESULTS:
      Relative to the controls, the intervention group significantly reduced workplace 
      sitting time (mean change [95%CI]: -125 [-161, -89] min/8-h workday), with
      changes primarily driven by a reduction in prolonged sitting time (-73 [-108,
      -40] min/8-h workday). Workplace sitting was almost exclusively replaced by
      standing (+127 [+92, +162] min/8-h workday) with non-significant changes to
      stepping time (-2 [-7, +4] min/8-h workday) and number of steps (-70 [-350,
      210]). CONCLUSIONS: This multicomponent workplace intervention demonstrated that 
      substantial reductions in sitting time are achievable in an office setting.
      Larger studies with longer timeframes are needed to assess sustainability of
      these changes, as well as their potential longer-term impacts on health and
      work-related outcomes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - The University of Queensland, School of Population Health, Brisbane, Australia;
      Baker IDI Heart and Diabetes Institute, Melbourne, Australia. Electronic address:
      g.healy@uq.edu.au.
FAU - Healy, Genevieve N
AU  - Healy GN
FAU - Eakin, Elizabeth G
AU  - Eakin EG
FAU - Lamontagne, Anthony D
AU  - Lamontagne AD
FAU - Owen, Neville
AU  - Owen N
FAU - Winkler, Elisabeth A H
AU  - Winkler EA
FAU - Wiesner, Glen
AU  - Wiesner G
FAU - Gunning, Lynn
AU  - Gunning L
FAU - Neuhaus, Maike
AU  - Neuhaus M
FAU - Lawler, Sheleigh
AU  - Lawler S
FAU - Fjeldsoe, Brianna S
AU  - Fjeldsoe BS
FAU - Dunstan, David W
AU  - Dunstan DW
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Prev Med
JT  - Preventive medicine
JID - 0322116
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/12/18 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S0091-7435(13)00113-8 [pii]
AID - 10.1016/j.ypmed.2013.04.004 [doi]
PST - ppublish
SO  - Prev Med. 2013 Jul;57(1):43-8. doi: 10.1016/j.ypmed.2013.04.004. Epub 2013 Apr
      15.

PMID- 23597589
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 62
IP  - 3
DP  - 2013 Jun
TI  - Self-antigen expression in thymic epithelial cells in Ifn-gamma or Tnf-alpha
      deficiency.
PG  - 433-8
LID - 10.1016/j.cyto.2013.03.026 [doi]
LID - S1043-4666(13)00145-2 [pii]
AB  - Insulin expression in the thymic medullary epithelial cells (mTECs) is found to
      be a critical aspect of maintaining self-tolerance towards that antigen. A
      lowered insulin expression level in the thymus correlates with susceptibility to 
      Type 1 Diabetes in humans and lead to higher levels of autoreactive T cells in
      mice. It is therefore, essential to understand the regulatory mechanism of
      insulin in the mTECs. Previous in vitro studies have shown a negative effect on
      the expression of insulin in mTECs upon stimulation with the cytokines Ifn-gamma 
      and Tnf-alpha, separately. The objective of this study was to examine the
      physiological role of these cytokines in vivo. For this purpose, we examined
      whether these cytokines have a physiological role in regulating thymic insulin
      expression using the Ifn-gamma and Tnf-alpha knockout models. We found that
      insulin expression increased in the knockout mice compared to their wild-type
      counterparts. Aire transcriptional regulator, a known switch for self-antigen
      expression in the thymus, was also increased in the knockout animals. Four
      antigens targeted in other autoimmune disorders were also found to have a pattern
      of increase in the Ifn-gamma or Tnf-alpha knockout models, including one that is 
      known to be Aire-independent in its expression. An increase in mTEC population or
      thymocyte population was not seen in these knockout mice, revealing a regulatory 
      mechanism that involves cytokine action directly on the transcription of the
      antigens. These findings suggest regulation of tissue-specific antigen production
      in the thymus by these two cytokines that is parallel to that controlled by AIRE.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Endocrine Genetics, Research Institute of the McGill University Health Center,
      Montreal, Quebec, Canada.
FAU - Levi, Dina
AU  - Levi D
FAU - Polychronakos, Constantin
AU  - Polychronakos C
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Cytokine
JT  - Cytokine
JID - 9005353
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/01/11 [received]
PHST- 2013/03/23 [revised]
PHST- 2013/03/23 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - S1043-4666(13)00145-2 [pii]
AID - 10.1016/j.cyto.2013.03.026 [doi]
PST - ppublish
SO  - Cytokine. 2013 Jun;62(3):433-8. doi: 10.1016/j.cyto.2013.03.026. Epub 2013 Apr
      15.

PMID- 23597520
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1875-9572 (Electronic)
DP  - 2013 Mar 13
TI  - Limbic Encephalitis in Taiwanese Children and Adolescence: A Single Center Study.
LID - S1875-9572(13)00017-X [pii]
LID - 10.1016/j.pedneo.2013.01.016 [doi]
AB  - BACKGROUND: Non-viral limbic encephalitis, which may be paraneoplastic or
      idiopathic, is increasingly recognized in adults and children. Early
      identification of potential patients, who have neuronal autoantibodies to
      intracellular or neuronal surface antigens in order to give appropriate
      immunotherapy, is key to improving the prognosis. This cross-sectional study
      describes the clinical manifestation and the serological evidence of the presence
      of neuronal antibodies in Taiwanese children with limbic encephalitis. METHOD: We
      enrolled children and adolescents who had been hospitalized due to nonviral
      limbic encephalitis. Serum samples from these patients were collected to screen
      antibodies against intracellular antigens [amphiphysin, Ma2, Ri, Yo, Hu and
      antiglutamic acid decarboxylase (GAD)] and neuronal surface antigens
      [N-methyl-d-aspartate (NMDA) receptor, gamma-amino butyric acid (GABAB) receptor 
      and voltage-gated potassium channel complexes (VGKCs)]. RESULTS: All of the 10
      enrolled patients had acute onset of fever and rapid clinical deterioration. They
      had persistent neuropsychiatric symptoms and 90% developed refractory epilepsy,
      despite six patients having been treated with methylprednisolone pulse therapy or
      intravenous immunoglobulin (IVIG) at the acute stage. In the laboratory findings,
      half of the cases were positive for antibodies with regards to intracellular
      antigens (amphiphysin or GAD). The general outcomes, assessed by Glasgow Outcome 
      Scale, were similar between patients with and those without the antibodies
      (Mann-Whitney U test, p = 0.43). One patient, who was positive for antibodies to 
      amphiphysin 10 years after disease onset, still had a significant response to
      oral prednisolone therapy. At the end of the follow-up period, no cancer or
      insulin-dependent diabetes mellitus was detected in any of the patients.
      CONCLUSION: This study provides evidence for a potential association between
      antibodies and limbic encephalitis. The presence of antibodies, especially
      antibodies to GAD, may serve as an indicator for immunotherapy.
CI  - Copyright (c) 2013. Published by Elsevier B.V.
AD  - Division of Pediatric Neurology, Chang Gung Memorial Hospital, Chang Gung
      University, College of Medicine, Taoyuan, Taiwan; Division of Pediatric General
      Medicine, Chang Gung Memorial Hospital, Chang Gung University, College of
      Medicine, Taoyuan, Taiwan; Chang Gung Children's Hospital Study Group for
      Children with Encephalitis/Encephalopathy Related Status Epilepticus and Epilepsy
      (CHEESE), Taiwan.
FAU - Chou, I-Jun
AU  - Chou IJ
FAU - Wang, Huei-Shyong
AU  - Wang HS
FAU - Lin, Jainn-Jim
AU  - Lin JJ
FAU - Kuo, Chang-Fu
AU  - Kuo CF
FAU - Lin, Kuang-Lin
AU  - Lin KL
FAU - Chou, Min-Liang
AU  - Chou ML
FAU - Hung, Po-Cheng
AU  - Hung PC
FAU - Hsieh, Meng-Ying
AU  - Hsieh MY
FAU - Lin, Yun-Tong
AU  - Lin YT
CN  - the CHEESE Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130313
TA  - Pediatr Neonatol
JT  - Pediatrics and neonatology
JID - 101484755
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/07/24 [received]
PHST- 2012/11/26 [revised]
PHST- 2013/01/23 [accepted]
AID - S1875-9572(13)00017-X [pii]
AID - 10.1016/j.pedneo.2013.01.016 [doi]
PST - aheadofprint
SO  - Pediatr Neonatol. 2013 Mar 13. pii: S1875-9572(13)00017-X. doi:
      10.1016/j.pedneo.2013.01.016.

PMID- 23597503
OWN - NLM
STAT- Publisher
DA  - 20130506
IS  - 1873-4596 (Electronic)
IS  - 0891-5849 (Linking)
DP  - 2013 Apr 16
TI  - Epidemiology of selenium and type2 diabetes: Can we make sense of it?
LID - S0891-5849(13)00143-3 [pii]
LID - 10.1016/j.freeradbiomed.2013.04.003 [doi]
AB  - The potential of some selenoproteins to protect against oxidative stress led to
      the expectation that selenium would be protective against type2 diabetes, and
      indeed in early in vivo and in vitro studies, selenium (as selenate) was shown to
      have antidiabetic and insulin-mimetic effects. However, more recently, findings
      from observational cross-sectional studies have raised concern that high selenium
      exposure may be associated with type2 diabetes or insulin resistance, at least in
      well-nourished populations, though trial results have been inconsistent.
      Moreover, the largest trials that investigated the effects of selenium
      supplementation on diabetes endpoints have had cancer prevention as their primary
      outcome, casting doubt on the interpretation of posthoc analyses. Factors
      affecting serum/plasma selenium are not just location and level of
      disease-associated inflammation but the fact that higher concentrations of plasma
      selenoprotein P yet lower glutathione peroxidase are found in type2 diabetes
      compared to normal subjects. From a public health perspective, selenium is
      marketed as a dietary supplement and is commonly added to multivitamin/mineral
      preparations that are consumed in many Western countries. Based on current
      evidence, however, the indiscriminate use of selenium supplements in individuals 
      and populations with adequate-to-high selenium status cannot be justified and may
      increase risk. In conclusion, although there is a clear link between certain
      selenoproteins and glucose metabolism or insulin resistance, the relationship
      between selenium and type2 diabetes is undoubtedly complex. It is possible that
      the relationship is U-shaped, with possible harm occurring both below and above
      the physiological range for optimal activity of some or all selenoproteins.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7XH, 
      UK. Electronic address: m.rayman@surrey.ac.uk.
FAU - Rayman, Margaret P
AU  - Rayman MP
FAU - Stranges, Saverio
AU  - Stranges S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/01/23 [received]
PHST- 2013/04/01 [revised]
PHST- 2013/04/02 [accepted]
AID - S0891-5849(13)00143-3 [pii]
AID - 10.1016/j.freeradbiomed.2013.04.003 [doi]
PST - aheadofprint
SO  - Free Radic Biol Med. 2013 Apr 16. pii: S0891-5849(13)00143-3. doi:
      10.1016/j.freeradbiomed.2013.04.003.

PMID- 23597493
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1558-1497 (Electronic)
IS  - 0197-4580 (Linking)
VI  - 34
IP  - 9
DP  - 2013 Sep
TI  - IDE (rs6583817) polymorphism and type 2 diabetes differentially modify executive 
      function in older adults.
PG  - 2208-16
LID - 10.1016/j.neurobiolaging.2013.03.010 [doi]
LID - S0197-4580(13)00110-3 [pii]
AB  - We tested independent and interactive contributions of a recently noted and
      promising insulin degrading enzyme polymorphism (IDE; rs6583817) and type 2
      diabetes (T2D) to executive function performance, concurrently and
      longitudinally. Regarding normal neurocognitive decline and Alzheimer's disease, 
      T2D is a known risk factor and this IDE variant might contribute risk or risk
      reduction via the minor (A) or major (G) allele. We compared normal aging and T2D
      groups (baseline n = 574; ages 53-95 years) over 2 longitudinal waves (mean
      interval = 4.4 years). We used confirmatory factor analysis, latent growth curve 
      modeling, and path analysis. A confirmed single-factor model of 4 executive
      function tasks established the cognitive phenotype. This IDE variant predicted
      concurrent group differences and differential change in cognitive performance.
      Furthermore, the IDE major allele reduced risk of cognitive decline. T2D
      predicted performance only concurrently. Both IDE and T2D are associated with
      executive function levels in older adults, but only IDE moderated 2-wave change. 
      Previously linked to Alzheimer's disease, this IDE variant should be further
      explored for its potential influence on cognitive phenotypes of normal aging.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Psychology, University of Alberta, Edmonton, Alberta, Canada.
FAU - McFall, G Peggy
AU  - McFall GP
FAU - Wiebe, Sandra A
AU  - Wiebe SA
FAU - Vergote, David
AU  - Vergote D
FAU - Westaway, David
AU  - Westaway D
FAU - Jhamandas, Jack
AU  - Jhamandas J
FAU - Dixon, Roger A
AU  - Dixon RA
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - Neurobiol Aging
JT  - Neurobiology of aging
JID - 8100437
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/08/30 [received]
PHST- 2013/02/27 [revised]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - S0197-4580(13)00110-3 [pii]
AID - 10.1016/j.neurobiolaging.2013.03.010 [doi]
PST - ppublish
SO  - Neurobiol Aging. 2013 Sep;34(9):2208-16. doi:
      10.1016/j.neurobiolaging.2013.03.010. Epub 2013 Apr 16.

PMID- 23597490
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
DP  - 2013 Apr 15
TI  - Anti-diabetic activity of embelin: Involvement of cellular inflammatory
      mediators, oxidative stress and other biomarkers.
LID - S0944-7113(13)00089-5 [pii]
LID - 10.1016/j.phymed.2013.03.003 [doi]
AB  - Embelin (benzoquinone), an active constituent of methanolic extracts of the fruit
      of Embelia basal (Myrsinaceae), was studied in high fat diet (HFD)+streptozotocin
      (STZ) diabetic rats. Treatment of embelin (25 and 50mg/kg/day, p.o.) for 3 weeks 
      to HFD+STZ diabetic rats elicited insignificant increase in body weight, reduced 
      the elevated plasma glucose, glycosylated haemoglobin and pro-inflammatory
      mediators (interleukin 6 and tumour necrosis factor alpha) significantly.
      Furthermore, embelin treatment at both the doses significantly decreased the
      elevated malondialdehyde, restored depleted glutathione, antioxidant enzymes,
      superoxide dismutase and catalase in liver. The increased lipid profiles in
      HFD+STZ diabetic rats were also reduced by embelin treatment significantly.
      Embelin treatment to HFD+STZ diabetic rats also improved the altered
      histoarchitecture of beta-islets of pancreas and hepatocytes. The embelin effect 
      on progression of type 2 diabetes mellitus in rats appears to be through the
      inhibition of intracellular pro-inflammatory mediators, lowering of lipid profile
      and amelioration of oxidative stress. Considering the pharmacological activity
      profile of embelin, it is suggested that embelin be a useful diabetic modulator
      or adjuvant along with clinically effective anti-diabetic drugs in the treatment 
      of type 2 diabetes mellitus and needs to be clinically evaluated on human
      subjects.
CI  - Copyright (c) 2013. Published by Elsevier GmbH.
AD  - Sinhgad Institute of Pharmaceutical Sciences, Kusgaon (Bk), Lonavala, Pune 410
      401, India. Electronic address: srnaik5@rediffmail.com.
FAU - Naik, Suresh R
AU  - Naik SR
FAU - Niture, Netaji T
AU  - Niture NT
FAU - Ansari, Ansar A
AU  - Ansari AA
FAU - Shah, Priyank D
AU  - Shah PD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/10/11 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/03/09 [accepted]
AID - S0944-7113(13)00089-5 [pii]
AID - 10.1016/j.phymed.2013.03.003 [doi]
PST - aheadofprint
SO  - Phytomedicine. 2013 Apr 15. pii: S0944-7113(13)00089-5. doi:
      10.1016/j.phymed.2013.03.003.

PMID- 23597482
OWN - NLM
STAT- MEDLINE
DA  - 20130419
DCOM- 20130610
IS  - 1878-1551 (Electronic)
IS  - 1534-5807 (Linking)
VI  - 25
IP  - 1
DP  - 2013 Apr 15
TI  - Gene regulatory networks governing pancreas development.
PG  - 5-13
LID - 10.1016/j.devcel.2013.03.016 [doi]
LID - S1534-5807(13)00187-1 [pii]
AB  - Elucidation of cellular and gene regulatory networks (GRNs) governing organ
      development will accelerate progress toward tissue replacement. Here, we have
      compiled reference GRNs underlying pancreas development from data mining that
      integrates multiple approaches, including mutant analysis, lineage tracing, cell 
      purification, gene expression and enhancer analysis, and biochemical studies of
      gene regulation. Using established computational tools, we integrated and
      represented these networks in frameworks that should enhance understanding of the
      surging output of genomic-scale genetic and epigenetic studies of pancreas
      development and diseases such as diabetes and pancreatic cancer. We envision
      similar approaches would be useful for understanding the development of other
      organs.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Developmental Biology, Stanford University School of Medicine,
      Stanford, CA 94305-5329, USA.
FAU - Arda, H Efsun
AU  - Arda HE
FAU - Benitez, Cecil M
AU  - Benitez CM
FAU - Kim, Seung K
AU  - Kim SK
LA  - eng
GR  - 5 T32 GM007790/GM/NIGMS NIH HHS/United States
GR  - U01 DK089532/DK/NIDDK NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Dev Cell
JT  - Developmental cell
JID - 101120028
RN  - 0 (Basic Helix-Loop-Helix Transcription Factors)
RN  - 0 (NEUROG3 protein, human)
RN  - 0 (Nerve Tissue Proteins)
SB  - IM
MH  - Acinar Cells/cytology/metabolism
MH  - Animals
MH  - Basic Helix-Loop-Helix Transcription Factors/genetics/metabolism
MH  - Cell Dedifferentiation
MH  - Cell Differentiation
MH  - Computational Biology/methods
MH  - Data Mining
MH  - Diabetes Mellitus/genetics
MH  - *Gene Regulatory Networks
MH  - Humans
MH  - Insulin-Secreting Cells/cytology/metabolism
MH  - Nerve Tissue Proteins/genetics/metabolism
MH  - Nucleotide Motifs
MH  - Pancreas/*cytology/*growth & development
MH  - Stem Cells/cytology/metabolism
PMC - PMC3645877
MID - NIHMS462459
OID - NLM: NIHMS462459 [Available on 04/15/14]
OID - NLM: PMC3645877 [Available on 04/15/14]
EDAT- 2013/04/20 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/04/20 06:00
PMCR- 2014/04/15 00:00
PHST- 2013/03/26 [received]
AID - S1534-5807(13)00187-1 [pii]
AID - 10.1016/j.devcel.2013.03.016 [doi]
PST - ppublish
SO  - Dev Cell. 2013 Apr 15;25(1):5-13. doi: 10.1016/j.devcel.2013.03.016.

PMID- 23597421
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1557-8550 (Electronic)
IS  - 1549-5418 (Linking)
VI  - 31
IP  - 5
DP  - 2013 May
TI  - Absorption Spectroscopy for the Estimation of Glycated Hemoglobin (HbA1c) for the
      Diagnosis and Management of Diabetes Mellitus: A Pilot Study.
PG  - 219-24
LID - 10.1089/pho.2012.3421 [doi]
AB  - Abstract Objective: The purpose of this study was to explore the possibility of
      using absorption spectroscopy technique for the estimation of glycated hemoglobin
      HbA1c (%). Background data: Glycated hemoglobin (HbA1c) is an important marker in
      the diagnosis and management of diabetes mellitus. Different assay techniques
      have been employed for the estimation of glycated hemoglobin, including ion
      exchange high performance liquid chromatography (HPLC), electrophoresis, affinity
      chromatography, immunoturbidimetric assay and colorimetric assays, which measure 
      different glycated products and report using different units. Spectroscopic
      measurements have been shown to be very sensitive and nondestructive, and require
      very little quantity of material for analysis. In the present study, we have
      employed absorption spectroscopy technique for the estimation of glycated
      hemoglobin in hemolysate samples of diabetic patients. Materials and methods: The
      blood samples of individuals with normal glycemic status and confirmed diabetic
      patients were collected from the Clinical Biochemistry Laboratory, Kasturba
      Hospital, Manipal. The absorption spectra of glycated hemoglobin (HbA1c) samples 
      were recorded in the spectral range 200-850 nm using an optic fiber based Ocean
      Optics CHEMUSB4-UV-VIS single beam spectrophotometer. The parameter "area under
      the curve" of each baseline corrected absorption spectrum was used for the
      estimation of HbA1c (%). The glycated hemoglobin values obtained by this
      spectroscopic method were compared with the values reported by the standard ion
      exchange HPLC method. Results: A total of 30 absorption spectra were recorded
      from hemolysate samples with HbA1c (%) in the range 4-10.5%. A good correlation
      was observed between the glycated hemoglobin values obtained by the spectroscopic
      method and those obtained by the standard HPLC method. Conclusions: It appears
      that the direct absorption spectroscopy of hemolysate samples, therefore, may be 
      utilized as a supplementary technique for the estimation of HbA1c (%), even at
      the primary healthcare centers.
AD  - 1 Department of Biochemistry, KMC International Center, Manipal University ,
      Manipal, Karnataka, India .
FAU - Mallya, Madhukar
AU  - Mallya M
FAU - Shenoy, Revathi
AU  - Shenoy R
FAU - Kodyalamoole, Gopalkrishna
AU  - Kodyalamoole G
FAU - Biswas, Monalisa
AU  - Biswas M
FAU - Karumathil, Jisha
AU  - Karumathil J
FAU - Kamath, Sudha
AU  - Kamath S
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - Photomed Laser Surg
JT  - Photomedicine and laser surgery
JID - 101222340
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/04/18 [aheadofprint]
AID - 10.1089/pho.2012.3421 [doi]
PST - ppublish
SO  - Photomed Laser Surg. 2013 May;31(5):219-24. doi: 10.1089/pho.2012.3421. Epub 2013
      Apr 18.

PMID- 23597390
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
DP  - 2013 Apr 17
TI  - An Overview Of Valuable Scientific Models For Diabetes Mellitus.
AB  - Diabetes mellitus is one of the major clinical problems worldwide. Previously,
      most of the investigational studies for identification of disease and new
      therapies were based on animal studies; however, present research methods involve
      high throughput screening, molecular targeting, nanotechnology for recent
      discovery of drugs and disease identification to combat against hazardous
      diseases like diabetes mellitus. In this review, we have depicted an outlines
      enfolding various disease-specific animal modeling, sensing technologies,
      biomarker analysis, and novel scientific techniques that could be helpful in
      exploring the impending strategies for diabetes detection and treatment. To
      conclude, we believe that endorsement and upgrading of such novel high throughput
      screening assays and nanotechnology described herein may surely represent a
      significant improvement in the capability for screening and identifying the
      population at elevated risk of expected diabetes. Thereby in future, appreciation
      of such investigational techniques and technologies including metabolomics and
      genetic screening may help in early prediction of diabetes in patients at risk
      and may display a significant improvement over the researchers conducted after
      the declaration of the disease.
AD  - Institute of Pharmacology, Toxicology and Biochemical Pharmaceutics, College of
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
      sajidakash@gmail.com.
FAU - Akash, Muhammad Sajid Hamid
AU  - Akash MS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/10/02 [received]
PHST- 2013/04/11 [revised]
PHST- 2013/04/11 [accepted]
AID - CDR-EPUB-20130417-1 [pii]
PST - aheadofprint
SO  - Curr Diabetes Rev. 2013 Apr 17.

PMID- 23597388
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1475-2662 (Electronic)
IS  - 0007-1145 (Linking)
DP  - 2013 Apr 18
TI  - Current issues surrounding the definition of trans-fatty acids: implications for 
      health, industry and food labels.
PG  - 1-15
AB  - The definition of trans-fatty acids (TFA) was established by the Codex
      Alimentarius to guide nutritional and legislative regulations to reduce TFA
      consumption. Currently, conjugated linoleic acid (CLA) is excluded from the TFA
      definition based on evidence (primarily preclinical studies) implying health
      benefits on weight management and cancer prevention. While the efficacy of CLA
      supplements remains inconsistent in randomised clinical trials, evidence has
      emerged to associate supplemental CLA with negative health outcomes, including
      increased subclinical inflammation and oxidative stress (particularly at high
      doses). This has resulted in concerns regarding the correctness of excluding CLA 
      from the TFA definition. Here we review recent clinical and preclinical
      literature on health implications of CLA and ruminant TFA, and highlight several 
      issues surrounding the current Codex definition of TFA and how it may influence
      interpretation for public health. We find that CLA derived from ruminant foods
      differ from commercial CLA supplements in their isomer composition/distribution, 
      consumption level and bioactivity. We conclude that health concerns associated
      with the use of supplemental CLA do not repudiate the exclusion of all forms of
      CLA from the Codex TFA definition, particularly when using the definition for
      food-related purposes. Given the emerging differential bioactivity of TFA from
      industrial v. ruminant sources, we advocate that regional nutrition
      guidelines/policies should focus on eliminating industrial forms of trans-fat
      from processed foods as opposed to all TFA per se.
AD  - Metabolic and Cardiovascular Diseases Laboratory, Molecular Cell Biology of
      Lipids Group, Alberta Diabetes and Mazankowski Alberta Heart Institutes, 4-002J
      Li Ka Shing Centre for Health Research Innovation, University of Alberta,
      Edmonton, AB, Canada T6G 2E1.
FAU - Wang, Ye
AU  - Wang Y
FAU - Proctor, Spencer D
AU  - Proctor SD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Br J Nutr
JT  - The British journal of nutrition
JID - 0372547
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - S0007114513001086 [pii]
AID - 10.1017/S0007114513001086 [doi]
PST - aheadofprint
SO  - Br J Nutr. 2013 Apr 18:1-15.

PMID- 23597378
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1541-0048 (Electronic)
IS  - 0090-0036 (Linking)
VI  - 103
IP  - 6
DP  - 2013 Jun
TI  - Integrating oral and general health screening at senior centers for minority
      elders.
PG  - 1022-5
LID - 10.2105/AJPH.2013.301259 [doi]
AB  - Racial/ethnic and socioeconomic disparities regarding untreated oral disease
      exist for older adults, and poor oral health diminishes quality of life. The
      ElderSmile program integrated screening for diabetes and hypertension into its
      community-based oral health activities at senior centers in northern Manhattan.
      The program found a willingness among minority seniors (aged >/= 50 years) to be 
      screened for primary care sensitive conditions by dental professionals and a high
      level of unrecognized disease (7.8% and 24.6% of ElderSmile participants had
      positive screening results for previously undiagnosed diabetes and hypertension, 
      respectively). Dental professionals may screen for primary care-sensitive
      conditions and refer patients to health care providers for definitive diagnosis
      and treatment. The ElderSmile program is a replicable model for community-based
      oral and general health screening.
AD  - At the time of the writing, Stephen E. Marshall, Carol Kunzel, and Ira B. Lamster
      were with the Columbia University College of Dental Medicine, New York, NY. Bin
      Cheng, Mary E. Northridge, Catherine Huang, Carol Kunzel, and Ira B. Lamster were
      either full-time or part-time with the Columbia University Mailman School of
      Public Health, New York, NY. Mary E. Northridge was full-time with the New York
      University College of Dentistry, New York.
FAU - Marshall, Stephen E
AU  - Marshall SE
FAU - Cheng, Bin
AU  - Cheng B
FAU - Northridge, Mary E
AU  - Northridge ME
FAU - Kunzel, Carol
AU  - Kunzel C
FAU - Huang, Catherine
AU  - Huang C
FAU - Lamster, Ira B
AU  - Lamster IB
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - United States
TA  - Am J Public Health
JT  - American journal of public health
JID - 1254074
SB  - AIM
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/04/18 [aheadofprint]
AID - 10.2105/AJPH.2013.301259 [doi]
PST - ppublish
SO  - Am J Public Health. 2013 Jun;103(6):1022-5. doi: 10.2105/AJPH.2013.301259. Epub
      2013 Apr 18.

PMID- 23597331
OWN - NLM
STAT- In-Process
DA  - 20130419
IS  - 1879-1360 (Electronic)
IS  - 0022-3999 (Linking)
VI  - 74
IP  - 5
DP  - 2013 May
TI  - Purpose in life and reduced incidence of stroke in older adults: 'The Health and 
      Retirement Study'.
PG  - 427-32
LID - 10.1016/j.jpsychores.2013.01.013 [doi]
LID - S0022-3999(13)00039-1 [pii]
AB  - OBJECTIVE: To determine whether purpose in life is associated with reduced stroke
      incidence among older adults after adjusting for relevant sociodemographic,
      behavioral, biological, and psychosocial factors. METHODS: We used prospective
      data from the Health and Retirement Study, a nationally representative panel
      study of American adults over the age of 50. 6739 adults who were stroke-free at 
      baseline were examined. A multiple imputation technique was used to account for
      missing data. Purpose in life was measured using a validated adaptation of Ryff
      and Keyes' Scales of Psychological Well-Being. After controlling for a
      comprehensive list of covariates, we assessed the odds of stroke incidence over a
      four-year period. We used psychological and covariate data collected in 2006,
      along with occurrences of stroke reported in 2008, 2010, and during exit
      interviews. Covariates included sociodemographic factors (age, gender,
      race/ethnicity, marital status, education level, total wealth, functional
      status), health behaviors (smoking, exercise, alcohol use), biological factors
      (hypertension, diabetes, systolic blood pressure, diastolic blood pressure, BMI, 
      heart disease), negative psychological factors (depression, anxiety, cynical
      hostility, negative affect), and positive psychological factors (optimism,
      positive affect, and social participation). RESULTS: Greater baseline purpose in 
      life was associated with a reduced likelihood of stroke during the four-year
      follow-up. In a model that adjusted for age, gender, race/ethnicity, marital
      status, education level, total wealth, and functional status, each standard
      deviation increase in purpose was associated with a multivariate-adjusted odds
      ratio of 0.78 for stroke (95% CI, 0.67-0.91, p=.002). Purpose remained
      significantly associated with a reduced likelihood of stroke after adjusting for 
      several additional covariates including: health behaviors, biological factors,
      and psychological factors. CONCLUSION: Among older American adults, greater
      purpose in life is linked with a lower risk of stroke.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Psychology, University of Michigan, Ann Arbor 48109-1043, USA.
      kimeric@umich.edu
FAU - Kim, Eric S
AU  - Kim ES
FAU - Sun, Jennifer K
AU  - Sun JK
FAU - Park, Nansook
AU  - Park N
FAU - Peterson, Christopher
AU  - Peterson C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130228
PL  - England
TA  - J Psychosom Res
JT  - Journal of psychosomatic research
JID - 0376333
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/07/13 [received]
PHST- 2013/01/19 [revised]
PHST- 2013/01/22 [accepted]
PHST- 2013/02/28 [aheadofprint]
AID - S0022-3999(13)00039-1 [pii]
AID - 10.1016/j.jpsychores.2013.01.013 [doi]
PST - ppublish
SO  - J Psychosom Res. 2013 May;74(5):427-32. doi: 10.1016/j.jpsychores.2013.01.013.
      Epub 2013 Feb 28.

PMID- 23597300
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1875-6557 (Electronic)
IS  - 1573-403X (Linking)
VI  - 9
IP  - 2
DP  - 2013 May 1
TI  - Heart failure in the middle East.
PG  - 174-8
AB  - The clinical syndrome of heart failure is the final pathway for a myriad of
      diseases that affect the heart, and is a leading and growing cause of morbidity
      and mortality worldwide. Evidence-based guidelines have provided clinicians with 
      valuable data for better applying diagnostic and therapeutic tools, particularly 
      the overwhelming new imaging technology and other, often expensive, therapies and
      devices, in heart failure patients. In the Middle East, progress has recently
      been made with the development of regional and multi-centre registries to
      evaluate the quality of care for patients with heart failure. A new heart
      function clinic recently began operation and has clearly resulted in a reduced
      readmission rate for heart failure patients. Many Middle Eastern countries have
      observed increases in the prevalence of the risk factors for the development of
      heart failure, including diabetes mellitus, obesity, and hypertension, with heart
      failure in the Middle Eastern population developing earlier than it is in their
      Western counterparts by at least 10 years. The earlier onset of disease is the
      result of the earlier onset of coronary artery disease, highlighting the need for
      Middle Eastern countries to establish prevention programs across all age groups. 
      The health systems across the Middle East need to be modified in order to provide
      improved evidence-based medical care. Existing registries also need to be
      expanded to include long-term survey data, and additional funding for heart
      failure research is warranted.
AD  - Department of Cardiac Science, King Fahad Cardiac Center, King Khalid University 
      Hospital, King Saud University PO Box 7805(38), Riyadh 11472, Kingdom of Saudi
      Arabia. mshamiri@hotmail.com.
FAU - Al-Shamiri, Mostafa Q
AU  - Al-Shamiri MQ
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Cardiol Rev
JT  - Current cardiology reviews
JID - 101261935
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/08/29 [received]
PHST- 2012/12/13 [revised]
PHST- 2013/01/02 [accepted]
AID - CCR-EPUB-20130415-6 [pii]
PST - ppublish
SO  - Curr Cardiol Rev. 2013 May 1;9(2):174-8.

PMID- 23597297
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1875-6557 (Electronic)
IS  - 1573-403X (Linking)
VI  - 9
IP  - 2
DP  - 2013 May 1
TI  - Heart failure in South Asia.
PG  - 102-11
AB  - South Asia (SA) is both the most populous and the most densely populated
      geographical region in the world. The countries in this region are undergoing
      epidemiological transition and are facing the double burden of infectious and
      non-communicable diseases. Heart failure (HF) is a major and increasing burden
      all over the world. In this review, we discuss the epidemiology of HF in SA today
      and its impact in the health system of the countries in the region. There are no 
      reliable estimates of incidence and prevalence of HF (heart failure) from this
      region. The prevalence of HF which is predominantly a disease of the elderly is
      likely to rise in this region due to the growing age of the population. Patients 
      admitted with HF in the SA region are relatively younger than their western
      counterparts. The etiology of HF in this region is also different from the
      western world. Untreated congenital heart disease and rheumatic heart disease
      still contribute significantly to the burden of HF in this region. Due to
      epidemiological transition, the prevalence of hypertension, diabetes mellitus,
      obesity and smoking is on the rise in this region. This is likely to escalate the
      prevalence of HF in South Asia. We also discuss potential developments in the
      field of HF management likely to occur in the nations in South Asia. Finally, we 
      discuss the interventions for prevention of HF in this region.
AD  - Department of Cardiology, SreeChitraTirunal Institute for Medical Sciences and
      Technology, Trivandrum, India - 695011. drhari@sctimst.ac.in.
FAU - Pillai, Harikrishnan Sivadasan
AU  - Pillai HS
FAU - Ganapathi, Sanjay
AU  - Ganapathi S
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Cardiol Rev
JT  - Current cardiology reviews
JID - 101261935
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/08/12 [received]
PHST- 2012/11/03 [revised]
PHST- 2012/12/17 [accepted]
AID - CCR-EPUB-20130415-3 [pii]
PST - ppublish
SO  - Curr Cardiol Rev. 2013 May 1;9(2):102-11.

PMID- 23597296
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1875-6557 (Electronic)
IS  - 1573-403X (Linking)
VI  - 9
IP  - 2
DP  - 2013 May 1
TI  - Heart failure in north america.
PG  - 128-46
AB  - Heart failure is a major health problem that affects patients and healthcare
      systems worldwide. Within the continent of North America, differences in economic
      development, genetic susceptibility, cultural practices, and trends in risk
      factors and treatment all contribute to both inter-continental and
      within-continent differences in heart failure. The United States and Canada
      represent industrialized countries with similar culture, geography, and advanced 
      economies and infrastructure. During the epidemiologic transition from rural to
      industrial in countries such as the United States and Canada, nutritional
      deficiencies and infectious diseases made way for degenerative diseases such as
      cardiovascular diseases, cancer, overweight/obesity, and diabetes. This in turn
      has resulted in an increase in heart failure incidence in these countries,
      especially as overall life expectancy increases. Mexico, on the other hand, has a
      less developed economy and infrastructure, and has a wide distribution in the
      level of urbanization as it becomes more industrialized. Mexico is under a period
      of epidemiologic transition and the etiology and incidence of heart failure is
      rapidly changing. Ethnic differences within the populations of the United States 
      and Canada highlight the changing demographics of each country as well as
      potential disparities in heart failure care. Heart failure with preserved
      ejection fraction makes up approximately half of all hospital admissions
      throughout North America; however, important differences in demographics and
      etiology exist between countries. Similarly, acute heart failure etiology,
      severity, and management differ between countries in North America. The overall
      economic burden of heart failure continues to be large and growing worldwide,
      with each country managing this burden differently. Understanding the inter-and
      within-continental differences may help improve understanding of the heart
      failure epidemic, and may aid healthcare systems in delivering better heart
      failure prevention and treatment.
AD  - San Antonio Military Medical Center/Wilford Hall Ambulatory Surgical Center, 2200
      Bergquest Drive, Lackland AFB, TX 78236,USA. Jblair1@gmail.com.
FAU - Blair, John E A
AU  - Blair JE
FAU - Huffman, Mark
AU  - Huffman M
FAU - Shah, Sanjiv J
AU  - Shah SJ
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Cardiol Rev
JT  - Current cardiology reviews
JID - 101261935
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/10/29 [received]
PHST- 2012/11/13 [revised]
PHST- 2012/12/03 [accepted]
AID - CCR-EPUB-20130415-2 [pii]
PST - ppublish
SO  - Curr Cardiol Rev. 2013 May 1;9(2):128-46.

PMID- 23597295
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1875-6557 (Electronic)
IS  - 1573-403X (Linking)
VI  - 9
IP  - 2
DP  - 2013 May 1
TI  - Heart failure in East Asia.
PG  - 112-22
AB  - Heart failure (HF) carries a major burden of disease in East Asia, with high
      associated risk of mortality and morbidity. In recent decades, the epidemiology
      of HF has changed with social and economical development in East Asia. The burden
      of HF is still severe in East Asia. The prevalence of HF ranges from 1.3% to 6.7%
      throughout the region. As aetiological factors, ischaemic heart disease has
      increased and valvular disease reduced in most East Asian countries. Diuretics
      are the most commonly used drugs (51.0%-97%), followed by renin-angiotensin
      system (RAS) inhibitors (59%-77%), with angiotensin-converting enzyme inhibitors,
      ACEI, (32%-52%) and has angiotensin-2 receptor blockers, ARBs (31%-44%) in
      similar proportions. Betablocker use has also increased in recent years. Total
      mortality from HF ranges from 2% to 9% in China, Taiwan, Singapore, Thailand, and
      Japan. Age>65 years, diabetes mellitus, anaemia, renal dysfunction and atrial
      fibrillation (AF) are associated with adverse outcome. More prospective,
      region-specific data are still required, particularly regarding new drug
      therapies such as eplerenone and ivabradine.
AD  - University of Birmingham Centre for Cardiovascular Sciences, City Hospital,
      Birmingham, United Kingdom. a.banerjee.1@bham.ac.uk.
FAU - Guo, Yutao
AU  - Guo Y
FAU - Lip, Gregory Yh
AU  - Lip GY
FAU - Banerjee, Amitava
AU  - Banerjee A
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Cardiol Rev
JT  - Current cardiology reviews
JID - 101261935
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/10/14 [received]
PHST- 2012/12/02 [revised]
PHST- 2013/01/19 [accepted]
AID - CCR-EPUB-20130415-1 [pii]
PST - ppublish
SO  - Curr Cardiol Rev. 2013 May 1;9(2):112-22.

PMID- 23597278
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1521-043X (Electronic)
IS  - 0146-0862 (Linking)
VI  - 36
IP  - 1-2
DP  - 2013
TI  - The management of type 1 diabetes in primary school: review of the literature.
PG  - 98-119
LID - 10.3109/01460862.2013.782079 [doi]
AB  - Type 1 diabetes is one of the most common chronic health conditions in childhood.
      The introduction of intensive insulin therapy and the rising prevalence of
      diabetes in younger children has increased the need for involvement of diabetes
      educators and school personnel in school diabetes care. School encompasses a
      significant proportion of a child's day, therefore diabetes treatment at school
      needs to be optimal or the child will have poor metabolic control. The aim of
      this literature review is to examine diabetes management in the early primary
      school setting. The main areas of diabetes management explored are: type,
      provision, and location of treatment, the impact on the child, and the role of
      the credentialed diabetes educator. The review identifies that the majority of
      children are not receiving intensive diabetes treatment at school. Younger
      children require more assistance with care and may be disadvantaged due to lack
      of appropriate school staff support. Most schools do not have nurses to assist
      with diabetes care, therefore teaching and administration staff are utilized. The
      use of insulin pump therapy may increase access to insulin at school, as children
      and teaching staff appear more confident with this method of delivery than
      injections. Treatment is frequently performed away from the classroom and can
      impact on class attendance, metabolic control, and emergencies. Diabetes
      educators need to work in collaboration with children, parents, and school
      personnel to ensure diabetes care is fully integrated into the school day.
AD  - Faculty of Health, University of Technology Sydney , Australia .
FAU - Marks, Anne
AU  - Marks A
FAU - Wilson, Valerie
AU  - Wilson V
FAU - Crisp, Jackie
AU  - Crisp J
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - England
TA  - Issues Compr Pediatr Nurs
JT  - Issues in comprehensive pediatric nursing
JID - 7702326
SB  - N
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/04/18 [aheadofprint]
AID - 10.3109/01460862.2013.782079 [doi]
PST - ppublish
SO  - Issues Compr Pediatr Nurs. 2013;36(1-2):98-119. doi:
      10.3109/01460862.2013.782079. Epub 2013 Apr 18.

PMID- 23597205
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1466-609X (Electronic)
IS  - 1364-8535 (Linking)
VI  - 17
IP  - 2
DP  - 2013 Apr 18
TI  - Managing blood glucose in critically ill patients with or without diabetes.
PG  - 134
AB  - Relationships between blood glucose concentration and outcome and also the
      optimum management of blood glucose remain highly contentious issues for critical
      care practitioners. Among the many controversies is whether critically ill
      patients with diabetes should be treated differently from those without diabetes.
      Krinsley and colleagues assembled a large observational database that sheds
      further light on the relationships of hyperglycemia, hypoglycemia and glucose
      variability and risk of death in critically ill patients with and without
      diabetes. Defining the optimum treatment and whether this should differ by
      diabetic status requires high-quality primary interventional research.
AD  - The George Institute for Global Health, University of Sydney, PO Box M201,
      Missenden Road, Sydney, NSW 2050, Australia. sfinfer@georgeinstitute.org.au.
FAU - Finfer, Simon
AU  - Finfer S
FAU - Billot, Laurent
AU  - Billot L
LA  - ENG
PT  - EDITORIAL
DEP - 20130418
TA  - Crit Care
JT  - Critical care (London, England)
JID - 9801902
PMC - PMC3672639
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PMCR- 2014/04/18 00:00
PHST- 2013/04/18 [aheadofprint]
AID - cc12591 [pii]
AID - 10.1186/cc12591 [doi]
PST - aheadofprint
SO  - Crit Care. 2013 Apr 18;17(2):134.

PMID- 23597156
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1758-5996 (Print)
VI  - 5
IP  - 1
DP  - 2013 Apr 18
TI  - Cardiometabolic risk reduction through lifestyle intervention programs in the
      Brazilian public health system.
PG  - 21
AB  - Public health strategies to reduce cardiovascular morbidity and mortality should 
      focus on global cardiometabolic risk reduction. The efficacy of lifestyle changes
      to prevent type 2 diabetes have been demonstrated, but low-cost interventions to 
      reduce cardiometabolic risk in Latin-America have been rarely reported. Our group
      developed 2 programs to promote health of high-risk individuals attending a
      primary care center in Brazil. This study compared the effects of two 9-month
      lifestyle interventions, one based on medical consultations (traditional) and
      another with 13 multi-professional group sessions in addition to the medical
      consultations (intensive) on cardiometabolic parameters. Adults were eligible if 
      they had pre-diabetes (according to the American Diabetes Association) and/or
      metabolic syndrome (International Diabetes Federation criteria for
      Latin-America). Data were expressed as means and standard deviations or
      percentages and compared between groups or testing visits. A p-value < 0.05 was
      considered signicant. Results: 180 individuals agreed to participate (35.0% men, 
      mean age 54.7 +/- 12.3 years, 86.1% overweight or obese). 83 were allocated to
      the traditional and 97 to the intensive program. Both interventions reduced body 
      mass index, waist circumference and tumor necrosis factor-alpha. Only intensive
      program reduced 2-hour plasma glucose and blood pressure and increased
      adiponectin values, but HDL-cholesterol increased only in the traditional. Also, 
      responses to programs were better in intensive compared to traditional program in
      terms of blood pressure and adiponectin improvements. No new case of diabetes in 
      intensive but 3 cases and one myocardial infarction in traditional program were
      detected. Both programs induced metabolic improvement in the short-term, but if
      better results in the intensive are due to higher awareness about risk and
      self-motivation deserves further investigation. In conclusion, these low-cost
      interventions are able to minimize cardiometabolic risk factors involved in the
      progression to type 2 diabetes and/or cardiovascular disease.
FAU - Siqueira-Catania, Antonela Siqueira-Catania A
AU  - Siqueira-Catania A Siqueira-Catania A
FAU - Cezaretto, Adriana Cezaretto A
AU  - Cezaretto A Cezaretto A
FAU - Barros, Camila R Barros Cr
AU  - Barros CR Barros Cr
FAU - Salvador, Emanuel P Salvador Ep
AU  - Salvador EP Salvador Ep
FAU - Carvalho, Taina Carvalho T
AU  - Carvalho T Carvalho T
FAU - Ferreira, Sandra Rg Ferreira Srg
AU  - Ferreira SR Ferreira Srg
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/09/11 [received]
PHST- 2013/04/18 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 1758-5996-5-21 [pii]
AID - 10.1186/1758-5996-5-21 [doi]
PST - aheadofprint
SO  - Diabetol Metab Syndr. 2013 Apr 18;5(1):21.

PMID- 23597149
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1471-2164 (Electronic)
IS  - 1471-2164 (Linking)
VI  - 14
DP  - 2013
TI  - Dynamic recruitment of microRNAs to their mRNA targets in the regenerating liver.
PG  - 264
LID - 10.1186/1471-2164-14-264 [doi]
AB  - BACKGROUND: Validation of physiologic miRNA targets has been met with significant
      challenges. We employed HITS-CLIP to identify which miRNAs participate in liver
      regeneration, and to identify their target mRNAs. RESULTS: miRNA recruitment to
      the RISC is highly dynamic, changing more than five-fold for several miRNAs.
      miRNA recruitment to the RISC did not correlate with changes in overall miRNA
      expression for these dynamically recruited miRNAs, emphasizing the necessity to
      determine miRNA recruitment to the RISC in order to fully assess the impact of
      miRNA regulation. We incorporated RNA-seq quantification of total mRNA to
      identify expression-weighted Ago footprints, and developed a microRNA regulatory 
      element (MRE) prediction algorithm that represents a greater than 20-fold
      refinement over computational methods alone. These high confidence MREs were used
      to generate candidate 'competing endogenous RNA' (ceRNA) networks. CONCLUSION:
      HITS-CLIP analysis provide novel insights into global miRNA:mRNA relationships in
      the regenerating liver.
AD  - Department of Genetics and Institute for Diabetes, Obesity and Metabolism,
      Perelman School of Medicine, University of Pennsylvania, Philadelphia,
      Pennsylvania, USA. Linda.greenbaum@jefferson.edu.
FAU - Schug, Jonathan
AU  - Schug J
FAU - McKenna, Lindsay B
AU  - McKenna LB
FAU - Walton, Gabriel
AU  - Walton G
FAU - Hand, Nicholas
AU  - Hand N
FAU - Mukherjee, Sarmistha
AU  - Mukherjee S
FAU - Essuman, Kow
AU  - Essuman K
FAU - Shi, Zhongjie
AU  - Shi Z
FAU - Gao, Yan
AU  - Gao Y
FAU - Markley, Karen
AU  - Markley K
FAU - Nakagawa, Momo
AU  - Nakagawa M
FAU - Kameswaran, Vasumathi
AU  - Kameswaran V
FAU - Vourekas, Anastassios
AU  - Vourekas A
FAU - Friedman, Joshua R
AU  - Friedman JR
FAU - Kaestner, Klaus H
AU  - Kaestner KH
FAU - Greenbaum, Linda E
AU  - Greenbaum LE
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - England
TA  - BMC Genomics
JT  - BMC genomics
JID - 100965258
SB  - IM
PMC - PMC3639193
OID - NLM: PMC3639193
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/01/23 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 1471-2164-14-264 [pii]
AID - 10.1186/1471-2164-14-264 [doi]
PST - epublish
SO  - BMC Genomics. 2013 Apr 18;14:264. doi: 10.1186/1471-2164-14-264.

PMID- 23597124
OWN - NLM
STAT- Publisher
DA  - 20130419
IS  - 1651-1999 (Electronic)
IS  - 0803-7051 (Linking)
DP  - 2013 Apr 18
TI  - Local application of tropicamide 0.5% reduces retinal capillary blood flow.
AB  - Introduction. Scanning laser Doppler flowmetry (SLDF) plays an important role in 
      the study of arterial hypertension, diabetes and stroke. The technology enables
      non-invasive measurement of the retinal capillary perfusion (RCF), retinal
      haemodynamics and arteriolar morphology in human. The values can be measured in
      mydriasis or in non-mydriatic eyes. It is not clear whether the using of
      vasoactive mydriatica for pupil dilation affects the measured parameters in
      retina. Acetylcholine, a vasoactive neurotransmitter in human retina, affects the
      contractility of pericytes using muscarinic receptors and stimulates endothelial 
      synthesis of nitric oxide (NO). We examined whether blockade of the retinal
      cholinergic receptors by tropicamide affects the RCF. Methods. We measured RCF in
      both eyes of 13 healthy subjects before and 30 min after the local application of
      one drop of 0.5% tropicamide to the right eye. The mean age of the group was 44
      +/- 14 years. The left eye was used as control. RCF was measured by Heidelberg
      retina flowmetry. Results. Thirty minutes after local application of one drop of 
      0.5% tropicamide to the right eye RCF decreased significantly (p = 0.001) by 31.9
      +/- 13% but did not change in the control eye. The maximal decrease was observed 
      20 min after application of the tropicamide. Conclusion. Locally administered
      tropicamide profoundly affects the RCF. Thus pupil dilatation impairs any
      assessment of retinal microcirculation.
AD  - Ophthalmology Department Friedrich-Alexander University , Erlangen , Germany.
FAU - Harazny, Joanna M
AU  - Harazny JM
FAU - Schmieder, Roland E
AU  - Schmieder RE
FAU - Welzenbach, Juergen
AU  - Welzenbach J
FAU - Michelson, Georg
AU  - Michelson G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Blood Press
JT  - Blood pressure
JID - 9301454
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - 10.3109/08037051.2013.782956 [doi]
PST - aheadofprint
SO  - Blood Press. 2013 Apr 18.

PMID- 23597082
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1479-5868 (Electronic)
IS  - 1479-5868 (Linking)
VI  - 10
DP  - 2013
TI  - Motivational interviewing and problem solving treatment to reduce type 2 diabetes
      and cardiovascular disease risk in real life: a randomized controlled trial.
PG  - 47
LID - 10.1186/1479-5868-10-47 [doi]
AB  - BACKGROUND: Intensive lifestyle interventions in well-controlled settings are
      effective in lowering the risk of chronic diseases such as type 2 diabetes (T2DM)
      and cardiovascular diseases (CVD), but there are still no effective lifestyle
      interventions for everyday practice. In the Hoorn Prevention Study we aimed to
      assess the effectiveness of a primary care based lifestyle intervention to reduce
      the estimated risk of developing T2DM and for CVD mortality, and to motivate
      changes in lifestyle behaviors. METHODS: The Hoorn Prevention Study is a parallel
      group randomized controlled trial, implemented in the region of West-Friesland,
      the Netherlands. 622 adults with >/=10% estimated risk of T2DM and/or CVD
      mortality were randomly assigned and monitored over a period of 12 months. The
      intervention group (n=314) received a theory-based lifestyle intervention based
      on an innovative combination of motivational interviewing and problem solving
      treatment, provided by trained practice nurses in 12 general practices. The
      control group (n=308) received existing health brochures. Primary outcomes was
      the estimated diabetes risk according to the formula of the Atherosclerosis Risk 
      In Communities (ARIC) Study, and the estimated risk for CVD mortality according
      to the Systematic COronary Risk Evaluation (SCORE) formula. Secondary outcomes
      included lifestyle behavior (diet, physical activity and smoking). The research
      assistants, the principal investigator and the general practitioners were blinded
      to group assignment. Linear and logistic regression analysis was applied to
      examine the between-group differences in each outcome measure, adjusted for
      baseline values. RESULTS: 536 (86.2%) of the 622 participants (age 43.5 years)
      completed the 6-month follow-up, and 502 (81.2%) completed the 12-month
      follow-up. The mean baseline T2DM risk was 18.9% (SD 8.2) and the mean CVD
      mortality risk was 3.8% (SD 3.0). The intervention group participated in a median
      of 2 sessions. Intention-to-treat analyses showed no significant differences in
      outcomes between the two groups at 6 or 12-months follow-up. CONCLUSIONS: The
      lifestyle intervention was not more effective than health brochures in reducing
      risk scores for T2DM and CVD or improving lifestyle behavior in an at-risk
      population. TRIAL REGISTRATION: Current Controlled Trials: ISRCTN59358434.
AD  - Department of General Practice and the EMGO Institute for Health and Care
      Research, VU University Medical Center, van der Boechorststraat 7, Amsterdam,
      1081 BT, The Netherlands. j.lakerveld@vumc.nl.
FAU - Lakerveld, Jeroen
AU  - Lakerveld J
FAU - Bot, Sandra D
AU  - Bot SD
FAU - Chinapaw, Mai J
AU  - Chinapaw MJ
FAU - van Tulder, Maurits W
AU  - van Tulder MW
FAU - Kostense, Piet J
AU  - Kostense PJ
FAU - Dekker, Jacqueline M
AU  - Dekker JM
FAU - Nijpels, Giel
AU  - Nijpels G
LA  - eng
PT  - Journal Article
DEP - 20130419
PL  - England
TA  - Int J Behav Nutr Phys Act
JT  - The international journal of behavioral nutrition and physical activity
JID - 101217089
SB  - IM
PMC - PMC3639181
OID - NLM: PMC3639181
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/05/19 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - 1479-5868-10-47 [pii]
AID - 10.1186/1479-5868-10-47 [doi]
PST - epublish
SO  - Int J Behav Nutr Phys Act. 2013 Apr 19;10:47. doi: 10.1186/1479-5868-10-47.

PMID- 23597066
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1477-7827 (Electronic)
IS  - 1477-7827 (Linking)
VI  - 11
DP  - 2013
TI  - Maternal diabetes causes abnormal dynamic changes of endoplasmic reticulum during
      mouse oocyte maturation and early embryo development.
PG  - 31
LID - 10.1186/1477-7827-11-31 [doi]
AB  - BACKGROUND: The adverse effects of maternal diabetes on oocyte maturation and
      embryo development have been reported. METHODS: In this study, we used time-lapse
      live cell imaging confocal microscopy to investigate the dynamic changes of ER
      and the effects of diabetes on the ER's structural dynamics during oocyte
      maturation, fertilization and early embryo development. RESULTS: We report that
      the ER first became remodeled into a dense ring around the developing MI spindle,
      and then surrounded the spindle during migration to the cortex. ER reorganization
      during mouse early embryo development was characterized by striking localization 
      around the pronuclei in the equatorial section, in addition to larger areas of
      fluorescence deeper within the cytoplasm. In contrast, in diabetic mice, the ER
      displayed a significantly higher percentage of homogeneous distribution patterns 
      throughout the entire ooplasm during oocyte maturation and early embryo
      development. In addition, a higher frequency of large ER aggregations was
      detected in GV oocytes and two cell embryos from diabetic mice. CONCLUSIONS:
      These results suggest that the diabetic condition adversely affects the ER
      distribution pattern during mouse oocyte maturation and early embryo development.
AD  - Department of Reproductive Medicine, Peking University Shenzhen Hospital, Medical
      Center of Peking University, Shenzhen, Guangdong, China.
FAU - Zhang, Chun-Hui
AU  - Zhang CH
FAU - Qian, Wei-Ping
AU  - Qian WP
FAU - Qi, Shu-Tao
AU  - Qi ST
FAU - Ge, Zhao-Jia
AU  - Ge ZJ
FAU - Min, Ling-Jiang
AU  - Min LJ
FAU - Zhu, Xiu-Lang
AU  - Zhu XL
FAU - Huang, Xin
AU  - Huang X
FAU - Liu, Jing-Ping
AU  - Liu JP
FAU - Ouyang, Ying-Chun
AU  - Ouyang YC
FAU - Hou, Yi
AU  - Hou Y
FAU - Schatten, Heide
AU  - Schatten H
FAU - Sun, Qing-Yuan
AU  - Sun QY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130419
PL  - England
TA  - Reprod Biol Endocrinol
JT  - Reproductive biology and endocrinology : RB&E
JID - 101153627
SB  - IM
PMC - PMC3637269
OID - NLM: PMC3637269
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/09/15 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/19 [aheadofprint]
AID - 1477-7827-11-31 [pii]
AID - 10.1186/1477-7827-11-31 [doi]
PST - epublish
SO  - Reprod Biol Endocrinol. 2013 Apr 19;11:31. doi: 10.1186/1477-7827-11-31.

PMID- 23597065
OWN - NLM
STAT- In-Process
DA  - 20130506
IS  - 1744-8603 (Electronic)
IS  - 1744-8603 (Linking)
VI  - 9
DP  - 2013
TI  - Management of diabetes and diabetes policies in Turkey.
PG  - 16
LID - 10.1186/1744-8603-9-16 [doi]
AB  - BACKGROUND: Diabetes and its complications are among the present and future
      challenges of the Turkish health care system. The objective of this paper is to
      discuss the current situation of diabetes and its management in Turkey with
      special emphasis on the changing policy environment. METHODS: A literature review
      in databases such as PUBMED was performed from 2000 to 2011. This synthesis was
      complemented by grey literature, personal communication and contact with national
      and provincial health authorities and experts in diabetes from Turkey. RESULTS:
      The literature review and expert consultations indicated a growing policy
      emphasis on diabetes. Both the public and private sectors, non-governmental
      organizations have initiated policy papers to shape the outlook of diabetes care 
      in the future. This is in line with the current dynamics of the healthcare
      system. CONCLUSIONS: Diabetes care will be high on the agenda in future. Evidence
      based policy-making is the key to implement the policies adopted so far and a
      supportive environment is needed.
AD  - Department of Healthcare Management, Faculty of Economics and Administrative
      Sciences, Hacettepe University, Beytepe 06800, Ankara, Turkey.
      mtatar@hacettepe.edu.tr
FAU - Tatar, Mehtap
AU  - Tatar M
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - England
TA  - Global Health
JT  - Globalization and health
JID - 101245734
SB  - IM
PMC - PMC3644279
OID - NLM: PMC3644279
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/10/13 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 1744-8603-9-16 [pii]
AID - 10.1186/1744-8603-9-16 [doi]
PST - epublish
SO  - Global Health. 2013 Apr 18;9:16. doi: 10.1186/1744-8603-9-16.

PMID- 23597047
OWN - NLM
STAT- In-Data-Review
DA  - 20130523
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 56
IP  - 10
DP  - 2013 May 23
TI  - Structure-Based Approaches to Ligands for G-Protein-Coupled Adenosine and P2Y
      Receptors, from Small Molecules to Nanoconjugates.
PG  - 3749-67
LID - 10.1021/jm400422s [doi]
AB  - Adenosine receptor (ARs) and P2Y receptors (P2YRs) that respond to extracellular 
      nucleosides/nucleotides are associated with new directions for therapeutics. The 
      X-ray structures of the A2AAR complexes with agonists and antagonists are
      examined in relationship to the G-protein-coupled receptor (GPCR) superfamily and
      applied to drug discovery. Much of the data on AR ligand structure from early SAR
      studies now are explainable from the A2AAR X-ray crystallography. The
      ligand-receptor interactions in related GPCR complexes can be identified by means
      of modeling approaches, e.g., molecular docking. Thus, molecular recognition in
      binding and activation processes has been studied effectively using homology
      modeling and applied to ligand design. Virtual screening has yielded new
      nonnucleoside AR antagonists, and existing ligands have been improved with
      knowledge of the receptor interactions. New agonists are being explored for
      central nervous system and peripheral therapeutics based on in vivo activity,
      such as chronic neuropathic pain. Ligands for receptors more distantly related to
      the X-ray template, i.e., P2YRs, have been introduced and are mainly used as
      pharmacological tools for elucidating the physiological role of extracellular
      nucleotides. Other ligand tools for drug discovery include fluorescent probes,
      radioactive probes, multivalent probes, and functionalized nanoparticles.
AD  - Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National
      Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of
      Health , Bethesda, Maryland 20892, United States.
FAU - Jacobson, Kenneth A
AU  - Jacobson KA
LA  - eng
PT  - Journal Article
DEP - 20130509
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PHST- 2013/05/09 [aheadofprint]
AID - 10.1021/jm400422s [doi]
PST - ppublish
SO  - J Med Chem. 2013 May 23;56(10):3749-67. doi: 10.1021/jm400422s. Epub 2013 May 9.

PMID- 23596966
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
VI  - 125
IP  - 6
DP  - 2013 Sep 1
TI  - Non-alcoholic fatty liver disease is associated with an increased prevalence of
      atrial fibrillation in hospitalized patients with Type 2 diabetes.
PG  - 301-9
LID - 10.1042/CS20130036 [doi]
AB  - NAFLD (non-alcoholic fatty liver disease) and AF (atrial fibrillation) are two
      pathological conditions that are highly prevalent in developed countries and
      share multiple risk factors. The relationship between NAFLD and AF in Type 2
      diabetes is currently unknown. We studied a hospital-based sample of 702 patients
      with Type 2 diabetes discharged from our Division of Endocrinology during
      2007-2011. The diagnosis of AF was confirmed in affected participants on the
      basis of ECGs and medical history by experienced cardiologists. NAFLD was defined
      by ultrasonographic detection of hepatic steatosis in the absence of other liver 
      diseases. Of the 702 hospitalized patients included in the study, 514 (73.2%) of 
      them had NAFLD and 85 (12.1%) had persistent or permanent AF. NAFLD was
      associated with an increased risk of prevalent AF {OR (odds ratio), 3.04 [95% CI 
      (confidence interval), 1.54-6.02]; P<0.001}. Adjustments for age, sex, systolic
      BP (blood pressure), HbA1c, (glycated haemoglobin), estimated GFR (glomerular
      filtration rate), total cholesterol, electrocardiographic LVH (left ventricular
      hypertrophy), COPD (chronic obstructive pulmonary disease), and prior history of 
      HF (heart failure), VHD (valvular heart disease) or hyperthyroidism did not
      attenuate the association between NAFLD and AF [adjusted OR, 5.88 (95% CI,
      2.72-12.7); P<0.001]. In conclusion, our results show that ultrasound-diagnosed
      NAFLD is strongly associated with an increased prevalence of persistent or
      permanent AF in patients with Type 2 diabetes, independently of several clinical 
      risk factors for AF. The potential impact of NAFLD on AF deserves particular
      attention, especially with respect to the implications for screening and
      surveillance strategies in the growing number of patients with NAFLD.
AD  - *Section of Endocrinology, Diabetes and Metabolism, University and Azienda
      Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
FAU - Targher, Giovanni
AU  - Targher G
FAU - Mantovani, Alessandro
AU  - Mantovani A
FAU - Pichiri, Isabella
AU  - Pichiri I
FAU - Rigolon, Riccardo
AU  - Rigolon R
FAU - Dauriz, Marco
AU  - Dauriz M
FAU - Zoppini, Giacomo
AU  - Zoppini G
FAU - Morani, Giovanni
AU  - Morani G
FAU - Vassanelli, Corrado
AU  - Vassanelli C
FAU - Bonora, Enzo
AU  - Bonora E
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
SB  - IM
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
AID - CS20130036 [pii]
AID - 10.1042/CS20130036 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 2013 Sep 1;125(6):301-9. doi: 10.1042/CS20130036.

PMID- 23596646
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1746-076X (Electronic)
IS  - 1746-0751 (Linking)
VI  - 8
IP  - 2
DP  - 2013 Mar
TI  - Cardioprotection by encapsulated GLP-1-producing mesenchymal stem cells.
PG  - 117-8
AD  - Pediatric Diabetes Research Center, University of California, San Diego, 9500
      Gilman Drive, 0721, La Jolla, CA 92093-0721, USA. chking@ucsd.edu
FAU - King, Charles C
AU  - King CC
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - England
TA  - Regen Med
JT  - Regenerative medicine
JID - 101278116
CON - Stem Cells Transl Med. 2012 Oct;1(10):759-69. PMID: 23197668
EDAT- 2013/04/20 06:00
MHDA- 2013/04/20 06:00
CRDT- 2013/04/20 06:00
PST - ppublish
SO  - Regen Med. 2013 Mar;8(2):117-8.

PMID- 23596491
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 5
IP  - 4
DP  - 2013 Apr
TI  - Analysis of factors related to short-term prognosis in patients undergoing
      percutaneous coronary intervention for acute myocardial infarction.
PG  - 1206-1210
AB  - The present study aimed to investigate the factors related to short-term
      prognosis in patients undergoing direct percutaneous coronary intervention (PCI) 
      for acute ST-segment elevation myocardial infarction (STEMI). A total of 805
      patients were included and divided into a control group and an adverse
      cardiovascular events group based on the prognosis, to compare risk factors and
      coronary angiographic characteristics in the two groups. In the adverse events
      group, the ages, admission blood glucose, uric acid (UA), homocysteine (HCY),
      creatine kinase (CK) and peak creatine kinase-MB (CKMB) isozyme levels were
      clearly higher compared with those in the control group, while the levels of
      total cholesterol (TC), triglycerides (TGs) and low-density lipoprotein (LDL)
      were lower compared with those in the control group. The incidence of
      hypertension in females in the adverse events group was markedly higher compared 
      with that in the control group, while the diabetes rate was lower compared with
      that in the control group. Logistic regression analysis revealed that age,
      gender, hypertension, diabetes and admission blood glucose, HCY, TC and UA levels
      were independent risk factors of short-term prognosis in patients undergoing
      emergency PCI. The majority of the patients in the adverse events group were
      elderly females with hypertension, a large area of myocardial infarction and
      increased admission blood glucose, UA and HCY levels, as well as a low diabetes
      rate and decreased levels of acute-phase TC and LDL.
AD  - Department of Cardiovascular Medicine, The Tangshan Affiliated Clinical Hospital 
      of Hebei Medical University, Tangshan, Hebei 063000, P.R. China.
FAU - Ma, Yi
AU  - Ma Y
FAU - Li, Li
AU  - Li L
FAU - Shang, Xiao-Ming
AU  - Shang XM
FAU - Tan, Zheng
AU  - Tan Z
FAU - Geng, Xue-Bin
AU  - Geng XB
FAU - Zhao, Bi-Qiong
AU  - Zhao BQ
FAU - Tian, Mei-Rong
AU  - Tian MR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130125
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3627441
OTO - NOTNLM
OT  - myocardial infarction
OT  - percutaneous coronary intervention
OT  - risk factors
OT  - short-term prognosis
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/10/29 [received]
PHST- 2013/01/07 [accepted]
PHST- 2013/01/25 [epublish]
AID - 10.3892/etm.2013.927 [doi]
AID - etm-05-04-1206 [pii]
PST - ppublish
SO  - Exp Ther Med. 2013 Apr;5(4):1206-1210. Epub 2013 Jan 25.

PMID- 23596421
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130418
DCOM- 20130419
LR  - 20130422
IS  - 1664-042X (Electronic)
IS  - 1664-042X (Linking)
VI  - 4
DP  - 2013
TI  - Mitochondrial permeability transition and cell death: the role of cyclophilin d.
PG  - 76
LID - 10.3389/fphys.2013.00076 [doi]
AB  - Mitochondria serve as a "powerhouse" which provides near 90% of ATP necessary for
      cell life. However, recent studies provide strong evidence that mitochondria also
      play a central role in cell death. Mitochondrial permeability transition (mPT) at
      high conductance in response to oxidative or other cellular stresses is
      accompanied by pathological and non-specific mPT pore (mPTP) opening in the inner
      membrane of mitochondria. Mitochondrial PTP can serve as a target to prevent cell
      death under pathological conditions such as cardiac and brain
      ischemia/reperfusion injury and diabetes. On the other hand, mPTP can be used as 
      an executioner to specifically induce cell death thus blocking tumorigenesis in
      cancer diseases. Despite many studies, the molecular identity of the mPTP remains
      unclear. Cyclophilin D (CyP-D) plays an essential regulatory role in pore
      opening. This review will discuss direct and indirect mechanisms underlying CyP-D
      interaction with a target protein of the mPTP complex. Understanding of the
      mechanisms of mPTP opening will be helpful to further develop new pharmacological
      agents targeting mitochondria-mediated cell death.
AD  - Department of Physiology, School of Medicine, University of Puerto Rico San Juan,
      PR, USA.
FAU - Javadov, Sabzali
AU  - Javadov S
FAU - Kuznetsov, Andrey
AU  - Kuznetsov A
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - Switzerland
TA  - Front Physiol
JT  - Frontiers in physiology
JID - 101549006
PMC - PMC3622878
OID - NLM: PMC3622878
OTO - NOTNLM
OT  - cell death
OT  - cyclophilin D
OT  - mitochondria
OT  - permeability transition pore
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:01
CRDT- 2013/04/19 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/25 [received]
PHST- 2013/03/21 [accepted]
PHST- 2013/04/11 [epublish]
AID - 10.3389/fphys.2013.00076 [doi]
PST - epublish
SO  - Front Physiol. 2013 Apr 11;4:76. doi: 10.3389/fphys.2013.00076. Print 2013.

PMID- 23596182
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 17
TI  - The Effect of Insulin Infusion on the Metabolites in Cerebral Tissues Assessed
      With Proton Magnetic Resonance Spectroscopy in Young Healthy Subjects With High
      and Low Insulin Sensitivity.
AB  - OBJECTIVEInsulin may play important roles in brain metabolism. Proton magnetic
      resonance spectroscopy (1H-MRS) of the central nervous system gives information
      on neuronal viability, cellular energy, and membrane status. To elucidate the
      specific role of insulin action in the brain, we estimated neurometabolites with 
      1H-MRS and assessed their regulation by insulin infusion and their relationship
      with insulin sensitivity.RESEARCH DESIGN AND METHODSWe studied 16 healthy young
      men. 1H-MRS was performed at baseline and after 240 min of
      euglycemic-hyperinsulinemic clamp. Voxels were positioned in the left frontal
      lobe, left temporal lobe, and left thalamus. The ratios of N-acetylaspartate
      (NAA), choline-containing compounds (Cho), myo-inositol, and
      glutamate/glutamine/gamma-aminobutyric acid complex (Glx) to creatine (Cr) and
      nonsuppressed water signal were determined. The participants were divided into
      subgroups of high (high IS) and low insulin sensitivity (low IS).RESULTSBaseline 
      neurometabolic substrates were not different between the groups. Insulin infusion
      resulted in an increase in frontal NAA/Cr and NAA/H2O and frontal and temporal
      Glx/Cr and Glx/H2O and a decrease in frontal Cho/Cr and temporal Cho/H2O and
      myo-inositol/H2O (all P < 0.05, except temporal Glx/H2O, P = 0.054, NS) in the
      high-IS, but not in the low-IS, group. Insulin sensitivity correlated positively 
      with frontal NAA/Cr and NAA/H2O and temporal Glx/H2O and negatively with temporal
      myo-inositol/Cr and myo-inositol/H2O assessed during the second 1H-MRS (all P <
      0.05).CONCLUSIONSInsulin might influence cerebral metabolites, and this action is
      impaired in subjects with low whole-body insulin sensitivity. Thus, our results
      provide a potential link between insulin resistance and altered metabolism of the
      central nervous system.
AD  - Department of Endocrinology, Diabetology, and Internal Medicine, Medical
      University of Bialystok, Bialystok, Poland.
FAU - Karczewska-Kupczewska, Monika
AU  - Karczewska-Kupczewska M
FAU - Tarasow, Eugeniusz
AU  - Tarasow E
FAU - Nikolajuk, Agnieszka
AU  - Nikolajuk A
FAU - Stefanowicz, Magdalena
AU  - Stefanowicz M
FAU - Matulewicz, Natalia
AU  - Matulewicz N
FAU - Otziomek, Elzbieta
AU  - Otziomek E
FAU - Gorska, Maria
AU  - Gorska M
FAU - Straczkowski, Marek
AU  - Straczkowski M
FAU - Kowalska, Irina
AU  - Kowalska I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - dc12-1437 [pii]
AID - 10.2337/dc12-1437 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 17.

PMID- 23596181
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 17
TI  - Modulation by Dietary Fat and Carbohydrate of IRS1 Association With Type 2
      Diabetes Traits in Two Populations of Different Ancestries.
AB  - OBJECTIVEInsulin receptor substrate 1 (IRS1) is central to insulin signaling
      pathways. This study aimed to examine the association of IRS1 variants with
      insulin resistance (IR) and related phenotypes, as well as potential modification
      by diet.RESEARCH DESIGN AND METHODSTwo IRS1 variants (rs7578326 and rs2943641)
      identified by genome-wide association studies as related to type 2 diabetes were 
      tested for their associations with IR and related traits and interaction with
      diet in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study (n = 
      820) and the Boston Puerto Rican Health Study (BPRHS) (n =
      844).RESULTSMeta-analysis indicated that rs7578326 G-allele carriers and
      rs2943641 T-allele carriers had a lower risk of IR, type 2 diabetes, and
      metabolic syndrome (MetS). Significant interactions on IR and MetS were found for
      these two variants and their haplotypes with diet. In GOLDN, rs7578326 G-allele
      carriers and rs2943641 T-allele carriers and their haplotype G-T carriers had a
      significantly lower risk of IR and MetS than noncarriers only when the dietary
      saturated fatty acid-to-carbohydrate ratio was low (</=0.24). In both GOLDN (P = 
      0.0008) and BPRHS (P = 0.011), rs7578326 G-allele carriers had a lower risk of
      MetS than noncarriers only when dietary monounsaturated fatty acids were lower
      than the median intake of each population.CONCLUSIONS IRS1 variants are
      associated with IR and related traits and are modulated by diet in two
      populations of different ancestries. These findings suggest that IRS1 variants
      have important functions in various metabolic disorders and that dietary factors 
      could modify these associations.
AD  - Department of Food Science and Nutrition, Zhejiang University, Hangzhou, China.
FAU - Zheng, Ju-Sheng
AU  - Zheng JS
FAU - Arnett, Donna K
AU  - Arnett DK
FAU - Parnell, Laurence D
AU  - Parnell LD
FAU - Smith, Caren E
AU  - Smith CE
FAU - Li, Duo
AU  - Li D
FAU - Borecki, Ingrid B
AU  - Borecki IB
FAU - Tucker, Katherine L
AU  - Tucker KL
FAU - Ordovas, Jose M
AU  - Ordovas JM
FAU - Lai, Chao-Qiang
AU  - Lai CQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - dc12-2607 [pii]
AID - 10.2337/dc12-2607 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 17.

PMID- 23596180
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 17
TI  - Evidence of Reduced Beta Cell Function in Asian Indians With Mild Dysglycemia.
AB  - OBJECTIVETo examine beta-cell function across a spectrum of glycemia among Asian 
      Indians, a population experiencing type 2 diabetes development at young ages
      despite low BMI.RESEARCH DESIGN AND METHODSOne-thousand two-hundred sixty-four
      individuals without known diabetes in the Diabetes Community Lifestyle
      Improvement Program in Chennai, India, had a 75-g oral glucose tolerance test,
      with glucose and insulin measured at 0, 30, and 120 min. Type 2 diabetes,
      isolated impaired fasting glucose (iIFG), isolated impaired glucose tolerance
      (iIGT), combined impaired fasting glucose and impaired glucose tolerance, and
      normal glucose tolerance (NGT) were defined by American Diabetes Association
      guidelines. Measures included insulin resistance and sensitivity (homeostasis
      model assessment of insulin resistance [HOMA-IR], modified Matsuda Index,
      1/fasting insulin) and beta-cell function (oral disposition index =
      [Deltainsulin0-30/Deltaglucose0-30] x [1/fasting insulin]).RESULTSMean age was
      44.2 years (SD, 9.3) and BMI 27.4 kg/m2 (SD, 3.8); 341 individuals had NGT, 672
      had iIFG, IGT, or IFG plus IGT, and 251 had diabetes. Patterns of insulin
      resistance or sensitivity were similar across glycemic categories. With mild
      dysglycemia, the absolute differences in age- and sex-adjusted oral disposition
      index (NGT vs. iIFG, 38%; NGT vs. iIGT, 32%) were greater than the differences in
      HOMA-IR (NGT vs. iIFG, 25%; NGT vs. iIGT, 23%; each P < 0.0001). Compared with
      NGT and adjusted for age, sex, BMI, waist circumference, and family history, the 
      odds of mild dysglycemia were more significant per SD of oral disposition index
      (iIFG: odds ratio [OR], 0.36; 95% CI, 0.23-0.55; iIGT: OR, 0.37; 95% CI,
      0.24-0.56) than per SD of HOMA-IR (iIFG: OR, 1.69; 95% CI, 1.23-2.33; iIGT: OR,
      1.53; 95% CI, 1.11-2.11).CONCLUSIONSAsian Indians with mild dysglycemia have
      reduced beta-cell function, regardless of age, adiposity, insulin sensitivity, or
      family history. Strategies in diabetes prevention should minimize loss of
      beta-cell function.
AD  - Nutrition and Health Sciences Program, Graduate Division of Biomedical and
      Biological Sciences, Laney Graduate School, Emory University, Atlanta, Georgia.
FAU - Staimez, Lisa R
AU  - Staimez LR
FAU - Weber, Mary Beth
AU  - Weber MB
FAU - Ranjani, Harish
AU  - Ranjani H
FAU - Ali, Mohammed K
AU  - Ali MK
FAU - Echouffo-Tcheugui, Justin B
AU  - Echouffo-Tcheugui JB
FAU - Phillips, Lawrence S
AU  - Phillips LS
FAU - Mohan, Viswanathan
AU  - Mohan V
FAU - Narayan, K M Venkat
AU  - Narayan KM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - dc12-2290 [pii]
AID - 10.2337/dc12-2290 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 17.

PMID- 23596179
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 17
TI  - Use of the Estimated Glucose Disposal Rate (eGDR) as a Measure of Insulin
      Resistance in an Urban Multiethnic Population With Type 1 Diabetes.
AB  - OBJECTIVEInsulin resistance has been described in type 1 diabetes mellitus, is
      related to risk of vascular complications, and may be more common in certain
      ethnic groups. Estimated glucose disposal rate (eGDR) is a validated clinical
      tool for estimating insulin sensitivity in type 1 diabetes. Because previous
      reports of eGDR in adults with type 1 diabetes have included few ethnic
      minorities, this study explored interethnic differences in eGDR and the
      relationship of eGDR with diabetic vascular complications.RESEARCH DESIGN AND
      METHODSWe conducted a cross-sectional study using a sample that included 207
      white, black, or Hispanic adults with prior clinical diagnosis of type 1 diabetes
      who were receiving care at an urban academic medical center. eGDR (milligrams per
      kilogram per minute) was calculated using HbA1c, waist circumference, and
      hypertensive status. Race/ethnicity was self-reported. Multivariable logistic
      regression models were used to estimate odds ratios (ORs) and 95% CIs of
      association of eGDR with diabetes complications (cardiovascular disease,
      retinopathy, albuminuria, and chronic kidney disease above stage
      3).RESULTSForty-two percent of the participants were women, and mean age was 45
      +/- 15 years; 34% were white, 32% were Hispanic, and 34% were black. Ethnicity
      was significantly associated with eGDR; blacks had significantly lower eGDR (5.66
      +/- 2.34) than Hispanics (6.70 +/- 2.29) and whites (7.20 +/- 2.03) (P < 0.001). 
      Patients with the lowest eGDR compared with the highest had a significantly
      greater risk of any diabetes complication (OR 3.1 [95% CI 1.2-8.1]) compared with
      the least insulin-resistant patients.CONCLUSIONSIn an urban clinic population of 
      patients with type 1 diabetes, blacks were significantly less insulin sensitive
      than whites or Hispanics, and lower eGDR was associated with diabetes
      complications. Further study is needed to determine whether using eGDR to target 
      interventions can improve outcomes.
AD  - Division of Endocrinology, Montefiore Medical Center, Bronx, New York.
FAU - Epstein, Eric J
AU  - Epstein EJ
FAU - Osman, Jamie L
AU  - Osman JL
FAU - Cohen, Hillel W
AU  - Cohen HW
FAU - Rajpathak, Swapnil N
AU  - Rajpathak SN
FAU - Lewis, Oksana
AU  - Lewis O
FAU - Crandall, Jill P
AU  - Crandall JP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - dc12-1693 [pii]
AID - 10.2337/dc12-1693 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 17.

PMID- 23596147
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 17
TI  - Incretin Therapy and Islet Pathology - A Time for Caution.
AD  - Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA
      Puget Sound Health Care System and University of Washington.
FAU - Kahn, Steven E
AU  - Kahn SE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - db13-0520 [pii]
AID - 10.2337/db13-0520 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 17.

PMID- 23596141
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 5
DP  - 2013 May
TI  - High long-term cortisol levels, measured in scalp hair, are associated with a
      history of cardiovascular disease.
PG  - 2078-83
LID - 10.1210/jc.2012-3663 [doi]
AB  - Background: Stress is associated with an increased incidence of cardiovascular
      disease. The impact of chronic stress on cardiovascular risk has been studied by 
      measuring cortisol in serum and saliva, which are measurements of only 1 time
      point. These studies yielded inconclusive results. The measurement of cortisol in
      scalp hair is a novel method that provides the opportunity to measure long-term
      cortisol exposure. Our aim was to study whether long-term cortisol levels,
      measured in scalp hair, are associated with cardiovascular diseases. Methods: A
      group of 283 community-dwelling elderly participants were randomly selected from 
      a large population-based cohort study (median age, 75 y; range, 65-85 y).
      Cortisol was measured in 3-cm hair segments, corresponding roughly with a period 
      of 3 months. Self-reported data concerning coronary heart disease, stroke,
      peripheral arterial disease, diabetes mellitus, and other chronic
      noncardiovascular diseases were collected. Results: Hair cortisol levels were
      significantly lower in women than in men (21.0 vs 26.3 pg/mg hair; P < .001).
      High hair cortisol levels were associated with an increased cardiovascular risk
      (odds ratio, 2.7; P = .01) and an increased risk of type 2 diabetes mellitus
      (odds ratio, 3.2; P = .04). There were no associations between hair cortisol
      levels and noncardiovascular diseases. Conclusions: Elevated long-term cortisol
      levels are associated with a history of cardiovascular disease. The increased
      cardiovascular risk we found is equivalent to the effect of traditional
      cardiovascular risk factors, suggesting that long-term elevated cortisol may be
      an important cardiovascular risk factor.
AD  - Erasmus MC, Department of Internal Medicine, Room Ee-542, P.O. Box 2040, 3000 CA 
      Rotterdam, The Netherlands. l.manenschijn@erasmusmc.nl.
FAU - Manenschijn, L
AU  - Manenschijn L
FAU - Schaap, L
AU  - Schaap L
FAU - van Schoor, N M
AU  - van Schoor NM
FAU - van der Pas, S
AU  - van der Pas S
FAU - Peeters, G M E E
AU  - Peeters GM
FAU - Lips, P
AU  - Lips P
FAU - Koper, J W
AU  - Koper JW
FAU - van Rossum, E F C
AU  - van Rossum EF
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/17 [aheadofprint]
AID - jc.2012-3663 [pii]
AID - 10.1210/jc.2012-3663 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 May;98(5):2078-83. doi: 10.1210/jc.2012-3663. Epub 
      2013 Apr 17.

PMID- 23596136
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 6
DP  - 2013 Jun
TI  - Metabolic inflexibility is a feature of women with polycystic ovary syndrome and 
      is associated with both insulin resistance and hyperandrogenism.
PG  - 2581-8
LID - 10.1210/jc.2013-1161 [doi]
AB  - Context: Metabolic inflexibility, ie, the impaired ability of the body to switch 
      from fat to carbohydrate oxidation under insulin-stimulated conditions, is
      associated with insulin resistance. This alteration in metabolic plasticity can
      lead to organ dysfunction and is considered a key issue among the abnormalities
      of the metabolic syndrome. It is still unknown whether this phenomenon occurs in 
      women with polycystic ovary syndrome (PCOS). Objective: Our objective was to
      examine whether metabolic inflexibility is a feature of PCOS women and whether
      hyperandrogenism may contribute to this phenomenon. Design and Patients:
      Eighty-nine Caucasian women with PCOS were submitted to
      hyperinsulinemic-euglycemic clamp. Respiratory exchange ratios were evaluated at 
      baseline and during hyperinsulinemia by indirect calorimetry to quantify
      substrate oxidative metabolism. Total testosterone was measured by liquid
      chromatography mass spectrometry and free testosterone by equilibrium dialysis.
      Setting: Outpatients were seen in a tertiary care academic center. Main Outcome
      Measure: Metabolic flexibility was assessed by the change in respiratory quotient
      upon insulin stimulation. Results: Sixty-five of the 89 PCOS women (73%) had
      increased serum free testosterone, 68 (76%) were insulin resistant, and 62 (70%) 
      had an impaired metabolic flexibility. Comparison of hyperandrogenemic and
      normoandrogenemic women showed that the 2 subgroups were of similar age but
      differed in terms of several anthropometric and metabolic features. In
      particular, hyperandrogenemic women had greater body mass index (32.9 +/- 1.0 vs 
      24.7 +/- 0.9 kg/m(2), P < .001) and lower glucose utilization during the clamp
      (9.2 +/- 0.4 vs 10.9 +/- 0.7 mg/kg fat-free mass . min, P = .023) and metabolic
      flexibility (0.09 +/- 0.06 vs 0.12 +/- 0.01, P = .014). In univariate analysis,
      metabolic flexibility was associated with several anthropometric, endocrine, and 
      metabolic features. In multivariate analysis, this feature was directly
      associated with baseline respiratory quotient and insulin sensitivity and
      inversely with free testosterone and free fatty acids concentrations under
      insulin suppression (R(2) = 0.634, P < .001). Conclusions: Metabolic
      inflexibility is a feature of PCOS women. Both insulin resistance and androgen
      excess might contribute to this abnormality.
AD  - Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine,
      University of Verona, P.le Stefani 1. I-37126 Verona, Italy.
      paolo.moghetti@univr.it.
FAU - Di Sarra, Daniela
AU  - Di Sarra D
FAU - Tosi, Flavia
AU  - Tosi F
FAU - Bonin, Cecilia
AU  - Bonin C
FAU - Fiers, Tom
AU  - Fiers T
FAU - Kaufman, Jean-Marc
AU  - Kaufman JM
FAU - Signori, Chiara
AU  - Signori C
FAU - Zambotti, Francesca
AU  - Zambotti F
FAU - Dall'alda, Marlene
AU  - Dall'alda M
FAU - Caruso, Beatrice
AU  - Caruso B
FAU - Zanolin, Maria Elisabetta
AU  - Zanolin ME
FAU - Bonora, Enzo
AU  - Bonora E
FAU - Moghetti, Paolo
AU  - Moghetti P
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/17 [aheadofprint]
AID - jc.2013-1161 [pii]
AID - 10.1210/jc.2013-1161 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Jun;98(6):2581-8. doi: 10.1210/jc.2013-1161. Epub
      2013 Apr 17.

PMID- 23596082
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
DP  - 2013 Apr 17
TI  - Racial/ethnic Differences in Clinical and Biochemical Type 2 Diabetes Mellitus
      Risk Factors in Children.
LID - 10.1002/oby.20483 [doi]
AB  - Objective: To examine whether peri-adolescent children demonstrate the
      significant racial/ethnic differences in body fatness relative to BMI and in the 
      prevalence and relationship of body composition to risk factors for type 2
      diabetes (T2DM) as in adults. Design and Methods: We examined family history of
      obesity and T2DM, anthropometry, insulin sensitivity and secretory capacity,
      lipids, and cytokines (IL-6, CRP, TNF-alpha, and adiponectin) in a cohort of 994 
      middle school students (47% male, 53%, female; 12% African American, 14% East
      Asian, 13% South Asian, 9% Caucasian, 44% Hispanic, and 8% other). Results:
      Fractional body fat content was significantly greater at any BMI among South
      Asians. There were racial/ethnic specific differences in lipid profiles, insulin 
      secretory capacity, insulin sensitivity, and inflammatory markers corrected for
      body fatness that are similar to those seen in adults. Family history of T2DM was
      associated with lower insulin secretory capacity while family history of obesity 
      was more associated with insulin resistance. Conclusion: Children show some of
      the same racial/ethnic differences in risk factors for adiposity-related
      co-morbidities as adults. BMI and waist circumference cutoffs to identify
      children at-risk for adiposity-related co-morbidities should be adjusted by
      racial/ethnic group as well as other variables such as birthweight and family
      history.
CI  - Copyright (c) 2013 The Obesity Society.
AD  - Pediatrics, New York Presbyterian Hospital/Columbia University Medical Center,
      New York, NY.
FAU - Rosenbaum, Michael
AU  - Rosenbaum M
FAU - Fennoy, Ilene
AU  - Fennoy I
FAU - Accacha, Siham
AU  - Accacha S
FAU - Altshuler, Lisa
AU  - Altshuler L
FAU - Carey, Dennis E
AU  - Carey DE
FAU - Holleran, Steven
AU  - Holleran S
FAU - Rapaport, Robert
AU  - Rapaport R
FAU - Shelov, Steven P
AU  - Shelov SP
FAU - Speiser, Phyllis W
AU  - Speiser PW
FAU - Ten, S
AU  - Ten S
FAU - Bhangoo, Amrit
AU  - Bhangoo A
FAU - Boucher-Berry, Claudia
AU  - Boucher-Berry C
FAU - Espinal, Yomery
AU  - Espinal Y
FAU - Gupta, Rishi
AU  - Gupta R
FAU - Hassoun, Abeer A
AU  - Hassoun AA
FAU - Iazetti, Loretta
AU  - Iazetti L
FAU - Jacques, Fabien J
AU  - Jacques FJ
FAU - Jean, Amy M
AU  - Jean AM
FAU - Klein, Michelle L
AU  - Klein ML
FAU - Levine, Robert
AU  - Levine R
FAU - Lowell, Barbara
AU  - Lowell B
FAU - Michel, Lesley
AU  - Michel L
FAU - Rosenfeld, Warren
AU  - Rosenfeld W
LA  - ENG
GR  - P30 DK063608/DK/NIDDK NIH HHS/United States
GR  - T32 DK065522/DK/NIDDK NIH HHS/United States
GR  - UL1 TR000040/TR/NCATS NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/06/30 [received]
PHST- 2013/03/21 [revised]
PHST- 2013/03/24 [accepted]
AID - 10.1002/oby.20483 [doi]
PST - aheadofprint
SO  - Obesity (Silver Spring). 2013 Apr 17. doi: 10.1002/oby.20483.

PMID- 23596049
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
DP  - 2013 Apr 17
TI  - Genetic and biochemical evidence for a functional role of BACE1 in the regulation
      of insulin mRNA expression.
LID - 10.1002/oby.20482 [doi]
AB  - Objective: Beta-site amyloid precursor protein cleaving enzyme (BACE-1) is highly
      expressed in pancreatic beta-cells. The BACE1 gene is located in a region
      associated with a high diabetes risk in PIMA Indians. Design and Methods: We used
      INS-1E cells to study the impact of siRNA-mediated BACE1 knockdown and
      characterized glucose metabolism in Bace1-/- mice. BACE1 gene was sequenced in
      DNA samples from 48 subjects and thirteen representative single nucleotide
      polymorphisms (SNPs) were then genotyped for association studies in 1,527
      Caucasians. Results: Reduction of Bace1 expression results in a significant
      decrease in insulin mRNA expression in INS-1E cells. Bace1-/- mice display
      significantly lower body weight, lower plasma insulin concentrations, but normal 
      glucose tolerance and insulin sensitivity. In a case-control study including 538 
      healthy controls and 989 patients with type 2 diabetes (T2D), one SNP (rs535860) 
      was significantly associated with T2D (P<3.5x10-5 , adjusted for age, sex and
      BMI). Conclusions: Reduced Bace1 expression causes impaired insulin expression in
      pancreatic beta-cells of Bace1-/- mice, suggesting that BACE1 plays a role in the
      regulation of insulin biogenesis. The functionally relevant rs535860 SNP may
      decrease BACE1 expression by creating a new miR-661 binding site and could
      therefore contribute to T2D development.
CI  - Copyright (c) 2013 The Obesity Society.
FAU - Hoffmeister, Albrecht
AU  - Hoffmeister A
FAU - Tuennemann, Jan
AU  - Tuennemann J
FAU - Sommerer, Ines
AU  - Sommerer I
FAU - Mossner, Joachim
AU  - Mossner J
FAU - Rittger, Andrea
AU  - Rittger A
FAU - Schleinitz, Dorit
AU  - Schleinitz D
FAU - Kratzsch, Jurgen
AU  - Kratzsch J
FAU - Rosendahl, Jonas
AU  - Rosendahl J
FAU - Kloting, Nora
AU  - Kloting N
FAU - Stahl, Tobias
AU  - Stahl T
FAU - Rossner, Steffen
AU  - Rossner S
FAU - Paroni, Federico
AU  - Paroni F
FAU - Maedler, Kathrin
AU  - Maedler K
FAU - Kovacs, Peter
AU  - Kovacs P
FAU - Bluher, Matthias
AU  - Bluher M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/07/16 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/03/18 [accepted]
AID - 10.1002/oby.20482 [doi]
PST - aheadofprint
SO  - Obesity (Silver Spring). 2013 Apr 17. doi: 10.1002/oby.20482.

PMID- 23595988
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 288
IP  - 22
DP  - 2013 May 31
TI  - Ligand-bound Thyroid Hormone Receptor Contributes to Reprogramming of Pancreatic 
      Acinar Cells into Insulin-producing Cells.
PG  - 16155-66
LID - 10.1074/jbc.M112.438192 [doi]
AB  - One goal of diabetic regenerative medicine is to instructively convert mature
      pancreatic exocrine cells into insulin-producing cells. We recently reported that
      ligand-bound thyroid hormone receptor alpha (TRalpha) plays a critical role in
      expansion of the beta-cell mass during postnatal development. Here, we used an
      adenovirus vector that expresses TRalpha driven by the amylase 2 promoter
      (AdAmy2TRalpha) to induce the reprogramming of pancreatic acinar cells into
      insulin-producing cells. Treatment with l-3,5,3-triiodothyronine increases the
      association of TRalpha with the p85alpha subunit of phosphatidylinositol 3-kinase
      (PI3K), leading to the phosphorylation and activation of Akt and the expression
      of Pdx1, Ngn3, and MafA in purified acinar cells. Analyses performed with the
      lectin-associated cell lineage tracing system and the Cre/loxP-based direct cell 
      lineage tracing system indicate that newly synthesized insulin-producing cells
      originate from elastase-expressing pancreatic acinar cells. Insulin-containing
      secretory granules were identified in these cells by electron microscopy. The
      inhibition of p85alpha expression by siRNA or the inhibition of PI3K by LY294002 
      prevents the expression of Pdx1, Ngn3, and MafA and the reprogramming to
      insulin-producing cells. In immunodeficient mice with streptozotocin-induced
      hyperglycemia, treatment with AdAmy2TRalpha leads to the reprogramming of
      pancreatic acinar cells to insulin-producing cells in vivo. Our findings suggest 
      that ligand-bound TRalpha plays a critical role in beta-cell regeneration during 
      postnatal development via activation of PI3K signaling.
AD  - From the Third Department of Internal Medicine and.
FAU - Furuya, Fumihiko
AU  - Furuya F
FAU - Shimura, Hiroki
AU  - Shimura H
FAU - Asami, Keiichi
AU  - Asami K
FAU - Ichijo, Sayaka
AU  - Ichijo S
FAU - Takahashi, Kazuya
AU  - Takahashi K
FAU - Kaneshige, Masahiro
AU  - Kaneshige M
FAU - Oikawa, Yoichi
AU  - Oikawa Y
FAU - Aida, Kaoru
AU  - Aida K
FAU - Endo, Toyoshi
AU  - Endo T
FAU - Kobayashi, Tetsuro
AU  - Kobayashi T
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
SB  - IM
PMC - PMC3668771
OID - NLM: PMC3668771 [Available on 05/31/14]
OTO - NOTNLM
OT  - Diabetes
OT  - Insulin
OT  - Pancreas
OT  - Phosphatidylinositol 3-Kinase
OT  - Thyroid Hormone
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PMCR- 2014/05/31 00:00
PHST- 2013/04/17 [aheadofprint]
AID - M112.438192 [pii]
AID - 10.1074/jbc.M112.438192 [doi]
PST - ppublish
SO  - J Biol Chem. 2013 May 31;288(22):16155-66. doi: 10.1074/jbc.M112.438192. Epub
      2013 Apr 17.

PMID- 23595987
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 288
IP  - 22
DP  - 2013 May 31
TI  - cAMP-responsive Element-binding Protein (CREB)-regulated Transcription
      Coactivator 2 (CRTC2) Promotes Glucagon Clearance and Hepatic Amino Acid
      Catabolism to Regulate Glucose Homeostasis.
PG  - 16167-76
LID - 10.1074/jbc.M113.460246 [doi]
AB  - cAMP-responsive element-binding protein (CREB)-regulated transcription
      coactivator 2 (CRTC2) regulates transcription of gluconeogenic genes by
      specifying targets for the transcription factor CREB in response to glucagon. We 
      used an antisense oligonucleotide directed against CRTC2 in both normal rodents
      and in rodent models of increased gluconeogenesis to better understand the role
      of CRTC2 in metabolic disease. In the context of severe hyperglycemia and
      elevated hepatic glucose production, CTRC2 knockdown (KD) improved glucose
      homeostasis by reducing endogenous glucose production. Interestingly, despite the
      known role of CRTC2 in coordinating gluconeogenic gene expression, CRTC2 KD in a 
      rodent model of type 2 diabetes resulted in surprisingly little alteration of
      glucose production. However, CRTC2 KD animals had elevated circulating
      concentrations of glucagon and a approximately 80% reduction in glucagon
      clearance. When this phenomenon was prevented with somatostatin or a
      glucagon-neutralizing antibody, endogenous glucose production was reduced by
      CRTC2 KD. Additionally, CRTC2 inhibition resulted in reduced expression of
      several glucagon-induced pyridoxal 5'-phosphate-dependent enzymes that convert
      amino acids to gluconeogenic intermediates, suggesting that it may control
      substrate availability as well as gluconeogenic gene expression. CRTC2 is an
      important regulator of gluconeogenesis with tremendous impact in models of
      elevated hepatic glucose production. Surprisingly, it is also part of a
      previously unidentified negative feedback loop that degrades glucagon and
      regulates amino acid metabolism to coordinately control glucose homeostasis in
      vivo.
AD  - From the Departments of Internal Medicine.
FAU - Erion, Derek M
AU  - Erion DM
FAU - Kotas, Maya E
AU  - Kotas ME
FAU - McGlashon, Jacob
AU  - McGlashon J
FAU - Yonemitsu, Shin
AU  - Yonemitsu S
FAU - Hsiao, Jennifer J
AU  - Hsiao JJ
FAU - Nagai, Yoshio
AU  - Nagai Y
FAU - Iwasaki, Takanori
AU  - Iwasaki T
FAU - Murray, Susan F
AU  - Murray SF
FAU - Bhanot, Sanjay
AU  - Bhanot S
FAU - Cline, Gary W
AU  - Cline GW
FAU - Samuel, Varman T
AU  - Samuel VT
FAU - Shulman, Gerald I
AU  - Shulman GI
FAU - Gillum, Matthew P
AU  - Gillum MP
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
SB  - IM
PMC - PMC3668772
OID - NLM: PMC3668772 [Available on 05/31/14]
OTO - NOTNLM
OT  - Amino Acid
OT  - CRTC2
OT  - Diabetes
OT  - Glucagon
OT  - Gluconeogenesis
OT  - Liver
OT  - Physiology
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PMCR- 2014/05/31 00:00
PHST- 2013/04/17 [aheadofprint]
AID - M113.460246 [pii]
AID - 10.1074/jbc.M113.460246 [doi]
PST - ppublish
SO  - J Biol Chem. 2013 May 31;288(22):16167-76. doi: 10.1074/jbc.M113.460246. Epub
      2013 Apr 17.

PMID- 23595969
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
DP  - 2013 Apr 17
TI  - Histone demethylase KDM1A represses inflammatory gene expression in
      preadipocytes.
LID - 10.1002/oby.20479 [doi]
AB  - OBJECTIVE: Persistent inflammation and impaired adipogenesis are frequent
      features of obesity and underlie the development of its complications. However,
      the factors behind adipose tissue dysfunction are not completely understood. We
      have previously shown that histone demethylase KDM1A is required for
      adipogenesis. DESIGN AND METHODS: Kdm1a expression was knocked down in 3T3-L1
      preadipocytes by siRNA transfection and whole-genome expression profiling was
      performed by microarray hybridization. The role of NF-kappabeta and C/EBPbeta was
      analyzed by incubation with the inhibitor parthenolide and by cebpb knockdown,
      respectively. RESULTS: Knockdown of kdm1a or rcor2 in 3T3-L1 preadipocytes
      results in impaired differentiation and induction of inflammatory gene
      expression. Enhanced expression of il6 in kdm1a knocked down preadipocytes is
      associated with increased recruitment of C/EBPbeta and the NF-beta subunit RelA
      to the il6 promoter. Cebpb knockdown attenuates the induction of il6 expression
      in kdm1a knocked down cells, whereas simultaneous cebpb knockdown and NF-beta
      inhibition abrogates it. Dietary-induced and genetic mouse models of obesity
      display decreased KDM1A in adipose tissue, and this correlates with increased
      expression of proinflammatory genes and C/EBPbeta. CONCLUSION: KDM1A represses
      the expression of inflammatory genes in preadipocytes. Dysregulated kdm1a
      expression in preadipocytes may thus participate in the development of
      obesity-associated inflammation.
CI  - Copyright (c) 2013 The Obesity Society.
AD  - Diabetes and Obesity Laboratory, IDIBAPS, CIBERDEM, Barcelona, Spain;
      Endocrinology and Nutrition Unit, Hospital Clinic, Barcelona, Spain.
FAU - Hanzu, Felicia A
AU  - Hanzu FA
FAU - Musri, Melina M
AU  - Musri MM
FAU - Sanchez-Herrero, Alvaro
AU  - Sanchez-Herrero A
FAU - Claret, Marc
AU  - Claret M
FAU - Esteban, Yaiza
AU  - Esteban Y
FAU - Kaliman, Perla
AU  - Kaliman P
FAU - Gomis, Ramon
AU  - Gomis R
FAU - Parrizas, Marcelina
AU  - Parrizas M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/11/30 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/03/20 [accepted]
AID - 10.1002/oby.20479 [doi]
PST - aheadofprint
SO  - Obesity (Silver Spring). 2013 Apr 17. doi: 10.1002/oby.20479.

PMID- 23595962
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1877-8755 (Electronic)
IS  - 1138-7548 (Linking)
DP  - 2013 Apr 18
TI  - Adverse cardiac responses to alpha-lipoic acid in a rat-diabetic model: possible 
      mechanisms?
AB  - Alpha-lipoic acid (ALA) is widely used as an antioxidant for the treatment of
      diabetes and its complications; however, the pro-oxidant potential of ALA has
      recently been reported. This study was designed to investigate whether ALA
      supplementation could have pro-oxidant effects on cardiac tissues in normal and
      diabetic rats. Diabetes was induced by a single dose of streptozotocin (STZ; 55
      mg/kg (intraperitoneal). Diabetic and normal rats were treated with ALA (100 mg
      kg-1 day-1) for 45 days. ALA supplementation resulted in oxidative protein damage
      as evident by significant reduction in the cardiac levels of protein thiol in
      ALA-treated normal rats (P < 0.01) together with a significant elevation (P <
      0.001) in the plasma levels of advanced oxidation protein products in ALA-treated
      normal rats and in ALA + STZ-diabetic rats compared with the normal control rats.
      Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase has emerged as the
      major source of superoxide anion and enhanced oxidative damage in heart failure. 
      ALA supplementation increased the myocardial immunoreactivity of p47phox subunit 
      of NADPH oxidase in both normal nondiabetic and diabetic rats reflecting its
      pro-oxidant effect. Data showed that ALA supplementation failed to prevent
      cardiac complications in diabetic rats and led to cardiac toxicity in normal rats
      as indicated by pathological changes (cellular infiltration, fibrosis, and
      degeneration) and by the elevation of serum cardiac biomarkers compared with
      normal controls. The pro-oxidant effects of ALA suggest that careful selection of
      appropriate doses of ALA in reactive oxygen species-related diseases are
      critical.
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud
      University, Riyadh, 11495, Kingdom of Saudi Arabia.
FAU - Al-Rasheed, Nouf M
AU  - Al-Rasheed NM
FAU - Al-Rasheed, Nawal M
AU  - Al-Rasheed NM
FAU - Attia, Hala A
AU  - Attia HA
FAU - Hasan, Iman H
AU  - Hasan IH
FAU - Al-Amin, Maha
AU  - Al-Amin M
FAU - Al-Ajmi, Hanaa
AU  - Al-Ajmi H
FAU - Mohamad, Raeesa A
AU  - Mohamad RA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Physiol Biochem
JT  - Journal of physiology and biochemistry
JID - 9812509
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/09/26 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s13105-013-0252-9 [doi]
PST - aheadofprint
SO  - J Physiol Biochem. 2013 Apr 18.

PMID- 23595950
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 97
IP  - 5
DP  - 2013 May
TI  - Predictors of anxiety and depression in Egyptian thalassemic patients: A single
      center study.
PG  - 604-9
LID - 10.1007/s12185-013-1322-z [doi]
AB  - Thalassemic patients are vulnerable to emotional and behavioral problems. Each
      patient age group exhibits problems unique to that stage of development, and
      although up to 80 % of thalassemic patients are likely to have psychological
      disorders, e.g., anxiety and depression, predictors of these disorders remain
      poorly understood. The present study was designed to assess the prevalence of
      anxiety and depression in a sample of Egyptian thalassemic patients and to
      identify predictors of these psychiatric disorders. A case-control study was
      conducted in 218 thalassemic patients, with 244 healthy subjects as a control.
      All patients and control subjects were subjected to thorough evaluation of
      medical history and clinical examination, and examined by a psychiatrist using
      the clinician version of the structured clinical interview for DSM-IV (SCID-CV), 
      hospital anxiety and depression scale and Coopersmith self-esteem inventory.
      Abnormal and borderline anxieties were reported by 36.7 and 20.6 % of thalassemic
      patients, respectively, while abnormal and borderline depressions were reported
      by 32.1 and 16.1 % of patients, respectively. Hospitalization, low self-esteem,
      diabetes mellitus and heart failure were independent predictors of anxiety. The
      independent predictors of depression were heart failure, hospitalization,
      diabetes mellitus, short stature and delayed puberty. Thalassemic patients were
      more vulnerable to anxiety and depression, indicating that screening and
      management for such psychiatric disorders should be considered in treating all
      such patients.
AD  - Pediatric Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt, 
      sohier_yahia@yahoo.com.
FAU - Yahia, Sohier
AU  - Yahia S
FAU - El-Hadidy, Mohamed Adel
AU  - El-Hadidy MA
FAU - El-Gilany, Abdel-Hady
AU  - El-Gilany AH
FAU - Anwar, Rokiah
AU  - Anwar R
FAU - Darwish, Ahmad
AU  - Darwish A
FAU - Mansour, A K
AU  - Mansour AK
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/12/20 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/03 [revised]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s12185-013-1322-z [doi]
PST - ppublish
SO  - Int J Hematol. 2013 May;97(5):604-9. doi: 10.1007/s12185-013-1322-z. Epub 2013
      Apr 18.

PMID- 23595890
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1432-1173 (Electronic)
IS  - 0017-8470 (Linking)
DP  - 2013 Apr 19
TI  - [Successful treatment of a patient with ulcerated necrobiosis lipoidica non
      diabeticorum with adalimumab.]
AB  - Necrobiosis lipoidica is a rare inflammatory granulomatous skin disease of
      unknown etiology which is associated with diabetes mellitus in about 60 % of the 
      patients. In up to 30 % of these patients extremely painful and often
      hard-to-heal ulcerations occur in the course of the disease. We present a new
      therapeutic option using adalimumab to treat refractory ulcerated necrobiosis
      lipoidica non diabeticorum. The clinical efficacy of adalimumab probably reflects
      an immunomodulatory effect through the specific TNF-alpha inhibition which is one
      central aspect of the underlying inflammation. Thus, adalimumab could represent
      promising new treatment option, especially for patients with otherwise
      therapy-refractory ulcerated necrobiosis lipoidica.
AD  - Klinik und Poliklinik fur Dermatologie, Venerologie und Allergologie,
      Universitatsklinikum Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
FAU - Leister, L
AU  - Leister L
FAU - Korber, A
AU  - Korber A
FAU - Dissemond, J
AU  - Dissemond J
LA  - GER
PT  - JOURNAL ARTICLE
TT  - Erfolgreiche Behandlung einer Patientin mit therapierefraktarer, exulzerierter
      Necrobiosis lipoidica non diabeticorum mit Adalimumab.
DEP - 20130419
TA  - Hautarzt
JT  - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
JID - 0372755
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1007/s00105-013-2535-z [doi]
PST - aheadofprint
SO  - Hautarzt. 2013 Apr 19.

PMID- 23595797
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 121
IP  - 4
DP  - 2013 Apr
TI  - Effect of pregabalin on erectile function and penile NOS expression in rats with 
      streptozotocin-induced diabetes.
PG  - 230-3
LID - 10.1055/s-0033-1341428 [doi]
AB  - OBJECTIVES: To investigate the effect of pregabalin on erectile function and on
      the penile expression of nitric oxide synthase (NOS) isoforms in diabetic rat
      models. METHODS: Male Sprague-Dawley rats were injected with streptozotocin to
      induce diabetes mellitus. The rats with blood glucose levels above 300 mg/dL were
      selected for the study. Those were randomly divided into 2 groups (N=10 per
      group): i) EDDM (erectile dysfunction diabetes mellitus) group fed with saline
      and ii) EDDM+Pregabalin treated group receiving pregabalin (10 mg/k/day) by
      intragastric administration. 10 animals served as a control group and received no
      streptozotocin. 4 weeks later, the erectile function of the rats was assessed by 
      recording frequency of erection after subcutaneous apomorphine (80 ug/kg)
      injection. Superoxide anion generation and the expression of mRNA of nNOS and
      eNOS were evaluated in corpora cavernosum tissue. RESULTS: Penile erection, the
      expression of both nNOS, eNOS and superoxide generation were significantly
      decreased in pregabalin treated group compared to control group. CONCLUSION:
      Treatment with pregabalin for 4 weeks decreases superoxide production but cannot 
      improve erectile dysfunction in diabetic rats probably by inhibiting Ca(2)(+)
      channel-mediated NOS activation.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Associate Professor of Clinical pharmacology, Clinical Pharmacology Department,
      Faculty of Medicine, Mansoura-University, Egypt. m_h_s_amany@yahoo.com
FAU - Amany, S
AU  - Amany S
FAU - Heba, K
AU  - Heba K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130417
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/17 [epublish]
AID - 10.1055/s-0033-1341428 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):230-3. doi: 10.1055/s-0033-1341428.
      Epub 2013 Apr 17.

PMID- 23595796
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 121
IP  - 4
DP  - 2013 Apr
TI  - Micro-inflammation characterized by disturbed Treg/Teff balance with increasing
      sIL-2R in patients with type 2 diabetes.
PG  - 214-9
LID - 10.1055/s-0033-1333687 [doi]
AB  - OBJECTIVES: Type 2 diabetes mellitus (T2DM) has been gradually considered as a
      micro- inflammatory disease. To explore the significance of peripheral CD4(+)
      regulatory T cells and CD4(+) effector T cells in T2DM, we analyzed inflammation,
      humoral and cellular immune state in patients with T2DM. PATIENTS AND METHODS:
      118 patients with T2DM without complications and 116 healthy volunteers were
      included. Serum C-reactive protein (CRP), Complement 3 (C3), Complement 4 (C4),
      IgG, IgA, IgM, plasma sIL-2 R and peripheral T lymphocyte subsets (including
      CD4(+)CD25(high) regulatory T cells (Treg) and CD4(+)CD25(low+median) effector T 
      cells (Teff)) were analyzed by rate nephelometry immunoassay, chemiluminescence
      immunoassay and flow cytometry, respectively. RESULTS: (1) micro-inflammation
      state in T2DM: Serum CRP, C3, IgA and plasma sIL-2 R were all significantly
      higher in T2DM than those in healthy control (HC) (all P<0.05). (2) Disturbance
      of cellular immune in T2DM: Compared with HC, the percentage of peripheral
      CD3(+)CD4(+)T cells and ratio of CD3(+)CD4(+)T cells to CD3(+)CD8(+)T cells in
      T2DM were both significantly increased (P<0.05); and the percentage of peripheral
      CD4(+)CD25(+)T cells, Teff cells increased (P>0.05), Treg cells strikingly
      decreased in T2DM (P<0.05). A positive correlation between sIL-2R levels and
      peripheral CD4(+)CD25(+)T cells or Teff cell percentages, as well as a negative
      correlation between plasma sIL-2 R levels and serum HDL, LDL or CHOL levels in
      T2DM were shown (all P <0.05). CONCLUSIONS: Micro-inflammation state in T2DM was 
      characterized by increased sIL-2 R, elevated CD3(+)CD4(+)T cells and the
      imbalance of Treg cells and Teff cells, which as one of the pathogeneses took
      part in inflammation reaction in T2DM.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Department of Laboratory Medicine, West China Hospital of Sichuan University,
      Sichuan, PR China.
FAU - Cai, B
AU  - Cai B
FAU - Zhang, J
AU  - Zhang J
FAU - Zhang, M
AU  - Zhang M
FAU - Li, L
AU  - Li L
FAU - Feng, W
AU  - Feng W
FAU - An, Z
AU  - An Z
FAU - Wang, L
AU  - Wang L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130417
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/17 [epublish]
AID - 10.1055/s-0033-1333687 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):214-9. doi: 10.1055/s-0033-1333687.
      Epub 2013 Apr 17.

PMID- 23595795
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 121
IP  - 4
DP  - 2013 Apr
TI  - Macroprolactinemia in patients with prolactinomas: prevalence and clinical
      significance.
PG  - 201-5
LID - 10.1055/s-0032-1333232 [doi]
AB  - BACKGROUND: Data on the prevalence of macroprolactinemia in patients with
      prolactinomas is quite limited as the presence of high-molecular prolactin forms 
      is suspected mainly in subjects with mild hyperprolactinemia and negative
      pituitary imaging. OBJECTIVE: The main objective of this observational
      case-control study was to assess the prevalence and clinical significance of
      macroprolactinemia among patients with prolactinomas. METHODS: The study
      population consisted of 239 subjects: 131 prolactinoma patients and 108 sex-,
      age- and ethnicity- matched healthy controls. Macroprolactinemia was defined by a
      PRL recovery after PEG precipitation of<40%. RESULTS: The prevalence of
      macroprolactinemia among newly diagnosed prolactinoma patients did not differ
      statistically from the prevalence in the control group (3.5 vs. 3.7%; p=1.000)
      but was lower although non-significantly than the subgroup of patients treated
      with dopamine agonists (DA) (3.5 vs.10.8%; p=0.072). Significant association
      between disruptions of ovarian function and serum levels of the monomeric as well
      as high-molecular prolactin isoform was found. CONCLUSIONS: In few cases, the
      presence of typical hyperprolactinemia-related clinical symptoms and their
      disappearance after treatment with DA suggests biological activity of
      macroprolactin comparable with that of monomeric prolactin isoform. Decrease of
      macroprolactin levels after DA treatment could suggest tumoral origin of the
      high-molecular isoform in these rare cases. Although macroprolactinemia is
      considered a benign condition, pituitary imaging, DA treatment, and prolonged
      follow-up may be necessary in certain cases. An individualized approach to the
      management of patients with macroprolactinemia should be applied.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
AD  - Clinical Centre of Endocrinology and Gerontology, Medical University, Sofia.
      atanaskae@yahoo.com
FAU - Elenkova, A
AU  - Elenkova A
FAU - Genov, N
AU  - Genov N
FAU - Abadzhieva, Z
AU  - Abadzhieva Z
FAU - Kirilov, G
AU  - Kirilov G
FAU - Vasilev, V
AU  - Vasilev V
FAU - Kalinov, K
AU  - Kalinov K
FAU - Zacharieva, S
AU  - Zacharieva S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130417
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/17 [epublish]
AID - 10.1055/s-0032-1333232 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):201-5. doi: 10.1055/s-0032-1333232.
      Epub 2013 Apr 17.

PMID- 23595787
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1436-2813 (Electronic)
IS  - 0941-1291 (Linking)
DP  - 2013 Apr 18
TI  - The outcomes of surgery in lung cancer patients with schizophrenia.
AB  - PURPOSE: There are very few reports regarding the outcome of lung cancer surgery 
      in patients with schizophrenia, and the clinical features of such patients are
      still unclear. METHODS: From 2004 to 2012, 11 lung cancer patients (six male,
      five female; mean age, 62.7 years) with schizophrenia underwent lung resections
      at our institutions. All patients had been institutionalized because they were
      unable to live independently at home. We retrospectively evaluated their
      postoperative clinical outcomes and long-term results. RESULTS: Ten of the 11
      patients had comorbidities, such as diabetes mellitus and chronic obstructive
      pulmonary disease. Preoperatively, two patients had a history of treatment for
      other primary cancers in other organs, and one was on hemodialysis. A lobectomy
      was performed in nine patients, a segmentectomy in one, and a partial resection
      in one. There were no hospital deaths. The postoperative morbidity included two
      cases of pneumonia, one of atelectasis, and one of prolonged air leakage lasting 
      more than 7 days. Wandering was postoperatively observed in two patients; one of 
      these fell and fractured the left femur. At the time of our investigation, two
      patients were deceased, and the overall 5-year survival rate was 74.1 %.
      CONCLUSIONS: The postoperative morbidity and long-term results of schizophrenic
      patients with lung cancer were acceptable. Therefore, even in patients with
      schizophrenia, surgical treatment for lung cancer should be recommended when
      deemed to be necessary.
AD  - Department of Thoracic Surgery, St. Mary's Hospital, Tsubuku-hon-machi 422,
      Kurume, 830-8543, Japan, fukuoka_obuchi@yahoo.co.jp.
FAU - Obuchi, Toshiro
AU  - Obuchi T
FAU - Okabayashi, Kan
AU  - Okabayashi K
FAU - Imakiire, Takayuki
AU  - Imakiire T
FAU - Yoneda, Satoshi
AU  - Yoneda S
FAU - Iwasaki, Akinori
AU  - Iwasaki A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Surg Today
JT  - Surgery today
JID - 9204360
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/12/21 [received]
PHST- 2013/04/01 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s00595-013-0599-0 [doi]
PST - aheadofprint
SO  - Surg Today. 2013 Apr 18.

PMID- 23595657
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 99
IP  - 12
DP  - 2013 Jun
TI  - Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year 
      follow-up in the Copenhagen Male Study.
PG  - 882-7
LID - 10.1136/heartjnl-2012-303375 [doi]
AB  - OBJECTIVE: To examine whether elevated resting heart rate (RHR) is an independent
      risk factor for mortality or a mere marker of physical fitness (VO2Max). METHODS:
      This was a prospective cohort study: the Copenhagen Male Study, a longitudinal
      study of healthy middle-aged employed men. Subjects with sinus rhythm and without
      known cardiovascular disease or diabetes were included. RHR was assessed from a
      resting ECG at study visit in 1985-1986. VO2Max was determined by the Astrand
      bicycle ergometer test in 1970-1971. Subjects were classified into categories
      according to level of RHR. Associations with mortality were studied in
      multivariate Cox models adjusted for physical fitness, leisure-time physical
      activity and conventional cardiovascular risk factors. RESULTS: 2798 subjects
      were followed for 16 years. 1082 deaths occurred. RHR was inversely related to
      physical fitness (p<0.001). Overall, increasing RHR was highly associated with
      mortality in a graded manner after adjusting for physical fitness, leisure-time
      physical activity and other cardiovascular risk factors. Compared to men with RHR
      </=50, those with RHR >90 had an HR (95% CI) of 3.06 (1.97 to 4.75). With RHR as 
      a continuous variable, risk of mortality increased with 16% (10-22) per 10 beats 
      per minute (bpm). There was a borderline interaction with smoking (p=0.07); risk 
      per 10 bpm increase in RHR was 20% (12-27) in smokers, and 14% (4-24) in
      non-smokers. CONCLUSIONS: Elevated RHR is a risk factor for mortality independent
      of physical fitness, leisure-time physical activity and other major
      cardiovascular risk factors.
AD  - Department of Cardiology, Copenhagen University Hospital Gentofte, Niels
      Andersens Vej 65, 2900 Hellerup, Denmark; magnustjensen@gmail.com.
FAU - Jensen, Magnus Thorsten
AU  - Jensen MT
FAU - Suadicani, Poul
AU  - Suadicani P
FAU - Hein, Hans Ole
AU  - Hein HO
FAU - Gyntelberg, Finn
AU  - Gyntelberg F
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
SB  - AIM
SB  - IM
PMC - PMC3664385
OID - NLM: PMC3664385
OTO - NOTNLM
OT  - Cardiac Function
OT  - Coronary Physiology
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/17 [aheadofprint]
AID - heartjnl-2012-303375 [pii]
AID - 10.1136/heartjnl-2012-303375 [doi]
PST - ppublish
SO  - Heart. 2013 Jun;99(12):882-7. doi: 10.1136/heartjnl-2012-303375. Epub 2013 Apr
      17.

PMID- 23595636
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1096-9071 (Electronic)
IS  - 0146-6615 (Linking)
DP  - 2013 Apr 17
TI  - A single amino acid substitution in viral VP1 protein alters the lytic potential 
      of clone-derived variants of echovirus 9 DM strain in human pancreatic islets.
LID - 10.1002/jmv.23574 [doi]
AB  - In vitro studies with primary human pancreatic islets suggest that several
      enterovirus serotypes are able to infect and replicate in beta cells. Some
      enterovirus strains are highly cytolytic in vitro whereas others show virus
      replication with no apparent islet destruction. The capability to induce islet
      destruction is determined only partially by the virus serotype, since strain
      specific differences have been detected within some serotypes including echovirus
      9 (E-9). In this study, the viral genetic factors determining the outcome of
      islet infection (i.e., destructive vs. benign) were investigated by constructing 
      parallel infectious clones of lytic E-9-DM strain that was isolated from a small 
      child at the clinical onset of type 1 diabetes. The capabilities of these
      clone-derived viruses to induce islet destruction were monitored and the lytic
      potential of clones was modified by site-directed mutagenesis. The lytic
      capabilities of these clone-derived viruses in human pancreatic islets were
      modified by a single amino acid substitution (T81A) in the capsid protein VP1.
      The data presented outline the importance of amino acid point mutations in the
      pathogenetic process leading to islet necrosis. However, although the amino acid 
      substitution (T81A) modifies the lytic capabilities of E-9-DM strain-derived
      microvariant strains, it is likely that additional viral genetic determinants of 
      pancreatic islet pathogenicity exist in other E-9 strains. J. Med. Virol. (c)
      2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Intestinal Viruses Unit, National Institute for Health and Welfare, Helsinki,
      Finland.
FAU - Paananen, A
AU  - Paananen A
FAU - Ylipaasto, P
AU  - Ylipaasto P
FAU - Smura, T
AU  - Smura T
FAU - Lempinen, M
AU  - Lempinen M
FAU - Galama, J
AU  - Galama J
FAU - Roivainen, M
AU  - Roivainen M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - J Med Virol
JT  - Journal of medical virology
JID - 7705876
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/02/06 [accepted]
AID - 10.1002/jmv.23574 [doi]
PST - aheadofprint
SO  - J Med Virol. 2013 Apr 17. doi: 10.1002/jmv.23574.

PMID- 23595620
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1460-2199 (Electronic)
IS  - 1047-3211 (Linking)
DP  - 2013 Apr 17
TI  - Altered Expression of Diabetes-Related Genes in Alzheimer's Disease Brains: The
      Hisayama Study.
AB  - Diabetes mellitus (DM) is considered to be a risk factor for dementia including
      Alzheimer's disease (AD). However, the molecular mechanism underlying this risk
      is not well understood. We examined gene expression profiles in postmortem human 
      brains donated for the Hisayama study. Three-way analysis of variance of
      microarray data from frontal cortex, temporal cortex, and hippocampus was
      performed with the presence/absence of AD and vascular dementia, and sex, as
      factors. Comparative analyses of expression changes in the brains of AD patients 
      and a mouse model of AD were also performed. Relevant changes in gene expression 
      identified by microarray analysis were validated by quantitative real-time
      reverse-transcription polymerase chain reaction and western blotting. The
      hippocampi of AD brains showed the most significant alteration in gene expression
      profile. Genes involved in noninsulin-dependent DM and obesity were significantly
      altered in both AD brains and the AD mouse model, as were genes related to
      psychiatric disorders and AD. The alterations in the expression profiles of
      DM-related genes in AD brains were independent of peripheral DM-related
      abnormalities. These results indicate that altered expression of genes related to
      DM in AD brains is a result of AD pathology, which may thereby be exacerbated by 
      peripheral insulin resistance or DM.
AD  - Division of Neurofunctional Genomics, Department of Immunobiology and
      Neuroscience, Medical Institute of Bioregulation.
FAU - Hokama, Masaaki
AU  - Hokama M
FAU - Oka, Sugako
AU  - Oka S
FAU - Leon, Julio
AU  - Leon J
FAU - Ninomiya, Toshiharu
AU  - Ninomiya T
FAU - Honda, Hiroyuki
AU  - Honda H
FAU - Sasaki, Kensuke
AU  - Sasaki K
FAU - Iwaki, Toru
AU  - Iwaki T
FAU - Ohara, Tomoyuki
AU  - Ohara T
FAU - Sasaki, Tomio
AU  - Sasaki T
FAU - Laferla, Frank M
AU  - Laferla FM
FAU - Kiyohara, Yutaka
AU  - Kiyohara Y
FAU - Nakabeppu, Yusaku
AU  - Nakabeppu Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Cereb Cortex
JT  - Cerebral cortex (New York, N.Y. : 1991)
JID - 9110718
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - bht101 [pii]
AID - 10.1093/cercor/bht101 [doi]
PST - aheadofprint
SO  - Cereb Cortex. 2013 Apr 17.

PMID- 23595611
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
DP  - 2013 Apr 18
TI  - Current status of bariatric surgery in Japan and effectiveness in obesity and
      diabetes.
AB  - The rate of obesity in Japan, defined as having a body mass index (BMI) of 25
      kg/m2 or greater, is reportedly at 24 %, a lower level of severe obesity than in 
      the EU and US. However, the incidence of obesity-related health problems is
      reportedly higher among Asians. Laparoscopic sleeve gastrectomy (LSG) is the most
      frequently performed bariatric surgery in Japan and accounted for 54 % of such
      surgeries in 2011; procedures such as laparoscopic adjustable gastric banding and
      laparoscopic Roux-en-Y gastric bypass (LRYGB), practiced frequently worldwide,
      were uncommon. Possible reasons include concern over delayed postoperative
      discovery of gastric cancer in LRYGB, and rapid adoption of the comparatively
      simple LSG procedure. In type 2 diabetes mellitus (T2DM) patients, where
      continued pursuit of medical treatment is difficult and a potential exists for
      future deterioration of diabetes-complicated diseases, the criterion for surgical
      indication in the EU and US is a BMI of 30-35 kg/m2, with priority given to BMI
      >35 kg/m2. For Asian patients, the recommendation is to lower this indication
      criterion by 2.5 kg/m2. Efficacy of metabolic surgery is anticipated particularly
      among T2DM patients with obesity complication, a short history of insulin
      treatment, and intact insulin secreting ability, and in these cases bariatric
      surgery should be contemplated.
AD  - Department of Surgery, Iwate Medical University School of Medicine, Morioka,
      Japan.
FAU - Sasaki, Akira
AU  - Sasaki A
FAU - Wakabayashi, Go
AU  - Wakabayashi G
FAU - Yonei, Yoshikazu
AU  - Yonei Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/01/18 [received]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s00535-013-0802-5 [doi]
PST - aheadofprint
SO  - J Gastroenterol. 2013 Apr 18.

PMID- 23595529
OWN - NLM
STAT- In-Data-Review
DA  - 20130418
IS  - 1994-8220 (Print)
VI  - 16
IP  - 2
DP  - 2013 Mar
TI  - Problem drinking and associated factors in older adults in South Africa.
PG  - 104-9
LID - http://dx.doi.org/10.4314/ajpsy.v16i2.13 [doi]
AB  - OBJECTIVE: Alcohol abuse poses special risks for increased morbidity and
      mortality among older adults. Little attention has focused on assessing alcohol
      use and associated factors among older adults in transitional societies such as
      South Africa. This study aimed to determine the prevalence of alcohol use and
      associated factors in older South Africans who participated in the Study of
      Global Ageing and Adults Health (SAGE) in 2008. METHOD: We conducted a national
      population-based cross-sectional study with a sample of 3840 aged 50 years or
      older in South Africa in 2008. In this study we analysed data from all 2144
      participants who were over 60 years old. The questionnaire included
      socio-demographic characteristics, alcohol intake as well as comorbidity. Risky
      drinking was defined in two ways: heavy drinkers (>7 drinks/week) and binge
      drinkers (>3 drinks/one occasion/week). RESULTS: Four percent of participants
      reported heavy drinking and 3.7% binge drinking. Male gender (Odds Ratio (OR)
      =3.79, Confidence Interval (CI) =1.38-10.37) and white population group (OR=3.01,
      CI=1.31-6.89) were associated with risky drinking in multivariate analysis; as
      well as tobacco use (OR=5.25, CI=2.20-12.52) and not being obese (OR=0.14,
      CI=0.05-0.35). Hypertension, diabetes and depression were not associated.
      CONCLUSION: This study reveals moderate rates of risky drinking among older
      adults (60 years and more) in South Africa that puts them at risk of morbidity.
      Alcohol problems among older adults are commonly under-recognized, indicating a
      need for health care worker intervention.
AD  - HIV/AIDS/SIT/and TB (HAST), Human Sciences Research Council, Pretoria South
      Africa.
FAU - Peltzer, K
AU  - Peltzer K
FAU - Phaswana-Mafuya, N
AU  - Phaswana-Mafuya N
LA  - eng
PT  - Journal Article
PL  - South Africa
TA  - Afr J Psychiatry (Johannesbg)
JT  - African journal of psychiatry
JID - 101465030
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/01/31 [received]
PHST- 2012/02/28 [accepted]
AID - http://dx.doi.org/10.4314/ajpsy.v16i2.13 [doi]
PST - ppublish
SO  - Afr J Psychiatry (Johannesbg). 2013 Mar;16(2):104-9. doi:
      http://dx.doi.org/10.4314/ajpsy.v16i2.13.

PMID- 23595523
OWN - NLM
STAT- Publisher
DA  - 20130607
IS  - 1613-7671 (Electronic)
IS  - 0043-5325 (Linking)
VI  - 125
IP  - 9-10
DP  - 2013 May
TI  - Moderate- and vigorous-intensity exercise behaviour according to the
      Transtheoretical Model: associations with smoking and BMI among Austrian adults.
PG  - 270-278
AB  - INTRODUCTION: Regular physical activity leads to a number of physiological
      benefits, such as reduced risk of coronary heart disease, diabetes mellitus and
      obesity. In Austria, there is little information about the prevalence of
      physically inactive people, as well as about who is more likely to belong to the 
      inactive or irregularly active groups. The aim of this study is to describe the
      socio-demographic distributions across the stages of behavioural change for
      moderate- and vigorous-intensity physical activity, according to the
      Transtheoretical Model, and to identify associations with smoking and body mass
      index (BMI). METHOD: Data were collected in a standardised procedure using a
      self-report questionnaire from 489 adults who attended a health check in an
      outpatient clinic in southern Austria. Height and weight were measured by
      physicians. The subjects were categorised into the five stages of change
      (pre-contemplation, contemplation, preparation, action, maintenance), separately 
      assessed for moderate- and vigorous-intensity physical activity. RESULTS: The
      likelihood of being in the stage of maintenance of moderate-intensity physical
      activity was highest in older subjects (p < 0.05). Participants of a high
      educational level showed the highest likelihood of being physically active in
      vigorous-intensity physical activity (p < 0.05). Furthermore, the lowest stages
      of change behaviour were associated with higher BMI levels for vigorous-intensity
      physical activity (p < 0.05). Smokers were significantly (p < 0.05) more likely
      not to perform vigorous-intensity physical activity than non-smokers. CONCLUSION:
      Our findings contribute to a better understanding of behavioural correlates of
      regular physical activity. The results may prove useful for developing promotion 
      programmes for physical activity, allowing targeting of the identified risk
      groups.
AD  - Institute for Social Medicine and Epidemiology, Medical University of Graz,
      Universitatsplatz 6/I, 8010, Graz, Austria, franziska.grossschaedl@medunigraz.at.
FAU - Grossschadl, Franziska
AU  - Grossschadl F
FAU - Titze, Sylvia
AU  - Titze S
FAU - Burkert, Nathalie
AU  - Burkert N
FAU - Stronegger, Willibald J
AU  - Stronegger WJ
LA  - ENG
PT  - JOURNAL ARTICLE
TT  - Korperliche und sportliche Aktivitat in Anlehnung an das Transtheoretische
      Modell: Zusammenhange mit Rauchen und BMI bei Erwachsenen in Osterreich.
DEP - 20130418
TA  - Wien Klin Wochenschr
JT  - Wiener klinische Wochenschrift
JID - 21620870R
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/12/10 [received]
PHST- 2013/03/20 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s00508-013-0361-z [doi]
PST - ppublish
SO  - Wien Klin Wochenschr. 2013 May;125(9-10):270-278. Epub 2013 Apr 18.

PMID- 23595384
OWN - NLM
STAT- In-Data-Review
DA  - 20130418
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 126
IP  - 8
DP  - 2013 Apr
TI  - Accelerated healing of diabetic wound using artificial dermis constructed with
      adipose stem cells and poly (L-glutamic acid)/chitosan scaffold.
PG  - 1498-503
AB  - BACKGROUND: Diabetic wound is one of the most serious complications of diabetes
      mellitus. There are no significantly effective therapies for chronic non-healing 
      diabetes ulcer so far. This study aimed to explore the feasibility of healing
      impaired wound using artificial dermis constructed with human adipose derived
      stem cells (ASCs) and poly (L-glutamic acid)/chitosan (PLGA/CS) scaffold in
      streptozotocin-induced diabetic mice. METHODS: ASCs were isolated from fresh
      human lipoaspirates and expanded ex vivo for three passages, and then cells were 
      seeded onto PLGA/CS scaffold to form artificial dermis. Expression of VEGF and
      TGFbeta1 by ASCs presented in artificial dermis was determined. The artificial
      dermis was transplanted to treat the 20 mm x 20 mm full-thickness cutaneous wound
      created on the back of diabetic mice. Wound treated with scaffold alone and
      without treatment, and wound in normal non-diabetic mice served as control.
      RESULTS: Cells growing within scaffold showed great proliferation potential,
      depositing abundant collagen matrix. Meanwhile, expression of VEGF and TGF-beta1 
      by seeded ASCs maintained at a consistent high level. After treated with ASC
      based artificial dermis, diabetic wounds exhibited significantly higher healing
      rate compared with wounds treated with scaffold alone or without treatment.
      Histological examination also demonstrated an improvement in cutaneous
      restoration with matrix deposition and organization. Further quantitative
      analysis showed that there was a significant increase in dermis thickness and
      collagen content on artificial dermis treated wounds. CONCLUSION: ASC/PLGA
      artificial dermis can effectively accelerate diabetic wound healing by promoting 
      angiogenic growth factors and dermal collagen synthesis.
AD  - Department of Ophthalmology, Zhejiang Provincial People's Hospital, Hangzhou,
      Zhejiang 310014, China.
FAU - Shen, Ting
AU  - Shen T
FAU - Pan, Zhi-Gang
AU  - Pan ZG
FAU - Zhou, Xiao
AU  - Zhou X
FAU - Hong, Chao-Yang
AU  - Hong CY
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PST - ppublish
SO  - Chin Med J (Engl). 2013 Apr;126(8):1498-503.

PMID- 23595358
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Linking)
VI  - 15
IP  - 3
DP  - 2013 Jun
TI  - Role of ambulatory blood pressure monitoring in hypertension and diabetes.
PG  - 137-42
LID - 10.1007/s11906-013-0352-5 [doi]
AB  - The prevalence of hypertension and diabetes are both rising in the USA and around
      the globe. The treatment of hypertension in the ambulatory setting begins with
      proper blood pressure measurement, and often the involvement of home blood
      pressure monitoring. If the diagnosis of hypertension is confirmed, then
      education on lifestyle modifications is the foundation to reaching blood pressure
      goals. If it is unclear, then ambulatory blood pressure monitoring should be
      performed to properly evaluate daily trends in blood pressure. The National
      Institute for Health and Clinical excellence (NICE) recommends 24-hour ambulatory
      blood pressure evaluation in all newly diagnosed patients with hypertension. The 
      much-anticipated JNC 2013, while not likely to endorse this approach, will likely
      recommend an office goal systolic blood pressure of less than 140 mmHg in
      patients with diabetes as do the most recent American Diabetes Association
      clinical practice guidelines. All new guidelines are derived from a critical
      evidence based evaluation of the available data.
AD  - Department of Medicine, ASH Comprehensive Hypertension Center, Section of
      Endocrinology, Diabetes and Metabolism, The University of Chicago Medicine, 5841 
      S. Maryland Ave. MC 1027, Chicago, IL, 60637, USA.
FAU - Flynn, Colleen
AU  - Flynn C
FAU - Bakris, George L
AU  - Bakris GL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1007/s11906-013-0352-5 [doi]
PST - ppublish
SO  - Curr Hypertens Rep. 2013 Jun;15(3):137-42. doi: 10.1007/s11906-013-0352-5.

PMID- 23595343
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1573-9104 (Electronic)
IS  - 0921-9668 (Linking)
VI  - 68
IP  - 2
DP  - 2013 Jun
TI  - Cooked Common Beans (Phaseolus vulgaris) Protect Against beta-cell Damage in
      Streptozotocin-Induced Diabetic Rats.
PG  - 207-12
LID - 10.1007/s11130-013-0353-1 [doi]
AB  - Diabetes is a disease characterized by a hyperglycemic stage that leads to a
      chronic inflammatory state. We evaluated the in vivo effect of a diet
      supplemented with 25 % cooked black bean cultivar Negro 8025 (N8025) flour in
      streptozotocin-induced diabetic rats. The effect was assessed before
      (preventive-treatment) and after (treatment) the onset of diabetes. There is a
      significant decrease of total phenolic, tannins and anthocyanins content after
      cooking, and the concentration of most of the single phenols analyzed are only
      slightly decreased. The treatment group showed a significant reduction of glucose
      (22.8 %), triglycerides (21.9 %), total cholesterol (29.9 %) and LDL (56.1 %)
      that correlates with a protection of pancreatic ss-cells. The diet with N8025
      flour before the induction of diabetes did not exert a protective effect (glucose
      levels are similar to the diabetic control) but they have low levels of total
      cholesterol (47.5 %) and LDL (56.1 %). The preventive-treatment group did not
      inhibit the increase of TNF-alpha and IL-1beta, whereas the treatment group did, 
      compared to the diabetic control. Therefore, N8025 bean supplementation can be
      recommended to control diabetes.
AD  - Research and Graduate Studies in Food Science, School of Chemistry, UAQ, Santiago
      de Queretaro, Queretaro, Mexico.
FAU - Hernandez-Saavedra, Diego
AU  - Hernandez-Saavedra D
FAU - Mendoza-Sanchez, Magdalena
AU  - Mendoza-Sanchez M
FAU - Hernandez-Montiel, Hebert L
AU  - Hernandez-Montiel HL
FAU - Guzman-Maldonado, Horacio S
AU  - Guzman-Maldonado HS
FAU - Loarca-Pina, Guadalupe F
AU  - Loarca-Pina GF
FAU - Salgado, Luis M
AU  - Salgado LM
FAU - Reynoso-Camacho, Rosalia
AU  - Reynoso-Camacho R
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Plant Foods Hum Nutr
JT  - Plant foods for human nutrition (Dordrecht, Netherlands)
JID - 8803554
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1007/s11130-013-0353-1 [doi]
PST - ppublish
SO  - Plant Foods Hum Nutr. 2013 Jun;68(2):207-12. doi: 10.1007/s11130-013-0353-1.

PMID- 23595248
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Co-regulation of intragenic microRNA miR-153 and its host gene Ia-2 beta:
      identification of miR-153 target genes with functions related to IA-2beta in
      pancreas and brain.
PG  - 1547-56
LID - 10.1007/s00125-013-2901-5 [doi]
AB  - AIMS/HYPOTHESIS: We analysed the genomic organisation of miR-153, a microRNA
      embedded in genes that encode two of the major type 1 diabetes autoantigens,
      islet-associated protein (IA)-2 and IA-2beta. We also identified miR-153 target
      genes that correlated with IA-2beta localisation and function. METHODS: A
      bioinformatics approach was used to identify miR-153's genomic organisation. To
      analyse the co-regulation of miR-153 and IA-2beta, quantitative PCR analysis of
      miR-153 and Ia-2beta (also known as Ptprn2) was performed after a glucose
      stimulation assay in MIN6B cells and isolated murine pancreatic islets, and also 
      in wild-type Ia-2 (also known as Ptprn), Ia-2beta single knockout and
      Ia-2/Ia-2beta double knockout mouse brain and pancreatic islets. Bioinformatics
      identification of miR-153 target genes and validation via luciferase reporter
      assays, western blotting and quantitative PCR were also carried out. RESULTS: Two
      copies of miR-153, miR-153-1 and miR-153-2, are localised in intron 19 of Ia-2
      and Ia-2beta, respectively. In rodents, only miR-153-2 is conserved. We
      demonstrated that expression of miR-153-2 and Ia-2beta in rodents is partially
      co-regulated as demonstrated by a strong reduction of miR-153 expression levels
      in Ia-2beta knockout and Ia-2/Ia-2beta double knockout mice. miR-153 levels were 
      unaffected in Ia-2 knockout mice. In addition, glucose stimulation, which
      increases Ia-2 and Ia-2beta expression, also significantly increased expression
      of miR-153. Several predicted targets of miR-153 were reduced after glucose
      stimulation in vitro, correlating with the increase in miR-153 levels.
      CONCLUSIONS/INTERPRETATION: This study suggests the involvement of miR-153,
      IA-2beta and miR-153 target genes in a regulatory network, which is potentially
      relevant to insulin and neurotransmitter release.
AD  - VIB Center for the Biology of Disease, Gasthuisberg O&N4, Herestraat 49-bus 602, 
      3000, Leuven, Belgium.
FAU - Mandemakers, W
AU  - Mandemakers W
FAU - Abuhatzira, L
AU  - Abuhatzira L
FAU - Xu, H
AU  - Xu H
FAU - Caromile, L A
AU  - Caromile LA
FAU - Hebert, S S
AU  - Hebert SS
FAU - Snellinx, A
AU  - Snellinx A
FAU - Morais, V A
AU  - Morais VA
FAU - Matta, S
AU  - Matta S
FAU - Cai, T
AU  - Cai T
FAU - Notkins, A L
AU  - Notkins AL
FAU - De Strooper, B
AU  - De Strooper B
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
PMC - PMC3671108
OID - NLM: PMC3671108
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/01/23 [received]
PHST- 2013/02/26 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s00125-013-2901-5 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1547-56. doi: 10.1007/s00125-013-2901-5. Epub 2013
      Apr 18.

PMID- 23595247
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Expression of anti-inflammatory macrophage genes within skeletal muscle
      correlates with insulin sensitivity in human obesity and type 2 diabetes.
PG  - 1623-8
LID - 10.1007/s00125-013-2897-x [doi]
AB  - AIMS/HYPOTHESIS: Low-grade systemic inflammation and adipose tissue inflammatory 
      macrophages are frequently detected in patients with obesity and type 2 diabetes.
      Whether inflammatory macrophages also increase in skeletal muscle of individuals 
      with metabolic disorders remains controversial. Here, we assess whether
      macrophage polarisation markers in skeletal muscle of humans correlate with
      insulin sensitivity in obesity and type 2 diabetes. METHODS: Skeletal muscle
      biopsies were obtained from individuals of normal weight and with normal glucose 
      tolerance (NGT), and overweight/obese individuals with or without type 2
      diabetes. Insulin sensitivity was determined by euglycaemic-hyperinsulinaemic
      clamps. Expression of macrophage genes was analysed by quantitative RT-PCR.
      RESULTS: Gene expression of the inflammatory macrophage phenotype marker cluster 
      of differentiation (CD)11c was higher in muscle of type 2 diabetes patients (p = 
      0.0069), and correlated with HbA1c (p = 0.0139, rho = 0.48) and fasting plasma
      glucose (p = 0.0284, rho = 0.43), but not after correction for age. Expression of
      TGFB1, encoding the anti-inflammatory marker TGF-beta1, correlated inversely with
      HbA1c (p = 0.0095, rho = -0.50; p = 0.0484, rho = -0.50) and fasting plasma
      glucose (p = 0.0471, rho = -0.39; p = 0.0374, rho = -0.52) in two cohorts, as did
      HbA1c with gene expression of macrophage galactose-binding lectin (MGL) (p =
      0.0425, rho = -0.51). TGFB1 expression was higher in NGT individuals than in
      individuals with type 2 diabetes (p = 0.0303), and correlated with low fasting
      plasma insulin (p = 0.0310, rho = -0.42). In exercised overweight/obese
      individuals, expression of genes for three anti-inflammatory macrophage markers, 
      MGL (p = 0.0031, rho = 0.71), CD163 (p = 0.0268, rho = 0.57) and mannose receptor
      (p = 0.0125, rho = 0.63), correlated with high glucose-disposal rate.
      CONCLUSIONS/INTERPRETATION: Muscle expression of macrophage genes reveals a link 
      between inflammatory macrophage markers, age and high glycaemia, whereas
      anti-inflammatory markers correlate with low glycaemia and high glucose-disposal 
      rate.
AD  - Cell Biology Program, The Hospital for Sick Children, 555 University Avenue,
      Toronto, ON, Canada, M5G 1X8.
FAU - Fink, L N
AU  - Fink LN
FAU - Oberbach, A
AU  - Oberbach A
FAU - Costford, S R
AU  - Costford SR
FAU - Chan, K L
AU  - Chan KL
FAU - Sams, A
AU  - Sams A
FAU - Bluher, M
AU  - Bluher M
FAU - Klip, A
AU  - Klip A
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/12/21 [received]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s00125-013-2897-x [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1623-8. doi: 10.1007/s00125-013-2897-x. Epub 2013
      Apr 18.

PMID- 23595206
OWN - NLM
STAT- Publisher
DA  - 20130516
IS  - 1438-2199 (Electronic)
IS  - 0939-4451 (Linking)
DP  - 2013 Apr 18
TI  - Functional amino acids in nutrition and health.
AB  - The recent years have witnessed growing interest in biochemistry, physiology and 
      nutrition of amino acids (AA) in growth, health and disease of humans and other
      animals. This results from the discoveries of AA in cell signaling involving
      protein kinases, G protein-coupled receptors, and gaseous molecules (i.e., NO, CO
      and H2S). In addition, nutritional studies have shown that dietary
      supplementation with several AA (e.g., arginine, glutamine, glutamate, leucine,
      and proline) modulates gene expression, enhances growth of the small intestine
      and skeletal muscle, or reduces excessive body fat. These seminal findings led to
      the new concept of functional AA, which are defined as those AA that participate 
      in and regulate key metabolic pathways to improve health, survival, growth,
      development, lactation, and reproduction of the organisms. Functional AA hold
      great promise in prevention and treatment of metabolic diseases (e.g., obesity,
      diabetes, and cardiovascular disorders), intrauterine growth restriction,
      infertility, intestinal and neurological dysfunction, and infectious disease
      (including viral infections).
AD  - Department of Animal Science, Department of Veterinary Integrative Biosciences,
      and Faculty of Nutrition, Texas A&M University, College Station, TX, 77845, USA, 
      g-wu@tamu.edu.
FAU - Wu, Guoyao
AU  - Wu G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Amino Acids
JT  - Amino acids
JID - 9200312
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/07 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1007/s00726-013-1500-6 [doi]
PST - aheadofprint
SO  - Amino Acids. 2013 Apr 18.

PMID- 23595176
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with 
      type 2 diabetes mellitus.
LID - 10.1136/bcr-2012-008528 [doi]
LID - bcr2012008528 [pii]
AB  - Hypoglycaemia is a well-recognised untoward effect of sulfonylureas. We report a 
      case of severe hypoglycaemia after isoniazid initiation in a type 2 diabetic
      patient. An oral glucose tolerance test revealed high serum insulin and C
      peptide, suggesting hyperinsulinaemia, and it was used to ascertain the
      relationship between insulin, glucose and C peptide levels. Insulin and C peptide
      elevation was attributed to the interaction between the two drugs. As a
      cytochrome inhibitor, isoniazid increased serum glimepiride concentration,
      resulting in hyperinsulinaemia. The diagnosis of occult insulinoma or
      nesidioblastosis was ruled out by CT and MRI, as we could not perform more
      sensitive, still invasive, diagnostic procedures. After isoniazid withdrawal,
      hypoglycaemia regressed and glimepiride was reinitiated. In conclusion, this case
      illustrates the need of caution when prescribing isoniazid in patients with type 
      2 diabetes mellitus receiving glimepiride to avoid hypoglycaemia.
AD  - Department of Pneumonology, Democritus University of Thrace, Alexandroupolis,
      Greece.
FAU - Boglou, Panagiotis
AU  - Boglou P
FAU - Steiropoulos, Paschalis
AU  - Steiropoulos P
FAU - Papanas, Nikolaos
AU  - Papanas N
FAU - Bouros, Demosthenes
AU  - Bouros D
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - bcr-2012-008528 [pii]
AID - 10.1136/bcr-2012-008528 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 16;2013. pii: bcr2012008528. doi: 10.1136/bcr-2012-008528.

PMID- 23595174
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - An ulcerated nodule on the nose.
LID - 10.1136/bcr-2012-008296 [doi]
LID - bcr2012008296 [pii]
AB  - A 75-year-old retired nurse, originally from Barbados, presented to her general
      practitioner (GP) with a scaling ulcerated nodule on the left side of her nose.
      She was taking medication for type 2 diabetes, hypertension and glaucoma, but was
      otherwise well with no systemic symptoms. Her GP diagnosed a patch of eczema;
      however, a trial of topical steroids was not effective and she was referred to
      dermatology. A skin biopsy confirmed the clinical suspicion that this patient had
      a nodular basal cell carcinoma (BCC). BCCs account for 75% of all skin cancers;
      they very rarely metastasise, but can spread to invade local structures. Our
      patient has type VI skin. Skin cancer is rare in patients with skin type VI;
      however, in this group, morbidity and mortality are disproportionately high in
      relation to cancer incidence.
AD  - Department of Dermatology, Guys and St Thomas' Hospital Trust, London, UK.
      catriona.maybury@gmail.com
FAU - Maybury, Catriona M
AU  - Maybury CM
FAU - Craythorne, Emma
AU  - Craythorne E
FAU - Martin, Blanca
AU  - Martin B
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - bcr-2012-008296 [pii]
AID - 10.1136/bcr-2012-008296 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 16;2013. pii: bcr2012008296. doi: 10.1136/bcr-2012-008296.

PMID- 23595159
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1476-5527 (Electronic)
IS  - 0950-9240 (Linking)
DP  - 2013 Apr 18
TI  - Biomarkers of cardiovascular risk in sleep-deprived people.
LID - 10.1038/jhh.2013.27 [doi]
AB  - The global increase in both coronary heart disease (CHD) and cardiovascular
      disease (CVD) and the associated increase in undetected subclinical
      cardiovascular pathology highlight the continuing need for improved risk
      prediction. Traditional risk factors fail to identify all 'at-risk' individuals. 
      Although new risk factors, associated with endothelial function, inflammatory and
      oxidative stress pathways, for example, have been identified, studies have often 
      observed only minimal improved risk classification when such markers are added.
      We examine the emerging evidence that short sleep may be a risk factor for
      obesity, type 2 diabetes and hypertension, and an independent predictor of
      stroke, CHD and CVD. We examine the underlying mechanisms and the evidence to
      suggest that short sleep may modulate the association between established factors
      and CVD. We consider whether the levels of markers of obesity and appetite
      control, energy metabolism, glucose homoeostasis, inflammation, thrombosis and
      haemostasis, which are affected by short duration of sleep, might be useful
      predictors of the risk of developing CVD. Finally, the usefulness of such markers
      for disease detection, management and prevention is considered.Journal of Human
      Hypertension advance online publication, 18 April 2013; doi:10.1038/jhh.2013.27.
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
FAU - Miller, M A
AU  - Miller MA
FAU - Cappuccio, F P
AU  - Cappuccio FP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Hum Hypertens
JT  - Journal of human hypertension
JID - 8811625
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/18 [aheadofprint]
AID - jhh201327 [pii]
AID - 10.1038/jhh.2013.27 [doi]
PST - aheadofprint
SO  - J Hum Hypertens. 2013 Apr 18. doi: 10.1038/jhh.2013.27.

PMID- 23595158
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1476-5527 (Electronic)
IS  - 0950-9240 (Linking)
DP  - 2013 Apr 18
TI  - Association of the G-protein beta3 subunit gene polymorphism with the incidence
      of cardiovascular disease independent of hypertension: the Funagata study.
LID - 10.1038/jhh.2013.28 [doi]
AB  - Association of the C825T G-protein beta3 subunit (GNB3) gene polymorphism with
      cardiovascular disease (CVD) incidence was examined in a population-based
      longitudinal study of the Japanese individuals. The incidence of CVD (stroke and 
      coronary heart disease (CHD)) was assessed in a cohort population (n=1524)
      consisting of participants of the 2001-2005 Funagata study through March 2008.
      Cumulative incidences according to genotype were compared with the Kaplan-Meier
      product-limit method. During the follow-up, 78 subjects experienced a CVD event
      (stroke: n=54; CHD: n=30; both consecutively: n=6). At the end of the follow-up
      (longest and median follow-up periods: 81 and 68 months, respectively), the
      cumulative incidence of CVD for the TT genotype was significantly higher than
      that of the C-carriers (0.077 vs 0.042, P=0.004). Blood pressures and the
      prevalence of hypertension were not different between the genotypes. Cox's
      proportional hazard analysis showed that the TT genotype is a significant risk
      factor for CVD (hazard ratio (HR)=1.82 (95% confidence interval (CI) 1.14-2.89); 
      P=0.012) and stroke (HR=1.76 (95% CI: 1.01-3.07); P=0.048) incidences after
      adjustment for age, sex, hypertension, hyperlipidemia, diabetes, alcohol drinking
      and smoking at baseline. The TT genotype of the C825T GNB3 gene polymorphism was 
      found to be a significant risk factor for the incidence of CVD and stroke
      independent of hypertension and other established CVD risk factors in a Japanese 
      population.Journal of Human Hypertension advance online publication, 18 April
      2013; doi:10.1038/jhh.2013.28.
AD  - 1] Department of Neurology, Hematology, Metabolism, Endocrinology and Diabetology
      (DNHMED), Yamagata University School of Medicine, Yamagata, Japan [2] Global
      Center of Excellence Program Study Group, Yamagata University School of Medicine,
      Yamagata, Japan.
FAU - Daimon, M
AU  - Daimon M
FAU - Sato, H
AU  - Sato H
FAU - Kaino, W
AU  - Kaino W
FAU - Tada, K
AU  - Tada K
FAU - Takase, K
AU  - Takase K
FAU - Karasawa, S
AU  - Karasawa S
FAU - Wada, K
AU  - Wada K
FAU - Kameda, W
AU  - Kameda W
FAU - Susa, S
AU  - Susa S
FAU - Oizumi, T
AU  - Oizumi T
FAU - Kayama, T
AU  - Kayama T
FAU - Muramatsu, M
AU  - Muramatsu M
FAU - Kato, T
AU  - Kato T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Hum Hypertens
JT  - Journal of human hypertension
JID - 8811625
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/18 [aheadofprint]
AID - jhh201328 [pii]
AID - 10.1038/jhh.2013.28 [doi]
PST - aheadofprint
SO  - J Hum Hypertens. 2013 Apr 18. doi: 10.1038/jhh.2013.28.

PMID- 23595139
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1524-4563 (Electronic)
IS  - 0194-911X (Linking)
VI  - 61
IP  - 5
DP  - 2013 May
TI  - Diabetes mellitus and vascular disease.
PG  - 943-7
LID - 10.1161/HYPERTENSIONAHA.111.00612 [doi]
AD  - Professor of Medicine, and Medical Pharmacology and Physiology, Director Division
      of Endocrinology and Metabolism, Director of the Diabetes and Cardiovascular
      Center of Excellence, University of Missouri-Columbia School of Medicine, One
      Hospital Dr, Columbia, MO 65212, USA. sowersj@health.missouri.edu
FAU - Sowers, James R
AU  - Sowers JR
LA  - eng
GR  - R01 HL073101/HL/NHLBI NIH HHS/United States
GR  - R01 HL107910/HL/NHLBI NIH HHS/United States
GR  - R01 HL107910-01/HL/NHLBI NIH HHS/United States
GR  - R01 HL73101-01A1/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Hypertension
JT  - Hypertension
JID - 7906255
SB  - IM
PMC - PMC3648858
MID - NIHMS454161
OID - NLM: NIHMS454161 [Available on 05/01/14]
OID - NLM: PMC3648858 [Available on 05/01/14]
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PMCR- 2014/05/01 00:00
AID - 61/5/943 [pii]
AID - 10.1161/HYPERTENSIONAHA.111.00612 [doi]
PST - ppublish
SO  - Hypertension. 2013 May;61(5):943-7. doi: 10.1161/HYPERTENSIONAHA.111.00612.

PMID- 23595124
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Linking)
DP  - 2013 Apr 18
TI  - Replication study for the association of a single-nucleotide polymorphism,
      rs3746876, within KCNJ15, with susceptibility to type 2 diabetes in a Japanese
      population.
LID - 10.1038/jhg.2013.28 [doi]
AB  - By an association mapping for the candidate locus in chromosome 21q, rs3746876
      within KCNJ15 was shown to be associated with type 2 diabetes in Japanese
      populations. However, the association of rs3746876 with type 2 diabetes has not
      been validated in an independent cohort. The aim of the present study was to
      ascertain the association of rs3746876 with type 2 diabetes in an independent
      larger Japanese sample. We genotyped 7885 Japanese participants (4967 individuals
      with type 2 diabetes and 2918 control individuals) for rs3746876 with
      polymerase-chain reaction-invader assay. The association of rs3746876 with type 2
      diabetes was examined by using logistic regression analysis. Quantitative traits 
      analyses for homeostasis model assessment (HOMA) of beta-cell function, HOMA of
      insulin resistance, fasting plasma glucose, fasting immunoreactive insulin and
      body mass index (BMI) were performed in control individuals by using
      multiple-linear regression analysis. We observed a significant association of
      rs3746876-T with type 2 diabetes (P=0.0281, odds ratio (OR)=0.82, 95% confidence 
      interval (CI, 0.68-0.98)), but the direction of effect was opposite to that in
      the original report. The association of rs3746876 with type 2 diabetes was more
      significant in obese patients (BMI>/=25 kg m-2, P=0.0025, OR=0.62, 95% CI,
      0.45-0.84). We did not observe significant association of rs3746876 with any of
      the quantitative traits in the control individuals. We could not replicate the
      original finding for the association of rs3746876 with type 2 diabetes, although 
      rs3746876 was significantly associated with obese type 2 diabetes in the present 
      Japanese population.Journal of Human Genetics advance online publication, 18
      April 2013; doi:10.1038/jhg.2013.28.
AD  - 1] Laboratory for Endocrinology and Metabolism, RIKEN Center for Genomic
      Medicine, Yokohama, Japan [2] Division of Metabolism and Endocrinology,
      Department of Internal Medicine, St Marianna University School of Medicine,
      Kawasaki, Kanagawa, Japan.
FAU - Fukuda, Hisashi
AU  - Fukuda H
FAU - Imamura, Minako
AU  - Imamura M
FAU - Tanaka, Yasushi
AU  - Tanaka Y
FAU - Iwata, Minoru
AU  - Iwata M
FAU - Hirose, Hiroshi
AU  - Hirose H
FAU - Kaku, Kohei
AU  - Kaku K
FAU - Maegawa, Hiroshi
AU  - Maegawa H
FAU - Watada, Hirotaka
AU  - Watada H
FAU - Tobe, Kazuyuki
AU  - Tobe K
FAU - Kashiwagi, Atsunori
AU  - Kashiwagi A
FAU - Kawamori, Ryuzo
AU  - Kawamori R
FAU - Maeda, Shiro
AU  - Maeda S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/18 [aheadofprint]
AID - jhg201328 [pii]
AID - 10.1038/jhg.2013.28 [doi]
PST - aheadofprint
SO  - J Hum Genet. 2013 Apr 18. doi: 10.1038/jhg.2013.28.

PMID- 23595122
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Linking)
DP  - 2013 Apr 18
TI  - WFS1 variants in Finnish patients with diabetes mellitus, sensorineural hearing
      impairment or optic atrophy, and in suicide victims.
LID - 10.1038/jhg.2013.29 [doi]
AB  - Mutations in the wolframin gene, WFS1, cause Wolfram syndrome, a rare recessive
      neurodegenerative disorder. The clinical features include early-onset bilateral
      optic atrophy (OA), diabetes mellitus (DM), diabetes insipidus, hearing
      impairment, urinary tract abnormalities and psychiatric illness, and,
      furthermore, WFS1 variants appear to be associated with non-syndromic DM and
      hearing impairment. Variation of WFS1 was investigated in Finnish subjects
      consisting 182 patients with DM, 117 patients with sensorineural hearing
      impairment (SNHI) and 44 patients with OA, and in 95 suicide victims. Twenty-two 
      variants were found in the coding region of WFS1, including three novel
      nonsynonymous variants. The frequency of the p.[His456] allele was significantly 
      higher in the patients with SNHI (11.5%; corrected P=0.00008), DM (6.6%;
      corrected P=0.036) or OA (9.1%; corrected P=0.043) than that in the 285 controls 
      (3.3%). The frequency of the p.[His611] allele was 55.8% in the patients with DM 
      being higher than that in the controls (47%; corrected P=0.039). The frequencies 
      of p.[His456] and p.[His611] were similarly increased in an independent group of 
      patients with DM (N=299). The results support previous findings that genetic
      variation of WFS1 contributes to the risk of DM and SNHI.Journal of Human
      Genetics advance online publication, 18 April 2013; doi:10.1038/jhg.2013.29.
AD  - 1] Department of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland 
      [2] Department of Neurology, Oulu University Hospital, Oulu, Finland [3] Clinical
      Research Center, Oulu University Hospital, Oulu, Finland.
FAU - Kytovuori, Laura
AU  - Kytovuori L
FAU - Seppanen, Allan
AU  - Seppanen A
FAU - Martikainen, Mika H
AU  - Martikainen MH
FAU - Moilanen, Jukka S
AU  - Moilanen JS
FAU - Kamppari, Seija
AU  - Kamppari S
FAU - Sarkioja, Terttu
AU  - Sarkioja T
FAU - Remes, Anne M
AU  - Remes AM
FAU - Rasanen, Pirkko
AU  - Rasanen P
FAU - Ronnemaa, Tapani
AU  - Ronnemaa T
FAU - Majamaa, Kari
AU  - Majamaa K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/18 [aheadofprint]
AID - jhg201329 [pii]
AID - 10.1038/jhg.2013.29 [doi]
PST - aheadofprint
SO  - J Hum Genet. 2013 Apr 18. doi: 10.1038/jhg.2013.29.

PMID- 23595104
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1476-5489 (Electronic)
IS  - 0955-9930 (Linking)
DP  - 2013 Apr 18
TI  - Panax notoginseng saponins improve the erectile dysfunction in diabetic rats by
      protecting the endothelial function of the penile corpus cavernosum.
LID - 10.1038/ijir.2013.19 [doi]
AB  - Diabetes mellitus (DM)-associated ED is predominantly due to neurovascular
      dysfunction mediated by nitric oxide (NO) suppression. Panax notoginseng saponins
      (PNS) are widely used for treating cardiovascular disease in China. The aim of
      this study was to evaluate the effects of PNS on penile erection and corpus
      cavernosum tissues in rats with diabetes-associated ED. Four weeks after PNS
      treatment, erectile function was assessed by intracavernous pressure (ICP) and
      mean arterial pressure (MAP) measurements. The level of NO, cyclic guanosine
      monophosphate (cGMP) and advanced glycation end products (AGEs) in cavernous
      tissue were assessed. Immunohistochemical staining and TUNEL (terminal
      deoxynucleotidyl transferase dUTP nick end labeling) were performed for detecting
      endothelial NO synthase (eNOS) and apoptosis, respectively. The results show that
      ICP/MAP ratio was significantly increased in high-dose (150 mg kg-1 per day)
      PNS-treated group compared with the diabetic ED untreated group (DM group).
      Compared with the untreated group, the expression of eNOS and the levels of NO
      and cGMP were increased in the PNS-treated groups. Moreover, apoptosis was
      markedly decreased in the group that received 150 mg kg-1 per day of PNS. These
      results suggest that PNS may be used for improving the ED in diabetic rats via
      the NO/cGMP pathway and restores the function of endothelium in corpus
      cavernosum.International Journal of Impotence Research advance online
      publication, 18 April 2013; doi:10.1038/ijir.2013.19.
AD  - Department of Urology, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Lin, F
AU  - Lin F
FAU - Gou, X
AU  - Gou X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130418
TA  - Int J Impot Res
JT  - International journal of impotence research
JID - 9007383
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/18 [aheadofprint]
AID - ijir201319 [pii]
AID - 10.1038/ijir.2013.19 [doi]
PST - aheadofprint
SO  - Int J Impot Res. 2013 Apr 18. doi: 10.1038/ijir.2013.19.

PMID- 23595044
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1348-4214 (Electronic)
IS  - 0916-9636 (Linking)
VI  - 36
IP  - 6
DP  - 2013 Jun
TI  - Resistant hypertension and target organ damage.
PG  - 485-91
LID - 10.1038/hr.2013.30 [doi]
AB  - Cardiovascular (CV) complications such as myocardial infarction, heart failure,
      stroke and renal failure are related to both the degree and the duration of blood
      pressure (BP) increase. Resistant hypertension (RH) is associated with a higher
      risk of CV complications and a higher prevalence of target organ damage (TOD).
      The relationship between CV disease and TOD can be bidirectional. Elevated BP in 
      RH may cause CV structural and functional alterations, and the development or
      persistence of left ventricular hypertrophy, aortic stiffness, atherosclerotic
      plaques, microvascular disease and renal dysfunction, may render hypertension
      more difficult to control. Specifically, RH is related to several conditions,
      including obesity, sleep apnea, diabetes, metabolic syndrome and
      hyperaldosteronism, characterized by an overexpression of humoral and hormonal
      factors that are involved in the development and maintenance of TOD. Optimal
      therapeutic strategies, including pharmacological treatment and innovative
      invasive methodologies, have been shown to achieve adequate BP control and induce
      the regression of TOD, thereby potentially improving patient prognosis.
AD  - Clinica Medica, Department of Clinical and Experimental Sciences, University of
      Brescia, Brescia, Italy.
FAU - Muiesan, Maria Lorenza
AU  - Muiesan ML
FAU - Salvetti, Massimo
AU  - Salvetti M
FAU - Rizzoni, Damiano
AU  - Rizzoni D
FAU - Paini, Anna
AU  - Paini A
FAU - Agabiti-Rosei, Claudia
AU  - Agabiti-Rosei C
FAU - Aggiusti, Carlo
AU  - Aggiusti C
FAU - Agabiti Rosei, Enrico
AU  - Agabiti Rosei E
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - England
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/18 [aheadofprint]
AID - hr201330 [pii]
AID - 10.1038/hr.2013.30 [doi]
PST - ppublish
SO  - Hypertens Res. 2013 Jun;36(6):485-91. doi: 10.1038/hr.2013.30. Epub 2013 Apr 18.

PMID- 23594962
OWN - NLM
STAT- Publisher
DA  - 20130604
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Linking)
VI  - 15
IP  - 2
DP  - 2013 Apr 17
TI  - Anti-inflammatory properties of a dual PPARgamma/alpha agonist muraglitazar in in
      vitro and in vivo models.
PG  - R51
AB  - INTRODUCTION: Peroxisome proliferator-activated receptor (PPAR) agonists are
      widely used drugs in the treatment of diabetes and dyslipidemia. In addition to
      their metabolic effects, PPAR isoforms PPARalpha and PPARgamma are also involved 
      in the regulation of immune responses and inflammation. In the present study, we 
      investigated the effects of a dual PPARgamma/alpha agonist muraglitazar on
      inflammatory gene expression in activated macrophages and on carrageenan-induced 
      inflammation in the mouse. METHODS: J774 murine macrophages were activated by
      lipopolysaccharide (LPS) and treated with dual PPARgamma/alpha agonist
      muraglitazar, PPARgamma agonist GW1929 or PPARalpha agonist fenofibrate. The
      effects of PPAR agonists on cytokine production and the activation of inducible
      nitric oxide synthase (iNOS) pathway were investigated by ELISA, Griess method,
      Western blotting and quantitative RT-PCR. Nuclear translocation, DNA-binding
      activity and reporter gene assays were used to assess the activity of nuclear
      factor kappa B (NF-kB) transcription factor. Carrageenan-induced paw oedema was
      used as an in vivo model of acute inflammation. RESULTS: Muraglitazar as well as 
      PPARgamma agonist GW1929 and PPARalpha agonist fenofibrate inhibited LPS-induced 
      iNOS expression and NO production in activated macrophages in a dose-dependent
      manner. Inhibition of iNOS expression by muraglitazar included both
      transcriptional and post-transcriptional components; the former being shared by
      GW1929 and the latter by fenofibrate. All tested PPAR agonists also inhibited
      IL-6 production, while TNFalpha production was reduced by muraglitazar and
      GW1929, but not by fenofibrate. Interestingly, the anti-inflammatory properties
      of muraglitazar were also translated in vivo. This was evidenced by the finding
      that muraglitazar inhibited carrageenan-induced paw inflammation in a
      dose-dependent manner in mice as did iNOS inhibitor L-NIL and anti-inflammatory
      steroid dexamethasone. CONCLUSIONS: These results show that muraglitazar has
      anti-inflammatory properties both in vitro and in vivo and these effects reflect 
      the agonistic action through both PPARalpha and PPARgamma.
AD  - The Immunopharmacology Research Group, University of Tampere School of Medicine
      and Tampere University Hospital, Medisiinarinkatu 3, Tampere, FI-33014, Finland. 
      eeva.moilanen@uta.fi.
FAU - Paukkeri, Erja-Leena
AU  - Paukkeri EL
FAU - Leppanen, Tiina
AU  - Leppanen T
FAU - Lindholm, Mira
AU  - Lindholm M
FAU - Yam, Mun Fei
AU  - Yam MF
FAU - Asmawi, Mohd Zaini
AU  - Asmawi MZ
FAU - Kolmonen, Anne
AU  - Kolmonen A
FAU - Aulaskari, Paula H
AU  - Aulaskari PH
FAU - Moilanen, Eeva
AU  - Moilanen E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/08/20 [received]
PHST- 2013/02/14 [revised]
PHST- 2013/04/09 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - ar4211 [pii]
AID - 10.1186/ar4211 [doi]
PST - aheadofprint
SO  - Arthritis Res Ther. 2013 Apr 17;15(2):R51.

PMID- 23594859
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1421-9824 (Electronic)
IS  - 1420-8008 (Linking)
VI  - 35
IP  - 5-6
DP  - 2013
TI  - Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain
      imaging.
PG  - 280-90
LID - 10.1159/000348407 [doi]
AB  - Background/Aims: We attempted to define possible subgroups of Alzheimer's disease
      (AD) associated with diabetes mellitus (DM) based on brain imaging. Methods: We
      classified 175 patients with clinically diagnosed AD and type 2 DM into 4
      subgroups on the basis of the presence or absence of cerebrovascular disease
      (CVD) on MRI (CVD or no CVD) and posterior cerebral hypoperfusion on SPECT (AD
      pattern or no AD pattern). Differences in the clinical characteristics among the 
      subgroups were examined. Results: The subgroup showing neither a CVD pattern nor 
      an AD pattern had significantly older age, higher hemoglobin A1c level, longer
      duration of diabetes, higher frequency of insulin therapy, lower frequency of
      apolipoprotein E4 carriers, less severe medial temporal lobe atrophy, more
      impaired attention, less impaired word recall, and slower progression of
      cognitive impairment than the subgroup showing an AD pattern. We found no
      characteristic features of other subgroups. Conclusion: The clinical features of 
      subjects with AD associated with DM may differ depending on brain imaging
      patterns. Among them, there may be a dementia subgroup with characteristics
      predominantly associated with DM-related metabolic abnormalities.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.
FAU - Fukazawa, Raita
AU  - Fukazawa R
FAU - Hanyu, Haruo
AU  - Hanyu H
FAU - Sato, Tomohiko
AU  - Sato T
FAU - Shimizu, Soichiro
AU  - Shimizu S
FAU - Koyama, Shunichi
AU  - Koyama S
FAU - Kanetaka, Hidekazu
AU  - Kanetaka H
FAU - Sakurai, Hirofumi
AU  - Sakurai H
FAU - Iwamoto, Toshihiko
AU  - Iwamoto T
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - Switzerland
TA  - Dement Geriatr Cogn Disord
JT  - Dementia and geriatric cognitive disorders
JID - 9705200
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/01/01 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - 000348407 [pii]
AID - 10.1159/000348407 [doi]
PST - ppublish
SO  - Dement Geriatr Cogn Disord. 2013;35(5-6):280-90. doi: 10.1159/000348407. Epub
      2013 Apr 13.

PMID- 23594857
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
DP  - 2013 Apr 16
TI  - Fracture Risk in Kidney Transplant Recipients: A Systematic Review.
AB  - BACKGROUND: Fractures in men and women after kidney transplantation are
      associated with morbidity (including acute and chronic pain), mortality, and high
      economic costs. METHODS: We systematically reviewed cohort studies that provided 
      estimates on incidence and risk factors for fracture in kidney transplant
      recipients. We abstracted data in duplicate and assessed the methodological
      quality of each study on a 17-point scale (17 representing the highest quality). 
      RESULTS: We screened 2715 articles, reviewed 81, and included 10 studies totaling
      262,678 recipients (study mean, 26,268 recipients; range, 61-77,430). The average
      follow-up ranged from 1.7 to 5.3 years. The study quality scores ranged from 8 to
      13. Fracture sites varied by study resulting in a highly variable incidence rate 
      ranging from 3.3 to 99.6 fractures per 1000 person-years. Similarly, the 5-year
      cumulative incidence for fracture varied ranging from 0.85% to 27%. Common
      factors associated with an increased fracture risk were older age, female sex,
      the presence of diabetes, and receipt of dialysis before transplantation. Other
      less common but statistically significant risk factors were a previous history of
      fracture and receipt of a kidney from a deceased (vs. living) donor. CONCLUSIONS:
      There is poor consensus on the incidence and risk factors for fractures in kidney
      transplant recipients. Previous studies vary substantially in quality, fracture
      definitions, and the characteristics of recipients studied. Future research
      should clarify fracture incidence and risk, which will inform the design of
      future prevention trials and guide prognostication.
AD  - 1 Division of Nephrology, Western University, London, Ontario, Canada. 2
      Department of Epidemiology & Biostatistics, Western University, London, Ontario, 
      Canada. 3 Department of Medicine, University of Toronto, Toronto, Ontario,
      Canada. 4 Multidisciplinary Osteoporosis Program, Women's College Hospital,
      Toronto, Ontario, Canada. 5 Women's College Research Institute, Women's College
      Hospital, Toronto, Ontario, Canada. 6 Institute for Clinical Evaluative Sciences,
      Toronto, Ontario, Canada. 7 Address correspondence to: Kyla L. Naylor, B.H.K.,
      M.E.S., London Kidney Clinical Research Unit, Room ELL-101, Westminster, London
      Health Sciences Centre, 800 Commissioners Road East, London, Ontario N6A 4G5,
      Canada.
FAU - Naylor, Kyla L
AU  - Naylor KL
FAU - Li, Alvin H
AU  - Li AH
FAU - Lam, Ngan N
AU  - Lam NN
FAU - Hodsman, Anthony B
AU  - Hodsman AB
FAU - Jamal, Sophie A
AU  - Jamal SA
FAU - Garg, Amit X
AU  - Garg AX
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Transplantation
JT  - Transplantation
JID - 0132144
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1097/TP.0b013e31828eead8 [doi]
PST - aheadofprint
SO  - Transplantation. 2013 Apr 16.

PMID- 23594831
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
DP  - 2013 Apr 17
TI  - Risk assessment for incident heart failure in individuals with atrial
      fibrillation.
AB  - BackgroundAtrial fibrillation (AF) is a strong risk factor for heart failure
      (HF); HF onset in patients with AF is associated with increased morbidity and
      mortality. Risk factors that predict HF in individuals with AF in the community
      are not well established. METHODS AND RESULTS: We examined clinical variables
      related to the 10-year incidence of HF in 725 individuals (mean 73.3 years, 45%
      women) with documented AF in the Framingham Heart Study. Event rates for incident
      HF (n = 161, 48% in women) were comparable in women (4.30 per 100 person-years)
      and men (3.34 per 100 person-years). Age, body mass index, ECG LV hypertrophy,
      diabetes, significant murmur, and history of myocardial infarction were
      positively associated with incident HF in multivariable models (C-statistic 0.71;
      95% confidence interval 0.67-0.75). We developed a risk algorithm for estimating 
      absolute risk of HF in AF patients with good model fit and calibration (adjusted 
      calibration chi2 statistic 7.29; Pchi2 = 0.61). Applying the algorithm, 47.6% of 
      HF events occurred in the top tertile in men compared with 13.1% in the bottom
      tertile, and 58.4% in women in the upper tertile compared with 18.2% in the
      lowest category. For HF type, women had a non-significantly higher incidence of
      HF with preserved EF compared with men. CONCLUSIONS: We describe advancing age,
      LV hypertrophy, body mass index, diabetes, significant heart murmur, and history 
      of myocardial infarction as clinical predictors of incident HF in individuals
      with AF. A risk algorithm may help identify individuals with AF at high risk of
      developing HF.
AD  - NHLBI's and Boston University's Framingham Heart Study, Framingham, MA, USA.
FAU - Schnabel, Renate B
AU  - Schnabel RB
FAU - Rienstra, Michiel
AU  - Rienstra M
FAU - Sullivan, Lisa M
AU  - Sullivan LM
FAU - Sun, Jenny X
AU  - Sun JX
FAU - Moser, Carlee B
AU  - Moser CB
FAU - Levy, Daniel
AU  - Levy D
FAU - Pencina, Michael J
AU  - Pencina MJ
FAU - Fontes, Joao D
AU  - Fontes JD
FAU - Magnani, Jared W
AU  - Magnani JW
FAU - McManus, David D
AU  - McManus DD
FAU - Lubitz, Steven A
AU  - Lubitz SA
FAU - Tadros, Thomas M
AU  - Tadros TM
FAU - Wang, Thomas J
AU  - Wang TJ
FAU - Ellinor, Patrick T
AU  - Ellinor PT
FAU - Vasan, Ramachandran S
AU  - Vasan RS
FAU - Benjamin, Emelia J
AU  - Benjamin EJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - hft041 [pii]
AID - 10.1093/eurjhf/hft041 [doi]
PST - aheadofprint
SO  - Eur J Heart Fail. 2013 Apr 17.

PMID- 23594830
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1423-0143 (Electronic)
IS  - 1420-4096 (Linking)
VI  - 37
IP  - 2-3
DP  - 2013
TI  - Angiotensinogen polymorphisms and post-transplantation diabetes mellitus in
      korean renal transplant subjects.
PG  - 95-102
LID - 10.1159/000343404 [doi]
AB  - Background : Post-transplant diabetes mellitus (PTDM) is a common and serious
      metabolic complication. Genetic polymorphisms of angiotensin-converting enzyme
      (ACE) and angiotensinogen (AGT) genes have been reported to be related to
      diabetes mellitus and insulin sensitivity; however, the role of these genes in
      the development of PTDM is not known. For this purpose, we investigated the
      association of ACE and AGT genetic polymorphisms with PTDM. Methods : A total of 
      302 subjects without previously diagnosed diabetes who had received kidney
      transplants were included. One ACE single nucleotide polymorphism (SNP) (rs4291) 
      and two AGT SNPs (rs 699 and rs 4762) were genotyped from genomic DNA with direct
      sequencing. Results : PTDM developed in 49 (16.2%) of 302 subjects. Subjects in
      the PTDM were older than those in the non-PTDM. There was a significant
      difference between the two groups in tacrolimus use (p=0.03). Of the three SNPs, 
      the rs4762 of the AGT gene was significantly associated with the development of
      PTDM in the dominant models (p = 0.03) after adjusting for age and tacrolimus
      usage. Conclusions : AGT gene rs4762 polymorphisms may serve as genetic markers
      for the development of PTDM. The exact molecular mechanisms still need to be
      clarified.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Division of Nephrology, School of Medicine, Kyung Hee University, Seoul, Republic
      of Korea.
FAU - Lee, Sul Ra
AU  - Lee SR
FAU - Moon, Joo Young
AU  - Moon JY
FAU - Lee, Sang Ho
AU  - Lee SH
FAU - Ihm, Chun Gyoo
AU  - Ihm CG
FAU - Lee, Tae Won
AU  - Lee TW
FAU - Kim, Su Kang
AU  - Kim SK
FAU - Chung, Joo-Ho
AU  - Chung JH
FAU - Kang, Sun Woo
AU  - Kang SW
FAU - Kim, Tae Hee
AU  - Kim TH
FAU - Park, Seok Ju
AU  - Park SJ
FAU - Kim, Yeong Hoon
AU  - Kim YH
FAU - Jeong, Kyung Hwan
AU  - Jeong KH
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Switzerland
TA  - Kidney Blood Press Res
JT  - Kidney & blood pressure research
JID - 9610505
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/03/08 [accepted]
PHST- 2013/03/31 [aheadofprint]
AID - 000343404 [pii]
AID - 10.1159/000343404 [doi]
PST - ppublish
SO  - Kidney Blood Press Res. 2013;37(2-3):95-102. doi: 10.1159/000343404. Epub 2013
      Mar 31.

PMID- 23594825
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1522-1466 (Electronic)
IS  - 1522-1466 (Linking)
DP  - 2013 Apr 17
TI  - BARDOXOLONE METHYL ANALOG RTA 405 AND DH404 ARE WELL-TOLERATED AND EXHIBIT
      EFFICACY IN RODENT MODELS OF TYPE 2 DIABETES AND OBESITY.
AB  - Bardoxolone methyl and related triterpenoids are well-tolerated and efficacious
      in numerous animal models potentially relevant to patients with type 2 diabetes
      and chronic kidney disease. These agents enhance glucose control and regulate
      lipid accumulation in rodent models of diabetes and obesity, and improve renal
      function, reduce inflammation, and prevent structural injury in models of renal
      disease. However, a recent study in Zucker Diabetic Fatty (ZDF) rats noted poor
      tolerability with the bardoxolone methyl analog RTA 405 within one month
      following treatment initiation, although this study was confounded in part by the
      use of an impure RTA 405 batch. To resolve these discordant observations, the
      present studies were conducted to further characterize triterpenoids in rodent
      models of diabetes and obesity. A follow-up study was conducted in ZDF rats with 
      two related triterpenoids (RTA 405 and dh404) for 1.5 months. Consistent with
      previous rodent experience, and in contrast to the more recent ZDF report, ZDF
      rats administered RTA 405 or dh404 exhibited no adverse clinical signs, had
      laboratory values similar to controls, and exhibited no evidence of adverse liver
      or kidney histopathology. Additionally, RTA 405 was well-tolerated in
      streptozotocin (STZ)-induced type 1 diabetic rats and high fat diet (HFD)-induced
      obese mice. The present results are consistent with the overall published body of
      data obtained with triterpenoids, and provide further evidence that these
      molecules are well-tolerated without adverse effects on hepatobiliary or renal
      function in rodent models of diabetes and obesity.
AD  - 1Reata Pharmaceuticals.
FAU - Chin, Melanie
AU  - Chin M
FAU - Lee, Chun-Yue Ivy
AU  - Lee CY
FAU - Chuang, Jen-Chieh
AU  - Chuang JC
FAU - Bumeister, Ron
AU  - Bumeister R
FAU - Wigley, W Christian
AU  - Wigley WC
FAU - Sonis, Stephen T
AU  - Sonis ST
FAU - Ward, Keith W
AU  - Ward KW
FAU - Meyer, Colin
AU  - Meyer C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Am J Physiol Renal Physiol
JT  - American journal of physiology. Renal physiology
JID - 100901990
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - ajprenal.00387.2012 [pii]
AID - 10.1152/ajprenal.00387.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Renal Physiol. 2013 Apr 17.

PMID- 23594765
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1536-4798 (Electronic)
IS  - 0277-3740 (Linking)
VI  - 32
IP  - 7
DP  - 2013 Jul
TI  - Reply.
PG  - e179-80
LID - 10.1097/ICO.0b013e31828a282a [doi]
AD  - *Institute of Health and Biomedical Innovation, Queensland University of
      Technology, Queensland, Australia daggerDepartment of Diabetes and Endocrinology,
      Princess Alexandra Hospital, Woolloongabba, Queensland, Australia School of
      Medicine, University of Queensland, St. Lucia, Queensland, Australia double
      daggerCentre for Endocrinology and Diabetes, Institute of Human Development,
      University of Manchester, Manchester, United Kingdom.
FAU - Edwards, Katie
AU  - Edwards K
FAU - Pritchard, Nicola
AU  - Pritchard N
FAU - Gosschalk, Kevin
AU  - Gosschalk K
FAU - Sampson, Geoff P
AU  - Sampson GP
FAU - Russell, Anthony
AU  - Russell A
FAU - Malik, Rayaz A
AU  - Malik RA
FAU - Efron, Nathan
AU  - Efron N
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cornea
JT  - Cornea
JID - 8216186
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1097/ICO.0b013e31828a282a [doi]
PST - ppublish
SO  - Cornea. 2013 Jul;32(7):e179-80. doi: 10.1097/ICO.0b013e31828a282a.

PMID- 23594745
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1421-9670 (Electronic)
IS  - 0250-8095 (Linking)
VI  - 37
IP  - 5
DP  - 2013
TI  - Using hemoglobin a1c to derive mean blood glucose in peritoneal dialysis
      patients.
PG  - 413-20
LID - 10.1159/000349929 [doi]
AB  - Background: Although hemoglobin A1c (HbA1c) has been widely used as a clinical
      assessment tool for outcome analyses related to glycemic control, the
      relationship between HbA1c and average blood glucose (BG) specific to peritoneal 
      dialysis (PD) patients with diabetes has not been characterized. We sought to
      develop HbA1c-BG equation models for PD patients. Methods: We examined
      associations between HbA1c and random serum BG values over time in a contemporary
      5-year (2001-2006) cohort of DaVita PD patients with diabetes. We identified 850 
      patients (mean age: 58 +/- 13 years, 56% male) with 4,566 paired measurements of 
      HbA1c and BG. The bootstrapping method was used to estimate average BG and
      corresponding HbA1c. Results: Linear regression analyses yielded the following
      HbA1c-BG equations: (1) BG (mg/dl) = 24.1 + 28.6 x HbA1c - 12.2 x albumin
      [adjusted R(2) (R(2)adj = 0.454)], (2) BG = 55.3 + 28.8 x HbA1c - 10.2 x albumin 
      - 3.3 x Hb (R(2)adj = 0.457), and (3) BG = 69.5 + 28.7 x HbA1c - 10.1 x albumin -
      3.7 x Hb - 0.1 x age + race/ethnicity (-10.1 African Americans, -5.4 other
      race/ethnicities; R(2)adj = 0.457). All models showed greater explanatory power
      of BG variation than previously established HbA1c-BG equation models defined
      within non-PD cohorts [R(2)adj = 0.446 for both the Diabetes Control and
      Complications Trial (DCCT) and the A1c-Derived Average Glucose (ADAG) equations].
      Conclusions: The association between HbA1c and BG in PD patients is different
      than that of patients with normal kidney function. Our analysis suggests that
      equations incorporating serum albumin and/or Hb values better estimate the
      HbA1c-BG relationship in PD patients compared to equations using HbA1c alone.
CI  - Copyright (c) 2013 S. Karger AG, Basel.
AD  - Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles 
      Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, Calif.,
      USA.
FAU - Hoshino, Junichi
AU  - Hoshino J
FAU - Mehrotra, Rajnish
AU  - Mehrotra R
FAU - Rhee, Connie M
AU  - Rhee CM
FAU - Yamagata, Kunihiro
AU  - Yamagata K
FAU - Ubara, Yoshifumi
AU  - Ubara Y
FAU - Takaichi, Kenmei
AU  - Takaichi K
FAU - Kovesdy, Csaba P
AU  - Kovesdy CP
FAU - Molnar, Miklos Z
AU  - Molnar MZ
FAU - Kalantar-Zadeh, Kamyar
AU  - Kalantar-Zadeh K
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/01/17 [received]
PHST- 2013/02/17 [accepted]
PHST- 2013/04/09 [aheadofprint]
AID - 000349929 [pii]
AID - 10.1159/000349929 [doi]
PST - ppublish
SO  - Am J Nephrol. 2013;37(5):413-20. doi: 10.1159/000349929. Epub 2013 Apr 9.

PMID- 23594738
OWN - NLM
STAT- MEDLINE
DA  - 20130509
DCOM- 20130530
IS  - 1476-4687 (Electronic)
IS  - 0028-0836 (Linking)
VI  - 497
IP  - 7448
DP  - 2013 May 9
TI  - A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway.
PG  - 244-8
LID - 10.1038/nature12119 [doi]
AB  - The pluripotency factor Lin28 blocks the expression of let-7 microRNAs in
      undifferentiated cells during development, and functions as an oncogene in a
      subset of cancers. Lin28 binds to let-7 precursor (pre-let-7) RNAs and recruits
      3' terminal uridylyl transferases to selectively inhibit let-7 biogenesis.
      Uridylated pre-let-7 is refractory to processing by Dicer, and is rapidly
      degraded by an unknown RNase. Here we identify Dis3l2 as the 3'-5' exonuclease
      responsible for the decay of uridylated pre-let-7 in mouse embryonic stem cells. 
      Biochemical reconstitution assays show that 3' oligouridylation stimulates Dis3l2
      activity in vitro, and knockdown of Dis3l2 in mouse embryonic stem cells leads to
      the stabilization of pre-let-7. Our study establishes 3' oligouridylation as an
      RNA decay signal for Dis3l2, and identifies the first physiological RNA substrate
      of this new exonuclease, which is mutated in the Perlman syndrome of fetal
      overgrowth and causes a predisposition to Wilms' tumour development.
AD  - Stem Cell Program, Boston Children's Hospital, Massachusetts 02115, USA.
FAU - Chang, Hao-Ming
AU  - Chang HM
FAU - Triboulet, Robinson
AU  - Triboulet R
FAU - Thornton, James E
AU  - Thornton JE
FAU - Gregory, Richard I
AU  - Gregory RI
LA  - eng
GR  - R01 GM086386/GM/NIGMS NIH HHS/United States
GR  - R01GM086386/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130417
PL  - England
TA  - Nature
JT  - Nature
JID - 0410462
RN  - 0 (Lin-28 protein, mouse)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA Precursors)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (mirnlet7 microRNA, mouse)
RN  - 58-97-9 (Uridine Monophosphate)
RN  - 84-53-7 (3'-uridylic acid)
RN  - EC 3.1.- (Dis3l2 protein, mouse)
RN  - EC 3.1.- (Exonucleases)
RN  - EC 3.1.- (Exoribonucleases)
RN  - EC 3.1.- (Ribonucleases)
RN  - Nephroblastomatosis, fetal ascites, macrosomia and Wilms tumor
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Embryonic Stem Cells/metabolism
MH  - Exonucleases/*metabolism
MH  - Exoribonucleases/*metabolism
MH  - Fetal Macrosomia/*enzymology/*genetics/metabolism
MH  - HEK293 Cells
MH  - Humans
MH  - Mice
MH  - MicroRNAs/genetics/*metabolism
MH  - RNA Precursors/genetics/metabolism
MH  - RNA Processing, Post-Transcriptional
MH  - *RNA Stability
MH  - RNA-Binding Proteins/*metabolism
MH  - Ribonucleases/*metabolism
MH  - Substrate Specificity
MH  - Uridine Monophosphate/analogs & derivatives/metabolism
MH  - Wilms Tumor/*enzymology/etiology/*genetics/metabolism
PMC - PMC3651781
MID - NIHMS460782
OID - NLM: NIHMS460782 [Available on 11/09/13]
OID - NLM: PMC3651781 [Available on 11/09/13]
EDAT- 2013/04/19 06:00
MHDA- 2013/06/01 06:00
CRDT- 2013/04/19 06:00
PMCR- 2013/11/09 00:00
PHST- 2012/10/17 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - nature12119 [pii]
AID - 10.1038/nature12119 [doi]
PST - ppublish
SO  - Nature. 2013 May 9;497(7448):244-8. doi: 10.1038/nature12119. Epub 2013 Apr 17.

PMID- 23594710
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1473-6535 (Electronic)
IS  - 0957-9672 (Linking)
VI  - 24
IP  - 3
DP  - 2013 Jun
TI  - Novel benefits of peroxisome proliferator-activated receptors on cardiovascular
      risk.
PG  - 233-8
LID - 10.1097/MOL.0b013e3283613a7d [doi]
AB  - PURPOSE OF REVIEW: This review provides an overview of newly described mechanisms
      by which peroxisome proliferator-activated receptors (PPARs) (alpha, gamma, and
      delta) regulate several factors associated with cardiovascular risk. RECENT
      FINDINGS: PPAR agonists have known effects on plasma lipoprotein levels,
      inflammation, and insulin resistance all of which influence the risk of
      cardiovascular disease. Recent studies provide more detail regarding the
      mechanisms behind these changes. PPAR-alpha activation in the enterocyte on HDL
      and chylomicron formation. PPAR-gamma agonists reduce inflammation, in part,
      through direct effects on adipocytes and regulatory T cells within visceral
      adipose. PPAR-delta also has a relatively high expression in the macrophage.
      Incubation of macrophages with PPAR-delta agonists was shown to inhibit foam cell
      formation induced excessive levels of VLDL remnants. SUMMARY: Treatments that
      activate PPAR-alpha, PPAR-gamma, and PPAR-delta alone or in combination have the 
      potential to reduce cardiovascular risk although multiple independent mechanisms.
      Treatment with PPAR agonists can reduce the burden of atherogenic postprandial
      lipoproteins and improve vascular function, reduce inflammation and inhibit foam 
      cell formation. All of these would be expected to have favorable effects on
      cardiovascular risk. The challenge remains to develop compounds that maximize
      these potential cardiovascular benefits while minimizing undesirable effects of
      these compounds.
AD  - Division of Translational Medicine and Human Genetics; Institute of Diabetes,
      Obesity and Metabolism, University of Pennsylvania, Philadelphia, Pennsylvania,
      USA.
FAU - Millar, John S
AU  - Millar JS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Lipidol
JT  - Current opinion in lipidology
JID - 9010000
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1097/MOL.0b013e3283613a7d [doi]
PST - ppublish
SO  - Curr Opin Lipidol. 2013 Jun;24(3):233-8. doi: 10.1097/MOL.0b013e3283613a7d.

PMID- 23594708
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1473-6535 (Electronic)
IS  - 0957-9672 (Linking)
VI  - 24
IP  - 3
DP  - 2013 Jun
TI  - Adverse metabolic effects of dietary fructose: results from the recent
      epidemiological, clinical, and mechanistic studies.
PG  - 198-206
LID - 10.1097/MOL.0b013e3283613bca [doi]
AB  - PURPOSE OF REVIEW: The effects of dietary sugar on risk factors and the processes
      associated with metabolic disease remain a controversial topic, with recent
      reviews of the available evidence arriving at widely discrepant conclusions.
      RECENT FINDINGS: There are many recently published epidemiological studies that
      provide evidence that sugar consumption is associated with metabolic disease.
      Three recent clinical studies, which investigated the effects of consuming
      relevant doses of sucrose or high-fructose corn syrup along with ad libitum
      diets, provide evidence that consumption of these sugars increase the risk
      factors for cardiovascular disease and metabolic syndrome. Mechanistic studies
      suggest that these effects result from the rapid hepatic metabolism of fructose
      catalyzed by fructokinase C, which generates substrate for de novo lipogenesis
      and leads to increased uric acid levels. Recent clinical studies investigating
      the effects of consuming less sugar, via educational interventions or by
      substitution of sugar-sweetened beverages for noncalorically sweetened beverages,
      provide evidence that such strategies have beneficial effects on risk factors for
      metabolic disease or on BMI in children. SUMMARY: The accumulating
      epidemiological evidence, direct clinical evidence, and the evidence suggesting
      plausible mechanisms support a role for sugar in the epidemics of metabolic
      syndrome, cardiovascular disease, and type 2 diabetes.
AD  - aDepartment of Molecular Biosciences, School of Veterinary Medicine bDepartment
      of Nutrition, University of California, Davis, Davis, California cDepartment of
      Basic Sciences, College of Osteopathic Medicine, Touro University, Vallejo,
      California dDepartment of Medicine, University of California, San Francisco, San 
      Francisco, California, USA.
FAU - Stanhope, Kimber L
AU  - Stanhope KL
FAU - Schwarz, Jean-Marc
AU  - Schwarz JM
FAU - Havel, Peter J
AU  - Havel PJ
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Lipidol
JT  - Current opinion in lipidology
JID - 9010000
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1097/MOL.0b013e3283613bca [doi]
PST - ppublish
SO  - Curr Opin Lipidol. 2013 Jun;24(3):198-206. doi: 10.1097/MOL.0b013e3283613bca.

PMID- 23594688
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1532-8511 (Electronic)
IS  - 1052-3057 (Linking)
DP  - 2013 Apr 14
TI  - Investigation of Vaspin Level in Patients with Acute Ischemic Stroke.
LID - S1052-3057(13)00105-5 [pii]
LID - 10.1016/j.jstrokecerebrovasdis.2013.03.023 [doi]
AB  - BACKGROUND: Cerebrovascular event is a clinical condition characterized by
      symptoms and findings pertaining to loss of focal cerebral function because of
      the vascular causes. Atherosclerosis has a forefront role in the pathogenesis of 
      stroke. Inflammation has an important place in the formation of atherogenesis and
      atherosclerosis. Visceral adipose tissue-derived serpin (vaspin) is a new
      adipokine, which is identified recently, associated with obesity and diabetes and
      also has a proinflammatory characteristic. This study was intended to investigate
      the relation between vaspin and stroke and stroke and other risk factors.
      METHODS: A total of 50 patients with stroke, as 28 men (56%) and 22 women (44%), 
      and a total of 50 healthy individuals, as 25 men (50%) and 25 women (50%), were
      enrolled in the study. Blood samples were taken in the acute period (first 48
      hours) in the patient group, and serum vaspin levels were measured. Vaspin level 
      was also measured in the control group. The association of vaspin with the lipid 
      parameters, gender, and the severity of internal carotid artery (ICA) stenosis in
      the patient group was evaluated. Stenotic plaques in ICA were classified as
      normal, mild (stenosis under 50%), moderate (stenosis 50%-69%), severe (stenosis 
      70%-99% to preocclusion), and occlusion. RESULTS: No statistically significant
      difference was found between 2 groups in terms of age and gender (P > .05).
      Vaspin levels were found to be significantly higher in the patient group (164.73 
      +/- 153.76 ng/mL) compared with the control group (116.21 +/- 34.60 ng/mL) (P <
      .05). However, no relation was established between vaspin level and the severity 
      of ICA stenosis. CONCLUSIONS: Vaspin levels have been shown to increase in acute 
      ischemic stroke patients. The increased vaspin levels may vary depending on
      several factors in acute period of ischemic stroke.
CI  - Copyright (c) 2013 National Stroke Association. Published by Elsevier Inc. All
      rights reserved.
AD  - Neurology Clinics, Turhal State Hospital, Tokat.
FAU - Cura, Hasan S
AU  - Cura HS
FAU - Ozdemir, Hasan H
AU  - Ozdemir HH
FAU - Demir, Caner F
AU  - Demir CF
FAU - Bulut, Serpil
AU  - Bulut S
FAU - Ilhan, Nevin
AU  - Ilhan N
FAU - Inci, Mehmet Fatih
AU  - Inci MF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130414
TA  - J Stroke Cerebrovasc Dis
JT  - Journal of stroke and cerebrovascular diseases : the official journal of National
      Stroke Association
JID - 9111633
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/01/11 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/03/19 [accepted]
AID - S1052-3057(13)00105-5 [pii]
AID - 10.1016/j.jstrokecerebrovasdis.2013.03.023 [doi]
PST - aheadofprint
SO  - J Stroke Cerebrovasc Dis. 2013 Apr 14. pii: S1052-3057(13)00105-5. doi:
      10.1016/j.jstrokecerebrovasdis.2013.03.023.

PMID- 23594619
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - Glomerular filtration rate and albuminuria predict mortality independently from
      coronary artery calcified plaque in the Diabetes Heart Study.
PG  - 68
LID - 10.1186/1475-2840-12-68 [doi]
AB  - BACKGROUND: Risk stratification in individuals with type 2 diabetes (T2D) remains
      an important priority in the management of associated morbidity and mortality,
      including from cardiovascular disease (CVD). The current investigation examined
      whether estimated glomerular filtration rate (eGFR) and urine albumin:creatinine 
      ratio (UACR) were independent predictors of CVD-mortality in European Americans
      (EAs) with T2D after accounting for subclinical CVD. METHODS: The family-based
      Diabetes Heart Study (DHS) cohort (n=1,220) had baseline measures of serum
      creatinine, eGFR, UACR and coronary artery calcified plaque (CAC) assessed by
      non-contrast computed tomography scan. Cox proportional hazards regression was
      performed to determine risk for all-cause mortality and CVD-mortality associated 
      with indices of kidney disease after accounting for traditional CVD risk factors 
      and CAC as a measure of subclinical CVD. RESULTS: Participants were followed for 
      8.2+/-2.6 years (mean+/-SD) during which time 247 (20.9%) were deceased, 107
      (9.1%) from CVD. Univariate analyses revealed positive associations between serum
      creatinine (HR:1.56; 95% CI:1.37-1.80; p<0.0001) and UACR (1.59; 1.43-1.77;
      p>0.0001) and negative associations between serum albumin (0.74; 0.65-0.84;
      p<0.0001) and eGFR (0.66; 0.58-0.76; p<0.0001) with all-cause mortality.
      Associations remained significant after adjustment for traditional CVD risk
      factors, as well as for CAC. Similar trends were noted when predicting risk for
      CVD-mortality. CONCLUSIONS: The DHS reveals that kidney function and albuminuria 
      are independent risk factors for all-cause mortality and CVD-mortality in EAs
      with T2D, even after accounting for CAC.
AD  - Center for Human Genomics, Wake Forest School of Medicine, Winston-Salem, NC,
      USA.
FAU - Cox, Amanda J
AU  - Cox AJ
FAU - Hsu, Fang-Chi
AU  - Hsu FC
FAU - Carr, J Jeffrey
AU  - Carr JJ
FAU - Freedman, Barry I
AU  - Freedman BI
FAU - Bowden, Donald W
AU  - Bowden DW
LA  - eng
GR  - F32 HL085989/HL/NHLBI NIH HHS/United States
GR  - M01 RR07122/RR/NCRR NIH HHS/United States
GR  - R01 HL092301/HL/NHLBI NIH HHS/United States
GR  - R01 HL67348/HL/NHLBI NIH HHS/United States
GR  - R01 NS058700/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130418
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3637614
OID - NLM: PMC3637614
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/03/07 [received]
PHST- 2013/04/12 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 1475-2840-12-68 [pii]
AID - 10.1186/1475-2840-12-68 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 Apr 18;12:68. doi: 10.1186/1475-2840-12-68.

PMID- 23594567
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 14
IP  - 1
DP  - 2013 Apr 17
TI  - U-shaped association between central body fat and the urinary
      albumin-to-creatinine ratio and microalbuminuria.
PG  - 87
AB  - BACKGROUND: The prevalence of obese and overweight patients has increased
      dramatically worldwide. Both are common risk factors for chronic kidney disease
      (CKD) as indicated by a diminished estimated glomerular filtration rate (eGFR) or
      microalbuminuria. This study aimed to investigate whether anthropometric
      parameters [waist circumference (WC), waist-to-height ratio (WHtR) and body mass 
      index (BMI)] are associated with renal function in a population-based study of
      Caucasian subjects. METHODS: Data from 3749 subjects (1825 women) aged 20 to 81
      years from the Study of Health in Pomerania (SHIP) were analysed. Renal indices, 
      including the urinary albumin-to-creatinine ratio (uACR), microalbuminuria, eGFR 
      and CKD, were studied. Parameters of anthropometry (WC, WHtR and BMI) were
      categorised into sex-specific quintiles. RESULTS: Analysis of variance (ANOVA)
      models, adjusting for age, sex, type 2 diabetes mellitus and hypertension,
      revealed that a high and low WC or WHtR and low BMI were independently related to
      a higher uACR. Logistic regression models confirmed these results with respect to
      uACR and showed that subjects with a high or low WC or a high WHtR had increased 
      odds of microalbuminuria. The ANOVA models revealed no relations of the
      investigated anthropometric parameters with eGFR. However, subjects with high
      values for these parameters had increased odds of CKD. CONCLUSIONS: Our results
      demonstrate U-shaped associations between markers of central fat distribution and
      uACR or microalbuminuria in the general population, suggesting that both obese
      and very thin subjects have a higher risk of renal impairment.
FAU - Dittmann, Kathleen
AU  - Dittmann K
FAU - Hannemann, Anke
AU  - Hannemann A
FAU - Wallaschofski, Henri
AU  - Wallaschofski H
FAU - Rettig, Rainer
AU  - Rettig R
FAU - Stracke, Sylvia
AU  - Stracke S
FAU - Volzke, Henry
AU  - Volzke H
FAU - Nauck, Matthias
AU  - Nauck M
FAU - Friedrich, Nele
AU  - Friedrich N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
PMC - PMC3637595
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/06/18 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 1471-2369-14-87 [pii]
AID - 10.1186/1471-2369-14-87 [doi]
PST - aheadofprint
SO  - BMC Nephrol. 2013 Apr 17;14(1):87.

PMID- 23594442
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1662-4033 (Electronic)
IS  - 1662-4025 (Linking)
VI  - 6
IP  - 2
DP  - 2013
TI  - Defining and predicting complete remission of type 2 diabetes: a short-term
      efficacy study of open gastric bypass.
PG  - 176-84
LID - 10.1159/000351018 [doi]
AB  - OBJECTIVE: To investigate the metabolic effects of open Roux-en Y gastric bypass 
      (RYGB) on pancreatic endocrine reserve in overweight/obese Chinese patients with 
      type 2 diabetes during postoperative year 1. METHODS: Retrospective analysis
      comparing pre- and postoperative results of oral glucose tolerance tests (OGTT)
      with determinations of insulin and C-peptide, glycated hemoglobin (HbA1c),
      insulin resistance (HOMA-IR), and BMI at 1, 3, 6, and 12 months in 99 overweight 
      patients (BMI 26.3 +/- 4.0 kg/m(2); 59 men) with type 2 diabetes at the General
      Hospital of Chengdu Military Region. RESULTS: 79 patients (80%) achieved complete
      remission (maintaining random blood glucose levels < 11.1 mmol/l, fasting blood
      glucose levels < 7.0 mmol/l, 2-hour OGTT blood glucose levels < 11.1 mmol/l, and 
      glycated hemoglobin < 6.5%). Nine cases (9%) were 'improved' (reduced medication 
      or diet controlled blood sugar), and 11 cases did not meet either criterion
      ('unchanged'). Patients in complete remission were younger and heavier, more
      often men, had significantly shorter history of diabetes (4.3 +/- 3.8 years vs.
      7.6 +/- 3.8 years, p < 0.05), and exhibited significantly higher fasting and OGTT
      levels of C-peptide and insulin, and HOMA-IR than the other 2 groups (p <
      0.05-0.01). CONCLUSION: Open gastric bypass achieved complete remission of type 2
      diabetes in Chinese overweight/obese, heavier, younger, predominantly male
      patients with shorter duration of disease exhibiting greater pancreatic endocrine
      reserve.
CI  - Copyright (c) 2013 S. Karger GmbH, Freiburg.
AD  - General Surgery Center of PLA, Chengdu Military General Hospital, Chengdu, China.
FAU - Yan, Hongtao
AU  - Yan H
FAU - Tang, Lijun
AU  - Tang L
FAU - Chen, Tao
AU  - Chen T
FAU - Kral, John G
AU  - Kral JG
FAU - Jiang, Li
AU  - Jiang L
FAU - Li, Yunming
AU  - Li Y
FAU - Hu, Ruidong
AU  - Hu R
FAU - Cui, Jiangfeng
AU  - Cui J
FAU - Li, Shi
AU  - Li S
FAU - Tian, Fuzhou
AU  - Tian F
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - Switzerland
TA  - Obes Facts
JT  - Obesity facts
JID - 101469429
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2011/12/01 [received]
PHST- 2012/09/05 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - 000351018 [pii]
AID - 10.1159/000351018 [doi]
PST - ppublish
SO  - Obes Facts. 2013;6(2):176-84. doi: 10.1159/000351018. Epub 2013 Apr 12.

PMID- 23594420
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1708-8186 (Electronic)
IS  - 1499-2027 (Linking)
VI  - 52
IP  - 6
DP  - 2013 Jun
TI  - Healthy diets, healthy hearing: National Health and Nutrition Examination Survey,
      1999-2002.
PG  - 369-76
LID - 10.3109/14992027.2013.780133 [doi]
AB  - Abstract Objective: A significant relationship between dietary nutrient intake
      and susceptibility to acquired hearing loss is emerging. Variability in the
      outcomes across studies is likely related to differences in the specific metrics 
      used to quantify nutrient intake and hearing status. Most studies have used
      single nutrient analysis. Although this analysis is valuable, interactions
      between nutrients are increasingly recognized and could modify modeling of single
      nutrient effects. Therefore, we examined the potential relationship between diet 
      and hearing using a metric of overall dietary quality. Design: This
      cross-sectional analysis was based on healthy eating index data and audiological 
      thresholds. Study sample: Data for adults between the ages of 20 to 69 years of
      age were drawn from the National Health and Nutrition Examination Survey,
      1999-2002. Results: Controlling for age, race/ethnicity, sex, education,
      diabetes, and noise exposure, we found a significant negative relationship (Wald 
      F = 6.54, df = 4, 29; p </= 0.05) between dietary quality and thresholds at
      higher frequencies, where higher dietary quality was associated with lower
      hearing thresholds. There was no statistically significant relationship between
      dietary quality and threshold sensitivity at lower frequencies. Conclusions: The 
      current findings support an association between healthier eating and better high 
      frequency thresholds in adults.
AD  - Department of Speech, Language, and Hearing Sciences, University of Florida ,
      Gainesville, Florida , USA.
FAU - Spankovich, C
AU  - Spankovich C
FAU - Le Prell, C G
AU  - Le Prell CG
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - England
TA  - Int J Audiol
JT  - International journal of audiology
JID - 101140017
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/04/18 [aheadofprint]
AID - 10.3109/14992027.2013.780133 [doi]
PST - ppublish
SO  - Int J Audiol. 2013 Jun;52(6):369-76. doi: 10.3109/14992027.2013.780133. Epub 2013
      Apr 18.

PMID- 23594366
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1749-8090 (Electronic)
IS  - 1749-8090 (Linking)
VI  - 8
IP  - 1
DP  - 2013 Apr 17
TI  - Impact of prosthesis-patient mismatch on early and late mortality after aortic
      valve replacement.
PG  - 96
AB  - BACKGROUND: The influence of prosthesis-patient mismatch (PPM) on survival after 
      aortic valve replacement (AVR) remains controversial. In this study, we sought to
      determine the effect of PPM on early (<= 30 days) and late mortality (> 30 days) 
      after AVR or AVR combined with coronary artery bypass grafting (AVR with CABG).
      METHODS: Between January 1998 and March 2012, 2976 patients underwent AVR (n=
      1718) or AVR with CABG (n=1258) at a single institution. PPM was defined as an
      indexed effective orifice area (EOAI) <=0.85 cm2/m2 and patients were divided
      into two groups based on the existence of PPM. Cumulative probability values of
      survival were estimated with Kaplan-Meier method and compared between groups
      using Breslow test. Univariate and multivariate independent predictors of early
      mortality were identified using logistic regression. Cox proportional-hazard
      regression analysis was used to determine univariate and multivariate independent
      predictors of late mortality. RESULTS: Early mortality was 6.7% in the PPM group 
      vs 4.7% in the group with no PPM (p=0.013). Late mortality for the PPM group at
      1, 5 and 10 years was 4%, 16% and 43%, respectively. Late mortality for the group
      with no PPM at 1, 5 and 10 years was 4%, 15% and 33% respectively. Independent
      predictors of early mortality included age, severely impaired left ventricular
      (LV) function, endocarditis, renal dysfunction, chronic obstructive pulmonary
      disease (COPD) and cardiopulmonary bypass (CPB) time. Multivariate independent
      predictors of late mortality included age, severely impaired LV function,
      diabetes, peripheral vascular disease (PVD), renal dysfunction, history of a
      cerebrovascular accident (CVA), CPB time and a history of previous cardiac
      surgery. PPM was not an independent predictor of early or late mortality.
      CONCLUSION: PPM is not an independent predictor of both early and late mortality 
      after AVR or AVR combined with CABG.
FAU - Koene, Bart M
AU  - Koene BM
FAU - Soliman Hamad, Mohamed A
AU  - Soliman Hamad MA
FAU - Bouma, Wobbe
AU  - Bouma W
FAU - Mariani, Massimo A
AU  - Mariani MA
FAU - Peels, Kathinka C
AU  - Peels KC
FAU - van Dantzig, Jan-Melle
AU  - van Dantzig JM
FAU - van Straten, Albert H
AU  - van Straten AH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - J Cardiothorac Surg
JT  - Journal of cardiothoracic surgery
JID - 101265113
PMC - PMC3639861
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/02/19 [received]
PHST- 2013/04/17 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 1749-8090-8-96 [pii]
AID - 10.1186/1749-8090-8-96 [doi]
PST - aheadofprint
SO  - J Cardiothorac Surg. 2013 Apr 17;8(1):96.

PMID- 23594336
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 43
IP  - 7
DP  - 2013 Jul
TI  - Lectin-like oxidized low-density lipoprotein receptor 1 pathways.
PG  - 740-5
LID - 10.1111/eci.12092 [doi]
AB  - BACKGROUND: The role of lectin-like oxidized low-density lipoprotein receptor
      (LOX)-1 has been implicated in the pathogenesis of different diseases, including 
      atherosclerosis, hypertension, obesity, diabetes mellitus and metabolic syndrome.
      To date, several studies aimed at partially investigating the mechanistic role of
      LOX-1 in these various pathologies. Still, so far, the precise signal
      transduction pathways involving LOX-1 have not yet been elucidated. MATERIALS AND
      METHODS: The most recent data published by the authors as well as others
      concerning different pathways involving LOX-1 are collected to formulate the
      presented updated review. RESULTS: One of the most prominent pathways highlighted
      in the present review is the relationship of LOX-1 to NADPH oxidase that acts as 
      a major source of harmful free radicals causing oxidative stress in blood
      vessels. Other pathways involve lipid and glucose metabolism-mediated signal
      transduction. DISCUSSION: The modulatory role of LOX-1 on nitric oxide and
      renin/angiotensin systems as well as on fibrosis, apoptosis and inflammatory
      pathways is discussed. CONCLUSION: The current review revisits LOX-1 and its
      related pathways, implicating LOX-1 as a target for ameliorating various
      pathological conditions.
CI  - (c) 2013 Stichting European Society for Clinical Investigation Journal
      Foundation. Published by John Wiley & Sons Ltd.
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University,
      Minia, Egypt.
FAU - Taye, Ashraf
AU  - Taye A
FAU - El-Sheikh, Azza A K
AU  - El-Sheikh AA
LA  - eng
PT  - Journal Article
DEP - 20130418
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2012/09/26 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/18 [aheadofprint]
AID - 10.1111/eci.12092 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2013 Jul;43(7):740-5. doi: 10.1111/eci.12092. Epub 2013 Apr
      18.

PMID- 23594260
OWN - NLM
STAT- Publisher
DA  - 20130531
IS  - 1537-6524 (Electronic)
IS  - 1537-6516 (Linking)
DP  - 2013 May 30
TI  - Potential nephrotoxic effects produced by steroidal saponins from hydro alcoholic
      extract of Tribulus terrestris in STZ-induced diabetic rats.
AB  - Abstract Chronic hyperglycemia leads to the development of microvascular
      complications like diabetic nephropathy. The present study investigated the
      potential effects of the hydroalcoholic extract of Tribulus terrestris, a plant
      of Zygophyllaceae family, on the renal complications in streptozotocin
      (STZ)-induced diabetic rats. Diabetes was induced by administering STZ (90 mg/kg)
      to the 2-days old neonates. After 6 weeks of induction, diabetic rats were
      treated with 50 mg/kg hydroalcoholic extract of T. terrestris for 8 weeks. The
      anti-hyperglycaemic nature was confirmed by reduction in blood glucose and
      improvement in insulin levels. Diabetic renal injury associated with decrease in 
      total proteins and albumin levels was observed to be improved by T. terrestris
      extract. Glomerular filtration rate along with inflammatory and growth factors,
      adiponectin and erythropoietin were also improved by the treatment, though the
      findings were not significant. However, the beneficial antidiabetic effects of T.
      terrestris extract in plasma were not observed in kidney histopathology. This was
      confirmed by the quantitative estimation of unhydrolyzed fraction of saponins
      (major component: protodioscin) in plasma and kidney samples of normal and
      diabetic rats. Hence, it can be concluded that 8 weeks treatment with T.
      terrestris extract produces potential toxic effects in kidney, which are
      independent of its anti-diabetic action.
AD  - Delhi Institute of Pharmaceutical Sciences and Research , New Delhi , India.
FAU - Gandhi, Sonia
AU  - Gandhi S
FAU - Srinivasan, B P
AU  - Srinivasan BP
FAU - Akarte, Atul S
AU  - Akarte AS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130530
TA  - Toxicol Mech Methods
JT  - Toxicology mechanisms and methods
JID - 101134521
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.3109/15376516.2013.797533 [doi]
PST - aheadofprint
SO  - Toxicol Mech Methods. 2013 May 30.

PMID- 23594109
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
DP  - 2013 Apr 17
TI  - Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical
      trials.
LID - 10.1111/dom.12116 [doi]
AB  - AIM: Cardiovascular safety of sulfonylurea has been questioned by some authors.
      This article aims at collecting all available data on this issue from randomized 
      trials. METHODS: A meta-analysis was performed including all trials with a
      duration of at least 6 months, comparing a sulfonylurea with a non-sulfonylurea
      agent in type 2 diabetes. Major cardiovascular events (MACE) and mortality were
      retrieved and combined to calculate Mantel-Haenzel odds ratio (MH-OR). RESULTS:
      Of the 115 selected trials, 62 reported information on MACE, and 30 reported at
      least one event. MH-OR for sulfonylurea was 1.08 [0.86-1.36], p = 0.52 (1.85
      [1.20-2.87], p = 0.005, in the five trials vs. DPP4 inhibitors, no significant
      differences vs. other comparators). The MH-OR for myocardial infarction and
      stroke was 0.88 [0.75-1.04], p = 0.13 and 1.28 [1.03-1.60], p = 0.026,
      respectively. Mortality was significantly increased with sulfonylureas (MH-OR:
      1.22 [1.01-1.49], p = 0.047). CONCLUSIONS: In type 2 diabetes, the use of
      sulfonylureas is associated with increased mortality and a higher risk of stroke,
      whereas the overall incidence of MACE appears to be unaffected. Significant
      differences in cardiovascular risk could be present in direct comparisons with
      specific classes of glucose-lowering agents, such as DPP4 inhibitors, but this
      hypothesis needs to be confirmed in long-term cardiovascular outcomes trials. The
      results of this meta-analysis need to be interpreted with caution, mainly because
      of limitations in trial quality and under-reporting of information on
      cardiovascular events and mortality. However, the cardiovascular safety of
      sulfonylureas cannot be considered established unless it is evaluated in
      long-term cardiovascular outcomes trials.
CI  - (c) 2013 John Wiley & Sons Ltd.
AD  - Geriatric Cardiology, Careggi Teaching Hospital, Florence, Italy.
FAU - Monami, M
AU  - Monami M
FAU - Genovese, S
AU  - Genovese S
FAU - Mannucci, E
AU  - Mannucci E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PHST- 2013/02/07 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/04/05 [accepted]
AID - 10.1111/dom.12116 [doi]
PST - aheadofprint
SO  - Diabetes Obes Metab. 2013 Apr 17. doi: 10.1111/dom.12116.

PMID- 23594041
OWN - NLM
STAT- Publisher
DA  - 20130510
IS  - 1520-4812 (Electronic)
IS  - 1043-1802 (Linking)
DP  - 2013 May 9
TI  - Polyethylene Glycol Modified FGF21 Engineered to Maximize Potency and Minimize
      Vacuole Formation.
AB  - Fibroblast growth factor 21 (FGF21) is involved in regulating energy metabolism, 
      and it has shown significant promise as a treatment for type II diabetes;
      however, the native protein has a very short circulating half-life necessitating 
      frequent injections to maintain a physiological effect. Polyethylene glycol (PEG)
      conjugation to proteins has been used as a method for extending the circulating
      half-life of many pharmaceutical proteins; however, PEG does carry the risk of
      vacuole formation, particularly in the renal tubular epithelium. Since renal
      vacuole formation may be particularly problematic for diabetic patients, we
      engineered site-directed PEGylated variants of FGF21 with sustained potency and
      minimized vacuole formation. This was accomplished both by probing the site of
      PEGylation on FGF21 as well as by examining various PEG configurations. While the
      site of PEGylation has a significant impact on the bioactivity of FGF21, it has
      only a marginal impact on vacuole formation; however, the configuration and
      number of PEGs conjugated to the protein has a much more profound effect on
      vacuologenesis.
AD  - Department of Metabolic Disorders, double daggerDepartment of Comparative Biology
      and Safety Sciences, parallelDepartment of Molecular Structure and
      Characterization, and section signDepartment of Biologics, Amgen Inc. , One Amgen
      Center Drive, Thousand Oaks, California 91320, United States.
FAU - Xu, Jing
AU  - Xu J
FAU - Bussiere, Jeanine
AU  - Bussiere J
FAU - Yie, Junming
AU  - Yie J
FAU - Sickmier, Allen
AU  - Sickmier A
FAU - An, Phil
AU  - An P
FAU - Belouski, Ed
AU  - Belouski E
FAU - Stanislaus, Shanaka
AU  - Stanislaus S
FAU - Walker, Kenneth W
AU  - Walker KW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130509
TA  - Bioconjug Chem
JT  - Bioconjugate chemistry
JID - 9010319
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1021/bc300603k [doi]
PST - aheadofprint
SO  - Bioconjug Chem. 2013 May 9.

PMID- 23594032
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 17
TI  - Effects of Different Proportion of Carbohydrate in Breakfast on Postprandial
      Glucose Excursion in Normal Glucose Tolerance and Impaired Glucose Regulation
      Subjects.
AB  - Abstract Background: The variability of postprandial plasma glucose is an
      independent risk factor for diabetes. The type and amount of carbohydrate may be 
      important determinants of glycemic control. The aim of the study was to compare
      the effects of different proportions of carbohydrate in breakfast on postprandial
      blood glucose fluctuations in impaired glucose regulation (IGR) and normal
      glucose tolerance (NGT) subjects. Subjects and Methods: This is a cross-sectional
      study of two groups including 55 subjects with IGR and 78 individuals with NGT.
      Their recorded breakfast was sorted into low-carbohydrate (LC) (carbohydrate
      <45%), medium-carbohydrate (MC) (carbohydrate 45-65%), and high-carbohydrate (HC)
      (carbohydrate >65%) meals according to the proportion of carbohydrate. Glucose
      concentrations were continuously measured with a continuous glucose monitoring
      system, and parameters such as the incremental area under the curve (iAUC) of
      glucose and postprandial glucose excursion (PPGE) were calculated to evaluate
      postprandial glucose fluctuations. Results: The postprandial fluctuations of
      glucose increased gradually with increased proportions of carbohydrate in
      breakfast in both IGR and NGT subjects. For the MC and HC meals, iAUC, PPGE,
      postprandial glucose spike (PGS), and mean blood glucose were significantly
      greater than those in the NGT group (P<0.05), respectively. The median time to
      PGS and the time period in which glucose concentrations decreased to baseline
      after the MC and HC meals in the IGR group were significantly longer than those
      in the NGT group (P<0.01), respectively. Compared with the NGT subjects for the
      HC meal, the IGR subjects consuming the MC meal had greater PGS, range of glucose
      concentrations, SD, and PPGE (P<0.05). Conclusions: The proportion of
      carbohydrate in breakfast contributes to glucose excursions in the NGT and IGR
      subjects. In the IGR subjects, a HC meal should be avoided and a LC meal should
      be recommended to prevent development of diabetes.
AD  - 1 Department of Endocrinology and Metabolism, Sichuan University , Chengdu,
      Sichuan, People's Republic of China .
FAU - Kang, Xin
AU  - Kang X
FAU - Wang, Chun
AU  - Wang C
FAU - Lv, Lifang
AU  - Lv L
FAU - Chen, Dawei
AU  - Chen D
FAU - Yang, Yanzhi
AU  - Yang Y
FAU - Liu, Guanjian
AU  - Liu G
FAU - Hu, Wen
AU  - Hu W
FAU - Chen, Lihong
AU  - Chen L
FAU - He, Liping
AU  - He L
FAU - Li, Xiujun
AU  - Li X
FAU - Tian, Haoming
AU  - Tian H
FAU - Jia, Weiping
AU  - Jia W
FAU - Ran, Xingwu
AU  - Ran X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1089/dia.2012.0305 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 17.

PMID- 23594031
OWN - NLM
STAT- Publisher
DA  - 20130418
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
DP  - 2013 Apr 17
TI  - Prognostic Accuracy of Continuous Glucose Monitoring in the Prediction of
      Diabetes Mellitus in Children with Incidental Hyperglycemia: Receiver Operating
      Characteristic Analysis.
AB  - Abstract Aim: The purpose of this study is to evaluate continuous glucose
      monitoring (CGM) in predicting diabetes mellitus in children with incident
      hyperglycemia (IH) and negativity for some insular autoantibodies. Subjects and
      Methods: Thirty-one autoantibody-negative children who presented at our center
      with IH underwent a baseline assessment and were followed up for 23.8 months
      (range, 6-48 months). At the end of the follow-up, we compared the receiver
      operating characteristic (ROC) areas under the curve (AUCs) of metabolic markers 
      from 17 children who developed diabetes (Group A; n=17) and 14 children who did
      not develop diabetes (Group B; n=14). Results: Only two oral glucose tolerance
      test (OGTT)-derived markers and three CGM-derived markers showed a good
      prognostic performance, with ROC AUCs indicating significant results (P<0.0001)
      for the following markers: 2-h glucose, OGTT (0.813; 95% confidence interval [CI]
      0.621-0.954); AUC glucose, OGTT (0.832; 95% CI 0.611-0.950); CGM glucose
      measurement peak (0.803; 95% CI 0.621-0.923); percentage of CGM glucose
      measurements inside the range 70-125 mg/dL (0.866; 95% CI 0.695-0.961); and
      percentage of CGM measurements >/=126 mg/dL (0.889; 95% CI 0.724-0.973). The
      combination of the OGTT-derived markers did not increase the predictive value,
      but the combination of CGM markers with each other or with the OGTT markers
      yielded higher ROC AUCs (ranging from 0.828 to 0.945). Conclusions: This is the
      first study showing that CGM is useful in predicting diabetes mellitus in
      children with IH.
AD  - Regional Reference Center for Diabetology and Insulin Pumps, Department of
      Internal Medicine and Diabetology, Hospital of Partinico , ASP 6 Palermo, Italy .
FAU - Brancato, Davide
AU  - Brancato D
FAU - Saura, Gabriella
AU  - Saura G
FAU - Fleres, Mattia
AU  - Fleres M
FAU - Ferrara, Lidia
AU  - Ferrara L
FAU - Scorsone, Alessandro
AU  - Scorsone A
FAU - Aiello, Vito
AU  - Aiello V
FAU - Noto, Anna Di
AU  - Noto AD
FAU - Spano, Lucia
AU  - Spano L
FAU - Provenzano, Vincenzo
AU  - Provenzano V
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
AID - 10.1089/dia.2013.0030 [doi]
PST - aheadofprint
SO  - Diabetes Technol Ther. 2013 Apr 17.

PMID- 23593819
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 0933-4548 (Print)
VI  - 65
IP  - 1
DP  - 2013 Mar 1
TI  - [In Process Citation].
PG  - 46-7
LA  - ger
PT  - Journal Article
TT  - Diabetes und Fahrtauglichkeit.
PL  - Germany
TA  - Versicherungsmedizin
JT  - Versicherungsmedizin / herausgegeben von Verband der
      Lebensversicherungs-Unternehmen e.V. und Verband der Privaten Krankenversicherung
      e.V
JID - 8803623
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PST - ppublish
SO  - Versicherungsmedizin. 2013 Mar 1;65(1):46-7.

PMID- 23593817
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 0933-4548 (Print)
VI  - 65
IP  - 1
DP  - 2013 Mar 1
TI  - [Diabetes mellitus].
PG  - 39-42
FAU - Heiermann, J
AU  - Heiermann J
LA  - ger
PT  - Journal Article
TT  - [In Process Citation]
PL  - Germany
TA  - Versicherungsmedizin
JT  - Versicherungsmedizin / herausgegeben von Verband der
      Lebensversicherungs-Unternehmen e.V. und Verband der Privaten Krankenversicherung
      e.V
JID - 8803623
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PST - ppublish
SO  - Versicherungsmedizin. 2013 Mar 1;65(1):39-42.

PMID- 23593719
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 6
IP  - 2
DP  - 2013 Mar
TI  - US FDA approves three new drugs for Type 2 diabetes.
PG  - 101
FAU - Bond, Theo
AU  - Bond T
LA  - eng
PT  - News
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/19 06:00
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2013 Mar;6(2):101.

PMID- 23574021
OWN - NLM
STAT- In-Process
DA  - 20130411
IS  - 1439-0507 (Electronic)
IS  - 0933-7407 (Linking)
VI  - 56 Suppl 1
DP  - 2013 May
TI  - Inflammatory tinea pedis with bacterial superinfection effectively treated with
      isoconazole nitrate and diflucortolone valerate combination therapy.
PG  - 23-5
LID - 10.1111/myc.12056 [doi]
AB  - Undetected tinea pedis in a patient with diabetes can lead to serious bacterial
      infections with potentially serious consequences, such as foot amputations. Here 
      we report on a 60-year-old patient with diabetes presenting with pain, severe
      pruritus, and malodour in the foot's interdigital area, and subsequently,
      diagnosed with inflammatory tinea pedis with bacterial superinfection. The
      patient was successfully treated with Travocort cream containing isoconazole
      nitrate 1% and diflucortolone valerate 0.1%; marked improvement occurred within 5
      days.
CI  - (c) 2013 Blackwell Verlag GmbH.
AD  - Private Praxis, Bernauer Street 66, Oranienburg, Germany.
      friedrich.hautarzt@googlemail.com
FAU - Friedrich, Markus
AU  - Friedrich M
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Mycoses
JT  - Mycoses
JID - 8805008
SB  - IM
EDAT- 2013/04/19 06:00
MHDA- 2013/04/19 06:00
CRDT- 2013/04/12 06:00
PHST- 2012/12/21 [received]
PHST- 2012/12/21 [revised]
PHST- 2012/12/29 [accepted]
AID - 10.1111/myc.12056 [doi]
PST - ppublish
SO  - Mycoses. 2013 May;56 Suppl 1:23-5. doi: 10.1111/myc.12056.

PMID- 23593534
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130417
DCOM- 20130418
LR  - 20130419
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr 15
TI  - Negative association between trunk fat, insulin resistance and skeleton in obese 
      women.
PG  - 31-9
LID - 10.4239/wjd.v4.i2.31 [doi]
AB  - AIM: To evaluate the potential interference of trunk fat (TF) mass on metabolic
      and skeletal metabolism. METHODS: In this cross-sectional study, 340 obese women 
      (mean age: 44.8 +/- 14 years; body mass index: 36.0 +/- 5.9 kg/m(2)) were
      included. Patients were evaluated for serum vitamin D, osteocalcin (OSCA),
      inflammatory markers, lipids, glucose and insulin (homeostasis model assessment
      of insulin resistance, HOMA-IR) levels, and hormones profile. Moreover, all
      patients underwent measurements of bone mineral density (BMD; at lumbar and hip
      site) and body composition (lean mass, total and trunk fat mass) by dual-energy
      X-ray absorptiometry. RESULTS: Data showed that: (1) high TF mass was inversely
      correlated with low BMD both at lumbar (P < 0.001) and hip (P < 0.01) sites and
      with serum vitamin D (P < 0.0005), OSCA (P < 0.0001) and insulin-like growth
      factor-1 (IGF-1; P < 0.0001) levels; (2) a positive correlation was found between
      TF and HOMA-IR (P < 0.01), fibrinogen (P < 0.0001) and erythrocyte sedimentation 
      rate (P < 0.0001); (3) vitamin D levels were directly correlated with IGF-1 (P < 
      0.0005), lumbar (P < 0.006) and hip (P < 0.01) BMD; and (4) inversely with
      HOMA-IR (P < 0.001) and fibrinogen (P < 0.0005).Multivariate analysis
      demonstrated that only vitamin D was independent of TF variable. CONCLUSION: In
      obese women, TF negatively correlates with BMD independently from vitamin D
      levels. Reduced IGF-1 and increased inflammatory markers might be some important 
      determinants that account for this relationship.
AD  - Emanuela A Greco, Davide Francomano, Rachele Fornari, Chiara Marocco, Carla
      Lubrano, Lorenzo M Donini, Andrea Lenzi, Antonio Avers, Silvia Migliaccio,
      Department of Experimental Medicine, Section of Medical Pathophysiology,
      Endocrinology and Nutrition, University "Sapienza" of Rome, 00195 Rome, Italy.
FAU - Greco, Emanuela A
AU  - Greco EA
FAU - Francomano, Davide
AU  - Francomano D
FAU - Fornari, Rachele
AU  - Fornari R
FAU - Marocco, Chiara
AU  - Marocco C
FAU - Lubrano, Carla
AU  - Lubrano C
FAU - Papa, Vincenza
AU  - Papa V
FAU - Wannenes, Francesca
AU  - Wannenes F
FAU - Di Luigi, Luigi
AU  - Di Luigi L
FAU - Donini, Lorenzo M
AU  - Donini LM
FAU - Lenzi, Andrea
AU  - Lenzi A
FAU - Aversa, Antonio
AU  - Aversa A
FAU - Migliaccio, Silvia
AU  - Migliaccio S
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC3627415
OID - NLM: PMC3627415
OTO - NOTNLM
OT  - Inflammation
OT  - Insulin resistance
OT  - Obesity
OT  - Osteocalcin
OT  - Skeleton
OT  - Trunk fat
OT  - Vitamin D
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:01
CRDT- 2013/04/18 06:00
PHST- 2012/12/13 [received]
PHST- 2013/02/14 [revised]
PHST- 2013/03/15 [accepted]
AID - 10.4239/wjd.v4.i2.31 [doi]
PST - ppublish
SO  - World J Diabetes. 2013 Apr 15;4(2):31-9. doi: 10.4239/wjd.v4.i2.31.

PMID- 23593533
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130417
DCOM- 20130418
LR  - 20130419
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr 15
TI  - Diabetes and renal tubular cell apoptosis.
PG  - 27-30
LID - 10.4239/wjd.v4.i2.27 [doi]
AB  - Apoptosis contributes to the development of diabetic nephropathy, but the
      mechanism by which high glucose induces apoptosis is not fully understood.
      Apoptosis of tubular epithelial cells is a major feature of diabetic kidney
      disease, and hyperglycemia triggers the generation of free radicals and oxidant
      stress in tubular cells. Hyperglycemia and high glucose in vitro also lead to
      apoptosis, a form of programmed cell death. High glucose similar to those seen
      with hyperglycemia in people with diabetes mellitus, lead to accelerated
      apoptosis, a form of programmed cell death characterized by cell shrinkage,
      chromatin condensation and DNA fragmentation, in variety of cell types, including
      renal proximal tubular epithelial cells.
AD  - Samy L Habib, South Texas Veterans Health Care System, Departments of Cellular
      and Structural Biology, University of Texas Health Science Center, San Antonio,
      TX 78229, United States.
FAU - Habib, Samy L
AU  - Habib SL
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC3627416
OID - NLM: PMC3627416
OTO - NOTNLM
OT  - Apoptosis
OT  - Diabetes
OT  - Renal
OT  - Tubular cells
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:01
CRDT- 2013/04/18 06:00
PHST- 2012/01/10 [received]
PHST- 2013/03/26 [revised]
PHST- 2013/03/28 [accepted]
AID - 10.4239/wjd.v4.i2.27 [doi]
PST - ppublish
SO  - World J Diabetes. 2013 Apr 15;4(2):27-30. doi: 10.4239/wjd.v4.i2.27.

PMID- 23593532
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130417
DCOM- 20130418
LR  - 20130419
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr 15
TI  - Bevacizumab for the management of diabetic macular edema.
PG  - 19-26
LID - 10.4239/wjd.v4.i2.19 [doi]
AB  - Diabetic retinopathy (DR) is a leading cause of vision loss in the working-age
      population and is relatedto 1%-5% of cases of blindness worldwide. Diabetic
      macular edema (DME) is the most frequent cause of DR vision loss and is an
      important public health problem. Recent studies have implicated vascular
      endothelial growth factor (VEGF) in DR and DME pathogenesis, as well as provided 
      evidence of the benefits of anti-VEGF agents for the management of such
      conditions. Despite the benefits of intravitreal ranibizumab injection for the
      management of DME, the cost-effectiveness of intravitreal bevacizumab therapy has
      gained increasing interest in the scientific community. This review summarizes
      the studies examining bevacizumab for the management of DME, focusing on the
      efficacy and duration of the clinical benefits of decreasing DME and the
      improvement of best-corrected visual acuity (BCVA). There is strong evidence that
      intravitreal bevacizumab injection therapy has a good cost-effective profile in
      the management of DME and may be associated with laser photocoagulation; however,
      its clinical superiority in terms of the duration of DME regression and the
      improvement of BCVA compared with intravitreal ranibizumab and other intravitreal
      anti-VEGF therapies remains unclear and deserves further investigation.
AD  - Francisco Rosa Stefanini, Mauricio Maia, The Retina Division, Ophthalmology
      Department, Federal University of Sao Paulo, Sao Paulo, SP 04023-062, Brazil.
FAU - Stefanini, Francisco Rosa
AU  - Stefanini FR
FAU - Arevalo, J Fernando
AU  - Arevalo JF
FAU - Maia, Mauricio
AU  - Maia M
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC3627413
OID - NLM: PMC3627413
OTO - NOTNLM
OT  - Anti-vascular endothelial growth factor
OT  - Bevacizumab
OT  - Diabetic macular edema
OT  - Diabetic retinopathy
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:01
CRDT- 2013/04/18 06:00
PHST- 2012/10/24 [received]
PHST- 2013/02/15 [revised]
PHST- 2013/03/23 [accepted]
AID - 10.4239/wjd.v4.i2.19 [doi]
PST - ppublish
SO  - World J Diabetes. 2013 Apr 15;4(2):19-26. doi: 10.4239/wjd.v4.i2.19.

PMID- 23593531
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130417
DCOM- 20130418
LR  - 20130419
IS  - 1948-9358 (Electronic)
IS  - 1948-9358 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr 15
TI  - Bariatric surgery as a treatment option in patients with type 2 diabetes
      mellitus.
PG  - 14-8
LID - 10.4239/wjd.v4.i2.14 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a leading cause of blindness, non-traumatic
      amputation and end-stage renal disease as well as a major cardiovascular risk
      factor. Tight glycemic control reduces the incidence of microvascular
      complications of T2DM whereas its effects on macrovascular complication are more 
      controversial. However, glycemic targets are achieved by a minority of diabetic
      patients despite the availability of several antidiabetic agents. In the present 
      commentary, we discuss the findings of two recent randomized studies that
      compared bariatric surgery with medical treatment in patients with uncontrolled
      T2DM. Both studies showed that bariatric surgery results in remission of T2DM in 
      the majority of patients. However, both studies were limited to relatively young 
      patients without comorbidities, had relatively short follow-up and did not assess
      the effects of surgery on T2DM complications. Moreover, the perioperative
      complications of bariatric surgery and its limited availability in some areas are
      additional barriers to the wider implementation of this therapeutic approach. On 
      the other hand, the elucidation of the mechanisms underpinning the resolution of 
      T2DM following bariatric surgery might result in the development of novel, more
      effective pharmacotherapies for this common disease.
AD  - Marianna Spanou, Konstantinos Tziomalos, First Propedeutic Department of Internal
      Medicine, Medical School, AHEPA Hospital, Aristotle University of Thessaloniki,
      54636 Thessaloniki, Greece.
FAU - Spanou, Marianna
AU  - Spanou M
FAU - Tziomalos, Konstantinos
AU  - Tziomalos K
LA  - eng
PT  - Journal Article
PL  - China
TA  - World J Diabetes
JT  - World journal of diabetes
JID - 101547524
PMC - PMC3627414
OID - NLM: PMC3627414
OTO - NOTNLM
OT  - Adjustable gastric banding
OT  - Bariatric surgery
OT  - Biliopancreatic diversion
OT  - Roux-en-Y gastric bypass
OT  - Sleeve gastrectomy
OT  - Type 2 diabetes mellitu
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:01
CRDT- 2013/04/18 06:00
PHST- 2012/12/23 [received]
PHST- 2013/02/10 [revised]
PHST- 2013/03/06 [accepted]
AID - 10.4239/wjd.v4.i2.14 [doi]
PST - ppublish
SO  - World J Diabetes. 2013 Apr 15;4(2):14-8. doi: 10.4239/wjd.v4.i2.14.

PMID- 23593464
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Modification of the FoxP3 transcription factor principally affects inducible t
      regulatory cells in a model of experimental autoimmune encephalomyelitis.
PG  - e61334
LID - 10.1371/journal.pone.0061334 [doi]
AB  - T regulatory (Treg) cells expressing the transcription factor FoxP3 play a key
      role in protection against autoimmune disease. GFP-FoxP3 reporter mice have been 
      used widely to study the induction, function and stability of both thymically-
      and peripherally-induced Treg cells. The N-terminal modification of FoxP3,
      however, affects its interaction with transcriptional co-factors; this can alter 
      Treg cell development and function in certain self-antigen specific animal
      models. Interestingly, Treg cell function can be negatively or positively
      affected, depending on the nature of the model. In this study, we focused on the 
      effect of the GFP-FoxP3 reporter on Treg cell development and function in the Tg4
      mouse model. In this model, T cells express a transgenic T cell receptor (TCR)
      specific for the Myelin Basic Protein (MBP) peptide Ac1-9, making the animals
      susceptible to experimental autoimmune encephalomyelitis (EAE), a disease akin to
      multiple sclerosis in humans. Unlike diabetes-susceptible mice, Tg4 FoxP3(gfp)
      mice did not develop spontaneous autoimmune disease and did not demonstrate
      augmented susceptibility to induced disease. Concurrently, thymic generation of
      natural Treg cells was not negatively affected. The induction of FoxP3 expression
      in naive peripheral T cells was, however, significantly impaired as a result of
      the transgene. This study shows that the requirements for the interaction of
      FoxP3 with co-factors, which governs its regulatory ability, differ not only
      between natural and inducible Treg cells but also between animal models of
      diseases such as diabetes and EAE.
AD  - School of Cellular and Molecular Medicine, University of Bristol, Bristol, United
      Kingdom. Johan.Verhagen@bristol.ac.uk
FAU - Verhagen, Johan
AU  - Verhagen J
FAU - Burton, Bronwen R
AU  - Burton BR
FAU - Britton, Graham J
AU  - Britton GJ
FAU - Shepard, Ella R
AU  - Shepard ER
FAU - Anderton, Stephen M
AU  - Anderton SM
FAU - Wraith, David C
AU  - Wraith DC
LA  - eng
GR  - 091074/z/09/z/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130408
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3620162
OID - NLM: PMC3620162
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/12 [received]
PHST- 2013/03/07 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1371/journal.pone.0061334 [doi]
AID - PONE-D-12-35636 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 8;8(4):e61334. doi: 10.1371/journal.pone.0061334. Print 2013.

PMID- 23593264
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Drug target prediction and repositioning using an integrated network-based
      approach.
PG  - e60618
LID - 10.1371/journal.pone.0060618 [doi]
AB  - The discovery of novel drug targets is a significant challenge in drug
      development. Although the human genome comprises approximately 30,000 genes,
      proteins encoded by fewer than 400 are used as drug targets in the treatment of
      diseases. Therefore, novel drug targets are extremely valuable as the source for 
      first in class drugs. On the other hand, many of the currently known drug targets
      are functionally pleiotropic and involved in multiple pathologies. Several of
      them are exploited for treating multiple diseases, which highlights the need for 
      methods to reliably reposition drug targets to new indications. Network-based
      methods have been successfully applied to prioritize novel disease-associated
      genes. In recent years, several such algorithms have been developed, some
      focusing on local network properties only, and others taking the complete network
      topology into account. Common to all approaches is the understanding that novel
      disease-associated candidates are in close overall proximity to known disease
      genes. However, the relevance of these methods to the prediction of novel drug
      targets has not yet been assessed. Here, we present a network-based approach for 
      the prediction of drug targets for a given disease. The method allows both
      repositioning drug targets known for other diseases to the given disease and the 
      prediction of unexploited drug targets which are not used for treatment of any
      disease. Our approach takes as input a disease gene expression signature and a
      high-quality interaction network and outputs a prioritized list of drug targets. 
      We demonstrate the high performance of our method and highlight the usefulness of
      the predictions in three case studies. We present novel drug targets for
      scleroderma and different types of cancer with their underlying biological
      processes. Furthermore, we demonstrate the ability of our method to identify
      non-suspected repositioning candidates using diabetes type 1 as an example.
AD  - IP & Science, Thomson Reuters, Carlsbad, California, United States of America.
FAU - Emig, Dorothea
AU  - Emig D
FAU - Ivliev, Alexander
AU  - Ivliev A
FAU - Pustovalova, Olga
AU  - Pustovalova O
FAU - Lancashire, Lee
AU  - Lancashire L
FAU - Bureeva, Svetlana
AU  - Bureeva S
FAU - Nikolsky, Yuri
AU  - Nikolsky Y
FAU - Bessarabova, Marina
AU  - Bessarabova M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130404
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3617101
OID - NLM: PMC3617101
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/11 [received]
PHST- 2013/02/28 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1371/journal.pone.0060618 [doi]
AID - PONE-D-13-02256 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 4;8(4):e60618. doi: 10.1371/journal.pone.0060618. Print 2013.

PMID- 23593254
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Revising a personal genome by comparing and combining data from two different
      sequencing platforms.
PG  - e60585
LID - 10.1371/journal.pone.0060585 [doi]
AB  - For the robust practice of genomic medicine, sequencing results must be
      compatible, regardless of the sequencing technologies and algorithms used.
      Presently, genome sequencing is still an imprecise science and is complicated by 
      differences in the chemistry, coverage, alignment, and variant-calling
      algorithms. We identified ~3.33 million single nucleotide variants (SNVs) and
      ~3.62 million SNVs in the SJK genome using SOLiD and Illumina data, respectively.
      Approximately 3 million SNVs were concordant between the two platforms while
      68,532 SNVs were discordant; 219,616 SNVs were SOLiD-specific and 516,080 SNVs
      were Illumina-specific (i.e., platform-specific). Concordant, discordant, and
      platform-specific SNVs were further analyzed and characterized. Overall, a large 
      portion of heterozygous SNVs that were discordant with genotyping calls of single
      nucleotide polymorphism chips were highly confident. Approximately 70% of the
      platform-specific SNVs were located in regions containing repetitive sequences.
      Such platform-specificity may arise from differences between platforms, with
      regard to read length (36 bp and 72 bp vs. 50 bp), insert size (~100-300 bp vs.
      ~1-2 kb), sequencing chemistry (sequencing-by-synthesis using single nucleotides 
      vs. ligation-based sequencing using oligomers), and sequencing quality. When data
      from the two platforms were merged for variant calling, the proportion of
      callable regions of the reference genome increased to 99.66%, which was 1.43%
      higher than the average callability of the two platforms, representing ~40
      million bases. In this study, we compared the differences in sequencing results
      between two sequencing platforms. Approximately 90% of the SNVs were concordant
      between the two platforms, yet ~10% of the SNVs were either discordant or
      platform-specific, indicating that each platform had its own strengths and
      weaknesses. When data from the two platforms were merged, both the overall
      callability of the reference genome and the overall accuracy of the SNVs
      improved, demonstrating the likelihood that a re-sequenced genome can be revised 
      using complementary data.
AD  - Lee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea.
FAU - Kim, Deokhoon
AU  - Kim D
FAU - Kim, Woo-Yeon
AU  - Kim WY
FAU - Lee, Sun-Young
AU  - Lee SY
FAU - Lee, Sung-Yeoun
AU  - Lee SY
FAU - Yun, Hongseok
AU  - Yun H
FAU - Shin, Soo-Yong
AU  - Shin SY
FAU - Lee, Jungyoun
AU  - Lee J
FAU - Hong, Yoojin
AU  - Hong Y
FAU - Won, Youngmi
AU  - Won Y
FAU - Kim, Seong-Jin
AU  - Kim SJ
FAU - Lee, Yong Seok
AU  - Lee YS
FAU - Ahn, Sung-Min
AU  - Ahn SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130408
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3620462
OID - NLM: PMC3620462
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/15 [received]
PHST- 2013/02/26 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1371/journal.pone.0060585 [doi]
AID - PONE-D-12-32782 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 8;8(4):e60585. doi: 10.1371/journal.pone.0060585. Print 2013.

PMID- 23593233
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Mutual antagonism between circadian protein period 2 and hepatitis C virus
      replication in hepatocytes.
PG  - e60527
LID - 10.1371/journal.pone.0060527 [doi]
AB  - BACKGROUND: Hepatitis C virus (HCV) infects approximately 3% of the world
      population and is the leading cause of liver disease, impacting hepatocyte
      metabolism, depending on virus genotype. Hepatic metabolic functions show
      rhythmic fluctuations with 24-h periodicity (circadian), driven by molecular
      clockworks ticking through translational-transcriptional feedback loops, operated
      by a set of genes, called clock genes, encoding circadian proteins. Disruption of
      biologic clocks is implicated in a variety of disorders including fatty liver
      disease, obesity and diabetes. The relation between HCV replication and the
      circadian clock is unknown. METHODS: We investigated the relationship between HCV
      core infection and viral replication and the expression of clock genes
      (Rev-Erbalpha, Roralpha, ARNTL, ARNTL2, CLOCK, PER1, PER2, PER3, CRY1 and CRY2)
      in two cellular models, the Huh-7 cells transiently expressing the HCV core
      protein genotypes 1b or 3a, and the OR6 cells stably harboring the full-length
      hepatitis C genotype 1b replicon, and in human liver biopsies, using qRT-PCR,
      immunoblotting, luciferase assays and immunohistochemistry. RESULTS: In Huh-7
      cells expressing the HCV core protein genotype 1b, but not 3a, and in OR6 cells, 
      transcript and protein levels of PER2 and CRY2 were downregulated. Overexpression
      of PER2 led to a consistent decrease in HCV RNA replicating levels and
      restoration of altered expression pattern of a subset of interferon stimulated
      genes (ISGs) in OR6 cells. Furthermore, in liver biopsies from HCV genotype 1b
      infected patients, PER2 was markedly localized to the nucleus, consistent with an
      auto-inhibitory transcriptional feedback loop. CONCLUSIONS: HCV can modulate
      hepatic clock gene machinery, and the circadian protein PER2 counteracts viral
      replication. Further understanding of circadian regulation of HCV replication and
      rhythmic patterns of host-hosted relationship may improve the effectiveness of
      HCV antiviral therapy. This would extend to hepatic viral infections the current 
      spectrum of chronotherapies, implemented to treat metabolic, immune related and
      neoplastic disease.
AD  - Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza, Hospital San
      Giovanni Rotondo, FG, San Giovanni, Italy.
FAU - Benegiamo, Giorgia
AU  - Benegiamo G
FAU - Mazzoccoli, Gianluigi
AU  - Mazzoccoli G
FAU - Cappello, Francesco
AU  - Cappello F
FAU - Rappa, Francesca
AU  - Rappa F
FAU - Scibetta, Nunzia
AU  - Scibetta N
FAU - Oben, Jude
AU  - Oben J
FAU - Greco, Azzura
AU  - Greco A
FAU - Williams, Roger
AU  - Williams R
FAU - Andriulli, Angelo
AU  - Andriulli A
FAU - Vinciguerra, Manlio
AU  - Vinciguerra M
FAU - Pazienza, Valerio
AU  - Pazienza V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130408
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3620463
OID - NLM: PMC3620463
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/30 [received]
PHST- 2013/02/27 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.1371/journal.pone.0060527 [doi]
AID - PONE-D-13-04192 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 8;8(4):e60527. doi: 10.1371/journal.pone.0060527. Print 2013.

PMID- 23593231
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Morphometric changes in lateral ventricles of patients with recent-onset type 2
      diabetes mellitus.
PG  - e60515
LID - 10.1371/journal.pone.0060515 [doi]
AB  - It is becoming increasingly evident that type 2 diabetes mellitus can have
      effects on global and regional brain morphology. Ventricular enlargement
      reflecting cerebral atrophy has been reported particularly in elderly type 2
      diabetes patients. However, little is known about its timing through the disease 
      course and morphological variability. Using the combined volumetric and advanced 
      three-dimensional morphological approach, we identified differences in size and
      shape of the lateral ventricles between recent-onset type 2 diabetes patients and
      healthy individuals. High-resolution T1-weighted images were obtained from 23
      type 2 diabetes patients whose illness duration was less than 1 year and 23
      carefully matched healthy individuals. By volume measurement, we found enlarged
      lateral and third ventricles in type 2 diabetes patients, relative to healthy
      individuals (F(1,41 )= 7.96, P = 0.007; F(1,41) = 11.16, P = 0.002,
      respectively). Morphological analysis revealed that the expansion of lateral
      ventricles in the diabetic brain was prominent in the bilateral frontal horns.
      The current findings suggest that atrophic changes particularly of the anterior
      frontal lobe can occur as early as the first year after the clinical diagnosis of
      type 2 diabetes mellitus.
AD  - Department of Pharmacy, Ewha University College of Pharmacy, Seoul, South Korea.
FAU - Lee, Junghyun H
AU  - Lee JH
FAU - Yoon, Sujung
AU  - Yoon S
FAU - Renshaw, Perry F
AU  - Renshaw PF
FAU - Kim, Tae-Suk
AU  - Kim TS
FAU - Jung, Jiyoung J
AU  - Jung JJ
FAU - Choi, Yera
AU  - Choi Y
FAU - Kim, Binna N
AU  - Kim BN
FAU - Jacobson, Alan M
AU  - Jacobson AM
FAU - Lyoo, In Kyoon
AU  - Lyoo IK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130404
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3617143
OID - NLM: PMC3617143
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
PHST- 2012/08/30 [received]
PHST- 2013/02/28 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1371/journal.pone.0060515 [doi]
AID - PONE-D-12-26658 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 4;8(4):e60515. doi: 10.1371/journal.pone.0060515. Print 2013.

PMID- 23593212
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Bioluminescence imaging of beta cells and intrahepatic insulin gene activity
      under normal and pathological conditions.
PG  - e60411
LID - 10.1371/journal.pone.0060411 [doi]
AB  - In diabetes research, bioluminescence imaging (BLI) has been applied in studies
      of beta-cell impairment, development, and islet transplantation. To develop a
      mouse model that enables noninvasive imaging of beta cells, we generated a
      bacterial artificial chromosome (BAC) transgenic mouse in which a mouse 200-kbp
      genomic fragment comprising the insulin I gene drives luciferase expression
      (Ins1-luc BAC transgenic mouse). BLI of mice was performed using the IVIS
      Spectrum system after intraperitoneal injection of luciferin, and the
      bioluminescence signal from the pancreatic region analyzed. When compared with
      MIP-Luc-VU mice [FVB/N-Tg(Ins1-luc)VUPwrs/J] expressing luciferase under the
      control of the 9.2-kbp mouse insulin I promoter (MIP), the bioluminescence
      emission from Ins1-luc BAC transgenic mice was enhanced approximately 4-fold.
      Streptozotocin-treated Ins1-luc BAC transgenic mice developed severe diabetes
      concomitant with a sharp decline in the BLI signal intensity in the pancreas.
      Conversely, mice fed a high-fat diet for 8 weeks showed an increase in the
      signal, reflecting a decrease or increase in the beta-cell mass. Although the
      bioluminescence intensity of the islets correlated well with the number of
      isolated islets in vitro, the intensity obtained from a living mouse in vivo did 
      not necessarily reflect an absolute quantification of the beta-cell mass under
      pathological conditions. On the other hand, adenovirus-mediated gene transduction
      of beta-cell-related transcription factors in Ins1-luc BAC transgenic mice
      generated luminescence from the hepatic region for more than 1 week. These
      results demonstrate that BLI in Ins1-luc BAC transgenic mice provides a
      noninvasive method of imaging islet beta cells and extrapancreatic activity of
      the insulin gene in the liver under normal and pathological conditions.
AD  - Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba,
      Tennodai, Tsukuba, Ibaraki, Japan.
FAU - Katsumata, Tokio
AU  - Katsumata T
FAU - Oishi, Hisashi
AU  - Oishi H
FAU - Sekiguchi, Yukari
AU  - Sekiguchi Y
FAU - Nagasaki, Haruka
AU  - Nagasaki H
FAU - Daassi, Dhouha
AU  - Daassi D
FAU - Tai, Pei-Han
AU  - Tai PH
FAU - Ema, Masatsugu
AU  - Ema M
FAU - Kudo, Takashi
AU  - Kudo T
FAU - Takahashi, Satoru
AU  - Takahashi S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130404
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3617225
OID - NLM: PMC3617225
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/18 [received]
PHST- 2013/02/27 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1371/journal.pone.0060411 [doi]
AID - PONE-D-12-32627 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 4;8(4):e60411. doi: 10.1371/journal.pone.0060411. Print 2013.

PMID- 23593162
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Skin and soft tissue infections and associated complications among commercially
      insured patients aged 0-64 years with and without diabetes in the U.S.
PG  - e60057
LID - 10.1371/journal.pone.0060057 [doi]
AB  - INTRODUCTION: Skin and soft tissue infections (SSTIs) are common infections
      occurring in ambulatory and inpatient settings. The extent of complications
      associated with these infections by diabetes status is not well established.
      METHODS: Using a very large repository database, we examined medical and pharmacy
      claims of individuals aged 0-64 between 2005 and 2010 enrolled in U.S. health
      plans. Diabetes, SSTIs, and SSTI-associated complications were identified by
      ICD-9 codes. SSTIs were stratified by clinical category and setting of initial
      diagnosis. RESULTS: We identified 2,227,401 SSTI episodes, 10% of which occurred 
      in diabetic individuals. Most SSTIs were initially diagnosed in ambulatory
      settings independent from diabetes status. Abscess/cellulitis was the more common
      SSTI group in diabetic and non-diabetic individuals (66% and 59%, respectively). 
      There were differences in the frequencies of SSTI categories between diabetic and
      non-diabetic individuals (p<0.01). Among SSTIs diagnosed in ambulatory settings, 
      the SSTI-associated complication rate was over five times higher in people with
      diabetes than in people without diabetes (4.9% vs. 0.8%, p<0.01) and
      SSTI-associated hospitalizations were 4.9% and 1.1% in patients with and without 
      diabetes, respectively. Among SSTIs diagnosed in the inpatient setting,
      bacteremia/endocarditis/septicemia/sepsis was the most common associated
      complication occurring in 25% and 16% of SSTIs in patients with and without
      diabetes, respectively (p<0.01). CONCLUSIONS: Among persons with SSTIs, we found 
      SSTI-associated complications were five times higher and SSTI-associated
      hospitalizations were four times higher, in patients with diabetes compared to
      those without diabetes. SSTI prevention efforts in individuals with diabetes may 
      have significant impact on morbidity and healthcare resource utilization.
AD  - GlaxoSmithKlineVaccines, Philadelphia, Pennsylvania, United States of America.
      Jose.2.Suaya@GSK.com
FAU - Suaya, Jose A
AU  - Suaya JA
FAU - Eisenberg, Debra F
AU  - Eisenberg DF
FAU - Fang, Christy
AU  - Fang C
FAU - Miller, Loren G
AU  - Miller LG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130410
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3622669
OID - NLM: PMC3622669
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
PHST- 2012/08/08 [received]
PHST- 2013/02/22 [accepted]
PHST- 2013/04/10 [epublish]
AID - 10.1371/journal.pone.0060057 [doi]
AID - PONE-D-12-24393 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 10;8(4):e60057. doi: 10.1371/journal.pone.0060057. Print 2013.

PMID- 23593142
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients
      with uncontrolled type 1 diabetes: a pilot study.
PG  - e59524
LID - 10.1371/journal.pone.0059524 [doi]
AB  - The unpredictable behavior of uncontrolled type 1 diabetes often involves
      frequent swings in blood glucose levels that impact maintenance of a daily
      routine. An intensified insulin regimen is often unsuccessful, while other
      therapeutic options, such as amylin analog injections, use of continuous glucose 
      sensors, and islet or pancreas transplantation are of limited clinical use. In
      efforts to provide patients with a more compliable treatment method, Oramed
      Pharmaceuticals tested the capacity of its oral insulin capsule (ORMD-0801, 8 mg 
      insulin) in addressing this resistant clinical state. Eight Type I diabetes
      patients with uncontrolled diabetes (HbA1c: 7.5-10%) were monitored throughout
      the 15-day study period by means of a blind continuous glucose monitoring device.
      Baseline patient blood glucose behavior was monitored and recorded over a
      five-day pretreatment screening period. During the ensuing ten-day treatment
      phase, patients were asked to conduct themselves as usual and to self-administer 
      an oral insulin capsule three times daily, just prior to meal intake. CGM data
      sufficient for pharmacodynamics analyses were obtained from 6 of the 8 subjects. 
      Treatment with ORMD-0801 was associated with a significant 24.4% reduction in the
      frequencies of glucose readings >200 mg/dL (60.1 +/- 7.9% pretreatment vs. 45.4
      +/- 4.9% during ORMD-0801 treatment; p = 0.023) and a significant mean 16.6%
      decrease in glucose area under the curve (AUC) (66055 +/- 5547 mg/dL/24 hours vs.
      55060 +/- 3068 mg/dL/24 hours, p = 0.023), with a greater decrease during the
      early evening hours. In conclusion, ORMD-0801 oral insulin capsules in
      conjunction with subcutaneous insulin injections, well tolerated and effectively 
      reduced glycemia throughout the day. TRIAL REGISTRATION: Clinicaltrials.gov
      NCT00867594.
AD  - Diabetes Unit, Internal Medicine, Hadassah University Hospital, Jerusalem,
      Israel. eldorroy@yahoo.com
FAU - Eldor, Roy
AU  - Eldor R
FAU - Arbit, Ehud
AU  - Arbit E
FAU - Corcos, Asher
AU  - Corcos A
FAU - Kidron, Miriam
AU  - Kidron M
LA  - eng
SI  - ClinicalTrials.gov/NCT00867594
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130409
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3622027
OID - NLM: PMC3622027
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/11 [received]
PHST- 2013/02/15 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1371/journal.pone.0059524 [doi]
AID - PONE-D-12-31478 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 9;8(4):e59524. doi: 10.1371/journal.pone.0059524. Print 2013.

PMID- 23593036
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1553-7404 (Electronic)
IS  - 1553-7390 (Linking)
VI  - 9
IP  - 4
DP  - 2013 Apr
TI  - Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and
      influences risk of diverse inflammatory diseases.
PG  - e1003444
LID - 10.1371/journal.pgen.1003444 [doi]
AB  - Inflammation, which is directly regulated by interleukin-6 (IL-6) signaling, is
      implicated in the etiology of several chronic diseases. Although a common,
      non-synonymous variant in the IL-6 receptor gene (IL6R Asp358Ala; rs2228145 A>C) 
      is associated with the risk of several common diseases, with the 358Ala allele
      conferring protection from coronary heart disease (CHD), rheumatoid arthritis
      (RA), atrial fibrillation (AF), abdominal aortic aneurysm (AAA), and increased
      susceptibility to asthma, the variant's effect on IL-6 signaling is not known.
      Here we provide evidence for the association of this non-synonymous variant with 
      the risk of type 1 diabetes (T1D) in two independent populations and confirm that
      rs2228145 is the major determinant of the concentration of circulating soluble
      IL-6R (sIL-6R) levels (34.6% increase in sIL-6R per copy of the minor allele
      358Ala; rs2228145 [C]). To further investigate the molecular mechanism of this
      variant, we analyzed expression of IL-6R in peripheral blood mononuclear cells
      (PBMCs) in 128 volunteers from the Cambridge BioResource. We demonstrate that,
      although 358Ala increases transcription of the soluble IL6R isoform (P =
      8.3x10(-)(2)(2)) and not the membrane-bound isoform, 358Ala reduces surface
      expression of IL-6R on CD4+ T cells and monocytes (up to 28% reduction per
      allele; P</=5.6x10(-)(2)(2)). Importantly, reduced expression of membrane-bound
      IL-6R resulted in impaired IL-6 responsiveness, as measured by decreased
      phosphorylation of the transcription factors STAT3 and STAT1 following
      stimulation with IL-6 (P</=5.2x10(-)(7)). Our findings elucidate the regulation
      of IL-6 signaling by IL-6R, which is causally relevant to several complex
      diseases, identify mechanisms for new approaches to target the IL-6/IL-6R axis,
      and anticipate differences in treatment response to IL-6 therapies based on this 
      common IL6R variant.
AD  - Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation
      Laboratory, Department of Medical Genetics, NIHR Cambridge Biomedical Research
      Centre, Cambridge Institute for Medical Research, University of Cambridge,
      Cambridge, United Kingdom.
FAU - Ferreira, Ricardo C
AU  - Ferreira RC
FAU - Freitag, Daniel F
AU  - Freitag DF
FAU - Cutler, Antony J
AU  - Cutler AJ
FAU - Howson, Joanna M M
AU  - Howson JM
FAU - Rainbow, Daniel B
AU  - Rainbow DB
FAU - Smyth, Deborah J
AU  - Smyth DJ
FAU - Kaptoge, Stephen
AU  - Kaptoge S
FAU - Clarke, Pamela
AU  - Clarke P
FAU - Boreham, Charlotte
AU  - Boreham C
FAU - Coulson, Richard M
AU  - Coulson RM
FAU - Pekalski, Marcin L
AU  - Pekalski ML
FAU - Chen, Wei-Min
AU  - Chen WM
FAU - Onengut-Gumuscu, Suna
AU  - Onengut-Gumuscu S
FAU - Rich, Stephen S
AU  - Rich SS
FAU - Butterworth, Adam S
AU  - Butterworth AS
FAU - Malarstig, Anders
AU  - Malarstig A
FAU - Danesh, John
AU  - Danesh J
FAU - Todd, John A
AU  - Todd JA
LA  - eng
GR  - 061858/Wellcome Trust/United Kingdom
GR  - 068545/Z/02/Wellcome Trust/United Kingdom
GR  - 076113/C/04/Z/Wellcome Trust/United Kingdom
GR  - 096388/Wellcome Trust/United Kingdom
GR  - 100140/Wellcome Trust/United Kingdom
GR  - G0000934/Medical Research Council/United Kingdom
GR  - RG/08/014/British Heart Foundation/United Kingdom
GR  - U01 DK062418/DK/NIDDK NIH HHS/United States
GR  - Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130404
PL  - United States
TA  - PLoS Genet
JT  - PLoS genetics
JID - 101239074
SB  - IM
PMC - PMC3617094
OID - NLM: PMC3617094
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04 [ppublish]
PHST- 2012/12/29 [received]
PHST- 2013/02/26 [accepted]
PHST- 2013/04/04 [epublish]
AID - 10.1371/journal.pgen.1003444 [doi]
AID - PGENETICS-D-13-00012 [pii]
PST - ppublish
SO  - PLoS Genet. 2013 Apr;9(4):e1003444. doi: 10.1371/journal.pgen.1003444. Epub 2013 
      Apr 4.

PMID- 23592809
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1757-790X (Electronic)
VI  - 2013
DP  - 2013
TI  - Erdheim-Chester disease with isolated craniocerebral involvement.
LID - 10.1136/bcr-2012-006823 [doi]
LID - bcr2012006823 [pii]
AB  - Erdheim-Chester disease (ECD) is a rare non-Langerhans form of histiocytosis with
      distinctive radiographic and pathological features. Intracranial involvement is
      further a rarity, usually producing diabetes insipidus or cerebellar-brainstem
      symptoms. We report a 40-year-old man presenting with recurrent secondarily
      generalised seizures. An MRI scan of the brain revealed multiple enhancing
      intracranial masses in frontal, temporal and parietal regions. Biopsy from the
      left frontotemporal lesion confirmed it to be a rare case of ECD. The patient
      received a short course of corticosteroids initially and subsequently remained
      well-controlled on antiepileptic therapy alone. A repeat MRI of his brain showed 
      significant resolution of lesions. Osteolytic lesions in the skull vault were
      detected during follow-up which also disappeared. Interestingly, there was no
      involvement of long bones or any other system even after 12 years of follow-up.
AD  - Department of Neurology, SMS Medical College Hospital, Jaipur, Rajasthan, India. 
      drrsjain@yahoo.com,
FAU - Jain, Rajendra Singh
AU  - Jain RS
FAU - Sannegowda, Raghavendra Bakki
AU  - Sannegowda RB
FAU - Jain, Rahul
AU  - Jain R
FAU - Mathur, Tarun
AU  - Mathur T
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - bcr-2012-006823 [pii]
AID - 10.1136/bcr-2012-006823 [doi]
PST - epublish
SO  - BMJ Case Rep. 2013 Apr 15;2013. pii: bcr2012006823. doi: 10.1136/bcr-2012-006823.

PMID- 23592790
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 288
IP  - 22
DP  - 2013 May 31
TI  - Diabetes-induced Central Neuritic Dystrophy and Cognitive Deficits Are Associated
      with the Formation of Oligomeric Reticulon-3 via Oxidative Stress.
PG  - 15590-9
LID - 10.1074/jbc.M112.440784 [doi]
AB  - Diabetes is a high risk factor to dementia. To investigate the molecular
      mechanism of diabetic dementia, we induced type 2 diabetes in rats and examined
      potential changes in their cognitive functions and the neural morphology of the
      brains. We found that the diabetic rats with an impairment of spatial learning
      and memory showed the occurrence of RTN3-immunoreactive dystrophic neurites in
      the cortex. Biochemical examinations revealed the increase of a high molecular
      weight form of RTN3 (HW-RTN3) in diabetic brains. The corresponding decrease of
      monomeric RTN3 was correlated with the reduction of its inhibitory effects on the
      activity of beta-secretase (BACE1), a key enzyme for generation of beta-amyloid
      peptides. The results from immunoprecipitation combined with protein carbonyl
      detection showed that carbonylated RTN3 was significantly higher in cortical
      tissues of diabetic rats compared with control rats, indicating that
      diabetes-induced oxidative stress led to RTN3 oxidative damage. In neuroblastoma 
      SH-SY5Y cells, high glucose and/or H2O2 treatment significantly increased the
      amounts of carbonylated proteins and HW-RTN3, whereas monomeric RTN3 was reduced.
      Hence, we conclude that diabetes-induced cognitive deficits and central neuritic 
      dystrophy are correlated with the formation of aggregated RTN3 via oxidative
      stress. We provided the first evidence that oxidative damage caused the formation
      of toxic RTN3 aggregates, which participated in the pathogenesis of central
      neuritic dystrophy in diabetic brain. Present findings may offer a new
      therapeutic strategy to prevent or reduce diabetic dementia.
AD  - From the Institutes for Biomedical Science and Department of Neurobiology of the 
      School of Basic Medical Sciences, Shanghai 200032.
FAU - Zhao, Bei
AU  - Zhao B
FAU - Pan, Bai-Shen
AU  - Pan BS
FAU - Shen, Su-Wen
AU  - Shen SW
FAU - Sun, Xiao
AU  - Sun X
FAU - Hou, Zheng-Zhou
AU  - Hou ZZ
FAU - Yan, Riqiang
AU  - Yan R
FAU - Sun, Feng-Yan
AU  - Sun FY
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
SB  - IM
PMC - PMC3668720
OID - NLM: PMC3668720 [Available on 05/31/14]
OTO - NOTNLM
OT  - Aggregation
OT  - Alzheimer Disease
OT  - Axon
OT  - Central Dystrophic Neurite
OT  - Dementia
OT  - Diabetes
OT  - Dystrophin
OT  - Oxidative Stress
OT  - Reticulon
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PMCR- 2014/05/31 00:00
PHST- 2013/04/16 [aheadofprint]
AID - M112.440784 [pii]
AID - 10.1074/jbc.M112.440784 [doi]
PST - ppublish
SO  - J Biol Chem. 2013 May 31;288(22):15590-9. doi: 10.1074/jbc.M112.440784. Epub 2013
      Apr 16.

PMID- 23592686
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Mar
TI  - The association between acanthosis nigricans and dysglycemia in an ethnically
      diverse group of eighth grade students.
PG  - E328-33
LID - 10.1002/oby.20129 [doi]
AB  - OBJECTIVE: The purpose of this study was to describe the prevalence of acanthosis
      nigricans (AN) and to quantify its association with dysglycemia in an ethnically 
      diverse group of eighth-grade students. DESIGN AND METHODS: Data were collected
      in 2003 from a cross-sectional study of students from 12 middle schools in three 
      US states. Sex, race/ethnicity, and pubertal status were self-reported.
      Anthropometric measures were recorded. Trained staff identified the presence and 
      severity of AN by inspection of the back of the neck. Fasting and 2 h blood
      samples were analyzed for impaired fasting glucose (IFG), impaired glucose
      tolerance (IGT), and high-risk glycated hemoglobin (A1C), respectively, defined
      as >/=100 mg/dl, >/=140 mg/dl, and >/= 5.7-6.4%. RESULTS: Overall, 25.0%, 58.2%, 
      and 16.8% were Black, Hispanic, and White, respectively. AN was present among
      406/1,438 (28.2%) of students: 39% among Black, 30% among Hispanic, and 5.4%
      among White. IGT and high-risk A1C were present among 2.1%, and 12.4%,
      respectively. In multivariate logistic modeling after adjusting for gender,
      family history of diabetes, BMI percentile, and pubertal staging, the presence
      (vs. absence) of AN was associated with a 59% increased likelihood of high-risk
      A1C: (P = 0.04), twice the likelihood of IGT (P = 0.06), and 47% greater
      likelihood of IGT/IFG combined (P < 0.0001). Adjustment for insulin attenuated
      the ORs by 25-70%. CONCLUSION: In a racially/ethnically diverse sample of US
      adolescents, AN was common, occurring in 28% of the sample. AN was associated
      with a 50-100% increased likelihood of dysglycemia even after consideration of
      established diabetes risk factors.
CI  - Copyright (c) 2012 The Obesity Society.
AD  - Health Service Administration, D'Youville College, Buffalo, New York, USA.
      rafalson@dyc.edu
FAU - Rafalson, Lisa
AU  - Rafalson L
FAU - Pham, Trang H
AU  - Pham TH
FAU - Willi, Steven M
AU  - Willi SM
FAU - Marcus, Marsha
AU  - Marcus M
FAU - Jessup, Ann
AU  - Jessup A
FAU - Baranowski, Tom
AU  - Baranowski T
LA  - eng
GR  - U01 DK061231/DK/NIDDK NIH HHS/United States
GR  - U01-DK6122/DK/NIDDK NIH HHS/United States
GR  - U01-DK61230/DK/NIDDK NIH HHS/United States
GR  - U01-DK61231/DK/NIDDK NIH HHS/United States
GR  - U01-DK61249/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
PMC - PMC3630476
MID - NIHMS416072
OID - NLM: NIHMS416072 [Available on 09/01/13]
OID - NLM: PMC3630476 [Available on 09/01/13]
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PMCR- 2013/09/01 00:00
PHST- 2011/07/07 [received]
PHST- 2012/09/04 [accepted]
AID - 10.1002/oby.20129 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Mar;21(3):E328-33. doi: 10.1002/oby.20129.

PMID- 23592681
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Mar
TI  - Longitudinal associations between BMI, waist circumference, and cardiometabolic
      risk in US youth: monitoring implications.
PG  - E271-9
LID - 10.1002/oby.20080 [doi]
AB  - OBJECTIVE: This study examined whether change in body mass index (BMI) or waist
      circumference (WC) is associated with change in cardiometabolic risk factors and 
      differences between cardiovascular disease specific and diabetes specific risk
      factors among adolescents. We also sought to examine any differences by gender or
      baseline body mass status. DESIGN: The article is a longitudinal analysis of pre-
      and post-data collected in the HEALTHY trial. Participants were 4,603 ethnically 
      diverse adolescents who provided complete data at 6th and 8th grade assessments. 
      METHODS: The main outcome measures were percent change in the following
      cardiometabolic risk factors: fasting triglycerides, systolic and diastolic blood
      pressure, high density lipoprotein cholesterol, and glucose as well as a
      clustered metabolic risk score. Main exposures were change in BMI or WC z-score. 
      Models were run stratified by gender; secondary models were additionally
      stratified by baseline BMI group (normal, overweight, or obese). RESULTS:
      Analysis showed that when cardiometabolic risk factors were treated as continuous
      variables, there was strong evidence (P < 0.001) that change in BMI z-score was
      associated with change in the majority of the cardiovascular risk factors, except
      fasting glucose and the combined risk factor score for both boys and girls. There
      was some evidence that change in WC z-score was associated with some
      cardiovascular risk factors, but change in WC z-score was consistently associated
      with changes in fasting glucose. CONCLUSIONS: In conclusion, routine monitoring
      of BMI should be continued by health professionals, but additional information on
      disease risk may be provided by assessing WC.
CI  - Copyright (c) 2013 The Obesity Society.
AD  - Centre for Exercise, Nutrition & Health Sciences, School for Policy Studies,
      University of Bristol, Tyndall Avenue, Bristol BS8 1TP, UK. russ.jago@bris.ac.uk.
FAU - Jago, R
AU  - Jago R
FAU - Mendoza, J A
AU  - Mendoza JA
FAU - Chen, T
AU  - Chen T
FAU - Baranowski, T
AU  - Baranowski T
LA  - eng
GR  - K07 CA131178/CA/NCI NIH HHS/United States
GR  - K07CA131178/CA/NCI NIH HHS/United States
GR  - U01 DK061231/DK/NIDDK NIH HHS/United States
GR  - U01 DK61223/DK/NIDDK NIH HHS/United States
GR  - U01-DK61230/DK/NIDDK NIH HHS/United States
GR  - U01-DK61231/DK/NIDDK NIH HHS/United States
GR  - U01-DK61249/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
PMC - PMC3630468
MID - NIHMS414083
OID - NLM: NIHMS414083 [Available on 09/01/13]
OID - NLM: PMC3630468 [Available on 09/01/13]
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PMCR- 2013/09/01 00:00
PHST- 2012/03/16 [received]
PHST- 2012/07/07 [revised]
PHST- 2012/08/16 [accepted]
AID - 10.1002/oby.20080 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Mar;21(3):E271-9. doi: 10.1002/oby.20080.

PMID- 23592675
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Mar
TI  - Utility-based quality of life associated with overweight and obesity: the
      Australian diabetes, obesity, and lifestyle study.
PG  - 652-5
LID - 10.1002/oby.20290 [doi]
AB  - OBJECTIVE: This study aimed to estimate utility-based quality of life (UQoL)
      differences between healthy body weight and excess body weight categories. DESIGN
      AND METHODS: Cross-sectional analysis of 10,959 adults, participating in baseline
      data collection of the nationally representative Australian Diabetes, Obesity,
      and Lifestyle (AusDiab) Study was undertaken. Height and weight were measured by 
      trained personnel. Body weight categories were assigned as healthy weight,
      overweight, and obesity subclasses I, II and III. UQoL was assessed using the
      SF-6D, which captures physical functioning, role limitation, social functioning, 
      pain, mental health, and vitality on a score of 0.00-1.00 (worst-best). The
      relationship between body weight categories and UQoL was assessed using linear
      regression, adjusting for age, sex, education, and smoking. RESULTS: Relative to 
      the healthy weight group (mean UQoL score 0.77), mean adjusted UQoL differences
      (95% confidence intervals) were 0.001 (-0.008, 0.010) for overweight, -0.012
      (-0.022, -0.001) for class-I obese, -0.020 (-0.041, 0.001) for class-II obese,
      and -0.069 (-0.099, -0.039) for class-III obese groups. Adding metabolic syndrome
      markers to the covariates had little impact on these differences. CONCLUSION:
      Results confirmed an inverse dose-response relationship between body weight and
      UQoL in this study of Australian adults. This highlights the need to incorporate 
      UQoL measures which are sensitive to the subclasses of obesity when evaluating
      obesity interventions.
CI  - Copyright (c) 2012 The Obesity Society.
AD  - Deakin Health Economics, Deakin University, Melbourne, Australia.
      catherine.keating@deakin.edu.au
FAU - Keating, Catherine L
AU  - Keating CL
FAU - Peeters, Anna
AU  - Peeters A
FAU - Swinburn, Boyd A
AU  - Swinburn BA
FAU - Magliano, Dianna J
AU  - Magliano DJ
FAU - Moodie, Marjory L
AU  - Moodie ML
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/01/16 [received]
PHST- 2012/05/15 [accepted]
AID - 10.1002/oby.20290 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Mar;21(3):652-5. doi: 10.1002/oby.20290.

PMID- 23592674
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Mar
TI  - Dietary patterns, abdominal visceral adipose tissue, and cardiometabolic risk
      factors in African Americans: the Jackson heart study.
PG  - 644-51
LID - 10.1002/oby.20265 [doi]
AB  - OBJECTIVE: To examine the relative association of abdominal visceral adipose
      tissue (VAT) with cardiometabolic risk factors between African and European
      Americans. DESIGN AND METHODS: We conducted a cross-sectional study of 2035
      African Americans from Jackson Heart Study (JHS) and 3170 European Americans from
      Framingham Heart Study (FHS) who underwent computed tomography assessment of VAT 
      and subcutaneous adipose tissue (SAT). The FHS participants were weighted to
      match the age distribution of the JHS participants and the metabolic risk factors
      were examined by study groups in relation to VAT. RESULTS: JHS participants had
      higher rates of obesity, hypertension, diabetes and metabolic syndrome than FHS
      participants (all p = 0.001). The associations were weaker in JHS women for VAT
      with blood pressure, triglycerides, HDL-C, and total cholesterol (pinteraction = 
      0.03 to 0.001) than FHS women. In contrast, JHS men had stronger associations for
      VAT with high triglycerides, low HDL, and metabolic syndrome (all pinteraction = 
      0.001) compared to FHS men. Similar associations and gender patterns existed for 
      SAT with most metabolic risk factors. CONCLUSIONS: The relative association
      between VAT and cardiometabolic risk factors is weaker in JHS women compared to
      FHS women, whereas stronger association with triglycerides and HDL were observed 
      in JHS men.
CI  - Copyright (c) 2012 The Obesity Society.
AD  - Jackson Heart Study, University of Mississippi Medical Center, Jackson State
      University, Jackson, Mississippi, USA. jliu@umc.edu
FAU - Liu, Jiankang
AU  - Liu J
FAU - Hickson, DeMarc A
AU  - Hickson DA
FAU - Musani, Solomon K
AU  - Musani SK
FAU - Talegawkar, Sameera A
AU  - Talegawkar SA
FAU - Carithers, Teresa C
AU  - Carithers TC
FAU - Tucker, Katherine L
AU  - Tucker KL
FAU - Fox, Caroline S
AU  - Fox CS
FAU - Taylor, Herman A
AU  - Taylor HA
LA  - eng
GR  - N01-HC-95170/HC/NHLBI NIH HHS/United States
GR  - N01-HC-95171/HC/NHLBI NIH HHS/United States
GR  - N01-HC-95172/HC/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2011/11/17 [received]
PHST- 2012/05/11 [accepted]
AID - 10.1002/oby.20265 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Mar;21(3):644-51. doi: 10.1002/oby.20265.

PMID- 23592670
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Mar
TI  - Placental weight mediates the effects of prenatal factors on fetal growth: the
      extent differs by preterm status.
PG  - 609-20
LID - 10.1002/oby.20254 [doi]
AB  - OBJECTIVE: Elevated pre-pregnancy BMI, excessive gestational weight gain (GWG),
      and gestational diabetes mellitus (GDM) are known determinants of fetal growth.
      The role of placental weight is unclear. We aimed to examine the extent to which 
      placental weight mediates the associations of pre-pregnancy BMI, GWG, and GDM
      with birth weight-for-gestational age, and whether the relationships differ by
      preterm status. DESIGN AND METHODS: We examined 1,035 mother-infant pairs at
      birth from the Boston Birth Cohort. Data were collected by questionnaire and
      clinical measures. Placentas were weighed without membranes or umbilical cords.
      We performed sequential models excluding and including placental weight,
      stratified by preterm status. RESULTS: We found that 21% of mothers were obese,
      42% had excessive GWG, and 5% had GDM. Forty-one percent were preterm. Among term
      births, after adjustment for sex, gestational age, maternal age, race, parity,
      education, smoking, and stress during pregnancy, birth weight-for-gestational age
      z-score was 0.55 (0.30, 0.80) units higher for pre-pregnancy obesity vs. normal
      weight. It was 0.34 (0.13, 0.55) higher for excessive vs. adequate GWG, 0.67
      (0.24, 1.10) for GDM vs. no DM, with additional adjustment for pre-pregnancy BMI.
      Adding placental weight to the models attenuated the estimates for pre-pregnancy 
      obesity by 20%, excessive GWG by 32%, and GDM by 21%. Among preterm infants, GDM 
      was associated with 0.67 (0.34, 1.00) higher birth weight-for-gestational age
      z-score, but pre-pregnancy obesity and excessive GWG were not. Attenuation by
      placental weight was 36% for GDM. CONCLUSIONS: These results suggest that
      placental weight partially mediates the effects of pre-pregnancy obesity, GDM,
      and excessive GWG on fetal growth among term infants.
CI  - Copyright (c) 2012 The Obesity Society.
AD  - MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, 
      Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Ouyang, Fengxiu
AU  - Ouyang F
FAU - Parker, Margaret
AU  - Parker M
FAU - Cerda, Sandra
AU  - Cerda S
FAU - Pearson, Colleen
AU  - Pearson C
FAU - Fu, Lingling
AU  - Fu L
FAU - Gillman, Matthew W
AU  - Gillman MW
FAU - Zuckerman, Barry
AU  - Zuckerman B
FAU - Wang, Xiaobin
AU  - Wang X
LA  - eng
GR  - R01 HD041702/HD/NICHD NIH HHS/United States
GR  - R21 ES011666/ES/NIEHS NIH HHS/United States
GR  - R21 HD066471/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2011/07/21 [received]
PHST- 2012/03/23 [accepted]
AID - 10.1002/oby.20254 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Mar;21(3):609-20. doi: 10.1002/oby.20254.

PMID- 23592669
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Mar
TI  - Adolescent exergame play for weight loss and psychosocial improvement: a
      controlled physical activity intervention.
PG  - 598-601
LID - 10.1002/oby.20282 [doi]
AB  - Overweight and obese youth, who face increased risk of medical complications
      including heart disease and type II diabetes, can benefit from sustainable
      physical activity interventions that result in weight loss. OBJECTIVE: This study
      examined whether a 20-week exergame (i.e., videogame that requires gross motor
      activity) intervention can produce weight loss and improve psychosocial outcomes 
      for 54 overweight and obese African-American adolescents. DESIGN AND METHODS:
      Participants were recruited from a public high school and randomly assigned to
      competitive exergame, cooperative exergame, or control conditions. All exergame
      participants were encouraged to play the Nintendo Wii Active game for 30-60 min
      per school day in a lunch-time or after-school program. Cooperative exergame
      participants worked with a peer to expend calories and earn points together,
      whereas competitive exergame participants competed against a peer. Control
      participants continued regular daily activities. Outcome measures included
      changes in weight, peer support, self-efficacy, and self-esteem, measured at
      baseline, and at approximately 10 and 20 weeks. RESULTS: Growth curve analysis
      revealed that cooperative exergame players lost significantly more weight (mean =
      1.65 kg; s.d. = 4.52) than the control group, which did not lose weight. The
      competitive exergame players did not differ significantly from the other
      conditions. Cooperative exergame players also significantly increased in
      self-efficacy compared to the control group, and both exergame conditions
      significantly increased in peer support more than the control group. CONCLUSION: 
      Exergames, especially played cooperatively, can be an effective technological
      tool for weight loss among youth.
CI  - Copyright (c) 2012 The Obesity Society.
AD  - Division of Population Science, Pennington Biomedical Research Center, Baton
      Rouge, Louisiana, USA. amanda.staiano@pbrc.edu
FAU - Staiano, Amanda E
AU  - Staiano AE
FAU - Abraham, Anisha A
AU  - Abraham AA
FAU - Calvert, Sandra L
AU  - Calvert SL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2011/08/03 [received]
PHST- 2012/05/09 [accepted]
AID - 10.1002/oby.20282 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Mar;21(3):598-601. doi: 10.1002/oby.20282.

PMID- 23592659
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Mar
TI  - Nicotinamide nucleotide transhydrogenase mRNA expression is related to human
      obesity.
PG  - 529-34
LID - 10.1002/oby.20095 [doi]
AB  - OBJECTIVE: A spontaneous deletion in the nicotinamide nucleotide transhydrogenase
      (Nnt) gene eliminating exons 7-11 in C57BL/6J (B6J) mice is associated with
      reduced glucose-stimulated insulin secretion in vitro, impaired glucose
      tolerance, higher epigonadal fat mass, and altered susceptibility to diet induced
      obesity of male B6J mice was proposed. A potential implication for NNT in human
      adipose tissue distribution has not been investigated so far. DESIGN AND METHODS:
      Therefore, NNT mRNA expression in paired human samples of visceral (vis) and
      subcutaneous (sc) adipose tissue from 221 subjects with a wide range of body mass
      index (BMI), insulin sensitivity, and glucose tolerance was analyzed. RESULTS:
      NNT mRNA expression is significantly higher in visceral fat of obese patients and
      correlates with body weight, BMI, % body fat, visceral and sc fat area, waist and
      hip circumference, and fasting plasma insulin (FPI). Multivariate linear
      regression analysis revealed visceral NNT expression as age and gender
      independent predictor of BMI, waist circumference, visceral fat area, and % body 
      fat, but not FPI and 2 h OGTT glucose. CONCLUSION: In conclusion, a functional
      relevance of NNT in the development of human obesity and visceral fat
      distribution was suggested here.
CI  - Copyright (c) 2013 The Obesity Society.
AD  - Department of Medicine, Endocrinology and Diabetes, Universitat Leipzig, Leipzig,
      Germany.
FAU - Heiker, John T
AU  - Heiker JT
FAU - Kern, Matthias
AU  - Kern M
FAU - Kosacka, Joanna
AU  - Kosacka J
FAU - Flehmig, Gesine
AU  - Flehmig G
FAU - Stumvoll, Michael
AU  - Stumvoll M
FAU - Shang, Edward
AU  - Shang E
FAU - Lohmann, Tobias
AU  - Lohmann T
FAU - Dressler, Miriam
AU  - Dressler M
FAU - Kovacs, Peter
AU  - Kovacs P
FAU - Bluher, Matthias
AU  - Bluher M
FAU - Kloting, Nora
AU  - Kloting N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/04/24 [received]
PHST- 2012/08/20 [accepted]
AID - 10.1002/oby.20095 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Mar;21(3):529-34. doi: 10.1002/oby.20095.

PMID- 23592657
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Linking)
VI  - 21
IP  - 3
DP  - 2013 Mar
TI  - The association between self-reported sleep quality and overweight in a Chinese
      population.
PG  - 486-92
LID - 10.1002/oby.20259 [doi]
AB  - OBJECTIVE: Sleep quality and obesity are associated with type 2 diabetes,
      hypertension, and metabolic syndrome. However, there is limited research on the
      association between sleep quality and obesity, and thus the aim of this study is 
      to investigate this relationship in a Chinese population. DESIGN AND METHODS:
      Subjects were recruited from the Prevention Health Center of National Cheng Kung 
      University Hospital. Anthropometric data and metabolic parameters were measured. 
      Being overweight or obese was defined according to the recommendations of the
      Department of Health in Taiwan. Sleep quality was assessed using the Pittsburgh
      Sleep Quality Index (PSQI). RESULTS: Of the total 2,803 subjects, 1,059 were
      classified as normal weight, 1,127 were overweight, and 617 were obese. The
      global PSQI score were 6.30 +/- 2.56, 6.61 +/- 2.96, and 7.02 +/- 2.95 in
      subjects who were normal weight, overweight, and obese, respectively (test for
      trend, P < 0.001). Of the variables tested in the multivariate linear regression 
      model, female gender, being overweight, obesity, sleep duration, and alcohol
      drinking were significantly associated with global PSQI scores, and in the
      multivariate logistic regression model, female gender, being overweight, obesity,
      and sleep duration were independent predictors of poor sleepers after controlling
      for age, gender, BMI or different weight statuses, sleep duration, alcohol
      drinking, smoking, habitual exercise, hypertension, newly diagnosed diabetes,
      total cholesterol, high-density lipoprotein, triglyceride, estimated glomerular
      filtration rate, and alanine aminotransferase. CONCLUSIONS: In conclusion, female
      gender, being overweight, obesity, and sleep duration were associated with poor
      sleep quality independent of cardiometabolic risk factors. In clinical practice, 
      subjects who are obese, or even only overweight, should be evaluated for the
      presence of sleep disturbance.
CI  - Copyright (c) 2012 The Obesity Society.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      National Cheng Kung University Hospital, Taiwan, Republic of China.
FAU - Hung, Hao-Chang
AU  - Hung HC
FAU - Yang, Yi-Ching
AU  - Yang YC
FAU - Ou, Horng-Yih
AU  - Ou HY
FAU - Wu, Jin-Shang
AU  - Wu JS
FAU - Lu, Feng-Hwa
AU  - Lu FH
FAU - Chang, Chih-Jen
AU  - Chang CJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2011/10/15 [received]
PHST- 2012/05/23 [accepted]
AID - 10.1002/oby.20259 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2013 Mar;21(3):486-92. doi: 10.1002/oby.20259.

PMID- 23592612
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1521-0081 (Electronic)
IS  - 0031-6997 (Linking)
VI  - 65
IP  - 3
DP  - 2013 Jul
TI  - Adenosine kinase: exploitation for therapeutic gain.
PG  - 906-43
LID - 10.1124/pr.112.006361 [doi]
AB  - Adenosine kinase (ADK; EC 2.7.1.20) is an evolutionarily conserved
      phosphotransferase that converts the purine ribonucleoside adenosine into
      5'-adenosine-monophosphate. This enzymatic reaction plays a fundamental role in
      determining the tone of adenosine, which fulfills essential functions as a
      homeostatic and metabolic regulator in all living systems. Adenosine not only
      activates specific signaling pathways by activation of four types of adenosine
      receptors but it is also a primordial metabolite and regulator of biochemical
      enzyme reactions that couple to bioenergetic and epigenetic functions. By
      regulating adenosine, ADK can thus be identified as an upstream regulator of
      complex homeostatic and metabolic networks. Not surprisingly, ADK dysfunction is 
      involved in several pathologies, including diabetes, epilepsy, and cancer.
      Consequently, ADK emerges as a rational therapeutic target, and
      adenosine-regulating drugs have been tested extensively. In recent attempts to
      improve specificity of treatment, localized therapies have been developed to
      augment adenosine signaling at sites of injury or pathology; those approaches
      include transplantation of stem cells with deletions of ADK or the use of gene
      therapy vectors to downregulate ADK expression. More recently, the first human
      mutations in ADK have been described, and novel findings suggest an unexpected
      role of ADK in a wider range of pathologies. ADK-regulating strategies thus
      represent innovative therapeutic opportunities to reconstruct network homeostasis
      in a multitude of conditions. This review will provide a comprehensive overview
      of the genetics, biochemistry, and pharmacology of ADK and will then focus on
      pathologies and therapeutic interventions. Challenges to translate ADK-based
      therapies into clinical use will be discussed critically.
AD  - Legacy Research Institute, 1225 NE 16th Ave, Portland, OR 97202, USA.
      dboison@downeurobiology.org
FAU - Boison, Detlev
AU  - Boison D
LA  - eng
GR  - MH083973/MH/NIMH NIH HHS/United States
GR  - NS061844/NS/NINDS NIH HHS/United States
GR  - NS065957/NS/NINDS NIH HHS/United States
GR  - R01 MH083973/MH/NIMH NIH HHS/United States
GR  - R01 NS061844/NS/NINDS NIH HHS/United States
GR  - R01 NS065957/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130416
PL  - United States
TA  - Pharmacol Rev
JT  - Pharmacological reviews
JID - 0421737
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
AID - 65/3/906 [pii]
AID - 10.1124/pr.112.006361 [doi]
PST - epublish
SO  - Pharmacol Rev. 2013 Apr 16;65(3):906-43. doi: 10.1124/pr.112.006361. Print 2013
      Jul.

PMID- 23592567
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
DP  - 2013 Apr 16
TI  - A randomized, controlled, multi-center trial to evaluate the safety and efficacy 
      of zotarolimus vs. paclitaxel-eluting stents in de novo occlusive lesions in
      coronary arteries: Five-year results from the ZOMAXX I trial.
LID - 10.1002/ccd.24958 [doi]
AB  - Background: The ZOMAXX I trial tested the non-inferiority of a
      zotarolimus-eluting coronary stent (ZoMaxx) as compared to a paclitaxel-eluting
      coronary stent (Taxus Express2 ) in a randomized trial of percutaneous
      intervention for de novo coronary artery stenosis. Angiographic analysis at the
      primary endpoint of nine months has been reported previously. The purpose of this
      follow-on analysis was to describe the clinical results of the ZoMaxx and Taxus
      cohorts of the ZOMAXX I trial after five years. Methods and Results: In the
      ZOMAXX I trial, 199 patients received a ZoMaxx stent and 197 patients received a 
      Taxus stent at 29 investigative sites in Europe, Australia, and New Zealand. The 
      two groups were generally well-matched with respect to both clinical and lesional
      characteristics, including the incidence of diabetes (ZoMaxx 22% vs. Taxus 26%;
      p=0.29), reference vessel diameter (ZoMaxx 2.79+/-0.43 mm vs. Taxus 2.81+/-0.46
      mm; p=0.65), and lesion length (ZoMaxx 14.9+/-5.7 mm vs. Taxus 14.6+/-5.5;
      p=0.61). Through five years of follow-up, a total of 21 patients had died, 6
      patients had withdrawn, 9 had been lost to follow-up and 13 missed their
      five-year visit, leaving a total of 347 patients for analysis (169 ZoMaxx and 178
      Taxus). At the five-year time point, there were no significant differences in any
      clinical metric including ischemia-driven target lesion revascularization (ZoMaxx
      10.6% vs. Taxus 7.1%; p=0.29), Q-wave myocardial infarction (ZoMaxx 1.5% vs.
      Taxus 1.0%; p=0.99), definite/probable stent thrombosis (ZoMaxx 1.5% vs. Taxus
      3.0%; p=0.34) and cardiac death (ZoMaxx 3.0% vs. Taxus 1.0%; p=0.28).
      Conclusions: After five years, the differences is clinical outcome between
      patients treated with ZoMaxx vs. Taxus stents did not reach statistical
      significance. However, the nominally higher rate of ischemia-driven target lesion
      revascularization (10.6% v. 7.1%) and the previously reported higher rate of
      restenosis after nine months, suggests that the ZoMaxx stent afforded less
      neointimal inhibition as compared to Taxus. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc., a Wiley company.
AD  - Centre Cardiologique du Nord, Saint-Denis, France.
FAU - Chevalier, Bernard
AU  - Chevalier B
FAU - Dimario, Carlo
AU  - Dimario C
FAU - Neumann, Franz-Josef
AU  - Neumann FJ
FAU - Cutlip, Donald E
AU  - Cutlip DE
FAU - Williams, David O
AU  - Williams DO
FAU - Ormiston, John
AU  - Ormiston J
FAU - Grube, Eberhard
AU  - Grube E
FAU - Whitbourn, Robert
AU  - Whitbourn R
FAU - Coe, Jessie
AU  - Coe J
FAU - Schwartz, Lewis B
AU  - Schwartz LB
CN  - ZOMAXX I Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the
      Society for Cardiac Angiography & Interventions
JID - 100884139
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/08/29 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/04/07 [accepted]
AID - 10.1002/ccd.24958 [doi]
PST - aheadofprint
SO  - Catheter Cardiovasc Interv. 2013 Apr 16. doi: 10.1002/ccd.24958.

PMID- 23592501
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1464-3502 (Electronic)
IS  - 0735-0414 (Linking)
DP  - 2013 Apr 16
TI  - Relationship Between Alcohol Intake and Lipid Accumulation Product in Middle-aged
      Men.
AB  - AIMS: Lipid accumulation product (LAP), defined as a product of waist
      circumference and triglycerides, has recently been proposed as a predictor of
      cardiovascular disease and diabetes mellitus. The purpose of this study was to
      determine whether and how LAP is associated with alcohol drinking. METHODS:
      Subjects were 21,378 men aged 35-60 years and they were divided by alcohol intake
      into non-, light (<22 g ethanol/day), heavy (>/=22 and <44 g ethanol/day) and
      very heavy (>/=44 g ethanol/day) drinkers. Relationships between alcohol intake
      and LAP were analyzed by using multivariate analyses with adjustment for age,
      smoking and habitual exercise. RESULTS: Log-transformed LAP levels in light
      drinkers and very heavy drinkers were significantly (P< 0.01) lower and higher,
      respectively, than the level in non-drinkers, and the levels were comparable in
      non- and heavy drinkers (non-drinkers, 1.335 +/- 0.005; light drinkers, 1.290 +/-
      0.009; heavy drinkers, 1.348 +/- 0.005 and very heavy drinkers, 1.414 +/- 0.006).
      The inverse association of alcohol intake with LAP was more prominent in smokers 
      and subjects without regular exercise than in non-smokers and subjects with
      regular exercise, respectively, while the positive association of alcohol with
      LAP was more prominent in non-smokers than in smokers. Odds ratio for
      hyperglycemia of subjects with vs. subjects without high LAP was significantly
      higher than a reference level of 1.00, and this association was not different
      among the four alcohol groups. CONCLUSION: There is a J-shaped relationship
      between alcohol intake and LAP, which is confounded by smoking and habitual
      exercise.
AD  - Department of Environmental and Preventive Medicine, Hyogo College of Medicine,
      Mukogawa-cho 1-1, Nishinomiya, Hyogo 663-8501, Japan.
FAU - Wakabayashi, Ichiro
AU  - Wakabayashi I
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Alcohol Alcohol
JT  - Alcohol and alcoholism (Oxford, Oxfordshire)
JID - 8310684
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - agt032 [pii]
AID - 10.1093/alcalc/agt032 [doi]
PST - aheadofprint
SO  - Alcohol Alcohol. 2013 Apr 16.

PMID- 23592489
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 Apr 16
TI  - Improvement of beta-cell function after achievement of optimal glycemic control
      via long-term continuous subcutaneous insulin infusion therapy in non-newly
      diagnosed type 2 diabetic patients with suboptimal glycemic control.
LID - 10.1002/dmrr.2416 [doi]
AB  - BACKGROUND: Achieving euglycemia by continuous subcutaneous insulin infusion
      (CSII) therapy alone has been shown to restore beta-cell function in patients
      with newly diagnosed type 2 diabetes. However, the efficacy has not been
      evaluated in patients with non-newly diagnosed type 2 diabetes and suboptimal
      glycemic control. METHODS: Of the 1220 patients with type 2 diabetes who began
      CSII therapy from March 2000 to March 2007, we retrospectively selected patients 
      using the following inclusion criteria: HbA1c >/=7.0%, diabetes duration >/=1
      year before CSII therapy, and duration of CSII therapy >/=6 months. We evaluated 
      sequential changes in HbA1c and serum C-peptide levels measured at a 6- to
      12-month intervals during CSII therapy. RESULTS: In the 521 subjects included in 
      this study (median diabetes duration, 10 years [interquartile range, IQR,
      6.0-17.0]; CSII therapy, </=30 months), median HbA1c decreased from 8.7% (IQR
      7.7-10.0) at baseline to 6.3% (IQR 5.9-6.9) after 6 months of CSII therapy (p <
      0.0001). During the subsequent 24 months, median HbA1c levels were maintained
      between 6.3% and 6.5% (p < 0.0001 for all time points versus baseline). At 12
      months after CSII therapy, median C-peptide levels began to increase compared
      with baseline (fasting level, 23% increase, p < 0.0001; 2-h postprandial level,
      26% increase, p = 0.022), and the increase was maintained at 30 months (fasting
      level, 39%; 2-h postprandial level, 53%; p < 0.0001 for all versus baseline).
      CONCLUSIONS: beta-cell function was significantly improved in patients with
      non-newly diagnosed and suboptimally controlled type 2 diabetes after achieving
      and maintaining optimal glycemic control with long-term CSII therapy alone. This 
      article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Internal Medicine, School of Medicine, Konkuk University Hospital, 
      Chungju, South Korea.
FAU - Choi, Soo-Bong
AU  - Choi SB
FAU - Lee, Jun-Ho
AU  - Lee JH
FAU - Lee, Ju-Han
AU  - Lee JH
FAU - Kim, Seonguk
AU  - Kim S
FAU - Han, Sang-Don
AU  - Han SD
FAU - Kim, Ick-Hee
AU  - Kim IH
FAU - Noh, Yun-Hee
AU  - Noh YH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/05/24 [received]
PHST- 2013/03/01 [revised]
PHST- 2013/03/11 [accepted]
AID - 10.1002/dmrr.2416 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 Apr 16. doi: 10.1002/dmrr.2416.

PMID- 23592484
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Apr 16
TI  - A novel method for measuring intestinal and hepatic triacylglycerol kinetics.
AB  - The study aimed to 1] develop a method which completely separated hepatic (VLDL1,
      VLDL2) and intestinal (chylomicron, CM) lipoproteins and 2] use the method to
      measure triacylglycerol (TAG) kinetics in these lipoproteins in the fed and
      fasting state in healthy subjects using intravenous 2H5-glycerol as the tracer.
      An immunoaffinity method which completely separated hepatic and intestinal
      particles using sequential binding to three antibodies to apolipoprotein B100
      (apoB100) was established and validated. Six healthy volunteers were studied in a
      fasted and continuous feeding study (study 1). Five additional healthy volunteers
      were studied in a continuous feeding study which included an oral 13C3-glycerol
      tripalmitin tracer (study 2). In both studies an intravenous bolus of
      2H5-glycerol was administered to label TAG in hepatic and intestinal
      lipoproteins. In both feeding studies there was sufficient incorporation of the
      glycerol tracer into the exogenous lipoproteins to enable isotopic enrichment to 
      be measured. In study 2 the oral tracer enrichment in VLDL1 was <5% of CM
      enrichment, 150 minutes after tracer administration demonstrating negligible
      contamination of VLDL1 with apoB48. Western blotting showed no detectable apoB100
      in CMs. VLDL1 and VLDL2 TAG fractional catabolic rate (FCR) did not differ
      between feeding and fasting (study 1). There was no difference between CM and
      VLDL1 TAG FCR in both fed studies. In fed study 2, 47% of the total TAG
      production rate (CM+VLDL1) was from CM. This methodology may be a useful tool for
      understanding the abnormalities in postprandial TAG kinetics in metabolic
      syndrome and type 2 diabetes.
AD  - 1University of Surrey.
FAU - Sun, Feifei
AU  - Sun F
FAU - Stolinski, Mike
AU  - Stolinski M
FAU - Shojaee-Moradie, Fariba
AU  - Shojaee-Moradie F
FAU - Lou, Shaoying
AU  - Lou S
FAU - Ma, Yuying
AU  - Ma Y
FAU - Hovorka, Roman
AU  - Hovorka R
FAU - Umpleby, A Margot
AU  - Umpleby AM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - ajpendo.00105.2013 [pii]
AID - 10.1152/ajpendo.00105.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Apr 16.

PMID- 23592483
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Apr 16
TI  - Antecedent Glycemic Control Reduces Severe Hypoglycemia-Induced Neuronal Damage
      in Diabetic Rats.
AB  - Brain damage due to severe hypoglycemia occurs in insulin treated people with
      diabetes. This study tests the hypothesis that chronic insulin therapy that
      normalizes elevated blood glucose in diabetic rats would be neuroprotective
      against brain damage induced by an acute episode of severe hypoglycemia. Male
      Sprague-Dawley rats were split into 3 groups, 1) control, non-diabetic, 2)
      STZ-diabetic, and 3) insulin treated STZ-diabetic. After 3 weeks of chronic
      treatment, unrestrained, awake rats underwent acute hyperinsulinemic/severe
      hypoglycemic (10-15 mg/dl) clamps for 1 hour. Rats were subsequently analyzed for
      brain damage and cognitive function. Severe hypoglycemia-induced 15-fold more
      neuronal damage in STZ diabetic rats as compared to non-diabetic rats. Chronic
      insulin treatment of diabetic rats, that nearly normalized glucose levels,
      markedly reduced neuronal damage induced by severe hypoglycemia. Fortunately, no 
      cognitive defects associated with the hypoglycemia-induced brain damage were
      observed in any group. In conclusion, antecedent blood glucose control represents
      a major modifiable therapeutic intervention that can afford diabetic subjects
      neuroprotection against severe hypoglycemia-induced brain damage.
AD  - 1Washington University in St. Louis.
FAU - Reno, Candace M
AU  - Reno CM
FAU - Tanoli, Tariq
AU  - Tanoli T
FAU - Bree, Adam
AU  - Bree A
FAU - Daphna-Iken, Dorit
AU  - Daphna-Iken D
FAU - Cui, Chen
AU  - Cui C
FAU - Maloney, Susan E
AU  - Maloney SE
FAU - Wozniak, David F
AU  - Wozniak DF
FAU - Fisher, Simon J
AU  - Fisher SJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - ajpendo.00084.2013 [pii]
AID - 10.1152/ajpendo.00084.2013 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Apr 16.

PMID- 23592481
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1522-1555 (Electronic)
IS  - 0193-1849 (Linking)
DP  - 2013 Apr 16
TI  - Upregulation of p21 activates the intrinsic apoptotic pathway in beta cells.
AB  - Diabetes manifests from a loss in functional beta cell mass, which is regulated
      by a dynamic balance of various cellular processes including beta cell growth,
      proliferation, and death as well as secretory function. The cell cycle machinery 
      comprised of cyclins, kinases, and inhibitors regulate proliferation. However,
      their involvement during beta cell stress during the development of diabetes is
      not well understood. Interestingly, in a screen of multiple cell cycle
      inhibitors, p21 was dramatically upregulated in INS-1-derived 832/13 cells and
      rodent islets by two pharmacologic inducers of beta cell stress, dexamethasone
      and thapsigargin. We hypothesized that beta cell stress upregulates p21 to
      activate the apoptotic pathway and suppress cell survival signaling. To this end,
      p21 was adenovirally overexpressed in pancreatic rat islets and 832/13 cells. As 
      expected, p21 overexpression resulted in decreased [3H]-thymidine incorporation. 
      Flow cytometry analysis in p21-transduced 832/13 cells verified lower replication
      as indicated by a decreased cell population in S-phase and a block in G2/M
      transition. The sub-G0 cell population was higher with p21 overexpression and was
      attributable to apoptosis, demonstrated by increased annexin-positive stained
      cells and cleaved caspase 3 protein. p21-mediated caspase 3 cleavage was
      inhibited by either overexpression of the anti-apoptotic mitochondrial protein
      Bcl-2 or siRNA-mediated suppression of the pro-apoptotic proteins Bax and Bak.
      Therefore, an intact intrinsic apoptotic pathway is central for p21-mediated cell
      death. In summary, our findings indicate that beta cell apoptosis can be
      triggered by p21 during stress, thus being a potential target to inhibit for
      protection of functional beta cell mass.
AD  - 1Indiana University School of Medicine.
FAU - Hernandez, Angelina M
AU  - Hernandez AM
FAU - Colvin, E Scott
AU  - Colvin ES
FAU - Chen, Yi-Chun
AU  - Chen YC
FAU - Geiss, Steven L
AU  - Geiss SL
FAU - Eller, Lindsay E
AU  - Eller LE
FAU - Fueger, Patrick T
AU  - Fueger PT
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Am J Physiol Endocrinol Metab
JT  - American journal of physiology. Endocrinology and metabolism
JID - 100901226
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - ajpendo.00663.2012 [pii]
AID - 10.1152/ajpendo.00663.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Endocrinol Metab. 2013 Apr 16.

PMID- 23592441
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
DP  - 2013 Apr 16
TI  - Immunometabolic role of long-chain omega-3 fatty acids in obesity-induced
      inflammation.
LID - 10.1002/dmrr.2414 [doi]
AB  - Inflammation links obesity with development of insulin resistance. Macrophages
      and phagocytic immune cells communicate with metabolic tissues to direct an
      inflammatory response caused by overnutrition and expanding adipose tissue.
      Marine-derived omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and 
      docosahexaenoic acid (DHA), modulate inflammatory signaling events, providing
      various anti-inflammatory and cardioprotective benefits. Moreover, EPA and DHA
      may improve insulin sensitivity by generating pro-resolving lipid mediators and
      promoting alternatively activated macrophages. This review will assess the role
      of EPA and DHA in ameliorating obesity-induced inflammation, evaluating clinical 
      evidence and mechanisms of action. The pathophysiology of insulin resistance
      resulting from obesity-induced inflammation will be discussed, highlighting the
      relationship between metabolism and immunity, and in particular, how EPA and DHA 
      work with both systems to modulate immunometabolic complications and chronic
      disease. This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - The Pennsylvania State University, Nutritional Sciences, University Park, PA,
      USA.
FAU - Flock, Michael Ryan
AU  - Flock MR
FAU - Rogers, Connie J
AU  - Rogers CJ
FAU - Prabhu, Kumble Sandeep
AU  - Prabhu KS
FAU - Kris-Etherton, Penny M
AU  - Kris-Etherton PM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/11/19 [received]
PHST- 2013/01/17 [revised]
PHST- 2013/03/06 [accepted]
AID - 10.1002/dmrr.2414 [doi]
PST - aheadofprint
SO  - Diabetes Metab Res Rev. 2013 Apr 16. doi: 10.1002/dmrr.2414.

PMID- 23592405
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1875-8312 (Electronic)
IS  - 1569-5794 (Linking)
VI  - 29
IP  - 4
DP  - 2013 Apr
TI  - Impact of cardiac magnetic resonance imaging on cardiac device and surgical
      therapy: a prospective study.
PG  - 855-64
LID - 10.1007/s10554-012-0131-4 [doi]
AB  - Cardiac magnetic resonance (CMR) imaging may allow more appropriate selection of 
      patients for cardiac device implantation and/or cardiac surgery. In this
      prospective observational study we evaluated the impact of CMR imaging on cardiac
      device and surgical therapy. All CMR examinations performed in a single centre
      over a 2 year period were prospectively recorded in a dedicated database under 4 
      clinical pathways [cardiomyopathy, viability, tumour/mass and arrythmogenic right
      ventricular cardiomyopathy (ARVC)]. Baseline data entered included planned
      cardiac device implantation and/or cardiac surgical intervention. Patients were
      contacted 6 months following CMR to evaluate the impact of CMR on planned
      therapy. Cost savings due to CMR were calculated as the number of surgical or
      device procedures averted following CMR scanning multiplied by their respective
      cost weights. Of 732 CMR examinations performed, the clinical pathway was
      cardiomyopathy in 488 (67 %), ARVC in 118 (16 %), viability in 92 (12 %) and
      tumour/mass in 34 (5 %). Six month follow-up was available in 666/732 patients.
      Following CMR, 56/150 (37 %) of patients with an initial plan for device
      implantation or cardiac surgery, did not undergo the planned intervention (P <
      0.001, one-sample exact binomial test). Of 516 patients without an initial device
      or surgical plan, 33 (6 %) CMR resulted in device implantation or cardiac surgery
      (P < 0.001, Chi squared). Overall, the estimated saving due to CMR-guided
      management changes was AUD$737,270. CMR has a significant impact on patient
      management and offers potential cost savings with respect to selection of device 
      and surgical therapy for cardiac disease.
AD  - Alfred Heart Centre and BakerIDI Heart and Diabetes Research Institute,
      Melbourne, Australia, andrew.taylor@bakeridi.edu.au.
FAU - Taylor, Andrew J
AU  - Taylor AJ
FAU - Ellims, Andris
AU  - Ellims A
FAU - Lew, Philip J K
AU  - Lew PJ
FAU - Murphy, Bridie
AU  - Murphy B
FAU - Pally, Suzana
AU  - Pally S
FAU - Younie, Sandra
AU  - Younie S
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - United States
TA  - Int J Cardiovasc Imaging
JT  - The international journal of cardiovascular imaging
JID - 100969716
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/08/09 [received]
PHST- 2012/09/19 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 10.1007/s10554-012-0131-4 [doi]
PST - ppublish
SO  - Int J Cardiovasc Imaging. 2013 Apr;29(4):855-64. doi: 10.1007/s10554-012-0131-4. 
      Epub 2013 Apr 17.

PMID- 23592316
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1098-8785 (Electronic)
IS  - 0735-1631 (Linking)
DP  - 2013 Apr 16
TI  - Risk Factors for Preeclampsia in Twin Pregnancies.
AB  - Objective Twin pregnancy is associated with an increased incidence of
      preeclampsia. However, it is unknown if the risk factors for preeclampsia in twin
      pregnancies are the same as those in singleton pregnancies.Methods Case-control
      analysis of all twin pregnancies managed by one maternal-fetal medicine practice 
      from 2005 to 2012. Patients with chronic hypertension were excluded, as were
      monochorionic-monoamniotic twins. We compared patient and pregnancy
      characteristics between patients who did and did not develop preeclampsia,
      according to standard American College of Obstetricians and Gynecologists
      definitions. Odds ratios, adjusted odds ratios (aORs), and 95% confidence
      intervals (CIs) were obtained using chi-square analysis and logistic
      regression.Results Of the patients with twin pregnancies, 513 were included, and 
      76 (14.8%) patients developed preeclampsia. On univariable analysis, the risk
      factors associated with preeclampsia in twin pregnancies were egg donation,
      nonwhite race, nulliparity, prepregnancy obesity, and gestational diabetes. On
      adjusted analysis, the risk factors independently associated with preeclampsia
      were egg donation (aOR 2.409, 95% CI 1.051, 5.524) and prepregnancy obesity (aOR 
      2.367, 95% CI 1.079, 5.192).Conclusions In twin pregnancy, the risk factors
      independently associated with preeclampsia are egg donation and prepregnancy
      obesity.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
AD  - Department of Obstetrics, Gynecology, and Reproductive Science, Mount Sinai
      School of Medicine, New York, New York.
FAU - Fox, Nathan S
AU  - Fox NS
FAU - Roman, Ashley S
AU  - Roman AS
FAU - Saltzman, Daniel H
AU  - Saltzman DH
FAU - Hourizadeh, Tanya
AU  - Hourizadeh T
FAU - Hastings, Jeffrey
AU  - Hastings J
FAU - Rebarber, Andrei
AU  - Rebarber A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Am J Perinatol
JT  - American journal of perinatology
JID - 8405212
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/16 [epublish]
AID - 10.1055/s-0033-1343775 [doi]
PST - aheadofprint
SO  - Am J Perinatol. 2013 Apr 16.

PMID- 23592164
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1879-1883 (Electronic)
IS  - 0002-9610 (Linking)
VI  - 205
IP  - 5
DP  - 2013 May
TI  - Factors affecting healing and survival after finger amputations in patients with 
      digital artery occlusive disease.
PG  - 566-9; discussion 569-70
LID - 10.1016/j.amjsurg.2013.01.019 [doi]
LID - S0002-9610(13)00121-9 [pii]
AB  - BACKGROUND: Finger amputations are typically performed as distal as possible to
      preserve maximum finger length. Failure of primary amputation leads to additional
      procedures, which could potentially be avoided if a more proximal amputation was 
      initially performed. The effect of single versus multiple procedures on morbidity
      and mortality is not known. We evaluated factors that predicted primary healing
      and the effects of secondary procedures on survival. METHODS: Patients undergoing
      finger amputations from 1995 to 2011 were evaluated for survival with uni- and
      multivariate analysis of demographic data and preoperative vascular laboratory
      studies to assess factors influencing primary healing. RESULTS: Seventy-six
      patients underwent 175 finger amputations (range 1 to 6 fingers per patient).
      Forty-one percent had diabetes, 33% had nonatherosclerotic digital artery
      disease, and 29% were on dialysis. Sex distribution was equal. Primary healing
      occurred in 78.9%, with the remainder requiring revisions. By logistic regression
      analysis, nonatherosclerotic digital artery disease was associated with failure
      of primary healing (odds ratio = 7.5; 95% confidence interval, 1.03 to 54; P =
      .047). Digital photoplethysmography did not predict primary healing. The overall 
      healing of primary and secondary finger amputations was 96.0%. The mean survival 
      after the initial finger amputation was 34.3 months and did not differ between
      patients undergoing single (35.6 months) versus multiple procedures (33.6
      months). Dialysis dependence was associated with decreased survival (hazard ratio
      = 2.9; 95% confidence interval, 1.13 to 7.25; P = .026). CONCLUSIONS: Failure of 
      primary healing is associated with the presence of nonatherosclerotic digital
      artery disease and is not predicted by digital photoplethysmographic studies.
      Dialysis dependence is associated with decreased survival in patients with finger
      amputations, but failure of primary healing does not adversely affect survival. A
      strategy of aggressive preservation of finger length is appropriate for most
      patients.
CI  - Copyright (c) 2013. Published by Elsevier Inc.
AD  - Knight Cardiovascular Institute, Oregon Health & Science University, 3181 SW Sam 
      Jackson Park Road, Mail Code OP11, Portland, OR 97239-3098, USA. landryg@ohsu.edu
FAU - Landry, Gregory J
AU  - Landry GJ
FAU - McClary, Ashley
AU  - McClary A
FAU - Liem, Timothy K
AU  - Liem TK
FAU - Mitchell, Erica L
AU  - Mitchell EL
FAU - Azarbal, Amir F
AU  - Azarbal AF
FAU - Moneta, Gregory L
AU  - Moneta GL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg
JT  - American journal of surgery
JID - 0370473
SB  - AIM
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/11/09 [received]
PHST- 2013/01/10 [revised]
PHST- 2013/01/14 [accepted]
AID - S0002-9610(13)00121-9 [pii]
AID - 10.1016/j.amjsurg.2013.01.019 [doi]
PST - ppublish
SO  - Am J Surg. 2013 May;205(5):566-9; discussion 569-70. doi:
      10.1016/j.amjsurg.2013.01.019.

PMID- 23592138
OWN - NLM
STAT- In-Data-Review
DA  - 20130417
IS  - 1672-0733 (Print)
IS  - 1672-0733 (Linking)
VI  - 33
IP  - 2
DP  - 2013 Apr
TI  - Inhibitory effects of high glucose/insulin environment on osteoclast formation
      and resorption in vitro.
PG  - 244-9
LID - 10.1007/s11596-013-1105-z [doi]
AB  - Patients with type 2 diabetes mellitus (T2DM) exhibit hyperglycemia and
      hyperinsulinemia and increased risk of fracture at early stage, but they were
      found to have normal or even enhanced bone mineral density (BMD). This study was 
      aimed to examine the molecular mechanisms governing changes in bone structure and
      integrity under both hyperglycemic and hyperinsulinemic conditions. Monocytes
      were isolated from the bone marrow of the C57BL/6 mice, induced to differentiate 
      into osteoclasts by receptor activator of nuclear factor kappa-B ligand (RANKL)
      and macrophage colony-stimulating factor (M-CSF) and exposed to high glucose
      (33.6 mmol/L), high insulin (1 mumol/L), or a combination of high glucose/high
      insulin (33.6 mmol/L glucose and 1 mumol/L insulin). Cells cultured in alpha-MEM 
      alone served as control. After four days of incubation, the cells were harvested 
      and stained for tartrate resistant acid phosphatase (TRAP). Osteoclast-related
      genes including RANK, cathepsin K and TRAP were determined by using real-time
      PCR. The resorptive activity of osteoclasts was measured by using a pit formation
      assay. Osteoclasts that were derived from monocytes were of multinucleated nature
      and positive for TRAP, a characteristic marker of osteoclasts. Cell counting
      showed that the number of osteoclasts was much less in high glucose and high
      glucose/high insulin groups than in normal glucose and high insulin groups. The
      expression levels of RANK and cathepsin K were significantly decreased in high
      glucose, high insulin and high glucose/high insulin groups as compared with
      normal glucose group, and the TRAP activity was substantially inhibited in high
      glucose environment. The pit formation assay revealed that the resorptive
      activity of osteoclasts was obviously decreased in high glucose group and high
      glucose/high insulin group as compared with normal group. It was concluded that
      osteoclastogenesis is suppressed under hyperglycemic and hyperinsulinemic
      conditions, suggesting a disruption of the bone metabolism in diabetic patients.
AD  - Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong
      University of Science and Technology, Wuhan, 430030, China,
      skyfrost444@gmail.com.
FAU - Xu, Fei
AU  - Xu F
FAU - Ye, Ya-Ping
AU  - Ye YP
FAU - Dong, Yong-Hui
AU  - Dong YH
FAU - Guo, Feng-Jing
AU  - Guo FJ
FAU - Chen, An-Min
AU  - Chen AM
FAU - Huang, Shi-Long
AU  - Huang SL
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/10/08 [received]
PHST- 2013/04/17 [aheadofprint]
AID - 10.1007/s11596-013-1105-z [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):244-9. doi:
      10.1007/s11596-013-1105-z. Epub 2013 Apr 17.

PMID- 23592065
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1578-2735 (Electronic)
IS  - 1139-9287 (Linking)
VI  - 41
IP  - 2
DP  - 2013 Mar-Apr
TI  - No association between perception of family functioning and treatment modality
      for chronic renal disease secondary to diabetes mellitus.
PG  - 63-6
AB  - INTRODUCTION: This work was undertaken with the aim of studying the association
      between perception of family functioning and mode of medical treatment in
      Mexicans between 40 and 65 years whose suffer from chronic kidney disease.
      MATERIAL AND METHODS: Participants 37 patients, 22 men, 40 to 65 years of age
      with chronic renal disease secondary to diabetes mellitus. Patients were assigned
      to three groups, diet, diet + dialysis and diet + hemodialysis, they responded to
      four self-administered questionnaires, a demographic questionnaire and three
      questionnaires to assess family functioning, the Apgar family test, the family
      functioning perception test, and the scale of Garcia et al. RESULTS: There was no
      relationship between perception of family functioning of patients with chronic
      kidney disease secondary to diabetes mellitus and type of medical treatment.
      CONCLUSIONS: The perception of family functioning was not associated with the
      type of medical treatment of adults with chronic renal failure secondary to
      diabetes mellitus. The use of various instruments to explore family functioning
      is important to identify areas to address the psychotherapeutic management of the
      family. Key words: Family functioning, Diabetes mellitus type 2, Chronic renal
      disease, Middle adulthood.
AD  - Division de Posgrado, Facultad de Medicina Dr Ignacio Chavez, Universidad
      Michoacana de San Nicolas De Hidalgo, Morelia, Michoacan, Mexico.
      arorozco69@yahoo.com.mx
FAU - Rodriguez-Orozco, Alain R
AU  - Rodriguez-Orozco AR
FAU - Kanan-Cedeno, Esther G
AU  - Kanan-Cedeno EG
FAU - Bautista de la Cruz, Julieta
AU  - Bautista de la Cruz J
FAU - Polina-Carrillo, Rosalinda
AU  - Polina-Carrillo R
FAU - Gomez-Alonso, Carlos
AU  - Gomez-Alonso C
LA  - eng
PT  - Journal Article
DEP - 20130301
PL  - Spain
TA  - Actas Esp Psiquiatr
JT  - Actas espanolas de psiquiatria
JID - 100886502
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/03/01 [received]
PHST- 2013/03/01 [accepted]
PHST- 2013/03/01 [aheadofprint]
PST - ppublish
SO  - Actas Esp Psiquiatr. 2013 Mar-Apr;41(2):63-6. Epub 2013 Mar 1.

PMID- 23592051
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1559-0755 (Electronic)
IS  - 0257-277X (Linking)
DP  - 2013 Apr 17
TI  - E148Q MEFV mutation carriage and longevity in individuals of Ashkenazi origin.
AB  - The high carriage rate of MEFV mutations in at risk populations suggests that
      they confer a selective advantage, possibly by way of protection from infections.
      Here, we sought to assess whether this putative protection contributes to
      longevity, by studying MEFV mutation status in nonagenarians and the association 
      of mutation carriage with life-threatening conditions. DNA samples and a medical 
      history questionnaire were obtained from 200 nonagenarians (>90 years of age),
      who received medical treatment at a large tertiary hospital in Israel. The
      prevalence of MEFV mutations in the study group was compared to the known
      prevalence, by ethnic group, in the Israeli population. The presence of
      associated diseases in mutation carriers versus noncarriers was compared. The
      majority of study subjects were females (67.5 %) of Ashkenazi origin (78 %). A
      fifth carried an MEFV mutation, most commonly E148Q (73 % of total mutations),
      followed by V726A (5 %). Only the frequency of E148Q in Ashkenazi subjects was
      found to be higher than expected in the general Ashkenazi population (19.8 vs.
      2.6 %, p < 0.0001). Cardiac arrhythmias and hypothyroidism were more common in
      mutation carriers, while no difference was noted, between carriers and
      noncarriers, in the rates of ischemic heart disease, diabetes, stroke and a wide 
      range of other serious conditions. Our findings suggest that E148Q carriage
      contributes to longevity in the Ashkenazi population, perhaps by enhancing
      resistance to infections.
AD  - Medicine F and Heller Institute of Medical Research, Sheba Medical Center
      (affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv,
      Israel), Tel-Hashomer, Israel, merav.lidar@gmail.com.
FAU - Lidar, Merav
AU  - Lidar M
FAU - Shinar, Yael
AU  - Shinar Y
FAU - Goldberg, Marina
AU  - Goldberg M
FAU - Ben-Zvi, Ilan
AU  - Ben-Zvi I
FAU - Langevitz, Pnina
AU  - Langevitz P
FAU - Livneh, Avi
AU  - Livneh A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Immunol Res
JT  - Immunologic research
JID - 8611087
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - 10.1007/s12026-013-8414-y [doi]
PST - aheadofprint
SO  - Immunol Res. 2013 Apr 17.

PMID- 23592049
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1473-0189 (Electronic)
IS  - 1473-0189 (Linking)
VI  - 13
IP  - 11
DP  - 2013 May 7
TI  - Genotyping of single nucleotide polymorphisms by melting curve analysis using
      thin film semi-transparent heaters integrated in a lab-on-foil system.
PG  - 2075-82
LID - 10.1039/c3lc50171j [doi]
AB  - The recent technological advances in micro/nanotechnology present new
      opportunities to combine microfluidics with microarray technology for the
      development of small, sensitive, single-use, point-of-care molecular diagnostic
      devices. As such, the integration of microarray and plastic microfluidic systems 
      is an attractive low-cost alternative to glass based microarray systems. This
      paper presents the integration of a DNA microarray and an all-polymer
      microfluidic foil system with integrated thin film heaters, which demonstrate DNA
      analysis based on melting curve analysis (MCA). A novel micro-heater concept
      using semi-transparent copper heaters manufactured by roll-to-roll and lift-off
      on polyethylene naphthalate (PEN) foil has been developed. Using a mesh
      structure, heater surfaces have been realized in only one single metallization
      step, providing more efficient and homogenous heating characteristics than
      conventional meander heaters. A robust DNA microarray spotting protocol was
      adapted on Parylene C coated heater-foils, using co-polymer poly(DMA-NAS-MAPS) to
      enable covalent immobilization of DNA. The heaters were integrated in a
      microfluidic channel using lamination foils and MCA of the spotted DNA duplexes
      showed single based discrimination of mismatched over matched target DNA-probes. 
      Finally, as a proof of principle, we perform MCA on PCR products to detect the
      Leu7Pro polymorphism of the neutropeptide Y related to increased risk of Type II 
      diabetes, BMI and depression.
AD  - Fraunhofer EMFT, Hansastrasse 27d, 80686 Munich, Germany.
      anna.ohlander@emft.fraunhofer.de.
FAU - Ohlander, Anna
AU  - Ohlander A
FAU - Zilio, Caterina
AU  - Zilio C
FAU - Hammerle, Tobias
AU  - Hammerle T
FAU - Zelenin, Sergey
AU  - Zelenin S
FAU - Klink, Gerhard
AU  - Klink G
FAU - Chiari, Marcella
AU  - Chiari M
FAU - Bock, Karlheinz
AU  - Bock K
FAU - Russom, Aman
AU  - Russom A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lab Chip
JT  - Lab on a chip
JID - 101128948
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - 10.1039/c3lc50171j [doi]
PST - ppublish
SO  - Lab Chip. 2013 May 7;13(11):2075-82. doi: 10.1039/c3lc50171j.

PMID- 23592021
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1097-0290 (Electronic)
IS  - 0006-3592 (Linking)
DP  - 2013 Apr 16
TI  - The Challenge of Improved Secretory Production of Active Pharmaceutical
      Ingredients in Saccharomyces cerevisiae: A Case Study on Human Insulin Analogs.
LID - 10.1002/bit.24928 [doi]
AB  - The yeast Saccharomyces cerevisiae has widely been used as a host for the
      production of heterologous proteins. Great attention has been put on improved
      secretory production of active pharmaceutical ingredients, and the secretory
      pathway of this eukaryotic host has been the playground of diverse strain
      engineering studies, aiming at enhanced cellular capacities for folding and
      trafficking of the target proteins. However, the cellular quality assessment for 
      secretory proteins remains mostly unpredictable, and different target proteins
      often do not picture similar secretion yields, underlining the dependency of
      efficient secretion on the physicochemical properties of the protein of interest.
      In this study, two human insulin analog precursors (IAPs) with minor differences 
      in their amino acid sequences were used as model secretory proteins. No
      differences between cells expressing these two proteins were found in the IAP
      transcript levels, gene copy numbers, or intra-cellularly accumulated proteins,
      yet a more than sevenfold difference in their secretion yields was found.
      Physiological characterization of cells expressing these proteins in batch
      processes revealed no significant difference in their specific growth rate, but
      an altered overflow metabolism. Global transcriptome analysis carried out in
      chemostat experiments pinpointed distinct steps during the protein maturation
      pathway to be differentially regulated and indicated an increased degradation of 
      the IAP with the low secretion yield. In silico protein structure modeling of the
      IAPs suggested a difference in conformational stability, induced by the amino
      acid substitution, which most likely resulted in disparity in trafficking through
      the secretory pathway and thus a large difference in secretion yields.
      Biotechnol. Bioeng. 2013 9999:XX-XX. (c) 2013 Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Industrial Biotechnology, Department of Chemical and Biological Engineering,
      Chalmers University of Technology, Gothenburg, Sweden; Diabetes Protein
      Engineering, Diabetes Research Unit, Novo Nordisk A/S, DK-2780, Malov, Denmark.
FAU - Kazemi Seresht, Ali
AU  - Kazemi Seresht A
FAU - Palmqvist, Eva A
AU  - Palmqvist EA
FAU - Schluckebier, Gerd
AU  - Schluckebier G
FAU - Pettersson, Ingrid
AU  - Pettersson I
FAU - Olsson, Lisbeth
AU  - Olsson L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Biotechnol Bioeng
JT  - Biotechnology and bioengineering
JID - 7502021
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/11/30 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/03/28 [accepted]
AID - 10.1002/bit.24928 [doi]
PST - aheadofprint
SO  - Biotechnol Bioeng. 2013 Apr 16. doi: 10.1002/bit.24928.

PMID- 23591995
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1521-0103 (Electronic)
IS  - 0022-3565 (Linking)
DP  - 2013 Apr 16
TI  - Selective kinin receptor agonists as cardioprotective agents in myocardial
      ischemia and diabetes.
AB  - Cardiac ischemia is a leading cause of death, especially in diabetic patients.
      The diabetic ischemic heart is resistant experimentally to established
      cardioprotective treatments. New pharmacological approaches to cardiac protection
      are warranted. The kallikrein-kinin system is involved in myocardial protection
      in ischemia. Respective role of B1 (B1R) and B2 (B2R) receptors remains
      controversial. We tested whether pharmacological activation of kinin receptors
      may have therapeutic effect in cardiac ischemia-reperfusion in non diabetic
      (NDiab) and diabetic (Diab) mice. We assessed effect on infarct size (IS) and
      signaling pathways involved in myocardial protection of potent selective
      pharmacological agonists of B1R or B2R given at reperfusion. In NDiab mice, a B2R
      agonist reduced significantly IS by 47%, similarly to ramiprilat or ischemic
      postconditioning, via activation of PI3K/Akt pathway leading to inhibition of
      GSK3beta. B1R agonist has no effect on IS. In contrast, in Diab mice, the B2R
      agonist, ramiprilat or ischemic postconditioning failed to reduce IS but a B1R
      agonist significantly reduced IS by 44% via activation of PI3K/Akt and ERK1/2,
      both leading to GSK3beta inhibition. Differential effect of B2R or B1R agonists
      in NDiab and Diab mice can be linked to inactivation of B2R signaling and
      induction of B1R in heart of Diab mice. Thus, a pharmacological B2R agonist is
      cardioprotective in acute ischemia in non diabetic animals. B1R agonist overcomes
      resistance of diabetic heart to cardioprotective treatments. Pharmacological
      activation of B1R and B2R may become treatment for diabetic and non diabetic
      patients respectively in acute coronary syndromes.
AD  - 1 INSERM U872, Centre de Recherche des Cordeliers, Paris;
FAU - Potier, Louis
AU  - Potier L
FAU - Waeckel, Ludovic
AU  - Waeckel L
FAU - Vincent, Marie-Pascale
AU  - Vincent MP
FAU - Chollet, Catherine
AU  - Chollet C
FAU - Gobeil, Fernand
AU  - Gobeil F
FAU - Marre, Michel
AU  - Marre M
FAU - Bruneval, Patrick
AU  - Bruneval P
FAU - Richer, Christine
AU  - Richer C
FAU - Roussel, Ronan
AU  - Roussel R
FAU - Alhenc-Gelas, Francois
AU  - Alhenc-Gelas F
FAU - Bouby, Nadine
AU  - Bouby N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - jpet.113.203927 [pii]
AID - 10.1124/jpet.113.203927 [doi]
PST - aheadofprint
SO  - J Pharmacol Exp Ther. 2013 Apr 16.

PMID- 23591914
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1479-6805 (Electronic)
IS  - 0022-0795 (Linking)
VI  - 218
IP  - 1
DP  - 2013
TI  - DPP-4 inhibitors improve cognition and brain mitochondrial function of
      insulin-resistant rats.
PG  - 1-11
LID - 10.1530/JOE-12-0521 [doi]
AB  - Recent evidence has demonstrated that insulin resistance is related to the
      development of type 2 diabetes mellitus. Our previous study found that high-fat
      diet (HFD) consumption caused not only peripheral and brain insulin resistance
      but also brain mitochondrial dysfunction and cognitive impairment. Vildagliptin
      and sitagliptin, dipeptidyl-peptidase-4 inhibitors, are recently developed
      anti-diabetic drugs. However, the effects of both drugs on cognitive behaviors
      and brain mitochondrial function in HFD-induced insulin-resistant rats have not
      yet been investigated. Sixty male Wistar rats were divided into two groups to
      receive either normal diet or HFD for 12 weeks. Rats in each group were then
      further divided into three treatment groups to receive either vehicle,
      vildagliptin (3 mg/kg per day), or sitagliptin (30 mg/kg per day) for 21 days.
      The cognitive behaviors of the rats were tested using the Morris Water Maze test.
      Blood samples were collected to determine metabolic parameters and plasma
      oxidative stress levels. Upon completion of the study, the animals were killed
      and the brains were removed to investigate brain and hippocampal mitochondrial
      function as well as to determine oxidative stress levels. We demonstrated that
      both drugs significantly improved the metabolic parameters and decreased
      circulating and brain oxidative stress levels in HFD-induced insulin-resistant
      rats. In addition, both drugs completely prevented brain and hippocampal
      mitochondrial dysfunction and equally improved the learning behaviors impaired by
      the HFD. Our findings suggest that the inhibition of dipeptidyl-peptidase-4
      enzymes with vildagliptin or sitagliptin in insulin-resistant rats not only
      increases peripheral insulin sensitivity but also decreases brain dysfunction.
AD  - Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center,
      Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand Department
      of Oral Biology and Diagnostic Science, Faculty of Dentistry, Chiang Mai
      University, Chiang Mai 50200, Thailand.
FAU - Pintana, Hiranya
AU  - Pintana H
FAU - Apaijai, Nattayaporn
AU  - Apaijai N
FAU - Chattipakorn, Nipon
AU  - Chattipakorn N
FAU - Chattipakorn, Siriporn C
AU  - Chattipakorn SC
LA  - eng
PT  - Journal Article
DEP - 20130528
PL  - England
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
SB  - IM
OTO - NOTNLM
OT  - DDP-4 inhibitors
OT  - brain mitochondrial dysfunction
OT  - high-fat diet
OT  - insulin resistance
OT  - memory decline
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013 [ppublish]
AID - JOE-12-0521 [pii]
AID - 10.1530/JOE-12-0521 [doi]
PST - epublish
SO  - J Endocrinol. 2013 May 28;218(1):1-11. doi: 10.1530/JOE-12-0521. Print 2013.

PMID- 23591760
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 95
IP  - 10
DP  - 2013 May 27
TI  - Impact of renal posttransplantation amputation on allograft outcomes: a study of 
      United States renal data system.
PG  - 1249-53
LID - 10.1097/TP.0b013e31828e72b4 [doi]
AB  - BACKGROUND: The prevalence of renal posttransplantation amputation and its impact
      on allograft and patient survival have not been widely reported. METHODS: We used
      an incident cohort of patients who underwent renal transplantation between June
      2004 and September 2009. Amputation data were obtained using Medicare
      institutional claim forms. Baseline demographics and comorbidities, such as
      peripheral vascular disease (PVD), diabetes, ischemic heart disease,
      cerebrovascular disease, hypertension, and smoking, were captured. The chi-square
      and t tests were used for statistical associations. Kaplan-Meier survival curves 
      were plotted for renal allograft and patient survival. Independent associations
      between patient factors and amputation were examined using multivariable Cox
      regression analysis. RESULTS: Of the 85,873 renal transplant recipients, 1062
      patients had amputation. The prevalence of amputation was higher in those with
      PVD versus those without PVD at listing (5.6% vs. 1%; P=0.0001). Mean allograft
      survival was 55.5+/-0.55 months in patients with amputation versus 60.6+/-0.06
      months in patients without amputation (P=0.0001). All-cause mortality was higher 
      in patients with amputation versus those without amputation (19.9% vs. 7.3%;
      P=0.0001). Mean allograft survival was 60.97+/-0.67 months in non-African
      Americans without amputation versus 55.7+/-0.65 months in non-African Americans
      with amputation. Allograft survival was 59.73+/-0.13 months in African Americans 
      without amputation versus 54.9+/-1.06 months in African Americans with
      amputation. In patients with amputation, race did not have any impact. Infectious
      complications were noted in 39 patients leading to death. CONCLUSIONS: Amputation
      is associated with decreased allograft and patient survival. Early detection and 
      preventive strategies for PVD may decrease amputation rate and improve survival.
AD  - 1 Department of Medicine and Surgery, SUNY Downstate School of Medicine,
      Brooklyn, NY. 2 Organ Transplant Service, Walter Reed National Military Medical
      Center and Department of Surgery, Uniformed Services University of Health
      Sciences, Bethesda, MD. 3 Address correspondence to: Rahul M. Jindal, M.D.,
      Ph.D., M.B.A., Walter Reed National Military Medical Center, 8901 Wisconsin
      Avenue, Bethesda, MD 20889.
FAU - Brar, Amarpali
AU  - Brar A
FAU - Jindal, Rahul M
AU  - Jindal RM
FAU - Sumrani, Nabil
AU  - Sumrani N
FAU - John, Devon
AU  - John D
FAU - Mondal, Zahidul
AU  - Mondal Z
FAU - Tedla, Fasika
AU  - Tedla F
FAU - Salifu, Moro O
AU  - Salifu MO
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - 10.1097/TP.0b013e31828e72b4 [doi]
PST - ppublish
SO  - Transplantation. 2013 May 27;95(10):1249-53. doi: 10.1097/TP.0b013e31828e72b4.

PMID- 23591747
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1550-7416 (Electronic)
IS  - 1550-7416 (Linking)
DP  - 2013 Apr 17
TI  - Resveratrol Suppresses T0901317-Induced Hepatic Fat Accumulation in Mice.
AB  - Liver X receptor (LXR) has been identified as a potential target for treatment of
      atherosclerosis and diabetes. Activation of LXR, however, is associated with
      increased lipogenesis and fat accumulation in the liver. The objective of the
      current study was to examine the effect of resveratrol on LXR activator-induced
      fat accumulation in liver using mice as an animal model. Three groups of C57BL/6 
      mice were studied. Animals in group 1 were treated with T0901317, a potent
      activator of LXR in mice. Animals in group 2 served as the control and were
      treated with carrier solution and those in group 3 were treated with
      T0901317/resveratrol combination. Using histochemical and biochemical methods, we
      demonstrate that resveratrol treatment significantly suppressed fat accumulation 
      in the liver induced by T0901317. In addition, resveratrol completely blocked
      elevation of blood levels of triglyceride and cholesterol and reduced blood
      glucose level. Quantitative PCR analysis revealed that resveratrol treatment did 
      not change the mRNA levels of abca1, abcg1, cyp7a1, srebp-1c, chrebp, and acc
      genes compared to that of animals treated with T0901317 alone but reduced pepck
      and g6p gene expressions. Immunohistochemistry and Western blot analyses show
      resveratrol treatment activated AMP-activated protein kinase (AMPK) and increased
      phosphorylation of acetyl-CoA carboxylase. Treatment with T0901317 on hepatocytes
      increased intracellular fat accumulation and this increase was suppressed by
      resveratrol; the suppressive effect of resveratrol was greatly repressed by
      Compound C which is an inhibitor of AMPK. Collectively, these data suggest that
      resveratrol blocks T0901317-induced lipid accumulation in the liver and can be
      considered for inclusion into the treatment of diseases involving activation of
      liver X receptor.
AD  - Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy,
      University of Georgia, 450 Pharmacy South, 250 West Green Street, Athens,
      Georgia, 30602, USA.
FAU - Gao, Mingming
AU  - Gao M
FAU - Liu, Dexi
AU  - Liu D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - AAPS J
JT  - The AAPS journal
JID - 101223209
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/12/10 [received]
PHST- 2013/03/04 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 10.1208/s12248-013-9473-7 [doi]
PST - aheadofprint
SO  - AAPS J. 2013 Apr 17.

PMID- 23591721
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
DP  - 2013 Apr 17
TI  - Is residual renal function and better phosphate control in peritoneal dialysis an
      answer for the lower prevalence of valve calcification compared to hemodialysis
      patients?
AB  - INTRODUCTION: Cardiac valve calcification (CVC) has long been regarded as a
      consequence of abnormal calcium-phosphate metabolism in uremic patient associated
      with increased cardiovascular mortality in this population. We evaluated the
      association between residual renal function (RRF), phosphate level and valve
      calcification in peritoneal dialysis (PD) and hemodialysis (HD) patients.
      METHODS: We studied 30 stable PD patients (60 % males; mean age 57 +/- 12.36
      years) and 34 HD patients (58.8 % males; mean age 50.8 +/- 10.4 years) on renal
      replacement therapy (RRT) from 6 up to 36 months. The presence of CVC was
      assessed by standard bi-dimensional echocardiography. RRF was calculated by
      standard technique. RESULTS: Valve calcification was more frequently found in HD 
      compared to PD patients (70.6 vs 29.4 %, p = 0.007). Significantly lower
      phosphate [1.38 +/- 0.41 versus 1.99 +/- 0.35 mmol/L (p < 0.0001)], a higher RRF 
      [4.09 +/- 2.09 ml/min vs 0.62 +/- 0.89 ml/min (p < 0.0001)], and older age [57
      +/- 12.36 years vs 50.8 +/- 10.4 years (p = 0.033)] were observed in PD as
      compared to HD patients. The logistic regression analysis for the presence of
      valve calcification when adjusted for age and diabetes, with type of therapy,
      serum phosphate, RRF, CRP, and serum albumin as variables in the model, revealed 
      significant association between the presence of valve calcification and age and
      RRF. The correlation between phosphate levels and RRF was even stronger in PD
      patients than in HD patients (r = -0.704; p = 0.0001) vs (r = -0.502; p = 0.02). 
      CONCLUSIONS: Our study shows that the residual renal function in PD patients
      contributes significantly to the maintenance of phosphate balance and may explain
      the lower prevalence of valve calcification in PD patients compared with HD
      patients in the period up to first 3 years under renal replacement therapy.
AD  - Department of Nephrology-Dialysis-Transplantation, UHC "Mother Teresa", Dibra
      Street Nr 370, Tirana, Albania, meritarroji@yahoo.com.
FAU - Rroji, Merita
AU  - Rroji M
FAU - Seferi, Saimir
AU  - Seferi S
FAU - Cafka, Majlinda
AU  - Cafka M
FAU - Petrela, Elizana
AU  - Petrela E
FAU - Likaj, Erjola
AU  - Likaj E
FAU - Barbullushi, Myftar
AU  - Barbullushi M
FAU - Thereska, Nestor
AU  - Thereska N
FAU - Spasovski, Goce
AU  - Spasovski G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/01/02 [received]
PHST- 2013/04/02 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 10.1007/s11255-013-0438-7 [doi]
PST - aheadofprint
SO  - Int Urol Nephrol. 2013 Apr 17.

PMID- 23591583
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1308-0032 (Electronic)
IS  - 1302-8723 (Linking)
VI  - 13
IP  - 4
DP  - 2013 Jun
TI  - Increased apolipoprotein A-I levels mediate the development of prehypertension
      among Turks.
PG  - 306-14
LID - 10.5152/akd.2013.106 [doi]
AB  - OBJECTIVE: We aimed to assess whether apolipoprotein (apo) A-I levels that
      generated type-2 diabetes and coronary disease among Turks contribute to
      prehypertension and hypertension. METHODS: A population-based sample of 2207
      adults (mean age 53+/-11 years) was studied prospectively over a 6.5 years'
      follow-up. Individuals with hypertension and/or prehypertension were excluded at 
      baseline. RESULTS: At baseline, levels of apoA-I increased in each sex, from the 
      normotensive to prehypertensive and hypertensive group (by mean 7.6 mg/dL,
      p<0.001) concomitantly with age, waist circumference, fasting triglycerides,
      apoB, C-reactive protein (CRP) and homeostasis model assessment. In logistic
      regression models, adjusted for confounders comprising waist circumference or
      triglycerides, prehypertension was predicted independently by apoA-I at RRs of
      1.23 (95%CI 0.97; 1.52)] or 1.32 (95%CI 1.04; 1.74), respectively. Despite
      showing a positive association, apoA-I did not independently predict in similar
      models the development of hypertension; the determinants were rather waist
      circumference, or fasting triglycerides or CRP [RR 1.16 (95%CI 1.05; 1.28)] and, 
      in women, diabetes. In a linear regression analysis for circulating apoA-I
      including 10 variables, apoB and in men systolic blood pressure were positively
      associated. CONCLUSION: In contributing to prehypertension, the pro-inflammatory 
      apoA-I, mediated by apoB, is independent of triglyceridemia. Other inflammatory
      processes conjointly are likely mechanistically involved in the development of
      hypertension in a population with prevalent metabolic syndrome.
AD  - Department of Cardiology, Turkish Society of Cardiology Cerrahpasa Medical
      Faculty, Istanbul-Turkey. alt_onat@yahoo.com.tr.
FAU - Onat, Altan
AU  - Onat A
FAU - Can, Gunay
AU  - Can G
FAU - Ornek, Ender
AU  - Ornek E
FAU - Cicek, Gokhan
AU  - Cicek G
FAU - Murat, Sani N
AU  - Murat SN
FAU - Yuksel, Husniye
AU  - Yuksel H
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - Turkey
TA  - Anadolu Kardiyol Derg
JT  - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
JID - 101095069
SB  - IM
OAB - Publisher: Abstract available from the publisher.
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/11 [aheadofprint]
AID - 10.5152/akd.2013.106 [doi]
PST - ppublish
SO  - Anadolu Kardiyol Derg. 2013 Jun;13(4):306-14. doi: 10.5152/akd.2013.106. Epub
      2013 Apr 11.

PMID- 23591557
OWN - NLM
STAT- In-Data-Review
DA  - 20130605
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 28
IP  - 4
DP  - 2013 Jul
TI  - Epicardial fat and vascular risk: a narrative review.
PG  - 458-63
LID - 10.1097/HCO.0b013e3283605fba [doi]
AB  - PURPOSE OF REVIEW: We comment on the associations between epicardial adiposity
      and cardiovascular disease (CVD) and associated risk factors. The effects of
      lifestyle measures and CVD drugs on cardiac adipose tissue are also discussed.
      RECENT FINDINGS: Epicardial adipose tissue exerts cardioprotective properties;
      however, in cases of pathological enlargement, epicardial fat can lead to
      myocardial inflammation and dysfunction as well as left ventricular hypertrophy
      and coronary artery disease (CAD) due to paracrine actions that include increased
      production of reactive oxygen species, atherogenic and inflammatory cytokines.
      Cardiac adiposity is associated with CAD, obesity, type 2 diabetes, metabolic
      syndrome, nonalcoholic fatty liver disease, and chronic kidney disease, as well
      as with CVD risk factors such as lipids, hypertension, obesity markers, and
      carotid atherosclerosis. SUMMARY: Due to its anatomical and functional proximity 
      to the coronary circulation, epicardial adipose tissue may represent an even more
      direct CVD risk marker than central adiposity. Lifestyle measures and certain
      drugs may affect its thickness, although there are limited data currently
      available. The clinical implications of epicardial fat in daily practice remain
      to be established in future studies.
AD  - aSecond Propedeutic Department of Internal Medicine, Medical School, Aristotle
      University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
      bDepartment of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal
      Free Hospital Campus, University College London Medical School, University
      College London (UCL) cDepartment of Metabolic Medicine/Chemical Pathology, St
      Thomas' Hospital, London, UK.
FAU - Katsiki, Niki
AU  - Katsiki N
FAU - Mikhailidis, Dimitri P
AU  - Mikhailidis DP
FAU - Wierzbicki, Anthony S
AU  - Wierzbicki AS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - 10.1097/HCO.0b013e3283605fba [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2013 Jul;28(4):458-63. doi: 10.1097/HCO.0b013e3283605fba.

PMID- 23591546
OWN - NLM
STAT- In-Process
DA  - 20130417
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 97
IP  - 5
DP  - 2013 May
TI  - Is diabetes, even without retinopathy, a risk factor for glaucoma filtering
      surgery failure in the age of anti-fibrosis agents?
PG  - 541-2
LID - 10.1136/bjophthalmol-2013-303070 [doi]
FAU - Chen, Philip P
AU  - Chen PP
LA  - eng
PT  - Comment
PT  - Editorial
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
SB  - IM
CON - Br J Ophthalmol. 2013 May;97(5):561-6. PMID: 23355527
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - bjophthalmol-2013-303070 [pii]
AID - 10.1136/bjophthalmol-2013-303070 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 2013 May;97(5):541-2. doi: 10.1136/bjophthalmol-2013-303070.

PMID- 23591416
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 228
IP  - 2
DP  - 2013 Jun
TI  - Low normal thyroid function enhances plasma cholesteryl ester transfer in Type 2 
      diabetes mellitus.
PG  - 466-71
LID - 10.1016/j.atherosclerosis.2013.03.009 [doi]
LID - S0021-9150(13)00184-6 [pii]
AB  - BACKGROUND: Plasma cholesteryl ester transfer (CET), reflecting endogenous
      transfer of cholesteryl esters from HDL to very low and low density lipoproteins,
      is elevated in Type 2 diabetes mellitus (T2DM), and may predict (subclinical)
      cardiovascular disease. Low normal thyroid function may adversely affect
      lipoprotein metabolism and atherosclerosis development. We tested whether plasma 
      CET is related to thyroid function in euthyroid T2DM and non-diabetic subjects.
      SUBJECTS AND METHODS: Plasma CET was measured in 74 T2DM and 82 non-diabetic
      subjects with thyroid-stimulating hormone (TSH) and free thyroxine levels within 
      the reference range. RESULTS: Plasma CET was 20% higher in T2DM (P = 0.003)
      coinciding higher cholesteryl ester transfer protein (CETP) mass (P = 0.009) and 
      triglycerides (P = 0.02). In univariate analysis, plasma CET was correlated
      positively with TSH in T2DM only (r = 0.330, P = 0.004). Multiple linear
      regression analysis revealed a positive interaction between the presence of T2DM 
      and TSH on plasma CET after controlling for age, sex, body mass index, non-HDL
      cholesterol, triglycerides and CETP mass (beta = 0.167, P = 0.030). The
      relationship of plasma CET with TSH was also positively modified by plasma
      glucose and HbA1c (interaction terms: beta = 0.119, P = 0.036, beta = 0.170, P = 
      0.001, respectively). Additionally, plasma triglycerides interacted positively
      with TSH on plasma CET in T2DM (beta = 0.198, P = 0.011). CONCLUSIONS: Low normal
      thyroid function, as inferred from higher TSH, confers increased plasma CET in
      the context of chronic hyperglycemia. Effects of thyroid function on plasma CET
      may be particularly relevant in hypertriglyceridemic T2DM. Low normal thyroid
      function could influence atherosclerosis susceptibility in T2DM by affecting the 
      plasma cholesteryl ester transfer process.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Endocrinology, University of Groningen and University Medical
      Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
FAU - Triolo, Michela
AU  - Triolo M
FAU - Kwakernaak, Arjan J
AU  - Kwakernaak AJ
FAU - Perton, Frank G
AU  - Perton FG
FAU - de Vries, Rindert
AU  - de Vries R
FAU - Dallinga-Thie, Geesje M
AU  - Dallinga-Thie GM
FAU - Dullaart, Robin P F
AU  - Dullaart RP
LA  - eng
PT  - Journal Article
DEP - 20130406
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/01/07 [received]
PHST- 2013/02/25 [revised]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/06 [aheadofprint]
AID - S0021-9150(13)00184-6 [pii]
AID - 10.1016/j.atherosclerosis.2013.03.009 [doi]
PST - ppublish
SO  - Atherosclerosis. 2013 Jun;228(2):466-71. doi:
      10.1016/j.atherosclerosis.2013.03.009. Epub 2013 Apr 6.

PMID- 23591375
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - Diabetes: Risk of cardiovascular disease in patients with T2DM.
PG  - 316
LID - 10.1038/nrendo.2013.83 [doi]
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/16 [aheadofprint]
AID - nrendo.2013.83 [pii]
AID - 10.1038/nrendo.2013.83 [doi]
PST - ppublish
SO  - Nat Rev Endocrinol. 2013 Jun;9(6):316. doi: 10.1038/nrendo.2013.83. Epub 2013 Apr
      16.

PMID- 23591370
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - The GH/IGF-1 axis in ageing and longevity.
PG  - 366-76
LID - 10.1038/nrendo.2013.67 [doi]
AB  - Secretion of growth hormone (GH), and consequently that of insulin-like growth
      factor 1 (IGF-1), declines over time until only low levels can be detected in
      individuals aged >/=60 years. This phenomenon, which is known as the
      'somatopause', has led to recombinant human GH being widely promoted and abused
      as an antiageing drug, despite lack of evidence of efficacy. By contrast, several
      mutations that decrease the tone of the GH/IGF-1 axis are associated with
      extended longevity in mice. In humans, corresponding or similar mutations have
      been identified, but whether these mutations alter longevity has yet to be
      established. The powerful effect of reduced GH activity on lifespan extension in 
      mice has generated the hypothesis that pharmaceutically inhibiting, rather than
      increasing, GH action might delay ageing. Moreover, mice as well as humans with
      reduced activity of the GH/IGF-1 axis are protected from cancer and diabetes
      mellitus, two major ageing-related morbidities. Here, we review data on mouse
      strains with alterations in the GH/IGF-1 axis and their effects on lifespan. The 
      outcome of corresponding or similar mutations in humans is described, as well as 
      the potential mechanisms underlying increased longevity and the therapeutic
      benefits and risks of medical disruption of the GH/IGF-1 axis in humans.
AD  - Edison Biotechnology Institute, Ohio University, 1 Water Tower Drive, The Ridges,
      Athens, OH 45701, USA.
FAU - Junnila, Riia K
AU  - Junnila RK
FAU - List, Edward O
AU  - List EO
FAU - Berryman, Darlene E
AU  - Berryman DE
FAU - Murrey, John W
AU  - Murrey JW
FAU - Kopchick, John J
AU  - Kopchick JJ
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - England
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/16 [aheadofprint]
AID - nrendo.2013.67 [pii]
AID - 10.1038/nrendo.2013.67 [doi]
PST - ppublish
SO  - Nat Rev Endocrinol. 2013 Jun;9(6):366-76. doi: 10.1038/nrendo.2013.67. Epub 2013 
      Apr 16.

PMID- 23591369
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Apr 16
TI  - Diabetes: Diabetes clinical trials are not addressing key issues.
LID - 10.1038/nrendo.2013.94 [doi]
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/16 [aheadofprint]
AID - nrendo.2013.94 [pii]
AID - 10.1038/nrendo.2013.94 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Apr 16. doi: 10.1038/nrendo.2013.94.

PMID- 23591366
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1759-5037 (Electronic)
IS  - 1759-5029 (Linking)
DP  - 2013 Apr 16
TI  - Risks and benefits of testosterone therapy in older men.
LID - 10.1038/nrendo.2013.73 [doi]
AB  - In young men (defined as age <50 years) with classic hypogonadism caused by known
      diseases of the hypothalamus, pituitary or testes, testosterone replacement
      therapy induces a number of beneficial effects, for example, the development of
      secondary sex characteristics, improvement and maintenance of sexual function,
      and increases in skeletal muscle mass and BMD. Moreover, testosterone treatment
      in this patient population is associated with a low frequency of adverse events. 
      Circulating testosterone levels decline progressively with age, starting in the
      second and third decade of life, owing to defects at all levels of the
      hypothalamic-pituitary-testicular axis. In cohort studies, testosterone levels
      are associated weakly but consistently with muscle mass, strength, physical
      function, anaemia, BMD and bone quality, visceral adiposity, and with the risk of
      diabetes mellitus, coronary artery disease, falls, fractures and mortality.
      However, the clinical benefits and long-term risks of testosterone
      therapy-especially prostate-related and cardiovascular-related adverse
      events-have not been adequately assessed in large, randomized clinical trials
      involving older men (defined as age >65 years) with androgen deficiency.
      Therefore, a general policy of testosterone replacement in all older men with
      age-related decline in testosterone levels is not justified.
AD  - The Research Program in Men's Health: Ageing and Metabolism, Brigham and Women's 
      Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, USA.
FAU - Spitzer, Matthew
AU  - Spitzer M
FAU - Huang, Grace
AU  - Huang G
FAU - Basaria, Shehzad
AU  - Basaria S
FAU - Travison, Thomas G
AU  - Travison TG
FAU - Bhasin, Shalender
AU  - Bhasin S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Nat Rev Endocrinol
JT  - Nature reviews. Endocrinology
JID - 101500078
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/16 [aheadofprint]
AID - nrendo.2013.73 [pii]
AID - 10.1038/nrendo.2013.73 [doi]
PST - aheadofprint
SO  - Nat Rev Endocrinol. 2013 Apr 16. doi: 10.1038/nrendo.2013.73.

PMID- 23591277
OWN - NLM
STAT- Publisher
DA  - 20130520
IS  - 1542-7714 (Electronic)
IS  - 1542-3565 (Linking)
DP  - 2013 Apr 13
TI  - Association of Barrett's Esophagus With Type II Diabetes Mellitus: Results From a
      Large Population-Based Case-Control Study.
LID - S1542-3565(13)00464-3 [pii]
LID - 10.1016/j.cgh.2013.03.024 [doi]
AB  - BACKGROUND & AIMS: Central obesity could increase the risk for Barrett's
      esophagus (BE) and esophageal adenocarcinoma by mechanical and/or metabolic
      mechanisms, such as hyperinsulinemia. We performed an epidemiologic study to
      determine whether prior type 2 diabetes mellitus (DM2) is associated with BE.
      METHODS: We performed a population-based case-control study using the General
      Practice Research Database, a UK primary care database that contains information 
      on more than 8 million subjects, to identify cases of BE (using previously
      validated codes; n = 14,245) and matched controls without BE (by age, sex,
      enrollment date, duration of follow-up evaluation, and practice region by
      incidence density sampling; n = 70,361). We assessed the association of a prior
      diagnosis of DM2 with BE using conditional univariate and multivariable
      regression analysis. Confounders assessed included smoking, obesity measured by
      body mass index (BMI), and gastroesophageal reflux disease. RESULTS: BE cases
      were more likely than controls to have smoked (52.4% vs 49.9%), have a higher
      mean BMI (27.2 vs 26.9), and a higher prevalence of DM2 than controls (5.8% vs
      5.3%). On multivariable analysis, DM2 was associated with a 49% increase in the
      risk of BE, independent of other known risk factors (odds ratio, 1.49; 95%
      confidence interval, 1.16-1.91). This association was stronger in women than men.
      Results remained stable with sensitivity analyses. CONCLUSIONS: In a large
      population-based case-control study, DM2 was a risk factor for BE, independent of
      obesity (as measured by BMI) and other risk factors (smoking and gastroesophageal
      reflux disease). These data suggest that metabolic pathways related to DM2 should
      be explored in BE pathogenesis and esophageal carcinogenesis.
CI  - Copyright (c) 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
AD  - Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
      Electronic address: iyer.prasad@mayo.edu.
FAU - Iyer, Prasad G
AU  - Iyer PG
FAU - Borah, Bijan J
AU  - Borah BJ
FAU - Heien, Herbert C
AU  - Heien HC
FAU - Das, Ananya
AU  - Das A
FAU - Cooper, Gregory S
AU  - Cooper GS
FAU - Chak, Amitabh
AU  - Chak A
LA  - ENG
GR  - U54 CA163060/CA/NCI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - Clin Gastroenterol Hepatol
JT  - Clinical gastroenterology and hepatology : the official clinical practice journal
      of the American Gastroenterological Association
JID - 101160775
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/01/17 [received]
PHST- 2013/02/16 [revised]
PHST- 2013/03/01 [accepted]
AID - S1542-3565(13)00464-3 [pii]
AID - 10.1016/j.cgh.2013.03.024 [doi]
PST - aheadofprint
SO  - Clin Gastroenterol Hepatol. 2013 Apr 13. pii: S1542-3565(13)00464-3. doi:
      10.1016/j.cgh.2013.03.024.

PMID- 23591154
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
DP  - 2013 Mar 28
TI  - Plasma fatty acid composition, estimated desaturase activities, and their
      relation with the metabolic syndrome in a population at high risk of
      cardiovascular disease.
LID - S0261-5614(13)00079-4 [pii]
LID - 10.1016/j.clnu.2013.03.001 [doi]
AB  - BACKGROUND & AIMS: The metabolic syndrome (MetS) is a clustering of various
      metabolic abnormalities which is associated with increased risk of cardiovascular
      disease (CVD) and type 2 diabetes mellitus. Due to its increasing prevalence, it 
      has become an important public health concern. Altered fatty acid (FA)
      composition and desaturase activities have been associated with several metabolic
      diseases, including MetS. The aim of the present study was to evaluate the
      relationship of the plasma FA profile and desaturase activities with the MetS in 
      a Mediterranean population at high risk of CVD. METHODS: Baseline data from 427
      participants aged 55-80 years who took part in the interventional PREDIMED study 
      were obtained. Individual FA was determined in plasma and desaturase activities
      were estimated from product/precursor ratios. Odds ratios (OR) and partial
      correlation coefficients were used to examine these relations with MetS and its
      components, respectively. RESULTS: We found higher levels of C14:0, C16:0,
      C16:1n-7, estimated Delta9- or stearoyl-CoA desaturase (SCD), and estimated
      Delta6 desaturase (D6D), and lower levels of C18:2n-6 in people with MetS
      compared to those without it. After adjustment for several confounders, only
      higher quartiles of C14:0, C16:0, C16:1n-7, and D6D were found to be associated
      with an increasing prevalence of MetS, while higher quartiles of C18:2n-6 were
      inversely associated with MetS. High proportions of C14:0, C16:0, C16:1n-7,
      C20:3n-6, SCD, and D6D, and decreased proportions of C18:2n-6 and estimated
      Delta5-desaturase (D5D) were associated with adverse profiles of several
      metabolic risk factors. Women showed more unhealthy FA pattern and lipid profiles
      than men, but only among those with MetS. CONCLUSION: A FA composition and
      estimated desaturase activities consisting in high levels of SFA, SCD and D6D,
      and low levels of PUFA and D5D are associated with increased MetS probability and
      are characteristic of people presenting MetS, especially women. These findings
      support those observed in non-Mediterranean populations in which an altered FA
      profile and estimated desaturase activities are associated with MetS.
CI  - Copyright (c) 2013 Elsevier Ltd and European Society for Clinical Nutrition and
      Metabolism. All rights reserved.
AD  - CIBER Epidemiologia y Salud Publica (CIBERESP), Spain.
FAU - Mayneris-Perxachs, Jordi
AU  - Mayneris-Perxachs J
FAU - Guerendiain, Marcela
AU  - Guerendiain M
FAU - Castellote, Ana I
AU  - Castellote AI
FAU - Estruch, Ramon
AU  - Estruch R
FAU - Covas, Maria Isabel
AU  - Covas MI
FAU - Fito, Montserrat
AU  - Fito M
FAU - Salas-Salvado, Jordi
AU  - Salas-Salvado J
FAU - Martinez-Gonzalez, Miguel A
AU  - Martinez-Gonzalez MA
FAU - Aros, Fernando
AU  - Aros F
FAU - Lamuela-Raventos, Rosa M
AU  - Lamuela-Raventos RM
FAU - Lopez-Sabater, M Carmen
AU  - Lopez-Sabater MC
CN  - for PREDIMED Study Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130328
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/01/18 [received]
PHST- 2013/02/08 [revised]
PHST- 2013/03/03 [accepted]
AID - S0261-5614(13)00079-4 [pii]
AID - 10.1016/j.clnu.2013.03.001 [doi]
PST - aheadofprint
SO  - Clin Nutr. 2013 Mar 28. pii: S0261-5614(13)00079-4. doi:
      10.1016/j.clnu.2013.03.001.

PMID- 23591151
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1532-1983 (Electronic)
IS  - 0261-5614 (Linking)
DP  - 2013 Mar 26
TI  - Dietary flavonoids intake and risk of type 2 diabetes: A meta-analysis of
      prospective cohort studies.
LID - S0261-5614(13)00089-7 [pii]
LID - 10.1016/j.clnu.2013.03.011 [doi]
AB  - BACKGROUND & AIMS: Flavonoids may have cardioprotective effects, but
      epidemiological evidence on the relationship of dietary flavonoids with diabetes 
      has not been systematically assessed. To examine the association between dietary 
      flavonoids and type 2 diabetes, we performed a meta-analysis on this topic.
      METHODS: We searched PubMed through March 2013 for relevant cohort studies that
      assessed total flavonoids and type 2 diabetes risks. A fixed-effect model was
      used to calculate the summary risk estimates. RESULTS: Four articles consisting
      of 6 prospective cohorts that involved 18,146 cases and 284,806 participants were
      identified. The summary relative risk (RR) of type 2 diabetes for the highest
      intake of total flavonoids compared with the lowest was 0.91 (95% confidence
      interval (CI): 0.87-0.96). Furthermore, an increase in the total flavonoids
      intake of 500mg/d was associated with a significant risk reduction of 5%
      (RR=0.95, 95% CI: 0.91-0.98). In subgroup analyses, the observed beneficial
      effects were observed in US population, in those mean age>40 years old people and
      in studies >/=20 years in duration. CONCLUSIONS: The present meta-analysis
      indicates that consumption of dietary total flavonoids is associated with a
      reduced risk of type 2 diabetes.
CI  - Copyright (c) 2013 Elsevier Ltd and European Society for Clinical Nutrition and
      Metabolism. All rights reserved.
AD  - School of Public Health, Wuhan University, Wuhan, PR China.
FAU - Liu, Yu-Jian
AU  - Liu YJ
FAU - Zhan, Jian
AU  - Zhan J
FAU - Liu, Xiao-Li
AU  - Liu XL
FAU - Wang, Ying
AU  - Wang Y
FAU - Ji, Jie
AU  - Ji J
FAU - He, Qi-Qiang
AU  - He QQ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130326
TA  - Clin Nutr
JT  - Clinical nutrition (Edinburgh, Scotland)
JID - 8309603
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/11/27 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/03/18 [accepted]
AID - S0261-5614(13)00089-7 [pii]
AID - 10.1016/j.clnu.2013.03.011 [doi]
PST - aheadofprint
SO  - Clin Nutr. 2013 Mar 26. pii: S0261-5614(13)00089-7. doi:
      10.1016/j.clnu.2013.03.011.

PMID- 23591026
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
DP  - 2013 Apr 15
TI  - Association of Traits of Metabolic Syndrome With Glucose Abnormalities.
AB  - The association of glucose abnormalities (GAs) with the early appearance of
      traits of the metabolic syndrome (MS) was studied in an unselected sample of
      apparently healthy Urban Hispanics. GAs were defined as impaired fasting glucose 
      (IFG), impaired glucose tolerance (IGT), and newly diagnosed diabetes mellitus
      (DM). Overall, GAs were associated with older age, abdominal obesity, low
      high-density lipoprotein cholesterol levels, hypertriglyceridemia,
      hyperinsulinemia, hypertension, and MS. Prevalence of MS defined as per
      NCPE-ATPIII was the greatest in subjects with DM (54.3%) and with combined
      abnormalities (IFG + IGT) (54.1%; P > 0.5). Similar prevalence of MS was found in
      subjects with isolated IFG (34.3%) and isolated IGT (36.8%) but higher than in
      normal fasting-glucose tolerant individuals (23.3%) (P < 0.01). The average
      number of traits of the MS coexisting in normal fasting glucose-tolerant
      individuals was 1.6 [95% confidence interval (CI), 1.5-1.8; median 2], in
      isolated IFG: 2.05 (95% CI, 1.8-2.2; median 2); isolated IGT: 2.16 (95% CI,
      1.8-2.3; median 2); combined IFG + IGT: 2.7 (95% CI, 2.3-3.1; median 3); and DM: 
      2.7 (95% CI, 2.25-3.1; median 3) (P < 0.01). Postload insulin levels were higher 
      in isolated IGT than in isolated IFG, whereas HOMA-IR was higher in IFG. Indices 
      of early and total insulin secretion were markedly reduced in DM, IFG-IGT, and
      IGT. In conclusion, GAs are strongly associated with the number and severity of
      traits of the MS, defects in insulin secretion, and sustained hyperinsulinemia in
      response to oral glucose. Subjects with combined GA and newly diagnosed type 2 DM
      had not only an increased prevalence of MS, but also the MS was characterized by 
      the presence of more than 3 traits, and by a greater severity of each of the
      coexisting traits.
AD  - 1Division of Clinical Pharmacology, Center for the Detection and Treatment of
      Silent Risk factors for Metabolic and Cardiovascular Disease, School of Pharmacy,
      Central University of Venezuela, Caracas, Venezuela 2Chief Cardiovascular and
      Metabolic Research Unit, College of Pharmacy, Nova Southeastern University, Fort 
      Lauderdale, FL.
FAU - Hoffmann, Irene S
AU  - Hoffmann IS
FAU - Cubeddu, Luigi X
AU  - Cubeddu LX
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - 10.1097/MJT.0b013e318235f2b8 [doi]
PST - aheadofprint
SO  - Am J Ther. 2013 Apr 15.

PMID- 23591024
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
DP  - 2013 Apr 15
TI  - Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for
      Cardiovascular Events.
AB  - Existing epidemiologic and clinical trial data suggest that the blood pressure in
      patients with hypertension at high risk for cardiovascular events because of
      coronary artery disease, diabetes mellitus, chronic kidney disease, stroke, or
      heart failure should be reduced to <140/90 mm Hg in patients younger than 80
      years and the systolic blood pressure be reduced to 140-145 mm Hg if tolerated in
      patients aged 80 years and older. Studies from patients with coronary artery
      disease, diabetes mellitus, chronic kidney disease, stroke, and heart failure
      will be discussed that support a blood pressure goal of <140/90 mm Hg in patients
      younger than 80 years at high risk for cardiovascular events.
AD  - Department of Medicine, Division of Cardiology, New York Medical College,
      Valhalla, NY.
FAU - Aronow, Wilbert S
AU  - Aronow WS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - 10.1097/MJT.0b013e31827c5372 [doi]
PST - aheadofprint
SO  - Am J Ther. 2013 Apr 15.

PMID- 23590933
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 Apr 13
TI  - Simvastatin treatment inhibits hypoxia inducible factor
      1-alpha-(HIF-1alpha)-prolyl-4-hydroxylase 3 (PHD-3) and increases angiogenesis
      after myocardial infarction in streptozotocin-induced diabetic rat.
LID - S0167-5273(13)00423-3 [pii]
LID - 10.1016/j.ijcard.2013.03.005 [doi]
AB  - BACKGROUND: Statins (HMG-CoA reductase inhibitors), are known to improve cardiac 
      function in diabetes-induced cardiovascular disease. We investigated the
      mechanism by which statins ameliorate cardiac function after myocardial
      infarction (MI). Simvastatin (S) increased tube formation and migration of HUVEC 
      in vitro. We examined the role of simvastatin on cardiac function in
      streptozotocin (STZ) induced diabetic rats subjected to MI. METHODS: Rats were
      randomly assigned to 1) Control (non-diabetic) Sham (CS); 2) Control
      (non-diabetic) MI (CMI); 3) Control Statin treated Sham (CSS); 4) Control Statin 
      treated MI (CSMI); 5) Diabetic Sham (DS); 6) Diabetic MI (DMI); 7) Diabetic
      Statin treated Sham (DSS); 8) Diabetic Statin treated MI (DSMI). Two weeks after 
      STZ/saline injection Simvastatin (1mg/kg.b.wt) was gavaged for 15days (d). MI was
      induced 30 d after treatment by permanent LAD ligation. RESULTS: The S treated MI
      groups exhibited increased arteriolar density (23+/-0.6 vs. 14.8+/-0.4
      counts/mm2, DSMI vs. DMI) and reduced fibrosis at 30d post-MI. VEGF measurement
      by ELISA after 4d post-MI showed increased expression in DSMI group compared to
      DMI group. Western blot analysis showed decreased Prolyl-4-Hydroxylase 3 (PHD-3) 
      in DSMI group as compared to DMI group. Echocardiographic analysis 4weeks after
      post-MI showed significant improvement in ejection fraction (50.11+/-1.83 vs.
      32.46+/-2.19%; DSMI vs. DMI) and fractional shortening (26.77+/-1.12
      vs.16.36+/-1.22%; DSMI vs. DMI) in both statin-treated MI groups regardless of
      diabetic status. CONCLUSION: These results suggest that statin therapy mitigates 
      impairment of angiogenesis and myocardial dysfunction following MI in the
      diabetic rat through PHD3 inhibition.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Department of Surgery, Molecular Cardiology and Angiogenesis Laboratory,
      University of Connecticut Health Center, Farmington, CT, USA. Electronic address:
      mthirunavukkarasu@uchc.edu.
FAU - Thirunavukkarasu, Mahesh
AU  - Thirunavukkarasu M
FAU - Selvaraju, Vaithinathan
AU  - Selvaraju V
FAU - Dunna, Nageswara Rao
AU  - Dunna NR
FAU - Foye, Jocelyn L C
AU  - Foye JL
FAU - Joshi, Mandip
AU  - Joshi M
FAU - Otani, Hajime
AU  - Otani H
FAU - Maulik, Nilanjana
AU  - Maulik N
LA  - ENG
GR  - R01 HL056803/HL/NHLBI NIH HHS/United States
GR  - R01 HL069910/HL/NHLBI NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/12/21 [received]
PHST- 2013/03/09 [accepted]
AID - S0167-5273(13)00423-3 [pii]
AID - 10.1016/j.ijcard.2013.03.005 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 Apr 13. pii: S0167-5273(13)00423-3. doi:
      10.1016/j.ijcard.2013.03.005.

PMID- 23590931
OWN - NLM
STAT- In-Data-Review
DA  - 20130524
IS  - 1873-2747 (Electronic)
IS  - 0361-9230 (Linking)
VI  - 95
DP  - 2013 Jun
TI  - Food-intake regulation during stress by the hypothalamo-pituitary-adrenal axis.
PG  - 46-53
LID - 10.1016/j.brainresbull.2013.04.002 [doi]
LID - S0361-9230(13)00068-3 [pii]
AB  - The prevalence of obesity is increasing worldwide with serious consequences such 
      as diabetes mellitus type 2 and cardiovascular diseases. Emotional stress is
      considered to be one of the main reasons of obesity development in humans.
      However, there are some contradictory results, which should be addressed. First
      of all stress induces anorexia, but not overeating in laboratory animals.
      Glucocorticoids, the effector molecules of the
      hypothalamo-pituitary-adrenocortical (HPA) axis stimulate and stress inhibits
      food intake. It is also not clear if stress is diabetogenic or an
      antidiabetogenic factor. The review will discusses these issues and the
      involvement of the whole HPA axis and its separate molecules (glucocorticoids,
      adrenocorticotropin, corticotropin-releasing hormone) in food intake regulation
      under stress.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Institute of Cytology and Genetics, Russia Academy of Sciences, Novosibirsk,
      Russia. Electronic address: bazhan-nm@yandex.ru.
FAU - Bazhan, Nadezhda
AU  - Bazhan N
FAU - Zelena, Dora
AU  - Zelena D
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - United States
TA  - Brain Res Bull
JT  - Brain research bulletin
JID - 7605818
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/11/02 [received]
PHST- 2013/03/14 [revised]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - S0361-9230(13)00068-3 [pii]
AID - 10.1016/j.brainresbull.2013.04.002 [doi]
PST - ppublish
SO  - Brain Res Bull. 2013 Jun;95:46-53. doi: 10.1016/j.brainresbull.2013.04.002. Epub 
      2013 Apr 13.

PMID- 23590862
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
IS  - 1743-7075 (Electronic)
IS  - 1743-7075 (Linking)
VI  - 10
IP  - 1
DP  - 2013
TI  - Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance
      and ameliorates hepatic steatosis in high fructose-fed rats.
PG  - 35
LID - 10.1186/1743-7075-10-35 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (DM), characterized by peripheral insulin
      resistance, is the most common form of diabetes. Probiotics are live
      micro-organisms that, when administered in adequate amounts, confer delaying
      effect on DM development. In this study, the effects Lactobacillus reuteri
      GMNL-263 (Lr263), a new probiotic strain developed by our laboratory, on insulin 
      resistance and the development of hepatic steatosis in high-fructose fed rats
      were explored. Furthermore, the relevant regulatory pathways involved were also
      investigated. METHOD: Male Sprague-Dawley rats were fed a high-fructose diet with
      or without Lr263 administration for 14 weeks. The composition of fecal
      microbiota, oral glucose tolerance, glycated haemoglobin, insulin, leptin,
      C-peptide, and incretins were measured. The markers of liver injury, serum and
      hepatic lipids profile, activity of hepatic antioxidant enzyme, and
      proinflammatory cytokines in adipose tissue were investigated. Additionally, the 
      expression of hepatic lipogenic genes and insulin signaling related genes in
      adipose tissue were also studied. Liver sections were examined for hepatic
      steatosis using hematoxylin-eosin staining. RESULTS: The levels of serum glucose,
      insulin, leptin, C-peptide, glycated hemoglobin, GLP-1, liver injury markers,
      lipid profile in serum and liver were significantly increased in
      high-fructose-fed rats. However, after Lr263 administration, the elevation of
      these parameters was significantly suppressed. Feeding of Lr263 reversed the
      decreased number of bifidobacterium species and lactobacillus species and
      increased number of clostridium species induced by high fructose treatment. The
      decreased activities of hepatic antioxidant enzymes in HFD rats were dramatically
      reversed by Lr263 treatment. Concentrations of IL-6 and TNF-alpha in adipose
      tissue which were elevated in high fructose treatment were markedly decreased
      after Lr263 feeding. Decreased levels of PPAR-gamma and GLUT4 mRNA after high
      fructose treatment were significantly enhanced by Lr263 administration. Lr263
      consumption normalized the increased lipogenic gene (Srebp-1c, FAS, and Elvol6)
      expressions stimulated by high fructose. Administration of Lr263 significantly
      ameliorated hepatic steatosis observed in high fructose treated rats. CONCLUSION:
      Our study provided evidences clarifying the effectiveness of Lr263 on reducing
      insulin resistance as well as hepatic steatosis formation in high-fructose-fed
      rats and suggested that Lr263 may be a promising therapeutic agent in treating
      type 2 diabetes.
AD  - Department of Medical Laboratory Science and biotechnology, Kaohsiung Medical
      University, 6F, Chi-Shih Building, 100, Shih-Chuan 1st Road, Kaohsiung, 80708,
      Taiwan. m785034@kmu.edu.tw.
FAU - Hsieh, Feng-Ching
AU  - Hsieh FC
FAU - Lee, Chia-Lin
AU  - Lee CL
FAU - Chai, Chee-Yin
AU  - Chai CY
FAU - Chen, Wan-Tzu
AU  - Chen WT
FAU - Lu, Ying-Chen
AU  - Lu YC
FAU - Wu, Ching-Shuang
AU  - Wu CS
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - England
TA  - Nutr Metab (Lond)
JT  - Nutrition & metabolism
JID - 101231644
PMC - PMC3637306
OID - NLM: PMC3637306
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:01
CRDT- 2013/04/18 06:00
PHST- 2012/08/17 [received]
PHST- 2013/04/14 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 1743-7075-10-35 [pii]
AID - 10.1186/1743-7075-10-35 [doi]
PST - epublish
SO  - Nutr Metab (Lond). 2013 Apr 17;10(1):35. doi: 10.1186/1743-7075-10-35.

PMID- 23590852
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1557-8674 (Electronic)
IS  - 1096-2964 (Linking)
DP  - 2013 Apr 16
TI  - Negative Pressure Therapy for High-Risk Abdominal Wall Reconstruction Incisions.
AB  - Abstract Background: A high rate of surgical site infection (SSI) accompanies the
      repair of large ventral hernias in the presence of bacterial contamination.
      Recent clinical and laboratory studies suggest that negative-pressure therapy
      (NPT) applied to closed surgical incisions may reduce the risk of SSI in
      high-risk populations. We hypothesized that NPT would reduce the risk of SSI in
      patients undergoing the repair of contaminated ventral hernias. Methods: We
      reviewed retrospectively our prospectively collected database for patients
      undergoing repair of potentially contaminated and infected ventral hernias with
      or without NPT. All of the patients had primary wound closure. In the NPT group, 
      a vacuum dressing was applied over the closed midline wound. The primary outcome 
      measure was SSI at 30 d post-operatively. Results: We evaluated 119 patients (70 
      with a standard wound dressing (SWD) and 49 with NPT). The groups were similar in
      age, gender, body mass index (BMI), the prevalence of chronic obstructive
      pulmonary disease (COPD), diabetes mellitus (DM), and smoking; and the number of 
      prior abdominal operations. The SWD group had a higher American Society of
      Anesthesiologists (ASA) score than did the NPT group (3.0 vs. 2.8; p=0.01). The
      two groups were similar in the sizes of their hernia defects and duration of
      surgery, and did not differ in their 30-d rates of SSI (25.8% SWD vs. 20.4% NPT; 
      p=0.50) or in the distribution of major and minor SSIs (SWD: 6 major, 12 minor
      vs. NPT: 2 major, 8 minor; p=0.56). Factors associated with an increased risk of 
      SSI included ASA score (p=0.02), BMI (p=0.05), defect area (p<0.01), DM (p=0.01),
      and duration of surgery, (p<0.01). Conclusions: This retrospective,
      non-randomized study found that NPT in the setting of a closed surgical incision 
      after potentially contaminated or infected ventral hernia repair (VHR) did not
      reduce the incidence of SSI. Although prophylactic NPT has reduced wound
      morbidity in some surgical populations, it does not appear to offer the same
      reduction in wound morbidity in high-risk, contaminated, and potentially
      contaminated open VHR.
AD  - Department of Surgery, Case Comprehensive Hernia Center, University Hospitals
      Case Medical Center , Cleveland, Ohio.
FAU - Pauli, Eric M
AU  - Pauli EM
FAU - Krpata, David M
AU  - Krpata DM
FAU - Novitsky, Yuri W
AU  - Novitsky YW
FAU - Rosen, Michael J
AU  - Rosen MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Surg Infect (Larchmt)
JT  - Surgical infections
JID - 9815642
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
AID - 10.1089/sur.2012.059 [doi]
PST - aheadofprint
SO  - Surg Infect (Larchmt). 2013 Apr 16.

PMID- 23590722
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 30
IP  - 6
DP  - 2013 Jun
TI  - Charcot neuroarthropathy triggered and complicated by osteomyelitis. How limb
      salvage can be achieved.
PG  - e229-32
LID - 10.1111/dme.12191 [doi]
AB  - BACKGROUND: Charcot neuroarthropathy is a severe complication in the feet of
      patients with diabetes, which can lead to a major amputation. Osteomyelitis and
      surgery for osteomyelitis have been reported as trigger mechanisms of developing 
      Charcot neuroarthropathy. However, the development of acute Charcot
      neuroarthropathy triggered by osteomyelitis during conservative antibiotic
      treatment is not well outlined in the medical literature. CASE REPORTS: Two
      patients apparently developed mid and rear foot Charcot neuroarthropathy, which
      was clinically suspected while being treated with antibiotics for osteomyelitis. 
      One of them presented osteomyelitis of the navicular bone and subsequently
      developed acute Charcot neuroarthropathy of the tarsometatarsal joints. The other
      presented calcaneal osteomyelitis with pathological fracture and developed
      Charcot neuroarthropathy of the transverse tarsal joint. No offloading had been
      implemented in either case. A major amputation had been indicated in both cases
      in their teaching hospitals. Limb salvage was achieved in both cases by means of 
      surgery, culture-guided post-operative antibiotics, intraosseus instillation of
      super-oxidized solution, bed rest before placing a total contact cast and
      stabilization of the unstable foot with a total contact cast with an opening for 
      checking the healing course and to detect any complications. The mechanisms of
      the development of acute Charcot neuroarthropathy in a patient with osteomyelitis
      are discussed. CONCLUSIONS: Osteomyelitis in the feet of patients with diabetes
      and neuropathy may trigger the development of acute Charcot neuroarthropathy.
      Fractures and dislocated joints may subsequently become infected from the index
      focus, producing a severe infected and unstable foot that may require a major
      amputation. Limb salvage can be achieved in specialized departments.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Diabetic Foot Unit, La Paloma Hospital, Las Palmas de Gran Canaria, Spain.
FAU - Aragon-Sanchez, J
AU  - Aragon-Sanchez J
FAU - Lazaro-Martinez, J L
AU  - Lazaro-Martinez JL
FAU - Quintana-Marrero, Y
AU  - Quintana-Marrero Y
FAU - Alvaro-Afonso, F J
AU  - Alvaro-Afonso FJ
FAU - Hernandez-Herrero, M J
AU  - Hernandez-Herrero MJ
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/03/18 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 10.1111/dme.12191 [doi]
PST - ppublish
SO  - Diabet Med. 2013 Jun;30(6):e229-32. doi: 10.1111/dme.12191. Epub 2013 Apr 17.

PMID- 23590717
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
DP  - 2013 Apr 2
TI  - Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic
      Diseases?
AB  - This review examines the biological role of oxidants and antioxidants
      continuously produced by all living cells. Physiologically in human beings, who
      have inherited good genes, used to eat moderately a healthy diet and practising
      exercise every day, both systems are equally important and essential to maintain 
      a normal long life. However the aging process slowly leads to a disequilibrium
      that becomes accentuated in pathologies such as diabetes, cardiovascular,
      degenerative, pulmonary, infective diseases and cancer. All of these diseases
      shorten the life span in about 80% of individuals and represent a huge
      social-economic problem for health authorities. Several factors as excessive
      feeding, smoking, alcoholism and a poor life-style conjure up to their
      realization. Their progress, initially promoted by some pathogens and a wrong
      life-style, is deeply accentuated by an excessive and deranged production of
      deadly oxidants no longer tamed by an inhibited control of the antioxidant
      defences. Effective orthodox drugs are able to slow down these ailments but they 
      impoverish the quality of life because they cannot reactivate the innate ability 
      to restore the complexity of the antioxidant system. Several potential approaches
      to renew this system have been discussed and their possible role to reactivate a 
      valid protection in at least some of the outlined pathologies. It is hoped to
      pursue the evaluation of this integrated medical approach because it represents a
      sheet anchor for many patients.
AD  - Department of Life Science and Biotechnologie, University of Ferrara, Via Luigi
      Borsari, 46, 44100 Ferrara, Italy. giuseppe.valacchi@unife.it.
FAU - Bocci, Velio
AU  - Bocci V
FAU - Valacchi, Giuseppe
AU  - Valacchi G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130402
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/12/07 [received]
PHST- 2013/04/01 [accepted]
AID - CMC-EPUB-20130402-4 [pii]
PST - aheadofprint
SO  - Curr Med Chem. 2013 Apr 2.

PMID- 23590715
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 20
IP  - 21
DP  - 2013 Jul 1
TI  - Medicinal agents and metabolic syndrome.
PG  - 2626-40
AB  - The definition of the Metabolic Syndrome (MS) has encountered difficulty in
      reaching a universal consensus although there exists an agreement of its main
      pathologies which are hypertension, obesity, dyslipidemia, insulin resistance,
      inflammation and renal damage. The prevalent opinion is that three of those
      alterations may define the syndrome. The incidence of the MS has increased
      globally, particularly in the last few years, to the point of being regarded as
      an epidemic. The treatment of the MS can be approached from different angles,
      since it may be a multifaceted health problem. A healthy lifestyle, which means
      the practice of regular exercise is suggested to MS patients. Increasing physical
      activity has anti-inflammatory effects since there is an inverse association of
      physical activity and inflammatory biomarker concentrations. An adequate diet is 
      recommended, such as the Mediterranean, which contains fish, tomatoes, garlic,
      red peppers, olive oil and includes red wine, that is, antioxidants and
      non-saturated oils. There are also the traditional herbal preparations, used in
      the alternative medicine. Several therapeutic tools can be used; the most common 
      are the pharmaceutical products to deal with obesity, hypertension,
      dyslipidemias, diabetes and inflammation. In addition several pharmacological
      therapies such as non steroidal anti-inflammatory drugs are recommended. Recently
      new mechanisms of action of statins, fibrates, metformin and thiazolidinediones
      have demonstrated their anti-inflammatory effect and potential use to treat MS.
AD  - Departamento de Fisiologia, Instituto Nacional de Cardiologia "Ignacio Chavez",
      Juan Badiano 1, 14080, Tlalpan, Mexico D.F. gualanv@yahoo.com.
FAU - Rubio-Ruiz, M E
AU  - Rubio-Ruiz ME
FAU - El Hafidi, M
AU  - El Hafidi M
FAU - Perez-Torres, I
AU  - Perez-Torres I
FAU - Banos, G
AU  - Banos G
FAU - Guarner, V
AU  - Guarner V
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/08/23 [received]
PHST- 2013/02/24 [revised]
PHST- 2013/04/01 [accepted]
AID - CMC-EPUB-20130402-2 [pii]
PST - ppublish
SO  - Curr Med Chem. 2013 Jul 1;20(21):2626-40.

PMID- 23590699
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1524-475X (Electronic)
IS  - 1067-1927 (Linking)
VI  - 21
IP  - 3
DP  - 2013 May
TI  - Prognostic factors predicting ischemic wound healing following hyperbaric
      oxygenation therapy.
PG  - 418-27
LID - 10.1111/wrr.12038 [doi]
AB  - Identifying patients who benefit from hyperoxygenation therapy is important,
      because treatment is time-consuming and involves high costs and complications
      (minor). Our objective was to develop a model for predicting therapy outcome
      based on population of patients with and without diabetes. A retrospective cohort
      study was carried out in a major hospital in Israel. All 385 patients treated
      between 1/1/1998 and 1/1/2007 for ischemic nonhealing lower extremities wounds
      were included. Data on medical history, demographic, transcutaneous oximetry,
      wounds, treatment, and outcome characteristics were collected. Eight factors were
      identified to optimally predict wound healing: (1) number of hyperbaric
      oxygenation treatments (odds ratio [OR] = 1.034, p < 0.001), (2) transcutaneous
      oximetry values at hyperbaric conditions (OR = 1.001, p = 0.019), (3) wound
      duration (OR = 0.988, p = 0.022), (4) absence of heart disease (OR = 3.304, p <
      0.001), (5) being employed (OR = 3.16, p = 0.008), (6) low socioeconomic status
      (OR = 2.50, p = 0.004), (7a) good/partial granulation wound appearance (OR =
      2.73, p = 0.022), (7b) wounds covered with fibrin (OR = 3.16, p = 0.015), and (8)
      absence of anemia (OR = 2.13, p = 0.016). The model's sensitivity is 78.7%,
      specificity is 62.9%, and accuracy is 71.8%. We suggest using our model as an
      adjunct to patients' clinical evaluation. Also, we recommend initiating
      hyperoxygenation therapy no later than 2 months after wound appearance.
CI  - (c) 2013 by the Wound Healing Society.
AD  - School of Public Health, Faculty of Social Welfare and Health Sciences,
      University of Haifa; Hyperbaric Medical Center, Elisha Hospital, Rambam Health
      Care Campus, affiliated with Rappaport Faculty of Medicine, Technion-Israel
      Institute of Technology.
FAU - Feldman-Idov, Yulie
AU  - Feldman-Idov Y
FAU - Melamed, Yehuda
AU  - Melamed Y
FAU - Linn, Shai
AU  - Linn S
FAU - Ore, Liora
AU  - Ore L
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - Wound Repair Regen
JT  - Wound repair and regeneration : official publication of the Wound Healing Society
      [and] the European Tissue Repair Society
JID - 9310939
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/07/12 [received]
PHST- 2013/02/06 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1111/wrr.12038 [doi]
PST - ppublish
SO  - Wound Repair Regen. 2013 May;21(3):418-27. doi: 10.1111/wrr.12038. Epub 2013 Apr 
      16.

PMID- 23590680
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 Apr 17
TI  - Liraglutide protects pancreatic beta-cells during an early intervention in
      Gato-Kakizaki rats.
LID - 10.1111/1753-0407.12061 [doi]
AB  - BACKGROUND: Glucagon-like peptide-1(GLP-1) analogues are emerged as insulin
      secretagogues and widely used in type 2 diabetic patients. GLP-1 analogues also
      demonstrate a promotion of beta cell proliferation and reduction of apoptosis in 
      rodents.In the present study, we investigated the protection of pancreatic beta
      cells by early use (at age of 2 weeks) of GLP-1 analogue, Liraglutide in GK rats 
      and explored the underlying mechanisms. METHODS: Effects of Liraglutide on
      glucose tolerance were evaluated by intraperitoneal glucose tolerance test
      (IPGTT) and insulin release tests (IRT). Ki67 and TUNEL immunostaining, Western
      blots and real-time PCR were applied to evaluate cell proliferation, apoptosis
      and related gene expressions. RESULTS: Our results demonstrated that early use of
      Liraglutide improved glucose tolerance during Liraglutide treatment in GK rats.
      Liraglutide increased pancreatic insulin contents and markedly reduced beta cell 
      apoptosis. Liraglutide also downregulated pro-apoptotic gene expressions and
      reduced intra-islet macrophage infiltration. CONCLUSIONS: This experiment
      reported for the first time that early use of Liraglutide could protect beta cell
      failure in pre-diabetic GK rats through reduction of beta cell apoptosis and
      ameliorating islet inflammation. SIGNIFICANT FINDINGS OF THE STUDY: Early use of 
      Liraglutide could protect beta cells through reduction of beta cell apoptosis and
      ameliorating islet inflammation. THIS STUDY ADDS: Liraglutide could protect beta 
      cell failure and delay diabetes progression in pre-diabetic GK rats through
      reduction of beta cell apoptosis and ameliorating islet inflammation.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Endocrine and Metabolic Diseases, Shanghai Institute of
      Endocrinology and Metabolism, Ruijin Hospital, Shanghai Jiao Tong University
      School of Medicine.
FAU - Luo, Xiu
AU  - Luo X
FAU - Pan, Linlin
AU  - Pan L
FAU - Nie, Aifang
AU  - Nie A
FAU - Wang, Qidi
AU  - Wang Q
FAU - Gu, Yanyun
AU  - Gu Y
FAU - Li, Fengying
AU  - Li F
FAU - Zhang, Hongli
AU  - Zhang H
FAU - Li, Wenyi
AU  - Li W
FAU - Li, Xiaoying
AU  - Li X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/13 [accepted]
AID - 10.1111/1753-0407.12061 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 Apr 17. doi: 10.1111/1753-0407.12061.

PMID- 23590576
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
DP  - 2013 Apr 16
TI  - Association between Seizures and Diabetes Mellitus: A Comprehensive Review of
      Literature.
AB  - Epilepsy or seizures are often observed in patients with diabetes mellitus (DM), 
      and an emerging association between the two diseases is more than coincidental
      based on recent research. Approximately 25% of patients with DM experience
      different types of seizures. Furthermore, diabetic patients who experienced
      episodes of DKA also have seizures more frequently. The precise pathogenesis of
      seizures in the diabetes patient remains undetermined. Currently, the leading
      hypotheses in the literature suggest that multiple physiological factors, such as
      immune abnormalities, microvascular lesions in the brain, local brain damage,
      metabolic factors and gene mutation, may contribute to this condition. To date,
      there are no international criteria for the diagnosis and treatment of this
      condition. Although it is commonly assumed that antiepileptic drugs are
      necessary, most of the partial epilepsy patients with non-ketotic diabetes are
      resistant to frequently used antiepileptic drugs. In contrast, partial status
      epilepticus can be treated by diazepam, and carbamazepine is reported to be
      effective to some DM patients with epilepsy. However, anti-diabetic drugs are
      considered to be the most important factors in the treatment of this condition.
      When the blood glucose levels gradually return to normal levels, patients can no 
      longer generate seizures even when antiepileptic drugs are discontinued.
AD  - Department of Neurology, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing 400016, China xfyp@163.com.
FAU - Xuefeng, Wang
AU  - Xuefeng W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/01/25 [received]
PHST- 2013/04/13 [revised]
AID - CDR-EPUB-20130416-1 [pii]
PST - aheadofprint
SO  - Curr Diabetes Rev. 2013 Apr 16.

PMID- 23590571
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 43
IP  - 6
DP  - 2013 Jun
TI  - Baseline comorbidities in a skin cancer prevention trial in Bangladesh.
PG  - 579-88
LID - 10.1111/eci.12085 [doi]
AB  - BACKGROUND: Epidemiologic research suggests that increased cancer risk due to
      chronic arsenic exposure persists for several decades even after the exposure has
      terminated. Observational studies suggest that antioxidants exert a protective
      effect on arsenical skin lesions and cancers among those chronically exposed to
      arsenic through drinking water. This study reports on the design, methods and
      baseline analyses from the Bangladesh Vitamin E and Selenium Trial (BEST), a
      population-based chemoprevention study conducted among adults in Bangladesh with 
      visible arsenic toxicity. MATERIALS AND METHODS: Bangladesh Vitamin E and
      Selenium Trial is a 2x2 full factorial, double-blind, randomized controlled trial
      of 7000 adults having manifest arsenical skin lesions evaluating the efficacy of 
      6-year supplementation with alpha-tocopherol (100 mg daily) and
      L-selenomethionine (200 mug daily) for the prevention of nonmelanoma skin cancer.
      RESULTS: In cross-sectional analyses, we observed significant associations of
      skin lesion severity with male gender (female prevalence odds ratio (POR) = 0.87;
      95% CI = 0.79-0.96), older age (aged 36-45 years, POR = 1.27; 95% CI = 1.13-1.42;
      aged 46-55 years, POR = 1.44; 95% CI = 1.27-1.64 and aged 56-65 years, POR =
      1.50; 95% CI = 1.26-1.78 compared with aged 25-35 years), hypertension (POR =
      1.29; 95% CI = 1.08-1.55), diabetes (POR = 2.13; 95% CI = 1.32-3.46), asthma (POR
      = 1.55; 95% CI = 1.03-2.32) and peptic ulcer disease (POR = 1.20; 95% CI =
      1.07-1.35). CONCLUSIONS: We report novel associations between arsenical skin
      lesions with several common chronic diseases. With the rapidly increasing burden 
      of preventable cancers in developing countries, efficient and feasible
      chemoprevention study designs and approaches, such as employed in BEST, may prove
      both timely and potentially beneficial in conceiving cancer chemoprevention
      trials in Bangladesh and beyond.
CI  - (c) 2013 Stichting European Society for Clinical Investigation Journal
      Foundation. Published by John Wiley & Sons Ltd.
AD  - Department of Health Studies, The University of Chicago, Chicago, IL, USA.
FAU - Argos, Maria
AU  - Argos M
FAU - Rahman, Mahfuzar
AU  - Rahman M
FAU - Parvez, Faruque
AU  - Parvez F
FAU - Dignam, James
AU  - Dignam J
FAU - Islam, Tariqul
AU  - Islam T
FAU - Quasem, Iftekhar
AU  - Quasem I
FAU - K Hore, Samar
AU  - K Hore S
FAU - T Haider, Ahmed
AU  - T Haider A
FAU - Hossain, Zahid
AU  - Hossain Z
FAU - I Patwary, Tazul
AU  - I Patwary T
FAU - Rakibuz-Zaman, Muhammad
AU  - Rakibuz-Zaman M
FAU - Sarwar, Golam
AU  - Sarwar G
FAU - La Porte, Paul
AU  - La Porte P
FAU - Harjes, Judith
AU  - Harjes J
FAU - Anton, Kristen
AU  - Anton K
FAU - Kibriya, Muhammad G
AU  - Kibriya MG
FAU - Jasmine, Farzana
AU  - Jasmine F
FAU - Khan, Rashed
AU  - Khan R
FAU - Kamal, Mohammed
AU  - Kamal M
FAU - Shea, Christopher R
AU  - Shea CR
FAU - Yunus, Muhammad
AU  - Yunus M
FAU - Baron, John A
AU  - Baron JA
FAU - Ahsan, Habibul
AU  - Ahsan H
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/09/28 [received]
PHST- 2013/03/09 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 10.1111/eci.12085 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2013 Jun;43(6):579-88. doi: 10.1111/eci.12085. Epub 2013 Apr
      17.

PMID- 23590551
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
IP  - 1
DP  - 2013
TI  - Common variants in adiponectin gene are associated with coronary artery disease
      and angiographical severity of coronary atherosclerosis in type 2 diabetes.
PG  - 67
LID - 10.1186/1475-2840-12-67 [doi]
AB  - BACKGROUND: Adiponectin, an adipokine facilitating insulin action, has
      antiatherogenic effects. This study investigated whether common single nucleotide
      polymorphisms (SNPs) in the adiponectin gene influenced plasma adiponectin level 
      and whether they were associated with the risk of coronary artery disease (CAD)
      and its angiographical severity in type 2 diabetes in Chinese population.
      METHODS: 11 tagging SNPs were genotyped in 1110 subjects with or without CAD in
      type 2 diabetes. Variants of adiponectin gene were determined by Taqman
      polymerase chain reaction method. The plasma adiponectin concentrations were
      measured by sandwich enzyme-linked immunosorbent assay. The severity and extent
      of coronary atherosclerosis were assessed using the angiographic Gensini score
      and Sullivan Extent score. RESULTS: Among the 11 SNPs, the minor G allele of SNP 
      rs266729 was significantly associated with higher odds of CAD (odds ratio (95%
      CI) = 1.49 (1.10 - 2.16), P = 0.022) after adjusting for covariates. In stepwise 
      multivariate logistic regression, SNP rs266729 was a significant independent
      factor of CAD. Multivariate linear regression analysis revealed that rs266729
      (beta = -0.101, P < 0.0001), rs182052 (beta = -0.044, P = 0.0035), and rs1501299 
      (beta = 0.073, P < 0.0001) were significantly associated with adiponectin level, 
      and also indicated that the minor G allele of SNP rs266729 had higher Gensini
      score (beta = 0.139, P < 0.001) and Sullivan Extent score (beta = 0.107, P <
      0.001). Haplotypes analysis revealed different haplotype distributions in case
      and control subjects (P = 0.0003), with two common haplotypes GGG and GAG of the 
      rs266729, rs182052, and rs1501299 being associated in heterozygotes with a
      greater than threefold increase in cardiovascular risk (odds ratio (95% CI)=3.39 
      (1.83 - 6.30), P = 0.0001). CONCLUSIONS: In our population, genetic variants in
      the adiponectin gene influence plasma adiponectin levels, and one of them is a
      strong determinant of CAD susceptibility and its angiographical severity in type 
      2 diabetes. This study has provided further evidence for a role of adiponectin in
      the development of CAD.
AD  - Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University,
      Beijing, China. sunnystewen@sina.com.
FAU - Tong, Guoxin
AU  - Tong G
FAU - Wang, Ningfu
AU  - Wang N
FAU - Leng, Jianhang
AU  - Leng J
FAU - Tong, Xiaoshan
AU  - Tong X
FAU - Shen, Yun
AU  - Shen Y
FAU - Yang, Jianmin
AU  - Yang J
FAU - Ye, Xianhua
AU  - Ye X
FAU - Zhou, Liang
AU  - Zhou L
FAU - Zhou, Yujie
AU  - Zhou Y
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3648457
OID - NLM: PMC3648457
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/01/23 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 1475-2840-12-67 [pii]
AID - 10.1186/1475-2840-12-67 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 Apr 17;12(1):67. doi: 10.1186/1475-2840-12-67.

PMID- 23590548
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 43
IP  - 6
DP  - 2013 Jun
TI  - Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD.
PG  - 562-9
LID - 10.1111/eci.12079 [doi]
AB  - BACKGROUND: Knowledge of the role of the receptor for advanced glycation end
      products (RAGE), particularly its soluble form (sRAGE), and of its advanced
      glycation end product (AGE) ligand, N-(carboxymethyl)lysine adducts (CML), is
      limited in chronic heart failure (CHF) and in chronic obstructive pulmonary
      disease (COPD). We evaluated whether the AGE/RAGE system is activated in stable
      CHF and COPD, and whether plasma sRAGE and CML levels are affected by clinical
      and functional parameters. MATERIALS AND METHODS: We measured plasma levels of
      sRAGE and CML using a sandwich enzyme-linked immunosorbent assay (ELISA) in 143
      subjects, aged >/= 65 years, divided into five groups: 58 with CHF, 23 with COPD,
      27 with CHF+COPD and 35 controls (17 healthy smokers and 18 healthy nonsmokers). 
      Individuals with diabetes were excluded from the study. RESULTS: Plasma levels of
      sRAGE and CML were higher in CHF patients than in controls [sRAGE: 0.48
      (0.37-0.83) vs. 0.42 (0.29-0.52) ng/mL, P = 0.01; CML: 1.95 (1.58-2.38) vs. 1.68 
      (1.43-2.00) ng/mL, P = 0.01]. By contrast, sRAGE and CML were not different
      between both COPD and CHF+COPD patients and controls (P > 0.05). N-terminal
      pro-brain natriuretic peptide (Nt-pro BNP) correlated with sRAGE, but not with
      CML, in the patient groups: CHF (r = 0.43, P < 0.001), COPD (r = 0.77, P <
      0.0001) and CHF/COPD (r = 0.43, P = 0.003). CONCLUSIONS: Plasma levels of sRAGE
      and CML are increased in CHF, but not in COPD patients. The robust association
      between NT-pro BNP, a diagnostic and prognostic marker in CHF, and sRAGE
      concentrations might suggest a possible BNP pathway of amplification of
      inflammation via the AGE/RAGE system.
CI  - (c) 2013 Stichting European Society for Clinical Investigation Journal
      Foundation. Published by John Wiley & Sons Ltd.
AD  - Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara,
      Italy.
FAU - Boschetto, Piera
AU  - Boschetto P
FAU - Campo, Ilaria
AU  - Campo I
FAU - Stendardo, Mariarita
AU  - Stendardo M
FAU - Casimirri, Enrico
AU  - Casimirri E
FAU - Tinelli, Carmine
AU  - Tinelli C
FAU - Gorrini, Marina
AU  - Gorrini M
FAU - Ceconi, Claudio
AU  - Ceconi C
FAU - Fucili, Alessandro
AU  - Fucili A
FAU - Potena, Alfredo
AU  - Potena A
FAU - Papi, Alberto
AU  - Papi A
FAU - Ballerin, Licia
AU  - Ballerin L
FAU - Fabbri, Leonardo
AU  - Fabbri L
FAU - Luisetti, Maurizio
AU  - Luisetti M
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/11/05 [received]
PHST- 2013/03/04 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 10.1111/eci.12079 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2013 Jun;43(6):562-9. doi: 10.1111/eci.12079. Epub 2013 Apr
      17.

PMID- 23590534
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
DP  - 2013 Apr 11
TI  - A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian
      American Subgroups.
AB  - This systematic review synthesizes data published between 1988 and 2009 on mean
      BMI and prevalence of overweight, obesity, and type 2 diabetes among Asian
      subgroups in the U.S. We conducted systematic searches in PubMed for
      peer-reviewed, English-language citations that reported mean BMI and percent
      overweight, obesity, and diabetes among South Asians/Asian Indians, Chinese,
      Filipinos, Koreans, and Vietnamese. We identified 647 database citations and 23
      additional citations from hand-searching. After screening titles, abstracts, and 
      full-text publications, 97 citations remained. None were published between 1988
      and 1992, 28 between 1993 and 2003, and 69 between 2004 and 2009. Publications
      were identified for the following Asian subgroups: South Asian (n=8), Asian
      Indian (n=20), Chinese (n=44), Filipino (n=22), Korean (n= 8), and Vietnamese
      (n=3). The observed sample sizes ranged from 32 to 4245 subjects with mean ages
      from 24 to 78 years. Among samples of men and women, the lowest reported mean BMI
      was in South Asians (22.1 kg/m2), and the highest was in Filipinos (26.8 kg/m2). 
      Estimates for overweight (12.8 - 46.7%) and obesity (2.1 - 59.0%) were variable. 
      Among men and women, the highest rate of diabetes was reported in Asian Indians
      with BMI >/= 30 kg/m2 (32.9%, age and sex standardized). This review suggests
      heterogeneity among U.S. Asian populations in cardiometabolic risk factors, yet
      comparisons are limited due to variability in study populations, methods, and
      definitions used in published reports. Future efforts should adopt standardized
      methods to understand overweight, obesity and diabetes in this growing U.S.
      ethnic population.
AD  - 1518 Clifton Road, NE, CNR Rm. 7043, Atlanta, GA 30322. lisa.staimez@emory.edu.
FAU - Staimez, Lisa R
AU  - Staimez LR
FAU - Weber, Mary Beth
AU  - Weber MB
FAU - Narayan, K M Venkat
AU  - Narayan KM
FAU - Oza-Frank, Reena
AU  - Oza-Frank R
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/09/27 [received]
PHST- 2013/04/05 [revised]
AID - CDR-EPUB-20130411-1 [pii]
PST - aheadofprint
SO  - Curr Diabetes Rev. 2013 Apr 11.

PMID- 23590422
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
DP  - 2013 Apr 17
TI  - Psychological factors associated with successful outcomes in home haemodialysis.
LID - 10.1111/nep.12089 [doi]
AB  - AIM: Performing haemodialysis therapy at home has been associated with improved
      survival for end stage kidney disease patients and can generally be delivered at 
      a lower cost to the health care system when compared to centre and satellite unit
      dialysis. However, only a minority of dialysis dependent ESKD patients
      successfully sustain haemodialysis at home. Current practice for determining
      dialysis treatment modality and location takes into account medical suitability
      and social situation, but infrequently formally examines the contribution of
      psychological factors. This study explores demographic, health, and psychological
      factors that may predict patients' ability to sustain home haemodialysis.
      METHODS: One hundred and thirteen successful and unsuccessful home haemodialysis 
      users were recruited to the study, and 55 responded to self-report measures.
      Demographic (age, gender, education level, carer support), health
      (co-morbidities, diabetes, psychiatric condition) and psychological (locus of
      control beliefs, coping styles) information was used as predictor variables for
      the participants' time maintaining home therapy (Home Time). RESULTS: In a 3-step
      regression, the model explained 32% of variance in Home Time. Coping styles
      significantly contributed 16% of the variance in Home Time after accounting for
      other variables. Adaptive Coping was significantly correlated with the length of 
      time sustaining home therapy. CONCLUSIONS: Adaptive coping strategies are
      associated with improved ability to sustain home haemodialysis therapy.
      Evidence-based psychological approaches can help patients develop more adaptive
      coping strategies. More research is needed to assess whether instituting these
      psychological interventions will assist patients to adopt and sustain dialysis
      therapies which require increased patient self management.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Psychology, Princess Alexandra Hospital, Brisbane, Queensland,
      Australia.
FAU - Nearhos, Jane
AU  - Nearhos J
FAU - Van Eps, Carolyn
AU  - Van Eps C
FAU - Connor, Jason
AU  - Connor J
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/10 [accepted]
AID - 10.1111/nep.12089 [doi]
PST - aheadofprint
SO  - Nephrology (Carlton). 2013 Apr 17. doi: 10.1111/nep.12089.

PMID- 23590413
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment
      of type 2 diabetes mellitus.
PG  - 763-75
LID - 10.1517/17425255.2013.791282 [doi]
AB  - Introduction: Canagliflozin is an orally administered sodium glucose
      cotransporter 2 inhibitor proposed for the treatment of type 2 diabetes.
      Canagliflozin improves glycemic control in an insulin-independent fashion through
      inhibition of glucose reuptake in the kidney. Areas covered: This article reviews
      the available data on the pharmacodynamics, the pharmacokinetics and metabolism, 
      and the efficacy and safety of canagliflozin. Relevant articles were identified
      via PubMed using the search term canagliflozin with no date restriction. The
      authors also discuss the abstracts from canagliflozin studies presented at large 
      diabetes conferences. Expert opinion: Canagliflozin offers a relatively modest
      reduction in HbA1c, FPG, and PPG. It has a low incidence of hypoglycemia and a
      reduction in body weight. Dose adjustment may be recommended in the elderly,
      those on loop diuretics, and those with an estimated glomerular filtration rate
      (eGFR) < 60 ml/min/1.73 m(2) if there are concerns or symptoms of volume-related 
      side effects. Issues remain with observed increases in low-density lipoprotein
      cholesterol (LDL-C) and the odds of heart attack and stroke. Canagliflozin offers
      a novel mechanism of action, a modest glycemic control, and a favorable
      side-effect profile. It was approved by the US Food and Drug Administration in
      April 2013 and is undergoing evaluation by the European Medicines Agency.
AD  - University of Maryland School of Medicine, Department of Medicine , 22 S. Greene 
      Street, Room N3W42, Baltimore, MD 21201 , USA.
FAU - Lamos, Elizabeth M
AU  - Lamos EM
FAU - Younk, Lisa M
AU  - Younk LM
FAU - Davis, Stephen N
AU  - Davis SN
LA  - eng
PT  - Journal Article
DEP - 20130417
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/17 [aheadofprint]
AID - 10.1517/17425255.2013.791282 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi:
      10.1517/17425255.2013.791282. Epub 2013 Apr 17.

PMID- 23590338
OWN - NLM
STAT- In-Data-Review
DA  - 20130515
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 61
IP  - 5
DP  - 2013 May
TI  - Exclusion of older adults from ongoing clinical trials about type 2 diabetes
      mellitus.
PG  - 734-8
LID - 10.1111/jgs.12215 [doi]
AB  - OBJECTIVE: To assess the extent of exclusion of older individuals from ongoing
      clinical trials regarding type 2 diabetes mellitus. DESIGN: Cohort study.
      SETTING: World Health Organization Clinical Trials Registry Platform.
      PARTICIPANTS: Using the Participation of the Elderly in Clinical Trials
      methodology, data from ongoing clinical trials on type 2 diabetes mellitus were
      extracted from the platform on July 31, 2011. MEASUREMENTS: Proportion of trials 
      excluding individuals using an arbitrary upper age limit or other exclusion
      criteria that might indirectly cause limited recruitment of older individuals.
      Exclusion criteria were classified as justified or poorly justified. RESULTS: Of 
      440 trials investigating treatments for type 2 diabetes mellitus, 289 (65.7%)
      excluded individuals using an arbitrary upper age limit. Such exclusion was
      significantly more common in trials with calculated sample sizes of less than 100
      subjects (73.6% vs 59.5%; P = .002). Exclusion for comorbidity was present in 338
      trials (76.8%); this exclusion was poorly justified in 236 trials (53.6%).
      Exclusion for polypharmacy (29.5% of trials), cognitive impairment (18.4%), short
      life expectancy (8.9%), and other poorly justified exclusion criteria that could 
      limit the inclusion of older individuals was also present. Only six trials (1.4%)
      were designed specifically to study older adults. CONCLUSION: Despite the
      recommendations of international regulatory agencies, exclusion of older
      individuals from ongoing trials regarding type 2 diabetes mellitus is
      frequent-higher than reported for other age-related diseases. This exclusion
      limits the value of the evidence that clinicians use when treating old, frail,
      complex patients with diabetes mellitus.
CI  - (c) 2013, Copyright the Authors Journal compilation (c) 2013, The American
      Geriatrics Society.
AD  - Department of Geriatrics, Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Cruz-Jentoft, Alfonso J
AU  - Cruz-Jentoft AJ
FAU - Carpena-Ruiz, Marina
AU  - Carpena-Ruiz M
FAU - Montero-Errasquin, Beatriz
AU  - Montero-Errasquin B
FAU - Sanchez-Castellano, Carmen
AU  - Sanchez-Castellano C
FAU - Sanchez-Garcia, Elisabet
AU  - Sanchez-Garcia E
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/04/16 [aheadofprint]
AID - 10.1111/jgs.12215 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2013 May;61(5):734-8. doi: 10.1111/jgs.12215. Epub 2013 Apr 16.

PMID- 23590337
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
IP  - 1
DP  - 2013 Apr 16
TI  - Early impairment of contractility reserve in patients with insulin resistance in 
      comparison with healthy subjects.
PG  - 66
AB  - BACKGROUND: Insulin resistance (IR) is currently considered a crucial
      cardiovascular (CV) risk factor, which seems to play a dominant role in the
      evolution toward cardiac and vascular impairment. Early IR-induced cardiac
      dysfunction can be assessed by Doppler-derived myocardial systolic strain rate
      (SR) index, measured at baseline and after dobutamine stress echocardiography
      (DSE). METHODS: Thirty IR patients (HOMA-IR = 7 +/- 5.2, age 52.6 +/- 2.1 years),
      and 20 healthy, age and sex matched controls were studied. IR had been diagnosed 
      in all patients in the 3 months preceding the study. Dobutamine echocardiography 
      was performed in all subjects to exclude ischemic heart disease, and left
      ventricular contractile reserve (LVCR) was then assessed. LVCR was evaluated as
      an increase in the peak of an average longitudinal SR, measured in the basal and 
      mid segments of 2 and 4 chamber ventricular walls. RESULTS: No significant
      differences between the 2 groups were revealed by baseline echocardiography. In
      contrast, after DSE a significant decrease of Delta SR was found in the IR group 
      in comparison to the controls (0.54+/-0.31 s-1 vs 1.14+/-0.45 s-1; p < 0.0001).
      CONCLUSIONS: Our results show that IR, even if isolated and arising within a
      short time period, not only represents the initial phase of future diabetes, but 
      may adversely affect heart function, as evidenced by the depressed LVCR. Our data
      strengthen the need for attention to be paid to IR state and for an early
      therapeutic approach.
FAU - Cadeddu, Christian
AU  - Cadeddu C
FAU - Nocco, Silvio
AU  - Nocco S
FAU - Piano, Davide
AU  - Piano D
FAU - Deidda, Martino
AU  - Deidda M
FAU - Cossu, Efisio
AU  - Cossu E
FAU - Baroni, Marco Giorgio
AU  - Baroni MG
FAU - Mercuro, Giuseppe
AU  - Mercuro G
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
PMC - PMC3637195
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/02/05 [received]
PHST- 2013/04/16 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 1475-2840-12-66 [pii]
AID - 10.1186/1475-2840-12-66 [doi]
PST - aheadofprint
SO  - Cardiovasc Diabetol. 2013 Apr 16;12(1):66.

PMID- 23590331
OWN - NLM
STAT- Publisher
DA  - 20130417
IS  - 1365-2826 (Electronic)
IS  - 0953-8194 (Linking)
DP  - 2013 Apr 16
TI  - The GLP-1 receptor in the brain: role in neuroendocrine control of energy
      metabolism and treatment target for obesity.
LID - 10.1111/jne.12039 [doi]
AB  - The central GLP-1 receptor mediates a number of metabolic processes, including
      feeding, body weight, and glucose homeostasis. More recently, roles in energy
      expenditure and reward pathway modulation have been described. GLP-1 receptor
      agonism promotes insulin release and is currently used to treat type 2 diabetes
      humans, with a common side effect being weight loss. It is likely that many of
      these metabolic effects are mediated by GLP-1Rs located in the central nervous
      system, throughout areas known to be important in control of energy homeostasis. 
      The physiological role of the GLP-1 receptor signalling in each of these brain
      nuclei is becoming clearer and the GLP-1 system appears to act as an integrator
      of peripheral energy availability and effector of metabolic regulation. This
      makes it an attractive target for obesity therapies, with excellent pre-clinical 
      efficacy seen in molecules combining GLP-1 receptor agonism with glucagon
      receptor agonism. This review discusses what is known about the functions of the 
      GLP-1 receptor in the central nervous system, and highlights the ways this system
      may be targeted for development of new obesity therapeutics. This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Monash University, Physiology, Building 13F, Wellington Rd, Clayton, Victoria,
      Australia, 3800.
FAU - Lockie, Sarah Haas
AU  - Lockie SH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2012/11/02 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/04/07 [accepted]
AID - 10.1111/jne.12039 [doi]
PST - aheadofprint
SO  - J Neuroendocrinol. 2013 Apr 16. doi: 10.1111/jne.12039.

PMID- 23590285
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 13
DP  - 2013
TI  - Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress.
PG  - 67
LID - 10.1186/1471-230X-13-67 [doi]
AB  - BACKGROUND: FGF21 is a promising intervention therapy for metabolic diseases as
      fatty liver, obesity and diabetes. Recent results suggest that FGF21 is highly
      expressed in hepatocytes under metabolic stress caused by starvation,
      hepatosteatosis, obesity and diabetes. Hepatic FGF21 elicits metabolic benefits
      by targeting adipocytes of the peripheral adipose tissue through the
      transmembrane FGFR1-KLB complex. Ablation of adipose FGFR1 resulted in increased 
      hepatosteatosis under starvation conditions and abrogation of the anti-obesogenic
      action of FGF21. These results indicate that FGF21 may be a stress responsive
      hepatokine that targets adipocytes and adipose tissue for alleviating the
      damaging effects of stress on the liver. However, it is unclear whether hepatic
      induction of FGF21 is limited to only metabolic stress, or to a more general
      hepatic stress resulting from liver pathogenesis and injury. METHODS: In this
      survey-based study, we examine the nature of hepatic FGF21 activation in liver
      tissues and tissue sections from several mouse liver disease models and human
      patients, by quantitative PCR, immunohistochemistry, protein chemistry, and
      reporter and CHIP assays. The liver diseases include genetic and chemical-induced
      HCC, liver injury and regeneration, cirrhosis, and other types of liver diseases.
      RESULTS: We found that mouse FGF21 is induced in response to chemical (DEN
      treatment) and genetic-induced hepatocarcinogenesis (disruptions in LKB1, p53,
      MST1/2, SAV1 and PTEN). It is also induced in response to loss of liver mass due 
      to partial hepatectomy followed by regeneration. The induction of FGF21
      expression is potentially under the control of stress responsive transcription
      factors p53 and STAT3. Serum FGF21 levels correlate with FGF21 expression in
      hepatocytes. In patients with hepatitis, fatty degeneration, cirrhosis and liver 
      tumors, FGF21 levels in hepatocytes or phenotypically normal hepatocytes are
      invariably elevated compared to normal health subjects. CONCLUSION: FGF21 is an
      inducible hepatokine and could be a biomarker for normal hepatocyte function.
      Activation of its expression is a response of functional hepatocytes to a broad
      spectrum of pathological changes that impose both cellular and metabolic stress
      on the liver. Taken together with our recent data, we suggest that hepatic FGF21 
      is a general stress responsive factor that targets adipose tissue for normalizing
      local and systemic metabolic parameters while alleviating the overload and
      damaging effects imposed by the pathogenic stress on the liver. This study
      therefore provides a rationale for clinical biomarker studies in humans.
AD  - Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology,
      Texas A&M Health Science Center, 2121 W, Holcombe Blvd,, Houston, TX 77030-3303, 
      USA.
FAU - Yang, Chaofeng
AU  - Yang C
FAU - Lu, Weiqin
AU  - Lu W
FAU - Lin, Tao
AU  - Lin T
FAU - You, Pan
AU  - You P
FAU - Ye, Min
AU  - Ye M
FAU - Huang, Yanqing
AU  - Huang Y
FAU - Jiang, Xianhan
AU  - Jiang X
FAU - Wang, Cong
AU  - Wang C
FAU - Wang, Fen
AU  - Wang F
FAU - Lee, Mong-Hong
AU  - Lee MH
FAU - Yeung, Sai-Ching J
AU  - Yeung SC
FAU - Johnson, Randy L
AU  - Johnson RL
FAU - Wei, Chongjuan
AU  - Wei C
FAU - Tsai, Robert Y
AU  - Tsai RY
FAU - Frazier, Marsha L
AU  - Frazier ML
FAU - McKeehan, Wallace L
AU  - McKeehan WL
FAU - Luo, Yongde
AU  - Luo Y
LA  - eng
GR  - DK56338/DK/NIDDK NIH HHS/United States
GR  - P50 CA140388/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130417
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
SB  - IM
PMC - PMC3637159
OID - NLM: PMC3637159
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/01/02 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/04/17 [aheadofprint]
AID - 1471-230X-13-67 [pii]
AID - 10.1186/1471-230X-13-67 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2013 Apr 17;13:67. doi: 10.1186/1471-230X-13-67.

PMID- 23590234
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1742-4658 (Electronic)
IS  - 1742-464X (Linking)
DP  - 2013 Apr 17
TI  - A role of intracellular mono-ADP-ribosylation in cancer biology.
LID - 10.1111/febs.12290 [doi]
AB  - During the development, progression and dissemination of neoplastic lesions,
      cancer cells can hijack normal pathways and mechanisms. This includes the control
      of the function of cellular proteins through reversible post-translational
      modifications, such as ADP-ribosylation, phosphorylation, and acetylation. In the
      case of mono-ADP-ribosylation and poly-ADP-ribosylation, the addition of one or
      several units of ADP-ribose to target proteins occurs via two families of enzymes
      that can generate ADP-ribosylated proteins: the diphtheria toxin-like
      ADP-ribosyltransferase (ARTD) family, comprising 17 different proteins that are
      either poly-ADP-ribosyltransferases or mono-ADP-ribosyltransferases or inactive
      enzymes; and the clostridial toxin-like ADP-ribosyltransferase family, with four 
      human members, two of which are active mono-ADP-ribosyltransferases, and two of
      which are enzymatically inactive. In line with a central role for poly-ADP-ribose
      polymerase 1 in response to DNA damage, specific inhibitors of this enzyme have
      been developed as anticancer therapeutics and evaluated in several clinical
      trials. Recently, in combination with the discovery of a large number of enzymes 
      that can catalyse mono-ADP-ribosylation, the role of this modification has been
      linked to human diseases, such as inflammation, diabetes, neurodegeneration, and 
      cancer, thus revealing the need for the development of specific ARTD inhibitors. 
      This will provide a better understanding of the roles of these enzymes in human
      physiology and pathology, so that they can be targeted in the future to generate 
      new and efficacious drugs. This review summarizes our present knowledge of the
      ARTD enzymes that are involved in mono-ADP-ribosylation reactions and that have
      roles in cancer biology. In particular, the well-documented role of
      macro-containing ARTD8 in lymphoma and the putative role of ARTD15 in cancer are 
      discussed.
CI  - (c) 2013 The Authors Journal compilation (c) 2013 FEBS.
AD  - G-Protein-mediated Signalling Laboratory, Department of Cellular and
      Translational Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro,
      Chieti, Italy.
FAU - Scarpa, Emanuele S
AU  - Scarpa ES
FAU - Fabrizio, Gaia
AU  - Fabrizio G
FAU - Di Girolamo, Maria
AU  - Di Girolamo M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130417
TA  - FEBS J
JT  - The FEBS journal
JID - 101229646
EDAT- 2013/04/18 06:00
MHDA- 2013/04/18 06:00
CRDT- 2013/04/18 06:00
PHST- 2013/03/11 [received]
PHST- 2013/04/09 [accepted]
AID - 10.1111/febs.12290 [doi]
PST - aheadofprint
SO  - FEBS J. 2013 Apr 17. doi: 10.1111/febs.12290.

PMID- 23589828
OWN - NLM
STAT- MEDLINE
DA  - 20130416
DCOM- 20130607
IS  - 1522-1210 (Electronic)
IS  - 0031-9333 (Linking)
VI  - 93
IP  - 2
DP  - 2013 Apr
TI  - Somatotropic signaling: trade-offs between growth, reproductive development, and 
      longevity.
PG  - 571-98
LID - 10.1152/physrev.00006.2012 [doi]
AB  - Growth hormone (GH) is a key determinant of postnatal growth and plays an
      important role in the control of metabolism and body composition. Surprisingly,
      deficiency in GH signaling delays aging and remarkably extends longevity in
      laboratory mice. In GH-deficient and GH-resistant animals, the "healthspan" is
      also extended with delays in cognitive decline and in the onset of age-related
      disease. The role of hormones homologous to insulin-like growth factor (IGF, an
      important mediator of GH actions) in the control of aging and lifespan is
      evolutionarily conserved from worms to mammals with some homologies extending to 
      unicellular yeast. The combination of reduced GH, IGF-I, and insulin signaling
      likely contributes to extended longevity in GH or GH receptor-deficient
      organisms. Diminutive body size and reduced fecundity of GH-deficient and
      GH-resistant mice can be viewed as trade-offs for extended longevity. Mechanisms 
      responsible for delayed aging of GH-related mutants include enhanced stress
      resistance and xenobiotic metabolism, reduced inflammation, improved insulin
      signaling, and various metabolic adjustments. Pathological excess of GH reduces
      life expectancy in men as well as in mice, and GH resistance or deficiency
      provides protection from major age-related diseases, including diabetes and
      cancer, in both species. However, there is yet no evidence of increased longevity
      in GH-resistant or GH-deficient humans, possibly due to non-age-related deaths.
      Results obtained in GH-related mutant mice provide striking examples of mutations
      of a single gene delaying aging, reducing age-related disease, and extending
      lifespan in a mammal and providing novel experimental systems for the study of
      mechanisms of aging.
AD  - Southern Illinois University School of Medicine, Department of Internal Medicine,
      Geriatric Research, Springfield, Illinois 62703, USA. abartke@siumed.edu
FAU - Bartke, Andrzej
AU  - Bartke A
FAU - Sun, Liou Y
AU  - Sun LY
FAU - Longo, Valter
AU  - Longo V
LA  - eng
GR  - AG025135/AG/NIA NIH HHS/United States
GR  - AG20642/AG/NIA NIH HHS/United States
GR  - P01 AG031736/AG/NIA NIH HHS/United States
GR  - P01 AG034906/AG/NIA NIH HHS/United States
GR  - R01 AG019899/AG/NIA NIH HHS/United States
GR  - R21 AG038850/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Physiol Rev
JT  - Physiological reviews
JID - 0231714
RN  - 0 (Receptors, Somatotropin)
RN  - 9002-72-6 (Growth Hormone)
SB  - IM
MH  - Animals
MH  - Growth Hormone/genetics/*metabolism
MH  - Humans
MH  - Longevity/genetics/*physiology
MH  - Receptors, Somatotropin/genetics/metabolism
MH  - Reproduction/genetics/*physiology
MH  - *Signal Transduction
EDAT- 2013/04/17 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/04/17 06:00
AID - 93/2/571 [pii]
AID - 10.1152/physrev.00006.2012 [doi]
PST - ppublish
SO  - Physiol Rev. 2013 Apr;93(2):571-98. doi: 10.1152/physrev.00006.2012.

PMID- 23589759
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 1942-0994 (Electronic)
VI  - 2013
DP  - 2013
TI  - Therapeutic effect of MG132 on the aortic oxidative damage and inflammatory
      response in OVE26 type 1 diabetic mice.
PG  - 879516
LID - 10.1155/2013/879516 [doi]
AB  - The present study tested whether MG132 increases vascular nuclear factor
      E2-related factor-2 (Nrf2) expression and transcription to provide a therapeutic 
      effect on diabetes-induced pathogenic changes in the aorta. To this end,
      three-month-old OVE26 diabetic and age-matched control mice were
      intraperitoneally injected with MG-132, 10 mu g/kg daily for 3 months. OVE26
      transgenic type 1 diabetic mice develop hyperglycemia at 2-3 weeks of age and
      exhibit albuminuria at 3 months of age with mild increases in TNF- alpha
      expression and 3-NT accumulation in the aorta. Diabetes-induced significant
      increases in the wall thickness and structural derangement of aorta were found in
      OVE26 mice with significant increases in aortic oxidative and nitrosative damage,
      inflammation, and remodeling at 6 months of diabetes, but not at 3 months of
      diabetes. However, these pathological changes seen at the 6 months of diabetes
      were abolished in OVE26 mice treated with MG-132 for 3 months that were also
      associated with a significant increase in Nrf2 expression in the aorta as well as
      transcription of downstream genes. These results suggest that chronic treatment
      with low-dose MG132 can afford an effective therapy for diabetes-induced
      pathogenic changes in the aorta, which is associated with the increased Nrf2
      expression and transcription.
AD  - The Second Hospital of Jilin University, Changchun 130041, China.
FAU - Miao, Xiao
AU  - Miao X
FAU - Cui, Wenpeng
AU  - Cui W
FAU - Sun, Weixia
AU  - Sun W
FAU - Xin, Ying
AU  - Xin Y
FAU - Wang, Bo
AU  - Wang B
FAU - Tan, Yi
AU  - Tan Y
FAU - Cai, Lu
AU  - Cai L
FAU - Miao, Lining
AU  - Miao L
FAU - Fu, Yaowen
AU  - Fu Y
FAU - Su, Guanfang
AU  - Su G
FAU - Wang, Yuehui
AU  - Wang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130326
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
SB  - IM
PMC - PMC3622385
OID - NLM: PMC3622385
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/01/15 [received]
PHST- 2013/02/28 [accepted]
PHST- 2013/03/26 [epublish]
AID - 10.1155/2013/879516 [doi]
PST - ppublish
SO  - Oxid Med Cell Longev. 2013;2013:879516. doi: 10.1155/2013/879516. Epub 2013 Mar
      26.

PMID- 23589729
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130416
DCOM- 20130417
LR  - 20130419
IS  - 1754-6605 (Electronic)
IS  - 1754-6605 (Linking)
VI  - 7
DP  - 2013
TI  - Aspirin for the next generation.
PG  - 300
LID - 10.3332/ecancer.2013.300 [doi]
AB  - First used as an analgesic and antipyretic, investigations into aspirin's
      anti-inflammatory effects led to its establishment in 1974 as a drug that altered
      the activity of platelets to influence the course and incidence of myocardial
      infarction and cerebrovascular disease. It became the standard in treatment and
      prevention of vascular disorders. The 25th International Scientific Meeting on
      aspirin held at the Royal College of Physicians in London on 24th October 2012
      took aspirin into fresh fields, among them cancer, diabetes, dementia and
      gynaecology.
AD  - Aspirin Foundation, PO Box 223, Haslemere GU27 3ZJ, UK.
FAU - Henderson, Nick
AU  - Henderson N
FAU - Smith, Tom
AU  - Smith T
LA  - eng
PT  - Journal Article
DEP - 20130402
PL  - England
TA  - Ecancermedicalscience
JT  - Ecancermedicalscience
JID - 101392236
PMC - PMC3622499
OID - NLM: PMC3622499
OTO - NOTNLM
OT  - Hughes syndrome
OT  - aspirin
OT  - cancer
OT  - dementia
OT  - diabetes
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:01
CRDT- 2013/04/17 06:00
PHST- 2013 [ppublish]
PHST- 2013/02/22 [received]
PHST- 2013/04/02 [epublish]
AID - 10.3332/ecancer.2013.300 [doi]
AID - can-7-300 [pii]
PST - epublish
SO  - Ecancermedicalscience. 2013 Apr 2;7:300. doi: 10.3332/ecancer.2013.300. Print
      2013.

PMID- 23589711
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130416
DCOM- 20130417
LR  - 20130419
IS  - 1654-661X (Electronic)
IS  - 1654-661X (Linking)
VI  - 57
DP  - 2013
TI  - Breastfeeding, introduction of other foods and effects on health: a systematic
      literature review for the 5th Nordic Nutrition Recommendations.
LID - 10.3402/fnr.v57i0.20823 [doi]
AB  - The present systematic literature review is part of the 5th revision of the
      Nordic Nutrition Recommendations. The overall aim was to review recent scientific
      data valid in a Nordic setting on the short- and long-term health effects of
      breastfeeding (duration of both any and exclusive breastfeeding) and introduction
      of foods other than breast milk. The initial literature search resulted in 2,011 
      abstracts; 416 identified as potentially relevant. Full paper review resulted in 
      60 quality assessed papers (6A, 48B, and 6C). A complementary search found some
      additional papers. The grade of evidence was classified as convincing, probable, 
      limited-suggestive, and limited-no conclusion. The evidence was convincing of a
      protective dose/duration effect of breastfeeding against overweight and obesity
      in childhood and adolescence, overall infections, acute otitis media, and
      gastrointestinal and respiratory tract infections. The evidence was probable that
      exclusive breastfeeding for longer than 4 months is associated with slower weight
      gain during the second half of the first year which could be part of the reason
      behind the reduced risk of later overweight or obesity. There was also probable
      evidence that breastfeeding is a protective factor against inflammatory bowel
      disease, celiac disease, and diabetes (type 1 and 2), provides beneficial effects
      on IQ and developmental scores of children as well as a small reductive effect on
      blood pressure and blood cholesterol levels in adulthood. Other associations
      explored were limited-suggestive or inconclusive. In conclusion, convincing and
      probable evidence was found for benefits of breastfeeding on several outcomes.
      The recommendation in NNR2004 about exclusive breastfeeding for 6 months and
      continued partial breastfeeding thereafter can stand unchanged. The relatively
      low proportion of infants in the Nordic countries following this recommendation
      indicates that strategies that protect, support and promote breastfeeding should 
      be enhanced, and should also recognize the benefits for long-term health.
AD  - Department of Food and Nutrition, Umea, University, Umea Sweden.
FAU - Hornell, Agneta
AU  - Hornell A
FAU - Lagstrom, Hanna
AU  - Lagstrom H
FAU - Lande, Britt
AU  - Lande B
FAU - Thorsdottir, Inga
AU  - Thorsdottir I
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - Sweden
TA  - Food Nutr Res
JT  - Food & nutrition research
JID - 101488795
PMC - PMC3625706
OID - NLM: PMC3625706
OTO - NOTNLM
OT  - atopic disease
OT  - blood pressure
OT  - celiac disease
OT  - diabetes
OT  - infectious disease
OT  - overweight
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:01
CRDT- 2013/04/17 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/23 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/12 [epublish]
AID - 10.3402/fnr.v57i0.20823 [doi]
AID - 20823 [pii]
PST - epublish
SO  - Food Nutr Res. 2013 Apr 12;57. doi: 10.3402/fnr.v57i0.20823. Print 2013.

PMID- 23589710
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130416
DCOM- 20130417
LR  - 20130419
IS  - 1654-661X (Electronic)
IS  - 1654-661X (Linking)
VI  - 57
DP  - 2013
TI  - Genetic variation in the fat mass and obesity-associated gene (FTO) in
      association with food preferences in healthy adults.
LID - 10.3402/fnr.v57i0.20028 [doi]
AB  - BACKGROUND: Earlier studies have indicated that the fat mass and
      obesity-associated gene (FTO) is not only associated with BMI and weight but also
      with appetite and dietary intake. OBJECTIVES: We investigated if the FTO
      rs9939609 associates with food preferences in healthy adults with no cancer,
      cardiovascular disease, or diabetes. Additionally, we challenged the question if 
      the associations are modified by obesity status (BMI </=25 or >25 kg/m(2)).
      DESIGN: The analyses are made with 22,799 individuals from the Swedish
      population-based Malmo Diet and Cancer Cohort Study, who were born between 1923
      and 1945. To investigate food preference, 27 food groups conducted from a
      modified diet history method including a 7-day registration of cooked meals and
      cold beverages were used in the analyses. Bonferroni correction was used to
      correct for multiple testing, resulting in a cut-off value for significance level
      of p<0.002. RESULTS: We observed that the obesity susceptible A-allele carriers
      reported a higher consumption of biscuits and pastry but lower consumption of
      soft drinks (P for trend <0.0001 for both) as compared to TT genotype carriers.
      In contrast to our hypothesis, the results did not significantly differ depending
      on obesity status except for consumption of juice, where only the overweight
      individuals with A-allele had a higher consumption as compared to TT carriers (P 
      for interaction=0.04). CONCLUSION: Our results indicate that the FTO A-allele may
      associate with certain food preference and in particular with certain
      energy-dense foods.
AD  - Diabetes and Cardiovascular Disease - Genetic Epidemiology, Department of
      Clinical Sciences in Malmo, Lund University, Malmo, Sweden.
FAU - Brunkwall, Louise
AU  - Brunkwall L
FAU - Ericson, Ulrika
AU  - Ericson U
FAU - Hellstrand, Sophie
AU  - Hellstrand S
FAU - Gullberg, Bo
AU  - Gullberg B
FAU - Orho-Melander, Marju
AU  - Orho-Melander M
FAU - Sonestedt, Emily
AU  - Sonestedt E
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - Sweden
TA  - Food Nutr Res
JT  - Food & nutrition research
JID - 101488795
PMC - PMC3625705
OID - NLM: PMC3625705
OTO - NOTNLM
OT  - Sweden
OT  - adults
OT  - food preference
OT  - genetic
OT  - nutrition intake
OT  - obesity
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:01
CRDT- 2013/04/17 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/05 [received]
PHST- 2013/03/04 [revised]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/12 [epublish]
AID - 10.3402/fnr.v57i0.20028 [doi]
AID - 20028 [pii]
PST - epublish
SO  - Food Nutr Res. 2013 Apr 12;57. doi: 10.3402/fnr.v57i0.20028. Print 2013.

PMID- 23589703
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 1537-744X (Electronic)
IS  - 1537-744X (Linking)
VI  - 2013
DP  - 2013
TI  - The relationship between health-promoting behaviors and resilience in patients
      with chronic kidney disease.
PG  - 124973
LID - 10.1155/2013/124973 [doi]
AB  - This cross-sectional research study explored differences in health-promoting
      behavior and resilience among three groups of chronic kidney disease patients
      (high-risk, early chronic kidney disease; early CKD and pre-end stage renal
      disease; pre-ESRD) treated at the Nephrology outpatient clinic in northern
      Taiwan. A total of 150 CKD outpatients were interviewed using structured
      questionnaires including a CKD Health to Promote Lifestyle Scale, and resilience 
      scale. We found that the pre-ESRD group had lower resilience than either
      high-risk or early CKD groups. Factors affecting pre-ESRD resilience were gender,
      occupational status, diabetes and health-promoting behaviors. Factors affecting
      resilience of the high-risk group included level of education and
      health-promoting behaviors while factors affecting resilience in the early CKD
      group involved whether they are employed and health promoting behaviors. A
      significant positive correlation was found between health promoting behavior and 
      resilience in all study subjects. Multiple regression analysis found that factors
      which could effectively predict resilience in patients at high-risk for CKD were 
      gender, whether the patient had a job, nutrition, self-actualization, and stress 
      level, accounting for 69.7% of the variance. Therefore, nursing education should 
      focus on health promotion advocacy throughout the life of not only patients but
      also their families.
AD  - Department of Nursing, Cardinal Tien Hospital, New Taipei, Taiwan.
FAU - Ma, Li-Ching
AU  - Ma LC
FAU - Chang, Hong-Jer
AU  - Chang HJ
FAU - Liu, Yueh-Min
AU  - Liu YM
FAU - Hsieh, Hsiang-Li
AU  - Hsieh HL
FAU - Lo, Lan
AU  - Lo L
FAU - Lin, Mei-Yu
AU  - Lin MY
FAU - Lu, Kuo-Cheng
AU  - Lu KC
LA  - eng
PT  - Journal Article
DEP - 20130325
PL  - England
TA  - ScientificWorldJournal
JT  - TheScientificWorldJournal
JID - 101131163
SB  - IM
PMC - PMC3621294
OID - NLM: PMC3621294
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013 [ppublish]
PHST- 2013/01/07 [received]
PHST- 2013/01/29 [accepted]
PHST- 2013/03/25 [epublish]
AID - 10.1155/2013/124973 [doi]
PST - epublish
SO  - ScientificWorldJournal. 2013 Mar 25;2013:124973. doi: 10.1155/2013/124973. Print 
      2013.

PMID- 23589647
OWN - NLM
STAT- MEDLINE
DA  - 20130416
DCOM- 20130611
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 80
IP  - 16
DP  - 2013 Apr 16
TI  - Teaching Video NeuroImages: hemichorea-hemiballismus secondary to nonketotic
      hyperglycemia.
PG  - e178
LID - 10.1212/WNL.0b013e31828cf85d [doi]
AD  - Movement Disorders Unit, Faculty of Medicine, Federal University of Minas Gerais 
      (UFMG), Belo Horizonte, Minas Gerais, Brazil. thiagocardosovale@hotmail.com
FAU - Vale, Thiago Cardoso
AU  - Vale TC
FAU - Freitas, Denise da Silva
AU  - Freitas Dda S
FAU - Maciel, Ricardo Oliveira Horta
AU  - Maciel RO
FAU - Miranda, Eduardo Carvalho
AU  - Miranda EC
FAU - Cardoso, Francisco
AU  - Cardoso F
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Ketone Bodies)
RN  - 106266-06-2 (Risperidone)
SB  - AIM
SB  - IM
MH  - Antipsychotic Agents/therapeutic use
MH  - Brain/pathology
MH  - Chorea/*etiology/pathology
MH  - Diabetes Mellitus, Type 2/complications
MH  - Dyskinesias/*etiology/pathology
MH  - Female
MH  - Humans
MH  - Hyperglycemia/*complications
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Ketone Bodies/urine
MH  - Magnetic Resonance Imaging
MH  - Middle Aged
MH  - Muscle Weakness/etiology
MH  - Neurologic Examination
MH  - Risperidone/therapeutic use
EDAT- 2013/04/17 06:00
MHDA- 2013/06/12 06:00
CRDT- 2013/04/17 06:00
AID - 80/16/e178 [pii]
AID - 10.1212/WNL.0b013e31828cf85d [doi]
PST - ppublish
SO  - Neurology. 2013 Apr 16;80(16):e178. doi: 10.1212/WNL.0b013e31828cf85d.

PMID- 23589598
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 1576-8260 (Electronic)
IS  - 0004-0614 (Linking)
VI  - 66
IP  - 2
DP  - 2013 Mar
TI  - [ESSIC criteria for the diagnosis of bladder pain syndrome/interstitial cystitis 
      (BPS/IC) and comparison with the NIDDK criteria].
PG  - 206-14
AB  - OBJECTIVES: To apply the diagnostic criteria of the National Institute of
      Diabetes and Digestive and Kidney Diseases (NIDDK) and the criteria of the
      European Society for Study of Interstitial Cystitis (ESSIC) in our population
      with Bladder Pain Syndrome /interstitial cystitis (BPS/IC). METHODS: A cohort of 
      36 patients with the endoscopic clinical diagnosis of BPS/IC were evaluated
      retrospectively in the Hospital de Clinicas Jose de San Martin and Urology Center
      CDU over a period of 5 year. Cystoscopy with diagnostic and therapeutic
      hydrodistention was applied a to all patients. The NIDDK criteria were applied to
      the patients with endoscopic clinical diagnosis of BPS/IC. The new criteria
      proposed by the ESSIC were contrasted and results were compared. RESULTS: Of a
      total of 36 patients treated, 33 were women and 3 were men with ages between 30
      and 75 years, 100% presented pain or urgency. Glomerulation or Hunner lesions
      appeared in 30 patients (83%). 35 patients (97%) had urinary frequency >8/day,
      and 22 patients (61%) had bladder capacity <350 cc. Only 22 patients (61%)
      completed the strict diagnostic criteria of the NIDDK. On the other hand, using
      the new criteria proposed by the ESSIC for the diagnosis of BPS/IC 35 patients
      (97%) were included in this pathology, with normal cystoscopy in 6 patients (17%)
      and 14 patients (39%) with bladder capacity >350 cc. CONCLUSION: The widest
      diagnostic criteria of the ESSIC allow the inclusion of more patients in the
      certainty diagnosis of BPS/IC than the NIDDK criteria, facilitating the diagnosis
      of this strange urological disease.
AD  - Division de Urologia, Hospital de Clinicas Jose de San Martin, Universidad de
      Buenos Aires, Argentina. soninonino@hotmail.com
FAU - Proano, Angel
AU  - Proano A
FAU - Garde, Guillermo
AU  - Garde G
FAU - Garrido, Gustavo
AU  - Garrido G
FAU - Mazza, Osvaldo
AU  - Mazza O
LA  - eng
LA  - spa
PT  - Journal Article
PL  - Spain
TA  - Arch Esp Urol
JT  - Archivos espanoles de urologia
JID - 0064757
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PST - ppublish
SO  - Arch Esp Urol. 2013 Mar;66(2):206-14.

PMID- 23589542
OWN - NLM
STAT- In-Process
DA  - 20130424
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 5
DP  - 2013 May
TI  - Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes
      Association and the Endocrine Society.
PG  - 1384-95
LID - 10.2337/dc12-2480 [doi]
AB  - OBJECTIVE: To review the evidence about the impact of hypoglycemia on patients
      with diabetes that has become available since the past reviews of this subject by
      the American Diabetes Association and The Endocrine Society and to provide
      guidance about how this new information should be incorporated into clinical
      practice. PARTICIPANTS: Five members of the American Diabetes Association and
      five members of The Endocrine Society with expertise in different aspects of
      hypoglycemia were invited by the Chair, who is a member of both, to participate
      in a planning conference call and a 2-day meeting that was also attended by staff
      from both organizations. Subsequent communications took place via e-mail and
      phone calls. The writing group consisted of those invitees who participated in
      the writing of the manuscript. The workgroup meeting was supported by educational
      grants to the American Diabetes Association from Lilly USA, LLC and Novo Nordisk 
      and sponsorship to the American Diabetes Association from Sanofi. The sponsors
      had no input into the development of or content of the report. EVIDENCE: The
      writing group considered data from recent clinical trials and other studies to
      update the prior workgroup report. Unpublished data were not used. Expert opinion
      was used to develop some conclusions. CONSENSUS PROCESS: Consensus was achieved
      by group discussion during conference calls and face-to-face meetings, as well as
      by iterative revisions of the written document. The document was reviewed and
      approved by the American Diabetes Association's Professional Practice Committee
      in October 2012 and approved by the Executive Committee of the Board of Directors
      in November 2012 and was reviewed and approved by The Endocrine Society's
      Clinical Affairs Core Committee in October 2012 and by Council in November 2012. 
      CONCLUSIONS: The workgroup reconfirmed the previous definitions of hypoglycemia
      in diabetes, reviewed the implications of hypoglycemia on both short- and
      long-term outcomes, considered the implications of hypoglycemia on treatment
      outcomes, presented strategies to prevent hypoglycemia, and identified knowledge 
      gaps that should be addressed by future research. In addition, tools for patients
      to report hypoglycemia at each visit and for clinicians to document counseling
      are provided.
AD  - Department of Medicine, University ofMinnesota, Minneapolis, MN, USA.
      seaqu001@umn.edu
FAU - Seaquist, Elizabeth R
AU  - Seaquist ER
FAU - Anderson, John
AU  - Anderson J
FAU - Childs, Belinda
AU  - Childs B
FAU - Cryer, Philip
AU  - Cryer P
FAU - Dagogo-Jack, Samuel
AU  - Dagogo-Jack S
FAU - Fish, Lisa
AU  - Fish L
FAU - Heller, Simon R
AU  - Heller SR
FAU - Rodriguez, Henry
AU  - Rodriguez H
FAU - Rosenzweig, James
AU  - Rosenzweig J
FAU - Vigersky, Robert
AU  - Vigersky R
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
SB  - IM
PMC - PMC3631867
OID - NLM: PMC3631867 [Available on 05/01/14]
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PMCR- 2014/05/01 00:00
PHST- 2013/04/15 [aheadofprint]
PHST- 2013/04/22 [aheadofprint]
AID - dc12-2480 [pii]
AID - 10.2337/dc12-2480 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 May;36(5):1384-95. doi: 10.2337/dc12-2480. Epub 2013 Apr 15.

PMID- 23589524
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 5
DP  - 2013 May
TI  - Hypoglycemia and diabetes: a report of a workgroup of the american diabetes
      association and the endocrine society.
PG  - 1845-59
LID - 10.1210/jc.2012-4127 [doi]
AB  - Objective: To review the evidence about the impact of hypoglycemia on patients
      with diabetes that has become available since the past reviews of this subject by
      the American Diabetes Association and The Endocrine Society and to provide
      guidance about how this new information should be incorporated into clinical
      practice. Participants: Five members of the American Diabetes Association and
      five members of The Endocrine Society with expertise in different aspects of
      hypoglycemia were invited by the Chair, who is a member of both, to participate
      in a planning conference call and a 2-day meeting that was also attended by staff
      from both organizations. Subsequent communications took place via e-mail and
      phone calls. The writing group consisted of those invitees who participated in
      the writing of the manuscript. The workgroup meeting was supported by educational
      grants to the American Diabetes Association from Lilly USA, LLC and Novo Nordisk 
      and sponsorship to the American Diabetes Association from Sanofi. The sponsors
      had no input into the development of or content of the report. Evidence: The
      writing group considered data from recent clinical trials and other studies to
      update the prior workgroup report. Unpublished data were not used. Expert opinion
      was used to develop some conclusions. Consensus Process: Consensus was achieved
      by group discussion during conference calls and face-to-face meetings, as well as
      by iterative revisions of the written document. The document was reviewed and
      approved by the American Diabetes Association's Professional Practice Committee
      in October 2012 and approved by the Executive Committee of the Board of Directors
      in November 2012 and was reviewed and approved by The Endocrine Society's
      Clinical Affairs Core Committee in October 2012 and by Council in November 2012. 
      Conclusions: The workgroup reconfirmed the previous definitions of hypoglycemia
      in diabetes, reviewed the implications of hypoglycemia on both short- and
      long-term outcomes, considered the implications of hypoglycemia on treatment
      outcomes, presented strategies to prevent hypoglycemia, and identified knowledge 
      gaps that should be addressed by future research. In addition, tools for patients
      to report hypoglycemia at each visit and for clinicians to document counseling
      are provided.
AD  - MD, University of Minnesota, MMC 101, 420 Delaware Street SE, Minneapolis,
      Minnesota 55455. seaqu001@umn.edu.
FAU - Seaquist, Elizabeth R
AU  - Seaquist ER
FAU - Anderson, John
AU  - Anderson J
FAU - Childs, Belinda
AU  - Childs B
FAU - Cryer, Philip
AU  - Cryer P
FAU - Dagogo-Jack, Samuel
AU  - Dagogo-Jack S
FAU - Fish, Lisa
AU  - Fish L
FAU - Heller, Simon R
AU  - Heller SR
FAU - Rodriguez, Henry
AU  - Rodriguez H
FAU - Rosenzweig, James
AU  - Rosenzweig J
FAU - Vigersky, Robert
AU  - Vigersky R
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/15 [aheadofprint]
AID - jc.2012-4127 [pii]
AID - 10.1210/jc.2012-4127 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 May;98(5):1845-59. doi: 10.1210/jc.2012-4127. Epub 
      2013 Apr 15.

PMID- 23589428
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1488-2329 (Electronic)
IS  - 0820-3946 (Linking)
VI  - 185
IP  - 9
DP  - 2013 Jun 11
TI  - Serum C-peptide levels and risk of death among adults without diabetes mellitus.
PG  - E402-8
LID - 10.1503/cmaj.121950 [doi]
AB  - BACKGROUND: Connecting peptide (C-peptide) plays a role in early atherogenesis in
      patients with diabetes mellitus and may be a marker for cardiovascular morbidity 
      and mortality in patients without diabetes. We investigated whether serum
      C-peptide levels are associated with all-cause, cardiovascular-related and
      coronary artery disease-related mortality in adults without diabetes. METHODS: We
      used data from the Third Nutrition and Health Examination Survey (NHANES III) and
      the NHANES III Linked Mortality File in the United States. We analyzed mortality 
      data for 5902 participants aged 40 years and older with no history of diabetes
      and who had available serum C-peptide levels from the baseline examination. We
      grouped the participants by C-peptide quartile, and we performed Cox proportional
      hazards regression analysis. The primary outcome was all-cause,
      cardiovascular-related and coronary artery disease-related mortality. RESULTS:
      The mean serum C-peptide level in the study sample was 0.78 (+/- standard
      deviation 0.47) nmol/L. The adjusted hazards ratio comparing the highest quartile
      with the lowest quartile was 1.80 (95% confidence interval [CI] 1.33-2.43) for
      all-cause mortality, 3.20 (95% CI 2.07-4.93) for cardiovascular-related
      mortality, and 2.73 (95% CI 1.55-4.82) for coronary artery disease-related
      mortality. Higher C-peptide levels were associated with increased mortality among
      strata of glycated hemoglobin and fasting serum glucose. INTERPRETATION: We found
      an association between serum C-peptide levels and all-cause and cause-specific
      mortality among adults without diabetes at baseline. Our finding suggests that
      elevated C-peptide levels may be a predictor of death.
FAU - Min, Jin-Young
AU  - Min JY
FAU - Min, Kyoung-Bok
AU  - Min KB
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - Canada
TA  - CMAJ
JT  - CMAJ : Canadian Medical Association journal = journal de l'Association medicale
      canadienne
JID - 9711805
SB  - AIM
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/15 [aheadofprint]
AID - cmaj.121950 [pii]
AID - 10.1503/cmaj.121950 [doi]
PST - ppublish
SO  - CMAJ. 2013 Jun 11;185(9):E402-8. doi: 10.1503/cmaj.121950. Epub 2013 Apr 15.

PMID- 23589390
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1099-1166 (Electronic)
IS  - 0885-6230 (Linking)
DP  - 2013 Apr 16
TI  - Performance of a computer-based assessment of cognitive function measures in two 
      cohorts of seniors.
LID - 10.1002/gps.3949 [doi]
AB  - BACKGROUND: Computer-administered assessment of cognitive function is being
      increasingly incorporated in clinical trials; however, its performance in these
      settings has not been systematically evaluated. DESIGN: The Seniors Health and
      Activity Research Program pilot trial (N = 73) developed a computer-based tool
      for assessing memory performance and executive functioning. The Lifestyle
      Interventions and Independence for Elders investigators incorporated this battery
      in a full-scale multicenter clinical trial (N = 1635). We describe relationships 
      that test scores have with those from interviewer-administered cognitive function
      tests and risk factors for cognitive deficits and describe performance measures
      (completeness, intraclass correlations [ICC]). RESULTS: Computer-based
      assessments of cognitive function had consistent relationships across the pilot
      and full-scale trial cohorts with interviewer-administered assessments of
      cognitive function, age, and a measure of physical function. In the Lifestyle
      Interventions and Independence for Elders cohort, their external validity was
      further demonstrated by associations with other risk factors for cognitive
      dysfunction: education, hypertension, diabetes, and physical function. Acceptable
      levels of data completeness (>83%) were achieved on all computer-based measures; 
      however, rates of missing data were higher among older participants (odds ratio =
      1.06 for each additional year; p < 0.001) and those who reported no current
      computer use (odds ratio = 2.71; p < 0.001). ICCs among clinics were at least as 
      low (ICC < 0.013) as for interviewer measures (ICC < 0.023), reflecting good
      standardization. All cognitive measures loaded onto the first principal component
      (global cognitive function), which accounted for 40% of the overall variance.
      CONCLUSION: Our results support the use of computer-based tools for assessing
      cognitive function in multicenter clinical trials of older individuals. Copyright
      (c) 2013 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
AD  - Department of Biostatistical Sciences, Wake Forest School of Medicine,
      Winston-Salem, NC, USA.
FAU - Espeland, Mark A
AU  - Espeland MA
FAU - Katula, Jeffrey A
AU  - Katula JA
FAU - Rushing, Julia
AU  - Rushing J
FAU - Kramer, Arthur F
AU  - Kramer AF
FAU - Jennings, Janine M
AU  - Jennings JM
FAU - Sink, Kaycee M
AU  - Sink KM
FAU - Nadkarni, Neelesh K
AU  - Nadkarni NK
FAU - Reid, Kieran F
AU  - Reid KF
FAU - Castro, Cynthia M
AU  - Castro CM
FAU - Church, Timothy
AU  - Church T
FAU - Kerwin, Diana R
AU  - Kerwin DR
FAU - Williamson, Jeff D
AU  - Williamson JD
FAU - Marottoli, Richard A
AU  - Marottoli RA
FAU - Rushing, Scott
AU  - Rushing S
FAU - Marsiske, Michael
AU  - Marsiske M
FAU - Rapp, Stephen R
AU  - Rapp SR
CN  - LIFE Study Group
LA  - ENG
GR  - M01 RR007122/RR/NCRR NIH HHS/United States
GR  - R01 AG029285/AG/NIA NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Int J Geriatr Psychiatry
JT  - International journal of geriatric psychiatry
JID - 8710629
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/11/27 [received]
PHST- 2013/01/29 [accepted]
AID - 10.1002/gps.3949 [doi]
PST - aheadofprint
SO  - Int J Geriatr Psychiatry. 2013 Apr 16. doi: 10.1002/gps.3949.

PMID- 23589327
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May-Jun
TI  - Learning needs of youth with type 2 diabetes.
PG  - 314-9
LID - 10.1177/0145721713485305 [doi]
AB  - Purpose The purpose of this study was to examine reports of diabetes learning
      needs by youth with type 2 diabetes and their family support person (FSP) and to 
      examine correlations of these perceptions with demographic variables. Methods
      Data were analyzed from the Participant Needs Assessment (PNA), a routinely
      self-administered questionnaire designed to assess learning needs, in 191 youth
      (mean age = 14.0 +/- 1.9 years, duration 8.78 +/- 6.30 months; 36% black,
      non-Hispanic; 40% Hispanic; 20% white) enrolled in the TODAY (Treatment Options
      for Type 2 Diabetes in Adolescents and Youth) study. Youth and their FSPs
      completed the PNA at scheduled study visits, rating their learning needs on a
      5-point scale, with higher scores indicating higher needs. Paired t tests and
      ANOVA were used. Results There were no differences in reported learning needs by 
      gender, although scores on the Teen Issues scale approached significance, with
      girls reporting higher needs than boys. Youth and FSPs were similar on their
      reports of needs on 3 scales (Ordinary Day, Nutrition, and Living With Diabetes),
      but youth reported higher needs than FSPs on Focus and Teen Issues. Controlling
      for duration of diabetes, these differences between youth and FSPs persisted. In 
      general, learning needs for both youth and FSPs decreased over time. Conclusions 
      Youth with type 2 diabetes and their FSPs have high levels of ongoing learning
      needs despite completion of a standard diabetes education program. Continued
      assessment of learning needs, follow-up education, and behavioral approaches are 
      warranted for these high-risk youth.
AD  - Denise Richards, MSN, FNP, Mass General Hospital, 50 Staniford St, Suite 340,
      Boston, MA 02114. drichards1@partners.org.
FAU - Richards, Denise
AU  - Richards D
FAU - Larkin, Mary
AU  - Larkin M
FAU - Milaszewski, Kerry
AU  - Milaszewski K
FAU - Javier, Elaine
AU  - Javier E
FAU - Casey, Terri
AU  - Casey T
FAU - Grey, Margaret
AU  - Grey M
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
SB  - N
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/15 [aheadofprint]
AID - 0145721713485305 [pii]
AID - 10.1177/0145721713485305 [doi]
PST - ppublish
SO  - Diabetes Educ. 2013 May-Jun;39(3):314-9. doi: 10.1177/0145721713485305. Epub 2013
      Apr 15.

PMID- 23589326
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1554-6063 (Electronic)
IS  - 0145-7217 (Linking)
VI  - 39
IP  - 3
DP  - 2013 May-Jun
TI  - Effectiveness of prediabetes nutrition shared medical appointments: prevention of
      diabetes.
PG  - 344-53
LID - 10.1177/0145721713484812 [doi]
AB  - Purpose The purpose of this study is to evaluate the effectiveness of a
      nutrition-based shared medical appointment (SMA) intervention in the treatment of
      prediabetes compared to the individualized counseling standard of care. Methods A
      randomized controlled trial design comparing health outcomes in patients with
      prediabetes attending either an individualized counseling (control group) or
      three 90-minute nutrition SMA (intervention group) sessions. Demographic,
      anthropometric (weight and body mass index), clinical (blood pressure), and
      biochemical (lipid profile, fasting blood sugar, glycated hemoglobin,
      albumin-to-creatinine ratio) measures were obtained from all participants at
      baseline, at 3 months, and at 1 year. Results Ninety-four participants were
      randomized into the 2 study groups with a 69% completion rate at 1 year (n = 34
      SMA, n = 31 control). The average participant was Caucasian (64%), male (54%),
      58.3 +/- 9.6 years, had a BMI of 30.8 +/- 4.9 kg/m(2) (obese), and fasting blood 
      glucose of 109 +/- 9.5 mg/dL. The SMA and control participants lost a mean of 6.6
      pounds and 3.6 pound, respectively; neither group met the 5% modest weight loss
      expected. The SMA and control group experienced a mean drop in fasting blood
      glucose of 6 mg/dL. Conclusions As demands on health care providers continue to
      rise, finding innovative ways to manage the patient load while providing quality 
      health care is increasingly important. SMA health outcomes were equivalent to
      individual counseling outcomes, while increasing the provider's productivity by
      treating 6 to 8 people with prediabetes in 90 minutes compared to 1 patient in 60
      minutes.
AD  - Renee E. Cole, US Army Medical Department Center & School, 3599 Winfield-Scott
      Ave, Joint Base San Antonio-Fort Sam Houston, TX, 78234, USA.
      renee.e.cole.mil@mail.mil.
FAU - Cole, Renee E
AU  - Cole RE
FAU - Boyer, Kathleen M
AU  - Boyer KM
FAU - Spanbauer, Sean M
AU  - Spanbauer SM
FAU - Sprague, Denise
AU  - Sprague D
FAU - Bingham, Mona
AU  - Bingham M
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - Diabetes Educ
JT  - The Diabetes educator
JID - 7701401
SB  - N
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/15 [aheadofprint]
AID - 0145721713484812 [pii]
AID - 10.1177/0145721713484812 [doi]
PST - ppublish
SO  - Diabetes Educ. 2013 May-Jun;39(3):344-53. doi: 10.1177/0145721713484812. Epub
      2013 Apr 15.

PMID- 23589295
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
VI  - 288
IP  - 22
DP  - 2013 May 31
TI  - Insulin Directly Regulates Steroidogenesis via Induction of the Orphan Nuclear
      Receptor DAX-1 in Testicular Leydig Cells.
PG  - 15937-46
LID - 10.1074/jbc.M113.451773 [doi]
AB  - Testosterone level is low in insulin-resistant type 2 diabetes. Whether this is
      due to negative effects of high level of insulin on the testes caused by insulin 
      resistance has not been studied in detail. In this study, we found that insulin
      directly binds to insulin receptors in Leydig cell membranes and activates
      phospho-insulin receptor-beta (phospho-IR-beta), phospho-IRS1, and phospho-AKT,
      leading to up-regulation of DAX-1 (dosage-sensitive sex reversal, adrenal
      hypoplasia critical region, on chromosome X, gene 1) gene expression in the MA-10
      mouse Leydig cell line. Insulin also inhibits cAMP-induced and liver receptor
      homolog-1 (LRH-1)-induced steroidogenic enzyme gene expression and
      steroidogenesis. In contrast, knockdown of DAX-1 reversed insulin-mediated
      inhibition of steroidogenesis. Whether insulin directly represses steroidogenesis
      through regulation of steroidogenic enzyme gene expression was assessed in
      insulin-injected mouse models and high fat diet-induced obesity. In
      insulin-injected mouse models, insulin receptor signal pathway was activated and 
      subsequently inhibited steroidogenesis via induction of DAX-1 without significant
      change of luteinizing hormone or FSH levels. Likewise, the levels of
      steroidogenic enzyme gene expression and steroidogenesis were low, but
      interestingly, the level of DAX-1 was high in the testes of high fat diet-fed
      mice. These results represent a novel regulatory mechanism of steroidogenesis in 
      Leydig cells. Insulin-mediated induction of DAX-1 in Leydig cells of testis may
      be a key regulatory step of serum sex hormone level in insulin-resistant states.
AD  - From the National Creative Research Initiatives Center for Nuclear Receptor
      Signals and.
FAU - Ahn, Seung Won
AU  - Ahn SW
FAU - Gang, Gil-Tae
AU  - Gang GT
FAU - Kim, Yong Deuk
AU  - Kim YD
FAU - Ahn, Ryun-Sup
AU  - Ahn RS
FAU - Harris, Robert A
AU  - Harris RA
FAU - Lee, Chul-Ho
AU  - Lee CH
FAU - Choi, Hueng-Sik
AU  - Choi HS
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
SB  - IM
PMC - PMC3668749
OID - NLM: PMC3668749 [Available on 05/31/14]
OTO - NOTNLM
OT  - DAX-1
OT  - Diabetes
OT  - Insulin
OT  - Insulin resistance
OT  - Nuclear receptors
OT  - Steroidogenesis
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PMCR- 2014/05/31 00:00
PHST- 2013/04/15 [aheadofprint]
AID - M113.451773 [pii]
AID - 10.1074/jbc.M113.451773 [doi]
PST - ppublish
SO  - J Biol Chem. 2013 May 31;288(22):15937-46. doi: 10.1074/jbc.M113.451773. Epub
      2013 Apr 15.

PMID- 23589285
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Linking)
DP  - 2013 Apr 15
TI  - Kruppel-like Factor 11 Regulates the Expression of Metabolic Genes via an
      Evolutionarily Conserved Protein-Interaction Domain Functionally Disrupted in
      Maturity Onset Diabetes of the Young.
AB  - The function of Kruppel-like Factor 11 (KLF11) in the regulation of metabolic
      pathways is conserved from flies to human. Alterations in KLF11 function result
      in Maturity Onset Diabetes of the Young 7 (MODY7) and neonatal diabetes, however,
      the mechanisms underlying the role of this protein in metabolic disorders remain 
      unclear. Here, we seek to investigate how the A347S genetic variant, present in
      MODY7 patients, modulates KLF11 transcriptional activity. A347S affects a
      previously identified transcriptional regulatory domain 3 (TRD3) for which
      co-regulators remain unknown. Structure-oriented sequence analyses, described
      here, predict that the KLF11 TRD3 represents an evolutionarily conserved protein 
      domain. Combined, yeast two-hybrid and protein arrays demonstrate that the TRD3
      binds WD40, WWI, WWII, and SH3-domain containing proteins. Using one of these
      proteins as a model, guanine nucleotide binding protein beta 2 (Gbeta2), we
      investigate the functional consequences of KLF11 coupling to a TRD3 binding
      partner. Combined, immunoprecipitation and biomolecular fluorescence
      complementation assays confirm that activation of three different metabolic GPCR 
      receptors (beta-adrenergic, secretin and CCK) induce nuclear translocation of
      Gbeta2 to directly bind KLF11 in a manner that is disrupted by the MODY7 A347S
      variant. Using genome-wide expression profiles, we identify metabolic gene
      networks impacted upon TRD3 disruption. Furthermore, A347S disrupts
      KLF11-mediated increases in basal insulin levels and promoter activity, combined 
      with blunted glucose-stimulated insulin secretion. Thus, this study characterizes
      a novel protein-protein interaction domain disrupted in a KLF gene variant that
      associates to MODY7, contributing to our understanding of gene regulation events 
      in complex metabolic diseases.
AD  - Mayo Clinic, United States;
FAU - Lomberk, Gwen
AU  - Lomberk G
FAU - Grzenda, Adrienne
AU  - Grzenda A
FAU - Mathison, Angela
AU  - Mathison A
FAU - Escande, Carlos
AU  - Escande C
FAU - Zhang, Jin-San
AU  - Zhang JS
FAU - Calvo, Ezequiel
AU  - Calvo E
FAU - Miller, Laurence J
AU  - Miller LJ
FAU - Iovanna, Juan
AU  - Iovanna J
FAU - Chini, Eduardo N
AU  - Chini EN
FAU - Fernandez-Zapico, Martin E
AU  - Fernandez-Zapico ME
FAU - Urrutia, Raul
AU  - Urrutia R
LA  - ENG
GR  - R01 DK052913/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - M112.434670 [pii]
AID - 10.1074/jbc.M112.434670 [doi]
PST - aheadofprint
SO  - J Biol Chem. 2013 Apr 15.

PMID- 23589231
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1439-4286 (Electronic)
IS  - 0018-5043 (Linking)
DP  - 2013 Apr 15
TI  - MicroRNA Expressions in PMBCs, CD4+, and CD8+ T-Cells from Patients Suffering
      from Autoimmune Addison's Disease.
AB  - Autoimmune Addison's disease (AD) is a rare but potentially life threatening
      disease. The exact etiology of the immune response to the adrenal gland is still 
      unknown. MicroRNAs (miRNAs) critically control gene-expression and play an
      important role in regulating the immune response. The aim of this study was to
      determine key immunoregulatory miRNAs influencing autoimmune adrenal
      insufficiency. For this purpose selected miRNAs were amplified by a
      semiquantitative SYBR Green PCR from blood mononuclear cells and after
      purification from CD4+ and CD 8+ cells of 6 patients with autoimmune adrenal
      insufficiency and 10 healthy controls. In CD4+ T-cells miRNA 181a*_1 (18.02 in AD
      vs. 11.99 in CG, p=0.0047) is significantly increased whereas miRNA 200a_1 (12.48
      in AD vs. 19.40 in CG, p=0.0003) and miRNA 200a_2* (8.59 in AD vs. 17.94 in CG,
      p=0.0160) are significantly decreased. miRNA 200a_1 (12.37 in AD group vs. 18.12 
      in control group, p=0.001) and miRNA 200a_2* (10.72 in AD group vs. 17.84 in
      control group, p=0.022) are also significantly decreased in CD8+ T-cells. This
      study could show for the first time a significant change of three defined miRNAs 
      in PBMCs, CD4+, and CD8+ T-cells of autoimmune AD patients in vivo. These data
      may help to better understand the cause of the autoimmune processes leading to
      autoimmune AD. They extend our very limited knowledge concerning miRNAs in
      autoimmune Addison's disease.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Department of Endocrinology and Diabetes, Medical Faculty, Heinrich-Heine
      University Dusseldorf, Germany.
FAU - Bernecker, C
AU  - Bernecker C
FAU - Halim, F
AU  - Halim F
FAU - Haase, M
AU  - Haase M
FAU - Willenberg, H S
AU  - Willenberg HS
FAU - Ehlers, M
AU  - Ehlers M
FAU - Schott, M
AU  - Schott M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/15 [epublish]
AID - 10.1055/s-0033-1341511 [doi]
PST - aheadofprint
SO  - Horm Metab Res. 2013 Apr 15.

PMID- 23589188
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1573-2584 (Electronic)
IS  - 0301-1623 (Linking)
DP  - 2013 Apr 16
TI  - Prevalence and predictors of renal artery stenosis in patients undergoing
      peripheral and coronary angiography.
AB  - BACKGROUND: Renal artery stenosis is a potential cause of secondary hypertension,
      ischemic nephropathy and end-stage renal disease. Atherosclerosis is by far the
      most common etiology of renal artery stenosis in elderly. We investigated whether
      the presence of significant atherosclerotic renal artery stenosis (ARAS) with
      luminal diameter narrowing >/=50 % could be predicted in patients undergoing
      peripheral and coronary angiography. METHODS: The records of 3,500 consecutive
      patients undergoing simultaneous renal angiography along with peripheral and
      coronary angiography were reviewed. The patients with known renal artery disease 
      were excluded. RESULTS: Prevalence of ARAS was 5.7 %. Significant ARAS (luminal
      diameter narrowing >/=50 %) was present in 139 patients (3.9 %). Hypertension
      with altered serum creatinine and triple-vessel CAD were associated with
      significant renal artery stenosis in multivariate analysis. No significant
      relationship between the involved coronary arteries like left anterior
      descending, left circumflex, right coronary artery and ARAS was found. Only
      hypertension and altered serum creatinine were associated with bilateral ARAS.
      Extent of CAD or risk factors like diabetes, hyperlipidemia or smoking did not
      predict the unilateral or bilateral ARAS. CONCLUSION: Prevalence of ARAS among
      the patients in routine cardiac catheterization was 5.7 %. Hypertension is
      closely associated with significant ARAS. Significant CAD in the form of
      triple-vessel disease and altered renal function tests are closely associated
      with ARAS. They predict the presence of significant renal artery stenosis in
      patients undergoing routine peripheral and coronary angiography. Moreover,
      hypertension and altered renal functions predict bilateral ARAS.
AD  - Department of Cardiology, U.N.Mehta Institute of Cardiology and Research Centre
      (UNMICRC), Civil Hospital Campus, Ahmedabad, 380016, Gujarat, India,
      dranand1978@yahoo.co.in.
FAU - Shukla, Anand N
AU  - Shukla AN
FAU - Madan, Tarun H
AU  - Madan TH
FAU - Jayaram, Ashwal A
AU  - Jayaram AA
FAU - Kute, Vivek B
AU  - Kute VB
FAU - Rawal, Jayesh R
AU  - Rawal JR
FAU - Manjunath, A P
AU  - Manjunath AP
FAU - Udhreja, Satyam
AU  - Udhreja S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Int Urol Nephrol
JT  - International urology and nephrology
JID - 0262521
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/01/16 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s11255-013-0435-x [doi]
PST - aheadofprint
SO  - Int Urol Nephrol. 2013 Apr 16.

PMID- 23589150
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1573-2606 (Electronic)
IS  - 1389-9155 (Linking)
DP  - 2013 Apr 16
TI  - The role of endothelial insulin signaling in the regulation of glucose
      metabolism.
AB  - The skeletal muscle is one of the major target organs of insulin and plays an
      essential role in insulin-induced glucose uptake. Some evidence indicates that
      insulin delivery to skeletal muscle interstitium through the endothelial cells is
      the rate-limiting step in insulin-stimulated glucose uptake. Researchers have
      also found that this process is impaired by insulin resistance in type 2 diabetes
      and obesity. A recent study of ours demonstrated that insulin signaling in the
      endothelial cells plays a pivotal role in the regulation of glucose uptake by the
      skeletal muscle. Specifically, impaired insulin signaling in the endothelial
      cells, with reduction of insulin-induced eNOS phosphorylation, causes attenuation
      of the insulin-induced capillary recruitment and insulin delivery, which, in turn
      reduces glucose uptake by the skeletal muscle in high-fat diet-fed mice.
      Moreover, restoration of the insulin-induced eNOS phosphorylation in the
      endothelial cells completely reverses the reduction in the capillary recruitment 
      and insulin delivery, and as a result, significantly restores glucose uptake by
      the skeletal muscle. In the present review, we describe the recent progress in
      research on the physiological and pathophysiological roles of endothelial insulin
      signaling in the regulation of insulin-induced glucose uptake by the skeletal
      muscle.
AD  - Department of Diabetes and Metabolic Diseases, Graduate School of Medicine,
      University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
FAU - Kubota, Tetsuya
AU  - Kubota T
FAU - Kubota, Naoto
AU  - Kubota N
FAU - Kadowaki, Takashi
AU  - Kadowaki T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Rev Endocr Metab Disord
JT  - Reviews in endocrine & metabolic disorders
JID - 100940588
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - 10.1007/s11154-013-9242-z [doi]
PST - aheadofprint
SO  - Rev Endocr Metab Disord. 2013 Apr 16.

PMID- 23589045
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 138
IP  - 16
DP  - 2013 Apr
TI  - [Isolated gonadotropic deficiency after multiple concussions in a professional
      soccer player].
PG  - 831-3
LID - 10.1055/s-0033-1343099 [doi]
AB  - HISTORY AND CLINICAL PRESENTATION: A 27-year-old man was admitted to our
      outpatient clinic with symptoms of loss at libido, erectile dysfunction and
      fatigue. He had been playing soccer from the age of 7, for the last 10 years as a
      high-level professional. During that time repeated mild head-trauma without loss 
      of consciousness had occurred, mainly triggered by excessive header-training and 
      occasional collisions. INVESTIGATIONS: Serum levels of testosterone and
      luteinizing hormone were low. A gonadotropin releasing hormone loading test
      revealed significant gonadotropin responses, therefore pituitary gonadotropic
      insufficiency was unlikely. Further pituitary insufficiency of any other axis was
      also excluded by insulin hypoglycemia test. Magnetic resonance imaging of the
      brain revealed no significant abnormalities of the hypothalamic-pituitary unit.
      TREATMENT AND COURSE: Testosterone substitution, at first applied transdermally, 
      then intramuscularly, was initiated after approval by the National Anti Doping
      Agency. Four months later most of the symptoms had regressed. CONCLUSION:
      Pituitary deficiency in the course of craniocerebral trauma is frequent and may
      be transient or permanent, mostly affecting somatotropic or gonadotropic
      function. Hormonal imbalances may also be observed after mild but repeated trauma
      without loss of consciousness and should be considered in cases of isolated
      pituitary dysfunction, since such traumas may often occur in contacts sports such
      as boxing or intensive soccer play.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
AD  - Abteilung fur Innere Medizin, Endokrinologie und Diabetes, Max-Planck-Institut
      fur Psychiatrie, Munchen. mauer@mpipsykl.mpg.de
FAU - Auer, M
AU  - Auer M
FAU - Stalla, G K
AU  - Stalla GK
FAU - Athanasoulia, A P
AU  - Athanasoulia AP
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Wie harmlos sind Kopfballe? Hypogonadotroper Hypogonadismus nach leichten
      Schadel-Hirn-Traumata bei einem Profi-Fussballspieler.
DEP - 20130415
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/15 [epublish]
AID - 10.1055/s-0033-1343099 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2013 Apr;138(16):831-3. doi: 10.1055/s-0033-1343099. Epub
      2013 Apr 15.

PMID- 23588996
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1432-0932 (Electronic)
IS  - 0940-6719 (Linking)
DP  - 2013 Apr 16
TI  - Experience with wound complications after surgery for sacral tumors.
AB  - PURPOSE: The aim of this article is to summarize our experience in treating
      sacral wound complications after sacrectomy. We focus, in particular, on factors 
      associated with wound complications, including surgical site infection (SSI) and 
      wound dehiscence. METHODS: The definition of SSI devised by Horgan et al. was
      applied. Wound dehiscence was defined as a wound showing breakdown in the absence
      of clinical signs meeting the diagnostic standard for SSI. Between September 1997
      and August 2009, 387 patients with a sacral tumor underwent sacrectomy performed 
      by the same team of surgeons and were followed up for >/=12 months. Potential
      risk factors were evaluated for univariate associations with SSI and wound
      complications. Multivariable conditional logistic regression was used to identify
      the combined effects of several risk factors. RESULTS: Of the 387 wounds studied,
      274 healed uneventfully, and 113 (29.2 %) broke down because of infection or
      dehiscence. Fifty-one (13.2 %) patients developed a postoperative SSI, and 62
      (16.0 %) patients developed wound dehiscence. Gram-negative bacteria grew in 45
      cultures (91.8 %) and included 38 cases of Escherichia coli. Previous radiation, 
      rectum rupture, longer duration of surgery, and cerebrospinal fluid leakage were 
      significantly associated with increased likelihood of developing an SSI. Previous
      radiation, rectum rupture, age <40 years, history of diabetes mellitus, maximum
      tumor diameter >/=10 cm, and instrumentation used were risk factors for wound
      complications. CONCLUSIONS: The incidence of wound complications is not so high
      at a musculoskeletal tumor center with surgeons experienced in treating sacral
      tumors. Controlling for these risk factors when possible may improve clinical
      outcomes.
AD  - Musculoskeletal Tumor Center, People's Hospital, Peking University, Xizhimen Nan 
      11#, Xicheng District, 100044, Beijing, China.
FAU - Li, Dasen
AU  - Li D
FAU - Guo, Wei
AU  - Guo W
FAU - Qu, Huayi
AU  - Qu H
FAU - Yang, Rongli
AU  - Yang R
FAU - Tang, Xiaodong
AU  - Tang X
FAU - Yan, Taiqiang
AU  - Yan T
FAU - Tang, Shun
AU  - Tang S
FAU - Yang, Yi
AU  - Yang Y
FAU - Ji, Tao
AU  - Ji T
FAU - Dong, Sen
AU  - Dong S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Eur Spine J
JT  - European spine journal : official publication of the European Spine Society, the 
      European Spinal Deformity Society, and the European Section of the Cervical Spine
      Research Society
JID - 9301980
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/08/16 [received]
PHST- 2013/03/30 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s00586-013-2765-x [doi]
PST - aheadofprint
SO  - Eur Spine J. 2013 Apr 16.

PMID- 23588883
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Linking)
DP  - 2013 Apr 16
TI  - Bone metabolism and the 10-year probability of hip fracture and a major
      osteoporotic fracture using the country-specific FRAX algorithm in men over 50
      years of age with type 2 diabetes mellitus: a case-control study.
AB  - The aim of the study was to evaluate the 10-year probability of hip fracture and 
      a major osteoporotic fracture using the FRAX algorithm, vitamin D status, bone
      mineral density (BMD), and biochemical markers of bone turnover in men over 50
      years of age with type 2 diabetes mellitus (T2DM). We estimated FRAX-predicted
      10-year fracture probability, levels of 25-hydroxyvitamin D (25-OH-D), markers of
      bone turnover, and bone mineral density at the L1-L4 (lumbar spine (LS)) and
      femur neck (FN) in 68 men with T2DM and compared these with an age-matched group 
      (n = 68). The mean (range) age of the T2DM group was 61.4 (51-78) years. The
      prevalence of hypovitaminosis D (25-OH-D <75 nmol/L) was 59 %. The mean (range)
      FRAX hip fracture and FRAX major osteoporotic fracture was 0.7 (0-2.8) and 3.2
      (0-8.5) %, respectively. BMD at the FN (0.974 vs. 0.915 g/cm2, p = 0.008) and LS 
      (1.221 vs. 1.068 g/cm2, p < 0.001) was significantly higher in the T2DM cohort as
      compared to the healthy age-matched males. 25-OH-vitamin D (67.7 vs.79.8 nmol/L, 
      p < 0.001), crosslaps (0.19 vs. 0.24 mug/L, p = 0.004), and osteocalcin (13.3 vs.
      15.7 mug/L, p = 0.004) were significantly lower in the T2DM group. There was no
      difference in FRAX-related fracture probability between the two groups.
      Acknowledging the limitations of our study size, we suggest that the increased
      BMD in T2DM and the noninclusion of T2DM as a secondary risk factor in the FRAX
      algorithm may be probable explanations for the discordance between
      literature-observed and FRAX-related fracture probabilities.
AD  - Department of Laboratory Medicine, Medical and Health Science Center, University 
      of Debrecen, Nagyerdei krt. 98, 4032, Debrecen, Hungary, harjit@med.unideb.hu.
FAU - Bhattoa, Harjit P
AU  - Bhattoa HP
FAU - Onyeka, Ugo
AU  - Onyeka U
FAU - Kalina, Edit
AU  - Kalina E
FAU - Balogh, Adam
AU  - Balogh A
FAU - Paragh, Gyorgy
AU  - Paragh G
FAU - Antal-Szalmas, Peter
AU  - Antal-Szalmas P
FAU - Kaplar, Miklos
AU  - Kaplar M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/12/09 [received]
PHST- 2013/04/01 [accepted]
PHST- 2013/03/06 [revised]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s10067-013-2254-y [doi]
PST - aheadofprint
SO  - Clin Rheumatol. 2013 Apr 16.

PMID- 23588862
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1532-6551 (Electronic)
IS  - 1071-3581 (Linking)
DP  - 2013 Apr 16
TI  - Association of linear F-sodium fluoride accumulation in femoral arteries as a
      measure of diffuse calcification with cardiovascular risk factors: A PET/CT
      study.
AB  - BACKGROUND: The aim of this study was to correlate linear 18F-sodium fluoride
      accumulation in the femoral arteries as a measure of diffuse mineral deposition
      in medial elastocalcinosis with cardiovascular risk factors (RFs) and calcified
      plaque burden (CPB). METHODS AND RESULTS: In this study, 409 patients were
      examined by 18F-sodium fluoride positron emission tomography/computed tomography 
      (PET/CT). Tracer accumulation was analyzed both qualitatively and
      semiquantitatively by measuring the target-to-background ratio, and compared with
      cardiovascular RFs and CPB. Linear 18F-sodium fluoride accumulation was observed 
      in 159 (38.9%) patients and correlated significantly with age (P < .0001),
      hypertension (P < .0001), hypercholesterolemia (P = .0003), diabetes (P = .0003),
      history of smoking (P = .0007), prior cardiovascular events (P = .03), and CPB (P
      < .0001). The prevalence of linear tracer uptake increased as the number of
      cardiovascular RFs increased (P < .0001). CONCLUSIONS: Linear 18F-sodium fluoride
      uptake in the femoral arteries (1) provides a measure of diffuse mineral
      deposition, (2) demonstrates a highly significant correlation with cardiovascular
      RFs and CPB, and (3) is found to accumulate more frequently in patients with a
      high-risk profile for cardiovascular events. 18F-sodium fluoride PET/CT may
      become a unique tool for in vivo visualization and quantification of ongoing
      calcification in large arteries.
AD  - Department of Nuclear Medicine, University Medical Center Hamburg-Eppendorf,
      Martinistr. 52, 20246, Hamburg, Germany, t.derlin@uke.uni-hamburg.de.
FAU - Janssen, Tido
AU  - Janssen T
FAU - Bannas, Peter
AU  - Bannas P
FAU - Herrmann, Jochen
AU  - Herrmann J
FAU - Veldhoen, Simon
AU  - Veldhoen S
FAU - Busch, Jasmin D
AU  - Busch JD
FAU - Treszl, Andras
AU  - Treszl A
FAU - Munster, Silvia
AU  - Munster S
FAU - Mester, Janos
AU  - Mester J
FAU - Derlin, Thorsten
AU  - Derlin T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Nucl Cardiol
JT  - Journal of nuclear cardiology : official publication of the American Society of
      Nuclear Cardiology
JID - 9423534
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/10/03 [received]
PHST- 2013/01/21 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s12350-013-9680-8 [doi]
PST - aheadofprint
SO  - J Nucl Cardiol. 2013 Apr 16.

PMID- 23588856
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1534-3111 (Electronic)
IS  - 1522-6417 (Linking)
VI  - 15
IP  - 3
DP  - 2013 Jun
TI  - Potential role of uric Acid in metabolic syndrome, hypertension, kidney injury,
      and cardiovascular diseases: is it time for reappraisal?
PG  - 175-81
LID - 10.1007/s11906-013-0344-5 [doi]
AB  - Elevated serum uric acid concentration is a common laboratory finding in subjects
      with metabolic syndrome/obesity, hypertension, kidney disease and cardiovascular 
      events. Hyperuricemia has been attributed to hyperinsulinemia in metabolic
      syndrome and to decreased uric acid excretion in kidney dysfunction, and is not
      acknowledged as a main mediator of metabolic syndrome, renal disease, and
      cardiovascular disorder development. However, more recent investigations have
      altered this traditional view and shown, by providing compelling evidence, to
      support an independent link between hyperuricemia and increased risk of metabolic
      syndrome, diabetes, hypertension, kidney disease and cardiovascular disorders.
      However, despite these new findings, controversy regarding the exact role of uric
      acid in inducing these diseases remains to be unfolded. Furthermore, recent data 
      suggest that the high-fructose diet in the United State, as a major cause of
      hyperuricemia, may be contributing to the metabolic syndrome/obesity epidemic,
      diabetes, hypertension, kidney disease and cardiovascular disorder. Our focus in 
      this review is to discuss the available evidence supporting a role for uric acid 
      in the development of metabolic syndrome, hypertension, renal disease, and
      cardiovascular disorder; and the potential pathophysiology mechanisms involved.
AD  - Section of Nephrology and Hypertension, Louisiana State University Health
      Sciences Center, 1542 Tulane Avenue, Room 330A, New Orleans, LA, 70112, USA,
      zsolta@lsuhsc.edu.
FAU - Soltani, Zohreh
AU  - Soltani Z
FAU - Rasheed, Kashaf
AU  - Rasheed K
FAU - Kapusta, Daniel R
AU  - Kapusta DR
FAU - Reisin, Efrain
AU  - Reisin E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Hypertens Rep
JT  - Current hypertension reports
JID - 100888982
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - 10.1007/s11906-013-0344-5 [doi]
PST - ppublish
SO  - Curr Hypertens Rep. 2013 Jun;15(3):175-81. doi: 10.1007/s11906-013-0344-5.

PMID- 23588823
OWN - NLM
STAT- In-Data-Review
DA  - 20130416
IS  - 0148-5598 (Print)
IS  - 0148-5598 (Linking)
VI  - 37
IP  - 3
DP  - 2013 Jun
TI  - Facebook as a platform for health information and communication: a case study of 
      a diabetes group.
PG  - 9942
LID - 10.1007/s10916-013-9942-7 [doi]
AB  - As one of the largest social networking sites in the world, Facebook holds a
      great potential for promoting health. In this exploratory study, we analyzed 1352
      messages posted to an active Facebook diabetes group to identify the
      characteristics of the group. The results revealed that the group was
      international in nature. Users overcame language barriers to communicate with
      people with similar conditions. Users' interactions were structured around
      information, emotion, and community building. They exchanged medical and
      lifestyle information, and highly valued their peers' personal experiences,
      opinions, and advice. They also demonstrated a positive attitude toward the
      reality of living with diabetes and generously provided encouragements and
      affirmations to one another. Great efforts were made to maintain the proper
      operation of the community by the administrator and a group of core members. As a
      result, the group was shaped as a social network where peer users share social
      support, cultivate companionship, and exert social influence. Based on the
      results, we discussed future directions for research of health communities in a
      highly connected world.
AD  - School of Information, University of Texas at Austin, 1616 Guadalupe Street,
      Austin, TX, 78701, USA, yanz@ischool.utexas.edu.
FAU - Zhang, Yan
AU  - Zhang Y
FAU - He, Dan
AU  - He D
FAU - Sang, Yoonmo
AU  - Sang Y
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - J Med Syst
JT  - Journal of medical systems
JID - 7806056
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/12/18 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s10916-013-9942-7 [doi]
PST - ppublish
SO  - J Med Syst. 2013 Jun;37(3):9942. doi: 10.1007/s10916-013-9942-7. Epub 2013 Apr
      16.

PMID- 23588773
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130416
DCOM- 20130531
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 158
IP  - 8
DP  - 2013 Apr 16
TI  - ACP Journal Club: review: dipeptidyl peptidase-4 inhibitors do not increase
      overall adverse events in type 2 diabetes.
PG  - JC8
LID - 10.7326/0003-4819-158-8-201304160-02008 [doi]
FAU - Chatterjee, Saurav
AU  - Chatterjee S
FAU - Chatterjee, Sanjay
AU  - Chatterjee S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:01
CRDT- 2013/04/17 06:00
AID - 1676477 [pii]
AID - 10.7326/0003-4819-158-8-201304160-02008 [doi]
PST - ppublish
SO  - Ann Intern Med. 2013 Apr 16;158(8):JC8. doi:
      10.7326/0003-4819-158-8-201304160-02008.

PMID- 23588769
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130416
DCOM- 20130531
IS  - 1539-3704 (Electronic)
IS  - 0003-4819 (Linking)
VI  - 158
IP  - 8
DP  - 2013 Apr 16
TI  - ACP Journal Club: metformin reduced CV events compared with glipizide in patients
      with type 2 diabetes and CAD.
PG  - JC4
LID - 10.7326/0003-4819-158-8-201304160-02004 [doi]
FAU - Tanner, Michael
AU  - Tanner M
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Ann Intern Med
JT  - Annals of internal medicine
JID - 0372351
CON - Diabetes Care. 2013 May;36(5):1304-11. PMID: 23230096
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:01
CRDT- 2013/04/17 06:00
AID - 1676473 [pii]
AID - 10.7326/0003-4819-158-8-201304160-02004 [doi]
PST - ppublish
SO  - Ann Intern Med. 2013 Apr 16;158(8):JC4. doi:
      10.7326/0003-4819-158-8-201304160-02004.

PMID- 23588704
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1179-2019 (Electronic)
IS  - 1174-5878 (Linking)
VI  - 15
IP  - 3
DP  - 2013 Jun
TI  - Safety and pharmacokinetics of atypical antipsychotics in children and
      adolescents.
PG  - 217-33
LID - 10.1007/s40272-013-0024-6 [doi]
AB  - Pediatric behavioral and affective disorders often require antipsychotic therapy,
      in combination with psychotherapeutic interventions, for their treatment and
      stabilization. Although pharmacotherapy can include either typical or atypical
      antipsychotics, the latter are generally preferred because of their apparently
      lower risk of adverse effects. Recent controlled trials have demonstrated the
      efficacy of some of these agents (including aripiprazole, clozapine, olanzapine, 
      paliperidone, quetiapine, risperidone, ziprasidone) in adolescent schizophrenia
      and children or adolescent bipolar mania, or to treat severe aggression and
      self-injury in the context of autism in children and adolescents. Although few
      studies have systematically monitored their short- and, more importantly,
      long-term safety, current evidence indicates that sedation, hyperprolactinemia,
      and metabolic abnormalities such as excess weight gain, diabetes, and related
      cardiovascular effects were clinically relevant adverse effects in young
      patients, with the individual agents differing in their propensity to induce
      these effects. When prescribing antipsychotics for children and adolescents,
      physicians should therefore be aware of the specific adverse effect profiles and 
      patients should be closely monitored for the short- and long-term development of 
      adverse events. In pediatric patients, the starting dose, titration plan, and
      maintenance dose of antipsychotics must be based on their pharmacokinetics and
      metabolism, as in adults. Because there are significant individual differences in
      drug and active metabolite(s) pharmacokinetics and metabolism, which may be
      further affected by a number of confounding factors (including demographic
      variables, phenotype and drug interactions), therapeutic drug monitoring may be a
      valid tool for individualizing dosage, but its interpretation should also take
      account of changes in pharmacodynamic sensitivity with the development during
      childhood and adolescence.
AD  - Istituto di Ricerche Farmacologiche "IRCCS-Mario Negri", via Giuseppe La Masa 19,
      20156, Milan, Italy, silvio.caccia@marionegri.it.
FAU - Caccia, Silvio
AU  - Caccia S
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Paediatr Drugs
JT  - Paediatric drugs
JID - 100883685
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - 10.1007/s40272-013-0024-6 [doi]
PST - ppublish
SO  - Paediatr Drugs. 2013 Jun;15(3):217-33. doi: 10.1007/s40272-013-0024-6.

PMID- 23588623
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1555-8932 (Print)
IS  - 1555-8932 (Linking)
DP  - 2013 Apr 16
TI  - The nutrigenomic investigation of C57BL/6N mice fed a short-term high-fat diet
      highlights early changes in clock genes expression.
AB  - Mice fed long-term high-fat diets (HFD) are an established model for human
      metabolic disorders, such as obesity and diabetes. However, also the effects of
      short-term HFD feeding should be investigated to understand which are the first
      events that trigger the onset of a pre-disease condition, the so-called metabolic
      syndrome, that increases the risk of developing clinical diseases. In this study,
      C57BL/6N mice were fed a control diet (CTR) or a HFD for 1 (T1) or 2 weeks (T2). 
      Metabolic and histological effects were examined. Cecum transcriptomes of HFD and
      CTR mice were compared at T2 by microarray analysis. Differentially expressed
      genes were validated by real-time PCR in the cecum and in the liver. After 2
      weeks of diet administration, HFD mice showed an altered expression pattern in
      only seven genes, four of which are involved in the circadian clock regulatory
      pathway. Real-time PCR confirmed microarray results of the cecum and revealed the
      same trend of clock gene expression changes in the liver. These findings suggest 
      that clock genes may play an important role in early controlling gut output
      systems in response to HFD in mice and that their expression change may also
      represent an early signaling of the development of an intestinal pro-inflammatory
      status.
AD  - Centro Ricerche Biotecnologiche, Istituto di Microbiologia, Universita Cattolica 
      del Sacro Cuore, via Milano 24, 26100, Cremona, Italy,
      michela.lizier@humanitasresearch.it.
FAU - Lizier, Michela
AU  - Lizier M
FAU - Bomba, Lorenzo
AU  - Bomba L
FAU - Minuti, Andrea
AU  - Minuti A
FAU - Chegdani, Fatima
AU  - Chegdani F
FAU - Capraro, Jessica
AU  - Capraro J
FAU - Tondelli, Barbara
AU  - Tondelli B
FAU - Mazza, Raffaele
AU  - Mazza R
FAU - Callegari, Maria Luisa
AU  - Callegari ML
FAU - Trevisi, Erminio
AU  - Trevisi E
FAU - Rossi, Filippo
AU  - Rossi F
FAU - Marsan, Paolo Ajmone
AU  - Marsan PA
FAU - Lucchini, Franco
AU  - Lucchini F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Genes Nutr
JT  - Genes & nutrition
JID - 101280108
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/12/17 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s12263-013-0344-8 [doi]
PST - aheadofprint
SO  - Genes Nutr. 2013 Apr 16.

PMID- 23588576
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1938-2715 (Electronic)
IS  - 1049-9091 (Linking)
DP  - 2013 Apr 15
TI  - Aggravation of Fatigue by Steroid Therapy in Terminally Ill Patients With Cancer.
AB  - Steroids are commonly used for fatigue relief in terminally ill cancer patients. 
      However, steroid-induced adverse effects including depression, myopathy, and
      hyperglycemia may contribute to fatigue. We report our experiences with
      aggravation of fatigue with steroid use in three cases. Case 1 was a 65-year-old 
      man with advanced gastric cancer. He was started on betamethasone (2 mg/d) for
      fatigue, but the fatigue worsened due to steroid-induced depression.
      Discontinuation of steroids and initiation of an antidepressant ameliorated the
      fatigue. Case 2 was a 68-year-old man with advanced lung cancer. He complained of
      fatigue. Betamethasone (1 mg/d) was started and alleviated the fatigue. However, 
      when the betamethasone dose was increased to 2 mg/d, the fatigue, with muscle
      weakness and myalgia, worsened due to steroid-induced myopathy. We therefore
      switched from betamethasone (2 mg/d) to prednisolone (10 mg /d). The fatigue
      resolved and the patient returned to his previous condition. Case 3 was a
      73-year-old man with recurrent bile duct cancer. He also had diabetes mellitus.
      He developed fatigue, anorexia and fever. We started betamethasone (1.5 mg/d) for
      these symptoms, but the fatigue and anorexia worsened due to steroid-induced
      hyperglycemia. Blood glucose rose to 532 mg/dL. Therefore, insulin therapy was
      started, and the dose of betamethasone was reduced to 0.5 mg/d. His glucose level
      decreased to less than 320 mg/dL and he recovered from the fatigue while
      achieving moderate oral intake. In conclusion, the possibility of steroid-induced
      secondary fatigue in terminally ill cancer patients should be taken into
      consideration.
AD  - 1Hospice, Medical corporation Junkei-kai Sotoasahikawa Hospital, Akita, Japan.
FAU - Matsuo, Naoki
AU  - Matsuo N
FAU - Yomiya, Kinomi
AU  - Yomiya K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Am J Hosp Palliat Care
JT  - The American journal of hospice & palliative care
JID - 9008229
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - 1049909113485280 [pii]
AID - 10.1177/1049909113485280 [doi]
PST - aheadofprint
SO  - Am J Hosp Palliat Care. 2013 Apr 15.

PMID- 23588568
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
DP  - 2013 Apr 16
TI  - Lazy Sunday afternoons: the negative impact of interruptions in patients' daily
      routine on adherence to oral antidiabetic medication. A multilevel analysis of
      electronic monitoring data.
AB  - PURPOSE: Considerable variability in adherence over time exists. The aim of this 
      study was to investigate to what extent deviations from the prescribed regimen in
      type 2 diabetes patients can be explained by characteristics of the individual
      'medication intake moments' and the patient. METHODS: Medication intake of 104
      non-adherent type 2 diabetes patients from 37 community pharmacies was
      electronically monitored for 6 months. The primary outcome measures were: (1)
      whether or not the intake occurred and (2) whether or not the intake occurred
      within the agreed-upon time period (correct timing). Multilevel logistic
      regression analyses were performed to account for the nested structure of the
      data. RESULTS: Medication intakes in the evening and during weekends and holidays
      were more likely to be incorrectly timed and also more likely to be completely
      missed. Irrespective of timing, most intakes occurred in the mornings of Monday
      through Thursday (96 %), and least intakes occurred on Saturday evening (82 %).
      Correctly timed intakes most often occurred on Monday and Tuesday mornings (61 %)
      in contrast to Sunday evenings (33 %). A patient's medication regimen was
      significantly associated with adherence. CONCLUSION: Based on our results, among 
      patients who already have difficulties in taking their oral antidiabetic
      medication, interruptions in the daily routine negatively influence the intake of
      their medication. Professionals need to be aware of this variation in adherence
      within patients. As regular medication intake is important to maintain glycaemic 
      control, healthcare professionals and patients should work together to find
      strategies that prevent deviations from the prescribed regimen at these
      problematic dosing times.
AD  - Netherlands Institute for Health Services Research (NIVEL), P.O. Box 1568, 3500
      BN, Utrecht, The Netherlands, M.Vervloet@nivel.nl.
FAU - Vervloet, M
AU  - Vervloet M
FAU - Spreeuwenberg, P
AU  - Spreeuwenberg P
FAU - Bouvy, M L
AU  - Bouvy ML
FAU - Heerdink, E R
AU  - Heerdink ER
FAU - de Bakker, D H
AU  - de Bakker DH
FAU - van Dijk, L
AU  - van Dijk L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/01/20 [received]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s00228-013-1511-y [doi]
PST - aheadofprint
SO  - Eur J Clin Pharmacol. 2013 Apr 16.

PMID- 23588558
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1432-1041 (Electronic)
IS  - 0031-6970 (Linking)
DP  - 2013 Apr 16
TI  - Adherence to preventive statin therapy according to socioeconomic position.
AB  - AIM: To explore whether long-term adherence to preventive statin therapy depends 
      on socioeconomic position (SEP). METHODS: A cohort of individuals without
      established cardiovascular disease (CVD) or diabetes initiating preventive statin
      therapy during 2002-2005 was followed in the individual-level Danish registries
      for 4 years or until censoring events (death, emigration, CVD or diabetes). Only 
      individuals aged 40-84 years for whom information was available on the SEP
      indicators, education and income were included (N = 76,038). Two different
      aspects of poor adherence were applied as outcome measures: (1) Proportion of
      days covered (PDC) with medication below 80 %, assuming a daily dose of one
      tablet (continuity); (2) Discontinuation defined as a gap between two consecutive
      prescriptions exceeding 365 days (persistence). Stratum-specific logistic
      regression analyses were applied to estimate the odds ratio (OR) for PDC <80 %
      across SEP, adjusting for age and hypertension. Hazard ratio (HR) for
      discontinuation was estimated by Cox regression analyses. RESULTS: Adjusting
      mutually for income and education, the OR for PDC <80 % decreased with increasing
      income. Comparing the highest income quintile with the lowest, the OR were 0.64
      (95 % Confidence Interval 0.64-0.65) and 0.73 (0.73-0.74) in men aged 40-64 and
      65-84 years, respectively; in women, the figures were 0.79 (0.79-0.79) and 0.95
      (0.94-0.95), respectively. While observed increases in adherence with longer
      education in unadjusted analyses were attenuated after adjustment for income
      among men, the potential inverse relationship between length of education and
      adherence was enhanced among women. Applying discontinuation as outcome,
      analogous differences were demonstrated. CONCLUSION: Adherence to preventive
      statin therapy in Denmark decreases with decreasing income-especially in men aged
      40-64 years.
AD  - Section for Health Service Research, Centre for Healthy Ageing, Faculty of Health
      and Medical Science, University of Copenhagen, CSS, Oster Farimagsgade 5, 1014,
      Copenhagen, Denmark, hewk@sund.ku.dk.
FAU - Wallach-Kildemoes, Helle
AU  - Wallach-Kildemoes H
FAU - Andersen, Morten
AU  - Andersen M
FAU - Diderichsen, Finn
AU  - Diderichsen F
FAU - Lange, Theis
AU  - Lange T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Eur J Clin Pharmacol
JT  - European journal of clinical pharmacology
JID - 1256165
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/11/15 [received]
PHST- 2013/02/19 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s00228-013-1488-6 [doi]
PST - aheadofprint
SO  - Eur J Clin Pharmacol. 2013 Apr 16.

PMID- 23588492
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1438-2199 (Electronic)
IS  - 0939-4451 (Linking)
DP  - 2013 Apr 16
TI  - Synthesis of stable isotope-labelled monolysyl advanced glycation endproducts.
AB  - Advanced Glycation Endproducts (AGEs) are modified amino acids that form on
      proteins and are known to be implicated in the pathogenesis of diabetes and
      related diseases. Ready access to synthetic stable isotope-labelled AGEs allows
      for quantitative mass spectrometry studies to be undertaken, providing key
      insights into the roles AGEs play in the progression of such diseases. However,
      the majority of current syntheses of these compounds suffer from poor yields and 
      lengthy procedures and are not suitable for the purposes required here. Here, we 
      report robust syntheses of stable isotope-labelled monolysyl AGEs,
      Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and pyrraline, that
      provide straightforward access to these compounds for quantitative amino acid
      analysis. This work will facilitate future investigations with these compounds
      and lead to a better understanding of the roles they play in diabetes and related
      diseases.
AD  - School of Chemical Sciences, The University of Auckland, 23 Symonds Street,
      Auckland, New Zealand.
FAU - Woods, Tom M
AU  - Woods TM
FAU - Cooper, Garth J S
AU  - Cooper GJ
FAU - Brimble, Margaret A
AU  - Brimble MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Amino Acids
JT  - Amino acids
JID - 9200312
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/03/04 [received]
PHST- 2013/04/05 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s00726-013-1498-9 [doi]
PST - aheadofprint
SO  - Amino Acids. 2013 Apr 16.

PMID- 23588262
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
DP  - 2013 Apr 12
TI  - Association of Brachial-Ankle Pulse Wave Velocity, Ankle-Brachial Index and Ratio
      of Brachial Pre-Ejection Period to Ejection Time With Left Ventricular
      Hypertrophy.
AB  - BACKGROUND:: Arterial stiffness, peripheral artery disease and left ventricular
      systolic dysfunction contributed to left ventricular hypertrophy (LVH). Using an 
      ABI-form device, we can obtain brachial-ankle pulse wave velocity (baPWV),
      ankle-brachial index (ABI) and the ratio of brachial pre-ejection period to
      ejection time (bPEP/bET), which are markers for arterial stiffness, peripheral
      artery disease and left ventricular systolic function, respectively. The aim of
      this study was to assess whether "BAP score" calculated from the 3 measures of
      baPWV, ABI and bPEP/bET is associated with LVH. METHODS:: A total of 1,146
      patients were included in the study. BAP score was calculated based on a point
      system in which 1 point was assigned for baPWV above the median value of 1670
      cm/s, ABI < 0.9 or >/= 1.3 in either leg and bPEP/bET > 0.38. RESULTS:: There was
      a significant trend for a stepwise increase in the left atrial diameter, left
      ventricular mass index (LVMI) and the prevalence of LVH and a stepwise decrease
      in the left ventricular ejection fraction corresponding to advancement in BAP
      score from 0 to 3. In addition, increased BAP score is significantly associated
      with increased LVMI and LVH. CONCLUSIONS:: Our results demonstrated increased BAP
      score was related to increased LVMI and LVH independent of traditional risk
      factors such as old age, diabetes, hypertension, obesity, anemia, hyperlipidemia 
      and chronic kidney disease. Therefore, the BAP score obtained from the same
      examination might be useful and convenient in identifying patients with increased
      LVMI and LVH.
AD  - Division of Cardiology (H-MS, T-HL, P-CH, C-SL, W-HL, W-CV, W-TL, S-HS), Division
      of Nephrology, Department of Internal Medicine, Kaohsiung Medical University
      Hospital (S-CC), Kaohsiung Medical University, Kaohsiung, Taiwan; Department of
      Internal Medicine (H-MS, S-CC), Kaohsiung Municipal Hsiao-Kang Hospital,
      Kaohsiung Medical University, Kaohsiung, Taiwan; and Faculty of Medicine (H-MS,
      T-HL0, C-SL, S-CC, W-CV, W-TL, S-HS), College of Medicine, Kaohsiung Medical
      University, Kaohsiung, Taiwan.
FAU - Su, Ho-Ming
AU  - Su HM
FAU - Lin, Tsung-Hsien
AU  - Lin TH
FAU - Hsu, Po-Chao
AU  - Hsu PC
FAU - Lee, Chee-Siong
AU  - Lee CS
FAU - Lee, Wen-Hsien
AU  - Lee WH
FAU - Chen, Szu-Chia
AU  - Chen SC
FAU - Voon, Wen-Chol
AU  - Voon WC
FAU - Lai, Wen-Ter
AU  - Lai WT
FAU - Sheu, Sheng-Hsiung
AU  - Sheu SH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - 10.1097/MAJ.0b013e31828c5bee [doi]
PST - aheadofprint
SO  - Am J Med Sci. 2013 Apr 12.

PMID- 23588209
OWN - NLM
STAT- In-Process
DA  - 20130418
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 31
IP  - 6
DP  - 2013 Jun
TI  - Anti-inflammatory effects of tectroside on UVB-induced HaCaT cells.
PG  - 1471-6
LID - 10.3892/ijmm.2013.1343 [doi]
AB  - Ultraviolet B (UVB) irradiation causes skin damage and inflammation by inducing
      the secretion of various cytokines, which are immune regulators produced by
      cells. To prevent skin inflammation, keratinocytes that have been irreversibly
      damaged by UVB must be eliminated through apoptosis. Ixeris dentata (I. dentata) 
      (family Asteraceae) is a perennial medicinal herb indigenous to Korea. It is used
      in Korea, China and Japan to treat indigestion, pneumonia, diabetes, hepatitis,
      contusions and tumors. Guaiane-type sesquiterpene lactones were isolated from the
      whole extract of I. dentata. This led to the isolation of the anti-inflammatory
      sesquiterpene lactone compound tectroside (TES), which was tested on a human
      keratinocyte cell line. To determine the anti-inflammatory effects of TES, we
      examined its influence on UVB-induced pro-inflammatory cytokine production in
      human keratinocytes (HaCaT cells) by observing these cells in the presence or
      absence of TES. In the present study, pro-inflammatory cytokine production was
      determined by performing enzyme-linked immunosorbent assay, reverse
      transcription-polymerase chain reaction and western blot analysis to evaluate the
      activation of mitogen-activated protein kinases (MAPKs). TES inhibited
      UVB-induced production of the pro-inflammatory cytokines interleukin (IL)-6 and
      IL-8 in a dose-dependent manner. In addition, TES inhibited the expression of
      cyclooxygenase (COX)-2 and the phosphorylation of c-Jun NH2-terminal kinase (JNK)
      and extracellular signal-regulated kinase (ERK) MAPKs, suggesting that it
      inhibits the secretion of the pro-inflammatory cytokines IL-6 and IL-8 and COX-2 
      expression by blocking MAPK phosphorylation. These results suggest that TES can
      potentially protect against UVB-induced skin inflammation.
AD  - Institute of Biotechnology, Wonkwang University, Jeonbuk, Republic of Korea.
FAU - Kim, Sung-Bae
AU  - Kim SB
FAU - Kang, Ok-Hwa
AU  - Kang OH
FAU - Joung, Dae-Ki
AU  - Joung DK
FAU - Mun, Su-Hyun
AU  - Mun SH
FAU - Seo, Yun-Soo
AU  - Seo YS
FAU - Cha, Mi-Ran
AU  - Cha MR
FAU - Ryu, Shi-Yong
AU  - Ryu SY
FAU - Shin, Dong-Won
AU  - Shin DW
FAU - Kwon, Dong-Yeul
AU  - Kwon DY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130411
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/01/02 [received]
PHST- 2013/03/21 [accepted]
PHST- 2013/04/11 [aheadofprint]
AID - 10.3892/ijmm.2013.1343 [doi]
PST - ppublish
SO  - Int J Mol Med. 2013 Jun;31(6):1471-6. doi: 10.3892/ijmm.2013.1343. Epub 2013 Apr 
      11.

PMID- 23588202
OWN - NLM
STAT- MEDLINE
DA  - 20130416
DCOM- 20130606
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 95
IP  - 8
DP  - 2013 Apr 27
TI  - Islet transplantation in a subarachnoid cavity surrounding olfactory bulb of
      diabetic rats.
PG  - e54-7
LID - 10.1097/TP.0b013e3182875ddc [doi]
FAU - Bloch, Konstantin
AU  - Bloch K
FAU - Vanichkin, Alexey
AU  - Vanichkin A
FAU - Vardi, Pnina
AU  - Vardi P
LA  - eng
PT  - Evaluation Studies
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
SB  - IM
MH  - Animals
MH  - Blood Glucose/metabolism
MH  - C-Peptide/blood
MH  - Diabetes Mellitus, Experimental/blood/pathology/*surgery
MH  - Graft Survival
MH  - Islets of Langerhans Transplantation/*methods/pathology/physiology
MH  - Male
MH  - Olfactory Bulb/pathology/*surgery
MH  - Rats
MH  - Rats, Inbred Lew
MH  - Subarachnoid Space/pathology/*surgery
EDAT- 2013/04/17 06:00
MHDA- 2013/06/07 06:00
CRDT- 2013/04/17 06:00
AID - 10.1097/TP.0b013e3182875ddc [doi]
AID - 00007890-201304270-00014 [pii]
PST - ppublish
SO  - Transplantation. 2013 Apr 27;95(8):e54-7. doi: 10.1097/TP.0b013e3182875ddc.

PMID- 23588194
OWN - NLM
STAT- Publisher
DA  - 20130502
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 31
IP  - 6
DP  - 2013 Jun
TI  - Prevalence and covariates of electrocardiographic left ventricular hypertrophy in
      the Hypertension in the Very Elderly Trial.
PG  - 1224-1232
AB  - OBJECTIVE:: To estimate the prevalence and covariates of electrocardiographic
      left ventricular hypertrophy (LVH) in the Hypertension in the Very Elderly Trial.
      METHODS:: A total of 2993 hypertensive people aged at least 80 years with
      technically codable ECGs without pacing, bundle branch block, or ECG myocardial
      infarction were studied. LVH was assessed using Sokolow-Lyon (SL-LVH), Cornell
      voltage (CV-LVH), and Cornell product criterion (CP-LVH). RESULTS:: The
      prevalence of LVH varied from 2.4 to 17.5% depending on sex, race, and ECG
      criterion. The highest prevalence of SL-LVH (12.0%) was in Chinese men and in
      white women for both CV-LVH (17.5%) and CP-LVH (12.9%). Increasing SBP was an
      independent covariate of the presence of LVH in Chinese women independently of
      the criterion used (beta = 0.052-0.069, P < 0.001), of SL-LVH in Chinese men
      (beta = 0.047 P = 0.006). In white women, CP-LVH was associated with increasing
      age (beta = 0.055, P = 0.027) and SBP (beta = 0.023, P = 0.040). Increasing BMI
      was associated inversely with SL-LVH; the association in white men only was not
      significant. In white men, a history of diabetes was directly and history of
      antihypertensive drug treatment inversely related to CV-LVH and CP-LVH. SL-ECG
      was associated inversely to serum uric acid concentration in Chinese women and to
      serum hemoglobin concentration in Chinese men. CONCLUSION:: Prevalence and
      covariates of electrocardiographic LVH varied by sex, race, and ECG criterion.
      CP-LVH may prove to be the most useful measure of LVH in this study owing to its 
      close relationship to SBP, at least in women, and independence from BMI.
AD  - aCare of the Elderly, Imperial College, London, UK bInstitute of Health Sciences 
      (Geriatrics), Oulu University and Oulu City Hospital, Oulu, Finland cFaculty of
      Medicine, Hypertension and Cardiovascular Rehabilitation Unit, Department of
      Cardiovascular Diseases, KU Leuven University, Leuven, Belgium dBrighton and
      Sussex Medical School, Brighton, UK eCentre for Epidemiological Studies and
      Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital,
      Shanghai Jiaotong University School of Medicine, Shanghai, China fNMTH'Tsar Boris
      III' Department of Cardiology, Sofia, Bulgaria.
FAU - Antikainen, Riitta L
AU  - Antikainen RL
FAU - Beckett, Nigel
AU  - Beckett N
FAU - Peters, Ruth
AU  - Peters R
FAU - Fagard, Robert
AU  - Fagard R
FAU - Rajkumar, Chakravarthi
AU  - Rajkumar C
FAU - Wang, Jiguang
AU  - Wang J
FAU - Stoyanovsky, Vassil
AU  - Stoyanovsky V
FAU - Barrowdale, Daniel
AU  - Barrowdale D
FAU - Bulpitt, Christopher J
AU  - Bulpitt CJ
CN  - HYVET Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - 10.1097/HJH.0b013e32836040a4 [doi]
PST - ppublish
SO  - J Hypertens. 2013 Jun;31(6):1224-1232.

PMID- 23588192
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 42
IP  - 5
DP  - 2013 May
TI  - [Gestational diabetes: Diagnosis, short and long term management].
PG  - 893-9
LID - 10.1016/j.lpm.2013.02.316 [doi]
LID - S0755-4982(13)00481-8 [pii]
AB  - Universal consensus on the diagnosis methods and thresholds has long been
      lacking. The recently published Hyperglycemia and Adverse Pregnancy Outcome
      (HAPO) study has been used to confirm the link between hyperglycemia and
      materno-fetal complications. Consequently, in France, the Societe francophone du 
      diabete (SFD) and the College national des gynecologues et obstetriciens francais
      (CNGOF) proposed an expert consensus on gestational diabetes mellitus for
      clinical practice. Fasting blood glucose should be measured at the first visit
      during early pregnancy for women with risk factors to identify the women with
      pregestational diabetes. It is proposed a selective screening on risk factors
      rather than universal screening. Specific treatment of gestational diabetes
      reduced materno-fetal complications compared to the absence of therapy. Women
      with a history of gestational diabetes mellitus are characterized by a high risk 
      of type 2 diabetes mellitus.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - CHRU Rue-Polonovski, hopital Claude-Huriez, pole d'endocrinologie et de
      diabetologie, 59037 Lille cedex, France; EA << 4489 >> Environnement perinatal et
      croissance >>, faculte de medecine, pole recherche, 59037 Lille cedex, France.
      Electronic address: anne.vambergue@chru-lille.fr.
FAU - Vambergue, Anne
AU  - Vambergue A
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Le diabete gestationnel : diagnostic et prise en charge a court et a long terme.
DEP - 20130412
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/10/02 [received]
PHST- 2013/02/21 [revised]
PHST- 2013/02/21 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - S0755-4982(13)00481-8 [pii]
AID - 10.1016/j.lpm.2013.02.316 [doi]
PST - ppublish
SO  - Presse Med. 2013 May;42(5):893-9. doi: 10.1016/j.lpm.2013.02.316. Epub 2013 Apr
      12.

PMID- 23588189
OWN - NLM
STAT- In-Data-Review
DA  - 20130531
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 42
IP  - 5
DP  - 2013 May
TI  - [Insulin therapy among inpatients].
PG  - 871-9
LID - 10.1016/j.lpm.2013.02.319 [doi]
LID - S0755-4982(13)00484-3 [pii]
AB  - To identify patients with known diabetes or hospital-related hyperglycemia. To
      establish blood glucose targets according to patient's clinical state. To draw up
      protocols by using basal, bolus (nutritional/prandial), and supplemental insulin 
      and not "sliding scale insulin". To avoid hypoglycaemia particularly during
      intravenous insulin protocols in intensive care unit. To set up glucose
      monitoring with a regular training of medical staff. To perform HbA1c during
      hospital stay to plan the treatment after discharge. To organize follow-up of the
      patients with hospital-related hyperglycemia.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - CHNO des Quinze-Vingts, service de medecine interne, 28, rue de Charenton, 75571 
      Paris cedex 12, France. Electronic address: s.feldman@quinze-vingts.fr.
FAU - Feldman-Billard, Sylvie
AU  - Feldman-Billard S
FAU - Altman, Jean-Jacques
AU  - Altman JJ
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - L'insulinotherapie a l'hopital.
DEP - 20130412
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2011/06/20 [received]
PHST- 2013/02/18 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - S0755-4982(13)00484-3 [pii]
AID - 10.1016/j.lpm.2013.02.319 [doi]
PST - ppublish
SO  - Presse Med. 2013 May;42(5):871-9. doi: 10.1016/j.lpm.2013.02.319. Epub 2013 Apr
      12.

PMID- 23588112
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1097-6809 (Electronic)
IS  - 0741-5214 (Linking)
DP  - 2013 Apr 12
TI  - The influence of patient and wound variables on healing of venous leg ulcers in a
      randomized controlled trial of growth-arrested allogeneic keratinocytes and
      fibroblasts.
LID - S0741-5214(13)00063-3 [pii]
LID - 10.1016/j.jvs.2012.12.055 [doi]
AB  - OBJECTIVE: To examine patient and wound variables presumed to influence healing
      outcomes in the context of therapeutic trials for chronic venous leg ulcers.
      METHODS: This double-blind, vehicle-controlled study was conducted with
      randomized assignment to one of four cell therapy dose groups (n = 46, 43, 44,
      45) or vehicle control (n = 50). A 2-week run-in period was used to exclude rapid
      healers and those with infection or uncontrolled edema. This was a multicenter
      (ambulatory, private, hospital-based and university-based practices, and wound
      care centers in North America) study. Adults >/=18 years old with chronic venous 
      insufficiency associated with an uninfected venous leg ulcer (2-12 cm2 area,
      6-104 weeks' duration) were included in the study. Excluded were pregnant or
      lactating women, wounds with exposed muscle, tendon or bone, patients unable to
      tolerate compression bandages, or patients who had exclusionary medical
      conditions or exposure to certain products. Exclusion during run-in included
      patients with infection, uncontrolled severe edema or with healing rates >/=0.349
      cm/2 wk. Screen fail rate was 37% (134/362), and the withdrawal rate was
      approximately 10% (23 of 228). Growth-arrested neonatal dermal fibroblasts and
      keratinocytes were delivered via pump spray in a fibrin sealant-based matrix,
      plus a foam dressing and four-layer compression bandaging. Treatment continued
      for 12 weeks or until healed, whichever occurred first. Patient demographic and
      wound-related variables were evaluated for influence on complete wound healing in
      all patients, as well as the subsets of treated and control patients. RESULTS:
      Wound duration (P = .004) and the presence of specific quantities of certain
      bacterial species (P < .001) affected healing in the vehicle group, while healing
      in the cell-treated groups was influenced by wound duration (P = .012), wound
      area (P = .026), wound location (P = .011), and specific quantities of certain
      bacterial species (P = .002). Age, sex, race, diabetes, HbA1C, peripheral
      neuropathy, and serum prealbumin did not significantly affect healing. Body mass 
      index was positively associated with healing in cell-treated patients.
      CONCLUSIONS: Wound duration is a quantifiable surrogate for one or more undefined
      variables that can have a profound negative effect on venous leg ulcer healing.
      Although cell therapy overcame barriers to healing, the only specific barrier
      identified was the presence of certain bacterial species. Interventional trials
      of potentially effective new therapies can be most informative when patients with
      suspected barriers to healing are included. The specific measurement of candidate
      barriers such as microbial pathogens, wound inflammatory state, and fibroblast
      function should be considered in future randomized trials to improve our
      understanding of the basis for chronicity.
CI  - Copyright (c) 2013 Society for Vascular Surgery. Published by Mosby, Inc. All
      rights reserved.
AD  - The Division of Vascular and Endovascular Surgery, St. Luke's Roosevelt Hospital 
      Center, New York, NY.
FAU - Lantis, John C 2nd
AU  - Lantis JC 2nd
FAU - Marston, William A
AU  - Marston WA
FAU - Farber, Alik
AU  - Farber A
FAU - Kirsner, Robert S
AU  - Kirsner RS
FAU - Zhang, Yuxin
AU  - Zhang Y
FAU - Lee, Tommy D
AU  - Lee TD
FAU - Cargill, D Innes
AU  - Cargill DI
FAU - Slade, Herbert B
AU  - Slade HB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Vasc Surg
JT  - Journal of vascular surgery
JID - 8407742
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/09/21 [received]
PHST- 2012/11/13 [revised]
PHST- 2012/12/22 [accepted]
AID - S0741-5214(13)00063-3 [pii]
AID - 10.1016/j.jvs.2012.12.055 [doi]
PST - aheadofprint
SO  - J Vasc Surg. 2013 Apr 12. pii: S0741-5214(13)00063-3. doi:
      10.1016/j.jvs.2012.12.055.

PMID- 23588078
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 0736-4679 (Electronic)
IS  - 0736-4679 (Linking)
DP  - 2013 Apr 12
TI  - Blood Culture Results Do Not Affect Treatment in Complicated Cellulitis.
LID - S0736-4679(13)00096-6 [pii]
LID - 10.1016/j.jemermed.2013.01.016 [doi]
AB  - BACKGROUND: Cellulitis, a frequently encountered complaint in the Emergency
      Department, is typically managed with antibiotics. There is some debate as to
      whether obtaining blood cultures and knowing their results would change the
      management of cellulitis, although most authors argue that information from blood
      cultures does not change the empirical management of uncomplicated cellulitis.
      However, for complicated cellulitis (as defined by the presence of significant
      comorbidity), there is considerable disagreement and lack of evidence as to the
      utility of blood cultures. OBJECTIVE: Our aim was to determine the role of blood 
      cultures in the management of complicated cellulitis. METHODS: This retrospective
      chart review assessed the utility of obtaining blood cultures in complicated
      cellulitis (as defined by active chemotherapy, dialysis, human immunodeficiency
      virus/acquired immune deficiency syndrome, diabetes, or organ transplantation)
      vs. a cohort of individuals without medical comorbidity. RESULTS: Six hundred and
      thirty-nine patients were identified, 314 of which were deemed cases and 325
      controls. Within the cases, 29 of 314 returned as positive blood cultures vs. 17 
      of 325 positive blood culture controls within the cases (p = 0.05; odds ratio =
      1.84; 95% confidence interval 0.99-3.43). A clinically significant change in
      management (a change in the class of antibiotic) was found in 6 of 314 cases vs. 
      4 of 325 controls (p = 0.578; odds ratio = 1.5525; 95% confidence interval
      0.434-5.5541). CONCLUSIONS: Within this cohort of patients with complicated
      cellulitis, blood cultures rarely changed management from empirical coverage.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Emergency Medicine, SUNY Upstate, Syracuse, New York.
FAU - Paolo, William F
AU  - Paolo WF
FAU - Poreda, Andrew R
AU  - Poreda AR
FAU - Grant, William
AU  - Grant W
FAU - Scordino, David
AU  - Scordino D
FAU - Wojcik, Susan
AU  - Wojcik S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Emerg Med
JT  - The Journal of emergency medicine
JID - 8412174
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/09/08 [received]
PHST- 2013/01/10 [revised]
PHST- 2013/01/10 [accepted]
AID - S0736-4679(13)00096-6 [pii]
AID - 10.1016/j.jemermed.2013.01.016 [doi]
PST - aheadofprint
SO  - J Emerg Med. 2013 Apr 12. pii: S0736-4679(13)00096-6. doi:
      10.1016/j.jemermed.2013.01.016.

PMID- 23587840
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
DP  - 2013 Apr 12
TI  - Screening for impaired fasting glucose and diabetes using available health plan
      data.
LID - S1056-8727(13)00004-4 [pii]
LID - 10.1016/j.jdiacomp.2013.01.003 [doi]
AB  - AIMS: To develop and validate prediction equations to identify individuals at
      high risk for type 2 diabetes using existing health plan data. METHODS: Health
      plan data from 2005 to 2009 from 18,527 members of a Midwestern HMO without
      diabetes, 6% of whom had fasting plasma glucose (FPG) >/=110mg/dL, and health
      plan data from 2005 to 2006 from 368,025 members of a West Coast-integrated
      delivery system without diabetes, 13% of whom had FPG >/=110mg/dL were analyzed. 
      Within each health plan, we used multiple logistic regression to develop
      equations to predict FPG >/=110mg/dL for half of the population and validated the
      equations using the other half. We then externally validated the equations in the
      other health plan. RESULTS: Areas under the curve for the most parsimonious
      equations were 0.665 to 0.729 when validated internally. Positive predictive
      values were 14% to 32% when validated internally and 14% to 29% when validated
      externally. CONCLUSION: Multivariate logistic regression equations can be applied
      to existing health plan data to efficiently identify persons at higher risk for
      dysglycemia who might benefit from definitive diagnostic testing and
      interventions to prevent or treat diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Internal Medicine/Metabolism, Endocrinology and Diabetes,
      University of Michigan, Ann Arbor, MI 48105, USA. Electronic address:
      lmattei@med.umich.edu.
FAU - McEwen, Laura N
AU  - McEwen LN
FAU - Adams, Sara R
AU  - Adams SR
FAU - Schmittdiel, Julie A
AU  - Schmittdiel JA
FAU - Ferrara, Assiamira
AU  - Ferrara A
FAU - Selby, Joseph V
AU  - Selby JV
FAU - Herman, William H
AU  - Herman WH
LA  - ENG
GR  - P30 DK092924/DK/NIDDK NIH HHS/United States
GR  - P30 DK092926/DK/NIDDK NIH HHS/United States
GR  - P60 DK020572/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/10/18 [received]
PHST- 2012/12/21 [revised]
PHST- 2013/01/15 [accepted]
AID - S1056-8727(13)00004-4 [pii]
AID - 10.1016/j.jdiacomp.2013.01.003 [doi]
PST - aheadofprint
SO  - J Diabetes Complications. 2013 Apr 12. pii: S1056-8727(13)00004-4. doi:
      10.1016/j.jdiacomp.2013.01.003.

PMID- 23587769
OWN - NLM
STAT- Publisher
DA  - 20130513
IS  - 1872-8057 (Electronic)
IS  - 0303-7207 (Linking)
DP  - 2013 Apr 13
TI  - Genetics of diabetes - Are we missing the genes or the disease?
LID - S0303-7207(13)00140-8 [pii]
LID - 10.1016/j.mce.2013.04.002 [doi]
AB  - Diabetes is a group of metabolic diseases characterized by hyperglycemia
      resulting from defects in insulin secretion, insulin action, or both. The chronic
      hyperglycemia of diabetes is associated with long-term damage, dysfunction, and
      failure of different organs, especially the eyes, kidneys, nerves, heart, and
      blood vessels. Several pathogenic processes are involved in the development of
      diabetes. These range from autoimmune destruction of the beta-cells of the
      pancreas with consequent insulin deficiency to abnormalities that result in
      resistance to insulin action (American Diabetes Association, 2011). The vast
      majority of cases of diabetes fall into two broad categories. In type 1 diabetes 
      (T1D), the cause is an absolute deficiency of insulin secretion, whereas in type 
      2 diabetes (T2D), the cause is a combination of resistance to insulin action and 
      an inadequate compensatory insulin secretory response. However, the subdivision
      into two main categories represents a simplification of the real situation, and
      research during the recent years has shown that the disease is much more
      heterogeneous than a simple subdivision into two major subtypes assumes.
      Worldwide prevalence figures estimate that there are 280 million diabetic
      patients in 2011 and more than 500 million in 2030
      (http://www.diabetesatlas.org/). In Europe, about 6-8% of the population suffer
      from diabetes, of them about 90% has T2D and 10% T1D, thereby making T2D to the
      fastest increasing disease in Europe and worldwide. This epidemic has been
      ascribed to a collision between the genes and the environment. While our
      knowledge about the genes is clearly better for T1D than for T2D given the strong
      contribution of variation in the HLA region to the risk of T1D, the opposite is
      the case for T2D, where our knowledge about the environmental triggers (obesity, 
      lack of exercise) is much better than the understanding of the underlying genetic
      causes. This lack of knowledge about the underlying genetic causes of diabetes is
      often referred to as missing heritability (Manolio et al., 2009) which exceeds
      80% for T2D but less than 25% for T1D. In the following review, we will discuss
      potential sources of this missing heritability which also includes the
      possibility that our definition of diabetes and its subgroups is imprecise and
      thereby making the identification of genetic causes difficult.
CI  - Copyright (c) 2013. Published by Elsevier Ireland Ltd.
AD  - Department of Clinical Sciences, Diabetes and Endocrinology, Lund University,
      University Hospital Skane, Malmo, Sweden; Glostrup Research Institute, Glostrup
      University Hospital, Glostrup, Denmark. Electronic address: Leif.Groop@med.lu.se.
FAU - Groop, Leif
AU  - Groop L
FAU - Pociot, Flemming
AU  - Pociot F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - Mol Cell Endocrinol
JT  - Molecular and cellular endocrinology
JID - 7500844
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/04/04 [received]
PHST- 2013/01/25 [revised]
PHST- 2013/04/02 [accepted]
AID - S0303-7207(13)00140-8 [pii]
AID - 10.1016/j.mce.2013.04.002 [doi]
PST - aheadofprint
SO  - Mol Cell Endocrinol. 2013 Apr 13. pii: S0303-7207(13)00140-8. doi:
      10.1016/j.mce.2013.04.002.

PMID- 23587667
OWN - NLM
STAT- Publisher
DA  - 20130429
IS  - 1876-7737 (Electronic)
DP  - 2013 Apr 13
TI  - Advanced oxidative and glycoxidative protein damage markers in the elderly with
      type 2 diabetes.
LID - S1874-3919(13)00181-4 [pii]
LID - 10.1016/j.jprot.2013.03.034 [doi]
AB  - We aimed to explore the association of advanced oxidation and advanced glycation 
      of proteins, and their interrelations with endothelial nitric oxide synthesis,
      oxidative stress, metabolic profile as well as other atherosclerotic risk markers
      in prediabetic and diabetic elderly subjects. Advanced glycation end products
      (AGEs), advanced oxidation protein products (AOPPs), low-density lipoprotein
      susceptibility to oxidation (oxLDL) and nitric oxide metabolic pathway products
      (NOx) were assessed in subjects with impaired fasting glucose (prediabetes, IFG; 
      n=90), and type 2 diabetes mellitus (T2DM, n=95) versus control subjects (n=88). 
      Higher levels of AOPPs, AGEs, oxLDL, NOx, atherosclerosis risk markers, and
      insulin resistance were pointed out in IFG and T2DM groups compared with control.
      Strong positive associations (p<0.01) of AGEs with fasting glucose and HbA1c were
      found in both hyperglycemic groups, whereas AOPPs were significantly correlated
      (p<0.01) only in T2DM. In T2DM, AGEs and AOPPs significantly (p<0.01) correlated 
      with insulin resistance index HOMA-IR, oxLDL and small LDL particle size
      (TG/HDL-C), and positively with NOx. Direct associations of AGEs and AOPPs with
      TC/HDL-C and oxLDL/HDL-C, and AGEs-AOPPs interrelations (p<0.01) were identified 
      in IFG and T2DM groups. AGEs and AOPPs in combination with oxLDL and NOx could be
      important biomarkers for evaluating the association between diabetes and
      atherosclerotic disorders in aging diabetic patients. BIOLOGICAL SIGNIFICANCE: In
      the present study we have made an attempt to approach the biological and clinical
      significance of the oxidative and glycoxidative protein damage, in subjects with 
      prediabetes and type-2 diabetes mellitus. AGEs and AOPPs in combination with
      oxLDL and NOx appear to be important biomarkers for evaluating the association
      between diabetes and atherosclerotic disorders in aging diabetic patients. More
      importantly, this cluster of biomarkers that links the short term, "real time"
      metabolic impairment parameters (NOx, serum glucose, HOMA-IR, serum lipid
      profile) and the "metabolic memory" markers resulting from the long-term
      hyperglycemia and hyperlipidemia-induced oxidative stress (HbA1c, AGEs, AOPPs and
      oxLDL), could be valuable in predicting not only vascular complications in T2DM, 
      but also the onset of diabetes, hence enabling therapeutic interventions from the
      early stages of diabetes. This article is part of a Special Issue entitled:
      Protein Modifications.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Ana Aslan - National Institute of Gerontology and Geriatrics, Bucharest, Romania;
      Carol Davila - University of Medicine and Pharmacy, Faculty of Pharmacy,
      Department of Biochemistry, Bucharest, Romania. Electronic address:
      danielagrdnr@yahoo.com.
FAU - Gradinaru, Daniela
AU  - Gradinaru D
FAU - Borsa, Claudia
AU  - Borsa C
FAU - Ionescu, Cristina
AU  - Ionescu C
FAU - Margina, Denisa
AU  - Margina D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - J Proteomics
JT  - Journal of proteomics
JID - 101475056
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/01/06 [received]
PHST- 2013/03/03 [revised]
PHST- 2013/03/23 [accepted]
AID - S1874-3919(13)00181-4 [pii]
AID - 10.1016/j.jprot.2013.03.034 [doi]
PST - aheadofprint
SO  - J Proteomics. 2013 Apr 13. pii: S1874-3919(13)00181-4. doi:
      10.1016/j.jprot.2013.03.034.

PMID- 23587640
OWN - NLM
STAT- MEDLINE
DA  - 20130416
DCOM- 20130607
IS  - 1756-1833 (Electronic)
IS  - 0959-535X (Linking)
VI  - 346
DP  - 2013
TI  - Personalised care for patients with type 2 diabetes reduces complications, study 
      finds.
PG  - f2393
LID - 10.1136/bmj.f2393 [doi]
LID - bmj.f2393 [pii]
FAU - Anekwe, Lilian
AU  - Anekwe L
LA  - eng
PT  - News
DEP - 20130415
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
SB  - AIM
SB  - IM
MH  - Combined Modality Therapy
MH  - Denmark
MH  - Diabetes Complications/*prevention & control
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology/psychology/therapy
MH  - Humans
MH  - Outcome and Process Assessment (Health Care)
MH  - Patient Care Planning/*organization & administration
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Risk Reduction Behavior
EDAT- 2013/04/17 06:00
MHDA- 2013/06/08 06:00
CRDT- 2013/04/17 06:00
PST - epublish
SO  - BMJ. 2013 Apr 15;346:f2393. doi: 10.1136/bmj.f2393.

PMID- 23587596
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 1950-6112 (Electronic)
IS  - 0003-3898 (Linking)
VI  - 71
IP  - 2
DP  - 2013 Mar-Apr
TI  - [Congenital nephrogenic diabetes insipidus: about a case report].
PG  - 241-5
LID - 10.1684/abc.2013.0794 [doi]
AB  - Congenital nephrogenic diabetes insipidus is a rare, hereditary in nature,
      characterized by an inability of the kidney to concentrate urine, secondary to
      the manifold resistance to the action of vasopressin. X-linked forms of
      transmission (90%) are expressed in boys, from the neonatal period in general, by
      polyuria and polydipsia. Symptomatology in transmissive girls is variable but can
      sometimes be quite marked. These forms are secondary to mutations in the gene
      encoding the vasopressin V2 receptor, located at position Xq28, responsible for a
      loss of function of this receptor. Some of these mutations may cause a partial
      phenotype, less severe. Forms of autosomal, recessive or dominant are more rare
      (10%). Treatment is symptomatic, sometimes difficult in infants. It aims to avoid
      episodes of dehydration. It is based on a conventional diet hypo-osmotic and
      administration of hydrochlorothiazide and indomethacin. We report here the case
      of a child with congenital nephrogenic diabetes insipidus hospitalized at
      Children's Hospital of Rabat and throughout this case we review the
      pathophysiology and clinical and biological characteristics of the disease and
      including importance of contribution of clinical biochemistry laboratory in the
      diagnosis and monitoring of this disease.
AD  - Laboratoire central de biochimie, Hopital Ibn Sina, Rabat, Morocco.
FAU - Esselmani, Hicham
AU  - Esselmani H
FAU - Yassine, Asmaa
AU  - Yassine A
FAU - Bouabdellah, Mounya
AU  - Bouabdellah M
FAU - Benchekroun, Laila
AU  - Benchekroun L
FAU - Handor, Najat
AU  - Handor N
FAU - Elalami, Sanae
AU  - Elalami S
FAU - Chabraoui, Layachi
AU  - Chabraoui L
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Diabete insipide nephrogenique congenital : a propos d'une observation.
PL  - France
TA  - Ann Biol Clin (Paris)
JT  - Annales de biologie clinique
JID - 2984690R
SB  - IM
OTO - NOTNLM
OT  - children
OT  - congenital
OT  - nephrogenic diabetes insipidus
OT  - osmolarity
OT  - receiver V2
OT  - vasopressin
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - abc.2013.0794 [pii]
AID - 10.1684/abc.2013.0794 [doi]
PST - ppublish
SO  - Ann Biol Clin (Paris). 2013 Mar-Apr;71(2):241-5. doi: 10.1684/abc.2013.0794.

PMID- 23587481
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Beta-cell function and insulin sensitivity at various degrees of glucose
      tolerance in Chinese subjects.
PG  - 391-7
LID - 10.1016/j.diabres.2013.03.022 [doi]
LID - S0168-8227(13)00103-4 [pii]
AB  - AIMS: The aim of this study was to evaluate the relative importance of insulin
      sensitivity (SI), and the first (1st ISEC) and second phase insulin secretion
      (2nd ISEC) in the development of type 2 diabetes (T2D) in Chinese subjects.
      METHODS: A total of 96 subjects, including 19 with normal fasting glucose, 21
      with pre-diabetes, and 56 with T2D were enrolled. Subjects underwent a modified
      low dose graded glucose infusion (M-LDGGI; a simplified version of Polonsky's
      method) and frequently sampled intravenous glucose tolerance test. The results
      were interpreted as the slope of the changes of plasma insulin against the
      glucose levels. By observing the respective percentage reduction, the
      deterioration rate of each parameter was compared. RESULTS: As fasting plasma
      glucose (FPG) levels increased, SI decreased mildly and non-significantly, while 
      the 1st and 2nd ISECs decreased more dramatically and significantly. More
      importantly, the decrease of the 1st ISEC from baseline was greater than that of 
      the 2nd ISEC. CONCLUSIONS: Since the 1st ISEC decreased the most with increasing 
      FPG levels, it is concluded that the 1st ISEC is the key trigger of T2D
      development. On the contrary, the 2nd ISEC remained more stable across increasing
      FPG levels. This latter finding may explain the effectiveness of insulin
      secretagogues during the early stage of T2D. The results of this study can be
      helpful in the development of interventions aimed at stopping the progression
      and/or treating T2D in Chinese populations.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Shuang
      Ho Hospital, School of Medicine, College of Medicine, Taipei Medical University, 
      Taiwan, ROC.
FAU - Lin, Jiunn-Diann
AU  - Lin JD
FAU - Chen, Yen-Lin
AU  - Chen YL
FAU - Hsu, Chun-Hsien
AU  - Hsu CH
FAU - Wu, Chung-Ze
AU  - Wu CZ
FAU - Hsieh, An-Tsz
AU  - Hsieh AT
FAU - Hsieh, Chang-Hsun
AU  - Hsieh CH
FAU - Chang, Jin-Biou
AU  - Chang JB
FAU - Liang, Yao-Jen
AU  - Liang YJ
FAU - Pei, Dee
AU  - Pei D
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/08/06 [received]
PHST- 2012/12/19 [revised]
PHST- 2013/03/14 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - S0168-8227(13)00103-4 [pii]
AID - 10.1016/j.diabres.2013.03.022 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):391-7. doi:
      10.1016/j.diabres.2013.03.022. Epub 2013 Apr 13.

PMID- 23587399
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 Apr 12
TI  - Hysterectomy in young women associates with higher risk of stroke: A nationwide
      cohort study.
LID - S0167-5273(13)00461-0 [pii]
LID - 10.1016/j.ijcard.2013.03.042 [doi]
AB  - BACKGROUND AND PURPOSE: Hysterectomy is a common procedure for treatment of
      numerous gynecologic diseases. However, reduction of endogenous sex hormone
      levels has been reported in hysterectomized women, and the association of
      hysterectomy with the cardiovascular risk remains controversial. We aimed to
      investigate the influence of hysterectomy on the risk of stroke and coronary
      heart disease, with adjustment for traditional risk factors. METHODS: A
      nationwide population-based study was conducted using the Taiwan National Health 
      Insurance database from 1million sampling cohort data set. A total of 7605 women 
      who underwent hysterectomy without simultaneous oophorectomy from 1997 to 2009
      were identified. The control group consisted of 30,420 women without
      hysterectomy, selected by matching the age, hypertension, diabetes, dyslipidemia,
      and the commencement date of follow-up. RESULTS: A total of 558 strokes and 599
      coronary heart diseases (CHD) developed during a median 7.24years follow-up. The 
      difference was not significant between women with and without hysterectomy for
      stroke (2.34 vs. 2.08 per 1000 person-year, p=0.26) and CHD (2.39 vs. 2.26,
      p=0.53). However, of the women who underwent hysterectomy before 45years, the
      hazard ratio of hysterectomy was 2.29 (95% CI, 1.52-3.44) for stroke and 1.14
      (95% CI, 0.71-1.83) for CHD. CONCLUSIONS: Categorized by the patients' age at
      operation, the associations between hysterectomy and the risk of stroke were
      different. The excess risk of stroke was observed in women who had hysterectomy
      before 45years and remained significant even after accounting for baseline
      cardiovascular risk factors.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Cardiology Division, Internal Medicine Department, Taipei Medical University
      Wan-Fang Hospital, Taipei, Taiwan; Department of Medicine, Taipei Medical
      University, Taipei, Taiwan.
FAU - Yeh, Jong Shiuan
AU  - Yeh JS
FAU - Cheng, Hao-Min
AU  - Cheng HM
FAU - Hsu, Pai-Feng
AU  - Hsu PF
FAU - Sung, Shih-Hsien
AU  - Sung SH
FAU - Liu, Wen-Ling
AU  - Liu WL
FAU - Fang, Hsin-Ling
AU  - Fang HL
FAU - Chuang, Shao-Yuan
AU  - Chuang SY
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/04/16 [received]
PHST- 2013/01/01 [revised]
PHST- 2013/03/17 [accepted]
AID - S0167-5273(13)00461-0 [pii]
AID - 10.1016/j.ijcard.2013.03.042 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 Apr 12. pii: S0167-5273(13)00461-0. doi:
      10.1016/j.ijcard.2013.03.042.

PMID- 23587364
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1471-244X (Electronic)
IS  - 1471-244X (Linking)
VI  - 13
DP  - 2013
TI  - A randomised, controlled trial of a dietary intervention for adults with major
      depression (the "SMILES" trial): study protocol.
PG  - 114
LID - 10.1186/1471-244X-13-114 [doi]
AB  - BACKGROUND: Despite increased investment in its recognition and treatment,
      depression remains a substantial health and economic burden worldwide. Current
      treatment strategies generally focus on biological and psychological pathways,
      largely neglecting the role of lifestyle. There is emerging evidence to suggest
      that diet and nutrition play an important role in the risk, and the genesis, of
      depression. However, there are limited data regarding the therapeutic impact of
      dietary changes on existing mental illness. Using a randomised controlled trial
      design, we aim to investigate the efficacy and cost-efficacy of a dietary program
      for the treatment of Major Depressive Episodes (MDE). METHODS/DESIGN: One hundred
      and seventy six eligible participants suffering from current MDE are being
      randomised into a dietary intervention group or a social support group.
      Depression status is assessed using the Montgomery-Asberg Depression Rating Scale
      (MADRS) and Structured Clinical Interview for Diagnostic and Statistical Manual
      of Mental Disorders (Non Patient Edition) (SCID-I/NP). The intervention consists 
      of 7 individual nutrition consulting sessions (of approximately 60 minutes),
      delivered by an Accredited Practising Dietitian (APD). Sessions commence within
      one week of baseline assessment. The intervention focuses on advocating a healthy
      diet based on the Australian Dietary Guidelines and the Dietary Guidelines for
      Adults in Greece. The control condition comprises a befriending protocol using
      the same visit schedule and length as the diet intervention. The study is being
      conducted at two locations in Victoria, Australia (a metropolitan and regional
      centre). Data collection occurs at baseline (pre-intervention), 3-months
      (post-intervention) and 6- months. The primary endpoint is MADRS scores at 3
      months. A cost consequences analysis will determine the economic value of the
      intervention. DISCUSSION: If efficacious, this program could provide an
      alternative or adjunct treatment strategy for the management of this highly
      prevalent mental disorder; the benefits of which could extend to the management
      of common co-morbidities including cardiovascular disease (CVD), obesity, and
      type 2 diabetes. TRIAL REGISTRATION: Australia and New Zealand Clinical Trials
      Register (ANZCTR): ACTRN12612000251820.
AD  - IMPACT Strategic Research Centre, Deakin University, Deakin, VIC, Australia.
      AONEIL@barwonhealth.org.au
FAU - O'Neil, Adrienne
AU  - O'Neil A
FAU - Berk, Michael
AU  - Berk M
FAU - Itsiopoulos, Catherine
AU  - Itsiopoulos C
FAU - Castle, David
AU  - Castle D
FAU - Opie, Rachelle
AU  - Opie R
FAU - Pizzinga, Josephine
AU  - Pizzinga J
FAU - Brazionis, Laima
AU  - Brazionis L
FAU - Hodge, Allison
AU  - Hodge A
FAU - Mihalopoulos, Cathrine
AU  - Mihalopoulos C
FAU - Chatterton, Mary Lou
AU  - Chatterton ML
FAU - Dean, Olivia M
AU  - Dean OM
FAU - Jacka, Felice N
AU  - Jacka FN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130415
PL  - England
TA  - BMC Psychiatry
JT  - BMC psychiatry
JID - 100968559
SB  - IM
PMC - PMC3636120
OID - NLM: PMC3636120
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/07 [received]
PHST- 2013/04/09 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - 1471-244X-13-114 [pii]
AID - 10.1186/1471-244X-13-114 [doi]
PST - epublish
SO  - BMC Psychiatry. 2013 Apr 15;13:114. doi: 10.1186/1471-244X-13-114.

PMID- 23587351
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 0003-4266 (Print)
IS  - 0003-4266 (Linking)
VI  - 74
IP  - 2
DP  - 2013 May
TI  - [New perspectives for metformin in cancer therapy].
PG  - 130-6
LID - 10.1016/j.ando.2013.02.002 [doi]
LID - S0003-4266(13)00020-6 [pii]
AB  - Cancer and type II diabetes are two diseases that appear to be associated. In
      fact, diabetes increases the incidence of several cancers (colon, endometrium,
      rectum and breast). Retrospective epidemiological studies show that metformin, a 
      drug commonly used in type II diabetes, has antitumor properties. Therefore, many
      experimental studies (in vivo and in vitro) have been initiated in recent years
      to understand the cellular and molecular mechanisms that may explain the
      protective effects of metformin against cancer. Two main mode of action have been
      proposed. The first, indirect, involves the decrease of insulinemia. The second, 
      via a direct action on cells, results in the regulation of the activated AMPK
      kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway, which plays a central
      role in many cellular processes such as energy metabolism, protein synthesis,
      autophagy and apoptosis. Here, we review recent results concerning the antitumor 
      action of metformin: epidemiological, metabolic, cellular and molecular levels.
      Ongoing experimental and clinical trials should help us better understand the
      mechanisms of action of metformin and allow us to determine whether the drug can 
      be used in the treatment of cancer.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Inserm U1065, centre mediterraneen de medecine moleculaire, equipe <<
      physiopathologie cellulaire et moleculaire de l'obesite et du diabete >>, 06204
      Nice, France; Faculte de medecine, IFR50, universite de Nice-Sophia-Antipolis,
      06000 Nice, France.
FAU - Loubiere, Camille
AU  - Loubiere C
FAU - Dirat, Beatrice
AU  - Dirat B
FAU - Tanti, Jean-Francois
AU  - Tanti JF
FAU - Bost, Frederic
AU  - Bost F
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Metformine et cancer : de nouvelles perspectives pour un ancien medicament.
DEP - 20130412
PL  - France
TA  - Ann Endocrinol (Paris)
JT  - Annales d'endocrinologie
JID - 0116744
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/12 [aheadofprint]
AID - S0003-4266(13)00020-6 [pii]
AID - 10.1016/j.ando.2013.02.002 [doi]
PST - ppublish
SO  - Ann Endocrinol (Paris). 2013 May;74(2):130-6. doi: 10.1016/j.ando.2013.02.002.
      Epub 2013 Apr 12.

PMID- 23587308
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 13
DP  - 2013
TI  - Healthcare cost of type 1 diabetes mellitus in new-onset children in a hospital
      compared to an outpatient setting.
PG  - 55
LID - 10.1186/1471-2431-13-55 [doi]
AB  - BACKGROUND: Type 1 diabetes is among the most prevalent chronic childhood
      diseases in the US. Initial type 1 diabetes management education and care can
      take place in different clinical settings. This study assessed metabolic outcomes
      (i.e. hemoglobin A1C), healthcare utilization and costs among new-onset type 1
      diabetic children who received initial diabetes education and care in a hospital 
      compared to those children in an outpatient pediatric endocrinology clinic.
      METHODS: A retrospective cross-sectional study was conducted from the payer's
      perspective. New-onset type 1 diabetic children, aged 1-18, presented at Baystate
      Children's Hospital (Massachusetts) from 2008-2009 were included in the study if 
      lab test confirmed diagnosis and there was one year of follow-up. Inpatients
      spent at least one night in the hospital during a 10-day diagnosis period and
      received all or part of diabetes education there. Outpatients were diagnosed and 
      received all diabetes education in a pediatric endocrinology clinic. Metabolic
      outcomes were measured at diagnosis and at one year post-diagnosis. Healthcare
      charges and electronic medical records data were reviewed from 2008-2010.
      Healthcare costs components included diagnostic test, pediatric, endocrinology
      and hospitalists care, critical and emergency care, type 1 diabetes related
      supplies, prescription drugs, and IV products. RESULTS: Study sample included 84 
      patients (33 inpatient and 51 outpatients). No statistically significant
      differences in patient demographic characteristics were found between groups.
      There were no statistically significant differences in metabolic outcomes between
      groups. Total cost at one year post-diagnosis per new-onset type 1 diabetic child
      was $12,332 and $5,053 in the inpatient and outpatient groups, respectively. The 
      average healthcare cost for pediatric endocrinology care was $4,080 and $3,904
      per child in the inpatient and outpatient groups, respectively. CONCLUSION:
      Provision of initial type 1 diabetes education and care to new-onset
      non-critically ill children in a hospital setting increases healthcare costs
      without improving patient's glycemic control in the first year post-diagnosis.
AD  - School of Public Health and Health Sciences, University of Massachusetts,
      Amherst, 715 N. Pleasant Street, Amherst, MA 01003, USA.
FAU - Jasinski, Christopher F
AU  - Jasinski CF
FAU - Rodriguez-Monguio, Rosa
AU  - Rodriguez-Monguio R
FAU - Tonyushkina, Ksenia
AU  - Tonyushkina K
FAU - Allen, Holley
AU  - Allen H
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - England
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
SB  - IM
PMC - PMC3637533
OID - NLM: PMC3637533
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/12/11 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - 1471-2431-13-55 [pii]
AID - 10.1186/1471-2431-13-55 [doi]
PST - epublish
SO  - BMC Pediatr. 2013 Apr 15;13:55. doi: 10.1186/1471-2431-13-55.

PMID- 23587277
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Apr 12
TI  - Cardiovascular Risk Profile and Lifestyle Habits in a Cohort of Italian
      Cardiologists (from the SOCRATES Survey).
LID - S0002-9149(13)00816-3 [pii]
LID - 10.1016/j.amjcard.2013.03.020 [doi]
AB  - Cardiologists' cardiovascular profile and lifestyle habits are poorly known
      worldwide. To offer a snapshot of the personal health habits of Italian
      cardiologists, the Survey on Cardiac Risk Profile and Lifestyle Habits in a
      Cohort of Italian Cardiologists (SOCRATES) was undertaken. A Web-based electronic
      self-reported survey, accessible through a dedicated Web site, was used for data 
      entry, and data were transferred through the Web to a central database. The
      survey was divided into 4 sections: baseline characteristics, medical illnesses
      and traditional cardiovascular risk factors, lifestyle habits, and selected
      medication use. The e-mail databases of 3 national scientific societies were used
      to survey a large and representative sample of Italian cardiologists. During the 
      3-month period of the survey, 1,770 of the 5,240 cardiologists contacted (33.7%) 
      completed and returned >/=1 sections of the questionnaire. More than 49% of the
      participants had 1 of the 5 classic risk factors (hypertension,
      hypercholesterolemia, active smoking, diabetes, and previous vascular events).
      More than 28% of respondents had 2 to 5 risk factors, and only 22.1% had none and
      therefore, according to age and gender, could be considered at low to
      intermediate risk. Despite the reported risk factors, >90% of cardiologists had a
      self-reported risk perception quantified as mild, such as low or intermediate.
      Furthermore, overweight and obesity, physical inactivity, and stress at work or
      at home were commonly reported, as well as limited use of cardiovascular drugs,
      such as statins or aspirin. In conclusion, the average cardiovascular profile of 
      Italian cardiologist is unlikely to be considered ideal or even favorable
      according to recent statements and guidelines regarding cardiovascular risk.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Cardiology Division, Fondazione Salvatore Maugeri, IRCCS, Veruno, Italy.
      Electronic address: pierluigi.temporelli@fsm.it.
FAU - Temporelli, Pier Luigi
AU  - Temporelli PL
FAU - Zito, Giovanni
AU  - Zito G
FAU - Faggiano, Pompilio
AU  - Faggiano P
CN  - SOCRATES Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/02/14 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/08 [accepted]
AID - S0002-9149(13)00816-3 [pii]
AID - 10.1016/j.amjcard.2013.03.020 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Apr 12. pii: S0002-9149(13)00816-3. doi:
      10.1016/j.amjcard.2013.03.020.

PMID- 23587270
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1743-8977 (Electronic)
IS  - 1743-8977 (Linking)
VI  - 10
IP  - 1
DP  - 2013 Apr 15
TI  - Impact of experimental type 1 diabetes mellitus on systemic and coagulation
      vulnerability in mice acutely exposed to diesel exhaust particles.
PG  - 14
AB  - BACKGROUND: Epidemiological evidence indicates that diabetic patients have
      increased susceptibility to adverse cardiovascular outcomes related to acute
      increases in exposures to particulate air pollution. However, mechanisms
      underlying these effects remain unclear. METHODS: To evaluate the possible
      mechanisms underlying these actions, we assessed the systemic effects of diesel
      exhaust particles (DEP) in control mice, and mice with streptozotocin--induced
      type 1 diabetes. Four weeks following induction of diabetes, the animals were
      intratracheally instilled (i.t.) with DEP (0.4 mg/kg) or saline, and several
      cardiovascular endpoints were measured 24 h thereafter. RESULTS: DEP caused
      leucocytosis and a significant increase in plasma C-reactive protein and
      8-isoprostane concentrations in diabetic mice compared to diabetic mice exposed
      to saline or non-diabetic mice exposed to DEP. The arterial PO2 as well as the
      number of platelets and the thrombotic occlusion time in pial arterioles assessed
      in vivo were significantly decreased following the i.t. instillation of DEP in
      diabetic mice compared to diabetic mice exposed to saline or non-diabetic mice
      exposed to DEP. Both alanine aminotransferase and aspartate transaminase
      activities, as well as the plasma concentrations of plasminogen activator
      inhibitor and von Willebrand factor were significantly increased in DEP-exposed
      diabetic mice compared to diabetic mice exposed to saline or DEP-exposed
      non-diabetic mice. The in vitro addition of DEP (0.25-1 mug/ml) to untreated
      mouse blood significantly and dose-dependently induced in vitro platelet
      aggregation, and these effects were exacerbated in blood of diabetic mice.
      CONCLUSION: This study has shown that systemic and coagulation events are
      aggravated by type 1 diabetes in mice, and described the possible mechanisms for 
      these actions that may also be relevant to the exacerbation of cardiovascular
      morbidity accompanying particulate air pollution in diabetic patients.
FAU - Nemmar, Abderrahim
AU  - Nemmar A
FAU - Subramaniyan, Deepa
AU  - Subramaniyan D
FAU - Yasin, Javed
AU  - Yasin J
FAU - Ali, Badreldin H
AU  - Ali BH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Part Fibre Toxicol
JT  - Particle and fibre toxicology
JID - 101236354
PMC - PMC3641025
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/12/13 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - 1743-8977-10-14 [pii]
AID - 10.1186/1743-8977-10-14 [doi]
PST - aheadofprint
SO  - Part Fibre Toxicol. 2013 Apr 15;10(1):14.

PMID- 23587268
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 4
DP  - 2013 Apr
TI  - Cumulative burden of oral corticosteroid adverse effects and the economic
      implications of corticosteroid use in patients with systemic lupus erythematosus.
PG  - 486-97
LID - 10.1016/j.clinthera.2013.03.001 [doi]
LID - S0149-2918(13)00111-2 [pii]
AB  - BACKGROUND: Corticosteroids (CSs) are used to treat patients with systemic lupus 
      erythematosus (SLE) and are associated with potential adverse events (AEs).
      However, few data are currently available on the risk of AEs in CS users in an
      SLE population. OBJECTIVE: To examine AEs related to CS use and costs of treating
      CS-related AEs in patients with SLE. METHODS: In a retrospective cohort study
      using claims data (study period: January 1, 2000-June 30, 2010), patients aged
      >/=18 years having >/=2 SLE-related (International Classification of Diseases,
      Ninth Revision, Clinical Modification code 710.0x) outpatient or >/=1
      inpatient/emergency department claim were identified with an index diagnosis date
      deemed as the date of first SLE diagnosis. Receipt of CS therapy was assessed
      within 6 months of the index diagnosis date. Cox models were used to evaluate
      risk of AEs in CS users and nonusers. Associated costs were computed for AEs
      where risk was significantly different among the cohorts. RESULTS: Of 2717
      patients with SLE, 989 received CSs and 1728 did not. Users of CSs were ~1.5
      times more likely to develop chronic AEs (sleep disturbances, migraines,
      cataracts, hypertension, and type 2 diabetes mellitus) and ~2 times more likely
      to develop acute AEs (pneumonia, herpes zoster, fungal infections, and
      nausea/vomiting) compared with CS nonusers. The mean annual cost for managing AEs
      was $4607 and was highest for diabetes mellitus ($9764), hypertension ($8773),
      and sleep disturbances ($5599). Applying differences in 1-year event rates (CS
      user: 58.1%; CS nonuser: 75.1%) to cost estimates yielded an additional $784 per 
      year per CS user to manage known CS-related AEs compared with CS nonusers.
      CONCLUSIONS: Although CSs are prescribed to control SLE symptoms, these results
      highlight potential risks and costs associated with their use, which
      providers/payers should consider when making treatment decisions.
CI  - Copyright (c) 2013. Published by EM Inc USA.
AD  - Xcenda LLC, Palm Harbor, FL 34685, USA. manan.shah@bms.com
FAU - Shah, Manan
AU  - Shah M
FAU - Chaudhari, Sham
AU  - Chaudhari S
FAU - McLaughlin, Trent P
AU  - McLaughlin TP
FAU - Kan, Hong J
AU  - Kan HJ
FAU - Bechtel, Benno
AU  - Bechtel B
FAU - Dennis, Gregory J
AU  - Dennis GJ
FAU - Molta, Charles T
AU  - Molta CT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/12/17 [received]
PHST- 2013/02/22 [revised]
PHST- 2013/03/05 [accepted]
AID - S0149-2918(13)00111-2 [pii]
AID - 10.1016/j.clinthera.2013.03.001 [doi]
PST - ppublish
SO  - Clin Ther. 2013 Apr;35(4):486-97. doi: 10.1016/j.clinthera.2013.03.001.

PMID- 23587252
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Apr 15
TI  - Retinal upregulation of inflammatory and proangiogenic markers in a model of
      neonatal diabetic rats fed on a high-fat-diet.
PG  - 14
AB  - BACKGROUND: The contemporary peak of diabetes seems to be related to obesity,
      sedentary lifestyle and diet. Diabetic retinopathy is the most leading cause of
      blindness in adulthood in industrialized countries. Our purpose was to evaluate
      the effect of a high-fat-diet (HFD) on the retina of diabetic rats. METHODS: Two 
      groups of Wistar rats were injected with streptozotocin (STZ) two days after
      birth using 45 and 90 mg/kg, respectively. At 8 weeks the group on lower doses
      started to be fed on a HFD. Animals were sacrificed at 37 weeks of diabetes. A
      control group was made up of non-diabetic rats. Retinal flat mounts were examined
      using the trypsin digestion technique. Pericytes counts were compared between
      diabetic and control rats. Cross retinal sections were analyzed by histological
      techniques and immunohistochemistry and immunofluorescent technique. Primary
      antibodies against inflammatory and proangiogenic mediators such as RAGE, GFAP,
      5-LO, VEGF and TNF-a were used for immunohistochemistry and Western Blot (WB)
      analyses. RESULTS: In the two diabetic groups we observed GFAP-positive cells
      with a morphology and spatial organization similar to those seen in Muller cells.
      Both diabetic groups had a significantly lower number of pericytes than
      non-diabetic animals.Increased retinal immunoreactivity of GFAP, RAGE, TNF-
      inverted question mark, VEGF and 5-LO was seen in diabetic animals fed on HFD
      compared to the other groups of animals. WB analysis revealed a higher expression
      of 5-LO, VEGF, TNF- inverted question mark and RAGE in the retina of diabetic
      rats on HFD than in controls and diabetics fed on a normal diet. The percentage
      of RAGE-stained ganglion cells and ganglion cells was found to be significantly
      lower in animals on a HFD than in the other animals. CONCLUSIONS: Diabetic
      animals fed on a HFD showed an increased upregulation of inflammatory and
      proangiogenic markers. This animal model may be useful to study mechanisms of
      diabetic retinopathy and therapeutic targets.
FAU - Mancini, Jorge E
AU  - Mancini JE
FAU - Ortiz, Gustavo
AU  - Ortiz G
FAU - Croxatto, Juan Oscar
AU  - Croxatto JO
FAU - Gallo, Juan E
AU  - Gallo JE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/10/23 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - 1471-2415-13-14 [pii]
AID - 10.1186/1471-2415-13-14 [doi]
PST - aheadofprint
SO  - BMC Ophthalmol. 2013 Apr 15;13(1):14.

PMID- 23587174
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130429
DCOM- 20130430
IS  - 1478-7547 (Electronic)
IS  - 1478-7547 (Linking)
VI  - 11
IP  - 1
DP  - 2013
TI  - A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of
      generalized anxiety disorder in Portugal.
PG  - 8
LID - 10.1186/1478-7547-11-8 [doi]
AB  - BACKGROUND: Generalized anxiety disorder is characterized by excessive anxiety
      and worry about several events and activities. The estimated 1-year prevalence
      for adults is around 2% and the lifetime prevalence could reach more than 6%. The
      disease is associated with reduced quality of life, being comparable to that of
      major depressive disorder and to chronic illnesses such as diabetes and
      arthritis, and high consumption of health care resources. METHODS: A previously
      published patient-level simulation cost-utility model was adapted to the
      Portuguese context in order to evaluate clinical and economic consequences of
      using pregabalin in place of venlafaxine XR in the treatment of generalized
      anxiety disorder. The model predicts the evolution of 1,000 patients with
      generalized anxiety disorder, simulating their pathway in weekly cycles over one 
      year treatment. This is done by setting a pre-treatment Hamilton Anxiety Scale
      score and projecting the weekly impact of the pharmacotherapy on this score. The 
      model uses clinical data from an 8-week flexible dose direct comparison clinical 
      trial between the two drugs; utility values based on a Spanish study; and
      Portuguese economic data, being the resource consumption obtained via an expert
      panel. RESULTS: Pregabalin patients benefited from 0.738 quality adjusted life
      years while those on venlafaxine XR achieved 0.712. Moreover, the number of weeks
      with no or minimal anxiety symptoms was estimated to be 12.9 for pregabalin and
      only 3.8 for venlafaxine XR. Those clinical gains were achieved at the expense of
      an extra 715euro per patient, implying an incremental cost per quality adjusted
      life year of 27,199euro and an incremental cost per week with no or minimal
      symptoms of 79euro. Sensitivity analysis shows that results are robust to main
      assumptions. CONCLUSIONS: Assuming a threshold of 30,000euro per quality adjusted
      life year, pregabalin is cost-effective in comparison with venlafaxine XR in the 
      treatment of generalized anxiety disorder in Portugal.
AD  - Research Centre on the Portuguese Economy (CISEP), Instituto Superior de Economia
      e Gestao, Technical University of Lisbon, Lisbon, Portugal.
      luissm@cisep.iseg.utl.pt.
FAU - Silva Miguel, Luis
AU  - Silva Miguel L
FAU - Silva Miguel, Nuno
AU  - Silva Miguel N
FAU - Ines, Monica
AU  - Ines M
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - England
TA  - Cost Eff Resour Alloc
JT  - Cost effectiveness and resource allocation : C/E
JID - 101170476
PMC - PMC3637226
OID - NLM: PMC3637226
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:01
CRDT- 2013/04/17 06:00
PHST- 2012/03/15 [received]
PHST- 2013/03/27 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - 1478-7547-11-8 [pii]
AID - 10.1186/1478-7547-11-8 [doi]
PST - epublish
SO  - Cost Eff Resour Alloc. 2013 Apr 12;11(1):8. doi: 10.1186/1478-7547-11-8.

PMID- 23587172
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 6
IP  - 1
DP  - 2013 Apr 15
TI  - Relationship between exercise induced dyspnea and functional capacity with
      doppler-derived diastolic function'
PG  - 150
AB  - BACKGROUND: Dyspnea is the frequent cause of exercise intolerance and physical
      inactivity among patients referred for exercise tolerance test. Diastolic
      dysfunction has shown significant correlation with exercise capacity and exercise
      induced dyspnea. To find out the frequency of diastolic dysfunction (DD) and the 
      relationships between impaired exercise capacity and exercise induced dyspnea
      with DD by Doppler-derived indices among patients referred for stress test in a
      tertiary care hospital of Karachi. METHODS: For this study 135 consecutive
      patients who were referred for stress test at our non-invasive lab were screened 
      for eligibility. Patients with valvular pathology, atrial fibrillation (AF) and
      coronary artery disease (CAD) were excluded. Stress test was performed on
      treadmill using Bruce protocol. Assessment of diastolic function as determined by
      trans-mitral flow velocity pattern was carried at baseline and at peak exercise. 
      We evaluated impaired exercise capacity and exercise induced dyspnea using
      validated Borg Scale among study subjects. RESULTS: Study subjects 88% were
      males, mean age was 46 +/- 16 years, BMI 27 +/- 5 kg/m2, prevalence of diabetes
      mellitus (DM) 15%, hypertension 28% and smoking 21%. Exercise induced DD occurred
      among 44.6%. Patients with exercise induced DD had lower exercise capacity (9.2
      vs. 10.2 METS; p = 0.04) and higher Borg Scale (5.2 vs. 4.0; p < 0.001). DD at
      baseline was present in 25(26%) of patients so they were excluded from the study.
      Five patients develop ischemia during stress test so were also excluded. So final
      analysis was done on 105 patients. Among patients without DD at baseline, there
      was significant vicariate linear inverse correlation between post exercise E/A
      ratio and Borg scale (r = -0.23; p = 0.02) and exercise capacity was assessed by 
      exercise duration and MET (r-0.825; p = 0.04). Multivariate regression analysis
      revealed post exercise E/A ratio as an independent determinant of severity of
      exercise induced dyspnea and impaired exercise tolerance. CONCLUSION: DD is
      significantly associated with impaired functional capacity and dyspnea among
      patients referred for exercise tolerance test.
FAU - Nasim, Sumera
AU  - Nasim S
FAU - Nadeem, Najaf
AU  - Nadeem N
FAU - Zahidie, Aysha
AU  - Zahidie A
FAU - Sharif, Tabbasum
AU  - Sharif T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
PMC - PMC3636105
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/09/19 [received]
PHST- 2013/04/15 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - 1756-0500-6-150 [pii]
AID - 10.1186/1756-0500-6-150 [doi]
PST - aheadofprint
SO  - BMC Res Notes. 2013 Apr 15;6(1):150.

PMID- 23587153
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 0946-1965 (Print)
IS  - 0946-1965 (Linking)
DP  - 2013 Apr 16
TI  - N-acetyltransferase-2 genotypes among Jordanian patients with diabetes mellitus.
AB  - Background: There are inconsistent reports concerning N-acetyltransferase 2
      (NAT2) genotypes in diabetes mellitus (DM). Objective: The objective of the study
      was to explore any association between NAT2 genotypes and Type 1 and Type 2 DM in
      Jordanians. Methods: 106 Type 1 and 110 Type 2 DM patients attending the
      "National Center for Diabetes, Endocrinology and Genetics", Amman, Jordan, were
      included in the study. DNA was extracted from venous blood using a commercial DNA
      extraction kit. NAT2 genotyping was performed using polymerase chain
      reaction-restriction fragment length polymorphism (PCR-RFLP). Results: The
      frequency of the genotype that encodes rapid acetylation (the wild-type genotype 
      NAT2*4/4) was similar in the two types of diabetes mellitus. Those which encode
      intermediate acetylation (NAT2*4/5, NAT2*4/6, and NAT2*4/7) were higher in Type 2
      diabetes (0.482) compared to Type 1 diabetes (0.339), while the frequency of
      genotypes which encode slow acetylation (NAT2*5/5, NAT2*5/6, NAT2*5/7, NAT2*6/6, 
      NAT2*6/7, and NAT2*7/7) were higher in Type 1 diabetes (0.547) compared to Type 2
      diabetes (0.418). Conclusion: There is excess of genotypes encoding intermediate 
      acetylation in Type 2 DM and an excess of slow acetylator genotypes in Type 1 DM.
      Furthermore, NAT2*4/6 genotype (which encodes intermediate acetylation) was more 
      prevalent in Type 2 DM. Type 1 DM behaved similar to non-diabetic controls in
      regard to acetylation status.
FAU - Irshaid, Yacoub M
AU  - Irshaid YM
FAU - Abujbara, Mousa A
AU  - Abujbara MA
FAU - Ajlouni, Kamel M
AU  - Ajlouni KM
FAU - El-Khateeb, Mohammed
AU  - El-Khateeb M
FAU - Jarrar, Yazun B
AU  - Jarrar YB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Int J Clin Pharmacol Ther
JT  - International journal of clinical pharmacology and therapeutics
JID - 9423309
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/16 [accepted]
AID - 10.5414/CP201883 [doi]
AID - 10569 [pii]
PST - aheadofprint
SO  - Int J Clin Pharmacol Ther. 2013 Apr 16.

PMID- 23587134
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 6
DP  - 2013
TI  - Concordance studies between hospital discharge data and medical records for the
      recording of lower extremity amputation and diabetes in the Republic of Ireland.
PG  - 148
LID - 10.1186/1756-0500-6-148 [doi]
AB  - BACKGROUND: Hospital discharge data have been used to study trends in Lower
      Extremity Amputation (LEA) rates in people with and without diabetes. The aim of 
      this study was to assess the reliability of routine hospital discharge data in
      the Republic of Ireland (RoI) for this purpose by determining the level of
      agreement between hospital discharge data and medical records for both the
      occurrence of LEA and diagnosis of diabetes. METHODS: Two concordance studies
      between hospital discharge data (HIPE) and medical records were performed. To
      determine the level of agreement for LEA occurrence, HIPE records were compared
      to theatre logbooks in 9 hospitals utilising HIPE over a two-year period in a
      defined study area. To determine the level of agreement for diabetes diagnosis,
      HIPE records were compared to laboratory records in each of the 4 largest
      hospitals utilising HIPE over a one week period in the same study area. The
      proportions of positive and negative agreement and Cohen's kappa statistic of
      agreement were calculated. RESULTS: During a two-year study period in 9
      hospitals, 216 LEAs were recorded in both data sources. Sixteen LEAs were
      recorded in medical records alone and 25 LEAs were recorded in hospital discharge
      records alone. The proportion of positive agreement was 0.91 (95% CI 0.88-0.94), 
      the proportion of negative agreement was 0.99 (95% CI 0.98-0.99) and the kappa
      statistic was 0.91 (95% CI 0.88-0.94).During a one-week study period in 4
      hospitals, 49 patients with diabetes and 716 patients without diabetes were
      recorded in both data sources. Eighteen patients had diabetes in medical records 
      alone and 2 patients had diabetes in hospital discharge records alone. The
      proportion of positive agreement was 0.83 (95% CI 0.76-0.9), the proportion of
      negative agreement was 0.99 (95% CI 0.98-0.99) and the kappa statistic was 0.82
      (95% CI 0.75-0.89). CONCLUSIONS: This study detected high levels of agreement
      between hospital discharge data and medical records for LEA and diabetes in a
      defined study area. Based on these findings, we suggest that HIPE is sufficiently
      reliable to monitor trends in LEAs in people with and without diabetes in the
      RoI.
AD  - Department of General Practice, University College Cork, Room 2,57, Western
      Gateway Building, Cork, Ireland. Claire.buckley@ucc.ie.
FAU - Buckley, Claire M
AU  - Buckley CM
FAU - Kearney, Patricia M
AU  - Kearney PM
FAU - Ali, Fawzi
AU  - Ali F
FAU - Bhuachalla, Cliodhna Ni
AU  - Bhuachalla CN
FAU - Casey, Caoimhe
AU  - Casey C
FAU - Roberts, Graham
AU  - Roberts G
FAU - Perry, Ivan J
AU  - Perry IJ
FAU - Bradley, Colin P
AU  - Bradley CP
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
SB  - IM
PMC - PMC3640954
OID - NLM: PMC3640954
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/12/26 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - 1756-0500-6-148 [pii]
AID - 10.1186/1756-0500-6-148 [doi]
PST - epublish
SO  - BMC Res Notes. 2013 Apr 15;6:148. doi: 10.1186/1756-0500-6-148.

PMID- 23587116
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013
TI  - Effects of secondhand smoke on the birth weight of term infants and the
      demographic profile of Saudi exposed women.
PG  - 341
LID - 10.1186/1471-2458-13-341 [doi]
AB  - BACKGROUND: Maternal exposure to tobacco smoke during pregnancy is associated
      with detrimental effects on the mother and the fetus including; impaired fetal
      growth, low birth weight and preterm delivery. In utero exposure to tobacco is
      implicated in the etiology of many adults' diseases including obesity, diabetes
      and hypertension.The objectives of this study were to evaluate the effects of
      Secondhand Tobacco Smoke (SHS) exposure on newborns' anthropometric measurements 
      and to compare the demographic profile of the women exposed to SHS to those who
      were not. METHOD: This is a retrospective cohort study investigating the effects 
      of SHS during pregnancy on newborns' anthropometry. Women who self-reported SHS
      exposure were compared with those not exposed. The primary outcomes were birth
      weight, newborn length and head circumference. Univariate analysis and
      multivariate regression analysis were performed. Adjusted differences with 95%
      confidence intervals were calculated. RESULTS: Mothers exposed to SHS constituted
      31% of the cohort. The mean birth weight of infants of exposed mothers was
      significantly lower by 35 g, 95% CI: 2-68 g, (P = 0.037) and the mean length was 
      shorter by 0.261 cm, 95% CI 0.058-0.464 cm, (P = 0.012) compared to the infants
      of unexposed mothers. Women exposed to SHS, were younger, of lower parity and
      more likely to be illiterate than those who were not exposed in addition, exposed
      women were less likely to be primiparous. CONCLUSION: The prevalence of exposure 
      of Saudi pregnant women to SHS is high at 31% and it is associated with reduced
      birth weight, and shorter length of the newborn.
AD  - Sheikh Bahamdan Research Chair of Evidence-based Healthcare and Knowledge
      translation, College of Medicine, King Saud University, P,O Box 102799, Riyadh,
      11685, Kingdom of Saudi Arabia. umlena@yahoo.com.
FAU - Wahabi, Hayfaa A
AU  - Wahabi HA
FAU - Alzeidan, Rasmieh A
AU  - Alzeidan RA
FAU - Fayed, Amel A
AU  - Fayed AA
FAU - Mandil, Ahmed
AU  - Mandil A
FAU - Al-Shaikh, Ghadeer
AU  - Al-Shaikh G
FAU - Esmaeil, Samia A
AU  - Esmaeil SA
LA  - eng
PT  - Journal Article
DEP - 20130415
PL  - England
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
PMC - PMC3641009
OID - NLM: PMC3641009
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/01/07 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/04/15 [aheadofprint]
AID - 1471-2458-13-341 [pii]
AID - 10.1186/1471-2458-13-341 [doi]
PST - epublish
SO  - BMC Public Health. 2013 Apr 15;13:341. doi: 10.1186/1471-2458-13-341.

PMID- 23587090
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 1471-2393 (Electronic)
IS  - 1471-2393 (Linking)
VI  - 13
DP  - 2013
TI  - The DIAMIND study: postpartum SMS reminders to women who have had gestational
      diabetes mellitus to test for type 2 diabetes: a randomised controlled trial -
      study protocol.
PG  - 92
LID - 10.1186/1471-2393-13-92 [doi]
AB  - BACKGROUND: Postpartum follow up of women who have been found to have gestational
      diabetes during pregnancy is essential because of the strong association of
      gestational diabetes with subsequent type 2 diabetes. Postal reminders have been 
      shown to increase significantly attendance for oral glucose tolerance testing
      postpartum. It is possible that a short message service (text) reminder system
      may also be effective. This trial aims to assess whether a text message reminder 
      system for women who have experienced gestational diabetes in their index
      pregnancy will increase attendance for oral glucose tolerance testing within six 
      months after birth. METHODS/DESIGN: Design: Single centre (Women's and Children's
      Hospital, South Australia), parallel group randomised controlled trial.Inclusion 
      criteria: Women diagnosed with gestational diabetes in their index pregnancy
      (oral glucose tolerance test with fasting glucose >/= 5.5 mmol/L and/or two hour 
      glucose >/= 7.8 mmol/L), with access to a mobile phone, whose capillary blood
      glucose profile measurements prior to postnatal discharge are all normal (fasting
      glucose < 6.0 mmol/L, postprandial glucoses < 8.0 mmol/L).Exclusion criteria:
      Pregestational diabetes mellitus, triplet/higher order multiple birth or
      stillbirth in the index pregnancy, requirement for interpreter.Trial entry and
      randomisation: Allocation to intervention will be undertaken using a telephone
      randomisation service (computer-generated random number sequence generation, with
      balanced variable blocks, and stratification by insulin requirement).Study
      groups: Women in the intervention group will receive a text reminder to attend
      for an oral glucose tolerance test at 6 weeks postpartum, with further reminders 
      at 3 months and 6 months if they do not respond to indicate test completion.
      Women in the control group will receive a single text message reminder at 6
      months postpartum.Blinding: Baseline data collection will be undertaken blinded. 
      Blinding of participants and blinded collection of primary outcome data will not 
      be possible for this study.Primary study outcome: Attendance for the oral glucose
      tolerance test within 6 months postpartum.Sample size: 276 subjects will be
      required to show an 18% absolute increase in the rate of attendance (alpha=0.05
      two tailed, beta=80%, 5% loss to follow up) from 37% to 55% in the intervention
      group. DISCUSSION: Given the heightened risk of impaired glucose tolerance and
      type 2 diabetes in women who have had gestational diabetes, ensuring the highest 
      possible rate of attendance for postpartum glucose tolerance testing, so that
      early diagnosis and intervention can occur, is important. A text message reminder
      system may prove to be an effective method for achieving improved attendance for 
      such testing. This randomised controlled trial will assess whether such a system 
      will increase rates of attendance for postpartum oral glucose tolerance testing
      in women who have experienced gestational diabetes. TRIAL REGISTRATION:
      Australian New Zealand Clinical Trials Registry - ACTRN12612000621819.
AD  - Australian Research Centre for Health of Women and Babies, Robinson Institute,
      The University of Adelaide, 72 King William Road North, Adelaide, SA 5006,
      Australia. emer.heatley@adelaide.edu.au
FAU - Heatley, Emer
AU  - Heatley E
FAU - Middleton, Philippa
AU  - Middleton P
FAU - Hague, William
AU  - Hague W
FAU - Crowther, Caroline
AU  - Crowther C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130412
PL  - England
TA  - BMC Pregnancy Childbirth
JT  - BMC pregnancy and childbirth
JID - 100967799
SB  - IM
PMC - PMC3626874
OID - NLM: PMC3626874
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/03/28 [received]
PHST- 2013/04/08 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - 1471-2393-13-92 [pii]
AID - 10.1186/1471-2393-13-92 [doi]
PST - epublish
SO  - BMC Pregnancy Childbirth. 2013 Apr 12;13:92. doi: 10.1186/1471-2393-13-92.

PMID- 23587029
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - In-treatment HDL cholesterol levels and development of new diabetes mellitus in
      hypertensive patients: The LIFE Study.
LID - 10.1111/dme.12213 [doi]
AB  - AIMS: Although hypertensive patients with low baseline HDL cholesterol levels
      have a higher incidence of diabetes mellitus, whether changing levels of HDL over
      time are more strongly related to the risk of new diabetes in hypertensive
      patients has not been examined. METHODS: Incident diabetes mellitus was examined 
      in relation to baseline and in-treatment HDL levels in 7485 hypertensive patients
      with no history of diabetes randomly assigned to losartan- or atenolol-based
      treatment. RESULTS: During 4.7 +/- 1.2 years follow-up, 520 patients (6.9%)
      developed new diabetes. In univariate Cox analyses, compared with the highest
      quartile of HDL levels (> 1.78 mmol/l), baseline and in-treatment HDL in the
      lowest quartile (< 1.21 mmol/l) identified patients with > 5-fold and > 9 fold
      higher risks of new diabetes, respectively; patients with baseline or
      in-treatment HDL in the 2nd and 3rd quartiles had intermediate risk of diabetes. 
      In multivariable Cox analyses, adjusting for randomized treatment, age, sex,
      race, prior anti-hypertensive therapy, baseline uric acid, serum creatinine and
      glucose entered as standard covariates, and in-treatment non-HDL cholesterol,
      Cornell product left ventricular hypertrophy, diastolic and systolic pressure,
      BMI, hydrochlorothiazide and statin use as time-varying covariates, the lowest
      quartile of in-treatment HDL remained associated with a nearly 9-fold increased
      risk of new diabetes (hazard ratio 8.7, 95% CI 5.0-15.2), whereas the risk of new
      diabetes was significantly attenuated for baseline HDL < 1.21 mmol/l (hazard
      ratio 3.9, 95% CI 2.8-5.4). CONCLUSIONS: Lower in-treatment HDL is more strongly 
      associated with increased risk of new diabetes than baseline HDL level. (Clinical
      Trials Registry No; NCT 00338260).
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Division of Cardiology, Weill Cornell Medical College, New York, NY, USA.
FAU - Okin, P M
AU  - Okin PM
FAU - Hille, D A
AU  - Hille DA
FAU - Wiik, B P
AU  - Wiik BP
FAU - Kjeldsen, S E
AU  - Kjeldsen SE
FAU - Lindholm, L H
AU  - Lindholm LH
FAU - Dahlof, B
AU  - Dahlof B
FAU - Devereux, R B
AU  - Devereux RB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12213 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12213.

PMID- 23587021
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 1742-4658 (Electronic)
IS  - 1742-464X (Linking)
DP  - 2013 Apr 15
TI  - The tail wagging the dog - regulation of lipid metabolism by protein kinase C.
LID - 10.1111/febs.12285 [doi]
AB  - Upon their discovery almost 40 years ago, isoforms of the lipid-activated protein
      kinase C (PKC) family were initially regarded only as downstream effectors of the
      second messengers calcium and diacylglycerol, undergoing activation upon
      phospholipid hydrolysis in response to acute stimuli. Subsequently, several
      isoforms were found to be associated with the inhibitory effects of lipid
      over-supply on glucose homeostasis, especially the negative cross-talk with
      insulin signal transduction, observed upon accumulation of diacylglycerol in
      insulin target tissues. The PKC family has therefore attracted much attention in 
      diabetes and obesity research, because intracellular lipid accumulation is
      strongly correlated with defective insulin action and the development of type 2
      diabetes. Causal roles for various isoforms in the generation of insulin
      resistance have more recently been confirmed using PKC-deficient mice. However,
      during characterization of these animals, it became increasingly evident that the
      enzymes play key roles in the modulation of lipid metabolism itself, and may
      control the supply of lipids between tissues such as adipose and liver. Molecular
      studies have also demonstrated roles for PKC isoforms in several aspects of lipid
      metabolism, such as adipocyte differentiation and hepatic lipogenesis. While the 
      precise mechanisms involved, especially the identities of protein substrates, are
      still unclear, the emerging picture suggests that the currently held view of the 
      contribution of PKC isoforms to metabolism is an over-simplification. Although
      PKCs may inhibit insulin signal transduction, these enzymes are not merely
      downstream effectors of lipid accumulation, but in fact control the fate of fatty
      acids, thus the tail wags the dog.
CI  - (c) 2013 Commonwealth of Australia.
AD  - Diabetes and Obesity Program, Garvan Institute of Medical Research, Sydney, NSW, 
      Australia; St Vincent's Clinical School, Faculty of Medicine, University of New
      South Wales, Sydney, NSW, Australia.
FAU - Schmitz-Peiffer, Carsten
AU  - Schmitz-Peiffer C
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - FEBS J
JT  - The FEBS journal
JID - 101229646
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/01/27 [received]
PHST- 2013/03/19 [revised]
PHST- 2013/04/11 [accepted]
AID - 10.1111/febs.12285 [doi]
PST - aheadofprint
SO  - FEBS J. 2013 Apr 15. doi: 10.1111/febs.12285.

PMID- 23587011
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - Pesticides and human diabetes: a link worth exploring?
LID - 10.1111/dme.12212 [doi]
AB  - It is no exaggeration to claim that the 'diabetes epidemic' has become a 'runaway
      train' causing huge health and economic consequences, especially in the
      developing nations. Traditionally, the risk factors for diabetes have largely
      focused on genetics and lifestyle. Great emphasis is placed on lifestyle measures
      and finding novel pharmacological treatment options to combat diabetes, but there
      is increasing evidence linking environmental pollutants, especially pesticides,
      to the development of insulin resistance and Type 2 diabetes. Pesticide use has
      increased dramatically worldwide and the effects of pesticides on glucose
      metabolism are too significant for a possible diabetogenic link to be dismissed. 
      The aim of this review article was to assess the links between pesticides and
      human diabetes with the goal of stimulating further research in this area. This
      article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Diabetes and Endocrinology, Apollo Speciality Hospital, Madurai,
      India.
FAU - Swaminathan, K
AU  - Swaminathan K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/02/19 [received]
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12212 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12212.

PMID- 23586973
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - Investigation of known estimated glomerular filtration rate loci in patients with
      Type 2 diabetes.
LID - 10.1111/dme.12211 [doi]
AB  - AIMS: To replicate the association of genetic variants with estimated glomerular 
      filtration rate (GFR) and albuminuria, which has been found in recent genome-wide
      studies in patients with Type 2 diabetes. METHODS: We evaluated 16 candidate
      single nucleotide polymorphisms for estimated GFR in 3028 patients with Type 2
      diabetes sampled from clinics across Tayside, Scotland, UK, who were included in 
      the Genetics of Diabetes Audit and Research Tayside (GoDARTs) study. These single
      nucleotide polymorphisms were tested for their association with estimated GFR at 
      entry to the study, with albuminuria, and with time to stage 3B chronic kidney
      disease (estimated GFR<45 ml/min/1.73 m2 ). We also stratified the effects on
      estimated GFR in patients with (n = 2096) and without albuminuria (n = 613).
      RESULTS: rs1260326 in GCKR (beta=1.30, P = 3.23E-03), rs17319721 in SHROOM3 (beta
      = -1.28, P-value = 3.18E-03) and rs12917707 in UMOD (beta = 2.0, P-value =
      8.84E-04) were significantly associated with baseline estimated GFR. Analysis of 
      effects on estimated GFR, stratified by albuminuria status, showed that in those 
      without albuminuria (normoalbuminura; n = 613), UMOD had a significantly stronger
      effect on estimated GFR (betanormo = 4.03 +/- 1.23 vs betaalbuminuria = 1.72 +/- 
      0.76, P = 0.002) compared with those with albuminuria, while GCKR (betanormo =
      0.45 +/- 0.89 vs betaalbuminuria = 1.12 +/- 0.55, P = 0.08) and SHROOM3
      (betanormo = -0.07 +/- 0.89 vs betaalbuminuria = -1.43 +/- 0.53, P = 0.003) had a
      stronger effect on estimated GFR in those with albuminuria. UMOD was also
      associated with a lower rate of transition to stage 3B chronic kidney disease
      (hazard ratio = 0.83[0.70, 0.99], P = 0.03). CONCLUSION: The genetic variants
      that regulate estimated GFR in the general population tend to have similar
      effects in patients with Type 2 diabetes and in this latter population, it is
      important to adjust for albuminuria status while investigating the genetic
      determinants of renal function.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Division of Population Health Sciences, University of Dundee, Dundee, UK.
FAU - Deshmukh, H A
AU  - Deshmukh HA
FAU - Palmer, C N A
AU  - Palmer CN
FAU - Morris, A D
AU  - Morris AD
FAU - Colhoun, H M
AU  - Colhoun HM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12211 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12211.

PMID- 23586940
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1939-0599 (Electronic)
IS  - 0012-1649 (Linking)
DP  - 2013 Apr 15
TI  - Intraindividual Variability Is a Fundamental Phenomenon of Aging: Evidence From
      an 8-Year Longitudinal Study Across Young, Middle, and Older Adulthood.
AB  - Moment-to-moment intraindividual variability (IIV) in cognitive speed is a
      sensitive behavioral indicator of the integrity of the aging brain and brain
      damage, but little information is known about how IIV changes from being
      relatively low in young adulthood to substantially higher in older adulthood. We 
      evaluated possible age group, sex, and task differences in IIV across adulthood
      using a large, neurologically normal, population-based sample evaluated thrice
      over 8 years. Multilevel modeling controlling for education, diabetes,
      hypertension, and anxiety and depressive symptoms showed expected age group
      differences in baseline IIV across the adult lifespan. Increase in IIV was not
      found until older adulthood on simple tasks but was apparent even in the 40s on a
      more complex task. Females were more variable than males but only at baseline.
      IIV in cognitive speed is a fundamental behavioral characteristic associated with
      growing older, even among healthy adults. (PsycINFO Database Record (c) 2013 APA,
      all rights reserved).
FAU - Bielak, Allison A M
AU  - Bielak AA
FAU - Cherbuin, Nicolas
AU  - Cherbuin N
FAU - Bunce, David
AU  - Bunce D
FAU - Anstey, Kaarin J
AU  - Anstey KJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Dev Psychol
JT  - Developmental psychology
JID - 0260564
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - 2013-13274-001 [pii]
AID - 10.1037/a0032650 [doi]
PST - aheadofprint
SO  - Dev Psychol. 2013 Apr 15.

PMID- 23586928
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - Atypical phenotype associated with reported GCK exon 10 deletions: clinical
      judgement is needed alongside appropriate genetic investigations.
LID - 10.1111/dme.12210 [doi]
AB  - BACKGROUND: Maturity-onset diabetes of the young (MODY) caused by heterozygous
      mutations in the glucokinase (GCK) gene typically presents with lifelong, stable,
      mild fasting hyperglycaemia. With the exception of pregnancy, patients with
      GCK-MODY usually do not require pharmacological therapy. We report two unrelated 
      patients whose initial genetic test results indicated a deletion of GCK exon 10, 
      but whose clinical phenotypes were not typical of GCK-MODY. CASE REPORTS: In case
      1, the patient was hyperglycaemic at diagnosis (glucose > 30 mmol/l) and elevated
      glucose levels > 10 mmol/l persisted after withdrawal of insulin therapy. The
      patient in case 2 was also hyperglycaemic at diagnosis [HbA1c > 86 mmol/mol
      (10%)], which improved with the introduction of oral hypoglycaemic agents. These 
      clinical features were not consistent with GCK-MODY. Both patients had a single
      nucleotide variant that prevented multiplex ligation-dependent probe analysis,
      which generated a false positive result of a GCK exon 10 deletion. CONCLUSION:
      False positive genetic results in these two unrelated cases were attributable to 
      the presence of a rare single nucleotide variant that prevented ligation of the
      probe in the multiplex ligation-dependent probe analysis kit used and falsely
      indicated deletion of exon 10 within GCK. Both cases had clinical features that
      did not tally with the typical GCK-MODY phenotype. These cases emphasize the need
      to interpret the results of definitive genetic tests within the specific clinical
      context. Increased medical sequencing is likely to lead to more reports of novel 
      mutations of uncertain significance. If genetic investigations do not agree with 
      the clinical picture, clinicians should exercise caution when making therapeutic 
      changes based on these results. This article is protected by copyright. All
      rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of
      Oxford, University of Exeter Medical School, Exeter, UK; Oxford NIHR Biomedical
      Research Centre, Churchill Hospital, University of Exeter Medical School, Exeter,
      UK.
FAU - Thanabalasingham, G
AU  - Thanabalasingham G
FAU - Kaur, K
AU  - Kaur K
FAU - Talbot, F
AU  - Talbot F
FAU - Colclough, K
AU  - Colclough K
FAU - Mathews, A
AU  - Mathews A
FAU - Taylor, J
AU  - Taylor J
FAU - Ellard, S
AU  - Ellard S
FAU - Owen, K R
AU  - Owen KR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/11/28 [received]
PHST- 2013/02/14 [revised]
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12210 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12210.

PMID- 23586900
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - Enhanced carbohydrate craving in patients with poorly controlled Type 2 diabetes 
      mellitus.
LID - 10.1111/dme.12209 [doi]
AB  - AIMS: Although hyperphagia is a common manifestation of diabetes mellitus, data
      on food craving in patients with diabetes are limited. This study compared food
      craving in patients with Type 2 diabetes mellitus and a control group without
      diabetes. METHODS: A total of 210 subjects (105 with Type 2 diabetes and 105
      age-, sex- and BMI-matched control subjects) participated in two food craving
      surveys. The surveys were as follows: the General Food Cravings
      Questionnaire-Trait, which assesses the general trait of food craving; and the
      Food Cravings Questionnaire-State, which assesses the state of food craving or
      current desire for high-carbohydrate or high-fat foods in response to pictures of
      food. Follow-up Food Cravings Questionnaire-State surveys were administered
      approximately 3 months later to the subjects with diabetes. Survey results were
      analysed to assess relationships between food craving and glycaemic control.
      RESULTS: The General Food Cravings Questionnaire-Trait scores in the group with
      Type 2 diabetes and the control group were not significantly different. The group
      with Type 2 diabetes had higher carbohydrate craving scores, but lower fat
      craving scores, than the control group. Carbohydrate craving scores in subjects
      with diabetes were positively correlated with HbA1c. In follow-up surveys,
      carbohydrate craving scores declined in patients with improved glycaemic control.
      CONCLUSIONS: The surveys showed that patients with Type 2 diabetes had higher
      carbohydrate cravings and lower fat cravings than the age-, sex- and BMI-matched 
      control group. Carbohydrate craving in patients with diabetes was associated with
      poor glycaemic control.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine,
      University of Ulsan College of Medicine, Seoul, Korea; Diabetes Center, Seoul,
      Korea.
FAU - Yu, J H
AU  - Yu JH
FAU - Shin, M S
AU  - Shin MS
FAU - Kim, D J
AU  - Kim DJ
FAU - Lee, J R
AU  - Lee JR
FAU - Yoon, S-Y
AU  - Yoon SY
FAU - Kim, S G
AU  - Kim SG
FAU - Koh, E H
AU  - Koh EH
FAU - Lee, W J
AU  - Lee WJ
FAU - Park, J-Y
AU  - Park JY
FAU - Kim, M-S
AU  - Kim MS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12209 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12209.

PMID- 23586854
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - A rightward shift of the distribution of fasting and post-load glucose in
      northern Sweden between 1990 and 2009 and its predictors. Data from the Northern 
      Sweden MONICA study.
LID - 10.1111/dme.12208 [doi]
AB  - AIMS: Most Swedish studies show stable diabetes prevalence despite increasing
      obesity, but glucose levels may shift upwards below the diagnostic threshold for 
      diabetes. Our aim was to explore trends in glucose distribution in northern
      Sweden; whether these trends were uniformly distributed throughout the spectrum
      of glucose concentrations; and to relate trends to traditional risk factors and
      the obesity-related adipokine leptin. METHODS: The project consisted of four
      cross-sectional surveys between 1990 and 2009, with 7069 participants aged 25-64 
      years. The overall participation rate was 74.4%. Trend analyses of glucose
      concentrations along the entire distribution and linear regression in relation to
      survey years and risk markers were used. RESULTS: Fasting and post-load glucose
      increased in women (both P < 0.001) and post-load glucose in men (P = 0.004). The
      increase was seen in most deciles of glucose concentrations. The prevalence of
      impaired glucose tolerance doubled in women to 14.5% and tripled in men to 10.1% 
      (both P = 0.004). The prevalence of impaired fasting glucose rose in women from
      4.5 to 7.7% (P < 0.001). The prevalence of diabetes was unchanged-6.4% in 2009.
      In men, leptin, together with traditional risk factors, explained 7.8 and 10.8%
      of the variance in fasting (P = 0.008) and post-load (P < 0.001) glucose,
      respectively. CONCLUSIONS: Increasing fasting and post-load glucose
      concentrations were seen in most deciles of the glucose distribution, indicating 
      a shift in the entire population. Leptin was significantly associated with
      fasting and post-load glucose in men.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Department of Public Health and Clinical Medicine, Family Medicine, Umea
      University, Umea, Sweden.
FAU - Lilja, M
AU  - Lilja M
FAU - Eliasson, M
AU  - Eliasson M
FAU - Eriksson, M
AU  - Eriksson M
FAU - Soderberg, S
AU  - Soderberg S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12208 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12208.

PMID- 23586846
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 Apr 16
TI  - Meta-analysis of insulin aspart versus regular human insulin used in a
      basal-bolus regimen for the treatment of diabetes mellitus.
LID - 10.1111/1753-0407.12060 [doi]
AB  - OBJECTIVE: To compare the efficacy of two different insulin formulations, insulin
      aspart (IAsp) and regular human insulin (RHI), for prandial insulin coverage with
      neutral protamine Hagedorn (NPH) insulin as basal insulin using a meta-analysis
      approach. The primary endpoint was change in A1c over time Secondary endpoints
      included incidence of hypoglycemia and postprandial glycemic control. METHODS:
      Clinical trials (Type 1 and Type 2 diabetes) complying with Good Clinical
      Practice, and with individual patient data, were included in the meta-analysis.
      Trials were randomized, consisted of (at least) two treatment arms and had a
      minimum duration of 12 weeks. Estimates were calculated using fixed-effects and
      random-effects models. Heterogeneity was assessed for each analysis. The effect
      of baseline parameters on A1c was analyzed in extended simultaneous models.
      RESULTS: The mean difference in A1c was 0.1% (95% CI [-0.15; -0.04], P < 0.001)
      in favor of IAsp. Higher accumulated dose of IAsp, higher age and increased rates
      of hypoglycemia were associated with improved A1c outcome. Fasting plasma glucose
      was not significantly different between regimens. Postprandial glucose was
      significantly lower after treatment with IAsp compared with RHI, but the analysis
      did present a significant level of heterogeneity (P < 0.001). The overall rate of
      hypoglycemia was the same with both regimens, but nocturnal hypoglycemia was
      significantly lower with IAsp. CONCLUSIONS: A basal-bolus regimen with IAsp as
      bolus insulin provided minimal, but statistically significant, improvement in
      overall glycemic control with a lower rate of nocturnal hypoglycemic episodes,
      compared with a corresponding regimen with bolus RHI.
CI  - This article is protected by copyright. All rights reserved.
AD  - School of Medicine and Biochemical Sciences, Sheffield, UK.
FAU - Heller, Simon
AU  - Heller S
FAU - Bode, Bruce
AU  - Bode B
FAU - Kozlovski, Plamen
AU  - Kozlovski P
FAU - Svendsen, Anne Louise
AU  - Svendsen AL
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/11 [accepted]
AID - 10.1111/1753-0407.12060 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 Apr 16. doi: 10.1111/1753-0407.12060.

PMID- 23586806
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 Apr 16
TI  - Anti-inflammatory effects of simvastatin in diabetic compared to non-diabetic
      patients on chronic hemodialysis.
LID - 10.1111/1753-0407.12059 [doi]
AB  - Statins, beyond their lipid lowering effects, exert their cardiovascular effects 
      through their pleiotropic actions.1 We undertook this study to determine the
      potential differences in intensity and timing of the anti-inflammatory effects of
      statins between patients with and without diabetes mellitus (DM) so as to detect 
      the particular traits associated with cardiovascular risk as well as benefits
      from statins in patients with DM, a known state of chronic inflammation and high 
      oxidative stress and an independent risk factor for CVD.2 Both patient groups
      were recruited amongst patients with end-stage renal disease (ESRD) on chronic
      hemodialysis (HD), a subpopulation already at chronic inflammation and oxidative 
      stress and, thus, undergoing accelerated atherogenetic process,3 in anticipation 
      that these patients are more amenable to measurable short-term effects from the
      treatment.
CI  - This article is protected by copyright. All rights reserved.
AD  - Department of Nephrology, Aristotle University, Laboratory of Biochemistry,
      Thessaloniki, Greece.
FAU - Kirmizis, Dimitrios
AU  - Kirmizis D
FAU - Papagianni, Aikaterini
AU  - Papagianni A
FAU - Dogrammatzi, Fani
AU  - Dogrammatzi F
FAU - Efstratiadis, Georgios
AU  - Efstratiadis G
FAU - Memmos, Dimitrios
AU  - Memmos D
LA  - ENG
PT  - LETTER
DEP - 20130416
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/11 [accepted]
AID - 10.1111/1753-0407.12059 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 Apr 16. doi: 10.1111/1753-0407.12059.

PMID- 23586796
OWN - NLM
STAT- In-Data-Review
DA  - 20130611
IS  - 1540-8183 (Electronic)
IS  - 0896-4327 (Linking)
VI  - 26
IP  - 3
DP  - 2013 Jun
TI  - Long-term clinical follow-up after drug-eluting stent implantation for bare metal
      in-stent restenosis.
PG  - 271-7
LID - 10.1111/joic.12027 [doi]
AB  - OBJECTIVES: We aimed to evaluate the long-term safety and efficacy of
      drug-eluting stent (DES) implantation in the treatment of diffuse bare metal
      stent (BMS) restenosis as compared to the treatment of de novo coronary lesions
      in high restenosis risk patient population. BACKGROUND: To date limited long-term
      data are available about the treatment of BMS restenosis with DES. METHODS: Five 
      hundred and fourteen consecutive patients who underwent DES implantation between 
      January 2003 and October 2006 at our institute were studied: 201 patients
      received DES for treatment of BMS restenosis and 313 patients received DES for
      high restenosis risk de novo lesions. Outcomes were calculated using propensity
      score adjustment. Mean follow-up length was 45.6 +/- 21.5 months. RESULTS: The
      rates of acute coronary syndrome, three-vessel disease, and diabetes were high in
      both restenosis and de novo groups: 44.8% versus 46.3%, 20.9% versus 28.7%, and
      34.3% versus 38.9%, respectively. The incidence of ischemia-driven target lesion 
      revascularization (TLR) yielded similar results in the restenosis group and de
      novo group at 4 years (10.4% vs 12.4%, P = 0.490). All-cause mortality was lower 
      in the restenosis group at 4 years (7.4% vs 14.7%, P = 0.032); however, the
      incidence of definite and probable stent thrombosis did not differ (1.9% vs 1.6%,
      P = 0.708) between the 2 groups. CONCLUSIONS: DESs are safe in the treatment of
      diffuse BMS restenosis and the rate of additional TLR is acceptable as compared
      to the use of DES in de novo lesions. (J Interven Cardiol 2013;26:271-277).
CI  - Copyright (c) 2013, Wiley Periodicals, Inc.
AD  - Semmelweis University, Heart Center, Budapest, Hungary.
FAU - Berta, Balazs
AU  - Berta B
FAU - Ruzsa, Zoltan
AU  - Ruzsa Z
FAU - Barczi, Gyorgy
AU  - Barczi G
FAU - Becker, David
AU  - Becker D
FAU - Geller, Laszlo
AU  - Geller L
FAU - Jambrik, Zoltan
AU  - Jambrik Z
FAU - Molnar, Levente
AU  - Molnar L
FAU - Szabo, Gyorgy
AU  - Szabo G
FAU - Merkely, Bela
AU  - Merkely B
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - United States
TA  - J Interv Cardiol
JT  - Journal of interventional cardiology
JID - 8907826
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/16 [aheadofprint]
AID - 10.1111/joic.12027 [doi]
PST - ppublish
SO  - J Interv Cardiol. 2013 Jun;26(3):271-7. doi: 10.1111/joic.12027. Epub 2013 Apr
      16.

PMID- 23586795
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 43
IP  - 6
DP  - 2013 Jun
TI  - Screening for obstructive sleep apnoea in obesity and diabetes - potential for
      future approaches.
PG  - 640-55
LID - 10.1111/eci.12083 [doi]
AB  - BACKGROUND: It is recognised that sleep-disordered breathing (SDB), in
      particular, obstructive sleep apnoea (OSA) is associated with obesity and
      diabetes. The complications of OSA include dysregulation of metabolic and
      cardiovascular homeostasis. With the growing population of diabetes and obesity
      globally, it is becoming apparent that identifying and screening patients who are
      at risk is becoming increasingly crucial. Many patients may remain unaware of the
      potential diagnosis and continue to be undiagnosed. The high prevalence of OSA
      poses a demanding challenge to healthcare providers in order to provide
      sufficient resources and facilities for patient diagnosis and treatment. DESIGN: 
      In this article, we review the evidence in favour of screening populations deemed
      to be at increased risk of OSA, with particular reference to patients with
      obesity and diabetes. We consider the recent advances in potential screening
      methods that may allow new prognostic and predictive tools to be developed. A
      detailed search of Medline and Web of Science electronic databases for relevant
      articles in English was performed. RESULTS: Apart from the use of screening tools
      such as questionnaires and clinical decision models, there is increasing evidence
      to suggest that there are differences in biological parameters in patients with
      OSA. Although further studies are required, there may be potential for such
      biomarkers to contribute to and augment the screening process. However, the
      significance of such biological tools remains to be elucidated. CONCLUSIONS: A
      fundamental role for improved screening in patients with conditions such as
      obesity and diabetes can enable early interventions that may improve health
      outcomes relating to the adverse consequences of OSA. The future will see further
      research being carried out in the development of potential screening methods with
      emphasis on the selection of patients at risk of sleep disorders, thereby
      allowing more detailed physiological studies to be carried out where needed.
CI  - (c) 2013 Stichting European Society for Clinical Investigation Journal
      Foundation. Published by John Wiley & Sons Ltd.
AD  - Department of Obesity & Endocrinology, University of Liverpool, Clinical Sciences
      Centre, University Hospital Aintree, Liverpool, UK.
FAU - Seetho, Ian W
AU  - Seetho IW
FAU - Wilding, John P H
AU  - Wilding JP
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/01/23 [received]
PHST- 2013/03/07 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1111/eci.12083 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2013 Jun;43(6):640-55. doi: 10.1111/eci.12083. Epub 2013 Apr
      16.

PMID- 23586772
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 Apr 16
TI  - Interpretation of Chinese Society of Endocrinology consensus statement on
      hyperglycemia management target in adult inpatients in China.
LID - 10.1111/1753-0407.12058 [doi]
AB  - Hyperglycemia of inpatients will increase the incidence of complications,
      mortality and medical cost, meanwhile prolong the hospitalized course. A
      consensus on hyperglycemia management target in adult inpatients is proposed by
      experts of Chinese Society of Endocrinology in order to control hyperglycemia of 
      inpatients safely and effectively. Individualization is emphasized in this
      consensus. Different stratified glycemic targets should be established according 
      to different patients and conditions. Target blood glucose control is unnecessary
      for diabetic patients during hospital stay. Glycemic decrement should generally
      not be quick. Hypoglycemia should be avoided as much as possible, and for
      overweight and obesity individuals weight gain should be avoided as much as
      possible also. At the same time, the risks of infection and hyperglycemic crisis 
      must also be avoided due to loose glycemic control.
CI  - This article is protected by copyright. All rights reserved.
AD  - Division of Endocrinology and Metabolism, West China Hospital of Sichuan
      University, No. 37 Guoxue Lane, Chengdu, China.
FAU - Lu, Qing-Guo
AU  - Lu QG
FAU - Tong, Nan-Wei
AU  - Tong NW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/11 [accepted]
AID - 10.1111/1753-0407.12058 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 Apr 16. doi: 10.1111/1753-0407.12058.

PMID- 23586735
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
DP  - 2013 Apr 16
TI  - The potential for cardiac protection with DPP4 inhibition: the stromal
      cell-derived factor-1 (SDF-1alpha) hypothesis.
LID - 10.1111/1753-0407.12053 [doi]
AB  - The prevention of cardiovascular disease is among our highest priorities in
      managing patients with diabetes. The concerns that arose from the association
      between rosiglitazone use and the incidence of myocardial infarction have led
      drug regulation authorities to mandate evidence of cardiovascular safety before a
      new anti-hyperglycaemic agent can be approved. For the di-peptidyl peptidase-4
      (DPP4) inhibitors, the availability and analysis of these data have to date not
      only shown apparent safety but have also raised the tantalising possibility of
      cardiovascular protection. There are, however, numerous caveats to such analyses 
      and their interpretation. Foremost, the trials are primarily designed to
      determine the glucose lowering properties of these agents and not their effects
      on cardiovascular outcomes, which are instead captured as adverse events. In
      addition, the majority of these studies are of short duration, have relatively
      few patients and mostly do not focus on subjects with pre-existing heart disease 
      or at high risk of developing it. These limitations notwithstanding, some
      interesting findings are evident.
CI  - This article is protected by copyright. All rights reserved.
AD  - Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's
      Hospital, 30 Bond Street, Toronto, Ontario, Canada, M5B 1W8.
FAU - Gilbert, Richard E
AU  - Gilbert RE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/03/25 [accepted]
AID - 10.1111/1753-0407.12053 [doi]
PST - aheadofprint
SO  - J Diabetes. 2013 Apr 16. doi: 10.1111/1753-0407.12053.

PMID- 23586673
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1600-0765 (Electronic)
IS  - 0022-3484 (Linking)
DP  - 2013 Apr 16
TI  - Chronic treatment with the glucocorticoid receptor antagonist RU486 inhibits
      diabetes-induced enhancement of experimental periodontitis.
LID - 10.1111/jre.12076 [doi]
AB  - BACKGROUND AND OBJECTIVE: Chronic hypothalamic-pituitary-adrenal (HPA) axis
      hyperactivity and excessive glucocorticoid hormone release have been associated
      with diabetes, altered immune responses and increased susceptibility to
      periodontitis. In the present study we tested the impact of streptozotocin
      (STZ)-induced diabetes on ligature-induced periodontitis and the effect of
      subsequent treatment with the glucocorticoid receptor (GR) antagonist, RU486.
      MATERIAL AND METHODS: A single dose of STZ [45 mg/kg, intraperitoneally (i.p.)]
      or vehicle was given 10 d before induction of ligature-induced periodontitis and 
      implantation subcutaneously of a drug pellet containing the GR antagonist, RU486,
      or a placebo pellet. Periodontitis was assessed when the ligatures had been in
      place for 21 d. Two hours before decapitation all rats received gram-negative
      bacterial lipopolysaccharide (LPS) (150 mug/kg, i.p.) to induce a robust immune
      and stress response. RESULTS: Compared with control rats, STZ-treated rats
      developed significantly more periodontal bone loss, and RU486 treatment of STZ
      -treated rats significantly inhibited this effect. STZ-treated rats also showed
      significantly higher levels of the HPA axis-derived hormone, corticosterone, as
      well as of the proinflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha),
      but lower levels of the anti-inflammatory cytokines interleukin-10 (IL-10) and
      transforming growth factor-1beta (TGF-1beta) after LPS stimulation. GR blockade
      had no statistically significant effects on these measurements in diabetic rats, 
      but tended to enhance the levels of TNF-alpha and TGF-1beta, and reduce the
      levels of IL-10 and blood glucose. CONCLUSION: In diabetic subjects, excessive GR
      activation as a result of chronic high levels of glucocorticoid hormones may
      alter immune-system responses in a manner that may increase the susceptibility to
      periodontitis.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
AD  - Faculty of Dentistry, Department of Periodontology, University of Oslo, Oslo,
      Norway; Division of Protection, Norwegian Defence Research Establishment,
      Kjeller, Norway.
FAU - Breivik, T
AU  - Breivik T
FAU - Gundersen, Y
AU  - Gundersen Y
FAU - Gjermo, P
AU  - Gjermo P
FAU - Opstad, P-K
AU  - Opstad PK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Periodontal Res
JT  - Journal of periodontal research
JID - 0055107
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/02/12 [accepted]
AID - 10.1111/jre.12076 [doi]
PST - aheadofprint
SO  - J Periodontal Res. 2013 Apr 16. doi: 10.1111/jre.12076.

PMID- 23586625
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1502-3850 (Electronic)
IS  - 0001-6357 (Linking)
DP  - 2013 Apr 16
TI  - Pre-diabetes and diabetes: Medical risk factors and periodontal conditions.
AB  - Abstract Objective. The aim of this study was to evaluate the difference between 
      subjects with pre-diabetes, well or poorly controlled diabetes mellitus type 2
      (T2D) and non-diabetes concerning such medical risk factors as hemoglobin A1c,
      body mass index (BMI) and waist circumference (WC) with periodontal conditions.
      Materials and methods. BMI, WC, PI, BOP, PD and marginal bone level (MBL) were
      recorded. Hemoglobin A1c (HbA1c) level and random blood glucose level (RBGL) were
      analyzed. Results. Forty-five subjects were pre-diabetics, 64 subjects had poorly
      controlled T2D, 28 subjects had well controlled T2D and 76 subjects were
      non-diabetics. Non-diabetics, pre-diabetics as well as subjects with T2D were
      overweight. Females in all groups had increased mean levels of WC. Number of PD
      >/= 6 mm were increased in subjects with poorly controlled T2D compared to
      non-diabetics and pre-diabetics (p < 0.05). Conclusions. Pre-diabetic subjects
      showed the same periodontal conditions as non-diabetic subjects. Forty-five of
      the subjects reporting to have no diabetes were pre-diabetics. Non-diabetic,
      pre-diabetic and diabetic subjects were overweight. Subjects with poorly
      controlled T2D had severe periodontal conditions.
AD  - Karolinska Institutet, Department of Dental Medicine, Division of Periodontology 
      , Huddinge , Sweden.
FAU - Altamash, Murad
AU  - Altamash M
FAU - Arledal, Sophia
AU  - Arledal S
FAU - Klinge, Bjorn
AU  - Klinge B
FAU - Engstrom, Per-Erik
AU  - Engstrom PE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Acta Odontol Scand
JT  - Acta odontologica Scandinavica
JID - 0370344
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
AID - 10.3109/00016357.2013.788207 [doi]
PST - aheadofprint
SO  - Acta Odontol Scand. 2013 Apr 16.

PMID- 23586620
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1470-8744 (Electronic)
IS  - 0885-4513 (Linking)
DP  - 2013 Apr 4
TI  - A direct fluorescent-based technique for cellular localization of amylin.
LID - 10.1002/bab.1113 [doi]
AB  - Amylin has been implicated in type II diabetes due to its inherent property to
      misfold into toxic aggregates. Although it has been shown that amylin interacts
      with cell membranes, no study to date has monitored the association process using
      a direct approach. The present study uses confocal microscopy to identify the
      localization of carboxyfluorescein-labeled amylin in RIN-5F cells. In addition,
      the size of the aggregates that forms were evaluated using nanoparticle tracking 
      analysis (NTA). In support of previous findings, amylin was observed to interact 
      with and remain associated to the cell membrane. The cell membrane-associated
      aggregates spanned a size range of 130-800 nm.
CI  - (c) 2013 International Union of Biochemistry and Molecular Biology, Inc.
AD  - School of Life Sciences, University of KwaZulu-Natal, South Africa.
FAU - Pillay, Karen
AU  - Pillay K
FAU - Govender, Patrick
AU  - Govender P
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130404
TA  - Biotechnol Appl Biochem
JT  - Biotechnology and applied biochemistry
JID - 8609465
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/12/11 [received]
PHST- 2013/03/11 [accepted]
AID - 10.1002/bab.1113 [doi]
PST - aheadofprint
SO  - Biotechnol Appl Biochem. 2013 Apr 4. doi: 10.1002/bab.1113.

PMID- 23586571
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 1440-1584 (Electronic)
IS  - 1038-5282 (Linking)
VI  - 21
IP  - 2
DP  - 2013 Apr
TI  - The sociodemographic and health-related characteristics of a regional population 
      with chronic disease at an interprofessional student-assisted clinic in
      Queensland Capricornia Allied Health Partnership.
PG  - 97-104
LID - 10.1111/ajr.12017 [doi]
AB  - OBJECTIVE: This paper describes the sociodemographic and health-related
      characteristics of people with chronic disease attending an interprofessional
      student-assisted clinic in regional Queensland. DESIGN: A retrospective review of
      data collected during the first 10 months of operation of the clinic was
      conducted. SETTING, PARTICIPANTS AND OUTCOME MEASURES: Data was collected on up
      to 378 patients during an intake appointment at the Capricornia Allied Health
      Partnership (CAHP) community-based clinic and compared with normative reference
      groups where available. Sociodemographic characteristics included age, gender and
      education level; health-related characteristics included body mass index and
      hospitalisations in the previous 12 months; and risk factors included prescribed 
      medications, smoking status and general practitioner-diagnosed medical
      conditions. RESULTS: Patients attending the CAHP clinic had a mean number of
      chronic conditions of 4.9 +/- 2.1 per patient, and 97% of patients had
      multimorbidities. A high level of socioeconomic disadvantage was found in
      comparison with normative comparison groups based on employment, highest level of
      schooling completed and the index of social disadvantage. Patients predominantly 
      lived in inner regional areas (76.7%). The most common diagnoses of patients
      attending the clinic for the first time were hypertension, osteoarthritis, high
      cholesterol, diabetes and chronic back pain. CONCLUSIONS: The CAHP clinic offers 
      a unique student-assisted service model for interprofessional management of
      patients who are socioeconomically disadvantaged, have multimorbid chronic
      disease and live in regional areas. The description of baseline data in this
      paper is important to refine clinic services, to guide other chronic disease
      clinics and to inform future research study designs.
CI  - (c) 2013 The Authors. Australian Journal of Rural Health (c) National Rural
      Health Alliance Inc.
AD  - Central Queensland Hospital and Health Service, Queensland Health, Rockhampton,
      Australia. kerrieanne_frakes@health.qld.gov.au
FAU - Frakes, Kerrie-Anne
AU  - Frakes KA
FAU - Brownie, Sharon
AU  - Brownie S
FAU - Davies, Lauren
AU  - Davies L
FAU - Thomas, Janelle
AU  - Thomas J
FAU - Miller, Mary-Ellen
AU  - Miller ME
FAU - Tyack, Zephanie
AU  - Tyack Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Aust J Rural Health
JT  - The Australian journal of rural health
JID - 9305903
SB  - N
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/09/06 [accepted]
AID - 10.1111/ajr.12017 [doi]
PST - ppublish
SO  - Aust J Rural Health. 2013 Apr;21(2):97-104. doi: 10.1111/ajr.12017.

PMID- 23586474
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - The association between adherence to oral anti-diabetic drugs and hypoglycaemia
      in persons with Type 2 diabetes.
LID - 10.1111/dme.12217 [doi]
AB  - AIM: To quantify the relationship between adherence to oral anti-diabetic drugs
      and incident hypoglycaemia in Type 2 diabetes. METHODS: Utilizing a claims
      database, we identified patients with Type 2 diabetes initiating metformin,
      sulphonylureas or thiazolidinediones and classified adherence over the next 6
      months, creating markers of changes in therapy (switches/additions). We created
      nine mutually exclusive exposure groups, including: metformin >/= 80% adherence; 
      metformin < 80% adherence; sulphonylurea >/= 80% adherence; sulphonylurea < 80%
      adherence; thiazolidinediones >/= 80% adherence; thiazolidinediones < 80%
      adherence; switching to a new class; adding on therapy; and switching to two or
      more different classes of medication. We followed patients for incident
      hypoglycaemia medical visits and developed a Cox proportional hazards model to
      compare rates of hypoglycaemia across exposure groups. RESULTS: Adherence to
      monotherapy was high (86.0 +/- 17.8% for metformin, 87.2 +/- 17.5% for
      sulphonylureas and 87.8 +/- 16.9 for thiazolidinediones). The incidence of
      hypoglycaemia ranged from 93.1 to 259.9 per 10 000 person-years in the nine
      exposure groups. Relative to metformin users with >/= 80% adherence, those
      switching from any monotherapy to combination therapy had a 32% increased rate
      (hazard ratio 1.32; 95% CI 1.07-1.64) of hypoglycaemia. Thiazolidinediones users 
      with >/= 80% adherence had a decreased hazard rate (hazard ratio 0.67; 95% CI
      0.46-0.98) relative to metformin users with >/= 80% adherence. All other groups
      on oral anti-diabetic drugs, regardless of adherence, were not associated with
      hypoglycaemia CONCLUSIONS: We found that the relative rate of hypoglycaemia was
      highest in patients switching from monotherapy to combination therapy, while
      rates of hypoglycaemia in monotherapy users were largely unrelated to level of
      adherence.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
FAU - Quilliam, B J
AU  - Quilliam BJ
FAU - Ozbay, A B
AU  - Ozbay AB
FAU - Sill, B E
AU  - Sill BE
FAU - Kogut, S J
AU  - Kogut SJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12217 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12217.

PMID- 23586438
OWN - NLM
STAT- Publisher
DA  - 20130524
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - Validation of the German Diabetes Risk Score within a population-based
      representative cohort.
LID - 10.1111/dme.12216 [doi]
AB  - AIM: To validate the German Diabetes Risk Score within the population-based
      cohort of the Cardiovascular Disease - Living and Ageing in Halle (CARLA) study. 
      METHODS: The sample included 582 women and 719 men, aged 45-83 years, who did not
      have diabetes at baseline. The individual risk of every participant was
      calculated using the German Diabetes Risk Score, which was modified for 4 years
      of follow-up. Predicted probabilities and observed outcomes were compared using
      Hosmer-Lemeshow goodness-of-fit tests and receiver-operator characteristic
      analyses. Changes in prediction power were investigated by expanding the German
      Diabetes Risk Score to include metabolic variables and by subgroup analyses.
      RESULTS: We found 58 cases of incident diabetes. The median 4-year probability of
      developing diabetes based on the German Diabetes Risk Score was 6.5%. The
      observed and predicted probabilities of developing diabetes were similar,
      although estimation was imprecise owing to the small number of cases, and the
      Hosmer-Lemeshow test returned a poor correlation (chi-squared = 55.3; P =
      5.8*10-12 ). The area under the receiver-operator characteristic curve (AUC) was 
      0.70 (95% CI 0.64-0.77), and after excluding participants >/=66 years old, the
      AUC increased to 0.77 (95% CI 0.70-0.84). Consideration of glycaemic diagnostic
      variables, in addition to self-reported diabetes, reduced the AUC to 0.65 (95% CI
      0.58-0.71). A new model that included the German Diabetes Risk Score and blood
      glucose concentration (AUC 0.81; 95% CI 0.76-0.86) or HbA1c concentration (AUC
      0.84; 95% CI 0.80-0.91) was found to peform better. CONCLUSIONS: Application of
      the German Diabetes Risk Score in the CARLA cohort did not reproduce the findings
      in the European Prospective Investigation into Cancer and Nutrition (EPIC)
      Potsdam study, which may be explained by cohort differences and model overfit in 
      the latter; however, a high score does provide an indication of increased risk of
      diabetes.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Institute of Medical Epidemiology, Biostatistics, and Informatics,
      Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
FAU - Hartwig, S
AU  - Hartwig S
FAU - Kuss, O
AU  - Kuss O
FAU - Tiller, D
AU  - Tiller D
FAU - Greiser, K H
AU  - Greiser KH
FAU - Schulze, M B
AU  - Schulze MB
FAU - Dierkes, J
AU  - Dierkes J
FAU - Werdan, K
AU  - Werdan K
FAU - Haerting, J
AU  - Haerting J
FAU - Kluttig, A
AU  - Kluttig A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12216 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12216.

PMID- 23586429
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1440-1754 (Electronic)
IS  - 1034-4810 (Linking)
DP  - 2013 Apr 16
TI  - Rapidly evolving hypopituitarism in a boy with multiple autoimmune disorders.
LID - 10.1111/jpc.12169 [doi]
AB  - A 10-year-old boy with acute onset cranial diabetes insipidus and multiple
      autoimmune disorders had evolving panhypopituitarism, thought to be due to
      autoimmune hypophysitis. Over 18 months, a dramatic clinical course with
      progressive hypopituitarism and development of type 1 diabetes mellitus was
      evident. Serial brain imaging showed changes suggestive of germinoma.
CI  - (c) 2013 The Authors. Journal of Paediatrics and Child Health (c) 2013
      Paediatrics and Child Health Division (Royal Australasian College of Physicians).
AD  - Department of Endocrinology and Diabetes, The Royal Children's Hospital, Murdoch 
      Childrens Research Institute, Melbourne, Victoria, Australia.
FAU - Jevalikar, Ganesh
AU  - Jevalikar G
FAU - Wong, Sze Choong
AU  - Wong SC
FAU - Zacharin, Margaret
AU  - Zacharin M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - J Paediatr Child Health
JT  - Journal of paediatrics and child health
JID - 9005421
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/08/22 [accepted]
AID - 10.1111/jpc.12169 [doi]
PST - aheadofprint
SO  - J Paediatr Child Health. 2013 Apr 16. doi: 10.1111/jpc.12169.

PMID- 23586419
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1520-5118 (Electronic)
IS  - 0021-8561 (Linking)
VI  - 61
IP  - 18
DP  - 2013 May 8
TI  - Supplementation of a high-fat diet with chlorogenic Acid is associated with
      insulin resistance and hepatic lipid accumulation in mice.
PG  - 4371-8
LID - 10.1021/jf400920x [doi]
AB  - The increasing prevalence of the metabolic syndrome requires a greater need for
      therapeutic and prevention strategies. Higher coffee consumption is consistently 
      associated with a lower risk of type 2 diabetes in population studies. Dietary
      polyphenols have been linked to benefits on several features of the metabolic
      syndrome. Chlorogenic acid (CGA), a major component of coffee, is one of the most
      consumed polyphenols in the diet. In our study, we conducted a controlled dietary
      intervention over 12 weeks in male mice. There were three dietary groups: (i)
      normal diet, (ii) high-fat diet, and (iii) high-fat diet + CGA. We assessed the
      effect of CGA at a physiologically obtainable dose (1 g/kg of diet) on
      high-fat-diet-induced obesity, glucose intolerance, insulin resistance, and also 
      fatty acid oxidation and insulin signaling in C57BL/6 male mice. Supplementation 
      of CGA in the high-fat diet did not reduce body weight compared to mice fed the
      high-fat diet alone (p = 0.32). CGA resulted in increased insulin resistance
      compared to mice fed a high-fat diet only (p < 0.05). CGA resulted in decreased
      phosphorylation of AMP-activated protein kinase (AMPK) (p < 0.001) and acetyl
      carboxylase beta (ACCbeta), a downstream target of AMPK (p < 0.05), in liver. The
      liver of mice fed a high-fat diet supplemented with CGA had a higher lipid
      content (p < 0.05) and more steatosis relative to mice fed a high-fat diet only, 
      indicating impaired fatty acid oxidation. This study suggests that CGA
      supplementation in a high-fat diet does not protect against features of the
      metabolic syndrome in diet-induced obese mice.
AD  - School of Plant Biology, and the Institute of Agriculture, University of Western 
      Australia , Crawley, Western Australia 6009, Australia.
FAU - Mubarak, Aidilla
AU  - Mubarak A
FAU - Hodgson, Jonathan M
AU  - Hodgson JM
FAU - Considine, Michael J
AU  - Considine MJ
FAU - Croft, Kevin D
AU  - Croft KD
FAU - Matthews, Vance B
AU  - Matthews VB
LA  - eng
PT  - Journal Article
DEP - 20130426
PL  - United States
TA  - J Agric Food Chem
JT  - Journal of agricultural and food chemistry
JID - 0374755
SB  - IM
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/26 [aheadofprint]
AID - 10.1021/jf400920x [doi]
PST - ppublish
SO  - J Agric Food Chem. 2013 May 8;61(18):4371-8. doi: 10.1021/jf400920x. Epub 2013
      Apr 26.

PMID- 23586406
OWN - NLM
STAT- Publisher
DA  - 20130416
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - The roadmap to close the gap for vision-diabetes-related eye care in the
      Indigenous Australian population.
LID - 10.1111/dme.12215 [doi]
AB  - Blindness from diabetic retinopathy is almost entirely preventable with regular
      eye examinations and timely laser surgery. The international community through
      the establishment of Vision 2020 aim to eliminate avoidable blindness worldwide
      and in the Australian community through the establishment of the close the gap to
      life expectancy are committed to reducing avoidable blindness associated with
      diabetic retinopathy in the Indigenous population [1, 2]. This article is
      protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Indigenous Eye Health Unit, Melbourne School of Population Health, The University
      of Melbourne, Vic., Australia; Department of Optometry and Vision Sciences, The
      University of Melbourne, Vic., Australia.
FAU - Tapp, R J
AU  - Tapp RJ
FAU - Anjou, M D
AU  - Anjou MD
FAU - Boudville, A I
AU  - Boudville AI
FAU - Taylor, H R
AU  - Taylor HR
LA  - ENG
PT  - LETTER
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2012/11/12 [received]
PHST- 2013/02/05 [revised]
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12215 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12215.

PMID- 23586333
OWN - NLM
STAT- Publisher
DA  - 20130529
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2013 Apr 16
TI  - Trends in selection and timing of first-line pharmacotherapy in older patients
      with Type 2 diabetes diagnosed between 1994 and 2006.
LID - 10.1111/dme.12214 [doi]
AB  - AIMS: To characterize temporal trends in the selection and timing of first-line
      pharmacotherapy among older patients with Type 2 diabetes. DESIGN AND METHODS: We
      studied five population-based cohorts every 3 years, from 1994 to 2006. In each
      of those years, we identified all subjects aged 66 years or older newly diagnosed
      with diabetes and determined the initial glucose-lowering drug and the time
      between diagnosis and drug initiation. We calculated the proportion of patients
      prescribed each agent and estimated time from diagnosis to initiation using
      Kaplan-Meier survival analysis. RESULTS: We identified a total of 64 368 eligible
      people who initiated drug therapy during the study period. From 1994 to 2006,
      first-line metformin use increased from 20.1 to 79.0%. Glyburide (glibenclamide) 
      decreased from 71.1% of all first-line therapies in 1994 to 9.8% in 2006, while
      first-line use of insulin or combination therapy have changed little at
      approximately 5% each. No other medication exceeded 2% of first-line therapies.
      The median time from diagnosis to initiation of pharmacotherapy increased
      dramatically during the study period, from 1.8 years in 1994 to 4.6 years in
      2006. CONCLUSIONS: Metformin has become the most commonly used initial medication
      for the treatment of diabetes. Although guidelines have evolved to recommend more
      aggressive initiation and intensification of pharmacotherapy, our results suggest
      that the time from diagnosis to initiation has increased substantially.
CI  - (c) 2013 The Authors. Diabetic Medicine (c) 2013 Diabetes UK.
AD  - Schulich School of Medicine and Dentistry, University of Western Ontario, London;
      Applied Health Research Centre, St. Michael's Hospital, Toronto, ON, Canada.
FAU - Foster, P D
AU  - Foster PD
FAU - Mamdani, M M
AU  - Mamdani MM
FAU - Juurlink, D N
AU  - Juurlink DN
FAU - Shah, B R
AU  - Shah BR
FAU - Paterson, J M
AU  - Paterson JM
FAU - Gomes, T
AU  - Gomes T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130416
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PHST- 2013/04/10 [accepted]
AID - 10.1111/dme.12214 [doi]
PST - aheadofprint
SO  - Diabet Med. 2013 Apr 16. doi: 10.1111/dme.12214.

PMID- 23586178
OWN - NLM
STAT- In-Process
DA  - 20130416
IS  - 2046-2336 (Print)
IS  - 2046-2336 (Linking)
VI  - 25
IP  - 2
DP  - 2013 Mar
TI  - Type 2 diabetes: an epidemic in children.
PG  - 14-7
AB  - Increasing numbers of children and adolescents are developing type 2 diabetes.
      Symptoms of this condition include obesity, a sedentary lifestyle, insulin
      resistance and hypertension. Type 2 diabetes is more common in girls and families
      with a positive history of the disease. Diagnosis is often delayed and may
      identify the presence of chronic complications. An oral glucose tolerance test
      and a two-hour plasma glucose assessment are the best screening and diagnostic
      investigations. Treatment is based on weight reduction with diet and exercise,
      glycaemia monitoring and medication if necessary.
AD  - Centre for Nursing and Healthcare Research, University of Greenwich.
      drvwilson@gmail.com
FAU - Wilson, Valerie
AU  - Wilson V
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nurs Child Young People
JT  - Nursing children and young people
JID - 101554473
SB  - N
EDAT- 2013/04/17 06:00
MHDA- 2013/04/17 06:00
CRDT- 2013/04/17 06:00
PST - ppublish
SO  - Nurs Child Young People. 2013 Mar;25(2):14-7.

PMID- 23586057
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 2314-6141 (Electronic)
VI  - 2013
DP  - 2013
TI  - Aldose reductase inhibitory activity of compounds from Zea mays L.
PG  - 727143
LID - 10.1155/2013/727143 [doi]
AB  - Aldose reductase (AR) inhibitors have a considerable therapeutic potential
      against diabetes complications and do not increase the risk of hypoglycemia.
      Through bioassay-guided fractionation of an EtOH extract of the kernel from
      purple corn (Zea mays L.), 7 nonanthocyanin phenolic compounds (compound 1-7) and
      5 anthocyanins (compound 8-12) were isolated. These compounds were investigated
      by rat lens aldose reductase (RLAR) inhibitory assays. Kinetic analyses of
      recombinant human aldose reductase (rhAR) were performed, and intracellular
      galactitol levels were measured. Hirsutrin, one of 12 isolated compounds, showed 
      the most potent RLAR inhibitory activity (IC(50), 4.78 mu M). In the kinetic
      analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate concentration,
      hirsutrin showed competitive inhibition against rhAR. Furthermore, hirsutrin
      inhibited galactitol formation in rat lens and erythrocytes sample incubated with
      a high concentration of galactose; this finding indicates that hirsutrin may
      effectively prevent osmotic stress in hyperglycemia. Therefore, hirsutrin derived
      from Zea mays L. may be a potential therapeutic agent against diabetes
      complications.
AD  - Department of Food Science and Nutrition, Hallym University, Chuncheon 200-702,
      Republic of Korea.
FAU - Kim, Tae Hyeon
AU  - Kim TH
FAU - Kim, Jin Kyu
AU  - Kim JK
FAU - Kang, Young-Hee
AU  - Kang YH
FAU - Lee, Jae-Yong
AU  - Lee JY
FAU - Kang, Il Jun
AU  - Kang IJ
FAU - Lim, Soon Sung
AU  - Lim SS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130317
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
SB  - IM
PMC - PMC3613087
OID - NLM: PMC3613087
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/09 [received]
PHST- 2013/01/11 [revised]
PHST- 2013/01/11 [accepted]
PHST- 2013/03/17 [epublish]
AID - 10.1155/2013/727143 [doi]
PST - ppublish
SO  - Biomed Res Int. 2013;2013:727143. doi: 10.1155/2013/727143. Epub 2013 Mar 17.

PMID- 23585969
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130415
DCOM- 20130416
LR  - 20130417
IS  - 2090-3464 (Print)
VI  - 2013
DP  - 2013
TI  - Retrospective analysis of arthroscopic superior labrum anterior to posterior
      repair: prognostic factors associated with failure.
PG  - 125960
LID - 10.1155/2013/125960 [doi]
AB  - Background. The purpose of this study was to report on any prognostic factors
      that had a significant effect on clinical outcomes following arthroscopic Type II
      SLAP repairs. Methods. Consecutive patients who underwent arthroscopic Type II
      SLAP repair were retrospectively identified and invited to return for follow-up
      examination and questionnaire. Statistical analysis was performed to determine
      associations between potential prognostic factors and failure of SLAP repair as
      defined by ASES of less than 50 and/or revision surgery. Results. Sixty-two
      patients with an average age of 36 +/- 13 years met the study criteria with a
      mean followup of 3.3 years. There were statistically significant improvements in 
      mean ASES score, forward elevation, and external rotation among patients.
      Significant associations were identified between ASES score less than 50 and age 
      greater than 40 years; alcohol/tobacco use; coexisting diabetes; pain in the
      bicipital groove on examination; positive O'Brien's, Speed's, and/or Yergason's
      tests; and high levels of lifting required at work. There was a significant
      improvement in ASES at final followup. Conclusions. Patients younger than 20 and 
      overhead throwers had significant associations with cases requiring revision
      surgery. The results from this study may be used to assist in patient selection
      for SLAP surgery.
AD  - Division of Sports Medicine, Department of Orthopaedic Surgery, Rush University
      Medical Center, 1611 West Harrison Street, Suite 300, Chicago, IL 60612, USA.
FAU - Frank, Rachel M
AU  - Frank RM
FAU - Nho, Shane J
AU  - Nho SJ
FAU - McGill, Kevin C
AU  - McGill KC
FAU - Grumet, Robert C
AU  - Grumet RC
FAU - Cole, Brian J
AU  - Cole BJ
FAU - Verma, Nikhil N
AU  - Verma NN
FAU - Romeo, Anthony A
AU  - Romeo AA
LA  - eng
PT  - Journal Article
DEP - 20130325
PL  - Egypt
TA  - Adv Orthop
JT  - Advances in orthopedics
JID - 101565129
PMC - PMC3621156
OID - NLM: PMC3621156
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:01
CRDT- 2013/04/16 06:00
PHST- 2012/10/21 [received]
PHST- 2013/02/19 [accepted]
PHST- 2013/03/25 [epublish]
AID - 10.1155/2013/125960 [doi]
PST - ppublish
SO  - Adv Orthop. 2013;2013:125960. doi: 10.1155/2013/125960. Epub 2013 Mar 25.

PMID- 23585904
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Fructus Xanthii attenuates hepatic steatosis in rats fed on high-fat diet.
PG  - e61499
LID - 10.1371/journal.pone.0061499 [doi]
AB  - Fructus Xanthii (FX) has been widely used as a traditional herbal medicine for
      rhinitis, headache, cold, etc. Modern pharmacological studies revealed that FX
      possesses anti-inflammatory, anti-oxidative, and anti-hyperglycemic properties.
      The present study was designed to investigate the effects of FX on glucose and
      insulin tolerance, and hepatic lipid metabolism in rats fed on high-fat diet
      (HFD). Hepatic steatosis was induced by HFD feeding. Aqueous extraction fractions
      of FX or vehicle were orally administered by gavage for 6 weeks. Body weight and 
      blood glucose were monitored. Glucose and insulin tolerance test were performed. 
      Liver morphology was visualized by hematoxylin and eosin, and oil red O staining.
      Expression of liver lipogenic and lipolytic genes was measured by real-time PCR. 
      We showed here that FX improved glucose tolerance and insulin sensitivity in HFD 
      rats. FX significantly decreased the expression of lipogenic genes and increased 
      the expression of lipolytic genes, ameliorated lipid accumulation and decreased
      the total liver triglyceride (TG) content, and thus attenuated HFD-induced
      hepatic steatosis. In conclusion, FX improves glucose tolerance and insulin
      sensitivity, decreases lipogenesis and increases lipid oxidation in the liver of 
      HFD rats, implying a potential application in the treatment of non-alcoholic
      fatty liver disease.
AD  - Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University,
      Xiamen, China.
FAU - Li, Xiumin
AU  - Li X
FAU - Li, Zhipeng
AU  - Li Z
FAU - Xue, Mei
AU  - Xue M
FAU - Ou, Zhimin
AU  - Ou Z
FAU - Liu, Ming
AU  - Liu M
FAU - Yang, Mingxing
AU  - Yang M
FAU - Liu, Suhuan
AU  - Liu S
FAU - Yang, Shuyu
AU  - Yang S
FAU - Li, Xuejun
AU  - Li X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130409
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3621865
OID - NLM: PMC3621865
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/12 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1371/journal.pone.0061499 [doi]
AID - PONE-D-12-35918 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 9;8(4):e61499. doi: 10.1371/journal.pone.0061499. Print 2013.

PMID- 23585903
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Pneumonia and mortality risk in continuous ambulatory peritoneal dialysis
      patients with diabetic nephropathy.
PG  - e61497
LID - 10.1371/journal.pone.0061497 [doi]
AB  - BACKGROUND: Although clinical experience suggests that patients with diabetes
      mellitus are more susceptible to several types of infections, the overall scope
      of pneumonia in continuous ambulatory peritoneal dialysis (CAPD) patients with
      diabetic nephropathy (DN) has received little attention. METHODS: This was a
      prospective observational cohort study in CAPD patients in which prognostic risks
      of pneumonia were evaluated in DN and non-DN patients by Cox regression analysis.
      Hazard ratios of pneumonia events, all-cause and pneumonia-related mortality were
      calculated by Kaplan-Meier curves and the Cox proportional hazards model for DN
      versus non-DN patients. RESULTS: A total of 1148 patients (58.6% male,
      48.34+/-15.78 years) had a median follow-up of 23.8 months and a maximum
      follow-up of 72.0 months. The pneumonia incidence rate of 62.3/1,000
      patient-years in CAPD patients with DN was significantly higher than that of
      28.5/1,000 patient-years in non-DN patients. On multivariate analysis,
      independent predictors of pneumonia occurrence in CAPD patients with DN were high
      body mass index (hazard ratio [HR], 1.15; 95% confidence interval [CI],
      1.01-1.31; P = 0.037) and low serum albumin level (HR, 0.87; 95% CI, 0.78-0.98; P
      = 0.014). Older age (HR, 1.63; 95% CI, 1.35-1.96; P<0.001) was an independent
      risk factor for the presence of pneumonia in non-DN patients. CAPD patients with 
      DN had higher pneumonia-related mortality (HR, 4.424; 95% CI, 1.871-10.461;
      P<0.001) and all-cause mortality (HR, 2.608; 95% CI, 1.890-3.599; P<0.001)
      hazards than their non-DN counterparts, even when extensive demographics,
      comorbidities, and lab adjustments were made. CONCLUSIONS: The pneumonia and
      all-cause mortality risks were strikingly higher in CAPD patients with DN than in
      non-DN counterparts, which may warrant further investigation and therapeutic care
      intensification.
AD  - Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China. hfxyl@163.net
FAU - He, Feng
AU  - He F
FAU - Wu, Xianfeng
AU  - Wu X
FAU - Xia, Xi
AU  - Xia X
FAU - Peng, Fenfen
AU  - Peng F
FAU - Huang, Fengxian
AU  - Huang F
FAU - Yu, Xueqing
AU  - Yu X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130409
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3621817
OID - NLM: PMC3621817
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/11 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1371/journal.pone.0061497 [doi]
AID - PONE-D-12-31341 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 9;8(4):e61497. doi: 10.1371/journal.pone.0061497. Print 2013.

PMID- 23585876
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Association between vitamin D insufficiency and elevated serum uric acid among
      middle-aged and elderly Chinese Han women.
PG  - e61159
LID - 10.1371/journal.pone.0061159 [doi]
AB  - BACKGROUND: Association between vitamin D insufficiency and hyperuricemia has not
      been reported so far. We aimed to study the association of vitamin D
      insufficiency with elevated serum uric acid among middle-aged and elderly Chinese
      Han women. METHODS: We collected data from participants residing in Jinchang
      district of Suzhou from January to May, 2010. Serum uric acid, 25-hydroxy vitamin
      D and other traditional biomarkers including fasting plasma glucose and blood
      lipids were determined in 1726 women aged above 30 years. Association between
      vitamin D insufficiency and elevated uric acid was analyzed in premenopausal and 
      postmenopausal women, respectively. RESULTS: Among postmenopausal women,
      25-hydroxy vitamin D level of participants with elevated uric acid was lower than
      that of those with normal uric acid (median [interquartile range]: 35[28-57] vs
      40[32-58], microg/L; P = 0.006). Elevated uric acid was more prevalent in
      participants with vitamin D insufficiency compared to those without vitamin D
      insufficiency (16.50% vs 8.08%; P<0.001). Association between vitamin D
      insufficiency and elevated uric acid was not significant among premenopausal
      women. However, participants with vitamin D insufficiency were more likely to
      have elevated uric acid compared with those without vitamin D insufficiency among
      postmenopausal women (OR, 95% CI: 2.38, 1.47-3.87). Moreover, after excluding
      individuals with diabetes and/or hypertension, the association of vitamin D
      insufficiency with elevated uric acid was still significant (OR, 95% CI: 2.48,
      1.17-5.44). CONCLUSIONS: Vitamin D insufficiency was significantly associated
      with elevated uric acid among postmenopausal Chinese Han women. This study
      suggested that a clinical trial should be conducted to confirm the association of
      vitamin D insufficiency with hyperuricemia.
AD  - Department of Epidemiology, School of Public Health, Medical College of Soochow
      University, Suzhou, China.
FAU - Peng, Hao
AU  - Peng H
FAU - Li, Hongmei
AU  - Li H
FAU - Li, Chao
AU  - Li C
FAU - Chao, Xiangqin
AU  - Chao X
FAU - Zhang, Qiu
AU  - Zhang Q
FAU - Zhang, Yonghong
AU  - Zhang Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130409
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3621974
OID - NLM: PMC3621974
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/10 [received]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1371/journal.pone.0061159 [doi]
AID - PONE-D-12-31697 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 9;8(4):e61159. doi: 10.1371/journal.pone.0061159. Print 2013.

PMID- 23585875
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Adiponectin-11377CG gene polymorphism and type 2 diabetes mellitus in the chinese
      population: a meta-analysis of 6425 subjects.
PG  - e61153
LID - 10.1371/journal.pone.0061153 [doi]
AB  - BACKGROUND: Although adiponectin -11377CG gene polymorphism is implied to be
      associated with increased type 2 diabetes mellitus (T2DM) risk, results of
      individual studies are inconsistent. OBJECTIVE AND METHODS: A meta-analysis
      consisting of 12 individual studies, including a total of 6425 participants, was 
      carried out in order to investigate the association of adiponectin -11377CG gene 
      polymorphism with T2DM. The pooled odds ratio (OR) and its corresponding
      confidence interval (CI) at 95% were assessed through the random- or fixed-
      effect model. RESULTS: A significant relationship was observed between
      adiponectin -11377CG gene polymorphism and T2DM under allelic (OR: 1.150, 95% CI:
      1.060 to 1.250, P = 0.001), recessive (OR: 1.450, 95% CI: 1.180-1.770, P =
      0.0004), dominant (OR: 1.071, 95% CI: 1.013-1.131, P = 0.015), additive (OR:
      1.280, 95% CI: 1.090-1.510, P = 0.002), and homozygous genetic models (OR: 1.620,
      95% CI: 1.310-1.990, P<0.00001). No significant association was found between
      them under the heterozygous genetic model (OR: 1.640, 95% CI: 0.850-3.170, P =
      0.140). CONCLUSIONS: Adiponectin -11377CG gene polymorphism was significantly
      associated with T2DM risk susceptibility. G allele carriers are predisposed to
      T2DM risk.
AD  - Department of Geriatrics, First Affiliated Hospital of Nanjing Medical
      University, Nanjing, China. lyynjmu123@126.com
FAU - Li, Yan-Yan
AU  - Li YY
FAU - Yang, Zhi-Jian
AU  - Yang ZJ
FAU - Zhou, Chuan-Wei
AU  - Zhou CW
FAU - Wang, Xiang-Ming
AU  - Wang XM
FAU - Qian, Yun
AU  - Qian Y
FAU - Xu, Jian
AU  - Xu J
FAU - Wang, Bei
AU  - Wang B
FAU - Wu, Jun
AU  - Wu J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130409
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3621968
OID - NLM: PMC3621968
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/11/15 [received]
PHST- 2013/03/06 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1371/journal.pone.0061153 [doi]
AID - PONE-D-12-35921 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 9;8(4):e61153. doi: 10.1371/journal.pone.0061153. Print 2013.

PMID- 23585839
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 8
IP  - 4
DP  - 2013
TI  - Adenoviral gene transfer of PLD1-D4 enhances insulin sensitivity in mice by
      disrupting phospholipase D1 interaction with PED/PEA-15.
PG  - e60555
LID - 10.1371/journal.pone.0060555 [doi]
AB  - Over-expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in
      astrocytes (PED/PEA-15) causes insulin resistance by interacting with the D4
      domain of phospholipase D1 (PLD1). Indeed, the disruption of this association
      restores insulin sensitivity in cultured cells over-expressing PED/PEA-15.
      Whether the displacement of PLD1 from PED/PEA-15 improves insulin sensitivity in 
      vivo has not been explored yet. In this work we show that treatment with a
      recombinant adenoviral vector containing the human D4 cDNA (Ad-D4) restores
      normal glucose homeostasis in transgenic mice overexpressing PED/PEA-15 (Tg
      ped/pea-15) by improving both insulin sensitivity and secretion. In skeletal
      muscle of these mice, D4 over-expression inhibited PED/PEA-15-PLD1 interaction,
      decreased Protein Kinase C alpha activation and restored insulin induced Protein 
      Kinase C zeta activation, leading to amelioration of insulin-dependent glucose
      uptake. Interestingly, Ad-D4 administration improved insulin sensitivity also in 
      high-fat diet treated obese C57Bl/6 mice. We conclude that PED/PEA-15-PLD1
      interaction may represent a novel target for interventions aiming at improving
      glucose tolerance.
AD  - Dipartimento di Scienze Mediche e Traslazionali, Universita di Napoli Federico II
      and Istituto di Endocrinologia e Oncologia Sperimentale Gaetano Salvatore,
      Consiglio Nazionale delle Ricerche, Naples, Italy.
FAU - Cassese, Angela
AU  - Cassese A
FAU - Raciti, Gregory A
AU  - Raciti GA
FAU - Fiory, Francesca
AU  - Fiory F
FAU - Nigro, Cecilia
AU  - Nigro C
FAU - Ulianich, Luca
AU  - Ulianich L
FAU - Castano, Ilenia
AU  - Castano I
FAU - D'Esposito, Vittoria
AU  - D'Esposito V
FAU - Terracciano, Daniela
AU  - Terracciano D
FAU - Pastore, Lucio
AU  - Pastore L
FAU - Formisano, Pietro
AU  - Formisano P
FAU - Beguinot, Francesco
AU  - Beguinot F
FAU - Miele, Claudia
AU  - Miele C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130409
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
PMC - PMC3621763
OID - NLM: PMC3621763
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/19 [received]
PHST- 2013/02/27 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1371/journal.pone.0060555 [doi]
AID - PONE-D-12-33347 [pii]
PST - epublish
SO  - PLoS One. 2013 Apr 9;8(4):e60555. doi: 10.1371/journal.pone.0060555. Print 2013.

PMID- 23585733
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1545-7885 (Electronic)
IS  - 1544-9173 (Linking)
VI  - 11
IP  - 4
DP  - 2013 Apr
TI  - Reduction of the cholesterol sensor SCAP in the brains of mice causes impaired
      synaptic transmission and altered cognitive function.
PG  - e1001532
LID - 10.1371/journal.pbio.1001532 [doi]
AB  - The sterol sensor SCAP is a key regulator of SREBP-2, the major transcription
      factor controlling cholesterol synthesis. Recently, we showed that there is a
      global down-regulation of cholesterol synthetic genes, as well as SREBP-2, in the
      brains of diabetic mice, leading to a reduction of cholesterol synthesis. We now 
      show that in mouse models of type 1 and type 2 diabetes, this is, in part, the
      result of a decrease of SCAP. Homozygous disruption of the Scap gene in the
      brains of mice causes perinatal lethality associated with microcephaly and
      gliosis. Mice with haploinsufficiency of Scap in the brain show a 60% reduction
      of SCAP protein and ~30% reduction in brain cholesterol synthesis, similar to
      what is observed in diabetic mice. This results in impaired synaptic
      transmission, as measured by decreased paired pulse facilitation and long-term
      potentiation, and is associated with behavioral and cognitive changes. Thus,
      reduction of SCAP and the consequent suppression of cholesterol synthesis in the 
      brain may play an important role in the increased rates of cognitive decline and 
      Alzheimer disease observed in diabetic states.
AD  - Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, United
      States of America.
FAU - Suzuki, Ryo
AU  - Suzuki R
FAU - Ferris, Heather A
AU  - Ferris HA
FAU - Chee, Melissa J
AU  - Chee MJ
FAU - Maratos-Flier, Eleftheria
AU  - Maratos-Flier E
FAU - Kahn, C Ronald
AU  - Kahn CR
LA  - eng
GR  - 5 T32 DK007260-34/DK/NIDDK NIH HHS/United States
GR  - P30 DK036836/DK/NIDDK NIH HHS/United States
GR  - R01 DK31036/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130409
PL  - United States
TA  - PLoS Biol
JT  - PLoS biology
JID - 101183755
SB  - IM
PMC - PMC3621654
OID - NLM: PMC3621654
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04 [ppublish]
PHST- 2012/12/27 [received]
PHST- 2013/02/26 [accepted]
PHST- 2013/04/09 [epublish]
AID - 10.1371/journal.pbio.1001532 [doi]
AID - PBIOLOGY-D-12-05154 [pii]
PST - ppublish
SO  - PLoS Biol. 2013 Apr;11(4):e1001532. doi: 10.1371/journal.pbio.1001532. Epub 2013 
      Apr 9.

PMID- 23585666
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 5
DP  - 2013 May
TI  - The Dynamic Pituitary Response to Escalating-Dose TRH Stimulation Test in
      Hypothyroid Patients Treated With Liothyronine or Levothyroxine Replacement
      Therapy.
PG  - E862-6
LID - 10.1210/jc.2012-4196 [doi]
AB  - Context: A recent trial showed that 1:3 mug:mug liothyronine (L-T3) substitution 
      for levothyroxine (L-T4) achieving near-identical TSH levels resulted in a
      significant decrease in weight and cholesterol levels with no appreciable changes
      in cardiovascular parameters, suggesting a differential peripheral response to
      the therapy. Objective: We characterized the pituitary-thyroid axis in
      hypothyroid patients receiving equivalent doses of L-T3 or L-T4 by
      escalating-dose TRH stimulation test. Design: A secondary analysis of a L-T3 vs
      L-T4 therapy trial was performed. Setting: The study was conducted at the
      National Institutes of Health. Patients: Thirteen patients were studied.
      Interventions: Escalating-dose (5, 15, and 200 mug) TRH stimulation test on both 
      treatment arms. Main Outcome Measures: Study outcomes were peak serum TSH
      concentration (Cmax), time to peak TSH concentration (Tmax), area under the curve
      from 0 to 60 minutes (AUC0-60) after TRH injection. Results: Thirteen patients
      aged 51.2 +/- 8.29 years completed escalating-dose TRH stimulation test. No
      significant difference between L-T3 and L-T4 treatments was observed in TSH Cmax 
      or area under the curve. L-T4 resulted in a small but significantly shorter Tmax 
      compared to L-T3 (3.5 +/- 0.73 min on 200 mug TRH dose, P < .03). In addition, 5 
      mug TRH dose compared to 200 mug resulted in a shorter Tmax on both treatment
      arms (6.9 +/- 0.59 min L-T3, 4 +/- 0.3 min L-T4; P = .0002). Conclusions: The
      assessment of the dynamic pituitary response to escalating doses of TRH confirms 
      that substitution of L-T3 for L-T4 on a 1:3 ratio achieves a near-identical
      degree of pituitary euthyroidism. Furthermore, the data suggest that lower doses 
      of TRH might provide clinically relevant information of thyrotroph function,
      particularly when investigating partial pituitary insufficiency states.
AD  - MD, MHSc, Diabetes, Endocrinology, and Obesity Branch, National Institute of
      Diabetes and Digestive and Kidney Diseases, National Institutes of Health,
      Building 10, Clinical Research Center, Room 6-3940, 10 Center Drive, Bethesda, MD
      20892-1613. fc93a@nih.gov.
FAU - Yavuz, Sahzene
AU  - Yavuz S
FAU - Linderman, Joyce D
AU  - Linderman JD
FAU - Smith, Sheila
AU  - Smith S
FAU - Zhao, Xiongce
AU  - Zhao X
FAU - Pucino, Frank
AU  - Pucino F
FAU - Celi, Francesco S
AU  - Celi FS
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
PMC - PMC3644597
OID - NLM: PMC3644597 [Available on 05/01/14]
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PMCR- 2014/05/01 00:00
PHST- 2013/04/12 [aheadofprint]
AID - jc.2012-4196 [pii]
AID - 10.1210/jc.2012-4196 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 May;98(5):E862-6. doi: 10.1210/jc.2012-4196. Epub
      2013 Apr 12.

PMID- 23585665
OWN - NLM
STAT- In-Data-Review
DA  - 20130507
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 5
DP  - 2013 May
TI  - Validation of a Novel Method for Determining the Renal Threshold for Glucose
      Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes
      Mellitus.
PG  - E867-71
LID - 10.1210/jc.2012-4205 [doi]
AB  - Context: The stepwise hyperglycemic clamp procedure (SHCP) is the gold standard
      for measuring the renal threshold for glucose excretion (RTG), but its use is
      limited to small studies in specialized laboratories. Objective: The objective of
      the study was to validate a new method for determining RTG using data obtained
      during a mixed-meal tolerance test (MMTT) in untreated and canagliflozin-treated 
      subjects with type 2 diabetes mellitus (T2DM). Design: This was an open-label
      study with 2 sequential parts. Setting: The study was performed at a single
      center in Germany. Patients: Twenty-eight subjects with T2DM were studied.
      Interventions: No treatment intervention was given in part 1. In part 2, subjects
      were treated with canagliflozin 100 mg/d for 8 days. In each part, subjects
      underwent an MMTT and a 5-step SHCP on consecutive days. Main Outcome Measures:
      For both methods, RTG was estimated using measured blood glucose (BG) and urinary
      glucose excretion (UGE); estimated glomerular filtration rates were also used to 
      determine RTG during the MMTT. The methods were compared using the concordance
      correlation coefficient and geometric mean ratios. Results: In untreated and
      canagliflozin-treated subjects, the relationship between UGE rate and BG was well
      described by a threshold relationship. Good agreement was obtained between the
      MMTT-based and SHCP-derived RTG values. The concordance correlation coefficient
      (for all subjects) was 0.94; geometric mean ratios (90% confidence intervals) for
      RTG values (MMTT/SHCP) were 0.93 (0.89-0.96) in untreated subjects and 1.03
      (0.78-1.37) in canagliflozin-treated subjects. Study procedures and treatments
      were generally well tolerated in untreated and canagliflozin-treated subjects.
      Conclusions: In both untreated and canagliflozin-treated subjects with T2DM, RTG 
      can be accurately estimated from measured BG, UGE, and estimated glomerular
      filtration rates using an MMTT-based method.
AD  - PhD, Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, CA
      92121. DPolido1@its.jnj.com.
FAU - Polidori, David
AU  - Polidori D
FAU - Sha, Sue
AU  - Sha S
FAU - Ghosh, Atalanta
AU  - Ghosh A
FAU - Plum-Morschel, Leona
AU  - Plum-Morschel L
FAU - Heise, Tim
AU  - Heise T
FAU - Rothenberg, Paul
AU  - Rothenberg P
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/12 [aheadofprint]
AID - jc.2012-4205 [pii]
AID - 10.1210/jc.2012-4205 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 May;98(5):E867-71. doi: 10.1210/jc.2012-4205. Epub 
      2013 Apr 12.

PMID- 23585664
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 6
DP  - 2013 Jun
TI  - Serum Vitamin D and Parathyroid Hormone in Relation to Cardiac Structure and
      Function: The ICELAND-MI Substudy of AGES-Reykjavik.
PG  - 2544-52
LID - 10.1210/jc.2012-4252 [doi]
AB  - Context: Emerging evidence suggests that vitamin D and PTH may play a role in the
      development of cardiac diseases. Objective: We investigated whether
      25-hydroxyvitamin D (25OHD) and PTH concentrations are cross-sectionally
      associated with cardiac structure and function using magnetic resonance imaging
      (MRI). Design, Setting, and Participants: ICELAND-MI is a substudy of the Age,
      Gene/Environment Susceptibility-Reykjavik Study, an older-aged community-dwelling
      cohort with oversampling of participants with diabetes (29%) and measurements
      between 2004 and 2007. Serum 25OHD concentrations were measured using an
      immunoassay (n = 992). Intact PTH concentrations were measured using a 2-site
      immunoassay (n = 203). We included 969 participants for this cross-sectional
      analysis (mean age 76 +/- 5.3 years, 51% female). Mean 25OHD was 54.2 +/- 25.5
      nmol/L and the median PTH was 4.5 pmol/L (range 1.5-18). Main Outcomes: MRI to
      measure cardiac structure and function was the main outcome. Results: The lowest 
      25OHD category (<25 nmol/L) compared with the highest category (>/=75 nmol/L) was
      associated with a smaller left and right atrial area in unadjusted analyses;
      however, the associations became nonsignificant after adjustment for covariates. 
      The highest PTH quartile compared with the lowest quartile was significantly
      associated with a 7.3 g (95% confidence interval 0.8, 13.8) greater left
      ventricular (LV) mass and a 5.1% (-9.1, -1.1) lower LV ejection fraction compared
      with the lowest PTH quartile in the fully adjusted model. Conclusions: Serum
      25OHD concentrations were not associated with MRI measures in an older white
      population. Higher PTH concentrations were associated with greater LV mass and
      lower systolic function and may point to a potential role for PTH as a
      determinant of cardiac remodeling.
AD  - MSc, Department of Health Sciences, Faculty of Earth and Life Sciences, VU
      University Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands.
      hanne.van.ballegooijen@vu.nl.
FAU - van Ballegooijen, A J
AU  - van Ballegooijen AJ
FAU - Visser, M
AU  - Visser M
FAU - Cotch, M F
AU  - Cotch MF
FAU - Arai, A E
AU  - Arai AE
FAU - Garcia, M
AU  - Garcia M
FAU - Harris, T B
AU  - Harris TB
FAU - Launer, L J
AU  - Launer LJ
FAU - Eiriksdottir, G
AU  - Eiriksdottir G
FAU - Gudnason, V
AU  - Gudnason V
FAU - Brouwer, I A
AU  - Brouwer IA
LA  - eng
GR  - Z01 EY000401-06/EY/NEI NIH HHS/United States
GR  - Z01 EY000401-07/EY/NEI NIH HHS/United States
GR  - Z99 EY999999/EY/NEI NIH HHS/United States
GR  - ZIA EY000401-08/EY/NEI NIH HHS/United States
GR  - ZIA EY000401-09/EY/NEI NIH HHS/United States
GR  - ZIA EY000401-10/EY/NEI NIH HHS/United States
GR  - ZIA EY000401-11/EY/NEI NIH HHS/United States
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/12 [aheadofprint]
AID - jc.2012-4252 [pii]
AID - 10.1210/jc.2012-4252 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Jun;98(6):2544-52. doi: 10.1210/jc.2012-4252. Epub 
      2013 Apr 12.

PMID- 23585661
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 98
IP  - 6
DP  - 2013 Jun
TI  - The prevalence and natural history of pituitary hemorrhage in prolactinoma.
PG  - 2362-7
LID - 10.1210/jc.2013-1249 [doi]
AB  - Context: Incidental pituitary hemorrhage, without full pituitary apoplexy, is a
      recognized radiological finding, but little information exists on its clinical
      behavior, with most reports describing surgically treated macroprolactinoma or
      nonfunctioning adenoma. Objective: Our aim was to characterize the prevalence,
      natural history, and risk factors associated with pituitary hemorrhage in a large
      clinic prolactinoma population. Design: The design consisted of a retrospective
      analysis of a clinic population. Setting: The setting was a tertiary endocrine
      center in a large teaching hospital. Patients: We studied three hundred
      sixty-eight patients with prolactinoma. The presence of hemorrhage was documented
      on magnetic resonance imaging. Main outcome measure: The main outcome measures
      were the prevalence, risk factors, and natural history of pituitary hemorrhage.
      Results: Pituitary hemorrhage was found in 25 patients, giving an overall
      prevalence of 6.8%, and was significantly higher in macroprolactinoma (20.3%)
      compared to microprolactinoma (3.1%, P < .0001). Three patients had classical
      pituitary apoplexy. The majority of patients in the hemorrhage group had
      macroprolactinomas (16/25 [64%]) and were women (22/25 [88%]). The proportion of 
      women with macroprolactinoma was higher in the hemorrhage group (14/16
      macroprolactinomas [87.5%]) than in the nonhemorrhage group (36/63
      macroprolactinomas [57.1%], P = .02). The majority of pituitary hemorrhages (92%)
      were treated conservatively with dopamine agonist therapy for hyperprolactinemia.
      Eighty-seven percent of patients had complete resolution of their hemorrhage
      within 26.6 +/- 23.3 (mean +/- SD) months. The presence of macroprolactinoma
      (odds ratio 9.00 [95%CI 3.79-23.88], P < .001) and being female (odds ratio 8.03 
      [95%confidence interval 1.22-52.95], P = .03) were independently associated with 
      hemorrhage. Conclusions: These data show that incidental hemorrhage in
      prolactinoma is not uncommon. It is more likely to occur in macroprolactinoma,
      where 1 in 5 develop hemorrhage, and is particularly common in women with
      macroprolactinoma. The majority are asymptomatic and resolve spontaneously.
AD  - MD, FRCP, Consultant Physician and Honorary Senior Lecturer, Guy's and St Thomas'
      NHS Foundation Trust, Diabetes and Endocrine Unit, Southwark Wing, Guy's
      Hospital, Great Maze Pond, London SE1 9RT, United Kingdom. jake.powrie@kcl.ac.uk.
FAU - Sarwar, K N
AU  - Sarwar KN
FAU - Huda, M S B
AU  - Huda MS
FAU - Van de Velde, V
AU  - Van de Velde V
FAU - Hopkins, L
AU  - Hopkins L
FAU - Luck, S
AU  - Luck S
FAU - Preston, R
AU  - Preston R
FAU - McGowan, B M
AU  - McGowan BM
FAU - Carroll, P V
AU  - Carroll PV
FAU - Powrie, J K
AU  - Powrie JK
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
SB  - AIM
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/12 [aheadofprint]
AID - jc.2013-1249 [pii]
AID - 10.1210/jc.2013-1249 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2013 Jun;98(6):2362-7. doi: 10.1210/jc.2013-1249. Epub
      2013 Apr 12.

PMID- 23585643
OWN - NLM
STAT- In-Data-Review
DA  - 20130502
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 47
IP  - 5
DP  - 2013 May
TI  - Impact of medication therapy management on underserved, primarily Hispanic
      patients with diabetes.
PG  - 665-70
LID - 10.1345/aph.1R648 [doi]
AB  - BACKGROUND: Diabetes-related complications are more pronounced in Hispanic
      patients versus patients of other ethnicities. It is documented that medication
      therapy management (MTM) can improve diabetes outcomes; however, data regarding
      Hispanic patients are limited. OBJECTIVE: To evaluate the impact of MTM on
      hemoglobin A1c (A1C), blood pressure (BP), and low-density lipoprotein
      cholesterol (LDL-C) in underserved, primarily Hispanic patients who use a
      safety-net clinic as their medical home. METHODS: A retrospective, observational 
      study of uninsured, primarily Hispanic patients with diabetes who received MTM
      from October 2009 through March 2011. Patients were stratified into 2 cohorts:
      A1C less than 9% and A1C greater than or equal to 9%. Patients were also
      stratified by frequency of MTM visits and insulin use, regardless of A1C. A chart
      review was conducted to evaluate diabetes-related outcomes pre- and
      postimplementation of MTM. The primary study outcome was reduction of A1C.
      Secondary outcomes included reduction of BP and LDL-C and reduction of A1C based 
      on MTM visit frequency or insulin use. RESULTS: Sixty-four patients with at least
      1 MTM visit and pre- and postimplementation A1C data were included. In the cohort
      with A1C greater than or equal to 9%, mean (SD) A1C values decreased from 10.9%
      (1.4%) to 8.8% (1.5%) versus the cohort with A1C less than 9%, whose A1C changed 
      minimally, from 7.2% (0.9%) to 7.4% (1.4%). Regardless of their A1C, patients who
      were using insulin at baseline had a change in A1C of -0.8% (1.5%) versus -0.1%
      (1.6%) in those who were not using insulin at baseline (p = 0.04); patients who
      participated in multiple MTM visits had a significant reduction in A1C, from 9%
      to 8.3% (95% CI -1.26 to -0.03; p = 0.02) compared with patients participating in
      only 1 MTM visit. CONCLUSIONS: Pharmacist-provided MTM can significantly improve 
      diabetes control in uninsured, primarily Hispanic patients with poorly controlled
      diabetes and in those who are using insulin. Multiple MTM visits also yielded
      significant A1C reductions.
AD  - School of Pharmacy, University of Maryland, Shady Grove Campus, Rockville.
FAU - Congdon, Heather B
AU  - Congdon HB
FAU - Dowling, Thomas C
AU  - Dowling TC
FAU - Cheng, Iliana
AU  - Cheng I
FAU - Truong, Hoai-An
AU  - Truong HA
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/12 [aheadofprint]
AID - aph.1R648 [pii]
AID - 10.1345/aph.1R648 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2013 May;47(5):665-70. doi: 10.1345/aph.1R648. Epub 2013 Apr
      12.

PMID- 23585636
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1745-9206 (Electronic)
IS  - 1742-3953 (Linking)
DP  - 2013 Apr 12
TI  - A diabetes peer support intervention that improved glycemic control: mediators
      and moderators of intervention effectiveness.
AB  - OBJECTIVE: In a randomized trial, a guided diabetes peer support intervention
      improved glycemic control (A1c), with a difference in A1c change between groups
      of 0.58% (p = 0.004). The current study examined whether improvements in insulin 
      uptake and perceived diabetes social support mediated the intervention's impact
      on A1c. We also examined potential moderation by patients' health literacy,
      diabetes social support, or diabetes distress. METHODS: We conducted secondary
      analyses for 212 type 2 diabetes patients participating in the trial using
      accepted methods for testing mediation and moderation effects. RESULTS: Roughly
      half (49%, 95% CI: 3-80%) of the A1c effect was mediated by increased insulin
      use, while changes in diabetes social support had a negligible impact. A1c
      impacts varied across subgroups defined by baseline diabetes social support and
      functional health literacy (both p < 0.01). The intervention was particularly
      beneficial among patients with low baseline diabetes support or literacy levels. 
      The intervention had a greater impact on A1c among patients with more frequent
      engagement in peer support calls (p < 0.01). DISCUSSION: Patients receiving
      increased peer support had improved glycemic control largely due to their greater
      likelihood of initiating insulin. Greater intervention engagement was associated 
      with stronger effects. The intervention had its greatest benefits among patients 
      with low support or poorer health literacy.
AD  - VA Ann Arbor Center for Clinical Management Research, HSR&D Center of Excellence,
      Ann Arbor, MI, USA.
FAU - Piette, John
AU  - Piette J
FAU - Resnicow, Ken
AU  - Resnicow K
FAU - Choi, Hwajung
AU  - Choi H
FAU - Heisler, Michele
AU  - Heisler M
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Chronic Illn
JT  - Chronic illness
JID - 101253019
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 1742395313476522 [pii]
AID - 10.1177/1742395313476522 [doi]
PST - aheadofprint
SO  - Chronic Illn. 2013 Apr 12.

PMID- 23585634
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1745-9206 (Electronic)
IS  - 1742-3953 (Linking)
VI  - 9
IP  - 2
DP  - 2013 Jun
TI  - Diabetes self-management in a low-income population: impacts of social support
      and relationships with the health care system.
PG  - 145-55
LID - 10.1177/1742395313475674 [doi]
AB  - OBJECTIVES: This article reports on results of a qualitative study of social
      supports and institutional resources utilized by individuals living with diabetes
      in a high-poverty urban setting. The goal was to examine how access to social
      capital among low-income populations facilitates and impedes their self-efficacy 
      in diabetes self-management. METHODS: Semi-structured interviews were conducted
      with 34 patients with diabetes from a safety net primary care practice in
      Buffalo, New York. RESULTS: Facilitators and barriers to successful
      self-management were identified in three broad areas: (1) the influence of social
      support networks; (2) the nature of the doctor-patient relationship; and (3) the 
      nature of patient-health care system relationship. Patients' unmet needs were
      also highlighted across these three areas. DISCUSSION: Participants identified
      barriers to effective diabetes self-management directly related to their
      low-income status, such as inadequate insurance, and mistrust of the medical
      system. It may be necessary for patients to activate social capital from multiple
      social spheres to achieve the most effective diabetes management.
AD  - 1Primary Care Research Institute, Department of Family Medicine, State University
      of New York at Buffalo, Buffalo, NY, USA.
FAU - Vest, Bonnie M
AU  - Vest BM
FAU - Kahn, Linda S
AU  - Kahn LS
FAU - Danzo, Andrew
AU  - Danzo A
FAU - Tumiel-Berhalter, Laurene
AU  - Tumiel-Berhalter L
FAU - Schuster, Roseanne C
AU  - Schuster RC
FAU - Karl, Renee
AU  - Karl R
FAU - Taylor, Robert
AU  - Taylor R
FAU - Glaser, Kathryn
AU  - Glaser K
FAU - Danakas, Alexandra
AU  - Danakas A
FAU - Fox, Chester H
AU  - Fox CH
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - Chronic Illn
JT  - Chronic illness
JID - 101253019
SB  - IM
OTO - NOTNLM
OT  - Diabetes
OT  - low-income populations
OT  - qualitative
OT  - self-management
OT  - social capital
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/12 [aheadofprint]
AID - 1742395313475674 [pii]
AID - 10.1177/1742395313475674 [doi]
PST - ppublish
SO  - Chronic Illn. 2013 Jun;9(2):145-55. doi: 10.1177/1742395313475674. Epub 2013 Apr 
      12.

PMID- 23585547
OWN - NLM
STAT- In-Data-Review
DA  - 20130503
IS  - 1468-201X (Electronic)
IS  - 1355-6037 (Linking)
VI  - 99
IP  - 11
DP  - 2013 Jun
TI  - Reply: diagnosing vascular mild cognitive impairment with atrial fibrillation
      remains a challenge.
PG  - 819-20
LID - 10.1136/heartjnl-2013-303965 [doi]
AD  - NHMRC Centre of Research Excellence to Reduce Inequality in Heart Disease,
      Preventative Health, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 3004,
      Australia; Simon.Stewart@bakeridi.edu.au.
FAU - Ball, Jocasta
AU  - Ball J
FAU - Carrington, Melinda J
AU  - Carrington MJ
FAU - Stewart, Simon
AU  - Stewart S
CN  - SAFETY investigators
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - England
TA  - Heart
JT  - Heart (British Cardiac Society)
JID - 9602087
SB  - AIM
SB  - IM
OTO - NOTNLM
OT  - Quality Of Care And Outcomes
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/12 [aheadofprint]
AID - heartjnl-2013-303965 [pii]
AID - 10.1136/heartjnl-2013-303965 [doi]
PST - ppublish
SO  - Heart. 2013 Jun;99(11):819-20. doi: 10.1136/heartjnl-2013-303965. Epub 2013 Apr
      12.

PMID- 23585338
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1933-7205 (Electronic)
IS  - 1933-7191 (Linking)
DP  - 2013 Apr 12
TI  - The Role of TGF-beta in Polycystic Ovary Syndrome.
AB  - Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by 
      chronic oligoanovulation and hyperandrogenism and associated with insulin
      resistance, type 2 diabetes, and cardiovascular risk. In recent years, genetic
      studies have linked PCOS to a dinucleotide marker D19S884 in the fibrillin 3
      gene. Fibrillins make up the major component of microfibrils in the extracellular
      matrix (ECM) and interact with molecules in the ECM to regulate transforming
      growth factor beta (TGF-beta) signaling. Therefore, variations in fibrillin 3 and
      subsequent dysregulation of TGF-beta may contribute to the pathogenesis of PCOS. 
      Here, we review the evidence from genetic studies supporting the role of TGF-beta
      in PCOS and describe how TGF-beta dysregulation may contribute to (1) the fetal
      origins of PCOS, (2) reproductive abnormalities in PCOS, and (3) cardiovascular
      and metabolic abnormalities in PCOS.
AD  - 1Division of Endocrinology, Diabetes, and Metabolism, Pennsylvania State
      University College of Medicine, M.S. Hershey Medical Center, Hershey, PA, USA.
FAU - Raja-Khan, Nazia
AU  - Raja-Khan N
FAU - Urbanek, Margrit
AU  - Urbanek M
FAU - Rodgers, Raymond J
AU  - Rodgers RJ
FAU - Legro, Richard S
AU  - Legro RS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Reprod Sci
JT  - Reproductive sciences (Thousand Oaks, Calif.)
JID - 101291249
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 1933719113485294 [pii]
AID - 10.1177/1933719113485294 [doi]
PST - aheadofprint
SO  - Reprod Sci. 2013 Apr 12.

PMID- 23585317
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1735-9694 (Electronic)
IS  - 0044-6025 (Linking)
VI  - 51
IP  - 2
DP  - 2013
TI  - Effects of diabetes mellitus type Iota with or without neuropathy on vestibular
      evoked myogenic potentials.
PG  - 107-12
AB  - Diabetes mellitus type Iota is a metabolic disorder that affects multiple systems
      including the inner ear. Patients with diabetes mellitus commonly complain about 
      dizziness, floating sensation, tinnitus and sweating. The aim of this study was
      to compare vestibular evoked myogenic potentials (VEMPs) between diabetic
      patients with or without neuropathy. Subjects included 14 patients with diabetes 
      mellitus type Iota with polyneuropathy, 10 patients with diabetes mellitus type
      Iota without polyneuropathy and 24 healthy volunteers. Range of age in
      participants was 15-40 years old. The VEMPs were recorded with 500 Hz tone bursts
      with intensity at 95 dB. There was statistically significant difference between
      the groups in P13 and N23 latencies (P&lt;0.05). There was no statistically
      significant difference between groups in absolute and relative amplitudes.
      Prolonged latencies of the VEMP suggest lesions in the retrolabyrinthine,
      especially in the vestibulospinal tract.
AD  - Department of Audiology, Faculty of Rehabilitation, Tehran University of Medical 
      Sciences, Tehran, Iran. abolhassani@sina.tums.ac.ir
FAU - Kamali, Behnoush
AU  - Kamali B
FAU - Hajiabolhassan, Fahimeh
AU  - Hajiabolhassan F
FAU - Fatahi, Jamileh
AU  - Fatahi J
FAU - Nasli Esfahani, Ensieh
AU  - Nasli Esfahani E
FAU - Sarrafzadeh, Javad
AU  - Sarrafzadeh J
FAU - Faghihzadeh, Soghrat
AU  - Faghihzadeh S
LA  - eng
PT  - Journal Article
DEP - 20130316
PL  - Iran
TA  - Acta Med Iran
JT  - Acta medica Iranica
JID - 14540050R
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/03/16 [received]
PHST- 2013/03/16 [accepted]
PST - epublish
SO  - Acta Med Iran. 2013 Mar 16;51(2):107-12.

PMID- 23585309
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1179-2027 (Electronic)
IS  - 1170-7690 (Linking)
VI  - 31
IP  - 6
DP  - 2013 Jun
TI  - Simulating lifetime outcomes associated with complications for people with type 1
      diabetes.
PG  - 509-18
LID - 10.1007/s40273-013-0047-4 [doi]
AB  - OBJECTIVES: The aim of this study was to develop a discrete-time simulation model
      for people with type 1 diabetes mellitus, to estimate and compare mean life
      expectancy and quality-adjusted life-years (QALYs) over a lifetime between
      intensive and conventional blood glucose treatment groups. METHODS: We
      synthesized evidence on type 1 diabetes patients using several published sources.
      The simulation model was based on 13 equations to estimate risks of events and
      mortality. Cardiovascular disease (CVD) risk was obtained from results of the
      DCCT (diabetes control and complications trial). Mortality post-CVD event was
      based on a study using linked administrative data on people with diabetes from
      Western Australia. Information on incidence of renal disease and the progression 
      to CVD was obtained from studies in Finland and Italy. Lower-extremity amputation
      (LEA) risk was based on the type 1 diabetes Swedish inpatient registry, and the
      risk of blindness was obtained from results of a German-based study. Where
      diabetes-specific data were unavailable, information from other populations was
      used. We examine the degree and source of parameter uncertainty and illustrate an
      application of the model in estimating lifetime outcomes of using intensive and
      conventional treatments for blood glucose control. RESULTS: From 15 years of age,
      male and female patients had an estimated life expectancy of 47.2 (95 % CI
      35.2-59.2) and 52.7 (95 % CI 41.7-63.6) years in the intensive treatment group.
      The model produced estimates of the lifetime benefits of intensive treatment for 
      blood glucose from the DCCT of 4.0 (95 % CI 1.2-6.8) QALYs for women and 4.6 (95 
      % CI 2.7-6.9) QALYs for men. Absolute risk per 1,000 person-years for fatal CVD
      events was simulated to be 1.37 and 2.51 in intensive and conventional treatment 
      groups, respectively. CONCLUSIONS: The model incorporates diabetic complications 
      risk data from a type 1 diabetes population and synthesizes other type 1-specific
      data to estimate long-term outcomes of CVD, end-stage renal disease, LEA and risk
      of blindness, along with life expectancy and QALYs. External validation was
      carried out using life expectancy and absolute risk for fatal CVD events. Because
      of the flexible and transparent nature of the model, it has many potential future
      applications.
AD  - Centre for Health Policy, Programs and Economics, School of Population Health,
      The University of Melbourne, Melbourne, VIC, 3053, Australia,
      tom.lung@unimelb.edu.au.
FAU - Lung, Tom W C
AU  - Lung TW
FAU - Clarke, Philip M
AU  - Clarke PM
FAU - Hayes, Alison J
AU  - Hayes AJ
FAU - Stevens, Richard J
AU  - Stevens RJ
FAU - Farmer, Andrew
AU  - Farmer A
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Pharmacoeconomics
JT  - PharmacoEconomics
JID - 9212404
SB  - T
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1007/s40273-013-0047-4 [doi]
PST - ppublish
SO  - Pharmacoeconomics. 2013 Jun;31(6):509-18. doi: 10.1007/s40273-013-0047-4.

PMID- 23585143
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 13
IP  - 3
DP  - 2013 Jun
TI  - Clinical inertia in poorly controlled elderly hypertensive patients: a
      cross-sectional study in spanish physicians to ascertain reasons for not
      intensifying treatment.
PG  - 213-9
LID - 10.1007/s40256-013-0025-4 [doi]
AB  - BACKGROUND: Clinical inertia, the failure of physicians to initiate or intensify 
      therapy when indicated, is a major problem in the management of hypertension and 
      may be more prevalent in elderly patients. Overcoming clinical inertia requires
      understanding its causes and evaluating certain factors, particularly those
      related to physicians. OBJECTIVE: The objective of our study was to determine the
      rate of clinical inertia and the physician-reported reasons for it. METHODS: An
      observational, cross-sectional, multi-center study was carried out in a primary
      care setting. We included 512 physicians, with a consecutive sampling of 1,499
      hypertensive patients with clinical inertia. MAIN OUTCOME MEASURE: Clinical
      inertia was defined when physicians did not modify treatment despite knowing that
      the therapeutic target had not been reached. Clinical inertia was considered to
      be justified (JCI) when physicians provided an explanation for not intensifying
      treatment and as not justified (nJCI) when no reasons were given. RESULTS: JCI
      was observed in 30.1 % (95 % CI 27.8-32.4) of patients (n = 451) and nJCI in 69.9
      % (95 % CI 67.6-72.2) (n = 1,058). JCI was associated with higher blood pressure 
      (BP) values (both systolic and diastolic) and diabetes (p = 0.012) than nJCI.
      nJCI was associated with patients having an isolated increase of systolic or
      diastolic or high borderline BP values or cardiovascular disease. CONCLUSION:
      Physicians provided reasons for not intensifying treatment in poorly controlled
      patients in only 30 % of instances. Main reasons for not intensifying treatment
      were borderline BP values, co-morbidity, suspected white coat effect, or
      perceived difficulty achieving target. nJCI was associated with high borderline
      BP values and cardiovascular disease.
AD  - Catedra de Medicina de Familia, Departamento de Medicina Clinica, Universidad
      Miguel Hernandez, Ctra. De Valencia N332 Km 87, San Juan, 03550, Alicante, Spain,
      atencion.primaria@umh.es.
FAU - Gil-Guillen, Vicente
AU  - Gil-Guillen V
FAU - Orozco-Beltran, Domingo
AU  - Orozco-Beltran D
FAU - Carratala-Munuera, Concepcion
AU  - Carratala-Munuera C
FAU - Marquez-Contreras, Emilio
AU  - Marquez-Contreras E
FAU - Durazo-Arvizu, Ramon
AU  - Durazo-Arvizu R
FAU - Cooper, Richard
AU  - Cooper R
FAU - Pertusa-Martinez, Salvador
AU  - Pertusa-Martinez S
FAU - Pita-Fernandez, Salvador
AU  - Pita-Fernandez S
FAU - Gonzalez-Segura, Diego
AU  - Gonzalez-Segura D
FAU - Martin-de-Pablo, Jose Luis
AU  - Martin-de-Pablo JL
FAU - Pallares, Vicente
AU  - Pallares V
FAU - Fernandez, Antonio
AU  - Fernandez A
FAU - Redon, Josep
AU  - Redon J
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other
      interventions
JID - 100967755
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1007/s40256-013-0025-4 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2013 Jun;13(3):213-9. doi: 10.1007/s40256-013-0025-4.

PMID- 23585138
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1522-1539 (Electronic)
IS  - 0363-6135 (Linking)
DP  - 2013 Apr 12
TI  - Nitric Oxide Regulates Vascular Adaptive Mitochondrial Dynamics.
AB  - Cardiovascular disease (CVD) risk factors, such as diabetes, hypertension,
      dyslipidemia, obesity and physical inactivity, are all correlated with impaired
      endothelial Nitric Oxide Synthase (eNOS) function and decreased nitric oxide (NO)
      production. NO-mediated regulation of mitochondrial biogenesis has been
      established in many tissues, yet the role of eNOS in vascular mitochondrial
      biogenesis and dynamics is unclear. We hypothesized that genetic eNOS deletion
      and 3-day NOS inhibition in rodents would result in impaired mitochondrial
      biogenesis and defunct fission/fusion and autophagy profiles within the aorta. We
      observed a significant, eNOS expression-dependent decrease in mitochondrial
      electron transport chain (ETC) protein subunits from complexes I, II, III, and V 
      in eNOS heterozygotes and eNOS null mice compared to age-matched controls. In
      response to NOS inhibition with Lg-Nitro-Arginine Methyl Ester (L-NAME) treatment
      in Sprague Dawley rats, significant decreases were observed in ETC protein
      subunits from complexes I, III, and IV as well as VDAC1. Decreased protein
      content of upstream regulators of mitochondrial biogenesis, CREB and PGC1-alpha, 
      were observed in response to 3-day L-NAME treatment. Both genetic eNOS deletion
      and NOS inhibition resulted in decreased MnSOD protein. L-NAME treatment resulted
      in significant changes to mitochondrial dynamics protein profiles with decreased 
      fusion, increased fission, and minimally perturbed autophagy. In addition, L-NAME
      treatment blocked mitochondrial adaptation to an exercise intervention in the
      aorta. These results suggest that eNOS/NO play a role in basal and adaptive
      mitochondrial biogenesis in the vasculature and regulation of mitochondrial
      turnover.
AD  - 1University of Colorado.
FAU - Miller, Matthew W
AU  - Miller MW
FAU - Knaub, Leslie A
AU  - Knaub LA
FAU - Olivera-Fragoso, Luis F
AU  - Olivera-Fragoso LF
FAU - Keller, Amy C
AU  - Keller AC
FAU - Balasubramaniam, Vivek
AU  - Balasubramaniam V
FAU - Watson, Peter A
AU  - Watson PA
FAU - Reusch, Jane E B
AU  - Reusch JE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - ajpheart.00987.2012 [pii]
AID - 10.1152/ajpheart.00987.2012 [doi]
PST - aheadofprint
SO  - Am J Physiol Heart Circ Physiol. 2013 Apr 12.

PMID- 23585076
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
DP  - 2013 Apr 15
TI  - Reduction of Intestinal Electrogenic Glucose Absorption After Duodenojejunal
      Bypass in a Mouse Model.
AB  - BACKGROUND: The role of intestinal glucose absorption in reducing glycemic levels
      after duodenojejunal bypass (DJB) is unclear. We hypothesized that DJB surgery
      decreases intestinal electrogenic glucose absorption by sodium glucose
      co-transporter 1 (SGLT1), leading to decreased glucose absorption and reduced
      blood glucose. Six groups of C57/BL6 mice were studied (n = 6 each) 2 weeks, 1
      month, and 2 months after DJB or sham surgery. METHODS: Daily weight and food
      intake were measured for 1 month and an oral glucose tolerance test was performed
      2 months after surgery. Electrogenic glucose absorption was quantified in an
      Ussing chamber according to the sodium-dependent increase of short-circuit
      current (Isc). Intestinal morphology was assessed by hematoxylin and eosin
      staining. Expression of SGLT1 was determined by quantitative PCR and Western
      blotting. RESULTS: The DJB mice lost weight compared with the sham group and
      exhibited significant adaptive changes, with increased villus height, crypt
      depth, and villus surface area. Oral glucose absorption was significantly reduced
      in the DJB mice compared with the sham group. Glucose-induced Isc was
      significantly lower in the DJB mice than in the sham mice 1 and 2 months after
      surgery, indicating that SGLT1 activity was reduced after DJB. Transcript levels 
      and protein abundance of SGLT1 after DJB were also decreased compared with the
      sham group. CONCLUSIONS: DJB surgery reduced intestinal glucose absorption by
      reducing the activity and expression of the glucose transporter SGLT1, which
      represents a potential therapeutic target for patients with diabetes.
AD  - Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery; First
      Affiliated Hospital, School of Medicine; Key Laboratory of Combined Multi-Organ
      Transplantation, Ministry of Public Health; Key Laboratory of Organ
      Transplantation, Zhejiang University, Hangzhou, Zhejiang Province, 310003, China,
      shengyan@zju.edu.cn.
FAU - Yan, Sheng
AU  - Yan S
FAU - Sun, Fei
AU  - Sun F
FAU - Li, Zhiwei
AU  - Li Z
FAU - Xiang, Jie
AU  - Xiang J
FAU - Ding, Yuan
AU  - Ding Y
FAU - Lu, Zhongjie
AU  - Lu Z
FAU - Tian, Yang
AU  - Tian Y
FAU - Chen, Hui
AU  - Chen H
FAU - Zhang, Jinhua
AU  - Zhang J
FAU - Wang, Yan
AU  - Wang Y
FAU - Song, Penghong
AU  - Song P
FAU - Zhou, Lin
AU  - Zhou L
FAU - Zheng, Shusen
AU  - Zheng S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1007/s11695-013-0954-7 [doi]
PST - aheadofprint
SO  - Obes Surg. 2013 Apr 15.

PMID- 23584985
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1559-0755 (Electronic)
IS  - 0257-277X (Linking)
DP  - 2013 Apr 13
TI  - Novel risk factors for cardiovascular disease in rheumatoid arthritis.
AB  - Since cardiovascular disease (CVD) is the most common cause of mortality in
      patients with rheumatoid arthritis (RA), we aimed to determine factors associated
      with such a complication in a large series of Colombian patients. This was a
      cross-sectional analytical study in which 800 consecutive Colombian patients with
      RA were assessed for variables associated with CVD. Furthermore, a systematic
      literature review was performed to address the state of the art about
      non-traditional risk factors for CVD in RA. The preferred reporting items for
      systematic reviews and meta-analyses guidelines were followed in data extraction,
      analysis, and reporting of articles selected. Hypercholesterolemia, type 2
      diabetes mellitus, abnormal body mass index, abdominal obesity, and current
      smoking were all traditional risk factors significantly associated with CVD in
      Colombians. As non-traditional risk factors, familial autoimmunity, more than 10 
      years of duration of the disease, patients working on household duties, use of
      systemic steroids, and low education level were associated with CVD in the
      studied population. Out of a total of 9,812 articles identified in PubMed and
      Scopus databases, 140 fulfilled the eligibility criteria and were included.
      Through this systematic review, several factors and outcomes related to CVD were 
      confirmed and identified. These were categorized into genetics, RA-related, and
      others. Traditional risk factors do not completely explain the high rates of CVD 
      in patients with RA; thus, novel risk factors related to autoimmunity are now
      recognized predicting the presence of CVD as strong as traditional risk factors. 
      Our results may assist health professionals and policymakers in making decisions 
      about CVD in patients with RA.
AD  - Center for Autoimmune Diseases Research (CREA), School of Medicine and Health
      Sciences, Universidad del Rosario, Carrera 24 No. 63C-69, Bogota, Colombia.
FAU - Amaya-Amaya, Jenny
AU  - Amaya-Amaya J
FAU - Sarmiento-Monroy, Juan Camilo
AU  - Sarmiento-Monroy JC
FAU - Mantilla, Ruben-Dario
AU  - Mantilla RD
FAU - Pineda-Tamayo, Ricardo
AU  - Pineda-Tamayo R
FAU - Rojas-Villarraga, Adriana
AU  - Rojas-Villarraga A
FAU - Anaya, Juan-Manuel
AU  - Anaya JM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - Immunol Res
JT  - Immunologic research
JID - 8611087
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1007/s12026-013-8398-7 [doi]
PST - aheadofprint
SO  - Immunol Res. 2013 Apr 13.

PMID- 23584958
OWN - NLM
STAT- Publisher
DA  - 20130605
IS  - 1097-0010 (Electronic)
IS  - 0022-5142 (Linking)
DP  - 2013 Apr 12
TI  - Key points for maximum effectiveness and safety for cholesterol-lowering
      properties of plant sterols and use in the treatment of metabolic syndrome.
LID - 10.1002/jsfa.6174 [doi]
AB  - According to the American Diabetes Association and the Adult Treatment Panel III,
      the starting point for treating metabolic syndrome (MS) is a change of lifestyle.
      In addition, action on the main symptoms of MS by means of dietary supplements,
      can be helpful in view of the chronic course of the disease. The term
      'phytosterols' refers to sterols and stanols composed of lipophilic triterpenes, 
      a family that is widely distributed in the plant kingdom and whose
      cholesterol-lowering properties have been amply demonstrated. In the light of the
      recent literature, the key points for maximum effectiveness and safety of sterols
      are the following. (A) Plant sterols should be taken with meals: clinical trials 
      have shown that when plant sterols are consumed close to mealtimes, low-density
      lipoprotein cholesterol may decrease by 9.4%, while when they are taken between
      meals, the reduction is about 6%. (B) The optimal dosage is 2-2.5 g day-1 in a
      single dose. More than 3 g day-1 has not been found to have any additional
      beneficial effect and increases the risk of side effects. (C) The food matrix
      used to dissolve the phytosterols should contain a certain amount of fat. A
      milk-based matrix appears optimal from this point of view. (c) 2013 Society of
      Chemical Industry.
CI  - (c) 2013 Society of Chemical Industry.
AD  - Human Nutrition Section, Health Sciences Department, University of Pavia, Azienda
      di Servizi alla Persona, Pavia, Italy.
FAU - Rondanelli, Mariangela
AU  - Rondanelli M
FAU - Monteferrario, Francesca
AU  - Monteferrario F
FAU - Faliva, Milena Anna
AU  - Faliva MA
FAU - Perna, Simone
AU  - Perna S
FAU - Antoniello, Neldo
AU  - Antoniello N
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Sci Food Agric
JT  - Journal of the science of food and agriculture
JID - 0376334
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/01/19 [received]
PHST- 2013/04/02 [revised]
PHST- 2013/04/12 [accepted]
AID - 10.1002/jsfa.6174 [doi]
PST - aheadofprint
SO  - J Sci Food Agric. 2013 Apr 12. doi: 10.1002/jsfa.6174.

PMID- 23584921
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1179-1985 (Electronic)
IS  - 1120-9879 (Linking)
DP  - 2013 Apr 13
TI  - Non-Alcoholic Fatty Liver Disease is Not Associated with Vitamin D Deficiency in 
      Essential Hypertension.
AB  - An independent association between non-alcoholic fatty liver disease (NAFLD), a
      condition characterized by insulin-resistance, and low serum 25-hydroxyvitamin D 
      [25(OH)D] levels has been reported. 25(OH)D concentrations are directly related
      with insulin sensitivity, whereas low [25(OH)D] predicts development of
      hypertension independent of glucose homeostasis alterations. We hypothesized that
      hypertensive patients with NAFLD have lower 25(OH)D than those without.
      Forty-four essential hypertensive (EH) patients with (n = 23) or without (n = 21)
      NAFLD were studied. No patient had diabetes mellitus, obesity, hyperlipidemia.
      The two hypertensive groups were compared with 24 healthy normotensive sex-,
      age-, body mass index (BMI)-matched subject, as controls. The two hypertensive
      groups had comparable age, sex, and blood pressure. BMI, glucose, insulin,
      homeostasis model assessment (HOMA) index and alanine aminotransferase were
      higher (P < 0.001 to <0.05) and plasma adiponectin was lower (P < 0.05) in EH
      patients with NAFLD than in those without NAFLD. Vitamin D deficiency, as defined
      by 25(OH)D levels <50 nmol/L, was similarly frequent in EH patients and controls 
      (47.7 % vs. 45.8 %, P NS). Prevalence of hypovitaminosis D was not different in
      EH patients with and without NAFLD (37.5 % vs. 38.8 %, P NS). In patients with EH
      and no additional cardiometabolic risk factors NAFLD is not associated with
      vitamin D deficiency.
AD  - Department of Experimental and Clinical Medicine, University of Udine, Udine,
      Italy.
FAU - Catena, Cristiana
AU  - Catena C
FAU - Cosma, Chiara
AU  - Cosma C
FAU - Camozzi, Valentina
AU  - Camozzi V
FAU - Plebani, Mario
AU  - Plebani M
FAU - Ermani, Mario
AU  - Ermani M
FAU - Sechi, Leonardo A
AU  - Sechi LA
FAU - Fallo, Francesco
AU  - Fallo F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - High Blood Press Cardiovasc Prev
JT  - High blood pressure & cardiovascular prevention : the official journal of the
      Italian Society of Hypertension
JID - 9421087
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/07 [received]
PHST- 2013/01/14 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - 10.1007/s40292-013-0010-7 [doi]
PST - aheadofprint
SO  - High Blood Press Cardiovasc Prev. 2013 Apr 13.

PMID- 23584890
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1097-0223 (Electronic)
IS  - 0197-3851 (Linking)
DP  - 2013 Apr 13
TI  - First trimester prediction of early onset preeclampsia using demographic,
      clinical, and sonographic data: a cohort study.
PG  - 1-5
LID - 10.1002/pd.4113 [doi]
AB  - OBJECTIVE: The aim of this research was to evaluate the performance of a
      predictive model for early onset preeclampsia (PE) during early gestation.
      METHOD: Prospective multicenter cohort study was performed in women attending
      11-14 weeks ultrasound. Medical history and biometrical variables were recorded
      and uterine artery Doppler was performed. All patients were followed until
      postpartum period. Constructed predictive models were compared using the area
      under the associated receiver operating characteristic curve. Sensitivity,
      specificity, and likelihood ratios were estimated for each outcome. RESULTS: A
      total of 627 patients were enrolled. Sixty-five (10.4%) developed gestational
      hypertension, of which 29 developed PE (4.6% of the total sample) and nine
      occurred before 34 weeks (1.5% of total sample). Prediction model generated for
      early onset PE (ePE) with 5% false positive achieve sensitivity of 62.5% and
      specificity of 95.5%. The positive and negative likelihood ratios for ePE were
      13.9 and 0.39, respectively. Development of ePE was significantly associated with
      history of preterm labor (p = 0.002) and diabetes mellitus (p = 0.02).
      CONCLUSIONS: This study confirms the advantage of combining multiple variables
      for prediction of ePE. (c) 2013 John Wiley & Sons, Ltd.
CI  - (c) 2013 John Wiley & Sons, Ltd.
AD  - Universidad de los Andes, Fetal Medicine Unit, Departments of Obstetrics &
      Gynecology and Reproduction Biology Laboratory, Santiago, Chile.
FAU - Caradeux, Javier
AU  - Caradeux J
FAU - Serra, Ramon
AU  - Serra R
FAU - Nien, Jyh-Kae
AU  - Nien JK
FAU - Perez-Sepulveda, Alejandra
AU  - Perez-Sepulveda A
FAU - Schepeler, Manuel
AU  - Schepeler M
FAU - Guerra, Francisco
AU  - Guerra F
FAU - Gutierrez, Jorge
AU  - Gutierrez J
FAU - Martinez, Jaime
AU  - Martinez J
FAU - Cabrera, Cristian
AU  - Cabrera C
FAU - Figueroa-Diesel, Horacio
AU  - Figueroa-Diesel H
FAU - Soothill, Peter
AU  - Soothill P
FAU - Illanes, Sebastian E
AU  - Illanes SE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - Prenat Diagn
JT  - Prenatal diagnosis
JID - 8106540
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/07 [received]
PHST- 2013/03/03 [revised]
PHST- 2013/03/21 [accepted]
AID - 10.1002/pd.4113 [doi]
PST - aheadofprint
SO  - Prenat Diagn. 2013 Apr 13:1-5. doi: 10.1002/pd.4113.

PMID- 23584834
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1758-0463 (Electronic)
VI  - 2013
DP  - 2013
TI  - A database for curating the associations between killer cell immunoglobulin-like 
      receptors and diseases in worldwide populations.
PG  - bat021
LID - 10.1093/database/bat021 [doi]
AB  - The killer cell immunoglobulin-like receptors (KIR) play a fundamental role in
      the innate immune system, through their interactions with human leucocyte antigen
      (HLA) molecules, leading to the modulation of activity in natural killer (NK)
      cells, mainly related to killing pathogen-infected cells. KIR genes are hugely
      polymorphic both in the number of genes an individual carries and in the number
      of alleles identified. We have previously developed the Allele Frequency Net
      Database (AFND, http://www.allelefrequencies.net), which captures worldwide
      frequencies of alleles, genes and haplotypes for several immune genes, including 
      KIR genes, in healthy populations, covering >4 million individuals. Here, we
      report the creation of a new database within AFND, named KIR and Diseases
      Database (KDDB), capturing a large quantity of data derived from publications in 
      which KIR genes, alleles, genotypes and/or haplotypes have been associated with
      infectious diseases (e.g. hepatitis C, HIV, malaria), autoimmune disorders (e.g. 
      type I diabetes, rheumatoid arthritis), cancer and pregnancy-related
      complications. KDDB has been created through an extensive manual curation effort,
      extracting data on more than a thousand KIR-disease records, comprising >50 000
      individuals. KDDB thus provides a new community resource for understanding not
      only how KIR genes are associated with disease, but also, by working in tandem
      with the large data sets already present in AFND, where particular genes,
      genotypes or haplotypes are present in worldwide populations or different ethnic 
      groups. We anticipate that KDDB will be an important resource for researchers
      working in immunogenetics. Database URL:
      http://www.allelefrequencies.net/diseases/.
AD  - Institute of Integrative Biology, Functional and Comparative Genomics, University
      of Liverpool, Liverpool, L69 7ZB, UK. L.Takeshita@liverpool.ac.uk
FAU - Takeshita, Louise Y C
AU  - Takeshita LY
FAU - Gonzalez-Galarza, Faviel F
AU  - Gonzalez-Galarza FF
FAU - dos Santos, Eduardo J M
AU  - dos Santos EJ
FAU - Maia, Maria Helena T
AU  - Maia MH
FAU - Rahman, Mushome M
AU  - Rahman MM
FAU - Zain, Syed M S
AU  - Zain SM
FAU - Middleton, Derek
AU  - Middleton D
FAU - Jones, Andrew R
AU  - Jones AR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130412
PL  - England
TA  - Database (Oxford)
JT  - Database : the journal of biological databases and curation
JID - 101517697
SB  - IM
PMC - PMC3625957
OID - NLM: PMC3625957
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013 [ppublish]
AID - bat021 [pii]
AID - 10.1093/database/bat021 [doi]
PST - epublish
SO  - Database (Oxford). 2013 Apr 12;2013:bat021. doi: 10.1093/database/bat021. Print
      2013.

PMID- 23584706
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1432-0878 (Electronic)
IS  - 0302-766X (Linking)
VI  - 352
IP  - 3
DP  - 2013 Jun
TI  - Expression of insulin signalling components in the sensory epithelium of the
      human saccule.
PG  - 469-78
LID - 10.1007/s00441-013-1614-x [doi]
AB  - Several studies have demonstrated a link between diabetes and the dysfunction of 
      the inner ear. Few studies, however, have reported the signalling mechanisms
      involved in metabolic control in human inner ear cells. Knowledge of the
      expression and role of the insulin receptor and downstream signalling components 
      in the inner ear is sparce. Our immunohistochemistry approach has shown that the 
      insulin receptor, insulin receptor substrate 1 (IRS1), protein kinase B (PKB) and
      insulin-sensitive glucose transporter (GLUT4) are expressed in the sensory
      epithelium of the human saccule, which also exhibits expression of a
      calcium-sensitive cAMP/cGMP phosphodiesterase 1C (PDE1C) and the vasopressin type
      2 receptor. IRS1 and PDE1C are selectively expressed in sensory epithelial hair
      cells, whereas the other components are expressed in sensory epithelial
      supporting cells or in both cell types, as judged from co-expression or
      non-co-expression with glial fibrillary acidic protein, a marker for supporting
      cells. Furthermore, IRS1 appears to be localized in association with sensory
      nerves, whereas GLUT4 is expressed in the peri-nuclear area of stromal cells, as 
      is the case for aquaporin 2. Thus, the insulin receptor, insulin signalling
      components and selected cAMP signalling components are expressed in the human
      saccule. In addition to well-known mechanisms of diabetes complications, such as 
      neuropathy and vascular lesions, the expression of these proteins in the saccule 
      could have a role in the observed link between diabetes and balance/hearing
      disorders.
AD  - Department of Experimental Medical Sciences, Section for Diabetes, Metabolism and
      Endocrinology, Lund University, Biomedical Center, C11, 221 84, Lund, Sweden,
      eva.degerman@med.lu.se.
FAU - Degerman, Eva
AU  - Degerman E
FAU - Rauch, Uwe
AU  - Rauch U
FAU - Lindberg, Sven
AU  - Lindberg S
FAU - Caye-Thomasen, Per
AU  - Caye-Thomasen P
FAU - Hultgardh, Anna
AU  - Hultgardh A
FAU - Magnusson, Mans
AU  - Magnusson M
LA  - eng
PT  - Journal Article
DEP - 20130416
PL  - Germany
TA  - Cell Tissue Res
JT  - Cell and tissue research
JID - 0417625
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/25 [received]
PHST- 2013/03/08 [accepted]
PHST- 2013/04/16 [aheadofprint]
AID - 10.1007/s00441-013-1614-x [doi]
PST - ppublish
SO  - Cell Tissue Res. 2013 Jun;352(3):469-78. doi: 10.1007/s00441-013-1614-x. Epub
      2013 Apr 16.

PMID- 23584702
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1539-2864 (Electronic)
IS  - 0275-004X (Linking)
DP  - 2013 Apr 11
TI  - CHRONIC RETINAL NECROSIS: Cytomegalovirus Necrotizing Retinitis Associated With
      Panretinal Vasculopathy in Non-HIV Patients.
AB  - PURPOSE:: To characterize a unique cytomegalovirus (CMV)-associated retinopathy
      in patients with limited immune dysfunction. METHODS:: Retrospective
      observational case series. CMV was confirmed as the pathogenic agent via
      polymerase chain reaction analysis of aqueous or vitreous humor samples or via
      immunohistochemical analysis of retinal biopsy specimens. RESULTS:: Five non-HIV 
      patients with granular necrotizing retinitis, vitritis, and severe occlusive
      vasculopathy were identified. Patient histories all suggested a basis for limited
      immune dysfunction including advanced age (n = 4), diabetes mellitus (n = 4), and
      noncytotoxic immunotherapy (n = 3). Diagnosis of CMV retinitis was delayed in all
      cases and patients received either no antiviral therapy (n = 2) or incorrect
      antiviral therapy (n = 3) for presumed herpes simplex/varicella zoster-related
      acute retinal necrosis. Retinitis subsequently regressed in all cases with
      introduction of systemic ganciclovir/valganciclovir (n = 5) and/or intravitreal
      foscarnet (n = 2). Four of five patients developed neovascularization because of 
      extensive retinal ischemia. CONCLUSION:: The clinical expression of
      CMV-associated retinopathy is strongly related to immune status. In patients with
      limited immune dysfunction, a mixed clinical picture of intraocular inflammation 
      with panretinal occlusive vasculopathy, more characteristic of acute retinal
      necrosis, and peripheral slowly progressive granular retinitis, more
      characteristic of classic CMV retinitis, is observed. Recognition of this
      atypical clinical presentation, which the authors term chronic retinal necrosis, 
      should prompt molecular testing for CMV to determine the appropriate antiviral
      therapy. Consideration should also be given to prophylactic panretinal
      photocoagulation in such eyes, given the high risk of neovascular complications.
AD  - *Department of Ophthalmology and Visual Sciences, University of Michigan, W.K.
      Kellogg Eye Center, Ann Arbor, Michigan; daggerDepartment of Ophthalmology,
      University of Minnesota, Minneapolis, Minnesota; double daggerDepartment of
      Ophthalmology, Mount Sinai School of Medicine, New York, New York; and section
      signMassachusetts Eye and Ear Infirmary, Harvard Medical School, Boston,
      Massachusetts.
FAU - Schneider, Eric W
AU  - Schneider EW
FAU - Elner, Susan G
AU  - Elner SG
FAU - van Kuijk, Frederik J
AU  - van Kuijk FJ
FAU - Goldberg, Naomi
AU  - Goldberg N
FAU - Lieberman, Ronni M
AU  - Lieberman RM
FAU - Eliott, Dean
AU  - Eliott D
FAU - Johnson, Mark W
AU  - Johnson MW
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Retina
JT  - Retina (Philadelphia, Pa.)
JID - 8309919
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1097/IAE.0b013e318285f486 [doi]
PST - aheadofprint
SO  - Retina. 2013 Apr 11.

PMID- 23584676
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1552-4469 (Electronic)
IS  - 1552-4450 (Linking)
VI  - 9
IP  - 6
DP  - 2013 Jun
TI  - Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives.
PG  - 374-82
LID - 10.1038/nchembio.1230 [doi]
AB  - Chaperone-mediated autophagy (CMA) contributes to cellular quality control and
      the cellular response to stress through the selective degradation of cytosolic
      proteins in lysosomes. A decrease in CMA activity occurs in aging and in
      age-related disorders (for example, neurodegenerative diseases and diabetes).
      Although prevention of this age-dependent decline through genetic manipulation in
      mice has proven beneficial, chemical modulation of CMA is not currently possible,
      owing in part to the lack of information on the signaling mechanisms that
      modulate this pathway. In this work, we report that signaling through retinoic
      acid receptor alpha (RARalpha) inhibits CMA and apply structure-based chemical
      design to develop synthetic derivatives of all-trans-retinoic acid to
      specifically neutralize this inhibitory effect. We demonstrate that chemical
      enhancement of CMA protects cells from oxidative stress and from proteotoxicity, 
      supporting a potential therapeutic opportunity when reduced CMA contributes to
      cellular dysfunction and disease.
AD  - Department of Development and Molecular Biology, Albert Einstein College of
      Medicine, Bronx, New York, USA.
FAU - Anguiano, Jaime
AU  - Anguiano J
FAU - Garner, Thomas P
AU  - Garner TP
FAU - Mahalingam, Murugesan
AU  - Mahalingam M
FAU - Das, Bhaskar C
AU  - Das BC
FAU - Gavathiotis, Evripidis
AU  - Gavathiotis E
FAU - Cuervo, Ana Maria
AU  - Cuervo AM
LA  - eng
SI  - PubChem-Substance/162010013
SI  - PubChem-Substance/162010014
SI  - PubChem-Substance/162010015
SI  - PubChem-Substance/162010016
SI  - PubChem-Substance/162010017
SI  - PubChem-Substance/162010018
SI  - PubChem-Substance/162010019
SI  - PubChem-Substance/162010020
SI  - PubChem-Substance/162010021
GR  - R00 HL095929/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20130414
PL  - United States
TA  - Nat Chem Biol
JT  - Nature chemical biology
JID - 101231976
SB  - IM
PMC - PMC3661710
MID - NIHMS454928
OID - NLM: NIHMS454928 [Available on 10/14/13]
OID - NLM: PMC3661710 [Available on 10/14/13]
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PMCR- 2013/10/14 00:00
PHST- 2013/01/12 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/14 [aheadofprint]
AID - nchembio.1230 [pii]
AID - 10.1038/nchembio.1230 [doi]
PST - ppublish
SO  - Nat Chem Biol. 2013 Jun;9(6):374-82. doi: 10.1038/nchembio.1230. Epub 2013 Apr
      14.

PMID- 23584532
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1460-2075 (Electronic)
IS  - 0261-4189 (Linking)
VI  - 32
IP  - 11
DP  - 2013 May 29
TI  - Counterbalance between BAG and URX neurons via guanylate cyclases controls
      lifespan homeostasis in C. elegans.
PG  - 1529-42
LID - 10.1038/emboj.2013.75 [doi]
AB  - Lifespan of C. elegans is affected by the nervous system; however, the underlying
      neural integration still remains unclear. In this work, we targeted an
      antagonistic neural system consisting of low-oxygen sensing BAG neurons and
      high-oxygen sensing URX neurons. While ablation of BAG neurons increases lifespan
      of C. elegans, ablation of URX neurons decreases lifespan. Genetic analysis
      revealed that BAG and URX neurons counterbalance each other via different
      guanylate cyclases (GCYs) to control lifespan balance. Lifespan-modulating
      effects of GCYs in these neurons are independent of the actions from
      insulin/IGF-1 signalling, germline signalling, sensory perception, or dietary
      restriction. Given the known gas-sensing property of these neurons, we profiled
      that lifespan of C. elegans is promoted under moderately low oxygen (4-12%) or
      moderately high carbon dioxide (5%) but inhibited under high-level oxygen (40%); 
      however, these pro-longevity and anti-longevity effects are counteracted,
      respectively, by BAG and URX neurons via different GCYs. In conclusion, BAG and
      URX neurons work as a neural-regulatory system to counterbalance each other via
      different GCYs to control lifespan homeostasis.
AD  - Department of Molecular Pharmacology, Institute of Aging, Diabetes Research
      Center, Albert Einstein College of Medicine, Bronx, NY, USA.
FAU - Liu, Tiewen
AU  - Liu T
FAU - Cai, Dongsheng
AU  - Cai D
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - England
TA  - EMBO J
JT  - The EMBO journal
JID - 8208664
SB  - IM
PMC - PMC3671255
OID - NLM: PMC3671255 [Available on 05/29/14]
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PMCR- 2014/05/29 00:00
PHST- 2012/08/15 [received]
PHST- 2013/03/12 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - emboj201375 [pii]
AID - 10.1038/emboj.2013.75 [doi]
PST - ppublish
SO  - EMBO J. 2013 May 29;32(11):1529-42. doi: 10.1038/emboj.2013.75. Epub 2013 Apr 12.

PMID- 23584434
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 6
DP  - 2013 Jun
TI  - Insulin- and glucagon-like peptide-1-induced changes in heart rate and
      vagosympathetic activity: why they matter.
PG  - 1196-200
LID - 10.1007/s00125-013-2909-x [doi]
AB  - Heart rate (HR) predicts cardiovascular morbidity and mortality in individuals
      either with or without diabetes. In type 2 diabetic patients, cardiac autonomic
      neuropathy is a risk marker for cardiac morbidity and mortality. A major
      pathogenic potential may be attributed to vagal depression and sympathetic
      predominance. In this issue of Diabetologia, Berkelaar et al (DOI:
      10.1007/s00125-013-2848-6 ) examined the effects of euglycaemic, and
      hyperglycaemic clamp with the addition of glucagon-like-peptide-1 (GLP-1) and
      arginine, on cardiac vagal control in a large number of healthy subjects. After
      adjustments for age, BMI and insulin sensitivity, insulin associations with HR
      remained partially intact while those with vagal control disappeared. This
      suggested that BMI and insulin sensitivity, but not insulin levels, were the main
      drivers of cardiac vagal control. GLP-1 infusion during hyperglycaemia increased 
      HR and BP and produced a statistically non-significant decrease in measures of
      cardiac vagal control compared with values before any manipulation of insulin
      levels. This commentary summarises how, and to what extent, insulin and GLP-1
      affect autonomic nervous system activity, HR and BP. More information is needed
      on the mechanisms through which acute administration of, and long-term treatment 
      with, GLP-1 may affect haemodynamics and autonomic activity in diabetic and obese
      patients, since this may influence cardiovascular outcomes.
AD  - Department of Endocrinology-Diabetology-Nutrition, AP-HP, Jean Verdier Hospital, 
      Paris-Nord University, CRNH-IdF, Avenue du 14 juillet, 93143, Bondy Cedex,
      France, paul.valensi@jvr.aphp.fr.
FAU - Valensi, P
AU  - Valensi P
FAU - Chiheb, S
AU  - Chiheb S
FAU - Fysekidis, M
AU  - Fysekidis M
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/02/06 [received]
PHST- 2013/03/07 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - 10.1007/s00125-013-2909-x [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jun;56(6):1196-200. doi: 10.1007/s00125-013-2909-x. Epub 2013 
      Apr 13.

PMID- 23584433
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 7
DP  - 2013 Jul
TI  - Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2
      diabetes: a meta-analysis.
PG  - 1489-93
LID - 10.1007/s00125-013-2902-4 [doi]
AB  - AIMS/HYPOTHESIS: Precise estimates of progression rates from 'prediabetes' to
      type 2 diabetes are needed to optimise prevention strategies for high-risk
      individuals. There is acceptance of prediabetes defined by impaired fasting
      glucose (IFG) and impaired glucose tolerance (IGT), but there is some controversy
      surrounding HbA1c-defined prediabetes ranges, with some favouring 6.0-6.4% (42-46
      mmol/mol). Comparing progression rates between groups might aid this issue, thus 
      we aimed to accurately estimate progression rates to diabetes from different
      prediabetes categories. METHODS: Meta-analysis of prospective observational
      studies in which participants had prediabetes at baseline (ADA-defined IFG
      [5.6-6.9 mmol/l], WHO-defined IFG [6.1-6.9 mmol/l], IGT (7.8-11.0 mmol/l) or
      raised HbA1c [6.0-6.4%/42-46 mmol/mol]) and were followed up for incident
      diabetes. Incidence rates were combined using Bayesian random effects models.
      RESULTS: Overall, 70 studies met the inclusion criteria. In the six studies that 
      used raised HbA1c, the pooled incidence rate (95% credible interval) of diabetes 
      was 35.6 (15.1, 83.0) per 1,000 person-years. This rate was most similar to that 
      for ADA-defined IFG (11 studies; 35.5 [26.6, 48.0]) and was non-significantly
      lower than WHO-defined IFG (34 studies; 47.4 [37.4, 59.8]), IGT (46 studies, 45.5
      [37.8, 54.5]) and IFG plus IGT (15 studies, 70.4 [53.8, 89.7]). Similar results
      were seen when the data were analysed by the criteria used to diagnose diabetes. 
      CONCLUSIONS/INTERPRETATION: This study provides evidence that progression rates
      differ by prediabetes definition, which has implications for the planning and
      implementation of diabetes prevention programmes. HbA1c 6.0-6.4% might identify
      people at a lower diabetes risk than other prediabetes definitions, but further
      research is needed.
AD  - Diabetes Research Unit, Leicester Diabetes Centre, University of Leicester,
      Leicester General Hospital, Gwendolen Road, Leicester, LE5 4PW, UK,
      dhm6@le.ac.uk.
FAU - Morris, D H
AU  - Morris DH
FAU - Khunti, K
AU  - Khunti K
FAU - Achana, F
AU  - Achana F
FAU - Srinivasan, B
AU  - Srinivasan B
FAU - Gray, L J
AU  - Gray LJ
FAU - Davies, M J
AU  - Davies MJ
FAU - Webb, D
AU  - Webb D
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/02/15 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - 10.1007/s00125-013-2902-4 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jul;56(7):1489-93. doi: 10.1007/s00125-013-2902-4. Epub 2013
      Apr 13.

PMID- 23584432
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 56
IP  - 6
DP  - 2013 Jun
TI  - Should more attention be paid to school performance in children and adolescents
      with diabetes?
PG  - 1193-5
LID - 10.1007/s00125-013-2900-6 [doi]
AB  - Diabetes with onset in childhood and adolescence has consequences for the family 
      and the child, and the negative health effects and burden of daily disease
      management are well known. Less is known about the socioeconomic consequences of 
      the disease and how it impacts on school performance. In this issue of
      Diabetologia, Persson et al report from a Swedish study regarding the impact of
      childhood-onset type 1 diabetes on school performance (doi:
      10.1007/s00125-013-2870-8 ). Results indicate that onset of type 1 diabetes in
      childhood has adverse effects on school achievement and potentially on future
      successful employment. The authors suggest that attention must be paid in school 
      to the particular needs of children with diabetes, although the question needs to
      be raised as to whether the differences are of such a magnitude that they matter 
      and are relevant for healthcare and school personnel. The study provides a novel 
      addition and is important because of the limited information available on
      educational performance among children and adolescents with diabetes. However,
      the results should be interpreted with caution because of the limitations of the 
      study design, the relatively small differences detected and the fact that results
      from one country are not transferable to other countries without further
      research. The challenge is to find the resources to set up population-based
      studies in countries where appropriate data are available to investigate the
      long-term effects of type 1 diabetes on education and employment in different
      settings.
AD  - Department of Pediatrics, Women and Children's Division, Oslo University
      Hospital, P.O. Box 4956, Nydalen, 0424, Oslo, Norway, geir.joner@medisin.uio.no.
FAU - Joner, G
AU  - Joner G
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/03/04 [received]
PHST- 2013/03/11 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - 10.1007/s00125-013-2900-6 [doi]
PST - ppublish
SO  - Diabetologia. 2013 Jun;56(6):1193-5. doi: 10.1007/s00125-013-2900-6. Epub 2013
      Apr 13.

PMID- 23584372
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1591-9528 (Electronic)
IS  - 1591-8890 (Linking)
DP  - 2013 Apr 13
TI  - The antioxidant effect of the Malaysian Gelam honey on pancreatic hamster cells
      cultured under hyperglycemic conditions.
AB  - Type 2 diabetes consists of progressive hyperglycemia, insulin resistance, and
      pancreatic beta-cell failure which could result from glucose toxicity,
      inflammatory cytokines, and oxidative stress. In the present study, we
      investigate the effect of pretreatment with Gelam honey (Melaleuca spp.) and the 
      individual flavonoid components chrysin, luteolin, and quercetin, on the
      production of reactive oxygen species (ROS), cell viability, lipid peroxidation, 
      and insulin content in hamster pancreatic cells (HIT-T15 cells), cultured under
      normal and hyperglycemic conditions. Phenolic extracts from a local Malaysian
      species of Gelam honey (Melaleuca spp.) were prepared using the standard
      extraction methods. HIT-T15 cells were cultured in 5 % CO2 and then preincubated 
      with Gelam honey extracts (20, 40, 60, and 80 mug/ml) as well as some of its
      flavonoid components chrysin, luteolin, and quercetin (20, 40, 60, and 80 muM),
      prior to stimulation by 20 and 50 mM of glucose. The antioxidative effects were
      measured in these cultured cells at different concentrations and time point by
      DCFH-DA assay. Pretreatment of cells with Gelam honey extract or the flavonoid
      components prior to culturing in 20 or 50 mM glucose showed a significant
      decrease in the production of ROS, glucose-induced lipid peroxidation, and a
      significant increase in insulin content and the viability of cells cultured under
      hyperglycemic condition. Our results show the in vitro antioxidative property of 
      the Gelam honey and the flavonoids on the beta-cells from hamsters and its
      cytoprotective effect against hyperglycemia.
AD  - Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala
      Lumpur, Malaysia, kalaivanibatumalaie@gmail.com.
FAU - Batumalaie, Kalaivani
AU  - Batumalaie K
FAU - Qvist, Rajes
AU  - Qvist R
FAU - Yusof, Kamaruddin Mohd
AU  - Yusof KM
FAU - Ismail, Ikram Shah
AU  - Ismail IS
FAU - Sekaran, Shamala Devi
AU  - Sekaran SD
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - Clin Exp Med
JT  - Clinical and experimental medicine
JID - 100973405
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/10/29 [received]
PHST- 2013/03/24 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - 10.1007/s10238-013-0236-7 [doi]
PST - aheadofprint
SO  - Clin Exp Med. 2013 Apr 13.

PMID- 23584214
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1938-2022 (Electronic)
VI  - 5
IP  - 2
DP  - 2013 Mar 1
TI  - Clinical utility of insulin and insulin analogs.
AB  - Diabetes is a pandemic disease characterized by autoimmune, genetic and metabolic
      abnormalities. While insulin deficiency manifested as hyperglycemia is a common
      sequel of both Type-1 and Type-2 diabetes (T1DM and T2DM), it does not result
      from a single genetic defect-rather insulin deficiency results from the
      functional loss of pancreatic beta cells due to multifactorial mechanisms. Since 
      pancreatic beta cells of patients with T1DM are destroyed by autoimmune reaction,
      these patients require daily insulin injections. Insulin resistance followed by
      beta cell dysfunction and beta cell loss is the characteristics of T2DM.
      Therefore, most patients with T2DM will require insulin treatment due to eventual
      loss of insulin secretion. Despite the evidence of early insulin treatment
      lowering macrovascular (coronary artery disease, peripheral arterial disease and 
      stroke) and microvascular (diabetic nephropathy, neuropathy and retinopathy)
      complications of T2DM, controversy exists among physicians on how to initiate and
      intensify insulin therapy. The slow acting nature of regular human insulin makes 
      its use ineffective in counteracting postprandial hyperglycemia. Instead,
      recombinant insulin analogs have been generated with a variable degree of
      specificity and action. Due to the metabolic variability among individuals,
      optimum blood glucose management is a formidable task to accomplish despite the
      presence of novel insulin analogs. In this article, we present a recent update on
      insulin analog structure and function with an overview of the evidence on the
      various insulin regimens clinically used to treat diabetes.
AD  - Human Gene and Cell Therapy Center; Akdeniz University Faculty of Medicine;
      Antalya, Turkey; Department of Medical Biology and Genetics; Akdeniz University
      Faculty of Medicine; Antalya, Turkey.
FAU - Sanlioglu, Ahter D
AU  - Sanlioglu AD
FAU - Altunbas, Hasan Ali
AU  - Altunbas HA
FAU - Balci, Mustafa Kemal
AU  - Balci MK
FAU - Griffith, Thomas S
AU  - Griffith TS
FAU - Sanlioglu, Salih
AU  - Sanlioglu S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130301
TA  - Islets
JT  - Islets
JID - 101495366
OTO - NOTNLM
OT  - diabetes
OT  - genetic engineering
OT  - insulin
OT  - insulin analogues
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 24590 [pii]
PST - aheadofprint
SO  - Islets. 2013 Mar 1;5(2).

PMID- 23584148
OWN - NLM
STAT- Publisher
DA  - 20130501
IS  - 1876-7737 (Electronic)
DP  - 2013 Apr 11
TI  - Oxidative stress and protein carbonylation in adipose tissue - Implications for
      insulin resistance and diabetes mellitus.
LID - S1874-3919(13)00183-8 [pii]
LID - 10.1016/j.jprot.2013.04.002 [doi]
AB  - While historically considered simply as a depot for excess energy, white adipose 
      tissue is a dynamically active endocrine organ capable of responding to a variety
      of efferent stimuli resulting in the synthesis and secretion of peptides,
      proteins and metabolites that serve as signal transducers to the peripheral and
      central circulation. Such regulation controls a variety of physiological
      processes including energy expenditure, food intake, reproductive capacity and
      responsiveness to insulin. Indeed, the accumulation of inflammatory cells in
      white adipose tissue is considered to be causative in the development of insulin 
      resistance and eventually type 2 diabetes mellitus. A large body of evidence
      suggests that oxidative stress in adipose tissue not only correlates with insulin
      resistance but is also causative in its development. Moreover, using the
      available plasma oxidative stress biomarkers, many clinical studies have shown
      the presence of systemic oxidative stress in obese insulin resistant subjects,
      and its decrease after the successful treatment of obesity. In this review we
      emphasize the role of protein carbonylation in dysfunctional obese white adipose 
      tissue and its metabolic implications. We focus on glutathione S-transferase A4
      as the key enzyme for trans-4-hydroxy-2-nonenal and trans-4-oxo-2-nonenal removal
      from the cell, thus preventing protein carbonylation. This article is part of a
      Special Issue entitled: Protein Modifications.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Faculty of Medical Sciences, Goce Delcev University, Stip, Former Yugolav
      Republic of Macedonia. Electronic address: tatjana.ruskovska@ugd.edu.mk.
FAU - Ruskovska, Tatjana
AU  - Ruskovska T
FAU - Bernlohr, David A
AU  - Bernlohr DA
LA  - ENG
GR  - P30 DK050456/DK/NIDDK NIH HHS/United States
GR  - R01 DK084669/DK/NIDDK NIH HHS/United States
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - J Proteomics
JT  - Journal of proteomics
JID - 101475056
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/01/12 [received]
PHST- 2013/03/15 [revised]
PHST- 2013/04/03 [accepted]
AID - S1874-3919(13)00183-8 [pii]
AID - 10.1016/j.jprot.2013.04.002 [doi]
PST - aheadofprint
SO  - J Proteomics. 2013 Apr 11. pii: S1874-3919(13)00183-8. doi:
      10.1016/j.jprot.2013.04.002.

PMID- 23584084
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 5
IP  - 4
DP  - 2013
TI  - Dyslipidemia in obesity: mechanisms and potential targets.
PG  - 1218-40
LID - 10.3390/nu5041218 [doi]
AB  - Obesity has become a major worldwide health problem. In every single country in
      the world, the incidence of obesity is rising continuously and therefore, the
      associated morbidity, mortality and both medical and economical costs are
      expected to increase as well. The majority of these complications are related to 
      co-morbid conditions that include coronary artery disease, hypertension, type 2
      diabetes mellitus, respiratory disorders and dyslipidemia. Obesity increases
      cardiovascular risk through risk factors such as increased fasting plasma
      triglycerides, high LDL cholesterol, low HDL cholesterol, elevated blood glucose 
      and insulin levels and high blood pressure. Novel lipid dependent, metabolic risk
      factors associated to obesity are the presence of the small dense LDL phenotype, 
      postprandial hyperlipidemia with accumulation of atherogenic remnants and hepatic
      overproduction of apoB containing lipoproteins. All these lipid abnormalities are
      typical features of the metabolic syndrome and may be associated to a
      pro-inflammatory gradient which in part may originate in the adipose tissue
      itself and directly affect the endothelium. An important link between obesity,
      the metabolic syndrome and dyslipidemia, seems to be the development of insulin
      resistance in peripheral tissues leading to an enhanced hepatic flux of fatty
      acids from dietary sources, intravascular lipolysis and from adipose tissue
      resistant to the antilipolytic effects of insulin. The current review will focus 
      on these aspects of lipid metabolism in obesity and potential interventions to
      treat the obesity related dyslipidemia.
AD  - Department of Internal Medicine, Diabetes and Vascular Centre, Sint Franciscus
      Gasthuis, Rotterdam, P.O. Box 10900, 3004 BA, The Netherlands.
      m.castrocabezas@sfg.nl
FAU - Klop, Boudewijn
AU  - Klop B
FAU - Elte, Jan Willem F
AU  - Elte JW
FAU - Cabezas, Manuel Castro
AU  - Cabezas MC
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/21 [received]
PHST- 2013/02/14 [revised]
PHST- 2013/03/27 [accepted]
AID - nu5041218 [pii]
AID - 10.3390/nu5041218 [doi]
PST - epublish
SO  - Nutrients. 2013 Apr 12;5(4):1218-40. doi: 10.3390/nu5041218.

PMID- 23583988
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 52
IP  - 8
DP  - 2013
TI  - An increased circulating angiotensin II concentration is associated with
      hypoadiponectinemia and postprandial hyperglycemia in men with nonalcoholic fatty
      liver disease.
PG  - 855-61
AB  - OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is a condition associated
      with type 2 diabetes (T2D). Insulin resistance, a common pathogenesis of NAFLD
      and T2D, is partially caused by alterations in angiotensin II (Ang II) and is
      accompanied by hypoadiponectinemia. We aimed to investigate whether the
      circulating Ang II and adiponectin concentrations are related to hyperglycemia in
      male NAFLD patients. METHODS: Thirty-five controls and 85 NAFLD patients without 
      prior known T2D were enrolled. All participants were non-smoking men who
      performed 75-g oral glucose tolerance tests. According to the American Diabetes
      Association (ADA) criteria, the NAFLD patients were divided into the euglycemia
      and hyperglycemia groups. The NAFLD patients with hyperglycemia were further
      divided into the isolated impaired fasting glucose (I-IFG) and postprandial
      hyperglycemia subgroups. The fasting serum Ang II and adiponectin concentrations 
      were measured. RESULTS: Among the 85 NAFLD patients, 40 (47%) had hyperglycemia, 
      including I-IFG (18%) and postprandial hyperglycemia (29%). The serum Ang II
      concentrations in the euglycemia and hyperglycemia groups were significantly
      higher than those observed in the control and euglycemia groups, respectively;
      whereas the serum adiponectin concentrations were significantly lower. The serum 
      Ang II concentrations were significantly higher in the postprandial hyperglycemia
      subgroup than in the I-IFG subgroup. The serum Ang II and adiponectin
      concentrations were found to be independent predictors of hyperglycemia in the
      NAFLD patients. The serum Ang II concentration was significantly associated with 
      the serum adiponectin and 2-hour postprandial glucose concentrations in the NAFLD
      patients. CONCLUSION: An increased circulating Ang II concentration is associated
      with hypoadiponectinemia and postprandial hyperglycemia in male NAFLD patients
      and may be involved in the pathogenesis of T2D in NAFLD patients.
AD  - Department of Gastroenterology and Hepatology, the Second Affiliated Hospital of 
      Chongqing Medical University, China.
FAU - Xu, Yi-Zhi
AU  - Xu YZ
FAU - Zhang, Xia
AU  - Zhang X
FAU - Wang, Le
AU  - Wang L
FAU - Zhang, Feng
AU  - Zhang F
FAU - Qiu, Qiu
AU  - Qiu Q
FAU - Liu, Mei-Ling
AU  - Liu ML
FAU - Zhang, Gui-Rong
AU  - Zhang GR
FAU - Wu, Xiao-Ling
AU  - Wu XL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130415
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/15 [epublish]
AID - DN/JST.JSTAGE/internalmedicine/52.8839 [pii]
PST - ppublish
SO  - Intern Med. 2013;52(8):855-61. Epub 2013 Apr 15.

PMID- 23583956
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1095-8541 (Electronic)
IS  - 0022-5193 (Linking)
VI  - 330
DP  - 2013 Aug 7
TI  - Assessment of autonomic dysfunction in patients with type 2 diabetes using
      reactive hyperemia.
PG  - 9-17
LID - 10.1016/j.jtbi.2013.03.022 [doi]
LID - S0022-5193(13)00148-3 [pii]
AB  - It is known that aging and type 2 diabetes mellitus contribute to atherosclerosis
      and autonomic dysfunction. By using the air pressure sensing system (APSS),
      peak-peak intervals (PPIs) of wrist arterial waveforms from baseline and reactive
      hyperemia (RH) were obtained. Through frequency domain analysis of heart rate
      variability (HRV) and nonlinear Poincare method, the HRV of healthy young
      individuals (Group 1, n=25), healthy upper middle-aged individuals (Group 2,
      n=22), and patients with type 2 diabetes (Group 3, n=28) were assessed. By using 
      the standard deviation (SD) of the instantaneous PPI variability (SD1)/the SD of 
      the long PPI variability (SD2) ratio (SSR), PPIs of the same individuals before
      and after RH induction were compared. Reduced SSR1-10 was noted only in patients 
      with diabetes. Moreover, a significient correlation between SSR1-10 and
      endothelial function was observed in all subjects (r=0.290, p=0.033) after RH.
      However, no correlation with low-frequency to high-frequency power ratio (LHR)
      was noted before and after RH. In conclusion, according to our results, campared 
      to the baseline, there were more significant changes of SSR1-10 after RH in
      patients with diabetes; and, a significient correlation between SSR1-10 and
      endothelial function at the moment of RH was noted.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Electrical Engineering, National Dong Hwa University, Hualien,
      Taiwan.
FAU - Wu, Hsien-Tsai
AU  - Wu HT
FAU - Hsu, Po-Chun
AU  - Hsu PC
FAU - Sun, Cheuk-Kwan
AU  - Sun CK
FAU - Wang, Hou-Jun
AU  - Wang HJ
FAU - Liu, Cyuan-Cin
AU  - Liu CC
FAU - Chen, Hong-Ruei
AU  - Chen HR
FAU - Liu, An-Bang
AU  - Liu AB
FAU - Tang, Chieh-Ju
AU  - Tang CJ
FAU - Lo, Men-Tzung
AU  - Lo MT
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - England
TA  - J Theor Biol
JT  - Journal of theoretical biology
JID - 0376342
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/03/12 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/03/25 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0022-5193(13)00148-3 [pii]
AID - 10.1016/j.jtbi.2013.03.022 [doi]
PST - ppublish
SO  - J Theor Biol. 2013 Aug 7;330:9-17. doi: 10.1016/j.jtbi.2013.03.022. Epub 2013 Apr
      10.

PMID- 23583909
OWN - NLM
STAT- Publisher
DA  - 20130603
IS  - 1096-0309 (Electronic)
IS  - 0003-2697 (Linking)
VI  - 439
IP  - 1
DP  - 2013 Apr 9
TI  - Improving the reliability of human serum albumin-thiol group determination.
PG  - 17-22
LID - S0003-2697(13)00161-9 [pii]
LID - 10.1016/j.ab.2013.03.033 [doi]
AB  - The thiol (Cys34) content of human serum albumin (HSA-SH) decreases during
      oxidative and carbonyl stress and, therefore, could represent a useful parameter 
      in clinical practice. Nevertheless, the reliability of HSA-thiol determination
      with Ellman's method depends on the purity of isolated HSA. Determination of
      total serum thiols (mmol/L) and HSA-SH content (mmol -SH/mmol HSA) after HSA
      isolation from diabetic patient and control sera by a two-step precipitation with
      ammonium sulfate (AS), as well as HSA-SH contribution (%) to total serum thiols, 
      was assessed. Purity and yield of isolated HSA were monitored
      spectrophotometrically and by native polyacrylamide gel electrophoresis.
      Precipitation of HSA from serum via a two-step method with AS produced HSA with
      91.9+/-3.6% purity and 69.7+/-4.4% yield, allowing for precise (relative standard
      deviation of 3.2%) and reliable (comparing with total serum thiols) measurement
      of HSA-SH content with DTNB [5,5'-dithiobis-(2-nitrobenzoic acid)]. The content
      of the HSA-SH group in patients with type 2 diabetes was significantly (P<0.05)
      lower compared with that of the healthy cohort (0.483+/-0.067 vs.
      0.561+/-0.054mmol -SH/mmol HSA). Because the proposed method of HSA isolation is 
      simple, time-efficient, and technically less demanding, and it also enables
      reliable determination of HSA-SH content, it is suitable for clinical practice.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Biochemistry, Faculty of Chemistry, University of Belgrade,
      Belgrade 11158, Serbia.
FAU - Jovanovic, Vesna B
AU  - Jovanovic VB
FAU - Penezic-Romanjuk, Ana Z
AU  - Penezic-Romanjuk AZ
FAU - Pavicevic, Ivan D
AU  - Pavicevic ID
FAU - Acimovic, Jelena M
AU  - Acimovic JM
FAU - Mandic, Ljuba M
AU  - Mandic LM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130409
TA  - Anal Biochem
JT  - Analytical biochemistry
JID - 0370535
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/28 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/03/27 [accepted]
AID - S0003-2697(13)00161-9 [pii]
AID - 10.1016/j.ab.2013.03.033 [doi]
PST - aheadofprint
SO  - Anal Biochem. 2013 Apr 9;439(1):17-22. doi: 10.1016/j.ab.2013.03.033.

PMID- 23583762
OWN - NLM
STAT- In-Data-Review
DA  - 20130530
IS  - 1873-7544 (Electronic)
IS  - 0306-4522 (Linking)
VI  - 244
DP  - 2013 Aug 6
TI  - Therapeutic potential of VEGF and VEGF-derived peptide in peripheral
      neuropathies.
PG  - 77-89
LID - 10.1016/j.neuroscience.2013.03.050 [doi]
LID - S0306-4522(13)00305-9 [pii]
AB  - Besides its prominent role in angiogenesis, the vascular endothelial growth
      factor (VEGF) also exerts important protective effects on neurons. In particular,
      mice expressing reduced levels of VEGF suffer from late-onset motor neuron
      degeneration, whereas VEGF delivery significantly delays motor neuron death in
      ALS mouse models, at least partly through neuroprotective effects. Additionally, 
      VEGF protects dorsal root ganglion (DRG) neurons against paclitaxel-induced
      neurotoxicity. Here, we demonstrate that VEGF also protects DRG neurons against
      hyperglycemia-induced neuronal stress as a model of diabetes-induced peripheral
      neuropathy. Specifically, VEGF decreased expression of the stress-related gene
      activating transcription factor 3 (ATF3) in DRG neurons isolated from
      streptozotocin-induced diabetic mice (ex vivo) and in isolated DRG neurons
      exposed to high glucose concentrations (in vitro). In vivo, local VEGF
      application also protected against paclitaxel- and diabetes-induced neuropathies 
      without causing side effects. A small synthetic VEGF mimicking pentadecapeptide
      (QK) exerted similar effects on DRG cultures: the peptide reduced ATF3 expression
      in vitro and ex vivo in paclitaxel- and hyperglycemia-induced models of
      neuropathy to a similar extent as the full-length recombinant VEGF protein. By
      using transgenic mice selectively overexpressing the VEGF receptor 2 in postnatal
      neurons, these neuroprotective effects were shown to be mediated through VEGF
      receptor 2. Overall, these results underscore the potential of VEGF and
      VEGF-derived peptides for the treatment of peripheral neuropathies.
CI  - Copyright (c) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
AD  - Department of Neuroscience, Janssen Research & Development, A Division of Janssen
      Pharmaceutica NV, B-2340 Beerse, Belgium.
FAU - Verheyen, A
AU  - Verheyen A
FAU - Peeraer, E
AU  - Peeraer E
FAU - Lambrechts, D
AU  - Lambrechts D
FAU - Poesen, K
AU  - Poesen K
FAU - Carmeliet, P
AU  - Carmeliet P
FAU - Shibuya, M
AU  - Shibuya M
FAU - Pintelon, I
AU  - Pintelon I
FAU - Timmermans, J-P
AU  - Timmermans JP
FAU - Nuydens, R
AU  - Nuydens R
FAU - Meert, T
AU  - Meert T
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/05 [received]
PHST- 2013/03/04 [revised]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/11 [aheadofprint]
AID - S0306-4522(13)00305-9 [pii]
AID - 10.1016/j.neuroscience.2013.03.050 [doi]
PST - ppublish
SO  - Neuroscience. 2013 Aug 6;244:77-89. doi: 10.1016/j.neuroscience.2013.03.050. Epub
      2013 Apr 11.

PMID- 23583730
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1830
IP  - 8
DP  - 2013 Aug
TI  - (pGlu-Gln)-CCK-8[mPEG]: A novel, long-acting, mini-PEGylated cholecystokinin
      (CCK) agonist that improves metabolic status in dietary-induced diabetes.
PG  - 4009-16
LID - 10.1016/j.bbagen.2013.04.004 [doi]
LID - S0304-4165(13)00132-3 [pii]
AB  - BACKGROUND: Cholecystokinin (CCK) is a gastrointestinal hormone that has been
      proposed as a potential therapeutic option for obesity-diabetes. As such,
      (pGlu-Gln)-CCK-8 is an N-terminally modified CCK-8 analogue with improved
      biological effectiveness over the native peptide. METHODS: The current study has 
      examined the in vitro stability, biological activity and in vivo therapeutic
      applicability of a novel second generation mini-PEGylated form of
      (pGlu-Gln)-CCK-8, (pGlu-Gln)-CCK-8[mPEG]. RESULTS: (pGlu-Gln)-CCK-8[mPEG] was
      completely resistant to enzymatic degradation and in addition displayed similar
      insulinotropic (p<0.05 to p<0.001) and satiating effects (p<0.01 to p<0.001) as
      (pGlu-Gln)-CCK-8. This confirmed the capability of (pGlu-Gln)-CCK-8[mPEG] to bind
      to and activate the CCK receptor. Sub-chronic twice daily injection of
      (pGlu-Gln)-CCK-8[mPEG] in high fat fed mice for 35days significantly decreased
      body weight gain (p<0.05), food intake (p<0.01 to p<0.001) and triacylglycerol
      deposition in liver (p<0.001) and muscle (p<0.001). Furthermore,
      (pGlu-Gln)-CCK-8[mPEG] markedly improved intraperitoneal glucose tolerance
      (p<0.05) and insulin sensitivity (p<0.001). Despite this therapeutic profile,
      once daily injection of (pGlu-Gln)-CCK-8[mPEG] in high fat fed mice for 33days,
      at the same dose, was not associated with alterations in food intake and body
      weight. In addition, metabolic responses to exogenous glucose and insulin
      injection were similar to saline treated controls. CONCLUSION: These studies
      emphasise the therapeutic potential of (pGlu-Gln)-CCK-8[mPEG] and similar
      molecules. GENERAL SIGNIFICANCE: A more detailed analysis of the dose and
      administration schedule employed for (pGlu-Gln)-CCK-8[mPEG] could provide a novel
      and effective compound to treat obesity-diabetes.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, University 
      of Ulster, Coleraine, Northern Ireland, UK. Electronic address:
      n.irwin@ulster.ac.uk.
FAU - Irwin, Nigel
AU  - Irwin N
FAU - Frizelle, Pamela
AU  - Frizelle P
FAU - O'Harte, Finbarr P M
AU  - O'Harte FP
FAU - Flatt, Peter R
AU  - Flatt PR
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/02/12 [received]
PHST- 2013/03/29 [revised]
PHST- 2013/04/02 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0304-4165(13)00132-3 [pii]
AID - 10.1016/j.bbagen.2013.04.004 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2013 Aug;1830(8):4009-16. doi:
      10.1016/j.bbagen.2013.04.004. Epub 2013 Apr 10.

PMID- 23583721
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1831
IP  - 7
DP  - 2013 Jul
TI  - Malfunctioning of adipocytes in obesity is linked to quantitative surfaceome
      changes.
PG  - 1208-16
LID - 10.1016/j.bbalip.2013.04.001 [doi]
LID - S1388-1981(13)00086-3 [pii]
AB  - Increased triglyceride accumulation in adipocytes caused by a misbalance between 
      energy intake and energy consumption, results in increased adipocyte size, excess
      adipose tissue, increased body weight and ultimately, obesity. It is well
      established that enlarged adipocytes exhibit malfunctions that contribute to
      whole body insulin resistance, a key factor for the development of type 2
      diabetes. However, the underlying molecular cause for dysfunctional adipocyte
      behavior and signaling is poorly understood. Since the adipocyte cell surface
      proteome, or surfaceome, represents the cellular signaling gateway to the
      microenvironment, we studied the contribution of this subproteome to adipocyte
      malfunctions in obesity. By using the chemoproteomic Cell Surface Capture (CSC)
      technology, we established surfaceome maps of primary adipocytes derived from
      different mouse models for metabolic disorders. Relative quantitative comparison 
      between these surfaceome maps revealed a set of cell surface glycoproteins with
      modulated location-specific abundance levels. RNAi mediated targeting of a subset
      of the detected obesity modulated cell surface glycoproteins in an in vitro model
      system provided functional evidence for their role in adiponectin secretion and
      the lipolytic activity of adipocytes. Thus, we conclude that the identified cell 
      surface glycoproteins which exhibit obesity induced abundance changes and impact 
      adipocyte function at the same time contribute to adipocyte malfunction in
      obesity. The regulation of their concerted activities could improve adipocyte
      function in obesity.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
AD  - Institute of Molecular Systems Biology, ETH Zurich, Switzerland; Institute of
      Food, Nutrition and Health, ETH Zurich, Switzerland.
FAU - Moest, Hansjoerg
AU  - Moest H
FAU - Frei, Andreas P
AU  - Frei AP
FAU - Bhattacharya, Indranil
AU  - Bhattacharya I
FAU - Geiger, Matthias
AU  - Geiger M
FAU - Wollscheid, Bernd
AU  - Wollscheid B
FAU - Wolfrum, Christian
AU  - Wolfrum C
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/16 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S1388-1981(13)00086-3 [pii]
AID - 10.1016/j.bbalip.2013.04.001 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2013 Jul;1831(7):1208-16. doi:
      10.1016/j.bbalip.2013.04.001. Epub 2013 Apr 10.

PMID- 23583718
OWN - NLM
STAT- Publisher
DA  - 20130507
IS  - 2173-9188 (Electronic)
IS  - 1130-1406 (Linking)
DP  - 2013 Apr 11
TI  - [Saccharomyces cerevisiae infections.]
LID - S1130-1406(13)00023-5 [pii]
LID - 10.1016/j.riam.2013.03.001 [doi]
AB  - BACKGROUND: Saccharomyces cerevisiae (S. cerevisiae) is a ubiquitous yeast widely
      used in industry and it is also a common colonizer of the human mucosae. However,
      the incidence of invasive infection by these fungi has significantly increased in
      the last decades. AIMS: To evaluate the infection by S. cerevisiae in a hospital 
      in southern Brazil during a period of 10 years (2000-2010). METHODS: Review of
      medical records of patients infected by this fungus. RESULTS: In this period, 6
      patients were found to be infected by S. cerevisiae. The age range of the
      patients was from 10 years to 84. Urine, blood, ascitic fluid, peritoneal
      dialysis fluid, and esophageal biopsy samples were analyzed. The most common
      predisposing factors were cancer, transplant, surgical procedures, renal failure,
      use of venous catheters, mechanical ventilation, hospitalization in Intensive
      Care, diabetes mellitus, chemotherapy, corticosteroid use, and parenteral
      nutrition. Amphotericin B and fluconazole were the treatments of choice. Three of
      the patients died and the other 3 were discharged from hospital. CONCLUSIONS: We 
      must take special precautions in emerging infections, especially when there are
      predisposing conditions such as immunosuppression or patients with serious
      illnesses. The rapid and specific diagnosis of this yeast is important for
      therapeutic decision. Furthermore, epidemiological and efficacy studies of
      antifungal agents are necessary for a better therapeutic approach.
CI  - Copyright (c) 2012 Revista Iberoamericana de Micologia. Published by Elsevier
      Espana. All rights reserved.
AD  - Programa de Pos-Graduacao em Ciencias Pneumologicas, Universidade Federal do Rio 
      Grande do Sul, Rio Grande do Sul, Brasil; Universidade Federal de Ciencias da
      Saude de Porto Alegre, Porto Alegre, Brasil.
FAU - Souza Goebel, Cristine
AU  - Souza Goebel C
FAU - de Mattos Oliveira, Flavio
AU  - de Mattos Oliveira F
FAU - Severo, Luiz Carlos
AU  - Severo LC
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Infeccion por Saccharomyces cerevisiae.
DEP - 20130411
TA  - Rev Iberoam Micol
JT  - Revista iberoamericana de micologia
JID - 9425531
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/10/11 [received]
PHST- 2013/03/13 [revised]
PHST- 2013/03/20 [accepted]
AID - S1130-1406(13)00023-5 [pii]
AID - 10.1016/j.riam.2013.03.001 [doi]
PST - aheadofprint
SO  - Rev Iberoam Micol. 2013 Apr 11. pii: S1130-1406(13)00023-5. doi:
      10.1016/j.riam.2013.03.001.

PMID- 23583607
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1879-2219 (Electronic)
IS  - 0966-6362 (Linking)
DP  - 2013 Apr 11
TI  - Gait characteristics of people with diabetes-related peripheral neuropathy, with 
      and without a history of ulceration.
LID - S0966-6362(13)00168-9 [pii]
LID - 10.1016/j.gaitpost.2013.03.009 [doi]
AB  - Biomechanical alterations in diabetes are believed to contribute to plantar
      neuropathic ulceration. This exploratory study documents clinical measures of
      flexibility and strength, alongside three-dimensional biomechanical gait data of 
      the lower limb, in 10 patients with a history of neuropathic ulceration (DNU;
      n=10). Comparative data is presented from age and gender matched groups with;
      diabetes peripheral neuropathy and no ulcer history (DWN; n=10), diabetes and no 
      peripheral neuropathy (DNN; n=10) and a non-diabetes reference group (NOND;
      n=10). Biomechanical data were collected at a comfortable walking speed with a
      Vicon motion analysis system. Clinical measures showed a non-significant trend
      toward decreased static range of motion at the ankle and first
      metatarsophalangeal joints, with worsening neuropathy status. Of the diabetes
      groups, knee and ankle strength was significantly lower in those with an ulcer
      history (p=0.01-0.03), with the exception of knee extension. In the DNU group,
      walking speed was on average 0.17ms slower compared to NOND (p=0.04). The DNU
      group demonstrated a lower range of motion than NOND at the: hips (frontal plane,
      by 25%: p=0.03); hips and knees (transverse plane, 31%: p=0.01 and 32%: p<0.01); 
      ankles (sagittal plane, 22%: p<0.01) and first metatarsophalangeal joints
      (sagittal plane, 32%: p=0.01), with less foot rotation (24%: p=0.04). Kinetic
      alterations in DNU included lower: ankle maximum power (21%: p=0.03) and vertical
      ground reaction force 2nd peak (6%: p<0.01). The study findings identified gait
      alterations in people with clinically severe peripheral neuropathy and related
      plantar foot ulcer history. Further research is needed to explore potential
      casual pathways.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Podiatry and Lower Extremity Gait Studies Program, School of Allied
      Health, Faculty of Health Sciences, La Trobe University, Bundoora, Victoria 3086,
      Australia. Electronic address: a.raspovic@latrobe.edu.au.
FAU - Raspovic, Anita
AU  - Raspovic A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Gait Posture
JT  - Gait & posture
JID - 9416830
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/10/24 [received]
PHST- 2013/02/19 [revised]
PHST- 2013/03/09 [accepted]
AID - S0966-6362(13)00168-9 [pii]
AID - 10.1016/j.gaitpost.2013.03.009 [doi]
PST - aheadofprint
SO  - Gait Posture. 2013 Apr 11. pii: S0966-6362(13)00168-9. doi:
      10.1016/j.gaitpost.2013.03.009.

PMID- 23583575
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 92
IP  - 20-21
DP  - 2013 May 30
TI  - GPCR responses in vascular smooth muscle can occur predominantly through dual
      transactivation of kinase receptors and not classical Galphaq protein signalling 
      pathways.
PG  - 951-6
LID - 10.1016/j.lfs.2013.03.017 [doi]
LID - S0024-3205(13)00197-5 [pii]
AB  - GPCR signalling is well known to proceed through several linear pathways
      involving activation of G proteins and their downstream signalling pathways such 
      as activation of phospholipase C. In addition, GPCRs signal via transactivation
      of Protein Tyrosine Kinase receptors such as that for Epidermal Growth Factor
      (EGF) and Platelet-Derived Growth Factor (PDGF) where GPCR agonists mediate
      increase levels of phosphorylated Erk (pErk) the immediate downstream product of 
      the activation of EGF receptor. It has recently been shown that this paradigm can
      be extended to include the GPCR transactivation of a Protein Serine/Threonine
      Kinase receptor, specifically the Transforming Growth Factor beta Type I receptor
      (also known as Alk V) (TbetaRI) in which case GPCR activation leads to the
      formation of carboxy terminal polyphosphorylated Smad2 (phosphoSmad2) being the
      immediate downstream product of the activation of TbetaRI. Growth factor and
      hormone regulation of proteoglycan synthesis in vascular smooth muscle cells
      represent one component of an in vitro model of atherosclerosis because modified 
      proteoglycans show enhanced binding to lipoproteins as the initiating step in
      atherosclerosis. In the example of proteoglycan synthesis stimulated by GPCR
      agonists such as thrombin and endothelin-1, the transactivation pathways for the 
      EGF receptor and TbetaRI are both active and together account for essentially all
      of the response to the GPCRs. In contrast, signalling downstream of GPCRs such as
      increased inositol 1,4,5 trisphosphate (IP3) and intracellular calcium do not
      have any effect on GPCR stimulated proteoglycan synthesis. These data lead to the
      conclusion that dual transactivation pathways for protein tyrosine and
      serine/threonine kinase receptors may play a far greater role in GPCR signalling 
      than currently recognised.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Discipline of Pharmacy, School of Medical Sciences and Diabetes Complications
      Group, Metabolism, Exercise and Disease Program, Health Innovations Research
      Institute, RMIT University, Bundoora, VIC 3083, Australia. Electronic address:
      peter.little@rmit.edu.au.
FAU - Little, Peter J
AU  - Little PJ
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/02/14 [received]
PHST- 2013/03/20 [revised]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/09 [aheadofprint]
AID - S0024-3205(13)00197-5 [pii]
AID - 10.1016/j.lfs.2013.03.017 [doi]
PST - ppublish
SO  - Life Sci. 2013 May 30;92(20-21):951-6. doi: 10.1016/j.lfs.2013.03.017. Epub 2013 
      Apr 9.

PMID- 23583514
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 23
IP  - 10
DP  - 2013 May 15
TI  - Flaxseed (Linum usitatissimum L.) extract as well as (+)-secoisolariciresinol
      diglucoside and its mammalian derivatives are potent inhibitors of alpha-amylase 
      activity.
PG  - 3007-12
LID - 10.1016/j.bmcl.2013.03.029 [doi]
LID - S0960-894X(13)00345-4 [pii]
AB  - Type 2 diabetes mellitus (T2DM) is one of the common global diseases. Flaxseed is
      by far the richest source of the dietary lignans (i.e., secoisolariciresinol
      diglucoside) which have been shown to delay the development of T2DM in animal
      models. Herein, we propose the first evidences for a mechanism of action
      involving the inhibition of the pancreatic alpha-amylase (EC 3.2.1.1) by
      flaxseed-derived lignans that could therefore constitute a promising
      nutraceutical for the prevention and the treatment of T2DM.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Laboratoire de Biologie des Ligneux et des Grandes Cultures UPRES EA 1207, Equipe
      Lignanes des Linacees, Antenne Scientifique Universitaire de Chartres, 21 rue de 
      Loigny la Bataille, F28000 Chartres, France. christophe.hano@univ-orleans.fr
FAU - Hano, Christophe
AU  - Hano C
FAU - Renouard, Sullivan
AU  - Renouard S
FAU - Molinie, Roland
AU  - Molinie R
FAU - Corbin, Cyrielle
AU  - Corbin C
FAU - Barakzoy, Esmatullah
AU  - Barakzoy E
FAU - Doussot, Joel
AU  - Doussot J
FAU - Lamblin, Frederic
AU  - Lamblin F
FAU - Laine, Eric
AU  - Laine E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130316
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/26 [received]
PHST- 2013/03/05 [revised]
PHST- 2013/03/07 [accepted]
PHST- 2013/03/16 [aheadofprint]
AID - S0960-894X(13)00345-4 [pii]
AID - 10.1016/j.bmcl.2013.03.029 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2013 May 15;23(10):3007-12. doi:
      10.1016/j.bmcl.2013.03.029. Epub 2013 Mar 16.

PMID- 23583468
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1879-0038 (Electronic)
IS  - 0378-1119 (Linking)
VI  - 523
IP  - 1
DP  - 2013 Jul 1
TI  - Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with 
      coronary heart disease based on the presence of diabetes.
PG  - 20-6
LID - 10.1016/j.gene.2013.03.136 [doi]
LID - S0378-1119(13)00433-2 [pii]
AB  - BACKGROUND: The aim of this study was to investigate the individual or combined
      effects of PPARA-L162V, PPARG-C161T and APOE polymorphisms on hyperlipidemia in
      coronary heart disease (CHD) patients. METHODS: Our study included 223 patients
      with CHD (103 with type 2 diabetes (T2DM), 120 without diabetes) and 101
      controls. All genotypes were determined by PCR-RFLP technique. RESULTS: Genotypic
      and allelic distributions of PPARA-L162V polymorphism were similar between study 
      and control groups (p>0.05). The serum total-cholesterol (TC) and LDL-cholesterol
      (LDL-C) levels were higher in PPARA-V162 allele carriers in non-diabetic CHD
      patients (p=0.007 and p=0.038, respectively). The increasing effect of the
      PPARA-V162 allele on serum TC and LDL-C levels was weakened with the presence of 
      PPARG-161T allele in the non-diabetic CHD patients. The ApoE4-PPARA-V162 allelic 
      combination of the ApoE/PPARA genes was found to be more frequent in diabetic CHD
      patients independent of serum lipids (p=0.035). CONCLUSIONS: The PPARA V162
      allele has an increasing effect on TC and LDL-C levels and this effect was
      reduced by carrying PPARG T161 allele in non-diabetic CHD patients. On the other 
      hand, the V162 allele may be associated with an increased risk of CHD in diabetic
      CHD patients due to the presence of ApoE4 allele independent of serum lipids. We 
      suggest that the PPARA L162V polymorphism may have diverse effects on serum
      lipids and CHD risk depends on the presence of T2DM.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Department of Molecular Medicine, The Institute of Experimental Medicine,
      Istanbul University, Istanbul, Turkey. Electronic address: hulyilmaz@yahoo.com.
FAU - Yilmaz-Aydogan, Hulya
AU  - Yilmaz-Aydogan H
FAU - Kurnaz, Ozlem
AU  - Kurnaz O
FAU - Kucukhuseyin, Ozlem
AU  - Kucukhuseyin O
FAU - Akadam-Teker, Basak
AU  - Akadam-Teker B
FAU - Kurt, Ozlem
AU  - Kurt O
FAU - Eronat, Allison Pinar
AU  - Eronat AP
FAU - Tekeli, Atike
AU  - Tekeli A
FAU - Bugra, Zehra
AU  - Bugra Z
FAU - Ozturk, Oguz
AU  - Ozturk O
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - Netherlands
TA  - Gene
JT  - Gene
JID - 7706761
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/01/11 [received]
PHST- 2013/03/18 [revised]
PHST- 2013/03/28 [accepted]
PHST- 2013/04/11 [aheadofprint]
AID - S0378-1119(13)00433-2 [pii]
AID - 10.1016/j.gene.2013.03.136 [doi]
PST - ppublish
SO  - Gene. 2013 Jul 1;523(1):20-6. doi: 10.1016/j.gene.2013.03.136. Epub 2013 Apr 11.

PMID- 23583377
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 434
IP  - 3
DP  - 2013 May 10
TI  - Ellagic acid improves hepatic steatosis and serum lipid composition through
      reduction of serum resistin levels and transcriptional activation of hepatic
      ppara in obese, diabetic KK-A(y) mice.
PG  - 486-91
LID - 10.1016/j.bbrc.2013.03.100 [doi]
LID - S0006-291X(13)00579-2 [pii]
AB  - Ellagic acid (EA) is a polyphenol found in a wide variety of plant foods that not
      only exhibits free radical-scavenging activity, but also confers protective
      effects against liver injury. Previously, we reported that pomegranate fruit
      extract (PFE) had an inhibitory effect on resistin secretion from differentiated 
      murine 3T3-L1 adipocytes and identified EA contained in PFE as a potent
      suppressor of resistin secretion. Resistin, an adipocytokine, is considered the
      link between obesity and type 2 diabetes. In this study, we explored whether EA
      supplementation reduces serum resistin and improves hepatic steatosis and serum
      lipid profile by using KK-A(y) mice fed high-fat diet as a model for obese type 2
      diabetes. We found that EA supplementation improved serum lipid profile and
      hepatic steatosis, and reduced serum resistin levels without altering mRNA
      expression levels in adipose tissue. Moreover, EA supplementation upregulated
      mRNA expression of apoa1, ldlr, cpt1a, and ppara genes in the liver. In
      conclusion, our findings indicate that EA is a potent suppressor of resistin
      secretion in vivo and a transcriptional activator of ppara in the liver,
      suggesting a possibility for improving obesity-induced dyslipidemia and hepatic
      steatosis in KK-A(y) mice.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Applied Biological Chemistry, Graduate School of Agricultural
      Science, Kinki University, 204-3327 Nakamachi, Nara City, Nara 631-8505, Japan.
FAU - Yoshimura, Yukihiro
AU  - Yoshimura Y
FAU - Nishii, Saori
AU  - Nishii S
FAU - Zaima, Nobuhiro
AU  - Zaima N
FAU - Moriyama, Tatsuya
AU  - Moriyama T
FAU - Kawamura, Yukio
AU  - Kawamura Y
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/03/18 [received]
PHST- 2013/03/24 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0006-291X(13)00579-2 [pii]
AID - 10.1016/j.bbrc.2013.03.100 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2013 May 10;434(3):486-91. doi:
      10.1016/j.bbrc.2013.03.100. Epub 2013 Apr 10.

PMID- 23583324
OWN - NLM
STAT- In-Data-Review
DA  - 20130603
IS  - 1879-3150 (Electronic)
IS  - 0041-0101 (Linking)
VI  - 69
DP  - 2013 Jul
TI  - New insights on arthropod toxins that potentiate erectile function.
PG  - 152-9
LID - 10.1016/j.toxicon.2013.03.017 [doi]
LID - S0041-0101(13)00112-8 [pii]
AB  - The use of natural substances for the treatment of diseases or injuries is an
      ancient practice of many cultures. According to folklore, natural aphrodisiacs
      may help to raise libido and increase desire. The supposed aphrodisiacs mainly
      include a plethora of preparations of plants, among other substances. However,
      the real boundary between myth and reality has not been established yet in most
      cases and such boundaries must be drawn by scientific methods. A growing interest
      of the scientific community has been focused on animal venoms, especially those
      from arthropods, i.e. spiders and scorpions, which cause priapism, a prolonged
      and painful erection. This review highlights the studies that have been performed
      with venoms and toxins from arthropods known to cause priapism, among other toxic
      symptoms, pointing out some pharmacological approaches for better understanding
      this effect. To date, the venom of some spiders, mainly Phoneutria nigriventer,
      and scorpions, such as the yellow South American scorpion Tityus serrulatus,
      among others, have been known to cause priapism. Since erectile dysfunction (ED) 
      is a growing health problem in the world, more common in patients with vascular
      diseases as diabetes and hypertension, the use of animal venoms and toxins as
      pharmacological tools could not only shed light to the mechanisms involved in
      erectile function, but also represent a possible model for new drugs to treat ED.
      Unfortunately, attempts to correlate the structure of those priapism-related
      toxins were unfruitful. Such difficulties lie firstly on the poor data concerning
      purified priapism-related toxins, instead of whole venoms and/or semi-purified
      fractions, and secondly, on the scarce available primary sequences and structural
      data, mainly from spider toxins. It has been shown that all these toxins modify
      the sodium (Na(+)) channel activity, mostly slowing down its inactivation
      current. Improving the knowledge on the tertiary structure of these toxins could 
      provide a key in the search of a new drug for ED treatment.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Physiology, Georgia Health Sciences University, Augusta, GA, USA.
FAU - Nunes, Kenia P
AU  - Nunes KP
FAU - Torres, Fernanda S
AU  - Torres FS
FAU - Borges, Marcia H
AU  - Borges MH
FAU - Matavel, Alessandra
AU  - Matavel A
FAU - Pimenta, Adriano M C
AU  - Pimenta AM
FAU - De Lima, Maria E
AU  - De Lima ME
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - England
TA  - Toxicon
JT  - Toxicon : official journal of the International Society on Toxinology
JID - 1307333
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/25 [received]
PHST- 2013/02/21 [revised]
PHST- 2013/03/22 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0041-0101(13)00112-8 [pii]
AID - 10.1016/j.toxicon.2013.03.017 [doi]
PST - ppublish
SO  - Toxicon. 2013 Jul;69:152-9. doi: 10.1016/j.toxicon.2013.03.017. Epub 2013 Apr 10.

PMID- 23583279
OWN - NLM
STAT- Publisher
DA  - 20130503
IS  - 1879-1220 (Electronic)
IS  - 0960-0760 (Linking)
DP  - 2013 Apr 10
TI  - Steroid profiling in pregnancy: A focus on the human fetus.
LID - S0960-0760(13)00057-5 [pii]
LID - 10.1016/j.jsbmb.2013.03.008 [doi]
AB  - In this review we focused on steroid metabolomics in human fetuses and newborns
      and its role in the physiology and pathophysiology of human pregnancy and
      subsequent stages of human life, and on the physiological relevance of steroids
      influencing the nervous systems with regards to their concentrations in the
      fetus. Steroid profiling provides valuable data for the diagnostics of diseases
      related to altered steroidogenesis in the fetal and maternal compartments and
      placenta. We outlined a potential use of steroid metabolomics for the prediction 
      of reproductive disorders, misbalance of hypothalamic-pituitary-adrenal axis, and
      impaired insulin sensitivity in subsequent stages of human life. A possible role 
      of steroids exhibiting a non-genomic effect in the development of gestational
      diabetes and in the neuroprotection via negative modulation of AMPA/kainate
      receptors was also indicated. Increasing progesterone synthesis and catabolism,
      declining production of tocolytic 5beta-pregnane steroids, and rising activities 
      of steroid sulfotransferases with the approaching term may be of importance in
      sustaining pregnancy. An increasing trend was demonstrated with advancing
      gestation toward the production of ketones (and 3beta-hydroxyl groups in the case
      of 3alpha-hydroxy-steroids) was demonstrated in the fetus on the expense of
      3alpha-hydroxy-, 17beta-hydroxy-, and 20alpha-hydroxy-groups weakening in the
      sequence C17, C3, and C20. There was higher production of active progestogen but 
      lower production of active estrogen and GABAergic steroids with the approaching
      term. Rising activities of placental CYP19A1 and oxidative isoforms of HSD17B,
      and of fetal CYP3A7 with advancing gestation may protect the fetus from
      hyperestrogenization. This article is part of a Special Issue entitled 'Pregnancy
      and Steroids'.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Institute of Endocrinology, Narodni trida 8, Prague CZ 116 94, Czech Republic.
      Electronic address: mhill@endo.cz.
FAU - Hill, Martin
AU  - Hill M
FAU - Paskova, Andrea
AU  - Paskova A
FAU - Kanceva, Radmila
AU  - Kanceva R
FAU - Velikova, Marta
AU  - Velikova M
FAU - Kubatova, Jana
AU  - Kubatova J
FAU - Kancheva, Lyudmila
AU  - Kancheva L
FAU - Adamcova, Karolina
AU  - Adamcova K
FAU - Mikesova, Michaela
AU  - Mikesova M
FAU - Zizka, Zdenek
AU  - Zizka Z
FAU - Koucky, Michal
AU  - Koucky M
FAU - Sarapatkova, Hana
AU  - Sarapatkova H
FAU - Kacer, Viktor
AU  - Kacer V
FAU - Matucha, Petr
AU  - Matucha P
FAU - Meloun, Milan
AU  - Meloun M
FAU - Parizek, Antonin
AU  - Parizek A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130410
TA  - J Steroid Biochem Mol Biol
JT  - The Journal of steroid biochemistry and molecular biology
JID - 9015483
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/10/02 [received]
PHST- 2013/03/24 [revised]
PHST- 2013/03/26 [accepted]
AID - S0960-0760(13)00057-5 [pii]
AID - 10.1016/j.jsbmb.2013.03.008 [doi]
PST - aheadofprint
SO  - J Steroid Biochem Mol Biol. 2013 Apr 10. pii: S0960-0760(13)00057-5. doi:
      10.1016/j.jsbmb.2013.03.008.

PMID- 23583197
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 434
IP  - 4
DP  - 2013 May 17
TI  - Development of Akt-activated GSK3beta inhibitory peptide.
PG  - 735-9
LID - 10.1016/j.bbrc.2013.03.103 [doi]
LID - S0006-291X(13)00582-2 [pii]
AB  - Abnormal overexpression of GSK3beta has been implicated in insulin resistance.
      Although many potent GSK3beta inhibitors have been developed as drug candidates
      for anti-insulin resistance, the inhibitors are prone to show side effects
      because they interfere with normal GSK3beta function without regulation.
      Recently, it was reported that the PPPSPxS motifs in the Wnt coreceptor LRP6 were
      able to directly inhibit GSK3beta only when the motif was phosphorylated. Here,
      we generated a new GSK3beta inhibitory peptide that can be activated by Akt by
      combining the PPPSPxS motif and an Akt target sequence. The peptide exhibited an 
      inhibitory effect on GSK3beta only when it was phosphorylated by Akt in a
      purified system and in cells when stimulated by insulin. Thus, our findings
      provide a novel concept for drugs against diseases that are involved in the
      abnormal GSK3beta activity, including type 2 diabetes mellitus.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Manufacturing Pharmacy, College of Pharmacy, Pusan National
      University, Busan 609-735, Republic of Korea.
FAU - Kim, Jin-Sik
AU  - Kim JS
FAU - Piao, Shunfu
AU  - Piao S
FAU - Lee, Eunjin
AU  - Lee E
FAU - Yoon, Bo-Young
AU  - Yoon BY
FAU - Moon, Hyung Ryong
AU  - Moon HR
FAU - Lee, Jaewon
AU  - Lee J
FAU - Jung, Yunjin
AU  - Jung Y
FAU - Ha, Nam-Chul
AU  - Ha NC
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/03/08 [received]
PHST- 2013/03/24 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0006-291X(13)00582-2 [pii]
AID - 10.1016/j.bbrc.2013.03.103 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2013 May 17;434(4):735-9. doi:
      10.1016/j.bbrc.2013.03.103. Epub 2013 Apr 10.

PMID- 23583184
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1138-3593 (Print)
IS  - 1138-3593 (Linking)
DP  - 2013 Apr 11
TI  - [Lifestyles of primary care physicians: Perception and implications on
      cardiovascular prevention.]
LID - S1138-3593(13)00016-6 [pii]
LID - 10.1016/j.semerg.2013.01.006 [doi]
AB  - OBJECTIVES: To analyze the lifestyles of family physicians, their influence on
      cardiovascular prevention activities carried out on their patients and the
      difficulties in carrying them out. MATERIAL AND METHODS: Design cross-sectional
      study, using as an anonymous ad hoc questionnaire, implemented in 2010. LOCATION:
      Primary care of Mallorca. PARTICIPANTS: Representative sample of 185 primary care
      medical professionals of Mallorca. RESULTS: There was a response rate of 78.9%
      (146/185). Characteristics of physicians surveyed: the mean age was 43.6 years,
      24.6% following a healthy diet, 18.6% were smokers, 32.7% did not consume
      alcohol, and 80.8% performed physical exercise. The most frequent prevention
      activity on their patients was anti-smoking advice (52.3%), followed by those
      related to cardiovascular risk factors, hypertension, diabetes, dyslipidemia
      (22.7%), dietary advice (14.4%), advice about exercise (5.3%), and alcohol
      consumption (0.8%). Doctors who smoked and drank more alcohol offered less
      preventive activities to their patients (P<.05). Lack of time was the main
      limiting factor to properly perform prevention activities. CONCLUSIONS: There is 
      a relationship between lifestyle habits of primary care physicians and preventive
      activities carried out with their patients. Family physicians have relatively
      healthy lifestyles and promote preventive activities among their patients. The
      limited investigation into alcohol consumption should be noted.
CI  - Copyright (c) 2012 Sociedad Espanola de Medicos de Atencion Primaria (SEMERGEN). 
      Publicado por Elsevier Espana. All rights reserved.
AD  - Medicina de Familia y Comunitaria, Centro de Salud del Coll d'en Rebassa,
      Gerencia de Atencion Primaria de Mallorca, Ib-Salut. Palma de Mallorca, Espana;
      Departamento de Neurociencias, Facultad de Medicina y Odontologia, Universidad
      del Pais Vasco/Euskal Herriko Unibertsitatea, Leioa, Espana.
FAU - Fonseca, M
AU  - Fonseca M
FAU - Fleitas, G
AU  - Fleitas G
FAU - Tamborero, G
AU  - Tamborero G
FAU - Benejam, M
AU  - Benejam M
FAU - Leiva, A
AU  - Leiva A
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Estilos de vida de los medicos de atencion primaria: percepcion e implicaciones
      sobre la prevencion cardiovascular.
DEP - 20130411
TA  - Semergen
JT  - Semergen / Sociedad Espanola de Medicina Rural y Generalista
JID - 9610769
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/10/16 [received]
PHST- 2013/01/08 [revised]
PHST- 2013/01/17 [accepted]
AID - S1138-3593(13)00016-6 [pii]
AID - 10.1016/j.semerg.2013.01.006 [doi]
PST - aheadofprint
SO  - Semergen. 2013 Apr 11. pii: S1138-3593(13)00016-6. doi:
      10.1016/j.semerg.2013.01.006.

PMID- 23583166
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1549-4713 (Electronic)
IS  - 0161-6420 (Linking)
VI  - 120
IP  - 6
DP  - 2013 Jun
TI  - Screening for Diabetic Retinopathy with or without a Copayment in a Randomized
      Controlled Trial: Influence of the Inverse Care Law.
PG  - 1247-53
LID - 10.1016/j.ophtha.2012.11.024 [doi]
LID - S0161-6420(12)01103-7 [pii]
AB  - OBJECTIVE: To examine whether the inverse care law operates in a screening
      program for diabetic retinopathy (DR) based on fee for service in Hong Kong.
      DESIGN: Randomized controlled trial. PARTICIPANTS: All those with type 1 or 2
      diabetes from 2 clinics were recruited. INTERVENTION: Diabetic retinopathy
      screening with a small copayment versus free access in a publicly funded family
      medicine service. MAIN OUTCOME MEASURES: Uptake of screening and severity of DR
      detected. Association between these outcome variables and independent variables
      were determined using multivariate logistic regression models and reported as
      odds ratios (ORs). RESULTS: After randomization, 1387 subjects in the free group 
      and 1379 subjects in the pay group were eligible for screening, and 94.9%
      (1316/1387) and 92.6% (1277/1379), respectively, agreed to participate in the
      study. The offer of screening was accepted by 94.8% (1247/1316) in the free group
      and 91.2% (1164/1277) in the pay group, and the final uptake ratios were 88.5%
      (1165/1316) and 82.4% (1052/1277), respectively (Pearson chi = 19.74, P<0.001).
      Being in the pay group was associated with a lower uptake of screening than being
      in the free group (OR, 0.59; confidence interval [CI], 0.47-0.74) and a lower
      detection rate of DR (OR, 0.73; CI, 0.60-0.90) after adjustment for potential
      confounding factors. Subjects with higher socioeconomic status were more likely
      to attend screening and had a lower prevalence of DR detected. CONCLUSIONS: The
      inverse care law seems to operate in a preventive intervention when a relatively 
      small copayment is applied. There is a case for making effective preventive
      services free of charge. FINANCIAL DISCLOSURE(S): The author(s) have no
      proprietary or commercial interest in any materials discussed in this article.
CI  - Copyright (c) 2013 American Academy of Ophthalmology. Published by Elsevier Inc. 
      All rights reserved.
AD  - School of Public Health, The University of Hong Kong, Hong Kong.
FAU - Lian, Jin Xiao
AU  - Lian JX
FAU - McGhee, Sarah M
AU  - McGhee SM
FAU - Gangwani, Rita A
AU  - Gangwani RA
FAU - Hedley, Anthony J
AU  - Hedley AJ
FAU - Lam, Cindy Lo Kuen
AU  - Lam CL
FAU - Yap, Maurice Keng Hung
AU  - Yap MK
FAU - Lai, Wico W
AU  - Lai WW
FAU - Chu, Daniel Wai Sing
AU  - Chu DW
FAU - Wong, David S H
AU  - Wong DS
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - Ophthalmology
JT  - Ophthalmology
JID - 7802443
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/07/13 [received]
PHST- 2012/11/08 [revised]
PHST- 2012/11/13 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - S0161-6420(12)01103-7 [pii]
AID - 10.1016/j.ophtha.2012.11.024 [doi]
PST - ppublish
SO  - Ophthalmology. 2013 Jun;120(6):1247-53. doi: 10.1016/j.ophtha.2012.11.024. Epub
      2013 Apr 12.

PMID- 23583042
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1542-0124 (Print)
IS  - 1542-0124 (Linking)
VI  - 11
IP  - 2
DP  - 2013 Apr
TI  - Corneal crosslinking with riboflavin and ultraviolet A. I. Principles.
PG  - 65-74
LID - 10.1016/j.jtos.2013.01.002 [doi]
LID - S1542-0124(13)00009-8 [pii]
AB  - Changes in the biomechanical properties of the human cornea play an important
      role in the pathogenesis of corneal ectatic diseases. Biomechanical investigation
      shows significant differences between human ectatic corneas and normal corneas,
      including decreased stiffness and reduction of collagen crosslinks in the ectatic
      cornea. Induction of crosslinks is a well-established procedure in polymer
      chemistry to increase the elastic modulus of materials. Crosslinking (CXL) in
      connective tissue can occur during aging and as a side effect of diabetes
      mellitus. CXL has been used medically to increase stability and reduce the
      biodegradation of collagen-based biomaterials for bioprostheses. CXL of the
      cornea using riboflavin and UVA light with a wavelength of 370 nm and a dosage of
      5.4 J/cm(2) is a new approach that increases the mechanical and biochemical
      stability of stromal tissue. This technique combines the principles of CXL
      (chemical and nonenzymatic) and the biochemical mechanisms of photo-oxidative CXL
      with riboflavin as a photosensitizer. In this review, the enrichment of
      riboflavin in the stroma by standard (epi-off) and transepithelial (epi-on) CXL
      is discussed. The theoretical and experimental measurements of the absorption of 
      UV light explain the stronger CXL effect in the anterior stroma and its
      importance for the prevention of damage to the endothelial cells. UV devices are 
      described. Changes of the physical properties after CXL, as well as the cellular 
      changes, are discussed. From these basic investigations, treatment parameters for
      effective and safe CXL are identified.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Ophthalmology, Carl Gustav Carus University Hospital, Dresden,
      Germany. Frederik.Raiskup@uniklinikum-dresden.de
FAU - Raiskup, Frederik
AU  - Raiskup F
FAU - Spoerl, Eberhard
AU  - Spoerl E
LA  - eng
PT  - Journal Article
DEP - 20130124
PL  - United States
TA  - Ocul Surf
JT  - The ocular surface
JID - 101156063
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/01 [accepted]
PHST- 2013/01/24 [aheadofprint]
AID - S1542-0124(13)00009-8 [pii]
AID - 10.1016/j.jtos.2013.01.002 [doi]
PST - ppublish
SO  - Ocul Surf. 2013 Apr;11(2):65-74. doi: 10.1016/j.jtos.2013.01.002. Epub 2013 Jan
      24.

PMID- 23583038
OWN - NLM
STAT- In-Data-Review
DA  - 20130510
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 34
IP  - 22
DP  - 2013 Jul
TI  - Porcine pancreas extracellular matrix as a platform for endocrine pancreas
      bioengineering.
PG  - 5488-95
LID - 10.1016/j.biomaterials.2013.03.054 [doi]
LID - S0142-9612(13)00364-5 [pii]
AB  - Emergent technologies of regenerative medicine have the potential to overcome the
      limitations of organ transplantation by supplying tissues and organs
      bioengineered in the laboratory. Pancreas bioengineering requires a scaffold that
      approximates the biochemical, spatial and vascular relationships of the native
      extracellular matrix (ECM). We describe the generation of a whole organ,
      three-dimensional pancreas scaffold using acellular porcine pancreas. Imaging
      studies confirm that our protocol effectively removes cellular material while
      preserving ECM proteins and the native vascular tree. The scaffold was seeded
      with human stem cells and porcine pancreatic islets, demonstrating that the
      decellularized pancreas can support cellular adhesion and maintenance of cell
      functions. These findings advance the field of regenerative medicine towards the 
      development of a fully functional, bioengineered pancreas capable of establishing
      and sustaining euglycemia and may be used for transplantation to cure diabetes
      mellitus.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Wake Forest Institute for Regenerative Medicine, Winston Salem, NC, USA.
FAU - Mirmalek-Sani, Sayed-Hadi
AU  - Mirmalek-Sani SH
FAU - Orlando, Giuseppe
AU  - Orlando G
FAU - McQuilling, John P
AU  - McQuilling JP
FAU - Pareta, Rajesh
AU  - Pareta R
FAU - Mack, David L
AU  - Mack DL
FAU - Salvatori, Marcus
AU  - Salvatori M
FAU - Farney, Alan C
AU  - Farney AC
FAU - Stratta, Robert J
AU  - Stratta RJ
FAU - Atala, Anthony
AU  - Atala A
FAU - Opara, Emmanuel C
AU  - Opara EC
FAU - Soker, Shay
AU  - Soker S
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/25 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0142-9612(13)00364-5 [pii]
AID - 10.1016/j.biomaterials.2013.03.054 [doi]
PST - ppublish
SO  - Biomaterials. 2013 Jul;34(22):5488-95. doi: 10.1016/j.biomaterials.2013.03.054.
      Epub 2013 Apr 10.

PMID- 23583010
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1573-2509 (Electronic)
VI  - 147
IP  - 1
DP  - 2013 Jun
TI  - The effect of zonisamide on antipsychotic-associated weight gain in patients with
      schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
PG  - 110-5
LID - 10.1016/j.schres.2013.03.021 [doi]
LID - S0920-9964(13)00167-9 [pii]
AB  - BACKGROUND: Many patients with schizophrenia suffer from metabolic symptoms and
      weight gain in which predispose them to obesity, diabetes, and cardiovascular
      problems. This trial examines the efficacy and safety of zonisamide on weight and
      body mass index in patients with schizophrenia being administered with atypical
      antipsychotics. METHOD: In this 10-week, double blind randomized placebo
      controlled clinical trial, forty one patients with schizophrenia diagnosed
      according to DSM-IV-TR criteria who were taking a stable dose of atypical
      antipsychotic are allocated into one of the two groups of zonisamide or placebo
      group. Weight, body mass index, waist circumference, and adverse effects were
      assessed. RESULTS: The two groups were not statistically different regarding
      baseline characteristics on age, gender, education, diagnosis, weight, body mass 
      index, daily cigarette smoking, and the duration of illness. After 10weeks, the
      patients in the placebo group had significantly gained weight, while the patients
      in the zonisamide group lost weight (mean=1.9, SD=2.2 versus mean=-1.1kg,
      SD=1.4). The changes of body mass index in the two groups were significantly
      different. Body mass index decreased in the zonisamide group (mean=-0.3, SD=0.4) 
      while it increased in the placebo group (mean=2.2, SD=6.9). There was a
      significance difference between the two groups regarding waist circumference at
      the end of trial (P<0.0001), too. The waist increased in the placebo group while 
      it decreased in the zonisamide group (mean=1.1, SD=1.7 versus mean=-0.7, SD=1.2, 
      respectively), as well. The frequencies of adverse effects were not significantly
      different between the two groups and zonisamide was tolerated well. CONCLUSION:
      Zonisamide as an adjuvant treatment is tolerated well and markedly affect on the 
      weight loss of patients with schizophrenia being treated with atypical
      antipsychotics.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - Research Center for Psychiatry and Behavioral Sciences, Shiraz University of
      Medical Sciences, School of Medicine, Shiraz, Iran; Department of Psychiatry,
      Shiraz University of Medical Sciences, School of Medicine, Shiraz, Iran.
      Electronic address: ghanizad@sina.tums.ac.ir.
FAU - Ghanizadeh, Ahmad
AU  - Ghanizadeh A
FAU - Nikseresht, Mohammad Saeed
AU  - Nikseresht MS
FAU - Sahraian, Ali
AU  - Sahraian A
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/01/23 [received]
PHST- 2013/03/02 [revised]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/11 [aheadofprint]
AID - S0920-9964(13)00167-9 [pii]
AID - 10.1016/j.schres.2013.03.021 [doi]
PST - ppublish
SO  - Schizophr Res. 2013 Jun;147(1):110-5. doi: 10.1016/j.schres.2013.03.021. Epub
      2013 Apr 11.

PMID- 23582888
OWN - NLM
STAT- In-Data-Review
DA  - 20130506
IS  - 1532-2777 (Electronic)
IS  - 0306-9877 (Linking)
VI  - 80
IP  - 6
DP  - 2013 Jun
TI  - Meal related glucose monitoring is a method of diagnosing glucose intolerance in 
      pregnancies with high probability of gestational diabetes but normal glucose
      tolerance by oral glucose tolerance test.
PG  - 816-8
LID - 10.1016/j.mehy.2013.03.019 [doi]
LID - S0306-9877(13)00137-0 [pii]
AB  - Gestational diabetes mellitus diagnosed by classical oral glucose tolerance test 
      can result in fetal complications like macrosomia and polyhydramnios. Guidelines 
      exist on management of patients diagnose by abnormal oral glucose tolerance test 
      with diet modification followed by insulin. Even patients with abnormal oral
      glucose tolerance test maintaining apparently normal blood sugars with diet are
      advised insulin if there is accelerated fetal growth. But patients with normal
      oral glucose tolerance test can present with macrosomia and polyhydramnios. These
      patients are labelled as not having gestational diabetes mellitus and are
      followed up with repeat oral glucose tolerance test. We hypothesise that these
      patients may have an altered placental threshold to glucose or abnormal
      sensitivity of fetal tissues to glucose. Meal related glucose monitoring in these
      patients can identify minor abnormalities in glucose disturbance and should be
      treated to targets similar to physiological levels of glucose in non pregnant
      adults.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Providence Endocrine and Diabetes Specialty Centre, TC 1/2138, Near GG Hospital, 
      Murinjapalam, Trivandrum 695011, India. Electronic address:
      drmathewjohn@yahoo.com.
FAU - John, Mathew
AU  - John M
FAU - Gopinath, Deepa
AU  - Gopinath D
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - United States
TA  - Med Hypotheses
JT  - Medical hypotheses
JID - 7505668
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/08/01 [received]
PHST- 2013/03/09 [accepted]
PHST- 2013/04/09 [aheadofprint]
AID - S0306-9877(13)00137-0 [pii]
AID - 10.1016/j.mehy.2013.03.019 [doi]
PST - ppublish
SO  - Med Hypotheses. 2013 Jun;80(6):816-8. doi: 10.1016/j.mehy.2013.03.019. Epub 2013 
      Apr 9.

PMID- 23582874
OWN - NLM
STAT- In-Data-Review
DA  - 20130604
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 100
IP  - 3
DP  - 2013 Jun
TI  - Diabetes and ageing in the Melbourne Collaborative Cohort Study (MCCS).
PG  - 398-403
LID - 10.1016/j.diabres.2013.03.024 [doi]
LID - S0168-8227(13)00105-8 [pii]
AB  - AIMS: To examine the association between diabetes, and ageing 12 years later.
      METHODS: Subjects reporting angina, cancer, heart attack or stroke at baseline
      (1990-1994) were excluded. Diabetes at baseline was identified by self-report or 
      elevated plasma glucose (>/=7.0mmol/l fasting or >/=11.1mmol/l non-fasting). 6431
      eligible men and women had survived to age 70 years at follow-up (2003-2007), and
      5704 with complete data were included in these analyses. Those without ischemic
      heart disease, stroke, and cancer, no perceived major difficulty with physical
      functioning, and no evidence of psychological distress were considered to have
      aged successfully, irrespective of diabetes at follow-up (n=1271). Logistic
      regression was used to examine the independent association between baseline
      diabetes and successful ageing. RESULTS: At baseline 216 eligible people were
      identified with diabetes. This was inversely associated with successful ageing at
      follow-up independent of smoking, physical activity, alcohol use and obesity (OR 
      0.65, 95% 0.42-0.99), Of the people with diabetes at follow-up, only 12.5% did
      not have another condition characteristic of usual ageing, compared with 22.7% of
      people who did not have diabetes. CONCLUSIONS: Diabetes is strongly associated
      with factors characterising less successful ageing, suggesting that the impact of
      diabetes may be larger than currently estimated.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Cancer Epidemiology Centre, Cancer Council Victoria, Australia. Electronic
      address: allison.hodge@cancervic.org.au.
FAU - Hodge, Allison M
AU  - Hodge AM
FAU - Flicker, Leon
AU  - Flicker L
FAU - O'Dea, Kerin
AU  - O'Dea K
FAU - English, Dallas R
AU  - English DR
FAU - Giles, Graham G
AU  - Giles GG
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/10/19 [received]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0168-8227(13)00105-8 [pii]
AID - 10.1016/j.diabres.2013.03.024 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Jun;100(3):398-403. doi:
      10.1016/j.diabres.2013.03.024. Epub 2013 Apr 10.

PMID- 23582850
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 0003-4266 (Print)
IS  - 0003-4266 (Linking)
VI  - 74
IP  - 2
DP  - 2013 May
TI  - [Cross-talk between insulin signaling and cell proliferation pathways].
PG  - 74-8
LID - 10.1016/j.ando.2013.02.003 [doi]
LID - S0003-4266(13)00021-8 [pii]
AB  - Epidemiological studies provide evidence for a close relationship between
      diabetes and cancer. Insulin is in fact a growth factor, and its binding to its
      membrane receptor activates intracellular signaling pathways involved in the
      regulation of both metabolism and cell proliferation. The balance between
      mitogenic and metabolic actions of insulin can be modulated by various
      mechanisms, including the way the ligand binds to its receptor or to the closely 
      related insulin-like growth factor-1 (IGF-1) receptor. Cross-talks with other
      signaling pathways implicated in cell proliferation have also been described,
      like the Wnt/beta catenin pathway, and involve the activation of common
      downstream effectors such as insulin receptor substrate-1 (IRS-1). Finally, the
      identification of new proteins activated by insulin and involved in intracellular
      signaling would allow a better understanding of the complex connections linking
      metabolic and proliferative regulatory pathways. As an example, the molecular
      adaptor Grb14, which is a specific inhibitor of insulin receptor catalytic
      activity, also controls insulin-induced metabolic and mitogenic signaling
      pathways through post-receptor mechanisms that remain to be fully elucidated.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Inserm, U1016, institut Cochin, Paris, France; Cnrs, UMR8104, Paris, France;
      Universite Paris Descartes, Sorbonne Paris Cite, 24, rue du
      Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address:
      anne-francoise.burnol@inserm.fr.
FAU - Burnol, Anne-Francoise
AU  - Burnol AF
FAU - Morzyglod, Lucille
AU  - Morzyglod L
FAU - Popineau, Lucie
AU  - Popineau L
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Dialogue entre les voies de signalisation de l'insuline et les voies de
      proliferation cellulaire.
DEP - 20130409
PL  - France
TA  - Ann Endocrinol (Paris)
JT  - Annales d'endocrinologie
JID - 0116744
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/09 [aheadofprint]
AID - S0003-4266(13)00021-8 [pii]
AID - 10.1016/j.ando.2013.02.003 [doi]
PST - ppublish
SO  - Ann Endocrinol (Paris). 2013 May;74(2):74-8. doi: 10.1016/j.ando.2013.02.003.
      Epub 2013 Apr 9.

PMID- 23582849
OWN - NLM
STAT- In-Data-Review
DA  - 20130513
IS  - 0003-4266 (Print)
IS  - 0003-4266 (Linking)
VI  - 74
IP  - 2
DP  - 2013 May
TI  - Revisiting the mechanisms of metformin action in the liver.
PG  - 123-9
LID - 10.1016/j.ando.2013.03.006 [doi]
LID - S0003-4266(13)00033-4 [pii]
AB  - Although considerable efforts have been made since the 1950s to better understand
      the action of metformin, the first line therapeutic for type 2 diabetes, its
      mechanisms of action has not been fully elucidated. The main antidiabetic effect 
      of this drug is to decrease hepatic glucose production. A plausible molecular
      mechanism of action now emerges from recent breakthroughs that place metformin at
      the control of energy homeostasis. Metformin was shown to induce a mild and
      transient inhibition of the mitochondrial respiratory chain complex 1. The
      resulting decrease in hepatic energy state activates the AMP-activated protein
      kinase (AMPK), a cellular metabolic sensor, and provided a generally accepted
      mechanism for metformin action on hepatic gluconeogenic program. However, the
      role of AMPK activation in metformin action has recently been challenged by
      loss-of-function experiments. Recent evidence showed that metformin-induced
      inhibition of hepatic glucose output is mediated by reducing cellular energy
      charge rather than direct inhibition of gluconeogenic gene expression.
      Furthermore, recent data support a novel mechanism of action for metformin
      involving antagonism of glucagon signaling pathways by inducing the accumulation 
      of AMP, which inhibits adenylate cyclase and reduced levels of cAMP.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Departement endocrinologie, metabolisme et cancer, Inserm, U1016, Institut
      Cochin, 24, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Cnrs, UMR8104,
      75014 Paris, France; Universite Paris Descartes, Sorbonne Paris cite, 75014
      Paris, France. Electronic address: benoit.viollet@inserm.fr.
FAU - Viollet, Benoit
AU  - Viollet B
FAU - Foretz, Marc
AU  - Foretz M
LA  - eng
PT  - Journal Article
DEP - 20130410
PL  - France
TA  - Ann Endocrinol (Paris)
JT  - Annales d'endocrinologie
JID - 0116744
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/10 [aheadofprint]
AID - S0003-4266(13)00033-4 [pii]
AID - 10.1016/j.ando.2013.03.006 [doi]
PST - ppublish
SO  - Ann Endocrinol (Paris). 2013 May;74(2):123-9. doi: 10.1016/j.ando.2013.03.006.
      Epub 2013 Apr 10.

PMID- 23582679
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1875-2128 (Electronic)
IS  - 1875-2128 (Linking)
VI  - 106
IP  - 3
DP  - 2013 Mar
TI  - Pathophysiology of persistent pulmonary hypertension of the newborn: impact of
      the perinatal environment.
PG  - 169-77
LID - 10.1016/j.acvd.2012.12.005 [doi]
LID - S1875-2136(13)00007-7 [pii]
AB  - The main cause of pulmonary hypertension in newborn babies results from the
      failure of the pulmonary circulation to dilate at birth, termed 'persistent
      pulmonary hypertension of the newborn' (PPHN). This syndrome is characterized by 
      sustained elevation of pulmonary vascular resistance, causing extrapulmonary
      right-to-left shunting of blood across the ductus arteriosus and foramen ovale
      and severe hypoxaemia. It can also lead to life-threatening circulatory failure. 
      There are many controversial and unresolved issues regarding the pathophysiology 
      of PPHN, and these are discussed. PPHN is generally associated with factors such 
      as congenital diaphragmatic hernia, birth asphyxia, sepsis, meconium aspiration
      and respiratory distress syndrome. However, the perinatal environment-exposure to
      nicotine and certain medications, maternal obesity and diabetes, epigenetics,
      painful stimuli and birth by Caesarean section-may also affect the maladaptation 
      of the lung circulation at birth. In infants with PPHN, it is important to
      optimize circulatory function. Suggested management strategies for PPHN include: 
      avoidance of environmental factors that worsen PPHN (e.g. noxious stimuli, lung
      overdistension); adequate lung recruitment and alveolar ventilation; inhaled
      nitric oxide (or sildenafil, if inhaled nitric oxide is not available);
      haemodynamic assessment; appropriate fluid and cardiovascular resuscitation and
      inotropic and vasoactive agents.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - EA4489, Environnement Perinatal et Croissance, Faculte de Medecine, Universite
      Lille-2, Lille, France. lstorme@chru-lille.fr
FAU - Storme, Laurent
AU  - Storme L
FAU - Aubry, Estelle
AU  - Aubry E
FAU - Rakza, Thameur
AU  - Rakza T
FAU - Houeijeh, Ali
AU  - Houeijeh A
FAU - Debarge, Veronique
AU  - Debarge V
FAU - Tourneux, Pierre
AU  - Tourneux P
FAU - Deruelle, Philippe
AU  - Deruelle P
FAU - Pennaforte, Thomas
AU  - Pennaforte T
CN  - French Congenital Diaphragmatic Hernia Study Group
LA  - eng
PT  - Journal Article
DEP - 20130329
PL  - Netherlands
TA  - Arch Cardiovasc Dis
JT  - Archives of cardiovascular diseases
JID - 101465655
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/07/26 [received]
PHST- 2012/12/08 [revised]
PHST- 2012/12/11 [accepted]
PHST- 2013/03/29 [aheadofprint]
AID - S1875-2136(13)00007-7 [pii]
AID - 10.1016/j.acvd.2012.12.005 [doi]
PST - ppublish
SO  - Arch Cardiovasc Dis. 2013 Mar;106(3):169-77. doi: 10.1016/j.acvd.2012.12.005.
      Epub 2013 Mar 29.

PMID- 23582677
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1875-2128 (Electronic)
IS  - 1875-2128 (Linking)
VI  - 106
IP  - 3
DP  - 2013 Mar
TI  - Impact of multivessel disease on myocardial perfusion and survival among patients
      undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa 
      inhibitors.
PG  - 155-61
LID - 10.1016/j.acvd.2012.12.007 [doi]
LID - S1875-2136(13)00033-8 [pii]
AB  - BACKGROUND: Although primary angioplasty achieves thrombolysis in myocardial
      infarction (TIMI) 3 flow in most patients with ST-elevation myocardial
      infarction, epicardial recanalization does not guarantee optimal perfusion in a
      large proportion of patients. The influence of multivessel disease on myocardial 
      reperfusion and survival after primary angioplasty has not been extensively
      investigated. AIM: To evaluate the impact of multivessel disease on myocardial
      perfusion and survival in a large cohort of patients with ST-elevation myocardial
      infarction treated with angioplasty and glycoprotein (GP) IIb/IIIa inhibitors.
      METHODS: This analysis is based on 1494 patients undergoing primary angioplasty
      included in the EGYPT database. Myocardial perfusion was evaluated by angiography
      or ST-segment resolution, whereas infarct size was estimated by using peak
      creatine kinase-MB (CK-MB). Follow-up data were collected between 30 days and 1
      year after primary angioplasty. RESULTS: Multivessel disease was observed in 870 
      patients (58.2%). The extent of coronary artery disease was associated with age, 
      diabetes, hypertension, previous myocardial infarction, previous
      revascularization, abciximab treatment and longer ischaemic time, and was
      independently associated with impaired angiographic myocardial perfusion
      (adjusted odds ratio 1.18, 95% confidence interval [CI] 1.01-1.40, P=0.049). At
      208+/-160 days, the extent of coronary artery disease was independently
      associated with higher mortality (adjusted hazard ratio 1.54, 95% CI 1.06-2.24,
      P=0.022). CONCLUSIONS: Among patients with ST-elevation myocardial infarction
      undergoing primary angioplasty with GP IIb/IIIa inhibitor treatment, the extent
      of coronary artery disease was independently associated with impaired myocardial 
      perfusion and survival.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
AD  - Division of Cardiology, "Maggiore della Carita" Hospital, Eastern Piedmont
      University, Novara, Italy. giuseppe.deluca@maggioreosp.novara.it
FAU - De Luca, Giuseppe
AU  - De Luca G
FAU - Gibson, Michael
AU  - Gibson M
FAU - Cutlip, Donald
AU  - Cutlip D
FAU - Huber, Kurt
AU  - Huber K
FAU - Dudek, Dariusz
AU  - Dudek D
FAU - Bellandi, Francesco
AU  - Bellandi F
FAU - Noc, Marko
AU  - Noc M
FAU - Maioli, Mauro
AU  - Maioli M
FAU - Zorman, Simona
AU  - Zorman S
FAU - Zeymer, Uwe
AU  - Zeymer U
FAU - Secco, Gioel Gabrio
AU  - Secco GG
FAU - Mesquita Gabriel, Henrique
AU  - Mesquita Gabriel H
FAU - Emre, Ayse
AU  - Emre A
FAU - Arntz, Hans-Richard
AU  - Arntz HR
FAU - Rakowski, Tomasz
AU  - Rakowski T
FAU - Gyongyosi, Maryann
AU  - Gyongyosi M
FAU - Hof, Arnoud W J Van't
AU  - Hof AW
CN  - EGYPT Cooperation
LA  - eng
PT  - Journal Article
DEP - 20130402
PL  - Netherlands
TA  - Arch Cardiovasc Dis
JT  - Archives of cardiovascular diseases
JID - 101465655
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/10/24 [received]
PHST- 2012/12/11 [revised]
PHST- 2012/12/18 [accepted]
PHST- 2013/04/02 [aheadofprint]
AID - S1875-2136(13)00033-8 [pii]
AID - 10.1016/j.acvd.2012.12.007 [doi]
PST - ppublish
SO  - Arch Cardiovasc Dis. 2013 Mar;106(3):155-61. doi: 10.1016/j.acvd.2012.12.007.
      Epub 2013 Apr 2.

PMID- 23582648
OWN - NLM
STAT- Publisher
DA  - 20130528
IS  - 1579-2242 (Electronic)
IS  - 0300-8932 (Linking)
VI  - 66
IP  - 6
DP  - 2013 Jun
TI  - Polymer-free Sirolimus-eluting Versus Polymer-based Paclitaxel-eluting Stents: An
      Individual Patient Data Analysis of Randomized Trials.
PG  - 435-442
LID - S0300-8932(13)00055-9 [pii]
LID - 10.1016/j.recesp.2012.11.017 [doi]
AB  - INTRODUCTION AND OBJECTIVES: The angiographic and clinical efficacy of
      polymer-free sirolimus-eluting stents vs polymer-based paclitaxel-eluting stents 
      remain a matter of debate. We sought to investigate angiographic and clinical
      measures of efficacy of polymer-free sirolimus-eluting stents vs polymer-based
      paclitaxel-eluting stents. METHODS: Patient data from the randomized
      intracoronary stenting and angiographic restenosis-test equivalence between the 2
      drug-eluting stents (ISAR-TEST) clinical trial and the LIPSIA Yukon clinical
      trial (randomized comparison of a polymer-free sirolimus-eluting stent vs a
      polymer-based paclitaxel-eluting stent in patients with diabetes mellitus) were
      pooled. The angiographic (primary) endpoint was in-stent late lumen loss at 6
      months to 9 months. The clinical (secondary) endpoints were death or myocardial
      infarction, cardiac death or myocardial infarction, target lesion
      revascularization, and myocardial infarction. RESULTS: A total of 686 patients
      (polymer-free sirolimus-eluting stents, n=345 vs polymer-based paclitaxel-eluting
      stents, n=341) and 751 lesions (polymer-free sirolimus-eluting stents, n=383 vs
      polymer-based paclitaxel-eluting stents, n=368) were included in the study.
      Control angiography (606 lesions, 80.6%) showed comparable in-stent late lumen
      loss for polymer-free sirolimus-eluting stents vs polymer-based
      paclitaxel-eluting stents (0,53 [0,59] mm vs 0,46 [0,57] mm; P=.15). Median
      follow-up was 34.8 months. Polymer-free sirolimus-eluting stents and
      polymer-based paclitaxel-eluting stents were associated with comparable risk of
      death or myocardial infarction (relative risk=1.17; 95% confidence interval,
      0,49-2.80; P=.71), cardiac death or myocardial infarction (relative risk=1.17;
      95% confidence interval, 0,72-1.89; P=.50), target lesion revascularization
      (relative risk=0,98; 95% confidence interval, 0,65-1.47; P=.93), and myocardial
      infarction (relative risk=1.79; 95% confidence interval, 0,85-3.76; P=.12).
      CONCLUSIONS: In this pooled analysis, polymer-free sirolimus-eluting stents were 
      comparable to polymer-based paclitaxel-eluting stents with respect to both
      angiographic and clinical efficacy. Full English text available
      from:www.revespcardiol.org.
CI  - Copyright (c) 2012 Sociedad Espanola de Cardiologia. Publicado por Elsevier
      Espana. All rights reserved.
AD  - Deutsches Herzzentrum, Technische Universitat, Munich, Alemania.
FAU - Cassese, Salvatore
AU  - Cassese S
FAU - Desch, Steffen
AU  - Desch S
FAU - Kastrati, Adnan
AU  - Kastrati A
FAU - Byrne, Robert A
AU  - Byrne RA
FAU - King, Lamin
AU  - King L
FAU - Tada, Tomohisa
AU  - Tada T
FAU - Lauer, Bernward
AU  - Lauer B
FAU - Schomig, Albert
AU  - Schomig A
FAU - Thiele, Holger
AU  - Thiele H
FAU - Pache, Jurgen
AU  - Pache J
LA  - ENG
LA  - SPA
PT  - JOURNAL ARTICLE
TT  - Stents liberadores de rapamicina sin polimero frente a stents liberadores de
      paclitaxel con polimero: un analisis de datos de pacientes procedentes de ensayos
      aleatorizados.
DEP - 20130410
TA  - Rev Esp Cardiol
JT  - Revista espanola de cardiologia
JID - 0404277
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/07/11 [received]
PHST- 2012/11/28 [accepted]
PHST- 2013/04/10 [aheadofprint]
AID - S0300-8932(13)00055-9 [pii]
AID - 10.1016/j.recesp.2012.11.017 [doi]
PST - ppublish
SO  - Rev Esp Cardiol. 2013 Jun;66(6):435-442. doi: 10.1016/j.recesp.2012.11.017. Epub 
      2013 Apr 10.

PMID- 23582629
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Apr 11
TI  - Management and Outcomes of Non-ST Elevation Acute Coronary Syndromes in Relation 
      to Previous Use of Antianginal Therapies (from the Canadian Global Registry of
      Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events
      [CANRACE]).
LID - S0002-9149(13)00708-X [pii]
LID - 10.1016/j.amjcard.2013.02.053 [doi]
AB  - Randomized trials have established the efficacy of antianginal medications in the
      treatment of chronic stable coronary disease. Using data from the Global Registry
      of Acute Coronary Events (GRACE) and Canadian Registry of Acute Coronary Events
      (CANRACE), we examined the temporal trends in antianginal use (beta blockers,
      calcium antagonists, and nitrates) before non-ST-elevation acute coronary
      syndrome presentation from 1999 to 2008 in 10,019 patients. The relationships
      among previous antianginal use, clinical characteristics on presentation, and
      in-hospital management and outcomes were examined. Beta blockers were the most
      commonly used agents, and there was a significant decline in the use of nitrates 
      over time. Compared with patients not on any antianginal therapy before
      presentation, those on treatment were more likely to be older, female, and have a
      history of hypertension, diabetes, previous angina, and myocardial infarction;
      they were less likely to present with positive biomarkers (all p <0.001).
      Patients not on antianginal therapy before presentation were more likely to
      undergo coronary angiography and percutaneous coronary intervention and less
      likely to have recurrent ischemia during hospitalization (all p <0.001). In
      multivariable analysis, previous antianginal use was independently associated
      with lower use of coronary angiography in hospital (p = 0.034) but not with
      in-hospital mortality. In conclusion, there has significant temporal decline in
      nitrate use before non-ST-elevation acute coronary syndrome. Patients receiving
      antianginal therapy before presentation more frequently had preexisting
      cardiovascular disease and previous revascularization and were less likely to
      present with non-ST-segment elevation MI compared with patients on no antianginal
      therapies. Previous antianginal use was independently associated with a lower use
      of coronary angiography in hospital.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Terrence Donnelly Heart Centre, St Michael's Hospital, University of Toronto,
      Toronto, Ontario, Canada.
FAU - Kang, Jaskaran S
AU  - Kang JS
FAU - Goodman, Shaun G
AU  - Goodman SG
FAU - Yan, Raymond T
AU  - Yan RT
FAU - Lopez-Sendon, Jose
AU  - Lopez-Sendon J
FAU - Pesant, Yves
AU  - Pesant Y
FAU - Graham, John J
AU  - Graham JJ
FAU - Fitchett, David
AU  - Fitchett D
FAU - Wong, Graham C
AU  - Wong GC
FAU - Rose, Barry F
AU  - Rose BF
FAU - Spencer, Frederick A
AU  - Spencer FA
FAU - Yan, Andrew T
AU  - Yan AT
CN  - Canadian GRACE and CANRACE Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/14 [received]
PHST- 2013/02/19 [revised]
PHST- 2013/02/19 [accepted]
AID - S0002-9149(13)00708-X [pii]
AID - 10.1016/j.amjcard.2013.02.053 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Apr 11. pii: S0002-9149(13)00708-X. doi:
      10.1016/j.amjcard.2013.02.053.

PMID- 23582626
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Apr 11
TI  - Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk
      Patients With Hypertension and Coronary Artery Disease.
LID - S0002-9149(13)00822-9 [pii]
LID - 10.1016/j.amjcard.2013.03.026 [doi]
AB  - Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been
      shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ)
      25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with
      stage 2 hypertension with similar blood pressure reductions. In the present post 
      hoc analysis, we evaluated whether B+A is more effective than B+H for reducing CV
      events in patients with known coronary artery disease (CAD) at baseline in a
      subgroup analysis of the Avoiding Cardiovascular events through COMbination
      therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) study. The
      main trial randomized 11,506 patients. Of those, 5,744 received B+A and 5,762
      received B+H. Of the 11,506 patients, 5,314 (46%) were classified as having CAD
      at baseline. The mean patient follow-up period was 35.7 months for the B+A group 
      and 35.6 months for the B+H group. The primary end point was the interval to the 
      first event of composite CV morbidity and mortality. At baseline, significant
      differences were present between the 5,314 with CAD and the 6,192 without CAD.
      The patients with CAD had a lower systolic blood pressure and heart rate, a lower
      incidence of diabetes, and greater incidence of dyslipidemia. However, no
      baseline differences were found between the randomized B+A and B+H groups. In the
      patients with CAD, an 18% reduction occurred in the hazard ratio for CV events
      (primary end point) with B+A versus B+H (p = 0.0016). In a prespecified secondary
      analysis of the composite end point, including only CV death, myocardial
      infarction, and stroke, the hazard ratio in the patients with CAD was reduced by 
      25% (p = 0.0033) in the B+A group compared with the B+H group. B+A was more
      effective than B+H at comparable blood pressure reductions for reducing CV events
      in patients, regardless of the presence of CAD. In conclusion, our findings
      suggest that the combination of B+A should be preferentially used for older
      patients with high-risk, stage 2 hypertension.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - University of Chicago Pritzker School of Medicine, Chicago, Illinois. Electronic 
      address: gbakris@gmail.com.
FAU - Bakris, George
AU  - Bakris G
FAU - Briasoulis, Alexandros
AU  - Briasoulis A
FAU - Dahlof, Bjorn
AU  - Dahlof B
FAU - Jamerson, Kenneth
AU  - Jamerson K
FAU - Weber, Michael A
AU  - Weber MA
FAU - Kelly, Roxzana Y
AU  - Kelly RY
FAU - Hester, Allen
AU  - Hester A
FAU - Hua, Tsushung
AU  - Hua T
FAU - Zappe, Dion
AU  - Zappe D
FAU - Pitt, Bertram
AU  - Pitt B
CN  - ACCOMPLISH Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/02/06 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/08 [accepted]
AID - S0002-9149(13)00822-9 [pii]
AID - 10.1016/j.amjcard.2013.03.026 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Apr 11. pii: S0002-9149(13)00822-9. doi:
      10.1016/j.amjcard.2013.03.026.

PMID- 23582592
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1538-3199 (Electronic)
IS  - 1538-3199 (Linking)
VI  - 43
IP  - 5
DP  - 2013 May-Jun
TI  - PCOS: perspectives from a pediatric endocrinologist and a pediatric gynecologist.
PG  - 104-13
LID - 10.1016/j.cppeds.2013.01.002 [doi]
LID - S1538-5442(13)00027-8 [pii]
AB  - Polycystic ovary syndrome is most common endocrinopathy recognized in women of
      childbearing age with a prevalence of 4-12%. The prevalence of the disorder in
      adolescent population is poorly defined. The pathogenesis as well as the
      management of this disorder is widely debated.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Department of Pediatrics, Section of Endocrinology & Diabetes, Medical College of
      Wisconsin, Milwaukee, WI, USA. akansra@mcw.edu
FAU - Kansra, Alvina R
AU  - Kansra AR
FAU - Menon, Seema
AU  - Menon S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Probl Pediatr Adolesc Health Care
JT  - Current problems in pediatric and adolescent health care
JID - 101134613
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/02/03 [received]
PHST- 2013/01/10 [revised]
PHST- 2013/01/15 [accepted]
AID - S1538-5442(13)00027-8 [pii]
AID - 10.1016/j.cppeds.2013.01.002 [doi]
PST - ppublish
SO  - Curr Probl Pediatr Adolesc Health Care. 2013 May-Jun;43(5):104-13. doi:
      10.1016/j.cppeds.2013.01.002.

PMID- 23582589
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 228
IP  - 2
DP  - 2013 Jun
TI  - Prognostic value of multiple emerging biomarkers in cardiovascular risk
      prediction in patients with stable cardiovascular disease.
PG  - 478-84
LID - 10.1016/j.atherosclerosis.2013.03.017 [doi]
LID - S0021-9150(13)00193-7 [pii]
AB  - BACKGROUND: Few studies have examined simultaneously the prognostic value of
      traditional and emerging biomarkers including atrial natriuretic peptide (ANP)
      and brain-type natriuretic peptide (BNP), for major cardiovascular disease (CVD) 
      outcomes in patients with stable CVD, and results are equivocal. DESIGN: and
      Methods: Mid-regional pro-ANP (MR-proANP) and N-Terminal pro-BNP (NT-proBNP), CRP
      and homocysteine were measured in stable CVD patients (n = 1456; age: 61.8 y) at 
      inclusion in the SU.FOL.OM3 cohort. Prospective association of biomarkers with
      risk of heart failure, major cardiovascular (non-fatal myocardial infarction,
      ischemic stroke or death from CVD) or overall cardiovascular event were examined 
      with Cox proportional-hazards analyses. Increase in prediction risk upon addition
      of biomarker(s) to the traditional risk model was examined by change in
      C-statistic, NRI and IDI. RESULTS: During follow-up (median: 4.7 y), 40 heart
      failure, 145 major cardiovascular and 493 overall cardiovascular events were
      diagnosed. In models adjusted for age, sex, smoking, diabetes, serum creatinine
      and CVD inclusion criteria, NT-proBNP and CRP associated significantly with heart
      failure. Both natriuretic peptides predicted the risk of major cardiovascular
      events in adjusted models; Hazard ratio (HR) and 95% CI for each SD increase in
      MR-proANP and NT-proBNP were 1.24 (1.04-1.47), and 1.31 (1.09-1.57),
      respectively. The addition of NT-proBNP to a traditional risk model increased
      significantly the area-under-curve for heart failure and overall cardiovascular
      events (by 6 and 12%, respectively); addition of MR-proANP or homocysteine
      yielded modest (2%) but statistically significant increase for major
      cardiovascular events. CONCLUSION: NT-proBNP consistently predicted CVD outcomes 
      and may be useful singly or in combination with MR-proANP for risk-stratification
      in high-risk patients.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - UMR U557 Inserm, U1125 Inra, Cnam, UFR SMBH, Universite Paris 13, CRNH IdF, 74
      rue Marcel Cachin, F-93017 Bobigny, France.
FAU - Ahluwalia, Namanjeet
AU  - Ahluwalia N
FAU - Blacher, Jacques
AU  - Blacher J
FAU - Szabo de Edelenyi, Fabien
AU  - Szabo de Edelenyi F
FAU - Faure, Patrice
AU  - Faure P
FAU - Julia, Chantal
AU  - Julia C
FAU - Hercberg, Serge
AU  - Hercberg S
FAU - Galan, Pilar
AU  - Galan P
LA  - eng
PT  - Journal Article
DEP - 20130326
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/19 [received]
PHST- 2013/02/13 [revised]
PHST- 2013/03/11 [accepted]
PHST- 2013/03/26 [aheadofprint]
AID - S0021-9150(13)00193-7 [pii]
AID - 10.1016/j.atherosclerosis.2013.03.017 [doi]
PST - ppublish
SO  - Atherosclerosis. 2013 Jun;228(2):478-84. doi:
      10.1016/j.atherosclerosis.2013.03.017. Epub 2013 Mar 26.

PMID- 23582559
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 0104-4230 (Print)
IS  - 0104-4230 (Linking)
VI  - 59
IP  - 2
DP  - 2013 Mar-Apr
TI  - Effects of intermittent fasting on metabolism in men.
PG  - 167-73
LID - 10.1016/j.ramb.2012.09.003 [doi]
LID - S0104-4230(13)00021-3 [pii]
AB  - This review analyzes the available literature on the impact of intermittent
      fasting (IF), a nutritional intervention, on different aspects of metabolism. The
      epidemic of metabolic disturbances, such as obesity, metabolic syndrome (MS), and
      diabetes mellitus type 2 has led to an increase in the prevalence of
      cardiovascular diseases, and affected patients might significantly benefit from
      modifications in nutritional habits. Recent experimental studies have elucidated 
      some of the metabolic mechanisms involved with IF. Animal models have shown
      positive changes in glucose (lower plasma glucose and insulin levels) and in
      lipid metabolism (reduced visceral fat tissue and increased plasma adiponectin
      level), and an increased resistance to stress. Despite the limited number of
      samples studied, positive results have been reported on the impact of IF for
      human health. IF is reported to improve the lipid profile; to decrease
      inflammatory responses, reflected by changes in serum adipokine levels; and to
      change the expression of genes related to inflammatory response and other
      factors. Studies on obese individuals have shown that patient compliance was
      greater for IF than other traditional nutritional approaches (calorie
      restriction), and IF was found to be associated with low oxidative stress. Recent
      reports suggest that IF exerts a positive impact on the metabolic derangements
      commonly associated with cardiovascular diseases, and that it may be a viable and
      accessible intervention for most individuals. Therefore, further clinical studies
      are essential to test the effectiveness of IF in preventing and controlling
      metabolic and cardiovascular diseases.
CI  - Copyright (c) 2013 Elsevier Editora Ltda. All rights reserved.
AD  - Interdisciplinary Medicine in Cardiology Unit, Heart Institute InCor, Medical
      School, Universidade de Sao Paulo, Sao Paulo, SP, Brazil. freis@usp.br
FAU - de Azevedo, Fernanda Reis
AU  - de Azevedo FR
FAU - Ikeoka, Dimas
AU  - Ikeoka D
FAU - Caramelli, Bruno
AU  - Caramelli B
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Rev Assoc Med Bras
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/07/27 [received]
PHST- 2012/09/18 [revised]
PHST- 2012/09/27 [accepted]
AID - S0104-4230(13)00021-3 [pii]
AID - 10.1016/j.ramb.2012.09.003 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras. 2013 Mar-Apr;59(2):167-73. doi: 10.1016/j.ramb.2012.09.003.

PMID- 23582556
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 0104-4230 (Print)
IS  - 0104-4230 (Linking)
VI  - 59
IP  - 2
DP  - 2013 Mar-Apr
TI  - [The influence of food preparation methods on atherosclerosis prevention].
PG  - 148-54
LID - 10.1016/j.ramb.2012.10.001 [doi]
LID - S0104-4230(13)00002-X [pii]
AB  - OBJECTIVE: To analyze the influence of food preparation methods on the
      composition of fatty acids and cholesterol in foods. METHODS: The chemical
      composition of cholesterol and fatty acids was analyzed in eight different types 
      of meat and feijoada in relation to different methods of preparation. RESULTS:
      Feijoada, when prepared with the beans and meats in separate pots, has less
      cholesterol (12.1 vs. 16.1mg, respectively, p=0.005) and saturated fat (1.4 vs.
      1.9mg, p=0.046) than when it is prepared in a single pot. Broiled chicken without
      the skin has less saturated fat when compared with skinless fried chicken (1,505 
      vs. 7,645mg, p=0.049). Broiled shrimp also has a lower saturated fat content than
      fried shrimp (532 vs. 1,262mg, p=0.049). Broiled ribeye steak without fat has a
      lower cholesterol content when compared with the fried steak (102 vs. 114mg,
      p=0.049). CONCLUSION: The analysis indicates that the method of food preparation 
      influences the fat content of foods, with potential impact on the prescription of
      low-fat and low-cholesterol diets.
CI  - Copyright (c) 2013 Elsevier Editora Ltda. All rights reserved.
AD  - Instituto do Coracao e do Diabetes, Rio de Janeiro, RJ, Brasil. scherr@all.com.br
FAU - Scherr, Carlos
AU  - Scherr C
FAU - Ribeiro, Jorge Pinto
AU  - Ribeiro JP
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Influencia do modo de preparo de alimentos na prevencao da aterosclerose.
PL  - Brazil
TA  - Rev Assoc Med Bras
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/02/28 [received]
PHST- 2012/10/15 [accepted]
AID - S0104-4230(13)00002-X [pii]
AID - 10.1016/j.ramb.2012.10.001 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras. 2013 Mar-Apr;59(2):148-54. doi: 10.1016/j.ramb.2012.10.001.

PMID- 23582554
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 0104-4230 (Print)
IS  - 0104-4230 (Linking)
VI  - 59
IP  - 2
DP  - 2013 Mar-Apr
TI  - [Diabetes mellitus risk screening of parents of private school students in the
      city of Jundiai, Sao Paulo, Brazil].
PG  - 136-42
LID - 10.1016/j.ramb.2012.09.002 [doi]
LID - S0104-4230(13)00016-X [pii]
AB  - OBJECTIVE: To screen the risk of developing diabetes mellitus type 2 (DM2) in
      adult individuals. METHODS: Several risk factors for DM2 (sedentary lifestyle,
      previous coronary artery disease, hyperglycemia-inducing medications, body mass
      index [BMI], blood pressure, serum triglyceride, and HDL-cholesterol levels) were
      assessed in 314 adults as a function of gender and age group. RESULTS: 73.2% of
      the population had two or more concurrent risk factors and 26.8% had less than
      two factors. The occurrence of risk factors for DM2 development was observed even
      in young adults, and the risk factors are likely associated with aging.
      Differences in risk factors and incidence were observed between men and women in 
      the same age group. CONCLUSION: Regardless the age studied, the most prevalent
      risk factors associated with DM2 were: BMI, sedentary lifestyle, and reduced
      serum HDL-cholesterol, which are modifiable, thus increasing the importance of
      preventive measures. Discrepancies found in prevalent risk factors in men and
      women also suggest that sociocultural differences influence the risk of
      developing DM.
CI  - Copyright (c) 2013 Elsevier Editora Ltda. All rights reserved.
AD  - School of Nutrition, Centro Universitario Padre Anchieta, Jundiai, SP, Brazil.
FAU - Mazzini, Maria Cristina Ritter
AU  - Mazzini MC
FAU - Blumer, Milena Grossi
AU  - Blumer MG
FAU - Hoehne, Eduardo Luiz
AU  - Hoehne EL
FAU - Guimaraes, Katia Regina Leoni Silva Lima de Queiroz
AU  - Guimaraes KR
FAU - Caramelli, Bruno
AU  - Caramelli B
FAU - Fornari, Luciana
AU  - Fornari L
FAU - Malheiros, Sonia Valeria Pinheiro
AU  - Malheiros SV
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Rastreamento do risco de desenvolvimento de diabetes mellitus em pais de
      estudantes de uma escola privada na cidade de Jundiai, Sao Paulo.
PL  - Brazil
TA  - Rev Assoc Med Bras
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/05/21 [received]
PHST- 2012/09/05 [revised]
PHST- 2012/09/20 [accepted]
AID - S0104-4230(13)00016-X [pii]
AID - 10.1016/j.ramb.2012.09.002 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras. 2013 Mar-Apr;59(2):136-42. doi: 10.1016/j.ramb.2012.09.002.

PMID- 23582414
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
DP  - 2013 Apr 9
TI  - Percutaneous revascularization and long term clinical outcomes of diabetic
      patients randomized in the Occluded Artery Trial (OAT).
LID - S0167-5273(13)00360-4 [pii]
LID - 10.1016/j.ijcard.2013.02.004 [doi]
AB  - BACKGROUND: Percutaneous coronary intervention (PCI) of a persistently totally
      occluded infarct-related artery (IRA) in stable high-risk patients >24h after
      myocardial infarction (MI) does not reduce the occurrence of death,
      re-infarction, or heart failure. Diabetic patients are at higher risk for
      cardiovascular events; we examined their outcomes overall with PCI and optimal
      medical therapy alone (MED). METHODS: The long-term (7-year) outcomes of 454
      diabetic patients (20.6%) randomized to PCI or MED in the Occluded Artery Trial
      (OAT) were assessed for the composite primary endpoint of death, re-MI, or New
      York Heart Association class IV heart failure. Diabetics and non-diabetics were
      compared and outcomes assessed by treatment strategy. RESULTS: The 7-year
      cumulative primary event rate for diabetic patients was 35.0% vs. 19.4% in the
      non-diabetic cohort (p<0.001). Multivariable analyses revealed diabetes to be an 
      independent predictor (p<0.01) for the primary outcome, fatal or nonfatal
      recurrent MI, Class IV Heart Failure (HF), and death. The 7-year cumulative
      primary event rates were 35.3% in the PCI group vs. 34.5% in the medical therapy 
      group in diabetic patients (p=0.19) and 19.3% in the PCI group vs. 19.5% in the
      medical therapy group in patients without diabetes (p=0.60). CONCLUSIONS: Despite
      the higher overall risk conferred by the presence of diabetes, PCI did not
      improve clinical outcomes in this subpopulation, and is not indicated in
      otherwise stable patients with a totally occluded infarct-related artery in the
      sub-acute phase after MI.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
AD  - Peter Munk Cardiac Centre, University Heath Network, Toronto, Ontario, Canada.
FAU - Overgaard, Christopher B
AU  - Overgaard CB
FAU - Dzavik, Vladimir
AU  - Dzavik V
FAU - Buller, Christopher E
AU  - Buller CE
FAU - Liu, Li
AU  - Liu L
FAU - Banasiak, Waldemar
AU  - Banasiak W
FAU - Devlin, Gerard
AU  - Devlin G
FAU - Maggioni, Aldo P
AU  - Maggioni AP
FAU - Leor, Jonathan
AU  - Leor J
FAU - Burton, Jeffery R
AU  - Burton JR
FAU - Reis, Gilmar
AU  - Reis G
FAU - Ruzyllo, Witold
AU  - Ruzyllo W
FAU - Forman, Sandra A
AU  - Forman SA
FAU - Lamas, Gervasio A
AU  - Lamas GA
FAU - Hochman, Judith S
AU  - Hochman JS
CN  - for the OAT Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130409
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/27 [received]
PHST- 2013/01/24 [revised]
PHST- 2013/02/11 [accepted]
AID - S0167-5273(13)00360-4 [pii]
AID - 10.1016/j.ijcard.2013.02.004 [doi]
PST - aheadofprint
SO  - Int J Cardiol. 2013 Apr 9. pii: S0167-5273(13)00360-4. doi:
      10.1016/j.ijcard.2013.02.004.

PMID- 23582408
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
DP  - 2013 Apr 9
TI  - The anti-diabetic effects and pharmacokinetic profiles of berberine in mice
      treated with Jiao-Tai-Wan and its compatibility.
LID - S0944-7113(13)00090-1 [pii]
LID - 10.1016/j.phymed.2013.03.004 [doi]
AB  - Jiao-Tai-Wan (JTW), a classical Chinese prescription, has been clinically
      employed to treat diabetes mellitus in recent years. To investigate the
      comparative evaluations on anti-diabetic effects and pharmacokinetics of the
      active ingredient berberine in mice treated with JTW in various combinations of
      its constituent herbs. In our study, the anti-diabetic study was carried out in
      diabetic mice induced by intraperitoneal injection of streptozotocin. The
      diabetic mice were randomly assigned to three therapy groups and orally
      administered with different prescription proportions of Rhizoma Coptidis and
      Cinnamomum cassia respectively. The level of plasma glucose, lipid profile and
      parameters related to oxidative stress were determined. The concentrations of
      berberine in non-diabetic mice plasma were determined using HPLC, and main
      pharmacokinetic parameters were investigated. The results indicated that the
      compatibility effects of ingredients present in Cinnamomum cassia could affect
      the anti-diabetic ability and pharmacokinetics of berberine in JTW.
CI  - Copyright (c) 2013 Elsevier GmbH. All rights reserved.
AD  - Department of Integrative Traditional & Western Medicine, Tongji Hospital, Tongji
      Medical College, Huazhong University of Science & Technology, Wuhan 430030,
      China.
FAU - Chen, Guang
AU  - Chen G
FAU - Lu, Fuer
AU  - Lu F
FAU - Xu, Lijun
AU  - Xu L
FAU - Dong, Hui
AU  - Dong H
FAU - Yi, Ping
AU  - Yi P
FAU - Wang, Fang
AU  - Wang F
FAU - Huang, Zhaoyi
AU  - Huang Z
FAU - Zou, Xin
AU  - Zou X
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130409
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/03 [received]
PHST- 2013/02/06 [revised]
PHST- 2013/03/09 [accepted]
AID - S0944-7113(13)00090-1 [pii]
AID - 10.1016/j.phymed.2013.03.004 [doi]
PST - aheadofprint
SO  - Phytomedicine. 2013 Apr 9. pii: S0944-7113(13)00090-1. doi:
      10.1016/j.phymed.2013.03.004.

PMID- 23582329
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1097-4172 (Electronic)
IS  - 0092-8674 (Linking)
VI  - 153
IP  - 2
DP  - 2013 Apr 11
TI  - The fractalkine/CX3CR1 system regulates beta cell function and insulin secretion.
PG  - 413-25
LID - 10.1016/j.cell.2013.03.001 [doi]
LID - S0092-8674(13)00287-0 [pii]
AB  - Here, we demonstrate that the fractalkine (FKN)/CX3CR1 system represents a
      regulatory mechanism for pancreatic islet beta cell function and insulin
      secretion. CX3CR1 knockout (KO) mice exhibited a marked defect in glucose and
      GLP1-stimulated insulin secretion, and this defect was also observed in vitro in 
      isolated islets from CX3CR1 KO mice. In vivo administration of FKN improved
      glucose tolerance with an increase in insulin secretion. In vitro treatment of
      islets with FKN increased intracellular Ca(2+) and potentiated insulin secretion 
      in both mouse and human islets. The KO islets exhibited reduced expression of a
      set of genes necessary for the fully functional, differentiated beta cell state, 
      whereas treatment of wild-type (WT) islets with FKN led to increased expression
      of these genes. Lastly, expression of FKN in islets was decreased by aging and
      high-fat diet/obesity, suggesting that decreased FKN/CX3CR1 signaling could be a 
      mechanism underlying beta cell dysfunction in type 2 diabetes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Department of Medicine, Division of Endocrinology and Metabolism, University of
      California, San Diego, La Jolla, CA 92093, USA.
FAU - Lee, Yun Sok
AU  - Lee YS
FAU - Morinaga, Hidetaka
AU  - Morinaga H
FAU - Kim, Jane J
AU  - Kim JJ
FAU - Lagakos, William
AU  - Lagakos W
FAU - Taylor, Susan
AU  - Taylor S
FAU - Keshwani, Malik
AU  - Keshwani M
FAU - Perkins, Guy
AU  - Perkins G
FAU - Dong, Hui
AU  - Dong H
FAU - Kayali, Ayse G
AU  - Kayali AG
FAU - Sweet, Ian R
AU  - Sweet IR
FAU - Olefsky, Jerrold
AU  - Olefsky J
LA  - eng
GR  - DK-033651/DK/NIDDK NIH HHS/United States
GR  - DK-063491/DK/NIDDK NIH HHS/United States
GR  - DK-074868/DK/NIDDK NIH HHS/United States
GR  - P30 DK017047/DK/NIDDK NIH HHS/United States
GR  - T32-DK-007494/DK/NIDDK NIH HHS/United States
GR  - U54-HD-012303-25/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cell
JT  - Cell
JID - 0413066
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/05/09 [received]
PHST- 2012/10/31 [revised]
PHST- 2013/02/25 [accepted]
AID - S0092-8674(13)00287-0 [pii]
AID - 10.1016/j.cell.2013.03.001 [doi]
PST - ppublish
SO  - Cell. 2013 Apr 11;153(2):413-25. doi: 10.1016/j.cell.2013.03.001.

PMID- 23582275
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1464-3405 (Electronic)
IS  - 0960-894X (Linking)
VI  - 23
IP  - 10
DP  - 2013 May 15
TI  - Design and synthesis of 2-N-substituted indazolone derivatives as non-carboxylic 
      acid glycogen synthase activators.
PG  - 2936-40
LID - 10.1016/j.bmcl.2013.03.049 [doi]
LID - S0960-894X(13)00365-X [pii]
AB  - Glycogen synthase (GS) catalyzes the transfer of glucose residues from
      UDP-glucose to a glycogen polymer chain, a critical step for glucose storage.
      Patients with type 2 diabetes normally exhibit low glycogen levels and decreased 
      muscle glucose uptake is the major defect in whole body glucose disposal.
      Therefore, activating GS may provide a potential approach for the treatment of
      type 2 diabetes. In order to identify non-carboxylic acids GS activators, we
      designed and synthesized a series of 2-N-alkyl- and 2-N-aryl-indazolone
      derivatives and studied their activity in activating human GS.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Discovery Chemistry, Small Molecule Research, Pharmaceutical Research and Early
      Drug Development, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110,
      United States. yiminqian81@gmail.com
FAU - Qian, Yimin
AU  - Qian Y
FAU - Bolin, David
AU  - Bolin D
FAU - Conde-Knape, Karin
AU  - Conde-Knape K
FAU - Gillespie, Paul
AU  - Gillespie P
FAU - Hayden, Stuart
AU  - Hayden S
FAU - Huang, Kuo-Sen
AU  - Huang KS
FAU - Olivier, Andree R
AU  - Olivier AR
FAU - Sato, Tsutomu
AU  - Sato T
FAU - Xiang, Qing
AU  - Xiang Q
FAU - Yun, Weiya
AU  - Yun W
FAU - Zhang, Xiaolei
AU  - Zhang X
LA  - eng
PT  - Journal Article
DEP - 20130322
PL  - England
TA  - Bioorg Med Chem Lett
JT  - Bioorganic & medicinal chemistry letters
JID - 9107377
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/01/24 [received]
PHST- 2013/03/09 [revised]
PHST- 2013/03/12 [accepted]
PHST- 2013/03/22 [aheadofprint]
AID - S0960-894X(13)00365-X [pii]
AID - 10.1016/j.bmcl.2013.03.049 [doi]
PST - ppublish
SO  - Bioorg Med Chem Lett. 2013 May 15;23(10):2936-40. doi:
      10.1016/j.bmcl.2013.03.049. Epub 2013 Mar 22.

PMID- 23582198
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 99
IP  - 3
DP  - 2013 Mar
TI  - Reforming the global food system to tackle diabetes and obesity: IDF perspective.
PG  - 396-7
LID - 10.1016/j.diabres.2013.03.021 [doi]
LID - S0168-8227(13)00099-5 [pii]
LA  - eng
PT  - Journal Article
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - S0168-8227(13)00099-5 [pii]
AID - 10.1016/j.diabres.2013.03.021 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2013 Mar;99(3):396-7. doi:
      10.1016/j.diabres.2013.03.021.

PMID- 23582191
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
DP  - 2013 Apr 15
TI  - The impact of Lost Therapeutic Benefit (LTB) in high-risk hypertensive patients: 
      two-year follow-up data from the Australian REACH registry.
LID - 10.1111/1755-5922.12034 [doi]
AB  - OBJECTIVE: The aim of the study is to determine the extent of lost therapeutic
      benefit (LTB) in the hypertensive patients, and to determine the relationship
      between the presence of LTB and clinical outcomes. METHODS: Prospective-cohort
      study of 2873 patients with or at high risk of atherothrombosis. LTB was
      calculated as the proportion of patients receiving blood-pressure medication who 
      were not attaining guideline BP control targets (<140/90 mmHg). Logistic
      regression analysis was performed to identify predictor of LTB at baseline, and
      propensity score matching (PSM) was undertaken to estimate the treatment effects 
      by matching case LTB and control non-LTB cohorts based on the nearest neighbour
      matching. RESULTS: Of the total sample of 2856, 45.6% had uncontrolled BP, and
      LTB was present in 46.7% (n=1178) patients. The likelihood of LTB was less in
      males (OR=0.78 (95% CI; 0.64-0.97), and those with a previous
      myocardial-infarction (OR=0.66 (0.53-0.81), or heart-failure (OR=0.58
      (0.42-0.82). LTB was more common in those with diabetes (OR=1.44 (1.16-1.79),
      aged >65 years (OR=1.36 (1.06-1.75) and having an ABI<0.09 in either leg at rest 
      (OR=1.30 (1.02-1.75). Following PSM, the combination of ischemic events (55-64
      age category) was more likely to occur in the LTB compared with non-LTB group
      (4.38% and 0.68% respectively (p=0.046). CONCLUSION: Presence of HF, previous MI 
      and being male decreased the likelihood of LTB, while presence of diabetes, age >
      65 and ABI < 0.09 increased the risk of LTB. Patients with LTB in age category
      55-64 had higher incidence of vascular events compared to those with non-LTB.
      This article is protected by copyright. All rights reserved.
CI  - This article is protected by copyright. All rights reserved.
AD  - Melbourne EpiCentre, Department of Medicine (The Royal Melbourne Hospital),
      University of Melbourne, Australia; Department of Epidemiology & Preventive
      Medicine, Monash University, Australia.
FAU - Ademi, Zanfina
AU  - Ademi Z
FAU - Huq, Molla M
AU  - Huq MM
FAU - Liew, Danny
AU  - Liew D
FAU - Steg, Ph Gabriel
AU  - Steg PG
FAU - Bhatt, Deepak L
AU  - Bhatt DL
FAU - Nelson, Mark
AU  - Nelson M
FAU - Reid, Christopher M
AU  - Reid CM
CN  - The REACH Registry investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/12/12 [received]
PHST- 2013/03/24 [revised]
PHST- 2013/04/10 [accepted]
AID - 10.1111/1755-5922.12034 [doi]
PST - aheadofprint
SO  - Cardiovasc Ther. 2013 Apr 15. doi: 10.1111/1755-5922.12034.

PMID- 23582135
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1097-6833 (Electronic)
IS  - 0022-3476 (Linking)
DP  - 2013 Apr 10
TI  - Arteriovascular Calcification Leading to Diagnosis of Maturity-Onset Diabetes of 
      the Young Type 3.
LID - S0022-3476(13)00281-3 [pii]
LID - 10.1016/j.jpeds.2013.03.005 [doi]
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Rhode Island
      Hospital, The Warren Alpert Medical School of Brown University, Providence, Rhode
      Island.
FAU - Quintos, Jose Bernardo
AU  - Quintos JB
FAU - Pingul, Mia M
AU  - Pingul MM
FAU - Boney, Charlotte M
AU  - Boney CM
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130410
TA  - J Pediatr
JT  - The Journal of pediatrics
JID - 0375410
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/02/04 [received]
PHST- 2013/03/06 [accepted]
AID - S0022-3476(13)00281-3 [pii]
AID - 10.1016/j.jpeds.2013.03.005 [doi]
PST - aheadofprint
SO  - J Pediatr. 2013 Apr 10. pii: S0022-3476(13)00281-3. doi:
      10.1016/j.jpeds.2013.03.005.

PMID- 23582124
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1603-6824 (Electronic)
IS  - 0041-5782 (Linking)
VI  - 175
IP  - 15
DP  - 2013 Apr 8
TI  - [Bariatric surgery is more efficient than medical treatment in achieving
      remission in diabetes mellitus type 2].
PG  - 1029-32
AB  - Observational studies have shown that bariatric surgery can lead to remission of 
      diabetes mellitus type 2 (DMII), but randomized controlled trials have been
      lacking. Recently, randomized controlled trials comparing bariatric surgery with 
      optimal medical treatment in patients suffering from poorly controlled DMII, have
      been performed. These trials show that bariatric surgery in general, and the
      malabsorptive procedures in particular, are more effective than medical treatment
      in achieving remission of DMII. These procedures should therefore be considered
      in the treatment of patients with DMII and obesity.
AD  - Center for Peri--operativ Optimering, Gastroenheden, Herlev Hospital, Denmark.
      madsklein1@gmail.com
FAU - Klein, Mads
AU  - Klein M
FAU - Rosenberg, Jacob
AU  - Rosenberg J
FAU - Gogenur, Ismail
AU  - Gogenur I
LA  - dan
PT  - English Abstract
PT  - Journal Article
TT  - Fedmekirurgi er mere effektiv end medicinsk behandling til opnaelse af remission 
      af type 2-diabetes.
PL  - Denmark
TA  - Ugeskr Laeger
JT  - Ugeskrift for laeger
JID - 0141730
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - VP06120356 [pii]
PST - ppublish
SO  - Ugeskr Laeger. 2013 Apr 8;175(15):1029-32.

PMID- 23582078
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1873-1244 (Electronic)
IS  - 0899-9007 (Linking)
VI  - 29
IP  - 5
DP  - 2013 May
TI  - Validity of the Willett food frequency questionnaire in assessing the iron intake
      of French-Canadian pregnant women.
PG  - 752-6
LID - 10.1016/j.nut.2012.12.019 [doi]
LID - S0899-9007(13)00008-7 [pii]
AB  - OBJECTIVE: Maternal intake is crucial to pregnancy outcomes. Evidence shows that 
      both nutrient deficiency and excess can have adverse effects. In pregnancy,
      changes in iron metabolism occur; therefore, dietary reference intakes increase
      to support expansion of red cells and maternal-fetal transfer of iron.
      Appropriate and valid assessment tools are required to investigate nutritional
      concerns in mothers with and without gestational diabetes mellitus (GDM). The
      objective of this study was to assess the Willett food frequency questionnaire
      (FFQ) to assess iron intake in women with (n = 15) and without (n = 45) GDM.
      METHODS: To validate the modified FFQ, estimated total iron intake during the
      third trimester was compared with biomarkers of iron status such as serum
      ferritin, soluble transferrin receptor (sTfR), and the sTfR:F index at delivery. 
      Data were tested for normality using the D'Agostino-Pearson test. Differences
      between groups were tested using t tests or Mann-Whitney tests. Correlations were
      tested using Spearman's rho. Significance was set at P < 0.05. RESULTS:
      Significant crude and energy-adjusted serum ferritin and total iron intake were
      related (rho = 0.30; P < 0.05) in women without GDM. Serum ferritin, sTfR, and
      the sTfR:F index were different (P < 0.05) between women with intakes above and
      below the recommended levels. Cross-classification showed agreement between
      methods in mothers with and without GDM; on average, 63% of the women were
      classified into the same or adjacent quartile when ranked by FFQ and iron status.
      CONCLUSION: These findings suggest the Willett FFQ is a good tool for assessing
      total iron intake of French-Canadian pregnant women.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - School of Dietetics and Human Nutrition, McGill University, Macdonald Campus,
      Ste. Anne-de-Bellevue, Quebec, Canada.
FAU - Baddour, Stephanie E
AU  - Baddour SE
FAU - Virasith, Helene
AU  - Virasith H
FAU - Vanstone, Catherine
AU  - Vanstone C
FAU - Forest, Jean-Claude
AU  - Forest JC
FAU - Giguere, Yves
AU  - Giguere Y
FAU - Charland, Marc
AU  - Charland M
FAU - Weiler, Hope A
AU  - Weiler HA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Nutrition
JT  - Nutrition (Burbank, Los Angeles County, Calif.)
JID - 8802712
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/09/04 [received]
PHST- 2012/11/20 [revised]
PHST- 2012/12/13 [accepted]
AID - S0899-9007(13)00008-7 [pii]
AID - 10.1016/j.nut.2012.12.019 [doi]
PST - ppublish
SO  - Nutrition. 2013 May;29(5):752-6. doi: 10.1016/j.nut.2012.12.019.

PMID- 23582041
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
DP  - 2013 Apr 14
TI  - Prediction of hemorrhagic transformation in acute ischaemic stroke by micro- and 
      macroalbuminuria after intravenous thrombolysis.
LID - 10.1111/ene.12127 [doi]
AB  - BACKGROUND AND PURPOSE: Hemorrhagic transformation (HT) is one of the most
      problematic complications to arise from intravenous thrombolysis (IVT). This
      study was conducted to assess whether micro- and macroalbuminuria could be
      associated with HT after IVT in patients with acute ischaemic stroke, and to
      investigate whether the value of urinary albumin-to-creatinine ratios would
      correlate with the degree of HT. METHODS: This was a retrospective study of
      stroke patients who had undergone IVT within 3 h of symptom onset. Albuminuria
      assessment was based on random morning spot urine collection with patients in a
      fasting state, the first morning after IVT. Multiple logistic regression analysis
      was used to evaluate whether the presence of micro- and macroalbuminuria might be
      independent predictors of HT. RESULTS: One-hundred and fifty-four patients were
      included in the study. Fifty-one patients had HT. The presence of micro- or
      macroalbuminuria was associated with HT after adjustment for variables with
      clinical significance (adjusting for age, atrial fibrillation, platelet counts,
      baseline National Institutes of Health Stroke Scale score, hypertension and
      diabetes mellitus; odds ratio, 2.542; 95% confidence interval, 1.106-5.841; P =
      0.028). There were significant relationships between the presence of micro- and
      macroalbuminuria and types of HT. CONCLUSION: In conclusion, the results of this 
      study suggest that the presence of micro- and macroalbuminuria after IVT could be
      a predictor of severe HT in patients with acute ischaemic stroke.
CI  - (c) 2013 The Author(s) European Journal of Neurology (c) 2013 EFNS.
AD  - Department of Neurology, Cerebrovascular Center, Chonnam National University
      Hospital, Gwangju, Korea.
FAU - Cho, B-H
AU  - Cho BH
FAU - Kim, J-T
AU  - Kim JT
FAU - Chang, J
AU  - Chang J
FAU - Choi, K-H
AU  - Choi KH
FAU - Park, M-S
AU  - Park MS
FAU - Cho, K-H
AU  - Cho KH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130414
TA  - Eur J Neurol
JT  - European journal of neurology : the official journal of the European Federation
      of Neurological Societies
JID - 9506311
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/10/25 [received]
PHST- 2013/01/30 [accepted]
AID - 10.1111/ene.12127 [doi]
PST - aheadofprint
SO  - Eur J Neurol. 2013 Apr 14. doi: 10.1111/ene.12127.

PMID- 23582022
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1479-828X (Electronic)
IS  - 0004-8666 (Linking)
DP  - 2013 Apr 15
TI  - Ethnic disparities in repeat caesarean rates at Auckland Hospital.
LID - 10.1111/ajo.12078 [doi]
AB  - BACKGROUND: New Zealand guidelines recommend that information regarding
      childbirth choices be given to women with previous caesarean, so they can make
      informed decisions about their care. We hypothesised that rates of trial of
      labour (TOL) and vaginal birth after caesarean (VBAC) would vary by women's
      ethnicity. AIM: To estimate the association of ethnicity with TOL and VBAC rates.
      MATERIALS AND METHODS: Clinical data were used to identify women who gave birth
      at Auckland Hospital in 2006-2009 with history of previous caesarean eligible for
      TOL. Multivariable models were used to estimate the association of women's
      characteristics (ethnicity, age, socio-economic status (SES), height, body mass
      index, lead maternity carer, diabetes, hypertension, haemorrhage, labour
      induction, gestational age) with rates of TOL and VBAC. RESULTS: In the study
      cohort of 2400 women, the TOL rate was 39.5%; the VBAC rate was 57.4%. Pacific
      women were twice as likely to have TOL, while Asian and non-New Zealand European 
      women were half as likely to have VBAC, compared with New Zealand European women.
      Women in more deprived areas were more likely to have TOL, but SES was not
      associated with VBAC rates. Women under the care of private obstetricians were
      least likely to have TOL or VBAC. CONCLUSIONS: There are ethnic disparities in
      TOL and VBAC rates at our hospital. Strategies need to be developed to ensure
      that women of all ethnicities have access to both options for mode of delivery.
CI  - (c) 2013 The Authors ANZJOG (c) 2013 The Royal Australian and New Zealand College
      of Obstetricians and Gynaecologists.
AD  - Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences,
      University of Auckland, Auckland, New Zealand.
FAU - Wise, Michelle R
AU  - Wise MR
FAU - Anderson, Ngaire H
AU  - Anderson NH
FAU - Sadler, Lynn
AU  - Sadler L
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Aust N Z J Obstet Gynaecol
JT  - The Australian & New Zealand journal of obstetrics & gynaecology
JID - 0001027
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/18 [received]
PHST- 2013/02/12 [accepted]
AID - 10.1111/ajo.12078 [doi]
PST - aheadofprint
SO  - Aust N Z J Obstet Gynaecol. 2013 Apr 15. doi: 10.1111/ajo.12078.

PMID- 23581982
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1538-0254 (Electronic)
IS  - 0739-1102 (Linking)
DP  - 2013 Apr 13
TI  - Energetic domains and conformational analysis of human serum albumin upon
      co-incubation with sodium benzoate and glucose.
AB  - Sodium benzoate (SB), a powerful inhibitor of microbial growth, is one of the
      most commonly used food preservative. Here, we determined the effects of SB on
      human serum albumin (HSA) structure in the presence or absence of glucose after
      35 days of incubation under physiological conditions. The biochemical,
      biophysical, and molecular approaches including free amine content assay (TNBSA
      assay), fluorescence, and circular dichroism spectroscopy (CD), differential
      scanning calorimetry (DSC), and molecular docking and LIGPLOT studies were
      utilized for structural studies. The TNBSA results indicated that SB has the
      ability to bind Lys residues in HSA through covalent bonds. The docking and
      LIGPLOT studies also determined another specific site via hydrophobic
      interactions. The CD results showed more structural helicity for HSA incubated
      with SB, while HSA incubated with glucose had the least, and HSA incubated with
      glucose + SB had medium helicity. Fluorescence spectrophotometry results
      demonstrated partial unfolding of HSA incubated with SB in the presence or
      absence of glucose, while maximum partial unfolding was observed in HSA incubated
      with glucose. These results were confirmed by DSC and its deconvoluted
      thermograms. The DSC results also showed significant changes in HSA energetic
      structural domains due to HSA incubation with SB in the presence or absence of
      glucose. Together, our studies showed the formation of three different
      intermediates and indicate that biomolecular investigation are effective in
      providing new insight into safety determinations especially in health-related
      conditions including diabetes.
AD  - a Institute of Biochemistry and Biophysics, University of Tehran , Tehran , Iran.
FAU - Taghavi, F
AU  - Taghavi F
FAU - Moosavi-Movahedi, A A
AU  - Moosavi-Movahedi AA
FAU - Bohlooli, M
AU  - Bohlooli M
FAU - Habibi-Rezaei, M
AU  - Habibi-Rezaei M
FAU - Hadi Alijanvand, H
AU  - Hadi Alijanvand H
FAU - Amanlou, M
AU  - Amanlou M
FAU - Sheibani, N
AU  - Sheibani N
FAU - Saboury, A A
AU  - Saboury AA
FAU - Ahmad, F
AU  - Ahmad F
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - J Biomol Struct Dyn
JT  - Journal of biomolecular structure & dynamics
JID - 8404176
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1080/07391102.2013.775599 [doi]
PST - aheadofprint
SO  - J Biomol Struct Dyn. 2013 Apr 13.

PMID- 23581934
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 61
IP  - 4
DP  - 2013 Apr
TI  - Effect of different diabetes mellitus treatments on functional decline and death 
      in elderly adults with diabetes mellitus.
PG  - 666-7
LID - 10.1111/jgs.12191 [doi]
FAU - Gazzaruso, Carmine
AU  - Gazzaruso C
FAU - Coppola, Adriana
AU  - Coppola A
FAU - Luppi, Chiara
AU  - Luppi C
FAU - Giustina, Andrea
AU  - Giustina A
FAU - Solerte, Sebastiano B
AU  - Solerte SB
LA  - eng
PT  - Comment
PT  - Letter
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
CON - J Am Geriatr Soc. 2012 Jul;60(7):1215-21. PMID: 22702660
CIN - J Am Geriatr Soc. 2013 Apr;61(4):667-8. PMID: 23581935
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1111/jgs.12191 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2013 Apr;61(4):666-7. doi: 10.1111/jgs.12191.

PMID- 23581913
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 61
IP  - 4
DP  - 2013 Apr
TI  - Venous thromboembolism after joint replacement in older male veterans with
      comorbidity.
PG  - 590-601
LID - 10.1111/jgs.12161 [doi]
AB  - OBJECTIVES: To identify older adults with comorbidities or poor functional status
      at high risk of postoperative venous thromboembolism (VTE). DESIGN: Retrospective
      cohort study. SETTING: Veterans Affairs Medical Center (VAMC). PARTICIPANTS:
      Older adults who underwent total hip and knee replacement (THR and TKR) from 2002
      to 2009. MEASUREMENTS: Using multivariate logistic regression, the independent
      effect of cardiopulmonary comorbidities and diabetes on VTE was analyzed.
      Functional status expressed in a summary physical component score (PCS) was also 
      analyzed in a subset of individuals in whom information on it was available.
      RESULTS: There were 23,326 THR and TKR surgeries performed at the VAMC during the
      study period. Individuals with chronic obstructive pulmonary disease (COPD) had a
      25% greater risk of VTE (odds ratio (OR) = 1.25, 95% confidence interval (CI) =
      1.06-1.48), whereas those with coronary artery disease, congestive heart failure,
      and cerebrovascular disease did not have a greater risk of VTE. Individuals with 
      diabetes mellitus had a lower risk of VTE (OR = 0.77, 95% CI = 0.64-0.92).
      Individuals with low PCS, which were available for 3,169 patients, had a 62%
      greater risk, although the effect did not reach statistical significance (lowest 
      vs highest quartile OR = 1.62, 95% CI = 0.93-2.80). CONCLUSION: Individuals with 
      COPD had slightly greater risk of VTE, whereas low functional status had a larger
      effect that did not reach statistical significance. The constraints of
      administrative data analysis and sample size available for PCS limit conclusions 
      about the role of these comorbidities and functional status.
CI  - (c) 2013, Copyright the Authors Journal compilation (c) 2013, The American
      Geriatrics Society.
AD  - Hospital Medicine Unit, School of Medicine, Boston University, Boston, MA 02118, 
      USA. Alok.kapoor@bmc.org
FAU - Kapoor, Alok
AU  - Kapoor A
FAU - Chew, Priscilla
AU  - Chew P
FAU - Silliman, Rebecca A
AU  - Silliman RA
FAU - Hylek, Elaine M
AU  - Hylek EM
FAU - Katz, Jeffrey N
AU  - Katz JN
FAU - Cabral, Howard
AU  - Cabral H
FAU - Berlowitz, Dan
AU  - Berlowitz D
LA  - eng
GR  - KL2RR025770/RR/NCRR NIH HHS/United States
GR  - P60 AR 47782/AR/NIAMS NIH HHS/United States
GR  - R01 HL106029/HL/NHLBI NIH HHS/United States
GR  - R03 AG043906-01/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130321
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/03/21 [aheadofprint]
AID - 10.1111/jgs.12161 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2013 Apr;61(4):590-601. doi: 10.1111/jgs.12161. Epub 2013 Mar
      21.

PMID- 23581911
OWN - NLM
STAT- In-Process
DA  - 20130415
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 61
IP  - 4
DP  - 2013 Apr
TI  - Contributions of basal and prandial hyperglycemia to total hyperglycemia in older
      and younger adults with type 2 diabetes mellitus.
PG  - 535-41
LID - 10.1111/jgs.12167 [doi]
AB  - OBJECTIVES: To evaluate the relative contributions of basal and prandial
      components to total hyperglycemia in older and younger adults with type 2
      diabetes mellitus. DESIGN: Participant-level data were pooled from six randomized
      studies of 24 weeks or longer treatment with insulin glargine or an active
      comparator. SETTING: Prospective, randomized Phase 3 or 4 controlled trials.
      PARTICIPANTS: One thousand six hundred ninety-nine individuals: 509 (30%) aged 65
      and older and 1,190 (70%) younger than 65. MEASUREMENTS: Contributions of basal
      hyperglycemia (BHG) and postprandial hyperglycemia (PPHG) to total hyperglycemia,
      defined as the incremental area under the curve of daytime blood glucose (BG)
      from the overall glucose profile calculated from 7-point self-measured BG
      profiles, of participants aged 65 and older were compared with those of
      participants younger than 65. RESULTS: After 24 weeks of treatment, glycosylated 
      hemoglobin (HbA1c) decreased in the older (8.6-7.0%) and younger (8.7-7.1%)
      groups; the relative contribution of BHG was significantly lower in both age
      groups (P < .001). The relative contribution of BHG to that of PPHG was
      significantly smaller in older than in younger participants at baseline (75.4% vs
      79.4%; P < .001) and 24 weeks (37.6% vs 44.7%; P < .001). The relative
      contribution of BHG to total hyperglycemia was not correlated with HbA1c at
      baseline and after 24 weeks of treatment in older participants but was positively
      correlated at baseline (correlation coefficient (r) = 0.082; P = .005) and 24
      weeks (r = 0.062; P = .03) in younger participants. A significantly lower
      proportion of older participants reported symptomatic, glucose-confirmed, and
      nocturnal hypoglycemia during 24 weeks of treatment (P < .001). CONCLUSION: The
      relative contribution of BHG was lower, and that of PPHG was greater in older
      than in younger participants, suggesting that different therapeutic approaches
      may be required to treat hyperglycemia effectively in these different age groups.
CI  - (c) 2013, Copyright the Authors Journal compilation (c) 2013, The American
      Geriatrics Society.
AD  - Beth Israel Deaconess Medical Center, Joslin Diabetes Center, and Harvard Medical
      School, Boston, MA 02215, USA. medha.munshi@joslin.harvard.edu
FAU - Munshi, Medha N
AU  - Munshi MN
FAU - Pandya, Naushira
AU  - Pandya N
FAU - Umpierrez, Guillermo E
AU  - Umpierrez GE
FAU - DiGenio, Andres
AU  - DiGenio A
FAU - Zhou, Rong
AU  - Zhou R
FAU - Riddle, Matthew C
AU  - Riddle MC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130321
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/03/21 [aheadofprint]
AID - 10.1111/jgs.12167 [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2013 Apr;61(4):535-41. doi: 10.1111/jgs.12167. Epub 2013 Mar
      21.

PMID- 23581713
OWN - NLM
STAT- Publisher
DA  - 20130530
IS  - 1557-7716 (Electronic)
IS  - 1523-0864 (Linking)
DP  - 2013 May 29
TI  - Role of Vitamin C in the Function of the Vascular Endothelium.
AB  - Abstract Significance: Vitamin C, or ascorbic acid, has long been known to
      participate in several important functions in the vascular bed in support of
      endothelial cells. These functions include increasing the synthesis and
      deposition of type IV collagen in the basement membrane, stimulating endothelial 
      proliferation, inhibiting apoptosis, scavenging radical species, and sparing
      endothelial cell-derived nitric oxide to help modulate blood flow. Although
      ascorbate may not be able to reverse inflammatory vascular diseases such as
      atherosclerosis, it may well play a role in preventing the endothelial
      dysfunction that is the earliest sign of many such diseases. Recent Advances:
      Beyond simply preventing scurvy, evidence is mounting that ascorbate is required 
      for optimal function of many dioxygenase enzymes in addition to those involved in
      collagen synthesis. Several of these enzymes regulate the transcription of
      proteins involved in endothelial function, proliferation, and survival, including
      hypoxia-inducible factor-1alpha and histone and DNA demethylases. More recently, 
      ascorbate has been found to acutely tighten the endothelial permeability barrier 
      and, thus, may modulate access of ascorbate and other molecules into tissues and 
      organs. Critical Issues: The issue of the optimal cellular content of ascorbate
      remains unresolved, but it appears that low millimolar ascorbate concentrations
      are normal in most animal tissues, in human leukocytes, and probably in the
      endothelium. Although there may be little benefit of increasing near maximal
      cellular ascorbate concentrations in normal people, many diseases and conditions 
      have either systemic or localized cellular ascorbate deficiency as a cause for
      endothelial dysfunction, including early atherosclerosis, sepsis, smoking, and
      diabetes. Future Directions: A key focus for future studies of ascorbate and the 
      vascular endothelium will likely be to determine the mechanisms and clinical
      relevance of ascorbate effects on endothelial function, permeability, and
      survival in diseases that cause endothelial dysfunction. Antioxid. Redox Signal. 
      00, 000-000.
AD  - Department of Medicine, Vanderbilt University School of Medicine , Nashville,
      Tennessee.
FAU - May, James M
AU  - May JM
FAU - Harrison, Fiona E
AU  - Harrison FE
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130529
TA  - Antioxid Redox Signal
JT  - Antioxidants & redox signaling
JID - 100888899
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1089/ars.2013.5205 [doi]
PST - aheadofprint
SO  - Antioxid Redox Signal. 2013 May 29.

PMID- 23581630
OWN - NLM
STAT- In-Process
DA  - 20130423
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 78
IP  - 6
DP  - 2013 Jun
TI  - Plasma calcium as a predictor of cardiovascular disease in a community-based
      cohort.
PG  - 852-7
LID - 10.1111/cen.12081 [doi]
AB  - OBJECTIVE: Primary hyperparathyroidism and calcium supplementation have been
      linked to cardiovascular outcomes. The study objective was to examine plasma
      calcium as a predictor of cardiovascular disease in the general population, as
      results from previous cohort studies are conflicting. DESIGN, PARTICIPANTS AND
      MEASUREMENTS: Plasma calcium was measured in 4003 participants (aged 25-84 years)
      in the 1994/1995 Busselton Health Survey. Using a Cox proportional hazards model,
      we examined albumin-corrected calcium as a predictor of total mortality,
      cardiovascular mortality and cardiovascular events up to the end of 2010.
      RESULTS: At baseline, there were significant positive relationships between
      plasma calcium and each of body mass index, systolic and diastolic blood
      pressure, glucose and total cholesterol. During the follow-up period, 666
      participants died (278 from cardiovascular disease) and 652 had incident
      cardiovascular events. After adjustment for age and sex, each additional 0.1 mm
      of albumin-corrected calcium at baseline was associated with a hazard ratio (HR) 
      of 1.09 [95% confidence interval (CI) 0.99, 1.20; P = 0.062] for total mortality,
      1.06 (95% CI 0.92, 1.23; P = 0.41) for cardiovascular mortality and 1.13 (95% CI 
      1.03, 1.24; P = 0.012) for cardiovascular events. These associations were
      attenuated by further adjustment for standard cardiovascular risk factors with HR
      1.03 (95% CI 0.94, 1.14), 0.99 (95% CI 0.86, 1.16) and 1.05 (95% CI 0.95, 1.15), 
      respectively. CONCLUSION: After adjustment for age and sex, plasma calcium is a
      predictor of cardiovascular events. This appears to be mediated by conventional
      cardiovascular risk factors, and calcium is not an independent predictor of
      cardiovascular disease.
CI  - (c) 2012 John Wiley & Sons Ltd.
AD  - Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital,
      Nedlands, WA, Australia. john.walsh@health.wa.gov.au
FAU - Walsh, John P
AU  - Walsh JP
FAU - Divitini, Mark L
AU  - Divitini ML
FAU - Knuiman, Matthew W
AU  - Knuiman MW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130413
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/08/24 [received]
PHST- 2012/09/17 [revised]
PHST- 2012/10/02 [revised]
PHST- 2012/10/17 [accepted]
PHST- 2013/04/13 [aheadofprint]
AID - 10.1111/cen.12081 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2013 Jun;78(6):852-7. doi: 10.1111/cen.12081. Epub 2013
      Apr 13.

PMID- 23581598
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1447-0594 (Electronic)
IS  - 1447-0594 (Linking)
DP  - 2013 Apr 15
TI  - Control of glycemia and other cardiovascular disease risk factors in older adults
      with type 2 diabetes mellitus: Data from the Adult Diabetes Control and
      Management.
LID - 10.1111/ggi.12070 [doi]
AB  - AIM: The aims of the present study were to assess the control of glycemia and
      other cardiovascular disease risk factors, and the association between age and
      these controls among older adults with type 2 diabetes in Malaysia. METHODS: A
      cross-sectional study was carried out using cases notified to the Adult Diabetes 
      Control and Management database between 1 January and 31 December 2009. A total
      of 10 363 people aged over 60 years with type 2 diabetes mellitus were included
      in the analyses. A standard online case report form was used to record
      demographic data, clinical factors (diabetes duration, comorbid condition and
      treatment modalities), cardiovascular disease risk factors, diabetes
      complications and laboratory assessments. The cardiovascular disease risk factors
      controls assessed included glycosylated hemoglobin (HbA1c ) <7.0%, blood
      pressure, body mass index, waist circumference and lipid profiles. RESULTS: The
      proportion of older adults who achieved target HbA1c (<7.0%) was 41.7%. A greater
      proportion of older adults aged >/=80 years significantly achieved the targets of
      HbA1c <7% (P < 0.001), waist circumference (P < 0.001), low-density lipoprotein
      cholesterol <2.6 mmol/L (P = 0.007) and triglycerides <1.7 mmol/L (P = 0.001)
      when compared with the younger elderly groups. They were also associated with
      achieving target HbA1c <7.0% (OR = 1.90, 95% CI 1.68-2.26) and triglycerides <1.7
      mmol/L (OR = 1.20, 95%CI 1.04-1.46) than those aged 60-69 years. CONCLUSION: The 
      control of cardiovascular disease risk factors was suboptimal in older adults
      with type 2 diabetes. The oldest elderly were more likely to achieve target HbA1c
      (<7.0%) and triglycerides (<1.7 mmol/L) than older adults aged 60-69 years.
      Geriatr Gerontol Int 2013; : -.
CI  - (c) 2013 Japan Geriatrics Society.
AD  - Department of Family Medicine, Faculty of Medicine and Health Sciences,
      Universiti Putra Malaysia, Serdang, Malaysia; Institute of Gerontology,
      Universiti Putra Malaysia, Serdang, Malaysia.
FAU - Sazlina, Shariff-Ghazali
AU  - Sazlina SG
FAU - Mastura, Ismail
AU  - Mastura I
FAU - Ahmad, Zaiton
AU  - Ahmad Z
FAU - Cheong, Ai-Theng
AU  - Cheong AT
FAU - Adam, Bujang-Mohamad
AU  - Adam BM
FAU - Jamaiyah, Haniff
AU  - Jamaiyah H
FAU - Lee, Ping-Yein
AU  - Lee PY
FAU - Syed-Alwi, Syed-Abdul-Rahman
AU  - Syed-Alwi SA
FAU - Chew, Boon-How
AU  - Chew BH
FAU - Sriwahyu, Taher
AU  - Sriwahyu T
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130415
TA  - Geriatr Gerontol Int
JT  - Geriatrics & gerontology international
JID - 101135738
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/02/27 [accepted]
AID - 10.1111/ggi.12070 [doi]
PST - aheadofprint
SO  - Geriatr Gerontol Int. 2013 Apr 15. doi: 10.1111/ggi.12070.

PMID- 23581491
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
VI  - 56
IP  - 8
DP  - 2013 Apr 25
TI  - New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives 
      with antioxidant, antihyperlipidemic, and antidiabetic action.
PG  - 3330-8
LID - 10.1021/jm400101e [doi]
AB  - Oxidative stress, inflammation, and hyperlipidemia are common factors involved in
      the pathophysiology of atherosclerosis and type 2 diabetes. We have previously
      developed multifunctional antidyslipidemic derivatives with antioxidant and
      antiatherogenic properties. We now report the design, synthesis, and evaluation
      of two such novel derivatives that incorporate a structural moiety of the
      antidiabetic agent succinobucol. The new compounds exhibited a much improved in
      vitro antioxidant and squalene synthase inhibitory activity (at lower micromolar 
      concentrations) as well as a significant antihyperlipidemic effect, reducing
      plasma total cholesterol, triglycerides, and MDA by 65-90%. Compound 2 also
      indicated a good anti-inflammatory activity, decreasing edema by 44%, while it
      was further evaluated for its antidiabetic activity using a type 2 diabetes
      experimental mouse model. After 7 weeks of administration, it produced a
      significant antihyperglycemic and antihyperlipidemic activity. In conclusion,
      rational drug design led to a compound combining improved antioxidant,
      antidyslipidemic, and antidiabetic action that may serve as a potential
      therapeutic strategy in metabolic syndrome disorders.
AD  - Department of Medicinal Chemistry, School of Pharmacy, University of Athens,
      15771 Athens, Greece.
FAU - Ladopoulou, Eleni
AU  - Ladopoulou E
FAU - Matralis, Alexios N
AU  - Matralis AN
FAU - Kourounakis, Angeliki P
AU  - Kourounakis AP
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
SB  - IM
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2013/04/12 [aheadofprint]
AID - 10.1021/jm400101e [doi]
PST - ppublish
SO  - J Med Chem. 2013 Apr 25;56(8):3330-8. doi: 10.1021/jm400101e. Epub 2013 Apr 12.

PMID- 23581463
OWN - NLM
STAT- Publisher
DA  - 20130515
IS  - 1471-4159 (Electronic)
IS  - 0022-3042 (Linking)
DP  - 2013 Apr 13
TI  - Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the
      inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells
      and primary neurons.
LID - 10.1111/jnc.12264 [doi]
AB  - The peroxisome proliferator-activated receptor gamma (PPARgamma) agonists
      thiazolidinediones (TZDs) are prescribed for the treatment of type 2 diabetes
      mellitus. Furthermore, it has been reported that TZDs have a beneficial effect on
      neurodegenerative disorders, such as Alzheimer's disease. However, the molecular 
      mechanisms underlying this effect are not fully understood. Here, we investigated
      whether and how troglitazone, a parent TZD drug, inhibits tau phosphorylation.
      Treatment with troglitazone decreased tau-Thr231 phosphorylation and p35, the
      specific activator of cyclin-dependent kinase 5 (CDK5), in a dose- and
      time-dependent manner. Troglitazone also decreased CDK5 enzymatic activity, and
      ectopic expression of p25, the cleaved and more active form of p35, restored the 
      troglitazone-induced decrease in tau-Thr231 phosphorylation. Treatment with
      either MG-132, a reversible proteasome inhibitor, or lactacystin, a specific and 
      irreversible 26S proteasome inhibitor, significantly reversed the observed
      inhibitory effects of troglitazone. However, GW9662, a specific and irreversible 
      PPARgamma antagonist, did not alter the observed inhibitory effects. Similar
      results were also found when other TZD drugs, pioglitazone and rosiglitazone,
      were used. Treatment with various inhibitors revealed that troglitazone-induced
      inhibitions of tau-Thr231 phosphorylation and p35 expression were not mediated by
      glycogen synthase kinase 3beta, protein kinase A, and protein phosphatase 2A
      signaling pathways. Finally, we also found that the same observed inhibitory
      effects of troglitazone hold true for the use of primary cortical neurons. Taken 
      together, we demonstrated that TZDs repressed tau-Thr231 phosphorylation via the 
      inhibition of CDK5 activity, which was mediated by the proteasomal degradation of
      p35 and a PPARgamma-independent signaling pathway.
CI  - (c) 2013 International Society for Neurochemistry.
AD  - Department of Neurology, Konkuk University Medical Center, Konkuk University,
      Seoul, South Korea; Department of Pharmacology, Center for Geriatric Neuroscience
      Research, SMART Institute of Advanced Biomedical Science School of Medicine,
      Konkuk University, Seoul, South Korea.
FAU - Cho, Du-Hyong
AU  - Cho DH
FAU - Lee, Eun Joo
AU  - Lee EJ
FAU - Kwon, Kyoung Ja
AU  - Kwon KJ
FAU - Shin, Chan Young
AU  - Shin CY
FAU - Song, Kee-Ho
AU  - Song KH
FAU - Park, Jung-Hyun
AU  - Park JH
FAU - Jo, Inho
AU  - Jo I
FAU - Han, Seol-Heui
AU  - Han SH
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130413
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/13 [received]
PHST- 2013/03/11 [revised]
PHST- 2013/04/10 [accepted]
AID - 10.1111/jnc.12264 [doi]
PST - aheadofprint
SO  - J Neurochem. 2013 Apr 13. doi: 10.1111/jnc.12264.

PMID- 23581458
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1557-7708 (Electronic)
IS  - 1075-5535 (Linking)
DP  - 2013 Apr 12
TI  - A Randomized, Placebo-Controlled, Crossover Study of an Herbal Preparation
      Containing Vernonia cinerea in the Treatment of Type 2 Diabetes.
AB  - Abstract Objective: A randomized, single-center, double-blind, crossover clinical
      trial investigated the effects of an herbal preparation containing Vernonia
      cinerea in patients with type 2 diabetes mellitus. Methods: 48 patients with type
      2 diabetes mellitus for longer than 6 months were divided into two groups matched
      for demographic and paraclinical variables. One group received a standard
      preparation of V. cinerea for 3 months, followed by placebo for another 3 months,
      and the other group received treatment in the reverse order. All patients
      received detailed advice on diet, exercise, and lifestyle modification. Glucose
      level was documented every 2 weeks, and hemoglobin A1c, total cholesterol,
      low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, 
      triglycerides, aspartate aminotransferase, alanine aminotransferase, and
      creatinine levels were determined at recruitment, 3 months, and study completion 
      at 6 months. Results: Glucose, hemoglobin A1c, cholesterol, LDL cholesterol, and 
      triglyceride levels decreased significantly in both groups. No significant
      differences were seen in aspartate aminotransferase, alanine aminotransferase, or
      creatinine levels, indicating that use of the herbal preparation had no adverse
      effect on liver or renal function. Conclusion: Herbal treatment with V. cinerea
      has a beneficial effect on reducing the glycemic state in patients with type 2
      diabetes.
AD  - 1 Department of Clinical Pharmacy and Pharmacology, University of Dhaka ,
      Bangladesh .
FAU - Sayeed, Muhammad Shahdaat Bin
AU  - Sayeed MS
FAU - Mostofa, A G M
AU  - Mostofa AG
FAU - Ferdous, F M Touhidul Islam
AU  - Ferdous FM
FAU - Islam, Md Siddiqul
AU  - Islam MS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Altern Complement Med
JT  - Journal of alternative and complementary medicine (New York, N.Y.)
JID - 9508124
EDAT- 2013/04/16 06:00
MHDA- 2013/04/16 06:00
CRDT- 2013/04/16 06:00
AID - 10.1089/acm.2012.0063 [doi]
PST - aheadofprint
SO  - J Altern Complement Med. 2013 Apr 12.

PMID- 23580788
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1554-6179 (Electronic)
IS  - 1539-4182 (Linking)
DP  - 2013 Apr 12
TI  - Patient Characteristics Associated with Medication Adherence.
AB  - ObjectiveDespite evidence indicating therapeutic benefit for adhering to a
      prescribed regimen, many patients do not take their medications as prescribed.
      Non-adherence often leads to morbidity and to higher health care costs. The
      objective of the study was to assess patient characteristics associated with
      medication adherence across eight diseases.DesignRetrospective data from a
      repository within an integrated health system was used to identify patients >/=18
      with ICD-9-CM codes for primary or secondary diagnoses for any of eight
      conditions (depression, hypertension, hyperlipidemia, diabetes, asthma or chronic
      obstructive pulmonary disease, multiple sclerosis, cancer, or osteoporosis).
      Electronic pharmacy data was then obtained for 128 medications used for
      treatment.MethodsMedication possession ratios (MPR) were calculated for those
      with one condition and one drug (n=15,334) and then for the total population
      having any of the eight diseases (n=31, 636). The proportion of patients adherent
      (MPR>/=80%) was summarized by patient and living-area (census) characteristics.
      Bivariate associations between drug adherence and patient characteristics (age,
      sex, race, education, and comorbidity) were tested using contingency tables and
      chi-square tests. Logistic regression analysis examined predictors of adherence
      from patient and living area characteristics.ResultsMedication adherence for
      those with one condition was higher in males, Caucasians, older patients, and
      those living in areas with higher education rates and higher income. In the total
      population, adherence increased with lower comorbidity and increased number of
      medications. Substantial variation in adherence was found by condition with the
      lowest adherence for diabetes (51%) and asthma (33%).ConclusionsThe expectation
      of high adherence due to a covered pharmacy benefit, and to enhanced medication
      access did not hold. Differences in medication adherence were found across
      condition and by patient characteristics. Great room for improvement remains,
      specifically for diabetes and asthma.
AD  - *HealthPartners Research Foundation, Pharmacy Services Minneapolis, MN.
FAU - Rolnick, Sharon J
AU  - Rolnick SJ
FAU - Pawloski, Pamala A
AU  - Pawloski PA
FAU - Hedblom, Brita D
AU  - Hedblom BD
FAU - Asche, Stephen E
AU  - Asche SE
FAU - Bruzek, Richard J
AU  - Bruzek RJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Clin Med Res
JT  - Clinical medicine & research
JID - 101175887
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/04/11 [aheadofprint]
AID - cmr.2013.1113 [pii]
AID - 10.3121/cmr.2013.1113 [doi]
PST - aheadofprint
SO  - Clin Med Res. 2013 Apr 12.

PMID- 23580786
OWN - NLM
STAT- Publisher
DA  - 20130415
IS  - 1554-6179 (Electronic)
IS  - 1539-4182 (Linking)
DP  - 2013 Apr 12
TI  - Circadian Patterns of ST Elevation Myocardial Infarction in the New Millennium.
AB  - ObjectiveNearly four decades ago, a circadian pattern of acute myocardial
      infarction (AMI) with a peak in the early morning waking hours was described. The
      goal of the present study was to determine whether major changes in lifestyle and
      significant advances in medical therapy have altered this pattern in the
      intervening years.DesignRetrospective chart review.SettingTertiary care hospital 
      in central Wisconsin.MethodsWe examined circadian patterns of ST elevation
      myocardial infarction (STEMI) in 519 patients diagnosed with STEMI over a 5-year 
      period. Time of symptom onset was obtained from patient self-reports in the
      medical record and was recorded over 24 hours.ResultsWe observed a circadian
      pattern of STEMI occurrence with a morning peak at approximately 11:30 AM. This
      pattern was highly significant in patients who were not using beta-blockers (P
      <0.0001) and had no history of diabetes (P <0.0001), but was otherwise absent.
      The circadian pattern appeared to be attenuated in patients of a younger age,
      female gender, or who used statins or aspirin. Peak STEMI occurrence was earlier 
      in smokers than non-smokers.ConclusionsDespite significant lifestyle changes and 
      medical advances in the nearly four decades since a circadian pattern of AMI
      occurrence was first described, patients with STEMI had a circadian pattern of
      symptom onset with a morning peak. Use of beta-blockers and a history of diabetes
      mellitus abolished this pattern. Other modifying factors, including medications, 
      age, and gender attenuated, but did not abolish, the circadian pattern.
AD  - *Department of Internal Medicine, Marshfield Clinic, Marshfield, WI USA.
FAU - Kanth, Rajan
AU  - Kanth R
FAU - Ittaman, Sunitha
AU  - Ittaman S
FAU - Rezkalla, Shereif
AU  - Rezkalla S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Clin Med Res
JT  - Clinical medicine & research
JID - 101175887
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/04/11 [aheadofprint]
AID - cmr.2013.1120 [pii]
AID - 10.3121/cmr.2013.1120 [doi]
PST - aheadofprint
SO  - Clin Med Res. 2013 Apr 12.

PMID- 23580698
OWN - NLM
STAT- Publisher
DA  - 20130611
IS  - 1538-7755 (Electronic)
IS  - 1055-9965 (Linking)
VI  - 22
IP  - 6
DP  - 2013 Jun
TI  - Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Case-Control Study
      within PCBaSe Sweden.
PG  - 1102-1109
AB  - BACKGROUND: Diabetes mellitus (DM) increases the risk for cancer at almost all
      sites, but data on the association with prostate cancer are inconsistent.
      METHODS: We assessed the risk of a prostate cancer diagnosis among men with type 
      2 (T2)DM in a nationwide population-based case-control study including 44,352 men
      with prostate cancer identified through the Prostate Cancer data Base Sweden
      (PCBaSe) between 2002 and 2006 and 221,495 age-matched men from the general
      population. RESULTS: Overall, the risk of prostate cancer among men with T2DM was
      lower than among men without T2DM [OR, 0.80; 95% confidence interval (CI),
      0.76-0.85]. The risk decreased with longer disease duration and was observed
      across all tumor risk categories, although most clearly among men with low risk
      tumors (OR, 0.71; 95% CI, 0.64-0.80). The risk for prostate cancer was reduced
      among diabetic men on dietary treatment only (OR, 0.89; 95% CI, 0.80-0.99) but
      more markedly among men on oral hypoglycemic agents (OR, 0.80; 95% CI, 0.74-0.87)
      and insulin (OR, 0.72; 95% CI, 0.69-0.81). Obese diabetic men (BMI > 30 kg/m2)
      showed a reduced risk (OR, 0.72; 95% CI, 0.65-0.80) compared with men without
      diabetes. There was a trend of decreasing risk with increasing levels of HbA1c (P
      < 0.05). CONCLUSIONS: This nationwide study confirmed a reduced risk of being
      diagnosed with prostate cancer among men with T2DM, especially for low-risk
      tumors. An altered hormonal milieu is a plausible explanation, although the
      possibility of decreased prostate cancer detection among diabetic men cannot be
      ruled out. IMPACT: This is the largest study to examine the association between
      T2DM and prostate cancer accounting for tumor risk group and diabetes treatment. 
      Cancer Epidemiol Biomarkers Prev; 22(6); 1102-9. (c)2013 AACR.
AD  - Authors' Affiliations: Clinical Epidemiology and Biostatistics, Orebro University
      Hospital and University, Orebro, Sweden; Harvard School of Public Health, Boston,
      Massachusetts; Regional Oncology Center; Department of Public Health and Caring
      Sciences/Geriatrics, Uppsala University; Medical Products Agency, Uppsala;
      Department of Medicine, Sahlgrenska University Hospital, Gothenburgh University, 
      Goteborg, Sweden; and Department of Surgery, Urology Service, Memorial
      Sloan-Kettering Cancer Center, New York City, New York.
FAU - Fall, Katja
AU  - Fall K
FAU - Garmo, Hans
AU  - Garmo H
FAU - Gudbjornsdottir, Soffia
AU  - Gudbjornsdottir S
FAU - Stattin, Par
AU  - Stattin P
FAU - Zethelius, Bjorn
AU  - Zethelius B
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Cancer Epidemiol Biomarkers Prev
JT  - Cancer epidemiology, biomarkers & prevention : a publication of the American
      Association for Cancer Research, cosponsored by the American Society of
      Preventive Oncology
JID - 9200608
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/04/11 [aheadofprint]
PHST- 2013/05/20 [aheadofprint]
AID - 1055-9965.EPI-12-1046 [pii]
AID - 10.1158/1055-9965.EPI-12-1046 [doi]
PST - ppublish
SO  - Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1102-1109. Epub 2013 Apr 11.

PMID- 23580624
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
DP  - 2013 Apr 10
TI  - Preoperative Neutrophil-Lymphocyte Ratio and Saphenous Vein Graft Patency After
      Coronary Artery Bypass Grafting.
AB  - Aim: The aim of the present study was to investigate the predictive value of
      preoperative neutrophil-lymphocyte ratio (NLR) in postoperative saphenous vein
      graft patency in patients undergoing coronary artery bypass grafting (CABG)
      surgery. Method: We retrospectively analyzed 444 patients who had undergone CABG 
      and a further control coronary angiography due to recurrence of symptoms. The
      patients were divided into tertile groups according to the NLR. The primary end
      point was 50% saphenous vein graft stenosis or more or complete occlusion.
      Result: The saphenous vein graft failure in the 3 groups based on NLR was 33%,
      66.2%, and 79.1%, in the low-, middle- and high-risk groups, respectively. In
      multivariate regression modeling, current smoker, diabetes mellitus, target
      artery diameter <1.5 mm, and NLR independently predicted saphenous vein graft
      patency in patients after CABG. Conclusion: Preoperative NLR is clearly an
      independent predictor of saphenous vein graft patency in patients after CABG.
FAU - Tasoglu, Irfan
AU  - Tasoglu I
FAU - Turak, Osman
AU  - Turak O
FAU - Nazli, Yunus
AU  - Nazli Y
FAU - Ozcan, Firat
AU  - Ozcan F
FAU - Colak, Necmettin
AU  - Colak N
FAU - Sahin, Serpil
AU  - Sahin S
FAU - Kavasoglu, Kemal
AU  - Kavasoglu K
FAU - Genc, Bahadir
AU  - Genc B
FAU - Sert, Dogan
AU  - Sert D
FAU - Karahan, Mehmet
AU  - Karahan M
FAU - Cicek, Omer
AU  - Cicek O
FAU - Ecevit, Ata
AU  - Ecevit A
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130410
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 1076029613484086 [pii]
AID - 10.1177/1076029613484086 [doi]
PST - aheadofprint
SO  - Clin Appl Thromb Hemost. 2013 Apr 10.

PMID- 23580605
OWN - NLM
STAT- Publisher
DA  - 20130514
IS  - 1755-3245 (Electronic)
IS  - 0008-6363 (Linking)
DP  - 2013 May 12
TI  - Biomechanical factors as triggers of vascular growth.
AB  - Haemodynamic factors influence all forms of vascular growth (vasculogenesis,
      angiogenesis, arteriogenesis). Because of its prominent role in atherosclerosis, 
      shear stress has gained particular attention, but other factors such as
      circumferential stretch are equally important to maintain the integrity and to
      (re)model the vascular network. While these haemodynamic forces are crucial
      determinants of the appearance and the structure of the vasculature, they are in 
      turn subjected to structural changes in the blood vessels, such as an increased
      arterial stiffness in chronic arterial hypertension and ageing. This results in
      an interplay between the various forces (biomechanical forces) and the involved
      vascular elements. Although many molecular mediators of biomechanical forces
      still need to be identified, there is plenty of evidence for the causal role of
      these forces in vascular growth processes, which will be summarized in this
      review. In addition, we will discuss the effects of concomitant diseases and
      disorders on these processes by altering either the biomechanics or their
      transduction into biological signals. Particularly endothelial dysfunction,
      diabetes, hypercholesterolaemia, and age affect mechanosensing and -transduction 
      of flow signals, thereby underpinning their influence on cardiovascular health.
      Finally, current approaches to modify biomechanical forces to therapeutically
      modulate vascular growth in humans will be described.
AD  - Laboratory of Experimental Cardiology, University Medical Center, G02.523,
      Heidelberglaan 100, Utrecht 3584 CX, The Netherlands.
FAU - Hoefer, Imo E
AU  - Hoefer IE
FAU - den Adel, Brigit
AU  - den Adel B
FAU - Daemen, Mat J A P
AU  - Daemen MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130512
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
OTO - NOTNLM
OT  - Biomechanics
OT  - Circumferential stretch
OT  - Shear stress
OT  - Vascular growth
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/04/10 [aheadofprint]
AID - cvt089 [pii]
AID - 10.1093/cvr/cvt089 [doi]
PST - aheadofprint
SO  - Cardiovasc Res. 2013 May 12.

PMID- 23580443
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1522-2586 (Electronic)
IS  - 1053-1807 (Linking)
DP  - 2013 Apr 11
TI  - Measurement of interscapular brown adipose tissue of mice in differentially
      housed temperatures by chemical-shift-encoded water-fat MRI.
LID - 10.1002/jmri.24138 [doi]
AB  - PURPOSE: To determine differences in fat-signal fraction (FF) from
      chemical-shift-encoded water-fat MRI of interscapular BAT in mice housed at
      different ambient temperatures (Ta ). MATERIALS AND METHODS: C57BL/6J male mice
      (8 weeks old) were singly housed at 16 degrees C, 23 degrees C, or 30 degrees C
      (n = 16/group) for 4 weeks. Measures included food intake, body weight (both
      measured weekly) and body composition (at baseline, 2, and 4 weeks post-thermal
      exposure); chemical-shift-encoded water-fat MRI was performed on a 9.4 Tesla
      Bruker magnet with respiratory gating and anesthesia at 4 weeks post-thermal
      exposure. RESULTS: A significant inverse relationship between food intake and Ta 
      was evidenced (P < 0.0001). Lean mass was similar among groups, while total fat
      mass was significantly different among groups ([mean +/- SE]: 30 degrees C = 5.10
      +/- 0.19 g; 23 degrees C = 4.18 +/- 0.16 g; 16 degrees C = 3.48 +/- 0.54 g; P <
      0.0001). Mean BAT-FF was positively related to Ta (means: 30 degrees C = 79.4%;
      23 degrees C = 61.8%; 16 degrees C = 50.9%; P < 0.0001). CONCLUSION: These
      cross-sectional results demonstrate that MRI measurement of FF within the
      interscapular BAT in mice reflects recent functional status of the tissue, with a
      lower Ta leading to a significantly reduced BAT-FF, indicative of the tissue's
      involvement in thermogenesis.J. Magn. Reson. Imaging 2013;00:000-000. (c) 2013
      Wiley Periodicals, Inc.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
AD  - Department of Nutrition Sciences, University of Alabama at Birmingham,
      Birmingham, Alabama, USA; Nutrition Obesity Research Center, University of
      Alabama at Birmingham, Birmingham, Alabama, USA; Diabetes Research Training
      Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.
FAU - Smith, Daniel L Jr
AU  - Smith DL Jr
FAU - Yang, Yongbin
AU  - Yang Y
FAU - Hu, Houchun H
AU  - Hu HH
FAU - Zhai, Guihua
AU  - Zhai G
FAU - Nagy, Tim R
AU  - Nagy TR
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - J Magn Reson Imaging
JT  - Journal of magnetic resonance imaging : JMRI
JID - 9105850
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/07/18 [received]
PHST- 2013/02/26 [accepted]
AID - 10.1002/jmri.24138 [doi]
PST - aheadofprint
SO  - J Magn Reson Imaging. 2013 Apr 11. doi: 10.1002/jmri.24138.

PMID- 23580393
OWN - NLM
STAT- In-Data-Review
DA  - 20130527
IS  - 1179-2035 (Electronic)
IS  - 0112-1642 (Linking)
VI  - 43
IP  - 6
DP  - 2013 Jun
TI  - The latest on the effect of prior exercise on postprandial lipaemia.
PG  - 463-81
LID - 10.1007/s40279-013-0046-9 [doi]
AB  - This review examines the effect of prior exercise on postprandial triacylglycerol
      (pTAG) concentrations, an independent risk factor for cardiovascular diseases.
      Numerous studies have shown that a single bout of exercise reduces pTAG
      concentrations; however, several modulators such as exercise energy
      expenditure/deficit, mode of exercise (aerobic/resistance/high
      intensity/intermittent exercise or combinations), type of meal (moderate or high 
      fat), time frame between exercise and meal and target group may individually or
      in conjunction influence this effect. On the other hand, at least for aerobic
      exercise, training reduces pTAG concentrations transiently (~2 days); therefore, 
      exercise sessions should be frequent enough to maintain this clinically
      significant improvement. For the healthy population, it seems that a subject's
      preference and ability determine which type of exercise to undertake to attenuate
      pTAG concentrations; an energy expenditure of ~30 kJ/kg of body mass (or ~2-2.5
      MJ) not combined with a corresponding increase in energy intake is required; for 
      resistance or intermittent exercise, for those following a moderate rather than a
      high-fat diet, and for those with obesity (expressed as kJ/kg of body mass), a
      smaller energy expenditure is probably sufficient. More studies are needed to
      investigate dose-response/plateau effects, as well as the threshold of energy
      expenditure in those with diabetes mellitus and other high-risk populations.
      Finally, investigation of the underlying mechanisms may be clinically helpful in 
      individualizing the appropriate intervention.
AD  - Laboratory of Nutrition and Clinical Dietetics, Department of Nutrition and
      Dietetics, Harokopio University, Athens, Greece.
FAU - Maraki, Maria I
AU  - Maraki MI
FAU - Sidossis, Labros S
AU  - Sidossis LS
LA  - eng
GR  - UL1 RR029876/RR/NCRR NIH HHS/United States
PT  - Journal Article
PL  - New Zealand
TA  - Sports Med
JT  - Sports medicine (Auckland, N.Z.)
JID - 8412297
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 10.1007/s40279-013-0046-9 [doi]
PST - ppublish
SO  - Sports Med. 2013 Jun;43(6):463-81. doi: 10.1007/s40279-013-0046-9.

PMID- 23580344
OWN - NLM
STAT- In-Data-Review
DA  - 20130529
IS  - 1179-2019 (Electronic)
IS  - 1174-5878 (Linking)
VI  - 15
IP  - 3
DP  - 2013 Jun
TI  - Managing cardiovascular risk in overweight children and adolescents.
PG  - 181-90
LID - 10.1007/s40272-013-0011-y [doi]
AB  - The scientific, medical, and lay communities are currently confronted with a
      serious medical and public health problem related to the marked non-remitting
      worldwide epidemic of obesity. This ever-increasing prevalence of obesity is
      accompanied by a host of inherently associated co-morbidities. As a result,
      obesity is fast becoming the major cause of premature death in the developed
      world. As pediatric and adult cardiologists, we have seen a dramatic increase in 
      office referrals of overweight and obese children and adolescents, who already
      have obesity-related degenerative disease processes such as hypertension,
      dyslipidemia, the metabolic syndrome, and type 2 diabetes mellitus, as well as
      manifestations of early preclinical atherosclerotic cardiovascular disease, not
      previously observed in this age group. This article presents a review of the
      literature and recent scientific statements and recommendations issued by the
      American Heart Association (AHA) and the American Academy of Pediatrics (AAP)
      regarding the metabolic abnormalities associated with obesity, including newer
      identification and treatment strategies for obesity, dyslipidemia, and early
      subclinical coronary artery disease seen in high-risk children and adolescents.
AD  - Department of Pediatric Cardiology, Brookdale University Hospital and Medical
      Center, 1 Brookdale Plaza, Room 300CHC, Brooklyn, NY, 11212, USA,
      sdhuper@brookdale.edu.
FAU - Dhuper, Sarita
AU  - Dhuper S
FAU - Buddhe, Sujatha
AU  - Buddhe S
FAU - Patel, Sunil
AU  - Patel S
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Paediatr Drugs
JT  - Paediatric drugs
JID - 100883685
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 10.1007/s40272-013-0011-y [doi]
PST - ppublish
SO  - Paediatr Drugs. 2013 Jun;15(3):181-90. doi: 10.1007/s40272-013-0011-y.

PMID- 23580229
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1869-6953 (Print)
DP  - 2013 Apr 12
TI  - Omitting Follow-up Food After Initial Hypoglycaemic Treatment Does not Increase
      the Likelihood of Repeat Hypoglycaemia.
AB  - INTRODUCTION: Guidelines for self-treatment of hypoglycaemia specify initial
      treatment with quick-acting carbohydrate until blood glucose levels normalize and
      then follow-up with longer-acting carbohydrate. The few studies investigating
      follow-up show 29-57% omission or undertreatment with follow-up carbohydrate but 
      do not investigate the association of this with repeat hypoglycaemia. This study 
      aimed to develop, validate and administer a questionnaire to delineate this
      association. The timeframe targeted was 2 h post primary hypoglycaemic event
      (PPHE), the time influenced by long-acting carbohydrate. METHODS: A questionnaire
      was generated, test-retest reliability assessed, and it was piloted on
      convenience samples from the target population. The final version was
      administered to all insulin-treated individuals attending an outpatient diabetes 
      clinic over 4 weeks (169). RESULTS: Questionnaire development: readability
      (69.6-standard/easy), test-retest reliability (Cohen's kappa 0.57-0.91) and
      return rate (72.2%) were all acceptable. Questionnaire data: questionnaires were 
      returned by 122 participants (63 males/59 females). Method of insulin
      administration was subcutaneous insulin injections (91%) and continuous
      subcutaneous insulin infusion (CSII) (9%). Repeat hypoglycaemia within 2 h PPHE
      was reported by 8.2% of respondents. There was no significant difference for age,
      gender and diabetes duration between those reporting repeat hypoglycaemia and
      those without. Consumption of follow-up longer-acting carbohydrate was reported
      by 58.2% of responders with 48% of these using long-acting and 52% medium-acting 
      carbohydrate foods. Method of insulin administration and consumption of follow-up
      food were significantly associated with repeat hypoglycaemia (P = 0.015, 0.039)
      but presence or absence of symptoms and duration of action of carbohydrate were
      not significantly associated (P = 0.103, 0.629). Hierarchical logistic regression
      analysis showed omission of follow-up food PPHE was not a significant predictor
      of increased likelihood of repeat hypoglycaemia within 2 h PPHE, irrespective of 
      method of insulin administration (P = 0.085). CONCLUSION: This study supports
      guidelines that recommend judicious, rather than routine use of follow-up
      longer-acting carbohydrate PPHE.
AD  - Department of Endocrinology and Diabetes, Royal Perth Hospital, GPO Box X2213,
      Perth, WA, 6001, Australia, sally.vindedzis@postgrad.curtin.edu.au.
FAU - Vindedzis, Sally
AU  - Vindedzis S
FAU - Marsh, Beryl
AU  - Marsh B
FAU - Sherriff, Jill
AU  - Sherriff J
FAU - Dhaliwal, Satvinder
AU  - Dhaliwal S
FAU - Stanton, Kim
AU  - Stanton K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related
      disorders
JID - 101539025
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/02/27 [received]
PHST- 2013/04/12 [aheadofprint]
AID - 10.1007/s13300-013-0019-x [doi]
PST - aheadofprint
SO  - Diabetes Ther. 2013 Apr 12.

PMID- 23580160
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1877-8755 (Electronic)
IS  - 1138-7548 (Linking)
DP  - 2013 Apr 12
TI  - Simvastatin and vitamin E effects on cardiac and hepatic oxidative stress in rats
      fed on high fat diet.
AB  - High fat diet (HFD) is a common cause of metabolic syndrome and type 2 diabetes
      mellitus. Published data showed that HFD and subsequent dyslipidemia are major
      triggers for oxidative stress. Forty-eight male Sprague-Dawley rats, weighing
      170-200 g, were divided into six groups: control, control with vitamin E (100
      mg/kg/day, i.p.), control with simvastatin (SIM) (10 mg/kg of body weight/day),
      HFD, HFD with vitamin E, and HFD with SIM. Standard and high cholesterol diets
      were given for 15 weeks and SIM and vitamin E were added in the last 4 weeks. In 
      all rats, serum vitamin E, total cholesterol (TC), triglycerides (TG), low (LDL) 
      and high (HDL) density lipoproteins, alanine (ALT) and aspartate (AST)
      transaminases, alkaline phosphatase (ALP), and gamma glutamyl transpeptidase
      (GGT) as well as cardiac and hepatic thiobarbituric acid-reactive substances
      (TBARS) and antioxidants (reduced glutathione (GSH), superoxide dismutase (SOD), 
      and catalase (CAT)) were measured. Also, electrocardiogram (ECG) was recorded.
      HFD significantly increased QTc interval, heart rate (HR), serum TC, TG, LDL,
      ALT, AST, ALP, GGT, liver TG, and cardiac and hepatic TBARS but decreased
      antioxidants and HDL, while SIM decreased HR, liver TG, serum TC, TG, and LDL and
      increased HDL in HFD rats. Vitamin E had no effect. Moreover, SIM and vitamin E
      decreased QTc interval, serum ALT, AST, ALP, GGT, and cardiac and hepatic TBARS
      and increased antioxidants in HFD rats. Histopathological observations confirm
      the biochemical parameters. SIM and vitamin E slow progression of
      hypercholesterolemia-induced oxidative stress in liver and heart and improve
      their functions.
AD  - Medical Physiology Department, Faculty of Medicine, Mansoura University, PO Box: 
      35516, Mansoura, Egypt.
FAU - Abbas, Amr M
AU  - Abbas AM
FAU - Sakr, Hussein F
AU  - Sakr HF
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Physiol Biochem
JT  - Journal of physiology and biochemistry
JID - 9812509
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/11/11 [received]
PHST- 2013/03/19 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - 10.1007/s13105-013-0250-y [doi]
PST - aheadofprint
SO  - J Physiol Biochem. 2013 Apr 12.

PMID- 23580106
OWN - NLM
STAT- In-Process
DA  - 20130412
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Linking)
VI  - 19
DP  - 2013
TI  - 25-OH-Vitamin D and procalcitonin levels after correction of acute hyperglycemia.
PG  - 264-8
LID - 10.12659/MSM.883880 [doi]
AB  - BACKGROUND: Hyperglycemia is a common complication of diabetes melitis (DM) and
      in the absence of metabolic decompensation is a common finding in the Emergency
      Department (ED). We aimed to evaluate the 25 OH Vit D [25(OH)D] and procalcitonin
      (PCT) levels during hyperglycemia and after normalization of blood glucose.
      MATERIAL AND METHODS: The study included 88 patients over the age of 18 years who
      presented with acute hyperglycemia at the Hacettepe University Department of
      Emergency Medicine. Euglycemia was obtained within 6-12 hours and serum samples
      were taken from patients on admission and 6 hours after normalization of blood
      glucose. Along with plasma glucose, plasma 25(OH)D and PCT levels were measured
      using ELISA. RESULTS: There were 88 (45 males) patients, with a median age of
      60.0+/-13.9 years. Serum 25(OH)D levels increased in all patients after
      normalization of blood glucose, and serum PCT levels decreased in the whole
      group. This decrease was independent of type of diabetes or presence of
      infection. CONCLUSIONS: We demonstrated an increase in 25(OH)D after
      normalization of blood glucose, and a decrease in PCT in patients with
      hyperglycemia. This effect was independent of the type of diabetes and presence
      of infection. Further studies are needed to evaluate the faster link between
      metabolic abnormalities, vitamin D, PCT, and inflammation.
AD  - Hacettepe University, Department of Emergency Medicine, Ankara, Turkey.
      nmaksu@superposta.com
FAU - Aksu, Nalan Metin
AU  - Aksu NM
FAU - Aksoy, Duygu Yazgan
AU  - Aksoy DY
FAU - Akkas, Meltem
AU  - Akkas M
FAU - Yilmaz, Hakki
AU  - Yilmaz H
FAU - Akman, Canan
AU  - Akman C
FAU - Yildiz, Bulent Okan
AU  - Yildiz BO
FAU - Ozmen, Mahir M
AU  - Ozmen MM
FAU - Usman, Aydan
AU  - Usman A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130412
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and
      clinical research
JID - 9609063
SB  - IM
PMC - PMC3659112
OID - NLM: PMC3659112
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 883880 [pii]
AID - 10.12659/MSM.883880 [doi]
PST - epublish
SO  - Med Sci Monit. 2013 Apr 12;19:264-8. doi: 10.12659/MSM.883880.

PMID- 23580102
OWN - NLM
STAT- In-Process
DA  - 20130412
IS  - 1550-5138 (Electronic)
IS  - 0887-9311 (Linking)
VI  - 27
IP  - 3
DP  - 2013 May-Jun
TI  - Partnership among a faith-based organization and community.
PG  - 162-7
LID - 10.1097/HNP.0b013e31828a099a [doi]
AB  - In a collaborative effort, a community-based participatory research approach was 
      used to address the holistic health needs of a community while including a
      multilanguage view, a faith-based organization, The Legacy Center Community
      Development Corporation, and several health agencies partnered in organizing and 
      conducting a health fair in West Central Queens. Health awareness and health
      promotion activities were provided through presentations, health screenings, and 
      education materials (on diabetes, hypertension, nutrition, cholesterol, and heart
      disease). To meet the needs of community and/or faith-based organization members,
      translation services were available: nurses translated for non-English-speaking
      participants in Spanish, Mandarin, or Cantonese, and sign language interpreters
      used American Sign Language to translate for deaf participants.
AD  - Department of Nursing, Hunter-Bellevue School of Nursing, Hunter College, City
      University of New York, New York 10010, USA. jap@hunter.cuny.edu
FAU - Aponte, Judith
AU  - Aponte J
FAU - Cruz, Henry
AU  - Cruz H
FAU - Arce, Samuel
AU  - Arce S
FAU - Durso, Rev Michael
AU  - Durso RM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Holist Nurs Pract
JT  - Holistic nursing practice
JID - 8702105
SB  - N
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 10.1097/HNP.0b013e31828a099a [doi]
AID - 00004650-201305000-00006 [pii]
PST - ppublish
SO  - Holist Nurs Pract. 2013 May-Jun;27(3):162-7. doi: 10.1097/HNP.0b013e31828a099a.

PMID- 23580087
OWN - NLM
STAT- In-Data-Review
DA  - 20130514
IS  - 1873-4626 (Electronic)
IS  - 1091-255X (Linking)
VI  - 17
IP  - 6
DP  - 2013 Jun
TI  - Mechanism of Roux-en-Y Gastric Bypass Treatment for Type 2 Diabetes in Rats.
PG  - 1073-83
LID - 10.1007/s11605-013-2188-3 [doi]
AB  - OBJECTIVES: Roux-en-Y gastric bypass (RYGB) is a novel therapy for diabetes. We
      aimed to explore the therapeutic mechanism of RYGB. METHODS: After RYGB, animal
      models were established, and gene expression profile of islets was assessed.
      Additionally, gastrointestinal hormones were measured using enzyme-linked
      immunosorbent assays. Ca(2+) was studied using confocal microscopy and
      patch-clamp technique. The morphology of islets and beta cells was observed using
      optical microscopy and electron microscopy. RESULTS: RYGB was an effective
      treatment in diabetic rats. Expression profiling data showed that RYGB produced a
      new metabolic environment and that gene expression changed to adapt to the new
      environment. The differential expression of genes associated with hormones,
      Ca(2+) and cellular proliferation was closely related to RYGB and diabetes
      metabolism. Furthermore, the data verified that RYGB led to changes in hormone
      level and enhanced Ca(2+) concentration changes and Ca(2+) channel activity.
      Morphological data showed that RYGB induced the proliferation of islets and
      improved the function of beta cells. CONCLUSIONS: RYGB promoted a new metabolic
      environment while triggering changes to adapt to the new environment. These
      changes promoted the cellular proliferation of islets and improved the function
      of beta cells. The quantity of beta cells increased, and their quality improved, 
      ultimately leading to insulin secretion enhancement.
AD  - School of Medicine, Tsinghua University, Beijing, People's Republic of China.
FAU - Yu, Hongwei
AU  - Yu H
FAU - Zheng, Xiyan
AU  - Zheng X
FAU - Zhang, Zongming
AU  - Zhang Z
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - United States
TA  - J Gastrointest Surg
JT  - Journal of gastrointestinal surgery : official journal of the Society for Surgery
      of the Alimentary Tract
JID - 9706084
SB  - IM
PMC - PMC3653054
OID - NLM: PMC3653054
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/12/05 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - 10.1007/s11605-013-2188-3 [doi]
PST - ppublish
SO  - J Gastrointest Surg. 2013 Jun;17(6):1073-83. doi: 10.1007/s11605-013-2188-3. Epub
      2013 Apr 12.

PMID- 23580083
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 Apr 12
TI  - Effects of short-term intensive glycemic control on insulin, glucagon, and
      glucagon-like peptide-1 secretion in patients with type 2 diabetes.
AB  - Background: Short-term intensive insulin therapy in patients with type 2 diabetes
      mellitus has beneficial effects on insulin secretion. However, intensive insulin 
      therapy effect on glucagon and glucagon-like peptide-1 secretion is unknown. Aim:
      We evaluated short-term intensive glycemic control effects on insulin, glucagon, 
      and glucagon-like peptide-1 secretory dynamics in type 2 diabetes mellitus.
      Materials and Methods: Twenty-six patients with type 2 diabetes mellitus were
      hospitalized and treated with intensive insulin therapy for 10-14 days. A meal
      tolerance test was performed before and after intensive insulin therapy and the
      differences in serum immunoreactive insulin and C-peptide immunoreactivity as
      well as plasma glucagon and active glucagon-like peptide-1 levels were evaluated.
      Results: Glycoalbumin levels decreased significantly from 23.0% before to 19.6%
      after intensive insulin therapy (P < 0.001). However, pre- and post-intensive
      insulin therapy immunoreactive insulin and C-peptide immunoreactivity levels were
      not significantly different; post-intensive insulin therapy glucose levels were
      significantly decreased. The post-intensive insulin therapy glucagon levels at 0 
      and 60 min were lower than pre-intensive insulin therapy levels. Moreover,
      post-intensive insulin therapy area under the curve of glucagon significantly
      reduced from 6755 +/- 996 pg/dL.60 min to 5796 +/- 1074 pg/dL.60 min (P < 0.001).
      Furthermore, post-intensive insulin therapy glucagon-like peptide-1 levels and
      area under the curve were significantly higher than pre-intensive insulin therapy
      values. Conclusions: Our results suggest that patients with type 2 diabetes
      mellitus who received short-term intensive insulin therapy demonstrated decreased
      postprandial glucagon levels and increased glucagon-like peptide-1 levels
      following a meal tolerance test.
AD  - Departments of Internal Medicine, Iida Municipal Hospital, Nagano, Japan.
FAU - Shimodaira, Masanori
AU  - Shimodaira M
FAU - Muroya, Youhei
AU  - Muroya Y
FAU - Kumagai, Naoko
AU  - Kumagai N
FAU - Tsuzawa, Kaoru
AU  - Tsuzawa K
FAU - Honda, Kazufumi
AU  - Honda K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 8934 [pii]
AID - 10.3275/8934 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 Apr 12.

PMID- 23580027
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 Apr 12
TI  - Female sexual dysfunction in women with thyroid disorders.
AB  - Background. Few data exist on the prevalence of FSD in thyroid disorders. Aim. We
      evaluated FSD in women with thyroid diseases and in control age matched healthy
      women to investigate the relationship between sexual function, and thyroid
      hormones. Methods. One hundred and four women with thyroid diseases and 53
      controls participated in the study. Eighteen with hyperthyroidism (Group1), 22
      hypothyroidism (Group2), 45 Hashimoto's thyroiditis (Group3), 19 nodular goiter
      (Group4) underwent thyroid function evaluation and sonography. The Female Sexual 
      Function Index (FSFI) assessed sexual function. Results. The prevalence of FSD
      was 46.1% in thyroid diseases and 20.7% in controls. Only in Group4, the
      prevalence (68.4 %) was significantly higher than in controls (P < 0.005). The
      mean total FSFI score were 20.1+/-7.1 in women with thyroid diseases and
      25.6+/-4.7 in the controls (P<0.001). Compared with controls, there was a
      significant decrease of desire in Group2; desire, arousal and lubrication in
      Group3; desire, arousal, lubrication, orgasm and satisfaction in Group4. In
      thyroid diseases the prevalence of FSD was 53% and 42%, while in the controls was
      55% and 20%, in menopausal and pre-menopausal groups, respectively. We found a
      significant inverse correlation between TSH and FSFI (r =-0.7, P= 0.01) in Group 
      4, which showed the lowest FSFI score (17.8+/-5.7) and the highest BMI
      (28.4+/-7.1 Kg/m2).Conclusions: Women with thyroid diseases present a higher
      prevalence of FSD than controls. Although our findings suggest a higher
      impairment of sexual function in Group4 and a role for TSH in FSD, further
      researches are needed.
AD  - Department of Cardio-Toracic and Respiratory Sciences, Unit of Endocrinology and 
      Diabetes Clinic, Second University of Naples.
FAU - Pasquali, D
AU  - Pasquali D
FAU - Maiorino, M I
AU  - Maiorino MI
FAU - Renzullo, A
AU  - Renzullo A
FAU - Bellastella, G
AU  - Bellastella G
FAU - Accardo, G
AU  - Accardo G
FAU - Esposito, D
AU  - Esposito D
FAU - Barbato, F
AU  - Barbato F
FAU - Esposito, K
AU  - Esposito K
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 8933 [pii]
AID - 10.3275/8933 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 Apr 12.

PMID- 23580001
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
DP  - 2013 Apr 12
TI  - The efficacy of metformin in pregnant women with polycystic ovary syndrome: a
      meta-analysis of clinical trials.
AB  - Objectives: The role of metformin in the treatment of pregnant women with
      polycystic ovary syndrome is controversial. Therefore, we evaluated whether the
      use of metformin during pregnancy in women with polycystic ovary syndrome could
      reduce pregnancy-related complications. Research design and methods: MEDLINE was 
      searched to retrieve relevant trials. In addition, reviews and reference lists of
      the retrieved articles were scanned for further appropriate studies. The primary 
      outcome measure was the incidence of complications of pregnancy, which included
      early pregnancy loss, gestational diabetes, preeclampsia and preterm delivery.
      Results: In total, eight studies with 1106 patients were included. The pooled ORs
      (95% CIs) of outcome for pregnant women with polycystic ovary syndrome prescribed
      metformin were 0.32 (0.19-0.55) for early pregnancy loss, 0.37 (0.25-0.56) for
      gestational diabetes, 0.53 (0.30-0.95) for preeclampsia and 0.30 (0.13-0.68) for 
      preterm delivery. Conclusions: Metformin therapy throughout pregnancy decreased
      the ORs of early pregnancy loss, gestational diabetes, preeclampsia and preterm
      delivery in pregnant PCOS women with no serious detrimental sideeffects.
AD  - Department of Endocrinology and Metabolism, the Second Affiliated Hospital
      ZheJiang University College of Medicine, Hangzhou, Zhejiang, P.R. China.
FAU - Zheng, Jia
AU  - Zheng J
FAU - Shan, Peng-Fei
AU  - Shan PF
FAU - Gu, Wei
AU  - Gu W
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 8932 [pii]
AID - 10.3275/8932 [doi]
PST - aheadofprint
SO  - J Endocrinol Invest. 2013 Apr 12.

PMID- 23579979
OWN - NLM
STAT- Publisher
DA  - 20130422
IS  - 1536-0229 (Electronic)
IS  - 0363-9762 (Linking)
DP  - 2013 Apr 10
TI  - An Atypical Case of IgG4-Related Sclerosing Pancreatitis on PET/CT Imaging.
AB  - A 62-year-old man presented with pain in the upper abdomen persisting for 2
      months. He had the clinical history of diabetes for approximately 10 years. CT
      and MRI showed a mass located in processus uncinatus of caput pancreatis. The
      laboratory tests, including pancreas-originated amylase, tumor marker, IgG, IgG4,
      and so on, were normal. For suspicion of pancreatic cancer, the patient underwent
      F-FDG PET/CT, which demonstrated focal and high radioactivity accumulation in
      processus uncinatus of pancreas, without extrapancreatic radioactivity uptake
      observed. Finally, the surgical pathology confirmed IgG4-related sclerosing
      pancreatitis.
AD  - From the *Departments of Nuclear Medicine and daggerPathology, Zhongshan
      Hospital, Fudan University, Shanghai, China.
FAU - Han, Lei
AU  - Han L
FAU - Jiang, Lei
AU  - Jiang L
FAU - Tan, Hui
AU  - Tan H
FAU - Chen, Lingli
AU  - Chen L
FAU - Hu, Pengcheng
AU  - Hu P
FAU - Shi, Hongcheng
AU  - Shi H
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130410
TA  - Clin Nucl Med
JT  - Clinical nuclear medicine
JID - 7611109
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 10.1097/RLU.0b013e3182816752 [doi]
PST - aheadofprint
SO  - Clin Nucl Med. 2013 Apr 10.

PMID- 23579862
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 30
IP  - 4
DP  - 2013 Apr
TI  - Key advances in clinical cardiology.
PG  - 369-86
LID - 10.1007/s12325-013-0024-5 [doi]
AB  - Multiple key cardiology trials with the potential to change practice or advance
      understanding have been presented over the past 12 months at international
      meetings, including the American College of Cardiology (ACC, Chicago, USA, March 
      2012), European Association for Percutaneous Cardiovascular Interventions
      (EuroPCR, Paris, France, May 2012), European Society of Cardiology (ESC, Munich, 
      Germany, August 2012), Transcatheter Cardiovascular Therapeutics (TCT, Miami,
      USA, October 2012), and the American Heart Association (AHA, Los Angeles, USA,
      November 2012). In this paper, the authors describe and place in clinical context
      new acute coronary syndrome data, including use of oral antiplatelets and
      anticoagulants (prasugrel, rivaroxaban, vorapaxar), personalized antiplatelet
      therapy guided by platelet aggregometry, glucose-insulin-potassium infusion, and 
      changing trends in myocardial infarction. New trial data are also described for
      interventional cardiology (revascularization in multivessel disease, fractional
      flow reserve-guided intervention, radial access, bioabsorbable polymer stents,
      drug-eluting balloons, intraaortic balloon pump use, transcatheter aortic valve
      implantation), in heart failure (copeptin, angiotensin receptor neprilysin
      inhibition, aldosterone blockade in diastolic heart failure, biventricular
      pacing), atrial fibrillation (surgical ablation, antithrombotic strategy after
      stenting), implantable defibrillator use, and in prevention (renal denervation in
      hypertension, dalcetrapib, lomitapide, proprotein convertase subtilisin/kexin
      type 9 in dyslipidemia, insulin glargine/fish oils, and bariatric surgery in
      diabetes).
AD  - Craigavon Cardiac Centre, Craigavon Hospital, Southern Trust, Northern Ireland,
      BT63 5QQ, UK.
FAU - Connolly, Michael
AU  - Connolly M
FAU - Menown, Ian B A
AU  - Menown IB
LA  - eng
PT  - Journal Article
DEP - 20130409
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
SB  - T
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/02/18 [received]
PHST- 2013/04/09 [aheadofprint]
AID - 10.1007/s12325-013-0024-5 [doi]
PST - ppublish
SO  - Adv Ther. 2013 Apr;30(4):369-86. doi: 10.1007/s12325-013-0024-5. Epub 2013 Apr 9.

PMID- 23579860
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1364-548X (Electronic)
IS  - 1359-7345 (Linking)
VI  - 49
IP  - 42
DP  - 2013 Apr 30
TI  - A foldamer approach to targeting membrane bound helical states of islet amyloid
      polypeptide.
PG  - 4749-51
LID - 10.1039/c3cc41452c [doi]
AB  - A small molecule, protein mimetic based approach is shown to specifically inhibit
      lipid catalysed self-assembly of islet amyloid polypeptide (IAPP). The
      lipid-bound oligomerization of this peptide is implicated in cellular dysfunction
      of insulin secreting beta-cells in type II diabetes.
AD  - Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, 
      CT 06520, USA. Andrew.Miranker@yale.edu.
FAU - Kumar, Sunil
AU  - Kumar S
FAU - Miranker, Andrew D
AU  - Miranker AD
LA  - eng
PT  - Journal Article
PL  - England
TA  - Chem Commun (Camb)
JT  - Chemical communications (Cambridge, England)
JID - 9610838
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - 10.1039/c3cc41452c [doi]
PST - ppublish
SO  - Chem Commun (Camb). 2013 Apr 30;49(42):4749-51. doi: 10.1039/c3cc41452c.

PMID- 23579764
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1861-0692 (Electronic)
IS  - 1861-0684 (Linking)
DP  - 2013 Apr 12
TI  - Electrical myostimulation improves left ventricular function and peak oxygen
      consumption in patients with chronic heart failure: results from the exEMS study 
      comparing different stimulation strategies.
AB  - AIMS: Electromyostimulation (EMS) of thigh and gluteal muscles is a strategy to
      increase exercise capacity in patients with chronic heart failure (CHF). The aim 
      of this non-randomised pilot study was to investigate the effects of different
      stimulation strategies in CHF patients using a newly developed stimulation suit
      also involving trunk and arm muscles [extended electromyostimulation (exEMS)] in 
      comparison with EMS therapy limited to gluteal and leg muscles (limEMS). METHODS:
      60 individuals joined the EMS training programme. Stable CHF patients (NYHA class
      II-III) received either exEMS (22 patients, 15 males, mean age 59.95 +/- 13.16
      years) or limEMS (12 patients, 9 males, 62.75 +/- 8.77 years). 26 participants
      served as healthy control group (CG) receiving exEMS. Training was performed for 
      10 weeks twice weekly for 20 min, and the level of daily activity remained
      unchanged. Effects on exercise capacity, oxygen uptake, left ventricular function
      (EF) and biomarkers were evaluated. RESULTS: There was a significant increase of 
      oxygen uptake at aerobic threshold in all groups (exEMS: 13.7 +/- 3.9-17.6 +/-
      5.1 ml/kg/min (+28.46 %, p < 0.001); limEMS 13.6 +/- 3.0-16.0 +/- 3.8 ml/kg/min
      (+17.6 %, p = 0.003); CG 15.0 +/- 4.9-17.0 +/- 6.4 ml/kg/min (+13.3 %, p =
      0.005). LVEF increased from 38.3 +/- 8.4 to 43.4 +/- 8.8 % (+13.3 %, p = 0.001)
      (limEMS 37.1 +/- 3.0-39.5 +/- 5.3 % (+6.5 %, p = 0.27); CG 53.9 +/- 6.7-53.7 +/- 
      3.9 % (-0.4 %, p = 0.18). In CHF patients changes in oxygen consumption and LVEF 
      were higher in the exEMS group than in limEMS (not significant). Maximal workload
      improved in healthy controls (p = 0.002) but not in CHF patients. CONCLUSION:
      Extended EMS can improve oxygen uptake and EF in CHF. In patients with limited
      EMS and in control patients without heart failure but extended EMS, oxygen uptake
      can be improved but EF is unaltered. For all groups, NT proBNP is unaffected by
      EMS.
AD  - Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, Ruhr 
      University Bochum, Georgstr. 11, 32545, Bad Oeynhausen, Germany,
      fvbuuren@hdz-nrw.de.
FAU - van Buuren, Frank
AU  - van Buuren F
FAU - Mellwig, Klaus Peter
AU  - Mellwig KP
FAU - Prinz, Christian
AU  - Prinz C
FAU - Korber, Britta
AU  - Korber B
FAU - Frund, Andreas
AU  - Frund A
FAU - Fritzsche, Dirk
AU  - Fritzsche D
FAU - Faber, Lothar
AU  - Faber L
FAU - Kottmann, Tanja
AU  - Kottmann T
FAU - Bogunovic, Nicola
AU  - Bogunovic N
FAU - Dahm, Johannes
AU  - Dahm J
FAU - Horstkotte, Dieter
AU  - Horstkotte D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Clin Res Cardiol
JT  - Clinical research in cardiology : official journal of the German Cardiac Society
JID - 101264123
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/11/17 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - 10.1007/s00392-013-0562-5 [doi]
PST - aheadofprint
SO  - Clin Res Cardiol. 2013 Apr 12.

PMID- 23579632
OWN - NLM
STAT- In-Data-Review
DA  - 20130509
IS  - 1414-431X (Electronic)
IS  - 0100-879X (Linking)
VI  - 46
IP  - 4
DP  - 2013 Apr 12
TI  - Association of rs12255372 in the TCF7L2 gene with type 2 diabetes mellitus: a
      meta-analysis.
PG  - 382-93
LID - S0100-879X2013005032677 [pii]
AB  - Our objective was to evaluate the association of rs12255372 in the TCF7L2 gene
      with type 2 diabetes mellitus (T2DM) in the world population. We carried out a
      survey of the literature about the effect of rs12255372 on genetic susceptibility
      to T2DM by consulting PubMed, the Cochrane Library, and Embase from 2006 to 2012,
      and then performed a meta-analysis of all the studies in order to evaluate the
      association between rs12255372 and T2DM. A total of 33 articles including 42
      studies (with 34,076 cases and 36,192 controls) were confirmed to be eligible and
      were included in the final meta-analysis: 6 studies conducted on Europeans, 14 on
      Caucasians, 17 on Asians, 2 on Africans, and 3 on Americans. Overall, the effect 
      size was as follows: for the variant allele T (OR = 1.387, 95%CI = 1.351-1.424), 
      for the TT genotype (OR = 1.933, 95%CI = 1.815-2.057), for the GT genotype (OR = 
      1.363, 95%CI = 1.315-1.413), for the dominant model (OR = 1.425, 95%CI =
      1.344-1.510), and for the recessive model (OR = 1.659, 95%CI = 1.563-1.761). In
      summary, by pooling all available qualified data from genetic studies on
      rs12255372 and T2DM, we have confirmed that rs12255372 is significantly
      associated with susceptibility to T2DM in the global population.
FAU - Wang, Jinjin
AU  - Wang J
FAU - Zhang, Jianfeng
AU  - Zhang J
FAU - Li, Linlin
AU  - Li L
FAU - Wang, Yan
AU  - Wang Y
FAU - Wang, Qian
AU  - Wang Q
FAU - Zhai, Yujia
AU  - Zhai Y
FAU - You, Haifei
AU  - You H
FAU - Hu, Dongsheng
AU  - Hu D
LA  - eng
PT  - Journal Article
DEP - 20130412
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de
      pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.]
JID - 8112917
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/10/16 [received]
PHST- 2013/01/25 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - S0100-879X2013005032677 [pii]
PST - ppublish
SO  - Braz J Med Biol Res. 2013 Apr 12;46(4):382-93. Epub 2013 Apr 12.

PMID- 23579598
OWN - NLM
STAT- In-Process
DA  - 20130412
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 28
IP  - 4
DP  - 2013 Apr
TI  - Chlorogenic acid decreases retinal vascular hyperpermeability in diabetic rat
      model.
PG  - 608-13
LID - 10.3346/jkms.2013.28.4.608 [doi]
AB  - To evaluate the effect of chlorogenic acid (CGA), a polyphenol abundant in
      coffee, on retinal vascular leakage in the rat model of diabetic retinopathy,
      Sprague-Dawley rats were divided into four groups: controls,
      streptozotocin-induced diabetic rats, and diabetic rats treated with 10 and 20
      mg/kg chlorogenic acid intraperitoneally daily for 14 days, respectively.
      Blood-retinal barrier (BRB) breakdown was evaluated using FITC-dextran. Vascular 
      endothelial growth factor (VEGF) distribution and expression level was evaluated 
      with immunohistochemistry and Western blot analysis. Expression of tight junction
      proteins, occludin and claudin-5, and zonula occludens protein, ZO-1 was also
      evaluated with immunohistochemistry and Western blot analysis. BRB breakdown and 
      increased vascular leakage was found in diabetic rats, with increased VEGF
      expression and down-regulation of occludin, claudin-5, and ZO-1. CGA treatment
      effectively preserved the expression of occludin, and decreased VEGF levels,
      leading to less BRB breakdown and less vascular leakage. CGA may have a
      preventive role in BRB breakdown in diabetic retinopathy by preserving tight
      junction protein levels and low VEGF levels.
AD  - Department of Ophthalmology, Seoul National University College of Medicine, Seoul
      National University Hospital, Seoul, Korea.
FAU - Shin, Joo Young
AU  - Shin JY
FAU - Sohn, Joonhong
AU  - Sohn J
FAU - Park, Kyu Hyung
AU  - Park KH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130327
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
SB  - IM
PMC - PMC3617316
OID - NLM: PMC3617316
OTO - NOTNLM
OT  - Blood-Retinal Barrier
OT  - Chlorogenic Acid
OT  - Diabetes Rat Model
OT  - Diabetic Retinopathy
OT  - Vascular Endothelial Growth Factor
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/11/20 [received]
PHST- 2013/02/15 [accepted]
PHST- 2013/03/27 [epublish]
AID - 10.3346/jkms.2013.28.4.608 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2013 Apr;28(4):608-13. doi: 10.3346/jkms.2013.28.4.608. Epub
      2013 Mar 27.

PMID- 23579596
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130412
DCOM- 20130415
LR  - 20130415
IS  - 1662-4548 (Print)
IS  - 1662-453X (Linking)
VI  - 7
DP  - 2013
TI  - The role of leptin in the control of insulin-glucose axis.
PG  - 51
LID - 10.3389/fnins.2013.00051 [doi]
AB  - Obesity and diabetes mellitus are great public health concerns throughout the
      world because of their increasing incidence and prevalence. Leptin, the adipocyte
      hormone, is well known for its role in the regulation of food intake and energy
      expenditure. In addition to the regulation of appetite and satiety that recently 
      has attracted much attentions, insight has also been gained into the critical
      role of leptin in the control of the insulin-glucose axis, peripheral glucose and
      insulin responsiveness. Since the discovery of leptin, leptin has been taken for 
      its therapeutic potential to obesity and diabetes. Recently, the therapeutic
      effects of central leptin gene therapy have been reported in insulin-deficient
      diabetes in obesity animal models such as ob/ob mise, diet-induced obese mice,
      and insulin-deficient type 1 diabetes mice, and also in patients with
      inactivating mutations in the leptin gene. Herein, we review the role of leptin
      in regulating feeding behavior and glucose metabolism and also the therapeutic
      potential of leptin in obesity and diabetes mellitus.
AD  - Department of Psychosomatic Internal Medicine, Kagoshima University Graduate
      School of Medical and Dental Sciences Kagoshima, Japan.
FAU - Amitani, Marie
AU  - Amitani M
FAU - Asakawa, Akihiro
AU  - Asakawa A
FAU - Amitani, Haruka
AU  - Amitani H
FAU - Inui, Akio
AU  - Inui A
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - Switzerland
TA  - Front Neurosci
JT  - Frontiers in neuroscience
JID - 101478481
PMC - PMC3619125
OID - NLM: PMC3619125
OTO - NOTNLM
OT  - adipo-insulin axis
OT  - food intake
OT  - leptin
OT  - leptin gene therapy
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:01
CRDT- 2013/04/13 06:00
PHST- 2013 [ppublish]
PHST- 2012/10/30 [received]
PHST- 2013/03/18 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.3389/fnins.2013.00051 [doi]
PST - epublish
SO  - Front Neurosci. 2013 Apr 8;7:51. doi: 10.3389/fnins.2013.00051. Print 2013.

PMID- 23579541
OWN - NLM
STAT- MEDLINE
DA  - 20130412
DCOM- 20130603
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
VI  - 257
IP  - 5
DP  - 2013 May
TI  - GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y
      gastric bypass surgery in morbidly obese subjects.
PG  - 894-9
LID - 10.1097/SLA.0b013e31826b8603 [doi]
AB  - OBJECTIVE: To evaluate the association between glucagon-like peptide 1 (GLP-1)
      secretion and the long-term (>2 years) outcome of type 2 diabetes mellitus (T2DM)
      after Roux-en-Y gastric bypass (RYGBP). METHODS: Cross-sectional study in 18 T2DM
      morbidly obese subjects who underwent RYGBP but differed in the long-term outcome
      of T2DM (remission: G1, n = 6; relapse: G2, n = 6; lack of remission: G3: n = 6).
      Groups were matched for their sex, age, and body mass index. The GLP-1, glucose, 
      C-peptide, and glucagon responses to a standardized test meal (STM) were
      evaluated. Insulin secretion and insulin sensitivity were estimated from the STM 
      and by frequently sampling intravenous glucose tolerance test (FSIVGTT).
      Dual-energy X-ray absorptiometry was used to assess body composition. RESULTS:
      Patients in G1 presented a lower area under the curve (AUC0-120) of glucose in
      response to the STM as compared with G2, and G3 (P < 0.01). In contrast, the
      AUC0-120 of GLP-1 (P = 0.884) and glucagon (P = 0.630) did not differ
      significantly among the 3 groups. Indices of insulin secretion adjusted by the
      prevailing insulin sensitivity derived from STM and FSIVGTT, demonstrated larger 
      beta-cell function in subjects in G1 as compared with G2 or G3 (Disposition
      Index-STM, P = 0.005; DI-FSIVGTT, P = 0.006). Body composition and inflammatory
      markers did not differ significantly among the 3 study groups. CONCLUSIONS: Our
      data show that in subjects with T2DM an enhanced GLP-1 response to meal intake is
      not sufficient to maintain normal glucose tolerance in the long term after RYGBP.
      Our data suggest that beta-cell function is a key determinant of the long-term
      remission of T2DM after this bariatric surgery technique.
AD  - Obesity Unit, Hospital Clinic Universitari, Institut d'Investigacions Biomediques
      August Pi Sunyer (IDIBAPS), Barcelona, Spain.
FAU - Jimenez, Amanda
AU  - Jimenez A
FAU - Casamitjana, Roser
AU  - Casamitjana R
FAU - Flores, Lilliam
AU  - Flores L
FAU - Delgado, Salvadora
AU  - Delgado S
FAU - Lacy, Antonio
AU  - Lacy A
FAU - Vidal, Josep
AU  - Vidal J
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
RN  - 0 (Biological Markers)
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Insulin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-92-5 (Glucagon)
SB  - AIM
SB  - IM
MH  - Absorptiometry, Photon
MH  - Aged
MH  - Biological Markers/blood
MH  - Blood Glucose/metabolism
MH  - Body Composition
MH  - C-Peptide/blood
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/blood/complications/*surgery
MH  - Female
MH  - Follow-Up Studies
MH  - *Gastric Bypass
MH  - Glucagon/blood
MH  - Glucagon-Like Peptide 1/*blood
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - Obesity, Morbid/complications/*surgery
MH  - Treatment Outcome
EDAT- 2013/04/13 06:00
MHDA- 2013/06/05 06:00
CRDT- 2013/04/13 06:00
AID - 10.1097/SLA.0b013e31826b8603 [doi]
AID - 00000658-201305000-00016 [pii]
PST - ppublish
SO  - Ann Surg. 2013 May;257(5):894-9. doi: 10.1097/SLA.0b013e31826b8603.

PMID- 23579487
OWN - NLM
STAT- In-Data-Review
DA  - 20130520
IS  - 1944-9917 (Electronic)
IS  - 0888-8809 (Linking)
VI  - 27
IP  - 6
DP  - 2013 Jun
TI  - Cellular insulin resistance disrupts leptin-mediated control of neuronal
      signaling and transcription.
PG  - 990-1003
LID - 10.1210/me.2012-1338 [doi]
AB  - Central resistance to the actions of insulin and leptin is associated with the
      onset of obesity and type 2 diabetes mellitus, whereas leptin and insulin
      signaling is essential for both glucose and energy homeostasis. Although it is
      known that leptin resistance can lead to attenuated insulin signaling, whether
      insulin resistance can lead to or exacerbate leptin resistance is unknown. To
      investigate the molecular events underlying crosstalk between these signaling
      pathways, immortalized hypothalamic neuronal models, rHypoE-19 and mHypoA-2/10,
      were used. Prolonged insulin exposure was used to induce cellular insulin
      resistance, and thereafter leptin-mediated regulation of signal transduction and 
      gene expression was assessed. Leptin directly repressed agouti-related peptide
      mRNA levels but induced urocortin-2, insulin receptor substrate (IRS)-1, IRS2,
      and IR transcription, through leptin-mediated phosphatidylinositol 3-kinase/Akt
      activation. Neuronal insulin resistance, as assessed by attenuated Akt
      phosphorylation, blocked leptin-mediated signal transduction and agouti-related
      peptide, urocortin-2, IRS1, IRS2, and insulin receptor synthesis. Insulin
      resistance caused a substantial decrease in insulin receptor protein levels,
      forkhead box protein 1 phosphorylation, and an increase in suppressor of cytokine
      signaling 3 protein levels. Cellular insulin resistance may cause or exacerbate
      neuronal leptin resistance and, by extension, obesity. It is essential to unravel
      the effects of neuronal insulin resistance given that both peripheral, as well as
      the less widely studied central insulin resistance, may contribute to the
      development of metabolic, reproductive, and cardiovascular disorders. This study 
      provides improved understanding of the complex cellular crosstalk between
      insulin-leptin signal transduction that is disrupted during neuronal insulin
      resistance.
AD  - PhD, Department of Physiology, University of Toronto, Medical Sciences Building
      3247A, 1 Kings College Circle, Toronto, Ontario, Canada M5S 1A8.
      d.belsham@utoronto.ca.
FAU - Nazarians-Armavil, Anaies
AU  - Nazarians-Armavil A
FAU - Menchella, Jonathan A
AU  - Menchella JA
FAU - Belsham, Denise D
AU  - Belsham DD
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - United States
TA  - Mol Endocrinol
JT  - Molecular endocrinology (Baltimore, Md.)
JID - 8801431
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/04/11 [aheadofprint]
AID - me.2012-1338 [pii]
AID - 10.1210/me.2012-1338 [doi]
PST - ppublish
SO  - Mol Endocrinol. 2013 Jun;27(6):990-1003. doi: 10.1210/me.2012-1338. Epub 2013 Apr
      11.

PMID- 23579395
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1473-5644 (Electronic)
IS  - 0022-2615 (Linking)
DP  - 2013 Apr 11
TI  - Rapid diagnosis of Mycobacterium abscessus endophthalmitis.
AB  - Nontuberculous mycobacteria (NTM) are widely distributed in the environment and
      have the potential to cause a wide spectrum of infections including pulmonary,
      bone, soft tissue, or ocular infections. They are a rare cause of
      endophthalmitis, a potentially devastating condition, which may be acquired
      thorough contamination of water or antiseptic solutions. Diagnosis is often
      delayed due to low clinical suspicion resulting in poor clinical outcomes. Newer 
      laboratory techniques such as real-time polymerase chain reaction (PCR) can be
      used for rapid detection, identification, and speciation of mycobacteria and
      allows for initiation of focused antibiotic therapy. We describe a case of
      Mycobacterium abscessus endophthalmitis that developed thirty years after
      traumatic loss of cornea in a patient with diabetes mellitus.
AD  - 1 University of South Florida Morsani College of Medicine;
FAU - Rolfe, Nancy E
AU  - Rolfe NE
FAU - Garcia, Catherine
AU  - Garcia C
FAU - Widen, Raymond H
AU  - Widen RH
FAU - Taylor, Stephanie P
AU  - Taylor SP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - J Med Microbiol
JT  - Journal of medical microbiology
JID - 0224131
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - jmm.0.051771-0 [pii]
AID - 10.1099/jmm.0.051771-0 [doi]
PST - aheadofprint
SO  - J Med Microbiol. 2013 Apr 11.

PMID- 23579345
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130412
DCOM- 20130415
LR  - 20130415
IS  - 1738-3536 (Print)
IS  - 1738-3536 (Linking)
VI  - 74
IP  - 3
DP  - 2013 Mar
TI  - Risk factors influencing rebleeding after bronchial artery embolization on the
      management of hemoptysis associated with pulmonary tuberculosis.
PG  - 111-9
LID - 10.4046/trd.2013.74.3.111 [doi]
AB  - BACKGROUND: Hemoptysis due to pulmonary tuberculosis (TB) frequently develops in 
      Korea where the prevalence of TB is intermediate. The effect of bronchial artery 
      embolization (BAE) on the control of massive hemoptysis has been well known. This
      study is designed to identify the risk factors contributing to rebleeding after
      BAE in patients with TB. METHODS: We retrospectively evaluated risk factors and
      the time for rebleeding after BAE in 72 patients presenting with hemoptysis.
      RESULTS: The overall immediate success rate of BAE was 93.1% (67 of 72 patients).
      Of the 29 patients (40.3%) who showed rebleeding after BAE, 13 patients
      experienced rebleeding within 1 month, and 14 patients between 1 month to 1 year.
      The existence of a shunt in angiographic finding, aspergilloma, and diabetes
      mellitus were risk factors of rebleeding after BAE in multivariate analysis.
      CONCLUSION: BAE was very effective for obtaining immediate bleeding control in
      hemoptysis associated with active TB or post-TB sequelae. It is important to
      observe whether or not rebleeding occurs up to 1 year of BAE especially in TB
      patients with aspergilloma, DM, or a shunt. Even rebleeding can be managed well
      by second BAE.
AD  - Respiratory Devision, Department of Internal Medicine, Soonchunhyang University
      Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Korea.
FAU - Hwang, Hun-Gyu
AU  - Hwang HG
FAU - Lee, Ho-Sung
AU  - Lee HS
FAU - Choi, Jae-Sung
AU  - Choi JS
FAU - Seo, Ki-Hyun
AU  - Seo KH
FAU - Kim, Yong-Hoon
AU  - Kim YH
FAU - Na, Ju-Ock
AU  - Na JO
LA  - eng
PT  - Journal Article
DEP - 20130329
PL  - Korea (South)
TA  - Tuberc Respir Dis (Seoul)
JT  - Tuberculosis and respiratory diseases
JID - 101479418
PMC - PMC3617130
OID - NLM: PMC3617130
OTO - NOTNLM
OT  - Aspergillosis
OT  - Bronchial Arteries
OT  - Embolization, Therapeutic
OT  - Hemoptysis
OT  - Tuberculosis
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:01
CRDT- 2013/04/13 06:00
PHST- 2012/11/14 [received]
PHST- 2012/11/27 [revised]
PHST- 2013/02/26 [accepted]
PHST- 2013/03/29 [epublish]
AID - 10.4046/trd.2013.74.3.111 [doi]
PST - ppublish
SO  - Tuberc Respir Dis (Seoul). 2013 Mar;74(3):111-9. doi: 10.4046/trd.2013.74.3.111. 
      Epub 2013 Mar 29.

PMID- 23579266
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130412
DCOM- 20130415
LR  - 20130415
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 4
DP  - 2013
TI  - Biological rhythms and preeclampsia.
PG  - 47
LID - 10.3389/fendo.2013.00047 [doi]
AB  - The impact of impaired circadian rhythm on health has been widely studied in
      shift workers and trans-meridian travelers. A part from its correlation with
      sleep and mood disorders, biological rhythm impairment is a recognized risk
      factor for cardiovascular diseases and breast cancer. Preeclampsia is a major
      public health issue, associated with a significant maternal and fetal morbidity
      and mortality worldwide. While the risks factors for this condition such as
      obesity, diabetes, pre-existing hypertension have been identified, the underlying
      mechanism of this multi-factorial disease is yet not fully understood. The
      disruption of the light/dark cycle in pregnancy has been associated with adverse 
      outcomes. Slightly increased risk for "small for gestational age" babies, "low
      birth weight" babies, and preterm deliveries has been reported in shift working
      women. Whether altered circadian cycle represents a risk factor for preeclampsia 
      or preeclampsia is itself linked with an abnormal circadian cycle is less clear. 
      There are only few reports available, showing conflicting results. In this
      review, we will discuss recent observations concerning circadian pattern of blood
      pressure in normotensive and hypertensive pregnancies. We explore the hypothesis 
      that circadian misalignments may represent a risk factor for preeclampsia.
      Unraveling potential link between circadian clock gene and preeclampsia could
      offer a novel approach to our understanding of this multi-system disease specific
      to pregnancy.
AD  - Hypertension Unit, Division of Endocrinology, Diabetes, Hypertension and
      Nutrition, Department of Specialties of Medicine and Primary Care, Hopitaux
      Universitaires de Geneve Geneva, Switzerland.
FAU - Ditisheim, Agnes J
AU  - Ditisheim AJ
FAU - Dibner, Charna
AU  - Dibner C
FAU - Philippe, Jacques
AU  - Philippe J
FAU - Pechere-Bertschi, Antoinette
AU  - Pechere-Bertschi A
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
PMC - PMC3619120
OID - NLM: PMC3619120
OTO - NOTNLM
OT  - circadian clock
OT  - preeclampsia
OT  - pregnancy
OT  - shift work
OT  - women health
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:01
CRDT- 2013/04/13 06:00
PHST- 2013 [ppublish]
PHST- 2012/12/23 [received]
PHST- 2013/03/26 [accepted]
PHST- 2013/04/08 [epublish]
AID - 10.3389/fendo.2013.00047 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2013 Apr 8;4:47. doi: 10.3389/fendo.2013.00047.
      Print 2013.

PMID- 23579248
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 0920-9069 (Print)
IS  - 0920-9069 (Linking)
DP  - 2013 Apr 12
TI  - Carvacrol partially reverses symptoms of diabetes in STZ-induced diabetic rats.
AB  - Little is known about the protective effects of carvacrol on the symptoms of
      streptozotocin induced diabetes in rats. Hence, this present study was designed
      to evaluate the protective effect of the strong antioxidant, carvacrol, on the
      symptoms of streptozotocin induced diabetes in rats. Carvacrol at the doses of 25
      and 50 mg/kg body weight were orally administered to diabetic rats for a period
      of 7 days after the onset of diabetes. Food-water intake and body weight changes 
      were daily recorded. Biochemical parameters such as serum glucose, insulin, total
      cholesterol, alanine aminotransferase, aspartate aminotransferase and lactate
      dehydrogenase were measured. Although treatment of diabetic rats with oral
      administration of carvacrol resulted in a slight reduction in serum glucose level
      and significant reduction in serum total cholesterol, alanine aminotransferase,
      aspartate aminotransferase and lactate dehydrogenase in comparison with diabetic 
      control rats, there were no significant differences in serum insulin levels,
      food-water intake values and body weight changes. Despite the inadequacy of
      carvacrol on diabetes treatments, it was determined to have at least a partially 
      protective role on liver enzymes.
AD  - Science and Arts Faculty, Department of Biology, Artvin Coruh University, 08000, 
      Artvin, Turkey, gbayramoglu@artvin.edu.tr.
FAU - Bayramoglu, Gokhan
AU  - Bayramoglu G
FAU - Senturk, Hakan
AU  - Senturk H
FAU - Bayramoglu, Aysegul
AU  - Bayramoglu A
FAU - Uyanoglu, Mustafa
AU  - Uyanoglu M
FAU - Colak, Suat
AU  - Colak S
FAU - Ozmen, Ayse
AU  - Ozmen A
FAU - Kolankaya, Durdane
AU  - Kolankaya D
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130412
TA  - Cytotechnology
JT  - Cytotechnology
JID - 8807027
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/03/02 [received]
PHST- 2013/04/03 [accepted]
PHST- 2013/04/12 [aheadofprint]
AID - 10.1007/s10616-013-9563-5 [doi]
PST - aheadofprint
SO  - Cytotechnology. 2013 Apr 12.

PMID- 23579186
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1535-9484 (Electronic)
IS  - 1535-9476 (Linking)
DP  - 2013 Apr 11
TI  - Protein sets define disease states and predict in vivo effects of drug treatment.
AB  - Gaining understanding of common complex diseases and their treatments are the
      main drivers for life sciences. As we show here, comprehensive protein set
      analyses offer new opportunities to decipher functional molecular networks of
      diseases and assess the efficacy and side-effects of treatments in vivo. Using
      mass spectrometry, we quantitatively detected several thousand proteins and
      observed significant changes in protein pathway (dys-) regulated in diet-induced 
      obesity mice. Analysis of the expression and posttranslational modifications of
      proteins in various peripheral metabolic target tissues including adipose, heart 
      and liver tissue generated functional insights in the regulation of cell and
      tissue homeostasis during high fat diet and medication with two anti-diabetic
      compounds. Protein set analyses singled out pathways for functional
      characterization, and indicated for example early on potential cardiovascular
      complication of the diabetes drug rosiglitazone. In vivo protein set detection
      can provide new avenues for monitoring complex disease processes, and for
      evaluating preclinical drug candidates.
AD  - Max-Planck-Institute for Molecular Genetics, Germany;
FAU - Meierhofer, David
AU  - Meierhofer D
FAU - Weidner, Christopher
AU  - Weidner C
FAU - Hartmann, Ludger
AU  - Hartmann L
FAU - Mayr, Johannes A
AU  - Mayr JA
FAU - Han, Chung-Ting
AU  - Han CT
FAU - Schroeder, Frank C
AU  - Schroeder FC
FAU - Sauer, Sascha
AU  - Sauer S
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Mol Cell Proteomics
JT  - Molecular & cellular proteomics : MCP
JID - 101125647
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - M112.025031 [pii]
AID - 10.1074/mcp.M112.025031 [doi]
PST - aheadofprint
SO  - Mol Cell Proteomics. 2013 Apr 11.

PMID- 23579182
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 11
TI  - Clinical and Subclinical Macrovascular Disease as Predictors of Cognitive Decline
      in Older Patients With Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study.
AB  - OBJECTIVEMacrovascular disease may contribute to increased risk of accelerated
      cognitive decline in patients with type 2 diabetes. We aimed to determine
      associations of measures of macrovascular disease with cognitive change in a
      cognitively healthy older population with type 2 diabetes.RESEARCH DESIGN AND
      METHODSEight-hundred thirty-one men and women (aged 60-75 years) attended two
      waves of the prospective Edinburgh Type 2 Diabetes Study (ET2DS). At baseline,
      clinical and subclinical macrovascular disease was measured, including
      cardiovascular event history, carotid intima-media thickness (cIMT), ankle
      brachial index (ABI), and serum N-terminal probrain natriuretic peptide
      (NT-proBNP). Seven neuropsychological tests were administered at baseline and
      after 4 years; scores were combined to a standardized general ability factor (g).
      Adjustment of follow-up g for baseline g assessed 4-year cognitive change.
      Adjustment for vocabulary (estimated premorbid ability) was used to estimate
      lifetime cognitive change.RESULTSMeasures of cognitive decline were significantly
      associated with stroke, NT-proBNP, ABI, and cIMT, but not with nonstroke vascular
      events. The association of stroke with increased estimated lifetime cognitive
      decline (standardized beta, -0.12) and of subclinical markers with actual 4-year 
      decline (standardized beta, -0.12, 0.12, and -0.15 for NT-proBNP, ABI, and cIMT, 
      respectively) reached the Bonferroni-adjusted level of statistical significance
      (P < 0.006). Results altered only slightly on adjustment for vascular risk
      factors.CONCLUSIONSStroke and subclinical markers of cardiac stress and
      generalized atherosclerosis are associated with cognitive decline in older
      patients with type 2 diabetes. Further investigation into the potential use of
      subclinical vascular disease markers in predicting cognitive decline is
      warranted.
AD  - Centre for Population Health Sciences, University of Edinburgh, Edinburgh,
      Scotland, United Kingdom.
FAU - Feinkohl, Insa
AU  - Feinkohl I
FAU - Keller, Marketa
AU  - Keller M
FAU - Robertson, Christine M
AU  - Robertson CM
FAU - Morling, Joanne R
AU  - Morling JR
FAU - Williamson, Rachel M
AU  - Williamson RM
FAU - Nee, Lisa D
AU  - Nee LD
FAU - McLachlan, Stela
AU  - McLachlan S
FAU - Sattar, Naveed
AU  - Sattar N
FAU - Welsh, Paul
AU  - Welsh P
FAU - Reynolds, Rebecca M
AU  - Reynolds RM
FAU - Russ, Tom C
AU  - Russ TC
FAU - Deary, Ian J
AU  - Deary IJ
FAU - Strachan, Mark W J
AU  - Strachan MW
FAU - Price, Jackie F
AU  - Price JF
CN  - On behalf of the Edinburgh Type 2 Diabetes Study (ET2DS) Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - dc12-2241 [pii]
AID - 10.2337/dc12-2241 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 11.

PMID- 23579181
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 11
TI  - Structure-Function Relationship Between Corneal Nerves and Conventional
      Small-Fiber Tests in Type 1 Diabetes.
AB  - OBJECTIVEIn vivo corneal confocal microscopy (IVCCM) has been proposed as a
      noninvasive technique to assess small nerve fiber structural morphology. We
      investigated the structure-function relationship of small fibers in diabetic
      sensorimotor polyneuropathy (DSP).RESEARCH DESIGN AND METHODSNinety-six type 1
      diabetic subjects with a spectrum of clinical DSP and 64 healthy volunteers
      underwent IVCCM examinations to determine corneal nerve structure, including
      corneal nerve fiber length (CNFL), fiber density (CNFD), branch density (CNBD),
      and fiber tortuosity (CNFT). Small nerve fiber function was assessed by cooling
      detection thresholds (CDTs), axon reflex-mediated neurogenic vasodilatation in
      response to cutaneous heating by laser Doppler imaging flare technique
      (LDIFLARE), and heart rate variability (HRV). Linear associations between
      structural and functional measures in type 1 diabetic subjects were determined
      using Spearman correlation coefficients and linear regression analysis.RESULTSOf 
      the type 1 diabetic subjects, with a mean age of 38.2 +/- 15.5 years and a mean
      HbA1c of 7.9 +/- 1.4%, 33 (34%) had DSP according to the consensus definition.
      Modest correlations were observed between CNFL, CNFD, and CNBD and all functional
      small-fiber tests (rs = 0.25 to 0.41; P </= 0.01 for all comparisons). For
      example, quantitatively every 1 mm/mm2 lower CNFL was associated with a 0.61
      degrees C lower CDT, a 0.07 cm2 lower LDIFLARE area, and a 1.78% lower HRV. No
      significant associations were observed for CNFT and the functional small-fiber
      measures.CONCLUSIONS Small nerve fiber structural morphology assessed by IVCCM
      correlated well with functional measures of small nerve fiber injury. In
      particular, CNFL, CNFD, and CNBD demonstrated clear structure-function
      relationships.
AD  - Division of Endocrinology and Metabolism, Department of Medicine, University of
      Toronto, Toronto, Ontario, Canada.
FAU - Sivaskandarajah, Gavasker A
AU  - Sivaskandarajah GA
FAU - Halpern, Elise M
AU  - Halpern EM
FAU - Lovblom, Leif E
AU  - Lovblom LE
FAU - Weisman, Alanna
AU  - Weisman A
FAU - Orlov, Steven
AU  - Orlov S
FAU - Bril, Vera
AU  - Bril V
FAU - Perkins, Bruce A
AU  - Perkins BA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - dc12-2075 [pii]
AID - 10.2337/dc12-2075 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 11.

PMID- 23579180
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 11
TI  - Independent and Combined Association of Muscle Strength and Cardiorespiratory
      Fitness in Youth With Insulin Resistance and beta-Cell Function in Young
      Adulthood: The European Youth Heart Study.
AB  - OBJECTIVETo examine the independent and combined association of isometric muscle 
      strength of the abdomen and back and cardiorespiratory fitness (CRF) in youth
      with indices of glucose metabolism in young adulthood among boys and girls from
      the European Youth Heart Study.RESEARCH DESIGN AND METHODSWe used data from a
      population-based prospective cohort study among youth followed-up for up to 12
      years (n = 317). In youth, maximal voluntary contractions during isometric back
      extension and abdominal flexion were determined using a strain-gauge dynamometer 
      and CRF was obtained from a maximal cycle ergometer test. Insulin resistance
      (homeostasis model assessment of insulin resistance [HOMA-IR]) and beta-cell
      function (homeostasis model assessment of beta-cell function [HOMA-B]) were
      estimated from fasting serum insulin and glucose that were obtained in youth and 
      at follow-up in young adulthood.RESULTSFor each 1-SD difference in isometric
      muscle strength (0.16 N/kg) in youth, fasting insulin, HOMA-IR, and HOMA-B in
      young adulthood changed with -11.3% (95% CI, -17.0 to -5.2), -12.2% (-18.2 to
      -5.7), and -8.9% (-14.4 to -3.0), respectively, in young adulthood after
      adjustment for CRF and personal lifestyle and demographic factors. Results for
      CRF were very similar in magnitude, and the magnitude of associations for both
      exposures was unchanged with additional adjustment for general or abdominal
      adiposity in youth. Combined associations of muscle strength and CRF with fasting
      insulin, HOMA-IR, and HOMA-B were additive, and adolescents in the highest
      sex-specific tertile for both isometric muscle strength and CRF had the lowest
      levels of these glucose metabolism outcomes.CONCLUSIONSIncreasing muscle strength
      and CRF should be targets in youth primordial prevention strategies of insulin
      resistance and beta-cell dysfunction.
AD  - Institute of Sport Science and Clinical Biomechanics, Research Unit for Exercise 
      Epidemiology, Centre of Research in Childhood Health, University of Southern
      Denmark, Odense M, Denmark.
FAU - Grontved, Anders
AU  - Grontved A
FAU - Ried-Larsen, Mathias
AU  - Ried-Larsen M
FAU - Ekelund, Ulf
AU  - Ekelund U
FAU - Froberg, Karsten
AU  - Froberg K
FAU - Brage, Soren
AU  - Brage S
FAU - Andersen, Lars B
AU  - Andersen LB
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - dc12-2252 [pii]
AID - 10.2337/dc12-2252 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 11.

PMID- 23579179
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 11
TI  - Internet Psycho-Education Programs Improve Outcomes in for Youth With Type 1
      Diabetes.
AB  - OBJECTIVEThe purpose of this study was to determine the efficacy of two
      internet-based psycho-educational programs designed to improve outcomes for youth
      with type 1 diabetes transitioning to adolescence.RESEARCH DESIGN AND METHODSThe 
      study was a multisite clinical trial of 320 youth (age 11-14 years; 37% minority;
      55% female) randomized to one of two internet-based interventions: TeenCope or
      Managing Diabetes. Primary outcomes were HbA1c and quality of life (QOL).
      Secondary outcomes included coping, self-efficacy, social competence,
      self-management, and family conflict. Data were collected at baseline and after
      3, 6, and 12 months online. Youth were invited to cross over to the other program
      after 12 months, and follow-up data were collected at 18 months. Analyses were
      based on mixed models using intent-to-treat and per-protocol
      procedures.RESULTSYouth in both groups had stable QOL and minimal increases in
      HbA1c levels over 12 months, but there were no significant differences between
      the groups in primary outcomes. After 18 months, youth who completed both
      programs had lower HbA1c (P = 0.04); higher QOL (P = 0.02), social acceptance (P 
      = 0.01), and self-efficacy (P = 0.03) and lower perceived stress (P = 0.02) and
      diabetes family conflict (P = 0.02) compared with those who completed only one
      program.CONCLUSIONSInternet interventions for youth with type 1 diabetes
      transitioning to adolescence result in improved outcomes, but completion of both 
      programs was better than only one, suggesting that these youth need both diabetes
      management education and behavioral interventions. Delivering these programs via 
      the internet represents an efficient way to reach youth and improve outcomes.
AD  - Yale University School of Nursing, New Haven, Connecticut.
FAU - Grey, Margaret
AU  - Grey M
FAU - Whittemore, Robin
AU  - Whittemore R
FAU - Jeon, Sangchoon
AU  - Jeon S
FAU - Murphy, Kathryn
AU  - Murphy K
FAU - Faulkner, Melissa S
AU  - Faulkner MS
FAU - Delamater, Alan
AU  - Delamater A
CN  - for the TeenCope Study Group
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - dc12-2199 [pii]
AID - 10.2337/dc12-2199 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 11.

PMID- 23579178
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 11
TI  - Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin
      When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.
AB  - OBJECTIVETo assess glucose-lowering mechanisms of sitagliptin (S), metformin (M),
      and the two combined (M+S).RESEARCH DESIGN AND METHODSWe randomized 16 patients
      with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), 
      M, S, and M+S. After each period, subjects received a 6-h meal tolerance test
      (MTT) with [14C]glucose to calculate glucose kinetics. Fasting plasma glucose
      (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting 
      plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal
      insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 +/- 4 
      to M, 150 +/- 4; S, 154 +/- 4; and M+S, 125 +/- 3 mg/dL. Mean post-MTT PG
      decreased from P, 207 +/- 5 to M, 191 +/- 4; S, 195 +/- 4; and M+S, 161 +/- 3
      mg/dL (P < 0.01]. The increase in mean post-MTT plasma insulin and in ISR was
      similar in P, M, and S and slightly greater in M+S. Fasting plasma glucagon was
      equal ( approximately 65-75 pg/mL) with all treatments, but there was a
      significant drop during the initial 120 min with S 24% and M+S 34% (both P <
      0.05) vs. P 17% and M 16%. Fasting and mean post-MTT plasma bioactive GLP-1 were 
      higher (P < 0.01) after S and M+S vs. M and P. Basal endogenous glucose
      production (EGP) fell from P 2.0 +/- 0.1 to S 1.8 +/- 0.1 mg/kg min, M 1.8 +/-
      0.2 mg/kg min [both P < 0.05 vs. P), and M+S 1.5 +/- 0.1 mg/kg min (P < 0.01 vs. 
      P). Although the EGP slope of decline was faster in M and M+S vs. S, all had
      comparable greater post-MTT EGP inhibition vs. P (P < 0.05).CONCLUSIONSM+S
      combined produce additive effects to 1) reduce FPG and postmeal PG, 2) augment
      GLP-1 secretion and beta-cell function, 3) decrease plasma glucagon, and 4)
      inhibit fasting and postmeal EGP compared with M or S monotherapy.
AD  - University of Texas Health Science Center, Texas Diabetes Institute, San Antonio,
      Texas.
FAU - Solis-Herrera, Carolina
AU  - Solis-Herrera C
FAU - Triplitt, Curtis
AU  - Triplitt C
FAU - Garduno-Garcia, Jose de Jesus
AU  - Garduno-Garcia JD
FAU - Adams, John
AU  - Adams J
FAU - Defronzo, Ralph A
AU  - Defronzo RA
FAU - Cersosimo, Eugenio
AU  - Cersosimo E
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - dc12-2072 [pii]
AID - 10.2337/dc12-2072 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 11.

PMID- 23579177
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2013 Apr 11
TI  - Skin Autofluorescence Reflects Integration of Past Long-Term Glycemic Control in 
      Patients With Type 1 Diabetes.
AB  - OBJECTIVEThe aim was to investigate the relationships between skin
      autofluorescence (AF) and the impact of past glycemic control and microvascular
      complications in Japanese patients with type 1 diabetes.RESEARCH DESIGN AND
      METHODSTwo hundred forty-one patients and 110 controls were enrolled. Advanced
      glycation end product accumulation was measured with AF reader. Three monthly
      HbA1c levels during the past 20 years were determined from medical records, and
      the HbA1c area under the curve (AUC) was calculated. We performed multivariate
      regression analyses to examine the associations between the severity of diabetes 
      complications and various variables.RESULTSSkin AF values increased with
      increasing the severity of retinopathy (P < 10-11, linear regression analysis)
      and nephropathy (P < 10-5 for chronic kidney disease stage; P < 10-5 for
      albuminuria-based stage). HbA1c AUC values over the past 15 years were
      significantly correlated with skin AF values (past 5 years: R = 0.35, P < 0.0001;
      past 10 years: R = 0.36, P < 0.0001; past 15 years: R = 0.55, P < 0.0001; past 20
      years: R = 0.22, P = 0.13). HbA1c AUC values over the past 3, 5, 10, and 15 years
      were significantly associated with the severity of both nephropathy and
      retinopathy. Multivariate analyses in which HbA1c AUC value was removed from the 
      independent variables indicated that only skin AF was independently associated
      with nephropathy, whereas age at registration, age at onset of diabetes, and skin
      AF were independently associated with retinopathy.CONCLUSIONSkin AF reflects past
      long-term glycemic control and may serve as a surrogate marker for the
      development of microvascular complications in place of HbA1c AUC value.
AD  - Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo,
      Japan.
FAU - Sugisawa, Eri
AU  - Sugisawa E
FAU - Miura, Junnosuke
AU  - Miura J
FAU - Iwamoto, Yasuhiko
AU  - Iwamoto Y
FAU - Uchigata, Yasuko
AU  - Uchigata Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - dc12-1077 [pii]
AID - 10.2337/dc12-1077 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2013 Apr 11.

PMID- 23579096
OWN - NLM
STAT- Publisher
DA  - 20130521
IS  - 1878-5875 (Electronic)
IS  - 1357-2725 (Linking)
VI  - 45
IP  - 7
DP  - 2013 Apr 8
TI  - Amadori products promote cellular senescence activating insulin-like growth
      factor-1 receptor and down-regulating the antioxidant enzyme catalase.
PG  - 1255-1264
LID - S1357-2725(13)00093-9 [pii]
LID - 10.1016/j.biocel.2013.03.018 [doi]
AB  - Activation of the insulin growth factor receptor-1 signaling pathways has been
      largely related to the aging process. Amadori products are produced in
      pathological conditions such as diabetes and aging, and are potentially involved 
      in diabetic nephropathy or age-associated decline of renal function. We
      hypothesize that Amadori products induce senescence in primary human mesangial
      cells through the activation of IGF-1 receptor and investigate, in the present
      work, the intracellular mechanism involved after this activation. We treated
      cultured human mesangial cells with glycated albumin, one of the most abundant
      Amadori product, and senescence was assessed by determining the senescence
      associated beta-galactosidase activity and the expression of the cell cycle
      regulators p53 and p21. We demonstrated that prolonged exposition (more than 24h)
      to glycated albumin induced senescence and, in parallel, incremented the release 
      of IGF-1 and the activation of the IGF-1 receptor. Inhibition of the IGF-1
      activation prevented the GA induced senescence. Activation of IGF-1R, after GA
      addition, promoted a reduction in the catalase content through the constitutive
      activation of Ras and erk1/2 proteins which were, in turn, responsible of the
      observed GA-induced senescence. In conclusion, we propose that the Amadori
      product, glycated albumin, promotes premature cell senescence in mesangial cells 
      through the activation of the IGF-1 receptor and the subsequent reduction in the 
      antioxidant enzyme catalase.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Department of Physiology, University of Alcala, Alcala de Henares, Madrid 28871, 
      Spain; Reina Sofia Institutute of Nephrology Research (IRSIN), Spain; RedinREn
      from ISCIII, Madrid, Spain.
FAU - Del Nogal-Avila, Maria
AU  - Del Nogal-Avila M
FAU - Troyano-Suarez, Nuria
AU  - Troyano-Suarez N
FAU - Roman-Garcia, Pablo
AU  - Roman-Garcia P
FAU - Cannata-Andia, Jorge B
AU  - Cannata-Andia JB
FAU - Rodriguez-Puyol, Manuel
AU  - Rodriguez-Puyol M
FAU - Rodriguez-Puyol, Diego
AU  - Rodriguez-Puyol D
FAU - Kuro-O, Makoto
AU  - Kuro-O M
FAU - Ruiz-Torres, Maria P
AU  - Ruiz-Torres MP
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130408
TA  - Int J Biochem Cell Biol
JT  - The international journal of biochemistry & cell biology
JID - 9508482
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/11/16 [received]
PHST- 2013/03/08 [revised]
PHST- 2013/03/28 [accepted]
AID - S1357-2725(13)00093-9 [pii]
AID - 10.1016/j.biocel.2013.03.018 [doi]
PST - aheadofprint
SO  - Int J Biochem Cell Biol. 2013 Apr 8;45(7):1255-1264. doi:
      10.1016/j.biocel.2013.03.018.

PMID- 23579070
OWN - NLM
STAT- In-Data-Review
DA  - 20130610
IS  - 0006-3002 (Print)
IS  - 0006-3002 (Linking)
VI  - 1832
IP  - 8
DP  - 2013 Aug
TI  - miR-135a targets IRS2 and regulates insulin signaling and glucose uptake in the
      diabetic gastrocnemius skeletal muscle.
PG  - 1294-303
LID - 10.1016/j.bbadis.2013.03.021 [doi]
LID - S0925-4439(13)00104-X [pii]
AB  - Although aberrant miRNA signatures are associated with diabetes, yet, the status 
      and role of altered miRNAs in the diabetic skeletal muscle is currently poorly
      understood. Here, we report that 41 miRNAs are altered in the diabetic
      gastrocnemius skeletal muscle and of these, miR-135a that is identified as a
      critical regulator of myogenesis, is significantly up-regulated. IRS2 is
      predicted as its potential putative target and its levels are down-regulated in
      the diabetic gastrocnemius skeletal muscle. In C2C12 cells, while miR-135a levels
      decreased during differentiation, IRS2 levels were up-regulated. miR-135a
      significantly reduced IRS2 protein levels and its 3'UTR luciferase reporter
      activity and these were blunted by the miR-135a inhibitor and mutation in the
      miR-135a binding site. Knock-down of endogenous miR-135a levels increased IRS2 at
      the mRNA and protein levels. miR-135a also attenuated insulin stimulated
      phosphorylation and activation of PI3Kp85alpha and Akt and glucose uptake.
      miR-135a levels were also found to be elevated in the human diabetic skeletal
      muscle. In-vivo silencing of miR-135a alleviated hyperglycemia, improved glucose 
      tolerance and significantly restored the levels of IRS2 and p-Akt in the
      gastrocnemius skeletal muscle of db/db mice without any effect on their hepatic
      levels. These suggest that miR-135a targets IRS2 levels by binding to its 3'UTR
      and this interaction regulates skeletal muscle insulin signaling.
CI  - Copyright (c) 2013 Elsevier B.V. All rights reserved.
AD  - CSIR-Institute of Genomics and Integrative Biology, Mall Road, Delhi-110 007,
      India; Department of Biochemistry, Jamia Hamdard, Hamdard Nagar, New Delhi-110
      062, India.
FAU - Agarwal, Priyanka
AU  - Agarwal P
FAU - Srivastava, Rohit
AU  - Srivastava R
FAU - Srivastava, Arvind K
AU  - Srivastava AK
FAU - Ali, Shakir
AU  - Ali S
FAU - Datta, Malabika
AU  - Datta M
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - Netherlands
TA  - Biochim Biophys Acta
JT  - Biochimica et biophysica acta
JID - 0217513
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/01/18 [received]
PHST- 2013/03/06 [revised]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/08 [aheadofprint]
AID - S0925-4439(13)00104-X [pii]
AID - 10.1016/j.bbadis.2013.03.021 [doi]
PST - ppublish
SO  - Biochim Biophys Acta. 2013 Aug;1832(8):1294-303. doi:
      10.1016/j.bbadis.2013.03.021. Epub 2013 Apr 8.

PMID- 23579029
OWN - NLM
STAT- In-Process
DA  - 20130429
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 62
IP  - 2
DP  - 2013 May
TI  - Protective effect of interleukin-23A (IL23A) haplotype variants on type 1A
      diabetes mellitus in a Brazilian population.
PG  - 327-33
LID - 10.1016/j.cyto.2013.03.015 [doi]
LID - S1043-4666(13)00117-8 [pii]
AB  - The Interleukin 23 (IL-23) has a central role in autoimmunity. Allelic variants
      of p19 subunit of IL-23 (IL23A) and IL-23 receptor (IL23R) genes and increased
      IL-23 serum concentrations were associated with autoimmune diseases. We therefore
      searched for variants of IL23A and IL23R that could predispose to Type 1 diabetes
      (T1D). The coding regions and boundary intron sequences of IL23A were sequenced. 
      Variants of IL23A and of IL23R were also genotyped. Pancreatic and
      extrapancreatic autoantibodies and IL-23 serum levels were determined. The cohort
      involved 370 patients with T1D and 351 healthy control subjects. We observed only
      one coding IL23A variant (rs11171806 G>A) out of the 6 described in databases. As
      the G alleles of rs11171806 and rs2066808 variants of IL23A gene were in strong
      linkage disequilibrium (D'=-0.825 for controls, p<2.0 x 10(-6) and D'=-0.902,
      p<2.0 x 10(-17) for patients), further analyses were performed with the
      haplotypes. The GG haplotype was more frequent in controls (16.7%) than in T1D
      patients (9.5%), conferring a protection to T1D (OR=0.53; pc=0.0003). No
      association was found between IL23A allelic variants with age at diagnosis of
      diabetes, C-peptide levels or frequency of autoantibodies. IL23R variants
      (rs10889677 and rs11209026) frequency and IL-23 serum concentrations were similar
      between groups. The GG haplotype of lL23A variants (rs11171806 and rs2066808) was
      protective against T1D. IL23R variants (rs11209026 and rs10889677) were not
      associated with T1D. IL-23 serum concentrations did not differ between groups.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Laboratorio de Carboidratos e Radioimunoensaio (LIM18), Faculdade de Medicina da 
      Universidade de Sao Paulo, Departamento de Endocrinologia, Brazil.
      vinicius.scosta@usp.br
FAU - Costa, V S
AU  - Costa VS
FAU - Santos, A S
AU  - Santos AS
FAU - Fukui, R T
AU  - Fukui RT
FAU - Mattana, T C C
AU  - Mattana TC
FAU - Matioli, S R
AU  - Matioli SR
FAU - Silva, M E R
AU  - Silva ME
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130409
PL  - United States
TA  - Cytokine
JT  - Cytokine
JID - 9005353
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/12/13 [received]
PHST- 2013/03/07 [revised]
PHST- 2013/03/10 [accepted]
PHST- 2013/04/09 [aheadofprint]
AID - S1043-4666(13)00117-8 [pii]
AID - 10.1016/j.cyto.2013.03.015 [doi]
PST - ppublish
SO  - Cytokine. 2013 May;62(2):327-33. doi: 10.1016/j.cyto.2013.03.015. Epub 2013 Apr
      9.

PMID- 23579026
OWN - NLM
STAT- Publisher
DA  - 20130610
IS  - 1873-4596 (Electronic)
IS  - 0891-5849 (Linking)
VI  - 61C
DP  - 2013 Apr 8
TI  - Methylglyoxal-induced modification of arginine residues decreases the activity of
      NADPH-generating enzymes.
PG  - 229-242
LID - S0891-5849(13)00130-5 [pii]
LID - 10.1016/j.freeradbiomed.2013.03.025 [doi]
AB  - Inadequate control of plasma and cellular glucose and ketone levels in diabetes
      is associated with increased generation of reactive aldehydes, including
      methylglyoxal (MGO). These aldehydes react with protein side chains to form
      advanced glycation end-products (AGEs). Arg residues are particularly susceptible
      to MGO glycation and are essential for binding NADP+ in several enzymes that
      generate NADPH, a coenzyme for many critical metabolic and antioxidant enzymes.
      In most animal cells, NADPH is produced predominantly by glucose-6-phosphate
      dehydrogenase (G6PD) in the oxidative phase of the pentose phosphate pathway and,
      to a lesser extent, by isocitrate dehydrogenase (IDH) and malic enzyme (ME). In
      this study, the activities of isolated G6PD, IDH, and ME were inhibited by MGO
      (0-2.5mM, 2-3h, 37 degrees C), in a dose- and time-dependent manner, with G6PD
      and IDH more sensitive to modification than ME. Significant inhibition of these
      two enzymes occurred with MGO levels >/=500muM. Incubation with radiolabeled MGO 
      (0-500microM, 0-3h, 37 degrees C) demonstrated dose- and time-dependent adduction
      to G6PD and IDH. HPLC analysis provided evidence for AGE formation and
      particularly the hydroimidazolones MG-H1 and MG-H2 from Arg residues, with
      corresponding loss of parent Arg residues. Peptide mass mapping studies confirmed
      hydroimidazolone formation on multiple peptides in G6PD and IDH, including those 
      critical for NADP+ binding, and substrate binding, in the case of IDH. These
      results suggest that modification of NADPH-producing enzymes by reactive
      aldehydes may result in alterations to the cellular redox environment,
      potentially predisposing cells to further damage by oxidants and reactive
      aldehydes.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Free Radical Group, The Heart Research Institute, Newtown, NSW 2042, Australia;
      Faculty of Medicine, University of Sydney, Sydney, NSW 2006, Australia.
      Electronic address: morganp@hri.org.au.
FAU - Morgan, Philip E
AU  - Morgan PE
FAU - Sheahan, Pamela J
AU  - Sheahan PJ
FAU - Pattison, David I
AU  - Pattison DI
FAU - Davies, Michael J
AU  - Davies MJ
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130408
TA  - Free Radic Biol Med
JT  - Free radical biology & medicine
JID - 8709159
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/07/11 [received]
PHST- 2013/03/25 [revised]
PHST- 2013/03/28 [accepted]
AID - S0891-5849(13)00130-5 [pii]
AID - 10.1016/j.freeradbiomed.2013.03.025 [doi]
PST - aheadofprint
SO  - Free Radic Biol Med. 2013 Apr 8;61C:229-242. doi:
      10.1016/j.freeradbiomed.2013.03.025.

PMID- 23578994
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2013 Apr 11
TI  - Pancreatic beta-cell response to increased metabolic demand and to pharmacologic 
      secretagogues requires EPAC2A.
AB  - Incretin hormone action on ss-cells stimulates in parallel two different
      intracellular cyclic AMP-dependent signaling branches mediated by PKA and EPAC2A.
      Both pathways contribute towards potentiation of glucose-stimulated insulin
      secretion (GSIS). However, the overall functional role of EPAC2A in ss-cells as
      it relates to in vivo glucose homeostasis remains incompletely understood.
      Therefore, we have examined in vivo GSIS in global EPAC2A knockout mice.
      Additionally, we have conducted in vitro studies of GSIS and calcium dynamics in 
      isolated EPAC2A-deficient islets. EPAC2A deficiency does not impact
      glucose-stimulated insulin secretion in mice under basal conditions. However,
      when mice are exposed to diet-induced insulin resistance, pharmacologic
      secretagogue stimulation of ss-cells with an incretin hormone glucagon-like
      peptide-1 analogue or with a Fatty Acid Receptor 1/GPR40 selective activator,
      EPAC2A is required for the increased ss-cell response to secretory demand. Under 
      these circumstances, EPAC2A is required for potentiating the early dynamic
      increase in islet calcium levels after glucose stimulation, which is reflected in
      potentiated first phase insulin secretion. These studies broaden our
      understanding of EPAC2A function and highlight its significance during increased 
      secretory demand or drive on ss-cells. Our findings advance the rationale for
      developing EPAC2A selective pharmacologic activators for ss-cell targeted
      pharmacotherapy in type 2 diabetes mellitus.
AD  - Department of Pediatrics, Johns Hopkins University.
FAU - Song, Woo-Jin
AU  - Song WJ
FAU - Mondal, Prosenjit
AU  - Mondal P
FAU - Li, Yuanyuan
AU  - Li Y
FAU - Lee, Suh Eun
AU  - Lee SE
FAU - Hussain, Mehboob A
AU  - Hussain MA
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
AID - db12-1394 [pii]
AID - 10.2337/db12-1394 [doi]
PST - aheadofprint
SO  - Diabetes. 2013 Apr 11.

PMID- 23578806
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1479-666X (Electronic)
IS  - 1479-666X (Linking)
DP  - 2013 Apr 8
TI  - Fournier's gangrene.
LID - S1479-666X(13)00012-7 [pii]
LID - 10.1016/j.surge.2013.02.001 [doi]
AB  - Fournier's gangrene (FG) is a synergistic polymicrobial gangrenous infection of
      the perineum, scrotum and penis which is characterised by obliterative
      endarteritis of the subcutaneous arteries, resulting in gangrene of the
      subcutaneous tissue and the overlying skin. FG affects all ages and both genders,
      with a male preponderance. It is a rare but life-threatening disease, and despite
      therapeutic advances in recent years, the mortality rate is 3%-67%, with an
      incidence of 1:7500-1:750,000. Anorectal, genitourinary and cutaneous sources of 
      infection are the most common causes of FG, with diabetes mellitus being the most
      common risk factor. The clinical condition presents evolution from 2 to 7 days
      and is characterised by uneasiness, local swelling and discomfort, fever,
      crepitus and sometimes frank septic shock. Current imaging techniques for initial
      evaluation of the disease include radiography, Ultrasonography (USG), Computed
      Tomography (CT) and Magnetic Resonance Imaging (MRI). However, the diagnosis of
      FG is usually clinical and imaging can be helpful in uncertain diagnosis and when
      clinical findings are ambiguous. Treatment of FG is based on a multimodal
      approach which includes intensive fluid resuscitation to stabilise the patient
      and correction of electrolyte imbalance, if any. This is followed by extensive
      debridements and resections in order to remove all necrotic and infected tissue, 
      wide spectrum antibiotics and reconstructive surgery, whenever required. However,
      despite all the advances in treatment today, FG remains a surgical emergency,
      hence, early recognition with aggressive haemodynamic stabilisation, parenteral
      broad spectrum antibiotics and urgent surgical debridement are the mainstay of
      treatment.
CI  - Copyright (c) 2013 Royal College of Surgeons of Edinburgh (Scottish charity
      number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier 
      Ltd. All rights reserved.
AD  - Department of General Surgery, North Eastern Indira Gandhi Regional Institute of 
      Health and Medical Sciences, India. Electronic address: devajit_cs@yahoo.com.
FAU - Shyam, Devajit Chowlek
AU  - Shyam DC
FAU - Rapsang, Amy Grace
AU  - Rapsang AG
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130408
TA  - Surgeon
JT  - The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
JID - 101168329
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/11/02 [received]
PHST- 2013/01/30 [revised]
PHST- 2013/02/01 [accepted]
AID - S1479-666X(13)00012-7 [pii]
AID - 10.1016/j.surge.2013.02.001 [doi]
PST - aheadofprint
SO  - Surgeon. 2013 Apr 8. pii: S1479-666X(13)00012-7. doi:
      10.1016/j.surge.2013.02.001.

PMID- 23578754
OWN - NLM
STAT- In-Process
DA  - 20130422
IS  - 1532-2238 (Electronic)
IS  - 1096-6374 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Jun
TI  - An ocular view of the IGF-IGFBP system.
PG  - 45-52
LID - 10.1016/j.ghir.2013.03.001 [doi]
LID - S1096-6374(13)00018-X [pii]
AB  - IGFs and their binding proteins have been shown to exhibit both protective and
      deleterious effects in ocular disease. Recent studies have characterized the
      expression patterns of different IGFBPs in retinal layers and within the
      vitreous. IGFBP-3 has roles in vascular protection stimulating proliferation,
      migration, and differentiation of vascular progenitor cells to sites of injury.
      IGFBP-3 increases pericyte ensheathment and shows anti-inflammatory effects by
      reducing microglia activation in diabetes. IGFBP-5 has recently been linked to
      mediating fibrosis in proliferative vitreoretinopathy but also reduces
      neovascularization. Thus, the regulatory balance between IGF and IGFBPs can have 
      profound impact on target tissues. This review discusses recent findings of IGF
      and IGFBP expression in the eye with relevance to different retinopathies.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
AD  - Department of Pharmacology and Therapeutics, College of Medicine, University of
      Florida, Gainesville, FL, USA.
FAU - Nguyen, Dung V
AU  - Nguyen DV
FAU - Li Calzi, Sergio
AU  - Li Calzi S
FAU - Shaw, Lynn C
AU  - Shaw LC
FAU - Kielczewski, Jennifer L
AU  - Kielczewski JL
FAU - Korah, Hannah E
AU  - Korah HE
FAU - Grant, Maria B
AU  - Grant MB
LA  - eng
GR  - R01 DK090730/DK/NIDDK NIH HHS/United States
GR  - R01 DK090730/DK/NIDDK NIH HHS/United States
GR  - R01 EY007739/EY/NEI NIH HHS/United States
GR  - R01 EY007739/EY/NEI NIH HHS/United States
GR  - R01 EY012601/EY/NEI NIH HHS/United States
GR  - R01 EY12601/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130408
PL  - Scotland
TA  - Growth Horm IGF Res
JT  - Growth hormone & IGF research : official journal of the Growth Hormone Research
      Society and the International IGF Research Society
JID - 9814320
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/08/21 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/03/13 [accepted]
PHST- 2013/04/08 [aheadofprint]
AID - S1096-6374(13)00018-X [pii]
AID - 10.1016/j.ghir.2013.03.001 [doi]
PST - ppublish
SO  - Growth Horm IGF Res. 2013 Jun;23(3):45-52. doi: 10.1016/j.ghir.2013.03.001. Epub 
      2013 Apr 8.

PMID- 23578643
OWN - NLM
STAT- In-Process
DA  - 20130412
IS  - 0308-8146 (Print)
IS  - 0308-8146 (Linking)
VI  - 140
IP  - 1-2
DP  - 2013 Sep 1
TI  - Effect of 5-hydroxymethylfurfural derived from processed Cornus officinalis on
      the prevention of high glucose-induced oxidative stress in human umbilical vein
      endothelial cells and its mechanism.
PG  - 273-9
LID - 10.1016/j.foodchem.2012.11.143 [doi]
LID - S0308-8146(13)00167-2 [pii]
AB  - The aim of this study was to investigate the protective effect of 5-HMF on human 
      umbilical vein endothelial cells (HUVECs) injured by high glucose in vitro, and
      the mechanism underlying this process. Our results demonstrated that high
      glucose-induced oxidative stress in HUVECs was mainly mediated through activation
      of reactive oxygen species (ROS), Jun N-kinase 2/3 (JNK2/3) and plasma
      interleukin-8 (IL-8), and inactivation of phosphorylated protein kinase B
      (P-Akt). Treatment of HUVECs with media containing high glucose (4.5%) in the
      presence of 5-HMF (100, 200 and 400 muM) resulted in significant inhibition of
      high glucose-induced oxidative stress and expression of JNK1 and JNK2/3.
      Furthermore, 5-HMF rapidly inhibited high glucose-induced activation of IL-8, a
      downstream activator of P-Akt. Diabetes mellitus can cause a wide variety of
      vascular complications and high glucose can induce vascular endothelial cell
      apoptosis. Free radicals are formed disproportionately in diabetes by glucose
      oxidation. The finding of this study highlights the pharmacological application
      of 5-HMF for preventing cardiovascular and diabetes mellitus diseases, and
      provides the theoretical basis for further development of a Cornus officinalis
      agent for diabetes-associated vascular diseases.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
AD  - Research Center of TCM Processing Technology, Zhejiang Chinese Medical
      University, Hangzhou 310053, PR China.
FAU - Cao, Gang
AU  - Cao G
FAU - Cai, Hao
AU  - Cai H
FAU - Cai, Baochang
AU  - Cai B
FAU - Tu, Sicong
AU  - Tu S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130224
PL  - England
TA  - Food Chem
JT  - Food chemistry
JID - 7702639
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/07/26 [received]
PHST- 2012/10/19 [revised]
PHST- 2012/11/20 [accepted]
PHST- 2013/02/24 [aheadofprint]
AID - S0308-8146(13)00167-2 [pii]
AID - 10.1016/j.foodchem.2012.11.143 [doi]
PST - ppublish
SO  - Food Chem. 2013 Sep 1;140(1-2):273-9. doi: 10.1016/j.foodchem.2012.11.143. Epub
      2013 Feb 24.

PMID- 23578605
OWN - NLM
STAT- In-Data-Review
DA  - 20130521
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 5
DP  - 2013 May
TI  - A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability 
      and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes.
PG  - 634-645.e1
LID - 10.1016/j.clinthera.2013.03.011 [doi]
LID - S0149-2918(13)00123-9 [pii]
AB  - BACKGROUND: Exenatide, a glucagon-like peptide-1 receptor agonist administered by
      self-injection, decreases plasma glucose, glycosylated hemoglobin (HbA1c), and
      weight in patients with type 2 diabetes. ITCA 650 is an investigational new drug 
      that provides continuous subcutaneous delivery of exenatide. OBJECTIVE: This
      randomized, open-label, multicenter, 28-day study evaluated the tolerability,
      pharmacodynamics, and pharmacokinetics of ITCA 650 in patients with type 2
      diabetes. METHODS: The study enrolled patients with type 2 diabetes who were
      receiving a stable regimen of diet and exercise alone or a stable dose of
      metformin monotherapy, thiazolidinedione monotherapy, or metformin plus
      thiazolidinedione combination therapy. Patients were randomized to receive 10,
      20, 40, or 80 mug/d of ITCA 650 placed subcutaneously for 28 days. Plasma
      glucose, HbA1c, insulin, and weight were measured at regular intervals throughout
      the study. Exenatide levels and anti-exenatide antibodies were also assessed.
      RESULTS: Forty-four patients were randomized to treatment. From baseline to end
      point, significant (P < 0.05) decreases in fasting plasma glucose levels, 2-hour 
      postprandial glucose levels, and glucose AUC curve were seen in all treatment
      groups. HbA1c levels also decreased significantly (P < 0.001) in all 4 treatment 
      groups. Weight was significantly (P < 0.05) lowered in the 40- and 80-mug/d
      groups. Detectable levels of exenatide were noted within 12 to 24 hours of ITCA
      650 placement, reached steady state by 24 hours, and then remained relatively
      steady during a plateau period until device removal on day 29. Exenatide levels
      declined to undetectable levels within 24 hours after removal of the ITCA 650.
      The most common adverse events were nausea, decreased appetite, and vomiting;
      these were transient and mostly mild or moderate in severity. Mild local adverse 
      events related to the healing process were common at the placement site but
      abated after 1 week. Twelve patients developed anti-exenatide antibodies;
      however, the pharmacokinetics of ITCA 650 were not altered compared with those
      who did not develop antibodies. CONCLUSIONS: ITCA 650 provided continuous and
      controlled subcutaneous delivery of exenatide for 28 days that was generally well
      tolerated and produced significant reductions in plasma glucose, HbA1c, and
      weight. Further studies are warranted to characterize the long-term tolerability 
      and efficacy of ITCA 650 for the treatment of patients with type 2 diabetes.
      ClinicalTrials.gov identifier: NCT01798264.
CI  - Copyright (c) 2013 Elsevier HS Journals, Inc. All rights reserved.
AD  - University of California, San Diego, La Jolla, California, and Center for
      Metabolic Research, VA San Diego Healthcare System, San Diego, California.
FAU - Henry, Robert R
AU  - Henry RR
FAU - Logan, Douglas
AU  - Logan D
FAU - Alessi, Thomas
AU  - Alessi T
FAU - Baron, Michelle A
AU  - Baron MA
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/02/28 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/15 [accepted]
PHST- 2013/04/08 [aheadofprint]
AID - S0149-2918(13)00123-9 [pii]
AID - 10.1016/j.clinthera.2013.03.011 [doi]
PST - ppublish
SO  - Clin Ther. 2013 May;35(5):634-645.e1. doi: 10.1016/j.clinthera.2013.03.011. Epub 
      2013 Apr 8.

PMID- 23578478
OWN - NLM
STAT- Publisher
DA  - 20130423
IS  - 1878-1810 (Electronic)
IS  - 1878-1810 (Linking)
DP  - 2013 Apr 8
TI  - Urine output and resultant osmotic water shift are major determinants of plasma
      sodium level in syndrome of inappropriate antidiuretic hormone secretion.
LID - S1931-5244(13)00080-7 [pii]
LID - 10.1016/j.trsl.2013.03.007 [doi]
AB  - Although various formulas predicting plasma sodium level ([Na]) are proposed for 
      correction of hyponatremia, it seems that an anticipated [Na] frequently exceeds 
      or falls below the measured [Na], especially in syndrome of inappropriate
      antidiuretic hormone secretion (SIADH). The causative factors of the fluctuation 
      have never been investigated clearly. The aim of this study was to identify the
      determining factors for accurate prediction of [Na] by comparing data from
      previously proposed formulas and a novel osmotic compartment model (O-C model).
      The O-C model, which simulates the amounts of osmoles in extracellular and
      intracellular fluids, can estimate resultant osmotic water shift (OWS) and [Na]. 
      The accuracy of representative formulas was verified in a point-to-point study
      using blood and urine samples obtained every 4 hours from 9 patients. Among 161
      measurement points, a large fluctuation of urine volume and urine sodium level
      was observed. The gap between anticipated and measured [Na] in the widely used
      Adrogue-Madias formula was -0.5 +/- 0.1 mEq/L/4 h (mean +/- standard error),
      showing a marked tendency to underestimate [Na]. The gap in the O-C model
      including OWS was 0.1 +/- 0.1 mEq/L/4 h, and that in the O-C model eliminating
      OWS was 1.9 +/- 0.2 mEq/L/4 h, indicating that measurement of urine output and
      estimation of resulting OWS are essential for a superior prediction of [Na] in
      SIADH. A simulation study with the O-C model including OWS unveiled a distinctive
      correction pattern of [Na] dependent on the urine volume and urine sodium level, 
      providing a useful choice for the proper type and rate of infusion.
CI  - Copyright (c) 2013 Mosby, Inc. All rights reserved.
AD  - Department of Endocrinology and Diabetes, Okazaki City Hospital, Okazaki, Aichi
      Prefecture, Japan; and the Department of Endocrinology and Diabetes, Nagoya
      University Graduate School of Medicine, Nagoya, Aichi Prefecture, Japan.
      Electronic address: aokumura-endo@umin.net.
FAU - Okumura, Ataru
AU  - Okumura A
FAU - Ishikawa, Kota
AU  - Ishikawa K
FAU - Watanabe, Risako
AU  - Watanabe R
FAU - Tsunekawa, Taku
AU  - Tsunekawa T
FAU - Asai, Chikako
AU  - Asai C
FAU - Kiyota, Atsushi
AU  - Kiyota A
FAU - Watanabe, Minemori
AU  - Watanabe M
FAU - Oiso, Yutaka
AU  - Oiso Y
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130408
TA  - Transl Res
JT  - Translational research : the journal of laboratory and clinical medicine
JID - 101280339
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/09/23 [received]
PHST- 2013/02/04 [revised]
PHST- 2013/03/16 [accepted]
AID - S1931-5244(13)00080-7 [pii]
AID - 10.1016/j.trsl.2013.03.007 [doi]
PST - aheadofprint
SO  - Transl Res. 2013 Apr 8. pii: S1931-5244(13)00080-7. doi:
      10.1016/j.trsl.2013.03.007.

PMID- 23578417
OWN - NLM
STAT- In-Data-Review
DA  - 20130430
IS  - 1557-9034 (Electronic)
IS  - 1092-6429 (Linking)
VI  - 23
IP  - 5
DP  - 2013 May
TI  - Analysis of predictive risk factors for postoperative complications of
      laparoscopy-assisted distal gastrectomy.
PG  - 425-30
LID - 10.1089/lap.2012.0374 [doi]
AB  - Abstract Background: Despite the popularity of laparoscopic-assisted distal
      gastrectomy (LADG), studies have reported a high incidence of postoperative
      complications in patients who have had LADG. The present study explores the
      preoperative risk factors for complications from LADG. Patients and Methods: This
      study involves 1257 patients who underwent standardized LADG in a single
      institution between January 2006 and June 2011. The risk factors for
      postoperative complications of LADG were evaluated by univariate and multivariate
      analyses. Results: In univariate analysis of overall postoperative complications,
      there were significant effects of age (above 65 years), obesity (a body mass
      index above 25 kg/m(2)), comorbidity, cerebrovascular disease, heart disease,
      hypertension, diabetes mellitus, and combined comorbidities (three or more).
      Multivariate analysis of these risk factors showed that old age (P=.006), obesity
      (P<.001), and heart disease (P=.014) were independent risk factors for
      postoperative complications. Univariate analysis showed that obesity also had a
      significant effect on severe postoperative complications. Conclusions: Older age,
      obesity, and heart disease are risk factors for postoperative complications after
      LADG. Greater caution or more limited surgery is required to reduce the high rate
      of complications in patients with these risk factors.
AD  - 1 Department of Gastric Surgery, Asan Medical Center, Ulsan University School of 
      Medicine , Seoul, Korea.
FAU - Kim, Hee Sung
AU  - Kim HS
FAU - Kim, Min Gyu
AU  - Kim MG
FAU - Kim, Beom Su
AU  - Kim BS
FAU - Lee, In Seob
AU  - Lee IS
FAU - Lee, Sol
AU  - Lee S
FAU - Yook, Jeoung Hwan
AU  - Yook JH
FAU - Kim, Byung Sik
AU  - Kim BS
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - United States
TA  - J Laparoendosc Adv Surg Tech A
JT  - Journal of laparoendoscopic & advanced surgical techniques. Part A
JID - 9706293
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/04/11 [aheadofprint]
AID - 10.1089/lap.2012.0374 [doi]
PST - ppublish
SO  - J Laparoendosc Adv Surg Tech A. 2013 May;23(5):425-30. doi:
      10.1089/lap.2012.0374. Epub 2013 Apr 11.

PMID- 23578397
OWN - NLM
STAT- Publisher
DA  - 20130508
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 4
IP  - 2
DP  - 2013 Apr 11
TI  - Identification of p63+ keratinocyte progenitor cells in circulation and their
      matrix-directed differentiation to epithelial cells.
PG  - 38
AB  - INTRODUCTION: In the event of chronic diabetes or burn wounds, accomplishing skin
      regeneration is a major concern. Autologous skin grafting is the most effective
      remedy, but the tissue harvest may create more nonhealing wounds. Currently
      available skin substitutes have a limited clinical outcome because of immune
      reactions arising from the xenobiotic scaffold or allogenous cells. Autologous
      stem cells that can be collected without an additional injury may be a viable
      option for skin-tissue engineering. Presence of a low number of keratinocyte
      progenitor cells (KPCs) within the peripheral blood mononuclear cell (PBMNC)
      population has been indicated. Identification, isolation, expansion, and
      differentiation of KPCs is necessary before they are considered for skin
      regeneration, which is the focus of this study. METHODS: Culture of isolated
      human PBMNCs on a cell-specific matrix was carried out to induce differentiation 
      of KPCs. Flow cytometry and reverse transcriptase polymerase chain reaction were 
      done for epithelial stem cell marker p63 and lineage markers cytokeratin 5 and
      cytokeratin 14, to track differentiation. Proliferation was confirmed by
      quantifying the proliferating cell nuclear antigen-expressing cells.
      Immunostaining with epithelial cell markers, involucrin and filaggrin, was
      carried out to establish terminal differentiation. Microscopic analysis confirmed
      growth and survival of KPCs on the dermal fibroblast monolayer and on a
      transplantable fibrin sheet. RESULTS: We demonstrated that KPCs are p63+ and
      CD34-. The specifically designed composition of the extracellular matrix was
      found to support selective adhesion, proliferation, and differentiation of p63+
      KPCs. The PBMNC culture for 12 days under controlled conditions resulted in a
      homogenous population that expressed cytokeratins, and >90% of the cells were
      found to proliferate. Subculture for 5 days resulted in expression of filaggrin
      and involucrin, suggesting terminal differentiation. Transfer of matrix-selected 
      KPCs to a dermal fibroblast monolayer or fibrin supported cell proliferation and 
      showed typical hexagonal morphology of keratinocytes within 15 days. CONCLUSIONS:
      Circulating KPCs were identified with p63, which differentiated into
      keratinocytes with expression of the cytokeratins, involucrin and filaggrin.
      Components of the specifically designed matrix favored KPC attachment, directed
      differentiation, and may turn out to be a potential vehicle for cell
      transplantation.
AD  - Thrombosis Research Unit, Biomedical Technology Wing, Sree Chitra Tirunal
      Institute for Medical Sciences and Technology, Trivandrum, 695012, India.
      lissykk@sctimst.ac.in.
FAU - Nair, Renjith P
AU  - Nair RP
FAU - Krishnan, Lissy K
AU  - Krishnan LK
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/12/18 [received]
PHST- 2013/03/12 [revised]
PHST- 2013/03/20 [accepted]
PHST- 2013/04/11 [aheadofprint]
AID - scrt186 [pii]
AID - 10.1186/scrt186 [doi]
PST - aheadofprint
SO  - Stem Cell Res Ther. 2013 Apr 11;4(2):38.

PMID- 23578364
OWN - NLM
STAT- In-Data-Review
DA  - 20130508
IS  - 1520-5118 (Electronic)
IS  - 0021-8561 (Linking)
VI  - 61
IP  - 18
DP  - 2013 May 8
TI  - Dietary flavonol epicatechin prevents the onset of type 1 diabetes in nonobese
      diabetic mice.
PG  - 4303-9
LID - 10.1021/jf304915h [doi]
AB  - Type 1 diabetes (T1D) is an autoimmune disease characterized by the selective
      destruction of pancreatic beta-cells. Although successful islet transplantation
      provides a promising treatment, high cost, lack of donor organs, immune-mediated 
      destruction of transplanted islets, and side effects from immunosuppressive drugs
      greatly limit its uses. Therefore, the search for novel and cost-effective agents
      that can prevent or ameliorate T1D is extremely important to decrease the burden 
      of T1D. In this study, we discovered that epicatechin (EC, 0.5% in drinking
      water), a flavonol primarily in cocoa, effectively prevented T1D in nonobese
      diabetic (NOD) mice. At 32 weeks of age, 66.7% of control mice had overt
      diabetes, whereas only 16.6% of EC-treated mice became diabetic. Consistently, EC
      mice had significantly higher plasma insulin levels but lower glycosylated
      hemoglobin concentrations compared to control mice. EC had no significant effects
      on food or water intake and body weight gain in NOD mice, suggesting that EC's
      effect was not due to alterations in these variables. Treatment with EC elevates 
      circulating anti-inflammatory cytokine interleukin-10 levels, ameliorates
      pancreatic insulitis, and improves pancreatic islet mass. These findings
      demonstrate that EC may be a novel, plant-derived compound capable of preventing 
      T1D by modulating immune function and thereby preserving islet mass.
AD  - Department of Human Nutrition, Foods and Exercise, College of Agriculture and
      Life Sciences, Virginia Tech , Blacksburg, Virginia 24061, United States.
FAU - Fu, Zhuo
AU  - Fu Z
FAU - Yuskavage, Julia
AU  - Yuskavage J
FAU - Liu, Dongmin
AU  - Liu D
LA  - eng
PT  - Journal Article
DEP - 20130430
PL  - United States
TA  - J Agric Food Chem
JT  - Journal of agricultural and food chemistry
JID - 0374755
SB  - IM
PMC - PMC3660227
MID - NIHMS468440
OID - NLM: NIHMS468440 [Available on 05/08/14]
OID - NLM: PMC3660227 [Available on 05/08/14]
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PMCR- 2014/05/08 00:00
PHST- 2013/04/30 [aheadofprint]
AID - 10.1021/jf304915h [doi]
PST - ppublish
SO  - J Agric Food Chem. 2013 May 8;61(18):4303-9. doi: 10.1021/jf304915h. Epub 2013
      Apr 30.

PMID- 23578350
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
DP  - 2013 Apr 8
TI  - Exercise Stress Tests for Detecting Myocardial Ischemia in Asymptomatic Patients 
      With Diabetes Mellitus.
LID - S0002-9149(13)00702-9 [pii]
LID - 10.1016/j.amjcard.2013.02.047 [doi]
AB  - The predominant cause of death in diabetes mellitus (DM) is coronary artery
      disease (CAD). Little is known about prevalence of silent ischemia in developing 
      nations. We compared prevalence of silent ischemia in DM to a control group by
      exercise myocardial perfusion imaging (MPI) and electrocardiogram (ECG) in
      developing nations. The prospective multinational Ischemia Assessment with
      Exercise imaging in Asymptomatic Diabetes study recruited participants at 12
      sites in Asia, Africa, and Latin America. DM participants were age- and
      gender-matched 2:1 to non-DM individuals with >/=1 CAD risk factor. Subjects
      underwent exercise tests that were interpreted in core labs in blinded fashion.
      The study included 392 DM and 205 control participants. Among participants with
      diagnostic ECGs, a similar proportion of DM and controls had ischemic ECG (15% vs
      12%, p = 0.5). A significantly higher proportion of DM group had MPI
      abnormalities compared with controls (26% vs 14%, p <0.001). In participants with
      ischemia on MPI, only 17% had ischemic ECG, whereas in those without ischemia on 
      MPI, 10% had ischemic ECG. In a multivariable model, DM was independently
      associated with abnormal MPI (odds ratio 2.1, 95% confidence interval 1.3-3.5, p 
      = 0.004). Women were less likely to have ischemia by MPI than men (10% vs 30%, p 
      <0.001) and concordance between ECG and MPI was much worse in women. In
      conclusion, in this large prospective study, asymptomatic DM participants had (1)
      more ischemia by exercise MPI than ECG, (2) more ischemia by MPI but not ECG than
      control group, and (3) ischemia by MPI was less in women than men.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - University of Alabama at Birmingham, Birmingham, Alabama; Birmingham Veterans
      Affairs Medical Center, Birmingham, Alabama. Electronic address:
      fadihage@uab.edu.
FAU - Hage, Fadi G
AU  - Hage FG
FAU - Lusa, Lara
AU  - Lusa L
FAU - Dondi, Maurizio
AU  - Dondi M
FAU - Giubbini, Raffaele
AU  - Giubbini R
FAU - Iskandrian, Ami E
AU  - Iskandrian AE
CN  - IAEA Diabetes Investigators
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130408
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/12/03 [received]
PHST- 2013/02/28 [revised]
PHST- 2013/02/28 [accepted]
AID - S0002-9149(13)00702-9 [pii]
AID - 10.1016/j.amjcard.2013.02.047 [doi]
PST - aheadofprint
SO  - Am J Cardiol. 2013 Apr 8. pii: S0002-9149(13)00702-9. doi:
      10.1016/j.amjcard.2013.02.047.

PMID- 23578347
OWN - NLM
STAT- In-Data-Review
DA  - 20130517
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 111
IP  - 11
DP  - 2013 Jun 1
TI  - Functional aerobic capacity in patients with sleep-disordered breathing.
PG  - 1650-4
LID - 10.1016/j.amjcard.2013.02.008 [doi]
LID - S0002-9149(13)00542-0 [pii]
AB  - Few studies have examined exercise capacity or cardiovascular responses to
      maximal exercise testing and recovery in patients with sleep-disordered breathing
      (SDB), and results from these studies are conflicting. The objective of this
      cross-sectional study conducted at a tertiary referral center was to examine the 
      association between SDB and exercise testing outcomes independent of body mass
      index (BMI) and other cardiopulmonary risk factors. Between January 1, 2005 and
      January 1, 2010, 1,424 adults underwent exercise testing and within 6 months
      before first-time diagnostic polysomnography. Subjects were categorized by
      apnea-hypopnea index (AHI) into 4 groups: <5, 5 to 14, 15 to 29, and >/=30. A
      logistic regression model incorporated age, gender, BMI, smoking, hypertension,
      diabetes, beta-blocker use, and cardiac and pulmonary disease as covariates. The 
      primary variable of interest was functional aerobic capacity (FAC). Mean age was 
      56.4 +/- 12.4 years; 75% were men. Mean BMI was 32.4 +/- 7.1 kg/m(2), and mean
      AHI 19.5 +/- 22.1 per hour. On multivariate analysis, AHI as a continuous
      variable showed a negative correlation with FAC (R(2)adj = 0.30, p <0.001) and
      postexercise SBP (R(2)adj = 0.23, p = 0.03), and positively correlated with
      resting and peak DBP (R(2)adj = 0.09, p = 0.01 and R(2)adj = 0.09, p = 0.04
      respectively). When comparing patients with severe SDB (AHI >/=30) with those
      without SDB (AHI <5), FAC and heart rate recovery were significantly lower, and
      resting, peak, and postexercise DBP were higher in those with severe apnea (all p
      <0.05), after accounting for confounders. In conclusion, SDB severity was
      associated with reduced FAC and increased resting and peak DBP. Even after
      accounting for confounders, severe SDB was associated with attenuated FAC,
      impaired heart rate recovery, and higher resting, peak, and postexercise DBP.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
AD  - Center for Sleep Medicine, Mayo Clinic, Minnesota.
FAU - Mansukhani, Meghna P
AU  - Mansukhani MP
FAU - Allison, Thomas G
AU  - Allison TG
FAU - Lopez-Jimenez, Francisco
AU  - Lopez-Jimenez F
FAU - Somers, Virend K
AU  - Somers VK
FAU - Caples, Sean M
AU  - Caples SM
LA  - eng
PT  - Journal Article
DEP - 20130408
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
SB  - AIM
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/11/27 [received]
PHST- 2013/02/05 [revised]
PHST- 2013/02/05 [accepted]
PHST- 2013/04/08 [aheadofprint]
AID - S0002-9149(13)00542-0 [pii]
AID - 10.1016/j.amjcard.2013.02.008 [doi]
PST - ppublish
SO  - Am J Cardiol. 2013 Jun 1;111(11):1650-4. doi: 10.1016/j.amjcard.2013.02.008. Epub
      2013 Apr 8.

PMID- 23578341
OWN - NLM
STAT- Publisher
DA  - 20130412
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
IP  - 1
DP  - 2013 Apr 11
TI  - Asymmetric dimethylarginine predicts decline of glucose tolerance in men with
      stable coronary artery disease: a 4.5-year follow-up study.
PG  - 64
AB  - BACKGROUND: Endothelial dysfunction, largely dependent on impaired nitric oxide
      bioavailability, has been reportedly associated with incident type 2 diabetes.
      Our aim was to test the hypothesis that asymmetric dimethylarginine (ADMA), an
      endogenous inhibitor of nitric oxide formation, might be linked to future
      deterioration in glucose tolerance in stable coronary artery disease (CAD).
      METHODS: We studied 80 non-diabetic men (mean age 55 +/- 11 years) with stable
      angina who underwent successful elective complex coronary angioplasty and were
      receiving a standard medical according to practice guidelines. Plasma ADMA and
      its structural isomer symmetric dimethylarginine (SDMA) were measured prior to
      coronary angiography. An estimate of insulin resistance by homeostasis model
      assessment (HOMA-IR index) was calculated from fasting insulin and glucose.
      Deterioration in glucose tolerance was defined as development of type 2 diabetes 
      or progression from a normal glucose tolerance to impaired fasting glucose.
      RESULTS: Over a median follow-up of 55 months 11 subjects developed type 2
      diabetes and 13 progressed to impaired fasting glucose. Incident deterioration of
      glucose tolerance was associated with ADMA (hazard ratio [HR] per 1-SD increment 
      1.64 [95% CI: 1.14--2.35]; P = 0.007), log (HOMA-IR index) (HR = 1.60
      [1.16--2.20]; P = 0.004) and body-mass index (HR = 1.44 [0.95--2.17]; P = 0.08)
      by univariate Cox regression. ADMA (HR = 1.65 [1.14--2.38]; p = 0.008) and log
      (HOMA-IR index) (HR = 1.55 [1.10--2.17]; P = 0.01) were multivariate predictors
      of a decline in glucose tolerance. ADMA and SDMA were unrelated to body-mass
      index, HOMA-IR index, insulin or glucose. CONCLUSIONS: ADMA predicts future
      deterioration of glucose tolerance independently of baseline insulin resistance
      in men with stable CAD. Whether this association reflects a contribution of
      endothelial dysfunction to accelerated decline of insulin sensitivity, or
      represents only an epiphenomenon accompanying pre-diabetes, remains to be
      elucidated. The observed relationship might contribute to the well-recognized
      ability of ADMA to predict cardiovascular outcome.
FAU - Surdacki, Andrzej
AU  - Surdacki A
FAU - Kruszelnicka, Olga
AU  - Kruszelnicka O
FAU - Rakowski, Tomasz
AU  - Rakowski T
FAU - Ja Wi Ska-Kozuba, Aleksandra
AU  - Ja Wi Ska-Kozuba A
FAU - Dubiel, Jacek S
AU  - Dubiel JS
LA  - ENG
PT  - JOURNAL ARTICLE
DEP - 20130411
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
PMC - PMC3642017
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/02/26 [received]
PHST- 2013/04/11 [accepted]
PHST- 2013/04/11 [aheadofprint]
AID - 1475-2840-12-64 [pii]
AID - 10.1186/1475-2840-12-64 [doi]
PST - aheadofprint
SO  - Cardiovasc Diabetol. 2013 Apr 11;12(1):64.

PMID- 23578325
OWN - NLM
STAT- In-Process
DA  - 20130426
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 12
DP  - 2013
TI  - The adaptability of red blood cells.
PG  - 63
LID - 10.1186/1475-2840-12-63 [doi]
AB  - The most important function of red blood cells (RBCs) is the carrying of oxygen, 
      but they are also involved in inflammatory processes and during coagulation. RBCs
      are extremely deformable and elastic, as they are exposed to shear forces as they
      travel through the vascular system. In inflammatory conditions, and in the
      presence of hydroxyl radicals, RBCs loose their discoid shape. Here,
      ultrastructure of RBCs is studied using a scanning electron microscope, and we
      determine how fast changes in healthy individuals are noted after exposure to
      iron and glucose. We compare shape changes in these experiments to RBCs from
      diabetic and hemochromatosis patients (wild type, as well as hereditary
      hemochromatosis with mutations H63D/H63D, C282Y/C282Y, H63D/C282Y, C282Y/wild
      type and H63D/wild type). Thrombin is also added to whole blood exposed to iron, 
      glucose and blood from diabetes and hemochromatosis patients. RBCs are easily
      deformed to a pointed shape in smears, and, with the addition of thrombin they
      are entrapped in the fibrin mesh of dense matted fibrin deposits. This entrapping
      causes severe shape changes due to the pressure of the fibrin onto the stressed
      cells. The most important observation of the current research is therefore how
      fast RBC can adapt in a changed environment and that the pressure of fibrin
      fibers may trap the RBC tightly in the resulting clot.
AD  - Department of Physiology, Faculty of Health Sciences, University of Pretoria,
      Private Bag x323, Arcadia 0007, South Africa. resia.pretorius@up.ac.za
FAU - Pretorius, Etheresia
AU  - Pretorius E
LA  - eng
PT  - Journal Article
DEP - 20130411
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
SB  - IM
PMC - PMC3637111
OID - NLM: PMC3637111
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/03/20 [received]
PHST- 2013/04/07 [accepted]
PHST- 2013/04/11 [aheadofprint]
AID - 1475-2840-12-63 [pii]
AID - 10.1186/1475-2840-12-63 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2013 Apr 11;12:63. doi: 10.1186/1475-2840-12-63.

PMID- 23578302
OWN - NLM
STAT- In-Data-Review
DA  - 20130606
IS  - 1742-4658 (Electronic)
IS  - 1742-464X (Linking)
VI  - 280
IP  - 12
DP  - 2013 Jun
TI  - The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein
      tyrosine phosphatases.
PG  - 2830-41
LID - 10.1111/febs.12283 [doi]
AB  - The families of protein tyrosine phosphatases (PTPs) and protein tyrosine kinases
      (PTKs) function in a coordinated manner to regulate signal transduction events
      that are critical for cellular homeostasis. Aberrant tyrosine phosphorylation,
      resulting from disruption of either PTP or PTK function, has been shown to be the
      cause of major human diseases, including cancer and diabetes. Consequently, the
      characterization of small-molecule inhibitors of these kinases and phosphatases
      may not only provide molecular probes with which to define the significance of
      particular signaling events, but also may have therapeutic implications.
      BAY-11-7082 is an anti-inflammatory compound that has been reported to inhibit
      IkappaB kinase activity. The compound has an alpha,beta-unsaturated electrophilic
      center, which confers the property of being a Michael acceptor; this suggests
      that it may react with nucleophilic cysteine-containing proteins, such as PTPs.
      In this study, we demonstrated that BAY-11-7082 was a potent, irreversible
      inhibitor of PTPs. Using mass spectrometry, we have shown that BAY-11-7082
      inactivated PTPs by forming a covalent adduct with the active-site cysteine.
      Administration of the compound caused an increase in protein tyrosine
      phosphorylation in RAW 264 macrophages, similar to the effects of the generic PTP
      inhibitor sodium orthovanadate. These data illustrate that BAY-11-7082 is an
      effective pan-PTP inhibitor with cell permeability, revealing its potential as a 
      new probe for chemical biology approaches to the study of PTP function.
      Furthermore, the data suggest that inhibition of PTP function may contribute to
      the many biological effects of BAY-11-7082 that have been reported to date.
CI  - (c) 2013 The Authors Journal compilation (c) 2013 FEBS.
AD  - Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
FAU - Krishnan, Navasona
AU  - Krishnan N
FAU - Bencze, Gyula
AU  - Bencze G
FAU - Cohen, Philip
AU  - Cohen P
FAU - Tonks, Nicholas K
AU  - Tonks NK
LA  - eng
GR  - P30 CA045508/CA/NCI NIH HHS/United States
GR  - R01 CA053840/CA/NCI NIH HHS/United States
GR  - R01 GM055989/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20130509
PL  - England
TA  - FEBS J
JT  - The FEBS journal
JID - 101229646
SB  - IM
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:00
CRDT- 2013/04/13 06:00
PHST- 2013/01/30 [received]
PHST- 2013/04/06 [revised]
PHST- 2013/04/08 [accepted]
PHST- 2013/05/09 [aheadofprint]
AID - 10.1111/febs.12283 [doi]
PST - ppublish
SO  - FEBS J. 2013 Jun;280(12):2830-41. doi: 10.1111/febs.12283. Epub 2013 May 9.


<!-- download operation failed -->
